|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|165|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients will be enrolled from the offices (at clinic or hospital) of primary care        physicians across Canada treating HIV (Human Immunodeficiency Virus) positive patients.|January 2016|January 7, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662336||81131|
NCT01658618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-030|Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer|A Non-Interventional Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer||Healthpoint|Yes|Enrolling by invitation|September 2012|May 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|||Both|18 Years|N/A|No|Non-Probability Sample|The cohorts will be carried over and include all subjects who were randomized in        802-247-09-029 and received at least one application of a test article. Subjects will be        enrolled based on participation in the 802-247-09-029 trial, evidenced by randomization        and completion (or discontinuation) in that trial and having received at least one        application of test article.|January 2014|January 31, 2014|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658618||81413|
NCT01658631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/42|Evaluation of Nexfin During Anesthesia and in Intensive Care (NexfinEval)|Evaluation of Nexfin During Induction of General Anesthesia and in Intensive Care During a Passive Legs Raising Test||Hopital Foch|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing major surgery with the need for an invasive blood pressure measurement        and ICU patients requiring a passive legs raising test|April 2015|April 14, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658631||81412|
NCT01650103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2660P|Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys by Measuring Some Physiological Substances in Blood and Urines|Hemodynamic Indexes and Renal Perfusion: Indirect Evaluation of Blood Volume Using the Association Between ScvO2 and Urinary Electrolytes in Patients Undergoing Major Surgery.||Azienda Ospedaliera di Padova|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing major surgery.|November 2014|November 19, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650103||82062|
NCT01650116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2661P|Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys During Liver Transplant by Measuring Some Physiological Substances in Blood and Urines|Evaluation of Sodium Urinary Excretion, Chlorine Urinary Excretion, Urinary Partial CO2 Pressure as Renal Perfusion Indicators During Liver Transplant. Comparison With Other Polemic State Indicators (Such as PiCCO, ScvO2, O2 Delivery).||Azienda Ospedaliera di Padova|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing liver transplantation|November 2014|November 19, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650116||82061|
NCT01651000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-3001|Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency||OPKO Health, Inc.|Yes|Completed|September 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|213|||Both|18 Years|85 Years|No|||October 2015|December 17, 2015|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651000||81993|
NCT01650987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEXUTOX|Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function|Prospective Observational Study of Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function|SEXUTOX|Centre Oscar Lambret|No|Recruiting|May 2009|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|180|||Female|18 Years|N/A|No|Non-Probability Sample|Women with a corpus uteri carcinoma, without metastasis.|July 2012|July 26, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01650987||81994|
NCT01651988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketofol-001|Efficacy of Ketamine-Propofol for Short Surgical Procedures|EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES||Universidad de Cartagena|Yes|Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|77|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651988||81917|
NCT01652508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSRF9101421|Acceptance and Commitment Therapy for Smoking Cessation in the Primary Care Setting|Individual, Telephone-delivered Acceptance and Commitment Therapy for Smoking Cessation in the Primary Healthcare Setting: Feasibility and Potential Efficacy|ACT|The Hong Kong Polytechnic University|Yes|Completed|July 2012|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|156|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652508||81877|
NCT01652521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0083-12-WOMC|Effects of Pleural Effusion Drainage on Respiratory System Mechanics|Effects of Pleural Effusion Drainage on Respiratory System Mechanics in Mechanically Ventilated Patients, as Measured by Esophageal Balloon.||Wolfson Medical Center|No|Not yet recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated patients with significant pleural fluid documented by CT scan or        US.|July 2012|July 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652521||81876|
NCT01652794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8810|Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer|A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer||Case Comprehensive Cancer Center|Yes|Completed|May 2012|March 2015|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|19 Years|N/A|No|||August 2015|August 3, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652794||81855|
NCT01661998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009HSGF05|Prospective Study of Motion Preservation Evaluation Below Fusions of the Spine in Adolescent Idiopathic Scoliosis|Motion Preservation Evaluation Below Fusions of the Spine in Adolescent Idiopathic Scoliosis|POM|Setting Scoliosis Straight Foundation|No|Enrolling by invitation|June 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|273|||Both|N/A|21 Years|No|Non-Probability Sample|Patients who present to the investigator's clinic, who meet the inclusion criteria will be        offered enrollment in the study|December 2013|December 20, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01661998||81156|
NCT01653288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009336|A Trial of "Coping Coach," a Web-based Preventive Intervention for Children|A Randomized Controlled Trial of "Coping Coach," a Web-based Preventive Intervention for Children||Children's Hospital of Philadelphia|Yes|Enrolling by invitation|March 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|8 Years|12 Years|No|||October 2015|October 5, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653288||81817|
NCT01653301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|515(A1144)/2005|Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study|INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy|INTERACT|Catholic University of the Sacred Heart|No|Recruiting|October 2005|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|616|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01653301||81816|
NCT01662206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236-2012|Probiotics (L. Gasseri, B. Bifidum, B. Longum) on Immune and Intestinal Health in Healthy Older Adults|Probiotics (Lactobacillus Gasseri, Bifidobacterium Bifidum, Bifidobacterium Longum) on Immune and Intestinal Health in Healthy Older Adults||University of Florida|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|46|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01662206||81140|
NCT01658176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1271005|Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer|An Open-Label Randomized Phase 2 Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Advanced Breast Cancer||Pfizer|No|Withdrawn|January 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||October 2012|October 26, 2012|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658176||81446|
NCT01658189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-1158-AMSYS-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2012|||||N/A|N/A|N/A||||||||||||||August 6, 2012|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658189||81445|
NCT01659684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG-001|Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection|Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection||Fondazione Onlus Camillo De Lellis|No|Recruiting|October 2010|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Female|N/A|N/A|No|||August 2012|August 3, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01659684||81332|
NCT01658995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008933|Management of Etonogestrel Subdermal Implant-related Bleeding|Management of Etonogestrel Subdermal Implant-related Bleeding in US Women: a Prospective, Randomized, Placebo-controlled Trial.||Mayo Clinic|No|Recruiting|August 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|51 Years|No|||October 2015|October 28, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658995||81385|
NCT01659346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HCC-01|Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.|A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis||Institute of Liver and Biliary Sciences, India|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659346||81358|
NCT01659359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|virtual reality glasses|The Effect of Virtual Reality Glasses on Pain and Anxiety|Vice-presidency for Research||Mashhad University of Medical Sciences|Yes|Completed|January 2011|August 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659359||81357|
NCT01662362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7B5-02-10P02-01|Abbott ESA Chagas Assay Post-Market Study|Abbott ESA Chagas Assay Post-Market Study|ESA|Abbott Diagnostics Division|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|63|||Both|17 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 8, 2014|August 8, 2012|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01662362||81129|
NCT01662375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0038|A Prospective Study Evaluating the Feasibility and Ethical Perspective of Maastricht III Organ Procurement in French Intensive Care Unit Patients||MIII|Nantes University Hospital|No|Completed|August 2012|July 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|29|||Both|N/A|N/A|No|Non-Probability Sample|These are patients medical or surgical intensive care who are subject to a collective        decision to stop intensive care treatments|October 2014|October 20, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01662375||81128|
NCT01658345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87768|Microvascular Dysfunction in Aortic Stenosis|Prognostic Importance of Microvascular Dysfunction in Asymptomatic Patients With Aortic Stenosis (PRIMID-AS)|PRIMID-AS|University Hospitals, Leicester|Yes|Completed|April 2012|October 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|Samples Without DNA|With consent, a blood sample (up to 50ml) will be drawn and banked for prospective research      studies. All research projects will be related to cardiovascular disease and approved by the      Trial Steering Committee (TSC) or a committee delegated this responsibility by the TSC.      All tissue will be collected, stored and disposed of in accordance with the Codes of      Practice as laid out by the Human Tissue Authority.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cardiology outpatients department and echocardiography department.|February 2015|February 20, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01658345||81433|
NCT01653730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC-325|Comparative Study of 3 Portable Oxygen Concentrators During a 6-minute Walk Test in Patients With Chronic Lung Disease|A Comparative Pilot Study of the Efficacy of Three Portable Oxygen Concentrators During a 6-Minute Walk Test in Patients With Chronic Lung Disease||Ottawa Hospital Research Institute|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|24|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01653730||81783|
NCT01653743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701173_002|Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women|Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa||Merck KGaA|No|Completed|September 2012|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Female|20 Years|39 Years|No|||December 2015|December 1, 2015|July 20, 2012||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01653743||81782|
NCT01649869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 11-0069|Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy|A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss||University of Alabama at Birmingham|Yes|Recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|1 Month|48 Months|No|||March 2016|March 6, 2016|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649869||82080|
NCT01650454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/02|Sleep, Cognition and Memory Disorder||SCOAL|University Hospital, Bordeaux|No|Active, not recruiting|January 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01650454||82035|
NCT01651507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLP|Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function|Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function. A Multicenter Retrospective Study|HLP|Assistance Publique - Hôpitaux de Paris|No|Completed|June 1989|September 2010|Actual|February 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|49|||Both|14 Years|N/A|No|Non-Probability Sample|-  Patients with pulmonary LCH          -  enrolled in eight teaching hospitals          -  evaluated between June 1989 and February 2005|September 2010|July 25, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651507||81954|
NCT01661036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912176|Testing the FLASHE Survey|Cognitive Testing of the Family Life, Activity, Sun, Health, and Eating (FLASHE) Survey||National Institutes of Health Clinical Center (CC)||Completed|July 2012|August 2015||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|40|||Both|11 Years|N/A|No|||August 2015|August 8, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661036||81230|
NCT01661283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC016|SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors|Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors||Sarcoma Alliance for Research through Collaboration||Active, not recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661283||81211|
NCT01661504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-3968|Evaluating Violence Against Women Screening in Mexico|Evaluating Violence Against Women Screening in Mexico||Yale University|No|Recruiting|March 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|1400|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661504||81194|
NCT01661777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR08012012112856|Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops|Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops?||Vanderbilt University|No|Withdrawn|August 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|70 Years|No|||May 2014|May 28, 2014|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01661777||81173|
NCT01658202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00116 TD 1 04|Nicotine Patch Bioequivalence Study|||Pierre Fabre Medicament||Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658202||81444|
NCT01658215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00116 TD 1 05|Nicotine Patch - Multidose Bioequivalence Study|||Pierre Fabre Medicament||Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658215||81443|
NCT01658449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS/2009 HYANEB|Comparison of the Tolerability of Two Formulations of Hypertonic Saline in Cystic Fibrosis Patients|||Ospedale Civile Ca' Foncello||Completed|December 2009|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|8 Years|N/A|No|||February 2009|August 9, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01658449||81425|
NCT01658462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAROCE - 1206|Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer|A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer|VAROCE-1206|Centre Oscar Lambret|Yes|Recruiting|May 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Female|18 Years|N/A|No|||May 2015|November 3, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658462||81424|
NCT01658709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC-15|Predicting Ankle Injury Through Clinical Functional Measures in Adolescent Athletes|Using Dynamic Postural Control and Functional Testing to Predict Ankle Injury in Adolescent Athletes||University of Toledo Health Science Campus|No|Active, not recruiting|September 2012|||September 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|||Both|14 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males and female athletes between the ages of 14 and 24 enrolled at one of three        designated high schools in Toledo, OH or at the University of Toledo will be recruited for        this study.|December 2013|December 9, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658709||81406|
NCT01660594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1693|CT Calcium Scoring in Suspected Stable Angina|Comparison of CT Coronary Artery Calcium Scoring With Traditional Assessment in Patients Presenting to the Rapid Access Chest Pain Clinic With Non-acute Chest Pain and Its Prognostic Value||Royal Brompton & Harefield NHS Foundation Trust|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|705|||Both|40 Years|80 Years|No|Non-Probability Sample|Patients who presented to our chest pain clinic between October 2003 to March 2010 with        stable (non-acute) chest pain and assessed with history, physical examination,        cardiovascular risk factors, chest X-ray, 12-lead resting ECG and exercise ECG.|August 2012|August 8, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660594||81264|
NCT01660607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT236|Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell|Phase I/II Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T Cell Depleted Graft With Simultaneous Infusion of Conventional T Cells and Regulatory T Cells||Stanford University|Yes|Recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|13 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660607||81263|
NCT01659372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-1233-RV|Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain|Phase 1 Study of Low Level Laser Therapy Versus Naproxen||Shahid Beheshti University|No|Recruiting|June 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659372||81356|
NCT01659385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276-12-EP|Leptin Levels in Papillary Thyroid Cancer|Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls|LL-PTC|University of Nebraska|No|Active, not recruiting|August 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|||Female|19 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females with no prior history of thyroid disease and not on thyroid medications.        Active recruitment will be for normal controls only. They will be age and weight/height        matched to females with prior diagnosis of thyroid cancer or thyroid nodules who are        already part of another study.|June 2013|June 17, 2013|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659385||81355|
NCT01695330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05384|Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens|A Phase II Study of Subcutaneous (SC) Bortezomib-Regimens for Patients With Relapsed/Refractory Multiple Myeloma (MM) Failing Prior Intravenous (IV) Bortezomib-Containing Regimens||Oncotherapeutics|Yes|Terminated|May 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2015|March 8, 2016|August 24, 2012|Yes|Yes|Terminated by Sponsor of this study.|No||https://clinicaltrials.gov/show/NCT01695330||78615|
NCT01662141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-S-COstatus-13A-H|Measure Cardiac Output Using Ultrasound Dilution in Mechanically Ventilated Children|Investigation of the Reliability to Measure Cardiac Output by a New Ultrasound Dilution Method in Mechanically Ventilated Children After Pediatric Cardiac Surgery||Transonic Systems Inc.|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|33|||Both|N/A|21 Years|No|Non-Probability Sample|Pediatric Patients (< 15) in the ICU|August 2012|August 7, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01662141||81145|
NCT01662388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proximal composite|A Clinical Trial of Proximal Composite Restorations|A Clinical Trial of Proximal Composite Restorations|Automatrix|Aga Khan University|Yes|Completed|November 2007|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662388||81127|
NCT01649882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0411|Ultrasound Evaluation of Endotracheal Tube Depth|Ultrasound Evaluation of Endotracheal Tube Depth for Proper Tube Placement in Different Patient Groups||University of Arizona|No|Recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|85 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649882||82079|
NCT01650129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1352|Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes|An Open-labelled, Randomised, Parallel Group, Multicentre, Safety and Efficacy Study of NN-X14Mix50 (BIAsp50) in a Twice Daily Regimen in Type 2 Diabetic Subjects||Novo Nordisk A/S|No|Completed|December 2000|October 2001|Actual|October 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|20 Years|N/A|No|||July 2012|July 24, 2012|July 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01650129||82060|
NCT01650467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/JBG-02|Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms|Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms|abl LMC|Centre Hospitalier Universitaire de Nīmes|No|Suspended|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|120|Samples With DNA|Two 7 ml EDTA tubes for genotyping abl and bcr-abl polymorphisms|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will include 60 healthy controls (free of hematologic pathology, seen in genetic        counseling) and stratify the recruitment of patients with CML among 30 patients with        optimal imatinib response and 30 with primary resistance.|October 2015|October 21, 2015|July 24, 2012||No|Funding is late, unforseeable.|No||https://clinicaltrials.gov/show/NCT01650467||82034|
NCT01650714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000714|Endoscopic Full Thickness Biopsy, Gastric Wall.|Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes||Mayo Clinic|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|70 Years|No|||May 2015|May 13, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650714||82015|
NCT01651221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8879B|Repeated Food Exposure Via the Olfactory and Gustatory Systems|Repeated Food Exposure Via the Olfactory and Gustatory Systems||University of Tennessee|Yes|Completed|July 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Anticipated|45|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651221||81976|
NCT01651234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC4401C-101|A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC-4401C in Healthy Subjects||Green Cross Corporation|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|July 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651234||81975|
NCT01651520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB 2011-A00836-35|Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis|Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.|Flumatep_2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651520||81953|
NCT01651754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201009|Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome|Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome.||Radboud University|No|Completed|September 2010|June 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|July 26, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01651754||81935|
NCT01661790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA304DN-001|Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer|Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients||Chinese PLA General Hospital|Yes|Completed|August 2009|October 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|85 Years|No|||March 2015|March 13, 2015|July 25, 2012|Yes|Yes||No|February 16, 2015|https://clinicaltrials.gov/show/NCT01661790||81172|
NCT01662011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMC-2010001|Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery|Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery: the Effect of Patient-ventilator Interaction, Gas Exchange and Hemodynamics||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2010|December 2012|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|18 Years|No|||August 2012|August 7, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01662011||81155|
NCT01662219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0210-A|Effect of Superficial Cervical Plexus Block on the Postoperative Quality of Recovery|Effect of Superficial Cervical Plexus Block on the Postoperative Quality of Recovery After Anterior Cervical Discectomy and Fusion|QoR|University Health Network, Toronto|Yes|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|80 Years|No|||June 2014|August 18, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01662219||81139|
NCT01662232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Char-EGCG-FMD|Improvement of Endothelial Function by EGCG|The Role of EGCG in Different Application Forms on Flow-mediated Dilation in Healthy Volunteers||Charite University, Berlin, Germany|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|50|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662232||81138|
NCT01658228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6459|Combination Treatment Study for Memory Impairment and Depression|Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression|DEP-CI|New York State Psychiatric Institute|Yes|Active, not recruiting|September 2011|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|55 Years|95 Years|No|||December 2015|December 1, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658228||81442|
NCT01658241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/18|Panobinostat Biological Correlates Study|A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy|VEG VCA1|Peter MacCallum Cancer Centre, Australia|Yes|Active, not recruiting|July 2012|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01658241||81441|
NCT01658475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUGSMDPS-350&453|P. Gingivalis IgG Titer Test for Periodontitis|Assessment of Use of Plasma or Serum IgG Test to Screen for Periodontitis||Okayama University|No|Completed|January 2007|March 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1387|Samples Without DNA|plasma and/or serum|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who visit university hospitals to receive periodontal treatment are patients        group.        Employees who receive occupational health check at a company facility.|August 2012|August 2, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658475||81423|
NCT01659398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13106|Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients|Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients||University of Kansas Medical Center|No|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|August 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01659398||81354|
NCT01660009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW-MEW3|Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans|Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans||Medical College of Wisconsin|No|Terminated|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|5|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|August 6, 2012||No|Insufficient Funding|No||https://clinicaltrials.gov/show/NCT01660009||81307|
NCT01660347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.214|Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant|Compassionate Use of the CliniMACS® CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells||Thomas Jefferson University|Yes|Withdrawn|August 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 9, 2015|August 5, 2012|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01660347||81283|
NCT01660620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108298|Topical Betaxolol for the Prevention of Retinopathy of Prematurity|Topical Betaxolol for the Prevention of Retinopathy of Prematurity||Smith-Kettlewell Eye Research Institute|Yes|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Both|32 Weeks|32 Weeks|No|||August 2012|January 2, 2013|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660620||81262|
NCT01659983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 04-55-18 ว|Efficacy Study of Delayed Primary Closure to Reduce Rate of Wound Infection in Complicated Appendicitis|Comparison of Surgical Site Infection Between Delayed Primary Closure Versus Primary Closure in Complicated Appendicitis: A Multicenter Randomized Controlled Trial||Ramathibodi Hospital|Yes|Recruiting|November 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01659983||81309|
NCT01659996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA55|Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age|An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.||Sanofi|No|Completed|July 2012|September 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1394|||Both|9 Months|18 Months|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 2, 2012|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01659996||81308|
NCT01695551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13054|Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia|Assessment of Intracardiac and Surgace Electrogram Characteristics Correlated to Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia||University of Kansas Medical Center|No|Enrolling by invitation|July 2012|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from those that visit University of Kansas Medical Center        Cardiology clinics.|November 2015|November 13, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01695551||78598|
NCT01695564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13240|Safety and Efficacy of Left Atrial Appendage Occlusion Devices|Comparison of Safety and Efficacy of Left Atrial Appendage Occlusion Devices||University of Kansas Medical Center|No|Enrolling by invitation|May 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had a LARIAT LAA device occlusion.|November 2015|November 10, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01695564||78597|
NCT01653496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHGES-001|Compliance to ERAS After Gastric Surgery|Phase II Study Evaluating the Compliance to the Enhanced Recovery After Surgery (ERAS) Program in Patients Undergoing Gastrectomy for Gastric Carcinoma|ERAS|Chonnam National University Hospital|No|Completed|July 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01653496||81801|
NCT01653756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-03|A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects Undergoing Allergen Challenge||Infinity Pharmaceuticals, Inc.|No|Completed|July 2012|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|No|||April 2015|April 13, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01653756||81781|
NCT01650142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10 005|Modifying Genes in Neurofibromatosis 1|Study of the Neurofibromatosis 1 Expression: Identification of the Modifying Genes|NFGENMODIF|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Whole blood for DNA samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with neurofibromatosis 1 according to the NIH criteria followed in NF        France network, a national network devoted in to neurofibromatosis 1|June 2014|June 13, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01650142||82059|
NCT01650155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1294.1|Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.|Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1005273 in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)||Boehringer Ingelheim||Completed|July 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|88|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|July 18, 2012||||No||https://clinicaltrials.gov/show/NCT01650155||82058|
NCT01650480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/R/RES/02|HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)|HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease (COPD) Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)|HELP-COPD|University of Edinburgh|Yes|Completed|January 2012|December 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|44|||Both|N/A|N/A|No|||July 2012|February 11, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650480||82033|
NCT01651013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALLAS|Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras|Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras|CALLAS|National Cancer Institute, Naples|No|Recruiting|October 2010|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients at participating Institutes who are candidate for first-line treatment of        metastatic colorectal cancer|November 2015|November 25, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651013||81992|
NCT01660217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAP-1|Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management|Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management: A Randomized Controlled Trial||Dermatology & Aesthetics of Wicker Park|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|37|||Both|N/A|N/A|No|||August 2012|August 3, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01660217||81291|
NCT01660516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA-IRI|Effect of Tea on Endothelial Function and Ischaemia-reperfusion Injury|Effect of Black Tea Consumption on Endothelial Function and Ischaemia-reperfusion Injury in Humans||Radboud University|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Twenty-one volunteers, aged between 30 and 70 years, were included in our study. All        subjects were healthy and free of (a history of) cardiovascular disease or obesity (BMI        >30 kg/m2). Individuals were excluded if they reported a chronic or acute disease,        including any kind of metabolic abnormality (such as diabetes mellitus) or cardiovascular        disease. Habitual smokers (n=3) were instructed to withdraw from smoking on the day of        testing. To further avoid confounding factors, the investigators also excluded individuals        reporting daily intense sporting activities (>10 h/w), and/or were treated with a diet due        to any reason.|July 2012|February 1, 2013|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660516||81270|
NCT01660789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-132|"Fit For Kids"-Copenhagen|"Fit For Kids" Copenhagen - an Interventions Study on Obesity and Physical Inactivity in Children.|FFK|Rigshospitalet, Denmark|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|7 Years|10 Years|No|||August 2012|August 30, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01660789||81249|
NCT01661296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPMC/09/10|Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India|An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India||Sarder Patel Medical College|Yes|Completed|August 2009|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|1 Year|90 Years|No|||August 2012|August 31, 2012|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01661296||81210|
NCT01661517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110829003|Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting|Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting (Screening and Brief Treatment for Substance Use Disorders in the Emergency Room Department)||University of Alabama at Birmingham|No|Completed|September 2011|||September 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|5271|||Both|19 Years|N/A|No|||June 2013|January 2, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661517||81193|
NCT01661803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acpm anesthesia.dhule.|Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation|Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation||ACPM Medical College|Yes|Completed|November 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|3 Years|10 Years|Accepts Healthy Volunteers|Probability Sample|prospective,randomized,double blind study cariied in 60 ASA grade 1 pediatric patients        undergoing surgeries below T8 dermatome upto two hours duration.|August 2012|August 9, 2012|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01661803||81171|
NCT01661816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KALICOU|Breast Cancer and Quality of Life|Impact of Breast Cancer on Quality of Life of the Young Women, Her Life Partner and Her Couple|KALICOU|Centre Oscar Lambret|No|Completed|April 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|171|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|patient with breast cancer, diagnosed before aged 45, having a life partner|August 2012|August 7, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661816||81170|
NCT01662024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000799|Endoscopic Suturing for Primary Obesity Treatment|Primary Obesity Multicenter Incisionless Suturing Evaluation: The PROMISE Trial|PROMISE|Brigham and Women's Hospital|No|Active, not recruiting|February 2013|December 2014|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|60 Years|No|||June 2014|June 23, 2014|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662024||81154|
NCT01658722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAB-001-ALZ-3300|Retrieval of Patient Information After Discontinuation|A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351|RAPID|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Terminated|December 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|169|||Both|55 Years|N/A|No|Non-Probability Sample|Subjects with Alzheimer's disease who discontinued treatment in bapineuzumab Phase 3        clinical studies (ELN115727-301/302/351) or who completed studies ELN115727-301 or 302 but        did not enroll in study ELN115727-351|August 2012|August 31, 2015|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658722||81405|
NCT01659034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-645|Short and Optimal Duration of Dual Antiplatelet Therapy Study|Short and Optimal Duration of Dual Antiplatelet Therapy Study|STOPDAPT|Kyoto University, Graduate School of Medicine|Yes|Completed|September 2012|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1525|||Both|N/A|N/A|No|||December 2015|December 9, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01659034||81382|
NCT01659047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0120|A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia|A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Withdrawn|August 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659047||81381|
NCT01659411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-433|Adult Congenital Heart Disease Registry (QuERI)|Adult Congenital Heart Disease Quality Enhancement Research Initiative||Actelion|No|Active, not recruiting|December 2011|August 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Adult CHD patients meeting inclusion and exclusion criteria may be enrolled|March 2016|March 1, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01659411|3 Years|81353|
NCT01660321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-109-11|Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation|A Single Treatment, Pharmacokinetic (PK) and Tolerance Study of Natroba (Spinosad) Topical Suspension, 0.9% in Pediatric Subjects 6 Months to 4 Years of Age With an Active Head Lice Infestation||ParaPRO LLC|No|Completed|September 2011|March 2012|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|26|||Both|6 Months|4 Years|No|||November 2012|November 16, 2012|August 6, 2012|No|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT01660321||81285|It is suspected for Subject 02-202, at 0.5 hours, the sample to determine the spinosyn A and spinosyn D concentrations were possibly contaminated with Natroba.
NCT01660334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501077|Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)|Special Investigation of Vfend on Scedosporisis||Pfizer|No|Completed|July 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|13|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A1501077 prescribes the voriconazole (VFEND).|October 2013|October 30, 2013|August 6, 2012||No||No|May 14, 2013|https://clinicaltrials.gov/show/NCT01660334||81284|
NCT01660633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX-353-002|Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free)for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation||Spectrum Pharmaceuticals, Inc|Yes|Completed|December 2012|August 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|N/A|70 Years|No|||May 2015|May 11, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660633||81261|
NCT01660906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-400|This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib|A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib||Bristol-Myers Squibb|No|Completed|November 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2015|January 26, 2016|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660906||81240|
NCT01660919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-201105|Vascular and Metabolic Effects of Rosuvastatin|||Gachon University Gil Medical Center|Yes|Completed|October 2011|December 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|160|||Both|25 Years|80 Years|No|||August 2012|November 1, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01660919||81239|
NCT01695824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA-PR-AF|Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation|Implantation of Left Atrial Appendage Occluders Concomitantly With Catheter Ablation in Patients With Atrial Fibrillation||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|December 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695824||78577|
NCT01695603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intellibrain|Comparison of a New Automated Ventilatory Mode Named Intellivent to Standard Controlled Ventilation in Brain Injured Patients|Comparison of a New Automated Ventilatory Mode Named Intellivent to Standard Controlled Ventilation in Brain Injured Patients||University of Lausanne Hospitals|No|Recruiting|March 2012|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|23|||Both|16 Years|N/A|No|||June 2015|June 7, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01695603||78594|
NCT01653509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7411153|An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode|An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode||GlaxoSmithKline|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|July 10, 2014|July 19, 2012||No||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01653509||81800|The study was not formally powered to detect statistically significant differences, but to provide information for methods development and develop sample size calculation for future studies.
NCT01653522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-061|The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine|The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine||The Cleveland Clinic|No|Recruiting|July 2012|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 20, 2014|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653522||81799|
NCT01649895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011‐002819‐28|D-Cycloserine as an Adjunct to Internet-CBT for OCD|Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial||Karolinska Institutet|Yes|Active, not recruiting|August 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649895||82078|
NCT01650727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07974|A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)|A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||Merck Sharp & Dohme Corp.|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|July 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01650727||82014|
NCT01650740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081-2012|Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder|A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder||Sunnybrook Health Sciences Centre|Yes|Terminated|August 2012|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|65 Years|No|||December 2014|December 19, 2014|July 24, 2012|Yes|Yes|Poor recruitment results.|No||https://clinicaltrials.gov/show/NCT01650740||82013|
NCT01650753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNL 222-12 FB|Colonization and Persistence of Bifidobacterium Longum|Quantitative Evaluation of the Colonization and Persistence of Bifidobacterium Longum Ssp Longum AH1206 in the Gastrointestinal Tract and Its Tolerance by Human Subjects||University of Nebraska Lincoln|No|Completed|August 2012|November 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650753||82012|
NCT01651026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROSS-1|Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer|Multicentered Observational Prospective Cohort Study on Multidisciplinary Treatment of Rectal Cancer|CROSS-1|National Cancer Institute, Naples|No|Recruiting|January 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients at participating Institutes with confirmed diagnosis of colorectal        cancer.|November 2015|November 27, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651026||81991|
NCT01660802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-020|Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)|||Allergan|No|Completed|September 2012|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|August 7, 2012|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01660802||81248|
NCT01660815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-J02|A Study of Florbetapir (18F) in Japanese Healthy Volunteers|PET Whole Body Biodistribution Using Florbetapir (18F)||Avid Radiopharmaceuticals||Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|45 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|August 7, 2012|No|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01660815||81247|
NCT01661049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090377|Duodenal Cancer - Retrospective Analysis|1997-2011 Duodenal Cancer Analysis in Southern Denmark||Odense University Hospital|No|Completed|March 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|55|||Both|N/A|N/A|No|Non-Probability Sample|Patients with duodenal cancer|August 2012|August 8, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661049||81229|
NCT01661062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.084|A Study Using Cone Beam CT for Head and Neck Cancer|A Pilot Study of Tumor and Critical Normal Tissue Motion in Head and Neck Cancer Using Cone Beam CT||University of Michigan Cancer Center|Yes|Active, not recruiting|January 2009|June 2016|Anticipated|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|September 26, 2011||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01661062||81228|
NCT01661309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Methylcobalamin|Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians - Clinical Trial|To Critically Investigate and Evaluate Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians, Who May Have a Resultant Susceptibility to Hyperhomocysteinemia Related Diseases.||University of West London|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 18, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01661309||81209|
NCT01661530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/0036/12|Piloting a Dietary Vitamin E Intervention During Pregnancy|A Double Blind Randomised Placebo Controlled Pilot Study of a Dietary Soup Intervention During Pregnancy to Optimise Dietary Vitamin E Intake in Relation to Childhood Asthma.||University of Aberdeen|Yes|Completed|December 2012|January 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|59|||Female|16 Years|50 Years|No|||January 2014|January 13, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661530||81192|
NCT01658254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 738|Posting of Basic Results of Clinical Trials|A Cohort Randomized Controlled Trial Evaluating the Effect of Sending a Reminder to Responsible Parties of Clinical Trials in the Posting of Basic Results Onto ClinicalTrials.Gov|REGIST|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|379|||Both|N/A|N/A|No|||June 2012|September 29, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01658254||81440|
NCT01658488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12026|Pilot Study of the Effect of Iron Fortified Rice in Iron Deficient Anemic Women|Pilot Study of the Effect of Iron Fortified Rice on Iron Stores and Reticulocytes in Iron Deficient Anemic Women||Pennington Biomedical Research Center|No|Completed|July 2012|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|50 Years|No|||December 2015|December 17, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01658488||81422|
NCT01659060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119.05.03|Chocolate Consumption in Healthy Pregnant Women Trial|Assessment of Blood Pressure and Endothelial Function Pregnancy After Acute and Daily Consumption Flavanol-rich Chocolate Among Healthy Pregnant Women: a Pilot Randomized Controlled Trial||Laval University|Yes|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|44|||Female|18 Years|35 Years|No|||August 2012|August 2, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01659060||81380|
NCT01659073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18878|Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation|Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation||Lawson Health Research Institute|No|Not yet recruiting|September 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01659073||81379|
NCT01659086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116358|Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age||GlaxoSmithKline||Completed|August 2012|March 2014|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|11||Actual|422|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|October 9, 2014|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659086||81378|
NCT01659697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057/2012|Diabetes Prevention in Prediabetic Patients|Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention|DPEP|Meir Medical Center|No|Not yet recruiting|August 2012|July 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|200|||Both|25 Years|55 Years|No|Non-Probability Sample|patients aged 25-55 from Ethiopian origin leaving in Israel with pre diabetes|August 2012|August 5, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01659697||81331|
NCT01660022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_12_002|Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects|A Phase I Study to Investigate the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects||Medicines for Malaria Venture|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|August 6, 2012|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01660022||81306|
NCT01660932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-201103|Vascular and Metabolic Effects of Omega-3 Fatty Acids|||Gachon University Gil Medical Center|Yes|Completed|March 2011|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|176|||Both|25 Years|80 Years|No|||August 2012|November 1, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01660932||81238|
NCT01660945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-201102|Vascular and Metabolic Effects of Vytorin|||Gachon University Gil Medical Center|Yes|Completed|July 2011|November 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|204|||Both|25 Years|80 Years|No|||August 2012|November 1, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01660945||81237|
NCT01695616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-SNT-03(01/12)|Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms|A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms.|Monalisa|Ache Laboratorios Farmaceuticos S.A.|Yes|Not yet recruiting|August 2013|March 2015|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Female|40 Years|65 Years|No|||September 2012|September 27, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695616||78593|
NCT01649609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI9004|Using mTOR Inhibitors in the Prevention of BK Nephropathy|Using mTOR Inhibitors in the Prevention of BK Nephropathy||Columbia University|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649609||82100|
NCT01649622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0345|Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)|Phase II Trial of Bendamustine in Adult Patients With Acute Lymphoblastic Leukemia/Lymphoma||M.D. Anderson Cancer Center|No|Withdrawn|December 2012|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649622||82099|
NCT01649908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501961|Open Bifurcation Surgery Study|Evaluation of Cardiac Function in Different Techniques in Infrarenal Aortic Surgery|OBI|Heidelberg University|No|Active, not recruiting|July 2012|||||N/A|Observational|Time Perspective: Prospective||3|Actual|60|||Male|18 Years|N/A|No|Probability Sample|Patients with infrarenal aortic aneurysms|August 2012|August 6, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649908||82077|
NCT01650493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-012|In-situ Evaluation of Anti-caries Technology|In-situ Evaluation of Anti-caries Technology||3M|No|Completed|June 2012|July 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Generally healthy subjects in need of a full-coverage crown on a mandibular first or        second molar|July 2014|July 9, 2014|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01650493||82032|
NCT01651247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114535|Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants Aged 2 and 6 Months and Toddlers Aged 4-6 Years Following Administration of GlaxoSmithKline (GSK) Biologicals' IPV-containing Vaccines||GlaxoSmithKline||Completed|May 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|Samples With DNA|Serum|Both|2 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Infants aged 2 and 6 months who were previously given a primary vaccination series        consisting of a single dose of combination DTaP-HepB-IPV (PEDIARIX®) vaccine at 2, 4, and        6 months of age or separately administered DTaP (INFANRIX®), HepB (ENGERIX-B®), and IPV        (Sanofi-Pasteur's IPOL) vaccines in the study 217744/085 and toddlers aged 4-6 years who        were previously vaccinated with a single dose of either the combination DTaP-IPV (KINRIX®)        vaccine or separately administered DTaP and IPV vaccines in the study 213503/048.|July 2012|July 24, 2012|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651247||81974|
NCT01651533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0216|Mental Practice in Chronic, Stroke Induced Hemiparesis|Mental Practice in Chronic, Stroke-Induced Hemiparesis||Ohio State University|Yes|Recruiting|September 2010|October 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|80 Years|No|||December 2014|December 23, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01651533||81952|
NCT01660841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16260|Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging|A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)||Bayer|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|223|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01660841||81245|
NCT01661543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFH-11-044|U of A/ U of M Beans and Peas Health Claim Project|Substantiating a Health Claim for Pulses (Beans and Peas) and Cholesterol Lowering Abilities||University of Alberta|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661543||81191|
NCT01661075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7419_2|Quantification of Balance in Acutely Concussed Athletes|Quantification of Balance in Acutely Concussed Athletes, Implications for Return to Play Determination||Oregon Health and Science University|No|Recruiting|August 2012|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Collegiate atheltes|March 2016|March 3, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661075||81227|
NCT01662037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJTUMS-20120314|Bosentan Therapy in Children With Functional Single Ventricle|Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle||Shanghai Jiao Tong University School of Medicine|Yes|Completed|January 2010|June 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|4 Months|18 Years|No|||August 2012|August 7, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01662037||81153|
NCT01662258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN272201000040C|Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP|Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For Community-Acquired Pneumonia|NIHCAP|University of Pittsburgh|Yes|Not yet recruiting|October 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5500|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01662258||81137|
NCT01658267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK86|Compliance With Dietary Recommendations in Children at Risk for Undernutrition|Compliance With Dietary Recommendations in Meeting Nutritional Requirements in Children at Risk of Undernutrition||Abbott Nutrition|Yes|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|36 Months|48 Months|Accepts Healthy Volunteers|||January 2015|January 19, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01658267||81439|
NCT01658501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1023-PT-CL-0004|Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM|Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the Pharmacodynamic Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Once-Weekly Subcutaneous Dosing in Adult Subjects With Inadequately Treated Type 2 Diabetes Mellitus||PhaseBio Pharmaceuticals Inc.|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|593|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658501||81421|
NCT01659424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDRBT for Rectal cancer|Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer|Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) FOLFOX Chemotherapy for Stage II/III Rectal Cancer|HDRBT|Beth Israel Medical Center|No|Withdrawn|June 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|April 24, 2012|Yes|Yes|No participants were enrolled|No||https://clinicaltrials.gov/show/NCT01659424||81352|
NCT01659710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-14808|Effects of Medical Complexity Using GMA on Lurie Children's In- and Outpatients|Effects of Medical Complexity on the Development of Fidgety Movements and Feasibility of Screening Utilizing the General Movement Assessment for Lurie Children's ICU Patients and Graduates|CIMA|Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|January 2012|||March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|||Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children's Memorial ICU Patients and Graduates|August 2015|August 10, 2015|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01659710||81330|
NCT01660360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC1101-TAAC01|Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer|A Phase I Study of the Safety and Pharmacokinetics of a Fully Human Monoclonal Antibody to the Vascular Endothelial Growth Factor Receptor2 (Tanibirumab) in Patients With Advanced Cancers or Metastatic Cancer||PharmAbcine|No|Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|N/A|No|||January 2014|January 27, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660360||81282|
NCT01660958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00048720|Project Grow Smart: Intervention Trial of Multiple Micronutrients and Early Learning Among Infants in India|Innovative Strategies to Promote Early Child Development Among Low-income Rural Infants and Preschoolers in India Through Multiple Micronutrient Fortification and Early Learning Opportunities|GrowSmart|University of Maryland|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|720|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||August 2012|August 6, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01660958||81236|
NCT01661140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28096|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage|Randomised, Phase IV, Placebo-controlled, Comparative Study to Evaluate the Efficacy and Safety of Tapering Methotrexate (MTX) Dosage Versus Maintaining the Dosage in Patients With Severe Active Rheumatoid Arthritis (RA) Who Have Demonstrated an Inadequate Response to Prior Conventional Disease-modifying Anti-rheumatic Drugs (DMARDs) Treatment and Have Initiated RoActemra® (Tocilizumab, TCZ) in Combination With MTX||Hoffmann-La Roche||Terminated|November 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01661140||81222|
NCT01695629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPN-42377|In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy|In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy||University of Michigan|No|Completed|January 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|Samples Without DNA|Skin biopsy from leg|Both|18 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|Subjes\cts with diabetes with none, mild or severe neuropathy|December 2015|December 3, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695629||78592|
NCT01695863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11042705|Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep|Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep||Rush University Medical Center|Yes|Active, not recruiting|February 2012|June 2013|Anticipated|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 20, 2013|August 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695863||78574|
NCT01650168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2013_08|Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)|Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)|PRO-E2|Center for Epidemiology and Health Research, Germany|Yes|Recruiting|July 2012|October 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|101000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using oral contraceptives|January 2016|January 27, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01650168||82057|
NCT01651039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0469|Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)|A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat (LBH589) When Administered In Combination With Lenalidomide And Weekly Dexamethasone In Patients With Multiple Myeloma||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651039||81990|
NCT01660230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ-3K3A-001|Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers||ZZ Biotech, LLC|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|11||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|July 25, 2012||No||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01660230||81290|Samples were analyzed from 4 treated subjects in the 6 μg/kg dose group, but all values were below the lower limit of quantitation for the assay (75 ng/mL) and therefore no PK analysis could be performed.
NCT01660529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03111|Multi-peptide Vaccine With Basilixumab for Breast Cancer|A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660529||81269|
NCT01660542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0068|An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer|||Yonsei University|No|Recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Female|20 Years|70 Years|No|||February 2014|February 17, 2014|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660542||81268|
NCT01661556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICHQ|Clinical Trial of Hydroquinone Versus Miconazol in Melasma|Double Blind Randomized Study of 2% Miconazol Versus 4% Hydroquinone in the Treatment for Melasma.||Universidad Autonoma de San Luis Potosí|No|Recruiting|October 2011|December 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|60 Years|No|||December 2014|December 1, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661556||81190|
NCT01661829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSVHCRC trial-01|An RCT for the Effect of Biofeedback Therapy the Prevention of AR Syndrome in Rectal Cancer Patients|A Randomised Controlled Trial for the Effect of Biofeedback Therapy for the Preveintion of Anterior Resection Syndrome in Rectal Cancer Patients Who Have Undergone Low Anterior Resection With Total Mesorectal Excision Following Neoadjuvant Chemoradiation Therapy||The Catholic University of Korea|Yes|Completed|March 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|56|||Both|18 Years|N/A|No|Probability Sample|Rectal cancer patients who underwent sphincter saving surgery with total mesorectal        excision and diverting stoma after neoadjuvant chemoradiation therapy.|February 2015|February 2, 2015|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01661829||81169|
NCT01662050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL-RBAC500|Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma|Phase II Study of Age‐Adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)|FIL-RBAC500|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|February 2012|January 2016|Anticipated|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|57|||Both|65 Years|N/A|No|||July 2015|July 14, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01662050||81152|
NCT01662271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384e|Course of Obesity and Extreme Obesity in Adolescents|Course of Obesity and Extreme Obesity in Adolescents, in the Context of Different Treatment Options - a Longitudinal Prospective Observation Study|YES|University of Ulm|Yes|Active, not recruiting|July 2012|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|429|Samples With DNA|Samples of fasting plasma, serum, DNA, and urine will be retained.|Both|14 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general population through different healthcare- and        non healthcare settings to ascertain the inclusion of treatment-seeking and non        treatment-seeking individuals. Healthcare settings include university based obesity        clinics, physician offices and health insurance agencies. Non-healthcare settings include        schools, job centers, and employment agencies.|September 2015|September 28, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01662271||81136|
NCT01659099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAINED|GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma|Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognostic Factors of the Age-adjusted IPI|GAINED|The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|September 2012|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|670|||Both|18 Years|60 Years|No|||August 2015|August 31, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659099||81377|
NCT01659112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010T03102001|Effects of Core Stabilization Approach on Patients With Upper Extremity Injuries|Does Core Stabilization Enhance Neuromuscular Control and Functional Status of the Upper Extremity?||Hacettepe University|Yes|Completed|March 2008|March 2010|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||August 2012|October 15, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659112||81376|
NCT01659723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RICH-ART 2012-001381-15|Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial|Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial|RICH-ART|Göteborg University|Yes|Recruiting|August 2012|August 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||October 2015|October 26, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01659723||81329|
NCT01660035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSR-REVERSE|The Product Surveillance Registry REVERSE Post Approval Study|The REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) Post Approval Study|PSR-REVERSE|Medtronic|No|Recruiting|July 2012|||October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Heart failure patients that are implanted with a Medtronic CRT-D device and meet the        expanded indication criteria.|December 2015|December 21, 2015|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660035||81305|
NCT01660048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTranSILStrial|A Prospective Study Comparing Single and Multiport Laparoscopic Inguinal Hernia Repair|Prospective Randomized Single Blind Controlled Study Comparing Single and Multiport Laparoscopic Total Extraperitoneal Inguinal Hernia Repair|SILSTEP|The Sydney Hernia Specialists Clinic|Yes|Completed|December 2011|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|16 Years|86 Years|No|||March 2013|March 18, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01660048||81304|
NCT01660971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01290|Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|July 2012|||September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01660971||81235|
NCT01661166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15810|A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy )||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Primary Purpose: Treatment|1||Anticipated|146|||Male|30 Years|90 Years|No|||October 2014|October 10, 2014|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661166||81220|
NCT01661153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25312|An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer|A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|March 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|HER2-negative breast cancer patients in first-line treatment of metastatic disease|March 2016|March 1, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661153||81221|
NCT01695421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSF-01|The Effect of a Five Week Electrical Myostimulation Program in Chronic Diseases|Soft-hard Technologies to Assistance and Accessibility in Patients With Chronic Diseases: The Effect of a Five Week Electrical Myostimulation Program.||University of Brasilia|No|Recruiting|November 2012|July 2015|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|40|||Both|21 Years|80 Years|No|||September 2012|June 6, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01695421||78608|
NCT01650766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGC-307PLAH-XJM|Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers|Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Recruiting|February 2012|October 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|The paraffin-embedded pathelogical tissues of tumors and the blood samples before and after      medication are retained.|Both|18 Years|N/A|No|Probability Sample|patients with inoperable or advanced gastric cancers|July 2012|July 24, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01650766||82011|
NCT01659905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONT-CT5-PVFS-1|Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fasted Conditions||Roxane Laboratories|No|Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659905||81315|
NCT01659918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONT-T10-PVFD-1|Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|February 2008|February 2008|Actual|February 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659918||81314|
NCT01659931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONT-T10-PVFS-1|Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fasted Conditions||Roxane Laboratories|No|Completed|February 2008|February 2008|Actual|February 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659931||81313|
NCT01660555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 2011_026#C201136|The Real Distribution of Microbiota Along the Colon Using a Novel Device Along the Colon Using a Novel Device|The Real Distribution of Microbiota Along the Colonic Mucosa Using a Novel Device Capable of Taking 'Protected' Biopsies||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|Samples With DNA|mucosal biopsies will be screened for diversity by Denaturing Gradient Gel Electrophoresis      of 16S rRNA genes and subsequently analysed with the HITChip.      (-> DNA from microbiota instead of human DNA will be analysed)|Both|18 Years|N/A|No|Probability Sample|outpatients scheduled for colonoscopy for diagnostical purposes who are not known with        infectious enterocolitis.|August 2014|September 1, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660555||81267|
NCT01660828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXTROP2|Exercise Test and Cardiac Injury|The Effect of Remote Ischemic Preconditioning on Plasma Troponin I Appearance After a Standardized Cycling Test in Healthy Volunteers||Radboud University|No|Completed|September 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01660828||81246|
NCT01662284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO12901|Study of 124I-NM404 in Advanced Solid Malignancies|A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies||University of Wisconsin, Madison|Yes|Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||9|Anticipated|108|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be referred to the Phase I oncology research office by their treating        oncologist. Outside referrals will be managed by Cancer Connect who will ensure that        potential subjects are first evaluated by a UW medical oncologist in the cancer clinic who        will then refer them, if appropriate, to the Phase I oncology office.|February 2016|February 26, 2016|August 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662284||81135|
NCT01661842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-006|Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis|Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Autoimmune Liver Disease||Beijing 302 Hospital|Yes|Recruiting|October 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2013|May 30, 2013|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01661842||81168|
NCT01658514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCRM101|Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction|A Randomized, Crossover Study Assessing the Single Dose Pharmacokinetics of Delayed-Release Metformin in Subjects With Renal Dysfunction||Elcelyx Therapeutics, Inc.|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|39|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 1, 2012|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01658514||81420|
NCT01658527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1211|TAK-700 in Castration Resistant Prostate Cancer|Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Withdrawn|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||June 2014|June 30, 2014|July 27, 2012||No|Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer|No||https://clinicaltrials.gov/show/NCT01658527||81419|
NCT01658774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2242|Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children|Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya||London School of Hygiene and Tropical Medicine|No|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2377|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||February 2014|April 9, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01658774||81401|
NCT01658787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT 10-11|Global Registry for Endovascular Aortic Treatment (GREAT)|'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation|GREAT|W.L.Gore & Associates|Yes|Recruiting|July 2013|November 2026|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4600|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive series of patients who undergo treatment with Gore endovascular aortic        products.|November 2015|November 19, 2015|August 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658787|10 Years|81400|
NCT01713491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_04|Pre-stroke Cognitive Status and Thrombolytic Therapy|Influence of the Pre-existing Cognitive Status on the Outcome in Patients Treated by Thrombolytic Therapy for Acute Cerebral Ischaemia|OPHELIE-COG|University Hospital, Lille|Yes|Active, not recruiting|November 2011|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1040|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated by iv tPA for acute cerebral ischaemia in routine practice|November 2014|November 12, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713491||77224|
NCT01713504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_29|Identification of New Markers in the Hypereosinophilic Syndrome|Identification of New Markers in the Hypereosinophilic Syndrome|SHE|University Hospital, Lille|No|Recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713504||77223|
NCT01713517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHO_IR_SUDAN|Impact of Insecticide Resistance on Vector Control|Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan||London School of Hygiene and Tropical Medicine|Yes|Recruiting|April 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28000|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713517||77222|
NCT01713803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNX-350|Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects|Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects||BioDelivery Sciences International|No|Withdrawn||||||Phase 3|Interventional|N/A|2||Actual|0|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|October 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01713803||77200|
NCT01714349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTSCI|Nerve Transfer After Spinal Cord Injuries|Restoring Hand Function Using Nerve Transfers in Persons With Spinal Cord Injury||Washington University School of Medicine|No|Recruiting|October 2012|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01714349||77158|
NCT01714908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28545|Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21|A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21|RECEL|Shandong Cancer Hospital and Institute|Yes|Not yet recruiting|October 2012|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2012|October 26, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714908||77116|
NCT01715207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-025|Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol|Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol||Samsung Medical Center|No|Recruiting|June 2010|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|14 Years|55 Years|No|||October 2012|October 29, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715207||77093|
NCT01710085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUAP(T)-2012/39|Value of Diffusion Weighted Magnetic Resonance Imaging in Detection of Recurrent Disease in Surgically Treated Cervical and Endometrial Cancer Patients|Diagnostic Value of Diffusion Weighted Imaging in Detection of Recurrent Disease in Cervical and Endometrial Cancer Treated With Curative Surgery||Uludag University|No|Recruiting|August 2012|February 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||October 2012|October 16, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01710085||77483|
NCT01711060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICATAC|A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix|||Poitiers University Hospital||Recruiting|December 2010|||||N/A|Interventional|N/A|2||||||Female|18 Years|45 Years||||October 2012|October 19, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01711060||77410|
NCT01708200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #12-3749|A Comparison of the Effectiveness of Two Types of Memory Training Programs in People With a Diagnosis of Mental Illness.|A Comparison of the Effectiveness of Two Types of Cognitive Training Interventions Administered to Individuals With a Diagnosis of a Mental Health Condition.||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|65 Years|No|||October 2012|October 15, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01708200||77628|
NCT01708213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 10664|Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device|A Multi-center, Open-label, Prospective Study of Implanted Cross-linked HA Device, Aline HA, for Soft Tissue Augmentation, to Treat Only One Anatomic Feature in up to 100 Subjects for 6 Months||TauTona Group|Yes|Completed|October 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|October 12, 2012||No||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01708213||77627|
NCT01716013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-100-002|Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions|A Multi-Center, Prospective, Open-label, Randomized Study of the Safety and Efficacy of BondEase™ Topical Skin Adhesive for the Closure of Traumatic Lacerations and Surgical Incisions||OptMed, Inc.|Yes|Completed|September 2012|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716013||77031|
NCT01716299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|msf09|Comparison of HIV Testing Algorithms|Comparison of HIV Testing Algorithms in Two Sites in Ethiopia||Medecins Sans Frontieres|No|Completed|December 2010|December 2013|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|495|||Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting the Counseling and Testing centres in the two study sites|January 2014|January 20, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716299||77009|
NCT01716312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130005|Omalizumab for Lupus|A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS)||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|July 2020|Anticipated|July 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|January 16, 2016|October 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716312||77008|
NCT01716988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39246.042.12|Pharmacokinetics of Micafungin in Critically Ill Patients|Pharmacokinetics of Micafungin in Critically Ill Patients With Invasive Candidiasis||University Medical Center Groningen|No|Recruiting|October 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Adult patients with invasive candidiasis admitted to an intensive care unit.|June 2015|June 17, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01716988||76956|
NCT01717300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-021|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)|A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Merck Sharp & Dohme Corp.|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|459|||Both|18 Years|80 Years|No|||April 2015|April 9, 2015|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717300||76932|
NCT01717313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-011|A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)|A Multicenter, Phase III, Randomized, Placebo-controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Completed|December 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717313||76931|
NCT01717755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33550.100.10|Basilar Artery International Cooperation Study|Basilar Artery International Cooperation Study|BASICS|St. Antonius Hospital|Yes|Recruiting|October 2011|October 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717755||76897|
NCT01717482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006865|Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer|A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer||Mayo Clinic|No|Recruiting|October 2012|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717482||76918|
NCT01717729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-2000-235|Hepatocellular Carcinoma Treated With Iodine-125 Implantation|Hepatocellular Carcinoma Treated With Radiofrequency Ablation With or Without Iodine-125 Implantation: A Prospective Study||The Second People's Hospital of GuangDong Province|Yes|Completed|January 2000|October 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|75 Years|No|||October 2012|October 26, 2012|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717729||76899|
NCT01713816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208M18321|Human Brain Antioxidants During Oxidative Stress|Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|June 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|86|||Both|65 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|All data have been accrued for the healthy aging aim, which included healthy people age        18-22 and age 70-89. To study the second aim, 23 patients with AD will be recruited from        the Minneapolis, MN VA medical center. 23 age - and gender- matched controls will be        recruited to study neurodegenerative disease associated demand on the antioxidant system.        We do NOT currently have the resources to screen candidates with AD who are not current        patients at the VA medical center in Minneapolis.|February 2016|February 15, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713816||77199|
NCT01714063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD-2010-001|Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use|Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use||Philips Respironics|No|Recruiting|December 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|5 Years|8 Years|No|Non-Probability Sample|40 subjects aged 5-8 diagnosed with asthma|November 2012|April 21, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01714063||77180|
NCT01714076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB-3|Co-infections in Children Hospitalised for Bronchiolitis|Co-infections in Children Hospitalised for Bronchiolitis: Incidence, Clinical Symptoms and Influence of Cohort Isolation||Princess Amalia Children's Clinic|No|Completed|November 2012|October 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|172|Samples Without DNA|sputum tested for viral agents by PCR-techniques|Both|N/A|24 Months|No|Probability Sample|children < 2 years admitted for bronchiolitis|October 2015|October 21, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01714076||77179|
NCT01714921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_13|Protecta Smart Analysis Register|ProSA Protecta Smart Analysis Register|ProSA|Medtronic Bakken Research Center|No|Active, not recruiting|July 2011|November 2016|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|428|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that suffuse the inclusion criteria and signed the informed consent|April 2015|April 22, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01714921||77115|
NCT01714934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9440-TS-CTIL|The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis|Study of Pepsin Levels in the Broncho-Alveolar-Lavage Fluid of Patients With Idiopathic Pulmonary Fibrosis||Sheba Medical Center|No|Not yet recruiting|January 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40||BAL broncho alveolar lavage at bronchoscopy|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with IPF versus patients with other interstitial lung disorders (non IPF)|October 2012|October 25, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714934||77114|
NCT01714947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14014|Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib|Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas||Millennium Pharmaceuticals, Inc.|No|Completed|January 2013|August 2013|Actual|April 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714947||77113|
NCT01715220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0003|Treatment of Suspected Cholelithiasis With Nitroglycerin|Treatment of Suspected Cholelithiasis With Nitroglycerin: a Randomized, Prospective Double-blind Trial||United States Naval Medical Center, San Diego|Yes|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|60 Years|No|||September 2014|September 30, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715220||77092|
NCT01710722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 20034|The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man|The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man||Pennington Biomedical Research Center|No|Completed|February 2001|February 2002|Actual|February 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|October 17, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01710722||77436|
NCT01707056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-338|The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma|The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma||Washington Hospital Center|No|Recruiting|September 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|60 Years|No|||May 2013|May 21, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01707056||77716|
NCT01708499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-128|Feasibility Study: Evaluation of the Ulthera® System for Treatment of Abdominal Tissue|Feasibility Study: Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Laxity/Crepiness and Texture of Abdominal Tissue||Ulthera, Inc|No|Completed|March 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708499||77605|
NCT01716325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHOW|E-support for Healthcare Processes - WEIGHT LOSS|E-support for Healthcare Processes - WEIGHT LOSS||University of Primorska|No|Recruiting|February 2012|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|25 Years|70 Years|No|||October 2012|October 24, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01716325||77007|
NCT01716650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007710|A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle|A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle||Mayo Clinic|Yes|Enrolling by invitation|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with degenerative joint disease of the ankle evaluated in the orthopedic        department|April 2015|April 10, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01716650||76982|
NCT01716663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUAF|CARTO® 3 System and Real Time Intracardiac Ultrasound|CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study|IUAF|Biosense Webster, Inc.|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 18 years and older with drug refractory recurrent symptomatic paroxysmal AF|November 2014|November 24, 2014|October 19, 2012||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01716663||76981|
NCT01717001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Komistek 1|Comparison of Knee Kinematics for Subjects Implanted With Either a ConforMIS or Traditional Knee Implant|In Vivo Determination & Comparison of Knee Kinematics for Subjects Implanted With Either a Personalized ConforMIS or Traditional Knee Implant||ConforMIS, Inc.|No|Recruiting|August 2012|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|70 Years|No|Non-Probability Sample|Patients who are at least 6 month post-op with a ConforMIS knee replacement or a standard        total knee replacement who meets the inclusion/exclusion criteria|May 2015|May 29, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717001||76955|
NCT01704963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100896|A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms|A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms||Janssen Pharmaceutical K.K.|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704963||77876|
NCT01705236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE15TS|A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®|A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya®|PASSOS|Novartis||Recruiting|August 2012|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01705236||77856|
NCT01717534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.42.NRC|Children Immune Functions|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Heat-treated Lactobacilli on Infections and Immune Status in Healthy Children||Nestlé|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|374|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||August 2013|August 26, 2013|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717534||76914|
NCT01717508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001844|Neural Components Underlying the Treatment of Adolescent Depression|Examination of the Neural Components Underlying the Treatment of Adolescent Major Depression||Mclean Hospital|No|Recruiting|October 2012|||June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717508||76916|
NCT01717521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42398|Effects of IV Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris|The Effects of Intravenous Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris Device||University of Washington|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|No|Non-Probability Sample|Women undergoing gynecological/abdominal surgery|January 2013|January 15, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01717521||76915|
NCT01717742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000033767|Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)|Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)||The Hospital for Sick Children|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|6 Months|18 Years|No|||January 2016|January 21, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01717742||76898|
NCT01713530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3996|A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin|A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin||Novo Nordisk A/S|No|Completed|February 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 22, 2012|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01713530||77221|
NCT01714089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.1.1.H1|Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis|A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis||Revalesio Corporation||Not yet recruiting|October 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|50 Years|No|||May 2015|May 4, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714089||77178|
NCT01714362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Ow-003|Autonomic Nervous System Activity and Oculocardiac Reflex.|Prediction of Oculocardiac Reflex in Relationship to Autonomic Nervous System Activity, Mesured With the Use of ECG HRV Analysis.||Medical University of Gdansk|No|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|65 Years|No|Probability Sample|patients operated bacause of retinal pathology|January 2016|January 25, 2016|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714362||77157|
NCT01714375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509000588|Daily Exposure Monitoring to Prevent Hearing Loss|Daily Exposure Monitoring of Noise Study|DEMON|Yale University|No|Recruiting|July 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|800|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01714375||77156|
NCT01714115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Slakter 1234|Use of Eylea for the Treatment of an Optic Nerve Hemangioma|Use of Eylea for the Treatment of an Optic Nerve Hemangioma||Vitreous -Retina- Macula Consultants of New York||Available||||||N/A|Expanded Access|N/A|||||||Male|18 Years|N/A||||July 2015|July 6, 2015|October 16, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01714115||77176|
NCT01714609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 1002006266|Pilot Study of Effect of Sorafenib on Portal Pressure|A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization||Yale University|Yes|Completed|August 2011|September 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|75 Years|No|||November 2015|November 3, 2015|October 23, 2012|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01714609||77139|
NCT01714622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0550|Prospective Cohort Study for Analyzing the Effect of Gastric Cancer Surgery to the Metabolic Syndrome and Insulin Resistance|||Yonsei University|No|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|270|||Both|20 Years|80 Years|No|Non-Probability Sample|in plan to underwent curative gastrectomy for gastric cancer|February 2014|February 17, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714622||77138|
NCT01714635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIOL-106-ZMLA|Clinical Investigation of Expanded Designs of a Multifocal IOL|Clinical Investigation of Expanded Designs of the Tecnis® Multifocal 1-Piece IOL||Abbott Medical Optics|No|Completed|November 2012|July 2014|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|445|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|February 26, 2015|October 24, 2012|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01714635||77137|
NCT01714648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-ELISHA1|Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?|An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS||Elisha Hospital|No|Terminated|November 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Female|18 Years|42 Years|No|||August 2015|August 3, 2015|October 20, 2012||No|Terminated: recruiting or enrolling participants has halted prematurely and will not resume;    participants are no longer being examined or treated|No||https://clinicaltrials.gov/show/NCT01714648||77136|
NCT01714960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ99030_1001_1|Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients|Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients||Merz Pharmaceuticals GmbH|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|70|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714960||77112|
NCT01714973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-02-12|Study of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline in Treating Skin Irritation From Radiation|Phase I Randomized, Blinded Safety and Efficacy Trial of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline Sprayed on the Breast of Women Undergoing Radiation Therapy for Breast Cancer After Surgical Removal of the Tumor||Stemnion, Inc.|Yes|Active, not recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|80 Years|No|||January 2015|January 14, 2015|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714973||77111|
NCT01706718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/18|Beetroot Enriched Bread, Blood Pressure and Vascular Function|The Effects of Beetroot Enriched Bread on Postprandial Vascular Function, Arterial Stiffness and Blood Pressure in Healthy Men||University of Reading|Yes|Completed|June 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|24|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01706718||77742|
NCT01706731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|918|Effectiveness of Buddhist Monks in Providing Cognitive Behavior Therapy|A Randomized Controlled Trial of Cognitive Behavior Therapy Provided by Buddhist Monks vs. Treatment as Usual in the Treatment of Late Life-depression|Add-CBT|Chiang Mai University|No|Not yet recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|60 Years|95 Years|No|||October 2012|October 12, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01706731||77741|
NCT01707862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHBeijing-20121012|Surgery for Intravenous Leiomyomatosis|Surgical Management of Intravenous Leiomyomatosis With Intracardiac Extension: Our Experience and Outcomes|SIVL|General Hospital of Beijing PLA Military Region|Yes|Completed|March 1997|October 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|6|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|From March 1997 to June 2011, 6 women patients were admitted to our hospital with        intravenous leiomyomatosis with intracardiac extension.|October 2012|October 15, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01707862||77654|
NCT01707875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0062-12-CTIL|Fetal Brain Asymmetry: in Utero and Early Neonatal Follow up|||HaEmek Medical Center, Israel|No|Terminated|November 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Female|18 Years|42 Years|No|Non-Probability Sample|Pregnant women with fetal ventricle brain asymmetry|July 2012|June 14, 2015|October 14, 2012||No|Difficulties in recruiting|No||https://clinicaltrials.gov/show/NCT01707875||77653|
NCT01704560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39377|Improving Measurement Of Parents' Understanding Of Research Permission|IMPROVING MEASUREMENT OF PARENTS' UNDERSTANDING OF RESEARCH PERMISSION||University of Rochester|Yes|Recruiting|March 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|45 Years|No|||February 2016|February 18, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704560||77907|
NCT01716338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15112.b|Glyburide Healthy Volunteer Study|Glyburide Healthy Volunteer Study||Washington University School of Medicine|Yes|Completed|January 2013|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716338||77006|
NCT01716676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPAR-PII2011|Telemedicine in Sleep Breathing Disorders: a Multicenter Study.|||Hospital Clinic of Barcelona||Completed||||September 2014|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|75 Years|No|||October 2012|December 8, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01716676||76980|
NCT01716364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeYPh1|Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase I Study Investigating Safety Immunological Effects of Peripheral Blood T Lymphocytes Transduced With Anti LewisY Chimeric Receptor Gene in LewisY Positive Myeloma, Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome||Peter MacCallum Cancer Centre, Australia|Yes|Active, not recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2012|December 3, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716364||77004|
NCT01716689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC1201|Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas|Phase II Clinical Study of Metronomic Oral Cyclophosphamide in Elderly and/or Pre-treated Patients With Advanced Sarcomas||National Cancer Centre, Singapore|No|Recruiting|August 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|21 Years|N/A|No|||August 2015|September 22, 2015|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01716689||76979|
NCT01708408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011196|The MURDOCK Study Registry and Biorepository Horizon 1.5|Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis The MURDOCK Study Registry and Biorepository Horizon 1.5|MURDOCK|Duke University|Yes|Recruiting|February 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50000|Samples With DNA|Blood, 50 mL (whole blood, plasma, serum, buffy coat, PAXgene); Urine, 36 mL|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Community Registry and Biorepository is designed to create a community registry and        biorepository populated by approximately 50,000 residents of Cabarrus County and/or the        city of Kannapolis in North Carolina.|January 2016|January 19, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708408||77612|
NCT01705548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055063|Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis|Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Brain Metastasis||Emory University|Yes|Recruiting|September 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705548||77832|
NCT01705808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR/40/04/12|Administration of Protein C Concentrates in Adult Critically Ill Septic Patients|Administration of Protein C Concentrates in Adult Critically Ill Septic Patients||Università Vita-Salute San Raffaele||Terminated|September 2012|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||December 2015|December 14, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01705808||77812|
NCT01717781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thunder Cervix|Thunderbeat Technology vs Standard Bipolar Electro Surgery in Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy for Cervical Cancer|Prospective Randomized Trial on Laparoscopic Radical Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Early Stage Cervical Cancer (FIGO Stages IA2-IB1-IIA<2cm) and Advanced Stage Cervical Cancer (FIGO Stages IB2-IIA>2 Cm-IIB) Submitted to NACT With Complete Clinical Response: Thunderbeat Technology Versus Standard Bipolar Electro Surgery|Thunder Cervix|Catholic University of the Sacred Heart|Yes|Recruiting|October 2012|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Female|N/A|75 Years|No|||November 2012|November 5, 2012|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01717781||76895|
NCT01713829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-472-2012|Cranberry Consumption Improves γδ T Cell Function|Cranberry Consumption Improves γδ T Cell Function||University of Florida|No|Completed|October 2012|August 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|52|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|September 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01713829||77198|
NCT01713842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 11-075 TENOR|Tocilizumab Effect iN pOlymyalgia Rheumatica|Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)|TENOR|University Hospital, Brest|Yes|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|50 Years|80 Years|No|||January 2015|February 10, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01713842||77197|
NCT01714102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWA-0786|Resveratrol and the Metabolic Syndrome|The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.||Rockefeller University|No|Active, not recruiting|October 2012|January 2017|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01714102||77177|
NCT01713855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 04-10-143|Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura|Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)||Neufeld, Ellis J, MD, PhD|No|Completed|October 2004|March 2006|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|10|||Both|18 Months|18 Years|No|||October 2012|October 24, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713855||77196|
NCT01713868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HD072815-01|Social Media And Risk-reduction Training for Infant Care Practices (SMART)|Social Media And Risk-reduction Training for Infant Care Practices (SMART)|SMART|University of Virginia|Yes|Enrolling by invitation|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|1600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01713868||77195|
NCT01706081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-210|Acupuncture for Chronic Lymphedema|Acupuncture for Chronic Lymphedema: A Randomized Wait-list Controlled Trial||Memorial Sloan Kettering Cancer Center||Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706081||77791|
NCT01714388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Ow-004|Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.|Vagotonic Effect of Remifentanil in Reference to Sympathetic or Parasympathetic Predominance of Autonomic Nervous System.||Medical University of Gdansk|No|Completed|May 2010|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714388||77155|
NCT01706627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRCIT|Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial|Melatonin In Cancer Patients Receiving Chemotherapy: A Randomized, Double Blind, Placebo, Controlled Trial|MIRCIT|Khon Kaen University|No|Completed|August 2007|June 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|70 Years|No|||October 2012|October 11, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706627||77749|
NCT01706978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-042|A Comparison of Two Adjunctive Treatments in Arthroscopic Cuff Repair|A Comparison of Two Adjunctive Treatments in Arthroscopic Cuff Repair: Soft Tissue or Bone Trephination, a Prospective Cohort Study||Ottawa Hospital Research Institute|Yes|Recruiting|April 2012|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|90 Years|No|||September 2015|September 8, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01706978||77722|
NCT01706991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rebiscan-003|Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|MEPEDS New Device Pediatric Vision Scanner||Rebiscan, Inc.||Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|32|||Both|6 Months|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children presenting for ophthalmic exam at eye clinic.|October 2012|October 12, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01706991||77721|
NCT01707615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010GGC10294|Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use|Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Carotid Intima-media Thickness and Atherosclerotic Plaques in Clinical Use|GSPE|Shandong University|Yes|Completed|October 2006|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|287|||Both|43 Years|75 Years|No|||October 2012|October 14, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01707615||77673|
NCT01707628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37320.100.11|Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab|Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab|Rituxivac|St. Antonius Hospital|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 30, 2014|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01707628||77672|
NCT01708226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-001459|Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series|Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series|AMPOCD|University of California, Los Angeles|Yes|Active, not recruiting|November 2012|August 2016|Anticipated|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|8 Years|17 Years|No|||February 2016|February 25, 2016|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708226||77626|
NCT01704833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505007908|Cognitive Behavioral Therapy for Paranoia in Schizophrenia|Cognitive Behavioral Therapy for Paranoia in Schizophrenia|CBTp|Weill Medical College of Cornell University|No|Active, not recruiting|September 2006|December 2012|Anticipated|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||October 2012|October 10, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01704833||77886|
NCT01704846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.53|Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules|Assessment of Bioequivalence Between Two Different Formulations of BI 201335 NA Soft Gelatine Capsules in Healthy Male Volunteers. (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|October 9, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01704846||77885|
NCT01716052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-45|Women's Mammography Study To Improve Comfort During Mammography|Women's Mammography Study Attempting to Improve the Comfort During Screening Mammography CTRC#11-45||The University of Texas Health Science Center at San Antonio|No|Terminated|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2|||Female|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 18, 2012||No|Lack of funding.|No|January 13, 2015|https://clinicaltrials.gov/show/NCT01716052||77028|
NCT01716351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#SR-1569|The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients|The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients||Yale University|No|Completed|August 2007|February 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01716351||77005|
NCT01716702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2013-076|A Feasibility Study of an Online Intervention for Sexual Rehabilitation in Prostate Cancer|A Feasibility Study of an Online Intervention for Sexual Rehabilitation in Prostate Cancer||Nova Scotia Health Authority|Yes|Recruiting|November 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|48|||Both|N/A|N/A|No|||March 2014|March 13, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01716702||76978|
NCT01707576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090103|Screening of Adolescent Mental Suffering|SCREENING OF ADOLESCENT MENTAL SUFFERING CONSULTANT TO EMERGENCIES, MANAGEMENT AND Later MONITORING|DESPERADOS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2010|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|346|||Both|13 Years|17 Years|No|||January 2010|October 15, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707576||77676|
NCT01704729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-WEAR-1|The Children's WEAR Trial(Phase 1&2)|The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial(Phase 1&2)|WEAR|Sun Yat-sen University|Yes|Enrolling by invitation|September 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|2300|||Both|12 Years|17 Years|No|||October 2012|October 10, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01704729||77894|
NCT01706094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeadPoST1|Head Position in Stroke Trial|Head Position in Stroke Trial|HeadPoST-Pilot|Clinica Alemana de Santiago|Yes|Completed|January 2013|October 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706094||77790|
NCT01706393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-Cell-01|Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)|Double Blind Placebo Controled Randomized Trial, Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Patients Who Get Pelvic/Abdominal Radiotherapy|RTxIMprobio|Seoul National University Hospital|Yes|Recruiting|October 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|75 Years|No|||April 2013|April 18, 2013|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01706393||77767|
NCT01706640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM/CTVS/2012/001|An Open Label,Observational, Real Time Data Capturing of Usage & Outcome of Coseal|An Open- Label,Multicentre, Observational, Prospective, Real-time Data Capturing of Usage, Outcome & Physician Satisfaction of Coseal in Cardio- Vascular- Thoracic Operative and Re- Operative Procedures||Medanta, The Medicity, India|Yes|Not yet recruiting|December 2012|May 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient falling under inclusion criteria can take part in to bthe study|October 2012|October 12, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01706640||77748|
NCT01706653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSB101118|The Effects of a Polyphenol-enriched Fruit Drink on Metabolic Health|Fruit Polyphenols: Maximising Knowledge of Their Metabolic Health Benefits and Practical Applications||King's College London|No|Completed|October 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|23|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706653||77747|
NCT01717768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-002|Oral Testosterone for the Treatment of Hypogonadism|A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism||TesoRx Pharma, LLC|No|Completed|October 2012|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|130|||Male|18 Years|N/A|No|||December 2015|December 14, 2015|October 25, 2012|Yes|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01717768||76896|
NCT01713556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 106 01|Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial|Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial|REDUCTRAUMA2|University Hospital, Toulouse|No|Recruiting|November 2012|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713556||77219|
NCT01705795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191/11|Anti-IL-5 Therapy in Bullous Pemphigoid (BP)|Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid.||University Hospital Inselspital, Berne|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01705795||77813|
NCT01705561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECOPERU 01-2012|Evaluation of Attitudes About Fertility|Evaluation of Attitudes of Premenopausal Latin American Patients With Breast Cancer Towards the Risk of Loss Their Fertility by Chemotherapy||Grupo de Estudios Clínicos Oncológicos Peruano|Yes|Not yet recruiting|December 2012|June 2013|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|450|||Female|18 Years|45 Years|No|Probability Sample|women with diagnosis of breast cancer in pre menopausal status|October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705561||77831|
NCT01705574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0128|Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women|A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women|WAVES|Gilead Sciences|Yes|Active, not recruiting|October 2012|June 2017|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|583|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|October 10, 2012|Yes|Yes||No|February 11, 2016|https://clinicaltrials.gov/show/NCT01705574||77830|There were no limitations affecting the analysis or results.
NCT01706380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M Study|3M Study - Maria Malmö Mobile Telephone Study|A Randomized Controlled Trial of Interactive Voice Response With and Without Personal Feedback in the Treatment of Adolescents With Substance Use Disorders||Region Skane|No|Recruiting|October 2012|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|25 Years|No|||October 2012|October 11, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01706380||77768|
NCT01707290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-770-112|Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation|A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation|KONTINUE|Vertex Pharmaceuticals Incorporated|No|Active, not recruiting|February 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|6 Years|N/A|No|||December 2015|December 1, 2015|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707290||77698|
NCT01708135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005535|Feasibility of Use of BariCare App in Pre-bariatric Surgery.|Feasibility and Efficacy of Engagement Modules for Pre-Bariatric Surgery Patients.||Mayo Clinic|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 15, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01708135||77633|
NCT01708148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW EK982/2010|Oral Administration of Four Lactobacillus Species Preparation to Improve the Quality of the Neovaginal Flora in Male to Female Transsexual Patients|||Medical University of Vienna|Yes|Completed|September 2011|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708148||77632|
NCT01707888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEKUPH1201|VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer|VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung cancer-a Registry Study||Peking University People's Hospital|No|Recruiting|September 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|clinical early stage(I/II) lung cancer|January 2015|January 24, 2015|October 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01707888|3 Years|77652|
NCT01704274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # CAUR 09|GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy|A Double-Blind, Randomised, Placebo-Controlled Study of the Effect of Transdermal Nitroglycerin (Glyceryl Trinitrate; GTN) Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy|GTN|Queen's University|No|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Male|18 Years|90 Years|No|||November 2013|November 5, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01704274||77929|
NCT01704573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812051|Nicotinic Receptor Levels After Stopping Smoking|Nicotinic Receptor Availability in Slow and Fast Nicotine Metabolizers||University of Pennsylvania|No|Completed|October 2010|December 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Two saliva samples will be collected at the medical screening session. A 6ml saliva sample      will be used for nicotine metabolite ratio (NMR) estimation, and a 2ml saliva sample for DNA      extraction (using an Oragene collection kit).|Both|18 Years|65 Years|No|Probability Sample|20 adult, non-treatment seeking smokers, reporting consumption of greater than/equal to 10        cigarettes per day for at least 6 months will be the target population for the study.        Participants will first be screened over the phone and then complete an in-person medical        screen to ensure final eligibility. Enrolled participants will complete 2 PET scans and an        MRI scan.        Previous participants whose nicotine metabolite ratio (NMR) has been determined, and have        agreed to be re-contacted for future studies will be invited to participate in this study.        Other smokers may be recruited via advertising (i.e., newspaper, TV, Craigslist, and radio        ads) from the general population.        6 smokers who have completed the study and have agreed to be re-contacted for future        studies will be invited to participate in an additional procedure. Participants will be        screened over the phone and complete an in-person medical screen to ensure final        eligibility. Enrolled participants will complete 1 PET scan.|December 2012|February 15, 2013|October 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01704573||77906|
NCT01704586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKW-NUK-I-124|I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer|Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design|CLERAD-PROBE|University of Wuerzburg|Yes|Recruiting|May 2015|April 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704586||77905|
NCT01705288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS096|Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study|Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|January 2013|August 2016|Anticipated|August 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|112|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705288||77852|
NCT01705847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-315-0102|A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies|A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies||Gilead Sciences|No|Active, not recruiting|November 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705847||77809|
NCT01707043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21361|Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris|Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris|PS Taclonex|Wake Forest School of Medicine|No|Completed|October 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01707043||77717|
NCT01708083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1629-31/3|Polymorphids an mRNA Expression in Obese Genes|Polymorphids and mRNA Expression in Genes, Significant for Developing Obesity and Typ II Diabetes in Different Types/Localisations of Fat Tissue||Karolinska Institutet|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|Samples With DNA|biopsys; Fat from oment, thigh and abdomen|Both|18 Years|80 Years|No|Non-Probability Sample|Tree groups; group I: diabetes type II with BMI>35 Group II: no diabetes BMI>35 Group III:        no diabetes BMI 18-27|August 2013|August 21, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708083||77637|
NCT01708096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/931-31/2|Mechanisms Behind Antidiabetic Effects by Gastric By-pass|Mechanisms Behind Antidiabetic Effects by Gastric By-pass||Karolinska Institutet|No|Completed|October 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|70 Years|No|||March 2014|March 11, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708096||77636|
NCT01705249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLIM-1408|Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women|Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens®||Novo Nordisk A/S|No|Completed|August 2001|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|191|||Female|50 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 11, 2012|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705249||77855|
NCT01716754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031B2201|Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma|A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists||Novartis|No|Recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Anticipated|457|||Both|18 Years|75 Years|No|||January 2015|January 15, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716754||76974|
NCT01716767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA07|Acute Effect of Topical Menthol on Carpal Tunnel Syndrome|Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01716767||76973|
NCT01707004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO11421|Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms||University of Wisconsin, Madison|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707004||77720|
NCT01707277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMI|The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction|The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction||Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|March 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|N/A|N/A|No|||February 2016|February 3, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01707277||77699|
NCT01707524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02885|Left Versus Right Radial Artery and Radiation Exposure in Patients With Predictors of Trans-radial Failure|Effect of Left Versus Right Radial Artery Access on Radiation Exposure in Patients With Predictors of Potential Trans-radial Access Failure||New York University School of Medicine||Completed|August 2012|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707524||77680|
NCT01713569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-122|Feasibility Study: Histological Characterization After Treatment With the Ulthera® System|Feasibility Study: Histological Characterization of Dermal and Subdermal Thermal Coagulation Points in Rhytidectomy Patients After Treatment With the Ulthera® System||Ulthera, Inc|No|Terminated|October 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|6||Actual|2|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|October 22, 2012|Yes|Yes|Slow subject enrollment; study to be obtained is no longer required.|No||https://clinicaltrials.gov/show/NCT01713569||77218|
NCT01705535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-067|The Effect of Physiotherapy for the Treatment of Fecal Incontinence.|The Effect of Physiotherapy for the Treatment of Fecal Incontinence - a Randomized, Controlled Trial.||Copenhagen University Hospital, Hvidovre|No|Recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705535||77833|
NCT01704742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU1411|Prospective Study of Lymphoproliferative Diseases|A Prospective Clinicopathological Cohort Study of Lymphoproliferative Diseases at Kenyatta National Hospital in Nairobi, Kenya||West Virginia University|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Tumor tissue, blood plasma and serum upon consent and suitability of sample preparation.|Both|N/A|N/A|No|Probability Sample|Patients at Kenyatta National Hospital in Kenya being treated for non-Hodgkin's lymphoma        or Hodgkin's lymphoma.|September 2015|September 10, 2015|October 3, 2012||No|Protocol not considered a clinical trial for registration purposes; no subjects enrolled to    date pending further grant funding|No||https://clinicaltrials.gov/show/NCT01704742||77893|
NCT01705262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAX-001|Comparing Oral Preparation With Macrogol (Moviprep) and Natriumdihydrogenphosphatdihydrat (Phosphoral)|||Odense University Hospital|No|Terminated|October 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients referred to colonoscopy by the house doctors|April 2010|October 11, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01705262||77854|
NCT01706107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-TYS-12-10333|Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants|Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients|COSTAN|Biogen|No|Terminated|April 2012|January 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|18 Years|65 Years|No|Probability Sample|Patients who choose to participate in the study will receive a thorough description of the        study protocol and an informed consent document describing the study and the risks and        benefits of participating. Recruitment will continue until approximately 150 patients have        been enrolled in the study at approximately 15 sites across Canada.|December 2015|January 8, 2016|October 11, 2012|No|Yes|Due to on-going enrollment challenges|No||https://clinicaltrials.gov/show/NCT01706107||77789|
NCT01706120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-16 - MANGO-OV2|Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab|A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS|MITO16/MANGO-2|National Cancer Institute, Naples|No|Active, not recruiting|October 2012|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Female|18 Years|N/A|No|||October 2015|October 28, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706120||77788|
NCT01706406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0400-II|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties, Phase II|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties, Phase II|Group PED|University of British Columbia|No|Completed|November 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Female|19 Years|65 Years|No|||June 2015|June 17, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01706406||77766|
NCT01707017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53709|The Effects of Low- and High-intensity Resistance Exercise on Force-velocity Characteristics in Older Adults|||Universitaire Ziekenhuizen Leuven||Completed|January 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|56|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||November 2011|February 19, 2013|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01707017||77719|
NCT01707823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THN 1227|Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer|Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin||Vanderbilt-Ingram Cancer Center|Yes|Suspended|October 2012|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|N/A|N/A|No|||August 2015|August 11, 2015|October 12, 2012|Yes|Yes|temporary nursing shortage|No||https://clinicaltrials.gov/show/NCT01707823||77657|
NCT01707329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV44|Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment|A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|September 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||September 2015|September 5, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707329||77695|
NCT01708512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-130|Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and Neck|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity Using a Customized, High-Density and Vectoring Treatment Approach||Ulthera, Inc|No|Completed|April 2012|July 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708512||77604|
NCT01704261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-022|Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin||Merck Sharp & Dohme Corp.|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 8, 2012|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01704261||77930|
NCT01704599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dermatology 1104009591|Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis|A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI||Wayne State University|Yes|Terminated|January 2009|May 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|October 3, 2012|Yes|Yes|side effect and poor clinical outcome|No|December 8, 2014|https://clinicaltrials.gov/show/NCT01704599||77904|Early termination due to high amount of combination of side effects and poor outcomes leading to small numbers of subjects analyzed.
NCT01707836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208141|NF1 Brain Tumor Genetic Risk|Genetic Variation and Risk of Pediatric Brain Cancers||Washington University School of Medicine|No|Active, not recruiting|October 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples With DNA|Blood or saliva samples|Both|N/A|18 Years|No|Non-Probability Sample|Families will be recruited from the Washingington University Neurofibromatosis-1 (NF1)        Patient Registry Initiative (NPRI) and NF Center Clinic.|November 2014|November 10, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707836||77656|
NCT01707303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000240|Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure|Effect Of Acute Inflammatory Mediators On Duration Of Functional Limitations In Patients With Acute Respiratory Failure, A Randomized, Controlled Pilot Study of Early ICU Rehabilitation Strategies||Wake Forest School of Medicine|Yes|Completed|July 2007|August 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01707303||77697|
NCT01704443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00885|Integrated Mindfulness for Provoked Vestibulodynia|Integrated Mindfulness for Provoked Vestibulodynia|IMPROVED|University of British Columbia|No|Completed|April 2008|April 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Female|19 Years|N/A|No|||June 2013|June 3, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01704443||77916|
NCT01716117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-04|Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms|The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial)|SCENT|Stryker Neurovascular|Yes|Recruiting|October 2012|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|19 Years|80 Years|No|||November 2015|November 16, 2015|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716117||77023|
NCT01716429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019109|Healthy Eating for Reproductive Health: Greenville|Healthy Eating for Reproductive Health: Greenville|HER Health|University of South Carolina|No|Withdrawn|October 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|October 25, 2012||No|No participants were recruited over the course of the study time period|No||https://clinicaltrials.gov/show/NCT01716429||76999|
NCT01716442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTX-2012|Rituximab Trial for Pediatric Nephrotic Syndrome|A Multi-center Randomized Controlled Trial of Rituximab for Refractory Nephrotic Syndrome in Children|RTX2012|Seoul National University Childrens Hospital|No|Recruiting|August 2012|November 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|88|||Both|1 Year|18 Years|No|||October 2012|October 26, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716442||76998|
NCT01716455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-104|Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function|A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function||Shire|No|Completed|November 2012|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|66|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|October 25, 2012|No|Yes||No|January 2, 2014|https://clinicaltrials.gov/show/NCT01716455||76997|
NCT01716468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00000367|Ketogenic Diet in Advanced Cancer|A Low-Carbohydrate Diet for Advanced or Metastatic Cancer||VA Pittsburgh Healthcare System|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients chosen must be diagnosed with advanced or metastatic cancer of the following        tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma,        sarcoma, non-small cell /small cell lung, genitourinary cancers).|October 2012|October 26, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01716468||76996|
NCT01717092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-CTPH20121026|Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in China|||Fourth Military Medical University|Yes|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|80 Years|No|Probability Sample|Consecutive patients with an acute episode of pulmonary embolism but without prior venous        thromboembolism.|February 2014|February 26, 2014|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717092||76948|
NCT01707810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVER TRANSPLANT OUTFLOW|Prospective Trial Comparing Conventional Versus Piggyback Method in Venous Drainage of the Transplanted Liver|Prospective Randomized Trial Comparing the Clinical Efficiency of Conventional Versus Piggyback Method in Venous Drainage of the Transplanted Liver|LTx-outflow|University of Sao Paulo|No|Completed|October 1999|October 2000|Actual|September 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707810||77658|
NCT01708109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/873-31/3|Optimal Handling of Common Bile Duct Calculus, a Prospective Study|Optimal Handling of Common Bile Duct Calculus, a Prospective Randomized Study||Karolinska Institutet|Yes|Recruiting|November 2011|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708109||77635|
NCT01707537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBC101|To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men|Phase I Study to Determine the Safety and Immunogenicity of Euvichol(Oral Cholera Prevention Vaccine)in Healthy Adult Men ; Open, Non-comparative Clinical Trial|OCV|EuBiologics Co.,Ltd|Yes|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Male|20 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 18, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01707537||77679|
NCT01707550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25048|An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients|Observational, Non-interventional Survey of Renal Allograft Recipients Receiving CellCept as Part of Their Immunosuppressive Protocol||Hoffmann-La Roche||Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|414|||Both|18 Years|N/A|No|Probability Sample|Renal allograft recipients receiving CellCept as part of their immunosuppressive protocol|March 2016|March 1, 2016|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707550||77678|
NCT01707797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR 11-101|Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings|Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire||University of Michigan|Yes|Active, not recruiting|November 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1326|||Both|9 Months|15 Months|Accepts Healthy Volunteers|Probability Sample|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status        and/or race/ethnicity to ensure a diverse representation. Each child will be paired with        the primary caregiver, whom the investigators expect to most likely be the adult parent or        legal guardian.|January 2016|January 26, 2016|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707797||77659|
NCT01708421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037891|Symptom Clusters in Children With Leukemia|Phenotypic and Genotypic Associations With Symptom Clusters During Childhood Leukemia Treatment||Duke University|Yes|Active, not recruiting|November 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|A baseline CSF sample will be obtained prior to intrathecal chemotherapy. CSF biomarkers      will be obtained at the initiation of post-induction, 4 and 6 months into post-induction      therapy, and at the start of maintenance therapy.A saliva sample will be obtained for      genotypic analysis at one of the four data collection times.|Both|3 Years|18 Years|No|Non-Probability Sample|Children between 3-18 years of age undergoing treatment for leukemia.|October 2015|October 1, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708421||77611|
NCT01708434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-115|Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Knees|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Knees||Ulthera, Inc|No|Completed|June 2011|August 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708434||77610|
NCT01705275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-8539POE012|A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Acid-induced Oesophageal Hypersensitivity in Healthy Male Adult Volunteers||Ono Pharmaceutical Co. Ltd|No|Completed|January 2013|||March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|July 4, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01705275||77853|
NCT01705821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121194|Forces During Skull Base Surgery|Measuring Forces Applied During Skull Base Surgery||Vanderbilt University|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|75 Years|No|Non-Probability Sample|All adult patients undergoing standard endonasal skull base surgery.|December 2014|December 8, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01705821||77811|
NCT01706666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1186|Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant|A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|December 2012|||July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706666||77746|
NCT01706679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-11-24|Evaluation of the Effect of ATX-101 on QT/QTc Intervals|A Four-Arm, Parallel Design, Randomized, Double-Blinded, Placebo and Active Controlled Study for the Evaluation of the Effect of Maximum Therapeutic and Supratherapeutic Single-Dose ATX-101 on the QT/QTc Intervals in Healthy Volunteers|ATX-101-11-24|Kythera Biopharmaceuticals|No|Completed|October 2012|June 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|November 12, 2013|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706679||77745|
NCT01707030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-009|Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C|Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C||VA Office of Research and Development|Yes|Recruiting|March 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01707030||77718|
NCT01704469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0066|A Comparison of the Perception of a Needle Injection Pain Between Cancer Patients Receiving Opioid Therapy Versus Opioid-naive Patients|||Yonsei University|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|20 Years|80 Years|No|||October 2012|October 8, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704469||77914|
NCT01704482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tafanono01003060187|N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement|N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.||Assiut University||Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704482||77913|
NCT01707641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD2 AIRO|Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer|A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients.||S. Andrea Hospital|No|Recruiting|November 2012|December 2019|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707641||77671|
NCT01704287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08719|Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)|Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma||Merck Sharp & Dohme Corp.|Yes|Completed|November 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|540|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704287||77928|
NCT01704300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 10_14|Body Mass Index and Initial Presentations of Cardiovascular Diseases|Body Mass Index and Initial Presentations of Cardiovascular Diseases|CALIBER|University College, London|Yes|Completed|January 2001|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2240000|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The cohort we will use in the present analysis has been drawn from patients across 225        practices in England contributing data to GPRD, covering approximately 5% of the UK        population (Figure 1). The study period is 1st January 2001 to 25th March 2010 (the date        of the last GPRD data submission). To allow time for medical history and risk factors to        be measured and recorded we require that patients enter the cohort after having completed        at least 1 year of registration with their current practice during which the practice        provides data that meet research quality criteria. Patients are followed up from the date        they become eligible to be included in the cohort until the earliest date among a) the        date of an initial presentation with one of the endpoints of interest, b) the date of        leaving the practice or c) the date of last data submission from their practice.|October 2012|October 10, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704300||77927|
NCT01704612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-PC001|Evaluation of Block Duration in Type 2 Diabetes Patients|Comparison of Subgluteal Sciatic Nerve Block Duration in Type-2 Diabetic and Non Diabetic Patients|Diabeteblock|Pierre and Marie Curie University|Yes|Completed|July 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|October 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01704612||77903|
NCT01706692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 10-0138; P21007224R|Swiss Dermatology Network of Targeted Therapies (SDNTT)|Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics|SDNTT|Swiss Dermatology Network for Targeted Therapies|No|Recruiting|July 2011|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient with psoriasis or psoriatic-arthritis meeting the inclusion criteria and not        meeting the exclusion criteria will be eligible to participate in this registry.|November 2015|November 16, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01706692||77744|
NCT01706705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0546|Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study|3D Image-guided Intracavitary Brachytherapy Treatment Planning for Cervical Cancer Using a Novel Shielded Applicator||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2012|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|57|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|October 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706705||77743|
NCT01707784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295/12|Effects of Stress on Glucose Tolerance During Pregnancy|Effects of Stress on Glucose Tolerance During Pregnancy||University of Lausanne Hospitals|No|Active, not recruiting|October 2012|September 2015|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|December 2014|December 12, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707784||77660|
NCT01715896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-CAM-3001-1107|A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis|A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis||MedImmune LLC|Yes|Completed|March 2013|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715896||77040|
NCT01716130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0611|Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators|Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators||Touro University, California|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|249|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|October 2012|October 24, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01716130||77022|
NCT01716143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-SR-014|Left Atrium Substrate Based Ablation Plus Circumferential Pulmonary Vein Isolation to Treat Chronic Atrial Fibrillation|Left Atrium Substrate Based Ablation Plus Circumferential Pulmonary Vein Isolation in the Treatment of Persistent and Long-standing Atrial Fibrillation||The First Affiliated Hospital with Nanjing Medical University||Recruiting|March 2010|December 2012|Anticipated|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|18 Years|80 Years|No|||October 2012|October 25, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01716143||77021|
NCT01716481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-047|The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study|Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study|STARTING-2|Samsung Medical Center|Yes|Recruiting|November 2012|February 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|75 Years|No|||May 2014|May 8, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716481||76995|
NCT01716780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3439|Pain: Screen and Treat|Towards a Pain Free Hospital: Effect and Cost Effectiveness of Routine Screening and Treatment for Pain in Head and Neck Oncology Outpatients||Royal Marsden NHS Foundation Trust|No|Active, not recruiting|January 2011|October 2012|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|156|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01716780||76972|
NCT01717365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15007|Psychometric / Validation Study|SCOPE: A Psychometric Study||Texas Woman's University|No|Recruiting|March 2008|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|21 Years|No|Non-Probability Sample|The subjects from the data shared by the therapists are from the ages of 0-21, both male        and female, and of any ethnicity.|May 2013|November 14, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717365||76927|
NCT01708122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13623-01|Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures|A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures||Los Angeles Biomedical Research Institute|Yes|Completed|May 2009|February 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|71|||Both|18 Years|N/A|No|||July 2015|July 25, 2015|March 30, 2012|Yes|Yes||No|July 25, 2015|https://clinicaltrials.gov/show/NCT01708122||77634|
NCT01704456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02358|Integrated Mindfulness-based Cognitive Behaviour Therapy Versus Cognitive Behaviour Therapy for Provoked Vestibulodynia|Integrated Mindfulness-based Cognitive Behaviour Therapy Versus Cognitive Behaviour Therapy for Provoked Vestibulodynia|COMFORT|University of British Columbia|No|Recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|19 Years|N/A|No|||June 2015|June 11, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01704456||77915|
NCT01705834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dataglove-01|Dataglove to Measure Joint Stiffness in Patients With Arthritis|The Evaluation of a Dataglove to Measure Joint Stiffness in Patients With Arthritis||Western Health and Social Care Trust|No|Withdrawn||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Rheumatoid arthritis causing pain and stiffness in their hands.|April 2014|April 8, 2014|October 4, 2012||No|The study protocol has been replaced with a two-glove protocol NCT02026245|No||https://clinicaltrials.gov/show/NCT01705834||77810|
NCT01713660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTO-105-CCIP|Corneal Incisions With the IntraLase iFS Femtosecond Laser System|A MULTI-CENTER PROSPECTIVE STUDY TO EVALUATE THE USE OF THE INTRALASE iFS™ FEMTOSECOND LASER SYSTEM TO CREATE CLEAR CORNEAL INCISIONS AND PARACENTESIS INCISIONS FOR CATARACT SURGERY||Abbott Medical Optics|No|Completed|November 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 4, 2013|October 22, 2012|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01713660||77211|
NCT01713933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-114|Evaluation of the Ulthera® System for Treatment of the Brachia|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Brachia||Ulthera, Inc|No|Completed|June 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|October 15, 2012|Yes|Yes||No|January 13, 2014|https://clinicaltrials.gov/show/NCT01713933||77190|- Poor subject selection (high BMI with large volume arms enrolled rather than subjects with laxity and wrinkled skin)
NCT01713946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001M2304|A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures|A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures|EXIST-3|Novartis|Yes|Active, not recruiting|April 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|365|||Both|2 Years|65 Years|No|||March 2016|March 24, 2016|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713946||77189|
NCT01707563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071009|Clinical Variability in Marfan Syndrome|Correlations' Study Between Variability of Expression in FBN1 Gene and Clinical Features in Marfan Patients.|Variarfan|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2009|January 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|November 5, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707563||77677|
NCT01714479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-18-HC|Skeletal Muscle Response to Amino Acids and Load Carriage Exercise|Skeletal Muscle and Physical Performance Responses to Leucine-Enriched Nutrition Supplementation During Load Carriage||United States Army Research Institute of Environmental Medicine|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714479||77149|
NCT01708252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-127|Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera Treatment|Feasibility Study: Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Neck in Post-Surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ultherapy™ Treatment||Ulthera, Inc|No|Completed|September 2011|August 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 28, 2013|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708252||77624|
NCT01704313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WS/0089|A Trial of Interrupted vs Continuous Suturing Techniques for Radiocephalic Fistulae|A Randonimised Trial Comparing Interrupted to Continuous Suturing Techniques in Radiocephalic Fistulae||NHS Greater Glasgow and Clyde|No|Recruiting|May 2012|May 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704313||77926|
NCT01704326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEUK01|A Study of Patients Treated With the Journey Deuce Bicompartmental Knee System|A Prospective, Multicenter Consecutive Series Study of Patients Treated With the Journey Deuce Bicompartmental Knee System||Smith & Nephew, Inc.|No|Completed|September 2006|May 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|59|||Both|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients eligible for this study are non-inflammatory degenerative joint disease        patients requiring a primary unilateral knee surgery. The affected areas must be limited        to the medial and patellofemoral compartments.|October 2012|October 9, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01704326||77925|
NCT01704625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-013|Will the Use of Osteopathic Manipulative Treatments Help Alleviate Headache Pain|Will the Use of Osteopathic Manipulative Treatments on Patients With Headache in the Emergency Department Result in Decreased Pain on 100 Point Pain Scale?||Good Samaritan Hospital Medical Center, New York|No|Recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 10, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01704625||77902|
NCT01707511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diskapianesthesia-01|The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery|Cohort Study on Patients Underwent Colorectal Surgery||Diskapi Teaching and Research Hospital|No|Recruiting|January 2012|December 2013|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients scheduled whom planned for elective laparoscopic colorectal resection.|October 2012|October 15, 2012|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01707511||77681|
NCT01708655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1463|Sweat Evaporimeter Measurement|Evaluation of the Accuracy and Reliability of B-Adrenergic Sweat Secretion Using an Evaporimeter to Assess CFTR Function in Cystic Fibrosis||University of Colorado, Denver|Yes|Completed|December 2011|December 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708655||77593|
NCT01715909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25719|A Pharmacokinetic/Pharmacodynamic Study of Tamiflu (Oseltamivir) in Immunocompromised Children With Confirmed Influenza Infection|AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU®) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN, FROM 2 WEEKS TO LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION||Hoffmann-La Roche||Recruiting|January 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|12 Years|No|||March 2016|March 1, 2016|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715909||77039|
NCT01716156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-039|A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)|A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|No|Completed|January 2013|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 25, 2012|Yes|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01716156||77020|
NCT01716169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24915|Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care|Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care||Stanford University|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|7 Years|N/A|No|||March 2014|March 27, 2014|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716169||77019|
NCT01716182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0018|RAMP Study: A Study Comparing Two Lumbar Fusion Procedures|RAMP Study: A Prospective Randomized Study Comparing Two Lumbar Fusion Procedures|RAMP|Baxano Surgical, Inc.|No|Terminated|June 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|To be eligible to participate in this study, the subject must meet all of the inclusion        criteria and none of the exclusion criteria.|July 2014|July 8, 2014|October 24, 2012||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01716182||77018|
NCT01717391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204712|[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers|Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging||University of Iowa|Yes|Active, not recruiting|October 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717391||76925|
NCT01717105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGCP 048-10|Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients|Observational Post-authorization Prospective Study to Characterize the Incidence of Epidermal Growth Factor Receptor (EGFR) Mutation Positive and Advanced Non-small Cell Lung Cancer Patients and Their Clinical Management in Galicia||Grupo Gallego de Cancer de Pulmon|Yes|Active, not recruiting|March 2011|February 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|None Retained|Tumor tissue Plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|Outpatient consultation in oncology|November 2012|November 5, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717105||76947|
NCT01717118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|883|Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico|Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico||Instituto Nacional de Salud Publica, Mexico|No|Active, not recruiting|November 2009|December 2017|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|2000|||Female|9 Years|24 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717118||76946|
NCT01708668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMCHH-2012-A010|The Effects of Intermittent Epidural Bolus on Fever During Labor Analgesia|The Effects of Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Fever for Labor Analgesia in Primiparous Women|EIEBFLA|Nanjing Medical University|Yes|Recruiting|October 2012|June 2017|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|12000|||Female|20 Years|45 Years|No|||January 2015|January 14, 2015|October 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708668||77592|
NCT01708681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIFES-001|Lean Seafood Intake and Postprandial Metabolism|Ability of a Lean Seafood Diet to Modulate Postprandial Metabolism in Human-beings - a Controlled Intervention Study With Cross-over Design|LeSIP|National Institute of Nutrition and Seafood Research, Norway||Completed|October 2012|September 2015|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708681||77591|
NCT01704976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSc-study (Biel)|SR-WBV Training for Frail Elderly in the Skilling up Stage|Effects of Whole Body Vibration With Stochastic Resonance and Dance Therapy in the Elderly: Effects on Physical Functional Performance||Bern University of Applied Sciences|No|Completed|September 2012|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|October 7, 2012||No||No|July 12, 2014|https://clinicaltrials.gov/show/NCT01704976||77875|
NCT01713673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-125|Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis|Feasibility Study: A Prospective, Parallel, Randomized, Sham-controlled, Blinded Pilot Trial of the Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis||Ulthera, Inc|No|Completed|December 2011|April 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||June 2013|June 28, 2013|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713673||77210|
NCT01713699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12CLM|Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases|Determining the Sensitivity and Specificity of Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases||The Netherlands Cancer Institute|No|Recruiting|September 2012|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713699||77208|
NCT01714180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 031112|Effect of Body Mass on Acyclovir Pharmacokinetics|Effect of Body Mass on Acyclovir Pharmacokinetics||West Virginia University|Yes|Completed|October 2012|March 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Obese and normal weight patients treated with acyclovir in an inpatient setting.|June 2015|June 2, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714180||77171|
NCT01714466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1006-01/2012 (OPT)|Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy|Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy||Norgine|No|Completed|October 2012|January 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|240|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01714466||77150|
NCT01714193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014755|A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers|An Open-label Drug-Drug Interaction Study in Healthy Female Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714193||77170|
NCT01708525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-132|Feasibility Study: Heavy Water Tissue Labeling Protocol|Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin||Ulthera, Inc|No|Completed|August 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|2|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|October 15, 2012|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01708525||77603|A limitation of this trial includes only a two subject study population due to the extremely high expense of the tissue analyses conducted. High expense precluded further research in a randomized designed trial with a broader patient population.
NCT01708538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rush CXL|The Effects of Corneal Collagen Cross-linking|Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.||Rush Eye Associates|Yes|Recruiting|October 2012|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|70 Years|No|||May 2015|May 11, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708538||77602|
NCT01704339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12RE072|Qutenza for Critical Ischaemia in End Stage Renal Failure|The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure||NHS Greater Glasgow and Clyde|No|Not yet recruiting|December 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704339||77924|
NCT01704898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bdbeq-efv600/icuvita-020|Efavirenz Comparative Bioavailability|Comparative Bioavailability Study of Two Efavirenz 600 mg Formulations in Healthy Volunteers.|efv600|Center for Clinical Pharmacology Research Bdbeq S.A.|No|Completed|April 2013|August 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704898||77881|
NCT01715324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-09-03|Adjuvant Growth Therapy in in Vitro Fertilization|Adjuvant Growth Therapy in in Vitro Fertilization: A Randomized Control Trial||OVO R & D|Yes|Recruiting|September 2013|June 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|528|||Female|35 Years|42 Years|No|||February 2016|February 1, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715324||77084|
NCT01715636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0 dated 28 May 2012|Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.|Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)|EPEP|St Vincent's Hospital, Sydney|No|Completed|December 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01715636||77060|
NCT01716494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206102|Washington University Severe Asthma Research Program III|Severe Asthma Research Program (SARP)-Washington University|WU SARPIII|Washington University School of Medicine|Yes|Recruiting|October 2012|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|130|Samples With DNA|whole blood, serum, plasma, DNA, RNA, sputum, urine, bronchial tissue, bronchoalveolar      lavage, bronchial brushings, exhaled breath condensate|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with asthma (severe asthma, well controlled asthma) and healthy normal controls        from St. Louis region|June 2015|June 30, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716494||76994|
NCT01716208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#232|Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma|Phase II Trial of Ofatumumab and Fresh Frozen Plasma in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||University of California, Davis|Yes|Recruiting|January 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716208||77016|
NCT01716221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1141|An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia|||University of Colorado, Denver||Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|1|||Both|N/A|N/A|No|||October 2013|October 4, 2013|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716221||77015|
NCT01716793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-99|Risk-adapted Therapy for Adult Acute Myeloid Leukemia.|Risk Adapted Treatment for Primary AML in Adults up to the Age of 60 Years.||Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias|Yes|Completed|September 1998|November 2003|Actual|September 1998|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|354|||Both|18 Years|60 Years|No|||October 2012|October 31, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01716793||76971|
NCT01716806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-015|A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)|A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above||Seattle Genetics, Inc.|No|Recruiting|October 2012|October 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|60 Years|N/A|No|||February 2016|February 25, 2016|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716806||76970|
NCT01716819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00574-39|Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity|Role of the Renin Angiotensin Aldosterone System and Remodeling of the Matrix Cardiac Extra Cellular in the Mechanisms of Transition to Heart Failure in Abdominal Obesity: Prospective Longitudinal Study R2C2 II|R2C2-II|Central Hospital, Nancy, France|No|Completed|November 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|101|||Both|43 Years|72 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716819||76969|
NCT01716832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walking_Stress_Reduction|Walking for Stress Reduction|Effectiveness of Mindfulness Walking on Stress Reduction||Charite University, Berlin, Germany||Completed|March 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01716832||76968|
NCT01717612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrombin study|A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding|A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding||National Science Council, Taiwan|No|Recruiting|October 2012|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|20 Years|80 Years|No|||November 2012|November 2, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717612||76908|
NCT01717586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPRU Pravastatin|Pravastatin for Prevention of Preeclampsia|Pravastatin for the Prevention of Preeclampsia in High-Risk Women: A Phase I Pilot Study||The University of Texas Medical Branch, Galveston|Yes|Recruiting|August 2012|April 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|November 18, 2015|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717586||76910|
NCT01713374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-1|Physiological Assessment of the Endothelium - Circadian Rhythm and Role of the Sympathetic Nervous System|Studies on the Physiological Meaning of Flow-mediated Constriction, Flow-mediated Dilatation and Vasomotion/Flowmotion: Circadian Variability and Role of the Sympathetic Nervous System.|PAN|Johannes Gutenberg University Mainz|No|Completed|October 2012|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713374||77233|
NCT01713387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1202|A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy|A Phase I Study of Adjuvant Chemotherapy With Gemcitabine Plus S-1 in Patients With Biliary Tract Cancer Undergoing Curative Resection Without Major Hepatectomy||Kansai Hepatobiliary Oncology Group|Yes|Recruiting|April 2012|March 2017|Anticipated|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||April 2015|April 1, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713387||77232|
NCT01713400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16743|Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease|Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation|Ustekinumab|H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|February 2013|June 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|October 22, 2012|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01713400||77231|
NCT01713686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-129|Evaluation of the Ulthera System for the Treatment of the Decolletage|Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera® System for Improvement in Lines and Wrinkles of the Décolletage||Ulthera, Inc|Yes|Completed|October 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|129|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|October 22, 2012|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01713686||77209|
NCT01714206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016465|A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.|An Open-Label, 2-Period, Crossover Study to Evaluate the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics of Multiple Doses of Digoxin in Healthy Subjects.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714206||77169|
NCT01714219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-URO-2012-02|Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy|Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy: Prospective, Single-blinded, Randomized Controlled Trial||Seoul National University Hospital|Yes|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Male|N/A|N/A|No|||September 2014|September 25, 2014|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01714219||77168|
NCT01713959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-121|Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis|Feasibility Study: Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Axillary Hyperhidrosis||Ulthera, Inc|No|Completed|August 2011|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713959||77188|
NCT01714778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMUL201208a|Toxins and Delivery in e-Cigarette Users|Electronic Cigarettes: Potential Toxicant (Acrolein) and Nicotine Delivery in Users|TADEUS|Queen Mary University of London|No|Completed|February 2013|January 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Urine is collected for analysis of a metabolite of acrolein (3-HPMA_.      Blood is collected for analysis of nicotine.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smokers from the community who wish to stop smoking.|March 2014|March 12, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714778||77126|
NCT01715077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-181|Study of Ipilimumab in the Immune System|A Correlative Study of Melanoma Tumor-Infiltrating Lymphocytes (TILs) and Response to Ipilimumab||University Health Network, Toronto|Yes|Active, not recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01715077||77103|
NCT01708551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-134|Histological Analysis Following Ulthera System Treatment for Hyperhidrosis|Histological Analysis and Correlation With Ultrasound Imaging to Evaluate the Safety and Effectiveness of Treating Axillary Hyperhidrosis Subjects With the Ulthera® System||Ulthera, Inc|No|Completed|August 2012|August 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|59|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708551||77601|
NCT01708564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-FVIIa-005-11|A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B|A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients|rhFVIIa|rEVO Biologics|Yes|Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|15|||Male|18 Years|75 Years|No|||July 2013|July 29, 2013|October 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01708564||77600|
NCT01704638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fluvoxaminedigoxin|Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes|||Karolinska Institutet|Yes|Completed|August 2008|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01704638||77901|
NCT01704651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004082|Accelerating Gastrointestinal Recovery|Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial||Mayo Clinic|No|Completed|January 2013|October 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|134|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|October 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704651||77900|
NCT01704378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1386|Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes|A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236||Novo Nordisk A/S|No|Completed|April 2001|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01704378||77921|
NCT01704664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-37878 L|Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients|Prospective Study of the Effect of Perioperative Immunonutrition on the Immune Host Defense and the Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients.||Medical University of Bialystok|Yes|Recruiting|March 2007|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|240|||Both|18 Years|N/A|No|||March 2014|May 29, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01704664||77899|
NCT01715337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD muscle 2011|Effects of Rehabilitation on Muscle Fibre Composition and Capillaries in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Pulmonary Rehabilitation on Muscle Fibre Composition and Capillaries in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|February 2010|April 2014|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|40 Years|75 Years|No|||April 2014|April 14, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715337||77083|
NCT01715350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM012-P2|Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease|A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study|ADD|Purimed Co., Ltd.|Yes|Recruiting|May 2012|May 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|126|||Both|50 Years|85 Years|No|||October 2012|October 25, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715350||77082|
NCT01715649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208042ex|Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes|Evaluation of a Telehealth Intervention Combining Structured Self-Monitoring of Blood Glucose and Nurse Care Coordination Among People With Type 2 Diabetes Noninsulin-Treated||Sutter Health|Yes|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|30 Years|70 Years|No|||November 2014|November 17, 2014|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01715649||77059|
NCT01715935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-000882-11|Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus|A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma|NEORAD|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|No|Recruiting|June 2012|||August 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01715935||77037|
NCT01716234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03579|A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)|Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)||Merck Sharp & Dohme Corp.|Yes|Completed|April 2008|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|3 Months|17 Years|No|||August 2015|August 5, 2015|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716234||77014|
NCT01716533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116509|Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)|A Serological Study in Adult Subjects With Clostridium Difficile Infection||GlaxoSmithKline||Completed|February 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|57|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01716533||76991|
NCT01716507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23VS20RD|23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments|A Prospective, Randomized Study Comparing 23-gauge and 20-gauge Pars Plana Vitrectomy for Repair of Pseudophakic Rhegmatogenous Retinal Detachments||Wills Eye|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|46|||Both|18 Years|N/A|No|||November 2012|November 5, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716507||76993|
NCT01716520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116133|Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|40 Years|N/A|No|||December 2013|February 13, 2014|October 11, 2012|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01716520||76992|
NCT01716845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12001|SynapDx Autism Gene Expression Analysis Study|SynapDx Autism Spectrum Disorder Gene Expression Analysis Study|SAGA|SynapDx|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|660|Samples With DNA|DNA, RNA|Both|18 Months|5 Years|No|Probability Sample|Children 18 months to < 5 years referred to a developmental evaluation centers for        evaluation of a possible developmental disorder.|December 2014|December 15, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01716845||76967|
NCT01717170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28522|Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study|Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study|STOP-Uveitis|Johns Hopkins University|No|Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717170||76942|
NCT01717378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08393|UCSF Research Participant Registry|Facilitating Enrollment Into UCSF Clinical Studies Via a Volunteer Research Participant Registry||University of California, San Francisco|No|Terminated|March 2012|February 2015|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1541|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General public. Anyone may join the UCSF Registry, but adult & pediatric residents of the        San Francisco Bay Area are targeted because of their proximity to UCSF research clinics.|March 2015|March 9, 2015|October 26, 2012||No|This is a voluntary registry formerly managed by a unit within CTSI that was disbanded in    2013. The registry has been dormant since that time.|No||https://clinicaltrials.gov/show/NCT01717378|4 Years|76926|
NCT01717599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0466|Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis|||Yonsei University|No|Recruiting|August 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|380|||Both|20 Years|N/A|No|||October 2012|October 29, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01717599||76909|
NCT01713972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 12066|Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors|A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|November 2012|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713972||77187|
NCT01713725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUN-OMAL-CU-2010|Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria|Multicenter, Double- Blinded, Placebo- Controlled, Randomized, Cross-over (2x2) Clinical Trial, to Assess Efficacy and Safety of a New Indication for Omalizumab (Xolair®, Novartis) in Autoimmune and no Autoimmune Chronic Urticaria.||Clinica Universidad de Navarra, Universidad de Navarra|No|Enrolling by invitation|March 2012|June 2017|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713725||77206|
NCT01713738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 02-12-160|Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)in Children and Adolescents||Neufeld, Ellis J, MD, PhD|Yes|Completed|May 2003|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Months|18 Years|No|||November 2012|November 8, 2012|October 18, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01713738||77205|
NCT01714505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16457|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy||University of Virginia|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|64 Years|No|||August 2014|September 5, 2014|October 23, 2012|No|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01714505||77147|
NCT01714232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2012-008-01|Evaluation of Blood Glucose Meter Systems|Evaluation of Blood Glucose Meter Systems - Contour® PLUS Study||Ascensia Diabetes Care|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|106|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 23, 2012||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT01714232||77167|
NCT01714245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 003.6|A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients|A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis|CLeaN|TopMD Skin Care, Inc.|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|6 Months|18 Years|No|Probability Sample|Pediatric patients with Atopic Dermatitis|July 2014|July 10, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01714245||77166|
NCT01708577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-111|UMIC Validation Study|Ultra High Speed Mobile Information and Communication||RWTH Aachen University|No|Completed|July 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01708577||77599|
NCT01704352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1033|Cognitive Behavioral Therapy for Insomnia in Euthymic Bipolar Disorder|Cognitive Behavioral Therapy for Insomnia in Euthymic Bipolar Disorder: a Randomized Controlled Trial||Norwegian University of Science and Technology|No|Recruiting|January 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704352||77923|
NCT01704677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2177|Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up|Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation in Chronic Back Pain and Localized Degenerative Disc. Long Term Follow-up of a Randomized Multicentre Trial||Oslo University Hospital|Yes|Completed|September 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|25 Years|55 Years|No|||January 2016|January 18, 2016|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01704677||77898|
NCT01704924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCI-2011-8268|Prospective Observation of Wound Healing With Prevena Incision Management System|Prospective Observation of Wound Healing With Prevena Incision Management System||University of California, Irvine|No|Recruiting|October 2012|June 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 9, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704924||77879|
NCT01705197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-AVA-302|This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.|A Double-blind, Stratified Randomization, Placebo Controlled, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Avanafil in Subjects With Moderate to Severe Erectile Dysfunction in Korea.|SPEED|JW Pharmaceutical|No|Completed|February 2012|November 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Male|20 Years|N/A|No|||November 2013|November 18, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01705197||77859|
NCT01715922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12257 Flucocrypto|Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa|Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures|Flucocrypto|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|May 2012|December 2015|Anticipated|September 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2015|December 8, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01715922||77038|
NCT01716195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRO022|Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer|Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)||University of California, Davis|Yes|Active, not recruiting|October 2012|October 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716195||77017|
NCT01715948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2013-118|Comparison of BAHA and CROS Hearing Aid in Single-Sided Deafness|Comparison of BAHA and CROS Hearing Aid in Single-Sided Deafness||Nova Scotia Health Authority|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01715948||77036|
NCT01715961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 11-02|Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma|Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma|SARCOPENIE|Centre Henri Becquerel|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|98|||Both|70 Years|N/A|No|||July 2015|July 21, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01715961||77035|
NCT01716572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERITRO2011|Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding|Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial.||Hospital Universitari de Bellvitge|No|Active, not recruiting|February 2012|December 2015|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01716572||76988|
NCT01716546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/09.10|Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer|Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination With Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal Junction.||Hellenic Oncology Research Group|No|Terminated|July 2011|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|70 Years|No|||October 2015|October 7, 2015|October 2, 2012||No|Not reached the primary endpoint target according to the statistical design|No||https://clinicaltrials.gov/show/NCT01716546||76990|
NCT01717196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX0001|Diagnostic Accuracy of FNA: is Aspiration- Related?|Diagnostic Accuracy of FNA (Fine Needle Aspiration) on Solid Pancreatic Lesions: is Aspiration- Related?|expect fna|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|Yes|Active, not recruiting|October 2012|||October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||October 2012|October 26, 2012|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717196||76940|
NCT01717131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC / IPC 2012-001|Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node|A Non Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus no Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer||Institut Paoli-Calmettes|No|Recruiting|July 2012|July 2025|Anticipated|July 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01717131||76945|
NCT01717144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 150 07|Education in Therapy of Parkinson's Disease|EVALUATION OF A THERAPEUTIC EDUCATION PROGRAMME IN PARKINSON'S DISEASE|ETPARK|University Hospital, Toulouse|No|Completed|December 2008|April 2011|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|120|||Both|30 Years|75 Years|No|||October 2012|October 29, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01717144||76944|
NCT01713413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYM2012|Effects of an Oxymizer on Endurance Time in Patients With Chronic Lung Diseases|Effects of an Oxymizer Versus Conventional Nasal Cannula on Endurance Time in Patients With Chronic Obstructive Pulmonary Disease IV (COPD) or Interstitial Lung Disease (ILD)||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|February 2012|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|75 Years|No|||April 2014|April 14, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01713413||77230|
NCT01713426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTZ-EC-0004|A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment|Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study|ELEVATE|Astellas Pharma Inc|No|Completed|July 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|568|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713426||77229|
NCT01713712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-070|Access to Nutritional Services and the Effect on Maternal Weight Gain|Ease of Access to Nutritional Services and the Effect on Maternal Weight in an Obese Urban Population||Abington Memorial Hospital|Yes|Recruiting|December 2012|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|19 Years|40 Years|No|||April 2013|April 18, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01713712||77207|
NCT01713439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6441 CYCHEALL|Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL|Phase 1 Study of Chemokine and Cytokine Gene Modified Allogeneic Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma Using a Retroviral Vector (CYCHEALL)|CYCHEALL|Baylor College of Medicine|Yes|Active, not recruiting|December 1997|April 2016|Anticipated|January 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||February 2016|February 11, 2016|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01713439||77228|
NCT01713751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUOGRCT03-2012|Surgical Site Infection Rates in Obese Patients After Cesarean Delivery|Surgical Site Infection Rates of Two Different Skin Closure Methods Used in Obese Patients After Cesarean Delivery||Ain Shams University|Yes|Completed|March 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Female|20 Years|45 Years|No|||October 2012|October 24, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01713751||77204|
NCT01713985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-135|Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck|Feasibility Study: Evaluation of the Ulthera® System vs Thermage® for Lifting and Tightening of the Full Face and Neck||Ulthera, Inc|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713985||77186|
NCT01714258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaraMat|A Non Invasive Estimation of Cardiac Output in Mechanically Ventilated Patients|A Non Invasive Estimation of Cardiac Output in Mechanically Ventilated Patients: a Prolonged Expiration Method||Campus Bio-Medico University|Yes|Completed|September 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|85 Years|No|||December 2012|December 5, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714258||77165|
NCT01704365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX757.201|RSV-F Vaccine Dose Ranging Study in Young Women|A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age||Novavax|No|Completed|October 2012|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|330|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704365||77922|
NCT01708603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120103|Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2|AMAGINE-2|Amgen|Yes|Terminated|August 2012|August 2015|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1831|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|September 12, 2012|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01708603||77597|
NCT01704937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001657|Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum|Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum||Massachusetts General Hospital|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|90 Years|No|||June 2014|June 18, 2014|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01704937||77878|
NCT01705210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34329.068.10 / METC 10-2-023|Functional MRI Biomarkers of Cognitive Decrements in Diabetes|Functional MRI Biomarkers of Cognitive Decrements in Diabetes||Maastricht University Medical Center|No|Completed|May 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|106|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Matched subjects aged 40-75 years with Diabetes mellitus type 2, metabolic syndrome, and        healthy controls|April 2015|April 9, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01705210||77858|
NCT01705223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X111012202|Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)|Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)||National Center for AIDS/STD Control and Prevention, China CDC|Yes|Completed|August 2012|January 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|150|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|May 5, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01705223||77857|
NCT01715376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007001-3-1|Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events|Prospective Cohort Study on Integrated Treatment by Traditional Chinese and Western Medicine of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina||Changchun University of Chinese Medicine|Yes|Active, not recruiting|April 2012|August 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|treat with combination of standardized western medical drug therapy and Chinese medical        continued treatment|October 2012|October 26, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01715376||77080|
NCT01715688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2012-003|Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff on the Incidence of Coughing During Emergence|Efficacy of Endotracheal Tube Cuffs Pre-filled With Alkalinized Lidocaine Compared to Endotracheal Tube Cuffs Filled With Saline on the Incidence of Coughing During Emergence of Anesthesia.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715688||77056|
NCT01716247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-214|Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer|Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|1000|||Female|21 Years|N/A|No|||July 2015|July 22, 2015|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716247||77013|
NCT01716559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25362|An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy|Multicenter, Observational Study to Evaluate NeoRecormon Treatment in Anemic Patients Suffering From Non-myeloid Malignancy Receiving Chemotherapy||Hoffmann-La Roche||Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|N/A|No|Probability Sample|Anemic patients with non-myeloid malignancy|January 2016|January 11, 2016|October 11, 2012|No|Yes||No|January 11, 2016|https://clinicaltrials.gov/show/NCT01716559||76989|
NCT01716585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-646|A Study to Evaluate Chronic Hepatitis C Infection|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)||AbbVie|Yes|Completed|November 2012|October 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|636|||Both|18 Years|70 Years|No|||October 2015|October 9, 2015|October 18, 2012|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01716585||76987|
NCT01716858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chiba_SFN_Openstudy2012|An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia|Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia||Chiba University|Yes|Completed|October 2012|March 2014|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|65 Years|No|||October 2012|July 28, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01716858||76966|
NCT01717209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25471|Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement|Combined Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplantation and for Left Ventricular Assist Device Placement||Stanford University|No|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717209||76939|
NCT01717157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100879|A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers|An Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 4 New Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Subjects||Janssen Research & Development, LLC||Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|October 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717157||76943|
NCT01717404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006842|Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)|Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation||Mayo Clinic|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|60 Years|70 Years|No|||September 2013|September 30, 2013|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717404||76924|
NCT01717417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVM1|Three Dimensional Movement Analysis of Maxillary Impacted Canine: a Randomized Clincial Trial|Three Dimensional Movement Analysis of Maxillary Impacted Canine Using TADs: a Randomized Clinical Trial||University of Genova|No|Recruiting|September 2011|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|10 Years|60 Years|No|Non-Probability Sample|Patients referred to the Orthodontic Department, Genoa University.|December 2013|December 9, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717417||76923|
NCT01717625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT2-11-242|The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia|The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia|BPD|Ajou University School of Medicine|Yes|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|N/A|10 Weeks|No|||February 2015|February 9, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717625||76907|
NCT01717638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P12E2|Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1|A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1||Novartis|No|Completed|November 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|13||Actual|805|||Both|48 Months|60 Months|Accepts Healthy Volunteers|||December 2014|December 29, 2014|October 18, 2012||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01717638||76906|
NCT01713452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0806M37362|A Randomized Trial of Ostomy Closure Techniques|A Randomized Trial of Ostomy Closure Techniques: An Outcomes Evaluation of Primary Closure Versus Pursestring Closure||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2008|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|125|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713452||77227|
NCT01713764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09549|A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics|A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics|SUCCEED|University of California, San Francisco|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2013|December 24, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01713764||77203|
NCT01713998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-300|Treatment of the Face and Neck With Lower Ulthera System Energy Settings|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck With Lower Energy Settings||Ulthera, Inc|No|Completed|September 2011|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|October 15, 2012|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT01713998||77185|
NCT01714271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50HL105188-6094|Promotora-based Latino Family CVD Risk Reduction|Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment||University of California, Los Angeles|No|Recruiting|October 2010|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01714271||77164|
NCT01704391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110154|Haemodynamic Response to Aortic Surgery|Haemodynamic Response to Aortic Surgery||Sygehus Lillebaelt|No|Recruiting|January 2012|||May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Urine samples taken from urinary catheter. Centrifuged, supernatant frozen at -80 degrees C.      Immunoassay analyzed at Roche modular P quantifying NGAL.|Both|18 Years|N/A|No|Non-Probability Sample|10 patients sceduled for elective open operation for aortic aneurysm disease and 10        patients sceduled for elective open operation for aortic occlusive disease|October 2012|October 9, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704391||77920|
NCT01704404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0091|7 Days of TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD−4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease||Theravance Biopharma R & D, Inc.|No|Completed|December 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|60|||Both|40 Years|75 Years|No|||March 2015|March 4, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704404||77919|
NCT01704950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-11|Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial|Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial||Integra LifeSciences Services|No|Completed|February 2013|August 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Global population|February 2016|February 24, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704950||77877|
NCT01710059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10010402|Using Mobile Phones to Improve Adherence to Inhaled Steroids|Refined ADEPT: Human Augmentics for Sustained Wellbeing|ADEPT4|Rush University Medical Center|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Both|11 Years|16 Years|No|||February 2014|February 10, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710059||77485|
NCT01710683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-006|Early Mobilisation Following Discectomy|Early Mobilisation Following Discectomy||Northern Orthopaedic Division, Denmark|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic.|May 2015|May 27, 2015|October 17, 2012||No|No participants were enrolled.|No||https://clinicaltrials.gov/show/NCT01710683||77439|
NCT01715389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009407|Evaluation of a Shared Decision Making Portal for Pediatric Asthma|Evaluation of a Shared Decision Making Portal for Pediatric Asthma||Children's Hospital of Philadelphia|No|Completed|November 2012|March 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|6 Years|12 Years|No|||June 2015|June 26, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01715389||77079|
NCT01715402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11060|Optimization of Health Expenditure in Liver Surgery|Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery||Centre Hospitalier Universitaire, Amiens|No|Enrolling by invitation|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|the population corresponds to patients operated in one of the thirteen hospitals.        These hospitals are distributed on the french territory to ensure that the recruitment is        representative of the general population|July 2015|July 28, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01715402||77078|
NCT01715701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG2012-003|Efficacy of Paravertebral Nerve Blockade to Reduce Pain Following Thoracoscopy|Efficacy of Multilevel Thoracic Paravertebral Nerve Blockade to Reduce Postoperative Pain Following Video-assisted Thoracic Surgery||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||June 2014|June 5, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715701||77055|
NCT01716260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bhutan_APMEN_CQ PQ_2013|Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan|Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria on Chloroquine and Primaquine Therapy||Menzies School of Health Research|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Year|N/A|No|Non-Probability Sample|Patients with P.vivax infections will be recruited from 6 sentinel sites and will be        recruited for the study after informed consent is received.        An amendment has been approved to extend the study to 12 sites.|April 2015|April 21, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716260||77012|
NCT01716598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-002|Evaluation of the IPS System for TLD Therapy in Patients With COPD|IPS-II Study: Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) - A Pilot Study.|IPS-II|Holaira|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|40 Years|N/A|No|||September 2015|September 8, 2015|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716598||76986|
NCT01716611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010412|Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites|Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial|TONIC|Konkuk University Medical Center|Yes|Not yet recruiting|November 2012|February 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|105|||Both|20 Years|N/A|No|||October 2012|October 29, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01716611||76985|
NCT01716871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lagauche 2011-RC-11|The Using of NEurocryostimulation in Military Ankle Sprains|COMPARAISON D'EFFICACITÉ ENTRE LA CRYOTHÉRAPIE GAZEUSE HYPERBARE ET LA CRYOTHÉRAPIE CONVENTIONNELLE DANS LE TRAITEMENT DES ENTORSES EXTERNES DE LA CHEVILLE Étude randomisée auprès d'Une Population de Militaires|TUNEMAS|Direction Centrale du Service de Santé des Armées|No|Recruiting|September 2011|July 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|40 Years|No|||October 2012|October 26, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01716871||76965|
NCT01716884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011[436]|China STEMI-PCI Program|China STEMI-PCI Program||Peking University First Hospital|Yes|Recruiting|December 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|STEMI Patients enrolled and followed up 1 year|October 2012|October 26, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716884||76964|
NCT01717222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEC/2011/4/109|Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy|Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy - A Randomized Clinical Trial||Jawaharlal Institute of Postgraduate Medical Education & Research|Yes|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|60 Years|No|||October 2012|October 29, 2012|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717222||76938|
NCT01717183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-12-05-310 3113|Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers|Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomised, Controlled, Double-blind, European Multicentre Clinical Trial||Laboratoires URGO||Recruiting|April 2013|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||April 2014|April 10, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717183||76941|
NCT01717456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1569|Educational-Medical-Behavioral Treatment of Fecal Incontinence|Conservative Treatment of Fecal Incontinence: Community-Based Effectiveness Trial|FIX|University of North Carolina, Chapel Hill|No|Terminated|January 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 15, 2012||No|Low enrollment led sponsor to terminate study early.|No||https://clinicaltrials.gov/show/NCT01717456||76920|
NCT01717430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:062|Metabolic and Endocrine Effects of Repeated Epidural and Sacroiliac Joint Corticosteroid Injections|Repeated Epidural and Sacroiliac Joint Glucocorticoid Injections and Their Effect on Hypothalamic-Pituitary-Adrenal Axis Suppression and Metabolic Status||University of Manitoba|No|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|126|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving initial or repeated sacroiliac (SI) joint injections or single- or        multi-level epidural injections with corticosteroids as part of their management plan for        chronic SI joint, neck, back, or radicular pain.|December 2014|December 10, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01717430||76922|
NCT01717651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0290|Muscle Atrophy in Patients With Severe Sepsis|Muscle Atrophy in Patients With Severe Sepsis||Ohio State University|No|Terminated|December 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|A) Inclusion Criteria          1. Age ≥ 18 years          2. Required mechanical ventilation for at least 24 hours|January 2016|January 15, 2016|October 4, 2012|Yes|Yes|slow accrual made study completion unfeasible|No||https://clinicaltrials.gov/show/NCT01717651||76905|
NCT01717664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHB-104-02|Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)|A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis|CEASE-MS|RedHill Biopharma Limited|No|Active, not recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01717664||76904|
NCT01713465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIA22012|Use of Computers to Prevent Metabolic Syndrome|An Innovative Informatics Platform to Deliver a Multidimensional Intervention to Prevent and Manage Metabolic Syndrome||Asian Institute of Public Health|Yes|Recruiting|March 2012|April 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|750|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713465||77226|
NCT01714284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSODIET1|Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis|Multicenter Randomized Clinical Study Evaluating the Efficacy of Dietary Intervention and Weight Loss in Improving Psoriasis||Centro Studi Gised|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714284||77163|
NCT01714297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK Sør-øst s-08012d|Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)|A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin||Martina Hansen's Hospital|No|Completed|January 2008|April 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 7, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714297||77162|
NCT01714310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH093582|Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation|Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation||University of California, Los Angeles|Yes|Recruiting|January 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|7 Years|17 Years|No|||January 2016|January 8, 2016|October 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714310||77161|
NCT01714011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS001|Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome|Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus.||University of Malaya|No|Completed|May 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714011||77184|
NCT01714856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLL/RPR/1123/08|Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS||Lupin Ltd.|Yes|Completed|September 2008|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01714856||77120|
NCT01714869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040759|Exploring Massage Benefits for Arthritis of the Knee for VA Healthcare Users|Multisite RCT Investigating the Efficacy of Massage in Osteoarthritis for VA Healthcare Users|EMBARK VA|Duke University|Yes|Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|35 Years|N/A|No|||November 2013|November 22, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714869||77119|
NCT01704417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3999|A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine|A Trial Comparing the Effect of Exercise on Blood Glucose Between Insulin Degludec and Insulin Glargine in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||October 2015|October 14, 2015|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01704417||77918|
NCT01704690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC001|Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer|Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer||Peking University|Yes|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|75 Years|No|||October 2014|May 28, 2015|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704690||77897|
NCT01704703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-12-03|Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques|Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques.|ULTRA|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Active, not recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||March 2015|November 17, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01704703||77896|
NCT01709799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179-2010|Village Interactive Training and Learning Study|The Village Interactive Training and Learning Study|VITAL|University of Florida|No|Completed|January 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|60 Years|95 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|September 18, 2012||No||No|June 3, 2015|https://clinicaltrials.gov/show/NCT01709799||77505|
NCT01710696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHTUR/E/2|Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome|Induction of Puberty With 17-Beta Estradiol in Girls With Turner Syndrome. An Open Randomized Trial||Novo Nordisk A/S|No|Completed|July 1998|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||October 2012|October 19, 2012|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710696||77438|
NCT01710709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-252|Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder|A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder|ATLAS|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|November 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|755|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710709||77437|
NCT01715974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC0003|Use of G-CSF Treatment in Recurrent Implantation Failure|Administration of G-CSF in Women With Recurrent Implantation Failure in IVF Cycles||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|December 2012|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|40 Years|No|||February 2015|February 3, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01715974||77034|
NCT01716273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4106|Use of White Granulated Sugar on Wounds|A Randomised Controlled Trial to Investigate the Clinical and Cost-effectiveness of White Granulated Sugar Dressing Compared With Standard Treatment in the Management of Exudating Wounds With Parallel Economic Evaluation||University Hospital Birmingham|No|Recruiting|June 2011|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01716273||77011|
NCT01716286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOG2|Neural Correlates of an Olive Oil Essence|||University Hospital Tuebingen|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|11|||Male|20 Years|33 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01716286||77010|
NCT01716936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0056|A Retrospective Review of Early Onset Spinal Deformity Patients Treated With the Ellipse MAGEC System|A Retrospective Multicenter Review of Early Onset Spinal Deformity Patients That Underwent Either a Primary or Revision Spinal Bracing Procedure With the Ellipse Technologies MAGEC Spinal Bracing and Distraction System||Ellipse Technologies, Inc.|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|54|||Both|N/A|11 Years|No|Non-Probability Sample|All patients worldwide implanted with the Ellipse Technologies Spinal Bracing and        Distraction System (Invitation to Volunteer Non-Probability Sample).|August 2013|August 13, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01716936||76960|
NCT01716949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHO201107/001|Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer|Multi-institutional Phase I/II Study: Neoadjuvant Chemoradiation With 5-FU (or Capecitabine) and Oxaliplatin Combined With Deep Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer|HyRec|University of Erlangen-Nürnberg Medical School|No|Recruiting|September 2012|April 2020|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01716949||76959|
NCT01716897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-007|An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption|A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults||Eisai Inc.|No|Completed|October 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||February 2013|May 20, 2013|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716897||76963|
NCT01716910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-H-4-2010-137|Effect of Synbiotic on Composition of Human Gut Microbiota and Production of Short and Branched-chain Fatty Acids|||University of Copenhagen|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01716910||76962|
NCT01716923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00070|Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia|A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia||Cerus Corporation|No|Completed|April 2013|October 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|81|||Both|18 Years|N/A|No|||June 2015|August 24, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716923||76961|
NCT01717495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq: 0730/11|Thromboembolic Complications After Pacemaker or Implantable Cardioverter-Defibrillator Procedures|Thromboembolic Complications Associated With Pacemaker or Implantable Cardioverter-Defibrillator Procedures: a Prospective Registry||University of Sao Paulo|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1|Samples Without DNA|Blood Fibrinogen, D Dimer, Antithrombin, Prothrombin fragment 1 +2, thromboxane B,      Platelets, Plasminogen|Both|18 Years|90 Years|No|Probability Sample|Patients|May 2013|May 4, 2013|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01717495||76917|
NCT01717690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCGC-CHG-2012|Study of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization in Complex Continuing Care|Randomized Controlled Clinical Trial of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization on Complex Continuing Care Units of Baycrest Hospital||Baycrest|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|122|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717690||76902|
NCT01717443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38266.091.11|Genital HPV Infections Before and After Renal Transplantation|The Incidence, Prevalence and Genotype of Genital Human Papillomavirus Infections in Females Before and After Renal Transplantation||University Medical Center Nijmegen|No|Active, not recruiting|February 2012|April 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|The study population consists of women above 18 years of age with end stage renal disease        who are registered for renal transplantation|December 2015|December 23, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717443||76921|
NCT01717677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 65/11|Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk|Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk|PREFERE|Association of Urogenital Oncology (AUO)|Yes|Recruiting|October 2012|December 2030|Anticipated|December 2029|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|7600|||Male|18 Years|75 Years|No|||November 2012|June 11, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717677||76903|
NCT01713777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQUIGEN Chronic Dose|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study)|Chronic Dose|University of Cincinnati|Yes|Completed|April 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01713777||77202|
NCT01714024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMU 11-2539|Dental Implant Study Comparing Two Types of Metals Used for Dental Implants|A Molecular and Cellular Comparison of Bone Inductive Properties Of Trabecular Metal® Vs. Titanium Among Healthy, Diabetic, and Osteopenic Subjects|ZMU|University of North Carolina, Chapel Hill|Yes|Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714024||77183|
NCT01714037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 0932-201|A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]|A Phase I-II Evaluation of the Safety and Efficacy of the Oral HSP90 Inhibitor Debio 0932 in Combination With Standard of Care in first-and Second-line Therapy of Patients With Stage IIIb or IV Non-small Cell Lung Cancer-the HALO Study (HSP90 Inhibition And Lung Cancer Outcomes)|HALO|Debiopharm International SA|No|Terminated|August 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01714037||77182|
NCT01714570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTZ-20120702|Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia|A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation||Chinese PLA General Hospital|Yes|Completed|November 2012|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|13 Years|65 Years|No|||April 2014|April 16, 2014|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01714570||77142|
NCT01714323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL111821|Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers|Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers|Helping HAND2|Massachusetts General Hospital|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1350|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714323||77160|
NCT01714583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI T32 HL007106-34|The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol|The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With ARDS Managed on a Fluid Protocol: A Secondary Analysis of a Prospective Trial||Yale University|No|Completed|April 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|367|||Both|18 Years|N/A|No|Non-Probability Sample|This is a secondary cross-sectional analysis of the FACTT multi-center randomized        controlled trial enrolling adult patients within 48 hours of ARDS onset from twenty        medical centers across the US, some of which included more than one hospital. We studied        the patients who were randomized to the pulmonary artery catheter arm of the FACTT study.        We included patients that had PEEP and cardiac index measurements performed within a short        period of each other during the first 3 days of the FACTT study enrollment.|October 2012|October 25, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01714583||77141|
NCT01704716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-NBL-1.7 / SIOPEN|High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)|High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)||St. Anna Kinderkrebsforschung|Yes|Recruiting|February 2002|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|2700|||Both|1 Month|21 Years|No|||October 2014|October 30, 2014|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01704716||77895|
NCT01709500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1112|Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|ODYSSEY FH II|Regeneron Pharmaceuticals|Yes|Completed|December 2012|January 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 8, 2012|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01709500||77528|
NCT01710319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110275|Mechanisms of Immunosurveillance for Lung Cancer|Mechanisms of Immunosurveillance for Lung Cancer|MechLungCa|Washington University School of Medicine|No|Recruiting|September 2012|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|160|Samples Without DNA|A blood draw will be obtained from patients in order to complete flow cytometry to analyze      NK-specific markers to determine NK cell abundance and phenotypic expression. Obtain an      optional blood draw on pts at least 30 days from the initial draw if transient confounders      (viral infections or leukemoid reactions-a benign transient post-viral increase in WBCs)      noted that could affect the NK Cell's behavior and interfere with the results.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be patients that visit the Thoracic Surgery clinic or healthy        volunteers.|June 2015|June 2, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01710319||77466|
NCT01711034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|317-11-201|A First in Man Trial for Patients With Cancer|A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Active, not recruiting|June 2012|December 2015|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|158|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|October 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711034||77412|
NCT01711294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00049998|Evaluation of PCLs Using Three EUS-FNA Needles|A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration||Boston Scientific Corporation|No|Recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711294||77392|
NCT01715714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1341|Statin Recapture Therapy Before Coronary Artery Bypass Grafting|Statin Recapture Therapy Before Coronary Artery Bypass Grafting|StaRT-CABG|University of Cologne|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2630|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01715714||77054|
NCT01715727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-3761A3|Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance Imaging|Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance Imaging||Chang Gung Memorial Hospital|Yes|Recruiting|July 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|284|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from the movement disorder clinics in ChangGung memorial        hospital LinKou. The healthy control will be recruited from the local community in        northern Taiwan.|February 2014|February 19, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715727||77053|
NCT01715987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS AI463-254|Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment|A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment||New Discovery LLC|No|Terminated|October 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|Samples With DNA|Blood Urine|Both|18 Years|70 Years|No|Probability Sample|Asian Americans with hepatitis B taking Entecavir or Tenofovir.|June 2015|June 7, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01715987||77033|
NCT01716624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-140|Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder|A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder||Lawson Health Research Institute|No|Completed|May 2011|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|5 Years|20 Years|No|||October 2012|October 25, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01716624||76984|
NCT01716637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL025|Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease|Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.||Life Extension Foundation Inc.|No|Active, not recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|12|||Both|60 Years|85 Years|No|||August 2015|August 31, 2015|October 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716637||76983|
NCT01717261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12030|Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer||SPORT|Maisonneuve-Rosemont Hospital|No|Recruiting|August 2012|May 2019|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|60 Years|N/A|No|||April 2015|April 23, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01717261||76935|
NCT01717274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSI-2012|Hot Saline Irrigation Study|Hot Saline Irrigation vs Room Temperature Saline Irrigation in the Control of Intraoperative Bleeding During Functional Endoscopic Sinus Surgery (FESS)|HSI|St. Paul's Hospital, Canada|No|Active, not recruiting|November 2012|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|19 Years|75 Years|No|||November 2014|November 19, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717274||76934|
NCT01717235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLL/RPR/1122/08|Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS||Lupin Ltd.|Yes|Completed|September 2008|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01717235||76937|
NCT01717248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS-100-CS-4001|Safety Study of GCS-100 to Treat Chronic Kidney Disease|A Phase 1 Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease||La Jolla Pharmaceutical Company|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|75 Years|No|||June 2013|June 19, 2013|October 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717248||76936|
NCT01713543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRG10MAY002|Community-based Falls Prevention Program for the Elderly|Multifactorial, Evidence-based Program of Screening, Risk Modification and Physical Therapy to Prevent Falls Among Vulnerable Elderly Recently Discharged From Hospital to the Community.||National University, Singapore|No|Completed|December 2012|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|354|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713543||77220|
NCT01717469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 00610412.2.0000.0068|Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias|Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias|SAFE-LVPACE|University of Sao Paulo|Yes|Recruiting|June 2012|June 2017|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|90 Years|No|||November 2012|November 5, 2012|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01717469||76919|
NCT01717703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2009-020-001|Sugars-sweetened Commercial Beverages on Short-term Food Intake|Effect of Sugars-Sweetened Commercial Beverages on Short-Term Food Intake Regulation in Normal Weight and Overweight/Obese 9-14 Year Old Boys and Girls||Ryerson University|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|55|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717703||76901|
NCT01717716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2010-017-001|Sugars-containing Beverage and Food Intake in Children|Role of Sugars in Solution on Subjective Appetite and Short-term Food Intake in Normal Weight 9-14 Year Old Boys||Ryerson University|Yes|Completed|June 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|15|||Male|9 Years|14 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717716||76900|
NCT01713478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRRHECHO|Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis|An Integrated Approach of Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis: Echocardiography, Specific Biomarkers, and Vascular Assessment|CIRRHECHO|Carol Davila University of Medicine and Pharmacy|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713478||77225|
NCT01713790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Main study (PhD)- part II|Innovative Training Methods for Frail Elderly in the Training Gain Stage|Effects of Whole Body Vibration With Stochastic Resonance and Exergames in the Elderly in Need of Care: Effects on Physical Functional Performance||Bern University of Applied Sciences|No|Completed|October 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01713790||77201|
NCT01714050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078982|Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence|Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence||University of Vermont|No|Active, not recruiting|July 2008|February 2014|Anticipated|February 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714050||77181|
NCT01714336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004599|Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?|Is Tranexamic Acid Effective in Limiting Transfusion After Hip Replacement for Femoral Neck Fracture: A Randomized Controlled Trial||Mayo Clinic|Yes|Active, not recruiting|September 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|152|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|October 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714336||77159|
NCT01714596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METRC POvIV|A Prospective Randomized Trial to Assess PO Versus IV Antibiotics for the Treatment of Post-op Wound Infection After Extremity Fractures|A Prospective Randomized Trial to Assess PO Versus IV Antibiotics for the Treatment of Post-op Wound Infection After Extremity Fractures (POvIV)|POvIV|Major Extremity Trauma Research Consortium|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|84 Years|No|||January 2016|January 13, 2016|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01714596||77140|
NCT01714895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7-PEOPLE-2009-IEF #252085-2|Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring|New Strategies for Automated Glycaemic Control: the Issue of Continuous Glucose Monitoring Accuracy Under Hypoglycaemic Conditions||Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|October 2011|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714895||77117|
NCT01710072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108750|Aspirin Attenuates Inflammation in Human Cerebral Aneurysms|Aspirin as a Promising Agent to Attenuate Inflammation in the Wall of Human Cerebral Aneurysms||University of Iowa|Yes|Completed|August 2011|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01710072||77484|
NCT01710332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSRII|The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy|Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study|CONTAIN|Wills Eye|No|Active, not recruiting|October 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|No|||June 2013|June 24, 2013|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710332||77465|
NCT01710345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP202|Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy|||AcelRx Pharmaceuticals, Inc.||Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|80 Years|No|||January 2015|January 23, 2015|October 17, 2012|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01710345||77464|
NCT01710358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13978|A Study in Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy|RA-BEAM|Eli Lilly and Company|Yes|Completed|October 2012|September 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1304|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710358||77463|
NCT01707316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100923|A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers|A Double-Blind, Randomized, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of JNJ-28431754 (Canagliflozin) in Healthy Chinese Subjects||Janssen Research & Development, LLC|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|October 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707316||77696|
NCT01715740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG1B0081|Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria|Study of the Effects of Antipruritic Chinese Herbal Medicine on Chronic Urticaria: a Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial.||Chang Gung Memorial Hospital|Yes|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 1, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715740||77052|
NCT01716000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038440|Optical Imaging and User Perception Study of Vaginal Gel|Optical Imaging and User Perception Study of Vaginal Gel||Duke University|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|56|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716000||77032|
NCT01716962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMF IRB 100-4473A3|Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome|Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome.||Chang Gung Memorial Hospital|No|Not yet recruiting|November 2012|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|mechanically ventilated ALL/ARDS patients conforming to the American European Consensus        Conference criteria with acute circulatory failure for whom the attending clinician had        decided to administer fluid will be enrolled.This decision was based on the presence of at        least one clinical sign of inadequate tissue perfusion in the absence of contraindication        for fluid infusion.|November 2012|November 30, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716962||76958|
NCT01716975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-016|Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy||FORUM Pharmaceuticals Inc|No|Active, not recruiting|October 2012|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|700|||Both|18 Years|50 Years|No|||June 2015|June 23, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716975||76957|
NCT01717287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-248|A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)|A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination With Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and Antiretroviral Activity in HIV-1 Infected Russian Children and Adolescents||Merck Sharp & Dohme Corp.|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|2 Years|17 Years|No|||June 2015|June 1, 2015|October 26, 2012|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT01717287||76933|
NCT01707121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physsurg|The Impact of Physical Activity on the Outcome of Surgery|The Impact of Physical Activity on the Outcome of Surgery||Sahlgrenska University Hospital, Sweden|No|Completed|December 2012|November 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients planned for a surgical procedure with a planned hospital stay of at least 1 day.|November 2015|November 18, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707121||77711|
NCT01707134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA/DCD/050|Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes|An Open-labelled, Controlled, Multicentre, Multinational, Extension Study Assessing Safety and Efficacy of the Human Insulin Analogue Insulin Aspart (X14) and Human Soluble Insulin as Meal Related Insulin in a Multiple Injection Regimen in Type 1 Diabetic Subjects||Novo Nordisk A/S|No|Completed|September 1997|May 2000|Actual|May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|753|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707134||77710|
NCT01707407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-CP-008|A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|DDI|Celgene|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|December 3, 2012|October 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707407||77689|
NCT01707667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD555-403|Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity|An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation||Shire||Completed|January 2013|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|75 Years|No|||October 2014|October 17, 2014|October 12, 2012|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01707667||77669|
NCT01707940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1313.7|Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of BI 144807 (Oral Solution) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Tablet) in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)||Boehringer Ingelheim||Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|October 15, 2012||||No||https://clinicaltrials.gov/show/NCT01707940||77648|
NCT01707953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074-OJ1|Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty|Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty - a Randomized, Placebo Controlled Trial.||Rigshospitalet, Denmark|Yes|Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01707953||77647|
NCT01707966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/11|Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy|Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy: a Multicenter Randomized Double-blind Placebo-controlled Phase III Trial.||Swiss Group for Clinical Cancer Research|Yes|Suspended|September 2012|December 2020|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Male|18 Years|N/A|No|||September 2014|September 2, 2014|September 13, 2012||No|Due to decision of Pharmaceuticals to discontinue the development support on orteronel    (TAK-700) in prostate cancer.|No||https://clinicaltrials.gov/show/NCT01707966||77646|
NCT01708265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39851.041.12.|The Dutch Asymptomatic Mitral Regurgitation Trial|Dutch AMR; Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation; a Multicenter, Randomised Trial.|Dutch AMR|UMC Utrecht|Yes|Recruiting|February 2013|February 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708265||77623|
NCT01712360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90200/1023/0|Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis|An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis||Merz Pharmaceuticals, LLC|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|65|||Both|12 Years|65 Years|No|||August 2014|August 1, 2014|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712360||77310|
NCT01712854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1932|Effects of Symbicort on the Ventilatory Kinematics|Investigating the Effects of Symbicort on the Ventilatory Kinematics in Patients With Obstructive Disease With Optoelectronic Plethysmography||Columbia University|No|Terminated|March 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|40 Years|75 Years|No|||April 2015|April 16, 2015|October 21, 2012|No|Yes|Closed by study sponsor; PI left the institution; responsible party changed to Columbia|No||https://clinicaltrials.gov/show/NCT01712854||77272|
NCT01712867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vayarol_006|The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels|The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels in Hypertriglyceridemia Patients: A Double-blind, Randomized, Noninferiority Trial||Enzymotec||Active, not recruiting|October 2012|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|N/A|No|||September 2012|August 6, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01712867||77271|
NCT01712594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP223|Safety and Effectiveness Study of a Closed Loop System Maintaining Patients' Glucose Levels During an Overnight Period|Feasibility and Safety of a Closed Loop Insulin Delivery System (Aka AAGC) With an Artificially Induced Calibration Error During the Overnight Period||Medtronic Diabetes|No|Completed|May 2013|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|70 Years|No|||May 2015|May 28, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712594||77292|
NCT01712607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Warm-Up-1.0|Preoperative Warm-up in Gynecologic Surgery|Preoperative Warm-up in Gynecologic Surgery Using a Virtual Reality Simulator.||Medical University of Vienna|No|Completed|October 2012|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 14, 2015|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712607||77291|
NCT01712828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CP-011|Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males|A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects||Celgene|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|31|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|February 12, 2013|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01712828||77274|
NCT01708486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-FLUSAL-EL-24|BALLOON (Corticosteroid/laBA inhaLers in adoLescents' Asthma: Assessment Of Patients satisfactiON) Study|Multicenter, Prospective, Non-interventional, Observational Study on Treatment of Asthma in Children.|BALLOON|Elpen Pharmaceutical Co. Inc.|No|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|35|||Both|12 Years|18 Years|No|Non-Probability Sample|180 asthmatic adolescents (60 per device) aged 12-18 years using their inhalation device        at least one month before study enrolment. This will be a real-life, regular clinical        practice assesment.|August 2014|August 18, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708486||77606|
NCT01704547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047123|Breast Cup Immobilization Device II (GCC 1047)|Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II|BCID II|University of Maryland|Yes|Recruiting|October 2012|December 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|No|Non-Probability Sample|Cancer Center, Primary Care Clinic|November 2015|November 30, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01704547||77908|
NCT01704807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-12-RD0519110317|Duration of Spinal Manipulation Effects as Influenced by Orthotics|Duration of Spinal Manipulation Effects as Influenced by Orthotics||Logan College of Chiropractic|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01704807||77888|
NCT01705665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-70-10|Histopathology of the Aspirated Thrombus During Acute Myocardial Infarction|||Hillel Yaffe Medical Center|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients admitted for an acute coronary syndrome who undergo angiography, found to have a        coronary thrombosis that is aspirated and which yields thrombus fragments.|October 2012|October 22, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705665||77823|
NCT01706250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114550|U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™|U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects With Acne||GlaxoSmithKline|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|29 Years|No|||July 2013|July 3, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706250||77778|
NCT01706822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVLARL0287|Radial Reload Laparoscopic LAR Case Series|Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series||Medtronic - MITG|No|Terminated|April 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|85 Years|No|||March 2015|March 17, 2015|October 11, 2012||No|Slow recruitment|No|February 13, 2015|https://clinicaltrials.gov/show/NCT01706822||77734|
NCT01706835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P1-PK-01|Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors|An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors||CytRx|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706835||77733|
NCT01706861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-302|A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision|A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid LEsions Treated Adjunctive to suRgical Excision. PMCS: EURO-KLEAR|EURO KLEAR|Halscion, Inc.|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|May 24, 2014|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01706861||77731|
NCT01707147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.104|A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus|A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)||Boehringer Ingelheim||Recruiting|November 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Probability Sample|Korean patients with T2DM|March 2016|March 16, 2016|October 1, 2012||||No||https://clinicaltrials.gov/show/NCT01707147||77709|
NCT01707160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA/DCD/031|Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers|A Randomised, Double-blind 2 Way Crossover Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Insulin X14 30/70 PreMix Compared to Human Insulin 30/70 PreMix in Healthy Volunteers||Novo Nordisk A/S|No|Completed|November 1995|December 1995|Actual|December 1995|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707160||77708|
NCT01707420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1687|Preoperative Gabapentin for Post-tonsillectomy Pain in Children|Preoperative Gabapentin for Reduction of Post-tonsillectomy Pain in Children||University of Colorado, Denver|No|Active, not recruiting|August 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|5 Years|16 Years|No|||January 2016|January 8, 2016|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707420||77688|
NCT01707680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005022|Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients|Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients|NICEWEAN|Orion Corporation, Orion Pharma|No|Recruiting|June 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Adult general intensive care patients Need of mechanical ventilation >24 hours Need of        light to moderate sedation|November 2012|November 1, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707680||77668|
NCT01707992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAQ-MS-305|The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod (0.6 mg/d or 1.2 mg/d) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|CONCERTO|Teva Pharmaceutical Industries|Yes|Active, not recruiting|February 2013|April 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2199|||Both|18 Years|55 Years|No|||March 2016|March 4, 2016|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707992||77644|
NCT01708278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM000061735|Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)|Phase I/II Study to Determine the Safety and Efficacy of Quercetin in COPD Patients|Quercetin|University of Michigan|Yes|Completed|February 2014|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|40 Years|80 Years|No|||January 2016|January 20, 2016|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708278||77622|
NCT01708291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMA 2-12213|HEALTHY (Health Education Adolescent Leadership Training to Help Youth) Leaders||HEALTHY|University of Rochester|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|September 4, 2012||No||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01708291||77621|
NCT01708837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSDIPR0003|Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction|Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction : A Multi-Center Study||Xiangya Hospital of Central South University|Yes|Active, not recruiting|October 2012|June 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|50 Years|70 Years|No|||October 2012|May 29, 2013|October 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01708837||77579|
NCT01712633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130003|Tests of Functional Magnetic Resonance Imaging Techniques|Imaging Techniques in fMRI and fMRI Reproducibility: An NIH/FDA Interagency Collaboration||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712633||77289|
NCT01713153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.9|Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal||Gynuity Health Projects|Yes|Completed|June 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1365|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713153||77250|
NCT01713166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_crystalloid vs colloid|Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery|||Seoul National University Hospital|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|N/A|No|||June 2015|June 7, 2015|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01713166||77249|
NCT01713179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-63|Effects of Oral Mucolytics on Tear Film and Ocular Surface|||Hallym University Medical Center|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|20|||Male|25 Years|29 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713179||77248|
NCT01713140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2012_2013|Experimental Study of Strength Training to Activate the Quadriceps Muscle After Total Knee Arthroplasty|Central (CNS) Activation of the Quadriceps Muscle During Strength Training With Repetitions to Contraction Failure After Total Knee Arthroplasty||Copenhagen University Hospital, Hvidovre|Yes|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|80 Years|No|||June 2013|June 24, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713140||77251|
NCT01704248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440/2555 (EC4)|The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients|The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients.||Mahidol University|No|Recruiting|October 2012|April 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704248||77931|
NCT01705093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333071 (UC Davis - IRB)|The Effects of California Strawberries on Parameters of Cardiovascular Health|The Effects of California Strawberries on Parameters of Cardiovascular Health||University of California, Davis|No|Not yet recruiting|February 2013|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|25|||Male|14 Years|18 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01705093||77867|
NCT01705405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 12 06|Merging of Endoscopic and Ultrasound Images for Laparoscopic Surgery|Merging of Endoscopic and Ultrasound Images for Laparoscopic Surgery|FEE|University Hospital, Grenoble|Yes|Suspended|October 2012|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Male|18 Years|90 Years|No|||June 2015|June 18, 2015|October 5, 2012||No|due to a problem of device|No||https://clinicaltrials.gov/show/NCT01705405||77843|
NCT01705964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caperell-Epi-001|Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation|Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation||University of Louisville|No|Recruiting|June 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|6 Years|17 Years|No|||December 2015|December 4, 2015|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705964||77800|
NCT01706263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114551|U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne|U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne||GlaxoSmithKline|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|16 Years|29 Years|No|||October 2012|October 11, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706263||77777|
NCT01705951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19KT-0028|Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk|Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk|START|University of California, Los Angeles|No|Recruiting|April 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01705951||77801|
NCT01706237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVS-SOVR-001|Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens|Evaluation Of Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens||Durrie Vision|No|Withdrawn|May 2012|||June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 3, 2014|October 11, 2012|Yes|Yes|Nexis Vision was unable to provide the shields to continue with the study.|No||https://clinicaltrials.gov/show/NCT01706237||77779|
NCT01706523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209AS209|Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders||Seaside Therapeutics, Inc.|Yes|Terminated|November 2011|July 2013|Anticipated|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|5 Years|21 Years|No|||July 2013|July 30, 2013|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706523||77757|
NCT01706510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0076|Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients|A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease||Rapid City Regional Hospital, Inc|No|Completed|December 2012|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706510||77758|
NCT01706848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-0297|Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound|A Post Market Clinical Study Evaluating the Safety, Device Performance and Possible Emergent Risks of Celotres in the Improvement of Wound Healing and the Resulting Scar Consequences Following Suturing of a Wound|PMCS EURO HEAL|Halscion, Inc.|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|May 24, 2014|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01706848||77732|
NCT01707173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 HD064770-01A1|Improving the Self-Efficacy of African American Parents in Infant Supine Sleep|Improving the Self-Efficacy of African American Parents in Infant Supine Sleep|PrAAIS|University of Michigan|Yes|Active, not recruiting|October 2012|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|735|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707173||77707|
NCT01707186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010930|Pictorial Representation of Illness and Self Measure|Pictorial Representation of Illness and Self Measure|PRISM|University of Oxford|No|Active, not recruiting|October 2012|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|220|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with rheumatoid arthritis from hospital clinics|December 2015|December 8, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707186||77706|
NCT01707433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSHIP|Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease|Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease||Children's Hospitals and Clinics of Minnesota|No|Completed|October 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|22|||Both|N/A|21 Years|No|Non-Probability Sample|Males/females less than or equal to 21 years of age who have been seen at Gillette        Children's Specialty Healthcare or Children's Hospitals and Clinics of Minnesota and carry        a diagnosis of spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral        Legg-Calve-Perthes disease or bilateral proximal femoral epiphyseal dysplasia.|July 2015|July 31, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707433||77687|
NCT01707693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135603|A Lifestyle Physical Activity Intervention for Older Sedentary Women|A Lifestyle Physical Activity Intervention for Older Sedentary Women||University of Arkansas|Yes|Completed|April 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|144|||Female|60 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707693||77667|
NCT01707979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIR|NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes|NIR (Near Infrared)- Spectroscopy and Multifrequent Impedance Spectroscopy on the Skin to Detection of Sensory and Autonomic Neuropathy Among Patients With Type 1 Diabetes|NIR|Steno Diabetes Center|Yes|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|30|||Male|35 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control group men without diabetes Type1 diabetic men without neuropathy complications        Type 1 diabetic men with neuropathy complications|October 2012|October 15, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01707979||77645|
NCT01708330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0039|The Effect of Topical Lidocaine on Pain Scores During Manual Vacuum Aspiration for Nonviable Pregnancies|||Bridgeport Hospital|No|Active, not recruiting|October 2012|||July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||July 2015|July 20, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708330||77618|
NCT01708304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41906-D|Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)|From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services|RDAD|University of Washington|Yes|Active, not recruiting|November 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|510|||Both|65 Years|N/A|No|||March 2016|March 16, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708304||77620|
NCT01708317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110243|Computer-Assisted Self-Interviews and Health Screening in the Pediatric Emergency Department|The Use of Computer-Assisted Self-Interviews to Improve Adolescent and Young Adult Health Screening in the Pediatric Emergency Department||Washington University School of Medicine|No|Completed|April 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|801|||Both|15 Years|21 Years|No|||December 2012|December 4, 2012|October 9, 2012||No||No|October 17, 2012|https://clinicaltrials.gov/show/NCT01708317||77619|
NCT01708863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002887|A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation|A PROSPECTIVE STUDY OF PATIENTS WITH HYPOPLASTIC LEFT HEART SYNDROME FOLLOWING STAGE II SURGICAL PALLIATION||Mayo Clinic|No|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|18 Months|No|Non-Probability Sample|Children with HLHS up to 18 months of age requiring a planned Stage II bi-directional        Glenn surgery|March 2016|March 11, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708863||77577|
NCT01712880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12055|Treatment of Acute Periprosthetic Total Hip Arthroplasty Infections|The Treatment of the Acute Periprosthetic Hip Infection After Uncemented Total Hip Arthroplasty: A Randomized Study Comparing Open Debridement Component Retention (ODCR) With Modular Exchange Versus One Stage Exchange Arthroplasty||OrthoCarolina Research Institute, Inc.|Yes|Withdrawn|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|October 22, 2012||No|The study was not feasible.|No||https://clinicaltrials.gov/show/NCT01712880||77270|
NCT01713192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_Registry|Registry for Perioperative Data in Patients Undergoing Cardiac Surgery|||Seoul National University Hospital|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|20 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery|November 2015|November 16, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713192||77247|
NCT01708785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120431|Learning Theory to Improve Obesity Treatment|Learning Theory to Improve Obesity Treatment (Intervention for Regulation of Cues)|iROC|University of California, San Diego|Yes|Recruiting|October 2012|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|13||Anticipated|230|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708785||77583|
NCT01704820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retro-View|Right Sided Colon Polyp Miss Rate: Impact Of Retroflexion In The Right Colon|RIGHT SIDED COLON POLYP MISS RATE: IMPACT OF RETROFLEXION IN THE RIGHT COLON||Washington University School of Medicine|Yes|Recruiting|September 2012|November 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|1020|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704820||77887|
NCT01705106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1318|Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies|A Drug-drug Interaction Study of Capecitabine and Celecoxib in Patients With Advanced Solid Malignancies||University of Chicago|No|Active, not recruiting|August 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705106||77866|
NCT01705418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12PHR02|Behavior Addictions Improvement in Parkinson Disease's Patients Treated by Subthalamic Stimulation : Long Term Follow-up|Behavior Addictions Improvement in Parkinson Disease's Patients Treated by|PDdicted|University Hospital, Grenoble|No|Completed|November 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|N/A|N/A|No|Non-Probability Sample|Parkinson's desesase patients included in another protocol evaluating Apathy after deep        brain stimulation.|October 2012|March 8, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705418||77842|
NCT01705678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO-001|Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease|An Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease in Males With Metabolic Syndrome||Liverpool John Moores University|No|Completed|May 2009|March 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|19|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01705678||77822|
NCT01705977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115467|Belimumab Assessment of Safety in SLE|A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab|BASE|GlaxoSmithKline|Yes|Recruiting|November 2012|January 2023|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5000|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01705977||77799|
NCT01706276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20120902|MASIMO Radical 7 and Laboratory Measurement|||Huazhong University of Science and Technology|Yes|Completed|March 2012|July 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|225|||Both|18 Years|75 Years|No|Probability Sample|Adult patients, American Society of Anesthesiologists Physical Status Ⅰor Ⅱ, scheduled for        potentially hemorrhagic major hepatic resection under general anesthesia and requiring an        arterial line|November 2013|November 19, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706276||77776|
NCT01706536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-101-04|A Study of the Efficacy and Safety of EP-101 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|GOLDEN-2|Sunovion Respiratory Development Inc.|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|275|||Both|35 Years|75 Years|No|||May 2014|May 14, 2014|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706536||77756|
NCT01706874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011- AO1271 - 40|Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.|Assessment of the Effect of an Intervention (Periodontal Scaling + Mouthwash + Toothpaste) to Reduce the Load on Oral Bacterial Activity of Rheumatoid Arthritis: a Randomized Trial Nested in the Cohort ESPOIR|BHYRRA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2012|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|92|Samples Without DNA|Biospecimen: gingival fluid      A first sampling will take place at T0 and the second at Month 12 (test end).      A bacterial sampling at 4 deepest periodontal pockets will be carried. It will quantify the      9 following bacteria:      Aggregatibacter actinomycetemcomitans Porphyromonas gingivalis Prevotella intermedia      Tannerella forsythensis Treponema denticola Peptostreptococcus micros Fusobacterium      nucleatum Eikenella corrodens Campylobacter rectus|Both|18 Years|80 Years|No|Probability Sample|Population selected from the ESPOIR early arthritis Cohort|April 2015|April 20, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01706874||77730|
NCT01706887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060215|Genetic Determinant of Blood Pressure Sensitivity to Salt Intake|Clinical, Pharmacological and Biological Investigations of a Polymorphism of Nedd4 , a Regulatory Protein of the Epithelial Sodium Channel|JEU004|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|April 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|219|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|October 12, 2012|April 27, 2012||No|end of recruitment period was reach|No||https://clinicaltrials.gov/show/NCT01706887||77729|
NCT01707199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPK|SPK Study in Afghanistan|Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan||University of Oxford|No|Recruiting|October 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|4 Months|N/A|No|||August 2013|August 27, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707199||77705|
NCT01707719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERASE|Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's Disease|Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Patients Affected by Alzheimer's Disease and Healthy Controls||Campus Bio-Medico University|Yes|Not yet recruiting|October 2012|October 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Whole blood|Both|50 Years|N/A|No|Probability Sample|Patients meeting NINCDS-ADRDA criteria for Alzheimer's disease and age- / sex-matched        elderly subjects without dementia, will be recruited from those referring neurologists or        geriatricians on an outpatient basis|October 2012|October 15, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01707719||77665|
NCT01707706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUP-004|Acupuncture for Persistent Insomnia Associated With Major Depressive Disorder|A Randomized Controlled Trial of Electroacupuncture for Persistent Insomnia Symptoms Associated With Major Depressive Disorder||The University of Hong Kong|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01707706||77666|
NCT01708590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120102|Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1|AMAGINE-1|Amgen|Yes|Terminated|August 2012|August 2015|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|661|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|September 10, 2012|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01708590||77598|
NCT01708876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-12-89-11005|P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine|Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia|ACT KNOW|Menzies School of Health Research|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|1 Year|N/A|No|||April 2015|April 7, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708876||77576|
NCT01709097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011/471-31/4|Compliance/Adherence After Kidney Transplant, With or With Out Med-O-Wheel™.|Compliance/Adherence After Kidney Transplant, With or With Out an Electronic Drug Dispenser(Med-O-Wheel™), Karolinska University Hospital.|C/A|Karolinska University Hospital|Yes|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|N/A|N/A|No|Probability Sample|Kidney Transplant Recipients in Karolinska University Hospital|August 2013|August 30, 2013|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709097||77559|
NCT01713205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jiang-2012BAI11B01|Prediction Study of Complications After Severe Trauma|Identifying Severe Trauma Patients at High Risk of Post-traumatic Complications|PSCAT|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|whole blood, serum, white cells, urine and tissue|Both|18 Years|65 Years|No|Probability Sample|Adult severe trauma patients with no serious co-morbidity|October 2012|October 22, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713205||77246|
NCT01708798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00185|Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer|A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer||University of British Columbia|Yes|Recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|78|||Female|18 Years|N/A|No|||January 2015|January 6, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708798||77582|
NCT01705119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1773|The Effects of Vertical Position on Gas Exchange in Patients With Respiratory Failure|The Effects of Vertical Position on Gas Exchange in Patients With Respiratory Failure||University of Chicago|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01705119||77865|
NCT01705431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IES R324A110370|Students, Parents, and Teachers On Track: Intervention Development for Youth With Emotional Disturbance|Students, Parents, and Teachers On Track: Intervention Development for Youth With Emotional Disturbance|OnTrack|Oregon Social Learning Center|No|Completed|October 2011|November 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|10 Years|15 Years|No|||December 2015|December 10, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705431||77841|
NCT01705444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-11-541|The Spanner Prostatic Stent and Patient's Quality of Life|The Impact of the Temporary Stent on Parameters of Voiding Function and on the Quality of Life Among Patients With LUTS|SpannerQoL|Princess Al-Johara Al-Ibrahim Cancer Research Center|Yes|Suspended|March 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Male|45 Years|85 Years|No|||October 2012|April 30, 2015|October 9, 2012||No|logistic problems|No||https://clinicaltrials.gov/show/NCT01705444||77840|
NCT01705691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-9|Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer|A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer||NSABP Foundation Inc|No|Completed|September 2012|October 2015|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01705691||77821|
NCT01706302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116357|Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009|Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009||GlaxoSmithKline||Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|Subjects included in the 116273 study who were registered with an acceptable flag in the        CPRD, or with a potentially RSV-related event in the HES database or the ONS mortality        data.|April 2013|April 25, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706302||77774|
NCT01706315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116778|This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects|A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)||GlaxoSmithKline|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|12||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|October 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706315||77773|
NCT01706289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH20090323HRV|The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy|The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy||National Taiwan University Hospital|No|Recruiting|March 2009|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|whole blood|Both|10 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|type 2 diabetes mellitus|September 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706289||77775|
NCT01706913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermFound-2008A058574|Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis|A Randomized Controlled Study to Assess the Impact of Dermatology Consultations on the Hospital Course of Patients Admitted for Cellulitis||Massachusetts General Hospital|No|Recruiting|October 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|248|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01706913||77727|
NCT01706900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbnSina Hospital|Incubator Temperature for Culturing Human Embryos|Incubator Temperature for Culturing Human Embryos||Ibn Sina Hospital|Yes|Recruiting|November 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|280|||Female|18 Years|33 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706900||77728|
NCT01707446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0650-A|Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery|Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery||University Health Network, Toronto|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|266|||Both|60 Years|N/A|No|||April 2015|April 23, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01707446||77686|
NCT01707732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/056/HP|Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin|Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin|ITOHENOX|University Hospital, Rouen|No|Completed|November 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707732||77664|
NCT01707745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avastin for threshold ROP.|Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.|||Dubai Health Authority|Yes|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|32 Weeks|42 Weeks|No|||October 2012|October 15, 2012|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01707745||77663|
NCT01708031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAT STRESS|Computerized Mental Arthimetic Task Based Human Stress Level Detection Using Physiological Signal|Computerized Mental Arthimetic Task Based Human Stress Level Detection Using Physiological Signal|UNIMAP|Universiti Malaysia Perlis|Yes|Enrolling by invitation|October 2011|December 2014|Anticipated|April 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Anticipated|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01708031||77641|
NCT01708044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5570C00001|Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM|A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycemic Control in Subjects With Type 1 Diabetes Mellitus||AstraZeneca|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|70 Years|No|||October 2014|October 17, 2014|October 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01708044||77640|
NCT01708005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00453-40|DIetary Supplements, Executive funcTions and Vitamin D (DIET-D)|DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial|DIET-D|University Hospital, Angers|Yes|Enrolling by invitation|November 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|60 Years|N/A|No|||October 2012|October 15, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708005||77643|
NCT01708018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058/12|Effects of Relaxing Hydrotherapy in Third Trimester of Pregnancy|Pilot Study: Effects of Relaxing Hydrotherapy WATSU in Third Trimester of Pregnancy, an Explorative Cohort-Study||University Hospital Inselspital, Berne|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 9, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01708018||77642|
NCT01708343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS-DIMS|Paraspinal Stimulation in Treating MPS|Paraspinal Stimulation Combined With Trigger Point Needling and Needle Rotation in Treating Myofascial Pain: Randomized Sham-controlled Clinical Trial|DIMMST|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|January 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Female|19 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708343||77617|
NCT01708356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00902|Cycling, Air Pollution and Health|Cycling, Air Pollution and Health|CAPaH|University of British Columbia||Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|19 Years|39 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01708356||77616|
NCT01709162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-243|Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma|A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment Versus Chemotherapy for Subjects With Advanced Melanoma Who Progressed After Initially Achieving Disease Control With Ipilimumab Therapy||Bristol-Myers Squibb|No|Terminated|March 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||September 2015|October 27, 2015|October 12, 2012|Yes|Yes|Discontinued early due to enrollment challenges and changes in treatment standards|No|September 17, 2015|https://clinicaltrials.gov/show/NCT01709162||77554|As planned, accrual of participants was to be completed within 21 months. However, current projections showed that 4 to 5 years were needed. The study was terminated early because the scientific objective could not be met in the predefined timeframe.
NCT01709461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 06 - 12|Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial|Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial||Rabin Medical Center|No|Not yet recruiting|October 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|30 Years|80 Years|No|Non-Probability Sample|subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving        Rasgiline Mesylate.|June 2012|October 16, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01709461||77531|
NCT01709084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100875|A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment|A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF)|SALIF|Janssen-Cilag International NV|Yes|Active, not recruiting|October 2013|October 2018|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|427|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709084||77560|
NCT01704859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002005|Vitamin D and Omega-3 Fatty Acids (VITAL Trial): Effects on Fractures|Vitamin D and Omega-3 Fatty Acids (VITAL Trial): Effects on Fractures||Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704859||77884|
NCT01704872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOPENRNET001|ch14.18/CHO Bridging Study|Bridging Study Using ch14.18/CHO Antibody in Children With Refractory Neuroblastoma||St. Anna Kinderkrebsforschung|No|Completed|July 2005|March 2012|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|1 Year|21 Years|No|||October 2012|October 11, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704872||77883|
NCT01705132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205M13905|Urinary Biomarkers of the Progression of Alport Kidney Disease|Urinary Biomarkers of the Progression of Alport Kidney Disease||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2012|July 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Subjects submit first morning urine. Portion of urine retained for ASTOR repository.|Both|5 Years|65 Years|No|Probability Sample|The study population will be comprised of male and female subjects ≥ 5 years of age, with        or without existing Alport genotyping, regardless of specific genotype, and who meet all        other eligibility criteria. Subjects with existing Alport genotyping are preferred. Alport        subjects will be enrolled via ASTOR, and healthy volunteers will be enrolled elsewhere,        outside the scope of this protocol. Approximately 80 Alport syndrome subjects will be        enrolled in this study. Of the 80 subjects, 75% (N = 60) should have non-postural,        non-nephrotic proteinuria (defined as spot urine protein-to-creatinine ratio < 3 on at        least 2 of the last 3 clinical assessments).|July 2013|July 26, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01705132||77864|
NCT01705457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-03-161-19476|Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis|Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients|RAR|Tehran University of Medical Sciences|Yes|Enrolling by invitation|February 2010|August 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|45 Years|No|||October 2012|October 11, 2012|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01705457||77839|
NCT01705704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV28333|A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B|An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys ± Lamivudine.||Hoffmann-La Roche||Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|269|||Both|18 Years|N/A|No|Probability Sample|Stored serum samples obtained from patients with chronic hepatitis B, who have completed        therapy with Pegasys +/- lamivudine.|March 2016|March 1, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705704||77820|
NCT01705717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25436|A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C|Treatment Outcomes in the Management of Patients With Chronic Hepatitis C: A Case Study of Faculty of Medicine Vajira Hospital, University of Bangkok Metropolis||Hoffmann-La Roche||Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|49|||Both|18 Years|N/A|No|Probability Sample|Retrospective survey of medical records of patients with chronic hepatitis C|January 2015|January 5, 2015|October 10, 2012||No||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01705717||77819|
NCT01706328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116974|A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|828|||Both|40 Years|N/A|No|||April 2014|July 24, 2014|October 11, 2012|Yes|Yes||No|January 23, 2014|https://clinicaltrials.gov/show/NCT01706328||77772|
NCT01706549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11190|Clinical Analysis of Pain After Hysterectomy|Chronic Pain After Hysterectomy, Qualitative Analysis of Pain and Its Impact on Quality of Life||Tampere University Hospital|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Female|18 Years|69 Years|No|Non-Probability Sample|Women undergone hysterectomy for 1-3 years previously and suffering from persistent pain 6        months after surgery. The patients are invited to participate in this study, if they have        participated in previous studies "Sevoflurane, Propofol, Postoperative pain" by        Yli-Hankala and Pokkinen and study:" Vaginal hysterectomy, laparoscopic hysterectomy,        postoperative pain" by Yli-Hankala and Pokkinen.|June 2015|June 1, 2015|October 10, 2012||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01706549||77755|Low participation rate. Inadequate filling of questionnaires. Time from surgery to clinical examination varied from 10 to 44 months. No preoperative quality of life measure.
NCT01706926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-CAM-3001-1071|A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis|A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis||MedImmune LLC|Yes|Completed|August 2012|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|422|||Both|18 Years|80 Years|No|||August 2014|August 15, 2014|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706926||77726|
NCT01707212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0134-E|Prenatal Education About Infant Immunization Pain Management|A Prenatal Education Module for Parents to Improve the Use of Pain-management Strategies for Immunization in Two-month Old Infants: a Randomized Controlled Trial of Knowledge Translation||University of Toronto|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Female|16 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 26, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707212||77704|
NCT01707459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN090090BE|The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery|The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery||University Health Network, Toronto|No|Completed|March 2010|August 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|Samples With DNA|TEG-PMA and gene polymorphism analysis on blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have coronary stents and undergoing non-cardiac surgery|June 2015|June 17, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01707459||77685|
NCT01707472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0107|A Phase 2a Study of Simtuzumab in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis|A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis||Gilead Sciences|No|Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707472||77684|
NCT01707758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13421|Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence||University of Kansas Medical Center|Yes|Withdrawn|October 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Approximately 1 tablespoon of blood will be collected from each subject.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the University of Kansas Cancer Center prior to any        treatment for their pancreatic cancer. Final histology and staging will be recorded and        correlated with protease concnentration. Healthy subjects will be recruited from the        University of Kansas and Kansas State community.|May 2013|May 15, 2013|October 12, 2012||No|Trial terminated - Nanoscale Company out of business|No||https://clinicaltrials.gov/show/NCT01707758||77662|
NCT01708057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00007|A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomised, Double-blind Placebo- and Active-controlled, Multi-centre, 6-way Cross-over, Single-dose Phase IIa Study to Investigate the Bronchodilatory and Systemic Effects of 4 Different Doses of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca||Terminated|October 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|3|||Both|40 Years|N/A|No|||December 2013|December 13, 2013|October 1, 2012|Yes|Yes||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01708057||77639|
NCT01708369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15GM096074|Alcohol Inhibits Drug Metabolism by Carboxylesterases|Inhibition of Carboxylesterase Metabolism by Ethanol||University of Tennessee|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|19|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01708369||77615|
NCT01708616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28318|A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers|A Single-center, Randomized, Double-blind, Two-period Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Subjects||Hoffmann-La Roche||Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator)|4||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708616||77596|
NCT01700088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|541/2555(EC2)|The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy|The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient||Mahidol University|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patient undergoing lung resection surgery.|December 2015|December 10, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700088||78251|
NCT01708850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catheter 2|Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)|A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)||London Health Sciences Centre|No|Active, not recruiting|November 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708850||77578|
NCT01709383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF 2012062|Using Transcranial Direct Current Stimulation (tDCS) to Improve Post-Stroke Aphasia|Can Enhancing Left Lateralization Using Transcranial Direct Current Stimulation Improve Recovery From Post-Stroke Aphasia?||Georgetown University|No|Completed|December 2012|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709383||77537|
NCT01709396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011064-01|ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS|Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome|ED-TBI|Ottawa Hospital Research Institute|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||October 2014|October 14, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709396||77536|
NCT01704885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Z11|A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer|A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer: A Pilot Study||Case Comprehensive Cancer Center|Yes|Terminated|September 2011|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|5|||Both|4 Years|10 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|October 9, 2012||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01704885||77882|
NCT01705470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHERLOCK|Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2012|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705470||77838|
NCT01705730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28269|A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy|Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy||Hoffmann-La Roche||Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra in        monotherapy|March 2016|March 1, 2016|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705730||77818|
NCT01705990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI S001|Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers|A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers||International AIDS Vaccine Initiative|Yes|Completed|March 2013|||March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|65|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705990||77798|
NCT01706341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCU-573|The Effect of Administering a Small Dose of Glucose During Cesarean Section|The Effect of Administering a Small Dose of Glucose on the Pregnant Women and Their Neonates During Cesarean Section||Nagoya City University|Yes|Recruiting|October 2012|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|40 Years|No|||October 2012|October 11, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01706341||77771|
NCT01706575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28262|A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression|A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression||Hoffmann-La Roche||Completed|April 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706575||77753|
NCT01706562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017839|A Study of Empirical Antifungal Therapy With Itraconazole|Retrospective Observation of Empirical Antifungal Therapy With Itraconazole||Janssen Korea, Ltd., Korea||Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|138|||Both|20 Years|N/A|No|Non-Probability Sample|Study population consists of patients with hematologic malignancy who visited a study        center and were treated with itraconazole intravenous (IV) for more than 7 days.|February 2013|February 18, 2013|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706562||77754|
NCT01706588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12UK/DCsc04|Injectable Diclofenac for the Prevention of Post-operative Dental Pain|Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery|DP4|IBSA Institut Biochimique SA|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|65 Years|No|||August 2014|August 28, 2014|October 1, 2012||No||No|August 13, 2014|https://clinicaltrials.gov/show/NCT01706588||77752|
NCT01706939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1050|The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer|The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2012|June 2021|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|365|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706939||77725|
NCT01706952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-251-SDR|Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery|Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery: Cocaine Versus Adrenaline||McGill University Health Center|No|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|45|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01706952||77724|
NCT01707225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14516|Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)|Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI)||Virginia Commonwealth University|Yes|Completed|February 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 11, 2012|No|Yes||No|December 7, 2015|https://clinicaltrials.gov/show/NCT01707225||77703|
NCT01707485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-12303|Duration of Antimicrobial Therapy for Paediatric Pneumonia|Short Course Antimicrobial Therapy for Paediatric Community-Acquired Pneumonia: A Pilot Study||Hamilton Health Sciences Corporation|No|Completed|November 2012|May 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|1 Year|10 Years|No|||March 2015|March 4, 2015|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707485||77683|
NCT01708070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 098240|Trial of Asthma Self-Management Education in Patients With Depressive Symptoms|Trial of Asthma Self-Management Education in Patients With Depressive Symptoms||Hospital for Special Surgery, New York|Yes|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|66|||Both|18 Years|85 Years|No|||April 2015|April 7, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708070||77638|
NCT01708395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMICADEIBD4007|IBD-OPERA Database, UC Protocol|IBD-OPERA Database: Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment Database|OPERA|Dartmouth-Hitchcock Medical Center|No|Completed|October 2012|June 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Adults over 18 years of age|August 2015|August 14, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708395||77613|
NCT01708382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-108|Feasibility Study: Lifting and Tightening of the Elbows|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Elbow Tissue - A Feasibility Study||Ulthera, Inc|No|Completed|September 2011|February 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708382||77614|
NCT01708629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120104|Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3|AMAGINE-3|Amgen|Yes|Terminated|September 2012|October 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1881|||Both|18 Years|75 Years|No|||November 2015|November 20, 2015|September 21, 2012|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01708629||77595|
NCT01700101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20123|MelaFind Evaluations for Patients With Multiple Nevi|MelaFind Evaluations for Patients With Multiple Nevi||MELA Sciences, Inc.|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have at least one lesion that meets the inclusion/exclusion criteria (see        eligibility criteria below) AND each lesion enrolled must be clinically atypical (i.e.,        contain at least one of the following ABCDEPRU characteristics: Asymmetry, Border        irregularity, Color variegation, Diameter < 6 mm, Evolving, Patient's concern, Regression,        Ugly duckling).        Lesions should be selected to have characteristics that may affect the repeatability of        lesion scores: anatomic site (often exposed to UV - sun or tanning beds - or not;        sun-damage may affect the repeatability); lesion diameter (6 mm, e.g. ~5 mm or > 6 mm,        e.g., 10 mm); and melanin content relative to normal skin (dark pigmentation or light        pigmentation).        A maximum of 8 lesions may be enrolled per patient|August 2014|August 25, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700101||78250|
NCT01709136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07100379|Pharmacokinectics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity|Pharmacokinectics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Early Nephrotoxicity and/or Hypertension Due to Tacrolimus|Sirolimus|University of Pittsburgh|Yes|Terminated|December 2005|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2011|October 16, 2012|June 29, 2010||No|Sirolimus usage discontinued since black box warning|No||https://clinicaltrials.gov/show/NCT01709136||77556|
NCT01709110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14536|VERtebral Fracture Treatment Comparisons in Osteoporotic Women|Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures|VERO|Eli Lilly and Company|No|Active, not recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1340|||Female|45 Years|N/A|No|||August 2015|August 17, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709110||77558|
NCT01709123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-08-028|Effects of Micronutrient (Chromium) Supplementation on Diabetes|Ketosis, Vascular Inflammation, and Its Therapy (Chromium Supplementation) in Diabetic Patients||Louisiana State University Health Sciences Center Shreveport|Yes|Recruiting|August 2007|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|8 Years|21 Years|No|||October 2012|October 29, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709123||77557|
NCT01705145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-770-108|Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation|A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation||Vertex Pharmaceuticals Incorporated|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|2 Years|5 Years|No|||April 2015|April 23, 2015|October 8, 2012|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01705145||77863|
NCT01705158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCA (GINECO-OV220)|Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum|Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum|MYCA|ARCAGY/ GINECO GROUP|No|Active, not recruiting|October 2012|June 2016|Anticipated|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Female|18 Years|N/A|No|||October 2015|October 22, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01705158||77862|
NCT01705171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGP1345012|Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?|Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?||Brain-Gut Research Group|No|Completed|December 2011|October 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Patients referred to our practice for evaluation of symptoms consistent with FGID        undergoing upper GI endoscopy with biopsy and fructose breath testing as part of their        usual clinical evaluation.|March 2014|March 10, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705171||77861|
NCT01705483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9853-CL-0101|A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies||Astellas Pharma Inc|No|Terminated|August 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 10, 2012|No|Yes|Based on the results of the Phase 1 data, the company decided not to pursue the development of    this drug at this time.|No||https://clinicaltrials.gov/show/NCT01705483||77837|
NCT01705743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20120903|Minimum Alveolar Concentration of Sevoflurane With Nitrous Oxide Inducing Isoelectric EEG|Minimum Alveolar Concentration of Sevoflurane With 60% Nitrous Oxide Inducing Isoelectric EEG in Mid-aged Adults||Huazhong University of Science and Technology|Yes|Completed|September 2012|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|45 Years|64 Years|No|||February 2014|February 3, 2014|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705743||77817|
NCT01706003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK0974-071-00|The Utility of Telemedicine in the Management of Migraine|The Utility of Telemedicine in the Management of Migraine: A Pilot Study :MK0974-071-00||University of Texas Southwestern Medical Center|No|Enrolling by invitation|October 2012|April 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|46|||Both|18 Years|89 Years|No|Probability Sample|Patients must be diagnosed with Migraine Headaches|October 2012|October 18, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706003||77797|
NCT01706016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00448-35|Local Treatment by Thermic Destruction of Primitive Breast Cancer|Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.|LASERBREAST1|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|80 Years|No|||October 2015|October 20, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706016||77796|
NCT01706614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-565/2011|Biochemical and Genetic Markers in Liver Diseases|Biochemical and Genetic Markers in Liver Diseases||University Hospital Heidelberg||Recruiting|April 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|patients with liver disease seen at department of Gastroenterology, University Hospital        Heidelberg|October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706614||77750|
NCT01710943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA020181|Web-based CBT for Recent Veterans Experiencing Problems With Trauma Symptoms or Alcohol/Drug Use|Web-based CBT for Substance Misusing and PTSD Symptomatic OEF/OIF Veterans|Web CBT|National Development and Research Institutes, Inc.|No|Recruiting|September 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01710943||77419|
NCT01706601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1108-31/1|Patients With Hemorrhoids Referred to a Surgical Specialist Department|Patients With Hemorrhoids Referred to a Surgical Specialist Department||Karolinska Institutet|No|Active, not recruiting|February 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|90 Years|No|Probability Sample|Patients whith hemorrhoids|March 2015|March 9, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706601||77751|
NCT01707251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_436|Intravenous Ibuprofen for Laparoscopic Bariatric Surgery|Intravenous Ibuprofen for Laparoscopic Bariatric Surgery||Jacobi Medical Center|Yes|Completed|October 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707251||77701|
NCT01707238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-39|Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses|Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses||Coopervision, Inc.|Yes|Completed|October 2012|March 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Both|16 Years|45 Years|No|||August 2014|August 25, 2014|September 21, 2012|Yes|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT01707238||77702|
NCT01707771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL-2008|Bariatric Surgery and HDL-cholesterol|Effect of Gastric Bypass Versus Diet on Cardiovascular Risk Factors||Catholic University of the Sacred Heart|No|Completed|September 2008|September 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|60 Years|No|||October 2012|October 15, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01707771||77661|
NCT01712737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Raisins_part1_UofT|The Effects of Ad Libitum Pre-Meal Raisin Snack on Satiety and Food Intake in Children|The Effects of Ad Libitum Pre-Meal Raisin Snack on Satiety and Food Intake in Children||University of Toronto|No|Completed|January 2011|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|26|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712737||77281|
NCT01713010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11212PSC002|Study of Variables Related to the Discontinuation of Mechanical Ventilation in Patients With Head Injury|Evaluation of Integrated Predictive Index of Weaning From Mechanical Ventilation in Patients With Traumatic Brain Injury|INDEXTBI|Federal University of Uberlandia|Yes|Recruiting|March 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the intensive care unit with brain trauma in the process of weaning        from mechanical ventilation.|October 2012|October 24, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713010||77261|
NCT01713322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-195C|Testing Educational Materials in a Paediatric Setting|Testing Educational Materials About Immunizations in a Paediatric Setting||University of Toronto|No|Recruiting|November 2012|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 21, 2012|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01713322||77237|
NCT01708642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074-OJ2|The Effect of Administration of Low Dose Adrenaline During Surgery on Bleeding During Hip Surgery|The Effect of Intraoperative Low Dose Adrenaline on Bleeding in Total Hip Arthroplasty - a Randomized Placebo-controlled Trial||Rigshospitalet, Denmark|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708642||77594|
NCT01704430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAZ_CVICU_001|Glutamine to Improve Outcomes in Cardiac Surgery|GLutamine Enterally After carDiac Surgery for Inflammation Attenuation and ouTcOme impRovement (GLADIATOR): A Phase II Randomized, Blinded, Placebo-Controlled Trial|GLADIATOR|University of Alberta|No|Recruiting|September 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01704430||77917|
NCT01700660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_238|Reperfusion-induced Self-antigen Excretion Following Major Liver Surgery|Reperfusion-induced Self-antigen Excretion Following Major Liver Surgery|RISE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples With DNA|2 liver biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with a malignant or benign hepatic tumor that are scheduled for a liver        resection.|January 2016|January 25, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01700660||78207|
NCT01709149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4026|Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)|A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)||Cytokinetics|Yes|Completed|October 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|711|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709149||77555|
NCT01709422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1774906506805161|Efficacy and Safety Profiles of Combination Sedation Propofol With Midazolam and Meperidine.|Efficacy and Safety Profiles of Sedation With Propofol Combined With Intravenous Midazolam and Meperidine Versus Intravenous Midazolam and Meperidine for Ambulatory Endoscopic Retrograde-cholangiopancreatography(ERCP).|ERCP|Prince of Songkla University|Yes|Completed|June 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|September 27, 2012|No|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT01709422||77534|
NCT01709734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOK-200-10|A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer|ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer|ARMOR2|Tokai Pharmaceuticals|Yes|Recruiting|December 2012|August 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709734||77510|
NCT01704911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRAGON|Evaluate the Safety And Efficacy of the Transradial Coronary in Comparison With the Transfemoral Coronary Intervention|Determination of the Transradial Versus Transfemoral Coronary Angioplasty||CCRF Consulting Co., Ltd.|Yes|Not yet recruiting|October 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1700|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704911||77880|
NCT01705496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVD002|[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint|Sensitivity and Specificity of [124I]FIAU PET-CT Scanning in Patients Presenting With Pain in a Prosthetic Knee or Hip Joint|PJI|BioMed Valley Discoveries, Inc|No|Terminated|August 2012|November 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 10, 2012|Yes|Yes|The sensitivity and specificity were not able to be assessed in this study due to the poor    image quality.|No|January 11, 2016|https://clinicaltrials.gov/show/NCT01705496||77836|
NCT01705756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8557-AL-CTIL|Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever|A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever|FMF|Sheba Medical Center|No|Completed|November 2012|June 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01705756||77816|
NCT01706029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11013/|Pain Evaluation in Rheumatoid Arthritis|Multidimensional Evaluation of Pain in Rheumatoid Arthritis (Douleur PR)|Douleur-PR|University Hospital, Limoges|No|Active, not recruiting|October 2012|September 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Sampling of blood for dosage of IL-6, IL-17 and IL-33 serum level|Both|18 Years|N/A|No|Probability Sample|Patients are selected from those coming to the Department of Rheumatology of each        partcipating center.|March 2015|March 8, 2015|October 10, 2012||||No||https://clinicaltrials.gov/show/NCT01706029||77795|
NCT01706042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|668/2008|Effects of Legumes on Glucose Regulation|Over-night Metabolic Effects of Legumes||Lund University||Completed|February 2010|August 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706042||77794|
NCT01710956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-531|Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer|Randomized Phase II Study of Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer||National Cancer Center, Korea|No|Recruiting|March 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710956||77418|
NCT01711580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01-25/01-intern-6810|Re-irradiation of High Grade Gliomas: a Quality of Life Study|Re-irradiation of High Grade Gliomas: a Quality of Life Study||Maastricht Radiation Oncology|Yes|Withdrawn|March 2013|September 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of subjects with a histologically proven high-grade        glioma (anaplastic astrocytoma, anaplastic oligodendroglioma or glioblastoma multiforme)        at primary diagnosis, who are now eligible for re-irradation because of a recurrence.|May 2015|May 11, 2015|October 12, 2012||No|Another study was commenced for this patient group|No||https://clinicaltrials.gov/show/NCT01711580||77370|
NCT01706965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6320|Kuvan in People With Schizophrenia and Schizoaffective Disorder|6R-BH 4 in People With Schizophrenia and Schizoaffective Disorder||New York State Psychiatric Institute|No|Suspended|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||March 2016|March 17, 2016|October 10, 2012|Yes|Yes|suspended due to study drug expiration|No||https://clinicaltrials.gov/show/NCT01706965||77723|
NCT01711567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEEP study|Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study||STEEP|Korea University|Yes|Recruiting|April 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|19 Years|N/A|No|||February 2014|February 26, 2014|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711567||77371|
NCT01711866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0009|A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease|An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4||UCB Pharma|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|30 Years|80 Years|No|||February 2014|February 25, 2014|October 18, 2012|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01711866||77348|
NCT01707498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00613-40|Robust Intelligent Keyboard for Quadraplegic Patients|Clinical Evaluation of Brain-Computer Interface for Helping Communication of Quadriplegic Patients|PVCRoBIK|Centre d'Investigation Clinique et Technologique 805|Yes|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 31, 2014|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01707498||77682|
NCT01712750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-17456|Near-Infrared Spectroscopic (NIRS) Tissue Oxygen Saturation and the Vascular Occlusion Test in Cardiac Surgery Patients|||London Health Sciences Centre|No|Completed|February 2011|September 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Elective cardiac surgery patients undergoing coronary artery bypass and valve surgery        using cardiopulmonary bypass.|October 2012|October 25, 2012|October 23, 2012||||No||https://clinicaltrials.gov/show/NCT01712750||77280|
NCT01713335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-56|Proteasis Evaluation in COPD|Proteasis Evaluation in COPD|Pro-BPCO|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|October 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Sputum|Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Stable COPD patients were recruited from pulmonary primary care of pulmonary division of        CHRU of Tours.        COPD with acute exacerbation were recruited from hospitalisation of pulmonary division of        CHRU of Tours and intensive care unit of CHRU of Tours.|October 2012|April 24, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01713335||77236|
NCT01708941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01932|Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-α in Advanced Melanoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2013|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|88|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708941||77571|
NCT01709188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-2201B|Musical Dual Task Training to Improve Attention Control for Dementia|The Effects of Musical Dual Task Training on Attention Control and Associated Gait Stability of Patients With Mild to Moderate Dementia||Chang Gung Memorial Hospital|Yes|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||October 2012|November 6, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01709188||77552|
NCT01709201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP01009751|Reducing Problematic Substance Use in Youth With Chronic Medical Conditions|Reducing Problematic Substance Use in Youth With Chronic Medical Conditions||Children's Hospital Boston|No|Not yet recruiting|July 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|14 Years|18 Years|No|||January 2013|January 2, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01709201||77551|
NCT01708928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-107|Feasibility Study: Lifting and Tightening Neck Skin in Patients|Feasibility Study: Evaluation Of The Ulthera™ System For Obtaining Lift And Tightening Of The Neck Skin In Patients With A History Of Submentoplasty And Or Rhytidectomy Vs Patients Naïve To Submentoplasty Or Rhytidectomy - A Feasibility Study||Ulthera, Inc|No|Completed|August 2010|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708928||77572|
NCT01709175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB-007|Strength Training Study for Survivors of Breast and Gynecologic Cancer|The Effect of Resistance Exercise Frequency in Breast and Gynecologic Cancer Survivors||Nova Scotia Health Authority|No|Completed|November 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|20|||Female|18 Years|N/A|No|||June 2015|June 4, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01709175||77553|
NCT01709487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPEC|Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy|Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy||Jules Bordet Institute|No|Completed|May 2010|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||July 2014|February 23, 2016|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709487||77529|
NCT01701284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12CC12|Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety|A RANDOMIZED OPEN-LABEL PILOT TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN CANCER PATIENTS WITH DEPRESSION AND ANXIETY|rTMSinCP|Northwestern University|Yes|Recruiting|December 2012|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|22 Years|70 Years|No|||February 2016|February 2, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701284||78159|
NCT01709474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALE05|Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus|Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|5 Years|20 Years|No|||December 2015|December 15, 2015|October 16, 2012|Yes|Yes|Due to slow enrollment|No|October 20, 2015|https://clinicaltrials.gov/show/NCT01709474||77530|The study terminated early due to recruitment feasibility issues. Seven subjects were enrolled and received treatment in contrast to the planned number of 78 subjects for randomization/receipt of treatment. No mechanistic analyses were performed.
NCT01709435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01890|Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors|A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|2 Years|18 Years|No|||March 2016|March 11, 2016|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01709435||77533|
NCT01709448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AI080202-01|Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV|Predictive Modeling of Anal Dysplasia Progression in HIV||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|January 2009|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|165|Samples With DNA|Anal cytology Anal biopsies|Both|18 Years|N/A|No|Non-Probability Sample|HIV primary care clinic|October 2012|October 16, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709448||77532|
NCT01705184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1102|Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.|Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.|BUCiL|Intergroupe Francophone de Cancerologie Thoracique|No|Active, not recruiting|December 2012|December 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01705184||77860|
NCT01705769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC538|Effects of Three Feeding Regimens on Recovery of Uncomplicated Severely Acute Malnourished Children|To Evaluate the Impact of Three Feeding Regimens on the Recovery of Children From Uncomplicated Severe Acute Malnutrition (SAM) in India and to Use the Evidence to Inform National Policy|SAMPOORNA|Society for Applied Studies|Yes|Completed|October 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|911|||Both|6 Months|59 Months|No|||June 2015|June 4, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01705769||77815|
NCT01705782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-410-12|The Effects of Amino Acid Supplement During Acute Inflammation.|Metabolic Effects of Endotoxin Induced Acute Inflammation in Healthy Young Men With and Without Supplement of Amino Acids.||University of Aarhus|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|8|||Male|25 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 11, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01705782||77814|
NCT01706055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16400|Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)|Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon®|INFLUENCE|Bayer|No|Active, not recruiting|September 2012|January 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|629|||Both|18 Years|N/A|No|Non-Probability Sample|Adult MS patients starting Betaferon therapy|January 2016|January 22, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01706055||77793|
NCT01706068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECGCTIL|Transient ECG Changes in Patients With Acute Biliary Disease|Transient ECG Changes in Patients With Acute Biliary Disease||Ziv Hospital|Yes|Not yet recruiting|November 2012|May 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with ECG changes|October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706068||77792|
NCT01706354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WS/0199|Local Anaesthesia vs Regional Block for Arteriovenous Fistulae|Does Regional Compared to Local Anaesthesia Influence Outcome After Arteriovenous Fistula Creation?||NHS Greater Glasgow and Clyde|No|Recruiting|October 2012|October 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01706354||77770|
NCT01706367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5091001|Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years|A Phase 1, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine Administered With Or Without Adjuvant, In A 3-Dose Regimen In Healthy Adults Aged 50 To 85 Years||Pfizer|Yes|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|6||Actual|192|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|September 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706367||77769|
NCT01711242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC-12068|Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma|Phase III Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection||Wenzhou Medical University||Recruiting|January 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2012|December 20, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01711242||77396|
NCT01711554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02011|Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma|A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma||National Cancer Institute (NCI)||Recruiting|February 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|N/A|21 Years|No|||January 2016|February 5, 2016|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711554||77372|
NCT01712477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|r039226|A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function|Propofol Versus Midazolam for Sedation in Mechanically Ventilated Critically Ill Patients Who Presented With Traumatic Brain Injury: Cytokine Response and Neuropsychological Assessment (IRRC#1201M)||Michigan State University|No|Recruiting|November 2011|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712477||77301|
NCT01713023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debora-TAS1R2|Fructose and Glucose and TAS1R2 in Type 1 Diabetes|Effect of Fructose and Glucose and TAS1R2 in Glucose, Triglycerides, Uremia, Oxidative Stress, Feelings Related to Food Intake of Individuals With Type 1 Diabetes|TAS1R2|Universidade Federal do Rio de Janeiro|Yes|Active, not recruiting|March 2013|January 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|50 Years|No|||May 2015|May 12, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01713023||77260|
NCT01713036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066-008|Oral Bioavailability and Mass Balance Trial With Pimasertib|A Phase I, Open-Label, Single Center Trial to Investigate the Mass Balance, Metabolite Profile and Oral Bioavailability of Pimasertib in Cancer Patients With Locally Advanced or Metastatic Solid Tumors||Merck KGaA|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|65 Years|No|||April 2015|April 17, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01713036||77259|
NCT01708954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01938|Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer|A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2013|||August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|117|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708954||77570|
NCT01709214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT-MD-101|Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain|A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee||Grünenthal GmbH|No|Completed|November 2012|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|619|||Both|18 Years|80 Years|No|||June 2015|June 3, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709214||77550|
NCT01709513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1119|Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)|A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins||Regeneron Pharmaceuticals|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|October 8, 2012|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01709513||77527|
NCT01709526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5702803|How the Adolescent Inpatients Are Rehabilitated After Discharge|Prospective Study the Adolescent Inpatients Rehabilitation|AdolInpRehabi|Kuopio University Hospital|Yes|Terminated|January 2009|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|14 Years|18 Years|No|||October 2012|October 17, 2012|June 29, 2011||No|Study couldn´t start due to investigator|No||https://clinicaltrials.gov/show/NCT01709526||77526|
NCT01709812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE19|Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS|A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis|STAY|Novartis||Withdrawn|July 2013|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709812||77504|
NCT01700374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812880|Happy Mommy! Happy Baby! Study|Prepubertal Adversity Effect on Maternal Arousal, Preterm Birth and Infant Stress Response|FAP|University of Pennsylvania|No|Recruiting|August 2012|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples Without DNA|-  Salivary cortisol;        -  Blood plasma Corticotropin-releasing Hormone (CRH).|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women from the greater Philadelphia and surrounding areas who are ages 18 to 45 and        between 8 to 17 weeks pregnant will be considered for enrollment into this study. All        subjects must be physically healthy without a serious major medical illness as well as be        carrying a healthy fetus. Subject will be enrolled through OB/GYN waiting room recruiting,        fliers, advertisements and social media outlets.|December 2015|December 4, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700374||78229|
NCT01709786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tsuei-2012-06|Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage|Non-Invasive Hemoglobin Monitoring in the Patient With Suspected Hemorrhage||University of Cincinnati|No|Recruiting|September 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Surgical Intensive Care Unit of University Hospital, Cincinnati        will be eligible for this study if they are at risk of ongoing bleeding and require serial        CBC measurements. A patient will not be eligible if he or she is:(1) less than 18 years of        age, (2) a prisoner, or if (3) clinicians are unable to take pulse oximetry readings due        to injuries, burns, amputations, or related problems.|October 2012|October 16, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709786||77506|
NCT01705509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121250|The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|ERIC|Cardiovascular Institute of the South Clinical Research Corporation|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705509||77835|
NCT01710046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921147|Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis|An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 16, 2012|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01710046||77486|
NCT01710293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-033|Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis (CREATE)|Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis||VA Office of Research and Development|Yes|Withdrawn|January 2015|January 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|2||Actual|0|||Both|21 Years|N/A|No|||October 2012|October 18, 2012|October 16, 2012||No|Not recruiting at this time. The first phase of this study is to develop an intervention.|No||https://clinicaltrials.gov/show/NCT01710293||77468|
NCT01710631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-049|Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia|A Randomized, Double-Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of (S)-Zopiclone in Adult Subjects With Insomnia||Sunovion|No|Completed|February 2001|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|791|||Both|21 Years|64 Years|No|||October 2012|October 18, 2012|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710631||77443|
NCT01710644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-BL-101|Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis||Nordmark Arzneimittel GmbH & Co. KG|Yes|Completed|May 2013|August 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|12 Years|N/A|No|||August 2014|August 27, 2014|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710644||77442|
NCT01711879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1526|Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma|Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma||University of Colorado, Denver|No|Active, not recruiting|January 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|21 Years|90 Years|No|||March 2016|March 10, 2016|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711879||77347|
NCT01711892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRE-04|Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy|A Randomized Controlled Clinical Trial on the Effects of Recreational Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: The FC Prostate Study||University of Copenhagen|Yes|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|57|||Male|18 Years|75 Years|No|||April 2014|April 16, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01711892||77346|
NCT01712217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT13387-05|A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib|A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)||Astex Pharmaceuticals|No|Active, not recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|228|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712217||77321|
NCT01712204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-201-GOU-001|A Proof-of-Concept Study of AC-201 to Prevent Gout Flares|A Randomized, Double-Blind, Placebo-Controlled Trial Of AC-201 In Subjects With Gout Initiating Urate-Lowering Therapy||TWi Biotechnology, Inc.|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|82|||Both|20 Years|80 Years|No|||November 2014|November 24, 2014|October 19, 2012|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01712204||77322|
NCT01712490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25003|Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma|A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma||Millennium Pharmaceuticals, Inc.|Yes|Enrolling by invitation|November 2012|March 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1040|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712490||77300|
NCT01712503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1518/WSHT/2012|A Trial of Toric Versus Non-toric Intraocular Lenses in Phacoemulsification Cataract Surgery|||Western Sussex Hospitals NHS Trust|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 22, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712503||77299|
NCT01712763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06/2012|Degarelix in the Treatment of Endometriosis Recurrence|Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|November 2012|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|45 Years|No|||February 2015|February 3, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01712763||77279|
NCT01713049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001043M|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound|Use of 18F-FLT Positron Emission Tomography to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: A Pilot Study||National Taiwan University Hospital|Yes|Recruiting|August 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|70|||Female|20 Years|80 Years|No|||August 2010|October 23, 2012|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01713049||77258|
NCT01708694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12009|Role of Slowly Digesible Starch on Diabetes Risk Factors|Role of Slowly Digesible Starch on Diabetes Risk Factors In Pre-diabetic People|STARCH|Pennington Biomedical Research Center|No|Recruiting|August 2012|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|95|||Both|35 Years|65 Years|No|||December 2015|December 1, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01708694||77590|
NCT01709227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1730|Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass|Early Renal Replacement Therapy vs. Furosemide for Neonates With Oliguria After Cardiopulmonary Bypass||Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|N/A|6 Months|No|||June 2015|June 24, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01709227||77549|
NCT01709552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA031881-02|Brief Intervention for Substance Use and Partner Abuse Among Females in the ER|A Computer-based Intervention for Women With Substance Use and Intimate Partner Violence in the Emergency Department|B-SAFER|Rhode Island Hospital|Yes|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|No|||May 2015|May 21, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01709552||77524|
NCT01705873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANV-10-0165|Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen|Retrospective Analysis on the Risk of Cardiovascular (CV) Events in HIV- Infected Subjects From Latin America Treated With a Lopinavir/Ritonavir (LPV/r) Based HAART Regimen vs. an Efavirenz (EFV) Based HAART Regimen||Helios Salud|No|Recruiting|September 2012|August 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|HIV-infected patients with first line HAART with EFV or LPV/r or second line HAART with        LPV/r|October 2012|October 11, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01705873||77807|
NCT01709539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPF-DC|Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden|Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden|CPF-DC|Region Skane|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1725|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709539||77525|
NCT01709825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403-2012|The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health|The Effect of Probiotics on Immune Function, and Digestive Health in Academically-stressed University Students: A Randomized, Double-blinded, Placebo-controlled Study||University of Florida|No|Completed|September 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|583|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709825||77503|
NCT01700972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-12B03|Feasibility and Diagnostic Accuracy of Myocardial Perfusion Imaging Using Early Imaging Protocol|Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study||St. Louis University|Yes|Withdrawn|February 2013|August 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|August 14, 2012||No|The study did not recruit/no study activity occurred.|No||https://clinicaltrials.gov/show/NCT01700972||78183|
NCT01700985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-0551-203|A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis|A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment||Therapeutics, Inc.|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700985||78182|
NCT01700387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001AL|A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency|A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care||Cady, Roger, M.D.|Yes|Completed|October 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||November 2014|November 12, 2014|October 1, 2012|Yes|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01700387||78228|
NCT01700400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAB CTC 10-001|Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer|Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer||Cancer Research and Biostatistics Clinical Trials Consortium|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||May 2014|November 21, 2014|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01700400||78227|
NCT01700621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS677|Coadministration of Measles-rubella and Rotavirus Vaccines|Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh||PATH|Yes|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|480|||Both|9 Months|11 Months|Accepts Healthy Volunteers|||May 2014|May 5, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700621||78210|
NCT01705522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-GASTRO-3|Multimodal Approach in IBD Patients|Multimodal Approach in IBD Patients|MAID|Clinical Hospital Colentina|No|Recruiting|October 2012|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|serum and fecal samples|Both|18 Years|85 Years|No|Non-Probability Sample|all patients with IBD over 18 years of age, currently in clinical remission|October 2015|October 14, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705522||77834|
NCT01710670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0041|A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Three-way Crossover Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects.||UCB Pharma|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710670||77440|
NCT01710969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA023156|Individual and Group Intervention Formats With Aggressive Children|Individual and Group Intervention Formats With Aggressive Children||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 2008|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|360|||Both|9 Years|12 Years|No|||April 2015|April 14, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710969||77417|
NCT01710982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPJ5004-04/2011 (SDS)|A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection|A Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection||Norgine||Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|80 Years|No|||September 2012|October 17, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01710982||77416|
NCT01710995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG-02/2010 (BE)|A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions|A Randomised, Three-Period, Single Dose, Open-Label, Crossover Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions||Norgine|Yes|Completed|October 2010|February 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01710995||77415|
NCT01711255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-12A-1323|Evaluation of Coagulation in Multiple Sclerosis|A Cross-Sectional Study of Coagulation in Multiple Sclerosis||Bastyr University|No|Recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|Six (6) whole blood vials of 10ml each will be collected from each subject. Three (3) will      be stored for future use. Three will be used immediately for coagulation analysis using      Sonoclot.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be sixty (60) individuals with diagnosed or probable multiple        sclerosis, verified by board certified neurologist, and forty (40) age and sex matched        healthy controls.|January 2016|January 13, 2016|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01711255||77395|
NCT01712529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09295-5|Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients|Effect of Supervised Physical Exercise on Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus||Federal University of São Paulo|Yes|Active, not recruiting|September 2010|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|45 Years|No|||October 2012|October 22, 2012|October 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01712529||77297|
NCT01712789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-010|Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma|STRATUS|Celgene|Yes|Active, not recruiting|November 2012|December 2019|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|682|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712789||77277|
NCT01712516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2337|A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation|A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation||Novartis|No|Completed|December 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1001|||Both|40 Years|N/A|No|||July 2015|July 13, 2015|October 19, 2012|No|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01712516||77298|
NCT01713062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1113|Longterm-Evaluation of Vitelene® Against Standard|Randomised Prospective Multicenter Longterm-Evaluation of the Survival Rate of the Implant, Wear and Periprosthetic Osteolysis of Highly Cross-linked Polyethylene With and Without Addition of Vitamin E (UHMWPE-XE vs. UHMWPE-X)|VITAS|Aesculap AG|No|Active, not recruiting|January 2012|April 2030|Anticipated|April 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|75 Years|No|Probability Sample|adult patients|February 2016|February 5, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01713062||77257|
NCT01712776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEB-01|Vapocoolant (Pain Ease) Use for Venipuncture|Prospective, Randomized, Blinded,Comparative Efficacy and Safety Trial of Vapocoolant (Pain Ease Medium Stream) for Venipuncture||The Cleveland Clinic|Yes|Completed|April 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|October 4, 2012||No||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01712776||77278|This study enrolled only adults. No pediatric patients were enrolled. However, an earlier study by Farion KJ et al in CMAJ in 2008 found that the use of a vapocoolant (pain-ease) significantly decreased the pain of intravenous cannulation in children
NCT01708967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTSMVSSCM|Trial of New Pretreatment Method in Transnasal Endoscopy|One-time Spray of Epinephrine (1cc) Plus 4% Lidocaine (4cc) is Sufficient Pretreatment Method for the Preparation of Transnasal Endoscopy|RTNPMTNE|Chuncheon Sacred Heart Hospital|Yes|Completed|March 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 16, 2012||No||No|November 9, 2013|https://clinicaltrials.gov/show/NCT01708967||77569|A limitation of this study was the small number of patients; n = 93 is insufficient to conclusively generalize the efficiency of the catheter-free method.
NCT01708980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-09-TLJ|Descriptive Study of Strength Training Exercises to Activate the Muscles of the Operated Leg After Total Knee Replacement|Neuromuscular Activity of the Operated Leg During Strength Training Performed in Machines and in More Simple Forms After Total Knee Replacement||Copenhagen University Hospital, Hvidovre|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||October 2013|October 22, 2013|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01708980||77568|
NCT01705886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAKO-02|Clinical and Economic Comparison of Robot Assisted Versus Manual Knee Replacement|Clinical and Economic Comparison of Robotic Versus Manual Knee Arthroplasty||Northwest Surgical Specialists, Vancouver|No|Recruiting|October 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|80 Years|No|Non-Probability Sample|Male and non-pregnant females undergoing knee replacement who are between 21 and 80 years        of age with stable health and are willing and able to have physical therapy.|October 2015|October 8, 2015|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705886||77806|
NCT01709838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670E2419|Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia|An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia|THETIS|Novartis|No|Active, not recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|10 Years|N/A|No|||June 2015|June 22, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709838||77502|
NCT01710098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCM12-01|Treatment of Prostate Cancer With Firmagon®|Effectiveness and Safety as Well as Adherence of the "S3 Guidelines for the Treatment of Prostate Cancer" in the Treatment of Patients of Patients With Firmagon®||United Clinic Management GmbH|No|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|95 Years|No|Probability Sample|adult male patients of outpatient urological medical practice|October 2012|October 16, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01710098||77482|
NCT01710371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001458|Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls|Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133)||Avid Radiopharmaceuticals|No|Completed|December 2012|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710371||77462|
NCT01710384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006111|Effect of Antenatal Corticosteroids in Late Preterm|||Meir Medical Center|Yes|Not yet recruiting|November 2012|November 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710384||77461|
NCT01700998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MgICU|Magnesium Replacement Therapy to Prevent Acute Renal Failure in Critically Ill Patients|Randomized Trial of Magnesium Replacement Therapy to Prevent Acute Renal Failure in Hypomagnesemic Critically Ill Patients||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|Yes|Completed|September 2012|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||November 2014|November 1, 2014|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700998||78181|
NCT01700946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLR18|Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma|A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma||St. Jude Children's Research Hospital|No|Recruiting|October 2012|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|21 Years|No|||November 2015|November 30, 2015|October 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700946||78185|
NCT01700959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIND|Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort|Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort||St. Jude Children's Research Hospital|No|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|848|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700959||78184|
NCT01700634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MON-SC-2012-01|fMRI Evaluation of Pain Central Sensitization Phenomena in Subjects With Knee Osteoarthritis|fMRI Evaluation of Pain Central Sensitization Phenomena in Subjects With Knee Osteoarthritis||Parc de Salut Mar|No|Recruiting|September 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with HIGH / LOW central sensitation, and control subjects.|February 2013|February 6, 2013|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700634||78209|
NCT01700647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/11/QRBW/471|Breath Testing in Laryngeal Cancer|Breath Testing in Laryngeal Cancer- Comparing in Situ Cancer and Advanced Cancer||Royal Brisbane and Women's Hospital|Yes|Active, not recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|30|None Retained|Breath test- for analysis in ENose as well as massspectroscopy gas chromatography|Both|N/A|N/A|No|Non-Probability Sample|Patients at risk for larynx cancer|October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700647||78208|
NCT01710306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-039|Web and Shared Decision Making for Reserve/National Guard Women's PTSD Care|Web and Shared Decision Making for Reserve/National Guard Women's PTSD Care||VA Office of Research and Development|No|Enrolling by invitation|September 2013|March 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01710306||77467|
NCT01710657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0008|A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization||UCB Pharma|No|Completed|September 2012|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|548|||Both|16 Years|70 Years|No|||March 2015|March 4, 2015|October 17, 2012|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01710657||77441|
NCT01711268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGWH008|Sunitinib Drug Levels and Outcomes in Kidney Cancer|Correlating Renal Cell Cancer Treatment Efficacy With Sunitinib Therapeutic Levels and Outcomes|CRESTO|Western Sydney Local Health District|No|Recruiting|May 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Adults being treated with sunitinib monotherapy for metastatic renal cell carcinoma|May 2014|May 13, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01711268||77394|
NCT01711593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P0001076|Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma|Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma|MGH-002|Massachusetts General Hospital|Yes|Recruiting|January 2013|January 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711593||77369|
NCT01711905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0315668|Study on the Effects of a Recommendation Based Supply of Vitamin D3 in Healthy Volunteers|Study on the Effects of a Recommendation Based Supply of Vitamin D3 in Healthy Volunteers - a Randomized Trail||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01711905||77345|
NCT01712230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1157|Females, Aging, Metabolism, and Exercise|Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women|FAME|University of Colorado, Denver|No|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|132|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712230||77320|
NCT01712243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1I21RX000773-01A2|Light to Maximize Vision, Minimize Insomnia|Toileting at Night in Older Adults: Light to Maximize Vision, Minimize Insomnia||VA Palo Alto Health Care System|No|Enrolling by invitation|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|27|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712243||77319|
NCT01704495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3551C00001|A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.|A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma|NIMBUS|AstraZeneca||Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1147|||Both|18 Years|150 Years|No|||February 2016|February 1, 2016|October 9, 2012|Yes|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01704495||77912|
NCT01704768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR012171|COPE/Healthy Lifestyles for Teens: A School-Based RCT|COPE/Healthy Lifestyles for Teens: A School-Based RCT||Arizona State University|Yes|Active, not recruiting|January 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1219|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01704768||77891|
NCT01713075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589DL00001|Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients|Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for COPD Patients||AstraZeneca||Completed|November 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1183|||Both|N/A|N/A|No|Non-Probability Sample|Among patients treated with Symbicort Turbuhaler due to chronic obstructive pulmonary        disease(COPD), those who received the drug for the first time|January 2016|January 13, 2016|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01713075||77256|
NCT01708707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Banner IRB 01-13-0030|Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)|A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)||Mednax Center for Research, Education and Quality|Yes|Enrolling by invitation|December 2012|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|N/A|1 Year|No|||October 2014|April 6, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708707||77589|
NCT01705613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100540|Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil|Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil||Hospital de Clinicas de Porto Alegre|Yes|Completed|April 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|120|||Both|6 Years|18 Years|No|Non-Probability Sample|Children and adolescents with indication of Attention Deficit/Hyperactivity Disorder        treatment|April 2014|April 10, 2014|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705613||77827|
NCT01705587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12040560 (FiX-IT)|Fracture (FX) Improvement With Teriparatide: FiX-IT Study|Fracture (FX) Improvement With Teriparatide: FiX-IT Study|FiX-IT|University of Pittsburgh|No|Recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Female|N/A|N/A|No|||December 2015|December 1, 2015|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01705587||77829|
NCT01705600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23210|Verbalization in Patients With Non-specific Low Back Pain and Central Sensitization|Protocol for the Evaluation of the Effects of Limiting Verbal Complaints on Pain and Pain Catastrophizing in Individuals With LBP Who Are in a State of Central Sensitization||Keystone Rehabilitation Systems|No|Active, not recruiting|September 2012|||August 2013|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01705600||77828|
NCT01706159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8717-3946|A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis|A Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis||Novo Nordisk A/S|No|Terminated|October 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|64 Years|No|||September 2014|September 22, 2014|October 9, 2012|Yes|Yes|Trial screening data did not support the medical hypothesis|No|July 10, 2014|https://clinicaltrials.gov/show/NCT01706159||77785|The trial was terminated earlier than planned as the hypothesis of a correlation between low levels of FXIII and disease activity of UC could not be confirmed.
NCT01706458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11816|Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer|Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer||University of Wisconsin, Madison|Yes|Recruiting|February 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01706458||77762|
NCT01706146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00064217|Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring|Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring|REACT COM|Northwestern University|Yes|Completed|October 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|59|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 10, 2012|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01706146||77786|
NCT01706432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16802B|Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer|Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)||University of Chicago|No|Active, not recruiting|June 2009|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706432||77764|
NCT01706445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kid'strainingCF|Combined Inspiratory Muscle and 'Whole Muscle' Training in Children With Cystic Fibrosis|||Universidad Europea de Madrid|Yes|Completed|September 2011|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|20|||Both|6 Years|17 Years|No|||October 2012|October 11, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01706445||77763|
NCT01711307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1|Operative vs. Non-Operative Treatment of Acute Ruptures of the Achilles Tendon|Operative vs. Non-Operative Treatment of Acute Ruptures of the Achilles Tendon: A Multi-centered Randomized Control Trial Using Standardized Objective and Subjective Outcome Measurement to Determine Rerupture Rate.|AchillesRCT|Nova Scotia Health Authority|No|Recruiting|October 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01711307||77391|
NCT01711320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120925XJYYYJK|Effect of Omeprazole on Metformin|Effect of Omeprazole, an OCT Inhibitor, on the Pharmacodynamics and Pharmacokinetics of Metformin, Involved the Mechanism of Attenuating AMPK Phosphorylation||Xijing Hospital|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 16, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01711320||77390|
NCT01701531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBC100312|Red Blood Cell Precursor Formulation to Determine Increased Production|An Open-Label, Pilot Study of a Red Blood Cell Precursor Formulation to Determine Increased Production in Subjects With Mild to Moderate Anemia|RBCPF|Targeted Medical Pharma||Recruiting|October 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||October 2012|October 4, 2012|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701531||78140|
NCT01701271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXIS-HAIR LOSS-STUDY 1.2012|Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females|Evaluation of the Efficacy of the Cosmetic Lotion M.P.A.F. (Mixture of Paraffin, Alcohol and Fur) MEXIS PATENT in the Treatment of Androgenetic Alopecia by Decreasing of Hair Loss and Strengthening and Thickening of Hair in Males and Females.|MEXISPATENT|Mexis George|Yes|Completed|February 2001|June 2001|Actual|June 2001|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 1, 2012||No||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01701271||78160|
NCT01711008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29W5|The Effect of Breakfast Size Prior to Morning Exercise on Cognition, Mood and Appetite in Habitually Active Women|The Effect of Breakfast Size Prior to Morning Exercise on Cognition, Mood and Appetite Later in the Day in Habitually Active Women||Northumbria University|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01711008||77414|
NCT01711021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N25-006|Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children & Adolescents With ADHD|A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD||Noven Pharmaceuticals, Inc.|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|6 Years|17 Years|No|||October 2015|October 14, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711021||77413|
NCT01711606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056BDE-EPI-01|EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes|EXPLAIN - FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes|EXPLAIN|Novartis||Terminated|March 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|N/A|N/A|No|Non-Probability Sample|Patients with fragile-X Syndrome|March 2016|March 2, 2016|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711606||77368|
NCT01711619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.02.7007|SubQStim: A Post-market Study of Subcutaneous Nerve Stimulation in Failed Back Surgery Syndrome (FBSS) Patients|Interventional, Prospective, Multicenter, Randomized, Parallel-arm Study to Compare the Effectiveness of Peripheral Nerve Stimulation (PNS) Utilizing a Subcutaneous Lead Implant Technique (SQS) Plus Optimized Medical Management (OMM) Versus OMM Alone in Patients Suffering From Back Pain Due to Failed Back Surgery Syndrome (FBSS)||Medtronic International Trading Sarl|Yes|Terminated|November 2012|June 2016|Anticipated|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 12, 2012|Yes|Yes|Challenges to recruit qualified participants|No||https://clinicaltrials.gov/show/NCT01711619||77367|
NCT01711632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-200|BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia|A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia||Memorial Sloan Kettering Cancer Center||Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711632||77366|
NCT01711918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Domperidone|Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis|Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis||University of Iowa|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|60 Years|No|||April 2014|April 24, 2014|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711918||77344|
NCT01704196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA/VA CS#1031|A Multi-Center Trial of Nepicastat for Cocaine Dependence|Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Nepicastat for Cocaine Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2013|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704196||77935|
NCT01704209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU67333|Collagen Injections for the Treatment of Acne Scars and Wrinkles|Pilot Study of Autologous Fibroblast Injection for Acne Scars, Forehead Lines, Lip Lines, Horizontal Neck Lines, and Static Crow's Feet||Northwestern University|Yes|Terminated|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|September 27, 2012|No|Yes|Company stopped making product for cosmetic use. All consented subjects withdrew before any    study interventions were performed.|No||https://clinicaltrials.gov/show/NCT01704209||77934|
NCT01704508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eurartesim-2012|Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A|Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau.||Bandim Health Project|No|Recruiting|November 2012|January 2015|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Both|6 Months|12 Years|No|||December 2013|December 5, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01704508||77911|
NCT01704521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12053004|Viral Kinetics in HCV Clearance in Subjects With Hemophilia|Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir|HCV/Hemophil|University of Cincinnati|Yes|Completed|December 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|October 5, 2012||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01704521||77910|
NCT01704781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-BI Vacc-4x/IMiD-2010/1|Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)|A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).|IMID|Bionor Immuno AS|Yes|Completed|September 2012|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|36|||Both|18 Years|55 Years|No|||October 2014|October 13, 2014|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704781||77890|
NCT01705002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMITIL-01|Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.|A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.||Lipomedix Pharmaceuticals Inc.|Yes|Recruiting|October 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|67|||Both|18 Years|80 Years|No|||November 2015|November 15, 2015|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705002||77873|
NCT01705301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007441|Neurotransmitter Measurements Using (WINCS) During Deep Brain Stimulation Neurosurgery|Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During Deep Brain Stimulation Neurosurgery.||Mayo Clinic|No|Recruiting|January 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|90 Years|No|Probability Sample|Adult Patients with medically intractable Essential Tremor, Parkinson's Disease, and        Dystonia who have been approved for DBS surgery by the interdisciplinary Mayo DBS        committee.|January 2016|January 15, 2016|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705301||77851|
NCT01706471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0109|Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation|||Yonsei University|No|Completed|June 2009|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01706471||77761|
NCT01705899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2006H0200|Islet Allotransplantation in Type 1 Diabetes|Islet Allotransplantation in Type 1 Diabetes||Ohio State University|Yes|Enrolling by invitation|November 2006|May 2017|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|No|||February 2014|February 7, 2014|May 3, 2012|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01705899||77805|
NCT01706770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC111216|Evaluation of CooperVision Avaira Toric (Enfilcon A) Soft Contact Lens When Compared to Acuvue Advance Toric Soft Contact Lens|Evaluation of CooperVision Avaira Toric (Enfilcon A) Soft Contact Lens (Test) When Compared to Acuvue Advance Toric (Galyfilcon A) Soft Contact Lens (Control)||Coopervision, Inc.|Yes|Completed|May 2012|October 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 28, 2014|October 5, 2012|Yes|Yes||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01706770||77738|
NCT01707095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0906|Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord|Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord: A Randomized, Controlled Trial||University of Colorado, Denver|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 3, 2014|September 21, 2012||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT01707095||77713|
NCT01706744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1697|Effect of Discharge Via an Intermediate Care Unit|Can Discharge Via an Intermediate Care Unit Prevent Aggravation of Disease and Loss of Functionality, Without Increasing the Level of Cost? A Controlled Observational Study||Norwegian University of Science and Technology|No|Completed|February 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|328|||Both|60 Years|99 Years|No|||December 2015|December 7, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706744||77740|
NCT01706757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-05|Assessment of Motivity in People Aged 65 to 86 Years|Assessment of Motivity in People Aged 65 to 86 Years : Comparison of a Standard Assessment Versus a Technological Solution||Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|65 Years|86 Years|Accepts Healthy Volunteers|||July 2012|October 12, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01706757||77739|
NCT01707069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI-2012|A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid|A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid||Immunomic Therapeutics, Inc.|No|Completed|October 2012|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|63 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707069||77715|
NCT01707082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5211002|A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults|A Phase 1, Randomized, Placebo-Controlled, Multiple Dose Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of PF-06282999 In Healthy Overweight Subjects And A Fixed-Sequence Study To Assess The Effect Of PF-06282999 On The Pharmacokinetics Of Midazolam In Healthy Subjects|B521MAD|Pfizer|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|69|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707082||77714|
NCT01712295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-3128|17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts|New Formulation of Salicylate to Improve Treatment of Common Skin Warts||Grossman, Michael, D.P.M.|No|Recruiting|November 2011|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|75 Years|No|||October 2012|October 22, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712295||77315|
NCT01712308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0534|Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia|A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia||M.D. Anderson Cancer Center|No|Recruiting|February 2013|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712308||77314|
NCT01712321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VII-IT-07|Study of Vilazodone to Treat Social Anxiety Disorder|Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study||The Medical Research Network|No|Active, not recruiting|October 2012|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||January 2014|January 16, 2014|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712321||77313|
NCT01701297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10GA021|VSL#3 and Spontaneous Bacterial Peritonitis|The Effect of Probiotics on the Incidence of Spontaneous Bacterial Peritonitis in Patients With Cirrhosis and Ascites||Nottingham University Hospitals NHS Trust|Yes|Recruiting|February 2012|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01701297||78158|
NCT01701791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2316063|Telemedicine for Depression in Primary Care|The Efficacy of Telemedicine for Improving Depression Outcomes in Primary Care||IRCCS Centro San Giovanni di Dio Fatebenefratelli|Yes|Active, not recruiting|November 2012|May 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701791||78120|
NCT01701804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2011-2|The Effectiveness of Non-surgical Integrative Package on Failed Back Surgery Syndrome|The Effectiveness of Non-surgical Integrative Package on Failed Back Surgery Syndrome : A Multicenter, Prospective, Case Series Observational Study||Jaseng Hospital of Korean Medicine||Completed|September 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|69 Years|No|Probability Sample|Consecutive patient sampling within Failed Back Surgery Syndrome clinic|September 2014|September 24, 2014|October 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01701804||78119|
NCT01711047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0605/97|Benefit of CFAE Ablation|A Study to Investigate the Benefit Of Complex Fractionated Atrial Electrogram (CFAE) Ablation in Addition to Circumferential Pulmonary Vein and Linear Ablations in the Treatment of Persistent Atrial Fibrillation. (BOCA)|BOCA|Oxford University Hospitals NHS Trust|Yes|Active, not recruiting|March 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||October 2012|October 17, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01711047||77411|
NCT01711281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010|Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement|Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement|BIODetectHFII|Biotronik SE & Co. KG|No|Completed|October 2012|||June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|68|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01711281||77393|
NCT01708161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719X2105J|A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors|A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors||Novartis|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708161||77631|
NCT01708460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-118|Feasibility Study: Ulthera Treatment of the Buttocks and Thighs|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening the Buttocks and Thighs||Ulthera, Inc|No|Completed|December 2011|July 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708460||77608|
NCT01708473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-123|Feasibility Study: Compare the Effectiveness Between Two Pain Medications When Used Prior to Ultherapy™ Treatments|Feasibility Study: Comparison Of Advil® Vs. Lortab® For Reducing Discomfort Associated With Ultherapy™ Treatment||Ulthera, Inc|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708473||77607|
NCT01704222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07040 CrèchMV|Epidemiology of Human Cytomegalovirus Excretion in the Saliva of Children Attending Nursery in France|Epidemiology of Human Cytomegalovirus Excretion in the Saliva of Children Attending Nursery in France.|CrèchMV|University Hospital, Limoges|No|Completed|September 2009|September 2013|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2001|Samples With DNA|Direct DNA amplification, viral isolation and specific antibody measurement in saliva|Both|3 Years|6 Years|Accepts Healthy Volunteers|Probability Sample|Children older than 3 months and less than 6 years kept in nurseries retained, regardless        of the duration of custody of the child in the manger concerned.|October 2012|October 31, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704222||77933|
NCT01705340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01759|Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery|A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer||National Cancer Institute (NCI)||Terminated|September 2012|||May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705340||77848|
NCT01705353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-090B|The Role of HMGB-1 in Chronic Stroke|Pilot Study of the Role of HMGB-1 in Retarding Recovery in Chronic Stroke||Northwell Health|Yes|Recruiting|September 2012|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood, DNA, serum/serum cytokines|Both|18 Years|N/A|No|Non-Probability Sample|Acute care hospital (stroke unit)|October 2015|October 19, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705353||77847|
NCT01705626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAP 08-2012|Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy|TTR-FAP Screening - Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy - a National, Multicentre, Epidemiological Protocol|TTR-FAP|University of Rostock|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|550|Samples With DNA|For the molecular genetic diagnosis of the disease TTR-FAP a sequencing of the entire TTR      gene in all study patients will be performed. Dried blood spots will be used for this      procedure.|Both|18 Years|N/A|No|Probability Sample|adult Patients with a polyneuropathy of undetermined etiology based on the normal results        of laboratory data (CRP, glucose, electrolytes, urea, transaminases, TSH, immunoglobulins,        cryoglobulins, vitamin B12, RF, ANA, antibodies against Lyme borrelia, HIV, anti-GM1        antibodies) and CSF; no anamnesis for carcinoma, no continuous alcohol consumption; no        light-chain-amyloidosis; no anamnesis for heavy metal exposure|February 2014|February 4, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705626||77826|
NCT01705015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC101-2314-B-002-006-MY3|Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement|Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement for Heart or Liver Transplantation Recipients in Early Postoperative Period||National Taiwan University Hospital|No|Recruiting|September 2012|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||September 2012|October 15, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01705015||77872|
NCT01705041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA LFT Study|Preliminary Evaluation of a Point-Of-Care Liver Function Test|Preliminary Field Evaluation of a Point-of-Care Transaminase Test|DFA|PATH|No|Completed|June 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|700|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01705041||77871|
NCT01705314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD2012|A Trial of Vitamin D to Reduce Influenza: Pilot Study|A Randomized Trial of Vitamin D to Reduce Influenza: Pilot Study||McMaster University|Yes|Recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|3 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705314||77850|
NCT01705327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioFIND|Fox Investigation for New Discovery of Biomarkers|Fox Investigation for New Discovery of Biomarkers (BioFIND)|BioFIND|Michael J. Fox Foundation for Parkinson's Research|No|Completed|October 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|240|Samples With DNA|Cerebrospinal Fluid (CSF), whole blood, DNA, plasma|Both|55 Years|93 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's disease and healthy control subjects|December 2013|October 2, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705327||77849|
NCT01707108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-12-RMB CTIL|Survival and Success of MIS C1 Implants- a Field Study|Survival and Success of MIS C1 Implants- a Field Study||Rambam Health Care Campus|No|Recruiting|February 2013|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 10, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01707108||77712|
NCT01706783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-3947|A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency|A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092) Compared to Once-daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|20 Years|70 Years|No|||November 2013|November 26, 2013|October 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01706783||77737|
NCT01707654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen6017|Repair of Infective Wound Associated With Nerve Defect in the Finger Using A Bipedicled Nerve Flap|||The Second Hospital of Tangshan||Completed|July 2008|February 2012|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|9|||Both|16 Years|55 Years|Accepts Healthy Volunteers|||April 2012|August 18, 2013|October 12, 2012|Yes|Yes||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01707654||77670|
NCT01707342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100901|A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients|A Phase I, Open-Label, Sequential, Single-Dose Study to Assess the Absolute Bioavailability and Pharmacokinetics of TMC435 Administered as Single Oral Doses of 50 mg and 150 mg and an Intravenous Microdose of 100 μg [3H]-TMC435 in Healthy Male Subjects||Janssen R&D Ireland|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707342||77694|
NCT01711957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1487|The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation|The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation||University of Zurich|Yes|Enrolling by invitation|January 2008|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with end stage liver disease and/or primary liver tumor undergoing liver        transplantation|October 2012|October 23, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711957||77341|
NCT01711970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-111-157|A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer|A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Recruiting|November 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711970||77340|
NCT01711983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSO 10-09|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||October 22, 2015|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711983||77339|
NCT01712334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28249|A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis|A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System||Genentech, Inc.||Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|6 Years|N/A|No|||March 2014|March 31, 2014|October 19, 2012|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01712334||77312|
NCT01711671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEK-DKK1-P101|A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Leap Therapeutics, Inc.|No|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|30 Years|N/A|No|||November 2015|November 30, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711671||77363|
NCT01701544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0516|Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's.|Double Blind, Randomised, Single Centre, Crossover Pilot Trial of Bilateral Nucleus Basalis of Meynert Deep Brain Stimulation to Improve Cognitive Deficits in Patients With Parkinson's Disease.||University College, London|Yes|Enrolling by invitation|August 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|35 Years|80 Years|No|||August 2014|August 28, 2014|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701544||78139|
NCT01711645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0035|Tdap Vaccine in Post-Partum Women|Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Female|18 Years|45 Years|No|||April 2015|September 17, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711645||77365|
NCT01711658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-3501|TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.|TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation|TRYHARD|Radiation Therapy Oncology Group|Yes|Recruiting|November 2012|November 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711658||77364|
NCT01707849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVL-VHC-HVH.12|The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation|An Unicenter, Prospective, Randomized, Pilot Study Comparing the Effect of Everolimus-containing Versus mTOR Inhibitor Free Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation.||Hospital Vall d'Hebron|Yes|Active, not recruiting|October 2012|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|68 Years|No|||January 2016|January 2, 2016|October 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707849||77655|
NCT01708174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225C2301|A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)|A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma||Novartis|Yes|Active, not recruiting|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|4 Months|N/A|No|||January 2016|January 25, 2016|October 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01708174||77630|
NCT01708187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-12-00396|The Role of C-HAM in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model|The Role of Cryopreserved Human Amniotic Membrane in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model|Amniox|Orthopedic Foot and Ankle Center, Ohio|No|Terminated|October 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 5, 2012||No|Protocol halted due to less than anticipated recruitment.|No||https://clinicaltrials.gov/show/NCT01708187||77629|
NCT01705054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0157|Angina Prevalence and Provider Evaluation of Angina Relief|Angina Prevalence and Provider Evaluation of Angina Relief|APPEAR|Saint Luke's Health System|No|Enrolling by invitation|July 2013|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1250|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient cardilogy practice.|November 2015|November 16, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01705054||77870|
NCT01705067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011JBCK151|Safety and Efficacy of the Journey II BCS Total Knee System|A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate the Outcomes of Total Knee Arthroplasty (TKA) Using JOURNEY™ II BCS TotaL Knee SystEm (The NIMBLE Study)|NIMBLE|Smith & Nephew, Inc.|Yes|Active, not recruiting|June 2012|June 2024|Anticipated|April 2024|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|209|||Both|N/A|N/A|No|||September 2015|September 1, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01705067||77869|
NCT01705392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/910|Bevacizumab vs Dacarbazine in Metastatic Melanoma|A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.||Haukeland University Hospital|Yes|Suspended|January 2013|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|October 8, 2012||No|Lack of financing of the study drug. Not sufficient financial support.|No||https://clinicaltrials.gov/show/NCT01705392||77844|
NCT01705639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-2011-005360-22|Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene|Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?|MELAG|Helsinki University|No|Not yet recruiting|November 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01705639||77825|
NCT01705652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20100308H|Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients|Phase II Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients Undergoing Surgery or Radiation Therapy|Nexrutine|The University of Texas Health Science Center at San Antonio|Yes|Terminated|July 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|N/A|No|||May 2015|May 26, 2015|October 9, 2012|Yes|Yes|loss of funding|No|March 12, 2015|https://clinicaltrials.gov/show/NCT01705652||77824|
NCT01705938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP333101|Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects|A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects||Synergy Pharmaceuticals Inc.|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|7||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|August 15, 2013|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705938||77802|
NCT01705912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLLGF01|Fall Prevention Among Community Living Elderly|Fall Prevention by Assistant Nurses Among Community Living Elderly With Risk of Falling - a Randomized Controlled Trial||Örebro County Council|No|Completed|January 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|148|||Both|65 Years|N/A|No|||October 2012|October 11, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705912||77804|
NCT01705925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-002-11|Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome|Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome||Mednax Center for Research, Education and Quality|No|Recruiting|March 2012|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|20 Years|No|Non-Probability Sample|Children and Young Adults with Genotype Positive Long QT Syndrome|March 2016|March 22, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01705925||77803|
NCT01706172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMJS|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection: A Randomised Clinical Trial of Efficacy||Chisel Peak Medical Clinic|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706172||77784|
NCT01707368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-Daivobet-longterm-NIS-2012|Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation|Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation||LEO Pharma|No|Completed|October 2012|July 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|561|||Both|18 Years|N/A|No|Probability Sample|Patients with Psoriasis vulgaris visiting their attending dermatologist in the primary        care clinic|November 2013|October 29, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707368||77692|
NCT01707381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803|BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.|Constellation|Bausch & Lomb Incorporated|No|Completed|November 2012|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|90 Years|No|||November 2014|November 24, 2014|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707381||77691|
NCT01707394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-118|Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder|Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder||Bristol-Myers Squibb|Yes|Recruiting|January 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Anticipated|40|||Both|37 Weeks|18 Years|No|||September 2015|March 11, 2016|October 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01707394||77690|
NCT01707355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1307|Effectiveness of Educational Poster to Primary and Secondary Teachers Regarding Emergency Management of Dental Trauma|Effectiveness of Educational Poster to Primary and Secondary Teachers Regarding Emergency Management of Dental Trauma - A Cluster Randomised Controlled Trial||The University of Hong Kong|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|403|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 15, 2012|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01707355||77693|
NCT01707914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGU-01|Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease|Effects of Chinese Bayberry Juice on Liver Enzymes and Plasma Antioxidant Activity in Adult Subjects With Features of Fatty Liver Disease: a Randomised Placebo-controlled Trial||Shaoguan University|Yes|Completed|June 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|25 Years|No|||December 2012|December 1, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01707914||77650|
NCT01707927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2596/REK|Comparison of Two Biological Aortic Valves. Mosaic Ultra and Trifecta.|||Oslo University Hospital|No|Recruiting|September 2012|December 2022|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Patients operated elektively for aortic valve disease with the need of a biological valve|October 2014|October 12, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707927||77649|
NCT01707901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-8539POE011|A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease|A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease||Ono Pharmaceutical Co. Ltd|No|Completed|December 2012|||October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01707901||77651|
NCT01708239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geneva University Hospital|Left Rule, D-Dimer Measurement and Complete Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy.|Sequential Use of the LEFt Rule, D-dimer Measurement and Complete Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy: a Prospective Outcome Study.||University Hospital, Geneva|No|Recruiting|October 2012|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women with suspected DVT|May 2015|May 27, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01708239||77625|
NCT01711996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0421|The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients|||Yonsei University|No|Recruiting|August 2012|August 2013|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: 20 patients with UPJO undergo pyeloplasty Group 2: 20 patients with        hydronephrosis who does not meet the indication of pyeloplasty Group 3: 20 normal control|October 2012|October 22, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01711996||77338|
NCT01712009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110147|NOLAN: Naproxen or Loratadine and Neulasta|Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim|NOLAN|Amgen|No|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|600|||Female|18 Years|100 Years|No|||February 2016|February 9, 2016|October 19, 2012|Yes|Yes||No|February 9, 2016|https://clinicaltrials.gov/show/NCT01712009||77337|
NCT01712841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00008749|Non-exudative Age-related Macular Degeneration|A Prospective Study Examining Patients With Non-exudative Age-related Macular Degeneration (NEAMD) of Different Severity|NEAMD|Oregon Health and Science University||Recruiting|October 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|20|||Both|60 Years|85 Years|No|Non-Probability Sample|Individuals between the ages of 60 and 85 years of age presenting to the Retina Service        within the Department of Ophthalmology at the Casey Eye Institute of Oregon Health &        Science University with signs and symptoms of non-exudative AMD.|April 2015|April 21, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01712841||77273|
NCT01712581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/071/HP|Heart Map Study -Determination of Myocardial Relaxation Times Values in Healthy Volunters|Determination of Myocardial Relaxation Times Values in Healthy Volunters|HeartMS|University Hospital, Rouen|Yes|Completed|August 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|175|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01712581||77293|
NCT01711944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA159013-01A1|Online Problem Solving Skills Training|Online Implementation of Problem Solving Skills Training for Mothers of Newly Diagnosed Childhood Cancer Patients||University of Rochester|Yes|Recruiting|July 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|620|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01711944||77342|
NCT01707589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric Elfi-Monitor|Noninvasive Monitoring of Vital Signs in Neonates|||Meir Medical Center||Not yet recruiting|May 2013|||October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|6 Months|No|||February 2013|February 11, 2013|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01707589||77675|
NCT01707602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120201|Routes of Immunization and Flu Immune Responses|Impact of Immunization Routes on the Immune Response to Influenza Vaccine|FLUWAY|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2012|April 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|August 2, 2013|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01707602||77674|
NCT01704235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008709|Vietnamese Women's Health Project III|Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women||OHSU Knight Cancer Institute|No|Active, not recruiting|November 2012|December 2016|Anticipated|November 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|35|||Female|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Potential participants will be recruited from the Portland, Oregon Metropolitan area        through referrals and snowball method. Primary health care providers are eligible to        participate in the study if they meet the following criteria: self-identify as currently        practicing as a primary licensed independent practitioner including as a medical physician        or nurse practitioner, whose service populations include Vietnamese American women, and        are able to understand and speak English or Vietnamese. Vietnamese American women are        eligible to participate in the study if they meet the following criteria: self-identify as        a Vietnamese American woman, between ages 21 to 65 years old, have not had a hysterectomy,        and are able to understand and speak English or Vietnamese.|February 2016|February 11, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704235||77932|
NCT01704534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662507|A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa|A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)|HiTS|University Medical Center Groningen|Yes|Completed|May 2012|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||February 2015|February 12, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01704534||77909|
NCT01704794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASUTH/SCD01/2012|Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)|Antioxidant Effect of the Extract of Jobelyn (Sorghum Bicolor) on the Quality of Life of Patients With Sickle Cell Disease||Lagos State University|Yes|Recruiting|April 2013|September 2014|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|14 Years|40 Years|No|||April 2013|April 1, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01704794||77889|
NCT01705080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201|IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN|IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN|EnligHTN-II|St. Jude Medical|Yes|Recruiting|January 2013|December 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with uncontrolled hypertension|October 2015|October 21, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01705080||77868|
NCT01705366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAKO-01|Clinical Outcomes of Knee Replacement|Clinical Outcomes of Joint Arthroplasty||Northwest Surgical Specialists, Vancouver|No|Recruiting|October 2012|October 2025|Anticipated|October 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|N/A|No|Non-Probability Sample|All male and non-pregnant females undergoing knee replacement|October 2015|October 8, 2015|October 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01705366||77846|
NCT01705379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_45OB|Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older|A Multicenter, Single Arm, Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects 2 Years of Age and Older in the Philippines||Novartis|No|Suspended|March 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|3000|||Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female subjects 2 years of age and older|June 2013|July 22, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01705379||77845|
NCT01706211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/128|A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes|A Double-blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of BRL 49653C With Concurrent Sulphonylurea Therapy, When Administered to Patients With Non-insulin Dependent Diabetes Mellitus.||National Taiwan University Hospital|Yes|Completed|October 1998|April 2000|Actual|April 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|30 Years|80 Years|No|||September 2012|October 12, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706211||77781|
NCT01706224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115539|Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals|Sero-prevalence of Pertussis Antibodies and Disease Awareness Among Healthcare Professionals in Spain||GlaxoSmithKline||Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|757|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthcare professionals actively working and involved with patient care in Spanish        hospitals.|January 2014|January 9, 2014|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01706224||77780|
NCT01706497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUL-S54474|Predictive Value of the FORE-SIGHT™ Monitor for Hemodynamic Deterioration|Validation of the Predictive Value of the FORE-SIGHT™ Monitor for Early Detection of Hemodynamic Deterioration After Pediatric Cardiac Surgery. A Data-mining Study.||Katholieke Universiteit Leuven|No|Recruiting|October 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|12 Years|No|Probability Sample|All children younger than 12 years, admitted after cardiac surgery in the pediatric        intensive care unit (PICU) of the university hospitals Leuven, Belgium, on mechanical        ventilation or intubated after admission. Children are monitored with the FORE-SIGHT™,        from admission until they are weaned off mechanical ventilation (typically, most of these        patients are mechanically ventilated between 12 hours and two weeks after ICU admission).|November 2012|November 8, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706497||77759|
NCT01706185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111294|Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer|Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer||GlaxoSmithKline||Completed|January 2008|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|156|||Both|N/A|N/A|No|Non-Probability Sample|Previously collected samples and data of patients with pathologically demonstrated bladder        cancer.|October 2012|October 18, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01706185||77783|
NCT01706198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115150|An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma|A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma||GlaxoSmithKline|Yes|Active, not recruiting|November 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4036|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01706198||77782|
NCT01706484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-02|Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Chronic Rhinosinusitis||Bionorica SE|No|Completed|September 2012|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|927|||Both|18 Years|75 Years|No|||July 2014|July 7, 2014|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01706484||77760|
NCT01706796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5261003|A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State|A Phase 1, Open Label, Randomized, Single Dose, 5 Period Crossover Relative Bioavailability Study In Healthy Volunteers Evaluating Spray Dried Dispersion (SDD) Immediate Release (IR) PF-06273340 Tablet, Two SDD Modified Release (MR) Matrix Tablets In Comparison With PF-06273340 Oral Solution, Including Preliminary Assessment Of Food Effect||Pfizer|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706796||77736|
NCT01706809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100006|Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer|||Odense University Hospital|No|Recruiting|September 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing open LAR for rectum cancer is subjected.|February 2014|February 4, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706809||77735|
NCT01711775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25230|A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers|A Single-center, Non-randomized, Open-label Study to Assess the Pharmacokinetics of Aleglitazar (RO0728804) After Administration of Single and Multiple Oral Doses of 150 µg Tablet in Healthy Chinese Subjects||Hoffmann-La Roche||Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711775||77355|
NCT01712074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2081011|Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil|A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil||Pfizer|Yes|Terminated|November 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|60 Years|N/A|No|||January 2016|January 29, 2016|October 19, 2012|Yes|Yes|The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria    were met. The termination was not due to safety concerns.|No||https://clinicaltrials.gov/show/NCT01712074||77332|
NCT01712087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-PMK-1001|Long-term Surveillance of the MedStream Programmable Infusion System|Long-term Surveillance of the MedStream Programmable Infusion System for the Intrathecal Infusion of Baclofen in the Treatment of Spasticity||Codman & Shurtleff|Yes|Terminated|October 2012|July 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects presenting for a de novo programmable pump implant or replacement of an        implantable, programmable infusion pump for the treatment of severe spasticity with        intrathecal Baclofen are potential study candidates and will be screened for study        eligibility. Subjects who do not meet all inclusion/exclusion criteria will not be        enrolled into this study.|February 2016|February 8, 2016|October 19, 2012||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01712087||77331|
NCT01712386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SW/0327|Nitrate, Chronic Obstructive Pulmonary Disease (COPD) and Exercise|The Effects of Dietary Nitrate Supplementation on the Oxygen Cost of Moderate-Intensity Exercise and Functional Capacity in Mild-Moderate COPD Patients||NIHR Exeter Clinical Research Facility|No|Completed|November 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|1||Actual|13|||Both|40 Years|75 Years|No|||October 2014|October 2, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01712386||77308|
NCT01712646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130004|Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia|The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|72|||Both|10 Years|99 Years|No|||May 2015|October 29, 2015|October 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712646||77288|
NCT01712659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130006|Ruxolitinib for Adult T-Cell Leukemia|Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|99 Years|No|||May 2015|March 24, 2016|October 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712659||77287|
NCT01712906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMumps-KMB17-I-IMB-CAMS|A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children|A Phase II Clinical Trial for Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children||Chinese Academy of Medical Sciences|Yes|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|18||Actual|300|||Both|8 Months|59 Years|Accepts Healthy Volunteers|||October 2012|April 26, 2013|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712906||77268|
NCT01712919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-chemoR-c225|Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)|IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study||Jiangsu Cancer Institute & Hospital|Yes|Completed|May 2010|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712919||77267|
NCT01713244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKLKF201209|Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma|A Randomized Controlled Trial of Radiofrequency Ablation Assisted Hepatectomy and Hepatectomy Alone in the Treatment of Advanced Hepatocellular Carcinoma||Southwest Hospital, China|Yes|Recruiting|October 2012|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||November 2015|November 19, 2015|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01713244||77243|
NCT01686451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wenzhou|The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin|Comparison Between XueZhiKang and Simvastatin on Fatigue: a Single-center, Randomized Clinical Trial||Wenzhou Medical University|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|20 Years|65 Years|No|||April 2014|April 20, 2014|September 3, 2012|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT01686451||79298|There are some limitations to this research. First, the sample size was relative small. Second, the follow-up period was short (4 weeks).
NCT01682473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSTK474-201|A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies|A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies||Zenyaku Kogyo Co., Ltd.|Yes|Recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|N/A|No|||January 2015|January 15, 2015|September 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01682473||79603|
NCT01682486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1842-2026-CDOC|BIP ETT Clinical Tolerability, Safety and Performance Study|Evaluation of Tolerability, Safety and Performance of BIP Endotracheal Tubes With Bactiguard Coating|BIPETT|Bactiguard AB|Yes|Completed|April 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01682486||79602|
NCT01682759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-016|A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.|Yes|Completed|September 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|751|||Both|18 Years|N/A|No|||December 2015|January 6, 2016|September 7, 2012|Yes|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01682759||79581|
NCT01708772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1381/09/12|Serum TNF-a in Comparison to Sequential Organ Failure Assessment (SOFA) Score Monitoring in Critically Ill Patients|The Predictive Prognostic Values of Serum TNF-a in Comparison to SOFA Score Monitoring in Critically Ill Patients||Tanta University|Yes|Completed|November 2012|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|60 Years|No|Probability Sample|A total of ninety patients (52men and 38women) were included in the study. Forty five        patients developed septic complication during ICU stay (sepsis group). Forty five patients        were critically ill without evidence of infectious organism (SIRS group). Patients were        classified into their groups at the time of the first blood analysis for these biomarkers        at ICU admission.|June 2013|June 6, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01708772||77584|
NCT01709318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06109|A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)|A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012||Merck Sharp & Dohme Corp.|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|666|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01709318||77542|
NCT01709331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07937|A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)|A Phase III, Multi-center, Open Label, Uncontrolled Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) in Inducing Increased Testicular Volume and Spermatogenesis in Adult Men With Hypogonadotropic Hypogonadism Who Remain Azoospermic When Treated With hCG Alone (Phase III; Protocol No. MK-8962-031-00 [Also Known as SCH 900962, P07937])||Merck Sharp & Dohme Corp.|No|Completed|February 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|50 Years|No|||May 2015|May 6, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709331||77541|
NCT01710579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.729|Normal Values in Ano-rectal 3D High Resolution Manometry|Ano-rectal 3D High Resolution Manometry: Normal Values and Comparison With Ultrasound Examination in Healthy Volunteers, Patients With Fecal Incontinence and Patients With Constipation|NOMAD|Hospices Civils de Lyon|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|127|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|May 6, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01710579||77447|
NCT01710865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041386|Effectiveness of Two Sealant Materials Over 5 Years|Evidence Based Effectiveness of Pit and Fissure Sealants Applied By Students and Paediatric Dentists After (Three) Five Years.||Lawson Health Research Institute|No|Not yet recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|2 Years|14 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710865||77425|
NCT01710202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-0017|Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration|Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration|5-HTTLPR|University of Texas at Austin|Yes|Completed|October 2012|November 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|120|Samples With DNA|Saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|University of Texas at Austin students|August 2013|March 18, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710202||77474|
NCT01710215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102011-069|Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies|Parkland-UT Southwestern PROSPR Center: Colon Cancer Screening in a Safety Net: Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies||University of Texas Southwestern Medical Center|No|Active, not recruiting|April 2013|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Actual|5999|||Both|50 Years|64 Years|No|||March 2016|March 11, 2016|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01710215||77473|
NCT01710540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116728|BE Study of Metformin GSK 850mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN GSK 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|BA/BE 198/11|GlaxoSmithKline|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01710540||77450|
NCT01710826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFD00311|A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers|A Single-center, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending 14-day Repeated Oral Doses of Genz-682452 in Healthy Male and Female Subjects||Sanofi|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710826||77428|
NCT01710553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116729|BE STUDY OF METFORMIN GSK 1000mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|BA/BE 199/11|GlaxoSmithKline|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01710553||77449|
NCT01711164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5129-BE|The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis|The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis||University Health Network, Toronto|Yes|Recruiting|January 2014|September 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|168|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients being followed by hepatologists and considering treatment of Hepatitis C vs        controls derived from potential live liver donors (for transplant)|December 2015|December 2, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01711164||77402|
NCT01711424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/DE/012|An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease|||Allergan|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1209|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dry eye|January 2014|January 29, 2014|October 18, 2012|Yes|Yes||No|January 29, 2014|https://clinicaltrials.gov/show/NCT01711424||77382|
NCT01711437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-P2|Different Bowel Preparations for Colonoscopy In Children|EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN||Azienda Policlinico Umberto I|Yes|Recruiting|January 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|4||Anticipated|400|||Both|2 Years|18 Years|No|||October 2012|November 5, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711437||77381|
NCT01712412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-112-201|Phase 2a Study of IW-9179 to Treat Functional Dyspepsia|||Ironwood Pharmaceuticals, Inc.|No|Terminated|October 2012|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2013|March 18, 2014|October 11, 2012||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01712412||77306|
NCT01712152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 11-228- 0112|Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study|||Hospital Rudolfstiftung||Recruiting|October 2012|March 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|data base of carriers of Duchenne muscular dystrophy|October 2012|October 22, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712152||77326|
NCT01712438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-05|Human-cl-rhFVIII in Previously Untreated Patients|Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A||Octapharma|Yes|Recruiting|February 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|N/A|N/A|No|||October 2015|October 29, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712438||77304|
NCT01712399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-CAM-3001-1109|A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis|An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis||MedImmune LLC|Yes|Completed|December 2002|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|409|||Both|18 Years|150 Years|No|||February 2016|February 1, 2016|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712399||77307|
NCT01712945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-005606-30|Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis|Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis|CAM-THY|Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|June 2012|October 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|86|||Both|18 Months|50 Years|No|||October 2012|October 23, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712945||77266|
NCT01712958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0148|Quantifying Micro RNA Levels of Colon|Quantifying Micro RNA Levels to Obtain a Micro RNA Signature of Colon Tumor Phenotypes and Sub Phenotypes|CRC|Meir Medical Center|Yes|Not yet recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100||human colon and rectal tumors, tumor adjacent and normal tissues|Both|18 Years|N/A|No|Non-Probability Sample|CRC patients|October 2012|October 23, 2012|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01712958||77265|
NCT01713257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNN-TOP-2010-01|Study of Arginine Free IED in Critically Ill Patients.|A Comparative Randomized Controlled Study of Arginine Free Immunoenhancing Diet and Isocaloric, Isonitrogenous Formula in Critically Ill Patients|ROSIED|Thai Otsuka Pharmaceutical Co.,Ltd.|Yes|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|172|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713257||77242|
NCT01686230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB518501-4|Acupuncture in Patients With Stable Angina Pectoris|Effect of Acupuncture in Patients With Stable Angina Pectoris: an Open Label, Randomized, Controlled,Multi-center Clinical Study|ASAP|Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|404|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 7, 2014|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686230||79315|
NCT01686464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wykq2012|A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's Palsy|A New Clinical Therapy for Bell's Palsy||Wenzhou Medical University|Yes|Completed|June 1998|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|882|||Both|10 Years|74 Years|No|||September 2012|September 12, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01686464||79297|
NCT01686477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2006|PREterM FOrmula Or Donor Breast Milk for Premature Babies|Preterm Formula or Donor Breast Milk to Make up Any Shortfall in Mother's Own Milk|PREMFOOD|Imperial College London|No|Recruiting|August 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|66|||Both|25 Weeks|31 Weeks|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01686477||79296|
NCT01683032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA -0011-12|A Study on the Effect of Methylphenidate on Creativity of Healthy Adults|||Shalvata Mental Health Center|Yes|Completed|October 2012|August 2014|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|38|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|August 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01683032||79560|
NCT01683045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-02|Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats|Ablation for the Treatment of Concomitant Atrial Fibrillation in Non-Paroxysmal Patients (ATTAC-AF)||Endoscopic Technologies, Inc|No|Terminated|September 2012|May 2014|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|80 Years|No|||April 2014|April 22, 2014|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683045||79559|
NCT01683903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCARD|Comparison of Cardiac Rehabilitation Benefits Between Coronary and Non-coronary Patients Through a 24 Months Follow-up After Myocardial Infarction: the "INCARD" Study|Comparison of Cardiac Rehabilitation Benefits Between Coronary and Non-coronary Patients Through a 24 Months Follow-up : the "INCARD" Study|INCARD|Centre Hospitalier Sud Francilien|No|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic heart failure patients|September 2012|September 10, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01683903||79493|
NCT01684163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYX13-C-202|Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants|Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder||Naurex, Inc|No|Completed|November 2012|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|369|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684163||79473|
NCT01709058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRCA-02-2011|Study on the Effects of Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older|Prospective, Randomized, Single Blind Trial on the Effects of Paravertebral Intramuscular Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older|O2-O3|Istituto Nazionale di Ricovero e Cura per Anziani|No|Recruiting|August 2012|August 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|65 Years|N/A|No|||October 2012|October 17, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709058||77562|
NCT01709071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-256B|Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants|Double Blind Dose - Escalation, Randomized, Controlled, Phase I-II Trial to Evaluate Safety and Immunogenicity of Three Doses of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Infants||National Institute for Public Health and the Environment (RIVM)|Yes|Completed|February 2012|May 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|140|||Both|56 Days|63 Days|Accepts Healthy Volunteers|||February 2014|February 20, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709071||77561|
NCT01709344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12110|Reducing Disability in Older Adult Cancer Survivors|A Phase I Randomized Controlled Trial of a Problem-solving Occupational Therapy Intervention for Older Adult Cancer Survivors||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|February 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|72|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709344||77540|
NCT01709656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2012]2-31|A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis|A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis||Sun Yat-sen University|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Both|16 Years|65 Years|No|||February 2015|February 10, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01709656||77516|
NCT01710254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-12F08|Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients|Detection of Coronary Artery Disease in Patients With Atrial Fibrillation Using Regadenoson Stress MRI|RECAD-AF|University of Utah|Yes|Recruiting|January 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|32|||Both|18 Years|100 Years|No|||March 2016|March 21, 2016|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710254||77471|
NCT01710878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR07-001|Performance and Safety of a Second Generation Antimicrobial Graft in Abdominal Position|Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in Abdominal Position|SYNERGY|Maquet Cardiovascular|No|Completed|February 2008|December 2012|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|85 Years|No|||November 2013|November 24, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01710878||77424|
NCT01711190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53708|Astigmatism Post-trabeculectomy|The Effect of Trabeculectomy on Astigmatism.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Probability Sample|All patients having a primary trabeculectomy between January and April 2012 for glaucoma        that was not adequately controlled with maximal tolerated medical therapy and/or laser        therapy.|June 2013|June 22, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01711190||77400|
NCT01710839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12246|Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion|A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.|WAVE|Greater Houston Retina Research|No|Completed|October 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710839||77427|
NCT01710852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 329993-CS6|Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation|A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients With Paroxysmal Atrial Fibrillation|ASET|Ionis Pharmaceuticals, Inc.|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01710852||77426|
NCT01711177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM3117-Dubois/Pham|Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma|Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma||Université de Montréal|Yes|Not yet recruiting|October 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01711177||77401|
NCT01711450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-263-SDR|Success of Paravertebral Blocks in Analgesia for Interventional Hepatic Procedures|Randomised Double Blind Controlled Study of the Effectiveness of Paravertebral Nerve Block in Decreasing Analgesia Requirements and Improving Patient Experience During Interventional Hepatic Procedures.||McGill University Health Center|No|Withdrawn|December 2012|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|95 Years|No|||March 2016|March 22, 2016|October 18, 2012||No|Institutional Ethics Board concern regarding sham procedure, requiring modifications that are    not feasible within the man-power limitations of our institution.|No||https://clinicaltrials.gov/show/NCT01711450||77380|
NCT01712126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRHY-T300-PVFD-1|Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712126||77328|
NCT01711801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28373|A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.||Hoffmann-La Roche||Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|3||Actual|53|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711801||77353|
NCT01712451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-11|Dose-ranging Study|Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects|LIPO-102-CL-11|Neothetics, Inc|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712451||77303|
NCT01712698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI|Diffusion Tensor Imaging to Assess the Functional Outcomes of Adults With Cervical Spinal Cord Injuries|Diffusion Tensor MRI to Assess Subacute Functional Outcomes in Patients With Acute Cervical Spinal Cord Injuries||Washington University School of Medicine|No|Recruiting|January 2014|June 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Probability Sample|Patients with a traumatic cervical spinal cord injury|February 2014|February 3, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01712698||77284|
NCT01712971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPD|Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery|Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Randomized Trial on Standard Open Versus Minimally Invasive Surgery||University Hospital, Gasthuisberg|No|Withdrawn|November 2012|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Patients suffering from pancreatic or peri-ampullary tumour|September 2013|September 16, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01712971||77264|
NCT01713270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-SR-080|Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation|RSDforAF|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|July 2012|July 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2013|July 4, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713270||77241|
NCT01713283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0114|Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection||Gilead Sciences|No|Completed|October 2012|February 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 17, 2012|Yes|Yes||Yes|November 18, 2014|https://clinicaltrials.gov/show/NCT01713283||77240|
NCT01682499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB/COSA # 079-12|Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy|Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy in Earlier Stage Breast Cancer||Beth Israel Medical Center|Yes|Completed|August 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|21 Years|N/A|No|||September 2014|September 24, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01682499||79601|
NCT01682798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL/LC-001|Study of Yili "Changqing" Pro-ABB Yoghurt in the Improvement of Human Gastrointestinal Tract System|The Clinical Research on the Efficiency of Yili "Changqing" Pro-ABB Probiotic Yogurt in the Improvement of Human Gastrointestinal Tract System||Inner Mongolia Yili Industrial Group Co., Ltd||Completed|May 2009|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|400|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01682798||79578|
NCT01683630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICID-2012-FLU-A,B-02|Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada|Comparison of the Epidemiology and Clinical Outcomes of Laboratory-Confirmed Influenza A and Influenza B Cases in Manitoba, Canada||International Centre for Infectious Diseases, Canada|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1849|||Both|6 Months|N/A|No|Non-Probability Sample|Any person who normally resides in Manitoba and who has been continuously covered during        the study period will be eligible for inclusion in the study.|September 2015|September 25, 2015|August 31, 2012||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01683630||79514|
NCT01683357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-1STAGE LONG-TERM|Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases|LONG-TERM RESULTS AFTER ONE-STAGE ULTRASOUND-GUIDED HEPATECTOMY IN PATIENTS WITH MULTIPLE BILOBAR COLORECTAL LIVER METASTASES: TOWARDS NEW CONCEPTS OF RADICAL RESECTION BY MEANS OF AN INTENTION TO TREAT ANALYSES||University of Milan|No|Completed|September 2001|July 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|N/A|N/A|No|Probability Sample|Patients with multiple (> or = to 4) and bilobar colorectal liver metastases|September 2012|September 6, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01683357||79535|
NCT01683916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12-198|Anesthetic Requirement and Stress Hormone Response During Surgery in Spinal Cord-injured Patients|Chonnam National University Hospital IRB||Chonnam National University Hospital|No|Recruiting|January 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|45|||Both|10 Years|70 Years|No|Non-Probability Sample|ASA physical status II, with chronic, clinically complete cord injuries scheduled for a        surgery for pressure sore below the level of the neurologic lesion under general        anesthesia.|December 2010|September 11, 2012|September 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01683916||79492|
NCT01708811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOF-KS1|Hyponatremia and Myometrium Contractility. An Invitro Study|Will Reduction in Plasma Sodium Reduce Myometrium Contractility in Humans? An Invitro Study of Pregnant Myometrium at Term.||Karolinska University Hospital|No|Terminated|October 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|None Retained|Biopsies of pregant myometrium|Female|18 Years|48 Years|No|Non-Probability Sample|Healthy women with singleton pregancies requiring delivery planned caesarean section.|October 2015|October 12, 2015|October 15, 2012||No|Few biopsies showed the expected pattern We suspect erroeneous method.|No||https://clinicaltrials.gov/show/NCT01708811||77581|
NCT01708824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCRF 2012/595|Diet and Physical Activity Intervention in CRC Survivors|The Acceptability and Feasibility of a Diet and Physical Activity Intervention to Prevent Recurrence in Colorectal Cancer Survivors: a Phase 2 Study||The University of Hong Kong|No|Active, not recruiting|April 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01708824||77580|
NCT01709955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-13|The Effects of Glucomannan on Weight Loss|||New York Chiropractic College|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709955||77493|
NCT01710228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU092011-077|Alternative Treatment Paradigm for Natalizumab Trial|Alternative Treatment Paradigm for Natalizumab Trial|ATP|University of Texas Southwestern Medical Center|Yes|Withdrawn|July 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||July 2012|December 1, 2014|September 4, 2012||No|sponsor stopped|No||https://clinicaltrials.gov/show/NCT01710228||77472|
NCT01710605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2011-09|Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers|Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.||Institut Curie|No|Recruiting|February 2012|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01710605||77445|
NCT01710592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 06-05|A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer|A Randomised Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer|ELECT|ICORG- All Ireland Cooperative Oncology Research Group|No|Completed|May 2007|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01710592||77446|
NCT01710891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 11-3338|Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management|Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management||Minneapolis Medical Research Foundation|Yes|Completed|October 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710891||77423|
NCT01711463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115199|Relovair PD PK in Chinese Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Four-way Crossover Study to Evaluate and Compare the Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate /Vilanterol in Different Dose Combination (50/25mcg, 100/25mcg and 200/25mcg) After Single and Repeat Dose Administration From a Novel Dry Powder Device in Healthy Chinese Subjects||GlaxoSmithKline|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01711463||77379|
NCT01711788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-UCBT|Intrabone Infusion of Umbilical Cord Blood Stem Cells|A New Approach to Improve Long-term Hematopoietic Recovery After Allogeneic Umbilical Cord Blood Transplantation in Children - Intrabone Infusion of Umbilical Cord Blood Stem Cells||St. Justine's Hospital|Yes|Recruiting|November 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|1 Year|21 Years|No|||November 2015|November 16, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711788||77354|
NCT01712100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBE-T300-PVFD-1|Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|August 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712100||77330|
NCT01712113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBE-T300-PVFS-1|Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|August 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712113||77329|
NCT01712139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRHY-T300-PVFS-1|Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712139||77327|
NCT01711476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCCBI 018-2008-104|Meal Timing on Glucose and Hyperandrogenism in PCOS Women|Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|MealTimePCOS|Hospital de Clinicas Caracas|Yes|Recruiting|October 2012|January 2013|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|22 Years|50 Years|No|||January 2013|January 20, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01711476||77378|
NCT01712165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FON-ALTHEA-SG-2012-01|Micronutrient-supplemented Milk Study in Women of Childbearing Age|Micronutrient-supplemented Milk Study in Women of Childbearing Age||Fonterra Research Centre|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|70|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712165||77325|
NCT01712178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-390|A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety|Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis||AbbVie|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|June 14, 2012|No|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT01712178||77324|
NCT01712724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSN1207-000144|Effects of Combined Resistance and Aerobic Training vs Aerobic Training on Cognition and Mobility Following Stroke|Effects of Combined Resistance and Aerobic Training vs Aerobic Training on Cognition and Mobility Following Stroke|TRI-RAvA|University Health Network, Toronto|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||December 2015|December 8, 2015|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712724||77282|
NCT01712672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130014|Bacterial Arrangement on the Teeth|Bacterial Arrangement in Supragingival Biofilms||National Institutes of Health Clinical Center (CC)||Completed|October 2012|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|January 8, 2016|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712672||77286|
NCT01712685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130018|Imaging Studies of Kidney Cancer Using 18F-VM4-037|PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status||National Institutes of Health Clinical Center (CC)|No|Terminated|October 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 20, 2012|Yes|Yes|Study was closed to accrual because imaging agent was no longer available.|No|July 31, 2014|https://clinicaltrials.gov/show/NCT01712685||77285|Study was closed to accrual because imaging agent was no longer available.
NCT01712984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QID01|Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years|Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 Through 64 Years||Sanofi|No|Completed|October 2012|October 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3360|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|October 22, 2012|Yes|Yes||No|December 15, 2013|https://clinicaltrials.gov/show/NCT01712984||77263|
NCT01713296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/11.01|Pazopanib in Relapsed and Refractory Small Cell Lung Cancer|A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC)||Hellenic Oncology Research Group|No|Completed|November 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01713296||77239|
NCT01683331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK092475-01|A Clinical Trial to Prevent New Onset Diabetes After Transplantation|A Clinical Trial to Prevent New Onset Diabetes After Transplantation|ITP-NODAT|University of Michigan|Yes|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01683331||79537|
NCT01683344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE044PIC|Clinical and Health Economic Study of PICO in a Community Care Setting|A 100 Patient, Prospective, Randomised, Clinical Evaluation Comparing Clinical and Health Economic Outcomes Between Patients With Chronic or Sub-acute Wounds Treated With Either PICO or Standard Care Dressings||Smith & Nephew Wound Management Inc|No|Recruiting|January 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683344||79536|
NCT01683643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA031879|Screening, Brief Intervention, and Referral to Treatment for Offenders|Screening, Brief Intervention, and Referral to Treatment for Offenders|SBIRT|University of California, Los Angeles|Yes|Active, not recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|100 Years|No|||February 2016|February 3, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01683643||79513|
NCT01683695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101103|Safety Study of AMG 557 in Subjects With Lupus Arthritis|A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis||Amgen|No|Active, not recruiting|June 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||March 2016|March 24, 2016|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01683695||79509|
NCT01714661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-015|Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy||FORUM Pharmaceuticals Inc|No|Active, not recruiting|October 2012|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|700|||Both|18 Years|50 Years|No|||June 2015|June 23, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714661||77135|
NCT01709669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001191|The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease|The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease|GRACE|Massachusetts General Hospital|No|Completed|September 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|212|Samples Without DNA|Analyzed Blood Samples:      Subjects will have a blood draw for the following biological factors that are important to      cardiac health and may be modified by psychological states: Inflammation will be measured      via interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP), soluble      intercellular adhesion molecule-1 (sICAM-1), tumor necrosis factor alpha (TNF-α), and      overall cardiac prognosis will be assessed using N-terminal pro-brain natriuretic peptide      (NT-proBNP). A total of 15 ml/cc of blood will be drawn (this is equivalent to 3 tablespoons      of blood).      Retained Blood Samples:      Given that additional, more sensitive/critical markers of cardiac outcomes may be identified      in the near future, participants will be given the option to allow us to store their blood      samples for additional biomarker analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Ellison Cardiac Care Units at Massachusetts General Hospital.|March 2015|April 28, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01709669||77515|
NCT01709682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAF-DT-RA|A Comparison of the Drug Therapy Versus Re-Ablation|Progression of Atrial Fibrillation After a Failed Initial Ablation Procedure in Patients With Paroxysmal Atrial Fibrillation: A Randomized Comparison of the Drug Therapy Versus Re-Ablation||Meshalkin Research Institute of Pathology of Circulation|No|Completed|November 2007|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|65 Years|No|||October 2012|October 16, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709682||77514|
NCT01710566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3.4|Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in Uniject®||Gynuity Health Projects|Yes|Withdrawn|July 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|No|||February 2016|February 12, 2016|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01710566||77448|
NCT01709981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02573|Anti-inflammatory Effects of Colchicine in PCI|Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention||New York University School of Medicine||Recruiting|June 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709981||77491|
NCT01710618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359367-12|SEXI: Sciatic Expression and Identification of Differential Proteins in Traumatized Versus Nontraumatized Nerves|SEXI: Sciatic Expression and Identification of Differential Proteins in Traumatized Versus Non-traumatized Nerves|SEXI|Defense and Veterans Center for Integrative Pain Management|No|Recruiting|July 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|sciatic nerve specimen will be obtained|Both|18 Years|89 Years|No|Non-Probability Sample|Male or female Operation Iraqi Freedom (OIF)/(Operation New Dawn (OND) or Operation        Enduring Freedom (OEF) veterans who meet eligibility criteria who require an amputation        revision occurring during their initial hospital admission.|November 2012|November 14, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710618||77444|
NCT01710917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN9512|A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment|The Efficacy of Targinact® Treatment With Respect to Quality of Life (Overall Health Assessment) in Chronic Severe Pain Patients Compared to Previous Analgesic Treatment: a Non-interventional, Observational Study.||Mundipharma CVA||Recruiting|September 2012|January 2014|Anticipated|November 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Both|18 Years|N/A|No|Probability Sample|Primary and Secondary care|November 2013|November 11, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01710917||77421|
NCT01710904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN9511|A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain|The Evaluation of Targinact® in Daily Practice, With Regards to Pain Relief and Constipation, in Chronic Severe Pain Patients Compared to Previous Prolonged Release Oxycodone Treatment: a Non-interventional, Observational Study.||Mundipharma CVA||Completed|September 2012|January 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|N/A|No|Probability Sample|Primary and Secondary Care|April 2015|April 7, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710904||77422|
NCT01711203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spondy 12-35|The Addition of a Pilates Program for Short-Term Improvements in Patients With Spondylolysis or Spondylolisthesis|The Addition of a Pilates Program for Short-Term Improvements in Self Report and Physical Functions With Patients With Spondylolysis or Spondylolisthesis: A Randomized Clinical Trial||Walsh University|No|Completed|October 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|8 Years|21 Years|No|||January 2015|January 18, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01711203||77399|
NCT01711489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0030|A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711489||77377|
NCT01711814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RA25|A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study|A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study||Astellas Pharma Inc|No|Active, not recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|611|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711814||77352|
NCT01712191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00017|Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant|Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant||Active Implants|Yes|Active, not recruiting|January 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|35 Years|75 Years|No|||June 2015|June 22, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01712191||77323|
NCT01712464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-033|Modulation of Reinforcement Learning|Modulation of Reinforcement Learning and Neuronal Activation in Ventral Stratum by Oxytocin - a Pilot Study at Autism Spectrum Disorder||RWTH Aachen University|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|46|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01712464||77302|
NCT01703520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-162|Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).|Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden||Merck Sharp & Dohme Corp.|No|Active, not recruiting|May 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|428000|||Male|35 Years|N/A|No|Probability Sample|Population-based health and medical registries, prescription registries, and mortality        registries in Denmark, Finland, Norway, and Sweden|March 2016|March 21, 2016|September 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703520||77987|
NCT01712425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChAd-MVA.HIVconsv-BCN01|Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals|Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals With Early Viral Suppression After Initiation of Antiretroviral Therapy (HAART)||IrsiCaixa|No|Active, not recruiting|October 2012|October 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|60 Years|No|||September 2015|September 7, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01712425||77305|
NCT01713309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBP01|Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)|Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With Granulocyte Colony-stimulating Factor (Filgrastim)|HBP-Neupogen|Helsinki University Central Hospital|No|Completed|January 1996|September 1998|Actual|June 1998|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01713309||77238|
NCT01708889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-019|Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction|An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction|PK|Bristol-Myers Squibb|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|43|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01708889||77575|
NCT01708902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.18|Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients|A Phase III Randomised, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Fix Dose Combination of Linagliptin 2.5 mg + Metformin 500 mg, or of Linagliptin 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg, Twice Daily), and Linagliptin (5.0 mg, Once Daily) Over 24 Weeks in Treatment naïve Type 2 Diabetic Patients With Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|876|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|October 16, 2012||||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01708902||77574|
NCT01708915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69.52|Nonivamide/Nicoboxil Ointment in Acute Low Back Pain|A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2.5% Nicoboxil/0.4% Nonivamide Versus 2.5% Nicoboxil, 0.4% Nonivamide and Placebo in Patients 18 to 65 Years of Age With Acute Low Back Pain||Boehringer Ingelheim||Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|805|||Both|18 Years|65 Years|No|||May 2014|May 20, 2014|October 16, 2012||||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01708915||77573|
NCT01683929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc017112CTIL|The Effects of Oral Glucose Compared to Sweetener Drinking on Hormonal/Metabolic Responses|The Effects of Oral Glucose Compared to Sweetener Drinking on Hormonal/Metabolic Responses and 24 Hour Macronutrient Consumption - A Double Blind, Cross-over Study||Meir Medical Center|No|Completed|May 2013|January 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|12|||Both|25 Years|35 Years|Accepts Healthy Volunteers|||May 2014|April 13, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01683929||79491|
NCT01715571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052709|Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate and No Erectile Dysfunction|Clinical and Physiological Assessment of Noninvasive Penile Afferent Vibratory Stimulation of Both Surfaces of the Penis Using the Viberect® Device in Men With Mild to Moderate and No Erectile Dysfunction.||Johns Hopkins University|No|Recruiting|March 2013|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|October 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715571||77065|
NCT01715584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5982|Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics|Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics? - A Pilot Study. Optional Deoxyribo-Nucleic Acid Donation for the Study of Hypertension.||Lawson Health Research Institute|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|80|||Both|40 Years|N/A|No|||April 2015|April 8, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01715584||77064|
NCT01709357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-001|Short and Medium-term Effects of Manual Therapy on Latent Myofascial Pain|Short and Medium-term Effects of Manual Therapy on Latent Myofascial Pain : a Comparative Study||Escola Superior de Tecnologia da Saúde do Porto|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 16, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709357||77539|
NCT01709370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOTR-N007/LET-CDK|Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women|Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women||Organisation for Oncology and Translational Research|Yes|Recruiting|February 2012|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||October 2012|December 29, 2013|October 15, 2012||||No||https://clinicaltrials.gov/show/NCT01709370||77538|
NCT01709968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Com120009ctil|Magnesium Oxide Monohydrate for Nocturnal Leg Cramps|Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.|MgNLC|Clalit Health Services|Yes|Terminated|February 2013|April 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|21 Years|N/A|No|||January 2016|January 19, 2016|October 17, 2012||No|Blinded interim analysis was presented to an independent data monitoring committee.    Recommendation, submitted April 1, 2014, was early termination for futility.|No||https://clinicaltrials.gov/show/NCT01709968||77492|
NCT01710267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12041|Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)|Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)|RivaMoS2|Luzerner Kantonsspital|Yes|Completed|March 2013|December 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Plasma samples for coagulation assays|Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteers aged 18-65 years|March 2015|March 31, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710267||77470|
NCT01701713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS_CSB-Brandenburg|TDCS in Acute Stroke|Safety Study of Transcranial Direct Current Stimulation in Aphasia Therapy in Acute and Post-acute Stroke|TDCS-aphasia|Charite University, Berlin, Germany|No|Recruiting|June 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|85 Years|No|||October 2012|October 5, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01701713||78126|
NCT01701726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB518501-1|Effect of Acupuncture on Patients With Mild Hypertension|Acupuncture for Patients With Mild Hypertension: Study Protocol of an Open-label Multicenter Randomized Controlled Trial|EAPMH|Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|428|||Both|40 Years|75 Years|No|||September 2014|September 7, 2014|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701726||78125|
NCT01710930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11-0158|Protocol TARC-ABPA|Interest of TARC Serum Marker for Follow-up of Patients With Allergic Broncho-Pulmonary Aspergillosis (ABPA), Excluding Cystic Fibrosis||Nantes University Hospital|Yes|Active, not recruiting|July 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01710930||77420|
NCT01711216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-688|Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan|A Post-Marketing, Prospective, Multicenter, Observational Program: Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan||Abbott|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|999|||Female|18 Years|40 Years|No|Non-Probability Sample|women with irregular menstrual cycle due to progesterone deficiency|November 2015|November 23, 2015|August 22, 2012||No||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01711216||77398|Follow up period was limited to 6 months of observation. Pregnancy incidence was not the aim of research, however, spontaneous pregnancies were observed in 56 (5.6%) patients following standard dosages of dydrogesterone for irregular cycle treatment.
NCT01711502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORO-XXX-2012/1|Epidemiology and Management of Metastatic Breast Cancer|Epidemiology and Therapeutic Management of Metastatic Breast Cancer in Romania: A Retrospective Cohort Study||AstraZeneca|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|128|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients diagosed with metastatic breast cance, age > 18 years|January 2014|January 29, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711502||77376|
NCT01711515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01733|Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer|A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes||National Cancer Institute (NCI)||Recruiting|October 2012|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Female|18 Years|N/A|No|||January 2016|March 14, 2016|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711515||77375|
NCT01711827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0024|A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects|A Phase 1, Open-label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|October 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711827||77351|
NCT01711840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589LL00001|Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy|Symbicort Turbuhaler 30/60 Clinical Experience Investigation for Treatment With Symbicort as Maintenance Therapy and as Needed in Response to Symptoms||AstraZeneca||Completed|November 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2409|||Both|N/A|N/A|No|Non-Probability Sample|Patients receiving Symbicort Turbuhaler as maintenance and reliever therapy for the first        time due to 'bronchial asthma ',and possibly requiring as-needed inhalations during the        observation period|September 2015|September 2, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01711840||77350|
NCT01703221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-020|Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)|A Phase III, Multicenter, Randomized, Placebo- and Sitagliptin-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitis Who Have Inadequate Glycemic Control on Diet/Exercise Therapy||Merck Sharp & Dohme Corp.|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|414|||Both|20 Years|N/A|No|||September 2015|September 29, 2015|October 5, 2012|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01703221||78010|
NCT01703234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATARAMFGF232012|FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients|||Gulhane School of Medicine||Completed|January 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 6, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01703234||78009|
NCT01703533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-RETT-001|A Safety Study of NNZ-2566 in Patients With Rett Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome||Neuren Pharmaceuticals Limited|Yes|Completed|March 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|16 Years|45 Years|No|||March 2016|March 21, 2016|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703533||77986|
NCT01699581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-HEM-03-MCC|Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant|Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant||University of Kentucky|Yes|Terminated|September 2012|October 2015|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|September 27, 2012|Yes|Yes|Research cancelled following interim analysis|No||https://clinicaltrials.gov/show/NCT01699581||78290|
NCT01712711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1391/7/24-579|Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Diabetic Subjects With Non-alcoholic Fatty Liver Disease||Tehran University of Medical Sciences|No|Completed|September 2012|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||March 2013|March 21, 2013|October 19, 2012||No||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01712711||77283|No limitation existed.
NCT01703780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI11B04|The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis|The Prevalence and the Prognosis of Resistant Hypertension Ascertained With Systemic Investigation and Optimal Treatment With Antihypertensive Drugs|doublepres|Chinese Academy of Medical Sciences, Fuwai Hospital||Active, not recruiting|July 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Actual|9638|Samples With DNA|whole blood, serum, peripheral white blood cells, urine|Both|30 Years|75 Years|No|Probability Sample|50% hypertensive patients from community population, 50% hypertensive patients from clinic        as consecutive patients|March 2016|March 9, 2016|October 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01703780||77967|
NCT01699828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186/2011|Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET|Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET||Centre for Addiction and Mental Health|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|6|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01699828||78271|
NCT01683123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|get-buf-2010-02|Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT|Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.|BUFLU|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|Yes|Active, not recruiting|July 2007|October 2012|Anticipated|June 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|143|||Both|N/A|N/A|No|Non-Probability Sample|Adults with myeloid malignancies submitted to allogeneic HSCT with an HLA identical        sibling donor|September 2012|September 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683123||79553|
NCT01683136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-09-11|Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder|||Shalvata Mental Health Center|Yes|Not yet recruiting|September 2012|||March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||September 2012|September 6, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01683136||79552|
NCT01682811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 14555|Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)|Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light||Medical College of Wisconsin|No|Recruiting|November 2011|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||October 2015|October 23, 2015|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682811||79577|
NCT01683084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL0041ARG|Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms|Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms|TEDY|Palo Alto Veterans Institute for Research|No|Active, not recruiting|September 2012|August 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|85 Years|No|||March 2015|March 2, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01683084||79556|
NCT01715298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2318|NVA237 BID Versus Placebo Twelve-week Efficacy Study|A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients||Novartis|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|432|||Both|40 Years|N/A|No|||March 2015|March 9, 2015|October 24, 2012|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01715298||77086|
NCT01715597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_GO_016|Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma|Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy||Seoul National University Hospital|No|Recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|N/A|N/A|No|||December 2013|December 24, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01715597||77063|
NCT01709695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1825|Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD|Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD): an Functional Magnetic Resonance Imaging(fMRI) Study of Brain Activation Pre and Post Treatment||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|8 Years|15 Years|No|||June 2013|August 22, 2013|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709695||77513|
NCT01709708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004TI|Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine|Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study|Tx360|Tian Medical Inc.|Yes|Completed|September 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|80 Years|No|||November 2014|November 12, 2014|October 16, 2012|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01709708||77512|
NCT01709721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-HYD201US|Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump|A Controlled, Two-Arm, Parallel Group, Randomized Withdrawal Study to Assess the Safety and Efficacy of Hydromorphone Hydrochloride Delivered by Intrathecal Administration Using a Programmable Implantable Pump||Mallinckrodt|No|Recruiting|February 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709721||77511|
NCT01710280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS|Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia|||King's College London|No|Completed|May 2011|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710280||77469|
NCT01702025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N66001-10-C-2134|Rapid Acclimatization to Hypoxia at Altitude|Rapid Acclimatization to Hypoxia at Altitude||Colorado State University|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|41|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 3, 2012|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01702025||78102|
NCT01711229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ofirmev|Equality Study of Ofirmev vs Oral Acetaminophen|Prospective Randomized Equivalence Trial Comparing the Analgesic Efficacy of Ofirmev® Compared to a 1.5 Gram Dose of Oral Acetaminophen for Arthroscopic Rotator Cuff Repair||Babiash, Kimberly H., M.D.|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711229||77397|
NCT01711528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01737|Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma||National Cancer Institute (NCI)||Recruiting|December 2012|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711528||77374|
NCT01711541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02009|Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer|Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - A Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)|No|Recruiting|October 2012|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|February 15, 2016|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711541||77373|
NCT01711853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.166|Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.|An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal||Boehringer Ingelheim||Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|80 Years|No|||January 2015|January 9, 2015|October 19, 2012||||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01711853||77349|
NCT01703247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP-LL-AF|Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation|Ganglionated Plexi Ablation vs Linear Ablation in Patients Undergoing Pulmonary Vein Isolation for Persistent/Longstanding Persistent Atrial Fibrillation: A Randomized Comparison||Meshalkin Research Institute of Pathology of Circulation|No|Completed|January 2008|May 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|65 Years|No|||October 2012|October 9, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703247||78008|
NCT01703260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-NASH_205|Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis|A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis||Takeda|No|Terminated|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|October 2, 2012|Yes|Yes|Company decision; No safety or efficacy concerns (see detailed description)|No|September 21, 2015|https://clinicaltrials.gov/show/NCT01703260||78007|
NCT01703273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384b|Low-level Intervention for Adolescents With Extreme Obesity|Structured Low-level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents With Extreme Obesity, Subproject 2|STEREO|University of Ulm|Yes|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|14 Years|24 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01703273||78006|
NCT01699594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-A-524|Change in Airway Responsiveness After Allergen Exposure|Allergen Induced Increase in Indirect Non-allergic Bronchial Reactivity||University of Saskatchewan|No|Completed|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|65 Years|No|||October 2013|April 8, 2015|October 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699594||78289|
NCT01712997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPH-20121022|Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients|Phase Ⅲ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients|BIPH|Fourth Military Medical University|Yes|Recruiting|September 2012|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|80 Years|No|||February 2014|February 26, 2014|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712997||77262|
NCT01703793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1001-01|Safety and Efficacy Study in Subjects With Seborrheic Dermatitis|A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis||Medicis Global Service Corporation|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|12 Years|N/A|No|||January 2013|January 7, 2013|October 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703793||77966|
NCT01704131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCE12.001|Levosimendan Pharmacokinetics in Children|Pharmacokinetics of Levosimendan in Children With Acute Heart Failure|LevoCorKids|Leiden University Medical Center|No|Recruiting|November 2012|November 2016|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|||Both|N/A|16 Years|No|Probability Sample|All children admitted to the Pediatric Intensive Care Unit with Acute Heart Failure who        will receive Levosimendan as part of their treatment.        Patients will receive Levosimendan whether they participate in the study (sampling        levosimendan levels) or not.|April 2015|April 14, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01704131||77940|
NCT01699841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1111002616|Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events|||Cornell University|No|Active, not recruiting|April 2012|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|208|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV+ and HIV- mothers and their infants attending a semi-rural clinic and/or rural        dispensaries from birth to 6 months of infant age in north western Tanzania.|November 2014|November 21, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01699841||78270|
NCT01699854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-055|Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy|||Rigshospitalet, Denmark|Yes|Terminated|August 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|September 21, 2012||No|Expiration of the placebo patch|No||https://clinicaltrials.gov/show/NCT01699854||78269|
NCT01714999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-12|Treatment of Acute Traumatic Laceration of the Olecranon and Prepatellar Bursa|A Prospective Evaluation of the Current Treatment Regime for Acute Traumatic Laceration of the Olecranon and Prepatellar Bursa||Ludwig-Maximilians - University of Munich|No|Recruiting|April 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||April 2014|April 14, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714999||77109|
NCT01684215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481010|A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer|A Phase 1/2 Study Of The Efficacy, Safety, And Pharmacokinetics Of Oral PD-0332991, A Cyclin-Dependent Kinase 4 And 6 (CDK4/6) Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer||Pfizer|No|Active, not recruiting|October 2012|January 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|58|||Both|20 Years|N/A|No|||February 2016|February 5, 2016|September 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01684215||79469|
NCT01683383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22993|California Transport Cooling Trial|A Randomized Clinical Trial of Therapeutic Hypothermia During Transport for Hypoxic Ischemic Encephalopathy (HIE): Device-regulated Cooling Versus Standard Practice.|CTCT|Stanford University|Yes|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|N/A|6 Hours|No|||December 2014|December 1, 2014|September 6, 2012|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01683383||79533|1, The criteria used to initiate hypothermia varied. 2, Operational errors occurred in 9 newborns during device regulated cooling. 3, 9.6% of temperatures in the control arm were missing.
NCT01715623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12002 PRIERR|Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.|Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.|PRIERR|University Hospital, Limoges|No|Completed|October 2012|June 2015|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|486|Samples Without DNA|We previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and      antibody secretion are controlled by a polymorphic "3' regulatory region" (3'RR) of the      immunoglobulin heavy chain (IgH) locus|Both|4 Years|N/A|Accepts Healthy Volunteers|Probability Sample|4 populations :          -  Healthy Volunteers          -  subjects with HPS          -  subjects with peanut allergy or hymenoptera venom allergy          -  lymphoma (biological collection)|October 2015|October 6, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01715623||77061|
NCT01709409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curosurf-01|A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants|A Randomized, Controlled, Partially Double-blinded, Phase 3, Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 31+6 Weeks Gestational Age||Ottawa Hospital Research Institute|Yes|Active, not recruiting|March 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|24 Weeks|31 Weeks|No|||October 2015|January 27, 2016|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01709409||77535|
NCT01709994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG001|Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients|Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)||Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales|No|Recruiting|May 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|97|||Both|45 Years|79 Years|No|||October 2012|October 17, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01709994||77490|
NCT01701193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADE001-2011|A Phase I Study For the Reduction of Scar Tissue in Adult Females Undergoing Surgery for an Ectopic Pregnancy|A Randomized, Double-Blind, Placebo Controlled Phase I Study of an Amino Acid For the Reduction of Peritoneal Adhesions in Adult Females Undergoing a Laparoscopic Salpingostomy for the Removal of an Ectopic Pregnancy||AdeTherapeutics Inc.|Yes|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|38|||Female|18 Years|50 Years|No|||October 2012|October 3, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701193||78166|
NCT01701206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH090884-01|Online Social Networks for HIV Prevention Among African American and Latino MSM|||University of California, Los Angeles||Recruiting||||||N/A|Interventional|N/A|2||||||Male|18 Years|N/A||||October 2012|October 4, 2012|October 4, 2012||||No||https://clinicaltrials.gov/show/NCT01701206||78165|
NCT01701492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-077 BMTPE3|Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation|Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|8 Years|N/A|No|Non-Probability Sample|Survivors of SCT who are > 5 years since transplant and are returning for a transplant        clinic outpatient follow-up visit will be recruited to participate on study. We will        recruit patients beginning at age 8 years, with no upper age limit, although we anticipate        that most patients will be between 8 and 25 years at the time of assessment. For patients        in the age range 8-21 we will obtain data by both self- and parent-report. However, if        patients age 18-21 present to clinic without a parent, they will still be eligible for        study, and for these patients, as well as those ≤ 21 years, we will obtain performance        based and self-report measures only.|October 2015|October 16, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701492||78143|
NCT01701739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25562|A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers|An Open-label, Two-period Fixed-sequence Study to Investigate the Effect of Multiple Doses of Aleglitazar on a Single Dose of Digoxin in Healthy Subjects||Hoffmann-La Roche||Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701739||78124|
NCT01701752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-01.1_CS_03|Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults|A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.||Immune Targeting Systems Ltd|Yes|Completed|September 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|120|||Both|65 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701752||78123|
NCT01702337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114420|Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine|Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model||GlaxoSmithKline||Completed|February 2010|February 2010|Actual|February 2010|Actual|N/A|Observational|N/A||2|Actual|1|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hypothetical group of women vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan.|October 2012|October 4, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01702337||78078|
NCT01702350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115244|A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study|A Study to Evaluate the Relative Bioavailability of Five Different Oral Formulations of GSK2251052 and the Multiple-dose, Safety, Tolerability, and Pharmacokinetics of GSK2251052 With and Without Food in Male and Female, Young and Elderly Healthy Volunteers|Relative Bio|GlaxoSmithKline|No|Terminated|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 4, 2012|September 20, 2012||No|Study was terminated in March 2012 due to lack of eficacy in a seperate Phase II study in    patients.|No||https://clinicaltrials.gov/show/NCT01702350||78077|
NCT01702701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCWEoEMVF|Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone|Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone||Medical College of Wisconsin|No|Active, not recruiting|January 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702701||78050|
NCT01702948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912479|Studying Nicotine Addiction With Transcranial Magnetic Stimulation|Understanding the Neurocircuitry of Nicotine Addiction Using Repetitive Transcranial Magnetic Stimulation (rTMS)||National Institutes of Health Clinical Center (CC)||Completed|September 2012|||||Phase 0|Observational|Time Perspective: Retrospective|||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01702948||78031|
NCT01703845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.24|A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.|A Randomised, Open-label, Parallel-group Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) Delivered by the RESPIMAT Inhaler After 3 Weeks Once Daily Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|October 8, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01703845||77962|
NCT01703858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.3|Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608|An Open Label, Randomised, Single Dose, 3-way Cross Over Study to Investigate Relative Bioavailability and Food Effect on Different Formulations of BI 113608 in Healthy Male Subjects, Followed by Fixed Sequence Periods Investigating Influence of Pantoprazole Coadministration and Food Effect on Pharmacokinetics of Different Formulations of BI 113608||Boehringer Ingelheim||Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|October 8, 2012||||No||https://clinicaltrials.gov/show/NCT01703858||77961|
NCT01703871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-1|Music During Diagnostic Hysteroscopy|||Campus Bio-Medico University|No|Active, not recruiting|September 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|N/A|N/A|No|Probability Sample|primary care clinic|September 2012|October 8, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703871||77960|
NCT01699620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66.20.19.1.LV|Comparative Study of Two Surgical Techniques for Soft Tissue Healing and Implant Stability of Cochlear BI300 Implants.|Evaluation of Soft Tissue Healing and Implant Stability of Cochlear Baha BI300 Implants Loaded From 2 Weeks Post-surgery: a Comparison Between Two Surgical Techniques.||Aarhus University Hospital|No|Completed|August 2012|June 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01699620||78287|
NCT01703806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0264|Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation|Early Surgery Versus Conventional Treatment for Asymptomatic Patients With Severe Degenerative Mitral Regurgitation: A Propensity Analysis||Asan Medical Center|Yes|Recruiting|December 2007|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|20 Years|80 Years|No|Probability Sample|From 2007 to 2016, 600 consecutive, asymptomatic patients with severe degenerative MR who        are potential candidates for early surgery, will be enrolled in the present study. Severe        degenerative MR is defined as severe prolapse and/or flail leaflet of the mitral valve        with a proximal isovelocity surface area (PISA) radius > 8 mm.|December 2015|December 29, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703806||77965|
NCT01703819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1201|Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects|Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Double-blind Study in Healthy Probands|NEUPRO-DB|Biologische Heilmittel Heel GmbH|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|31 Years|59 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|October 8, 2012|Yes|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01703819||77964|
NCT01704144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-PTBHIV03|Rifampin and Efavirenz Interactions in Older Children|Effect of Rifampin-containing Anti-TB Treatment on Efavirenz Pharmacokinetics in HIV/TB Co-infected Children Aged 3 - 14 Years||The Miriam Hospital|Yes|Recruiting|October 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|EDTA plasma Whole blood DNA|Both|3 Years|14 Years|No|Non-Probability Sample|HIV-infected children with and with TB aged 3 to 14 years old|September 2012|October 16, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704144||77939|
NCT01704157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0601|A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device|A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device||MyoScience, Inc|No|Completed|September 2012|July 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01704157||77938|
NCT01700413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CSF-2011-141|Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia|Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy.||Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias|No|Completed|October 2012|April 2015|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|70 Years|No|||January 2016|January 27, 2016|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700413||78226|
NCT01715285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100900|A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)|A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)||Janssen Research & Development, LLC|Yes|Active, not recruiting|February 2013|August 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1209|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715285||77087|
NCT01685073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068969|The Role of Sleep in the Treatment of Cannabis Use Disorders|The Role of Sleep in the Treatment of Cannabis Use Disorders||Johns Hopkins University|Yes|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685073||79403|
NCT01685333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOBLA0512IV-I2|PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Crossover Study.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|February 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01685333||79383|
NCT01709747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-HYD202US|Single-arm Study to Assess the Safety of Hydromorphone HCl by Intrathecal Administration|A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration||Mallinckrodt|No|Recruiting|June 2013|June 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709747||77509|
NCT01709760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHEN1101|A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis|ENIA11|TSH Biopharm Corporation Limited|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|N/A|No|||February 2016|February 4, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709760||77508|
NCT01710007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCR10022|Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia|A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With Hypercholesterolemia||Orient Pharma Co., Ltd.|No|Completed|November 2011|November 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|20 Years|80 Years|No|||June 2013|June 14, 2013|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710007||77489|
NCT01701505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-03|Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects|A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects||St. Renatus, LLC|No|Completed|October 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701505||78142|
NCT01701765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-2-PEV|Outcomes and Discharge of Long-stay Psychiatric Patients|Epidemiological Study on Outcomes and Discharges of Psychiatric Patients Living in Italian Residential Facilities (PERDOVE)|PERDOVE|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Yes|Completed|September 2010|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|||Both|18 Years|65 Years|No|Probability Sample|Psychiatric patients staying in residential facilities.|October 2012|October 6, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701765||78122|
NCT01702051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-09/02/2012|Extending Indication for Islet Autotransplantation in Pancreatic Surgery|Autologous Pancreatic Islet Cell Transplantation for Improved Glycaemic Control After Pancreatectomy: Observational Study|AutoTx|Ospedale San Raffaele|Yes|Recruiting|February 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|150|Samples With DNA|Serum, PBMC|Both|18 Years|N/A|No|Probability Sample|Patients who underwent partial or total pancreatectomy|October 2012|March 4, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702051||78100|
NCT01702064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17114|Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients|A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702064||78099|
NCT01702389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1639|Opioid-induced Hyperalgesia After Remifentanil Infusion|Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil?||Oslo University Hospital|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|16|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702389||78074|
NCT01702727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10OY006|I-BiT - Evaluation of a Novel Binocular Treatment System (I-BiTTM) in Children With Amblyopia|Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye').|I-BiT|Nottingham University Hospitals NHS Trust|No|Recruiting|May 2012|May 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|4 Years|8 Years|No|||October 2012|October 5, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01702727||78048|
NCT01702038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALE01|Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE|Rituximab in SLE: Understanding of Long-term Responses and the Impact of B Cell Depletion on T Cells||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn|September 2009|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|65 Years|No|||October 2012|October 4, 2012|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702038||78101|
NCT01702363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115361|Long-term Safety Study for GSK573719 in Japanese|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.|AC4115361|GlaxoSmithKline|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|40 Years|N/A|No|||August 2014|August 21, 2014|September 20, 2012||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01702363||78076|
NCT01702376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113789|This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.|A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers||GlaxoSmithKline|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702376||78075|
NCT01702714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28577|A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease|A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE.||Hoffmann-La Roche||Suspended|August 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|October 1, 2012|Yes|Yes|Project Team decision|No||https://clinicaltrials.gov/show/NCT01702714||78049|
NCT01702961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11892|Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease|A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease|Rituxan+BEAM|Baylor College of Medicine|Yes|Active, not recruiting|June 2002|August 2018|Anticipated|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|N/A|N/A|No|||February 2016|February 1, 2016|October 5, 2012|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT01702961||78030|
NCT01703884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B00531|ANC & Malaria Diagnostic in Pregnancy|Improved Quality of ANC and Diagnostic Services for Malaria in Pregnancy|AQUAMOD|Centre Muraz|No|Completed|August 2012|December 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5254|||Female|16 Years|50 Years|No|||July 2015|July 29, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703884||77959|
NCT01699607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910005822|Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm|Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion|phno_amth|Yale University|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|October 1, 2012||No||No|July 14, 2015|https://clinicaltrials.gov/show/NCT01699607||78288|Preliminary data. Small subject number.
NCT01699867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DxP 2012-02 (Part A)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)||Diagnostic Photonics, Inc.|No|Completed|December 2012|April 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Female|18 Years|N/A|No|Non-Probability Sample|Women with breast cancer undergoing lumpectomy|December 2014|December 12, 2014|October 2, 2012|No|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01699867||78268|
NCT01700114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 20111|Post-Approval Study of MelaFind|Post-Approval Study of MelaFind||MELA Sciences, Inc.|No|Terminated|November 2012|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|487|Samples Without DNA|pathology slides of biopsied tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients of any age, race, ethnicity, or gender, presenting with pigmented skin        lesions that that meet the Indications for Use and Lesion Inclusion and Exclusion        Criteria, including signing the Informed Consent Form, are eligible to participate in this        study. This single-arm study has one study group consisting of eligible lesions on        eligible patients.        Up to six clinical sites in the US will participate in this study, one in each of the six        states in which MelaFind is commercially available. Some of the sites will be located in        urban settings, and some will be located in a suburban or rural setting. At least 50% of        the sites will new, i.e., they did not participate in the MelaFind pivotal study. Some        sites will be academic centers and some private practices.|March 2016|March 10, 2016|October 2, 2012|Yes|Yes|FDA withdrew requirement to complete study|No||https://clinicaltrials.gov/show/NCT01700114||78249|
NCT01700673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1240|A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS|A Phase II Study of 5-Azacitidine (5AC) in Combination With Sargramostim (GM-CSF) as Maintenance Treatment, After Definitive Therapy With Either Stem Cell Transplant (SCT) or Cytarabine-based Chemotherapy, in Patients With Poor-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|June 2013|October 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|6 Months|100 Years|No|||November 2015|November 17, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700673||78206|
NCT01714128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dehdashti FES NCI#9167|FES-PET for Patients Treated on NCI Protocol 8762|Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762||Washington University School of Medicine|Yes|Withdrawn|June 2013|December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||February 2014|February 5, 2014|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714128||77175|
NCT01714141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTI-1R34HL107664-01A1|Multi-Component Technology Intervention for Minority Emerging Adults With Asthma|Multi-Component Technology Intervention for Minority Emerging Adults With Asthma||Wayne State University|Yes|Enrolling by invitation|December 2011|November 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|29 Years|No|||June 2014|June 2, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714141||77174|
NCT01714154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28326|A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls|A Multi Center, Sequential, Open-Label, Multiple-Dose Study of Setrobuvir (STV) Alone and With Co-Administration of Ritonavir-boosted Danoprevir to Evaluate the Safety, Tolerability and Pharmacokinetics of STV, DNV, and Ritonavir (RTV) in Subjects With Mild Hepatic Impairment Compared to Healthy Controls||Hoffmann-La Roche||Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714154||77173|
NCT01714427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXA - LIM|Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment|Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment||Medical University of Vienna|Yes|Completed|July 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01714427||77152|
NCT01714713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-017|A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy||FORUM Pharmaceuticals Inc|No|Suspended|June 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1050|||Both|18 Years|50 Years|No|||September 2015|September 14, 2015|October 19, 2012|Yes|Yes|Study has been suspended due to clinical hold.|No||https://clinicaltrials.gov/show/NCT01714713||77131|
NCT01715012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-03-12|Study of ACCS (Amnion-derived Cellular Cytokine Solution) in Diabetic Subjects With Deep Burns Managed With Skin Grafts|A Phase 2a Randomized, Double Blind, Placebo Controlled, Single-center Study of ACCS (Amnion-derived Cellular Cytokine Solution) Spray in Diabetic Subjects With Deep Burns Managed With Meshed Skin Grafts.||Stemnion, Inc.|Yes|Terminated|October 2012|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|October 22, 2012|Yes|Yes|Enrollment futility|No||https://clinicaltrials.gov/show/NCT01715012||77108|
NCT01686100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102841|CT-angiographic Follow up of Patients That Underwent Coronary Bypass Surgery Between 1993-1997|CT-angiographic Follow Upp of Patients That Underwent Coronary Bypass Surgery Between 1993-1997. A Randomized Longitudinal Trial.||Örebro County Council|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|N/A|N/A|No|||September 2012|September 18, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686100||79325|
NCT01709773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF_Focaltx|Focal Ablation of Cervical Precancer|Focal Ablation of High-grade Cervical Intraepithelial Neoplasia||University of California, San Francisco|No|Active, not recruiting|April 2013|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|21 Years|45 Years|No|||August 2014|August 7, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01709773||77507|
NCT01710020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921004|Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease|Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis||Pfizer|No|Completed|February 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|No|||November 2012|November 19, 2012|October 16, 2012|No|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01710020||77488|
NCT01700881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-ARTH-2|A Nutrition Intervention for Arthritis -2|A Nutrition Intervention for Arthritis-2|WCCR-ARTH2|Physicians Committee for Responsible Medicine|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Both|18 Years|90 Years|No|||October 2015|October 20, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700881||78190|
NCT01700894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09021301-IRB01|Women's Walking Program|Reducing Health Disparities in African American Women: Lifestyle Physical Activity Adherence|WWP3|Rush University Medical Center|Yes|Completed|March 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|288|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01700894||78189|
NCT01702077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0206017435|Neurofeedback for Tourette Syndrome|Neurofeedback of Activity in the Supplementary Motor Area for Tourette Syndrome||Yale University|No|Recruiting|October 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|11 Years|19 Years|No|||December 2015|December 30, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702077||78098|
NCT01702402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000149|Operations Research to Address Unmet Need for Contraception in the Postpartum Period in Sylhet District, Bangladesh|Operations Research to Address Unmet Need for Contraception in the Postpartum Period in Sylhet District, Bangladesh (Healthy Fertility Study)||Johns Hopkins Bloomberg School of Public Health|No|Completed|June 2007|August 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|6916|||Both|N/A|49 Years|No|||September 2014|September 12, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01702402||78073|
NCT01702740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013000|A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus|A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus||Centocor Research & Development, Inc.|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|70 Years|No|||October 2012|October 5, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01702740||78047|
NCT01702974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREHIV-2012|Immune Reconstitution in HIV Disease (IREHIV)|Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate|IREHIV|Karolinska Institutet|Yes|Completed|September 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01702974||78029|
NCT01702987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-31415|Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS|Evaluation of Ubiquinol on the Association of Statins and Mitochondrial Oxidative Capacity Using 31P Magnetic Resonance Imaging||Beth Israel Deaconess Medical Center|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|21|||Both|18 Years|80 Years|No|||February 2015|February 3, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01702987||78028|
NCT01703000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG PROMUS Clinical Trial S2294|NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions|NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)||Boston Scientific Corporation|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|October 5, 2012|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01703000||78027|
NCT01703286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.105|Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)|Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')||Boehringer Ingelheim||Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|65 Years|No|||January 2015|January 12, 2015|October 1, 2012||||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01703286||78005|
NCT01703299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC11016|Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments|Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments|ERIC|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2012|March 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|35|Samples Without DNA|faeces, bacterial DNA|Both|18 Years|N/A|No|Non-Probability Sample|hospitalized patients initiating a carbapenem treatment|June 2014|May 12, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01703299||78004|
NCT01703546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-277A|Weight Loss & Comorbidity Resolution With LAGB Alone vs. LAGB With Gastric Plication|Weight Loss & CoMorbidity Resolution With Laparoscopic Adjustable Gastric Band Alone vs. Laparoscopic Adjustable Gastric Band With Gastric Plication||Northwell Health|Yes|Completed|November 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|420|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01703546||77985|
NCT01703832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1202|Explorative Open Label Study of Efficacy Profile of Neurexan® in Experimental Acute Stress Setting in Healthy Subjects|Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Open-Label Study in Healthy Probands|NEUPRO-OL|Biologische Heilmittel Heel GmbH|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|31 Years|59 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|October 8, 2012|Yes|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01703832||77963|
NCT01709565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SamsungMC|Lactate Clearance According to the Presence of Hepatic Dysfunction|Lactate Clearance and Mortality in Patients With Severe Sepsis and Septic Shock: Comparison by Hepatic Dysfunction||Samsung Medical Center|Yes|Recruiting|July 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|245|Samples Without DNA|Interleukin-1, Interleukin-6, Interleukin-10, TNF-alfa|Both|20 Years|N/A|No|Probability Sample|Patients presenting to the emergency department and meeting criteria for severe sepsis or        septic shock at Samsung Medical Center (a 1,960 bed, university-affiliated, tertiary        referral hospital in Seoul, South Korea)|October 2012|October 16, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01709565||77523|
NCT01700127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS/RCN/201208|Predictors of Poor Immune Response to Rotavirus Vaccine in Infants|Predictors of Poor Immune Response to Rotavirus Vaccine in Infants|PPIR|Society for Applied Studies|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|400|||Both|6 Weeks|7 Weeks|Accepts Healthy Volunteers|||June 2013|June 25, 2013|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01700127||78248|
NCT01700140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010003|Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)|Phase II Clinical Study of SyB D-0701 for Radiotherapy Induced Nausea and Vomiting||SymBio Pharmaceuticals||Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind|3||Actual|189|||Both|20 Years|N/A|No|||November 2014|November 11, 2014|September 11, 2012||||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01700140||78247|
NCT01699880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_JDR1|Efficacy of High Flow Nasal Cannula Oxygen to Reduce Desaturation During Tracheal Intubation|High Flow Nasal Cannula Oxygen for Pre and During Procedure Oxygenation During Tracheal Intubation: Comparison With High FiO2 Non Rebreathing Bag Reservoir Facemasks|HAPI|Hôpital Louis Mourier|No|Completed|March 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|101|||Both|18 Years|N/A|No|Probability Sample|ICU patients requiring tracheal intubation|August 2014|August 11, 2014|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699880||78267|
NCT01700426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1234|Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E|Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E||University of Colorado, Denver|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|9 Months|2 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700426||78225|
NCT01700439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-02|Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve|Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent|TRANSFORM™|Edwards Lifesciences|Yes|Recruiting|September 2012|September 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|950|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700439||78224|
NCT01711073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot001|Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease|Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease||Proteonomix, Inc.|Yes|Recruiting|October 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2013|January 23, 2013|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711073||77409|
NCT01715025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2012-7|A New Treatment Option for Heavy Menstrual Bleeding|An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB)||Sydney Centre for Reproductive Health Research|No|Recruiting|April 2013|August 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 17, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01715025||77107|
NCT01715311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2425|Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control|A Randomized, Double-blind Placebo-controlled Study to Compare the Efficacy of Indacaterol With That of Placebo in Patients With COPD Who Have Not Previously Received Maintenance COPD Medication, Using Blinded Tiotropium as Active Control|INITIATE|Novartis|No|Withdrawn|November 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|40 Years|N/A|No|||February 2013|February 5, 2013|October 24, 2012||No|withdrawn prior to patient recruitment|No||https://clinicaltrials.gov/show/NCT01715311||77085|
NCT01710033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921007|A Study Of CP-690,550 In Stable Kidney Transplant Patients|Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients||Pfizer|No|Completed|September 2003|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|28|||Both|18 Years|70 Years|No|||November 2012|November 26, 2012|October 16, 2012|No|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT01710033||77487|
NCT01700907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DES-40-POCD|Optimization of Desflurane in Elderly Patients|Optimization of Desflurane in Elderly Patients Compared With Sevoflurane: A Pilot Study||Sapporo Medical University|Yes|Completed|August 2012|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|65 Years|N/A|No|||November 2014|November 25, 2014|September 30, 2012||No||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01700907||78188|
NCT01701219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-MD-32|Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia|A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia||Forest Laboratories|No|Completed|January 2013|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701219||78164|
NCT01702753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBBIC I Study|Bifidobacterium Animalis Subsp. Lactis in Prevention of Common Infections in Healthy Children Attending Day Care Centers|Bifidobacterium Animalis Subsp. Lactis in Prevention of Common Infections in Healthy Children Attending Day Care Centers - Randomized, Double Blind, Placebo Controlled Study|PROBBIC|Children's Hospital Zagreb|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|1 Year|7 Years||||July 2013|July 24, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702753||78046|
NCT01703026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC0900328|Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses|Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses||Changi General Hospital|No|Completed|August 2009|October 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|21 Years|N/A|No|Probability Sample|A total of 50 subjects will be enrolled. The study population will be drawn from patients        referred for EUS evaluation on basis of suspected pancreatic cancer. These patients could        be either from clinics or from the hospital wards.|October 2012|October 9, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703026||78025|
NCT01712542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannWGUH_Curcumin-01|Curcumin Bioavailability in Glioblastoma Patients|Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|Tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients harboring Glioblastoma|June 2013|June 1, 2013|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712542||77296|
NCT01703585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATCH-001|Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples|A Feasibility Study of Genomic Profiling Methods and Timing of Sample Collection to Evaluate Clonal Evolution and Tumor Heterogeneity||University Health Network, Toronto|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|50|Samples With DNA|Fresh tumor tissue|Both|18 Years|N/A|No|Probability Sample|metastatic breast, colorectal, gynecological cancer or melanoma|November 2015|November 19, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703585||77982|
NCT01703598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007508|Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis|Clinical Outcomes of Deep Brain Stimulator Electrodes Placed Using Intraoperative Computed Tomography and Frameless Stereotaxis Versus Microelectrode Recording and Frame-based Stereotaxis||Oregon Health and Science University|No|Recruiting|September 2011|August 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01703598||77981|
NCT01703013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSG-Pneumo-0001|The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases|The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases||Cantonal Hospital of St. Gallen|No|Not yet recruiting|January 2013|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Blood leukocytes, serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pneumonia patients (n=30) COPD patients (n=30) Healthy controls (n=15)|October 2012|October 9, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703013||78026|
NCT01703897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Linde-Imped|Esophageal Manometry and Impedance Study in Obese Patients Before and During Anesthesia|Evaluation of Esophageal Pressures and Reflux in Obese Patients Before and During Anesthesia Using High-resolution Solid-state Manometry||Örebro University, Sweden|No|Withdrawn|October 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|60 Years|No|Probability Sample|Obese patients|November 2014|November 4, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703897||77958|
NCT01703312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031B2203|A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma|A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation||Novartis|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|October 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703312||78003|
NCT01703559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-NYX-01|The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints|Double-masked Parallel Evaluation of the Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints||Ocularis Pharma Inc.|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703559||77984|
NCT01703572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52M51-001|A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies|A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies||OncoMed Pharmaceuticals, Inc.|No|Recruiting|October 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|90 Years|No|||February 2016|February 26, 2016|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703572||77983|
NCT01710124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816224|Buy 1 Get 1: Role of Grocery Coupons in Promoting Obesogenic Home Food Environments and Eating Behaviors|Buy 1 Get 1: Role of Grocery Coupons in Promoting Obesogenic Home Food||University of Pennsylvania|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2012|June 9, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01710124||77480|
NCT01700153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONS-Gilliaux-01|Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy|Study of the Effectiveness of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy by Evaluating the 3 Fields of the ICF: A Prospective, Randomized, Controlled, Simple Blind Study.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|September 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|4 Years|18 Years|No|||May 2013|May 6, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01700153||78246|
NCT01700452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCD Test 17Jul2012|Diagnostic Study for Lung Cancer Detection Test|Clinical Study of BioView Target -FISH Lung Cancer Detection Test||Bioview, Inc.|No|Active, not recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|Samples Without DNA|sputum specimens, fixed and stained for diagnostic testing|Both|18 Years|N/A|No|Non-Probability Sample|The subjects will be selected from pulmonary clinics and physician's practice in community        hospital settings.|August 2015|August 20, 2015|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700452||78223|
NCT01700686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBPK|The Effect of Gastric Bypass Surgery on Gut Hormones Related to Bone Remodeling and Intestinal Growth.|The Effect of Gastric Bypass Surgery on Gut Hormones Related to Bone Remodeling and Intestinal Growth.||University of Copenhagen|No|Completed|October 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|Samples Without DNA|Plasma and serum samples are retained.|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects are recruited from The Bariatric Clinic, The Hospital of Roskilde-Koege, The        University of Copenhagen.|December 2014|December 16, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700686||78205|
NCT01710397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31880|Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study)|Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study)|RapIT|Boston University|No|Active, not recruiting|May 2013|May 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|600|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01710397||77460|
NCT01711684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0788|Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)|An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases||Rockefeller University|No|Active, not recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711684||77362|
NCT01684527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039-12-HYMC|Immature Myeloid Cells in Respiratory Syncytial Virus Bronchioliltis|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|55|||Both|N/A|2 Years|Accepts Healthy Volunteers|Probability Sample|Children presenting in our pediatric department suffering from bronchiolitis|September 2012|September 10, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01684527||79445|
NCT01684540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL-047|Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis|Non-interventional Study: Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis|SNS01|Bitop AG|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|September 2012|September 21, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684540||79444|
NCT01684787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miguel Santín|Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients|Open Multicentre, Phase IV Study to Evaluate Efficacy and Safety of Pegylated Interferon Alpha-2a (40 KD) Plus Ribavirin for Chronic Hepatitis C With Normal Transaminases in Human Immunodeficiency Virus-infected Patients|CONTRA|Hospital Universitari de Bellvitge|Yes|Completed|September 2006|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||September 2012|September 12, 2012|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01684787||79425|
NCT01685619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-MDS 01-2011|AML-MDS Novel Prognostic Tests Clinical Study|A Multi-Centre Observational Prospective Cohort Study Involving the Collection of Clinical Information and Biological Specimens for the Evaluation of Novel Prognostic Tests for Myelodysplasia and Acute Myeloid Leukemia||Nova Scotia Health Authority|Yes|Recruiting|September 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Some of the laboratory tests that will be evaluated as part of this study will utilize RNA      and/or DNA. There may be biospecimens left over after the work related to this study is      complete. At the time of consent for the study, participants will be asked to provide      consent (or decline their consent) regarding the use of leftover specimens (including RNA      and DNA) for other research. The details regarding this other research are provided in the      protocol and consent template.|Both|18 Years|N/A|No|Probability Sample|Prospective participants will include patients with known or supsected AML or MDS who are        being treated and/or assessed at a participating site.|February 2013|February 4, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685619||79361|
NCT01685632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-01|Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences|Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences|CHIP|Centre Hospitalier Universitaire de Nice|No|Terminated|September 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685632||79360|
NCT01686152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM 2012-01|Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp||Teva Pharmaceuticals USA|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|589|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686152||79321|
NCT01700920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/ON/2011|PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells|PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells|CSM/ON/2011|Red de Terapia Celular|Yes|Recruiting|July 2012|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||10|||Both|18 Years|70 Years|No|||October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700920||78187|
NCT01700933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DROAPS1|Dose-response: Exercise Therapy on Hip Osteoarthritis|Dose-response: Exercise Therapy on Hip Osteoarthritis, a Pilot Study||Norwegian University of Science and Technology|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|35|||Both|45 Years|N/A|No|||March 2016|March 22, 2016|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700933||78186|
NCT01701232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIORIX (BCD-020-3)|Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma|A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma||Biocad|No|Recruiting|September 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|95 Years|No|||January 2016|January 12, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701232||78163|
NCT01701245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-002|Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care|A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care.||ElectroCore LLC|No|Recruiting|October 2012|March 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||December 2013|December 2, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701245||78162|
NCT01701258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002593|An Investigation of Early Life Stress and Depression|Early Life Stress and Depression: Molecular and Functional Imaging Approaches||Mclean Hospital|No|Recruiting|November 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|92|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|October 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701258||78161|
NCT01712256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-BI Vacc-4x 2012/1|Re-boosting of HIV-1 Infected Subjects With Vacc-4x|Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART|Re-boost|Bionor Immuno AS|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|63 Years|No|||January 2014|January 13, 2014|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712256||77318|
NCT01712555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|New York Eye and Ear Infirmary|Autologous Fat Grafting With PRP (Platelet Rich Plasma) to Anophthalmic Sockets|Autologous Fat Grafting to Anophthalmic Sockets With PRP (Platelet Rich Plasma) Using a Closed Cannula Technique||Fox, Donald Munro, M.D., P.C.|Yes|Recruiting|December 2011|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01712555||77295|
NCT01712802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAKEN-24390439|Multicenter Study of Denture Adhesive|Multicenter Randomized Clinical Study of Denture Adhesive to Establish the Guideline|DAG|Nihon University|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01712802||77276|
NCT01713088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSTBC2012|A Trial of Multisystemic Therapy in UK a Statutory Therapeutic Intervention for Young Offenders|||The Brandon Centre, London|Yes|Active, not recruiting|November 2003|February 2014|Anticipated|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Both|13 Years|16 Years|No|||October 2012|October 23, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713088||77255|
NCT01703910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIO-GI-01-2012|Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic|Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.||Centro Nacional de Investigaciones Oncologicas CARLOS III|Yes|Completed|November 2012|December 2014|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|76 Years|No|||October 2015|October 8, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703910||77957|
NCT01708720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-256A|Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults|Safety and Immunogenicity of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Adults||National Institute for Public Health and the Environment (RIVM)|No|Completed|August 2011|February 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|45|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708720||77588|
NCT01699633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-TBHIV02|Rifampin and Nevirapine Interactions in Young Children|Effect of Rifampin-containing Anti-TB Therapy on Nevirapine Plasma Pharmacokinetics in HIV/TB Co-infected Children < 3 Years Old||The Miriam Hospital|Yes|Recruiting|October 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|58|Samples With DNA|EDTA Plasma Whole blood DNA|Both|3 Months|35 Months|No|Non-Probability Sample|Children aged 3 to 35 months with HIV infection with or without TB|September 2012|October 11, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01699633||78286|
NCT01699646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTG+ST vs CTG +scalp-pH, DK|Cadiotocography Combined With ST-analysis Versus Cardiotocography Combined With Scalp-pH|Cardiotocography Combined With ST-analysis Versus Cardiotocography Combined With Scalp-pH in Deliveries With Abnormal CTG - A Randomised Trial||Hvidovre University Hospital|No|Terminated|December 2005|December 2012|Anticipated|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1025|||Female|18 Years|50 Years|No|||October 2012|October 3, 2012|January 10, 2012||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01699646||78285|
NCT01699893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00238-35|Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine|Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine|LabExMI|Institut Pasteur|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1012|||Both|20 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01699893||78266|
NCT01709240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW102|Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure|Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure||IonMed Ltd|No|Withdrawn|January 2013|April 2014|Anticipated|April 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|20 Years|40 Years|No|||October 2012|March 26, 2015|October 16, 2012|Yes|Yes|Internal decision|No||https://clinicaltrials.gov/show/NCT01709240||77548|
NCT01709851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMD_05|Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes|A Single-center, Open, Pilot Trial to Investigate the Performance of the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes||Medical University of Graz|No|Completed|November 2012|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|75 Years|No|Probability Sample|Subjects with type 1 diabetes|April 2013|April 15, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709851||77501|
NCT01710111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12074|Evaluating Modes of Influenza Transmission|Evaluating Modes of Influenza Transmission Using a Human Challenge Model|EMIT|University of Nottingham|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|127|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01710111||77481|
NCT01710735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muscle and needling|Skeletal Muscle Contractility, Self-reported Pain and Tissue Sensitivity in Females With Neck/Shoulder Pain and Trapezius MFTrPs|Skeletal Muscle Contractility, Self-reported Pain and Tissue Sensitivity in Females With Neck/Shoulder Pain and Upper Trapezius Myofascial Trigger Points- a Randomized Intervention Study||University of Southern Denmark|No|Completed|April 2011|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Female|20 Years|46 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710735||77435|
NCT01711346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00073|A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells|A Randomized, Controlled, Single-Blind, 2-Period Crossover Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells|S303 RBC|Cerus Corporation|No|Completed|October 2012|November 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711346||77388|
NCT01711359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14062|A Study in Participants With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs|RA-BEGIN|Eli Lilly and Company|Yes|Completed|November 2012|August 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|581|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711359||77387|
NCT01685086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110013RC|Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis|Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis||National Taiwan University Hospital|No|Recruiting|March 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|20 Years|N/A|No|Non-Probability Sample|The patients with severe chronic kidney disease or long term dialysis|November 2011|September 12, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685086||79402|
NCT01685359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOBLA0612IV-I2|PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|February 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01685359||79381|
NCT01685372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0829|Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults|Immunogenicity and Efficacy of High-dose Trivalent Inactivated Seasonal Influenza Vaccine(Fluzone High Dose) in Immunocompromised Children and Young Adults.||University of Colorado, Denver|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|360|||Both|5 Years|35 Years|No|||January 2016|January 13, 2016|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685372||79380|
NCT01685840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033097|Guiding Evidence Based Therapy Using Biomarker Intensified Treatment|Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.|GUIDE-IT|Duke University|Yes|Recruiting|December 2012|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|N/A|No|||January 2016|March 7, 2016|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685840||79344|
NCT01686386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-GIMEMA/GISL430|Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma|A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.||Gruppo Italiano Studio Linfomi|No|Recruiting|February 2010|October 2013|Anticipated|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01686386||79303|
NCT01686399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO 0645-11|A Sustainable Diet for Hadassah Employees Workers|A Sustainable Diet for Hadassah Employees||Hadassah Medical Organization|No|Not yet recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|450|||Both|21 Years|67 Years|No|||March 2015|March 22, 2015|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01686399||79302|
NCT01701518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZ123|A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes|A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex®) in Vitrectomy Surgery for Epiretinal Membranes||Sunnybrook Health Sciences Centre|No|Recruiting|October 2012|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701518||78141|
NCT01701778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FujianPH|Caudal Versus Intravenous Dexmedetomidine for Supplementation of Caudal Analgesia in Children|Double-blind Randomized Controlled Trial of Caudal Versus Intravenous Dexmedetomidine for Supplementation of Caudal Analgesia in Children||Fujian Provincial Hospital|Yes|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|90|||Male|2 Years|5 Years|No|||May 2014|May 7, 2014|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701778||78121|
NCT01712815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-11-9|PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer|Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer||University of Southern California|Yes|Suspended|October 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Female|18 Years|N/A|No|||July 2015|July 31, 2015|October 18, 2012|Yes|Yes|interim analysis|No||https://clinicaltrials.gov/show/NCT01712815||77275|
NCT01713101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1207-163-002|Tranexamic Acid for Upper Gastrointestinal Bleeding|Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy|TAUGIB|Seoul National University Hospital||Recruiting|October 2012|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|414|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01713101||77254|
NCT01708746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER-0008|Investigation of the Impact of Noninvasive Prenatal Testing for Fetal Aneuploidy on Utilization of Prenatal Diagnostic Procedures and Pregnant Women's Views|||Verinata Health, Inc.|No|Completed|November 2012|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|205|||Female|18 Years|N/A|No|Probability Sample|The study population is comprised of pregnant women at least 18 years of age, who meet the        inclusion criteria but none of the exclusion criteria described below. Women who present        for prenatal genetic counseling at one of the designated study clinics will be recruited.|September 2014|September 24, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708746||77586|
NCT01708733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101001-62-010|The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function|An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.||Taipei City Hospital|Yes|Completed|August 2012|March 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708733||77587|
NCT01709019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX757.102|RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly|A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.||Novavax|No|Completed|October 2012|March 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|220|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 4, 2014|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709019||77565|
NCT01708993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I211|Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy|A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.||Canadian Cancer Trials Group|Yes|Active, not recruiting|October 2012|August 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|165|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01708993||77567|
NCT01709006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL IMRT/Elderly population|Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy|Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy||Centre hospitalier de l'Université de Montréal (CHUM)|No|Active, not recruiting|August 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|70 Years|80 Years|No|||July 2015|August 31, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709006||77566|
NCT01709253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS 07-253|Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma|Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma||National Cancer Center, Korea|No|Recruiting|March 2007|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|117|||Male|N/A|N/A|No|||October 2012|October 16, 2012|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01709253||77547|
NCT01709864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2317|NVA237 Versus Placebo 12-week Efficacy Study|A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients||Novartis|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|40 Years|N/A|No|||February 2015|February 12, 2015|October 16, 2012|Yes|Yes||No|October 12, 2014|https://clinicaltrials.gov/show/NCT01709864||77500|
NCT01710748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEC-RES-2012-01|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial|RESERVOIR|Spanish Society of Cardiology|No|Active, not recruiting|October 2012|October 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710748||77434|
NCT01710761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-0033|Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance|Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance||University of Texas at Austin|Yes|Active, not recruiting|October 2012|May 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Both|21 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710761||77433|
NCT01710410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016-2015|Transcranial Direct Current Stimulation in a Smoking Cessation Trial|Pilot Study of Transcranial Direct Current Stimulation (tDCS) as a Smoking Cessation Treatment for Nicotine Dependent Smokers|tDCS|Centre for Addiction and Mental Health|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|32|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01710410||77459|
NCT01711086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401-11-RMC|Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol|Double Blind Placebo Controlled Trial Checking the Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol||Rabin Medical Center|No|Not yet recruiting|October 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|18 Years|No|||October 2012|October 17, 2012|September 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01711086||77408|
NCT01711099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGEL_v01|Efficacy of Extracorporeal Shockwave Myocardial Revascularization|Hungarian Study on the Efficacy of Extracorporeal Shockwave Myocardial Revascularization in Patients With Therapy-refracter Angina Pectoris|ANGEL|Salus Ltd.||Recruiting|October 2012|||September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01711099||77407|
NCT01711333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOA-1102i|A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease|||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Not yet recruiting|October 2012|April 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|40 Years|75 Years|No|||October 2012|October 23, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711333||77389|
NCT01711697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056552|An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)||Emory University|Yes|Recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711697||77361|
NCT01685099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207061RIC|Evaluating the Diagnostic Validity of Inflammation-associated Markers for Tuberculous Pleurisy|Evaluating the Diagnostic Validity of Inflammation-associated Markers for Tuberculous Pleurisy||National Taiwan University Hospital|No|Recruiting|August 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|pleural effusion|Both|20 Years|N/A|No|Non-Probability Sample|1. Patients with tuberculous pleural effusion          2. Patients with pleural effusion due to causes other than tuberculosis|August 2012|September 11, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685099||79401|
NCT01685112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207079RIC|Comparison of ECMO Use and Conventional Treatment in Adults With Septic Shock|Comparison of ECMO Use and Conventional Treatment in Adults With Septic Shock||National Taiwan University Hospital|No|Recruiting|September 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|Adults patient who admitted to ICU and had severe sepsis and progressed to septic shock|September 2012|October 10, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685112||79400|
NCT01685385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGIMS001/2012|B-type NAtriuretic Peptide In Critically Ill : A Multicentric Diagnostic Study (B-rAPID)|B-type NAtriuretic Peptide In Critically Ill : A Multicentric Diagnostic Study (B-rAPID)|B-RAPID|Mahatma Gandhi Institute of Medical Sciences|No|Recruiting|October 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|September 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01685385||79379|
NCT01685866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC/DM_JDS_2012-1_V1.0-20120605|3V- Improve Venous Access in Pediatric Anesthesia|Difficult Venous Access in Pediatric Anesthesia: Evaluation of a New Medical Device in Multicenter Trial.|3V|Fondation Ophtalmologique Adolphe de Rothschild|No|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|311|||Both|N/A|7 Years|No|||August 2014|August 5, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685866||79342|
NCT01686139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8802-IS-SMC|Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers|Phase 1 Study: Treatment of Patients With Diabetic Foot Complications With Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC)||Sheba Medical Center|No|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|81 Years|No|||January 2016|January 26, 2016|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686139||79322|
NCT01686412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2012/10|Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency|Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency in Patients With Breast and Advanced Hepatocellular Cancer.||Hospital Sirio-Libanes|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 10, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686412||79301|
NCT01686425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML8383|Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage|Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage in Advanced Biliary Tract Malignancy That Failed ERCP (PETRUS Study): A Randomized Pilot Study|PETRUS|Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2012|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01686425||79300|
NCT01702090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100712|Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients|Early Access to TMC114 in Combination With Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or TMC114-naive, Early Treatment Experienced in HIV-1 Infected Patients||Janssen-Cilag Ltd.|Yes|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||June 2015|June 4, 2015|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702090||78097|
NCT01702103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT-01-12|Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays|MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS.|PHT-01-12|PH&T S.p.A.|No|Not yet recruiting|October 2012|March 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|360|||Both|12 Years|65 Years|No|||October 2012|October 4, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01702103||78096|
NCT01702415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01612|Zoledronic Acid in Cystic Fibrosis|Randomised, Double Blind, Placebo Controlled Trial to Ascertain the Efficacy and Safety of Intravenous Zoledronic Acid in Adult Patients With Cystic Fibrosis.|IZAC|Papworth Hospital NHS Foundation Trust|Yes|Withdrawn|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 4, 2012||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01702415||78072|
NCT01709032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009449|Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia|Pilot Study of Deferasirox and Deferiprone Combination Oral Chelation for Individuals With Transfusion Dependent Thalassemia and High Iron Burden||Children's Hospital of Philadelphia|No|Active, not recruiting|September 2012|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709032||77564|
NCT01709279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1133|Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure|||Kanazawa University|No|Enrolling by invitation|August 2012|September 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|N/A|No|||October 2012|October 16, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709279||77545|
NCT01709292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0471|Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer|Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer||M.D. Anderson Cancer Center|No|Recruiting|November 2012|||November 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709292||77544|
NCT01709604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120830|Role of CVVH in Patients With Acute Paraquat Poisoning|The Efficacy and Safety of Continuous Venovenous Hemofiltration in Patients With Severe Acute Paraquat Poisoning|PQ|Shanghai 10th People's Hospital|Yes|Recruiting|October 2008|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|70 Years|No|||November 2014|November 17, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709604||77520|
NCT01709266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40301.081.12|The Effect of Probiotics on E. Coli-induced Gastroenteritis|A Randomized, Placebo-controlled, Double Blind Volunteer Study Into the Effect of Probiotics on Gastroenteritis Caused by an Attenuated E. Coli.|PROTETEC|NIZO Food Research|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709266||77546|
NCT01709578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10832|To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)|A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists||Sanofi|Yes|Completed|October 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|522|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709578||77522|
NCT01709591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-081|Effect of Prenatal Education on Perceptions of Epidural Acceptance|Effect of Targeted Prenatal Education on Perceptions of Epidural on Acceptance of Epidural Analgesia: a Randomized Controlled Trial||Santa Clara Valley Health & Hospital System|No|Active, not recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01709591||77521|
NCT01709877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOUP_1|EndoCone Single Port Versus Conventional Multi-port Laparoscopic Approach|Randomised Non-inferiority Trial of Laparoscopic Cholecystectomy Performed With EndoCone Single Port Versus Conventional Multi-port Laparoscopic Approach Using Clinical, PROMS and Health Economic Endpoints||Azienda Ospedaliero, Universitaria Pisana|Yes|Recruiting|April 2013|November 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||June 2013|June 28, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01709877||77499|
NCT01710774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS-ID210|Telemedicine Follow-up in Primary Health Care for Diabetes-related Foot Ulcers|Effect of Telemedicine Follow-up Care in Primary Health Care Versus Traditional Follow-up in Specialist Health Care on the Healing Time for Diabetes-related Foot Ulcers - a Cluster-randomized Controlled Trial|DiaFOTo|Helse Stavanger HF|No|Recruiting|October 2012|October 2019|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Both|20 Years|N/A|No|||November 2015|November 30, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710774||77432|
NCT01711398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP N02|Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors|A Non-randomized, Open-label, Multi-centric Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Repeated Intravenous IPP-204106N Administrations in Adult Patients With Advanced Solid Tumors|IP N02|Elro Pharma|Yes|Completed|July 2012|February 2015|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01711398||77384|
NCT01711112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03-072|Salvage Docetaxel for Pretreated Urothelial Cancer|A Phase II Study of Salvage Docetaxel in Patients With Advanced Urothelial Cancer Failed to Prior Chemotherapy||Samsung Medical Center|No|Completed|August 2010|December 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|20 Years|75 Years|No|||October 2012|May 14, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01711112||77406|
NCT01711372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131209-12|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices, Phase 2 Trials||CogCubed, Corp|No|Recruiting|June 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|34|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01711372||77386|
NCT01711385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6446|Undiagnosed Diabetes in a Dental Setting|Screening for Undiagnosed Diabetes in a Dental Setting - A New Paradigm for Dental Practice||Columbia University|No|Active, not recruiting|April 2009|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|101|||Both|30 Years|N/A|No|||October 2012|October 18, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01711385||77385|
NCT01712620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120211|Spironolactone for Pulmonary Arterial Hypertension|A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|99 Years|No|||July 2015|October 22, 2015|October 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712620||77290|
NCT01685398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088/2555(EC4)|Topical Timolol for Superficial Infantile Hemangioma|Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital||Mahidol University|No|Recruiting|September 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|N/A|2 Years|Accepts Healthy Volunteers|||June 2012|November 26, 2012|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685398||79378|
NCT01685645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/JKJR-01|Does the Measurement of Pupillary Reactivity by an Automated Pupillometer Determine the Effectiveness of Local Anesthesia Under General Anesthesia?|Does the Measurement of Pupillary Reactivity to Painful Stimulation by an Automated Pupillometer Determine the Effectiveness of Local Anesthesia When Undergoing General Anesthesia?|ALGISCAN|Centre Hospitalier Universitaire de Nīmes|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685645||79359|
NCT01686165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0288-04|Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL|A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma||University of Arizona|Yes|Recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686165||79320|
NCT01686438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-296|Telemedicine Management of Chronic Insomnia|Telemedicine Management of Veterans With PTSD and Chronic Insomnia|VIP|VA Office of Research and Development|Yes|Recruiting|April 2013|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01686438||79299|
NCT01682434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH_LASIK|Wavefront-guided LASIK for Correction of Myopia|Wavefront-guided LASIK for Correction of Myopia||Aarhus University Hospital|No|Withdrawn|May 2011|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|50 Years|No|||April 2014|April 30, 2014|September 4, 2012||No|Institution changed surgical method to small-incision lenticule extraction. Study never    started.|No||https://clinicaltrials.gov/show/NCT01682434||79606|
NCT01701817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100871|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II)|ORBIT-AF II|Janssen Scientific Affairs, LLC|No|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|15000|||Both|21 Years|N/A|No|Non-Probability Sample|Enrolling physicians will include cardiologists, internists, and electrophysiologists from        both academic and private practice who preferably have experience in registry        participation.|March 2016|March 11, 2016|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701817||78118|
NCT01711931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043/12-CER-FR|Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents|Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents|EVERBIOII|University of Freiburg|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|70 Years|No|||May 2014|May 27, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711931||77343|
NCT01712568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLL/RPR/1117/08|Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS||Lupin Ltd.|Yes|Completed|September 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712568||77294|
NCT01709305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-313|Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)|A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus (Phase IV; Protocol No. MK-0431-313-01)||Merck Sharp & Dohme Corp.|No|Completed|November 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|5570|||Both|18 Years|75 Years|No|||June 2015|June 8, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01709305||77543|
NCT01709617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3-048|Carbohydrate Use During and Following Exercise|Sucrose as a Preferred Carbohydrate in Sports Nutrition|CHO-use|Maastricht University Medical Center|No|Not yet recruiting|November 2012|January 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|17|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709617||77519|
NCT01709630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-2803|PK/PD Modeling of Magnesium in the Mother and Neonate|Pharmacokinetics (PK)/Pharmacodynamics (PD) Modeling of Magnesium Sulfate In the Mother and Exposed Neonate||Stanford University|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|151|Samples Without DNA|Blood specimens will be obtained to test magnesium levels in the mother and neonate.|Both|18 Years|45 Years|No|Non-Probability Sample|Pregnant women and neonates exposed to magnesium sulfate infusion around the time of        delivery for one of three reasons: 1.) preeclampsia 2.) tocolysis 3.) neuroprotection.|November 2014|November 19, 2014|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01709630||77518|
NCT01710150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDUCE AF|Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter|Randomized Trial Comparing Long Term Occurrence of Atrial Arrhythmias Including Atrial Fibrillation (AF) and Thromboembolic Complications in Patients With Typical Atrial Flutter (AFLT) Undergoing Cavo-tricuspid Isthmus (CTI) Ablation Alone Versus CTI Ablation Combined With Pulmonary Vein Isolation (PVI).|REDUCE AF|University of Pennsylvania|Yes|Withdrawn|November 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 11, 2012|No|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01710150||77478|
NCT01709890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZENG1.0|Evaluation of a New Airway Device - the YO2(R) Catheter in Patients Under Sedation|||The University of Hong Kong||Not yet recruiting|December 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing anesthesiologist-administered sedation for diagnostic/ therapeutic        procedures|October 2012|October 29, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709890||77498|
NCT01710137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033681-01|Varenicline for Nicotine Dependence Among Those With HIV/AIDS|A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS||University of Pennsylvania|Yes|Recruiting|October 2012|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710137||77479|
NCT01710423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009579|Peer-mentored Cooking Classes for Parents of Toddlers: Do Families Cook More and Eat Healthier After the Intervention?|Improving Home Food Preparation Practices Among Families With Young Children: A Peer Mentoring Intervention||Children's Hospital of Philadelphia|No|Completed|November 2012|November 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|N/A|N/A|No|||February 2015|February 4, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710423||77458|
NCT01710436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDPAC2012|Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype||RDPAC|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Active, not recruiting|October 2012|||November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|880|||Both|18 Years|N/A|No|Probability Sample|Chinese coronary heart disease (CHD) patient|May 2013|May 16, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01710436||77457|
NCT01711125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X11-0154|Baclofen in the Treatment of Alcoholic Liver Disease|Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease|BacALD|South West Sydney Local Health District|Yes|Recruiting|March 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|75 Years|No|||September 2014|September 28, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01711125||77405|
NCT01711151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012RESP05|Interstitial Lung Disease Questionnaire|Questionnaire Study for Patients With Interstitial Lung Disease||University of East Anglia|No|Not yet recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|304|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Secondary Care|October 2012|October 17, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01711151||77403|
NCT01711710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2010-095|Clinical Trial to Evaluate the Safety and Efficacy of Breast Implant|Clinical Trial to Evaluate the Safety and Efficacy of Cohesive Silicone Gel-Filled Breast Implant (CoSBI) in Women Aged 22 and Over With Breast Reconstruction or Augmentation Mammoplasty.||Seoul National University Hospital|No|Completed|October 2010|December 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Female|22 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 16, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711710||77360|
NCT01712022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-48071|Evaluation of Corneal Epithelial Thickness Mapping|Evaluation of Corneal Epithelial Thickness Mapping||Optovue|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|seeing eye doctor for routine or follow-up care|September 2014|September 9, 2014|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712022||77336|
NCT01712347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28233|An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer|AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER||Hoffmann-La Roche||Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer receiving Avastin in combination with        first-line fluoropyrimidine-based chemotherapy|March 2016|March 1, 2016|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712347||77311|
NCT01711723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115676|A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment||GlaxoSmithKline|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||June 2013|August 29, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711723||77359|
NCT01712035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00008360|Neovascular Age-related Macular Degeneration|OCT Evaluation of Treated and Untreated Choroidal Neovascular Membranes in Age-Related Macular Degeneration|NVAMD|Oregon Health and Science University||Active, not recruiting|October 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|15|||Both|50 Years|N/A|No|Non-Probability Sample|Adults older than age 50 with clinical findings of neovascular AMD with clinical evidence        of active choroidal neovascular membrane|April 2015|April 21, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712035||77335|
NCT01712048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.070-2|Submucosal Injection EMR vs. Underwater EMR for Colorectal Polyps|Submucosal Injection Assisted Endoscopic Resection vs. Underwater EMR for Large Sessile Colorectal Polyps|IvU|California Pacific Medical Center Research Institute|No|Recruiting|September 2012|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712048||77334|
NCT01685658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/PGC-01|Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations|Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial|PIVKIV|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|September 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|338|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685658||79358|
NCT01685879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARice|Glycemic Response to High Amylose Rice|Glycemic Response to High Amylose Rice||University of Hawaii|No|Completed|October 2012|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685879||79341|
NCT01685684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-OXYDET-08|Oxycodone DETERx™ Versus Placebo in CLBP|A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of Oxycodone DETERx™ Versus Placebo in Opioid-Experienced and Opioid-Naive Subjects With Moderate-to-Severe Chronic Low Back Pain||Collegium Pharmaceutical, Inc.|No|Completed|August 2012|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|389|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685684||79356|
NCT01686178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CA152074-01|Countering Young Adult Tobacco Marketing in Bars|Countering Young Adult Tobacco Marketing in Bars||University of California, San Francisco|No|Recruiting|September 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|25200|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686178||79319|
NCT01686191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0869|Genetic Predictors of Renal Dysfunction Following Heart Transplantation|Pharmacogenomics of Calcineurin Inhibitor Nephrotoxicity in Cardiac Transplantation||University of Colorado, Denver|No|Active, not recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|195|Samples With DNA|Buccal cell and blood sample for genomic DNA|Both|18 Years|90 Years|No|Non-Probability Sample|Cardiac transplant clinic|July 2015|July 1, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686191||79318|
NCT01683006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|753/2009UH|Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest|Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest||Medical University of Vienna|No|Active, not recruiting|April 2012|April 2014|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01683006||79562|
NCT01682772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2011/10030|TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer|A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer (TOPARP)|TOPARP|Institute of Cancer Research, United Kingdom|Yes|Recruiting|July 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Male|18 Years|N/A|No|||October 2014|October 2, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01682772||79580|
NCT01712269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2011P002188|Assessment of Sleep Apnea and Its Causes Before and After Weight Loss Surgery|Understanding the Role Obesity Plays in the Pathogenesis of Obstructive Sleep Apnea||Brigham and Women's Hospital|No|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|65 Years|No|||October 2012|October 19, 2012|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01712269||77317|
NCT01712282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30704 part 3|Physical Activity Immediately After Acute Cerebral Ischemia 3|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much||Hillerod Hospital, Denmark|No|Recruiting|December 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01712282||77316|
NCT01708759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1380/09/12|IL8 Monitoring and Its Correlation With 251-gene Polymorphism|The Value of Admission Serum Il-8 Monitoring and the Detection of IL8 (-251 A/T) Polymorphism in Critically Ill Patients||Tanta University|Yes|Completed|November 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|60 Years|No|Probability Sample|A total of eighty African patients (47men and 33 women) were included in the study. Forty        patients developed septic complication during ICU stay (sepsis group). Forty patients were        critically ill without evidence of infectious organism (SIRS group).|April 2014|April 6, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01708759||77585|
NCT01709643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-025|Postprandial IHL and IMCL Measured With Proton Magnetic Resonance Spectroscopy|Postprandial Intrahepactic Lipid (IHL) and Intramyocellular Lipid (IMCL) Levels Measured With Proton Magnetic Resonance Spectroscopy (1H-MRS)||Maastricht University Medical Center|No|Recruiting|September 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01709643||77517|
NCT01710501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-038|A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)|A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|No|Completed|December 2012|January 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|87|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 17, 2012|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01710501||77453|
NCT01710514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000072|A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment|A Multi-Center, Randomized, Open-Label, Parallel Group Study of FE 999913 Vaginal Tablet 100 mg in Japanese Female Patients Undergoing Fertility Treatment [In Vitro Fertilization/Embryo Transfer (IVF-ET)]||Ferring Pharmaceuticals|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Female|20 Years|42 Years|No|||August 2014|August 29, 2014|October 9, 2012|Yes|Yes||No|July 11, 2014|https://clinicaltrials.gov/show/NCT01710514||77452|
NCT01710527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116723|BE Study of Metformin GSK 500mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|BA/BE 173/11|GlaxoSmithKline|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 17, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01710527||77451|
NCT01710449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015170|Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen|Evaluation of Regional Ventilation in Normal Subjects and Subjects With Airway and Lung Disorders (COPD, Asthma, Emphysema, Small Airway Disease and Cystic Fibrosis) Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen.||Duke University|No|Completed|September 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|December 5, 2013|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710449||77456|
NCT01710462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF129|Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease||PANDA|Eurofarma Laboratorios S.A.|No|Withdrawn|August 2013|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||October 2012|July 23, 2015|October 15, 2012||No|Change of company's strategy|No||https://clinicaltrials.gov/show/NCT01710462||77455|
NCT01710787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 3-02|Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults|A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults||St. Renatus, LLC|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|October 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01710787||77431|
NCT01710800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20593-8|Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy|Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy||Walter Reed National Military Medical Center|Yes|Completed|September 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|January 8, 2013|October 17, 2012|Yes|Yes||No|October 24, 2012|https://clinicaltrials.gov/show/NCT01710800||77430|Single center study. Relatively small number of patients studied, although recruitment goal reached.
NCT01710813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU06909|Alglucosidase Alfa Pompe Safety Sub-Registry|A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment||Sanofi|Yes|Recruiting|March 2015|September 2022|Anticipated|August 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Patients who are enrolled in the Pompe Registry will be enrolled in this sub-registry        include patients with infantile-onset Pompe disease, as well as those with late-onset        Pompe disease.        An approximately equal proportion of currently treated and treatment-naïve patients is        targeted for enrollment at each site.|March 2016|March 15, 2016|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01710813|4 Years|77429|
NCT01711138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01439|An Intervention Study to Assess the Role of the Built Environment on Physical Activity and Active Transportation to School in Children and Youth|Active Streets, Active People - Junior: An Integrated Community Partnership to Enhance Physical Activity and Active Transport to School in Children and Youth|ASAP-Jr|University of British Columbia|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|998|||Both|9 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who attend school grades 4-10 at baseline (Fall 2012) will be invited to        participate (intervention group). Participants (n-matched) who attend school grades 4-10        at baseline (Fall 2012) in a neighbouring catchment boundary will be invited to        participate (comparison group).|April 2015|April 7, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01711138||77404|
NCT01712061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261007|A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy||Pfizer|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 19, 2012|Yes|Yes||No|September 22, 2015|https://clinicaltrials.gov/show/NCT01712061||77333|
NCT01712373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1270|Ginseng in Treatment of Fatigue in Multiple Sclerosis|Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis||Isfahan University of Medical Sciences|Yes|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01712373||77309|
NCT01711411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10376|Observational Study of Male Circumcision Using PrePex Device|Prospective Observational Study of Male Circumcision Using the PrePex Device in Routine Clinical Settings in Kenya||FHI 360|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 4|Observational|N/A||1|Actual|427|||Male|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men aged 18-49 years|November 2013|November 25, 2013|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711411||77383|
NCT01711736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116926|Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children||GlaxoSmithKline||Completed|November 2012|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|606|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||February 2014|June 18, 2015|October 18, 2012|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT01711736||77358|
NCT01712893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD trial|Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer|A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for ≤ 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer||Fudan University|Yes|Recruiting|June 2009|September 2018|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|N/A|45 Years|No|||October 2012|October 23, 2012|October 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01712893||77269|
NCT01713218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003516-31|Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer|Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma|NEOPACHI-001|Erasme University Hospital|No|Not yet recruiting|December 2012|December 2016|Anticipated|June 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01713218||77245|
NCT01713231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02-M14-12A|Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta|Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta||Shriners Hospitals for Children|Yes|Completed|September 2012|July 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|6 Years|19 Years|No|||September 2014|September 8, 2014|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01713231||77244|
NCT01685424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-162|Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)|Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis||Merck Sharp & Dohme Corp.|No|Active, not recruiting|June 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|30000|||Both|N/A|N/A|No|Probability Sample|All participants in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one        electronic outpatient prescription record for etoricoxib issued by a General Practitioner        during the period (April 1, 2002 to December 31, 2015) at the date of query execution        against the FF-GPRD data warehouse.|February 2016|February 19, 2016|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01685424||79376|
NCT01685671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136HPS12C|Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of CKD-11101 and NESP After SC Administration in Health Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|October 2012|||January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685671||79357|
NCT01685892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28331|A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia|A Phase Ib Multicenter Dose-Finding and Safety Study Of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia||Genentech, Inc.||Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01685892||79340|
NCT01682460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18262|Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients|Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients|IVES|University of Waterloo|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|17 Years|N/A|No|||July 2014|July 2, 2014|August 29, 2012|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT01682460||79604|
NCT01682733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003195|Endoscopic Gastric Reduction for Weight Management|Endoscopic Gastric Reduction for Weight Management: A Pilot Feasibility Study||Mayo Clinic|Yes|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|No|||April 2015|April 6, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01682733||79583|
NCT01682746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163588-1|Photodynamic Therapy (PDT) for Brain Tumors|Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study||Medical College of Wisconsin|Yes|Active, not recruiting|March 2013|April 2021|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|6 Months|18 Years|No|||February 2016|February 10, 2016|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682746||79582|
NCT01682785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDD-Met|Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder|Incidence and Prevalence of and Factors Associated With Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder||ChaingMai University||Not yet recruiting|September 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Probability Sample|major depressive disorder|September 2012|September 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01682785||79579|
NCT01683318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R913/22/2012|Treatment of Meibomian Gland Dysfunction|Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction||Singapore National Eye Centre|No|Completed|September 2012|||October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|21 Years|N/A|No|||September 2012|November 11, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01683318||79538|
NCT01713114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV1223|Effects of a Variety of Meals on Satiety|A Randomized, Controlled Crossover Trial to Assess the Effects of Varying Meals on Satiety||The Hillshire Brands Company||Recruiting|October 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Anticipated|38|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|October 22, 2012||||No||https://clinicaltrials.gov/show/NCT01713114||77253|
NCT01713127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFTN-02|Remifentanil in Ventilated Preterm Infants|Efficacy and Safety of Remifentanil in Preterm Infants Who Require Ventilator Support||Seoul National University Hospital|Yes|Terminated|August 2012|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|12|||Both|N/A|48 Hours|No|||October 2012|November 18, 2015|August 31, 2012||No|declined enrollment|No||https://clinicaltrials.gov/show/NCT01713127||77252|
NCT01709045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2-048|ParisK: Correlation of Imaging Techniques With Histology|The Assessment of the Plaque at RISK by Non-invasive (Molecular) Imaging and Modelling (ParisK): Correlation of Imaging Techniques With Histology|ParisK|Maastricht University Medical Center|No|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Carotid plaque removed during carotid endarterectomy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a carotid artery stenosis, who are scheduled for carotid endarterectomy,        will be included.|September 2013|September 12, 2013|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01709045||77563|
NCT01709929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1713|Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|A Multicentre, Open Label, Nonrandomised, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|PREDICTIVE™|Novo Nordisk A/S|No|Completed|October 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2287|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01709929||77495|
NCT01709942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05|Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)|Use of Long Acting GnRH Antagonist to Prevent Ovarian HyperStimulation Syndrome (OHSS) in PCOS Women Undergoing COH for IVF||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|November 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Female|20 Years|38 Years|No|||February 2015|February 3, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01709942||77494|
NCT01709903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2331|A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149|A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD||Novartis|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|744|||Both|40 Years|N/A|No|||March 2015|March 13, 2015|October 16, 2012||No||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01709903||77497|
NCT01709916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0037-CTIL|Comparing Diurnal Fluctuations in Intra Ocular Pressure Measured in Same Day Versus Different Days in Glaucoma Patients|Comparing Diurnal Fluctuations in Intra Ocular Pressure Measured in Same Day Versus Different Days in Glaucoma Patients|IOP|Carmel Medical Center||Completed|November 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Glaucoma patients using eye drops to lower intra ocular pressure.|February 2015|February 23, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01709916||77496|
NCT01710163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIQUELI|Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients|ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole|ARIQUELI|University of Sao Paulo|No|Recruiting|June 2012|June 2015|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||October 2012|October 16, 2012|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01710163||77477|
NCT01710176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISG-STS 10-01|Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy|Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy||Italian Sarcoma Group|Yes|Recruiting|June 2011|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01710176||77476|
NCT01710189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC306|Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac|Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants|CRC306|University of Surrey|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01710189||77475|
NCT01710488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT N. 2008-003842-27|Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD|A Randomized, Controlled, Single-blind, Parallel-group Comparison Between Levofloxacin and Prulifloxacin, in Patients With Acute Exacerbation of COPD Unresponsive to Other Antibiotics and Admitted to the Internal Medicine|FLOR|Fadoi Foundation, Italy|Yes|Recruiting|May 2009|November 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|60 Years|N/A|No|||October 2012|October 17, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01710488||77454|
NCT01711749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117120|Rosuvastatin Calcium Bioequivalence Study - Fast|Study of Bioequivalence Between Two Formulations of 20 mg Rosuvastatin Calcium Tablets, Administered Under Fasting to Healthy Volunteers of Both Genders, Being the Test Formulation Manufactured by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda. and the Reference Formulation (Crestor®) Commercialized by AstraZeneca do Brasil Ltda.||GlaxoSmithKline|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01711749||77357|
NCT01711762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28369|A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0973 Following Single Oral Dose Administration in Healthy Male Subjects||Genentech, Inc.||Completed|September 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01711762||77356|
NCT01674959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 CH-GI-024|Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients|Phase II Study of Postoperative Intensity-modulated Radiotherapy (IMRT) Combined With Capecitabine for Stage II/III Gastric Cancer Patients||Chinese Academy of Medical Sciences|No|Recruiting|October 2011|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||February 2015|February 3, 2015|August 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01674959||80180|
NCT01675804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83-6516|Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD|A Randomized Clinical Trial Comparing Computer-assisted Cognitive Rehabilitation (CACR), Psycho-stimulants, and Placebo CACR in the Treatment of Attention Deficit/ Hyperactivity Disorder||Allameh Tabatabai University|No|Completed|November 2011|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Male|7 Years|12 Years|No|||April 2015|April 3, 2015|July 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675804||80115|
NCT01675778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-445|Association Between Body Size and Response to Hydromorphone in ED|Influence of Body Size and Composition on Response to Hydromorphone in ED Patients With Acute Pain||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|October 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||August 2012|August 28, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01675778||80117|
NCT01675791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-02|A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet|A Dose-response Evaluation of ALK Tree AIT||ALK-Abelló A/S|No|Completed|August 2012|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|637|||Both|12 Years|65 Years|No|||January 2014|January 20, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675791||80116|
NCT01676077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85750|Clinical Outcome Study for Dysferlinopathy|International Clinical Outcome Study for Dysferlinopathy|Jain COS|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Active, not recruiting|September 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Serum, Plasma, DNA, RNA, Skin fibroblasts|Both|10 Years|N/A|No|Non-Probability Sample|A diagnosis of Limb Girdle Muscular Dystrophy type 2B (LGMD2B), Miyoshi myopathy, or any        other clinical diagnosis associated with dysferlinopathies|October 2015|October 7, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676077||80094|
NCT01677195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TxESI 12-001|Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"|"Phase II, Reduction of Dietary Mycotoxin Exposure in Persons in Bexar County, Texas by Ingestion of ACCS100 Capsules Compared to Placebo."|RDMEACCS100|Texas Enterosorbents Incorporated|Yes|Completed|September 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|234|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 29, 2012|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01677195||80008|Unlike our clinical trials in Africa, where maximum compliance was achieved through the daily in-home monitoring, the current study relied on participant reports during monthly visits in which total compliance was difficult to assess.
NCT01677208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH20120423|Danhong Injection in the Treatment of Acute Ischemic Stroke|A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke||China Academy of Chinese Medical Sciences|Yes|Recruiting|December 2012|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1513|||Both|18 Years|70 Years|No|||March 2016|March 20, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677208||80007|
NCT01668446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|radvin123|Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles|Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles|sildenafil|Shahid Sadoughi University of Medical Sciences and Health Services|Yes|Completed|September 2009|February 2011|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|June 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668446||80679|
NCT01715155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OBG-XXX-2012/1|Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study|A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria||AstraZeneca|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|171|||Female|18 Years|N/A|No|Probability Sample|Patients newly diagnosed with breast cancer (according to ICD-10) with confirmed        metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic        stage.|August 2013|August 21, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01715155||77097|
NCT01715168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI0918-101|A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer|A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy||Azaya Therapeutics, Inc.|No|Active, not recruiting|October 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|70 Years|No|||January 2015|January 13, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715168||77096|
NCT01715415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-098|A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)||AbbVie|Yes|Completed|November 2012|October 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|395|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|October 25, 2012|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01715415||77077|
NCT01715428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRAGLUTIDE UNIPA|Liraglutide and Cardio-Metabolic Risk Markers|Effects of Liraglutide on Cardio-Metabolic Risk Markers||University of Palermo|No|Active, not recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|serum and plasma samples|Both|18 Years|80 Years|No|Probability Sample|adult subjects with type-2 diabetes|June 2015|June 2, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01715428||77076|
NCT01715454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-018|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||April 17, 2015|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715454||77074|
NCT01715753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037110|Measuring Eating, Activity and Strength: Understanding the Response -Using Protein|Does Enhanced Protein Intake Preserve Function and Lean Muscle Mass During Weight Reduction in Frail, Obese Older Adults?|MEASUR-UP|Duke University|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|71|||Both|60 Years|N/A|No|||January 2015|January 20, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715753||77051|
NCT01667523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-058|The Effect of Capsaicin and Cinnamaldehyde on Intestinal Permeability|The Effect of Capsaicin and Cinnamaldehyde on Intestinal Permeability, Gallbladder Motility and Satiety||Maastricht University Medical Center|No|Completed|February 2011|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|April 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01667523||80750|
NCT01667549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD37119|Sensitive Periods in Human Flavor Learning|Sensitive Periods in Human Flavor Learning||Monell Chemical Senses Center|No|Active, not recruiting|August 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|240|||Both|N/A|3 Weeks|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667549||80748|
NCT01667809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVC CBT vs RTW II|CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care|Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Subclinical Common Mental Illness in Primary Care: a Randomized Controlled Trial||Karolinska Institutet|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01667809||80728|
NCT01677351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0609/01-clonidine|Assessment of the Effect of Clonidine for Cataract Surgery|Assessment of the Effect of Clonidine on Pain, Arterial and Intraocular Pressure and Arrhythmias for Cataract Surgery||Federal University of São Paulo|Yes|Recruiting|July 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||August 2012|August 31, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01677351||79996|
NCT01677338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URA-12-001|Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects|A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects||Otsuka Pharmaceutical Co., Ltd.|No|Completed|July 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|21 Years|65 Years|No|||February 2016|February 4, 2016|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677338||79997|
NCT01677624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7040-J081-301|A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation|A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation||Eisai Inc.||Completed|August 2012|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|75 Years|No|||January 2016|January 25, 2016|August 30, 2012||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01677624||79975|
NCT01673542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMLAX 2012-001976-13|Evaluating the Effectiveness of Dermal Analgesia Provided by the Application of Lidocaine and Prilocaine Cream 5% on the Puncture Site of Axillary Blocks|||Poitiers University Hospital|Yes|Active, not recruiting||||||Phase 2|Interventional|N/A|2||||||Both|18 Years|N/A||||July 2012|August 23, 2012|July 9, 2012||||No||https://clinicaltrials.gov/show/NCT01673542||80289|
NCT01673815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01885|Video Diversion During Fundoscopic Exam in Children|Video Diversion During Fundoscopic Exam in Children: A Randomized Controlled Trial|CAFE|University of British Columbia|Yes|Completed|August 2011|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|60|||Both|1 Year|8 Years|Accepts Healthy Volunteers|||August 2012|August 23, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01673815||80268|
NCT01674114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1|Postoperative Morphine Consumption After Caesarean Section- TAP Block vs Intracutaneous Infiltration|Postoperative Morphine Consumption After Caesarean Section- TAP Block vs Intracutaneous Infiltration||St. Olavs Hospital|No|Completed|September 2012|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Female|18 Years|50 Years|No|||July 2014|July 25, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674114||80245|
NCT01674127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390306|Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia|||Isfahan University of Medical Sciences||Completed|August 2011|May 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||August 2012|August 27, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674127||80244|
NCT01674361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN28137|A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder|A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF RO4917838 IN COMBINATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH OBSESSIVE COMPULSIVE DISORDER||Hoffmann-La Roche||Recruiting|December 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|65 Years|No|||April 2013|April 30, 2013|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674361||80226|
NCT01674374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 184910|Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy|A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC)||Roswell Park Cancer Institute|Yes|Withdrawn|May 2013|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674374||80225|
NCT01675492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-112-IDMA|Safety and Effectiveness of Wavefront-guided LASIK for the Correction of Mixed Astigmatism|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Mixed Astigmatic Refractive Errors With the iDESIGN Advanced Wavescan Studio™ System and STAR S4 IR™ Excimer Laser System||Abbott Medical Optics|No|Recruiting|December 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675492||80139|
NCT01675505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phd Antoniadis|Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery|Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery||Aristotle University Of Thessaloniki|Yes|Recruiting|May 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|60 Years|No|Probability Sample|Greek population from Northern Greece who are diagnosed with colon cancer for the first        time and are admitted to the 1st Propedeutic Surgical Department of AHEPA General        University Hospital of Thessaloniki for surgery.|July 2013|July 9, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675505||80138|
NCT01675817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-190|Evaluation of Heparin Rebound in Cardiac Surgery|Evaluation of Heparin Rebound in Cardiac Surgery||Lawson Health Research Institute|No|Recruiting|April 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Probability Sample|Patients undergoing elective cardiac surgery|September 2012|September 27, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675817||80114|
NCT01676090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52800-020|IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population|An Epidemiologic, Descriptive and Cross-sectional Study of the IGF-1, IGFBP-3 and ALS Normative Ranges in a Healthy Paediatric Spanish Population, Divided Into Chronological Age, Sex and Pubertal Stage|EDISON|Ipsen|No|Terminated|July 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|304|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy paediatric Spanish population|December 2013|December 19, 2013|August 22, 2012||No|Participant enrolment was lower than expected|No||https://clinicaltrials.gov/show/NCT01676090||80093|
NCT01676337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00239|Text Message Appointment Reminders|A Text-message Appointment Reminder System to Improve Patient Adherence With Outpatient Follow-up Appointments|TAR|University of Southern California|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|374|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676337||80074|
NCT01668186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-090-PED|Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)|Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)||McGill University Health Center|No|Recruiting|January 2012|January 2022|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|Blood, Dried blood spots, Urine, Cultured fibroblasts|Both|N/A|N/A|No|Non-Probability Sample|Any patient with a PBD diagnosis|December 2015|December 11, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01668186||80699|
NCT01668199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPJ5004-03/2011 (MET)|A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101|An Open-Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101||Norgine|No|Completed|February 2012|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01668199||80698|
NCT01668732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD101SCW01|Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts|Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts||National Health Research Institutes, Taiwan|No|Not yet recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1|||Both|20 Years|65 Years|No|Non-Probability Sample|community heroin addicts|August 2012|August 17, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668732||80657|
NCT01668745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMUNISE_NOUNA_early MV|Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.|A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau||Bandim Health Project||Recruiting|May 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4050|||Both|4 Months|6 Months|No|||August 2014|August 6, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668745||80656|
NCT01714882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007272|Stress Management for Couples Undergoing In Vitro Fertilization (IVF)|Stress Management for Couples With Infertility Undergoing In Vitro Fertilization (IVF)||Mayo Clinic|No|Completed|October 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|39 Years|No|||November 2015|November 5, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01714882||77118|
NCT01715181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALIDII|Volunteers Adding Life in Dementia: VALID|A Cluster-Randomized Controlled Trial Evaluating the Effects of a Volunteer-Led Nonpharmacological Intervention to Reduce Neuropsychiatric Symptoms of Dementia in Long-Term Care Residents|VALID|Queen's University|No|Recruiting|January 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|65 Years|N/A|No|||October 2014|October 23, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715181||77095|
NCT01716026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-04-2012|Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia|Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.|BENEMCOR|Instituto Universitario de Oftalmobiología Aplicada|No|Active, not recruiting|October 2012|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716026||77030|
NCT01667796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH067055|Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health|Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls||Johns Hopkins University|Yes|Completed|November 2010|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|57|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|August 13, 2012||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01667796||80729|The generalizability of the findings of this study (beyond female Caucasians) has to be further tested. It is possible that there were unmeasured confounders influencing results.
NCT01668134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1345 / 201107319|Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma|Feasibility Study of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma||Washington University School of Medicine|No|Active, not recruiting|September 2009|December 2018|Anticipated|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|August 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668134||80703|
NCT01668394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics app. number: 20100230|Effect of Learning and Coping Strategies in Cardiac Rehabilitation - Group Study|Effect of Learning and Coping Strategies in Cardiac Rehabilitation - A Randomised Controlled Parallelgroup Study|LM-REHAB|Herning Hospital|No|Active, not recruiting|November 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01668394||80683|
NCT01677663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103003RB|Neuropsychopathological Study of Autism|Neuropsychopathological Study of Autism: From Clinical, Neurocognitive, to Genetic Studies and Animal Models||National Taiwan University Hospital|Yes|Recruiting|August 2011|July 2016|Anticipated|||N/A|Observational|Observational Model: Family-Based||1|Anticipated|350|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|3 Years|25 Years|No|Non-Probability Sample|The sample will consist of 350 probands with ASD, aged 3-25.|August 2012|August 31, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677663||79972|
NCT01677676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-01.1_CS_02|Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)|A Randomised, Double-Blind, Double Observer, Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of Two Different Formulations of an Influenza A Vaccine (FP-01.1)||Immune Targeting Systems Ltd|Yes|Completed|January 2012|September 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01677676||79971|
NCT01677650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00064915|Pharmacogenomics of Methadone in Spine Fusion Surgery|The Influence of Pharmacogenetics on Methadone Dose, Safety, and Outcomes After Spine Fusion||Northwestern University|No|Withdrawn|March 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|August 30, 2012||No|Investigator moved to new institution|No||https://clinicaltrials.gov/show/NCT01677650||79973|
NCT01674140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1207|S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer|Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer|e3|Southwest Oncology Group|Yes|Recruiting|April 2013|January 2030|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1900|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674140||80243|
NCT01674387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64385700|Clinical Study on Electroacupuncture Therapy for Chronic Neck Pain|Lu's Acupuncture Protocol for Chronic Neck Pain||Shanghai University of Traditional Chinese Medicine|Yes|Completed|August 2012|January 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2014|May 4, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01674387||80224|
NCT01674400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-2P|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2011|||||N/A|N/A|N/A||||||||||||||July 31, 2013|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674400||80223|
NCT01674673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-130|A Long-term Observational Study on the Efficacy of SSRIs or Combined Treatment(SSRIs+ CBT) in Panic Disorder Patients|A Long-term Observational Study on the Efficacy of SSRIs Pharmacotherapy or Combined Treatment(SSRIs Pharmacotherapy + CBT) in Panic Disorder Patients||Samsung Medical Center|No|Recruiting|February 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|110|Samples With DNA|whole blood|Both|20 Years|N/A|No|Probability Sample|Panic disorder patients 20 years of age or older to visit the Samsung Seoul Hospital, and        the Department of Mental Health, a foreign patients, patients who agreed to participate in        this study will be of. Plan the patient-specific total of 100 patients on each drug        treatment group and combined treatment group, 55 patients recruited by the first year of        study commences 1 years F / U to enforce the number of subjects.|August 2012|December 26, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674673||80202|
NCT01674686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-069|The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm|A Prospective, Single-center, Randomized Study to Evaluate the Effect of Sarpogrelate, a Selective Serotonin Receptor Antagonist, and High Dose Statin on the Reduction of Coronary Spasm in the Patients With Variant Angina||Samsung Medical Center|Yes|Recruiting|August 2012|February 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|70 Years|No|||October 2014|October 19, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674686||80201|
NCT01674946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 140/11|Effect of Bile Acids on the Secretion of Satiation Peptides in Humans|Effect of Intraduodenal Perfusion of Bile Acids on the Secretion of Gastrointestinal Satiation Peptides in Healthy Male Volunteers||University Hospital, Basel, Switzerland|Yes|Completed|September 2011|May 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674946||80181|
NCT01674699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCOR PAS|Berlin Heart EXCOR Pediatric Post Approval Study|Berlin Heart EXCOR Pediatric Post Approval Study||Berlin Heart, Inc|No|Enrolling by invitation|August 2012|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|49|||Both|N/A|21 Years|No|Non-Probability Sample|The study will be an "all-comers" prospective study including subjects whom meet the        Inclusion and Exclusion Criteria. Pediatric candidates with severe isolated left        ventricular or biventricular dysfunction who are candidates for cardiac transplant and        require circulatory support may be treated using the EXCOR® Pediatric.|August 2012|August 28, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01674699||80200|
NCT01675518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7991-CL-0001|A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers|A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Oral Administration of ASP7991 in Healthy Volunteers||Astellas Pharma Inc|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|9||Actual|56|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675518||80137|
NCT01676363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03547|Pilot Study of Diflunisal in HIV-infected Adults|Pilot Study of Diflunisal in HIV-infected Adults||University of British Columbia|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2015|January 6, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676363||80072|
NCT01676103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-797|The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease|The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease||New York Institute of Technology|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|80 Years|No|||April 2014|April 15, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676103||80092|
NCT01676116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3851|The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy|The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)|DUAL™ III|Novo Nordisk A/S|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|438|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676116||80091|
NCT01676350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299341|Intraosseous Access in the Emergency Department for Patients With Failed Attempts at Intravenous Access: A Randomized Trial Examining Resource Utilization and Patient Satisfaction|Intraosseous Access in the Emergency Department for Patients With Failed Attempts at Intravenous Access: A Randomized Trial Examining Resource Utilization and Patient Satisfaction||WellSpan Health|No|Recruiting|August 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676350||80073|
NCT01668485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DM/ITX|Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation|Metabolic Studies in Type 1 Diabetic Patients After Allogenic Intraportal Islet Transplantation.||University of Giessen|No|Completed|November 2001|November 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 17, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01668485||80676|
NCT01715194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 12/076|Telemedicine to Enhance Adherence to CPAP Therapy in Patients With OSAS|Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study||Cantonal Hospital of St. Gallen|No|Not yet recruiting|December 2012|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01715194||77094|
NCT01715467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-901|CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment|Community Registry Study Evaluating Dupuytren's Contracture Treatment. A Prospective, Observational, Longitudinal, Multicenter Study of the Treatment Patterns and Outcomes in Patients With Dupuytren's Contracture.|CORRECT|Endo Pharmaceuticals|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|N/A|No|Non-Probability Sample|Community based sample|June 2015|June 12, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715467||77073|
NCT01716039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1204|Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)|A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis||University of Western Ontario, Canada|No|Enrolling by invitation|June 2013|May 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01716039||77029|
NCT01668160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000925|Stability of Revision Total Hip Arthroplasty Implants Using Radiostereometric Analysis|Analysis of the Stability of Total Hip Arthroplasty Implants Used in Revision Surgery Using Radiostereometric Analysis (RSA)||Massachusetts General Hospital|Yes|Withdrawn|February 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668160||80701|
NCT01696344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_TARGET|Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome?|Does AF Termination Without Additional Ablation Influence Outcome?|TARGET|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|May 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|Drug-refractory long-standing persistent atrial fibrillation|May 2015|May 20, 2015|September 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01696344||78537|
NCT01677702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL/CL-002|Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization|The Clinical Research on the Efficiency of Yili Lactoferrin Shuhua Milk in the Improvement of Human Immunization||Inner Mongolia Yili Industrial Group Co., Ltd||Completed|March 2011|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|240|||Both|6 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01677702||79969|
NCT01673555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116008|Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers|A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|49|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673555||80288|
NCT01674153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB - 2011/01942|Investigating the Effects of Exercise on Physiological Changes and Toxin Removal in Hemodialysis Patients|A Multi Protocol Investigation to Compare the Effects of Intra-dialytic Exercise on Physiological Changes and Toxin Removal in Maintenance Hemodialysis Patients||National University Hospital, Singapore|Yes|Recruiting|August 2012|July 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|21 Years|75 Years|No|||April 2014|April 1, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674153||80242|
NCT01674413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbott IMM 10-0105|Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)|Calprotectin-Directed Humira® Maintenance Therapy, a Double-blind, Double-dummy, Randomized Controlled Trial in Crohn's Disease|CADHUM|University of Michigan|No|Not yet recruiting|October 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674413||80222|
NCT01674426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH50748|Pathogenesis of Functional Hypothalamic Amenorrhea|Pathogenesis of Functional Hypothalamic Amenorrhea||University of Pittsburgh|No|Completed|November 1997|August 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|18 Years|35 Years|No|||August 2012|August 24, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01674426||80221|
NCT01675245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006373|An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade|Velcade (Bortezomib for Injection) Observational Study||Xian-Janssen Pharmaceutical Ltd.|No|Completed|March 2006|May 2010|Actual|May 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|532|||Both|N/A|18 Years|No|Non-Probability Sample|Patients diagnosed with multiple myeloma (based on standard diagnosis criteria),        initiating Velcade therapy within the approved indication.|June 2014|June 10, 2014|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675245||80158|
NCT01676129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101R104054-TMJ|Nocipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation in Treating Pain From TMJ Disorder|Comparing the Effect of Typical Electrical Stimulation Therapy With Nocipoint Stimulation Therapy on TMD-Related Myofascial Pain||National Taiwan University Hospital|No|Recruiting|July 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|65 Years|No|||August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676129||80090|
NCT01667341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-003-001|Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine|A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection||Genocea Biosciences, Inc.|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|143|||Both|18 Years|50 Years|No|||January 2016|January 12, 2016|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667341||80764|
NCT01676636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000032744|Delivery Vehicles for Prenatal Calcium Supplementation|Preference, Acceptability, and Palatability of Alternative Delivery Vehicles for Prenatal Calcium Supplementation Among Pregnant Women in Bangladesh||The Hospital for Sick Children|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|149|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are between 13 and 30 weeks pregnant. Participants will be recruited from        Shimantik .|April 2013|April 12, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01676636||80051|
NCT01676649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-195|Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma|A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma||Jewish General Hospital|No|Active, not recruiting|November 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676649||80050|
NCT01676909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-276|Wellness Self-Management|A Hybrid Effectiveness-Implementation Trial of a Wellness Self-Management Program||VA Office of Research and Development|No|Recruiting|October 2013|November 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01676909||80030|
NCT01668290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMI 1D|Assessment of Patients With Suspected Coronary Artery Disease (CAD): What is the Best Initial Imaging Strategy?|Assessment of Patients With Suspected CAD: What is the Best Initial Imaging Strategy? Cardiac Computed Tomographic Angiography,(CCTA) vs Stress Echocardiography (SE) vs SPECT|IMAGE-CAD|University of Alberta|No|Recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Men and women without known CAD who present with symptoms suggestive of CAD and require        diagnostic/prognostic workup.|December 2015|December 9, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01668290||80691|
NCT01668758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120165|fMRI and NIRS Imaging for Traumatic Brain Injury|Detection of Hemodynamic Changes in Traumatic Brain Injuries Population With Functional Near Infrared Spectroscopy||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2012|July 2013||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|October 24, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668758||80655|
NCT01668771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912162|Self-Affirmation and Response to Health Risk Information|Self-Affirmation, Affect, and Implementation Intentions for Alcohol Cessation||National Institutes of Health Clinical Center (CC)||Completed|August 2012|May 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1116|||Female|18 Years|N/A|No|||May 2013|September 24, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668771||80654|
NCT01715480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033630|Effect of Broccoli Sprouts Homogenate on SS RBC|Physiological Effect of Sulforaphane Obtained From Broccoli Sprouts Homogenates (BSH) on the HbF and Anti-oxidative Capacity of Human Sickle Red Blood Cells (SS RBC)|BSH|Duke University|Yes|Completed|March 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|May 27, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01715480||77072|
NCT01715766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360806-15|VIPER: Veterans Integrated Pain Evaluation Research|VIPER: Veterans Integrated Pain Evaluation Research- Molecular Subtypes of Chronic Pain Syndromes|VIPER|Defense and Veterans Center for Integrative Pain Management|No|Completed|January 2012|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|Samples With DNA|Blood draw will consist of, two BD™ P100 tubes (2x8.5mL=17mL) where the plasma will be      separated by centrifuge then placed in a -80ºC freezer. Two RNA tubes (2 x 2.5mL=5mL) and      one DNA tube (8.5mL) will be place first, in a -20ºC freezer for 24-36 hours then moved to a      -80ºC freezer. All the blood samples will remain in a -80ºC freezer at the Department of      Clinical Investigation(DCI) laboratory until they are sent to Duke University after every 8      subjects.|Both|18 Years|N/A|No|Non-Probability Sample|Male and female active duty military personnel age 18 years and older presenting with the        diagnosis of amputation of 1 limb in the previous 18 months. At least 3 months must have        passed since the first amputation procedure.|April 2014|April 22, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01715766||77050|
NCT01715792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116602|Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK|Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in the United Kingdom||GlaxoSmithKline||Completed|October 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|587|||Both|N/A|N/A|No|Probability Sample|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant        rejection reported during the overall study periods (01 September 2006 to 31 October        2010).|February 2014|February 6, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715792||77048|
NCT01676805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120193|Tissue Collection for Studies of Lymph Cancer|Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|August 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|99 Years|No|||February 2016|March 1, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676805||80038|
NCT01677091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00667-36|Balance Rehabilitation With Sensory Recalibration After Stroke|Effectiveness of a Balance Rehabilitation Program With Sensory Recalibration After Stroke: A Randomized Controlled Trial.|AVCPOSTIM|Rennes University Hospital|No|Recruiting|May 2013|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|148|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677091||80016|
NCT01673828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR081314|Allopregnanolone for the Treatment of Traumatic Brain Injury|A Double-blind, Placebo-controlled, Randomized Clinical Trial of Allopregnanolone for the Treatment of Traumatic Brain Injury||University of California, Davis|Yes|Recruiting|April 2013|April 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|16 Years|65 Years|No|||February 2015|February 2, 2015|August 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673828||80267|
NCT01674712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-377|A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease|A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Cardiovascular Disease.||Abbott||Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|575|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|June 26, 2012||No||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01674712||80199|
NCT01674972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 224/02.2|Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls|Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls||University Hospital, Basel, Switzerland|No|Completed|January 2011|June 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|102|Samples With DNA|Plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with biopsy proven NAFLD and NASH will be recruited from the Hepatology        Outpatient Clinic, Division of Gastroenterology and Hepatology, University Hospital Basel.        Healthy control subjects will be matched to NAFLD and NASH patients.|August 2012|August 24, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674972||80179|
NCT01674985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST/MDS-307PLAH-ASH|Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes|||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Recruiting|September 2009|December 2013|Anticipated|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|10 Years|90 Years|No|||March 2013|March 27, 2013|August 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01674985||80178|
NCT01675258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSA003-HMO-CTIL|Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers|||Hadassah Medical Organization||Not yet recruiting|September 2012|||September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples With DNA|whole saliva|Both|18 Years|N/A|No|Probability Sample|Patients identified with gastric, colorectal (including pre-cancer polyps) or pancreatic        cancer|July 2012|August 27, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675258||80157|
NCT01675843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG/4/2010|Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome|Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome|OSIPS|Mansoura University|Yes|Completed|May 2010|||March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Female|21 Years|38 Years|No|||August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675843||80112|
NCT01667107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5592-105|A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)|A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients|PAPAL|Merck Sharp & Dohme Corp.|No|Terminated|January 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|August 14, 2012|No|Yes|Study terminated due to an unfavorable risk-benefit analysis|No|December 22, 2014|https://clinicaltrials.gov/show/NCT01667107||80782|
NCT01667328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-2|Preoperative Massage in Breast Surgery Patients|Utility of Preoperative Massage in Breast Surgery Patients||Vassar Brothers Medical Center|No|Recruiting|June 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01667328||80765|
NCT01667614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-2-27-16-10|Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure|Comparison of Efficacy of Losartan/Spironolactone and Losartan/Enalapril on Urinary Albumin Excretion, Estimated Glomerular Filtration Rate, and Blood Pressure in Patients With Type 2 Diabetes Nephropathy||Tehran University of Medical Sciences|No|Completed|May 2010|July 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|40 Years|80 Years|No|||August 2012|August 27, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667614||80743|
NCT01667926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001042|Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder|Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression||Massachusetts General Hospital|Yes|Recruiting|January 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|August 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01667926||80719|
NCT01668238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201105|Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry|Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry||Peking University|No|Recruiting|August 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|600|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Hospitalized patients undergoing thyroid and breast tumor sugery;          2. Healthy volunteers|August 2012|August 14, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01668238||80695|
NCT01668576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00053075|Properties of Mesenchymal Stem Cells in Lung Transplant|Properties of Mesenchymal Stem Cells in Lung Transplant Candidates||Emory University|No|Terminated|August 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4|Samples With DNA|mesenchymal stem cells derived from subject bone marrow aspiration|Both|18 Years|70 Years|No|Non-Probability Sample|Lung transplant candidates|January 2016|January 13, 2016|August 15, 2012||No|Loss of funding|No||https://clinicaltrials.gov/show/NCT01668576||80669|
NCT01668550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/07/061|A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours|A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours|AZD0424|Cancer Research UK|No|Recruiting|October 2012|||September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01668550||80671|
NCT01715493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYS-0003|Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom|Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study||Eisai Inc.|No|Completed|October 2012|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|20 Years|84 Years|No|||July 2014|July 17, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01715493||77071|
NCT01715506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/304|Continuing Education in Nursing Home Dementia Care|Modeling and Evaluating Evidence Based Continuing Education in Nursing Home Dementia Care|MEDCED|Bergen University College|Yes|Recruiting|August 2011|August 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|220|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715506||77070|
NCT01715779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116951|Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies|An Observational Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies||Novartis|No|Active, not recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|18 Years|N/A|No|Non-Probability Sample|The patients under study are patients who experienced a thromboembolic event during        participation in the ENABLE clinical trials.|March 2016|March 16, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01715779||77049|
NCT01715532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCS-2012|Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase|Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase||Fudan University|Yes|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01715532||77068|
NCT01676506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-1000-LC|Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)|The Impact of Genetic Polymorphisms on Ranibizumab Treatment Outcomes in Wet Age-Related Macular Degeneration (AMD)||Russian Academy of Medical Sciences|No|Recruiting|October 2011|October 2015|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|50 Years|N/A|No|||August 2012|August 30, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01676506||80061|
NCT01677104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/SW/0195|The Microvascular Function of GLP-1 and Its Analogues|The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition||Royal Devon and Exeter NHS Foundation Trust|Yes|Recruiting|August 2012|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677104||80015|
NCT01677364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7862/PG/2Trg/08|Elective Induction vs Spontaneous Labour in Patients With Heart Disease|ELECTIVE INDUCTION OF LABOUR VS SPONTANEOUS LABOUR IN WOMEN WITH HEART DISEASE - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL||Postgraduate Institute of Medical Education and Research||Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|19 Years|37 Years|No|||August 2012|August 29, 2012|August 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01677364||79995|
NCT01677377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-09-0009|Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy|Phase 2A Study as an Open Label, Multiple Ascending Dose With Randomized Subjects to Receive a Single Dose of One of Three Dose Levels||Indivior Inc.|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677377||79994|
NCT01673568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-BINDER|Abdominal Binder to Reduce Pain and Seroma Formation|Postoperative Abdominal Binder in Reducing Seroma Formation and Pain After Ventral (Umbi/Epi) Hernia Repair.|ABD- BINDER|Hvidovre University Hospital|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|56|||Both|18 Years|80 Years|No|||May 2014|May 21, 2014|July 4, 2012||No||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01673568||80287|
NCT01673841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/126|Relation Between Mixed Venous Oxygen Saturation and Cerebral Oxygen Saturation Measured by Absolute and Relative Near-infrared Spectroscopy During Off-pump Coronary Artery Bypass Grafting.|Relation Between Mixed Venous Oxygen Saturation and Cerebral Oxygen Saturation Measured by Absolute and Relative Near-infrared Spectroscopy During Off-pump Coronary Artery Bypass Grafting.||University Hospital, Ghent|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|25 Years|N/A|No|Non-Probability Sample|Patients undergoing elective off-pump coronary artery bypass grafting.|August 2012|August 28, 2012|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01673841||80266|
NCT01673854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-240|Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma|A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma||Bristol-Myers Squibb|No|Completed|September 2012|May 2015|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 24, 2012|Yes|Yes||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01673854||80265|
NCT01674725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-389|A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C|A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-II)|PEARL-II|AbbVie|Yes|Completed|August 2012|October 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|July 27, 2012|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01674725||80198|
NCT01674998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-DAT-013|Understanding the Natural History of REM Sleep Behavior Disorder|Understanding Autonomic Function in REM Sleep Behavior Disorder, Parkinsonism and Controls||The Parkinson's Institute||Recruiting|July 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15|Samples With DNA|Blood and/or saliva DNA|Both|21 Years|N/A|No|Non-Probability Sample|Sleep disorders clinics Neurology practices Medical practices Sleep disorders support        groups Web-based advertisements Community outreach|August 2012|August 27, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01674998||80177|
NCT01675011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-001|Embozene Microspheres for Uterine Fibroid Embolization (UFE)|Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization Compared to Embosphere for Symptomatic Relief From Uterine Fibroids||Boston Scientific Corporation|Yes|Terminated|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Female|30 Years|50 Years|No|||February 2016|February 10, 2016|August 25, 2012|Yes|Yes|Inadequate enrollment|No|January 28, 2015|https://clinicaltrials.gov/show/NCT01675011||80176|The trial was terminated early due to insufficient enrollment, therefore formal statistical analyses were not possible.
NCT01668940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031589|Freezie Remedy to Alleviate Morning Sickness|Effectiveness of a Natural Non-medicinal Freezie Remedy to Alleviate Morning Sickness||The Hospital for Sick Children|Yes|Recruiting|August 2012|June 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|180|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668940||80641|
NCT01667666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB #11-0706|Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury|A Clinical Study to Determine if Nebulized Hypertonic Saline Attenuates Acute Lung Injury Following Trauma and Hemorrhagic Shock||Denver Health and Hospital Authority|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01667666||80739|
NCT01667627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-RD-0491-CTIL|Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea|A Double-blind, Placebo-controlled Study to Assess the Effect of Probiotic on Symptom Relief and Indices of Micro-inflammation and Cholinergic Status in IBS Patients With Diarrhea.|IBS-D|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|70 Years|No|||August 2012|March 26, 2014|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667627||80742|
NCT01667640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sektorradv_4.0_04-2012|Sector Irradiation Versus Whole Brain Irradiation for Brain Metastasis|Sector Irradiation Versus Whole Brain Irradiation After Resection of Singular or Solitary Brain Metastasis - a Prospective Randomized Monocentric Trial||Medical University Innsbruck|No|Recruiting|April 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||April 2015|April 28, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01667640||80741|
NCT01667952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-143|Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness|Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness||Memorial Sloan Kettering Cancer Center||Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Saliva or blood samples will be collected in the clinic at the time of a routine visit.|Both|N/A|N/A|No|Non-Probability Sample|Patients from the Adult Long-Term Follow-Up Program, the Pediatric Long Term Follow-up        Program, or Lymphoma Service will be recruited at a routine visit to MSKCC.|January 2016|January 13, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667952||80717|
NCT01667965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-172|Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy|Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy||Memorial Sloan Kettering Cancer Center||Completed|August 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients will be approached regarding study enrollment at the time that they are        evaluated by the inpatient radiation oncology team for palliative radiation therapy.|July 2015|July 13, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667965||80716|
NCT01668472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SriLankaROMStudy062012|A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes||University of Colombo|Yes|Withdrawn|August 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Sample of diluted vaginal secretion into buffer|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any pregnant woman who presents with alleged leakage of amniotic fluid is eligible for        recruitment|December 2013|December 20, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01668472||80677|
NCT01668511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-756|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee|A Randomized, Double-Blind, Placebo Controlled Study in Patients With Osteoarthritis of the Knee to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of ABT-981||AbbVie|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|40 Years|70 Years|No|||November 2013|November 4, 2013|August 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668511||80674|
NCT01668602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058363|Stroke Gait Rehabilitation Using Functional Electrical Stimulation|Cortical and Spinal Correlates of Post-stroke Gait Rehabilitation||Emory University|No|Active, not recruiting|August 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|30 Years|80 Years|No|||July 2015|July 12, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01668602||80667|
NCT01668836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|788012|Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years|Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years.||InCor Heart Institute|No|Recruiting|August 2012|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Both|55 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 17, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01668836||80649|
NCT01715233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1248|A Phase II Study Investigating Checkpoint With Forkhead and Ring Finger Domains (CHFR) Methylation Status In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer|A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Flourouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|October 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|127|||Both|18 Years|80 Years|No|||November 2013|November 7, 2013|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715233||77091|
NCT01715246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.26.INF|Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)|Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)||Nestlé|No|Completed|October 2012|July 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|176|||Both|N/A|14 Days|Accepts Healthy Volunteers|||July 2014|September 10, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715246||77090|
NCT01715519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VII-IT-05|Vilazodone for the Treatment of Posttraumatic Stress Disorder|A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder||Southern California Institute for Research and Education|Yes|Completed|October 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|55 Years|No|||December 2015|December 8, 2015|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715519||77069|
NCT01715545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200601YJ|Availability of Poor Quality Embryos|Availability of Poor Quality Embryos in Frozen-thawed Embryo Transfer Cycles|Availability|The Second Affiliated Hospital of Kunming Medical University|No|Completed|January 2011|October 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|481|||Female|20 Years|40 Years|No|Non-Probability Sample|unfertile women|October 2012|October 25, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715545||77067|
NCT01704170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM12-001|Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound|A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound on Patients With Refractory Hypertension||Kona Medical Inc.|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704170||77937|
NCT01676818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5C-11-2|Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer|Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer||University of Southern California|Yes|Recruiting|August 2012|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676818||80037|
NCT01677117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECMO treatment|Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality|||Southeast University, China|Yes|Not yet recruiting|August 2012|December 2012|Anticipated|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|25|||Both|18 Years|70 Years|No|Probability Sample|severe ARDS patients|August 2012|August 29, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677117||80014|
NCT01677390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN75-002|A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma|A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma||Seattle Genetics, Inc.|No|Terminated|August 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677390||79993|
NCT01677689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCR09032|Study to Investigate the Efficacy and Safety of Apomivir®|A Prospective, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Apomivir® in Relieving Influenza Symptoms||Far East Bio-Tec Co., Ltd|No|Not yet recruiting|September 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Both|20 Years|65 Years|No|||November 2013|November 12, 2013|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677689||79970|
NCT01673867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-057|Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC|An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)|CheckMate057|Bristol-Myers Squibb|No|Active, not recruiting|October 2012|May 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|792|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 24, 2012|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT01673867||80264|
NCT01674166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-12|Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention|A Single-dose Pharmacokinetic Trial of 0.03 mg/kg R108512 Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR).||Movetis||Completed|November 1998|May 1999|Actual|May 1999|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|4 Years|12 Years||||June 2012|August 27, 2012|August 24, 2012||||||https://clinicaltrials.gov/show/NCT01674166||80241|
NCT01674439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1069/08|Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells|Randomized Controlled Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells for Facial Soft Tissue Augmentation in Patients With Craniofacial Microsomia.||University of Sao Paulo|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|10 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01674439||80220|
NCT01675271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300/E9/06|Autonomic Nervous System and Exercise In Gestational Diabetes|Effect Of Individual Exercise Prescription On Cardiovascular Risk Factors In Woman At Risk For Gestational Diabetes - Focus On Autonomic Nervous System And Inflammation|ANS-EXE|Helsinki University Central Hospital|No|Active, not recruiting|February 2012|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01675271||80156|
NCT01675531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN12-KR-402|A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment||Mundipharma Korea Ltd|No|Completed|December 2012|June 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|73|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675531||80136|
NCT01675830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00001161|Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass|Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass||Cardiology Clinical Research & Regulatory Group|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|N/A|1 Year|No|||March 2015|March 11, 2015|July 19, 2012||No||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01675830||80113|Investigators could not account for differences in the room temperature, heated and humidified gases, CPB regulation, regulation of forced air warming system, warming of IV fluids, and temperature of irrigation solutions in the OR.
NCT01667380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25617|An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)|Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis||Hoffmann-La Roche||Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|No|Probability Sample|Anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD        stage V on dialysis|March 2016|March 1, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667380||80761|
NCT01667393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEV POP-01-US/OUS|Popliteal Artery of Treatment With Balloon Angioplasty vs. SUPERA VERITAS Peripheral Stent System|Popliteal Artery Trial of Patients Undergoing Treatment With Balloon Angioplasty vs. the Adaptive SUPERA VERITAS Peripheral Stent System|PARADIGM|IDev Technologies, Inc.|Yes|Withdrawn|January 2013|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667393||80760|
NCT01667185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL900803|Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus|Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus.||DexCom, Inc.|No|Completed|July 2012|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|176|||Both|2 Years|17 Years|No|Non-Probability Sample|Pediatric subjects with diabetes mellitus|February 2013|February 7, 2013|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667185||80776|
NCT01667991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDR in China 123|Evaluation of the American Thoracic Society Criteria for Predicting Multidrug-resistant Bacteria in Critically Ill Patients|||Southeast University, China|Yes|Completed|April 2010|September 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|610|||Both|18 Years|90 Years|No|Probability Sample|Critically ill patients admitted to icu|August 2012|August 17, 2012|August 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01667991||80714|
NCT01668264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000017963|Imaging Assessment of Diastolic Function|Combined Echocardiographic and MRI Assessment of Diastolic Function in Patients With Congenital Heart Disease||The Hospital for Sick Children|No|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|18 Years|No|||August 2012|August 14, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01668264||80693|
NCT01668017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066-010|A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy|A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy||Merck KGaA|Yes|Terminated|September 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 15, 2012||No|The sponsor decided not to conduct the expansion part of trial (part 2)|No||https://clinicaltrials.gov/show/NCT01668017||80712|
NCT01668329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00822-55|Bio-clinical Evolutive Dynamic in Patients Suffering From Communitary Septic Shock (Biosepsis)|Bio-clinical Evolutive Dynamic in Patients Suffering From Communitary Septic Shock (Biosepsis)|BIOSEPSIS|University Hospital, Grenoble|Yes|Completed|September 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|Samples Without DNA|hormons, inflammatory markers, vitamines recovered from the patients serum.|Both|18 Years|N/A|No|Non-Probability Sample|All immunocompetent patients hospitalised in intensive care from the beginning of the        septic shock state.|August 2012|January 16, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01668329||80688|
NCT01668888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaHealth_Progranulin|Progranulin and CTRP3 in Metabolic Syndrome|||Korea University|Yes|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|127|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The subjects who visited for a routine health check-up at the Health Promotion Center of        Korea University Guro Hospital were enrolled using predefined inclusion and exclusion        criteria.|August 2012|August 16, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01668888||80645|
NCT01668901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WASAK|Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease|A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease||Seoul National University Hospital||Not yet recruiting|September 2012|June 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|720|||Both|18 Years|90 Years||||August 2012|August 20, 2012|August 16, 2012||||No||https://clinicaltrials.gov/show/NCT01668901||80644|
NCT01668862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-TE/11-12/003|A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate in Lateral Epicondylitis (Tennis Elbow)|A Prospective, Multicentric, Open Label, Randomised, Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For The Treatment Of Lateral Epicondylitis (Tennis Elbow)||Kasiak Research Pvt. Ltd.|Yes|Recruiting|March 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2012|August 16, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01668862||80647|
NCT01667029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-p-001443|Study of Sulfasalazine in Treating Painful Neuropathy|A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Neuropathy||Massachusetts General Hospital|No|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667029||80788|
NCT01707264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOD001-001|Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis||Prothena Therapeutics Ltd.|Yes|Active, not recruiting|April 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||October 2015|October 10, 2015|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01707264||77700|
NCT01704183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-2012-SS|Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis|Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis|FingoHRV|Kuopio University Hospital||Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|65 Years|No|Probability Sample|Neurological clinic|May 2014|May 7, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704183||77936|
NCT01676844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEC1112/65|Investigating a New Way of Giving Medicine to Newborn and Preterm Babies|Oral Potassium Acid Phosphate Supplementation for Preterm Neonates; a Comparison of Oral Thin Films and Standard Oral Therapy.||University of Strathclyde|No|Not yet recruiting|February 2013|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|26 Weeks|40 Weeks|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676844||80035|
NCT01677728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSTCC|Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases|A Randomized, Controlled Trial of Target Therapy Plus Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases||Fudan University|No|Recruiting|January 2007|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|75 Years|No|Probability Sample|From Zhongshan hospital|August 2012|August 30, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677728||79967|
NCT01673880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-005|Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations|A Single-center, Open-label, Randomized, Multi-cohort, Crossover Study of Relative Bioavailability of Tablet Versus Capsule Formulation of E2006 in Healthy Adult Subjects||Eisai Inc.||Completed|August 2012|December 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|May 20, 2013|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673880||80263|
NCT01673893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K061680|ClearWay Rx Readmission Registry|ClearWay Rx Readmission Registry|ClearWay|Cardiovascular Institute of the South Clinical Research Corporation|No|Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|80 Years|No|Non-Probability Sample|patients presenting with myocardial infarction|January 2016|January 26, 2016|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673893||80262|
NCT01673906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000994-22|68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours|Accuracy and Clinical Impact of 68-Ga-labeled Octreotide Analogues PET in Diagnosis and Staging of Duodenal-pancreatic Neuroendocrine Tumours; Proposal of a Multicenter, Prospective Clinical Trial||Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|142|||Both|18 Years|90 Years|No|||July 2014|July 1, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01673906||80261|
NCT01674179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM 10-26|Quantitative EEG During PSG in Patients With and Without Fibromyalgia|Quantitative EEG During PSG in Patients With and Without Fibromyalgia|FMQEEG-10-26|SouthCoast Medical Group|No|Active, not recruiting|July 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|560|||Both|18 Years|80 Years|No|Non-Probability Sample|Private Sleep Practice|August 2012|August 27, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01674179||80240|
NCT01674452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC003|Home-based Exercises for Patients With Stroke|Home-based Exercises for Patients With Stroke||University of Sao Paulo General Hospital|Yes|Completed|January 2010|July 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|75 Years|No|||August 2012|August 24, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01674452||80219|
NCT01668680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0047-11|Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma|Metronomic Chemotherapy With Anti-angiogenic Effect as Maintenance Treatment for Metastatic Colorectal Carcinoma Following Response to FOLFIRI+Bevacizumab: Clinical and Laboratory Studies||HaEmek Medical Center, Israel|No|Terminated|September 2012|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||July 2015|July 6, 2015|March 11, 2012||No|No satisfactory acrual|No||https://clinicaltrials.gov/show/NCT01668680||80661|
NCT01667419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27826|BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence||Hoffmann-La Roche||Recruiting|September 2012|October 2020|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|475|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667419||80758|
NCT01667497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102825|Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?|Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study||London Health Sciences Centre|No|Completed|September 2012|August 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|64 Years|No|||September 2015|September 1, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667497||80752|
NCT01667510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lyc-2012-01|Effect of Cardio Mato (a Tomato Extracted Lycopene) on Blood Pressure and Serum Lycopene, Phytofluene, and Phytoene Levels in Pre-hypertensive Otherwise Healthy Subjects|Effect of Cardio Mato (Grade A Lyc-O-Mato, a Tomato Extracted Lycopene) on Blood Pressure and Serum Lycopene, Phytofluene, and Phytoene Levels in Pre-hypertensive Otherwise Healthy Subjects||LycoRed Ltd.|No|Recruiting|August 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01667510||80751|
NCT01667458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25702|An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)|F-ACT Trial: Observational Study on Fatigue and Its Evolution During Treatment With Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis in Daily Clinical Practice||Hoffmann-La Roche||Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis with an inadequate response to at        least two DMARDs or an inadequate response to anti-TNF treatment, eligible for treatment        with RoActemra/Actemra|March 2016|March 1, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667458||80755|
NCT01667471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25756|A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977)||Hoffmann-La Roche||Completed|January 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|9 Years|18 Years|No|||February 2016|February 1, 2016|August 15, 2012|No|Yes||No|July 9, 2015|https://clinicaltrials.gov/show/NCT01667471||80754|
NCT01667705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMCSkyceiling01032012|To Examine the Effect of a View of Nature on Patient's Stress and Anxiety|Patient Experience in the CT Scan Suite|Skyceiling|Erasmus Medical Center|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|120|||Both|18 Years|85 Years|No|Non-Probability Sample|120 Out-patients, age 18-85, who are scheduled to undergo a thorax and/or abdomen CT scan        with intravenous contrast.|January 2015|January 26, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01667705||80736|
NCT01668355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 12-177|PACT for Individuals With Serious Mental Illness|PACT to Improve Health Care in People With Serious Mental Illness (SMI-PACT)|SMI-PACT|VA Office of Research and Development|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01668355||80686|
NCT01667094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249/12|A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis|Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis|CISTIC|The Alfred|No|Recruiting|September 2012|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667094||80783|
NCT01667068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4970-BO|Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up|HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients||University Hospital, Essen|Yes|Completed|April 2012|October 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1481|Samples With DNA|Stored blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Participiants were included in several cities of the Ruhrarea. Locations were Essen,        Bochum, Dortmund and Duisburg The study population included outpatients who were at least        18 years of age, had a known HIV-infection and exhibited a stable disease status within 4        weeks before inclusion of the trial. Written informed consent was obtained from all        participants.|October 2014|October 27, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01667068||80785|
NCT01708447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-117|Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment|Feasibility Study: Evaluation of the Efficacy of a Liposome-encapsulated Lidocaine Topical Anesthetic for Reducing Discomfort Associated With Ultherapy™ Treatment||Ulthera, Inc|No|Completed|July 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01708447||77609|
NCT01704989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP-SLT-2012|The Laser in Pseudoexfoliation (LIP) Study|A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma|LIP|Nova Scotia Health Authority|No|Not yet recruiting|October 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01704989||77874|
NCT01677403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qlhqiqian|A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis|A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis||Shandong University|No|Recruiting|August 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2012|December 4, 2012|August 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01677403||79992|
NCT01677715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL/CL-003|Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System|Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal||Inner Mongolia Yili Industrial Group Co., Ltd||Completed|August 2011|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|240|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01677715||79968|
NCT01677754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28248|MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy|A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIENTS WITH MODERATE SEVERITY ALZHEIMER'S DISEASE||Hoffmann-La Roche||Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|531|||Both|50 Years|90 Years|No|||March 2016|March 11, 2016|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677754||79965|
NCT01673581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-463|Shared Decision Making in Low Risk Prostate Cancer|Shared Decision Making: A Study Assessing the Benefit of a Web Based Aid Presenting Treatment Options for Patients With Low Risk Prostate Cancer||Massachusetts General Hospital|No|Active, not recruiting|August 2012|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|141|||Male|18 Years|N/A|No|Non-Probability Sample|Low risk prostate cancer patients seen wthin the Claire & John Bertucci Center for        Genitourinary Cancers multidisciplinary clinic at MGH.|March 2016|March 14, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01673581||80286|
NCT01674192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-6|Prucalopride Subjects With Renal Impairment|Single Dose Pharmacokinetic Trial of Oral Prucalopride (R093877) in Subjects With Mild, Moderate and Severe Renal Impairment||Movetis||Completed|July 1997|August 1999|Actual|August 1999|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|N/A||||June 2012|August 27, 2012|August 24, 2012||||||https://clinicaltrials.gov/show/NCT01674192||80239|
NCT01674205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 12-001|Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines|Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|36|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||October 2015|December 14, 2015|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674205||80238|
NCT01674465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nox2 and CNI|Role of Nox2 in CNI-induced Renal Fibrosis|The Role of Nox2 in CNI-Induced Renal Fibrosis|Nox2|University of Wisconsin, Madison|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 0|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Study population will be chosen from non-kidney transplant patients scheduled for a        standard of care kidney biopsy.|October 2015|October 9, 2015|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674465||80218|
NCT01668173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-076|HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET|A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET||Memorial Sloan Kettering Cancer Center||Terminated|August 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|August 13, 2012|Yes|Yes|patient safety|No||https://clinicaltrials.gov/show/NCT01668173||80700|
NCT01674738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-2011-NSCLC-03|TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV|TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV|SELECT-A|Aktion Bronchialkarzinom e.V.|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||October 2013|October 10, 2013|August 23, 2012||No|Decision of the Sponsor, as the funding of the study was no longer guaranteed.|No||https://clinicaltrials.gov/show/NCT01674738||80197|
NCT01675024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0913|Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects|A Single-site, Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects.||UCB Pharma|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 3, 2012|August 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01675024||80175|
NCT01668407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|545/2012/61/2012|Robot Walking Rehabilitation in Parkinson's Disease|Use of a Robot for the Rehabilitation of Walking in Patients With Parkinson's Disease.|Robopark|IRCCS San Raffaele|No|Recruiting|February 2012|February 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2012|August 17, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01668407||80682|
NCT01668420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980332|Effect of Thermal Stimulation for Lower Extremity Movement and Function in Patients With Stroke|Effect of Thermal Stimulation for Lower Extremity Movement and Function in Patients With Stroke||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|80 Years|No|||November 2012|November 7, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01668420||80681|
NCT01666964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350758-12|Hormone Deficiency After Brain Injury During Combat|Prevalence of Hypopituitarism Following Combat-related Traumatic Brain Injury in a Military Population||Walter Reed National Military Medical Center|No|Not yet recruiting|October 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|No specimens will be stored.      Blood Testing:      Testosterone 2ml Estradiol 2ml LH/FSH 3ml Prolactin 2ml IGF-1 1ml TSH 2ml Free T4 1ml Sodium      2ml Total blood for cosyntropin stim test 9ml Total blood for glucagon stim test 15ml Water      deprivation testing 12ml-32ml      Urine Testing:      HCG 2ml Water deprivation testing 8ml-18ml|Both|18 Years|N/A|No|Probability Sample|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic        Brain Injury that occurred 3 and 6 months prior to enrollment.|August 2012|August 14, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666964||80793|
NCT01667536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-1404-201|A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology|A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology||Molecular Insight Pharmaceuticals, Inc.|No|Active, not recruiting|August 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|21 Years|N/A|No|||November 2013|November 12, 2013|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667536||80749|
NCT01667744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11146121|Citalopram for Sx/Util in Acute Coronary Syndrome Patients|Citalopram for Sx/Util in Acute Coronary Syndrome Patients||Henry Ford Health System|Yes|Withdrawn|January 2018|February 2021|Anticipated|February 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 12, 2012|Yes|Yes|unfunded|No||https://clinicaltrials.gov/show/NCT01667744||80733|
NCT01668043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBI Protocol A201|Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults|A Phase IIa, Open-label, Multiple-Dose Trial to Investigate the Safety and Efficacy of the UB-421 in Asymptomatic HIV-1 Infected Adults||United Biomedical|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|20 Years|N/A|No|||August 2014|August 18, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01668043||80710|
NCT01668381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010B031600209|Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy|Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy||First Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|August 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|hepatocellular carcinoma patients underwent radiofrequency ablation therapy|February 2013|February 20, 2013|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01668381||80684|
NCT01675713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKD1|Lifestyleintervention for the Treatment of Severe Obesity|Intensive Lifestyleintervention for the Treatment of Severe Obesity||Norwegian School of Sport Sciences|Yes|Completed|September 2009|September 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01675713||80122|
NCT01667315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bupivacaine 0,375%|Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block|Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery||Federal University of São Paulo|No|Recruiting|August 2012|September 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|33|||Both|21 Years|65 Years|No|||August 2012|August 16, 2012|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667315||80766|
NCT01704755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-099|A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)|TURQUOISE-II|AbbVie|Yes|Completed|October 2012|September 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|381|||Both|18 Years|70 Years|No|||September 2015|September 24, 2015|September 28, 2012|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01704755||77892|
NCT01706133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-201 l-785-056|An Intervention for Elderly in Emergency Services|Elderly in Emergency Services: Effectiveness of an Intervention to Improve Health Outcomes||Coordinación de Investigación en Salud, Mexico|No|Completed|June 2013|||March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|1400|||Both|70 Years|N/A|No|||February 2015|February 3, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01706133||77787|
NCT01677416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP/2011|Joint Ultrasound Evaluation of Asymptomatic Rheumatic Feet|Joint Ultrasound Evaluation of Asymptomatic Feet in Patients With Rheumatoid Arthritis: A Controlled Study||Federal University of São Paulo|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rheumatoid Arthritis|August 2012|August 29, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01677416||79991|
NCT01677741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116013|A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects|Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors||GlaxoSmithKline|No|Recruiting|February 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|60|||Both|12 Months|17 Years|No|||August 2015|October 22, 2015|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677741||79966|
NCT01673594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000918|Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist|Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist||Massachusetts General Hospital|Yes|Completed|September 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|30 Years|No|||February 2016|February 1, 2016|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673594||80285|
NCT01674751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4262|What to Eat for Lunch? A Pilot Study to Improve Healthier Eating at Work|What to Eat for Lunch? A Pilot Study to Improve Healthier Eating at Work||Albert Einstein Healthcare Network|No|Completed|June 2012|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|February 21, 2014|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01674751||80196|
NCT01668459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4368|Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel|Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.|CabB1|University Hospital Birmingham NHS Foundation Trust|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01668459||80678|
NCT01668719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1211|S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma|S1211, A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)||Southwest Oncology Group|Yes|Recruiting|September 2012|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|120 Years|No|||September 2015|September 28, 2015|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668719||80658|
NCT01668979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NG-0363-CTIL|Assessment of a New System to Detect, Quantify and Treat Near Falls in Older Adults|Assessment of a New System to Detect, Quantify and Treat Near Falls in Older Adults||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy older adults with a history of falls|August 2012|August 16, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668979||80638|
NCT01668966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28080|A Long Term Extension Study of WA19926 of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Active, not recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668966||80639|
NCT01667120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00554|The Use of Ketorolac in Surgical Neonates|||Nationwide Children's Hospital|Yes|Not yet recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|N/A|3 Months|No|||August 2012|August 16, 2012|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667120||80781|
NCT01667133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-11-106|A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)|A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs)||Ariad Pharmaceuticals|No|Active, not recruiting|August 2012|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667133||80780|
NCT01667211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GYN-001|Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer|A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer|CSAPPPCC|Chinese Academy of Medical Sciences|No|Recruiting|November 2011|December 2016|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01667211||80774|
NCT01667562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27860|An Open-Label Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase IIIb, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE)||Hoffmann-La Roche||Active, not recruiting|January 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01667562||80747|
NCT01667874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102635|Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections|Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections||Lawson Health Research Institute|No|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667874||80723|
NCT01667770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11BN113|Dural Graft Equivalent Comparison Trial|Dural Graft Equivalent Comparison Trial|DECOMPRESS|St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|January 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 16, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667770||80731|
NCT01667783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK089557|Improving Diabetes Through Lifestyle and Surgery|Improving Diabetes Through Lifestyle and Surgery Study|IDeaLS|Johns Hopkins University|Yes|Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|21 Years|64 Years|No|||March 2015|March 30, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01667783||80730|
NCT01668069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD-2011-0151|Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy|Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy||United States Naval Medical Center, San Diego|Yes|Completed|October 2012|April 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|90 Years|No|||July 2013|July 11, 2013|August 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668069||80708|
NCT01668927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls_2012009|Empirical Rescue Therapies of Helicobacter Pylori Infection|Helicobacter Pylori Treatment||Shanghai Jiao Tong University School of Medicine|No|Completed|July 2012|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|424|||Both|18 Years|70 Years|No|||June 2013|June 1, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668927||80642|
NCT01675427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV25600|A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C|An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C||Hoffmann-La Roche||Completed|August 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4766|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 24, 2012||No||No|May 21, 2015|https://clinicaltrials.gov/show/NCT01675427||80144|
NCT01675726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00193-40|QUALITY OF LIFE OF CHILDREN BORN VERY PRETERM AT SCHOOL-AGE|QUALITY OF LIFE OF CHILDREN BORN VERY PRETERM AT SCHOOL-AGE||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|325|||Both|7 Years|9 Years|No|||November 2015|November 16, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675726||80121|
NCT01676012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38719|Hd-bronchoscopy, Comparison to Standard White Light and Autofluorescence Bronchoscopy|High Definition Bronchoscopy; an Exploratory Study of Diagnostic Value in Comparison to Standard White Light Bronchoscopy and Autofluorescence Bronchoscopy||Radboud University|No|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected or proven head and neck or lung cancer fit for surgery and        scheduled for diagnostic or therapeutic surgical procedure in the Radboud University        Medical Center Nijmegen|May 2015|May 8, 2015|August 15, 2012||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01676012||80099|
NCT01705860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-032|Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation|A Long Term Follow-Up to Study 017-101-09-001: Effect of Collagenase Santyl® Ointment vs. Placebo on Healing and Scarring Characteristics of 600um Dermatome Wounds||Healthpoint|No|Completed|September 2012|April 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adult volunteers who were previously treated in study 017-101-09-001 with        Collagenase Santyl Ointment and Vehicle (white petrolatum ointment).|April 2013|April 11, 2013|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01705860||77808|
NCT01706419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORISCA|Fortified Rice for School Children in Cambodia|Fortified Rice for School Children in Cambodia: Effects on Micronutrient Status, Growth, Cognition and Health.|FORISCA|Institut de Recherche pour le Developpement|Yes|Completed|October 2012|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|9500|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01706419||77765|
NCT01677767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25475|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia|Efficacy of C.E.R.A. for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients on Dialysis , Treated According to Routine Clinical Practice||Hoffmann-La Roche||Completed|April 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|65 Years|No|Probability Sample|Patients with chronic kidney disease on dialysis receiving treatment with Mircera for        chronic renal anemia|February 2016|February 8, 2016|August 30, 2012||No||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01677767||79964|
NCT01673607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METAHEP|Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer||METAHEP|Poitiers University Hospital||Recruiting||||April 2015|Anticipated|Phase 2|Interventional|N/A|||||||Both|18 Years|N/A||||April 2013|April 3, 2013|February 13, 2012||||No||https://clinicaltrials.gov/show/NCT01673607||80284|
NCT01673919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28166|A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977)||Hoffmann-La Roche||Completed|February 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|4 Years|N/A|No|||November 2015|November 2, 2015|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673919||80260|
NCT01668212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-11-01|Perifollicular Doppler in Natural Cycle In Vitro Fertilization|Perifollicular Doppler in Natural Cycle In Vitro Fertilization||OVO R & D|No|Completed|March 2012|||May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|160|||Female|18 Years|38 Years|No|Probability Sample|Women following In Vitro Fertilization cycle|June 2013|June 21, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01668212||80697|
NCT01668225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-11-02|Impact of Follicular and Blood G-CSF on Pregnancy and Implantation Rate During Modified Natural in Vitro Fertility Cycle|Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle|G-CSF FIVnat|OVO R & D|No|Recruiting|March 2012|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|224|Samples Without DNA|Serum sample Follicular fluid|Female|18 Years|43 Years|No|Probability Sample|Women with a natural cycle of an In Vitro Fecondation|February 2016|February 1, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01668225||80696|
NCT01668251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS Prenatal Study|Turner Syndrome Prenatal Diagnosis Study|National Collaborative Study of Girls Prenatally Diagnosed With Turner Syndrome Karyotypes||Seattle Children's Hospital|No|Recruiting|January 2006|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|N/A|3 Months|No|Non-Probability Sample|Girls who are diagnosed with Turner syndrome prenatally.|August 2012|August 14, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01668251||80694|
NCT01668498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-LQ-0110|Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer|Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer||AIO-Studien-gGmbH|No|Active, not recruiting|May 2011|March 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Both|18 Years|N/A|No|||September 2015|February 17, 2016|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668498||80675|
NCT01668524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS907-205|ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects|A Phase 2a Open-Label, Dose-ranging Study of the Safety and Tolerability of ATS907 in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension||Altheos, Inc.|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668524||80673|
NCT01668537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-027|A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects|A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects||Bavarian Nordic|Yes|Completed|March 2013|June 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|651|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668537||80672|
NCT01667159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA020705-01A1|Community-Based Integrated Treatment for Adolescents|Adolescents With Major Depression and AUD: Community-Based Integrated Treatment||Brown University|Yes|Recruiting|July 2012|June 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|18 Years|No|||February 2016|February 29, 2016|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01667159||80778|
NCT01667237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20525|Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery|Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery||Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|45 Years|80 Years|No|||January 2013|January 9, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01667237||80772|
NCT01667250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-US-02|Non-Invasive Neurostimulation for the Prevention of Chronic Migraine|Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine||ElectroCore LLC||Completed|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667250||80771|
NCT01667887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MotionLoc Screw|Plating of Distal Femur Fractures by Far Cortical Locking Using MotionLoc Screws|MotionLoc Study: Healing of Distal Femur Fractures Stabilized With a Flexible Plating Construct Using MotionLoc Screws||Legacy Biomechanics Laboratory|Yes|Completed|April 2011|January 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|33|||Both|17 Years|N/A|No|Probability Sample|Distal femur fractures (AO/OTA Type 33A and 33C)|January 2013|January 28, 2013|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667887||80722|
NCT01674335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACING-2012|The Effectiveness of Operant Learning Versus Energy Conservation Activity Pacing Treatments in Fibromyalgia|Operant Learning Versus Energy Conservation Activity Pacing Interventions in a Sample of Fibromyalgia Patients: A Randomized Controlled Trial||Lawson Health Research Institute|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01674335||80228|
NCT01667822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Self help CBT|Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy|||Karolinska Institutet|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|396|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01667822||80727|
NCT01667835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK11-04|South Asian Women & Yoga Education Study|Yoga for Post-menopausal South Asian Women at Risk for Cardiovascular Disease: A Randomized Control Pilot Study|SAWYES|Kwantlen Polytechnic University|No|Recruiting|November 2012|August 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01667835||80726|
NCT01668095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B8|Biomarkers in Patients With Advanced Rhabdomyosarcoma|Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas||Children's Oncology Group|No|Active, not recruiting|August 2012|||October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|Samples With DNA|tumor tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients with rhabdomyosarcoma that has spread to other places in the body and usually        cannot be cured or controlled with treatment.|May 2015|May 5, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01668095||80706|
NCT01668108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONKOPAC 01|A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.||Onkovis GmbH|Yes|Recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Patients treated in practices, clinics, hospitals|October 2015|October 26, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01668108||80705|
NCT01675440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10050361DOC|Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® U.S. Expanded Use Study||Medtronic Cardiovascular|Yes|Recruiting|August 2012|April 2021|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|916|||Both|N/A|N/A|No|Probability Sample|Subjects with symptomatic severe aortic stenosis requiring aortic valve replacement, with        predicted operative mortality or serious, irreversible morbidity risk of ≥ 50% at 30 days,        and at least one of the following conditions:          -  Severe (≥3-4+) mitral valve regurgitation          -  Severe (≥3-4+) tricuspid valve regurgitation          -  End stage renal disease (ESRD) requiring renal replacement therapy or creatinine             clearance <20cc/min, but not requiring renal replacement therapy          -  Low gradient, low output aortic stenosis          -  Failed bioprosthetic surgical aortic valve          -  2 or more conditions (listed above)|October 2015|October 26, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675440||80143|
NCT01676038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/519/D|Pinless-Navigated Versus Conventional Total Knee Arthroplasty|Radiographic Analysis Comparing Pinless-Navigated and Conventional Total Knee Arthroplasty: A Randomized Controlled Trial||Singapore General Hospital|Yes|Completed|July 2011|August 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|45 Years|90 Years|No|||December 2014|December 19, 2014|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676038||80097|
NCT01676025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyu.eun.lee-001|Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy|Randomized Controlled Trial Between PRA(Posterior Retroperitoneoscopic Adrenalectomy) and LA(Laparoscopic Adrenalectomy)|PRA|Seoul National University Hospital|No|Recruiting|September 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|79 Years|No|||December 2013|December 3, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01676025||80098|
NCT01714739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA223-001|A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Patients With Advanced Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2012|October 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|162|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714739||77129|
NCT01715038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252233|Effectiveness of LNS and MNP Supplements to Prevent Malnutrition in Women and Their Children in Bangladesh|Home-fortification Approaches for the Prevention of Malnutrition in Pregnant and Lactating Women and Their Children in Bangladesh: Program Effectiveness Study|RDNS|University of California, Davis|No|Completed|October 2011|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|4011|||Both|6 Months|49 Years|No|||November 2015|November 30, 2015|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01715038||77106|
NCT01715051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW-116541|D-Serine for Cocaine Dependence Pilot|A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of D-Serine for Cocaine Dependence|STED-CD|University of Cincinnati|No|Withdrawn|February 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|October 9, 2012|Yes|Yes|Funding was not received|No||https://clinicaltrials.gov/show/NCT01715051||77105|
NCT01673620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476A-484|A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Combination Montelukast/Loratadine (MK-0476A) in Mexican Patients With Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|15 Years|65 Years|No|||November 2015|November 19, 2015|August 3, 2012|No|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01673620||80283|
NCT01673633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sacroiliitis in SSc|Sacroiliitis in Systemic Sclerosis|||Cukurova University||Completed|January 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|175|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive systemic sclerosis and rheumatoid arthritis patients and healthy volunteers|August 2012|August 27, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01673633||80282|
NCT01674478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFIRB00021481|Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies|Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies|EMLFO-2|Wake Forest School of Medicine|No|Recruiting|October 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|N/A|2 Months|No|||May 2013|May 24, 2013|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01674478||80217|
NCT01667978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00005|The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception|The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception|NET|University of Southern California|No|Completed|June 2012|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 15, 2012||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01667978||80715|
NCT01668004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8259-012|The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)|Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012|GO-EASY|Merck Sharp & Dohme Corp.|Yes|Completed|September 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668004||80713|
NCT01668277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000026525|Effects of Saline on Circulation in Children|Effects of Hypertonic Saline on the Pulmonary Circulation in Children||The Hospital for Sick Children|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|2 Years|18 Years|No|||December 2014|December 19, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01668277||80692|
NCT01668563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 12.136|International Subarachnoid Aneurysm Trial II|International Subarachnoid Aneurysm Trial II Comparing Clinical Outcomes of Surgical Clipping and Endovascular Coiling for Ruptured Intracranial Aneurysms Not Included in the Original ISAT Study.|ISAT II|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|October 2012|June 2024|Anticipated|December 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1724|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01668563||80670|
NCT01668823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 05903|Photodynamic Therapy in Treating Patients With Lung Cancer|A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study||Roswell Park Cancer Institute|Yes|Completed|February 2004|June 2014||June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668823||80650|
NCT01668784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-025|Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)|A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy||Bristol-Myers Squibb|Yes|Active, not recruiting|September 2012|September 2017|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|822|||Both|18 Years|N/A|No|||August 2015|January 26, 2016|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668784||80653|
NCT01667276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10196|Acceptability of Depo-subQ in Uniject|Acceptability of Depo-subQ in Uniject||FHI 360|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|476|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 560 participants will be enrolled in the study in the following groups:          -  360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients             who seek re-injection of DMPA from either CHWs or clinic-based providers; and are             18-40 years of age; received their most recent DMPA injection no more than 13 weeks             prior to enrollment in the study [16].          -  Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who             meet the inclusion/exclusion criteria but do not want to receive the injection with             Depo-subQ in Uniject and are willing to complete a short questionnaire          -  80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal             only) who are trained to give Depo-subQ in Uniject as part of this study|July 2013|July 16, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01667276||80769|
NCT01674621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA058-05-007|Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 (Abaloparatide) Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal (Abaloparatide Transdermal)) in Healthy Postmenopausal Women With Osteoporosis||Radius Health, Inc.|No|Completed|August 2012|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|250|||Female|N/A|85 Years|No|||June 2014|June 25, 2014|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674621||80206|
NCT01668147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205135|Efavirenz and Ritonavir on Human Brian P-Glycoprotein|Influence of Efavirenz and Ritonavir on Human Brain P-Glycoprotein Activity Using PET Imaging|dLOP|Washington University School of Medicine|No|Active, not recruiting|August 2012|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668147||80702|
NCT01668667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114025|Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)|CONCORD|XenoPort, Inc.|No|Completed|June 2012|||November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|501|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|June 14, 2012|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01668667||80662|
NCT01675739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-CFS|Effectiveness of Fixed PC Interval Using SMS for Afternoon Colonoscopy|Effectiveness of Fixed Preparation-to-Colonoscopy Interval Using Short Message Service (SMS) for Afternoon Colonoscopy: a Randomized Control Study||Inje University|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|280|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675739||80120|
NCT01675752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE ICH 37/11|Small Hyperplastic and Adenomatous Reliability Protocol|Accuracy of Narrow Band Imaging in Predicting Colonoscopy Surveillance Intervals and Histology of Distal Diminutive Polyps (Small Hyperplastic and Adenomatous Reliability Protocol; SHARP Trial)|SHARP|Istituto Clinico Humanitas|No|Completed|May 2011|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive adult patients who were referred for elective outpatient colonoscopy will be        asked to enroll into this trial if the candidate meets the study inclusion and exclusion        criteria.|August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675752||80119|
NCT01676584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28410|A Study of Single Dose RO6811135 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Healthy Subjects.||Hoffmann-La Roche||Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676584||80055|
NCT01714492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11019|Mechanics Analysis of Patients Having a Sigma Mobile Bearing TKA|In Vivo Mechanics Analysis of Patients Having a Sigma Mobile Bearing TKA|Sigma MB TKA|The University of Tennessee Knoxville|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|8|||Both|40 Years|85 Years|No|Probability Sample|Patients are eight mobile bearing subjects that were implanted over 10 years ago with a        custom polyethylene insert that has four beads rigidly inserted into the polyethylene        component.|January 2014|January 21, 2014|October 23, 2012|No|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01714492||77148|Small study population; only one specific type of mobile bearing implant was analyzed; no definitive way to quantitatively measure level of wear on various implants to determine if there was any influence on the kinematic performance.
NCT01714752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02|Evaluation of Left Ventricular Filling Pressures During Exercise|Evaluation of Left Ventricular Filling Pressures During Exercise: Comparative Study, Catheterization Versus Echocardiography|PREFFORT|French Cardiology Society|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01714752||77128|
NCT01714765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007422QM|Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer|A Phase I Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer|DEVELOP|Queen Mary University of London||Completed|April 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714765||77127|
NCT01715064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA_CSP2012|Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients|Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients||University of Guelph-Humber|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Male|45 Years|85 Years|No|||January 2014|January 12, 2014|October 9, 2012||No||No|May 24, 2013|https://clinicaltrials.gov/show/NCT01715064||77104|
NCT01674218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0058|Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers|Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male and Female Volunteers Aged 18 to 45 Years||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|74|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|November 13, 2014|August 23, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01674218||80237|
NCT01667939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMPMP05/06/09|A Supervised Nutritional Program in Pregnancies and NF-κB Expression in Placenta|A Supervised Nutritional Program in Pregnancies Diminish the NF-κB Expression in Placenta||Materno-Perinatal Hospital of the State of Mexico|No|Completed|June 2009|June 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667939||80718|
NCT01667692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ssu.hakimi-89027|Aizthromycin or Clarithromycin in H-pylori Eradication Regimen|Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen|H-pylori|Shahid Sadoughi University of Medical Sciences and Health Services|No|Completed|March 2011|March 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|65 Years|No|||August 2012|August 15, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01667692||80737|
NCT01667718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls2012011|Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment|Levofloxacin-containing Therapy for Helicobacter Pylori Treatment||Shanghai Jiao Tong University School of Medicine|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|75 Years|No|||December 2012|December 12, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01667718||80735|
NCT01668030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0456|Comparison of Wound Bed Establishment in Facial Burns|Comparison of Wound Bed Establishment in Facial Burns Using Two Standard Ointments||University of Louisville|No|Recruiting|April 2012|December 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01668030||80711|
NCT01668303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017478|Family-Based Juvenile Drug Court Services|Family-Based Juvenile Drug Court Services|JDC|University of Miami|No|Completed|June 2004|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01668303||80690|
NCT01668316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-12-0059|Get Active and Eat Right: Moms at Work|Get Active and Eat Right: Moms at Work|GEM|University of North Carolina, Greensboro||Recruiting|July 2012|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01668316||80689|
NCT01668849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0220|Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer|Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients||James Graham Brown Cancer Center|Yes|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|85 Years|No|||January 2016|February 29, 2016|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01668849||80648|
NCT01666990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-007|Tripterygium Wilfordii Hook F (TwHF) Treatment for Immune Non-responders With HIV-1 Infection|Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection||Beijing 302 Hospital|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||August 2015|August 14, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01666990||80791|
NCT01667588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031590|Sleep Disorders in Pediatric Dialysis|Sleep Disorders in Pediatric Dialysis||The Hospital for Sick Children|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|||Both|N/A|18 Years|No|Non-Probability Sample|The two study cohorts will be age and sex matched and constructed as follows:          1. Pre-dialysis: Stage 4 CKD with an estimated GFR of 15-30 ml/min/1.73m2 based on IDMS             Schwartz GFR          2. Dialysis: CKD receiving outpatient hemodialysis (HD) or peritoneal dialysis (PD) for             a minimum of 1 month. The PSG will be completed after the longest inter-dialytic             interval for HD patients. Patients on PD will undergo PSG while on their usual cycler             nocturnal dialysis regimen.|May 2015|May 20, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667588||80745|
NCT01674634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-867|Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures|A Phase 3b Open-label, Historically-controlled Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures With Palpable Cords||Endo Pharmaceuticals|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|715|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|August 27, 2012|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01674634||80205|
NCT01674647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15693|Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion|A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion|X-VERT|Bayer|Yes|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1504|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|August 27, 2012|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01674647||80204|
NCT01674894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000063|Study of the Cleavage of the Egg in Relation to the Stimulation Treatment|Kinetics in Time-lapse Culture of Human Preembryos||Ferring Pharmaceuticals|No|Recruiting|January 2013|February 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Female|38 Years|45 Years|No|Non-Probability Sample|Women suffering from infertility|October 2015|October 27, 2015|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674894||80185|
NCT01674907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22399|An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)|Non-interventional Study of Avastin in 1st Line Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|March 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer without prior chemotherapy in the metastatic        setting|March 2016|March 1, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01674907||80184|
NCT01675154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3940|Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia|Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia||University of Texas Southwestern Medical Center|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|12 Years|100 Years|No|||December 2015|December 3, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675154||80165|
NCT01675167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3409-307|Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects|Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety, and Tolerability of Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects With Chronic Lower Back Pain Requiring Opioid Analgesia||Endo Pharmaceuticals|No|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|815|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 27, 2012|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01675167||80164|
NCT01676311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-p-002490|Effects of Huperzine A in Treatment of Moderate to Severe TBI|Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI||Spaulding Rehabilitation Hospital|Yes|Recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||September 2015|October 9, 2015|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676311||80076|
NCT01676571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14077A|Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women|A Single-centre, Open-label, Single-dose Interventional Study Investigating the Pharmacokinetic Properties of Lu AA21004 in Healthy Young Chinese Men and Women||H. Lundbeck A/S|No|Completed|October 2012|||November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676571||80056|
NCT01676597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HPS-01|Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome|||Institute of Liver and Biliary Sciences, India|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|64 Years|No|||December 2012|December 16, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676597||80054|
NCT01715090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 40248.018.12|Web-based Insulin Titration - An Efficacy Study|Web-based Insulin Titration: Improving Diabetes Care in the Netherlands. An Efficacy Study.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|December 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|80 Years|No|||November 2014|November 19, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01715090||77102|
NCT01715363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003446-41|Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer|Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency|PRIMM|Gustave Roussy, Cancer Campus, Grand Paris|No|Terminated|July 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||February 2016|February 9, 2016|October 24, 2012||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01715363||77081|
NCT01715662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01246|A Pilot RCT to Investigate the Use of a Home-based Nintendo Wii Program for Rehabilitation in Older Adults With Lower Limb Amputation|WiiHOME-AMPS: A Pilot Randomized Controlled Trial to Investigate the Use of a Home-based Nintendo Wii Program for Rehabilitation in Older Adults With a Unilateral Transtibial or Transfemoral Amputation||University of British Columbia|No|Completed|January 2013|August 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01715662||77058|
NCT01715675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-010|Effects of Plant Stanols on Immune Function in Asthma Patients|The Effect of Plant Stanols on the Immune Function of Asthma Patients||Maastricht University Medical Center|No|Completed|October 2010|January 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|70 Years|No|||January 2014|January 9, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01715675||77057|
NCT01667354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250147|Vaccine Hesitancy Intervention--Provider (VHIP)|Vaccine Hesitancy Intervention--Provider (VHIP)|VHIP|Group Health Cooperative|No|Completed|February 2012|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|491|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01667354||80763|
NCT01667367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25611|A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662|A Single-center, Single Blind Molecular and Functional Imaging Study to Assess GABAAalpha5 Receptor Expression, Occupancy and Functional Connectivity in the Brains of Individuals With Down Syndrome and Healthy Controls Following a Single Oral Administration of RG1662 or Placebo||Hoffmann-La Roche||Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|13|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01667367||80762|
NCT01667653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11PDHD|Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment|A Randomized Parallel Group Study to Evaluate the Effect of a Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment||Danisco|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01667653||80740|
NCT01667731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0123|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects||Gilead Sciences|Yes|Completed|July 2012|February 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|224|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|August 9, 2012|Yes|Yes||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01667731||80734|
NCT01668342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12030542|Mobile Phone Text Message Program to Understand Symptoms and Improve Outcomes in Minor Head Injury Patients|Mobile Phone Text Message Program to Understand Symptoms and Improve Outcomes in Minor Head Injury Patients||University of Pittsburgh|Yes|Completed|June 2012|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|55 Years|No|||May 2015|May 26, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01668342||80687|
NCT01668589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110126|Observational Study of Prolia® in Postmenopausal Women With Osteoporosis|Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium||Amgen|No|Completed|November 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1501|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women indicated for treatment of osteoporosis at increased risk of        fractures according to the approval regional prescribing information, e.g. EU SmPC|October 2015|October 30, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668589||80668|
NCT01668875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU-AMS-PT|Hemodynamic and Ventilatory Responses to Head-down Postural Drainage Position|Acute Hemodynamic and Ventilatory Responses to Head-down 30° Postural Drainage Position in Critically Traumatic Patients||Khon Kaen University|Yes|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|11|||Both|15 Years|50 Years|No|||November 2012|November 17, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01668875||80646|
NCT01667016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1210|BIOFLOW-III Austria Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Austria||Biotronik Vertriebs-GmbH|No|Active, not recruiting|August 2012|December 2015|Anticipated|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|September 2015|September 7, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667016||80789|
NCT01674088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBT-01|Sucrose Breath Test to Determine Intestinal Permeability in IBS|The Use of a Novel 13C Sucrose Breath Test (13C SBT) to Determine Intestinal Permeability in Irritable Bowel Syndrome (IBS) Patients||Metabolic Solutions Inc.|Yes|Completed|October 2012|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinics of Shands Hospital, Gainesville, FL, residents within Gainesville, FL        and students of the University of Florida.|February 2014|February 6, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674088||80247|
NCT01674933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC12CO201|Fluoride Varnish For Childsmile Nursery School Attenders|Comparison Of The Caries-Protective Effect Of Fluoride Varnish (Duraphat®) With Treatment As Usual In Nursery School Attendees Receiving Preventive Oral Health Support Through The Childsmile Oral Health Improvement Programme: An RCT|PT@3|University of Glasgow|No|Recruiting|October 2012|August 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1610|||Both|36 Months|50 Months|Accepts Healthy Volunteers|||December 2014|December 9, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674933||80182|
NCT01674920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD050962|CHOICES: Family Physicians Treat Overweight Children|CHOICES: Family Physicians Treat Overweight Children|CHOICES|University of Arizona|Yes|Completed|January 2006|June 2008|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|May 18, 2008||No||No||https://clinicaltrials.gov/show/NCT01674920||80183|
NCT01675180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/633/REK nord|Self Reported Oral Health, Awareness and Attitude Towards Dental Care Among Pregnant Women|Self Reported Oral Health, Awareness and Attitude Towards Dental Care and Risk of Dental Caries Among Pregnant Women in Norway||University of Tromso|No|Recruiting|February 2013|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675180||80163|
NCT01675193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ErasmusMC MEC-2012-003|Disinvestment Study of Population-Based Vision Screening in Children|Disinvestment Study of Population-Based Vision Screening in Preverbal Children in the Netherlands||Erasmus Medical Center||Recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|11770|||Both|6 Months|14 Months|Accepts Healthy Volunteers|||August 2013|August 14, 2013|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675193||80162|
NCT01676324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01499|FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)|FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of IBD|FOCUS|University of British Columbia|Yes|Completed|September 2012|September 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|289|||Both|19 Years|N/A|No|Non-Probability Sample|Patients will be those age 19 or older seen by community and academic gastroenterologists        and may be referred for Fecal Calprotectin testing at the discretion of the        Gastroenterologist.|June 2014|June 5, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676324||80075|
NCT01676883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1018|Plantar Callosities and the Validity of Body Composition Assessment by Bio-impedance in Severely Obese Persons|Plantar Callosities and the Validity of Body Composition Assessment by Bio-impedance in Severely Obese Persons||Norwegian University of Science and Technology|No|Completed|October 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|50 Years|No|||April 2013|April 8, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676883||80032|
NCT01714518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_KryoVATS_80/2012|Cryobiopsy vs. VATS in Diagnosis of Interstitial Lung Diseases|Cryobiopsy vs. VATS: Efficiency and Safety in the Diagnosis of Interstitial Lung Diseases||Wissenschaftliches Institut Bethanien e.V|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Inpatients undergoing routine diagnosis of known or suspected interstitial lung disease|February 2016|February 17, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01714518||77146|
NCT01714791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.07/cardio09.01|Effects of Osteopathic Treatment on Pulmonary Function After Coronary Artery Bypass Graft Surgery|Effect of Osteopathy on Pulmonary Function in Patients After Coronary Artery Bypass Graft Surgery: a Randomized Controlled Trial|OSTinCARE|Hartcentrum Hasselt|No|Recruiting|January 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Both|N/A|N/A|No|||February 2016|February 21, 2016|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01714791||77125|
NCT01714804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC3-US-2012-1|Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion||Integra LifeSciences Corporation|No|Active, not recruiting|August 2012|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714804||77124|
NCT01714817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-291|Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis||Bristol-Myers Squibb|Yes|Recruiting|January 2013|May 2019|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714817||77123|
NCT01715103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS VEP1|Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women|Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women|MUCOVAC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Terminated|July 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|October 10, 2012||No|Results of primary outcome are not satisfactory in terms of RNA quality|No||https://clinicaltrials.gov/show/NCT01715103||77101|
NCT01667406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1473|The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment|The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment||Imperial College London|Yes|Recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Female|18 Years|34 Years|No|||February 2016|February 16, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01667406||80759|
NCT01667445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102837|Evaluation of the Use of Spinal Epimorph in Total Knee Arthroplasty|Determination of Effectiveness of Periarticular Local Infiltration When Compared to Spinal Epimorph for Analgesia in Total Knee Arthroplasty||Lawson Health Research Institute|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|40 Years|90 Years|No|||April 2015|April 27, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01667445||80756|
NCT01667679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-SUM-MIG-3302|Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without|A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study A Phase III Study Evaluating the Efficacy and Safety of 20 mg SuMatriptan Powder Delivered IntrAnasally With the Bi-directional Device Compared With 100 mg Sumatriptan TabletsS in Adults With Acute Migraine With or Without Aura|COMPASS|Optinose US Inc.|No|Completed|August 2012|June 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|65 Years|No|||October 2014|October 20, 2014|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667679||80738|
NCT01668056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1099/09|Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence|The Role of Controlling Follicular Wave Emergence to Synchronize Ovarian Stimulation for in Vitro Fertilization||University of Sao Paulo General Hospital|Yes|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|35 Years|No|||September 2013|September 9, 2013|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01668056||80709|
NCT01668368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0082-12-WOMC|Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance|Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance Approach Guided by Esophageal Pressure in Acute Respiratory Failure.||Wolfson Medical Center|No|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01668368||80685|
NCT01668615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jsxys-123|Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia|Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia|ITP|First Affiliated Hospital of Suzhou Medical College|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|35 patients of RITP who do not response to prednisone,immunosuppressive agents and/or        splenectomy were observed in our study .|October 2012|October 21, 2012|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668615||80666|
NCT01667081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-017|Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)|A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Clinical Trial||Merck Sharp & Dohme Corp.|No|Enrolling by invitation|October 2012|September 2021|Anticipated|September 2021|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3250|Samples With DNA|Blood samples will be collected and retained for purposes of DNA testing and plasma will be      retained for future biomedical research.|Both|18 Years|N/A|No|Non-Probability Sample|Participants who received at least one dose of grazoprevir while enrolled in a study and        that achieved undetectable HCV-RNA status and did not start any new HCV-RNA therapy        between the end of the previous study and enrollment in this study.|March 2016|March 15, 2016|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01667081||80784|
NCT01667055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 002/12|The Diagnosis of Penicillin/Aminopenicillin Allergy in Thailand|The Optimized Diagnostic Methods for the Confirmation of Penicillin/Aminopenicillin Allergy in Thailand||Chulalongkorn University|Yes|Recruiting|November 2012|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|Samples With DNA|Whole blood|Both|7 Years|N/A|No|Non-Probability Sample|Patients with a history of penicillin/aminopenicillin allergy|September 2015|January 31, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667055||80786|
NCT01667302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 12-02|Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma|A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma||Fudan University|No|Recruiting|June 2012|December 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2013|March 2, 2013|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667302||80767|
NCT01674348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2202/47/10|A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes|A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Two-staged, Fixed Design Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Overweight/Obese Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Metformin, Sulphonylurea, or Both.||Piramal Enterprises Limited|Yes|Terminated|April 2011|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||August 2013|August 2, 2013|August 21, 2012||No|Due to non-recruitment, the study is being halted. There are no major safety or tolerability    concerns in the study conducted so far.|No||https://clinicaltrials.gov/show/NCT01674348||80227|
NCT01675466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC123|Study Comparing Early Laparoscopy With Active Observation in Acute Non-specific Abdominal Pain|First Laparoscopy or Active Observation in Acute Non-specific Abdominal Pain: The FLO Trial|FLO|Mid Western Regional Hospital, Ireland|No|Terminated|August 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||March 2013|March 24, 2013|July 20, 2012||No|Difficulties with recruitment|No||https://clinicaltrials.gov/show/NCT01675466||80141|
NCT01675206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/066|Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients|Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients||Onze Lieve Vrouw Hospital|No|Completed|May 2011|April 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|165|||Both|18 Years|N/A|No|||August 2012|August 25, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01675206||80161|
NCT01675453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHHS|The Efficacy and Safety of Hypertonic Saline in Cardiac Surgery Patients.|The Efficacy and Safety of 7.2% NaCl Plus 6% Hydroxyethyl 200/0.5 in Patients Scheduled for First-time Coronary Artery Bypass Grafting With Cardiopulmonary Bypass.|ESHHS|Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|40|||Both|30 Years|70 Years|No|||May 2014|May 18, 2014|August 5, 2012||No||No|May 18, 2014|https://clinicaltrials.gov/show/NCT01675453||80142|
NCT01676051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12080340|Surgical Prep in Hand Surgery|Efficacy of Surgical Preparation Solutions in Hand Surgery||University of Pittsburgh|Yes|Completed|December 2012|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|240|||Both|18 Years|89 Years|No|Probability Sample|All patients undergoing clean, elective hand surgery without implants|June 2015|June 2, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676051||80096|
NCT01676610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000028096|Infant Pulse Oximetry in Pakistan Study|Infant Pulse Oximetry in Pakistan (iPOP) Study: Utility and Feasibility of Integrating Pulse Oximetry Into the Routine Assessment of Young Infants at First-level Clinics in Karachi, Pakistan|iPOP|The Hospital for Sick Children|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3149|||Both|N/A|59 Days|No|Non-Probability Sample|Young infants, aged 0-59 days.|May 2014|May 21, 2014|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01676610||80053|
NCT01677182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375SL_301|Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects||Takeda|Yes|Terminated|August 2012|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|535|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|August 29, 2012|Yes|Yes|Business Decision; Terminated due to futility, with no safety concerns (see below)|No|February 16, 2016|https://clinicaltrials.gov/show/NCT01677182||80009|
NCT01677455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-11|An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer|An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer|Enchant|Synta Pharmaceuticals Corp.|No|Completed|July 2012|August 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677455||79988|
NCT01714531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111484|Improving Outcomes After Traumatic Injury: A Goal Management Approach|Improving Trauma Outcomes: A Goal Management Approach|GMT|Vanderbilt University|No|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|21 Years|80 Years|No|||June 2015|June 1, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01714531||77145|
NCT01714544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC1201|Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis|An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days||Promius Pharma, LLC|No|Completed|October 2012|||March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|October 23, 2012|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01714544||77144|
NCT01714830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IsfahanUMS1|Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome|The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome||Isfahan University of Medical Sciences|No|Active, not recruiting|August 2011|||November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|90 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01714830||77122|
NCT01715116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/301|ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator (ICD) Patients|ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator Patients: A Prospective, Single-arm Safety Monitoring Study (ENHANCED-ICD Study)|ENHANCED-ICD|UMC Utrecht|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||April 2013|April 16, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01715116||77100|
NCT01715129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-52014-200|Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer|A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer|DKP 3M SC|Ipsen|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Male|18 Years|N/A|No|||September 2015|September 23, 2015|October 24, 2012||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01715129||77099|
NCT01667172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54271|Technical Accuracy and Userfriendliness of Two Point-of-care C Reactive Protein Devices in Comparison With Laboratory CRP Testing.|Study of Technical Accuracy and Userfriendliness of Two Point-of-care C Reactive Protein Devices||Katholieke Universiteit Leuven|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|1||Actual|300|||Both|1 Month|65 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01667172||80777|
NCT01667432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25626|An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B|A Multicenter, Prospective, Observational, Non-interventional Study Evaluating On-treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD)||Hoffmann-La Roche||Completed|July 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|141|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B on treatment with PEGASYS.|November 2015|November 3, 2015|August 15, 2012||No||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01667432||80757|
NCT01667484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102774|Adderall XR and Processing Speed in Multiple Sclerosis (MS)|Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?||London Health Sciences Centre|No|Completed|September 2012|February 2015|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|59 Years|No|||May 2015|May 7, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01667484||80753|
NCT01668082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062010-157|An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection|An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection||University of Texas Southwestern Medical Center|Yes|Recruiting|May 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|June 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01668082||80707|
NCT01668628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOLD_01_052012|Quality of Life and Depression in Dialysis Patients|Quality of Life and Depression in Peritoneal Dialysis Patients and Hemodialysis Patients|QOLD|Fresenius Medical Care Korea|No|Completed|August 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1068|||Both|18 Years|75 Years|No|Non-Probability Sample|1. Incident PD patients group : 250 subjects, First treatment for ESRD by any peritoneal             dialysis modality within 30 days prior to or following enrollment (patients may be             enrolled prior to commencing first treatment if there is clear indication that the             treatment modality is CAPD or APD and they consent in advance to enter the study) and             patients who don't have any experience of dialysis treatment before this study          2. Prevalent PD patients : 250 subjects, Prevalent peritoneal dialysis(PD) patients who             are under peritoneal dialysis treatment more than 6 months          3. Prevalent HD patients : 250 subjects, Prevalent hemodialysis(HD) patients who are             under hemodialysis treatment more than 6 months|August 2015|August 21, 2015|May 24, 2012||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01668628||80665|
NCT01668914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMSN002|Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive|Phase II Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive|IMSLNB-CANP|Shandong Cancer Hospital and Institute|No|Recruiting|August 2012|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|4|||Female|18 Years|70 Years|No|||August 2013|August 24, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668914||80643|
NCT01673516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/145/REK|Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography|Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography|OsloRDN|Oslo University Hospital|Yes|Active, not recruiting|August 2012|August 2022|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01673516||80291|
NCT01673789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-TH01|Stem Cell Educator Therapy in Alopecia Areata|Phase 1/Phase 2 Study of Stem Cell Educator Therapy in Alopecia Areata||Tianhe Stem Cell Biotechnologies Inc.|Yes|Recruiting|August 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||August 2012|August 23, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01673789||80270|
NCT01674660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingCYH|Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients|Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients||Beijing Chao Yang Hospital||Not yet recruiting|September 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|Samples With DNA|whole blood, serum, white cells, urine.|Both|24 Years|85 Years|No|Non-Probability Sample|hemodialysis patients of Beijing Chaoyang Hospital|August 2012|August 29, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01674660||80203|
NCT01675232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC-1206010366|A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis|A Randomized, Investigator-Blinded Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis||Yale University|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|N/A|18 Years|No|||July 2014|July 25, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01675232||80159|
NCT01675479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-111-IDHP|Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System||Abbott Medical Optics|No|Active, not recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675479||80140|
NCT01675765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADU-CL-02|Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma|A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma||Aduro Biotech, Inc.|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675765||80118|
NCT01676064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003-12-ZIV|Influence of Perioperative Fluid Management on Intraocular Pressure During Hynecologic Laparoscopic Pelvic Surgery|Influence of Perioperative Fluid Management on Intraocular Pressure During Hynecologic Laparoscopic Pelvic Surgery||Ziv Hospital|Yes|Not yet recruiting|August 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|70 Years|No|||August 2012|August 27, 2012|August 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676064||80095|
NCT01676623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFPRI-S-01 (2)|Impact Evaluation of a Social Franchise Model for Improving Infant and Young Child Feeding and Child Nutrition in Vietnam|Impact Evaluation of a Social Franchise Model Implemented by Alive & Thrive for Improving Infant and Young Child Feeding and Child Nutrition in Rural Vietnam||International Food Policy Research Institute|No|Completed|April 2010|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4000|||Both|N/A|60 Months|Accepts Healthy Volunteers|||February 2016|February 29, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676623||80052|
NCT01676896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR007770|Asthma in Central Texas Project|Enhancing Children's and Parents' Asthma Management||University of Texas at Austin|Yes|Completed|December 2008|November 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|292|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|August 24, 2012||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01676896||80031|
NCT01677468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-122|Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma|Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma||Hallym University Medical Center|No|Recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|19 Years|N/A|No|||August 2012|August 29, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01677468||79987|
NCT01668433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1201|Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency|Open Label Randomized Controlled Trial Pharmacokinetic and Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency||University of Oxford|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01668433||80680|
NCT01714557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-HEM-20120608|Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation|Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study||Chinese PLA General Hospital|No|Not yet recruiting|September 2012|November 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|13 Years|65 Years|No|||October 2012|October 25, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01714557||77143|
NCT01714843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-CL-0021|A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome|Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Constipation-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|559|||Both|20 Years|64 Years|No|||April 2014|April 29, 2014|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01714843||77121|
NCT01715142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003592-19|Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer|Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma|NEOPAX-001|Erasme University Hospital|No|Not yet recruiting|December 2012|September 2015|Anticipated|June 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715142||77098|
NCT01715441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEXIRI2|Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors|A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective|NEXIRI2|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|September 2012|September 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01715441||77075|
NCT01667198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP2010016270|Randomized Study of Train the Colonoscopy Leaders Course Versus Audit and Feedback on Colonoscopy Quality Indicators|Quality Improvement in Screening Colonoscopy - a Randomized Trial of Tailored Training Intervention Versus Simple Feedback on the Quality Indicators.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|N/A|N/A|No|||April 2014|April 15, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01667198||80775|
NCT01667757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-2-1208-026|Optimal Physiologic Intravascular Ultrasound Imaging Criteria After Drug Eluting Stent Implantation|Angiographic and IVUS Criteria Defining Physiologic Optimization By the Fractional Flow Reserve After DES Implantation||Inje University|Yes|Completed|March 2010|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|200|||Both|20 Years|85 Years|No|Probability Sample|Patients who underwent coronary angiography and percutaneous coronary intervention for the        diagnosis and treatment purposes because of clinical angina pectoris. Patient who        underwent simultaneous IVUS and FFR measurement after DES implantation would be enrolled        consecutively.|March 2015|March 23, 2015|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01667757||80732|
NCT01677078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01272-39|Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression|Assessment of the Neuronavigation System Coupled With Repetitive Transcranial Magnetic Stimulation. A Randomized Double Blind Study|TMS|Rennes University Hospital|No|Recruiting|November 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677078||80017|
NCT01668641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-202|Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone||Galapagos NV|No|Completed|May 2012|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|91|||Both|18 Years|70 Years|No|||June 2013|June 26, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01668641||80664|
NCT01668654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113388|Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS|RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old)||GlaxoSmithKline|Yes|Terminated|September 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|12 Years|29 Years|No|||March 2014|July 10, 2014|May 17, 2012|Yes|Yes|FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in    subjects; early termination allows for timely reporting of results.|No|July 10, 2014|https://clinicaltrials.gov/show/NCT01668654||80663|This study was terminated early and only 4 of the planned 500 participants were enrolled. Due to the early study termination and small sample size, many planned analyses were not completed therefore lmiited results data were available.
NCT01677637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-BOD-EL-02|Osteoporosis Screening Trial|Epidemiological, Observational, Multicenter Clinical Trial|OSTRIA|Elpen Pharmaceutical Co. Inc.|No|Completed|February 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5500|||Female|30 Years|90 Years|No|Non-Probability Sample|Postmenopausal females screened for osteoporosis|May 2013|August 18, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677637||79974|
NCT01673529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115246|Investigation of Topical SB705498 on Healthy Volunteers|A Two Part Randomized, Double-blind, Placebo Controlled Study to Investigate the Effects of Topical Doses of SB705498 on Capsaicin, Histamine, and Cowhage Responses in Healthy Volunteers.||GlaxoSmithKline||Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01673529||80290|
NCT01673802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-153|The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma|The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma||University of Alabama at Birmingham|No|Completed|August 2012|January 2014|Actual|January 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|19 Years|N/A|No|||May 2014|May 20, 2014|August 13, 2012|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01673802||80269|
NCT01674101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSARC|Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy|A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy||St. Jude Children's Research Hospital|No|Completed|September 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|6 Years|30 Years|No|||December 2015|December 3, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674101||80246|
NCT01675219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FinnBladder 9|Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)|Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)||Turku University Hospital|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|100 Years|No|||November 2015|November 5, 2015|August 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01675219||80160|
NCT01733784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957D|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study D|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study D||Brigham and Women's Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|21 Years|65 Years|No|||September 2013|September 25, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01733784||75672|
NCT01725295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST|Neurostructural Integration Technique for Fibromyalgia||NST|University College Dublin|No|Completed|April 2003|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|80 Years|No|||November 2012|November 9, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725295||76319|
NCT01726075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2011-02|Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy|Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy|EUROCONDOR|BCN Peptides|Yes|Completed|February 2013|November 2015|Actual|November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|450|||Both|45 Years|75 Years|No|||January 2016|January 11, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726075||76259|
NCT01734603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 12|Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery|Randomized, Monocentric and Multidisciplinary Study of the Effects of an Intensive Rehabilitation by Interval Training With Active Recovery in Peripheral Arterial Disease With Claudication|ARTEX|University Hospital, Grenoble|Yes|Completed|October 2011|September 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||June 2015|June 24, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734603||75610|
NCT01726374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2008/10019|Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours|A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT)|111|Institute of Cancer Research, United Kingdom|Yes|Active, not recruiting|February 2010|August 2019|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|236|||Male|16 Years|N/A|No|||September 2015|September 18, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726374||76237|
NCT01723280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001710-32-follow-up|Supplemental Oxygen - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial)|Perioperative Inspiratory Oxygen Fraction - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial)|PROXI|Rigshospitalet, Denmark|No|Completed|October 2006|November 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1386|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in the PROXI trial|November 2012|November 5, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723280||76474|
NCT01723878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28361|ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations|Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line.||Hoffmann-La Roche||Active, not recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations        receiving first-line treatment with Tarceva|March 2016|March 1, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723878||76428|
NCT01724112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14791|Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)|8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)||Eli Lilly and Company|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||March 2014|April 14, 2014|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724112||76410|
NCT01724619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 85111|Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT|Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT||Comprehensive Cancer Center of Wake Forest University|No|Terminated|November 2012|||March 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|7|||Male|30 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 22, 2014|November 5, 2012|No|Yes|Study tracer can no longer be obtained at our institution|No||https://clinicaltrials.gov/show/NCT01724619||76371|
NCT01731652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-101-003|Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer|Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer||Telormedix SA|No|Completed|February 2013|October 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731652||75834|
NCT01731912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7846|Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer|Degarelix Acetate Prior to Radiation Therapy||University of Washington|No|Recruiting|May 2013|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|N/A|No|||February 2016|February 1, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731912||75814|
NCT01732172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 111004|Chronic Inflammatory Condition of the Male Genital Tract|Study of the Prevalence of a Chronic Inflammatory Condition of the Male Genital Tract at a Distance and Urethritis Following.|URIS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2012|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|113|||Male|18 Years|N/A|No|||October 2015|October 15, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732172||75794|
NCT01732185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100510|Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations|Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations|MAKP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|N/A|8 Years|No|||December 2015|December 15, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732185||75793|
NCT01732445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1283|Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis|A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia||Mayo Clinic|Yes|Active, not recruiting|April 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|28|||Both|18 Years|N/A|No|||October 2015|January 4, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732445||75773|
NCT01732458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-219|A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219)|A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting||Merck Sharp & Dohme Corp.|No|Recruiting|February 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|260|||Both|N/A|17 Years|No|||February 2016|February 11, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732458||75772|
NCT01732731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-97|Effects of Intensive Locomotor Treadmill Training on Gross Motor Function in Young Children With Neuromotor Impairment|Effects of Intensive Locomotor Treadmill Training on Gross Motor Function in Young Children With Neuromotor Impairment||University of the Pacific|No|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|9 Months|36 Months|No|||November 2012|November 23, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01732731||75751|
NCT01733004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-141-01-01-01|A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors|A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors||Merrimack Pharmaceuticals|No|Completed|November 2012|||December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733004||75730|
NCT01733212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB:147810|Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients|Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients.||New York Methodist Hospital|Yes|Completed|June 2010|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|239|||Female|20 Years|49 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733212||75714|
NCT01733485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10HL098177|Electrophilic Fatty Acid Derivatives in Asthma|Electrophilic Fatty Acid Derivatives in Asthma|EFADA|University of Pittsburgh|Yes|Recruiting|October 2011|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|60 Years|No|||January 2016|January 6, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733485||75694|
NCT01733511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-03-2012|the Patients Journey Through Surgical Admission Ward Versus Emergency Department|||University of Southern Denmark|No|Completed|February 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|109|||Both|15 Years|N/A|No|Non-Probability Sample|all acute admissions to hospital due to abdominal pain|November 2012|November 20, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01733511||75693|
NCT01733238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNT2258-02|Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma||ProNAi Therapeutics, Inc|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733238||75713|
NCT01733251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0305|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2012|||||N/A|N/A|N/A||||||||||||||October 23, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733251||75712|
NCT01734057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-008|Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|July 2012|October 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||November 2012|November 21, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734057||75652|
NCT01734330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/2010|Cognitive Behaviour Therapy and Nicotine Replacement to Increase Tobacco Cessation|Efficacy of Cognitive Behaviour Therapy Associated to Nicotine Replacement in Tobacco Cessation: a Randomised Open Label Clinical Trial||Hospital do Coracao|No|Completed|July 2010|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||November 2012|November 26, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734330||75631|
NCT01734070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL40|Role of Cherry Consumption in Reducing Risk Factors for Chronic Inflammatory Diseases|Role of Cherry Consumption in Reducing Risk Factors for Human Chronic Inflammatory Diseases||USDA, Western Human Nutrition Research Center|No|Completed|May 2003|September 2004|Actual|September 2003|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734070||75651|
NCT01722994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0180|A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites|A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites||University of Mississippi Medical Center|No|Completed|August 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|100 Years|No|||February 2016|February 2, 2016|October 29, 2012|Yes|Yes||No|December 26, 2015|https://clinicaltrials.gov/show/NCT01722994||76496|
NCT01723891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-002-01|Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers|||Hyundai Pharmaceutical Co., LTD.||Completed|November 2012|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|November 6, 2012||||No||https://clinicaltrials.gov/show/NCT01723891||76427|
NCT01723904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0015|A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease|An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B||UCB Pharma|No|Completed|October 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|30 Years|80 Years|No|||May 2014|May 7, 2014|November 6, 2012|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01723904||76426|
NCT01724125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012759|An Electronic Personal Health Record for Mental Health Consumers|An Electronic Personal Health Record for Mental Health Consumers||Emory University|No|Completed|March 2009|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|170|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01724125||76409|
NCT01724372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-094|The Role of Antidepressants or Antipsychotics in Preventing Psychosis|The Role of Antidepressants or Antipsychotics in Preventing Psychosis||St. Luke's-Roosevelt Hospital Center|No|Withdrawn|October 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|25 Years|No|||November 2012|May 23, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01724372||76390|
NCT01728935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDF-HKU|Tenofovir in Asian Chronic Hepatitis B Patients|Serologic and Virologic Outcomes of Tenofovir in Asian Chronic Hepatitis B Patients With Prior Nucleoside Analogue Exposure||The University of Hong Kong||Completed|April 2008|March 2013|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|75 Years|No|||December 2014|December 29, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01728935||76042|
NCT01731665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0634|Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.|Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.||Asan Medical Center|No|Recruiting|December 2012|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|The study is performed in the Songpa-Kangdong district, a well-defined administrative area        in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was        diagnosed, until 2017. The population of the study area was racially and ethnically        homogeneous and was relatively stable in number.|January 2015|January 12, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01731665||75833|
NCT01732510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8226-003|A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)|A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis||Merck Sharp & Dohme Corp.|No|Terminated|December 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|64|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732510||75768|
NCT01732523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK145/12|Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS|Predictive Value of Carotid Lesion Neovascularization Detected by Contrast-enhanced Ultrasound (CEUS) in Patients With Asymptomatic Carotid Stenosis||University Hospital, Basel, Switzerland|No|Recruiting|October 2012|September 2020|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|In-and out-patients referred to our ultrasound laboratory for carotid ultrasound for a        clinical indication (preoperative, carotid murmur, known carotid lesion) will be ask to        participate in this clinical study and will be asked to undergo study carotid ultrasound        including CEUS.|November 2015|November 23, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01732523||75767|
NCT01732198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-NU300-02|A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers|A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®||Nuron Biotech Inc.|Yes|Active, not recruiting|March 2013|April 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||September 2013|September 20, 2013|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732198||75792|
NCT01732471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700773_510|Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria|A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels||Merck KGaA|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|4 Years|18 Years|No|||July 2014|July 25, 2014|November 19, 2012||No||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01732471||75771|
NCT01732484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1444/2012|Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF|||Medical University of Vienna||Completed|August 2009|September 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|100|||Both|40 Years|N/A|No|||April 2013|April 30, 2013|November 19, 2012||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01732484||75770|
NCT01732497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0009|Axillary Hair Reduction Study|A Prospective Study of Axillary Hair Loss in Patients Treated With the miraDry System||Miramar Labs|No|Completed|September 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732497||75769|
NCT01732744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORP_491|A Castor Bean Solution for Cleaning Dentures|A Castor Bean Solution Reduces Complete Denture Biofilm|ACBSFCD|University of Sao Paulo|No|Completed|March 2008|May 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|50|||Both|45 Years|80 Years|No|||November 2012|November 19, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01732744||75750|
NCT01733290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL006|Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding|Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding - A Multicenter Study, Randomized, Double-Blind, Placebo Control||Buddhist Tzu Chi General Hospital|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||June 2014|June 25, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01733290||75709|
NCT01733017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1NR013430|Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure|Nutrition Intervention to Reduce Symptoms in Patients With Advanced Heart Failure|NIHFT|University of Kentucky|Yes|Recruiting|November 2011|September 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|N/A|No|||December 2014|December 1, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01733017||75729|
NCT01733264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0315|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2012|||||N/A|N/A|N/A||||||||||||||October 23, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733264||75711|
NCT01733199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0059|Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological and Pharmacokinetic Profiles|Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological and Pharmacokinetic Profiles.|PARKADD|Nantes University Hospital||Recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733199||75715|
NCT01733524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HD071263-01|Pet Ownership and Glucose Control in Type 1 Diabetes|Impact of Pet Ownership on Glycemic Control in Youth With Type 1 Diabetes||University of Texas Southwestern Medical Center|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|10 Years|17 Years|No|||December 2014|December 9, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01733524||75692|
NCT01733797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09DOG0843|Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients|Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial)||Christie Hospital NHS Foundation Trust|No|Completed|December 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01733797||75671|
NCT01734356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/10/11-P|Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells|Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells|Diag-iPS|Nantes University Hospital||Terminated|November 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Masking: Open Label|3||Anticipated|20|||Both|22 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734356||75629|
NCT01734369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130015|Environmental Risk Factors for Myositis in Military Personnel|Environmental Risk Factors for the Development of Myositis in Military Personnel||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A|||Anticipated|300|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734369||75628|
NCT01723007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABPM_NCT_APPLE_BR1999|Weight Loss Associated With the Consumption of Apple|Modifications of Body Weight and Plasma Lipids With Diet Added of Fruits: Randomized Clinical Trial in Overweight Women|NCTAPPLEBR|Universidade Federal do Amazonas|Yes|Completed|August 1999|June 2001|Actual|June 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|49|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723007||76495|
NCT01723618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardoz-005|Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.|An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)||RSPR Pharma AB|No|Completed|November 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Both|50 Years|N/A|No|||November 2012|November 28, 2012|November 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723618||76448|
NCT01727804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Raucci-Neto|Neodymiun:Yttrium Aluminum Garnet Laser in Caries Prevention of Primary Teeth: One-year Follow-up|Clinical Effect of Neodymiun:Yttrium Aluminum Garnet Laser in Occlusal Caries Prevention of Primary Teeth: One Year Follow up.||University of Sao Paulo|Yes|Active, not recruiting|August 2009|||November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|40|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||August 2012|November 12, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727804||76129|
NCT01728090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 0388/2008|Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections|Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections||Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1640|||Both|4 Years|12 Years|No|||November 2012|November 16, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728090||76107|
NCT01728636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00066949|The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery|The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery|TXA|Northwestern University|No|Enrolling by invitation|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01728636||76065|
NCT01728948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16399|Sorafenib in Elderly mRCC|Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib||Bayer|No|Active, not recruiting|December 2012|September 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|65 Years|N/A|No|Non-Probability Sample|mRCC patients, >= 65 years of age, No prior systemic treatment, need systemic therapy|February 2016|February 5, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01728948||76041|
NCT01732211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6261009|A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis|A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis||Pfizer|Yes|Terminated|March 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|1|||Both|21 Years|75 Years|No|||October 2015|October 30, 2015|November 19, 2012|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01732211||75791|
NCT01732757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LAS-12-023|A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis|||Allergan|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|157|||Both|10 Years|N/A|No|||November 2013|November 27, 2013|November 19, 2012|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT01732757||75749|
NCT01732536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-1012|Safety and Efficacy of Bioabsorbable Drug-Eluting Sinus Implant for Chronic Sinusitis|A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant Used in Post-Sinus Surgery Patients With Recurrent Sinus Obstruction|RESOLVE|Intersect ENT|Yes|Completed|January 2013|May 2014|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732536||75766|
NCT01732549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-58102-002|A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy|A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy||Ipsen|Yes|Terminated|January 2013|May 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Male|18 Years|N/A|No|||June 2015|June 29, 2015|October 24, 2012||No|Development of tasquinimod in prostate cancer discontinued|No||https://clinicaltrials.gov/show/NCT01732549||75765|
NCT01732796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.20|IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1|A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection||Boehringer Ingelheim||Completed|December 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|470|||Both|18 Years|75 Years|No|||February 2015|February 4, 2015|November 6, 2012||||No||https://clinicaltrials.gov/show/NCT01732796||75746|
NCT01733303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003065R|Fracture and Fall Prevention in Elderly With Osteoporosis|Fracture and Fall Prevention in Elderly With Osteoporosis||National Taiwan University Hospital||Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 20, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01733303||75708|
NCT01733056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044264|Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression|Characterization of Immune Response to Vaccination in Patients Receiving Single-Drug Immunosuppressive Therapy||Emory University|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|43|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|November 20, 2012||No||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01733056||75726|
NCT01733576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB64|High-definition Transcranial Direct Current Stimulation (HD-tDCS) Verbal Learning|Enhancing Verbal Learning and Memory Using High-Definition Transcranial Direct Current Stimulation (HD-tDCS)||The University of New South Wales|No|Completed||||March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01733576||75688|
NCT01733589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2012]-10-24|Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC|Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|November 2012|May 2014|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|70 Years|No|||December 2012|December 23, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01733589||75687|
NCT01733563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSB-Effects on metabolism|Sugar Sweetened Beverages (SSB)- Effects on Metabolism|Effects of Carbohydrate Containing Diets on Lipid Metabolism & Fatty Acid Oxidation in Healthy Young Men - a Randomized, Double-Blinded Study.||University of Zurich|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|96|||Male|18 Years|30 Years|No|||October 2015|October 27, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01733563||75689|
NCT01733277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A122-MER12H|Osteoarthritis Structural Changes Assessed by Magnetic Resonance Imaging and Neuropathic Pain in Knee Osteoarthritis|A Cross-sectional Study to Explore the Osteoarthritis Structural Changes Assessed by MRI That Are Biomarkers of Neuropathic Pain in Knee Osteoarthritis||ArthroLab Inc.|No|Completed|January 2013|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|40 Years|90 Years|No|Non-Probability Sample|Presence or absence of neuropathic pain on a population of patients with OA of the knee        experiencing moderate to severe pain (VAS ≥ 40 mm)|May 2014|May 30, 2014|November 16, 2012||No||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01733277||75710|
NCT01733537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034415|Improving Motorcycle Taxi Driver Visibility in Tanzania|Improving Motorcycle Taxi Driver Visibility in Tanzania—A Cluster Randomized Controlled Trial||Duke University|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|180|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733537||75691|
NCT01733810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DK063621-11|The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis|The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis||Dallas VA Medical Center|No|Active, not recruiting|February 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01733810||75670|
NCT01733823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 28A|Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole|Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity|DAHANCA28A|Danish Head and Neck Cancer Group|No|Recruiting|January 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01733823||75669|
NCT01734083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20120929006|Whole Body Vibration Exercise for Elderly With Cognitive Impairments|The Effects of Whole Body Vibration Exercise Training on Physical Functioning and Falls in Community-dwelling Elderly With Cognitive Impairments||The Hong Kong Polytechnic University|Yes|Recruiting|November 2012|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|65 Years|N/A|No|||November 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734083||75650|
NCT01734096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ00P3_121655|Renal Response to Lower Body Negative Pressure in Pre-hypertensive States|Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial.||Centre Hospitalier Universitaire Vaudois|No|Completed|May 2009|April 2014|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734096||75649|
NCT01734382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA28029|A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)|A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab||Hoffmann-La Roche||Recruiting|June 2013|September 2019|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|65|||Both|2 Years|17 Years|No|||March 2016|March 1, 2016|November 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01734382||75627|
NCT01723631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/06-S|Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis|Study Multicenter, Controlled, Prospective, Non-randomized Test to Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis|TRAP-Myéline|Nantes University Hospital|No|Terminated|April 2012|April 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|189|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 6, 2012||No|The number of patients achieved is sufficient to evaluate the diagnostic performance of the    test TRAP-myelin|No||https://clinicaltrials.gov/show/NCT01723631||76447|
NCT01723644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_151|Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia|CLINPCT Study: Clinical Reassessment Versus Procalcitonin-guided Algorithm in Order to Reduce Antibiotic Consumption in Community-acquired Pneumonia|CLINPCT|Nantes University Hospital|No|Completed|October 2012|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|286|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723644||76446|
NCT01728662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC127000 CTIL|Emphysematous Lung Sealant Therapy in Homogeneous Emphysema|Post Market Investigator Sponsored Study of Emphysematous Lung Sealant Therapy in Homogeneous Emphysema Using a Modified Treatment Strategy||Rabin Medical Center|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|40 Years|85 Years|No|||November 2012|November 13, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01728662||76063|
NCT01728649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSNC 02|Reperfusion With Cooling in Cerebral Acute Ischemia II|Phase 2 Study of Mild Hypothermia in Combination With Acute Cerebral Vascular Reperfusion in the Setting of Acute Ischemic Stroke|ReCCLAIM II|Emory University|Yes|Withdrawn|February 2013|June 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||November 2013|November 10, 2013|September 5, 2012|Yes|Yes|unable to be funded|No||https://clinicaltrials.gov/show/NCT01728649||76064|
NCT01732237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100878|A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants|A Single Dose Study to Investigate the Pharmacokinetics of an Oral Microdose of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Subjects||Janssen-Cilag International NV|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732237||75789|
NCT01732822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5135C00001|A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease|A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)|EUCLID|AstraZeneca|Yes|Active, not recruiting|December 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|13500|||Both|50 Years|130 Years|No|||December 2015|December 21, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732822||75744|
NCT01732835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-01-022|The HAART 300 Annuloplasty Ring Extended Safety and Performance Trial Used in Surgical Repair of the Aortic Valve|HAART 300 Trial Extended Safety and Performance||Biostable Science & Engineering|Yes|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01732835||75743|
NCT01732848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-013|A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)|A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)||Bristol-Myers Squibb|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|113|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who participated in prior trial with BMS-986094/INX-08189 and received at least 1        dose of INX-08189 or placebo in trials INH-189-002 or INH-189-006|August 2014|August 13, 2014|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01732848||75742|
NCT01733030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH080130|The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.|The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.|DCS|University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults between the ages of 18-55.|March 2014|March 18, 2014|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01733030||75728|
NCT01733043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033021|Sedative Effects in Obstructive Sleep Apnea|Dexmedetomidine for Sedation in Individuals With Obstructive Sleep Apnea||Duke University|No|Withdrawn|March 2015|November 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|November 20, 2012|Yes|Yes|Failure to secure funding|No||https://clinicaltrials.gov/show/NCT01733043||75727|
NCT01733069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2PS-US11-001|Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System|Clinical Evaluation of the APTIMA® COMBO 2®Assay Using the PANTHER™ System||Gen-Probe, Incorporated|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1912|Samples With DNA|4 specimens will be collected from each female subject in the following order: 1 first-catch      urine specimen, 1 vaginal swab specimen (patient or clinician-collected), 1 cervical      specimen (using a broomlike collection device or a brush/spatula combination), and 1      endocervical swab specimen. An additional cervical specimen may be collected from female      subjects for other clinical trial purposes or research studies. Up to 2 specimens will be      collected from each male subject in the following order: 1 urethral swab specimen and 1      first-catch urine specimen|Both|14 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Male and Females at least 14 years of age at the time of informed consent and sexually        active.|November 2013|November 26, 2013|November 20, 2012|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01733069||75725|
NCT01733342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP2012-k|Single-center Randomized Trial for Comparison of Performance Between Domestic and Imported Chemoport|Single-center Randomized Trial for Comparison of Performance Between Domestic and Imported Chemoport|SiCDIP|Seoul National University Hospital|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|176|||Both|20 Years|N/A|No|||December 2013|December 2, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01733342||75705|
NCT01733316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-07|Open-Label Safety & Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cystinosis|A Long-Term, Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis||Raptor Pharmaceuticals Inc.|No|Active, not recruiting|January 2013|December 2015|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|N/A|No|||June 2015|June 10, 2015|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733316||75707|
NCT01733329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI07-011|Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage|Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage in Women With Risk Factors for Uterine Atony||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|February 2008|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|123|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 12, 2014|November 16, 2012||No||No|December 14, 2013|https://clinicaltrials.gov/show/NCT01733329||75706|Technical problems with blood loss measurement leading to blood transfusion before receiving hematocrit result.Small number of patients fulfill inclusion criteria.
NCT01733875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-220-CP-001|2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects|A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of CC-220 and to Explore the Effect of Food on the Bioavailability of CC-220 in Healthy Subjects||Celgene|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|9||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733875||75665|
NCT01733862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116929|Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis|A Study to Assess the Impact of Rotavirus Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis (RV GE) in Japan||GlaxoSmithKline||Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|13500|||Both|N/A|1824 Days|No|Non-Probability Sample|The study population will include children less than five years of age, hospitalized for        RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE,        between November 2007 and October 2016 (i.e., before and after the introduction of RV        vaccination in Japan) in any of the selected hospitals.|February 2016|February 4, 2016|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733862||75666|
NCT01733550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54640|ICare Self-tonometry - A Head-to-head Comparison to the Gold Standard Goldmann Tonometer|ICare Self-tonometry - A Head-to-head Comparison to the Gold Standard Goldmann Tonometer||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|November 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma patients who are admitted to the hospital for repeated eye pressure measurements        learn how to handle the home i care during their stay.|September 2012|November 27, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01733550||75690|
NCT01733836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS_001|Prostate Cancer Active Surveillance Metformin Trial|A Randomized Double Blind Placebo Controlled Single Institution Phase 2 Study of Metformin in Patients Undergoing Active Surveillance for Prostate Cancer.||University Health Network, Toronto|Yes|Withdrawn|January 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|80 Years|No|||May 2013|May 23, 2013|November 20, 2012||No|The reason for this decision is that this study is being merged with a larger multi-centre    study using the same agent in the same population.|No||https://clinicaltrials.gov/show/NCT01733836||75668|
NCT01733849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116621|A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and Latvia|An Observational Study to Estimate the Disease Burden of Rotavirus Gastroenteritis in Infants/Children Less Than Five Years of Age in Primary Care Settings, in Bulgaria and Latvia||GlaxoSmithKline||Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1266|||Both|N/A|5 Years|No|Non-Probability Sample|Infants/children less than five years of age with home visits by the GP/paediatrician for        the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.|November 2014|December 18, 2014|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733849||75667|
NCT01734109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITIQ002A|Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.|A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers.||Innovative Therapies, Inc.|No|Not yet recruiting|December 2012|March 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||November 2012|November 27, 2012|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734109||75648|
NCT01734122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120632|Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor|Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor||Vanderbilt University|No|Recruiting|November 2012|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|This trial enrolls persons with essential tremor or Parkinsonian tremor that is        inadequately controlled by medications.|December 2015|December 9, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734122||75647|
NCT01734928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-007|Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)|OPTIMISMM|Celgene|Yes|Recruiting|January 2013|April 2022|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734928||75585|
NCT01734941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0522-12-HMO|TSO in Pediatric Autistic Spectrum Disorders|A Phase 2 Randomized Three-Arm Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of 16 Weeks of Treatment With Trichuris Suis Ova (TSO) Therapy in Pediatric Patients Ages 6 to 17 With Autism|TSO|Hadassah Medical Organization|Yes|Terminated|April 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|9|||Both|6 Years|17 Years|No|||April 2014|January 31, 2016|November 19, 2012|Yes|Yes|Well tolerated but failed to demonstrate significant activity. So it did not meet its primary    endpoint or key secondary endpoints.|No||https://clinicaltrials.gov/show/NCT01734941||75584|
NCT01723657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-03|Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)|Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.||Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias|No|Completed|October 2003|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|862|||Both|18 Years|70 Years|No|||October 2012|November 6, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01723657||76445|
NCT01728675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUC-017|Eccentric Exercise and Oxidative Stress|The Effect of Eccentric Exercise on Oxidative Stress in the Elderly||European University Cyprus|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01728675||76062|
NCT01728376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-005|Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)|A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.||Cubist Pharmaceuticals LLC|Yes|Completed|November 2012|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|1 Year|17 Years|No|||February 2016|February 2, 2016|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728376||76085|
NCT01728389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBT-COI-01|Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.|Efficacy and Safety of Direct Intrabone Transplantation of Peripheral Blood Haematopoietic Stem Cells Form HLA-matched Sibling Donors in Patients With Myeloid and Lymphoid Malignancies.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|November 2012|April 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|55 Years|No|||July 2013|July 23, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728389||76084|
NCT01729221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.|||Cairo University|Yes|Active, not recruiting|January 2010|December 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|280|||Both|20 Years|65 Years|No|Non-Probability Sample|Hepatitis C virus infected patients indicated for stem cell therapy|November 2012|November 18, 2012|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01729221||76020|
NCT01731977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCU-708|Strengths-Based Family Psychoeducation for Youth Psychosis|Effectiveness of the Strengths-Based Family Psychoeducation for Youth Psychosis: Randomized Controlled Trial||Nagoya City University|No|Completed|July 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|74|||Both|20 Years|74 Years|No|||January 2016|January 2, 2016|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01731977||75809|
NCT01732562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103027|A Trial to Establish Realistic Patient Expectations of Total Knee Replacement|A Randomized Controlled Trial to Establish Realistic Patient Expectations of Total Knee Arthroplasty||Lawson Health Research Institute|No|Recruiting|April 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|352|||Both|20 Years|90 Years|No|||August 2015|August 31, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01732562||75764|
NCT01733381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0370-02|Effects of Barefoot Running vs. in Shoes on Physiology and Mood|An Examination of the Differential Effects of Running Minimally Shod vs. in Shoes on Physiology and Emotional States Relevant to Major Depression.||University of Arizona|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Avid barefoot runners and regular 'shoed' runners will be selected from local running        groups and clubs.|February 2014|February 4, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01733381||75702|
NCT01732783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120100|Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients|Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer||Amgen|No|Active, not recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|242|||Both|18 Years|N/A|No|Non-Probability Sample|All treatment centres (inpatient and outpatient) with a focus on treating subjects with        mCRC. Centres will be selected to represent academic, oncology and specialist settings and        to provide geographical diversity in France and Germany.|February 2016|February 26, 2016|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01732783||75747|
NCT01733355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T807000|A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807|A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807||Avid Radiopharmaceuticals|No|Terminated|July 2012|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|September 25, 2012|No|Yes|Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|No||https://clinicaltrials.gov/show/NCT01733355||75704|
NCT01733368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1 2-015-SP-HF|QUARTO-II Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead|Observational Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead|QUARTO-II|St. Jude Medical|No|Active, not recruiting|November 2012|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients|June 2015|June 16, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01733368||75703|
NCT01733615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058450|Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA|Discovering New Biomarkers for Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA (MPSIVA)||Emory University|No|Terminated|June 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|Samples Without DNA|Frozen urine|Both|N/A|N/A|No|Non-Probability Sample|Newly diagnosed or untreated Mucopolysaccharidosis IVA patients across the nation        collected from national major genetic laboratories, national major genetic clinics,        Includes the Emory Genetics Clinic, Mayo Clinic, UPMC, Children's Hospital of        Philadelphia, and Nationwide Children's Center in Washington, DC.|September 2014|September 2, 2014|November 21, 2012||No|Original PI relocated to another institution|No||https://clinicaltrials.gov/show/NCT01733615||75685|
NCT01733628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2011-04|Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer|Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).|BRECOL|Spanish Breast Cancer Research Group|No|Recruiting|November 2012|December 2015|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|137|Samples With DNA|Blood samples (serum or plasma) Tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic (disseminated at the time of diagnosis) breast cancer or        colorectal cancer, treated with bevacizumab.|June 2013|May 18, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733628||75684|
NCT01733602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/188|tDCS to Enhance Cognitive Training in Schizophrenia|Does Transcranial Direct Current Stimulation (tDCS) Enhance Outcomes From Computerised Cognitive Remediation in Patients With Schizophrenia?||The University of New South Wales||Recruiting|November 2012|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|65 Years|No|||August 2014|August 11, 2014|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733602||75686|
NCT01734148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10000 26217|The RELAX TO SLEEP Study|The RELAX TO SLEEP Study: A Pilot Randomized Controlled Trial||The Hospital for Sick Children|No|Completed|September 2011|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|4 Years|10 Years|No|||November 2014|November 17, 2014|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734148||75645|
NCT01734135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFQUERI-1101|Provider Notification for High B-type Natriuretic Peptide Values|Trial of Provider Notification for Patients With High B-type Natriuretic Peptide and no Imaging to Identify Unsuspected Heart Failure.||VA Palo Alto Health Care System|No|Active, not recruiting|October 2010|September 2014|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734135||75646|
NCT01734395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100958|A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease|An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease||Janssen Korea, Ltd., Korea|No|Completed|March 2007|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1882|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with Alzheimer's disease|August 2013|August 2, 2013|November 22, 2012|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01734395||75626|
NCT01734655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12013|Study of the Validity of Using the MEQ to Measure Mindful Eating in Pregnant Women|Qualitative Evaluation of the Mindful Eating Questionnaire (MEQ) in Pregnant Women|MEQ|Pennington Biomedical Research Center|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty pregnant women (11 will participate in the focus group and 29 will complete        individual cognitive interviews) will be recruited who are similar in age, ethnicity,        education, and marital status to the women who will be recruited for the parent study.|February 2016|February 3, 2016|November 20, 2012||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT01734655||75606|
NCT01730898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL14|Lutein Absorption in Healthy Adults|Lutein Absorption in Healthy Adults||Abbott Nutrition|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01730898||75891|
NCT01730911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ3059|Quick Start Insertion of Mirena and ParaGard|Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices||Columbia University|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|230|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 22, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01730911||75890|
NCT01730924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008205 QM|Comparison of Pulmonary Vein Isolation Using SmartTouch® Catheter With or Without Real-time Contact Force Data|A Randomised Study Comparing Pulmonary Vein Isolation Using SmartTouch® Catheter With or Without Real-time Contact Force Data. The SMART Trial||Queen Mary University of London||Recruiting|December 2012|||||N/A|Interventional|Allocation: Randomized|2||Anticipated|120|||Both|18 Years|85 Years|No|||August 2014|August 1, 2014|November 15, 2012||||No||https://clinicaltrials.gov/show/NCT01730924||75889|
NCT01728103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATVTS-US12-001|Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays|Prospective Collection of Female First-catch Urine, Vaginal Swab,Cervical, and Endocervical Swab Specimens for Testing With the APTIMA Assays||Gen-Probe, Incorporated|No|Active, not recruiting|January 2013|October 2015|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2100|Samples With DNA|urine; endocervical and vaginal swabs|Female|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female subjects at least 16 years of age, with or without symptoms of sexually transmitted        disease.|March 2015|March 19, 2015|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728103||76106|
NCT01728688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120912-2|Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis||Fourth Military Medical University|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2012|November 13, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01728688||76061|
NCT01728701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP5|Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis||Sanaria Inc.|Yes|Completed|September 2012|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01728701||76060|
NCT01728961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1079|Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy|Pharmacology of Artemisinin-Based Antimalarial Therapy Within the Context of Antiretroviral Therapy||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Terminated|February 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|19|||Both|3 Years|12 Years|No|||May 2014|May 16, 2014|September 12, 2012|No|Yes|Slow accrual and funding limitations.|No||https://clinicaltrials.gov/show/NCT01728961||76040|
NCT01729494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST|Belatacept Early Steroid Withdrawal Trial|Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation||University of Cincinnati|Yes|Recruiting|September 2012|March 2019|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|315|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729494||75999|
NCT01729507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|489-11|tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy|Transcranial Direct Current Stimulation (TDCS) as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy - Active and Placebo Controlled Double Blind Study||Ludwig-Maximilians - University of Munich|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2012|November 25, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01729507||75998|
NCT01732250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0276-12-RMC|Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem|Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem||Rabin Medical Center|No|Recruiting|March 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732250||75788|
NCT01732263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-105|Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function|A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects||Shire|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|November 19, 2012|No|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT01732263||75787|
NCT01732276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120314|The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer|Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer||Jiangmen Central Hospital|Yes|Not yet recruiting|January 2013|October 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||November 2012|November 30, 2012|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732276||75786|
NCT01733108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014872|A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers|An Open-Label Drug-Drug Interaction Study in Healthy Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of Glyburide||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733108||75722|
NCT01725763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMR-12-PH|Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension|Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension|CMR-PH|Medical University of Graz|Yes|Enrolling by invitation|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01725763||76283|
NCT01732809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2011|Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses|FIELDS OF EFFECTS OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A AT EQUAL LABELED UNIT DOSES|ABO ONA|Brazilan Center for Studies in Dermatology|No|Completed|January 2011|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01732809||75745|
NCT01733082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22679|The Mycophenolate Pregnancy Registry|The Mycophenolate Pregnancy Registry||Genentech, Inc.||Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|N/A|N/A|No|Probability Sample|Pregnancy and reported exposure to mycophenolate during pregnancy or within 6 weeks of        discontinuing treatment|March 2016|March 1, 2016|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733082||75724|
NCT01733641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052187|Test-Retest Reliability in DETECT|Test-Retest Psychometrics of a Novel Neuropsychological Assessment Tool: Reliability Measures for DETECT||Emory University|No|Terminated|September 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteer athletes without concussion|December 2014|December 10, 2014|November 21, 2012||No|Limited eligible sample size for study outcomes|No||https://clinicaltrials.gov/show/NCT01733641||75683|
NCT01733654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23708|Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder|A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder||Stanford University|Yes|Withdrawn|September 2012|May 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|65 Years|No|||September 2013|September 10, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733654||75682|
NCT01733927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEECII #3|An Evaluation of a Rapid Test for HIV|An Evaluation of an Oral Rapid Test for HIV||Pontificia Universidad Catolica de Chile|No|Completed|May 2010|March 2011|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|497|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733927||75661|
NCT01733901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21012-SR-132|Renal Sympathetic Denervation as Secondary Prevention for Patients After Percutaneous Coronary Intervention.|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation as a Method of Secondary Prevention for Patients After Percutaneous Coronary Intervention.|RSD4CHD2PRE|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|November 2012|July 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||November 2012|November 21, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01733901||75663|
NCT01733914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007CB512501|Contralateral Acupuncture in the Treatment of Chronic Shoulder Pain|Phase II Study of Contralateral Acupuncture in the Treatment of Chronic Shoulder Pain||Peking University|No|Completed|September 2011|August 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|25 Years|65 Years|No|||May 2014|April 12, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733914||75662|
NCT01733888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUORIC|Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Fluorosis Stains|Evaluating the Effect of Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Non Pitted Fluorosis Stains in Indian Population||DMG Dental Material Gesellschaft mbH|No|Completed|July 2013|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|80|||Both|6 Years|12 Years|No|||June 2014|June 20, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01733888||75664|
NCT01734408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT005b|A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children|A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|November 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|773|||Both|21 Months|51 Months|No|||October 2013|October 21, 2013|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734408||75625|
NCT01734668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0143-01|Sofia RSV FIA Field Study|Sofia RSV FIA Field Study||Quidel Corporation|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2468|||Both|N/A|18 Years|No|Probability Sample|Recruitment of RSV symptomatic pediatric subjects who are less than nineteen (19) years of        age.|February 2013|February 5, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734668||75605|
NCT01734954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IACES|Comparison of Two Techniques of Sciatic Nerve Block With Levobupivacaine 0.5% in Orthopedic Surgery|Comparison of Two Techniques of Ultrasound-guided Sciatic Nerve Block Using Levobupivacaine 0.5% in Orthopedic Surgery at the Hospital Pablo Tobon Uribe - Clínica CES, 2013, Randomized Clinical Trial||CES University|No|Not yet recruiting|April 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||April 2013|April 17, 2013|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01734954||75583|
NCT01734967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|herlev|Needle-based Confocal Endomicroscopy Examination of Pancreatic Masse|Needle-based Confocal Endomicroscopy Examination of Pancreatic Masses||Herlev Hospital|Yes|Recruiting|November 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01734967||75582|
NCT01734993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28544|A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|A MULTICENTER, OPEN-LABEL LONG-TERM EXTENSION STUDY OF WA22762 TO EVALUATE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS||Hoffmann-La Roche||Completed|November 2012|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01734993||75580|
NCT01730950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-1205|Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma|RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA||Radiation Therapy Oncology Group|Yes|Recruiting|December 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730950||75887|
NCT01728402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004422|Pathogenesis of Hematologic Malignancies|Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders||OHSU Knight Cancer Institute|No|Enrolling by invitation|September 2008|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|1 Year|N/A|No|Non-Probability Sample|Patients of any age with a diagnosis or suspected diagnosis of a blood or bone marrow        cancer may be a part of this study. The provider who will perform the blood draw, bone        marrow aspirate, or biopsy as part of the patient's routine care will identify possible        participants from their clinic schedule or patient list, give them information about what        would be involved in participating in the study including possible risks, and ask if they        are interested in participating.|October 2015|October 13, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728402||76083|
NCT01728415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1459|Effects of High-intensity Interval Training in Patients in Hemodialysis|Effects of High-intensity Interval Training in Patients in Hemodialysis|OsloExDia|Oslo University Hospital|No|Recruiting|October 2012|September 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|75 Years|No|||September 2014|September 19, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728415||76082|
NCT01729000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13971|Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis|Gloving and Handwashing to Prevent Invasive Infections in Necrotizing Enterocolitis||University of Virginia|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|124|||Both|N/A|8 Days|No|||November 2012|November 13, 2012|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01729000||76037|
NCT01728974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957A|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study A|Mechanisms of Pharyngeal Collapse in Sleep Apnea||Brigham and Women's Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01728974||76039|
NCT01729520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-2012-BR|Descriptive Study of Knee Joint Pain During Strength Training After Total Knee Arthroplasty|Knee Joint Pain During Strength Training After Total Knee Arthroplasty: Effect of Loading and Repetitions to Failure||Hvidovre University Hospital|Yes|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|80 Years|No|||June 2013|June 24, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729520||75997|
NCT01729533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMSI_unexplained infertility|The Benefits of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) in Couples With Unexplained Infertility|The Benefits of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) in Couples With Unexplained Infertility||Sapientiae Institute|No|Withdrawn|December 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|N/A|36 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729533||75996|
NCT01732861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-292-CLL-001|Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma|A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA||Celgene|No|Active, not recruiting|December 2012|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01732861||75741|
NCT01725178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTB-01|Train the Brain - Cognitive and Physical Training for Slowing Dementia|Train the Brain - Effective of Cognitive and Physical Training in Slowing Progression to Dementia: a Clinical and Experimental Study|TTB|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|No|Active, not recruiting|March 2012|October 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|65 Years|89 Years|No|||May 2015|May 11, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725178||76328|
NCT01725490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0491|The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study|||Yonsei University|No|Recruiting|November 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|20 Years|65 Years|No|||July 2013|July 8, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01725490||76304|
NCT01726465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE ICH 178-12|Methylprednisolone N Acetylcysteine in Hepatic Resections|Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections.|MENHIR|Istituto Clinico Humanitas|No|Terminated|November 2012|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|70 Years|No|||November 2013|November 9, 2013|November 7, 2012||No|The first phase was completed|No||https://clinicaltrials.gov/show/NCT01726465||76230|
NCT01726478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXY168|Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital|Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital; Adouble Blinded Clinical Trial.||Makerere University|Yes|Completed|February 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|386|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01726478||76229|
NCT01733095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoPH-GRZ ambrisentan|Ambrisentan for Treatment of Portopulmonary Hypertension|Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study||Medical University of Graz|No|Recruiting|July 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2013|December 26, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733095||75723|
NCT01733940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/12|Efficacy of Tegaderm-CHG® Dressing vs. Tegaderm-IV® Dressing|Efficacy of Tegaderm-CHG® Dressing vs. Tegaderm-IV® Dressing in the Reduction of Central Catheter Colonization in Patients of the Intensive Care Unit of the University "Gómez Ulla" Hospital.|EAC-UCI|Hospital Central de la Defensa Gómez Ulla|Yes|Recruiting|September 2012|June 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|398|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733940||75660|
NCT01734213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JINR-COG-ERIO|Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function|||Chonbuk National University Hospital|Yes|Recruiting|May 2012|December 2012|Anticipated|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734213||75640|
NCT01734187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEVIGEN-OBESE-DB|Efficacy and Safety of Fermented Cinnamon Vine Powder on Decrement of Body Fat|||Chonbuk National University Hospital|Yes|Recruiting|January 2012|November 2012|Anticipated|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734187||75642|
NCT01734200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INs-MF-ERIO|Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function|Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function: a 12 Week, Randomized Double-blind, Placebo-controlled Clinical Trial||Chonbuk National University Hospital|Yes|Completed|November 2012|November 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734200||75641|
NCT01734174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012636|Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography|Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography||Weill Medical College of Cornell University|No|Recruiting|September 2012|||August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having elective coronary artery bypass grafting surgery, valve repair or        replacement surgery, aortic repair or replacement surgery, or any combination of these        surgeries.|June 2013|June 13, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734174||75643|
NCT01734161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012632|Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections|A Prospective, Randomized, Double-Blinded Study to Evaluate the Efficacy of Intravenous Dexamethasone for Nausea Prophylaxis Prior to Duramorph and Bupivacaine Spinal Anesthesia for Scheduled Cesarean Section||Weill Medical College of Cornell University|No|Recruiting|November 2012|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|108|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734161||75644|
NCT01734421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01977|Efficacy of a Mobile Application in the Smoking Cessation Among Young People|Efficacacy of a Mobile Application in the Smoking Cessation Among Young Poeple: Cluster Randomized Trial|TOBB_STOP|Jordi Gol i Gurina Foundation||Not yet recruiting|January 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|604|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734421||75624|
NCT01734460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-RT-0510-12-TLV-CTIL|Maternal Sleep Disordered Breathing and Fetal Growth|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|230|||Female|18 Years|40 Years|No|Non-Probability Sample|women health care centers|August 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734460||75621|
NCT01734681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G202-002|Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer|An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer||GenSpera, Inc.|No|Withdrawn|May 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||February 2013|February 16, 2014|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734681||75604|
NCT01734980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-018|Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction|Comparison Of Cytologic Accuracy Of Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction||Northwell Health|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 25, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01734980||75581|
NCT01731223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeFAM, Karolinska Institutet|Group Treatment for Insomnia in Primary Health Care|Group Treatment for Insomnia in Primary Health Care: a Randomized Controlled Trial|Sleep Prime|Karolinska Institutet|No|Active, not recruiting|August 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731223||75866|
NCT01731496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K08HS017951-03|The Efficacy of Reminders to Complete HPV Series|Improving Communication and Health for Adolescents With Technology - Implementation of Immunization Strategy|ICHAT|University of Rochester|No|Completed|April 2012|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|749|||Both|10 Years|21 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731496||75845|
NCT01728428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116414|A Multicenter, Observational Study to Evaluate Clinical Manifestation, Diagnosis and Treatment of Primary Hemifacial Spasm in Chinese Patients|||Peking Union Medical College Hospital|Yes|Completed|February 2012|November 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1003|||Both|18 Years|80 Years|No|Probability Sample|About 1000 Outpatient subjects from 15 centers across China.|November 2012|November 13, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728428||76081|
NCT01728441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prov 01-2012|Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery|REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery||Provascular GmbH|Yes|Completed|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728441||76080|
NCT01729260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1194|Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide|Phase I Study of Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide|Mebendazole|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|November 2012|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729260||76017|
NCT01728987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TromsøEndo-2012-1|The Significance of Vitamin D Storage in Adipose Tissue|The Significance of Vitamin D Storage in Adipose Tissue||University of Tromso|No|Not yet recruiting|August 2016|February 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|75|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01728987||76038|
NCT01729234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nitrate for vascular age|Effects of Dietary Nitrate on Age-related Vascular Function|Effects of Dietary Nitrate Supplementation on Age-related Vascular Dysfunction||Heinrich-Heine University, Duesseldorf|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 6, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729234||76019|
NCT01729780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0565-12-TLV|Early EEG-NF Intervention for the Prevention of PTSD|Early EEG-NF Intervention for the Prevention of PTSD in First Time ACS Patients||Tel-Aviv Sourasky Medical Center||Not yet recruiting|December 2012|December 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|70 Years|No|||October 2012|November 19, 2012|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729780||75977|
NCT01725776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 06-888|Inhaled Milrinone in Cardiac Surgery|Pharmacokinetic and Pharmacodynamic of Inhaled Milrinone in Cardiac Surgical Patients||Montreal Heart Institute|No|Completed|December 2006|June 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|90 Years|No|||November 2012|November 8, 2012|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725776||76282|
NCT01726023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00018|Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections|A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults|RECLAIM3|AstraZeneca||Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|486|||Both|18 Years|90 Years|No|||April 2015|April 15, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01726023||76263|
NCT01726283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-RSR|Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia|Combined Collagen Crosslinking/Ultraviolet-A and Photorefractive Keratectomy or LASIK in Forme Fruste Keratoconus or Eyes With Potentially Elevated Risk of Ectasia||Cxlusa|No|Completed|October 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|22|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|August 2015|August 20, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726283||76244|
NCT01722305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1281|Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma|Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma||Mayo Clinic|No|Recruiting|April 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722305||76549|
NCT01733667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA2011-01|A Prospective, Randomized, Multi-Center Evaluation of MediENT® Middle Turbinate Implant Versus MeroPack®, a Bioresorbable Nasal Dressing / Sinus Stent After Endoscopic Sinus Surgery|A Prospective, Randomized, Multi-Center Evaluation of MediENT® Middle Turbinate Implant Versus MeroPack®, a Bioresorbable Nasal Dressing / Sinus Stent After Endoscopic Sinus Surgery|MISTY|ENTrigue Surgical, Inc.|No|Completed|December 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|No|||June 2013|June 3, 2013|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733667||75681|
NCT01726270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.82|An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms|A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment||Boehringer Ingelheim||Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|689|||Male|18 Years|N/A|No|||March 2014|March 25, 2014|November 9, 2012||||No||https://clinicaltrials.gov/show/NCT01726270||76245|
NCT01726452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-14|MAGIC vs. CROSS Upper GI. ICORG 10-14, V3|Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|August 2012|||January 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726452||76231|
NCT01722825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14854|Study of LY2157299 in Japanese Participants With Cancer|Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors||Eli Lilly and Company|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||June 2014|June 30, 2014|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722825||76509|
NCT01734499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-3719|The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors|The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors|CCIP|Texas Tech University Health Sciences Center|No|Active, not recruiting|October 2012|December 2015|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||April 2015|April 10, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734499||75618|
NCT01734473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0561|Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)|Casein Protein and Leucine Supplementation to Induce Anabolism in COPD Patients and Healthy Elderly||Texas A&M University|No|Active, not recruiting|November 2012|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|36|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734473||75620|
NCT01734486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHTUR/F/3|Growth Response in Girls With Turner Syndrome|Growth Response in Girls With Turner Syndrome During a Three-year GH Treatment Comparing Two Dose Regimens. Identification of Predictive Factors of Growth Response||Novo Nordisk A/S|No|Completed|September 1996|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|N/A|N/A|No|||November 2012|November 22, 2012|November 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01734486||75619|
NCT01734434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_15OB|Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems|A Multicenter, Observational Study to Identify Factors That Influence Access of Pregnant Women and Their Infants to Their Local Healthcare Systems||Novartis|No|Completed|November 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|3257|||Female|N/A|N/A|No|Probability Sample|Pregnant women of gestational age 24 weeks or more|February 2015|February 24, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734434||75623|
NCT01734447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRETARD/F/2/F|Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation|Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy||Novo Nordisk A/S|No|Completed|April 2000|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|N/A|N/A|No|||November 2012|November 26, 2012|November 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01734447||75622|
NCT01734694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7089|Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients|Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients|STOP-NT|Henry Ford Health System||Terminated|October 2011|||September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|November 14, 2012|Yes|Yes|Independent biostatistician recommended early termination of the trial due to low probability    of success.|No||https://clinicaltrials.gov/show/NCT01734694||75603|
NCT01735006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-003|Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine|A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women||Xiamen University|Yes|Active, not recruiting|November 2012|September 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6000|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01735006||75579|
NCT01723917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG033288|Phytoserms for Menopause Symptoms and Age-Associated Memory Decline|Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated Memory Decline|phytoSERM|University of Southern California|Yes|Completed|July 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|71|||Female|48 Years|58 Years|No|||January 2015|January 13, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723917||76425|
NCT01728714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CPO-XXX-2012/1|Better Diabetes Control, Quality - Educate to Achieve Compliance|Prospective Study to Evaluate Impact of an Educational Programme About Diabetes, Comparing to Normal Clinical Practice, on Treatment Compliance and Disease Control of People With Type 2 Diabetes Followed in Primary Care Units in Portugal|MINERVA|AstraZeneca|No|Active, not recruiting|May 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|primary care setting patients|February 2016|February 24, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01728714||76059|
NCT01729013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tromsø-Endo-2012-2|Duration of Vitamin D Stores After Prolonged Vitamin D Substitution|Duration of Vitamin D Stores After Prolonged Vitamin D Substitution||University of Tromso|No|Completed|November 2012|August 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|78|Samples Without DNA|blood samples and fat biopsy|Both|25 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who have previously participated in a vitamin D study|September 2015|September 18, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729013||76036|
NCT01729793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEC-001|Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal|A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal||National Enzyme Company|Yes|Enrolling by invitation|November 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729793||75976|
NCT01729247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-043|Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age|||Aerocrine AB|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|7 Years|60 Years|No|Non-Probability Sample|Male and female subjects, 7 to 60 years of age, inclusive, with asthma will be recruited|January 2014|January 15, 2014|November 12, 2012||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT01729247||76018|
NCT01730287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZadUMS-|Effect Of Different Lining Materials in Stepwise Excavation|Effect Of Different Lining Materials on Clinical Symptoms of Stepwise Excavation Without Re-enter: Double Blind Randomizd Clinical Trial||Azad University of Medical Sciences|Yes|Recruiting|May 2010|May 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730287||75938|
NCT01726036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11121|Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial|Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial: The GMRT Study.|GMRT|TriHealth Inc.|No|Completed|October 2012|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|274|||Male|N/A|4 Days|Accepts Healthy Volunteers|||March 2014|November 11, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01726036||76262|
NCT01726296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-841|Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care|Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care||Fox Chase Cancer Center|No|Recruiting|January 2013|||July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1440|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726296||76243|
NCT01722292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14631|A Study of LY2940680 in Small Cell Lung Cancer|A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer||Eli Lilly and Company|No|Terminated|January 2013|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|November 2, 2012|Yes|Yes|Change in clinical strategy.|No||https://clinicaltrials.gov/show/NCT01722292||76550|
NCT01723735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD12910|Effect of Alirocumab SAR236553 (REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects|A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subjects||Sanofi|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2014|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723735||76439|
NCT01725997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-lux|Operative or Conservative Treatment of Acute Acromioclavicular Joint Dislocation|Operative or Conservative Treatment of Acute Acromioclavicular Joint Dislocation Rockwood Grade III and V - a Prospective Randomized Study||St Goran's Hospital|No|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||November 2012|November 15, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01725997||76265|
NCT01726010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102012|22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract|Endoscopic Ultrasound Guided Biopsy of Subepithelial Tumors of the Upper Gastrointestinal Tract Using the 22-G-Procore Needle|PRO-SET|Technische Universität München||Recruiting|September 2012|October 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2012|November 8, 2012|November 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01726010||76264|
NCT01723072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EDE16|Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy|A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy.|X-ACT|Novartis|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||February 2015|February 23, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723072||76490|
NCT01722799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIX-STENT-001|Randomized Trial of Coronary Angioplasty for de Novo Lesions in sMall vesSElS With Drug Eluting Balloon.|PROSPECTIVE RANDOMIZED TRIAL Multicentric Study to Evaluate the Treatment and the Efficiency of Paclitaxel-coated Balloon IN.PACT FALCON ® in Small-vessel Coronary Stenosis.|RAMSES|Hospital de Meixoeiro|Yes|Recruiting|December 2012|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01722799||76511|
NCT01734733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCT/PD-012|Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease|A Phase I/IIa, Open-label Investigation of the Safety and Clinical Effects of NTCELL [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease||Living Cell Technologies|Yes|Completed|July 2013|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|40 Years|70 Years|No|||February 2016|February 9, 2016|November 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734733||75600|
NCT01734746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40323.068.12|Sentinel Node in Ovarian Cancer|Sentinel Node in Ovarian Cancer|SONAR|Maastricht University Medical Center|No|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||November 2012|November 21, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01734746||75599|
NCT01734707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAR-AMAR|Atherosclerosis Monitoring and Atherogenicity Reduction Study|||Institute for Atherosclerosis Research, Russia||Completed|January 2004|October 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|300|||Male|40 Years|74 Years|Accepts Healthy Volunteers|||January 2005|November 21, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01734707||75602|
NCT01734720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/533-31/2|Common Bile Duct Stones - Natural History and Interventions|Common Bile Duct Stones - Natural History and Interventions : Data From the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangio Pancreatography (ERCP) (GallRiks)||Karolinska Institutet|No|Completed|May 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3828|||Both|11 Years|N/A|No|Non-Probability Sample|Patients undergoing cholecystectomy with common bile duct stones found in peroperative        cholangiogram|August 2013|August 28, 2013|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01734720||75601|
NCT01735019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0350|Estimating EC95 of Remifentanil for Cough Prevention During Emergence From Total Intravenous Anesthesia With Propofol and Remifentanil in Patients Undergoing Transsphenoidal Hypophysectomy|||Yonsei University|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|40|||Both|20 Years|65 Years|No|||November 2012|September 17, 2013|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01735019||75578|
NCT01730963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRT-12-01|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians||Reproductive Research Technologies, LP|No|Completed|January 2007|September 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|30|||Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant women with uncomplicated singleton pregnancies|November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730963||75886|
NCT01730976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R13-3217B|Asthma in the Elderly: The Role of Vitamin D|Asthma in the Elderly: The Role of Vitamin D||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|N/A|No|||September 2014|September 8, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730976||75885|
NCT01724398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-PE|Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Liver Failure|Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Acute-on-Chronic Liver Failure Caused by Hepatitis B Virus (HBV)||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|November 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|16 Years|65 Years|No|||February 2013|February 27, 2013|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01724398||76388|
NCT01729026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0809-P|A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD)|A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder|VITAL|VA Office of Research and Development|No|Completed|October 2013|March 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729026||76035|
NCT01725867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003038R|Comparing the Effect of Physical Therapy With Oral Appliance on Temporomandibular Disorder Related Myofascial Pain|Comparing the Effect of Physical Therapy With Oral Appliance on Temporomandibular Disorder Related Myofascial Pain||National Taiwan University Hospital|No|Completed|June 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Female|20 Years|65 Years|No|||November 2012|November 8, 2012|May 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01725867||76275|
NCT01726127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0872|Green Vegetables and Women's Health|Effect of Cruciferous Vegetables or a Cruciferous Supplement on Urinary Estrogen Metabolites in Premenopausal Women||University of Wisconsin, Madison|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|3||Actual|66|||Female|40 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01726127||76256|
NCT01729546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1212|Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus|Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus [Following EN ISO 15197:2003 - 7.3 System Accuracy Evaluation] Part 40 of Study IDT-2010||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|November 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|N/A|||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|January 13, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729546||75995|
NCT01729559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-12-5973|Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin|Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin||Scripps Health|Yes|Completed|November 2012|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|495|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729559||75994|
NCT01726335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012484|Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia|An Open-Label Study of Oral Antipsychotics Replacement by Prolonged Release Risperidone (Risperdal Consta) in Schizophrenic Subjects With Bad Adhesion to the Treatment||Janssen-Cilag Ltd.|No|Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|50 Years|No|||April 2014|April 10, 2014|November 9, 2012|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT01726335||76240|
NCT01722318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304-20212|The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|CIBS|Synergy Pharmaceuticals Inc.|No|Completed|November 2012|October 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|350|||Both|18 Years|75 Years|No|||January 2015|January 13, 2015|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722318||76548|
NCT01722331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3222-010|A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)|A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2012|October 2019|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|772|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722331||76547|
NCT01722578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEAL-123|L-ornithine L-aspartate in Overt Hepatic Encephalopathy|Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial|HEAL|Dayanand Medical College and Hospital|Yes|Recruiting|December 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2016|January 23, 2016|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01722578||76528|
NCT01722591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PRO-01|Safety and Efficacy Study of the Cardiapex Percutaneous Trans-apical Access and Closure System|A Prospective, Multicenter, Uncontrolled Study to Evaluate the Safety and Efficacy of the Cardiapex Percutaneous Trans-apical Access and Closure System||Cardiapex Ltd.|No|Terminated|January 2013|||February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|38|||Both|70 Years|N/A|No|||February 2015|February 3, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722591||76527|
NCT01722552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA032423-01A1|China Adherence Through Technology Study|China Adherence Through Technology Study|CATS|Boston University|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 21, 2014|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01722552||76530|
NCT01722565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAP-APR-2012-028|Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection|Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection||Corporacion Parc Tauli|No|Completed|January 2012|December 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|90 Years|No|||September 2015|September 9, 2015|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01722565||76529|
NCT01722812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0075-34|Cromoglicate in Psoriasis|An Exploratory Study Evaluating the Efficacy of Cromoglicate Cream Compared to Cream Vehicle in the Treatment of Itch in Psoriasis||LEO Pharma|No|Completed|November 2012|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722812||76510|
NCT01723085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH|Anti-Mullerian Hormone Levels Before and After an Open Myomectomy|Anti-Mullerian Hormone Levels Variations Following an Open Myomectomy||OVO R & D|No|Suspended|March 2012|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|Samples Without DNA|Blood samples collected to measure Anti-Mullerian hormone levels|Female|18 Years|42 Years|No|Non-Probability Sample|Women 18 to 42 tears old Indication for myomectomy by laparotomy|October 2015|October 13, 2015|November 5, 2012||No|It has been put on hold for the moment due to logistic problems|No||https://clinicaltrials.gov/show/NCT01723085||76489|
NCT01723098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maternal cardiovascular system|Effect of Regular Exercise on Maternal Cardiovascular System During Pregnancy|Effect of Supervised Exercise Program on Cardiovascular Function and Structure in Pregnant Women. Randomized Controlled Trial||Technical University of Madrid|Yes|Recruiting|February 2009|September 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|800|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|November 13, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723098||76488|
NCT01723358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020206|Neuromuscular Electrical Stimulation (NMES) Treatment Technique Therapy in the Management of Young Infants With Severe Dysphagia|Effectiveness of a New Neuromuscular Electrical Stimulation (NMES) Treatment Technique (VitalStim® Therapy) in the Management of Young Infants With Severe Dysphagia: a Prospective Pilot Study||The Hospital for Sick Children|No|Completed|September 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|12 Months|No|||July 2015|July 17, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723358||76468|
NCT01723059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-060|Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection|Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection||Dallas VA Medical Center|No|Recruiting|February 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723059||76491|
NCT01723345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-1-94-8048|Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)?|||Shiraz University of Medical Sciences||Recruiting|February 2012|April 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2013|January 26, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723345||76469|
NCT01735032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-703|Multimodal Imaging in Pre-surgical Evaluation of Epilepsy|Contribution of Multimodal Imaging (MRI, PET, MEG) in Pre-surgical Evaluation of Drug-resistant Focal Epilepsy|EPIMAGE|Hospices Civils de Lyon|No|Recruiting|October 2012|May 2016|Anticipated|November 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|140|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 patients with drug-resistant focal epilepsy and candidates for epilepsy surgery will        be recruited.|October 2012|November 29, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735032||75577|
NCT01735045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-2010-01|LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear|LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear||Szabocsik and Associates, Inc.|Yes|Completed|May 2010|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 25, 2012|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735045||75576|
NCT01730989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESP-CPR-0312|Estromineral Serena Plus and Symptomatic Menopause|Controlled Clinical Study on the Activity of the Combination of Isoflavones, Agnocastus and Magnolia Extract in Menopause||Rottapharm|No|Not yet recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|45 Years|65 Years|No|||November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730989||75884|
NCT01731002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS202|A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure|A Phase 2 Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|224|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731002||75883|
NCT01723670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1109-PR-0072|Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment|CT05|CERESPIR|Yes|Withdrawn|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|45 Years|64 Years|No|||February 2015|February 9, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723670||76444|
NCT01723683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-221|Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS|Minimally Invasive Surfactant Therapy Followed by Early CPAP (MISTCPAP) in Very Preterm Infants With RDS|MISTCPAP|China Medical University Hospital|Yes|Recruiting|February 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|36 Hours|No|||November 2012|November 6, 2012|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01723683||76443|
NCT01724671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPLA 6656|Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline|A Case Series of Ceftaroline-treated Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline, Compared to Vancomycin-treated Patients||CPL Associates|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|30|Samples Without DNA|MRSA cultures obtained retrospectively from Microbiology labs if available for patients.|Both|18 Years|N/A|No|Non-Probability Sample|Investigators will retrospectively capture patient cases that have been treated for MRSA        with ceftaroline, either in response to cultures or empirically with subsequent discovery        of MRSA. Cases will only be included if the isolate was tested against vancomycin and        ceftaroline, unless the isolate is available in the microbiology lab to send to the study        coordinating center for subsequent testing of minimum inhibitory concentrations (MIC).        Case matched patients treated with vancomycin will also be collected as the control group.|November 2012|November 7, 2012|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724671||76367|
NCT01724684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106097RB|Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan|Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan||National Taiwan University Hospital|No|Recruiting|December 2011|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|20 Years|N/A|No|||November 2012|November 7, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01724684||76366|
NCT01729572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0004-12-SHA|Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients|The Effect of add-on Tele Medicine Monitoring of Medication Adherence, on the Risk of Re-hospitalisation of Ambulatory Schizophrenic Patients. an Open, Prospective, Randomised Controled Trial||Shalvata Mental Health Center|Yes|Recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||April 2014|April 24, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729572||75993|
NCT01726140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRHACS CEI-457|CPAP Reduces Hypoxemia After Cardiac Surgery|CPAP Reduces Hypoxemia After Cardiac Surgery (CRHACS Trial). A Randomized Controlled Trial|CRHACS|University of Turin, Italy|No|Recruiting|April 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|960|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726140||76255|
NCT01730040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1110|Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)|A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin||Regeneron Pharmaceuticals|Yes|Completed|October 2012|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|355|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|November 9, 2012|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01730040||75957|
NCT01722396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG-10-179|Pharmacogenetics of Vitamin D Supplementation in Tuberculosis|The Pharmacogenetics of Vitamin D Supplementation in Tuberculosis||University of Birmingham|No|Completed|March 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|16 Years|N/A|No|||January 2013|January 14, 2013|November 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722396||76542|
NCT01722409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121009|A Better Choice for Patients Undergoing Endovascular Coil Embolization|Sevoflurane, Laryngeal Mask Airway and Single-dose Dexmedetomidine: A Better Choice for Patients Undergoing Endovascular Coil Embolization||China Medical University, China|Yes|Completed|December 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|65 Years|No|||October 2013|June 23, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01722409||76541|
NCT01726322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-16|Anti-Mullerian Hormone Study. ICORG 10-16, V2|A Study to Determine Alteration of Anti-mullerian Hormone (AMH) Concentrations in Premenopausal Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Breast Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|September 2012|||September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|42 Years|No|Non-Probability Sample|Premenopausal breast cancer patients who are to receive chemotherapy|February 2016|February 15, 2016|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726322||76241|
NCT01723397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1252|Effect of Nasaleze on Nasal Challenge With Allergen|Effect of Nasaleze on the Early Reaction to Nasal Challenge With Allergen||University of Chicago|No|Recruiting|November 2012|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 27, 2013|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723397||76465|
NCT01723410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGSC-GRAT|Neural and Physiological Responses to Real-World Experiences|Neural and Physiological Responses to Real-World Experiences||University of California, Los Angeles|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|70|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01723410||76464|
NCT01723956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA.09.0265|Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women|Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women|VICAR2|University of Witwatersrand, South Africa|Yes|Completed|March 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Female|18 Years|65 Years|No|||August 2014|September 19, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723956||76422|
NCT01723969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40CRC|Screening Platform for Clinical Trials in Advanced Colorectal Cancer|Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer "SPECTAcolor"|SPECTAcolor|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|September 2013|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2600|Samples With DNA|FFPE blocks of tumour tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced or metastatic colo-rectal cancer|January 2016|January 18, 2016|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723969||76421|
NCT01724203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111104-SUS-FON-ICP-MS|Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months.|Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months: a Double-blind, Randomized, Placebo-controlled Study.||Fonterra Research Centre|Yes|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|192|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||October 2013|October 10, 2013|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724203||76403|
NCT01722838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01PS001574|Black Men Evolving Behavioral HIV Prevention Intervention for Black MSM|An Evaluation of a Locally Developed Homegrown HIV Prevention Intervention|B-ME|Loyola University Chicago|Yes|Active, not recruiting|September 2012|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|438|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722838||76508|
NCT01726062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0641|Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes|Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes (The Baby's Breath II Project)||The University of Texas Health Science Center, Houston|Yes|Recruiting|August 2012|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|396|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726062||76260|
NCT01723371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031903|Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children|Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children||The Hospital for Sick Children|No|Withdrawn|September 2012|||September 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|8 Years|17 Years|No|||December 2015|December 30, 2015|October 31, 2012||No|Due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT01723371||76467|
NCT01723384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09809|Intermittent Naltrexone Among Polysubstance Users||Project iN|University of California, San Francisco|Yes|Completed|May 2013|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01723384||76466|
NCT01723709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00023791|The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort|The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort||Duke University|Yes|Recruiting|June 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|7.5 mL PaxGene RNA collection 6 mL DNA whole blood collection 40 mL urine collection 20 mL      serum SST tube collection 16 mL plasma EDTA tube collection|Both|18 Years|N/A|No|Non-Probability Sample|Participants must enroll or have enrolled in the MURDOCK Study Community Registry and        Biorepository prior to joining the Multiple Sclerosis Cohort. At the MURDOCK Study visit,        or after the participant has enrolled in the MURDOCK Study, they will be asked (either in        person or via the phone) if they would be willing to join the Multiple Sclerosis cohort        study.|November 2015|November 16, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01723709||76441|
NCT01723696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL105447|Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function|Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function|VCSIP|Oregon Health and Science University|Yes|Recruiting|December 2012|November 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|278|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723696||76442|
NCT01723930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5328|Transpulmonary Gradient After Cardiac Surgery Under Cardiopulmonary Bypass|Transpulmonary Gradient of Inflammation Biomarkers and Pulmonary Vascular Resistance in Acute Respiratory Failure After Cardiac Surgery Under Cardiopulmonary Bypass||University Hospital, Strasbourg, France|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||30|||Both|18 Years|N/A|No|Non-Probability Sample|Recruitment concerns only patients with high risk of postoperative respiratory failure        (SLIP score > 22).|November 2012|November 7, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723930||76424|
NCT01724151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812152R|Effects of Exercise Training in Patients With Mild Cognitive Impairment|Effects of Exercise Training in Patients With Mild Cognitive Impairment||National Taiwan University Hospital|Yes|Completed|April 2009|April 2012|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic,community sample|April 2014|April 21, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01724151||76407|
NCT01724957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120109-05|FFR vs. icECG in Coronary Bifurcations|Fractional Flow Reserve Versus Intracoronary ECG for Detection of Post Stenting Ischemia in Side Branch Territory in coronAry Bifurcation Lesions|FIESTA|University National Heart Hospital|Yes|Recruiting|September 2012|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Non-Probability Sample|-  Significant, >50% diameter stenosis artery scheduled for stent insertion at the main             vessel (Medina types: 1xx, x1x, 11x);          -  Side branch vessel at least 2.0mm|December 2014|December 1, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01724957||76345|
NCT01725607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121101|Postoperative Sleep Quality in Patients Undergoing Thoracic Surgery With Different Types of Anesthesia Management|Postoperative Sleep Quality in Patients Undergoing Thoracic Surgery With Different Types of Anesthesia Management||China Medical University, China|Yes|Completed|January 2013|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|219|||Both|18 Years|65 Years|No|||October 2013|July 7, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01725607||76295|
NCT01725620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ECCL003|Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®|A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compate the Safety and Pharmacokinetic Characteristics of LBEC0101(Etanercept) 25mg With Those of Enbrel® 25mg After Subcutaneous Injection in Healthy Male Volunteers||LG Life Sciences||Completed|November 2012|April 2014|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01725620||76294|
NCT01726361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFI 2506|Multidimensional Treatment Foster Care for Adolescents|Multidimensional Treatment Foster Care for Adolescents||The Danish National Centre For Social Research|No|Withdrawn|November 2012|June 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|17 Years|No|||November 2013|November 6, 2013|November 9, 2012||No|We were not able to recruit families|No||https://clinicaltrials.gov/show/NCT01726361||76238|
NCT01726114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8CSP_19042012|A Clinical Study of the C8 MediSensors Optical Glucose Monitor™|A Clinical Study to Evaluate the Performance of the C8 MediSensors Optical Glucose Monitor™ During On-Site Testing and Real Time Use Monitoring|Spectrum|C8 MediSensors, Inc.|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|86|||Both|18 Years|N/A|No|||March 2013|March 23, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01726114||76257|
NCT01722695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1499|Performance Comparison of Revaclear With Larger Dialyzer|HD Performance Comparison of Revaclear 200 and Revaclear 400 With Larger-surface Competitor Dialyzers|Revacom HD|Gambro Dialysatoren GmbH|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01722695||76519|
NCT01726049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil Groningen Study|Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH|Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension||University Medical Center Groningen|Yes|Completed|October 2011|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|September 21, 2012||No||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01726049||76261|
NCT01722864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15010233|Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)|An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain||Mallinckrodt|No|Completed|November 2012|August 2013|Actual|February 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722864||76506|
NCT01732146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110111|Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy|Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn|Neurepo|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2013|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|12 Hours|No|||August 2015|August 18, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732146||75796|
NCT01724450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ceccy|Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity|Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.|Ceccy|University of Sao Paulo|No|Recruiting|June 2012|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01724450||76384|
NCT01732393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89470|Effect of Quercetin in Prevention and Treatment of Oral Mucositis|Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias||Mashhad University of Medical Sciences|Yes|Completed|January 2010|January 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|40 Years|No|||December 2012|December 4, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732393||75777|
NCT01724710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206038RIC|To Study the Effect of Organic Light Emitting Diodes (OLED) on Cultured Fibroblast|To Study the Effect of Organic Light Emitting Diodes (OLED) on Cultured Fibroblast||National Taiwan University Hospital|No|Recruiting|August 2012|||August 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|Samples With DNA|Fibroblasts of Chronic ulcer and normal skin will be cultured. Fibroblast culture will be      analyzed with quantitative PCR.|Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. The process of collecting chronic ulcer skin: When the patient accept wound             debridement surgery, visiting staff will take 1x1cm2 skin of chronic ulcer.          2. The process of collecting normal skin: When the patient accept skin-grafting surgery,             visiting staff will take 1x1x0.1cm3 skin.|November 2012|November 9, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01724710||76364|
NCT01724970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2276P|Laryngeal Masks for Bariatric Surgery|A Randomized Comparative Study on Proseal LMATM and Supreme LMATM for Bariatric Surgery.||University of Padova|No|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||November 2012|November 7, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01724970||76344|
NCT01724983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET2271|Ketamine in Bariatric Surgery|Effects of Ketamine on Recovery From Bariatric Surgery||University of Padova|No|Active, not recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||November 2012|November 7, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01724983||76343|
NCT01725568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60|BioMonitor Master Study|Master Study of the Implantable Cardiac Monitor "BioMonitor"|BioMonitor|Biotronik SE & Co. KG|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard ICM indication who are referred to the hospital|November 2014|November 19, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01725568||76298|
NCT01722344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCK-2012-CT-2912|Improving Work Outcome for People With Severe Mental Illness|Individual Placement and Support (IPS) Enhanced With Cognitive Remediation and Social Skills Training in Denmark: a Randomized Controlled Trial||Mental Health Centre Copenhagen|Yes|Active, not recruiting|October 2012|May 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|717|||Both|18 Years|64 Years|No|||February 2016|February 7, 2016|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722344||76546|
NCT01723722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2-M-107|Treatment of Neonatal Abstinence Syndrome|Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments|HOMENOW|Eastern Maine Medical Center|Yes|Completed|January 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|6 Days|No|||November 2013|November 5, 2013|January 27, 2011||No||No|March 1, 2013|https://clinicaltrials.gov/show/NCT01723722||76440|
NCT01723943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8061|Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients|Psychoeducation for Spouses/Partners of Women With Breast Cancer||University of Washington|No|Completed|March 2009|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|108|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 29, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723943||76423|
NCT01724164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003058R|Robot- Versus Mirror-Assisted Rehabilitation in Stroke Patients|Robot- Versus Mirror-Assisted Motor Interventions in Rehabilitating Upper-Limb Motor and Muscle Performance and Daily Functions Poststroke: A Comparative Effectiveness Study||National Taiwan University Hospital|No|Recruiting|August 2011|July 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|40 Years|75 Years|No|||November 2012|November 8, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01724164||76406|
NCT01724177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-ATLL-002|A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma|A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma||Celgene|Yes|Active, not recruiting|November 2012|December 2017|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|N/A|No|||November 2015|November 26, 2015|November 7, 2012|No|Yes||No|September 4, 2015|https://clinicaltrials.gov/show/NCT01724177||76405|
NCT01724411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/040/12|Satiety Innovation- Study 793. University of Aberdeen|SATIN: Satiety Innovation, Study 1|SATIN|University of Aberdeen|Yes|Completed|August 2012|December 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01724411||76387|
NCT01725880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N03-SC|Long-Term Follow-Up of Transplanted Human Central Nervous System Stem Cells (HuCNS-SC) in Spinal Cord Trauma Subjects|Long-term Follow-up (LTFU) Study of the Phase I/II Safety and Preliminary Efficacy Investigation of Intramedullary Spinal Cord Transplantation of HuCNS-SC® in Subjects With Thoracic (T2-T11) Spinal Cord Trauma||StemCells, Inc.|No|Enrolling by invitation|November 2012|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who had undergone intramedullary transplantation of HuCNS-SC cells in the        thoracic region.|January 2015|January 13, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01725880||76274|
NCT01726153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0018767|A Pilot Trial of an Individualized Web-Based Condom Use Intervention|A Pilot Randomized Control Trial (RCT) of an Individualized Condom-HIM Web-based Intervention for Condom USe Among HIV+ Gay Males||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 9, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726153||76254|
NCT01722708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012-12-EMC|Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies|Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies||HaEmek Medical Center, Israel|No|Recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 10, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01722708||76518|
NCT01722721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-01-2012|Physicians Work Distribution in a Danish Emergency Department|||University of Southern Denmark|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|N/A|N/A|No|Probability Sample|Emergency Department physicians|November 2012|November 5, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01722721||76517|
NCT01726348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014686|A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Darunavir on Filipino Patients With Human Immunodeficiency Virus-Type I (HIV-1) Infection||Janssen Pharmaceutica|No|Withdrawn|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include adult Filipino patients who are diagnosed with human        immunodeficiency virus-type 1 (HIV-1), and who are eligible for darunavir (in combination        with ritonavir) treatment.|November 2015|November 30, 2015|November 9, 2012||No|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01726348||76239|
NCT01723254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4901001|A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis|A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, and Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-ige Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis||Pfizer|No|Completed|December 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|190|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723254||76476|
NCT01723111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|knuhhermes|Impact of Dialysis Modality on Hepcidin and Iron Metabolism|A Prospective, Multicenter, Observational Study to Evaluate the Impact of Peritoneal Dialysis Compared With Hemodialysis on Iron Metabolism and Hepcidin|HERMES|Kyungpook National University|No|Active, not recruiting|November 2012|August 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|Samples Without DNA|2 ml serum will be retained|Both|18 Years|N/A|No|Probability Sample|New ESRD patients whose dialysis treatment is expected over 3 months|February 2016|February 29, 2016|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01723111||76487|
NCT01731613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8648|Adjustable Fortification of Human Milk Fed to Chinese Preterm Infants|Adjustable Fortification of Human Milk Fed to Chinese Preterm Infants||Peking Union Medical College Hospital|No|Recruiting|August 2012|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|40 Days|No|||November 2015|November 2, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01731613||75836|
NCT01732406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001556|Acromegaly Treatment Quality of Life Study|Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life||Massachusetts General Hospital|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|Plasma and blood serum|Both|18 Years|75 Years|No|Non-Probability Sample|There will be 3 groups/cohorts: 1) Patients with active acromegaly (n=30), 2) patients        receiving pegvisomant monotherapy to treat acromegaly (n=30), and 3) patients receiving        somatostatin analog monotherapy to treat acromegaly (n=60)|March 2016|March 9, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732406||75776|
NCT01731886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ2355|Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma|A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma||Columbia University|Yes|Active, not recruiting|September 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731886||75816|
NCT01725256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR001-CS05|A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)|A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)||Aires Pharmaceuticals, Inc.|Yes|Terminated|November 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|75 Years|No|||April 2014|April 7, 2014|November 8, 2012|Yes|Yes|Terminated early dt to acquisition of Sponsor and change in corporate priorities|No||https://clinicaltrials.gov/show/NCT01725256||76322|
NCT01725269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR001-CS06|Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05|A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension||Aires Pharmaceuticals, Inc.|Yes|Terminated|March 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|75 Years|No|||April 2014|April 7, 2014|November 8, 2012|Yes|Yes|Terminated early dt acquisition of Sponsor and change in corporate priorities|No||https://clinicaltrials.gov/show/NCT01725269||76321|
NCT01725828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012|Accuracy of Ultrasound of Identification of Cricothyroid Membrane.A Randomized Control Trial.|Accuracy of Ultrasound Compared to Conventional Methods of Identification of Cricothyroid Membrane in Subjects With Poorly Defined Neck Landmarks. A Randomized Control Trial.||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|Yes|Completed|October 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|227|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01725828||76278|
NCT01726309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 08-40|Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4|Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|May 2011|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patient Population:        150 Patients with histologically proven stage IV (AJCC 7th Edition) colorectal cancer        (CRC) expressing wild-type KRAS or stage IV non-small cell lung cancer (NSCLC) expressing        EGFR (tested by immunohistochemistry (IHC)), with no previous exposure to Cetuximab or        Panitumumab, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).|October 2015|October 23, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726309||76242|
NCT01723137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3189|Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales|Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales||Minneapolis Medical Research Foundation||Completed|May 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3630|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department at an urban county hospital.|October 2013|October 24, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01723137||76485|
NCT01723423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PAF07150|Mastectomy Reconstruction Outcomes Consortium (MROC) Study|Mastectomy Reconstruction Outcomes Consortium (MROC) Study|MROC|University of Michigan|Yes|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|7170|||Female|18 Years|N/A|No|Non-Probability Sample|Women undergoing first-time breast reconstruction at one of 13 consortium sites.|August 2015|August 3, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01723423||76463|
NCT01724190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285412|Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes|Effect of Vitamin D Supplementation on Rate of Partial Clinical Remission in Children and Adolescents With Type 1 Diabetes||Nationwide Children's Hospital|Yes|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|36|||Both|4 Years|18 Years|No|||June 2015|June 19, 2015|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724190||76404|
NCT01724424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/057/11|Melatonin in Healthy Volunteers|A Dose Escalation Study of Melatonin in Healthy Volunteers as a Potential Treatment for Sepsis|DAMSEL1|University of Aberdeen|Yes|Completed|June 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01724424||76386|
NCT01724437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3503|Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation|||Universitätsklinikum Hamburg-Eppendorf||Completed|November 2009|November 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01724437||76385|
NCT01724697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120912-1|Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Autologous Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis||Fourth Military Medical University|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2012|November 7, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01724697||76365|
NCT01722617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01349-32|A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.|A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.|FLARE|Central Hospital, Nancy, France|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|207|||Both|18 Years|N/A|No|||January 2012|September 22, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01722617||76525|
NCT01722630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRF-2012-DH|Renal Function During Laparoscopic Surgery|Dopamine Infusion and Crystalloids Administration Improve Renal Function During Laparoscopic Surgery||Catholic University of the Sacred Heart|No|Completed|March 2012|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Female|24 Years|42 Years|No|||November 2012|November 5, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722630||76524|
NCT01726166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011813-01H|Suprapubic Aspiration Versus Urinary Catheterization In Neonates.|A Randomized Controlled Trial: Suprapubic Aspiration Versus Urinary Catheterization in the Neonatal Intensive Care Unit.|SPA|Children's Hospital of Eastern Ontario|No|Recruiting|April 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|165|||Both|N/A|12 Months|No|||August 2015|August 20, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726166||76253|
NCT01723566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANORAMA 2|PANORAMA 2 Observational Study|Panorama 2 Medtronic CRDM Implantable Cardiac Device Long Term Registry||Medtronic Bakken Research Center|No|Recruiting|July 2012|July 2020|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients that have a Medtronic implantable CRDM Device implanted (including Vitatron),        which is commercially available at the start of the registry or becomes commercially        available during the course of the registry, and used within its intended use, may be        included.        These products are:          -  Pacemaker systems: Implantable Pulse Generators (IPG) and cardiac leads          -  Defibrillation systems: Implantable Cardioverter Defibrillators (ICD) and cardiac             leads          -  Resynchronization systems: Cardiac Resynchronization Therapy (CRT):               -  Cardiac Resynchronization Therapy - Pacemaker (CRT-P) and cardiac leads               -  Cardiac Resynchronization Therapy - Defibrillator (CRT-D) and cardiac leads          -  Implantable Loop Recorders (ILR)|January 2015|January 27, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723566||76452|
NCT01722422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 11-05|Hyperoxia and Hypertonic Saline in Septic Shock||Hyper2S|University Hospital, Angers|Yes|Terminated|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|441|||Both|18 Years|N/A|No|||November 2012|November 19, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722422||76540|
NCT01722435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIS-OST-PV3718|Completion of OST - a Prospective Study|Completion of Substitution Treatment With Methadone/Levomethadone - a Prospective Study||Universitätsklinikum Hamburg-Eppendorf|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in primary care setting (GPs) or specialized clinics likely to complete opiate        substitution treatment (OST) during the next 12 months.|August 2014|August 5, 2014|November 2, 2012||No||No|June 3, 2014|https://clinicaltrials.gov/show/NCT01722435||76539|
NCT01724086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100882|A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus|A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients||Janssen R&D Ireland|No|Completed|October 2012|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|90|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01724086||76412|
NCT01731873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2268|Patient Controlled Analgesia Pharmacogenetic Study|Non-Interventional Pharmacogenetic Study of Patient / Proxy Controlled Analgesia in Children Undergoing Surgery||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|650|Samples With DNA|A database/ repository will be constructed for future research, analysis, and recruitment.      De-identified study subjects' genetic information and their responses to pain and pain      medications, side-effects will be included in the database. Blood specimens will be included      in the repository for exploring potentially important SNPs and biomarkers in future. No      patient identifiers will be included in the repository and there will be a confidential      (access limited to investigators only) code or link between the repository/database and      other information about the participant.|Both|N/A|18 Years|No|Non-Probability Sample|All children up to the age of 18 years undergoing surgery and clinically requiring        Patient/Nurse/Parent Controlled analgesia with opioids (P/NCA), shall be eligible for the        study|November 2012|November 28, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01731873||75817|
NCT01731639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSOME_Grades|Motile Sperm Organelle Morphology Examination (MSOME) Influence on Intracytoplasmic Sperm Injection (ICSI) Outcomes in Infertile Couples|The Influence of Motile Sperm Organelle Morphology Examination on ICSI Outcomes||Sapientiae Institute|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|72|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01731639||75835|
NCT01732159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K110601|Impact of a Checklist on the Rate of Late Cancellation in Ambulatory Surgery|Impact of a Checklist on the Rate of Late Cancellation in Ambulatory Surgery|AMBUPROG|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2012|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4093|||Both|N/A|N/A|No|||April 2015|April 20, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732159||75795|
NCT01732692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-9999-301-RU|Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation|Multicenter Endoscopist-blinded Randomized Parallel-group Comparative Study to Assess Efficacy, Safety and Tolerance of Morning-only Dosing Compared to Control Split-dosing With Nocturnal Pause in MOVIPREP® Bowel Preparation Prior to Colonoscopy||Takeda|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|85 Years|No|||April 2014|April 16, 2014|October 19, 2012||No||No|April 5, 2014|https://clinicaltrials.gov/show/NCT01732692||75754|
NCT01732965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS Vitiligo Phototherapy|NB-UVB and PUVA Vitiligo Study|Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo||Henry Ford Health System|No|Recruiting|March 2013|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732965||75733|
NCT01732978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208093|Are Parents Privileged Listeners Their Baby ?|Are Parents Privileged Listeners Their Baby ?|BABIES_CRY|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|24|||Both|N/A|1 Week|Accepts Healthy Volunteers|||January 2015|January 28, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01732978||75732|
NCT01732705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT-T2DM|High Intensity Interval Training (HIT) in Patients With Type 2 Diabetes|Effect of High Intensity Interval Training (HIT) on Insulin Sensitivity in Patients With Type 2 Diabetes|HIT_T2DM|University of Copenhagen|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01732705||75753|
NCT01722877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-ISR-001, version 1, Rev 2|JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions|Safety and Effectiveness of JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions: A Prospective Registry|JetStreamISR|Midwest Cardiovascular Research Foundation|No|Completed|October 2012|September 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722877||76505|
NCT01723124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004322|Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up|Comparison of Breast Cancer Detection Rate for Prevalent Screen Low-dose Molecular Breast Imaging and Incident Biennial Screen Low-dose Molecular Breast Imaging in Women With Mammographically Dense Breasts||Mayo Clinic|No|Suspended|July 2012|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|2000|||Female|40 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|July 24, 2012||No|Evaluating the quality of images from lower dose of 99m Sestamibi (4mCi).|No||https://clinicaltrials.gov/show/NCT01723124||76486|
NCT01723748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-491-12|Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects|Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects||University of Aarhus|Yes|Active, not recruiting|December 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723748||76438|
NCT01723982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000048|Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions|A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients|BASIC|Ferring Pharmaceuticals|No|Completed|November 2012|May 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Female|18 Years|37 Years|No|||June 2015|June 15, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723982||76420|
NCT01724216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2012-GES-0014|Magnetic Resonance Imaging Using Innovative Pulse Sequences|Magnetic Resonance Imaging Using Innovative Pulse Sequences||GE Healthcare|No|Completed|October 2012|April 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|November 7, 2012|Yes|Yes||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01724216||76402|
NCT01724996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1|Usefulness of Chest Wall Tenderness as Bedside Test to Exclude Acute Coronary Syndrome in Different Demographic Groups|Usefulness of Chest Wall Tenderness as Bedside Test to Exclude Acute Coronary Syndrome in Different Demographic Groups||University of Zurich|No|Completed|October 2012|April 2014|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|16 Years|N/A|No|Non-Probability Sample|Patiens seaking the Emergency room of the University Hospital Zurich because of chest pain|May 2014|May 26, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01724996||76342|
NCT01725009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0038|Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males|A Single-center, Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Levetiracetam Administered as Intravenous Infusion in Japanese and Caucasian Healthy Male Subjects||UCB Pharma|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725009||76341|
NCT01725841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809012R|The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan|The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan||National Taiwan University Hospital|Yes|Completed|April 2009|September 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|300|None Retained|bacterial isolates|Both|N/A|N/A|No|Probability Sample|ENTEROBACTERIACEAE FROM TSAR COLLECTION|November 2012|November 8, 2012|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01725841||76277|
NCT01725633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC 14-170|Aerobic Training in Metastatic Breast Cancer|Phase II Trial of Aerobic Training in Metastatic Breast Cancer|Breast Mets|Memorial Sloan Kettering Cancer Center||Recruiting|December 2010|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Female|21 Years|N/A|No|||March 2016|March 2, 2016|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01725633||76293|
NCT01725646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM3-99001|An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients|A Randomized, Double-blinded, Placebo-controlled Study to Assess the Efficacy and Safety of Omacor® in Taiwanese Hypertriglyceridemic Patients||Excelsior|No|Completed|July 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|253|||Both|20 Years|79 Years|No|||May 2014|May 16, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01725646||76292|
NCT01722448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0504|Nutritional Prevention of Exertional Muscle Dysfunction|Nutritional Prevention of Exertional Muscle Dysfunction|MUSREC|University of North Carolina, Chapel Hill|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722448||76538|
NCT01722461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-119|A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis|A Prospective, Multi-Center, Parallel, Randomized, Double-Blinded Study of the Efficacy and Safety of the Ulthera® System for the Treatment of Primary Axillary Hyperhidrosis||Ulthera, Inc|Yes|Terminated|November 2012|November 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|November 2, 2012|Yes|Yes|Sponsor decision; unexpectedly high sham response at primary outcome time point.|No||https://clinicaltrials.gov/show/NCT01722461||76537|
NCT01723579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07057|Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)|An Open-label, Multi-center Trial to Evaluate the Contraceptive Efficacy, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) in Indian Women. Protocol MK-8175A-017-00||Merck Sharp & Dohme Corp.|No|Withdrawn|July 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723579||76451|
NCT01723592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW EK 1417/2012|The Ability of Orally Administered Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.|The Ability of an Orally Administered Preparation of Four Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy. A Prospective Randomized Placebo-controlled, Double-blind Trial||Medical University of Vienna|Yes|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|N/A|No|||April 2015|April 9, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723592||76450|
NCT01722981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-PS-0408-12-CTIL|Percutaneous Tracheostomy - Systematic Comparison Among Three Methods: Prospective Study|Percutaneous Tracheostomy - Systematic Comparison Among Three Methods: US-guided Tracheostomy, Bronchoscopy Guided Tracheostomy, and Direct Laryngoscopy Tracheostomy.||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01722981||76497|
NCT01723241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XAF5 A1|Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers|A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose Study to Assess the Safety and Tolerability of XAF5 Gel Applied to the Skin of Healthy Volunteers||Topokine Therapeutics, Inc.|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||April 2013|January 9, 2016|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723241||76477|
NCT01724346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1116-CA|An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)|An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)||Pharmacyclics|No|Active, not recruiting|January 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|232|||Both|65 Years|N/A|No|||September 2015|September 25, 2015|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724346||76392|
NCT01731353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fungi001|Fungiscope - A Global Emerging Fungal Infection Registry|Fungiscope - A Global Emerging Fungal Infection Registry|Fungiscope|University of Cologne|No|Recruiting|March 2003|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|-  fixed tissue        -  fungal culture|Both|N/A|N/A|No|Non-Probability Sample|Invasive infections caused by emerging fungi|December 2014|December 5, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731353||75856|
NCT01731925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNLAND D12-01|A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors|A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS|SUNLAND|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01731925||75813|
NCT01731938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1103|Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries||Grifols Biologicals Inc.|No|Completed|November 2012|June 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|327|||Both|N/A|N/A|No|||October 2015|October 14, 2015|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731938||75812|
NCT01731899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-2010|Agomelatine in Depressed Patients With Fibromyalgia|Observational Study Evaluating the Efficacy and Tolerability of Agomelatine in the Treatment of Depressed Patients With Fibromyalgia||Universidad de Granada|No|Completed|June 2010|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients suffering fibromyalgia and concomitant major depression|May 2014|May 6, 2014|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01731899||75815|
NCT01732419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDSS FIT@Home|Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation|Effects of Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation|FIT@Home|Maxima Medical Center|No|Completed|January 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|N/A|N/A|No|||March 2016|March 15, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732419||75775|
NCT01732718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1354|Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease|The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)|ENDO|University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|19|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732718||75752|
NCT01732991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 2012 - FB / PROPIL|Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound|Assessing the Impact of the Prostatic Photo-vaporization (PVP) With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound|PROPIL|University Hospital, Tours|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||August 2015|August 31, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732991||75731|
NCT01724463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eASSIST-M|Electronic Application of a Severe Sepsis Screening Tool and Management Bundle|Application of a Severe Sepsis Electronic Health Record Integrated Screening Tool and Management Bundle Study to Improve Sepsis Related Outcomes|eASSIST-M|University of Tennessee|No|Recruiting|March 2013|October 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|1 Month|18 Years|No|Non-Probability Sample|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to        the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response        Syndrome (SIRS).|March 2015|March 30, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01724463||76383|
NCT01724723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH-IRB-201109046MB|Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment|Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment|HBV|National Taiwan University Hospital|No|Not yet recruiting|December 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|80 Years|No|||November 2012|November 7, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01724723||76363|
NCT01725282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0005|Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder|Phase II Study of FK949E -Placebo-controlled, Double-blind, Parallel-group Comparative Study in Major Depressive Disorder Patients With Lack of Response to Existing Antidepressants-||Astellas Pharma Inc|No|Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|172|||Both|20 Years|64 Years|No|||August 2014|August 14, 2014|November 8, 2012|No|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01725282||76320|
NCT01725581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAT|A Study to Test a New Pelvic Examination Assessment Tool|A Study to Test the Validity and Reliability of an Objective Structured Assessment of Technical Skills in Pelvic Examination|PEAT|Birmingham Women's NHS Foundation Trust|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical students and junior doctors will be approached by the clinical sub dean for O&G at        Birmingham Women's Hospital (Justin Clark - chief investigator) during the beginning of        their O&G placement. They will be made aware that outcome and assessment as part of the        trial will not be incorporated into their final academic grade.|June 2013|April 2, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01725581||76297|
NCT01723761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIAPOL 01|Correlations Between Arrhythmias and Air Pollution in Patients With Pacemaker and ICD|Correlations Between Arrhythmias, Climatic Variables and Air Pollution in Patients With Pacemaker and ICD, Followed by Remote Monitoring.|ARIA|Effect Group, Italy|No|Completed|April 2011|June 2015|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|473|||Both|19 Years|N/A|No|Non-Probability Sample|Males and females, aged ≥ 18 years of age who have been implanted with a dual-chamber        pacemaker, an ICD or ICD-CRT.|July 2015|July 1, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01723761||76437|
NCT01725659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2801R|Innovative Modalities for Restoring Upper Limb Function Post Stroke|Innovative Modalities for Restoring Upper Limb Function Post Stroke||Malcom Randall VA Medical Center|No|Completed|September 2001|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|November 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725659||76291|
NCT01725893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202038RIC|Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity|Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity||National Taiwan University Hospital|Yes|Recruiting|March 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|14|||Both|18 Years|73 Years|No|Probability Sample|There were fourteen patients with checkrein deformity who underwent surgery in our        hospital between 1993 and 2010.|November 2012|November 13, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01725893||76273|
NCT01723267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmcavibh-1|Automated 3D (SonoAVC) Versus 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial|Automated 3D (SonoAVC) vs 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial||Rabin Medical Center|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Female|18 Years|39 Years|No|||July 2012|November 5, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01723267||76475|
NCT01723865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect|Clinical Efficacy of Remote Monitoring in the Management of Heart Failure|Clinical Efficacy of a Specifically Dedicated Remote Monitoring System in the Management of Patients With Heart Failure and ICD&CRT-D.|EFFECT|Effect Group, Italy|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|988|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of both gender implanted or eligible for implant with ICD-CRT-D, for heart        failure treatment and/or primary prevention of sudden death, followed or not by a remote        monitoring system.|August 2014|August 4, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01723865||76429|
NCT01723852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDI-2012-01|Vitamin D Intervention in Infants|Vitamin D Intervention in Infants|VIDI|Helsinki University Central Hospital|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|N/A|5 Days|Accepts Healthy Volunteers|||December 2014|December 5, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723852||76430|
NCT01724099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP001|Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity|A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Euiiyin-tang on Obese Patients||Kyunghee University Medical Center|No|Recruiting|October 2012|May 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|65 Years|No|||December 2015|December 10, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01724099||76411|
NCT01724359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017413|Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia|PERFLEX|Janssen-Cilag, S.A.|No|Completed|February 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|November 7, 2012||No||No|November 27, 2012|https://clinicaltrials.gov/show/NCT01724359||76391|
NCT01731366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M206|The Effect of Whole Grain on Gut Microbiome and Metabolic Health|Gut, Grain and Greens (3G): The Effect of Wholegrain on Gut Microbiome and Metabolic Health|3G|University of Copenhagen|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 1, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731366||75855|
NCT01732770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110153|Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis|A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates||Amgen|No|Completed|November 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|643|||Female|55 Years|N/A|No|||January 2016|January 28, 2016|November 20, 2012|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT01732770||75748|
NCT01732432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210/12|Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)|Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) - Epidemiological and Molecular Pathological Aspects|EAOC|University Hospital, Basel, Switzerland|Yes|Withdrawn|October 2012|December 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Female|30 Years|85 Years|No|Non-Probability Sample|primary care hospital, university hospital|March 2015|March 31, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01732432||75774|
NCT01727375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreDeLight-ICU|Prevention of Delirium With Light in the Intensive Care Unit|Prevention of Delirium With Light in the Intensive Care Unit|PreDeLight-ICU|Charite University, Berlin, Germany|No|Withdrawn|July 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01727375||76162|
NCT01727609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIFT01|Speed of Increasing Milk Feeds Trial|A Multi-centre Randomised Controlled Trial of Two Speeds of Daily Increment of Milk Feeding in Very Preterm or Very Low Birth Weight Infants|SIFT|University of Oxford|Yes|Active, not recruiting|February 2013|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2806|||Both|N/A|32 Weeks|No|||August 2015|August 7, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01727609||76144|
NCT01727856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0060|Usability and Reliability of a New Physical Therapy Tool|An Evaluation of a Novel Motion Tracking Enabled Knee Physical Therapy Application With Healthy Patients to Assess Reliability and Usability||Reflexion Health, Inc.|No|Completed|October 2012|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy males and femailes, ages 18-35|November 2014|November 5, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01727856||76125|
NCT01727869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1400-ST-1113|Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer|||Regeneron Pharmaceuticals|No|Completed|October 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|November 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727869||76124|
NCT01727817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0052904|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy)|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy||University of Virginia|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|64 Years|No|||September 2014|September 29, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727817||76128|
NCT01727830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2012-0042|Hemodilution and Coagulopathy With 3 Colloids|Influence of Hemodilution on Coagulation, pH, Platelet Function, Laboratory Values and ROTEM in Volunteers Using HES 6%, Gelatine and Balanced Gelatine and the Reversal of Coagulopathy With F XIII and Fibrinogen||University of Zurich|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|volunteers|November 2012|November 12, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01727830||76127|
NCT01721174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 2012.153|Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures|A Randomized Controlled Trial of Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures.||Chinese University of Hong Kong|No|Recruiting|November 2012|||November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721174||76636|
NCT01721421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-LL-0505|Effects of Extended Haemodialysis Treatment Duration in Patients With End-stage Renal Disease|Feasibility and Physiological and Nutritional Effects of Extended Treatment Duration in Patients With End-stage Renal Disease on Haemodialysis||Imperial College London|No|Recruiting|September 2011|February 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|52|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721421||76617|
NCT01718314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEK 11/33-21|Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Hysteroscopy|Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Pain Relief in Office Hysteroscopy: A Randomized, Double Blind, Placebo-Controlled Trial||Dr. Sami Ulus Children's Hospital|No|Completed|March 2008|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Female|18 Years|51 Years|No|||October 2012|October 30, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718314||76854|
NCT01718639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/012512|Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn|Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn||InQpharm Group|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 7, 2013|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01718639||76829|
NCT01718054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFIT001|Vascular Function Intervention Trial in Sickle Cell Disease|Development of a Ready-to-use Nutraceutical Food for Patients With Sickle Cell Disease (SCD): Testing of Vascular Support Components|V-FIT|London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|August 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|11 Years|No|||March 2013|March 25, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01718054||76874|
NCT01724606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-046|Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)|Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study||Memorial Sloan Kettering Cancer Center||Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724606||76372|
NCT01724866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-GCF-12-201|Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients|Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen||Spectrum Pharmaceuticals, Inc|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|148|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724866||76352|
NCT01725139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116711|A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||GlaxoSmithKline|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Anticipated|24|||Both|45 Years|N/A|No|||June 2015|June 4, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725139||76331|
NCT01725451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15083|A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants|Effects of Deodorant and Antiperspirant Use and the Presence of Axillary Hair on the Absorption of Testosterone Applied as Testosterone 2% Solution||Eli Lilly and Company|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|30|||Male|50 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 7, 2014|November 8, 2012|No|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01725451||76307|Not specified.
NCT01725750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1256|Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy|Treatment of Post-TBI Fatigue With Light Therapy||Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2012|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725750||76284|
NCT01730183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPSC/POC/BMSC/SCI|To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury|To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury (SCI)|ABSCI|Max Institute of Neurosciences|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||November 2012|November 15, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730183||75946|
NCT01726257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0008|Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System|Prospective, Multicenter, Single Arm Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System: A Pivotal and Continued Access Study|EVAS IDE|Endologix|Yes|Recruiting|December 2013|June 2021|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|279|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726257||76246|
NCT01730729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12B06|Cabergoline in Metastatic Breast Cancer|A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer||Northwestern University|Yes|Active, not recruiting|November 2012|||October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730729||75904|
NCT01726764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-382|Interaction Between St John's Wort and Metformin?|Is There a Pharmacokinetic Interaction Between St John's Wort and Metformin?||University of Southern Denmark|No|Completed|January 2013|May 2014|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01726764||76207|
NCT01727089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02206|Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2012|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|February 11, 2016|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727089||76182|
NCT01727388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-PR-REGIMBEAU|Informativeness to Digital Rectal Examination|Prospective Randomized Study Comparing the Results of Digital Rectal Examination in the Supine and Lateral Decubitus|RIFIONA|Centre Hospitalier Universitaire, Amiens|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|320|||Male|18 Years|N/A|No|||November 2013|November 26, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01727388||76161|
NCT01727622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815471|Arterial Spin Labeling (ASL) MRI for Cognitive Decline|Optimized Arterial Spin Labeling MRI for Cognitive Decline||University of Pennsylvania|Yes|Recruiting|August 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|55 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727622||76143|
NCT01727882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535629|Automated Telephone Follow-up in the Swedish Prison and Probation Services|Automated Telephone Follow-up in the Swedish Prison and Probation Services. A Randomized Controlled Trail.||Region Skane|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|108|||Both|N/A|N/A|No|||November 2012|November 12, 2012|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01727882||76123|
NCT01727895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Betaglucan_immunity|Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans|Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans, a Pilot Study|BG|Radboud University|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|36 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|November 12, 2012||No||No|July 1, 2014|https://clinicaltrials.gov/show/NCT01727895||76122|
NCT01728116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1|Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese|A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents|ENDO|GI Dynamics|Yes|Terminated|December 2012|December 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|406|||Both|21 Years|65 Years|No|||October 2014|July 31, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728116||76105|
NCT01721733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI743-12-002|Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome|A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome||Edison Pharmaceuticals Inc|Yes|Completed|October 2012|May 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|17 Years|No|||October 2013|March 18, 2016|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721733||76593|
NCT01722019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/693|Prospective Multicentric Trial Between Radiofrequency Ablation With VNUS Closure Fast ® and Endovenous Ablation With 1470 nm Diode Laser and Tulip Fiber ® for Treatment of Primary Venous Insufficiency.|Prospective Multicentric Randomised Trial Between Radiofrequency Ablation With VNUS Closure Fast ® and Endovenous Ablation With 1470 nm Diod Laser and Tulip Fiber ® for Treatment of Primary Venous Insufficiency.|VNUS vs TULIP|University Hospital, Ghent|No|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01722019||76571|
NCT01717833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN01032010|The Role of NEMS for Post ICU Rehabilitation|The Role of Neuromuscular Electrical Stimulation as a Tool for Post ICU Rehabilitation||University of Athens|No|Active, not recruiting|November 2010|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||June 2015|June 17, 2015|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01717833||76891|
NCT01718093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29924|A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes|A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Mellitus||Baylor College of Medicine|Yes|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|13 Years|18 Years|No|||May 2012|October 29, 2012|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01718093||76871|
NCT01718925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3256|25-hydroxyvitamin D and Fatigue: The VITALITY Study|Vitamin D, Fatigue and Patient Reported Outcome (PRO) in Chronic Somatic and Functional Disorders.||Ostfold Hospital Trust|No|Completed|October 2012|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|614|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an established diagnose of IBD, DIA, IBS or RA is eligible for inclusion in        this study. Patients must be over 18 years of age. Disease activity will be measured using        the SCCAI for ulcerative colitis, SCDAI for Crohn's disease, DAS-28 for rheumatoid        arthritis. In Dia and IBD objective activity measures, such as calprotectin in stools and        HbA1C, will be collected.|October 2015|October 14, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718925||76808|
NCT01724879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL-PH-01|Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)|Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)||Johann Wolfgang Goethe University Hospitals|Yes|Completed|November 2011|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|55 Years|No|||February 2016|February 10, 2016|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01724879||76351|
NCT01724892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|othana001|Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing|||Khon Kaen University|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|40 Years|No|||March 2014|March 14, 2014|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724892||76350|
NCT01725152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0800|Ganaxolone Treatment in Children With Fragile X Syndrome|A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome||Marinus Pharmaceuticals|Yes|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|17 Years|No|||March 2016|March 14, 2016|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725152||76330|
NCT01725464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|541/2555(EC)|The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy|The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy||Mahidol University|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725464||76306|
NCT01725477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Methylen blue|Laparoscopic Tubal Patency Assessment|||Pourmatroud, Elham, M.D.|Yes|Active, not recruiting|September 2012|March 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725477||76305|
NCT01729923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7707|A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer|A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer|ADAPT|University of Washington|No|Recruiting|March 2013|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729923||75966|
NCT01730742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192837465|Sleep Deprivation's Regulation of Immune System Function and Behavior|The Role of Sleep Deprivation in the Regulation of Immune System, Neuroendocrine Responses, and Behavioral Measures.|SS|Uppsala University|No|Active, not recruiting|February 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 15, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01730742||75903|
NCT01730469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116431|Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function|An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)||Amicus Therapeutics|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730469||75924|
NCT01727063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRTCC-ISQ2|Cell Therapy in Severe Chronic Ischemic Heart Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery|MiHeart|Ministry of Health, Brazil|Yes|Recruiting|January 2006|July 2013|Anticipated|July 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2012|November 12, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727063||76184|
NCT01727115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.04.INF|Althera® Versus Nutramigen / Cow's Milk Intolerance|Comparison of Two Extensively Hydrolyzed Formulas for the Treatment of Children With Cow's Milk Intolerance||Nestlé|Yes|Completed|April 2008|July 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|N/A|6 Months|No|||November 2012|November 12, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727115||76181|
NCT01727128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120C2104|Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment|A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairmen||Novartis|No|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|31|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 26, 2014|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727128||76180|
NCT01727141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2336|A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.|A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.||Novartis|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1042|||Both|40 Years|N/A|No|||July 2015|July 13, 2015|November 12, 2012|No|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01727141||76179|
NCT01727401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/2012|Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia|Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia|FAITH|G. d'Annunzio University|Yes|Recruiting|November 2012|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|117|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727401||76160|
NCT01727414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADDMedStudy|Attention Deficit Disorder Medication Response Study|Medication Response in Children With Predominately Inattentive Type ADHD||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2006|July 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|165|||Both|7 Years|11 Years|No|||November 2012|November 15, 2012|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727414||76159|
NCT01728168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H54-12|Prevalence of Food Allergies to Proteins From Different Legumes|Prevalence of Food Allergies to Proteins From Different Legumes (Lupin, Peanut, Soy, and Pea) in Atopic and Healthy Subjects||University of Jena||Completed|December 2012|December 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|183|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female subjects. Age: 18 to 75 years. Subjects with Atopy or non-atopic subjects.|February 2014|February 3, 2014|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01728168||76101|
NCT01728181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI59004|A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation|A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation||University of Utah|Yes|Withdrawn|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|November 12, 2012|Yes|Yes|Stopped before approval due to ineffective drug|No||https://clinicaltrials.gov/show/NCT01728181||76100|
NCT01728129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10228|DANA Compared to MACE in Evaluation of Suspected Acute Concussion|Comparison of the Defense Automated Neurobehavioral Assessment (DANA) Tool to the Military Acute Concussion Evaluation (MACE) in the Evaluation of Suspected Acute Concussion||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Recruiting|January 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|220|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01728129||76104|
NCT01717820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16850|Effect of Whole-grape Powder on Body Composition, Fat and Bone Serum Biomarkers in Postmenopausal Women|The Effect of Whole-grape Powder on Body Composition, Fat, and Bone Serum Biomarkers in Postmenopausal Women||Texas Woman's University|Yes|Completed|April 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01717820||76892|
NCT01718067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2793|Efficacy of Vakum Technology in Patients With Chronic Hypersecretion|Efficacy of Vakum Technology in Patients With Chronic Hypersecretion.||Villa Pineta Hospital|No|Recruiting|January 2013|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||December 2014|December 9, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01718067||76873|
NCT01718080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29652|The Effects of Puberty and Weight on Sugar Metabolism in Children|The Role of Puberty and Insulin Resistance in the Development of Hyperglucagonemia||Baylor College of Medicine|No|Recruiting|January 2012|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|64|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prepubertal and pubertal subjects.|March 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718080||76872|
NCT01722058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00068009|A Phase I In-Vivo Peptide Applied in the Right Colon|A Phase I In-Vivo Colon Protocol for Detection of Neoplasia in the Digestive Tract (U54)||University of Michigan|Yes|Completed|February 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 14, 2013|October 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722058||76568|
NCT01718340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetRPL|Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia|Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages|MetRPL|Woman's Health University Hospital, Egypt|Yes|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|396|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 25, 2014|August 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718340||76852|
NCT01718678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-12111|Effect of Melatonin on Multiple Sclerosis Related Fatigue|Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis||Isfahan University of Medical Sciences|Yes|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01718678||76827|
NCT01718691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011002|Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma|||SymBio Pharmaceuticals||Completed||||||Phase 2|Interventional|N/A|1||||||Both|20 Years|79 Years|No|||December 2013|December 17, 2013|October 29, 2012||||No||https://clinicaltrials.gov/show/NCT01718691||76826|
NCT01718327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-CK D09-2|A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma|A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma|SUN-CK|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Active, not recruiting|September 2011|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01718327||76853|
NCT01729182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961PC00002|Nexium Capsules LDA Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With LDA||AstraZeneca||Active, not recruiting|January 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|The patients who are continuously given Low dose Aspirin (LDA) to suppress        thrombus/embolism and who will be given Nexium for the first time to suppress recurrence        of gastric ulcer and duodenal ulcer.        (Patients who have previous experience of Nexium given in the treatment for gastric ulcer        or duodenal ulcer can be registered to this S-CEI.)|January 2016|January 25, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729182||76023|
NCT01729442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.730|Assessment of HIFU-induced Prostate Necrosis With Shear-wave Ultrasound Elastography|Transrectal Prostate Cancer High-Intensity Focused Ultrasound Ablation: Assessment of Tissue Destruction With Shear-wave Ultrasound Elastography|IDITOP-1|Hospices Civils de Lyon|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|30|||Male|18 Years|N/A|No|||October 2014|October 21, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729442||76003|
NCT01729429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP100047|An Intervention Promoting HPV Vaccination in Safety-net Clinics|An Intervention Promoting HPV Vaccination in Safety-net Clinics||University of Texas Southwestern Medical Center|No|Completed|May 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|831|||Female|11 Years|18 Years|Accepts Healthy Volunteers|||December 2012|April 30, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729429||76004|
NCT01729689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0053|Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers|Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers||Stanford University||Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|N/A|N/A|No|||August 2014|August 20, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729689||75984|
NCT01730209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38619.078.11|Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex|Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex|RAPIT|Erasmus Medical Center|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|15 Years|No|||May 2015|May 4, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01730209||75944|
NCT01730482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116435|A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C] AT1001 (Migalastat Hydrochloride) Following a Single Oral Administration in Healthy Volunteers (AT1001-014)||Amicus Therapeutics|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730482||75923|
NCT01726491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007028|Epigenetics and the Origin of Muscle Insulin Resistance in Humans|Epigenetics and the Origin of Muscle Insulin Resistance in Humans||Mayo Clinic|No|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|72|Samples With DNA|thigh muscle biopsies bloodsamples|Both|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of volunteers will be studied: 1) lean, healthy volunteers, 2)obese        volunteers without type 2 diabetes, and 3) volunteers with type 2 diabetes.|January 2016|January 13, 2016|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726491||76228|
NCT01730508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28516|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B|A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA||Hoffmann-La Roche||Active, not recruiting|November 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|978|||Both|18 Years|N/A|No|Probability Sample|Chinese patients with HBeAg negative chronic hepatitis B receiving treatment with Pegasys|March 2016|March 1, 2016|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730508||75921|
NCT01726777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTRS-27546|Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D.|Effect of Vitamin D Supplementation on Oral Glucose Tolerance in Subjects Exhibiting Marginal Vitamin D Status and an Increased Risk of Developing Diabetes.|EVIDENCE|University of Toronto|No|Completed|October 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|75 Years|No|||September 2015|September 15, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726777||76206|
NCT01727076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02205|Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer|A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-small Cell Lung and Squamous Cell Head and Neck Cancer||National Cancer Institute (NCI)||Recruiting|February 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||March 2016|March 10, 2016|November 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727076||76183|
NCT01727908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol ID 2012/270|Screening for Familial Gastric Cancer in First Degree Relatives|Screening for Familial Gastric Cancer in First Degree Relatives|FamGaCan|Radboud University|Yes|Active, not recruiting|November 2012|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727908||76121|
NCT01728155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINES|European Low and Intermediate Risk Neuroblastoma Protocol|European Low and Intermediate Risk Neuroblastoma Protocol||Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|December 2011|December 2026|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|685|||Both|90 Days|18 Years|No|||July 2015|July 21, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728155||76102|
NCT01728480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 209611|Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy|A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy||Roswell Park Cancer Institute|Yes|Withdrawn|January 2014|||October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 13, 2012|Yes|Yes|Financial Sponsor requested termination|No||https://clinicaltrials.gov/show/NCT01728480||76077|
NCT01728142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10244|Comparison of the DANA to the ANAM in the Evaluation of Cognitive Changes After Concussion|Comparison of the Defense Automated Neurobehavioral Assessment (DANA) Brief Exam to the Automated Neuropsychological Assessment Metrics (ANAM) Battery in the Evaluation of Cognitive Changes During Concussion Recovery||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Recruiting|January 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|118|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728142||76103|
NCT01721772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-066|Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma|A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|CheckMate 066|Bristol-Myers Squibb|Yes|Terminated|January 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|583|||Both|18 Years|N/A|No|||November 2015|January 27, 2016|November 2, 2012|Yes|Yes|The study was terminated early due to the clear benefit of nivolumab on survival|No|November 20, 2015|https://clinicaltrials.gov/show/NCT01721772||76590|An independent data monitoring committee (DMC) found that data from a DMC-requested database lock showed clear survival benefit with nivolumab and thus recommended unblinding the study and switching patients randomized to dacarbazine to nivolumab.
NCT01722071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR024986|Deciphering the Role of Oxytocin in Motivation: an fMRI Study|Deciphering the Role of Oxytocin in Motivation: an fMRI Study||University of Michigan|No|Completed|October 2012|October 2015|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 29, 2012|No|Yes||No|April 22, 2015|https://clinicaltrials.gov/show/NCT01722071||76567|
NCT01717846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-356|Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis|In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis|RA|University of California, Los Angeles|No|Not yet recruiting|December 2012|November 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|85 Years|No|||October 2012|October 30, 2012|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717846||76890|
NCT01717885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04798|Antimalarial Pharmacology in Children and Pregnant Women in Uganda|Antimalarial Pharmacology in HIV Infected and Uninfected Children and Pregnant Women in Uganda||University of California, San Francisco|No|Recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|458|Samples With DNA|Samples are for drug level measurements,parasite density. RNA samples are for host      transcriptional and molecular markers of resistance. Samples are also retained for future      use including possible genetic testing for drug metabolism variants|Both|6 Months|N/A|No|Non-Probability Sample|HIV infected and uninfected children and pregnant women residing in Tororo, Uganda and        receiving care at local health care facilities including the Tororo District Hospital        (TDH), perinatal facilities, HIV clinics and the IDRC research clinic. HIV uninfected        children, pregnant women and non-pregnant adults also enrolled through TDH, perinatal        facilities or other area clinics. Each participant can enroll at the time they present to        one of the clinics with uncomplicated malaria|October 2014|October 29, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01717885||76887|
NCT01717898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC#125510|A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer|A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer||University of California, San Francisco|Yes|Terminated|January 2013|June 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|October 23, 2012|No|Yes|Dose limiting toxicities on lowest dose level|No||https://clinicaltrials.gov/show/NCT01717898||76886|
NCT01718951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC/769/09|Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial|Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial||Tuen Mun Hospital|No|Completed|August 2012|October 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718951||76806|
NCT01729455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116543|Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry|A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)|SABLE|GlaxoSmithKline|Yes|Recruiting|February 2013|April 2025|Anticipated|April 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|General population: patients with active autoantibody-positive SLE.|February 2016|March 10, 2016|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729455|12 Years|76002|
NCT01729702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08|Neurohormonal Parameters in Hypertrophic Cardiomyopathies|Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies|REEF-CMH|French Cardiology Society|No|Completed|April 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|131|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01729702||75983|
NCT01729715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00439|Helping Young Children Sleep|Helping Young Children Sleep||Nationwide Children's Hospital|No|Active, not recruiting|November 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||January 2016|January 28, 2016|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01729715||75982|
NCT01729936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01082|SedestActiv Project: Intervention to Reduce Diary Hours of Sitting Time in Overweight and Obese Patients|Effectiveness of an Intervention to Reduce Diary Hours of Sitting Time in Overweight and Obese Patients (SEDESACTIV):Simple Randomized Controlled Trial|SedestActiv|Jordi Gol i Gurina Foundation|Yes|Recruiting|June 2012|December 2016|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|450|||Both|25 Years|65 Years|No|||February 2014|February 7, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01729936||75965|
NCT01730196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK082401|Lifestyle Change to Prevent Diabetes Via African-American Churches|Fit Body and Soul: A Lifestyle Intervention for Diabetes Prevention Conducted Through African American Churches||Georgia Regents University|Yes|Completed|September 2009|April 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|604|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730196||75945|
NCT01730495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2500|Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome|Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab.||Haukeland University Hospital|No|Terminated|October 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|66 Years|No|||November 2015|November 30, 2015|November 8, 2012|Yes|Yes|After inclusion of four patients, two experienced moderate worsening of symptoms|No||https://clinicaltrials.gov/show/NCT01730495||75922|
NCT01726816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-KOA-1201i|Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy|A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|October 2012|September 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|126|||Both|20 Years|80 Years|No|||January 2015|January 27, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01726816||76203|
NCT01727154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4|Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T|Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T|PRIME|Dendreon|No|Recruiting|October 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Whole blood, serum, manufacturing samples|Male|18 Years|N/A|No|Non-Probability Sample|Men at least 18 years of age with prostate cancer who are enrolled in a clinical trial of        sipuleucel-T (including a Dendreon-sponsored clinical trial or registry, or an IIT), and        have not yet undergone leukapheresis for their first dose of sipuleucel-T.|February 2016|February 29, 2016|November 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727154||76178|
NCT01726790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE541020|Effect of Intravitreal Bevacizumab on Corneal Endothelium|Effect of Intravitreal Bevacizumab on Corneal Endothelium||Khon Kaen University|Yes|Recruiting|August 2011|October 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|37|||Both|18 Years|80 Years|No|Non-Probability Sample|Patient in retinalvascular clinic with diagnosis of retinal vein occlusion with macular        edema, diabetic macular edema, wet aged related macular degeneration and submacular        hemorrhage)treated with intravitreal Bevacizumab|November 2012|November 11, 2012|November 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01726790||76205|
NCT01726803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS018672|Comparative Effectiveness of Acute Low Back Pain Management|Comparative Effectiveness of Management Strategies for Acute Low Back Pain||University of Utah|Yes|Completed|April 2011|November 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|60 Years|No|||November 2014|May 27, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01726803||76204|
NCT01727635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200909010R|The Long-term Effects of Body-mind-spirit Group Therapy|The Long-term Effects of Body-mind-spirit Group Therapy on Close Relationships, Sleeping Quality, Depression, Quality of Life, Meaning of Life, and Saliva Cortisol Responses in Breast Cancer Survivors and Partners||National Taiwan University Hospital|No|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|60|||Both|18 Years|65 Years|No|||November 2012|November 12, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01727635||76142|
NCT01728194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH097735-01|Emotional and Cognitive Control in Late-Onset Depression|White Matter and Emotional and Cognitive Control in Late-Onset Depression||Weill Medical College of Cornell University|Yes|Recruiting|July 2012|||July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|140|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||November 2012|November 12, 2012|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728194||76099|
NCT01728207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-114-01|Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL|A Phase I Dose Escalation Study of Immunotherapy With IMMU-114 in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)||Immunomedics, Inc.|No|Recruiting|March 2013|August 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728207||76098|
NCT01729039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7613-R|Vestibular Rehabilitation and Dizziness|Vestibular Rehabilitation and Dizziness in Geriatric Patients|DZO|VA Office of Research and Development|No|Recruiting|November 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|97|||Both|50 Years|N/A|No|||November 2015|November 4, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729039||76034|
NCT01728454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPE-202|The Evaluation of Safety and Efficacy of Proellex in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis|A Phase 2, Multi-Center, Three-Arm, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis||Repros Therapeutics Inc.|Yes|Recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|47 Years|No|||October 2015|January 7, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728454||76079|
NCT01728467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-010|The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes|Phase 2 Randomised, Double-blind, Placebo-controlled, Cross-over Study for the Assessment of Glucose Metabolism Changes With RVX000222 in Individuals With Pre-diabetes||Resverlogix Corp|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|70 Years|No|||March 2014|March 31, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728467||76078|
NCT01722084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/380|Community-embedded Reproductive Health Care for Adolescents in Latin America.|Community-embedded Reproductive Health Care for Adolescents in Latin America (CERCA).|CERCA|University Ghent|No|Completed|July 2011|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9625|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01722084||76566|
NCT01717859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28542|Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab|Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab|RASTS|University of California, Los Angeles|No|Recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|51|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717859||76889|
NCT01717872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lerman Blade study|Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age|Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age||State University of New York at Buffalo|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|2 Years|No|||August 2013|August 1, 2013|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01717872||76888|
NCT01718743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0277|MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients|Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2012|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01718743||76822|
NCT01718990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPG-IPF|Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis|Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months.||University of California, San Francisco|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Serum, plasma, Bronchiolavage (BAL) supernatant, and BAL cell pellets|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|IPF|December 2015|December 1, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718990||76803|
NCT01718106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|846/CE|Single Long vs Two Short Overlapping Bioabsorbable Polymer DES|Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent vs 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis.|ROCCO|Azienda Ospedaliero Universitaria Maggiore della Carita|Yes|Recruiting|March 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|October 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01718106||76870|
NCT01718119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3803_HCG_III|Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel|Phase III Clinical Trial Comparing the Efficacy and Safety of DA-3803(Recombinant Human Chorionic Gonadotrophin) and Ovidrel for Inducting Final Follicular Maturation and Early Luteinization in Women Undergoing Ovulation|DA-3803|Dong-A ST Co., Ltd.|No|Completed|February 2012|||February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|180|||Female|20 Years|38 Years|No|||August 2013|August 12, 2013|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01718119||76869|
NCT01729195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A204-CI-1|Ankle Syndesmosis Fixation by Antibiotic Releasing Bioabsorbable Screw|An Antibiotic Releasing Bone Screw: a Randomized Clinical Trial of Patients With Weber C Type Ankle Fractures||Turku University Hospital|No|Completed|March 2006|January 2014|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||February 2014|February 14, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729195||76022|
NCT01729208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVI08008|An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression|A Multicentre Dispensing Clinical Evaluation of MiSight® Lenses||Coopervision, Inc.|No|Active, not recruiting|November 2012|May 2019|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|8 Years|12 Years|No|||January 2016|January 20, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729208||76021|
NCT01729741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rec Ref 2010-139|Drain or no Drain After Thyroid Surgery: a Randomized Clinical Trial at Mulago Hospital|Drain or no Drain After Thyroid Surgery: a Randomized Clinical Trial at Mulago Hospital||Makerere University|Yes|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|68|||Both|18 Years|79 Years|No|||December 2010|November 19, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729741||75980|
NCT01729728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503/68|Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain|Open-label Evaluation of the Pharmacokinetic Profile, Safety, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children and Adolescents Aged From 2 Years to Less Than 18 Years.||Grünenthal GmbH||Completed|November 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|2 Years|17 Years|No|||July 2015|July 16, 2015|November 6, 2012|Yes|Yes||No|September 9, 2014|https://clinicaltrials.gov/show/NCT01729728||75981|Another opioid may been given according to medical judgment/standard of care if the participant had persistent intolerable pain 2 hours or more after administration of tapentadol oral solution despite having received a non-opioid analgesic.
NCT01729949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPF 2012-073|The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)|A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)||Institute for Food Safety and Health, United States|No|Active, not recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01729949||75964|
NCT01726829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc007053ctil|Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home|Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home, Pilot Study.||Rabin Medical Center|No|Active, not recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|10 Years|65 Years|No|||May 2014|March 18, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01726829||76202|
NCT01726504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01|The Efficacy and Safety Study of Electro-acupuncture for Severe Chronic Functional Constipation|The Efficacy and Safety Study of Electro-acupuncture for Severe Chronic Functional Constipation - a Multi-center, Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|October 2012|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1075|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|October 30, 2012||No||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01726504||76227|The 8-week treatment and 12-week follow-up may not be long enough for EA to show its specific therapeutic effect. Efficacy of electro-acupuncture in relieving severe constipation was evaluated without classifying the types of constipation.
NCT01727648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112104RIB|Effects of RAT in Sequential Combination With CIT in Stroke Rehabilitation|Effects of Robot-Assisted Therapy in Sequential Combination With Constraint-Induced Therapy in Stroke Rehabilitation||National Taiwan University Hospital|No|Recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|92|||Both|20 Years|75 Years|No|||December 2012|December 19, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01727648||76141|
NCT01727921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08-066-001|Comparative Study of 22 and 25 Gauge ProCore EUS-guided Biopsy in Pancreatic Mass|Endoscopic Ultrasound-guided Fine Needle Tissue Acquisition With 22- and 25-gauge ProCore Needle in Solid Pancreatic and Peripancreatic Masses: A Prospective Comparative Study||Samsung Medical Center|Yes|Completed|January 2013|November 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|219|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01727921||76120|
NCT01728740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15420|Bioequivalence Study for Acarbose / Metformin FDC|Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healthy Adult Male Subjects||Bayer|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01728740||76057|
NCT01728753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T705aUS213|T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza|Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza|FAVOR|MDVI, LLC|Yes|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|550|||Both|18 Years|80 Years|No|||September 2015|September 30, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728753||76056|
NCT01728727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120912-3|Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis||Fourth Military Medical University|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2012|November 13, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01728727||76058|
NCT01722110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-10/436|Bioequivalence Study of Indomethacin Extended-Release Capsules 75 mg Under Fed Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Indomethacin Extended-Release Capsules 75 mg of Ipca Laboratories Ltd., With Indomethacin Extended-Release Capsules USP 75 mg of Epic Pharma, USA, in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.||IPCA Laboratories Ltd.|Yes|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 2, 2012|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722110||76564|
NCT01722123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn -816696|Effects of Frequent Decision Making Among Patients With Serious Illnesses|Pilot Study of Repeated Decision Making in Patients||University of Pennsylvania|No|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Anticipated|66|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01722123||76563|
NCT01729806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02213|Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma|A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|November 2012|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||October 2015|March 3, 2016|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729806||75975|
NCT01729819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000085|Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women|A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women||Ferring Pharmaceuticals|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729819||75974|
NCT01718132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWR-2012-STZ|Reduction of Postoperative Pain, Nausea and Vomiting|Reduction of Postoperative Pain, Nausea and Vomiting||Triemli Hospital|No|Completed|January 2009|June 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16309|||Both|18 Years|N/A|No|Probability Sample|All patients that have been transferred to the postanesthesia care unit postoperatively|October 2012|October 30, 2012|October 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01718132||76868|
NCT01718145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-031|A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects|A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers||Bristol-Myers Squibb|No|Completed|November 2012|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|258|||Both|20 Years|75 Years|No|||September 2015|September 23, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718145||76867|
NCT01729468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN08-FP/PERASTUN|Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers|Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers|PERASTUN|University Hospital, Tours|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4972|||Female|18 Months|N/A|No|||September 2015|September 28, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01729468||76001|
NCT01729481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005471-17|Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer|Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances|ML22774|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|July 2012|July 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||November 2015|November 22, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01729481||76000|
NCT01729988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBR-GDAPL-CIBIEM|Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study|Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study||Noblewell|Yes|Active, not recruiting|November 2012|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01729988||75961|
NCT01729962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-3|Comparative Study of the Optical Biometer for Measurements of the Eye|Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter||Nidek Co. LTD.|No|Completed|December 2012|May 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal eyes(phakic eyes without cataracts or corneal disease), eyes with cataracts, eyes        without a natural lens (including aphakic and pseudophakic eyes), eyes with corneal        disease (including eyes post keratorefractive surgery).|June 2013|June 26, 2013|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729962||75963|
NCT01730521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2012-N-27|The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation|The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation||Swiss Federal Institute of Technology|No|Completed|October 2012|June 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Whole blood and serum samples|Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects studying or working at the University of Zürich or ETH Zürich|September 2013|September 12, 2013|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01730521||75920|
NCT01730222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT-19|A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma|A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma|PACT-19|IRCCS San Raffaele|No|Recruiting|November 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01730222||75943|
NCT01730235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS018168|My MediHealth: A Paradigm for Children-centered Medication Management|My MediHealth: A Paradigm for Children-centered Medication Management|mymedihealth|Vanderbilt University|No|Completed|May 2012|||October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|115|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adolescents between the ages of 12 and 17 with a diagnosis of asthma and on        at least one daily medication.|November 2012|November 14, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01730235||75942|
NCT01727427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215/2012|Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients|Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients||G. d'Annunzio University|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|610|||Both|18 Years|N/A|No|Probability Sample|All ambulatory or hospitalized cancer patients with a first diagnosis of unsuspected PE.        Both solid and hematological cancers at any stage of disease will be considered for        inclusion|August 2015|August 12, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727427||76158|
NCT01727934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-207|Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C|A Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection||Santaris Pharma A/S|No|Active, not recruiting|November 2012|April 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|70 Years|No|||January 2014|January 3, 2014|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727934||76119|
NCT01728220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-7002-COPD-201|Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD|A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1||Bellerophon|No|Completed|December 2012|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|159|||Both|40 Years|80 Years|No|||January 2015|January 30, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728220||76097|
NCT01728493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40133.091.12|Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment|Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment|PAGODE|Radboud University|No|Not yet recruiting|September 2013|February 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1100|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Newly diagnosed hypertensive patients in general practice (primary care).|May 2013|July 23, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728493||76076|
NCT01728506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1109|An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors|An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program|iWEB|University of Vermont|Yes|Active, not recruiting|October 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|48|||Female|21 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01728506||76075|
NCT01725048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1021|Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer|A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|January 2011|October 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725048||76338|
NCT01725061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014152|Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis|Alveolar Macrophage Function in ALI and Sepsis|AMFAS|Emory University|No|Completed|December 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|Samples Without DNA|Plasma and bronchoalveolar lavage fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients in the ICU with severe sepsis ot septic shock that are on mechanical ventilation.|December 2014|December 17, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725061||76337|
NCT01724736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrCo Study|A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome|A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Fecal Bacteroidetes: Firmicutes Ratio in Pre-Diabetic Subjects.||NuMe Health|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01724736||76362|
NCT01724749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20120056|Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT|Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT: The CAMONA Study|CAMONA|Odense University Hospital|No|Recruiting|November 2012|December 2016|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|144|Samples Without DNA|Whole blood, serum.|Both|21 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy control subjects will be recruited from a random sample of Danish citizens. To        secure timely inclusion of healthy controls, blood donors will be approached for inclusion        as well.        Subjects with symptoms suggesting angina pectoris will be recruited from the Department of        Cardiology, Odense University Hospital. Each patient referred for symptoms suggesting        angina pectoris and eligibility for a coronary artery calcium scoring (CACS) will be        eligible for inclusion in the investigators study.|November 2012|November 7, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01724749||76361|
NCT01729273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRI-23724|Vascular Health and Exercise Performance of Overweight Children|Vascular Health and Exercise Performance of Overweight Children in 12 Weeks Using Skype|VHEPOC|Stanford University|Yes|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729273||76016|
NCT01729286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-007|Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix|A Multi-Center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold Moist Wound Therapy and Standard of Care Moist Wound Therapy for the Treatment of Chronic Diabetic Foot Ulcers|HEALED|Integra LifeSciences Corporation|No|Active, not recruiting|September 2012|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729286||76015|
NCT01721824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-FSP20|The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders|IPS-MA - A Randomized Clinical Trial Examining the Effect of a Modified IPS Intervention in Addition to Treatment as Usual Versus Treatment as Usual Alone for Individuals With Mood or Anxiety Disorders||Mental Health Centre Copenhagen|No|Active, not recruiting|October 2011|March 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|326|||Both|18 Years|60 Years|No|||March 2016|March 17, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01721824||76586|
NCT01718405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0049|Genetic Polymorphism as Moderator of the Effect of an Acute Bout of Exercise on Cognitive Function|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|November 2012|November 2017|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Anticipated|150|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01718405||76847|
NCT01718418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2010/457|Role of Colonic Events on Metabolism and Appetite Control: A Synbiotic Approach|Prebiotics and Probiotics as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety||Lund University|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|21|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01718418||76846|
NCT01718431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2010/457 - 3day|Prebiotics as a Means to Modulate Gut Fermentation, Metabolism, Appetite and Cognition|Prebiotics as Means to Modulate Colonic Events, With the Purpose to Increase Beneficial Effects on Metabolism, Satiety and Cognition.||Lund University|No|Completed|October 2010|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01718431||76845|
NCT01730313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6318|Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012|Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012||Centers for Disease Control and Prevention|Yes|Not yet recruiting|February 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|5 Years|17 Years|No|||November 2012|November 20, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730313||75936|
NCT01719250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1183|Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma||Mayo Clinic|No|Active, not recruiting|December 2012|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|December 9, 2015|October 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01719250||76783|
NCT01719263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-1570|Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study|Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study||Uptake Medical Corp|No|Completed|June 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|40 Years|75 Years|No|||October 2015|October 27, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719263||76782|
NCT01729754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3222-011|A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)|A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|February 2013|June 2019|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1090|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729754||75979|
NCT01729975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEM-530-US-001|Comparative Study of Specular Microscope for Cell Density, Coefficient of Variation, Hexagonality and Corneal Thickness|Comparative Study of Specular Microscopes for the Measurement of Endothelial Cell Densities, Coefficient of Variation of Endothelial Cell Area, ％Hexagonality, and Central Corneal Thickness||Nidek Co. LTD.||Completed|October 2012|||October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology Practice|November 2012|November 19, 2012|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729975||75962|
NCT01730001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLA-3104-03/04|Early Versus Late Intubation Trial in Physician Manned Emergency Medical Services|A Prospective Randomized Controlled Trial Comparing Competent EARLY-intubation to LATE-intubation in Patients With Prehospital GCS < 9 and Short Transport Time to Hospital.|ELITE|Norwegian Air Ambulance Foundation|Yes|Suspended|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|November 10, 2012||No|Change in study protocol, needs new ethical consideration.|No||https://clinicaltrials.gov/show/NCT01730001||75960|
NCT01730014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1436-3955|A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0148-0000-0287 in Healthy Subjects and in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|70|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730014||75959|
NCT01730248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2104|A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis|A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)||Novartis|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01730248||75941|
NCT01730534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1693C00001|Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events|Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes|DECLARE-TIMI58|AstraZeneca||Active, not recruiting|April 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|17276|||Both|40 Years|130 Years|No|||March 2016|March 21, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730534||75919|
NCT01730547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-MS|Mesenchymal Stem Cells for Multiple Sclerosis|Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis||Karolinska Institutet|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|50 Years|No|||January 2015|January 14, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730547||75918|
NCT01726517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0118|Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects|A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|No|Completed|October 2012|January 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|November 10, 2012|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01726517||76226|
NCT01726530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE541094|Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial|Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial||Khon Kaen University|No|Completed|June 2011|August 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01726530||76225|
NCT01727167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031899|CO as a Stimulant for Mitochondrial Biogenesis in Human Cardiac Muscle|Effects of Low Level Carbon Monoxide Preconditioning on Human Mitochondrial Biogenesis in Aortic Valve Surgery Patients||Duke University|No|Completed|February 2014|March 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|1|||Both|20 Years|N/A|No|||March 2016|March 14, 2016|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727167||76177|
NCT01727180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100047-E|Pruritus in Patients With Chronic Kidney Disease|||Far Eastern Memorial Hospital|No|Completed|June 2011|December 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|108|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with CKD stage 3 to 5D, followed-up in the Far Eastern Memorial Hospital|March 2015|March 4, 2015|November 12, 2012||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01727180||76176|
NCT01727440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030862|Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment|Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment|SA|Duke University|Yes|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|250|Samples With DNA|Whole blood collected in three 2-mL EDTA tubes|Both|12 Years|N/A|No|Non-Probability Sample|Participants must enroll or have enrolled in the MURDOCK Study Community Registry and        Biorepository prior to joining this Severe Acne Study. At the MURDOCK Study visit, or        after the participant has enrolled in the MURDOCK Study, they will be asked (either in        person or via phone) if they would be willing to join the Severe Acne Study.        Participants between ages 12 and 18 may also join the MURDOCK Study if they meet the        eligibility criteria for this Severe Acne Study (a pediatric consent form will be used).|January 2016|January 20, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01727440||76157|
NCT01724242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEA-HMO-CTIL|Vaginal DHEA for Women After Breast Cancer|Vaginal DHEA to Ease Vaginal Dryness in Women With a Contraindication to Estrogen Therapy||Hadassah Medical Organization|No|Withdrawn|February 2013|December 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|35 Years|55 Years|No|||July 2015|July 26, 2015|November 7, 2012||No|Inability to recruit patients|No||https://clinicaltrials.gov/show/NCT01724242||76400|
NCT01724255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StapleDressingRemoval-HMO-CTIL|Optimal Time for Staple/Dressing Removal|The Influence of the Timing of Staple and Dressing Removal After Cesarean Section on the Surgical Incision Healing||Hadassah Medical Organization|No|Completed|January 2013|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|1500|||Female|18 Years|60 Years|No|Non-Probability Sample|All patients undergoing a cesarean section at our facility|July 2015|July 26, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724255||76399|
NCT01724489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002276|Study of Growth Hormone and Bone in Obesity|Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone||Massachusetts General Hospital|Yes|Recruiting|August 2013|April 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724489||76381|
NCT01725906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202068MIC|Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication|Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection||National Taiwan University Hospital|No|Recruiting|November 2012|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|20 Years|85 Years|No|||January 2016|January 31, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01725906||76272|
NCT01725321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI_1|Narrow Band Imaging for Diagnosis of Proximal Serrated Polyps|Colonoscopy With Narrow Band Imaging for Diagnosis of Proximal Serrated Polyps||The University of Hong Kong|No|Completed|October 2012|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|360|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients scheduled to have colonoscopy for screening, surveillance or symptoms|May 2015|May 28, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725321||76317|
NCT01718158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-021|Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy|A Phase 3 Evaluation of Daclatasvir in Combination With Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination With Peginterferon Alfa-2a and RBV in Patients With Chronic Hepatitis C Genotype 1b Who Are Treatment naïve or Prior Relapsers to Alfa/RBV Therapy (the STRUCTURE Study)|STRUCTURE|Bristol-Myers Squibb|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|444|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718158||76866|
NCT01729585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2009-0918|The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis|The Effects of Massage Therapy on Quality of Life in Youth and Young Adults With Cystic Fibrosis: A Pilot Study||Children's Hospital Medical Center, Cincinnati|No|Completed|July 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01729585||75992|
NCT01730079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130007|Near Infrared Spectroscopy in Children With Autism and ADHD|Near Infra-Red Spectroscopy (NIRS) in Neurodevelopmental Disorders and Typically Developing Children||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|130|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||May 2015|August 13, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01730079||75954|
NCT01730053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1118|Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)|A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin||Regeneron Pharmaceuticals|Yes|Completed|November 2012|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|305|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 9, 2012|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01730053||75956|
NCT01729767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-03-48-9453|Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease|Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital||Tehran University of Medical Sciences||Recruiting|August 2011|||December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||November 2012|November 19, 2012|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729767||75978|
NCT01730274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cerebellum 1.1|Cerebellum - Cognitive Outcome and Functional Connectivity|Cerebellar Tumors of Childhood - Impact on Cognition and Functional Connectivity||Medical University of Vienna|No|Not yet recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|15 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|young adolescent operated on a cerebellar tumor as a child|November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730274||75939|
NCT01730261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1256-3|Online Emotional Regulation Group Treatment|Online Emotional Regulation Group Treatment for Individuals With Traumatic Brain Injury (TBI)||Icahn School of Medicine at Mount Sinai|No|Completed|November 2012|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730261||75940|
NCT01726855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sun_rising|Prevention of Adhesions Following Flexor Tendon Injury Within Zone II With Vascularized Finger Dorsal Fascial Flap|||The Second Hospital of Tangshan|Yes|Completed|January 2010|July 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|patients requiring flexor tendon repair or reconstruction within zoneⅡ|November 2012|November 14, 2012|November 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726855||76200|
NCT01726543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW1 151/12|Safety and Efficacy of Canaloplasty and Non-penetrating Deep Sclerectomy With Phacoemulsification to Treat Glaucoma and Cataract|Comparison of Safety and Efficacy of Canaloplasty and Non-penetrating Deep Sclerectomy Combined With Phacoemulsification to Treat Glaucoma and Cataract. A Randomised, Prospective Study.||Military Institute of Medicine, Poland||Recruiting|February 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|No|||November 2012|November 10, 2012|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726543||76224|
NCT01726556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Trg-PG-2012/5054|A Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions|A Randomized Controlled Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions|RISE|Postgraduate Institute of Medical Education and Research|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|70|||Both|12 Years|N/A|No|||January 2013|January 9, 2013|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726556||76223|
NCT01727453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPACO|Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.|Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding.|HEPACO|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|December 2011|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01727453||76156|
NCT01727661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201005RIC|Cardiopulmonary Fitness, Lung Function, Muscular Oxygen Saturation, and Quality of Life in T1DM|Cardiopulmonary Fitness, Lung Function, Muscular Oxygen Saturation, and Quality of Life in Patients With Type 1 Diabetes Mellitus||National Taiwan University Hospital|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|outpatient department|March 2013|March 6, 2013|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727661||76140|
NCT01724502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006065 Aim 4|Mitochondrial Dysfunction in Diabetes|PGC-1 and Mitochondrial Dysfunction in Diabetes, Aims 4 & 5|PGC-1|Mayo Clinic|No|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724502||76380|
NCT01724515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006065 Aim 5|PGC-1 and Mitochondrial Dysfunction in Diabetes|PGC-1 and Mitochondrial Dysfunction in Diabetes||Mayo Clinic|No|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724515||76379|
NCT01724762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP0447|Efficacy of Nursing Orientation to Reduce the Anxiety of Patients Undergoing Bed Bath|Evaluation of the Efficacy of Nursing Orientation to Reduce the Anxiety of Patients With Acute Coronary Syndrome Undergoing Bed Bath||Federal University of São Paulo|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|75 Years|No|||November 2012|November 9, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01724762||76360|
NCT01722474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:040|Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.|Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.|ASI-2012|University of Manitoba|No|Terminated|October 2012|September 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|15|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|November 2, 2012||No|Minor device modifications required, move revised device to clinical site in USA.|No||https://clinicaltrials.gov/show/NCT01722474||76536|
NCT01722734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19850-101|Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment|Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment|PACT|Harvard School of Public Health|No|Completed|June 2011|January 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|1140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|November 2, 2012||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT01722734||76516|Main outcome is self-reported adherence. Study was restricted to urban population with mobile phone ownership.
NCT01725035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008007192|Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth|The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents|DNL|Yale University|No|Active, not recruiting|December 2010|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Serum|Both|12 Years|18 Years|No|Non-Probability Sample|The majority of the research subjects will be recruited from the Yale Pediatric Obesity        Clinic and the Endocrine Clinic. Following the oral glucose tolerance test (OGTT):normal        glucose tolerant if plasma glucose at two hours is <140 mg/dl and impaired glucose        tolerant if plasma glucose is ≥140 mg/dl. All subjects must be in good general health,        have a normal medical history and physical exam, and have no endocrinopathies or other        diseases that might affect glucose metabolism. They will not be on any medications that        are known to alter glucose or insulin metabolism or certain psychiatric medications.        Subjects determined to be eligible will receive a MRI to determine Hepatic Fat Content.        Subjects will agree to genetic testing to determine genotype.|March 2015|March 3, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01725035||76339|
NCT01725334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078/2011|Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia|Deep Brain Stimulation for the Management of Treatment Refractory Negative Symptoms in Schizophrenia||Centre for Addiction and Mental Health|No|Withdrawn|September 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|25 Years|60 Years|No|||July 2015|July 31, 2015|November 8, 2012||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01725334||76316|
NCT01729299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12070904|Ghrelin Effect on Beta Cell Function in Health and Disease|Ghrelin Effect on Beta Cell Function in Health and Disease||University of Cincinnati|Yes|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729299||76014|
NCT01730066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProOncENT|Probiotics Against Pathogenic Bacteria in Advanced ENT-Surgery|Probiotics for Reduction of Pathogenic Bacteria in Connection With Advanced Surgery in the Mouth, the Oropharynx, and on the Neck||Region Skane|No|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01730066||75955|
NCT01730638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 11/5-L|ImmunoTEP for Patients With Medullary Thyroid Carcinoma.|Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.|iTEP-CMT|Nantes University Hospital|Yes|Recruiting|January 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01730638||75911|
NCT01730599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-NG-0473|A Longitudinal Study in Parkinson's Disease (PD) Patients|A Longitudinal 5 Years Follow up Study in Parkinson's Disease (PD) Patients Carriers of the LRRK2 Gene G2019S Mutation||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2012|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|30 Years|N/A|No|Non-Probability Sample|PD patients carriers of the G2019S mutation in the LRRK2 gene|November 2012|November 15, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01730599||75914|
NCT01730027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC3680-07|A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma|A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and When Co-Administered With Montelukast in Subjects With Inadequately-Controlled Asthma.||Pulmagen Therapeutics|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|248|||Both|18 Years|50 Years|No|||December 2014|December 7, 2014|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730027||75958|
NCT01722643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23559|Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes|Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|January 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|95|||Both|13 Years|17 Years|No|||August 2015|August 25, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01722643||76523|
NCT01722656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVEN Study|Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment|Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment.|EVEN|Southern California Desert Retina Consultants, MC|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|50 Years|N/A|No|||January 2016|January 20, 2016|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722656||76522|
NCT01726569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-CREST1|Post-operative Satisfaction With Glaucoma Surgery Trial|A Randomized Trial of the Impact of Multifaceted Education on Post-operative Satisfaction With Glaucoma Surgery in Rural China||Sun Yat-sen University|Yes|Active, not recruiting|December 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|356|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01726569||76222|
NCT01726842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rebiscan-001|Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|Pediatric Vision Scanner for the Eradication of Amblyopia||Rebiscan, Inc.||Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|300|||Both|2 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children presenting for ophthalmic exam at eye clinic.|October 2015|October 27, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01726842||76201|
NCT01723189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.12.04|Pathophysiology of Central Apnoeas in Stroke Patients|Central Apnoeas in the Course of Transient Ischemic Attack/Ischemic Stroke: Clinical, Prognostic, Pathophysiological Elements.||Ospedale Civico, Lugano|Yes|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|November 2012|November 5, 2012|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01723189||76481|
NCT01723787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0482|Genetic Studies in Patients and Families With Infantile Spasms|Genetic Studies in Patients and Families With Infantile Spasms||University of Colorado, Denver|No|Recruiting|March 2013|September 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|blood, saliva, buccal cells,urine|Both|31 Days|21 Years|No|Non-Probability Sample|All patients trios (both parents + patient with IIS = trio) with IIS retrospectively        identified to have been treated with ACTH according to FDA-approved protocol will be        eligible for inclusion in this study regardless of age, sex, ethnicity/race, or        socioeconomic status. The principal recruitment venues will be Neurology clinics,        in-patient service and Medical Genetics Clinics at Children's Hospital Colorado and        University of Colorado Health Sciences Center (UCHSC_|December 2015|December 9, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723787||76435|
NCT01723436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816697|Effects of Repeated Decision Making Among Surrogates of Seriously Ill Patients|Pilot Study of Repeated Decision Making in Surrogates||University of Pennsylvania|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|132|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01723436||76462|
NCT01723449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS-ED-01-2012|Predictors for Admission to Emergency Department More Than 48 Hours|||University of Southern Denmark|No|Completed|November 2012|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|730|||Both|15 Years|N/A|No|Probability Sample|all admissions to Emergency department|February 2016|February 13, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01723449||76461|
NCT01723462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-02-2012|How Often Are Pharmacist Recommendations Followed by Emergency Physicians in Emergency Departments?|||University of Southern Denmark|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|15 Years|N/A|No|Non-Probability Sample|all acute admissions to emergency department|November 2012|November 7, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723462||76460|
NCT01723774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301106|PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer|A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer||Washington University School of Medicine|Yes|Recruiting|June 2013|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723774||76436|
NCT01724008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01327|The Efficacy of a Dentifrice in Providing Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity.||GlaxoSmithKline|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724008||76418|
NCT01724021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28457|A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a|A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a||Hoffmann-La Roche||Active, not recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|746|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724021||76417|
NCT01724528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLO-01|Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies|Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol|FLORENCE|Menarini Group|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|346|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 7, 2012||No||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01724528||76378|
NCT01724541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UE-NNP-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||September 22, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724541||76377|
NCT01724775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPH-CME|Efficacy and Safety Study of Complete Mesocolic Excision for Colon Cancer|A Prospective, Non-randomized, Double-blind, Single-center Study to Evaluate Efficacy and Safety of Complete Mesocolic Excision for Colon Cancer.|ESCME|Peking University People's Hospital|Yes|Recruiting|November 2012|December 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Adult patients of colon caner in China|November 2012|November 21, 2012|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01724775||76359|
NCT01722487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1115-CA|A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)|A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)||Pharmacyclics|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722487||76535|
NCT01725347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29112|Validation of a Digital Diet Method for Use With Preschoolers|Validation of a Digital Diet Method for Use With Preschoolers||Baylor College of Medicine|Yes|Active, not recruiting|February 2012|May 2016|Anticipated|December 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|94|Samples Without DNA|Urine samples are to be collected.|Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|With an anticipated attrition rate of 15%, 62 children will be recruited, resulting in a        sample size of 54 after attrition (14 HA boys; 14 HA girls; 13 AA boys; 13 AA girls).|January 2016|January 13, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01725347||76315|
NCT01729598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0068-F6A|Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study|Safety And Target Engagement Of Clu1 By Valproic Acid In Subjects With Intact Cognition: Proof Of Concept For The Development Of A Prevention Trial For Alzheimer's Disease|VPA|University of Kentucky|No|Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|14|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 15, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729598||75991|
NCT01729832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10106|Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer|Intraoperative Stereotactic Image-guided Navigation of Perforators for DIEP Flap Breast Reconstruction.||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|January 2011|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Female|18 Years|N/A|No|||August 2015|August 27, 2015|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729832||75973|
NCT01729845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2652.00|Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study||Fred Hutchinson Cancer Research Center|No|Recruiting|December 2012|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729845||75972|
NCT01726699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-6011|Scripps Tumorgraft Study|Scripps Tumorgraft Study||Scripps Translational Science Institute|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|Samples With DNA|Blood and tissue samples|Both|21 Years|N/A|No|Probability Sample|Adults with a solid tumor malignancy or a hematologic malignancy|April 2015|April 1, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726699||76212|
NCT01726972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|369439-1|A Retrospective Review of FloSeal Use in Total Shoulder Arthroplasty|A Retrospective Review of FloSeal Use in Total Shoulder Arthroplasty||Western Orthopaedics Research and Education Foundation|No|Active, not recruiting|November 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|21 Years|90 Years|No|Probability Sample|Patients who have previously undergone anatomic total shoulder arthroplasty for the        treatment of glenohumeral osteoarthritis.|November 2012|November 14, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01726972||76191|
NCT01730326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|turkcuer 001|Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack|The Comparison of the Effectiveness of Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack in Emergency Service||Pamukkale University|Yes|Completed|March 2012|November 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||November 2012|November 15, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01730326||75935|
NCT01722916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU68166|Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase|Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial||Northwestern University|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722916||76502|
NCT01722929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU69718|Study of Skin and Muscle Parameters Using a Skin Sensor|A Pilot Study of Skin and Muscle Parameters Using a Multifunctional Skin Sensor||Northwestern University|Yes|Enrolling by invitation|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722929||76501|
NCT01722903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39748EP|Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer|Perioperative Detection and Characterization of Circulating Tumor Cells in Patients Undergoing Colorectal Cancer Liver and Lung Metastasectomy||Milton S. Hershey Medical Center|No|Recruiting|August 2012|July 2017|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Colorectal liver and lung metastases, adjacent healthy liver and lung metastases, isolated      circulating tumor cells|Both|18 Years|N/A|No|Non-Probability Sample|50 patients with colorectal cancer metastatic to liver and/or lungs will be enrolled.        Patients must be older than 18 years. No healthy volunteers/control group will be        included.|November 2012|November 6, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722903||76503|
NCT01723475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15590|First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer||Bayer|Yes|Recruiting|November 2012|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01723475||76459|
NCT01723488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T808000|A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808|A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808|T808|Avid Radiopharmaceuticals|No|Terminated|July 2012|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|November 1, 2012|No|Yes|Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|No||https://clinicaltrials.gov/show/NCT01723488||76458|
NCT01723800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12219|PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer|Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)||City of Hope Medical Center|Yes|Active, not recruiting|July 2013|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723800||76434|
NCT01724034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094/2011|Lung Ultrasound Assisting Weaning in Difficult-to-wean Patients|Daily Lung Ultrasound Assisting Weaning From Mechanical Ventilation in Difficult-to-wean Adult Patients - a Randomized Trial.|WeanUS|Hospital Ernesto Dornelles|No|Recruiting|October 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01724034||76416|
NCT01724268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11224-12|Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient|Randomized Controlled Clinical Trial of Low Dose Corticosteroids vs Anti TNF Treatment in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient- a Pilot Study||Hamad Medical Corporation|Yes|Recruiting|May 2012|September 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724268||76398|
NCT01724281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059-12|Outcome of Babies With Asymetry of Lateral Brain Ventricles|Outcome of Babies With Asymetry of Lateral Brain Ventricles||Hillel Yaffe Medical Center|No|Not yet recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|None Retained|not relevant|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|women at 19-30 weeks who attend ultrasound exam and diagnosed with asymetry of lateral        brain ventricles.|November 2012|November 8, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01724281||76397|
NCT01724294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28497|An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma|Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP||Hoffmann-La Roche||Recruiting|December 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Probability Sample|Patients with diffuse large B-cell lymphoma treated in first line with R-CHOP|March 2016|March 1, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724294||76396|
NCT01725360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-BE 240/06|Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma|Change of Airway Hyperresponsiveness to Mannitol and Methacholine During Intensified Anti-inflammatory Treatment in Patients With Asthma.||University Hospital, Basel, Switzerland|Yes|Completed|January 2007|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725360||76314|
NCT01725373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRB-06-012|Angioplasty of Left Main - lAriboisiere Registry|Prospective Registry in Patients With Unprotected Left Main Disease Treated by Percutaneous Coronary Intervention: The ALMA (Angioplasty of Left Main - lAriboisiere) Registry|ALMA|Hopital Lariboisière|No|Completed|January 2007|November 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with stenosis of unprotected left main and schedulded angioplasty in        the Department of Cardiology, Lariboisiere Hospital.|January 2014|January 12, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725373||76313|
NCT01725672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116806|Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers|An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations, 500 mg or 1000 mg Extended Release Metformin and 1 mg or 2 mg Extended Release Glimepiride, in Healthy Adult Male and Female Subjects in the Fed State||GlaxoSmithKline||Terminated|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|November 1, 2012||No|Due to changes in EMA guidelines on modified release dosage forms (Feb 2013;    EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines.|No||https://clinicaltrials.gov/show/NCT01725672||76290|
NCT01723020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120106|A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma||Amgen|No|Recruiting|December 2012|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723020||76494|
NCT01726179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECIPRJ13|Efficacy of Proximal Caries Infiltration|Efficacy of Resin Infiltration of Proximal Caries Lesions in Primary Molars: Randomized Clinical Trial||DMG Dental Material Gesellschaft mbH|No|Active, not recruiting|December 2012|August 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|5 Years|7 Years|No|||November 2015|November 5, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01726179||76252|
NCT01726192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLOCSTIM2|Comparison of Two Techniques for Placement of Perineural Femoral Catheters.|Comparison of Ultrasound Hydrolocalization Technique Versus Neurostimulation for Placement of Continuous Femoral Catheters.|HLOCSTIM2|Attikon Hospital|No|Recruiting|August 2012|||January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726192||76251|
NCT01729325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKULBUSO2012|Prevention of Post-Traumatic Stress Disorder in Soldiers|Prevention of Post-Traumatic Stress Disorder in Relation to Appetitive Aggression in Burundian Soldiers Deployed in a Peace-keeping Mission in Somalia||University of Konstanz|Yes|Completed|November 2012|April 2015|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|118|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729325||76012|
NCT01729611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tonella1|Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension|Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension||The Cleveland Clinic|No|Recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|17 Years|90 Years|No|Non-Probability Sample|Patients with scleroderma or cirrhosis. These patients may or may not have known PAH or be        on treatment of this condition.|August 2015|August 20, 2015|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729611||75990|
NCT01730352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/56706-0|Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients|Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial||Federal University of São Paulo|Yes|Completed|October 2008|March 2012|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|20 Years|No|||November 2012|November 20, 2012|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730352||75933|
NCT01730651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS 12-615|High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies.|A Phase II Study of High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis.||National Cancer Center, Korea|Yes|Recruiting|July 2012|July 2022|Anticipated|July 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Female|18 Years|N/A|No|||September 2015|September 7, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730651||75910|
NCT01726712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0654|Network Supported Engagement In HIV Care|Network Supported Engagement In HIV Care|NSEC|University of Chicago|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|141|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01726712||76211|
NCT01726660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-121B|The General Use of Robots in Stroke Recovery|Pilot Study of the Effects of Protocol-Specific Robotic Arm Therapy in Stroke Recovery||Northwell Health|No|Withdrawn|December 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|October 26, 2012||No|Unfunded|No||https://clinicaltrials.gov/show/NCT01726660||76215|
NCT01726673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-102B|Robots Paired With tDCS in Stroke Recovery|Effects of Transcranial Direct Current Stimulation Paired With Robotic Arm Therapy on Recovery of Upper Extremity Motor Function in Stroke Patients||Northwell Health|No|Recruiting|September 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01726673||76214|
NCT01722357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09110|Promoting Physical Activity Among Bariatric Surgery Patients|Promoting Physical Activity Among Bariatric Surgery Patients||St. Vincent Carmel Hospital|No|Active, not recruiting|November 2009|July 2020|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722357||76545|
NCT01722370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG-11-132|Ambulatory Oxygen Effects on Muscles in COPD|Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion?|OM-COPD|University of Birmingham|No|Completed|August 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722370||76544|
NCT01722942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAGASICS|Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death|CHronic Use of Amiodarone aGAinSt Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study (CHAGASICS)|CHAGASICS|InCor Heart Institute|Yes|Not yet recruiting|October 2014|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|75 Years|No|||September 2014|September 8, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01722942||76500|
NCT01723202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12064|Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer|A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|November 2012|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723202||76480|
NCT01723514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101268|Ascending Multiple-Doses of AMG 334 in Healthy Subjects and in Migraine Patients|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and in Migraine Patients||Amgen|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723514||76456|
NCT01724060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS|Effects of Obesity Treatments on Food Preferences and Metabolism|The Effects of Current Treatments of Obesity on Food Preferences, Gut Hormones, Bile Acids and Hepatic Glucose Output in Humans.|FPS|Imperial College London|Yes|Recruiting|September 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|400|Samples Without DNA|Human plasma|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the community or hospital care|February 2016|February 26, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01724060||76414|
NCT01724320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX008_101|A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors|A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors||Oncoethix GmbH|No|Recruiting|February 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724320||76394|
NCT01724047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001120|Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools|Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.|AIR-B II|Health Resources and Services Administration (HRSA)|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|250|||Both|4 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 22, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01724047||76415|
NCT01724307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0009|Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma|Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma.||Ohio State University|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01724307||76395|
NCT01725074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHK ProMA|Randomized Control Trial to Evaluate Effectiveness of a Case Managment Program Regarding Psychosocial Well-being and Disease Symptoms Health for Patients With Multimorbid Coronary Heart Disease (CHD) Patients (KHK ProMA)|Koronare Herzkrankheit Projekt Mannheim|KHK ProMA|Genossenschaft Gesundheitsprojekt Mannheim e.G|No|Active, not recruiting|July 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|320|||Both|30 Years|N/A|No|||November 2012|November 9, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725074||76336|
NCT01725919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60034699|Examining How Motor Rehabilitation Promotes Brain Reorganization Following Stroke, an MRI Study|Examining Mechanisms of Neuroplasticity Following Motor Rehabilitation in Stroke||Ohio State University|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725919||76271|
NCT01726205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGCWI1|Perioperative Pregabalin and Continuous Wound Infusion for Pain Control Following Thoracotomy|||Attikon Hospital|No|Completed|October 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726205||76250|
NCT01726387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMADS|Self-Management for Anxiety, Depression and Somatoform Disorders|Self-Management Support in Primary Care|SMADS|Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01726387||76236|
NCT01723033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHMC-5200|Differences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD|Differences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD||Beersheva Mental Health Center|Yes|Not yet recruiting|December 2012|||December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be recruited from the outpatient clinic of the Beersheva Mental Health        Center. 15 OCT and 15 PTSD patients|November 2012|November 7, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723033||76493|
NCT01722747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA120958|Bihar School Teachers Study|Promoting Tobacco Control Among Teachers in India|BSTS|Harvard School of Public Health|Yes|Completed|June 2009|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|945|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01722747||76515|
NCT01729858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 D2007-46|Survival of Implant-Supported All-Ceramic Prostheses|Factors Influencing the Survival of Implant-Supported All-Ceramic Prostheses||University of Florida|No|Active, not recruiting|December 2008|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729858||75971|
NCT01730092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130012|Natural History Study of Biomarkers in Pulmonary Arterial Hypertension|A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension||National Institutes of Health Clinical Center (CC)||Recruiting|October 2012|August 2022|Anticipated|August 2021|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 12, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01730092||75953|
NCT01730105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130013|Chronic Cold Exposure and Energy Metabolism in Humans|Impact of Chronic Cold Exposure on Energy Metabolism in Humans||National Institutes of Health Clinical Center (CC)||Completed|October 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|7|||Male|18 Years|40 Years|No|||May 2015|December 11, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01730105||75952|
NCT01730339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5301001|Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery|A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring||Pfizer|No|Completed|December 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|55 Years|No|||January 2016|January 19, 2016|November 12, 2012|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01730339||75934|
NCT01726686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIA-Pump_AA|Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump|Evaluation of Intra-articular Continuous Infusion Pump With Ropivacaine in Addition to Local Infiltration Analgesia (LIA) in Total Knee Arthroplasty (TKA). A Placebo Controlled Randomised Trial.||Region Skane|No|Completed|February 2010|April 2014|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|N/A|N/A|No|||November 2014|November 24, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01726686||76213|
NCT01727024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BBR02|Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients|Study to Evaluate the Preference, Satisfaction and Correct Use of Inhalers in Patients With Chronic Obstructive Pulmonary Disease|INHALATOR|Novartis||Completed|April 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727024||76187|
NCT01726985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121368|Model for Heart Failure ExAcerbation Reduction Trial|Model for Heart Failure ExAcerbation Reduction Trial - "Model HEART"|Model HEART|Cleveland Clinic Florida|No|Recruiting|November 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All patients aged 18 and over hospitalized at Cleveland Clinic Florida with diagnosis of        CHF.|November 2012|November 14, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01726985||76190|
NCT01722383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3917|What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study|What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study|RIISC|University Hospital Birmingham NHS Foundation Trust|No|Recruiting|October 2010|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Serum, Plasma, Urine, DNA, Saliva, Dental Plaque|Both|18 Years|N/A|No|Non-Probability Sample|Secondary care kidney disease clinics|November 2012|November 11, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722383||76543|
NCT01722669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000022|Quercetin PK/PD Study in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies|Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies|PK/PD|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|May 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722669||76521|
NCT01723228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/PM106|Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease|A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease||Teva Pharmaceutical Industries|No|Completed|November 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|45 Years|80 Years|No|||February 2016|February 29, 2016|November 5, 2012|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01723228||76478|
NCT01723826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN28525|A Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab|A Multicenter, Open-Label, Long-Term Safety Extension Of Phase II Studies ABE4869g And ABE4955g In Patients With Mild To Moderate Alzheimer's Disease||Genentech, Inc.||Active, not recruiting|December 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|360|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723826||76432|
NCT01723215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TelAvivU|Prevention of Combat-related PTSD Using Attention Bias Modification (ABM): A Randomized Controlled Trial|Prevention of Posttraumatic Symptoms in IDF Soldiers Using Attention Bias Modification (ABM): A Randomized Controlled Trial||Tel Aviv University|No|Completed|December 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|862|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723215||76479|
NCT01723501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHKC-Chx2012|Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth|Whole Body Cleansing With 0.25% Chlorhexidine at Birth for Prevention of Sepsis in Infants <1500 g: a Multi-center, Blinded, Randomized Trial|CAPS|All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|November 2012|December 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1282|||Both|N/A|28 Days|No|||November 2012|November 6, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723501||76457|
NCT01723813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUC 10-001|Peptide Vaccinations Plus GM-CT-01 in Melanoma|Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|April 2012|April 2015|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01723813||76433|
NCT01724814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-INS-101|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A|HM12460A|Hanmi Pharmaceutical Company Limited|No|Active, not recruiting|January 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724814||76356|
NCT01724554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDROID|Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion|A Single-center, Open-label Study Evaluating the Impact of Repeat Intravitreal Injections of Aflibercept on Capillary Non-Perfusion (CNP) in Subjects With Proliferative Retinopathy and/or Macular Edema Secondary to Proliferative Diabetic Retinopathy and Central Retinal Venous Occlusive Disease|ANDROID|Ophthalmic Consultants of Boston|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724554||76376|
NCT01724788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUROSL06121|Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation (PRLasix® Special, Tablets 500 mg) in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis||Sanofi|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|October 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01724788||76358|
NCT01724801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|c-tong1201|Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy|Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy|BRAIN|Guangdong Association of Clinical Trials||Recruiting|October 2012|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|170|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|October 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724801||76357|
NCT01725087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF6005/06|Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.|Efficacy, Safety, and Tolerability of GRT6005 in Subjects With Moderate to Severe Chronic Low Back Pain.||Grünenthal GmbH||Completed|November 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1089|||Both|18 Years|80 Years|No|||August 2014|August 28, 2014|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725087||76335|
NCT01725386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25640|An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic or Advanced Breast Cancer|Study on Xeloda to Document Its Use in Routine Practice in Patients With Metastatic or Advanced Breast Cancer||Hoffmann-La Roche||Completed|March 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|||Female|18 Years|N/A|No|Probability Sample|Patients with metastatic breast cancer initiated on therapy with Xeloda|March 2016|March 1, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725386||76312|
NCT01726218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048694|Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision|Enhancing Stroke Recovery Through Cortical Stimulation: The Role of the Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision|RIMC|Emory University|No|Recruiting|May 2011|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 Stroke patients with 15 in each group based on location of stroke 50 healthy volunteers|November 2015|November 16, 2015|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726218||76249|
NCT01726400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPCIDIN-11/225|In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia|Is Hepcidin a Possible Contributor to Impaired Iron Mobilization and Anaemia in Hepatitis C Patients Treated With Pegylated Interferon Alpha and Ribavirin Therapy? A Pilot Study||Fremantle Hospital and Health Service|Yes|Completed|December 2012|July 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples With DNA|Whole blood is collect for genomic DNA extraction. Serum samples will be stored for hepcidin      analysis.|Both|18 Years|70 Years|No|Non-Probability Sample|Hepatitis C patients undergoing standard of care treatment with interferon alpha.|November 2015|November 9, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726400||76235|
NCT01722760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-091|Tidal Neonatal NO, Vitamins A and D, and Infant Lung Disease - The AD-ON Study|AD-ON: The Danish Study on Tidal Neonatal Nitrogen Oxide (NO) and Vitamins A and D as Possible Predictors of BPD||Hillerod Hospital, Denmark|Yes|Completed|August 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|Samples Without DNA|Air samples for Nitrogen oxide NO. Maternal, cord and neonatal blood samples for vitamins A      and D.|Both|N/A|2 Days|Accepts Healthy Volunteers|Non-Probability Sample|Term and preterm infants admitted to Neonatal Care Unit for reference material as control        group.        Preterm infants admitted to Neonatal Intensive Care Unit developing BPD as study group.|November 2015|November 5, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01722760||76514|
NCT01730118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130016|Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing|A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|June 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|99 Years|No|||February 2016|February 19, 2016|November 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730118||75951|
NCT01730365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40578.031.12|Optical Detection of Malignancy During Percutaneous Interventions|Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques||Philips Healthcare|Yes|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|70|Samples Without DNA|Biopsies are taken from the enrolled patients and these biopsies are send to the pathology      department for histopathological analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients are all patients, who are scheduled for a standard core biopsy of lung,        liver or breast; or percutaneous RFA of liver in the Netherlands Cancer Institute        (NKI-AvL), Amsterdam, The Netherlands. In the enrollment process the "patient informatie"        will be used and the informed consent must be signed prior to the intervention.|November 2015|November 2, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01730365||75932|
NCT01730664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETB/V0.2|PK/PD of Ertapenem In Patients With TB|Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis||University Medical Center Groningen|No|Suspended|February 2013|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|64 Years|No|||June 2015|June 17, 2015|November 9, 2012||No|problems with drug susceptibility testing of ertapenem|No||https://clinicaltrials.gov/show/NCT01730664||75909|
NCT01727037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIABI v1|Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for Emphysema|A Feasibility and Safety Study of Bronchoscopic Intrabullous Autologous Blood Instillation for the Treatment of Severe Bullous Emphysema (BIABI Study)|BIABI|Chelsea and Westminster NHS Foundation Trust|No|Recruiting|October 2012|||September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|35 Years|90 Years|No|||November 2012|November 19, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727037||76186|
NCT01726998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0005|Effects of Locomotion Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Subacute Stroke|||Yonsei University|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|80 Years|No|||February 2014|February 17, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726998||76189|
NCT01727011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/09 - SIFEBI|Single Fraction Elderly Breast Irradiation (SiFEBI)|A Phase I-II Trial Evaluating the Toxicity of Early Breast Partial Irradiation in Patients Aged at Least of 70 Years With Breast Cancer at Low Risk of Local Recurrence|SIFEBI|Centre Antoine Lacassagne|Yes|Completed|November 2012|November 2015|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|70 Years|N/A|No|||November 2015|November 13, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727011||76188|
NCT01722682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IsletBOM2|Bone Marrow vs Liver as Site for Islet Transplantation|Bone Marrow vs Liver as Site for Islet Transplantation in Patients With Type 1 Diabetes: Pilot Study to Evaluate Efficacy|IsletBOM2|Ospedale San Raffaele|Yes|Active, not recruiting|June 2012|November 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01722682||76520|
NCT01722955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prewarmed fluid|Pre-warmed Intravenous Fluids and Monitored Anesthesia Care|Effect of Pre-warmed Intravenous Fluids on the Early Outcomes After Ambulatory Surgery Under Monitored Anesthesia Care||Samsung Medical Center|Yes|Completed|September 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|20 Years|70 Years|No|||November 2014|November 17, 2014|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01722955||76499|
NCT01723839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002262 RV-CLL-PI-0530|Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide|Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance|FCR|Hackensack University Medical Center|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723839||76431|
NCT01723527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA033510-01|Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin|||Johns Hopkins University|Yes|Completed|December 2012|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|No|||December 2014|December 10, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723527||76455|
NCT01723540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204520|A Comparison of Laparoscopic Cholecystectomy Versus Ultrasonic Dissection Assisted Minilaparotomy Cholecystectomy|A Comparison of Ultrasonic Dissection Assisted Minilaparotomy Cholecystectomy Versus Laparoscopic Cholecystectomy; a Randomised Two-center Study.|MC-UsD|Kuopio University Hospital|No|Completed|September 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|75 Years|No|||November 2012|November 6, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01723540||76454|
NCT01724567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUT-IT|Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training|Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training: A Randomized Clinical Trial|CUT-IT|Bispebjerg Hospital|No|Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|45 Years|75 Years|No|||August 2014|August 3, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01724567||76375|
NCT01725399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1792|Does First Oral Intake After Emergence Predict the Incidence of Post-operative Vomiting in Children?|Randomized Controlled Trial: Does First Oral Intake After Emergence From Anesthesia Predict the Incidence of Post-operative Vomiting in Children?|XOndansetron|University of North Carolina, Chapel Hill|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|183|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||July 2014|August 5, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725399||76311|
NCT01725412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio REB #12-59|Prevention of Renal Complications of Diabetes With Thiamine|||University of Saskatchewan||Not yet recruiting|November 2012|||June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|50 Years|No|||November 2012|November 9, 2012|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725412||76310|
NCT01725100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114656|A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies|An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies||GlaxoSmithKline|No|Completed|February 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|61|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725100||76334|
NCT01725685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116524|To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)|A Randomized, Double Blind, Single-dose, Three-period, Crossover Study to Investigate Pharmacokinetic, Safety and Tolerability of Fluticasone Furoate With Umeclidinium When Administered in Combination and as Monotherapies in Adult Healthy Volunteer Subjects||GlaxoSmithKline|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|November 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725685||76289|
NCT01725932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT_SHCBTD_2012|Randomized Controlled Trial of Cognitive Therapy Based Self Help Manual for Depression|A Multicentre Randomised Controlled Trial of Culturally Adapted CBT Based Self Help Manual for Depression in Pakistan|CaCBT_SH|Pakistan Association of Cognitive Therapists|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|60 Years|No|||June 2013|June 16, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01725932||76270|
NCT01722500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10042CC|International Study of Childhood Obesity, Lifestyle and the Environment|International Study of Childhood Obesity, Lifestyle and the Environment (ISCOLE)|ISCOLE|Pennington Biomedical Research Center|Yes|Completed|December 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7806|||Both|9 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|boys and girls who are approximately 10 years|February 2016|February 4, 2016|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01722500||76534|
NCT01722773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPPV|Trial of Non-invasive Ventilation for Stable COPD|||University of Iowa|No|Completed|April 2001|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|N/A|No|||November 2012|November 5, 2012|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01722773||76513|
NCT01722786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADOA-Registry|Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists|Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Management of Severe Bleeding and/or Urgent Interventions During Treatment With Direct Oral Anticoagulants or Vitamin K Antagonists|RADOA|Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|August 2013|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|Samples Without DNA|If possible, left-over from plasma samples ("retention sample") should be used to perform      further analyses as drug concentrations. Retention samples of very low volume would suffice      for HPLC (information on collection method needed) to assess plasma concentrations of      anticoagulants in these patients.|Both|18 Years|N/A|No|Probability Sample|Expected number of patients estimated by study duration        N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding N= 90        treated with vitamin K antagonists (VKA) with acute bleeding        N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical        intervention N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical        intervention|May 2014|May 27, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01722786||76512|
NCT01723046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT120278|Therapeutic Effects of a New Upper Limb Robot Assisted Therapy Device for Persons After Stroke|Active Smart Wearable Orthosis Using Painted EMG Electrodes for Home Based Therapy With Augmentative Feedback|ARTHE|Thomas More Kempen|No|Not yet recruiting|February 2013|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|10|||Both|18 Years|85 Years|No|||December 2012|December 10, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01723046||76492|
NCT01723293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fetal responses to exercise|Fetal Cardiovascular Response to Maternal Exercise During Third Trimester|Effect of a Specific Exercise Program During Whole Pregnancy on Fetal Heart Rate Response to Maternal Effort in Third Trimester. A Randomised Controlled Trial||Technical University of Madrid|Yes|Recruiting|March 2010|June 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|November 13, 2014|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723293||76473|
NCT01723605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32012|Insitu Repair Versus Uterine Exeriorization During Cesarean Section|Insitu Repair Versus Uterine Exeriorization During Cesarean Section: A Randomised Controlled Trial||Cairo University|Yes|Completed|October 2012|December 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1000|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||December 2013|December 28, 2013|November 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723605||76449|
NCT01730131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130017|Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)|Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|2 Years|N/A|No|||April 2015|September 24, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01730131||75950|
NCT01730378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114695|Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old|Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old||GlaxoSmithKline||Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|November 15, 2012|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01730378||75931|
NCT01730391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114989|Neisseria Meningitidis Burden of Disease Study|Neisseria Meningitidis Burden of Disease||GlaxoSmithKline||Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|521|Samples Without DNA|Cerebrospinal Fluid (CSF) sample (collected as part of routine practice)|Both|N/A|N/A|No|Non-Probability Sample|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and        Vietnam.|November 2015|November 9, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730391||75930|
NCT01730404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1201-PR-0079|Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients|A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 µg Daily) in Subjects With COPD||Chiesi Farmaceutici S.p.A.|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|40 Years|70 Years|No|||November 2014|November 18, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01730404||75929|
NCT01726725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:099|Hemifacial Spasm and Desflurane|Investigating the Etiology of Hemifacial Spasm (HFS): The Role of Desflurane|HFS|University of Manitoba|Yes|Enrolling by invitation|November 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with hemifacial spasm who will be undergoing microvascular        decompression surgery|November 2012|November 15, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726725||76210|
NCT01722006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-618A|Drug Effects on Preference and Reward|Drug Effects on Preference and Reward||University of Chicago|No|Completed|December 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|103|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|healthy adults|November 2012|September 4, 2013|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01722006||76572|
NCT01718028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-262|The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects|The Effect of SYSTANE® BALANCE on Non-Invasive Tear Film Break Up Time (NITFBUT) in Dry Eye Subjects With Lipid Deficiency Following 30 Days of Use||Alcon Research|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|October 29, 2012||No||No|November 15, 2013|https://clinicaltrials.gov/show/NCT01718028||76876|
NCT01727310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10013|Filling Pressures of the Left Ventricle in Patients With Significant Aortic Stenosis|Filling Pressures of the Left Ventricle in Patients With Significant Aortic Stenosis: Study of Echocardiographic Parameters Compared to Invasive Evaluation|PRESSEVAL|University Hospital, Limoges|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of both gender hospitalized for a coarctation review, and has received or will be        receiving during their stay a complete echocardiography and coronary angiography, and left        and right catheterization .|May 2014|May 24, 2014|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727310||76166|
NCT01722968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no: 2012-003743-30|A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel|A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).|BEVPAC|Karolinska University Hospital|Yes|Recruiting|November 2012|December 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01722968||76498|
NCT01724073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD-UMR204-NA1|Regular Consumption of Leafy Vegetable Sauces and Micro-nutrient Status of Young Children in Burkina Faso|Effect of the Regular Consumption of Leafy-vegetable Sauces, Rich in Iron, Zinc and Vitamin A, on Growth and Micro-nutrient Status of Young Children in Burkina Faso|Instapa-WP4|Institut de Recherche pour le Developpement|No|Withdrawn|December 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|0|||Both|12 Months|15 Months|No|||March 2014|March 4, 2014|October 25, 2012||No|Approval denied by national ethical committee of Burkina Faso|No||https://clinicaltrials.gov/show/NCT01724073||76413|
NCT01725113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12027|Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol|A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients|ECRIP|Winthrop University Hospital|No|Terminated|November 2012|October 2015|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 7, 2012|Yes|Yes|Nationwide shortage of study meds in 2013 loss of funding & competing studies|No||https://clinicaltrials.gov/show/NCT01725113||76333|
NCT01725945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34HL108753|The DASH Diet for Adults With Uncontrolled Asthma|A Pilot Study of the DASH Diet in Not-Well-Controlled Adult Asthma||Palo Alto Medical Foundation|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|90|||Both|18 Years|70 Years|No|||September 2014|September 17, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01725945||76269|
NCT01725958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSE 12-PHX-08-NU-02|Effects of a Nutritional Supplement Combination on Body Weight Management|A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period||Pharmanex|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||November 2012|October 27, 2014|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01725958||76268|
NCT01725698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCNONUNION12|The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect|||Indonesia University||Not yet recruiting|November 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|5|||Both|17 Years|65 Years|No|||November 2012|November 8, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01725698||76288|
NCT01725711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R402-98|Osseointegrated Prostheses for the Rehabilitation of Amputees|Osseointegrated Prostheses for the Rehabilitation of Amputees.|OPRA|Integrum|No|Active, not recruiting|May 1999|May 2027|Anticipated|May 2027|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|70 Years|No|||November 2012|November 13, 2012|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01725711||76287|
NCT01726413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 17536-203|A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).|A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy.||Glenmark Pharmaceuticals Ltd. India|No|Completed|November 2012|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|75 Years|No|||October 2014|October 1, 2014|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726413||76234|
NCT01726426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-001-CT|Modulation of Anaerobic Gut Bacteria of Arsenicosis Patients by Probiotics|Modulation of Anaerobic Gut Bacteria in Palmer Arsenical Keratosis Patients by Supplementation With Probiotics||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|November 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01726426||76233|
NCT01722513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20120312|Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy|Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization||Shanghai 10th People's Hospital|Yes|Active, not recruiting|November 2012|February 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|November 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722513||76533|
NCT01722526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI13412|Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients|An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)||Sanofi|Yes|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01722526||76532|
NCT01727596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904034R|The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome|The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome||National Taiwan University Hospital|No|Completed|April 2009|June 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|60 Years|No|||November 2012|November 15, 2012|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01727596||76145|
NCT01723306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306-04|Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas|"Phase II/Pilot Study of 2nd Generation Anti-CEA Esigner T Cells in Adenocarcinomas"||Roger Williams Medical Center|Yes|Active, not recruiting|October 2012|August 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|80 Years|No|||June 2014|June 20, 2014|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723306||76472|
NCT01730417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019124 (MIP-CA130394-01)|Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG|Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals|mIBG|Duke University|No|Completed|November 2009|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730417||75928|
NCT01730677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-583|Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab|Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment|LV|National Cancer Center, Korea|No|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|N/A|No|||March 2014|March 11, 2014|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730677||75908|
NCT01730690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC11040|Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae|Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae|COMBAT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|patients with bacterial meningitis adults|January 2015|February 2, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730690||75907|
NCT01726738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1128|LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations|LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|October 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01726738||76209|
NCT01726751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS-IBS-004|Spinal Cord Stimulation for Pain Relief in Irritable Bowel Syndrome|Spinal Cord Stimulation in the Irritable Bowel Syndrome - a Randomized Cross-over Trial||Uppsala University|No|Completed|August 2005|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|No|||April 2014|April 17, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01726751||76208|
NCT01727336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A041-04|Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma|A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma||Acceleron Pharma, Inc.|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727336||76165|
NCT01727349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00686-35|Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk|Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.|DESCENDANCE|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|35 Years|N/A|Accepts Healthy Volunteers|||August 2015|January 26, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727349||76164|
NCT01723553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007139|Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD|Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD||Mayo Clinic|Yes|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01723553||76453|
NCT01724333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1390REK|International Validation of the QLQ-OH17 for Oral Health|International Validation and Testing of a Supplementary Questionnaire Module for Assessment of Oral and Dental Health in Cancer; the QLQ-OH17|QLQ-OH17|Oslo University Hospital|No|Not yet recruiting|December 2012|December 2015|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|530|||Both|18 Years|N/A|No|Probability Sample|An international, cross-cultural sample of cancer patients with different diagnoses in        different phases of treatment|November 2012|November 6, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01724333||76393|
NCT01724580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14559|Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes|Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis||Eli Lilly and Company||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Months|N/A|No|||March 2016|March 8, 2016|November 5, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01724580||76374|
NCT01724840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GraftJacket01|GraftJacket Versus Tendon Interposition for Trapeziometacarpal Osteoarthritis|Resection Suspension Arthroplasty With Interposition of GraftJacket Versus Tendon Interposition for Trapeziometacarpal Osteoarthritis: A Randomised Controlled Trial||Schulthess Klinik|No|Recruiting|September 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2013|November 28, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01724840||76354|
NCT01724827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110129|Ceramic Versus Composite in the Treatment of Posterior Teeth by Inlays or Onlays|Ceramic Versus Composite in the Treatment by Inlays or Onlays of Posterior Teeth Affected by Tooth Substance Loss : a Multicenter Randomized Controlled Trial|CECOIA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01724827||76355|
NCT01725724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/763|Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients|Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients||Haukeland University Hospital|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|162|||Both|16 Years|N/A|No|||August 2013|March 27, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01725724||76286|
NCT01725737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09MMHIS178|Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)|Placebo-Controlled Trial With GlyTI-M Among Children With ADHD||Mackay Memorial Hospital|Yes|Completed|April 2012|April 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|6 Years|12 Years|No|||July 2013|July 14, 2013|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01725737||76285|
NCT01726231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEH GynObs-2|Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion|Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion||Bagcilar Training and Research Hospital|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|||Female|18 Years|60 Years|No|Probability Sample|the patiens undergoing laparoscopic surgery for various indications|December 2013|December 24, 2013|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726231||76248|
NCT01726244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-01|Self-care Program in the Prevention of Admissions of Patients|Effectiveness of an Self-care Program in the Prevention of Admissions of Patients With Hospitalizations Potentially Avoidable: Randomized Clinical Trial|AUTOCUID|Basque Health Service|No|Recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|144|||Both|N/A|N/A|No|||November 2012|March 4, 2013|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01726244||76247|
NCT01722539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIP-IPT|Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren|Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial|PIP-IPT|Universiteit Antwerpen|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|616|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01722539||76531|
NCT01727362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU in breast cancer|Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy|Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy- A Pragmatic Randomized Trial||Charite University, Berlin, Germany|No|Active, not recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01727362||76163|
NCT01727843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-263-12|Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures|Phase III Examining the Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures: a Randomized Control Trial.||Queen's University|Yes|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|65 Years|95 Years|No|||May 2013|May 13, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01727843||76126|
NCT01723319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-0025-12|A Double Blind Randomized Controlled Evaluation of the HBLPADD-coil Transcranial Magnetic Stimulation (TMS) Device - Efficacy and Safety In Subjects With ADHD.|||Shalvata Mental Health Center|Yes|Not yet recruiting|November 2012|||May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2012|November 5, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723319||76471|
NCT01723332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAPTER II|The CHAPTER II Study - Congenital Heart Adolescents Participating in Transition Evaluation Research|The CHAPTER II Study - Congenital Heart Adolescents Participating in Transition Evaluation Research||University of Alberta|No|Active, not recruiting|November 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|17 Years|No|||April 2015|April 21, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723332||76470|
NCT01730430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033660|Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias|Investigation of Biomarkers of Disease State in Alzheimer's Disease and Non-AD Dementias||Duke University|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|40|Samples With DNA|Blood, urine and cerebral spinal fluid.|Both|55 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Duke Memory Disorders Clinic|April 2014|April 18, 2014|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730430||75927|
NCT01730443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014409a|Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury|Biomarkers of Injury and Outcome in ProTECT III (BIO-ProTECT)|BIO-ProTECT|Emory University|Yes|Terminated|July 2011|July 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|576|Samples Without DNA|with consent there will be long term storage of serum for Non-DNA testing|Both|18 Years|N/A|No|Probability Sample|patients with a moderate to severe blunt traumatic brain injury who meet the inclusion and        exclusion criteria for the ProTECT III study.|December 2014|December 2, 2014|July 26, 2011|Yes|Yes|Parent trial (ProTECT III) stopped for futility|No||https://clinicaltrials.gov/show/NCT01730443||75926|
NCT01730456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28133|A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926|A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS||Hoffmann-La Roche||Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730456||75925|
NCT01730703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815599|Why Join a Walking Program?|Why Join a Walking Program?||University of Pennsylvania|No|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults ages 65 and older who are generally in good health and are not enrolled in daily        walking exercise programs, and are able to provide their own verbal informed consent.|November 2012|November 15, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730703||75906|
NCT01730716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2012-3|Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis||Neuralstem Inc.|Yes|Active, not recruiting|May 2013|November 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||May 2013|April 16, 2015|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01730716||75905|
NCT01721720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120202|Genetic, Brain Structure, and Environmental Effects on ADHD|The Neurobehavioral, Environmental and Genetic Factors Impacting the Clinical Course of Attention Deficit Hyperactivity Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|||||N/A|Observational|N/A|||Anticipated|1200|||Both|3 Years|N/A|Accepts Healthy Volunteers|||April 2015|March 22, 2016|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01721720||76594|
NCT01722266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1962|Liraglutide in the Treatment of Type 1 Diabetes Mellitus|Liraglutide in the Treatment of Type 1 Diabetes Mellitus||Kaleida Health|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|72|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|November 2, 2012|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01722266||76552|Three subjects randomized to 1.2 mg group and one subject randomized to 1.8 mg group tolerated only 0.6 mg. These 4 subjects were included in the 0.6 mg group for analysis.
NCT01722279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10070|The Long Term Impact of Bariatric Surgery on Quality of Life|The Long Term Impact of Bariatric Surgery on Quality of Life||St. Vincent Carmel Hospital|No|Completed|July 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|414|||Both|18 Years|N/A|No|Non-Probability Sample|Bariatric surgery patients of the St. Vincent Bariatric Center of Excellence who had        surgery at least 5 years before the survey was administered.|November 2012|November 2, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722279||76551|
NCT01718041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRS-317 Protocol 12VR2|Versartis Trial in Children to Assess Long-Acting Growth Hormone|A Long-acting Human Growth Hormone (VRS-317) in Pre-pubertal Children With Growth Hormone Deficiency: A Randomized, Open-label, Multi-center, Phase 1b/2a Study of Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy After Subcutaneous Administration for 6 Months|VERTICAL|Versartis Inc.|No|Completed|October 2012|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|3 Years|11 Years|No|||December 2014|December 8, 2014|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718041||76875|
NCT01724593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS REB No. 12-475|Functional Recovery in Critically Ill Children|Functional Recovery in Critically Ill Children - the Wee-Cover Pilot Study||McMaster University|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|12 Months|17 Years|No|Probability Sample|Critically Ill Children|November 2013|November 3, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01724593||76373|
NCT01724853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASSH01|Outcomes of Treatment for Trapeziometacarpal Osteoarthritis|Outcomes of Treatment for Trapeziometacarpal Osteoarthritis Using a Comprehensive Core Set.|RASSH|Schulthess Klinik|Yes|Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|177|||Both|18 Years|N/A|No|||November 2013|November 28, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01724853||76353|
NCT01725126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116623|To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes|A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes||GlaxoSmithKline|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|53|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|February 14, 2014|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725126||76332|
NCT01725425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8964B|The Effect of Portion Sizes on Mood|The Impact of Portion Size of Foods on Mood in Normal Weight Adults 18-35||University of Tennessee|No|Active, not recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|25|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725425||76309|
NCT01725438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10123|Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Fetal Cells|Clinical Validation of the ISET Method for the Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Trophoblastic Cells|ISETTRI21|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725438||76308|
NCT01725984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1201|AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up|AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up||American Medical Systems|No|Completed|August 2012|January 2014|Actual|January 2013|Actual|Phase 3|Observational|Observational Model: Cohort||2|Actual|80|||Male|40 Years|N/A|No|Non-Probability Sample|Male subject ≥40 years of age who received the AdVance male sling after January 1, 2010 or        the AdVance XP male sling after July 1, 2010 for the treatment of post prostatectomy SUI        at one institution in Munich, Germany.|June 2015|June 25, 2015|July 13, 2012||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01725984||76266|
NCT01725971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silicose2012|Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis|The Use of Forced Oscillation Technique in the Analysis of Respiratory System in Never-smoking Patients With Silicosis:Pathophysiological Study and Evaluation of Diagnostic Accuracy||Rio de Janeiro State University|No|Completed|July 2010|June 2013|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|67|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The control group will consist of healthy subjects, nonsmokers, who had no episode of        respiratory infection thirty days before the examinations.        The group with diagnosis of silicosis was established based on a history of substantial        exposure to silica dusts and compatible radiological features, together with exclusion of        other competing diagnoses.|October 2014|October 21, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01725971||76267|
NCT01726439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-952|Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China|A 5-year Prospective and Observational Study to Evaluate the Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Chronic Hepatitis B (CHB) Patients Naive to NUC in Real World Practice at Hospitals in Tier 2 Cities in China (the EVOLVE Study)|EVOLVE|Bristol-Myers Squibb|No|Active, not recruiting|December 2012|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3435|Samples With DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Hospitals in Chinese tier 2 cities. The definition of these hospitals is the following:          -  Hospitals where 300 or more CHB patients are treated monthly          -  Hospitals where PCR can be performed in the hospital's laboratory to measure HBV DNA             serum levels|February 2016|February 17, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726439||76232|
NCT01727050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSMSLH|Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty|Randomized Prospective Trial of Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty||Chinese University of Hong Kong|No|Completed|June 2007|December 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|70 Years|No|||November 2012|November 16, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727050||76185|
NCT01720589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-33610-19482|Effect of Dietary Fat Cooking Blend on Energy Expenditure in Children|Development of Rich & Creamy Melt® Organic Cooking Blend for Oxidative Stability and Reducing Childhood Obesity|Melt|St. Luke's-Roosevelt Hospital Center|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|5|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01720589||76681|
NCT01720602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7841|Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy|A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B||University of Washington|No|Active, not recruiting|November 2012|December 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 31, 2012|No|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01720602||76680|
NCT01720966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-RTB-0004|Adhesions After Open Versus Laparoscopic Resection of Colorectal Malignancies Detected During Liver Resection|Adhesions After Open Versus Laparoscopic Resection of Colorectal Malignancies Detected During Liver Resection|ALIVE|Radboud University|No|Completed|January 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|100 Years|No|Non-Probability Sample|All consecutive patients undergoing laparotomy or laparoscopy for intended liver resection        or radio frequency ablation for colorectal metastases in the before mentioned centers will        be assessed for eligibility. The planned number of patients will be recruited in        approximately 1 year.|November 2015|November 9, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01720966||76652|
NCT01721486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-162|Acetaminophen's Efficacy For Post-operative Pain|Efficacy of IV vs Oral Administration Of Acetaminophen For Pain Control Following Tonsillectomy With OR Without Adenoidectomy||William Beaumont Hospitals|Yes|Completed|September 2012|January 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|41|||Both|5 Years|13 Years|No|||June 2015|June 3, 2015|September 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01721486||76612|
NCT01721785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2-051|Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer|Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer||Maastricht University Medical Center|No|Suspended|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|All patients diagnosed with rectal cancer in one of the participating centres will be        considered for inclusion in the study.|November 2014|March 15, 2016|November 1, 2012|Yes|Yes|Temporary suspension of approval|No||https://clinicaltrials.gov/show/NCT01721785||76589|
NCT01721798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10369|Comparison of Two IUDs Among Cape Town HIV-positive Women|Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa||FHI 360|Yes|Recruiting|November 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|288|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|October 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01721798||76588|
NCT01734850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-USA-11|Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection|An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART||Calimmune, Inc.|Yes|Recruiting|April 2013|September 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734850||75591|
NCT01701310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11GS005|IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia|An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy|IVICA|Nottingham University Hospitals NHS Trust|No|Recruiting|April 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01701310||78157|
NCT01734811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV130-SLG-002|Efficacy and Safety Evaluation in Recurrent Bronchospasms|Randomized Double-blind Placebo-controlled, Parallel, Single Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm for the Evaluation of Efficacy, Security and Clinical Impact.|MV130|Inmunotek S.L.|No|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|12 Months|36 Months|No|||December 2015|December 22, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01734811||75594|
NCT01734824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vinforce-012|Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo|Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo||Medical University of Vienna|Yes|Suspended|May 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|90|||Both|18 Years|65 Years|No|||September 2015|September 22, 2015|June 2, 2012||No|no patients randomized|No||https://clinicaltrials.gov/show/NCT01734824||75593|
NCT01730781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006735|Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning|Characterization of CB1 Receptors Using [11-C]OMAR||Yale University|Yes|Recruiting|July 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Observational|N/A||5|Anticipated|100|Samples With DNA|At the screening visit, genomic DNA will be extracted from whole blood, assigned a code, and      stored for analysis of group differences in the frequency of CB1R alleles and to examine the      relationship between allelic variation at the CB1R locus and [11-C] OMAR binding. In      addition, other genes or markers that may be related to brain function or to behavior may be      studied.|Male|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|The study population is composed of schizophrenia, cannabis dependence, prodromal for        psychotic illness, family history of alcoholism, and healthy volunteers.|October 2015|October 13, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01730781||75900|
NCT01731067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coktail DBS|Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot|||University Hospital, Geneva|No|Completed|November 2012|January 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731067||75878|
NCT01703078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-68|Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis|A Phase 1 Exploratory Trial Evaluating Safety and Tolerability of Topical Administration of Different Concentrations of an Ingenol Derivative Compared to Ingenol Mebutate Gel 0.05% Applied on Two Consecutive Days to Four Separate 25cm2 Treatment Areas on the Forearms of Subjects With Actinic Keratosis (Field Therapy)||LEO Pharma|No|Completed|November 2012|April 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|N/A|No|||February 2013|April 3, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703078||78021|
NCT01718652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017926|A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers|An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01718652||76828|
NCT01718912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVTRI|Periodontal Disease Treatment of a Physically Challenged Population|The Effect of an Antibiotic-antifungal Rinse on Periodontal Disease|PDT|Oravital Inc|No|Not yet recruiting|November 2012|February 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718912||76809|
NCT01719692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|low dose rituximab for ITP|Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia|Prospective Multi-center Randomized Controlled Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia|ITP|Institute of Hematology & Blood Diseases Hospital|Yes|Recruiting|August 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||August 2013|August 8, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719692||76749|
NCT01719705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/60|Effects of Pregabalin on Post-cesarean Pain|Efficacy of Preoperative Pregabalin on the Post-caesarean Pain; a Dose-response Study||Mansoura University|Yes|Completed|November 2012|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Female|18 Years|38 Years|No|||July 2015|July 29, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01719705||76748|
NCT01719406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB # 8895|The OHSU Pregnancy Exercise & Nutrition (PEN) Program|Randomized Control Pilot of a Behavior-based Exercise and Diet Intervention to Reduce Risk Factors for Gestational Diabetes Among Otherwise Healthy Pregnant Women.|PEN|Oregon Health and Science University|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|October 14, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719406||76771|
NCT01719640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-CNS|Mesenchymal Stem Cells in Central Nervous System Injury|Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System Injury||Fuzhou General Hospital|Yes|Active, not recruiting|January 2011|January 2018|Anticipated|January 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||October 2012|October 30, 2012|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01719640||76753|
NCT01719679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0204|School Located Adolescent Vaccination Study|Examination of the Effectiveness of Adolescent Vaccines Given in Schools||University of Colorado, Denver|No|Completed|August 2010|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2000|||Both|10 Years|18 Years|No|||September 2012|December 31, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719679||76750|
NCT01719965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSG1201|Evaluation of Tak Community Advisory Board|Evaluation of the Tak Province Community Ethics Community Advisory Board: Interviews and Focus Group Discussions||University of Oxford|No|Recruiting|October 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|N/A||5|Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community members who work in Tak Province, Thailand.|August 2013|August 27, 2013|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01719965||76729|
NCT01720277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC75-HD Nursing Home Pilot|High Dose Influenza Vaccine in Nursing Home|High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation||Insight Therapeutics, LLC|No|Active, not recruiting|September 2012|September 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|210|||Both|65 Years|N/A|No|||January 2013|January 9, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01720277||76705|
NCT01720290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3018|Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes|A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.||Novo Nordisk A/S|No|Completed|July 2002|February 2003|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|35 Years|70 Years|No|||October 2012|October 31, 2012|October 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720290||76704|
NCT01721226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030747-01|CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)|CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)|CARE+|George Washington University|Yes|Recruiting|August 2013|November 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2013|March 9, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01721226||76632|
NCT01721200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0294|"Learning About Biologics"-Rheumatoid Arthritis|"Learning About Biologics"||Geisinger Clinic|No|Completed|November 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|126|||Both|18 Years|N/A|No|||November 2013|March 19, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01721200||76634|
NCT01721213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116771|Trobalt™ Products Risk Survey|European Survey of Patient and Prescriber Understanding of Risks Associated With Trobalt™||GlaxoSmithKline|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A random sample of 350 patients who are currently being treated with Trobalt™or who have        received Trobalt™within the last 3 months. Patients will be recruited by prescribers, who        will be asked to provide survey invitations to their patients being treated with Trobalt™.        A random sample of 300 neurologists prescribing anti-epileptic drug (AEDs) and who have        been sent the Trobalt™ Physician's Guide. A sample of 200 neurologists will be recruited        from across the same eight countries, with up to 100 neurologists from Germany. The        recruitment will be from among those who have prescribed an AED at least once in the last        3 months, and who were on the list to which a letter including the Physician's Guide        Trobalt™ was distributed. The survey will aim to recruit at least 75 physicians (from the        seven specified countries) and 50 physicians from Germany with experience of prescribing        Trobalt™ for sub-analyses, as these individuals would be expected to be more aware of the        risks of Trobalt™.|January 2015|January 19, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01721213||76633|
NCT01721499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809004271|Decreasing Stress and Improving Self-control With "Stress in Control" (Sync) Training|Decreasing Stress and Improving Self-control With "Stress in Control" (Sync) Training|Sync|Yale University|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01721499||76611|
NCT01721512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Grow|The Growth and Development of Breast and Formula Fed Term Asian Infants|The Growth and Development of Breast and Formula Fed (Containing Synbiotics and LCPUFA) Term Asian Infants.||Indonesia University|Yes|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|160|Samples With DNA|Faecal samples|Both|N/A|6 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Healthy infants recruited from Jati Padang, Pasar Minggu District, South Jakarta,        Indonesia|November 2012|November 2, 2012|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721512||76610|
NCT01721811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klefter2|Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism|Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism||Glostrup University Hospital, Copenhagen|No|Recruiting|October 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721811||76587|
NCT01722097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMBDK2012|Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure|Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure||Herlev Hospital|Yes|Completed|November 2012|July 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|November 2, 2012||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01722097||76565|
NCT01701323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2584.00|Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage||Fred Hutchinson Cancer Research Center|No|Recruiting|December 2012|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|6 Months|30 Years|No|||October 2015|October 1, 2015|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701323||78156|
NCT01701336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV004|Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients|Phase Ib Study to Assess the Safety and Immunogenicity of a Novel HCV Vaccine, Based on the Sequential Injection of Ad6NSmut and MVA-NSmut, Given in Combination With PEG-Interferon Alfa Plus Ribavirin for Re-treatment of Chronic Hepatitis C|HCV004|ReiThera Srl|Yes|Completed|March 2012|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||August 2013|August 28, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01701336||78155|
NCT01701869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH MED 1055|Microbiology & Immunology of the Chronically-inflamed Airway|Microbiology & Immunology of the Chronically-inflamed Airway (RESP RES-001 (117027))|MICA|University Hospital Southampton NHS Foundation Trust.|No|Active, not recruiting|September 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|32|Samples With DNA|Serum, plasma, inflammatory cell RNA/DNA, nasopharyngeal swabs, urine, sputum supernatants,      sputum cells, bronchial epitehlial cells, BAL supernatants, BAL cells, bronchial biopsies.|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers will be recruited from General Practice in the form of patient screening        clinics,and GP Mailshot. Quitters and pulmonary rehabilitation, would also be approached.        The Respiratory Centre, patient support groups, and outpatient departments and wards,        would also be areas of recruitment.|May 2015|May 29, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01701869||78114|
NCT01734837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1111|TICAP - Titanium Clips for Appendiceal Stump Closure|Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.|TICAP|Aesculap AG|No|Completed|October 2011|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|390|||Both|16 Years|N/A|No|Probability Sample|adult patients and children|September 2015|September 8, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01734837||75592|
NCT01731340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-11-231|A Study on the Impact of Calcium on Woman's Vascular Health|The Effect of Dietary Calcium Intake as Compared to Calcium Supplementation on Vascular Health and Bone Health in Postmenopausal Women||McGill University Health Center|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Female|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731340||75857|
NCT01731587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 63325-019|Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer|Phase Ib, Single-arm, Proof-of-principle Trial Investigating the Cytokine Profile and Specific T Cell Response in Peripheral Blood of Non-small Cell Lung Cancer (NSCLC) Subjects With Unresected Stage III Disease Treated With L-BLP25|FINGERPRINT|Merck KGaA|No|Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|October 11, 2012||No|The objectives of this trial are no longer deemed appropriate for the clinical development of    L-BLP25 therefore this trial is withdrawn|No||https://clinicaltrials.gov/show/NCT01731587||75838|
NCT01731600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7088-3885|A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A|A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A|pathfinder™5|Novo Nordisk A/S|No|Active, not recruiting|February 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Male|N/A|11 Years|No|||March 2016|March 18, 2016|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731600||75837|
NCT01702142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Molfenter_2012_008|To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine|To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine||University of Wisconsin, Madison|Yes|Active, not recruiting|March 2012|May 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|15|None Retained|Biospecimens are not part of this study.|Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Treatment agencies and Ohio County Boards|May 2013|June 10, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01702142||78093|
NCT01702155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11-11002|Phase I/II Study of DFP-10917 in Patients With Acute Leukemia|A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia||Delta-Fly Pharma, Inc.||Recruiting|September 2012|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702155||78092|
NCT01703390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_ERCC1|Biomarker Directed Treatment in Metastatic Colorectal Cancer|||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Recruiting|August 2012|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|October 4, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01703390||77997|
NCT01719185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001323|The Effect of Phentermine and B12 on Weight Loss Among Obese Patients|A Pilot Study to Assess Whether the Combination of Phentermine and B12 Has a Significant Effect on Weight Loss Among an Obese Study Population||East Carolina University|Yes|Completed|September 2012|April 2013|Actual|January 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719185||76788|
NCT01719432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 021112|Effect of Body Mass on Filgrastim Pharmacokinetics|Effect of Body Mass on Filgrastim Pharmacokinetics||West Virginia University|Yes|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Obese and non-obese patients receiving filgrastim|December 2015|December 11, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719432||76769|
NCT01719172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVEUST0278|A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue|A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue||Medtronic - MITG|Yes|Completed|September 2012|June 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|October 30, 2012||No||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01719172||76789|
NCT01719419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12014|The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects|The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects: A Pilot Study||Pennington Biomedical Research Center|No|Withdrawn|March 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719419||76770|
NCT01719666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.651|Medial Patellofemoral Ligament Reconstruction With or Without Lateral Retinaculum Release|Randomized Control Trial on Lateral Retinaculum Release in MPFL Reconstruction||Hospices Civils de Lyon|No|Recruiting|November 2011|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|45 Years|No|||November 2015|November 13, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01719666||76751|
NCT01720329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-2012|Use of Probiotics to Prevent Influenza|A Randomized Controlled Trial of Probiotics to Prevent Influenza and Other Respiratory Infections in Residents of Long-term Care Facilities: A Pilot Study||McMaster University|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|1440|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01720329||76701|
NCT01719978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTornelli|Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics|Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind "Split-mouth" Controlled Trial.||University of Sao Paulo|No|Completed|October 2007|December 2011|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 31, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01719978||76728|
NCT01720303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3020|Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes|A Multi-centre, Open, Randomised, Parallel, Controlled Trial to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin With Insulin Alone in Type 2 Diabetic Subjects Inadequately Controlled With Sulphonylurea ± Biguanide Therapy||Novo Nordisk A/S|No|Completed|September 2002|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|70 Years|No|||October 2012|October 31, 2012|October 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720303||76703|
NCT01720316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p001597|Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders|Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase||Mclean Hospital|Yes|Enrolling by invitation|December 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720316||76702|
NCT01720576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1033-HV-1204|Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)|||Regeneron Pharmaceuticals|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 10, 2013|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720576||76682|
NCT01720979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37226.029.11|TBI Project Amsterdam|Attention, Learning and Behaviour Following Traumatic Brain Injury in Children||VU University of Amsterdam|No|Completed|November 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|90|||Both|6 Years|12 Years|No|Non-Probability Sample|Children that have been admitted to the hospital after sustaining trauma.|December 2015|December 2, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01720979||76651|
NCT01721239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIH-01863-2012-011|Recovery and Aftercare in Post Intensive Care Therapy Patients - RAPIT Study|Recovery and Aftercare in Post Intensive Care Therapy Patients - The RAPIT Study. The Effectiveness and Experiences of a Follow-up Program for Danish Mechanically Ventilated ICU Patients: A Pragmatic Randomized Controlled Multicentre Trial.|RAPIT|Hillerod Hospital, Denmark|Yes|Active, not recruiting|November 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|340|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721239||76631|
NCT01721252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 08-41|Tarceva. ICORG 08-41|Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Completed|December 2009|||August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient (18 years of age or older) diagnosed with non-small cell lung cancer at any        stage who is to be treated with erlotinib.|March 2015|March 27, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01721252||76630|
NCT01721265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-009|3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals|3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals||Merck Sharp & Dohme Corp.|No|Terminated|October 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|Samples Without DNA|Human plasma|Both|18 Years|65 Years|No|Non-Probability Sample|The population will include subjects who participated in studies of Idenix anti-HCV DAAs.|April 2015|April 15, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721265||76629|
NCT01721525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-150|Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)|Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|November 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01721525||76609|
NCT01721538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCENARIO OP1|Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction|Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial|SCENARIO|Philipps University Marburg Medical Center|Yes|Recruiting|October 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|85 Years|No|||November 2012|November 2, 2012|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721538||76608|
NCT01722136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11530-FA79|"We Walk": Impact of Exercise Dose on Health Outcomes Among Women Ages 60-75|We Walk - Energy Expenditure and Health Outcomes in Older, Sedentary Women.|WW|University of South Carolina|No|Recruiting|August 2012|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||August 2015|January 14, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01722136||76562|
NCT01701882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 047|A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine|||St Stephens Aids Trust||Active, not recruiting||||||Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01701882||78113|
NCT01731080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI-2011|Arterial Wall Calcium Load in Pseudoxanthoma Elasticum|Arterial Wall Calcium Load and Preferential Sites in Pseudoxanthoma Elasticum Versus Type 2 Diabetes and Chronic Kidney Disease.|Ca-Art-PXE2|University Hospital, Angers|Yes|Recruiting|January 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Pseudoxanthoma Elasticum (PXE)|November 2012|November 20, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731080||75877|
NCT01701830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/02|Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease|The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease||Kocaeli Derince Education and Research Hospital||Recruiting|October 2012|May 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|85|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Department of Nephrology, Check-up clinic|October 2012|October 4, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701830||78117|
NCT01701843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0074-33|Cromoglicate in Mastocytosis|A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis||LEO Pharma|No|Terminated|October 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|70 Years|No|||March 2013|March 6, 2013|July 11, 2012||No|prematurely terminated because of low recruitment|No||https://clinicaltrials.gov/show/NCT01701843||78116|
NCT01701856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.11.01|Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis|Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis: A Swiss Multicenter Study Prospective, Controlled, Single-arm, Open-label, Multi-centre, Phase IV Study||Ospedale Civico, Lugano|Yes|Terminated|September 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||January 2014|January 21, 2014|September 18, 2012||No|Problems to recruit the needed number of patients in the planned time|No||https://clinicaltrials.gov/show/NCT01701856||78115|
NCT01702792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12209|Derivation of Tumor Specific Hybridomas|Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas||Dartmouth-Hitchcock Medical Center|Yes|Terminated|January 2014|||May 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 3, 2012|Yes|Yes|Investigator is leaving dartmouth|No||https://clinicaltrials.gov/show/NCT01702792||78043|
NCT01703117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APE-0792|Riluzole in Mild Alzheimer's Disease|Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease||Rockefeller University|Yes|Recruiting|April 2013|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|60 Years|85 Years|No|||March 2016|March 2, 2016|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703117||78018|
NCT01718704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069795|Viberect Penile Vibratory Stimulation to Enhance Recovery of Erectile Function and Urinary Continence Post-Prostatectomy|Study of Non-Invasive Viberect® Penile Vibratory Stimulation Regimen to Enhance Recovery of Erectile Function/Rigidity and Urinary Control/Continence After Nerve Sparing Radical Prostatectomy (RP) for Clinically Localized Prostate Cancer.||Johns Hopkins University|No|Recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Male|40 Years|70 Years|No|||September 2013|September 20, 2013|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718704||76825|
NCT01718717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA and AF|Effect of Thoracic Epidural Analgesia for Thoracotomy on the Occurrence of AF|Effect of Thoracic Epidural Analgesia for Thoracic Surgery on Arrhythiogenesis||Larissa University Hospital|No|Not yet recruiting|December 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|50 Years|N/A|No|||July 2014|July 9, 2014|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01718717||76824|
NCT01718938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0093|Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis|A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis||Theravance Biopharma R & D, Inc.|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|64 Years|No|||May 2015|May 11, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718938||76807|
NCT01719731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH095818|Psychoeducation of Borderline Patients|Psychoeducation of Borderline Patients||Mclean Hospital|Yes|Completed|July 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|30 Years|No|||September 2015|September 23, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719731||76746|
NCT01719744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-STS-001|Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma|A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma||University Health Network, Toronto|Yes|Completed|January 2013|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719744||76745|
NCT01719991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ-26758|Vulnerable Patients in Primary Care: Nurse Case Management and Self-management Support|Pragmatic Evaluation of Case Management and Self-management Support for Vulnerable People With Chronic Diseases in Primary Care|V1SAGES|Université de Sherbrooke|Yes|Completed|November 2012|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|247|||Both|18 Years|80 Years|No|||December 2014|December 1, 2014|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01719991||76727|
NCT01720004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGO-103690|A Pilot Randomized Controlled Trial of Repeated Hands-and-Knees Positioning During Labour|Repeated Hands-and-Knees Positioning During Labour: A Pilot Randomized Controlled Trial|LPT2|University of Toronto|No|Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 30, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01720004||76726|
NCT01719718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/075|The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair|The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair.|CLOSURE|University Hospital, Ghent|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719718||76747|
NCT01720615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001|Detection of Consciousness by EEG and Auditory Evoked Potentials|Detection of Consciousness by EEG and Auditory Evoked Potentials||Technische Universität München|Yes|Completed|January 2001|April 2003|Actual|November 2001|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|N/A|N/A|No|||October 2012|October 31, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01720615||76679|
NCT01720927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-12-02|Pakistan Epidemiological Survey in Acute Pharyngitis|Pakistan Epidemiological Survey in Acute Pharyngitis||Hill Park General Hospital|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5140|||Both|3 Years|N/A|No|Non-Probability Sample|The study population will include children and adults presenting with sore throat,        temperature greater than 100.40 F, tonsillar exudates and cervical adenopathy will be        included.|September 2014|September 12, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01720927||76655|
NCT01720940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHID-001|Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin|Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin||National University Hospital, Singapore|No|Recruiting|October 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|21 Years|80 Years|No|||November 2012|November 1, 2012|October 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720940||76654|
NCT01720667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoGA - R01 FD004147-01A1 Haas|Efficacy of Intravenous Levetiracetam in Neonatal Seizures|Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures|NEOLEV2|University of California, San Diego|Yes|Recruiting|March 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|14 Days|No|||October 2015|October 7, 2015|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720667||76675|
NCT01720992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFWBP|Enhancing Family Well-being Project|Enhancing Family Well-being Project||The University of Hong Kong|Yes|Completed|March 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2400|||Both|6 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01720992||76650|
NCT01721837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.170|Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment|Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment||Boehringer Ingelheim||Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4340|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|June 2014|June 30, 2014|November 2, 2012||||No|June 30, 2014|https://clinicaltrials.gov/show/NCT01721837||76585|This non-interventional studies is conducted according to §67, section 6 German Medicines Act. The term ‚principal investigator‘ is not applicable.
NCT01721850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiPP-505092|Evaluation of Safety and Efficacy of New Infant Formula in Infantile Colic|Evaluation of the Safety and Efficacy of New Infant Formula and Its Effects on the Gastrointestinal Tolerance (Crying Time) in Infantile Colic: a Double-blind, Randomized, Controlled Intervention Study|Coco|HiPP GmbH & Co.|No|Recruiting|December 2011|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|174|||Both|N/A|60 Days|Accepts Healthy Volunteers|||March 2016|March 3, 2016|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01721850||76584|
NCT01729052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/631|Acupuncture for Postoperative Nausea, Vomiting and Pain in Children: The Implication of Parental Attitudes|The Effect of Acupuncture for Alleviation of Postoperative Nausea, Vomiting, and Pain in Children: The Implications of Parental Attitudes and Expectations||University of Tromso|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|2 Years|11 Years|No|||September 2013|September 18, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729052||76033|
NCT01702194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0087|TD-1211 IV/Oral Mass Balance Study|A Single-Dose, Fixed-Sequence, Two-Period, Two−Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD−1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD−1211 in Healthy Male Subjects||Theravance Biopharma Antibiotics, Inc.|No|Completed|November 2012|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702194||78089|
NCT01701557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0846|Fluid Resuscitation for Pediatric Diabetic Ketoacidosis|Fluid Resuscitation for Pediatric Diabetic Ketoacidosis||University of Colorado, Denver|No|Completed|November 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|18 Years|No|||October 2012|October 3, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01701557||78138|
NCT01701570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0909|Barriers to Physical Activity in People With Type 2 Diabetes|Mediators of Perceived Exercise Effort in Type 2 Diabetes - Barriers to Physical Activity|Rxercise|University of Colorado, Denver|No|Recruiting|April 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01701570||78137|
NCT01702467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116698|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers|A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers||GlaxoSmithKline|No|Completed|October 2012|April 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702467||78068|
NCT01702480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116713|Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects|Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects With Age-Related Cognitive Decline||GlaxoSmithKline|No|Completed|November 2012|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|96|||Both|55 Years|80 Years|No|||March 2016|March 10, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702480||78067|
NCT01702493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117041|A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers|A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|7||Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702493||78066|
NCT01702506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471015|Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)|Phase 1 Three Period Crossover Study To Evaluate The Effect Of Food And Antacids On The Pharmacokinetics, Safety & Tolerability Of PF-299,804 In Healthy Volunteers Who Have Received PF-299,804||Pfizer|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702506||78065|
NCT01703091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14658|A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy||Eli Lilly and Company|No|Active, not recruiting|December 2012|August 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|20 Years|N/A|No|||January 2016|January 25, 2016|October 5, 2012|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01703091||78020|
NCT01703104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASUTH/SCD02/2012|The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia|The Effect of Jobelyn ( Extract of Sorghum Bicolor) on the Haematological Parameters of Patients With Sickle Cell Anaemia Disease.||Lagos State University|Yes|Completed|January 2012|August 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|150|||Both|14 Years|45 Years|No|||October 2012|October 5, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01703104||78019|
NCT01702818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02067|Stress Hormones, Mood and Women's Sexual Desire (MODEST)|Stress Hormones, Mood and Women's Sexual Desire (MODEST)|MODEST|University of British Columbia|No|Recruiting|February 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|320|Samples Without DNA|saliva and fingernail and toenail samples|Female|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with and without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).|June 2015|June 11, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01702818||78041|
NCT01703130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126-2012|Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia|Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia|MEAV 95|Sunnybrook Health Sciences Centre|Yes|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||May 2014|May 29, 2014|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01703130||78017|
NCT01718730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000335|Cortical Excitability and Inhibition in MDD|Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder||Mayo Clinic|No|Active, not recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|200|||Both|13 Years|21 Years|No|Non-Probability Sample|This protocol will plan to screen depressed children and adolescents who are seeking        treatment at Mayo Clinic in Rochester, MN, using strict inclusion and exclusion criteria.        These adolescents will represent gender and minority distribution consistent with the        Rochester metro/rural area demographic distribution. This study will be inclusive of all        races, genders, and socioeconomic classes.|September 2015|September 10, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718730||76823|
NCT01719458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705002688|Norepinephrine Transporter Imaging in Addiction Disorders|Norepinephrine Transporter Imaging in Addiction Disorders||Yale University|Yes|Active, not recruiting|July 2007|July 2014|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24        individually matched healthy control subjects|March 2014|March 10, 2014|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01719458||76767|
NCT01718964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012DR2144|Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)|Acute Effects of Cortisol on Heroin Craving in Opioid Dependence|Ghost-Basel|University of Basel|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01718964||76805|
NCT01719211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-p-007948|Genetic Basis of Mitral Valve Prolapse|Genetic Basis of Mitral Valve Prolapse|MVP|Massachusetts General Hospital|No|Recruiting|January 1999|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|DNA|Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred for 2D echo for MVP|April 2015|April 8, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719211||76786|
NCT01719224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001326|Incidence of Sleep-disordered Breathing and Upper Airway Collapsibility in Postpartum Patients and Its Intervention|Incidence of Sleep-disordered Breathing and Upper Airway Collapsibility in Postpartum Patients and Its Intervention||Massachusetts General Hospital|Yes|Completed|March 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719224||76785|
NCT01719445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10040|The Food Phone Project|Remote Food Photography for the Real-time Measurement of Children's Food Intake|FPP|Pennington Biomedical Research Center|Yes|Completed|October 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|Samples Without DNA|Urine collection as part DLW procedure.|Both|12 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|50 adolescents will be recruited.|January 2016|January 15, 2016|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719445||76768|
NCT01720342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASE Enable|Enable® Aortic Sutureless Bioprosthesis Evaluation|Enable® Aortic Sutureless Bioprosthesis Evaluation: A Post-market Release Non-interventional Study|EASE|Medtronic Cardiovascular|No|Active, not recruiting|February 2013|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with aortic valve stenosis, aortic valve insufficiency or a combination of the        two who require aortic valve replacement are eligible for this study, if they meet all        study inclusion criteria and none of the exclusion criteria.|October 2015|October 6, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01720342||76700|
NCT01720355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0377|Pulse Oximetry- Performance During Severe Signal Interference|||Medtronic - MITG|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy, well perfused|February 2013|February 12, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720355||76699|
NCT01720628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFV-5813|The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease|||Turkish Ophthalmology Society|Yes|Completed|November 2011|February 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|86|Samples With DNA|serum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Turkish patients fulfilling the international diagnostic criteria for Behçet's disease|October 2012|October 31, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01720628||76678|
NCT01720953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-311|Neuropsychiatric Mechanisms of Change in Mentalization Based Treatment of Borderline Personality Disorder (MENTAB)|Neuropsychiatric Mechanisms of Change in Mentalization Based Treatment of Borderline Personality Disorder (MENTAB)|MENTAB|Region Sjælland||Terminated|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood samples to measure DNA methylation and BDNF serum levels. Salivary samples to      measure cortisol levels.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fifty female patients diagnosed with BPD, who will undergo a year of intensive        Mentalization Based Therapy at the Psychiatric Clinic Roskilde, Denmark, and a matched        healthy control subjects matched on age, gender and socioeconomic status.|July 2014|July 24, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01720953||76653|
NCT01720680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_1202|Prospective Exploratory Study to Assess the Effects of the AlphaCore® Device in Patients With COPD|Open-label, Prospective Exploratory Study to Assess the Effects of the AlphaCore® Device on Central and Peripheral Airway Dimensions in Patients With COPD||University Hospital, Antwerp|No|Completed|October 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01720680||76674|
NCT01720693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypoperfusion|Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy|A Pilot Study to Examine a Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy||University Health Network, Toronto|No|Terminated|June 2012|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|18 Years|90 Years|No|||February 2015|February 10, 2015|October 29, 2012||No|Low accrual|No||https://clinicaltrials.gov/show/NCT01720693||76673|
NCT01721005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T31/2012|Screening Versus Routine Practice in Detection of Atrial Fibrillation in the Elderly Population of Lieto|Screening Versus Routine Practice in Detection of Atrial Fibrillation in the Elderly Population of Lieto|LietoAF|University of Turku|No|Active, not recruiting|April 2012|December 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|75 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01721005||76649|
NCT01728766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-035|Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age Bangladeshi Infants|Longitudinal Studies of Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age, Predominantly Breast Fed, Bangladeshi Infants||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|July 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|None Retained|Breast milk Plasma|Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|The participants were 46 mothers and their term infants, 20 of whom were classified as        appropriate for gestational age (AGA, birth weight >2800 g at ≥37 weeks of gestation) and        26 of whom were classified as small for gestational age (SGA, birth weight <2500 g at ≥37        weeks of gestation). Gestational age was assessed by ultrasonography at ~32 weeks of        gestation. Only mothers who were planning to breast feed exclusively for at least four        months were included in the study. Mothers with pregnancy-induced hypertension, multiple        pregnancies, known HIV or hepatitis B infection, or use of tobacco products or alcohol        were excluded from the study, as were infants with congenital abnormalities, chronic        infections, or acute illnesses at the time of enrollment.|November 2012|November 19, 2012|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01728766||76055|
NCT01728779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-12137|Stereotactic Body Radiation With Nelfinavir for Oligometastases|Single-Arm Phase II Study of Stereotactic Body Radiation Therapy Concurrent With Nelfinavir for Oligometastases||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2013|||July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728779||76054|
NCT01729312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|female acl prevention study|Female Acl Prevention Study Where we Look at Landing Techniques Pre/Post Nine Week Strenghtening Program|Pilot Study to See if There is a Improvement in Landing Techniques After a 9 Week Strenghtening Program, Which May Decrease ACL Tears in Female Athletes||Henry Ford Health System|No|Recruiting|January 2012|September 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|None Retained|No biospecimens are taken|Female|13 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|female athletes in age of 13-16|November 2012|November 19, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729312||76013|
NCT01701908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPC2012|Postoperative Pulmonary Complications in Abdominal Surgery|Postoperative Pulmonary Complications in Major (Abdominal) Surgery: a Multicenter Study||University of Udine||Not yet recruiting|January 2013|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|1500 patients undergoing elective major abdominal surgery, urologic surgery or major        gynecological surgery under general anaesthesia.|October 2012|October 5, 2012|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01701908||78111|
NCT01702168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23MH096029-01A1|Implementation of CPT for PTSD in Diverse Communities|Implementation of Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) in Diverse Communities||Massachusetts General Hospital|Yes|Active, not recruiting|October 2012|July 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will be working with community mental health workers and stakeholders at a community        clinic, MGH Chelsea.|April 2015|April 7, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702168||78091|
NCT01702181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-12-204|A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis|A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|65 Years|No|||January 2014|January 16, 2014|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702181||78090|
NCT01702805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0050|Transfusion of Prematures Trial|Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?|TOP|NICHD Neonatal Research Network|Yes|Recruiting|December 2012|August 2018|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1824|||Both|N/A|48 Hours|No|||July 2015|July 21, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01702805||78042|
NCT01702831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRN 001|Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance|A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.|BuMelMCRN001|University Health Network, Toronto|Yes|Recruiting|March 2013|July 2021|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01702831||78040|
NCT01702844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1210|Single Arm on the Tolerability of Weekly Nab-paclitaxel|LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|October 2012|June 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|70 Years|N/A|No|||June 2015|June 22, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702844||78039|
NCT01718353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZL06056|Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy|TAXYNERGY|Sanofi|No|Completed|March 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Male|18 Years|N/A|No|||August 2015|August 26, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718353||76851|
NCT01718366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-EXVD-AZA-2011-005623-41|A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS|Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)|GFM-EXVD-AZA|Groupe Francophone des Myelodysplasies|Yes|Recruiting|February 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01718366||76850|
NCT01719198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1220|Usefulness of Calprotectin for Colon Adenoma Screening|Usefulness of Fecal Calprotectin for Screening Colon Adenoma in Korean Population||Konkuk University Medical Center|No|Recruiting|October 2012|||March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|stool specimen|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients who visit KUH healthcare center for colonoscopy in Korea over 18 years old adult        population|November 2012|November 12, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719198||76787|
NCT01719237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChloroRopiSCB|Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture|Double Blinded Randomized Control Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture||University of New Mexico|No|Completed|August 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719237||76784|
NCT01719471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805003898|fMRI of Stress in Smoking Behavior|fMRI of Stress in Smoking Behavior||Yale University|Yes|Withdrawn|February 2008|December 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|30 tobacco dependent and 30 matched healthy controls who have never smoked will be        recruited for this study|December 2014|December 12, 2014|October 29, 2012||No|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT01719471||76766|
NCT01720017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0636|Impact of Manikin Training on Airtraq Avant Learning Curve in Predicted Difficult Airways|The Impact of Airway Manikin Training on the Airtraq Avant and Wireless Monitor System Learning Curve in Airways With Predictors for Difficult Intubation||University of Wisconsin, Madison|No|Terminated|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|September 30, 2015|October 24, 2012||No|Difficulty was encountered with the subjects completing their required 20 intubations in    patients with at least one predictor of difficult intubation.|No||https://clinicaltrials.gov/show/NCT01720017||76725|
NCT01720030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levosimendan in AKI Study|Levosimendan in Acute Kidney Injury Study|Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury|LAKIS|VieCuri Medical Centre|Yes|Active, not recruiting|March 2016|October 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01720030||76724|
NCT01720043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI57748|Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients|Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients||University of Utah|Yes|Active, not recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01720043||76723|
NCT01720368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 10-0162|OPERA Database - Crohn's Protocol|IBD-OPERA Database IBD OPERA Database: Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment Database - Crohn's Protocol|OPERA|Dartmouth-Hitchcock Medical Center|No|Completed|October 2012|June 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Men and women over 18 years of age with Crohn's disease|August 2015|August 14, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720368||76698|
NCT01720381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001078|OptiScanner Versus Standard Blood Glucose Monitoring|Manual vs. Automated moNitoring Accuracy of GlucosE II (MANAGE II)||OptiScan Biomedical Corporation|Yes|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|98|Samples Without DNA|One additional blood sample (4 ml)will be collected once a day, separated into Draw an      additional ~ 4.0 mL from the subject into a syringe once per every 24 hour period. The study      site will indicate where and at what time the sample was taken. This sample is placed into a      sodium heparin tube, labeled with the subject number and sampling time and centrifuged on a      refrigerated centrifuge. The gained plasma will be frozen at minus 70 degrees Celsius or      less and may be used for potential analysis by the Sponsor, should an analysis of outliers      indicate the potential presence of an interferent.|Both|18 Years|N/A|No|Probability Sample|Critically ill patients admitted to the intensive care unit (ICU) of Erasme University        Hospital in Brussels, Belgium.|June 2014|June 23, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720381||76697|
NCT01720641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH084611|Partner Notification Strategies for MSM in Peru|Partner Notification Strategies for STI Control in Urban Peru||University of California, Los Angeles|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|370|||Male|18 Years|N/A|No|||August 2014|August 4, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01720641||76677|
NCT01720654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH092232|Expedited Partner Therapy for MSM in Peru|Expedited Partner Therapy as STI Control Among MSM in Peru||University of California, Los Angeles|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|165|||Male|18 Years|N/A|No|||August 2014|August 4, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01720654||76676|
NCT01728233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT110/12|Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis|Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.|HER-Uro01|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Not yet recruiting|December 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Male|18 Years|75 Years|No|||November 2012|November 16, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728233||76096|
NCT01728519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN003|Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen|Phase I/IIa Study to Assess the Safety, Immunogenicity and Efficacy of AllerT, a Combination of Peptides Derived From Bet v 1, Administered Via the Subcutaneous or Intradermal Route to Volunteers Allergic to Birch Pollen|AN003|Anergis|No|Terminated|August 2008|July 2012|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|55 Years|No|||November 2012|November 13, 2012|November 9, 2012||No|Recruitment was stopped before start of the pollen season|No||https://clinicaltrials.gov/show/NCT01728519||76074|
NCT01729078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003216|Dietary Interventions in Prediabetes|The Effects of Dietary Supplementation on Hepatic Insulin Action and Glucose Tolerance in Pre-diabetes||Mayo Clinic||Completed|October 2012|February 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|48|||Both|30 Years|80 Years|No|||July 2015|July 27, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01729078||76031|
NCT01729091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0379|Cord Blood Natural Killer Cells for Myeloma|Phase I/II Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|June 2013|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729091||76030|
NCT01701362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081279|Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain|A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain||Pfizer|Yes|Completed|October 2012|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|544|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701362||78153|
NCT01701583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0780|Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria|Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria||University of Colorado, Denver|Yes|Active, not recruiting|April 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701583||78136|
NCT01701921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/13-07-2011|The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery|The Effects of Pregabalin on Acute and Chronic Postoperative Pain After Cardiac Surgery||Larissa University Hospital|No|Recruiting|July 2011|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|80|||Both|18 Years|85 Years|No|||October 2012|October 3, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701921||78110|
NCT01702519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01418|A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers|A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers||GlaxoSmithKline|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|40|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2015|March 19, 2015|October 4, 2012|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01702519||78064|
NCT01702532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01589|Nicotine Mouth Film for Craving Relief.|A Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Film and Nicotine Lozenge||GlaxoSmithKline|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|December 12, 2013|October 4, 2012|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01702532||78063|
NCT01702545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK-001|Determination of Drugs and Their Metabolites in Hospitalized Patients|||Klinikum Nürnberg||Recruiting|August 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000||Blood, Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients|February 2016|February 24, 2016|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01702545||78062|
NCT01702558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28230|A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer|||Hoffmann-La Roche||Recruiting|December 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|235|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702558||78061|
NCT01703429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-11A-1296|Complementary and Alternative Care in Multiple Sclerosis|Complementary and Alternative Medicine (CAM) in Multiple Sclerosis. A Prospective Observational Study of a CAM-using Cohort|CAM Care in MS|Bastyr University|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|100 Years|No|Non-Probability Sample|Any individual with multiple sclerosis is invited to participate.|October 2015|October 28, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01703429||77994|
NCT01703702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A18|Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline|A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline||Avid Radiopharmaceuticals|No|Completed|October 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|618|||Both|50 Years|90 Years|No|||April 2015|April 30, 2015|October 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703702||77973|
NCT01718379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-Len-Epo-08|Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.|A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.||Groupe Francophone des Myelodysplasies|Yes|Active, not recruiting|July 2010|January 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||October 2012|March 19, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01718379||76849|
NCT01718392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME 2011/311|Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity|||Hasselt University|Yes|Completed|March 2011|September 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|February 7, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01718392||76848|
NCT01730560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.615|Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach|Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach|VISIOTRAIN|Hospices Civils de Lyon|No|Recruiting|November 2010|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|22|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730560||75917|
NCT01718977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02945|Cardiovascular Health/Outcomes: Improvements Created by Exercise and Eduction in SCI (CHOICES)|Cardiovascular Health/Outcomes: Improvements Created by Exercise and Eduction in SCI (CHOICES)|CHOICES|University of British Columbia|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01718977||76804|
NCT01726868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCE-001|Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism|Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism||Sendai Shakaihoken Hospital|Yes|Not yet recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|20 Years|85 Years|No|||April 2013|April 1, 2013|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01726868||76199|
NCT01719484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805003899|fMRI of Stress in Obesity|Functional Magnetic Resonance Imaging of Stress in Obesity||Yale University|Yes|Active, not recruiting|May 2008|May 2015|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|30 obese subjects and 30 matched healthy controls will be recruited for this study.|September 2013|September 25, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719484||76765|
NCT01719497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906005296|Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET|Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET||Yale University|Yes|Active, not recruiting|June 2009|June 2014|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|N = 30 Medically Healthy control subjects N = 30 Subjects with high stress exposure N = 30        Subjects with Alcohol Dependence (AD) N = 30 Obese subjects|March 2014|March 10, 2014|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01719497||76764|
NCT01719757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN11-KR-404|PROspective Non-interventional Open Label Trial for Assessment in Routine Practice of the Efficacy and the Safety of TARGIN ® in Korean Patients With Cancer Pain (PROBE)|A 4-week, Open Label, Multi-center, Prospective, Single-arm, Non-interventional Phase IV Study to Evaluate the Efficacy of Targin for the Treatment of Korean Patients With Cancer Pain Under Conditions of Daily Practice||Mundipharma Korea Ltd|No|Completed|July 2012|April 2014|Actual|October 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|359|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01719757||76744|
NCT01719770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELAX1|Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest|Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study|RELAX|Medical University of Vienna|Yes|Completed|November 2010|April 2015|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01719770||76743|
NCT01720056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 067/2012|Verapamil vs Steroid to Prevent Keloid Recurrence|Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal||The University of Western Australia|Yes|Terminated|October 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|October 30, 2012||No|Objective of study achieved after interim analysis.|No||https://clinicaltrials.gov/show/NCT01720056||76722|
NCT01720069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR506/2/004|Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma|A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy.||Vectura Limited||Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|12 Years|65 Years|No|||September 2014|September 11, 2014|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720069||76721|
NCT01720095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA_RS/2010-116|Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis|A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis||Nova Scotia Health Authority|No|Completed|October 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|August 6, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01720095||76719|
NCT01720394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUG-CRB-2012|Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert|Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert - a Multicenter Randomized Controlled Trial||Medical University of Graz|No|Recruiting|November 2013|April 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|253|||Female|18 Years|N/A|No|||August 2014|August 21, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01720394||76696|
NCT01728532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/001|Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer|Open, Randomized Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer|PA0903|Ascopharm Groupe Novasco|Yes|Active, not recruiting|June 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01728532||76073|
NCT01728792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-DEN-105|Impact of SQ vs IM Administration of DENVax on Safety and Immunogenicity|Impact of Subcutaneous Versus Intramuscular Administration of Inviragens Live Attenuated Dengue Vaccine on Safety and Immunogenicity||Takeda|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728792||76053|
NCT01728805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-010|Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL|Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma||Kyowa Hakko Kirin Pharma, Inc.|Yes|Active, not recruiting|November 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|373|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728805||76052|
NCT01728818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004063-77|Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours|Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial|ACCEPT|Ludwig-Maximilians - University of Munich|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01728818||76051|
NCT01729065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007403|A Study to Assess the Efficacy of Early Physical Therapy Intervention Following a Modified Unilateral Neck Dissection for Treatment of Head and Neck Cancer|A Randomized Study to Assess the Efficacy of Early Physical Therapy Intervention on Upper Quarter Strength and Mobility, and Reported Upper Extremity Disability and Quality of Life Measures Following a Modified Unilateral Neck Dissection for Treatment of Head and Neck Cancer||Mayo Clinic|No|Completed|January 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||May 2015|May 21, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01729065||76032|
NCT01729104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0188|Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma|A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|April 2013|||April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729104||76029|
NCT01729624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rec No: 12/SW/0252|PRO Development for ANCA Associated Vasculitis|A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure||University of Oxford|Yes|Active, not recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ANCA-associated vasculitis seen at the Oxford University Hospitals NHS        Trust.|May 2015|May 27, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01729624||75989|
NCT01701895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 1213 - IRB 12-1550|Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera|CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF||University of North Carolina, Chapel Hill|No|Completed|October 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Female|18 Years|N/A|No|Non-Probability Sample|HIV positive females ≥ 18 years of age who are currently on Complera with suppressed viral        load (VL) defined as having VL <50 copies/ml in the 6 months prior to study entry and no        known resistance to FTC, TDF, or rilpivirine. Subjects may or may not be of child bearing        potential.|November 2015|November 30, 2015|October 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701895||78112|
NCT01701609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07/90054|Cognitive Remediation Therapy (CRT) in Adolescents With EOS|Efficacy of a Cognitive Remediation Treatment in Adolescents With Schizophrenia Spectrum Disorders||Hospital Clinic of Barcelona|Yes|Completed|January 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|12 Years|18 Years|No|||July 2013|July 6, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701609||78134|
NCT01702597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|315-12|WBV and Acute Lateral Ankle Sprain|The Effect of Whole Body Vibration and Acute Unilateral Unstable Lateral Ankle Sprain - A Biphasic Randomized Controlled Trial -|WBV and ALAS|Ludwig-Maximilians - University of Munich|No|Active, not recruiting|October 2012|April 2014|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702597||78058|
NCT01702207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTTEROD|Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk|A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.|ESTTEROD|University of Saskatchewan|No|Active, not recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|75|||Both|18 Years|74 Years|No|||June 2015|June 1, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01702207||78088|
NCT01702571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28231|A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment|A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment.||Hoffmann-La Roche||Recruiting|November 2012|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2220|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702571||78060|
NCT01702584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBRAIN1204|Efficacy and Safety of StENt-assisted Treatment for CErebral Aneurysms|Efficacy and Safety of StENt-assisted Treatment for CErebral Aneurysms||Kobe City General Hospital|No|Recruiting|September 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|stent assisted embolization of intracranial aneurysm|October 2012|October 4, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01702584||78059|
NCT01703156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Risk ACS|Low Risk Acute Coronary Syndrome|Stress Testing Versus Non-Stress Testing Based Strategy in Patients Hospitalized With Low-Risk Acute Coronary Syndromes: A Randomized, Single-Center Pilot Study|LOW ACT|University of Oklahoma|Yes|Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|70|||Both|30 Years|N/A|No|||October 2012|October 9, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01703156||78015|
NCT01703169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI54443|Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia|Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia||University of Utah|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703169||78014|
NCT01730300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LN-IUSBDSK|Genitourinary Symptoms With Levonorgestrel Releasing Intrauterine Systems|Genitourinary Symptoms in Women Using Levonorgestrel Releasing Intrauterine Systems||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Yes|Completed|June 2012|May 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Female|15 Years|55 Years|No|Probability Sample|15-55 aged women using levonorgestrel releasing intrauterine device for the treatment of        menorrhagia or adenomyosis|May 2013|May 14, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730300||75937|
NCT01730573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102994|Interscalene and Combined Supra Scapular and Axillary Nerve Blocks in Rotator Cuff Repair|A Randomized Comparison of Inter Scalene and Combined Supra Scapular and Axillary Nerve Blocks for Postoperative Pain Relief in Arthroscopic Shoulder Rotator Cuff Repair||Lawson Health Research Institute|No|Completed|November 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730573||75916|
NCT01730586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0776|Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas|Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2012|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730586||75915|
NCT01726582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW 15565|Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")|A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas||Medical College of Wisconsin|Yes|Recruiting|November 2011|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726582||76221|
NCT01726595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00030546|Ultrasound Measurement of Reactive Hyperemia in Critical Care|Ultrasound Measurement of Reactive Hyperemia in Critical Care: Prognostic and Pathophysiologic Significance|URHC|University of Rochester|No|Recruiting|January 2013|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|252|Samples With DNA|Blood and urine specimens will be obtained within 48 hours of diagnosis of severe sepsis or      severe non-infectious systemic inflammatory response syndrome. Subsequent blood and urine      samples will be obtained 3-5 days after the first set of samples, within 48 hours of ICU      discharge, and within 48 hours of hospital discharge. Samples will analyzed immediately or      stored at -80 degrees celsius until use.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Critically ill Patients:        Patients admitted to University of Rochester Medical Center ICU services with 2 of the 4        systemic inflammatory response syndrome (SIRS) criteria and acute organ dysfunction will        be considered for enrollment.        Healthy Control subjects:        Healthy control subjects >= 18 years of age will be recruited from the University and        Rochester region at large.|February 2016|February 17, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726595||76220|
NCT01726881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9572-GZ-SMC|Predicting Central Pain Among People With SCI by Evaluating Mechanisms Regulating Pain and Efficacy Testing of the TENS Apparatus|||Sheba Medical Center|No|Not yet recruiting|December 2012|||December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01726881||76198|
NCT01726894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0399|Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation|A Prospective Development Study Evaluating Focal Therapy Using Irreversible Electroporation (Nanoknife®) in Men With Localised Prostate Cancer|Nano|University College London Hospitals|Yes|Active, not recruiting|October 2013|||August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Male|18 Years|N/A|No|||June 2014|June 17, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01726894||76197|
NCT01727193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-LEF|The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy|||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|12 Years|60 Years|No|||November 2012|November 16, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727193||76175|
NCT01719783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-H5N2-01|Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine||PATH|Yes|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2013|June 27, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719783||76742|
NCT01719796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTAP|Effect of TAP Block on Ventilatory Function Following Abdominal Surgery|Assessment of the Ventilatory Effects of Transverse Abdominal Plan Regional Analgesia Following Abdominal Surgery.|KTAP|Pierre and Marie Curie University|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01719796||76741|
NCT01720082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOI - SICE|Laparoscopic Appendectomy by Multi-port vs Single Port.|Randomized Controlled Trial Comparing Single Incision Laparoscopic Appendectomy Versus Standard Three Port Appendectomy in a Selected Cohort of Patients|AMUSING|Associazione Chirurghi Ospedalieri Italiani|No|Not yet recruiting|March 2013|February 2014|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|14 Years|60 Years|No|||November 2012|November 2, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720082||76720|
NCT01720108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPCATII.001|Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty|Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty|EPCAT II|Nova Scotia Health Authority|Yes|Recruiting|February 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3426|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01720108||76718|
NCT01720407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD11/06-S|Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face|Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face|ImiReduc|Nantes University Hospital|No|Recruiting|December 2012|August 2019|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01720407||76695|
NCT01720420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-174|A Clinical Evaluation of NobelProcera Implant Bar Overdenture|A Clinical Evaluation of NobelProceraTM Implant Bar Overdenture in the Mandible or Maxilla on 4 NobelReplaceTM CC Implants||Nobel Biocare|Yes|Recruiting|October 2012|December 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|April 13, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01720420||76694|
NCT01728545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAB04-0249|The Collection and Storage of Umbilical Cord Blood for Transplantation|The Collection and Storage of Umbilical Cord Blood for Transplantation||M.D. Anderson Cancer Center|No|Recruiting|April 2005|||June 2099|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250000|Samples With DNA|Blood samples from the umbilical cords of newborn babies, a minimum of 40 ml is needed for      processing.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Neonates delievered by women age 18 years or older.|February 2016|February 15, 2016|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01728545||76072|
NCT01728831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-294|Study of Cerebral Tissue Oxygenation During Transfusion in Traumatic Brain Injury|Observational Study of Cerebral Tissue Oxygen Saturation During Blood Transfusion in Severe Traumatic Brain Injured Patients|NIRSTBI|St. Michael's Hospital, Toronto|No|Completed|November 2012|November 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Non-Probability Sample|30 Patient with clinical diagnosis of severe TBI and GCS <9 and Age > 18 years old|November 2015|December 1, 2015|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01728831||76050|
NCT01728844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2011-10-31-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||November 17, 2014|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728844||76049|
NCT01728857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-007|Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction|The Effects of Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction|TOPS|Zeltiq Aesthetics|No|Active, not recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|August 13, 2014|November 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01728857||76048|
NCT01729871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100732|A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy|A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation|VENTURE-AF|Janssen Scientific Affairs, LLC|No|Completed|February 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||November 2015|December 3, 2015|October 23, 2012|Yes|Yes||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01729871||75970|
NCT01701622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0186|The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study|The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study||University of Mississippi Medical Center|No|Terminated|January 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||December 2012|February 8, 2013|January 27, 2010||No|unable to enroll participants|No|November 9, 2012|https://clinicaltrials.gov/show/NCT01701622||78133|Early termination leading to no subjects analyzed
NCT01702259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMCTE002|Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia Scanner Device (GLS) Green Diode on Reducing the Appearance of Cellulite Clinical Study Protocol.||Erchonia Corporation|No|Completed|October 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 8, 2015|October 4, 2012|Yes|Yes||No|July 9, 2015|https://clinicaltrials.gov/show/NCT01702259||78084|
NCT01702272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENVTS-US12-002|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - Creative Testing Solutions||Gen-Probe, Incorporated|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|volunteer blood donors from the US and Puerto Rico|September 2014|September 11, 2014|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702272||78083|
NCT01702220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H30928|Calmer Life: Testing the Effectiveness of a Treatment for Anxiety|Calmer Life: A Randomized Controlled Trial of a Participant-Centered Treatment for Anxiety in Low-Income, Older Adults||Baylor College of Medicine|No|Completed|October 2012|August 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||January 2016|January 11, 2016|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702220||78087|
NCT01702233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRARO|TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study|Treatment of Rotator Cuff Syndrome and Bursitis: A Double Blind, Controlled Trial to Assess the Efficacy and Safety of Traumeel® S Injection Versus Corticosteroid Injections and Versus Placebo|TRARO|Biologische Heilmittel Heel GmbH|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|40 Years|65 Years|No|||January 2016|January 27, 2016|October 4, 2012||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01702233||78086|
NCT01703143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007909|Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy|A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy||Mayo Clinic|Yes|Completed|May 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||January 2015|January 23, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703143||78016|
NCT01703741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000077|A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel|A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males||Ferring Pharmaceuticals|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Male|18 Years|75 Years|No|||October 2014|October 7, 2014|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703741||77970|
NCT01703754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI001-201|Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.|A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions||Ziopharm|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703754||77969|
NCT01730612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/4-O|ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA|Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA|iTEPsein|Nantes University Hospital|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01730612||75913|
NCT01730625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABMT-RCT|Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial|Augmenting Effects of Attention Bias Modification Treatment on Cognitive Behavioral Therapy in Anxious Children: A Randomized Clinical Trial||Tel Aviv University|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|119|||Both|6 Years|18 Years|No|||November 2012|November 15, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730625||75912|
NCT01726621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP267|User Evaluation of the MiniMed 620G and 640G Insulin Pumps|A User Evaluation of the MiniMed® 620G and 640G Insulin Pumps and Guardian® Link Transmitter||Medtronic Diabetes|No|Recruiting|March 2013|||August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|7 Years|N/A|No|Non-Probability Sample|Patients within the research center diabetes population who currently use insulin pump for        their diabetes therapy.|November 2013|April 11, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01726621||76218|
NCT01726608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reda 7869|RFN for SIJ Disease Study|A Sham, Controlled, Randomised Trial to Investigate the Effects of Radiofrequency Neurotomy Using Simplicity III® on Patients With Sacroiliac Joint Pain.||Barts & The London NHS Trust|Yes|Recruiting|November 2012|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2013|January 28, 2013|November 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01726608||76219|
NCT01727219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-I010|COPD Assessment Test Can Predict Depression|COPD Assessment Test Can Predict Depression||Hallym University Medical Center|No|Not yet recruiting|December 2012|May 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|40 Years|N/A|No|Non-Probability Sample|Stable COPD patients who visit outpatient departments.|February 2011|November 18, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727219||76173|
NCT01727232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mondor-Rituxcompare|Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia|Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia||Henri Mondor University Hospital|No|Completed|January 2007|October 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|107|||Both|18 Years|N/A|No|Non-Probability Sample|Primary ITP patients treated with standard or RA regimen were retrospectively included in        the observationnal study.|November 2012|November 12, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727232||76172|
NCT01727206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECD-TCZ-01|Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease|Open-label, Single-arm, Phase II, Prospective, Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease||Ospedale San Raffaele|Yes|Terminated|November 2012|December 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727206||76174|
NCT01727466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0245|Treatment for Children With Autism and Anxiety|A Randomized Trial: Group Cognitive Behavior Therapy for Children With High-Functioning Autism Spectrum Disorders and Anxiety||University of Colorado, Denver|Yes|Completed|August 2006|December 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|8 Years|14 Years|No|||October 2012|November 12, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01727466||76155|
NCT01727674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207022RIB|Exploring the Experience of Communication for Patients With Depression|Exploring the Experience of Communication for Patients With Depression||National Taiwan University Hospital|No|Not yet recruiting|November 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|12|||Both|20 Years|N/A|No|Non-Probability Sample|depression|November 2012|November 12, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01727674||76139|
NCT01727947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSOME_SLV|Influence of Sperm With Large Nuclear Vacuole on ICSI Outcomes|Influence of Sperm With Large Nuclear Vacuoles on the Cycles' Outcomes of Couples Couples Undergoing ICSI||Sapientiae Institute|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727947||76118|
NCT01728870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0164-12-WOMC|Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease|Comparison of Partial Enteral Nutririon (Modulen) With a Unique Diet to Exclusive Enteral Nutrition (Modulen) for the Treatment of Pediatric Crohn's Disease. A Prospective Randomized Controlled Trial.||Wolfson Medical Center|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|4 Years|18 Years|No|||December 2015|December 6, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728870||76047|
NCT01729117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-08-00646|A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population|The 1,2,3 Plan: A Randomized Controlled Trial of Meal Replacement With a Lifestyle Modification Program vs. Standard Care at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population||University of Southern California|No|Completed|May 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729117||76028|
NCT01729338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038924|Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma|Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen||Duke University|Yes|Active, not recruiting|December 2012|December 2020|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729338||76011|
NCT01729884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7905|Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer|Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer||University of Washington|No|Terminated|December 2012|||June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|N/A|No|||October 2014|October 30, 2014|November 15, 2012|No|Yes|Study ended early due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01729884||75969|
NCT01702246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF-ICRA-2011|Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease|Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease||Children's Hospital & Research Center Oakland|Yes|Recruiting|February 2012|June 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|10 Years|N/A|No|||February 2015|February 2, 2015|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702246||78085|
NCT01702896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07|Interleukin-2 in Metastatic Melanoma|Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Melanoma||Western Regional Medical Center|No|Terminated|September 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|October 4, 2012|Yes|Yes|PI Decision|No||https://clinicaltrials.gov/show/NCT01702896||78035|
NCT01702909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08|Interleukin-2 in Metastatic Kidney Cancer|Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer||Western Regional Medical Center|No|Terminated|September 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|October 4, 2012|Yes|Yes|PI Decision|No||https://clinicaltrials.gov/show/NCT01702909||78034|
NCT01702857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-12|A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)|A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico|DPIV-002|U.S. Army Medical Research and Materiel Command|Yes|Active, not recruiting|November 2012|December 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|100|||Both|20 Years|39 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|October 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702857||78038|
NCT01702610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-08-013|Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|||McGill University Health Center|No|Completed|December 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702610||78057|
NCT01702870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoW-Myositis01|Diagnostic Accuracy of MR in Myositis|Comparison of Magnetic Resonance (MR) Imaging Against Clinical Criteria in the Diagnosis and Monitoring of Adult Idiopathic Myopathy||University of Warwick|No|Not yet recruiting|November 2012|November 2014|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study group will be patients attendeing rheumatology outpoatient clinics with a        suspected diagnosis of myopathy based on clinical criteria|October 2012|October 16, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702870||78037|
NCT01702883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20789|The Medication Experience Study|Using an Internet Survey to Improve Patient Adherence in Chronic Disease||Wake Forest School of Medicine|No|Active, not recruiting|October 2012|March 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|186|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702883||78036|
NCT01704105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA-2012-KE|WASH Benefits Kenya|WASH Benefits Kenya: A Cluster Randomized Controlled Trial of the Benefits of Sanitation, Water Quality, Handwashing, and Nutrition Interventions on Child Health and Development|WASHB-Kenya|Innovations for Poverty Action|Yes|Recruiting|September 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|8||Anticipated|8000|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01704105||77942|
NCT01699789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPIC-2012-KW|Community Partners in Care is a Research Project Funded by the National Institutes of Health|CPIC is a Community Partnered Participatory Research (CPPR) Project of Community and Academic Partners Working Together to Learn the Best Way to Reduce Depression in Our Communities.|CPIC|RAND|No|Active, not recruiting|January 2009|June 2016|Anticipated|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1246|||Both|18 Years|N/A|No|||September 2015|December 3, 2015|September 27, 2012||No||No|May 6, 2014|https://clinicaltrials.gov/show/NCT01699789||78274|Communities had history of using CPPR for depression. Response rates moderate for agencies, high for programs. Convenience samples of sites. Client retention rates lower than other QI studies. Outcomes rely on client self-report at 6-month follow-up.
NCT01726634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 06221012.9.0000.5505|Performance Evaluation on the Upper Limb Closed Kinetic Chain Test After Scapular Elastic Taping on Jiu Jitsu Practitioners|||Federal University of São Paulo||Recruiting|March 2012|May 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 11, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01726634||76217|
NCT01726647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.02.NRC|Metabolism Associated With Abdominal Fat Mass Distribution|Metabolism Associated With Abdominal Fat Mass Distribution||Nestlé|No|Completed|September 2008|April 2012|Actual|October 2009|Actual|N/A|Observational|N/A||1|Actual|40|||Female|25 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese women|November 2012|November 9, 2012|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01726647||76216|
NCT01726933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M41008-1102|LAS41008 in Moderate to Severe Chronic Plaque Psoriasis|A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis||Almirall, S.A.|Yes|Completed|November 2012|November 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|839|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01726933||76194|
NCT01726907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0819|A Prospective Comparison of Robotic and Endoscopic SMG Resection Via Retroauricular Approach|||Yonsei University|No|Recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||November 2012|November 11, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01726907||76196|
NCT01726920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-NRP-03(04/12)|Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.|A Phase III, Multicenter, National, Open, Randomized, Parallel and Comparative Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg for the Acute Treatment of Migraine.|Copérnico|Ache Laboratorios Farmaceuticos S.A.|Yes|Withdrawn|July 2014|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|November 12, 2012||No|Due to budget limitations, the company decided to withdraw this study.|No||https://clinicaltrials.gov/show/NCT01726920||76195|
NCT01727518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAD1|The Austrian LEAD (Lung hEart sociAl boDy) Study|The Austrian LEAD (Lung hEart sociAl boDy) Study|LEAD|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|No|Enrolling by invitation|October 2011|October 2023|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Samples of urine and blood|Both|6 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Community based cohort|January 2016|January 16, 2016|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01727518||76151|
NCT01727505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120623|Volume Guarantee Ventilation in Preterm Infants With Frequent Episodes of Hypoxemia|Volume Guarantee Ventilation in Preterm Infants With Frequent Episodes of Hypoxemia||University of Miami|No|Completed|November 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|N/A|N/A|No|||November 2015|November 18, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01727505||76152|
NCT01727479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-048|Ribose and Sport Performance|The Effect of Ribose on Performance and Recovery in Athletes||Laval University||Active, not recruiting|August 2012|||November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 24, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01727479||76154|
NCT01727492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/18/172|Prevention of Noise-induced Damage by Use of Antioxidants|||University Hospital, Antwerp||Recruiting|November 2012|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01727492||76153|
NCT01727687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDcrossroad|Investigation of Road-crossing Safety Before and After Training Between Parkinson Disease Pedestrians and Older Pedestrians|An Investigation of Road Crossing Safety Before and After Training Between Parkinson Disease Pedestrians and Older Pedestrians||National Taiwan University Hospital|Yes|Active, not recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 12, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01727687||76138|
NCT01727960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EduNSP|The Effect of Education on Decreasing the Prevalence and Severity of Neck and Shoulder Pain|||Soonchunhyang University Hospital|Yes|Recruiting|January 2012|December 2012|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1302|||Male|16 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|students from two academic high schools in the city of Seoul 912 students ranging in age        from participated.|November 2012|November 12, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727960||76117|
NCT01728246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013696|An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis|A Randomized Controlled Trial on the Efficacy, Safety and Quality of Life Effects of Add-on Tramadol/Paracetamol Combination in Chronic Osteoarthritis||Janssen Pharmaceutica|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|473|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|November 13, 2012||No||No|December 7, 2012|https://clinicaltrials.gov/show/NCT01728246||76095|
NCT01729351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01911|Qvar Therapy in Smoking Asthmatics|Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma — a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population||Research in Real-Life Ltd|Yes|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|7195|||Both|16 Years|70 Years|No|Non-Probability Sample|Patients are all current smokers ages between 16-70 years with evidence of asthma|November 2012|November 14, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01729351||76010|
NCT01729637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-EVLP|SI-EVLP Study: STRESS INDEX in Lung Reconditioning|Normothermic Ex-vivo Lung Perfusion: Clinical Experience of the Pressure/Time Curve Profile Study (Stress Index)||University of Turin, Italy|No|Completed|July 2011|June 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|11|||Both|65 Years|N/A|No|Probability Sample|consecutive patient sampling from University Ward of Cardio Surgery of St. Giovanni        Battista Hospital of Turin|July 2013|July 5, 2013|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01729637||75988|
NCT01730144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130020|Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults|Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|November 2012|October 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|10|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01730144||75949|
NCT01701960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120227|Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery|Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery||Loma Linda University|Yes|Withdrawn|November 2012|August 2014|Actual|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|16 Years|75 Years|No|Non-Probability Sample|Subjects ages 16-75 undergoing routine nasal surgery which will include septoplasty and        sinus surgery|March 2015|March 18, 2015|October 3, 2012||No|no time|No||https://clinicaltrials.gov/show/NCT01701960||78107|
NCT01703195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0656|Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina|Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina||M.D. Anderson Cancer Center|No|Recruiting|November 2012|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703195||78012|
NCT01703481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100845|A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma||Janssen Research & Development, LLC|Yes|Recruiting|June 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|260|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703481||77990|
NCT01702623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXCA-S600-PVFS-2|Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions||Roxane Laboratories|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01702623||78056|
NCT01703455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT29/10|Activity of Sorafenib in Salivary Gland Cancer|Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Active, not recruiting|September 2010|January 2013|Anticipated|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01703455||77992|
NCT01703468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXCA-S600-PVFD-2|Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions||Roxane Laboratories|No|Completed|September 2009|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703468||77991|
NCT01704118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inonu University|Comparison of Size 1 I-gel and ProSeal Laryngeal Mask|Is Size 1 I-gel More Effective Than Size 1 ProSeal Laryngeal Mask for Anesthetized Infants and Neonates?||Inonu University|Yes|Completed|January 2012|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|50|||Both|N/A|6 Months|No|||October 2012|October 9, 2012|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01704118||77941|
NCT01726959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRS1|Prediction of Methotrexate Response - A Pilot Study||MRS|Carolinas Healthcare System||Recruiting|December 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patient with rheumatic disease being newly treated with methotrexate, recruited from a        single rheumatology practice|February 2013|February 5, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01726959||76192|
NCT01727531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-2775L|IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy|IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy.||Main Line Health|No|Completed|December 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01727531||76150|
NCT01726946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-135-101|A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated||Completed|November 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|No|||March 2015|March 27, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726946||76193|
NCT01727245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1002-31/1|NEFA (Non Esterified Fatty Acid) , Adipose Factors Behind Insulin Sensitivity|The Role of Adipose Tissue in Atherogenic Conditions in Man - Mechanisms and Interventions||Karolinska Institutet|No|Active, not recruiting|November 2011|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|500|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727245||76171|
NCT01728012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2010/2926|Long-term Cardiovascular Risk Following Successful Renal Transplantation|The Prevalence of Cardiovascular Risk Factors in Patients More Than 10 Years Following Successful Renal Transplant.||Helse Stavanger HF|No|Completed|November 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|60|Samples Without DNA|Blood and urine will be collected along with the clinical observations. Serum, plasma and      urine will be frozen for later analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Patients registered in the Norwegian Renal Registry with transplan more than 10 years ago.|August 2014|August 14, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01728012||76113|
NCT01728025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-SV-0363-10-CTIL|Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine|||Tel-Aviv Sourasky Medical Center||Recruiting|October 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01728025||76112|
NCT01727713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-12-294|Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|January 2013|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|7 Years|18 Years|No|||September 2015|September 17, 2015|November 12, 2012|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01727713||76136|
NCT01727700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-12-293|Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2012|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|7 Years|17 Years|No|||February 2015|February 12, 2015|November 12, 2012|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01727700||76137|
NCT01727986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28413|An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study|Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977)||Hoffmann-La Roche||Completed|March 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|9 Years|18 Years|No|||March 2016|March 1, 2016|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727986||76115|
NCT01727973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-DOXY-1|Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy|Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study||Sun Yat-sen University|Yes|Completed|October 2012|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|60 Years|No|||December 2013|December 7, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727973||76116|
NCT01728259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-155|First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD|Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728259||76094|
NCT01728272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101066|Influence of CPB and Mini CPB to the Absorption of the Metoprolol|Influence of CPB and Mini CPB to the Absorption of the Metoprolol After CABG|Minimeto|Kuopio University Hospital|Yes|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728272||76093|
NCT01729364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vätskestudien|Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function|Colloid vs Crystalloid Infusion Postoperative in CABG Patients Regarding Renal Hemodynamics and Function||Sahlgrenska University Hospital, Sweden|No|Completed|April 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|90 Years|No|||May 2015|May 20, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01729364||76009|
NCT01729377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290466-HYMC|The Meaning of Suicidality for Older Persons With Suicidal Tendencies and Their Families|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2013|April 2016|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|60 Years|N/A|No|Probability Sample|Aged individuals from tertiary and primary care and from the community who have        experienced suicidality and their families.|November 2012|November 14, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729377||76008|
NCT01729650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01861|Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)|Effectiveness of a Physical Activity and Diet Program, Coordinated Between Primary Care and Mental Health, to Modify Cardiovascular Risk Factors in Patients With Schizophrenia or Bipolar Disorder (CapiCor)|CapiCor|Jordi Gol i Gurina Foundation|No|Recruiting|June 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|480|||Both|18 Years|65 Years|No|||November 2012|November 19, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729650||75987|
NCT01730157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1612|Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases|Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver||Case Comprehensive Cancer Center|Yes|Terminated|December 2012|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 12, 2012||No|Research Cancelled|No||https://clinicaltrials.gov/show/NCT01730157||75948|
NCT01730170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060793|Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure|Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs|MONEAD|Emory University|No|Active, not recruiting|January 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|565|Samples With DNA|Serum, cheek cells, urine|Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited by the investigators from their clinic populations and        advertisements.|February 2016|February 12, 2016|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730170||75947|
NCT01702285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-101-105|Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients|A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors||Curis, Inc.|No|Terminated|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|September 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702285||78082|
NCT01702298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431D-312|A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)|An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|79 Years|No|||April 2015|April 2, 2015|October 4, 2012|No|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01702298||78081|
NCT01702636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTA1201|STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial|STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.|STOP-AUST|Neuroscience Trials Australia|Yes|Recruiting|December 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702636||78055|
NCT01703182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCOM-2012|Transcutaneous Oximetry, Transcutaneous Carbon Dioxide and Supplemental Oxygen Therapy in Lower Limb Amputations|Transcutaneous Oximetry, Transcutaneous Carbon Dioxide and Supplemental Oxygen Therapy in Lower Limb Amputations - An Observational Study|TCOM|McMaster University|No|Terminated|April 2011|June 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing below-knee and above-ankle amputations due to vascular complications|September 2015|September 21, 2015|October 5, 2012||No|Stopped due to feasibility|No||https://clinicaltrials.gov/show/NCT01703182||78013|
NCT01703767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00053707|Gulf War 1 Veteran Healthcare Satisfaction|Gulf War 1 Veteran Patient Satisfaction With VA Primary Care: A Survey Study.||University of Utah|No|Not yet recruiting|December 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|180|||Both|38 Years|80 Years|No|Non-Probability Sample|Persian Gulf War Veterans who are currently treated by a primary care physician at the        VASLCHCS Blue Clinic and West Valley Clinic.|October 2012|October 5, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703767||77968|
NCT01734772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.142|Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor|Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects||Boehringer Ingelheim||Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|November 15, 2012||||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01734772||75597|
NCT01735058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13912134|Ultrasonography Guided Subacromial Sodium Hyaluronate Injection in Rotator Cuff Disease|Evaluating the Efficacy of Ultrasonography Guided Subacromial Sodium Hyaluronate Injection in the Treatment of Rotator Cuff Disease||Isfahan University of Medical Sciences|Yes|Recruiting|February 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2012|December 1, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01735058||75575|
NCT01727284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002245|MR-Guided Cryoablation of Prostate Bed Recurrences|Technical Success, Safety, and Short and Long-term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences||Mayo Clinic|No|Recruiting|November 2012|January 2022|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|30 Years|100 Years|No|||March 2016|March 15, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727284||76168|
NCT01727297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVEAL AF|REVEAL AF: Incidence of AF in High Risk Patients|Reveal XT Implantable Cardiac Monitor||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|October 2012|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|450|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727297||76167|
NCT01727726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-12-282|A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial|A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Recruiting|December 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2363|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727726||76135|
NCT01727739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:059|Tibial Tunnel Widening in Anterior Cruciate Ligament (ACL) Reconstruction-Comparing Two Bioscrews|Tibial Tunnel Widening in ACL Reconstruction-Comparing Two Bioscrews: A Prospective Randomized Clinical Trial||Panam Clinic|No|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|No|||October 2015|October 19, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01727739||76134|
NCT01728298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-M-01|A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy|A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy - The SUMMIT Trial|SUMMIT|ALK-Abelló A/S|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|219|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01728298||76091|
NCT01728311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15734|Open Label Study of BAY1082439 in Patients With Advanced Cancer|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies||Bayer|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01728311||76090|
NCT01727999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO 105489|Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics|Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics||Stanford University|No|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|Samples With DNA|RNA and DNA will be retained|Both|N/A|N/A|No|Non-Probability Sample|Patients with ITP receiving TPO agonists|November 2012|November 15, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727999||76114|
NCT01728285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-17 ITALY|Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis|A Multicentric Open Randomised, Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|GT-17|ALK-Abelló A/S|No|Completed|March 2007|October 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|65 Years|No|||November 2012|November 14, 2012|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01728285||76092|
NCT01728558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/YS003|Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients|Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients: a Prospective Multicentre Randomised Controlled Trial|SPICE III RCT|Australian and New Zealand Intensive Care Research Centre|Yes|Recruiting|November 2013|April 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4000|||Both|18 Years|N/A|No|||December 2013|February 26, 2015|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01728558||76071|
NCT01729390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodED501|Varying the Energy Density and Portion Size of the Main Course After a First-course Salad|Varying the Energy Density and Portion Size of the Main Course After a First-course Salad||Penn State University|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|53|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729390||76007|
NCT01729403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC28038|A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin|A SINGLE CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY||Hoffmann-La Roche||Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|30 Years|70 Years|No|||March 2016|March 1, 2016|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01729403||76006|
NCT01729897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC-20121001|Etomidate Emulsion for Sedation in Patients Scheduled for Upper Gastrointestinal (GI) Endoscopy|A Multicenter Open-label Randomized Controlled Clinical Trial of Etomidate Emulsion for Sedation in Patients Scheduled for Upper GI Endoscopy||Jiangsu Nhwa Pharmaceutical Co., Ltd.|Yes|Completed|May 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|80 Years|No|||May 2013|May 10, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01729897||75968|
NCT01720888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGS/1/2011/SKK/UKM/02/72|Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy|A Controlled Open Label Phase II Study Assessing the Efficacy of Intracoronary Autologous Mesenchymal Stem Cells in Patients With Ischemic Dilated Cardiomyopathy||National University of Malaysia|Yes|Active, not recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Years|75 Years|No|||April 2015|April 15, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01720888||76658|
NCT01702649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 401|Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 in Healthy Adult Subjects||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|September 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702649||78054|
NCT01702922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120206|Relationship Stressors in Parents of Children With Cancer|Understanding the Perceived Influence of Childhood Cancer on the Parents' Marital/Partner Relationship: A Descriptive Study||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|240|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01702922||78033|
NCT01702935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120212|Ovarian Stem Cells From Women With Ovarian Insufficiency|Oogonial Stem Cell Isolation in Ovarian Insufficiency Patients||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Female|18 Years|N/A|No|||July 2015|August 5, 2015|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01702935||78032|
NCT01703494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK093839-01A1|Fecal Transplant for Relapsing C. Difficile Infection|Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection||The Miriam Hospital|Yes|Active, not recruiting|October 2012|September 2015|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703494||77989|
NCT01703208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-018|A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|October 2012|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4202|||Both|40 Years|N/A|No|||January 2016|January 27, 2016|October 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703208||78011|
NCT01703507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12P.314|Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma|Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases||Thomas Jefferson University|Yes|Active, not recruiting|December 2012|November 2019|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703507||77988|
NCT01731522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTRI-Basic EF Study|Eating Frequency Study|||University of Tennessee|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731522||75843|
NCT01727570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-240-SDR|Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity|Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity||McGill University Health Center|Yes|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|85 Years|No|||November 2014|November 18, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01727570||76147|
NCT01727258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOXDHY0008|A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity|Evaluation of an Experimental Mouth Rinse Device for Relieving Dentinal Hypersensitivity||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|153|||Both|18 Years|N/A|No|||April 2015|June 8, 2015|November 12, 2012|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01727258||76170|
NCT01727271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4031-384|A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)|An Open-Label, Pilot, Randomized, Multi-Center Study to Compare Efficacy and Safety of Tenofovir Monotherapy Alone With Tenofovir Monotherapy Followed by Concurrent Combination of Pegylated Interferon-Alpha-2b and Tenofovir or Tenofovir Monotherapy Followed by Sequential Therapy of Pegylated Interferon-Alpha-2b and Tenofovir in HBeAG-Positive Chronic Hepatitis B Patients With Raised ALT.||Merck Sharp & Dohme Corp.|No|Withdrawn|August 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|November 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01727271||76169|
NCT01727544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001953|Vestibular Function Outcome After Cartilage Cap Occlusion Surgery|Objective Assessment of Vestibular Function Outcome After Cartilage Cap Occlusion Surgery for Dehiscent Superior Semicircular Canal||Mayo Clinic|No|Withdrawn|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 11, 2014|August 22, 2012||No|Changed to a retrospective chart review|No||https://clinicaltrials.gov/show/NCT01727544||76149|
NCT01728064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI2010-006|Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia|Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia||Edison Pharmaceuticals Inc|Yes|Completed|December 2012|February 2016|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|45 Years|No|||February 2016|March 18, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728064||76109|
NCT01728038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN381902|Exploring a Cessation Intervention for Smokers|Exploring a Cessation Intervention for Low Income Smokers in an Emergency Setting||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|March 2012|March 2016|Anticipated|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|N/A|N/A|No|||February 2016|February 1, 2016|November 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01728038||76111|
NCT01728051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL 2009-01|Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver|An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver||Delcath Systems Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2013|October 22, 2013|November 13, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01728051||76110|
NCT01728571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000622|LungVITamin D and OmegA-3 Trial (lungVITAL)|LungVITamin D and OmegA-3 Trial|lungVITAL|Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01728571||76070|
NCT01728883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44EY020016-03|Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study|Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy|DRAMA|Vital Art and Science Incorporated|Yes|Active, not recruiting|April 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with diabetic retinopathy requiring treatment|December 2015|December 8, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01728883||76046|
NCT01729130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-043|A Pilot Study to Identify the Differences in Adipose Tissue Function After Restoring Normal Glycemic Control Following Pancreas Transplantation|A Pilot Study to Identify the Differences in Adipose Tissue Function After Restoring Normal Glycemic Control Following Pancreas Transplantation||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|September 2009|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|15|Samples With DNA|adipose tissue blood samples|Both|18 Years|65 Years|No|Non-Probability Sample|Patients that have Diabetes mellitis and End Stage Renal Disease who will be receiving        pancreas/kidney or only kidney transplantation.        Patients that have End Stage Renal Disease and who will be receiving an isolated kidney        transplant. This control group will account for effects of immuno-suppression and for        potential metabolic changes induced by the kidney transplant on adipose tissue function.|July 2015|August 24, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729130||76027|
NCT01729910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15HD054950-01A2 REVISED|Primary Care Child Obesity Intervention Targeting Parents|Primary Care Child Obesity Intervention Targeting Parents||East Tennessee State University|No|Completed|September 2009|March 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|5 Years|11 Years|No|||November 2015|November 23, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01729910||75967|
NCT01721434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levo2|Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients|Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients||University Medical Center Nijmegen|No|Recruiting|September 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721434||76616|
NCT01733680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320969|Amiloride Hydrochloride as an Effective Treatment for ADHD|||State University of New York - Upstate Medical University|Yes|Recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||November 2014|November 19, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733680||75680|
NCT01733953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207M17202|Statin Therapy in Young Adult Survivors of Childhood Cancer|Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|November 2012|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|39 Years|No|||February 2016|February 24, 2016|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733953||75659|
NCT01734226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JINR-CON-PME|Efficacy and Safety of Prunus Mume Extract on Improvement of Constipation|||Chonbuk National University Hospital|Yes|Recruiting|August 2012|December 2012|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734226||75639|
NCT01734239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-018|A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)|A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population||Merck Sharp & Dohme Corp.|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|102|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|November 21, 2012|No|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT01734239||75638|
NCT01734512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#120817|PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children|PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children||University of California, San Francisco|Yes|Recruiting|November 2012|November 2022|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|3 Years|21 Years|No|||May 2015|May 20, 2015|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734512||75617|
NCT01734759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005823|Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits|Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers||Mayo Clinic|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 18, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01734759||75598|
NCT01731301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIV01|A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)|A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir||Liver Institute of Virginia|No|Not yet recruiting|January 2013|January 2015|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731301||75860|
NCT01727583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.10.MET|Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients|Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients||Nestlé|No|Completed|September 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|18|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727583||76146|
NCT01727557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV Fistulae|Anesthetic Technique for AV Fistulae Creation|||Montefiore Medical Center|No|Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|21 Years|70 Years|No|||March 2016|March 15, 2016|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727557||76148|
NCT01727752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTR1307|A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis|A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis|FELIX|Paradigm Spine|No|Active, not recruiting|October 2007|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|386|||Both|40 Years|85 Years|No|||October 2014|October 29, 2014|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727752||76133|
NCT01728610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-2|Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms|Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms (IBS-2)||Danisco|No|Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|391|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01728610||76067|
NCT01728623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-208|A Study of E7080 in Subjects With Advanced Thyroid Cancer|A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer||Eisai Inc.||Completed|September 2012|October 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01728623||76066|
NCT01728337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2012|Phase Iv Study On Muscle Activity Of Two Commercial Preparations Of Botulinum|PHASE IV STUDY ON MUSCLE ACTIVITY OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A ADMINISTERED TO THE UPPER THIRD OF THE FACE.||Brazilan Center for Studies in Dermatology|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|November 7, 2012||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01728337||76088|
NCT01728350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A120032-1|Improving Well-Being After TBI Through Structured Volunteer Activity|Improving Well-Being After TBI Through Structured Volunteer Activity||Craig Hospital|No|Recruiting|April 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01728350||76087|
NCT01728324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.36|Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2|A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naïve Patients That Includes Those Ineligible to Receive Peginterferon||Boehringer Ingelheim||Completed|November 2012|January 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|496|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|November 2, 2012||||No|January 14, 2016|https://clinicaltrials.gov/show/NCT01728324||76089|
NCT01728584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07982|A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)|Randomized, Controlled, Parallel-Group, Double-Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Factorial Design in Patients Undergoing Laparoscopic Cholecystectomy (Protocol No. MK-8616-076-03 Also Known as SCH 900616, P07982)||Merck Sharp & Dohme Corp.|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|127|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 16, 2012|No|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01728584||76069|
NCT01728896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX/12/06/051|Patient-Initiated and ConTrolled Oral Refeeding (PICTOR)|A Randomized Controlled Trial of Patient-Initiated and ConTrolled Oral Refeeding in Acute Pancreatitis|PICTOR|University of Auckland, New Zealand|No|Recruiting|December 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Anticipated|116|||Both|18 Years|80 Years|No|||January 2013|January 4, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01728896||76045|
NCT01729143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0468|Impact of Black Pepper on Energy Expenditure and Substrate Utilization|A Randomized, Cross-Over Trial to Evaluate the Acute Effects of Black Pepper on Energy Expenditure and Fat Oxidation in Humans||University of North Carolina, Chapel Hill|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729143||76026|
NCT01729663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASVAC0401|Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients|Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients||Laboratorio Pablo Cassará S.R.L.|Yes|Recruiting|April 2009|||December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01729663||75986|
NCT01729676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000059|Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation|Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY|FACT|Ferring Pharmaceuticals|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|315|||Male|18 Years|N/A|No|Non-Probability Sample|Men never previously treated with hormononal therapy for prostate cancer|July 2014|July 16, 2014|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01729676||75985|
NCT01722032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-05065|USDA Healthy Caregivers/Healthy Children: A Childhood Obesity Prevention Program|Healthy Caregivers/Healthy Children|HC2|University of Miami|No|Completed|June 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1100|||Both|2 Years|5 Years|No|||November 2012|November 2, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01722032||76570|
NCT01722045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-AMD-1124|Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)|An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration|RE-VIEW|Regeneron Pharmaceuticals|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|50 Years|N/A|No|||January 2016|January 12, 2016|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722045||76569|
NCT01734252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArgHeR|Argatroban in Critically Ill Patients With Heparin Resistance|A Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients With Heparin Resistance||Medical University Innsbruck|Yes|Recruiting|June 2012|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|85 Years|No|||April 2015|April 16, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734252||75637|
NCT01734265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6078-PG-PSC-193|Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).|Prospective, Open Uncontrolled Study to Evaluate the Safety of Depigoid With Two Pollen Combinations (Grasses/Olea and Grasses/Parietaria)2000DPP/ml in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Seasonal Asthma.||Laboratorios Leti, S.L.|No|Completed|November 2012|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|60 Years|No|||November 2012|January 28, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734265||75636|
NCT01734785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.9|Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.||Boehringer Ingelheim||Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|607|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 16, 2012||||No||https://clinicaltrials.gov/show/NCT01734785||75596|
NCT01735071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-OVA-6152|Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer|Multicenter, Randomized, Non-comparative, Open-label Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.||Mario Negri Institute for Pharmacological Research|No|Recruiting|July 2013|July 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|N/A|No|||July 2015|September 9, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01735071||75574|
NCT01735084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1046999|Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life|Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.|PREV-IX_B|Menzies School of Health Research|Yes|Enrolling by invitation|December 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|270|||Both|9 Months|3 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01735084||75573|
NCT01731249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO68.10|Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis|A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis||Stallergenes|Yes|Completed|November 2010|October 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|574|||Both|18 Years|65 Years|No|||November 2012|November 22, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731249||75864|
NCT01731262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|中大附三医伦[2012]2-75号|Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis|Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|November 2012|January 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|residents of south China|November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731262||75863|
NCT01731314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002386|The Learning and Memory of the Experience of Pain|||Massachusetts General Hospital|No|Recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731314||75859|
NCT01731327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921132|A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers|A Phase 1, Randomized, Open-Label, 2-Way Crossover Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of Tofacitinib Following Single Oral Dose Of MR 11 mg Compared To MR 22 mg In Healthy Volunteers||Pfizer|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 20, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731327||75858|
NCT01718288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract Number: 2006-001660-23|Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)|Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb), Unsuitable or Suitable to Surgical Revascularization / Endovascular With Reference to the Change of Pain-free Walking Distance and Other Endpoints|2bPILOT|Fadoi Foundation, Italy|Yes|Completed|November 2006|April 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01718288||76856|
NCT01727765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT and Asthma|Inspiratory Muscle Training and Asthma|Inspiratory Muscle Training as a Novel Approach in the Treatment of Asthma||University of Portsmouth|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|59 Years|No|||June 2015|June 2, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01727765||76132|
NCT01727778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATCT-SM6-02|Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma|Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma||Patrys Ltd.|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01727778||76131|
NCT01728077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01372|Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b||UCB Pharma|No|Active, not recruiting|October 2012|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|16 Years|N/A|No|||February 2016|February 10, 2016|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728077||76108|
NCT01728363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037820|Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)|Pharmacokinetics of Antistaphylococcal Antibiotics in Infants|Staph|Duke University|Yes|Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|N/A|32 Weeks|No|||June 2015|June 30, 2015|November 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01728363||76086|
NCT01728922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CIS/VD/SVUH|Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome|Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.|CISAVID|University College Dublin|Yes|Active, not recruiting|November 2012|June 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01728922||76043|
NCT01728597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMR-12-TECH-02|Non-contrast Enhanced Cardiac Magnetic Resonance Normal Values and Imaging Protocols|Optimization of Non-contrast Enhanced 1.5 Tesla and 3 Tesla Cardiac Magnetic Resonance Imaging Techniques and Acquisition of Normal Values|CMR-TECH|Medical University of Graz|Yes|Recruiting|December 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|March 2016|March 15, 2016|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01728597||76068|
NCT01728909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07691|Methadone Oxytocin Option|The Effects of Intranasal Oxytocin on Social Cognition and Social Approach Behaviors in Opioid-dependent Patients|MOO|University of California, San Francisco|Yes|Completed|May 2012|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01728909||76044|
NCT01729156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11palmitatMetformin|Effects of Metformin on Hepatic FFA Metabolism|Effects of Metformin on Hepatic Free Fatty Acid Metabolism in Patients Diagnosed With Type 2 Diabetes: A C11 PET Study||University of Aarhus|Yes|Not yet recruiting|January 2013|April 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|36|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729156||76025|
NCT01720901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV41|Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy|An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy||Betta Pharmaceuticals Co.,Ltd.|Yes|Suspended|February 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||May 2015|May 21, 2015|October 31, 2012||No|Accrual limitations|No||https://clinicaltrials.gov/show/NCT01720901||76657|
NCT01720550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP012 (II)|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care||PhytoHealth Corporation|Yes|Recruiting|November 2012|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|20 Years|N/A|No|||February 2016|February 1, 2016|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01720550||76684|
NCT01721187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOFIO3G|Satiety Effects on the Neural Valuation of Food|Functional Magnetic Resonance Imaging Study of the Valuation of Food as a Function of Satiety||Duke-NUS Graduate Medical School|No|Completed|October 2012|July 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|None Retained|(NA)|Both|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|August 2015|August 4, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01721187||76635|
NCT01734551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0534|NAS Treatment - Opiate Versus Non-Opiate|Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate|NAS|University of Kentucky|Yes|Active, not recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|7 Days|No|||October 2014|October 20, 2014|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01734551||75614|
NCT01734798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bladder-02|Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer|Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer||Cairo University|Yes|Completed|December 2002|November 2012|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|70 Years|No|||November 2012|November 22, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01734798||75595|
NCT01730755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-RUX-12-03|Ruxolitinib for Chuvash Polycythemia|Ruxolitinib for Chuvash Polycythemia||Washington University School of Medicine||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2016|January 6, 2016|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730755||75902|
NCT01702116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR2011|Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma|Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma||Stony Brook University|Yes|Recruiting|July 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01702116||78095|
NCT01702129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC1|Anti-EGFR Immunoliposomes in Solid Tumors|A Phase I Study of Doxorubicin-loaded Anti-EGFR Immunoliposomes in Patients With Advanced Solid Tumors||University Hospital, Basel, Switzerland|Yes|Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01702129||78094|
NCT01718301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOC-HIV|HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin|A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23|BOC-HIV|Fundacion Clinic per a la Recerca Biomédica|No|Completed|March 2013|June 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01718301||76855|
NCT01718626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTH101|Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer|||Hebei Tumor Hospital||Active, not recruiting|October 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2012|November 5, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01718626||76830|
NCT01727791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081181|A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women|A Multiple Dose Pharmacokinetic Open Label Study Of Pregabalin (Lyrica) In Healthy Lactating Women||Pfizer|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01727791||76130|
NCT01718899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-001|Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma|A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma||OncoPep, Inc.|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|22|||Both|18 Years|95 Years|No|||May 2015|May 14, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718899||76810|
NCT01719133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN002|Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen|Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1||Anergis|No|Completed|February 2008|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|18 Years|45 Years|No|||October 2012|October 31, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719133||76792|
NCT01719107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0003|Efficacy of Dietary Supplementation With Lactobacilllus Reuteri DSM 17938 on Functional Abdominal Pain (FAP) in Children|Efficacy of Dietary Supplementation With Lactobacilllus Reuteri DSM 17938 on Functional Abdominal Pain (FAP) in Children||Aghia Sophia Children's Hospital of Athens|Yes|Completed|November 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|5 Years|16 Years|No|||February 2016|February 20, 2016|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01719107||76794|
NCT01719380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818X2103|Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer|A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer||Array BioPharma||Active, not recruiting|November 2012|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719380||76773|
NCT01719393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207062RIC|Pulse Spectrum Analysis in Adult Asthmatics: Correlation With Lung Function, Asthma Control Exhaled Nitric Oxide and Metabolites in Exhaled Breath Condensate|Pulse Spectrum Analysis in Adult Asthmatics: Correlation With Lung Function, Asthma Control Exhaled Nitric Oxide and Metabolites in Exhaled Breath||National Taiwan University Hospital|No|Not yet recruiting|November 2012|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Exhaled brath condensate|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Asthma paitients|October 2012|October 31, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719393||76772|
NCT01729169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SarcoidosisPET|Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET|Diagnosing Cardiac Sarcoidosis Using FDG PET: Optimization||University of Aarhus|No|Recruiting|June 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis|November 2012|November 26, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01729169||76024|
NCT01729416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297959-4|Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting|Prospective Randomized Controlled Trial Comparing Water Exchange Colonoscopy and Air Colonoscopy in a Community Based Setting||University of California, Davis|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|178|||Both|50 Years|N/A|No|||December 2015|December 16, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01729416||76005|
NCT01720251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN004T|Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy|Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen||Anergis|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|55 Years|No|||March 2015|March 30, 2015|October 29, 2012||No||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01720251||76707|
NCT01720264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208009261; HL112669|Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant|A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies||Indiana University|Yes|Recruiting|November 2012|||November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|60 Years|No|||March 2015|March 6, 2015|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720264||76706|
NCT01720914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEAS|Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status|Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status|IDEAS|Charite University, Berlin, Germany|No|Completed|November 2012|December 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|N/A|No|Probability Sample|Male and female adult critically ill patients|December 2015|December 22, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01720914||76656|
NCT01721746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-037|A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)|A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy||Bristol-Myers Squibb|Yes|Active, not recruiting|December 2012|September 2018|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721746||76592|
NCT01721759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-063|Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens|A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens||Bristol-Myers Squibb|No|Active, not recruiting|November 2012|August 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 2, 2012|Yes|Yes||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01721759||76591|
NCT01721447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-OPT-018 GE|Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage|The Use of Optison Echocardiography Contrast in the Detection of Left Atrial Appendage Thrombus With Transesophageal Echocardiography.|DOLOP|University of Utah|Yes|Recruiting|June 2013|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|100 Years|No|||March 2016|March 21, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01721447||76615|
NCT01721460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0400|Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus|Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation Electrode Implantation Surgery||University of Wisconsin, Madison|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|85 Years|No|||October 2015|October 9, 2015|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721460||76614|
NCT01721473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-02-11S|Brain Nicotine Receptor Density in Veteran Smokers|Nicotinic Acetylcholine Receptor Density and Veteran Cigarette Smokers|BNRDVS|VA Office of Research and Development|No|Recruiting|January 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|198|None Retained|None retained.|Both|18 Years|65 Years|No|Probability Sample|Veterans who are cigarette smokers (10 to 40 cigarettes per day) who either use        significant amounts of caffeine or marijuana (or who have little or no such use).|March 2016|March 17, 2016|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01721473||76613|
NCT01734564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2010-01|Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors|Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734564||75613|
NCT01734577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLVPT-4059|Effect of Dry Needling Multifidus on Thickness of Transversus Abdominis in Healthy Individuals|The Effect of Trigger Point Dry Needling to the Multifidus Muscle on Resting and Contracted Thickness of Transversus Abdominis in Healthy Subjects||University of Nevada, Las Vegas|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734577||75612|
NCT01734525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Early Therapy|A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients|Pilot Study of Biomarkers in Invasive Candidiasis in Intensive Care Unit (ICU) Patients||Universidade Federal do Rio de Janeiro|No|Recruiting|November 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01734525||75616|
NCT01734538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12OC014|Effect of 12 wk of Omega-3 FA Supplementation on Metabolic and Physical Health Parameters in Older Adults|Effects of 12 Weeks of Omega-3 Fatty Acid Supplementation on Metabolic and Physical Health Parameters in Older Adults||University of Guelph||Not yet recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734538||75615|
NCT01730768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2207|A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients|A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients||Novartis|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|55 Years|No|||January 2015|January 13, 2015|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730768||75901|
NCT01731054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999LE002|Functional MRI in Lupus Nephritis|Noninvasive Assessment Of Renal Activity And Damage Using Renal Functional MRI In Normal Healthy Volunteers And Subjects With Lupus Nephritis||Biogen|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Blood Samples, Urine samples and Renal biopsy tissue samples.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic, community sample. 30 Normal Healthy Volunteers 30 Participants with        documented diagnosis of Lupus Nephritis|March 2015|April 23, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01731054||75879|
NCT01702441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-9778-CI-2002|Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema|Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema||Aerpio Therapeutics|Yes|Completed|September 2012|December 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||March 2015|March 9, 2015|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702441||78070|
NCT01702454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116023|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A, Administered to Children Who Previously Participated in Study 115345||GlaxoSmithKline||Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|470|||Both|17 Months|48 Months|Accepts Healthy Volunteers|||November 2015|November 5, 2015|October 4, 2012|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT01702454||78069|
NCT01719159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITT-PMS|Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis|Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis|ITT-PMS|Umeå University|No|Recruiting|November 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01719159||76790|
NCT01718613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91762|Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients|Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients|VANCS II|Instituto do Cancer do Estado de São Paulo||Active, not recruiting|November 2012|December 2015|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718613||76831|
NCT01718886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1000-0018|European Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight Loss|Feasibility Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight Loss||Obalon Therapeutics, Inc.|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|21 Years|64 Years|No|Non-Probability Sample|Patients were selected from investigators' patient population and included patients with a        BMI in the range of 27 - 35 kg/m^2|October 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718886||76811|
NCT01719146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK093832-01A1|Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease|Computational Approach to Personalized Anemia Management||University of Louisville|No|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|Blood, serum will be extracted and frozen for further analysis. Serum will be retained for      up to 60 days.|Both|18 Years|N/A|No|Non-Probability Sample|End Stage Renal Disease Patients undergoing hemodialysis treatments at:          1. University Kidney Center, Louisville, KY          2. Duke University, Durham, NC          3. WNERTA, Springfield, MA|November 2015|November 30, 2015|October 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01719146||76791|
NCT01719120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBTI-001|Internet-Based Cognitive-Behavioral Therapy for Insomnia|Internet-Based Self-Help Cognitive-Behavioral Therapy for Insomnia (CBTI): A Randomized Controlled Trial||The University of Hong Kong|No|Recruiting|August 2012|December 2015|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|297|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719120||76793|
NCT01719653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220121180|A Comparison of 5 Low Volume Bowel Preparations|A Randomized Comparison of Five Low Volume Bowel Preparations for Colonoscopy||Gastroenterology Services, Ltd.|Yes|Completed|October 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|October 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719653||76752|
NCT01719627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARAVIPREX|First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers|PILOT STUDY OF PROTECTION AGAINST ex Vivo HIV INFECTION IN RECTAL MUCOSA IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF MARAVIROC||Fundacio Lluita Contra la SIDA|No|Completed|October 2012|January 2015|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|10|||Male|18 Years|N/A|No|||March 2015|March 4, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01719627||76754|
NCT01719952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKMMC|Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin|Comparison of Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin in Women Undergoing Elective Caesarean Section: A Double-blinded Randomised Clinical Trial||Universiti Kebangsaan Malaysia Medical Centre|Yes|Completed|January 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|50 Years|No|||February 2015|February 26, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01719952||76730|
NCT01720563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP021|A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy|A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma||PhytoHealth Corporation|No|Terminated|December 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|20 Years|70 Years|No|||November 2015|November 3, 2015|October 29, 2012||No|Change study drug dosage form|No||https://clinicaltrials.gov/show/NCT01720563||76683|
NCT01713634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro0225|Dietary Intake Modifications to Protect Against Changes in Bone Metabolism|Dietary Intake Can Predict and Protect Against Changes in Bone Metabolism During Spaceflight and Recovery|ProK|National Aeronautics and Space Administration (NASA)|No|Completed|January 2009|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 13, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01713634||77213|
NCT01713647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLH423/PRO-00|Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions|Comparative, Randomized,, Single Dose, Open-label, Crossover Bioequivalence Study of LOSANET AM PLUS 10mg/100mg/12.5 mg Tablets (One Tablet) of (PHARMALINE, Lebanon) Versus NORVASC 10mg Tablets (One Tablet) of (Pfizer Canada Inc., Kirkland (Quebec)) and HYZAAR 100mg/12.5 Tablets (One Tablet) of (Merck Sharp & Dohme, Quimica de Puerto Rico, Inc, Road 2 Km. 60.3, Sabana Hoyos, Arecibo, PR 00688 for Merck Sharp & Dohme B.V. Haarlem, The Netherlands) in Healthy Subjects Under Fasting Conditions.||Pharmaceutical Research Unit, Jordan||Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|July 24, 2013|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01713647||77212|
NCT01717807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0365-12-HMO|C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).||EGFR; PET/CT|Hadassah Medical Organization||Not yet recruiting|April 2013|||April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|oncological patients with NSC type of lung cancer and with advanced pacreatic cancer.|October 2012|October 28, 2012|October 28, 2012||||No||https://clinicaltrials.gov/show/NCT01717807||76893|
NCT01713920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARTH|Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to ARB monoTHerapy Using 24h ABPM|Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM.|EARTH|The Catholic University of Korea|Yes|Completed|April 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|55 Years|N/A|No|||November 2015|November 6, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713920||77191|
NCT01714167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC-2011-8|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Treatment of Chronic Stroke||Wenzhou Medical University|Yes|Recruiting|June 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|70 Years|No|||June 2015|June 4, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01714167||77172|
NCT01684800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000029|Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Women|NOC|Ferring Pharmaceuticals|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|178|||Female|20 Years|N/A|No|||August 2013|August 22, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684800||79424|
NCT01684826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCY607-100084|X-ray Dose Reduction Study for Cardiac Angiography and Intervention|Clinical Validation and Evaluation of ClarityIQ Cardiac Image Processing for Cardiac Angiography and Intervention||Philips Healthcare|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|September 11, 2012||No||No|August 26, 2013|https://clinicaltrials.gov/show/NCT01684826||79422|
NCT01684813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERDI study|VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel|A Randomized Study With Loading Dose of Prasugrel Opposed to the Standard Dose of Clopidogrel in Type 2 Diabetic Patients in Acute Coronary Syndrome, Revascularized Through Drug-eluting Stent.|VERDI|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|80 Years|No|||September 2014|September 19, 2014|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684813||79423|
NCT01734863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-BoneT002|Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients|Post-operative Radiotherapy Randomization in Poor Responders Ewing's Sarcoma Patients||Children's Cancer Hospital Egypt 57357|Yes|Withdrawn|September 2012|December 2022|Anticipated|September 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|18 Years|No|||November 2012|January 11, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01734863||75590|
NCT01734876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D 03-673|Effects of Tactile Touch on Chronic Pain in Parkinson´s Disease|Short and Long-term Effects of Tactile Touch on Salivary Cortisol Concentrations in Parkinson's Disease.||FUTURUM, Academy of Health and Science|Yes|Completed|September 2004|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|45|||Both|45 Years|80 Years|No|||November 2012|November 27, 2012|November 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01734876||75589|
NCT01730820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO CO|Influence of Preload Dependence on the Effect of Phenylephrine on Cardiac Output|Influence of Preload Dependence on the Effect of Phenylephrine on Cardiac Output||University Hospital, Caen|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|General anesthesia.Orotracheal intubation and mechanical ventilation Advanced Hemodynamic        Monitoring intraoperative ( arterial pressure catheter, esophageal Doppler)|September 2014|September 12, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01730820||75897|
NCT01731379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 40893.031.12|Optical Detection of Peripheral Nerve Bundles During Surgery|In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study|NerveSpect|Philips Healthcare|Yes|Completed|December 2012|October 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|35|||Both|18 Years|N/A|No|Probability Sample|Eligible patients are patients of the Netherlands Cancer Institute (NKI-AvL), who are        scheduled for an elective inguinal, axillary or cervical lymph node dissection, or        parotidectomy as well as patients with rectal cancer undergoing rectal surgery and        patients undergoing resection of a soft tissue tumour.|November 2015|November 2, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731379||75854|
NCT01684176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-381|Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication|Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients||Odense University Hospital|No|Completed|August 2012|June 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|211|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684176||79472|
NCT01684189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP38887|Registry of Febrile Neutropenia and Invasive Fungal Infections|A Non-interventional Prospective Registry to Monitor the Events of Febrile Neutropenia and Invasive Fungal Infections and the Diagnostic and Therapeutic Management in Patients With Malignant Hematologic Diseases After Chemotherapy||Chang Gung Memorial Hospital|No|Recruiting|November 2011|August 2013|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with newly diagnosed malignant hematological diseases|November 2011|September 11, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684189||79471|
NCT01684423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14373|Oral Rivaroxaban in Children With Venous Thrombosis|30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children With Various Manifestations of Venous Thrombosis|EINSTEINJunior|Bayer|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Years|17 Years|No|||March 2016|March 21, 2016|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684423||79453|
NCT01684995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quit_RIte_RI|Motivation and Nicotine Patch Treatment for Under-served Smokers|Motivation and Nicotine Patch Treatment for Under-served Smokers||The Miriam Hospital|No|Completed|December 1996|November 1999|Actual|November 1999|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||August 2012|September 12, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01684995||79409|
NCT01685008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR208C201|Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)|A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin´s Lymphoma (NHL)||MorphoSys AG|No|Active, not recruiting|May 2013|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|September 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685008||79408|
NCT01685021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR208C202|Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)|A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)||MorphoSys AG|No|Terminated|April 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|N/A|No|||April 2015|April 27, 2015|September 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685021||79407|
NCT01716377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104106|Healing With Venlafaxine After Injury (HELP)|Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision|HELP|Rhode Island Hospital|Yes|Recruiting|October 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|50 Years|No|||October 2015|October 30, 2015|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716377||77003|
NCT01685528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30655|VA Home-Based Emotional Learning With Practical Skills|VA Home-Based Emotional Learning With Practical Skills (VA-HELPS): Treatment for Depressed and/or Anxious Rural Veterans in Home-Based Primary Care|VA-HELPS|Baylor College of Medicine|No|Active, not recruiting|December 2012|December 2015|Anticipated|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685528||79368|
NCT01717339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006285|Sleep Apnea and Vascular Function|Sleep Apnea and Vascular Function||Mayo Clinic|No|Recruiting|November 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01717339||76929|
NCT01713348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-PMR-APO-12015|Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes|Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes|SIGN|Abbott Diabetes Care|No|Completed|October 2012|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|105|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 22, 2012||No||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01713348||77235|
NCT01713361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 416858-CS3|Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty|An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty||Ionis Pharmaceuticals, Inc.|Yes|Completed|October 2012|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|315|||Both|18 Years|80 Years|No|||August 2014|August 25, 2014|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01713361||77234|
NCT01683435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11-134|The Value of HBA in the Evaluation of Idiopathic Infertility|The Value of Hyaluronic Binding Assays (HBA) in the Evaluation of Idiopathic Infertility||St. Luke's-Roosevelt Hospital Center|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|40 Years|No|||August 2015|August 31, 2015|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683435||79529|
NCT01683448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298807|The Effect of Perioperative Medications on the Outcomes of Patients Undergoing Cardiac Surgery|The Effect of Perioperative Medications on the Outcomes of Patients Undergoing Cardiac Surgery||University of California, Davis|No|Recruiting|February 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cardiac surgical patients|December 2014|December 3, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683448||79528|
NCT01683760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU_PK|Pharmacokinetic Study of Fluconazole in Premature Infants|||Seoul National University Hospital|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|N/A|4 Weeks|No|||November 2014|November 17, 2014|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01683760||79504|
NCT01683773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB032|Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A|A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)||University of Oxford|No|Completed|September 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01683773||79503|
NCT01685125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-12-1|Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Randomized Phase II Trial of Dasatinib Plus Abiraterone Compared to Abiraterone Alone for Metastatic, Castration-Resistant Prostate Cancer Prior to Chemotherapy||University of Southern California|Yes|Active, not recruiting|September 2012|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Male|18 Years|N/A|No|||June 2015|June 20, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685125||79399|
NCT01734343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr:847/2010|Posterior Capsule Opacification Development With Two Different Intraocular Lenses|Posterior Capsule Opacification Development and Frequency of Nd:YAG Treatment of Two Microincision IOLs: Hoya iMics Y-60H vs. PhysIOL microAY|MIPHY|Medical University of Vienna||Completed|January 2009|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|65|||Both|30 Years|N/A|No|||November 2012|November 22, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734343||75630|
NCT01734616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/3/2009|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People|Dunhill01|University of Nottingham|No|Completed|September 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|50|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734616||75609|
NCT01730846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111009293|Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?|Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?||Yale University|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01730846||75895|
NCT01731119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2302|Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents|An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents||University of North Carolina, Chapel Hill|No|Completed|December 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Years|19 Years|No|||August 2014|August 24, 2014|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731119||75874|
NCT01731132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16341|DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.|DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.|DIUQoL|Bayer|No|Completed|July 2012|July 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|||Female|18 Years|49 Years|No|Non-Probability Sample|Women who starts contraception with an IUD.|July 2015|July 15, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01731132||75873|
NCT01731392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.50.NRC|Children Immune Functions(2)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Milk-based Formulas on Infections and Immune Functions in Healthy Children||Nestlé|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|604|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|November 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01731392||75853|
NCT01731405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-5599|Consumer Understanding and Use of Medication Guides|Consumer Understanding and Use of Medication Guides||Northwestern University|Yes|Completed|November 2012|February 2014|Actual|March 2013|Actual|N/A|Observational|N/A||2|Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We are recruiting from 2 primary care clinics.|April 2014|April 8, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731405||75852|
NCT01684202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-12-001|A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)|A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|July 2012|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|20 Years|80 Years|No|||July 2014|July 7, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684202||79470|
NCT01684436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APMA-DE-0812|Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye|||Allergan|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|September 11, 2012|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01684436||79452|
NCT01684982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiLOR_2012|Everolimus Stent in Myocardial Infarction|Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With ST Elevation Myocardial Infarction (STEMI) (RaCES-MI Trial)|RaCES-MI|San Giuseppe Moscati Hospital|No|Completed|April 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|85 Years|No|||April 2013|April 1, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684982||79410|
NCT01715818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC28027|A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities|A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES||Hoffmann-La Roche||Completed|December 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1999|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715818||77046|
NCT01715831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28091|A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488|A Multicenter, Open-Label, Single-Arm Extension Study To Describe The Safety Of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 And MA21488 And Presenting An Indication Of Maintaining The Tocilizumab Treatment||Hoffmann-La Roche||Active, not recruiting|January 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01715831||77045|
NCT01716390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2010_029|Lipid-lowering Effect of Plant Stanol Drink|The Effect of Plant Stanol Drink on Serum Lipids in Comparison to Placebo in Subjects With Mildly to Moderately Elevated Serum Cholesterol Concentrations||Raisio Group|No|Completed|January 2011|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716390||77002|
NCT01716728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000418|Identification of Undiagnosed Lysosomal Acid Lipase Deficiency|Identification of Undiagnosed Lysosomal Acid Lipase Deficiency||Massachusetts General Hospital|No|Enrolling by invitation|August 2012|||August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|N/A|N/A|No|||August 2013|August 10, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716728||76976|
NCT01716715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02058|Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2012|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Female|18 Years|N/A|No|||January 2016|March 4, 2016|October 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01716715||76977|
NCT01717573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Defer-PG-11-2-28474|Deferred Stent Trial in STEMI|Randomised Controlled Study to Assess Whether Deferred Stenting in Acute STEMI Patients Might Reduce the Incidence of No-reflow Versus Conventional Treatment With Immediate Stenting||NHS National Waiting Times Centre Board|Yes|Completed|March 2012|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717573||76911|
NCT01683461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1070|Efficacy of HIV Post-Test Support for ANC in South Africa|Efficacy of HIV Posttest Support for ANC in South Africa|SAHAPS|University of North Carolina, Chapel Hill|No|Completed|May 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1500|||Female|18 Years|N/A|No|||September 2012|September 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683461||79527|
NCT01683474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Venus-A Study|Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis|Clinical Evaluation of the Safety and Performance of Percutaneous Implantation of the Venus MedTech Aortic Valve Prosthesis for Patients Who Cannot Undergo Surgical Valve Replacement|Venus-A|Venus MedTech (HangZhou) Inc.|Yes|Recruiting|September 2012|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2015|January 3, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683474||79526|
NCT01683162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNDLEIPI|Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants|Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|July 2012|February 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|150|||Both|N/A|1 Year|No|||September 2012|September 15, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01683162||79550|
NCT01683175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28280|Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation|A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation||Tianjin Medical University Cancer Institute and Hospital|No|Active, not recruiting|August 2012|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|75 Years|No|||August 2015|August 23, 2015|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683175||79549|
NCT01683188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12PLK01|HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma|A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma|PROCLIVITY 01|Prometheus Laboratories|Yes|Terminated|August 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|53|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|September 7, 2012||No|A shift in the melanoma treatment landscape adversely affected accrual & to early closure.|No||https://clinicaltrials.gov/show/NCT01683188||79548|
NCT01684007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-007|A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients|Clinical Outcomes After Implantation of the AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (MIOL) in the Dominant Eye and Randomization of the AcrySof® IQ ReSTOR® +2.5 D or +3.0 D MIOL in the Fellow Eye||Alcon Research|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|112|||Both|21 Years|N/A|No|||May 2015|May 26, 2015|September 10, 2012|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01684007||79485|
NCT01684280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-06-09-10|Obesity-related Genes in Taiwanese Undergoing Weight Loss|Searching for the Most Influential Obesity-related Diabetic Genes and Exploring the Expression Profiles of Those Genes in Taiwanese Undergoing Weight Loss||Taipei Medical University Hospital|Yes|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|20|None Retained|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were      obtained from men and women who underwent laparoscopic bariatric surgery.|Both|19 Years|63 Years|No|Probability Sample|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were        obtained from men (n = 9) and women (n =10) who underwent bariatric surgery. Their BMI        were all over 40 kg/ m2, and ages between 19-63 years.|September 2012|September 11, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684280||79464|
NCT01684293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA034883-02|Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study|Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study||University of California, San Francisco|Yes|Recruiting|July 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684293||79463|
NCT01685411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011OC139|Busulfan and Cyclophosphamide Followed By ALLO BMT|Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|January 2013|September 2025|Anticipated|September 2025|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|44 Years|No|||January 2016|January 22, 2016|September 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01685411||79377|
NCT01734629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/02814-0 FAPESP|Pulmonary Disease in Patients Referred for Coronary CT|Pulmonary Disease in Patients Referred for Coronary CT and Association Between Spirometric Abnormalities and Coronary Calcium Score.||University of Sao Paulo General Hospital|Yes|Completed|April 2011|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|205|Samples Without DNA|Blood Samples|Both|40 Years|N/A|No|Non-Probability Sample|Patients over 40 years old refereed to coronary CT in the investigator´s institution.|November 2013|December 2, 2014|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734629||75608|
NCT01734889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.NTBC-002|Taste and Palatability of Orfadin Suspension|Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin.||Swedish Orphan Biovitrum|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Month|17 Years|No|||October 2014|October 31, 2014|November 22, 2012|No|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01734889||75588|
NCT01734902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.846|Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers|Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide, Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Study)||Boehringer Ingelheim||Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|November 23, 2012||||No||https://clinicaltrials.gov/show/NCT01734902||75587|
NCT01730833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12147|Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer|Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer||City of Hope Medical Center|Yes|Recruiting|July 2013|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|19 Years|N/A|No|||March 2016|March 8, 2016|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730833||75896|
NCT01730859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-2339|The Effect of Ankle Taping and Balance Exercises on Postural Stability|The Effect of Ankle Taping and Balance Exercises on Postural Stability Indices in Healthy Women||Zahedan University of Medical Sciences|No|Completed|February 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Female|19 Years|22 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01730859||75894|
NCT01731145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1407-011-590|Assessment of Tremor Using SNUMAP Motion Sensing System|Quantitative Assessment of Tremor Using Portable Six-axis (Tri-axial Accelerometer and Tri-axial Gyroscope) Motion Sensing System|SNUMAP|Seoul National University Hospital|Yes|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|187|||Both|20 Years|80 Years|No|||July 2015|July 7, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731145||75872|
NCT01731678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-24656|Transcranial Magnetic Stimulation for Adolescent Depression|Transcranial Magnetic Stimulation for Adolescent Depression|TMSAD|University of Calgary|No|Recruiting|November 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01731678||75832|
NCT01731951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107110|Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis|A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies||Janssen Research & Development, LLC|Yes|Active, not recruiting|October 2012|January 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|81|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|November 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01731951||75811|
NCT01715259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016951|A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function|A Phase 1 Single Dose Open-Label Reduced/Staged Pharmacokinetic Study of Abiraterone Acetate in Male Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function||Cougar Biotechnology, Inc.|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01715259||77089|
NCT01715272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1008-01/2012 (DBC)|A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema|A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema||Norgine|No|Completed|October 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01715272||77088|
NCT01716403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211|Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy|Influence of Telaprevir Exposure on the Severe Anemia Induced by Ribavirin/Pegylated Interferon/Telaprevir Tri-therapy in HCV Infected Patients|Ribatela|University Hospital, Grenoble|No|Recruiting|October 2012|||October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|Samples With DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|48 HCV-genotype 1 infected patients (16 naive patients, 16 prior partial        responders/relapsers and 16 prior null responders to ribavirin/PEG-INF treatment)|January 2013|January 25, 2013|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716403||77001|
NCT01716741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000469|Identification of Undiagnosed Gaucher Disease|Identification of Undiagnosed Gaucher Disease||Brigham and Women's Hospital|No|Enrolling by invitation|August 2012|||August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2012|October 26, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01716741||76975|
NCT01717066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2011-002|the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma|A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma|Rg3|Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|April 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|480|||Both|18 Years|75 Years|No|||November 2012|November 19, 2012|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717066||76950|
NCT01717079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/122/HP|rTMS and Body Shape Perception|Effect of Transcranial Magnetic Stimulation on Disturbance of Body Shape Perception in Patients With Anorexia Nervosa|STIMOREX|University Hospital, Rouen||Recruiting|May 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|80 Years|No|||July 2015|July 29, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01717079||76949|
NCT01717040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kemp DBDAT|Pioglitazone for the Treatment of Bipolar Depression|Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression||University Hospital Case Medical Center|Yes|Active, not recruiting|September 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717040||76952|
NCT01717053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044071|Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer|A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer||Duke University|No|Recruiting|September 2013|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Male|18 Years|N/A|No|||January 2016|January 13, 2016|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01717053||76951|
NCT01682889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW_Arginin|The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation|The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation: a Randomized, Controlled Clinical Trial in Patients Receiving Peripheral Vascular Surgery||Medical Scientific Fund of the Mayor of Vienna||Completed|January 2007|January 2012|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|55 Years|75 Years|No|||September 2012|September 6, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01682889||79571|
NCT01682902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3930|A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes|A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01682902||79570|
NCT01683799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00044088|Sleep, Pain and Inflammatory Processes in Older Adults With Osteoarthritis|Slow Wave Sleep and Inflammatory Processes in Pain||University of Rochester|Yes|Active, not recruiting|February 2013|August 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|50 Years|75 Years|No|||January 2016|January 18, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683799||79501|
NCT01684046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-041|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2||Alcon Research|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|196|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|September 10, 2012|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01684046||79482|
NCT01683786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP39068|36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8|An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8||Chang Gung Memorial Hospital|No|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||September 2012|September 11, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01683786||79502|
NCT01684306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODREST_2011|Pharmacological Cognitive Enhancement|Acute Effects of Modafinil on Brain Resting State Networks in Young Healthy Subjects|MODREST|Università degli Studi 'G. d'Annunzio' Chieti e Pescara|No|Completed|February 2011|January 2012|Actual|April 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|26|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684306||79462|
NCT01684566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-396|A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis|A Multicenter, Open-label, Parallel Group Investigation to Compare the Performance of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis in Patients Receiving Conditioning Treatment for Hematopoietic Stem Cell Transplantation|episil(R)|Camurus AB|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|116|||Both|18 Years|N/A|No|||November 2015|February 17, 2016|September 11, 2012||No||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01684566||79442|
NCT01685151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375SL_302|A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects||Takeda|No|Withdrawn|September 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||January 2013|January 22, 2013|August 31, 2012|Yes|Yes|Business Decision (please see below)|No||https://clinicaltrials.gov/show/NCT01685151||79397|
NCT01734642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31025|Observational Study to Reduce Medication Errors|A Regional Project to Reduce Adverse Drug Reactions Due to Medication Errors in Hospital|OSME|Universita di Verona|Yes|Not yet recruiting|January 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8000|||Both|18 Years|N/A|No|Probability Sample|All patients from 18 to 65 and over 65 years old hospitalized in the involved departments        during the study period.|November 2012|November 28, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734642||75607|
NCT01734915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-353|Detecting EGFR T790M Mutations From Circulating Tumor Cells|Detecting EGFR T790M Mutations From Circulating Tumor Cells||Massachusetts General Hospital|No|Active, not recruiting|November 2012|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Circulating Tumor Cells (CTCs)|Both|18 Years|N/A|No|Non-Probability Sample|Receiving treatment for NSCLC at one of the participating cancer centers|August 2015|August 7, 2015|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01734915||75586|
NCT01731418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-10122012-UK|NET in Iranian Women Suffering From Post Traumatic Stress Symptoms|Efficacy of Narrative Exposure Therapy (NET) in a Sample of Iranian Women Exposed to Intimate Partner Violence (IPV)||University of Konstanz|Yes|Recruiting|November 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|16 Years|60 Years|Accepts Healthy Volunteers|||November 2012|April 8, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731418||75851|
NCT01731431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110104|Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes|Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes|INDAO|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2012|November 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Female|18 Years|45 Years|No|||October 2015|October 8, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01731431||75850|
NCT01731691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prolastin-C in HIV disease|Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease|Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects||Institute for Human Genetics and Biochemistry|No|Terminated|April 2012|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|November 19, 2012|Yes|Yes|Potential non compliance with Protocol.|No||https://clinicaltrials.gov/show/NCT01731691||75831|
NCT01731704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121010/12-01|Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases|A Randomized Controlled Study Of Neurocognitive Outcomes In Patients With Five Or More Brain Metastases Treated With Radiosurgery Or Whole-Brain Radiotherapy|NAGKC 12-01|University of California, San Francisco|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01731704||75830|
NCT01732224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HBV Reactivation-01|To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B|A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B.||Institute of Liver and Biliary Sciences, India|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||November 2012|March 22, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732224||75790|
NCT01715857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-934|Clinical Practice of Inhalation Anesthesia With Sevoflurane in China|A Multicenter Registry on the Clinical Practice of Inhalation Anesthesia With Sevoflurane in China||AbbVie||Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4100|||Both|18 Years|70 Years|No|Non-Probability Sample|Chinese patients undergoing surgery require general anesthesia (sevoflurane) with        endotracheal intubation or laryngeal mask.|August 2014|August 15, 2014|September 2, 2012||No||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01715857||77043|
NCT01684709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK088294|Enhancing Informal Caregiving to Support Diabetes Self-Management|Enhancing Informal Caregiving to Support Diabetes Self-Management||University of Michigan|Yes|Recruiting|December 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|890|||Both|21 Years|N/A|No|||January 2016|January 25, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01684709||79431|
NCT01684722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39113-EA|Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease|Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease|VITAL-DKD|University of Washington|Yes|Active, not recruiting|July 2010|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1320|||Both|50 Years|N/A|No|||December 2014|December 10, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01684722||79430|
NCT01684735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201213618|Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation|Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation||Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2012|June 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|N/A|N/A|No|Probability Sample|women diagnosed with breast cancer and treated with neo-adjuvant chemotherapy|September 2012|September 12, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01684735||79429|
NCT01686334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG12-001|Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission|Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Patients Older Than 65 Years With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial|WIDEA|University Hospital, Antwerp||Recruiting|October 2012|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|65 Years|N/A|No|||January 2016|January 7, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01686334||79307|
NCT01682304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC611|Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension|Observational Study of Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension||Ohio State University|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Sputum and peripheral blood will be collected for DNA extraction and epigenetic analyses.|Female|30 Years|65 Years|No|Probability Sample|Females diagnosed with chronic hypertension with a prior pregnancy|April 2015|April 22, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682304||79616|
NCT01717352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01CA150387-Study 5|Sleep Plus Eating Routines for Weight Loss|Increasing Sleep Duration: A Novel Approach to Weight Control. Study 5-Randomized Trial of Sleep Plus Eating Routines as An Approach to Prepare Participants for Weight Loss||The Miriam Hospital|No|Active, not recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717352||76928|
NCT01682603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL005|Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients|Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action||Buddhist Tzu Chi General Hospital|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|19 Years|65 Years|No|||June 2014|June 25, 2014|September 7, 2012||No||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01682603||79593|
NCT01683201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPF/2011/60|Functional Exercise After Total Hip Replacement|Functional Exercise After Total Hip Replacement: A Randomised Controlled Late Phase Trial|FEATHER|Health Service Executive, Ireland|No|Completed|September 2012|February 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|72|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683201||79547|
NCT01684332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNAV-078-2010|Postprandial Response to Different Jams|Study of the Effects of Three Strawberry Jams, Differing in Carbohydrate and Antioxidant Content, on Postprandial Response in Healthy Subjects||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|September 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684332||79460|
NCT01684345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052130/CL3-78989-005|Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis|A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis|EYEGUARD™-A|XOMA (US) LLC|No|Terminated|August 2012|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684345||79459|
NCT01684020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-RHI-12|A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty|A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty||DeNova Research|No|Recruiting|November 2012|July 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684020||79484|
NCT01684033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-038|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1||Alcon Research|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|207|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|September 10, 2012|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01684033||79483|
NCT01684579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2111|Exercising Our ABC's (African- American Breast Cancer Survivors)|Exercising Our ABC's (African- American Breast Cancer Survivors)||Case Comprehensive Cancer Center|Yes|Completed|June 2011|March 2013|Actual|August 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Female|18 Years|N/A|No|||March 2013|March 18, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684579||79441|
NCT01684839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-TS-120127|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap|||The Second Hospital of Tangshan||Completed|May 2007|March 2012|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|9|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||June 2012|August 19, 2013|September 11, 2012|Yes|Yes||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01684839||79421|
NCT01686204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0669|Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt|Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt||University of Wisconsin, Madison||Active, not recruiting|September 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|132|||Female|21 Years|55 Years|Accepts Healthy Volunteers|||April 2015|October 1, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686204||79317|
NCT01686217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK51|A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K|A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Compare the Pharmacokinetic Profiles of Three Different Strengths of ASP015K Extended Release Formulation With ASP015K Immediate Release Formulation and to Evaluate Food Effect on Extended Release Strengths in Healthy Volunteers||Astellas Pharma Inc|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|9||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686217||79316|
NCT01730872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-270-0007|Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model|A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model||ORA, Inc.|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730872||75893|
NCT01730885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGStar|A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes|||Profil Institut für Stoffwechselforschung GmbH|No|Completed|November 2012|||January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|74 Years|No|||November 2012|February 4, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730885||75892|
NCT01731158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-II-008|Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC)|A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)|BERAT|Central European Society for Anticancer Drug Research||Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01731158||75871|
NCT01731171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI/SPHS: 2012/1|Probiotics to Prevent Relapse After Hospitalization for Mania|A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Mania||Sheppard Pratt Health System|Yes|Enrolling by invitation|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||August 2015|August 26, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731171||75870|
NCT01731717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KQ1002B-TP7|Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression|Effektivität Und Effizienz Von Behandlungspfaden für Patienten Mit Depressiven Erkrankungen: Stepped Care Als Ansatz für Ein Leitliniengerechtes Und Integriertes Versorgungsmanagement|SCM|Universitätsklinikum Hamburg-Eppendorf|No|Completed|September 2012|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|737|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01731717||75829|
NCT01731730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADYX-002|Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery|Study to Evaluate the Safety & Efficacy of a Single Intrathecal Pre-Operative Administration of AYX1 Injection at Two Dose Levels Compared to Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty (TKA)||Adynxx, Inc.|Yes|Completed|January 2013|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|40 Years|80 Years|No|||January 2015|January 14, 2015|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731730||75828|
NCT01731964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA-NG-001 ASSAF HAROFEH|Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration|Pilot Study of WA-NG Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration||VisionCare Ophthalmic Technologies, Inc.|No|Withdrawn|November 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||April 2014|December 10, 2014|November 14, 2012||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01731964||75810|
NCT01684449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS-24|Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma|Phase 1/2, Randomized, Multicenter, Prospective Study of Gemcitabine and Rapamycin (Sirolimus) Combination Versus Gemcitabine Only to Treat Advanced Soft Tissue Sarcoma||Grupo Espanol de Investigacion en Sarcomas|Yes|Completed|January 2010|December 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01684449||79451|
NCT01684462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL_IIT_01|The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke|A Phase IIB Placebo Comparative, Double Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of ALbumin Therapy in Acute Ischemic Stroke Patients in Korea.|ALbumin|Seoul St. Mary's Hospital|Yes|Terminated|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||November 2013|November 28, 2013|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684462||79450|
NCT01685814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM XIV|Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance|Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV||Wuerzburg University Hospital|No|Recruiting|May 2012|May 2020|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|406|||Both|18 Years|65 Years|No|||September 2012|September 11, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01685814||79346|
NCT01685606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 273|Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma|BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study|273|Brown University|Yes|Terminated|March 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|September 12, 2012|Yes|Yes|Lack of accrual and low efficacy|No|June 4, 2015|https://clinicaltrials.gov/show/NCT01685606||79362|
NCT01715558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00053871 / 90942887|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications OPTI-MIND 2|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|OPTI-MIND 2|Boston Scientific Corporation|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with permanent pacemaker with RYTHMIQ programed to ON|September 2014|March 2, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01715558||77066|
NCT01715805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-72|An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)|A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder (MDD)||Forest Laboratories|No|Recruiting|November 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715805||77047|
NCT01686347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/146/HP|Epidural Analgesia and Troubles of Fetal Cardiaq Rythm : Effect of the Systemic Transfer of Ropivacaine and Sufentanil|Epidural Analgesia and Troubles of Fetal Cardiaq Rythm : Effect of the Systemic Transfer of Ropivacaine and Sufentanil|epidarc|University Hospital, Rouen|No|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01686347||79306|
NCT01682317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK IRB# FWA 6629|Healthy Eating Patterns During a Lifestyle Intervention|Healthy Eating Patterns During a Lifestyle Intervention|HEP|University of Tennessee|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682317||79615|
NCT01682616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-365|A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||AbbVie|No|Active, not recruiting|August 2012|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682616||79592|
NCT01683487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-CAP|Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.|Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia. Analysis of Risk Factors and Impact on the Outcome.||University of Zurich|Yes|Completed|October 2012|May 2014|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|122|||Both|16 Years|N/A|No|Non-Probability Sample|Patients admitted and treated at the University Hospital of Zurich because of severe        community-acquired pneumococcal pneumonia requiring hospilazation.|May 2014|May 26, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683487||79525|
NCT01683500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCESWT01|Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT)|Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT)||University of Zurich|Yes|Completed|August 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2015|June 2, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683500||79524|
NCT01684072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-2|Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin|Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin||Beijing Center for Disease Control and Prevention|No|Completed|January 2011|January 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||September 2012|September 9, 2012|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01684072||79480|
NCT01684319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-202 (MATPED 11-047)|Milk-induced Gastrointestinal Symptoms in Infants|Prospective, Randomized, Double Blind and Placebo Controlled Study With the Aim to Establish the Role of Milk Proteins in Gastrointestinal Diseases (GERD, Constipation and Colics) of Young Infants and to Determine the Diagnostic Value of Immunological Tests in These Pathologies.||University Hospital, Geneva|No|Completed|August 2012|November 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|120|||Both|N/A|6 Months|No|||January 2014|January 3, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684319||79461|
NCT01684852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL-046|Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution|Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution (BAT04) Compared to HA Eye Drops in the Treatment of Dry Eye Disease||Bitop AG|No|Completed|May 2012|||December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic The selection of appropriate patients for the observational study is        made by the individual physician in his treatment decisions in consultation with the        individual patient|January 2013|January 29, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684852||79420|
NCT01684865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27993|An Observational Study of First-Line Maintenance MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma|||Hoffmann-La Roche||Active, not recruiting|October 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Probability Sample|Patients with follicular non-Hodgkin's lymphoma receiving first-line Rituximab maintenance        treatment|March 2016|March 1, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684865||79419|
NCT01685138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2203|LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer|A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer||Novartis|Yes|Active, not recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01685138||79398|
NCT01685918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ederly_RA|Safety and Effectiveness of Biological DMARDs in Elderly Patients With Rheumatoid Arthritis|Safety and Effectiveness of Biological DMARDs in Elderly Patients With Rheumatoid Arthritis||Hanyang University|No|Recruiting|April 2012|August 2016|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|1. Retrospective study: 425 patients with RA We will collect data of Korean patients             with RA retrospectively. Subjects will be extracted from medical records of RA             patients who had treated with biological DMARDs or are currently using biological             DMARDs from Dec 2000 to Dec 2010.          2. Prospectively study: 203 patients with RA We will use the web-based registry of RA             patients with biologic DMARDs. This prospective study will be progressed during three             years.        We will compare the response in elderly RA patients versus young RA patients, and evaluate        the impact of old age on the response. The occurrence of adverse events during three years        will be described.|September 2012|September 12, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685918||79338|
NCT01731184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morphine Midazolam|Morphine-Midazolam in Pre-hospital Traumatic Patients With Severe Acute Pain|Randomized Double-blind Placebo-controlled Trial: Administration of Morphine-Placebo vs. Morphine-Midazolam in Pre-hospital Traumatic Patients With Severe Acute Pain.|Morphine-Mida|Centre Hospitalier de Cornouaille|No|Completed|November 2006|September 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||November 2012|November 16, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01731184||75869|
NCT01731444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhenylephrineRCT|Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury|Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial||University of Manitoba|Yes|Recruiting|December 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731444||75849|
NCT01731457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N403 589338-WUM-PD-Poland|Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function|Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function||Medical University of Warsaw|No|Recruiting|April 2011|March 2014|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731457||75848|
NCT01731743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|839 MP HEN 402-11|Evaluation of Visual Acuity and Patient Satisfaction With AT LISA TRI 839MP Intraocular Lenses|||Carl Zeiss Meditec AG|No|Active, not recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 18, 2013|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01731743||75827|
NCT01731756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-003-CT|Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis|Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis: Randomized, Double Blind, Placebo-controlled Trial||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|January 2013|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||May 2014|May 2, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01731756||75826|
NCT01714674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-033|Nitrate and Exercise-induced Cardiac Troponin T in Type 2 Diabetes|The Impact of Dietary Nitrate Supplementation on Exercise-induced Cardiac Troponin T Release in Type 2 Diabetic Patients|NO troponin|Maastricht University Medical Center|No|Recruiting|October 2012|May 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Male|40 Years|80 Years|No|||October 2012|October 31, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714674||77134|
NCT01714986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoU-Kronoberg 4522|Psychological Variables and Hyperglycemia in Diabetes Mellitus|Psychological Impact, Metabolic Control, Biological Stress Markers in Diabetes: Intervention With Affect School and Basal Body Awareness|ALEXIDIAB|Lund University|No|Enrolling by invitation|March 2009|December 2021|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|59 Years|No|||June 2014|June 17, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01714986||77110|
NCT01685827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiFEX004|Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2|Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study||Drugs for Neglected Diseases|Yes|Recruiting|October 2012|September 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|510|||Both|15 Years|N/A|No|||June 2014|June 19, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685827||79345|
NCT01682330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s53571|The Long-term Effects of Training on Muscle Strength and Functionality|||Universitaire Ziekenhuizen Leuven||Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|65|||Female|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Older adults (+65 years)|June 2012|September 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682330||79614|
NCT01716065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355841-17|Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)|Impact of Regional Anesthesia Versus General Anesthesia on Immune Modulation and Clearance of Circulating Tumor Cells (CTC) in Subjects Undergoing Surgery for Primary Nonmetastatic Breast Cancer|CTC|Defense and Veterans Center for Integrative Pain Management|No|Completed|June 2012|||May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|Samples collected for CTC analysis (2 tubes of 8ml of blood) will be drawn at 4 time points:      pre-operative (at least 24 hours before surgery), immediate prior to surgery, 12-24 hours      post-operative, and 5-7 days post-operative.|Both|18 Years|85 Years|No|Probability Sample|We will enroll female and male military health care beneficiaries between the ages 18-85        years old presenting with the diagnosis of primary non-metastatic breast cancer, American        Joint Committee on Cancer (AJCC) Stages I, II or III, undergoing surgery with curative        intent|April 2014|April 29, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01716065||77027|
NCT01686373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11560FA12|Brain Stimulation and Aphasia Treatment|Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes|tDCS|University of South Carolina|Yes|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|25 Years|80 Years|No|||December 2015|December 7, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01686373||79304|
NCT01682915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204071RIC|Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD|Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2012|July 2015|Anticipated|||N/A|Observational|N/A||5|Anticipated|240|||Both|12 Years|20 Years|No|Non-Probability Sample|The sample (n=240, 8 groups, ages 10-20, IQ > 80) consists of (1) 30 ADHD probands with        DAT1 variants, (2) 30 same-sex unaffected siblings, (3) 30 ADHD probands without DAT1 gene        variants, who were age-, sex-, and IQ-matched to Group 1, (4) 30 same-sex unaffected        siblings of Group 3, (5) 30 age-, sex- and IQ-matched TD controls for each of 4 groups        (Groups 1, 2, 3 & 4).|September 2012|September 7, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01682915||79569|
NCT01682629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Robertson|Examining the Effect of a Scripted Debriefing on Resuscitation Performance in Pediatrics|Examining Pediatric Resuscitation Education Using Simulation and Scripted Debriefing: A Multicenter, Randomized Controlled Trial|EXPRESS|Express Collaborative|No|Completed|April 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|4||Actual|443|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682629||79591|
NCT01683812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00003465|Cranial Cup Use for Correction of Head Shape Deformities|Cranial Cup Use for the Correction of Positional Head Shape Deformities in Hospitalized Premature Infants||Children's Hospital Boston|Yes|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|1 Year|No|||August 2014|August 26, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01683812||79500|
NCT01684904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120054|Proton Therapy for Esophageal Cancer|A Phase II Trial of Proton Chemotherapy (PCT) for Resectable Esophageal or Esophagogastric Junction Cancer||Loma Linda University|Yes|Recruiting|July 2012|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01684904||79416|
NCT01685164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491/13/03/03/2010|The Effect of Uterine Size and Posture on Intrauterine Contraception in Nulliparous Women|The Effect of Uterine Size and Posture on Intrauterine Contraception in Nulliparous Women||Helsinki University Central Hospital||Completed|January 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|161|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of nulliparous women attending the centralized Family        planning center of the City of Helsinki requesting intrauterine contraception, either the        LNG-IUS or a Cu-IUD.|April 2015|April 8, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01685164||79396|
NCT01684592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA032683-01A1|Phone-Based Postpartum Continuing Care for Smoking Cessation|Phone-Based Postpartum Continuing Care: Smoking Cessation Beginning in Pregnancy|PPCC|Battelle Memorial Institute|Yes|Completed|October 2012|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|No|||April 2015|April 9, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684592||79440|
NCT01684605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136HPS12D|Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of CKD-11101 and NESP After IV Administration in Health Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|October 2012|||January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684605||79439|
NCT01684618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP - HH 527|Neonatal Cerebral Oxygenation and Changes in CPAP Flow Pressure - Evaluation With INVOS Oximeter|Oxygenation of the Neonatal Brain - a Study Using the INVOS Oximeter||Copenhagen University Hospital, Hvidovre|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|N/A|4 Weeks|No|||November 2013|November 6, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684618||79438|
NCT01684878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28113|A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression|A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION||Hoffmann-La Roche||Active, not recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|208|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684878||79418|
NCT01684891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP28214|A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers|Single-center, Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of RG1662 Given BID Over 28 Days, and in Addition, the Excretion and Metabolism of [13C]-Labelled IV Microdoses and an Oral [14C]-Labelled Dose of RG1662 in Healthy Male Volunteers||Hoffmann-La Roche||Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684891||79417|
NCT01686243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-560|Real-time Ultrasound-guided Paramedian Epidural Access: Evaluation of a Novel In-plane Transverse View Technique|||The Cleveland Clinic|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|30 Years|80 Years|No|||September 2012|September 12, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01686243||79314|
NCT01686490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2924526|LifeSkills Video Training in Patients About to Receive an Automatic Implantable Cardioverter-Defibrillator (AICD)|LifeSkills Video Training in Patients About to Receive an Automatic Implantable Cardioverter-Defibrillator|AICD|Williams LifeSkills|Yes|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|21 Years|N/A|No|||September 2012|September 17, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01686490||79295|
NCT01730937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1112|Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer|Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|368|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730937||75888|
NCT01731197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-1245|Satiating Effects of Isolated Soy Proteins|Comparison of the Satiating Effects of Differentially Processed Isolated Soy Proteins||Solae, LLC|No|Completed|November 2012|November 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731197||75868|
NCT01731769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSF-2012|Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure|Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure--- a Randomized Control Clinical Trial||Changhai Hospital|No|Not yet recruiting|January 2013|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|80 Years|No|||November 2012|November 19, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01731769||75825|
NCT01732289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806069R|Genetic Study of Age Related Hearing Loss|Genetic Study of Age Related Hearing Loss|ARHL|National Taiwan University Hospital|Yes|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|1000|||Both|45 Months|N/A|Accepts Healthy Volunteers|||November 2012|November 21, 2012|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT01732289||75785|
NCT01731990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885M2201|Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication.||Novartis|No|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||October 2015|October 5, 2015|November 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731990||75808|
NCT01732575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enrich|Enrichment of Day Centers in Community-based Psychiatry|Effectiveness of an Intervention Tailored for Day Centers for People With Psychiatric Disabilities||Lund University|No|Completed|October 2008|March 2015|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01732575||75763|
NCT01715844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-citrulline Asthma|L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics|L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics|SANDIA|University of Pittsburgh|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|10|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01715844||77044|
NCT01682343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32AN2|Effect of High-calcium Intake on Appetite, Insulinemia and Incretins|Effect of High-calcium Intake on Appetite, Insulinemia and Incretins||Northumbria University|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|10|||Male|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682343||79613|
NCT01682356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRJ_201111134|Dietary Nitrates for Heart Failure|Dietary Nitrates for Heart Failure||Washington University School of Medicine|Yes|Recruiting|January 2012|December 2019|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682356||79612|
NCT01716078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|365681-8|The Effect of Brachial Plexus Nerve Block on Distal Peripheral Nerve Conduction|The Effect of Brachial Plexus Nerve Block on Distal Peripheral Nerve Conduction||Defense and Veterans Center for Integrative Pain Management|No|Withdrawn|November 2011|||September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female military health care beneficiaries age 18 years and older presenting for        hand surgery and eligible for a brachial plexus nerve block will be asked to participate        in this study.|January 2016|January 28, 2016|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01716078||77026|
NCT01716091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu 02|The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery|The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery on Maternal Morbidity and Gastrointestinal System Outcome||Istanbul Bakirkoy Maternity and Children Diseases Hospital|No|Completed|November 2012|October 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|430|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|all pregnant women between 18 years or older and who requıred cesarean delivery.|January 2015|January 6, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01716091||77025|
NCT01682668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-40|Subthalamic Nucleus, Akinesia and Parkinson's Disease|Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.|GB-MOV|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|January 27, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01682668||79588|
NCT01682941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08027|Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen|Bioavailability of Isoflavones Delivered by Soy Almond Bread in Men With Recurring Prostate Cancer and Rising Prostate Specific Antigen||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2009|December 2017|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|N/A|N/A|No|||June 2015|June 30, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682941||79567|
NCT01682928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRONG-2012|Hydrotherapy for the Reversal of Oligohydraminos|Submersion Therapy for the Reversal of Oligohydramnios; A Non-invasive Gentle Approach|STRONG|Mednax Center for Research, Education and Quality|No|Terminated|August 2012|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||December 2014|December 17, 2014|September 6, 2012||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01682928||79568|
NCT01682954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0149|Evaluation of a Lifestyle Intervention for Employees With Prediabetes|Evaluation of a Lifestyle Intervention for Employees With Prediabetes||Ohio State University|Yes|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|September 7, 2012||No||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01682954||79566|
NCT01683214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11122902|Brain Network Activation Analysis to Diagnose/Assess Treatment of Unipolar Major Depression and Bipolar I Depression|Potential Use of Brain Network Activation (BNA) Analysis Using Evoked Response Potentials to Diagnose Unipolar Major Depression and Bipolar I Depression and Assess Response to Treatment|BNA-Mood|Rush University Medical Center|No|Enrolling by invitation|August 2012|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will only enroll subjects who are participating in another specified clinical        trial.The inclusion/exclusion criteria will depend on the criteria for each of the studies        utilizing subjects with depression or bipolar type I disorder|November 2014|November 5, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683214||79546|
NCT01684059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Babil-2|Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway|Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway||Babylon University|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|60|||Male|27 Years|35 Years|No|Non-Probability Sample|this study includes 60 fertile male partners from couples who had consulted the        infertility clinic of babil hospital of maternity (Hilla city/ IRAQ).|September 2012|September 11, 2012|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01684059||79481|
NCT01684917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/L0/0139|Application of New Technologies and Tools to Nutrition Research|Application of New Technologies and Tools to Nutrition Research|NutriTech|Imperial College London|Yes|Recruiting|April 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684917||79415|
NCT01684358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-6163|A Trial on the Effect of Sino-implant (II) Use on Condom Use Among Women in Kingston, Jamaica|A Randomized Controlled Trial on the Effect of Sino-implant (II) Use on Condom Use Among Women in Kingston, Jamaica|SIS|Centers for Disease Control and Prevention|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|414|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||April 2013|November 4, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684358||79458|
NCT01685697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033526|Mask Ventilation With Different Face Masks During Neonatal Resuscitation|Comparison of Two Round Face Masks During Neonatal Resuscitation||University of Alberta|Yes|Completed|March 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|N/A|30 Minutes|No|||September 2013|September 26, 2013|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01685697||79355|
NCT01685905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TST_IGRA|The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection|Evaluation of the Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Mycobacterium Tuberculosis Infection in Korean Patients With Rheumatic Diseases||Hanyang University|No|Recruiting|April 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|1) Estimation of the positive rates and agreement between QFT-G and TST          -  Approximately 2,000 patients with rheumatic diseases who examined TST or QFT-G in             Hanyang university hospital from 2004 to 2010 2) Determining the difference in the             occurrence of active TB in the TNF inhibitor user according to the screening and the             treatment of LTBI.          -  Approximately 400 patients with rheumatic diseases who received TST or QFT-G before             using anti-TNF agents in Hanyang university hospital from 2004 to 2010|September 2012|September 17, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685905||79339|
NCT01683058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-12-297|Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia|A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|66 Years|No|||March 2015|March 25, 2015|September 7, 2012|No|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01683058||79558|
NCT01683071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-323|Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty||Pacira Pharmaceuticals, Inc|Yes|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|278|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683071||79557|
NCT01731210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCNA02 - LENEA|Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)|Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation|LENEA|LivaNova|No|Recruiting|November 2012|November 2014|Anticipated|November 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731210||75867|
NCT01731470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-024|Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)|Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)||William Beaumont Hospitals|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731470||75847|
NCT01731483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-1|Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections|Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections.||Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2012|||July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|Samples Without DNA|tissue specimens from endocarditis lesions and necrotizing fasciitis|Both|N/A|N/A|No|Non-Probability Sample|Material will be collected from all patients that undergo surgical treatment for invasive        streptococcal or staphylococcal infections, including acute infective endocarditis and        necrotizing fasciitis, from the UZ Leuven University Hospital|November 2012|November 20, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731483||75846|
NCT01732302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 1266-31|Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients|Educational Intervention to Reduce Drug-related Hospitalizations and Visits in Emergency Departments in Elderly Primary Health Care Patients - a Cluster-randomized Controlled Trial||Karolinska Institutet|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69|||Both|65 Years|N/A|No|||October 2013|October 18, 2013|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732302||75784|
NCT01732588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_12_003|A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route|Three Way Randomised CrossOver Study in Healthy Subjects to Compare the Relative Bioavailability of Nanoparticulate OZ439 Delivered Via the Enterion™ Capsule to the Proximal Small Bowel With Orally Administered OZ439 as PIB Suspension and Orally Administered Nanoparticulate||Medicines for Malaria Venture|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|October 22, 2012||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT01732588||75762|
NCT01715610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lawson -REB- 101813|Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage|Comparing Post-drainage Treatment of Peritonsillar Abscesses With Antibiotics (Clavulin or Clindamycin) to Treating With Placebo - a Double-blinded Randomized Control Trial|PTA|Lawson Health Research Institute|No|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01715610||77062|
NCT01715870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2012-04|Life Style and Food Habits Questionnaire in the Portuguese Population Aged 55 or More|Life Style and Food Habits Questionnaire in the Portuguese Population Aged 55 or More.||Association for Innovation and Biomedical Research on Light and Image|No|Completed|December 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2000|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that participated in the "Epidemiological study on the prevalence of Age related        Macular Degeneration in Portugal" (Protocol N. CC-01-2009) will be invited to answer a        validated life style and food habits questionnaire.|October 2015|October 7, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01715870||77042|
NCT01686113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205012317|Free Fatty Acids: Short Exposure Study|Free Fatty Acids: Short Exposure Study||Purdue University|Yes|Completed|May 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686113||79324|
NCT01686126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|feMMe|Improving the Treatment for Women With Early Stage Cancer of the Uterus|A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium|feMMe|Queensland Centre for Gynaecological Cancer|Yes|Recruiting|October 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686126||79323|
NCT01716104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-AZ-001-I|Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression||Materia Medica Holding|No|Recruiting|November 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Male|45 Years|60 Years|No|||August 2015|August 31, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01716104||77024|
NCT01716416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211110|Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma|HNSCC|Washington University School of Medicine|No|Recruiting|May 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|33|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01716416||77000|
NCT01686074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/679|Motor Control in Chronic Fatigue Syndrome and Fibromyalgia|Motor Control in Chronic Fatigue Syndrome and Fibromyalgia.||Norwegian University of Science and Technology|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|90|||Both|19 Years|49 Years|No|Non-Probability Sample|Patients with chronic fatigue syndrome and fibromyalgia from primary care clinics.|March 2015|March 10, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686074||79327|
NCT01683240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Short Access Cholangioscope|Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones|Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones|SAC|Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01683240||79544|
NCT01683227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1DA028031-01|Screening, Brief Intervention, and Referral to Treatment for Drug Use|Screening and Brief Intervention for Latino and Non-Latino White Drug Users|SBIRT|San Diego State University|No|Active, not recruiting|April 2010|October 2013|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 11, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683227||79545|
NCT01683513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dr. Decleer W|Trial Comparing hCG Triggering Versus GnRH Agonist Triggering in PCOS Patients|Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients||AZ Jan Palfijn Gent|Yes|Recruiting|November 2011|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|38 Years|No|||March 2015|March 27, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01683513||79523|
NCT01683526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139-12|Safety and Efficacy of Endotracheal Intubation Using Glidescope Video-Laryngoscope|Safety and Efficacy of Endotracheal Intubation by Pulmonary Critical Care Physicians in Critically-Ill Patients Using Glidescope Video-Laryngoscope||Beth Israel Medical Center|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|September 6, 2012||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01683526||79522|
NCT01683825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001322|Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography|Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography||Brigham and Women's Hospital|No|Recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01683825||79499|
NCT01683838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-F302|Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury|Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury||Acorda Therapeutics|Yes|Completed|June 2002|February 2004|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|70 Years|No|||January 2014|January 6, 2014|August 24, 2012|No|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01683838||79498|
NCT01684930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031918|Nitrites, Exercise, and Peripheral Arterial Disease|Increased Plasma Nitrite, Tissue Oxygenation and Functional Changes in PAD|NO-PAD|Duke University|No|Completed|June 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|75 Years|No|||November 2015|November 25, 2015|September 11, 2012|Yes|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01684930||79414|The largest limitation to the study was the evolving knowledge on conversion rates of oral inorganic nitrate to nitrite. We found a good deal of unexpected inter and intra-subject variation in conversion rates.
NCT01685190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2010/10025|A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer|A Randomised Phase II Trial of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer|PIVOTAL|Institute of Cancer Research, United Kingdom|Yes|Active, not recruiting|June 2011|March 2018|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Male|18 Years|N/A|No|||April 2013|April 3, 2013|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01685190||79394|
NCT01685437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-806|A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Male|18 Years|N/A|No|||March 2015|March 24, 2015|September 12, 2012|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01685437||79375|
NCT01685450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU 0123|NIMIP: Non Invasive Measurement of the Intracranial Pressure|Validation of a New Non Invasive Method of Indirect Measurement of the Intracranial Pressure Variations|MINIPIC|University Hospital, Clermont-Ferrand||Recruiting|June 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01685450||79374|
NCT01685710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4178|The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas|The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas||University Hospital Birmingham|Yes|Completed|April 2013|June 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01685710||79354|
NCT01682538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.NTBC-001|Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension|A Study to Evaluate the Bioequivalence of Orfadin Suspension 4 mg/mL Compared to Orfadin Capsules 10 mg, and the Effect of Food on the Bioavailability of the Suspension. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers||Swedish Orphan Biovitrum|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|September 7, 2012|No|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT01682538||79598|
NCT01731782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-12-03|Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain|Evaluation of a TAP Block as Part of an Enhanced Recovery Pathway in Laparoscopic Colorectal Surgery: A Prospective, Randomized, Double-blinded Multi-institution Trial|TAP Block|University Hospital Case Medical Center|Yes|Completed|July 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|79|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01731782||75824|
NCT01732003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SE032|The Effect of Omega-3 Fatty Acid Supplementation on Skeletal Muscle Membrane Composition and Cellular Metabolism|The Effect of Omega-3 Fatty Acid Supplementation on Skeletal Muscle Plasma and Mitochondrial Membrane Composition and Cellular Metabolism||University of Guelph|No|Recruiting|November 2011|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01732003||75807|
NCT01732016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02362|The Camera Oximeter: A Calibration Study|The Camera Oximeter: A Calibration Study||University of British Columbia|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 4, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01732016||75806|
NCT01724632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK095779|LIVE SMART: Smartphone Intervention for Weight Control|||The Miriam Hospital|No|Active, not recruiting|November 2012|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01724632||76370|
NCT01724905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18808|Weight Loss and Maintenance for Individuals With Intellectual Developmental Disabilities (IDD)|Weight Loss and Maintenance for Individuals With Intellectual Developmental Disabilities (IDD)||University of Kansas Medical Center|Yes|Completed|May 2011|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01724905||76349|
NCT01725165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0618|A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Oligometastatic Disease|A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Oligometastatic Disease||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2012|||November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01725165||76329|
NCT01715883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11030251|Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction|Sodium Nitrite Administration at the Time of Lung Organ Procurement and Transplantation to Minimize the Risk of Pulmonary Graft Dysfunction||University of Pittsburgh|Yes|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|8|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01715883||77041|
NCT01685346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6512|Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study|Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study||Case Comprehensive Cancer Center|Yes|Terminated|October 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|September 10, 2012||No|Research Cancelled|No||https://clinicaltrials.gov/show/NCT01685346||79382|
NCT01686087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6628|Attaining and Maintaining Wellness in Obsessive-compulsive Disorder|Attaining and Maintaining Wellness in OCD||New York State Psychiatric Institute|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||December 2015|December 3, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686087||79326|
NCT01683539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2837E|Understanding How Cognitive Remediation Works|A Dismantling Study of Cognitive Remediation for Supported Employment|Cog-2|Boston University|Yes|Recruiting|September 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01683539||79521|
NCT01683552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aprepitant-Itch|Aprepitant in the Management of Biological Therapies-related Severe Pruritus|Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients|AprepIt|Campus Bio-Medico University|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|85 Years|No|||September 2012|September 11, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01683552||79520|
NCT01684631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27062008|Evaluation of Implant Survival in Patients With a Pinnacle Ultamet Device in Conventional Total Hip Joint Replacement|Prospective, Multicentric, Observational Cohort Study for the Evaluation of Implant Survival in Patients With a Metal-on-Metal Pinnacle(R) Ultamet(TM) Device in Conventional Total Hip Joint Replacement.||DePuy International|No|Active, not recruiting|January 2009|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|18 Years|N/A|No|Probability Sample|Patients susceptible to receive a PINNACLE® ULTAMET™ implant|August 2015|August 26, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684631||79437|
NCT01684644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-10-1294|A Controlled Study of Parent Training in the Treatment of ADHD in Young Children|Parent Training for Preschool ADHD: A Randomised Controlled, Multicentre Effectiveness Trial of the New Forest Parenting Programme in a Clinical Sample of Danish Children|D'SNAPP|University of Aarhus|No|Recruiting|September 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|3 Years|7 Years|No|||September 2012|September 12, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01684644||79436|
NCT01685957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-01-2012|Optimal Dietary Treatment of Obese Adults|Optimal Dietary Treatment of Obese Adults|OPDIOS|Hospitalsenheden Vest|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 16, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685957||79335|
NCT01685177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SADI-CD|Single Anastomosis Duodeno-Ileal Bypass vs Standard Duodenal Switch as a Second Step After Sleeve Gastrectomy in the Super-Morbid Obese Patient|Prospective Randomized Trial Comparing Single-Anastomosis Duodeno-Ileal Bypass With Standard Roux-en-Y Duodenal Switch as a Second Step After a Sleeve Gastrectomy in the Super-Morbid Obese Patient|SADI vs CD|Hospital San Carlos, Madrid|No|Recruiting|September 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Fat, liver tissue|Both|18 Years|60 Years|No|Non-Probability Sample|Patients attended in the Surgery Clinic with Morbid Obesity submitted to a sleeve        gastrectomy and needing a second-step operation.|September 2012|September 11, 2012|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01685177||79395|
NCT01685723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cancer_rct_1|Smoking Cessation in Cancer Patients|Helping Cancer Patients Quit Smoking by Improving Their Risk Communication: a Cluster Randomized Controlled Trial||The University of Hong Kong|Yes|Recruiting|September 2012|August 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|August 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01685723||79353|
NCT01685931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100880|A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics|Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up||Xian-Janssen Pharmaceutical Ltd.|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|617|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685931||79337|
NCT01724138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ACN02|An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old|An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old|MACS2163|Novartis|No|Withdrawn|June 2013|October 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|71 Years|No|||August 2014|August 21, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01724138||76408|
NCT01724385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I55116|Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation||Khon Kaen University|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|60 Years|No|||April 2013|April 25, 2013|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724385||76389|
NCT01725191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02163|Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197) in Children With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|13 Months|21 Years|No|||May 2015|June 30, 2015|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725191||76327|
NCT01725204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NordCML007|Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia|A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia|NordCML007|Norwegian University of Science and Technology|Yes|Active, not recruiting|September 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725204||76326|
NCT01725217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_50|Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia|A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia||Novartis|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|198|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 24, 2014|November 8, 2012|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01725217||76325|
NCT01725503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|Creatine Kinetics, Synthesis From Glycine and Response to Creatine and Amino Acid Supplement in Healthy Humans|Creatine Metabolism in Humans:Effect of Creatine and Amino Acid Supplement||The Cleveland Clinic|No|Completed|January 2010|December 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725503||76303|
NCT01725516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-06-4234|Effect of Myofascial Release Technique on Reducing Symptoms in Patients With Chronic Disc Protrusion|||Shiraz University of Medical Sciences|Yes|Completed||||||N/A|Interventional|N/A|1||||||Both|18 Years|60 Years||||August 2011|November 13, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01725516||76302|
NCT01685593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2001.128|Abdominal Binder Study to Decrease Postoperative Pain|A Controlled Randomized Trial Examining the Ability of the Mott Compression Bonder to Decrease Postoperative Pain in Gynecologic Abdominal Laparotomy Patients.||Brooke Army Medical Center|Yes|Completed|January 2001|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|76|||Female|18 Years|N/A|No|||September 2012|September 13, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685593||79363|
NCT01682369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2012/04|ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses|A Multi-centre, Phase II, Open Labelled Randomised Control Trial to Describe Immune & Transcriptomic Responses to Trivalent Inactivated Vaccine (TIV) & MF59 Adjuvanted Influenza Vaccine (ATIV) in 14 -26 Month Healthy Children||University of Oxford|Yes|Completed|September 2012|January 2015|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|90|||Both|14 Months|26 Months|Accepts Healthy Volunteers|||July 2015|July 3, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682369||79611|
NCT01682382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-AMD-103|Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)|Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.||Sequenom, Inc.|No|Completed|August 2012|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|45|Samples With DNA|DNA extracted from whole blood and buccal cells will be analyzed. Remnant samples will be      stored for future research in AMD.|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Non-Hispanic Caucasian subjects 60 years of age and older diagnosed with either CNV or dry        AMD and a cohort of age-matched controls|January 2014|January 16, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682382||79610|
NCT01682395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1091|Best Management of Sigmoid Volvulus: A Prospective Randomized Trial|Best Management of Sigmoid Volvulus: A Prospective Randomized Trial||University of North Carolina, Chapel Hill|Yes|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682395||79609|
NCT01682642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000784-25|The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.|IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates.||AZ Jan Palfijn Gent|Yes|Completed|March 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|38 Years|No|||March 2015|March 9, 2015|August 23, 2012||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01682642||79590|
NCT01682655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101015-F|Genetic Variant in Apolipoprotein C3 Gene and Fatty Liver in Obese Children|The Influence of Apolipoprotein C3 Variants on Liver Steatosis and Serum Liver Enzyme Values in Obese Children||Far Eastern Memorial Hospital|Yes|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples With DNA|serum, WBC DNA|Both|6 Years|18 Years|No|Non-Probability Sample|Obese children and adolescents in Taiwan|November 2013|March 10, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01682655||79589|
NCT01682967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-11|Alteration in Hearing Following Accidental Dural Puncture. A Study in Parturients|Alteration in Hearing Following Accidental Dural Puncture. A Study in Parturients|AHEAD|Örebro University, Sweden|Yes|Completed|January 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|21|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experimental group: Parturients in labour with epidural and having PDPH Control group -        EDA: Parturients in labour with epidural and NOT having PDPH Control group - No EDA:        Parturients in labour without epidural and NOT having PDPH|September 2015|September 26, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01682967||79565|
NCT01682980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/334|Efficacy of Exercise on Physical Function and Cartilage Health in Patients With Knee Osteoarthritis|Efficacy of Strength and Aerobic Exercise on Patient-reported Outcomes and Structural Changes in Patients With Knee Osteoarthritis - A Randomised Controlled Trial.||Oslo University Hospital|Yes|Recruiting|March 2013|December 2025|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|207|||Both|35 Years|70 Years|No|||October 2014|October 22, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01682980||79564|
NCT01683253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKL004|Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa|The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy|REIN-PD|Sandoz Korea|No|Not yet recruiting|November 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|30 Years|80 Years|No|||October 2012|October 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683253||79543|
NCT01684371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EO-01|The Effects of Elmore Oil on Patients With Osteoarthritis|The Effects of a Herbal Remedy, Elmore Oil, on Pain and Well-being in Patients With Osteoarthritis: A Double-blind, Placebo-controlled, Randomised Trial.||Elmore Oil Company Pty Ltd|No|Completed|November 2008|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|45 Years|90 Years|No|Non-Probability Sample|Population from which the cohorts will be selected are from hospital primary care        arthritis clinic.|September 2012|September 10, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01684371||79457|
NCT01684657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asenapine Stuttering|A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering|A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering||University of California, Irvine|Yes|Suspended|September 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|July 24, 2012||No|Study transferring to another facility|No||https://clinicaltrials.gov/show/NCT01684657||79435|
NCT01685749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2011-8620|The Natural History of Human Stingray Injuries|||University of California, Irvine|No|Recruiting|July 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The targeted study population will include all people at Seal Beach who have been        identified by the Seal Beach Lifeguards to have been stung by a stingray over the course        of one year who are adults or children whose parent or guardian is present at the time of        the injury. Children and pregnant women are included.|September 2012|September 11, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685749||79351|
NCT01685463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDA P20 DA022658|Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving|Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving||Medical University of South Carolina|No|Recruiting|September 2008|||September 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 13, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01685463||79373|
NCT01686503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doris Duke CF-2012061|Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects|Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects|IDIPV|Eastern Virginia Medical School|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|231|||Both|18 Years|90 Years|No|||January 2015|January 22, 2015|September 13, 2012||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01686503||79294|Higher baseline antibody titers than expected making it more difficult to detect differences between the study groups.
NCT01682512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301.1|Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis|Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.||Boehringer Ingelheim||Active, not recruiting|September 2012|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||||||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|August 10, 2012||||No||https://clinicaltrials.gov/show/NCT01682512||79600|
NCT01682525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N09-454|Ovarian Tissue Cryopreservation for Fertility Preservation|Ovarian Tissue Cryopreservation for Fertility Preservation||Boston IVF|No|Withdrawn|May 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|No|||February 2016|February 3, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01682525||79599|
NCT01683656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILACH 2012DR4097|ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART|ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART|NILACH|University Hospital, Geneva|Yes|Terminated|August 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|N/A|No|||March 2013|March 14, 2013|August 31, 2012||No|Withdrawal of IMP from the market. Data on risk-benefit ratio pending.|No||https://clinicaltrials.gov/show/NCT01683656||79512|
NCT01683669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91/12|Effect of Variable PSV in Acute Lung Injury: Part I and Part II|Physiological Research on Variable Pressure Support Ventilation in Patients With Acute Acute Lung Injury: Part I and Part II||University of Genova|Yes|Recruiting|August 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01683669||79511|
NCT01683682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-2011-NSCLC-04|An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)|An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV|VENUS-2|Aktion Bronchialkarzinom e.V.|No|Completed|April 2013|||January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|71 Years|N/A|No|||January 2015|January 22, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01683682||79510|
NCT01724645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH_KOREAN-FOOD_2-2_2010|Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes|Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.||Chonbuk National University Hospital|Yes|Completed|September 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|19 Years|80 Years|No|||November 2012|November 9, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01724645||76369|
NCT01724658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU0115|Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women|Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women||Chulalongkorn University|Yes|Completed|June 2012|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01724658||76368|
NCT01724918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVE 001|Lacosamide IV and EEG/EKG (LIVE) Study|Lacosamide IV and EEG/EKG (LIVE) Study|LIVE|Lawson Health Research Institute|No|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01724918||76348|
NCT01724931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syntrix-AMT-RA-202|Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis|A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis||Syntrix Biosystems, Inc.|No|Completed|February 2013|February 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01724931||76347|
NCT01725529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017962|An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve, Genotype 1 Hepatitis C-Infected Subjects||Janssen R&D Ireland|Yes|Completed|November 2012|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|457|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|November 9, 2012|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01725529||76301|
NCT01725789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-12-644|Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)|A Randomized Patient -Blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject®) With Placebo in Patients With Acute Isovolemic Anemia After Gastrectomy||National Cancer Center, Korea|Yes|Active, not recruiting|November 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|450|||Both|19 Years|N/A|No|||October 2015|October 5, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01725789||76281|
NCT01686360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816186|Communicating Objective Risk for Personalized Decision Making About Mammography|Communicating Objective Risk for Personalized Decision Making About Mammography||University of Pennsylvania|No|Enrolling by invitation|September 2012|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|8||Anticipated|1600|||Female|35 Years|49 Years|Accepts Healthy Volunteers|||August 2012|September 17, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01686360||79305|
NCT01682694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7798|Glucosamine and Chondroitin Effects|Glucosamine and Chondroitin Effects|GLANCE|Fred Hutchinson Cancer Research Center|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01682694||79586|
NCT01682707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0021.0.185.000-09|Assessment of Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients|Randomized Clinical Trials to Compare the Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients Undergoing CABG||Federal University of Juiz de Fora|Yes|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|70 Years|No|||April 2012|September 10, 2012|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682707||79585|
NCT01682681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015865|An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy|A Prospective, Observational, Multi-center Study to Assess Long-term Retention Rate of Topiramate in Patients With Epilepsy||Janssen Korea, Ltd., Korea|Yes|Completed|July 2007|May 2009|Actual|May 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1234|||Both|2 Years|65 Years|No|Non-Probability Sample|The study population will include participants with epilepsy who visit an out-patient        clinic for two months and have not received topiramate treatment for at least three months        prior to Screening.|August 2013|August 21, 2013|August 22, 2012|No|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01682681||79587|The study design is single arm and open label, so bias could not be excluded in the subjective evaluation by Participants and Investigators.
NCT01683851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC200120233H|Isolite and Dental Treatment Under Conscious Sedation|Isolite and Dental Treatment Under Conscious Sedation: a Pilot Study to Assess the Upper Airway in a Pediatric Population||The University of Texas Health Science Center at San Antonio|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|4 Years|7 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric patients in need of a sedation dental appointment|December 2013|December 12, 2013|September 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01683851||79497|
NCT01683864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004405-25|Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer|Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer|HIPEC_Stomach|University Hospital Tuebingen|Yes|Recruiting|September 2012|September 2020|Anticipated|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01683864||79496|
NCT01684085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9175-JZ-CTIL|Explanation About Sleep in Post Trauma Patients|Explanation About Sleep Given After Traumatic Event, and Its Effect on the Trajectory of Post Traumatic Stress Disorder (PTSD)||Sheba Medical Center|No|Not yet recruiting|October 2012|||September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01684085||79479|
NCT01684384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2011-79|Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients.|Correlation of Functional Respiratory Imaging Parameters With Lung Function Parameters and Patient Reported Outcome Measures During Exacerbation of COPD.||FLUIDDA nv|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|53|||Both|40 Years|N/A|No|||November 2014|November 26, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01684384||79456|
NCT01684670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039730|Intensive Dysarthria Sessions in Adults and Children With Down Syndrome|Intensive Dysarthria Sessions in Adults and Children With Down Syndrome||Duke University|Yes|Active, not recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|8 Years|N/A|No|||January 2016|February 1, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684670||79434|
NCT01685736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA|Ambulatory Versus Home Blood Pressure Monitoring in Obstructive Sleep Apnea|Ambulatory Versus Home Blood Pressure Monitoring in Obstructive Sleep Apnea|OSA|University of Athens|No|Recruiting|February 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects referred to a sleep clinic|September 2012|September 11, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685736||79352|
NCT01682551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRICM-10101|Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness|Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness||China Medical University Hospital||Not yet recruiting|September 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682551||79597|
NCT01686256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.2|Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer|A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer||Endocyte||Completed|August 2001|||August 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Female|18 Years|N/A|No|||September 2012|September 12, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686256||79313|
NCT01686269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-95-C-018|Endothelial Progenitor Cells|Mobilization of Endothelial Progenitor Cells in Patients With Coronary Artery Bypass Surgery||Far Eastern Memorial Hospital|Yes|Recruiting|March 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|50|||Both|18 Years|85 Years|No|||January 2007|September 12, 2012|February 6, 2009||||No||https://clinicaltrials.gov/show/NCT01686269||79312|
NCT01686516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-58|Synaptic Plasticity Imaging With Diffusion MRI|Methodological Study of Synaptic Plasticity Imaging With Diffusion MRI||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|35|||Male|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|population free of any psychological or organic troubles, with no metal inclusions for MRI        convenience.|September 2012|September 17, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01686516||79293|
NCT01686529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-008-2010|Bevacizumab for Primary Pterygium Treatment|Conjunctival Autografting Alone or Combined With Subconjunctival Bevacizumab for Primary Pterygium Treatment.||Instituto de Oftalmología Fundación Conde de Valenciana|No|Completed|March 2010|February 2012|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|49|||Both|18 Years|70 Years|No|||December 2013|December 5, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01686529||79292|
NCT01724944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYANA|LYmphadenectomy After NeoAdjuvant Chemotherapy|Lymphadenectomy After Neo-Adjuvant Chemotherapy in Ovarian Neoplasm|LYANA|Catholic University of the Sacred Heart|Yes|Recruiting|February 2011|||February 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Female|18 Years|75 Years|No|||November 2012|November 9, 2012|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01724944||76346|
NCT01725230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00039|Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib|An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily|Statin DDI|AstraZeneca||Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|February 1, 2013|November 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725230||76324|
NCT01724476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002667|A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia|A Placebo-Controlled Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia||Massachusetts General Hospital|Yes|Recruiting|November 2014|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724476||76382|
NCT01726088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAVHS209470-1|Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)|A Double-Blind, Placebo-Controlled Trial of Modafinil in OEF/OIF Combat Veterans With PTSD||Biomedical Research Foundation|No|Recruiting|August 2012|May 2014|Anticipated|May 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|60 Years|No|||November 2012|November 9, 2012|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01726088||76258|
NCT01685853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S570 510|Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One|Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.||European Institute of Oncology|Yes|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|85 Years|No|||September 2012|September 18, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685853||79343|
NCT01682993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|367/2009|Corneal Cross Linking and Topography Guided Excimer Laser Treatment|Topography Guided Excimer Laser Surface Ablation in Combination With Corneal Cross-linking (CCL) in Patients With Progressive Ectatic Corneal Disorders.||Medical University of Vienna|No|Active, not recruiting|January 2010|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|40 Years|No|||December 2013|December 4, 2013|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01682993||79563|
NCT01683565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|752311|Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood|Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood||Nationwide Children's Hospital|Yes|Completed|September 2012|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Months|39 Months|No|||January 2016|January 26, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683565||79519|
NCT01683877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloSeal-OC|Efficacy Study of FloSeal in Hemostasis After Laparoscopic Ovarian Cystectomy|PROSPECTIVE RANDOMIZED CONPARISON OF ELECTRONIC DIATHERMY VERSUS FLOSEAL IN HEMOSTASIS AFTER LAPAROSCOPIC OVARIAN CYSTECTOMY||Asan Medical Center|No|Recruiting|September 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|N/A|No|||September 2012|September 16, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01683877||79495|
NCT01684098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.8|Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor|A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor||Endocyte||Completed|August 2003|August 2005||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1|||40|||Both|18 Years|N/A|No|||September 2012|September 9, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684098||79478|
NCT01684397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 191711|Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer|A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients||Roswell Park Cancer Institute|Yes|Recruiting|October 2012|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684397||79455|
NCT01685944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-619|Anti-Obesity Effect of Pediococcus Pentosaceus LP28|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Pediococcus Pentosaceus LP28 on Obesity||Hiroshima University|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|62|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685944||79336|
NCT01685970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGI-2012-09|Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy|Comparison of Using the Same-day 2 Sachets Picosulfate Versus High Volume PEG Bowel Preparation for Afternoon Colonoscopy|SP2HP|Inje University|Yes|Recruiting|September 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||September 2012|September 14, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685970||79334|
NCT01683370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFND2012B|Pediatric FN Definition 2012 Bern|Pediatric FN Definition 2012 Bern The Impact of Lowering Fever Limits on the Rate of Fever in Chemotherapy-induced Neutropenia (FN). A Prospective Single-center Observational Study in Children and Adolescents With Cancer.||Swiss Pediatric Oncology Group|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|Samples Without DNA|1 mL serum, kept refrigerated until the end of study, then analyed as batch for cortisol,      then discarded.|Both|1 Year|17 Years|No|Probability Sample|Pediatric patients diagnosed with cancer requiring chemotherapy, treated at the Division        of Pediatric Hematology/Oncology, Department of Pediatric, University of Bern /        Inselspital, CH-3010 Bern, Switzerland|August 2013|August 12, 2013|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01683370||79534|
NCT01714414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-IMPH-FATI-01|A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen|A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naïve, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast|FATI-01|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|December 2012|March 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01714414||77153|
NCT01714687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005030|Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)|Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients: A Randomized Controlled Study (CABERNET)|CABERNET|Acclarent|No|Active, not recruiting|October 2012|April 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Both|19 Years|N/A|No|||December 2015|December 10, 2015|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714687||77133|
NCT01682824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0628|MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors|MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors||M.D. Anderson Cancer Center|No|Recruiting|May 2013|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|15 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Adolescent and young adult (AYA) males and females (15 to 39 years old) who survived        childhood CNS tumors from MD Anderson Cancer Center, Texas Children's Cancer Center, and        Web sources.|February 2016|February 15, 2016|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01682824||79576|
NCT01682837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiqKMgCit-1208-01|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension||Meta Pharm Development, LLC|No|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|21 Years|N/A|No|||October 2012|October 29, 2012|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682837||79575|
NCT01725243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07|Carbetocin at Cesarean Delivery for Labor Arrest|Carbetocin at Cesarean Delivery for Labor Arrest: A Dose Finding Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725243||76323|
NCT01723163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-365|Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers|Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers||VA Office of Research and Development|No|Enrolling by invitation|November 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01723163||76483|
NCT01723176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-408A|Evaluation of Ultrasound of the Heart in Patients With Low Blood Pressure|Evaluating Critical Care Echocardiography in Patients With Cardiopulmonary Failure at the Time of Presentation||Northwell Health|No|Withdrawn|December 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present to the medical intensive care unit with cardiopulmonary failure|September 2015|September 24, 2015|November 1, 2012||No|study never got off the ground, no pts ever recruited|No||https://clinicaltrials.gov/show/NCT01723176||76482|
NCT01725854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-1-1011/ 367294|Relaxation Response Training for PTSD Prevention in US Military Personnel|Relaxation Response (RR) Training for PTSD Prevention in Soldiers a.k.a. "SPIRIT SMART" (Stemming PTSD, Increasing Resilience and Impeding Trauma in Service Members: Assessing Relaxation Response Training)|RR|Samueli Institute for Information Biology|Yes|Recruiting|July 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01725854||76276|
NCT01725802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612/002|A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients|A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients||NeuroDerm Ltd.|No|Active, not recruiting|December 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|30 Years|N/A|No|||June 2013|June 6, 2013|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01725802||76280|
NCT01725815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047631a|The Health Access and Recovery Peer Program|A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers|HARP|Emory University|Yes|Active, not recruiting|June 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01725815||76279|
NCT01682408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00019|Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability|An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets|PK Combination|AstraZeneca||Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 27, 2012|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01682408||79608|
NCT01682421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH_DSAEK_STEROID|Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation|Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation||Aarhus University Hospital|No|Withdrawn|September 2012|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01682421||79607|
NCT01683578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulmEngineering-2012-01|Protective Variable Ventilation for Open Abdominal Surgery|Effects of Variable Tidal Volumes During Open Abdominal Surgery on Lung Function and Systemic Inflammation|PROVAR|Technische Universität Dresden|No|Recruiting|September 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||September 2012|September 10, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01683578||79518|
NCT01683890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBSFSH|Study on Bladder and Sexual Function Change After Simple Hysterectomy|Incidence and Pattern of Overactive Bladder Symptoms Occurring After Hysterectomy||Asan Medical Center|No|Recruiting|September 2012|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|20 Years|80 Years|No|Probability Sample|Patinets who undergo simple hysterectomy due to benign uterine disease at university        hospital|September 2012|September 16, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01683890||79494|
NCT01684111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-2011-NSCLC-05|An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)|An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV|VENUS-1|Aktion Bronchialkarzinom e.V.|No|Completed|June 2013|||January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|71 Years|N/A|No|||January 2016|January 15, 2016|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01684111||79477|
NCT01684124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AICU2012-008|An Assessment of the Feasibility and Safety of Conservative Oxygen Therapy in Critically Ill Patients|A Before-and-after Assessment of Conservative Oxygen Therapy vs. Standard Care in Critically Ill Mechanically Ventilated Patients||Austin Health|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|90 Years|No|||July 2013|July 9, 2013|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01684124||79476|
NCT01684943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001005|Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling|Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling||Massachusetts General Hospital|Yes|Active, not recruiting|July 2010|September 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|12 Years|N/A|No|||March 2014|March 15, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01684943||79413|
NCT01685203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-393|A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)|PEARL-I|AbbVie|No|Completed|August 2012|February 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|316|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|September 12, 2012|Yes|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01685203||79393|
NCT01686282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021259|Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension|Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension.||Florida State University|Yes|Completed|January 2012|January 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Female|45 Years|65 Years|No|||January 2015|January 12, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01686282||79311|
NCT01686295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS940112|24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness|A Randomized, Double -Blind,, Sham-Device-Controlled, Multicenter, 24-Week Clinical Trial to Evaluate the Safety and Effectiveness of the iRestore ™ Hair Rejuvenation System in the Treatment of Male and Female Androgeneticalopecia||Freedom Laser Therapy, Inc.|No|Recruiting|July 2012|May 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01686295||79310|
NCT01683097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVH 1195|Patient Understanding of End of Life Care|Assessing Patient Understanding and Factors That Govern Advanced Directives and End of Life Discussion||Partners in Internal Medicine|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|300|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01683097||79555|
NCT01683110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-209|Expanded Access of Cabozantinib in Medullary Thyroid Cancer|An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer||Exelixis||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2013|January 15, 2013|September 7, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01683110||79554|
NCT01682564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m106CHF11E|To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure|Open Label, Randomized, Active Drug Comparative, Parallel Group, Multi-center, Phase IV Study to Compare and Evaluate the Efficacy and Safety of Candemore Tab and Atacand Tab.|CANTABILE|Chong Kun Dang Pharmaceutical|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|20 Years|N/A|No|||September 2015|September 22, 2015|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682564||79596|
NCT01713907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-109|Evaluation of the Ulthera® System for Treatment of the Face and Neck|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Facial Tissue and Improvement in Jawline Definition and Submental Skin Laxity||Ulthera, Inc|No|Terminated|June 2011|January 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2013|October 15, 2012|Yes|Yes|Inadequate study staff to appropriately manage trial.|No||https://clinicaltrials.gov/show/NCT01713907||77192|
NCT01714700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRELIN0912|Interactive Effects of an Isocaloric High-protein Diet and Resistance Exercise in Untrained Overweight Young Men|Interactive Effects of an Isocaloric High-protein Diet and Resistance Exercise on Body Composition, Ghrelin, and Metabolic and Hormonal Parameters in Untrained Overweight Young Men||Pusan National University Yangsan Hospital|Yes|Completed|August 2006|May 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01714700||77132|
NCT01722890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-09|CharactHer. ICORG 12-09, V3|CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|July 2012|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|150|||Female|N/A|N/A|No|Non-Probability Sample|Study population will consist of two separate cohorts of patients with HER2-positive        breast cancer that will be analysed based on their responsiveness to        trastuzumab-containing chemotherapy. Cohort 1 will include patients with TNM stage II-IV        breast cancer with highly trastuzumab-sensitive tumours. Results of laboratory analyses        from Cohort 1 will be matched with those from Cohort 2 (Control group) that includes        patients at the same TNM clinical stages but with trastuzumab-refractory disease.|October 2015|October 23, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01722890||76504|
NCT01723150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-KLASS|Antibiotics for Klebsiella Liver Abscess Study|A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess||National University Hospital, Singapore|Yes|Recruiting|November 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|21 Years|N/A|No|||December 2013|December 2, 2013|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723150||76484|
NCT01724229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV2012|Clinical Case Series Evaluating Skin Wellness System|An Open-Label Clinical Case Series to Demonstrate Efficacy of the Kendall Skin Wellness System||GM Associates|Yes|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01724229||76401|
NCT01725542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC30 QUADRIH|Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders|Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interferon -Ribavirin Regimen|QUADRIH|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|December 2012|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||March 2014|September 5, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01725542||76300|
NCT01725555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXL010|A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors|A Randomized, Open-label, Phase I, Crossover Study to Assess the Effect of Food on the Bioavailability of AXL1717, in Patients With Advanced Malignant Tumors||Axelar AB|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|13|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01725555||76299|
NCT01722604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-11-265|Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt|||InnoPharma Inc.|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|258|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722604||76526|
NCT01722851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-11|Circulating miRNAs. ICORG 10-11, V2|Circulating miRNAs: Novel Breast Cancer Biomarkers and Their Use for Guiding and Monitoring Response to Chemotherapy||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|May 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|122|||Female|18 Years|N/A|No|Non-Probability Sample|Investigators aim to study two populations of breast cancer patients:          1. Patients undergoing neoadjuvant chemotherapy for breast cancer at tertiary referral             breast cancer centres in Ireland.             For GUH only: Additionally,investigators wish to evaluate miRNA expression levels in             patients' diagnostic core biopsies.          2. Investigators also wish to study the same panel of miRNAs in patients who present             with disease recurrence or disease progression, and who are commenced on systemic             therapies (hormonal and/or chemotherapy).|October 2015|October 23, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01722851||76507|
NCT01682447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33713.008.10|Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD|Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)||University of Tilburg|No|Active, not recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|128|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01682447||79605|
NCT01682720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0133|Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection.||Gilead Sciences|Yes|Completed|September 2012|January 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|421|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|September 5, 2012|Yes|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01682720||79584|
NCT01683266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12456|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|EDITION IV|Sanofi|No|Completed|September 2012|March 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|549|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|September 7, 2012|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01683266||79542|
NCT01683279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAT-01|A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia|Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor||Seattle Children's Hospital|Yes|Active, not recruiting|December 2012|January 2031|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|26 Years|No|||December 2015|December 30, 2015|September 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01683279||79541|
NCT01683591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060613|Dysphagia Assessment in Acute Ischemic Stroke Using High-resolution Manometry|Dysphagia Screening in Acute Stroke Using High-resolution Impedance Manometry (DASH); Its Implication to Diet Decision and Clinical Outcome|DASH|The Catholic University of Korea|No|Completed|April 2009|November 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|293|||Both|N/A|N/A|No|Non-Probability Sample|Acute ischemic stroke patients at neurology department from April 2009 to November 2009        were evaluated.|September 2012|September 7, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01683591||79517|
NCT01684683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|theophylline in NCFB|The Effect of Theophylline in the Treatment of Bronchiectasis|Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis||The First Affiliated Hospital of Guangzhou Medical University|Yes|Completed|November 2012|September 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684683||79433|
NCT01684956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001098|Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes|Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Volunteers With Type 1 Diabetes||Massachusetts General Hospital|No|Active, not recruiting|August 2012|December 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01684956||79412|
NCT01685983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100009|A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer|A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.||Janssen Research & Development, LLC|No|Active, not recruiting|August 2011|September 2016|Anticipated|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Male|18 Years|N/A|No|||January 2016|January 18, 2016|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685983||79333|
NCT01685476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0124|NIMI-NICU: Non Invasive Monitoring of the Intracranial Pressure - NeuroIntensive Care Unit|Validation of a New Non Invasive Method for Intracranial Pressure Monitoring|MINIPIC REA|University Hospital, Clermont-Ferrand||Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|20|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01685476||79372|
NCT01685489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U19AT006028-01A1|A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer|A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer||Bastyr University|Yes|Withdrawn|May 2013|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||October 2015|October 23, 2015|September 6, 2012|Yes|Yes|funding sequestered|No||https://clinicaltrials.gov/show/NCT01685489||79371|
NCT01685502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16517|Special Drug Use Investigation of Glucobay OD|Special Drug Use Investigation of Glucobay OD||Bayer|No|Completed|November 2010|August 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2289|||Both|N/A|N/A|No|Non-Probability Sample|Glucobay OD naive diabetics. Patients with at least one of the following conditions:        Uncontrollable with dietary therapy,exercise cure, diabetes medication, insulin therapy.|October 2014|October 17, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685502||79370|
NCT01717794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thunder Endometrium|Thunderbeat Technology vs Standard Bipolar Electro-surgery in Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for Endometrial Cancer|Prospective Randomized Trial on Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Endometrial Cancer FIGO Stage IB-II: Thunderbeat Technology Versus Standard Bipolar Electro-surgery.|Thunder Endom|Catholic University of the Sacred Heart|Yes|Recruiting|October 2012|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Female|N/A|75 Years|No|||November 2012|November 5, 2012|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01717794||76894|
NCT01713582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-001|A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)|A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies||Oncoethix GmbH|Yes|Active, not recruiting|December 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01713582||77217|
NCT01686555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-093|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)|Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)||AbbVie|No|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|97|||Female|18 Years|65 Years|No|||July 2015|July 7, 2015|September 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686555||79290|
NCT01713595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001723|Safety Study of Inhaled Saline in Acute Lung Injury|Inhaled Hypertonic Saline for the Treatment of Acute Lung Injury||Mayo Clinic|No|Withdrawn|October 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|October 4, 2012||No|difficult getting subjects|No||https://clinicaltrials.gov/show/NCT01713595||77216|
NCT01713894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Decision Aid - Prematurity|Decision Aid - Extreme Prematurity|Utility of a Clinically Relevant Decision Aid, for Parents Facing Extremely Premature Delivery||Christiana Care Health Services|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713894||77193|
NCT01714401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ-1|Nebulized Bronchodilatators and Cardiac Repolarization|The Development of Procedures to Optimalize the Intensive Care Units Patients Clinical Condition. Evaluation of Influence of Nebulized Bronchodilatatory Drugs on Cardiac Repolarization||Medical University of Gdansk||Recruiting|March 2012|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|75|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01714401||77154|
NCT01714440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT GEN-03|Genomics of Kidney Transplantation|Genomics of Kidney Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|August 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|4300|||Both|N/A|N/A|No|Non-Probability Sample|3000 Kidney or Kidney-pancreas transplant recipients and 1300 of the donors|September 2015|September 21, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01714440||77151|
NCT01714726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5170C00001|Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.|A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy||AstraZeneca|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01714726||77130|
NCT01723995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1710-9|Laser Therapy in Nipples Injured During Breastfeeding|Effect of Low-level of Laser Therapy in Nipple Trauma During Breastfeeding|LTNIBF|Federal University of São Paulo|No|Recruiting|February 2011|July 2013|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|45 Years|No|||October 2012|November 6, 2012|October 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01723995||76419|
NCT01725308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0021|A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes|Phase II/III Study of FK949E — Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes —||Astellas Pharma Inc|No|Active, not recruiting|December 2011|October 2016|Anticipated|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|431|||Both|20 Years|64 Years|No|||September 2015|September 30, 2015|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725308||76318|
NCT01731093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0967-F2L|Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress|Multiple-ascending Dose Clinical Trial of the Safety and Tolerability of Antioxidant (AT-001) Treatment for Reducing Brain Oxidative Stress||Alltech Life Sciences Inc.|Yes|Completed|March 2012|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 22, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731093||75876|
NCT01683019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST#002|Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression|A MULTICENTER, RANDOMIZED, BLINDED, SHAM CONTROLLED, PARALLEL GROUP TRIAL TO TEST CLINICAL EFFICACY OF LOW FREQUENCY AC MAGNETIC FIELD INDUCED EEG SYNCHRONIZATION IN MAJOR DEPRESSION||NeoSync, Inc.|No|Completed|June 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|September 4, 2012|No|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01683019||79561|
NCT01683292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR040/001|Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease|An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease||South Glasgow University Hospitals NHS Trust|No|Completed|January 2006|May 2007|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|30 Years|N/A|No|||September 2012|September 7, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683292||79540|
NCT01683305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silbiotech:2012-01|Biomarker Breast Pap Test|||Silbiotech|No|Not yet recruiting|March 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any woman age 18 or older|September 2012|September 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683305||79539|
NCT01684137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-2011-05-JOALIS|Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg|||DSC Services, s.r.o.|No|Recruiting|August 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|100|||Both|9 Years|18 Years|No|||September 2012|September 10, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01684137||79475|
NCT01684410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T6005-201|Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis|A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.||Grifols Therapeutics Inc.|Yes|Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 6, 2012|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01684410||79454|
NCT01684696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09184|Virtual Intervention for Lung Cancer|Virtual Intervention for Lung Cancer|VILC|University of California, San Francisco|Yes|Not yet recruiting|August 2015|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|21 Years|N/A|No|||July 2015|July 2, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01684696||79432|
NCT01684969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005661|Evidence of Haloperidol Absorption After Topical Administration|Topical Haloperidol: Evidence of Absorption After Topical Administration||Mayo Clinic|No|Withdrawn|March 2012|May 2013|Actual|May 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 19, 2012|Yes|Yes|lack of accrual and funding is about to expire.|No||https://clinicaltrials.gov/show/NCT01684969||79411|
NCT01685515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE 10Z11|Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease|Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease||The Cleveland Clinic|Yes|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01685515||79369|
NCT01685216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-068|Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease|A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease||Shire|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|2 Years|17 Years|No|||October 2015|October 1, 2015|September 10, 2012|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01685216||79392|
NCT01685996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA034164|Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation|Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation|1207|Johns Hopkins University|Yes|Active, not recruiting|September 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||January 2014|January 29, 2014|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685996||79332|
NCT01686542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN-cpAF|CPVI Plus Renal Sympathetic Modification Versus CPVI Alone for AF（Atrial Fibrillation） Ablation|Circumferential Pulmonary Vein Isolation (CPVI) Plus Renal Sympathetic Modification Versus CPVI Alone for AF Ablation: a Pilot Study||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2013|May 2, 2013|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686542||79291|
NCT01713881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDEAMC-Fincher 1|Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations|Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations||United States Department of Defense|No|Active, not recruiting|August 2012|June 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon polyps|March 2014|March 19, 2014|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01713881||77194|
NCT01713608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_12_005|A Dose-escalation Study to Investigate Safety and Toleration of OZ439|A Randomised, Placebo-controlled, Dose-escalation Study to Investigate Safety and Toleration of OZ439 OD for 3 Days to Healthy Male and Female Volunteers||Medicines for Malaria Venture|No|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|October 22, 2012||No||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01713608||77215|
NCT01713621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_12_006|OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation|The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients||Medicines for Malaria Venture|No|Completed|March 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|60 Years|No|||May 2015|May 1, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01713621||77214|
NCT01683994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120204|Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer|A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|January 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|81|||Male|18 Years|N/A|No|||April 2015|July 10, 2015|September 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683994||79486|
NCT01684553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F10-39|The Effect of Changing the Eating Speed on Energy Intake|The Effect of Changing the Eating Speed on Energy Intake: a Randomized Cross-over Study|EatSpeed|Texas Christian University|Yes|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|70|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01684553||79443|
NCT01684267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000447|Pelvic Obliquity Rehabilitation in Stroke Patients Using Robotically Generated Force Fields|Pelvic Obliquity Rehabilitation in Stroke Patients Using Robotically Generated Force Fields||Spaulding Rehabilitation Hospital|No|Active, not recruiting|January 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684267||79465|
NCT01725022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032263|A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care|A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care||Duke University|Yes|Recruiting|February 2012|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|90|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01725022||76340|
NCT01725594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2003-101|A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003|A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects||Catabasis Pharmaceuticals|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|11||Actual|99|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01725594||76296|
NCT01730794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002419|Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure|A Comparative, Multicenter, Randomized, Controlled Study of Neurally Adjusted Ventilatory Assist (NAVA) vs. Conventional Lung Protective Ventilation in Patients With Acute Respiratory Failure||Massachusetts General Hospital|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01730794||75899|
NCT01730807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiFi-CTI|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||January 26, 2015|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01730807||75898|
NCT01731106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fundacio Unio CEIC 12/18|Cerebral Autoregulation in Non Neurological Critical Patients.|Cerebral Autoregulation in Non Neurological Critical Patients.||Althaia Xarxa Assistencial Universitària de Manresa|Yes|Recruiting|June 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood sample for biomarkers at admision, 72 hours and 7 days.|Both|18 Years|90 Years|No|Non-Probability Sample|Patients admited on the ICU that need mechanical ventialtion|December 2015|December 29, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01731106||75875|
NCT01683604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28144|Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|July 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients treated with tocilizumab|August 2015|August 17, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01683604||79516|
NCT01683617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03E901|Management and Treatment of Stress-related Disorders (INTERSTRESS)|INTERSTRESS - Interreality in the Management and Treatment of Stress-related Disorders|INTERSTRESS|Istituto Auxologico Italiano|No|Active, not recruiting|May 2012|July 2015|Anticipated|January 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|25 Years|60 Years|No|||January 2014|January 31, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01683617||79515|
NCT01684150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPZ-5676-12-001|A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene|A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies||Epizyme, Inc.|No|Active, not recruiting|September 2012|December 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||October 2015|October 6, 2015|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01684150||79474|
NCT01685229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005028|Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis|Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis (MERLOT)|MERLOT|Acclarent|No|Completed|September 2012|August 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|198|||Both|19 Years|N/A|No|Non-Probability Sample|Adult subjects age 19 or older with radiographically documented CRS|August 2015|August 27, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685229||79391|
NCT01685242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-100-0006|A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle|A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Aciex Therapeutics, Inc.|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|10 Years|N/A|No|||April 2015|April 30, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685242||79390|
NCT01685255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-210|A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy|A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy||Incyte Corporation|Yes|Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685255||79389|
NCT01685268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT13387-04|A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate|A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone||Astex Pharmaceuticals|No|Completed|September 2012|December 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Male|18 Years|N/A|No|||January 2016|January 8, 2016|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685268||79388|
NCT01685762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1205|Metformin for the Treatment of Endometrial Hyperplasia|Metformin for the Treatment of Endometrial Hyperplasia||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|September 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|75 Years|No|||August 2015|August 26, 2015|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685762||79350|
NCT01717014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVLARO0286|Radial Reload Open LAR Case Series|Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series||Medtronic - MITG|No|Terminated|May 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|85 Years|No|||February 2015|February 13, 2015|October 26, 2012|No|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT01717014||76954|
NCT01717027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501034|Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers|Open Label, Single Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics And Relative Bioavailability Of Oxycodone Following Oral Administration Of 40 Mg Doses Of PF 00345439 Taken Whole Under Fed Conditions And After Chewing Under Fasted Conditions In Healthy Volunteers||Pain Therapeutics|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|October 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717027||76953|
NCT01717326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-035|A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)|A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection|C-WORTHy|Merck Sharp & Dohme Corp.|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|20||Actual|573|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|October 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717326||76930|
NCT01717547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0641|Strength and Awareness in Action|Strength and Awareness in Action||VA Eastern Colorado Health Care System|No|Active, not recruiting|June 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01717547||76913|
NCT01717560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308006281|Hepatitis C Treatment in Underserved Populations|Hepatitis C Treatment in Underserved Populations||Weill Medical College of Cornell University|No|Enrolling by invitation|February 2005|December 2020|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01717560||76912|
NCT01751698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HD073975|Adaptive Interventions for Minimally Verbal Children With ASD in the Community|Adaptive Interventions for Minimally Verbal Children With ASD in the Community|AIM-ASD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|54 Months|96 Months|No|||October 2015|October 19, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751698||74296|
NCT01751724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120786|Caffeine to Reduce Mechanical Ventilation in Preterm Infants|Use of Caffeine to Reduce Length of Mechanical Ventilation in Preterm Infants||University of Miami|Yes|Terminated|December 2012|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|N/A|5 Days|No|||January 2016|January 25, 2016|December 12, 2012||No|Safety|No||https://clinicaltrials.gov/show/NCT01751724||74295|
NCT01740011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-1112-RL|Prospective Randomized Trial on Comparison of Standard- Carbon Dioxide Pressure Pneumoperitoneum Insufflators Versus AirSeal|A Prospective Randomized Trial on Comparison of Standard- Carbon Dioxide Pressure Pneumoperitoneum Insufflators Versus AirSeal|AirSeal|Krankenhaus Barmherzige Schwestern Linz|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||January 2014|September 5, 2014|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01740011||75194|
NCT01740024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206-PG-PRI-190|Biological Potency of the Cat Epithelial Allergenic Extracts|An Open-label, Multicentre Study Comparing the Biological Potency of the Native, Depigmented and Depigmented Polymerized Cat Epithelial Allergenic Extracts.||Laboratorios Leti, S.L.|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|60 Years|No|||November 2012|May 21, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01740024||75193|
NCT01740323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055328|Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy|Randomized Phase II Study of Curcumin Versus Placebo for Inhibition of NF-kB DNA Binding in Peripheral Blood Mononuclear Cells of Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy||Emory University|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740323||75170|
NCT01746394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHN_12_01|Delta Healthy Sprouts: Intervention to Promote Maternal Weight Control and Reduce Childhood Obesity in the MS Delta|Delta Healthy Sprouts: A Randomized Trial to Determine the Comparative Efficacy of Two Maternal, Infant, and Early Childhood Home Visiting Programs on Maternal Weight Control and Childhood Obesity in the Mississippi Delta||USDA, Delta Human Nutrition Research Program|No|Active, not recruiting|January 2013|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01746394||74704|
NCT01746407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09DELK12|Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis|Observational Study to Procure Human Specimens for Use in the Diagnosis and Management of Sepsis and Other Related Conditions|EMOS|Abbott Diagnostics Division|No|Completed|December 2012|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|872|Samples Without DNA|Plasma and serum samples stored @ -70C.|Both|18 Years|N/A|No|Non-Probability Sample|Presentation to an emergency department|December 2015|December 28, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746407||74703|
NCT01746992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTOP|CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma|An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma||Ruijin Hospital|Yes|Recruiting|September 2012|December 2018|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||November 2013|November 24, 2013|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746992||74658|
NCT01747291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0532|Atypical Fracture Cohort Study|Atypical Femur Fracture Ontario Cohort Registry||University Health Network, Toronto|No|Recruiting|June 2009|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|primary or tertiary care clinic patients who have experienced an atypical fracture at any        point in the past will be eligible for this observational study. Low trauma fractures are        defined as fractures sustained with minimal force, such as a fall from standing height.|December 2014|December 5, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747291|5 Years|74635|
NCT01747551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-401|FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer|Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|September 2013|||February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747551||74615|
NCT01747759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0133|Evaluation of a Preoperative Education in Total Knee Arthroplasty||EPOP|University Hospital, Clermont-Ferrand||Completed|November 2010|March 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|55 Years|75 Years|No|||December 2012|December 11, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747759||74599|
NCT01748019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1968-DM-06-001|ST1968 Intravenous (Weekly) in Solid Tumors|Phase I Dose Finding and Pharmacokinetic Study of the Intravenous Camptothecin ST1968 in Patients With Solid Tumors||sigma-tau i.f.r. S.p.A.|No|Completed|June 2007|December 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||June 2012|December 10, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01748019||74579|
NCT01742013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laennec-IIT|Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients|Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue||Kangbuk Samsung Hospital|No|Completed|January 2013|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|65 Years|No|||September 2013|September 24, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01742013||75040|
NCT01742325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904018R|The Effect of Walking Intervention on Sleep Related Symptom Distress in Pediatric Oncology Patients|The Effect of Walking Intervention on Sleep Related Symptom Distress in Pediatric Oncology Patients||National Taiwan University Hospital|No|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|55|||Both|10 Years|18 Years|No|||December 2012|December 3, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01742325||75016|
NCT01743196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGAFOLATEPILOT|Folate Metabolism in Normal Weight and Obese Women of Child-bearing Age|Pilot Study of Folate Pharmacokinetics in Normal Weight and Obese Women of Child-bearing Age||University of Georgia|No|Completed|May 2012|December 2014|Actual|August 2012|Actual|N/A|Observational|N/A||2|Actual|32|Samples With DNA|Buffy Coat Serum samples Plasma samples|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample from Athens, GA and surrounding area|October 2015|October 20, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743196||74949|
NCT01743456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHC11-001|Depth of Anaesthesia and Postoperative Cognitive Decline in Patients Undergoing Heart Surgery|Effect of Depth of Anaesthesia on Postoperative Cognitive Decline in Patients Undergoing Coronary Artery Bypass Graft Surgery - a Prospectively Randomized Controlled Study||King's College Hospital NHS Trust|Yes|Completed|January 2011|February 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|65 Years|N/A|No|||December 2012|May 13, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743456||74929|
NCT01743768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB010/04/2012|Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)|Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study||Sterna Biologicals GmbH & Co. KG|Yes|Completed|December 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Male|18 Years|60 Years|No|||March 2014|May 19, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743768||74905|
NCT01743157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI Total Therapy|Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma|A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)|BBI|California Pacific Medical Center Research Institute|Yes|Completed|December 2010|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|April 4, 2011|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01743157||74952|
NCT01743170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPTOHP|Telemonitoring of Hypertensive Patients|Leuven Academic Programme for Telemonitoring of Hypertensive Patients|LAPTOHP|Katholieke Universiteit Leuven|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|20 Years|79 Years|No|||February 2015|February 17, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01743170||74951|
NCT01743430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809040R|Development of Smart Holistic Telerehabilitation System: An Application of Stroke Patients- 3 Years Study|1. Telerehabilitation on Balance in Subacute Stroke; 2.Telerehabilitation on Balance and Daily Activities in Chronic Stroke; 3. Telerehabilitation on Quality of Life in Chronic Stroke; 4. Telerehabilitation on Satisfaction in Stroke|telerehab|National Taiwan University Hospital|Yes|Completed|November 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||November 2012|December 5, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01743430||74931|
NCT01743443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARVO - BN - 2013|Corneal Sensitivity Cross-linking Keratoconus|Corneal Sensitivity Changes Following Cross-linking for Progressive Lower Stage Keratoconus|CSK|Instituto de Olhos de Goiania|Yes|Completed|March 2009|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|26 Years|No|||December 2012|December 4, 2012|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01743443||74930|
NCT01743976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00022107|Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain|Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain||Wake Forest School of Medicine|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|80 Years|No|||June 2015|June 1, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743976||74889|
NCT01743989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AIC05|A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.|A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.|ENESTPath|Novartis|Yes|Active, not recruiting|April 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|619|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743989||74888|
NCT01739751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA10i20022|Physical Activity Enhancement Using Pedometers in COPD|Effect of a Program of Physical Activity Enhancement Using Pedometers in Chronic Obstructive Pulmonary Disease||University of Chile|No|Active, not recruiting|January 2011|April 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|40 Years|N/A|No|||November 2012|December 3, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739751||75214|
NCT01740037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-2-099|IntegRAted CarE for Atrial Fibrillation - RACE-4|IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, a Multicenter Randomized Controlled Clinical Trial|RACE-4|Maastricht University Medical Center|Yes|Recruiting|December 2012|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1716|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01740037||75192|
NCT01740336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28509|A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer||Genentech, Inc.||Active, not recruiting|February 2013|January 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|197|||Female|18 Years|N/A|No|||May 2015|May 28, 2015|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740336||75169|
NCT01747018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 10EISI0140|Platelet Rich Plasma Injection for Knee Pain|Intra-articular Injections of Platelet-rich Plasma in Patients With Knee Pain of Articular Cartilage Origin (Degenerative Chondropathy and Early OA).||The Catholic University of Korea|Yes|Completed|February 2011|September 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|44|||Both|18 Years|65 Years|No|||December 2012|December 10, 2012|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01747018||74656|
NCT01747304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVA 12-0352-AE|Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs|Evaluation of Dual Energy X-ray Absorptiometry Scanners in the Identification of Atypical Femur Fractures - A Validation Study||University Health Network, Toronto|No|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|500|||Female|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Osteoporosis/Bone Mineral Density Lab out-patients|November 2015|November 30, 2015|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747304||74634|
NCT01747564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-093|A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects|A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects||Astellas Pharma Inc|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747564||74614|
NCT01747785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005553|Myocardial Performance at Rest and During Exercise in Heart Failure With Preserved Ejection Fraction|Myocardial Performance at Rest and During Exercise in Heart Failure With Preserved Ejection Fraction: Speckle Tracking Echocardiography - One Piece of the Puzzle.|X-HF-SPECKLE|Mayo Clinic||Recruiting|June 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2015|May 6, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747785||74597|
NCT01748032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-28|Short-term Cognitive Training in Late-life Depression|The Effects of Short-term Cognitive Training on Cognition and Mood Symptoms in Late-life Depression: A Pilot Study||Rotman Research Institute at Baycrest||Recruiting|August 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||December 2012|December 10, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748032||74578|
NCT01744028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDD001D2401|Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.|A 52-week Multi-center Randomized Trial to Evaluate Remote Patient Monitoring Using the EXACT Patient-reported Outcome Tool on Reduction of Hospitalizations From Exacerbations in Patients With Chronic Obstructive Pulmonary Disease as Compared to Those Managed by Usual Care|PREMIERE|Novartis|No|Completed|June 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|118|||Both|40 Years|N/A|No|||February 2014|February 6, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01744028||74885|
NCT01742338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220120019|Dose of Corticosteroids in COPD|Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study|DOSE|Rutgers, The State University of New Jersey|No|Recruiting|May 2012|March 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|40 Years|N/A|No|||August 2014|August 14, 2014|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742338||75015|
NCT01742572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021116|New DIETs: New Dietary Interventions Enhancing the Treatment for Weight Loss|NEW Dietary Interventions to Enhance the Treatments for Weight Loss (NEW DIETs for Weight Loss Study)|New DIETs|University of South Carolina|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01742572||74997|
NCT01743209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/057/HP|Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders and Receiving Androgen Antagonists|A Retrospective Non-interventional Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders Receiving Androgen Antagonists Treatment|EPIPARA|University Hospital, Rouen|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|213|||Male|N/A|N/A|No|Non-Probability Sample|patients sex offenders with paraphilia and treatment with androgen antagonists|September 2014|September 5, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743209||74948|
NCT01743222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx621-0101|Intralymphatic eASC Administration in Healthy Volunteers|Cx621-0101 Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)||Cellerix|No|Completed|January 2012|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|March 5, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01743222||74947|
NCT01743469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-58102-004|A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers|A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas.||Ipsen|Yes|Active, not recruiting|December 2012|February 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01743469||74928|
NCT01743781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-CREST2|Uptake of Comprehensive Eye Examination Trial|The Impact of Multimedia Education on Uptake of Comprehensive Eye Examination in Rural Southern China:A Randomized, Controlled Trial||Sun Yat-sen University|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|459|||Both|40 Years|N/A|No|||January 2014|January 3, 2014|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01743781||74904|
NCT01739569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.A01.2012|Effect of Healthy Lunch and Snack Meal on Reaction Time and Well-being of Physicians and Nursing Staff (Go-No-Go)|Long-term Effect of Healthy Lunch and Snack Meal on Reaction Time and Well-being: A Randomised Controlled Intervention in Physicians and Nursing Staff.||Copenhagen University Hospital at Herlev|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|November 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739569||75228|
NCT01743755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Santeon-CAP|Santeon-CAP; Dexamethasone in Community-acquired Pneumonia|Santeon-CAP; Dexamethasone in Community-acquired Pneumonia.||St. Antonius Hospital|Yes|Recruiting|December 2012|May 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01743755||74906|
NCT01739764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28399|An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol|A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol||Hoffmann-La Roche||Recruiting|February 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739764||75213|
NCT01740050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42676.068.12|Weight-loss and Gut-brain Interactions|Effect of Different Weight-loss Methods on Gut-brain Interactions||Maastricht University Medical Center|No|Not yet recruiting|January 2013|||January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01740050||75191|
NCT01740349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCE-2 GIVEN|Evaluation Of The Pillcam™ Colon Capsule Endoscopy (Pcce-2) In Pediatric Ulcerative Colitis|EVALUATION OF THE PILLCAM™ COLON CAPSULE ENDOSCOPY (PCCE) IN PEDIATRIC ULCERATIVE COLITIS||Azienda Policlinico Umberto I|Yes|Completed|August 2012|February 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|6 Years|18 Years|No|Probability Sample|The Given® Diagnostic System offers an alternative approach for endoscopic visualization        of the colon using capsule endoscopy, a swallowable device which contains imagers, light        sources, a power source and a RF transmitter. Advantages of the Given® Diagnostic System        include the elimination of the need for conscious sedation, the minimally invasive,        painless nature of the exam, and the ability to pursue normal daily activities immediately        following the procedure. This prospective pilot study will evaluate the performance of        PCCE in visualizing the colon of children with UC. All subjects to be enrolled will be        appropriate candidates for standard colonoscopy based on their clinical indication.        Each subject will undergo PCCE. PCCE results will be compared with that of a colonoscopy        procedure.|November 2012|July 10, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740349||75168|
NCT01740375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esophageal cancer AMC02|Role of Esophagectomy in Complete Responders to CCRT|A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus||Asan Medical Center|Yes|Recruiting|November 2012|November 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|486|||Both|20 Years|70 Years|No|||January 2015|January 17, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01740375||75166|
NCT01740661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-HPL-01|Cryotherapy and Joint Biomechanics During Running|Effects of Cryotherapy on Lower Extremity Joint Biomechanics During Running in Healthy Adults||University of Calgary||Completed|November 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|April 15, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01740661||75144|
NCT01740674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-865|Does Internet Data Collection Improve Cohort Retention?|Is Internet Data Collection Superior to Traditional Methods in Retaining Participants in Longitudinal Research?||University of Calgary|No|Completed|December 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|301|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01740674||75143|
NCT01746706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 A00383-38|Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).|Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease?||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2011|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746706||74680|
NCT01747031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20121204|Determination of Instantaneous Wave-Free Ratio by Computed Tomography|Diagnostic Performance of Instantaneous Wave-Free Ratio From Computed Tomography|iFRCT|Shanghai 10th People's Hospital|Yes|Active, not recruiting|December 2012|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747031||74655|
NCT01747044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0130|Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy|||University Hospital, Clermont-Ferrand||Recruiting|April 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||July 2014|July 4, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01747044||74654|
NCT01747317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENTH1010|Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography|Individual-Patient-Data Pooled-Analysis of Diagnostic Accuracy of Noninvasive Fractional Flow Reserve From Anatomic CT Angiography|PERFECT|Shanghai 10th People's Hospital|Yes|Active, not recruiting|December 2012|April 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|December 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747317||74633|
NCT01747577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC-OAB-12-01|Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP|POST-TURP|Astellas Pharma Inc|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Male|50 Years|N/A|No|||December 2015|December 18, 2015|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747577||74613|
NCT01747772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002791|Sonoelastography: Ultrasound Method to Measure Liver Fibrosis|Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade.||Massachusetts General Hospital|Yes|Recruiting|February 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 16, 2014|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747772||74598|
NCT01747798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1162|Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Pilot Trial to Evaluate the Feasibility Auranofin (Ridaura®) for Asymptomatic Patients With First-Recurrence Epithelial Ovarian Cancer||Mayo Clinic|Yes|Active, not recruiting|November 2012|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2015|January 7, 2016|November 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747798||74596|
NCT01747811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001570/1|Effects of Bright Light Therapy in Mild Traumatic Brain Injury|Effects of Bright Light Therapy of Sleep, Cognition, Brain Function, and Neurochemistry in Mild Traumatic Brain Injury||University of Arizona|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|50 Years|No|||September 2014|September 5, 2014|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747811||74595|
NCT01748058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T87/2012|Active Video Games to Promote Physical Activity in Children With Cancer|Active Video Games to Promote Physical Activity, Motor Performance and Quality of Life in Children With Cancer: an Intervention Study With 2-year Follow-up||Turku University Hospital||Active, not recruiting|January 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|3 Years|16 Years|No|||April 2015|April 13, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01748058||74576|
NCT01748045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10487|Study of Inhaled Nitric Oxide and Respiratory Outcomes in Late Preterm Infants|The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants||Tufts Medical Center|Yes|Terminated|March 2013|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1|||Both|30 Weeks|36 Weeks|No|||November 2014|November 17, 2014|November 20, 2012|Yes|Yes|Enrollenment has been suspended due to poor enrollment|No||https://clinicaltrials.gov/show/NCT01748045||74577|
NCT01742585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0101|A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis|ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis||Astellas Pharma Inc|No|Completed|October 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|20 Years|N/A|No|||July 2014|July 15, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742585||74996|
NCT01742598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106|Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve System||Portico TA EU|St. Jude Medical|Yes|Withdrawn|December 2015|November 2020|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||December 2015|March 9, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742598||74995|
NCT01742611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0102|Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis|ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis||Astellas Pharma Inc|No|Completed|March 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|20 Years|N/A|No|||June 2015|June 8, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742611||74994|
NCT01742897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014524|Efficacy and Safety Study of Transdermal Therapeutic System (TTS) Fentanyl in Participants With Osteoarthritis Knee Pain|Evaluation of Efficacy and Safety of TTS-Fentanyl in Moderate to Severe Pain From Knee Osteoarthritis||Janssen-Cilag Ltd.,Thailand|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|40 Years|N/A|No|||May 2013|May 29, 2013|December 4, 2012||No||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01742897||74972|
NCT01743833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11-135-3|Effects of Thoracic Orthopedic Manual Therapy and Biopsychosocial Variables on Signs of Shoulder Impingement|Effects of Thoracic Orthopedic Manual Therapy and Biopsychosocial Variables on Signs of Shoulder Impingement: A Randomized Clinical Trial||University of Connecticut Health Center|No|Recruiting|June 2011|||January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|69 Years|No|||December 2012|December 4, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01743833||74900|
NCT01743482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT123/12|Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors|Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).|Pazotest-01|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Not yet recruiting|January 2013|April 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Male|18 Years|75 Years|No|||December 2012|December 4, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01743482||74927|
NCT01743495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00076471|CAPABLE for Frail Dually Eligible Older Adults|CAPABLE for Frail Dually Eligible Older Adults|CAPABLE500|Johns Hopkins University|Yes|Active, not recruiting|September 2012|July 2018|Anticipated|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|500|||Both|65 Years|N/A|No|||February 2016|February 25, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01743495||74926|
NCT01743794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008|Continuous Wound Infusion in Lumbar or Thoracic Surgery|Efficacy of Continuous Wound Infusion in Major Lumbar and Thoracic Spine Surgery : A Randomised, Double-blinded, Placebo-controlled Study||University Hospital, Grenoble|No|Completed|January 2011|July 2012|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01743794||74903|
NCT01739582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-301EXT|An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism||Repros Therapeutics Inc.|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Male|18 Years|60 Years|No|||April 2014|April 15, 2014|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739582||75227|
NCT01740063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181-2-04|Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza|Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza.||Ansun Biopharma, Inc.|Yes|Active, not recruiting|November 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|372|||Both|18 Years|70 Years|No|||July 2013|July 11, 2013|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740063||75190|
NCT01740388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801|Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis||Bausch & Lomb Incorporated|No|Terminated|February 2013|November 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|1 Year|N/A|No|||September 2014|September 17, 2014|November 29, 2012|Yes|Yes|Strategic business decision|No|September 11, 2014|https://clinicaltrials.gov/show/NCT01740388||75165|
NCT01740401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0677|CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma|Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2012|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2014|January 6, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740401||75164|
NCT01740687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16975|A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test|A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test|ESS-NSPAS|Bayer|No|Recruiting|November 2012|February 2021|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|21 Years|50 Years|No|Non-Probability Sample|clinics and hospitals|March 2016|March 10, 2016|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01740687||75142|
NCT01746719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/VIN-11/415|Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746719||74679|
NCT01747005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-0001|Effect of Enhanced Recovery After Surgery (ERAS) on Inflammatory Response After Planned Abdominal Hysterectomy|Effect of Enhanced Recovery After Surgery (ERAS) on Inflammatory Response After Planned Abdominal Hysterectomy: A Prospective Randomized Clinical Trial.|GERAS|Samoilova Maternity Home||Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|serum|Female|18 Years|80 Years|No|Probability Sample|Admitted patients in maternity home|November 2015|November 16, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01747005||74657|
NCT01747343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL-17816|Toilet Training Toddlers and Preschoolers|Changing the Number of Accidents, Percentage of Appropriate Eliminations, and Number of Self-Initiations Across Toddlers and Preschoolers||University of Kansas Medical Center|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Months|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|December 7, 2012||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01747343||74631|
NCT01747590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000058|Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T|Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T||Mclean Hospital|No|Recruiting|July 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|12|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747590||74612|
NCT01748071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Individual Variation|The Realtime Detection for Individual Variation of Analgesic ：A Comparison of Sufentanil vs Fentanyl|Study of Analgesic Effect and Individual Sensitivity Differences of Opioid Analgesics||Huazhong University of Science and Technology|Yes|Completed|June 2012|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|120|||Female|20 Years|65 Years|No|Probability Sample|120 Chinese female patients receiving elective surgery under general anesthesia|September 2013|September 22, 2013|December 9, 2012|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01748071||74575|Because 3 patients couldn't maintain the SPO2 at 90% and 1 patient was at deep sedation, 4 subject patients were not analysed in the final results. These patients were performed as a routine intravenous anesthetic induction.
NCT01744054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209062|Microsphere Localization Using PET/MRI in Patients With Liver Disease|Pilot Study of Microsphere Localization Using PET/MRI in Patients With Liver Disease Following Radioembolization|PET/MRI|Washington University School of Medicine|No|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01744054||74883|
NCT01742624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-KT-01|Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation|Multicenter, Open-label, Parallel Clinical Investigation of the Safety and Efficacy of Advagraf® (Extended Release Tacrolimus) vs. Prograf® (Tacrolimus) in de Novo Kidney Recipients 1 Month After Kidney Transplantation|AdProCISE|Astellas Pharma Inc|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|65 Years|No|||October 2014|October 8, 2014|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742624||74993|
NCT01742637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADBG-1206, 1302|Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.||Taro Pharmaceuticals USA|No|Completed|October 2012|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2008|||Both|12 Years|40 Years|No|||March 2014|March 8, 2014|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742637||74992|
NCT01742910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK128/2008|Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Tecnis ZCB00 and Acrysof SA60AT|||Medical University of Vienna||Completed|April 2008|October 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|54|||Both|40 Years|N/A|No|||December 2012|December 4, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742910||74971|
NCT01742923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-384|Tailored Intervention to Improve Medication Adherence in Patients With Hypertension|Pharmacist Intervention Programme in Secondary Care to Improve Medication Adherence in Patients With Hypertension||Odense University Hospital|No|Completed|December 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|532|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742923||74970|
NCT01743521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1102|DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)|DAA Based Therapy for Recently Acquired Hepatitis C|DARE-C|Kirby Institute|Yes|Active, not recruiting|January 2013|February 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|60 Years|No|||August 2015|August 31, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743521||74924|
NCT01741025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300134|iFuse Implant System® Minimally Invasive Arthrodesis|A Multicenter Randomized Controlled Post-market Clinical Follow-up Trial Comparing the Effectiveness and Safety of the iFuse Implant System® Versus Conservative Management for Patients With Chronic, Disabling SI Joint Pain.|iMIA|SI-BONE, Inc.|No|Active, not recruiting|June 2013|September 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|70 Years|No|||May 2015|May 18, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741025||75116|
NCT01741038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-008-INST-VAC-CRC|Study of AlloStim In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer|In-Situ Cancer Vaccine: A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStimTM Combined With Cryoablation to a Physician's Choice With Cryoablation in Metastatic Colorectal Cancer||Immunovative Therapies, Ltd.|Yes|Not yet recruiting|March 2016|October 2020|Anticipated|March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||August 2015|November 24, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741038||75115|
NCT01739595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-302|Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration||Repros Therapeutics Inc.|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|181|||Male|18 Years|60 Years|No|||May 2015|May 7, 2015|November 29, 2012|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01739595||75226|
NCT01743807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-008|Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia|A Phase I Study of GNKG168 in Pediatric Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (IND#113600)||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|November 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4|||Both|1 Year|21 Years|No|||November 2015|November 22, 2015|November 28, 2012|No|Yes|SBI Biotech who provided the drug for this study has decided to no longer support the study or    GNKG168.|No||https://clinicaltrials.gov/show/NCT01743807||74902|
NCT01743820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEG001|Phase2a Primaquine Dose Escalation Study|Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia||University of California, San Francisco|Yes|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|81|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01743820||74901|
NCT01740115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AA020784|Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort|Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort||Boston Medical Center|Yes|Active, not recruiting|November 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|We are storing serum and plasma for future use. We are also storing dried blood spots.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects from an existing cohort of HIV-infected adults (Facilitated Access to Substance        Abuse Treatment With Prevention and Treatment of HIV [FAST PATH]) who have indicated        interest in future studies and patients from HIV clinical care sites will be recruited.|November 2015|November 17, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740115||75186|
NCT01739556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-553-12|On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction|On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)|PLATFORM|Clinical Centre of Serbia|Yes|Recruiting|June 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|632|||Both|18 Years|90 Years|No|||January 2016|January 26, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01739556||75229|
NCT01739777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UANDES-C4C|Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy|Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology|RIMECARD|Universidad Los Andes, Chile|Yes|Completed|December 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||June 2015|June 2, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739777||75212|
NCT01740076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-001604|Soy Nuts and Cardiovascular Risk in Postmenopausal Women|Effect of Soy Nuts on Blood Pressure, Lipids and Inflammation in Postmenopausal Women||Beth Israel Deaconess Medical Center|No|Completed|September 2001|November 2012|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|21 Years|N/A|Accepts Healthy Volunteers|||November 2012|December 3, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740076||75189|
NCT01740362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921006|Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function|Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function||Pfizer|No|Completed|October 2003|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 3, 2012|October 16, 2012|No|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT01740362||75167|
NCT01740700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002|Zenith® p-Branch® OTS Multicenter Study|Zenith® p-Branch® Multicenter Study||Cook||Active, not recruiting|January 2013|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740700||75141|
NCT01740986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA09012-P2|Safety and Efficacy of SA09012 in Asthma|Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients||SamA Pharmaceutical Co., Ltd||Completed|November 2012|November 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|20 Years|79 Years|No|||January 2015|November 13, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740986||75119|
NCT01740999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIP_01|Silicone Arthroplasty vs. Arthrodesis in the Distal Interphalangeal Joint|Functional Outcome in Silicone Arthroplasty Compared to Arthrodesis Screws in Patients With Osteoarthritis in the Distal Interphalangeal Joint||Schulthess Klinik||Terminated|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 27, 2012||No|Non achievement of the estimated sample size of the group silicone arthroplasty in a    reasonable recruitment time.|No||https://clinicaltrials.gov/show/NCT01740999||75118|
NCT01746732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14617|A Study of Evacetrapib in Healthy Female Participants|Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects||Eli Lilly and Company|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746732||74678|
NCT01742182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Circadian Rhythms in PD|Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease|Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease||Northwestern University|No|Recruiting|June 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||September 2014|October 2, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742182||75027|
NCT01747603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-156|The GROWNDUP Study of Late Preterm Births|The GROWNDUP Study: Pilot to Assess the Feasibility of an RCT for Promoting Growth, Nutrition and Development Through a Specialized Late Preterm Clinic|GROWNDUP|McMaster University|No|Active, not recruiting|May 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|N/A|1 Month|Accepts Healthy Volunteers|||April 2015|April 7, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01747603||74611|
NCT01747824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3478|Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department|Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department|Agitation|Minneapolis Medical Research Foundation|Yes|Completed|December 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1322|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing treatment for acute agitation in the emergency department of an urban        Level 1 Trauma Center.|December 2015|December 22, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01747824||74594|
NCT01748084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110110|Rituximab in Systemic Sclerosis|Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis|RECOVER|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|April 2013|March 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||April 2015|April 20, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748084||74574|
NCT01742936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00762|Point of Care Testing for Coagulation Function Versus Standard Laboratory Testing in Pediatric Patients Undergoing Major Orthopedic Surgery|||Nationwide Children's Hospital|No|Completed|February 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|2 Years|18 Years|No|||February 2015|February 12, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742936||74969|
NCT01742949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-TS2012|Study to Predict the Benefits of First-line Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence|Evaluation of Advantages Linked to the Use of Humidification by ThermoSmart During Continuous Positive Airway Pressure||Fisher and Paykel Healthcare|Yes|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742949||74968|
NCT01743235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB90|Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems|A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms||Emotional Brain NY Inc.|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|207|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743235||74946|
NCT01743508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sida_2010|Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians in Uganda|Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians. A Randomized Control Trial in Uganda||Karolinska Institutet|Yes|Recruiting|April 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|994|||Female|15 Years|N/A|No|||February 2016|February 22, 2016|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01743508||74925|
NCT01740128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0881-W|Multimodal Exercises to Improve Leg Function After Spinal Cord Injury|A Hebbian Approach to Regaining Control of Spared Circuits in Spinal Cord Injury||VA Office of Research and Development|No|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|21 Years|65 Years|No|||December 2015|December 15, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740128||75185|
NCT01740141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/476a|Plexus Brachialis Block. Better to do by Start Than by End of Surgery?|Plexus Brachialis Block. Better to do by Start Than by End of Surgery?||Oslo University Hospital|No|Active, not recruiting|November 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01740141||75184|
NCT01741571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmericanUBMC|Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques|Randomized Controlled Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques||American University of Beirut Medical Center|No|Recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741571||75074|
NCT01741584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA_memory_01|Effects of Physical Activity on the Brain in Parkinson's Disease (PD)|||Charite University, Berlin, Germany|No|Completed|December 2010|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|35 Years|80 Years|No|||March 2016|March 15, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741584||75073|
NCT01741857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJGLYY005|Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus|Phase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus Erythematosus||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|15 Years|60 Years|No|||October 2012|November 1, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01741857||75052|
NCT01739842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001780|Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment|Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment|Kudzu MRS|Mclean Hospital|No|Withdrawn|November 2012|October 2015|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|November 13, 2012||No|Funding was not received for this study.|No||https://clinicaltrials.gov/show/NCT01739842||75207|
NCT01743547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU12G05|The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study|THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY||Northwestern University||Terminated|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|25|||Female|18 Years|N/A|No|||November 2013|November 5, 2013|November 30, 2012||No|The investigators concluded that it is not feasible due to the lack of participation and    difficulty in recruiting patients.|No||https://clinicaltrials.gov/show/NCT01743547||74922|
NCT01743560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001YGB11|An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis|A Phase IV Multicentre, Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane, With Exploratory Epigenetic Marker Analysis|4EVER UK|Novartis|No|Active, not recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01743560||74921|
NCT01739790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210M21542|N-Acetylcysteine for Patients With COPD and Chronic Bronchitis|Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3||University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|January 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|40 Years|85 Years|No|||January 2016|January 25, 2016|November 29, 2012|Yes|Yes|PI discretion|No||https://clinicaltrials.gov/show/NCT01739790||75211|
NCT01739803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7R01DK081347-04|Behavioral Contract Adherence Intervention|Behavioral Contract Intervention to Improve Adherence Among Renal Transplant Recipients||University of Tennessee|Yes|Completed|January 2010|June 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|21 Years|N/A|No|||December 2013|December 20, 2013|November 29, 2012||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01739803||75210|Did not include attention control group. Did not employ multiple study pharmacists to perform intervention. Limitations of pharmacy refill records: accuracy may be affected by dosage changes, do not indicate if drug actually consumed as prescribed.
NCT01740089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-IFNа-2|Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C|Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C||Biocad|No|Completed|November 2011|December 2013|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|70 Years|No|||July 2015|July 22, 2015|November 30, 2012||No||No|March 1, 2015|https://clinicaltrials.gov/show/NCT01740089||75188|
NCT01740102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2525|Clinical Value of Remote Ischemic Preconditioning|Does Remote Ischemic Preconditioning Reduce the Incidence of Postoperative Atrial Fibrillation in Patient Undergoing Coronary Artery Bypass Graft Surgery?||Norwegian University of Science and Technology|No|Completed|August 2012|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|80 Years|No|||October 2013|October 30, 2013|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01740102||75187|
NCT01741012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412GARDASIL|Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients|Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.|GARDASIL|Wayne State University|Yes|Recruiting|January 2013|November 2015|Anticipated|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|18 Years|50 Years|No|||June 2015|June 8, 2015|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741012||75117|
NCT01741285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20122011|Effects of QVAR in Smokers With Asthma|Effects Of Extra-fine Particle HFA-becLomethasone (HFA-QVAR) Versus Course Particle Treatment In Smokers and Ex-smokers With Asthma|OLiVIA|University Medical Center Groningen|Yes|Recruiting|April 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741285||75096|
NCT01747330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-277|Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency|An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Abbott|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|4 Years|No|||June 2014|June 13, 2014|November 23, 2012||No||No|December 23, 2013|https://clinicaltrials.gov/show/NCT01747330||74632|
NCT01742481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23CA124451|Study to Education Childhood Cancer Survivors About Survivorship Care|Childhood Cancer Survivor Program to Empower Action in Care|SPEAC|University of Illinois at Chicago|No|Completed|August 2010|November 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742481||75004|
NCT01747616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-290311|Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses|Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses||Medical University of Vienna|Yes|Completed|July 2011|December 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 10, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747616||74610|
NCT01747837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02-213|REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients|REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients|RESCUE|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2012|October 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747837||74593|
NCT01744080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:112|Rotator Cuff Injury to Surgery|Effect of Surgical Wait Times on Outcomes of Rotator Cuff Surgery|RC-IS|Panam Clinic|No|Suspended|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|45 Years|70 Years|No|||March 2015|March 9, 2015|December 4, 2012||No|Study suspended temporarily due to logistic challenges, study to re-open|No||https://clinicaltrials.gov/show/NCT01744080||74881|
NCT01744340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 254|A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer|A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study||Brown University|Yes|Completed|May 2012|July 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 23, 2012|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01744340||74861|
NCT01742663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCSG 1213|A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.||Taro Pharmaceuticals USA|No|Completed|October 2012|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|435|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742663||74990|
NCT01742676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-KT-03|A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients|A Single Center, Open-label, Randomized Pilot Study to Evaluate the Safety and Efficacy of Modified-release Tacrolimus, ADVAGRAF®, Versus Those of Twice-daily Tacrolimus, PROGRAF®, in Stable Renal Recipients (SINGLE)|SINGLE|Astellas Pharma Inc|No|Completed|April 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|N/A|No|||August 2014|August 4, 2014|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742676||74989|
NCT01743846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP 2010_3|CNAP Accuracy Dependent on Hemodynamic Variables|Accuracy of Continuous Non-invasive Arterial Pressure (CNAP) With Invasive Measurements Dependent on Cardiac Function, Vascular Resistance and Volume Status||University of Schleswig-Holstein|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|99 Years|No|Probability Sample|Patients undergoing major surgery under general anaesthesia|December 2015|December 5, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743846||74899|
NCT01743859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1283.cc|Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia|Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia||University of Colorado, Denver|Yes|Recruiting|December 2012|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|37|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743859||74898|
NCT01740726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061525|Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression|Randomized Trial of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Major Depression||Emory University|Yes|Terminated|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|13 Years|17 Years|No|||March 2015|March 26, 2015|November 28, 2012|No|Yes|Lack of success with recruitment|No|March 26, 2015|https://clinicaltrials.gov/show/NCT01740726||75139|
NCT01742130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0705|Early Hydration in Acute Myocardial Infarction|Early Hydration in Acute Myocardial Infarction: Sodium Bicarbonate Versus Saline for the Prevention on Contrast-induced Acute Kidney Injury||Ospedale Misericordia e Dolce|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|90 Years|No|||November 2013|November 5, 2013|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01742130||75031|
NCT01742143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-223|Impact of ICCAN on Cancer Treatment Completion and Quality of Life|A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life||Memorial Sloan Kettering Cancer Center||Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|21 Years|80 Years|No|Probability Sample|Eligible cancer patients will be recruited in person by multilingual ICCAN research        assistants for participation in the study at Ralph Lauren Center for Cancer Care and        Prevention (RLCCP), and Lincoln Hospital (LH). In the event that MSKCC staff is not        present when an eligible patient is identified on site, potential patients may be referred        to MSKCC for screening and enrollment using a Referral/Permission to Contact Form.|January 2016|January 11, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742143||75030|
NCT01742429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls2012008|Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection|||Shanghai Jiao Tong University School of Medicine|Yes|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|19 Years|75 Years|No|||June 2013|August 28, 2014|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01742429||75008|
NCT01742689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91/130/569|Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic|Assessment of Analgesic Efficacy of Intranasal Desmopressin in the Treatment of Acute Pain in Patients With Renal Colic||Tehran University of Medical Sciences|Yes|Recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|15 Years|65 Years|No|||December 2012|December 4, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742689||74988|
NCT01739621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPV-200EXT|Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200|A Phase 2, Multi-Center, Extension Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200||Repros Therapeutics Inc.|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|47 Years|No|||April 2014|April 15, 2014|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739621||75224|
NCT01739816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|evalPMC|Polymedication Check - a Randomised Controlled Trial|Polymedication Check - Evaluation of the Impact of Community Pharmacy Based Medication Review on Medicines Use and Humanistic Outcomes|evalPMC|University Hospital, Basel, Switzerland|No|Completed|June 2012|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|450|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739816||75209|
NCT01739829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCT/DIA-09|Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus|A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL® [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type 1 Diabetes Mellitus||Living Cell Technologies|Yes|Completed|August 2011|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||August 2014|August 17, 2014|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739829||75208|
NCT01740713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEEP-1|Pharmacokinetic Study of Deferiprone in Paediatric Patients|Multi-centre, Oral Single Dose Experimental and Modelling Study to Evaluate the Pharmacokinetics of Deferiprone in Patients Aged From 1 Month to Less Than 6 Years of Age Affected by Transfusion-dependent Haemoglobinopathies.|DEEP-1|Consorzio per Valutazioni Biologiche e Farmacologiche|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|1 Month|6 Years|No|||November 2014|November 17, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740713||75140|
NCT01741597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12228|Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung|A First Time in Human Phase I Imaging Study of iRGD in Patients With Advanced Breast and Pancreas Cancer||City of Hope Medical Center|Yes|Withdrawn|July 2014|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|December 3, 2012|No|Yes|PI chose to close the study|No||https://clinicaltrials.gov/show/NCT01741597||75072|
NCT01741870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tsai1943|A Need-based Nutritional Intervention in Nursing Home Residents|The Effectiveness of a Need-based Nutritional Intervention Strategy to Improve the Nutritional Status of Elderly Nursing Home Residents||Asia University|Yes|Completed|April 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|65 Years|N/A|No|||December 2012|December 3, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01741870||75051|
NCT01742702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06086M|Haemodynamics in Hypertension|HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study|DYNAMIC|University of Tampere|No|Recruiting|June 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Observational|Time Perspective: Prospective||7|Anticipated|2000|Samples With DNA|Whole blood, serum, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult hypertensive and normotensive subjects who were treated in Tampere University        Hospital clinics of internal medicine or cardiology, or visited medical doctors as        outpatients in several occupational health care providers in the Pirkanmaa Hospital        District.|December 2012|December 3, 2012|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742702||74987|
NCT01747070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110013|Effect of Cranial Stimulation and Acupuncture on Pain, Functional Capability and Cerebral Function in Osteoarthritis|Effect of Transcranial Direct Current Stimulation and Electro Acupuncture in Pain, Functional Capability and Cortical Excitability in Patients With Osteoarthritis.||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|January 2012|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|80|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01747070||74652|
NCT01742221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002|Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure|A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects||Neumedicines Inc.|Yes|Completed|August 2012|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742221||75024|
NCT01742234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RELIVE 03|RELIVE Informed Consent Study|RELIVE Informed Consent Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|624|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|People who will be donating at kidney at the University of Minnesota, Mayo Clinic, or        University of Alabama or people who will be donating a lung at University of Washington        Medical School or the University of Southern California|December 2012|December 3, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01742234||75023|
NCT01748097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV BIC for IVONCOL|Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy|Phase III Study to Assess the Utility of a New Innovative Technique Using Intravenous Bicarbonate to Verify the Correct Position of Patients Scheduled for Intravenous Bicarbonate|IVBICONCOL|Sheba Medical Center|No|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2012|December 30, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748097||74573|
NCT01742455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256/09|Assessment of Natural Bypasses in the Lower Limb|Quantitative Assessment of the Peripheral Artery Collateral Circulation in Patients With and Without Coronary Artery Disease (Pilot Study)||University Hospital Inselspital, Berne|No|Completed|February 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Blood samples (routine)|Both|18 Years|N/A|No|Non-Probability Sample|Thirty patients with stable angina pectoris electively referred for coronary angiography        to our department who give written informed consent.|June 2013|June 17, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01742455||75006|
NCT01743534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09023|Conservation of Praxis in the Food and Alzheimer Disease|Impact of the Shape of Plates on the Conservation of Praxis in the Food at the Old Persons Suffering From Severe Insanities of Chap Alzheimer or Mixed in Institution.|PRAXALIM|University Hospital, Limoges|No|Recruiting|July 2011|September 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|32|||Both|75 Years|N/A|No|Probability Sample|Patient achieves of the Alzheimer's disease|May 2011|March 19, 2014|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01743534||74923|
NCT01739855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vinforce-015|Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS)|Phase 2 Study of Patients Undergoing Bariatric Surgery (Laparoscopic Gastric Bypass) and Evaluation of Bone Metabolism With/Without Vitamin D/Calcium Supplementation|BABS|Medical University of Vienna|Yes|Completed|November 2012|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||August 2014|August 22, 2014|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01739855||75206|
NCT01741298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01 HL 36588- Proj 2|Biobehavioral Bases & Management of Metabolic Syndrome (CHARMS)|Biobehavioral Bases & Management of Metabolic Syndrome|CHARMS|University of Miami|No|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|112|||Both|30 Years|70 Years|No|||November 2012|November 30, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741298||75095|
NCT01749150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YV28218|A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis|STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR-BOOSTED DANOPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS OF ASIAN ORIGIN WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1 WITH OR WITHOUT COMPENSATED CIRRHOSIS||Hoffmann-La Roche||Completed|April 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749150||74492|
NCT01749163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PancClamp|Hyperglycemia and the Extra-pancreatic Effect of Incretins|Determining the Extra-pancreatic Effects of Incretin Hormones During Euglycemic and Hyperglycemic Pancreatic Clamps||Rigshospitalet, Denmark|No|Completed|September 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749163||74491|
NCT01742975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB ID: 2011-A01014-37|Efficacy Study of Ifabond in Breast Cancer Surgery|A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection|Ifabond|Hospital Ambroise Paré Paris|No|Recruiting|November 2011|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|102|||Female|18 Years|N/A|No|||December 2012|December 5, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742975||74966|
NCT01743274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2012/141|Does Optical Coherence Tomography Optimise Results of Stenting|Does Optical Coherence Tomography Optimise Results of Stenting: The DOCTORS Study|DOCTORS|Centre Hospitalier Universitaire de Besancon|No|Recruiting|October 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|80 Years|No|||March 2015|March 19, 2015|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01743274||74943|
NCT01740154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8811|Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer|Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue||Case Comprehensive Cancer Center|Yes|Terminated|September 2012|||March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|November 30, 2012||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01740154||75183|
NCT01740453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTBIS-2012-V1|Effect of Interscalene Block on Ventilatory Function|Interscalene Block on Ventilatory Function After Shoulder Surgery : Evaluation of Single or Continuous Injection|KTBIS|Pierre and Marie Curie University|Yes|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||January 2015|January 16, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01740453||75160|
NCT01740414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6021/7237R|Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers|Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers||New York State Psychiatric Institute|No|Active, not recruiting|November 2012|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|21 Years|55 Years|No|||December 2015|February 1, 2016|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740414||75163|
NCT01740739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-006|Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors|Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)|Cardiac-CV|Epic Research & Diagnostics, Inc.|No|Suspended|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Men and Women, as part of their standard or care, who are recommended for and who complete        a test resulting in a Coronary Calcium Score, hs-CRP, and MPO result.|June 2013|June 13, 2013|November 16, 2012||No|Evaluating cohort for value|No||https://clinicaltrials.gov/show/NCT01740739||75138|
NCT01742442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12224|Cancer in the Elderly: Prevalence and Impact of Age Related Problems|Cancer in the Elderly: Prevalence and Impact of Age Related Problems. A Prospective Observational Study||Sykehuset Innlandet HF|No|Active, not recruiting|January 2013|April 2017|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood samples (serum and EDTA blood) for analysis of inflammatory markers. Dependent on the      study results and results from other studies that may emerge during the study conduct,      analyses of other markers of ageing may also be conducted|Both|70 Years|N/A|No|Probability Sample|Consequetive patients referred to a specialist outpatient clinic for medical cancer        treatment|May 2015|May 11, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01742442||75007|
NCT01741922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAHPS-2011-004760-29|Effectiveness of Night Administration of Low Dose Aspirin in Hypertensive Patients|Effectiveness of the Timing of the Administration of Aspirin in Hypertensive Patients Treated With Low Doses of Acetyl Salicylic Acid for Secondary Prevention - TAHPS|TAHPS|Basque Health Service|No|Recruiting|December 2012|March 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|80 Years|No|||January 2015|January 28, 2015|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741922||75047|
NCT01747629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-304|Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics|A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|December 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|12 Years|N/A|No|||May 2015|May 28, 2015|December 7, 2012|Yes|Yes||No|May 2, 2015|https://clinicaltrials.gov/show/NCT01747629||74609|
NCT01741896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feeley01|Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?|Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?|CT RIPC CIN|Mid Western Regional Hospital, Ireland||Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|17 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01741896||75049|
NCT01742806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0017|Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer|Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer: Multicenter Prospective Randomized Comparison Study||Yonsei University|Yes|Recruiting|October 2012|June 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||December 2012|December 3, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01742806||74979|
NCT01742819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11-003602|Advanced Glaucoma Progression Study|Detection of Glaucoma Progression Study With Macular OCT Imaging|AGPS|University of California, Los Angeles|No|Active, not recruiting|May 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|40 Years|80 Years|No|Non-Probability Sample|Advanced glaucoma patients|December 2015|December 4, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742819||74978|
NCT01747850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/2011|Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence|Sativex Associated With Behavioral-relapse Prevention Strategy as Treatment for Cannabis Dependence||Centre for Addiction and Mental Health|Yes|Completed|March 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747850||74592|
NCT01748110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00070555|Health Interventions in Men Undergoing Radical Prostatectomy|Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial|HIM-UP|Johns Hopkins University|No|Recruiting|December 2012|January 2016|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Male|40 Years|65 Years|No|||September 2013|September 20, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748110||74572|
NCT01744093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012780|Doxycycline for COPD in HIV-Infected Patients|Doxycycline for COPD in HIV-Infected Patients||Weill Medical College of Cornell University|No|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||December 2015|December 10, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744093||74880|
NCT01744106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGO-PSE-09001|A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold|A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold||Perrigo Company|No|Recruiting|November 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|560|||Both|6 Years|11 Years|No|||November 2015|November 19, 2015|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744106||74879|
NCT01743339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44033|Managing Sleep Symptoms and Modifying Mechanisms of Traumatic Stress|A Randomized Controlled Trial of CBT for Insomnia in Patients With PTSD and Depression||University of Rochester|Yes|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|64 Years|No|||March 2016|March 23, 2016|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743339||74938|
NCT01743638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001584|MR-Guided Laser Ablation of Prostate Bed Recurrences|Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Prostate Bed Recurrences||Mayo Clinic|No|Withdrawn|April 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|50 Years|95 Years|No|||April 2014|April 9, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743638||74915|
NCT01739608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14334-c27.2|Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy|Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis|Proteus|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte|Yes|Recruiting|December 2010|December 2015|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|20000|||Both|58 Years|60 Years|No|||November 2012|November 29, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01739608||75225|
NCT01740427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481008|A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)|A Randomized, Multicenter, Double-Blind Phase 3 Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease||Pfizer|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740427||75162|
NCT01740440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRG-BMR Face01|Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance|Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance||Bio-Medical Research, Ltd.|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Female|35 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|November 21, 2012||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01740440||75161|
NCT01748890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-395|A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy|A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy||Massachusetts General Hospital|Yes|Terminated|December 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|4|||Male|18 Years|N/A|No|||April 2014|April 17, 2014|October 31, 2012||No|Insufficient recruitment|No|April 17, 2014|https://clinicaltrials.gov/show/NCT01748890||74512|
NCT01749176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dulce Digital|Dulce Digital-Project Dulce 2.0 Texting Study|Dulce Digital-Project Dulce 2.0 Texting Study in High Risk Latinos With Diabetes||Scripps Whittier Diabetes Institute|Yes|Completed|October 2012|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|126|||Both|18 Years|75 Years|No|||November 2014|November 17, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749176||74490|
NCT01749423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-CM-12-518|A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines|||Allergan|No|Withdrawn|November 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants with chronic migraines who received a minimum of two consecutive treatment        cycles of 100 units onabotulinumtoxinA and a minimum of two consecutive treatment cycles        with the OnabotulinumtoxinA dosing between 155 and 195 units.|January 2014|January 31, 2014|December 12, 2012|Yes|Yes|Company decision due to enrollment challenges.|No||https://clinicaltrials.gov/show/NCT01749423||74471|
NCT01743872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMISE|Optical Imaging Measurement of Intravascular Solution Efficacy Trial|Optical Imaging Measurement of Intravascular Solution Efficacy Trial|OPTIMISE|University Hospital Case Medical Center|Yes|Recruiting|September 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01743872||74897|
NCT01750047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain Epidemiology|A Epidemiological Survey of Preoperative Pain Perception and Postoperative Pain in Chinese Population|A Epidemiological Survey of Preoperative Pain Perception and Postoperative Pain in Chinese Population||Huazhong University of Science and Technology|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1327|||Both|18 Years|70 Years|No|Non-Probability Sample|Chinese patients receiving elective surgery under general anesthesia|September 2014|September 4, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750047||74423|
NCT01739868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/9-A|Screening and Understanding of the Pre-diabetes: DECODIAB|Screening and Understanding of the Pre-diabetes: DECODIAB|DECODIAB|Nantes University Hospital|No|Active, not recruiting|April 2011|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|103|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01739868||75205|
NCT01740466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epidemiological public profile|Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil|Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil|EPP|Instituto de Olhos de Goiania|Yes|Completed|March 2012|August 2012|Actual|July 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1670|||Both|N/A|N/A|No|Non-Probability Sample|Individuals underwent an ophthalmologic evaluation|December 2012|December 6, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740466|6 Months|75159|
NCT01741311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-050|Secondary HIV Prevention and Adherence Among HIV-infected Drug Users|Secondary HIV Prevention and Adherence Among HIV-infected Drug Users||University of Connecticut|Yes|Recruiting|September 2012|February 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741311||75094|
NCT01743586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912088R|Respiratory Muscle Function Changes and Effects of Chest Physiotherapy Education Interventionin Advanced Lung Cancer|The Impact of Changes in Respiratory Muscle Function on Dyspnea, Functional Capacity, and Quality of Life in Patients With Advanced Lung Cancer & the Effects of Chest Physiotherapy Education Intervention||National Taiwan University Hospital|Yes|Active, not recruiting|August 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|N/A|N/A|No|||November 2012|December 4, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01743586||74919|
NCT01741662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01129-34|Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog|Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog|LEA-PsyCog|Assistance Publique Hopitaux De Marseille|No|Recruiting|July 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|170|||Both|12 Years|17 Years|No|||November 2015|November 16, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741662||75067|
NCT01741909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-85-12-CTIL|Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy|Can the Cost of Azythromycin in be Reduced in Hospitalized Patients With Community Acquired Pneumonia by Quick Transfer From Intravenous to Oral Therapy?||HaEmek Medical Center, Israel|No|Not yet recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2012|August 18, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01741909||75048|
NCT01742468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H53-12|Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis|Intervention With Products Enriched With Long Chain n-3 Polyunsaturated Fatty Acids (n-3 LC-PUFA) From Microalgae Oil in Patients With Rheumatoid Arthritis - Influence on Disease Activity and Inflammation Status||University of Jena|Yes|Completed|February 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|80 Years|No|||October 2013|October 6, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742468||75005|
NCT01742741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|France|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)||University of Virginia|No|Completed|May 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|64 Years|No|||September 2013|September 6, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742741||74984|
NCT01742754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41454-K|Fecal Microbiota Transplantation for Ulcerative Colitis|Evaluation of Durability of Fecal Microbiota Transplantation in Patients With Mild to Moderate Ulcerative Colitis||University of Washington|No|Terminated|October 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Female|18 Years|N/A|No|||November 2013|November 11, 2013|November 29, 2012||No|IND required by the FDA for all future FMTs.|No||https://clinicaltrials.gov/show/NCT01742754||74983|
NCT01743079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080810|Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B|The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission||Beijing YouAn Hospital|Yes|Completed|January 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|700|||Female|20 Years|40 Years|No|||July 2013|July 29, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01743079||74958|
NCT01748357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCBorstel003|Siemens VOC TB Pilot Study|Pattern Recognition of Volatile Organic Compounds (VOC) in Exhaled Breath for the Diagnosis of Pulmonary Tuberculosis||Research Center Borstel|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Volatile compounds from exhaled breath|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|See groups described above|November 2014|November 5, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748357||74553|
NCT01748656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AGIR-02|Target Volume in Noninvasive Positive Pressure Ventilation|Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial|CIBLE|AGIR à Dom|No|Completed|January 2013|February 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|75 Years|No|||December 2012|March 13, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01748656||74530|
NCT01748903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19180|TARGET Intracranial Aneurysm Coiling Registry|TARGET Intracranial Aneurysm Coiling Registry: A Prospective Clinical Efficacy and Safety Study of Stryker Target® 360°, Target® Helical, and 2nd Generation Target® Nano Coils|TARGET|Medical College of Wisconsin|Yes|Suspended|February 2013|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|December 7, 2012|Yes|Yes|Principle Investigator is relocating to a new institution|No||https://clinicaltrials.gov/show/NCT01748903||74511|
NCT01749449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3v6-021904|Increased Dietary Protein and Meal Frequency Reduces Total and Abdominal Body Fat During Weight Maintenance and Weight Loss|Increased Protein Intake and Meal Frequency Reduces Abdominal Fat and Increases Postprandial Thermogenesis During Energy Balance and Energy Deficit|3v6|Skidmore College|Yes|Completed|January 2005|January 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2007|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749449||74469|
NCT01749462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5127L00001|Oxis 9mcg Turbuhaler Clinical Experience Investigation|Oxis 9mcg Turbuhaler Clinical Experience Investigation||AstraZeneca||Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|398|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Oxis for the first time due to 'relief of various symptoms        associated with airway obstructive disorders of chronic obstructive pulmonary disease        (Chronic bronchitis, Pulmonary emphysema), which is the indication of this drug.|February 2016|February 9, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749462||74468|
NCT01749436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG2012-001|Role of Lung Ultrasound Imaging for Intraoperative Monitoring of Atelectasis During Laparoscopic Surgery|Role of Lung Ultrasound Imaging for Intraoperative Monitoring of Atelectasis During Laparoscopic Surgery||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for laparoscopic surgery|September 2013|September 12, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749436||74470|
NCT01749722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-Eye 15502|Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy|Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy||Smart Medical Systems Ltd.|No|Completed|November 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|November 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749722||74448|
NCT01750073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264-12|Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer|A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Cancer||University of Nebraska|Yes|Recruiting|December 2012|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Female|19 Years|N/A|No|||December 2012|December 12, 2012|December 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750073||74421|
NCT01750307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCEAN protocol|The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment)|The Relationship of Essential Fatty Acids to Cognitive Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls|OCEAN|King's College London|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750307||74403|
NCT01750320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2012|||||N/A|N/A|N/A||||||||||||||January 12, 2016|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750320||74402|
NCT01741051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275997|A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community|A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community||Simon Fraser University|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741051||75114|
NCT01742156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTH-CAD|Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease|||McGill University Health Center|No|Not yet recruiting|January 2013|September 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|20 Years|70 Years|No|Non-Probability Sample|Inpatients (CCU) and Outpatients (CHF clinic, congenital heart clinic) who have had an        angiogram within the past 12 weeks documenting the extent of coronary artery disease|December 2012|December 4, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742156||75029|
NCT01750567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.025|A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL|A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q||University of Michigan Cancer Center|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|80 Years|No|||November 2015|November 17, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750567||74383|
NCT01750840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-101P|A Clinical Registry to Collect Patient Outcome Date for the BIOMET® Stimulator Systems|A Clinical Registry to Collect Patient Outcome Data for the BIOMET® EBI Bone Healing System, BIOMET® OrthoPak® Non-invasive Bone Growth Stimulator System, and the BIOMET® SpinalPak® Non-Invasive Spine Fusion Stimulator System||Biomet, Inc.|No|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|This clinical registry will be a prospective, multi-center study Subjects will undergo        treatment with Biomet's BHS or OrthoPak devices for non-spinal applications.        Subjects will undergo treatment with Biomet's SpinalPak for spinal applications|September 2015|February 29, 2016|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750840|12 Months|74362|
NCT01741948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levsagie OCP PVD|Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia|Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia- A Prospective Study||Clalit Health Services|No|Withdrawn|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Peripheral blood cells will be extracted from all blood samples. mRNA will be purified from      all samples. The mRNA will be divided to aliquots and will be frozen in -80°C until further      processing after all cohort samples have been collected.      mRNAs will be purified from whole blood using the QIAamp RNA purification kit (Quiagen      Germany). A DNase I (Qiagen) digestion step is included in order to eliminate genomic DNA.      Serum will be collected from all blood samples. It will will be frozen in -70°C until      further processing after all cohort samples have been collected.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will follow patients who are first time users of HCs for a full year after        initiation. Patients will be recruited in a gynecology clinic affiliated with the "Clalit"        Health Maintenance Organization in Jerusalem, Israel (Merkaz Briut Haisha, Ramat Eshkol,        Jerusalem). This is a primary care government funded clinic, treating a diverse        population.|February 2015|February 9, 2015|November 23, 2012||No|the study has never started. my grant request was denied.|No||https://clinicaltrials.gov/show/NCT01741948||75045|
NCT01742195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-20871|Comparison of Patient Comfort With the Nasal and Oral Insertion of the Endobronchial Ultrasound Bronchoscope|Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound||Laval University|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|220|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01742195||75026|
NCT01742208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-203-T1DM|Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus||Lexicon Pharmaceuticals||Completed|February 2013|||January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|No|||January 2015|January 28, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742208||75025|
NCT01742507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-093|A Study Comparing Two Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study|A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study|OCT-ORION|The University of Hong Kong|Yes|Active, not recruiting|April 2012|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||December 2015|December 9, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01742507||75002|
NCT01742520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9389-IM-CTIL|Neurodevelopmental Outcomes of Preterm Infants Treated for Pain Management With Repeated Doses of Sucrose 24%|Its an Interventional Study That Will Evaluate the Effect of Different Doses of Sucrose 24% on Neurodevelopmental Outcome of Preterm Infants||Sheba Medical Center|No|Recruiting|January 2013|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|27 Weeks|33 Weeks|Accepts Healthy Volunteers|||June 2013|June 9, 2013|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01742520||75001|
NCT01742767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001963-37|Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC|Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC)|PemSplitCisp|Universität Duisburg-Essen|Yes|Recruiting|November 2012|April 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742767||74982|
NCT01743066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-004-CT|Vitamin E Level in Buccal Cells of Arsenicosis Patients|Vitamin E Level in Buccal Cells of Arsenicosis Patients Following Vitamin E Supplementation||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01743066||74959|
NCT01743677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921028|CP-690,550 Thorough QTc Study|A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers||Pfizer|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01743677||74912|
NCT01743690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-143|The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus|The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus||University of Copenhagen|No|Completed|March 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743690||74911|
NCT01748370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitDTesto1.0|Vitamin D Treatment and Hypogonadism in Men|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men||Medical University of Graz|Yes|Recruiting|December 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748370||74552|
NCT01748682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Very Low Calorie Liquid Diet for Pre op Patients|Use of Very Low Calorie Liquid Diet in the Preoperative Phase of Bariatric Surgery||Gastrocirurgia, Brazil|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748682||74528|
NCT01748669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-005-CT|Effectiveness of Garlic Oil in the Treatment of Arsenical Palmer Keratosis|Effectiveness of Garlic Oil in the Treatment of Arsenical Palmer Keratosis||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01748669||74529|
NCT01749189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-D-179|Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength|A Randomized, Controlled Double Blind Longitudinal Study: Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength||Solae, LLC|No|Active, not recruiting|July 2012|June 2015|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01749189||74489|
NCT01749202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-10001|Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index|||Solae, LLC|Yes|Completed|August 2010|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|126|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749202||74488|
NCT01749761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02619|Blood Pressure Guided Biofeedback on Hemodialysis and the Reduction of IntraDialytic Hypotension|Blood Pressure Guided Biofeedback on Hemodialysis and the Reduction of IntraDialytic Hypotensive Episodes: A Randomized Cross Over Trial|BP-RIDH|University of Calgary|No|Completed|January 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|19 Years|N/A|No|||June 2014|June 14, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749761||74445|
NCT01749774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2008a|Physical Activity and Testicular Cancer|Physical Activity and Testicular Cancer - a Pilot Study: Feasibility and Effects of a Program Including Information, Counseling and a Physical Activity Program for Patients With Testicular Cancer During and After Chemotherapy||Oslo University Hospital|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Male|18 Years|N/A|No|||October 2014|October 15, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01749774||74444|
NCT01749748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806009R|The Study of Breast MRI Screening and Proton Magnetic Resonance Spectroscopy|The Study of Breast MRI Screening and Proton Magnetic Resonance Spectroscopy||National Taiwan University Hospital|No|Completed|July 2008|February 2016|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|270|||Female|25 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01749748||74446|
NCT01749735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000700|Transcranial Direct Current Stimulation and Motor Training for Traumatic Brain Injury Survivors|The Effect of Transcranial Direct Current Stimulation Combined With Functional Task Training on Motor Recovery in Traumatic Brain Injury Survivors|tDCS TBI|Spaulding Rehabilitation Hospital|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||September 2013|September 12, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01749735||74447|
NCT01750060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK2011-001|Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).|Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).||Incline Therapeutics, Inc.|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750060||74422|
NCT01750359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBM-2010|Efficacy and Safety Curcumin in Depression|The Efficacy and Safety of Adjunctive Curcumin for Treatment of Depression: A Randomized, Double-blind, Placebo-controlled Study||Beersheva Mental Health Center|Yes|Completed|August 2010|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|65 Years|No|||December 2012|February 6, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01750359||74399|
NCT01750294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206009002|A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD|||Indiana University|Yes|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750294||74404|
NCT01750580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA223-002|Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor|A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors||Bristol-Myers Squibb|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750580||74382|
NCT01750853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15035|A Study of LY3045697 in Healthy Participants|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Single Oral Dosing in Healthy Subjects||Eli Lilly and Company|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750853||74361|
NCT01751074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115677|To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers|A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|December 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751074||74344|
NCT01742273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaVasK|Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients|Vitamin K1 to Slow Progression of Vascular Calcification in Hemodialysis Patients|VitaVasK|RWTH Aachen University|Yes|Recruiting|October 2013|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742273||75020|
NCT01741935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC002.1|Continuous Monitoring of Patients With Chronic Obstructive Pulmonary Disease|Is COPD Patient Mobility in Combination With Other Parameters a Sensitive Measure and Predictive Indicator for Early Detection of Exacerbations in COPD?|CTC-Actiwise|CareTelCom AB|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|40 Years|90 Years|No|Non-Probability Sample|COPD patients|October 2013|October 30, 2013|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01741935||75046|
NCT01742247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUHDM-laser and moisturizers|Assessment of Needs of Moisturizers After Various Laser Treatments|Phase 4 Study of Assessment of Needs of Moisturizers After Various Laser Treatment||Pusan National University Hospital|No|Recruiting|September 2012|July 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742247||75022|
NCT01742533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-POF-1(Ⅰ)|Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure|A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Recruiting|March 2012|March 2014|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|39 Years|No|||December 2012|December 2, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01742533||75000|
NCT01742494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hybrid POEM|Comparison Study of Conventional POEM and Hybrid POEM for Esophageal Achalasia|Peroral Endoscopic Myotomy for Esophageal Achalasia: Randomized Comparison of Water-Jet Assisted Versus Conventional Dissection Technique||Shanghai Zhongshan Hospital|Yes|Recruiting|August 2011|December 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2012|December 2, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01742494||75003|
NCT01742780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-16|Evaluation of Various Methods Used to Identify the Proximal Humerus Intraosseous Vascular Access Site|A Study Evaluating Insertion Site Identification Methods Used to Establish Intraosseous Vascular Access in the Proximal Humerus||Vidacare Corporation|No|Enrolling by invitation|December 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 3, 2012|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742780||74981|
NCT01742793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112009392|An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)|An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)|RID|Yale University|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2012|December 3, 2012|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742793||74980|
NCT01743378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-068|Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial|Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial||Hvidovre University Hospital|Yes|Completed|February 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|N/A|No|||August 2013|August 28, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01743378||74935|
NCT01743703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00393-38|Utility of Whole-body MRI in the Detection of Traumatic Injuries of Undetermined Origin in Children|Utility of Whole-body MRI (STIR and Diffusion Weighted) in the Detection of Traumatic Injuries of Undetermined Origin in Children|PEDIMA|Rennes University Hospital||Recruiting|August 2011|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|3 Years|No|||November 2012|December 4, 2012|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01743703||74910|
NCT01748695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V158866-2Pa-01|A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury||Brigham and Women's Hospital|Yes|Completed|June 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||July 2015|October 7, 2015|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748695||74527|
NCT01748916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0336|Comparison of Carotenoid Bioavailability From Fresh Papaya, Tomato and Carrot|Evaluation of the Effect of the Consumption of Papaya, Tomato, and Carrot on the Bioavailability of Carotenoids||Ohio State University|Yes|Active, not recruiting|June 2011|January 2016|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|December 3, 2012||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01748916||74510|
NCT01748929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-198-GEN|Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth|Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth||McGill University Health Center|Yes|Active, not recruiting|February 2014|September 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1010|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748929||74509|
NCT01749228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/VIN-11/416|Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition.||IPCA Laboratories Ltd.|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749228||74486|
NCT01749475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPTEE|Hypnosis vs Midazolam for Sedation for TEE|Hypnosis for Sedation in Transesophageal Echocardiography: Comparison With Midazolam||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Completed|June 2010|September 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|98|||Both|18 Years|65 Years|No|Non-Probability Sample|patients admitting to cardiology department for transesophageal echocardiography (TEE)|February 2013|February 27, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749475||74467|
NCT01749787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100-104|Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis|A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis|SPARTA|Protalex, Inc.|Yes|Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|61|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749787||74443|
NCT01750099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042012-035|Pain Relief Effects on Length of Labor|A Randomized Single-blinded Trial of Combined Spinal-Epidural Versus Continuous Epidural Analgesia||University of Texas Southwestern Medical Center|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|202|||Female|16 Years|44 Years|No|||May 2014|May 23, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750099||74419|
NCT01750112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GC1201|Treatment of Pectus Excavatum Deformity Using Macrolane Filler|An Open Non Comparative Multicenter Prospective Study to Evaluate Efficacy and Safety of Macrolane VRF20 in Treatment of Pectus Excavatum||Q-Med AB|No|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||February 2015|March 2, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750112||74418|
NCT01750086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001956|Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption|Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption||Massachusetts General Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|45 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 28, 2014|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750086||74420|
NCT01750346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130022|Acetyl Hexapeptide-8 for Blepharospasm|Placebo Controlled Double Blind Study of Acetyl Hexapeptide-8 in Treatment of Blepharospasm||National Institutes of Health Clinical Center (CC)||Terminated|November 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2015|May 30, 2015|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750346||74400|
NCT01750606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH04|An MRI Investigation of Soft Tissues in Total Hip Arthroplasty|An MRI Investigation of Soft Tissues in Total Hip Arthroplasty|MoM_MRI|Biomet, Inc.|No|Enrolling by invitation|October 2012|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|436|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have received the indicated implants at one of four participating centers and        who meet the sampling plan requirements.|February 2015|June 25, 2015|November 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750606||74380|
NCT01750619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.090|Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions|Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions||California Pacific Medical Center Research Institute|No|Recruiting|July 2011|||January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to Interventional Endoscopy Services at CPMC for treatment of GI tract        tumors.|July 2015|July 27, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750619||74379|
NCT01750333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBETAD-01|Study on Correlation Between Vascular ET-1 and Adiponectin in Pediatric Obesity|Observational Retrospective Study on Correlation Between ET-1 and Ad in Obese Children||Montagnani, Monica, M.D., Ph.D.|No|Active, not recruiting|April 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|60|Samples Without DNA|-  serum        -  plasma|Both|5 Years|13 Years|No|Probability Sample|CHILDREN ATTENDING THE OUTPATIENT UNIT OF THE UNIVERSITY PEDIATRIC CLINIC|December 2012|December 12, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750333||74401|
NCT01750866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3811|Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer|Efficacy and Toxicity of Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer With Progression After Treatment With Docetaxel||Case Comprehensive Cancer Center|Yes|Withdrawn|February 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|75 Years|N/A|No|||October 2013|October 15, 2013|December 13, 2012|Yes|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT01750866||74360|
NCT01751087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9-500-25.1|Cervical Preparation Before Dilation and Evacuation|Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone.||Planned Parenthood League of Massachusetts|Yes|Completed|January 2013|June 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 12, 2012||No||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01751087||74343|Limitations include inadequate sample size to measure complications as a primary outcome and reliance on outcomes that measure efficacy of the cervical preparation rather than its direct effect on overall safety.
NCT01741987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346/08|Osmoprotective and Castor Oil Containing Lubricants in Dysfunctional Tear Syndrome and Post Refractive Surgery Patients|An Effectiveness of Osmoprotective and Castor Oil Containing Lubricants in Dysfunctional Tear Syndrome (DTS) and Post Refractive Surgery Patients||Federal University of São Paulo|Yes|Completed|October 2008|August 2015|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741987||75042|
NCT01742260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/047|Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials|A Pilot Study to Demonstrate Safety and Feasibility of Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials||Royal Perth Hospital|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||June 2015|June 7, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742260||75021|
NCT01743092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153-2012|Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment|Meeting the Unique Treatment Needs of Female Gamblers: A Workbook and Webinar Effectiveness Pilot Study||Centre for Addiction and Mental Health|No|Active, not recruiting|November 2012|August 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||May 2015|May 21, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01743092||74957|
NCT01743365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE7/12|Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer|A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer|A-GAPP|Hellenic Cooperative Oncology Group|No|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2015|February 11, 2016|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743365||74936|
NCT01743391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-158|Hysteroscopy Before in Vitro Fertilization - Does it Improve the Outcome?|||Hvidovre University Hospital|Yes|Recruiting|January 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01743391||74934|
NCT01748708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080-2012|Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.|Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.||Centre for Addiction and Mental Health|No|Not yet recruiting|December 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01748708||74526|
NCT01748942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8071|Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer|A Randomized, Placebo Controlled, Double Blinded Study of Corticosteroid Treatment for the Reduction of Postoperative Pain Following Transoral Robotic Surgery||OHSU Knight Cancer Institute|Yes|Recruiting|December 2012|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748942||74508|
NCT01749215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT110423|A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD|A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD|TAP2|University of California, San Francisco|Yes|Recruiting|February 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||June 2015|June 26, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749215||74487|
NCT01749488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2012/SB-01|The Impact of a Dietitian in the Implementation of Nutrition Recommendations During Intensive Care|The Impact of Involving a Dietitian in the Implementation of Expert Recommendations Concerning Nutrition During Intensive Care on Energy Balance|NutriSave|Centre Hospitalier Universitaire de Nīmes|No|Suspended|October 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|392|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|December 12, 2012||No|The intervention becomes obsolete for participating centres pending regulatories. Protocol    modifications are being considered.|No||https://clinicaltrials.gov/show/NCT01749488||74466|
NCT01750658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nº IB 497/05|Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain|ECOS: A Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain (o Estudio de Las Exacerbaciones de la EPOC en España)|ECOS|Cimera|No|Completed|September 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|Blood|Both|40 Years|80 Years|No|Non-Probability Sample|COPD patients admitted in any of the participating ECOS hospitals with a diagnosis of COPD        exacerbation|December 2012|December 13, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01750658||74376|
NCT01750125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16305|Validation of Pulse Wave Doppler Demodulation Algorithm for the Continuous, Non-invasive Measurement of Blood Flow Velocity|||University of Virginia|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects 18-65|April 2014|April 30, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750125||74417|
NCT01750372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38227-G|A Client-Based Outcome System for Individuals With Lower Limb Amputation|A Client-Based Outcome System for Individuals With Lower Limb Amputation||University of Washington|No|Active, not recruiting|April 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1380|||Both|18 Years|N/A|No|Non-Probability Sample|Persons with lower limb amputation living in the United States|May 2015|May 26, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750372||74398|
NCT01750632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab.Reprod.Biol.-Horsens-02|Subcapsular Orchiectomy in Men With Klinefelter Syndrome|||Odense University Hospital|Yes|Recruiting|August 2010|||February 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|15 Years|40 Years|No|||December 2012|December 13, 2012|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01750632||74378|
NCT01750645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLS-201207|Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review|Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature||Clínica Infantil Colsubsidio|No|Active, not recruiting|July 2012|January 2013|Anticipated|October 2012|Actual|N/A|Observational|N/A||2|||||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with idiopathic overactive bladder|December 2012|December 13, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750645||74377|
NCT01750593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yelizeminersoy|Radiofrequency Ablation in Thyroid Nodules|Efficacy of Radiofrequency Ablation in Thyroid Nodules||Bezmialem Vakif University|No|Recruiting|April 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||November 2013|November 27, 2013|October 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01750593||74381|
NCT01750879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002153|Tolerance Following Peanut Oral Immunotherapy|Clinical Desensitization and Tolerance Following Peanut Oral Immunotherapy and Subsequent Allergen Avoidance|PNOIT2|Massachusetts General Hospital|Yes|Active, not recruiting|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|7 Years|55 Years|No|||January 2016|January 11, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750879||74359|
NCT01751113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116572|A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects|A Randomised, Double-blind, Double Dummy, 3 Way Cross-over Study Evaluating the Effects of ADOAIR 50/250mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Treatments (Tiotropium Bromide 18mcg Alone and ADOAIR 50/250mcg Alone) in the Treatment of Japanese Subjects With COPD|SCO116572|GlaxoSmithKline|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|53|||Both|40 Years|80 Years|No|||September 2014|March 2, 2015|December 13, 2012||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01751113||74341|
NCT01751126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG09B113|Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis|A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis||Novagali Pharma|Yes|Active, not recruiting|March 2013|April 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|168|||Both|4 Years|18 Years|No|||August 2015|August 5, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751126||74340|
NCT01751412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-346|Proton Radiation for Lymphoma Involving Mediastinum|Pilot Study Evaluating the Use of Proton Radiation for Treatment of Lymphoma Involving the Mediastinum||Massachusetts General Hospital|Yes|Recruiting|February 2013|February 2020|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|N/A|No|||January 2016|January 19, 2016|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751412||74318|
NCT01746329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BNH-0809|Tea-beetroot-venous Occlusion Plethysmography|Exploratory Study on the Effect of Nutritional Intervention on Postprandial Skeletal Muscle Microcirculation in Obese Subjects||Unilever R&D|No|Completed|December 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|18|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 2, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01746329||74709|
NCT01742286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378X2103|Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)|A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)||Novartis|No|Recruiting|February 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|12 Months|17 Years|No|||January 2016|January 24, 2016|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742286||75019|
NCT01746615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-260612|Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects|Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects||Medical University of Vienna|Yes|Recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746615||74687|
NCT01746628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1971|Intrauterine Use of FloSeal: Is it Safe and Useful?|Intrauterine Use of FloSeal: Is it Safe and Useful?||David L Zisow MD LLC|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746628||74686|
NCT01746641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acta No. 197|Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures|Remifentanil Versus Propofol With Target Controlled Infusion Effect Site for the Sedation of Patients During Gastrointestinal Endoscopic Procedures: Randomized Controlled Trial||Fundación Universitaria de Ciencias de la Salud|Yes|Terminated|January 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|69|||Both|18 Years|70 Years|No|||December 2012|December 8, 2012|July 30, 2012||No|Occurrence of severe respiratory depression in the remifentanil group.|No||https://clinicaltrials.gov/show/NCT01746641||74685|
NCT01742832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012MDDVilaz|Double-Blind Treatment of Major Depressive Disorder With Vilazodone|Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI||University of Chicago|Yes|Recruiting|May 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|60 Years|No|||December 2015|December 10, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742832||74977|
NCT01743105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/XBAC-01|Reproductibility of TM-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in the ER|Reproductibility of Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in the Emergency Room|EDDRA-Repro|Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743105||74956|
NCT01747525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-258|Near-Infrared Spectroscopy and Ultrasound Investigation of Coronary Artery Plaque|Lipiscan and Ultrasound Interrogation of Atherosclerotic Coronary Arteries (LUNAR)|LUNAR|William Beaumont Hospitals|No|Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All patients presenting to Beaumont Hospital for elective invasive coronary angioplasty        and possible percutaneous intervention.|December 2012|December 7, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747525||74617|
NCT01748955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5933R|Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study|SSRI Versus Bupropion in High-Risk Major Depressive Disorder||New York State Psychiatric Institute|No|Completed|June 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||March 2015|October 5, 2015|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748955||74507|
NCT01749241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL31929|Efficacy of Loteprednol Ointment Following Eyelid Surgery|Loteprednol Etabonate Ophthalmic Ointment vs. Soothe Night Time Ointment for Inflammation Following Eyelid Surgery||University of California, San Diego|No|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 11, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01749241||74485|
NCT01750138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNE1725|SNE1725: Can Oral Glutamine Facilitate Early Return of Gut Function|Can Preoperative Oral Glutamine Facilitate Earlier Return of Gut Function in Patients Undergoing Colorectal Surgery. A Prospective Randomized Trial.||Scarborough General Hospital|Yes|Recruiting|June 2011|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|206|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750138||74416|
NCT01750905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001869|Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients|A Phase I, Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist||Mayo Clinic|No|Recruiting|April 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750905||74357|
NCT01750385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012-089|Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia|Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia||Shanghai Zhongshan Hospital|Yes|Active, not recruiting|October 2012|August 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2012|December 12, 2012|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750385||74397|
NCT01750398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1298|Bipolar Androgen-based Therapy for Prostate Cancer (BAT)|A Phase II Study of Bipolar Androgen-based Therapy for Men With Androgen Ablation NaÃ-ve Recurrent Prostate Cancer|BAT|Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|18 Years|N/A|No|||November 2015|November 17, 2015|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750398||74396|
NCT01751438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0705|Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)|Randomized, Phase II Trial of Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer (PC)||M.D. Anderson Cancer Center|Yes|Recruiting|March 2013|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|No|||October 2015|October 14, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751438||74316|
NCT01751100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-MH-13-092-001|The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies|Building Bridges: Addressing HIV Stigma in At-Risk Groups in Community Pharmacies||North Bronx Healthcare Network|No|Withdrawn|July 2013|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|December 13, 2012||No|We did not receive proper funding to complete this study.|No||https://clinicaltrials.gov/show/NCT01751100||74342|
NCT01751139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116606|An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil|An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Endemic Regions of Brazil||GlaxoSmithKline||Recruiting|February 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|3600|||Both|6 Months|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751139||74339|
NCT01751425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0697|Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)|Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors||M.D. Anderson Cancer Center|No|Recruiting|July 2013|||July 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751425||74317|
NCT01751672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP No. 4100055578|Integrating Substance Abuse Assessment & Intervention in Primary Care Settings|Integrating Substance Abuse Assessment & Intervention in Primary Care Settings||Treatment Research Institute|Yes|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01751672||74298|
NCT01746654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P128-001|Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients|A Randomized Double-Blind Placebo-Controlled Study to Determine Safety of P128 Applied to Nares of Healthy Volunteers and Safety And Efficacy of Any Patient Including Chronic Kidney Disease Patients Who Are Nasal Carriers of S.Aureus.||GangaGen, Inc.|Yes|Completed|December 2012|December 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|74|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01746654||74684|
NCT01746953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progress-06|The Effect of Red Blood Cells Transfusion in Trauma Patients|The Effect of Red Blood Cells Transfusion in Trauma Patients: A Risk Stratified Analysis||Progress|No|Completed|May 2005|March 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20211|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the Clinical Randomisation of an Antiﬁbrinolytic in Signiﬁcant Haemorrhage        (CRASH-2) trial. The trial included 20,127 trauma patients with, or at risk of,        significant bleeding, within 8 hours of injury, and was undertaken in 274 hospitals in 40        countries.|December 2012|December 10, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746953||74661|
NCT01747226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASAS-1205X|Effect of Mouth Rinses in Oral Malodor|Masking and Therapeutic Effect of Different Mouth Rinses in Patients With Oral Malodor.|MR2012|Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|March 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 10, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01747226||74640|
NCT01742845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2010/107|Ultrasound-guided Intermediate Cervical Block Versus Superficial Cervical Block for Carotid Endarterectomy (CERVECHO)|Ultrasound-guided Intermediate Cervical Block Versus Superficial Cervical Block for Carotid : a Randomised Controlled Trial|CERVECHO|Centre Hospitalier Universitaire de Besancon|Yes|Completed|April 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|86|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742845||74976|
NCT01743118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP001|Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris|Phase Ib, Two-centre, Randomised, Observer-blind, Placebo- and Comparator Controlled Trial to Evaluate the Safety, Tolerability and Antipsoriatic Efficacy of Three Strengths of a Topical SPS4251 Formulation in a Psoriasis Plaque Test||Circassia Limited|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||July 2013|July 16, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01743118||74955|
NCT01749501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-271|Premedication for Non-Emergency Endotracheal Intubation In the NICU|Premedication for Non-Emergency Endotracheal Intubation In the NICU||William Beaumont Hospitals|Yes|Completed|January 2011|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|No|||June 2015|June 2, 2015|September 28, 2012||No||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01749501||74465|
NCT01749800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000010|Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits|Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits|GVS TBI|Spaulding Rehabilitation Hospital|No|Completed|July 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|70 Years|No|||November 2014|November 20, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749800||74442|
NCT01742858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-07|Normative Data of Brain Network Activation|Establishment of Normative Data of Brain Network Activation Analysis (BNA) Using Evoked Response Potentials, in Adolescents and Young Adults||ElMindA Ltd|No|Withdrawn|February 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|15 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experimental subjects will include males and females recruited from the Eugene        metropolitan area.|August 2013|August 13, 2013|December 3, 2012||No|The study was halted due to logistical reasons.|No||https://clinicaltrials.gov/show/NCT01742858||74975|
NCT01750411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARP3, 1U10 HL109164-01|Severe Asthma Research Program - Wake Forest University|The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.|SARP3|Wake Forest School of Medicine|Yes|Active, not recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell      Pellet Bronch: BAl, Bronchial Brushings, Bronchial Biopsy|Both|6 Years|N/A|No|Probability Sample|The target recruitment goal for each center is 75% adults (age 18 and older) and 25%        children age 6-17 years. Within the pediatric age group, an attempt will be made to enroll        equal numbers of children 6-11 and 12-17 years of age. Similarly, an attempt will be made        to enroll at least 50% females and 30% minorities.        Given the mission of SARP, a diverse sample of subjects with asthma is needed to gain        better understanding of asthma and its endotypes. Because there are a number of        respiratory disorders that may be confused with asthma or confound asthma assessment, SARP        enrollees must meet the all following eligibility criteria as outlined below:|June 2015|June 23, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750411||74395|
NCT01750424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC-1209010842|3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites|3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites||Yale University|No|Recruiting|November 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2012|December 12, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750424||74394|
NCT01743131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058187|Abatacept as GVHD Prophylaxis Phase 2|Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial||Seattle Children's Hospital|Yes|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|6 Years|N/A|No|||February 2016|February 3, 2016|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743131||74954|
NCT01750671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0127|Influence Of Nutritional Status Of Patients In The Intensive Care Output On Long Term Fate|Influence Of Nutritional Status Of Patients In The Intensive Care Output On Long Term Fate|FEEDING|University Hospital, Clermont-Ferrand||Not yet recruiting|December 2012|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|680|||Both|18 Years|N/A|No|Probability Sample|patients malnourished and non-malnourished|December 2012|December 13, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01750671||74375|
NCT01751178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01561|An Efficacy Study of Chlorhexidine Mouthwashes|Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes||GlaxoSmithKline|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|July 3, 2014|December 13, 2012||No||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01751178||74336|
NCT01751152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8828-4004|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease||Novo Nordisk A/S|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|75 Years|No|||February 2015|February 17, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751152||74338|
NCT01751165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116697|Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older|Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged ≥ 50 Years||GlaxoSmithKline||Completed|March 2013|April 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|354|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751165||74337|
NCT01751451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-187|3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy|A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Male|18 Years|N/A|No|||February 2016|February 11, 2016|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751451||74315|
NCT01751464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:133|A WrapAround Case Management Program for Youth Injured by Violence|A WrapAround Case Management Program for Youth Injured by Violence: A Feasibility Study||University of Manitoba|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|10 Years|24 Years|No|||July 2013|July 4, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751464||74314|
NCT01750892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peter_12-009117|Primary Care Transition Study|Transition From Pediatric to Adult Services: A Primary Care Based Model for Patients With Chronic Conditions||Children's Hospital of Philadelphia|Yes|Completed|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|43|||Both|19 Years|N/A|No|||February 2015|February 2, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750892||74358|
NCT01751906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-392|ABSORB III Randomized Controlled Trial (RCT)|A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.|ABSORB-III|Abbott Vascular|Yes|Recruiting|December 2012|December 2019|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2250|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751906||74281|
NCT01752153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1929|Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major|||Shiraz University of Medical Sciences|Yes|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|12 Years|N/A|No|||November 2012|December 18, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01752153||74262|
NCT01746667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05510207|Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia|||VU University of Amsterdam|No|Recruiting|February 2012|February 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|65 Years|No|||December 2012|December 8, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01746667||74683|
NCT01746680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m308RAP11M|Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis|Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis|TIARA|Chong Kun Dang Pharmaceutical|Yes|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|20 Years|N/A|No|||July 2015|August 9, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01746680||74682|
NCT01746966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0260-10CTIL|Anterior Shoulder US - a New Access|US Investigation of Gleno-humeral Joint by Anterior Access With Measurement of Rotator Interval in Patients With Rheumatoid Arthritis and Healthy Controls||Rambam Health Care Campus|No|Recruiting|December 2012|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 healthy controls from department of preventive medicine and 20 patients with Rheumatoid        Arthritis age of 20-60|May 2014|May 4, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01746966||74660|
NCT01747239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaxOvar|Cabazitaxel in Platinum Refractory Ovarian Cancer|Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial||Vejle Hospital|Yes|Terminated|January 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||December 2014|December 3, 2014|December 6, 2012||No|Too low inclusion rate. Only 4 patients included over 16 months|No||https://clinicaltrials.gov/show/NCT01747239||74639|
NCT01747252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/12|Pharmacokinetics of Resveratrol Comprising Products|Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects||Fruitura Bioscience Ltd.|No|Completed|August 2012|March 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01747252||74638|
NCT01747265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-1243|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2013|||||N/A|N/A|N/A||||||||||||||December 10, 2012|December 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747265||74637|
NCT01746979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200592-001|Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|MAESTRO|EMD Serono|Yes|Active, not recruiting|December 2012|May 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|694|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746979||74659|
NCT01746940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol COCA4vs10-001|Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia|A Phase III Investigation of Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia for Diagnostic Procedures and Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities.||Lannett Company, Inc.|No|Terminated|March 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 12, 2015|January 23, 2012|Yes|Yes|Trial operational issues.|No||https://clinicaltrials.gov/show/NCT01746940||74662|
NCT01747213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130034|Bisnorcymserine in Healthy Adult Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|200|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 17, 2015|December 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747213||74641|
NCT01747720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002-1373|Vitamin D and Mammographic Breast Density|A Randomized Double-blind Placebo-controlled Trial of the Effect of Vitamin D Supplementation on Breast Density in Premenopausal Women|EVIDENSE|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|376|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747720||74602|
NCT01747733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNRO 336/13/03/02/2012|Assessment of Sedation During Endoscopy|Assessment of Sedation During Endoscopy, a Prospective Validation Study||Helsinki University Central Hospital|No|Completed|December 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|N/A|N/A|No|Probability Sample|Patients undergoing endoscopic procedures requiring anaesthesist administered sedation in        the endoscopy unit in HUCH|February 2016|February 18, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747733||74601|
NCT01749527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activity Study|Does Patient Activity Level Affect 24-Hour Pad Test Results in Stress-Incontinent Women|Does Patient Activity Level Affect 24-Hour Pad Test Results in Stress-Incontinent Women?||St George Hospital, Australia|No|Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749527||74463|
NCT01749540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A536-04|Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia|A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia||Acceleron Pharma, Inc.|No|Active, not recruiting|January 2013|March 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01749540||74462|
NCT01749813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23031|Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease|Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease|SCD|Stanford University|No|Active, not recruiting|April 2012|May 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Blood and stool|Both|N/A|30 Years|No|Probability Sample|Children under 18 Adult|May 2015|May 28, 2015|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749813||74441|
NCT01749826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10212009-4201|Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans|Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans||Stanford University||Suspended|January 2010|December 2016|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 9, 2009||No|Currently, we don't have the capacity to finish analyzing the data/samples.|No||https://clinicaltrials.gov/show/NCT01749826||74440|
NCT01750151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2012-120-001|Video Game Playing on Lunch-time Food Intake in Children|The Effect of Sedentary Video Game Playing Before a Mixed Meal on Subjective Appetite and Satiety Signals From a Glucose Preload in Normal Weight and Overweight/Obese Boys||Ryerson University|Yes|Completed|July 2011|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|16|||Male|9 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 20, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750151||74415|
NCT01742559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMSA-0101|The Anesthetic Effect of Anterior Middle Superior Alveolar Technique|The Anesthetic Effect of Anterior Middle Superior Alveolar Technique (AMSA) for Non-surgical Periodontal Procedures: a Randomized Controlled Clinical Study||State University of Maringá|Yes|Completed|January 2009|July 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|27 Years|60 Years|No|||December 2012|December 2, 2012|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742559||74998|
NCT01742884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-Thea-001-2012|Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz|Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz||Instituto Universitario de Oftalmobiología Aplicada|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742884||74973|
NCT01743144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-40-2012|Magnesium Sulphate and Sevoflurane Induced Emergence Agitation in Children|Study the Possible Effects of Intraoperative Intravenous Magnesium Sulphate Infusion on the Incidence of Sevoflurane Induced Emergence Agitation in Children Undergoing Adenotonsillectomy||Cairo University||Active, not recruiting|July 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|70|||Both|4 Years|7 Years|No|||February 2013|February 13, 2013|November 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743144||74953|
NCT01743404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAR-INFL|Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis|Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis||Institute for Atherosclerosis Research, Russia|Yes|Recruiting|September 2007|June 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|300|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||September 2012|December 4, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01743404||74933|
NCT01743417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD064416-01A1|Computerized Cognitive Rehabilitation in Children After Severe Malaria|Computerized Cognitive Rehabilitation in Children After Severe Malaria|CM_CCRT|Makerere University|No|Recruiting|April 2011|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||March 2014|March 31, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01743417||74932|
NCT01743742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antioxidants in Birth Asphyxia|Single High Dose Vitamin C, E in Severe Birth Asphyxia|Single High Dose Vitamin E and Vitamin C in Hypoxic Ischemic Encephalopathy (Following Birth Asphyxia)in Newborns||Sir Takhtasinhji General Hospital|No|Completed|May 2013|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|95|||Both|N/A|6 Hours|No|||August 2014|August 22, 2014|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01743742||74907|
NCT01751191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT16|HVPG for Rebleeding Risk Stratification|Study Protocol: Observational Cohort Study to Improve Rebleeding Risk Stratification for Patients With Cirrhosis and Portal Hypertension on Non-selective Beta-blockers||Hospital Clinic of Barcelona|No|Completed|August 2011|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|338|||Both|18 Years|80 Years|No|Probability Sample|Patients with liver cirrhosis who already experienced a esophageal variceal bleeding,        requiring therapy with non-selective beta-blockers for their portal hypertension.|December 2012|December 13, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751191||74335|
NCT01751204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-677|Comparison of Absorbability Between Calcium Tablet and Calcium Ion Water|A Randomized, Double-blind, Crossover Study to Compare the Absorbability Between Calcium Tablet and Calcium Ion Water||Hiroshima University|No|Completed|November 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|10|||Female|55 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751204||74334|
NCT01751685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0046955|Study of Hyperkyphosis, Exercise and Function-SHEAF|Study of Hyperkyphosis, Exercise and Function-SHEAF|sheaf|University of California, San Francisco|Yes|Active, not recruiting|February 2013|June 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01751685||74297|
NCT01751919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Imatinib_CML_I|A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)|A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400 mg (1 Tablet) and Glivec Film-coated Tablet 100 mg (4 Tablets) After Oral Administration in Healthy Male Subjects (Phase I)||Dong-A ST Co., Ltd.|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751919||74280|
NCT01752166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00031|Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)|Prospective Collection and Testing of Un-Spiked and Candida-Spiked Fresh Whole Blood Specimens From Patients Who Have Been Referred For a Diagnostic Blood Culture|direcT2|T2 Biosystems|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Whole blood specimens|Both|18 Years|95 Years|No|Non-Probability Sample|Adult patients who have had a blood culture ordered, per routine standard of care|May 2014|May 23, 2014|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752166||74261|
NCT01746381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2902|Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode|Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial||McGill University Health Center|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746381||74705|
NCT01746693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-291012|Neurovascular Coupling in Subjects With Amblyopia|Neurovascular Coupling in Subjects With Amblyopia||Medical University of Vienna|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746693||74681|
NCT01747278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-CTD-PCP|Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients|The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases||Peking Union Medical College Hospital|Yes|Recruiting|August 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||December 2012|December 9, 2012|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01747278||74636|
NCT01747538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052131/CL3-78989-006|Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment|A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment|EYEGUARD™-C|XOMA (US) LLC|No|Terminated|October 2012|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|281|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747538||74616|
NCT01747746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-139|Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study|Anticoagulation With Rivaroxaban in Post Cardioversion Patients|ARC|John H. Stroger Hospital|Yes|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01747746||74600|
NCT01748006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-019|The Correlation Between Filling Pressure, Cardiac Output and Plasma Copeptin in Patients With Systolic Heart Failure|The Correlation Between Filling Pressure, Cardiac Output and Plasma Copeptin in Patients With Systolic Heart Failure||Rigshospitalet, Denmark|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood and urine analyses|Both|18 Years|80 Years|No|Non-Probability Sample|The study population will consist of 30 patients with heart failure admitted to the        Department of Cardiology at the Copenhagen University Hospital, Rigshospitalet,Dennmark.        Only patients who are already referred to right heart catheterization by the attending        cardiologist will be recruited for the study.|October 2015|October 26, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01748006||74580|
NCT01742312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0405/38|Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer.|Effect of Neoadjuvant Chemotherapy on Muscle Mass and Peri-operative Cardiorespiratory Performance in Patients Undergoing Oesophageal Cancer- a Pilot Study|Oeso-Chemo|University of Nottingham|Yes|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|blood tests for serum albumin and total protien levels.|Both|18 Years|N/A|No|Non-Probability Sample|healthy volunteers oesophageal cancer patients|February 2016|February 17, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742312||75017|
NCT01742546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNMRC001|Effectiveness of Ultrasound Combine TENS in Treatment of Upper Trapezius Myofascial Pain|Effectiveness of Ultrasound Combine Transcutaneous Electrical Nerve Stimulation (TENS) in Treatment of Upper Trapezius Myofascial Pain: a Randomized Controlled Trial|MPS|Sirindhorn National Medical Rehabilitation Centre|Yes|Completed|June 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||February 2013|February 21, 2013|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01742546||74999|
NCT01743183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05135912.8.0000.5537|Influence of Respiratory Muscle Training in Elderly Hypertensive Women With Respiratory Muscle Weakness|Influence of Respiratory Muscle Training in Elderly Hypertensive Women With Respiratory Muscle Weakness||Universidade Federal do Rio Grande do Norte|Yes|Completed|September 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|60 Years|80 Years|No|||December 2012|December 4, 2012|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01743183||74950|
NCT01742871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0131|Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K|Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K||University Hospital, Clermont-Ferrand||Recruiting|August 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Be included in this study patients under anti-vitamin K supported or followed the        emergency department Adults.|December 2012|December 4, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742871||74974|
NCT01745913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205012374|Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies|A Randomized Study of Combined Haplo-identical Umbilical Cord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies||Weill Medical College of Cornell University|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745913||74740|
NCT01746745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14892|A Study of LY2940680 in Healthy Participants|Disposition of [14C]-LY2940680 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746745||74677|
NCT01747057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORESS|Monitoring Resuscitation in Severe Sepsis and Septic Shock|Monitoring Resuscitation in Severe Sepsis and Septic Shock||Corporacion Parc Tauli|Yes|Recruiting|March 2013|May 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|952|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01747057||74653|
NCT01738750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU56320|Laparoscopic Versus Open Appendectomy? Let the Patient Decide|Laparoscopic Versus Open Appendectomy? Let the Patient Decide||University of Utah|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|N/A|17 Years|No|||April 2014|April 16, 2014|November 22, 2012||No||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01738750||75291|
NCT01738763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIL-PIN-2011-01|Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects|Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study||University of Valencia|No|Completed|July 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01738763||75290|
NCT01738997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 02-499|Endoscopical Dilation of Benign Esophageal Strictures|Endoscopical Dilation of Benign Esophageal Strictures - a Randomized, Clinical Trial, Comparing Two Different Inflation Times.||University Hospital, Umeå|No|Completed|December 2003|||December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||November 2012|November 29, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738997||75272|
NCT01739010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060556|Hypothermia Following Acute Spinal Cord Injury|Efficacy of Intravenously Instituted Hypothermia Treatment in Improving Functional Outcomes in Patients Following Acute Spinal Cord Injury||University of Miami|Yes|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Acute spinal cord injury patients.|December 2015|December 11, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739010||75271|
NCT01739400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-308|Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome|Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome|MAESTRO-OL|Actelion|Yes|Recruiting|September 2013|August 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|12 Years|N/A|No|||February 2016|February 17, 2016|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739400||75241|
NCT01735240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00011|Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.|An Open-label, Fixed-sequence, Single-centre Phase I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of AZD5069 After Oral Administration of a Single Dose AZD5069 to Healthy Male Volunteers||AstraZeneca||Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01735240||75561|
NCT01735487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogEcig|CogEcig: Cognitive Functioning and Electronic Cigarette|Electronic Cigarette and Cognitive Functioning: (CogEcig)|CogEcig|Universita degli Studi di Catania|No|Completed|September 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735487||75542|
NCT01735747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI 002|Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma|Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)||Shandong Cancer Hospital and Institute|Yes|Active, not recruiting|June 2008|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|20 Years|75 Years|No|||March 2013|March 11, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735747||75522|
NCT01744262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0034|A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy|||Yonsei University|Yes|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Male|20 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01744262||74867|
NCT01744002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12812|Neck Mobs and Impingement|The Addition of Cervical Unilateral Posterior Anterior Mobilization (UPA) in the Treatment of Patients With Shoulder Impingement Syndrome: A Randomized Clinical Trial||Walsh University|No|Completed|December 2011|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||December 2012|July 9, 2013|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01744002||74887|
NCT01744236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2012SAFE001|SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies|A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naïve Patients With Type 2 Diabetes (T2DM).||VU University Medical Center|No|Completed|April 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|70|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01744236||74869|
NCT01744769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010379|Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer|Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer||Konkuk University Medical Center|No|Recruiting|July 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Non-Probability Sample|the patients who experience severe hypothyroidism after thyroid hormone withdrawal for        radioiodine therapy in differentiated thyroid cancer|December 2012|December 6, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744769||74828|
NCT01744782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-08|Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis|An Open-Label Safety and Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis||Raptor Pharmaceuticals Inc.|No|Active, not recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|6 Years|No|||October 2015|October 22, 2015|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744782||74827|
NCT01744743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12XD1401300|Preconceptional Thyroid Screening and Childhood Nerocognitive Function|Preconceptional Thyroid Screening and Childhood Nerocognitive Function||Fudan University|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Female|18 Years|55 Years|No|||December 2012|December 7, 2012|October 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744743||74830|
NCT01744756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pterygium bevacizumab|Subconjunctival Bevacizumab and Recurrent Pterygium|Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium|BRP|Instituto de Olhos de Goiania|Yes|Completed|February 2012|September 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|40 Years|80 Years|No|||December 2012|December 6, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01744756||74829|
NCT01740180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/GT|Cortico-saving Treatments Proposed for CLIPPERS: a First Cohort|Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|N/A|N/A|No|Non-Probability Sample|The population concerned by this study consists of patients diagnosed according to        CLIPPERS criteria (see inclusion and exclusion criteria).        Patients will be recruited from referral centers throughout France. We also intend to        communicate with all multiple sclerosis networks (French League against Multiple        Sclerosis) to facilitate the detection of new cases.|October 2015|October 30, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740180|3 Years|75181|
NCT01745692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11NE257|Pragmatic Ischaemic Stroke Thrombectomy Evaluation|A Randomised Controlled Clinical Trial of Adjunctive Mechanical Thrombectomy Compared With Intravenous Thrombolysis in Patients With Acute Ischaemic Stroke Due to an Occluded Major Intracranial Vessel.|PISTE|NHS Greater Glasgow and Clyde|Yes|Terminated|December 2012|July 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 30, 2012||No|IDMC decision - recommended on basis of results from other relevant clinical trials, there    were not safety concerns|No||https://clinicaltrials.gov/show/NCT01745692||74757|
NCT01745926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V/15/11|Implementation of LUCAS 2 in Helicopter Rescue in South Tyrol|Implementation of LUCAS 2 in Helicopter Rescue in South Tyrol||Institute of Mountain Emergency Medicine|Yes|Enrolling by invitation|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in cardiac arrest from all causes requiring CPR|December 2012|December 10, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745926|6 Months|74739|
NCT01746459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034781|Sustaining Transfers Through Affordable Research Translation (START)|Sustaining Transfers Through Affordable Research Translation (START): Knowledge Translation Interventions to Support the Uptake of Innovations in Continuing Care Settings|START|University of Alberta|Yes|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1158|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01746459||74699|
NCT01746472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA155369-01A1|Study of the Diffusion of a Smoking Cessation Application Through an Online Network|Online Social Networks for Dissemination of Smoking Cessation Interventions||Truth Initiative|Yes|Completed|December 2012|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|12||Actual|11413|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 14, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01746472||74698|
NCT01746498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Direct current in Alzheimer's|Therapeutic Effect of Direct Current Stimulation on Cognitive Function of Mild to Moderate Alzheimer Patients|||Assiut University|No|Completed|June 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|45 Years|79 Years|No|||December 2012|December 14, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01746498||74696|
NCT01746758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.94RS|Mobile Phone Text Messaging Referral|Establishing a Community Referral System to Improve Uptake of Adolescent Sexual Reproductive Health Services in Mwanza, Tanzania|SMS4Health|Liverpool School of Tropical Medicine|Yes|Recruiting|August 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|700|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||May 2012|December 7, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746758||74676|
NCT01738542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTC25102012|Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease|CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease|CLAU|Hospital Universitario Getafe|Yes|Completed|April 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|50 Years|60 Years|No|||November 2012|November 28, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01738542||75307|
NCT01738776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-0916901(REK)|Nutritional Risk Factors for Hip Fracture: a Case Control Study|Nutritional Risk Factors for Hip Fracture: a Case Control Study||Oslo University Hospital|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|184|Samples With DNA|For vitamin and hormone analysis serum was collected For some vitamin analysis EDTA blood      was collected For RNA analysis fullblood was collected|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Cases: The first 116 patients of an ongoing RCT were included consecutively and examined        by blood samples pre operatively for nutrition and hormone analysis. The catchment area        for the cases was the city of Oslo, Norway.        A control group, at the same age with no history of hip fracture, was drawn at random from        inhabitants aged 60 - 100 years (median age 82 years) at the census files of Oslo in 2005.|November 2012|November 30, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01738776||75289|
NCT01739023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081061|Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI|The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI)||University of Miami|Yes|Active, not recruiting|November 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||December 2015|December 15, 2015|November 28, 2012|No|Yes||Yes||https://clinicaltrials.gov/show/NCT01739023||75270|
NCT01739036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC052|A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1|A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1||University of Oxford|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739036||75269|
NCT01739413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-263-SDR|Effect of Anesthesia on Insulin Secretion in Patients With Preoperative Decreased Insulin Sensitivity|Effect of Epidural Anesthesia and Analgesia on Insulin Secretion in Patients With Preoperative Decreased Insulin Sensitivity||McGill University Health Center|No|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|80 Years|No|||November 2012|November 29, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739413||75240|
NCT01735253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inha 09-58|Prospective Observatonal Study for Effect of Duodenojejunal Bypass and Gastric Bypass on T2DM Patients|Metabolic Surgery for Type 2 Diabetes|T2DM|Inha University Hospital|Yes|Completed|December 2009|October 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|65 Years|No|||November 2012|November 27, 2012|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735253||75560|
NCT01735500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsTnT Elective CAG|hsTnT After Elective Coronary Angiography|Rise of hscTnT After Elective Coronary Angiography Without Coronary Intervention||University Hospital Heidelberg||Completed|February 2010|||November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|545|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients with stable or unknown CAD undergoing CAG with/or without PCI.        Patients receiving additional examination, such as biopsy, Ablation or any other procedure        that could lead to myocardial injury resulting in elevation of the cardiac Troponin are        being excluded, as well as Patients with acute coronary syndrome.|December 2014|December 6, 2014|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735500||75541|
NCT01735513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDHZ-TC-TAo-EmbolX|Intraprocedural Intraaortic Embolic Protection With the EmbolX Device in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation|Intraprocedural Intraaortic Embolic Protection With the EmbolX Device in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation: a Randomized-controlled Trial|TAo-EmbolX|University Hospital, Essen|No|Recruiting|July 2012|October 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735513||75540|
NCT01735760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-MC-001|Ultrasound Examination Versus Palpation to Locate the Cricothyroid Membrane|Comparison of Ultrasound Examination and Palpation to Locate the Cricothyroid Membrane - a Randomized Study||Rigshospitalet, Denmark||Completed|November 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|44|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|anesthesiologists|November 2013|November 23, 2013|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735760||75521|
NCT01735773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPCIDIN-HASEKI|Role of Prohepcidin in Uremic Patients|The Relationship of Prohepcidin Levels With Anemia and Inflammatory Markers in Non-diabetic Uremic Patients: A Controlled Study||Haseki Training and Research Hospital|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|We selected three groups of patients: Hemodialysis group, peritoneal dialysis group and        the group with stage 4 chronic kidney disease. A control group was formed from healthy        volunteers also.|November 2012|November 27, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735773||75520|
NCT01744041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203136|Mommy-Baby Treatment for Perinatal Depression|Perinatal Depression: Dyadic-IPT to Improve Health of Mother and Baby||Washington University School of Medicine|Yes|Active, not recruiting|November 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01744041||74884|
NCT01744275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCor|HOPE-Epilepsy Trial|High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial|HOPE-Epilepsy|Hospital do Coracao|Yes|Suspended|July 2013|July 2016|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|370|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|December 4, 2012||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01744275||74866|
NCT01744249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXI-IIG-02|Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas|Phase II Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Placebo in Patients With Progressive Advanced Well-differentiated Neuroendocrine Carcinomas of Non-pancreatic Origin||Grupo Espanol de Tumores Neuroendocrinos|No|Active, not recruiting|November 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01744249||74868|
NCT01744522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5147-BO|Leech Therapy for Postherpetic Neuralgia|Pilot Study on the Influence of Leech Therapy on Pain and Sensory Processing in Patients With Postherpetic Neuralgia|ZoHir|Universität Duisburg-Essen|No|Terminated|September 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|85 Years|No|Non-Probability Sample|patients from an outpatient clinic for naturopathy, traditional chinese and indian        medicine(secondary care)|April 2014|April 10, 2014|December 5, 2012||No|We were not able to recruit enough patients for this study within a given time frame.|No||https://clinicaltrials.gov/show/NCT01744522||74847|
NCT01744535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0802108|Pilot Trial of "My Meal Mate" (MMM), a Smartphone Application for Weight Loss|Pilot Trial of "My Meal Mate" (MMM), a Smartphone Application Designed to Facilitate Weight Loss.||University of Leeds|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744535||74846|
NCT01745029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012013250|Gastrointestinal Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Gastrointestinal Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit||University of Aarhus|Yes|Recruiting|April 2013|March 2015|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients suffering from severe Ulcerative Colitis|January 2014|January 6, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745029||74808|
NCT01739920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2516/2010|Comparative Efficacy of Different Regimens of PVPI 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora|Comparative Efficacy of Two Different Regimens of Povidone-iodine 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora||University of Sao Paulo|No|Active, not recruiting|February 2011|April 2015|Anticipated|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739920||75201|
NCT01745705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105-3780|Cervical Spine Manipulation Affects on Balance and Proprioception|Immediate Effects of Cervical Spine Manipulation on Balance and Joint Proprioception in Healthy Individuals||University of Nevada, Las Vegas|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745705||74756|
NCT01745939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLVPT-4056|Manipulation Effects on Abdominal Muscles|The Immmediate Effects of Thrust Joint Manipulation on the Resting and Contraction Thickness of Transversus Abdominis in Subjects With Low Back Pain||University of Nevada, Las Vegas|No|Completed|November 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745939||74738|
NCT01745952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52486|Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)|Multimodal Image-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Refractory Partial Epilepsy.||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|November 2012|June 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|16 Years|75 Years|No|||January 2015|May 28, 2015|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745952||74737|
NCT01746771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-PHI-A201|A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer|A Phase I-II Study to Assess the Safety, Efficacy and Pharmacokinetic Profile of HM781-36B Combined With Paclitaxel and Trastuzumab in Patients With HER-2 Positive Advanced Gastric Cancer||Hanmi Pharmaceutical Company Limited|No|Completed|November 2012|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|19 Years|N/A|No|||March 2016|March 1, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01746771||74675|
NCT01746784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N6022-1CF1-04|Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)|SNO-1|Nivalis Therapeutics, Inc.|Yes|Completed|February 2014|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|December 6, 2012|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01746784||74674|
NCT01746212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InQu ALIF|Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft|Outcomes of Patients With Lumbar Degenerative Disc Disease Treated Operatively With an Anterior-Only Approach Using InQu Bone Graft Extender and Substitute|InQu|Kansas Joint and Spine Institute|No|Recruiting|December 2012|May 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Probability Sample|Target population included adult patients from the normal patient population seen at        Kansas Joint and Spine Institute, currently also known as Kansas Spine Specialists, that        have the ability to provide informed consent without assistance. Each patient that is        qualified for an anterior lumbar interbody fusion, with an anterior only approach, will be        offered the InQu Bone Graft Extender and Substitute as the bone graft the investigator        will use in surgery. Patients that proceed with surgical intervention, and that meet all        inclusion/exclusion criteria, will be offered enrollment into the study.|December 2012|December 6, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01746212||74717|
NCT01746485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-DU-102|Three Times Daily Dosing of UT-15C|A PK Evaluation of Three Times Daily Dosing of UT-15C SR Tablets in Healthy Subjects||United Therapeutics|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746485||74697|
NCT01747356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-20121111|Efficacy and Safety of RESOLUTE Zotarolimus-Eluting Stent in Treatment of Chinese Diabetic Coronary Lesions|Study of Resolute Coronary Stent System in Treating Diabetic Coronary Lesions|RESOLUTE-DM|Shanghai Jiao Tong University School of Medicine|Yes|Completed|February 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1000|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01747356||74630|
NCT01738789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIFEM-2013-1|EURAD-MR Classification : European Multicenter Study|European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses: "EURAD-MR Classification"|EURAD|Société d'Imagerie de la Femme|No|Recruiting|March 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1340|||Female|18 Years|N/A|No|Probability Sample|All patients with a sonographically indeterminate adnexal mass referred for MR imaging        will be consecutively included in each center|November 2015|November 20, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738789||75288|
NCT01739049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF0192012|Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese|The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects||Universiti Kebangsaan Malaysia Medical Centre||Enrolling by invitation|November 2012|January 2015|Anticipated|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|November 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01739049||75268|
NCT01739062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-41-6904|The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice|Prostate Cancer Risk Assessment Using Genetic Markers in General Practice|ProCaRis|University of Aarhus|Yes|Active, not recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1298|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739062||75267|
NCT01735266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121108-5|Left-colon WEC May Reduce Insertion Time Compared With Whole-colon WEC.|Comparative Efficacy of Whole-colon Water Exchange, Left-colon Water Exchange and Air Methods of Colonoscopy on Cecum Intubation in Unsedated Outpatients - - - a Prospective, Randomized Controlled Trail||Fourth Military Medical University|Yes|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|3||Actual|300|||Both|18 Years|80 Years|No|||September 2013|September 11, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735266||75559|
NCT01735526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/2012|Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation|Changes in Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Allogeneic Versus Autologous Hematopoietic Stem-cell Transplantation|DLNO/DLCO|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Yes|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|70 Years|No|Probability Sample|All consecutive patients undergoing allogeneic and autologous HSCT for hematological        malignancies.|September 2014|September 21, 2014|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735526||75539|
NCT01744353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 278|BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study|BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study|278|Brown University|Yes|Active, not recruiting|November 2012|August 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744353||74860|
NCT01744587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2312|Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients|Study of Epstein-Barr Virus Reactivation and the Effect of Dietary Supplement Epigallocatechin Gallate (EGCG) on Virus Reactivation in Remission Patients With Nasopharyngeal Carcinoma - A Randomized Trial|NPC|National Health Research Institutes, Taiwan|Yes|Recruiting|April 2013|December 2020|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|352|||Both|20 Years|N/A|No|||October 2013|October 28, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744587||74842|
NCT01744301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612N00017|Acid Suppressing Drug Seizure Epidemiology Study|A Cohort Study With a Nested Case Control Analysis on the Association Between Acid-suppressing Drugs and Seizures Using THIN Database in the UK||AstraZeneca|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|8605|||Both|N/A|N/A|No|Non-Probability Sample|All individuals aged 20-84 years from 1 January 2005 to 31 December 2011, who have been        enrolled with their primary care physician for at least 2 years and have a computerized        prescription history of at least 1 year. Patients will have to be free of acid-suppressing        drugs (PPI or H2RA) for at least one year, and never have a diagnosis of cancer, alcohol        abuse or alcohol-related disease, or drug abuse.|December 2015|December 2, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744301||74864|
NCT01744314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102903|Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma|Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma: A Randomized Prospective Double-blinded Study.||Lawson Health Research Institute|No|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||May 2014|January 9, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01744314||74863|
NCT01744288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00079|Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets|A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition||AstraZeneca||Completed|December 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|258|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744288||74865|
NCT01744821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00064898|Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer|A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.||Northwestern University||Terminated|October 2012|April 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|7|||Female|18 Years|N/A|No|||July 2015|July 1, 2015|November 30, 2012||No|Inability to recruit study subjects|No|March 17, 2015|https://clinicaltrials.gov/show/NCT01744821||74824|Low accrual led to this pilot study closing early. Accrual barriers included the 4-week minimum treatment time frame and narrow eligibility criteria. Small numbers prohibit meaningful analysis. Study provides important insights to recruitment.
NCT01744795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-063|CardioQ vs Thermodilution Measurements of Cardiac Output|Comparison of CardioQ and Pulmonary Artery Thermodilution Derived Cardiac Output Measurements||Rigshospitalet, Denmark|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|90 Years|No|||June 2013|June 17, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01744795||74826|
NCT01744808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-1020-102|A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020|A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects||Euthymics BioScience, Inc.|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01744808||74825|
NCT01746225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 42-12/BIG 2-12|Schedules of Nab-Paclitaxel in Metastatic Breast Cancer|A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)|SNAP|International Breast Cancer Study Group|Yes|Active, not recruiting|April 2013|April 2023|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|258|||Female|18 Years|N/A|No|||August 2015|August 14, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01746225||74716|
NCT01746511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00040723|Glycerin Suppositories to Reduce Jaundice in Premature Infants|The Use of Glycerin Suppositories to Reduce Hyperbilirubinemia in Premature Infants Requiring Phototherapy||University of Rochester|No|Completed|July 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|30 Weeks|35 Weeks|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 8, 2012||No||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01746511||74695|
NCT01741077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012134|The Effect of Folic Acid Supplementation and Pregnancy on the Folate Forms in Red Blood Cells|The Effect of Folic Acid Supplementation and Pregnancy on the Folate Forms in Red Blood Cells||The Hospital for Sick Children|No|Completed|May 2008|April 2010|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|32|||Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|women of reproductive age|December 2013|December 3, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741077||75112|
NCT01747083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DMCL003|Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)|A Randomized, Open Label, Single Dose, Crossover Study to Investigate Food-effect Bioavailability of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)Under Fed and Fasting Conditions in Healthy Male Volunteers||LG Life Sciences||Completed|January 2013|April 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01747083||74651|
NCT01747096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 11/5-K|TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors|Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors|68-DOTANOC-GEP|Nantes University Hospital|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|130|||Both|18 Years|N/A|No|||April 2014|July 2, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01747096||74650|
NCT01741623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-12/147|Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 1, 2012|December 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741623||75070|
NCT01741636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12342|Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer|Survivorship Care Planning in Colorectal and Lung Cancer: A Feasibility Study||City of Hope Medical Center|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|21 Years|N/A|No|||December 2013|December 16, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741636||75069|
NCT01738802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361813|The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes|The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes|PMC|Walter Reed National Military Medical Center|Yes|Active, not recruiting|January 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|150|||Both|50 Years|N/A|No|||November 2015|November 19, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01738802||75287|
NCT01739075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-5-12|Assessment of Coronary Stenoses Using Coronary CT-angiography and Non-invasive Fractional Flow Reserve Measurement.|Assessment of the Functional Significance of Coronary Stenoses Using Coronary CT-angiography and Non-invasive Fractional Flow Reserve Measurement.||University of Aarhus|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with STEMI admitted at Aarhus Universtity Hospital and treated with primary PCI,        and where the operater finds one or more residual stenoses in non-culprit vessels that        needs to be assessed at a later time with ICA and FFR.|August 2013|May 30, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739075||75266|
NCT01744119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-PMS001|Vascutek Anaconda™ Abdominal Aortic Aneurysm (AAA) Post-Market Surveillance Registry|Vascutek Anaconda™ Stent Graft System for Infra-Renal Abdominal Aortic Aneurysm Repair||Vascutek Ltd.||Active, not recruiting|April 2005|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with a CE-Marked Vascutek Anaconda™ Stent Graft System for Infra-Renal        Abdominal Aortic Aneurysm Repair|March 2015|March 2, 2015|November 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744119||74878|
NCT01744366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000006|One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population|An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy|PANDA|Ferring Pharmaceuticals|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Male|18 Years|N/A|No|||June 2015|June 22, 2015|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744366||74859|
NCT01744600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTRP-301013|Music Therapy in Methodist Homes: a Study Investigating the Impact of a Music Therapy Programme|Music Therapy in Methodist Homes: a Cluster Randomised Controlled Trial Including Mixed Methods Analysis Investigating the Efficacy of the Impact of a Music Therapy Programme on Caring for People With Dementia Who Have Behavioural Symptoms.||Methodist Homes for the Aged|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|N/A|No|||December 2014|December 19, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01744600||74841|
NCT01744613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822|High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures|Clinical Impact of High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures. The PRECLOP Study (Platelet REsponsiveness to CLOpidogrel Treatment After Peripheral Angioplasty or Stenting)|PRECLOP|University of Patras|No|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|84 Years|No|Probability Sample|Consecutive patient sampling of all patients undergoing pre-scheduled infrainguinal        angioplasty or stenting due to symptomatic arterial disease in our Department from January        2010, treated with clopidogrel 75 mg daily.|January 2013|January 11, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744613|12 Months|74840|
NCT01744886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B126201215656|Comparison of Oxygen Saturation During Different Intraoperative Positions|A Comparison of Oxygen Saturation Between Lateral Decubitus Lung Surgery and Port Access Procedures in Dorsal Decubitus||Onze Lieve Vrouw Hospital|No|Terminated|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||October 2014|October 16, 2014|December 6, 2012||No|Inacceptable oxygen saturation values in one study group|No||https://clinicaltrials.gov/show/NCT01744886||74819|
NCT01744327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331536|TL1A Expression in Psoriatic Skin|An Exploratory Study Investigating TL1A Expression in Psoriatic Skin and Serum and Monocytes Capacity to Produce TL1A||Bispebjerg Hospital|No|Active, not recruiting|December 2012|||December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Plaque type psoriasis|May 2013|May 27, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744327||74862|
NCT01744548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1462|A Pilot Trial Of Transdiagnostic Cognitive Behavioural Therapy (tCBT) For Depression And Anxiety In Older People|A Pilot Randomised Controlled Trial (RCT) Examining The Feasibility, Acceptability And Efficacy Of Transdiagnostic Cognitive Behavioural Therapy (tCBT) For Depression And Anxiety In Older People.||King's College London||Recruiting|December 2012|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|60 Years|N/A|No|||January 2013|January 22, 2013|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01744548||74845|
NCT01744834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE2597/13-1;SM80/71;WI709/10-1|Learning in Young Adults as Predictor for the Development of Alcohol Use Disorders|Learning in Young Adults as Predictor for the Development of Alcohol Use Disorders|LeAD|Technische Universität Dresden|No|Active, not recruiting|December 2012|December 2017|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|Samples With DNA|Bloodsample are taken for genetic analysis|Male|18 Years|18 Years|No|Probability Sample|random, representative sample from the respective city area (100 in Dresden, 100 in        Berlin; male; born between January 1 1994 and November 30 1994|January 2016|January 20, 2016|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01744834||74823|
NCT01745055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921013|Co-Administration Of Methotrexate And CP-690,550|A Phase 1, Open Label Study Of The Pharmacokinetics Of Multiple Doses Of Oral CP-690,550 And Single Doses Of Oral Methotrexate In Rheumatoid Arthritis Subjects||Pfizer|No|Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|70 Years|No|||January 2013|January 29, 2013|December 4, 2012|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01745055||74806|Results were summarized for Ae(0-12) instead of planned Ae(0-24), as CP-690,550 was administered every 12 hours.
NCT01745068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR grant # 267395|Partnership for Applied Research in Fracture Prevention Programs for the Elderly|Partnership for Applied Research in Fracture Prevention Programs for the Elderly|OPTI-FRAC|Université de Sherbrooke|No|Active, not recruiting|January 2013|June 2019|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|630|||Both|50 Years|N/A|No|||December 2015|December 1, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745068||74805|
NCT01740193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1778|Comparison of Two Different Pain Management Techniques in Pediatric Patients Undergoing a Hernia Repair|Randomized Prospective Comparison of Analgesic Efficacy of Surgeon Performed IIlioinguinal/Iliohypogastric Blockade With Ultrasound-Guided TAP Blockade in Pediatric Patients Undergoing Unilateral Herniorrhaphy on an Outpatient Basis||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|August 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|12 Months|10 Years|No|||July 2015|July 28, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740193||75180|
NCT01740206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00721|Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)|||Nationwide Children's Hospital|No|Completed|November 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|18 Years|No|||January 2016|January 26, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740206||75179|
NCT01740492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298021|Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department|Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department||Rhode Island Hospital|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|No|||September 2012|October 30, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01740492||75157|
NCT01740765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0681|Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding|Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding||University of North Carolina, Chapel Hill|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|7|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01740765||75136|
NCT01741090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR109021|The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis|The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis||Yonsei University|Yes|Recruiting|September 2009|August 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|60 Years|No|||December 2012|December 7, 2012|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01741090||75111|
NCT01741116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-GU11-05|Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer|A Phase II Study of TKI258 in Patients With Castration-resistant Prostate Cancer||Korean Cancer Study Group|Yes|Recruiting|November 2012|June 2016|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Male|N/A|N/A|No|||November 2012|November 30, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01741116||75109|
NCT01741350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-215|Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users|Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users||University of Connecticut|Yes|Completed|September 2006|June 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|November 30, 2012||No||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01741350||75091|The drug-risk reducing effects of methadone may have restricted our ability to detect intervention effects on drug-related outcomes. Participants may have also been reluctant to report HIV risk related behaviors.
NCT01741649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-04|Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section|Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection in Patients After Cesarean Section. Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|October 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|800|||Female|N/A|N/A|No|||May 2013|May 16, 2013|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01741649||75068|
NCT01738815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256549|Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer|Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer||State University of New York - Upstate Medical University|Yes|Recruiting|December 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|21 Years|N/A|No|||December 2012|December 12, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738815||75286|
NCT01739088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032388|Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery|Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery|PREP|University of Alberta|No|Active, not recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|N/A|6 Weeks|No|||March 2016|March 23, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739088||75265|
NCT01739101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU-RLP-RCT-2012|The Reproductive Life Plan in Midwifery Counseling|The Reproductive Life Plan in Midwifery Counseling||Uppsala University|Yes|Completed|March 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|299|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 12, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739101||75264|
NCT01739426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/SK-02|Evaluation of Endoscopic Treatment of Zenker's Diverticulum Using LigaSure|Evaluation of Endoscopic Treatment of Zenker's Diverticulum Using the LigaSure Thermal Vessel Sealing System|ZENKER LS|Centre Hospitalier Universitaire de Nīmes|Yes|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739426||75239|
NCT01744379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-125|Single and Multiple Dose Study in Japanese|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects||Ardea Biosciences, Inc.|No|Completed|December 2012|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|November 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744379||74858|
NCT01744626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-292-CLL-002|Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.||Celgene|No|Active, not recruiting|December 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744626||74839|
NCT01745497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0466|Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder|Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder||University of Colorado, Denver|Yes|Terminated|December 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|2 Years|10 Years|No|||March 2016|March 10, 2016|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745497||74772|
NCT01744899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16518|Soleus H-Reflex in Different Sitting Postures|The Influence of Different Sitting Postures on Soleus H-Reflex in Normal Subjects||Texas Woman's University|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults from both genders.|December 2012|December 5, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01744899||74818|
NCT01744067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1419|The Effects of Omega-3 Fatty Acids in Renal Transplantation|The Effects of n-3 Polyunsaturated Fatty Acids on Renal and Cardiovascular Risk Markers in Renal Transplant Recipients: a Randomized Double Blinded Placebo Controlled Intervention Study.|ORENTRA|Oslo University Hospital|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01744067||74882|
NCT01744847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-2012-010|DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study|DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study||Soon Chun Hyang University|Yes|Completed|January 2005|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|111|||Both|20 Years|N/A|No|||December 2012|December 6, 2012|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01744847||74822|
NCT01744561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-CF-001|Effects of a Partially Supervised Conditioning Program in CF|Effects of a Partially Supervised Conditioning Program in CF: an International Multi-centre, Randomized Controlled Trial|ACTIVATE-CF|Wuerzburg University Hospital|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|292|||Both|12 Years|N/A|No|||January 2016|January 21, 2016|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744561||74844|
NCT01745432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T201E4|Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery|Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery|ADBEE|Terumo Europe N.V.|Yes|Active, not recruiting|August 2012|September 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|45 Years|No|||December 2012|May 11, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01745432||74777|
NCT01745081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study on cerebral relaxation|Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies|Comparison of the Efficacy Between 20% Mannitol and 3% Hypertonic Saline, Given as a Bolus at the Beginning of Elective Supratentorial Craniotomy for Tumor Resection, in Favoring Cerebral Relaxation Evaluated by a Sub-dural Intracranial Pressure Measurement.||Université de Sherbrooke|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745081||74804|
NCT01740219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19674|Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches|Promoting the Utilization of Cancer Early Detection Methods Among Latinos in Church: a Faith-based Approach|CRUZA|Dana-Farber Cancer Institute|No|Enrolling by invitation|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|348|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 21, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740219||75178|
NCT01740505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFMG-001|HealthySteps: Exercise for Older Adults With Mobility Limitation|HealthySteps: A Pilot Randomized Controlled Trial of Exercise to Improve Walking Energetics, Fatigue, and Activity in Older Adults With Mobility Limitation|HealthySteps|Simon Fraser University|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 19, 2015|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01740505||75156|
NCT01740518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCPD|Comparison of Low-volume PEG Plus Ascorbic Acid Versus Standard PEG Solution as Bowel Cleansing for Colonoscopy|Randomized Controlled Trial of Low-volume PEG Plus Ascorbic Acid Versus Standard PEG Solution as Bowel Cleansing for Colonoscopy||Kangbuk Samsung Hospital|Yes|Enrolling by invitation|March 2012|||December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|360|||Both|19 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Out-patients for colonoscopy in university hospital|November 2012|November 30, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740518||75155|
NCT01740778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-2009-Aurora|Lancing Device Comparison Study|Lancing Device Comparison Study||Facet Technologies|Yes|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Gender: Approximately 50% male, 50% female; Type Diabetes: 25% Type 1, 75% Type 2 Age: 18        or older|November 2012|November 30, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01740778||75135|
NCT01741129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB2611|Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|November 2012|November 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|N/A|2 Hours|No|||January 2013|March 7, 2014|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01741129||75108|
NCT01741363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205030RIB|Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing|Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing: a Population-based Randomized Study||National Taiwan University Hospital|No|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|40000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01741363||75090|
NCT01741376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50DA033942-01|Progesterone and Atomoxetine for Cocaine Cessation|Progesterone and Atomoxetine for Cocaine Cessation||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||July 2015|October 29, 2015|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01741376||75089|
NCT01741389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/295|The Role of Melatonin in the Regulation of Blood Coagulation|The Role of Melatonin in the Regulation of Blood Coagulation|COME|University of Oslo|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 9, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741389||75088|
NCT01747863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIME01|Prospective Research in Infants With Mild Encephalopathy|Prospective Research in Infants With Mild Encephalopathy: the PRIME Study.|PRIME|McGill University Health Center|No|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|57|||Both|N/A|6 Hours|No|Non-Probability Sample|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic        hypothermia. NE will be defined as the presence of abnormal neurological findings on the        modified Sarnat Score performed at ≤ 6 hrs of life. Evidence of a perinatal event will        include criteria described in details in the whole body hypothermia trial (NEJM, 2005).        The level of NE will be defined by the neurological exam performed by certified        neonatologists working at the 6 centers.|September 2015|September 21, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747863||74591|
NCT01747642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP2|Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma|Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma||Clinical Research Organization, Dhaka, Bangladesh|No|Recruiting|December 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||December 2012|December 11, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747642||74608|
NCT01748123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-EGID 4231|EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network|Creating an Active Collaborative Network of Comparative Effectiveness Researchers: A Randomized Study of Initial Diuretic Therapy for Hypertension.||Johns Hopkins University|No|Not yet recruiting|July 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|90 Years|No|||February 2016|February 11, 2016|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748123||74571|
NCT01745185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-CFCT-03|Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta|Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta||O & O Alpan LLC|No|Active, not recruiting|June 2012|July 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Blood, Urine|Both|7 Years|N/A|No|Non-Probability Sample|30 subjects of (7 and above) who meet eligibility criteria.|May 2015|May 6, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745185||74796|
NCT01745484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFE-1203|Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation|Role of SPECT in Radiotherapy Treatment Planning and Toxicity Evaluation for the Patients With Stage I-III NSCLC: a Randomized Phase II Trial||University of Aarhus|Yes|Completed|June 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745484||74773|
NCT01745510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHA-ECN|Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates|Efficacy of Enteral Administration of the Docosahexaenoic Acid on Necrotizing Enterocolitis, Cytokines and Hospital Stay in Preterm Neonates||Coordinación de Investigación en Salud, Mexico|Yes|Recruiting|October 2012|December 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|306|||Both|N/A|2 Weeks|No|||January 2016|January 26, 2016|November 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745510||74771|
NCT01745796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12SC02|Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)|Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia|PYO GEN|University Hospital, Grenoble|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|In order to achieve an antibiogram according to conventional methods and PCR genotyping Rep      (DiversiLab ®) to assess the clonality of bacterial populations, there will be taken 5      different isolated colonies (possibly diluted)from each clinical sample of bronchial      secretion, selected according to morphological criteria or randomly if no visible      differences are noted.|Both|18 Years|N/A|No|Non-Probability Sample|ICU patients over 72 hours of intubation and mechanically ventilated|December 2015|December 1, 2015|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01745796||74749|
NCT01744574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS074|Sex Differences, Hormones & Smoking Cessation|Sex Differences & Progesterone: Association With Impulsivity and Smoking Cessation||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744574||74843|
NCT01743313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyTe-2|Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement|Hyperglycemia in Joint Replacement Recipients: Glucose Metabolism Disorders and Metabolic Syndrome in Osteoarthritis Patients Before and After Primary Hip and Knee Replacement|HyTe-2|Coxa, Hospital for Joint Replacement|No|Active, not recruiting|April 2012|June 2016|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|Samples Without DNA|Plasma samples (one per patient).|Both|18 Years|N/A|No|Non-Probability Sample|tertiary care clinic|August 2015|August 9, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01743313||74940|
NCT01743599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab.Reprod.Biol.-Horsens-01|Retrograde Ejaculation and Sexual Dysfunction in Men With Diabetes Mellitus|||Odense University Hospital||Completed|February 2008|||April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|||Male|30 Years|55 Years|No|Non-Probability Sample|Diabetic men and non-diabetic men in Denmark.|December 2012|December 4, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01743599||74918|
NCT01745094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-110|A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients|Post-Marketing Clinical Study of Mirabegron -Add-on Therapy With Mirabegron in Patients With Overactive Bladder Under Treatment With Solifenacin-||Astellas Pharma Inc|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|20 Years|N/A|No|||August 2014|August 4, 2014|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01745094||74803|
NCT01739647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00001|A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers||AstraZeneca||Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|72|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01739647||75222|
NCT01739660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0403|Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis|A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis||Savient Pharmaceuticals|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|75 Years|No|||October 2013|October 24, 2013|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739660||75221|
NCT01745718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsloUH_2|Clinical Study Evaluating Targeted Biopsies and Cytological Imprints in Prostate Cancer|Targeted Biopsies and the Role of Cytological Imprints for Diagnosis of Prostate Cancer||Oslo University Hospital|No|Withdrawn|October 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|N/A|N/A|No|||September 2015|September 22, 2015|November 20, 2012||No|The study was stopped for technical reasons|No||https://clinicaltrials.gov/show/NCT01745718||74755|
NCT01740544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMS-Neglect 2|Computerised Assessment of Visual Neglect Symptoms in Peripersonal Space|Computerised Assessment of Visual Neglect Symptoms in Peripersonal Space|KMS-Neglect 2|Charite University, Berlin, Germany|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|16|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01740544||75153|
NCT01740557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0471|T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)|A Phase I/II Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and Nerve Growth Factor Receptor (NGFR) Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Recruiting|January 2015|||January 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|14 Years|N/A|No|||March 2016|March 14, 2016|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740557||75152|
NCT01740531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00076|Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion|A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion||Cerus Corporation|No|Active, not recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|70|||Both|10 Years|N/A|No|||September 2015|September 11, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01740531||75154|
NCT01740804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1202|Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC|A Prospective Observational Study on the Dynamic Changes of CTC Enumeration in Advanced NSCLC With 1st Line Chemotherapy|POLICE|Guangdong Association of Clinical Trials|Yes|Recruiting|November 2012|December 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|The DNA sample will be rtetained for molecular analysis such as EGFR, KRAS, etc.|Both|18 Years|N/A|No|Non-Probability Sample|Advanced NSCLC (stage IIIb/IV or recurrent NSCLC)|April 2014|April 11, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01740804||75133|
NCT01740791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-281-0102|Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection|Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection||Gilead Sciences|No|Completed|November 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|94|||Both|18 Years|65 Years|No|||March 2014|March 6, 2014|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740791||75134|
NCT01741103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1957|Sitagliptin in Type I Diabetic Patients|Effect of Sitagliptin on Glycemic Control, Post-prandial Glucagon, and Inflammation in Type 1 Diabetics||Kaleida Health|No|Recruiting|June 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||June 2012|November 30, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01741103||75110|
NCT01741415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032582|Distress Tolerance Treatment for Substance Users|Distress Tolerance Treatment for Substance Users||University of South Florida|No|Recruiting|May 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|325|||Both|18 Years|65 Years|No|||May 2015|May 6, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741415||75086|
NCT01741402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC004|Effects of Training in a Virtual Environment in Healthy Elderly|Effects of Training in a Virtual Environment on the Performance of Gait, Postural Control and Executive Functions in Healthy Elderly||University of Sao Paulo General Hospital|Yes|Active, not recruiting|February 2010|February 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741402||75087|
NCT01747876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2102|Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma|A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma||Novartis|No|Active, not recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|1 Year|21 Years|No|||October 2015|October 6, 2015|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747876||74590|
NCT01747889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATSAT-2012-1|Objective and Subjective Outcomes of an Electronic Chest Drainage System|Objective and Subjective Outcomes of an Electronic Chest Drainage System Versus Traditional Devices: a Randomized Comparison||Ospedali Riuniti Ancona||Recruiting|January 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|90 Years|No|||November 2013|November 29, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747889||74589|
NCT01748136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0491|Screening for Lung Cancer in the HIV Patient|Screening for Lung Cancer in the HIV Patient|NA_00036809|Sidney Kimmel Comprehensive Cancer Center|No|Completed|January 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|26 Years|N/A|No|||May 2013|May 3, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748136||74570|
NCT01744132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U58DP002655|Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes|||Wills Eye|Yes|Active, not recruiting|October 2012|||October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01744132||74877|
NCT01745198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-002c|Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements|Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Related Disorders||Pamlab, Inc.|No|Completed|December 2012|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|121|Samples With DNA|A single blood draw for approximately 6-10 mL of blood will be performed for the total      plasma homocysteine measurement and genetic studies.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with homocysteinemia plus past/current CFLN treatment (Treatment Group) will be        matched to those without homocysteinemia plus no past/current B12, folate or CFLN        treatment (Non-Treatment Group).|April 2015|April 27, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01745198||74795|
NCT01745822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD071889|Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand|Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization.|iTAP|Institut de Recherche pour le Developpement|Yes|Active, not recruiting|January 2013|October 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|328|||Female|18 Years|N/A|No|||October 2015|October 19, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745822||74747|
NCT01745809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814383|Bronchoscopy Study for Severe Asthma|An Exploratory Study to Obtain Functional and Transcriptional/Translational Profiling of Cells From Bronchial Lavages and Brushings in Severe Asthmatics and Healthy Control Subjects||University of Pennsylvania|Yes|Withdrawn|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|N/A||2|Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 severe asthma subjects matched with 10 healthy control subjects|October 2011|May 28, 2015|December 6, 2012||No|Contractual issues|No||https://clinicaltrials.gov/show/NCT01745809||74748|
NCT01746069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB-01|Effectiveness of Messages to Mobile Phone in Smoke Cessation|Evaluation of a Reinforcement Program Using Text Messages Through Mobile Phone in Smoking Cessation Programs in Primary Care||Basque Health Service|No|Completed|March 2013|October 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746069||74728|
NCT01742715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0156-12-WOMC|Three Methods for Best PEEP Determination Compared With PEEP Determination Guided by Adult Respiratory Distress Syndrome (ARDS) Network|Three Methods for Best PEEP Determination Compared With PEEP Determination Guided by Adult Respiratory Distress Syndrome (ARDS) Network, a Crossover Study.||Wolfson Medical Center|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||October 2012|December 2, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01742715||74986|
NCT01742728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|goto2012|Nagasaki and Tokushima|Oxidative Stress in Community-dwelling Adults||University of Tokushima||Recruiting|May 2009|March 2015|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|2000|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|December 2012|December 3, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01742728||74985|
NCT01743326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-2-031|RFD Versus Cervical Medial Branch Blocks in Chronic Degenerative Neck Pain|Percutaneous Radiofrequency Denervation of the Cervical Facet Joints Compared With Cervical Medial Branch Block of the Facet Joints for Patients With Chronic Degenerative Neck Pain : A Prospective Randomized Clinical Study||Maastricht University Medical Center|Yes|Recruiting|November 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|25 Years|90 Years|No|||January 2015|January 15, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01743326||74939|
NCT01743898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1254|A Prospective Pharmacodynamic Study of Rivaroxaban|A Prospective Pharmacodynamic Study of Rivaroxaban Using Peak and Trough Coagulation Test Results in Patients on Therapeutic Doses of Rivaroxaban||University of North Carolina, Chapel Hill|No|Completed|October 2012|August 2014|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|65|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients taking FDA-approved doses of rivaroxaban and control subjects not taking an        anticoagulant or antiplatelet were eligible for inclusion|August 2014|August 1, 2014|October 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01743898||74895|
NCT01743911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0044.0.146.000-09|Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients|Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients||University of Campinas, Brazil|No|Completed|September 2010|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|75 Years|No|||December 2012|December 4, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01743911||74894|
NCT01739907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2009-11437|Iron-fortified Flavoured Skimmed Milk With or Without Vitamin D in Iron Deficient Women|||National Research Council, Spain|No|Completed|January 2012|October 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|109|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|June 12, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01739907||75202|
NCT01739673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCXL|Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis|Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis||Cxlusa|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739673||75220|
NCT01740830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECU2012-003|The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis|||Hasselt University|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|70 Years|No|||June 2013|June 1, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01740830||75131|
NCT01740843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECU2012-004|The Effect of tDCS on Motor Performance and Cortical Excitability|||Hasselt University|No|Completed|August 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01740843||75130|
NCT01740817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20080015H|A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling|A Randomized, Crossover Study to Evaluate the Effect of Lipid Infusion on TLR4 Signaling and Insulin Resistance in Human Muscle||The University of Texas Health Science Center at San Antonio|No|Completed|January 2008|September 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|November 26, 2012|No|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01740817||75132|
NCT01741142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-733|Efficacy and Safety Study of ABT-436 in Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder||AbbVie|Yes|Terminated|January 2012|August 2015|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||October 2013|October 4, 2013|November 30, 2012|Yes|Yes|Decision based on strategic determination; not safety.|No||https://clinicaltrials.gov/show/NCT01741142||75107|
NCT01741428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/561a(REK-LHL)|"Hjerteloeftet" ("HeartLift"). Interaction For Preventing Cardiovascular Disease|"Hjerteloeftet". Early Interventions to Promote Physical Activity, Dietary Lifestyle Changes and Optimal Medication for Cardiovascular Risk Factor Reduction in Over 3 Years Follow-up.|HeartLift|LHL Helse|Yes|Active, not recruiting|November 2012|December 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|800|||Both|35 Years|67 Years|No|||March 2016|March 3, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741428||75085|
NCT01741701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13397|A Pilot Study of Oxaloacetate in Subjects With Treated PD|A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)||University of Kansas Medical Center|No|Completed|December 2012|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|30 Years|N/A|No|||February 2016|February 18, 2016|December 1, 2012||No||No|January 18, 2016|https://clinicaltrials.gov/show/NCT01741701||75064|
NCT01741961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahmed-LTO|Long Term Outcome After Ahmed Glaucoma Valve|4-year Follow-up After Ahmed Glaucoma Valve Implantation for Lowering Intraocular Pressure in Different Types of Glaucoma||Technische Universität Dresden|No|Completed|June 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|214|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from uncontrolled glaucoma, most often after multiple ocular surgery.|December 2012|December 3, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01741961||75044|
NCT01741675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFI - 2251|The Effect of Monetary Incentive on Survey Response for Vulnerable Children and Youth|The Effect of Monetary Incentive on Survey Response for Vulnerable Children and Youth||The Danish National Centre For Social Research|Yes|Completed|November 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|270|||Both|10 Years|30 Years|No|||February 2015|February 26, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01741675||75066|
NCT01744392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01658|Medication Adherence With Polyglot Meducation|Evaluate Changes in Medication Adherence and Patient Perspective of Polyglot Systems, Inc's Meducation Technology||Durham VA Medical Center|No|Completed|February 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|December 5, 2012||No||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01744392||74857|
NCT01744639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS 720-12/13-1|Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation|Analysis of Body Composition by Bioelectrical Impedance in Patients With Hepatocellular Carcinoma (HCC) Undergoing Treatment Radioablation||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Active, not recruiting|December 2012|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744639||74838|
NCT01744912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGTX 1101-102|Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies|Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy||TG Therapeutics, Inc.|Yes|Completed|December 2012|October 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744912||74817|
NCT01745523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206-C-103-AC|Use of a Synthetic Macromolecule (Hydroxypropyl Cellulose ) and Trehalose as Additives for Oocyte Vitrification|"Impact of Using Hydroxypropyl Cellulose (HPC) and Trehalose for Oocyte Vitrification in an Ovum Donation Program"||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|November 2012|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|440|||Female|18 Years|50 Years|No|||March 2015|March 9, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01745523||74770|
NCT01737294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTZ-EC-0003|Observation of the Use of QUTENZA™ in Standard Clinical Practice|The Use of QUTENZA™ in Standard Clinical Practice: a Phase IV, Multicentre, European Non-interventional Study|ASCEND|Astellas Pharma Inc|No|Completed|February 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|429|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving QUTENZA for PNP in routine clinical practice|October 2014|October 3, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01737294||75403|
NCT01746082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0011|Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations|A Phase II Open-Label Study in Healthy Adult and Elderly Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|211|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 27, 2014|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746082||74727|
NCT01746095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV005-02|Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients|A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients||Savara Inc.|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|12 Years|N/A|No|||December 2014|December 5, 2014|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746095||74726|
NCT01746108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115884|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection||GlaxoSmithKline||Completed|June 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|52|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||November 2015|December 10, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746108||74725|
NCT01743924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Broccoli_Bioav.|Bioavailability of Chemopreventive and Nutritional Compounds in Broccoli|Bioavailability of Bioactive Compounds in Broccoli||Universidad Politécnica de Cartagena|Yes|Completed|July 2011|July 2011|Actual|July 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|7|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01743924||74893|
NCT01743612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 11 25|Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.|Laser SPEckle Contrast Imaging Interest in dEtection of Cutaneous Microvascular Dysfunction in Systemic Sclerosis.|SPECIES|University Hospital, Grenoble|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743612||74917|
NCT01743625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15010232|Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension||Mallinckrodt|No|Completed|November 2012|July 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|406|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743625||74916|
NCT01739933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL111111|The MENDSII Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure|Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis|MENDSII|Vanderbilt University|Yes|Recruiting|August 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|530|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739933||75200|
NCT01740245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHX-PHMB|Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||Phase 4|Interventional|N/A|2||||||Female|20 Years|40 Years|No|||June 2012|November 30, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740245||75176|
NCT01740570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0228|Phase I/II Cabazitaxel for Recurrent Malignant Glioma|Phase I/II Trial of Cabazitaxel in Adult Patients With Recurrent Malignant Glioma||M.D. Anderson Cancer Center|No|Withdrawn|April 2013|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740570||75151|
NCT01740596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 03970-C|C-Pulse® System: A Heart Assist Device Clinical Study|C-Pulse Heart Assist Device pivOtal stUdy treatiNg paTients With modERate to Severe Heart Failure C-Pulse® System: A Heart Assist Device Pivotal IDE Study|COUNTER HF|Sunshine Heart Inc.|Yes|Active, not recruiting|November 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740596||75149|
NCT01741155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1620-12-201|Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)|A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|May 2013|December 2015|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|227|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741155||75106|
NCT01740609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4351001|A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers|A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers||Pfizer|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01740609||75148|
NCT01741688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28206|An Observational Study of Tocilizumab (Actemra) in Patients With Moderate to Severe Rheumatoid Arthritis|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche|No|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis (RA) initiated on treatment with tocilizumab|September 2015|September 9, 2015|November 30, 2012||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01741688||75065|
NCT01741441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTF-2002-TO|Laparoscopic Total Fundoplication for Duodenogastroesophageal Reflux|Study of Prognostic Factors for Long Term Results of Total Laparoscopic Fundoplication for Weakly Acidic or Mixed Reflux||University of Turin, Italy|No|Completed|June 2002|June 2012|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|188|||Both|14 Years|75 Years|No|Probability Sample|Between June 2002 and June 2007 188 patients with MR and WAR underwent LTF; 172 (91.5%)        completed the 5-year protocol. Among them, forty-two (24.4%) had preoperative moderately        delayed GE (DGE).|November 2012|November 30, 2012|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01741441||75084|
NCT01741974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAR-KT-PERI|Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women|Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women|PEARS|Institute for Atherosclerosis Research, Russia|Yes|Completed|October 2005|October 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|340|||Female|40 Years|55 Years|Accepts Healthy Volunteers|||January 2012|December 4, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01741974||75043|
NCT01744418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PRO-V001|Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD|A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease||Humacyte, Inc.|Yes|Active, not recruiting|December 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||March 2015|March 17, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744418||74855|
NCT01744652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0721|Dasatinib and Crizotinib in Advanced Cancer|A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|March 2013|||March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|16 Years|N/A|No|||March 2016|March 7, 2016|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744652||74837|
NCT01744665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS37|Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.|A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib|ENESTgoal|Novartis|No|Active, not recruiting|August 2013|December 2021|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744665||74836|
NCT01744925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV26|Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR|An Open-label,Randomized,Controlled Study to Evaluate the Safety and Efficacy for Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|October 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2012|December 8, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744925||74816|
NCT01744938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-STQ-201205001|Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice|Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice: A Phase III, Randomized, Controlled, Single Center Study.||Tianjin Medical University Cancer Institute and Hospital|Yes|Enrolling by invitation|September 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|65 Years|No|||May 2012|December 21, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744938||74815|
NCT01745211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO-STRIAE_RG4|755nm Alex Laser for Treatment of Stretch Marks|||Cynosure, Inc.|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|85 Years|No|||April 2014|April 9, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745211||74794|
NCT01737034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 0315681|A Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon|Ätiologie, Pathophysiologie Und Prävention Einer überschießenden Körperfettzunahme Nach Gewichtsreduktion - Vermeidung Des JoJo-Effektes in Der Behandlung Von Übergewicht||University of Kiel|No|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|32|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737034||75423|
NCT01737840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160|Comparison of Pantoprazole and Ranitidine in Dyspepsia|Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.||Akdeniz University|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||June 2015|June 27, 2015|November 24, 2012||No||No|March 16, 2015|https://clinicaltrials.gov/show/NCT01737840||75361|
NCT01737554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARMA|Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents|Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study||St. Jude Children's Research Hospital|No|Recruiting|December 2012|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|5 Years|24 Years|No|Non-Probability Sample|Participants will be drawn from current St. Jude patients who have a central venous access        device already in place as part of their standard clinical care.|October 2015|October 14, 2015|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737554||75383|
NCT01743014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/10-7-2012|Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy|A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy||AHEPA University Hospital|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2012|December 4, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01743014||74963|
NCT01743027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-053|Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis|Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model||Alcon Research|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|902|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|December 4, 2012|Yes|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT01743027||74962|
NCT01743040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038-001|Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases|Pivotal Study of the CADence Device in Detection of Coronary Artery Diseases|TURBULENCE|AUM Cardiovascular, Inc.|Yes|Completed|February 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|22 Years|N/A|No|Non-Probability Sample|All enrolled subjects that received nuclear stress testing and either CT or standard        coronary angiography after the CADence evaluation will be included in the analysis.|November 2015|November 16, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743040||74961|
NCT01743053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReCell VLU Pilot Study|A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers|||Avita Medical|No|Recruiting|January 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01743053||74960|
NCT01743664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/R/11|The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis|The Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Post Traumatic Stress Disorder in Multiple Sclerosis. A Randomized Controlled Trial.||San Luigi Gonzaga Hospital|No|Recruiting|May 2010|February 2014|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2012|December 6, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01743664||74913|
NCT01739686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR013422-02|Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial|Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial|CASA|Denver Research Institute|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|312|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01739686||75219|
NCT01739946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-143|Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.|Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.||William Beaumont Hospitals|No|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Female|18 Years|75 Years|No|Non-Probability Sample|Subjects with either have OAB and will be undergoing an InterStim® implant (InterStim®        group) or do not have bladder symptoms or an InterStim® device (Control group)|October 2015|October 20, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739946||75199|
NCT01740232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|meniskprojekt|Can a Simple Trephination Increase the Heeling Potential for All-inside Meniscal Repair in the Vascular Zone?|A Simple Trephination Increase the Heeling Potential for All-inside Meniscal Repair in the Vascular Zone||Amager Hospital|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|No|||January 2015|January 14, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01740232||75177|
NCT01740583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLPR-007|Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation|A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation|ALIGN|Mitralign, Inc.|Yes|Active, not recruiting|November 2012|September 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740583||75150|
NCT01740869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE12-021|Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders|Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders|Autism|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Recruiting|November 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|15 Years|No|||June 2015|June 3, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01740869||75128|
NCT01740882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABSTACK-123|Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks|Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks|ABSTACK|Hvidovre University Hospital|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|816|||Both|18 Years|90 Years|No|Non-Probability Sample|During the period 1 January 2008 to 31 June 2012 were recorded 355 laparoscopic incisional        hernia operations with absorbable tacks and 726 with non-absorbable tacks were registered        in the Dansih Hernia Database. Thus, we include 1081 patients in the study. It is expected        that about 300 patients will be offered physical examination.|April 2014|April 24, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740882||75127|
NCT01740856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 100401|Clinical Trial to Assess the Safety of Reducing the Time of Bed Rest After Cardiac Catheterization|Randomized Clinical Trial to Assess the Safety of Reducing the Time of Bed Rest Within Five to Three Hours After Diagnostic Cardiac Catheterization With a 6F Sheath|Three-Cath|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|January 2011|February 2014|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|730|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 8, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01740856||75129|
NCT01741168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11421|Brace Versus No Brace for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury|TLSO Versus No Orthosis for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury: A Multicenter Prospective Randomized Equivalence Trial||The London Spine Centre|No|Completed|June 2005|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|16 Years|60 Years|No|||November 2012|November 30, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01741168||75105|
NCT01745835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coolprep study|Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation|Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation for Colonoscopy||Seoul National University Hospital|No|Recruiting|January 2013|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|196|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01745835||74746|
NCT01745848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12060615|Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD|Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease||University of Pittsburgh|Yes|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|70 Years|No|||January 2016|January 5, 2016|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745848||74745|
NCT01741714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine-K34KSF-AHUS|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine? A Randomized Controlled Clinical Trial||University Hospital, Akershus|Yes|Completed|February 2013|September 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01741714||75063|
NCT01741727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-379|A Study of ABT-414 in Subjects With Solid Tumors|A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumors Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)||AbbVie|No|Completed|October 2012|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741727||75062|
NCT01744678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNX10AF47G|Fatigue Countermeasure Program in Operational Flight Controllers|Experimental Trial of Fatigue Countermeasure Program in Operational Flight Controllers||Brigham and Women's Hospital|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 5, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01744678||74835|
NCT01744951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT-02|Adoption-specific Treatment Prevention Pilot Trial|Evaluate the Adoption-specific Prevention Treatment Program (ADAPT)|ADAPT|University of California, Los Angeles|No|Recruiting|October 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01744951||74814|
NCT01744964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078-09-RBM|Apomorphine Effects on Experimental Pain|Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism||Rambam Health Care Campus|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|105|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01744964||74813|
NCT01745224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-REV-TRI-AK|Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma|||Cynosure, Inc.|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745224||74793|
NCT01736761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 049|A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.|||St Stephens Aids Trust||Recruiting|December 2012|||||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||December 2012|December 10, 2012|November 26, 2012||||No||https://clinicaltrials.gov/show/NCT01736761||75444|
NCT01737567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/11/WMEAD/223|Comparison Between White Light Endoscopy and Bright Narrow Band Imaging in Diagnosis Colonic Adenomas.|A Randomised Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Colonic Adenomas in Asymptomatic Subjects Undergoing Screening Colonoscopy.|WLEvB-NBI|Western Sydney Local Health District|Yes|Recruiting|February 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1000|||Both|50 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737567||75382|
NCT01738464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00055668|Microbiomes of Pelvic Pain|Microbiomes of Pelvic Pain||Northwestern University|No|Recruiting|June 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Stool specimen|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic patients Community sample|January 2016|January 7, 2016|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738464||75313|
NCT01738165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KINE-1203|Pilot Study of the KineSpring® System to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis|Prospective, Multi-Center, Pilot Study to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis (OA) Treated With the KineSpring® Knee Implant for Load Reduction|SOAR|Moximed|Yes|Active, not recruiting|December 2012|April 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|25 Years|80 Years|No|||January 2016|March 11, 2016|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738165||75336|
NCT01738438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-431|Cabozantinib for Metastatic Triple Negative BrCa|A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|February 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738438||75315|
NCT01743651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS440-3002|Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis|A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis||Osmotica Pharmaceutical Corp.|Yes|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|353|||Both|18 Years|65 Years|No|||May 2014|May 27, 2014|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743651||74914|
NCT01739699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH11-380|The Efficacy of Intravenous Acetaminophen During The Perioperative Period Of Neurosurgical Patients Undergoing Craniotomies|The Efficacy of Intravenous Acetaminophen During The Perioperative Period Of Neurosurgical Patients Undergoing Craniotomies||NorthShore University HealthSystem Research Institute|No|Recruiting|January 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|90 Years|No|||November 2012|November 29, 2012|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739699||75218|
NCT01740258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038098|Bevacizumab Beyond Progression (BBP)|Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)|BBP|Duke University|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740258||75175|
NCT01740271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEC100-01|A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients|Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy||AHS Cancer Control Alberta|Yes|Recruiting|December 2012|June 2025|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|No|||October 2014|October 1, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01740271||75174|
NCT01740284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-19|A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine|A Phase III Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|GT-19|ALK-Abelló A/S|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01740284||75173|
NCT01740297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110264|Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma|Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma||Amgen|Yes|Recruiting|February 2013|February 2019|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|219|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740297||75172|
NCT01745289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050408|Long-term Anastrozole Versus Tamoxifen Treatment Effects|Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)|LATTE|American Cancer Society, Inc.|No|Enrolling by invitation|October 2010|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|4337|||Female|18 Years|N/A|No|Non-Probability Sample|Post-menopausal women with breast cancer who were randomised to receive either anastrozole        or tamoxifen in the ATAC Trial and not known to have died or withdrawn consent before        April 1st 2009 over the age of 18, living in the United States are eligible for LATTE.|January 2015|January 21, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745289||74788|
NCT01745536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206-C-104-AC|Closed Vitrification of Oocytes|"Impact of a Closed System in Donor Oocyte Vitrification"||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Withdrawn|November 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Female|18 Years|50 Years|No|||March 2016|March 7, 2016|November 29, 2012||No|NO RECRUITMENT|No||https://clinicaltrials.gov/show/NCT01745536||74769|
NCT01746134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28264|The Management of Schizophrenia in Clinical Practice (MOSAIC)|A Prospective, Non-Interventional Registry of Diverse Patients With Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of Disease, Treatments, and Burden of Illness||Genentech, Inc.||Completed|December 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|557|||Both|18 Years|N/A|No|Probability Sample|Patients with schizophrenia, schizoaffective disorder, or schizophreniform across the        disease spectrum treated in usual care settings|March 2016|March 1, 2016|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01746134||74723|
NCT01746121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4266|Amelogenesis Imperfecta|Clinical and Molecular Study of Amelogenesis Imperfecta||University Hospital, Strasbourg, France|No|Recruiting|November 2009|||March 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|600|Samples With DNA|saliva|Both|N/A|N/A|No|Non-Probability Sample|The recruitment of patients comes from several sources. A first cohort of 40 families is        already followed by the reference center of Strasbourg. The reference center for rare        diseases dental manifestations of Strasbourg recruiting patients at regional,        interregional, national and international scale.|February 2013|February 4, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01746121||74724|
NCT01745250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1210|Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile|A Randomised, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile||Q-Med AB|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01745250||74791|
NCT01745263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2012-0249|DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial|Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH)|DO-HEALTH|University of Zurich|Yes|Active, not recruiting|December 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Anticipated|2152|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 22, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745263||74790|
NCT01745276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFX-2009378|Evaluation of Bisphosphonate Coated Pins for Extern Fixation in Tibia Osteotomy|Evaluation of Bisphosphonate Coated Pins for Extern Fixation in Tibia Osteotomy|PFX|Region Skane|Yes|Active, not recruiting|April 2011|February 2013|Anticipated|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|80 Years|No|||May 2012|December 7, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01745276||74789|
NCT01736501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001197|Surveying Parents About Genome Screening of Newborns|Surveying Parents About Genome Screening of Newborns|BabySeq|Brigham and Women's Hospital|No|Active, not recruiting|June 2012|August 2016|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|1101|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01736501||75464|
NCT01736514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMXALL-1001-TW|A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout|A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout||Astellas Pharma Inc|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|20 Years|65 Years|No|||October 2014|October 28, 2014|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736514||75463|
NCT01737307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZadUMS|Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy|Effect of Fluoride Varnish and CPP-ACP Paste on Oral and Salivary Symptoms of Patients Under Chemotherapy: A Double-blind Clinical Trial||Azad University of Medical Sciences|Yes|Completed|March 2011|December 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|30|||Both|12 Years|60 Years|No|||November 2012|November 27, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01737307||75402|
NCT01737320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0258-12-RMC|Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia|Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial||Rabin Medical Center||Recruiting|January 2013|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737320||75401|
NCT01738178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2778|Caffeine as a Therapy for Parkinson's Disease|Caffeine as a Therapeutic Agent in Parkinson's Disease||McGill University Health Center|Yes|Active, not recruiting|April 2014|||February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|45 Years|75 Years|No|||December 2015|December 7, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738178||75335|
NCT01739296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|839/2011|Lateral Wedge Insole With Subtalar Strapping for Knee Osteoarthritis|Lateral Wedge Insole With Subtalar Strapping for Knee Osteoarthritis: a Randomized Clinical Trial||University of Sao Paulo General Hospital|No|Completed|June 2011|July 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 10, 2013|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01739296||75249|
NCT01739309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13269|Study of LY2835219 for Mantle Cell Lymphoma|Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma||Eli Lilly and Company|No|Active, not recruiting|March 2013|January 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739309||75248|
NCT01738711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF Protocol 12/NE/0309|Does CBT Improve the Perception/Impact of Cough and Breathlessness in IPF Patients|Does Cognitive Behavioural Therapy (CBT) Delivered by a Respiratory Nurse Reduce Anxiety and the Impact of Cough and Breathlessness on Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF)?||Royal Victoria Infirmary|No|Not yet recruiting|December 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738711||75294|
NCT01743352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Comparison of Ultrafast Echo With Echotracking|Protocole ULTRAFAST - ECHOTRACKING : Remodelage pariétal et rigidité artérielle Chez l'Hypertendu : Nouvelle étude de Leur Relation Utilisant l'élastographie Par Ultrafast-écho et la séparation Intima/média Par écho-tracking||French Cardiology Society|No|Completed|March 2013|August 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|57|||Both|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting Essential untreated hypertension Healthy Volunteers|October 2015|October 1, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743352||74937|
NCT01743937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZUTSW|A Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans|A Randomized, Controlled, Open Label Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans|ETCH|University of Texas Southwestern Medical Center|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|74 Years|No|||December 2015|December 17, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743937||74892|
NCT01743950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11374|A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab|||University of Wisconsin, Madison|Yes|Recruiting|December 2012|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743950||74891|
NCT01739712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0733091|Sleep Intervention for Youth With Type 1 Diabetes|Students With Diabetes: Does Optimizing Sleep Promote Classroom, Behavioral, and Disease-Related Improvement||University of Arizona|No|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|10 Years|16 Years|No|||November 2012|November 29, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739712||75217|
NCT01739959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPH/NF/2000-2010|Exploratory Study of Raised Serum Lactate as a Marker of Necrotizing Fasciitis|Raised Serum Lactate as a Marker of Necrotizing Fasciitis; a Consecutive Prospective Review.||National Health Service, United Kingdom|No|Completed|September 2000|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|53|||Both|N/A|N/A|No|Non-Probability Sample|All patients referred to a single surgeon at one institution over 10 years (September 2000        - September 2010) with a suspected diagnosis of necrotizing fasciitis. Patients were        followed for the duration of their hospital stay.|November 2012|November 28, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01739959||75198|
NCT01739972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalterReedNMMC|Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment|Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.|DTE|Walter Reed National Military Medical Center|Yes|Recruiting|May 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||November 2012|December 3, 2012|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739972||75197|
NCT01739985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081228|Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis|Postoperative Vomiting in Children: Evaluation of the Addition of Droperidol to Conventional Bi-prophylaxis|VPOP2|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2010|May 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|322|||Both|3 Years|17 Years|No|||August 2013|July 25, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01739985||75196|
NCT01740622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-2903|Healthy Homes Healthy Children (H3C)|Healthy Homes Healthy Children (H3C)|H3C|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|October 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|520|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01740622||75147|
NCT01744977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01642|Cholesterol Medication Packaging Study|Evaluate the Efficacy, Perceptions and Cost of an Innovative Cholesterol Packaging|MWV_CAPS|Durham VA Medical Center|No|Completed|December 2012|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|245|||Both|18 Years|N/A|No|||July 2015|August 12, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744977||74812|
NCT01745302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH126|Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma|Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma: a Randomized Double-blind Controlled Clinical Trial||Shanghai University of Traditional Chinese Medicine|Yes|Enrolling by invitation|November 2011|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|470|||Both|18 Years|80 Years|No|Probability Sample|pulmonary adenocarcinoma patients with stage Ⅲa～Ⅳ; TCM syndromes are deficiency of Yin,        deficiency of Qi and deficiency of both Qi and Yin.|December 2012|May 12, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01745302||74787|
NCT01745315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|instruments in TLH|Comparison of Perioperative Outcomes of Three Different Instruments in Total Laparoscopic Hysterectomy|Comparison of the Use of LigaSure, Halo PKS Cutting Forceps and Enseal Tissue Sealer in Total Laparoscopic Hysterectomy: a Randomised Trial.||Adana Numune Training and Research Hospital|Yes|Not yet recruiting|February 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Female|N/A|N/A|No|||January 2013|January 29, 2013|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745315||74786|
NCT01745549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO01|Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.|Efficacy, Safety and Satisfaction of the New Pen Needle 33G x 4 mm 33G x 4 mm: Cross-over Randomized Controlled Clinical Trial. Studio AGO 01|AGO01|Consorzio Mario Negri Sud|No|Completed|December 2012|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745549||74768|
NCT01745562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116977|Bioequivalence Trial of Alprazolam 0.5 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations of Alprazolam 0.5 mg Alprazolam (Zamoprax GlaxoSmithKline México, S.A. de C.V. vs. Tafil 0.5mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745562||74767|
NCT01746147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLIVE-2012|Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial|Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in MDS or AML Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial|ALLIVE|GWT-TUD GmbH|No|Active, not recruiting|December 2012|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|134|||Both|18 Years|N/A|No|Non-Probability Sample|Men and women with AML or MDS according to WHO classification.|August 2015|August 19, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01746147||74722|
NCT01746342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSSC-G004|Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial|A Randomized, Controlled, Clinical Trial of Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Multiple Sclerosis|SAMSPAP|McGill University|No|Recruiting|February 2013|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||March 2013|March 3, 2013|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01746342||74708|
NCT01736527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808|Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation|Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% at 6, 9, 12, and 24 Hours Following a Single Instillation in Healthy Volunteers||Bausch & Lomb Incorporated|No|Completed|January 2013|April 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 27, 2013|November 27, 2012|No|Yes||No|August 27, 2013|https://clinicaltrials.gov/show/NCT01736527||75462|All 12 subjects were exposed to a single dose of LE Gel.
NCT01736774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG5580145|Exercise and Manipulative Therapy for Older Persons With Headache|A Randomized Controlled Trial of Exercise and Manipulative Therapy for Older Persons With Frequent Intermittent Headaches Associated With Neck Pain and Impairment||Chiang Mai University|No|Completed|December 2012|July 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|50 Years|75 Years|No|||January 2016|January 26, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01736774||75443|
NCT01737853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLE-GANFORT-001-4-2011|Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Comparison of Efficacy and Tolerability Between 2fixed Combinations for Treating Mexican Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: Ganforti vs Krytantek.A Phase IV,Examiner-masked Cross-over Multicenter Clinical Trial||Allergan S.A. DE C.V..|No|Completed|February 2011|June 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|90|||Both|N/A|N/A|No|Non-Probability Sample|The study will enroll 90 patients (45 per treatment group) to yield approximately 80        evaluable patients (40 per treatment group.        Sample size calculation will take into account the following assumptions:          -  standardized effect size of 0.60          -  2-sided α value of 0.01 and a β value of 0.10|November 2012|November 29, 2012|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01737853||75360|
NCT01738724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRPUSP-UROGIN-002|Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin|Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin||University of Sao Paulo|No|Not yet recruiting|January 2013|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|63|||Female|35 Years|55 Years|No|||November 2012|November 27, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01738724||75293|
NCT01735110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPARE|PREPARE：Assessing the Safety and Efficacy of Radial Versus Femoral Approach PCI|A Prospective, Multicenter, Randomized Trial Assessing the Safety and Efficacy of PCI Via Radial Versus Femoral Approach in Patients With Left Main and/or Three-Vessel Disease|PREPARE|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Withdrawn|March 2013|March 2018|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||December 2013|December 11, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735110||75571|
NCT01735123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1DP3DK094338-01|Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity|Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms|EDIA|Helsinki University|Yes|Recruiting|January 2013|April 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|12 Months|Accepts Healthy Volunteers|||March 2014|March 3, 2014|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735123||75570|
NCT01743716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002351|Genetic and Neural Predictors of Adolescent Depression|Towards Identification of Genetic and Neural Predictors of Adolescent Depression||Mclean Hospital|No|Recruiting|April 2013|||June 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|100|Samples With DNA|Adolescent participants will provide a saliva sample for DNA analysis.|Female|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include two adult and two adolescent cohorts. The adult cohort includes        two different groups of mothers: (a) MDD Mothers: Mothers with current or past major        depressive disorder and (b) Healthy Control Mothers: Mothers with no history of        psychopathology. The female adolescent cohorts are as follows: (c) High Risk Female        Adolescents: Healthy female adolescents aged 12-14 with a mother reporting past or current        MDD, (d) Healthy Female Adolescents: Healthy female adolescents aged 12-14 with a mother        reporting no history of psychopathology.|March 2016|March 14, 2016|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01743716||74909|
NCT01743963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176843|Intervention to Increase Screening for Glucocorticoid Induced Diabetes|Intervention to Increase Screening for Glucocorticoid Induced Diabetes|CDA-GID|VA Eastern Colorado Health Care System|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|90 Years|No|||June 2015|June 5, 2015|November 20, 2012||No||No|March 27, 2015|https://clinicaltrials.gov/show/NCT01743963||74890|
NCT01739725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03073|Study Evaluating the Helical Ureteral Stent|A Prospective Multicenter Clinical Trial to Evaluate the Comfort of the Percuflex Helical Ureteral Stent||University of British Columbia|Yes|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|19 Years|N/A|No|||February 2015|February 24, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739725||75216|
NCT01740310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057339|Vaccine Acceptance in Pregnant Minority Women|Vaccine Acceptance in Pregnant Minority Women||Emory University|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|121|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740310||75171|
NCT01744470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO2011/YL/ADEQUATE|Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)|Efficacy and Safety Outcome of Two Different Targets of Advagraf® Trough Levels Between 4 Months and 12 Months After Transplantation Among de Novo Renal Transplant Recipients.|ADEQUATE|University Hospital, Tours|Yes|Active, not recruiting|May 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|70 Years|No|||April 2014|April 7, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01744470||74851|
NCT01745341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25284|Rates of Apnea in Patients Undergoing Vitreoretinal Surgery|Rates of Apnea in Patients Undergoing Vitreoretinal Surgery||Stanford University||Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|99 Years|No|Non-Probability Sample|patients having vitreoretinal surgery under monitored anesthesia care|December 2015|December 2, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745341||74784|
NCT01745575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116981|Bioequivalence Trial of Alprazolam 2 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Trial With Single Dosageof Two Oral Preparations Containing 2 mg of Alprazolam (Zamoprax GlaxoSmithKline México, S.A. de C.V. vs. Tafil 2.0 mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745575||74766|
NCT01745588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-138|Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma|Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745588||74765|
NCT01744730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041855|Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile|Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (NICHD): CLIN01|CLIN01|Duke University|Yes|Completed|June 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|2 Years|17 Years|No|||November 2014|November 17, 2014|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744730||74831|
NCT01745614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117017|Bioequivalence Study of Nimesulide 100 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing Nimesulide 100 mg(Eskaflam®, GlaxoSmithKline México, S.A. de C.V. vs. Mesulid®, Producto de Roche, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|July 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745614||74763|
NCT01745874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247/12|Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging|Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment||University of Lausanne Hospitals|No|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|95 Years|No|Non-Probability Sample|patients with a rectal cancer|December 2012|December 7, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01745874||74743|
NCT01746355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG-01|Assessment and Treatment Patients With Atypical Facial Pain Trough Repetitive Transcranial Magnetic Stimulation|Assessment and Treatment Patients With Atypical Facial Pain Trough Repetitive Transcranial Magnetic Stimulation|EMTr-AFP|University of Sao Paulo|Yes|Completed|March 2011|January 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 24, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01746355||74707|
NCT01746368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 10-311|Enabling Advance Directive Completion|Enabling Advance Directive Completion by Rural Alabama Veterans: A Pilot Study|EADCRAV|VA Office of Research and Development|Yes|Completed|April 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 29, 2012||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01746368||74706|The local Institutional Review Board directed that the advance directive completion and satisfaction data for one participant randomized to the Nurse-Supported Advance Care Planning Intervention be excluded from analysis.
NCT01737333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOPM-101|Multidetector Computed Tomography (MDCT) Tailored Protocol|A Multicenter, Multinational, Randomized Study of Standard vs. Patient-Adapted Protocols in Multidetector Computed Tomography (MDCT) of the Chest, Abdomen, Liver or Aorta||Bracco Diagnostics, Inc|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1493|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing MDCT of the abdomen, liver, chest or aorta and receiving high        iodinated contrast agents|September 2013|September 27, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737333||75400|
NCT01737580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02574|Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists|Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists||University of British Columbia|Yes|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01737580||75381|
NCT01737593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001510|Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?|Can Acetaminophen PO Given 1-2 Hours Before Bilateral Myringotomy Tube (BMT) Placement Reduce Emergence Agitation (EA) in Children After General Sevoflurane Anesthesia?||University of California, Los Angeles|Yes|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|130|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737593||75380|
NCT01738477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116570|Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults|Evaluation of Immunogenicity and Safety of GSK Biologicals' Tdap Booster Vaccine (Boostrix™) in Young Adults, Administered 10 Years After Previous Tdap Boosting||GlaxoSmithKline||Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|165|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||January 2016|February 4, 2016|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738477||75312|
NCT01738971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol ECfe03|Initiating Contraception After Emergency Contraception From Pharmacy|Pharmacy Based Interventions for Initiating Effective Contraception Following the Use of Emergency Contraception : a Feasibility Study||University of Edinburgh|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|168|||Female|16 Years|45 Years|No|||August 2014|August 1, 2014|November 28, 2012||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01738971||75274|Loss to follow-up relatively high. Self-reporting of primary outcome measure (contraceptive method at time of follow-up). Would have been preferable to be able to validate this.Pharmacists unable to record demographic data of those not recruited.
NCT01739322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6022-PR-PRI-194|Biological Standardization of Platanus Acerifolia Allergen Extract|Biological Standardization of Platanus Acerifolia Allergen Extract to Determine the Biological Activity in HEP Units.||Laboratorios Leti, S.L.|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Both|18 Years|60 Years|No|||March 2013|November 8, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739322||75247|
NCT01739335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-04-11S|Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone||VA Office of Research and Development|Yes|Recruiting|November 2012|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|89 Years|No|||March 2016|March 15, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739335||75246|
NCT01735136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSAN-HP-BS|Efficacy and Safety of InSan Bamboo Salt on Improvement of Helicobacter Pylori Infection|||Chonbuk National University Hospital|Yes|Recruiting|November 2012|June 2013|Anticipated|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735136||75569|
NCT01743729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118-DRY-300|A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye|A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2)||Shire|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|720|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743729||74908|
NCT01739738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03027|The Impact of Ureteral Stents on Peristalsis|The Impact of Ureteral Stents on Peristalsis||University of British Columbia|No|Withdrawn|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who require unilateral insertion of a ureteral stent for the following        indications will be included in this clinical trial:          1. stone disease          2. localized tumor disease          3. hydronephrosis of unknown ethiology          4. patients who receive a prophylactic stent before a planned operation|February 2015|February 24, 2015|November 29, 2012||No|Study did not start|No||https://clinicaltrials.gov/show/NCT01739738||75215|
NCT01739998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOBO|Health Benefits of Functional Oil (Mega 3 Fatty Acids From Fish Oil) on Obese People|Randomized, Double-blind, Controlled Study to Evaluate the Efficacy of Omega 3 Fatty Acids on Different Inflammatory Markers in Obese Subjects With Dietary Intervention for Weight Lost|NOBO|Instituto de Investigación Hospital Universitario La Paz|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|52|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739998||75195|
NCT01744704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF0112|Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers|A Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Male and Female Volunteers|NGF0112|Dompé Farmaceutici S.p.A|No|Completed|July 2012|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|12||Actual|74|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744704||74833|
NCT01745016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1787|Effect of Beta-Alanine on Heart Rate Response|The Effect of 28 Days of Beta-alanine Supplementation on the Physical Working Capacity at Heart Rate Threshold (PWCHRT)||University of North Carolina, Chapel Hill|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|35|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745016||74809|
NCT01745861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP version 3 26-05-2011|Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients|Randomised Controlled Trial On The Effects Of Parenteral Fish Oil Emulsion In Patients With Severe Acute Pancreatitis||University Hospitals, Leicester|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|90 Years|No|||December 2012|December 7, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01745861||74744|
NCT01745887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-2|A Multi-Center Study Subjects With Dry Eye Syndrome|A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome|EBI|Eleven Biotherapeutics|No|Completed|November 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01745887||74742|
NCT01746160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1implantstability-HMO-CTIL|Longitudinal Follow-up After C1 Implant Stabilization Values|A Short-term Longitudinal Follow-up After C1 Implant Stability Values.||Hadassah Medical Organization|No|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 9, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01746160||74721|
NCT01737866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080676|Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency|An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics||Amgen|No|Completed|November 2012|May 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 9, 2013|October 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737866||75359|
NCT01738191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATM-Cog|Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)|Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)|ATM-Cog|Medical University of South Carolina|Yes|Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|75 Years|No|||March 2016|March 14, 2016|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738191||75334|
NCT01738204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00004267|The Women's Health Study: From Adolescence to Adulthood|The Women's Health Study: From Adolescence to Adulthood Sponsored by the Boston Center for Endometriosis.||Children's Hospital Boston|No|Recruiting|November 2012|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|urine, saliva, blood, tissue, peritoneal fluid|Female|7 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinic and community sample|January 2016|January 28, 2016|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738204||75333|
NCT01738490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33|Long-term Stability and Survival Rates of a Novel Oticon Medical Bone Conduction Device Implant|Long-term Stability and Survival Rates of a Novel Oticon Medical Bone Conduction Device Implant||Oticon Medical|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738490||75311|
NCT01738737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPESQ 455/11|Low-level Laser Therapy and Static Stretching in Knee Osteoarthritis.|Effect of Low-level Laser Therapy (904 nm) and Static Stretching in Patients With Knee Osteoarthritis: Randomised Controlled Trial.||University of Sao Paulo General Hospital|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|145|||Both|50 Years|75 Years|No|||September 2015|November 6, 2015|August 28, 2012||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01738737||75292|
NCT01735188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-MCD-502|A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies|A Natural History Study Of Molybdenum Cofactor And Isolated Sulfite Oxidase Deficiencies||Alexion Pharmaceuticals|No|Active, not recruiting|August 2013|April 2016|Anticipated|November 2015|Actual|N/A|Observational|N/A||2|Actual|65|Samples With DNA|Plasma, urine, whole blood|Both|N/A|N/A|No|Non-Probability Sample|The actual sample size will depend on successful identification of at least 30 MoCD Type A        patients|February 2016|February 17, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735188||75565|
NCT01738984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9R42DA031402|A Home Exercise Program for Women With Infants & Young Children|A Home Exercise Program for Women With Infants & Young Children|MamaMove|University of Hawaii|Yes|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|502|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738984||75273|
NCT01739348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07738|An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)|A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)|EPOCH|Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|November 2012|July 2019|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1960|||Both|55 Years|85 Years|No|||October 2015|October 30, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739348||75245|
NCT01747980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-112-01|Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients|An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients||Protalix|No|Completed|March 2013|March 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01747980||74582|
NCT01748201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0199/11|Viscosupplementation in Patients With Hemophilic Arthropathy|Viscosupplementation in Patients With Hemophilic Arthropathy||University of Sao Paulo General Hospital|Yes|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||September 2013|September 9, 2013|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748201||74565|
NCT01744197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12112|Synera Venipuncture Pain|Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures||US Oncology Research|No|Completed|January 2013|November 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|December 4, 2012|Yes|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT01744197||74872|
NCT01744990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER12-020|Tree Nuts Allergies: Does a Single Nut Allergy Necessitate the Dietary Eviction of Other Tree Nuts?|Tree Nuts Allergies: Does a Single Nut Allergy Necessitate the Dietary Eviction?|ProNut|University Hospital, Geneva|No|Recruiting|October 2012|January 2016|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|12 Months|16 Years|No|||December 2012|December 7, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01744990||74811|
NCT01745328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJUTI|Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine|Study on Treatment of Recurrent Urinary Tract Infection by Traditional Chinese Medicine||Beijing Institute of Disease Control and Prevention|No|Recruiting|January 2009|July 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||December 2012|December 7, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745328||74785|
NCT01745380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 3-03|Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults|A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Placebo for Anesthetizing Maxillary Teeth in Adults||St. Renatus, LLC|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745380||74781|
NCT01745042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150949/2011-1|Anthropometric, Metabolic, Cardiovascular and Symptomatic Profile in Postmenopausal Women|Impact of Fat Distribution on Metabolic, Cardiovascular and Symptomatic Aspects in Postmenopausal Women||University of Sao Paulo|Yes|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|45|||Female|50 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausal women from a community sample of São Carlos city - São Paulo State -        Brazil.|December 2012|December 5, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01745042||74807|
NCT01744483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42230-A|Endotracheal Tubes for Prevention of Ventilator-associated Pneumonia|Pilot Trial of Tubes to Prevent Ventilator-Associated Pneumonia (PreVent)|PreVent|University of Washington|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744483||74850|
NCT01744496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0004|Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain|A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain|DOLORES|UCB Pharma|No|Completed|November 2012|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|December 5, 2012|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01744496||74849|
NCT01745354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT235|Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)|Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation||Stanford University|Yes|Recruiting|August 2012|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01745354||74783|
NCT01745367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-12-204|Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer|BATON-BC|AVEO Pharmaceuticals, Inc.|Yes|Terminated|November 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||June 2015|June 22, 2015|December 6, 2012|Yes|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT01745367||74782|
NCT01745003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041993|Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia|Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia||University of Michigan|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Female|18 Years|65 Years|No|||December 2015|December 1, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01745003||74810|
NCT01745601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117003|Bioequivalence Study of Escitalopram Tablets 10 mg|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations in Tablets Containing Escitalopram 10 mg (Product From GlaxoSmithKline México, S.A. de C.V. vs. Lexapro® 10mg, Lundbeck México, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745601||74764|
NCT01746433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/EVFN-02|Mobility of Elderly Patients When Using the "l'Ergonome" Mobility Device|Evaluation of the Mobility of Elderly Patients (> 65 Years) When Using the "l'Ergonome" Mobility Device: a Randomized, Monocentric Study|L'ERGONOME|Centre Hospitalier Universitaire de Nīmes|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|37|||Both|65 Years|N/A|No|||March 2015|March 25, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746433||74701|
NCT01746173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-388|CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma|A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma||Dana-Farber Cancer Institute|Yes|Terminated|February 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||August 2015|August 7, 2015|December 4, 2012|Yes|Yes|Slow accrual and futility|No||https://clinicaltrials.gov/show/NCT01746173||74720|
NCT01737879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110209|Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis|Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis||Amgen|No|Terminated|October 2012|July 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|October 3, 2012|Yes|Yes|Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted    prematurely and will not resume; participants are no longer being treated|No|March 14, 2014|https://clinicaltrials.gov/show/NCT01737879||75358|
NCT01737892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-B4|Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults|Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)||Amphastar Pharmaceuticals, Inc.|No|Terminated|November 2012|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 20, 2012|Yes|Yes|unable to validate analytical method|No||https://clinicaltrials.gov/show/NCT01737892||75357|
NCT01738217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPATOFLUO|Assessment of Indocyanine Green as a Near-Infrared Fluorescent Contrast Agent for Image-guided Liver Surgery|Evaluation, for Patients Requiring a Liver Cancer Surgery, of the Use of Fluorescence Imaging Device: Faisability and Efficiency of Lesional and/or Anatomical Marking|HEPATOFLUO|Centre Leon Berard|Yes|Completed|April 2013|June 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01738217||75332|
NCT01738230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPI 007|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||August 6, 2013|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738230||75331|
NCT01739361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAP-121486|Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis|Phase IIa Randomized Controlled Trial of Acetaminophen for the Reduction of Oxidative Stress in Severe Sepsis|ACROSS|Vanderbilt University|Yes|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|November 26, 2012||No||No|March 11, 2015|https://clinicaltrials.gov/show/NCT01739361||75244|
NCT01739374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA5969|Efficacy and Safety of Reduced Pelvic Floor Mesh Implants|Phase 2-3 Study of Efficacy and Safety of Reduced Pelvic Floor Mesh Implants||Western Galilee Hospital-Nahariya|No|Completed|May 2013|March 2015|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|35 Years|95 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01739374||75243|
NCT01735201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-002|AGN-199201 for the Treatment of Erythema With Rosacea|||Allergan|No|Completed|December 2012|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|357|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|November 26, 2012|Yes|Yes||No|May 2, 2014|https://clinicaltrials.gov/show/NCT01735201||75564|
NCT01735214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/037|An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments|||Allergan|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|358|||Both|18 Years|N/A|No|Non-Probability Sample|POAG or OHT|May 2015|May 20, 2015|November 26, 2012||No||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01735214||75563|
NCT01735461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02525|Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients|Oral Calcium Supplementation, a Strategy to Reduce Kidney Stones in Crohn's Patients Living With a Small Bowel Resection||University of British Columbia|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|19 Years|N/A|No|||December 2015|December 10, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735461||75544|
NCT01735708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR13438|Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings|Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings|HIVPASS|Butler Hospital|Yes|Completed|November 2012|August 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|75 Years|No|||September 2015|November 10, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735708||75525|
NCT01747993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 101005|Tamsulosin for Urinary Retention in Hospitalized Older Women|Tamsulosin to Facilitate Early Catheter Removal After Urinary Retention in Older Women Hospitalized for an Acute Medical Condition|TAMSU|Assistance Publique - Hôpitaux de Paris|No|Terminated|January 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|75 Years|N/A|No|||October 2014|October 1, 2014|December 10, 2012||No|low inclusion|No||https://clinicaltrials.gov/show/NCT01747993||74581|
NCT01748214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13164|Premature Infant Exposure to Noise Generated by Respiratory Support|Premature Infant Exposure to Noise Generated by Respiratory Support||University of Virginia|No|Completed|November 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|28|||Both|N/A|N/A|No|Non-Probability Sample|Infants born < 32 weeks, in an incubator, and > 7 days postnatal admitted to the Newborn        Intensive Care Unit|December 2012|December 10, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01748214||74564|
NCT01744717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCID-02|Validation of "Escala de Conductas Indicadoras de Dolor" ESCID Scale for Measuring Pain in Critically Ill Patients|"Estudio multicéntrico de Validez y Fiabilidad de la Escala de Conductas Indicadoras de Dolor ESCID Para Medir el Dolor en Pacientes críticos, no Comunicativos y Sometidos a ventilación mecánica"|ESCID-MQ|Puerta de Hierro University Hospital|No|Active, not recruiting|November 2012|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients who are uncommunictive, receiving mechanical ventilation and undergoing any        of the study procedures. Consent to participate will be requested to the family of the        patient. Adults age 18 and over will be eligible for the study if they meet study        inclusion criteria and don't meet any exclusion criteria.|January 2016|January 28, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01744717||74832|
NCT01745406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP/107-11|Benefits of the Involvement of Nurses in Meetings Between Physicians and the Families of Patients in the ICU.|Benefits of the Involvement of Nurses in Meetings Between Physicians and the Families of Patients in the ICU.|NEWS|Groupe Hospitalier Paris Saint Joseph|Yes|Completed|January 2013|October 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Families of patients hospitalized in ICU.|April 2013|August 6, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01745406||74779|
NCT01745653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD11/3-J|Effect of Low Level Laser Therapy on Pain Occurring After Insertion of an Orthodontic Device|Monocentric, Randomized, Single Blinded Study Designed to Evaluate the Effect of Low Level Laser Therapy on Pain Occurring After Insertion of an Orthodontic Device : the "Quadhelix"|Ortholaser|Nantes University Hospital|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|69|||Both|8 Years|15 Years|No|||February 2013|February 4, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01745653||74760|
NCT01745900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-240|Evaluation and Comparison of Noninvasive Blood Glucose Concentrations|An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References||VeraLight, Inc.|No|Recruiting|December 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|125|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females 18-50 years of age selected from the community 30% with no history of Diabetes 70%        with diagnosis of Type I, Type II or Gestational Diabetes|December 2012|December 6, 2012|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745900||74741|
NCT01745627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN11-PICO_RG2_PL|755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars|||Cynosure, Inc.|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745627||74762|
NCT01745640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_52|Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)|A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02|IFM2010-02|University Hospital, Lille|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|19 Years|N/A|No|||December 2015|December 3, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745640||74761|
NCT01746199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum|Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study)|MACOMBA|Institut Pasteur|Yes|Not yet recruiting|December 2013|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|N/A|No|||December 2012|November 14, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01746199||74718|
NCT01746446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38632|LifeCourse: A Supportive Care Approach for Patients Late in Life|LifeCourse: A Supportive Care Approach for Patients Late in Life||Allina Health System|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1200|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01746446||74700|
NCT01737905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-D2|Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma|Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma (A Randomized, Double-Blind, Placebo-Controlled, Crossover, Single Dose Study in 4 - 11 Year Old Children With Asthma)||Amphastar Pharmaceuticals, Inc.|No|Completed|October 2012|December 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|4 Years|11 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737905||75356|
NCT01737918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URGE-II|Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa|Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence|URGE-II|Klinikum der Universität Köln|Yes|Recruiting|January 2013|July 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|40 Years|85 Years|No|||April 2015|April 6, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01737918||75355|
NCT01737931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-12-002|A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject|An Open-Label Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject||Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2012|November 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|November 25, 2012||No||No|February 9, 2014|https://clinicaltrials.gov/show/NCT01737931||75354|
NCT01738243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE#12-003174|Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease|Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease|HALR|University of California, Los Angeles|Yes|Recruiting|December 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|65 Years|No|||December 2014|December 2, 2014|October 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738243||75330|
NCT01738503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-12-0005|Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects|Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects||Indivior Inc.|No|Completed|September 2012|March 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|124|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738503||75310|
NCT01739387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFL9501|A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)|A Randomised, Open-label, Cross-over Study of Flutiform® BAI and Flutiform® pMDI Devices in Adolescents and Adult Subjects With Persistent Asthma or Chronic Obstructive Pulmonary Disease (COPD) to Assess Patient Handling.||Mundipharma Research Limited|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|332|||Both|12 Years|N/A|No|Probability Sample|Asthmas and COPD patients aged 12 and above obtained from primary care and advertising in        Glasgow and Belfast areas.|June 2013|June 27, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01739387||75242|
NCT01735227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH2012-9-20|Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)|Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials||Shenyang Northern Hospital|Yes|Not yet recruiting|November 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|620|||Both|18 Years|75 Years|No|||November 2012|November 27, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01735227||75562|
NCT01735474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0035UG|Results of Manual Therapy on Pulmonary Parameters|Manual Therapy Results on Pulmonary Function and Musculoskeletal Movement||Universidad de Granada|Yes|Active, not recruiting|November 2012|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01735474||75543|
NCT01735721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86319|Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Augmentation|Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Elevation Using Piezoelectric Surgery||Mashhad University of Medical Sciences|Yes|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01735721||75524|
NCT01735734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN|Assessing the Effects of Air-cooling on Capillary Malformations|An Observational Study as to the Effects of Cutaneous Air-cooling on Blood Vessel Diameter in Capillary Malformations||National Health Service, United Kingdom|No|Not yet recruiting|February 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Capillary Malformation identified through our department database|November 2012|November 25, 2012|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735734||75523|
NCT01744015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6291965|Influence of Patient-Informed Choice in a Novel Treatment Model for LBP|Influence of Patient-Informed Choice in a Novel Treatment Model for LBP: A Randomized Controlled Trial||Walsh University|No|Withdrawn|April 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|July 9, 2013|December 2, 2012||No|We did not receive funding|No||https://clinicaltrials.gov/show/NCT01744015||74886|
NCT01744509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-2011|PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program|PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening (CRC) Program: Comparison With a New Integrated Reference Standard||Valduce Hospital|No|Recruiting|March 2011|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|35|||Both|50 Years|85 Years|No|||December 2012|December 5, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01744509||74848|
NCT01744210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP081412|Evaluation of Blood Flow Patterns in Lung Blood Vessels Using Ultrasound Technique in Patients With Congestive Heart Failure|Evaluation of Pulmonary Blood Flow Patterns Using Transthoracic Doppler in Patients With Congestive Heart Failure||Echosense Ltd.|No|Withdrawn|September 2012|July 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|CHF patients admitted to the cardiology telemetry unit and to the CCU|August 2012|June 24, 2014|December 2, 2012||No|Decided not tostart study because of unavailability of staff|No||https://clinicaltrials.gov/show/NCT01744210||74871|
NCT01744223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-HM-001|Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant|A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)||Bellicum Pharmaceuticals|No|Recruiting|March 2013|December 2016|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|65 Years|No|||September 2014|September 17, 2014|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01744223||74870|
NCT01745419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0121-CTIL|Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators|Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators||Carmel Medical Center|No|Not yet recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|Samples Without DNA|3 ml of Serum will be collected from each patient|Both|40 Years|90 Years|No|Probability Sample|Patients with COPD|December 2012|December 19, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745419||74778|
NCT01745965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06/ADAPT HER2+/HR+|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.|ADAPT; T-DM1|West German Study Group|Yes|Active, not recruiting|November 2012|October 2020|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|380|||Female|18 Years|N/A|No|||June 2015|June 18, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01745965||74736|
NCT01745393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA158361|Kids Safe and Smokefree (KiSS)|Pediatrician Advice, Family Counseling & SHS Reduction for Underserved Children|KiSS|Temple University|Yes|Active, not recruiting|March 2012|February 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|325|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01745393||74780|
NCT01745666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0160|Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients|Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients With KCNQ1 or KCNH2 Mutation Without Long QT Interval in Rest ECG|QT long|Nantes University Hospital|No|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|130|||Both|15 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 23, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745666||74759|
NCT01745679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12-0171|Pharmacological Study of High Doses of Ceftriaxone in Meningitidis|Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections.||Nantes University Hospital|Yes|Recruiting|December 2012|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01745679||74758|
NCT01746186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB2010|The Energy Balance Study|||University of South Carolina||Completed|October 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 400 participants will take part in the Energy Balance Study; 200 men and 200        women from 2 age groups: Ages 21-27 and Ages 28-35. A subsample of 200 will be randomized        for doubly labeled water recruitment.|February 2016|February 26, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01746186||74719|
NCT01746420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTI-2010-02|Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis|A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis||BioMimetic Therapeutics|Yes|Recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|100|||Both|21 Years|80 Years|No|||December 2012|December 10, 2012|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746420||74702|
NCT01747395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRESP814/10|Exercise Training Associated With Inspiratory Muscle Training in Heart Failure|Effects of Aerobic Exercise Training Associated With Inspiratory Muscle Training in Patients With Heart Failure||University of Sao Paulo General Hospital|Yes|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|30 Years|70 Years|No|||December 2014|December 8, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01747395||74627|
NCT01747408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21012|Treatment of Subarachnoid Hemorrhage With Human Albumin|Treatment of Subarachnoid Hemorrhage With Human Albumin|ALISAH|Baylor College of Medicine|Yes|Terminated|June 2006|May 2011|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|80 Years|No|||December 2012|December 10, 2012|June 23, 2011|Yes|Yes|The study met the pre-specified criteria for stopping the trial|No||https://clinicaltrials.gov/show/NCT01747408||74626|
NCT01747421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-04-2012|Validation of a High-risk Versus Low-risk Referral Model in Suspected Acute Coronary Syndrome|||University of Southern Denmark|No|Completed|March 2009|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|495|||Both|15 Years|N/A|No|Non-Probability Sample|all acute admission to Emergency Department with the complaint Chestpain|December 2012|December 7, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747421||74625|
NCT01744145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255021-4|Effect of Exercise and Education After Pneumonia|Early Pneumonia Intervention to Prevent Chronic Complications in Patients Age 40 and Above|EPICC|Winthrop University Hospital|No|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|120|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01744145||74876|
NCT01747369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PneumoTone|Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013|||Agence de Médecine Préventive, France|No|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood, cerebro-spinal fluid, nasal aspirate|Both|N/A|N/A|No|Non-Probability Sample|Pneumonia surveillance:        -residents of Tône sanitary district requiring hospitaliation for suspected pneumonia and        presenting at one of the hospitals of Dapaong town (district capital)        Meningitis surveillance:        - residents fo Tône sanitary district presenting with suspected meningitis at one of the        hospitals of Dapaong town (district capital) or Sinkasse health center|December 2012|December 10, 2012|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01747369||74629|
NCT01747382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKFRC/2011/07/26|Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease|Catheter-based Renal Sympathetic Nerve Ablation for Treatment-resistant Hypertension in Patients With Chronic Kidney Disease||Singapore General Hospital|No|Recruiting|April 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|65 Years|No|||December 2012|December 10, 2012|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01747382||74628|
NCT01717937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVOCT-12-10060|Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging|Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in the Imaging of Retinovascular Disease|PVOCT|University of California, San Francisco|No|Terminated|February 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|13 Years|N/A|No|Non-Probability Sample|Consecutive patients seen in the University of California, San Francisco Retina Clinic        with suspected or established retinovascular disease and who are scheduled to undergo        fluorescein angiography as part of their normal clinical evaluation.|September 2014|September 3, 2014|October 28, 2012||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01717937||76883|
NCT01718197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARP-SF|Severe Asthma Research Program (SARP)- San Francisco Clinical Site|Clinical and Molecular Phenotypes of Severe Asthma|SARP|University of California, San Francisco|Yes|Active, not recruiting|November 2012|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|749|Samples With DNA|Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell      Pellet Bronchoscopy: BAL, Bronchial Brushings, Bronchial Biopsy|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A diverse sample of subjects with asthma is needed to gain better understanding of asthma        and its endotypes. SARP will therefore enroll subjects 6 years and older with a physician        diagnosis of asthma. The target recruitment goal for each center is 75% adults (age 18 and        older) and 25% children age 6-17 years. Within the pediatric age group, an attempt will be        made to enroll equal numbers of children 6-11 and 12-17 years of age. Similarly, an        attempt will be made to enroll at least 50% females and 30% minorities.|March 2015|March 4, 2015|October 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01718197||76863|
NCT01718483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-343|SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder||Shire|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|383|||Both|18 Years|55 Years|No|||August 2014|November 3, 2015|October 29, 2012|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01718483||76841|
NCT01718795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prehospital LTS vs. BVM|Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR|Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR- A Prospective, Controlled, Randomised, Multi-center Trial||Medical University Innsbruck|No|Terminated|September 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 7, 2012||No|Recruiting too slow, down to 1-0 patients per month|No||https://clinicaltrials.gov/show/NCT01718795||76818|
NCT01719029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0283|Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes|Role of Macronutrient Diet Composition on Maternal and Infant Metabolic Outcomes in Gestational Diabetes||University of Colorado, Denver|No|Completed|August 2007|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Female|18 Years|40 Years|No|||June 2015|June 8, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719029||76800|
NCT01752049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVMC 6207|Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept|Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept||St. Michael's Hospital, Toronto|No|Recruiting|May 2013|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752049||74270|
NCT01752062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML1012|Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors|Observational Study of Conception/Pregnancy in Adult Patients With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors|CML1012|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Adult (>18 years old) patients with a diagnosis of chronic myeloid leukemia (CML) who had        been pregnant / had conceived while diagnosed with CML and treated with TKIs.|December 2014|December 10, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752062||74269|
NCT01719510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111008|Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis|Study of the Digestive Colonization of the Newborn Children by the Streptococcus of the Group B|Col-Strepto B|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|900|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719510||76763|
NCT01719289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq 575320/2008-7|Efficacy of a Program for the Management of Depression in Pregnant Women in Primary Care in São Paulo, Brazil|Cluster Randomised Controlled Trial of a Primary-care Based Intervention to Improve Depressive Symptoms of Pregnant Women in Sao Paulo, Brazil|PROGRAVIDA|University of Sao Paulo General Hospital|No|Recruiting|March 2011|September 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||October 2012|October 31, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719289||76780|
NCT01736085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121218|Providing Free Nicotine Patches to Quitline Smokers|Distribution of Voucher vs. Direct Mailing of Nicotine Patches to Quitline Smokers||University of California, San Diego|No|Completed|April 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|3710|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01736085||75496|
NCT01736098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Energy Flux|The Energy Flux Study|Evaluation of Energy Balance at High vs. Low Energy Flux - Energy Flux Study||University of South Carolina|Yes|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|81|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01736098||75495|
NCT01745783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMMo/EM/2010|Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis|Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|January 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|No|||December 2015|December 11, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01745783||74750|
NCT01746030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207060|Geriatric Assessments in Senior Adults With Multiple Myeloma|Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma||Washington University School of Medicine|No|Completed|September 2012|July 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|42|||Both|65 Years|N/A|No|Non-Probability Sample|Bone Marrow Transplant Clinic at Siteman Cancer Center|November 2015|November 19, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01746030||74731|
NCT01736930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO1|An Outpatient Pump Shutoff Pilot Feasibility and Safety Study|Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension: An Outpatient Pilot Feasibility and Safety Study|PSO1|In Home Closed Loop Study Group|Yes|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|November 20, 2012|Yes|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01736930||75431|
NCT01737177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL R2-B|Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL|Bendamustine, Lenalidomide and Rituximab (R2-B) Combination as a Second-Line Therapy for First Relapsed-Refractory Mantle Cell Lymphomas: A Phase II Study|R2-B|Fondazione Italiana Linfomi ONLUS|No|Recruiting|April 2012|April 2017|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||November 2012|June 12, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737177||75412|
NCT01737190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0161-12-WOMC|PEEP Guided by Esophageal Balloon Measurement and Its Effect on Recruitment Maneuver|PEEP Guided by Esophageal Balloon Measurement and Its Effect on Recruitment Maneuver||Wolfson Medical Center|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737190||75411|
NCT01746251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-504|Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation|Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation||Massachusetts General Hospital|Yes|Recruiting|January 2013|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746251||74714|
NCT01746550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-12-001|A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese Patients|A Single Arm Clinical Trial in Japan for Reconstruction of Obstructive Lesions of the Superficial Femoral Artery or Proximal Popliteal Artery by Bard LifeStent.|Reliable|C. R. Bard|No|Active, not recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|20 Years|N/A|No|||March 2016|March 14, 2016|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746550||74692|
NCT01746238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-396|Bevacizumab/Doxorubicin/Radiation for Sarcoma|Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma||Massachusetts General Hospital|Yes|Recruiting|March 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746238||74715|
NCT01747135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130001|Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease|Intracerebroventricular 2-Hydroxypropyl-B-Cyclodextrin in Patients With Niemann-Pick Disease, Type C1||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|25 Years|No|||July 2015|January 12, 2016|December 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747135||74647|
NCT01747434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-05-2012|Complaints and Presumptive Diagnosis in a Danish Emergency Department|||University of Southern Denmark|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10070|||Both|N/A|N/A|No|Probability Sample|all acute admissions to a Danish Emergency Department in 2010|December 2012|December 7, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747434||74624|
NCT01747902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:113|Biceps Tenodesis Versus Tenotomy|Biceps Tenodesis Versus Tenotomy in the Treatment of Lesions of the Long Head of Biceps Brachii: a Randomized Controlled Trial|BicepsTvsT|Panam Clinic|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01747902||74588|
NCT01748149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#120819|Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas|PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas||University of California, San Francisco|Yes|Recruiting|February 2014|June 2018|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|N/A|25 Years|No|||November 2015|November 30, 2015|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748149||74569|
NCT01744158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC2202/8/12|Exploring Hypertonia in Children With Cerebral Palsy|Exploring Hypertonia in Children With Cerebral Palsy- a Population-based Approach.|HypE-CP|Women's and Children's Hospital, Australia|No|Recruiting|March 2011|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|2 Years|18 Years|No|Non-Probability Sample|Subjects will be those with cerebral palsy attending Rehabilitation clinics at the Women's        and Children's Hospital.|December 2012|December 4, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01744158||74875|
NCT01744405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACT-NIFURTIMOX|Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease|Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease|LACTNFX|Hospital de Niños R. Gutierrez de Buenos Aires|No|Completed|December 2012|March 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|breastmilk; plasma|Female|18 Years|40 Years|No|Non-Probability Sample|Population of young women with Chagas disease referred to our center for evaluation and        treatment|March 2015|March 17, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744405||74856|
NCT01722162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303043|Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer|Phase II Study of Levocetirizine in Combination With Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients With Refractory Colorectal Cancer||Washington University School of Medicine|No|Active, not recruiting|April 2013|December 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722162||76560|
NCT01722175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209123|Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer|Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Portal Vein Occlusion (PVO) to Induce Liver Regeneration for Resection of Liver Tumors That Are Unresectable in One Step - a Randomized Controlled Trial|ALPPS|Washington University School of Medicine|No|Withdrawn||January 2019|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 21, 2014|November 2, 2012||No|Safety concerns.|No||https://clinicaltrials.gov/show/NCT01722175||76559|
NCT01718210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC0005|Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure|GM-CSF Supplemented Medium for IVF Embryo Growth in Patients With Recurrent Implantation Failure||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|December 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|40 Years|No|||February 2015|February 3, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01718210||76862|
NCT01718496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2844|Morphine, Dyspnea, Exercise and COPD|Physiological Mechanisms of Dyspnea Relief and Improved Exercise Tolerance After Treatment With Oral Morphine in Patients With Advanced Chronic Obstructive Pulmonary Disease (COPD).||McGill University Health Center|Yes|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||September 2015|September 22, 2015|October 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718496||76840|
NCT01719055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7007|RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain|A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain|RELIEF|Boston Scientific Corporation|No|Recruiting|May 2013|December 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4800|||Both|18 Years|N/A|No|Probability Sample|Subjects who exhibit an on-label indication for neurostimulation to relieve chronic        intractable pain, according to the Directions for Use, as applicable in each country or        region|December 2015|December 3, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719055||76798|
NCT01718444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006213|Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)|Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS)||University of Illinois at Chicago|No|Recruiting|March 2015|January 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Female|18 Years|40 Years|No|||December 2015|December 7, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01718444||76844|
NCT01718756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/55|Continuous Lornoxicam Infusion for Orthopaedic Surgery|Efficacy of Continuous Intravenous Infusion vs. Scheduled Dosing of Lornoxicam on Patient Controlled Morphine Consumption After Orthopaedic Surgery: A Comparative Placebo Study||Mansoura University|Yes|Recruiting|June 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|55 Years|No|||March 2015|March 15, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01718756||76821|
NCT01718769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC206-2011KCTIL|Validation of the STAMP Screening Tool For Pediatric Nutritional Risk|Validation of the STAMP Screening Tool For Pediatric Nutritional Risk To Be Used in the Ambulatory Setting.|STAMP2|Meir Medical Center|No|Completed|October 2012|March 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|1 Year|6 Years|No|||April 2015|April 26, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01718769||76820|
NCT01719562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99112|MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy|Early Imaging Detection of Cardiovascular Injury After Cancer||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|January 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|22 Years|N/A|No|||September 2015|September 22, 2015|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01719562||76759|
NCT01744860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28471|Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples|Evaluation of Concordance Between the Cobas® BRAF V600 Mutation Assay and the Methods Used in INCa Platforms for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting||Hoffmann-La Roche||Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|420|||Both|N/A|N/A|No|Probability Sample|No patients are enrolled in this study. Use of melanoma tumor samples.|November 2015|November 2, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01744860||74821|
NCT01744873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-12/148|Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition.||IPCA Laboratories Ltd.|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744873||74820|
NCT01746576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16422|Use of Near Infrared Spectroscopy to Measure Intracranial ScvO2|||University of Virginia|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|April 15, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01746576||74690|
NCT01746589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS200SVR-10-2011|Visual Outcomes and Contrast Sensitivity After Myopic LASIK|Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser||Durrie Vision|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 25, 2013|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746589||74689|
NCT01746862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-533|A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)|A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature||Merck KGaA||Completed|January 2013|July 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|5 Years|N/A|No|||July 2015|July 20, 2015|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746862||74668|
NCT01745445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-PQS-201205001|Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)|Phase ⅡClinical Trial of Randomized Concurrent Chemoradiotherapy or Radiotherapy Alone for Local-advanced Small Cell Lung Cancer After Induced Chemotherapy|SCLC|Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|17 Years|75 Years|No|||January 2012|December 21, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745445||74776|
NCT01745731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/RH/2009|Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration|Clinical Trial Phase II Multicenter Open Randomized Trial of the Therapeutic Use of Cells Intraportal Infusion of Autologous Bone Marrow Mononuclear as Enhancing Liver Regeneration Prior to Performing Extended Hepatic Resection.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|March 2011|December 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01745731||74754|
NCT01745744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMAd/ICC/2009|Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.|Clinical Trial Phase I / II, Multicentre, Open, Randomized Study of the Use of Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Critical Chronic Ischemic Syndrome of Lower Limb in Nondiabetic Patients.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|89 Years|No|||October 2015|October 20, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01745744||74753|
NCT01746849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-077|Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Study of Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746849||74669|
NCT01746823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNKC-2011|Identification and Validation of Functional Biomarkers for Keratoconus|Identification of Disease Progression Specific Biomarkers and Their Pharmacologic Modulation for Keratoconus.||Narayana Nethralaya|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Tear samples and discarded epithelium from Keratoplasty surgeries.|Both|10 Years|80 Years|No|Non-Probability Sample|Patients detected with corneal thinning by keratometry at a tertiary level hospital|December 2012|March 5, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746823|6 Months|74671|
NCT01746836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0669|Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib|Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2013|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746836||74670|
NCT01747668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL05|Lactation Fortification Study|Impact of Nutrient Supplementation on Breast Milk Levels of Lactating Women||Abbott Nutrition|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747668||74606|
NCT01748162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00059385|Management of Recurrent Croup|Management of Recurrent Croup: Comparison Between Inhaled Fluticasone and Oral Prednisolone||University of Michigan|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|6 Months|15 Years|No|||November 2015|November 2, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01748162||74568|
NCT01744431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thrombin generation|Can Thrombin Generation Measurement Predict the Risk of Venous Thromboembolism in Acute Ill Patients|||HaEmek Medical Center, Israel|Yes|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|300 hospitalized patients|December 2015|December 15, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744431|1 Day|74854|
NCT01744444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.737|Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis|||Hospices Civils de Lyon|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01744444||74853|
NCT01717950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-12-01|Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® in Healthy Adults||Albert B. Sabin Vaccine Institute|Yes|Completed|September 2013|September 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|October 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01717950||76882|
NCT01718522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_DB_1|RANSuP Registerstudie|Registerstudie: Anwendung Und Nutzen Der Sensorunterstützten Pumpentherapie (SuP) Unter Alltagsbedingungen (RANSuP)|RANSuP|Medtronic Bakken Research Center|No|Completed|February 2012|January 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|6 Years|69 Years|No|Probability Sample|Type 1 diabetes mellitus|February 2014|February 17, 2014|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01718522||76838|
NCT01718808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/10|Cetuximab for Elderly Patients With mCRC|Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|November 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|70 Years|N/A|No|||January 2015|January 18, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01718808||76817|
NCT01718535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01001679|Method Comparison Study of the Spartan FRX CYP2C19 Genotyping System Against Bi-directional Sequencing|Method Comparison Study of the Spartan FRX CYP2C19 *2, *3, and *17 Genotyping System||Spartan Bioscience Inc.|Yes|Completed|September 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|327|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|320 Individuals with undetermined CYP2C19 *2 *3 and *17 Genotypes|May 2013|May 28, 2013|October 29, 2012||No||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01718535||76837|
NCT01718821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ER-101-134|Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients|Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients||National Cheng Kung University|No|Completed|September 2012|September 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|50|||Both|20 Years|N/A|No|Probability Sample|Admitted patients or out patients in National Cheng Kung University Hospital (a medical        center)|September 2014|September 24, 2014|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01718821||76816|
NCT01718782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN4111 292/4.23|Laryngeal Mask Ambu Aura Once vs. Supreme in Children|Ventilation With Laryngeal Mask Ambu Aura Once vs. Supreme in Children||Medical University Innsbruck|Yes|Withdrawn|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|September 27, 2012||No|Other studies with the same protocol have already published.|No||https://clinicaltrials.gov/show/NCT01718782||76819|
NCT01719016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05-05-02|Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics|Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics||University of Cincinnati|No|Recruiting|August 2010|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients with chest pain and suspected ischemia that needs to be assessed by a stress test|May 2015|May 27, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719016||76801|
NCT01719887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-118/13/03/02/2012|Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial|Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial.||Töölö Hospital|No|Recruiting|October 2012|October 2025|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01719887||76734|
NCT01745133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLX0112|Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis|Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis||Derm Research, PLLC|No|Completed|January 2013|August 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745133||74800|
NCT01745146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 ASMT HN4385|Anger Self-Management in Traumatic Brain Injury|Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial|ASMT|Albert Einstein Healthcare Network|No|Recruiting|September 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745146||74799|
NCT01746888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0165|Expanding Antimicrobial Stewardship|Expanding Antimicrobial Stewardship||Ohio State University|No|Completed|August 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|437|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults 65 years of age and older who present to the Emergency Department.|November 2013|November 6, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01746888||74666|
NCT01746901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531008|A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers|A Randomized, Double-blind, Double-dummy, Placebo Controlled, Single-Dose, 6-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Orally to Non-Dependent, Recreational Opioid Users||Pfizer|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746901||74665|
NCT01745770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT-25/UCA|TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With Active Ulcerative Colitis||Dr. Falk Pharma GmbH|Yes|Active, not recruiting|January 2013|June 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745770||74751|
NCT01746004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14671|A Study of LY2157299 Monohydrate in Healthy Volunteers|Disposition of [14C]-LY2157299 Monohydrate Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746004||74733|
NCT01746017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14796|A Study of LY2922470 in Healthy Participants and Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922470 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|25|||Both|21 Years|65 Years|No|||March 2013|March 29, 2013|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746017||74732|
NCT01747447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000560|VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture|VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture|VITAL|Brigham and Women's Hospital|Yes|Active, not recruiting|August 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|778|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01747447||74623|
NCT01747460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0250|Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly)|Controlled Acute Hypoxia Studies Using a Bedside Respiratory Patient Monitoring System With the Functional Patient Monitoring PCBA-1||Medtronic - MITG|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Subjects|December 2013|December 5, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01747460||74622|
NCT01747148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130029|Testing the AVI-7100 Flu Drug in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|September 30, 2015|December 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01747148||74646|
NCT01747915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081105|A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin As Adjunctive Therapy In Pediatric And Adult Subjects With Primary Generalized Tonic-clonic Seizures - Protocol A0081105||Pfizer|Yes|Recruiting|April 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|168|||Both|5 Years|65 Years|No|||March 2016|March 7, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747915||74587|
NCT01744171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 215912|Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma|A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma||Roswell Park Cancer Institute|No|Recruiting|March 2013|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744171||74874|
NCT01744691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1117-CA|A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion|An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)||Pharmacyclics|No|Active, not recruiting|January 2013|March 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|December 3, 2012|Yes|Yes||No|May 21, 2015|https://clinicaltrials.gov/show/NCT01744691||74834|
NCT01745237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008224|Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis|Detection and Prognostic Significance of Myocardial Damage Visualized by Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis||Duke University|No|Recruiting|September 2002|||December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with extra cardiac sarcoidosis (confirmed by biopsy) or suspected cardiac        sarcoidosis|November 2015|November 18, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745237|10 Years|74792|
NCT01718223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 217512|Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer|A Pilot Study of Interstitial Photodynamic Therapy for Recurrent Squamous Cell Carcinoma of the Oropharynx and Oral Cavity||Roswell Park Cancer Institute|Yes|Withdrawn|December 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|October 29, 2012|Yes|Yes|implementation issues|No||https://clinicaltrials.gov/show/NCT01718223||76861|
NCT01718509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-344|SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder||Shire|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|390|||Both|18 Years|55 Years|No|||August 2014|November 3, 2015|October 29, 2012|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01718509||76839|
NCT01718236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA NT 13906-4|Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section|Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section|RocSugIO|Brno University Hospital|Yes|Completed|September 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|500|||Female|14 Years|60 Years|No|||January 2015|January 27, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01718236||76860|
NCT01718548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0062-12-HYMC|The Effects of Cordyceps Sinensis and Lingzhi on Cardiovascular Fitness and Cognitive Function|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718548||76836|
NCT01719081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0880-AE|Sacroiliac Joint Injection: Comparison of Xray Versus Ultrasound|Ultrasound for Sacroiliac Joint Injection: Evaluation of the Efficacy of Two Image-Guided Techniques for Sacroiliac Joint Injection||University Health Network, Toronto|Yes|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||December 2013|December 9, 2013|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719081||76796|
NCT01719042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187-2012|Improving Tolerance of Treatment of Pulmonary MAC Infections|Improving Tolerance of Treatment of Pulmonary Mycobacterium Avium Complex Infections|ITT-MAC|University of Florida|No|Withdrawn|January 2013|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Female|50 Years|N/A|No|||April 2013|April 2, 2013|October 22, 2012|Yes|Yes|No recruitment was achievable|No||https://clinicaltrials.gov/show/NCT01719042||76799|
NCT01719302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1202|Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma|Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma||University of Vermont|No|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719302||76779|
NCT01719588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100918|A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain|A Post-Marketing Surveillance (PMS) Study on the Safety and Effectiveness of Prolonged Release Tapentadol Hydrochloride Among Adult Filipino Patients With Moderate To Severe Chronic Non-Cancer Pain||Janssen Pharmaceutica|No|Withdrawn|October 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Filipino patients with moderate to severe chronic non-cancer pain and who are on the        approved product label of prolonged release tapentadol hydrochloride|November 2015|November 30, 2015|October 30, 2012|Yes|Yes|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01719588||76757|
NCT01745471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 348525|Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)|Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)|EIFFEL|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Active, not recruiting|December 2012|January 2017|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|Samples With DNA|Blood Urine Adipose tissue|Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Study Population and screening: Healthy young women with a BMI > 30 will be recruited; 12        will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78 and 12 with        an android pattern as defined by a waist-to-hip greater than 0.85. A third group will        include 12 women with PCOS as defined by the NIH criteria. Subjects will be recruited via        a dedicated website, physician referrals, direct mail outs, newspaper advertisements, and        brochures. Only subjects that will sign informed consent and meet eligibility criteria        will be enrolled in this study.|January 2016|January 14, 2016|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01745471||74774|
NCT01747200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130035|Effects of Transcranial Magnetic Stimulation on Object Recognition|Modulating Behavior in Humans by Entrainment With Rhythmic Transcranial Magnetic Stimulation||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01747200||74642|
NCT01746043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0117|A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer|A Randomized Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2013|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01746043||74730|
NCT01746264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006349|Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents|Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents||Mayo Clinic|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2014|May 31, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01746264||74713|
NCT01746563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-RBZ2012|Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy|Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Treatment-Naive Proliferative Diabetic Retinopathy||University of Sao Paulo|Yes|Completed|May 2011|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01746563||74691|
NCT01747694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-2527A3|Respiratory Muscle Exercise Training in COPD Patients|The Effectiveness of Multi-respiratory Muscle Training on Respiratory Function in Patients With COPD||Chang Gung Memorial Hospital|No|Recruiting|December 2012|October 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||October 2012|December 10, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747694||74604|
NCT01747928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6711036|Users Study Of The Caverject Delivery System|A Representative Users Study Of The Operating Characteristics Of The Caverject Delivery System||Pfizer|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|48|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|November 20, 2012||No||No|April 1, 2014|https://clinicaltrials.gov/show/NCT01747928||74586|For outcome measure 7, the endpoint was originally the comments provided as part of the PAT. As clinicaltrials.gov do not support textual results, the number of participants who provided comments to any questions on the PAT are reported instead.
NCT01747681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-Microfracture|Results at 10 to 14 Years After Microfracture in the Knee|Results at 10 to 14 Years After Microfracture in Articular Cartilage Defects in the Knee||Bergen Orthopedic Study Group|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|110|||Both|18 Years|80 Years|No|Probability Sample|All patients operated with a microfracture of articular chondral defects in the knee at        the Deaconess University Hospital from 1999 to 2002.|January 2015|January 26, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747681||74605|
NCT01748175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010HL109152-01|Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma|Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma|SARPIII|University of Pittsburgh|Yes|Recruiting|January 2013|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|700|||Both|6 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01748175||74567|
NCT01744457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-161009|Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects|Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects||Medical University of Vienna|No|Completed|February 2011|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 5, 2012|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01744457||74852|
NCT01736254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14701|A Study of Evacetrapib in Healthy Participants|Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736254||75483|
NCT01717976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-052|Discharge Information and Support for Patients Receiving Outpatient Care in the Emergency Department|Discharge Information & Support for Patients Receiving Outpatient Care in the ED|DISPO ED|VA Office of Research and Development|No|Recruiting|December 2013|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|514|||Both|N/A|N/A|No|||December 2015|December 3, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01717976||76880|
NCT01718561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIFFICAIR|The Difficult Airway Management Trial: "The DIFFICAIR-Trial"|Incidence of Unanticipated Difficult Airway Using an Objective Airway Score Versus a Standard Clinical Airway Assessment, The DIFFICAIR Trial - A Cluster-randomized Clinical Trial on 28 Anaesthesia Departments With 70,000 Patients Registered in the Danish Anaesthesia Database|DIFFICAIR|Hillerod Hospital, Denmark|No|Completed|October 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|76058|||Both|15 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 7, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718561||76835|
NCT01718834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC|Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection|Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II|CENV3|National Liver Institute, Egypt|Yes|Recruiting|March 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01718834||76815|
NCT01719367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kolek 01|Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation|Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation||Vanderbilt University|No|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719367||76774|
NCT01719315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0201|Neurophysiologic Correlates of Hypersomnia|Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation||University of Wisconsin, Madison|No|Recruiting|November 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the greater Madison, WI area. Hypersomnolent subject        groups (n=30 in each group) may include unipolar MDD with hypersomnolence, primary        hypersomnia (idiopathic hypersomnia), bipolar disorder with hypersomnolence, and        narcolepsy. Non-hypersomnolent comparison groups (n=30 in each group) will include: MDD        without hypersomnolence, bipolar disorder without hypersomnolence, primary insomnia, and        healthy controls.|December 2014|October 1, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01719315||76778|
NCT01719575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9701_GA_IV|Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers|A Double-blind, Randomized, Two-way, Cross-over Study for Evaluating Motilitone on Gastric Motor Function in Healthy Volunteers|DA-9701|Dong-A ST Co., Ltd.|No|Completed|March 2012|||November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 13, 2013|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719575||76758|
NCT01719328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003669-01s1|Vinayasa Yoga and Mood|The Effects of Vinayasa Yoga on Mood and Stress||The Miriam Hospital|No|Completed|February 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719328||76777|
NCT01745159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-PRT-AD-12-1|Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis|Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study||Astellas Pharma Inc|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|2 Years|15 Years|No|||August 2014|August 4, 2014|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01745159||74798|
NCT01745172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBR-BRISTOL.UK-CIBIEM|Carotid Body Removal for the Treatment of Resistant Hypertension|Carotid Body Removal for the Treatment of Chronic Diseases Characterized by Excessive Central Sympathetic Activity Including Resistant Hypertension: a Pilot Study.||Noblewell|Yes|Active, not recruiting|January 2013|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01745172||74797|
NCT01746277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH S-462|Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy|A Phase Ⅱ Randomized Controlled Trial to Compare Chemotherapy Sequenced by EGFR-TKIs and Chemotherapy Combined With EGFR-TKIs for Advanced or Metastatic NSCLC Patients Failed to EGFR-TKIs Therapy||Peking Union Medical College Hospital|No|Recruiting|October 2012|June 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2012|December 7, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01746277||74712|
NCT01738425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIC P2-458|A Clinical Phase I Study on GIC-1001 in Healthy Volunteers|A Double-Blind, Placebo Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GIC-1001 in Normal Healthy Volunteers||gicare Pharma Inc.|Yes|Completed|November 2012|May 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|November 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738425||75316|
NCT01746875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1743|A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes|Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study.||Norwegian University of Science and Technology|Yes|Terminated|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9|||Both|50 Years|N/A|No|||September 2015|September 14, 2015|December 7, 2012||No|treatment effects not as desired|No||https://clinicaltrials.gov/show/NCT01746875||74667|
NCT01747161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/445|Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia|Randomized Placebo Controlled Double Blind Study: Efficacy and Safety of Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia.|VVS-01|University Hospital, Ghent|No|Recruiting|January 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01747161||74645|
NCT01747174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLRN 53469|REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction|Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary Intervention|REFLO-STEMI|University Hospitals, Leicester|Yes|Completed|October 2011|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|247|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01747174||74644|
NCT01747486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03712|CD19 Redirected Autologous T Cells|Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|December 2012|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747486||74620|
NCT01747499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303012|Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation|Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation||Washington University School of Medicine|No|Recruiting|April 2013|May 2018|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|64|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747499||74619|
NCT01747967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K 091101|Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes|Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes|IMMADIAB|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|156|||Both|6 Years|60 Years|No|||April 2015|April 20, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747967||74583|
NCT01747941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5281001|Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects||Pfizer|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01747941||74585|
NCT01747954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11112PSC009|Effects of Physiotherapy in Hemodynamics and Childrens Respiratory Mechanics|Respiratory Mechanics and Hemodynamics in Children With Respiratory Failure: Comparison of Two Techniques of Respiratory Physiotherapy||Federal University of Uberlandia|No|Terminated|March 2010|January 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|1 Month|60 Months|Accepts Healthy Volunteers|||November 2012|December 19, 2012|November 16, 2012||No|Terminated|No||https://clinicaltrials.gov/show/NCT01747954||74584|
NCT01744184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT1|A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy|A Single-centre, Randomised Controlled Study of Entonox Versus Midazolam Sedation in Gastroscopy.||The Royal Bournemouth Hospital|Yes|Recruiting|May 2013|December 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01744184||74873|
NCT01735903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMNI1|Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow After Nerve Decompression in Diabetic Neuropathy Patients|Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression In diabetiC Neuropathy PatiENTs|OMNIFICENT|Foot Surgery Center of Northern Colorado|Yes|Recruiting|November 2012|July 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Non-Probability Sample|Poudre Valley Foot and Ankle Clinic patients and Neuropathy Testing Center of Colorado|March 2013|March 27, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01735903||75510|
NCT01717989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080234|Study to Evaluate the Prospective Payment System|Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations|STEPPS™|Amgen|No|Completed|June 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2248|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of approximately 50 SDOs selected to participate in the        registry. All efforts will be made to select a diversified group of facilities by        evaluating geography, facility size (i.e., number of patients treated) and setting (i.e.,        rural and urban settings) and potentially, dialysis modalities offered as well as payor        mix.|November 2013|November 25, 2013|September 12, 2012||No||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01717989||76879|
NCT01718249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0126|Study of Conscious Behavior Under Low-frequency Deep Brain Stimulation in Chronic and Severe Post-coma Disorders of Consciousness|Study of Conscious Behavior Under Low-frequency Deep Brain Stimulation in Chronic and Severe Post-coma Disorders of Consciousness|Post-coma DBS|University Hospital, Clermont-Ferrand||Recruiting|April 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718249||76859|
NCT01718847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV120101-202|NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors|Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) in Lung Adenocarcinoma Patients With Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors|NSCLC|National OncoVenture|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|N/A|No|||August 2015|August 13, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01718847||76814|
NCT01749839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRM-SBMU0317|Pain Relief by Platelet-rich Plasma (PRP) Treatment|||Saint Bernard Mission University|Yes|Active, not recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Athlete community|December 2012|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749839||74439|
NCT01749852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-BW 01|Effect of Polyphenol-rich Dark Chocolate on Body Weight in Overweight and Obese Adults|Effect of Polyphenol-rich Dark Chocolate on Body Weight in Overweight and Obese Adults: A Pilot Study||Queen Margaret University|No|Completed|January 2013|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|October 20, 2014|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01749852||74438|
NCT01719094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99312|RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors|RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|August 2012|||February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|115|||Both|16 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Childhood cancer survivors, adolescent/young adults with no cancer history and newly        diagnosed cancer patients|May 2015|May 26, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719094||76795|
NCT01750437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH1885L-201|Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)|Randomized, Double-blind, Active-controlled, Multi-center Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)||Yuhan Corporation|No|Completed|January 2013|April 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|149|||Both|20 Years|N/A|No|||July 2014|July 8, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750437||74393|
NCT01719068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01812|Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos|Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos||British Columbia Cancer Agency|No|Recruiting|October 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|50 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Workers in British Columbia who have been exposed to asbestos.|October 2012|October 30, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719068||76797|
NCT01719341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00465|Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia|||National University Hospital, Singapore|Yes|Recruiting|September 2012|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|18 Years|70 Years|No|Probability Sample|Sample size estimation based on Case and Morgan Two Stage Phase II Design with an expected        duration of accrual of 2 years, assuming a power of 80% and a level of significance of        10%. With an S0 of 0.25 and SA of 0.50, an interim analysis will be performed after 14        patients are recruited with an anticipated final recruitment total of 21 patients for each        arm of the study.|December 2013|December 10, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719341||76776|
NCT01746056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209010850|A Comparative Study of Occlusive Heat Patch in the Treatment of Warts|A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca||Yale University|No|Recruiting|December 2012|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|N/A|No|||June 2014|June 13, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01746056||74729|
NCT01746290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228304|The PulsePoint Randomized Controlled Trial|The PulsePoint Smartphone Application: Recruiting Bystanders to Provide Basic Life Support for Victims of Out-of-Hospital Cardiac Arrest||Queen's University|No|Withdrawn|January 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 12, 2012||No|The intervention (PulsePoint application) could not be implemented in Toronto as planned|No||https://clinicaltrials.gov/show/NCT01746290||74711|
NCT01746602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-241010|Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects|Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects||Medical University of Vienna|Yes|Terminated|July 2011|January 2015|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746602||74688|
NCT01739218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28337|A Study of Avastin (Bevacizumab) in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Cancer, Initially Unresectable|A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable.||Hoffmann-La Roche||Active, not recruiting|February 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01739218||75255|
NCT01739231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 006|Safety, Immunogenicity and Efficacy Study of Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults|A Phase 1/2b Randomized, Double-Blinded, Placebo-controlled Study to Assess the Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers||PATH|Yes|Completed|September 2012|January 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|May 13, 2014|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739231||75254|
NCT01739244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL040012_III|Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma|Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma||Sylentis, S.A.|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01739244||75253|
NCT01739257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254423|Use of Theater to Invoke Empathy and Reduce Bias in Medical Students|||University of California, Davis|Yes|Completed|August 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|129|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01739257||75252|
NCT01747187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Septic Heart|Cardiac Stress in Septic Shock - Biomarkers, Echocardiography and Outcome|Cardiac Stress in Septic Shock - Biomarkers, Echocardiography and Outcome.|Septic Heart|University Hospital, Linkoeping|No|Recruiting|October 2012|April 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|50 adult patients admitted to ICU for severe sepsis or septic shock.|December 2012|December 10, 2012|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01747187||74643|
NCT01747473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0384|Pulse Oximetry_Performance During Severe Signal Interference - PCBA-1 (Printed Circuit Board Assembly)|Controlled Acute Hypoxia Studies Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well-perfused Subjects With the Functional Monitoring PCBA-1||Medtronic - MITG|No|Completed|November 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Well perfused|December 2013|December 5, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01747473||74621|
NCT01747707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-31|Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer|Phase II Clinical Trial of Cisplatin,Docetaxel and S-1 as First Line Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer||Chinese Academy of Medical Sciences|No|Recruiting|September 2012|May 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||December 2012|December 10, 2012|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01747707||74603|
NCT01739530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-adip-AL-001|Safety of Repaircell in Healthy Volunteers|Phase I Study to Evaluate Safety of Repaircell in Healthy Volunteers||Anterogen Co., Ltd.||Completed|March 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|19 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 3, 2012|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01739530||75231|
NCT01739543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_002|A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer|A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer||Plexus Biomedical, Inc.|No|Completed|April 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|102|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739543||75230|
NCT01748188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URV|The Effectiveness of Dexketoprofen on Shoulder Pain Using Different Physiotherapy Treatments|Valuation of the Dexketoprofen Effectiveness on Subacromial Syndrome With Different Physiotherapy Treatments.|DOFIS|University Rovira i Virgili|Yes|Completed|January 2012|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|99|||Both|36 Years|70 Years|No|||May 2014|May 27, 2014|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01748188||74566|
NCT01735617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUR-003|Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH|A Phase 2 Pilot Study to Characterize and Examine the Pharmacokinetics and Disease Bio-marker Response of Chronocort® in Adults With Congenital Adrenal Hyperplasia||Diurnal Limited|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01735617||75532|
NCT01737073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-006|Comprehensive Opioid Management in Patient Aligned Care Teams|Comprehensive Opioid Management in Patient Aligned Care Teams (COMPACT)|COMPACT|VA Office of Research and Development|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|380|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737073||75420|
NCT01737047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO: 1992|A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'|A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in England and Ireland|POPPY|Imperial College London|Yes|Active, not recruiting|April 2013|August 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1374|Samples With DNA|Blood for storage Blood (serum and plasma,) and urine samples will be collected at visits 1      and 3 stored for subsequent projects of the potential pathogenic mechanisms underlying      age-related diseases. This will include assessment of vitamin-D and PTH and probably DNA      analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV positive over 50 years HIV positive between 18 and 50 years HIV negative over 50 years        White Black african|October 2015|February 19, 2016|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737047||75422|
NCT01737060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTSA s422|Displaced Proximal Humeral Fractures: Delta Prothesis or Philos Plate?|Clinical Investigation for Fractures of the Proximal Humerus in Elderly Patients. A Randomized Study of Two Surgical Treatments: Reverse Total Shoulder Arthroplasty Versus Angular Stable Device Philos|DELPHI|Oslo University Hospital|No|Recruiting|January 2013|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|85 Years|No|||April 2015|April 21, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737060||75421|
NCT01718574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2888|Bibliotherapy for Patients With Cancer|Feasibility, Acceptability and Efficacy of Bibliotherapy for Patients With Cancer: a Randomized Control Trial||McGill University Health Center|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|89|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01718574||76834|
NCT01718587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-09 TC liver cirrhosis|Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients|Difference in Efficacy Between Umbilical Cord Mesenchyma Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients||General Hospital of Chinese Armed Police Forces|Yes|Not yet recruiting|November 2012|July 2014|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2012|October 30, 2012|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01718587||76833|
NCT01749865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00769106|CIK Treatment for HCC Patient Underwent Radical Resection|A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection||Sun Yat-sen University|Yes|Completed|October 2008|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749865||74437|
NCT01749878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1500-HV-1214|Study to Assess the Safety and Tolerability of Single Doses of REGN1500|||Regeneron Pharmaceuticals|No|Recruiting|December 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01749878||74436|
NCT01750931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117176|This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF MELOXICAM GSK 15 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND MOBIC® 15 MG TABLETS OF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BINGER STR.173, 5521 INGELHEIM AM RHEIN, GERMANY, IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FED CONDITION.|BA/BE: 250/12|GlaxoSmithKline|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|November 27, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01750931||74355|
NCT01750164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12168|Patient Derived Breast Cancer Xenografts|Patient Derived Breast Cancer Xenografts||Dartmouth-Hitchcock Medical Center|Yes|Terminated|December 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|Samples With DNA|whole blood and tumor tissue samples as well as DNA that has been extracted from both blood      and tiisue will be stored.|Female|18 Years|N/A|No|Non-Probability Sample|Women with invasive breast cancer with metastatic disease seen in Oncology clinic|December 2013|May 8, 2015|December 12, 2012||No|discontinued funding|No||https://clinicaltrials.gov/show/NCT01750164||74414|
NCT01751490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.024|Effectiveness of Surgery for Atraumatic Shoulder Instability|Does Surgery Followed by Physiotherapy Improve Short and Long Term Outcomes for Patients With Atraumatic Shoulder Instability Compared With Physiotherapy Alone?||Royal National Orthopaedic Hospital NHS Trust|Yes|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01751490||74312|
NCT01719354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1770|Aftercare in the Community Health Center|Aftercare in the Community Health Center - a Venue for Identifying and Coordinating Community Services||Norwegian University of Science and Technology|No|Completed|January 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719354||76775|
NCT01719601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100919|A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain|A Post-Marketing Surveillance (PMS) Study on the Safety and Effectiveness of Immediate Release Tapentadol Hydrochloride Among Adult Filipino Patients With Moderate to Severe Acute Non-Cancer Pain||Janssen Pharmaceutica|No|Withdrawn|October 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Filipino patients with moderate to severe acute non-cancer pain and who are on the        approved product label of Immediate release tapentadol hydrochloride|September 2015|September 25, 2015|October 30, 2012|Yes|Yes|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01719601||76756|
NCT01746303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG034617-01|Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline|Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline||University of Cincinnati|Yes|Active, not recruiting|January 2010|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|62 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01746303||74710|
NCT01746914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212|Morphofunctional Lung Analysis by PET and CT After Lung Transplantation|Morphofunctional Lung Analysis by Positron Emission Tomography and Computed Tomography After Lung Transplantation||Policlinico Hospital|No|Recruiting|January 2013|January 2016|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Lung Transplantated patients|April 2015|April 27, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746914||74664|
NCT01746927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH05|Does the Position of the Esophageal Entrance Determine the Cricoid Force Necessary to Occlude the Esophageal Lumen|Does the Position of the Esophageal Entrance Determine the Cricoid Force Necessary to Occlude the Esophageal Lumen?|CP|Procare Riaya Hospital|No|Recruiting|February 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|60 Years|No|Probability Sample|normal healthy non obese patients|December 2013|December 2, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746927||74663|
NCT01735370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/VIN-11/411|Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735370||75551|
NCT01735383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/VIN-11/412|Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition.||IPCA Laboratories Ltd.|Yes|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735383||75550|
NCT01747512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-CPERT-002|An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)|A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer||AHS Cancer Control Alberta|No|Recruiting|January 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|115|||Both|18 Years|79 Years|No|||March 2016|March 10, 2016|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747512||74618|
NCT01739192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032254|A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence|||University of Kentucky|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|48|||Both|18 Years|55 Years|No|||December 2015|December 3, 2015|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01739192||75257|
NCT01739205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 36588-P1|Biobehavioral Bases & Management of Type 2 Diabetes|Biobehavioral Bases & Management of Type 2 Diabetes|CALM-D|University of Miami|No|Completed|January 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|70 Years|No|||November 2012|November 30, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739205||75256|
NCT01735916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRACLE EF|MIRACLE EF Clinical Study|MIRACLE EF Clinical Study|MIRACLE EF|Medtronic Cardiac Rhythm Disease Management|Yes|Terminated|December 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|November 15, 2012|Yes|Yes|The study was terminated early due to low enrollment.|No|September 12, 2014|https://clinicaltrials.gov/show/NCT01735916||75509|
NCT01735344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-10/385|Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.||IPCA Laboratories Ltd.|Yes|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735344||75553|
NCT01736787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANABIO-PI-CM|Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity|||Chonbuk National University Hospital|Yes|Recruiting|September 2012|December 2012|Anticipated|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01736787||75442|
NCT01736800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05200|Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors|Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors||The Methodist Hospital System|Yes|Recruiting|March 2007|||March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|79 Years|No|||June 2013|June 18, 2013|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736800||75441|
NCT01737372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-001-GEN|A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis|A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis||Rocky Mountain MS Research Group, LLC|No|Recruiting|November 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|45|Samples Without DNA|Cerebrospinal fluid and blood may be stored for future immunological, cell product and      microRNA testing related to the primary outcome of the this study.|Both|18 Years|68 Years|Accepts Healthy Volunteers|Non-Probability Sample|45 participants will be enrolled into a study to examine the microRNA and cell products        profile in both cerebrospinal fluid (CSF) and blood. Study population will consist of a        total of: 20 CIS patients defined as patients having a single attack (or the appearance of        one or more symptoms characteristic of MS) high risk of developing MS, when no other        diseases or causes are apparent.        20 SPMS patients 5 normal, non-diseased controls|May 2015|May 6, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737372||75397|
NCT01737346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNOG-1201|Procarbazine and Lomustine in Recurrent Glioblastoma|Phase 2 Clinical Trial of PC(Procarbazine-CCNU) Chemotherapy in Patients With Recurrent or Resistant Glioblastoma With Methylated MGMT||Incheon St.Mary's Hospital|Yes|Recruiting|October 2012|April 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|20 Years|N/A|No|||November 2012|November 30, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737346||75399|
NCT01749553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011276|Effectiveness of an 8-week Posterior Shoulder Stretching Program on Varsity-level Overhead Athletes|Effectiveness of an 8-week Posterior Shoulder Stretch Program on Varsity-level Overhead Athletes||Shoulder & Upper Extremity Research Group of Edmonton|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749553||74461|
NCT01749566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059752|Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women|Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women|MVC-PREP|Emory University|No|Completed|December 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|31|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 8, 2015|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01749566||74460|
NCT01750463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2019|Comparing Validity of Non-Invasive Hemoglobin Monitoring to Laboratory Results in Critically Ill Children|Verifying the Accuracy of the Masimo Pronto Non-Invasive Hemoglobin (Hb) Monitor and Associated Rainbow Probes Compared to Measured Laboratory Values in Critically Ill Pediatric Patients||University of North Carolina, Chapel Hill|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|N/A|18 Years|No|Non-Probability Sample|pediatric patients admitted to the PICU requiring hemoglobin monitoring|December 2014|December 1, 2014|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750463||74391|
NCT01751230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12030|A Personalized Telehealth Intervention for Health and Weight Loss in Postpartum Women|E-Moms: A Personalized Telehealth Intervention for Health and Weight Loss in Postpartum Women|E-Moms|Pennington Biomedical Research Center|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751230||74332|
NCT01750944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/APM-02|Measurement of a Systolic Pressure Index at the Toe After a Walking Test|Validation of the Measurement of a Systolic Pressure Index at the Toe (IPSO) After a Walking Test|IPSO FACTO|Centre Hospitalier Universitaire de Nīmes|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750944||74354|
NCT01719614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100909|A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants|A Phase I, Open-Label Study in Healthy Subjects to Explore the Potential for a Pharmacokinetic Interaction Between Steady-State Rilpivirine and a Single Dose Of Metformin||Janssen R&D Ireland|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|October 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01719614||76755|
NCT01719926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40487.041.12|Phase I Platinum Based Chemotherapy Plus Indomethacin|Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy|PIFA|UMC Utrecht|No|Recruiting|September 2012|July 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|18|||Both|18 Years|70 Years|No|||February 2014|February 24, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01719926||76731|
NCT01737827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2201|Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.|A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma||Novartis|No|Recruiting|March 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01737827||75362|
NCT01738139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0784|Ipilimumab and Imatinib Mesylate in Advanced Cancer|A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|February 2013|||February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|15 Years|N/A|No|||February 2016|February 10, 2016|November 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738139||75338|
NCT01738152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-232|Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health|A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health||Memorial Sloan Kettering Cancer Center||Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||October 2015|October 9, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738152||75337|
NCT01735981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0109|The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease|The Effect of Video Game Biofeedback Modulated Exercise (ViBE)on Dynamic Balance and Gait in Individuals With Huntington's Disease||Ohio State University|No|Completed|June 2008|June 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|79 Years|No|||November 2012|November 21, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01735981||75504|
NCT01738685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050094|Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy|Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy.|Relief|University of Pittsburgh|No|Withdrawn|December 2012|December 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Female|50 Years|N/A|No|||December 2014|December 3, 2014|November 15, 2012||No|No funding.|No||https://clinicaltrials.gov/show/NCT01738685||75296|
NCT01738919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Janni1|Extension Block Technique Versus Splinting in Mallet Finger Fracture.|Ishiguro Extension Block Technique Versus Splinting in the Treatment of Mallet Finger Fracture. A Randomized Controlled Trial.|Ishiguro|University of Aarhus|No|Recruiting|November 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|60|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738919||75278|
NCT01735630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-AG201|Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease||Transition Therapeutics Ireland Limited||Completed|November 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|50 Years|95 Years|No|||July 2015|July 8, 2015|November 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735630||75531|
NCT01735929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU68167|Combination of Ultrasound Treatment and Neck Liposuction for Skin Tightening|Evaluating the Combined Skin Tightening Benefit of Non-Invasive Ultrasound Treatment and Neck Liposuction||Northwestern University|Yes|Not yet recruiting|March 2016|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|November 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01735929||75508|
NCT01736280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120195|Evaluating and Treating Potential Research Participants With Digestive Disorders|Evaluation and Treatment Protocol for Potential Research Participants With Digestive Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|August 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|September 3, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736280||75481|
NCT01736267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEI HSC 12-061|Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects|Study of Nucleus 24 Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects||Massachusetts Eye and Ear Infirmary|No|Recruiting|November 2012|November 2022|Anticipated|November 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2014|October 7, 2015|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736267||75482|
NCT01738256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salwe_27819_WP303.2-1|Study of Effectiveness of Different Lifestyle Interventions for Health and Wellbeing|Applicability and Efficiency of Different Approaches in Lifestyle Interventions - Lifestyle Management and Changes in Everyday Life||University of Jyvaskyla|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|339|||Both|25 Years|60 Years|No|||February 2014|February 7, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01738256||75329|
NCT01750710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0128|Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A|Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A|CCA1|University Hospital, Clermont-Ferrand||Not yet recruiting|December 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from CMT 1A neuropathy|December 2012|December 13, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01750710||74372|
NCT01750957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28571|A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome|A RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY AND EXPLORATORY EFFICACY AND PHARMACOKINETIC, STUDY OF RO4917523 IN PEDIATRIC PATIENTS WITH FRAGILE X SYNDROME||Hoffmann-La Roche||Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|5 Years|13 Years|No|||March 2016|March 1, 2016|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750957||74353|
NCT01750970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/34|Endoscopic Resection of Bladder Tumors|Endoscopic Rescetion of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?||Hopital Foch|No|Recruiting|November 2009|February 2013|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|N/A|No|||October 2009|December 13, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750970||74352|
NCT01750723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-137|Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow|Basic Research on Acetazolamide´s Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model||Danish Headache Center|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 8, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750723||74371|
NCT01750684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM-SI-1009|A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury|A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Determine the Safety, Tolerability and Potential Activity of AC105 Following a Regimen of 6 Doses Over 30 Hours in Patients With Acute Traumatic Spinal Cord Injury (SCI) as Compared to Patients Treated With Placebo.|AC105|Acorda Therapeutics|Yes|Completed|July 2013|May 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750684||74374|
NCT01750697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA25615|A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis|A PHASE IIa, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYANGIITIS (WEGENER S) OR MICROSCOPIC POLYANGIITIS||Hoffmann-La Roche||Recruiting|May 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|17 Years|No|||March 2016|March 1, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750697||74373|
NCT01751763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16621|Sorafenib for Residue Disease After Resection With Curative Intent|Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent|SECURE|Bayer|No|Active, not recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|HCC patients with residue disease after rescetion with curative inten|March 2016|March 9, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751763||74292|
NCT01738451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113773|A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors|A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors: An Open-label, Dose-escalating Safety Lead-in Study Followed by a Single-sequence, Placebo-controlled, Single-blind Study||GlaxoSmithKline|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|N/A|No|||April 2015|August 27, 2015|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738451||75314|
NCT01738698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-338|Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 40mg, 100mg, or 160mg as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia||Shire|Yes|Terminated|November 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|4|||Both|18 Years|65 Years|No|||May 2014|May 1, 2014|November 28, 2012|Yes|Yes|Study was discontinued due to non-safety related business prioritization decisions. No    subjects were randomized.|No|May 1, 2014|https://clinicaltrials.gov/show/NCT01738698||75295|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
NCT01738932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBLendo06|Genetic Polymorphisms of Mannan-binding Lectin (MBL)and Serum Levels of MBL in Patients With Endometriosis|Genetic Polymorphisms of Mannan-binding Lectin (MBL) and Serum Levels of MBL in Patients With Endometriosis||University of Aarhus|No|Completed|December 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|Samples With DNA|Serum, EDTA blood|Female|18 Years|50 Years|No|Non-Probability Sample|Endometriosis patients referred to the endometriosis clinic at Aarhus University Hospital|November 2012|November 29, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738932||75277|
NCT01738945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATACCBFGF23|Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose|||Gulhane School of Medicine||Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|32|||Both|18 Years|70 Years|No|||February 2008|November 29, 2012|November 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738945||75276|
NCT01735669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMIVER|Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation|Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation|REMIVER|Hospital de Cruces|No|Completed|July 2012|January 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|65 Years|No|||February 2015|February 14, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01735669||75528|
NCT01735357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDT|Differential Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Platelet, Endothelial and Vascular Function|Investigation Into Incorporation of (n-3) Polyunsaturated Fatty Acids Into Erythrocyte Membranes and Clearance, and Effects on Platelet Function, Arterial Function and Endothelial Repair||King's College London|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01735357||75552|
NCT01735942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU68227|Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions|A Comparison of Ingenol Mebutate and Cryotherapy for Treatment of Actinic Keratoses.||Northwestern University|Yes|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01735942||75507|
NCT01736826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/SB-01|Free DNA and Nucleosome Concentrations in Pathological Pregnancies|Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|June 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|180|Samples Without DNA|At each visit a total of 36 ml of blood will be drawn (5 x EDTA tube = 5 x 4.5ml; 2 x CTAD      tube = 2 x 4.5 ml and 1 dry tube = 4.5 ml).      Tubes will be rapidly conditioned and samples stored at -80°C. After analysis, remaining      samples will be stored in the Nîmes University Hospital Biological Collections.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes three groups:        Group P: 100 pregnant women with complications typical of placental vascular disease or        venous thromboembolism.        Group T1: 30 non-pregnant, healthy volunteers          -  The first 15 patients from group T1 will form group T1x. The latter group has two             months of additional follow up.        Group T2: 50 pregnant, healthy volunteers          -  The first 15 patients from group T2 will form group T2x. The latter group has 7             months of follow-up during pregnancy.|November 2015|November 9, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736826||75439|
NCT01737086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Profat|Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care|Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care|Profat|Umeå University|No|Terminated|December 2012|December 2014|Anticipated|May 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|6 Months|36 Months|No|||February 2014|May 6, 2014|November 26, 2012||No|Terminated due to lack of eligible patients.|No||https://clinicaltrials.gov/show/NCT01737086||75419|
NCT01737099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1048|Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia||DHA-O|DSM Nutritional Products, Inc.|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737099||75418|
NCT01736540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AAU05|An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)|An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)||Novartis|Yes|Completed|February 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|228|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736540||75461|
NCT01736813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARACON-001|CCR5-blockade in Metastatic Colorectal Cancer|Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial)|MARACON|National Center for Tumor Diseases, Heidelberg|No|Completed|November 2012|September 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Biopsies, Serum and DNA|Both|18 Years|N/A|No|Non-Probability Sample|large university hospital with local private practice referrers|July 2014|October 1, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01736813||75440|
NCT01737970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0170|A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy|A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy.||Oxford University Hospitals NHS Trust||Enrolling by invitation|February 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Patient will be selected from clinically diagnosed patients with breast cancer undergoing        neoadjuvant chemotherapy. These women will be recruited through the Oxford University NHS        Trust cancer centre and will consist primarily of women living within Oxfordshire.|November 2012|November 29, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737970||75351|
NCT01737606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 2012 - FP / COSTUM|Ultrasonic Explorations of Cerebral Tissue Motions - Influence of Aging|Ultrasonic Explorations of Cerebral Tissue Motions - Influence of Aging|COSTUM|University Hospital, Tours|No|Completed|September 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 27, 2013|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01737606||75379|
NCT01737619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0623|High Risk Endometrial Cancer and Lymph Nodes Metastasis|Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer||M.D. Anderson Cancer Center|No|Recruiting|April 2013|||April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737619||75378|
NCT01750190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-060|A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis|A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis||FibroGen|Yes|Recruiting|November 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750190||74412|
NCT01751269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 402|Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|December 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751269||74329|
NCT01751555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|co-us-104-0405|Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection|A Single-Arm Study Evaluating the Efficay and Safety of Tenofovir DF,Lamivudine and Efavirenz in Adults With HIV/HBV Coinfection||National Center for AIDS/STD Control and Prevention, China CDC|Yes|Completed|February 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|60 Years|No|||December 2010|June 27, 2013|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751555||74307|
NCT01751243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALODEPLETE|Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies|Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|20|||Both|16 Years|50 Years|No|||June 2015|June 23, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751243||74331|
NCT01751750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS38|Grape Polyphenol Kinetics in Humans|||USDA Beltsville Human Nutrition Research Center|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|N/A|59 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01751750||74293|
NCT01751776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293.2|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy|A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy||Boehringer Ingelheim||Completed|December 2012|April 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 10, 2015|December 14, 2012||||No||https://clinicaltrials.gov/show/NCT01751776||74291|
NCT01751984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-006|A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and a History of Statin Intolerance||Esperion Therapeutics|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751984||74275|
NCT01752205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC-307PLAH-XJM|Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma|A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma|ESCC-307PLAH|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Recruiting|November 2012|November 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2012|December 16, 2012|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01752205||74258|
NCT01738958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-096|Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF|Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF||University of Copenhagen||Completed|September 2012|March 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738958||75275|
NCT01739270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911|Dexamethasone Added to Levobupivacaine Improves Postoperative Analgesia|Dexamethasone Added to Levobupivacaine Improves Postoperative Analgesia After Supraclavicular Brachial Plexus Blockade||University Hospital Dubrava|No|Active, not recruiting|October 2012|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|80 Years|No|||July 2015|July 28, 2015|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01739270||75251|
NCT01739283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-078 33269|GIP and GLP-1 in Type 1 Diabetes|||University Hospital, Gentofte, Copenhagen|No|Completed|July 2012|November 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|50 Years|No|||July 2015|July 10, 2015|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01739283||75250|
NCT01735097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-002-CT|Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis|A Double-blind, Randomized, Placebo-controlled Trial of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||May 2014|May 2, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01735097||75572|
NCT01735682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20120730001|Whole Body Vibration Exercise Training for Institutionalized Elderly|The Effects of Whole Body Vibration Exercise Training on Physical Functioning and Falls in Institutionalized Elderly: a Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Recruiting|November 2012|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|68|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01735682||75527|
NCT01735695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laniado25112012|Performance Evaluation Study for a New Meconium Detection Test|Performance Evaluation Study for a New Meconium Detection Test||Laniado Hospital|No|Recruiting|December 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women|April 2013|April 28, 2013|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01735695||75526|
NCT01735643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wii study|Lifestyle Intervention With an Interactive Video Game for Type 2 Diabetes Patients|Spielend zu Mehr Bewegung - Lebensstilintervention Durch Das Interaktive Video-spiel "Wii Fit Plus" Bei Personen Mit Typ-2-Diabetes Mellitus||West German Center of Diabetes and Health|Yes|Completed|January 2011|September 2012|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|50 Years|75 Years|No|||November 2012|November 27, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735643||75530|
NCT01736553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN101|Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development|Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development||Ohio State University|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|53|Samples With DNA|Absolute quantification of full length SMN transcripts will be performed. The SMN1 and SMN2      transcripts will be measured in a multiplex reaction and SMN-del7 will be quantified      separately. Droplet digital PCR will be used to determine SMN levels to further increase      reliability and reduce variance in the SMN mRNA level determination. SMN protein in PBMCs      SMN cell-based immunoassays will be performed. This assay is performed using a single      monoclonal antibody for SMN and does not involve the disruption of cells. From the same PBMC      sample, a commercially available SMN ELISA will also be performed according to the      manufacturer's instructions. The B for SMA pilot study identified over 100 protein analytes      that significantly correlated with motor function in SMA patients compared to controls.|Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Fifty four (54) volunteers will be enrolled at 15 NeuroNEXT Network centers. Any volunteer        who signs an informed consent form and has blood collected for the study is considered        enrolled.        Recruitment will be coordinated nationally through the Families of SMA Patient Network and        NeuroNEXT who will help with the following:          -  Identifying infants diagnosed genetically with SMA because of a clinical suspicion             prior to 6 months of age.          -  Publicize the project to raise awareness in medical and non-medical communities.        Any normal infant may enroll in this study.|October 2015|October 13, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01736553||75460|
NCT01736566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedSeq™|A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare|The MedSeq Project Pilot Study: Integrating Whole Genome Sequencing Into the Practice of Clinical Medicine||Brigham and Women's Hospital|Yes|Enrolling by invitation|December 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01736566||75459|
NCT01736579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161202|Long-Term Study of IGIV, 10% in Alzheimer´s Disease|A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease||Baxalta US Inc.|Yes|Terminated|November 2012|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|51 Years|N/A|No|||May 2013|June 26, 2015|November 27, 2012|Yes|Yes|The study was terminated because the first Phase 3 did not demonstrate efficacy on the    co-primary endpoints. The known safety profile remained unchanged.|No||https://clinicaltrials.gov/show/NCT01736579||75458|
NCT01736839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-205-0171|Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution|Ultrasensitive Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine for Inhalation Solution||National Jewish Health||Recruiting|November 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Enrolled subjects will include adults with cystic fibrosis, over the age of 18 years, who        are at baseline health and colonized with Pseudomonas aeruginosa, and who are newly        prescribed Cayston (aztreonam lysine) for inhalation, or who are resuming use of this drug        after 28 days off of inhaled antimicrobial agents with activity against Pseudomonas        aeruginosa.|March 2016|March 23, 2016|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01736839||75438|
NCT01737359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFSP-AMDX-2010|A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.|A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.||RFS Pharma, LLC|No|Terminated|December 2012|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||March 2013|November 4, 2014|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737359||75398|
NCT01738282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALP 2011007/002|Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients|A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients|ALPADIR|Ethypharm|Yes|Completed|December 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01738282||75327|
NCT01737996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.35|Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects|An Open-label, Multiple Dose Study to Assess Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID Administered Orally for 9 Days (Part 1) and Multiple Doses of BI 207127 Combined With Faldaprevir Administered Orally for 16 Days (Part 2) in Healthy Male and Female Subjects||Boehringer Ingelheim||Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|November 26, 2012||||No||https://clinicaltrials.gov/show/NCT01737996||75349|
NCT01737632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA011328|Family-based and Adolescent Residential Drug Treatment|Family-Based Versus Adolescent Residential Drug Treatment|ART|University of Miami|No|Completed|August 2000|June 2010|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737632||75377|
NCT01750736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMUPT-001|Manual Therapy and Augmented Exercise for Neck Pain|The Use of a Home Exercise Program to Augment a Manual Therapy Intervention: a Randomized Controlled Trial||Des Moines University|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 10, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750736||74370|
NCT01752023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1230|A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.|A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.|NA_00067809|Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|December 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|100 Years|No|||November 2015|November 17, 2015|December 14, 2012|Yes|Yes|Low Accrual|No||https://clinicaltrials.gov/show/NCT01752023||74272|
NCT01752036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12133|Radiotherapy for Solid Tumor Spine Metastases|Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2013|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|12 Years|N/A|No|||July 2014|July 15, 2014|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752036||74271|
NCT01751256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoissyStGermainH|Additional Effect of Wound Infiltration After Cesarean Section With Optimal Standard Analgesia|Levobupivacaine Continuous Wound Infiltration and Optimal Standard Analgesia Versus Optimal Standard Analgesia Alone After Cesarean Section.|KTcesar|Poissy-Saint Germain Hospital|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Female|18 Years|50 Years|No|||December 2012|December 14, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751256||74330|
NCT01751503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT- PTTT|Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer|Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer.||Royal National Orthopaedic Hospital NHS Trust|No|Recruiting|March 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|16 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01751503||74311|
NCT01748279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113-46-966|The Effects of Atorvastatin Treatment in COPD Patients|The Effects of Atorvastatin Treatment in COPD Patients||Medical University of Bialystok|Yes|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|40 Years|N/A|No|||April 2013|April 21, 2013|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01748279||74559|
NCT01748578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-1|Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects|A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects|EBI-005-1|Eleven Biotherapeutics|No|Completed|November 2012|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748578||74536|
NCT01748591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000062|Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice|A Study of PICOPREP in Patients Needing to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery||Ferring Pharmaceuticals|No|Terminated|May 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3324|||Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for endoscopic examination or surgery|December 2015|December 21, 2015|November 9, 2012||No|Terminated due to problems enrolling adequate number of patients.|No||https://clinicaltrials.gov/show/NCT01748591||74535|
NCT01735396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1727|Abiraterone Acetate Trial in African American Prostate Cancer Patients|A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||July 2015|July 9, 2015|November 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735396||75549|
NCT01735409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABXDDP20101224|Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma|A Single Center Phase IIa Study of Nanoparticle Albumin-bound Paclitaxel in Combination With Cisplatin in Advanced Nasopharyngeal Carcinoma|ABX-DDP-Dose|Sun Yat-sen University|Yes|Active, not recruiting|November 2012|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|N/A|No|||January 2014|January 25, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735409||75548|
NCT01735656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the DK CULOTTE-I study|Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions|Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting in the Treatment of True Bifurcation Lesions: a Multicenter, Noninferior, Randomized, Controlled Trial (the DK Culotte-I Study)||Fujian Medical University|Yes|Recruiting|March 2014|July 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735656||75529|
NCT01735955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2409|Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study|An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment||Novartis|No|Active, not recruiting|March 2013|December 2023|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|N/A|N/A|No|||February 2016|February 5, 2016|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01735955||75506|
NCT01735968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571X2103|A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients|A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib||Novartis|No|Active, not recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735968||75505|
NCT01736293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120203|Natural History of Eye Diseases Related to ABCA4 Mutations|Natural History of ABCA4-Related Retinopathies||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|70|||Both|12 Years|N/A|No|||April 2015|October 22, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736293||75480|
NCT01736306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912132|Biomarkers for Breast Cancer Risk in African American Women|Epigenetics and Breast Cancer Risk in African American Women||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|500|||Female|10 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736306||75479|
NCT01737385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-31|Examination of Microcirculation of the Caput Humeri After Proximal Humerus Fracture|Intraoperative Examination of Microcirculation of the Caput Humeri After Traumatic Proximal Humerus Fracturation.||RWTH Aachen University|Yes|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|All patients that are treated for proximal humeral fratures in the University hospital of        the RWTH Aachen University.|November 2012|November 28, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737385||75396|
NCT01737645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-273|A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients|A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients||William Beaumont Hospitals|Yes|Terminated|August 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult Subjects undergoing prolonged procedures expected to be in steep Trendelenburg        position. Procedure must be scheduled for > 3 hours, eg. robotic prostatectomy,        hysterectomy, and cystectomy.|July 2014|July 16, 2014|March 16, 2012||No|Difficulty in enrolling subjects.|No||https://clinicaltrials.gov/show/NCT01737645||75376|
NCT01737112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM05|99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients|Safety and Diagnostic Performance of 99mTc-3PRGD2 SPECT/CT in Evaluation of Lung Cancer Patients|TcRGDLC|Peking Union Medical College Hospital|Yes|Recruiting|February 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|30 Years|80 Years|No|||November 2014|November 1, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737112||75417|
NCT01737125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5318|Morphological Study of Distal Tibio-fibular Joint on MRI|Morphological Study of Distal Tibio-fibular Joint by Static MRI, Dynamics of Movement and Effort in Spatial High Resolution. Clinical Implication||University Hospital, Strasbourg, France|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Major subjects without ankle surgical antecedent|July 2013|July 2, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737125||75416|
NCT01738009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957B|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study B|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study B||Brigham and Women's Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01738009||75348|
NCT01738516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01227-36|Contribution of High Resolution EEG Functional Connectivity Measures to Presurgical Evaluation of Patients With Intractable Epilepsy|Contribution of High Resolution EEG Functional Connectivity Measures to Presurgical Evaluation of Patients With Intractable Epilepsy|conneXion|Rennes University Hospital|No|Recruiting|February 2013|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738516||75309|
NCT01750996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR# 103146|Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior|Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior|Fin-Can|IWK Health Centre|No|Completed|October 2011|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|464|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01750996||74350|
NCT01752283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Video-Hypnose|Video-assisted Thyroid Surgery and Hypnosis in Thyroid Surgery|Combination of Video-assisted Thyroid Surgery and Hypnosis as a Complete Minimally Invasive Approach: a Comparative Pilot Study||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|January 2010|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|75 Years|No|||December 2012|December 18, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01752283||74252|
NCT01748331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-060|The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia|The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure|Decongest|Rigshospitalet, Denmark|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748331||74555|
NCT01751997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMTC-AML-1|Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors|The Comparison of Transplantation From Family-mismatched/Haploidentical Donors With Matched Unrelated Donors in Adult Patients With Acute Myeloid Leukemia||Seoul St. Mary's Hospital|No|Recruiting|January 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|17 Years|65 Years|No|||May 2015|May 19, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751997||74274|
NCT01752010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2009.098|Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.|A Randomized Study Comparing the Tennant BioModulator to Transcutaneous Electrical Nerve Stimulation (TENS) and Traditional Chinese Acupuncture for the Symptomatic Treatment of Chronic Pain Among Injured Service Members.||Samueli Institute for Information Biology|Yes|Completed|May 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|60 Years|No|||May 2015|May 18, 2015|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752010||74273|
NCT01751789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034261|Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care|Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care||Butler Hospital|Yes|Recruiting|October 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751789||74290|
NCT01751516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1225|PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study|PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|October 2012|October 2018|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|UNC Hospitals|October 2015|October 13, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751516||74310|
NCT01751529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1219|A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy|LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|May 2013|February 2020|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|December 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751529||74309|
NCT01751542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8888-B|Mindfulness and Acceptance Group Therapy for Substance Use|Mindfulness and Acceptance Group Therapy for Substance Use||The University of Tennessee Knoxville|No|Recruiting|August 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751542||74308|
NCT01748604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULaFe-LYMPHEDEMA-04|Physical Therapies in the Decongestive Treatment of Lymphedema|Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.||Hospital Universitario La Fe|Yes|Completed|February 2004|June 2012|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|194|||Both|18 Years|N/A|No|||December 2012|December 16, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01748604||74534|
NCT01748617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS41|The Potential for Pomegranate Juice to Ameliorate Endothelial Dysfunction|||USDA Beltsville Human Nutrition Research Center|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748617||74533|
NCT01735149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRCM-HL-KOCHUJANG|Efficacy and Safety of Kochujang Pills on Improvement of Blood Lipids|||Chonbuk National University Hospital|Yes|Recruiting|November 2012|June 2013|Anticipated|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735149||75568|
NCT01735422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21321|A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women|A Phase II, Single Center, Open, Randomized, Parallel Group, Dose Finding Study to Assess the Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH), Compared With Urinary Human Chorionic Gonadotrophin (u-hCG), in Inducing Ovulation in Infertile Women Undergoing Stimulation of Follicular Development With Recombinant Human Follicle Stimulating Hormone (Gonal F®).||Merck KGaA|No|Completed|December 1999|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|67|||Female|20 Years|40 Years|No|||February 2014|February 3, 2014|November 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01735422||75547|
NCT01735435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5744|Tight Caloric Balance in Geriatric Patients|Tight Caloric Balance in Geriatric Patients After Hip Fracture.|TICACOSiGP|Rabin Medical Center|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|65 Years|N/A|No|||November 2012|November 27, 2012|November 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01735435||75546|
NCT01736319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912163|Artemisinin-resistant Malaria in Cambodia|Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|860|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||April 2015|December 2, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736319||75478|
NCT01736332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912481|Factors Affecting Methamphetamine and Opiates Drug Testing|Evidence-Based Drug Policy and Legislation: Amphetamines and Opiates in Blood, Oral Fluid and Urine Following Intranasal l-Methamphetamine and Oral Poppy Seeds||National Institutes of Health Clinical Center (CC)||Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|October 24, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736332||75477|
NCT01736345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 29112|A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study|A Study of the Communication of Genetic Test Results by Telephone: a Multi-center Study||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|289|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Engligh speaking Male or Female Completed in person pretest counseling Decided to have        blood drawn for clinical BRCA 1/2 Age 18 or older|November 2015|November 23, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01736345||75476|
NCT01735994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11032|Efficacy of the Female Athlete Body Project (FAB)|Healthy Weight Intervention in Female Athletes: A Randomized Controlled Trial|FAB|Pennington Biomedical Research Center|No|Active, not recruiting|November 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|481|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01735994||75503|
NCT01736852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-014|Evaluation of CRB in PROM Patients|Randomized Study to Compare the Cook Cervical Ripening Balloon Plus Pitocin to Pitocin Alone in PROM Patients||Cook||Recruiting|November 2012|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736852||75437|
NCT01736865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK76092-06|Vitamin D for Established Type 2 Diabetes (DDM2)||DDM2|Tufts Medical Center|Yes|Recruiting|December 2012|||December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|25 Years|75 Years|No|||May 2013|May 24, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01736865||75436|
NCT01736878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARL-2|Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma|Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma|SUMMIT|Eanm Research Ltd|Yes|Withdrawn|October 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|October 23, 2012||No|Study was withdrawn due to unanticipated hassle in patient recruitment.|No||https://clinicaltrials.gov/show/NCT01736878||75435|
NCT01737398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 420915-CS2|Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy|A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy||Ionis Pharmaceuticals, Inc.|Yes|Active, not recruiting|December 2012|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|82 Years|No|||March 2016|March 23, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737398||75395|
NCT01737944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-10-001|Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration|Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis||Antares Pharma Inc.|No|Completed|January 2011|June 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|November 27, 2012|Yes|Yes||No|January 25, 2013|https://clinicaltrials.gov/show/NCT01737944||75353|
NCT01737957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-LFPRP|Safety and Efficacy of Low-Fluence PRP for PDR|Safety and Efficacy of Single-session, Low-fluence Panretinal Photocoagulation (PRP) for Proliferative Diabetic Retinopathy (PDR)||Asociación para Evitar la Ceguera en México|Yes|Recruiting|November 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01737957||75352|
NCT01738269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM RD001|Elecsys HE4 Chinese Reference Value Study|A Multi-center Reference Value Study of Elecsys HE4 in Chinese Population||Chinese PLA General Hospital|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|2351|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Except for samples from apparently healthy subjects, specimens for the entire clinical        section are supposed to be available in banks / archives. Thus, for the most part, no        prospective collection of serum should be necessary. Pseudonymized residual samples will        be used. All elements of the clinical part require samples from well characterized cohorts        are showed below.          1. Apparently Healthy: 300          2. Non-malignant Conditions: 650          3. Malignant Conditions: 800|July 2013|July 30, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738269||75328|
NCT01738529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-089 sub 3|Characterization of Crohn's Disease at Confocal Laser Endomicroscopy (CLE) and Related to Disease Activity|Characterization of Crohn's Disease at Confocal Laser Endomicroscopy and Related to Disease Activity||Herlev Hospital|Yes|Completed|November 2012|February 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01738529||75308|
NCT01751802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY102|Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease||Psyadon Pharma|Yes|Terminated|December 2012|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|6 Years|70 Years|No|||October 2015|October 5, 2015|December 14, 2012|Yes|Yes|Study terminated for commercial reasons|No|October 5, 2015|https://clinicaltrials.gov/show/NCT01751802||74289|
NCT01752257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033938|EF5 in Melanoma Patients|Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan||Duke University|No|Completed|July 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|October 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752257||74254|
NCT01752244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-02-27-18041|Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects|Assessing the Effects of Supplementary Alfacalcidol Intake on Peroxisome Proliferator-activated Receptor-coactivator-1α, Vitamin D Receptor and Peroxisome Proliferator-activated Receptor Gamma Gene Expression in Obese Subjects||Tehran University of Medical Sciences||Recruiting|January 2012|January 2013|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|94|||Both|22 Years|52 Years|Accepts Healthy Volunteers|||December 2012|December 24, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752244||74255|
NCT01748305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e8631|Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus|Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus: a Pilot Study||Oregon Health and Science University|No|Terminated|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|December 10, 2012||No|Recruitment issues.|No||https://clinicaltrials.gov/show/NCT01748305||74557|
NCT01752231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12050|Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring|Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring||City of Hope Medical Center|Yes|Enrolling by invitation|November 2012|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|December 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752231||74256|
NCT01748266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008018|Microcirculation of the Thenar Eminence|Interest of the Measure of the StO2 to Estimate the Microcirculatory Disturbances Following Cardiac Surgery With Cardiopulmonary Bypass||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|patients at high risk of post operative systemic inflammatory response syndrome after an        elective cardiac surgery with CPB|December 2012|December 11, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748266||74560|
NCT01748864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.11|Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers|A Single-Center Phase I Clinical Study to Evaluate The Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers||Endocyte||Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 28, 2014|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748864||74514|
NCT01735162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-AKI-CHERUB|Study of the Prediction of Acute Kidney Injury in Children Using Risk Stratification and Biomarkers|Prospective Study of Acute Kidney Injury in Critically Ill Children Predicted by Renal Angina and Urinary Biomarkers|AKI-CHERUB|Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2012|October 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|184|Samples Without DNA|Urinary samples, intended for discard so waiver of consent obtained. Urine samples spun and      frozen at -80C. Samples to be run for biomarker ELISA kits.|Both|N/A|N/A|No|Non-Probability Sample|All children admitted to a tertiary children's hospital pediatric intensive care unit with        an expected length of stay > 48 hours.|February 2015|February 2, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01735162||75567|
NCT01735175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-EP06-301|Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®|A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy|PROTECT-1|Sandoz||Completed|June 2012|September 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|318|||Female|18 Years|N/A|No|||April 2015|April 8, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735175||75566|
NCT01735448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-472|Improving Health for Aboriginal People Through Tobacco Related Research|Advancing the Understanding of Barriers and Facilitators for Tobacco Prevention, Cessation Treatments, Doctor Visits for Related Illnesses and Health Research for Aboriginal Australians||The Queen Elizabeth Hospital|Yes|Enrolling by invitation|March 2013|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||13|Anticipated|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who agree to be involved in the focus groups will be recruited via existing        community contacts (e.g., Aboriginal elders, leaders of community groups and doctors who        support the planned research) in urban Adelaide and regional Murray Bridge. We also intend        on actively recruiting through clinic visits made by our visiting respiratory clinicians.        Copies of the participant information sheet and consent form will be disseminated via        local healthcare workers to seek focus group volunteers and via existing contacts in        health and by word of mouth for one-on-one interview participants. Survey participants        will be recruited as per above methods in addition to use of delegate lists and mail outs.|March 2013|March 5, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735448||75545|
NCT01736007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCH-derm001|Childhood Alopecia Areata Study Using the 308-nm Excimer Laser|Childhood Alopecia Areata Study: Part 1: Feasibility of the 308-nm Excimer Laser in Treatment of Patch Type Alopecia Areata in Pediatric Patients||Phoenix Children's Hospital|No|Withdrawn|August 2012|August 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|November 1, 2012|No|Yes|was not able to recruit participants|No||https://clinicaltrials.gov/show/NCT01736007||75502|
NCT01736592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13588|A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration|An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration||Sanofi|Yes|Enrolling by invitation|December 2012|September 2032|Anticipated|September 2032|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736592||75457|
NCT01737151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14712|Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer|Study of 4-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Intermediate Risk Adenocarcinoma of the Prostate||Virginia Commonwealth University|Yes|Active, not recruiting|March 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737151||75414|
NCT01737138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-SR-142|Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension|RSD4CKD|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|November 2012|April 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||November 2012|November 30, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737138||75415|
NCT01737684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4618-013|A Single-Dose Study of the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency (MK-4618-013)|A Two-Part, Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency||Merck Sharp & Dohme Corp.||Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737684||75373|
NCT01737658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|accacha01|Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study|Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study||Winthrop University Hospital|No|Recruiting|December 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01737658||75375|
NCT01737671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0823|Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study|Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study||M.D. Anderson Cancer Center|Yes|Active, not recruiting|December 2012|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|22 Years|No|||April 2015|April 7, 2015|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737671||75374|
NCT01738295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-084-CERES|Donepezil Effect on Visual Attention and Training|Donepezil Effect on Visual Attention and Perceptual Training in Healthy Young Adults||Université de Montréal|Yes|Recruiting|January 2013|September 2013|Anticipated|August 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|34|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01738295||75326|
NCT01738555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFSP-AMDX-2012|A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects|An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.||RFS Pharma, LLC|No|Withdrawn|April 2013|October 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738555||75306|
NCT01751815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2011.442-T|Acu-TENS for Pain Relief During Colonoscopy|The Application of Transcutaneous Electric Nerve Stimulation on Acupoints (Acu-TENS) for Pain Relief During Colonoscopy: a Prospective, Randomized, Placebo-controlled Study||Chinese University of Hong Kong|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|60 Years|No|||February 2014|February 10, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751815||74288|
NCT01751828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121648|Late-life Depression and Cerebral Perfusion|Late-life Depression and Cerebral Perfusion||Vanderbilt University|No|Withdrawn|December 2012|||August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|60 Years|N/A|No|||July 2013|July 30, 2013|December 12, 2012|No|Yes|This was an initial unfunded pilot project stopped after similar studies were funded.|No||https://clinicaltrials.gov/show/NCT01751828||74287|
NCT01748344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4053POE003|Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis|A Randomised, Placebo Controlled, Four Period Crossover Study to Evaluate the Efficacy, Safety of Oral Repeat Doses of ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis in the Vienna Challenge Chamber.||Ono Pharmaceutical Co. Ltd|No|Completed|November 2012|||February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|58|||Both|18 Years|65 Years|No|||September 2012|April 14, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01748344||74554|
NCT01718171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-0044-2012|Inflammatory Response in Appendicitis|Progression of the Systemic Inflammatory Response in Patients With Appendicitis||Cirujanos la Serena|No|Completed|January 2011|July 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|183|||Both|15 Years|80 Years|No|Non-Probability Sample|Patients with appendicitis operated on and confirmed with biopsy|October 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718171||76865|
NCT01748318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 115653|New Mexico Honey Wound Treatment Research Study|New Mexico Honey Wound Treatment Research Study||Rankin, R. Stephen, M.D.|No|Recruiting|March 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748318||74556|
NCT01748292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28513|Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab|A Phase IIIb, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of IVT 0.5mg Ranibizumab Monthly Compared to a Treat & Extend Protocol in Patients With Wet Age-related Macular Degeneration (T-REX)|T-REX|Greater Houston Retina Research|Yes|Active, not recruiting|December 2012|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||March 2015|March 11, 2015|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748292||74558|
NCT01749124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHINO 2008-0132|My Coach Connect: An Automated Telephone-based Reporting System for Patients With Mental Illness|"My Coach Connect": Pilot Under the Partnered Research Center for Quality Care, RHINO 2008-0132|MCC|RAND|No|Active, not recruiting|December 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749124||74494|
NCT01749137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-493-003|Phase 2 Study to Evaluate Safety and Efficacy of Rm-493 in Obese Patients|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM 493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients||Rhythm Metabolic, Inc.|No|Completed|December 2012|September 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||November 2014|November 6, 2014|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749137||74493|
NCT01736020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB 1007, UCI 2004-3707|Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy|Developing Anesthesia as PTSD Therapy||Southern California Institute for Research and Education|Yes|Recruiting|September 2009|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|315|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01736020||75501|
NCT01736033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS1011|Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients|A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH|ABSOLUTE|Seoul National University Hospital|Yes|Active, not recruiting|February 2012|June 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|545|||Male|50 Years|N/A|No|||May 2014|May 13, 2014|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01736033||75500|
NCT01736384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/1010-31/3|Can Genetic Markers Predict Weight Loss After Gastric By-pass Surgery|Can Genetic Changes Predict Weight Loss and Outcome After Bariatric Surgery and Can it Related to Virus Infection and Function of Liver and Adipose Tissue as Well as Lipid and Protein Profiles.||Karolinska Institutet|No|Active, not recruiting|February 2009|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|2000|Samples With DNA|Tissue biopies, liver and subcutaneous and omental fat Whole blood EDTA-plasma Serum|Both|18 Years|65 Years|No|Non-Probability Sample|Obesity|February 2016|February 22, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01736384||75473|
NCT01736644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-07709|Bipolar Sealer Aquamantys Use in Total Knee Replacement|A Prospective Randomized Control Trial to Compare the Aquamantys System With Standard Electrocautery in Reducing Blood Loss in Primary Total Knee Arthroplasty||Medtronic Surgical Technologies|No|Active, not recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||February 2014|March 13, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01736644||75453|
NCT01736657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5001|Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients|Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.|ESSENTIAL|Terumo BCT|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|12 Years|N/A|No|||January 2014|July 10, 2014|November 27, 2012|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01736657||75452|
NCT01736605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008563|The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction|The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction - A Pilot Study||Mayo Clinic|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||April 2015|April 6, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01736605||75456|
NCT01736618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC CRM CDM00055718|S-ICD® System Post Approval Study|S-ICD® System Post Approval Study||Boston Scientific Corporation|No|Recruiting|March 2013|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1616|||Both|N/A|N/A|No|Probability Sample|The S-ICD System is intended to provide defibrillation therapy for the treatment of        life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic        bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring        ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.|November 2015|November 18, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736618||75455|
NCT01736891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLPDMF2010L03416|Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations|Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)||Chongqing Fortune Pharmaceutical Co., Ltd.|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|268|||Both|30 Years|75 Years|No|||November 2012|September 12, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736891||75434|
NCT01736917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QL12-153|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors|Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153||Hoosier Cancer Research Network|Yes|Completed|January 2013|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|15 Years|N/A|No|||July 2015|July 23, 2015|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736917||75432|
NCT01737411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URGE-I|Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women|Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women|URGE-I|Klinikum der Universität Köln|Yes|Recruiting|January 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|40 Years|80 Years|No|||April 2015|April 6, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737411||75394|
NCT01737424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-CYCL001|Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects|A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects||LG Life Sciences|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737424||75393|
NCT01737437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|php1|Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation|Effect of Lidocaine Sprayed on Direct Laryngoscopy and Trachea on Hemodynamics During Endotracheal Intubation||Seoul National University Hospital|No|Recruiting|October 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|80|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737437||75392|
NCT01737450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET12-034|Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive|A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a PI3K Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy|PIK-ORL|Centre Leon Berard|Yes|Recruiting|January 2013|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01737450||75391|
NCT01737983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lactobacillus reuteri in fc|Effect of Lactobacillus Reuteri in Cystic Fibrosis|Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.||Azienda Policlinico Umberto I|Yes|Completed|May 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|6 Years|42 Years|No|||November 2012|November 28, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01737983||75350|
NCT01747109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0178|Benefits of Optiflow® Device for Preoxygenation Before Intubation in Acute Hypoxemic Respiratory Failure : The PREOXYFLOW Study|A Prospective, Multicenter, Randomized, Controlled, Parallel-group, Open Label Trial Evaluating Benefits of Nasal High Flow Therapy (HFT) in Preoxygenation Before Tracheal Intubation in Acute Hypoxemic Respiratory Failure|PREOXYFLOW|Nantes University Hospital|No|Completed|November 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01747109||74649|
NCT01747122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/R/SU/01 - LIVER 2 Trial|The Effects of Local Infiltration Versus Epidural Following Liver Resection 2|A Randomised Trial of Peri-operative Nerve Block and Continuous Infusion of Local Anaesthetic Via Wound Catheter Versus Epidural in Patients Undergoing Open Liver Resection.|LIVER 2|University of Edinburgh|Yes|Completed|December 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||October 2014|October 13, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01747122||74648|
NCT01738568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003357|Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism|Effect of Aging and Aerobic Exercise Training on Brain Glucose Metabolism||Mayo Clinic|No|Active, not recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01738568||75305|
NCT01718184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RabinMC Sulcoflex Toric IOL|Piggyback Sulcoflex Toric IOL for Correcting Refractive Error Following Corneal Transplantation|||Rabin Medical Center|Yes|Recruiting|October 2012|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718184||76864|
NCT01718457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9626-GL-CTIL|Endobarrier Treatment in Obese Subjects With T2DM|Endobarrier Treatment in Obese Subjects With T2DM||Sheba Medical Center|No|Active, not recruiting|December 2012|January 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|No|||June 2014|June 30, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718457||76843|
NCT01748643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVRA-01|CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity|Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery|CURES|Ziekenhuis Oost-Limburg|No|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 24, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748643||74531|
NCT01748630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTM_Anaesthesia_MSA1|Effects of Dexmedetomidine on the Postoperative Experience in Children|Pain, Fentanyl Consumption, and Delirium in Children After Scoliosis Surgery: Dexmedetomidine Versus Midazolam||Inonu University|No|Completed|February 2012|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01748630||74532|
NCT01719809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR 0054|An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation|A Prospective Evaluation of the Effect of Training on Eye Drop Administration in Glaucoma Subjects Who Have Difficulties Properly Instilling Eye Drops||Robin, Alan L., M.D.|Yes|Terminated|October 2012|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|Private Ophthalmology Office (Specialty-Glaucoma)|October 2015|October 26, 2015|October 25, 2012||No|Enrollment Goals not met|No||https://clinicaltrials.gov/show/NCT01719809||76740|
NCT01736046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02211|Comparison of Standard and Low Dose CT Enterography for Crohn's Disease|Effects of CT Reconstruction Algorithm on the Quantitative Assessment of Crohn's Disease: A Comparison of Standard and Low Dose CT Enterography||University of British Columbia|No|Completed|December 2012|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|163|||Both|19 Years|80 Years|No|Probability Sample|Patients suspected of having Crohn's Disease who are referred for CT Enterography        examination by their gastroenterologist|July 2015|July 30, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01736046||75499|
NCT01745107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z121107001012004|Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;|Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;|IMRT|Chinese Academy of Medical Sciences|Yes|Recruiting|November 2012|November 2020|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|72 Years|No|||December 2015|December 9, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745107||74802|
NCT01745120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGB-204|A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects|A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral β-A(T87Q)-Globin Vector (LentiGlobin® BB305 Drug Product)||bluebird bio|Yes|Recruiting|August 2013|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|12 Years|35 Years|No|||January 2016|January 19, 2016|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01745120||74801|
NCT01736904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wXELIRI vs FOLFIRI in CRC|wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients|A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients||Fudan University|No|Recruiting|May 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||November 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01736904||75433|
NCT01737463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-2012-04|Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study|Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study|PDS|Soonchunhyang University Hospital|No|Enrolling by invitation|March 2010|October 2014|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|80 Years|No|||December 2012|December 1, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01737463||75390|
NCT01737476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor010912ctil|Trial to Evaluate the Efficacy of the HLPFC Coil Deep Transcranial Magnetic Stimulation System in Treating Attention Deficit and Hyperactivity Disorder (ADHD) in Adults|||Soroka University Medical Center||Not yet recruiting|November 2012|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Both|18 Years|65 Years|No|||November 2012|November 26, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01737476||75389|
NCT01737164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20100133H|Effect of Age on Glucose and Lipid Metabolism|Effect of Age on Glucose and Lipid Metabolism||The University of Texas Health Science Center at San Antonio|No|Completed|September 2010|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737164||75413|
NCT01738022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957C|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study C|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study C||Brigham and Women's Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01738022||75347|
NCT01737697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-003|Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia|Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia||ZS Pharma, Inc.|Yes|Completed|November 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|750|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737697||75372|
NCT01747655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-893|A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study|Analysis of MOtor and NOn Motor Symptoms, Quality of Life and Occurence of Dyskinesias in Advanced Parkinson's Disease Patients With 2 to 4 Hours 'Off-time' and Without Troublesome Dyskinesias Under Duodopa TREATment - a Multi-country Post-marketing Observational Study -MONOTREAT|MONOTREAT|AbbVie|No|Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|64|||Both|18 Years|N/A|No|Probability Sample|Hospital clinic|August 2015|August 24, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01747655||74607|
NCT01738581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSS0608M91226|Dystonia Synergistic Intervention|Determining the Efficacy of Synergistic Intervention With rTMS and Sensorimotor Retraining|DSS|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|75 Years|No|||February 2014|February 6, 2014|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738581||75304|
NCT01751581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR-P&F-1|Sleep Restriction and Energy Expenditure|The Effect of Sleep Reduction on Daily Energy Expenditure, Thermic Effect of Food, and Substrate Oxidation in Overweight Women||St. Luke's-Roosevelt Hospital Center|No|Completed|November 2011|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||December 2011|August 1, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01751581||74305|
NCT01752270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sunyatsen8362|the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome|The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization||First Affiliated Hospital, Sun Yat-Sen University|No|Not yet recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|45 Years|No|||December 2012|December 16, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01752270||74253|
NCT01717911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 201007016MB|ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia|ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia||Taipei Veterans General Hospital, Taiwan|No|Recruiting|September 2010|December 2018|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|30 Years|80 Years|No|||July 2010|October 28, 2012|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01717911||76885|
NCT01717924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_25|Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma|Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)|ADCI002|University Hospital, Lille|Yes|Recruiting|October 2012|April 2024|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01717924||76884|
NCT01718470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMAvsETT|Proseal Laryngeal Mask Airway or Endotracheal Tube for Emergence From Neuroanesthesia|Proseal Laryngeal Mask Airway Attenuates Systemic and Cerebral Hemodynamic Response During Awakening of Neurosurgical Patients||Fundacion Clinic per a la Recerca Biomédica|No|Completed|July 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01718470||76842|
NCT01748877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXN-462-201|Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)||NeurAxon Inc.|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01748877||74513|
NCT01719003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.1|Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes|A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|October 2012|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|9||Actual|1413|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 30, 2012||||No|November 23, 2015|https://clinicaltrials.gov/show/NCT01719003||76802|
NCT01736059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMSCRetPilot|Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy|A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy||University of California, Davis|No|Enrolling by invitation|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|100 Years|No|||January 2016|January 7, 2016|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736059||75498|
NCT01736072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2011-8537|RObotic Versus LAparoscopic Resection for Rectal Cancer|RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.|ROLARR|University of California, Irvine|Yes|Active, not recruiting|December 2011|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|520|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01736072||75497|
NCT01745458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104623|SB-659032 Platelet Aggregation Study|A Double Blind Study to Evaluate Effects of Repeat Doses of SB-659032 on Platelet Aggregation in Healthy Volunteers||GlaxoSmithKline||Completed|July 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745458||74775|
NCT01745757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0102/1203 - GRT02|Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer|Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer|COMET|UNICANCER|No|Recruiting|June 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|510|||Both|18 Years|N/A|No|Non-Probability Sample|cancer metastatic breast cancer|August 2014|August 5, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01745757||74752|
NCT01736358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sprix|The Use of Intranasal Ketoralac for Pain Management|Evaluating Post-operative Pain Management Efficacy of Intra Nasal Ketorolac in Ambulatory Urological Surgeries-A Randomized Double-blinded Placebo Controlled Study||Montefiore Medical Center|Yes|Recruiting|October 2012|||October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2012|November 28, 2012|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736358||75475|
NCT01736371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cis-sevo-123|Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.|Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.||Tianjin Medical University General Hospital|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|156|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01736371||75474|
NCT01736631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBTSPBD-001|Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder|Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder: A Pilot Study||Nova Scotia Health Authority|No|Recruiting|March 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736631||75454|
NCT01745978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|changhai-121202|Compare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation|The Efficacy and Safety of Precut Papillotomy Using the Knob-tipped Knife and Needle Knife in Difficult Biliary Cannulation: a Randomized-controlled Trial.||Changhai Hospital|Yes|Recruiting|December 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||December 2012|December 7, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745978||74735|
NCT01745991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKA/LTHT/UK/CoSealRCT|Trail to Investigate the Effectiveness of CoSeal in Reducing Adhesions Following the Kasai Hepatoportoenterostomy for Biliary Atresia|Randomised Control Trial to Investigate the Effectiveness of CoSeal® Surgical Sealant in Reducing Intra-abdominal Adhesions Following the Kasai Hepatoportoenterostomy for Biliary Atresia.|CoSRCT|The Leeds Teaching Hospitals NHS Trust|No|Recruiting|December 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|126|||Both|N/A|6 Months|No|Non-Probability Sample|126 patients over a three year period|September 2014|September 13, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01745991|5 Years|74734|
NCT01737710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADRN-05|Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study|A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|368|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737710||75371|
NCT01746524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10004|Prospective, Multiconfiguration Study to Assess Functional Performance of Primary Total Knee Arthroplasty System|Prospective, Single Arm Multiconfiguration Investigation to Assess Functional Performance of Attune™ Primary Total Knee Arthroplasty System|10004|DePuy Orthopaedics|No|Active, not recruiting|November 2012|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1138|||Both|22 Years|80 Years|No|||January 2016|January 19, 2016|December 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01746524||74694|
NCT01746537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-612|Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography|Automated Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography|ATAC|The Cleveland Clinic|No|Recruiting|June 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with inactive and active uveitis.|March 2016|March 14, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746537||74693|
NCT01746797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001637|Symptom Tracking in Assisted Reproductive Technologies|Symptom Tracking in Women With a History of Depression Going Through Infertility Treatment.|START|Massachusetts General Hospital||Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|samples obtained with permission from participant and stored for future proteomic research|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will include 60 women 18 years and older with histories of depression or bipolar        disorder who are planning infertility treatment, specifically in utero insemination (IUI)        or in vitro fertilization (IVF).|March 2016|March 14, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01746797||74673|
NCT01746810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1206|IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors|IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Lung Tumors Larger Than 3 cm: Phase I Dose Escalation and Pilot Study With Companion Biomarker Analysis||New Mexico Cancer Care Alliance|Yes|Active, not recruiting|July 2012|September 2018|Anticipated|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01746810||74672|
NCT01701102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11140|Study to Find Optimal Dose of Local Spinal Anesthetic (Mepivacaine) Combined With Narcotic (Fentanyl) For Knee Surgery|Optimal Dose of Spinal Mepivacaine Combined With Fentanyl For Knee Arthroscopy||Hospital for Special Surgery, New York|No|Completed|December 2011|December 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|February 11, 2016|January 4, 2012||No||No|February 11, 2016|https://clinicaltrials.gov/show/NCT01701102||78173|
NCT01701128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTPD-2011|The Effect of Exercise Training on Gait and Quality of Life in Parkinson's Disease|The Effect of Exercise Training on Gait and Quality of Life in Patients With Early Parkinson's Disease||Laval University|Yes|Terminated|October 2010|March 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|40 Years|80 Years|No|||September 2012|October 3, 2012|September 18, 2012||No|Protocol is completed|No||https://clinicaltrials.gov/show/NCT01701128||78171|
NCT01701440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310-0017|Efficacy Study for Magnetic Induction to Treat Wrinkles|Radiofrequency Magnetic Induction Device for Use In Dermatologic Procedures for the Non-Invasive Treatment of Wrinkles and Rhytides||Rocky Mountain Biosystems, Inc.|No|Active, not recruiting|October 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701440||78147|
NCT01701661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH4209|Compression Therapy Versus Surgery in the Treatment of Superficial Venous Reflux|Compression Therapy Versus Surgery in the Treatment of Superficial Venous Reflux - A Randomized Controlled Trial||Helsinki University Central Hospital|No|Completed|September 2004|September 2012|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|20 Years|70 Years|No|||October 2012|October 4, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701661||78130|
NCT01701674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17057|Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts|Co-stimulation With Ipilimumab to Enhance Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701674||78129|
NCT01752439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCSCMMOH1|Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache|Randomized Double-Blind Sham-Controlled Study of the Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache Patients||Mediterranean Neurological Institute|Yes|Enrolling by invitation|February 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||December 2012|December 14, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01752439||74240|
NCT01752452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE20116003|Effect of Ulnar Styloid Fracture on the Outcome of Distal Radial Fractures Treated With External Fixation|||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Completed|January 2009|October 2012|Actual|August 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|106|||Both|30 Years|90 Years|No|Probability Sample|unstable distal radial fracture patients: (1) the initial dorsal angulation ＞20°, (2) with        dorsal or volar comminution of the metaphysis, (3) shortening of radius ＞5 mm, and (4)        with an associated ulnar fracture.|December 2012|December 14, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01752452|2 Years|74239|
NCT01752400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-458|AUY922 for Advanced ALK-positive NSCLC|A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition||Massachusetts General Hospital|Yes|Active, not recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752400||74243|
NCT01752413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDAR-PN|Iron Depletion and Replacement in Blood Donors|Iron Depletion and Replacement in Blood Donors||Memorial Blood Centers, Minnesota|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01752413||74242|
NCT01752426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0086|Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL|A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2012|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752426||74241|
NCT01748461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML8733|Objective Assessment and Promotion of Physical Activity in Elderly|||Universitaire Ziekenhuizen Leuven||Completed|May 2013|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|105|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01748461||74545|
NCT01748474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2012-0251|Effect of Short-term Oxygen During CPET in Pulmonary Hypertension|Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension|ExOx-CPET|University of Zurich|No|Recruiting|December 2012|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|20 Years|80 Years|No|||October 2015|October 2, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01748474||74544|
NCT01741467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|369196|The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes|The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes|CGM PreDM|Walter Reed National Military Medical Center|Yes|Terminated|May 2012|November 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|July 19, 2012||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01741467||75082|
NCT01741480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210003|Early Warning System|Comparing an Early Warning Alert With a Standardized Triage Intervention to Standard Care for the Management of Hospitalized Patients on General Hospital Wards.||Washington University School of Medicine|No|Recruiting|February 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741480||75081|
NCT01741753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-121|BKM120+Abiraterone Acetate for Metastatic CRPC|Phase Ib Study of BKM120 Combined With Abiraterone Acetate for Docetaxel-pretreated, Castrate-resistant, Metastatic Prostate Cancer||Dana-Farber Cancer Institute|Yes|Terminated|November 2012|September 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|December 3, 2012|Yes|Yes|Due to continued slow accrual the supllier of BKM120 requested that we cease further    enrollment.|No||https://clinicaltrials.gov/show/NCT01741753||75060|
NCT01703052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1006-PR-0048|Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)|A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers||Chiesi Farmaceutici S.p.A.|Yes|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|October 8, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01703052||78023|
NCT01703377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203044RIC|Effect of Constraining Joint Motions on Postural Control|Effect of Constraining Joint Motions on Postural Control||National Taiwan University Hospital|Yes|Recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults from 18-65 years old|July 2015|July 7, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703377||77998|
NCT01703676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpigenMetabDisordKlinefelter|Epigenetics and Metabolic Disorders in Men With the Klinefelter Syndrome|Klinefelter Syndrome: Do the Parental Origin and Epigenetic Profile of the Supernumerary X Chromosome Determine Phenotype, Morbidity, Inflammatory Status and Cardiovascular Risk?|IZKF-CRA03-09|University Hospital Muenster|Yes|Completed|March 2010|August 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|300|Samples With DNA|Blood, Testicular Tissue, Mouth Epithelium|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients, their parents, male controls, female controls|October 2012|October 12, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703676||77975|
NCT01699698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMSC-PJD-1|Pancreatic Juice Diagnosis From Duodenum|Pancreatic Juice Diagnosis From Duodenum||Olympus Corporation|Yes|Completed|October 2012|||July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|105|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|September 24, 2012||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01699698||78281|
NCT01700218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-537 ex 11/12|Integrated Telemonitoring and Nurse Support Evaluation|Integrated Telemonitoring and Nurse Support Evaluation in Heart Failure|INTENSE-HF|Medical University of Graz|Yes|Recruiting|October 2012|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||November 2014|November 23, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700218||78241|
NCT01700231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVPG/Liver Regeneration Study|Plasma and Hemodynamic Markers During Hepatectomy|Monitoring Plasma and Hemodynamic Markers in Patients Undergoing Liver Resection to Identify Pathophysiological Mechanisms and Predict Clinical Outcome||Medical University of Vienna|No|Completed|October 2010|||August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|Samples With DNA|perioperative plasma samples|Both|18 Years|85 Years|No|Probability Sample|Patient with neoplastic liver tumors undergoing hepatectomy.|April 2015|April 6, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700231||78240|
NCT01700816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002801|Prevention of Delirium After Bone Marrow Transplantation|Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)||Massachusetts General Hospital|Yes|Recruiting|October 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|90 Years|No|||May 2013|May 16, 2013|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700816||78195|
NCT01701115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-011|Effect of Local Anesthetic Dose on Interscalene Block|Effect of Local Anesthetic Dose on Interscalene Block for Shoulder Arthroscopy, Patient Satisfaction and Return of Handgrip Strength|Low Dose ISB|Hospital for Special Surgery, New York|Yes|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01701115||78172|
NCT01701141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001360|Depression and Dopamine Transporter Function Study Using C-11 Altropane|Depression and Dopamine Transporter Function: A Positron Emission Tomography Study Using C-11 Altropane||Mclean Hospital|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|April 2015|April 6, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01701141||78170|
NCT01740635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02043|EPIC WheelS Feasibility Study|Enhancing Participation In the Community by Improving Wheelchair Skills (EPIC WheelS): A Feasibility Study||University of British Columbia|No|Recruiting|March 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||December 2015|December 2, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01740635||75146|
NCT01748487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143BYP|The Effect of Intravitreal Ozurdex on DME After Cataract Surgery|A Pilot Study of the Effect of Intravitreal Dexamethasone Implant (700 Micrograms) on Diabetic Macular Edema After Cataract Surgery||University Health Network, Toronto|No|Completed|December 2012|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748487||74543|
NCT01748500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANDORA|Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer|Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA)||University Health Network, Toronto|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Male|18 Years|N/A|No|||July 2015|July 6, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748500||74542|
NCT01740895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFC-001|ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II|A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.|ADVISEII|Volcano Corporation|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|818|||Both|18 Years|85 Years|No|Non-Probability Sample|Patient receiving a standard of care FFR measurment in the cath lab setting.|August 2014|August 5, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01740895||75126|
NCT01740908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI-2012-05-STCELL-001|Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments|Pilot Study for the Detection of Stem/Progenitor Cell Up-regulation Using Aldagen BRIGHT Technology in Peripheral Blood After Hyperbaric Oxygen Therapy (HBOT) Treatment||Restorix Research Institute, LLLP|Yes|Enrolling by invitation|December 2012|January 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will reflect the racial and ethnic distribution that exists in the Anacortes        metropolitan region.        B- Skagit County, WA: White (91.4%), Black (0.9%), American Indian (2.6%), Asian or        Pacific Islander (2.3%), Other (2.8%)|November 2012|November 30, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740908||75125|
NCT01741233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-071|The Genetics Behind Vitamin D Status (VitDgen)|The Genetics Behind Vitamin D Status (VitDgen)|VitDgen|Technical University of Denmark||Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|102|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|July 31, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741233||75100|
NCT01741181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMENSION-03|Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2|Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 and Low 25(OH)D Concentrations: Does it Help to Improve Endothelial Function-The DIMENSION TRIAL|DIMENSION|Tan Tock Seng Hospital|Yes|Completed|September 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|21 Years|80 Years|No|||November 2014|November 17, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741181||75104|
NCT01741194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-12-010|AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext|A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension|NOURISH AD|Accera, Inc.|Yes|Recruiting|March 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|480|||Both|66 Years|90 Years|No|||March 2016|March 22, 2016|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741194||75103|
NCT01741207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524|Effect of N-acetylcystein in Myocardial Infarction|Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention||Tehran University of Medical Sciences|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|90 Years|No|||November 2012|November 30, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741207||75102|
NCT01741220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMEDIA|Resilience and Mentoring in German-speaking Intensive Care Providers and Anesthesiologists|Resilience and Mentoring in German-speaking Intensive Care Providers and Anesthesiologists|REMEDIA|Medical University of Graz|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|German-speaking intensive-care providers and anesthetists|April 2015|April 4, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01741220||75101|
NCT01741766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2010.5615|The Effects of Stretching Training on Arterial Function and Autonomic Control|The Effects of 8 Weeks of Stretching Training on Arterial Stiffness, Wave Reflection, Endothelial Function and Cardiac Autonomic Control.||Florida State University|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741766||75059|
NCT01742039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF01|Prevention of Postoperative Atrial Fibrillation|A New Therapeutic Strategy to Reduce the Incidence of Postoperative Atrial Fibrillation||George Washington University||Completed|July 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|adult patients undergoing open heart surgery|December 2012|December 3, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01742039||75038|
NCT01742026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETH-PCRAGA|Aspergillus PCR Early Detection in High Risk Oncohematological Patients|ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS||Grupo Espanol de trasplantes hematopoyeticos y terapia celular|No|Active, not recruiting|February 2011|December 2012|Anticipated|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|225|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of hematological patients at high risk of invasive        fungal infection. Like: Leukemia acute mieloblasticas, myelodysplastic syndrome, patients        with intensive chemotherapy and allogeneic hematopoietic transplantation.|December 2012|December 3, 2012|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01742026||75039|
NCT01703663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U037625|Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.|Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.||University of Michigan|No|Completed|November 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703663||77976|
NCT01703689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARSMP.2010.1|Impact of Educational and Professional Supportive Interventions on Nursing Home Quality Indicators|Impact of Either Audit and Feedback Only or Audit and Feedback Associated to Cooperative Work Meetings Between Hospital Geriatricians and Nursing Home Staff on Quality Indicators and Health Care Practices in Nursing Homes.|IQUARE|Agence Régionale de la Santé - Midi Pyrénées|No|Active, not recruiting|May 2011|January 2013|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|6275|||Both|N/A|N/A|No|||September 2012|October 9, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01703689||77974|
NCT01703962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-28|Non Invasive IDentification of Gliomas With IDH1 Mutation|Non Invasive IDentification of Gliomas With IDH1 Mutation by Free Plasmatic DNA Analysis, 2-hydroxyglutarate Dosage in the Urines and 2-hydroxyglutarate Detection by Brain SPEctro-MRI: Diagnostic and Follow-up Application (IDASPE)|IDASPE|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|March 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Plasma samples containing free DNA fragments Urine|Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be recruited from the active file of patients with glioma II or III,        followed at the Pitié-Salpetrière Hospital, and whose status is known for IDH1.|February 2016|February 24, 2016|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703962||77953|
NCT01703975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRVK-35596|The Effects of Virtual Reality Ultrasound Training in Pairs Compared to Training Alone|||Rigshospitalet, Denmark|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|30|||Both|20 Months|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703975||77952|
NCT01703988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443 - CS2|An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy|An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy|SMNRx - CS2|Ionis Pharmaceuticals, Inc.|Yes|Completed|October 2012|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|2 Years|15 Years|No|||March 2015|March 9, 2015|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703988||77951|
NCT01699711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESDAD|Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool|Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool||Parc de Salut Mar|No|Completed|February 2012|March 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|14 Years|29 Years|No|||February 2016|February 10, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01699711||78280|
NCT01699932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMET_R_05823|Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled|A Multinational, Open Label, Non Comparative, 24-week Study to Evaluate the Blood Glucose Lowering Efficacy and Safety of a Fixed Dose Combination of Glimepiride and Metformin in Patients With Inadequately Controlled Type 2 Diabetes|LEGEND|Sanofi|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699932||78263|
NCT01700244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP004|Evaluation of a New Cardiac Pacemaker|||Nanostim, Inc.|Yes|Active, not recruiting|December 2012|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|October 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01700244||78239|
NCT01700569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO 2012-02|Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma|Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.|FOLAGLI|Institut Cancerologie de l'Ouest|Yes|Recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01700569||78214|
NCT01700829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6598|Ketamine in the Treatment of Suicidal Depression|Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression||New York State Psychiatric Institute|Yes|Recruiting|June 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700829||78194|
NCT01701687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12050|Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease|The Feasibility of Liver Biomarkers as Prognostic Markers in Decompensated Alcoholic Liver Disease|BANDED|University of Nottingham|No|Completed|September 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples Without DNA|Serum, plasma and urine stored at -80 degrees centigrade under written patient consent|Both|18 Years|75 Years|No|Non-Probability Sample|Potentially eligible patients are adult patients with decompensated liver disease with        alcohol as a major co-factor, and acutely admitted secondary to sequelae of hepatic        decompensation. 100 patients will be recruited for baseline visit over an 30 month study        enrolment period, with a 6 month follow up period for all patients.|July 2015|July 31, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701687||78128|
NCT01702311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056041|Point-of-Care Glucose Testing and Insulin Supplementation|Benefits of Point-of-Care Glucose Testing and Insulin Supplementation at Bedtime in Insulin Treated Patients With Type 2 Diabetes|POC|Emory University|Yes|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|80 Years|No|||June 2014|July 2, 2014|May 8, 2012||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01702311||78080|
NCT01702324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD-25|Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study|Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study||Fortuderm Ltd.|Yes|Recruiting|October 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||October 2012|October 4, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702324||78079|
NCT01701973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120078|Effect of DPP4 Inhibition on Growth Hormone Secretion|The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation||Vanderbilt University|Yes|Recruiting|January 2013|August 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01701973||78106|
NCT01701986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0506|Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas|Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas||M.D. Anderson Cancer Center|No|Recruiting|October 2012|||October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|12 Years|65 Years|No|||March 2016|March 14, 2016|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701986||78105|
NCT01740648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12054|Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer|A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|November 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01740648||75145|
NCT01740934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-012|A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea|An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension||Rock Creek Pharmaceuticals, Inc.|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01740934||75123|
NCT01740921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066|GLP-1 and Microvascular Function in Type 2 Diabetes|Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?|GLP-1ADDS|Royal Devon and Exeter NHS Foundation Trust|No|Completed|January 2011|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|39|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01740921||75124|
NCT01741506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPPVATS vs 1.1|Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer|Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial|COPPVATS|Aarhus University Hospital|Yes|Completed|March 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|116|||Both|18 Years|N/A|No|||April 2015|June 22, 2015|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01741506||75079|
NCT01741493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-845|A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494|A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494||AbbVie|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|67|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01741493||75080|
NCT01742052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E04|Dose-finding Study of MT-1303|A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|January 2013|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|415|||Both|18 Years|60 Years|No|||November 2014|November 10, 2014|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01742052||75037|
NCT01742065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH3CA188640|Strategies and Opportunities to Stop Colon Cancer in Priority Populations|Strategies and Opportunities to Stop Colon Cancer in Priority Populations|STOPCRC|Kaiser Permanente|Yes|Recruiting|January 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|20000|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742065||75036|
NCT01742351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39:2012|Internet-based Cognitive Behaviour Therapy (CBT) for Persons Diagnosed With Bipolar II|Internet-based Cognitive Behaviour Therapy for Persons Diagnosed With Bipolar II - a Pilot Study||Örebro County Council|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01742351||75014|
NCT01742364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 645|Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe|A Randomized Clinical Trial in Adults and Newborns to Compare the Safety, Reactogenicity and Immunogenicity of BCG Administration Via a Disposable Syringe Jet Injector (DSJI) to BCG Administration Via Syringe and Needle||PATH|Yes|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|96|||Both|N/A|50 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742364||75013|
NCT01703403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205036RIC|Physical Therapy Management in Degenerative Lumbar Diseases and Osteoporosis|Physical Therapy Management in Degenerative Lumbar Diseases and Osteoporosis||National Taiwan University Hospital|Yes|Recruiting|May 2012|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|120|||Both|50 Years|85 Years|No|Probability Sample|patients with the diagnosis including lumbar spondylosis, low back pain, osteoporosis,        compression fracture, back pain treated at National Taiwan University Hospital and        received rehabilitation at the Physical Therapy Center in recent ten years.|October 2012|October 9, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703403||77996|
NCT01699737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT851-U-12-002|Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus||Akros Pharma Inc.|No|Completed|September 2012|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|325|||Both|18 Years|70 Years|No|||July 2013|July 25, 2013|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699737||78278|
NCT01699750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-043 / ID11-59|Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems|Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems||Alcon Research|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|109|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 2, 2012|No|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01699750||78277|
NCT01704001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-123 IV-2|Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment|A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment||Asahi Kasei Pharma Corporation||Recruiting|October 2012|October 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|20 Years|N/A|No|||October 2012|October 16, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01704001||77950|
NCT01704014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01-034|Intraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists|Intraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists||Samsung Medical Center|Yes|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|150|||Both|N/A|N/A|No|Probability Sample|All korean patients who underwent cataract surgeries in Samsung Medical Center|October 2012|October 10, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704014||77949|
NCT01699724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501098|Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Assessing Bioequivalence Of Zoloft ODT 50 Mg Under Fasting Condition With And Without Water To Jzoloft Tablet 50 Mg Under Fasting Condition With Water In Healthy Japanese Subjects||Pfizer|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 31, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01699724||78279|
NCT01699958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StanfordIRB-20922|A Brief Outpatient Problem-solving Intervention to Promote Healthy Eating and Activity Habits in Adolescents|A Pilot Study of the "Healthy Living Study," a Randomized Controlled Trial of a Brief Outpatient Problem-solving Intervention to Promote Healthy Eating and Activity Habits in Adolescents.||Stanford University|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01699958||78261|
NCT01699945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC532(India)|Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way|Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way: The AMANHI* Study *Alliance for Maternal and Newborn Health Improvement (AMANHI)|AMANHI|Society for Applied Studies|Yes|Active, not recruiting|August 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|730|||Both|15 Years|49 Years|No|Non-Probability Sample|This study will be conducted in the same study areas and population as the parent study.        The participants in this study will be pregnant women identified through surveillance        among all women of reproductive age in the population where the parent study is being        conducted, and their newborn infants. The parent study is not conducting an intervention        related to maternal health or stillbirths. Therefore, the results of the AMANHI study        related to maternal and stillbirth outcomes are not likely to be influenced by what        happens in the parent study. However, only the control group in the parent study will be        considered for analysis of neonatal deaths in this observational study.|May 2015|May 29, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01699945||78262|
NCT01699971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/672-31/4|Randomized Controlled Study Comparing Three Different Techniques for Open Hernia Repair|Randomized Controlled Study Comparing Three Different Techniques for Open||Karolinska Institutet|No|Completed|October 2006|March 2012|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|160|||Male|18 Years|75 Years|No|||September 2012|October 3, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699971||78260|
NCT01701154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024468|The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease|The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease||Duke University|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|3 Years|N/A|No|Non-Probability Sample|Adults and children with Pompe disease|October 2012|January 16, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701154||78169|
NCT01701453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-070|Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)|Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)||Samsung Medical Center|Yes|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|20 Years|N/A|No|||October 2014|October 19, 2014|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01701453||78146|
NCT01732874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0329|DHA-1 for Lactating Mothers|Docosahexaenoic Acid Supplementation of Mothers to Improve Preterm Infant Nutrition and Immune Homeostasis|DHA-1|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|N/A|45 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732874||75740|
NCT01733121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1202|NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia||Neurocrine Biosciences|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|85 Years|No|||November 2014|November 20, 2014|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733121||75721|
NCT01733394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQUIGEN Single Dose Protocol|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)||University of Cincinnati|Yes|Active, not recruiting|April 2013|January 2016|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733394||75701|
NCT01702662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC2012_150, ABR: 40642|Photopill Treatment in Healthy Volunteers|The Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Healthy Volunteers, a Phase 1 Trial|Photopill|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702662||78053|
NCT01702675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-HML-01(03/12)|Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug|Phase I, Monocentric, Double-blind, Randomized Study to Assess Tolerability, Safety and Pharmacokinetics of ACH15 After Single Dose and Multiple Doses in Healthy Male Volunteers|ACH15|Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|April 2013|April 2014|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|11||Anticipated|60|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01702675||78052|
NCT01702688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 Lysine|Evaluation of Lysine-Specific Demethylase 1|Evaluation of Lysine-Specific Demethylase 1 As An Epigenetic Regulator of Salt Sensitive Hypertension||Brigham and Women's Hospital|Yes|Not yet recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|18 Years|65 Years|No|||October 2012|October 5, 2012|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01702688||78051|
NCT01740960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER001-02-03|Safety and Tolerability of Namisol in the Elderly|Safety and Tolerability of Oral Namisol®, a Tablet Containing Delta-9-Tetrahydrocannabinol, in Elderly Subjects: A Randomized Controlled Trial|THC|Radboud University|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2012|January 6, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01740960||75121|
NCT01740947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002211-28|Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?|Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial|SELECT|VU University Medical Center|No|Recruiting|January 2013|February 2021|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|762|||Both|N/A|N/A|No|||December 2015|December 8, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01740947||75122|
NCT01741519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOP LDLL600.101|Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers|A Single Centre Prospective, Randomized, Double Blind, Crossover, Pharmacokinetic, Safety and Tolerability Study to Compare Long-term Infusion Administration of LDLL600 Against Esmolol in Healthy Volunteers.||AOP Orphan Pharmaceuticals AG|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741519||75078|
NCT01741532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIRCON2012V1|A Two-arm Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)|A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)||ApoPharma|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|4 Years|N/A|No|||April 2014|March 30, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741532||75077|
NCT01741779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2011.6728|Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function|The Effect of Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function in Obese Postmenopausal Women||Florida State University|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|60|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 3, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741779||75058|
NCT01742078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11952|A Study of LY2541546 in Healthy Postmenopausal Women|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women||Eli Lilly and Company|No|Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|9||Actual|60|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742078||75035|
NCT01742377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 53-017-21-1-2|Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients|i-Scan Endoscopy in the Detection of Minimal Change Esophagitis in Dyspeptic Patients With or Without Gastroesophageal Reflux Disease by Gerd Q Questionnaire and by 24 Hour pH Monitoring.|MCE|Prince of Songkla University|Yes|Completed|February 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|174|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dyspepsia from clinics , primary care clinics ,community.|January 2015|April 11, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01742377||75012|
NCT01742390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI_IIT_01/02|A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders|||Peking University|Yes|Recruiting|February 2013|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|55 Years|No|||March 2013|March 13, 2013|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01742390||75011|
NCT01703416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RBG-ATC-2012/1|Correlation Between Patient Perception and Findings on Clinical Examination in Chronic Obstructive Pulmonary Disease (COPD) Patients|CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients Receiving Inhaled Combined Therapy (Corticosteroid/Long Acting ß2-agonist) - RELIEF Study|RELIEF|AstraZeneca|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|40 Years|N/A|No|Probability Sample|Chronic Obstructive Pulmonary Disease (COPD) patients group C and D|April 2013|April 24, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01703416||77995|
NCT01704066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCCTG-2012-ARDS-01|Interobserver Variation in Applying a Radiographic Definition for Acute Respiratory Distress Syndrome (ARDS)|Interobserver Variation in Applying a Radiographic Definition for ARDS: Impact of a Training Set of Berlin ARDS Definition||Society of Critical Care Medicine, China|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|286|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Intensivists working in the participating ICUs|December 2012|December 20, 2012|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01704066||77945|
NCT01704027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00694-39|Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer|Prospective Phase II Study Evaluating the Feasibility of a Conformational Pelvic and Prostatic Radiotherapy With Simultaneous Integrated Boost Modulated-intensity Arctherapy (SIB-IMAT) in Combination With Long Term Androgen Deprivation for High Risk Localized Prostate Cancer.||Centre Georges Francois Leclerc|No|Terminated|October 2012|||March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|85 Years|No|||September 2014|September 17, 2014|October 2, 2012||No|termination of the trial after interim analysis. the main criterion could not be reached|No||https://clinicaltrials.gov/show/NCT01704027||77948|
NCT01704040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100889|A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16|A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16||Janssen Research & Development, LLC|Yes|Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|76|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01704040||77947|
NCT01700296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34431|COPD, Inflammation and Rehabilitation|COPD, Inflammation and Rehabilitation||Odense University Hospital|No|Recruiting|January 2013|November 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700296||78235|
NCT01700283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208026RIC|Developing Objective Fatigue Indicators in Colorectal Cancer Survivors.|Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors.||National Taiwan University Hospital|Yes|Recruiting|October 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|306|||Both|20 Years|N/A|No|||October 2012|November 12, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700283||78236|
NCT01700556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRCA-01-2012|A Trial to Support Caregivers of Patients With Dementia in Italy: the UP-TECH Project|A Randomised Controlled Trial to Improve Support Services for Caregivers of Patients With Alzheimer Disease in Italy by UPgrading Quality of Care Through the Integration of Services and the Use of New TECHnologies (The UP-TECH Project)|UP-TECH|Istituto Nazionale di Ricovero e Cura per Anziani|No|Recruiting|November 2012|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|900|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01700556||78215|
NCT01701700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0211-24105|The Effectiveness of Portable Electronic Vision Enhancement Systems (p-EVES) for Near Vision in Visual Impairment|The Effectiveness of Portable Electronic Vision Enhancement Systems (EVES) in Comparison to Optical Magnifiers for Near Vision Activities in Visual Impairment - The p-EVES Study|p-EVES|Central Manchester University Hospitals NHS Foundation Trust|No|Completed|February 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|95 Years|No|||July 2015|July 27, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01701700||78127|
NCT01701999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rBV A/B-CL-001|Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid|Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection||California Department of Public Health|Yes|Completed|February 2013|October 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701999||78104|
NCT01702012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDIT-IRB00020672|Almased Multi-Center Diabetes Intervention Trial|Evaluation of Almased on Glycemic Control and Metabolic Effects in Patients With Type 2 Diabetes|AMDIT|Wake Forest School of Medicine|Yes|Completed|January 2013|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|240|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702012||78103|
NCT01733420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/538|Biodentine Versus White MTA Pulpotomy|The Clinical and Radiographic Efficacy of Biodentine™ and White Mineral Trioxide Aggregate in Deciduous Molar Pulpotomy - a Randomized Control Trial||University Ghent|No|Recruiting|October 2011|February 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01733420||75699|
NCT01733433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/480|Influence of Taping on Postural Control in Subjects With Chronic Ankle Instability|Influence of Taping on Postural Control in Subjects With Chronic Ankle Instability (CAI).|CAI|University Ghent|No|Recruiting|October 2012|May 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|30 Years|No|||December 2014|December 4, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01733433||75698|
NCT01733693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-433|Neurocognitive Effects of Opiate Agonist Treatment|Neurocognitive Effects of Opiate Agonist Treatment|NEO|Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01733693||75679|
NCT01733407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-04127-01|L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1||Massachusetts General Hospital|Yes|Active, not recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733407||75700|
NCT01740973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMBI-SILS-123|Risk of Umbilical Trocar-site Hernia After SILC Cholecystectomy Versus Conventional Cholecystectomy|Risk of Umbilical Trocar-site Hernia After SILC Versus Conventional Laparoscopic Cholecystectomy|UMBI-SILS|Hvidovre University Hospital|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|699|||Both|18 Years|90 Years|No|Non-Probability Sample|All patient having a SILC in Denmark from 1/1-2009-1/6-2011 and matched conventional lap.        cholecystectomies. Matched in gender, age, surgeons ecxperience|February 2015|February 11, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740973||75120|
NCT01741246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107004|Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging|Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging||University of California, San Francisco|No|Completed|September 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with episodic migraine, chronic migraine and control patients. Definitions are        taken for the International Classification of Headache Disorders-2nd Edition (see        references).|June 2015|June 26, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01741246||75099|
NCT01741831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100805|A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista|Regulatory Post Marketing Surveillance of Prezista 400mg Tablet||Janssen Korea, Ltd., Korea|No|Recruiting|July 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients who are diagnosed with Acquired Immune        Deficiency Syndrome (AIDS), and who are prescribed with darunavir for treatment of AIDS.|March 2016|March 11, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741831||75054|
NCT01742091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13405|A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women|A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women||Eli Lilly and Company|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|59|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742091||75034|
NCT01741792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-208|Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Amgen Research (Munich) GmbH|Yes|Active, not recruiting|July 2012|May 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|November 28, 2012||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01741792||75057|
NCT01741805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0032-CTIL|The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa|The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa.||Carmel Medical Center|No|Recruiting|December 2012|June 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|Population of petients with severe asthma, described by presence of symptoms despite        adequate treatment as described in the following sections.|December 2012|December 23, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01741805||75056|
NCT01742650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYS-7-2009|Screw Versus Tightrope Syndesmotic Injury Fixation in Weber C Ankle Fractures|Screw Versus Tightrope Syndesmotic Injury Fixation in Weber C Ankle Fractures. A Prospective Randomized Study.||University of Oulu|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|16 Years|N/A|No|||December 2012|December 2, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01742650||74991|
NCT01703715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12029|Hydration and Outcome in Older Patients|Hydration and Outcome in Older Patients|HOOP|University of Nottingham|Yes|Completed|August 2012|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Participants provide 5mls of whole blood on admission, at 48 hours post admission and at 3      month following discharge. This blood is to be analysed for urea, creatinine, sodium,      potassium, osmolality, full blood count as well as renin and aldosterone.|Both|65 Years|N/A|No|Non-Probability Sample|All patients admitted acutely to medical wards who are aged 65 years and over.|July 2014|July 14, 2014|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703715||77972|
NCT01704053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAPOC-271/12|Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study|Monitoring The Anticoagulatory Effects of Dabigatran and Rivaroxaban On Plasmatic and Cellular Coagulation by Rotational Thrombelastometry/-Graphy and Multiple Platelet Function Analyzer||Johann Wolfgang Goethe University Hospitals|Yes|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic. Patients with non-valvular atrial fibrillation who receive Dabigatran        or Rivaroxaban for prevention of stroke and systemic embolism.|August 2014|August 14, 2014|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01704053||77946|
NCT01700010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.045|Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer|Phase II Trial of Lapatinib and Weekly Paclitaxel for Advanced Platinum Refractory Urothelial Cancer||University of Michigan Cancer Center|Yes|Withdrawn|November 2012|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 2, 2012|Yes|Yes|Funding issues.|No||https://clinicaltrials.gov/show/NCT01700010||78257|
NCT01699984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1-PEV|PERDOVE ANZIANI: a Prospective Cohort Study on Older Patients|THE HOSPITALIZATION OF OLDER PATIENTS: RISK FACTORS, ADVERSE EVENTS AND OUTCOMES. A MULTICENTRE STUDY.||IRCCS Centro San Giovanni di Dio Fatebenefratelli|Yes|Completed|February 2011|September 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|329|Samples Without DNA|Blood samples for the assessment of APOE genetic polymorphisms; routine lab examinations.|Both|65 Years|N/A|No|Probability Sample|Patients aged 65 or older admitted to 4 geriatric inpatient facilities.|October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01699984||78259|
NCT01699997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2311148|Oxytocin as Adjunctive Therapy for Schizophrenia|The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial||IRCCS Centro San Giovanni di Dio Fatebenefratelli|Yes|Completed|January 2014|November 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|No|||February 2016|February 23, 2016|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699997||78258|
NCT01700309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2978|Young, Fit and Happy. A Web-based Intervention to Prevent Obesity in Adolescents.|Young Fit and Happy - Meaningful Physical Activity as Means to Improve Quality of Life and Prevent Weight Gain in Over-weight and Obese Adolescents. A Web-based Intervention.|YFH|Oslo and Akershus University College of Applied Sciences|No|Completed|January 2012|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|12 Years|14 Years|No|||April 2015|April 14, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700309||78234|
NCT01732315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0378|Adolescent Vaccination Reminder Study|Adolescent Vaccination Reminders Using Email||University of Colorado, Denver|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|3783|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01732315||75783|
NCT01732601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH097703-01|Intensive Outpatient Services for Teens|Intensive Outpatient Protocol for High Risk Suicidal Teens|INVEST|Brown University|Yes|Recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|12 Years|18 Years|No|||February 2016|February 29, 2016|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01732601||75761|
NCT01733706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S617/211|Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.|Evaluation of Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.||European Institute of Oncology|No|Completed|June 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||December 2015|January 21, 2016|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733706||75678|
NCT01733719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLRN 119238|Barrett&Apos;s Intervention for Dysplasia by Endoscopy|BRIDE (Barrett&Apos;s Randomised Intervention for Dysplasia by Endoscopy) - a Feasibility Study|BRIDE|University Hospitals, Leicester|Yes|Completed|February 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|76|||Both|18 Years|85 Years|No|||March 2016|March 10, 2016|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733719||75677|
NCT01733979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI- IDA-HIPk|Efficacy and Safety of Heme-Iron Polypeptide on Improvement of Anemia|||Chonbuk National University Hospital|Yes|Recruiting|February 2012|December 2012|Anticipated|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733979||75657|
NCT01733966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR_SIGMO_09|A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults|A Third Phase, Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults|DIVA|Quanta Medical|Yes|Terminated|May 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||March 2010|November 21, 2012|November 21, 2012||No|difficulties to recruit patients who suffer from this pathology|No||https://clinicaltrials.gov/show/NCT01733966||75658|
NCT01741272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001096|Early Mobilization Following Mini-Open Rotator Cuff Repair|Early Mobilization Following Mini-Open Rotator Cuff Repair: A Randomized Clinical Trial||Shoulder & Upper Extremity Research Group of Edmonton|No|Completed|September 2003|December 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|85 Years|No|||March 2015|March 3, 2015|November 29, 2012||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01741272||75097|
NCT01741259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371047-1|A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus|A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus||St. John's Health System, Missouri|Yes|Not yet recruiting|March 2013|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|272|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 1, 2013|November 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741259||75098|
NCT01741545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-030|Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia|A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin|MAGNITUDE|Bristol-Myers Squibb|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Male|18 Years|N/A|No|||March 2015|March 16, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741545||75076|
NCT01739881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB/2011/00380|Evaluating the Pulmonary Nodule With Imaging and Biomarkers|Evaluating the Pulmonary Nodule With Imaging and Biomarkers||National University Hospital, Singapore|No|Recruiting|April 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|21 Years|N/A|No|||July 2012|November 28, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01739881||75204|
NCT01739894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA01/12/12|Feasibility Study of Intraperitoneal Paclitaxel|Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer||National University Hospital, Singapore|Yes|Recruiting|January 2013|August 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01739894||75203|
NCT01742104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-OG1|Multicentric Observational Study on Quality of Life in Glaucoma|Multicentric Observational Clinical Study on Quality of Life in Patients With Glaucoma in Italy||Mario Negri Institute for Pharmacological Research|No|Completed|March 2012|April 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|3226|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary open-angle glaucoma (POAG).|April 2015|April 17, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742104||75033|
NCT01742403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-NSCCRO-P001|Continuous Monitoring of Prostate Position During Radiotherapy|Phase I Feasibility Study of Prostate Cancer Radiotherapy Gating Using kV Intrafraction Monitoring (KIM)|KIM Gating|Royal North Shore Hospital|No|Recruiting|January 2013|December 2018|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|N/A|N/A|No|||October 2015|October 8, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01742403||75010|
NCT01741883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG NE 1635/2-1|Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients|Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1)||Philipps University Marburg Medical Center|No|Active, not recruiting|November 2012|July 2020|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|165|||Female|18 Years|N/A|No|||May 2015|May 5, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01741883||75050|
NCT01703442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPERIA|Intraoperative Anuric Episodes in Patients Undergoing Laparotomy|Perioperative Relevance of Intraoperative Anuric Episodes Within a Goal-directed Haemodynamic Algorithm in Patients Undergoing Laparotomy Due to Epithelial Ovarian Cancer||Charite University, Berlin, Germany|No|Not yet recruiting|July 2016|September 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients being treated in the Department of Gynecology and Obstetrics, Campus        Virchow Klinikum, Charité - Universitaetsmedizin Berlin.|January 2016|January 25, 2016|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01703442||77993|
NCT01703728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000012|Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.|SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.|SHOview|Ferring Pharmaceuticals|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|455|None Retained|No biological samples|Female|18 Years|36 Years|No|Non-Probability Sample|Women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS)        for a first or second cycle of IVF / ICSI.|July 2014|July 16, 2014|October 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703728||77971|
NCT01700595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hocaoglupediatricperforator1|Preexpanded Perforator Flaps in Children|Preexpanded Perforator Flaps in Pediatric Patients||Istanbul University|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|18 Years|No|||October 2012|October 2, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700595||78212|
NCT01699763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2012-007-01|Evaluation of Blood Glucose Monitoring Systems|Evaluation of Blood Glucose Meter Systems - Contour® NEXT LINK Study||Ascensia Diabetes Care|No|Completed|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 2, 2012|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01699763||78276|
NCT01700582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers-France|French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings|French National Observatory of the Patients With Non-small Cell Lung (NSCLC) Benefiting From a Molecular Test on the Hospital Platforms of Molecular Genetics.||Intergroupe Francophone de Cancerologie Thoracique|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18858|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced non-small cell cancer|March 2016|March 22, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700582||78213|
NCT01700842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-IRU-XXX-2012/1|Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia|Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia|CERBERUS|AstraZeneca||Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|N/A||1|Actual|3000|None Retained|Microbiological strains|Both|N/A|N/A|No|Probability Sample|clinical material form patients in geographically distinct Russian cities|June 2013|June 26, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01700842||78193|
NCT01701466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-053|Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis|A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy||Sir Mortimer B. Davis - Jewish General Hospital|No|Terminated|December 2011|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701466||78145|
NCT01701479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012010|Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)|A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma|LTI|St. Anna Kinderkrebsforschung|Yes|Recruiting|November 2010|December 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|1 Year|21 Years|No|||October 2012|October 5, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701479||78144|
NCT01732887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCIL-CI-CF|Evaluating Short-term Effects of Computerized Brain Fitness Exercises in Adult Cochlear Implant and/or Hearing Aid Users|Evaluating Short-term Effects of Home-based Computerized Multi-domain Cognitive Training in Adult Cochlear Implant and/or Hearing Aid Users: A Prospective Randomized Intervention Study||Nova Scotia Health Authority|No|Active, not recruiting|January 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||February 2014|February 26, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01732887||75739|
NCT01733134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIVATE117|Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)|Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy|ACTIVATE|Maisel, Alan, M.D.|Yes|Not yet recruiting|January 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733134||75720|
NCT01733732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00976|SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers|Study to Evaluate the Efficacy of SYSTANE® BALANCE in Reducing Symptoms and Inflammatory Biomarker Expression of HLA-DR and Tear Film Cytokines in Dry Eye Subjects With Lipid Deficiency||Alcon Research|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|November 21, 2012||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01733732||75676|
NCT01733745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00978|SYSTANE® Family - Meibomian Deficiency|SYSTANE® Family Efficacy in Meibomian Gland Functionality for Lipid Deficient Evaporative Dry Eye Subjects|M-12-077|Alcon Research|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|November 21, 2012||No||No|June 2, 2014|https://clinicaltrials.gov/show/NCT01733745||75675|
NCT01733992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-932348-002|A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease|A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca||Rigel Pharmaceuticals|No|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|80 Years|No|||July 2014|July 31, 2014|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01733992||75656|
NCT01734278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBSERVA|Observational Post-Authorisation Safety Study of Asenapine (Sycrest)|An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England|OBSERVA|Drug Safety Research Unit, Southampton, UK|No|Recruiting|October 2012|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients prescribed asenapine in a NHS Mental Health Trust in England.|January 2016|January 25, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01734278||75635|
NCT01741558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4747/12|The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS (TETHYS Trial)|The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS: Randomized Double-blind, Placebo-controlled Trial (TETHYS Trial)|TETHYS|Instituto de Cardiologia do Rio Grande do Sul|Yes|Not yet recruiting|April 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741558||75075|
NCT01742988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-907-101|Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma|Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma||Curis, Inc.|No|Recruiting|December 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|138|||Both|18 Years|N/A|No|||April 2015|July 27, 2015|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742988||74965|
NCT01741818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUMS-14746|The Cutoff Point for Caval Index and Its Correlation With Central Venous Pressure and Plasma Lactate Level for Assessing Patients in Hypovolemic Hemorrhagic States|||Isfahan University of Medical Sciences|Yes|Completed|April 2011|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|cases in hypovolemic hemorrhagic status (class II or more) that presented to our ED|December 2012|December 3, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741818||75055|
NCT01743300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07.111|The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients|The Influence of Genotype/Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib (Sutent, SU011248) in Patient With Imatinib Resistant Gastrointestinal Stromal Cell Tumor (GIST) or Metastatic Renal Cell Carcinoma||Leiden University Medical Center|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|November 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01743300||74941|
NCT01742169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P01HS021141-01-Project1B|Improving Rates of Colorectal Cancer Screening Among Never Screened Patients|Center for Advancing Equity in Clinical Preventive Services Project 1B: Improving Rates of Colorectal Cancer Screening Among Never Screened Patients||Northwestern University|Yes|Completed|January 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|420|||Both|50 Years|75 Years|No|||January 2015|January 6, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01742169||75028|
NCT01741337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1225|PAC-IC-SAS Pilot Study - Central Sleep Apneas Syndrome and Ventricular Function|Central Sleep Apneas Syndrome and Ventricular Function in Patients With Heart Failure, After Coronary Artery Bypass Graft Surgery or Other Coronary Reperfusion||University Hospital, Grenoble|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|90 Years|No|||March 2016|March 4, 2016|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01741337||75092|
NCT01742416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000030723|Ultrasound Assisted Arterial Cannulation in Small Children|Ultrasound Assisted Arterial Cannulation in Small Children - To See or Not to See?||The Hospital for Sick Children|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|24 Months|No|||December 2014|December 19, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01742416||75009|
NCT01704079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-3002|Safety and Efficacy of CTAP101 Capsules for Treatment of SHPT and Vitamin D Insufficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency||OPKO Health, Inc.|Yes|Completed|November 2012|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|216|||Both|18 Years|85 Years|No|||November 2015|November 13, 2015|October 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01704079||77944|
NCT01704092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001|Dexmedetomidine's Cardiac and Cognitive Influence on Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Dexmedetomidine's Cardiac and Cognitive Influence on Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery||Huazhong University of Science and Technology|Yes|Recruiting|May 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|blood samples are drawn from patients recruited into the study. We planned to draw blood      samples from patients with their consent through the central line.|Both|35 Years|75 Years|No|Non-Probability Sample|Patients who are planned to undergo off-pump coronary bypass surgery|October 2012|October 26, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01704092||77943|
NCT01699776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG&PJ-Dig-Iva 2009-2012|Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure|Comparison of Digoxin and Ivabradine in Heart Failure With Preserved Systolic Function. Time to Rethink About Digoxin.|Dig&Iva|Cocco, Giuseppe, M.D.|Yes|Completed|April 2008|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|60 Years|78 Years|No|||October 2012|November 8, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01699776||78275|
NCT01700049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28485|Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes|ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma||St. Louis University|Yes|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01700049||78254|
NCT01700361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01852|Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)|Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)|VESPA|University of British Columbia|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|15|||Female|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy females.|June 2013|June 3, 2013|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01700361||78230|
NCT01700322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTH-C1|Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study|Effects of Clopidogrel vs Prasugel vs Ticagrelor on Endothelial Function, Inflammatory and Oxidative Stress Parameters and Platelet Function in Patients Undergoing Coronary Artery Stenting. A Randomised, Prospective Study.|EST|Johannes Gutenberg University Mainz|Yes|Recruiting|August 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|180|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700322||78233|
NCT01700335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011005|Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)|Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome||SymBio Pharmaceuticals||Recruiting|June 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||October 2012|October 1, 2012|August 7, 2012||||No||https://clinicaltrials.gov/show/NCT01700335||78232|
NCT01701167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMAN-01|Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain|ROMAN (PCA-9000A) PET/CT System Verification||Toshiba America Medical Systems, Inc.|No|Not yet recruiting|November 2012|||February 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|40 Years|N/A||Non-Probability Sample|Patients already scheduled for a FDG test.|October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01701167||78168|
NCT01701180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT-151/12|Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin|Neural Correlates of the Empathogenic and Affiliative Actions of Oxytocin|ODIS|University Hospital, Bonn|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01701180||78167|
NCT01732029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02365|Calibration and Evaluation of an Audio Pulse Oximeter Sensor (AudioOx) at Ascent and Descent From Simulated Altitude|Calibration and Evaluation of an Audio Pulse Oximeter Sensor (AudioOx) at Ascent and Descent From Simulated Altitude||University of British Columbia|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 25, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01732029||75805|
NCT01732042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB-2011-326|Retinal Venous Pressure (RVP) in Normals|Retinal Venous Pressure (RVP) in Normals||University Hospital, Basel, Switzerland|No|Completed|November 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|December 2013|December 10, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01732042||75804|
NCT01733147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005914|Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids|Modulation of Esophageal Inflammation in Barrett&Apos;s Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study||Mayo Clinic|No|Recruiting|November 2012|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733147||75719|
NCT01733446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816280|A Study of the Effect of Arterial Carbon Dioxide Tension on the Recovery of Spontaneous Respiration|A Study of the Effect of Arterial Carbon Dioxide Tension on the Recovery of Spontaneous Respiration With Respiratory Inductance Plethysmography (RIP) During High Frequency Jet Ventilation (HFJV) Under General Anesthesia|RIP03|University of Pennsylvania|Yes|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2013|June 18, 2013|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733446||75697|
NCT01733758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113121|A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|February 2013|February 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|494|||Both|20 Years|N/A|No|||October 2015|December 10, 2015|November 21, 2012||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01733758||75674|
NCT01734005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIMED-BF-GC|Efficacy and Safety of Red Ginseng on Decrement of Body Fat|||Chonbuk National University Hospital|Yes|Recruiting|September 2012|March 2013|Anticipated|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734005||75655|
NCT01734018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25614|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B|A Multicenter, Prospective, Non-Interventional Study Evaluating Response Parameters During and After Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B||Hoffmann-La Roche||Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B receiving treatment with Pegasys|March 2016|March 1, 2016|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734018||75654|
NCT01734291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCUPsychiatricNursing001|Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression|Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression: A Randomized Controlled Trial||Nagoya City University|No|Recruiting|October 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||April 2015|April 15, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734291||75634|
NCT01743001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-305|Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome|MAESTRO|Actelion|Yes|Recruiting|May 2013|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|12 Years|N/A|No|||February 2016|February 29, 2016|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01743001||74964|
NCT01743287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238KOA12F|The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|A Six-month, Multi Center, Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|ABSOLUTE-OS|Chong Kun Dang Pharmaceutical|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|234|||Both|40 Years|N/A|No|||July 2014|April 29, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01743287||74942|
NCT01743573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200811002R|Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.|Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.||National Taiwan University Hospital|No|Recruiting|March 2009|||March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|N/A|N/A|No|||December 2012|December 5, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01743573||74920|
NCT01741064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHPTTX-002|Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation|Secondary Hyperparathyroidism Related Vascular and Bone Morbidity After Renal Transplantation - a 6 Year Follow up Retrospective Cohort Study.|SHPT-RT|Skåne University Hospital|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|257|||Both|18 Years|85 Years|No|Probability Sample|All patients who underwent renal transplantation surgery between January 1:st 2003 to        December 31:st 2005 at Skane University Hospital or Karolinska University Hospital.|November 2012|December 3, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01741064||75113|
NCT01741324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dvisum|Comparing Different Amounts of Vitamin D Supplementation to Preschool Children Living in Northern and Southern Sweden||Dvisum|Umeå University|No|Completed|November 2012|July 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|220|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01741324||75093|
NCT01741610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZLTNS97|Fluid Coloading and the Incidence of Hypotension|Rapid Fluid Administration and the Incidence of Hypotension Induced by Spinal Anaesthesia and Ephedrine Requirement: the Effect of Crystalloid Versus Colloid Coloading||Cukurova University|No|Completed|October 2008|June 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Female|19 Years|46 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01741610||75071|
NCT01743248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00522-41|Vestibular Schwannoma and Psychological Factors|Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery||Central Hospital, Nancy, France|Yes|Recruiting|August 2012|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with vestibular schwanomma with an indication for surgery.|December 2012|December 4, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743248||74945|
NCT01743261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270360|Cost/Utility Ratio in the Management of Patients With Acquired Severe Brain Injury|Cost/Utility Ratio in the Management of Patients With Acquired Severe Brain Injury: Comparison Between a Programme of In-hospital Graded Intensity Rehabilitation and Usual Care.||Fondazione Don Carlo Gnocchi Onlus|No|Completed|January 2007|January 2012|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|249|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01743261||74944|
NCT01699802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/148|Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)|Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)||Region Skane|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|90 Years|No|||May 2015|May 13, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01699802||78273|
NCT01700023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-536 ex 11/12|3-dimensional Sensor Technology to Quantify Leg-edema|Pilot-study HI-SENS: Innovative Sensor Technology to Quantify Cardiac Control Mechanisms in Heart Failure||Medical University of Graz|No|Recruiting|September 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|patients hospitalized for decompensated heart failure with leg-edema|October 2012|October 3, 2012|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01700023||78256|
NCT01700036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umcc 2012.043|A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease|A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease||University of Michigan Cancer Center|Yes|Recruiting|July 2013|June 2019|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700036||78255|
NCT01700348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAH-12-0081|Philips AirFlosser Study|An Investigation of the Effects of a Oral Hygiene Regimen in Irregular Flossers on Gingivitis and Plaque||Tufts University School of Dental Medicine|No|Terminated|August 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|August 20, 2012|Yes|Yes|Study terminated by sponsor due to low accrual, and high number of protocol deviations due in    part to the impact of Hurricane Sandy on protocol compliance.|No|February 26, 2015|https://clinicaltrials.gov/show/NCT01700348||78231|Terminated by sponsor due to:Changes in business strategy/Target completion dates not being metHigher than anticipated screen failure rateHigher than anticipated early termination rateLarge number of protocol deviations encountered
NCT01700062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960022|Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery|Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|April 2007|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700062||78253|
NCT01731509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8353/12|Early FETO for Severe Congenital Diaphragmatic Hernia|"Early" Versus "Standard" Fetal Endoscopic Tracheal Occlusion for Severe Congenital Diaphragmatic Hernia - a Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Not yet recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|22 Weeks|28 Weeks|No|||November 2012|December 16, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731509||75844|
NCT01700855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mazuike-28|Electroacupuncture Anesthesia for Nasal Sinus Surgery and Mammaplasty|Electroacupuncture for Pain Relief in Patients With Nasal Sinus Surgery and Mammaplasty: a Randomized Controlled Study||Xijing Hospital|Yes|Completed|June 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|137|||Both|29 Years|60 Years|No|||May 2012|July 10, 2014|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01700855||78192|
NCT01700868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBNI-2|Practice Based Nutrition Intervention-2|Practice Based Nutrition Intervention-2|PBNI-2|Physicians Committee for Responsible Medicine|Yes|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|15|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700868||78191|
NCT01732627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET44|Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older|Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older||Sanofi|No|Completed|November 2012|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|301|||Both|56 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 11, 2013|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732627||75759|
NCT01732900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMA-201201|Gene Expression in Cumulus Cells to Predict Pregnancy|The Predictive Value of a Gene Expression Signature in Cumulus Cells Indicative of Embryo Implantation.||Gema Diagnostics|No|Completed|February 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|133|||Female|21 Years|39 Years|No|||July 2014|July 11, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01732900||75738|
NCT01732913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-313-0124|Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|Yosemite|Gilead Sciences|Yes|Active, not recruiting|January 2013|June 2022|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732913||75737|
NCT01732926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-313-0125|Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|Bridalveil|Gilead Sciences|Yes|Active, not recruiting|January 2013|August 2022|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|475|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732926||75736|
NCT01733160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRINT-AF 18-10-2012|Stroke Prevention and Rhythm Interventions in Atrial Fibrillation|SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation|SPRINT-AF|Canadian Cardiovascular Research Network|No|Recruiting|November 2013|July 2024|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Primary care and specialist clinics|October 2015|October 13, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01733160||75718|
NCT01734044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-007|Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|July 2012|October 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||November 2012|November 21, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734044||75653|
NCT01734317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxT Ag 02|An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.|An Open, Non Controled, Single-centre, Clinical Investigation to Evaluate Efficacy in Second Degree (Superficial, Deep or Mixed) Partial Thickness Burns When Using a Soft Silicone Wound Contact Ayer Containing Silver.||Molnlycke Health Care AB|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2013|February 3, 2016|November 22, 2012||No||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01734317||75632|
NCT01734304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022446-24|DC Vaccination for Postremission Therapy in AML|Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens||Ludwig-Maximilians - University of Munich|Yes|Recruiting|September 2013|April 2019|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2016|March 5, 2016|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01734304||75633|
NCT01743885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8638|Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma|Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma||University Hospital, Montpellier|Yes|Recruiting|November 2012|February 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|6 Months|No|||December 2014|December 3, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01743885||74896|
NCT01739634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL 2012-0584|The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer|The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer||Salient Pharmaceuticals Incorporated|Yes|Recruiting|November 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||November 2012|November 29, 2012|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739634||75223|
NCT01741844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100806|A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence|Regulatory Post Marketing Surveillance of Intelence Tablet||Janssen Korea, Ltd., Korea|No|Completed|September 2012|July 2014|Actual|July 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients who are diagnosed with Acquired Immune        Deficiency Syndrome (AIDS), and who are prescribed with etravirine for treatment of AIDS.|April 2015|April 16, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741844||75053|
NCT01742117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006837|Tailored Antiplatelet Therapy Following PCI|Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)|TAILOR-PCI|Mayo Clinic|Yes|Recruiting|May 2013|March 2020|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|5270|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01742117||75032|
NCT01752296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058524|Psychological Concomitants of Morquio Syndrome (The MAP Study)|Psychological Concomitants of Morquio Syndrome|MAP|Emory University|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|People with Morquio Disease|December 2013|December 2, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01752296||74251|
NCT01752309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC2009-333|The Predictive Value of Ultrasound in Early Rheumatoid Arthritis|The Predictive Value of Ultrasound in Early Rheumatoid Arthritis|EVA|Erasmus Medical Center|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Probability Sample|Starting in June 2010, all newly diagnosed rheumatoid arthritis patients who will be        participating in 2 ongoing trials will be invited to participate in this study. In Almelo        they will be recruited from the outpatient Rheumatology clinic.|November 2014|November 18, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752309||74250|
NCT01699815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036568|Time of Intravenous Acetaminophen Administration|Time of Intravenous Acetaminophen Administration for Total Hip Arthroplasty|TIAA|Duke University|Yes|Completed|October 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|126|||Both|30 Years|75 Years|No|||August 2014|August 26, 2014|September 28, 2012|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT01699815||78272|
NCT01700075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0109RK000079|Physical and Chemical Study of Atherosclerosis Mechanisms|Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention|PCSAM|Republican Scientific Center for Emergency Medicine|Yes|Completed|January 2009|December 2011|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|26 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 3, 2012|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700075||78252|
NCT01700608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011012|Prospective Observational Study on Plerixafor After Chemotherapy|Prospective Observational Study on Plerixafor After Chemotherapy||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|September 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after        chemotherapy and G-CSF|October 2012|October 2, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01700608||78211|
NCT01732328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0002.0361.000-09|Effect of Calcium Plus Vitamin D Supplementation on Adolescent Mother and Infant Bone Health|Calcium Plus Vitamin D Supplementation During Pregnancy of Adolescent Mothers: Effects on Maternal and Infant Bone Mass, Calcium and Bone Metabolism and Breast Milk Composition||Universidade Federal do Rio de Janeiro|No|Active, not recruiting|July 2009|June 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|76|||Female|13 Years|19 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732328||75782|
NCT01732614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topcon Endpoint Management|Topcon Endpoint Management|Safety Assessment and Therapeutic Effect of Non-damaging Patterned Scanning Laser Phototherapy in Patients With Diffuse Diabetic Macular Edema|Topcon EM|Retinal Consultants of Arizona|No|Completed|August 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01732614||75760|
NCT01732653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NG-0505-CTIL|A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults|V-TIME: A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults, Patients With Parkinson's Disease and Individuals With Mild Cognitive Impairments|VTIME|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|November 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|60 Years|85 Years|No|||November 2012|November 19, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01732653||75757|
NCT01733186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-0201-01|Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects|Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee||Medipost Co Ltd.|Yes|Active, not recruiting|November 2012|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01733186||75716|
NCT01703923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin01-003|An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough|An Exploratory, Randomized, Placebo-Controlled, Double-Blind, Crossover Study of FP01 Lozenges in Subjects With Chronic Refractory Cough||Cerecor Inc|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703923||77956|
NCT01700465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1437|Estimating and Predicting Hemodynamic Changes During Hemodialysis|Estimating and Predicting Hemodynamic Changes During Hemodialysis||University of Colorado, Denver|No|Active, not recruiting|September 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|2 Years|89 Years|No|Non-Probability Sample|Adult and pediatric patients undergoing hemodialysis at Fresenius Medical Centers,        University of Colorado Hospital or Children's Hospital Colorado will be the population        base for enrollment in this study. Patients may have acute kidney injury or end stage        renal disease. Subjects may be inpatients or outpatients.|December 2015|December 3, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01700465||78222|
NCT01700699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAF-TKI-DTC1|Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors|Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer||University of Salerno|No|Recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Anticipated|50|Samples With DNA|Primary and metastatic tumor tissue, frozen or formaldehyde fixed-paraffin embedded from      block, genomic DNA already extracted from tumor tissue|Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|October 2012|October 20, 2012|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01700699||78204|
NCT01734590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-0758|Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood|The Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood.||Unilever R&D|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01734590||75611|
NCT01740167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC101-2511-S-039-003|Health Promotion on Young Adults With High Risk Disability for Mental Health|Health Promotion on Young Adults With High Risk Disability for Mental Health: Development and Evaluation of the Screen Prevention Model|HPMI|China Medical University Hospital|No|Active, not recruiting|November 2012|October 2015|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|200|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01740167||75182|
NCT01740479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPLETE-2012|Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI|Randomized Comparative Effectiveness Study of Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease After Primary Percutaneous Coronary Intervention (PCI) for ST-segment Elevation Myocardial (STEMI) Infarction|COMPLETE|Population Health Research Institute|Yes|Recruiting|December 2012|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3900|||Both|N/A|N/A|No|||March 2015|March 23, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01740479||75158|
NCT01751841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806009851|Outcome Analysis for Minimally Invasive Spine Surgery|Outcome Analysis for Minimally Invasive Spine Surgery||Weill Medical College of Cornell University|No|Recruiting|May 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Our prospectively collected institutional database will be reviewed to identify all        consecutive patients with spinal fusion procedures using Silicate-Substituted Calcium        Phosphate (Actifuse®, Baxter, Deerfield, IL) as a bone graft substitute. Surgeries have        been performed at our hospital between 2007 and 2011. The estimated number of patients        enrolled in the study is 200 patients. Patient demographics will be extracted using the        database. The study population are from different age, gender and ethnicity groups. The        indications for surgery will be recorded for each patient, as well. Institutional Research        Board approval has been granted. All patients have provided informed consent for data        collection regarding their treatment and outcomes.|December 2012|December 13, 2012|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01751841||74286|
NCT01742962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-58-0015 / HEH.750.19-31|Prevalence of Neglected Side Effects to Radical Prostatectomy|Prevalence of Neglected Side Effects to Radical Prostatectomy||Copenhagen University Hospital at Herlev|No|Completed|December 2012|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|396|||Male|N/A|N/A|No|Probability Sample|Post prostatectomy patients operated at Copenhagen University Hospital in Herlev, Denmark.|July 2014|July 1, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01742962||74967|
NCT01752335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRC-TOC-2009-01|Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis|Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis|TOCRIVAR|Hospital Universitario de Canarias|No|Recruiting|December 2011|||April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|28|||Both|18 Years|70 Years|No|||December 2012|December 19, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01752335||74248|
NCT01752348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11422796|Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals.|Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals; a Study on Muscle Wasting and Metabolism During Acute Inflammation and Potential Anabolic Mechanisms.||University of Aarhus|Yes|Completed|February 2013|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|10|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2013|November 24, 2014|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752348||74247|
NCT01731015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024828|Imaging Lung Function Using Oxygen Enhanced MRI|A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent||Duke University|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|15|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2012|August 20, 2014|November 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01731015||75882|
NCT01731028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000091|Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®|Non-interventional, Observational Study of the Application of Zomacton® in the Treatment of Growth Hormone Deficiency in Routine Clinical Practice||Ferring Pharmaceuticals|No|Withdrawn|January 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|3 Years|18 Years|No|Non-Probability Sample|Children with inadequate secretion of growth-hormone; growth retardation due to Turner's        syndrome|January 2013|January 31, 2013|November 16, 2012||No|Change of local requirements|No||https://clinicaltrials.gov/show/NCT01731028||75881|
NCT01731236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-544|CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and cardioVAscuLar Disease|CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and cardioVAscuLar Disease|CARNIVAL|The Cleveland Clinic|No|Enrolling by invitation|July 2010|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01731236||75865|
NCT01732055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0235|Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression|Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression||University of North Carolina, Chapel Hill|No|Terminated|November 2012|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|November 6, 2012||No|Study ended because recruitment goals unmet and further funding unlikely|No||https://clinicaltrials.gov/show/NCT01732055||75803|
NCT01732068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/082|Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol|Phase II Study for the Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol||Universitair Ziekenhuis Brussel|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|45 Years|No|||May 2013|May 7, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01732068||75802|
NCT01731795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000775-17|Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome|A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome|DEXA-ARDS|Dr. Negrin University Hospital|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|N/A|N/A|No|||September 2015|September 24, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01731795||75823|
NCT01732640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1266|A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.|A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|November 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01732640||75758|
NCT01733173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-121|Functional Imaging of Cerebellar Mutism Syndrome|Pilot Study: Functional Imaging of Cerebellar Mutism Syndrome||Memorial Sloan Kettering Cancer Center||Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|3 Years|21 Years|No|Non-Probability Sample|Subjects for this study will be offered participation once they are referred to members of        the Departments of Neurosurgery or Pediatrics at the NYPH/WCMC or MSKCC.|December 2015|December 21, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733173||75717|
NCT01703936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK6203|Ex-combatant Reintegration in Liberia|Evaluating a Landmine Action Ex-combatant Reintegration Program in Liberia||Columbia University|No|Completed|May 2009|July 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1330|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 8, 2012|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01703936||77955|
NCT01699659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAS protocol #1|The Efficacy & Safety of the UAS Immunotherapy Protocol|The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol||United Allergy Services|Yes|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with allergic rhinitis pre and post immunotherapy (1 to 2 years).|October 2012|October 3, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01699659||78284|
NCT01733459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS3233-0811|Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)|The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS)||Dexa Medica Group|No|Recruiting|March 2013|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Female|18 Years|40 Years|No|||November 2015|November 25, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01733459||75696|
NCT01733472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip-CPH-2013|General or Regional Anesthesia for Hip Surgery|General Versus Intrathecal Anaesthesia for Patients Undergoing Elective Total Hip Arthroplasty||Region Skane|Yes|Completed|January 2013|June 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|46 Years|84 Years|No|||November 2014|November 5, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01733472||75695|
NCT01700478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-001|Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy|A Trial Comparing The Use Of Rectal Plus Perivascular Vasopressin With Perivascular Vasopressin Alone To Decrease Bleeding At The Time Of Myomectomy||University Hospital of the West Indies|No|Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|45|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||October 2012|February 7, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01700478||78221|
NCT01700712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-112|Acid Production in Dental Plaque After Exposure to Probiotic Bacteria|||University of Copenhagen||Completed|December 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 3, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700712||78203|
NCT01700725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW100054 US Dept of Defense|Gulf War Illness Nasal Irrigation Study|Nasal Irrigation for Chronic Rhinosinusitis and Fatigue in Patients With Gulf War Illness|GWINIS|University of Wisconsin, Madison|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|35 Years|75 Years|No|||October 2015|October 6, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700725||78202|
NCT01701011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRCI study|Coping Intervention After Embryo Transfer|Study of the Effectiveness of a Coping Selfhelp Intervention for Women in the Waiting Period After an Embryo Transfer During an IVF/ISCI Treatment||UMC Utrecht|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|377|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 22, 2014|October 6, 2010||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01701011||78180|
NCT01751061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021965|Improving Decision Making for Patients With Prolonged Mechanical Ventilation|Improving Decision Making for Patients With Prolonged Mechanical Ventilation||Duke University|Yes|Recruiting|January 2013|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|N/A|No|||August 2015|October 11, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751061||74345|
NCT01740752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1990|UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa|Enhancing Treatment for Adult Anorexia With a Couple-Based Approach|UCAN2|University of North Carolina, Chapel Hill|Yes|Recruiting|July 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01740752||75137|
NCT01751360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472/OCT-002|SYR-472 Open-label Study|||Takeda|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|N/A|No|||November 2013|November 5, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751360||74322|
NCT01752101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1013-12|Identification of a Plasma Proteomic Signature for Lung Cancer|Identification of a Plasma Proteomic Signature for Lung Cancer||Integrated Diagnostics|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|475|Samples Without DNA|Blood samples|Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing procedure for histologic diagnosis of lung nodule(s)|January 2015|January 7, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01752101||74266|
NCT01752075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-CC-5013-MM-009|A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan|A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan||Celgene|No|Completed|January 2011|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Taiwanese patients with relapsed/refractory multiple myeloma|February 2015|February 11, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752075|2 Years|74268|
NCT01752322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF10004/10|Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain|Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain||Grünenthal GmbH|No|Active, not recruiting|October 2012|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|444|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752322||74249|
NCT01748383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99|The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)|Autologous Mononuclear and Cluster of Differentiation 133+ (CD 133+) Bone Marrow Cells, Growth Factors and Cytokines in the Remodeling of the Heart in Patients During and in the Late Periods After STEMI.|ESTABOMA|Russian Academy of Medical Sciences|Yes|Active, not recruiting|September 2005|September 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|85|||Both|18 Years|75 Years|No|||December 2012|December 13, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748383||74551|
NCT01731808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0278/0|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration: a Pilot Study|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration: a Pilot Study||Zurich University of Applied Sciences|Yes|Completed|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|19|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01731808||75822|
NCT01731821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI001|Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy|A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy||Fudan University|No|Completed|October 2012|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|80 Years|No|||December 2014|December 2, 2014|November 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01731821||75821|
NCT01731288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00968|Pregnancy, Childbirth Intentions and Outcomes Under Sexual Pain|Pregnancy, Childbirth Intentions and Outcomes Under Sexual Pain|PRECIOUS|University of British Columbia|No|Active, not recruiting|March 2012|February 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|210|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The control group consists of a community sample. The vulvodynia group consists of women        who have been diagnosed with vulvodynia/provoked vestibulodynia and who have been assessed        and/or treated at 1 of 3 tertiary clinics:        1) Vulvar Pain Clinic (no longer active) located at the Women's Clinic, Willow Pavilion,        Vancouver General Hospital; 2) Multidisciplinary Vulvodynia Program (MVP); or 3) BC Centre        for Sexual Medicine|June 2015|June 17, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01731288||75861|
NCT01731535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0437|Evaluation of the Risk for Radiographic and Clinical Nonunion in Patients With Previous Bisphosphonates Therapy.|Evaluation of the Risk for Radiographic and Clinical Nonunion in Patients With Previous Bisphosphonates Therapy.||University of Wisconsin, Madison|No|Withdrawn|November 2012|July 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|60 Years|N/A|No|Non-Probability Sample|Men and women older than 60 years old with delayed or nonunion low trauma fracture beween        01/01/2000 - 12/31/2011.|October 2015|October 9, 2015|November 14, 2012||No|It was a project initiated by a trainee but did not progress to subject accrual.|No||https://clinicaltrials.gov/show/NCT01731535||75842|
NCT01731834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11212PSC014|Pain and Stress Assessment in Children|Pain and Stress Assessment in Children Undergoing Respiratory Physical Therapy Techniques||Federal University of Uberlandia|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|N/A|1 Year|No|||November 2013|November 27, 2013|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01731834||75820|
NCT01732341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STENTYS|Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction|APPOSITION V: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction|APPOSITION V|Stentys|Yes|Active, not recruiting|May 2013|September 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|318|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01732341||75781|
NCT01732354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX-US-174-0206|Study for Consolidation Period of Chronic Hepatitis B|A Prospective Study to Investigate the Consolidation Period of 12 Months Compared to 18 Months After Tenofovir Therapy With HBeAg Seroconversion in Asian Chronic Hepatitis B HBeAg-positive Patients||Tainan Municipal Hospital|Yes|Active, not recruiting|November 2012|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|136|||Both|18 Years|70 Years|No|Non-Probability Sample|136 patients|November 2015|November 4, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01732354||75780|
NCT01732952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-271-0|Dyslipidemia International Survey-China|Dyslipidemia International Survey - China|DYSIS-China|Chinese Society of Cardiology|Yes|Recruiting|February 2012|December 2012|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|25000|||Both|45 Years|N/A|No|Probability Sample|1. Patient is an outpatient > 45 years of age          2. Patient is currently* treated with a statin          3. Patient has a documented fasting lipid profile (> 1 lipid parameter within the last             12 months) performed while on lipid-modifying therapy for at least 3 months          4. Patient agrees to participate in the study by giving informed consent.               -  Patient is already being treated with a lipid-modifying drug just before the                  visit. Patient for whom a lipid-modifying therapy is initiated at the time of                  the visit must not be included.|November 2012|November 23, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01732952||75734|
NCT01733771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNZ-0041-09|The Effect of Complementary Medicine (CAM) Treatments on Common Symptoms in Hospitalized Patients|Patient Reported Outcomes Following Complementary Medicine Treatments in Hospitalized Patients||Bnai Zion Medical Center|No|Recruiting|April 2010|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|All hospitalized patients|January 2016|January 13, 2016|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01733771||75673|
NCT01700166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB IND #14576|Umbilical Cord Blood in the Treatment of Stroke in Children.|Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children.|Pedi Stroke|Memorial Hermann Health System|Yes|Withdrawn|September 2012|December 2016|Anticipated|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Weeks|6 Years|No|||January 2014|January 21, 2014|October 2, 2012|No|Yes|Principal Investigator relocated; Study may resume in Fl Hosp. for Children, Orlando FL|No||https://clinicaltrials.gov/show/NCT01700166||78245|
NCT01701375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1275|A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia|A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|September 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|September 11, 2012|Yes|Yes|Material sponsor withdrew support|No|June 14, 2013|https://clinicaltrials.gov/show/NCT01701375||78152|
NCT01701596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAISE|Safety and Efficacy of Rotational Atherectomy (RA) in Coronary Dissection|Safety and Efficacy of Immediate Rotational Atherectomy in Nondilatable Calcified Lesion Complicated by Coronary Dissection (RAISE)||Xijing Hospital|Yes|Completed|August 2004|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|30 Years|85 Years|No|||August 2014|August 18, 2014|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01701596||78135|
NCT01701024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-ACYC-301|Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of ACYC and ACYC Vehicle Gel in the Treatment of Acne Vulgaris|ACYC|Valeant Pharmaceuticals International, Inc.|No|Completed|October 2012|July 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|496|||Both|12 Years|40 Years|No|||February 2014|February 12, 2014|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701024||78179|
NCT01701349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX4317s|Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)|FACT2|OXiGENE|Yes|Withdrawn|March 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|October 2, 2012|Yes|Yes|Expected inability to recruit study participants in a reasonable amount of time.|No||https://clinicaltrials.gov/show/NCT01701349||78154|
NCT01751620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 108|Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care|Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care||Westat|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|167|||Both|16 Years|24 Years|No|||February 2016|February 29, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751620||74302|
NCT01751607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_DECAF|Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|DECAF|Texas Cardiac Arrhythmia Research Foundation|No|Completed|December 2012|August 2014|Actual|August 2013|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Blood samples will be collected from which DNA would be extracted for SNP analysis|Both|18 Years|85 Years|No|Probability Sample|patients with atrial fibrillation|September 2014|September 4, 2014|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751607||74303|
NCT01752114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANOPTIC (1001-12)|Early Diagnosis of Pulmonary Nodules|Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12||Integrated Diagnostics|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|684|Samples With DNA|Blood samples|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subject undergoing evaluation for a lung nodule by a pulmonologist in a pulmonary or chest        clinic, and/or by a thoracic surgeon at the time of enrollment|January 2016|January 26, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01752114||74265|
NCT01752361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110276|Gastrointestinal Transit Times and Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Gastrointestinal Transit Times and Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit||University of Aarhus|Yes|Recruiting|April 2013|March 2015|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients suffering from severe Ulcerative Colitis|January 2014|January 6, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01752361||74246|
NCT01748396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-FGF23|Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol|Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients||Seoul National University Hospital|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||February 2013|February 14, 2013|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01748396||74550|
NCT01748409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0264|Physiopathological Study of Autonomic Failure in Parkinson's Disease|Physiopathological Study of Autonomic Failure in Parkinson's Disease : a Monocentric Study|SYNAPark|Nantes University Hospital|No|Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|45|||Both|45 Years|80 Years|No|||November 2014|November 21, 2014|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748409||74549|
NCT01731847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS96-079|Combined NMES,FEES and Traditional Swallowing Rehabilitation in the Treatment of Stroke-related Dysphagia|Combined Neuromuscular Electrical Stimulation (NMES) With Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and Traditional Swallowing Rehabilitation in the Treatment of Stroke-related Dysphagia||Kaohsiung Veterans General Hospital.|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|20 Years|85 Years|No|||November 2012|November 18, 2012|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01731847||75819|
NCT01732094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/084|Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders|Phase II Study of Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders||Universitair Ziekenhuis Brussel|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Female|18 Years|45 Years|No|||May 2013|May 7, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01732094||75800|
NCT01732107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU12-157|Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression|A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157||Hoosier Cancer Research Network|Yes|Active, not recruiting|March 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01732107||75799|
NCT01732081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5452|"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection|Hepatitis B Cohort: Predictive Factors of the Outcome of Chronic Hepatitis B Virus Infection||University Hospital, Strasbourg, France|No|Recruiting|January 2011|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients chronically infected with hepatitis B virus (HBV), and followed in university        hospital of Strasbourg, France|November 2012|November 16, 2012|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01732081||75801|
NCT01732939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307BCNeo-01|Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer|||Hospital Affiliated to Military Medical Science, Beijing|No|Recruiting|May 2012|May 2014|Anticipated|December 2013|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|N/A|No|Probability Sample|diaganosis of invasive breast cancer, tumor size > 2.0cm by MRI or ultrasound or clinical        examination.|February 2014|February 17, 2014|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01732939||75735|
NCT01703611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Academy-India-1|Diabetes in India Nutrition Guidelines Study (DINGS)|Diabetes in India Nutrition Guidelines Study (DINGS)|DINGS|Academy of Nutrition and Dietetics|Yes|Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01703611||77980|
NCT01703624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSX100201|Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease|An Investigation of the Efficacy, Tolerability and Safety of a Range of Doses of Orally Inhaled Glycopyrronium Bromide (PSX1002-GB pMDI) in Male and Female Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease||Prosonix Limited|No|Completed|May 2013|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|37|||Both|40 Years|70 Years|No|||October 2013|October 17, 2013|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01703624||77979|
NCT01699906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHO-0785|Diet Induced Weight Loss to Reduce Inflammation in Obese Women|Diet Induced Weight Loss Reduces Inflammation and Crown-like Structures and Corrects Immune Dysfunction in Subcutaneous Adipose Tissue In Class 2-3 Obese Women: A Pilot Study||Rockefeller University|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||June 2013|November 4, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01699906||78265|
NCT01700192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05607|Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)|A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)||Merck Sharp & Dohme Corp.|Yes|Completed|January 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1482|||Both|12 Years|N/A|No|||May 2015|May 13, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700192||78243|
NCT01700179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH102-005|Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects|A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.||Achillion Pharmaceuticals|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|October 2, 2012|Yes|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01700179||78244|
NCT01701050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMETI-P2-2012|Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index|COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index|COMETI P2|Janssen Diagnostics, LLC|No|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|Samples With DNA|Cartridges containing Circulating Tumor Cells (isolated by CellSearch) as well as primary      and/or metastatic tumor tissue (blocks or slides).|Female|18 Years|N/A|No|Probability Sample|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative,        progressive metastatic breast cancer (MBC) after one or more lines of endocrine therapy        (ET) who are initiating a new ET will be enrolled into the study. Patients must have        immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ        hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2.        Patients with brain metastases only or those who are progressing on fulvestrant are not        eligible for the study.|January 2016|January 11, 2016|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01701050||78177|
NCT01701063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-118|An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus|A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus||Vertex Pharmaceuticals Incorporated|Yes|Completed|January 2013|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|3 Years|17 Years|No|||May 2015|May 12, 2015|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701063||78176|
NCT01701388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU59727|EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With SCI|Investigational Study of the Ekso Powered Exoskeleton for Ambulation in Individuals With Spinal Cord Injury (or Similar Neurological Weakness)|EKSO|Rehabilitation Institute of Chicago|Yes|Active, not recruiting|May 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01701388||78151|
NCT01751373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSRIIIT-01|Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A|Novel Assessment and Treatment Approaches for Detecting and Facilitating Functional Improvements in Post-Stroke Spasticity With Botulinum Toxin-A||Sunnybrook Health Sciences Centre|No|Completed|May 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751373||74321|
NCT01751386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130040|Baclofen for Treating Anxiety and Alcoholism|A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|November 25, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751386||74320|
NCT01751633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spine FA3|Spine FA3 - a Prospective, International, Multicenter Cohort Study on Treatment of of AO A3 Thoracolumbar Fractures|Comparison of Surgical Versus Conservative Treatment of AO Type A3 Thoracolumbar Fractures Without Neurological Deficits Prospective, International, Multicenter Cohort Study|FA3|AO Clinical Investigation and Documentation|No|Terminated|January 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|65 Years|No|Non-Probability Sample|140 subjects patients with thoracolumbar fractures will be assigned to ei-ther        conservative or surgical treatment depending on the surgeon's decision. Patients will be        treated at each institution per standard of care. Surgeons will use their expertise and        preferences to determine the method of surgical or conservative intervention.|July 2015|July 21, 2015|December 14, 2012||No|Administrative reason. Lack of funding.|No||https://clinicaltrials.gov/show/NCT01751633||74301|
NCT01751854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00014257|Enhanced Motor Recovery Using Serotonergic Agents in Stroke|Enhanced Motor Recovery Using Serotonergic Agents in Stroke||Rehabilitation Institute of Chicago|No|Completed|December 2004|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||December 2012|December 14, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751854||74285|
NCT01752088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC2012|Repair of Subscapularis Tear :Clinical Results and MRI Analysis|Arthroscopic Repair of Subscapularis Tear :Clinical Results and MRI Analysis||Peking University Third Hospital|Yes|Recruiting|June 2012|December 2014|Anticipated|June 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Probability Sample|Patients suffering from rotator cuff injury will be scheduled for an arthroscopic        procedure|June 2012|December 18, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752088|2 Years|74267|
NCT01752387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0133-12|The Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players|A Study, Based on Medical Record and Questionnaire, Investigate the Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players -Results of the Follow-up in Our Department and a Comparison the Medical Literature||HaEmek Medical Center, Israel|No|Completed|June 2006|August 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|246|||Both|14 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|soccer players with groin pain|November 2012|June 11, 2015|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01752387||74244|
NCT01752374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2493|Palonestron, Granisetron and Ramosetron for Prevention of Postoperative Nasea and Voming After Laparoscopic Abdominal Surgery|||Gachon University Gil Medical Center|No|Completed|December 2011|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|90|||Female|21 Years|80 Years|No|Probability Sample|The sample size was determined based on the ability to detect a difference in the primary        outcome variable, the incidence of nausea. With 30 patients in each group there was 80%        power at an a of 0.05 to detect a 30% difference in the number of patients with nausea up        to 24 h after surgery.|August 2015|August 28, 2015|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01752374||74245|
NCT01748721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1213|MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma|Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors||Morphotek|Yes|Completed|November 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|13 Months|21 Years|No|||December 2015|January 7, 2016|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748721||74525|
NCT01731041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2012-096|Impact of Ticagrelor Re-load on Pharmacodynamic Profiles|Impact of Ticagrelor Re-load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy||University of Florida|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|November 14, 2012||No||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01731041||75880|
NCT01731275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6011-J081-001|A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)|A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects||Eisai Inc.||Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01731275||75862|
NCT01731860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alpha Ring 12-001|Pilot Study Intended to Provide Input for Future Designs Using the PET Alpha Ring Detector|Pilot Study Intended to Provide Input for Future Designs Using the PET Alpha Ring Detector and to Support the Pre-market Notification of a Future Product||Philips Healthcare|Yes|Recruiting|November 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients already scheduled for a clinically necessary PET/CT scan.|October 2014|October 12, 2014|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731860||75818|
NCT01732120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|myIRB ID 201208091|Off Clamp Randomization|Evaluation of the Off-Clamp Robot-Assisted Partial Nephrectomy Technique in the Management of Renal Tumors||Washington University School of Medicine|Yes|Recruiting|November 2012|April 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01732120||75798|
NCT01732133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/27|Evaluation of NEXFIN During Cesarean Delivery to Detect Hypotension|Evaluation of the System NEXFIN for Continuous and Non-invasive Measure of the Blood Pressure During Cesarean Delivery Practised Under Spinal Anesthesia|NEXFIN-CESAR|Hopital Foch|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|18 Years|N/A|No|||June 2015|June 17, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732133||75797|
NCT01732367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDF0001|TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA|Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.||Keimyung University Dongsan Medical Center|Yes|Active, not recruiting|November 2012|April 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|171|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01732367||75779|
NCT01732666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0883|Effect of Nefopam on Remifentanil Induced Postoperative Hyperalgesia|||Yonsei University|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|25|||Both|20 Years|65 Years|No|||February 2014|February 17, 2014|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01732666||75756|
NCT01732679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINs stroke study|Sunnaas International Network´s Stroke Study|A Prospective Multicenter Study of Stroke Rehabilitation in Seven Countries: Norway, China, USA, Russia, Israel, Palestine, and Sweden.|SINs|Sunnaas Rehabilitation Hospital|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|270|||Both|18 Years|N/A|No|Non-Probability Sample|stroke patients in need of specialised comprehensive rehabilitation|May 2015|May 18, 2015|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01732679||75755|
NCT01700491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:038|Pilot Study: Paravertebral Analgesia vs Epidural Analgesia After Thoracotomy|Pilot Study: A Non-Inferiority Trial of the Analgesic Effect of Paravertebral Analgesia to Epidural Analgesia for the Management of Post-Operative Pain After Thoracotomy|ParaEpi|University of Manitoba|No|Terminated|October 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 27, 2012|Yes|Yes|Difficulty in recruiting and maintenance of blinding necessary for the trial|No||https://clinicaltrials.gov/show/NCT01700491||78220|
NCT01700504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/0009|Effect of Gentamicin Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume|||Hospital General Universitario Elche||Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Female|20 Years|90 Years|No|||September 2012|October 2, 2012|September 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01700504||78219|
NCT01700738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 - A00555-38|Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population.|Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population.|CHADO|University Hospital, Angers|No|Not yet recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|16 Years|No|||October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700738||78201|
NCT01700751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211047|Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation|A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation||Washington University School of Medicine|No|Active, not recruiting|February 2013|August 2016|Anticipated|November 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|17|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|September 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01700751||78200|
NCT01700764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-039|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2012|||||N/A|N/A|N/A||||||||||||||October 27, 2014|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01700764||78199|
NCT01700205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD072307|"Watch Your Baby Grow" Study|Impact of Diet Composition on Energy Balance and Satiety During Infancy|GRO|Monell Chemical Senses Center|No|Active, not recruiting|October 2012|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|144|||Both|N/A|3 Weeks|Accepts Healthy Volunteers|||March 2015|March 18, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700205||78242|
NCT01701076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU10.041/BRd|Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma|An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma|BRd|Cantonal Hospital of St. Gallen|No|Active, not recruiting|March 2012|August 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01701076||78175|
NCT01701635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD074253|SANKOFA Pediatric HIV Disclosure Intervention|A Bioecological Pediatric HIV Disclosure Intervention in Ghana - "SANKOFA"||Yale University|No|Recruiting|January 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|756|||Both|7 Years|18 Years|No|||August 2015|August 13, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01701635||78132|
NCT01701401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0102|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.||Gilead Sciences|Yes|Completed|September 2012|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|870|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|October 2, 2012|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01701401||78150|
NCT01751399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14205|A Single Dose Study of LY2605541 in Participants With Liver Impairment|A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment||Eli Lilly and Company|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751399||74319|
NCT01751646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 109 Version 2.0|Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy||Westat|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|214|||Both|16 Years|24 Years|No|||March 2016|March 9, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751646||74300|
NCT01751880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0221|Safety, Feasibility and Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Pilot Study|||Yonsei University|No|Recruiting|June 2012|June 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|28|||Both|20 Years|70 Years|No|||December 2012|December 13, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01751880||74283|
NCT01751867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017443|An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome|An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS)||Xian-Janssen Pharmaceutical Ltd.|No|Completed|August 2009|April 2013|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 25, 2012||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01751867||74284|
NCT01748734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07043|Cognitive Therapy in Reducing Depression in Patients With Cancer|An Examination of Cognitive Therapy for Depression in Cancer Patients.||Ohio State University Comprehensive Cancer Center|Yes|Completed|March 2011|||March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748734||74524|
NCT01748422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU11SB126|Qutenza for Painful Fistulae|The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure||NHS Greater Glasgow and Clyde|No|Not yet recruiting|April 2013|July 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with end stage renal failure and chronic neuroapthic pain arising fromt heir        arteriovenous fistulae|December 2012|December 10, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748422||74548|
NCT01749254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/R/CAR/13|Novel Imaging Approaches To Identify Unstable Coronary Plaques|Novel Imaging Approaches To Identify Unstable Coronary Plaques||University of Edinburgh|No|Recruiting|February 2012|||February 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|50 Years|N/A|No|Non-Probability Sample|The investigators will recruit two populations of 40 patients each. The first population        will be patients with known stable coronary heart disease. They will have previously        documented and angiographically proven coronary artery disease (≥70% luminal stenosis of a        major epicardial vessel). The second population will be patients with a recent (within 30        days) acute myocardial infarction defined by the Universal definition of myocardial        infarction. The culprit plaque will be defined according to the invasive coronary        angiogram appearances, electrocardiogram and clinical features by two cardiologists        blinded to the results of positron emission tomography.|December 2012|December 11, 2012|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01749254||74484|
NCT01731548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-25|A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer|Omitting Elective Nodal Irradiation and Irradiating Post-induction Versus Pre-induction Chemotherapy Tumor Extent for Limited-stage Small Cell Lung Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|June 2002|December 2016|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||January 2013|January 21, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01731548||75841|
NCT01702766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBBIC II Study|Bifidobacterium Animalis Subsp. Lactis for Lowering the Risk of Common Infections in Hospitalized Children||PROBIC II|Children's Hospital Zagreb|Yes|Completed|December 2012|||July 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|1 Year|18 Years||||July 2013|July 24, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01702766||78045|
NCT01703039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001841|Riluzole Augmentation Pilot in Depression (RAPID) Trial|Riluzole Augmentation Pilot in Depression (RAPID) Trial|RAPID|Brigham and Women's Hospital|Yes|Recruiting|January 2013|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01703039||78024|
NCT01732380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1stPeopleLianyungang|A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer|A Multicenter Randomized Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer||The First People's Hospital of Lianyungang|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|80 Years|No|||November 2012|November 19, 2012|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01732380||75778|
NCT01703637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qfsnfm-001|Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin|A Multicenter, Randomized, Double-Blind Comparative Study of Efficacy，Tolerance and Safety Between Sitagliptin ,Vildagliptin and Saxagliptin After 12-week Monotherapy in Drug-naive Adult Patients With Type 2 Diabetes Mellitus||Qianfoshan Hospital|Yes|Recruiting|October 2012|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|78 Years|No|||November 2014|November 12, 2014|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01703637||77978|
NCT01700257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oncimmune-2550|Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker|Different Strategies Using Autoantibodies and/or CT Scan Detection of Lung Cancer||National Jewish Health|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1600|||Both|50 Years|75 Years|No|||February 2015|February 13, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700257||78238|
NCT01700517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR-PAIN CONTROL|Postoperatory Analgesia After Total Knee Arthroplasty|Postoperatory Analgesia After Total Knee Arthroplasty Comparing Femoral and Sciatic-femoral Block|PAINCONTROL|Hospital Madre Teresa|Yes|Completed|December 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|120|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|September 25, 2012||No||No|October 21, 2012|https://clinicaltrials.gov/show/NCT01700517||78218|The relative small sample size is one of them. Differences between groups are expected to grow as sample size increases. Despite an improvement in pain control with femoral and sciatic femoral blocks, the morphine consumption was not reduced.
NCT01701037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 1263|Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery|Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|January 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|90 Years|No|||March 2013|March 29, 2013|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01701037||78178|
NCT01701934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMBO|Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease|Impact of Roflumilast on Visceral Adiposity and MetaBolic Profile in Chronic Obstructive Lung Disease: a Randomized and Controlled Trial: the RAMBO Trial.|RAMBO|Laval University|Yes|Terminated|February 2013|December 2014|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Male|40 Years|80 Years|No|||November 2014|November 10, 2014|October 3, 2012||No|The recruitment of the study was prematurely stopped in July 2014 for the following reason; no    more study medication.|No||https://clinicaltrials.gov/show/NCT01701934||78109|
NCT01701947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11-1102|HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency|HEMOLEVEN® Expanded Access Program for Prevention of Surgical and Postpartum Hemorrhage in Patients With Severe Inherited Factor XI Deficiency|EAP|Laboratoire français de Fractionnement et de Biotechnologies||No longer available||||||N/A|Expanded Access|N/A|||||||Both|6 Months|N/A||||August 2013|August 22, 2013|October 3, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01701947||78108|
NCT01751659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 111|Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention|Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention||Westat|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|62|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ATN-affiliated clinicians (including physicians, nurse practitioners, and physician        assistants) who EITHER 1) provide care for HIV-infected and HIV-uninfected adolescents OR        2) provide care to HIV-infected adolescents only.|March 2016|March 1, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751659||74299|
NCT01752140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPTRVienna|A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme|A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme||Hospital de Santa Maria, Portugal|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|463|||Male|N/A|N/A|No|||December 2012|December 15, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01752140||74263|
NCT01752127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The COPERES trial|COmparison of Xience PrimE Versus REsolute Integrity in Diabetes or Small Vessel Disease|Study for Investigate the Effectiveness and Safety of Resolute Integrity or Xience Prime in Diabetes or Small Vessels Lesion Patients|COPERES|Chonbuk National University Hospital||Recruiting|July 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|90 Years|No|||December 2012|December 18, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01752127||74264|
NCT01748747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0972|Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery|Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study||Mayo Clinic|Yes|Active, not recruiting|October 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748747||74523|
NCT01748968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0755|Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence|Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence||VA Eastern Colorado Health Care System|Yes|Completed|September 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans with HIV/AIDS|December 2012|December 11, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01748968||74506|
NCT01748981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FALC-2010-OUSNIH|Fitness, Activity and Lung Cancer Study|Cardiorespiratory Fitness and Effect of Training After Lung Cancer Surgery. A Randomized Controlled Trial|FALC|Oslo University Hospital|Yes|Completed|November 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|30 Years|79 Years|No|||June 2013|June 27, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01748981||74505|
NCT01749267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of Dentistry|Digital Subtraction Radiography Evaluation of SMART Restoration With Partial Caries Removal in Primary Teeth|Clinical and Digital Subtraction Radiography Evaluation of Partial Caries Removal in Primary Teeth|DSR|Mahidol University|No|Completed|September 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|6 Years|8 Years|No|||September 2010|December 11, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749267||74483|
NCT01749514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A536-03|Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)|A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)||Acceleron Pharma, Inc.|No|Recruiting|January 2013|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01749514||74464|
NCT01731561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110146|Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis|MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II|MAINRITSAN 2|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2012|February 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01731561||75840|
NCT01731574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 028|DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate|An Open-label, Randomized, Three-period Crossover Trial in Healthy HIV-negative Women to Assess the Drug-drug Interaction Between Dapivirine Vaginal Ring-004 and Miconazole Nitrate||International Partnership for Microbicides, Inc.|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|November 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01731574||75839|
NCT01703065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7819|Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer|A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer||University of Washington|Yes|Recruiting|September 2013|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|October 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703065||78022|
NCT01703351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0470|Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy|||Yonsei University|No|Recruiting|October 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|78 Years|No|||January 2016|January 1, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01703351||78000|
NCT01703364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_CLL-9|Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL|Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Active, not recruiting|September 2012|October 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 4, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01703364||77999|
NCT01703949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7808|Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma|A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every &gt;3 Week Brentuximab Vedotin||University of Washington|No|Recruiting|March 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01703949||77954|
NCT01703325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si599/2010|Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails|Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment||Mahidol University|Yes|Completed|November 2010|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||October 2012|October 7, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01703325||78002|
NCT01703338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112117RIC|Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery|Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery||National Taiwan University Hospital|Yes|Recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|45 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|All subjects will be recruited from Far Eastern Memorial Hospital. The study is approved        by the Institutional Medical Research Ethics Committees in both National Taiwan University        Hospital and Far Eastern Memorial Hospital. Our orthopedic surgeons will response for        subject screening and medical diagnose. According to the power analysis, fifty subjects        will be enrolled in this study. Eligible subject will be given the subjects informed        consent and sign it before the enrollment.|February 2012|October 9, 2012|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01703338||78001|
NCT01700270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2120|Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.|A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of the CYP1A2 Inhibitor, Fluvoxamine, on Dovitinib (TKI258) Pharmacokinetics in Patients With Advanced Solid Tumors|CTKI258A2120|Novartis|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|October 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01700270||78237|
NCT01700530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09CRP2260136|Exercise, Statins, and the Metabolic Syndrome|Exercise, Statins, and the Metabolic Syndrome||University of Kansas Medical Center|No|Completed|May 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|25 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 26, 2012||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01700530||78217|
NCT01700777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHMG-IONS-862010|Bimanual Training in Children With Hemiplegia With Lower Limb and Postural Stimulation (HABIT & Leg)|Effet de la réadaptation Sur Les déficiences, Limitations d'activité et Restriction de la Participation Des Enfants présentant Des lésions Neurologiques Non-évolutives (Infirmes Moteurs cérébraux).||University Hospital of Mont-Godinne|Yes|Recruiting|November 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700777||78198|
NCT01701414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210423|Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures|Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures: a Randomized Controlled Clinical Study|FNB|Rhode Island Hospital|Yes|Completed|November 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|55 Years|N/A|No|||February 2008|February 7, 2014|September 27, 2012||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT01701414||78149|
NCT01701427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-035|Pain After Deep Electrical Stimulation in the Groin in Pain Free Subjects|Hyperalgesia After Deep Electrical Stimulation in Pain Free Subjects|HADES-1|Rigshospitalet, Denmark|No|Completed|June 2012|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young men.|January 2013|January 4, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701427||78148|
NCT01701648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEA/VIT|Melanocyte Transplantation for Patients With Stable Vitiligo.|Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo.||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|December 2010|June 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||September 2013|October 11, 2013|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01701648||78131|
NCT01751893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-PPEHP-88|Testing the Effectiveness of Henna on Managing PPE|A Randomized Double-blind, Placebo-controlled Study of the Effects of Lawsonia Inermis on Palmar-Plantar Erythrodysesthesia Induced by Capecitabine and/or Pegylated Liposomal Doxorubicin||Cyprus University of Technology|Yes|Recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751893||74282|
NCT01748435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU11SU387|Pre-emptive Analgesia With Qutenza in Lower Limb Amputation|The Role of Pre-emptive Analgesia With Qutenza (Topical Capsaicin 8%) in Preventing Neuropathic Pain Following Lower Limb Amputation: a Pilot Randomised Controlled Study||NHS Greater Glasgow and Clyde|No|Not yet recruiting|February 2013|May 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing lower limb amputation|December 2012|December 10, 2012|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748435||74547|
NCT01748448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LRDVDCM|Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome|Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome|ViDMe|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01748448||74546|
NCT01741454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0279|Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction|Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms||University of Wisconsin, Madison|No|Active, not recruiting|November 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01741454||75083|
NCT01748994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10039|Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women|Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women|Apple/Pear|Pennington Biomedical Research Center|Yes|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748994||74504|
NCT01741740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMALLUMBI123|Chronic Complaints After Small Umbilical Hernia Repair|High Incidence of Chronic Complaints and Recurrence 5 Years After Simple Sutured Umbilical Hernia Repair||Hvidovre University Hospital|No|Completed|January 2000|January 2009|Actual|January 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|295|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing primary elective open non-mesh sutured umbilical or        epigastric hernia repair during a five years period|December 2012|December 21, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01741740||75061|
NCT01742000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAR-KT-POST|Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women|Double-blinded Placebo-controlled Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women|PEARS-POST|Institute for Atherosclerosis Research, Russia|Yes|Completed|January 2007|October 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|180|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|December 4, 2012|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01742000||75041|
NCT01742299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A2406|Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator|An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment||Novartis|No|Active, not recruiting|March 2013|September 2023|Anticipated|September 2023|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|N/A|N/A|No|||May 2015|May 15, 2015|November 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01742299||75018|
NCT01702428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115648|Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age|Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Healthy Children 12 to 15 Months of Age||GlaxoSmithKline||Completed|November 2012|April 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|5019|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||November 2015|November 23, 2015|October 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01702428||78071|
NCT01702779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0107|Nasal Humidified High Flow Oxygen During Weaning From Mechanical Ventilation : Ultrasonography Study||HiFloLUS|University Hospital, Clermont-Ferrand||Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01702779||78044|
NCT01703650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_ISS_2012|Role of Perfusion CT in Pancreatic Cancer|Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer||Seoul National University Hospital|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|N/A|No|Probability Sample|Resectable pancreas tumor group patients with resectable pancreas adenocarcinoma or        neuroendocrine tumor        Locally advanced pancreas tumor group Patients with locally advanced pancreas cancer|February 2016|February 2, 2016|October 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01703650||77977|
NCT01699685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237ACH01|Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.|A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.|SYNERGY|Novartis|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|40 Years|N/A|No|||January 2016|January 11, 2016|September 28, 2012||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01699685||78282|
NCT01699919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC No. : EC/2011/2/24|A Study to Assess Analgesic Efficacy of Intravenous Lignocaine|Effect of Perioperative Systemic Lignocaine on Postoperative Pain in Patients Undergoing Elective Open Abdominal Surgeries- a Double Blinded Randomized Control Trial||Jawaharlal Institute of Postgraduate Medical Education & Research|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699919||78264|
NCT01699672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2012/1238|Group-based or Individual Information About Disease and Treatment Plan|Cancer Patients' Knowledge and Satisfaction After Group-based or Individual Information About Their Disease and Treatment Plan||Norwegian University of Science and Technology|No|Terminated|October 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|98|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|September 21, 2012||No|Problems recruiting patients (not willing, travel time, no respons)|No||https://clinicaltrials.gov/show/NCT01699672||78283|
NCT01700543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME2012-01E|Sidus(TM) Post Market Clinical Follow-up (PMCF) Study|Sidus(TM) Stem-Free Shoulder - A Multi-center, Prospective, Non-controlled Post Market Clinical Follow-up Study.||Zimmer, Inc.|No|Active, not recruiting|October 2012|September 2024|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|80 Years|No|Probability Sample|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who        fulfill all inclusion and none of the exclusion criteria.|June 2015|June 2, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700543||78216|
NCT01700803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Betadine CS|Povidone Iodine and Cesarean Section Wound Infections|Povidone Iodine 10% Versus 7.5% Hand Scrub and Cesarean Section Wound Infections: A Randomized Trial||Assiut University|Yes|Completed|January 2012|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3231|||Female|18 Years|40 Years|No|||October 2012|October 3, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01700803||78196|
NCT01701089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28253|A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers|An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects||Hoffmann-La Roche||Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01701089||78174|
NCT01700790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100325|Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin|A Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir in Combination With Rifampin in HIV-1-infected Patients With Tuberculosis.||University of Miami|No|Not yet recruiting|January 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01700790||78197|
NCT01760850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 105707|Breast and Cervical Cancer Educational Intervention for Latinas in Western New York|Investigating a Breast and Cervical Cancer Intervention for Latinas in Western New York||Roswell Park Cancer Institute|No|Completed|June 2007|April 2015||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|959|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 21, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760850||73596|
NCT01761097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO92673|Endocuff Adenoma Detection Rate Pilot Study|A Pilot Study to Assess the Role for Endocuff© Assisted Colonoscopy in the Detection of Colonic Cancer and Polyps||Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|January 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|N/A|N/A|No|||January 2013|January 4, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761097||73577|
NCT01764659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00052534|4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation|Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation|GCC 1210|University of Maryland|Yes|Completed|July 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|GI/GU multi-d clinic|March 2015|March 16, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764659||73303|
NCT01764932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advocate-IRB-5242|Accuracy of the Thoracic Epidural Catheter Insertion Confirmed by Fluoroscopic Imaging|Determining the Accuracy of Thoracic Epidural Continuous Catheter Insertion With Confirmatory Fluoroscopic Imaging||Chicago Anesthesia Pain Specialists||Recruiting|December 2011|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764932||73282|
NCT01764945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.46|Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions|Relative Bioavailability of BI 201335 (Capsule) Compared to Three Different Oral Solutions of BI 201335 Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Four-way Crossover Study)||Boehringer Ingelheim||Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|January 8, 2013||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01764945||73281|
NCT01765205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 118-2010|Newborn Screening for Critical Congenital Heart Disease|The Efficacy of Newborn Screening for Critical Congenital Heart Disease||University of Florida|No|Completed|March 2010|January 2014|Actual|January 2014|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Healthy newborns and newborns diagnosed with congenital cardiovascular malformations|March 2014|March 13, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01765205||73261|
NCT01761409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-2000-2010|Epidemiological Analysis on Endometrial Cancer in Guangdong Province of China|Epidemiological Analysis on Endometrial Cancer.||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Active, not recruiting|January 2000|||January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10000|||Female|N/A|N/A|No|Non-Probability Sample|Patients who was diagnosed with endometrial carcinoma from 2000 to 2010 in Guangdong        province of China|January 2013|January 3, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761409||73553|
NCT01758536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIXING-2012|Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke|A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke|HTZZP-INF|Huashan Hospital|Yes|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|70 Years|No|||January 2013|January 18, 2013|December 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758536||73774|
NCT01758757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye010|Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy|Comparison of Small-gauge and Conventional Vitrectomy for Proliferative Diabetic Retinopathy||Kyorin University|No|Completed|September 2007|July 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|347|||Both|10 Years|90 Years|No|||December 2012|December 31, 2012|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758757||73757|
NCT01758770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jst2012cash|China Action on Spine and Hip Status|Multi Center Survey on Spine and Hip Status in Chinese Population Using Quantitative Computed Tomography (QCT)|CASH|Beijing Jishuitan Hospital|Yes|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|29 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a population-based study, the population of this study is the subset of        participants of the large-scale population-based study:the prospective urban rural        epidemiology (PURE) in China.|August 2015|August 20, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01758770||73756|
NCT01759264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-974|An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)|An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience|FAIR|AbbVie|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|101|Samples Without DNA|Stool|Both|19 Years|N/A|No|Probability Sample|Participants with moderate-to-severe Crohn's Disease|June 2015|June 12, 2015|December 28, 2012||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01759264||73718|
NCT01759576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014761|A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function|An Open-Label, Single-Dose Study to Evaluate JNJ-28431754 Pharmacokinetics, Pharmacodynamics and Safety in Non-Diabetic Subjects With Varying Degrees of Renal Function||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||May 2013|May 27, 2013|December 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01759576||73694|
NCT01758445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE008-12|Proton Radiation for Stage II/III Breast Cancer|Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients With Stage II/III,Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation With Lymph Node Irradiation||Proton Collaborative Group|Yes|Recruiting|February 2013|January 2030|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01758445||73781|
NCT01759472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI05B01|Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test|Effect of Montelukast on Leukotriene Sensitive Asthma Detected by LTD4 Bronchial Provocation Test||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|September 2012|||September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|15 Years|60 Years|No|Non-Probability Sample|Bronchial Asthma patients|January 2013|January 6, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01759472||73702|
NCT01759485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMHC-VITD|Vitamin D for Schizophrenia|Vitamin D Supplementation as Adjunct to Clozapine-treated Chronic Schizophrenia Patients||Geha Mental Health Center|No|Recruiting|May 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01759485||73701|
NCT01759511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-322-0206|Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)|ATLAS|Gilead Sciences|No|Terminated|October 2012|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759511||73699|
NCT01758731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1658.cc|Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History|Phase I Trial of Olaparib (AZD2281) in Combination With C225 and Radiation Therapy in Patients With Locally Advanced, Stage IVA-B Squamous Cell Carcinomas of the Head/Neck With Heavy Smoking Histories||University of Colorado, Denver|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758731||73759|
NCT01758965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD_SCHBC_IRB_2012-06|Surgicel® Fibrillar for Delayed Bleeding After ESD|Surgicel® (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study||Soonchunhyang University Hospital|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|146|||Both|20 Years|N/A|No|||May 2014|May 12, 2014|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758965||73741|
NCT01760330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00709|IV Acetaminophen in Children Undergoing Palatoplasty|A Prospective, Double-Blinded, Randomized Comparison of Intravenous Acetaminophen Versus Placebo in Children Undergoing Palatoplasty||Nationwide Children's Hospital|No|Withdrawn|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||March 2016|March 4, 2016|December 12, 2012|Yes|Yes|Unable to obtain funding|No||https://clinicaltrials.gov/show/NCT01760330||73636|
NCT01760343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL830_1001|A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor|A Randomized, Double-blind, Single-center, Cross-over Study to Evaluate the Safety, Bioavailability and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor Administered Intravenously||CSL Behring||Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|December 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01760343||73635|
NCT01760603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-04|Ischia Spinous Fascia Fixation Surgery for Pelvic Organ Prolapse|A Prospective,Multicenter Pilot Study to Evaluate the Clinical Performance of the Ischia Spinous Fascia Fixation Surgery for Pelvic Organ Prolapse.||Peking Union Medical College Hospital|No|Recruiting|December 2012|December 2017|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||December 2012|January 2, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01760603||73615|
NCT01760616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-201102|Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy|A Prospective, Multicenter, Open-labeled, Parallel -Controlled Clinical Study Investigating Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy||Qidong Gaitianli Medicines Co., Ltd|Yes|Enrolling by invitation|August 2011|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1680|||Both|18 Years|75 Years|No|||October 2014|October 29, 2014|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01760616||73614|
NCT01760863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11040802|Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty|The Utility of Oral Antibiotic Therapy Following 2-stage Revision Arthroplasty for Infected Prosthetic Hips and Knees||Rush University Medical Center|No|Recruiting|July 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|90 Years|No|||June 2014|June 26, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760863||73595|
NCT01760876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-454|Evaluation of HealinG of Polymer-Free Biomlimus A9-Coated Stent by Optical Coherence Tomography (EGO-BIOFREEDOM)|Evaluation of Healing the Biofreedom Stent Study||The University of Hong Kong|Yes|Completed|December 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|85 Years|No|||December 2015|December 10, 2015|December 20, 2012||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01760876||73594|2 patients had difficult guiding-catheter engagement for optimal baseline OCT imaging with lots of blood-displacement artifacts; obtaining good future OCT assessments were impossible and were excluded from the study (replaced by another 2 patients).
NCT01761110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA031066|Pilot Test of a Community-based Buprenorphine Treatment Intervention|Development of a Community-based Buprenorphine Treatment Intervention||Albert Einstein College of Medicine of Yeshiva University|No|Completed|December 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761110||73576|
NCT01764958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sponsor|Association Between Mother-Infant Attunement During Interaction and the Quality of General Movements|Association Between Mother-Infant Attunement During Interaction and the Quality of General Movements and Motor Development of Preterm Infants||Assuta Hospital Systems|Yes|Completed|April 2012|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|4 Months|8 Months|Accepts Healthy Volunteers|Probability Sample|Preterm infants at a corrected age of 3-4 months and their mothers|April 2012|July 7, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764958|12 Months|73280|
NCT01765218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_05_17_UCD|Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy|TOPIRAMATE AS AN ADJUVANT TO THERAPEUTIC HYPOTHERMIA FOR INFANTS WITH HYPOXIC ISCHEMIC ENCEPHALOPATHY||University of California, Davis|Yes|Recruiting|February 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|6 Hours|No|||March 2015|March 19, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765218||73260|
NCT01765491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-206|Comparison of Two Methods of Bowel Preparation for Colonoscopy in Hospitalized Patients|Comparison of Morning-only With Split-dose Polyethylene Glycol for Colonoscopy Preparation in Hospitalized Patients: A Randomized Controlled Non-Inferiority Study||John H. Stroger Hospital|No|Completed|August 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|120|||Both|18 Years|80 Years|No|||January 2013|January 8, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765491||73239|
NCT01765504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter NIRS Study|Pilot Study of the Feasibility of Multicenter NIRS Data Collection and Interventions for Desaturation in Cardiac Surgery|Pilot Study of the Feasibility of Multicenter NIRS Data Collection and Interventions for Desaturation in Cardiac Surgery||Johns Hopkins University|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|50 Years|N/A|No|Non-Probability Sample|Patient inclusion criteria will be male or female patients >50 years of age undergoing        primary or re-operative CABG and/or cardiac valve surgery that requires CPB who will have        NIRS monitoring for clinical indications.|August 2015|August 31, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01765504||73238|
NCT01761422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0132|Myocardial Inflammation in Systemic Lupus Erythematosus|Myocardial Inflammation in Systemic Lupus Erythematosus||Ohio State University|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|60 Years|No|Non-Probability Sample|Adults ages 18 years and older who are diagnosed with SLE|January 2014|January 23, 2014|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761422||73552|
NCT01759017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000570|PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease|Molecular Imaging to Predict Response to Infliximab Therapy in Patients With Crohn's Disease||Brigham and Women's Hospital|No|Terminated|December 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a new diagnosis of symptomatic Crohn's disease or an established        diagnosis of Crohn's disease with suspected flare. The diagnosis of Crohn's disease will        be based on the combination of clinical, imaging, endoscopic, and pathology findings.|July 2015|July 20, 2015|December 21, 2012||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01759017||73737|
NCT01759030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIORA (BCD-020-2)|Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis|Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies|BIORA|Biocad|No|Active, not recruiting|December 2012|July 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||July 2015|January 12, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01759030||73736|
NCT01759589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inonu University Anesthesia|Three Anaesthesic Method in Electroconvulsive Theraphy|Sevoflurane Alone and Propofol With or Without Remifentanil in Electroconvulsive Therapy||Inonu University|Yes|Completed|January 2011|August 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|65 Years|No|||December 2012|December 31, 2012|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01759589||73693|
NCT01759602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078437|C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation|Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations||Johns Hopkins University|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2014|July 17, 2014|December 29, 2012|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01759602||73692|
NCT01759875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS6537|Effects of Gastric pH on the Pharmacokinetics of Atazanavir|Effects of Gastric pH on the Pharmacokinetics of Atazanavir in Healthy Volunteers||University of California, San Francisco|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01759875||73671|
NCT01759888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-1926A|Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism|From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism||Chang Gung Memorial Hospital|No|Completed|August 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|49|||Both|20 Years|80 Years|No|||January 2015|January 23, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01759888||73670|
NCT01759186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6185|Airway Redox and Gender Determinants in Severe Asthma|Severe Asthma Research Program|SARP3|The Cleveland Clinic|Yes|Active, not recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|6 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients living in the greater Cleveland area, and in Virginia|September 2015|September 9, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01759186||73724|
NCT01759199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 11-157 STEPPER|The Six-minute Stepper Test as an Outcome Measure of Exercise Tolerance During Pulmonary Rehabilitation in With Chronic Obstructive Pulmonary Disease (COPD) Patients(STEPPER)?|The Six-minute Stepper Test : Marker of Exercise Tolerance's Evolution During Pulmonary Rehabilitation in Patients With COPD ?|STEPPER|University Hospital, Brest|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|72|||Both|18 Years|N/A|No|||November 2013|November 28, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01759199||73723|
NCT01759498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-12C/4|The Effects of Hydrogen-rich Formulation for Treatment of Sport-related Soft Tissue Injuries|||Center for Health, Exercise and Sport Sciences, Serbia|Yes|Completed|December 2012|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2013|September 27, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01759498||73700|
NCT01757522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01204-39|Detection of Right Ventricular Dysfunction by 2D Strain During Acute Respiratory Distress Syndrom (ARDS)|Detection of Right Ventricular Dysfunction by 2D Strain During Acute Respiratory Distress Syndrom (ARDS)|STRAIN|University Hospital, Grenoble|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|290|Samples Without DNA|Plasmatic levels of NT proBNP and pre pro endothelin are monitored in ARDS group to      determine whether these biomarkers can help detect right ventricular dysfunction.|Both|18 Years|N/A|No|Non-Probability Sample|Patients are recruited in our medical intensive care unit at Grenoble University Hospital.|March 2016|March 14, 2016|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01757522||73851|
NCT01759537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankylos-Bluestone|Study to Evaluate Bone and Gum Dimension Changes Around Dental Implants Placed in Different Positions in Bone.|Evaluation of Changes of Hard and Soft Tissues After Epi-crestal and Sub-crestal Placement of Ankylos Dental Implants.||Dentsply International|No|Active, not recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|December 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759537||73697|
NCT01759797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-005|Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS|Safety of Intravenous Transplantation of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS||Royan Institute|Yes|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||May 2012|August 27, 2013|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01759797||73677|
NCT01760057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01TW008398|Evaluating the Effect of a Novel Web-based Intervention to Increase HIV Testing in Men Who Have Sex With Men|Randomized Controlled Trial to Evaluate the Effect of a Novel Web-based Intervention to Increase HIV Testing in Men Who Have Sex With Men in Lima-Peru|TuNexo|Universidad Peruana Cayetano Heredia|No|Completed|January 2013|March 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01760057||73657|
NCT01759810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBM/2012|Proteome-based Personalized Immunotherapy of Glioblastoma|Proteome-based Personalized Immunotherapy of Malignant Brain Tumors||NeuroVita Clinic|Yes|Enrolling by invitation|December 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01759810||73676|
NCT01760655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.501|Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies||Thomas Jefferson University|Yes|Recruiting|December 2012|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760655||73611|
NCT01760629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3332/002|Hypothermia for Encephalopathy in Low Income Countries-Feasibilty|Hypothermia for Encephalopathy in Low Income Countries-Feasibility|HELIX-I|Thayyil, Sudhin|Yes|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|N/A|1 Month|No|||February 2015|February 20, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760629||73613|
NCT01760889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-335|SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia||Shire|Yes|Terminated|February 2013|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|65 Years|No|||May 2014|May 1, 2014|January 2, 2013|Yes|Yes|Study was discontinued due to non-safety related business prioritization decisions. No    subjects were randomized|No|May 1, 2014|https://clinicaltrials.gov/show/NCT01760889||73593|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
NCT01761123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXA02-002|Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum|An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males|ICC H1|Vaxart|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|January 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01761123||73575|
NCT01764971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS and chronic ITP|Cerebral Dysfunction in Chronic ITPwith High Risk of Serious Bleeding Excluding Intracranial Hemorrhage.|Cerebral Dysfunction in Chronic ITP With High Risk of Serious Bleeding Excluding Intracranial Hemorrhage.||Ain Shams University|Yes|Not yet recruiting|March 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|4 Years|18 Years|No|Probability Sample|Patients will be recruited from those treated in Hematology Clinic, Ain Shams University.|January 2013|January 8, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01764971|6 Months|73279|
NCT01764984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.5.04.12|Bone Mineral Density Changes Under Two Tibial Components in Total Knee Arthroplasty|Randomized Clinical Evaluation of Bone Mineral Density Changes Under Non-cemented Trabecular Metal Tibial Component and Cemented Titanium Controls.||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|November 2005|January 2015|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764984||73278|
NCT01765231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-2012111305|Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma|Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma||Peking University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765231||73259|
NCT01765244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAH/Ulc/2010|Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment|Multicenter Clinical Trial to Evaluate the Safety and Feasibility of an Allogeneic Tissue Engineered Drug (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers Refractory to Conventional Treatment||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|January 2014|September 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|August 4, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765244||73258|
NCT01765517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-MED2114-02|Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients|A 26-week, Randomized, Double-blind, Placebo-controlled Study to Explore the Effects of Probiotics on Endotoxin Levels in Patients With Type 2 Diabetes Mellitus||King Saud University|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|75 Years|No|||February 2016|February 22, 2016|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01765517||73237|
NCT01758783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiation Enteritis 001|Therapy of Radiation Enteritis With Glutamine|the Efficacy of Glutamine in the Therapy of Radiation Enteritis Among Patients Treated With Radiation of Abdomen and Pelvis.||Nanjing University School of Medicine|Yes|Enrolling by invitation|June 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||January 2013|January 3, 2013|December 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758783||73755|
NCT01759277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adductor Canal vs Femoral|Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty|Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty||University of California, San Diego|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759277||73717|
NCT01759615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIMS/06/AREDF|Early Versus Late Initiation of Feeding in Preterm Newborns With Prenatal AREDF in Umbilical Artery|A Randomized Clinical Trial on Comparison of Early Versus Late Initiation of Feeding in Preterm Small for Gestation Infants Below 35 Weeks Gestation With Prenatal Absent or Reversal of End Diastolic Flow (AREDF) in Umbilical Artery|AREDF|Lady Hardinge Medical College|Yes|Completed|April 2006|April 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|N/A|N/A|No|||December 2012|December 31, 2012|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01759615||73691|
NCT01759901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2012.351-T|Effect of Vascular Inflow Occlusion in Open Liver Resection for Hepatocellular Carcinoma|Open Liver Resection With or Without Vascular Inflow Occlusion for Hepatocellular Carcinoma: a Randomized Controlled Trial||Chinese University of Hong Kong|No|Recruiting|January 2013|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01759901||73669|
NCT01764763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0868|Intraoperative Epiaortic Scanning for Preventing Early Stroke After Off-pump Coronary Artery Bypass|||Yonsei University|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2292|||Both|31 Years|88 Years|No|Non-Probability Sample|From January 2001 to December 2011, 2292 patients who underwent isolated off-pump coronary        artery bypass at Yonsei Cardiovascular Hospital in Seoul|January 2013|January 7, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01764763||73295|
NCT01758939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients|Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients||Cairo University|Yes|Recruiting|January 2011|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|100000|||Both|18 Years|60 Years|No|Non-Probability Sample|chronic hepatitis C virus , genotype IV, infected Egyptian patients|April 2013|April 15, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01758939|18 Months|73743|
NCT01761136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-4|The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site|Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site||Beijing Center for Disease Control and Prevention|No|Completed|November 2011|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|680|||Both|2 Months|12 Months|Accepts Healthy Volunteers|||March 2013|March 27, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761136||73574|
NCT01758497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-042|Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty|Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty; A Randomized Double Blind, Placebo-Controlled Trial|FICB|St. Luke's-Roosevelt Hospital Center|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2011|December 24, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01758497||73777|
NCT01760096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNH-2013|Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)|Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)||Institute of Hematology & Blood Diseases Hospital|Yes|Active, not recruiting|January 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||January 2013|January 1, 2013|January 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01760096||73654|
NCT01760369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-JDHA-12|Study of the: Effect of Head Rotation in Prone Position on Regional Cerebral Oxygen Saturation.|Observation Study of the: Effect of Head Rotation in Prone Position on Regional Cerebral Oxygen Saturation (rSO2) in Anesthetized Patients.|NIRS|Glostrup University Hospital, Copenhagen|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing lowerback surgery under universal anesthesia at Glostrup Hospital,        Copenhagen.|January 2013|November 13, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01760369||73633|
NCT01760382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENOVAMI01|REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network|REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network|RENOVAMI|Azienda Ospedaliero Universitaria Maggiore della Carita|No|Recruiting|January 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chest pain or equivalents (dyspnea, epigastrial pain) and ST segmnent        elevation on more 2 or more contiguous ECG leads|March 2015|March 25, 2015|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01760382|1 Year|73632|
NCT01757002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL114981-01|Web-Based and Tailored Asthma Management Intervention (Puff City) in Teens With Asthma Attending Urban Clinics|Pragmatic Randomized Controlled Trial of the Web-Based Asthma Management Intervention (Puff City) in Teens With Asthma Attending Urban Clinics|PCC|Henry Ford Health System|Yes|Recruiting|March 2013|July 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|354|||Both|13 Years|19 Years|No|||October 2012|September 23, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01757002||73891|
NCT01757262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00078|A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient|Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study||AstraZeneca||Withdrawn|January 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757262||73871|
NCT01758523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-056-2|Dutasteride Treatment for the Reduction of Heavy Drinking in Men|Dutasteride Treatment for the Reduction of Heavy Drinking||University of Connecticut Health Center|No|Recruiting|January 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Male|18 Years|70 Years|No|||March 2015|March 2, 2015|December 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758523||73775|
NCT01758744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0560|Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1|TAPIT-1: Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1|TAPIT-1|University of Colorado, Denver|Yes|Recruiting|December 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|80 Years|No|||January 2016|January 5, 2016|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758744||73758|
NCT01757600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arnaud01|Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Macular Hole|Long-term Anatomical and Functional Outcomes of Idiopathic Macular Hole Surgery. The Yield of Spectral-domain OCT Combined With Microperimetry.||Centre Hospitalier Universitaire Dijon||Completed|August 2010|||November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|23|||Both|55 Years|85 Years|No|Non-Probability Sample|Patients who underwent successful surgery for MH defined as closure of the hole, at least        1 year before.|December 2012|December 21, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01757600||73845|
NCT01757938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUST2012-1|Randomized Control Trial of Shang Ring Versus Forceps-guided Adult Male Circumcision in Southwestern Uganda.|Shang Ring Versus Forceps-guided Adult Male Circumcision: a Randomized Controlled Effectiveness Study in Southwestern Uganda.||Mbarara University of Science and Technology|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 28, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01757938||73820|
NCT01758250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039256|Microvascular and Fibrosis Imaging Study|Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects||Duke University|No|Recruiting|February 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient population at Duke University Medical Center and healthy controls|March 2016|March 7, 2016|December 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758250||73796|
NCT01758549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00576|Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis|Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis||University of Southern California|Yes|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|70 Years|No|||June 2014|June 29, 2014|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01758549||73773|
NCT01759043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-7071-01 CHRDS|Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI|Safety and Feasibility of Using a Single Transradial Guiding Catheter for Both Left and Right Coronary Angiography and Intervention in Patients With ST-segment Myocardial Infarction(RAPID)|RAPID|Beijing Luhe Hospital|No|Completed|December 2012|December 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01759043||73735|
NCT01759056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB1101|Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis|A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis||Avaxia Biologics, Incorporated|Yes|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|No|||February 2014|March 4, 2014|December 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01759056||73734|
NCT01759290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-302|ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.|ABSORB FIRST Registry: An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS).||Abbott Vascular|No|Completed|January 2013|December 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled into this registry will be male and female patients derived from the        general interventional cardiology population who satisfy the inclusion and exclusion        criteria.|January 2016|February 9, 2016|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01759290|1 Year|73716|
NCT01764503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24|Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study|to Evaluate the Long-term Results of Endoscopic Papillectomy (EP)||Société Française d'Endoscopie Digestive|No|Completed|September 2003|June 2009|Actual|June 2009|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|93|||Both|N/A|N/A|No|Probability Sample|patient with ampullary tumor histologically confirmed|March 2013|March 11, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01764503|3 Years|73315|
NCT01764776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225A2113|Effect of Hepatic Impairment on LDE225..|A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.||Novartis||Completed|March 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01764776||73294|
NCT01765075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARLIGHT - 1012|Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment|Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment|STARLIGHT|Boston Scientific Corporation|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Permanent atrial fibrillation|March 2014|March 3, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765075||73271|
NCT01760356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3PIGREF- 2009 -1165|Clinical Study of the Pharmacogenetic / Pharmacokinetic / Pharmacodynamic Relationships of Calcineurin Inhibitors Cyclosporine and Tacrolimus in Liver Transplant Recipients|Phase IV - Study of PK,PD,PG Relationships of Anticalcineurin Drugs: Cyclosporin and Tacrolimus in Liver Transplant Recipients.|3PIGREF|UDA Centro Nacional Hepato-Bilio-Pancreático|No|Enrolling by invitation|May 2011|||February 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|46|Samples With DNA|Genetic analysis is carried out from whole blood samples,from which DNA is extracted for the      study of relevant polymorphisms.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Transplant Patients on anticalcineurin drugs and Transplant Waiting List Patients        comprising the National Program of Liver Transplantation in Uruguay.        Healthy Volunteers belonging to the Hospital payroll.|February 2014|February 16, 2014|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01760356|12 Months|73634|
NCT01757249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDOG-12/SC/0645|Pituitary Down-regulation Before IVF for Women With Endometriosis|A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study||University of Oxford|No|Terminated|January 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Female|19 Years|39 Years|No|||November 2013|November 11, 2013|December 20, 2012||No|Unable to recruit sufficient participants|No||https://clinicaltrials.gov/show/NCT01757249||73872|
NCT01758978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/1106|A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet|A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 30-mg and One 60-mg Hydrocodone Bitartrate Extended-Release Tablet||Teva Pharmaceutical Industries|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|December 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758978||73740|
NCT01759225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACCVREG1|Registry of Cardiovascular Disease Patients|Computerized Registry of Cardiovascular Disease Patients|CVD Registry|Maccabi Healthcare Services, Israel||Enrolling by invitation|January 1998|||December 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|110000|||Both|N/A|N/A|No|Non-Probability Sample|The electronic registry includes all patients that had been diagnosed twice or more by        hospital or outpatient cardiologists, primary physicians, or pediatricians with at least        one of the following clinical diagnoses, classified according to the International        Classification of Diseases, Ninth revision (ICD-9) codes: Ischemic Heart        Disease,MI,non-MI,congestive heart failure,peripheral vascular disease, cerebrovascular        disease CVA,TIA, Patients with prior coronary artery bypass grafting(CABG) or percutaneous        coronary intervention (PCI), using relevant Current Procedural Terminology (CPT) codes        were also included in the registry.|December 2012|December 27, 2012|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01759225|1 Month|73721|
NCT01769521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1011|Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG|A Single Center, Prospective, Open Label Study Assessing the Relationship Between the 24-hour Intraocular Pressure Pattern as Determined by Sensimed Triggerfish® and the 24-hour Blood Pressure Pattern in Patients With Primary Open Angle Glaucoma||Sensimed AG|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|99 Years|No|||November 2015|November 16, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769521||72930|
NCT01761149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYEYYCT2013001|Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy|Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial||Central South University|Yes|Recruiting|December 2012|||March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2013|January 3, 2013|December 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761149||73573|
NCT01757535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-AML-001|Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission|QUAZAR AML-001|Celgene|Yes|Recruiting|April 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|55 Years|N/A|No|||March 2016|March 10, 2016|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757535||73850|
NCT01757912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/668|Effect of Body Position Changes on Endotracheal Tube Cuff Pressure in Ventilated Critically Ill Patients|Effect of Body Position Changes on Endotracheal Tube Cuff Pressure in Ventilated Critically Ill Patients.|CP|University Hospital, Ghent|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|70 Years|No|||December 2012|December 28, 2012|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757912||73822|
NCT01759550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030546|Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip|Prospective Case-Series of LigaSure Advance Pistol Grip and LigaSure Blunt Tip in Gastric Procedures||Duke University|Yes|Terminated|September 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|This study will include 60 patients previously scheduled to undergo a Roux-en-Y or gastric        reduction precodures (sleeve gastrectomy or placation) using the LigaSure Advance Pistol        Grip or LigaSure Blunt Tip, repectively. The pricipal investigator will be responsible for        patient selection.|June 2015|June 9, 2015|December 31, 2012|No|Yes|The Sponsor terminated the study.|No||https://clinicaltrials.gov/show/NCT01759550||73696|
NCT01757613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KER-001|Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis|Three-armed, Randomized, Double-blind Dose-finding Trial on Efficiency and Safety of AK 3012 in 3 Different Concentrations in Patients With Actinic Keratosis Olsen Grade I/II||Dolorgiet GmbH & Co. KG|No|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757613||73844|
NCT01757626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-230|Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma|Phase I Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|1 Year|N/A|No|||March 2016|March 9, 2016|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757626||73843|
NCT01757977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.751|A Comparison of the Performance of Standard Double Lumen Tubes With Vivasight DL™ Double Lumen Tubes for Lung Isolation in Patients Undergoing Thoracic Surgery|A Comparison of the Performance of Standard Double Lumen Tubes With Vivasight DL™ Double Lumen Tubes for Lung Isolation in Patients Undergoing Thoracic Surgery||University College Hospital Galway|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|16 Years|85 Years|No|||March 2013|March 15, 2013|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01757977||73817|
NCT01757951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYSnilkka-RCT4|Unimalleolar Versus Bimalleolar Fixation in Bi- or Trimalleolar Ankle Fracture|Unimalleolar Versus Bimalleolar Fixation in Bi- or Trimalleolar Ankle Fracture - A Randomized Clinical Trial||University of Oulu|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|16 Years|N/A|No|||December 2012|December 21, 2012|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757951||73819|
NCT01757964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14267|Bacteriotherapy in Pediatric Inflammatory Bowel Disease|Bacteriotherapy in Pediatric Inflammatory Bowel Disease||Seattle Children's Hospital|Yes|Active, not recruiting|December 2012|January 2014|Anticipated|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|21 Years|No|||December 2013|December 11, 2013|December 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757964||73818|
NCT01758263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-HE-200|Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment|Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment: A Retrospective Database Analysis||Forest Laboratories|No|Active, not recruiting|October 2012|July 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patents treated for hypertension during the period of 2007-2011 in the United States.|December 2012|December 26, 2012|December 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758263||73795|
NCT01758562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capo|Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®|||University of Zurich|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Both|18 Years|80 Years|No|||August 2014|August 14, 2014|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758562||73772|
NCT01758796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYSrct-Ankle3.2|Study of Operative Versus Non-operative Treatment of ER-stress Positive Ankle Fractures|A Prospective Randomized Study of Operative Versus Non-operative Treatment of ER-stress Positive Weber-B Unimalleolar Fractures.||University of Oulu|Yes|Recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|16 Years|N/A|No|||June 2015|June 1, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01758796||73754|
NCT01759069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microscope|RCT: Effectiveness of a Microscope During Dental Root Apical Surgery|The Effectiveness of a Microscope During Apical Surgery; a Prospective Randomized Controlled Clinical Trial.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 17, 2014|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01759069||73733|
NCT01764243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P211-03|Safety and Efficacy of MT-4666|A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2012|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|450|||Both|50 Years|85 Years|No|||September 2015|September 24, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01764243||73335|
NCT01764256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 009|A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine|A Phase 1 Double Blinded, Randomized, Placebo-controlled Dose Escalation Study to Examine the Safety, Reactogenicity, Tolerability and Immunogenicity of the P2-VP8 Subunit Rotavirus Vaccine in Healthy Adult Volunteers||PATH|Yes|Completed|December 2012|September 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|January 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01764256||73334|
NCT01764789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10026|Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer|A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|39|||Female|21 Years|85 Years|No|||October 2015|October 8, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01764789||73293|
NCT01760642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP_metabolomics|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity in Female Subjects Using Metabolomics||Seoul National University Hospital|Yes|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01760642||73612|
NCT01760902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH5R24MD002769-02|Diet & Activity Community Trial: High-Risk Inflammation|Diet & Activity Community Trial: High-Risk Inflammation|CCTT|University of South Carolina|Yes|Completed|March 2010|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|438|||Both|30 Years|N/A|Accepts Healthy Volunteers|||January 2015|December 7, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01760902||73592|
NCT01757899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP 16487|Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children|Phase II, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children|PEDALI|Universidade Federal do Rio de Janeiro|Yes|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|17 Years|No|||December 2015|December 16, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757899||73823|
NCT01769274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291006|Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia|A Randomized, Double Blind Third Party Open Placebo-Controlled Exploratory Study To Evaluate The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia|IEM|Pfizer|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|78 Years|No|||July 2013|July 30, 2013|October 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769274||72949|
NCT01769287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF08004AF|EP Study of Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound|EP Study at >1 Year to Evaluate the Presence of Conduction Block Across the Cinch Line in Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound(HIFU)|AfMAZE EP|Plymouth Hospitals NHS Trust|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Secondary care clinic - Patients who have undergone an Epicor HIFU ablation >12 months ago|September 2013|September 16, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01769287||72948|
NCT01769027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spallanti|Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS|Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS|ATIVPANDAS|CNS Onlus|No|Not yet recruiting|June 2013|June 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|4 Years|40 Years|No|||January 2013|January 15, 2013|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01769027||72968|
NCT01769833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25659|HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance|HBsAg Decline and HBeAg Seroconversion Following 48 Weeks Peg-interferon-α Treatment in Patients With e Antigen Positive Chronic Hepatitis B After Nucleoside Analogue Maintenance Therapy Compared to Continuing Nucleoside Analogue Treatment||Pusan National University Hospital|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769833||72906|
NCT01765751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT004663|Manual Cervical Distraction: Measuring Chiropractic Delivery for Neck Pain Clinical Trial|Cervical Distraction Minimal Intervention Development: Translating From Basic to Clinical Studies|MCD|Palmer College of Chiropractic|Yes|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|48|||Both|18 Years|70 Years|No|||September 2015|September 4, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01765751||73219|
NCT01765764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-043|Bimatoprost for the Treatment of Eyebrow Hypotrichosis|||Allergan|No|Completed|March 2013|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|357|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|January 9, 2013|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT01765764||73218|
NCT01766284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUSHOCTII|Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix|Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix (PUSHOCTII)|PUSHOCTII|Preventive Oncology International, Inc.|No|Completed|November 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||February 2013|February 12, 2013|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01766284||73178|
NCT01757990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS_2012_10|The Effect of Stevia Rebaudiana Extracts on Different Variables Related to Caries: an in Vitro and in Vivo Evaluation.|A Comparative Clinical Evaluation of the Effect of Stevia Rebaudiana Extracts and Sucrose on Dental Plaque pH (Stephan Curve Trend) Using a Microtouch Electrode in Healthy Volunteers. A Phase II Study.||Università degli Studi di Sassari|No|Completed|March 2012|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|20|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 12, 2013|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01757990||73816|
NCT01758276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-12|Obstetric Complications in Women Who Smoke During Pregnancy|Obstetric Complications in Women Who Smoke During Pregnancy||Hillel Yaffe Medical Center|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|21000|||Female|18 Years|50 Years|No|Probability Sample|All women who delivered in McGill University health center between 2001-2008|December 2012|December 31, 2012|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01758276||73794|
NCT01758289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-785|Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients|A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis||AbbVie|No|Terminated|January 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|This study was conducted in 8 hemodialysis units distributed in Venezuela.|November 2014|November 7, 2014|December 27, 2012||No|Changes in country regulation|No|November 7, 2014|https://clinicaltrials.gov/show/NCT01758289||73793|
NCT01758575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/76|Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities|Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities||VU University Medical Center|No|Recruiting|November 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|120|Samples With DNA|Blood samples and blind biopsies of the oral mucosa, skin and colon mucosa will be taken      pre-treatment and after 4 weeks of treatment.|Both|18 Years|N/A|No|Probability Sample|Patients with advanced or metastatic solid malignancy, amenable to standard treatment with        targeted agents will be included from the VUmc Medical Oncology outpatient clinic.|December 2015|December 8, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01758575||73771|
NCT01758809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1009-111-015|Pain Control of Thoracoscopic Major Pulmonary Resection|Pain Control of Thoracoscopic Major Pulmonary Resection: Is Pre-emptive Local Bupivacaine Injection Able to Replace the Intravenous Patient Controlled Analgesia?||Seoul National University Bundang Hospital|Yes|Completed|December 2010|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|N/A|N/A|No|||December 2012|December 25, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01758809||73753|
NCT01763944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041857|Carbohydrate Restriction and Prostate Cancer Growth|A Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men With A Rising PSA After Failed Primary Therapy for Prostate Cancer|CAPS2|Duke University|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|N/A|No|||August 2015|October 20, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01763944||73358|
NCT01764516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f110@1958|Study on Serum Zinc and Selenium Levels in Epileptic Patients|Arak University of Medical Sciences , Ministry of Health and Education,I.R.Iran||Arak University of Medical Sciences|Yes|Completed|November 2011|May 2012|Actual|March 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Actual|40|None Retained|Serum were analysis for zinc and selenium|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|all generalized and single epileptic patiants which were identify for fist time|January 2013|January 5, 2013|January 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764516|1 Week|73314|
NCT01765088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSNO2012001|A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas|A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas||Sun Yat-sen University|Yes|Recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765088||73270|
NCT01756989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Angiocomb|ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors|ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors||Helsinki University Central Hospital|No|Completed|January 2005|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|16 Years|No|||May 2014|May 7, 2014|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01756989||73892|
NCT01769001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-102-F02|An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients|An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients||Protalix|No|Enrolling by invitation|March 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769001||72970|
NCT01768741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRRSH20121225-2|Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma|A Randomized Controlled Trial of Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma||Sir Run Run Shaw Hospital||Recruiting|December 2012|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01768741||72990|
NCT01769014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2012-0178|Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder|In the Cantons Graubunden and Glarus as Well as in the Principality of Liechtenstein: Influence of Intensive Outpatient Treatment of People With Schizophrenia and Schizoaffective Disorder on Quality of Life and Adherence||Psychiatrische Dienste Graubuenden|Yes|Enrolling by invitation|January 2013|December 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|People who suffer from schizophrenia or schizoaffective disorder, following DSM IV        criteria and who live in the cantons Glarus, Graubuenden or the Principality of        Liechtenstein.|January 2013|January 15, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769014||72969|
NCT01769313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202|A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery|A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery||Technolas Perfect Vision GmbH|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769313||72946|
NCT01769300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UB5MC20286|Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder|Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder|ePROS|American Academy of Pediatrics|No|Enrolling by invitation|January 2013|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|450|||Both|5 Years|12 Years|No|||January 2013|January 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01769300||72947|
NCT01769534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2487|Registry and Fluid Banking of Pancreatic Cystic Lesions|Prospective Registry and Cystic Fluid Banking for Patients Undergoing EUS-FNA for the Evaluation of Pancreatic Cystic Lesions.||University of Oklahoma|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3|Samples Without DNA|Pancreatic cyst fluid|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients will present to our endoscopy unit for EUS-FNA to work up pancreatic cystic        lesion(s).|December 2014|December 2, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769534|1 Year|72929|
NCT01769547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2012-DOVE-M|A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy|A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy|DOVE-M|Ontario Clinical Oncology Group (OCOG)|Yes|Terminated|March 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|January 9, 2013||No|Stage 1 accrual completed. Study did not proceed to Stage 2 accrual.|No||https://clinicaltrials.gov/show/NCT01769547||72928|
NCT01758224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-1-0707|Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation|Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis||The Cleveland Clinic|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|70 Years|No|||February 2014|February 26, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01758224||73798|
NCT01758510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYNR-CS-Allo-01|Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis|An Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell("HYNR-CS-Allo Inj") Treatment in Amyotrophic Lateral Sclerosis(ALS)||Hanyang University Seoul Hospital|Yes|Recruiting|December 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|25 Years|80 Years|No|||January 2013|January 16, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01758510||73776|
NCT01765777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-740|Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain|Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain||New York Institute of Technology|No|Recruiting|June 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765777||73217|
NCT01765790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391101|Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors|A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors||Baxalta US Inc.|No|Active, not recruiting|June 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01765790||73216|
NCT01762527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-KFE-1217|Adaptive Radiotherapy Using Plan Selection for Bladder Cancer|Adaptive Radiotherapy Using Plan Selection for Bladder Cancer: A Phase II Trial|plan selection|University of Aarhus|No|Recruiting|October 2012|April 2016|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762527||73467|
NCT01762787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114416|Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers|A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01762787||73447|
NCT01762800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116717|Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg|Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg||GlaxoSmithKline|No|Completed|February 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|407|||Both|40 Years|80 Years|No|||February 2016|February 11, 2016|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01762800||73446|
NCT01763099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSC-auto-HSCT-2013|Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure|Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Following Autologous Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|65 Years|No|||January 2013|January 15, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763099||73423|
NCT01763346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BETAFAT|Beta Cell Restoration Through Fat Mitigation|Beta Cell Restoration Through Fat Mitigation|BetaFat|University of Southern California|Yes|Recruiting|June 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|22 Years|65 Years|No|||February 2015|February 9, 2015|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01763346||73404|
NCT01763658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antioxident in ITP|Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia|Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy|ITP|Ain Shams University|Yes|Not yet recruiting|March 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|18 Years|No|||January 2013|January 8, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01763658||73380|
NCT01764269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK8100|Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014|Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014||Columbia University|No|Completed|January 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|656|||Both|24 Months|59 Months|No|||June 2014|June 22, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764269||73333|
NCT01764802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10077|Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer|Psychosexual Intervention for Gynecologic and Breast Cancer Patients||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|October 2010|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|21 Years|80 Years|No|||August 2015|August 7, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01764802||73292|
NCT01765361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-OCR|Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)|Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)||University Hospital, Basel, Switzerland|No|Active, not recruiting|September 2012|December 2016|Anticipated|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|The study population will be a sub-sample of the above mentioned multi-center, randomized,        double-blind, phase III trials ("Oratorio", "Opera I" and "Opera II") and will comprise        approximately 100 PPMS and 100 RRMS patients. Treatment groups will only be disclosed        after completion of the phase III trials.|January 2016|January 19, 2016|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01765361||73249|
NCT01768442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047152|MRI for Eval Tumor & Node Response & Normal Tissue Function to Concurrent Chemo & Radiation Therapy in H&N Cancer (GCC1043)|GCC1043: Magnetic Resonance Imaging for Evaluating Tumor and Node Response and Normal Tissue Function to Concurrent Chemotherapy and Radiation Therapy in Head and Neck Cancer||University of Maryland|Yes|Recruiting|September 2011|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|We will recruit patients with locally advanced head and neck cancer into the study. The        purpose of this study is to assess whether advanced MR imaging techniques can be used to        determine tumor and node response (i) four weeks following initiation of concurrent        chemoRT and (ii) after completion of chemoRT in head and neck cancer, and to assess        whether advanced MR imaging techniques can be used to predict early at-risk organ function        (salivary gland and mucosal injury) as measured by salivary flow and oral mucositis to        chemoradiation therapy (i) four weeks following initiation of concurrent chemoRT and (ii)        after completion of chemoRT in head and neck cancer.|February 2016|February 1, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768442||73013|
NCT01768715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETH-HA|Liver Transplantation in Alcoholic Hepatitis|Applicability of Liver Transplantation in Alcoholic Hepatitis|SETH-HA|Sociedad Española de Trasplante Hepático|No|Suspended|January 2013|December 2017|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with alcoholic hepatitis participating in this trial are going to be selected        from patients admitted to the hospital (from the emergency department or referred from        other hospital)|June 2014|June 2, 2014|December 29, 2012||No|Low rate of recruitment (only one patient up to May 2014)|No||https://clinicaltrials.gov/show/NCT01768715||72992|
NCT01768455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL013|Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Gemigliptin and Glimepiride in Healthy Male Subjects||LG Life Sciences||Completed|February 2013|||April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01768455||73012|
NCT01768728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRRSH20121225-1|Laparoscopic Versus Open Left Hemihepatectomy for Liver Benign Lesions|A Randomized Controlled Trial of Acute Surgical Trauma and Stress Response of Laparoscopic Versus Open Left Hemihepatectomy for Liver Benign Lesions||Sir Run Run Shaw Hospital||Completed|December 2012|||September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768728||72991|
NCT01769040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RifaxNK150612|Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis|Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study||Copenhagen University Hospital, Hvidovre|Yes|Completed|November 2012|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|54|||Both|18 Years|80 Years|No|||January 2016|January 18, 2016|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01769040||72967|
NCT01769326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2008-6432|Influence of Timing on Motor Learning|Influence of Timing on Motor Learning||University of California, Irvine|No|Active, not recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01769326||72945|
NCT01769560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00069032|MeFirst: A Tailored Intervention to HPV Vaccine Decision Making|MeFirst: A Tailored Intervention to HPV Vaccine Decision Making||University of Michigan|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|661|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769560||72927|
NCT01769573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1036|A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers|A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers|UWI-02|University of Wisconsin, Madison|Yes|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769573||72926|
NCT01769859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fan General|Systematic Genetic Analysis of Phenomenology and Treatment Response in Mood Disorders|Systematic Genetic Analysis of Phenomenology and Treatment Response in Mood Disorders||University Hospital Case Medical Center|Yes|Enrolling by invitation|January 2013|||January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|whole blood|Both|7 Years|N/A|No|Non-Probability Sample|Mood Disorders Program of University Hospitals Case Medical Center|March 2015|March 9, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01769859|10 Years|72904|
NCT01766050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-151|Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers|An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as "Inje Cocktail" in Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|January 10, 2013|No|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01766050||73196|
NCT01766063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16352|Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon|BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients|BetaSleep|Bayer|No|Active, not recruiting|December 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|138|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with relapsing remitting multiple sclerosis        (RRMS) or patients with a clinically isolated syndrome (CIS) with an Expanded Disability        Status Scale (EDSS) score ≤5 who tolerate Betaferon according to the investigator's        evaluation, but have not received Betaferon longer than six months. Participants will be        recruited from private neurological offices and neurology departments throughout Germany.        In this non-interventional observational study, the decision on the duration and dosage of        treatment is solely at the discretion of the attending physician.        The medication is prescribed at regular visits to the investigator's office. Commercially        available product will be used to treat the patients.|March 2016|March 15, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01766063||73195|
NCT01766310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Folic-01|Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children|Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children: a Randomized Double Blinded Placebo Controlled Trial||Queen Sirikit National Institute of Child Health|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|9 Years|18 Years|No|||November 2015|November 16, 2015|January 7, 2013||No||No|August 10, 2014|https://clinicaltrials.gov/show/NCT01766310||73176|
NCT01763112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Training With Whole Body Vibration Device in Patients With PAH|Influence of Training With Whole Body Vibration Device (Galileo) on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH). (GALILEO PAH)|GALILEO-PAH|Klinikum der Universität Köln|No|Active, not recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||March 2015|March 30, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763112||73422|
NCT01763359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55695|Hip Strength and Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation|Decreased Hip Adductor Strength and Obturator Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation: Is Retraction to Blame?||University of Utah|No|Enrolling by invitation|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pelvic fracture patients and patients treated for acetabular fractures with the modified        Stoppa approach will be asked to consent to a voluntary study investigating physical        function at their 2 week follow-up appointment.|January 2016|January 4, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763359||73403|
NCT01763671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1103|Paclitaxel-bevacizumab in Advanced Lung Cancer|Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer|Ultimate|Intergroupe Francophone de Cancerologie Thoracique|Yes|Active, not recruiting|May 2013|December 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01763671||73379|
NCT01763957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paula/PFMT-HMO-CTIL|Paula Method Compared to Pelvic Floor Muscle Training (PFMT), for Urinary Stress Incontinence|The Effectiveness of Circular Muscle Exercise (the Paula Method) as Compared to Pelvic Floor Muscle Training (PFMT), for Urinary Stress Incontinence (SUI) in Menopausal Women: A Randomized Controlled Trial||Hadassah Medical Organization|No|Withdrawn|March 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|40 Years|80 Years|No|||December 2012|October 10, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01763957||73357|
NCT01764282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX10001007-001|Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission|A Cluster-randomized Controlled Trial of Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission||National Center for AIDS/STD Control and Prevention, China CDC|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8000|||Both|18 Years|59 Years|No|||May 2015|May 5, 2015|December 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01764282||73332|
NCT01764529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVMC 6201|Modifiers of Disease Severity in Cerebral Cavernous Malformations|Modifiers of Disease Severity in Cerebral Cavernous Malformations||University of New Mexico|No|Recruiting|April 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|We collect and store saliva as well as whole blood for DNA and RNA extraction.|Both|6 Years|N/A|No|Non-Probability Sample|The study population includes individuals who carry the cerebral cavernous        malformation-common Hispanic mutation (CCM1-CHM). We are enrolling individuals who are        symptomatic as well as those individuals with no symptoms. Although this disease is common        in New Mexico, we are interested in enrolling individuals worldwide if they have CCM1-CHM.|January 2013|January 7, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764529|4 Years|73313|
NCT01765101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-102-DR-32|Therapeutic Effects of Insoles on Patients With Knee Osteoarthritis|Therapeutic Effects of Ready-made Full-length Lateral Wedged Insoles and Customized Full-length Lateral Wedged Insoles on Patients With Knee Osteoarthritis : a Double Blind, Randomized Controlled Study||Taipei Medical University|No|Not yet recruiting|January 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||January 2013|January 9, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01765101||73269|
NCT01765387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGEUGR01|Spa Effects After Exercise|SPA THERAPY AS RECOVERY PROCEDURE AFTER EXERCISE: A PRAGMATIC CONTROLLED TRIAL||University of Malaga|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|March 24, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765387||73247|
NCT01761305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-AA-2012-12-19|Trial on Three Treatments for Scoliosis|CONTRAIS: CONservative TReatment for Adolescent Idiopathic Scoliosis. A Randomised Controlled Trial|CONTRAIS|Karolinska Institutet|Yes|Recruiting|January 2013|December 2021|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|9 Years|17 Years|No|||February 2016|February 25, 2016|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01761305||73561|
NCT01767896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7374-CL-0103|Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine|Phase III Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects||Astellas Pharma Inc|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1020|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 8, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767896||73055|
NCT01767909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-046-INI|The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)|Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)||University of Southern California|Yes|Recruiting|September 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|55 Years|85 Years|No|||March 2016|March 4, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767909||73054|
NCT01768156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meta-Four|Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer|Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring|Meta-Four|Institut du Cancer de Montpellier - Val d'Aurelle|No|Recruiting|January 2011|January 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||March 2015|March 2, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768156||73035|
NCT01768169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|omega-3 fatty acids|Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal|Phase 2 Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal Replacements||Taipei Medical University Hospital|Yes|Recruiting|April 2012|July 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|65 Years|No|Probability Sample|community sample, residents of Taiwan|December 2012|January 11, 2013|December 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768169||73034|
NCT01768754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goldstein_Walk_COPD|Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease|Repeatability and Utility of the Usual and Fast Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease (COPD)||West Park Healthcare Centre|No|Completed|July 2012|March 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stable moderate-severe COPD will be recruited from those under the care of a        respirologist at West Park Health Care Centre|March 2013|March 8, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768754||72989|
NCT01768767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209010758|Trial of Ketamine and Lithium Therapy in Bipolar Depression|Novel Approach of Combined Lithium-Ketamine Therapy in Bipolar Depression: To Preserve Efficacy and Minimize Adverse Effects||Yale University|No|Withdrawn|January 2013|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||November 2013|November 27, 2013|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768767||72988|
NCT01769053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK235082012|Variable Pressure Support Trial|International Multicenter Randomized Controlled Open Trial on Variable vs. Non-Variable Pressure Support for Weaning From Mechanical Ventilation|ViPS|Technische Universität Dresden|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01769053||72966|
NCT01769885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 220412|Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer|A Pilot Clinical Trial of Neoadjuvant Tivozanib in Localized Renal Cell Carcinoma||Roswell Park Cancer Institute|Yes|Withdrawn|March 2013|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769885||72902|
NCT01769586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003|Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy|Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy||VA Connecticut Healthcare System|No|Recruiting|February 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769586||72925|
NCT01769599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0108-12-ZIV|Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections|||Ziv Hospital||Recruiting|January 2013|April 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|30 Years|80 Years|No|Non-Probability Sample|Diabetic people that suffer from macular edema|January 2013|January 14, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769599||72924|
NCT01769872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC-MSCs-SPI|Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury|Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury||Biostar||Recruiting|January 2013|April 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|70 Years|No|||March 2014|March 24, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769872||72903|
NCT01758328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-175|Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma|A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|21 Years|72 Years|No|||March 2016|March 11, 2016|December 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758328||73790|
NCT01769846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07201712.8.0000.5346|The Impact of Early Mobilization Protocol in Patients in the ICU|The Impact of Early Mobilization Protocol in Patients in the ICU of the University Hospital of Santa Maria.||Universidade Federal de Santa Maria|No|Recruiting|March 2013|December 2015|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01769846||72905|
NCT01766323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ModMorphine|Palliative Morphine With or Without Concurrent Modafinil|Prospective Randomized Study Evaluating the Effects of Modafinil in Patients Receiving Oral Morphine for Pain Palliation||Dr. Rajendra Prasad Government Medical College|Yes|Recruiting|September 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2013|January 10, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766323||73175|
NCT01766336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-AG251|A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease|A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease||Transition Therapeutics Ireland Limited|No|Terminated|January 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Both|50 Years|N/A|No|||September 2015|September 9, 2015|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766336||73174|
NCT01763372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58424|Functional Implications of Arthroscopic Iliopsoas Release|Functional Implications of Arthroscopic Iliopsoas Release||University of Utah|No|Active, not recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing arthroscopic surgery by Dr. Aoki, divided into two groups:        Those undergoing arthroscopic psoas release, and those undergoing arthroscopic surgery        without psoas release,|January 2016|January 13, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763372||73402|
NCT01763684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GK7|Oxford Signature vs. Conventional Global Study|A Global Comparison of Signature Guides and Conventional Instrumentation in the Oxford Partial Knee||Biomet, Inc.|No|Recruiting|September 2012|June 2024|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|21 Years|N/A|No|||September 2015|September 25, 2015|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763684||73378|
NCT01763697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046407|Taste Acuity and Caloric Intake After Acute Morphine Administration|Taste Acuity and Caloric Intake After Acute Morphine Administration||Johns Hopkins University|No|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|January 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01763697||73377|
NCT01763970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1367|Stereotactic Radiation Therapy for Pediatric Sarcomas|A Phase II Study of Hyperfractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2013|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|40 Years|No|||May 2015|May 27, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763970||73356|
NCT01764295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1276003|Clinical Study for Patients With Hypertension Associated With Dyslipidemia|Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia||Daewoong Pharmaceutical Co. LTD.|No|Completed|September 2012|July 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|20 Years|80 Years|No|||January 2013|August 22, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764295||73331|
NCT01764815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 072-12|Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation (DBS) Leads|Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation Leads for the Treatment of Movement Disorders||Aleva Neurotherapeutics SA|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|80 Years|No|||January 2014|March 20, 2014|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01764815||73291|
NCT01765114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEV-PEG-02|A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes|A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes||Devirex AG|No|Terminated|February 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||August 2014|August 4, 2014|December 14, 2012||No|insufficient patient recruitment|No||https://clinicaltrials.gov/show/NCT01765114||73268|
NCT01765374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/081/HP|Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis|Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis|SEWORRA|University Hospital, Rouen|No|Completed|February 2011|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01765374||73248|
NCT01761318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|379|Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients|Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus|MAGNA VICTORIA|Leiden University Medical Center|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|69 Years|No|||October 2015|October 9, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761318||73560|
NCT01761331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-HSC-KL2013|Acupuncture in Infantile Colic - a Three Armed Randomized Multi Center Trial (ACU-COL)|Acupuncture in Infantile Colic - a Three Armed Randomized Multi Center Trial Comparing Acupuncture in a Standardized Point, Acupuncture in Individually Chosen Points and no Acupuncture|ACU-COL|Lund University|No|Recruiting|January 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|192|||Both|N/A|8 Weeks|No|||April 2015|April 1, 2015|December 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01761331||73559|
NCT01768182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08035|Folinic Acid and Vascular Reactivity in HIV|Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-infected Individuals: a Randomized Trial||Hospital de Clinicas de Porto Alegre|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01768182||73033|
NCT01768468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAYLA-P4|To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients|Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase IV Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients||PMG Pharm Co., Ltd|Yes|Completed|October 2012|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|40 Years|80 Years|No|||October 2013|October 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768468||73011|
NCT01768481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR|Intima Media Thickness Regression in Dyslipidemic Teenagers|Intervention précoce Sur Les Indices d'athérogénèse Des Adolescents à Risque||Université de Montréal|No|Completed|January 2004|June 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768481||73010|
NCT01768780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0692|Efficacy of Peripheral Nerve Stimulator in Assessing Sensory Nerve Block Level of Spinal Anesthesia|||Yonsei University|No|Active, not recruiting|December 2012|November 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768780||72987|
NCT01769612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-14|Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia|Evaluation of a Rapid Diagnostic Device, CL Detect™, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia|CL Detect™|U.S. Army Medical Research and Materiel Command|No|Completed|January 2013|April 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|September 2014|September 5, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769612||72923|
NCT01757704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKML-003|Factors Responsible for the Effectiveness of the Lund De-airing Technique|Factors Responsible for the Effectiveness of the Lund Technique for De-airing Following Open Left Heart Surgery.||Lund University|No|Completed|September 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|90 Years|No|||January 2014|January 11, 2014|September 22, 2012||No||No|October 8, 2013|https://clinicaltrials.gov/show/NCT01757704||73838|This study is a small single center study. Though randomized and controlled, the surgeon and anesthesiologist were not blinded to which arm a participant belonged to during the course of surgery.
NCT01757717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-260|Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis|A Pilot Study of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01757717||73837|
NCT01765829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONSTOP|Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis|Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis.|NONSTOP|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|55 Years|No|||December 2014|December 4, 2014|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01765829||73213|
NCT01758341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1837/2012|Radiofrequency Ablation for Malignant Biliary Obstruction|Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction||Medical University of Vienna|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01758341||73789|
NCT01758367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN301-XYK-002|Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation|||Chinese PLA General Hospital||Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758367||73787|
NCT01765803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1208|Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells|A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells||New Mexico Cancer Care Alliance|Yes|Terminated|June 2013|December 2013|Actual|November 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|January 8, 2013|Yes|Yes|Primary objective not met after planned interim analysis|No|June 19, 2015|https://clinicaltrials.gov/show/NCT01765803||73215|
NCT01766089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/61|Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery|Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery||Mansoura University|Yes|Recruiting|January 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Female|18 Years|40 Years|No|||February 2016|February 5, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01766089||73193|
NCT01758822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/2011/PED/019|Role of Endotracheal Suction on the Occurrence of Meconium Aspiration Syndrome in Non-vigorous Meconium Stained Babies|Role of Endotracheal Suction on the Occurrence of Meconium Aspiration Syndrome in Non-vigorous Meconium Stained Neonates- A Randomized Controlled Trial|ETMAS|Lady Hardinge Medical College|Yes|Completed|May 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|175|||Both|N/A|N/A|No|||July 2014|July 9, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01758822||73752|
NCT01763385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-75-634|Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases|Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)|TRACTS|Wu Jieping Medical Foundation|Yes|Recruiting|November 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|85 Years|No|||December 2014|December 22, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763385||73401|
NCT01763398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0432|Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study|||Yonsei University|No|Recruiting|September 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by        CHOP-like regimen and primary G-CSF prophylactic therapy|February 2014|February 17, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763398||73400|
NCT01763710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCOSUR-2012-01|Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer|Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer.|neurabrax|Asociación Oncosur|No|Recruiting|December 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|60|||Female|18 Years|N/A|No|||May 2015|May 4, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01763710||73376|
NCT01763723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-025|Pigment-Tan-Safety Study of a Light-based Home Device for Hair Removal in Adult Subjects|||Bispebjerg Hospital||Completed|April 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01763723||73375|
NCT01763983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EG1290|Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis|A Randomized Controlled Trial Testing the Additive Benefits of CBT and Exercise For Psychological Stress and Cognitive Dysfunction in MS||Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|173|||Both|18 Years|50 Years|No|||November 2014|November 17, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01763983||73355|
NCT01763996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR-FEB-002|The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina|The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Subjects With Chronic Stable Angina: A Phase 4 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study||Takeda|No|Active, not recruiting|January 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||January 2015|January 7, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763996||73354|
NCT01764308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3FA|Effects of Omega-3 Fatty Acid Supplementation in Acne Patients|Omega-3 Fatty Acid Supplementation in Acne Patients|Omega-3|University of California, Los Angeles|No|Recruiting|January 2013|January 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764308||73330|
NCT01764542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLS-249941|Development of Dysplasia in the Pelvic Pouch in Patients With Ulcerative Colitis (UC) and Risk Factors|Critical Assessment of Routine Surveillance of Asymptomatic Patients With Ulcerative Colitis With Ileal Pouch-anal Anastomosis and Risk Factors for Dysplasia - is There a Rationale?||Sahlgrenska University Hospital, Sweden|No|Active, not recruiting|February 2010|November 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|56|||Both|N/A|N/A|No|||February 2013|February 19, 2013|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01764542||73312|
NCT01764828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14747|BAY86-9766 Plus Gemcitabine Phase I Study in Asian|A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors||Bayer|No|Completed|February 2013|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|January 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01764828||73290|
NCT01765400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574-11-FB|Platelet Inhibition in Patients With Systolic Heart Failure|Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure||University of Nebraska|Yes|Recruiting|February 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|75 Years|No|||January 2014|January 21, 2014|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765400||73246|
NCT01765413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC305A|Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines|A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Subcutaneous Immunisation With Either "Varilrix" Varicella-zoster Vaccine, "Stamaril" Yellow Fever Vaccine or Saline Placebo in Healthy Adults With Evidence of Pre-existing Immunity to Varicella-zoster and no Existing Immunity to Yellow Fever.||University of Surrey|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|February 12, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01765413||73245|
NCT01761578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTDIVA|ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent|First in Man Safety Evaluation of the ART18Z Bioresorbable Stent for the Treatment of Single de Novo Lesion of a Native Coronary Artery.||Arterial Remodeling Technologies|Yes|Completed|June 2012|||June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||January 2015|January 13, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761578||73540|
NCT01768195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-2012111304|Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy|Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy||Peking University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768195||73032|
NCT01768208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD016|Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients|||Shanghai Jiao Tong University School of Medicine||Recruiting|October 2012|||May 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1708|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01768208||73031|
NCT01768494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAGE-1|Optimizing Triage and Hospitalisation In Adult General Medical Emergency Patients: the TRIAGE Study|Optimizing Triage and Hospitalisation In Adult General Medical Emergency Patients: the TRIAGE Study|TRIAGE|University Hospital, Basel, Switzerland|No|Completed|March 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7000|Samples Without DNA|Left over blood samples of routinely collect blood tubes on admission will be asserved and      aliquoted for later batch analysis of blood biomarkers (bio-bank)|Both|18 Years|N/A|No|Non-Probability Sample|All consecutive medical patients seeking ED care will be included. There will be no        exclusions except for non-adult and non-medical patients. We expect to include 5000 - 8000        patients over one year of recruitment.|December 2014|December 11, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768494||73009|
NCT01769339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015721|An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis|Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis||Janssen Pharmaceutica|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Female|18 Years|60 Years|No|||February 2013|February 18, 2013|January 14, 2013|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01769339||72944|Data was not collected for pruritus symptom assessment by visual analog scale outcome measure as only few participants had pruritus after 1-hour of study drug application.
NCT01757353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00AA017877|Detroit Area Study of College Student Lifestyles|||Wayne State University||Completed|December 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|181|||Both|18 Years|23 Years|No|||February 2015|February 26, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757353||73864|
NCT01758029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBD01|Testosterone Undecanoate and Quality of Life of Men and Spouses|Satisfaction and Quality of Life of Men and Spouses of Hypogonadal Men Treated With Injectable Testosterone Undecanoate||Meir Medical Center|No|Not yet recruiting|January 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Male|40 Years|80 Years|No|Non-Probability Sample|community based population of hypogonadal men, who are eligible and choose the treatment        with testosterone undecanoate|December 2012|December 23, 2012|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01758029||73813|
NCT01758016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2304-2000-RMB CTIL|Haptoglobin and Diabetes Complications in Pregnancy|Haptoglobin and Diabetes Complications in Pregnancy||Rambam Health Care Campus|No|Recruiting|November 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Serum|Female|N/A|N/A|No|Probability Sample|1. Pregastetional diabetic patients currently pregnant          2. Gestational diabetes patients currently pregnant|October 2015|October 6, 2015|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01758016||73814|
NCT01758354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700818|Newborn Screening Assay of Pompe's Disease|Newborn Screening Assay of Pompe's Disease||National Taiwan University Hospital|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|236536|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|December 26, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT01758354||73788|
NCT01758380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2411|Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan|A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan|STEADFAST|Novartis|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|557|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758380||73786|
NCT01758861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0355|Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery|||Yonsei University|No|Completed|July 2011|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|98|||Both|20 Years|N/A|No|||December 2012|December 31, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01758861||73749|
NCT01765816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gen-100-sub1|Generation 100: Blood Volume and Cardiac Function in Healthy Aging|Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study||Norwegian University of Science and Technology|Yes|Completed|August 2012|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|25|||Both|70 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765816||73214|
NCT01758835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYSrctAnkle5|PRCT-study of Different Non-operative Treatment Protocols of ER-stress Negative Weber-B Unimalleolar Ankle Fractures.|Evaluation of Different Non-operative Treatment Protocols of ER-stress Negative Weber-B Unimalleolar Ankle Fractures. A Prospective Randomized Multicenter Trial.||University of Oulu|Yes|Active, not recruiting|October 2012|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|246|||Both|16 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01758835||73751|
NCT01758848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812091R|Physical Therapy for Overactive Bladder|Physical Therapy for Overactive Bladder||National Taiwan University Hospital|Yes|Terminated|September 2010|October 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women with overactive bladder|November 2012|December 27, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01758848||73750|
NCT01763736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-002287|Medical Use of Song In Critical Care (MUSIC)|Medical Use of Song In Critical Care (MUSIC)|MUSIC|Brigham and Women's Hospital|No|Terminated|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 3, 2013||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01763736||73374|
NCT01763749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO_1201|Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin|Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial)||Seoul St. Mary's Hospital|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|85 Years|No|||February 2015|February 28, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01763749||73373|
NCT01764009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA2011/15/02|Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma|Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open-label Phase I/II Clinical Trial - The AIMM Study (AMEP In Metastatic Melanoma)|AIMM|Onxeo|Yes|Withdrawn|June 2012|March 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|January 7, 2013||No|Study stopped due to low enrolment rate.|No||https://clinicaltrials.gov/show/NCT01764009||73353|
NCT01764022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-022-02|A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients|International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin® (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients||Biocad|No|Active, not recruiting|October 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|206|||Female|18 Years|75 Years|No|||February 2015|February 2, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764022||73352|
NCT01764321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0097|Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors|A Multi-center, Noninterventional Study With Certolizumab Pegol in Comparison With Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis|NexT|UCB Pharma|No|Recruiting|December 2012|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1360|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with diagnosed Rheumatoid Arthritis (RA)|March 2016|March 8, 2016|January 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01764321||73329|
NCT01764555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAP study|Pharmacokinetics of Acetaminophen in Morbidly Obese Patients|Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Morbidly Obese Patients|APAP|St. Antonius Hospital||Recruiting|December 2012|June 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01764555||73311|
NCT01764841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15625|Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)|Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.|RESPIRE 1|Bayer|Yes|Completed|May 2013|March 2016|Actual|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|414|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764841||73289|
NCT01765127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asenapine ModPEM|An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)|An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England||Drug Safety Research Unit, Southampton, UK|No|Recruiting|January 2012|January 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Patients prescribed asenapine for any indication by NHS GPs in England.|January 2016|January 25, 2016|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01765127||73267|
NCT01765426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0049|Phase 1b Study Investigating Safety & Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector|Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet® Injector in Healthy Adults||Takeda|Yes|Completed|March 2013|July 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765426||73244|
NCT01761838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027069|The Underlying Mechanism of Spinal Manipulative Therapy and the Effect of Pain on Physical Outcome Measures|The Underlying Mechanism of Spinal Manipulative Therapy and the Effect of Pain on Physical Outcome Measures||University of Alberta|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 9, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761838||73520|
NCT01768793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110073|Weight Management in Obese Pregnant Underserved African American Women|Weight Management in Obese Pregnant Underserved African American Women|LIFE-Moms|Washington University School of Medicine|Yes|Active, not recruiting|October 2012|November 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Female|18 Years|45 Years|No|||March 2016|March 16, 2016|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768793||72986|
NCT01769066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gefitinib-2009-cjh|Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC|Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research||Fudan University||Completed|December 2009|||February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769066||72965|
NCT01757106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR052012|Xenon in Off-pump Coronary Artery Bypass Graft Surgery|The Safety and Feasibility of Administering Xenon to Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery: a Pilot Study||Universitaire Ziekenhuizen Leuven|No|Completed|December 2012|January 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01757106||73883|
NCT01757730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0027|Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues|Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues|MRE|Ohio State University|Yes|Recruiting|March 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. You are 18 and over and affected by a certain disease condition such as             Heart/Kidney/Lung/liver/spleen or aortic aneurysms or any other kind of diseases             where stiffness of the soft tissue is thought to change.          2. You are 18 and over and a healthy volunteer and not affected by any of the conditions             mentioned in #1 above.|October 2015|October 1, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757730||73836|
NCT01757743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063.09|Fluid Balance During Closure of Atrial Septal Defect|Protein Distribution and Colloid Osmotic Pressure in Children With Volume and Pressure Loading Due to Congenital Heart Defects||Oslo University Hospital|No|Recruiting|February 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Interstitial fluid Serum|Both|6 Months|10 Years|No|Probability Sample|Children with Atrial Septal Defect scheduled for interventional closure with device or        surgical repair|April 2015|April 24, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757743||73835|
NCT01758627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0750|The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease|||Yonsei University|No|Recruiting|December 2012|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|20 Years|N/A|No|||February 2014|February 17, 2014|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758627||73767|
NCT01758393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-GC-IgG4RD|Glucocorticoids in Patients With IgG4-RD|A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease||Peking Union Medical College Hospital|Yes|Recruiting|December 2012|April 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2012|December 24, 2012|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758393||73785|
NCT01758614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XW125-S001|The Carotid and Middle Cerebral Artery Occlusion Surgery Study|The Carotid and Middle Cerebral Artery Occlusion Surgery Study|CMOSS|Xuanwu Hospital, Beijing|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|65 Years|No|||December 2012|December 31, 2012|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758614||73768|
NCT01759368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUSHAH|Heart at Home- a Self-care Study|Heart at Home- Remote Patient Monitoring in the Care of Heart Failure Patients||VTT Technical Research Centre of Finland|No|Completed|October 2010|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|90 Years|No|||September 2014|September 15, 2014|December 20, 2012|Yes|Yes||No|August 7, 2014|https://clinicaltrials.gov/show/NCT01759368||73710|
NCT01759381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040054|Incisional Negative Pressure Wound Therapy|The Efficacy of Negative Pressure Wound Therapy (NPWT) in the Postoperative Management of Complex Spinal Surgeries: A Randomized Outcomes Study.||Duke University|No|Terminated|December 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|December 7, 2012|Yes|Yes|PI leaving institution|No|June 25, 2015|https://clinicaltrials.gov/show/NCT01759381||73709|
NCT01758588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202012178|Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis|Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis||Weill Medical College of Cornell University|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|December 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758588||73770|
NCT01759355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1221|Hybrid PET/MR in the Therapy of Cervical Cancer|Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|October 2012|December 2017|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|||Female|18 Years|N/A|No|Non-Probability Sample|UNC Hospitals|October 2015|October 13, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01759355||73711|
NCT01763762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYSNXD-CC-ZDYJ010|A Comparison of Electrical Pudendal Nerve Stimulation and Pelvic Floor Muscle Training for Female Stress Incontinence|A Comparison of the Efficacy of Electrical Pudendal Nerve Stimulation to Pelvic Floor Muscle Training With Transvaginal Electrical Stimulation in Treating Female Stress Incontinence||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Completed|January 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|25 Years|85 Years|No|||September 2013|November 19, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01763762||73372|
NCT01764035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002550|Mindfulness Therapy on Disrupted Sleep in Bipolar Disorder|The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder||Massachusetts General Hospital|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764035||73351|
NCT01764334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRS-11-CA56|Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes|A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI.|FAMOUS NSTEMI|NHS National Waiting Times Centre Board|Yes|Active, not recruiting|October 2011|June 2017|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|350|||Both|18 Years|N/A|No|||July 2013|September 23, 2014|December 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764334||73328|
NCT01764568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01968|Contrasting Group Therapy Methods for Psychosis|Functional Brain Networks Underlying Non-pharmaceutical Interventions for Psychosis.|MCT|University of British Columbia|No|Recruiting|January 2013|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|19 Years|60 Years|No|||November 2015|November 30, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01764568||73310|
NCT01764854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00001|Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis||Ardelyx|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|80 Years|No|||February 2014|February 25, 2014|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764854||73288|
NCT01765140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007811|Treatment Use of 3,4-Diaminopyridine|Treatment Use of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia Gravis||Duke University||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2016|January 8, 2016|January 6, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01765140||73266|
NCT01761357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0387|Burden Comorbidities and Transcatheter Aortic Valve Implantation|Impact of Burden of Comorbidities on Health Related Quality of Life Six Months After Transcatheter Aortic Valve Implantation in Patients Aged 75 Years and Older.|TAVIQUAL|Nantes University Hospital|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|150|||Both|75 Years|N/A|No|||September 2015|September 22, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761357||73557|
NCT01761370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/05/338|Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)|Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)||National University Hospital, Singapore|No|Completed|November 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|21 Years|65 Years|No|||October 2011|January 3, 2013|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01761370||73556|
NCT01761851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS - APQ-04415-10|Resting Energy Expenditure in Patients on the Waiting List for Liver Transplantation|Metabolic and Nutritional Assessment in Patients on the Waiting List for Liver Transplantation||Federal University of Minas Gerais|Yes|Completed|March 2010|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|80 Years|No|Probability Sample|Patients on the waiting list for liver transplant|January 2013|January 4, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761851||73519|
NCT01761864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARMACA007|The Effect of Industry-independent Visits to Primary Care Physicians on Medication Prescribing for Pain Relief in Chronic Joint Pain.|The Effect of Academic Detailing on Prescribing of Analgesics in Primary Care: a Randomised Controlled Trial||Universiteit Antwerpen|Yes|Active, not recruiting|February 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|4000|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 14, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761864||73518|
NCT01761877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1 CA1615301A1|NSAID Effects on Clinical and Imaging Breast Biomarkers|NSAID Effects on Clinical and Imaging Breast Biomarkers||Stony Brook University|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|175|||Female|N/A|75 Years|No|||July 2015|July 14, 2015|December 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761877||73517|
NCT01761006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021832|Evaluation of FeNO During and Following Acute COPD Exacerbation|A Single-Center Exploratory Study to Evaluate FeNO Using the NIOX MINO® Device in COPD Patients Aged ≥40 Years During and Following Recovery From an Acute COPD Exacerbation||Wake Forest School of Medicine|No|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected based on the fact that they are currently experiencing an acute        COPD exacerbation. The study will be conducted at a single-center COPD Clinic at Wake        Forest University Baptist Medical Center, Winston-Salem NC, USA. It is anticipated that        approximately 35 Patients age 40 years and above will participate in the study.|March 2013|March 4, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01761006||73584|
NCT01761227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFDA2005L01916|Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia|The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial.||Dongzhimen Hospital, Beijing|Yes|Active, not recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|45 Years|80 Years|No|||June 2015|June 2, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761227||73567|
NCT01757366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTH102|Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer|Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer||Hebei Tumor Hospital|Yes|Recruiting|December 2012|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2012|March 30, 2014|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757366||73863|
NCT01757379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML5768|Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans|Evaluation of the Bioavailability and Production of Short Chain Fatty Acids in the Colon. A Stable Isotope Study in Healthy Humans.||Katholieke Universiteit Leuven|No|Completed|April 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757379||73862|
NCT01758406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Heart-003|Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart Failure|Therapeutic Outcome of Intracoronary Transplantation of Autologous Cardiac Stem Cells in Patients With Ischemic Heart Failure: Randomized Double Blind Clinical Trial||Royan Institute|Yes|Recruiting|December 2013|December 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|14 Years|75 Years|No|||November 2015|December 3, 2015|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758406||73784|
NCT01759121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-PASCAL-PRP|Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR|Randomized, Parallel Controlled, Clinical-trial on 532nm Laser Partially Subthreshold Panretinal Photocoagulation With PASCAL Endpoint Management Function for Severe Non-proliferative Diabetic Retinopathy(NPDR)|S-PRP|Sun Yat-sen University|Yes|Recruiting|December 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|45 Years|80 Years|No|||October 2015|October 23, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01759121||73729|
NCT01759407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00820|Femoral Nerve Block for Femur Fracture Repair in Pediatrics|A Prospective, Double-blinded, Randomized Comparison of Ultrasound-guided Femoral Nerve Block With Lateral Femoral Cutaneous Nerve Block Versus Standard Anesthetic Management for Traumatic Femur Fracture Repair in the Pediatric Population||Nationwide Children's Hospital|No|Enrolling by invitation|May 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|18 Years|No|||March 2016|March 6, 2016|December 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759407||73707|
NCT01759706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERAS_PANCREAS 01|Safety and Feasibility Study of Enhanced Recovery in Pancreaticoduodenectomy|Safety and Feasibility Study of an Enhanced Recovery After Surgery Protocol in Patients Undergoing Elective Pancreaticoduodenectomy.||Università Vita-Salute San Raffaele|Yes|Completed|October 2010|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|85 Years|No|||December 2014|December 3, 2014|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01759706||73684|
NCT01758601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISH-CARE|White Fish for Cardiovascular Risk Factors in Patients With Metabolic Syndrome: the WISH-CARE Study|Estudio de intervención Nutricional Para la evaluación de Los Beneficios Sobre la Salud Derivados Del Consumo de Merluza en población Con Alto Riesgo Cardiovascular.||Hospital Universitario Ramon y Cajal|No|Completed|January 2010|November 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|65 Years|No|||December 2012|December 31, 2012|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758601||73769|
NCT01760265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"|Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients|DARK|Hospices Civils de Lyon|No|Recruiting|January 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Lipid, apo E genotype when is necessary to complete the phenotype|Both|40 Years|N/A|No|Non-Probability Sample|Dysbetalipoproteinemia patients with APOE2/E2 or heterozygous mutation (negative        dominance) and hypercholesterolemia, ratio CT VLDL/Tg VLDL >0.40|January 2013|January 25, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760265||73641|
NCT01760538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1913|Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training|Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training||National Taiwan University Hospital|No|Completed|August 2001|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|70 Years|No|||November 2012|January 3, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760538||73620|
NCT01764048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120-12-EMC|To Compare the Efficacy and Patient's Satisfaction From Pain Management of Women After Cesarean Section by Pain Relievers' Administration in Fix Protocol Compared to Protocol Following Demand|||HaEmek Medical Center, Israel|No|Completed|November 2012|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764048||73350|
NCT01764061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100067|Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)|Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)||Haemonetics Corporation|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy blood donors|October 2013|October 9, 2013|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764061||73349|
NCT01764347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-10-6|Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer|Accuracy of Targeted Biopsies Using MRI-TRUS Fusion Guidance: Pilot Study on Ex Vivo Radical Prostatectomy Specimens||University of Southern California|Yes|Completed|November 2010|September 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Male|N/A|N/A|No|||January 2014|January 27, 2014|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764347||73327|
NCT01764581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BolognaCylex01|Randomized Controlled Trial of ImmuKnow in Liver Transplantation|Randomized Controlled Interventional Trial of Immunosuppression Modification Based on the Cylex™ ImmuKnow® Assay in Adult Liver Transplant Recipients||University of Bologna|Yes|Completed|July 2008|March 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|70 Years|No|||October 2010|January 7, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764581||73309|
NCT01764594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0014|Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus|A Multicenter, Investigator- and Subject-Blind, Randomized, Placebo-Controlled, Parallel-Group, Repeat-Dose Study to Evaluate the Effect of CDP7657 in Subjects With Active Systemic Lupus Erythematosus||UCB Pharma|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|24|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764594||73308|
NCT01761344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1856|Intraoperative Analysis of Cortisol During Adrenal Vein Sampling|Intraoperative Analysis of Cortisol During Adrenal Vein Catheterization and Sampling in Patients With Primary Hyperaldosteronism.||Haukeland University Hospital|No|Completed|January 2013|August 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761344||73558|
NCT01761604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advocate-IRB-5241|A Nasal Applicator for the Treatment of Trigeminal Neuralgia|The Use of Tx360™ Nasal Applicator for Sphenopalatine Ganglion Block in the Treatment of Trigeminal Neuralgia||Chicago Anesthesia Pain Specialists|No|Recruiting|December 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761604||73538|
NCT01761890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML1113|Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib|Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.|CML1113|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|January 2014|September 2020|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|133|||Both|18 Years|N/A|No|Non-Probability Sample|This is a multicentre, observational, prospective study of newly diagnosed chronic phase        CML patients treated frontline with Dasatinib 100 mg QD.|May 2015|May 26, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761890||73516|
NCT01762150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-RCC-120601|Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma|Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study||Beijing Cancer Hospital|Yes|Active, not recruiting|June 2011|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|70 Years|No|||February 2016|February 27, 2016|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01762150||73496|
NCT01761240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-066-001|Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC|A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies||Morphotek|Yes|Active, not recruiting|June 2013|June 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|99 Years|No|||March 2016|March 21, 2016|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761240||73566|
NCT01757145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7114|Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation|Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation||Rabin Medical Center|Yes|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2013|June 18, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757145||73880|
NCT01757119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00008 CP 1 01|Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia|Study of the Pharmacokinetics of Serum Iron After Single Oral Administration of Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia||Pierre Fabre Medicament||Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|45 Years|No|||April 2014|April 14, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01757119||73882|
NCT01758055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f-91-135|Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients|Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells Derived Bone Marrow in Patients With Emphysema||Masih Daneshvari Hospital|Yes|Not yet recruiting|December 2012|January 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|16 Years|70 Years|No|||November 2012|December 23, 2012|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01758055||73811|
NCT01758640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AINSHAMS2012|Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy|Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy Throughout Pregnancy In Patients With Mechanical Heart Valves Prosthesis||Ain Shams University|Yes|Completed|February 2010|August 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|40 Years|No|||January 2013|January 25, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01758640||73766|
NCT01758900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjer2011-70k|CO2 Versus Air Insufflation for Single-balloon Enteroscopy|CO2 Versus Air Insufflation for Single-balloon Enteroscopy: a Randomized, Controlled Trial||Shanghai Jiao Tong University School of Medicine|No|Recruiting|July 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|214|||Both|18 Years|75 Years|No|||March 2013|March 18, 2013|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758900||73746|
NCT01758874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-19|Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia|Phase 2 Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia|CLI-PH|Seoul Veterans Hospital|No|Completed|September 2006|April 2012|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|N/A|N/A|No|||December 2012|December 27, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01758874||73748|
NCT01758887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1207-055-417|Antipsychotic Discontinuation in High-risk Subjects|||Seoul National University Hospital|No|Active, not recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|16 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinical high risk subjects for psychosis who have been treated with antipsychotic        medication so that reach to the remission.|May 2013|May 18, 2013|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758887||73747|
NCT01759134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chammermanpdc|Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas|Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas||Shaare Zedek Medical Center|No|Terminated|January 2013|June 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|30 Weeks|34 Weeks|No|||December 2012|October 24, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01759134||73728|
NCT01759147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNStudy01|Clinical Outcome of Coracoclavicular Ligament Repair Using Autogenous Gracilis Tendon in Endobutton System.|Case Series to Evaluate Clinical Outcome of Coracoclavicular Ligament Repair Using Autogenous Gracilis Tendon in Endobutton System.||Helsingborgs Hospital|No|Active, not recruiting|January 2011|July 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||December 2012|December 23, 2012|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01759147||73727|
NCT01759394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-017|A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal|A Randomized, Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal||Eisai Inc.||Completed|October 2012|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759394||73708|
NCT01759719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000002|Novara Registry of Platinum-Chromium Platform Stents|Novara Platinum CROMium Everolimus EluTing StEnt SpontaneoUs RegiStry|PROMETEUS|Azienda Ospedaliero Universitaria Maggiore della Carita|No|Recruiting|January 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|90 Years|No|Probability Sample|253 consecutive all-comers patients treated in our Laboratory from January 2011 to August        2012 with PCI using a platinum-chromium platform based DES|March 2015|March 25, 2015|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01759719|1 Year|73683|
NCT01759108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116619963|Rebamipide for the Treatment of Xerostomia in sjögren Syndrome|||Faculty of Medicine, University of Alexandria|Yes|Recruiting|December 2012|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|N/A|N/A|No|||December 2012|December 23, 2012|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01759108||73730|
NCT01764867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI01B04-MDD|Algorithm Guided Treatment Strategies for Major Depressive Disorder|Algorithm Guided Treatment Strategies for Major Depressive Disorder|AGTs-MDD|Shanghai Mental Health Center|No|Recruiting|June 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|18 Years|75 Years|No|||January 2013|January 8, 2013|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01764867||73287|
NCT01765153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003873|Precision Versus Endurance Training to Improve Walking After Chronic Incomplete SCI|Precision Versus Endurance Training to Improve Walking After Chronic Incomplete SCI||University of Alberta|Yes|Completed|March 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||December 2014|December 17, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01765153||73265|
NCT01765439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL#3-2013-CR|The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease|The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease||Charles University, Czech Republic|No|Recruiting|February 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765439||73243|
NCT01765166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019396|Parent Treatment for Child Social Adjustment|Continuing the Research and Development of Parent Treatment for Child Social Adjustment|SSGRIN-PG|Duke University|No|Completed|January 2010|June 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|240|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01765166||73264|
NCT01765179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-12011|Safety and Efficacy Trial of Testosterone Undecanoate|Phase III, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU)in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Male|18 Years|75 Years|No|||December 2013|December 17, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765179||73263|
NCT01765452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CLO_401|Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone|Multi-center, Randomized, Open Study for Comparison of Efficacy and Safety of Plavix With Astrix and Closone in Patients With Post-Percutaneous Coronary Artery Intervention||CJ HealthCare Corporation|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|20 Years|85 Years|No|||May 2014|May 9, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765452||73242|
NCT01761617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005956-01A1|Yoga Dosing Study for Chronic Low Back Pain|Yoga Dosing Study for Chronic Low Back Pain in a Predominantly Low-Income Minority Population|YLBP2|Boston Medical Center|Yes|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|64 Years|No|||January 2013|January 16, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01761617||73537|
NCT01761630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001528|The Severe Asthma Research Program III-Boston Clinical Site|ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III|SARPIII-AMSA|Brigham and Women's Hospital|Yes|Active, not recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell Pellet      Bronch: BAl, Bronchial Brushings, Bronchial Biopsy|Both|6 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|The target recruitment goal for our center is 75% adults (age 18 to 60) and 25% children        age 6-17 years. Within the pediatric age group, an attempt will be made to enroll equal        numbers of children 6-11 and 12-17 years of age. Similarly, an attempt will be made to        enroll at least 50% females and 30% minorities.        Given the mission of SARP, a diverse sample of subjects with asthma is needed to gain        better understanding of asthma and its endotypes. Because there are a number of        respiratory disorders that may be confused with asthma or confound asthma assessment, SARP        enrollees must meet the all of the eligibility criteria described.|September 2015|September 21, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761630||73536|
NCT01761903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0289|Functional Connectivity in Primary Focal Dystonia|Functional Connectivity of the Basal Ganglia in Primary Focal Dystonia||University of Colorado, Denver|No|Recruiting|May 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|44|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult-onset primary focal dystonia patients 18 years old and older with symptoms affecting        muscles of the eye (blepharospasm), jaw or face (cranial), neck (cervical), limbs        (arm/leg), or vocal chords.|January 2016|January 5, 2016|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01761903||73515|
NCT01761916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLONCAP|Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure|Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure|CLONCAP|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|45 Years|No|||June 2013|July 25, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01761916||73514|
NCT01757392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nieslen Protocol CFW-2c|Candin Safety & Efficacy Study for the Treatment of Warts|Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts||Nielsen BioSciences, Inc.|No|Active, not recruiting|September 2012|April 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757392||73861|
NCT01757405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021101|Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen|A PHASE 3, PROSPECTIVE, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE SAFETY AND EFFICACY OF RECOMBINANT ACTIVATED FVII BI (rFVIIa BI) IN THE TREATMENT OF ACUTE BLEEDING EPISODES PER AN ON-DEMAND REGIMEN IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS||Baxalta US Inc.|Yes|Completed|February 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|12 Years|65 Years|No|||November 2015|November 18, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757405||73860|
NCT01757756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731017|Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects||Pfizer|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|October 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757756||73834|
NCT01758042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001355|Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders|Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders|BMT|Massachusetts General Hospital|Yes|Recruiting|November 2012|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01758042||73812|
NCT01758653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024109|Carbon Monoxide Blood and DNA Biorepository|Carbon Monoxide Blood and DNA Repository||Intermountain Health Care, Inc.|No|Enrolling by invitation|February 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood for plasma, serum, and DNA sequestration|Both|18 Years|N/A|No|Non-Probability Sample|Study population includes patients who present to LDS Hospital or Intermountain Medical        Center with symptomatic carbon monoxide poisoning and documented exposure to carbon        monoxide.|February 2015|February 19, 2015|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758653||73765|
NCT01759173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-18|Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion|Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in the College Age Athletes||ElMindA Ltd|No|Completed|September 2012|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|234|||Both|17 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|200-300 athletes from 3-9 college sport teams, from both genders, aged 17-24 years.|April 2015|April 8, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01759173||73725|
NCT01759446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-ADF-301|Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users|A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users.||Acura Pharmaceuticals Inc.|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 7, 2013|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759446||73704|
NCT01759160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFCfengxiar1|Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models|Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models in Propofol Plasma Target-controlled Infusion|TCI|First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|December 20, 2012||No||No|January 16, 2013|https://clinicaltrials.gov/show/NCT01759160||73726|
NCT01759459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3867-1|Local Anesthetics for Pain Reduction Prior to IV Line Placement|A Comparison of Lidocaine, Buffered Lidocaine, and Bacteriostatic Normal Saline for Local Anesthesia Prior to Peripheral Intravenous Catheterization||Allina Health System|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 9, 2013|December 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759459||73703|
NCT01759420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375393|Ondansetron and the QT Interval In Adult Emergency Department Patients|Ondansetron and the QT Interval In Adult Emergency Department Patients||C.R.Darnall Army Medical Center|No|Completed|December 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|The target population is adult (>18 years old) emergency department patients who have been        deemed appropriate to receive intravenous ondansetron.|June 2014|June 24, 2014|December 29, 2012||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01759420||73706|
NCT01759433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCWH001|Reference Intervals for Sonoclot Analysis in Chinese|Reference Ranges for Sonoclot Analysis in Chinese||Wuhan Asia Heart Hospital|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|None Retained|2.7 mL citrated blood.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chinese healthy adults aged 18 and older|December 2013|December 28, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01759433||73705|
NCT01760317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advocate-IRB-4917|Two Different Approaches During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection|Midline vs Lateral Parasagittal Approach During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection: the Role of Concordant Pressure Paresthesia in Determing Outcome.||Chicago Anesthesia Pain Specialists|No|Completed|August 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|80 Years|No|||February 2015|February 3, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01760317||73637|
NCT01759680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPEES/CB/WBV01|Effects of 3 Months of Controlled Whole Body Vibrations on the Risk of Falls Among Nursing Home Residents|Effects of 3 Months of Controlled Whole Body Vibrations With Low Exposure Period on the Risk of Falls Among Nursing Home Residents||University Hospital of Liege|Yes|Completed|January 2012|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|January 2, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01759680||73686|
NCT01759693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113|Platelet Activation in Chronic Inflammatory Skin Diseases|||Meir Medical Center|No|Not yet recruiting|February 2013|October 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospital clinic|December 2012|January 2, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01759693||73685|
NCT01759966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1428|Autonomic Cardiovascular Control After Heart Transplantation|Autonomic Cardiovascular Control After Heart Transplantation|AccHeart|Oslo University Hospital|No|Recruiting|January 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|1. Blood samples for analyses of: genomic DNA, RNA-transcription in whole blood,           cytokines, cathecholamines, other blood biomarkers        2. Urine samples for analyses of: catecholamines, cortisol, other urine biomarkers        3. Saliva samples for analyses of: cortisol        4. Heart biopsy specimen for analyses of: acute and chronic rejection (routine           surveillence procedure)|Both|17 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study is to enroll 50 Heart Transplant Recipients (HTRs) and 50 healthy control        subjects.        HTRs are consecutively invited to participate. Baseline investigations are carried out        7-12 weeks after transplantation surgery. Follow-up investigations are scheduled to 6        months and 1, 2 and 3 years after transplantation        Healthy control subjects will be recruited to matcht the distribution of age and gender        among HTRs. The will be examined at one time point only; thus, the healthy controls are        not subjected to prospective follow-up.|January 2013|January 18, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01759966||73664|
NCT01759979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00718|Laser Versus Mechanical Lithotripsy of Bile Duct Stones|Randomized Trial of Combination of Cholangioscopic Guided Laser Lithotripsy and Conventional Mechanical Versus Conventional Mechanical Methods for the Endoscopic Removal of Large Bile Duct Stones||University of Southern California|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01759979||73663|
NCT01764373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENRGy2 Addendum|Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - ENRGy2 Addendum|Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - Exercise and Neuropathy Research Group v.2 (ENRGy2) Addendum||University of Kansas Medical Center|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|40 Years|70 Years|No|||September 2013|September 26, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764373||73325|
NCT01764620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040/2011|Effects of Muscle Fatigue and a Taping Technique on Shoulder Motion of Athletes|Effects of Muscle Fatigue and Scapular Taping on Shoulder Kinematics of Overhead Athletes||Universidade Federal de Sao Carlos|Yes|Recruiting|May 2012|July 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2013|March 30, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01764620||73306|
NCT01764906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA06-CP01|The Clinical Study of Novosis in Posterolateral Fusion|The Clinical Study to Evaluate the Efficacy and Safety of Novosis in Posterolateral Fusion||BioAlpha Inc.|No|Enrolling by invitation|March 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2013|April 21, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764906||73284|
NCT01764880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST0001-STRCH-CR-11-002|SST0001 (Roneparstat) in Advanced Multiple Myeloma|Phase I Dose Finding Study Assessing Safety and Tolerability of SST0001 in Advanced Multiple Myeloma.||Sigma Tau Research Switzerland SA|No|Recruiting|November 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764880||73286|
NCT01761383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6006092|Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia|Nintendo Wii and Schizophrenia. A Pilot Study.||Queen's University|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|N/A|N/A|No|||February 2016|February 11, 2016|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01761383||73555|
NCT01761396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00075767|School-based Treatment of Anxiety Research Study (STARS)|Modular CBT for Reducing Anxiety and Improving Educational Outcomes|STARS|University of Connecticut Health Center|Yes|Enrolling by invitation|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|375|||Both|6 Years|18 Years|No|||February 2015|February 26, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01761396||73554|
NCT01761643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 595|CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM|CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM||California Collaborative Treatment Group|No|Active, not recruiting|January 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761643||73535|
NCT01762202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL0911|Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.|Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).|CLL0911|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|November 2013|November 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||July 2015|July 31, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762202||73492|
NCT01762215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POEM|Policy on Optimal Epilepsy Management|Policy on Optimized Epilepsy Management: The Use of an Online Social Media Platform to Collect Patient-Entered Data in the Veteran Population|POEM|Northern California Institute of Research and Education|No|Recruiting|October 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 4, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01762215||73491|
NCT01758068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIMS/06/TEWL|Effect of Twice Daily Application of Coconut Oil in Reducing Water Loss From Skin of Premature Babies in First Week of Life|Effect of Topical Oil Application on Trans-Epidermal Water Loss in Preterm Infants - A Randomized Clinical Trail|TEWL|Lady Hardinge Medical College|Yes|Completed|November 2005|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|N/A|7 Days|No|||December 2012|December 23, 2012|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01758068||73810|
NCT01758081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI093723|Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)|Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18||Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25874|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758081||73809|
NCT01758419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-101085-F|The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes.|The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes With Myocardial Perfusion, Cardiac Function, Metabolism and Clinical Prognosis.||Far Eastern Memorial Hospital|Yes|Recruiting|December 2012|November 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Venous blood sampling|Female|20 Years|80 Years|No|Non-Probability Sample|Female patients with breast cancer who scheduled further regional RT. Groups of left-sided        breast cancer (tomotherapy, conventional RT), and right breast cancer (conventional RT).|July 2013|May 6, 2014|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758419||73783|
NCT01758913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDA Ind Ibu ELBW|Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants|Pharmacological Closure of Patent Ductus Arteriosus in Extreme Low Birth Weight Infants. A Comparison of Efficacy, Side Effects and Outcomes Between Indomethacin and Ibuprofen||Taipei Medical University Hospital|No|Completed|February 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|N/A|6 Months|No|||December 2012|January 1, 2013|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01758913||73745|
NCT01760044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATP001|Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients|Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients||University of Michigan|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Both|N/A|18 Years|No|||December 2014|December 1, 2014|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01760044||73658|
NCT01759732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCPHO-SCT1202|Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia|Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia||Asan Medical Center||Recruiting|September 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|21 Years|No|||December 2012|December 30, 2012|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01759732||73682|
NCT01760018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0748|Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40|||Yonsei University|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|76|||Female|20 Years|65 Years|No|||February 2014|February 17, 2014|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01760018||73660|
NCT01760031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenPro1L|Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy|Remote Preconditioning for Contrast-Induced Acute Kidney Injury: Long-Term Follow up (RenPro Longterm)|RenProLong|University of Cologne|Yes|Active, not recruiting|July 2012|January 2013|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|81|||Both|18 Years|90 Years|No|Probability Sample|Patients refered for elective cardiac catherization to the university hospital of Cologne.        All patients who participated to the RenPro trial (www.germanctr.de; DRKS-ID DRKS00000666)|December 2012|December 28, 2012|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01760031||73659|
NCT01759992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UV-INV-PRECOMP12-80293|Effects and Costs of Respiratory Muscle Training in Institutionalized Elderly People|Determination of the Effects and Costs of Respiratory Muscle Training in Institutionalized Elderly People With Functional Impairment: A Randomized Controlled Trial||University of Valencia|No|Completed|January 2013|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|65 Years|N/A|No|||March 2014|March 18, 2014|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01759992||73662|
NCT01760005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAN-TU-001|Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.|A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease|DIAN-TU|Washington University School of Medicine|Yes|Active, not recruiting|December 2012|December 2019|Anticipated|September 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|210|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760005||73661|
NCT01760304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001576/1|Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo|Evaluation of Changes in Cardiac Function in COPD Patients With Resting Hyperinflation After Administration of Budesonide/Formoterol (Symbicort®) Compared With Placebo|AZCO|Brigham and Women's Hospital|No|Terminated|January 2012|October 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|40 Years|80 Years|No|||January 2013|January 7, 2013|October 23, 2012||No|Sponsor decided to stop the study due to expiration of blinded placebo .|No||https://clinicaltrials.gov/show/NCT01760304||73638|
NCT01764633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110118|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease|FOURIER|Amgen|Yes|Active, not recruiting|January 2013|February 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27564|||Both|40 Years|85 Years|No|||January 2016|January 20, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764633||73305|
NCT01764646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-196|Hypofractionated Radiation Therapy in Prostate Cancer|Stereotactic Body Radiation Therapy for cT1c - cT3a Prostate Cancer With a Low Risk of Nodal Metastases (≤ 20%, Roach Index): a Novalis Circle Phase II Prospective Randomized Trial||University Hospital, Geneva|Yes|Active, not recruiting|September 2012|September 2025|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Male|18 Years|85 Years|No|||March 2016|March 18, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01764646||73304|
NCT01764893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSU-SOL-001|Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder|A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder||Bay State Clinical Trials, Inc.|Yes|Terminated|January 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|January 3, 2013|Yes|Yes|Enrolling too slowly due to insurance plans no longer covering the cost of the Percutaneous    Tibial Nerve Stimulation treatment.|No||https://clinicaltrials.gov/show/NCT01764893||73285|
NCT01764919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVD003|[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection|Exploration of the Use of [124I]FIAU Positron Emission Tomography-Computed Tomography Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection.||BioMed Valley Discoveries, Inc|No|Terminated|April 2013|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 7, 2013|Yes|Yes|No correlation between FIAU uptake and bone biopsy results.|No||https://clinicaltrials.gov/show/NCT01764919||73283|
NCT01765192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-ASTHMA_202|Roflumilast Plus Montelukast in Adults With Severe Asthma|A Phase 2, Randomized, Double-Blind, 4-week Crossover Trial to Investigate the Effect of a Once-Daily Combination of 500 µg Roflumilast Plus 10 mg Montelukast vs 10 mg Montelukast Alone on Pulmonary Function, Asthma Symptoms, and Inflammatory Markers in Subjects With Severe Asthma Not Adequately Controlled With a Combination of at Least Medium Dose Inhaled Corticosteroids and Long-Acting Beta Agonists Maintenance Therapy||Takeda|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|January 8, 2013||No||No|June 12, 2015|https://clinicaltrials.gov/show/NCT01765192||73262|
NCT01765465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2012-E0816-00001|Effect of Rowachol on Prevention of Postcholecystectomy Syndrome|Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy||DongGuk University|Yes|Completed|January 2013|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|138|||Both|18 Years|84 Years|No|||November 2014|November 16, 2014|January 7, 2013||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01765465||73241|
NCT01765478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-HM71224-101|Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers|A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Anticipated|62|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|May 15, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01765478||73240|
NCT01761656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMYDA-IMR 01|Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR|Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR|ARMYDA-IMR|Central South University|Yes|Recruiting|December 2012|February 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01761656||73534|
NCT01761929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB '11-0886-C'|5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases|A Phase II Study on the Toxicity and Efficacy of a Normal Tissue Tolerance Adapted, 5 Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases||University Health Network, Toronto|Yes|Recruiting|March 2013|March 2022|Anticipated|March 2022|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01761929||73513|
NCT01759004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS4NL|Physical Condition in Lipedema and Obesity|Muscle Strength and Physical Fitness in Patients With Lipedema and Obesity: a Prospective Cross-sectional Pilot Study||Nij Smellinghe Hosptial|No|Completed|December 2012|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 4, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01759004||73738|
NCT01758094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24122012|Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism|||Gulhane School of Medicine|Yes|Completed|January 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|||Male|19 Years|26 Years|Accepts Healthy Volunteers|Probability Sample|Patients with hypogonadotrophic hypogonadism|January 2013|January 1, 2013|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758094||73808|
NCT01758107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monorapa|Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients|Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients||Chulalongkorn University|Yes|Recruiting|August 2010|October 2015|Anticipated|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|85 Years|No|||February 2015|February 1, 2015|December 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758107||73807|
NCT01758432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-502|Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests|A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers||Portola Pharmaceuticals|Yes|Completed|December 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758432||73782|
NCT01758666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-WAC-201205001|A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy|||Tianjin Medical University Cancer Institute and Hospital||Active, not recruiting|September 2012|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|12 Years|60 Years|No|||December 2012|December 21, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01758666||73764|
NCT01759745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEB_Gaze_Emotion|Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm|The Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm- a Pilot Study.||Medical University of Vienna|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|20 patients suffering from BEB, age 18-80 from our Botulinum toxin clinic will be        investigated.        For controls,20 healthy age matched subjects will be investigated. All participants will        sign an informed consent.|June 2014|June 29, 2014|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01759745||73681|
NCT01759758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-1012457|A Randomized Trial Comparing Conventional Plaster and Thermoplastic Splints to Treat Pediatric Boxer's Fractures|Conventional Plaster Versus Thermoplastic Splint for the Treatment of a Pediatric Metacarpal Neck Fracture: a Randomized Trial||IWK Health Centre|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|16 Years|No|||January 2016|January 12, 2016|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01759758||73680|
NCT01759771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-007-12S|Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial|Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial|VD3 PC|VA Office of Research and Development|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|19 Years|90 Years|No|||November 2015|November 6, 2015|December 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01759771||73679|
NCT01763411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOB-12/12|Visual Performance of Pseudophakic Patient With Different Intraocular Lenses|Visual Performance of Pseudophakic Patient With Different Intraocular Lenses|ETDRS|Hospital Oftalmologico de Brasilia|Yes|Active, not recruiting|January 2008|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|80|||Both|55 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population was derived from patients who had phacoemulsification with multifocal        or mono focal intraocular lens (IOL) in Sao Paulo University School of Medicine, Brazil.        Patients with senile cataract with vision-impairing disease characterized by gradual,        progressive opacity of the lens.|February 2016|February 21, 2016|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763411||73399|
NCT01756365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOEX 015|Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency|Autologous Cultured Corneal Epithelium ( Culture d'épithélium cornéen Autologue CECA) for the Treatment of Unilateral Corneal Lesions Associated With Limbal Stem Cell Deficiency|CECA|Centre Hospitalier Universitaire de Québec, CHU de Québec||Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756365||73939|
NCT01756378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/012/003|Effect of Mulligan'Mobilization With Movement on Pain, Disability and Range of Motion in Patients With Knee Osteoarthritis|Effect of Mulligan'Mobilization With Movement on Pain, Disability and Range of Motion in Patients With Knee Osteoarthritis||Cairo University|Yes|Completed|March 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|60 Years|No|||December 2012|December 20, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756378||73938|
NCT01756651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20812-01|Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures|A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures||Los Angeles Biomedical Research Institute|Yes|Recruiting|February 2013|November 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756651||73917|
NCT01753089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-306|Dendritic Cell Activating Scaffold in Melanoma|A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients||Dana-Farber Cancer Institute|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753089||74190|
NCT01753999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012002164|Obstructive Sleep Apnea in World Trade Center Responders|Obstructive Sleep Apnea in WTC Responders: Role of Nasal Pathology||Rutgers, The State University of New Jersey|No|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753999||74120|
NCT01753661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0125|Project ASPIRE Efficacy Pilot: Achieving Superior Parental Involvement for Rehabilitative Excellence|A Parent-Directed, Multimedia Early Intervention Tool to Improve Outcomes in Underserved Children Who Are Deaf or Hard-of-Hearing|ASPIRE|University of Chicago|No|Recruiting|June 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|32|||Both|6 Months|N/A|Accepts Healthy Volunteers|||December 2012|September 4, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753661||74146|
NCT01753960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-IM-0561-12-CTIL|Surgical Blood Management Using Noninvasive and Continuous Hemoglobin Monitoring(NACHO)|Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management (NACHO) - Matched-pair Cluster-randomized Controlled Trial||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Study population in this study is defined at two levels: 1.Consenting eligible        Anesthesiologists, and 2. Eligible patients under the case of the consenting eligible        Anesthesiologist. Each level has its own eligibility criteria.|January 2013|January 1, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01753960||74123|
NCT01754233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO-PL|Evaluation of the 755nm Alexandrite for the Treatment of Epidermal and Dermal Pigmented Lesions|||Cynosure, Inc.|No|Completed|December 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|85 Years|No|||July 2015|July 29, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754233||74102|
NCT01754246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO-PLASIAN|Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types|||Cynosure, Inc.|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||July 2015|July 29, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754246||74101|
NCT01754259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002537|Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD|Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease|RAND-CFR|Brigham and Women's Hospital|Yes|Active, not recruiting|April 2013|December 2015|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|70|||Both|18 Years|90 Years|No|||July 2015|October 23, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01754259||74100|
NCT01754506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0228|Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers|Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers||Ohio State University|Yes|Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|85 Years|No|||October 2015|October 14, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754506||74081|
NCT01759849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL311|CSL311 and Cell Viability in Asthma|The Effect of in Vitro CSL311 on the Function of Blood, Bone Marrow and Sputum Cells From Asthmatic Donors.||Hamilton Health Sciences Corporation|Yes|Completed|November 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759849||73673|
NCT01759862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24280|Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant|Perioperative Aminophylline to Improve High Risk Renal Graft Outcome- a Double Blinded, Placebo Controlled, Randomized Clinical Trial|RTphylline|Stanford University|Yes|Recruiting|November 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|21 Years|No|||June 2014|June 30, 2014|December 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759862||73672|
NCT01760447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-289|A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)|A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)||Merck Sharp & Dohme Corp.|Yes|Recruiting|February 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|17 Years|No|||March 2016|March 22, 2016|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760447||73627|
NCT01760460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-051|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)|A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Merck Sharp & Dohme Corp.|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|80 Years|No|||March 2015|March 11, 2015|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760460||73626|
NCT01760720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033130|Methadone Maintenance Treatment (MMT) Care for HIV Prevention|Methadone Maintenance Treatment (MMT) Care for HIV Prevention: A Randomized Controlled Trial (MMT2)||University of California, Los Angeles|Yes|Completed|March 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2866|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760720||73606|
NCT01761747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-327|Ponatinib for Squamous Cell Lung and Head and Neck Cancers|Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations||Dana-Farber Cancer Institute|Yes|Terminated|January 2013|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|September 26, 2012|Yes|Yes|FDA hold and toxicity associated with study drug|No|November 15, 2014|https://clinicaltrials.gov/show/NCT01761747||73527|
NCT01762319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOGMVA002|Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol|Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial||Mahidol University|No|Recruiting|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Female|35 Years|N/A|No|||September 2012|January 4, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01762319||73483|
NCT01762891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32323232|CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen|CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen. A Prospective Double-blind, Placebo Controlled Study.|CI(R)CA|Hospital Universitario Pedro Ernesto|No|Completed|March 2003|September 2009|Actual|July 2006|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||January 2013|January 6, 2013|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01762891||73439|
NCT01763164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162A2301|Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma|A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma||Array BioPharma|Yes|Active, not recruiting|July 2013|May 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763164||73418|
NCT01763177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC56-008-08-1-1|Use of Oxygen Nebulizer for Preventing Post-operative Sore Throat|Use of Oxygen Nebulizer for Preventing Post-operative Sore Throat|POST|Prince of Songkla University|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1036|||Both|18 Years|75 Years|No|||November 2015|November 15, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763177||73417|
NCT01763424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390134|Nicotinamide in the Treatment of Psoriasis|Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis.||Isfahan University of Medical Sciences|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||January 2013|January 5, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763424||73398|
NCT01763437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TET2013|Intralesional Tetracycline Injection in the Treatment of Chalazia|Intralesional Tetracycline Injection in the Treatment of Chalazia|TET|The Cleveland Clinic|No|Not yet recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|December 11, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763437||73397|
NCT01752790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2473|Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease|Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial||University of Roma La Sapienza|No|Withdrawn|December 2012|December 2015|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|18 Years|No|||March 2013|March 5, 2013|December 12, 2012||No|The study will be part of a European multicenter trial (Infliximab Top-down Study in Kids with    Crohn's disease)|No||https://clinicaltrials.gov/show/NCT01752790||74213|
NCT01753375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12816|Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis|Role of Vitamin D on the Relapse Rate of Multiple Sclerosis||King Saud University|Yes|Not yet recruiting|January 2013|October 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|55 Years|No|||December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753375||74168|
NCT01753388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 4928|Safety and Performance of the Penumbra Liberty Stent in the Treatment of Wide-Neck, Saccular, Intracranial Aneurysms|Safety and Performance of the Penumbra Liberty Stent in the Treatment of Wide-Neck, Saccular, Intracranial Aneurysms||Penumbra Inc.|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||November 2014|November 6, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753388||74167|
NCT01753700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300|Effect of UHT Treated Milk on Blolipid Profile|Effect of UHT Treated Milk on Blolipid Profile|UHT|University of Copenhagen|No|Recruiting|December 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753700||74143|
NCT01754012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266486|European Project on Nutrition in Elderly People|New Dietary Strategies Addressing the Specific Needs of Elderly Population for an Healthy Aging in Europe|NU-AGE|University of Bologna|No|Completed|April 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1190|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01754012||74119|
NCT01754298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00004016|Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee|Retro Versus Trans Articular Drilling for Juvenile Osteochondritis Dissecans of the Knee: A Multicenter, Randomized Controlled Trial||Children's Hospital Boston|No|Recruiting|November 2012|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|58|||Both|8 Years|18 Years|No|||September 2014|September 29, 2014|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01754298||74097|
NCT01753973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 164.096|Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation|Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation||University of Sao Paulo General Hospital|Yes|Completed|January 2013|December 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients will be selected by examining the clinical records of Renal Transplant Service,        Hospital das Clinicas, Faculty of Medicine, University of São Paulo (HCFMUSP). Patients        who meet the inclusion criteria and did not meet the exclusion criteria will be invited to        participate in the study, signing the Instrument of Consent (IC) and informed about the        objectives and procedures of the study to be performed.|June 2014|December 15, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753973||74122|
NCT01754272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX11080|A Non-Interventional Follow-Up to the VELOUR Study - Translational Research|A Non-Interventional Follow-Up to the VELOUR Study (Multicentre International Study of Aflibercept Versus Placebo in Combination With FOLFIRI for Metastatic Colorectal Cancer) - Translational Research||Katholieke Universiteit Leuven|No|Active, not recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Actual|1226|Samples With DNA|Archived FFPE (Formaldehyde fixed paraffin-embedded) primary tumour colorectal cancer      tissues Archived FFPE (Formaldehyde fixed paraffin-embedded) metastatic tumour tissue      Archived residual blood samples (plasma, serum) collected in the frame of the VELOUR trial|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastaic colorectal cancer who were refractory to an oxaliplatin-based        chemotherapy.|December 2012|December 18, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01754272||74099|
NCT01754285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-PB/11/04|Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea|A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Cancer||Chemi S.p.A.|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|114|||Female|18 Years|80 Years|No|||July 2014|July 28, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01754285||74098|
NCT01754519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 108907|Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery|Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer||Roswell Park Cancer Institute|Yes|Terminated|May 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|50 Years|N/A|No|||September 2015|September 2, 2015|November 23, 2012|Yes|Yes|IDE not submitted|No||https://clinicaltrials.gov/show/NCT01754519||74080|
NCT01754532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-12-0028|Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels|||Shalvata Mental Health Center|No|Recruiting|January 2013|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|10mg of posterior vertex hair|Both|18 Years|50 Years|No|Non-Probability Sample|Patients diagnosed with Schizophrenia or Schizo-Affective Disorder|November 2014|November 18, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01754532||74079|
NCT01760174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20120041|Comparing the Effect of TAP-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery|A Randomized Double Blind Trial Comparing the Effect of Transversus Abdominal Plane-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery||Aalborg Universitetshospital|No|Withdrawn|January 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|July 26, 2012||No|Because of logistic and practical reasons.|No||https://clinicaltrials.gov/show/NCT01760174||73648|
NCT01760187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-023|Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C|A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)||Aegerion Pharmaceuticals, Inc.|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01760187||73647|
NCT01760473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5879|Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone|Reinforcing Effects of Intranasal Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intranasal Drug Users||New York State Psychiatric Institute|No|Completed|May 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|27|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||January 2013|March 24, 2015|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760473||73625|
NCT01760733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF 81.25|Improved Selection of Elderly (> 65 Years) for Kidney Transplantation|Improved Selection of Elderly (> 65 Years) for Kidney Transplantation|QUESTION65|Sykehuset Telemark|No|Recruiting|December 2012|January 2018|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|65 Years|N/A|No|Non-Probability Sample|Patients older than 65 years listed for kidney transplantation on the Norwegian transplant        wait list|December 2014|December 2, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01760733||73605|
NCT01760746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02704|Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis|A Randomized, Multi-Centre, Double-Masked, Study to Compare Inflammatory Protein Changes in Aqueous Humour of Subjects Treated With Bevacizumab (Avastin) vs Ranibizumab (Lucentis) Pre-Vitrectomy for Proliferative Diabetic Retinopathy|Humour|University of British Columbia|No|Completed|July 2012|September 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Aqueous humour|Both|19 Years|N/A|No|Non-Probability Sample|In order to assess changes in intraocular levels of cytokines following anti-VEGF        treatment, the ideal time to measure these cytokines is at baseline and approximately 1        week later. In patients with PDR who are scheduled for vitrectomy, many vitreoretinal        surgeons now inject bevacizumab approximately 1 week prior to the surgery in order to        decrease the risk of intra-operative complications. These patients are thus an excellent        study group for studying intraocular cytokine changes in response to anti-VEGF therapy,        since that are already scheduled to have 2 intraocular procedures performed approximately        1 week apart, thereby minimizing the risk of obtaining aqueous humour.|April 2015|April 15, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01760746||73604|
NCT01762020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|London Regional Cancer Program|Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation|Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy||Lawson Health Research Institute|Yes|Recruiting|January 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|47|||Female|18 Years|80 Years|No|||March 2015|March 30, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762020||73506|
NCT01762332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medasense003|Clinical Validation of Medasense Pain Response Index (PRI)|Validation of Medasense Non-invasive Nociception Monitor During Surgery and Postoperative Recovery.||Medasense Biometrics Ltd|Yes|Recruiting|January 2013|January 2017|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|3||Anticipated|100|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01762332||73482|
NCT01762904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385-12|Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol|Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70%||Universidad de Guanajuato|No|Completed|January 2013|October 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|135|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 1, 2014|January 2, 2013||No||No|June 1, 2014|https://clinicaltrials.gov/show/NCT01762904||73438|
NCT01763450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avastin Study|Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer|LIAONING CANCER HOSPITAL&INSTITUTE||Liaoning Tumor Hospital & Institute|No|Active, not recruiting|September 2012|September 2014|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||September 2012|January 28, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01763450||73396|
NCT01763463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116952|WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects|WEUSKOP6416: Evaluating Serious Pneumonia in Subjects With Chronic Obstructive Pulmonary Disease (COPD) to Inform Risk Minimization: A Retrospective Observational Study||GlaxoSmithKline|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1|||Both|45 Years|N/A|No|Non-Probability Sample|Patients with COPD who are new users of ICS-containing medications or new user of LABD        will be included in the study if they are at least 45 years of age and have met the        inclusion/exclusion. Patients will have at least one prescription for ICS-containing        medications or LABD from January 2005 (the earliest use) until December, 2010 preceded by        a year of no use of these medicines . The one-year period of no use is referred to a        washout period rather than requiring no use of these medications ever in the patient's        history. Patients would be required to have at least one year in their history prior to        new user cohort entry to establish baseline disease severity and co-morbidities that would        be adjusted for in the modeling.|March 2015|March 9, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01763463||73395|
NCT01763775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13001_Body Scale|Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)|Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B|BS-BT|BTS International|No|Completed|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|January 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01763775||73371|
NCT01752504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 095 - Version 3.0|Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention|Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1550|||Both|12 Years|25 Years|No|||January 2015|February 9, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01752504||74235|
NCT01752517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-S463|Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer|A Phase Ⅱ Single-arm Clinical Trial to Investigate the Efficacy and Safety of Vinorelbine-ifosfamide Regimen as Third-line Treatment in Refractory or Recurrent Extensive Small Cell Lung Cancer Patients||Peking Union Medical College Hospital|No|Recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|75 Years|No|Non-Probability Sample|ED-SCLC patients who relapse after treatment with first-line EP or CE and second-line        topotecan.|December 2012|December 14, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752517||74234|
NCT01752803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-02-12-1815RU|RCT Examining Effects of Probiotics in T2DM Individuals|A Double-blind, Randomized Placebo-controlled Parallel Group Study of Probiotics as an Adjuvant Therapy for Individuals With Type 2 Diabetes Mellitus||Universiti Kebangsaan Malaysia Medical Centre|No|Recruiting|December 2012|July 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|65 Years|No|||September 2014|September 30, 2014|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01752803||74212|
NCT01752816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120178|Does Aerobic Training Followed by Resistance Training Enhance Aerobic Capacity in Seniors|Does Aerobic Training Followed by Resistance Training Enhance Aerobic Capacity in Seniors? A Randomized Controlled Trial.||University of Southern Denmark|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|33|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||April 2013|August 14, 2013|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752816||74211|
NCT01753687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-300511|Correlation of Different Signs for Assessment of Dry Eye Syndrome|Correlation of Different Signs for Assessment of Dry Eye Syndrome||Medical University of Vienna|No|Completed|September 2011|September 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753687||74144|
NCT01754896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209-2011|Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario|Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario||Sunnybrook Health Sciences Centre|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|28|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754896||74051|
NCT01754311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/B/01|Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1|Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1|HAMIL28B|Centre Hospitalier Universitaire de Fort-de-France|No|Not yet recruiting|February 2013|August 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|165|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|HTLV-1 infected patients :        Adult, followed in consultation of Neurology of the University Hospital of Fort-de-France        for their HTLV-1 infection.        Blood Donors ; Adult, age 18 to 70 years coming to give their blood in one of building or        mobile collection facilities of Martinique French Blood Establishement|December 2012|December 18, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01754311||74096|
NCT01754025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-360|INHERIT EGFR - Studying Germline EGFR Mutations|INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations|INHERIT|Dana-Farber Cancer Institute|No|Recruiting|December 2012|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be identified through participating cancer centers as well as a study        website (www.dana-farber.org/T790Mstudy)|January 2016|January 21, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01754025|2 Years|74118|
NCT01754545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133995|Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura|Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura||St. Olavs Hospital|Yes|Withdrawn|September 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|65 Years|No|||December 2012|December 18, 2012|December 12, 2012||No|altered situation in study population; not enough patients meeting enrollment criteria|No||https://clinicaltrials.gov/show/NCT01754545||74078|
NCT01754844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2550C00001|A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects|A Double-blind Placebo-controlled, Randomised, Single Centre, First Time in Man Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD7624 in Healthy Subjects||AstraZeneca||Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|57|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01754844||74055|
NCT01755299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5HE-TOL|Efficacy of Energy Shots and Caffeine for Energy and Wakefulness Levels|Efficacy of "5-hour Energy"®, "5-Hour Energy Decaf"®, and Caffeine for Perceived Energy and Wakefulness||ProMedica Health System|Yes|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 6, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755299||74020|
NCT01755312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2r44ago39178-02 (1208012596)|The Effect of Medication Reminder Technology on Medication Adherence and Hypertension Outcomes|The Effect of Medication Reminder Technology on Medication Adherence and Hypertension||Purdue University|No|Terminated|June 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|December 18, 2012||No|Research site no longer available|No||https://clinicaltrials.gov/show/NCT01755312||74019|
NCT01760200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000003|Drug Eluting Balloon Versus Drug Eluting Stent in PCI|Drug Eluting Balloon Versus Drug Eluting Stent in Coronary Artery Disease PCI: Insights From a Meta-analysis of 1462 Patients||Azienda Ospedaliero Universitaria Maggiore della Carita|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1462|||Both|18 Years|89 Years|No|Non-Probability Sample|Patient with CAD treated by coronary angiogrphy|January 2013|January 2, 2013|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01760200||73646|
NCT01765049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHBCC001|Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor|Prospective Study Analyzing Value of Breast Density Change Predicting ENdocrine Therapy Response in Postmenopausal Women Taking Adjuvant ARomatase Inhibitor|DEAR|Seoul National University Hospital|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|411|Samples With DNA|Postoperatively collected specimen (normal and cancer tissue) Preoperatively collected blood      sample|Female|N/A|70 Years|No|Non-Probability Sample|Postmenopausal women with ER positive invasive breast cancer taking adjuvant endocrine        therapy with aromatase inhibitor|June 2015|November 18, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765049|5 Years|73273|
NCT01765322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHC-2013-01|The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age|Center of Assisted Reproductive Technology||Shanxi Provincial Maternity and Children's Hospital|Yes|Recruiting|November 2013|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|35 Years|46 Years|No|||November 2013|November 25, 2013|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765322||73252|
NCT01765608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZON-01|Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients|A 1 Month Randomized Placebo Controlled, Double Blind Trial With a 5 Month Open Extension Phase to Explore the Efficacy of Zonisamide on Apnea/Hypopnea Index in Overweight/Obese Sleep Apnea Patients.||Göteborg University|Yes|Completed|March 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|75 Years|No|||February 2014|February 19, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765608||73230|
NCT01765621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHS022013|Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions|Clinical and Economic Impact of a Web Based, Electronic Medical Record Interfaced Electronic Decision Support System Incorporating Pharmacogenetic Evaluation for Physicians Intended, Mainly for Drug-drug Interaction. A Controlled Study in an Ambulatory Health Maintenance Organization Population|DDI+|Leumit Health Services|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|973|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 20, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765621||73229|
NCT01761474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP-Sedation|CO2 Versus O2 Insufflation During ERCP Depending on Sedation Protocols|Carbon Dioxide Insufflations vs. Air Insufflation in Therapeutic ERCP: A Randomized Double-blind Comparative Study Depending on Sedation Methods||Soon Chun Hyang University|No|Completed|December 2012|September 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|210|||Both|18 Years|N/A|No|Probability Sample|The study had an 80% power to detect a 20% difference in PAIN score any two groups,        assuming 2-sided tests at a 5% significance level.Assuming a 10 % dropout rate, 220        patients were needed.|March 2014|March 17, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01761474||73548|
NCT01762033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1009-Onc-002|A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma|A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of ASONEP™ (Sonepcizumab/LT1009) Administered as a Single Agent to Subjects With Refractory Renal Cell Carcinoma||Lpath, Inc.|No|Terminated|February 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762033||73505|
NCT01762592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/20-002|REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT|A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses||Wilex|No|Not yet recruiting|June 2017|June 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|350|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762592||73462|
NCT01763190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP13449|Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment|An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function||Sanofi|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|79 Years|No|||May 2015|May 12, 2015|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01763190||73416|
NCT01764360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0816|Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe|Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe (SIKO)|SIKO|University of Colorado, Denver|Yes|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1024|||Both|1 Year|80 Years|No|||December 2015|December 30, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764360||73326|
NCT01764607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514-2012|Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma|A Phase II Study of Sirolimus in Renal Transplant Patients Diagnosed With New or Recurrent Squamous Cell Skin Carcinoma Currently on Calcineurin-based Immunosuppression.||University of Florida|Yes|Terminated|April 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|December 18, 2012|Yes|Yes|Poor accrual|No|February 17, 2015|https://clinicaltrials.gov/show/NCT01764607||73307|
NCT01752530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120096|Cognitive Training in Children With Attention Deficit/ Hyperactivity Disorder (ADHD)|A Study of the Efficacy of Computerized Cognitive Training on Cognitive Function, Symptoms and Functional Outcome in Children With ADHD.||Region Syddanmark|No|Recruiting|December 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|6 Years|13 Years|No|||June 2015|June 29, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01752530||74233|
NCT01752543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-139|Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients|Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients||Rigshospitalet, Denmark|Yes|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||June 2015|June 16, 2015|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752543||74232|
NCT01753102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_10_19|Efficacy and Safety Of Spil's Estradiol Vaginal Tablet|EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY||Sun Pharmaceutical Industries Limited|No|Terminated|November 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|49|||Female|N/A|N/A|No|||December 2012|May 19, 2015|December 15, 2012||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01753102||74189|
NCT01753115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVA.009|Ciprofloxacin BioThrax Co-Administration Study|A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults||Emergent BioSolutions|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|December 14, 2012|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01753115||74188|
NCT01753414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-3502|Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC|POSTILV: A RANDOMIZED PHASE II TRIAL IN PATIENTS WITH OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: RADICAL RESECTION VERSUS ABLATIVE STEREOTACTIC RADIOTHERAPY - This is a Limited Participation Study.|POSTILV|Radiation Therapy Oncology Group|Yes|Recruiting|December 2012|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753414||74165|
NCT01753427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-XXX-2012/1|Perception of Symptom Variability in COPD|Perception of Symptom Variability in Chinese COPD Patients||AstraZeneca||Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|40 Years|N/A|No|Non-Probability Sample|Out-patient, male or female aged 40 years and over and Clinical diagnosis of COPD at least        6 months|December 2013|December 12, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753427||74164|
NCT01755104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCM-EFF-1|Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome|A Randomized Double-blind Placebo Controlled Trial on the Effect of Stablor™ on the Abdominal Visceral Fat Mass Loss in Patients With a Metabolic Syndrome||Laboratoires Nutrition et Cardiometabolisme|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|65 Years|No|||March 2014|March 6, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755104||74035|
NCT01755117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR obturator|Ultrasound Guided Obturator Nerve Block for Total Knee Replacement (TKR)|Comparison of Posterior Lumbar Plexus Block Plus Sciatic Nerve Block With Sciatic Plus Femoral Plus Obturator Nerve Block for Total Knee Replacement (TKR)||Larissa University Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||April 2014|April 27, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755117||74034|
NCT01754558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-252|One Year Outcome Using the Ajust System for Treatment of Urinary Stress Incontinence|||Roskilde County Hospital||Completed|May 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|60 Years|No|||May 2014|May 1, 2014|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01754558||74077|
NCT01754857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO11414|Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|HO11414: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)||University of Wisconsin, Madison|Yes|Recruiting|November 2013|November 2019|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754857||74054|
NCT01754870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO11415|Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)||University of Wisconsin, Madison|Yes|Withdrawn|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 27, 2012|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01754870||74053|
NCT01755078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-REN-002|Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients|Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients||Chugai Pharma Taiwan|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|70 Years|No|||December 2012|August 4, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755078||74037|
NCT01755091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM1HL112856 2011-06400|Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea|Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial|PACE|University of Illinois at Chicago|Yes|Recruiting|December 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|21 Years|64 Years|No|||May 2015|May 7, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755091||74036|
NCT01765062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRM-300585|One Year Skeletal and Dental Arch Changes Following Rapid Maxillary Expansion Treatment in Children|One Year Skeletal and Dental Arch Changes Following Rapid Maxillary Expansion Treatment in Children|ERM|State University of Maringá|No|Completed|July 2008|July 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|14|||Both|5 Years|11 Years|No|Non-Probability Sample|Community Sample|January 2013|January 8, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01765062||73272|
NCT01765309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0782|A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders|A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders||University of Colorado, Denver|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||March 2012|January 10, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765309||73253|
NCT01761487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0285-12|SDD for Eradicating CRKP Carriage|SELECTIVE DIGESTIVE DECONTAMINATION USING ORAL GENTAMICIN AND ORAL POLYMYXIN E FOR ERADICATION OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE CARRIAGE IN HOSPITALIZED PATIENTS||Soroka University Medical Center||Not yet recruiting|January 2013|||February 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2012|January 3, 2013|January 3, 2013||||No||https://clinicaltrials.gov/show/NCT01761487||73547|
NCT01761760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34DA033536-03|Videogame-based Incentives for Smoking Cessation|Game-based Contingency Management for Smoking Cessation||Rowan University|No|Not yet recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01761760||73526|
NCT01762345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012099|A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence|A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence||Procter and Gamble|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|December 12, 2012|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT01762345||73481|
NCT01762605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Treatment of Distal Radius Buckle Fractures|||Wake Forest School of Medicine|No|Terminated|March 2010|||November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|January 3, 2013||No|inadequate enrollment|No||https://clinicaltrials.gov/show/NCT01762605||73461|
NCT01762917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR_Vbag_MA|Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing|Influence of Bag Volume Variation in Inert Gas Rebreathing Pulmonary Blood Flow Measurements on the Reproducibility in Patients With Pulmonary Diseases||Universitätsmedizin Mannheim|No|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|45|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|inpatients and outpatients, internal medicine, university hospital|January 2013|January 7, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01762917||73437|
NCT01764087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-KXI-101|A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors|An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors||Hanmi Pharmaceutical Company Limited|No|Recruiting|December 2012|May 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||March 2014|May 15, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01764087||73347|
NCT01763814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advocate-IRB-5235|Three Different Approaches for Ultrasound Guided Femoral Nerve Block for Patients Undergoing Total Knee Arthroplasty|A Randomized, Single Blind Study of the Efficacy and Safety of Three Different Approaches for Ultrasound Guided Femoral Nerve Block for Patients Undergoing Total Knee Arthroplasty||Chicago Anesthesia Pain Specialists||Active, not recruiting|December 2011|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|90 Years|No|||July 2015|July 27, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01763814||73368|
NCT01763827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110114|Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2|A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less|MENDEL-2|Amgen|Yes|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|615|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|January 7, 2013|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01763827||73367|
NCT01764100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-MSC|Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)|Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial|MSC-GvHD|Azienda Ospedaliera San Gerardo di Monza|No|Recruiting|September 2009|September 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2013|January 7, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01764100||73346|
NCT01764113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004401|Effect of Mindful Eating on Body Mass Index in Obese Adolescents|Effect of Mindful Eating on Body Mass Index and Cardiovascular Risk Markers in Obese Adolescents: A Pilot Randomized Clinical Trial||Mayo Clinic|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|14 Years|N/A|No|||January 2014|January 21, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764113||73345|
NCT01752829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version PBS.V2.11.12|Post-marketing Surveillance Study of A.M.I. Protector Adjustable Gastric Band|A Single-arm, Observational, Post-marketing Study to Evaluate the Effects of the A.M.I. Protector Adjustable Gastric Band on Weight Loss, Co-morbidities, Adverse Events and Other Clinical Characteristics.||Weight to Go Ltd|No|Not yet recruiting|January 2013|||January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese subjects who are candidates for gastric banding|December 2012|December 18, 2012|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752829|3 Years|74210|
NCT01753401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC01-SLE-01|Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease|A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease||Mallinckrodt|No|Active, not recruiting|December 2012|December 2015|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753401||74166|
NCT01754038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040886|Registry for Integrative Medicine Interventions Effectiveness|Patients Receiving Integrative Medicine Interventions Effectiveness Registry|PRIMIER|BraveNet|No|Recruiting|August 2013|May 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients attending a participating Integrative Medicine Clinic|May 2015|May 26, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01754038|2 Years|74117|
NCT01754051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 4818|A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System in France|VOLCAN: A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System in France|VOLCAN|Penumbra Inc.|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Up to 200 patients with intracranial aneurysms treated by the PC 400 System at up to 20        centers will be enrolled.|November 2014|November 6, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01754051|1 Year|74116|
NCT01755130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0210|LOUIS-3D Breast Study|Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2014|||May 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|96|||Female|20 Years|85 Years|No|||November 2015|November 11, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755130||74033|
NCT01755143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5076 MRI|Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment|CapSureFix® Novus Model 5076 Lead MRI Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|266|||Both|N/A|N/A|No|||June 2015|June 22, 2015|December 18, 2012|No|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01755143||74032|
NCT01754324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC-PK-1|The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome|The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates||Children's Hospital Medical Center, Cincinnati|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|1 Month|No|Non-Probability Sample|Infants diagnosed with Neonatal Abstinence Syndrome and are treated with oral methadone.|June 2014|June 12, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01754324||74095|
NCT01754571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101041-E|CBT in Patients With Medication Overuse Headache|Cognitive Behavior Therapy in Patients With Medication Overuse||Far Eastern Memorial Hospital|Yes|Recruiting|July 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|80 Years|No|||November 2012|December 20, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01754571||74076|
NCT01754584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH 97055|The Effect and Mechanism of Hyaluronan on the Mucociliary Differentiation of Human Respiratory Epithelial Cells|The Effect and Mechanism of Hyaluronan on the Mucociliary Differentiation of Human Respiratory Epithelial Cells||Far Eastern Memorial Hospital|Yes|Not yet recruiting|January 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|N/A|N/A||Non-Probability Sample|PATIENTS UNDERWENT SEPTOMEATOPLASTY|November 2012|December 20, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01754584||74075|
NCT01754883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1170|Lithium Augmentation for Hyperarousal Symptoms of Post Traumatic Stress Disorder: Pilot Study|Lithium Augmentation for Hyperarousal Symptoms of Traumatic Stress Disorder: Pilot Study||VA Eastern Colorado Health Care System|No|Withdrawn|January 2011|January 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|50 Years|No|||December 2012|January 5, 2016|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01754883||74052|
NCT01765335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICaS CHF|Heart Failure Re-admission Risk Estimation Using NICaS System With Comparison to Serum BNP Levels|Heart Failure Re-admission Risk Estimation Using NICaS System With Comparison to Serum BNP Levels||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|85 Years|No|||January 2013|January 9, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765335||73251|
NCT01765634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSCs-aGVHD-2013|Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease|Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|65 Years|No|||January 2013|January 8, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01765634||73228|
NCT01761500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped-No-1|Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's Lymphoma|||Sun Yat-sen University|Yes|Completed|March 1998|December 2011|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|6 Months|20 Years|No|||January 2013|January 3, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01761500||73546|
NCT01761773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-017|A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function|A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function||Exelixis|Yes|Completed|December 2012|July 2014|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|January 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01761773||73525|
NCT01762358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KhalMUG1|Khalifa Effectiveness Study|Effectiveness of a Non-invasive Therapy for Treating Fully Ruptured Anterior Cruciate Ligaments in the Knee by Using MRI, Functional Tests and Scores: A Randomized Controlled Trial||Medical University of Graz|Yes|Completed|June 2005|October 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|No|||January 2013|January 4, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762358||73480|
NCT01762930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-12030|Field Application of Shanchol in Adults in Bangladesh|Study of Field Application of Oral Cholera Vaccine, Shanchol for Use in Developing Country Settings||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1015|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|July 26, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01762930||73436|
NCT01763801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaraPros|Optimization of EKG Method for Long Term Central Venous Catheter Tip Placement|P-max or P-submax? This is the Question! A Prospective Randomized Search of the Most Reliable ECG Landmark for a Long Term Central Venous Catheter.||Campus Bio-Medico University|Yes|Completed|July 2011|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|326|||Both|18 Years|80 Years|No|||January 2013|January 7, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763801||73369|
NCT01763489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV004|ASSIST Tool and Surgical Randomized Controlled Trial Applicability|Impact of a Graphical Tool on the Reader's Interpretation of Surgical RCT Applicability In the Field of Digestive Cancer|ASTA|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2015|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|130|||Both|N/A|N/A|No|||March 2013|January 21, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763489||73393|
NCT01763502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004649|The Impact of Cash and Food Transfers Linked to Preschool Enrollment on Child Nutrition and Cognitive Outcomes|The Impact of Cash and Food Transfers Linked to Preschool Enrollment on Child Nutrition and Cognitive Outcomes||International Food Policy Research Institute||Completed|August 2010|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|2561|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763502||73392|
NCT01764126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11023|Pneumococcal Protein Vaccine Safety and Immunogenicity Trial|Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh|PPR02|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|September 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|280|||Both|6 Weeks|50 Years|Accepts Healthy Volunteers|||January 2013|July 9, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01764126||73344|
NCT01764386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-404|Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects|A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)||Orexigen Therapeutics, Inc|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|January 4, 2013|Yes|Yes||No|September 7, 2015|https://clinicaltrials.gov/show/NCT01764386||73324|
NCT01753141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH076629-01A1|Smoking Treatment and Anxiety Management Program|Smoking Treatment and Anxiety Management Program|STAMP|Florida State University|No|Completed|January 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|378|||Both|18 Years|45 Years|No|||September 2013|September 25, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753141||74186|
NCT01752868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJH 6936-33|Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction?|Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction?||Washington University School of Medicine||Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752868||74207|
NCT01753154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-NL-04-EU|The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis|The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis||Fresenius Medical Care Deutschland GmbH|No|Completed|July 2011|December 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753154||74185|
NCT01754597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-39|Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines|Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines. Pilot Study in Patients Operated on for Breast Cancer. Monocentric Study Feasibility.|PEPNATB|Institut Bergonié|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01754597||74074|
NCT01755364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUV12T13C|A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old|||Adimmune Corporation|No|Recruiting|November 2012|February 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01755364||74015|
NCT01755624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-21|Effect of NovoTTF-100A in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)|A Phase II Randomized Study of TTField Therapy Versus Supportive Care in Non-small Cell Lung Cancer Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment||NovoCure Ltd.|No|Recruiting|January 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755624||73995|
NCT01755637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O7921353|Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population|A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males||GlaxoSmithKline|No|Completed|April 2012|June 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2013|July 11, 2013|December 19, 2012||No||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01755637||73994|
NCT01755377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOMARCHA|New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease|Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases|BIOMARCHA|Barcelona Centre for International Health Research|No|Active, not recruiting|December 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|Samples With DNA|Whole blood|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Migrants from Latin America visiting the Tropical Medicin Clinic|December 2015|December 10, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755377||74014|
NCT01765348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU 753610H|Evaluating Treatment Efficacy of Two Syntactic Treatment Procedures for Children With Specific Language Impairment (SLI): A Randomized Controlled Trial|Evaluating Treatment Efficacy of Two Syntactic Treatment Procedures for Children With Specific Language Impairment (SLI): A Randomized Controlled Trial||The University of Hong Kong|No|Completed|March 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|6 Years|12 Years|No|||January 2013|January 8, 2013|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01765348||73250|
NCT01761253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMC IRB No. 910010709|Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative Databases|Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative Databases||Weill Medical College of Cornell University|No|Active, not recruiting|June 2006|January 2015|Anticipated|July 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|241000|||Both|N/A|N/A|No|Probability Sample|Approximately 15,000 patients who were continuously enrolled during the calendar years        2006 and 2010 in the Generations Plus/ Northern Manhattan Health Network and 226,000        members of a large self insured union trust fund from 2007-2010 will be combined. The data        will include age, gender, length of plan enrollment, whether or not the patient is        disabled, their diagnoses, and their use of medical and social services.|August 2013|August 29, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761253||73565|
NCT01761266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-304|A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma|A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma||Eisai Inc.|Yes|Active, not recruiting|March 2013|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|954|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761266||73564|
NCT01761786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGxSTEMI05|Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment|Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).|POPGenetics|St. Antonius Hospital|Yes|Recruiting|June 2011|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2700|||Both|22 Years|N/A|No|||January 2013|January 11, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01761786||73524|
NCT01762046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p000193|Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans|Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans|SUGAR-MGH|Massachusetts General Hospital|Yes|Recruiting|January 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1000|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762046||73504|
NCT01762618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOCUIDA/FPM-0211|Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients|Experimental Study of the Impact of a Structured Psychological Intervention Based on Group Therapy for Caregivers of Alzheimer's Patients.|EMOCUIDA|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Completed|January 2012|July 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|83|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01762618||73460|
NCT01764074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRG-0-071-11|Brief Sleep Intervention for Bipolar Disorder|Brief Sleep Intervention for Suicide in Bipolar Disorder||Massachusetts General Hospital|Yes|Active, not recruiting|January 2013|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764074||73348|
NCT01763216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR013908|Improving Mood in Assisted Living Settings|Improving Mood in Assisted Living Settings Using a Cognitive Training Intervention||University of Iowa|No|Active, not recruiting|February 2013|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 11, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763216||73414|
NCT01763840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00004754|Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma|Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma||Children's Hospital Boston|No|Recruiting|April 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|2 Years|35 Years|No|||July 2015|July 27, 2015|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763840||73366|
NCT01764139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1689|Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes|Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes or Who Did Not Improve Symptoms Following Minor Knee Arthroscopic Procedures||Mid Essex Hospital NHS Trust|Yes|Terminated|March 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|40 Years|No|Non-Probability Sample|Male & no pregnant female age between 18-40 yrs, who continue to experience knee pain        following normal to Grade 2 knee arthroscopy findings.|March 2016|March 15, 2016|January 7, 2013||No|Lack of patients with recruitment criteria|No||https://clinicaltrials.gov/show/NCT01764139||73343|
NCT01764399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522-12-FB|Care4U: Self Management Intervention for Older Adult Caregivers|||University of Nebraska|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|65 Years|N/A|No|||December 2014|December 12, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764399||73323|
NCT01752881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU12T13A|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects||Adimmune Corporation|No|Completed|August 2012|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752881||74206|
NCT01753440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA_CTL_01|Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy|Study on the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Implantation Combined With Bypass Grafting in Patients With Coronary Artery Disease and Ischemic Cardiomyopathy.||AHEPA University Hospital|No|Recruiting|November 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2013|November 27, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01753440||74163|
NCT01753713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4312|Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma|Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)||Case Comprehensive Cancer Center|Yes|Active, not recruiting|December 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753713||74142|
NCT01754337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-03|Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Glucose Levels During 24 Hours in Adults and Adolescents With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|12 Years|N/A|No|||July 2014|July 3, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754337||74094|
NCT01754922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1079-P|Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function|Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function|AirHzds|VA Office of Research and Development|Yes|Completed|November 2013|December 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|53|None Retained|No biospecimens will be collected|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, outpatient clinic|January 2016|January 21, 2016|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754922||74049|
NCT01754610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040466|Strengthening Family Coping Resources Open Trials|Strengthening Family Coping Resources Open Trials|SFCR|University of Maryland|Yes|Recruiting|February 2006|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|1 Year|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|December 2015|December 7, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01754610||74073|
NCT01754909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-004-12S|Mitigation of Radiation Pneumonitis and Fibrosis|Mitigation of Radiation Pneumonitis and Fibrosis||VA Office of Research and Development|Yes|Recruiting|November 2013|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|200|||Both|35 Years|85 Years|No|||November 2015|November 4, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01754909||74050|
NCT01755390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED6189|A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors|A Phase I Dose Finding Study of XRP6258 Administered as a Weekly 1-hour Intravenous Infusion to Patients With Advanced Solid Tumors||Sanofi|No|Completed|October 1999|October 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||December 2012|December 21, 2012|December 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755390||74013|
NCT01761279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2009/046|High Definition Endoscopy With i-Scan for Small Colonic Polyp Evaluation: The HiScope Study|A Prospective Single-blind Observational Cohort Study of High Definition White Light Endoscopy and i-Scan Image Enhancement for the Characterisation of Small Colonic Polyps|HiSCOPE|Portsmouth Hospitals NHS Trust|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|60 Years|74 Years|No|Non-Probability Sample|UK Bowel Cancer Screening patients attending for colonoscopy|February 2013|February 25, 2013|January 3, 2013||No||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01761279||73563|Single centre study. Single endoscopist.
NCT01761513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-107|YH4808 Postprandial PK/PD Study in Healthy Subjects|A Randomized,Open Label,Active-controlled, Multiple Dosing and Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of YH4808 After Postprandial Oral Administration in Healthy Volunteers||Yuhan Corporation|No|Completed|November 2012|February 2014|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761513||73545|
NCT01761526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0717|Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects|Parallel Group Trial to Evaluate the Pharmacokinetics and Safety / Tolerability of Single-Dose Treatment With Rotigotine Continuous Delivery System (10 cm2 / 4.5 mg) in Japanese and Caucasian Healthy Subjects||UCB Pharma|No|Completed|October 2002|December 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|50|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|October 17, 2014|January 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01761526||73544|
NCT01761799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060292|Protecting Pregnant Women From Infectious Diseases|Protecting Pregnant Women From Infectious Diseases: a Cluster Randomized Evaluation of the Comprehensive "P3" Intervention Package Within Obstetric Practices in Georgia||Emory University|No|Completed|December 2012|August 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|330|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01761799||73523|
NCT01762059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002317|Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas|The Beacon Hill Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas||Massachusetts General Hospital|Yes|Active, not recruiting|January 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|N/A|No|||December 2013|December 4, 2013|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762059||73503|
NCT01762072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.30972464|Effect of Vitamin B12 and n-3 Polyunsaturated Fatty Acids on Plasma Homocysteine|||Zhejiang University|Yes|Not yet recruiting|January 2013|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|30|||Both|20 Years|28 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01762072||73502|
NCT01762371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KhalSbg1|Khalifa Acute Effects|Interdisciplinary Evaluation of Acute Effects From Khalifa's Therapy at Patients With Fully Ruptured Anterior Cruciate Ligament (ACL).||Medical University of Graz|Yes|Completed|December 2012|February 2014|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Male|18 Years|49 Years|No|||May 2015|May 4, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762371||73479|
NCT01763476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCAT(2)|Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions|Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions|ADCAT|Herz-Zentrums Bad Krozingen|Yes|Recruiting|January 2013|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|No|||August 2015|August 10, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763476||73394|
NCT01763788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14461|A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|189|||Both|20 Years|N/A|No|||February 2016|February 25, 2016|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763788||73370|
NCT01763229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1107-116-371|The Practical Use of Transthoracic Echocardiography for Obtaining an Optimal Depth of Internal Jugular Venous Catheters in Infants|||Seoul National University Hospital|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|108|||Both|N/A|1 Year|No|||May 2014|May 12, 2014|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763229||73413|
NCT01763515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13913008|Laterally Wedged Insoles for Patients With Knee Osteoarthritis|The Effects of Laterally Wedged Insoles on Symptoms Reduction of Patients With Knee Osteoarthritis||Isfahan University of Medical Sciences|No|Enrolling by invitation|October 2012|October 2013|Anticipated|August 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||January 2013|January 8, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01763515||73391|
NCT01763853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0134|Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)|Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)|IROCA|University Hospital, Clermont-Ferrand||Recruiting|December 2012|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01763853||73365|
NCT01764152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-57|Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)|Efficiency in Population of Influenza Vaccination for Seasonal 2012-2013 for Flu Prevention of the Hospitalized Adults: an Observational Study|FLUVAC EV-02|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|December 2012|May 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2012|January 7, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01764152||73342|
NCT01764672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005339-95|Effect of Methylphenidate on Connectivity|Effects of Methylphenidate on Resting State Connectivity in Healthy Controls and in Adults With Attention Deficit Hyperactivity Disorder.||UMC Utrecht|No|Withdrawn|April 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01764672||73302|
NCT01753453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12858|An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells|A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell (Plasma Cell) Mobilization and Apheresis Product Contamination in Plerixafor Plus Non-pegylated G-CSF Mobilized Patients and in Non-pegylated G-CSF Alone Mobilized Patients||Sanofi|No|Active, not recruiting|June 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753453||74162|
NCT01754064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 366|St. Jude Medical Product Longevity and Performance (SCORE) Registry|St. Jude Medical Product Longevity and Performance (SCORE) Registry||St. Jude Medical|No|Active, not recruiting|November 2007|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10957|||Both|18 Years|N/A|No|Probability Sample|Any patient indicated for a cardiac rhythm management (CRM) product like ICD, pacemaker,        CRT-D, CRT-P, leads, etc. would be eligible for participation in the study.|October 2015|October 6, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754064||74115|
NCT01754623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16932|GTX-RT in Borderline Resectable Pancreatic Cancer|Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated With Induction Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT)||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|February 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2015|August 6, 2015|December 18, 2012|Yes|Yes|Lack of pre-treatment tissue to make the study plan feasible.|No|June 17, 2015|https://clinicaltrials.gov/show/NCT01754623||74072|The study only accrued 9 (of planned 35) participants. It was not possible to collect adequate pre-treatment tissue for radiosensitivity index (RSI) analysis, pre-treatment. The study was terminated before planned completion.
NCT01754636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 11006|Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials|Elderly Patients With Colorectal Cancer in Clinical Trials: Factors Associated With Non Inclusion|SAGE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|696|||Both|18 Years|N/A|No|Non-Probability Sample|Population: all patients aged 18 years or more with a colorectal cancer followed in one of        the participating centers (amendment n°3 - 02/2014)|July 2015|July 30, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754636||74071|
NCT01765257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0138|Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study|Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.||University Hospital, Clermont-Ferrand||Not yet recruiting|June 2013|March 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|70 Years|No|||January 2013|January 9, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765257||73257|
NCT01765530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-ETT cleaning|Efficacy Study of a Novel Device to Clean the Endotracheal Tube|Endotracheal Tubes Cleaned With a Novel Mechanism for Secretions Removal||Massachusetts General Hospital|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|99 Years|No|||January 2014|December 4, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01765530||73236|
NCT01755403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINEBENZ|Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease|Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.|CINEBENZ|Barcelona Centre for International Health Research|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|60 Years|No|||May 2015|May 25, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755403||74012|
NCT01755416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-503|Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting|Phase 1 Study of Medtronic Closed Loop Device With ePID Algorithm and Enlite Sensors on Adjuvant Therapy With Insulin and Liraglutide to Minimize Post-prandial Hyperglycemia||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|40 Years|No|||June 2015|June 22, 2015|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755416||74011|
NCT01755676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL60EMS0511|Evaluation of Orlistat Versus Placebo for Adult Obesity Treatment|A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg for Adult Obesity Treatment Compared to Placebo Treatment.||EMS|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||November 2015|November 9, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01755676||73991|
NCT01755689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113823|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age||GlaxoSmithKline||Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|1300|||Female|9 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755689||73990|
NCT01755988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-456|Effectiveness of a Website and Telemonitoring in Patients With Heart Failure.|Effectiveness of an Interactive Web-based Platform and a Disease Specific Information Website in Patients With Heart Failure: a 3-arm Randomised Trial.||UMC Utrecht|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|414|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01755988||73968|
NCT01761292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/11/2357/43|A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givinostat in Ambulant Children With DMD|A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy||Italfarmaco|No|Active, not recruiting|May 2013|August 2017|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|7 Years|11 Years|No|||February 2016|February 23, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01761292||73562|
NCT01761539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00499|Moderate Versus Aggressive Fluids for Acute Pancreatitis|Moderate Versus Aggressive Fluid Therapy in Patient With Mild to Moderate Acute Pancratitis||University of Southern California|Yes|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2015|January 2, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761539||73543|
NCT01761812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334-2011|Multiparametric MRI for Prostate Cancer Localization and Characterization: New Methods|Determining the Extent and Grade of Prostate Cancer Using MR Elastography, Diffusion Weighted Imaging, and Dynamic Contrast Enhanced MRI With Gadofosveset||Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|September 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||November 2014|November 24, 2014|January 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761812||73522|
NCT01762085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20122035|Nerve Decompression for Ulcer Recurrence Avoidance (DURA)|A Prospective Study of Recurrence Risk in Diabetic Foot Ulceration After Nerve Decompression|DURA|Association of Extremity Nerve Surgeons|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||June 2015|June 25, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762085||73501|
NCT01762644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRL001-PB-01|The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients|A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.|IIT|Perle Bioscience, Inc.|No|Not yet recruiting|August 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Both|10 Years|20 Years|No|||July 2015|July 9, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01762644||73458|
NCT01763203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5155 U54-NS081764|The SUCCEED Trial of Secondary Stroke Prevention|Secondary Stroke Prevention by Uniting Community and Chronic Care Model Teams Early to End Disparities: the SUCCEED Trial|SUCCEED|University of California, Los Angeles|Yes|Enrolling by invitation|September 2013|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|40 Years|N/A|No|||June 2015|June 7, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763203||73415|
NCT01762956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/2015|Pelvic Floor Muscles Training in Men Undergoing Radiotherapy for Prostate Cancer: Randomized Controlled Trial|Pelvic Floor Muscles Training in Men Undergoing Radiotherapy for Prostate Cancer: Randomized Controlled Trial||University of Sao Paulo|No|Recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Male|45 Years|N/A|No|||August 2015|August 17, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762956||73434|
NCT01763528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|high protein in women|High Protein Weight Loss Diet, High Sensitivity C-Reactive Protein and Cardiovascular Risks Among Obese Women|High Protein Diet , CRP and CVD Risk Factors||Isfahan University of Medical Sciences|Yes|Completed|January 2011|August 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|63|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01763528||73390|
NCT01763866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110115|LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2|A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia|LAPLACE-2|Amgen|Yes|Completed|January 2013|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|24||Actual|2067|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|January 7, 2013|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01763866||73364|
NCT01764685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816082|Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers||University of Pennsylvania|No|Terminated|January 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|January 4, 2013||No|We terminated the study due to problems recruiting alcoholic subjects with HIV.|No|August 7, 2015|https://clinicaltrials.gov/show/NCT01764685||73301|We closed our enrollment before meeting recruitment goals, due to difficulties with recruitment. We didn't analyze our data, due to a sample size of 4, that were all randomized to placebo group and only 3 of the 4 completed the study procedures.
NCT01754350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGO2|Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma|Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study|ERGO2|Johann Wolfgang Goethe University Hospitals|No|Recruiting|May 2013|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01754350||74093|
NCT01754649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicamp/2012/LB|Use of Misoprostol in Case of Insertion Failure of Intrauterine Contraceptives|Assessment of Use of Misoprostol to Facilitate the Insertion of Intrauterine Contraceptives After Failure of Insertion. A Randomized Double-blind Clinical Trial||University of Campinas, Brazil|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754649||74070|
NCT01765543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28052|A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib||Hoffmann-La Roche||Recruiting|July 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01765543||73235|
NCT01765556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28054|A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma|A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib||Hoffmann-La Roche||Withdrawn|October 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01765556||73234|
NCT01761448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-020|Heart Cycle GEx (Guided- Exercise- Main Trial)|Guided Exercise (GEx) for CAD Patients|GEx|RWTH Aachen University|No|Completed|February 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|18 Years|90 Years|No|||November 2013|November 26, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01761448||73550|
NCT01761669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitamin D|Does Deficiency in Vitamin D Induced Hypercoagulation or Thrombin Generation|||HaEmek Medical Center, Israel|Yes|Completed|April 2013|July 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|400 healthy volunteers|December 2014|December 18, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01761669|3 Months|73533|
NCT01761682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-HEMREG-ALL|Acute Lymphoblastic Leukemia Registry at Asan Medical Center|Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center||Asan Medical Center|No|Recruiting|January 2013|December 2047|Anticipated|December 2047|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1400|Samples With DNA|Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected,      processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of      biospecimens will be proceeded if patient agree with the informed consent for donation of      biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data      will be used as a basic demographic and clinical information for the biospecimens.|Both|15 Years|N/A|No|Non-Probability Sample|Patients who are diagnosed and/or treated with acute lymphoblastic leukemia at Asan        Medical Center, Seoul, Korea|July 2015|July 1, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761682|10 Years|73532|
NCT01761942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/2011|Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa|A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa|FASAN|Institute of Psychiatry and Neurology, Warsaw|Yes|Recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|12 Years|19 Years|No|||January 2013|January 3, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761942||73512|
NCT01762228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUTUA-12|Efficacy of Two Interventions Increasing Sensory Stimulus in Elderly Patients With Oropharyngeal Dysphagia|Randomized Controled Clinical Study to Evaluate the Efficacy of the Increase of the Sensorial Stimuli as a Therapeutic Strategy for the Treatment of Elderly Patients With Oropharyngeal Dysphagia.||Hospital de Mataró|Yes|Completed|November 2012|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|70 Years|N/A|No|||March 2015|March 17, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01762228||73490|
NCT01761552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0513-12-HMO|A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients|A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients.||Hadassah Medical Organization||Recruiting|August 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2012|September 8, 2013|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761552||73542|
NCT01761565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP101|Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab|Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects||AcelRx Pharmaceuticals, Inc.|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|January 3, 2013|No|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01761565||73541|
NCT01761825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-JG-547-CTIL|The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome|The Effect of "Funny" Channel Blocker Ivabradine on Patients With Postural Tachycardia Syndrome.||Tel-Aviv Sourasky Medical Center||Enrolling by invitation|December 2012|||February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||January 2013|January 3, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01761825||73521|
NCT01762657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perle-1102|The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes|A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate the Safety and Efficacy in Diminishing Insulin Requirements Utilizing Oral Cyclosporine With Oral Lansoprazole in Children and Adults With Existing Type 1 Diabetes Mellitus|IIT|Perle Bioscience, Inc.|No|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|60 Years|No|||November 2013|October 3, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01762657||73457|
NCT01762943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1758|Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition|Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition||University of North Carolina, Chapel Hill|Yes|Recruiting|August 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|32|||Female|22 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762943||73435|
NCT01762670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA 1106|GoldenCareTM for the Treatment of Bacterial Vaginosis|An Open-Label, Randomized Study to Determine the Safety and Efficacy of GoldenCareTM for the Treatment of Bacterial Vaginosis||CDA Research Group, Inc.|No|Terminated|February 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|80 Years|No|||July 2013|February 2, 2015|January 4, 2013|Yes|Yes|Company decided to stop study for reasons other than safety|No||https://clinicaltrials.gov/show/NCT01762670||73456|
NCT01763242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC: 2010.267|Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease|EMAN-Anaemia: An Open Labelled Randomised Control Trial of the Synchronized Electronic MANagement of Anaemia in Chronic Kidney Disease (CKD) Compared to Usual Care Anaemia Management|EMAN-Anaemia|Western Health, Australia|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2013|January 6, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01763242||73412|
NCT01763541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002337|Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading|Gonadal Steroid Regulation of the Natriuretic Peptide System||Massachusetts General Hospital|Yes|Withdrawn|June 2014|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01763541||73389|
NCT01757028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9RPET0|Risk Factors for Severe Morbidity and Mortality in Mothers and Neonates|Risk Factors for Severe Morbidity and Mortality in Mothers and Neonates|KIPMAT|University of Oxford|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|4600|Samples With DNA|Cord blood Maternal blood|Female|N/A|N/A|No|Probability Sample|All mothers admitted for delivery at Kilifi District Hospital (KDH), Kilifi, Kenya|December 2014|December 18, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01757028||73889|
NCT01757041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9RUHL0|The Clinical and Molecular Epidemiology of Streptococcus Agalactiae Colonisation on the Kenyan Coast|The Clinical and Molecular Epidemiology of Streptococcus Agalactiae (Group B Streptococcus)Maternal Colonisation and Association With Adverse Perinatal Outcomes|GBS|University of Oxford|No|Completed|September 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7967|||Female|N/A|N/A|No|Probability Sample|Mothers admitted for delivery to participating health centres (Kilifi District Hospital,        Coast Provincial General Hospital, Bamba sub-District Hospital, Ganze Health Facility).|December 2014|December 18, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01757041||73888|
NCT01764412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01122-41|Study of Serum Hepcidin Rate Variations During Menstrual Cycle|Study of Serum Hepcidin Rate Variations During Menstrual Cycle|HEPMEN|Rennes University Hospital|No|Completed|March 2013|February 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|Samples Without DNA|Hepcidin Serum iron Transfferin saturation Serum transfferin Serum ferritin|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women|August 2014|March 27, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764412||73322|
NCT01764425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7435/66/11|Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight and/or Obese Subjects||Piramal Enterprises Limited|No|Terminated|May 2012|February 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 8, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01764425||73321|
NCT01757574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMIMD01108IST|Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)|An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)||Johns Hopkins University|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||December 2012|December 23, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01757574||73847|
NCT01757587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001813-14|Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin|Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled by Metformin and Basal Insulin, This One Having Been Properly Titrated.||Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|December 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01757587||73846|
NCT01754363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10008|Survivorship of Attune Primary Total Knee Prosthesis|Short, Medium and Long Term Survivorship of Attune Primary Knee Prosthesis||DePuy International|No|Active, not recruiting|February 2013|February 2030|Anticipated|February 2030|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|22 Years|75 Years|No|||July 2015|July 27, 2015|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754363||74092|
NCT01764997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11574|An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate|A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX|RA-COMPARE|Sanofi|Yes|Terminated|April 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|452|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 8, 2013|Yes|Yes|Internal company decision not related to any safety issue. Due to operational feasibility,    delays incurred to date, lack of ability for timely results vs plan|No||https://clinicaltrials.gov/show/NCT01764997||73277|
NCT01761461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-06-061|Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial||ARTIST-II|Samsung Medical Center|Yes|Recruiting|January 2013|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|900|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761461||73549|
NCT01761721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-FSP26|Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics|Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics|RALH|Copenhagen University Hospital at Herlev|No|Completed|January 2013|February 2016|Actual|February 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|139|||Female|N/A|N/A|No|Non-Probability Sample|Women suspected of endometrial cancer and treated with robot-assisted laparoscopic        hysterectomy at Copenhagen University Hospital, Herlev.|February 2016|February 2, 2016|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761721|4 Months|73529|
NCT01761734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK5058|Pilot Text Message for Influenza Vaccination|Pilot Study of Text Message Reminders for Flu Vaccine For Adults||Columbia University|No|Completed|January 2013|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1000|||Both|18 Years|N/A|No|||June 2014|June 22, 2014|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01761734||73528|
NCT01761994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0220|The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy|||Yonsei University|No|Completed|September 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|80 Years|No|||January 2013|January 3, 2013|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01761994||73508|
NCT01761435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TraNsgripe1-2|Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination|Randomized, Comparative and Prospective Clinical Trial Evaluating Efficacy and Safety of a Dose of Seasonal Flu Vaccine Compared to Two Doses of Vaccine for Prevention of Influenza in Solid Organ Transplant Recipients|TraNsgripe|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|499|||Both|16 Years|N/A|No|||April 2015|April 30, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01761435||73551|
NCT01761695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-HEMREG-CML|Chronic Myelod Leukemia Registry at Asan Medical Center|Prospective Observational Cohort Registry for Patients With Chronic Myeloid Leukemia at Asan Medical Center||Asan Medical Center|No|Recruiting|January 2013|December 2047|Anticipated|December 2047|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1050|Samples With DNA|Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected,      processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of      biospecimens will be proceeded if patient agree with the informed consent for donation of      biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data      will be used as a basic demographic and clinical information for the biospecimens.|Both|15 Years|N/A|No|Non-Probability Sample|Patients who are diagnosed and/or treated with chronic myeloid leukemia at Asan Medical        Center, Seoul, Korea|July 2015|July 1, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761695|30 Years|73531|
NCT01761955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J2008:075|Metabolic Health Benefits of Dairy Protein|Metabolic Health Benefits of Dairy Protein||University of Manitoba|Yes|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2008|January 9, 2013|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01761955||73511|
NCT01761591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Svelte_13-002|Acrobat Coronary Stent System Effectiveness European Study|Acrobat Coronary Stent System Effectiveness European Study (European Multicenter Effectiveness Randomized Study of Svelte Medical Systems Acrobat Stent on a Wire Compared to Other BMS PCI in de Novo Coronary Lesions) ACES Trial|ACES|Svelte Medical Systems Europe|No|Terminated|December 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|December 12, 2012||No|Difficulty to identify eligible patients: 8 centers contributed 54 patients in 6 months.|No||https://clinicaltrials.gov/show/NCT01761591||73539|
NCT01762098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-12-20|Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization|Prevalence of Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization||OVO R & D|Yes|Completed|November 2012|May 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|100|||Female|18 Years|45 Years|No|Non-Probability Sample|Population with recurrent miscarriage or repeated embryo implantation failures.|July 2015|July 24, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762098||73500|
NCT01762631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12035|Remote Food Photography Method in Infants|Baby Bottle: Remote Food Photography Method in Infants|BabyBottle|Pennington Biomedical Research Center|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Up to 75 men and women will be recruited to participate in a 2-week pilot study involving        infant formula preparation. Participation is open to all adult individuals.|March 2016|March 24, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01762631||73459|
NCT01762969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML-IS001|Treatment Modification Based on Early Assessment of CML Patients|Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients||Rabin Medical Center|No|Recruiting|January 2013|January 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|16 Years|N/A|No|||January 2013|January 7, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01762969||73433|
NCT01762995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116898|A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects|A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects||ViiV Healthcare|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|April 18, 2013|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01762995||73431|
NCT01763255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-003|Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy|The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy||Royan Institute|Yes|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|4 Years|12 Years|No|||January 2011|April 24, 2014|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01763255||73411|
NCT01764165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL105546-01|Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD)|Pathogenesis and Outcomes of Sleep Disordered Breathing in COPD||Johns Hopkins University|Yes|Recruiting|August 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01764165||73341|
NCT01757288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062012-053|A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC|A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2013|December 2019|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757288||73869|
NCT01757301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-095|Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) Trial|Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) Trial|CAMMPS|VA Office of Research and Development|Yes|Enrolling by invitation|January 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01757301||73868|
NCT01764698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7K23DA031677|Delivery of Anxiety Disorder Treatment in Addictions Centers|Adaptation of CALM for Comorbid Anxiety and Substance Use Disorders||University of California, Los Angeles|No|Recruiting|November 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||February 2016|February 29, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01764698||73300|
NCT01765270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041744|Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery|Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial|MAPSS|Duke University|No|Terminated|March 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|12|||Both|45 Years|75 Years|No|||April 2015|May 7, 2015|January 4, 2013|Yes|Yes|The study was stopped due to poor enrollment.|No|April 23, 2015|https://clinicaltrials.gov/show/NCT01765270||73256|Early termination leading to small numbers of subject analyzed.
NCT01752725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04122012|Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)|Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH): A Prospective, Controlled, Randomized, Non-inferiority in Vivo Human Study.||University Hospital Tuebingen|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||December 2012|December 14, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01752725||74218|
NCT01761708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Re-situp|Case-control Study of Mesh-infection After a Size Tailored Hernia Repair With C-Qur V-Patch|Case-control Study of Mesh-infection After a Size Tailored Hernia Repair With C-Qur V-Patch|Re-SITUP|Algemeen Ziekenhuis Maria Middelares|No|Active, not recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|community sample|January 2013|January 3, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761708|12 Months|73530|
NCT01761968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/11/2357/44|Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms|Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms||Italfarmaco|No|Recruiting|March 2013|December 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01761968||73510|
NCT01761981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1900|Institutional Registry of Haemorrhagic Hereditary Telangiectasia|Institutional Registry of Haemorrhagic Hereditary Telangiectasia||Hospital Italiano de Buenos Aires|No|Recruiting|June 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Patients with Haemorrhagic Hereditary Telangiectasia|December 2015|December 16, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761981||73509|
NCT01762254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2009-023|Prospective Randomized Trial of Incisionless Versus Conventional Laparoscopic Colectomy for Left-sided Colonic Tumors|Prospective Randomized Trial of Incisionless Versus Conventional Laparoscopic Colectomy for Left-sided Colonic Tumors||Pamela Youde Nethersole Eastern Hospital|No|Completed|June 2009|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01762254||73488|
NCT01762267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASH in corton therapy|Effects of DASH Diet on Corticosteroids Medication Use|Phase 3 Study of Beneficiary Effects of Dietary Approaches to Stop Hypertension (DASH) on the Metabolic Aeffects of Corticosteroids Medications Use||Isfahan University of Medical Sciences|Yes|Completed|January 2011|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|62|||Female|27 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01762267||73487|
NCT01762111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-12-22|AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol|AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol||OVO R & D|Yes|Suspended|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|918|||Female|18 Years|43 Years|No|Non-Probability Sample|Women followed at the clinique ovo, aged between 18 and 43 years old undergoing a        stimulate In-Vitro Fertilization cycle.|June 2013|June 21, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762111||73499|
NCT01762410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7170/70/11|Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors|An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.||Piramal Enterprises Limited|No|Suspended|September 2012|March 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|December 20, 2012|No|Yes|Sponsor decision not related to patient safety|No||https://clinicaltrials.gov/show/NCT01762410||73476|
NCT01762683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRUSSI-AOI-2011|Influence of Preconceptional Obesity on the Myometrial Cells Differentiation Toward a Contractyl Phenotype|Study of Role of Mononuclear Cells of Maternal Peripheric Blood in Human Myometrial Primar Cell Lines Differentiation Toward a Contratyl Phenotype: Influence of Preconceptional Obesity|ObeDi|Centre Hospitalier Universitaire Dijon|No|Recruiting|April 2012|||November 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01762683||73455|
NCT01762384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-05|Laparoscopic Sacral Colpopexy Versus Modified Total Pelvic Floor Reconstructive Surgery for Apical Prolapse Stage III-IV|Nationwide Multicenter Randomized Prospective Study to Compare Laparoscopic Sacral Colpopexy and Modified Total Pelvic Floor Reconstructive Surgery With Mesh for Apical Prolapse Stage III-IV||Peking Union Medical College Hospital|No|Recruiting|December 2012|December 2017|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|55 Years|65 Years|No|||December 2012|January 4, 2013|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01762384||73478|
NCT01762397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-S005|A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers||PharmaKing||Completed|December 2012|||May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|37|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01762397||73477|
NCT01763008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016972|A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Doripenem Among Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections||Janssen Pharmaceutica|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|170|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include adult Filipino patients who are diagnosed with        nosocomial pneumonia, complicated intra-abdominal infections and complicated urinary tract        infections, and who are eligible for doripenem treatment.|August 2013|August 6, 2013|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763008||73430|
NCT01763268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trivivac2012|Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants|||Queen Sirikit National Institute of Child Health||Recruiting|September 2012|August 2015|Anticipated|January 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|9 Months|14 Months|Accepts Healthy Volunteers|||January 2013|January 5, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763268||73410|
NCT01760928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9478|Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain|Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain||Universitaire Ziekenhuizen Leuven|No|Completed|January 2009|September 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|18|Samples With DNA|induced sputum cells and peripheral blood sample|Both|18 Years|65 Years|No|Non-Probability Sample|asthmatics with well-controlled asthma|January 2013|January 2, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01760928||73590|
NCT01761188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201|the Study of STABLE_SR for Persistent Atrial Fibrillation|The Study of CPVI Plus Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm (STABLE-SR) for the Treatment of Persistent Atrial Fibrillation|STABLE-SR|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|June 2013|January 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|80 Years|No|||June 2013|June 22, 2013|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01761188||73570|
NCT01757054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4141001|Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement|Randomized, Two Arm, Parallel Group, Open Label, Single Center Prospective Study of the Fecal Recovery of Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis (BB-12) in Healthy Humans Following Daily Consumption of ProNutrients Probiotic Powder Sachet|LGG BB-12|Pfizer|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01757054||73887|
NCT01757067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53625 Evac-HF|Early Elimination of Premature Ventricular Contractions in Heart Failure|EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.|EVAC-HF|University of Maryland|Yes|Not yet recruiting|January 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||December 2012|December 31, 2012|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757067||73886|
NCT01757639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02990|Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease||National Cancer Institute (NCI)|Yes|Recruiting|December 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2015|January 12, 2016|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757639||73842|
NCT01764711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120612|Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)|Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome Participating in the Dietary Salt in Orthostatic Tachycardia Study.||Vanderbilt University||Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764711||73299|
NCT01765010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-ENDO-2013|The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels|Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels||Seoul National University Hospital|Yes|Recruiting|January 2013|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|88|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765010||73276|
NCT01765023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_ATM_101|Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects|An Open-label, Fixed-sequence Study to Evaluate Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects||CJ HealthCare Corporation|No|Completed|October 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 7, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01765023||73275|
NCT01765296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG100649-3-01|Phase III Study of CG100649 in Osteoarthritis Patients|A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients||CrystalGenomics, Inc.|No|Recruiting|March 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|350|||Both|20 Years|N/A|No|||April 2013|April 27, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765296||73254|
NCT01765582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28442|STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer|STEAM (SEQUENTIAL TRIPLET AND AVASTIN MAINTENANCE): FOLFOXIRI/BEVACIZUMAB REGIMENS (CONCURRENT AND SEQUENTIAL) VS. FOLFOX/BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL CANCER||Hoffmann-La Roche||Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765582||73232|
NCT01765595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHS012013|Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System for Minimizing Severe Drug-Drug Interactions||DDI+|Leumit Health Services||Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|715|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 20, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765595||73231|
NCT01756859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12092|MRI in Portal Hypertension|Quantitative Magnetic Resonance Imaging (MRI) Techniques in the Evaluation and Estimation of Portal Hypertension|MRQuee|University of Nottingham|No|Recruiting|January 2013|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|49|Samples Without DNA|Blood, urine and stool samples.|Both|18 Years|N/A|No|Probability Sample|Participants will be recruited from liver services from Nottingham University Hospitals        NHS Trust and Derby Hospitals NHS Foundation Trust. All the patients will have had HVPG        measurements performed for clinical indications.|January 2014|January 14, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756859||73902|
NCT01752738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54909|Intestinal Transport of Microbial Metabolites in Chronic Kidney Disease|The Influence of Chronic Kidney Disease on Intestinal Transport of Gut Microbial Metabolites||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients will be recruited from the nephrology outpatient clinic and dialysis center at        University Hospital Leuven, Belgium.|December 2014|December 2, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01752738||74217|
NCT01753024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STPH-ICU-002|Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients|The Incidence of Pancreatic Exocrine Insufficiency and the Benefits of Pancreatic Enzyme Supplementation in Critically Ill Adult Patients||Shanghai 10th People's Hospital|Yes|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|1200|Samples Without DNA|Blood samples: lactate, hemoglobin, total bilirubin, trypsin, Vit D, etc. Stool samples: 24h      fecal fat; fetal elastase-1; Fecal chymotrypsin. Nutrition status: BMI, weight loss,      biomarkers such as albumin and prealbumin, etc.      Radiological assessments: MRCP & CT scanning.|Both|18 Years|80 Years|No|Probability Sample|All critically ill patients who are able to receive early enteral nutrition and estimated        to stay in ICU at least four days|September 2013|September 28, 2013|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01753024|2 Weeks|74195|
NCT01762280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-I|A Phase I Study of Famitinib Malate in Patients With Solid Tumor|A Phase I Study of Famitinib Malate in Patients With Solid Tumor||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|June 2009|||January 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01762280||73486|
NCT01762514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMF-BYA-02|A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens|A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday||Sun Yat-sen University|Yes|Recruiting|January 2013|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|360|||Both|18 Years|75 Years|No|||July 2013|July 2, 2013|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01762514||73468|
NCT01753869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12025JB-AS|Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis|Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis||Belfast Health and Social Care Trust|No|Recruiting|December 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||August 2014|August 9, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753869||74130|
NCT01753882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00056589|Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)|Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury||Rehabilitation Institute of Chicago|No|Recruiting|February 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|75 Years|No|||September 2015|September 8, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753882||74129|
NCT01762124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10022972DOC|Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)|Native Outflow Tract Transcatheter Pulmonary Valve Research Clinical Study||Medtronic Cardiovascular|Yes|Active, not recruiting|October 2012|May 2020|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||October 2015|October 20, 2015|November 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01762124||73498|
NCT01762137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO18426|LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy|LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy|LARGE|Medical University of South Carolina|Yes|Recruiting|February 2013|October 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|316|||Both|21 Years|75 Years|No|||September 2015|October 1, 2015|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762137||73497|
NCT01762423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12070504|PEMF Effects on Pain After Abdominal Body Contouring|PEMF Effects on Pain After Abdominal Body Contouring|PEMF|University of Pittsburgh|Yes|Withdrawn|December 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|January 3, 2013|Yes|Yes|Funding issues.|No||https://clinicaltrials.gov/show/NCT01762423||73475|
NCT01762696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA030535-01A1|A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth|A Real-time, Contextual Intervention Using PDAs to Reduce Marijuana Use in Youth|MOMENT|Children's Hospital Boston|Yes|Enrolling by invitation|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|15 Years|24 Years|No|||February 2015|February 2, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762696||73454|
NCT01762709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012080|Low Tidal Volume and EVLWI During OLV|Effects of Different Tidal Volumes on Extravascular Lung Water Content During One-lung Ventilation for Video-assisted Thoracoscopic Surgery: Dammam University Experience||Dammam University|Yes|Completed|April 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Female|18 Years|60 Years|No|||July 2013|July 24, 2013|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01762709||73453|
NCT01763554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV-LUT-001|Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and July 31, 2012|Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and July 31, 2012||AHS Cancer Control Alberta|No|Active, not recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|69|||Both|14 Years|90 Years|No|Non-Probability Sample|Limited to those subjects with neuroendocrine tumors who received Lu-177 DOTA-TATE between        January 2010 and July 2012 at the Cross Cancer Institute.|March 2016|March 14, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01763554||73388|
NCT01763879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012081|Pressure-controlled vs Volume Controlled Ventilation on RV Function During OLV|Right Ventricular Function During One-lung Ventilation: The Effects of Pressure Controlled and Volume Controlled Ventilation||Dammam University|Yes|Completed|April 2012|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||July 2013|July 24, 2013|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01763879||73363|
NCT01757080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|etiene|Cardiorespiratory Performance in Diabetic Elderly|||Universidade Federal de Pernambuco|Yes|Completed|January 2012|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|40|||Both|60 Years|85 Years|No|||October 2012|December 20, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01757080||73885|
NCT01757340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRL-201102153|Calorie Restriction With Leucine Supplementation|Calorie Restriction With Leucine Supplementation in Postmenopausal Women||Washington University School of Medicine|Yes|Recruiting|September 2012|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01757340||73865|
NCT01757314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001193|Comparing Palpation Guided and Ultrasound Guided Arterial Line Placement|A Prospective Study Comparing Palpation Guided and Ultrasound Guided Arterial Catheter Placement by Anesthesiology Residents in Training||Rutgers, The State University of New Jersey|No|Terminated|October 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4|||Both|25 Years|35 Years|No|Probability Sample|CA 1 and CA 2 residents assigned to surgical patients who require arterial lines due to        complex surgical procedures|September 2015|September 11, 2015|September 27, 2012||No|already several publications in the literature|No||https://clinicaltrials.gov/show/NCT01757314||73867|
NCT01757327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310007|LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer|A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer||Washington University School of Medicine|No|Withdrawn|April 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|December 20, 2012|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT01757327||73866|
NCT01757665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02|ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)|ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)|COMMENCE|Edwards Lifesciences|Yes|Recruiting|December 2012|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1025|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757665||73841|
NCT01757678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-902-001|HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography|HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography: NeXt sTeps|HFNXT|HeartFlow, Inc.|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|254|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757678||73840|
NCT01765036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004676-44|Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma|Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma: Results of the First Multicenter Prospective Study With Intra- and Interobserver Concordances Evaluation||Société Française d'Endoscopie Digestive|Yes|Completed|July 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01765036||73274|
NCT01765283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP001|Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)|A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.|HEP001|Promethera Biosciences|Yes|Completed|March 2012|April 2015|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|N/A|17 Years|No|||January 2014|May 16, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765283||73255|
NCT01765569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28394|A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma|A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy||Hoffmann-La Roche||Completed|July 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|January 9, 2013|No|Yes||No|July 14, 2015|https://clinicaltrials.gov/show/NCT01765569||73233|
NCT01756872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDOG-12/SC/0277|Clinical Measures of Ovarian Reserve in Predicting IVF Success|Determining the Accuracy of Clinical Measures of Ovarian Reserve in Predicting Successful In Vitro Fertilisation (IVF)Treatment.||University of Oxford|No|Active, not recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Women attending the Oxford Fertility Unit planning an IVF/IVF-ICSI treatment cycle|December 2014|December 2, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756872||73901|
NCT01753050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HipHop|HIP Surgery - Hemodynamic Optimization Project|A Quality Improvement Project for Goal-directed Intraoperative Hemodynamic Optimization in Patients Redo Hip Surgery|HipHop|Charite University, Berlin, Germany|Yes|Completed|December 2012|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|260|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753050||74193|
NCT01753063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00006045|Managing Patient Expectations in Pediatric Weight Management|Managing Expectations in Pediatric Weight Management: A Pilot Study in Focus on a Fitter Future III Hospitals||Children's Hospital Boston|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|405|||Both|2 Years|18 Years|No|||December 2013|December 16, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753063||74192|
NCT01752751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1224|Predicting Tolerance to Radiation Therapy in Older Adults With Cancer|Predicting Tolerance to Radiation Therapy in Older Adults With Cancer: A Prospective Blinded Study of the Comprehensive Geriatric Assessment||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|November 2012|July 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Whole blood|Both|65 Years|N/A|No|Non-Probability Sample|Patients age ≥ 65 years of age, with one of the inclusion diagnoses, and an appointment        for CT simulation for planning of radiation therapy at UNCH department of radiation        oncology will be assessed for inclusion for this study.|August 2015|August 26, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752751||74216|
NCT01753011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOT 1/2-Rule|Urethral Length and TOT (Transobturator Tape) Positioning|Prospective, Observational Study: Can Pelvic Floor Ultrasound Help to Optimize TOT (Transobturator Tape) Positioning?||Cantonal Hospital, Frauenfeld|Yes|Completed|May 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Female|18 Years|N/A|No|Probability Sample|The study population includes women with surgically-corrected stress urinary incontinence        who undergo a TOT operative procedure.|December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753011||74196|
NCT01753258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delivery-Dyspareunia-HMO-CTIL|Outcomes of Delivery in Patients With Dyspareunia|Outcomes of Delivery in Patients With Dyspareunia- A Prospective Study||Hadassah Medical Organization|No|Recruiting|January 2013|April 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous women admitted to the Labor and Delivery Department at the Hadassah Medical        Center, above the age of 18|February 2016|February 21, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01753258||74177|
NCT01753570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-F1|Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)|A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naïve or Have Received Interferon Based Therapy||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|20 Years|70 Years|No|||October 2015|October 23, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753570||74153|
NCT01753583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-041112|High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study|High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study||Medical University of Vienna|No|Recruiting|July 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753583||74152|
NCT01762163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QZTL2013|Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke|Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke With Qi Deficiency and Blood Stasis Syndrome: a Multicenter, Randomized,Double-blind，Placebo- and Active-controlled Adaptive Study||China Academy of Chinese Medical Sciences|Yes|Recruiting|October 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|624|||Both|35 Years|80 Years|No|||March 2016|March 17, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762163||73495|
NCT01762176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA-MRI-2012|Early RA MRI Early Intensive Treatment Study|Effect of Early Intensive Treatment in Chinese Patients With Recent-onset Rheumatoid Arthritis||Chinese University of Hong Kong|Yes|Recruiting|October 2012|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||January 2016|January 26, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762176||73494|
NCT01762436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Betablocker on CAP and BRS|Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension|A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension||Ruijin Hospital|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|25 Years|65 Years|No|||January 2013|January 7, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762436||73474|
NCT01762982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01379|Patch Test of Benzalkonium Chloride Disinfectant Spray|A Single Centre, Examiner-blind Human Patch Test of Bactroban Disinfectant Liquid on Normal Skin||GlaxoSmithKline|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|December 5, 2013|January 4, 2013|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01762982||73432|
NCT01762722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018006|Nonin 4 Wavelength Cerebral Oximeter Study|Calibration and Validation of the 4 Wavelength Nonin Non-invasive Cerebral Oxygen Saturation Oximeter and Cerebral Sensor|Nonin4|Duke University|No|Completed|September 2009|April 2012|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 17, 2012|Yes|Yes||No|March 6, 2013|https://clinicaltrials.gov/show/NCT01762722||73452|
NCT01760421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108006MB|The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis|The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis||National Taiwan University Hospital|No|Completed|October 2011|August 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|60 Years|No|||April 2014|April 22, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01760421||73629|
NCT01760681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-14-12|A Randomized Sham-Controlled Study of H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression|||Shalvata Mental Health Center||Not yet recruiting|January 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|85 Years|No|||June 2012|January 2, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01760681||73609|
NCT01760941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14596|Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients|Feasibility of a Compassionate Same-Day Evaluation and Delivery of Single Fraction Radiotherapy for Palliation of Symptomatic Bony Metastasis in Hospice Patients||Virginia Commonwealth University|Yes|Terminated|March 2013|June 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 20, 2012||No|Slow accrual|No|December 18, 2015|https://clinicaltrials.gov/show/NCT01760941||73589|No data analysis or outcome measures for one participant enrolled and zero participants analyzed. Early suspension and termination due to slow accrual from Protocol Review and Monitoring Committee.
NCT01757691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2402|Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)|A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis||Novartis|Yes|Terminated|August 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|50 Years|No|||April 2015|April 16, 2015|December 21, 2012|Yes|Yes|Discontinuation of this study was based on Novartis decision to discontinue development of    fingolimod for the treatment of ADON|No|April 16, 2015|https://clinicaltrials.gov/show/NCT01757691||73839|
NCT01758003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/08|Physical Activity in Healthy Over 40s|Patterns of Physical Activity in a Healthy Population Aged Over 40 Years Old||University of Ulster|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy convenience sample|April 2014|April 4, 2014|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01758003||73815|
NCT01758302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2T32HL076134-06XX|A Pilot Laboratory Study Investigating How Physical Tasks and Hunger Affect Taste Perception|A Pilot Laboratory Study Investigating How Physical Tasks and Hunger Affect Taste Perception||The Miriam Hospital|No|Recruiting|January 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 26, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01758302||73792|
NCT01758315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ HS10-021|Proactive Reduction of Outpatient Malpractice: Increasing Safety, Efficiency, and Satisfaction|Medical Malpractice and Patient Safety Proposal|PROMISES|Massachusetts Department of Health|Yes|Enrolling by invitation|July 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|213|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 24, 2012|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01758315||73791|
NCT01756326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREOB-NU3|Phase 2b/3 Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures|A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Non-Infected Hypotrophic Non-Union Fractures||Bone Therapeutics S.A|Yes|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|65 Years|No|||November 2013|November 22, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756326||73942|
NCT01756599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00984-39|Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA|Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA||Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2012|July 2023|Anticipated|December 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2900|||Both|8 Years|18 Years|No|||September 2015|October 16, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756599||73921|
NCT01752491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211713|A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme|A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme||University of Iowa|Yes|Active, not recruiting|April 2013|March 2017|Anticipated|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|December 17, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752491||74236|
NCT01753336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TL-52120-170|Long Term Safety And Effectiveness Of Dysport In Adults With Cervical Dystonia|A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport Using 2 mL Dilution In Adults With Cervical Dystonia||Ipsen|No|Completed|July 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753336||74171|
NCT01753349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-166|Phase IV-Cervical Dystonia-INTEREST IN CD2|An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact|INTEREST_INCD2|Ipsen|No|Active, not recruiting|December 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1050|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia.|September 2015|September 21, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753349||74170|
NCT01753037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mayo-06-004680|Effects of Androgen Administration on Inflammation in Normal Women|Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women||Mayo Clinic|No|Completed|December 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|November 14, 2013|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01753037||74194|
NCT01753271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208-122|Subacute Effects of Spinal Mobilization to Treat Subacromial Impingement|Subacute Effects of Cervicothoracic Spinal Manipulation in Addition to Shoulder Manual Therapy Plus Exercise Intervention in Individuals With Subacromial Impingement Syndrome: a Randomized, Controlled Clinical Trial Pilot Study||High Point University|No|Completed|September 2012|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|No|||August 2015|August 19, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01753271||74176|
NCT01753284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1650(REK)|First Episode Psychosis and Pathway to Care in Nordland|Patients and Carers Experiences With First Episode Psychosis and Pathway to Care in Nordland: A Qualitative Study||Nordlandssykehuset HF|No|Active, not recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|16 Years|35 Years|No|Probability Sample|Patients experiencing first and multiple episode psychosis carers siblings|April 2015|April 1, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753284||74175|
NCT01753596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-200612|Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease|Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease||Medical University of Vienna|Yes|Withdrawn|December 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 13, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753596||74151|
NCT01753908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 211911|Broccoli Sprout Extract in Treating Patients With Breast Cancer|A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer||Roswell Park Cancer Institute|Yes|Recruiting|May 2013|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Female|21 Years|N/A|No|||February 2016|February 18, 2016|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753908||74127|
NCT01762189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2012-319|The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants|Multicenter Prospective Study on the Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants||Nanjing Medical University|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13157|||Both|N/A|28 Days|Accepts Healthy Volunteers|Probability Sample|Term or late-preterm newborn infants from Seventeen hospitals in China were recruited.|October 2014|October 25, 2014|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762189||73493|
NCT01762735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIC-002|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Training the Beginners|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Training the Beginners||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|February 2013|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2013|February 10, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762735||73451|
NCT01763021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100929|A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants|An Open-Label, Sequential Design Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01763021||73429|
NCT01760694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRMC 12-08|Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer|Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer||Southwestern Regional Medical Center|Yes|Terminated|January 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|December 26, 2012|No|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01760694||73608|
NCT01760707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200200769|Exercise Capability and Training Effects in Diabetic Patients With Neuropathy|Exercise Capability and Training Effects in Diabetic Patients With Neuropathy||National Taiwan University Hospital|No|Completed|November 2002|May 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|70 Years|No|||November 2012|January 3, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760707||73607|
NCT01761201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLISH-ILT|"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".|"A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients".|FLISH-ILT|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Terminated|January 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|January 3, 2013||No|Recruitment rythm not sufficent to reach the simple size needed.|No||https://clinicaltrials.gov/show/NCT01761201||73569|
NCT01762306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOGMVA001|Efficacy of Diclofenac on Pain During Endometrial Sampling|Efficacy for Acute Pain Alleviation of 50 mg Diclofenac 1 Hour Prior to Endometrial Sampling in Cases of Abnormal Uterine Bleeding||Mahidol University|No|Recruiting|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|35 Years|N/A|No|||September 2012|January 4, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01762306||73484|
NCT01762540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK_nilani_2012|Glucocorticoid Induced Whole Body Catabolisme|Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.||University of Aarhus|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|19|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2016|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762540||73466|
NCT01762852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114674|Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy|BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy||GlaxoSmithKline|Yes|Withdrawn|April 2013|May 2016|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||August 2014|August 11, 2014|January 4, 2013|Yes|Yes|Withdrawn due to difficulties in to recruiting due to competing studies, changing treatment    practices, unavailability of eligible study population|No||https://clinicaltrials.gov/show/NCT01762852||73442|
NCT01762813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29034/2012|Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer|Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer|ACROBATICC|Helse Stavanger HF|No|Recruiting|August 2012|December 2027|Anticipated|December 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|Samples With DNA|Blood, whole blood, plasma, cancer tissue, normal tissue|Both|18 Years|N/A|No|Non-Probability Sample|All patients with colorectal cancer (primary and/or secondary) undergoing surgery for        curative intent|July 2015|July 27, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762813||73445|
NCT01762826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOS002|Myo-inositol, D-chiro-inositol, and D-chiro/Myo-inositol in Gestational Diabetes|Adverse Obstetric Outcomes in Gestational Diabetes Mellitus and Inositol Stereoisomears||G. d'Annunzio University|No|Enrolling by invitation|September 2012|September 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Non obese pregnant women during first trimester of pregnancy with scared fasting glucose        (above 92 mg%)|September 2012|January 4, 2013|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01762826||73444|
NCT01756339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-300|Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia|SOLITAIRE-ORAL|Cempra Inc|Yes|Completed|December 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|860|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756339||73941|
NCT01756612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28145|COMETE Study: Comorbidity Mircera Evolution of Hemoglobin Rate; A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease|A Non Interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CDK) Patients Not in Dialysis Treated With Mircera||Hoffmann-La Roche||Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|551|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease not on dialysis and ESA naïve|March 2016|March 1, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756612||73920|
NCT01756625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREMIUM|PREMIUM, Observational Study|Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer||Institut Sainte Catherine|No|Active, not recruiting|January 2010|June 2013|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Probability Sample|patients from private and public centers|December 2012|December 20, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756625||73919|
NCT01752764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-DRS-0573|Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing|Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing||Unilever R&D|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752764||74215|
NCT01752777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-159|Behavioral Intervention to Enhance HIV Test/Treat|Behavioral Intervention to Enhance HIV Test/Treat||University of Connecticut|Yes|Active, not recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01752777||74214|
NCT01753362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1965|Liraglutide In Overweight Patients With Type 1 Diabetes|LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES||University at Buffalo|Yes|Recruiting|December 2012|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|75 Years|No|||December 2015|December 11, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753362||74169|
NCT01753310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TL-52120-169|Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia.|A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia.||Ipsen|No|Completed|January 2013|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753310||74173|
NCT01753323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKAF156X2201|Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection||Novartis|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|20 Years|60 Years|No|||October 2015|October 1, 2015|December 17, 2012||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01753323||74172|
NCT01753297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52014-194|A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.|A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients|PRIORITI|Ipsen|No|Recruiting|December 2012|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753297||74174|
NCT01753609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULIP-PRT-002-05-B-CTIL|Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers|Safety and Performance Evaluation of TrimWeight Device - an Intragastric Auto-inflating & Degradable Balloon in a Swallow-able Capsule ("the Device"), for Enhancing Satiety and Satiation in Healthy Over Weight and Obese Volunteers||Tulip Medical Ltd.|Yes|Not yet recruiting|January 2013|July 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753609||74150|
NCT01753622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Overweight-obese pregnant|Physical Exercise Program in Obese and Overweight Pregnant Women|Effect of a Supervised Exercise Program in Obese and Overweight Pregnant Women on Outcomes and Level of Depression. A Randomized Controlled Trial||Technical University of Madrid|Yes|Recruiting|October 2009|November 2015|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|November 13, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753622||74149|
NCT01753921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22727|Evaluation of a Non-invasive Brain Compliance Measurement Device|Evaluation of a Non-invasive Brain Compliance Measurement Device||Stanford University|No|Recruiting|November 2011|||June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01753921||74126|
NCT01762449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026357|Morbidity and Mortality Follow Up for the Scleroderma Lung Study|Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1||Duke University|No|Completed|July 2012|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|158|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who participated in the Scleroderma Lung Study|January 2014|January 22, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762449||73473|
NCT01759563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCCTAVI-I|Oxygenation of the Cerebrum and Cooling During TAVI - Part I|Safety and Feasibility Study of Nasopharyngeal Cooling (RhinoChill Device) During Transcutaneous Aortic Valve Implantation|OCCTAVI-I|Hasselt University|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|N/A|N/A|No|||January 2013|January 2, 2013|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01759563||73695|
NCT01759836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-PC2012002|Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer|A Randomized Double Blind, Placebo-controlled Study Determining the Role of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer||Asan Medical Center|Yes|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|354|||Male|N/A|N/A|No|||January 2013|January 9, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01759836||73674|
NCT01760122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1211IFN|Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B|A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.||Xiamen Amoytop Biotech Co., Ltd.|No|Completed|March 2013|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|820|||Both|18 Years|65 Years|No|||March 2015|August 28, 2015|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01760122||73652|
NCT01760135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001|Nutritional Requirement for the Severe Trauma Patients|Nutritional Requirement for the Severe Trauma Patients||Asan Medical Center|Yes|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|61|||Both|20 Years|N/A|No|||January 2013|January 3, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01760135||73651|
NCT01760954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-667|Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||AbbVie|Yes|Active, not recruiting|December 2012|April 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|50 Years|No|||January 2016|January 20, 2016|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760954||73588|
NCT01760967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESIRE|Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial|Effect of Dexmedetomidine on Mortality, Duration of Mechanical Ventilation and Multi-organ Function in Sepsis Patients Under Lighter Sedation by Randomized Control Trial|DESIRE|Wakayama Medical University|Yes|Recruiting|January 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||February 2013|February 7, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01760967||73587|
NCT01761214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKLRD-2013-GWJ|Bacteriology and Inflammation in Bronchiectasis|Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis|BISER|Guangzhou Institute of Respiratory Disease|No|Recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||February 2016|February 14, 2016|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761214||73568|
NCT01757093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFL-0705|Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial.|Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial - A Randomized Crossover Controled Trial.||University of Sao Paulo|Yes|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01757093||73884|
NCT01762553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD068165-01|TEA for Families and Children: A Randomized Intervention Trial|TEA (Together for Empowerment Activities)for Families and Children: A Randomized Intervention Trial||University of California, Los Angeles|Yes|Completed|May 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1533|||Both|6 Years|N/A|No|||February 2016|February 16, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762553||73465|
NCT01762839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-12-02|A Study to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers||The Medicines Company|No|Completed|January 2013|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762839||73443|
NCT01762865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOREAABS|Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.|Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.||Hallym University Medical Center||Recruiting|April 2012|October 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Sputum specimens for microbiologic tests|Both|18 Years|N/A|No|Non-Probability Sample|adult patinets who visit hospitals for recent sputum and/or cough|January 2013|January 7, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01762865||73441|
NCT01762878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116617|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects|A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects Who Smoke Cigarettes||GlaxoSmithKline|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762878||73440|
NCT01763125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 366/2003|Tumor Bank for Blood Samples|Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.||Medical University of Vienna|No|Recruiting|November 2003|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|10000|Samples With DNA|Universal tumor bank|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Male and female patients/people.          -  Minimum age 18 years          -  Characteristics: Recruited at the Medical University Vienna or at one of the             facilities cooperating with the Vienna Med. University|September 2015|September 28, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763125||73421|
NCT01756352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P00 Pending|FET-PET for Evaluation of Response of Recurrent GBM to Avastin|Assessment of the Utility of the Radiotracer "FET"in PET Imaging of Recurrent Glioblastoma Multiforme (GBM): Monitoring Early Response to Antiangiogenic Therapy||Brigham and Women's Hospital|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|85 Years|No|||January 2016|January 28, 2016|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756352||73940|
NCT01756638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017059|A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer|A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naïve||Janssen Research & Development, LLC|Yes|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|20 Years|N/A|No|||October 2015|October 30, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756638||73918|
NCT01753076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112264|Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis|Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis||GlaxoSmithKline|Yes|Completed|December 2012|January 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|80 Years|No|||May 2015|July 9, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753076||74191|
NCT01753674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-256|The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome|The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome||University of Connecticut|Yes|Terminated|January 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 17, 2012|Yes|Yes|non-compliance issues|No||https://clinicaltrials.gov/show/NCT01753674||74145|
NCT01753986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210-005|Alcohol Use and Relationships - III|Impact of Brief Substance Use Intervention on Substance Use and Intimate Partner Violence||The University of Tennessee Knoxville|No|Recruiting|December 2012|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753986||74121|
NCT01753648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-220612|Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy|Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy||Medical University of Vienna|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753648||74147|
NCT01753635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.724|Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients|Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients||University College Hospital Galway|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Female|16 Years|85 Years|No|||March 2013|March 15, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753635||74148|
NCT01753947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deliberate Practice|Individualized Deliberate Practice on a Virtual Reality Simulator|Individualized Deliberate Practice on a Virtual Reality Simulator Improves Technical Performance of Surgical Novices in the Operating Room: A Randomized Controlled Trial||St. Michael's Hospital, Toronto|No|Completed|January 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753947||74124|
NCT01753934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05102011-7713|Diabetic Ketoacidosis and Its Impact on the Brain|Diabetic Ketoacidosis and Its Impact on Neurocognition||Stanford University|No|Recruiting|May 2011|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|None Retained|There is no intervention. All subjects with DM and controls get neurocognitive testing and      an MRI of the brain. We want to see if the scores are different but no changes in therapy      will be done.|Both|4 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sixty to 80 children between the ages of 4 to 17 years with Type 1 diabetes mellitus will        have neuropsychological testing and a non-sedated MRI scan of the head performed. We will        compare this to a control group of 30-40 children between the ages of 4 to 17 years        without Type 1 diabetes mellitus.|June 2014|June 10, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01753934||74125|
NCT01754207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN11-PICO-D-A-TAT|Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos|Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos||Cynosure, Inc.|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||February 2014|February 7, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754207||74104|
NCT01754220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALKA-03-12|Open-label Study of the Effects of Montelukast in Patients With Chronic Cough|The Effects of Alvokast (Montelukast) in Patients With Chronic Cough||Association Asthma, Bulgaria|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|12 Years|60 Years|No|||December 2012|December 18, 2012|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01754220||74103|
NCT01759251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-972|Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice|Post-marketing Observational Program of Betaserc® (Betahistine Dihydrochloride) to Evaluate Effectiveness in Patients With Vestibular Vertigo in Routine Practice|VIRTUOSO|Abbott|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|309|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients with vestibular vertigo|February 2015|February 12, 2015|December 28, 2012||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01759251||73719|4 patients had a treatment exposure of 30 days. No subgroup analyses were performed as the majority of patients had 60 days treatment with Betaserc®.
NCT01760148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX10002007|Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)|Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase)|sIFN-pred2|First Hospital of Jilin University|Yes|Recruiting|July 2012|March 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood serum,Peripheral blood mononuclear cells (PBMC)|Both|N/A|N/A|No|Non-Probability Sample|Patients are from the northeast of China. Most of the patients have been infected by the        hepatitis c virus due to the drug abuse. Many of them share the same syringe for drug        intravenous injection. However, HIV infection has been rarely detected.|January 2013|January 1, 2013|September 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01760148||73650|
NCT01760161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120042|Bilateral Dual Transversus Abdominis Plane Block for Robotic Assisted Laparoscopic Surgery|A Randomised, Double-blind Study to Evaluate the Effect of Bilateral Dual Transversus Abdominis Plane Block on Postoperative Pain and Plasma Concentration of Ropivacaine After Robotic Assisted Laparoscopic Surgery||Aalborg Universitetshospital|No|Terminated|April 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|December 19, 2012||No|No signal on pain-score|No||https://clinicaltrials.gov/show/NCT01760161||73649|
NCT01760434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008308|Long-Term Outcome Following the Treatment of Pediatric Scoliosis|Prospective Study: Long-Term Pulmonary Function, Health-Related Quality of Life, and Sagittal Plane Alignment Following the Treatment of Pediatric Scoliosis||Mayo Clinic|No|Completed|January 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|30 Years|99 Years|No|||January 2016|January 5, 2016|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760434||73628|
NCT01760980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXL209003|Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects|||Actavis Inc.||Suspended|November 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|90|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|January 2, 2013|No|Yes|Development halted by management|No||https://clinicaltrials.gov/show/NCT01760980||73586|
NCT01760993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-336|Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia|A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia||Shire|Yes|Terminated|February 2013|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||May 2014|May 1, 2014|January 2, 2013|Yes|Yes|Study was discontinued due to non-safety related business prioritization decisions. No    subjects were randomized.|No|May 1, 2014|https://clinicaltrials.gov/show/NCT01760993||73585|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
NCT01762007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0372|The Change of the Detrusor Thickness After Hypospadias Repair - Comparison With the Normal Control Group|||Yonsei University|No|Recruiting|November 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|56|||Male|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: 13 patients with 6Mo-2Yr old penile hypospadias patients before operation Group        2: 13 patients with 6Mo-2Yr old male patients without hypospadias Group 3: 15 patients        with penile hypospadias patients under the age of 5 Yr who got tubularized incised plate        operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have        passed Group 4: 15 patients with 2Yr-5Yr old male patients without hypospadias|January 2013|January 3, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01762007||73507|
NCT01762293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-IIb-CRC|A Study of Famitinib in Patients With Advanced Colorectal Cancer|A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|April 2012|January 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||January 2013|January 4, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762293||73485|
NCT01762566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM02|Bioelectrical Impedance Analysis of Not-celiac Wheat Sensitivity Patients|Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) in Wheat Sensitive Patients for Evaluation of Bio-Markers of a Single Referred Symptom (Bloating & Swelling)||University of Palermo|Yes|Completed|January 2012|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|65 Years|No|||September 2014|September 14, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762566||73464|
NCT01762579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM03|Bio-markers of Not-celiac Wheat Sensitivity|Not-celiac Wheat Sensitivity (NCWS) in Patients With Irritable Bowel Syndrome. Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) for Bio-markers Identification of NCWS and Understanding Its Pathogenetic Mechanisms.||University of Palermo|Yes|Recruiting|January 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762579||73463|
NCT01763151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viros_Askin|Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism|Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism||Vienna Institute for Research in Ocular Surgery||Completed|September 2010|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|N/A|No|||January 2013|January 8, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01763151||73419|
NCT01763138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fatima ishfaq|Effect of Educational Intervention in Mothers for Prevention of Caries in Their Children|Effect of Educational Intervention in Mothers for Prevention of Caries in Their Children, A Randomized Controlled Trial||University of the Punjab|Yes|Completed|June 2012|November 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|126|||Both|9 Months|15 Months|Accepts Healthy Volunteers|||January 2013|January 6, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01763138||73420|
NCT01752608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eCBT 201|Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder|A Randomized, Comparator-Controlled, Two-Arm, Parallel Group Study to Determine the Safety and Efficacy of eCBT Mood®, a Handheld, Computerized, Electronic Cognitive Behavioral Therapy Application, in Patients With Major Depressive Disorder||MindApps|No|Withdrawn|October 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|December 16, 2012||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01752608||74227|
NCT01753167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV28418|A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of RG7667 for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients||Genentech, Inc.||Completed|December 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753167||74184|
NCT01765673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43DC012754|The Passy Muir Swallowing Self Training Device to Enhance Recovery Post Stroke|Pass-Muir Swallowing Self Training Device to Enhance Recovery Post Stroke|PMSST|James Madison University|Yes|Completed|January 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|20 Years|N/A|No|Non-Probability Sample|Participants who have swallowing problems secondary to a stroke..|February 2016|February 22, 2016|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765673||73225|
NCT01765959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA2011-59|Auricular Acupuncture and Cognitive Behavioral Therapy Treatment for Insomnia|"Auricular Acupuncture and Cognitive Behavioral Therapy in the Context of Insomnia and Low Dose Dependence of Benzodiazepine-like Drugs and Other Sleep Medicine With Addiction Risk"|NADA|Uppsala University|No|Completed|December 2012|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765959||73203|
NCT01766726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001138|Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients|Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients|Quad|Massachusetts General Hospital|No|Completed|December 2012|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|Samples Without DNA|Plasma, serum.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with HIV infection being cared for in the Eastern Massachusetts area may be        appprised of the study by their treating infectious disease doctors. Additionally,        subjects with HIV infection from the community will be recruited via posters,        advertisements, e-postings. Healthy control subjects from the community will be recruited        via posters, advertisements, and e-postings.|March 2016|March 22, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766726||73145|
NCT01766739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-169|Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma|Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma||Memorial Sloan Kettering Cancer Center||Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01766739||73144|
NCT01767558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECISION GOLD|PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)|Phased RF Evaluation of Acute Pulmonary Vein Isolation in Paroxysmal AF With New GENius UI and PVAC GOLD||Medtronic Atrial Fibrillation Solutions|No|Completed|January 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|70 Years|No|||July 2014|July 30, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01767558||73081|
NCT01735539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNottingham F/3/2009|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance With Age; the Role of Amino Acids in Modulating Muscle Metabolism|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People; The Role of Essential Amino Acids in Modulating Muscle Protein Metabolism; Bolus vs. Pulse Feeding Strategies and the Ability of Arginine to Rejuvenate Microvascular Responsiveness.|Ajinomoto1A|University of Nottingham|Yes|Active, not recruiting|December 2011|January 2014|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|40|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735539||75538|
NCT01735552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51050|Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates|Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.||University of Utah|No|Terminated|June 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|N/A|12 Weeks|No|Non-Probability Sample|Premature infants admitted into the University of Utah (UUMC), Primary Children's Medical        Center (PCMC) and Intermountain Medical Center's (IMC) Neonatal Intesive Care Unit (NICUs)|May 2015|May 1, 2015|November 22, 2012||No|Unable to recruit participants|No||https://clinicaltrials.gov/show/NCT01735552||75537|
NCT01767545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mayer-DEX-001|Dexamethasone-implant for the Treatment of RVO|Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion||Ludwig-Maximilians - University of Munich|No|Completed|September 2010|February 2012|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|85 Years|No|||January 2013|January 10, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767545||73082|
NCT01735786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121125|EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)|EndoClotTM Absorbable Polysaccharide Hemostat for Preventing Rbleeding After Endoscopic Mucosal Resection (EMR)||Xijing Hospital of Digestive Diseases|Yes|Completed|April 2010|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|164|||Both|18 Years|80 Years|No|Probability Sample|Consecutive cases of colorectal mucosal and submucosal lesions with intented EMR treatment|November 2012|November 27, 2012|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01735786||75519|
NCT01736722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITT|MRI-Guided LITT for Treatment Metastatic Brain Tumors|Use of MRI-Guided Laser Induced Thermal Therapy (LITT) for Metastatic Brain Tumors||The Methodist Hospital System|No|Completed|January 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|19 Years|75 Years|No|||May 2014|May 8, 2014|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736722||75447|
NCT01736423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-703|A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome|A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Female|20 Years|64 Years|No|||October 2015|October 9, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736423||75470|
NCT01736436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APG101_CD_003|APG101 in Myelodysplastic Syndrome|APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome|APG101 in MDS|Apogenix GmbH|No|Active, not recruiting|January 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2015|June 15, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01736436||75469|
NCT01736683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-MDS-001|Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)|AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)||Celgene|No|Active, not recruiting|November 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|74|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736683||75450|
NCT01736696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921003|Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis|Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550||Pfizer|No|Completed|November 2002|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|59|||Both|18 Years|65 Years|No|||January 2013|January 16, 2013|November 26, 2012|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01736696||75449|
NCT01736709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-INF-4012|The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine|A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine||Sinovac Biotech Co., Ltd|Yes|Completed|November 2012|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|202|||Both|6 Months|85 Years|Accepts Healthy Volunteers|||November 2012|May 27, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736709||75448|
NCT01755585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No. 099148-F|Irradiation Modulates the Pharmacokinetics of Anticancer Drugs|||Far Eastern Memorial Hospital||Enrolling by invitation|July 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|whole blood collection|Both|18 Years|80 Years|No|Non-Probability Sample|Chemotherapy-naive patients with histologically confirmed, locally advanced rectal        adenocarcinoma and cervical cancer, who were prepared for concurrent chemoradiation        therapy, were consecutively enrolled in this study|January 2014|January 19, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755585||73998|
NCT01755026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22512|Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery|Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.||West Virginia University|No|Completed|November 2010|November 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Female|18 Years|N/A|No|||June 2013|June 12, 2013|June 29, 2011|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01755026||74041|
NCT01755286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201101|OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|A Prospective, Randomized, Double-Blind, Placebo- and Sham-Controlled, Multicenter, Phase 1b Study of OTO-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement||Otonomy, Inc.|Yes|Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Both|6 Months|12 Years|No|||June 2013|June 17, 2013|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755286||74021|
NCT01755936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/R/CAR/05|The Role of Myocardial Fibrosis in Patients With Aortic Stenosis|The Role of Myocardial Fibrosis in Patients With Aortic Stenosis||University of Edinburgh|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|Samples Without DNA|Full blood count and renal panel will be measured.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 240 individuals will be recruited. This includes 48 individuals who do not have        aortic stenosis. A total of 192 individuals with aortic stenosis will be recruited:          1. Mild aortic stenosis, n=48          2. Moderate aortic stenosis, n=48          3. Severe aortic stenosis, n=48          4. Symptomatic aortic stenosis with planned valve replacement, n=48|January 2013|January 15, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755936||73972|
NCT01756729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-19|Post-approval Study of NovoTTF-100A in Recurrent GBM Patients|A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient||NovoCure Ltd.|No|Terminated|December 2012|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|22 Years|N/A|No|||February 2016|February 29, 2016|December 20, 2012|Yes|Yes|Amendment of Study Protocol|No||https://clinicaltrials.gov/show/NCT01756729||73912|
NCT01752569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16059|A Study of Selumetinib in Patients With Kaposi's Sarcoma|Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).|SCART|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|June 2012|February 2016|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01752569||74230|
NCT01752582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version1.1|BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)|BuMA OCT Study(A Comparative Evaluation of BuMA Stent and of EXCEL Stent in Terms of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)||Sino Medical Sciences Technology Inc.|Yes|Completed|December 2012|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|85 Years|No|||March 2016|March 10, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01752582||74229|
NCT01752842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112122|Lipid Biomarkers for Diabetic Heart Disease|Lipid Biomarkers for Diabetic Heart Disease||Washington University School of Medicine|Yes|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|30 Years|65 Years|No|||December 2015|December 7, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752842||74209|
NCT01752855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-692|Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab|A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab||AbbVie|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|December 17, 2012|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01752855||74208|
NCT01753726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0037UG|Diaphragm Stretching Increases Spine and Thoracic Mobility|Diaphragm Stretching Technique Increases Spine Mobility and Thoracic Movement: a Randomized Controlled Trial||Universidad de Granada|Yes|Recruiting|June 2012|November 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753726||74141|
NCT01753739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823|Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Dose-Ranging Study to Evaluate the Safety and Efficacy of Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects With a Demonstrated History of Mountain Cedar Pollen Allergic Sensitivity||Bausch & Lomb Incorporated|No|Completed|January 2013|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|613|||Both|12 Years|N/A|No|||May 2014|July 30, 2014|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753739||74140|
NCT01765972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5252|Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear|||Johnson & Johnson Vision Care, Inc.|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765972||73202|
NCT01766687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-London RCT|Impact of Increased Water Intake in Chronic Kidney Disease|A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease|WIT|Lawson Health Research Institute|Yes|Recruiting|April 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766687||73148|
NCT01767259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT1|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers|PKVH|Damanhour University|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 12, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767259||73104|
NCT01735279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tobacco&Omega|Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence|"Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence"||Federal University of São Paulo|No|Not yet recruiting|January 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735279||75558|
NCT01736176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-920|A Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel for the Treatment of Non-motor Symptoms in Subjects With Advanced Parkinson's Disease|An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease||AbbVie|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|30 Years|99 Years|No|||January 2016|January 8, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736176||75489|
NCT01736111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0571|Text Messaging for Weight Loss|Text Messaging for Weight Loss in Primary Care Patients||The University of Texas Health Science Center, Houston|Yes|Completed|October 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|21 Years|N/A|No|||November 2015|November 9, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01736111||75494|
NCT01735799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068-12-ZIV|THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS|||Ziv Hospital||Not yet recruiting|November 2012|||||N/A|Observational|Time Perspective: Prospective||1|||||Female|18 Years|50 Years|No|Non-Probability Sample|Patients - women who will be diagnosed with PCOD following their initial referal to our        fertility clinic. Controls - normal ovulatory women who approached our fertility clinic        due to either unexplained or male factor infertility.|November 2012|November 27, 2012|November 25, 2012||||No||https://clinicaltrials.gov/show/NCT01735799||75518|
NCT01737255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3802|Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome|Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study|SIGNIFY|Institute of Cancer Research, United Kingdom|No|Recruiting|October 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|88|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The TP53 mutation carriers will be recruited from genetics clinics and through        advertising.        The population controls will be recruited through advertising|February 2016|February 29, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737255||75406|
NCT01737268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0022|Long-term Study of FK949E in Elderly Bipolar Disorder Patients|Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes-||Astellas Pharma Inc|No|Active, not recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|65 Years|N/A|No|||February 2016|February 11, 2016|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737268||75405|
NCT01736982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-186-2|Contingency Management for Smoking Cessation in the Homeless|Contingency Management for Smoking Cessation in the Homeless||University of Connecticut Health Center|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736982||75427|
NCT01736995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032723-01A1|Family and Adolescent Motivational Incentives for Leveraging Youth|Family and Adolescent Motivational Incentives for Leveraging Youth|FAMILY|Oregon Research Institute|Yes|Recruiting|July 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|13 Years|17 Years|No|||April 2015|April 21, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01736995||75426|
NCT01737242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/MRE02/4|UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies|UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies|UKGPCS|Institute of Cancer Research, United Kingdom|Yes|Recruiting|January 1993|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|26000|Samples With DNA|Whole blood, Prostate Tissue|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any patients that meets the eligibility criteria and may be attending a hospital that have        got ethical approval.|February 2016|February 22, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737242||75407|
NCT01755039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_Heimbeatmung_61/2009|Course and Complications of Invasive Out-of-hospital Ventilation|Verlauf Und Respiratorische Zwischenfälle Bei Patienten Mit außerklinischer Beatmung||Wissenschaftliches Institut Bethanien e.V||Completed|January 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Probability Sample|Patients with indication for out-of-hospital ventilation|December 2012|December 18, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01755039||74040|
NCT01756157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-206|Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks|A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema||Shire|No|Completed|December 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|47|||Both|12 Years|N/A|No|||June 2014|May 29, 2015|June 29, 2012|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01756157||73955|Results of efficacy endpoints (time to first angioedema attack, effects of C1 inhibitor and C4 levels on clinical outcome during treatment period) were not reported due to early termination of the study but later completed for safety data.
NCT01756196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1008/016-004|Incidence of Various Types of Systemic Reactions Related to Spinal Steroid Injection: A Prospective Study|Prospective Observational Study of Evaluate the Incidence and Types of Systemic Reactions After Spinal Steroid Injections||Seoul National University Bundang Hospital|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|997|||Both|13 Years|94 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients receiving the injection were informed of the aim and protocol of this study        and the possible local and systemic reactions associated with spinal steroid injection|December 2012|December 19, 2012|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756196|2 Weeks|73952|
NCT01756781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481012|A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.|A Phase 1 Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study Of The Effect Of Multiple Doses Of PD-0332991 On Midazolam Pharmacokinetics In Healthy Women of Non-Childbearing Potential||Pfizer|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756781||73908|
NCT01756170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC-11352|Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients|Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy||Wenzhou Medical University|No|Recruiting|January 2011|December 2016|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|75 Years|No|||December 2012|December 19, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01756170||73954|
NCT01756456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF0212|Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.|An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 48 or 56 Week Follow-up Period to Evaluate the Safety and Efficacy of Two Doses (10 µg/ml and 20 µg/ml) of Recombinant Human Nerve Growth Factor Eye Drops Solution Versus Vehicle in Patients With Stage 2 and 3 of Neurotrophic Keratitis|REPARO|Dompé Farmaceutici S.p.A|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756456||73932|
NCT01756742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0038UG|Effects of Respiratory Physiotherapy on Pleural Effusion|Effectiveness of a Program of Respiratory Physiotherapy on Pleural Effusion: a Randomized Controlled Trial||Universidad de Granada|Yes|Completed|February 2009|March 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||December 2012|December 20, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756742||73911|
NCT01756755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208067RIB|Endotoxin Adsorber Hemoperfusion and Microcirculation|The Effect of Endotoxin Adsorber Hemoperfusion on the Microcirculation in Patients With Severe Sepsis and Septic Shock||National Taiwan University Hospital|Yes|Recruiting|December 2012|July 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||February 2015|February 4, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756755||73910|
NCT01754077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-209-B|Thirty Million Words Project: A Feasibility Trial|Thirty Million Words Project: A Feasibility Trial|TMW|University of Chicago|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|40|||Both|17 Months|36 Months|Accepts Healthy Volunteers|||September 2013|September 4, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754077||74114|
NCT01766466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-CAN-12-03|Cangrelor Ticagrelor Transition Study|A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease||The Medicines Company|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|12|||Both|18 Years|75 Years|No|||April 2014|April 18, 2014|January 7, 2013|Yes|Yes||No|April 23, 2013|https://clinicaltrials.gov/show/NCT01766466||73164|
NCT01766479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTedeschi|Non-cathartic Computed Tomographic Colonography to Screen Subjects With a Family History of Colorectal Cancer|Non-cathartic Computed Tomographic Colonography to Screen for Colorectal Neoplasia in Subjects With a Family History of Colorectal Cancer||Istituto Clinico Humanitas|No|Completed|May 2009|November 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|1||Actual|844|||Both|40 Years|N/A|No|||January 2013|January 10, 2013|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01766479||73163|
NCT01739439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-046|Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery|RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer||Fox Chase Cancer Center|Yes|Active, not recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739439||75238|
NCT01735838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39385.060.12|Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study|Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study||Catharina Ziekenhuis Eindhoven|No|Completed|June 2012|July 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|All patients referred to our centre for implantation of a CRT-P or CRT-D device are        eligible. In the pilot phase 20 patients will be included. Data will be collected at        baseline and 3 months post-implantation.|January 2016|January 27, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735838||75515|
NCT01736163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYR04910|A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours|A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration||Sanofi|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|144|||Both|18 Years|N/A|No|Probability Sample|Historical records at clinical sites will be reviewed in a systematic fashion to identify        eligible patients.|March 2015|March 19, 2015|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736163||75490|
NCT01736735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTST-24|Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects|A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects|STEPWISE|Sorbent Therapeutics|Yes|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|21 Years|N/A|No|||March 2014|March 3, 2014|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736735||75446|
NCT01735812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICUFL-01|Laparoscopic Cryoablation of Uterine Fibroids|Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3™ System in a Percutaneous Laparoscopic-assisted Approach|UFREEZE-01|IceCure Medical Ltd.|No|Recruiting|December 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|30 Years|50 Years|No|||November 2012|February 5, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735812||75517|
NCT01736449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1108|Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management|Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management||Arrowhead Regional Medical Center|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A||||November 2012|November 26, 2012|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01736449||75468|
NCT01737541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83/11|Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage|Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial|FMRICH|Universidad Autónoma de Aguascalientes|Yes|Terminated|November 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|November 21, 2012||No|Study recruitment was suspended due to lack of funding|No||https://clinicaltrials.gov/show/NCT01737541||75384|
NCT01737528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVTR-2012-01|STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)|Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry).|TVTR|The Society of Thoracic Surgeons|No|Recruiting|June 2012|June 2022|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Transcatheter Aortic Valve Replacement must be furnished in a hospital with the        appropriate infrastructre that includes, but is not limited to On site heart valve surgery        program Cardiac catheterization lab or hybrid operating room with a fixed radiographic        imaging system with flat panel fluoroscopy, offering quality imaging Non-invasive imaging        such as echocardiography, vascular ultrasound, computed tomography and magnetic resonance        Sufficient space, in a sterile environment, to accomodate necessary equipment for cases        with and without complications Post-procedure intensive care facility with personnel        experienced in managing patients who have undergone open-heart valve procedures        Appropriate volume requirements|December 2012|December 27, 2012|November 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01737528|30 Days|75385|
NCT01737788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CervOcc-001|Cervical Occlusion for the Prevention of Preterm Birth|Randomised Trial of Cervical Cerclage With and Without Occlusion for the Prevention of Preterm Birth in Women Suspected for Cervical Insufficiency||Hvidovre University Hospital|Yes|Terminated|August 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|309|||Female|18 Years|N/A|No|||November 2012|November 29, 2012|November 24, 2012||No|Due to slow recruitment and an interim analysis showing no benefit of occlusion.|No||https://clinicaltrials.gov/show/NCT01737788||75365|
NCT01737801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-CF-2|Time to Perform Lung Function Test in Cystic Fibrosis|Time to Perform Lung Function Test in Cystic Fibrosis After Chest Physiotherapy.||Karolinska University Hospital|No|Completed|February 2008|September 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|5 Years|80 Years|No|||November 2012|November 29, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01737801||75364|
NCT01755052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT10974014|SILVER-AMI: Outcomes in Older Persons With Heart Attacks|SILVER-AMI: Risk Stratification in Older Persons With Acute Myocardial Infarction|SILVER-AMI|Yale University|No|Enrolling by invitation|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3100|||Both|75 Years|N/A|No|Non-Probability Sample|Older adults admitted to the hospital with a heart attack|October 2015|October 22, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01755052||74039|
NCT01755065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12020593|Clinical Meaning of Visual Analog Scales(VAS) for Teenage Pediatric Patients Undergoing Laparoscopic Surgical Procedures|Clinical Meaning of Visual Analog Scales (VAS) for Teenage Pediatric Patients Undergoing Laparoscopic Surgical Procedures||Children's Hospital of Pittsburgh||Recruiting|December 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|206|||Both|11 Years|17 Years|No|Non-Probability Sample|The participants will be selected based on medical records review and medical interview on        the day of surgery: we plan to enroll 206 teenager patients (11-17 years old) with        anticipated postoperative pain after any laparoscopic procedure and their parents and        nurses.|April 2015|April 16, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755065||74038|
NCT01755923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-S466|Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC|A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR||Peking Union Medical College Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2012|December 19, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01755923||73973|
NCT01755598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115616|Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults|Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region||GlaxoSmithKline||Active, not recruiting|August 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3506|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755598||73997|
NCT01752634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2312|Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis|A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis|FUTURE 2|Novartis||Active, not recruiting|April 2013|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|398|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752634||74225|
NCT01752946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009zx09502-030-07|A Registry Study of Shuxuening Injection Used in Hospitals in China|A Registry Study of Shuxuening (a Chinese Medicine Injection) Used in Hospitals in China|RSCMI-VII|China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|According to the 'rule of three', 30,000 cases need to be registered at least. The aim        population is who using Shuxuening injection's during inpatient time from December 2012 to        December.2014 in more than 30 hospitals in China.|December 2012|December 19, 2012|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01752946||74201|
NCT01756768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481011|A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PD-0332991 In Healthy Male Volunteers||Pfizer|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756768||73909|
NCT01752920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 087-101|Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations|A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion||ArQule|No|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01752920||74203|
NCT01752621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-3013-97/1/HKR|Epidemiology of Acromegaly in Denmark 1991-2010|Incidence and Late Prognosis of Acromegaly in Denmark From 1991 - 2010: Twenty Years of Medical Treatment||University of Aarhus|Yes|Active, not recruiting|February 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|The entire danish population in the period 1991-2010 by means of national register|December 2014|December 5, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01752621||74226|
NCT01752894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0047|DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)||DETECT-OCT|Yonsei University|No|Recruiting|January 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1100|||Both|20 Years|N/A|No|||February 2015|February 26, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752894||74205|
NCT01752907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110148|Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim|Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim|VINE|Amgen|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|304|||Female|18 Years|99 Years|No|||December 2015|December 6, 2015|November 15, 2012||No||No|December 6, 2015|https://clinicaltrials.gov/show/NCT01752907||74204|
NCT01753791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5301002|Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults|A Phase 1, Dose Expansion Of A Within-cohort, Randomized, Double-blind, Third-party Open, Placebo-controlled, Single-and Multiple-dose Escalation Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of Pf-06473871 In Normal Healthy Adults||Pfizer|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753791||74136|
NCT01754090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERAF-BALANCE-1|Testing the Efficacy of an Online Alcohol Intervention|Digital Therapy: Evaluation of the Fully Automated Alcohol Intervention "Balance".||University of Oslo|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|244|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01754090||74113|
NCT01766492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1175|Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery|Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)|PR-PROS|Georgetown University|No|Recruiting|December 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|99 Years|No|Non-Probability Sample|Men (> 18 y/o) with clinically localized prostate cancer,|July 2015|September 30, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766492||73162|
NCT01767012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viros_POLYLENS|Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties|Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties|POL|Vienna Institute for Research in Ocular Surgery||Completed|August 2010|November 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||January 2013|January 9, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01767012||73123|
NCT01735565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56286|Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant|Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant||University of Utah|No|Recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Patients who are undergoing bone marrow transplant, as well as patients who have completed        a bone marrow transplant within the previous year at Huntsman Cancer Institute and Primary        Children's Medical Center will be identified as possible participants.|December 2015|December 2, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735565||75536|
NCT01735825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KVO 631/2011 Pleva|Treatment of Coronary In-Stent Restenosis|Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus.|TIS|University Hospital Ostrava|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|90 Years|No|||January 2016|January 3, 2016|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01735825||75516|
NCT01736202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAME|Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity|Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study)|FLAME|German Diabetes Center|Yes|Recruiting|March 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736202||75487|
NCT01736462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|794|Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days|An Open-Label Study to Evaluate 3 Month Corneal Endothelial Cell Density Changes in Healthy Subjects When Mapracorat Ophthalmic Suspension, 3%, is Administered 4 Times Daily for 14 Days||Bausch & Lomb Incorporated|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 22, 2013|November 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736462||75467|
NCT01737021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2015|Improving Outcomes After PICU Admission: A Pilot Study|A Psycho-educational Intervention to Improve Family Mental Health and Child Educational Outcomes Following Admission to PICU: A Pilot Study||Imperial College London|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|31|||Both|4 Years|16 Years|No|||April 2015|April 24, 2015|November 1, 2012||No||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01737021||75424|
NCT01737008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XDC-001|Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck|Phase I Trial of Dacomitinib Concomitant With Radiotherapy With and Without Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck||University Health Network, Toronto|Yes|Active, not recruiting|January 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01737008||75425|
NCT01737814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-188-01|Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)|Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis|EPIC|Mast Therapeutics, Inc.|Yes|Recruiting|May 2013|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|388|||Both|4 Years|65 Years|No|||January 2016|January 9, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737814||75363|
NCT01738100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08-010|Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention|Effects of Ticagrelor and Intracoronary Morphine on Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Samsung Medical Center|No|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|20 Years|N/A|No|||October 2014|October 19, 2014|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01738100||75341|
NCT01738113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Youssef1|Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD|Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD||Cairo University|No|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|No|||July 2014|July 3, 2014|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738113||75340|
NCT01738126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-K01DA025289|fMRI and DTI of Cerebellar Responses to Pain in the Human Trigeminal System|||Mclean Hospital|No|Active, not recruiting|May 2009|December 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Healthy human volunteers|November 2012|November 29, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738126||75339|
NCT01767337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGN-NSR-2012-002|Intracutaneous Delivery of Varied Dose Volumes of Saline|Exploratory Evaluation of Healthy Subjects Receiving Varied Dose Volumes of Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array||FluGen Inc|Yes|Completed|December 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767337||73098|
NCT01755351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongPH|Comparative Study About the Influence of Diabetes Diatress and Depression on Treatment Adherence in Chinese Type 2 Diabetes Patients|||Shandong Provincial Hospital||Completed|December 2011|||December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with type 2 diabetes who visited the two local hospitals between December 2011        and April 2012, were invited to participate in this cross-sectional survey study.|January 2013|January 2, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755351|1 Year|74016|
NCT01755325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-CYP001|Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+|Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Ruijin Hospital|Yes|Enrolling by invitation|November 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|680|||Both|18 Years|75 Years|No|||August 2014|August 20, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755325||74018|
NCT01755338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004232-37|Effect of Steroids on Cerebral Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement|Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement||Sahlgrenska University Hospital, Sweden|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755338||74017|
NCT01755949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001686|Colchicine and CRP in Atrial Fibrillation and AF Ablation|Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation||Mayo Clinic|No|Recruiting|March 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|N/A|N/A|No|||March 2015|March 24, 2015|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755949||73971|
NCT01756183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPECIAL|Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer|Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|September 2011|December 2016|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||December 2012|December 19, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01756183||73953|
NCT01752660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAarhus100|Exercise in Severely Disabled Patients With MS|Endurance Training in Severely Disabled Patients With MS - a Feasibility Study||University of Aarhus|No|Completed|October 2012|July 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|12|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752660||74223|
NCT01752933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-110-03|SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)|A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib||Astex Pharmaceuticals|No|Completed|December 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752933||74202|
NCT01753180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO-201|Total Occlusion Study in Coronary Arteries - 5|A 2-stage Study to Evaluate Single Doses of MZ-004 at Different Dose Levels in Patients With Chronic Total Occlusions. Stage 1: Open Label Training Stage. Stage 2: Double-blind, Randomized, Placebo-Controlled Stage|TOSCA-5|Matrizyme Pharma Corporation|Yes|Active, not recruiting|April 2014|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|100 Years|No|||January 2016|January 7, 2016|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753180||74183|
NCT01753466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAU-6607-GD|The Water Intake Trial: Pilot Phase|The Water Intake Trial: Pilot Phase|WIT|Lawson Health Research Institute|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|30 Years|80 Years|No|||April 2013|April 19, 2013|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01753466||74161|
NCT01764438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INBU study|Utility Study of Primovist-MRI on HCC Staging|The Incidence of Change in BCLC Stage by add-on Primovist-enhanced MRI During Initial Staging Work-up in HCC Patients Who Can be Candidates for Curative Treatment by Liver Dynamic CT: A Prospective Multicenter Study|PrimovistMRI|Inha University Hospital|No|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|174|||Both|18 Years|N/A|No|Probability Sample|HCC patients with very early (BCCLC stage 0) or early (BCLC stage A) stage disease, but        with no suspicious intrahepatic HCC lesions by liver dynamic CT|August 2012|January 3, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01764438|1 Year|73320|
NCT01739114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034524|Assessment of Lung Aeration at Birth|Sustained Inflations to Achieve Lung Aeration at Birth - a Randomized Control Trial||University of Alberta|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|186|||Both|N/A|30 Minutes|No|||October 2014|October 29, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739114||75263|
NCT01739127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01611|Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI|A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI|CALM|University of British Columbia|No|Recruiting|November 2012|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|Participants will be offered the option of taking part in an optional biobanking component      of the main study. Six milliliters of whole blood samples will be collected and stored at      -80 degrees Celsius for genotyping to determine if certain genetic polymorphisms predispose      individuals to gain weight while taking antipsychotic medications.|Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who have recently been seen at a community Early Psychosis Intervention (EPI)        clinic, or at BC Children's Hospital for first-episode psychosis or bipolar disorder.        Age-, sex-, and weight-matched controls will be recruited from the general community.|November 2015|November 30, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739127||75262|
NCT01735851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB UWO 103035|Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery|Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery - A Randomized Open Label Study||Lawson Health Research Institute|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|85 Years|No|||August 2015|August 31, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735851||75514|
NCT01736189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-684|Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)|Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)||AbbVie||Active, not recruiting|September 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|16 Years|99 Years|No|Non-Probability Sample|Single-arm, Multi-center, Prospective Cohort|January 2016|January 27, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01736189||75488|
NCT01736748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRCUIT 1|Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors|Implementing Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors|CIRCUIT|St. Justine's Hospital|No|Not yet recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|6 Years|18 Years|No|||July 2013|July 11, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736748||75445|
NCT01736488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FA-CT-401|Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients|A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients||Boryung Pharmaceutical Co., Ltd||Recruiting|October 2012|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|20 Years|75 Years|No|||August 2015|August 31, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01736488||75465|
NCT01737281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-291|Proactive Outreach for Smokers in VA Mental Health|Proactive Outreach for Smokers in VA Mental Health|PROMH|VA Office of Research and Development|Yes|Active, not recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737281||75404|
NCT01766349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-100066-E|Effect of CCRT on Respiratory Performance and Functional Capacity in Esophagus Cancer Patients|Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Primary Esophagus Cancer||Far Eastern Memorial Hospital|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with primary esophagus cancer and receive radiation therapy|January 2013|February 3, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01766349||73173|
NCT01766830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP2-01-FEV|Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)|Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan||University Hospital, Geneva|No|Active, not recruiting|January 2013|July 2016|Anticipated|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|1927|||Both|5 Years|N/A|No|||April 2015|April 13, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766830||73137|
NCT01767077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TvärLivs-MFGM|Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans|Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans|MFGM|Uppsala University|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|52|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767077||73118|
NCT01755962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|546464|Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity|Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity|GET FIT|University of California, Los Angeles|No|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01755962||73970|
NCT01756209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine2010|Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood|The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood||University of Cantanzaro|Yes|Completed|January 2010|February 2012|Actual|February 2012|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|160|Samples With DNA|whole blood|Both|5 Years|18 Years|No|Probability Sample|we peformed a single blind study in outpatient children enrolled at the Pediatric        Unit-Pugliese Ciaccio Hospital in Catanzaro|December 2012|December 19, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756209|18 Months|73951|
NCT01756222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00035836|Bicuspid Aortic Valve Registry|Bicuspid Aortic Valve and Ascending Aortic Aneurysm Registry|BAV|University of Michigan|Yes|Recruiting|April 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary clinic|December 2015|December 9, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756222|30 Years|73950|
NCT01755611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116745|Bioequivalence Minocycline Bioequivalence|Bioequivalence Study Between Two Medications for Oral Administration of Minocycline in 100 mg Oral Solids in Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|December 19, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755611||73996|
NCT01753193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-MEDI-546-1145|An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults|A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus||MedImmune LLC|No|Enrolling by invitation|March 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|68 Years|No|||December 2015|December 23, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753193||74182|
NCT01753479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMSC-Mag-1|Spectroscopy From Duodenum|Duodenal Spectroscopy Study for Cancer Diagnosis||Olympus Corporation|Yes|Recruiting|January 2013|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753479||74160|
NCT01753752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT291211|Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation|||Medical University of Vienna|Yes|Completed|September 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01753752||74139|
NCT01753765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0613|Study Evaluating the Treatment of Occipital Neuralgia|A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Occipital Neuralgia With the Cryo-Touch III Device||MyoScience, Inc|Yes|Completed|October 2012|July 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01753765||74138|
NCT01764451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVMC 6205|Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins|Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins||University of New Mexico|No|Recruiting|March 2012|June 2019|Anticipated|June 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764451||73319|
NCT01764464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00041904|GRASSP: Gralise® for Spine Surgery Pain|Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome|GRASSP|University of Rochester|No|Recruiting|December 2012|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||September 2015|September 17, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01764464||73318|
NCT01739465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA2012|Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma|A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma||Guangzhou Medical University||Recruiting|November 2012|||December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|No|||February 2013|February 25, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739465||75236|
NCT01735292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209-12-HMO|Safety of the Automatic Respiration Transfer System- Timer|Safety of the Automatic Respiration Transfer System- Timer|Timer|Hadassah Medical Organization|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|13 Years|N/A|No|||November 2012|November 23, 2012|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01735292||75557|
NCT01736475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261201|Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)|A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A||Baxalta US Inc.|Yes|Completed|January 2013|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|159|||Male|12 Years|65 Years|No|||October 2015|October 30, 2015|November 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736475||75466|
NCT01736215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016558|An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy|Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy||Janssen-Cilag Ltd.,Thailand|No|Terminated|November 2010|February 2012|Actual|February 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|Samples Without DNA|Blood samples will be collected for hematological analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Participant with cancer related anemia receiving chemotherapy will be observed for        response to erythropoietin treatment.|March 2014|March 28, 2014|November 26, 2012|No|Yes|This study was terminated regarding to slow enrollment.|No|March 29, 2013|https://clinicaltrials.gov/show/NCT01736215||75486|
NCT01766583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEAR|A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma|A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA|CLEAR|The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|February 2013|June 2018|Anticipated|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01766583||73155|
NCT01766596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creuzot-Garcher PHRC IR 2009|Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Cohort)|Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Cohort): Seek Correlations Between Signs of Neurological and Vascular Degeneration and Signs of Ocular Aging|3C|Centre Hospitalier Universitaire Dijon||Recruiting|October 2009|||October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|3000|||Both|N/A|N/A|No|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766596||73154|
NCT01766570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHENOL-C11-12-155|Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.|Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.||Laval University|No|Completed|March 2012|August 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|60|||Both|40 Years|65 Years|No|||September 2015|September 1, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01766570||73156|
NCT01766843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106007, EudraCT 2012-00378-41|Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus|Bioequivalence Study Comparing Two Salmeterol/Fluticasone Propionate Dry Powder Inhalers, SF Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766843||73136|
NCT01767090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-CL-0011|A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment||Astellas Pharma Inc|Yes|Completed|December 2012|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|912|||Female|18 Years|45 Years|No|||August 2015|August 12, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01767090||73117|
NCT01755650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/31|Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies|A Phase 0 Exploratory Microdosing Study of S-(3-18Ffluoropropyl)Homocysteine Hydrochloride; 18FFPM Using PET/CT in Patients With a Variety of Malignancies.||Cooperative Research Centre for Biomedical Imaging Development|Yes|Recruiting|October 2011|July 2013|Anticipated|January 2013|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01755650||73993|
NCT01755663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmongkutklao|Comparison of Efficacy of Ivabradine Versus Metoprolol|Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients|IMAGE|Phramongkutklao College of Medicine and Hospital|Yes|Not yet recruiting|December 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2014|October 27, 2014|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755663||73992|
NCT01755975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-170|Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma|A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755975||73969|
NCT01756508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eculizumab for reperfusion|Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury|Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.||Russian Academy of Medical Sciences|No|Recruiting|March 2013|May 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|12 Months|80 Years|No|||July 2015|July 8, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756508||73928|
NCT01756794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-26|Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment|Validation of an Accelerated Procedure of Selection in Early Liver Transplantation for Severe Alcoholic Hepatitis Not Responding to Medical Treatment QuickTransHAA.|QuickTrans|University Hospital, Lille|No|Recruiting|December 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|263|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756794||73907|
NCT01756469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHE#KE.09.0235|Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya|Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya||FHI 360|No|Completed|March 2011|November 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|818|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756469||73931|
NCT01756482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-0103|Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)|Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)|Challenge|Gilead Sciences|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756482||73930|
NCT01756495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116628|A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin|A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756495||73929|
NCT01763281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12072012SCS|Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption|Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption||University of Nottingham|No|Completed|October 2012|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763281||73409|
NCT01752959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAcikgozEsmolol|A Comparison of Esmolol and Remifentanil to Reduce Blood Loss|A Randomized Comparison of Esmolol and Remifentanil on Intraoperative Bleeding and Surgical Field Conditionsin Nasal Surgery||Diskapi Teaching and Research Hospital|No|Recruiting|July 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|20 Years|60 Years|No|||December 2012|December 17, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01752959||74200|
NCT01753206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD_EPR_OS2012|Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals|Observational Study to Investigate Resistant Hypertension Prevalence Among the Hypertensive Patients Who Have Been Treated in Korean General Hospitals|Teveten_RH|Handok Pharmaceuticals Co., Ltd.|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1579|||Both|20 Years|N/A|No|Non-Probability Sample|General hospitals|January 2014|January 14, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753206||74181|
NCT01753492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42312.068.12/METC12-2-073|Trabeculectomy With Ologen|Trabeculectomy With Ologen-Pilot||Maastricht University Medical Center|No|Terminated|August 2013|March 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|December 12, 2012||No|The results were disappointing.|No||https://clinicaltrials.gov/show/NCT01753492||74159|
NCT01753778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0614|Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device|A Prospective Non-Randomized Unblinded Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device||MyoScience, Inc|No|Completed|November 2012|August 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|December 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01753778||74137|
NCT01739140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFCHR12-09424|Yoga for Chronic Low Back Pain and Its Mechanism of Action (YoMA)|Yoga for Chronic Low Back Pain and Its Mechanism of Action (YoMA)|YoMA|University of California, San Francisco|No|Active, not recruiting|December 2012|December 2015|Anticipated|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739140||75261|
NCT01739452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESMD-SPRESAS-2012-01|Spanish Registry of Erythropoietic Stimulating Agents Study|National Registry of Patients Diagnosed With Low-risk Myelodysplastic Syndromes According to the Criteria of the WHO / French-American-British Classification System (FAB) and IPSS and Treated With Erythropoietic Agents.|SPRESAS|Grupo Español de Síndromes Mielodisplásicos|No|Completed|January 2013|September 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|722|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with MDS according to WHO classifications or FAB low-risk (IPSS low and        intermediate-1) with anemia (Hb ≤ 11 g / dL) and treatment (support / ESA) started before        December 31, 2011.|April 2015|April 8, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739452||75237|
NCT01735578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58673|Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis|Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis||University of Utah|No|Completed|October 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|N/A|12 Weeks|No|Non-Probability Sample|Premature infants admitted to the University of Utah NICU with significant anemia.|December 2014|May 1, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01735578||75535|
NCT01765842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITULUP|Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy|Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Resistant to Conventional Treatments.|RITULUP|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Terminated|November 2012|December 2015|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|70 Years|No|||January 2013|July 9, 2015|January 3, 2013||No|The recruitment period has finished without reaching sample size|No||https://clinicaltrials.gov/show/NCT01765842||73212|
NCT01736228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCT/DIA-12|Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus|A Phase IIb Open-label Investigation of the Safety and Efficacy of DIABECELL [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type 1 Diabetes Mellitus||Living Cell Technologies|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||October 2013|March 15, 2015|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736228||75485|
NCT01736241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14514|A Study of LY3053102 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3053102 in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|53|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01736241||75484|
NCT01766102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-107|Intra-operative Digital vs. Standard Mammography|A Comparison of Intra-Operative Digital Specimen Mammography to Standard Specimen Mammography||Massachusetts General Hospital|No|Not yet recruiting|January 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|75|||Female|18 Years|N/A|No|||January 2013|January 9, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766102||73192|
NCT01766115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000954|Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers|Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers||Massachusetts General Hospital|Yes|Withdrawn|April 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|70 Years|No|||August 2014|August 12, 2014|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766115||73191|
NCT01767389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200065|Glucagon-like Peptide (GLP) Utilization and Safety|Glucagon-like Peptide-1 (GLP-1) Agonists: Treatment Utilization Patterns and Risk of Acute Pancreatitis||GlaxoSmithKline|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|18 Years|64 Years|No|Non-Probability Sample|The study population will include subjects aged ≥ 18 and ≤ 64 years as of index date and        those who have continuous enrolment for at least 12 months in Truven (Thomson Reuters)        commercial health insurance database from 2005-2011. The Truven database captures        person-specific clinical utilization, expenditures, and enrolment across inpatient,        outpatient, prescription drug, and carve-out services from a selection of large employers,        health plans, and government and public organizations. This databases links paid claims        and encounter data to detailed patient information across sites and types of providers,        and over time. The annual medical databases include private sector health data from        approximately 100 payers. Historically, more than 500 million claim records are available        in the database. The Commercial Claims and Encounters Database represents the medical        experience of insured employees and their dependents for active employees, early retirees,        COBRA continues, and their dependents i|July 2014|July 31, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01767389||73094|
NCT01766856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12040564|Eustachian Tube Function and Myringoplasty/Tympanoplasty|Eustachian Tube Function as a Predictor of Myringoplasty/Tympanoplasty Outcome||University of Pittsburgh|No|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|3 Years|16 Years|No|Non-Probability Sample|Children undergoing myringoplasty/tympanoplasty for eardrum perforation after a tube or        after a retained tube is removed.|January 2016|January 15, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766856||73135|
NCT01767740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15001105|Pilot Study of the Use of ULTRABRAID PLUS SUTURE in the Repair of Tears of the Rotator Cuff|Two-Arm, Single Blind, Randomized Pilot Study on the Use of ULTRABRAID PLUS SUTURE in the Repair of Tears of the Rotator Cuff||Smith & Nephew, Inc.|Yes|Active, not recruiting|February 2013|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767740||73067|
NCT01767116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-961|A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection|A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)|PEARL-III|AbbVie|Yes|Completed|December 2012|August 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|419|||Both|18 Years|70 Years|No|||August 2015|August 19, 2015|November 30, 2012|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01767116||73115|
NCT01767376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116705|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Healthy Adolescents and Young Adults Between 11 and 25 Years of Age||GlaxoSmithKline||Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|692|||Both|11 Years|25 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767376||73095|
NCT01762462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP13450|Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment|An Open-label, Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function||Sanofi|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|75 Years|No|||August 2013|August 28, 2013|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01762462||73472|
NCT01756521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOXI036|A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects|A Multi-center, Randomized, Open-label, Placebo-controlled, 3-way Crossover Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects||Seoul National University Hospital||Completed|January 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|39|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756521||73927|
NCT01752647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLCT-01|CT Screening For Lung Cancer in High Risk Patients: the Russian Study.|Cohort Study of Low Dose Computed Tomography for Lung Cancer Screening in Asymptomatic High-risk Patients.||Petrov Research Institute of Oncology|No|Active, not recruiting|November 2012|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|500|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752647||74224|
NCT01763294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/10|A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy|A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy||El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Yes|Completed|February 2012|April 2015|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|28|||Both|15 Years|65 Years|No|||April 2015|April 5, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01763294||73408|
NCT01763567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP244|Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)|A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients|MAHI|Medtronic Diabetes|No|Completed|March 2012|September 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the Intensive Care Unit (ICU) and on intravenous (IV) insulin        therapy for the treatment of transient or diabetes-related hyperglycemia|May 2015|May 5, 2015|December 21, 2012||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01763567||73387|
NCT01763580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGNS-11-02-KOR|A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome|Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS)|T-OPTIMUM|Astellas Pharma Inc|No|Recruiting|June 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|16 Years|78 Years|No|||October 2015|October 27, 2015|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01763580||73386|
NCT01763892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040284|Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)|Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)||Duke University|No|Completed|December 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples With DNA|Apolipoprotein E (apo-E) genotype/SNPs Endothelin 1 genotype/SNPs|Both|N/A|15 Years|No|Probability Sample|Children|October 2015|October 19, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01763892||73362|
NCT01764178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-PTV-102A|Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects|A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects||JW Pharmaceutical|No|Not yet recruiting|January 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|52|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01764178||73340|
NCT01764191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA-Cardiac PET|18F-FDG PET Imaging in Cardiac Sarcoidosis|[18 F]-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Cardiac Sarcoidosis||British Columbia Cancer Agency||Available||||||N/A|Expanded Access|N/A|||||||Both|19 Years|N/A||||March 2016|March 4, 2016|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01764191||73339|
NCT01764204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qingkailing-V5.0|Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years|Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years||China Academy of Chinese Medical Sciences||Recruiting|January 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|whole blood of the patient with severe adverse drug reactions|Both|1 Year|80 Years|No|Non-Probability Sample|all the patients treated by Qingkailing Injection in the certain centers(hospitals) in the        next 2 years.|February 2016|February 23, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01764204||73338|
NCT01735305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNH-20121113|Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease|Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease|OPT-CAD|Shenyang Northern Hospital|Yes|Completed|November 2012|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14032|||Both|18 Years|85 Years|No|Non-Probability Sample|Patient of coronary heart disease receiving any antiplatelet therapy|December 2015|December 10, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01735305||75556|
NCT01735864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC101-2325-B-182-018|Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment|Evaluation of the Efficacy and Safety of Indigo Naturalis Extract in Oil in the Topical Therapy of Psoriasis Vulgaris: Dosage Determination||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|November 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|20 Years|65 Years|No|||November 2012|November 26, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735864||75513|
NCT01765855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005|An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects|AN OPEN-LABEL, SINGLE-DOSE, MASS-BALANCE STUDY TO ASSESS THE DISPOSITION OF 14C-LABELED PRT054021 IN HEALTHY MALE SUBJECTS||Portola Pharmaceuticals|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||December 2012|January 8, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01765855||73211|
NCT01765868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-012|A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers|A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers.||Portola Pharmaceuticals|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01765868||73210|
NCT01766128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEPD-1091|Study of Zonisamide in Early Parkinson Disease|Randomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson Disease|ZONIST|Mazandaran University of Medical Sciences|No|Not yet recruiting|February 2013|April 2014|Anticipated|February 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|85 Years|No|||January 2013|January 9, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766128||73190|
NCT01766362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creuzot Innov 2010|Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.|Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.|Pascal|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|October 2011|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766362||73172|
NCT01766882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00054879|Volume,Sodium and Blood Pressure Management in HD|Fluid-Weight, Volume, Sodium, Blood Pressure Management in Hemodialysis by Limiting Intradialytic and Inter-dialytic Exposure to Sodium and Protocol-based Challenge of Post-dialysis Target Weight: A Pilot and Feasibility Trial|VSBP|University of Michigan|No|Recruiting|September 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|85 Years|No|||August 2015|August 4, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766882||73133|
NCT01767155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-108-050|Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer|Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.|ZoptEC|AEterna Zentaris|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|No|||July 2015|July 2, 2015|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767155||73112|
NCT01767753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1207|IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty|A Prospective, Observational, Open Label Study to Assess the 24-hour IOP Fluctuation Pattern Recorded With SENSIMED Triggerfish® in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty||Sensimed AG|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|99 Years|No|||November 2015|November 16, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767753||73066|
NCT01767168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 10-218|Study to Test the Value of a Pain Modulation Test in Predicting Persistent Postoperative Pain After Breast Cancer Surgery|Trial of Diagnostic Accuracy for the Prediction of Persistent Postoperative Pain After Breast Cancer Surgery Using a Conditioned Pain Modulation Test|PREDO|University Hospital, Geneva|No|Active, not recruiting|May 2011|May 2016|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|venous blood sample|Female|18 Years|N/A|No|Non-Probability Sample|women scheduled for any type of breast cancer surgery in a university hospital breast        cancer center|August 2015|August 26, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767168||73111|
NCT01768026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB-101-12|Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa|A Prospective, Longitudinal Assessment of Disease Severity in Subjects With Dystrophic Epidermolysis Bullosa (DEB)||Lotus Tissue Repair, Inc.|No|Withdrawn|February 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be selected from clinical sites with interdisciplinary clinics for        Dystrophic Epidermolysis Bullosa|February 2013|May 20, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01768026||73045|
NCT01762241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wii-1-10-72-593-12|Xbox Kinect Training in Men With Prostate Cancer|Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy||Hospitalsenheden Vest|No|Recruiting|February 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Male|40 Years|N/A|No|||February 2016|February 19, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01762241||73489|
NCT01756235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-683|Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice|Physical ACtivity in patiEnts With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (PACE)|PACE|AbbVie|No|Completed|December 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|445|||Both|18 Years|99 Years|No|Probability Sample|This study is a post-marketing observational study (PMOS) in which adalimumab is        prescribed in the usual manner in accordance with the terms of the local marketing        authorization with regards to dose, population and indication.        Study population will consist of adult (aged ≥18 years) patients with rheumatoid arthritis        (RA) that can be treated with adalimumab as per locally approved label and prescription        guidelines.|November 2015|November 19, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756235||73949|
NCT01756248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15895|EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan|Special Drug Use Investigation of EYLEA for AMD||Bayer|No|Active, not recruiting|December 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4041|||Both|N/A|N/A|No|Non-Probability Sample|Patients with subfovear choroidal neovascular age-related macular degeneration|March 2016|March 15, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756248||73948|
NCT01762475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-N-2215|Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.|Sildenafil for the Treatment of Cerebrovascular Dysfunction During the Chronic Stage After Traumatic Brain Injury.||Uniformed Services University of the Health Sciences|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01762475||73471|
NCT01763034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMA-CIN01|Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient|Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient||Ramathibodi Hospital|Yes|Recruiting|February 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|December 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763034||73428|
NCT01763047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5357|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2012|||||N/A|N/A|N/A||||||||||||||May 7, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763047||73427|
NCT01756807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-472 (IRB HK)|EGO-COMBO Angiographic Extension Study|Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent Angiographic Extension Study (EGO-COMBO Angiographic Extension Study)||The University of Hong Kong|Yes|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|85 Years|No|||October 2014|October 21, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756807||73906|
NCT01756820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ioannina-CTS-HV|Single-portal Endoscopic Carpal Tunnel Release Versus Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial|Single-portal Endoscopic Carpal Tunnel Release vs Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial.|CTS-HV|University of Ioannina|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|N/A|No|||April 2014|April 7, 2014|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756820||73905|
NCT01763632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2012-318|Development of TcB Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants|Development of Transcutaneous Bilirubin Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants: a Multicenter Study in China||Nanjing Medical University|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19601|||Both|N/A|28 Days|Accepts Healthy Volunteers|Probability Sample|Term or late-preterm newborn infants from thirteen hospital in China were recruited.|October 2014|October 25, 2014|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763632||73382|
NCT01763645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-021-02|A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer|International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients||Biocad|No|Active, not recruiting|October 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01763645||73381|
NCT01763593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUROSLEEK/CIP/001/2012|Safety and Surgical Performance Study of Aurosleek Surgical Blades|A Prospective, Open Label, Observational Study To Evaluate The Safety And Surgical Performance Of Surgical Blade (Aurosleek) In Cataract Patients|Aurosleek|Aurolab|No|Recruiting|March 2013|June 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cataract surgery would be included in this observational study|April 2013|April 29, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01763593||73385|
NCT01763606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-264|Enoxaparin Versus Aspirin in Patients With Cancer and Stroke|A Pilot Trial of Enoxaparin Versus Aspirin in Patients With Cancer and Stroke||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||March 2016|March 11, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01763606||73384|
NCT01763619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-300|Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease|Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease||AxioMed Spine Corporation|No|Recruiting|February 2013|May 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|65 Years|No|||January 2015|January 14, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763619||73383|
NCT01763905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110116|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2|A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor|GAUSS-2|Amgen|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|307|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|January 7, 2013|Yes|Yes||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01763905||73361|
NCT01763918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110117|Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia|RUTHERFORD-2|Amgen|Yes|Completed|February 2013|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|331|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|January 7, 2013|Yes|Yes||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01763918||73360|
NCT01764217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERVMA01|Prediction of Clinical Response and Outcome in Uterine Cervix Cancer|Predicting Clinical Response and Outcome After Definitive Irradiation With MRI-Guided Adaptive Brachytherapy in Uterine Cervix Cancer||Maastricht Radiation Oncology|No|Recruiting|July 2006|January 2013|Anticipated|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Histologically proven cervical uterine cancer, undergoing to conventional radiotherapy.|January 2013|January 7, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01764217||73337|
NCT01764724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103SOK-01|Attitudes and Understanding of Sodium Claims on Food Labels|Consumer Attitudes and Understanding of Low Sodium Claims on Food: An Analysis of Healthy and Hypertensive Individuals||University of Toronto|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|987|||Both|20 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|A subsection of the Canadian Consumer Monitor Panel - a national representative online        consumer panel comprised of 30,000 Canadians|January 2013|January 9, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01764724||73298|
NCT01735591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1WB/3DG1|Administration of Probiotics in Cirrhotic Patients Listed for Liver Transplantation|An Attempt to Optimize the Results of Liver Transplantation With Administration of Probiotics.||Medical University of Warsaw|Yes|Completed|November 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735591||75534|
NCT01735890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_AMV_102|Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers||CJ HealthCare Corporation|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2012|September 11, 2013|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01735890||75511|
NCT01769898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|theophylline in bronchiectasis|The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis|The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis||The First Affiliated Hospital of Guangzhou Medical University|Yes|Completed|July 2013|November 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769898||72901|
NCT01766609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02140|Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo|Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial||University of British Columbia|No|Recruiting|January 2013|January 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|19 Years|N/A|No|||June 2015|June 30, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766609||73153|
NCT01766869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054431|Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS|Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease|GCC 1261|University of Maryland|Yes|Active, not recruiting|April 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|N/A|No|Non-Probability Sample|prostate cancer patients that have elected to go for radical prostatectomy|August 2015|August 10, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766869||73134|
NCT01767129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AVR-133|Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients|A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.|LID in PD|Avanir Pharmaceuticals|No|Completed|July 2013|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|30 Years|80 Years|No|||June 2015|June 22, 2015|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767129||73114|
NCT01767142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-009|Feasibility Study of a Belt Applicator|Feasibility Study of a Belt Applicator for Non-Invasive Fat Reduction in the Outer Thigh||Zeltiq Aesthetics|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|October 14, 2014|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01767142||73113|
NCT01766895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980083|Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan|Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2011|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|Samples With DNA|host factors ssociated with viral hepatitis|Both|N/A|N/A|No|Probability Sample|Uremic patients will recruited from 15 hemodialysis units including one medical center, 3        satellite hospitals and 11 local clinics in Taiwan.|August 2015|September 23, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01766895||73132|
NCT01767402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100417|Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults||GlaxoSmithKline||Completed|October 2003|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767402||73093|
NCT01767415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106011772|Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection|Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection||Weill Medical College of Cornell University|No|Recruiting|March 2012|December 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767415||73092|
NCT01762501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS1|Azilsartan Circadian and Sleep Pressure|Azilsartan Circadian and Sleep Pressure - the 1st Study||Sogo Rinsho Médéfi Co., Ltd.|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|957|||Both|20 Years|N/A|No|||November 2015|November 19, 2015|December 18, 2012||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01762501||73469|
NCT01754142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-306|Korean Post-marketing Surveillance for Kombiglyze XR®|Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance||Bristol-Myers Squibb|No|Recruiting|November 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment        within the approved indications will be enrolled|August 2015|August 28, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754142||74109|
NCT01762748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIC 0609.0.203.000-09|Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant|Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant||Federal University of Minas Gerais|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01762748||73450|
NCT01762761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113765|Eltrombopag Phase III Study In Chinese Chronic ITP Patients|A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients||GlaxoSmithKline|No|Active, not recruiting|February 2013|July 2017|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||March 2015|February 4, 2016|December 19, 2012|Yes|Yes||No|January 19, 2015|https://clinicaltrials.gov/show/NCT01762761||73449|
NCT01763060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012/986-31/3|Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure|||Karolinska University Hospital|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|7|||Both|20 Years|60 Years||Non-Probability Sample|All patients who survived ECMO treatment due to infection with Influenza A/H1N1 2009 up to        3 years after discharge from hospital|November 2013|November 20, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01763060||73426|
NCT01763073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001794|Beliefs and Practice Intentions of Future Ob/Gyn Residents Regarding Reproductive Healthcare|Beliefs and Practice Intentions of Future Ob/Gyn Residents Regarding Reproductive Healthcare||Brigham and Women's Hospital|No|Active, not recruiting|January 2013|September 2015|Anticipated|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Fourth-year students in accredited US medical schools who have applied to, but not yet        been matched with, residency programs in obstetrics and gynecology.|April 2015|April 7, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01763073||73425|
NCT01763307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGFRI-MER-1a-HMO-CTIL|A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI|A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.|EGFRI|Hadassah Medical Organization|No|Not yet recruiting|January 2013|December 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2012|January 7, 2013|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01763307||73407|
NCT01763320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XW125-S002|China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis|China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China|CASSISS|Xuanwu Hospital, Beijing|Yes|Recruiting|March 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|30 Years|80 Years|No|||February 2015|February 3, 2015|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01763320||73406|
NCT01755208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-12-6|Light-Scattering Spectroscopy for Detection of Breast Cancer|Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study||University of Southern California|Yes|Recruiting|November 2012|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 24, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755208||74027|
NCT01763931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1232|DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer|Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|January 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|64|||Female|18 Years|70 Years|No|||October 2015|October 9, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01763931||73359|
NCT01764230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Masaryk University|Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients|Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients|OVARONKO|Masaryk University|No|Completed|January 2004|January 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Female|18 Years|35 Years|No|||January 2013|January 7, 2013|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01764230||73336|
NCT01764477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-724-102|Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma|Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination With Continuous Intravenous Doses of PRI-724, a CBP/ β- Catenin Inhibitor, to Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy With FOLFIRINOX (or FOLFOX)||Prism Pharma Co., Ltd.|No|Completed|April 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01764477||73317|
NCT01764490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REIPI-1WP701|Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study|Impact of Specific Antimicrobials and Minimal Inhibitory Concentration(MIC) Values on the Outcome of Bloodstream Infections Due to ESBL or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study|INCREMENT|Spanish Network for Research in Infectious Diseases|Yes|Completed|January 2013|May 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1344|||Both|N/A|N/A|No|Probability Sample|- Episode of clinically-significant monomicrobial BSI due to ESBL or        carbapenemase-producing Enterobacteriaceae, including community and nosocomial ones|June 2014|June 26, 2014|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01764490||73316|
NCT01764737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15/2503-N-101|Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis||Vaccinex Inc.|No|Completed|December 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||February 2015|February 5, 2015|January 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01764737||73297|
NCT01764750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012IntrasiteVanc|Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics|A Prospective Dose-Escalation Trial of the Pharmacokinetics and Preliminary Safety of Intrasite Lyophilized Vancomycin to Prevent Wound Infections in Instrumented Spinal Surgery||Washington University School of Medicine|Yes|Suspended|January 2013|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|December 14, 2012|No|Yes|awaiting FDA approval for next dose group|No||https://clinicaltrials.gov/show/NCT01764750||73296|
NCT01735877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2012|Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial|Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial|MUST|Christian Medical College and Hospital, Ludhiana, India|No|Completed|January 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||May 2014|May 24, 2014|November 26, 2012||No||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01735877||75512|
NCT01769911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2583.00|Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma|AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|February 2015|||February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|66 Years|No|||May 2015|May 6, 2015|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769911||72900|
NCT01769924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092761|A Prospective UK Multicentre Study of Kidney Donors|Effect of A Reduction in Glomerular Filtration Rate After Nephrectomy on Arterial Stiffness (EARNEST)||Cambridge University Hospitals NHS Foundation Trust|Yes|Not yet recruiting|February 2013|||February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|880|Samples With DNA|Urine, serum and plasma.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2013|January 15, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01769924||72899|
NCT01766154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicure 12001|Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function|A Pharmacokinetic, Pharmacodynamic, and Safety Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Normal Renal Function and Subjects With Moderate-to-Severe Renal Impairment With Non-Dialysis-Dependent Renal Insufficiency (NDDRI)||Medicure|No|Completed|January 2013|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01766154||73188|
NCT01766388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia||Gynuity Health Projects|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Female|N/A|N/A|No|Non-Probability Sample|All women presenting to a study clinic in Yerevan, Armenia for voluntary termination of        intrauterine pregnancy with gestational ages of 13-22 weeks|July 2014|July 7, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01766388||73170|
NCT01766622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130036|18F-CP18 Imaging Studies for Cancer Treatment With Birinapant|A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy||National Institutes of Health Clinical Center (CC)||Withdrawn|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|99 Years|No|||July 2013|November 18, 2015|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766622||73152|
NCT01766908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0270|Optimal Timing of Cord Clamping in Preterm Pregnancy Following Vaginal or Cesarean Delivery|Timing of Umbilical Cord Clamping After Vaginal or Cesarean Preterm Birth|CordClamp|University of Mississippi Medical Center|No|Completed|December 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|72|||Female|18 Years|45 Years|No|||December 2014|December 15, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766908||73131|
NCT01767194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03125|Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma|A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma||National Cancer Institute (NCI)|Yes|Suspended|February 2013|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|N/A|N/A|No|||July 2015|October 27, 2015|January 9, 2013|Yes|Yes|Temporarily stopped for assessment.|No||https://clinicaltrials.gov/show/NCT01767194||73109|
NCT01767181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuRhythDia-1|Light and Exercise in Night-shift Workers|Effects of Timed Intensive Light Therapy or Timed Physical Exercise on Markers of Central and Peripheral Circadian Rhythm and on Cardiometabolic Function in Night Shift Workers||Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767181||73110|
NCT01767428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1900832|Pharmacokinetic Study to Compare Two Formulations of Paracetamol|A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol From Two Formulations in an Indian Population.||GlaxoSmithKline|No|Completed|April 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01767428||73091|
NCT01767441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGZenti MMT|Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test|Effects of Bariatric Surgeries on Glucose Homeostasis and Its Determinants During a Mixed Meal Tolerance Test|BASMEAL|Azienda Ospedaliera Universitaria Integrata Verona|Yes|Recruiting|February 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|64|Samples Without DNA|serum, plasma|Both|18 Years|60 Years|No|Non-Probability Sample|A total of 64 morbidly obese patients will be studied, composed of:          -  16 subjects scheduled for Roux-en-Y-gastric bypass;          -  16 subjects scheduled for laparoscopic adjustable gastric banding;          -  16 subjects scheduled for laparoscopic sleeve gastrectomy;          -  16 subjects not undergoing bariatric surgery, on diet treatment (control group)|August 2012|March 17, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767441||73090|
NCT01754155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW55584|A Prospective Radiostereometric Analysis and Clinical Evaluation of the Zimmer® Continuum® Acetabular Cup With Vitamin E Stabilized Polyethylene|A Prospective Radiostereometric Analysis and Clinical Evaluation of the Zimmer® Continuum® Acetabular Cup With Vitamin E Stabilized Polyethylene||Central DuPage Hospital||Recruiting|January 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|55|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754155||74108|
NCT01762488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35218|Renal Denervation in Treatment Resistant Hypertension|Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial|ReSET-2|Aarhus University Hospital Skejby|Yes|Recruiting|January 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|70 Years|No|||November 2015|November 17, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01762488||73470|
NCT01763086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSC-allo-HSCT-2013|Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant|Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|14 Years|65 Years|No|||January 2013|January 15, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01763086||73424|
NCT01763333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.1|To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1026706 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability of BI 1026706 (Open-label, Randomised, Four-way Cross-over)||Boehringer Ingelheim||Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|January 7, 2013||||No||https://clinicaltrials.gov/show/NCT01763333||73405|
NCT01754974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-033|Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C|A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects|BASIS|Bristol-Myers Squibb|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||December 2013|January 27, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01754974||74045|
NCT01755481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327727-2|Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate|Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate||Arla Foods|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|||June 2015|June 23, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01755481||74006|
NCT01755780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intrerscalene beach chair|Effect of the Side of Interscalene Block on Bradycardia and Hypotension in Beach Chair Position|The Effect of the Side of Interscalene Block on the Occurrence of Bradycardia and Hypotension During Shoulder Surgery in the Beach Chair Position||Larissa University Hospital|No|Recruiting|December 2012|July 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|50 Years|80 Years|No|Probability Sample|Patients for elective shoulder surgery|July 2014|July 9, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755780||73983|
NCT01755806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ModarresH_001|Comparison of Aortic Root Dimension Changes During Cardiac Cycle Between the Patients With and Without Aortic Valve Calcification Using ECG-gated 64-slice and Dual-source 256-slice Computed Tomography Scanners: Results of a Multicenter Study|||Modarres Hospital|No|Completed|January 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|104|||Both|20 Years|90 Years|No|Probability Sample|patients referring for coronary CT angiography|December 2012|December 21, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01755806||73982|
NCT01756053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815238|Effects of ABT-089 on Smoking Abstinence Symptoms and Reward|A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward||University of Pennsylvania|Yes|Terminated|March 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||February 2014|October 23, 2014|December 19, 2012|Yes|Yes|Trial discontinued based on the results of an interim futility analysis.|No|September 23, 2014|https://clinicaltrials.gov/show/NCT01756053||73963|The study was terminated early due to the results of an interim futility analysis.
NCT01769625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807-001|Changes in Biomarkers Using Prostaglandin Inhibitors|Prostaglandin Inhibition to Prevent Breast Cancer||The University of Texas Health Science Center at Tyler|No|Recruiting|January 2009|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|31|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769625||72922|
NCT01766375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangXi-AML- HSCT-2012-07|the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient|A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient|IDBUCY|Guangxi Medical University|No|Recruiting|August 2012|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|No|||January 2013|January 9, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01766375||73171|
NCT01765907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/F/BM/Feb2012.|Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU)|Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU).||Theraclion|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765907||73207|
NCT01766167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-424-K01|Clinical Pharmacology Study of MP-424|Clinical Pharmacology Study of MP-424 in Healthy Male Adult Volunteers (Single- and Multiple-Dose Study)||Mitsubishi Tanabe Pharma Corporation|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01766167||73187|
NCT01766180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1048|Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)|Association Between Fruitflow-II Treatment (Alone or in Combination With Resveratrol) and Changes in Cerebral Blood Flow, Fitness and Cognitive Function in Adults With Memory Complaints|CCIRF-II|Neurolgy Institute for Brain Health and Fitness|Yes|Recruiting|January 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 19, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766180||73186|
NCT01766401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-06|Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder|A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder|VLZ-MD-06|Forest Laboratories|No|Completed|January 2013|April 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|70 Years|No|||February 2015|February 27, 2015|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766401||73169|
NCT01766648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03489|Far Cortical Locking Versus Standard Constructs for Distal Femur Fractures|A Multicentre, Randomized Trial of Far Cortical Locking Versus Standard Constructs for Acute, Displaced Fractures of the Distal Femur Treated With Locked Plate Fixation|FCL|University of British Columbia|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766648||73151|
NCT01767818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-12-011|Parkinson's Disease Biomarker Program|Longitudinal, Single-center Prospective Study to Assess Progression of Clinical Features and Biologic Markers of Parkinson's Disease Subjects of Varying Levels of Disease Severity|PDBP|University of Texas Southwestern Medical Center|No|Recruiting|November 2012|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|Samples With DNA|Blood specimen collection from all enrolled patients and cerebrospinal fluid (CSF) from      patients who have provided additional and optional consent to CSF collection.|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|(1) de-novo, previously untreated patients within 5 years of symptom onset, n=20, and (2)        patients on treatment with and clinically responsive to MAO-B inhibitors, dopamine        agonists, amantadine, or levodopa (or combinations), n=220 and (3) healthy control        patients without evidence of degenerative nerological disease.|December 2015|December 29, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01767818||73061|
NCT01768078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creuzot-Garcher PHRC IR 2007|Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis|Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis.|Endophtalmitis|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|September 2008|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|N/A|No|||January 2013|January 14, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768078||73041|
NCT01767454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115984|Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma|Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma||GlaxoSmithKline|Yes|Completed|February 2013|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01767454||73089|
NCT01767467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116428|Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers|Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies||GlaxoSmithKline||Active, not recruiting|March 2013|January 2017|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|566|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767467||73088|
NCT01767792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4807|Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas|Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation||University of Alabama at Birmingham|Yes|Recruiting|May 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|40 Years|No|||February 2016|February 24, 2016|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767792||73063|
NCT01767805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4563|Impact of Culture Conditions on the Embryo Quality|||University Hospital, Gasthuisberg|No|Completed|June 2009|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|790|||Both|N/A|3 Days|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01767805||73062|
NCT01753895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHU-0759|Mercury Versus Automated Blood Pressure Monitoring|Comparison of Manual Blood Pressure Monitoring Using a Mercury Sphygmomanometer to an Automated Blood Pressure Instrument in a Research Setting||Rockefeller University|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|156|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|May 2014|May 5, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01753895||74128|
NCT01762774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114068|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers||GlaxoSmithKline|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|May 28, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01762774||73448|
NCT01754701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203M11234|Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria|Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|June 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|6 Months|59 Months|No|||November 2015|November 25, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754701||74066|
NCT01754714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-397|Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group|Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group|EXPO|Abbott|Yes|Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|108|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|December 19, 2012||No||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01754714||74065|
NCT01754961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-111219|Effects of Vitamin D on Inflammation in Liver Disease|Effects of Vitamin D on Inflammation in Liver Disease||Veterans Medical Research Foundation|No|Recruiting|November 2011|January 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01754961||74046|
NCT01755494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1681C00001|A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration|A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects Under Fed Conditions|SAXA|AstraZeneca||Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|64|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|December 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755494||74005|
NCT01755819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL Tightrope vs. Biocomposite|Outcome and Tunnel Widening After ACL Reconstruction: Comparison of Aperture and Cortical Fixation|Clinical Outcome and Tunnel Widening After Hamstring Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Computed Tomography - Based Trial Comparing Aperture With Cortical Fixation||Medical University Innsbruck|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|No|||January 2013|January 15, 2013|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755819||73981|
NCT01756066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816444|A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance|A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance||University of Pennsylvania|No|Completed|January 2013|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1239|||Both|18 Years|80 Years|No|||December 2015|December 18, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756066||73962|
NCT01769638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0462|Safety and Pharmacokinetic Comparison of Sildenafil ODF and FCT Formulations in Healthy Korean Volunteers|||Seoul Pharma Co., Ltd.||Completed|September 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01769638||72921|
NCT01765920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-ER-006|Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients||Materia Medica Holding|No|Completed|December 2012|April 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|60 Years|No|||January 2013|August 31, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01765920||73206|
NCT01765933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMAA Pharmacokinetics|Pharmacokinetic Effects of Oral DMAA|Pharmacokinetic and Physiological Effects of Oral DMAA Administration||University of Memphis|No|Completed|April 2012|December 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765933||73205|
NCT01766193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/666|Delivery Method and Risk for Urogenital Prolapse 15-20 Years Later|Delivery Method and Risk for Urogenital Prolapse 15-20 Years Later|uropro|Norwegian University of Science and Technology|No|Completed|August 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1641|||Female|40 Years|60 Years|No|Non-Probability Sample|Women who delivered their first child at St. Olavs Hospital, Trondheim (Norway) between        1990-1997|February 2015|February 17, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01766193||73185|
NCT01766414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36688|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study|VECTORII|Radboud University|Yes|Completed|September 2013|January 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01766414||73168|
NCT01766427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LCSY026|Electroacupuncture for Hypertension Patients With Chronic Kidney Disease|Electroacupuncture for Hypertension Patients With Chronic Kidney Disease||Shanghai University of Traditional Chinese Medicine|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|Samples Without DNA|serum|Both|15 Years|75 Years|No|Probability Sample|in the ward of the department of nephrology|December 2013|December 19, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01766427||73167|
NCT01766661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURNBULL-BCN-01|Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal|Prospective Multicenter Randomized Controlled Trial Comparing Postoperative Complications and Quality of Life in Low Rectal Cancer Surgery Between Coloanal Anastomosis and Lateral Ileostomy Versus Two-Stage Turnbull-Cutait Coloanal Anastomosis|TURNBULL-BCN|Hospital Universitari de Bellvitge|Yes|Recruiting|January 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|92|||Both|18 Years|74 Years|No|||March 2016|March 23, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766661||73150|
NCT01767831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16226|Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management|Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management||University of Virginia|No|Terminated|March 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|15|||Both|21 Years|65 Years|No|Probability Sample|Type 1 Diabetes Mellitus study subjects that are currently identified in the Center for        Diabetes Technology recruitment database. Subject be currently wearing an insulin pump for        at least 6 months and must have worn a continuous glucose monitor for at least 6 weeks        during the past 2 years.|April 2014|April 24, 2014|January 8, 2013||No|study team will review the collected data and make any necessary changes to the educational    tool.|No||https://clinicaltrials.gov/show/NCT01767831||73060|
NCT01768390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|417/2007|Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients|Caries-preventive Effectiveness of a Dentifrice Containing 5.000 Ppm Fluoride - a Randomized Controlled Trial in Adolescents With Fixed Orthodontic Appliances||University of Copenhagen|No|Completed|January 2008|October 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|500|||Both|11 Years|16 Years|No|||January 2013|January 11, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01768390||73017|
NCT01768650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44437-G|Structured Treatment of Pain (STOP) Study|Telephone-Delivered Cognitive Behavioral Therapy for Chronic Pain Following Traumatic Brain Injury|STOP|University of Washington|No|Enrolling by invitation|June 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768650||72997|
NCT01754181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01489-34|Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.|Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.|DiabeloopWP6-0|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|March 2013|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|18|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754181||74106|
NCT01754467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCDTR01|NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes|NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes||Northwestern University|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|21 Years|70 Years|No|||January 2014|January 14, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754467||74084|
NCT01754415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-098101-3|Evaluation of Exercise Benefits to Promote Health Aging Among Chronically Ill Geriatrics in a Community|Evaluation of Exercise Benefits to Promote Health Aging Among Chronically Ill Geriatrics in a Community.||Far Eastern Memorial Hospital|Yes|Completed|February 2010|May 2013|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|160|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01754415||74088|
NCT01754428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-0111|Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age|A Multi-Center, Outpatient, Surveillance Study of Respiratory Syncytial Virus (RSV) Infection and Respiratory Syncytial Virus-related Hospitalizations Among Subjects < 24 Months of Age With a Medically Attended Respiratory Tract Infection||Gilead Sciences|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2432|Samples Without DNA|Nasal swabs|Both|N/A|24 Months|No|Probability Sample|Outpatient pediatric clinics, urgent care facilities or emergency departments|August 2013|August 19, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01754428||74087|
NCT01754441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82008|Mechanisms of Cell Death in Spinal Muscular Atrophy|Mechanisms of Cell Death in Spinal Muscular Atrophy||Nemours Children's Clinic|No|Enrolling by invitation|May 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Skin biopsy specimens|Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll Children with Spinal Muscular Atrophy (SMA)|August 2015|August 21, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754441||74086|
NCT01754454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-MSC-002|Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease|Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Acute Graft-versus-host Disease||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|November 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01754454||74085|
NCT01754727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-682|Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice|Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice|IDEA|AbbVie|No|Completed|December 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|421|||Both|18 Years|99 Years|No|Probability Sample|This study is a post-marketing observational study (PMOS) in which adalimumab is        prescribed in the usual manner in accordance with the terms of the local marketing        authorization with regards to dose, population and indication.        Study population will consist of adult (aged ≥18 years) patients with ankylosing        spondylitis (AS) that can be treated with adalimumab as per locally approved label and        prescription guidelines.|November 2015|November 19, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01754727||74064|
NCT01755221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71707|Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR|A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux||Northwestern University|No|Active, not recruiting|August 2012|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|89 Years|No|||December 2014|December 12, 2014|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755221||74026|
NCT01755507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC-3/PSC|Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis|Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis|NUC-3|Dr. Falk Pharma GmbH|No|Recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|80 Years|No|||September 2013|September 25, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755507||74004|
NCT01755832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1654|Heated Pool Exercise Groups for Patients With Rheumatic Diseases|Better Everyday-life With Heated Pool Exercise Groups for Patients With Inflammatory Rheumatic Diseases||National Resource Center for Rehabilitation in Rheumatology|No|Completed|September 2012|January 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with inflammatory rheumatic joint diseases with a medical referral to group        exercises in heated pool.|December 2012|January 8, 2015|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01755832||73980|
NCT01756079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3034-105|A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)|A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00)||Merck Sharp & Dohme Corp.|No|Completed|February 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|75 Years|No|||November 2015|November 29, 2015|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756079||73961|
NCT01766141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122002|Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients|Changes in Inflammatory Cytokine Levels in Response to Spinal Manipulative Treatment of Low Back Patients: A Single-blind Pilot Clinical Trial.||Canadian Memorial Chiropractic College|Yes|Recruiting|April 2012|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766141||73189|
NCT01765946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetAge|Metformin and Longevity Genes in Prediabetes|Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial||University of Padova|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|75 Years|No|||March 2013|March 12, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765946||73204|
NCT01766440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06. SPR.18104|PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis|Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis||Galderma|No|Recruiting|March 2013|||February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|12 Years|No|||August 2015|August 6, 2015|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766440||73166|
NCT01766674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0045190|Specialized Centers of Research (SCOR)on Sex Differences - Kyphosis Study|Specialized Centers of Research (SCOR) Kyphosis Study|SCOR|University of California, San Francisco|No|Active, not recruiting|February 2013|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766674||73149|
NCT01766921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V89_13|Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects|A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.||Novartis|No|Completed|January 2013|July 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1393|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|January 10, 2013|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01766921||73130|
NCT01767207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1009 (Rek)|Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway|Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway||University Hospital of North Norway|No|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|320|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred to pediatric rehabilitation outpatient clinic|July 2015|July 6, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767207||73108|
NCT01767844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WA/0320|Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients?|Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients? A Randomised Controlled Pilot Trial||Bangor University|No|Active, not recruiting|January 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01767844||73059|
NCT01768091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-201211-K2|POEM vs. Pneumatic Dilation for Esophageal Achalasia|Peroral Endoscopic Myotomy Versus Pneumatic Dilation for Esophageal Achalasia: a Prospective Randomized Controlled Trial||Nanfang Hospital of Southern Medical University|No|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||January 2013|January 11, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01768091||73040|
NCT01768403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CDZ-XXX-2012/1|Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia|Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca||Completed|September 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1236|Samples Without DNA|Whole blood serum|Both|19 Years|N/A|No|Non-Probability Sample|-  Subject must be 19 years of age or older of either gender or race.          -  Subject must provide informed consent and comply with the survey procedures.          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose             change for a minimum of 6 weeks|January 2013|January 14, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768403||73016|
NCT01768416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/895|Measuring Depth of Unconsciousness at the End of Life Using Bispectral Index (BIS)|Measuring Depth of Unconsciousness at the End of Life: the Reliability of the BIS Monitoring as an Assessment Tool Versus Sedation Scales|BISSOPS|University Hospital, Ghent|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Pre-terminal palliative patients|June 2015|June 2, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768416||73015|
NCT01754194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMBSG0167|Clinical and Economic Outcomes in Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Surgery|An Observational Study in Morbidly Obese Patients to Evaluate Laparoscopic Gastric Sleeve Resections and Roux-en-Y Gastric Bypass Surgery in Clinical and Health-Economic Terms|OPTIMIZE|Medtronic - MITG|No|Completed|April 2012|October 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|305|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients diagnosed as obese and eligible for weight loss surgery (BMI>40; or BMI>35 with        co-morbidities) and the following insurance approval status (Kostenubernahmeantrag):        approved.|November 2015|November 24, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754194||74105|
NCT01754493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6479R|Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression|Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression|IBS-MDD|New York State Psychiatric Institute|No|Completed|December 2008|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||December 2012|March 23, 2015|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754493||74082|
NCT01754168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00071121|Amyloid Beta and Cognition in Parkinson Disease|The Role of Amyloid Beta in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study||University of Michigan|No|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Saliva samples with DNA|Both|65 Years|N/A|No|Non-Probability Sample|UM and VA Movement Disorders Clinic        Primary Care Clinic        Community|July 2015|July 27, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754168||74107|
NCT01754987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.424|A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective|Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma||Thomas Jefferson University|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754987||74044|
NCT01755000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206070|Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings|A Pilot Feasibility Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings||Washington University School of Medicine|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|69|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755000||74043|
NCT01755533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA021670|Adaptation Processes in School-Based Substance Abuse Programs|Adaptation Processes in School-Based Substance Abuse Programs||Penn State University|No|Completed|February 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|2827|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||May 2012|December 21, 2012|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01755533||74002|
NCT01755234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00070833|Propofol Versus Sevoflurane Recovery After Gynecological Surgery|The Effects of Propofol vs. Sevoflurane Administered During Anesthesia Maintenance on Early and Late Recovery After Gynecological Surgery||Northwestern University|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|64 Years|No|||February 2016|February 18, 2016|December 18, 2012|Yes|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01755234||74025|We only studied patients undergoing outpatient laparoscopic gynecological surgery, therefore, our results cannot be generalizable to other surgical procedures.We also administered remifentanil which is has been linked to hyperalgesia.
NCT01755520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. D00112|Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG|A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG|TiCAB|Deutsches Herzzentrum Muenchen|Yes|Recruiting|April 2013|April 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3850|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755520||74003|
NCT01755845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC-11256|Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients|Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy||Wenzhou Medical University|Yes|Recruiting|January 2011|December 2016|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|75 Years|No|||December 2012|December 19, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755845||73979|
NCT01756092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10020385|Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)|Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)||University of Pittsburgh|Yes|Withdrawn|July 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|70 Years|No|||January 2016|January 2, 2016|December 19, 2012||No|funding|No||https://clinicaltrials.gov/show/NCT01756092||73960|
NCT01766206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_62|Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea|A Multicenter Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.||Novartis|No|Recruiting|March 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3300|||Both|2 Months|55 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766206||73184|
NCT01767220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2012-0125|Endo- and Epicardial vs. Endocardial Ablation of Ventricular Tachycardia in Patients With Cardiac Disease|Primary Endo- and Epicardial vs. Endocardial Ablation of Sustained Ventricular Tachycardia in Patients With Underlying Cardiac Disease (VTeee)|VTeee|University of Rostock|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2013|January 29, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01767220||73107|
NCT01767233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/2010|Prophylactic Pancreatic Duct Stenting in Acute Necrotizing Pancreatitis|Prophylactic Pancreatic Duct Stenting in Acute Necrotizing Pancreatitis: a Prospective Randomized Controlled Multicenter Study|ERPNEC|University of Oulu|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|75 Years|No|||January 2013|January 11, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767233||73106|
NCT01767857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-PT023|A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer|Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer|XCITE|XBiotech, Inc.|Yes|Recruiting|March 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767857||73058|
NCT01768104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEK-201211-K1|ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors|Endoscopic Submucosal Tunnel Dissection Versus Video-assisted Thoracoscopic Surgery for Upper Gastrointestinal Submucosal Tumors: a Prospective Randomized Controlled Trial||Nanfang Hospital of Southern Medical University|No|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|75 Years|No|||December 2011|January 11, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01768104||73039|
NCT01768429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFAKALA|The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism|The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism||University of Eastern Finland|No|Completed|October 2012|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|79|||Both|40 Years|70 Years|No|||December 2014|December 2, 2014|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768429||73014|
NCT01754766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229666-002|AGN-229666 for the Treatment of Allergic Conjunctivitis|||Allergan|No|Completed|October 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|20 Years|N/A|No|||December 2013|December 17, 2013|December 19, 2012|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01754766||74061|
NCT01754779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032012-058|Treatment for Calcium Phosphate Kidney Stone Disease|Pharmacological Therapy for Calcium Phosphate Urolithiasis||University of Texas Southwestern Medical Center|Yes|Recruiting|July 2012|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||February 2015|February 3, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01754779||74060|
NCT01754740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study|The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study|BMS|University of Sao Paulo General Hospital|No|Completed|January 2010|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|37 Years|88 Years|No|||December 2012|December 18, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754740||74063|
NCT01754753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3004-01|Putting Life in Years (PLINY): Telephone Friendship Groups Research Study|Evaluation of the Effectiveness and Cost Effectiveness of an Intervention to Promote Mental Wellbeing in Community Living Older People.|PLINY|University of Sheffield|Yes|Terminated|June 2012|December 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|157|||Both|75 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 22, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01754753||74062|
NCT01755546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3409-309|Long-term Open-Label Safety Study to Evaluate EN3409|A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time||Endo Pharmaceuticals|No|Completed|December 2012|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|554|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755546||74001|
NCT01755559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/Nig/2012/Palu3ACT|Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger|Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13||Epicentre|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|663|||Both|6 Months|59 Months|No|||November 2015|November 26, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755559||74000|
NCT01755858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRI-225|Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)|A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia™ (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)||Stealth BioTherapeutics Inc.|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|28|||Both|40 Years|80 Years|No|||April 2015|April 27, 2015|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755858||73978|
NCT01755871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINGOHHU|Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis|The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis|BiobankII|Heinrich-Heine University, Duesseldorf|No|Terminated|January 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|December 19, 2012||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01755871||73977|
NCT01755884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODEW|Oral Desensitization to Wheat in School Aged Children|Oral Desensitization to Wheat in Children Over 6 Years of Age With Wheat Allergy||Helsinki University Central Hospital|No|Completed|August 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|6 Years|16 Years|No|||March 2015|March 19, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755884||73976|
NCT01756105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4965|Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women|Gestational Diabetes in Non Obese Women and Metformine||University Hospital, Strasbourg, France|No|Recruiting|July 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|40 Years|No|||December 2012|December 19, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756105||73959|
NCT01756391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AI 0739654|Allergens in Inner-City Schools and Childhood Asthma|Allergens in Inner-City Schools and Childhood Asthma|SICAS-1|Children's Hospital Boston|No|Completed|March 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|||Both|4 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|elementary school students with asthma|December 2014|December 4, 2014|December 20, 2012||No||No|November 22, 2014|https://clinicaltrials.gov/show/NCT01756391||73937|
NCT01756664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj-Eucerin01|The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing|The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing - A Pilot Study.||Mahidol University|Yes|Recruiting|August 2012|August 2013|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|December 26, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756664||73916|
NCT01756690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0238|Predicting Lung Injury From Transfusion in Patients With Liver Disease|Endogenous Heparinoid Interference With Coagulation on Thromboelastogram as a Predictive Biomarker for Transfusion Related Acute Lung Injury (TRALI)||University of Colorado, Denver|Yes|Terminated|October 2011|December 2016|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|85 Years|No|Non-Probability Sample|Patient with chronic Liver disease admitted to an intensive care unit with a        gastrointestinal bleed and INR> 1.5 who may receive plasma transfusion therapy.|April 2014|May 26, 2015|December 20, 2012||No|Recruitment|No||https://clinicaltrials.gov/show/NCT01756690||73915|
NCT01765647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGY|Oral AGY for Celiac Disease|Use of an Orally Administered Antibody to Gluten to Prevent the Recurrence of Symptoms and Laboratory Parameters in Persons With Celiac Disease (Gluten Sensitive Enteropathy)||Igy Inc.|No|Active, not recruiting|May 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|75 Years|No|||May 2015|May 7, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01765647||73227|
NCT01765894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-074|Influence of Moderate Exercise on Blood Glucose in Type 2 Diabetics and Healthy Controls|Influence of Moderate Exercise on Blood Glucose in Type 2 Diabetics and Healthy Controls.|DIEGO|University of Copenhagen|Yes|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|24|Samples With DNA|whole blood and plasma|Male|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|-  10 type 2 Diabetics without medication          -  10 type 2 Diabetics on Metformin treatment          -  10 matched healthy controls|February 2014|February 21, 2014|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01765894||73208|
NCT01766934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP06-501|Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors|Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization|SMART|Sandoz|No|Active, not recruiting|May 2011|August 2024|Anticipated|August 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adult, unrelated, healthy volunteers who received at least one dose of Sandoz' filgrastim|March 2016|March 16, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766934||73129|
NCT01766947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1206|IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy|A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Primary Open Angle Glaucoma Before and After Deep Sclerectomy||Sensimed AG|No|Withdrawn|November 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766947||73128|
NCT01766960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1599|Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease|Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.||University of North Carolina, Chapel Hill|No|Completed|November 2012|June 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01766960||73127|
NCT01767246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00635|The Evaluation of a Novel Treatment Algorithm for Patients With Patellofemoral Syndrome|The Evaluation of a Novel Treatment Algorithm for Patients With Patellofemoral Syndrome: A Pilot Study|PFSAlgorithm|Nationwide Children's Hospital|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|N/A|No|||July 2015|July 2, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767246||73105|
NCT01767480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-3905A3|Effects of Intensive Robot-assisted Therapy in Patients With Subacute Stroke|Effects and Mechanisms of Intensive Robot-Assisted Therapy in Patients With Subacute Stroke: Outcomes in Brain/Movement Reorganization, Sensorimotor and Daily Functions, and Physiological Markers.|RT|Chang Gung Memorial Hospital|No|Completed|January 2013|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767480||73087|
NCT01767493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Florbetapir MS 01|Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients|An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis||Institute for Neurodegenerative Disorders|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01767493||73086|
NCT01767506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00076305|A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial|A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial|ASANTE|Johns Hopkins University|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 1, 2015|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767506||73085|
NCT01736124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-285|CCT for Diabetic Elderly Veterans|Computerized Cognitive Training to Improve Cognition in Diabetic Elderly Veterans|CCT_DEV|VA Office of Research and Development|No|Recruiting|April 2015|November 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|65 Years|99 Years|No|||January 2016|January 6, 2016|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01736124||75493|
NCT01736137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dont have|Evaluation of the Six Minute Walk Test and Other Instruments in Heart Failure|Evaluation of the Six Minute Walk Test, Heart Rate Variability and Quality of Life in Heart Failure Patients on Beta-blocker Treatment||Federal University of Uberlandia|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Heart failure patients routinely treated at the Amelio Marques Clinic, Hospital de        Clínicas, Federal University of Uberlandia, who have scheduled a visit during the period        of study and attends the criterias of the study will be included.        The sample will be a convenience, and included all patients who meet the study criteria.        The control group included healthy participants with the same gender and age of the        chronic heart failure group.|August 2014|August 5, 2014|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736137||75492|
NCT01768117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971042|Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age|A Single-arm, Open-label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers >=18 To < =65 Years Of Age|B1971042|Pfizer|Yes|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|January 8, 2013|Yes|Yes||No|February 23, 2015|https://clinicaltrials.gov/show/NCT01768117||73038|Results of immunogenicity endpoints were reported in ''number'' and not in ''proportion'' as per team's input.
NCT01768689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAKE IT - CML adherence|Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia|The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)|TAKE-IT|Rabin Medical Center|No|Recruiting|April 2013|April 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|88|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768689||72994|
NCT01768702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3BS-C-11-01|Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.|Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.|CHART-1|Celyad (formerly named Cardio3 BioSciences)|Yes|Active, not recruiting|November 2012|July 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||May 2015|May 18, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01768702||72993|
NCT01754792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIL-PIN-2012-02|Effects of Pinitol on Hidrocarbonated Metabolism Parameters in Diabetic, Impaired and Normal Fasting Glucose Subjects|A Randomized, Double-blind, Placebo-controlled Study on the Influence of Pinitol on Carbohydrate, Lipid and Inflammatory Parameters, Endothelial Function and Oxidative Stress in Diabetic, Impaired and Normal Fasting Glucose Subjects||University of Valencia|No|Completed|January 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01754792||74059|
NCT01754805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK13|A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis|A Phase 1b, Open-Label, Single Sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis||Astellas Pharma Inc|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|65 Years|No|||December 2012|December 19, 2012|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754805||74058|
NCT01754480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1102|Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries||Grifols Biologicals Inc.|No|Completed|December 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|325|||Both|N/A|N/A|No|||January 2016|January 12, 2016|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754480||74083|
NCT01755247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC004|A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers|A Phase One, Single-Center, Open-Label, Randomized, Parllel Group, 3 Day Study Evaluating the Safety and Cutaneous Toleraility of NVN10000 Topical Gel in Healthy Volunteers||Novan, Inc.|No|Completed|November 2012|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01755247||74024|
NCT01755260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202048RIB|Route of Nutritional Support for Pancreatic Fistula|Nutrition Through Oral Intake Versus Feeding Jejunostomy in the Conservative Treatment of Pancreatic Fistula After Pancreaticoduodenectomy: a Prospective Multicenter Randomized Clinical Trial||National Taiwan University Hospital|No|Recruiting|September 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|20 Years|N/A|No|||December 2014|December 2, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755260||74023|
NCT01755572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH-12-0020-A|Blood Pressure Outcomes With Liraglutide Therapy|Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.|BOLT|Mount Sinai Hospital, Canada|No|Completed|January 2013|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Both|30 Years|70 Years|No|||March 2015|March 23, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755572||73999|
NCT01755897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-GYN/CC-01|A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients|A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients|CC-01|Huazhong University of Science and Technology|Yes|Active, not recruiting|November 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|60 Years|No|||April 2015|April 11, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755897||73975|
NCT01756118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235ZDE01T|A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia|A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia||Johann Wolfgang Goethe University Hospitals|No|Active, not recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756118||73958|
NCT01756131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114433|A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects|An Observer- and Subject-Blinded, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects||ViiV Healthcare|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|9||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|May 16, 2013|September 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01756131||73957|
NCT01756404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013765|Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of JNJ-28431754 in Otherwise Healthy Obese Male and Female Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 9, 2013|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756404||73936|
NCT01752556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01240|Cost-effectiveness of Home Respiratory Polygraphy|Non-inferiority Randomized Control Trial About Efficacy and Cost-effectiveness of Home Respiratory Polygraphy Management in Sleep Apneas/Hypopneas Syndrome|HRP-M|Sociedad Española de Neumología y Cirugía Torácica|No|Recruiting|May 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|70 Years|No|||December 2012|June 3, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01752556||74231|
NCT01765660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSCs-cGVHD-2013|Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease|Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Chronic Graft-versus-host Disease||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|65 Years|No|||January 2013|January 8, 2013|January 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01765660||73226|
NCT01766700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1063|The Role of No-Calorie Beverages Within a Weight Loss Program|The Role of No-Calorie Sweetened Beverages Within a Weight Loss Behavior Change Program and During Subsequent Weight Maintenance||University of Colorado, Denver|No|Completed|September 2012|August 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|308|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01766700||73147|
NCT01766713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZE|Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis|Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis||University of California, San Diego|No|Completed|January 2013|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 9, 2013|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01766713||73146|
NCT01766973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-U.NA.NFLT.EGDF|Decoding Chronic Pain With fMRI|Observational Study to Determine Abnormalities in Resting State fMRI in Chronic Back Pain.||University of Cambridge|No|Not yet recruiting|April 2013|April 2018|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with >6 months of mechanical lower back pain, not sue to any major systemic disease|January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766973||73126|
NCT01766986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGII-2012|Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction|Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction||Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|130|||Both|18 Years|N/A|No|Probability Sample|One-hundred and thirty patients with Siewert types I and II AOG who did not have        neoadjuvant treatment were included in the study|November 2014|November 17, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766986||73125|
NCT01767870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR312033|Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia|Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial|FITS|Yonsei University|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|5282|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01767870||73057|
NCT01767883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAFP-CKD-102020846|Improving Evidence-Based Primary Care for Chronic Kidney Disease|Improving Evidence-Based Primary Care for Chronic Kidney Disease||American Academy of Family Physicians|Yes|Recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|27000|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767883||73056|
NCT01767519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-125|A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence|||Allergan|No|Completed|March 2013|March 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|356|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 11, 2013|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01767519||73084|
NCT01767532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116990|Bioequivalence Study of Cephalexin Suspension 125|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparation of Cephalexin 125 mg/ 5 ml (Ceporex® GlaxoSmithKline México, S.A. de C.V. vs. Keflex®, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline||Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767532||73083|
NCT01736150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB03808|Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis||Sanofi|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736150||75491|
NCT01736397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-204|Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis|A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis||Keryx Biopharmaceuticals|Yes|Completed|November 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|November 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736397||75472|
NCT01736410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC0906|A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer||National Cancer Centre, Singapore|No|Completed|May 2010|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||June 2013|June 14, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736410||75471|
NCT01736670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO#11-0008|An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses|An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses||Patel, Rita Vikram, M.D.|Yes|Completed|April 2012|||May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2012|December 3, 2012|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736670||75451|
NCT01754818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIO-101|A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)|Phase 1 Randomized, Double-blind, Placebo-controlled Study of The Safety, Tolerability and Pharmacokinetics of Single, Ascending Oral Doses Of Bendavia in Healthy Volunteers||Stealth BioTherapeutics Inc.|Yes|Completed|November 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|December 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754818||74057|
NCT01754831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41117|Fluoride Administered and Retained After Topical Fluoride Varnish|Fluoride Administered and Retained After Topical Fluoride Varnish||University of Washington|No|Active, not recruiting|December 2011|December 2013|Anticipated|March 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|6|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||December 2012|December 18, 2012|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754831||74056|
NCT01755013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110011999|Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma|Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma.||Weill Medical College of Cornell University|No|Recruiting|February 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|55|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01755013||74042|
NCT01755273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203073RIC|Effect of More Distal Enteral Bypass After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial|Compare More Distal Enteral Bypass With Standard Enteral Bypass in the Remission of Glucose Metabolism for Patients With Diabetes or Impaired Fasting Glucose After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial||National Taiwan University Hospital|No|Recruiting|January 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|90|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755273||74022|
NCT01756443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-786-GI|Sciatic Nerve Block for Ankle/Foot Surgeries. A Comparison Between a Premixed Solution of Lidocaine Plus Bupivacaine and Consecutive Infiltration of Lidocaine and Bupivacaine|Sciatic Nerve Block for Ankle/Foot Surgeries. A Comparison Between a Premixed Solution of Lidocaine Plus Bupivacaine and Consecutive Infiltration of Lidocaine and Bupivacaine. A Double Blinded Randomised Controlled Prospective Study||Cork University Hospital|No|Completed|August 2011|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||December 2013|December 6, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756443||73933|
NCT01755910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRV Thoracic paravertebral|Effect of Thoracic Paravertebral Block on Heart Rate Variability (HRV)|Effect of Thoracic Paravertebral Block on the Autonomous System as Measured by Heart Rate Variability (HRV)||Larissa University Hospital|No|Not yet recruiting|December 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|20 Years|65 Years|No|Probability Sample|Patients for elective breast surgery|July 2014|July 9, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755910||73974|
NCT01756144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005664-10|rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport|rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|July 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01756144||73956|
NCT01756417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013636|A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers|An Open-Label, Fixed Sequence, Single and Multiple Dose Study in Male and Female Subjects to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Metformin and JNJ-28431754||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 26, 2013|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756417||73935|
NCT01756430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125HT12001|Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension||Chong Kun Dang Pharmaceutical|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756430||73934|
NCT01756703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-E06|A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects With Albuminuria and an eGFR ≥60 mL/Min/1.73m^2||Mitsubishi Tanabe Pharma Corporation||Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756703||73914|
NCT01756716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-E07|A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects With Albuminuria and an eGFR ≥30-<60 mL/Min/1.73m^2||Mitsubishi Tanabe Pharma Corporation||Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756716||73913|
NCT01753128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334/2553 (EC3)|Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn|Efficacy of Imipramine for Treatment of Patients With Esophageal||Mahidol University|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753128||74187|
NCT01752595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-035|The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment|The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment Study|MAINTAIN|Toronto Rehabilitation Institute||Active, not recruiting|November 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|35|||Both|N/A|N/A|No|||November 2013|November 25, 2013|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01752595||74228|
NCT01721954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STX0112|FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer|Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study|FOXFIREGlobal|Sirtex Medical|Yes|Active, not recruiting|February 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721954||76576|
NCT01722227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1964 Liraglutide ADA|Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes|Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes||Kaleida Health|No|Recruiting|November 2012|May 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722227||76555|
NCT01759654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUV12T13A|A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects|||Adimmune Corporation|No|Recruiting|October 2012|January 2013|Anticipated|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 27, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01759654||73688|
NCT01759667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|DIT After RYGB - A Prospective Study|Diet-induced Thermogenesis After Roux-en-Y Gastric Bypass - A Prospective Study|DIT RYGB|Gastrocirurgia, Brazil|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 27, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01759667||73687|
NCT01759953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InsuOnline-01|Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians|Randomized Controlled Trial to Assess the Educational Efficacy of a Serious Game for Teaching Insulin Therapy to Primary Care Physicians||Universidade Estadual de Londrina|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|170|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01759953||73665|
NCT01761058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16400|Severe Asthma Research Program - University of Virginia|The Severe Asthma Research Program at University of Virginia - Airway Redox Biochemistry as a Determinant of Asthma Phenotype During Adolescence|SARP3|University of Virginia|Yes|Recruiting|December 2012|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100||Blood: CBC/DIFF, total IgE, Serum, plasma, DNA, RNA, sputum, urine, exhaled breath      condensate|Both|6 Years|17 Years|No|Non-Probability Sample|Children with asthma (severe, well controlled)from the Charlottesville enactment area.|July 2013|July 1, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761058||73580|
NCT01761071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0440|Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)|||Yonsei University|No|Completed|January 2012|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|94|||Both|18 Years|50 Years|No|||January 2013|January 2, 2013|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01761071||73579|
NCT01756924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE06-200|Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection|||Cempra Inc|No|Terminated|December 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|December 18, 2012|Yes|Yes|This study has been terminated; alternative study designs are being considered. Fusidic acid    remains available under an Expanded Access Protocol.|No||https://clinicaltrials.gov/show/NCT01756924||73897|
NCT01757171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012946|Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma|An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma||Weill Medical College of Cornell University|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757171||73878|
NCT01757808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0301|A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension|A Phase I Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension||University of Chicago|Yes|Completed|August 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|72 Years|No|||June 2015|June 11, 2015|April 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757808||73830|
NCT01757821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrainPrime|Primed vs. Unprimed rTMS in Chronic Stroke|6-Hz Primed vs. Unprimed Low-Frequency rTMS in Chronic Stroke||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757821||73829|
NCT01758926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012SDU-QILU-G03|Association Between Inflammatory Activities and Gap Density|Association Between Inflammatory Activities and Epithelial Gap Density in Inflammatory Bowel Disease||Shandong University|Yes|Recruiting|December 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Observational Study Model: Case-Control|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with indications for colonoscopy in Qilu Hospital outpatient and inpatient        department.|December 2012|December 27, 2012|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758926||73744|
NCT01719276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mauriciomag20|Graded Activity Versus Supervised Exercises in Patients With Chronic Non-specific Low Back Pain|EFFECT OF COGNITIVE-BEHAVIORAL THERAPY AND EXERCISE VERSUS SUPERVISED EXERCISE PROGRAM IN PATIENTS WITH CHRONIC PAIN LUMBAR NO SPECIFIC: RANDOMIZED CONTROLLED TRIAL||University of Sao Paulo|Yes|Active, not recruiting|February 2013|December 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||June 2014|June 13, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01719276||76781|
NCT01719848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-079-001|Evaluation of Clinical Airway Assessments With a Gray Zone Approach|Evaluation of Clinical Airway Assessments for Predicting Difficult Laryngoscopy Using a Gray Zone Approach||Samsung Medical Center|Yes|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients undergoing general anesthesia for any surgery at Samsung medical center|April 2014|April 16, 2014|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719848||76737|
NCT01719861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0087|Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|A Phase IIa Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors||Stanford University|Yes|Terminated|October 2012|December 2014|Actual|May 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|October 29, 2012|No|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01719861||76736|
NCT01720706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA|Thermal Ablation in Larger Liver and Kidney Tumours|Thermal Ablation With a Loosely Wound Helical Coil for Radiofrequency Treatment of Large Renal and Hepatic Tumors in Patients Undergoing Partial or Total Nephrectomy or Heptectomy||University Health Network, Toronto|No|Recruiting|August 2011|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01720706||76672|
NCT01719822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LF002H|Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|July 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|155|||Both|N/A|N/A|No|||May 2015|May 12, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01719822||76739|
NCT01720784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-101|Effect of Beverages Containing Different Doses of Alginate Fibers on Appetite, Energy Intake and Glycemia|Effect of Beverages Containing Different Doses of Alginate Fibers on Appetite, Energy Intake and Glycemia|ALSAT|University of Copenhagen|No|Completed|October 2012|July 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 1, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720784||76666|
NCT01721083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDD# 602056|Comparison of Two Methods of Immunization for Intramuscular Injections|Comparison of Two Methods of Immunization for Intramuscular Injections||Christiana Care Health Services|No|Completed|October 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|511|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 15, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721083||76643|
NCT01721356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-1-0730|Neurobiological Basis of Emotional Intelligence|The Neurobiological Basis and Potential Modification of Emotional Intelligence Through Affective / Behavioral Training|EQ|Mclean Hospital|No|Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Between 70 and 80 healthy, English speaking, right-handed, adults between the ages of 18        and 45 participated. Attempts were made to include equal numbers of men and women to        permit the broadest generalization to the population and to permit direct assessment of        gender effects, an issue that has received considerable attention recently regarding the        neurobiology of affective processes. Subjects were not excluded on the basis of ethnicity,        gender, or sexual orientation. Healthy participants were recruited via local        advertisements, including email broadcasts such as the Harvard Hospital and Partners        Healthcare systems, internet advertisements, and posting of IRB-approved flyers in various        community centers. IRB-approved print advertisements were posted in local newspapers.|November 2012|November 1, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721356||76622|
NCT01721070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP104|Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics|IAP104 - Assessment of Pharmacokinetic Changes Following Concurrent Administration of Sufentanil NanoTab and Ketoconazole in Healthy Subjects||AcelRx Pharmaceuticals, Inc.|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|November 1, 2012|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01721070||76644|
NCT01721343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1193|Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer|MC1193: Collaborative Care to Preserve Performance in Cancer (COPE)||Mayo Clinic|Yes|Recruiting|November 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|516|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721343||76623|
NCT01718275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00406|Non-operative Management of Early Appendicitis in Children|Non-operative Management of Early Appendicitis in Children||Nationwide Children's Hospital|No|Active, not recruiting|October 2012|February 2024|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|||Both|7 Years|17 Years|No|Probability Sample|Children treated a tertiary care Children's Hospital|August 2015|August 14, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718275||76857|
NCT01718002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab. Comunicação EERP|Effect of the Use of Simulation (Video) on the Oral Hygiene|Effect of the Use of Simulation (Video) on the Oral Hygiene of People Undergoing Chemotherapy||University of Sao Paulo|Yes|Active, not recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01718002||76878|
NCT01718262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353368-19|Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion|Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion||Defense and Veterans Center for Integrative Pain Management|No|Completed|April 2010|November 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|Samples Without DNA|The plasma ropivacaine samples will be assayed at the Department of Research Programs      Laboratory (DRP) at WRNMMC. Once the whole blood sample has been centrifuged, the plasma      will be removed with a glass pipette, placed in a storage container. The blood samples will      be labeled with a non sequential serial number and will not include the time of the blood      draw. This will blind the DRP laboratory to the patient's identity and timing of the blood      draw.|Both|18 Years|89 Years|No|Non-Probability Sample|Military health care beneficiaries age 18 years and older presenting for upper or lower        extremity surgery requiring continuous infusions of local anesthetic either at WRNMMC will        be asked to participate in the study. We will recruit up to fifty patients for the study        at WRNMMC.|November 2012|November 14, 2012|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01718262||76858|
NCT01760551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR201201|Correlation Between the American Medical Association Guides to the Evaluation of Permanent Impairment and the Medical Outcomes Study 36-Item Short Form|Correlation Between the American Medical Association Guides to the Evaluation of Permanent Impairment and the Medical Outcomes Study 36-Item Short Form.||JointResearch|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|250|||Both|14 Years|N/A|No|Probability Sample|Patients who have had a medical legal examination by an orthopaedic surgeon working at        "Orthopedisch Expertise Centrum" and have completed a to Dutch translated SF-36 form.|January 2013|January 3, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01760551||73619|
NCT01760564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802043M|Application of Miglustat in Patients With Niemann-Pick Type C|Application of Miglustat in Patients With Niemann-Pick Type C||National Taiwan University Hospital|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||November 2012|January 3, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760564||73618|
NCT01760811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC0766|CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT|CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT||Rabin Medical Center|Yes|Not yet recruiting|January 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||January 2013|January 2, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760811||73599|
NCT01760824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-221|Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication|Ten Days Quadruple Versus Sequential Therapy as Empirical First and Second Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial||The University of Hong Kong|No|Completed|May 2011|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|December 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01760824||73598|
NCT01757184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL02|A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)|A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency||Alexion Pharmaceuticals|Yes|Active, not recruiting|January 2013|October 2015|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|4 Years|N/A|No|||April 2015|April 17, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757184||73877|
NCT01757457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000004|Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention|Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta||Azienda Ospedaliero Universitaria Maggiore della Carita|Yes|Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|90 Years|No|||December 2012|December 28, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01757457||73856|
NCT01758679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-XWG-201205001|A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma|A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|70 Years|No|||August 2012|February 14, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01758679||73763|
NCT01758692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-12-06|Measurement of Autonomic Cardiovascular Integrity in Persons With SCI|Measurement of Autonomic Cardiovascular Integrity in Persons With SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Two catecholamine samples are collected either pre/post tilt (in the ICU) or positional      shift (in the autonomics lab). Samples are collected once for individuals participants in      the non-invasive testing only subgroup, twice for individuals participating in the      ambulatory training subgroup, and on all 4 visits for individuals participating in the main      group.|Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty subjects with chronic SCI and 10 age and gender matched able-bodied controls will be        recruited. A subgroup of 20 subjects with SCI will be recruited solely for the        non-invasive portion of the study. These patients will not undergo the        pharmacological/placebo administration or any of the manipulations being performed in the        ICU. An additional 30 subjects will complete the non-invasive portion before and after        completion of an ambulatory training protocol. This includes subjects who have completed        various protocols in the Cardioautonomic Program or patients referred by their physician        following routine physical examinations. Physicians will be informed of the inclusion and        exclusion criteria for this study and will be able to provide us with the assurance that        the patient is an appropriate candidate for the study and that he/she was willing to speak        with the study coordinators.|February 2016|February 22, 2016|December 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758692||73762|
NCT01719536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV36|Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients|Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation|Convince|Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|December 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|75 Years|No|||September 2015|September 5, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01719536||76761|
NCT01719549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1202|Dovitinib for Gastric Cancer With FGFR2 Amplification|A Phase II Trial of Dovitinib Monotherapy as Salvage Treatment in Patients With Metastatic or Unresectable Gastric Cancer Harboring FGFR2(Fibroblast Growth Factor Receptor 2) Amplification After Failure of First or Second Line Chemotherapy||Asan Medical Center|No|Recruiting|October 2012|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01719549||76760|
NCT01720173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170R|Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Evaluation of Dalantercept (NSC #757172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Active, not recruiting|November 2012|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720173||76713|
NCT01719835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH CCR: 3549|CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study|CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study|CHEMO-T|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2012|August 2022|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01719835||76738|
NCT01720160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360032|Barostim HOPE4HF (Hope for Heart Failure) Study|Barostim HOPE4HF Study||CVRx, Inc.|Yes|Active, not recruiting|November 2012|January 2017|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720160||76714|
NCT01721109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0112|Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents|A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents||Gilead Sciences|Yes|Active, not recruiting|December 2012|October 2020|Anticipated|October 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|12 Years|17 Years|No|||November 2015|November 6, 2015|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721109||76641|
NCT01721122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-014|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2013|||||N/A|N/A|N/A||||||||||||||January 6, 2014|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721122||76640|
NCT01720810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW HSD: 37855|Pacific Northwest Udall Center (PANUC) Clinical Core|Pacific Northwest Udall Center (PANUC) Clinical Core|PANUC|University of Washington|Yes|Recruiting|March 2010|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Participants fall into either of two categories: A clinical sample (CS) that is evaluated        every 2-3 years or an annual sample (AS) that followed once yearly.        All subjects undergo the following procedures:          -  History and physical examination          -  Questionnaires about mood, activities of daily living, environmental exposures and             demographic information.          -  Psychometric tests        Study companions may also be asked to complete questionnaires about the study subject        regarding medical and psychiatric history, as well as activities of daily living.|October 2012|November 1, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720810||76664|
NCT01721135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112360|A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.|A Randomised, Placebo Controlled, Four-way Cross-over Study to Assess Cardiac Re-polarisation Following Repeat Dosing With GSK2190915 and Placebo for Five Days, With Moxifloxacin as a Positive Control, in Healthy Male and Female Subjects.||GlaxoSmithKline|No|Withdrawn|September 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|November 1, 2012||No|Study was terminated due to toxicology findings after screening started but before first    subject first dose.|No||https://clinicaltrials.gov/show/NCT01721135||76639|
NCT01721369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNCAT|Syncope in Cataluña SYNCAT|Observational Study of the Application of the ESC2009 Syncope Guidelines in Cataluña|SYNCAT|Medtronic Bakken Research Center|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|581|||Both|15 Years|N/A|No|Probability Sample|Patients with Transient Loss of Conscience: T-LOC|April 2014|April 8, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01721369||76621|
NCT01721655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24305|Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease|Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease||West Virginia University Healthcare|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||December 2015|December 7, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721655||76599|
NCT01749891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Focus 3|A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration|A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration||Allegro Ophthalmics, LLC|Yes|Recruiting|March 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|50 Years|N/A|No|||December 2012|December 12, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01749891||74435|
NCT01749904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|769|Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.|APOLLO|Bausch & Lomb Incorporated|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749904||74434|
NCT01718600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS070308|Long-term Neurocognitive Sequelae of Subclinical Microembolization During Carotid Interventions|||Stanford University|Yes|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing carotid intervention|April 2015|April 2, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718600||76832|
NCT01718860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000454|Safety of Intraoperative Use of Muscle Relaxants and Their Reversal Agent Neostigmine|Consequences on Respiratory Morbidity and Health-care Utilization of Partial Paralysis Upon Admission to the Postanesthesia Care.||Massachusetts General Hospital|No|Active, not recruiting|April 2011|December 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Patients given non-depolarizing neuromuscular blocking agents as part of general        anesthesia|March 2016|March 16, 2016|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718860||76813|
NCT01718873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBELICS|Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer|Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer|OBELICS|National Cancer Institute, Naples|No|Recruiting|May 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718873||76812|
NCT01760278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Time-lapse monitoring|Assessment of Implantation Potential of Embryos by Time-lapse Technology|Assessment of Implantation Potential of Embryos Cultured by Time-lapse Technology (Embryoscope) Before Transfer in In-vitro Fertilization (IVF) / Intracytoplasmic Sperm Injection (ICSI) Cycles: A Randomized Control Study.|Embryoscope|Bloom IVF and Fertility Centre|Yes|Active, not recruiting|December 2012|April 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01760278||73640|
NCT01760291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2278|Continued Access to PREVAIL (CAP2)|Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology|CAP2|Boston Scientific Corporation|Yes|Active, not recruiting|September 2012|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1500|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760291||73639|
NCT01760577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS100-061|Effects of Intraarticular Botulinum Toxin A in Ankle Osteoarthritis|Comparing Effects of Intraarticular Botulinum Toxin A Versus Hyaluronate Plus Rehabilitation Exercise in Patients With Unilateral Ankle Osteoarthritis||Kaohsiung Veterans General Hospital.|Yes|Completed|May 2010|November 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|85 Years|No|||January 2013|January 3, 2013|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01760577||73617|
NCT01756937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238KOA12G|Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|A Six-month, Multi Center, Randomizied, Double Blind, Parallel-group,Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|ABSOLUTE-R|Chong Kun Dang Pharmaceutical|No|Recruiting|January 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|324|||Both|40 Years|N/A|No|||September 2013|September 25, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01756937||73896|
NCT01758172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1001|Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy|Comparison of Hemodynamic and Clinical Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy||Asan Medical Center|Yes|Completed|October 2009|January 2012|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|75 Years|No|||January 2013|January 1, 2013|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01758172||73802|
NCT01758458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2586.00|Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma|Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2013|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01758458||73780|
NCT01758471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD017|Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes|An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of α-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|December 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|160|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 24, 2012|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758471||73779|
NCT01759524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-786-GS|To Compare lidocaine2%/Clonidine in Combination, With Bupivacaine 0.5 % Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade|To Compare lidocaine2%/Clonidine in Combination With Bupivacaine 0.5 % Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade||Cork University Hospital|No|Completed|October 2011|||January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||November 2013|November 17, 2013|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01759524||73698|
NCT01719874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCN-032-002|Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza|A Phase 2a, Double-Blind, Placebo-Controlled Study TCN 032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Subjects Challenged With H3N2 Influenza A Virus||Theraclone Sciences, Inc.|No|Recruiting|August 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01719874||76735|
NCT01720186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12POUM01|Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer|Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer|SPI COHERENCE|Institut Claudius Regaud|No|Terminated|May 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|46|||Both|18 Years|N/A|No|||September 2014|October 8, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01720186||76712|
NCT01720498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0581|The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation Under Propofol-remifentanil Anesthesia in Elderly Patients|||Severance Hospital|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|65 Years|N/A|No|||June 2013|June 16, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720498||76688|
NCT01720485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPCEMS0812|Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment|A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adults With Moderate - Severe Persistent Allergic Rhinitis||EMS|Yes|Not yet recruiting|October 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720485||76689|
NCT01720823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.589|Obstructive Sleep Apnea Syndrome (OSA) and Getemed|Diagnostic Characteristics of a Home Polysomnograph for the Diagnosis of Patients With Obstructive Sleep Apnea Syndrome - A Pilot Study|GETEMED|Hospices Civils de Lyon|No|Recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|62|||Both|2 Years|12 Years|No|||November 2015|November 12, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720823||76663|
NCT01721681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ten 02|A Study to Investigate BPL's Factor X in the Prophylaxis of Bleeding in Children <12 Years|A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL's High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years||Bio Products Laboratory|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|9|||Both|N/A|11 Years|No|||March 2016|March 4, 2016|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721681||76597|
NCT01721694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZILOT-12|Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection|Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection||Adapt Produtos Oftalmológicos Ltda.|No|Withdrawn|December 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|November 2, 2012||No|withdrawn by industry|No||https://clinicaltrials.gov/show/NCT01721694||76596|
NCT01721382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFRD-01|Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis|Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis.||Nemours Children's Clinic|No|Recruiting|November 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|13 Years|20 Years|No|||September 2014|September 25, 2014|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721382||76620|
NCT01750177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2012-120-002|Sedentary Screen Time Activities on Food Intake|Effect of Sedentary Screen Time Activities Before a Meal on Food Intake in Girls||Ryerson University|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|31|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750177||74413|
NCT01750450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16494|Validation of Peripheral Pressure Volume Loops and Ultrasound-derived "Cardiac Power" by Comparison With Invasive Left Ventricular Pressure Volume Loops|||University of Virginia|No|Completed|February 2013|June 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults 18 and over undergoing elective left heart catheterization|April 2014|April 30, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01750450||74392|
NCT01760590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRS2|The Effects of Thoracic Spine Manipulation in Individuals With Non-traumatic Cervical Pain|The Effects of Thoracic Spine Manipulation and Mobilization in Individuals With Nontraumatic Cervical Pain||Keystone Rehabilitation Systems|Yes|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||January 2013|January 2, 2013|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01760590||73616|
NCT01760837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0140-12-WOMC|Oral Immunotherapy With Baked Milk Products for Patients Allergic to Cow's Milk - A Multicenter Study|Oral Immunotherapy With Baked Milk Products for Patients Allergic to Cow's Milk - A Multicenter Study||Wolfson Medical Center|No|Completed|February 2013|November 2015|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|1 Year|18 Years|No|||November 2012|December 10, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01760837||73597|
NCT01761084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18539|Build Better Bones With Exercise|Build Better Bones With Exercise: A Pilot Randomized Controlled Trial of Exercise in Women With Osteoporotic Vertebral Fracture|B3E|University of Waterloo|Yes|Active, not recruiting|January 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|139|||Female|65 Years|N/A|No|||December 2015|December 1, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761084||73578|
NCT01757847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7400-R|Stress and Eating Study|Acceptance-based Group Intervention for Binge Eating||VA Office of Research and Development|No|Completed|January 2013|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01757847||73827|
NCT01758159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHlaing CFR Myanmar|Effect of CFR and Iron Supplementation on Iron Status and Gut Microbiota of 1-2 Years Old Myanmar Children|The Effect of Optimized Local Food-based Complementary Feeding With or Without Iron Supplementation on Iron Status and Gut Microbiota of 1-2 Years Old Myanmar Children|CFR|SEAMEO Regional Centre for Food and Nutrition|Yes|Active, not recruiting|February 2013|April 2014|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|433|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||September 2013|September 29, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01758159||73803|
NCT01757860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARD-024-C001|Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CARD-024 (1α-Hydroxy-Vitamin-D5) in Healthy Subjects|CARD-024|Cardiavent Inc.|Yes|Completed|September 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 28, 2012|December 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757860||73826|
NCT01757873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z160-PHN-202|Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia|PHN|Zalicus|Yes|Completed|December 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|December 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757873||73825|
NCT01758185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-3|Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine|Phase 4 Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine||Beijing Center for Disease Control and Prevention|No|Completed|August 2011|December 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3308|||Both|3 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 27, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01758185||73801|
NCT01758198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-338|Abatacept Post-marketing Clinical Study in Japan|A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate vs. Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate||Bristol-Myers Squibb|No|Active, not recruiting|April 2013|February 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|405|||Both|20 Years|N/A|No|||February 2016|February 2, 2016|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758198||73800|
NCT01758211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVM-125-FMRI|Functional Magnetic Resonance Imagine(fMRI)Navigation in Intracranial Arteriovenous Malformation Surgery|Blood Oxygen Level Dependent fMRI Navigation for Function Protection in Intracranial Arteriovenous Malformation Surgery: a Multicenter Prospective Randomized Controlled Single Blind Clinical Trial|FMRINAVMS|Beijing Tiantan Hospital|Yes|Recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|12 Years|60 Years|No|||March 2013|March 1, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01758211||73799|
NCT01760070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XIJINGHDD-20121227-01|Comparison of O-type Hybrid Knife and IT Knife in ESD|Comparison of O-type Hybrid Knife and IT Knife in Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasms: a Prospective Randomized Controlled Trial||Xijing Hospital of Digestive Diseases|Yes|Completed|December 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|80 Years|No|||January 2015|January 22, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01760070||73656|
NCT01760083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005905-64|A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions|A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions|EuroCTO|Euro CTO Club|Yes|Recruiting|March 2012|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01760083||73655|
NCT01720199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM2011-CUPJ19E11002100001|A School-based Prevention Intervention to Promote Wellbeing in Preadolescents|Diario Della Salute (DDS), a School-based Prevention Intervention to Promote Well-being for Grade 7 Students (12-13 Years)|DDS|Azienda Sanitaria Locale CN2 Alba-Bra|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2630|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||January 2014|January 18, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720199||76711|
NCT01720212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-091|Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers|An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers||Astellas Pharma Inc|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 31, 2012|October 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720212||76710|
NCT01720537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3091001|A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects|A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort||Pfizer|No|Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|136|||Both|18 Years|70 Years|No|||November 2013|November 19, 2013|August 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720537||76685|
NCT01720797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121593|Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment|Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment|Propel|University of Florida|Yes|Completed|February 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|55 Years|No|||June 2015|June 2, 2015|October 31, 2012|No|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01720797||76665|
NCT01721395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZB001|Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents|Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents||Penn State University|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|2 Months|48 Months|No|||October 2015|October 22, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01721395||76619|
NCT01722253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225|Postoperative Analgesia After Low Frequency Electroacupuncture|Postoperative Analgesia After Low Frequency Electroacupuncture as Adjunctive Therapy in Inguinal Hernia Surgery With Abdominal Wall Mesh Reconstruction|LFE|Aristotle University Of Thessaloniki|Yes|Completed|December 2008|April 2015|Actual|March 2015|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|54|Samples Without DNA|serum, plasma|Male|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients in the Surgical Clinic with right or left inguinal hernia, residents of Thessaly,        Greece.|June 2015|June 4, 2015|November 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01722253||76553|
NCT01721967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039302|Ranolazine for the Treatment of Chest Pain in HCM Patients|Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation|RHYME|Duke University|Yes|Active, not recruiting|November 2012|April 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721967||76575|
NCT01749280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/R1CARl05|Magnetic Resonance Imaging To Predict Outcomes In Aortic Aneurysms|Efficacy of Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide to Predict Clinical Outcome in Patients Under Surveillance for Abdominal Aortic Aneurysms||University of Edinburgh|No|Terminated|March 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16|||Both|40 Years|N/A|No|Non-Probability Sample|The investigators will recruit 237 patients with abdominal aortic aneurysms from the        clinical surveillance programme at the Royal Infirmary, Edinburgh. Inclusion criteria will        be patients with an abdominal aortic aneurysm >40 mm on ultrasound scanning. Exclusion        criteria will include patients with anticipated or planned abdominal aortic aneurysm        repair, women of child-bearing potential without contraception, inability to undergo        magnetic resonance or computed tomography scanning, life expectancy of <2 years, and those        with any form of collagen-vascular disease.|December 2012|December 11, 2012|November 30, 2012||No|Study being continued as a multi centre MA3RS study.The patients will be followed up under    MA3RS and AAA PET.|No||https://clinicaltrials.gov/show/NCT01749280||74482|
NCT01749943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-AVX-11-10213|Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis|Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|HHD|Brown, Theodore R., M.D., MPH|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|21|||Both|18 Years|N/A|No|Probability Sample|Stable patients with clinically definite Multiple Sclerosis, aged 18 over, no Multiple        Sclerosis exacerbation or change in disease modifying therapy for 30 days prior to        screening. Subjects will fall into 1 of 3 EDSS catagories: 0-3.5; 4.0-5.5; 6.0-7.5.|August 2013|August 20, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01749943||74431|
NCT01749956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 168|5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer|A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer||SCRI Development Innovations, LLC|No|Completed|January 2013|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749956||74430|
NCT01749592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0034|Single-sided Deafness and Cochlear Implants|Hemispheric Dominance in Single-sided Postlingual Deafness and Changes / Plasticity Induced by Cochlear Implants||University of Zurich|Yes|Recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2014|December 15, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749592||74458|
NCT01749917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0036UG|Exercise Intervention and Dexterity in Parkinson|Therapeutic Intervention in Motor Disorders in Parkinson.||Universidad de Granada|Yes|Recruiting|December 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|65 Years|No|||December 2014|December 9, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749917||74433|
NCT01749930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770|Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension|LUNAR|Bausch & Lomb Incorporated|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749930||74432|
NCT01756950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-M8-A001|Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR8020, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose and Repeat-Dose Intravenous Administration||Crucell Holland BV|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756950||73895|
NCT01757197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202012180|Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)|Tocilizumab (an Anti-human IL-6 Receptor Monoclonal Antibody) as a First Line Therapy for Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease (aGVHD) After Allogeneic Hematopoetic Stem Cell Transplant (HSCT), a Phase II Study.||Weill Medical College of Cornell University|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||November 2013|November 1, 2013|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757197||73876|
NCT01757470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00059|Vandetanib Risk Minimisation Effectiveness|Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada||AstraZeneca|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Convenience sample for patients and physicians|June 2014|June 13, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757470||73855|
NCT01757483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00009|Canadian Ticagrelor Survey|Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada||AstraZeneca|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|244|||Both|18 Years|85 Years|No|Non-Probability Sample|All physicians who have prescribed at least one dose of ticargrelor and complete the        Knowledge and understanding survey|December 2015|December 8, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757483||73854|
NCT01757834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41443-EA|Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules|Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules||University of Washington|No|Enrolling by invitation|November 2012|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|175|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01757834||73828|
NCT01757496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZA-11/44/334|Cough Assist in Bronchiolitis|Cough Assist in RSV-bronchiolitis||University Hospital, Antwerp|No|Active, not recruiting|September 2012|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|3 Months|18 Months|No|||November 2015|November 30, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757496||73853|
NCT01757275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961DC00007|High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer|A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding||AstraZeneca||Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|239|||Both|18 Years|70 Years|No|||February 2016|February 9, 2016|December 21, 2012||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01757275||73870|No hypothesis testing was performed in this study and, as such, no formal statistical comparisons were made. Two patients who were initially randomised to receive cimetidine treatment actually received esomeprazole treatment.
NCT01757925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JXBX 2012 11-214|Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention|Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention||UnitedHealth Group|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||December 2012|December 28, 2012|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757925||73821|
NCT01759212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA_CTL_02|Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.|Safety and Efficacy of Intramyocardial Implantation of Allogeneic Mesenchymal Stem Cells in Patients With End-stage Heart Failure Undergoing Left Ventricular Assist Device Implantation||AHEPA University Hospital|No|Recruiting|October 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|75 Years|No|||November 2013|November 27, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01759212||73722|
NCT01719913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNF-CBMR 3861-34275|The Effect of Gluten on Gut Microbiome and Metabolic Health.|Gut, Grain and Greens (3G): The Effect of Gluten on Gut Microbiome and Metabolic Health.|3G|University of Copenhagen|Yes|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01719913||76732|
NCT01719900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24804|Evaluation of Pulse Fibre Supplementation on Obesity and the Metabolic Syndrome|Evaluation of Pulse Fibre Supplementation in Obesity and the Metabolic Syndrome: Generating Evidence in Support of Health Claims||University of Calgary|Yes|Active, not recruiting|October 2012|May 2017|Anticipated|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01719900||76733|
NCT01720836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-094|Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer|Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer||University of Pittsburgh|Yes|Suspended|November 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720836||76662|
NCT01720511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12002|Pilot Study of the Effect of Purple Rice on Glucose Tolerance, Serum Lipids and Inflammation|Pilot Study of the Effect of Purple Rice on Glucose Tolerance, Serum Lipids and Inflammation.||Pennington Biomedical Research Center|No|Completed|September 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01720511||76687|
NCT01721980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0974-CL-102|Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects|Double-blind, Randomized, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0974 in Healthy Male Subjects||Galapagos NV|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 9, 2013|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01721980||76574|
NCT01721993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAR2011-1|Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women|Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01Fand T121E02F in Healthy Postmenopausal Women||Thar Pharmaceuticals, Inc|Yes|Completed|January 2013|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|71|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721993||76573|
NCT01748513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-042M|Volume-challenge in Morbid Obesity|Morbid Obesity and Optimization of Preoperative Fluid Therapy||Umeå University|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|65 Years|No|Probability Sample|Morbidly obese patients scheduled for bariatric surgery in Northern part of Sweden;        Norrbotten county council.|April 2013|April 28, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748513||74541|
NCT01748760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH090147|Coping Long Term With Attempted Suicide - Adolescents|Coping Long Term With Attempted Suicide - Adolescents|CLASP-A|Brown University|Yes|Completed|October 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|12 Years|18 Years|No|||January 2016|January 11, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01748760||74522|
NCT01718015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-470-12.|Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy|Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy||Aarhus University Hospital|Yes|Not yet recruiting|November 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|70|Samples With DNA|Cerebrospinal fluid, plasma and serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients who have performed a lumbar puncture at Department of Neurology and Department of        Clinical Medicine (Endocrinology and Diabetes) Aarhus University Hospital, Denmark.|October 2012|October 29, 2012|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01718015||76877|
NCT01750216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28344|An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1|An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C||Hoffmann-La Roche||Completed|July 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|196|||Both|18 Years|N/A|No|Probability Sample|Treatment-naïve patients with chronic hepatitis C genotype 1 initiated on treatment with        Pegasys and Copegus|March 2016|March 1, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750216||74410|
NCT01750229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1668|Spinal Cord Stimulation Frequency Study|Randomized Controlled Double-blind Cross-over Trial Evaluating the Role of Frequencies on Spinal Cord Stimulation in the Management of Failed Back Surgery Syndrome (SCS Frequency Study)||MedtronicNeuro||Active, not recruiting|December 2012|October 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01750229||74409|
NCT01750203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR-001-A|Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay|Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay||Systagenix Wound Management|Yes|Completed|December 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|N/A||1|Actual|135|None Retained|Swabs will be tested on day on collection. Test is destructive. No swabs will be retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult subjects (greater than 18 years old), presenting at participating clinical sites        with wounds of different etiologies, who are willing to provide informed consent and who        meet the inclusion / exclusion criteria, will be prospectively enrolled|December 2012|December 19, 2012|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01750203||74411|
NCT01750476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12010187|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives||Ohio State University|No|Terminated|December 2012|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|7|||Female|15 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Women interested in initiating hormonal contraceptive use|January 2014|January 5, 2014|December 10, 2012||No|PI and lab have re-located study to The Ohio State University|No||https://clinicaltrials.gov/show/NCT01750476||74390|
NCT01756963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 42101.068.12|Diet and Disease Activity in Patients With Inflammatory Bowel Disease|Diet and Disease Activity in Patients With Inflammatory Bowel Disease||Maastricht University Medical Center|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|75 Years|No|Non-Probability Sample|Consecutive IBD patients, visiting the gastroenterology outpatient clinic, participating        the IBD-SL cohort|December 2012|December 20, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756963|1 Year|73894|
NCT01757210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24267|A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients|A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients||West Virginia University Healthcare|Yes|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|1 Year|17 Years|No|Non-Probability Sample|This study will include pediatric patients with an active malignancy.|August 2013|August 21, 2013|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01757210||73875|
NCT01760408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SustainHPN2011|Sustain, A.S.P.E.N. HPN Registry 2011|SustainTM,LLC: A.S.P.E.N.'s National Patient Registry for Nutrition Care- Home Parenteral Nutrition||Sustain, LLC of the American Society for Parenteral and Enteral Nutrition|Yes|Recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|patients receiving parenteral nutrition at home|December 2012|December 31, 2012|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01760408|5 Years|73630|
NCT01757548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2011010005282|The Effect and Prognosis of Different Operations on Varicocele - a Single-center Clinical Study|The Effect and Prognosis of Different Operations on Varicocele - a Single-center Clinical Study||First Affiliated Hospital, Sun Yat-Sen University|Yes|Active, not recruiting|December 2012|November 2020|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Male|10 Years|50 Years|No|||December 2012|December 28, 2012|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01757548||73849|
NCT01757561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|伦审[2012]324号|The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane|The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|December 2012|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|144|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|Adult patients undergoing elective major surgery|August 2015|August 18, 2015|December 18, 2012||No||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01757561||73848|
NCT01757886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTERIA-2012|inflAmmatory maRkers in Blood and Thrombus Aspirated From Patients With acutE myocaRdial Infarction With St-segment elevAtion||ARTERIA|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||Recruiting|November 2012|November 2013|Anticipated|November 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Pilot, prospective cohort, which included all patients admitted with a diagnosis of        ST-elevation myocardial infarction and undergoing thrombus aspiration during a procedure        effective emerging percutaneous coronary revascularization.|December 2012|December 22, 2012|December 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01757886|12 Months|73824|
NCT01758718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye009|Eyelash Line Resection for Entropion Associated With Down's Syndrome|Eyelash Line Resection for Entropion Associated With Down's Syndrome||Kyorin University|No|Completed|April 2007|October 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|3 Years|90 Years|No|||December 2012|December 27, 2012|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758718||73760|
NCT01759784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-004|Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS|Safety of Intraventricular Injection of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS||Royan Institute|Yes|Withdrawn|March 2014|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||May 2012|December 31, 2015|December 29, 2012||No|The stereotaxis can be threatful for the patients because of respiratory insufficiency|No||https://clinicaltrials.gov/show/NCT01759784||73678|
NCT01720238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1211000039120003|Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis|Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis||Beijing Friendship Hospital|Yes|Active, not recruiting|March 2012|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|621|Samples With DNA|serum,plasma and DNA|Both|18 Years|70 Years|No|Non-Probability Sample|compensated HBV Related liver cirrhosis|July 2015|July 27, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720238||76708|
NCT01720225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0507|Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk|Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) in Myelodysplastic Syndrome (MDS) Patients With Low and Intermediate-1 Risk Disease||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2012|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720225||76709|
NCT01720524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481316|A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn|A Multi-centre, Randomized, Placebo-controlled, Double-blind, Two-armed, Parallel Group Study To Evaluate Efficacy And Safety Of Iv Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn (Pphn) Or Hypoxic Respiratory Failure And At Risk For Pphn, With A Long Term Follow-up Investigation Of Developmental Progress 12 And 24 Months After Completion Of Study Treatment||Pfizer|Yes|Recruiting|August 2013|December 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|N/A|4 Days|No|||March 2016|March 21, 2016|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720524||76686|
NCT01721161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215ON201|215ON201 BIIB033 In Acute Optic Neuritis (AON)|A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis|RENEW|Biogen|Yes|Completed|December 2012|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|55 Years|No|||August 2015|August 21, 2015|October 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721161||76637|
NCT01720849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FampyraCSS|Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis|||Vestre Viken Hospital Trust||Recruiting|December 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who according to the compound's Norwegian prescription guidelines are deemed        eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS        4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or        difficulties micturating.|June 2015|June 29, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720849||76661|
NCT01721148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN002-001|A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours|A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours||Aslan Pharmaceuticals|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721148||76638|
NCT01752465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01896|Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders?|Is Health Coaching a Useful Clinical Tool to Facilitate Healthy Lifestyle Change and Improve Metabolic Health in People With Psychotic Illness?||University of British Columbia|No|Enrolling by invitation|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 30, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752465||74238|
NCT01749020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-Ins01|Effect of Polyphenol-rich Dark Chocolate on Insulin Sensitivity in Normal Weight and Overweight Adults|Effect of Polyphenol-rich Dark Chocolate on Insulin Sensitivity in Normal Weight and Overweight Adults||Queen Margaret University|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01749020||74502|
NCT01749007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1039|Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS|Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS||VA Eastern Colorado Health Care System|No|Active, not recruiting|November 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans with HIV/AIDS|December 2012|June 8, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749007||74503|
NCT01749579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130-2640|Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation|Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation in Painful Procedures||Tehran University of Medical Sciences|Yes|Recruiting|May 2012|February 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||December 2012|December 11, 2012|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01749579||74459|
NCT01750762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-086|Lenalidomide After Allo Transplant|Phase I Study of Lenalidomide to Augment Anti-Tumor Immunity Following Allogeneic Transplantation||Dana-Farber Cancer Institute|Yes|Terminated|December 2012|March 2014|Actual|March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750762||74368|
NCT01750489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1937/1-1|Muscle Dysfunction in Patients With Chronic Obstructive Lung Disease (COPD): the Role of Sympathetic Activation|Skeletal and Respiratory Muscle Dysfunction in Patients With COPD: the Role of Sympathetic Activation||University Medical Center Goettingen|No|Completed|August 2011|||November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||||||Both|30 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01750489||74389|
NCT01750749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUV2011|Cell Therapy for Venous Leg Ulcers Pilot Study|Autologous Bone Marrow Derived Cells in the Treatment of Venous Leg Ulcers Pilot Study||Hospital de Clínicas Dr. Manuel Quintela|No|Active, not recruiting|May 2011|June 2014|Anticipated|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|40 Years|75 Years|No|||February 2014|February 20, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750749||74369|
NCT01750983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0795|Ipilimumab and Lenalidomide in Advanced Cancer|A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|March 2013|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|101|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750983||74351|
NCT01756976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100257|Clinical Evaluation of the OrthoPAT Advance System|Clinical Evaluation of the OrthoPAT Advance System||Haemonetics Corporation|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|84|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects scheduled for hysterectomy or orthopediac procedures.|September 2013|September 17, 2013|November 26, 2012|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01756976||73893|
NCT01759238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLGA|Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer|Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial)|OLGA|Universitätsklinikum Hamburg-Eppendorf|Yes|Terminated|May 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|December 17, 2012||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01759238||73720|
NCT01758237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEC-LPI|Dysphotopsia Following Laser Peripheral Iridotomy|Incidence of Visual Symptom Following Laser (Nd:YAG ) Peripheral Iridotomy (LPI) in Relation to Position of LPI||Credit Valley EyeCare|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01758237||73797|
NCT01757509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1|A Randomized Controlled Feasibility Trial to Determine the Effectiveness of Set Dancing for People With Parkinson's Disease|A Randomized Controlled Feasibility Trial to Determine the Effectiveness of Set Dancing for People With Parkinson's Disease||University of Limerick|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 25, 2013|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01757509||73852|
NCT01758952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peri-operativeStroke|Incidence and Risk Factors of Peri-operative Stroke in Non-cardiac,Non-neurosurgical Surgeries|Multi-center Prospective Investigation of Incidence and Risk Factors of Peri-operative Stroke in Non-cardiac,Non-neurosurgical Surgeries and Practicability of NIHSS in Screening Peri-operative Strokes|POSIC|Chinese Medical Association|No|Recruiting|March 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|10000|Samples With DNA|whole blood, serum, white cells|Both|60 Years|N/A|No|Probability Sample|We propose a sample size of 10,000 patients to ensure a stable logistic model for an        anticipated stroke rate of 1.0%.|November 2013|November 6, 2013|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01758952|1 Month|73742|
NCT01767571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116995|Bioequivalence Study of Cephalexin Suspension 250|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparation of Cephalexin 250 mg/5mL (Ceporex®, GlaxoSmithKline México, S.A. de C.V. vs. Keflex® , Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767571||73080|
NCT01767584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116999|Bioequivalence Study of Cephalexin Tablets 1g|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing 1 g of Cephalexin (GlaxoSmithKline México, S.A. de C.V. vs. Keflex® 1g, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers.||GlaxoSmithKline|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767584||73079|
NCT01720862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00051683|Migraine and Body Composition|Migraine and Body Composition||Johns Hopkins University|No|Completed|April 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|300|Samples Without DNA|serum|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Premenopausal Caucasian women ages 18-55 years with or without migraine.|January 2016|January 27, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720862||76660|
NCT01720875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11/10041|Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma|A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma|MUKfour|University of Leeds|Yes|Not yet recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||October 2012|November 1, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720875||76659|
NCT01751477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUV-Neo3|Infloran® for Prevention of Necrotizing Enterocolitis|Oral Probiotics (Infloran®) for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Infants||Medical University of Vienna|No|Completed|September 2010|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|463|||Both|N/A|7 Days|No|Probability Sample|Very low birth weight Infants (<1500g birth weight)|April 2015|April 20, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751477||74313|
NCT01721408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1811185|A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection|A Multicenter, Double-blind, Randomized, Comparison Study Of The Efficacy And Safety Of Tigecycline To Imipenem/Cilastatin To Treat Complicated Intra-abdominal Infections In Hospitalized Subjects.||Pfizer|Yes|Completed|November 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|470|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721408||76618|
NCT01721707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRINZLAT-12|Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH|Safety and Efficacy to Reduce the IOP of the Fixed Association of Latanoprost 0.005% (50 μg/mL)/ Brinzolamide 1% (10mg/mL) Drops, Compared to Latanoprost 0.005% (50 μg/mL) Drops, in Patients With Open Angle Glaucoma or Ocular Hypertension||Adapt Produtos Oftalmológicos Ltda.|No|Withdrawn|December 2012|June 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|November 2, 2012||No|withdrawn by industry|No||https://clinicaltrials.gov/show/NCT01721707||76595|
NCT01748773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25574|A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)|Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Adjuvant Setting in Operated HER2+ Patients With Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase II Study (TOXAG Study)||Hoffmann-La Roche||Active, not recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748773||74521|
NCT01749293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0170|Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation|Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies||University of Illinois at Chicago|Yes|Terminated|August 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|10 Years|75 Years|No|||May 2015|May 26, 2015|November 20, 2012||No|The protocol design is being reconfigured in order to open a new study.|No||https://clinicaltrials.gov/show/NCT01749293||74481|
NCT01749306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB01-ABH001|A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing|A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa||Shire Regenerative Medicine, Inc.||Terminated|December 2012|November 2013|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|N/A|N/A|No|||November 2013|November 20, 2013|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749306||74480|
NCT01749605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005757|A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department|||University of Iowa|Yes|Completed|October 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749605||74457|
NCT01749618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metrix II|Closing the Gap in Care in Seronegative Inflammatory Arthritis|Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change|Metrix II|Pope Research Corporation|No|Recruiting|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01749618||74456|
NCT01750775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yl-yxb07-lcsyfa-201202|Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions|Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions Multi-center,Randomized, Double-blind, Placebo-controlled Clinical Study|SS-SBVPT|The First Affiliated Hospital with Nanjing Medical University|Yes|Enrolling by invitation|August 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|70 Years|No|||December 2012|December 13, 2012|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750775||74367|
NCT01751009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORG0004854|Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.|A Randomised Controlled Home-based Trial of the Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.|vitapool|Kintampo Health Research Centre, Ghana|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|93|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||December 2012|December 14, 2012|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01751009||74349|
NCT01751282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1AR06034201A1|Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds|A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds||Roger Williams Medical Center|Yes|Active, not recruiting|June 2010|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751282||74328|
NCT01751568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1101|Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB|Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Children ≥ 2 Years to < 12 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|May 2014|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|2 Years|11 Years|No|||October 2015|October 21, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751568||74306|
NCT01758991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B039201111926|Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation|Therapeutic Impact of tDCS on Dysphagia in the Acute Phase of Stroke / Impact thérapeutique de la tDCS Sur la Dysphagie en Phase Aigue de l'Accident Vasculaire cérébral|iSWAT|University Hospital of Mont-Godinne|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758991||73739|
NCT01760109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002HL0153|Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|PIP-SBT|Xiangbei Welman Pharmaceutical Co., Ltd|Yes|Recruiting|July 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|70 Years|No|||December 2012|December 30, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01760109||73653|
NCT01760395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-surg-010|Complications in Inguinal Hernia Surgery|Complications in Inguinal Hernia Surgery - a Nationwide Registry Study||North Karelia Central Hospital|No|Completed|January 2002|December 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|335|||Both|16 Years|110 Years|No|Non-Probability Sample|Finnish patients having had complicated inguinal hernia surgery 2002-2010.|October 2015|October 11, 2015|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01760395||73631|
NCT01757015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2311|Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS|A 26-week Multi-center Randomized Double-blind Study to Compare Efficacy and Safety of NVA237 Versus Placebo as an add-on to Maintenance Therapy With Fixed-dose Combination Salmeterol/Fluticasone Propionate in COPD Patients With Moderate to Severe Airflow Limitation|GLOW8|Novartis||Withdrawn|April 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|N/A|No|||August 2013|August 26, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01757015||73890|
NCT01757223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204012330|Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery|Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium of Individuals With Diffuse Coronary Artery Disease Via Minimally Invasive Surgery||Weill Medical College of Cornell University|Yes|Not yet recruiting|January 2013|January 2028|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|41|||Both|18 Years|90 Years|No|||December 2012|December 20, 2012|October 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01757223||73874|
NCT01757236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO2011/LB/LIZ-BONE|Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection|Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive.|LIZ-BONE|University Hospital, Tours|Yes|Recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01757236||73873|
NCT01758484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2659.00|Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant|FEASIBILITY OF IMPLEMENTING PRE-TRANSPLANT EVALUATION BY THE SUPPORTIVE CARE TEAM FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES||Fred Hutchinson Cancer Research Center|No|Completed|April 2013|||November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01758484||73778|
NCT01758705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-709|Post Marketing Observational Study on Venezuelan Patients With Psoriasis|Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy||AbbVie|No|Terminated|February 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects male or female with moderate to severe chronic plaque psoriasis with or without        psoriatic arthritis. Patients with history of psoriatic arthritis or articular symptoms        must be evaluated by a Rheumatologist.|March 2016|March 7, 2016|December 26, 2012||No|Changes in country regulation regarding PMOS definition and requirements for Health Authority.|No||https://clinicaltrials.gov/show/NCT01758705||73761|
NCT01768130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-023|Variability in Thermal Thresholds in Patients With Persistent Pain After Open Inguinal Herniotomy|Variability in Thermal Thresholds in Patients With Persistent Pain After Open Inguinal Herniotomy||Rigshospitalet, Denmark|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|N/A|N/A|No|Non-Probability Sample|Patients with persistent pain after open inguinal herniotomy|February 2014|February 27, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01768130||73037|
NCT01768143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAT-003|Assessment of NAPS Performance.|A Reliable and Valid Assessment of Nurse Administered Propofol Sedation (NAPS) Performance.|NAPSAT|Copenhagen University Hospital at Herlev|No|Completed|January 2013|June 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Endoscopy nurses of different competencylevel|September 2013|August 19, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768143||73036|
NCT01767922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-ISO-2007-01|Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life|Multicentre, Double-blind Study Versus Placebo on the Impact and Safety of the Daily Administration of Extramel® 140 IU for 12 Weeks on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception, if Present, and the Impact on the Quality of Life of 70 Subjects Included, of Which 60 That Can be Evaluated|Ex Stress II|Bionov|No|Completed|September 2008|September 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|61|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767922||73053|
NCT01767935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97212|Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases|A Pilot Study of The Tandem Treatment of Painful Osseous Metastases With Cryoablation Followed by Radiation Therapy||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|July 2014|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767935||73052|
NCT01750918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116833|BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)|An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy||GlaxoSmithKline|No|Recruiting|December 2012|March 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750918||74356|
NCT01751217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032260-01A1|Family Therapy Via Video Teleconference for Substance-Abusing Rural Adolescents|Family Therapy Via Video Teleconference for Substance-Abusing Rural Adolescents|RAFT|Oregon Research Institute|No|Recruiting|February 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|13 Years|18 Years|No|||April 2015|April 21, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751217||74333|
NCT01751737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00059514|Choline PET/CT and MRI for Targeted Prostate Biopsy|Investigation of the Magnitude of Uptake, Retention, and Spatial Distribution Pattern of 18F-Choline in Comparison With MRI and Histology Obtained From Prostate Cancer Biopsies||University of Michigan|Yes|Recruiting|November 2012|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|66|||Male|40 Years|N/A|No|||March 2016|March 6, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01751737||74294|
NCT01749033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00046964|A New Insertion Technique for Laryngeal Mask Airway|A New Insertion Technique for Laryngeal Mask Airway||Northwestern University|No|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|450|||Both|18 Years|70 Years|No|||February 2015|February 6, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749033||74501|
NCT01749631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-805|Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients|A Prospective, Open-label, Multicenter, Post Marketing, Observational Study to Investigate the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients||AbbVie|No|Completed|December 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|97|||Both|19 Years|N/A|No|Non-Probability Sample|Hospitals with operation theaters|February 2016|February 2, 2016|December 12, 2012||No||No|February 2, 2016|https://clinicaltrials.gov/show/NCT01749631||74455|
NCT01749969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11863|SAR650984, Lenalidomide, and Dexamethasone in Combination in RRMM Patients|A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma||Sanofi|No|Recruiting|February 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749969||74429|
NCT01751035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009042|Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD|Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD|RRFT|Medical University of South Carolina|Yes|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|13 Years|18 Years|No|||September 2015|October 1, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01751035||74347|
NCT01751022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attain Performa(TM)|Attain Performa(TM) Quadripolar Lead Study|Attain Performa(TM) Quadripolar Lead Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|December 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1206|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751022||74348|
NCT01751295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08-052|Statin and Post-interventional Coronary Microcirculation Dysfunction|Effect of Statin on the Post-interventional Coronary Microcirculation Dysfunction||Samsung Medical Center|Yes|Active, not recruiting|December 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|84|||Both|21 Years|80 Years|No|||December 2012|December 13, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751295||74327|
NCT01759823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|stem cell therapy in T2DM|Bone Marrow Derived Stem Cell Transplantation in T2DM|Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus||Postgraduate Institute of Medical Education and Research|Yes|Completed|December 2012|October 2015|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|30 Years|70 Years|No|||October 2015|October 24, 2015|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01759823||73675|
NCT01766765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEN-001|Early Jejunostomy Nutrition Minimizes Time to Chemotherapy|Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer||Jinling Hospital, China|Yes|Not yet recruiting|April 2013|June 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2013|January 10, 2013|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766765||73142|
NCT01767025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/550|The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults|||University Ghent|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767025||73122|
NCT01767272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT2|Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers|Dose Proportionality of Fexofenadine|DPF|Damanhour University|Yes|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767272||73103|
NCT01767948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100944|A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment|An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment||Janssen Research & Development, LLC|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|75 Years|No|||October 2014|October 6, 2014|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01767948||73051|
NCT01752192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20120051|Teledi@Log - Tele-rehabilitation of Heart Patients|Tele-rehabilitation of Heart Patients|Teledi@log|Aalborg University|Yes|Completed|December 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|151|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752192||74259|
NCT01752179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90/801/T/1/5055|Kinesio Taping Technique and Trigger Point|The Effect of Kinesio Taping Technique on Trigger Point of Piriformis Muscle|KT|University of Social Welfare and Rehabilitation Science|Yes|Completed|May 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|70 Years|No|||February 2013|February 28, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01752179||74260|
NCT01752478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-Retina|Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery|Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery||University of California, San Francisco|Yes|Recruiting|January 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patient who undergo vitreoretinal surgery at the University of California, San Francisco,        and San Francisco General Hospital.|December 2015|December 1, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752478|6 Months|74237|
NCT01748526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014986|A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers|A Single-Dose, Open-Label, Randomized, Two-Way, Cross-Over Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Healthy Indian Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748526||74540|
NCT01749319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI 20873|Oral and IV Baclofen in Adult Volunteers|Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749319||74479|
NCT01750242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1669|Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study|OPTIVISE Map Concordance Study in DBS for Parkinson's Disease|DBS|MedtronicNeuro|No|Completed|November 2012|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Parkinson's disease patients who have been implanted with the DBS system|September 2014|September 10, 2014|December 11, 2012||No||No|March 21, 2014|https://clinicaltrials.gov/show/NCT01750242||74408|
NCT01750502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wenzhouhp|The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease|MIF Gene Polymorphism in Coronary Heart Disease：Clinical Meaning||Wenzhou Medical University|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|256|Samples Without DNA|The biospecimen is blood that taken from cubital vein.|Both|20 Years|90 Years|No|Probability Sample|Second Hispital of Wenzhou Medical College outpatient and inpatient|February 2015|February 17, 2015|November 24, 2012|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01750502||74388|There are some limitations to this research. First, the sample size was relative small. Second,no participants were retrospectively analyzed.
NCT01751048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0031|LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine|A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|48|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2015|June 4, 2015|December 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01751048||74346|
NCT01751308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12689|Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors|A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System||Sanofi|No|Completed|February 2013|February 2016|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|2 Years|18 Years|No|||March 2016|March 1, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751308||74326|
NCT01751321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40591|Glucose Variability With DPP-4 Inhibition|Glucose Variability With DPP-4 Inhibition||Research Clinical Centre of the Russian Railways, JSC|No|Not yet recruiting|May 2013|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|35 Years|75 Years|No|||December 2012|December 13, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751321||74325|
NCT01751594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 104|Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men|Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men||Westat|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Male|16 Years|24 Years|No|||March 2016|March 1, 2016|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01751594||74304|
NCT01760668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-561-12|Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome|Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome||University of Aarhus|No|Recruiting|February 2013|November 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|60|Samples With DNA|Aortic tissue      Blood Serum|Both|18 Years|90 Years|No|Non-Probability Sample|Individuals with Turner syndrome will be recruited from out-patient clinics. Individuals        with Turner syndrome, Marfan syndrome and bicuspid aortic valve will be recruited from        departments of cardiology or thoracic surgery in Odense, Copenhagen or Aarhus (Denmark).|June 2015|June 26, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760668||73610|
NCT01760915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0571|University of Wisconsin Severe Asthma Research Program III|Severe Asthma Research Program (SARP) - University of Wisconsin||University of Wisconsin, Madison|Yes|Recruiting|December 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples With DNA|whole blood, serum, plasma, DNA, RNA, sputum, urine, bronchial tissue, bronchoalveolar      lavage, bronchial brushings, exhaled breath condensate|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with asthma (severe asthma, well controlled asthma) and healthy normal controls        from Madison, WI region|October 2015|October 9, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01760915||73591|
NCT01761162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120226|ProMRI Study of the Entovis Pacemaker System|||Biotronik, Inc.|Yes|Completed|February 2013|May 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|229|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigators' general patient        population according to the inclusion and exclusion criteria.|May 2015|May 8, 2015|January 2, 2013|Yes|Yes||No|October 28, 2014|https://clinicaltrials.gov/show/NCT01761162||73572|
NCT01761175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-666|Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block|Comparison of Ultrasound-Guided Single Injection Infraclavicular Block or Ultrasound-Guided Double Injection Axillary Block : A Prospective Randomized Blinded Controlled Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|September 2012|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||February 2014|February 9, 2014|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01761175||73571|
NCT01767038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creuzot-Garcher PHRC N 2010|DOREFA (Retinal Detachment: Function and Anatomy)|Study of Anatomical and Functional Recovery Following Retinal Detachment: Identify Correlations Between Visual Acuity and SD-OCT and Microperimetry Findings.|DOREFA|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|November 2011|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767038||73121|
NCT01767285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030001|Immediate vs. Delayed Postpartum Etonogestrel Implant|A Randomized Controlled Trial of Immediate Postpartum Etonogestrel Implant Versus Six-week Postpartum Etonogestrel Implant: A Pilot Study||Duke University|Yes|Completed|January 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Female|12 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767285||73102|
NCT01767597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 38|Application of HBV Rapid Tests as a Tool for Wide-Use Screening|Is the Combination of Screening Algorithms and Use of Hepatitis B Rapid Tests Useful in Optimizing the Screening and Prevention of Hepatitis B?|OPTISCREEN-B|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Yes|Completed|February 2012|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767597||73078|
NCT01768507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinPharm 754|Reresveratrol Administered to Healthy Male Subjects|The Effects of the Dietary Supplement Trans-resveratrol on Heme Oxygenase-1 (HO-1) and Sirtuins Expression in PBMCs in Healthy Male Subjects: A Pilot Study.|REVAHS|Medical University of Vienna||Completed|March 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 13, 2013|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01768507||73008|
NCT01768520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_ENTR_302|Evaluation of the Efficacy and Safety of Entelon Tab. 150mg in Patients With Osteoarthritis of Knee|For 12 Weeks, the Multi-center, Randomized, Double-blinded, Clinical Study to Evaluate the Efficacy and Safety of Entelon Tab. 150mg Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee (Phase III)||Hanlim Pharm. Co., Ltd.|No|Recruiting|July 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|336|||Both|35 Years|75 Years|No|||January 2013|January 14, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768520||73007|
NCT01751932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACE2|Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems|Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems|SPACE2|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751932||74279|
NCT01751945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAF/FIN/AKU-2/2012/00030|Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project|Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project.|EmONC|Aga Khan University|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12000|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01751945||74278|
NCT01751958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1105/128-014|Radiation Exposure in Spine Intervention Under Angiography|Phase 3 Study of Evaluate Radiation Exposure and Procedure Times for Continuous Fluoroscopic Monitoring During Lumbar ESI||Seoul National University Bundang Hospital|No|Completed|July 2011|March 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751958||74277|
NCT01748240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-Aza-Vor 2012-001401-25|Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure|Addition of Suberoylanilide Hydroxamic Acid (Vorinostat) to Azacitidine in Patients With Higher Risk Myelodysplastic Syndromes (MDS): a Phase II add-on Study in Patients With Azacitidine Failure.|GFM-AZA-VOR|Groupe Francophone des Myelodysplasies|Yes|Suspended|March 2013|March 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|October 28, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748240||74562|
NCT01748253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067|ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)|ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing|ACROBAT|Acrobat Trial Group||Recruiting|November 2012|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||May 2013|May 20, 2013|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01748253||74561|
NCT01748227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-438|IMproving Pain Using Peer RE-inforced Self-management Skills|Improving Pain Using Peer RE-inforced Self-management Skills (IMPPRESS)|IMPPRESS|VA Office of Research and Development|No|Completed|January 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|November 21, 2012||No||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01748227||74563|This was a pilot study to examine feasibility and preliminary effectiveness of peer support for veterans with chronic pain. Because of the small sample size and pretest/posttest design of the study, results should be interpreted with caution.
NCT01748539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-002|A Phase 2 Clinical Study of KHK4827|A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis||Kyowa Hakko Kirin Company, Limited|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|140|||Both|20 Years|70 Years|No|||September 2013|September 3, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01748539||74539|
NCT01748552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14793|A Study of LY2922083 in Healthy Participants and Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922083 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|36|||Both|21 Years|65 Years|No|||August 2013|August 22, 2013|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748552||74538|
NCT01748786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZIMHR-01|Online Mindfulness Training Versus Health Education for Fibromyalgia|Emotional Resilience in Fibromyalgia: A Pilot Study of Web-based Treatment|EGIFT|Arizona State University|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01748786||74520|
NCT01749982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ1959|A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh|A Pilot Study of Choline and Betaine Supplementation in Arsenic-exposed Individuals in Bangladesh|CABS|Columbia University|No|Completed|December 2012|August 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|60|||Both|20 Years|65 Years|No|||August 2014|August 14, 2014|December 12, 2012|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01749982||74428|This is a pilot study that is not powered to detect statistically significant effects. The results given here are descriptive.
NCT01750255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMDADER-TABI-20111108|Effect of Pharmaceutical Care in Patients With Bipolar I Disorder (BD I)|Effect of Pharmaceutical Care in Patients With Bipolar I Disorder at St John of God Clinic. Randomized Trial.|EMDADER-TABI|Universidad de Antioquia|No|Completed|November 2011|June 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|200|||Both|18 Years|65 Years|No|||June 2014|June 3, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01750255||74407|
NCT01750515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094-12-ZIV|Acupuncture as an Adjunctive Treatment for Hepatitis C Patients|Acupuncture as an Adjunctive Treatment for Hepatitis C Patients||Ziv Hospital|Yes|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||December 2012|December 12, 2012|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01750515||74387|
NCT01750814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3102C_P3|To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults|A Phase III, Randomized, Double-blind, Multi-center Study to Compare the Immunological Efficacy and Safety of GC3102C With GC FLU Inj. Administered Intramuscularly in Healthy Adults||Green Cross Corporation|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01750814||74364|
NCT01751334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHOSKNEE01-RPFLPSF|Comparison of the Tibiofemoral Rotational Alignment After Mobile and Fixed Bearing Total Knee Arthroplasty|Comparison of the Tibiofemoral Rotational Alignment After Mobile and Fixed Bearing Total Knee Arthroplasty||Seoul National University Hospital|No|Completed|September 2005|August 2011|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||December 2012|December 13, 2012|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751334||74324|
NCT01751347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03477|Bupivacaine Versus Lidocaine Local Anesthesia|Bupivacaine Versus Lidocaine Local Anesthesia in Elective Outpatient Hand Surgery: A Randomized Controlled Trial||University of British Columbia|No|Completed|February 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|90 Years|No|||December 2015|December 10, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01751347||74323|
NCT01722149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPME-1|Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma|Phase I Study for the Adoptive Transfer of Re-directed FAP-specific T Cells in the Pleural Effusion of Patients With Malignant Pleural Mesothelioma.||University of Zurich|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|75 Years|No|||February 2016|February 8, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01722149||76561|
NCT01766518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m307LTP09D|The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)|Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.||Chong Kun Dang Pharmaceutical|No|Recruiting|November 2009|May 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|19 Years|65 Years|No|||November 2013|November 6, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766518||73160|
NCT01766531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0135|Evaluation of Nutritional Status in ICU : Interest for the Measurement of Body Composition by Body Bioelectrical Impedance and Comparison With Several Methods|Evaluation of Nutritional Status in ICU : Interest for the Measurement of Body Composition by Body Bioelectrical Impedance and Comparison With Several Methods|IMPREA|University Hospital, Clermont-Ferrand||Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01766531||73159|
NCT01766778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AHK01|Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin|A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin||Novartis|No|Completed|May 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766778||73141|
NCT01767051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOPS METC 12/308|Children Follow-up of PCOS Women|Children Follow-up of PCOS Women.Cardiovascular Health in Offspring of PCOS Mothers|CHOPS|UMC Utrecht|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|74|Samples Without DNA|saliva, serum, plasma|Both|30 Months|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases Children born from mothers who are diagnosed with PCOS at the UMCU will be asked to        participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU        will be asked to participate too. All mothers have been diagnosed with PCOS according to        standardised extensive diagnostic work-up and have given informed consent to be approached        for future research purposes.        Controls Children who participated in the WHISTLER study (protocol number 10-194) in . The        children were born from mothers with a regular cycle prior to conception and who conceived        naturally. The children were examined at the age of 2.5-4 years or at the age of 6-8        years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.|February 2015|February 19, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01767051||73120|
NCT01767298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT1 PART II|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers (PART II)|PKVH PART II|Damanhour University|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767298||73101|
NCT01767610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-PIF-101|Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin|Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects||Hanlim Pharm. Co., Ltd.|No|Recruiting|January 2013|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767610||73077|
NCT01767623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28053|A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients|An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients||Hoffmann-La Roche||Recruiting|August 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767623||73076|
NCT01768221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039370|Caregiver Outlook: An Evidence-based Intervention for the Chaplain Toolkit|Caregiver Outlook: An Evidence-based Intervention for the Chaplain Toolkit||Duke University|No|Active, not recruiting|January 2013|June 2016|Anticipated|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|October 15, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01768221||73030|
NCT01760759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-205O-2|Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus|Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus||University of Connecticut Health Center|Yes|Recruiting|November 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01760759||73603|
NCT01760772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09-20-01|Effect of GLP-1 on Postprandial Lipid Metabolism|The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery||University of Cincinnati|Yes|Not yet recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|42|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||November 2012|January 2, 2013|November 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760772||73602|
NCT01751971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001296-O2PSG|Estimating Apnea Phenotypes From Polysomnography: Oxygen|Estimating Apnea Phenotypes From Routine Polysomnography: Application to Oxygen Therapy|PSGtraits-O2|Brigham and Women's Hospital|No|Recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|79 Years|No|||January 2016|January 5, 2016|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01751971||74276|
NCT01748565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025462|Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia|Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia|GRP|Duke University|Yes|Enrolling by invitation|May 2012|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|urine specimens and saliva with DNA|Both|N/A|7 Days|No|Non-Probability Sample|Patients in the neonatal intensive care unit at Duke Medical Center or Riley Children's        Hospital|August 2015|August 18, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01748565||74537|
NCT01749046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-MPP02EPI|Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures|Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures||Valexfarm|Yes|Recruiting|March 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|65 Years|No|||December 2012|December 11, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749046||74500|
NCT01749059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-003-11|The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease|The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease|CCHD|Mednax Center for Research, Education and Quality|No|Active, not recruiting|June 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|30 Days|No|Non-Probability Sample|Neonates known to have a congenital heart defect at the time of screening.|February 2016|March 3, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749059||74499|
NCT01749644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9640-OE-CTIL|Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life|||Sheba Medical Center|No|Not yet recruiting|January 2013|January 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|6 Years|N/A|No|Non-Probability Sample|CF patients with chronic pseudomonas infection|December 2012|December 15, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749644||74454|
NCT01749657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15AR061737-01A1|Kinematic and Kinetic Effects of Orthotic Devices for Subjects With Stage II Posterior Tibial Tendon Dysfunction|Kinematic and Kinetic Effects of Orthotic Devices for Subjects With Stage II Posterior Tibial Tendon Dysfunction||State University of New York - Upstate Medical University|No|Recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|40 Years|N/A|No|||November 2014|November 19, 2014|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749657||74453|
NCT01750268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0145|Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI||VAT|University of California, San Francisco|Yes|Completed|November 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750268||74406|
NCT01750788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16371|Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia|Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study|XANAP|Bayer|No|Recruiting|January 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2300|||Both|18 Years|N/A|No|Probability Sample|Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with        rivaroxaban to prevent stroke or non-CNS systemic embolism|February 2016|February 2, 2016|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01750788||74366|
NCT01750801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propolis|Efficacy of a Mouthwash Containing Propolis|Clinical Evidence Efficacy of a Mouthwash Containing Propolis for the Control of Plaque and Gingivitis: Phase III, Randomized, Double-blind Comparison With Mouthwash Chlorhexidine Base.|PRO|Federal University of Minas Gerais|No|Not yet recruiting|February 2013|July 2016|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01750801||74365|
NCT01750827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102487|A Study to Assess the Effect of SB 659032 on Platelet Function|A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects||GlaxoSmithKline||Completed|September 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|December 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01750827||74363|
NCT01721551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTH2-3/10-10-2012|Sleep and Training Aspects in Dialysis Fatigue - Exercise Intervention|Phase 4 Exercise Training in Aspects of Fatigue in Patients Receiving Dialysis Therapy|StandFirm|University of Thessaly|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|70 Years|No|||June 2015|June 19, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01721551||76607|
NCT01721564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00595049|Bosentan and Pulmonary Endothelial Function|Pulmonary Artery Remodelling With Bosentan|PARBO|Royal Prince Alfred Hospital, Sydney, Australia||Completed|April 2006|December 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||January 2013|January 21, 2013|November 1, 2012||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT01721564||76606|
NCT01721577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11090804|Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas|Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas|AXL1717|Rush University Medical Center|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721577||76605|
NCT01721863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010032R|Effects of Exercise Training in Patients With Permanent Atrial Fibrillation|Effects of Exercise Training on Endothelial Function, Heart Rate Variability, Exercise Capacity, and Quality of Life in Patients With Permanent Atrial Fibrillation||National Taiwan University Hospital|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|40 Years|76 Years|Accepts Healthy Volunteers|||October 2012|November 2, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01721863||76583|
NCT01721876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.14|Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)|A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy||Boehringer Ingelheim||Active, not recruiting|January 2013|June 2016|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|666|||Both|N/A|N/A|No|||January 2016|January 6, 2016|November 2, 2012||||No||https://clinicaltrials.gov/show/NCT01721876||76582|
NCT01721889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSA100|Radiostereometric Analysis of Spine Arthrodesis|Radiostereometric Analysis of Spine Arthrodesis||OAD Orthopaedics|No|Recruiting|November 2012|January 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients between the ages of 18 and 75 that are diagnosed with lumbar DDD (L1-L5, and also        L5-S1) and scheduled for one or multi level spinal fusion surgery will be recruited for        the study.|June 2013|June 10, 2013|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721889||76581|
NCT01721902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801-133|Stem Cell Implantation in Patients Undergoing CABG|Stem Cell Implantation in Patients Undergoing CABG||Miltenyi Biotec, Inc.|Yes|Terminated|January 2010|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|October 1, 2012|No|Yes|The study was terminiated due the lack of recruitment.|No||https://clinicaltrials.gov/show/NCT01721902||76580|
NCT01766297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE007-12|Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer|Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer||Proton Collaborative Group|Yes|Recruiting|February 2013|January 2030|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Female|50 Years|N/A|No|||December 2015|December 7, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01766297||73177|
NCT01766804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-HCA-002|Effect of Bovine Colostrum on Toxicity and Inflammatory Responses|Effect of Bovine Colostrum on Toxicity and Inflammatory Responses During Treatment of Childhood Acute Lymphoblastic Leukaemia|CALL|Odense University Hospital|No|Recruiting|March 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|45 Years|No|||May 2013|May 31, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766804||73139|
NCT01767311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAN2401-G000-201|A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease|A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease||Eisai Inc.|Yes|Recruiting|December 2012|July 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|800|||Both|50 Years|90 Years|No|||February 2016|February 25, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767311||73100|
NCT01767636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1152|Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer|A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR|PINCR|Mayo Clinic|Yes|Recruiting|May 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767636||73075|
NCT01767649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10056|Inflammatory Signature of Human Chorionic Cells|Inflammatory Signature of Chorionic Cells as Markers of Premature Labor|TROPHY|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2010|November 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|Samples With DNA|Cord blood, placenta and maternal blood|Female|18 Years|N/A|No|Non-Probability Sample|Normal pregnant women followed for their pregnancy in the maternity|December 2014|December 19, 2014|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767649||73074|
NCT01767961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97312|Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer|A Pilot Study Assessing Swallowing Function After Transoral Robotic Surgery (TORS) for Head and Neck Cancer||Comprehensive Cancer Center of Wake Forest University|No|Withdrawn|September 2013|||January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|40 Years|89 Years|No|||January 2014|January 28, 2014|January 11, 2013||No|Unable to secure funding.|No||https://clinicaltrials.gov/show/NCT01767961||73050|
NCT01768234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062354|Dehydration Among School Children- Mali|Cognitive Effects of Drinking Water and Improving Hydration Status Among Schoolchildren||Emory University|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|120|||Both|6 Years|18 Years|No|||September 2013|September 29, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01768234||73029|
NCT01760486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211699-11|State-wide Health Approach to Increase Reach and Effectiveness: Study 3|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|SHARE|The Miriam Hospital|No|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|No|||December 2013|January 11, 2016|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760486||73624|
NCT01760499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17183|Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study|Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01760499||73623|
NCT01760785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0582|Valproate for Mood Swings and Alcohol Use Following Head Injury|A Double Blind Trial of Divalproex Sodium for Affective Lability and Alcohol Use Following Traumatic Brain Injury||University of Colorado, Denver|Yes|Active, not recruiting|September 2008|March 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760785||73601|
NCT01761019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100308|A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy|A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy||University of Pittsburgh|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761019||73583|
NCT01752218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209|A Study to Address Precision and Refractive Predictability of Femtosecond Laser-assisted Astigmatic Keratotomy Following the Cataract Surgery|A Single Centre Study to Address Precision and Refractive Predictability of Femtosecond Laser-assisted Astigmatic Keratotomy Following the Cataract Surgery||Technolas Perfect Vision GmbH|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|40 Years|N/A|No|||May 2014|May 21, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01752218||74257|
NCT01748799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103/2011|Fixed or Self-Titrated Dosages of Sativex on Cannabis Users|Effects of Fixed or Self-Titrated Dosages of Sativex on Cannabis Users||Centre for Addiction and Mental Health|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|16|||Both|18 Years|50 Years|No|||October 2015|December 30, 2015|December 8, 2012||No||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01748799||74519|The main limitation is the small sample size. Also our study did not include experimental conditions containing THC alone and CBD alone for comparison. The short duration of the experimental condition is also a limitation.
NCT01748812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130025|Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)|Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia||National Institutes of Health Clinical Center (CC)||Terminated|November 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||July 2015|November 4, 2015|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748812||74518|
NCT01748825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130032|AZD1775 for Advanced Solid Tumors|A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|120 Years|No|||February 2016|February 26, 2016|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01748825||74517|
NCT01748838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-4430-HV-001|Phase 1 Study Assessing the Safety and Tolerability of CTX-4430|A Phase I Randomised, Double-Blind, Placebo-Controlled, Ascending Single & Repeat-Dose Study of Safety, Tolerability & Pharmacokinetics of CTX-4430 When Administered Orally to Healthy Adult Subjects||Celtaxsys, Inc.|Yes|Completed|December 2012|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01748838||74516|
NCT01749332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-236|A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections|A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections||Memorial Sloan Kettering Cancer Center||Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|145|||Both|N/A|N/A|No|||December 2015|December 17, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749332||74478|
NCT01749345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17676|Social Determinants of Health in Diabetes Outcomes|Social Determinants of Health as Explanatory Factors for Ethnic Disparities in Diabetes Outcomes||Medical University of South Carolina||Recruiting|July 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Pimary care and internal medicine clinics|October 2012|December 11, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749345||74477|
NCT01749358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD065438|Dose Optimization for Stroke Evaluation|Optimizing the Dose of Rehabilitation After Stroke.|DOSE|University of Southern California|No|Recruiting|March 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|21 Years|N/A|No|||December 2014|December 22, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01749358||74476|
NCT01750528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 12-0004|Prevalence and Progression of Periodontitis in Ankylosing Spondylitis|The Prevalence and the Progression of Periodontitis in Ankylosing Spondylitis (AS) Patients Versus Non-AS Population||Seoul National University Hospital|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|168|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. AS group will consist of patients aged 18 years or more who meet the 1984 modified             New York criteria for AS.             i. AS group receiving anti-TNF-α agents will consists of AS patients who have             received adalimumab, etanercept, or infliximab before enrollment (or begin anti-TNF-α             agents at enrollment) and keep anti-TNF-α agents for 3 months or more after             enrollment.             ii. AS group not receiving anti-TNF-α agents will consists of AS patients who are             treated with a non-steroidal anti-inflammatory drug, sulfasalazine, or             non-pharmacological therapy and keep non-anti-TNF-α therapy for 3 months or more             after enrollment.          2. Control group will consist of age- (± 3 years) and gender-matched volunteers who do             not have inflammatory arthropathy.|June 2014|June 8, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01750528||74386|
NCT01721031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPNB120928|DPNB for Prevention of CRDB|Comparison of Dorsal Penile Nerve Block With 0.33% Ropivacaine and Intravenous Tramadol for Prevention of Catheter-related Bladder Discomfort: Study Protocol for a Randomized Controlled Trial||West China Hospital|Yes|Recruiting|October 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|50 Years|No|||October 2015|October 7, 2015|October 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01721031||76647|
NCT01721304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009001853 (0904-66B)|Decisionmaking for Abnormal Uterine Bleeding (AUB)|Decision Making Among Treatment Alternatives for Abnormal Uterine Bleeding (AUB)||Indiana University|No|Completed|May 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|380|||Female|18 Years|N/A|No|||April 2015|April 21, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01721304||76626|
NCT01721317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116878|Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures|Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures||GlaxoSmithKline|No|Terminated|December 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|16||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|May 1, 2014|November 1, 2012|Yes|Yes|After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe    the early adjunctive treatment study population is appropriate.|No|February 6, 2014|https://clinicaltrials.gov/show/NCT01721317||76625|
NCT01721590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNH-20120929|Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease|Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease|Talent|Shenyang Northern Hospital|Yes|Completed|November 2012|June 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|85 Years|No|||December 2015|December 21, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721590||76604|
NCT01721603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12857|A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases|A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases||University of California, San Francisco|Yes|Active, not recruiting|April 2013|October 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721603||76603|
NCT01766076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS1258|Atorvastatin for HAART Suboptimal Responders|Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial||Makerere University|Yes|Completed|January 2013|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||May 2015|May 20, 2015|December 10, 2012||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01766076||73194|
NCT01767324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGN-NSR-2012-001|Site Selection for Intracutaneous Saline Delivery|Exploratory Evaluation of Injection Sites in Healthy Subjects Receiving Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array||FluGen Inc|Yes|Completed|December 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01767324||73099|
NCT01759914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YM076710|Ocular Pressure in Steroid-treated Dermatology Patients|Intraocular Pressure in Corticosteroid-treated Dermatology Patients||University Hospitals Coventry and Warwickshire NHS Trust|No|Terminated|September 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Dermatology clinic|March 2014|March 6, 2014|December 30, 2012||No|Unable to recruit sufficient number of subjects in required timeline.|No||https://clinicaltrials.gov/show/NCT01759914||73668|
NCT01760213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRInternet|Brief Internet Based Treatment for PTSD|Internet Based Treatment Using Virtual Reality in the Prevention of PTSD||Hadassah Medical Organization|Yes|Not yet recruiting|January 2013|August 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|65 Years|No|||December 2012|May 22, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01760213||73645|
NCT01760512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002|Clinical and Health Economic Impact of Robot-assisted Surgery vs Conventional Laparoscopy : the Case of Gastric Bypass|Prospective, Single-blind, Randomized, Non-inferiority, and Controlled Study of Clinical and Health Economic Impact of Robot-assisted Surgery Versus Conventional Laparoscopy in Bariatric Surgery: the Case of Gastric Bypass||IHU Strasbourg|No|Completed|November 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|65 Years|No|||May 2015|December 9, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01760512||73622|
NCT01756885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA165001|Extended Varenicline Treatment for Smoking Among Cancer Patients|Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial||University of Pennsylvania|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756885||73900|
NCT01757132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAS-01|Post-Approval Study of the Implantable Miniature Telescope|Post-approval Study of VisionCare's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients With Bilateral Severe to Profound Central Vision Impairment Assoc. With End-stage Age-related Macular Degeneration|PAS-01|VisionCare Ophthalmic Technologies, Inc.|No|Enrolling by invitation|August 2010|December 2028|Anticipated|December 2023|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|770|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|November 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757132||73881|
NCT01748851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG ST12-05|XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)|A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC||Dong-A University Hospital|Yes|Terminated|December 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|December 9, 2012||No|Poor enrollment of patients|No||https://clinicaltrials.gov/show/NCT01748851||74515|
NCT01749371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-189|Vitamin E Supplementation in Burned Patients|Vitamin E Supplementation in Burned Patients||The University of Texas Medical Branch, Galveston|Yes|Recruiting|February 2013|||September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|16 Years|85 Years|No|||September 2015|September 16, 2015|December 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01749371||74475|
NCT01749384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02765|Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of Tivantinib Plus Bevacizumab||National Cancer Institute (NCI)||Active, not recruiting|December 2012|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|February 11, 2016|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01749384||74474|
NCT01750281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00064|Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.|A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)|SELECT-2|AstraZeneca|Yes|Active, not recruiting|December 2012|September 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|466|||Both|18 Years|150 Years|No|||February 2016|February 22, 2016|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01750281||74405|
NCT01749995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZGS2012061|Prospective Validation of the Use of the Freund Clock Drawing Test to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment|Prospective Validation of the Use of the Freund Clock Drawing Test (CDT) to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment (CGA)|PROACTIVE|General Hospital Groeninge||Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|70 Years|N/A|No|Non-Probability Sample|All consenting patients, aged ≥ 70, who are referred for anti-cancer treatment in the        General Hospital Groeninge and who are in need of a CGA.|March 2015|March 5, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749995||74427|
NCT01750008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0018|Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions|The LUSTOR (Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions)Trial|Lustor|Halt Medical, Inc|Yes|Active, not recruiting|November 2012|September 2018|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01750008||74426|
NCT01750541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-021|Haloperidol vs. Valproate in Agitation|Haloperidol vs. Valproate in the Management of Agitated Patients Presenting to the Emergency Department: A Randomized Clinical Trial||hahid Beheshti University of Medical Sciences|Yes|Completed|December 2012|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|No|||January 2013|January 5, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01750541||74385|
NCT01750554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00524D|The Influence of a Bupivacaine Digital Nerve Block Using Rev G.|The Influence of a Bupivacaine Digital Nerve Block With the New Continuous Sensor (Rev G) on the Accuracy of SpHb Monitoring.||University of California, San Francisco|Yes|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Both|18 Years|85 Years|No|||April 2015|April 9, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01750554||74384|
NCT01721330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-002252|A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital|No|Terminated|November 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|55 Years|No|||February 2015|March 17, 2015|October 30, 2012|Yes|Yes|Competing studies|No||https://clinicaltrials.gov/show/NCT01721330||76624|
NCT01721616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-13|Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis|A Randomized Clinical Trial of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis||University of Missouri, Kansas City|No|Withdrawn|November 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|No|||May 2015|May 4, 2015|November 1, 2012||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01721616||76602|
NCT01721915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitDPCOS1.0|Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism|A Randomized, Double‐Blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Metabolic and Fertility Parameters in PCOS Women||Medical University of Graz|No|Recruiting|October 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01721915||76579|
NCT01722188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0196|Lead Registry for Optim Leads|Optim Lead Insulation Material Registry|OPTIMUM|St. Jude Medical|No|Active, not recruiting|August 2006|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14124|||Both|18 Years|N/A|No|Probability Sample|Patients implanted with market released SJM Optim lead and a compatible market released        CRM implantable pulse generator (pacemaker, implantable cardioverter defibrillator (ICD),        or cardiac resynchronization therapy device (CRT)) is eligible for enrollment into the        registry.|October 2015|October 6, 2015|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722188||76558|
NCT01766557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS-09-08-078|Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.|Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.|PCOS|Laval University|No|Completed|August 2010|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01766557||73157|
NCT01766544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPC|Asthma & COPD Guideline Implementation|Asthma and COPD Guideline Implementation: Lessons Learned on Recruitment of Primary Care Physicians to a Knowledge Translation Study||Laval University|No|Terminated|September 2009|March 2010|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|92|||Both|N/A|N/A|No|||January 2013|January 9, 2013|January 7, 2013||No|Insufficient recruitment of physicians to participate to the study.|No||https://clinicaltrials.gov/show/NCT01766544||73158|
NCT01766791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUSH-D-ER|Resistance Exercise, Muscle Mass, Strength and Body Composition|Effects of Resistance Exercise on Muscle Mass, Strength, Body Composition and Heart in Men 30-50 Years Old.||University of Erlangen-Nürnberg Medical School|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|120|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01766791||73140|
NCT01766817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-003|Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis|Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis||Bristol-Myers Squibb|Yes|Recruiting|January 2013|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|40 Years|90 Years|No|||August 2015|August 11, 2015|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766817||73138|
NCT01759628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91138 - KAUMS|Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Function Tests in Subjects With Non-alcoholic Fatty Liver Disease||Tehran University of Medical Sciences|Yes|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01759628||73690|
NCT01759927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54788|Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees.|Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees in a Company in Flanders: a Randomized Control Trial.||Universitaire Ziekenhuizen Leuven|Yes|Completed|February 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|301|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01759927||73667|
NCT01759940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cervicalblock|Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Intermediate Cervical Block.|Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Block of the Regio Collis Lateralis for Carotid Endarterectomy: a Prospective, Randomized and Controlled Trail||Salzburger Landeskliniken|No|Completed|November 2012|December 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2014|March 15, 2014|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01759940||73666|
NCT01760226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30759, DA-EPOCH-R|Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies|Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies|DA-EPOCH-R|Baylor College of Medicine|Yes|Recruiting|January 2013|January 2026|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|21 Years|No|||February 2016|February 15, 2016|December 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01760226||73644|
NCT01761032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112011-012|Gauging Of Light Dependent Experiences Through Neuroimaging (GOLDEN)|Dopamine Response to Ultraviolet Light in Frequent and Infrequent Tanners|GOLDEN|University of Texas Southwestern Medical Center|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|22|||Both|21 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited though flyers and advertisements. Advertisements will be placed        in college newspapers. Flyers will be placed on college campuses, and local Dallas stores        and beauty salons.|September 2014|September 10, 2014|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01761032||73582|
NCT01757769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMD 3213 IT-CL 0376|Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia|Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study|SiRE|Recordati Industria Chimica e Farmaceutica S.p.A.|No|Completed|May 2011|August 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1036|||Male|60 Years|N/A|No|||April 2014|April 28, 2014|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01757769||73833|
NCT01749111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEDECH-2012|Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis|Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis|CICLODECH|Hospital Israelita Albert Einstein|No|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|60 Years|No|||December 2012|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749111||74495|
NCT01749696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/180/2009|Alterations in Connective Tissue in Patients With or Without Pelvic Organ Prolapse|Alterations in Connective Tissue in Patients With or Without Pelvic Organ Prolapse.||Turku University Hospital||Completed|November 2009|April 2014|Actual|September 2012|Actual|N/A|Observational|N/A||2|Actual|78|||Female|N/A|N/A|No|Non-Probability Sample|39 patients with pelvic organ prolapse and as controls 39 patients without prolapse.|May 2014|May 8, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749696||74450|
NCT01749709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85/180/2011|Music Listening and Stroke Recovery|Effect of Cognitive Stimulation on Recovery After Stroke|MUKU2|Turku University Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||June 2013|June 24, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749709||74449|
NCT01749072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-S464|Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients|A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients||Peking Union Medical College Hospital|No|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||December 2012|December 12, 2012|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01749072||74498|
NCT01749085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371010|Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels|A Phase 1, Open Label Study In Healthy Subjects To Estimate The Effect Of Food And The Drug-Drug Interaction Potential Of Ketoconazole On PF-04449913 Pharmacokinetics||Pfizer|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01749085||74497|
NCT01749098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701013|A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers|A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers||Pfizer|Yes|Completed|December 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|29|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01749098||74496|
NCT01721018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1716-12|Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.|A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma.|1716-12|Virttu Biologics Limited|No|Recruiting|October 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01721018||76648|
NCT01720459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|681/10|Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients|Effects of Micronized Trans-resveratrol Treatment on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Placebo-controlled Randomized Single-blind Study||Poznan University of Medical Sciences|No|Not yet recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|No|||October 2012|November 1, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720459||76691|
NCT01720719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2334187|Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease|An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease||Fudan University|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720719||76671|
NCT01721629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAUH190280|Weaning of Nasal Continuous Positive Airway Pressure (CPAP) in Premature Infants|Weaning of Nasal Continuous Positive Airway Pressure in Infants Born With a Gestational Age Under 32 Weeks: a Randomized Controlled Multicenter Trial||Aarhus University Hospital|Yes|Recruiting|September 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|6 Months|No|||June 2015|June 25, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01721629||76601|
NCT01721642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-DP1|A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device|A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device During and After Transcatheter Aortic Valve Implantation (TAVI) Procedures||Apica Cardiovascular Limited|Yes|Completed|May 2012|March 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01721642||76600|
NCT01722201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-12/126|Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Risperidone Tablet 1 mg With Risperdal® 1 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition||IPCA Laboratories Ltd.|Yes|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 2, 2012|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722201||76557|
NCT01717963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002858-31|Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway|Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway|NTX-SBX|University of Oslo|No|Active, not recruiting|October 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01717963||76881|
NCT01759082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHP|The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI)|The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI)|TALDI|University of Lausanne Hospitals|No|Enrolling by invitation|September 2012|October 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|1 Year|6 Years|No|Probability Sample|-  Subjects presenting at the CHUV with PWS will be screened and their parents asked to             join the study by a member of the research team.          -  Subjects who meet the inclusion criteria will be approached for informed written             consent and enrolled in the study.|December 2012|January 1, 2013|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01759082||73732|
NCT01759303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWACMOS1102|Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung|A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung||Vector Oncology|No|Recruiting|April 2013|February 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|16 Years|N/A|No|||January 2016|January 5, 2016|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01759303||73715|
NCT01767064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCalifornia|Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments|Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments||University of Southern California|No|Active, not recruiting|February 2012|February 2013|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|14|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767064||73119|
NCT01759316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lixue|Heliox in Preterm Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive Pressure Ventilation and Mechanical Ventilation With Heliox in Preterm Infants With Respiratory Distress Syndrome||Third Military Medical University|Yes|Completed|December 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|28 Weeks|37 Weeks|No|||October 2013|October 25, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01759316||73714|
NCT01759641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-MAL 01|Observational Study to Assess Oxygen Saturation Predictive Power Related to Intradialytic Acute Hypotension|Italian Group of Study on the Role of Oxygen Saturation as a Potential Surrogate Marker of Intradialytic Cardiovascular Instability|SOGLIA|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|January 2011|August 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|85 Years|No|Non-Probability Sample|ESRD patients on RRT with a recent clinical history of acute intradialytic hypotension.|December 2012|December 24, 2012|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01759641||73689|
NCT01760525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCGM097X2101|A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors|A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors|CCGM097X2101|Novartis||Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01760525||73621|
NCT01760798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|teriparatide|Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis|To Compare Efficacy of Weekly Versus Daily Teriparatide in the Management of Postmenopausal Osteoporosis||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|50 Years|70 Years|No|||April 2014|April 15, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760798||73600|
NCT01757418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-005341-01|Intravenous Gammaglobulin for Sickle Cell Pain Crises|Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|November 2008|July 2020|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|12 Years|65 Years|No|||January 2016|January 26, 2016|November 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757418||73859|
NCT01757431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-005J|The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)|||Alexion Pharmaceuticals||Recruiting|May 2012|||September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||March 2012|December 21, 2012|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757431||73858|
NCT01757782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil|Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns|Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns: A Randomized Placebo Controlled Trial||Sir Takhtasinhji General Hospital|No|Completed|December 2011|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|N/A|12 Hours|No|||June 2014|June 24, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01757782||73832|
NCT01757795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-8203-1001|Safety, Tolerability and Pharmacokinetics of SP-8203|A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8203||Shin Poong Pharmaceutical Co. Ltd.|No|Not yet recruiting|March 2013|July 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 28, 2012|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757795||73831|
NCT01749397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02767|Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers||National Cancer Institute (NCI)||Recruiting|December 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|December 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01749397||74473|
NCT01749410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-CM-12-491|A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines|||Allergan|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|33|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants who previously received at least 7 treatment cycles of onabotulinumtoxinA as        Treatment for Chronic Migraine.|August 2015|August 10, 2015|December 12, 2012|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01749410||74472|
NCT01720433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lap pain trial NGH|Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial|Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial.||Northampton General Hospital NHS Trust|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|127|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 31, 2012|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720433||76693|
NCT01749670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346301-1|Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder|Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder||State University of New York - Upstate Medical University|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|Samples With DNA|Whole Blood|Both|4 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children from the University Pediatric and Adolescent Center and the Center for        Development Behavior and Genetics in Syracuse, New York.|November 2014|November 25, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749670||74452|
NCT01749683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMyCE1|Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction|Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction|GEMyCE 1|State University of New York - Upstate Medical University|No|Recruiting|August 2011|||August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|71 Years|No|Non-Probability Sample|Diabetic and nondiabetic patients will be initially recruited and studied after acute        nonfatal MI and revascularization with either PCI or CABG|November 2014|November 19, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01749683||74451|
NCT01720147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2049|Quercetin in Children With Fanconi Anemia; a Pilot Study|Quercetin in Children With Fanconi Anemia; a Pilot Study||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2012|December 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|N/A|N/A|No|||November 2015|November 18, 2015|July 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01720147||76715|
NCT01720446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3744|Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes|A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)|SUSTAIN™ 6|Novo Nordisk A/S|No|Completed|February 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|3299|||Both|50 Years|N/A|No|||January 2016|January 25, 2016|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01720446||76692|
NCT01720758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0124-11-CTIL|Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease|Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease.|B-RAF V600E|HaEmek Medical Center, Israel|No|Not yet recruiting|November 2012|April 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|perpheral blood|Both|18 Years|N/A|No|Probability Sample|Patients who are followed up in the Haematology Department in the Emek Medical Center for        Hairy Cell Leukemia or chronic lymphoproliferative disease such as Splenic Marginal Zone        Lymphoma. Patients who are examined and suspected to have Hairy Cell Leukemia.|October 2012|November 1, 2012|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720758||76668|
NCT01720771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN-2011/530|Preventive Effect of a Probiotic Tablet on Oral Health in Preschool Children|Preventive Effect of a Probiotic Tablet on Oral Health in Preschool Children||University of Copenhagen|No|Completed|February 2013|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|138|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720771||76667|
NCT01721278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0768|Furlong Evolution® Hip Trial|A Prospective Multicentre Clinical Surveillance Study To Evaluate The Stability, Efficacy And Safety Of The Furlong Evolution® Hip Stem In Primary Total Hip Arthroplasty||Imperial College London|No|Recruiting|October 2012|October 2022|Anticipated|October 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|As per ODEP guidelines, a minimum of 500 cohort size is required for benchmark validation        of the clinical performance of a new orthopaedic implant. We will be using a total sample        size of 700 patients over 10 centres to ensure we meet the benchmark validation criteria.|September 2015|January 12, 2016|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01721278||76628|
NCT01721291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHRCDF|Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)|Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD)||Imperial College London|No|Active, not recruiting|October 2012|February 2016|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01721291||76627|
NCT01720732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL-NET2012|Lifeline-NET (Narrative Exposure Therapy): A Short-term Treatment for Traumatized Refugees and Asylum Seekers|||University of Konstanz|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|12 Years|60 Years|No|||December 2014|December 1, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01720732||76670|
NCT01721668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB1213|Improving Arm and Hand Functions in Chronic Stroke (CIHR 2012-2015)|Examination of Therapeutic Intervention Methods on the Brain Recovery||Baycrest|Yes|Active, not recruiting|November 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01721668||76598|
NCT01721928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/942|Norwegian Intensive Care Unit Dalteparin Effect Study|Norwegian Intensive Care Unit Dalteparin Effect Study|NORIDES|Oslo University Hospital|No|Recruiting|November 2012|December 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|12 ml whole blood (10 ml for storage and 2 ml for bedside TEG analysis) will be aspirated      from the arterial or the central venous catheter for each measurement. Four measurements      will be performed in each patient, from minimum day 2 to maximum day 30 dependent on the      dialysis therapy.      Four urinary samples (each of 20 ml) will be collected from urinary catheter collection bags      at the same time as blood samples are drawn.      Blood (20 mL stored as whole blood, serum and plasma) and urine samples (20 mL) will be      collected from each patient at the same time as blood samples are drawn. The samples will be      stored at - 70°C for future analysis.|Both|18 Years|N/A|No|Non-Probability Sample|The main objective is to compare the prophylactic effect of dalteparin in intensive care        unit patients with acute kidney injury and continuous renal replacement therapy with a        control group of intensive care unit patients with normal kidney function.|April 2015|April 23, 2015|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01721928||76578|
NCT01722214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6025|Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis|Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis||Innovaderm Research Inc.|No|Completed|November 2012|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|107|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01722214||76556|
NCT01759095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB54/12|Multidrug Blister Pack Study|Electronic Multidrug Blister Packs to Improve Clinical and Humanistic Outcomes in Patients After Hospital Discharge||University Hospital, Basel, Switzerland|No|Terminated|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|November 2, 2012||No|Difficulties with patient recruitement|No||https://clinicaltrials.gov/show/NCT01759095||73731|
NCT01759329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DüsselKaffee|Health Effects of Coffee Consumption|Health Effects of Coffee Consumption|DüsselKaffee|West German Center of Diabetes and Health|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|118|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||December 2012|December 28, 2012|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01759329||73713|
NCT01759342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.21.2012|Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation|The Efficacy of a Standardized Exercise Protocol in Inpatient Care of Patients With Cystic Fibrosis||University of Alabama at Birmingham|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|6 Years|21 Years|No|||December 2012|June 27, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01759342||73712|
NCT01760239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-090|EHR-Based Clinical Decision Support to Improve BP Management in Adolescents|EHR-Based Clinical Decision Support to Improve BP Management in Adolescents||HealthPartners Institute|Yes|Recruiting|April 2014|August 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|130|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||January 2016|February 17, 2016|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01760239||73643|
NCT01760252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPOXIRI|Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol|Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol||Beth Israel Medical Center|No|Recruiting|December 2011|December 2022|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01760252||73642|
NCT01761045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJU-S002|Effect of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) on Satiety and Food Intake|A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Study of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) to Evaluate the Effects on Satiety and Food Intakes at the Next Meal in Healthy Adults||Ajinomoto Co., Inc.|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|80|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01761045||73581|
NCT01756898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 704|A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis||Daiichi Sankyo Inc.|No|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|370|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|November 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756898||73899|
NCT01756911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC_0308_FRA|Evaluation of the Safety and Efficacy of the Multilayer Stent|Evaluation du Stent Multicouches Dans le Traitement Des anévrismes de l'Aorte Thoraco-abdominale|STRATO|Cardiatis|Yes|Completed|March 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01756911||73898|
NCT01757158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908010555|Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients|Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients Who Are Not Candidates for Lobectomy or Patients With High Risk of Local Recurrence||Weill Medical College of Cornell University|No|Recruiting|February 2012|June 2018|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01757158||73879|
NCT01757444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 - A00731 - 42|Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS|Clinical Benefits and Tolerance to a New Ventilatory Mode in Patients With Obesity Hypoventilation Syndrome (OHS).||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|Yes|Recruiting|June 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|85 Years|No|||July 2015|July 2, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01757444||73857|
NCT01758120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGH2012-36|Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy|A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy|TOPplus-IgAN|Guangdong General Hospital|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01758120||73806|
NCT01758133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006612-HYMC|Influence of Medical Clown Activity on Milk Production of Mothers of Premature Infants|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Mothers of premature infants|December 2012|December 24, 2012|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01758133||73805|
NCT01758146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI|Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors|Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors in Postmenopausal Patients With Early Breast Cancer||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2012|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Female|45 Years|80 Years|No|||February 2015|February 9, 2015|December 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01758146||73804|
NCT01720121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4250.08|Digital Videos Disc and Printed Guidelines and Improve the Knowledge of Patients Undergoing Cardiac Catheterization|Digital Videos Disc and Printed Guidelines and Improve the Knowledge of Patients Undergoing Cardiac Catheterization||Instituto de Cardiologia do Rio Grande do Sul|No|Completed|April 2009|October 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|150|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01720121||76717|
NCT01720134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53562|The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.|||Katholieke Universiteit Leuven||Completed|September 2010|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1258|||Both|18 Years|43 Years|No|Non-Probability Sample|patients undergoing IVF/ICSI cycles|October 2012|October 31, 2012|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01720134||76716|
NCT01719523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120100953972412|Open-Trial of EPI-743 for Adults With Tourette Syndrome|Open-Trial of EPI-743 for Adults With Tourette Syndrome||Yale University|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||March 2014|March 4, 2014|October 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01719523||76762|
NCT01750021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2282|Effects of Fat and Carbohydrates in Obese Men|Comparison of Two Weight Reducing Diets in Obese Men|FATFUNC|Haukeland University Hospital|No|Completed|December 2012|December 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01750021||74425|
NCT01750034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2288|Best Method of Burn Wound Care: A Prospective Randomized Trial|Best Method of Burn Wound Care: A Prospective Randomized Trial||University of North Carolina, Chapel Hill|Yes|Withdrawn|June 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||September 2015|September 2, 2015|December 12, 2012||No|Feasibility issues|No||https://clinicaltrials.gov/show/NCT01750034||74424|
NCT01720472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036608|Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository|Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository|PPS|Duke University|Yes|Recruiting|May 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Serum and plasma samples collected from MURDOCK Study enrollment visit and two year follow      up Physical Performance visit.|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include 1,000 participants ages 30 and older living in Cabarrus        County and/or the city of Kannapolis, or certain portions of Rowan, Mecklenburg, or Stanly        counties in North Carolina.|January 2016|January 19, 2016|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01720472|2 Years|76690|
NCT01721096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-398|XIENCE PRIME Japan Post-Marketing Surveillance (PMS)|XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan||Abbott Vascular|Yes|Active, not recruiting|November 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Only patients in Japan, who are eligible to receive treatment for coronary arteries using        the XIENCE PRIME Everolimus-Eluting Stent System are to be enrolled.|November 2014|November 5, 2014|September 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01721096||76642|
NCT01720745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA123|Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA|Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|October 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|No|Probability Sample|All patients undergoing endoscopic ultrasound examination of solid lesions in the        mediastinum, pancreas and abdomen requiring fine needle aspiration are recruited.|March 2015|March 27, 2015|October 25, 2012||No|PI no longer at University of Minnesota|No||https://clinicaltrials.gov/show/NCT01720745||76669|
NCT01721044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14058|A Moderate to Severe Rheumatoid Arthritis Study|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors|RA-BEACON|Eli Lilly and Company|Yes|Completed|January 2013|September 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|525|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721044||76646|
NCT01721057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14059|A Study in Moderate to Severe Rheumatoid Arthritis Participants|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis|RA-BUILD|Eli Lilly and Company|Yes|Completed|December 2012|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|684|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|November 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01721057||76645|
NCT01722240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1966|Liraglutide in Type 1 Diabetes|||University at Buffalo|Yes|Recruiting|November 2012|November 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01722240||76554|
NCT01721941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH302 TACE|TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma|A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma||Scripps Clinic Cancer Center|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|October 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01721941||76577|
NCT01780714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHX-EX-01|Exploratory THS 2.1 Biomarkers of Exposure Study|A Single-center, Open-label, Randomized, Controlled, 2-arm Parallel Group Study to Evaluate the Exposure to Selected Smoke Constituents in Smoking, But Otherwise Healthy Subjects Switching From Conventional Cigarettes to the Tobacco Heating System (THS) 2.1|ZRHX-EX-01|Philip Morris Products S.A.|No|Completed|June 2012|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|42|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01780714||72070|
NCT01781559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.35.NRC|Bioefficacy of Phenolic Acids|Effect of Phenolic Acids on the Human Vasculature||Nestlé|No|Completed|October 2012|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|14|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01781559||72005|
NCT01781572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2114|A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma|A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma||Array BioPharma|No|Recruiting|June 2013|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781572||72004|
NCT01781247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170/12|Myocardial Infarction - Stress Prevention Intervention|MI-SPRINT (Myocardial Infarction - Stress PRevention INTervention): A Randomized Controlled Minimal Early Behavioral Intervention Trial to Reduce the Development of Posttraumatic Stress Caused by Acute Myocardial Infarction|MI-SPRINT|University Hospital Inselspital, Berne|Yes|Terminated|January 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|190|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 21, 2013||No|Population of eligible patients smaller than anticipated|No||https://clinicaltrials.gov/show/NCT01781247||72029|
NCT01774708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21EB015943-01|Predict Near Future Initiation of Bed Exit|Predict Near Future Initiation of Bed Exit to Prompt Effective Intervention to Avoid Nighttime Falls With Pattern-recognition Algorithms Using Unobtrusive Monitoring of Movement and Vital Signs|BEDEXIT|Atlanta VA Medical Center|Yes|Active, not recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be up to 60 ambulatory Budd Terrace residents.|January 2014|January 6, 2014|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01774708||72531|
NCT01774942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#539-2007; #807_2011|Taking Out All Teeth and Replacing Them With Dentures That Rest on Implants in People With Type 2 Diabetes|Effect of Extractions and Straumann Dental Implants on Glycemic Control and Inflammatory Markers in Patients With Diabetes: A Pilot Study||University of Michigan|No|Active, not recruiting|June 2008|December 2016|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|30|||Both|N/A|N/A|No|||January 2013|January 21, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774942||72513|
NCT01779674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-079|Atrial Fibrillation/Sinus Rhythm Before and After Cardioversion|||RWTH Aachen University|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with atrial fibrillation|January 2014|January 7, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779674||72150|
NCT01779934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2306E1|OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|FTY720|Novartis||Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|579|||Both|28 Years|N/A|No|||February 2016|February 16, 2016|October 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779934||72130|
NCT01775475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-068|Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma|Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa||AIDS Malignancy Consortium|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775475||72472|
NCT01775488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.CP.0.2|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)||HistoSonics, Inc.||Withdrawn|June 2013|||June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|50 Years|N/A|No|||August 2015|August 17, 2015|January 21, 2013||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01775488||72471|
NCT01780467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0139|Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients|Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.||University Hospital, Clermont-Ferrand||Not yet recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01780467||72089|
NCT01780480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYPF-201212|Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke|Dynamic Combination Therapy on Chinese Herbal Granules Based on Differentiation of Syndrome (Zhenghou)of Traditional Chinese Medicine to Improve the Symptoms in the Convalescent Phase of Ischemic Stroke: a Pilot Study||China Academy of Chinese Medical Sciences|Yes|Completed|January 2013|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01780480||72088|
NCT01776021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-1201|Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections||Ocean Spray Cranberries, Inc.|No|Completed|January 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|330|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||November 2013|April 24, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776021||72430|
NCT01776944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00364|Resting Energy Expenditure Using a Handheld Calorimeter|Validating a Handheld Indirect Calorimeter in Overweight and Obese Pediatric Population|CalVal|University of British Columbia|No|Completed|May 2012|February 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|75|||Both|13 Years|18 Years|No|Non-Probability Sample|Obese children aged 13-18y of both gender|May 2015|May 29, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01776944||72359|
NCT01775982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2011/VA-04|Validation of a French Version of the Confusion Assessment Method (CAM)|Validation of a French Version of the Confusion Assessment Method (CAM): a Diagnostic Tool for Acute Confusion Among the Elderly||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|75 Years|N/A|No|Non-Probability Sample|Patients 75 years or older for whom a state of confusion is suspected during        hospitalization or during a consultation for a geriatric or memory assessment.|October 2015|October 26, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775982||72433|
NCT01777230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43062.041.13|The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer|The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer||UMC Utrecht|No|Withdrawn|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|None Retained|no biospecimens are to be retained.|Female|18 Years|N/A|No|Non-Probability Sample|Adult patients with histologically proven cervical cancer which are a candidate for        surgery, which includes an intra-operative SN procedure and pelvic lymph node dissection.        Subjects are derived form a tertiary referral center.|December 2014|December 17, 2014|January 17, 2013||No|Unable to get required research materials|No||https://clinicaltrials.gov/show/NCT01777230||72337|
NCT01777529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asclin 003/2012|Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations|Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age.|MMR|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Recruiting|October 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Anticipated|240|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||November 2012|January 24, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01777529||72315|
NCT01778309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACEXERCISE2011|NAC Supplementation and Skeletal Muscle Performance|Effects of NAC Supplementation on Skeletal Muscle Performance Following Aseptic Injury Induced by Exercise||Democritus University of Thrace|Yes|Completed|January 2010|April 2012|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01778309||72255|
NCT01778556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130057|Short-term Effects of Leptin in People With Lipodystrophy|Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|December 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Years|70 Years|No|||June 2015|November 4, 2015|January 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778556||72236|
NCT01778569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130065|The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)|Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|June 2022|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|18 Years|N/A|No|||October 2015|November 11, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778569||72235|
NCT01775163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10008-A|Effect of Exercise-Induced Weight Loss on Energy Metabolism|E-MECHANIC Ancillary Study: Effect of Exercise-Induced Weight Loss on Energy Metabolism||Pennington Biomedical Research Center|No|Completed|December 2010|February 2015|Actual|February 2015|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women enrolled in E-MECHANIC|March 2016|March 24, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775163||72496|
NCT01775176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11016-A|Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose|Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome: Studies in Skeletal Muscle and Adipose Tissue 'PULSE Ancillary Study'|PULSE-A|Pennington Biomedical Research Center|No|Active, not recruiting|May 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|52|||Female|20 Years|40 Years|No|||March 2016|March 24, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775176||72495|
NCT01781260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12098|Effect of Prone Position on Liver Blood Flow and Function|The Effect of Prone Positioning During Anaesthesia on Liver Blood Flow and Function|PLiF|University of Nottingham|No|Recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients between the age of 18-65, presenting for neurosurgical procedures to the Queen's        Medical Centre, Nottingham, England, UK.|December 2015|December 1, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781260||72028|
NCT01778335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 3.8|Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke|Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial|ESCAPE|University of Calgary|Yes|Terminated|January 2013|January 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|January 25, 2013||No|On DSMB advice, trial recruitment has been halted for efficacy. F/U continues.|No||https://clinicaltrials.gov/show/NCT01778335||72253|
NCT01781819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00063972|(ARFI) Shear Velocity Imaging of the Kidneys in Pediatric Patients|Ultrasound Based Acoustic Radiation Force Impulse (ARFI)Shear Wave Velocity Imaging (SVI)of the Kidneys in Pediatric Patients With Vesicoureteral Reflux||University of Michigan|Yes|Withdrawn|October 2012|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|18 Years|No|||May 2015|May 29, 2015|January 29, 2013|Yes|Yes|PI leaving institution|No||https://clinicaltrials.gov/show/NCT01781819||71985|
NCT01781832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00064416|Bladder ARFI (Acoustic Radiation Force Impulse) Study|Evaluation of Pediatric Urinary Bladder Wall Thickening and Fibrosis Using Acoustic Radiation Force Impulse (ARFI)-Derived Shear Wave Velocities||University of Michigan|Yes|Recruiting|October 2012|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|18 Years|No|||February 2016|February 29, 2016|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781832||71984|
NCT01779687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNAKF-12.03|Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.|Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin (AVIATOR).|AVIATOR|Radboud University|No|Completed|March 2013|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779687||72149|
NCT01779713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-15|Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage|Discovery of the Risk Factors Associated to the Development of Vasospasm Following a Sub-arachnoid Aneurismal Hemorrhage Via Genomic Studies Including Genetic and Transcriptomic||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2013|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Caucasian subjects, aged more than 18, suffering of sub-arachnoid hemorrhage|January 2013|April 24, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01779713||72147|
NCT01779947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-ESD-001|Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo|An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause||Amneal Pharmaceuticals, LLC|No|Completed|March 2012|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|519|||Female|30 Years|75 Years|No|||June 2014|June 25, 2014|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779947||72129|
NCT01779960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFIP-001-KCF-1|Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients With COPD|Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients||Universidade Estadual de Londrina|No|Recruiting|January 2013|November 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|The sample will be composed by at least 35 patients with moderate-severe COPD from each        institution involved (Catholic University of Leuven, Belgium and State University of        Londrina, Brazil), adding up to 70 patients. However, the sample size could be increased        if necessary to achieve intermediate calculation of the sample power performed during the        study. Both groups should be similar concerning anthropometric characteristics, gender        distribution and severity feature of the disease (especially FEV1). Therefore, an eventual        increase in the final number of patients may also be necessary in case this similarity is        not achieved in the final data collection of the planned sample.|June 2015|June 9, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779960|6 Months|72128|
NCT01779921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3578|Treatment of Congenital Factor VII Deficiency|Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study|F7CONDEF|Novo Nordisk A/S|No|Completed|October 2005|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|163|Samples Without DNA|Plasma for assaying of inhibiting antibodies to FVII. All samples, which are analysed at the      local hospital laboratory, are to be stored and destroyed according to local rules.      Inhibitor samples analysed at the central laboratory will be stored until data validation      has taken place at the end of the study after which the samples will be destroyed.|Both|N/A|90 Years|No|Non-Probability Sample|Patients with FVII deficiency (levels of FVII less than 50% of normal or a mutation known        to be associated to a FVII deficiency) can be enrolled.|August 2014|August 6, 2014|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779921||72131|
NCT01775709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2012-8774|Evaluation of a New Biocompatible Pressure Equalizing Tube|Evaluation of a New Biocompatible Pressure Equalizing Tube||University of California, Irvine|Yes|Withdrawn|July 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|N/A|N/A|No|||August 2015|August 5, 2015|January 14, 2013||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01775709||72454|
NCT01776463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01A10101|A Healthy Subject Study With Z-360 and Placebo|A Single Centre, Randomized, Double-blind, Ascending Dose, Placebo-controlled, and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Z-360 and Placebo in Healthy Subjects||Zeria Pharmaceutical|No|Completed|January 2013|July 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Male|20 Years|49 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01776463||72396|
NCT01777243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115570|A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis|A Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic Amyloidosis||GlaxoSmithKline|Yes|Active, not recruiting|May 2013|December 2015|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777243||72336|
NCT01778049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.10|Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes|A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy||Boehringer Ingelheim||Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|708|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|January 24, 2013||||No||https://clinicaltrials.gov/show/NCT01778049||72275|
NCT01778062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BKR01|Indacaterol EfectIveness In COPD Patients With Tuberculosis History|A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis|INFINITY|Novartis|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|19 Years|N/A|No|||October 2015|October 1, 2015|January 25, 2013||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01778062||72274|
NCT01774656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTAGE-UL|Remission From Stage D Heart Failure|Remission From Stage D Heart Failure (RESTAGE-HF)|RESTAGE-HF|University of Louisville|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|59 Years|No|||December 2015|December 2, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774656||72535|
NCT01774669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/065|Effectiveness Study on a Virtual Reality Based Training System for Stroke Patients|Effectiveness of the YouGrabber System Using Virtual Reality in Stroke Rehabilitation: a Single Blinded, Randomised Controlled Multi-centre Trial|YouGrabber|Reha Rheinfelden|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01774669||72534|
NCT01774916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00893-40|Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations|Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|10 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 29, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774916||72515|
NCT01782885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI13-001|Comparison of Acetaminophen and PRP Therapy for Knee OA|Comparison of Acetaminophen and Platelet-rich Plasma Therapy for the Treatment of Knee Osteoarthritis.||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|May 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|543|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 30, 2013||No||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01782885||71903|
NCT01782898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00066623|The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery|The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery||Northwestern University|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Female|18 Years|64 Years|No|||April 2015|April 29, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782898||71902|
NCT01778101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lanso_pilot|Lansoprazole in Preterm Infants With Reflux|A Pilot Study - Lansoprazole in Preterm Infants With Gastroesophageal Reflux||Seoul National University Hospital|Yes|Completed|January 2013|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|4 Months|No|||September 2013|September 11, 2013|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01778101||72271|
NCT01779128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-233|PET-CT vs. Integrated MR-PET Scanning of GYN Cancers|Comparing Preoperative PET-CT With Integrated MR-PET Scanning of Gynecologic Cancers||Massachusetts General Hospital|Yes|Not yet recruiting|March 2013|||March 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||January 2013|January 28, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779128||72192|
NCT01778595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913068|Colon Cancer Study of Fecal Samples in Shanghai, China|Pilot Study of the Fecal Microbiome in the Shanghai Population||National Institutes of Health Clinical Center (CC)||Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|700|||Both|50 Years|75 Years|No|||November 2015|December 15, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778595||72233|
NCT01779414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC-2012-3660|STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit|STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit|STAT-ED|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01779414||72170|
NCT01779427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B090010--03|Attention Intervention Management|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Attention Intervention Management|AIM|Children's Hospital Medical Center, Cincinnati|No|Withdrawn|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|18 Years|No|||March 2016|March 7, 2016|December 10, 2012||No|Based on data from pilot study, the PI and program officer have determined that this study was    not feasible.|No||https://clinicaltrials.gov/show/NCT01779427||72169|
NCT01779440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA158863-01A1|Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness|Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|110|||Both|18 Years|30 Years|No|||August 2015|August 17, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01779440||72168|
NCT01779700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11T-001|Fingolimod in Schizophrenia Patients|Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment|STEP|Indiana University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01779700||72148|
NCT01779726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/2011|Efficiency of Diagnostic Strategy for Fast Track Lung Cancer Diagnosis|Efficiency of Diagnostic Strategy for Fast Track Lung Cancer Diagnosis. A Randomised Controlled Trial.||University of Aarhus|No|Completed|January 2012|January 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|331|||Both|N/A|N/A|No|||August 2013|December 2, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779726||72146|
NCT01779739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FaVR@UAB2012|Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy|Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy|FaVR|University of Alabama at Birmingham|No|Recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|66|||Female|19 Years|105 Years|No|||December 2015|December 7, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779739||72145|
NCT01779986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAS-MCAS UdeS 12-073|Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram|Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram in Patient as Part of Preoperative Evaluation in Ascending Aorta Replacement Surgery Patients.|CTAS-MCAS|Université de Sherbrooke|No|Recruiting|January 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients with ascending aorta aneurysm undergoing preoperative evaluation of CAD by        CT-Angioscan and Coronary angiogramm before surgical reparation.|January 2013|January 29, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779986||72126|
NCT01780571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIDS CPAP|CPAP/PSV Preoxygenation in Obese Patients|Continuous Positive Airway Pressure/Pressure Support Preoxygenation of Morbidly Obese Patients||Karolinska Institutet|No|Completed|May 2009|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01780571||72081|
NCT01780181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12401905700zzy|Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer|Randomized Double-blind Controlled Clinical Study of Chemotherapy Combined With or Without Traditional Chinese Medicine on Survival Affect of Elderly Patients With Advanced Non-small-cell Lung Cancer||Shanghai University of Traditional Chinese Medicine|No|Recruiting|July 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|76|||Both|65 Years|80 Years|No|Probability Sample|Pathologically or cytologically confirmed of stage IIIb-IV NSCLC； Ages Eligible for Study:        ≥65 years old; TCM syndromes are deficiency of Yin, deficiency of Qi and deficiency of        both Qi and Yin.|November 2015|November 22, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780181||72111|
NCT01780194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSION_META_TYH_2013|Lumbar Fusion Compared With Conservative Treatment in Patients With Chronic Low Back Pain: a Meta-analysis|||Turku University Hospital||Completed|December 2012|||February 2013|Actual|N/A|Observational|N/A||2|Actual|666|||Both|18 Years|N/A|No|Probability Sample|People with chronic low back pain due to degenerative spinal conditions|November 2013|November 27, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780194||72110|
NCT01780207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066/10|Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea|Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea||University Hospital Inselspital, Berne||Completed||||May 2014|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||December 2014|December 29, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780207||72109|
NCT01780753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1203|Primaquine Pharmacokinetics in Lactating Women and Their Infants|A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax||University of Oxford|No|Completed|December 2012|December 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01780753||72067|
NCT01780766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMM|Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging|Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2008|September 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|25 Years|N/A|No|Non-Probability Sample|Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.        All patients underwent bone marrow biopsy.|January 2013|January 28, 2013|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01780766||72066|
NCT01776203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110523|Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist|Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized||Kaiser Permanente|No|Terminated|January 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|50 Years|No|||March 2015|March 10, 2015|June 14, 2011||No|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT01776203||72416|
NCT01786200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12SU401|Physiological Effects of Altering Cancer-related Inflammation|Pilot Study to Investigate the Physiological Effects Associated With Down-regulation of Host-tumour Inflammatory Responses in Colon Cancer||NHS Greater Glasgow and Clyde|No|Not yet recruiting|February 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|75 Years|No|||February 2013|February 5, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01786200||71648|
NCT01786798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA55/34|Transvaginal Ultrasound in Women With Abnormal Uterine Bleeding|Role of Transvaginal Ultrasonography in Evaluating Premenopausal Women Aged More Than 35 Years With Abnormal Uterine Bleeding||Chulalongkorn University|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|560|||Female|35 Years|N/A|No|||February 2016|February 9, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786798||71602|
NCT01787097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BC00004|Effect of Symbicort ® on GR in Sputum in COPD|GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD)||Imperial College London|No|Completed|January 2013|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|31|||Both|35 Years|80 Years|No|||January 2013|August 26, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787097||71579|
NCT01787084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVTR-2012-02|Alternative Access Approaches for Transcatheter Aortic Valve Replace (TAVR) in Inoperable Patients With Aortic Stenosis|Transcatheter Valve Therapy (TVT) Registry Assessment of Alternative Access Approaches for Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis|Inop AA|The Society of Thoracic Surgeons|No|Not yet recruiting||December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|The study cohort will include all TVT Registry data obtained for inoperable patients age        18 years or older who undergo TAVR for severe aortic stenosis using any non-femoral access        approach with an Edwards SAPIEN device between the start date and December 31, 2018|February 2013|March 18, 2013|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787084||71580|
NCT01775995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0656|Meditation-CBT for Opioid-treated Chronic Low Back Pain|Randomized Controlled Trial of Mindfulness Meditation and Cognitive Behavioral Therapy Intervention for Opioid-treated Chronic Low Back Pain||University of Wisconsin, Madison|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|January 22, 2013||No||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01775995||72432|Lack of blinding of study staff to group status (except the statistician who was blinded during initial primary analyses); conducting most study related activities by the same core group of research staff may have introduced bias and placebo effect.
NCT01782391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nighttime sleep-tSOS-MCI|Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Patients With Mild Cognitive Impairments|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Patients With Mild Cognitive Impairments(MCI)||Charite University, Berlin, Germany|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|50 Years|90 Years|No|||March 2016|March 15, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01782391||71941|
NCT01778855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HASTIER|Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization|An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis|HASTIER|University of California, Los Angeles|Yes|Completed|February 2013|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|6|||Both|22 Years|82 Years|No|||November 2015|November 30, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778855||72213|
NCT01782911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-IO-01-2013-01|Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients|Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.|RES-IVF|Instituto Valenciano de Infertilidad, IVI VALENCIA|Yes|Not yet recruiting|February 2013|||April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01782911||71901|
NCT01778868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDORUP|Environmental Chemicals and Their Role in Obesity|Endocrine Disrupting Environmental Chemicals: From Accumulation to Their Role in the Global "Neuro-endocrine" Epidemic of Obesity and Its Metabolic Consequences|ENDORUP|University Hospital, Antwerp|No|Active, not recruiting|August 2009|July 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|203|Samples With DNA|Blood samples Urinary samples Fat samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with BMI > 25kg/m² and a normal weight (BMI < 25 kg/m²) control population|January 2013|January 28, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01778868||72212|
NCT01779141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL01|Orchestra Pregnancy Observational Study in Poland|A Multi-center Observational Study During Pregnancy for Women With T1DM Treated With the Paradigm Insulin Pumps Donated by the 'Wielka Orkiestra Świątecznej Pomocy' Foundation in Poland||Medtronic Poland Spółka z ograniczoną odpowiedzialnością|No|Recruiting|May 2013|May 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|None Retained|Whole blood, serum, urine samples as required in routine practice before, during and after      pregnancy in women with Type 1 Diabetes Mellitus|Female|18 Years|45 Years|No|Probability Sample|Women with Type 1 Diabetes Mellitus planning pregnancy or being pregnant until the 16th        week of pregnacy|October 2014|October 15, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779141|22 Months|72191|
NCT01779466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000088|Daytime Impact Sleep Study|A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo|DAISS|Ferring Pharmaceuticals|No|Terminated|April 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5|||Both|25 Years|65 Years|No|||April 2015|April 24, 2015|January 23, 2013||No|Terminated due to lack of eligible patients|No||https://clinicaltrials.gov/show/NCT01779466||72166|
NCT01779752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-20|Vestibular Cortex and TMS|Functional Organisation of the Vestibular Cortical Pathways in Human: Transcranial Magnetic Stimulation (TMS) Approach|CoVest|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|January 2013|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Subjects|January 2013|January 28, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01779752||72144|
NCT01779973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816651|Remote Observed Dosing to Increase Suboxone Compliance||RODISC|University of Pennsylvania|Yes|Completed|February 2013|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|9|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779973||72127|
NCT01780584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB05.01/1.4/235/2010|Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?|Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease||National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Completed|April 2010|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|45|||Both|N/A|24 Months|No|||February 2013|February 2, 2013|January 28, 2013||No||No|February 2, 2013|https://clinicaltrials.gov/show/NCT01780584||72080|The lack of power to detect differences in clinical outcomes. There was also insufficient power to detect potentially subtle adverse effects of T3 supplementation.
NCT01780220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP12-UC-0101/1104|Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery||CARLHA|UNICANCER|Yes|Recruiting|December 2012|January 2018|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Male|18 Years|N/A|No|||January 2013|January 29, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780220||72108|
NCT01780233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-06-003|Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)|A Single-dose Crossover Study of Fentanyl Sublingual Spray 400 Mcg Versus Actiq® 400 Mcg Versus Fentanyl Citrate Injection (iv) 100 Mcg Under Fasted Conditions||INSYS Therapeutics Inc|No|Completed|April 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780233||72107|
NCT01780493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.04.2007/172|The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique|The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique: A Prospective Study||TC Erciyes University||Completed|March 2004|August 2011|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01780493||72087|
NCT01780506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0104|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults||Gilead Sciences|Yes|Active, not recruiting|December 2012|July 2016|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|872|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 16, 2013|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01780506||72086|There were no limitations affecting the analysis or results.
NCT01780519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006469|The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms|The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms||Mayo Clinic|No|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|75|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780519||72085|
NCT01785953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-TO-2012|Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia|CONVENTIONAL AND EXPERIMENTAL CHEMOTHERAPY WITH ALLOGENEIC TRANSPLANT IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKAEMIA|AML|Azienda Ospedaliera San Giovanni Battista|No|Recruiting|February 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|66 Years|No|Non-Probability Sample|Acute myeloid leukemia patients|February 2013|February 6, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785953||71667|
NCT01785732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-007|Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)||RENSYMPIS|The Hospital District of Satakunta|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|69 Years|No|||February 2013|February 8, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785732||71684|
NCT01776736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITF-237-11|Safety and Efficacy of Posture Correction Girdle for Adolescent With Early Scoliosis|Study of Posture Correction Girdle of Adolescents With Early Scoliosis||The Hong Kong Polytechnic University|Yes|Recruiting|July 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|10 Years|13 Years|No|||August 2015|August 25, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01776736||72375|
NCT01776970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANALS|Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease|A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients|CANALS|Ospedale San Raffaele|Yes|Recruiting|January 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2013|January 24, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01776970||72357|
NCT01786512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110151|COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.|A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction|COSMIC-HF|Amgen|Yes|Completed|February 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|544|||Both|18 Years|85 Years|No|||October 2015|November 5, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786512||71624|
NCT01775228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17897|Effect of Peer Support Intervention on Early Recovery Outcomes Post Coronary Artery Bypass Graft Surgery|The Effect of a Professionally-guided Telephone Peer Support Intervention on||University of Calgary|No|Completed|November 2006|November 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|185|||Male|36 Years|87 Years|No|||January 2013|January 23, 2013|December 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01775228||72491|
NCT01783132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1852011|Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home|Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home|OCTAGEN|Orion Corporation, Orion Pharma|No|Recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|64 Years|No|||January 2013|January 31, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01783132||71884|
NCT01783119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF.589|Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis|Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis|AVIUC|National Institute of Medical Sciences and Nutrition, Salvador Zubiran|Yes|Recruiting|August 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|59 Years|No|||January 2013|February 1, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783119||71885|
NCT01782404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-0008|Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine|Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine||Wellspect HealthCare||Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|January 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01782404||71940|
NCT01782638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0140|Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area|Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area.||University Hospital, Clermont-Ferrand||Recruiting|September 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01782638||71922|
NCT01778634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054998|Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants|A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants|AZIPIII|University of Maryland|Yes|Recruiting|July 2013|December 2021|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|72 Hours|No|||May 2015|May 28, 2015|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778634||72230|
NCT01778881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cinthiamiotto|Physical Therapy Interventions Relative to Dental Treatment in Individuals With Bruxism|Effectiveness of Physical Therapy Interventions, Relative to Dental Treatment in Individuals With Bruxism: a Randomized Clinical Trial|Bruxism|University of Sao Paulo General Hospital|Yes|Recruiting|March 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||||||Both|18 Years|60 Years|No|||November 2015|December 3, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778881||72211|
NCT01779154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136132|Eosinophilic Gastrointestinal Disorders Patient Registry|Eosinophilic Gastrointestinal Disorders Patient Registry||Arkansas Children's Hospital Research Institute|No|Enrolling by invitation|January 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|21 Years|No|Non-Probability Sample|Individuals with a diagnosis of an eosinophilic gastrointestinal disorder|January 2015|January 13, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779154|21 Years|72190|
NCT01779453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-007|A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia||Esperion Therapeutics|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779453||72167|
NCT01779479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 74|Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)|Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neo-adjuvant Treatment in Patients With Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)||German Breast Group|Yes|Completed|February 2013|February 2016|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|333|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01779479||72165|
NCT01780259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100942|A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants|A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780259||72105|
NCT01780272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3997|A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes|A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|26|||Both|18 Years|64 Years|No|||July 2014|August 4, 2014|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780272||72104|
NCT01780246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS10|An Open-label Safety and Tolerability Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1|An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1||Ionis Pharmaceuticals, Inc.|Yes|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|2 Years|15 Years|No|||July 2014|July 14, 2014|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780246||72106|
NCT01786213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TraCo|Training Effects in Colonoscopy|The Impact of Training Effects on Quality Indicators in Colonoscopy: a Retrospective Study.|TraCo|Technische Universität München|No|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Retrospective||10|Anticipated|3500|Samples Without DNA|Histological findings are recorded|Both|18 Years|N/A|No|Non-Probability Sample|Endoscopy Department of a university Hospital|February 2013|February 5, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786213||71647|
NCT01786525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000332|House Calls and Decision Support: Improving Access to Live Donor Transplantation|House Calls and Web-based Decision Support: Improving Access to Live Donor Kidney Transplantation||Beth Israel Deaconess Medical Center|No|Recruiting|June 2013|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|150|||Both|21 Years|N/A|No|||November 2015|November 14, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786525||71623|
NCT01786538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regorafenib/FOLFOX|Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines|Randomized Phase III Study of Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) With or Without Regorafenib in Patients With Metastatic Colorectal Cancer Progressed After First-line Irinotecan Plus Fluoropyrimidines||Asan Medical Center|Yes|Withdrawn|June 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|N/A|No|||March 2013|March 12, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01786538||71622|
NCT01786811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-027|Serious Illness Communication Project|Serious Illness Communication Project||Dana-Farber Cancer Institute|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|994|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01786811||71601|
NCT01776060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040961|Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study|Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study||Duke University|Yes|Recruiting|January 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|Blood (RNA/DNA), serum, plasma, urine|Both|18 Years|100 Years|No|Non-Probability Sample|Participants must enroll in the MURDOCK Study Horizon 1.5 (Pro00011196) as well as the        Multiple Sclerosis cohort (Pro00023791) in order to participate in this biannual        collection of a follow up questionnaire and blood/urine collection for participants who        have Primary Progressive MS. The biannual collection will continue for 5 years. Those        participants with PPMS who are already enrolled in the MURDOCK Study Horizon 1.5 and        Multiple Sclerosis cohort will be contacted via phone to assess interest in the PPMS        study. New participants with PPMS who enroll into the Horizon 1.5 study and Multiple        Sclerosis cohort will be asked during the time of enrollment if they would like to        participate in the PPMS study as well.|November 2015|December 14, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776060||72427|
NCT01775501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-218|Sorafenib + mFOLFOX for Hepatocellular Carcinoma|Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775501||72470|
NCT01775514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28579|A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics|OCCURRENCE RATE OF COLON CANCER, BREAST CANCER, GASTRIC CANCER AND MALIGNANT MELANOMA IN TURKEY & DIAGNOSIS AND TREATMENT CHARACTERISTICS||Hoffmann-La Roche||Completed|October 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32277|||Both|18 Years|N/A|No|Probability Sample|Patients with colon, breast or gastric cancer or malignant melanoma|March 2016|March 1, 2016|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01775514||72469|
NCT01775761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461031|A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)|A Randomized, Placebo- And Positive-Controlled Cross-Over Study To Evaluate The Effect Of Tafamidis On The QTC Interval In Healthy Volunteers||Pfizer|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775761||72450|
NCT01775774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDS MSC 001|Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome|A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome|START|University of California, San Francisco|Yes|Recruiting|July 2013|February 2017|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775774||72449|
NCT01782417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022836_1|Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.|Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.|PRIMO-Latino|Duke University|No|Completed|February 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2015|October 11, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782417||71939|
NCT01782651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116450|Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients|Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients||GlaxoSmithKline|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Female|18 Years|N/A|No|Non-Probability Sample|It is planned to capture data on approximately 180 patients with HER2-positive metastatic        breast cancer in about 20 medical centres in Hungary. Patients diagnosed with, or who        progressed to, metastatic disease between 01 September 2009 and 01 September 2010 will be        included. All patients will be followed until death, loss to follow-up or the end of the        study period (30 September 2012).|August 2015|August 6, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782651||71921|
NCT01782664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116679|A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis||GlaxoSmithKline|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|68|||Both|18 Years|75 Years|No|||May 2014|June 19, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782664||71920|
NCT01778647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ113607|Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD|Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD||Maimonides Medical Center|Yes|Terminated|December 2009|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|6 Years|15 Years|No|||October 2013|October 23, 2013|September 30, 2010|Yes|Yes|Co-Investigators left the Institution.|No||https://clinicaltrials.gov/show/NCT01778647||72229|
NCT01778660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSC-12-429|Standard Versus Mnemonic Counseling for Fecal Incontinence|Standard Versus Mnemonic Counseling for Fecal Incontinence: a Pilot Randomised Control Trial|FIT|University of New Mexico|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|N/A|No|||January 2013|April 4, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01778660||72228|
NCT01778894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|623-12|Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart|Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart||University of Nebraska|Yes|Recruiting|September 2013|||February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal controls will be recruited from the Omaha community. Subjects with Diastolic Heart        Dysfunction and/or Failure will be selected from The University of Nebraska Medical Center        Heart Clinic or from The Nebraska Medical Center Hospital.|October 2013|October 12, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778894||72210|
NCT01779492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL2907-102|A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers||GL Pharm Tech Corporation|No|Completed|April 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779492||72164|
NCT01779167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112012086|Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia|A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients With Previously Treated Waldenstrom Macroglobulinemia|THRiL for WM|Weill Medical College of Cornell University|Yes|Terminated|June 2012|April 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2014|May 1, 2014|January 7, 2013|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01779167||72189|
NCT01779999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGB0012226|Early Detection of PICC-related Deep Vein Thrombosis by US Surveillance: an Effective Approach for Secondary Prevention?|Observational Study With Ultrasonographic Screening for Early Detection of PICC-related DVT, Results of Early Beginning of Anticoagulant Treatment||University of Turin, Italy|No|Completed|June 2010|June 2012|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing a PICC-line positioning during a five-months period|January 2013|February 8, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779999||72125|
NCT01780012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVOST|Evaluation of an Osteoporosis Prevention Strategy in Women With Osteoporotic Fracture of the Upper Limb|Secondary Prevention of Osteoporosis in Women Over 50 Years Old After Low Intensity Fracture of the Upper Limb: Evaluation of an Intervention Focused on the Patient.|PREVOST|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|March 2012|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|446|||Female|50 Years|85 Years|No|||January 2013|January 29, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780012||72124|
NCT01781130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11-112-002|Effect of Steroid Injection Which is Added to Percutaneous Trigger Finger Release: a Double-blinded Randomized Controlled Trial.|||Samsung Medical Center|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|80 Years|No|||May 2015|May 15, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01781130||72038|
NCT01780844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7163-CL-0108|A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients|A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|149|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780844||72060|
NCT01775397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID-EC-0001|A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System|A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy|FREEDOM|Astellas Pharma Inc|Yes|Terminated|November 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|January 8, 2013||No|Study terminated due to difficulty in enrollment|No||https://clinicaltrials.gov/show/NCT01775397||72478|
NCT01775410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 0218|OptiCal COherence ToMography ABoard InformiNg AtherEctomy|A Non-randomized, Multi-center Feasibility Trial of the Avinger Wolverine System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries|COMBINE|Avinger, Inc.|No|Enrolling by invitation|February 2013|September 2014|Anticipated|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01775410||72477|
NCT01775423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-101|A Study of BBI608 in Adult Patients With Advanced Malignancies|A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies||Boston Biomedical, Inc|No|Active, not recruiting|March 2009|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775423||72476|
NCT01775436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR01405201|Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care|Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care|FACE|Children's Research Institute|Yes|Recruiting|April 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|444|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01775436||72475|
NCT01785706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2357|COPD Research Registry|||COPD Foundation||Completed|March 2007|||April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with COPD or at-risk of developing COPD.|June 2015|June 11, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01785706|20 Years|71686|
NCT01778608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS-001|Feasability Test of a Handset Device to Detect Levels of Sedation and Loss of Consciousness|Feasibility Test of a Handset Device to Detect Sedation Levels and Loss of Consciousness During Propofol Administration||University Medical Center Groningen|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|50 Years|72 Years|No|Non-Probability Sample|Twenty patients requiring anaesthesia for clinical surgical care. ASA physical status I,        II or III|May 2013|May 25, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01778608||72232|
NCT01774721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP312804|ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.|ARCHER 1050: A Randomized, Open Label Phase 3 Efficacy and Safety Study Of Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations|ARCHER 1050|SFJ Pharmaceuticals, Inc.|Yes|Active, not recruiting|April 2013|February 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774721||72530|
NCT01774955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAPE registry|The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention|The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention|GRAPE|University of Patras|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2047|||Both|18 Years|N/A|No|Probability Sample|Study population is consisted of patients with acute coronary syndrome subjected to PCI in        6 geographic regions of Greece|August 2015|August 19, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774955|12 Months|72512|
NCT01774968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14838|Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes|Two Treatment Approaches for Human Regular U-500 Insulin (Thrice-Daily Versus Twice-Daily) in Subjects With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Open-Label, Parallel Clinical Trial||Eli Lilly and Company|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Both|18 Years|75 Years|No|||September 2015|September 3, 2015|January 22, 2013|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01774968||72511|
NCT01776281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHyderali|Effects of Kangaroo Mother Care Among Low Birth Weight (LBW) and Preterm Infants|Effects of Kangaroo Mother Care Among LBW and Preterm Infants:A Randomized Control Trial in Karachi|KMC|Aga Khan University|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|82|||Both|N/A|1 Week|No|||January 2013|January 25, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776281||72410|
NCT01776268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121760|Effect of Colostrum on Mucosal Immunity in Very Low Birth Weight (VLBWs) Premature Infants|Effect of Colostrum on Innate Mucosal Immunity in Very Premature Infants||Vanderbilt University|Yes|Active, not recruiting|February 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|1 Year|No|||December 2014|December 9, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01776268||72411|
NCT01775787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECIG 13-002-3|Effects of Electronic Cigarettes on Nicotine Concentrations|Effects of Electronic Cigarettes on Nicotine Concentrations Before and 5, 10,15,20 and 30 Minutes After Use|ECIG|University of Connecticut Health Center|No|Active, not recruiting|October 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01775787||72448|
NCT01775800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012494|Treatment Modification to Reduce Symptom Burden in Hemodialysis|Treatment Modification and Symptom Burden in High-Risk Dialysis Patients||The Rogosin Institute|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|No|||February 2016|February 26, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01775800||72447|
NCT01782690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML23024|An Observational Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice||Hoffmann-La Roche||Completed|March 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|376|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic pancreatic cancer|March 2016|March 1, 2016|January 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01782690||71918|
NCT01778673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-213|Cortical Comminution and Intra-articular Involvement in Distal Radius Fractures Can Predict Radiological Outcome. A Prospective Multicenter Study|||Sundsvall Hospital||Completed|October 2009|||September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|15 Years|74 Years|No|Probability Sample|community sample|January 2013|January 24, 2013|January 24, 2013||||No||https://clinicaltrials.gov/show/NCT01778673||72227|
NCT01778686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002056-16|Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors|Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors||Rigshospitalet, Denmark|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01778686||72226|
NCT01782677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM-B|Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure|Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure||Noblewell|Yes|Completed|December 2012|||December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782677||71919|
NCT01779180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-VAS-Atopy|Vitamin A Supplementation at Birth and Atopy in Childhood|The Effect of Vitamin A Supplementation at Birth on the Development of Atopy in Childhood: Long-term Follow-up of a Randomised Placebo-controlled Trial||Bandim Health Project|No|Active, not recruiting|January 2013|February 2014|Anticipated|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|8 Years|12 Years|No|Non-Probability Sample|Participants in a previous neonatal vitamin A supplementation trial|February 2013|November 14, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779180||72188|
NCT01779193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-101-065|Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy|A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy||National Cheng-Kung University Hospital|Yes|Recruiting|June 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 26, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779193||72187|
NCT01779505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-13020-01|A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults|A Randomized, Open-Label, Multi-Arm, Dose Escalation, Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Hepatitis B Virus X, Surface and Core Antigens, at Various Dose Levels and Regimens in Healthy Adults.||Gilead Sciences|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779505||72163|
NCT01779206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06 / ADAPT HR+/HER2-|ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|ADAPT|West German Study Group|Yes|Recruiting|May 2012|||August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4936|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01779206||72186|
NCT01779765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NV-242-CTIL|The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)|The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study||Tel-Aviv Sourasky Medical Center|No|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||January 2013|March 26, 2014|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01779765||72143|
NCT01779518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0139|Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C|An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection||Gilead Sciences||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2014|January 15, 2014|January 23, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01779518||72162|
NCT01779778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0175|Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure|The Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure||University of Colorado, Denver|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients diagnosed with open angle glaucoma or ocular hypertension|March 2014|March 25, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779778||72142|
NCT01779791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100956|A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma|An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma||Janssen Research & Development, LLC|Yes|Active, not recruiting|April 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779791||72141|
NCT01780623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003569|An Investigation of Light Therapy for Cancer-related Fatigue (The LITE Study)|A Randomized Controlled Trial of Light Therapy on Biomarkers, Sleep/Wake Activity, and Quality of Life in Individuals With Post-treatment Cancer-related Fatigue|LITE|University of Calgary|No|Active, not recruiting|January 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|65 Years|No|||March 2015|March 14, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01780623||72077|
NCT01780870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000293|Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss|Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|September 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780870||72058|
NCT01780597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NewcastleNHS|Assessment of Hearts Deemed Unsuitable for Transplant With the Aim of Expanding the Donor Heart Pool.|Ex Vivo Assessment of Human Hearts Deemed Unsuitable for Cardiac Transplant With the Ultimate Aim of Increasing the Number of Hearts Available for Transplant for Cardiac Failure Patients.||Newcastle-upon-Tyne Hospitals NHS Trust|No|Not yet recruiting|February 2013|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|17|Samples With DNA|Myocardial biopsies, serum samples.|Both|18 Years|75 Years|No|Non-Probability Sample|Organ Donors (declared brainstem dead). The hearts are only to be studied after death and        removal from the body. Consent given first from the next of kin.|February 2013|February 3, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01780597||72079|
NCT01785719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSP 69298|Ultrasound Characterization of Ovarian Morphology During Weight Loss in Women With Polycystic Ovary Syndrome (PCOS)|Ultrasound Characterization of Follicle Dynamics During Weight Loss||Cornell University|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785719||71685|
NCT01785485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coors001|IMPACT - Integrative Medicine PrimAry Care Trial|IMPACT: Integrative Medicine PrimAry Care Trial: A Comparative Effectiveness Study of an Integrative Primary Care Clinic|IMPACT|University of Arizona|No|Not yet recruiting|February 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Only patients who are enrolled in primary care (members) at UAIHC and who meet the        inclusion/exclusion criteria are eligible to enroll in this study|February 2013|February 6, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01785485||71703|
NCT01774994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC04-021.3|Arginine and Nitric Oxide (NO) Metabolism in Healthy Human Volunteers|Arginine and Nitric Oxide (NO) Metabolism in Healthy Human Volunteers||Maastricht University Medical Center|No|Completed|November 2004|June 2012|Actual|January 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Actual|33|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774994||72509|
NCT01775241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-080|Sleep Apnoea Syndrome Without Chronic Heart Failure|Sleep Apnoea Syndrome Without Chronic Heart Failure||RWTH Aachen University|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with or with supected sleep apnoea syndrome|January 2014|January 7, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775241||72490|
NCT01775527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10 014|IgA Nephropathy, Lymphocyte Homing and IgA Class Switch|IgA Nephropathy, Lymphocyte Homing and IgA Class Switch|NIDOCIGA|University Hospital, Limoges|No|Recruiting|February 2013|July 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|72|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|March 26, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01775527||72468|
NCT01775826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA164993-01A1|Validating Machine -Learned Classifiers of Sedentary Behavior and Physical Activity|Validating Machine -Learned Classifiers of Sedentary Behavior and Physical Activity|iWatch|University of California, San Diego|No|Active, not recruiting|March 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|210|||Both|6 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit 210 volunteer participants over a 2-yr period. Fifty percent of the sample        will be women, and we will quota sample three specific age groups: 6-10 year olds (n =        70); 16-55 year olds (n=70); and 65-85 year olds (n= 70).|December 2015|December 1, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01775826||72445|
NCT01775813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0988|The Health Influences of Puberty (HIP) Study|Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents|HIP|University of Colorado, Denver|Yes|Recruiting|June 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|156|||Both|9 Years|17 Years|No|||October 2015|October 2, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01775813||72446|
NCT01776099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiNA-S DiNA-F|Diabetes Nutrition Algorithms - Sugars: Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes|Diabetes Nutrition Algorithms - Sugars: Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes|DiNA-S DiNA-F|German Institute of Human Nutrition|No|Recruiting|November 2012|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|79 Years|No|||November 2015|November 17, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776099||72424|
NCT01776294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04AMCRVCTZM12|Prehypertension Among Medical Students in Visakhapatnam and Association With Cardiovascular Risk Factors|Prevalence of Prehypertension Among Medical Students and Association With Cardiovascular Risk Factors||Andhra Medical College|Yes|Completed|March 2009|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|275|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Graduate Medical Students|January 2013|January 23, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01776294||72409|
NCT01776567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/12|Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms|Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.|APPOSE|Northern Hospital, Australia|Yes|Recruiting|July 2012|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 2, 2014|August 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01776567||72388|
NCT01776541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V89_04|Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults|A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.||Novartis|No|Completed|January 2013|May 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|979|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|January 20, 2013|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01776541||72390|
NCT01776554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V89_11|Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children|A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.||Novartis|No|Completed|January 2013|June 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|662|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|January 20, 2013|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01776554||72389|
NCT01782703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-15143|Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis|Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis||Northwestern University|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|500|Samples With DNA|We have retained whole blood and tissue samples (skin and cheek swabs)|Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited at Ann and Robert H. Lurie Children's Hospital of Chicago        Division of Dermatology outpatient clinics.          -  100 children with mild to severe AD, 100 aged-matched and sex-matched healthy (no             evidence of atopy) controls, 100 aged-matched and sex-matched controls with an atopic             condition (allergic rhinitis or asthma) but no history of atopic dermatitis will be             enrolled to obtain blood samples.          -  AD subjects between the ages of 0 months to 4 years of age will be asked to give             buccal (cheek) swabs to test for a mutation in filaggrin, a common skin protein.          -  70 children with mild to severe atopic dermatitis, and 70 age- and sex-matched (but             not site-matched) healthy controls (no evidence of atopy), will be enrolled to obtain             skin biopsies.          -  30 children with atopic dermatitis and 30 age/sex matched non-atopic controls, who             may or may not have participated in the aforementioned assessments, for imaging             evaluation.|December 2015|December 25, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782703||71917|
NCT01778907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUG11003|Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)|Effects and Cost-Effectiveness of Pharmacogenetic Screening Among Elderly Starters With Antidepressants: A Pragmatic Randomized Controlled Trial|CYSCE|University of Groningen|No|Recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|750|||Both|60 Years|N/A|No|||December 2015|December 9, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01778907||72209|
NCT01778920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC17 Lung Cancer|Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)|Pilot and Feasibility Study of the Imaging Potential of EC17||University of Pennsylvania|Yes|Recruiting|April 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778920||72208|
NCT01779219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAT2009|Intraoperative MRI-guidance in Frameless Stereotactic Biopsies|The Safety and Effectiveness of Low Field Intraoperative MRI-guidance in Frameless Stereotactic Biopsies of Brain Tumours - a Prospective Randomized Trial||Wroclaw Medical University|No|Terminated|June 2009|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|January 15, 2013||No|Primary investigator has changed his employee and the country of residence.|No|June 3, 2015|https://clinicaltrials.gov/show/NCT01779219||72185|
NCT01780610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYatsenU2H- QZhang|The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles|The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|670|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 31, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01780610||72078|
NCT01780038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|069-12-FB|Smokers' Response to Nicotine Dependence Genotyping|Smokers' Response to Nicotine Dependence Genotyping||University of Nebraska|No|Recruiting|October 2012|June 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01780038||72122|
NCT01780051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM0818-01|A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components|An Open-label, Randomized, Single-dose, 2-way Crossover Trial to Compare the Pharmacokinetics of Repaglinide2mg and MetforminHCl 500mg Complex to Combination Preparation of Repaglinide 2mg and MetforminHCl 500mg in Healthy Male Volunteers.||Dalim BioTech Co., Ltd.|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780051||72121|
NCT01780857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-275|Immune Signature of Palmoplantar Pustulosis|The Immune Signature of Palmoplantar Pustulosis|PPP|Baylor Research Institute||Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Blood and tissue samples. Blood from PPP patients. Skin biopsies from affected palms and      soles.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Number of Subjects             A total of 20 patients with palmoplantar pustulosis and 10 healthy controls will be             enrolled in this study.          2. Recruitment Procedures        Subjects will be recruited from: (1) the dermatology clinic at Texas Dermatology (in        conjunction with Menter Dermatology Research Institute) which include patients seen in the        clinic referred by the dermatologists providing their care, participants of clinical        trials in the clinic, or previously screened participants for clinical trials referred by        the study staff); (2) referrals from other dermatologists' or doctors' clinics.        Healthy volunteers will be recruited from the dermatology clinic. Where possible, healthy        volunteers and PPP patients will be matched for sample collection location, gender, age        and race.|July 2014|July 9, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780857||72059|
NCT01781481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/32E|The Pediatric Intermed: A New Clinical Decision Making Tool|The Pediatric Intermed: A New Clinical Decision Making Tool for Proactive Evaluation of Psychosocial Stress in Children With IBD.||Children's Hospital of Eastern Ontario|No|Recruiting|April 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|8 Years|17 Years|No|Non-Probability Sample|All children between the ages of 8 and 17 who are followed in the CHEO GI Clinic and who        have been diagnosed with an Inflammatory Bowel Disease (Crohn's Disease or Ulcerative        Colitus). Once diagnosed, children are followed on an ongoing basis in the clinic for        management of their chronic illness, with the frequency of follow-up appointments varying        depending on the nature and course of a child's disease. Both parents of the subjects will        be invited to participate in the study, although if only one parent is present only they        will be included. If a child/youth is in foster placement, consent will be obtained from        child protection officials to have the caregiver (s) most involved with the child/youth        participate in the interview.|January 2013|January 30, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01781481||72011|
NCT01781416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-XXX-2012/1|Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk|Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk|PERCEPTION|AstraZeneca|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|799|||Both|N/A|N/A|No|Probability Sample|All adults aged 50 and over who :          -  are currently in primary prevention for a cardiovascular event,          -  are usually treated by the general practitioner,          -  and have a medical visit during the study period.|May 2014|May 19, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781416||72016|
NCT01781429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVD-523-01|Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies|Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies||BioMed Valley Discoveries, Inc|Yes|Recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01781429||72015|
NCT01785498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB12/04X|Healthy Lifestyles for Children With Complex Heart Problems|Healthy Lifestyles for Children With Complex Heart Problems|ReACH|Children's Hospital of Eastern Ontario|No|Completed|January 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|4 Years|17 Years|No|||February 2015|February 10, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01785498||71702|
NCT01778348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCam08|Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting|An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes|APCam08|University of Cambridge|Yes|Completed|December 2013|May 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|6 Years|18 Years|No|||November 2015|November 14, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778348||72252|
NCT01775540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1230|Systane Ultra Versus Maxidex Versus Saline|Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls||Icahn School of Medicine at Mount Sinai|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|December 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01775540||72467|
NCT01775839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX_Clopidogrel_002|Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin|Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers||Seoul National University Hospital|Yes|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 8, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01775839||72444|
NCT01776073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060661|Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients|Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients||Emory University|Yes|Active, not recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|800|||Both|18 Years|95 Years|No|||December 2015|December 15, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776073||72426|
NCT01776606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL019|Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines||RADIANT|Revance Therapeutics, Inc.||Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|65 Years|No|||April 2014|April 14, 2014|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776606||72385|
NCT01776619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5281002|Safety and Tolerability Study of Multiple Doses of PF-06305591|A Double Blind (3rd Party Open) Randomized, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of Repeat Doses PF-06305591 Combined With a Cross-over Relative Bioavailability and Food Effect Evaluation After Single Dose of PF-06305591 in Healthy Young Subjects||Pfizer|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|43|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776619||72384|
NCT01776307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-224|A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer|A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer||Boston Biomedical, Inc|No|Recruiting|March 2012|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776307||72408|
NCT01776580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107060RC|The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms and Sexual Function|The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms and Sexual Function||National Taiwan University Hospital|No|Recruiting|July 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|20 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with lower urinary tract symptoms|January 2016|January 24, 2016|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01776580||72387|
NCT01776593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203078RIC|The Best Parameter of Bladder Diary Correlates With the Volume at Strong Desire to Void of Filling Cystometry|The Best Parameter of Bladder Diary Correlates With the Volume at Strong Desire to Void of Filling Cystometry||National Taiwan University Hospital|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|900|||Female|20 Years|N/A|No|Non-Probability Sample|Female patients with lower urinary tract symptoms|January 2013|January 23, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01776593||72386|
NCT01776827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168-12-FB|Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital|Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital||University of Nebraska|No|Recruiting|May 2012|||May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|70|||Both|19 Years|N/A|No|Non-Probability Sample|Patients who underwent paraesophageal hernia repair at the University of Nebraska Medical        Center.|December 2015|December 3, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776827||72368|
NCT01776840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100967|A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma|A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma||Janssen Research & Development, LLC|Yes|Active, not recruiting|May 2013|October 2019|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|524|||Both|65 Years|N/A|No|||January 2016|January 8, 2016|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776840||72367|
NCT01778933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC17 Renal Cell|Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)|A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules||University of Pennsylvania||Recruiting|May 2013|February 2018|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778933||72207|
NCT01778699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_01_21_a|Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2).|Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). A Randomized Double Blind Interventional Study.||Università degli Studi di Sassari|Yes|Recruiting|February 2013|April 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|6 Years|7 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01778699||72225|
NCT01780025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53530|Objective Measures in Implantable Hearing Devices|Clinical Trial on Objective Measures in Implantable Hearing Devices for Subjects With Mixed Hearing Loss.||Universitaire Ziekenhuizen Leuven|No|Enrolling by invitation|April 2012|October 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Mixed hearing loss|January 2013|January 30, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780025||72123|
NCT01780285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONMU-2|Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh|Prospective Randomized Phase III Study of Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh|GIANT|Odessa National Medical University|No|Active, not recruiting|June 2013|February 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||July 2015|July 21, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01780285||72103|
NCT01781156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012RES-047|Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients|Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients||Shanghai 10th People's Hospital|Yes|Recruiting|August 2012|June 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|serum|Both|18 Years|75 Years|No|Non-Probability Sample|The population will be selected from patients of nephrology department of Shanghai 10th        people's hospital in Shanghai,China.|November 2014|March 14, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01781156||72036|
NCT01780298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QASMC 202|Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study|A Biomarker Study to Compare Gene and Protein Expression Profiles in Four Separate Groups of Subjects Including COPD Cases (GOLD Stage 1-2 and Current Smokers With a ≥ 10 Pack Year Smoking History) and Three Control Groups of Matched Non-smoking Subjects (Never Smoked), ex Smokers and Current Smokers, to Identify Novel Biomarkers, to Assess Standard Biomarkers of Inflammation and to Compare Inflammatory Cell Responses and Selected Markers of Inflammation in Blood, Induced Sputum and Nasal Samples.||Philip Morris Products S.A.|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|739|Samples With DNA|Proteomic investigations: Blood serum, Induced Sputum and Nasal Lavage      Transcriptomics investigations (mRNA and micro RNA): Whole Blood, Nasal Scrapes, Induced      sputum cell pellet      Genomic DNA sequencing: Whole blood      Lipidomics: Whole blood|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|In this study, male and female subjects aged between 40-70 years will be included. All        subjects must be matched by ethnicity, gender and age (within 5 years) of the subjects        with COPD recruited in the study.|January 2013|January 28, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01780298||72102|
NCT01782313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12S02|A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas|A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas||Northwestern University|Yes|Active, not recruiting|February 2013|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782313||71947|
NCT01782326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2318|QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study|A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD.||Novartis|No|Completed|July 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3362|||Both|40 Years|N/A|No|||March 2016|March 23, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782326||71946|
NCT01781143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/669|Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF)|Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF).|SOET|University Hospital, Ghent|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Female|18 Years|40 Years|No|||June 2015|June 2, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01781143||72037|
NCT01774734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110605R|Effect of Combined Neck Strength Exerciser Plus Physiotherapy to Treatment Chronic Neck Pain|Effect of Combined Neck Strength Exerciser Plus Physiotherapy in Treatment of Patients With Chronic Neck Pain||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|N/A|No|||November 2014|November 24, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01774734||72529|
NCT01774981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14353|Study of LY3016859 in Participants With Diabetic Nephropathy|Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients||Eli Lilly and Company|No|Completed|March 2013|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|61|||Both|18 Years|75 Years|No|||December 2015|December 23, 2015|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774981||72510|
NCT01775280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-ZH-VIS-RESRAD|Response of Hepatic Tumors to Radioembolization|Radiologic, Histologic and Immunologic Response to Radioembolization of Hepatic Tumors|RESRAD|University of Zurich|No|Withdrawn|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|January 22, 2013||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01775280||72487|
NCT01775865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201739|Targeting Inflammation to Treat Cardiovascular Aging|Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)|TIVA|University of Iowa|Yes|Recruiting|September 2012|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|January 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775865||72442|
NCT01775553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1506|Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib|Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775553||72466|
NCT01775852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004763|Brief Behavioral Intervention for Comorbid Migraine and Depression|Brief, Behavioral Intervention of ACT & Illness Management for Comorbid Migraine and Depression|ACT-IM|University of Iowa|No|Completed|August 2010|December 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||October 2015|October 16, 2015|January 9, 2012||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01775852||72443|
NCT01776086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-471|Neuropsychological Testing Using Mobile Devices|Neuropsychological Testing Using Mobile Devices||Englewood Hospital and Medical Center|No|Withdrawn|January 2013|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 9, 2013|January 23, 2013||No|no subjects agreed to participate|No||https://clinicaltrials.gov/show/NCT01776086||72425|
NCT01776879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-TG-0556-CTIL|Speech Intelligibility of Patients With P D Compared to First Degree Relatives of P D Patients|Speech Intelligibility of Patients With Parkinsons Disease at Different Stages of the Disease Compared to First Degree Relatives of Parkinson's Disease Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2013|November 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Advanced PD patients Early PD patients First degree relatives|January 2013|January 23, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01776879||72364|
NCT01776866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130101|Image Content Analysis of Dural-axis Rotational Versus Standard Coronary Angiography|Comparison of Image Content Assessment Between Dural-axis Rotational and Standard Coronary Angiography||General Hospital of Chinese Armed Police Forces|Yes|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|80 Years|No|||June 2015|June 27, 2015|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01776866||72365|
NCT01776853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12102|Fructose and Fructans in IBS|Fructose and Fructans and Irritable Bowel Syndrome: MRI Study of Underlying Mechanisms|FABS|University of Nottingham|No|Completed|January 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|69|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776853||72366|
NCT01779271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plb CD 301 Version 3.10|Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection|||Daewon Pharmaceutical Co., Ltd.||Recruiting|January 2013|||June 2016|Anticipated|Phase 3|Interventional|N/A|2||||||Both|15 Years|N/A||||February 2014|March 26, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01779271||72181|
NCT01779232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-09-2013|Danazol Treatment in Endometriosis Women Before IVF|Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|October 2012|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|40 Years|No|||June 2015|June 16, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779232||72184|
NCT01779245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32AN3|Effect of High-calcium Intake on Substrate Metabolism During Exercise|The Impact of a Calcium Supplementation on Lipid Metabolism During Exercise.||Northumbria University|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|13|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779245||72183|
NCT01780324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24080004|Lidocaine Analgesia for Urethral Catheterization in Children|Randomized Clinical Trial of Lidocaine Analgesia for Urethral Catheterization in Children||Seattle Children's Hospital|No|Completed|January 2013|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|3 Years|No|||May 2015|May 19, 2015|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780324||72100|
NCT01779804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR000000185|Triage-Based Application of OFAR on the Number of Radiographs Ordered|The Effect of Triage-Based Application of the Ottawa Ankle and Foot Rules (OAR/OFR) on the Number of Radiographs Ordered: A Pilot Study|OFAR|Lehigh Valley Hospital|Yes|Completed|January 2013|June 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to an urban and suburban community hospital with acute foot or ankle        injury|June 2014|June 14, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01779804||72140|
NCT01781468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221101|Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma|A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma||Alliance for Clinical Trials in Oncology|Yes|Recruiting|June 2013|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|330|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781468||72012|
NCT01782040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 35/2010|Auriculotherapy in the Cares to the Premenstrual Syndrome|Auriculotherapy in the Cares to the Premenstrual Syndrome: Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|January 2011|July 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|21 Years|44 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782040||71968|
NCT01775254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCN-11-194-01|The Inland Northwest Colon Cancer Survivor's Study|Self Reported Changes in Quality of Life, Sexual Function, Peripheral Neuropathy, and Demands of Illness, Following Curative Resection and Adjuvant FOLFOX Chemotherapy in Colon Cancer Survivors||Washington State University|No|Recruiting|January 2013|June 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Persons newly diagnosed with colon cancer anticipated to undergo curative resection. To        include those who will receive adjuvant FOLFOX chemotherapy.|January 2013|January 31, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775254||72489|
NCT01775878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-08JMink-01|Diabetes Care Management Trial of Telemetric Monitoring|A Randomized Study Comparing Usual Diabetes Care Management to Telemetric Home-based Monitoring of Glucose and Blood Pressure in Patients With Diabetes (TELEGAP)|TELEGAP|Kaiser Permanente|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|75 Years|No|||January 2013|January 23, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775878||72441|
NCT01776112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG-EX-II|Enhancing Synaptic Plasticity and Cognition in Schizophrenia|Enhancing Synaptic Plasticity and Cognition by Physical Exercise and Cognitive Training in Schizophrenia: A Randomised Controlled Trial|EXERCISE-II|University Medical Center Goettingen|No|Completed|January 2011|August 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01776112||72423|
NCT01776320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103243|Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction|A Phase 4, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction.||Lawson Health Research Institute|No|Withdrawn|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||March 2014|March 3, 2014|December 7, 2012||No|No medication|No||https://clinicaltrials.gov/show/NCT01776320||72407|
NCT01776333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001820|A Randomized Controlled Trial of a Video Decision Aid in the ICU|Video Images of Disease for Ethical Outcomes|VIDEO|Massachusetts General Hospital|No|Not yet recruiting|January 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|21 Years|N/A|No|||January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776333||72406|
NCT01776892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dupuytren's 001|Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease|Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease||University of Alberta|No|Withdrawn|May 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01776892||72363|
NCT01777100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNESP|Sufentanil for Anesthesia Induction in Continuous Remifentanil Anesthesia|Phase IV Study of Postoperative Analgesic Efficacy and Safety of Anesthesia Induction With Single Dose Sufentanil for Open Abdominal Surgery Under Continuous Remifentanil Anesthesia Versus Total Intravenous Remifentanil Anesthesia|SAIRA|University of Sao Paulo|No|Completed|July 2012|January 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01777100||72347|
NCT01777087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050474|Functional Brain Imaging of Pain Phenotype and Genotype|Brain Imaging of Pain Phenotype and Genotype With Novel Scanning Techniques||University of Pittsburgh|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01777087||72348|
NCT01777386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hocaoglupreexpandedperforator1|Perforator Artery Changes During Suprafascial Pre-expansion of the Perforator Flaps|||Istanbul University||Completed|June 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|6 Years|60 Years|No|||January 2013|January 25, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01777386||72325|
NCT01779284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A23|Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy|24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy||Aristotle University Of Thessaloniki|No|Completed|January 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01779284||72180|
NCT01779557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-PD-2012|Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate|The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate|SEED|Chinese PLA General Hospital|Yes|Recruiting|February 2013|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||December 2015|December 25, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01779557||72159|
NCT01779531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGHBCRG|Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients|A Phase III，Randomized ，Multi-center Clinical Trail to Compare the Outcomes of XT and XEC Adjuvant Chemotherapy Protocol in HER-negative Luminal B Breast Cancer Patients Who Reached Pathologic Response After XT Neoadjuvant Chemotherapy||Guangdong Academy of Medical Sciences|Yes|Not yet recruiting|January 2013|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|640|Samples Without DNA|tissue，whole blood|Female|18 Years|70 Years|No|Non-Probability Sample|HER2 negative Luminal B subtype breast cancer patients|January 2013|January 28, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01779531||72161|
NCT01779544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1861|Rehabilitation After Lumbar Disc Surgery: Exercise Therapy and Brief Educational Intervention|Rehabilitation After Lumbar Surgery||Haukeland University Hospital|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||January 2016|January 21, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01779544||72160|
NCT01780649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 117 01|Evaluation of IMSI to Treat Male Infertility|Evaluation of the Efficiency and Indications of IMSI in Comparison With ICSI in Case of Male Infertility|PHRC-IMSI|University Hospital, Toulouse|No|Completed|October 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|38 Years|No|||January 2013|January 31, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01780649||72075|
NCT01780662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00107|Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|January 2013|||March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|13 Months|30 Years|No|||March 2016|March 24, 2016|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780662||72074|
NCT01780636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLERGAN-72570|Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome|Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome||University of California, Irvine|Yes|Recruiting|January 2013|July 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2013|January 28, 2013|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780636||72076|
NCT01780883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSM A91245-56|Melatonin Dose-effect Relation in Childhood Autism|Melatonin Dose-effect Relation in Childhood Autism|MELADOSE|Rennes University Hospital|Yes|Completed|February 2013|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|34|||Male|6 Years|8 Years|No|||September 2013|September 4, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01780883||72057|
NCT01780896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121101-R43TR000645-01|Relationship Between Vestibular Function and Topographic Memory|The Relationship Between Vestibular Function and Topographic Memory||Biomedical Development Corporation|No|Not yet recruiting|February 2013|June 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|70 Years|85 Years|No|Non-Probability Sample|Nominally healthy adults between the ages of 70 and 85 yrs who meet inclusion/exclusion        criteria. All study participants will be recruited from the San Antonio community.|January 2013|January 30, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780896||72056|
NCT01781169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD50kIU2011|Vitamin D Supplementation to Obese Chinese Males|Health Effect of Oral Vitamin D Supplementation on Obese Chinese Males||Shenzhen Center for Chronic Disease Control|Yes|Completed|April 2011|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|43|||Male|23 Years|66 Years|Accepts Healthy Volunteers|||September 2013|September 27, 2013|January 25, 2013||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT01781169||72035|The numbers of participants in both the obese group and normal-weight group were small.
NCT01781182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AI097284-01A1|Infant Antibiotic Resistance and Implications for Therapeutic Decision-making|Infant Antibiotic Resistance and Implications for Therapeutic Decision-making||University Hospital Case Medical Center|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|specific cultured antibiotic resistant organisms of interest|Both|N/A|18 Months|No|Non-Probability Sample|Newborn infants from the well baby nursery, followed during their first year of life|December 2015|December 15, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781182||72034|
NCT01781715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resolute Integrity for STEMI|Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI|Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents|ZES for STEMI|Russian Academy of Medical Sciences|No|Recruiting|September 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781715||71993|
NCT01782001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMANI|Evaluation of Vitamin A and Zinc Supplementation on Malarial Morbidity|Evaluation of the Impact of Vitamin A and Zinc Supplementation on Malarial Morbidity in Ghana||Kintampo Health Research Centre, Ghana|Yes|Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|6 Months|24 Months|No|||January 2013|January 30, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01782001||71971|
NCT01775020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC03-139.5|Dose-response Study of Arginine Supplementation in Severe Sepsis|Arginine and Nitric Oxide (NO) Metabolism in Sepsis; Dose-response Study on the Effect of L-arginine Supplementation on NO Metabolism and Gastric Perfusion in Severe Septic Patients.||Maastricht University Medical Center|No|Completed|October 2003|May 2012|Actual|May 2004|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775020||72507|
NCT01775267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-ZH-VIS-ALPPS|ALLPS VERSUS PVO Randomized Controlled Trial|ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial|ALPPS|University of Zurich|Yes|Terminated|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|January 22, 2013||No|Study stopped due to safety concerns in both study arms|No||https://clinicaltrials.gov/show/NCT01775267||72488|
NCT01776346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002224|Barrett's Esophagus Patient Registry|Barrett's Esophagus Patient Registry|BPR|Massachusetts General Hospital|No|Recruiting|January 2011|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|750|Samples With DNA|Serum (from whole blood), plasma (from whole blood), tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have been seen at Massachusetts General Hospital.|January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776346|5 Years|72405|
NCT01776359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 12-670|Effects of High Protein Intake With Intense Exercise and Energy Deficit|Effects of High Protein Intake With Intense Exercise and Energy Deficit|RIPPED|McMaster University|No|Completed|February 2013|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 6, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01776359||72404|
NCT01776632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA138894|Promoting Physical Activity in Churchgoing Latinas|Promoting Physical Activity in Churchgoing Latinas: Fe en Acción (Faith in Action)||San Diego State University|Yes|Active, not recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|436|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01776632||72383|
NCT01777438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102012|Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy|Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy||Universitaire Ziekenhuizen Leuven|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|434|||Both|19 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients who started immunotherapy|October 2013|October 24, 2013|January 23, 2013||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01777438||72322|
NCT01777451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEFIMAR|Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis|Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis|NEFIMAR|Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2010|January 2014|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|6 Years|50 Years|No|Non-Probability Sample|All patients with a clinically proven neurofibromatosis type 1 can be included.|January 2013|January 23, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777451||72321|
NCT01777113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIGHSTROKE-2012|High Intensity Interval Training in Chronic Stroke Patients|The Effects of a High Intensity Gait Training in Improving Oxygen Consumption in Chronic Stroke Patients: a Randomized Control Study.||Universita di Verona|Yes|Recruiting|October 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01777113||72346|
NCT01777412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avastin_NMO_1|Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations|An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD).||Johns Hopkins University|Yes|Completed|June 2013|May 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||August 2015|August 1, 2015|January 21, 2013|Yes|Yes||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01777412||72324|
NCT01780077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1202|Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109|A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects||RXi Pharmaceuticals, Corp.|Yes|Completed|December 2012|November 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780077||72119|
NCT01780090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010627|Handheld Technology for Speech Development in Students With Autism|Handheld Technology for Speech Development in Students With Autism Spectrum Disorders (ASDs)||Yale University|No|Completed|September 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|4 Years|19 Years|No|||January 2013|January 28, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780090||72118|
NCT01780064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAPI-1202|Early Individualized Psychosocial Assets to Facilitate the Return to Employment of Women With Breast Cancer|Early Individualized Psychosocial Assets to Facilitate the Return to Employment of Women With Breast Cancer|APAPI|Centre Oscar Lambret|No|Recruiting|February 2013|February 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Female|18 Years|65 Years|No|||November 2015|November 3, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780064||72120|
NCT01780311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo008|Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias||AVATAR|Ospedale San Donato|No|Recruiting|January 2013|||January 2014|Anticipated|Phase 4|Interventional|N/A|2||||||Both|18 Years|80 Years|No|||January 2013|January 30, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01780311||72101|
NCT01780675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12PHA|Hippocampus Avoidance PCI vs PCI|Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial|HA-PCI|The Netherlands Cancer Institute|No|Recruiting|April 2013|June 2021|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780675||72073|
NCT01780909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDD13PM|The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit|The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit. Evaluatie Van de Gastrointestinale Transit Aan de Hand Van de Niet-absorbeerbare Merker Paromomycine Sulfaat (Dutch Translation)||Katholieke Universiteit Leuven|No|Recruiting|February 2013|December 2017|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780909||72055|
NCT01781195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMUTECT2013-01|Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation|Effect of Delayed CNI-based Immunosuppression With Advagraf on Liver Function After MELD-based Liver Transplantation|IMUTECT|Heidelberg University|No|Recruiting|February 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood: HLA-DR status|Both|18 Years|64 Years|No|Non-Probability Sample|patients with different MELD-scores/Na-MELD-scores undergoing liver transplantation|May 2015|May 27, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781195||72033|
NCT01781494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001012|Immobilization Versus Immediate Motion After Anterior Submuscular Ulnar Nerve Transposition|Immobilization Versus Immediate Motion After Anterior Submuscular Ulnar Nerve Transposition: Affect on Flexor-pronator Integrity||Mayo Clinic|No|Withdrawn|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2014|November 26, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781494||72010|
NCT01782027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815075|Mendelian Reverse Cholesterol Transport Study|A Validation Study Evaluating the Use of 3H-Cholesterol Bound to Albumin as a Method to Assess Reverse Cholesterol Transport in Subjects With Monogenic Diseases Affecting HDL Metabolism||University of Pennsylvania|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782027||71969|
NCT01782339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007755|A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis|A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis|GAMMA|Barts & The London NHS Trust|Yes|Recruiting|July 2012|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|16 Years|65 Years|No|||September 2014|October 21, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782339||71945|
NCT01781728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1273|Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma|Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2013|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|100 Years|No|||September 2015|September 24, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01781728||71992|
NCT01775566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-EPT-PK-01|Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mgafter Oral Administration in Healthy Male Subjects.||Navipharm Corporation|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|27|Samples With DNA|plasma|Male|20 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|acute low back pain|December 2013|December 23, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01775566||72465|
NCT01775579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MERO-101|Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium|Randomized, Open Label, Multiple-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|January 2013|June 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775579||72464|
NCT01776125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF1 DOD 0804M30543|Genetic Evaluation of NF1 and Scoliosis Patients|Genetic Evaluation for the Scoliosis Gene(s) in Patients With Neurofibromatosis 1 and Scoliosis||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|August 2010|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|Samples With DNA|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek      (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will      not hurt. The swab kit will be provided by Axial Biotech Inc. It will include a      self-addressed stamped envelope to mail the swab back to Axial Biotech Inc. Participatns      existing x-rays will be reviewed as part of this study as well. We will review participant's      medical record to look at what treatments have been executed during the course of      participation. Once the individual agrees to participate in this project their private      health information will be sent to Axial Biotech Inc., the company that will be doing the      genetic testing.|Both|8 Years|65 Years|No|Non-Probability Sample|Candidates will be identified by spine surgeons who are members of the Spinal Deformity        Study Group. Participants need to be age 8 to 65 years old. These will be individuals who        have been clinically diagnosed with NF 1 and have undergone spinal fusion for scoliosis        (either dystrophic or non-dystrophic). The participating physicians will explain the        research to qualifying patients or their guardians. We have added a flyer for the        participating physicians to hand out to their patients. The patient/guardian may then take        this flyer home and contact study personnel directly, thus removing the participating        physician and/or his staff from the process.|December 2014|December 1, 2014|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01776125||72422|
NCT01776372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHHPleuralDrainageComparsion|Comparison of Pleural Drainage Systems on Reducing Pleural Effusion Formation Following Lung Resection|Effect of the Use of a Digital Pleural Drainage System on Reducing Pleural Effusion Formation Following Lung Resection||McMaster University|No|Completed|January 2013|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|103|||Both|18 Years|90 Years|No|||May 2014|May 12, 2014|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776372||72403|
NCT01776645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25883|Compassion Training and Pain|||Stanford University||Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 24, 2013|January 15, 2013||No||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01776645||72382|
NCT01776658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL1001_II|Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain|||Sylentis, S.A.||Completed|November 2012|||April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01776658||72381|
NCT01776918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02094|Energy Requirements in Mitochondrial Disease|Energy Requirements in Metabolic and Mitochondrial Disease||University of British Columbia|No|Completed|February 2012|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|23|||Both|1 Year|18 Years|No|Non-Probability Sample|Children (1-18y) diagnosed with either phenylketonuria or a mitochondrial disorder|May 2015|May 29, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01776918||72361|
NCT01777698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMECR1|Body Composition Analysis in Patients Undergoing Chemoembolization|Body Composition Analysis by Bioelectrical Impedance Vector Analysis in Patients With Hepatocellular Carcinoma Undergoing Chemoembolization.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Active, not recruiting|April 2012|March 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|70 Years|No|Probability Sample|The patients will be recruited from the Radiology Department of a tertiary care center.|September 2015|September 29, 2015|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777698||72302|
NCT01777152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-014|ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas|ECHELON-2|Seattle Genetics, Inc.|No|Recruiting|January 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777152||72343|
NCT01777425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082012|Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)|Long-term Control in Rhinosinusitis After FESS: Cross-sectional Observational Study on Control in Rhinosinusitis at a Mean Interval of 3 Years After FESS||Universitaire Ziekenhuizen Leuven|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|389|||Both|19 Years|74 Years|No|Non-Probability Sample|rhinosinusitis patients|December 2014|January 17, 2014|January 23, 2013||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01777425||72323|patients had to fill in the questionnaire at home, with no help of an expert
NCT01779817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2011-01|Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy|Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy|EDIEMHYPER|University Hospital, Angers|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|252|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779817||72139|
NCT01779830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12057|A Study of LY2624803 in Participants With Transient Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779830||72138|
NCT01779843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-531|Alisertib for Acute Myeloid Leukemia|A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia||Massachusetts General Hospital|Yes|Active, not recruiting|April 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779843||72137|
NCT01780103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0055-12-CTIL|Sonographic Follow up in Newborns Diagnosed With Prenatal Hydronephrosis|Sonographic Follow up in Newborns Diagnosed With Prenatal Hydronephrosis||Hillel Yaffe Medical Center|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|143|||Both|N/A|1 Month|No|Non-Probability Sample|newborns at the age of 0-1 months|January 2013|January 29, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780103||72117|
NCT01780337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC7383|Oxytocin Effects on Cardiac Electrophysiology|Pilot Study of Intranasal Oxytocin and Cardiac Electrophysiology in Humans||Columbia University|Yes|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|No|||October 2015|October 5, 2015|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780337||72099|
NCT01780350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-BAA-11-1|Assessment of the Implementation of the ResQGARD® Impedance Threshold Device by the San Antonio Fire Department|||Advanced Circulatory Systems|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|July 19, 2012|No|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01780350||72098|
NCT01781208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00063736|Ultrasound Based Acoustic Radiation Force Impulse, Shear Wave Velocity Imaging in Pediatric Patients Undergoing Liver Biopsy|||University of Michigan|Yes|Completed|November 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|62|||Both|N/A|18 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781208||72032|
NCT01781221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-200|Sinus Floor Elevation Using Separately Two Different Xenografts - A Prospective Randomized Clinical Trial|||University Hospital of Cologne||Not yet recruiting|February 2013|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01781221||72031|
NCT01781507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|Study of Bronchodilation Effects of Cetirizine|Assessment of Bronchodilatory Effects of Cetirizine in Adults With Concomitant Allergic Rhinitis and Mild Asthma as Measured by Impulse Oscillometry.||California Allergy and Asthma Medical Group, Inc.|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||August 2013|August 30, 2013|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781507||72009|
NCT01782053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA157824-01A1|Communicating Smoking Risks Through Graphic Warning Labels|Communicating Smoking Risks Through Graphic Warning Labels||University of Pennsylvania|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|245|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01782053||71967|
NCT01782066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENID-1|Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines|Dose Finding and Reactogenicity of Reduced-dose Intradermal Administration of Two Quadrivalent Meningococcal Conjugate Vaccines (Menveo® and Nimenrix®) in Healthy Adults (MENID-1).||Leiden University Medical Center|Yes|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 28, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782066||71966|
NCT01782599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-cigarettes and Cues|Electronic Cigarettes and Reactivity to Smoking Cues|Electronic Cigarettes and Reactivity to Smoking Cues||Mclean Hospital|No|Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|45 Years|No|||March 2013|March 5, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782599||71925|
NCT01782560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03495|Laryngomalacia Study|Improving Care For Infants With Laryngomalacia: A Pilot Randomized Controlled Trial of Omeprazole Versus Placebo||Children's & Women's Health Centre of British Columbia|No|Withdrawn|February 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|1 Year|No|||July 2015|July 28, 2015|January 17, 2013|Yes|Yes|Unable to recruit a sufficient amount of subjects|No||https://clinicaltrials.gov/show/NCT01782560||71928|
NCT01775605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-376|Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement|Randomized Study of the Use of Synera for Pain Relief During Local Lidocaine Needle Skin Infiltration for Epidural Placement in Subjects Undergoing Elective Cesarean Section.||Northwell Health|No|Withdrawn|November 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|December 10, 2012|Yes|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01775605||72462|
NCT01776671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advocate-IRB-5367|Once Daily Gabapentin in the Treatment of Post Amputation Pain|Efficacy of Once Daily Gastroretentive Gabapentin (Gralise) in the Treatment of Post Amputation Pain||Chicago Anesthesia Pain Specialists|No|Recruiting|February 2013|April 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776671||72380|
NCT01776684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-054|Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis|Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs||Samsung Medical Center|No|Recruiting|June 2012|May 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|20 Years|N/A|No|||January 2013|January 25, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776684||72379|
NCT01776905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133965|In Vivo Real-time Detection of Circulating Melanoma Cells|In Vivo Real-time Detection of Circulating Melanoma Cells||University of Arkansas|No|Recruiting|February 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75        subjects at this institution in three cohorts.|February 2016|February 25, 2016|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01776905||72362|
NCT01777126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONP|Oral Nutrition After Regular Radical Cystectomy|A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy|ONP|Universitaire Ziekenhuizen Leuven|No|Completed|January 2009|November 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|94|||Both|18 Years|N/A|No|||January 2011|July 16, 2014|January 15, 2013|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01777126||72345|
NCT01777139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114873|A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures|A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855)||GlaxoSmithKline|No|Active, not recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||October 2015|February 4, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777139||72344|
NCT01777490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-345|Helping Invested Families Improve Veterans Experiences Study|Helping Invested Families Improve Veterans Experiences Study (HI-FIVES)|HI-FIVES|VA Office of Research and Development|No|Recruiting|February 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777490||72318|
NCT01777165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-796|A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery|A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery||AbbVie|Yes|Completed|February 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|240|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777165||72342|
NCT01777178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-684|Comparison of Standard Versus Low Bicarbonate Hemodialysis|Intradialytic Acid-base Changes and Organic Anion Production With Standard Versus Low Bicarbonate Hemodialysis||Albert Einstein College of Medicine of Yeshiva University|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|N/A|No|||June 2013|June 24, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777178||72341|
NCT01777724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5TK90 HAPPY|Evaluation of a Parenting and Stress Management Programmme|Evaluation of a Parenting and Stress Management Programme: An Exploratory Randomised Controlled Trial of Triple P-Positive Parenting Program and Stress Control|HAPPY|Medical Research Council|No|Terminated|January 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|16 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 16, 2014|December 14, 2012||No|The study was terminated due to time constraints and the withdrawal of Stress Control from the    NHS Greater Glasgow and Clyde services.|No||https://clinicaltrials.gov/show/NCT01777724||72300|
NCT01777464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|september2012|Role of the Central Nervous System in Allergic Rhinitis|Role of the Central Nervous System in Allergic Rhinitis: Activation of Different Brain Regions After a Nasal Histamine Provocation in Healthy and Allergic Patients||Universitaire Ziekenhuizen Leuven|No|Terminated|November 2012|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|December 2, 2015|January 23, 2013||No|analysing images ongoing|No||https://clinicaltrials.gov/show/NCT01777464||72320|
NCT01779583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXO-PPP study|Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study")|Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients: A Prospective Observational Study ("EXO-PPP Study")|EXO-PPP|Hospital Miguel Servet|No|Recruiting|January 2013|||January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|-  Serum        -  Tumor tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be adults with advanced or metastatic gastric cancer (AGC), candidates to        receive a first-line systemic therapy, who meet all of the inclusion criteria and none of        the exclusion criteria within 28 days prior to the first day of study treatment.|March 2015|March 24, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01779583||72157|
NCT01780688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHX-PK-02|Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Explore the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System (THS) 2.1 Compared to Conventional Cigarettes Following Single and ad Libitum Use in Smoking, But Otherwise Healthy Subjects.||Philip Morris Products S.A.|No|Completed|May 2012|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|190|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01780688||72072|
NCT01780363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-MVK|MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE|||Cukurova University||Completed|January 2011|||December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Turkish kindred|January 2011|January 29, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780363||72097|
NCT01780376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-8|Latency of Vibration-Induced Reflex Muscle Activity|Latency of Whole-Body Vibration Induced Reflex Muscle Activity|LVIRMA|Bagcilar Training and Research Hospital|No|Completed|January 2013|February 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780376||72096|
NCT01780389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017445|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)||Duke University|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|January 29, 2013|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01780389||72095|Limitations include this was a small open label pilot study.
NCT01781520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1+DC CIK-P|Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer|||Capital Medical University|No|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781520||72008|
NCT01781780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30DK05633611|Study of the Effectiveness of Breakfast Recommendations On Reducing Body Weight|Randomized Controlled Trial of Breakfast Recommendations on Weight: A Multi-Site Effectiveness Trial||University of Alabama at Birmingham|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|309|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 16, 2014|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01781780||71988|
NCT01781793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00059|Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease|Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease|Dyspnea_ILD|University of British Columbia|No|Recruiting|September 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01781793||71987|
NCT01782079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB - 001|L. Brevis CD2 Strain Persistence in Oral Cavity|Assessment of Probiotic Lactobacillus Brevis CD2 Strain Persistence in Oral Cavity. A Pilot Study||University of Roma La Sapienza|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01782079||71965|
NCT01781741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 223812|Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer|A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA With or Without Minimally Invasive Surgery for Stage III and Stage IV (Oligometastatic) Non-small Cell Lung Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|March 2013|||November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781741||71991|
NCT01781754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-NV-561-CTIL|Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients|Changes in UCP2 mRNA in T2DM Patients|Diabetes|Tel-Aviv Sourasky Medical Center|No|Recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood for UCP2 mRNA|Both|20 Years|75 Years|No|Non-Probability Sample|Un balanced diabetic patients|January 2013|January 30, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01781754||71990|
NCT01781767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NV-376-CTIL|Changes in Metabolic Status in Patients With Total Thyroidectomy||Thyroid cancer|Tel-Aviv Sourasky Medical Center|No|Recruiting|January 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood for UCP2 mRNA|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who were diagnosed with thyroid carcinoma and are going throgh total        thyroidectomy and recive a thyroid replacement therapy.|January 2013|January 30, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01781767||71989|
NCT01775735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120051|Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE|Occipital Nerve Stimulation (ONS) for Migraine OPTIMISE|OPTIMISE|Boston Scientific Corporation|No|Recruiting|January 2013|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|21 Years|75 Years|No|||December 2015|December 3, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775735||72452|
NCT01782573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH - 110801|The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients|The Efficacy of Pre - Disinfection Skin Scrub With 4% Chlorhexidine Gluconate in Preventing Surgical Site Infections for Patients With Hepatectomy||Changhua Christian Hospital|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|92 Years|No|||January 2013|January 31, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01782573||71927|
NCT01776385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-08|The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma|Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?||Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|N/A|No|||November 2012|January 23, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01776385||72402|
NCT01775930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0694|Carfilzomib in Refractory Renal Cell Carcinoma (RCC)|Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2013|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775930||72437|
NCT01776151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603M83587 START 001D|Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)||University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2009|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|337|Samples Without DNA|Citrated plasma is collected at each study visit and stored at a central lab for future      assessment of changes in plasma markers of thrombosis and fibrinolysis.|Both|18 Years|N/A|No|Non-Probability Sample|Enrollees are HIV-positive, antiretroviral-naive individuals with CD4+ > 500 cells/mL        randomized to the START trial.|November 2015|November 30, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01776151||72420|
NCT01776398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204012331|Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies|Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies||Weill Medical College of Cornell University|Yes|Recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|2000|Samples With DNA|Specimens collected may include blood, urine and airway samples (nasal, airway brushing,      biopsy and/or washings) from consenting subjects. Subjects will include both individuals      diagnosed with lung disease and healthy control subjects.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|December 2015|December 9, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01776398||72401|
NCT01776697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW330SR-1001(Ver2.2)|Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects|A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects||Daewon Pharmaceutical Co., Ltd.||Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|N/A|3||||||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776697||72378|
NCT01778023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3899|Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature|A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea||Novo Nordisk A/S|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|4 Years|11 Years|No|||November 2015|November 27, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778023||72277|
NCT01778010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5738|Modafinil, DRD4 Genotype and Cocaine Relapse|Modafinil and DRD4 Genotype in a Human Laboratory Model of Cocaine Relapse||New York State Psychiatric Institute|No|Recruiting|March 2009|June 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|50 Years|No|||January 2013|January 24, 2013|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778010||72278|
NCT01778270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-078|Not Invasive Monitoring of Pleural Drainage|Not Invasive Monitoring of Pleural Drainage||RWTH Aachen University|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01778270||72258|
NCT01780402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035130|Comparison of Hand Feeding Techniques for Persons With Dementia|Comparison of Hand Feeding Techniques for Persons With Dementia Living in the Nursing Home||Duke University|Yes|Completed|March 2012|October 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|1||Actual|30|||Both|60 Years|N/A|No|||January 2016|January 21, 2016|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780402||72094|
NCT01780415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NewEra21972|Genomic DNA in Human Blastocoele Fluid|||Cervesi Hospital, Cattolica, Italy|Yes|Active, not recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|IVF patient with supernumerary embryos to vitrify at blastocyst stage|February 2015|February 3, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780415||72093|
NCT01780701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC110361/ PC110361P1|Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer|Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer|MRSI+RRP|OHSU Knight Cancer Institute|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|140|Samples Without DNA|Blood, Urine, Prostatic fluid and Prostatectomy tissue|Male|21 Years|N/A|No|Non-Probability Sample|all men newly-diagnosed with prostate cancer at the Portland VA and OHSU Urology clinics|October 2015|December 8, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01780701||72071|
NCT01780922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11369|Effect of a Single Dose of Cranberry Beverage on Inflammation and Oxidative Stress|Acute Bioavailability of Cranberry Polyphenols After A Single Dose In Healthy Adults and Its Antioxidative and Anti-Inflammatory Action||Washington State University|No|Completed|July 2010|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|January 29, 2013||No||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01780922||72054|
NCT01781533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACTbyALGO-1|Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor|An Open, Single-centre, Non-controlled Feasibility Study Using a Software-algorithm Based Insulin Therapy to Control Blood Glucose in Type 1 Diabetic Patients||Medical University of Graz|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01781533||72007|
NCT01781546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBUT|Drug-Eluting Balloon in Stable and Unstable Angina|Drug-Eluting Balloon in Stable and Unstable Angina: a Randomized Controlled Non-inferiority Trial|DEBUT|North Karelia Central Hospital|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781546||72006|
NCT01781806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI11-LA-002|A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services|A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among MSM and Transgender Women in Los Angeles County|PATH-PrEP|University of California, Los Angeles|No|Active, not recruiting|May 2013|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|375|||Male|18 Years|N/A|No|||September 2015|September 13, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781806||71986|
NCT01775189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531009|A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted|A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Single-Dose, 4-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Intranasally to Non-Dependent, Recreational Opioid Users||Pfizer|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|January 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775189||72494|
NCT01775202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-FSP69|Cognitive Changes After Fast-track Colon Surgery|||Rigshospitalet, Denmark|No|Recruiting|January 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|60 Years|N/A|No|Non-Probability Sample|elderly patients > 60 years, undergoing fast-track colon surgery at Hvidovre Hospital        during 2010-2012.|January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775202||72493|
NCT01782352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001797|Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)|Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)||Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 17, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782352||71944|
NCT01775748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31937|Effect of Concord Grape Juice on Endothelial Function|Effect Of Concord Grape Juice On Endothelial Function In Obese And Overweight Individuals Over Age 50||Boston University|No|Active, not recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 15, 2014|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775748||72451|
NCT01782586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT GEN-04|Validation of Gene Expression Markers of Renal Allograft Functional Decline|Multicenter Validation of Gene Expression Markers of Renal Allograft Functional Decline (GEN-04)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|480|Samples With DNA|biopsy & blood on 480 conventional kidney transplant participants|Both|18 Years|N/A|No|Non-Probability Sample|Kidney transplant recipients|January 2016|January 27, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782586||71926|
NCT01775644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28120|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (Koralle)|Non-interventional Study of Avastin® First-line in Metastatic Colorectal Cancer (Koralle)||Hoffmann-La Roche||Recruiting|December 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Patients with Metastatic colorectal cancer|March 2016|March 1, 2016|January 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775644||72459|
NCT01775657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120228-01H|Digital Versus Analog Pleural Drainage Following Pulmonary Resection|Digital Versus Analog Pleural Drainage Following Pulmonary Resection|DiVA Phase II|Ottawa Hospital Research Institute|Yes|Active, not recruiting|January 2013|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|176|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01775657||72458|
NCT01776710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17173|Structured EDucation for Rehabilitation in Intermittent Claudication|Development and Piloting of a Pragmatic Structured Education Programme That Promotes Walking in Patients With Intermittent Claudication|SEDRIC|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||February 2013|April 25, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776710||72377|
NCT01776931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02435|Determination of Lysine Requirements in Pregnancy|Determination of Lysine Requirements in Healthy Pregnant Women Using the Indicator Amino Acid Oxidation Technique||University of British Columbia|Yes|Completed|January 2012|June 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|20|||Female|19 Years|40 Years|No|||May 2015|May 29, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01776931||72360|
NCT01777191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14728|Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis|Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis|UNCOVER-A|Eli Lilly and Company|No|Completed|March 2013|May 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777191||72340|
NCT01777477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONK-USZ-004|Adjuvant Effect of Chloroquine on Gemcitabine|Gemcitabine Combined With Chloroquine in Patients With Metastatic or Unresectable Pancreatic Cancer. A Dose Finding Single Center Phase I Study||University of Zurich|Yes|Completed|July 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777477||72319|
NCT01777763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05615|Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)|Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615)||Merck Sharp & Dohme Corp.|Yes|Completed|June 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|230|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 25, 2013|No|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01777763||72297|
NCT01778283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297/55|Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration|Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration||Chulalongkorn University|Yes|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|N/A|No|||February 2013|February 12, 2013|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778283||72257|
NCT01778517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130047|Treatment of Functional Movement Disorders With Psychotherapy|Treatment of Functional Movement Disorders With Psychotherapy||National Institutes of Health Clinical Center (CC)||Completed|December 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|85 Years|No|||July 2015|July 25, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778517||72239|
NCT01778530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130048|TRC105 for Recurrent Glioblastoma|A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)||National Institutes of Health Clinical Center (CC)|No|Terminated|December 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 26, 2013|Yes|Yes|Study was terminated due to poor accrual.|No|April 10, 2014|https://clinicaltrials.gov/show/NCT01778530||72238|
NCT01780428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCT-002|Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain|A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain||Charleston Laboratories, Inc||Recruiting|January 2013|November 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|810|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780428||72092|
NCT01780948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7478|Pharmacokinetic of Everolimus and Atorvastatin Co-administration|Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient||Chulalongkorn University|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780948||72052|
NCT01780935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2405|Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|A 24-month, Phase IIIb, Randomized, Double-masked, Multicenter Study Assessing the Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|OCTAVE|Novartis|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|674|||Both|50 Years|N/A|No|||October 2015|October 9, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780935||72053|
NCT01781234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM-246|Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome|||University of New Mexico|Yes|Recruiting|August 2013|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781234||72030|
NCT01782092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-009|Activator and Type II Diabetics|Effect of Activator Methods Technique on Lowering A1c Levels in Type II Diabetics||Life University|No|Completed|August 2012|||August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be eligible to participate in the study if they are between the ages of        30-60 and are clinically diagnosed with Type II diabetes by their primary care providers        or endocrinologists (diagnosis usually based on FPG > 126 mg/dL on two occasions).        Participants must have been diagnosed for at least one year and currently be under medical        supervision for the disease. They must also have an A1c measurement above 7%, which        indicates less than optimal management of the disease.|September 2015|September 2, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782092||71964|
NCT01774929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014536|An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Participants With Osteoarthritis|Evaluation of Efficacy and Safety of TTS-Fentanyl in Moderate to Severe Pain in Osteoarthritis Patients||Janssen-Cilag Ltd.,Thailand|No|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|January 21, 2013|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01774929||72514|
NCT01775215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1846|A Comparison of Advanced Imaging Techniques in Aortic Stenosis|A Comparative Study of Advanced Imaging Techniques in Predicting the Clinical Outcome in Aortic Stenosis|AIm-AS|Royal Brompton & Harefield NHS Foundation Trust|No|Withdrawn|January 2013|January 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Blood serum sample.|Both|18 Years|N/A|No|Non-Probability Sample|Tertiary care Outpatient population under regular follow by either cardiology or cardio        thoracic team.|November 2014|November 27, 2014|January 22, 2013||No|Abandoned|No||https://clinicaltrials.gov/show/NCT01775215||72492|
NCT01775462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-002|Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)|A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)|ECP-002|Edimer Pharmaceuticals|Yes|Completed|April 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Male|N/A|14 Days|No|||January 2016|January 19, 2016|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775462||72473|
NCT01782859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-008|Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery|Effect of Steroids Given Over 24 Hours on Cytokine Release, Urinary Desmosine Level and Thrombogenic Markers in Patients Undergoing Unilateral Total Hip Replacement||Hospital for Special Surgery, New York|No|Recruiting|October 2012|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01782859||71905|
NCT01776008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00080|Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer|A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776008||72431|
NCT01776411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-J02|Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients|Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients||Mundipharma K.K.|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|N/A|No|||February 2015|February 19, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776411||72400|
NCT01776424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15786|Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease|A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS)|COMPASS|Bayer|Yes|Recruiting|February 2013|March 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|27400|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776424||72399|
NCT01777204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPEAL-20110714-TX|Gastrointestinal Transit and Motility in Renal Transplant Recipients|Non-invasive Assessment of Gastrointestinal Transit and Motility in Renal Transplant Recipients Employing a Biomagnetic Technique||Universidade Estadual de Ciências da Saúde de Alagoas|Yes|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Renal transplant recipients from Alagoas, Brazil|January 2013|January 23, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777204|5 Years|72339|
NCT01777217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESI-12J03|VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate|A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate||Advanced Research Network|Yes|Terminated|February 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 8, 2015|January 24, 2013|Yes|Yes|Terminated|No|October 10, 2014|https://clinicaltrials.gov/show/NCT01777217||72338|Early termination leading to small numbers of subjects analyzed.
NCT01777503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number: 2012-002882-37|The Elderly ACS II Trial|Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)||Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|November 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|75 Years|N/A|No|||April 2014|April 18, 2014|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01777503||72317|
NCT01776983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008SIA01|Skin Aging in Renal Transplant Patients|Skin Aging in Renal Transplant Patients||University of Zurich|No|Completed|September 2008|January 2014|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|100|||Both|N/A|N/A|No|Probability Sample|individuals between 18 and 90 years of age|June 2015|June 15, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01776983||72356|
NCT01777737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriSulfa-FPI-1|Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole|Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis|TriSulfa-FPI|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|June 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01777737||72299|
NCT01773304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M210|Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile|Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile in Urine and Plasma in Overweight Adults|MEDA|University of Copenhagen|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773304||72639|
NCT01773577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HITEC/HEAL5|The Effect of Interoperable Health IT on Efficiency in Ambulatory Practices|The Effect of Interoperable Health IT on Efficiency in Ambulatory Practices|HEAL5|University of Rochester|No|Completed|January 2010|August 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care and primary care specialty practices participating in EHR/VHR in the        Rochester Regional Health Information Organization|March 2012|January 17, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01773577||72618|
NCT01774188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EECP-IOP|the Impact of EECP on Intraocular Pressure|Study of the Impact of Enhanced Extracorporeal Counterpulsation Treatment on Intraocular Pressure||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2012|March 2013|Anticipated|February 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Select 40 cases of patients who had counter pulsation treatment at Enhanced External        Counter Pulsation (EECP) Specialist in First Affiliated Hospital of Sun Yat-sen University        .|January 2013|January 19, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01774188|7 Weeks|72571|
NCT01771120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-SAP/119192/2010|Control and Burden of Asthma and Rhinitis|Control and Burden of Asthma and Rhinitis|ICAR|Universidade do Porto|No|Completed|October 2012|September 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|858|Samples With DNA|Serum will be retained.|Both|3 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample.|November 2012|October 30, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771120||72807|
NCT01771445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSIL 294/10|Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise|Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise|MUSIL|University of Zurich||Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01771445||72782|
NCT01771458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2012-04|A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer|A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.|SHIVA|Institut Curie|Yes|Recruiting|October 2012|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01771458||72781|
NCT01771666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0022|Pilot Indocyanine Green™ Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer|A Pilot Study to Assess the Utility of Indocyanine Green™ (IC-GREEN™) SPY Imaging in the Mapping of Arm Draining Lymphatics and Nodes During Sentinel Node Resection With or Without Axillary Dissection in Breast Cancer||Stanford University||Recruiting|July 2012|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Female|18 Years|90 Years|No|Non-Probability Sample|Women undergoing sentinel node resection with or without axillary lymph node dissection        (ALND) for breast cancer|October 2013|October 25, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771666||72765|
NCT01771471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTO-NUQ02-10-12-00|A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo|A Phase II, Randomized, Double Blind, Placebo Controlled Study Evaluating the Treatment of Degenerative Lumbar Discs With Allogeneic Cultured Chondrocytes||ISTO Technologies, Inc.|Yes|Active, not recruiting|November 2012|June 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|21 Years|N/A|No|||July 2014|March 23, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771471||72780|
NCT01771692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIT001|A Randomised Clinical Trial: Conventional Ligation vs Figure of 8|A Study Into the Effects of Different Ligation Techniques on Orthodontic Mandibular Incisor Alignment||University of Birmingham|No|Active, not recruiting|January 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771692||72763|
NCT01771978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2276|Ischaemia-réperfusion During the Coronary Surgery With Beating Heart|Effects of Diltiazem and/or N-Acétylcystéine Versus Placebo on hémodynamiques and Biological Repercussions of the Ischaemia-réperfusion During the Coronary Surgery With Beating Heart||University Hospital, Strasbourg, France|No|Active, not recruiting|June 2002|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|60 Years|80 Years|No|||February 2008|January 16, 2013|December 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01771978||72741|
NCT01772836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 403|Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination in Healthy Adult Subjects.||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772836||72675|
NCT01776229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU 11-63RI|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child|ERRT-C|University of Tulsa|No|Recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|17 Years|No|||October 2015|October 2, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01776229||72414|
NCT01780740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0505/35|Statin Therapy In Atrial Refractoriness and Reperfusion Injury|Prevention of Atrial Oxidative Stress and Electrical Remodelling in Patients Undergoing Cardiac Surgery: Randomised Placebo-controlled Trial of Perioperative High-dose Atorvastatin|STARR|University of Oxford|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|85 Years|No|||August 2014|August 6, 2014|January 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780740||72068|
NCT01777009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patellar Mobilization|The Effect of Patellar Eversion on Functional Outcomes in Primary Total Knee Arthroplasty|A Randomized, Controlled, Prospective Study Evaluating the Effect of Patellar Eversion on Functional Outcomes in Primary Total Knee Arthroplasty.||Northwell Health|Yes|Completed|March 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01777009||72354|
NCT01781871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCH|Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients|Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients|SOT13|Helsinki University Central Hospital|Yes|Active, not recruiting|January 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|182|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01781871||71981|
NCT01782118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2013|LGG for Prevention of Infectious Complications During PPI Treatment in Children|Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial.||Medical University of Warsaw|No|Recruiting|February 2013|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|1 Month|5 Years|No|||October 2013|October 30, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01782118||71962|
NCT01782131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06200|A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069/P06200)|A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)||Merck Sharp & Dohme Corp.|Yes|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|13 Years|N/A|No|||March 2016|March 10, 2016|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782131||71961|
NCT01772732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-101-1|Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC|Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01772732||72683|
NCT01773018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-504-00AU1|Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors|HMPL-504|Hutchison Medipharma Limited|Yes|Recruiting|February 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|October 21, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773018||72661|
NCT01773317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225014-1|Can Neuromuscular Training Alter Movement Patterns|Can Neuromuscular Training Alter Movement Patterns After Anterior Cruciate Ligament Injury?||University of Delaware|No|Recruiting|August 2011|August 2017|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|14 Years|40 Years|No|||October 2015|October 6, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01773317||72638|
NCT01773590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1278|Mechanisms of Interplay Between Allergy and Viruses in Asthma|Mechanisms of Interplay Between Allergy and Viruses in Asthma: A Human Model of Rhinovirus Induced Acute Asthma Exacerbations||Imperial College London|Yes|Completed|February 2013|January 2016|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|February 15, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01773590||72617|
NCT01773603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0405|Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer|Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer||Memorial Sisli Hospital, Istanbul|No|Terminated|December 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|64|||Female|20 Years|35 Years|No|||January 2013|January 18, 2013|January 18, 2013||No|No statistical difference observed for outcomes.|No||https://clinicaltrials.gov/show/NCT01773603||72616|
NCT01773915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54591|New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study|New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2012|June 2014|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Urine, blood and saliva in Biobank|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Persons with Alzheimer's disease|January 2013|January 13, 2014|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01773915||72592|
NCT01770522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12068 MAGIC|Managing Weight in Pregnancy|A Longitudinal Study Exploring Factors Influencing Weight Gain During Pregnancy and Subsequent Weight Loss and Retention up to One Year Postpartum|MAGIC|University of Nottingham|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|368|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Particpants will be approached at their routine 12 or 20 weeks prnatal scan at the        antenatal scanning clinics at the Queens Medical Centre, Nottingham.|May 2015|May 28, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770522||72853|
NCT01770535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXO-PCR-01|Oxford Ovarian Cancer Predict Chemotherapy Response 01|A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy|OXO-PCR-01|University of Oxford|Yes|Recruiting|November 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|Ovarian cancer biopsy tissue samples Eyebrow hair follicles Blood samples Surgical tissue      samples|Female|18 Years|N/A|No|Non-Probability Sample|Patients with radiological and histological evidence of advanced ovarian cancer, who would        standardly be managed by primary chemotherapy and interval debulking surgery|January 2013|January 15, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770535||72852|
NCT01769976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP1023401|Effects of Periodic Fasting Versus Daily Energy Restriction on Metabolic Health|Effects of Periodic Fasting Versus Daily Energy Restriction on Metabolic Health|PREFER|University of Adelaide|Yes|Completed|January 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|88|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769976||72895|
NCT01770873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC2-2P20|A Multi-Center Randomized Controlled Trial of Mentoring to Prevent Youth Violence|Take Charge 2- A Multi-Center Randomized Trial of Mentoring to Prevent Youth Violence: Incorporating New Communication and Information Technology|TC2|Johns Hopkins University|Yes|Enrolling by invitation|October 2013|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770873||72826|
NCT01770886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UE2343|A Phase I Study of Oral UE2343 in Healthy Subjects|A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects|UE2343|University of Edinburgh|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01770886||72825|
NCT01771133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HD072834|Pregnancy and EARly Lifestyle Improvement Study|Pregnancy and EARly Lifestyle Improvement Study|PEARLS|University of Puerto Rico|Yes|Active, not recruiting|January 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771133||72806|
NCT01771484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121178|High Sodium Diet and External Abdominal Compression in POTS|Clinical Efficacy of High-Sodium Diet and External Abdominal Compression in the Treatment of Orthostatic Intolerance in POTS||Vanderbilt University|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01771484||72779|
NCT01772550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-11-ARCTR05|Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans|A Randomized Controlled Study to Determine Whether Smaller Gauge Fenestrated Catheters Are as Effective as Larger Gauge Non-fenestrated Catheters for Use in IV Contrast Enhanced CT Scans|ARCTR05|Becton, Dickinson and Company|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|238|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|January 17, 2013|Yes|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01772550||72697|
NCT01772576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-CDM00052753|Safety and Performance Study of the Reliance 4-Front Lead|RELIANCE 4-FRONT™ Active Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study||Boston Scientific Corporation|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|167|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772576||72695|
NCT01781013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-AE-10-001|Diabetes-Depression Care-management Adoption Trial|Care Management Technology to Facilitate Depression Care in Safety Net Diabetes Clinics|DCAT|University of Southern California|Yes|Completed|June 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1485|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781013||72047|
NCT01781026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010666|Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases|A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations||Yale University|Yes|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 29, 2013|No|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01781026||72046|
NCT01780155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913031|Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity|Candidate Genes Associated With Susceptibility to Bronchopulmonary Dysplasia and Retinopathy of Prematurity||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|3600|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|November 5, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780155||72113|
NCT01780168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130053|The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism|The NIH Mini Study: Metabolism, Infection and Immunity in Inborn Errors of Metabolism||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|250|||Both|2 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780168||72112|
NCT01780987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661024|AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients|Active-control, Multicenter, Randomized, Open-label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese||Pfizer|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|N/A|No|||February 2015|February 9, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780987||72049|
NCT01781000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO805/142|Cerebral Reorganization in Schizophrenia|Training-induced Cerebral Reorganization in Schizophrenia||University of Konstanz|No|Completed|December 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01781000||72048|
NCT01781884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-024|Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes|Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile||Huashan Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|5 Years|21 Years|No|||January 2013|January 31, 2013|January 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01781884||71980|
NCT01781897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB505203-1|Electroacupuncture for the Treatment of Functional Constipation|A Randomized Controlled Trial of Acupuncture to Treat Functional Constipation||Huazhong University of Science and Technology|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|243|||Both|18 Years|65 Years|No|||April 2014|March 17, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01781897||71979|
NCT01782144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12887|Effects of Weight Loss on Foot Structure and Function in Obese Adults: A Pilot Study|Effect of Weight Loss on Foot Structure and Function in Obese Adults: A Pilot Study|WLF|Temple University|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782144||71960|
NCT01773031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2012-1756|Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography|Pancreatic Duct Evaluation in Autoimmune Pancreatitis: Intraindividual Comparison of MR Pancreatography at 3.0 T and 1.5 T||Asan Medical Center|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|20 Years|N/A|No|Probability Sample|Patients with probable autoimmune pancreatitis based on clinical and CT findings|December 2015|December 28, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773031||72660|
NCT01773044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ulkü_1|Pain on Injection of Propofol: a Comparison of Lidocaine and Alkalinized Lidocaine|||Inonu University|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01773044||72659|
NCT01770301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALIENOR (GINECO-OV222)|Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)|A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours|ALIENOR|ARCAGY/ GINECO GROUP|Yes|Recruiting|February 2013|January 2021|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770301||72870|
NCT01770314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedSafetyStudy|Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.|Medication Safety Pilot Study||Inflexxion, Inc.|Yes|Completed|September 2012|September 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|176|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 21, 2014|January 11, 2013||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01770314||72869|
NCT01770015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00767-34|Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia|Study of the Impact of Bronchial Colonization With Fungi in the Occurrence of Late Ventilator Acquired Pneumonia|CBF et PAVMt|University Hospital, Grenoble|Yes|Recruiting|November 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|230|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01770015||72892|
NCT01770028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL118208|Ripple Effect of Lifestyle Intervention During Pregnancy on Partners' Weight|Ripple Effect of Lifestyle Intervention During Pregnancy on Partners' Weight||California Polytechnic State University-San Luis Obispo|Yes|Active, not recruiting|January 2013|April 2018|Anticipated|March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|384|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study uses a randomized repeated measures design. Partners will be categorized based        on randomized status of their pregnant partner (in the parent grants; NIH 1U01HL114377-01,        PI Phelan; NIH 3U01DK094418-01S1, PIs Redman and Martin). Partner participation in the        ancillary study will not be mandatory for participation in the parent grant. NOTE: There        is no intervention in partners.|December 2015|December 19, 2015|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770028|19 Months|72891|
NCT01770327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHI-FCNAUP|Influence of Different Sugary Beverages on Thirst Sensation|Influence of Different Sugary Beverages on Thirst Sensation||Universidade do Porto|No|Completed|June 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770327||72868|
NCT01770548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORT08-FBB/NMDA-Autism|Neurophysiological Molecular and Developmental Analysis of the Glutamate Synapse in Autism|Autism and Glutamatergic Synapse : Research of Genetic Mutations and Identification of Clinical and Neurophysiological Markers.|NMDA-Autism|University Hospital, Tours|No|Recruiting|January 2009|July 2013|Anticipated|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|600|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770548||72851|
NCT01770860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABDWDP0005|A Test of Different Kinds of Bandages on Healing of Wounds|An Assessment of QuiltVent™ Pad Technology on the Healing of Induced Dermabrasion Wounds||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|5||Actual|46|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|January 16, 2013||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01770860||72827|
NCT01770899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5441|Evaluation Montelukast in the Treatment of Status Asthmaticus|A Prospective Analysis of the Use of Oral Montelukast in Children With Status Asthmaticus||Advocate Center for Pediatric Research|Yes|Recruiting|January 2013|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|14 Years|No|||February 2013|February 22, 2013|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770899||72824|
NCT01771146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-180|Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer|A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)||Baylor Research Institute|No|Recruiting|October 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01771146||72805|
NCT01771159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Tissue Bonding Cystostomy(TBC)|Tissue Bonding Cystostomy(TBC)|TBC|Uro-Research, LLC|No|Not yet recruiting|January 2016|December 2022|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771159||72804|
NCT01771172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASQ|Acute Subcutaneous Defibrillation||ASQ|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|May 2013|July 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Subjects may be either male or female, and must meet all of the inclusion criteria and        none of the exclusion criteria of the study|May 2013|May 16, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771172||72803|
NCT01771497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-005|Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring|Koning Breast CT (KBCT)-Guided Neoadjuvant Treatment of Breast Cancer Monitoring Phase I Trial||Koning Corporation|Yes|Completed|July 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Female|18 Years|N/A|No|Non-Probability Sample|Twelve female patients at least 18 years of age undergoing neoadjuvant therapy for locally        advanced breast cancer with either chemotherapy or hormonal therapy will be recruited for        this study. Inclusion of those patients 18 years or older is important since as it is the        younger patients who present with breast cancer that often end up receiving neoadjuvant        treatment.|March 2015|January 12, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771497||72778|
NCT01772303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO-H2H-01-2011|Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds|An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds|H2H|HealOr|No|Recruiting|January 2013|December 2013|Anticipated|August 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|90 Years|No|||April 2013|April 3, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772303||72716|
NCT01772563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.24|Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours|An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours||Boehringer Ingelheim||Active, not recruiting|February 2013|September 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|January 17, 2013||||No||https://clinicaltrials.gov/show/NCT01772563||72696|
NCT01773746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-3602|Study of Room Air Versus 60% Oxygen for Resuscitation of Premature Infants|The Premature Infants Resuscitated With Oxygen or Air (PRESOX) Trial|PRESOX|Sharp HealthCare|Yes|Recruiting|August 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|1260|||Both|N/A|N/A|No|||May 2015|May 18, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01773746||72605|
NCT01780779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUBEO|Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults|Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults|FUBEO|Universitaire Ziekenhuizen Leuven|No|Recruiting|June 2009|June 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|25|||Both|6 Years|30 Years|No|Non-Probability Sample|patients with Ewing sarcoma or Osteosarcoma, proven by biopsy and histolopathology.|January 2013|January 28, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01780779||72065|
NCT01780792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0048|Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis|Examining the Effects of Dance, Dance Revolution on Mobility, Brain Plasticity and Cognition in Individuals With Multiple Sclerosis||Ohio State University|No|Active, not recruiting|August 2011|December 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|30 Years|59 Years|No|||September 2015|September 2, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01780792||72064|
NCT01781039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00652|Investigation of Anatomical Correlates of Speech Discrimination|||Steward St. Elizabeth's Medical Center of Boston, Inc.|Yes|Recruiting|January 2013|August 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients referred from the St. Elizabeth's Department of Otolaryngology and        self-referred patients to the Audiology Clinic.|November 2015|November 17, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781039||72045|
NCT01781273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-12-277|MedDrive's Responsiveness to Alcohol|MedDrive's Responsiveness to Different Blood Alcohol Concentrations and Concurrent Validity Against Performances on a Driving Simulator; a Phase I, Randomised, Double Blind, Placebo, Dose Response Validation Trial|OH-MedDrive|University of Lausanne|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|21|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 20, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01781273||72027|
NCT01781286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00039414|The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People|The Beneficial Effects of Protein-rich, Afternoon Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People||University of Missouri-Columbia|No|Completed|January 2013|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01781286||72026|
NCT01781598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMCBv1|Patient-specific Instruments as a Standard Procedure in Total Knee Arthroplasty|Patient-specific Instruments as a Standard Procedure in Total Knee Arthroplasty: Logistics, Learning Curve, and Postoperative Radiological Results in 70 Patients||Orthopedic Clinic Gersthof|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with GENESISII prothesis using VISIONAIRE are enrolled in the study|January 2013|January 30, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01781598||72002|
NCT01781910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS M12-101|Branched Chain Amino Acid Plus Glucose Supplement Reduces Exercise-Induced Delayed Onset Muscle Soreness in College Females|The Effects of Branched Chain Amino Acid and Nutrient Supplementation on Exercise-Induced Delayed Onset Muscle Soreness in College Females||University of Vermont|No|Completed|September 2011|||November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781910||71978|
NCT01782157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EB015853-01A1|Smart Environment Technology for Longitudinal Behavior Analysis and Intervention|Smart Environment Technology for Longitudinal Behavior Analysis and Intervention|CASAS/HH|Washington State University|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|42|||Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants are older adults age 75+ who are currently living independently.|December 2015|December 9, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01782157||71959|
NCT01782170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK12-0972-F2L|Efficacy of Iocide Oral Rinse Against Gingival Inflammation|Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease||Biomedical Development Corporation|No|Recruiting|February 2013|May 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782170||71958|
NCT01769989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259842|Electrodermabrasion Compared to Dermabrasion|Evaluation of the Safety and Efficacy of Electrodermabrasion in Improving the Appearance of Scars That Result From Dermatologic Surgery Compared to Treatment With Dermabrasion||University of California, Davis|No|Completed|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|33|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769989||72894|
NCT01770002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265161|Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?||University of California, Davis|No|Completed|January 2012|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770002||72893|
NCT01774227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 56-094-02-1-2|the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory Glaucoma|A Randomized Trial of the Pops-titration Versus the Slow-coagulation Energy Delivery Technique on the Outcome of Diode Laser Transcleral Cyclophotocoagulation in Treatment of Refractory Glaucoma With Dark Iris||Prince of Songkla University|Yes|Recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||June 2015|June 11, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01774227||72568|
NCT01770041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SS/0222|Paracetamol Metabolism After Liver Surgery|Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.|PETALS|University of Edinburgh|Yes|Completed|February 2013|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|Samples Without DNA|Urine and blood|Both|18 Years|N/A|No|Probability Sample|Patients with benign or malignant liver tumours that have been deemed by the hepatobiliary        multi-disciplinary team meetiong as requiring surgical intervention.|October 2014|October 15, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770041||72890|
NCT01770340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR:2010-0004/0|Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial|Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial||Kantonsspital Winterthur KSW|Yes|Recruiting|January 2011|January 2019|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||November 2015|November 9, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01770340||72867|
NCT01770561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER269|Feasibility Study of an Integrated Sensor and Infusion Set|Feasibility Study to Assess Performance of an Integrated Sensor and Infusion Set. TRIAL II||Medtronic Diabetes R&D Denmark|Yes|Completed|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|21 Years|70 Years|No|||January 2013|February 4, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01770561||72850|
NCT01771705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFAT dependent cytokines|NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients|NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients||University of California, San Francisco|No|Recruiting|April 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2015|January 27, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771705||72762|
NCT01771991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOD 2012|Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis|Topical Superoxide Dismutase For the Treatment of Radiation Induced Fibrosis in the Head and Neck Cancer Patient|Sodermix|Sanford Health|Yes|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 11, 2013||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01771991||72740|The # of patients reported as "complete" finished the entire study, including 3 mo post-treatment follow-up. Pts who did not complete the follow-up visit, but did complete treatment are listed as "completed treatment" and were considered evaluable.
NCT01772277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F20130115|Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis|Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis||Wenzhou Medical University|Yes|Completed|December 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|||Both|18 Years|80 Years|No|Probability Sample|Patients were scheduled to undergo endoscopic dacryocystorhinostomy and randomized to with        and without MMC|February 2014|February 12, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772277||72718|
NCT01772017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPEN-002|A Trial to Evaluate a Device for the Treatment of OSA and Snoring|A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)|OPEN|Sleepy, Inc|Yes|Terminated|October 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||November 2015|November 22, 2015|October 30, 2012||No|Sponsor decided to discontinue study for business reasons.|No||https://clinicaltrials.gov/show/NCT01772017||72738|
NCT01773434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-004-J081-103|A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)|A Phase 1 Study of MORAb-004 in Patients With Solid Tumor||Eisai Inc.|No|Active, not recruiting|December 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|20 Years|N/A|No|||December 2015|January 19, 2016|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01773434||72629|
NCT01770132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0319|Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer||Indiana University|Yes|Recruiting|April 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|60 Years|No|||November 2015|November 12, 2015|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01770132||72883|
NCT01780805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209010754|Second Young Adult Naturalistic Alcohol Study|Second Young Adult Naturalistic Alcohol Study (YANAS-2)|YANAS-2|Yale University|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|21 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young adults between the ages of 21-25 years of ago who regularly drink alcohol        and are not currently seeking treatment for alcohol.|January 2016|January 11, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01780805||72063|
NCT01781052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16133|Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients|DAILY: Observational Description of Compliance for the Daily Ventavis® Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients|DAILY|Bayer|No|Active, not recruiting|September 2013|March 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged ≥18 years and diagnosed with PAH (Pulmonary Arterial Hypertension), WHO/NYHA        functional class III, Group I of the Dana point Pulmonary Hypertension Classification and        newly Treated with Ventavis or treated with Ventavis for less than 6 months, with I-Neb        AAD device for the application.|January 2016|February 1, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01781052||72044|
NCT01781299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11020226|Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU|Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU||University of Pittsburgh|Yes|Completed|September 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781299||72025|
NCT01781611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 12-10|Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)|Dipyridamole Assessment for Flare Reduction in SLE|DARE|Oklahoma Medical Research Foundation|Yes|Active, not recruiting|February 2013|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|January 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781611||72001|
NCT01782430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0141|PREoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation|PREoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation|PREONIV|University Hospital, Clermont-Ferrand||Recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782430||71938|
NCT01782443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-456|Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors|Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2013|||March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782443||71937|
NCT01782456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL09|Tolerance of an Oral Nutritional Supplement(ONS)|Tolerance of an Oral Nutritional Supplement(ONS)With a New Protein Blend in Healthy Children||Abbott Nutrition|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782456||71936|
NCT01773967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R01 HD071915-02|Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis|Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis||Washington University School of Medicine|Yes|Recruiting|July 2014|May 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|3 Months|48 Months|No|||December 2014|December 8, 2014|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773967||72588|
NCT01774240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VJ1|Incidence, Severity and Treatment of Delirium in Cardiac Surgery Patients: A Before-after Study|Incidence, Severity and Treatment of Delirium in Cardiac Surgery Patients: A Before-after Study||Rigshospitalet, Denmark|No|Completed|April 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||January 2013|January 20, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01774240||72567|
NCT01774253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRCPG007|Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma|A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.||Spectrum Health Hospitals|Yes|Terminated|May 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|3 Years|18 Years|No|||October 2015|October 1, 2015|January 18, 2013|Yes|Yes|Lack of enrollment and commercial availability of drug|No||https://clinicaltrials.gov/show/NCT01774253||72566|
NCT01770600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1003310002|Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression|Assessment and Treatment of Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression.||University of Alabama at Birmingham|No|Withdrawn|April 2010|||September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|64 Years|No|||May 2015|May 26, 2015|August 7, 2012|No|Yes|never initiated, did different study|No||https://clinicaltrials.gov/show/NCT01770600||72847|
NCT01770613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM 103-M-STEMI|A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)|A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)||Stemedica Cell Technologies, Inc.|Yes|Active, not recruiting|February 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||December 2014|December 2, 2014|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770613||72846|
NCT01771185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUUSP001|Metabolic Effects of Gastrointestinal Surgery in T2DM|Metabolic Effects of Duodenal-jejunal Bypass Surgery in Non Morbidly Obese Subjects With Type 2 Diabetes||University of Sao Paulo|Yes|Active, not recruiting|October 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|65 Years|No|||January 2013|January 17, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01771185||72802|
NCT01770574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-250-12|New Bone Grafting Technique in Paediatric Foot Surgery. Validation of Outcome Measures|New Bone Grafting Technique in Paediatric Foot Surgery. Validation of Outcome Measures. A Randomized Controlled Non-inferiority Trial.||University of Aarhus|No|Recruiting|February 2013|January 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|16 Years|No|||May 2015|May 28, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01770574||72849|
NCT01770587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22393|A Sleep-Oriented Intervention for Suicidal Behaviors|A Sleep-Oriented Intervention for Suicidal Behaviors||Stanford University||Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01770587||72848|
NCT01771523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mütf2|Is the Use of Drain for Thyroid Surgery Realistic?|Is the Use of Drain for Thyroid Surgery Realistic?||Maltepe University|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01771523||72776|
NCT01772316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28488|A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|A MULTICENTER, OPEN-LABEL LONG-TERM EXTENSION STUDY OF WA22762 AND NA25220 TO EVALUATE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS||Hoffmann-La Roche||Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772316||72715|
NCT01771718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2011-8494|Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy|Non-invasive Skin Imaging Using Multiphoton Microscopy||University of California, Irvine|No|Recruiting|April 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from University of California Irvine Medical Clinic|February 2016|February 5, 2016|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771718||72761|
NCT01772004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 100070-001|Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications||EMD Serono|Yes|Recruiting|January 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1670|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772004||72739|
NCT01772290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28465|A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib|A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib||Genentech, Inc.||Completed|February 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|92|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772290||72717|
NCT01773174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.145|Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age|Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89||Boehringer Ingelheim||Withdrawn|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|2 Years|No|||October 2015|October 23, 2015|January 18, 2013||||No||https://clinicaltrials.gov/show/NCT01773174||72649|
NCT01774084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/3:6|Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery|Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery: A Randomised Doubled-blinded Control Study||Karolinska Institutet|Yes|Completed|January 2012|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|January 20, 2013||No||No|April 6, 2014|https://clinicaltrials.gov/show/NCT01774084||72579|
NCT01774344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15982|Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib|RESORCE|Bayer|Yes|Active, not recruiting|May 2013|October 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|573|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774344||72559|
NCT01774357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA102|Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems|Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems|MATRIX|Biotronik SE & Co. KG|No|Recruiting|January 2013|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients with an indication for implantation of a single chamber ICD (primary or secondary        prevention) according to current guidelines and after implantation of a BIOTRONIK Lumax        540 VR-T DX ICD with Linoxsmart S DX or successor single chamber DX system within 90 days        prior to enrollment|December 2015|December 21, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774357|2 Years|72558|
NCT01780532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0018|Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study|Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study||Stanford University|Yes|Withdrawn|September 2014|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|80 Years|No|||June 2015|June 2, 2015|November 14, 2011|No|Yes|Insufficient resources|No||https://clinicaltrials.gov/show/NCT01780532||72084|
NCT01780545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU12-160|Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer|The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160||Hoosier Cancer Research Network|Yes|Active, not recruiting|April 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780545||72083|
NCT01780818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG.2012.27110|A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in CRC Screening Patients||Presidio Ospedaliero Santa Barbara|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|288|||Both|50 Years|70 Years|No|||January 2014|January 14, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780818||72062|
NCT01780831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1110|Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection|A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at High Risk of Acquiring HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|July 2013|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780831||72061|
NCT01781065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2008-010 SNUBH|The Effects of Transcranial Direct Current Stimulation on Central Pain in Patients With Spinal Cord Injury|The Analgesic Effect of Transcranial Direct Current Stimulation Over the Primary Motor Cortex on Central Neuropathic Pain Patients With Spinal Cord Injury||Seoul National University Bundang Hospital|No|Completed|March 2008|June 2013|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|30 Years|60 Years|No|||July 2013|July 12, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781065||72043|
NCT01781078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-CDM00047737|ImageReady(TM) MR Conditional Pacing System Clinical Study|ImageReady(TM) MR Conditional Pacing System Clinical Study|SAMURAI|Boston Scientific Corporation|Yes|Active, not recruiting|February 2013|February 2019|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|363|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781078||72042|
NCT01781338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06 / ADAPT|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|ADAPT|West German Study Group|Yes|Recruiting|May 2012|||April 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|4936|||Female|18 Years|75 Years|No|||May 2015|May 18, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01781338||72022|
NCT01781312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2712|Probiotics in IgA Nephropathy|Proof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN Patients||Uppsala University Hospital|No|Not yet recruiting|January 2013|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01781312||72024|
NCT01781325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBEHR|Patient Self Monitoring of Physical Therapy Exercise|Patient Self Monitoring to Transfer Physical Therapy Exercise From Clinic to Home||University of Washington|No|Withdrawn|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|October 12, 2012||No|Grant ended before study could be initiated|No||https://clinicaltrials.gov/show/NCT01781325||72023|
NCT01781624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL13|Evaluation of an Oral Nutritional Supplement|Evaluation of an Oral Nutritional Supplement With a New Protein Blend||Abbott Nutrition|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01781624||72000|
NCT01782183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM120017CTIL|Thermographic Characteristics of Sore Throat by Thermographic Camera|Thermographic Characteristics of Sore Throat by Thermographic Camera|thermography|Clalit Health Services|No|Not yet recruiting|September 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01782183||71957|
NCT01782196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0512-12-U366|A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy|A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy|U366|ConvaTec Inc.||Terminated|October 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|December 19, 2012||No|Leakage|No||https://clinicaltrials.gov/show/NCT01782196||71956|
NCT01782209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 11-0071|BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients|Natural History of Infection Caused by BK Virus (and Other Opportunistic Viral Pathogens) in Renal Transplant Recipients||University of Alabama at Birmingham|No|Terminated|June 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Whole blood samples will be processed for serum and then evaluated for BK virus DNA|Both|18 Years|N/A|No|Non-Probability Sample|Male and female renal or renal-pancreas transplant recipients ages 18 and older at risk        for BKV infection|January 2014|May 19, 2014|January 30, 2013||No|This study is being withdrawn from Clinicaltrials.gov because it is not an ACT.|No||https://clinicaltrials.gov/show/NCT01782209||71955|
NCT01782469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-708|Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population|A Prospective, Multi-center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population||AbbVie|No|Terminated|October 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Private clinics|July 2015|July 2, 2015|January 31, 2013||No|Study stopped due to low enrollment|No|July 2, 2015|https://clinicaltrials.gov/show/NCT01782469||71935|
NCT01773980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009030|CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening|Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening||OHSU Knight Cancer Institute|No|Completed|August 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Actual|1570|||Female|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinics|May 2015|May 20, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773980||72587|
NCT01773993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081282|Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Pregabalin For Fibromyalgia||Pfizer|No|Active, not recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|Primary care clinic and hospital for Fibromyalgia|March 2016|March 7, 2016|January 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01773993||72586|
NCT01770067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0093-12-HYMC|Prophylactic Treatment of High-Risk Patients With Cardiovascular Implantable Electronic Devices (CIED)With Continuous In-Situ Ultra High-Dose Antibiotics (CITA) Under Regulated Negative Pressure-Assisted Wound Therapy (RNPT)|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|15 Years|N/A|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770067||72888|
NCT01770353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-398-01-01-02|Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent|A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment||Merrimack Pharmaceuticals|No|Recruiting|November 2012|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01770353||72866|
NCT01771211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL379101|Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment|Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment: A Proof-of-principle Study and Neural Correlates|STIMCI|Charite University, Berlin, Germany|No|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|45 Years|86 Years|No|||August 2013|August 20, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01771211||72800|
NCT01771536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004554|The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease|The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease||Mayo Clinic|Yes|Completed|November 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|132|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01771536||72775|
NCT01771510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B110051|Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis|A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis||Ministry of Health & Welfare, Korea|No|Recruiting|April 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Female|50 Years|N/A|No|||January 2013|January 16, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01771510||72777|
NCT01771198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE11.288|Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment|Preliminary Evaluation of SIMVASTATIN as an Alternative Anti-inflammatory Agent in Chronic Rhinosinusitis Refractory to Conventional Medical and Surgical Treatment||Centre hospitalier de l'Université de Montréal (CHUM)|No|Terminated|August 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|65 Years|No|||August 2012|July 9, 2015|December 3, 2012||No|Lack of efficacy with one month of treatement|No||https://clinicaltrials.gov/show/NCT01771198||72801|
NCT01772589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAW BLD|Effect of Cutting Blades for Total Knee Arthroplasty on Implant Migration|Effect of Cutting Blades for Total Knee Arthroplasty on Implant Migration. A Randomized Controlled Study With Radiostereometric Analysis||Nova Scotia Health Authority|No|Withdrawn||||February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|0|||Both|21 Years|80 Years|No|||February 2015|February 17, 2015|January 17, 2013||No|Comparator sawblade no longer available|No||https://clinicaltrials.gov/show/NCT01772589||72694|
NCT01772875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLLAV-1|Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients|Pilot Study to Evaluate the Efficacy of Antiseptic Bladder Lavage Versus Pulsatile Lavage With Physiologic Serum in Catheterized Patients With Asymptomatic Bacteriuria With Uropathogens.||National Multiple Sclerosis Center|Yes|Not yet recruiting|March 2013|August 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|85 Years|No|||January 2013|January 18, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772875||72672|
NCT01774097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTRN 581|Patients With Intermittent Claudication Injected With ALDH Bright Cells|Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells|PACE|The University of Texas Health Science Center, Houston|Yes|Active, not recruiting|June 2013|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|40 Years|N/A|No|||January 2016|January 11, 2016|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774097||72578|
NCT01774383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-005|Investigating the Pathophysiological Roles of Cortical, Sub-thalamic Nuclear and Pedunculo-pontine Nuclear Oscillation in Movement Termination of Parkinson Disease Patients|||China Medical University Hospital|Yes|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|20 Years|80 Years|No|Probability Sample|PD undergoing deep brain stimulation of the sub-thalamic nucleus.|January 2014|January 29, 2014|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774383||72556|
NCT01770145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-AP1-4001|Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)|A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action|AM IMPAKT|US WorldMeds LLC|No|Completed|December 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 7, 2013|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01770145||72882|Full analysis set (n=88) included patients who completed 5/7 days of diary entries in APO treatment period. The gastroparesis sub-study to assess prevalence and severity of gastroparesis was not analyzed because there were too few subjects enrolled.
NCT01780558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-design-FET|A Study:the Different Outcomes Between Natural Cycle and Hormone Replacement Cycle in FET|A Randomized Controlled Study:the Different Outcomes Between Natural Cycle and Hormon Replacement Cycle in FET||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|January 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 31, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01780558||72082|
NCT01781377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1632/08 COET|Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.|Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section.||G. d'Annunzio University|No|Completed|February 2008|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|112|||Female|18 Years|50 Years|No|||December 2014|December 15, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01781377||72019|
NCT01781650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG.2013.2470|A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in Diagnostic Patients||Presidio Ospedaliero Santa Barbara|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|288|||Both|18 Years|85 Years|No|||January 2014|January 14, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781650||71998|
NCT01781663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAM-ATOPIC-01|Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD)|||Kamedis Ltd.||Recruiting|February 2013|||June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|2 Years|12 Years|No|||July 2013|January 29, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781663||71997|
NCT01781351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407- 05_121126|Neuromuscular Control of the Ankle With External Support|||University Hospital Heidelberg|No|Active, not recruiting|March 2013|||March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01781351||72021|
NCT01781364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP16963311|Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia|Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia||University of Konstanz|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|17 Years|37 Years|No|||December 2014|December 15, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01781364||72020|
NCT01781637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peanut 002|Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial|Phase 2 Study of Omalizumab in Oral Peanut Desensitization|PRROTECT|Children's Hospital Boston|Yes|Active, not recruiting|January 2013|October 2017|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|7 Years|25 Years|No|||October 2015|October 19, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781637||71999|
NCT01782716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Other Identifier-2011/037|Effect of Different Scoring Systems on Mortality Rates and Length of Hospitalization in Cardiac Surgery Patients|Effect of Different Scoring Systems on Mortality Rates and Length of Hospitalization in Cardiac Surgery Patients||Cumhuriyet University Hospital|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|N/A||2|Actual|438|||Both|18 Years|70 Years|No|Probability Sample|Cardiac surgery patients|December 2011|February 1, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782716||71916|
NCT01782729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017827|An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis|The Efficacy and Safety of Tacrolimus Ointment in Pediatric Patients With Moderate to Severe Atopic Dermatitis||Janssen-Cilag Ltd.,Thailand|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|2 Years|12 Years|No|||April 2013|April 8, 2013|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782729||71915|
NCT01778712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09090108|Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation|Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation in Premenopausal Women: WISHfit Phase 2||Rush University Medical Center|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|71|||Female|42 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01778712||72224|
NCT01778959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFIS|Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery|Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery: an Exploratory Study|IFIS|Vienna Institute for Research in Ocular Surgery|Yes|Recruiting|February 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|21 Years|N/A|No|||January 2013|January 25, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778959||72205|
NCT01774279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WA/0336|interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)|interNational Anaplastic Thyroid Cancer Tissue Bank and Database (NATT).|iNATT|Velindre NHS Trust|No|Recruiting|June 2013|February 2019|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Anaplastic thyroid cancer tissue blocks and slides. EDTA blood sample|Both|18 Years|N/A|No|Probability Sample|Since August 2014 ethical approval has been granted to open this UK initiated study        internationally. The project has therefore been rebranded the interNational Anaplastic        Thyroid Cancer Tissue Bank (iNATT) project.        It is unknown with the currently available UK data on thyroid cancer incidence precisely        how many cases of anaplastic thyroid arise annually in the UK. If the annual incidence is        2-4% it is estimated that 50-100 new cases are diagnosed per year in the UK.|December 2015|December 7, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774279|12 Months|72564|
NCT01770054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP 001-2013|Prevalence of Metabolic Syndrome in Atahualpa|Evaluation of the Prevalence of Metabolic Syndrome in Atahualpa Residents Aged 40 Years or More.||Hospital Clínica Kennedy|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|517|Samples With DNA|Blood|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|all Atahualpa residents aged 40 years or more|March 2013|March 7, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770054|2 Months|72889|
NCT01770626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1106|A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients|A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])|BEAM|University of Alabama at Birmingham|Yes|Completed|April 2011|June 2014|Actual|July 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 25, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01770626||72845|
NCT01770639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFB Retro|A Retrospective Study to Assess the Outcome After Surgical Reconstruction of the Midfoot With the Midfoot Fusion Bolt in Patients With Neuroarthropathy|A Retrospective Study to Assess the Outcome After Surgical Reconstruction of the Midfoot With the Midfoot Fusion Bolt in Patients With Neuroarthropathy||AO Clinical Investigation and Documentation|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neuro-osteoarthropathy of the foot or with other neurological impairment in        combination with foot deformity who have previously undergone surgical reconstruction of        the midfoot with the Midfoot Fusion Bolt.|June 2014|June 24, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770639||72844|
NCT01772329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12031901|Preoperative Cognitive Therapy for Improving Health Outcomes After Total Knee Replacement in High-risk Catastrophizing Subjects|Preoperative Cognitive Therapy for Improving Health Outcomes After Total Knee Replacement in High-risk Catastrophizing Subjects|CT_TKA|Rush University Medical Center|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772329||72714|
NCT01770912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|351-2012|Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management|A Randomized, Double-Blind Study of the Efficacy of Steroid Supplementation After Temporomandibular Joint Arthrocentesis||University of Florida|No|Recruiting|March 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|80 Years|No|||November 2015|November 5, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01770912||72823|
NCT01770925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain shams university|Nasal Continuous Positive Airway Pressure (n-CPAP) Versus Nasal Bilevel Positive Airway Pressure (n-BiPAP) for RDS|Non-invasive Ventilation for RDS: a Randomized, Cotrolled Trial to Compare CPAP by Nasal Bipap||Ain Shams University|Yes|Not yet recruiting|January 2013|June 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|N/A|7 Days|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770925||72822|
NCT01772030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12060524|Atrial Fibrillation Recurrence After Cryoballoon Ablation|Mechanisms and Patterns of Atrial Fibrillation Recurrence After Cryoballoon Ablation||University of Pittsburgh|No|Active, not recruiting|January 2013|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772030||72737|
NCT01772043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAR0312|Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping|||Cooperative International Neuromuscular Research Group|Yes|Active, not recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|Samples With DNA|Blood samples with DNA Skin samples Muscle samples (optional)|Male|4 Years|N/A|No|Non-Probability Sample|Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in        the dystrophin gene. DMD participants over 4 years of age with known mutations that could        be targeted by exon skipping therapies will be recruited for this study.|July 2015|July 27, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772043||72736|
NCT01773447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247354|Set-back Suture Versus Traditional Vertical Mattress Suture|Comparing Wound Eversion and Clinical Outcomes in Surgical Wound Repair With Subcuticular Set-back Versus Traditional Vertical Mattress Suturing Techniques||University of California, Davis|No|Completed|August 2011|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Anticipated|47|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773447||72628|
NCT01773460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 76|Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane|A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus|Evelyn|German Breast Group|Yes|Terminated|July 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|January 15, 2013||No|Study was stopped terminated early due to low recruitment.|No||https://clinicaltrials.gov/show/NCT01773460||72627|
NCT01773759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP000500|Immunization Protection in Child Care (IPiCC) Project|Strategies to Improve Vaccination Coverage in Child Care Centers and Preschools|IPiCC|University of Utah|No|Recruiting|September 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01773759||72604|
NCT01774110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTT|Evaluation of Early Standardized Task-Specific Training (ESTT)|Evaluation of Early Standardized Task-Specific Training (ESTT) in Persons With Acute Stroke|ESTT|University of Texas Southwestern Medical Center|No|Terminated|August 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|16 Years|80 Years|No|||September 2015|September 1, 2015|January 18, 2013||No|Very limited enrollment|No|May 13, 2015|https://clinicaltrials.gov/show/NCT01774110||72577|
NCT01774370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.139|SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea|A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea)||Boehringer Ingelheim||Recruiting|January 2013|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Probability Sample|Korean patients with non-valvular AF|March 2016|March 16, 2016|January 16, 2013||||No||https://clinicaltrials.gov/show/NCT01774370||72557|
NCT01770158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG18-12|Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)|Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)||University of Ulm|No|Recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with acute myeloid leukaemia (AML) in first remission following completion        of consolidation therapy and concomitantly treated with interleukin-2 (IL-2) which will        receive treatment with CEPLENE® for the first time. Patients are eligible when gene status        was already determined for previous induction and consolidation therapy of AML and showed        carrier of NPM1, CBFβ-MYH11, or MLL-AF9 mutation.|January 2013|January 14, 2013|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01770158||72881|
NCT01781091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-2012-02|S4 :Trial Of Fully Closed-Loop Ventilation In ICU.|S4 :RANDOMIZED CONTROLLED TRIAL OF FULLY CLOSED-LOOP VENTILATION IN ICU.|S4|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01781091||72041|
NCT01781104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-006|Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation||Rhythm Pharmaceuticals, Inc.|No|Completed|March 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|No|||November 2014|November 6, 2014|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781104||72040|
NCT01781390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG.AMI-IC001|Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction|A Prospective, Double Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Immunoselected, Bone Marrow-derived Stro3 Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction|AMICI|Mesoblast, Ltd.|Yes|Recruiting|December 2012|June 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01781390||72018|
NCT01781403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28381|Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer|Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study||Asan Medical Center|No|Active, not recruiting|May 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|20 Years|N/A|No|||January 2016|January 11, 2016|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01781403||72017|
NCT01781676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-Ⅷ|Safety Study of Kudiezi(Yueanxin,a Chinese Medicine Injection)Used in Hospitals in China|Registry Study Intensive Hospital Monitoring Protocol of Kudiezi Injection ( Yueanxin ) 's Clinical Safety||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|An anticpcipated sample size was caculated in this study,about 30000.Patients using        Kudiezi injection from 2012 to 2014 in more than 20 hospital.|April 2013|May 13, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781676|14 Days|71996|
NCT01781949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAID R01 AI106057|The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial|Effectiveness of Rapid HIV Screening Methods in Urban Emergency Departments|HIV TESTED|Denver Health and Hospital Authority|No|Enrolling by invitation|April 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|120000|||Both|13 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01781949||71975|
NCT01781923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025985|Cognitive Remediation in 22q11DS|A Remediation Program for Children at High-Risk of Schizophrenia: 22q11.2 Deletion Syndrome||Duke University|Yes|Completed|October 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|38|||Both|11 Years|17 Years|No|||August 2015|August 6, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01781923||71977|
NCT01781936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033019|Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis|Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis|Iluvien|Duke University|No|Enrolling by invitation|June 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|6|||Both|N/A|N/A|No|||March 2015|March 18, 2015|December 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01781936||71976|
NCT01782482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-003|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers||Alcon Research|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|574|||Both|16 Years|N/A|No|||March 2014|April 25, 2014|January 31, 2013|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01782482||71934|
NCT01778725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9616-BW-CTIL|Early Identification of Brain Insult in Chorioamnionitis|S100B as a Marker for Fetal Brain Injury in Premature Rupture of Membranes||Sheba Medical Center|No|Not yet recruiting|January 2013|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with premature rupture of the amniotic sac.|January 2013|January 25, 2013|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01778725||72223|
NCT01778946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121759|Nicotine Treatment of Cognitive Decline in Down Syndrome|Nicotinic Treatment of Age-Related Cognitive Decline in Down Syndrome: An Open Label Pilot Trial||Vanderbilt University|No|Recruiting|April 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|25 Years|N/A|No|||November 2015|November 19, 2015|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01778946||72206|
NCT01779258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00034 CR 3 13 1B|Emollients in the Management of Atopic Dermatitis|Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares.||Pierre Fabre Medicament|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|347|||Both|2 Years|6 Years|No|||February 2014|February 18, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779258||72182|
NCT01778972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fall prevention UV|Fall Prevention for Old Community-dwelling People|Fall Prevention for Old Community-dwelling People in Uppsala, Västerås and Sörmland||Uppsala University|No|Active, not recruiting|November 2012|January 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|420|||Both|75 Years|N/A|No|||June 2015|February 10, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01778972||72204|
NCT01770366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-12-180|A Virtual Support Pilot Program for Weight Loss Surgery Patients|A Virtual Support Pilot Program for Weight Loss Surgery Patients Leveraging Wireless Goal-tracking Technologies||Baystate Medical Center|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 1, 2015|January 15, 2013|Yes|Yes||No|March 1, 2015|https://clinicaltrials.gov/show/NCT01770366||72865|
NCT01770938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 0326.0.135.000-11|Effects of Phototherapy by Low-level Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical, Biomechanical, Histologic and Genetic Responses of Muscle Performance of Young Males Submitted to Physical Strength Training|Effects of Phototherapy by Low-level Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical, Biomechanical, Histologic and Genetic Responses of Muscle Performance of Young Males Submitted to Physical Strength Training||Universidade Federal de Sao Carlos|Yes|Completed|May 2012|September 2014|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01770938||72821|
NCT01770951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-001r|A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)|A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)||Alexion Pharmaceuticals||Completed|August 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Male or female patients of any age who have been diagnosed with aHUS.|August 2009|January 16, 2013|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01770951||72820|
NCT01772615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-10|Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle|Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle||Hvidovre University Hospital|Yes|Completed|May 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772615||72692|
NCT01771731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HL117664-01|Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease|Cannabinoid-Based Therapy and Approaches to Quantify Pain in Sickle Cell Disease|Cannabis-SCD|University of California, San Francisco||Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771731||72760|
NCT01772914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoMeal 2013|Copeptin Changes After Food Intake|Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test|CoMeal|University Hospital, Basel, Switzerland|No|Completed|February 2013|February 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30||Serum EDTA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults|January 2013|May 19, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772914||72669|
NCT01773187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERSIST-1 (PAC325)|Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis|A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis||CTI BioPharma|Yes|Active, not recruiting|December 2012|January 2018|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|327|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773187||72648|
NCT01773486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051658|Effects of Hesperidin on Insulin Sensitivity|An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects|EHIS|University of Maryland|Yes|Withdrawn|June 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 17, 2013|Yes|Yes|Not funded|No||https://clinicaltrials.gov/show/NCT01773486||72625|
NCT01773785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1620-12-202|Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer|Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|April 2013|December 2015|Anticipated|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773785||72602|
NCT01773772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10504|Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls|Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls (JCM017)|JCM017|University of Virginia|No|Active, not recruiting|June 2003|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773772||72603|
NCT01774396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2012|Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid In Hands Rejuvenation|Clinical Trial On The Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid (Emervel® Volume Lidocaine, Emervel® Deep Lidocaine And Emervel® Touch) In Hands Rejuvenation||Brazilan Center for Studies in Dermatology|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01774396||72555|
NCT01778842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESET ELDERLY|Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome|PhaRmacodynamic Effect of Antiplatelet Agents in Elderly Patients: Standard Clopidogrel Versus prasugrEl Low Dose Therapy.|RESET ELDERLY|University of Roma La Sapienza|Yes|Not yet recruiting|March 2013|July 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|75 Years|N/A|No|||January 2013|January 24, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778842||72214|
NCT01779115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACCVREGDIAB|Registry of Diabetes Patients in a Large Health Maintenance Organization in Israel|Computerized Registry of Diabetes Patients in a Large Health Maintenance Organization in Israel||Maccabi Healthcare Services, Israel|Yes|Enrolling by invitation|January 1998|||December 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|126000|||Both|N/A|N/A|No|Non-Probability Sample|Diabetes patients.|January 2013|January 30, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779115|1 Month|72193|
NCT01781117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11-013|Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia|Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)||Samsung Medical Center|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||January 2014|February 12, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01781117||72039|
NCT01781975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-2013-6|Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus|Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus||University of California, San Francisco|Yes|Recruiting|January 2014|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781975||71973|
NCT01782235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5206|Efficacy of Tocilizumab in Primary Sjögren's Syndrome.|A Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy of Tocilizumab for the Treatment of Primary Sjögren's Syndrome.|ETAP|University Hospital, Strasbourg, France||Recruiting|July 2013|March 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||March 2014|March 11, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782235||71953|
NCT01782248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5289|Self-consciousness in Dementia|Self-consciousness in Dementia||University Hospital, Strasbourg, France||Not yet recruiting|February 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|65|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01782248||71952|
NCT01782261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPP004|Incretin Effect on the Immunological Phenotype|Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects||Medical University of Graz|Yes|Active, not recruiting|February 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782261||71951|
NCT01781962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-077|A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension|||Allergan|No|Terminated|January 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|18 Years|N/A|No|Probability Sample|Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension|July 2014|July 30, 2014|January 30, 2013||No|Study terminated due to corporate decision.|No|June 16, 2014|https://clinicaltrials.gov/show/NCT01781962||71974|
NCT01782222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0005|Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy|A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood|BRIGHT|UCB Pharma|No|Completed|February 2013|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 30, 2013|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01782222||71954|
NCT01782742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-IRB 12-783|Bexarotene Amyloid Treatment for Alzheimer's Disease|A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease|BEAT-AD|The Cleveland Clinic|Yes|Completed|February 2013|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|90 Years|No|||February 2016|February 10, 2016|January 29, 2013||No||No|February 10, 2016|https://clinicaltrials.gov/show/NCT01782742||71914|Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated.
NCT01782755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28012013|Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial|Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial|PROSPECT|McMaster University|No|Completed|October 2013|January 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782755||71913|
NCT01778738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1427b|Type 2 Diabetes After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Randomised Single Centre Study|Glycaemia, Insulin Secretion and Action in Morbidly Obese Subjects With Type 2 Diabetes After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Randomised Single Centre Study|OSEBERG|Sykehuset i Vestfold HF|No|Recruiting|January 2013|January 2020|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|60 Years|No|||January 2015|January 28, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01778738||72222|
NCT01779310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA731DCN01T|Clinical Pathway for Alzheimer's Disease in China (CPAD)|Clinical Pathway for Alzheimer's Disease in China (CPAD): A 8-week Multi-center Registry Study to Investigate AD Diagnostic Pattern in Chinese Local Real Clinical Practice||Peking University|Yes|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1024|||Both|45 Years|N/A|No|Non-Probability Sample|Outpatients with clinically significant cognitive impairment per judgment of the        participating physicians are registered.|April 2013|April 23, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01779310|2 Months|72178|
NCT01770652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA39-0412|An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment|An Open-label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox in Subjects With Impaired Renal Function and Healthy Volunteers||ApoPharma|No|Completed|January 2013|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 25, 2014|January 16, 2013|Yes|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT01770652||72843|
NCT01770665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAYO1000|Validation of the MiCK Assay|Mayo Clinic Validation of the MiCK Assay|MiCK Assay|DiaTech Oncology|Yes|Recruiting|June 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Human cancerous tumor.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.|January 2013|April 18, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770665|1 Year|72842|
NCT01772056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUTIDANENES08|Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children|Randomised Controlled, Double Blind Trial of Topical Twice Weekly Fluticasone Propionate Maintenance Treatment to Reduce Risk of Relapse in Mild or Moderate Atopic Dermatitis in Children||University of Valencia|No|Terminated|December 2009|March 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|2 Years|10 Years|No|||January 2015|January 8, 2015|January 16, 2013||No|Patient recruitment is very slow, economic grant has ended and the number of patients is    enough according to sample size (22 children/ arm).|No||https://clinicaltrials.gov/show/NCT01772056||72735|
NCT01772940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lubumbashi trial|Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting|Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study||Centre Hospitalier Universitaire Saint Pierre|Yes|Completed|December 2008|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|425|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01772940||72667|
NCT01772602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEH/ATSDR-5768|The National Amyotrophic Lateral Sclerosis Registry|The National Amyotrophic Lateral Sclerosis Registry||Centers for Disease Control and Prevention|No|Recruiting|October 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|13000|||Both|18 Years|N/A|No|Non-Probability Sample|ALS cases in the United States|July 2015|July 28, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772602|5 Years|72693|
NCT01772888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-103|Chewing Efficiency Measured by a Two Colour Chewing Gum Test in Amyotrophic Lateral Sclerosis (ALS) Patients?|Chewing Efficiency Measured by a Two Colour Chewing Gum Test: a Marker of Insufficient Nutritional Intakes and Percutaneous Gastrostomy (PEG) Necessity in ALS Patients?||University Hospital, Geneva|No|Recruiting|October 2012|January 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ALS patients participating in the cohort study of the University Hospital Geneva|June 2015|June 1, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772888||72671|
NCT01772901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIV-INT-1|Brief Influenza Vaccine Education to Pregnant Women|A Randomized Controlled Trial of a Brief Educational Intervention to Increase Uptake of Influenza Vaccine Among Pregnant Women||The University of Hong Kong|No|Completed|October 2013|July 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|321|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772901||72670|
NCT01773200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2012/153|Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage|Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)|EVAPROPEC|Centre Hospitalier Universitaire de Besancon|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|92|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients suffering from acute aneurysmal subarachnoid haemorrhage. .|November 2012|May 21, 2014|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773200||72647|
NCT01773473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14675|Comparison of Insulin Mix25 Versus Mix50|Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study)|CLASSIFY|Eli Lilly and Company|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|January 18, 2013|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01773473||72626|
NCT01773798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1050-4008|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|33|||Both|18 Years|64 Years|No|||March 2015|March 4, 2015|January 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01773798||72601|
NCT01774123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-422|Optical Coherence Tomography in Multiple Sclerosis Patients|Optical Coherence Tomography in Multiple Sclerosis Patients||The Cleveland Clinic|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospective, case-control study of patients from the Mellen Center and Cole Eye Institute        of the Cleveland Clinic in Cleveland Ohio. The study population will consist of MS        patients with a prior history optic neuritis in one eye. The affected eye will serve as        cases for the study. The contralateral, unaffected eye will be used as the control.        Controls will also be recruited from MS patients without a history of optic neuritis and        from healthy individuals from Cole Eye Institute.|May 2014|May 30, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01774123||72576|
NCT01770756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSU-2012.8601|FSU Hypertension Self-Care Training Study|Improving the Willpower-based Self-care for Hypertension||Florida State University|No|Active, not recruiting|August 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|N/A|No|||July 2015|July 30, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770756||72835|
NCT01771042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/13|The Effects of Weight Loss on Neuroadrenergic Function|Neuroadrenergic Dysfunction Along the Diabetes Continuum: Benefits of Weight Loss Within Different Strata of Metabolic Risk||Baker Heart Research Institute|No|Not yet recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|45 Years|65 Years|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771042||72813|
NCT01781689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS102-086|The Relationship Between Motor Cortex Oxygenation and Motor Function Recovery in Stroke Patients|The Relationship Between Motor Cortex Oxygenation and Motor Function Recovery in Stroke Patients||Kaohsiung Veterans General Hospital.|No|Enrolling by invitation|October 2012|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01781689||71995|
NCT01781702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW Plb RA301|Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients||Daewon Pharmaceutical Co., Ltd.|Yes|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|80 Years|No|||August 2013|August 7, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781702||71994|
NCT01781988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZMC12521|Personalized Therapy in Non-small Cell Lung Cancer|The Clinical Study of Personalized Therapy for Non-small Cell Lung Cancer Based on ERCC1/RRM1/TS Expression|PTINCLC|Guangzhou Medical University|Yes|Completed|June 2009|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|75 Years|No|||December 2014|December 15, 2014|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781988||71972|
NCT01782274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrCr/2012|Proteome-based Immunotherapy of Brain Metastases From Breast Cancer|Proteome-based Personalized Immunotherapy of Brain Metastases From Breast Cancer||NeuroVita Clinic|Yes|Enrolling by invitation|December 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2012|April 21, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782274||71950|
NCT01782495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-999|A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients|Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)|CORAL-I|AbbVie|Yes|Recruiting|February 2013|August 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|195|||Both|18 Years|115 Years|No|||January 2016|January 23, 2016|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782495||71933|
NCT01782768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zjianheng|Comparative Effects of Different Noninvasive Ventilation Mode on Neural Respiratory Drive in Recovering AECOPD Patients|Comparative Effects of Noninvasive Proportional Assist and Pressure Support Ventilation on Neural Respiratory Drive in Recovering Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD) Patients||The First Affiliated Hospital of Guangzhou Medical University|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|13|||Male|50 Years|75 Years|No|||February 2013|April 29, 2013|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01782768||71912|
NCT01779570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC CUHK468112|Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections|Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections||Chinese University of Hong Kong|No|Recruiting|February 2013|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01779570||72158|
NCT01780116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-2013|Effectiveness of Adherence Therapy for Schizophrenia|An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Completed|May 2013|February 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|134|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780116||72116|
NCT01771757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB-2011-327|Measurement of Retinal Venous Pressure Under Short-term Low-oxygen Environment|Measurement of Retinal Venous Pressure (Retinal Venous Pressure RVP) Under Conditions of Reduced Ambient Pressure and Oxygen Partial Pressure||University Hospital, Basel, Switzerland|No|Completed|December 2011|July 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|July 2014|July 18, 2014|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01771757||72758|
NCT01772342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01056|Effects of an Air Purifying Device (PureNight) on Sleep Quality in Obstructive Lung Disease|Effects of a Novel Purifying Device (PureNight) on Sleep Quality in Chronic Obstructive Pulmonary Disease||VA New York Harbor Healthcare System|No|Completed|March 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|50|||Both|35 Years|80 Years|No|||January 2013|January 23, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772342||72713|
NCT01772355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|core biopsy of orbital tumors|Effectiveness and Possible Complications of Core Needle Biopsy of Orbital Tumors|||The S.N. Fyodorov Eye Microsurgery State Institution||Recruiting|October 2008|June 2014|Anticipated|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|N/A|N/A|No|||January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772355||72712|
NCT01802944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW110054|Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness|Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness||Bronx Veterans Medical Research Foundation, Inc|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Both|40 Years|89 Years|No|||April 2014|April 23, 2014|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802944||70367|
NCT01772927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULGCHR-11012013-BAXTER|Clinical Tolerance of Numeta 13%|Use of Parenteral Nutrition in Premature Infants Weighing Less Than 1500 g Using Numeta G13% From the First Day of Life. A Prospective, Open-labeled Study on Intakes and Nutritional Markers.|BAXTERULG2|University Hospital of Liege|No|Not yet recruiting|January 2013|July 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|30 Days|No|Non-Probability Sample|Being a non-comparative study of therapeutic use, the sample size determination is not        inferred from statistical calculation. However, in order to collect a relevant number of        parenteral days in a relevant population of preterm infants, a total of 30 preterm infants        with a birth weight< 1500 g will be included in the study cohort.|January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772927||72668|
NCT01773499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMASSEDUS3|Sonographic Features of Cellulitis and Failure of Therapy|Sonographic Features of Cellulitis and Failure of Therapy||University of Massachusetts, Worcester|No|Terminated|January 2013|October 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Cellulitis|March 2015|March 18, 2015|January 17, 2013|No|Yes|Unable to enroll significant number of patients.|No||https://clinicaltrials.gov/show/NCT01773499||72624|
NCT01782612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THPPLA2013|The Assessments of the Postoperative Recovery on Elderly Patients Received General Anesthesia or Peripheral Nerve Blocks|Comparison of Peripheral Nerve Blocks With General Anesthesia on Elderly Patients Undergoing Total Hip Replacement (THR) by Assessing the Postoperative Recovery and Delirium||Chinese PLA General Hospital|Yes|Recruiting|March 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|75 Years|N/A|No|||March 2013|March 11, 2013|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782612||71924|
NCT01782872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-014|Analgesia After Total Shoulder Arthroplasty|Analgesia After Total Shoulder Arthroplasty||Hospital for Special Surgery, New York|Yes|Completed|October 2012|February 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|80 Years|No|||March 2014|March 20, 2014|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01782872||71904|
NCT01770457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:130|Cytokine Response in Septic Shock|Cytokine Response in Septic Shock||University of Manitoba|No|Recruiting|April 2006|December 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|325|Samples Without DNA|Serum samples will be collected at specific time points. Initial time point determined by      start of Vasopressors Then sequential serum samples will be drawn from patients to examine a      broad range of cytokine responses (TNF, IL-1, IL-6, MIF, LIF, HMGB1, etc)|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients with septic shock admitted to intensive care units who are receiving        vasopressors for septic shock for <24 hrs. No significant exclusions exist.|July 2013|July 24, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770457||72858|
NCT01770470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045129|Chitosan Chewing Gum Study in Dialysis Patients|A Pilot Study of Dietary Chitosan Chewing Gum in Dialysis Patients||University of Maryland|No|Completed|April 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|64 Years|No|Probability Sample|Outpatient hemodialysis facility|January 2013|January 15, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770470||72857|
NCT01770769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEM-2011/2296|Undisplaced Femoral Neck Fractures in the Elderly: A Trial Comparing Internal Fixation to Hemiarthroplasty|Undisplaced Femoral Neck Fractures in Patients Aged 70 Years and Older: A Multicentre Randomised Controlled Trial Comparing Internal Fixation to Hemiarthroplasty||University Hospital, Akershus|Yes|Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|214|||Both|70 Years|N/A|No|||June 2015|June 18, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01770769||72834|
NCT01781442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1771110|A Post Marketing Surveillance As Required By Philippine Food And Drug Administration|An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study||Pfizer|Yes|Withdrawn|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|This is a prospective observational, non-interventional study which will evaluate Torisel        in Filipino adult subjects. Because the data to be collected will be under routine        clinical conditions, subjects who have any of the contraindications specified in the        product package insert are to be excluded. Torisel will be prescribed and administered        according to the approved product information of the drug in the Philippines. Pfizer will        not provide the drug for this study.|April 2013|April 30, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781442||72014|
NCT01781455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-101|A Study of BBI503 in Adult Patients With Advanced Solid Tumors|A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors||Boston Biomedical, Inc|No|Active, not recruiting|February 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|310|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01781455||72013|
NCT01782534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR-RF-AD|Logistic Regression of Risk Factor for the 5-year Mortality of Aortic Dissection|Logistic Regression of Risk Factor for the 5-year Mortality of Aortic Dissection||Central South University|Yes|Completed|August 2002|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|111|||Both|18 Years|80 Years|No|Probability Sample|diagnosed AD patients in Our hospital From August 2001 to August2007|February 2013|February 22, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01782534||71930|
NCT01782781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIA-AH-1|Local Infiltration Analgesia After Abdominal Hysterectomy|Local Infiltration Analgesia After Abdominal Hysterectomy|LIA|Göteborg University|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|75 Years|No|||October 2014|January 19, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01782781||71911|
NCT01778751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-458|Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes|Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes|ACDC|VA Office of Research and Development|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|N/A|N/A|No|||December 2015|December 16, 2015|January 18, 2013||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01778751||72221|Single-center pilot studySmall, male Veteran population with type 2 diabetesUses VA-specific infrastructure, findings may not translate to other settings.
NCT01782508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMN107A2301|A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma|A Phase II Randomized Study of Imatinib Versus High Dose Interferon as Adjuvant Therapy in KIT-mutated Patients With Resected Melanoma||Beijing Cancer Hospital|Yes|Recruiting|August 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01782508||71932|
NCT01779297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMSU & TUMS|New Integrated Weaning Indexes|New Integrated Weaning Indexes From Mechanical Ventilation: A Prospective Clinical Trial|NIWIs|Baqiyatallah Medical Sciences University|Yes|Completed|October 2007|December 2012|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1175|||Both|18 Years|90 Years|No|Probability Sample|One thousand one hundred and seventy-five patients who were on mechanical ventilation for        more than 24 hours were evaluated.|January 2013|January 28, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01779297||72179|
NCT01778764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRN0022|Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases|A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases||Stanford University||Suspended|October 2014|||December 2019|Anticipated|Phase 1|Observational|Observational Model: Cohort||2|Anticipated|1000|||Both|21 Years|95 Years|No|Non-Probability Sample|Patients with all types of primary cancers which have metastasized to the brain.|August 2015|August 31, 2015|January 24, 2013||No|Insufficient resources - Staff|No||https://clinicaltrials.gov/show/NCT01778764||72220|
NCT01778998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCISIONS|Impact of Incision Size and Architecture on Wound Stability and Astigmatism in Cataract Surgery: an Exploratory Study|Impact of Incision Size and Architecture on Wound Stability and Astigmatism in Cataract Surgery: an Exploratory Study|INCISIONS|Vienna Institute for Research in Ocular Surgery|Yes|Completed|February 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|68|||Both|21 Years|N/A|No|||February 2014|February 7, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778998||72202|
NCT01780129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW6-01-US|Polydatin Injectable (HW6) for Shock Treatment|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HW6 in the Treatment of Traumatic/Hemorrhagic Shock and Septic Shock|PIST|Neptunus Pharmaceuticals Inc.|Yes|Not yet recruiting|February 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||January 2013|January 29, 2013|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780129||72115|
NCT01772069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC12QIMI0020|Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus:Focusing on Fibromyalgia|||The Catholic University of Korea|No|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Female|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|-  Patients : 150 women age 30 to 60 years with SLE          -  Control subjects : age, sex matched control subject (150 subjects)          -  Patients : First visit and second visit after an interval of six months          -  Control subjects : baseline only|January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772069|6 Months|72734|
NCT01772082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCFull2328|Use of Internet Mediated Walking Program and Pedometer in COPD|Randomized Study of Use of Internet Mediated Walking Program and Pedometer in COPD||VA Boston Healthcare System|No|Recruiting|January 2012|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|40 Years|90 Years|No|||January 2013|January 18, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772082||72733|
NCT01772628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241945 PREPARE|Parenting Styles and Parent-Offspring Communication on Sexuality Issues|Promoting Parent-Child Communication on Selected Sexual and Reproductive Health Issues Among Young Secondary School Adolescents in Kampala and Wakiso Districts|PREPARE|Makerere University||Active, not recruiting|January 2010|March 2014|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1700|||Both|12 Years|14 Years|No|||March 2013|March 1, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772628||72691|
NCT01773512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK2012|The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques|The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.|PREDICT|General University Hospital, Prague|No|Recruiting|June 2012|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||January 2013|January 18, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01773512||72623|
NCT01773213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0400|Detrusor Contraction During the Ice-water-test|Is the Detrusor Contraction During the Ice-water-test Provoked by the Ice Water or the Rapid Bladder Filling? A Randomized, Double-blind Clinical Trial||Balgrist University Hospital|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|90 Years|No|||January 2013|July 11, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01773213||72646|
NCT01782365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nap-tSOS-MCI|Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Patients With Mild Cognitive Impairment|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Slow Wave Sleep of a Daytime Nap in Patients With Mild Cognitive Impairment(MCI)||Charite University, Berlin, Germany|Yes|Recruiting|April 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|50 Years|90 Years|No|||March 2016|March 15, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782365||71943|
NCT01770171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITOBEVAEND2|Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer|A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer|MITOBEVAEND2|Catholic University of the Sacred Heart|Yes|Recruiting|April 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||December 2012|January 15, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01770171||72880|
NCT01770444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1211/177-005|Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain|Safety and Efficacy of Implementing Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain in Emergency Department||Seoul National University Hospital|Yes|Recruiting|December 2012|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|681|||Both|20 Years|55 Years|No|||November 2015|November 16, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01770444||72859|
NCT01770483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMS|The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients|The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients|HEP-C-FM|Services Institute of Medical Sciences, Pakistan|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|35 Years|55 Years|No|||September 2013|September 15, 2013|January 8, 2013||No||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01770483||72856|
NCT01770782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0949/09|Orthodontic Retention on the Maxillary Stability After SARME Using Laser Scanner|Orthodontic Retention on Dental and Skeletal Maxillary Transverse Stability After Surgically Assisted Rapid Maxillary Expansion (SARME)Using Laser Scanner||Federal University of São Paulo|Yes|Completed|August 2009|January 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|No|||July 2009|January 17, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770782||72833|
NCT01770795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-GIRBA-2351|A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer|A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer||Gachon University Gil Medical Center||Completed|January 2011|||October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770795||72832|
NCT01782287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL/2012|Proteome-based Immunotherapy of Lung Cancer Brain Metastases|Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer||NeuroVita Clinic|Yes|Enrolling by invitation|December 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782287||71949|
NCT01782521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|primerstudy01|Is a Primer Needed for Orthodontic Bonding? A Multi-centre Trial|Is a Primer Needed for Orthodontic Bonding? A Multi-centre RCT||Bradford Teaching Hospitals NHS Foundation Trust|Yes|Not yet recruiting|March 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 1, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782521||71931|
NCT01782300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 283|Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart|A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01782300||71948|
NCT01782547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00006175|Telehealth Intervention for Youth With T1DM|Telehealth Intervention for Youth With Type 1 Diabetes||Children's Hospital Boston|No|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|13 Years|17 Years|No|||December 2013|December 20, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01782547||71929|
NCT01778985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-042011-101|Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor|Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor|PET|University of Texas Southwestern Medical Center|No|Completed|December 2012|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|January 23, 2013|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01778985||72203|4 patients nonadherent to study protocol in the Premarin arm.
NCT01779596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-EX-ACUTE|ET-blockade and Exercise Induced Blood Flow in T2DM|Effect of a Dual ET-blocker on Exercise Induced Blood Flow and Endothelial Function in T2DM||Radboud University|No|Active, not recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||February 2010|January 28, 2013|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779596||72156|
NCT01779609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-EX-TRAINING|ET-blockade and Exercise-induced Vascular Adaptations in T2DM|Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)||Radboud University|No|Active, not recruiting|April 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|36|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||February 2010|January 28, 2013|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779609||72155|
NCT01779856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120171|Study the Characteristics of Cardiac Related Events in Hemodialysis Patients|Monitoring in Dialysis|MiD|Medtronic Corporate Technologies and New Ventures|Yes|Completed|January 2013|September 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|81|||Both|21 Years|N/A|No|||September 2015|September 9, 2015|January 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01779856||72136|
NCT01780441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00005074|Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)|Longitudinal Study to Identify Early Biomarkers of Autism Spectrum Disorder (ASD) in Infants With Tuberous Sclerosis Complex (TSC)||Children's Hospital Boston|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood|Both|3 Months|12 Months|No|Non-Probability Sample|A total of 150 evaluable infants with TSC will be recruited. Diagnosis of TSC will be        based on established clinical criteria and will not require genetic testing prior to        participation. The target age of entry into study is 3-6 months, but infants up to age 12        months (less than or equal to 13.5 months) will be included.|February 2016|February 18, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01780441||72091|
NCT01772368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-AS-201|Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects|A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate Spiromax and Open Label Advair Diskus in Adult and Adolescent Subjects With Persistent Asthma||Teva Pharmaceutical Industries||Completed|January 2013|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|72|||Both|12 Years|N/A|No|||March 2015|March 19, 2015|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772368||72711|
NCT01802632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00001|AZD9291 First Time In Patients Ascending Dose Study|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent|AURA|AstraZeneca|No|Active, not recruiting|March 2013|November 2016|Anticipated|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|974|||Both|18 Years|130 Years|No|||February 2016|February 15, 2016|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802632||70391|
NCT01802645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-CELIM2-050|Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases|Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.|CELIM2|Technische Universität Dresden|Yes|Recruiting|February 2013|July 2020|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|256|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01802645||70390|
NCT01773824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB-2012-074|Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care|Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care - a Pragmatic Randomised Controlled Trial||University Hospital, Basel, Switzerland|No|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2854|||Both|N/A|N/A|No|||November 2015|November 23, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01773824||72599|
NCT01803204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193.454|Patient Education Before Orthognathic Surgery|Evaluation of an Educational Booklet for Perioperative Orthognathic Surgery: Randomized Clinical Trial.||University of Sao Paulo|Yes|Recruiting|February 2013|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|60 Years|No|||December 2014|December 4, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01803204||70347|
NCT01774136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nompilo|Effectiveness of an HIV-adapted IMCI Training and Supervision Programme for Community Health Workers|The Effectiveness of an HIV-adapted IMCI Training and Supervision Programme of Community Caregivers to Support Interventions That Will Reduce MTCT and Improve Delivery of Other Essential Newborn and Child Survival Interventions||University of KwaZulu|No|Recruiting|April 2012|March 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|3840|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 20, 2013|January 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01774136||72575|
NCT01770184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HD073190-01|Clinical Effectiveness of Self-Management Education Post-Mild Stroke|Clinical Effectiveness of Self-Management Education Post-Mild Stroke||Washington University School of Medicine|No|Active, not recruiting|January 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||July 2015|July 9, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01770184||72879|
NCT01770808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC027|A Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort|A Randomised, Double-blind, Placebo-controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort in Healthy Subjects||University College Cork|Yes|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01770808||72831|
NCT01771081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16459|Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy|POLARIS: A Non-interventional Study in Patients With Diabetic Macular Edema (DME) With Central Involvement to Assess the Effectiveness of Existing Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment Regimens|POLARIS|Bayer|No|Completed|April 2013|April 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|911|||Both|N/A|N/A|No|Probability Sample|In- and outpatients at participating sites with a diagnosis of DME with central        involvement. Patients will be enrolled after the decision for treatment with an approved        anti-VEGF therapy has been made at or after October 2012 by the study physician.|October 2015|October 27, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01771081||72810|
NCT01782014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130003|Comparison of Adenoma Detection Rate Among Water, Carbon Dioxide and Air Methods of Minimal Sedation Colonoscopy|Water Infusion and Carbon Dioxide Insufflation Versus Air Insufflation Versus Air Insufflation Techniques in Screening Colonoscopies in the United States: A Comparative Study Evaluating Safety, Efficacy and Adenoma Detection Rate (ADR)||Loma Linda University|Yes|Terminated|February 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Anticipated|450|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|January 28, 2016|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01782014||71970|
NCT01778777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversRevers|Safety Study of Univers® Revers Shoulder Prosthesis|Safety, Function and Quality of Life in Patient With Rotator Cuff Tear Arthropathy Treated With the Univers® Revers Shoulder Prosthesis||Schulthess Klinik|Yes|Recruiting|September 2013|July 2017|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|166|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778777||72219|
NCT01779011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuTra² (Suivi et Traitement du|Monitoring and Treatment of Extremity Trauma for Mass Casualties in Difficult Contexts|Suivi et Traitement du Traumatisme Des Membres en Cas d'Afflux Massif de blessés Dans Les Contextes Difficiles|SuTra²|Alliance for International Medical Action|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|305|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited by phone from databases issued by:          -  A surgical clinic, The Clinique Lambert (Pétion-Ville, Haiti),          -  Two non-governmental organizations               -  Handicap International (HI)               -  Bangladesh Rural Advancement Committee (BRAC),          -  A local organization l'Union des Jeunes Victimes du Séisme (UJVS)|January 2013|January 28, 2013|December 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01779011||72201|
NCT01779024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130043|Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers|Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Anticipated|124|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2012|January 24, 2013|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779024||72200|
NCT01779037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFPAIdata|IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)|IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)||Uniform Data System for Medical Rehabilitation|Yes|Active, not recruiting|January 2001|||December 2050|Anticipated|N/A|Observational [Patient Registry]|N/A||1|||||Both|7 Years|N/A|No|Non-Probability Sample|inpatient rehabilitation patients|August 2014|August 26, 2014|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01779037|1 Day|72199|
NCT01779050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309084|Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells|A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells||Washington University School of Medicine|No|Recruiting|December 2013|September 2022|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779050||72198|
NCT01782794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113269|Acceptability of Hepatitis B Vaccination in General Population|Measurement of the Changes in Hepatitis B Immunization Coverage in Infants, and the Acceptability Thereof, Before Reimbursement, Then During the Three Years After Reimbursement of InfanrixHexa® in France, Among the General Population|PopCorn|GlaxoSmithKline|Yes|Completed|May 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|2413|||Both|12 Months|27 Months|Accepts Healthy Volunteers|Probability Sample|The study population will consist of parents (with infants) agreeing to take part in a        personal interview.|January 2013|January 31, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01782794||71910|
NCT01782807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmc0029-11|Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy|Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy||Kaplan Medical Center|No|Recruiting|October 2011|||June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2011|January 31, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782807||71909|
NCT01779622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17|Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin Hormone Secretion in Healthy Volunteers|Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin||Lund University|Yes|Completed|June 2013|June 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01779622||72154|
NCT01779882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuCyBu study|Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT|Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity||University Hospital, Basel, Switzerland|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779882||72134|
NCT01779869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET/MR-Perfusion|Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson|Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson|PET/MR-P|Washington University School of Medicine|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779869||72135|
NCT01780974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFF01|Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention|Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention||Oregon Health and Science University|Yes|Recruiting|April 2013|September 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|55 Years|N/A|No|||June 2014|June 5, 2014|January 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01780974||72050|
NCT01777789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO16109|The Role of Mid-Life Adiposity in Functional Brain Connectivity|The Role of Mid-Life Adiposity in Functional Brain Connectivity||Medical College of Wisconsin|No|Terminated|December 2012|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Blood draw|Both|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers from the community|February 2016|February 8, 2016|January 24, 2013||No|This is a basic research study with no clinical data to report|No||https://clinicaltrials.gov/show/NCT01777789||72295|
NCT01802372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i12-01631|Task Shifting and Blood Pressure Control in Ghana|Task Shifting and Blood Pressure Control in Ghana: A Cluster-Randomized Trial|TASSH|New York University School of Medicine|Yes|Active, not recruiting|May 2012|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Both|40 Years|N/A|No|||April 2015|April 1, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802372||70411|
NCT01773226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSS-11-00|Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)|A Prospective Single-Center Clinical Study of a Single Intra-Articular Injection of Autologous Protein Solution ("APS(TM)") in Patients With Osteoarthritis (OA) of the Knee||Biomet, Inc.|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|40 Years|N/A|No|Non-Probability Sample|patients with OA of the knee who have failed conservative OA|April 2014|July 15, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01773226||72645|
NCT01773239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MH091793-01A1|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)|TARA|Posit Science Corporation|No|Recruiting|May 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01773239||72644|
NCT01773551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/DOD-20128714|Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response|Development of a Quantitative Tissue Optical Index of Breast Density||University of California, Irvine|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|36|||Female|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups of subjects will be recruited:          1. Pre-menopausal women who will receive the chemoprevention drug tamoxifen (treated)          2. Pre-menopausal women who will not receive any chemoprevention drug (control)|February 2016|February 5, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01773551||72620|
NCT01773811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMO-0004|Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD|Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD||University of Mississippi, Oxford|No|Completed|February 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773811||72600|
NCT01774162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022017|EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration|Endoscopic Ultrasound Guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration.||University of Alberta|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|57|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774162||72573|
NCT01774409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFILER|Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|PROFILER|Centre Leon Berard|No|Recruiting|February 2013|March 2019|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|N/A|N/A|No|||March 2015|March 4, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01774409||72554|
NCT01769937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11191966|Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus|A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)|ACTH|Fiechtner, Justus J., M.D., P.C.|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||July 2013|July 22, 2013|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769937||72898|
NCT01770197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090101|Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window|The Feasibility and Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window in China||Wuhan General Hospital of Guangzhou Military Command|Yes|Enrolling by invitation|January 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|40 Years|80 Years|No|Probability Sample|stroke patients in the 3-4.5 hour time window|December 2014|December 9, 2014|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770197|24 Weeks|72878|
NCT01770210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-ATR-EL-34|Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events|A Multicenter, Open-label, 30-week Observational Clinical Study to Examine the Progress of Patients After Leaving the Cardiology Clinic or Unit Due to Acute Cardiovascular Event.|EKVASIS|Elpen Pharmaceutical Co. Inc.|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|670|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on atorvastatin treatment after hospitalization due to cardiovascular events|August 2014|August 18, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01770210||72877|
NCT01770821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-2134|Rehabilitation After Intensive Care|REHABILITATION AFTER INTENSIVE CARE What Effect Does Physiotherapy and Proteinrich Sip Drink Have on Physical Performance, Bodycomposition, Bodyweight and Quality of Life?|REHAB|Haukeland University Hospital|No|Not yet recruiting|February 2013|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|45 Years|N/A|No|||January 2013|March 22, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770821||72830|
NCT01770834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25533|A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis in Routine Practice||Hoffmann-La Roche||Recruiting|April 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis and an inadequate response or        intolerant to previous therapy with conventional DMARDs|March 2016|March 1, 2016|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01770834||72829|
NCT01771094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS/FCNAUP-002|Effect of Sweetness of the Beverage in Thirst Sensation|Effect of Sweetness of the Beverage in Thirst Sensation||Universidade do Porto|No|Completed|February 2012|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771094||72809|
NCT01782820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dexarelax|Influence of a Single Dose Dexamethasone on the Time Course of Neuromuscular Blockade of Rocuronium|||Kreiskrankenhaus Dormagen|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|108|||Female|18 Years|65 Years|No|Non-Probability Sample|patients of a primary care clinic undergoing elective gynecologic abdominal surgery|January 2013|February 1, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782820||71908|
NCT01778790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-13-2319DBS|Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression|Assessment of Efficacy, Safety and Effects on Quality of Life of Deep Brain Stimulation to the Medial Forebrain Bundle in Patients With Treatment Resistant Major Depression (FORESEE II: FOREbrain Stimulation dEprEssion)|FORESEEII|University Hospital, Bonn|Yes|Active, not recruiting|August 2013|August 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|75 Years|No|||August 2014|August 21, 2014|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01778790||72218|
NCT01778803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-101|Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer|A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer||Verastem, Inc.|Yes|Active, not recruiting|January 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|January 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01778803||72217|
NCT01779063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124137-RSG-13-022-01-CPPB|Promoting Adherence to Lymphedema Self-care|Promoting Adherence to Lymphedema Self-care in Breast Cancer Survivors||Vanderbilt University|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01779063||72197|
NCT01779362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISE Adult|RISE Adult Medication Study|Restoring Insulin Secretion Adult Medication Study|RISE Adult|RISE Study Group|Yes|Recruiting|April 2013|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|255|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779362||72174|
NCT01779323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026977|Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling|Prospective Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling||Duke University|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Male|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the urology clinic.|March 2016|March 15, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779323||72177|
NCT01780454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000822|Renal Allograft Tolerance Through Mixed Chimerism|Renal Allograft Tolerance Through Mixed Chimerism||Massachusetts General Hospital|No|Active, not recruiting|March 2013|||October 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01780454||72090|
NCT01780142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130059|Longitudinal Observational Study of Severe Asthma|Longitudinal Observational Study of Severe Asthma||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|October 2032|Anticipated|October 2032|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780142||72114|
NCT01777802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008383|Monitoring Anti-Prostate Cancer Immunity Following Stereotactic Body Radiotherapy (SBRT)|Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)|SBRT|Mayo Clinic|No|Recruiting|January 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Whole Blood|Male|18 Years|N/A|No|Probability Sample|Oligometastatic prostate cancer patients|June 2015|June 25, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777802||72294|
NCT01782378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-014-12S|Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses|Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI|LED Treat GWVI|VA Office of Research and Development|Yes|Recruiting|December 2014|February 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|38 Years|65 Years|No|||February 2016|February 29, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01782378||71942|
NCT01772953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-TREO|Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT|A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation||Center for International Blood and Marrow Transplant Research|Yes|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|21 Years|No|||September 2015|September 15, 2015|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772953||72666|
NCT01773538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHECRT|Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement|Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement||Hospital of South West Jutland|Yes|Completed|January 2013|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01773538||72621|
NCT01773850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC-1232|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions|Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions.||UNC Lineberger Comprehensive Cancer Center|No|Recruiting|January 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Patients undergoing surgical breast biopsies for lesions detected on mammograms.|January 2016|January 19, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01773850||72597|
NCT01773863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACCE and CAP|MACCE in Hospitalized Patients With Community-acquired Pneumonia|Major Adverse Cardiac and Cerebrovascular Events in Hospitalized Patients With Community-acquired Pneumonia||University of Roma La Sapienza|Yes|Recruiting|October 2011|October 2014|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Plasma, serum and urine samples|Both|18 Years|95 Years|No|Non-Probability Sample|Patients hospitalized for community-acquired pneumonia|January 2013|January 22, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773863||72596|
NCT01774149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1939 (REK)|Model Driven Diabetes Care|Data Driven Feedback as a Method to Improve Glycaemic Control in Type 1 Diabetes|MDDC|University Hospital of North Norway|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|January 11, 2013||No||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01774149||72574|
NCT01769950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Choline-Prostate-1|Choline-PET for Evaluating the Incidence of Nodal Metastases Among Newly Diagnosed Patients of Prostate Cancer|Evaluation of the Incidence of Choline-PET Detected Nodal Metastases Among Newly Diagnosed Prostate Cancer Patients With Presumed Absence of Nodal and Distant Metastases.|ChoPEN|Bangalore Institute of Oncology|Yes|Recruiting|January 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Male|N/A|N/A|No|||January 2013|January 15, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769950||72897|
NCT01770223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3034-113|A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)|An Open Label Study Assessing SVR and Viral Resistance Profile With Boceprevir Plus PEG-IFN Plus Ribavirin Triple Therapy in HCV-1 Infected Patients With Insulin Resistance Who Have Failed PEG-IFN Plus Ribavirin Dual Therapy||Merck Sharp & Dohme Corp.|No|Withdrawn|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01770223||72876|
NCT01770236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-12-12-001|Pain Control After Minimally Invasive Coronary Artery Bypass Grafting|Optimal Method of Pain Control After Minimally Invasive Coronary Artery Bypass Grafting||Gundersen Lutheran Medical Foundation|No|Enrolling by invitation|January 2013|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|90 Years|No|||September 2015|September 4, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01770236||72875|
NCT01770249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-10|Evaluation of a Novel Endoscopic Treatment for Achalasia|Evaluation of a Novel Endoscopic Treatment for Achalasia: Per-oral Endoscopic Esophagomyotomy (POEM)|POEM|University Hospital Case Medical Center|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 16, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770249||72874|
NCT01770496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01IP000088-01|Age-Specific Strategies for Immunization Reminders and Recalls|||University of Michigan|No|Completed|October 2007|September 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|10175|||Both|7 Months|19 Months|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770496||72855|
NCT01771653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOI-SIUSOM-12-002|Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection|Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection||Southern Illinois University|No|Completed|September 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Both|18 Years|64 Years|No|Non-Probability Sample|Population of adults aged 18-64 years, diagnosed with HCV genotype 1, with an HCV RNA        >100,000. They should have had a liver biopsy within 5 years before enrollment. Lab work        to determine eligibility includes an absolute neutrophil count of at least 1200 per cubic        millimeter, a platelet count of at least 90,000 per cubic millimeter and a hemoglobin        level of at least 12 g per deciliter|January 2016|January 15, 2016|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01771653||72766|
NCT01771926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC024|Lifestyle Modification and Potato Consumption|Lifestyle Modification and Potato Consumption||USDA Grand Forks Human Nutrition Research Center|Yes|Active, not recruiting|February 2013|September 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01771926||72745|
NCT01782833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOA-1201n|Pletaal SR Post Marketing Observational Study|A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal® SR Capsule|PLT SR PMOS|Korea Otsuka Pharmaceutical Co.,Ltd.||Not yet recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Probability Sample|The patient who has below indication (1. Treatment of ischemic symptoms including        ulceration, pain and coldness in chronic arterial occlusion (Berger's disease,        arteriosclerosis obliterans, diabetic peripheral angiopathy). 2. Prevention of recurrence        of cerebral infarction (excluding cardiogenic cerebral embolism).)|January 2013|January 31, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782833||71907|
NCT01779076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012 / 539|Oxygen Level and Safe Emergence From Anesthesia|Emergence From General Anesthesia With Laryngeal Mask Airway and Increased End-expiratory Pressure Using 30% Oxygen is as Safe as With 100% Oxygen But Reduces the Area of Post Operative Atelectasis.||Landstinget Västmanland|No|Completed|February 2013|||June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|59|||Both|30 Years|85 Years|No|||June 2013|June 24, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779076||72196|
NCT01779089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013400|Minocycline and Proteinuria in Diabetic Nephropathy|The Safety and Efficacy of Minocycline as an Anti-Proteinuric in Diabetic Nephropathy||Los Angeles Biomedical Research Institute|Yes|Active, not recruiting|February 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779089||72195|
NCT01779375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISE Pediatric|RISE Pediatric Medication Study|Restoring Insulin Secretion Pediatric Medication Study|RISE Peds|RISE Study Group|Yes|Recruiting|April 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01779375||72173|
NCT01779401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-4003-03|Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients|Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.|CREATIVE|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Active, not recruiting|September 2012|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1050|||Both|18 Years|75 Years|No|||August 2015|January 27, 2016|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01779401||72171|
NCT01779336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL225B/71/11|Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors|An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.||Piramal Enterprises Limited|No|Suspended|December 2012|December 2014|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|90 Years|No|||September 2014|September 26, 2014|January 28, 2013|No|Yes|Sponsor decision not related to patient safety|No||https://clinicaltrials.gov/show/NCT01779336||72176|
NCT01779349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM - 005|Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter"|Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" With Correlation to Pressure Flow Study and Uroflowmetry.||P. Square Medical Ltd|Yes|Suspended|July 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Male|18 Years|N/A|No|||October 2014|October 30, 2014|January 28, 2013||No|sensor calibration and other R&D activities|No||https://clinicaltrials.gov/show/NCT01779349||72175|
NCT01777269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116115|Prospective Sexual Function Study for BPH Subjects|A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH||GlaxoSmithKline|No|Recruiting|February 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|476|||Male|50 Years|N/A|No|||February 2016|February 25, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777269||72334|
NCT01780727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-12-FB|Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery|Echocardiography-guided Hemodynamic (EGHEM) Management Strategy to Improve Clinical Outcomes for Elderly Patients With Left Ventricular Diastolic Dysfunction (LVDD) Undergoing Non-cardiac Surgery||University of Nebraska|Yes|Active, not recruiting|September 2014|January 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|70 Years|N/A|No|||November 2015|November 30, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01780727||72069|
NCT01780961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101765|Esophageal Cancer Tissue Banking|Prospective Collection of Health Information and Biospecimens in Esophageal Cancer|ESBX|Washington University School of Medicine|No|Recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|peripheral blood and Esophageal Tissue|Both|18 Years|N/A|No|Probability Sample|Subjects will be identified by participating staff in the clinics of the surgical oncology        or medical oncology clinics, and patients referred to the endoscopy center, and provided        information about the biorepository.|January 2013|January 29, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01780961|5 Years|72051|
NCT01782625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036937|Hypercapnia: Cognitive Effects and Monitoring|Hypercapnia: Cognitive Effects and Monitoring||Duke University|No|Recruiting|January 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|50|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01782625||71923|
NCT01772966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122008|Chiropractic Manual Therapy and Neck Pain|Generalizing a Valid Control Manipulation to a Multiple Operator, Longitudinal Randomized Controlled Study for Chronic Neck Pain||Canadian Memorial Chiropractic College|Yes|Not yet recruiting|February 2013|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|372|||Both|21 Years|60 Years|No|||January 2013|January 17, 2013|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01772966||72665|
NCT01773252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-0005|Right to Left Cardiac Shunt Detection|A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound|PFO Detection|Cardiox Corporation|No|Terminated|November 2012|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|141|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|January 8, 2013|Yes|Yes|Business decision to perform a market withdrawal of the product|No||https://clinicaltrials.gov/show/NCT01773252||72643|
NCT01773265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSI BGS Version Dec. 2012|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2013|||||N/A|N/A|N/A||||||||||||||January 25, 2016|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773265||72642|
NCT01773525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTS-2_LS|Testing NOTSSdk in the Clinical Setting|||Herlev Hospital|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Trainee surgeons in one surgical department|August 2013|August 23, 2013|January 14, 2013||||No||https://clinicaltrials.gov/show/NCT01773525||72622|
NCT01773278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-410|Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)|Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)||University of Colorado, Denver|No|Recruiting|December 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|65 Years|No|||January 2016|January 27, 2016|December 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01773278||72641|
NCT01773876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1126|Empirical Antifungal Treatment in ICUS|Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial|EMPIRICUS|University Hospital, Grenoble|Yes|Completed|July 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01773876||72595|
NCT01773889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090233H|A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer|A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, or Fallopian Tube Carcinoma Failing Ineligible for First-Line Therapy (OCR 09-01)||The University of Texas Health Science Center at San Antonio|Yes|Terminated|June 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||May 2013|May 8, 2013|January 14, 2013|Yes|Yes|Lack of funding|No|May 8, 2013|https://clinicaltrials.gov/show/NCT01773889||72594|
NCT01773902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PfP3.2|Protein for Premies|High Versus Standard Dose Protein for Very Preterm Infants||University Hospital Tuebingen|No|Active, not recruiting|October 2012|July 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|N/A|7 Days|No|||January 2015|January 19, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773902||72593|
NCT01773837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METILAS|Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients|Double-blind, Placebo-controlled, Multicenter Randomized Clinical Trial to Evaluate Short-term Efficacy of Palliative Treatment With Methylphenidate in Asthenia in Advanced Cancer Patients||Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|January 2012|||July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01773837||72598|
NCT01769963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F111220003|Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease|Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease||University of Alabama at Birmingham|No|Completed|April 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|19 Years|N/A|No|||March 2014|March 28, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769963||72896|
NCT01770262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVitamin-HMO-CTIL|Development of Non-invasive Method for Quantifying Vitamin D Levels in the Body Using Spectroscopy|||Hadassah Medical Organization||Withdrawn|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|0|Samples Without DNA|Blood samples for quantification of vitamin D levels|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|40 subjects aged 18 years and above will be recruited for this research: 20 patients be        recruited from the population of patients in the rehabilitation department who were        diagnosed with osteoporosis. Also, we will recruit 20 healthy subjects.        All participants will be able to understand the study protocol and sign a consent form        independently.|December 2012|January 4, 2016|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01770262||72873|
NCT01770275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UICC-VII-EC|UICC Classification of Esophageal Cancer|An Attempt at Validation of the Seventh Edition of the Classification by the International Union Against Cancer for Esophageal Carcinoma||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|605|||Both|18 Years|N/A|No|Probability Sample|The University-Hospital Hamburg-Eppendorf is a specialist reference centre for the        treatment of patients with esophageal carcinoma in Germany. A prospective database for all        patients with surgically resectable esophageal carcinoma was established in 1992 at the        Department for General, Visceral and Thoracic Surgery at the University Hospital        Hamburg-Eppendorf, Germany. Only patients without perioperative chemotherapy and        histologically proven esophageal cancer were included into this study.|November 2014|November 17, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770275||72872|
NCT01770509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA -11- 9204-SG-CTIL|The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study|A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer||M.D. Lederman Consulting Ltd|No|Not yet recruiting|February 2013|February 2015|Anticipated|February 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||January 2013|January 15, 2013|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01770509||72854|
NCT01771939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTCMER2|Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes|Morphologic and Functional Results After Phacoemulsification and 25 Gauge Vitrectomy Versus Phacoemulsification Only in Eyes Affected by Idiopathic Epiretinal Membranes||University of Turin, Italy|Yes|Completed|October 2006|July 2012|Actual|November 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|80 Years|No|||January 2013|January 16, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01771939||72744|
NCT01771952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14386|Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia|Prospective, Randomized, Double Blind Evaluation of the Efficacy of a Single Dose of Synvisc-One® (6.0 cc) for the Treatment of Patellofemoral Chondromalacia||University of Virginia|No|Recruiting|March 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|45 Years|No|||December 2014|December 4, 2014|May 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771952||72743|
NCT01771965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-298|Increasing Treatment Seeking Among Suicidal Veterans Calling the Crisis Line|Increasing Treatment Seeking Among Suicidal Veterans Calling the Crisis Line||VA Office of Research and Development|No|Active, not recruiting|October 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01771965||72742|
NCT01782846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/45|Trama-Code (Two Analgesics-comparative Study)|Double Blind-randomized Study Comparing the Efficacy of Two Analgesia (Ixprim® and Dafalgan-Codeine®) , in the Emergency Unit.|Trama-Code|Hopital Foch||Recruiting|March 2011|||April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study|2||Anticipated|800|||Both|18 Years|75 Years|No|||January 2013|January 31, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01782846||71906|
NCT01778816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RossoAchilles|Calf Muscle Atrophy After Achilles Tendon Rupture. A Clinical-Radiological-Biomechanical Multicenter Study.|||University Hospital, Basel, Switzerland|No|Completed|January 2009|December 2011|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|52|||Both|20 Years|65 Years|No|Probability Sample|-  Age 20-65 years          -  BMI < 40          -  no injury to leg          -  no injury on contralateral leg|January 2013|January 25, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778816||72216|
NCT01779102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-07|Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses|A Phase II/III Trial Investigating if Concomitant Injections of the Diagnostic Agents C-Tb and 2 T.U Tuberculin PPD RT 23 SSI Affect the Induration Responses in Combination With a Safety Assessment of C-Tb|TESEC-07|Statens Serum Institut|Yes|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|456|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01779102||72194|
NCT01779388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01201|Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules|Role of Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules of Indeterminate Nature. A Prospective Study by the European Lung Cancer Working Party.||European Lung Cancer Working Party|No|Recruiting|January 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01779388||72172|
NCT01779648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPCDVT|Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis|The Influence of the Different Ways of Pneumatic Compression on Clinical and Physiologic Efficacies in Preventing Deep Vein Thrombosis: a Randomised Comparative Study||Seoul National University Hospital|Yes|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|54|||Both|N/A|N/A|No|||April 2013|April 24, 2013|January 27, 2013||No||No|February 23, 2013|https://clinicaltrials.gov/show/NCT01779648||72152|
NCT01779635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB 2012/02222|Efficacy and Safety of Heparin-grafted Membrane for CRRT|Continuous Renal Replacement Therapy With Anticoagulation-free Regimen in Bleeding-risk Patients Using oXiris Membrane - CARROM Study|CARROM|National University Hospital, Singapore|Yes|Not yet recruiting|March 2013|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|21 Years|N/A|No|||January 2013|January 29, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01779635||72153|
NCT01781585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107015RC|The Hemodynamic Effects During Sustained Low-efficiency Dialysis Versus Continuous Veno-venous Hemofiltration for Patients With Intracranial Hypertension in a Cross Over Study|The Hemodynamic Effects During Sustained Low-efficiency Dialysis Versus Continuous Veno-venous Hemofiltration for Patients With Intracranial Hypertension in a Cross Over Study (NSARF)|NSARF|National Taiwan University Hospital|No|Withdrawn|August 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|The inclusion criteria were end stage renal disease (ESRD) patients with increased ICP        status post ICP monitor insertion|April 2014|April 11, 2014|September 17, 2012||No|Inclusion criteria difficulties to receive the case, it is taken off the case to apply|No||https://clinicaltrials.gov/show/NCT01781585||72003|
NCT01777555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-003|Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)||Acorda Therapeutics|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|30 Years|80 Years|No|||May 2015|May 4, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777555||72313|
NCT01777568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-891|Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project|||The Cleveland Clinic|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|5017|||Both|18 Years|80 Years|No|Non-Probability Sample|adult colorectal surgical patients|May 2015|May 15, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01777568||72312|
NCT01772979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO15|Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer|Phase II Study With Trabectedin (Yondelis®) in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Advanced Ovarian Cancer Patients|MITO15|Catholic University of the Sacred Heart|Yes|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||December 2012|January 17, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01772979||72664|
NCT01772680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-071|Zinc and Diabetes in Patients With Thalassemia: a Pilot Study|Zinc and Diabetes in Patients With Thalassemia: a Pilot Study||Children's Hospital & Research Center Oakland|Yes|Completed|November 2012|May 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|12 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772680||72687|
NCT01772992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065111|CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence|CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence|CVCTPLUS|University of Michigan|Yes|Recruiting|June 2014|June 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|3360|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772992||72663|
NCT01773291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8B1211|Adjuvant Acupuncture for Severe Head Injury|Adjuvant Acupuncture Therapy in Patients With Severe Head Injury: a Randomized Controlled Trial||Chang Gung Memorial Hospital|Yes|Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|12 Years|70 Years|No|||July 2015|December 22, 2015|January 11, 2013||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01773291||72640|Inclusion criteria leading to small numbers (24/583 in 2.5 years) of subjects analyzed.
NCT01773564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12SC03|Comparison of Two New Generation Dressings in Intensive Care (ADVANCED)|Comparison Between Two Types of Semipermeable Dressings of New Generation in the Prevention of Intravascular Catheters Related Complications in Intensive Care.|ADVANCED|University Hospital, Grenoble|Yes|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|629|||Both|18 Years|N/A|No|Probability Sample|Patients in Intensive Care Unit requiring at least one intravascular device.|December 2014|December 5, 2014|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01773564||72619|
NCT01773928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|721104|Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)|Randomized, Age-stratified, Double Blind, Controlled Phase 3 Study Comparing a Vero Cell-derived Trivalent Seasonal Influenza Vaccine Made by the Modified Manufacturing Process With Vaccine Made by the Current Manufacturing Process and a Licensed Trivalent Influenza Vaccine in Healthy Adults Aged 18 Years and Older||Baxter Healthcare Corporation|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Actual|1928|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 27, 2014|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773928||72591|
NCT01773941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spineology_62-088|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2013|||||N/A|N/A|N/A||||||||||||||June 2, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773941||72590|
NCT01774201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-260361|Respiratory Function and Walking Capacity in Multiple Sclerosis|Respiratory Function and Walking Capacity in Multiple Sclerosis||University Hospital Orebro||Active, not recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||January 2013|January 22, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774201||72570|
NCT01774175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOLPREPICOLYTE|Comparison Between Coolprep and Picolyte for Bowel Cleansing|A Randomised Controlled Trial of a 2 Litre Polyethylene Glycol Solution + Ascorbic Acid Versus Sodium Picosulphate + Magnesium Citrate Solution for Bowel Cleansing Prior to Colonoscopy||Gachon University Gil Medical Center|No|Enrolling by invitation|January 2013|March 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|19 Years|80 Years|No|Probability Sample|This study will include a total of 250 patients. All patient randomized PEG+ascorbica        acid(coolprep) and picosulfate magnesium citrate(picolyte), each group will include 125        patients.        The investigators decided sample size to 200 patients after comparing Ottawa scale. The        investigators assumed there would be defference about 20 percent of bowel preparation        between them. Recently, Ottawa scale of bowel preparation reported about 5 points. The        investigators assumed that there could be differences between them about 1 point. The        investigators decided each groups per 100 patients, if significance level was 0.05 and        test power is 80 percent. The investigators start this study with a total of 220 patients        because 10 percent of 200 patients could be drop out. The investigators readjust about 30        patients after interim analysis.|January 2013|January 23, 2013|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01774175||72572|
NCT01770288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-12|Psychophysical Aspects of Maximal Anaerobic Performance|Psychophysical Aspects of Maximal Anaerobic Performance||Hillel Yaffe Medical Center||Not yet recruiting|February 2013|April 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01770288||72871|
NCT01770847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12\SS\0088|Arterial Stiffness in Chronic Kidney Disease|Diurnal Variations in Arterial Stiffness in Patients With Chronic Kidney Disease and Healthy Age Matched Controls||University of Edinburgh|Yes|Recruiting|November 2012|||December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential patients will be identified from renal clinics at the Royal Infirmary and        Western General Hospital. Suitable participants will initially be identified by a member        of the direct healthcare team.        Healthy volunteers will be indentified through the Clinical Research Centre community        database and poster advertising at the University of Edinburgh.|March 2013|March 4, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01770847||72828|
NCT01771107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00046|Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma|A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma||National Cancer Institute (NCI)|No|Recruiting|March 2013|||June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|March 4, 2016|January 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771107||72808|
NCT01771419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H San Paolo|Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct|||Hospital San Paolo|Yes|Recruiting|October 2010|January 2014|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771419||72784|
NCT01771432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS11-1540|Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria|Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria. A Prospective Randomized Study.|BAC01|Hospital Universitari de Bellvitge|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|85 Years|No|||June 2015|June 19, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771432||72783|
NCT01771679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM 102-M|Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging|A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging||Stemedica Cell Technologies, Inc.|Yes|Recruiting|July 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|January 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771679||72764|
NCT01772264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291018|Safety And Tolerability Study Of BID Titration Scheme With PF-05089771|An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-05089771 In Healthy Subjects||Pfizer|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772264||72719|
NCT01778829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sa10i20033|Non Invasive Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants.|Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network.|VNINS|Pontificia Universidad Catolica de Chile|Yes|Recruiting|December 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|N/A|14 Days|No|||January 2013|January 28, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778829||72215|
NCT01776489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/2011|Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy|The Role of Sphingosine-1-phosphate in Food Allergy - Biomarker for Disease Severity and Anaphylaxis Outcome||Medical University of Vienna|No|Recruiting|December 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|whole blood, serum|Both|12 Months|17 Years|No|Non-Probability Sample|Children (age 1-17 years) being in medical care at the allergy clinic of the Department of        Pediatrics and Adolescent Medicine of the Medical University of Vienna for food related        immediate type symptoms (nausea, abdominal pain, vomiting, diarrhea or local symptoms like        burning, swelling, itching and erythema) immediately after ingestion of food compounds        will be enrolled in this study.|December 2015|December 9, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01776489||72394|
NCT01776762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.B01.2012|Nutritional Intervention in a Cross-sector Model for the Rehabilitation of Geriatric Patients|Effect of Nutritional Intervention in a Cross-sector Model for the Rehabilitation of Undernourished Geriatric Medical Patients: a Randomized Controlled Trial.||Copenhagen University Hospital at Herlev|Yes|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776762||72373|
NCT01779895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.18.MET|Probiotic Administration and Perennial Allergic Rhinitis|Effect of Probiotic Lactobacillus Paracasei NCC2461 on House Dust Mite Allergy||Nestlé|No|Completed|December 2012|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|20 Years|65 Years|No|||April 2014|April 8, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01779895||72133|
NCT01781858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scope-001|Study on the Clinical Course Of Pulmonary Embolism|Study on the Clinical Course Of Pulmonary Embolism|SCOPE|University of Padua|No|Completed|January 2008|July 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|||Both|18 Years|N/A|No|Probability Sample|Consecutive outpatients or inpatients with an objective diagnosis of first acute PE        episode.|January 2015|January 4, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01781858||71982|
NCT01781845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00064524|Hydronephrosis ARFI Study|Evaluation of Ultrasound Acoustic Radiation Force Impulse (ARFI)Shear Wave Velocity Imaging (SVI)in the Characterization of Pediatric Hydronephrosis||University of Michigan|Yes|Completed|November 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|N/A|18 Years|No|||May 2015|May 29, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01781845||71983|
NCT01782105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-CHANGE|Intervention to Promote Changes of Healthy Lifestyle (Physical Activity and Nutrition) During Gestation|Intervention en Changement Des Habitudes de Vie Par l'Activité Physique et un Support Nutritionnel Durant la Grossesse en Estrie||Université de Sherbrooke|Yes|Completed|December 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Female|18 Years|N/A|No|||December 2013|December 10, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01782105||71963|
NCT01772693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD001|ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease.||InSightec|No|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|30 Years|N/A|No|||February 2016|February 23, 2016|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772693||72686|
NCT01772719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-HEM-11-003|Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid|Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid||James Graham Brown Cancer Center|Yes|Recruiting|August 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772719||72684|
NCT01773005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-001-12|Caldolor Versus Caldolor Plus OFIRMEV in Total Knee or Hip Arthroplasty Surgeries|A Single Center, Randomized, Open-Label Trial to Compare the Safety and Efficacy of Caldolor Used Singly and in Combination With Ofirmev in Total Knee or Hip Arthroplasty Surgery Patients||Hahnemann University Hospital|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|78|||Both|18 Years|70 Years|No|||February 2016|February 26, 2016|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01773005||72662|
NCT01785342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECAMP-1|DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules|Detection of Early Lung Cancer Among Military Personnel Study 1 (DECAMP-1): Diagnosis and Surveillance of Indeterminate Pulmonary Nodules||Boston University|Yes|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood, Urine, Sputum, Nasal brushing, Buccal scraping, Bronchial Biopsy, Bronchial brushing,      lung tissue|Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Military personnel|November 2015|November 24, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785342||71714|
NCT01783301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/QD-CGRH-NCKH&DT|Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study|A Phase IV, Open-label 2 Arm Trial to Compare the Efficacy and Safety of a Pre-defined Dose of GONAL-f® Based on Antral Follicle Count [Follicles ≥2mm - <11mm]), or AMH for Ovarian Stimulation in Subjects Undergoing Assisted Reproductive Technology (ART) Treatment.||Vietnam National University|No|Completed|October 2011|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Female|20 Years|45 Years|No|||January 2013|January 31, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01783301||71871|
NCT01783795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006442|Dent Disease Mutation Genotyping|Screening for Dent Disease Mutations in Patients With Proteinuria||Mayo Clinic|Yes|Completed|August 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|602|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 19, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01783795||71833|
NCT01783015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801355|Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate|A Randomized, Double-blind, Placebo-controlled Study Of The Safety And Efficacy Of Etanercept In Subjects With Rheumatoid Arthritis Who Have Had An Inadequate Response To Adalimumab Or Infliximab Plus Methotrexate|SERUM|Pfizer|No|Terminated|September 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|79 Years|No|||December 2015|December 1, 2015|January 31, 2013|Yes|Yes|This study was prematurely terminated on June 25, 2014 due to lack of enrollment.|No|May 12, 2015|https://clinicaltrials.gov/show/NCT01783015||71893|This study was prematurely terminated on June 25, 2014. This termination was due to delays in achieving the enrolment target and not due to any safety concerns. No statistical analyses were done since there were a small number of participants.
NCT01784341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47709|Circadian Phase in Bipolar Depression: Is it Delayed and Does it Normalize With Remission?|Circadian Phase in Bipolar Depression: Is it Delayed and Does it Normalize With Remission?||Northwestern University|No|Active, not recruiting|August 2011|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Saliva Samples|Both|18 Years|55 Years|No|Non-Probability Sample|Adults between 18 and 55 who are currently diagnosed with Bipolar Disorder.|October 2015|October 21, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01784341|6 Months|71791|
NCT01784354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062868|Acupressure for the Treatment of Raynaud's Phenomenon|Acupressure in Raynaud's Phenomenon- A Pilot Study.||University of Michigan||Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01784354||71790|
NCT01784315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCAPES|Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria|PARASITIC CLEARANCE AND RECURRENCE RATES AMONG PATIENTS WITH VIVAX MALARIA ON CHLOROQUINE AND PRIMAQUINE THERAPY|BCAPES|Ministry of Health, Bhutan|No|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Filter blot paper will be retained to study the whole genome of P.vivax malaria in Bhutan.|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with P.vivax infections from 6 sentinel sites reported to health facility will be        recruited for the study after getting the consent signed.|November 2013|November 21, 2013|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01784315|12 Months|71793|
NCT01784328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013|Peristeen Bowel Irrigation System in Cauda Equina|The Use of the Peristeen Bowel Irrigation System for People With Cauda Equina Syndrome||University of Manitoba|No|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784328||71792|
NCT01785407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2012-N-44|Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation|Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation||Swiss Federal Institute of Technology|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|25|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785407||71709|
NCT01785420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH Project-982|Pre Operative Trastuzumab in Operable Breast Cancer|A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer||Tata Memorial Hospital|No|Recruiting|May 2013|February 2021|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1100|||Female|18 Years|80 Years|No|||November 2015|November 24, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785420||71708|
NCT01785173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB101-85|Endoscopic-guided Versus Cotton-tipped Applicator Gauze Pledgetting for Nasal Anesthesia Before Transnasal Endoscopy|A Randomized Study Comparing Endoscopic-guided Gauze Pledgetting and Cotton-tipped Applicator Packing for Nasal Anesthesia Before Transnasal Endoscopy||Buddhist Tzu Chi General Hospital|No|Recruiting|October 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|242|||Both|18 Years|65 Years|No|||February 2013|February 6, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785173||71727|
NCT01785186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PanACEA-MAMS-TB-01|Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design|A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis||Ludwig-Maximilians - University of Munich|Yes|Completed|April 2013|March 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|365|||Both|18 Years|N/A|No|||September 2015|March 10, 2016|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785186||71726|
NCT01785693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-129|Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream|Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream.|BLOC-FEMPOP|University Hospital, Clermont-Ferrand||Not yet recruiting|February 2013|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||February 2013|February 5, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01785693||71687|
NCT01772537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00067716|The Effects of Anethesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.|The Effect of Anesthesia on Potential CSF and Serum Markers of Alzheimer's Disease.||Johns Hopkins University|No|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|20|||Both|21 Years|N/A|No|||January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772537||72698|
NCT01773161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03210|Cerebral Palsy Hip Health Related Quality of Life|Health Related Quality of Life in Patients With Cerebral Palsy Undergoing Surgery for Dislocating Hips||University of British Columbia|No|Recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|4 Years|18 Years|No|Non-Probability Sample|Children with cerebral palsy who are undergoing surgery for hip subluxation/dislocation at        BC Children's Hospital|July 2015|July 16, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01773161||72650|
NCT01773408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28679|A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia|A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)||Hoffmann-La Roche||Active, not recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|122|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773408||72631|
NCT01773109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18512|Etirinotecan Pegol (NKTR-102) in NSCLC|Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|January 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|37|||Both|N/A|N/A|No|||October 2015|October 21, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773109||72654|
NCT01773122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-004|Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris|||Allergan|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|77|||Both|16 Years|35 Years|No|||February 2014|February 11, 2014|January 18, 2013|Yes|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01773122||72653|
NCT01774045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phase I study of PDC-1421|A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression|A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers||BioLite, Inc.|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|30|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|January 20, 2013|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01774045||72582|
NCT01774318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-01-2012|Early Development of Sleep-wake Cycles in Premature Infants and Its Impact on Neurodevelopmental Outcome|Early Development of Sleep-wake Cycles in Premature Infants and Its Impact on Neurodevelopmental Outcome|SWC|Medical University of Vienna|No|Recruiting|February 2012|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|23 Weeks|29 Weeks|No|||January 2013|January 20, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01774318||72561|
NCT01770106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2011.510|RA Denosumab on Bone Microstructure Study|Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial||Chinese University of Hong Kong|Yes|Completed|December 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|80 Years|No|||September 2014|September 10, 2014|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770106||72885|
NCT01771744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Revisional Limmi 1|Revisional Versus Primary Roux-en-Y Gastric Bypass: a Case Matched Analysis|Revisional Versus Primary Roux-en-Y Gastric Bypass: a Case Matched Analysis||University Hospital, Basel, Switzerland|No|Completed|January 2000|January 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|96|||Both|18 Years|65 Years|No|Non-Probability Sample|morbidly obese patients|January 2013|January 16, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771744||72759|
NCT01786993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60029161/D|MultiPoint Pacing IDE Study|MultiPoint Pacing IDE Study|MPP IDE|St. Jude Medical|No|Active, not recruiting|April 2013|||April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|506|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786993||71587|
NCT01786395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF-021-C003|Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa|Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period||R-Tech Ueno, Ltd.|No|Terminated|March 2013|||April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|20 Years|70 Years|No|||March 2013|January 27, 2016|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01786395||71633|
NCT01786408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-P001|A Study to Compare Analytes in Blood Collected Using an Investigational Collection Device With a Commercial Predicate|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System||Seventh Sense Biosystems|No|Withdrawn|March 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|November 24, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786408||71632|
NCT01783535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRET6|Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma|Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma||St. Jude Children's Research Hospital|No|Recruiting|June 2013|June 2022|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|155|||Both|N/A|N/A|No|||October 2015|October 26, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783535||71853|
NCT01783548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-306|Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR||Teva Pharmaceutical Industries|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|547|||Both|4 Years|11 Years|No|||September 2015|September 11, 2015|January 31, 2013|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01783548||71852|
NCT01783808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ambox-2012-MEUP|Intervention Study to Investigate Supplemental Oxygen in COPD|Effects on Exercise Capacity, Physical Activity and Quality of Life Using Ambulatory Oxygen in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Desaturate Only During Exercise||Uppsala University|No|Recruiting|November 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01783808||71832|
NCT01784081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1270|Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer|iPC3 - Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer|iPC3|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic pancreas cancer.|April 2014|April 8, 2014|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01784081||71811|
NCT01784640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-05|Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer|A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|January 2014|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01784640||71768|
NCT01784614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12662|A Study of LY2624803 in Japanese Participants With Transient Insomnia|Pharmacodynamics and Pharmacokinetics of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Japanese Subjects||Eli Lilly and Company|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|24|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|February 4, 2013|No|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT01784614||71770|
NCT01784627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JK R01 PA-12-031|Trial of Computerized SBI to Reduce Teen Alcohol Use|Randomized Controlled Trial of Computerized SBI to Reduce Teen Alcohol Use||Children's Hospital Boston|No|Not yet recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2500|||Both|12 Years|18 Years|No|||February 2013|February 5, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784627||71769|
NCT01784926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1981|Late Dislocation of Intraocular Lens (IOL) Following Cataract Surgery: an Evaluation of Two Different Surgical Methods|||Oslo University Hospital|No|Recruiting|January 2013|December 2020|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||February 2013|February 18, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01784926||71746|
NCT01785199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWB-C-008|Effects of Head Elevation by a Bed on Sleep-disordered Breathing|Effects of Head Elevation by an Adjustable Bed on Sleep-disordered Breathing||Mackay Memorial Hospital|Yes|Recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01785199||71725|
NCT01785459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-001|Bupivacaine for Benign Headache in the ED|Treatment of Benign Headache in the Emergency Department Population With Lower Cervical Paraspinous Bupivacaine Injections Versus Anti-Emetic Treatment in the Emergency Department Population: Randomized Prospective Control Trial||Carolinas Healthcare System|No|Recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|February 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785459||71705|
NCT01756534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-ZG-AA-0633-CTIL|Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study|The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study||Tel-Aviv Sourasky Medical Center|Yes|Active, not recruiting|January 2011|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2012|December 26, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756534||73926|
NCT01773135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mai-01110333535|Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor|Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor|PTL|Ain Shams Maternity Hospital|Yes|Completed|January 2013|January 2014|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|262|Samples Without DNA|serum|Female|17 Years|35 Years|No|Probability Sample|pregnant women aged between 17 and 35 years with singleton pregnancies between 28 and 36        completed weeks of gestation that had been diagnosed with threatened preterm labor|February 2014|February 21, 2014|January 15, 2013||No||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01773135|9 Weeks|72652|It's the different time of day that blood sampling was carried out, although this reflects normal clinical practice, blood samples were collected at the time of admission to hospital regardless of the time of day, rather than diurnal pattern of ACTH.
NCT01773148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-03773|Access Safety and Efficacy Post Endovascular Intervention|AXERA Access Safety and Efficacy Post Endovascular INtervention|ASPEN|Arstasis, Inc.|Yes|Active, not recruiting|December 2012|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773148||72651|
NCT01774331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS1-12-001|Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)|Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)|GOOD-SHEPARD|AxelaCare Health Solutions, LLC|No|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1500|||Both|7 Years|N/A|No|Probability Sample|Any patient who is aged 7 years or greater at time of enrollment; who is on Ig therapy,        have been on or is between doses of Ig therapy, or is being considered to be prescribed Ig        therapy; provides informed consent for participation; and who has been determined to be        clinically eligible for infusion services by AxelaCare Health Solutions, LLC, in        collaboration with the patient's prescribing physician. Subjects will be recruited from        the practices of participating physicians.|May 2015|May 15, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774331||72560|
NCT01773707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abatacept (IND)|CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1|CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|March 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|206|||Both|6 Years|45 Years|No|||February 2016|February 18, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773707||72608|
NCT01773720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UncalPCA-vs-TPTD|Reliability of Cardiac Output Monitoring Based on Uncalibrated Pulse Contour Analysis|Evaluation of Reliability of Cardiac Output Monitoring Based on Uncalibrated Pulse Contour Analysis During Off-pump Coronary Artery Bypass Grafting||Northern State Medical University|No|Recruiting|October 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|None Retained|No biospecimens are to be retained.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with coronary artery disease, ranked ASA II-III and scheduled for elective        off-pump coronary artery bypass grafting|January 2013|January 18, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01773720||72607|
NCT01770678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sophieis17|A Trial Comparing Two Methods of CIMT in the Hemiplegic Child|Randomised Controlled Trial to Compare Two Methods of Constraint Induced Movement Therapy to Improve Functional Ability in the Affected Upper Limb in Pre-school Children With Hemiplegic Cerebral Palsy|HCPCIMT|University of Birmingham|No|Completed|August 2010|||April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Months|4 Years|No|||June 2012|January 17, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01770678||72841|
NCT01770691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPI 004|Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence|Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence||Assuta Hospital Systems|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|60 Years|No|||January 2015|January 15, 2015|January 16, 2013||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01770691||72840|
NCT01770704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NCN-XXX-2012/1|Observation Study of the Clinical Management of Bipolar Disorder|Chinese Observation Study of the Clinical Management of Bipolar Disorder||AstraZeneca|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|520|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with bipolar disorder I or II with at least one mood event during the 3        and 12 months prior to the beginning of the study.|July 2015|July 3, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01770704||72839|
NCT01770964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPMF-0007-2012|Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy|Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN)||Analgesic Solutions|No|Recruiting|December 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|90|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770964||72819|
NCT01770977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 0327.0.135.000-11|Effects of Phototherapy by Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical and Biomechanical of Muscle Performance in Athletes|Effects of Phototherapy by Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical and Biomechanical of Muscle Performance in Athletes||Universidade Federal de Sao Carlos|Yes|Completed|May 2012|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Male|14 Years|28 Years|Accepts Healthy Volunteers|||September 2012|January 15, 2013|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01770977||72818|
NCT01783041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07-234|Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants|A Double-Blind, Controlled, Randomized Clinical Trial of the Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants||Montefiore Medical Center|Yes|Recruiting|January 2013|August 2020|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|3 Days|No|||September 2015|September 21, 2015|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783041||71891|
NCT01783028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSKC-AST-HomeBASE|Home-Based Asthma Support and Education for Adults|Home-Based Asthma Support and Education for Adults|HomeBase|Public Health - Seattle and King County|No|Completed|March 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783028||71892|
NCT01783834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-GIRBA-1739|Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients|Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer||Gachon University Gil Medical Center||Completed|February 2008|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01783834||71830|
NCT01783847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-124-12972|Traumatic Optic Neuropathy Treatment Trial (TONTT)|Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON)|TONTT|Tehran University of Medical Sciences|Yes|Recruiting|February 2015|March 2017|Anticipated|March 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|6 Years|90 Years|No|||March 2016|March 15, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783847||71829|
NCT01784107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-GIRBA-2550|A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer|A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer||Gachon University Gil Medical Center||Recruiting|July 2011|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784107||71809|
NCT01784120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-GIRBA-2566|A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer|A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer||Gachon University Gil Medical Center||Recruiting|January 2011|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784120||71808|
NCT01784133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-001|A Twelve Week Safety and Efficacy Study in Rosacea|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea||Cutanea Life Sciences, Inc.|No|Completed|March 2013|||March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784133||71807|
NCT01784094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AT006085|Connective Tissue Motion Measure 2|||Stromatec, Inc.|Yes|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|195|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|December 2014|December 29, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784094||71810|
NCT01784653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH R01 PA-13-077|Trial of Computerized MET for Adolescent Substance Use|Randomized Controlled Trial of Computerized MET for Adolescent Substance Use||Children's Hospital Boston|No|Withdrawn|October 2013|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|21 Years|No|||February 2016|February 8, 2016|February 4, 2013||No|No funding obtained.|No||https://clinicaltrials.gov/show/NCT01784653||71767|
NCT01784666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-002449/1|Adjunctive Isradipine for the Treatment of Bipolar Depression|Adjunctive Isradipine for the Treatment of Bipolar Depression|Isradipine|Massachusetts General Hospital|Yes|Recruiting|February 2013|August 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||June 2014|June 24, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784666||71766|
NCT01784939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01170-43|HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis|HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis|HEPFER|Rennes University Hospital|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|Samples Without DNA|Hepcidin serum ferritin serum transferrin serum iron serum|Male|18 Years|N/A|No|Non-Probability Sample|-  Men, at least 18 years old          -  hereditary hemochrmatosis C282Y homozygous diagnosed and followed in the service of             Liver Diseases, University Hospital of Rennes          -  Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the             basis of at least four previous plasma ferritin < 50μg / L,|July 2014|July 23, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01784939||71745|
NCT01756001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816493|GlowCaps Adherence Randomized Control Trial|Using Behavioral Economics to Promote Medication Adherence and Habit Formation||University of Pennsylvania|No|Not yet recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Anticipated|600|||Both|16 Years|84 Years|No|||November 2012|February 27, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01756001||73967|
NCT01756261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16656|EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan|Special Drug Use Investigation of EYLEA for Quality of Life||Bayer|No|Active, not recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|Patients with subfoveal choroidal neovascular age-related macular degeneration|March 2016|March 17, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756261||73947|
NCT01756274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2010-009-03|Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates|Performance of Three Bayer Blood Glucose Monitoring Systems With Blood Samples From Neonates||Ascensia Diabetes Care|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|162|||Both|N/A|30 Days|Accepts Healthy Volunteers|||January 2016|January 29, 2016|December 20, 2012|Yes|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01756274||73946|
NCT01756547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRENECAL|Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature|Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature.|PRENECAL|Hospital Clinic of Barcelona|Yes|Not yet recruiting|January 2013|January 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|74|||Both|N/A|16 Weeks|No|||December 2012|December 26, 2012|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756547||73925|
NCT01756560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-2191|Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair|A Study of the Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair||University of Chicago|No|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756560||73924|
NCT01772849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPECT - education|Rehabilitation Including Social Activity and Education in Children and Teenagers With Cancer|Rehabilitation Including Social Activity and Education in Children and Teenagers With Cancer|RESPECT-EDU|Rigshospitalet, Denmark|No|Recruiting|January 2013|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01772849||72674|
NCT01772862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPECT - physical activity|Rehabilitation Including Social and Physical Activity in Children and Teenagers With Cancer|Rehabilitation Including Social and Education in Children and Teenagers With Cancer|RESPECT|Rigshospitalet, Denmark|No|Recruiting|January 2013|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01772862||72673|
NCT01773421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7820-E044-110|An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors|An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors||Eisai Inc.|No|Active, not recruiting|July 2011|September 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773421||72630|
NCT01773733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMOMED-PRIMAVERA|The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity|All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice|Primavera|Promomed, LLC|Yes|Active, not recruiting|November 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100000|||Both|18 Years|65 Years|No|Non-Probability Sample|Men and women of 18-65 years old, in the random gender and demographical proportion, with        the diagnosed overweight (BMI ≥ 27 and < 30) and obesity (BMI ≥ 30).|August 2014|August 1, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01773733||72606|
NCT01771237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH079707|HIV Prevention Among Vulnerable Male Youth|Feasibility and Acceptability Trial of Behavioral Group-based HIV Prevention Intervention for Young Men Who Have Sex With Men (YMSM).||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|July 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Male|16 Years|20 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01771237||72798|
NCT01771783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USBMH-001|RAS-Peptide-Profile Study in Healthy Male Subjects|Single-center, Randomized, Open-label, 3-way Crossover Study to Characterize the RAS-peptide-profile After Single and Repeated Oral Administration of Different RAS-inhibitors in Healthy Male Subjects|RAS|University Hospital, Basel, Switzerland|No|Completed|November 2012|||April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771783||72756|
NCT01771796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM/RHB/CR/12|Training Effects Following Resection Surgery in Patients With Lung Cancer|Training Effects Following Resection Surgery in Patients With Lung Cancer|EMITOR|Parc de Salut Mar|No|Completed|November 2012|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|80 Years|No|||February 2016|February 15, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01771796||72755|
NCT01771549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007541|Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab|Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab||Mayo Clinic|No|Enrolling by invitation|January 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Whole blood 10 ml per draw, yielding 5 ml of serum. After testing, the remaining serum will      be stored.|Female|18 Years|N/A|No|Non-Probability Sample|Mayo Clinic Florida female, adult patients from Hematology/Oncology Department undergoing        clinically-indicated treatment for breast cancer which includes either, but not both,        adriamycin or trastuzamab will be eligible to participate|March 2015|March 24, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01771549||72774|
NCT01771770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB-2011-328|Measurement of Retinal Venous Pressure in Chronic Low-oxygen Environment|Measurement of the Retinal Venous Pressure (RVP) Under Conditions of Chronically Reduced Ambient Pressure and Oxygen Partial Pressure (Field Study)||University Hospital, Basel, Switzerland|No|Completed|December 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|December 2013|December 10, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771770||72757|
NCT01783561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2HRCAFFEINE|Early Versus Routine Caffeine Administration in Extremely Preterm Neonates|Early Versus Routine Caffeine Administration in Extremely Preterm Neonates|EARLYCAFFEINE|Sharp HealthCare|Yes|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|21|||Both|N/A|N/A|No|||September 2014|September 22, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783561||71851|
NCT01783821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008192|LIPS-B: Lung Injury Prevention Study With Budesonide and Beta|LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)|LIPS-B|Mayo Clinic|Yes|Active, not recruiting|July 2013|January 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783821||71831|
NCT01783860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-124-13076|Oral Azithromycin Versus Doxycycline in Posterior Blepharitis|Study of the Effect of Oral Azithromycin on Posterior Blepharitis||Tehran University of Medical Sciences|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|100|||Both|13 Years|90 Years|No|||December 2013|December 28, 2013|February 1, 2013||No||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01783860||71828|
NCT01784146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luciana 2|Plethysmography Opto-electronic and Asthma|Analysis of the Distribution of Pulmonary Ventilation After Nebulization by Heliox Associated With Positive Expiratory Pressure in Patients Asthmatics Stable.||Universidade Federal de Pernambuco|Yes|Completed|June 2009|November 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|65 Years|No|||December 2012|February 1, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784146||71806|
NCT01784367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4190|Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure|Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure|ECLAIR|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|December 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784367||71789|
NCT01755429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-004J|To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients|A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies||Alexion Pharmaceuticals|No|Completed|May 2012|July 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2|||Both|N/A|N/A|No|Non-Probability Sample|The two identified Japanese patients with aHUS for which eculizumab treatment was        initiated in 2011|February 2012|December 21, 2012|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01755429||74010|
NCT01755702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2260597|Paracetamol With Caffeine to Treat Episodic Tension Type Headache|A Study to Assess the Efficacy of Paracetamol Taken in Combination With Caffeine for the Treatment of Episodic Tension Type Headache||GlaxoSmithKline|No|Terminated|July 2009|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|66|||Both|18 Years|65 Years|No|||November 2014|March 12, 2015|June 23, 2011|No|Yes|Study was terminated due to unforeseen difficulties with subject recruitment. No safety issues    were identified in the study with this new formulation.|No|January 16, 2014|https://clinicaltrials.gov/show/NCT01755702||73989|
NCT01784952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WG_APOA5|Consumption of Whole Grains and Legumes Modulates the Genetic Effect of the APOA5 -1131C Variant|||Yonsei University|Yes|Completed|January 2012|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|200|||Both|25 Years|72 Years|No|||February 2013|February 5, 2013|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01784952||71744|
NCT01755715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KILKE|Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy|Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy||Helsinki University Central Hospital|No|Active, not recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01755715||73988|
NCT01756014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIN-HF|Brain Function and Perfusion in Patients With Heart Failure|Brain Function and Perfusion in Patients With Heart Failure|BRAIN-HF|University Medical Center Groningen|No|Recruiting|January 2012|||December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|-  Patients with heart failure due to dilated cardiomyopathy with NYHA II or NYHA II/IV.          -  Healthy patients|December 2012|December 21, 2012|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01756014||73966|
NCT01756287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB504601|Efficacy of Chinese Ocular Exercise on Visual Acuity and Ocular Accommodation in Myopic Teenager|A Randomized Controlled Trial to Alter Ocular Accommodation in Myopic Teenager With Chinese Ocular Exercise||Beijing Tongren Hospital|Yes|Completed|August 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|190|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756287||73945|
NCT01752998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA032800|Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings|Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings|BupPain|Butler Hospital|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|75 Years|No|||November 2015|December 10, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01752998||74197|
NCT01774058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILOFLOW2.0|The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation|The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy|ILOFLOW|Wilhelminenspital Vienna|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01774058||72581|
NCT01774071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-178|Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer|A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|27|||Male|21 Years|N/A|No|||February 2016|February 23, 2016|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774071||72580|
NCT01770405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT_2012_nCLE_03|Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract|Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract|US-nCLE|Mauna Kea Technologies|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Referral patients with a clinical indication for masses and cystic tumors of the pancreas,        lymph nodes, submucosal lesions of the GI tract coming in for first EUS-FNA procedure at        referral institution will be approached for possible inclusion into this registry|November 2015|November 3, 2015|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770405|1 Year|72862|
NCT01770717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2012-8868|Assessment of the Potential for Pressure Ulcer Formation|Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging||University of California, Irvine|No|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|175|||Both|18 Years|N/A|No|Non-Probability Sample|Study polpulation will be selected from UCIMC Inpatient care unit|February 2016|February 5, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01770717||72838|
NCT01770119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMR in pediatric OLT|Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients|Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland|MMRinOLT|University Hospital, Geneva|Yes|Recruiting|April 2013|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|12 Months|20 Years|No|||May 2015|May 26, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770119||72884|
NCT01771562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12279 MAGGSEN|Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent|Assessment of Risk Factors of Nutritional and Metabolic Disorders in Children and Adolescent Receiving or Not Antiretroviral Treatment : Growing up With HIV in Senegal||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Plasma, blood cells and urine samples to be retained|Both|2 Years|15 Years|No|Non-Probability Sample|HIV-1 infected individuals age between 2 ans 16 years|April 2013|April 3, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771562|3 Years|72773|
NCT01801839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009BAI86B03|Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients|||Chinese PLA General Hospital||Completed|August 2012|||July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were selected from among inpatients who were hospitalized between August 2012        and March 2013 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|January 2016|January 26, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801839||70452|
NCT01801852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-003|Autologous Natural Killer T Cells Infusion for the Treatment of Cancer|Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors||Chinese PLA General Hospital|Yes|Recruiting|January 2013|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|90 Years|No|||January 2016|January 26, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01801852||70451|
NCT01772095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-DON-EL-33|ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE|A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.|ADVANCE|Elpen Pharmaceutical Co. Inc.|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|389|||Both|50 Years|95 Years|No|Non-Probability Sample|Patients with dementia|August 2014|August 18, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772095||72732|
NCT01772108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-513|A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation|A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation|RESHAPE-HF|Evalve|Yes|Terminated|April 2013|January 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|90 Years|No|||January 2015|January 6, 2015|January 17, 2013||No|As recruitment rate was lower than anticipated|No||https://clinicaltrials.gov/show/NCT01772108||72731|
NCT01783314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009011259|Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium|Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium||Weill Medical College of Cornell University|No|Recruiting|December 2010|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 31, 2013|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783314||71870|
NCT01783327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112009416|Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes|Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes|TeensConnect|Yale University|Yes|Completed|July 2012|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Both|11 Years|14 Years|No|||January 2016|January 6, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01783327||71869|
NCT01783574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012D000537|Testosterone Antidepressant Augmentation in Women|Collaborative Study: Testosterone Antidepressant Augmentation in Women||Massachusetts General Hospital|Yes|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|21 Years|75 Years|No|||March 2016|March 9, 2016|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01783574||71850|
NCT01783587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-267|Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer|Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)||Dana-Farber Cancer Institute|Yes|Recruiting|February 2013|February 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783587||71849|
NCT01783873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4707|Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests|Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests||University Hospital, Strasbourg, France|No|Recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|50 Years|No|||September 2015|September 29, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01783873||71827|
NCT01784159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPM81449|Aspirin for Treatment of Severe Sepsis|Phase 2 Study of Aspirin Administration for Patients With Severe Sepsis and Septic Shock||Federal University of São Paulo|No|Active, not recruiting|June 2013|January 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01784159||71805|
NCT01784380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006A165|The Potential Biochemical Diagnosis Criteria and Therapeutic Effect Indexes: Sex Hormone Binding Globulin Levels and Free Androgen Index in Blood of Patients With Polycystic Ovary Syndrome|||Zhongshan Bo Ai Hospital||Completed|October 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|1159|||Female|20 Years|43 Years|No|Probability Sample|The investigators collected 534 PCOS patients as the case group, 580 infertile women with        normally ovulatory cycle as the control groupand.The patients of the case group aged from        20 to 42 years old, the average age was 27.87 years old, and the standard deviation of        ages was 3.75 years old. And patients' ovulation in the case group was normal, as control        group, aged from 20 to 43 years old, the average age was 28.18 years old; the standard        deviation of ages was 3.99 years old.Also the investigators also collected 579 patients as        the treatment group,who aged from 20 to 39 years, the average age was 27.93 years old, the        standard deviation of ages was 3.70 years old.|February 2013|February 2, 2013|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784380||71788|
NCT01755156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-024|A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755156||74031|
NCT01755442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120189|Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects|A Phase 1, Double-blind, Randomized, 2-Way Crossover, Placebo-controlled Study to Investigate the Effect of AMG 151 on 24-hour Ambulatory Blood Pressure and Glucose Levels in Subjects With Type 2 Diabetes Mellitus||Amgen|No|Terminated|November 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|75 Years|No|||April 2013|April 19, 2013|November 27, 2012|Yes|Yes|Amgen determined no further need for this study.|No||https://clinicaltrials.gov/show/NCT01755442||74009|
NCT01755728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77-12-HYMC-CTIL|Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants|Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants||Hillel Yaffe Medical Center|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|20|||Both|N/A|4 Months|No|||February 2016|February 18, 2016|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01755728||73987|
NCT01755741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 029|Functionality of Male Condomes With a Silicone Elastomer Vaginal RIng|A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring||International Partnership for Microbicides, Inc.|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755741||73986|
NCT01787110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETO2X-AMI 2012/287-12|An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction|DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry|DETO2X-AMI|Karolinska Institutet|No|Active, not recruiting|April 2013|September 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6650|||Both|30 Years|N/A|No|||January 2016|January 25, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01787110||71578|
NCT01783145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCFU-TC 1.2011|Shared Care Follow-up After Chemotherapy for Testicular Cancer|Shared Care Follow-up After Chemotherapy for Testicular Cancer|SCFU-TC|University Medical Center Groningen|No|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|245|Samples With DNA|whole blood, serum, plasma|Male|18 Years|N/A|No|Non-Probability Sample|Patients with disseminated TC who have finished their chemotherapy, if needed followed by        surgery, and who are in complete remission and currently in active follow-up.|October 2015|October 1, 2015|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01783145||71883|
NCT01770418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN005-12|A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer|A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer||Proton Collaborative Group|Yes|Recruiting|March 2013|||January 2038|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770418||72861|
NCT01770730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMRCT|A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients|A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings|LAMRCT|University of Cape Town|No|Completed|January 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2618|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01770730||72837|
NCT01771016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 114/07|Emergency Contraception - User's Profile|Emergency Contraception - Observational Study of User's Profile||University Hospital, Basel, Switzerland|No|Completed|January 2006|August 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|729|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pharmacies in Basle, Berne or Zurich, three major towns in the German speaking part of        Switzerland, were purposively recruited if they had extended opening hours (emergency        pharmacies) or if they were located downtown and open during traditional business hours        (walk-in pharmacies).        The pharmacists were asked if a pharmacy student could come to their place and photocopy        the completed official one-page EHC written assessment forms.|January 2013|January 15, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01771016||72815|
NCT01771250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14871|A Study of LY2605541 and Glargine on Fats in Participants With Type 1 Diabetes|Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01771250||72797|
NCT01770990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KQ1002B-TP7-Tel-PT|Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive Mail|Randomized Trial of Telephone-Based Psychotherapy for Depression With and Without Adjunctive Supportive Mail|Tel-PT|Universitätsklinikum Hamburg-Eppendorf|No|Completed|September 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01770990||72817|
NCT01771003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC|Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy|The Effect of Remote Ischemic Preconditioning in Partial Nephrectomy||University Health Network, Toronto|No|Terminated|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01771003||72816|
NCT01801592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01124-39|Obstructive Sleep Apnoea in Patients With Intermittent Claudication|Prevalence of Obstructive Sleep Apnoea in Patients With Intermittent Claudication|WITH-SAS|University Hospital, Angers|Yes|Recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|men or women over 18 years old with an Intermitent claudication.|February 2016|February 11, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01801592||70471|
NCT01772381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|noharabei|Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean Section in Term Fetus|Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean||Ain Shams Maternity Hospital|Yes|Completed|March 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|600|||Female|22 Years|44 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|December 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772381||72710|
NCT01802112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-001|Randomised Controlled Trial of Efficacy of Resistant Maltodextrins on Reducing Colonic Transit Time|Randomised Controlled Trial of Efficacy of Resistant Maltodextrins on Reducing Colonic Transit Time||San Antonio Technologies - San Antonio Catholic University of Murcia|No|Recruiting|February 2013|June 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01802112||70431|
NCT01783340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis|MMV|Radboud University|Yes|Withdrawn|April 2013|April 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|January 31, 2013||No|No funding|No||https://clinicaltrials.gov/show/NCT01783340||71868|
NCT01783353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS_PGH_2013_001|Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial|Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial||Philippine Dermatological Society|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 13, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01783353||71867|
NCT01783613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docosahexaenoic acid|Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis|Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|2 Months|N/A|No|||January 2015|April 14, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783613||71847|
NCT01754662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1188|Effects of Combining Cocoa and Soy in Type 2 Diabetes|A Pilot Study Investigating the Effects of the Combined Effects of Cocoa and Soy Polyphenols in a Soy Protein Matrix on Insulin Resistance and Cardiovascular Disease Risk in Type 2 Diabetes - A Randomised Placebo-Controlled Double-Blind Parallel Study||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|84|||Both|45 Years|80 Years|No|||November 2013|November 19, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754662||74069|
NCT01754675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 03807212.5.0000.0113|Cardiovascular Effects of a Soccer Match in Viewers With With Coronary Artery Disease|Cardiovascular Effects of a Soccer Match in Viewers With With Coronary Artery Disease||Instituto de Cardiologia de Santa Catarina|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|17|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754675||74068|
NCT01754935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-509-103|A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs||Vertex Pharmaceuticals Incorporated|No|Completed|January 2013|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|43|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754935||74048|
NCT01755169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiCK Pain|Ketamine in Chronic Kid's (KiCK) Pain|Ketamine in Chronic Kid's (KiCK) Pain|KiCK Pain|Medical University of South Carolina|Yes|Terminated|January 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|8|||Both|8 Years|20 Years|No|||May 2015|May 21, 2015|December 18, 2012|Yes|Yes|Inability to enroll sufficient patients|No||https://clinicaltrials.gov/show/NCT01755169||74030|
NCT01756300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENABLATE|RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension|A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02)||Biosense Webster, Inc.|Yes|Completed|December 2012|April 2015|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|19 Years|84 Years|No|||October 2015|October 15, 2015|December 20, 2012|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01756300||73944|
NCT01756313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-041|Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique|||Bispebjerg Hospital|Yes|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 25, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756313||73943|
NCT01756573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-2192|Dexamethasone and Block Duration in Upper Extremity|A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine||University of Chicago|No|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756573||73923|
NCT01756586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-2198|Dexamethasone and Lower Extremity Block Duration|||University of Chicago|No|Recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756586||73922|
NCT01786837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-182|Functional Magnetic Stimulation Enhances Gastrointestinal Motility in Patients With Chronic Constipation|A Prospective Trial to Study Whether Functional Magnetic Stimulation Enhances Gastrointestinal Motility in Patients With Chronic Constipation||The Cleveland Clinic|No|Withdrawn|December 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|February 6, 2013||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01786837||71599|
NCT01752712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054628|Oxytocin and CBSST for People With Schizophrenia|Combined Oxytocin and CBSST for Social Function in People With Schizophrenia||University of Maryland|Yes|Active, not recruiting|January 2014|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||December 2015|December 15, 2015|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752712||74219|
NCT01770431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-201101|Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy|A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy||Qidong Gaitianli Medicines Co., Ltd|Yes|Active, not recruiting|August 2011|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|18 Years|75 Years|No|||January 2013|October 29, 2014|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01770431||72860|
NCT01770743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVA.208 / DMID 11-0055|A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels|A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers||Emergent BioSolutions|Yes|Completed|January 2013|December 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|168|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|January 16, 2013|Yes|Yes||No|February 6, 2015|https://clinicaltrials.gov/show/NCT01770743||72836|A few events collected in e-diary were downgraded (severe to moderate) on verification by the PI but were unable to be corrected in subjects' e-diary data: headache & fatigue/tenderness in 2 subjects each; muscle ache & pain & AML in 1 subject each.
NCT01771029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC_1|Technical Evaluation of Brahms PCT Direct|Technical Evaluation of a Whole Blood Rapid Test Measuring Procalcitonin (BRAHMS PCT Direct)||University Hospital, Basel, Switzerland|Yes|Completed|February 2013|September 2014|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|One cohort of 150-250 patients, possible infection at initial presentation in        Kantonsspital Aarau.|December 2014|December 11, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01771029|1 Day|72814|
NCT01771263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2012-056|Closed-loop Control of Anesthesia: Controlled Delivery of Remifentanil and Propofol|Closed-loop Control of Anesthesia: Controlled Delivery of Remifentanil and Propofol|iControl-RP|Fraser Health|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|19 Years|N/A|No|||August 2014|May 22, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771263||72796|
NCT01771276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR602|ULTIMATE Study for Weight Loss|Evaluating Impact of ULTIMATE Number of G-CATH EZ- Suture Anchors Placed Endoscopically on Motility, Metabolism, Satiety, and Weight Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity|ULTIMATE|USGI Medical|Yes|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|60 Years|No|||April 2015|April 1, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01771276||72795|
NCT01771289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUPH-XW1301|Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC|Phase II Trial of Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC||Peking University People's Hospital|No|Recruiting|January 2013|||January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771289||72794|
NCT01772121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-US-174-0196|Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India|Prevalence of Host and Viral Genotypes in Patients With Chronic Hepatitis B and Hepatitis C Infection in India||Gilead Sciences|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1000|Samples With DNA|A portion of the blood drawn at the study visits will be frozen and stored. Stored blood      samples may be used by the Sponsor or its research partners for HCV/HBV      genotyping/phenotyping assays (as applicable) or their development or for retesting the      amount of HCV/HBV in the blood. At the conclusion of this study, these samples may be      retained in storage by Gilead Sciences or a designee for a period up to 10 years|Both|18 Years|N/A|No|Probability Sample|A total of 1000 subjects will be enrolled in the study. Of these, it is planned that        approximately 500 subjects will have a diagnosis of chronic HCV infection and        approximately 500 subjects will have a diagnosis of chronic HBV infection.Subjects        knowingly co-infected with HCV/HBV or HIV may not participate in the study|July 2015|July 7, 2015|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772121||72730|
NCT01772394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB-2011-A01280-41|Cognitive Remediation Therapy in Anorexia Nervosa|Cognitive Remediation Therapy Effectiveness in Anorexia Nervosa: a Multicenter Randomized Clinical Study|TreCogAM|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Female|15 Years|40 Years|No|||December 2015|December 8, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772394||72709|
NCT01772641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0879|A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation|A Combination of Scheduled Reduced Smoking With Varenicline to Enhance Cessation||Icahn School of Medicine at Mount Sinai|Yes|Terminated|December 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 17, 2013|Yes|Yes|difficulty recruiting and retaining participants|No||https://clinicaltrials.gov/show/NCT01772641||72690|
NCT01783366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNU03-2013-002|Nasogastric Tube Insertion Using Cook Airway Exchange Catheter in Anesthetized Patients|Nasogastric Tube Insertion Using Cook Airway Exchange Catheter in Anesthetized Patients||Pusan National University Hospital|No|Recruiting|January 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|70 Years|No|||February 2013|February 3, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01783366||71866|
NCT01783600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-111125|NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions|NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions||Flanders Medical Research Program|Yes|Active, not recruiting|January 2013|March 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01783600||71848|
NCT01754376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-343|Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma|COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma||Massachusetts General Hospital|Yes|Active, not recruiting|January 2013|||February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|December 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754376||74091|
NCT01755468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0263-A Pilot|Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)|A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT Pilot Study)||Mount Sinai Hospital, Canada|No|Active, not recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|80 Years|No|||September 2015|September 29, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01755468||74007|
NCT01755754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 033|Female Condom Functionality|A Multicenter, Open-label, Randomized, Two-period, Crossover Non-inferiority Trial to Assess the FunctionalityY of Female Condoms With a Silicone Elastomer Vaginal Ring||International Partnership for Microbicides, Inc.|No|Recruiting|August 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|160|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|December 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755754||73985|
NCT01755767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-A-U303|Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy|A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy|METIV-HCC|Daiichi Sankyo Inc.|Yes|Active, not recruiting|December 2012|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755767||73984|
NCT01755182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOTUS|Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors|Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Pharmacotherapy, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.|LOTUS|National Cancer Institute, Naples|No|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01755182||74029|
NCT01786551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002191|Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults|||Brigham and Women's Hospital|No|Completed|March 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01786551||71621|
NCT01786252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-hCG-755|Effect of hCG on Receptivity of the Human Endometrium|The Effect of hCG on the Human Endometrium||Michigan State University|No|Active, not recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||March 2015|March 8, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786252||71644|
NCT01786824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/PR-03|Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration|Preventing Nephropathy Induced by Iodinated Contrast Media in Patients With Renal Impairment: a Randomized Trial Evaluating the Effectiveness of Two Hydration Strategies and L-carnitine Administration|CinBiCarn|Centre Hospitalier Universitaire de Nīmes|Yes|Terminated|December 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|9|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 6, 2013||No|Patient pathway has become infeasible due to pressure for shorter hospital stays. Not enough    inclusions.|No||https://clinicaltrials.gov/show/NCT01786824||71600|
NCT01786850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreafus-01|Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer|Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer: Phase II Study for Pain Palliation and Local Tumor Control||University of Roma La Sapienza||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|90 Years||||June 2014|June 17, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786850||71598|
NCT01786863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00045|Frequency of Residual Neuromuscular Blockade in the Pediatric Population|||Nationwide Children's Hospital|No|Terminated|February 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|N/A|17 Years|No|Non-Probability Sample|Patients undergoing surgery that requires them to be paralyzed|March 2016|March 5, 2016|February 6, 2013||No|PI returned to her home country of Japan|No||https://clinicaltrials.gov/show/NCT01786863||71597|
NCT01783158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVO-FNOs/2012|Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma|Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma in Patients With Squamous Cell Carcinomas of the Head and Neck?|HNSCC|University Hospital Ostrava|No|Completed|January 2004|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|132|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with newly diagnosed head and neck carcinoma|January 2013|January 31, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01783158||71882|
NCT01779661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9524-OB-CTIL|Infant Aquatics Neurodevelopment Premature Infants|The Effect of Infant Aquatics for Neurodevelopment of Premature Infants|IA-NPI|Sheba Medical Center|No|Recruiting|April 2013|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||February 2014|February 12, 2014|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01779661||72151|
NCT01779908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA grant no OG-3-12-3681-CG|Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance|Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance|VIDIR|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|130|||Both|25 Years|75 Years|No|||January 2016|January 12, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01779908||72132|
NCT01771302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI-EC/12/Biomat|Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation|Randomized Clinical Trial on the Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation||Fundación Eduardo Anitua|No|Recruiting|January 2013|January 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771302||72793|
NCT01771809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281010|Long-Term Safety Of PF-00547659 In Ulcerative Colitis|A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Ulcerative Colitis (Turandot Ii)|TURANDOT II|Pfizer|Yes|Active, not recruiting|March 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|66 Years|No|||February 2016|March 9, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771809||72754|
NCT01771822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491004|Ibuprofen 5% Topical Gel CIPT|Cumulative Irritancy Patch Test (Cipt) of Ibuprofen 5% Topical Gel in Human Volunteers||Pfizer|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 27, 2013|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771822||72753|
NCT01772134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116135|Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks|A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks With COPD||GlaxoSmithKline|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|617|||Both|40 Years|N/A|No|||May 2014|May 8, 2014|January 17, 2013|Yes|Yes||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01772134||72729|
NCT01772147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116136|Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.|A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.||GlaxoSmithKline|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|608|||Both|40 Years|N/A|No|||March 2014|May 22, 2014|January 17, 2013|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT01772147||72728|
NCT01772407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIC ICO711|Laparoscopic Surgery Equivalent to Open Surgery in Right Colon Cancer Surgery?|Right Colon Cancer: Laparoscopic Surgery Versus Open Surgery, Costs, Mortality, Morbidity and Quality of Life|CHIRCOL|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Right colon cancer < T4 without metastasis needing colectomy|April 2015|April 23, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772407||72708|
NCT01772654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006882|Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy|Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy||Mayo Clinic|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|73|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 17, 2013|Yes|Yes||No|February 17, 2015|https://clinicaltrials.gov/show/NCT01772654||72689|Small sample size.
NCT01772667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrosis2013|Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis|Long Term Effects of a 3-week Inpatient Pulmonary Rehabilitation Program in Patients With Idiopathic Pulmonary Fibrosis||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Recruiting|October 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|51|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772667||72688|
NCT01754103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISION TACTIL|Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation|Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation||Universidad Complutense de Madrid|No|Recruiting|January 2012|December 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|7 Years|70 Years|No|||December 2012|December 17, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01754103||74112|
NCT01754116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116815|A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects|A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.||ViiV Healthcare|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|December 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01754116||74111|
NCT01755195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130044|Cabozantinib for Adults With Advanced Soft Tissue Sarcoma|A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|120 Years|No|||April 2015|February 6, 2016|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01755195||74028|
NCT01755455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11176|Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis|Iron Supplementation for the Hypoferremic Anemia of Cystic Fibrosis||Dartmouth-Hitchcock Medical Center|No|Completed|June 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||October 2014|October 3, 2014|December 19, 2012||No||No|December 31, 2013|https://clinicaltrials.gov/show/NCT01755455||74008|The power to detect changes in Akron PES was 42%; 160 subjects would be needed to ensure that exacerbation risk was lower for ferrous sulfate with 80% power and p <0.05.
NCT01785524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039608|Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD|Dietary Nitrate to Augment Exercise Training Benefits in Subjects With Type II Diabetes (DM) and Peripheral Arterial Disease (PAD)|DM+PAD|Duke University|No|Completed|February 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|50 Years|80 Years|No|||November 2015|November 25, 2015|February 5, 2013|Yes|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01785524||71700|The largest limitation to the study was the evolving knowledge on conversion rates of oral inorganic nitrate to nitrite. We found a good deal of unexpected inter and intra-subject variation in conversion rates.
NCT01756027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-131|Feasibility Study: Ulthera System for the Treatment of Rosacea|Feasibility Study: Evaluation of the Effectiveness and Safety of the Ulthera® System for Treatment of Erythematotelangiectatic Rosacea||Ulthera, Inc|No|Completed|November 2012|October 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01756027||73965|
NCT01756040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049647|Intestinal Permeability in Preterm Infants|Gut Permeability in Very Low Birth Weight Infants|IPPI|University of Maryland|Yes|Active, not recruiting|February 2013|December 2015|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|N/A|4 Days|No|||May 2015|May 28, 2015|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756040||73964|
NCT01786265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0993|Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone|A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy||M.D. Anderson Cancer Center|Yes|Recruiting|February 2013|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786265||71643|
NCT01786564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0696|Home Sleep and Circadian Phase: Mediators of Diabetes Risk|Home Sleep and Circadian Phase: Mediators of Diabetes Risk||University of Chicago||Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will recruit a total of 100 African Americans (AA) and 100 non-Hispanic whites        (WH) with equal numbers of men and women in each group completing the entire study. Ages        will be 21-50 years and body mass indices (BMI) will be <40 kg/m2.|May 2015|May 27, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01786564||71620|
NCT01786577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487-2012|Study To Analyze Memory/Thinking Problems In Older Adults After Surgery|Neuroimaging Biomarkers for Post-Operative Cognitive Decline in Older Adults|POCD|University of Florida|Yes|Recruiting|March 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|160|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786577||71619|
NCT01782937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-004|An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis|A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma||Kyowa Hakko Kirin Company, Limited|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01782937||71899|
NCT01787123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CESAR Study|Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage|Randomized, Double-blind, Placebo-controlled Pilot Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage|CESAR|Kwong Wah Hospital|Yes|Not yet recruiting|June 2013|February 2016|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||February 2013|February 6, 2013|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787123||71577|
NCT01783171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00153|Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer||National Cancer Institute (NCI)|No|Recruiting|January 2013|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01783171||71881|
NCT01771315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNR-2013112-4|Nurse Led Follow-up After Total Knee Arthroplasty|Nurse Led Follow-up After Total Knee Arthroplasty - a Randomized Trial|NFTKA|University of Southern Denmark|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|117|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771315||72792|
NCT01771328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/749|Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia|Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia|CAH|Haukeland University Hospital|Yes|Active, not recruiting|February 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01771328||72791|
NCT01771341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.646|Evaluation of Synchrony in the Post-operative Patient|Evaluation of Synchrony in the Post-operative Patient (NAVA vs Pressure Support)|SYNCHRONY|Hospices Civils de Lyon|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01771341||72790|
NCT01771835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|089-CYA-2012|Retinal Venous Pressure and ET-1 in Patients With Diabetes Mellitus|Measurement of Retinal Venous Pressure and Endothelin-1 in Patients With Diabetes Mellitus||University Hospital, Basel, Switzerland|No|Completed|August 2011|November 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabets mellitus type I or II, without diabetic retinopathy|January 2013|January 16, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01771835||72752|
NCT01771848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACHMI-01|Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults|A Study to Optimize Controlled Human Malarial Infection by Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults||Sanaria Inc.|Yes|Completed|December 2012|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|6||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|January 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01771848||72751|
NCT01772160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116208|Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy|Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy||GlaxoSmithKline||Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|409|||Both|50 Years|N/A|No|Non-Probability Sample|Adult population, male or female aged ≥ 50 years of age presenting with a HZ episode.|February 2016|March 10, 2016|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772160||72727|
NCT01772420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-407|Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome|Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS)||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|October 2012|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772420||72707|
NCT01772433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1391/7/18|Olive Oil Phonophoresis and Chronic Low Back|The Effect of Olive Oil Phonophoresis on Chronic Low Back Pain in Female Athletes: a Randomized Controlled Trial||Ardabil University of Medical Sciences|No|Recruiting|January 2013|October 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|No|||January 2013|January 17, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01772433||72706|
NCT01772706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP400|Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer|A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer.|LaserMucite|Institut Cancerologie de l'Ouest|No|Recruiting|October 2008|||March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2013|January 17, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772706||72685|
NCT01754389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-404|Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant|A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2013|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|138|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754389||74090|
NCT01754402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040206|Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma|A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Duke University|No|Recruiting|January 2013|January 2023|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01754402||74089|
NCT01754688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109M04335|Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries|Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|677|||Both|N/A|14 Days|No|Probability Sample|Neonates admitted to Massey Street Children's Hospital|November 2015|November 11, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01754688||74067|
NCT01754948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0488|Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children|Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children|EHF|Tel-Aviv Sourasky Medical Center|No|Recruiting|July 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|asthmatic and control children|December 2012|December 20, 2012|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754948||74047|
NCT01785745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|486/2012|Study of Neurocognitive Therapeutic Exercise in the Shoulder Impingement Syndrome in Comparison With Traditional Therapeutic Exercise|Evaluation of the Effectiveness of Neurocognitive Therapeutic Exercise in Pain Control and Functional Recovery of the Shoulder Impingement Syndrome in Comparison With Traditional Therapeutic Exercise||Catholic University of the Sacred Heart|No|Completed|July 2012|January 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 5, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785745||71683|
NCT01785537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLM001|The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up Study|Multicentric 5-year Follow-up Study to Assess the Efficacy of E-cigarettes as a Tool for Smoking Cessation and to Compare the Risk of Smoking-related Diseases Among Electronic and Traditional Cigarette Smokers, and Smokers of Both.||Università degli Studi 'G. d'Annunzio' Chieti e Pescara|Yes|Active, not recruiting|October 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1050|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult residents in the Abruzzo and Lazio Region of Italy that are smokers of traditional        or electronic cigarettes|July 2015|July 20, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785537||71699|
NCT01785966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11673812310010060|Checklist During Multidisciplinary Visits for Reduction of Mortality in Intensive Care Units|Checklist During Multidisciplinary Daily Visits and Clinician Prompting for Reduction of Mortality in Intensive Care Units: A Cluster Randomized Trial|CHECKLIST-ICU|Hospital do Coracao|Yes|Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13637|||Both|18 Years|N/A|No|||November 2014|March 2, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785966||71666|
NCT01785979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiHMS|Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly|Prednisone Plus Chloroquine Versus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly in Papua New Guinea: a Randomized Open-label Trial|LiHMS|Lihir Medical Centre|No|Withdrawn|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|February 5, 2013||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01785979||71665|
NCT01786226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibroma2.5normal|Mifepristone to Treat Uterine Fibroids|Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial.||Mediterranea Medica S. L.|Yes|Terminated|March 2010|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|50 Years|No|||September 2014|September 4, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786226||71646|
NCT01786239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-308B|Omega-3 Dietary Supplements in Schizophrenia|Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment||Northwell Health|Yes|Active, not recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|15 Years|40 Years|No|||August 2015|August 31, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786239||71645|
NCT01786278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGC-DYS-0254/281/2011-MUL|Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer|The Comparison of Value of Brachytherapy and Endoscopic Stenting With SEMS in Palliative Treatment of Dysphagia Resulting From Adenocarcinoma of the Esophago-Gastric Junction|BRASTEGAC|Medical University of Lublin|Yes|Recruiting|February 2013|December 2017|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2013|February 5, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786278||71642|
NCT01786590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5294-CE|Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)|Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)||University Health Network, Toronto|No|Recruiting|February 2013|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01786590||71618|
NCT01783223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3560|Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services|Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services||Minneapolis Medical Research Foundation|No|Active, not recruiting|November 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the emergency department for alcohol intoxication|March 2016|March 2, 2016|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01783223||71877|
NCT01782924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-003|A Phase 3 Clinical Study of KHK4827|An Extension Study in Subjects With Plaque Psoriasis||Kyowa Hakko Kirin Company, Limited|No|Completed|March 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|145|||Both|20 Years|70 Years|No|||February 2015|February 12, 2015|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01782924||71900|
NCT01783197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I215|Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC|A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.||Canadian Cancer Trials Group|No|Active, not recruiting|January 2013|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783197||71879|
NCT01771055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.0178|Direct Peritoneal Resuscitation Effects in the Damage Control Patient|Direct Peritoneal Resuscitation Effects in the Damage Control Patient||University of Louisville|No|Suspended|January 2012|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2014|June 8, 2015|January 11, 2013||No|Need for revised protocol|No||https://clinicaltrials.gov/show/NCT01771055||72812|
NCT01771354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC305B|Training Study to Characterise Biomarkers to the Engerix B Vaccine|Clinical Study to Generate Exploratory Training Data Characterising Clinical Events, Physiological & Metabolic Responses, & Innate & Adaptive Immune Responses Following 1st & 3rd of 3 IM Immunisations With "Engerix B" HepB Vaccine or Placebo in Healthy Adults With no Pre-existing Immunity to HepB||University of Surrey|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|February 12, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01771354||72789|
NCT01771367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC305C|Training Study to Characterize Biomarkers to Flu Vaccines|A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Intramuscular Immunisation With Either "Fluad" or "Agrippal" Influenza Vaccines or Saline Placebo in Healthy Adults.||University of Surrey|No|Completed|January 2013|November 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|49|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|February 12, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01771367||72788|
NCT01771380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tromsø-Endo-2013-1|Measurement of the Free Fraction of 25-hydroxyvitamin D in Serum|Measurement of the Free Fraction of 25-hydroxyvitamin D in Serum||University of Tromso|No|Completed|February 2013|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|78|||Both|25 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with known impaired glucose tolerance|September 2015|September 18, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01771380||72787|
NCT01771575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2013.0011|The Use of the PoNS™ Device in the Treatment of Blunt and Blast Induced Vestibular Disorders|The Use of the PoNS™ Device in the Treatment of Blunt and Blast Induced Vestibular Disorders||United States Naval Medical Center, San Diego|No|Withdrawn|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|40 Years|No|||August 2015|August 4, 2015|January 14, 2013||No|No funding received|No||https://clinicaltrials.gov/show/NCT01771575||72772|
NCT01771874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 190/12|Influence of Bupropion on the Effects of MDMA|Influence of Bupropion on the Effects of MDMA||University Hospital, Basel, Switzerland|Yes|Completed|January 2013|September 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01771874||72749|
NCT01772173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1084-P|Retinal Vessel Measurements as Clinically Useful Predictors in Veterans|Retinal Vessel Measurements as Clinically Useful Predictors in Veterans||VA Office of Research and Development|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|4500|None Retained|Retinal images - vessel parameters|Both|18 Years|99 Years|No|Probability Sample|The investigators will identify a random sample of 4500 veterans with diabetes from the        Greater LA and Iowa City screening programs, who were imaged at least 3 years ago for DR        screening, and did not have hypertension (AHA definition) at that time|October 2015|October 14, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01772173||72726|
NCT01772745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mütf3|The Comparison of Single Incision Laparoscopic Cholecystectomy and Three Port Laparoscopic Cholecystectomy|The Comparison of Single Incision Laparoscopic Cholecystectomy and Three Port Laparoscopic Cholecystectomy||Maltepe University|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772745||72682|
NCT01784705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCT-003|Transcranial Bright Light Therapy in Seasonal Affective Disorder (SAD)|Transcranial Bright Light Therapy in Seasonal Affective Disorder (SAD)- a Randomized Placebo-controlled Trial|SAD3|University of Oulu||Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||June 2013|June 27, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784705||71763|
NCT01784718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12070385|Buphenyl Therapy for Byler's Disease|Compassionate Use of Buphenyl® in the Treatment of Byler's Disease||University of Pittsburgh||No longer available||||||N/A|Expanded Access|N/A|||||||Both|1 Year|N/A||||February 2013|February 4, 2013|February 4, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01784718||71762|
NCT01785251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-NMES-DVT-011|Neuromuscular Electrical Stimulation Following Total Hip Arthroplasty|Haemodynamic Performance of Neuromuscular Electrical Stimulation (NMES) During Recovery From Total Hip Arthroplasty||National University of Ireland, Galway, Ireland|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|30 Years|90 Years|No|||February 2013|February 4, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785251||71721|
NCT01785511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA Study|Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?|Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?||University of Edinburgh|Yes|Completed|March 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01785511||71701|
NCT01785264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/530/REK|Treatment Results After Acute Rupture of the Achilles Tendon.|Non-operative Treatment of Acute Achilles Tendon Ruptures Versus Open and Mini-invasive Surgery: A Prospective Randomized Trial.||University Hospital, Akershus|Yes|Recruiting|February 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01785264||71720|
NCT01785784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci-002-CT|Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn|Phase IV Clinical Trial of rhGM-CSF Hydro-gel for Topical Application on Deep 2nd Partial Thickness Burn|rhGM-CSF|GeneScience Pharmaceuticals Co., Ltd.|Yes|Completed|November 2010|July 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2510|||Both|3 Years|N/A|No|||February 2013|February 5, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01785784||71680|
NCT01785758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sugamadex01|Efficacy and Safety of Sugammadex in Renal Diseased Patients|Efficacy and Safety of Sugammadex (Bridion™) in the Reversal of Profound Rocuronium-induced Neuromuscular Blockade in Patients With End-stage Renal Failure: Comparison With Healthy Patients||Federal University of São Paulo|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2013|February 5, 2013|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01785758||71682|
NCT01785992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/22/2011|A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.|A Phase II Study to Assess the Safety and Efficacy of the Steroid Sulfa-tase Inhibitor Irosustat When Added to an Aromatase Inhibitor in ER Positive Locally Advanced or Metastatic Breast Cancer Patients.|IRIS|Imperial College London|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|25 Years|N/A|No|||March 2014|March 23, 2015|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785992||71664|
NCT01786603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12312|Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis IND# 104,360||University of Kansas Medical Center|Yes|Active, not recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|80 Years|No|||November 2015|November 18, 2015|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786603||71617|
NCT01786616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-AG-16|Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma|Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results||Catholic University, Italy|No|Completed|January 2005|||April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|white cells|Both|18 Years|60 Years|No|Probability Sample|Pneumological outpatient clinic|February 2013|February 6, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01786616||71616|
NCT01786876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD557-107|Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]SPD557 Following a Single Oral Dose in Healthy Male Subjects||Shire|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|February 6, 2013|No|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01786876||71596|
NCT01786889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGI HE-1110|Identification, Molecular Epidemiology Angiosarcoma of the Liver France|Identification, Molecular Epidemiology Angiosarcoma of the Liver France|ANGIHE|Centre Oscar Lambret|No|Recruiting|June 2013|November 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|N/A|N/A|No|||June 2014|June 20, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786889||71595|
NCT01783236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204012295|Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery|A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain||Weill Medical College of Cornell University|No|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783236||71876|
NCT01783210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4043/CE|Pregnancy Complications in Women With BMI>25 kg/m2 Enrolled in a Healthy Lifestyle and Eating Habits Program|Pregnancy Complications in Women With BMI>25 kg/m2 Enrolled in a Healthy Lifestyle and Eating Habits Program: a Randomized Controlled Trial.|TLC|University of Modena and Reggio Emilia|Yes|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01783210||71878|
NCT01771068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTY12|Trial of a Parenting Discussion Group in Panama, Central America|||University of Manchester|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01771068||72811|
NCT01771627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 221312|Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers|Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation||Roswell Park Cancer Institute|No|Active, not recruiting|October 2012|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771627||72768|
NCT01771588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.08.INF|Human Milk Fortifier - Growth Evaluation|Evaluation of Growth of Pre-Term Infants Fed a Human Milk Fortifier||Nestlé|Yes|Completed|April 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|153|||Both|N/A|1 Month|No|||February 2016|February 12, 2016|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01771588||72771|
NCT01771861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1912 (REK)|Evaluation of Trauma Team Activation Criteria|Evaluation of a University Hospital Trauma Team Activation Protocol: a Prospective Cohort Study||University Hospital of North Norway|No|Active, not recruiting|February 2013|January 2016|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Severly injured and potentially severly injured patients admitted at the University        Hospital North Norway|June 2015|June 1, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771861|1 Month|72750|
NCT01771887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATALLAH-FSI-6|Effects of Education Program for Lebanese Diabetic T2 in Their Behavior of Auto Managing, of Self-efficacy and Adhesion|Assessing the Effects of Education Program for Lebanese Diabetic Type 2 in Their Behavior of Auto Managing Their Sense of Self-efficacy and on Their Adhesion Therapy||Université de Montréal|No|Completed|February 2013|December 2014|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|108|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01771887||72748|
NCT01772446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPPS-01|Effectiveness of SMS in Diabetes Control|Effectiveness of Sending Sms Text Messages to Mobile Phone Patients to Remind Upcoming Appointments and Improve the Control of Diabetic Patients in Primary Care|SMSaludD|Basque Health Service|No|Completed|June 2013|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|117|||Both|35 Years|74 Years|No|||October 2015|October 20, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01772446||72705|
NCT01772758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD Study|Cystic Fibrosis and Endothelial Function: At Rest and During Exercise|Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise||Georgia Regents University|No|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|80|||Both|7 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772758||72681|
NCT01784744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10-113-01|Hyperthermia and the Amelioration of Autism Symptoms|Hyperthermia and the Amelioration of Autism Symptoms||Montefiore Medical Center|No|Completed|November 2012|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|Samples With DNA|Buccal samples collected for DNA and RNA extraction.|Both|5 Years|17 Years|No|Non-Probability Sample|Patients aged 5 to 17 diagnosed with Autism Spectrum Disorder will be enrolled.|June 2014|June 17, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784744||71760|
NCT01785277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-SCIM-01-2013|Validation of a Translation Into Spanish (Mexico) of the Spinal Cord Independence Measure III|Validation of a Translation Into Spanish (Mexico) of the Spinal Cord Independence Measure III||American British Cowdray Medical Center|No|Recruiting|January 2013|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|12 Years|N/A|No|Probability Sample|Patients with spinal cord injury.|February 2013|February 6, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785277||71719|
NCT01786057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13914022|Effect of Extracorporeal Shock Wave Therapy of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis|The Effect of Extracorporeal Shock Wave Therapy (ESWT)of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis||Isfahan University of Medical Sciences|No|Enrolling by invitation|November 2012|October 2013|Anticipated|August 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|N/A|No|||February 2013|February 5, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01786057||71659|
NCT01785771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-103-Sub-Study|A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c|An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c||Intarcia Therapeutics||Active, not recruiting|May 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|February 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01785771||71681|
NCT01786031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00668-35|Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program|Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program|PETRUS|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|December 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|55|||Male|18 Years|N/A|No|||February 2016|February 5, 2016|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01786031||71661|
NCT01786005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-002|Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity|Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity|ANTMS|Russian Academy of Medical Sciences|Yes|Recruiting|February 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786005||71663|
NCT01786018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBF2012|Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas|Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial|TBF|Azienda Ospedaliera San Giovanni Battista|No|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786018||71662|
NCT01786915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIO-102|Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days|Phase 1 Randomized, Double-Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Repeat Administration (7 Days) of Ascending Oral Doses of Bendavia in Healthy Volunteers||Stealth BioTherapeutics Inc.|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 31, 2014|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786915||71593|
NCT01786928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTR-001-RCB|The Role of Resistance Exercise in Chronic Obstructive Pulmonary Disease Exacerbation|Impact of Resistance Training During Hospitalization in COPD Patients: a Randomized and Controlled Trial|RECOPD|University of Sao Paulo|No|Completed|April 2009|October 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|80 Years|No|||February 2013|February 5, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01786928||71592|
NCT01782950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDI|Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes|Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults|SOUTH|Makerere University|Yes|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01782950||71898|
NCT01782989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16586|Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)|A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration|TOGA|University of Virginia|Yes|Recruiting|February 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|286|||Both|55 Years|N/A|No|||June 2015|June 19, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782989||71895|
NCT01783470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000309|Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue|Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|January 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783470||71858|
NCT01771393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.711|Cone-beam vs Multidetector Computed Tomography (CT) for Arthrography of the Wrist, Ankle, Elbow and Knee|Performance of Cone-beam Computed Tomography (CT) Compared to Multidetector CT for Arthrography of the Wrist, Ankle, Elbow and Knee|ARCOBE|Hospices Civils de Lyon|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|69|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|October 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01771393||72786|
NCT01771640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-006|Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS|Intrathecal Transplantation of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS||Royan Institute|Yes|Completed|August 2013|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||May 2012|December 31, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771640||72767|
NCT01771601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090113OXYVOS|Cerebral Oximetry in Newborns - Comparing INVOS 5100c and OxyPrem vs. 1.2|Cerebral Oximetry in Newborns - Comparing INVOS 5100c and OxyPrem vs. 1.2's Absolute Values, Sensitivity for Low Oxygen Levels and Reproducibility||Rigshospitalet, Denmark|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|N/A|10 Minutes|Accepts Healthy Volunteers|Non-Probability Sample|Healthy term infants born by elective caesarean section at Rigshospitalet, Denmark|September 2013|September 30, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771601||72770|
NCT01771614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucotox-2|Acute Exercise and Glucotoxicity|||Rigshospitalet, Denmark|No|Not yet recruiting|July 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01771614||72769|
NCT01772199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116477|Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis|Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis||GlaxoSmithKline|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|50 Years|No|||January 2015|January 15, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772199||72724|
NCT01772459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01785|Paper vs. Internet|Internet-administered Adolescent Scoliosis Questionnaires Compared With Traditional Pencil and Paper Versions: a Randomized Crossover Design|P vs I|University of British Columbia|No|Completed|August 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|139|||Both|10 Years|18 Years|No|Non-Probability Sample|Adolescents with idiopathic scoliosis will be asked to participate during visits to the        orthopaedic spine clinic at BC Children's Hospital|June 2014|June 20, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772459||72704|
NCT01772472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO27938|A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)|A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy||Hoffmann-La Roche||Recruiting|April 2013|March 2023|Anticipated|March 2023|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1484|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772472||72703|
NCT01773954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLAS|Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration|Optical Coherence Tomography Guided Treat and Extend Therapy for Neovascular Age Related Macular Degeneration Using Aflibercept (the ATLAS Study)|ATLAS|Wills Eye|Yes|Active, not recruiting|December 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773954||72589|
NCT01774214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-358|Pediatric Fast Fluid Trial 2|Rapid Pediatric Fluid Resuscitation: a Randomized Controlled Trial Comparing the Efficiency of Two Provider-Endorsed Manual Fluid Resuscitation Techniques|PFFT2|McMaster Children's Hospital|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 26, 2013|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01774214||72569|
NCT01785030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK2807|Nitrous Oxide Vasodilation Healthy Adult Volunteers|Peripheral Vasodilation in Healthy Adult Volunteers Receiving 50% Nitrous Oxide||Columbia University|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||November 2015|November 11, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785030||71738|
NCT01784991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(H)N - 4325|Study of Respiratory Depression When Using a Hydromorphone Pain Protocol|"Does a 1 Plus 1 Hydromorphone Pain Protocol Have a Similar Rate of Respiratory Depression to Physician Discretion Protocol in a Geriatric Population With Moderate to Severe Pain?"||Albert Einstein Healthcare Network|Yes|Terminated|December 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|116|||Both|60 Years|90 Years|No|||June 2014|June 24, 2014|June 25, 2012||No|difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT01784991||71741|
NCT01785004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001304|Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)|Interrelationship of Vitamin D Supplementation, Adiposity and CVD Risk Factors in a Randomized Clinical Trial|VITAL|Brigham and Women's Hospital|No|Enrolling by invitation|July 2012|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|600|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785004||71740|
NCT01785550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042025|Neuromuscular Ultrasound in ALS|Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study||Duke University|No|Completed|February 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients referred to the electromyography laboratory for ALS.|March 2015|March 10, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785550||71698|
NCT01785797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Subdural Drain Study|The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study|The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study||Kwong Wah Hospital|Yes|Not yet recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|60 Years|N/A|No|||February 2013|February 6, 2013|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785797||71679|
NCT01786070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390104|Effect of Nebulized Budesonide on Preventing Postextubation Complications in Critically Patients|||Isfahan University of Medical Sciences||Recruiting|March 2011|||March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|65 Years|No|||February 2013|February 5, 2013|February 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01786070||71658|
NCT01786044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH 2012-P-002093/1|The Impact of a "Serious Game" on Improving Patient's Medication Knowledge|The Impact of a "Serious Game" on Improving Patient's Medication Knowledge||Massachusetts General Hospital|No|Enrolling by invitation|March 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|850|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 31, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786044||71660|
NCT01786291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uyku-cpet-1|PAP Therapy Sleep Apnea and Exercise|Effects of Positive Airway Pressure Therapy on Exercise Parameters in Obstructive Sleep Apnea||University of Gaziantep|No|Completed|May 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients newly diasgnosed with obstructive sleep apnea in whom CPAP        therapy was indicated|February 2013|February 6, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786291||71641|
NCT01786304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/091/HP|Effect of Sacral Nerve Stimulation on Enteric Nervous System|Effect of Sacral Nerve Stimulation on Enteric Nervous System|ENS-3|University Hospital, Rouen|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|colonic biopsies|Both|18 Years|75 Years|No|Non-Probability Sample|Patient with fecal incontience refractory to standard medical treatment|July 2015|July 29, 2015|February 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786304||71640|
NCT01786668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921119|Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)||Pfizer|No|Completed|April 2013|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|208|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786668||71612|
NCT01786681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leticia2011|Use of Positive Pressure in Morbidly Obese Patients Undergoing Reduction Stomach Surgery|Use of Positive Pressure in Morbidly Obese Patients Undergoing Gastroplasty||Universidade Metodista de Piracicaba||Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01786681||71611|
NCT01786694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0022|Feasibility of Microdialysis by Laparoscopy|Feasibility of Microdialysis by Laparoscopy|MTM-COLON-I|Centre Hospitalier Universitaire, Amiens|Yes|Completed|October 2013|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01786694||71610|
NCT01782963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-498|Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)|A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma|RVD Lite|Massachusetts General Hospital|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|60 Years|N/A|No|||August 2015|August 3, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782963||71897|
NCT01782976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTTC11-04|Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)|A Phase II Trial of Cilengitide Plus Bevacizumab in Patients With Recurrent Glioblastoma||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2013|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01782976||71896|
NCT01783288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 121817|Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening|Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome - Screening Protocol||Vanderbilt University|No|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|110|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01783288||71872|
NCT01783483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712|An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery|An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery: A Prospective, Randomized Trial|SB|Biomet, Inc.|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|236|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783483||71857|
NCT01783496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-136-TM-T|Thermage CPT for Treatment of Facial and Neck Laxity|Clinical Comparison of the Thermage CPT™ System's Framed and Pattern Tips for Treatment of Facial and Neck Laxity||Valeant Pharmaceuticals|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|50|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|January 31, 2013|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01783496||71856|
NCT01771406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54613|CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients.|Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients.|NEBOSA|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||August 2012|January 15, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01771406||72785|
NCT01772784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.36.NRC|Effects of Phenolic Acids on Endothelial Function|||Nestlé|Yes|Completed|June 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|24|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|January 17, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01772784||72679|
NCT01771900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050-05-FB|Heart Failure Exercise And Resistance Training Camp (HEART Camp)|Heart Failure Exercise and Resistance Training CAMP|HEART Camp|University of Nebraska|Yes|Completed|April 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|19 Years|N/A|No|||January 2013|January 16, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01771900||72747|
NCT01772186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112158DIB|Freezing of Gait Correction and Fall Prevention: Developing a Real-time Somatosensory Stimulation System|Freezing of Gait Correction and Fall Prevention in People With Parkinson's Disease: Developing and Application of a Real-time Somatosensory Stimulation System||National Taiwan University Hospital|No|Recruiting|February 2013|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|85 Years|No|||October 2013|October 22, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772186||72725|
NCT01772212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116827|Bioequivalence Study for Terbinafine 250 mg|Bioequivalence Study Between Two Medications for the Oral Administration of Terbinafine 250 mg in Oral Solids in Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772212||72723|
NCT01773616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2035|Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis|Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis|RITUXILUP|Imperial College London|Yes|Recruiting|April 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|12 Years|75 Years|No|||February 2016|March 16, 2016|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01773616||72615|
NCT01773629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-38-LGH|Care Managers for Perinatal Depression (CMPD)|Care Managers for Perinatal Depression (CMPD)|CMPD|Lancaster General Hospital|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|194|||Female|13 Years|N/A|No|||January 2014|January 29, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01773629||72614|
NCT01773642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric HIV Disclosure|Pediatric HIV Disclosure Intervention|Comparative Effectiveness of Pediatric HIV Disclosure Interventions in Uganda||Harvard University|No|Recruiting|August 2013|July 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|800|||Both|7 Years|N/A|No|||November 2014|November 17, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01773642||72613|
NCT01785303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL114529-01|Multidisciplinary Approach to the Treatment of Insomnia and Comorbid Sleep Apnea|Multidisciplinary Treatment for Obstructive Sleep Apnea and Insomnia|MATRICS|Rush University Medical Center|Yes|Recruiting|February 2013|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01785303||71717|
NCT01785017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006397|The Effects of a Standardized Management Plan on Children With Critical Asthma|The Effects of a Standardized Clinical Assessment Management Plan (SCAMP) on Clinical Outcomes in Children With Critical Asthma|AsthmaSCAMP|Children's Hospital Boston|No|Recruiting|January 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Both|2 Years|N/A|No|Non-Probability Sample|Hospitalized children 2 years and older requiring intensive care treatment for asthma|February 2013|February 5, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01785017||71739|
NCT01785810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04712|Phase II Maraviroc for GVHD Prevention|A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|February 2013|||January 2016|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785810||71678|
NCT01785823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE1-11-288|Fentanyl Background Infusion for Acute Postoperative Pain|The Efficacy of the Time-scheduled Decremental Continuous Infusion of Fentanyl for Postoperative Patient-controlled Analgesia After Total Intravenous Anesthesia||Ajou University School of Medicine|Yes|Completed|April 2012|February 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|99|||Female|20 Years|65 Years|No|||February 2013|February 6, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785823||71677|
NCT01785836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-005|An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris|||Allergan|No|Withdrawn|March 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|12 Years|35 Years|No|||February 2013|February 22, 2013|February 5, 2013|Yes|Yes|Study was never initiated due to company decision. No study subjects were ever enrolled or    dosed.|No||https://clinicaltrials.gov/show/NCT01785836||71676|
NCT01786317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/171/HP|Anal Motor Function in Fecal Incontinence|Measure of Ano-rectal Motility in Fecal Incontinence||University Hospital, Rouen|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Heathy controls Patient with Fecal Incontience|July 2015|July 21, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786317||71639|
NCT01786629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI800-480|BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects||Braintree Laboratories|No|Completed|December 2012|||May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|338|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|February 6, 2013|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01786629||71615|
NCT01786642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AETOB|Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial|Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial.||Katholieke Universiteit Leuven|No|Recruiting|February 2013|April 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|all patients referred for flexible bronchoscopy|February 2013|February 6, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01786642||71614|
NCT01786902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3002_ISS_III|Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature|Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature||Dong-A ST Co., Ltd.|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|4 Years|13 Years|No|||May 2015|May 11, 2015|February 6, 2013||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01786902||71594|
NCT01786967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036147|Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)|Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly|URGE|University of North Carolina, Chapel Hill|No|Active, not recruiting|September 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Female|50 Years|N/A|No|||February 2016|February 9, 2016|February 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786967||71589|
NCT01786941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034434|Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes|Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes: Responses to Exercise Training and Gastric Bypass Surgery|BCAAM-PD|Duke University||Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|132|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786941||71591|
NCT01786954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036498|iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery|A Comparative Study of Icare Rebound Tonometry With Other Tonometry Modalities in Patients Following Vitreoretinal Surgery.||Duke University|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|68|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 6, 2013|No|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT01786954||71590|
NCT01784874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRV02|Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use|Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in Pre-exposure Use in Healthy Adults||Sanofi|No|Completed|February 2013|December 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|410|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 16, 2016|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784874||71750|
NCT01784887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370421|Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Trial|Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Randomized Trial||Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Terminated|January 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 4, 2013||No|Did not have study population to continue|No||https://clinicaltrials.gov/show/NCT01784887||71749|
NCT01783249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37173MDS|Influence of Exercise on Anemia in MDS Patients|The Influence of Exercise on Anemia in MDS Patients||University of Rochester|Yes|Withdrawn|November 2011|November 2012|Actual|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|21 Years|N/A|No|||January 2013|January 31, 2013|November 30, 2011||No|We were unable to find patients that fit the eligibility criteria.|No||https://clinicaltrials.gov/show/NCT01783249||71875|
NCT01783262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interventional Study Design|The Role of Extracorporeal Shock Wave Therapy in the Treatment of Trapezial-Metacarpal Osteoarthritis. A Double Blind Randomized Controlled Study.|The Role of Extracorporeal Shock Wave Therapy in the Treatment of Trapezial-Metacarpal Osteoarthritis.||University of Roma La Sapienza|No|Completed|December 2009|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||January 2013|January 31, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01783262||71874|
NCT01783275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121031|The Effect of Exercise on Hepatic Glucose Metabolism|The Effect of Exercise on Hepatic Glucose Metabolism in Type 2 Diabetes Mellitus||Vanderbilt University|No|Enrolling by invitation|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|68|||Both|40 Years|60 Years|No|||June 2015|June 1, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01783275||71873|
NCT01772485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD-India|Online Neuroplasticity Training for Remediation of ADHD in Adolescent Children (ONTRAC)|Double Blind Randomized Controlled Trial Evaluation of a Novel Brain Plasticity-based Training Program for the Remediation of Cognitive Deficits in Adolescents With ADHD in New Delhi, India||Posit Science Corporation|Yes|Completed|January 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|11 Years|17 Years|No|||May 2015|May 23, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01772485||72702|
NCT01772771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11-0852|Personalized Cancer Therapy|Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program||M.D. Anderson Cancer Center|No|Recruiting|March 2012|||March 2032|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8000|Samples With DNA|Blood drawn once during a scheduled visit. Buccal swab or saliva sample may be collected      during a scheduled visit for patients with hematologic or other disease.|Both|N/A|N/A|No|Non-Probability Sample|Individuals diagnosed with cancer.|January 2016|January 25, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01772771||72680|
NCT01772498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRVB-123|HRV Biofeedback for Brain Tumour Survivors|Heart Rate Variability Biofeedback for Psychologically Distressed Brain Tumour Survivors||British Columbia Cancer Agency|No|Suspended|January 2013|June 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|N/A|No|||May 2015|May 5, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01772498||72701|
NCT01771913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|boosteredADSCs|Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts|Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts for Refinements of Reconstructed Breasts||University of Sao Paulo|No|Completed|March 2012|May 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 14, 2013||No||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01771913||72746|
NCT01773330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-2012|High Resolution Manometry for Swallowing|High Resolution Manometry: Optimizing the Swallow Protocol|HRM|University of Florida|No|Terminated|October 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|71|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|January 11, 2013|No|Yes|Study has been halted per PI and IRB recommendation|No||https://clinicaltrials.gov/show/NCT01773330||72637|
NCT01773343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100169|Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals|Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals. A Randomized Controlled Trial With Blinded Response Evaluations||University of Aarhus|No|Active, not recruiting|November 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01773343||72636|
NCT01773668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 271|Feasibility Study - Integrated Sensor and Infusion Set. Trial III|FEASIBILITY STUDY TO ASSESS PERFORMANCE OF THE INTEGRATED SENSOR AND INFUSION SET. WITH HIGH INSULIN NEED USERS (TRIAL III)||Medtronic Diabetes R&D Denmark||Completed|November 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|21 Years|70 Years|No|||January 2013|February 4, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01773668||72611|
NCT01773681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBCelltech|Novel Imaging Markers for Rheumatoid Arthritis|Novel Imaging Markers for Rheumatoid Arthritis|NIMRA|University of California, San Francisco||Enrolling by invitation|October 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples Without DNA|blood sample will be collected and stored at Mary Nakamura's lab at the SF VAMC for future      studies.|Both|18 Years|N/A|No|Probability Sample|Patients will be recruited from the UCSF RA Cohort by Drs. John Imboden and Jonathan Graf        at SFGH and UCSF Medical Center RA Clinics.|August 2015|August 27, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01773681||72610|
NCT01774006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SemmelweisU-001|Comparison of Individual Culture and Group Culture of Preimplantation Embryos in Human IVF Treatments|Comparison of Individual Culture and Group Culture of Preimplantation Embryos in Human IVF Treatments|GroupCulture|Semmelweis University|No|Completed|September 2012|September 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|532|||Female|18 Years|45 Years|No|Probability Sample|Patients entering in vitro fertilization and embryo transfer treatment|September 2015|September 1, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774006||72585|
NCT01785316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGBG-013001|The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases||SCANDIUM|Sahlgrenska University Hospital, Sweden|Yes|Recruiting|June 2013|June 2020|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785316||71716|
NCT01785082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM-001|Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test|Prospective, Randomized, Controlled, Multi-centric, Phase III Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test||Humedics GmbH|No|Recruiting|January 2013|May 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01785082||71734|
NCT01785290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delirium_Haldol-prophy|pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium|Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial|REDUCE|Radboud University|Yes|Recruiting|June 2013|August 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|2145|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785290||71718|
NCT01785589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5891|Validation of Myocardial Perfusion Imaging|Stress Thallium-201/Rest Technetium-99m Sequential Dual Isotope High-Speed Myocardial Perfusion Imaging Validation Versus Invasive Coronary Angiography|CameraCZT|University Hospital, Grenoble|Yes|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|220|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01785589||71695|
NCT01786096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN19A-001|A Safety Study of SGN-CD19A for Leukemia and Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas||Seattle Genetics, Inc.|No|Active, not recruiting|February 2013|May 2019|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|1 Year|N/A|No|||March 2016|March 4, 2016|February 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786096||71656|
NCT01786109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008314 Part B|Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome|Study on the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Diarrhea-Predominant Irritable Bowel Syndrome||Mayo Clinic|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|75|||Both|18 Years|75 Years|No|||March 2013|March 13, 2013|February 5, 2013|Yes|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT01786109||71655|
NCT01786330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220121565|Do Elastic Abdominal Binders Reduce Post Operative Pain and Blood Loss?|Do Elastic Abdominal Binders Reduce Post Operative Pain and Blood Loss?||University of Kansas Medical Center|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786330||71638|
NCT01786343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1017|Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)|A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|Yes|Recruiting|February 2013|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||September 2015|September 28, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786343||71637|
NCT01786655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00003344|Safety Study of Long-Acting Local Anesthetic|Neosaxitoxin (NeoSTX) Alone and in Combination With Bupivacaine as Prolonged Duration Local Anesthetics: A Phase I Investigator-initiated Dose Escalation Study||Children's Hospital Boston|Yes|Completed|May 2013|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|105|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786655||71613|
NCT01783002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01220|11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues|Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues||University of British Columbia|No|Recruiting|May 2014|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01783002||71894|
NCT01784068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107I2201|Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients|A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.|ENESTFreedom|Novartis|No|Active, not recruiting|March 2013|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|216|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784068||71812|
NCT01784900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000475-17|Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab|Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.|IIPOP|Gustave Roussy, Cancer Campus, Grand Paris|No|Terminated|November 2012|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784900||71748|
NCT01784913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002411-26|A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer|A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer|UV1/hTERT2012P|Ultimovacs AS|Yes|Active, not recruiting|February 2013|July 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Male|18 Years|N/A|No|||January 2016|January 5, 2016|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01784913||71747|
NCT01783769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRITE Trial|Evaluating the Impact That Personnel Traffic Through the Operating Room Has on Surgical Site Infections|Barrow Randomized O.R. Traffic Trial|BRITE|St. Joseph's Hospital and Medical Center, Phoenix|No|Enrolling by invitation|March 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783769||71835|
NCT01785160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.65|Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir|Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)||Boehringer Ingelheim||Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|December 13, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01785160||71728|
NCT01772511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274|Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?|BrUOG 274: Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?||Brown University|Yes|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer clinic|December 2014|January 26, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01772511||72700|
NCT01772524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD403-CLIN-002|Safety, Efficacy and Pharmacokinetics of ALD403|A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines||Alder Biopharmaceuticals, Inc.|No|Completed|January 2013|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|55 Years|No|||January 2016|January 6, 2016|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772524||72699|
NCT01773057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHGDoc 2012|Effects of 'NHGDoc' on Quality of Care|Effects of the Computerized Decision Support System 'NHGDoc' on Quality of Care: a Cluster Randomized Controlled Trial|NHGDoc|Radboud University|No|Active, not recruiting|April 2013|May 2016|Anticipated|May 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||May 2015|May 6, 2015|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01773057||72658|
NCT01773070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-102|A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study|A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Active, not recruiting|June 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|November 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773070||72657|
NCT01773096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX-2013|Methylnaltrexone Use for Opioid-induced Postoperative Constipation|The Use of Methylnaltrexone to Reduce Post-operative Opioid-induced Constipation in the Pediatric Spinal Fusion Patient||Shriners Hospitals for Children|No|Completed|May 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|21 Years|No|||May 2015|May 15, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773096||72655|
NCT01773356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WASABI|Effect of Dihydrocapsiate on Energy Expenditure in Women|Randomized, Controlled, Parallel Trial to Evaluate the Effects of Dihydrocapsiate on Energy Expenditure in Women||University of Georgia|No|Completed|January 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|126|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01773356||72635|
NCT01773655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-235|Clinical and Histopathologic Characteristics of BAP1 Mutations|Clinical and Histopathologic Characteristics of BAP1 Mutations||Memorial Sloan Kettering Cancer Center||Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|460|Samples With DNA|tissue specimens blood or saliva sample|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC's clinics|January 2016|January 20, 2016|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773655||72612|
NCT01774266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D09I1137|Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer|Screening and Triage Test for Early Detection of Gastric Cancer|DEMRAC|Pontificia Universidad Catolica de Chile|Yes|Recruiting|September 2012|March 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Blood and biopsy samples are collected|Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|3000 population base study from rural area in south of Chile. This is area has one of the        highest incidence of gastric cancer in the world (35/100.000).|May 2013|May 30, 2013|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01774266||72565|
NCT01770080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004777-89|Efficacy of Euminz® for Tension-Type Headache|Efficacy and Safety of Euminz® (10% Ethanolic Solution of Peppermint Oil for Topical Use) Compared to Placebo in Patients With Episodic Tension-type Headache (ETTH); Phase IV Clinical Trial|CAS/B/016611|Charite University, Berlin, Germany|Yes|Completed|February 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01770080||72887|
NCT01785095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11E/FSH03|Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles|Prospective, Open-label, Uncontrolled Clinical Trial Evaluating Multiple Controlled Ovarian Hyperstimulation Cycles in Oocyte Donor, to Assess the Immunogenicity of FSH-IBSA||IBSA Institut Biochimique SA|No|Completed|March 2013|November 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|January 23, 2013||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01785095||71733|
NCT01785563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasal NIV-NAVA|Nasal Noninvasive NAVA in the Very Low Birth Weight Infant|Nasal Noninvasive NAVA Provides Ventilation in the Very Low Birth Weight Infant||University of Iowa|No|Not yet recruiting|February 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|1 Year|No|||February 2013|February 7, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785563||71697|
NCT01785602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039X2201|Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis||Novartis|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|65 Years|No|||November 2015|November 11, 2015|February 5, 2013||No||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01785602||71694|
NCT01785849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120229|20120229: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis||Amgen|Yes|Completed|March 2013|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|508|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785849||71675|
NCT01786980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX10002016001004|The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene|||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|January 2012|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|70 Years|No|Non-Probability Sample|The patients with radical hepatectomy in Eastern Hepatobiliary Surgery Hospital, and were        confirmed hepatocellular carcinoma pathologically. The liver function was Child-Pugh A, as        well as the Child-Pugh B achieved to A after treatment, and the HAI score of cirrhosis was        <12.|February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786980||71588|
NCT01786083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070489|Caring for Family Caregivers:a Research-action Study|Depression and Anxiety Symptoms Reduction and Perceived Wellbeing Improvement in Female Primary Caregivers of Chronically Ill Patients by the Application of Problem Solving Technique by Primary Health Care Nurses||Jordi Gol i Gurina Foundation|No|Completed|September 2007|July 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|122|||Female|N/A|N/A|No|||February 2013|February 7, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01786083||71657|
NCT01786356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 931/2010|Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two IOLs: Hoya iMics Y-60H vs. Bausch&Lomb MI60 (MIMI)|||Medical University of Vienna||Completed|March 2008|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|30 Years|N/A|No|||February 2013|February 5, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786356||71636|
NCT01783522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2A10|Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib|A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients||Case Comprehensive Cancer Center|Yes|Terminated|February 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|January 31, 2013|Yes|Yes|Research Cancelled|No||https://clinicaltrials.gov/show/NCT01783522||71854|
NCT01783782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEANSING FOR PED-CE|Small Bowel Cleansing for Capsule Endoscopy in Pediatric Patients|SMALL BOWEL CLEANSING FOR CAPSULE ENDOSCOPY IN PEDIATRIC PATIENTS: A PROSPECTIVE RANDOMIZED SINGLE-BLINDED STUDY|PREP-CE|Azienda Policlinico Umberto I|Yes|Recruiting|November 2005|September 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|5||Anticipated|200|||Both|2 Years|18 Years|No|||November 2005|February 4, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783782||71834|
NCT01784575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS021864-01|Increasing Use of Publicly Reported Pediatric Quality Data|IDEAS for a Healthy Baby: Reducing Disparities in Consumer Use of Publicly Reported Quality Data|IDEAS|Baystate Medical Center|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|746|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784575||71773|
NCT01784588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U9915-Solyx|Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence|A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of the Solyx™ Single Incision Sling System vs. the Obtryx™ II Sling System for the Treatment of Women With Stress Urinary Incontinence|Solyx|Boston Scientific Corporation|No|Active, not recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|N/A|No|||June 2015|June 18, 2015|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784588||71772|
NCT01785667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100088|Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark|Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark|DCPD1987|Odense University Hospital|No|Completed|January 2011|February 2013|Actual|November 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|Samples With DNA|buffy coat, whole blood, urine|Both|25 Years|45 Years|No|Probability Sample|This study includes a cohort of type 1 diabetic patients, who originally were identified        in 21 paediatric departments and studied in 1986. This group initially consisted of 1033        children and was estimated to involve around 80 percent of all Danish type 1 diabetic        patients below the age of 18. In 1995 further examinations were performed on the cohort;        this time 339 chose to participate.        In this study we will invite the participants from 1995 who also participated in the eye        examinations, n=324, to participate in yet another follow-up examination.|July 2014|July 29, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785667|16 Years|71689|
NCT01785901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-SYM-2012/1|The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China|The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China||AstraZeneca|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1500|||Both|18 Years|N/A|No|Probability Sample|Asthma patients from clinic|October 2014|October 10, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785901||71671|
NCT01785914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-TO-2012|Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.|Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.|ALL|Azienda Ospedaliera San Giovanni Battista|No|Recruiting|February 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Acute lymphoblastic leukemia patients|February 2013|February 5, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785914||71670|
NCT01772225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116913|NSCLC Burden of Illness Study|A Burden-of Illness Study in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)|LuCaBIS|GlaxoSmithKline||Completed|September 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Patients (living or deceased) with complete resection (no residual disease) of stage        IB-IIIA NSCLC.|March 2014|March 27, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772225||72722|
NCT01772823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 110 Version 3.0|An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis|Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|November 2012|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Male|18 Years|22 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01772823||72676|
NCT01772797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378X2102|Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer|A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer||Novartis|No|Active, not recruiting|June 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01772797||72678|
NCT01773369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032297|Intensive Motor Training After Perinatal Stroke to Enhance Walking|Intensive Motor Training After Perinatal Stroke to Enhance Walking||University of Alberta|Yes|Recruiting|November 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|8 Months|4 Years|No|||November 2015|November 30, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01773369||72634|
NCT01773694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC IRB 38335EP|Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries|Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries||Milton S. Hershey Medical Center|No|Recruiting|March 2013|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|914|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01773694||72609|
NCT01770093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094-23-HYMC|Preferences of Parents for Pediatric Inpatient Ward Physicians' Attire|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Parents whose children have been hospitalized|January 2013|January 15, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01770093||72886|
NCT01770379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2311|Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.|A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents|REASSURE2|Novartis|Yes|Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|241|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|October 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01770379||72864|
NCT01785108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIABGAD-1|DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen|Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen||Linkoeping University|No|Active, not recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|10 Years|18 Years|No|||March 2015|March 25, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785108||71732|
NCT01785576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12-140|Couple-Based Intervention for Patients With Head and Neck Cancer and Their Partners|Couple-Based Intervention for Patients With Head and Neck Cancer and Their Partners|CoupleCare|NorthShore University HealthSystem Research Institute|No|Completed|March 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785576||71696|
NCT01786720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04512|Analysis of the Time Taken to Triple Therapy (NOVARTIS)|Analysis of the Time Taken for Newly Diagnosed COPD Patients to be Prescribed Triple Therapy||Research in Real-Life Ltd|No|Active, not recruiting|October 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|20154|||Both|40 Years|N/A|No|Non-Probability Sample|Patients will have a QoF approved COPD read code and must be aged ≥ 40.|April 2014|April 30, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786720||71608|
NCT01786369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-384B|Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.|Determination of Adherence in Patients Admitted to a Psychiatric Unit for Decompensated Psychosis: an Analysis of Serum Levels of Antipsychotics.||Northwell Health|No|Completed|February 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with schizophrenia, schizoaffective disorder, or bipolar 1 disorder presenting to a        psychiatric emergency room for acute psychosis and requiring inpatient hospital admission.|April 2015|April 13, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786369||71635|
NCT01786382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-102|A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole|A Phase 1, Open-Label Study to Evaluate the Potential Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole, and Potentially Telaprevir, in Healthy Adult Subjects||Presidio Pharmaceuticals, Inc.|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|February 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786382||71634|
NCT01786707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 13724|Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus|Phase 2 Study of Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus|HOT|University of Miami|Yes|Completed|July 2009|March 2013|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|45 Years|65 Years|No|||March 2014|March 18, 2014|February 5, 2013|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01786707||71609|
NCT01784601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103337|Incidence of Hemidiaphragmatic Palsy After Interscalene Block|Incidence of Hemidiaphragmatic Palsy After Single Shot Interscalene Block for Pain Relief in Shoulder Surgery||Lawson Health Research Institute|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Control Group:        We will be including all patients undergoing shoulder surgery not scheduled for a nerve        block.|December 2015|December 10, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01784601||71771|
NCT01785433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBB-COPD-201|To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Open-Label, Repeat Dosing, Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered Via Breath Actuated Inhaler (BAI), SPIRIVA® HandiHaler® and Respimat® Soft Mist™ Inhaler (SMI) in Subjects With COPD||Teva Pharmaceutical Industries|No|Completed|January 2013|August 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|40 Years|80 Years|No|||August 2014|August 7, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785433||71707|
NCT01785446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cis-123|Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System|Effect of Dexmedetomidine on Cisatracurium Infusion and Sufentanil Consumption and Its Variations in Different Age Groups, Using a Closed Loop Computer Controlled System.||Tianjin Medical University General Hospital|Yes|Recruiting|November 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01785446||71706|
NCT01772238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116984|Bioequivalence Study of an Amoxicillin-Clavulanic|Bioequivalence Study of an Amoxicillin-Clavulanic Acid Suspension Preparation. Cross-over, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences Trial in Fasting Conditions||GlaxoSmithKline|No|Completed|March 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772238||72721|
NCT01772251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-ICP-P1b-01|Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study|A Single-Center, Multiple-dose, Randomized, Cross-Over, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study||Oshadi Drug Administration|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2013|October 27, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01772251||72720|
NCT01773382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK8197|The Effects of Weight Reduction in IgA Nephropathy|The Effects of Weight Reduction in Chronic Proteinuric IgA Nephropathy|WeightPro|Chulalongkorn University|No|Recruiting|October 2012|April 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2013|January 18, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01773382||72633|
NCT01773395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-217|GVAX vs. Placebo for MDS/AML After Allo HSCT|A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Recruiting|January 2013|January 2033|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01773395||72632|
NCT01772810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2010-1|Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI|A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI|SCI|Neuralstem Inc.|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01772810||72677|
NCT01773083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepBurn|Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma|Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)|Hepburn|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Terminated|October 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 16, 2013||No|insufficient recruitment of patients and high costs associated with the purchase and blinding    of study medication|No||https://clinicaltrials.gov/show/NCT01773083||72656|
NCT01774019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00047339|Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer|Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer||Boston Scientific Corporation|No|Recruiting|February 2013|September 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774019||72584|
NCT01774032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811201|H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older|An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older||Nanotherapeutics, Inc.|Yes|Completed|March 2013|October 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|91|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|October 7, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01774032||72583|
NCT01774292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12182|Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation|Evaluation of the Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation in Surgeries Without Nitrous Oxide Lasting More Than 2 Hours||Université de Sherbrooke|No|Completed|January 2013|November 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01774292||72563|
NCT01774305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2012-0142|Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy|Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy||Yonsei University||Completed|December 2012|June 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|75 Years|No|||January 2014|January 13, 2014|December 22, 2012||No||No|June 17, 2013|https://clinicaltrials.gov/show/NCT01774305||72562|
NCT01770392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.162|Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin|Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence Phase I Trial)||Boehringer Ingelheim||Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|January 15, 2013||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01770392||72863|
NCT01771224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF453|Effect of FAn-7 in UC Activity|Effect of Palmitoleic Acid (FAn-7) on Expression of HNF4γ and Ulcerative Colitis (UC) Activity|FAUC|National Institute of Medical Sciences and Nutrition, Salvador Zubiran|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|59 Years|No|||January 2012|January 16, 2013|January 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01771224||72799|
NCT01786122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFICANCER PI12/02113|Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients|PHYSICAL EXERCISE TO IMPROVE THE QUALITY OF LIFE OF CANCER PATIENTS DURING TREATMENT PROCESS: EFICANCER STUDY|EFICANCER|Basque Health Service|No|Recruiting|April 2013|December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786122||71654|
NCT01785329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDR13362|Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects|A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects||Sanofi|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785329||71715|
NCT01777672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marató-11|Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia|Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia (OD). A Randomized Controlled Trial.||Hospital de Mataró||Recruiting|October 2012|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|N/A|N/A|No|||March 2015|March 17, 2015|January 21, 2013||||No||https://clinicaltrials.gov/show/NCT01777672||72304|
NCT01777659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0317|Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery|Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery|TEBCABG|Hospital de Clinicas de Porto Alegre|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|48 Years|70 Years|No|||November 2013|November 7, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777659||72305|
NCT01778426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1051|Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy (French SCS Registry)|Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy|SME|Medtronic International Trading Sarl|No|Active, not recruiting|January 2012|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|413|||Both|N/A|N/A|No|Non-Probability Sample|All patients implanted (first implant or replacements) with a Medtronic neurostimulator in        selected French sites .|February 2016|February 18, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778426|2 Years|72246|
NCT01778439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52M51-002|A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Recruiting|February 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|90 Years|No|||February 2016|February 26, 2016|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778439||72245|
NCT01774500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BISTRO|Biomarkers In Seizure To Predict Recurrence and Severe Outcomes|Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department|BISTRO|Bistro Study Group||Completed|January 2013|March 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|2 5ml serum sample for proteine S100Beta and copeptine analysis|Both|18 Years|N/A|No|Non-Probability Sample|Emergency department patients|March 2014|March 26, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774500|1 Month|72547|
NCT01774513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212013|EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis|||Technische Universität München|No|Recruiting|January 2013|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|January 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01774513||72546|
NCT01774864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_EDD_III|Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction|Phase 3 Study to Evaluate the Efficacy and Safety of Once-a-day Dosing of Udenafil in the Treatment of Erectile Dysfunction||Dong-A ST Co., Ltd.|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|349|||Male|20 Years|N/A|No|||January 2013|January 23, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774864||72519|
NCT01775098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allopurinol in acute gout|Allopurinol in Acute Gout|Allopurinol in Acute Gout||Université de Sherbrooke|Yes|Withdrawn||February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|January 21, 2013||No|because of a lack of funding|No||https://clinicaltrials.gov/show/NCT01775098||72501|
NCT01775917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0106-CTIL|The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception.|The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception.||Carmel Medical Center|Yes|Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|200|||Female|20 Years|45 Years|No|Probability Sample|women of age 20-45 with missed abortion up to 8 weeks of pregnancy or incomplete abortion        treated with misoprostol in the emergency room|June 2014|June 1, 2014|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775917|6 Weeks|72438|
NCT01776164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRDA_MRI|Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia|Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|January 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|32|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Friedreich's ataxia at the early stage of the disease (e.g. ambulatory and        not wheelchair bound and no to early cardiomyopathy) Age- and gender-matched healthy        volunteers|November 2015|November 16, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01776164||72419|
NCT01737762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-031|Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2|A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2||Healthpoint|Yes|Active, not recruiting|November 2012|May 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737762||75367|
NCT01738386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912153|Living With Frontotemporal Dementia|Challenges of Living With Frontotemporal Dementia: The Perspective of the Affected Individual||National Institutes of Health Clinical Center (CC)||Terminated|June 2012|February 2016||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738386||75319|
NCT01738399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.09.NRC|Coffee and Metabolic Health Outcomes|Influence of Coffee Consumption on Insulin Sensitivity in Overweight and Insulin Resistant Subjects.|COMETH|National University Hospital, Singapore|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|128|||Both|35 Years|69 Years|No|||March 2012|April 21, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738399||75318|
NCT01738906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9532|The Effect of Alcohol on Food Reward|The Effect of Moderate Alcohol Consumption on Subsequent Food Reward||TNO|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|24|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738906||75279|
NCT01738893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116850|Bioequivalence Study of 300 mg Gabapentin|Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738893||75280|
NCT01739504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-OR-001|Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis||Ageless Regenerative Institute|No|Recruiting|March 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01739504||75233|
NCT01739517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND104555|Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease|Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease||Amarnath, Rathna, M.D.|Yes|Recruiting|March 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|1 Year|No|||November 2012|November 29, 2012|November 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01739517||75232|
NCT01735331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEHGynObs-3|Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss||Bagcilar Training and Research Hospital|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Female|18 Years|45 Years|No|Probability Sample|The patients with Recurrent Pregnancy Loss|August 2015|August 6, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01735331||75554|
NCT01765881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1014301|Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2|Comparison Between 25 µg Vaginal Misoprostol Versus Slow Release Pessary Prostaglandin-E2 (PGE2) : Could we Used Low Dose Vaginal Misoprostol as a First Line Treatment for Induction of Labor ?|CYTOPRO|University Hospital, Toulouse|No|Completed|September 2012|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1700|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765881||73209|
NCT01777685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT3|Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers|Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride|SUL|Damanhour University|Yes|Completed|January 2013|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777685||72303|
NCT01777958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28750|HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy|Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)||Hoffmann-La Roche||Recruiting|June 2013|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|262|||Female|18 Years|N/A|No|Probability Sample|Female patients with HER2-positive advanced breast cancer (metastatic or locally        recurrent, inoperable)who relapsed after adjuvant Herceptin therapy, with indication for        treatment with Perjeta in combination with Herceptin|March 2016|March 1, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01777958||72282|
NCT01778231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/05v1|Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation|Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation||Queen's University, Belfast|No|Recruiting|March 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778231||72261|
NCT01778452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC18012013|Endometrial Genomic Profile in Endometrial Priming|Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|November 2009|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|6|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778452||72244|
NCT01778465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103330|Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease|Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease||Lawson Health Research Institute|No|Completed|May 2013|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 1, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778465||72243|
NCT01774526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-B/11/139|Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype|Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype||National University Hospital, Singapore|No|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|21 Years|N/A|No|||December 2012|January 21, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01774526||72545|
NCT01774539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03016|Diffusion MRI and Growth Plate Injuries: Pilot Study|Diffusion MRI as a Prognostic Tool in Growth Plate Injuries: A Pilot Study to Assess Feasibility||University of British Columbia|No|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|8 Years|12 Years|No|Non-Probability Sample|Study subjects will be selected from the Orthopaedic Trauma Clinic at BC Children's        Hospital|November 2015|November 30, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774539||72544|
NCT01774552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2012-9094|Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment|A Pilot Study of Photo Acoustic Microscopy and Optical Coherence Tomography Imaging Technologies to Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment.||University of California, Irvine|No|Recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from Beckman Laser Medical Clinic, UCI|February 2016|February 5, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774552||72543|
NCT01775683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120651-01H|Can we Predict Chronic Homelessness?|A Case-control Study to Determine Whether a Screening Measure of Executive Dysfunction, the Quick EXIT, is Predictive of Chronic Homelessness||Ottawa Hospital Research Institute|No|Not yet recruiting|January 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Homeless men and women, greater or equal to 18 years, English-speaking, in Ottawa, ON,        Canada|January 2013|January 22, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01775683||72456|
NCT01774838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1649|Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome|Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome||University of Cologne|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|75 Years|No|||June 2015|June 10, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01774838||72521|
NCT01774851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-111-13-02-04|A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach|Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy||Merrimack Pharmaceuticals|Yes|Completed|January 2013|December 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|December 15, 2015|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774851||72520|
NCT01775085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-291|Group Interventions for Breast Cancer Survivors|Development of Group Interventions for Breast Cancer Survivors||Memorial Sloan Kettering Cancer Center||Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|85|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775085||72502|
NCT01776723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17259|A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib|A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776723||72376|
NCT01738087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1205-PR-0087|Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder|A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhaler (Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 Mcg and 200 Mcg) Administered With and Without Activated Charcoal in Adult Asthmatic Patients.||Chiesi Farmaceutici S.p.A.|No|Completed|November 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Both|18 Years|70 Years|No|||January 2013|January 29, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01738087||75342|
NCT01738659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPA|Estimated Echocardiographic Pulmonary Capillary Wedge Pressure in Heart Failure|Moderate Versus Low Sodium Diet Intake Effects on Estimated Echocardiographic Pulmonary Capillary Wedge Pressure During 12 Months of Follow up in Compensated Heart Failure Patients.||University of Palermo|No|Completed|October 2008|September 2012|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|143|||Both|18 Years|85 Years|No|||November 2012|November 27, 2012|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01738659||75298|
NCT01738672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR011090221|Inhaled Nitrous Oxide and Labor Analgesia|Inhaled Nitrous Oxide and Labor Analgesia||University of Pittsburgh|Yes|Suspended|February 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|14 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01738672||75297|
NCT01768247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THINENDOM001|HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)|HCG Priming for Thin Endometrium in IVF||Universitair Ziekenhuis Brussel|No|Active, not recruiting|January 2012|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|30 Years|50 Years|No|||January 2013|January 16, 2013|January 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01768247||73028|
NCT01739179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/06|Keyhole Surgery for the Positioning of the Distal Catheter in Ventricular Peritoneal Shunt Placement|Laparoscopically Assisted Ventriculoperitoneal Shunt Placement: A Prospective, Randomized Two-arm Study||University Hospital Inselspital, Berne|No|Completed|March 2007|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Probability Sample|Randomized are all patients who are 18 years or older; who are treated at the Department        of Neurosurgery, Inselspital Bern; who are diagnosed with a Hydrocephalus and need a VP        Shunt; Patients who have a Shunt malfunction and Patient who have given the written        approval (informed consent)|December 2012|December 17, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739179||75258|
NCT01768806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3125511|Randomized Controlled Trial of the P.L.A.Y. (Play and Language for Autistic Youngsters) Project Intervention for Autism|Randomized Controlled Trial of the P.L.A.Y. Project Intervention for Autism|PLAY|Richard Solomon MD, Plc|No|Completed|September 2009|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|3 Years|5 Years|No|||January 2013|January 16, 2013|January 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01768806||72985|
NCT01768819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 - REVITA|Multimodal Physical Activity for the Elderly|The Effects of an Elderly-specific Multimodal Physical Activity Program: a Controlled Clinical Trial||Universidade Federal de Sao Carlos|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|60 Years|N/A|No|||January 2013|January 22, 2013|January 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01768819||72984|
NCT01769079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 08-168|Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina|Withdrawal of Nitrate in Patients With Stable Angina - Multicenter Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769079||72964|
NCT01769716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBGDD|Umbilical Cord Blood Therapy for Global Developmental Delay|Umbilical Cord Blood Therapy for Children With Global Developmental Delay||Bundang CHA Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|6 Months|15 Years|No|||March 2014|March 31, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769716||72915|
NCT01769729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH085762|Program for Emotional and Physical Pain - Pilot Randomized Clinical Trial|Program for Emotional and Physical Pain - Pilot Randomized Clinical Trial|PEPP - RCT|Butler Hospital|Yes|Completed|December 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769729||72914|
NCT01778244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRWu|Metformin for Treatment of Antipsychotic-induced Dyslipidemia|Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study||Central South University|Yes|Completed|November 2008|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|50 Years|No|||January 2013|January 25, 2013|January 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778244||72260|
NCT01778192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korea University|A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate|A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy||Korea University Anam Hospital|Yes|Completed|July 2012|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Actual|200|||Both|18 Years|75 Years|No|||January 2013|January 29, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778192||72264|
NCT01778205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISPV_Murphy1|The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.|Phase 1 Study of the Effect of Maternal Nutritional Status on Placental Vascular Function, Fetal Growth and Intrauterine Growth Retardation.||Institut Investigacio Sanitaria Pere Virgili|Yes|Recruiting|January 2005|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Plasma Serum Leukocytes Placenta|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women less than 12 weeks pregnant at their first pre-natal check up are recruited from the        URV University Hospitals: Sant Joan (Reus) and Joan XXIII (Tarragona)|November 2014|November 28, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778205||72263|
NCT01778218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-ECDG-C2|A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)|A Single Center Pilot Study to Establish the 99mTc-EC-DG Imaging Protocol to Evaluate the Presence and Severity of Coronary Artery Disease||Cell>Point LLC|Yes|Completed|January 2013|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778218||72262|
NCT01778491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130027|AMD Phenotype and Genotype Study|AMD Phenotype and Genotype Study (APGS)||National Institutes of Health Clinical Center (CC)||Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|49|||Both|60 Years|90 Years|No|||September 2015|October 27, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778491||72241|
NCT01774565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGIE02|Closed-loop Insulin Delivery in the General Ward|An Open-label, Single-centre, Randomised, Parallel Design Study to Assess the Efficacy and Safety of 72-hour Automated Closed-loop Glucose Control in Comparison With Conventional Treatment in Insulin Treated Type 2 Diabetes|ANGIE02|University of Cambridge|No|Recruiting|October 2014|||December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774565||72542|
NCT01774578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0301|Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer|An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer||NewLink Genetics Corporation|Yes|Recruiting|February 2013|||December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774578||72541|
NCT01775969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3329|Effect of Modality on Discharge Instruction in Patients Receiving Outpatient Antibiotic Prescriptions From the Emergency Department|Effect of Modality on Discharge Instruction in Patients Receiving Outpatient Antibiotic Prescriptions From the Emergency Department||Minneapolis Medical Research Foundation||Completed|May 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|2874|||Both|N/A|N/A|No|||October 2013|October 24, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775969||72434|
NCT01775358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALRN-100-01|Phase 1 Safety Study of ALRN-5281 in Healthy Subjects|A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers||Aileron Therapeutics|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|33|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775358||72481|
NCT01775670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis|Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis||Massachusetts General Hospital|No|Enrolling by invitation|February 2013|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775670||72457|
NCT01775943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIRES0070|Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC|Efficacy of EGFR Tyrosine Kinase Inhibitors (EGFR TKIs) in Patients With EGFR-mutated Non-small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L859R: A Retrospective Analysis||Ulsan University Hospital|No|Enrolling by invitation|March 2013|February 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|90|||Both|N/A|N/A|No|Non-Probability Sample|comprehensive cancer hospital|December 2013|December 10, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01775943||72436|
NCT01774643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XENO-METPANC|A Study of Pancreatic Cancer in Xenografts From Liver Metastases|A Feasibility Study Of Developing Murine Primary Xenografts From Biopsies Of Liver Metastases In Patients With Advanced Pancreatic Cancer||University Health Network, Toronto|No|Active, not recruiting|January 2013|December 2016|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|Samples With DNA|Tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Pancreatic cancer patients with liver metastases|March 2016|March 14, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774643||72536|
NCT01738412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-002|Validation of an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS|Validation of an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS.||Neurokeeper Technologies|No|Not yet recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Stroke patients|November 2012|November 29, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738412||75317|
NCT01767974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIRES0066|Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer|Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer|SPACE|Chonnam National University Hospital|No|Recruiting|January 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|DNA from lung cancer tumor tissue obtained by bronchoscopy, needle biopsy or surgical      resection|Both|N/A|N/A|No|Non-Probability Sample|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer|January 2013|January 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767974||73049|
NCT01767688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-031|A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-3102 in Patients With Impaired Hepatic Function||Merck Sharp & Dohme Corp.|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|January 10, 2013|No|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01767688||73071|
NCT01767987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISR IN-US-259-0139|Ranolazine Cardioprotection in PCI|Ranolazine Cardioprotection in PCI||Kettering Health Network|No|Terminated|November 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 28, 2012||No|Sponsor terminated study due to lack of enrollment|No|September 9, 2014|https://clinicaltrials.gov/show/NCT01767987||73048|
NCT01768260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eye EECP-1|Effect of EECP on Anterior Ischemic Optic Neuropathy|Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy|AION|First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|December 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 18, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768260||73027|
NCT01768533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K07CA113643|Pediatric Behavioral Informatics to Prevent Cancer|Pediatric Behavioral Informatics to Prevent Cancer|TIDE|University of Massachusetts, Boston|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|305|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population of parents with children ages 4-10 years who reside in the Greater        Boston area. Parents are defined as primary care givers or legal guardians who take        primary responsibility for the child's health which includes attending the child's        well-care visits.|January 2013|January 11, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01768533||73006|
NCT01768273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-824-CL-006|Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam|A Phase 1, Open-label, Multi-Dose Study to Assess Pharmacokinetic Interaction Between PA-824 and Midazolam||Global Alliance for TB Drug Development|No|Completed|December 2009|April 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|January 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01768273||73026|
NCT01768559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12626|Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients|A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin|GetGoal Duo-2|Sanofi|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|894|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768559||73004|
NCT01768832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS077959-01A1|Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms|Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms||Washington University School of Medicine|Yes|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|N/A|No|||December 2015|December 7, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768832||72983|
NCT01769092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNM1302|Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders|Double Blind Placebo Controlled Trial of Effects of DHA in Fish Oil for the Treatment of Seizure Disorders.||The Canadian College of Naturopathic Medicine|Yes|Recruiting|January 2013|January 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|15 Years|65 Years|No|||January 2016|January 27, 2016|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769092||72963|
NCT01769651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLiPID01|Clinician-patient Interaction During Addiction Consultation|Clinician-patient Interaction During Addiction Consultation and Drug Overdose Risk|CLiPID|University of St Andrews|Yes|Not yet recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|16|||Both|18 Years|65 Years|No|Probability Sample|All drug user patients refered to the NHS Fife Addiction Services by a Fife wide triage        contact point, patient GPs or Consultant, who are to have a first session with their        Addiction Nurses, are identified as potential patient participants.|February 2015|February 16, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769651||72920|
NCT01769742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG-12-237|Early Mobility Bundle to Prevent Hospital Acquired Pneumonia (HAP) in Medical Inpatients|Use of Early Mobilisation to Reduce Incidence of Hospital Acquired Pneumonia in Medical Inpatients||University of Birmingham|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1178|||Both|16 Years|N/A|No|||December 2014|December 1, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01769742||72913|
NCT01777971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-00672|The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis|The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis||New York University School of Medicine|No|Withdrawn|July 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with cirrhosis with diuretic-resistant refractory ascites (based on International        Ascites Club criteria)|August 2015|August 3, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777971||72281|
NCT01777984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-08-122-0708|Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration|Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration||Rudolf Foundation Clinic|No|Active, not recruiting|December 2009|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with age-related macular degeneration, over 60|January 2013|January 24, 2013|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777984||72280|
NCT01777997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5308|FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir|A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers||AIDS Clinical Trials Group|Yes|Active, not recruiting|February 2013|January 2017|Anticipated|February 2016|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777997||72279|
NCT01778478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130019|A Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults|Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778478||72242|
NCT01775111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ActiveAgeing|Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly|Influence of Strength Training and Nutritional Supplementation on Physical Performance and Well-being of Older People in Pensioner Homes||University of Vienna|No|Recruiting|January 2012|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 21, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775111||72500|
NCT01775371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-485|Effectiveness and Feasibility of Patient Controlled Analgesia in the ED|Effectiveness and Feasibility of Patient Controlled Analgesia in the ED||Albert Einstein College of Medicine of Yeshiva University|Yes|Enrolling by invitation|April 2013|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|65 Years|No|||January 2013|May 16, 2013|October 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775371||72480|
NCT01775384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0134|Polyphenols, Exercise, and Metabolomics|Influence of a Polyphenol-enriched Protein Powder on Exercise-induced Inflammation and Oxidative Stress in Athletes: a Metabolomics Approach||Appalachian State University|Yes|Completed|April 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01775384||72479|
NCT01776450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120003/S4|Compassionate Use of the Incraft® AAA Stent Graft System|Compassionate Use of the Incraft® AAA Stent Graft System||Cordis Corporation|No|Available|November 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||December 2014|December 31, 2014|January 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01776450||72397|
NCT01775956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2003:087|A Retrospective Review of a Comprehensive Cohort of Septic Shock: Assessment of Critical Determinants of Outcome|A Retrospective Review of a Comprehensive Cohort of Septic Shock: Assessment of Critical Determinants of Outcome||University of Manitoba|No|Recruiting|December 2003|July 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Medical charts from all patients coded as septic shock in an internal ICU registry since        1994.|July 2013|July 24, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01775956||72435|
NCT01776437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|673-103|Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers|A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers||Medivation, Inc.|No|Completed|February 2013|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01776437||72398|
NCT01778036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2522|Neck Motion and Motor Control in Chronic Neck Pain and Associations With Clinical Symptoms|Neck Motion and Motor Control in Chronic Neck Pain and Associations With Clinical Symptoms||Norwegian University of Science and Technology|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|67 Years|No|Probability Sample|Neck pain patients referred to physiotherapy treatment in primary health care|September 2014|September 25, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778036||72276|
NCT01775150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0029-01-04-01-01|Saving Mother and Baby With Text Messaging|Using Mobile Phone Text Messaging to Reduce Maternal and Infant Deaths in Remote Rural Areas in China||Ottawa Hospital Research Institute|No|Active, not recruiting|October 2011|May 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|5646|||Female|16 Years|45 Years|No|||January 2013|January 22, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775150||72497|
NCT01767662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si319/2011|Effectiveness of Parents' Manipulation in Newborn With Talipes Calcaneus|Natural History and Effectiveness of Parents' Manipulation in Newborn With Talipes Calcaneovalgus,a Randomized Controlled Trial||Mahidol University|No|Recruiting|May 2011|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|6 Months|No|||January 2013|January 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01767662||73073|
NCT01767675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-275|Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Female|21 Years|N/A|No|||December 2015|December 21, 2015|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767675||73072|
NCT01767701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008717QM|Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis|A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI|INSPIRE|Queen Mary University of London|Yes|Recruiting|April 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|No|||July 2013|July 12, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01767701||73070|
NCT01768585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HomRate04_2012|Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease|A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease||University Hospital, Saarland|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|90 Years|No|||January 2013|January 14, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768585||73002|
NCT01768546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project NOT ME 11-351|Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults|Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults|Project NOT ME|UnitedHealth Group|No|Completed|February 2012|September 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|306|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01768546||73005|
NCT01769378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13193|Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)|A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)|AWARD-8|Eli Lilly and Company|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|January 14, 2013|Yes|Yes||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01769378||72941|
NCT01769391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14790|A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769391||72940|
NCT01769664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBG 1209|A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to Duac® Topical Gel Clindamycin 1%/Benzoyl Peroxide 5% (Stiefel) in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|September 2012|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|650|||Both|12 Years|40 Years|No|||January 2014|January 19, 2014|October 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01769664||72919|
NCT01769677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/1099|A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet|A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 45-mg and One 90-mg Hydrocodone Bitartrate Extended-Release Tablet||Teva Pharmaceutical Industries|No|Completed|January 2013|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|January 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769677||72918|
NCT01765686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCS ED 2011739D|Comparing Harmonic Ultrasonic Scalpel to Small Jaw Bipolar Device in Thyroid Surgery|Randomized Controlled Trial Comparing the Utility of an Ultrasonic Coagulating Device (UCSD) With Electrothermal Bipolar Vessel Sealer (EBVS) in Thyroid Surgery.||National Cancer Centre, Singapore|No|Recruiting|December 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|75 Years|No|||November 2015|November 8, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01765686||73224|
NCT01777711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040490|Exploring Beliefs and Behaviors About Weight Loss in Couples|Exploring Beliefs and Behaviors About Weight Loss in Couples||Duke University|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01777711||72301|
NCT01774591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1179|Effect of Azilsartan on Aldosterone in Postmenopausal Females|Effect of Azilsartan on Aldosterone in Postmenopausal Females||University of Chicago|No|Completed|January 2013|January 2016|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|45 Years|70 Years|No|||January 2016|January 8, 2016|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774591||72540|
NCT01774604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#23749|Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Rectal Indomethacin to Prevent Post-ERCP Pancreatitis||Dartmouth-Hitchcock Medical Center|Yes|Terminated|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|449|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|January 21, 2013|Yes|Yes|Futility|No||https://clinicaltrials.gov/show/NCT01774604||72539|
NCT01778257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH_2011_GS_MATE|Efficacy and Safety of Mate Extracts on Decrement of Body and Abdominal Fat in Obese Subjects|Mate Extract Supplementation Reduces Body and Abdominal Fat in Obese Korean Subjects||Chonbuk National University Hospital|Yes|Completed|October 2011|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01778257||72259|
NCT01778088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-13-001|Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma|A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma||Cellectar Biosciences, Inc.|No|Withdrawn|May 2014|January 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778088||72272|
NCT01778582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913021|Perspective-taking, and Examining the Clinical Trial Informed Consent Process|Perspective-taking, and Examining the Clinical Trial Informed Consent Process||National Institutes of Health Clinical Center (CC)||Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 19, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778582||72234|
NCT01777516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsanMC_CPT_PAT_2012|In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid|In Vitro Study to Evaluate the Pharmacodynamic Interaction Between Ticagrelor and Its Active Metabolite (AR-C124910XX) and Their Effects on the Pharmacodynamics of Salicylic Acid : Concentration-antiplatelet Effect Relationships|In_vitro_PAT|Asan Medical Center|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|N/A||1|Actual|24|Samples With DNA|Plasma and white blood cells|Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|January 2013|January 24, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01777516||72316|
NCT01776957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00829|Post Abortion IUD & Recurrent Abortion 2005-2006|Preventing Repeat Abortion: Is the Immediate Insertion of Intrauterine Devices Post-abortion a Cost-effective Option Associated With Fewer Repeat Abortions? Findings From 2005-2006 Data||University of British Columbia|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1308|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female resident of Interior Health region seeking an abortion|February 2013|February 1, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01776957||72358|
NCT01778543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130049|Genetics of Uveal Coloboma|Genetics of Uveal Coloboma||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|240|||Both|1 Year|N/A|No|||January 2016|January 22, 2016|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778543||72237|
NCT01767350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55088|Determinants of Immunosuppressive Dose Requirements in Children After Solid Organ Transplantation|Study Aimed at Determining the Relation Between the Administered Dose and Exposure to Immunosuppressive Medication in Children After Solid Organ Transplantation||Universitaire Ziekenhuizen Leuven|No|Completed|February 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60|Samples With DNA|tube of whole blood (8 ml) to be processed for DNA extraction and storage|Both|1 Year|30 Years|No|Non-Probability Sample|Pediatric recipients of a solid organ transplantation|December 2015|December 14, 2015|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767350||73097|
NCT01767103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA40-0412|An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers|An Open-Label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox® in Subjects With Impaired Hepatic Function and Healthy Volunteers||ApoPharma|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|September 3, 2014|January 9, 2013|Yes|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01767103||73116|
NCT01767363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116059|WEUSKOP5723: Prostate Cancer Study|Prostate Cancer in Benign Prostatic Hyperplasia (BPH) Patients||GlaxoSmithKline|No|Active, not recruiting|November 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1|||Male|50 Years|N/A|No|Non-Probability Sample|All men age 50 years and older treated with a BPH medication (5ARI and/or alpha-blocker)        will be eligible for inclusion. Participants are not required to have a BPH diagnosis at        the time of their first 5ARI or alpha-blocker prescription as based upon data from the        feasibility report approximately half of all men received their first recorded BPH        diagnosis after initiating treatment. Furthermore, approximately 25% of participants        treated with 5ARIs or alpha-blockers did not have a diagnosis code for BPH in their        medical record. BPH diagnosis codes were not used in a consistent way historically in the        Kaiser data. Men should have coverage within the healthcare system for at least 1-year        before the first BPH medication prescription. Men with a history of prostate cancer or who        develop prostate cancer within <3 months of starting their first BPH medication are not        eligible for inclusion.|February 2016|February 11, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01767363||73096|
NCT01768286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0109|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection|ION-2|Gilead Sciences|Yes|Completed|January 2013|February 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|441|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|January 10, 2013|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01768286||73025|
NCT01768572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY13370|To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)|A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists||Sanofi|Yes|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768572||73003|
NCT01769105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHUAU052012|Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime|Prospective, Randomized, Controlled Comparison of an Automated Thermal Pulsation Treatment (Lipiflow ®) and a Standard Lid Hygiene Regime||Heinrich-Heine University, Duesseldorf|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|January 11, 2013|Yes|Yes||No|September 1, 2014|https://clinicaltrials.gov/show/NCT01769105||72962|For further information please have a look at Finis et al: Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.Ocul Surf. 2014 Apr;12(2):146-54.
NCT01769118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0442-12|The Influences of Caffeine on Heart Rate Variability of Preterm Infants|The Influences of Caffeine on HRV of Preterm Infants||Rambam Health Care Campus|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Both|25 Weeks|34 Weeks|No|Non-Probability Sample|25 preterm infants|May 2015|May 6, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769118||72961|
NCT01769417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ID-MEDI4893-1133|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects||MedImmune LLC|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769417||72938|
NCT01769690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121004006|The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients|The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD Patients||University of Alabama at Birmingham|No|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|48|||Both|19 Years|N/A|No|||January 2016|January 12, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769690||72917|
NCT01769703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATAS|Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke|Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke|DATAS|University of Alberta|Yes|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01769703||72916|
NCT01766453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFU|South Asian Yoga and Exercise Trial|Utility of a Culturally Relevant or a Standard Exercise Program to Reduce Visceral Adipose Tissue and Cardiovascular Disease Risk in Abdominally Obese Postmenopausal South Asian Women|SAYET|Simon Fraser University|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|75|||Female|45 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01766453||73165|
NCT01778504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130028|Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders|Diagnosis and Treatment of Childhood-onset Behavioral Disorders, Neuropsychiatric Disorders and Neurodevelopmental Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|N/A|||Anticipated|3500|||Both|N/A|99 Years|No|||April 2015|November 18, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01778504||72240|
NCT01775722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2012-9092|Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment|Combined Bipolar Radiofrequency and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks||University of California, Irvine|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|N/A|No|||August 2015|August 4, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01775722||72453|
NCT01774877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI26B02|A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome|Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial||The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Yes|Completed|July 2013|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774877||72518|
NCT01778322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 11-001|WEB Clinical Assessment of IntraSaccular Aneurysm Therapy|WEB Clinical Assessment of IntraSaccular Aneurysm Therapy|WEBCAST|Sequent Medical, Inc|No|Active, not recruiting|December 2011|June 2020|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Probability Sample|Subjects with:        - Diameter and width of the aneurysm is appropriate size for treatment with the WEB        Aneurysm Embolization System per device Instructions for Use|February 2016|February 24, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778322||72254|
NCT01775696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100145|Central and Systemic Inflammation in Alzheimer's Disease|The Role of Central and Systemic Inflammation and Aβ-specific Immune Responses in Early AD|IMABio3|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|125|Samples With DNA|blood|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate        dementia), 15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations, 30        asymptomatic relatives to familial AD patients, 40 controls, 5 genetic forms of FTD|December 2015|December 21, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775696||72455|
NCT01784965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17394|Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.|Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.||Stanford University|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784965||71743|
NCT01777750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI209|Cooling in Myocardial Infarction|Strategic Target Temperature Management in Myocardial Infarction|STATIM|Medical University of Vienna|No|Recruiting|February 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01777750||72298|
NCT01774903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014533|An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Severe Chronic Low Back Pain|Evaluation Study of Efficacy and Safety of TTS-Fentanyl in Severe Chronic Low Back Pain||Janssen-Cilag Ltd.,Thailand|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|January 21, 2013|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01774903||72516|
NCT01767714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12482|Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation||Sanofi|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||December 2014|December 8, 2014|December 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01767714||73069|
NCT01767727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-TS-0130067|Repair of Multiple Finger Defects Using the Dorsal Homodigital Island Flaps|||The Second Hospital of Tangshan|Yes|Completed|March 2008|October 2012|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||October 2012|January 11, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01767727||73068|
NCT01768000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173/2012|The Family Cognitive Adaptation Training Manual: A Test of Effectiveness|The Family CAT (Cognitive Adaptation Training Manual): A Test of Effectiveness||Centre for Addiction and Mental Health|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|N/A|No|||February 2016|February 1, 2016|January 9, 2013||No||No|September 22, 2015|https://clinicaltrials.gov/show/NCT01768000||73047|
NCT01768013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0904|The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris|||LEO Pharma||Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||May 2015|May 13, 2015|January 10, 2013||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT01768013||73046|
NCT01768325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104-03|Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)|Evaluation of a New EUS-guided Needle (ProCore) Comparing to Conventional EUS-TCB Needle (Quick-Core); A Prospective Randomized, Controlled Multi-center Study.||Indiana University|Yes|Completed|January 2012|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|85|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|January 9, 2013||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01768325||73022|
NCT01768338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0397|Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma|A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma||Indiana University|Yes|Recruiting|February 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|January 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01768338||73021|
NCT01768845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 1909|Cord Blood Transplant|Unrelated Umbilical Cord Blood (UCB) Transplantation||West Virginia University|Yes|Recruiting|February 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|70 Years|No|||January 2013|January 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768845||72982|
NCT01769131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB39|A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures|A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures|OB39|Carilion Clinic|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|81|||Female|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females between the ages of 18 and 89 years undergoing an IUD placement|August 2015|August 2, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769131||72960|
NCT01769144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS12-CT9-09|Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh|Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh---A Randomised Controlled Trial||Kaohsiung Veterans General Hospital.|No|Recruiting|January 2013|April 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||January 2013|February 20, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769144||72959|
NCT01769404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14870|A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes|Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|15|||Both|18 Years|65 Years|No|||December 2013|December 16, 2013|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769404||72939|
NCT01769157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC-TH-1101|Effects of L-carnitine on Hypothyroidism|Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine||Korea University Anam Hospital|Yes|Completed|August 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|70 Years|No|||December 2013|December 2, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01769157||72958|
NCT01769430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017086-001|Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza|Evaluating Modes of Influenza Transmission Work Package 1: Observational Study of Community Acquired Influenza|EMIT|University of Maryland|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|178|Samples With DNA|viral cultures, viral RNA, viral cDNA, NP swabs, exhaled breath particles|Both|10 Years|N/A|No|Non-Probability Sample|Students, faculty, and staff at the University of Maryland College Park and residents of        the surrounding communities|January 2014|January 28, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769430||72937|
NCT01766232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07-926|Lacrimal Drainage Resistance Study|Lacrimal Drainage Resistance Study|LDRS|The Cleveland Clinic|No|Completed|April 2009|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the oculoplastics service with epiphora.|February 2015|February 17, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01766232||73182|
NCT01774617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHL/UFRJ-04|Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List|Comparative Analysis of Indocyanine Green Clearance Test, Model for End Stage Liver Disease(MELD)Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List||Universidade Federal do Rio de Janeiro|No|Recruiting|February 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|69 Years|No|||February 2013|February 22, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774617||72538|
NCT01774630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/18|Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)|Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)|Nilo Post-STIM|University Hospital, Bordeaux|Yes|Recruiting|April 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774630||72537|
NCT01776476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR2278|A Randomized Controlled Trial of Glutamine Dipeptide in Severe Trauma|A Randomized Controlled Trial of Glutamine Dipeptide in Severe Trauma|GLND Trauma|Ziegler, Thomas R., M.D.|No|Not yet recruiting|February 2013|February 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||January 2013|January 22, 2013|January 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776476||72395|
NCT01776749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL324.091.10|Subcutaneous Stimulation as Add on Therapy to SCS toTreat Low Back Pain in FBSS|Subcutaneous Stimulation as Add on Therapy to Spinal Cord Stimulation (SCS) to Treat Low Back Pain in Failed Back Surgery Syndrome (FBSS) (SubQ Study)|SubQ|SubQ|Yes|Active, not recruiting|December 2011|July 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776749||72374|
NCT01775124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2413|Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)|A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular AMD|DRAGON|Novartis|No|Completed|February 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|333|||Both|50 Years|N/A|No|||January 2016|January 12, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775124||72499|
NCT01775137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2401E1|Ext. Long-term Safety Study in CF Patients: Single Arm TIP|A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.||Novartis|Yes|Completed|February 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|6 Years|N/A|No|||November 2015|November 5, 2015|January 22, 2013|No|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01775137||72498|
NCT01776177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28357|The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy|A REAL-LIFE RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND IMPACT OF LONG-TERM TREATMENT WITH OMALIZUMAB WITH EMPHASIS ON MARKERS OF RESPONSE IN A CLINICAL PRACTICE IN APPROXIMATELY 240 PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA|The Reality|Allergy & Asthma Research Center, San Antonio, TX|No|Active, not recruiting|September 2012|August 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|240|||Both|12 Years|65 Years|No|Non-Probability Sample|Single-center, retrospective study; total 240 patients. All 240 patients with        moderate-to-severe allergic asthma who have received Omalizumab therapy at AAIAST/AARC        [from February 2004 to December 2011].|January 2013|January 23, 2013|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01776177||72418|
NCT01778296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTS1301283|Repair of Soft Tissue Defect of the Finger Using the Heterodigital Neurocutaneous Island Flap|||The Second Hospital of Tangshan|Yes|Completed|January 2008|October 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||May 2012|October 23, 2013|January 25, 2013|Yes|Yes||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01778296||72256|The samples of our study are small, and the results may change as our experience grows.
NCT01785472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2315|Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension||Novartis|Yes|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1438|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|February 5, 2013|Yes|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT01785472||71704|
NCT01768299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008|Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)|Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial||Gynuity Health Projects|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|504|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768299||73024|
NCT01768312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_TSPR_301|Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease|Cyclosporine|Hanlim Pharm. Co., Ltd.||Recruiting|March 2012|July 2013|Anticipated|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|21 Years|N/A|No|||January 2013|January 11, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01768312||73023|
NCT01768598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00044|Risk Taking and Fracture Study|An Investigation Into Risk Taking Behaviour, Bone Microstructure and Fracture Between the Sexes: What Underpins Fracture in Boys Compared to Girls During Growth?||University of British Columbia|No|Active, not recruiting|January 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|400|||Both|8 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fracture patients will be recruited from the orthopaedic clinic at BC Children's Hospital.        Non-fracture subjects will be recruited from the community|July 2015|July 16, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768598||73001|
NCT01768351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCX1234|Paricalcitol Effect on Anemia in CKD|Direct Effect of Paricalcitol on Anemia in Chronic Kidney Disease||Federico II University|No|Completed|October 2010|October 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2012|July 29, 2014|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01768351||73020|
NCT01768611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUSP-LIM25-001|SLC2A1 Variants and Diabetic Nephropathy|Association of Single Nucleotide Polymorphisms in the Gene Coding GLUT-1 and Diabetic Nephropathy in Brazilian Patients With Type 1 Diabetes Mellitus||University of Sao Paulo General Hospital|Yes|Completed|October 2004|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|449|Samples With DNA|Whole Blood|Both|11 Years|N/A|No|Probability Sample|449 patients with type 1 diabetes (56.4% female, mean age 36.0±11.0 years) were included        between October 2004 and October 2012. Inclusion criterion was type 1 diabetes duration        ≥10 years. The patients presented a mixed ethnic background (European Caucasian, African,        Amerindian and Asian of several different countries of origin), which reflects the        Brazilian population.|January 2013|January 15, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01768611||73000|
NCT01768858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-562|Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice|Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice|Adherence|AbbVie|No|Recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|99 Years|No|Non-Probability Sample|primary care clinic and medical practice specialized in rheumatology|January 2016|January 27, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768858||72981|
NCT01769170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-301|A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients||Chimerix|Yes|Active, not recruiting|August 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|89 Years|No|||July 2015|July 20, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769170||72957|
NCT01769183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ohr-003|Squalamine for the Treatment in Proliferative Diabetic Retinopathy|Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy||Elman Retina Group|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 9, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769183||72956|
NCT01769443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-13|Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation|A Prospective, Randomized, Multicenter, Two-Parallel Arm Study Evaluating the Overall Efficacy and Safety of Desensitization Therapy on Selected Patients Awaiting Heart Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|January 14, 2013|Yes|Yes|Inability to enroll within funding period|No|October 13, 2015|https://clinicaltrials.gov/show/NCT01769443||72936|Study was terminated by the study sponsor, with agreement from the investigators. Reason: very slow rate of accrual and inability to meet the accrual goal within the funding period. (N=2 enrolled. Aim was 80 participants).
NCT01769755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA001-CD-003|A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease||Celgene|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|75 Years|No|||August 2015|August 17, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769755||72912|
NCT01766245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4010|A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes|A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes||Novo Nordisk A/S|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|December 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01766245||73181|
NCT01766258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939135|Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations|Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations|PARPOC|Orion Corporation, Orion Pharma|No|Completed|May 2011|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|117|||Both|30 Years|N/A|No|||November 2013|November 20, 2013|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01766258||73180|
NCT01775449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0137|Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet|Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet|NEUROXAPOL|University Hospital, Clermont-Ferrand||Recruiting|February 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01775449||72474|
NCT01777256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115919|An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184|An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus||GlaxoSmithKline|Yes|Terminated|March 2013|November 2015|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|75 Years|No|||October 2014|October 23, 2014|January 24, 2013||No|This study met a protocol defined futility criterion and will be terminated following    completion of the Follow Up Visit on the last subject randomised.|No||https://clinicaltrials.gov/show/NCT01777256||72335|
NCT01774682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-Pr. VERHAEGHE|Kinematics of Obese Patients Perambulation|Does the Sleeve Gastrectomy Improve the Kinematics of Obese Patients Perambulation ?|MARCHOBESE|Centre Hospitalier Universitaire, Amiens|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|65 Years|No|||July 2015|July 28, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774682||72533|
NCT01774695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUSA-181101|Physical Activity in IBS - a Long Term Follow up|An Intervention to Improve Physical Activity in IBS Patients Has Long Term Positive Effects|IBS|Sahlgrenska University Hospital, Sweden||Completed|June 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2013|January 21, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01774695||72532|
NCT01784406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-FSP(94)|Person-centred Support for Women After Treatment for Gynaecological Cancer|Person-centred Support for Women in the Follow-up Period After Surgical Treatment for Gynaecological Cancer - a Randomised Controlled Trial|PESU|Rigshospitalet, Denmark|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|165|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01784406||71786|
NCT01776190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072012-024|Low-dose UVA1 Radiation in Cutaneous Lupus Patients|Low-dose UVA1 Radiation in Cutaneous Lupus Patients||University of Texas Southwestern Medical Center|No|Recruiting|September 2012|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01776190||72417|
NCT01784679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX001-CL401|GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)||Ultragenyx Pharmaceutical Inc|No|Recruiting|March 2013|February 2028|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Must have a diagnosis of HIBM, GNE myopathy, Quadriceps Sparing Myopathy (QSM), Inclusion        Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease.|January 2016|January 26, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784679|15 Years|71765|
NCT01784692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0255|Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals|Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals||University of Mississippi Medical Center||Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|21|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784692||71764|
NCT01785212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0|The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver|The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver||Medical University of Vienna|No|Completed|March 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||April 2015|April 6, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01785212||71724|
NCT01785225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-589-12|Ultrasound-guided Blood Sampling With a Sterile and Dry Puncture Area|Ultrasound-guided Blood Sampling With a Sterile and Dry Puncture Area||Aarhus University Hospital|Yes|Recruiting|February 2013|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785225||71723|
NCT01785238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0238|Nephronic Reduction After Neonatal Acute Renal Failure in Preterm|Renal Prognosis of Former Preterm Infants 3 to 10 Years After Neonatal Acute Renal Failure|IRENEO|Nantes University Hospital|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|75|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01785238||71722|
NCT01767766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGR-1202-101 (HEMREF 31)|Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies||TG Therapeutics, Inc.|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01767766||73065|
NCT01768039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-1191|Vitamine D in Multiple Sclerosis|Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis|MSVit|Mazandaran University of Medical Sciences|Yes|Not yet recruiting|March 2013|October 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|50 Years|No|||January 2013|January 11, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768039||73044|
NCT01768637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12CRP11830004|Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study|Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin|WiCKDonASA|University of Texas Southwestern Medical Center|No|Recruiting|January 2013|June 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|January 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01768637||72998|
NCT01768624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-1/12|PINOT Follow-up Study in End-stage Kidney Disease|Patient Information About Options for Treatment (PINOT) Follow up Study: Answering Important Questions in Home Dialysis and Conservative Care.||University of Sydney|No|Active, not recruiting|October 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|721|||Both|N/A|N/A|No|Non-Probability Sample|Adults and children with chronic kidney disease attending renal treatment centres in        Australian public hospitals and private practices|March 2012|January 5, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01768624||72999|
NCT01768871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1105|Evaluation of the VEGA Knee System® Range of Motion|Prospective, Long-Term, Multi-Center Study on the Efficacy of the VEGA System® for Total Knee Arthroplasty.||Aesculap Implant Systems|No|Terminated|January 2013|July 2020|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|21 Years|75 Years|No|Non-Probability Sample|Patients who have undergone a total knee arthroplasty with the VEGA knee system®|January 2016|January 28, 2016|January 14, 2013||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01768871||72980|
NCT01768884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT_CP_BRONC01.01|Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis|Phase IIa Prospective, Double Blind, Randomized Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis||Advanced Inhalation Therapies Ltd|No|Active, not recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|2 Months|1 Year|No|||July 2015|February 3, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768884||72979|
NCT01769456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 113 Version 2.0|An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)|Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States||Westat|Yes|Active, not recruiting|March 2013|November 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|79|||Male|15 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769456||72935|
NCT01766219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 59212|CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery|A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|May 2013|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|January 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01766219||73183|
NCT01765998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-2012.CTIL|The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)|The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation||The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|February 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2013|January 10, 2013|January 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01765998||73200|
NCT01766752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinDiab-03|Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management|An Open, Single-centre, Non-controlled Feasibility Study of the Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at the General Ward||Medical University of Graz||Completed|November 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||January 2013|April 9, 2013|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01766752||73143|
NCT01766999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetHb02|Methemoglobinemia After Liposuction - Diagnostic by Pulse Oximetry and Blood Gas Analysis.|Methemoglobinemia After Liposuction Under Tumescent Local Anesthesia - Timecourse and Diagnostics by Pulse Oximetry and Blood Gas Analysis.||University of Schleswig-Holstein|No|Completed|August 2008|December 2010|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|133|||Female|18 Years|N/A|No|Non-Probability Sample|- female patients scheduled for liposuction|January 2013|January 9, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01766999||73124|
NCT01776216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-C11-02-163|Impact of Dairy Consumption on Hypertension: a Clinical Study|Impact of Dairy Consumption on Hypertension: a Clinical Study.|PLAT|Laval University|No|Completed|August 2011|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|70 Years|No|||February 2014|February 6, 2014|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01776216||72415|
NCT01777542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00005610|Treatment of Rett Syndrome With Recombinant Human IGF-1|Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)||Children's Hospital Boston|Yes|Recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|2 Years|10 Years|No|||September 2015|September 16, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777542||72314|
NCT01777776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2105|Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.|A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.||Array BioPharma|No|Completed|July 2013|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777776||72296|
NCT01778075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100924|A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition|A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition||Janssen Korea, Ltd., Korea|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|20 Years|55 Years|No|||February 2014|February 7, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778075||72273|
NCT01777022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFIRM|Promoting Awareness Fetal Movements to Reduce Fetal Mortality Stillbirth, a Stepped Wedge Cluster Randomised Trial.|Promoting Awareness Fetal Movements and Focussing Interventions Reduce Fetal Mortality Stillbirth, a Stepped Wedge Cluster Randomised Trial.|AFFIRM|University of Edinburgh|Yes|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|110000|||Female|16 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01777022||72353|
NCT01784393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone-X-11|Chemoradiation for Bone Metastasis|Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis||Rabin Medical Center|Yes|Completed|May 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||April 2007|February 3, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01784393||71787|
NCT01777581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020888|Milnacipran for Lumbosacral Radicular Pain|A Ten-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Milnacipran for Radicular Pain Associated With Lumbosacral Disk Disease||Duke University|Yes|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||April 2014|July 14, 2014|November 30, 2012|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01777581||72311|
NCT01777815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-610404-100|Safety and Performance Study of the NeoChord Device|Safety and Performance Study of the NeoChord Suturing Device in Subjects With Degenerative Mitral Valve Disease; Diagnosed With Severe Mitral Regurgitation|TACT|NeoChord|Yes|Completed|October 2009|August 2014|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|79 Years|No|||September 2014|September 23, 2014|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777815||72293|
NCT01784978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNRISES STUDY (CRAD001LIC34T)|Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer|Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer|SUNRISES|Associació per a la Recerca Oncologica, Spain|Yes|Recruiting|October 2012|February 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01784978||71742|
NCT01777828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12650|Registry of Aortic Valve Bioprostheses Established by Catheter|Registry of Aortic Valve Bioprostheses Established by Catheter|FRANCE-TAVI|French Cardiology Society|No|Recruiting|February 2013|February 2034|Anticipated|February 2033|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|patients having a change of valves implanted catheter in a cardiology hospitals authorized        to perform this type of installation|February 2015|February 12, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01777828|5 Years|72292|
NCT01778114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26117|Availability of Vitamin D in Orange Juice|Bioavailability of Vitamin D2 and Vitamin D3 in Supplements Compared to Vitamin D3 and Vitamin D2 in Fortified Orange Juice||Boston Medical Center|No|Completed|December 2006|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 25, 2013|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778114||72270|
NCT01767779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P20NS080199-01|Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC|Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC||University of Alabama at Birmingham|No|Active, not recruiting|September 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|A single venous blood sample will be drawn from the child and parents/family guardian for      future research studies and future genetic testing|Both|N/A|6 Months|No|Non-Probability Sample|Infants that are seizure free at the time of the study enrollment and meets genetic or        clinical diagnostic criteria for TSC (determined as standard of care); parent/family        guardian health status is unknown|January 2016|January 13, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01767779||73064|
NCT01768052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002394|Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression|Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression||Mclean Hospital|No|Recruiting|June 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|21 Years|45 Years|No|Non-Probability Sample|Male and female participants with major depressive disorder (single or recurrent episode),        current episode depressed with current episode duration of three years or less.        Of note, subjects are referred by the Transcranial Magnetic Stimulation (TMS) Service at        McLean Hospital only.|May 2015|May 1, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768052||73043|
NCT01768364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/953|Antibiotic Prophylaxis When Removing Ureteric Stent After Stone Surgery|||University Hospital, Akershus|No|Not yet recruiting|January 2013|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|124|||Both|N/A|N/A|No|||January 2013|January 14, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768364||73019|
NCT01769469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 117 Version 2.0|Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).|Renal, Endocrine, and Bone Changes in Response to Treatment With Coformulated Emtricitabine-Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex With Men. Sub-Study of Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 110 and/or ATN 113||Westat|No|Completed|November 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|Samples Without DNA|Blood and urine samples to measure:      Calcium-Phosphate Balance: Parathyroid hormone (PTH), Serum Calcium (SCa), Urine Calcium      (UCa), Urine Creatinine (UCr), Serum Creatinine (SCr), Serum phosphate (SPO4), urine      phosphate (UPO4), serum Fibroblast Growth Factor 23 (FGF23), vit D metabolites 25-OHD,      1,25-OHD, albumin, and magnesium (Mg).      Bone Turnover: Bone alkaline phosphatase (BAP), Osteocalcin (OC) and C-telopeptide (CTX)      Renal Glomerular Function: SCr to calculate glomerular filtration rate (GFR) Renal Tubular      Function: Urine Glucose (UGluc), Urine Retinol Binding Protein (URBP, Urine Beta-2      Microglobulin (UB2MG), Urine Protein (UProt) Dried blood spots (DBS) for FTC and Tenofovir      (TFV)concentrations; red blood cell (RBC) for TFV-diphosphate (DP); plasma for FTC, TFV;      peripheral blood mononuclear cells (PBMC) for TFV-DP and FTC-triphosphate (TP) collected as      part of ATN 110 and ATN 113 will be used in the ATN 117 analysis.|Male|15 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals between the ages 15 years 0 days to 22 years 364 days, who are enrolled in ATN        110 or ATN 113, and agree to enter this sub-study at the same time they begin ATN 110 or        ATN 113.|February 2016|February 29, 2016|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769469||72934|
NCT01768897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22112|CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|January 2013|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|January 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01768897||72978|
NCT01769196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-322-0207|A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|RAINIER|Gilead Sciences|Yes|Terminated|January 2013|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|544|||Both|45 Years|85 Years|No|||March 2016|March 3, 2016|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769196||72955|
NCT01765699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3878|Predicting Poor Outcomes After Primary Knee Arthroplasty|Predicting Poor Outcomes After Primary Knee Arthroplasty||Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1300|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have undergone primary knee arthroplasty in our centre.|October 2015|October 7, 2015|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01765699||73223|
NCT01765985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-CRO-01|Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current|Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current||Association Niçoise Pour la Recherche En Dermatologie|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|90 Years|No|||January 2015|January 13, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01765985||73201|
NCT01766011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL01|Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital|Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital||Abbott Nutrition|Yes|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|N/A|21 Days|No|||March 2015|March 2, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01766011||73199|
NCT01738828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0001|GLOBAL Clinical Study|Genetic Loci and the Burden of Atherosclerotic Lesions|GLOBAL|Global Genomics Group, LLC|No|Active, not recruiting|December 2012|December 2016|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|Whole blood, serum, plasma, buffy coat and RNA PAXgene|Both|18 Years|90 Years|No|Probability Sample|Patients presenting for clinically indicated coronary CT angiography for an assessment of        possible CAD are potential study candidates.|February 2016|February 8, 2016|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738828||75285|
NCT01738841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114229|Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines|Post-marketing Surveillance Study of GSK Biologicals' Live, Attenuated Measles, Mumps, Rubella and Varicella Vaccine, Priorix-Tetra, Following a Single Vaccine Dose Given According to Local Prescribing Information in the Philippines||GlaxoSmithKline||Withdrawn|August 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|12 Months|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 12 months to 12 years living in Philippines will receive Priorix-Tetra as        prescribed by the physician.|July 2013|July 18, 2013|November 28, 2012|No|Yes|Local authorities no longer require routine PMS studies; GSK does not believe the study would    add meaningfully to the safety data already available for MMRV.|No||https://clinicaltrials.gov/show/NCT01738841||75284|
NCT01776996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116278|An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc|An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc||ViiV Healthcare|No|Active, not recruiting|May 2012|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|124|||Both|16 Years|N/A|No|||September 2015|February 4, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01776996||72355|
NCT01783886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15161|Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement|A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema|VIVID EAST|Bayer|Yes|Completed|February 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|378|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783886||71826|
NCT01783899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemospray Varices|Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding|Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding||Theodor Bilharz Research Institute|No|Completed|January 2013|June 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 25, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783899||71825|
NCT01774890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0599-12-HMO|ST2, a Novel Biomarker for Cardiac Remodeling in Adults With Congenital Heart Disease|||Hadassah Medical Organization|No|Recruiting|March 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Blood|Both|18 Years|85 Years|No|Non-Probability Sample|Adults born with congenital heart disease in stable clinical condition|September 2013|September 10, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01774890||72517|
NCT01777035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0218|Early Mobilization in the ICU|Early Mobilization in the ICU||University of Chicago|No|Recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01777035||72352|
NCT01777295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116640|Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System|Development of Read-outs to Detect and Characterise the Early and Adaptive Immune Responses in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen in Combination With a GSK Biologicals' Adjuvant System||GlaxoSmithKline||Recruiting|February 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777295||72332|
NCT01777282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116170|A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus|A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|February 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|374|||Both|20 Years|N/A|No|||January 2016|February 24, 2016|January 24, 2013||No||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01777282||72333|
NCT01777841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008757|Mayo Clinic Health Connection Discovery Trial|Clinical Pilot:myCare||Mayo Clinic|No|Completed|February 2012|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|250|||Both|50 Years|N/A|No|||January 2013|January 28, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777841||72291|
NCT01778361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVUPBEAT|HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected Patients.|HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected. A Prospective Cohort Study of HIV-infected Patients and HIV-negative Subjects.|UPBEAT|University College Dublin|No|Recruiting|February 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|serum, plasma, buffy coat, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive patients and HIV negative subjects|January 2013|January 25, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778361||72251|
NCT01778621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINA-1978|Effect of Follicular Phase Acupuncture on Anti-Mullerian Hormone in Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF And The Effect on Assisted Reproduction Outcome|Acupuncture Treatment Versus Non-acupuncture During IVF||Huazhong University of Science and Technology|No|Completed|March 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Female|20 Years|40 Years|No|||January 2013|January 25, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01778621||72231|
NCT01775007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002176/10|A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer|A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer|Brillouin I|Massachusetts General Hospital|No|Recruiting|March 2011|January 2014|Anticipated|January 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775007||72508|
NCT01768065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008691|Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome|Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome||Children's Hospital of Philadelphia|No|Completed|July 2012|April 2013|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01768065||73042|
NCT01768377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130-1928|Comparison of Intubation With Nerve Block and With Sedation in Awake Patients|Comparison of in Intubation With Nerve Block and Intubation With Sedation in Awake Patients in Terms of Efficacy, Complications and Physician's Satisfaction||Tehran University of Medical Sciences|Yes|Recruiting|November 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01768377||73018|
NCT01769209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMALL0008|Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia||Stanford University||Recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||November 2015|November 15, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769209||72954|
NCT01769222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0090|Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer|A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA||Stanford University||Suspended|February 2013|||March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|January 14, 2013|No|Yes|DMSC audit results|No||https://clinicaltrials.gov/show/NCT01769222||72953|
NCT01769235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBG 1210|Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|November 2012|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1215|||Both|12 Years|40 Years|No|||January 2014|January 19, 2014|January 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769235||72952|
NCT01769768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225A2112|Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients|A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors||Novartis|No|Recruiting|April 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01769768||72911|
NCT01769781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013-01|Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence|Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|50 Years|No|||February 2015|February 3, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769781||72910|
NCT01769794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaACMS-HFMD|Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study|||China Academy of Chinese Medical Sciences|Yes|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|1 Year|13 Years|No|||January 2013|January 16, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01769794||72909|
NCT01765712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-160A|The Effect of Platelet Rich Plasma (PRP) on Post Operative Pain in Anterior Cruciate Ligament Reconstruction|"Effect of Intraoperative Application of Autologous PRP on Post Operative Morbidity in ACL Reconstruction Using Autologous Bone Patellar Tendon Bone Graft Harvest"||Northwell Health|Yes|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765712||73222|
NCT01766271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029973|GENErating Behavior Change, An Integrative Health Coaching and Genetic Risk Testing Pilot|GENErating Change, An Integrative Health Coaching and Genetic Risk Testing Pilot in Primary Care: A Multidisciplinary Approach to Personalized Medicine Targeting CHD Risk||Duke University|No|Completed|October 2012|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 6, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01766271||73179|
NCT01766505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m111HHF11F|The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)|Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.||Chong Kun Dang Pharmaceutical|No|Terminated|June 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|75 Years|No|||March 2014|March 12, 2014|January 10, 2013||No|lack of the subjects|No||https://clinicaltrials.gov/show/NCT01766505||73161|
NCT01738854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0043|The Comparison of Airway Sealing With the Laryngeal Mask Airway (LMA) Supreme at Different Intracuff Pressure in Children|||Yonsei University|No|Completed|November 2012|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver)|3||Actual|36|||Both|N/A|9 Years|No|||April 2014|April 6, 2014|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01738854||75283|
NCT01738867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116753|To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers||GlaxoSmithKline|No|Completed|December 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738867||75282|
NCT01783626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1498|Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)|Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study||Gambro Lundia AB|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01783626||71846|
NCT01776502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0255|Evaluation of Non Specific Symptoms and Quality of Life Before and After Surgery for Mild Primary Hyperparathyroidism|A Prospective, Non Randomized, Open, Multicenter Trial to Evaluate Non Specific Symptoms and Quality of Life (SF 36) Before and After Surgery for Mild Primary Hyperparathyroidism||Nantes University Hospital|No|Completed|December 2007|June 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|||Both|N/A|50 Years|No|Non-Probability Sample|A prospective, non randomized, open, multicenter trial to evaluate non specific symptoms        and quality of life (SF 36) before and after surgery for mild primary hyperparathyroidism|January 2013|January 23, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01776502||72393|
NCT01776515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW 0919 301 Version 1.00|Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients|A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients||Daewon Pharmaceutical Co., Ltd.||Completed|January 2012|June 2012|Actual|March 2012|Actual|Phase 1|Interventional|N/A|2||||||Both|20 Years|N/A|No|||January 2013|January 23, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01776515||72392|
NCT01784172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-2|Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial|The Efficacy and Safety Study of Electro-acupuncture for Simple Female Stress Urinary Incontinence- a Multicenter, Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|504|||Female|40 Years|75 Years|No|||December 2014|December 21, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01784172||71804|
NCT01777854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC 12 0020|Anti-reflux Control to Decrease Post Tonsillectomy Pain|Anti-reflux Control to Decrease Post Tonsillectomy Pain||Genesys Regional Medical Center|No|Terminated|January 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 25, 2013|Yes|Yes|Lack of patient interest in the study.|No||https://clinicaltrials.gov/show/NCT01777854||72290|
NCT01777308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116727|Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination|The Vaccine Response and Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Administered as One Dose at 6 Years Post-MenC Primary Vaccination in Healthy Subjects Aged 12-18 Months at Primary Vaccination||GlaxoSmithKline||Active, not recruiting|May 2013|July 2018|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|156|||Both|84 Months|95 Months|Accepts Healthy Volunteers|||November 2015|November 19, 2015|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777308||72331|
NCT01777594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-202-003|Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma|A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma|G-202-003|GenSpera, Inc.|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777594||72310|
NCT01778374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-BRiHT|Mater-Bronx Rapid HIV Testing Project.|Mater _Bronx Rapid HIV Testing Project. Prospective Randomised Trial of Recruitment Methods in Implementation of a HIV Screening Programme in the Emergency Department.|M-BRiHT|University College Dublin|Yes|Recruiting|September 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|17000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 25, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778374||72250|
NCT01774747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7750090|A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder|MAD|Sunovion|No|Terminated|December 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|January 8, 2013|Yes|Yes|This program was terminated for financial reasons|No||https://clinicaltrials.gov/show/NCT01774747||72528|
NCT01774760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T14/2013|Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer|Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer||Turku University Hospital||Recruiting|March 2013|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774760||72527|
NCT01768910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0346|Supraspinal Control of Lower Urinary Tract Function in Healthy Controls & Patients With Bladder Dysfunction|The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques|2011-0346|University of Zurich|No|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01768910||72977|
NCT01768923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA-Alx-2012|Early RA Vascular Randomised Controlled Study|Effect of Treat-to-target Strategies Aiming at Remission Compared With Minimal Disease Activity on Arterial Stiffness in Early Rheumatoid Arthritis - a Randomised Controlled Study||Chinese University of Hong Kong|Yes|Recruiting|October 2012|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||January 2016|January 26, 2016|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01768923||72976|
NCT01768936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUM-PCT-1|Procalcitonin Ratio's Impact on the Decision Upon On-demand Relaparotomy in Septic Peritonitis|Procalcitonin Ratio's Impact on the Decision Upon On-demand Relaparotomy in Septic Peritonitis||CHIR-Net||Completed|January 2009|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|234|||Both|18 Years|N/A|No|Non-Probability Sample|consecutive postoperative surgical patients on ICU after intestinal perforation or        anastomotic leakage with indication for surgical focus elimination|January 2013|January 15, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01768936||72975|
NCT01768949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2012/131|Echocardiography Predictive of the Inefficacy and/or of the Unsafeness of Recruitment Maneuvers in Patients With Acute Respiratory Distress Syndrome.|Identification of Echocardiographic Criteria Predictive of the Inefficacy and/or the Unsafeness of Recruitment Maneuvers in Patients Suffering From Acute Respiratory Distress Syndrome|RV STAR|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|February 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01768949||72974|
NCT01768962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-014|Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel|A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women||CONRAD|Yes|Completed|April 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768962||72973|
NCT01769248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNAFNBmucin|Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle|Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle|MUCIN|Northwestern University|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|140|||Both|18 Years|90 Years|No|||April 2015|April 11, 2015|January 10, 2013||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01769248||72951|
NCT01769482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-048|Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image|Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image|UMPIRE|Samsung Medical Center|Yes|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|80 Years|No|||November 2012|March 24, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01769482||72933|
NCT01769807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDOC|Efficacy Study of CPAP on Nitrate and Norepinephrine Levels in Severe and Mild-moderate Sleep Apnea (SABIO)|Effects of CPAP on Nitrate and Norepinephrine Levels in Severe and Mild-moderate Sleep Apnea|SABIO|University of Lisbon|No|Completed|July 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Male|20 Years|65 Years|No|||January 2013|January 16, 2013|November 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01769807||72908|
NCT01765725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/894/REK nord|Coping With Chronic Fatigue Syndrome: Development of a Community-based Patient Education Program|Coping With Chronic Fatigue Syndrome: Development of a Community-based Patient Education Program||Oslo University Hospital|No|Active, not recruiting|April 2011|December 2015|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01765725||73221|
NCT01738594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12H06|Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma|A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma||Northwestern University|Yes|Recruiting|January 2013|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738594||75303|
NCT01776034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14-16|Health Promotion and Wellness Program for Stroke Survivors|Examining the Efficacy of a SystemCHANGE™ Weight Management Intervention in Stroke Survivors||Case Western Reserve University|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|45|||Both|30 Years|75 Years|No|||January 2015|January 22, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776034||72429|
NCT01776242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39009-EA|Back Pain Outcomes Using Longitudinal Data (BOLD)|Back Pain Outcomes Using Longitudinal Data (BOLD) Registry and Repository|BOLD|University of Washington|Yes|Completed|September 2010|September 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5239|||Both|65 Years|N/A|No|Probability Sample|Adults over age 65|March 2014|March 21, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01776242|24 Months|72413|
NCT01776528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0101|Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants|A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants||NGM Biopharmaceuticals, Inc|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|119|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01776528||72391|
NCT01776775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSAB|The Effect of Postoperative Abdominal Binder to Improve Outcomes After Incisional Hernia Repair|The Effect of Postoperative Abdominal Binder to Reduce Seroma Formation and Improve Early Clinical Outcome After Incisional Hernia Repair.|INSAB|Hvidovre University Hospital|No|Not yet recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01776775||72372|
NCT01778153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Equinox Study|Equinox Personal Coaching Versus Self-Directed Exercise|Effectiveness of Equinox Fitness Club's Personal Coaching Method Versus Self-Directed Exercise Training on Increasing Lean Body Mass in Men Aged 30-44 Years of Age||University of California, Los Angeles|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Male|30 Years|44 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01778153||72267|
NCT01778387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECUHV|Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia|Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia: Randomized Clinical Trial||Fundación Andaluza Beturia para la Investigación en Salud|Yes|Completed|January 2005|December 2012|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|130|||Both|18 Years|90 Years|No|||January 2013|January 25, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01778387||72249|
NCT01778127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAMZEE|A Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer|A Randomized Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer||St. Jude Children's Research Hospital|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|105|||Both|11 Years|14 Years|No|||April 2015|May 5, 2015|January 18, 2013||No||No|April 14, 2015|https://clinicaltrials.gov/show/NCT01778127||72269|
NCT01778140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC100-2320-B-038-034|Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System|Randomized Controlled Trial: Comparing Effects of Patient-Specific Versus Non-Patient-Specific Computerized Reminder System to Reduce Contrast-Induced Nephropathy||Taipei Medical University|Yes|Active, not recruiting|January 2012|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|90|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01778140||72268|
NCT01774474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42463.068.12|PRevention of Macular EDema After Cataract Surgery|PRevention of Macular EDema After Cataract Surgery|PREMED|Maastricht University Medical Center|Yes|Recruiting|July 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Anticipated|1350|||Both|21 Years|N/A|No|||April 2015|April 9, 2015|January 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01774474||72549|
NCT01774422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0136|Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation|Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation|DECAP CO2|University Hospital, Clermont-Ferrand||Not yet recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|90 Years|No|||January 2013|January 21, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01774422||72553|
NCT01775293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1209-170-002|Clinical Trial to Evaluate the Efficacy and Safety in Nasolabial Fold After Rhytidectomy Using Non-absorbable Mesh|A Multi Center, Non-comparative Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety After Rhytidectomy Using Non-absorbable Mesh(RPM)||Seoul National University Hospital|No|Completed|January 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775293||72486|
NCT01768663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-809-009|A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects|A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|January 2013|||September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768663||72996|
NCT01768975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLT1177-02|Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee|Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy||Olatec Industries LLC|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|35 Years|80 Years|No|||September 2014|September 25, 2014|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01768975||72972|
NCT01769508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 166|Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer|A Phase II Study With Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination With Radiation Therapy as Neoadjuvant Treatment for Patients With Localized HER2 Positive Esophagogastric Adenocarcinomas||SCRI Development Innovations, LLC|No|Terminated|February 2013|February 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 11, 2013|Yes|Yes|Study closed due to slow accrual.|No||https://clinicaltrials.gov/show/NCT01769508||72931|
NCT01769495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE 6366-SP|Can a Rapid 2 Day Followup After Discharge From the ED Reduce Readmissions and Death for Patients 75 Years and Older?|A Randomized Trial of the Effect of a Geriatrics Appointment Within 2-3 Days of Discharge From the Emergency Department(ED) in Reducing ED and Hospital Readmissions for Patients 75 Years of Age and Older.||University of North Carolina, Chapel Hill|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|75 Years|N/A|No|||April 2015|April 21, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769495||72932|
NCT01765738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICC Line Comparison|Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting|Randomized Double Blind Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting||Medical University of South Carolina|No|Not yet recruiting|February 2013|July 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|90 Years|No|||January 2013|January 9, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01765738||73220|
NCT01766024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-033-1|Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers|International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers||Biocad|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|January 10, 2013||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01766024||73198|
NCT01766037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-001V|Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study|Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study|PATHWAY|Aspire Bariatrics, Inc.|Yes|Active, not recruiting|November 2012|June 2019|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|21 Years|65 Years|No|||July 2015|July 2, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01766037||73197|
NCT01738607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR007756|Dietary Fiber for Fecal Incontinence|The Impact of Fiber Fermentation on Fecal Incontinence||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2004|December 2010|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|206|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01738607||75302|
NCT01776047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0081_BA_I|A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers|A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers||Dong-A ST Co., Ltd.|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776047||72428|
NCT01776801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 299 03|Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human|Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human|CESNA|University Hospital, Toulouse|No|Completed|January 2009|December 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01776801||72370|
NCT01776255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0578|Healthy Children, Strong Families: American Indian Communities Preventing Obesity|Healthy Children, Strong Families: American Indian Communities Preventing Obesity|HCSF2|University of Wisconsin, Madison|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|900|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01776255||72412|
NCT01777334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117115|The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD.|A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD).||GlaxoSmithKline|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|905|||Both|40 Years|N/A|No|||June 2014|June 19, 2014|January 24, 2013|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01777334||72329|
NCT01776788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bmd-201207-xm|Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients|Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on β-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients||The First Affiliated Hospital of Xiamen University|Yes|Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|30 Years|70 Years|No|||January 2013|March 8, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01776788||72371|
NCT01778166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISEEN001|Gastrointestinal Postoperative Early Enteral Nutrition: Immuno-enhanced Versus Standard Early Enteral Nutrition|Immuno-enhanced Versus Standard Early Enteral Nutrition Use in Gastrointestinal Postoperative Patients|ISEEN|Jinling Hospital, China|Yes|Not yet recruiting|February 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|75 Years|No|||January 2013|January 30, 2013|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01778166||72266|
NCT01778400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJH_PCYST|RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules|Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial||Asan Medical Center|No|Enrolling by invitation|February 2013|January 2014|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||November 2013|November 7, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01778400||72248|
NCT01774461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC12-2-038|Ischemic Preconditioning in Endurance Athletes|Influence of Remote Ischemic Preconditioning on Cardiac Function After Endurance Exercise||Maastricht University Medical Center|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01774461||72550|
NCT01774773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-J081-015|A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)|A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet||Eisai Inc.||Completed|January 2013|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||January 2014|January 31, 2014|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01774773||72526|
NCT01774435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3342-102|Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant|A Phase 1, Open-Label, Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH) Risperidone When Risperidone is Administered From a Polyurethane Implant||Endo Pharmaceuticals|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|60 Years|No|||October 2014|October 30, 2014|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774435||72552|
NCT01774448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-1309|Mindfulness Research Program: Designed to Enhance Wellbeing in People Living With Dementia and Their Spouses|The Efficacy of Mindfulness-Based Cognitive Therapy (MBCT) to Improve Depression Symptoms and Quality of Life in Individuals With Dementia and Their Caregivers: A Pilot Study|MBCT_AD|Lakehead University|No|Completed|August 2013|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|50 Years|85 Years|No|||April 2015|April 2, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01774448||72551|
NCT01775306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-081|Not Invasive Monitoring at Cardiac Recompensation|||RWTH Aachen University|No|Completed|October 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with cardiac recompensation|January 2014|January 7, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775306||72485|
NCT01775592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMPE - ITM|Plasmodium Falciparum Artemisinin Resistance Vietnam|Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam||National Institute of Malariology, Parasitology and Entomology, Vietnam|Yes|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|2 Months|N/A|No|||January 2013|January 25, 2013|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01775592||72463|
NCT01768676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-401|Study Evaluating the Effects of Avanafil on Semen Parameters|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction||VIVUS, Inc.|No|Completed|December 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|January 11, 2013|Yes|Yes||No|October 7, 2015|https://clinicaltrials.gov/show/NCT01768676||72995|
NCT01769261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM09213 - K081204|Sentinel Patients: Value of an Information System Collecting Patient's Own Report on His Healthcare Management|Sentinel Patients : Value of an Information System Collecting Patient's Own Report on His Healthcare Management. Application to the Detection of Adverse Events After Hospital Discharge.|SENTIPAT|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|2090|||Both|18 Years|N/A|No|||October 2014|May 27, 2015|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01769261||72950|
NCT01737489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007641|Title: "Development and Implementation of Innovative Auditory Training Methods and Verification of These Training Methods"|Title: "Development and Implementation of Innovative Auditory Training Methods and Verification of These Training Methods"||Mayo Clinic|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737489||75388|
NCT01769820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dexfemv2|Dexamethasone for Excessive Menstruation|Developmental Clinical Studies - Reversing Endometrial Glucocorticoid Deficiency in Heavy Menstrual Bleeding|dexFEM|University of Edinburgh|Yes|Recruiting|January 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|60 Years|No|||May 2015|May 27, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01769820||72907|
NCT01738035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nef-202|The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease|A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease|NEFIGAN|Pharmalink AB|Yes|Completed|December 2012|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01738035||75346|
NCT01738048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0099B|Persistent Pain After Reconstruction Following Mastectomy|Persistent Pain After Reconstruction Following Mastectomy||Rigshospitalet, Denmark|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1352|||Female|18 Years|70 Years|No|Probability Sample|Nationwide cross-sectional cohort|November 2012|November 29, 2012|November 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01738048||75345|
NCT01738308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1572|The Effects of Healing Touch on Post Operative Pediatric Patients|Investigating the Effect of Healing Touch on Post-Operative Recovery of Pediatric Tonsillectomies and Adenoidectomies Patients Ages 3 & 4||Children's Hospital Medical Center, Cincinnati|No|Recruiting|September 2013|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738308||75325|
NCT01738321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00715|Changes in Intracuff Pressure of a Cuffed Endotracheal Tube During Prolonged Surgical Procedures.|||Nationwide Children's Hospital|No|Completed|January 2013|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing surgery lasting longer than 4 hours.|July 2015|July 6, 2015|November 28, 2012||No||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01738321||75324|
NCT01739478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWRC-PPAC|Packing of Perianal Abscess Cavities Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity|Packing of Perianal Abscess Cavities (PPAC) Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity|PPAC|North Western Research Collaborative||Not yet recruiting||December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2012|December 2, 2012|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01739478||75235|
NCT01735318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-10/384|Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions.||IPCA Laboratories Ltd.|Yes|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01735318||75555|
NCT01776814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIRB2963-2012|Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-naïve Patients With Chronic Hepatitis B in Korea|||Gachon University Gil Medical Center|Yes|Not yet recruiting|February 2013|||February 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|treatment of nucleos(t)ide-naive patients who were diagnosed with chronic hepatitis B in        Korea|January 2013|January 25, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01776814||72369|
NCT01777048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203/12|Omega-3 Fatty Acids Supplementation in ADHD|Augmenting the Effects of Methylphenidate: A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids Supplementation in Children With Attention Deficit Hyperactivity Disorder||University Hospital, Basel, Switzerland|Yes|Terminated|April 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|6 Years|12 Years|No|||June 2015|June 23, 2015|January 16, 2013||No|Low recruitment numbers|No||https://clinicaltrials.gov/show/NCT01777048||72351|
NCT01777321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116760|Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine When Administered Under the Skin (Subcutaneously) vs. Into a Muscle (Intramuscularly) in Adults 50 Years of Age and Older|Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously vs. Intramuscularly in Adults Aged ≥50 Years||GlaxoSmithKline||Completed|June 2013|November 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777321||72330|
NCT01777633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|027812-HMO-CTIL|Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children|Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children||Hadassah Medical Organization|No|Completed|February 2013|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|1 Year|22 Years|No|||December 2012|April 19, 2015|January 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777633||72307|
NCT01777607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Recover Right|The Use of Impella RP Support System in Patients With Right Heart Failure|The Use of Impella RP Support System in Patients With Right Heart Failure: A Clinical and Probable Benefit Study||Abiomed Inc.|Yes|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2013|May 11, 2013|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777607||72309|
NCT01777620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-12-001|A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides|||Allergan|No|Completed|January 2013|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|65 Years|No|||May 2014|May 2, 2014|January 25, 2013|Yes|Yes||No|May 2, 2014|https://clinicaltrials.gov/show/NCT01777620||72308|
NCT01778413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TRI-WEEK|Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine|Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine|A-TRI-WEEK|Fundacion Clinic per a la Recerca Biomédica|No|Completed|May 2013|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2013|September 1, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01778413||72247|
NCT01774487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM/TCH-H-31387|Pentoxifylline Therapy in Biliary Atresia|A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia||Baylor College of Medicine|Yes|Recruiting|January 2013|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|180 Days|No|||January 2016|January 11, 2016|January 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774487||72548|
NCT01774786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25114|A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer|A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER||Hoffmann-La Roche||Recruiting|June 2013|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|780|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01774786||72525|
NCT01774799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-013|Educational Video to Improve Nursing Home Care in End-stage Dementia|Educational Video to Improve Nursing Home Care in End-stage Dementia|EVINCE|Hebrew Rehabilitation Center, Boston|Yes|Recruiting|March 2013|February 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|720|||Both|65 Years|N/A|No|||March 2016|March 16, 2016|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774799||72524|
NCT01775033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3AMC24076|Regionalized Pediatric Emergency Care in Rural Pennsylvania|Regionalized Pediatric Emergency Care in Rural Pennsylvania: the Optimizing Utilization and Rural Emergency Access for Children Study|OUTREACH|University of Pittsburgh|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|5000|||Both|N/A|18 Years|No|||May 2015|May 26, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775033||72506|
NCT01775891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIL245|Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation|Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation Compared With Other Class IC Anti-arrhythmic Drugs||Korea University|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|245|||Both|18 Years|80 Years|No|||February 2013|February 23, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01775891||72440|
NCT01775904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14249|A Study of Two Dosage Forms of LY2886721 in Healthy Participants|A Comparison Study of Capsule and Orally Disintegrating Tablet and to Determine the Effect of Food and Water on the Pharmacokinetics of LY2886721 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 23, 2013|January 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775904||72439|
NCT01768988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANPAIN/1|Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study|Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study||Parc de Salut Mar|No|Recruiting|August 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|64 Years|No|||January 2013|January 15, 2013|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01768988||72971|
NCT01737203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481315|Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Sildenafil 50 Mg Orally-Disintegrating Tablet With Or Without Water To Viagra® 50 Mg Oral Tablet With Water Under Fasted Condition||Pfizer|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|53|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01737203||75410|
NCT01737216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTH201|Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer|||Hebei Tumor Hospital||Active, not recruiting|November 2012|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|70 Years|N/A|No|||November 2012|December 28, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737216||75409|
NCT01737502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1125|Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer|A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options||Mayo Clinic|Yes|Recruiting|November 2012|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01737502||75387|
NCT01738360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0021|Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)|Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)|LUPSENIC|Nantes University Hospital||Terminated|July 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|November 28, 2012||No|Difficulty of inclusions and a sufficient number of relevant clinical information|No||https://clinicaltrials.gov/show/NCT01738360||75321|
NCT01737723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-NK-1|Electroencephalograph for Detection of Acute Ischemic Stroke|Collecting Data for an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS||Neurokeeper Technologies|No|Recruiting|August 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Stroke patients|November 2012|November 27, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737723||75370|
NCT01738061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-WHP-99|A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan|A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan||Asia University|Yes|Completed|January 2010|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|108|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01738061||75344|
NCT01738334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC 001|Effects Of The Mindfulness Meditation Practices On Cognition|EVALUATION OF THE EFFECTS OF THE MINDFULNESS MEDITATION PRACTICES ON COGNITION OF ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER||Federal University of São Paulo|Yes|Completed|February 2012|May 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01738334||75323|
NCT01738347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-180-001|Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).|Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)||GE Healthcare|Yes|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01738347||75322|
NCT01735604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-001|Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy|Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma||Chinese PLA General Hospital|Yes|Recruiting|January 2013|October 2018|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|No|||September 2015|September 27, 2015|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01735604||75533|
NCT01777061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13429|Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan|Clinical Management Decisions Based on [11C]Acetate Positron Emission Tomography Performed on Prostate Cancer Patients With Biochemical Recurrence||University of Kansas Medical Center||Available|January 2013|December 2017|Anticipated|January 2016|Anticipated|Phase 3|Expanded Access|N/A|||||||Male|45 Years|80 Years|No|||January 2016|January 21, 2016|January 17, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01777061||72350|
NCT01777347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB 2012-A00228-35|Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis|3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial|GUERANDE|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|778|||Both|6 Weeks|12 Months|No|||July 2014|July 25, 2014|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01777347||72328|
NCT01777646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-NTF-002-HMO-CTIL|Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).||Hadassah Medical Organization||Active, not recruiting|December 2012|October 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|75 Years|No|||January 2014|February 4, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01777646||72306|
NCT01777867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006873|Cough Reflex Sensitivity and Bronchial Hyper-responsiveness|Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.||Mayo Clinic|No|Recruiting|December 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|This study will recruit participants into three groups ages 18-60 years: 12 reflux        patients with non-erosive disease (NERD) with abnormal levels of acid reflux, 12 NERD        patients with normal levels of reflux and 12 healthy volunteers.|January 2016|January 19, 2016|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777867||72289|
NCT01777880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0521|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||February 16, 2016|January 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777880||72288|
NCT01777893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B303|Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes|PREVention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around the World|PREVIEW|University of Copenhagen|Yes|Active, not recruiting|June 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2500|||Both|10 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777893||72287|
NCT01774812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-Neph-2012001|Vitamin D and Cardiac Autonomic Tone in Hemodialysis|Vitamin D Supplementation and Cardiac Autonomic Tone in Hemodialysis Patients: A Blinded, Randomized-controlled Trial|VITAH|University of Calgary|Yes|Active, not recruiting|January 2013|April 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01774812||72523|
NCT01774825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/028111|IQP-CL-101 in IBS Management|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)||InQpharm Group|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01774825||72522|
NCT01775059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 277|Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4|||Medtronic Diabetes R&D Denmark||Not yet recruiting|March 2013|||July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2013|February 4, 2013|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775059||72504|
NCT01775319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNL/CTC_Zn_wheat|Evaluation of Human Zinc Absorption From Wheat-based Meals|Evaluation of Human Zinc Absorption From Wheat-based Meals||Swiss Federal Institute of Technology|No|Completed|February 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775319||72484|
NCT01775046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDTVCFRANCE001|Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)|Post-market Study on Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases||Medtronic Endovascular|No|Active, not recruiting|March 2013|December 2021|Anticipated|November 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|Subjects diagnosed with a disease of descending thoracic aorta (DTA) and requiring        endovascular treatment with Stent Graft.|January 2016|January 11, 2016|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775046||72505|
NCT01776138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1206|Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer|PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy|PORCH|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|April 2012|April 2021|Anticipated|April 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Whole blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a known pathologic diagnosis of lower tract urothelial carcinoma who are        eligible to undergo radical cystectomy with or without neoadjuvant chemotherapy for        definitive diagnosis and treatment.|October 2015|October 29, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01776138||72421|
NCT01736943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#230|Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia|Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML)||University of California, Davis|Yes|Recruiting|December 2012|March 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 2, 2015|November 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736943||75430|
NCT01736956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08688|Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome|Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome||University of California, San Francisco|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01736956||75429|
NCT01737229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/001|Efficacy and the Safety Study of RD94 in Patients With Endodontic Care|Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III|RD94|Ascopharm Groupe Novasco|No|Completed|January 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|53|||Both|3 Years|N/A|No|||July 2013|July 23, 2013|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01737229||75408|
NCT01738373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ22510|Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation|Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study||Sanofi|Yes|Completed|December 2011|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|262|||Both|N/A|N/A|No|Probability Sample|The selection of the registry's participants will be based on an exhaustive request of all        apheresis centers distributed in the French territory.|March 2015|March 19, 2015|November 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01738373||75320|
NCT01738633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOLEC1 - step 2|Quality of Life After Esophagectomy for Cancer - Step 2|Quality of Life After Esophagectomy for Cancer - Step 2||University of Padova|No|Recruiting|January 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01738633||75300|
NCT01737736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-004|Validation of Neurokeeper's Algorithm on Patients Undergoing Carotid Endarterectomy|||Neurokeeper Technologies|No|Recruiting|June 2013|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing Carotid Endarterectomy|July 2013|July 17, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737736||75369|
NCT01737749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-005|Validation of Neurokeeper's Algorithm on Patients Undergoing Cardiac Surgery.|||Neurokeeper Technologies|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery.|November 2012|November 27, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737749||75368|
NCT01738880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0404|Effect of Goal-directed Fluid Therapy Based on Stroke Volume Variation on Metabolic Acidosis in Patients Undergoing Brain Tumor Surgery|||Yonsei University|No|Completed|December 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|20 Years|65 Years|No|||January 2015|January 26, 2015|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01738880||75281|
NCT01739153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B302|Effect of Cheese on Cardiovascular Risk|Effect of Cheese on Cardiovascular Risk|ECCA|University of Copenhagen|No|Completed|January 2013|November 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|19|||Female|45 Years|68 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739153||75260|
NCT01769352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00074523|Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)|Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)|TEMPEST|Johns Hopkins University|No|Active, not recruiting|August 2012|September 2016|Anticipated|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01769352||72943|
NCT01777074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113385|Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians|Measurement of the Changes in Acceptability of Hepatitis B Immunization Among General Practitioners and Open-care Paediatricians|PRALINE|GlaxoSmithKline|Yes|Completed|November 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|474|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|An eligibility register will be kept throughout the inclusion period by the investigators.        All children aged 12 to 15 months and 24 to 27 months, seen by the physician during this        period, will be entered on this register General practitioners and open-care        paediatricians drawn at random and agreeing to participate in the study.|January 2013|January 31, 2013|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777074||72349|
NCT01777360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 120102|Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma|Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma|ASMATHERM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2012|November 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||August 2014|August 25, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01777360||72327|
NCT01777932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21647|AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer|A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avastin) Treatment in Patients With Metastatic Breast Cancer (AVAREG Study)||Hoffmann-La Roche||Completed|December 2007|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic breast cancer initiated on treatment with Avastin in combination        with paclitaxel|January 2016|January 7, 2016|January 24, 2013||No||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01777932||72284|
NCT01777945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28505|XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Patients With HER2-Negative Metastatic Breast Cancer|Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)||Hoffmann-La Roche||Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Probability Sample|Patients with HER2-negative metastatic breast cancer initiated on first-line therapy with        Xeloda in combination with docetaxel|February 2016|February 1, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01777945||72283|
NCT01777906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130043|Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps|Comparison of Topical Nasal Steroids in Postoperative Sinus Patients With Nasal Polyps|dexamethasone|Loma Linda University|Yes|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|17 Years|85 Years|No|Non-Probability Sample|Group 1 - will be given fluticasone nasal spray Group 2- will be given dexamethasone nasal        spray The 2 groups will be compared in terms of symptom control and polyp size|February 2016|February 24, 2016|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01777906||72286|
NCT01777919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-18081973|Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform|A PHASE II CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY OF DISULFIRAM/COPPER COMBINATION AS AN ADJUVANT AND CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORM|GLIODIS|Olympion Medical Center|Yes|Not yet recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2014|October 18, 2014|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01777919||72285|
NCT01778179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy|SAFETY AND EFFICACY OF A TRIPLE COMBINATION CREAM AS ADJUVANT TREATMENT OF SOLAR LENTIGINES WITH CRYOTHERAPY.||Brazilan Center for Studies in Dermatology|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01778179||72265|
NCT01775072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-245|Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy|Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|tissue, blood, saliva or nail clippings|Both|N/A|N/A|No|Non-Probability Sample|Patients with solid or hematologic cancers who may be and considered potential candidates        for a therapeutic protocol will be recruited to Part A of this study. Enrollment to        therapeutic clinical trials will not be contingent on enrollment in this protocol.        Part B: Research Collection Cohort Patients potentially appropriate will be identified by        their treating physician in each participating Disease Management Team.|March 2016|March 9, 2016|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01775072||72503|
NCT01775332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMHAIF - 058|Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools|Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools||St. Michael's Hospital, Toronto|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775332||72483|
NCT01775631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-017|Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma|A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies||Bristol-Myers Squibb|No|Active, not recruiting|March 2013|December 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|January 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775631||72460|
NCT01775618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15912|Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A|A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A||Bayer|Yes|Recruiting|May 2013|December 2019|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|77|||Male|N/A|12 Years|No|||March 2016|March 10, 2016|January 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01775618||72461|
NCT01775345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENFIS|Assessment of Different Rehabilitation Treatments After a Partial Removal of the Meniscus|Assessment of Different Treatments of Muscle Strengthening in Post-meniscectomy Knee.|MENFIS|University Rovira i Virgili|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|60 Years|No|||March 2014|March 14, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01775345||72482|
NCT01736969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSM-RD-023|A Substantial Equivalence Study of RD04723 and Predicate Device|Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars||Oculus Innovative Sciences, Inc.|No|Active, not recruiting|August 2012|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2012|November 30, 2012|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01736969||75428|
NCT01737515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbdoWaistHip|Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery|Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|November 2008|June 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1415|||Both|18 Years|N/A|No|Non-Probability Sample|Patients for whom elective colorectal resectional surgery (open and laparoscopic) is        indicated.|November 2012|November 27, 2012|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01737515||75386|
NCT01737775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.718|Comparative Ultrasonic Study of Post Operative Diaphragmatic Dysfunction in Abdominal and Head and Neck Surgery|Comparative Ultrasonic Study of Post Operative Diaphragmatic Dysfunction in Abdominal and Head and Neck Surgery|Under the Dome|Hospices Civils de Lyon|No|Completed|October 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|43|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01737775||75366|
NCT01738074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNCDC-001|Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine|||Center for Disease Control and Prevention, Henan Province||Active, not recruiting|August 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|10020|||Both|6 Weeks|13 Weeks|Accepts Healthy Volunteers|||November 2012|November 28, 2012|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01738074||75343|
NCT01738646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024983|Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients|Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients||Duke University|Yes|Completed|January 2013|November 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|120 Years|No|||November 2015|January 20, 2016|November 28, 2012|Yes|Yes||No|September 30, 2015|https://clinicaltrials.gov/show/NCT01738646||75299|
NCT01738620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOLEC1 - step 1|Quality of Life After Esophagectomy for Cancer - Step 1|Quality of Life After Esophagectomy for Cancer - QOLEC1||University of Padova|No|Recruiting|January 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|October 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01738620||75301|
NCT01739166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-10-07|QI Study of a Practice Facilitator's Impact in Working With Clinics on Improving Dental, Lead & Obesity Measures for Children|Child Healthcare Excellence Center - A University-Practice-Public Partnership (CHEC-UPPP)||University Hospital Case Medical Center|No|Completed|October 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01739166||75259|
NCT01739491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100917|A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia|A Post-Marketing Surveillance Study on the Safety And Effectiveness of Bendamustine Hydrochloride Among Adult Filipino Patients With Chronic Lymphocytic Leukemia||Janssen Pharmaceutica|No|Withdrawn|October 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include adult Filipino patients who are diagnosed with chronic        lymphocytic leukemia.|November 2015|November 30, 2015|November 29, 2012|Yes|Yes|The study is cancelled. FDA Circular 2013-004 mandates that PMSs like this are not required|No||https://clinicaltrials.gov/show/NCT01739491||75234|
NCT01769365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS99-CT7-10|Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection|Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan||Kaohsiung Veterans General Hospital.|Yes|Completed|July 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|307|||Both|20 Years|90 Years|No|||September 2015|September 6, 2015|January 14, 2013||No||No|September 6, 2015|https://clinicaltrials.gov/show/NCT01769365||72942|The trial was performed in a single country
NCT01777373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110902|Conducting Airways in Lung Fibrosis (VACFI)|Conducting Airways in Lung Fibrosis|VACFI|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2012|February 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|141|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|IPF will be diagnosed according to ATS/ERS/JRS/ALAT 2012 guidelines, either in the        presence of a typical Usual Interstitial Pneumonia pattern on CT imaging of the lung or in        the presence of a probable UIP pattern on a pathological lung specimen, and in the absence        of any identified cause of secondary interstitial pneumonia.        Patients with non-IPF interstitial pneumonias will be recruited. Due to the case mix at        Bichat and Pompidou hospitals, patients with idiopathic Non Specific Interstitial        Pneumonia and interstitial pneumonia associated with sarcoidosis and auto-immune disease        will be recruited.        In some patients, a definitive diagnosis of either IPF or non-IPF interstitial pneumonia        will not be available at the time of inclusion.|December 2014|April 9, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01777373||72326|
NCT01797536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8742-009|The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)|A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742||Merck Sharp & Dohme Corp.|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|February 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01797536||70779|
NCT01797770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVS2|Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery|A Randomised Controlled Trial On Mechanical Bowel Preparation Versus No Mechanical Bowel Preparation In Elective Laparoscopic Surgery For Left Sided Colonic Tumours|MBP|PVS Memorial Hospital|No|Recruiting|January 2012|February 2014|Anticipated|January 2014|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|90|||Both|25 Years|75 Years|No|Probability Sample|Randomized open label study to assess effect of mechanical bowel preparation in elective        laparoscopic surgery for left sided colon tumours|February 2013|February 21, 2013|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01797770||70761|
NCT01797757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.29.NRC|Comparison of MAG and Fish Oil Efficacy|Comparison of the Efficacy of Monoacylglycerol (MAG) and Triacylglycerol (TAG) to Deliver Long Chain Polyunsaturated Fatty Acids (LC-PUFA) Under Malabsorption Conditions||Nestlé|No|Completed|January 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|4||Actual|46|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01797757||70762|
NCT01798329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOS|ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study|Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study.|ETOS|A.O. Ospedale Papa Giovanni XXIII|Yes|Not yet recruiting|March 2013|September 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|20 Years|No|||February 2013|February 21, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798329||70718|
NCT01798342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|brianez|Safety of Gastric Volume Emptying After the Intake of Maltodextrin and Glutamine|Gastric Residual Volume After He Intake Of Maltodextrin And Glutamine. A Randomized Double-Blind, Crossover Study||Federal University of Mato Grosso do Sul|No|Completed|March 2012|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|11|||Male|21 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798342||70717|
NCT01798602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCTG|Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|CHAT Pilot|Canadian Critical Care Trials Group|No|Terminated|December 2009|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|16 Years|N/A|No|||February 2013|February 22, 2013|February 19, 2013||No|H1N1 pandemic concluded|No||https://clinicaltrials.gov/show/NCT01798602||70697|
NCT01798927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD AFO|Effect of Lower Extremity Ankle Foot Orthoses in Parkinson's Disease|Investigation of Lower Extremity Orthoses on Gait in Persons With Parkinson's Disease: a Case Series.||University of Texas Southwestern Medical Center|No|Terminated|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|50 Years|75 Years|No|||July 2015|July 6, 2015|February 11, 2013||No|Modifications are being made to protocol|No|May 13, 2015|https://clinicaltrials.gov/show/NCT01798927||70674|
NCT01798940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-082|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fed Conditions.||Torrent Pharmaceuticals Limited||Completed||||September 2008|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798940||70673|
NCT01799200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55028|Hip Pathomorphology in Collegiate Athletes and Controls|Prevalence of Hip Pathomorphology in Collegiate Athletes and Age-Matched Controls: Radiographic and Physical Exam Findings||University of Utah|No|Completed|June 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|63|||Both|18 Years|30 Years|No|Non-Probability Sample|Male and Female 18-30 years old and athletes. Age matched controls.|August 2015|August 12, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01799200||70653|
NCT01796730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRDBAM201201|Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients|A 12-week, Double-blind, Multicenter, 3-crossover, Placebo Controlled and Randomized Trial to Investigate the Efficacy and Safety of 10mg and 5mg Bambuterol Tablets Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)||The First Affiliated Hospital of Guangzhou Medical University|Yes|Completed|February 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|40 Years|80 Years|No|||March 2015|March 10, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01796730||70841|
NCT01796106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETECT13|Clinical Trial Proximal Caries Infiltration and Detection|Clinical Efficacy of Caries Infiltration (Icon) - A Randomized, Blinded and Controlled Pilot Study of Early Caries Progression Detection||DMG Dental Material Gesellschaft mbH|No|Recruiting|March 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|6 Years|13 Years|No|||November 2015|November 5, 2015|November 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01796106||70889|
NCT01793675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2013] (04)|Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome|Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome||Peking University People's Hospital||Completed|April 2003|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|||Both|2 Years|60 Years|No|Probability Sample|patients with MDS:1)intermediate-2 or high risk 2)low or intermediate-1 risk, drug        resistance or disease progression|April 2015|April 27, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793675||71076|
NCT01793688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9231002|Drug Use Investigation Of Sulbactam/Ampicillin (UNASYN) 12g (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Sulbactam/Ampicillin 12g||Pfizer|No|Completed|March 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|986|||Both|15 Years|99 Years|No|Probability Sample|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per        day) from the first dosing date or the second dosing date.          1. Pneumonia          2. Lung Abscess          3. Peritonitis|December 2015|December 7, 2015|February 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01793688||71075|
NCT01794702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1064|Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia|Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia||M.D. Anderson Cancer Center|No|Recruiting|February 2013|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|64 Years|No|||October 2015|October 20, 2015|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794702||70997|
NCT01793922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55020|POEM Trial: Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM)|A Prospective Randomized Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM) as Treatment of Idiopathic Achalasia||Katholieke Universiteit Leuven|Yes|Recruiting|October 2013|January 2023|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01793922||71057|
NCT01794130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V/4/11|The Incidence of Subclinical High-altitude Pulmonary Oedema at High Altitude|||Institute of Mountain Emergency Medicine|Yes|Completed|July 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|Samples With DNA|blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|February 2013|February 15, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794130||71041|
NCT01795456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-595|Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis|Contrast Enhanced Ultrasound for Assessment of Carotid Artery Neovascularization as a Marker of Disease Activity in Takayasu's Arteritis and Giant Cell Arteritis||The Cleveland Clinic|No|Completed|August 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Takayasu's arteritis or giant cell arteritis will be screened from the        clinics of the Vasculitis Clinic and the Vascular Medicine Clinic at the Cleveland Clinic.|July 2015|July 27, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795456||70939|
NCT01795729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081262|Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction|Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction: THE ARCHER TRIAL|ARCHER|Assistance Publique - Hôpitaux de Paris|No|Terminated|February 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01795729||70918|
NCT01797198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0006|A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects|An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide||Astellas Pharma Inc|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01797198||70805|
NCT01797185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_11_04|An Open Label and Safety Study of the Safety Of SPARC1104|||Sun Pharma Advanced Research Company Limited|No|Recruiting|April 2013|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|90 Years|No|||March 2016|March 8, 2016|February 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797185||70806|
NCT01797523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0543|A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma|A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma||M.D. Anderson Cancer Center|No|Recruiting|October 2013|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797523||70780|
NCT01797796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5281005|Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare|A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Cross-Over Study To Examine The Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare In Healthy Volunteers||Pfizer|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|February 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01797796||70759|
NCT01797809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16344|Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea|Qlaira® Regulatory Post Marketing Surveillance Study in Korea||Bayer|No|Recruiting|May 2013|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Female|N/A|N/A|No|Non-Probability Sample|Generally healthy women after menarche and before menopause desiring contraception with or        without HMB will be recruited who are determined to start Qlaira|March 2016|March 14, 2016|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797809||70758|
NCT01797783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-054|Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens|Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens||Alcon Research|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|February 21, 2013|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01797783||70760|
NCT01798030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43973|Vitamin D Retrospective Study|Association of Vitamin D With Diabetes, Osteoporosis and Cardiovascular Risk||Baltimore VA Medical Center|No|Active, not recruiting|November 2009|September 2015|Anticipated|November 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|362|Samples With DNA|Vitamin D, IGF-1, and PTH levels will be measured in coded plasma samples belonging to the      PI and collaborating Investigators within the GRECC that are stored in our freezers (from      previously approved studies: HP-00040261,HP-00040975, HP-00041166 and HP-00041199) . The      Nutrition Obesity research center genetics core will determine Vitamin D receptor      polymorphisms on de-identified samples. No clinical information will accompany the samples.|Both|45 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|obese, older men and postmenopausal women|September 2014|September 5, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798030||70741|
NCT01798381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCEAN-GER|Essential Fatty Acids in Adult ADHD|The Relationship of Essential Fatty Acids to Cognitive, Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls|OCEAN-GER|Saarland University|Yes|Recruiting|December 2012|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798381||70714|
NCT01798654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-Spirit1201|EUS-FNA for Patients With Antithrombotic Agents|Safety of Endoscopic Ultrasound-guided Fine Needle Aspiration for Patients With Antithrombotic Agents||Hokkaido Pancreatobiliary Endoscopic Intervention Study Group|No|Completed|September 2012|||September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|N/A|N/A|No|Probability Sample|In hospital|February 2016|February 18, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798654||70694|
NCT01798667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8031_PE_II|Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 After Oral Administration in Male Patients With Premature Ejaculation||Dong-A ST Co., Ltd.||Recruiting|January 2013|September 2013|Anticipated|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|220|||Male|20 Years|64 Years|No|||August 2013|August 14, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01798667||70693|
NCT01798628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016960|A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients|A Phase 1, Single Dose, Open-Label, Three-Period, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Subjects||Cougar Biotechnology, Inc.|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|October 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01798628||70696|
NCT01798641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042178|A Randomized Cross-over Study for Normal Pressure Hydrocephalus|Efficacy of Shunt Surgery in Normal Pressure Hydrocephalus: a Randomized Cross-over Study|ARCS NPH|Johns Hopkins University|No|Recruiting|January 2013|May 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|60 Years|85 Years|No|||March 2015|March 17, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798641||70695|
NCT01798953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|326-10|Surgical Reconstruction in Ulcerative Colitis With Primary Sclerosing Cholangitis|Ileal Pouch-anal Anastomosis or Ileo-rectal Anastomosis for Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis?||Sahlgrenska University Hospital, Sweden|No|Active, not recruiting|January 2010|November 2013|Anticipated|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Anticipated|175|||Both|10 Years|90 Years|No|Probability Sample|Patients with UC/PSC vs patients with UC only reconstructed surgically with IPAA or IRA.|February 2013|February 22, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798953||70672|
NCT01799512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGIMEN|Glucose Control in the ICU Using Continuous Glucose Monitoring|Randomized Evaluation of Glycaemic Control in the Medical Intensive Care Unit Using Continuous Glucose Monitoring (REGIMEN Trial)|REGIMEN|University Hospital, Antwerp|No|Completed|July 2007|February 2013|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|75 Years|No|||February 2013|February 22, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01799512||70629|
NCT01799980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009471-01H|Evaluation of Endobronchial Ultrasound (EBUS) for Staging Lung Cancer|Evaluation of Endobronchial Ultrasound (EBUS) for Staging Lung Cancer|EBUS|Ottawa Hospital Research Institute|No|Recruiting|June 2012|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing a staging procedure for lung cancer (either cervical mediastinoscopy        or endobronchial ultrasound).|October 2015|October 21, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799980||70594|
NCT01796418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BESTinDN-001|Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy|Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)||Seoul National University Hospital|No|Recruiting|March 2013|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|20 Years|75 Years|No|||December 2013|December 13, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796418||70865|
NCT01796431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 048|Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers|||St Stephens Aids Trust||Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01796431||70864|
NCT01796743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shaftner T2 AMI MRI|T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events|T2 Mapping of the Heart in Acute MI Population for the Prediction of Short Term Major Adverse Cardiovascular Events|T2 AMI MRI|University of Arizona|No|Not yet recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients between 18 to 89 years in the University of Arizona Medical Center with chest        pain/discomfort suggestive of acute coronary event, elevated cardiac troponin levels        and/or positive ECG criteria for MI.|September 2015|October 12, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01796743||70840|
NCT01797263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1100-R|Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial|Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial|POYSE|VA Office of Research and Development|No|Recruiting|August 2013|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797263||70800|
NCT01794169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEAML12-a|Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML|Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission||Karolinska University Hospital|Yes|Terminated|March 2013|March 2018|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|65 Years|N/A|No|||September 2015|September 19, 2015|February 13, 2013||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01794169||71038|
NCT01795742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-HR-2433|Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer|Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador||Marquette University|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|6 Years|65 Years|No|||February 2013|February 18, 2013|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01795742||70917|
NCT01795755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAT-11-1|YATEP - The Impact of Horse Assisted Therapy (HAT) on Treatment Outcomes|The Impact of Horse Assisted Therapy (HAT) on Treatment Outcomes|HAT|Oslo University Hospital|No|Recruiting|January 2013|January 2017|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|26 Years|No|||March 2013|March 11, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01795755||70916|
NCT01794442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S120213|Study on the Oxygen Saturation in Pulsating and Non-pulsating Central Retinal Veins|Correlation Between Retinal Metabolism and the Observation of a Visible Retinal Spontaneous Venous Pulse||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|January 2013|May 28, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01794442||71017|
NCT01792037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26177|Single Dose of Etomidate and Adrenal Cortex|the Effect of Single Dose of Etomidate Used During Emergency Intubation on Hemodynamics and Adrenal Cortex: a Randomized Clinical Trial||Istanbul University|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|90|||Both|25 Years|65 Years|No|||February 2013|August 23, 2013|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792037||71201|
NCT01792050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2101|Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer|A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer||NewLink Genetics Corporation|Yes|Active, not recruiting|February 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|169|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792050||71200|
NCT01792063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43430|Two Different Preparations of Sevoflurane in Induction|A Randomized Clinical Trial on the Efficiency, Hemodynamic Effects and Patient Comfort of Two Different Preparations of Sevoflurane After Vital Capacity Rapid Inhalation Induction||Istanbul University|Yes|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|No|||April 2013|April 18, 2013|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792063||71199|
NCT01792362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-015|Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)|Comparing the Basal Anti-mullerian Hormone Levels Between Responders and Non-responders to Weight Loss Diet in Obese Infertile Women With PCOS Population||Royan Institute||Completed|October 2012|April 2014|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|May 5, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792362||71177|
NCT01797211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Mediterranean Diet and Endothelial Function|Mediterranean Diet and Endothelial Function in Obese and Overweight Patients: the Role of Olive Oil, Non Fried Fish and Nuts||University of Bari|No|Completed|June 2010|May 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01797211||70804|
NCT01797549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0189AP|Detection of Hemodynamic Changes in TBI Population With Functional Near Infrared Spectroscopy|Detection of Hemodynamic Changes in TBI Population With Functional Near Infrared Spectroscopy||Uniformed Services University of the Health Sciences|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Males and females (military health care beneficiaries and non military health care        beneficiaries) age between 18 and 60 years who have a diagnosis of moderate or severe        traumatic brain injury as well as age, gender, education matched non-TBI volunteers.|December 2015|December 30, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01797549|2 Years|70778|
NCT01797822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31756|Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca|Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca.||Baylor College of Medicine|No|Completed|February 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797822||70757|
NCT01797835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA021786|Alcohol Screening in an Ethnically Diverse Sample of Adolescents in Primary Care|||RAND|Yes|Recruiting|March 2013|August 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2375|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797835||70756|
NCT01798043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-12-048-CH-LV|Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance|Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance||St. Jude Medical|No|Active, not recruiting|January 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798043||70740|
NCT01799239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP237|Safety and Performance of Newly Developed 1-piece Ostomy Product Compared With SenSura|Investigating the Safety and Performance of Newly Developed 1-piece Ostomy Product Concept Compared With SenSura 1-piece in Subjects With an Ileostomy||Coloplast A/S|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|February 22, 2013||No||No|October 7, 2013|https://clinicaltrials.gov/show/NCT01799239||70650|
NCT01798966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1111|Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease|The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®||Sensimed AG|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|90 Years|No|||February 2016|February 15, 2016|February 21, 2013|No|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01798966||70671|
NCT01799213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-113|Discontinuing NSAIDs|Discontinuing NSAIDs in Veterans With Knee Osteoarthritis||VA Office of Research and Development|Yes|Recruiting|August 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|680|||Both|20 Years|N/A|No|||November 2015|November 5, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799213||70652|
NCT01799226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00055445|Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model|Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model||University of Michigan|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|February 24, 2013||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01799226||70651|
NCT01796119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1665|Ridge Expansion in the Maxillary Aesthetic Zone Using Piezo-electric Surgery|Lateral Alveolar Ridge Expansion in the Maxillary Aesthetic Zone Using Piezo-electric Surgery and Threaded Osteotomes for Immediate Implant Placement.||Clinique Dentaire et d'implantologie Dr.Vinh Nguyen|Yes|Completed|February 2013|February 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796119||70888|
NCT01796444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z0011-China|Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node|A Prospective Randomized Multicenter Phase III Study of Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node--the Validation of Z0011 in China|Z0011-China|Shandong Cancer Hospital and Institute|No|Recruiting|January 2013|June 2026|Anticipated|December 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4|||Female|18 Years|70 Years|No|||February 2013|February 20, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796444||70863|
NCT01797003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKN-003|Time-dependent Functional Results Following HTO. Closing Wedge vs Opening Wedge Technique.|Time-dependent Functional Results Following HTO. Closing Wedge vs Opening Wedge Technique.||Martina Hansen's Hospital|No|Active, not recruiting|March 2007|January 2023|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|60 Years|No|||October 2013|October 26, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797003||70820|
NCT01797315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSKIN 01|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|PROSKIN|University Hospital of Berlin|No|Terminated|March 2007|June 2013|Anticipated|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|February 15, 2013||No|no adequate recruitment|No||https://clinicaltrials.gov/show/NCT01797315||70796|
NCT01796977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-12-0001|Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy|A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy|NSM|Halyard Health|No|Terminated|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|21 Years|N/A|No|||March 2015|February 11, 2016|January 9, 2013||No|inability to enroll in this subject population|No|March 26, 2015|https://clinicaltrials.gov/show/NCT01796977||70822|
NCT01797276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 420-05|Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label|Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Open Label|CLA|University of Florida|No|Active, not recruiting|June 2005|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|6 Years|30 Years|No|||September 2015|September 17, 2015|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797276||70799|
NCT01794182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPI 203|Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals|A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema|GAMES-RP|Remedy Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2013|April 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|80 Years|No|||May 2015|May 31, 2015|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794182||71037|
NCT01794468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3030|A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study|A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study|MDBF-CIP|Rabin Medical Center|No|Completed|June 2003|July 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794468||71015|
NCT01795482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THER-6|Preoperative Patient Warming for Prevention of Perioperative Hypothermia in Major Abdominal Surgery|The Effect of Preoperative Patient Warming in the Prevention of Perioperative Hypothermia in Major Abdominal Surgery Under Combined General/Epidural Anaesthesia|THER-6|University of Schleswig-Holstein|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795482||70937|
NCT01795768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3689|Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours|Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours|FGFR|Royal Marsden NHS Foundation Trust|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|25 Years|N/A|No|||March 2013|March 14, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01795768||70915|
NCT01794689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00071465|Mechanisms of Sleep Disruption Hyperalgesia|Mechanisms of Sleep Disruption Hyperalgesia|ESP2|Johns Hopkins University|No|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|48 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794689||70998|
NCT01792089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193/11|Fructose-induced Intestinal de Novo Lipogenesis|Measure of Intestinal Lipogenesis in Healthy Volunteers and Obese Subjects Before and After Gastroplasty: Modulation by Glucose and Fructose|FIDNL|University of Lausanne|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|24|||Both|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|8 non-obese healthy male and female subjects with BMI <25 8 obese male and female subjects        with BMI> 35 8 post-gastric bypass male and female subjects 8 healthy subjects matched to        post-gastric bypass subjects for age, gender and weight|June 2014|June 3, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792089||71198|
NCT01792102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-585|Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma|A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma||Oncotherapeutics|No|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792102||71197|
NCT01792375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWP_PG_Null|Concurrent Membrane Sweeping With Dinoprostone Versus Dinoprostone in Labor Induction of Nulliparas at Term With an Unfavorable Cervix|||Seoul National University Hospital|No|Recruiting|February 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Female|N/A|N/A|No|||December 2013|May 19, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792375||71176|
NCT01792388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vip|Vitd and Barrier Function in IBD|Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission|VIP|University of Dublin, Trinity College|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|30|||Both|18 Years|70 Years|No|||July 2014|July 21, 2014|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01792388||71175|
NCT01798069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV001|Impact of Narrative Medicine (Workshop Reflexive Writing)|Impact of an Educational Program 'Narrative Medicine (Workshop Reflexive Writing) ' Dedicated to Medical Students. A Randomized Controlled Trial.|INAMERE|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2012|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2013|April 17, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798069||70738|
NCT01797562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP 12 7NEW 401|Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents|Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II)||Allerderm|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|6 Years|17 Years|No|||December 2013|September 22, 2014|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797562||70777|
NCT01798680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK098075|Trial of Vitamin D in HIV Progression|Trial of Vitamin D in HIV Progression|TOV4|Harvard School of Public Health|Yes|Recruiting|February 2014|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4000|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798680||70692|
NCT01798056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116427|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy|An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age or Older With Solid Tumours Receiving Chemotherapy||GlaxoSmithKline||Active, not recruiting|March 2013|August 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|237|||Both|18 Years|N/A|No|||December 2015|January 28, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798056||70739|
NCT01798355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIPED20130218|Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy|Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy||Karolinska Institutet|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|7 Years|19 Years|No|||October 2015|October 25, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01798355||70716|
NCT01798368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS002|PBASE-system Safety and Tolerability Clinical Investigation|An Open Label Study to Evaluate the Safety and Tolerability of Nasal Stimulation Using the PBASE System in Non-patient Volunteers||Chordate Medical||Completed|January 2013|||April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|65 Years||||July 2013|July 1, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798368||70715|
NCT01799746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817330|Mechanisms of Response to Diesel Exhaust in Subjects With Asthma|Mechanisms of Response to Diesel Exhaust in Subjects With Asthma||University of Pennsylvania||Recruiting|March 2013|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover||1|Anticipated|10|||Both|18 Years|55 Years|No|Non-Probability Sample|All subjects will have been verified to meet criteria for mild/moderate asthma. At the        same time all subjects will have been verified to be able to produce adequate sputum plugs        for analysis.|February 2013|May 28, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01799746||70611|
NCT01799993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13084|Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia|INHALE 1|Bayer|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799993||70593|
NCT01799525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUE102/12|Hypercapnia to Prevent Secondary Ischemia in SAH|Therapeutical Hypercapnia to Prevent Secondary Ischemic Events in Aneurysmal Subarachnoid Hemorrhage (aSAH)|SAHCO2|Wuerzburg University Hospital|Yes|Completed|January 2013|August 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01799525||70628|
NCT01799733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT007169-01A1|Alternative Treatments for Premenstrual Dysphoric Disorder|Alternative Treatments for Premenstrual Dysphoric Disorder||University of California, San Diego|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|No|||November 2015|November 30, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799733||70612|
NCT01799967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007173-01H|Minimally Invasive Surgery of the Gastro-esophageal Junction|Functional Assessment Following Minimally Invasive Surgery of the Gastro-Esophageal Junction|MISGEJ|Ottawa Hospital Research Institute|No|Recruiting|November 2007|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing minimally invasive surgery of the gastro-esophageal junction at        the Ottawa Hospital.|July 2015|July 29, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799967||70595|
NCT01796158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR34_PA-13-078|Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use|Pilot Test of Computerized MET Intervention to Reduce Adolescent Alcohol Use||Children's Hospital Boston|No|Withdrawn|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|18 Years|No|||March 2014|March 18, 2015|February 20, 2013||No|not funded|No||https://clinicaltrials.gov/show/NCT01796158||70885|
NCT01796171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2011-000033-36|A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma|A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.|LYMRIT-37-01|Nordic Nanovector|Yes|Recruiting|December 2012|December 2021|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|49|||Both|18 Years|N/A|No|||December 2015|January 5, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796171||70884|
NCT01796756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03542|Quality Improvement in Handover of General Internal Medicine In-patients|Quality Improvement in Handover of General Internal Medicine In-patients||University of British Columbia|No|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|1168|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01796756||70839|
NCT01787409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS1293|Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency|Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer||Mayo Clinic|No|Recruiting|March 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|713|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787409||71555|
NCT01787708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02235b|Efficacy of Red Light in Vitiligo|Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial||University of British Columbia|No|Recruiting|February 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|16|||Both|19 Years|N/A|No|||June 2015|June 30, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787708||71532|
NCT01796990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Likes-01|Developing a Physically More Active Lifestyle Based on One's Own Values - RCT Among Sedentary Adults|Developing a Physically More Active Lifestyle Based on One's Own Values - Randomized Controlled Trial Among Sedentary Adults||Likes - Foundation for Sport and Health Sciences|No|Completed|August 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|136|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01796990||70821|
NCT01797328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nystrom_koldstudie|Does Cold Provocation Increase Brown Adipose Tissue Volume?|Study of the Effects of Temperature on Amount of Brown Adipose Tissue in Humans||University Hospital, Linkoeping|No|Completed|February 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01797328||70795|
NCT01795469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00033 (NCH IRB number)|Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients|Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients||Nationwide Children's Hospital|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|12 Years|19 Years|No|||December 2014|December 27, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795469||70938|
NCT01791803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPP|Smoking Cessation After Hospitalization for a Cardiopulmonary Illness|Smoking Cessation Treatment of CardioPulmonary Hospitalized Patients|STOPP|North Shore Medical Center|No|Completed|January 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|164|||Both|18 Years|75 Years|No|||February 2013|February 13, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791803||71219|
NCT01792115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130002|Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E|Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792115||71196|
NCT01792128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPICS2010|SPICS-BIPOLAR for Long Term Follow up|SPICS (Secure Platform for Integrating Clinical Studies) for Recurrent (Bipolar) Affective Disorders for Long Term Follow up Treatment Regiments and Outcome in a Natural Setting||Österreichische Gesellschaft für Bipolare Erkrankungen|Yes|Enrolling by invitation|May 2000|December 2014|Anticipated|January 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|600|||Both|N/A|N/A|No|Non-Probability Sample|community of wiener neustadt and neunkirchen|February 2013|February 12, 2013|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01792128||71195|
NCT01794949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057208|Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome|Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)|OFDI-DM|Emory University|Yes|Active, not recruiting|September 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|80 Years|No|Probability Sample|Non-insulin dependent diabetic and non- diabetic patients undergoing percutaneous        transluminal cononary intervention (PTCI) for the treatment of acute coronary syndrome        with a single drug eluting stent (DES).|February 2016|February 2, 2016|November 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794949||70978|
NCT01795196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10110203-IRB01|Integrated Pulmonary Index (IPI) as a Determinate of Weaning Success and/or Failure in the Pediatric Population|The Use of Integrated Pulmonary Index (IPI) as a Determinate of Weaning Success and/or Failure in the Pediatric Population|IPI|Rush University Medical Center|No|Recruiting|May 2011|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|1 Year|18 Years|No|Non-Probability Sample|Mechanically ventilated pediatric patients undergoing the weaning process.|December 2014|December 23, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01795196||70959|
NCT01792674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ob-an-op-simulation-trial|'In Situ Simulation' Versus 'Off Site Simulation' in Obstetric Emergencies|A Randomised Educational Feasibility Trial: 'In Situ Simulation' Versus 'Off Site Simulation' in Obstetric Emergencies and the Effect on Knowledge, Safety-attitudes, Team Performance, Stress, and Motivation||Rigshospitalet, Denmark|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|97|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01792674||71153|
NCT01792687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103306|Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate|Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)||Aragon Pharmaceuticals, Inc.|No|Active, not recruiting|February 2013|April 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01792687||71152|
NCT01792986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024469|The Fasting II Study|Preparatory Study to Determine Which Risk Markers May be Reduced by Fasting and Should be Evaluated in a Future Randomized Trial||Intermountain Health Care, Inc.|No|Completed|February 2013|||June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|30 Years|69 Years|No|||July 2013|August 1, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792986||71129|
NCT01792999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-CN-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||March 10, 2015|January 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792999||71128|
NCT01793259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-MTX.11/RA|Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)|An Open-label, Randomized, Two-period Cross-over Study of Repeated Subcutaneous Injections of Methotrexate 50mg/ml Solution Either by a Pre-filled Syringe (Reference) or by a Disposable Pre-filled Pen (Test) to Assess Patient's Preference and Self-injection Experience and to Compare the Local Tolerability in Patients With Active Rheumatoid Arthritis||medac GmbH|No|Completed|July 2012|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||July 2013|July 12, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793259||71108|
NCT01793519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130056|Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis|Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|August 4, 2015|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793519||71088|
NCT01798082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAZ003846HU|Effect of a Decision Aid on Decision Making for the Treatment of Pelvic Organ Prolapse|||Hartford Hospital|No|Active, not recruiting|December 2012|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|126|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 27, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01798082||70737|
NCT01798394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS059|Progesterone & Postpartum Relapse to Smoking|Progesterone & Postpartum Relapse to Smoking||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798394||70713|
NCT01798407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1815|A Pilot Study of Deep Brain Stimulation to the Lateral Habenulae in Treatment-Resistant Depression|A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|21 Years|70 Years|No|||October 2015|October 13, 2015|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798407||70712|
NCT01798992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0242|Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart|Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart|BORG|University of Colorado, Denver|Yes|Completed|September 2000|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|51|||Both|18 Years|N/A|No|||January 2013|May 1, 2013|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798992||70669|
NCT01799265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800383|Transcend Auto Clinical Evaluation|Transcend Auto Clinical Evaluation||Somnetics International, Inc.|No|Active, not recruiting|February 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799265||70648|
NCT01798979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-103|A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects|A Phase I, Open Interaction Study Between Oral Doses of GLPG0634 (200 mg QD) and Single Oral Doses of Midazolam (2 mg) in Healthy Subjects||Galapagos NV|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 5, 2013|February 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01798979||70670|
NCT01800006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16691|Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region|XANTUS-EL, Xarelto® on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study|XANTUS-EL|Bayer|No|Recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under        routine treatment conditions to prevent stroke or noncentral nervous system systemic        embolism.|March 2016|March 15, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800006||70592|
NCT01800227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-09-181|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of FDC of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Actoplus Met® 15 mg/850 mg Tablets (Reference Formulation, Takeda Pharmaceuticals America Inc., USA) in Healthy Human Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited|No|Completed||||March 2010|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 25, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800227||70575|
NCT01800214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP-13129|The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias|In Vivo Brain Mapping in Cognitive Impairment From Alzheimer's, Vascular and Other Demenitas: A Longitudinal Brain-Behaviour Study With a Focus on Cerebrovascular Disease||Sunnybrook Health Sciences Centre|No|Active, not recruiting|September 1995|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1200|Samples With DNA|Whole blood|Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population consisted of a sample of outpatients who attended a tertiary-care        neurology clinic at the Sunnybrook Health Sciences Centre.|May 2015|May 19, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800214||70576|
NCT01796457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864 Immunology Treatment|HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B|HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B||University of Pittsburgh|Yes|Active, not recruiting|March 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|The study population will be recruited from multi-site clinical centers in the United        States and Canada including primary care hospitals and community centers that have        enrolled into the HBRN clinical trials (NCT01369212 or NCT01369199).|January 2016|January 27, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796457||70862|
NCT01787422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUIRB1210008469|Comparison of Telemedicine Versus Traditional Practice in a University Health Center|Comparison of Telemedicine Versus Traditional Practice in a University Health Center||Arizona State University|Yes|Not yet recruiting|February 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787422||71554|
NCT01787721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UB-SMP-001|Effect of Manipulation of the Ankle Joint on Gait|Effect of Manipulation of the Tibiotalar Joint on Gait||University of Bridgeport|No|Terminated|February 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|November 5, 2012||No|Unable to recruit more than 2 subjects|No||https://clinicaltrials.gov/show/NCT01787721||71531|
NCT01788371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.6|Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus|Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus||Beijing YouAn Hospital|No|Completed|March 2009|July 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|700|||Female|20 Years|35 Years|No|||July 2013|July 29, 2013|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788371||71483|
NCT01788384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1001|Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris|A Multicenter, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel and Acanya® 1.2%/2.5% and Both Active Treatments to Vehicle Control for Treating Acne Vulgaris||Watson Laboratories, Inc.|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|708|||Both|12 Years|40 Years|No|||February 2013|February 7, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788384||71482|
NCT01788397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHSS|Effect of Comprehensive Rehabilitation at Beitostølen Healthsports Centre|Effect of Comprehensive Rehabilitation at Beitostølen Healthsports Centre. A Randomized Study.||Beitostølen Health Sports Center|Yes|Completed|September 2010|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|67 Years|No|||January 2015|January 11, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788397||71481|
NCT01795495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0036|Methadone vs Magnesium in Spinal Fusion|Analgesia Following Posterior Spinal Fusion: Methadone vs Magnesium||Nationwide Children's Hospital|Yes|Recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|12 Years|19 Years|No|||March 2016|March 7, 2016|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795495||70936|
NCT01795222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307/2011|Midazolam Efficacy for Sedating Preschoolers Undergoing Dental Treatment|A Randomised Controlled Trial of Pediatric Sedation for Dental Treatment Using Oral Midazolam or Placebo|Pedsed-I|Universidade Federal de Goias|Yes|Completed|March 2012|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|2 Years|5 Years|No|||December 2013|December 2, 2013|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01795222||70957|
NCT01793272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2-13|Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males|Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males With Mild and Moderate Asthenozoospermia: Randomized Controlled Prospective Crossover Study||Adam International Hospital|Yes|Completed|October 2010|October 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|N/A|35 Years|No|||February 2013|February 14, 2013|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793272||71107|
NCT01791751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOFA|Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles|Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial.|CLOFA|Fundació Privada Eugin|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01791751||71223|
NCT01791764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMU-01|Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)|Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients.||Federal University of São Paulo|Yes|Completed|November 2010|October 2012|Actual|October 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|368|||Both|18 Years|N/A|No|Non-Probability Sample|The patients will be selected from primary care clinic.|February 2013|February 12, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01791764|15 Days|71222|
NCT01794013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si089/2013|DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities|A Randomized Controlled Trial of DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities|RCT/DD|Mahidol University|Yes|Recruiting|March 2013|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|24 Months|72 Months|No|||April 2015|April 11, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794013||71050|
NCT01794260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFTA-01|Efficacy and Safety of Topical Essential Oil Extracted From Zingiber Cassumunar Rokb in Osteoarthritis|Efficacy and Safety of Topical Preparation of Essential Oil Extracted From Zingiber Cassumunar Rokb in Patients With Osteoarthritis||Mahidol University|Yes|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||December 2012|February 14, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01794260||71031|
NCT01794273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0147|Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery|Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery. Prospective Randomised Controlled and Single Centre Trial|VP-hTA-XCar|University Hospital, Clermont-Ferrand||Recruiting|July 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794273||71030|
NCT01798706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12703|Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen|GetGoal-O|Sanofi|Yes|Completed|June 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|70 Years|N/A|No|||February 2016|February 11, 2016|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798706||70690|
NCT01798420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hb-A1C-2012|Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation|The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation||The Nazareth Hospital, Israel|Yes|Completed|April 2012|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic patients with COPD ecaxerbation who are admitted to the hospital|February 2013|February 22, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798420||70711|
NCT01798693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORB-12-2374|Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology|Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology||University of North Carolina, Chapel Hill|Yes|Terminated|August 2013|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|January 18, 2013||No|Poor subject compliance and inadequate recruitment|No||https://clinicaltrials.gov/show/NCT01798693||70691|
NCT01799278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210013164|A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer|A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer||Weill Medical College of Cornell University|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||September 2015|September 1, 2015|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799278||70647|
NCT01799252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7000|Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion|Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion||Gynuity Health Projects|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|582|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll 610 women. Women will be recruited from 5 clinics and will        self-administer, or if necessary, a study coordinator will administer, a computer-based        questionnaire 7-14 days following administration of mifepristone.|January 2014|January 30, 2014|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01799252||70649|
NCT01799538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130051|Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis|Bronchodilator Effects of Nebulized Versus Inhaled Albuterol In Subjects With Lymphangioleiomyomatosis||National Institutes of Health Clinical Center (CC)||Recruiting|December 2012|November 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|80 Years|No|||October 2015|November 3, 2015|February 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799538||70627|
NCT01800019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011824-01H|The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers|The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers|CANQUIT|Ottawa Hospital Research Institute|Yes|Active, not recruiting|January 2014|January 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|256|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800019||70591|
NCT01800240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-09-182|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of FDC of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Actoplus Met® 15 mg/850 mg Tablets (Reference Formulation, Takeda Pharmaceuticals America Inc., USA) in Healthy Human Volunteers Under Fed Conditions.||Torrent Pharmaceuticals Limited|No|Completed||||March 2010|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 25, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800240||70574|
NCT01800032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1222|PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)|Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|6 Years|N/A|No|Non-Probability Sample|UNC Hospitals|October 2015|October 13, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800032||70590|
NCT01796132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSRI-Milk|Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications|Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child||Centre Hospitalier Universitaire Vaudois|No|Recruiting|August 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01796132||70887|
NCT01796145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC033|Fibroscan Study in HCC|A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma||Chinese University of Hong Kong|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01796145||70886|
NCT01791608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAZO-01|Zinc Sulphate vs. Zinc Amino Acid Chelate|Effect of Zinc Sulphate and Zinc Amino Acid Chelate in Prevention Acute Diarrhea and Acute Respiratory Infection, Medellín 2012|ZAZO|CES University|No|Completed|March 2012|November 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|360|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791608||71234|
NCT01791621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNM1301|The Diagnostic Predictability of Food Allergy Testing|The Diagnostic Predictability of Food Allergy Testing in Individuals With Irritable Bowel Syndrome (IBS): A Comparison Between Various Laboratory Methods and an Elimination Diet. (The FAST Study)|FAST|The Canadian College of Naturopathic Medicine|No|Completed|January 2013|May 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|64 Years|No|||July 2013|July 17, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791621||71233|
NCT01787747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AVR-132|Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers|A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers||Avanir Pharmaceuticals|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787747||71530|
NCT01787760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1561AC|Controlling Myopia Progression With Soft Contact Lenses|Controlling Myopia Progression With Soft Contact Lenses||Johnson & Johnson Vision Care, Inc.|Yes|Completed|April 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|221|||Both|8 Years|12 Years|No|||July 2015|July 1, 2015|February 6, 2013|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT01787760||71529|
NCT01792414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC12143|Transcranial Electrical Stimulation (TES) for the Treatment of Depression.|||The University of New South Wales|Yes|Recruiting|January 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792414||71173|
NCT01792427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B51060|Mortality in Non-cystic Fibrosis Bronchiectasis|Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis||Universitaire Ziekenhuizen Leuven|No|Completed|June 2006|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|253|||Both|18 Years|N/A|No|Non-Probability Sample|non-cystic fibrosis bronchiectasis|February 2013|February 18, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792427||71172|
NCT01795781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/117|Assays for and Reversal of New Anticoagulants|Development of Anticoagulant Assays for New Anticoagulants and Their Reversibility in Vitro||Royal Perth Hospital|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with atrial fibrillation receiving dabigatran for thrombosis prevention or        patients with osteoarthritis of the hip or knee receiving rivaroxaban after total hip or        knee replacement respectively for thrombosis prevention|April 2013|April 30, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01795781||70914|
NCT01791777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10099|Effectiveness and Cost-effectiveness of Coaching Models to Promote Implementation of an Evidence-based Parenting Program|Effectiveness and Cost-effectiveness of Coaching Models to Promote Implementation of an Evidence-based Parenting Program||Georgia State University|No|Enrolling by invitation|September 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 12, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01791777||71221|
NCT01791790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nighttime sleep-tSOS-Old|Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Elderly Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Elderly Healthy Subjects||Charite University, Berlin, Germany|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791790||71220|
NCT01793831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMC-CN-121101|Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases|Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Crohn&Apos;s Diseases in Ileum and Colon||The Second Hospital of Nanjing Medical University|Yes|Recruiting|November 2012|June 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|70 Years|No|||November 2014|November 21, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793831||71064|
NCT01799031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS12115|Educational Intervention for Reducing Work Disability in Breast Cancer Survivors|Reducing Work Disability in Breast Cancer Survivors||University of Wisconsin, Madison|Yes|Completed|July 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Female|25 Years|64 Years|No|||July 2015|July 22, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799031||70666|
NCT01798745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100985|A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies|A Randomized, Double-blind, Placebo-controlled Pharmacokinetic and Pharmacodynamic Two Part Cohort Study of JNJ-54452840 in Subjects With Reduced Systolic Function Heart Failure and Elevated Levels of Anti-Beta 1 Adrenergic Receptor Autoantibodies||Janssen Research & Development, LLC|Yes|Withdrawn|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|February 22, 2013|Yes|Yes|study not required for development|No||https://clinicaltrials.gov/show/NCT01798745||70687|
NCT01799005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHS|FLAVIOLA Health Study|Impact of Dietary Flavanols on Vascular Health in a General Population of Healthy Middle-aged Europeans: a Randomized Controlled Study|FHS|Heinrich-Heine University, Duesseldorf|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 1, 2015|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01799005||70668|
NCT01799018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#225490|Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage|Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage||State University of New York - Upstate Medical University|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples With DNA|Cerebrospinal Fluid (CSF)|Both|18 Years|89 Years|No|Probability Sample|Patients admitted to University Hospital.|November 2014|November 19, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01799018||70667|
NCT01799551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PakistanACT|Brief Culturally Adapted Cognitive Behaviour Therapy for Depression|A Randomised Controlled Trial of Brief Culturally Adapted CBT for Depression in Pakistan||Pakistan Association of Cognitive Therapists|Yes|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||October 2014|October 27, 2014|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01799551||70626|
NCT01799564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPL4DRY|Micropulse Laser for Geographic Atrophy|A Phase I Study to Establish the Safety and Efficacy of Retinal Pigment Epithelium Micropulse Laser in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration|MPL4DRY|Institut de la Macula y la Retina|No|Recruiting|August 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|50 Years|N/A|No|||March 2015|March 23, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799564||70625|
NCT01800279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-12|Physiotherapy and Deontology in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome.|Comparative Study on the Effectiveness of Physical Therapy and Deontology for Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome.||Universidad de Almeria|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|65 Years|No|||December 2013|December 9, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01800279||70571|
NCT01800292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0006-01|Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.|Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension|LV strain|University of Arizona|No|Completed|February 2013|December 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800292||70570|
NCT01800253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepMetaJCCB2013|The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism|The Role of Acute Total Sleep Deprivation in the Regulation of Metabolism, Neuroendocrine Responses, and Behavioral Measures||Uppsala University|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||November 2013|December 6, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01800253||70573|
NCT01800266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A64442|Randomized Controlled Trial of Supervision Strategies to Improve Clinician Fidelity to Trauma-focused CBT|Improving Practice in Community-based Settings: A Randomized Trial of Supervision Strategies|STEPS|University of Washington|Yes|Recruiting|July 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1280|||Both|6 Years|17 Years|No|||April 2015|April 30, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01800266||70572|
NCT01787435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612N00018|Acid-suppressing Drugs Pregnancy Asthma Offspring Study|A Cohort Study on the Association Between Acid-suppressing Drugs in Pregnancy and Asthma in the Offspring||AstraZeneca|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|10116|||Female|N/A|N/A|No|Non-Probability Sample|All women aged 18-45 years and with at least one pregnancy between 1 January 1995 and 31        December 2010 who have been enrolled with their PCP (Primary Care Physician) for at least        1 year and have had a health contact in the year prior to the last menstrual period (LMP)        of the respective pregnancy. The final study population will include pregnancies that can        be unequivocally linked with live birth(s) and only the first pregnancy ascertained during        the study period for each woman will be retained|April 2015|April 3, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787435||71553|
NCT01787448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491007|RIPT of Ibuprofen Topical Gel|Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers||Pfizer|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 27, 2013|December 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787448||71552|
NCT01797406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIC-003|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Experienced Endoscopists|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Experienced Endoscopists||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2013|February 21, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797406||70789|
NCT01797419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-0104|Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection||Gilead Sciences|Yes|Withdrawn|May 2013|August 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|24 Months|No|||October 2013|October 24, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797419||70788|
NCT01788085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-41|Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)|RD-41 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance||Given Imaging Ltd.|No|Withdrawn|August 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788085||71505|
NCT01788098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASGENAS|Genetics and Mechanisms of Rheumatoid Arthritis|Rheumatoid Arthritis Susceptibility Genes in Austrian and Slovak Population|RASGENAS|Slovak Academy of Sciences|No|Completed|October 2009|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|790|Samples With DNA|frozen immune cells frozen serum frozen DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with rheumatoid arthritis and healthy controls from Slovakia and Austria|February 2013|February 7, 2013|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01788098||71504|
NCT01792726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGIT Boost|A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.|An International Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy Boost With Conventional External Beam Radiotherapy Boost After Lumpectomy for Breast Cancer in Women With a High Risk of Local Recurrence.|TARGIT-B|University College, London|Yes|Recruiting|June 2013|April 2022|Anticipated|January 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1796|||Female|N/A|N/A|No|||October 2015|October 7, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792726||71149|
NCT01792739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU_probiotics|Lactobacillus Preparation on the Incidence of Diarrhea|The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial||Seoul National University Hospital|No|Recruiting|November 2010|October 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|124|||Both|20 Years|N/A|No|||February 2013|February 13, 2013|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01792739||71148|
NCT01792700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0603/031-013|Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy|||Seoul National University Bundang Hospital||Completed|January 2003|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|648|||Both|23 Years|84 Years|No|||February 2013|February 14, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792700||71151|
NCT01792713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E550-PRU-2012|Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis|Randomisierte, Doppelblinde, Plazebo-kontrollierte Prüfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Verträglichkeit Einer 2%Igen Sertaconazol-Crème Bei Patienten Mit Atopischer Dermatitis (Abridged)||Spirig Pharma Ltd.|No|Completed|February 2013|February 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792713||71150|
NCT01793012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUC 428-12|Drug Monitoring of Antibiotics in Critical Care Patients|Drug Monitoring of Antibiotics in Critical Care Patients|DRAK|Ludwig-Maximilians - University of Munich|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalisation in the critical care unit of the Department of Anaesthesiology of the        University Hospital of Munich|March 2015|March 30, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01793012||71127|
NCT01793025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATAC-AML-01|Mismatched Donor Cells to Treat Acute Myeloid Leukemia|Adoptive Transfer of Alloreactive Cells to Treat Patients With Poor-Prognosis Acute Myeloid Leukemia-01|ATAC-AML-01|Maisonneuve-Rosemont Hospital||Recruiting|September 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01793025||71126|
NCT01792401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEFCIP|Probiotics in Enteral Feeding in Critically Ill Patients|Probiotics in Enteral Feeding in Critically Ill Patients||University of Malaya|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792401||71174|
NCT01793571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40460.094.12|Pilot Study on the Effectiveness of a TAP-block for Inguinal Hernia Repair|A Pilot Study on the Effectiveness of the Echoguided Transversus Abdominis Plane Block During Inguinal Hernia Repair Surgery||Westfriesgasthuis|No|Active, not recruiting|September 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01793571||71084|
NCT01793844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWOG0001|A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients|A Prospective , Multicenter, Randomized Phase III Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients||Sun Yat-sen University|Yes|Recruiting|January 2008|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|732|||Both|18 Years|70 Years|No|Probability Sample|untreated CD20 positive Difussed large B cell lymphoma adults|December 2015|December 10, 2015|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT01793844||71063|
NCT01793545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913073|Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples|Methylation Markers for Natural History and Early Detection of Endometrial Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Female|45 Years|120 Years|No|||October 2015|November 5, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793545||71086|
NCT01793818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVATAT|Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein|Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein|EVATAT|BIOSANTECH|Yes|Active, not recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|64 Years|No|||February 2016|February 9, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793818||71065|
NCT01798771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannWGUH_IMAGER|Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery|Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery|IMAGER|Johann Wolfgang Goethe University Hospitals||Not yet recruiting|March 2013|February 2016|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798771||70686|
NCT01799291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2KR401204-MMJ|Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder|Decision Making and Mental Health: Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder||University of North Carolina, Chapel Hill|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|240|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 3, 2013|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01799291||70646|
NCT01799304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC - 13 01|Static and Dynamic Postural Stability in Cerebral Palsy Children|Is it Possible to Improve Static and Dynamic Postural Stability in Cerebral Palsy Children by Modulating Attention?|Dual-Task|University Hospital, Grenoble|No|Completed|February 2013|December 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|24|||Both|7 Years|12 Years|No|||March 2016|March 22, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01799304||70645|
NCT01790451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-252|Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans|The Safety and Efficacy of Irreversible Electroporation for the Ablation of Prostate Cancer Assessed by Procedural Related Side Effects and Post Prostatectomy Histology: A Prospective Human In-Vivo Study.||Clinical Research Office of the Endourological Society|Yes|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|N/A|N/A|No|||August 2014|February 19, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790451||71323|
NCT01799759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-1625|Project Fun: Parents And Youth Together|Project Fun: Parents And Youth Together||Marquette University|No|Recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|9 Years|15 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799759||70610|
NCT01799772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11030404|The Feasibility of a Comprehensive Behavioral Intervention in Patient Post TKA|The Feasibility of a Comprehensive Behavioral Intervention in Patient Post Total Knee Arthroplasty||University of Pittsburgh|Yes|Completed|September 2011|August 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 9, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01799772||70609|
NCT01790984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN0172 A/B|How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?|How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype?|CHOT|University of Surrey|No|Completed|April 2009|September 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 11, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790984||71282|
NCT01796184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS11/02219|Inflammation and Glycation in a General Adult Population|Inflammation and Glycation in a General Adult Population|AES|Hospital Clinico Universitario de Santiago|No|Completed|November 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1516|Samples With DNA|whole blood, serum|Both|18 Years|N/A|No|Probability Sample|This cross-sectional is being performed in the municipality of A-Estrada, in Northern        Spain.        An age-stratified random sample of the population 18 years and older was drawm from the        National Health System Registry|May 2015|May 21, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01796184||70883|
NCT01796197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-497|Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa|Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|March 2013|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796197||70882|
NCT01787773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL-HUM-002P|VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism|VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism|VERITAS|Veniti|No|Active, not recruiting|March 2013|April 2017|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787773||71528|
NCT01797081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-114|BOTOX® in the Treatment of Crow's Feet Lines in Japan|||Allergan|No|Completed|January 2013|July 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|300|||Both|20 Years|64 Years|No|||January 2015|January 27, 2015|February 20, 2013|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01797081||70814|
NCT01798875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLovaRIS|PCOS, Therapy and Markers of Cardiovascular Risk|Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS)||Medical University of Gdansk|No|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798875||70678|
NCT01798888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130038|Deep Brain Stimulation for Refractory Alcoholism|Pilot Study of Deep Brain Stimulation (DBS) for Refractory Alcoholism||National Institutes of Health Clinical Center (CC)||Withdrawn|November 2012|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|60 Years|No|||November 2015|November 14, 2015|February 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01798888||70677|
NCT01797679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR213335/h10|Study of Cartilage Relaxometry and Physical Activity in Osteoarthritis|Efficacy of Strength and Aerobic Exercise on the Articular Cartilage of Patients With Mild and Moderate Knee Osteoarthritis Measured by T2 and T1 Rho MR Imaging - A Randomized Controlled Trial||University Hospital, Akershus|Yes|Withdrawn|March 2013|March 2017|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|0|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797679||70768|
NCT01792752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK8805|Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico|Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico||Columbia University|No|Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01792752||71147|
NCT01793038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mific-3|Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women|Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women||Mansoura Integrated Fertility Center|No|Recruiting|March 2013|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|38 Years|No|||March 2013|March 5, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01793038||71125|
NCT01793051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0413|Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma|A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden During Maintenance Therapy for Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Recruiting|March 2013|||March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793051||71124|
NCT01793064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-31475|An Adaptive Physical Activity Intervention for Overweight Adults|An Adaptive Physical Activity Intervention for Overweight Adults: A Randomized Controlled Trial||Arizona State University|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793064||71123|
NCT01793298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM-024/I-II/STA-03|Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ASM-024 Administered by Dry Powder Inhalation to Healthy Subjects and Subjects With Stable Moderate Asthma||Asmacure Ltée|No|Terminated|March 2013|December 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 14, 2013||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01793298||71105|
NCT01793311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-11-03-03A-12-X|The Effect of Dosage of Caffeine on Intraocular Pressure|The Effect of Dosage of Caffeine on Intraocular Pressure in Healthy Subjects||Chiang Mai University|Yes|Recruiting|February 2013|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793311||71104|
NCT01793805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP MPR-1|NSABP Patient Registry and Biospecimen Profiling Repository|NSABP Patient Registry and Biospecimen Profiling Repository||NSABP Foundation Inc|No|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Tissue blocks from the primary tumor site and an uninvolved margin of resection (normal      tissue).|Both|18 Years|N/A|No|Non-Probability Sample|Metastatic colorectal cancer patients.|January 2016|January 19, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01793805|2 Years|71066|
NCT01794364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4801009|Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06291874 After Administration Under Fasted And Fed Conditions In Healthy Adult Subjects||Pfizer|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|December 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01794364||71023|
NCT01794039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1187|Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide|Randomized Phase 2 Trial of Retreatment With Pomalidomide or Lenalidomide With Dexamethasone for Patients With Relapsed Myeloma||Mayo Clinic|Yes|Active, not recruiting|March 2014|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794039||71048|
NCT01789892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10012|Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer|FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|June 2011|||January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|February 8, 2013|Yes|Yes|no patient accrual|No||https://clinicaltrials.gov/show/NCT01789892||71366|
NCT01789905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1811187|Tygacil Drug Use Investigation|Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-drug Resistance)|TIGER|Pfizer|No|Active, not recruiting|April 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil).|March 2016|March 22, 2016|February 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789905||71365|
NCT01799044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 41089.029.12 COLDFIRE|Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases|Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Colorectal Liver Metastases - "Ablate and Resect"|IRE|VU University Medical Center|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799044||70665|
NCT01799057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|493/12|The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication||Baker IDI Heart and Diabetes Institute|No|Terminated|July 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|40 Years|N/A|No|||February 2016|February 7, 2016|February 22, 2013||No|The trial has been terminated due to difficulties with recruitment.|No||https://clinicaltrials.gov/show/NCT01799057||70664|
NCT01790152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE11C2|Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment|Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy|HEART|Children's Oncology Group|No|Recruiting|August 2013|||January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|420|Samples With DNA|serum|Both|N/A|N/A|No|Probability Sample|Long-term pediatric T-cell leukemia and Hodgkin lymphoma survivors enrolled on 3        front-line Children's Oncology Group (COG) clinical trials (POG 9404, 9425, 9426) between        1996-2001 that featured upfront DRZ randomization and a range of anthracycline exposures        commonly used in contemporary therapy (100-360 mg/m2 doxorubicin).|September 2015|September 11, 2015|February 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01790152||71346|
NCT01790477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0102|Auricular Acupuncture for The Treatment of Post-Tonsillectomy Pain|AURICULAR ACUPUNCTURE FOR THE TREATMENT OF POST-TONSILLECTOMY PAIN||United States Naval Medical Center, San Diego|Yes|Recruiting|November 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790477||71321|
NCT01790763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-203|Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds|Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds||The University of Texas Medical Branch, Galveston|Yes|Withdrawn|April 2015|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|18 Years|No|||May 2015|May 12, 2015|November 13, 2012|No|Yes|Due to lack of funding from the sponsor this study is being withdrawn.|No||https://clinicaltrials.gov/show/NCT01790763||71299|
NCT01799785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LZPTMH1|Effects of Aerobic Training on Exercise Capacity in Patients With Cirrhosis|Aerobic Training in Patients With Cirrhosis||University of Alberta|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||October 2013|October 8, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01799785||70608|
NCT01800045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-05 / Pitolisant|Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)|A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.||Bioprojet|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01800045||70589|
NCT01791296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10053|Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?|The Effect of a Dexmedetomidine-focussed Sleep Protocol* on Delirium Incidence and Healthcare Costs in Critically Ill Patients: A Prospective Randomized, Double-blind, Pilot Study.|SKY-DEX|Maisonneuve-Rosemont Hospital|Yes|Recruiting|January 2011|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2013|February 13, 2013|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791296||71258|
NCT01791270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-CTS-4971|Obstructive Sleep Apnea (OSA), Hypertension , β1 Subunit of Maxi-k+ Channel and Cardiovascular Risk|Expression of Maxi-k+ Channel β1 Subunit in Peripheral Leukocytes, Blood Pressure Values and the Presence of Endothelial Dysfunction in Patients With Obstructive Sleep Apnea|OSAS|Sociedad Española de Neumología y Cirugía Torácica|No|Completed|February 2010|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|Samples Without DNA|Periferical blood|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group of OSA patients and a control group without OSA|June 2013|June 20, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791270||71260|
NCT01791283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FourCompv1|Real-time Comparison of Left Ventricular Strokevolume Measurement by Four Different Methods|Real-time Comparison of Left Ventricular Strokevolume Measurement by Four Different Methods|FourComp|University Hospital, Linkoeping|Yes|Completed|August 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volounteers|February 2013|February 12, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791283||71259|
NCT01797692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGE|Study of Geriatric Patients Aged 75 Years or Older Treated and Cured for Localized Prostate Cancer: Case-control Study|Study of Geriatric Patients Aged 75 Years or Older Treated and Cured for Localized Prostate Cancer: Case-control Study|PROGE|Centre Francois Baclesse|No|Completed|January 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|74|||Male|75 Years|N/A|Accepts Healthy Volunteers|||July 2013|March 3, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01797692||70767|
NCT01797705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-002|Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP)|Revised Algorithm for Next Generation DeVilbiss AutoAdjust CPAP||DeVilbiss Healthcare LLC|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|January 8, 2013|Yes|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01797705||70766|
NCT01799655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D deficiency|Does Vitamin D Deficiency Associated With Hypercoagulability & Increased Thrombin Generation?|Does Vitamin D Deficiency Associated With Hypercoagulability & Increased Thrombin Generation?||HaEmek Medical Center, Israel|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|hospitalized patient|February 2013|May 4, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01799655|1 Day|70618|
NCT01799668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001-13 HYMC|Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance|Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance||Hillel Yaffe Medical Center|No|Not yet recruiting|February 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients in the psychiatric department|February 2013|February 26, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01799668|3 Weeks|70617|
NCT01792479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIND-014-005|A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer||BIND Therapeutics||Active, not recruiting|April 2013|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792479||71168|
NCT01792765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22487 (CPHS)|Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach|Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach||Dartmouth-Hitchcock Medical Center|Yes|Completed|October 2011|October 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792765||71146|
NCT01793077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-11-EGD-04|Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients|Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients|TREMODI|Astellas Pharma Inc|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|259|||Male|N/A|N/A|No|Non-Probability Sample|Consultation at urology department|January 2014|January 10, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793077||71122|
NCT01793324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00128|EMR Data to Assess Monitoring of Patients Treated With Quetiapine|Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel® or Seroquel® XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany||AstraZeneca|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|6153|||Both|18 Years|N/A|No|Non-Probability Sample|Cross sectional assessment of physician encounters with patients|January 2014|January 27, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793324||71103|
NCT01793285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801136|An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial|Retrospective, Multicentric, National, Observational Study, to Follow-up the Patients Who Participated in the Loadet Study (RELOADET Study)|RELOADET|Pfizer|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|85|||Both|18 Years|N/A|No|Non-Probability Sample|Ankylosing Spondylitis subjects who were treated with ETN when participating in the        previous LoadET study (0881A3-102090)|February 2013|February 14, 2013|January 30, 2013||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01793285||71106|
NCT01794052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCDC-2013/001|To Develop a High Quality Health Care Delivery Model for the Management of Hypertension and Diabetes at CHCs and District Hospitals of Himachal Pradesh.|m-Power Heart Project|m-Power Heart|Centre for Chronic Disease Control, India|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40500|||Both|30 Years|N/A|No|||March 2015|March 10, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01794052||71047|
NCT01789645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI01223|Physical Therapy in Carpal Tunnel Syndrome|Efficacy of Conservative Versus Surgical Therapy for Carpal Tunnel Syndrome: a Randomised Clinical Trial||Universidad Rey Juan Carlos|Yes|Completed|February 2013|August 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|65 Years|No|||August 2014|August 16, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789645||71385|
NCT01789918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-0030-HT|TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)|TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation|ACHIEVE|ReCor Medical, Inc.|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789918||71364|
NCT01789931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9435-BA-CTIL|Examination of a New Non Invasive Sensor "Lifebeam" During HTT in Protective Clothing|Examination of a New Non Invasive Sensor "Lifebeam" During HTT (Heat Tolerance Test) in Protective Clothing|lifebeam|Sheba Medical Center|No|Not yet recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Male|21 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01789931||71363|
NCT01790165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-067-II-02|TDT 067 Open Label Multi-Dose Onychomycosis Study|A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails||Celtic Pharma Development Services|No|Completed|December 2009|June 2012|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|27|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790165||71345|
NCT01790178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041999|Ultrasound in Muscle Biopsy|Outcomes of Ultrasound-guided Versus Blind Core Muscle Biopsy||Duke University|No|Completed|February 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients referred to the Duke EMG Laboratory for core (needle) muscle        biopsies.|January 2016|January 19, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790178||71344|
NCT01790191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T221_HabEat|Comparison of Effect of Repeated Exposure, Flavor-Flavor and Flavor-Nutrient Learning on Vegetable Acceptance in Infants|Comparison of the Effect of Repeated Exposure, Flavor-Flavor Learning and Flavor-Nutrient Learning on Vegetable Acceptance in Weaning Age Infants|T221_HabEat|Centre des Sciences du Goût et de l'Alimentation|Yes|Completed|October 2010|February 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Actual|100|||Both|4 Months|8 Months|Accepts Healthy Volunteers|||February 2013|February 13, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01790191||71343|
NCT01791010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT in elders|Effects of Inspiratory Muscle Training in Elders|Respiratory Muscle Training in the Elderly: a Strategy for Preservation of Inspiratory and Expiratory Pressures Impacting on Mobility and Thickness of the Diaphragm.||Universidade Federal de Pernambuco|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 9, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01791010||71280|
NCT01791309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-221|Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer|A Pilot Study of Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791309||71257|
NCT01791322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM 01.1|NovellusDx Tissue Collection Protocol|An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery||NovellusDx|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|Samples Without DNA|pathology samples of tissue|Both|18 Years|85 Years|No|Probability Sample|Patients that have been diagnosed with cancer and are eligible for tumor biopsy will be        enrolled.|October 2015|October 6, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791322||71256|
NCT01790750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201200340|Pocket Echocardiography System (PES) for Detection of PDA in Neonates|Pocket Echocardiography System (PES) for Detection of Patent Ductus Arteriosus (PDA) in Neonates||University of Florida|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|N/A|90 Days|Accepts Healthy Volunteers|||March 2014|March 5, 2014|February 11, 2013||No||No|January 15, 2014|https://clinicaltrials.gov/show/NCT01790750||71300|
NCT01787136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH-C97-87|Dextromethorphan Added on for the Patients With ADHD|Dextromethorphan Added on Methylphenidate in the Treatment of the Patients With ADHD|DAOFTPWA|Tri-Service General Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|6 Years|25 Years||||May 2015|May 12, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787136||71576|
NCT01791634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1 Jan 4 2007|Prospective, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle|Prospective, Randomized, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle|Hallux valgus|Nova Scotia Health Authority|No|Completed|April 2007|June 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 12, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791634||71232|
NCT01798563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1311|Functional Connectivity Parkinson Disease|Functional Connectivity of the Motor Network in Two Major Subtypes of Parkinson Disease||University of Colorado, Denver|No|Recruiting|June 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|72|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with PD according to UK Brain Bank Criteria will be recruited from the UCD        Neurology clinic. Controls will be recruited from spouses and from the community|January 2016|January 5, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01798563||70700|
NCT01799460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiMEC-2011|Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy|Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies||Shanghai University of Traditional Chinese Medicine|No|Recruiting|December 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|80|Samples With DNA|whole blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|idiopathic membranous nephropathy|April 2013|April 22, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01799460||70633|
NCT01799473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-404|Tyvaso Dosing and Titration Evaluation: TyTRATE Registry|A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso®||United Therapeutics|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|N/A|N/A|No|Non-Probability Sample|Patients newly initiating on Tyvaso therapy for the treatment of PAH|May 2014|March 20, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01799473|6 Months|70632|
NCT01797965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205MS303|Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019|A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301|EXTEND|Biogen|Yes|Enrolling by invitation|February 2013|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1600|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797965||70746|
NCT01797978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1210/173-002|Methylene Blue in Severe Sepsis and Septic Shock|Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded||Seoul National University Hospital|Yes|Recruiting|February 2013|March 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|354|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797978||70745|
NCT01798238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP_C302|Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus|A Phase III Double-blind, Parallel Group, Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of MP-513 Monotherapy in Patients With Type 2 Diabetes Mellitus||Handok Pharmaceuticals Co., Ltd.|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01798238||70725|
NCT01798251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG20120101009|XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach|A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach||Harbin Medical University|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|No|||May 2013|May 3, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01798251||70724|
NCT01793350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-222|Safety and Efficacy Study of BC-DN-01 in Painful Diabetic Peripheral Neuropathy|A Combined Phase 1 + 2 Clinical Trial Evaluating the Safety and Efficacy of BC-DN-01 in the Treatment of Painful Diabetic Peripheral Neuropathy||BioChemics, Inc.|Yes|Withdrawn|June 2013|December 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 24, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01793350||71101|
NCT01793363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0144|Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score|Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score|TRAWELUS|University Hospital, Clermont-Ferrand||Completed|August 2012|November 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01793363||71100|
NCT01793584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032012-067|Surgical Success After Laparoscopic vs Abdominal Hysterectomy|Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success||University of Texas Southwestern Medical Center|No|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|75|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793584||71083|
NCT01798199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-04|Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project|VERVE* PROJECT: Study of the Acceptability of a Virtual Reality System on the Cognitive Stimulation of Patients With Alzheimer's Disease or Related Conditions. (*Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment)|VERVE|Centre Hospitalier Universitaire de Nice|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|21|||Both|60 Years|N/A|No|||August 2015|August 31, 2015|November 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01798199||70728|
NCT01793857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116895|Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to Less Than 30 Months in Panama|Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media in Children Aged 6 Months to Less Than 30 Months in Panama||GlaxoSmithKline||Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|1330|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary caregivers with at least one child aged 6 months to less than 30 months visiting a        clinic in Panama primarily for well-baby visits or sickness visit.|September 2015|December 3, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793857||71062|
NCT01793558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THER-5|Incidence and Prevention of Hypothermia in Newborns Bonding During Caesarean Section|Study That Evaluates the Incidence and Possibilities for Prevention of Hypothermia in Newborns Bonding During Caesarean Section|THER5|University of Schleswig-Holstein|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|20 Minutes|Accepts Healthy Volunteers|||May 2013|May 11, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793558||71085|
NCT01800318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109236|Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?|Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?||University of Arkansas|Yes|Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|162|||Both|N/A|3 Days|Accepts Healthy Volunteers|||November 2015|November 3, 2015|February 21, 2013|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01800318||70568|We had difficulty collecting adequate saliva for salivary cortisol analysis. Many infants had insufficient saliva to run a reliable analysis, and numbers of infants with adequate saliva samples both before and after the heel stick were limited.
NCT01797042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20122091|A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old|A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels on Liver and Muscle Fatty Infiltration, Insulin Resistance, Glucose, Insulin, Leptin, Ghrelin, Postprandial Triglycerides, LDL Particle Size, Uric Acid and Appetite in Adults Aged 20-60 Years Old||Rippe Lifestyle Institute|No|Completed|March 2012|July 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|366|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797042||70817|
NCT01797055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD2009.04|Apotransferrin in Atransferrinemia|Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients||Sanquin|No|Recruiting|December 2010|May 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||May 2015|May 18, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797055||70816|
NCT01790204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA1000853|A Study of the Effects of PEITC on Oral Cells With Mutant p53|||Georgetown University|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|20 Years|65 Years|No|||November 2013|March 19, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790204||71342|
NCT01790490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6162|Glutamatergic Modulation of Cocaine-related Deficits|||New York State Psychiatric Institute|Yes|Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|8|||Both|21 Years|52 Years|No|||February 2013|February 11, 2013|February 8, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01790490||71320|
NCT01790464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-201-SDR|Glossopharyngeal Nerve Block for Awake Intubation|Glossopharyngeal Nerve Blockade for Awake Videolaryngoscopy Assisted Endotracheal Intubation in the Morbidly Obese||McGill University Health Center|No|Completed|April 2012|April 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|24|||Both|18 Years|60 Years|No|||September 2014|September 15, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790464||71322|
NCT01791023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cortisolexercise01|Stress Reactivity of Physical Stressor on Depression|The Effect of Acute Exercise on Reactivity and Recovery of Cortisol and DHEAS Levels in Depressive and Healthy Older Adults.||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 9, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01791023||71279|
NCT01790997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-UST-001.11|Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke|The Role of DLBS1033 in Evaluating Bleeding Profile and Clinical Outcome in Patients With Acute Ischemic Stroke: Comparison With Aspirin and Clopidogrel||Dexa Medica Group|No|Completed|May 2012|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|20 Years|80 Years|No|||January 2014|June 3, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01790997||71281|
NCT01787461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5271003|A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure|Randomized, Double-blind, Placebo Controlled Trial Assessing The Effects Of An Oral Dietary Supplement Containing Marine And Plant Extracts On Overall Facial Skin Appearance Among Healthy Adult Women With Photo-aged Skin||Pfizer|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|194|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|December 5, 2012||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01787461||71551|
NCT01787474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0079|IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML)|A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|59 Years|No|||February 2016|February 10, 2016|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787474||71550|
NCT01799434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407-05-130203|Dynamic Postural Control After Exercise|Influence of an Exercise on the Dynamic Postural Control in Athletes||University Hospital Heidelberg|No|Completed|February 2006|||December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|83|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 25, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01799434||70635|
NCT01799447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TiMM, AU, NN, FiM|Early Intervention With the Marte Meo Method|The Relations Between Infants and Vulnerable First Time Mothers. Does Video Guidances With the Marte Meo Method Promote the Process? Intervention Study in a Community Setting|TiMM|University of Aarhus|No|Enrolling by invitation|May 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|7 Weeks|6 Months|No|||February 2013|May 28, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01799447||70634|
NCT01799694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLPURO-2009-01|Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)|Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Stem Cells Use Derived From Adipose Tissue (e-ASC) for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery|FLPURO|Instituto de Investigación Hospital Universitario La Paz|No|Completed|July 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||September 2012|March 7, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01799694||70615|
NCT01799148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRACOS|Air Pollution, Inflammation and Acute Coronary Syndrome|Impact of AIR Pollution on Inflammation, Oxidative Stress and 1-year Prognosis in Patients Hospitalized for Acute COronary Syndrome|AIRACOS|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||Completed|November 2011|November 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|307|||Both|18 Years|85 Years|No|Probability Sample|Cohort of consecutive patients admitted with diagnosis of aucte coronary, which will        quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to        admission. Also be determined inflammatory molecules and oxidative stress in admission.        During the evolution of these patients, after 30 days, 6 and 12 months will recorded major        adverse cardiovascular events. It also will quantify the exposure of air pollutant        particles, in all patients included at 30 days, 6 and 12 months.|January 2015|January 19, 2015|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01799148|360 Days|70657|
NCT01797367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603M83587 START 001E|Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|25 Years|N/A|No|Non-Probability Sample|Enrollees are HIV-positive, antiretroviral-naive individuals with CD4+ > 500 cells/mL        randomized to the START trial.|November 2015|November 30, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01797367||70792|
NCT01797380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000703|A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women|A Double-Blind, Placebo-Controlled Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women||Duke University|No|Terminated|January 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|70 Years|No|||March 2013|May 17, 2013|February 20, 2013|Yes|Yes|Failure to recruit.|No|February 25, 2013|https://clinicaltrials.gov/show/NCT01797380||70791|
NCT01798498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVN1|Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds|Open-label Uncontrolled, Multicenter Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds||Croma-Pharma GmbH|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|30 Years|65 Years|No|||July 2014|July 29, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798498||70705|
NCT01793337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V/31/10|Core Body Temperature Measurement During Hot and Cold Environmental Exposure|Tympanic and Frontal Versus Oesophageal Core Temperature Reading During Hot and Cold Environmental Exposure||Institute of Mountain Emergency Medicine||Completed|September 2012|||October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 14, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793337||71102|
NCT01794065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS PE|The Promus Element Rewards Study|The Promus Element Rewards Study||Medstar Research Institute|No|Active, not recruiting|October 2012|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are scheduled to receive a Promus Element stent implant, and have de novo        coronary lesions.|August 2014|August 8, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794065||71046|
NCT01796795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTCWA|Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients|A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.||G&E Herbal Biotechnology Co., LTD|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|102|||Both|17 Years|N/A|No|||February 2016|February 17, 2016|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796795||70836|
NCT01796808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100139|Fat Grafting for Pedal Fat Pad Atrophy|Autologous Fat Grafting for Pedal Fat Pad Atrophy||University of Pittsburgh|No|Active, not recruiting|March 2013|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796808||70835|
NCT01795989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2154|Use of Specially Designed Pediatric MR Coils on Clinical Scanners|Novel Coils for Pediatric Musculoskeletal MRI||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795989||70898|
NCT01790217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27895|An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)|GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients||Hoffmann-La Roche||Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced or metastatic EGFR mutation positive non-small cell lung        cancer|March 2016|March 1, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790217||71341|
NCT01790230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-LS-0105|LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection|LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection||LifeBond Ltd.||Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 1, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01790230||71340|
NCT01790503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-08|A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma|An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma||Plexxikon|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790503||71319|
NCT01795963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.2841|ePREP for Community Couples|ePREP for Community Couples||Brigham Young University|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01795963||70900|
NCT01790776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/902|Diagnosis of Urethral Stricture With Sono-urethrography vs Conventional Urethrography (SONO-URETHRA)|Diagnosis of Urethral Stricture With Sono-urethrography vs Conventional Urethrography: Evaluation of the Diagnostic Value and Evaluation of the Reduction of the Radiation Dose With Sono-urethrography (SONO-URETHRA)|SONO-URETHRA|University Hospital, Ghent|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790776||71298|
NCT01796548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015205|Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity|Extended-Release Oxybutynin in the Treatment of Neurogenic Detrusor Overactivity (RONDO)|RONDO|Janssen-Cilag Ltd.,Thailand|Yes|Terminated|December 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|January 30, 2013|No|Yes|Slow rate of participant's enrollment|No|March 21, 2013|https://clinicaltrials.gov/show/NCT01796548||70855|
NCT01796561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLE chronic study|The Effect of Olive Leaf Extract on Blood Pressure in Overweight Prehypertensives|Effect of Chronic Polyphenol-rich Olive Leaf Extract Intake on Cardiovascular Risk Markers||University of Reading|Yes|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01796561||70854|
NCT01791335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIVGlottis|NIV and Glottis-diaphragm Synchrony|Effect of Noninvasive Ventilation on the Synchrony of the Upper Airways and Inspiration.||University Medical Center Nijmegen|No|Recruiting|October 2012|||January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population for this study will be included from the intensive care. All        patients at the intensive care unit who are in clinical need of noninvasive mechanical        ventilation due to hypercapnic COPD and with a NAVA catheter in situ, will be screened and        asked for informed consent to participate.|June 2015|June 9, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791335||71255|
NCT01796509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100147|Study in Intensive Care Follow-up Programme in Improving Long-term Outcomes of ICU Survivors|Multicenter Randomised, Controlled Trial of a Intensive Care Follow -up Programme in Improving Long-term Outcomes of ICU Survivors|ICU-Follow-up|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01796509||70858|
NCT01796522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTM/2012|Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery|Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery|UTM/2012|Instituto de Investigacion Sanitaria La Fe||Withdrawn|March 2013|May 2013|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|60 Years|No|||July 2015|July 21, 2015|February 14, 2013||No|have been published new studies that it showed the ineffectiveness of the treatments proposed    in this study.|No||https://clinicaltrials.gov/show/NCT01796522||70857|
NCT01796535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP201|The PerX360º System™ Registry|An Observational, Multi Center, Non-Randomized (Single Arm) Registration of the PerX360º System™|OptiLIF™|Interventional Spine, Inc.|No|Recruiting|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects treated with the Optiport™ and Opticage™ products|March 2013|March 13, 2013|December 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01796535|1 Year|70856|
NCT01796821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTGWA|Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)|A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)||G&E Herbal Biotechnology Co., LTD|No|Recruiting|August 2014|November 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|20 Years|N/A|No|||February 2016|February 17, 2016|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796821||70834|
NCT01797068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR024139|Patient Navigation for Medicaid Frequent ED Users|Patient Navigation to Improve Care and Reduce Costs for High Utilizers of the Emergency Department||Yale University|No|Completed|March 2013|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|62 Years|No|||July 2015|July 14, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797068||70815|
NCT01799174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022012025|Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea|Something New Under the Sun: A Randomized, Double-Blinded, Controlled Trial of UVA1 Phototherapy in Morphea||University of Texas Southwestern Medical Center|No|Recruiting|May 2012|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|6 Years|95 Years|No|||December 2014|December 2, 2014|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799174||70655|
NCT01799707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRT 03-2003|Vision Restoration Training in Glaucoma|Vision Restoration Training in Glaucoma - A Double-blind, Randomized, Placebo-controlled Clinical Trial|VRT-G|University of Magdeburg|No|Active, not recruiting|July 2004|March 2013|Anticipated|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|25 Years|80 Years|No|||February 2013|February 26, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799707||70614|
NCT01799876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOG-TOH125|Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery|Autologous Cell Therapy Enhancement of Microfracture Surgery||Fondren Orthopedic Group L.L.P.|No|Recruiting|February 2013|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|68 Years|No|||August 2015|August 12, 2015|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799876||70601|
NCT01799330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0809004250|Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation|Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation||Yale University|No|Recruiting|December 2008|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|75 Years|No|||June 2014|June 13, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799330||70643|
NCT01799070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-20130113|Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy|Velocity Systolic Blood Pressure Index in Accurately Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy||Peking Union Medical College Hospital|Yes|Not yet recruiting|March 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|30 Years|85 Years|No|Probability Sample|Patients who with carotid stenosis will accept CEA in PUMCH from March 2013 to September        2014.|February 2013|February 25, 2013|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01799070||70663|
NCT01799083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-002|Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas|Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas|CIK|Chinese PLA General Hospital|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||January 2016|January 26, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799083||70662|
NCT01794351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22P5|Cognitive Effects of 500mg Trans-resveratrol|Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.||Northumbria University|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01794351||71024|
NCT01794416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-EA-001|Thoracoscopic Versus Endocardial Ablation in Patient With Paroxysmal AF After Failed Initial Endocardial Ablation|Thoracoscopic Ablation Versus Endocardial Ablation in Patient With Paroxysmal Atrial Fibrillation After Failed Initial Endocardial Ablation||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|May 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||March 2013|March 24, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794416||71019|
NCT01794637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103363|Study of Peripheral Tissue Oxygenation in End-stage Liver Disease Patients During Liver Transplantation|Study of Peripheral Microcirculatory Dysfunction in End-stage Liver Disease Patients During Liver Transplantation Using Near Infrared Spectroscopy||Lawson Health Research Institute|Yes|Not yet recruiting|February 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients suffering from end-stage liver disease scheduled for liver transplantation|February 2013|February 19, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01794637|1 Day|71002|
NCT01796587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOF-0017|Non-Interventional Study Among Users Of LoFric Origo|Non-Interventional Study Among Users Of LoFric Origo||Wellspect HealthCare||Completed|January 2013|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|||Male|18 Years|N/A|No|Non-Probability Sample|Patients prescribed LoFric Origo for intermittent catheterization, attending any of the        involved clinics.|May 2015|May 7, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796587||70852|
NCT01797146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|656/2555(EC1)|Effectiveness of Catheter Reminder and Evaluation Program|Effectiveness of Catheter Reminder and Evaluation (CARE) Program in Reducing the Catheter-day and Prevention of Catheter-associated Infections|CARE|Siriraj Hospital|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|874|||Both|15 Years|N/A|No|||November 2015|November 18, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01797146||70809|
NCT01800097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ModaA001|Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent|Treatment of Post Stroke Fatigue With Modafinil, Effect on Rehabilitation, Fatigue and Bonemass Index||Herlev Hospital|Yes|Terminated|October 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 23, 2012||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01800097||70585|
NCT01795976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_DOG14_22|NY-ESO-1 T Cells in OG Cancer|A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer|ATTACK-OG|Christie Hospital NHS Foundation Trust|Yes|Active, not recruiting|October 2014|August 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01795976||70899|
NCT01796574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00073063|Ketogenic Diet for Refractory Status Epilepticus|Feasibility and Tolerability of the Ketogenic Diet in the Treatment of Refractory Status Epilepticus in a Neurointensive Care Unit.||Johns Hopkins University|Yes|Recruiting|November 2012|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01796574||70853|
NCT01790789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0027|Stress Reduction in Ovarian Cancer|Stress Reduction During Primary Adjuvant Chemotherapy for Ovarian Cancer||University of Wisconsin, Madison|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|80|||Female|18 Years|N/A|No|||October 2015|October 9, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790789||71297|
NCT01797458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB 39/11|European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth|Randomised Control Trial on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth||University Medicine Greifswald|No|Recruiting|May 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|464|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797458||70785|
NCT01796834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT003919-01A2|Managing Diabetes Mindfully Study|Managing Diabetes Mindfully Study|MDM|HealthPartners Institute|Yes|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|80 Years|No|||February 2013|February 20, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796834||70833|
NCT01797094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-122|BOTOX® in the Treatment of Upper Facial Lines in Japan|||Allergan|No|Completed|February 2013|July 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|20 Years|64 Years|No|||January 2015|January 27, 2015|February 20, 2013|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01797094||70813|
NCT01797107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40958|Study to Determine the Effect of Azasite on Corneal Surface Irregularity|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Azasite on Corneal Surface Irregularity in Subjects With Meibomian Gland Dysfunction||Philadelphia Eye Associates|Yes|Terminated|March 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|January 30, 2013|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01797107||70812|
NCT01797432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907M69801|Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata|Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2009|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797432||70787|
NCT01797445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0111|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults||Gilead Sciences|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|872|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|February 20, 2013|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01797445||70786|There were no limitations affecting the analysis or results.
NCT01799486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Professor Bingliang Lin|Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial|Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial||Sun Yat-sen University|Yes|Active, not recruiting|February 2013|March 2015|Anticipated|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||February 2013|February 23, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01799486||70631|
NCT01799941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AVR-401|Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)|A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)|PRISM II|Avanir Pharmaceuticals|No|Active, not recruiting|February 2013|December 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|750|||Both|18 Years|N/A|No|||February 2015|December 18, 2015|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799941||70597|
NCT01799954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 096|Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults|A Phase 1 Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and to Compare the Priming Ability of NYVAC Alone Versus NYVAC + AIDSVAX® B/E, and DNA Alone Versus DNA + AIDSVAX® B/E When Followed by NYVAC + AIDSVAX® B/E Boosts in Healthy, HIV-1-uninfected Adult Participants||HIV Vaccine Trials Network|Yes|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799954||70596|
NCT01799681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|approvalletter_20110823001|The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance Performance in Parkinsonian Non-fallers and Single Fallers|The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance, Gait and Functional Performance in Parkinsonian Non-fallers and Single Fallers - a Randomized Controlled Trial With 12-month Follow-up||The Hong Kong Polytechnic University|Yes|Completed|August 2011|December 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|30 Years|85 Years|No|||March 2015|March 18, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799681||70616|
NCT01797627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49237|Ventricular Size Involvement in Neuropsychological Outcomes in Pediatric Hydrocephalus|Ventricular Size Involvement in Neuropsychological Outcomes in Pediatric Hydrocephalus (VINOH)|VINOH|University of Utah|No|Active, not recruiting|August 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|62|||Both|5 Years|17 Years|No|Non-Probability Sample|Pediatric, school-aged patients presenting with a first time diagnosis of hydrocephalus.|January 2016|January 7, 2016|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01797627||70772|
NCT01797640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50553|Intramedullary Nailing of Tibia Fractures|Intramedullary Nailing of Tibia Fractures in the Presence of Medial or Posterior Malleolar Fractures||University of Utah|No|Completed|October 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospectively evaluating all patients that have been treated at the University of Utah        over the past five years for Tibial Fracture combined with medial or posterior malleloar        fracture.|July 2015|July 8, 2015|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01797640||70771|
NCT01798186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082269|Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation|Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation||Johns Hopkins University|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798186||70729|
NCT01793636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008424 QM|A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer|An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy|ZEBRA|Queen Mary University of London|Yes|Terminated|February 2013|November 2015|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|February 14, 2013||No|Inferior efficacy of study drug in renal indication.|No||https://clinicaltrials.gov/show/NCT01793636||71079|
NCT01793649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-234-0103|A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects||Gilead Sciences|No|Terminated|October 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|February 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01793649||71078|
NCT01799590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013684|Continuous Treatment Study of Topiramate in Migraine Participants|A Continuous Treatment Study of JNS019 (Topiramate) in Migraine Patients||Janssen Pharmaceutical K.K.|No|Completed|August 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|296|||Both|20 Years|65 Years|No|||May 2013|May 24, 2013|February 25, 2013|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01799590||70623|
NCT01796236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAS5439|Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique|Clinical and Health Economic Evaluation of a New Baha® Abutment, With a Minimally Invasive Surgical Technique. An International Multicentre, Open, Randomised, Comparative, Parallel Group, Investigation. 1y Investigation, 2y Follow-up||Cochlear Bone Anchored Solutions|No|Active, not recruiting|February 2013|June 2017|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 16, 2013||No||No|November 18, 2015|https://clinicaltrials.gov/show/NCT01796236||70879|
NCT01794429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2012-005404-17|Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue|Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue|TAO|University of Copenhagen|Yes|Completed|February 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794429||71018|
NCT01796301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080289|An Open-label Study to Evaluate the Effect of Treatment With AMG 785 or Teriparatide in Postmenopausal Women (STRUCTURE)|An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With AMG 785 in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy|STRUCTURE|Amgen|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|436|||Female|55 Years|90 Years|No|||February 2016|February 5, 2016|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796301||70874|
NCT01796847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAVPTEN|Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients|Influence of PTEN on Glycemic Variability and Clinical Outcome in the Critically Ill Patient.|GLUPTEN|University of Roma La Sapienza|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Truma patients admitted to general ICU|December 2014|December 4, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01796847||70832|
NCT01797471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20100446|Phase 1 Study Evaluating Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer|A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|March 2013|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|N/A|No|||May 2014|July 25, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797471||70784|
NCT01796275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFK2|Happy Family Kitchen Project II|A "Happy Family Kitchen" Initiative for Promoting Family Health, Happiness, and Harmony in Tsuen Wan, Kwai Chung and Tsing Yi District||The University of Hong Kong|No|Completed|August 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|2000|||Both|6 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796275||70876|
NCT01796288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209114-5|The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment|The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment: a Randomized Controlled Phase II Clinical Trial|ROLE|Wu Jieping Medical Foundation|Yes|Recruiting|October 2012|October 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||October 2012|February 20, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796288||70875|
NCT01798004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12P1|Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma|Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma||Children's Oncology Group|Yes|Suspended|April 2013|October 2018|Anticipated|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|N/A|30 Years|No|||May 2015|May 1, 2015|January 6, 2013|No|Yes|CRM: 31684 - CTEP PIO requested|No||https://clinicaltrials.gov/show/NCT01798004||70743|
NCT01798290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV002 INAMEDI|Impact of Narrative Medicine (Workshop Reading Diaries)|Impact of an Educational Program 'Narrative Medicine (Workshop Reading Diaries) ' Dedicated to Medical Students. A Randomized Controlled Trial.|INAMEDI|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2012|||June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|April 17, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798290||70721|
NCT01797718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT:2012-002477-59|Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment|Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment|CDGP|Helsinki University Central Hospital|No|Recruiting|February 2013|December 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|14 Years|17 Years|No|||February 2016|February 17, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01797718||70765|
NCT01797991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.270|Comparison of Two Regimens of Dexamethasone in the Prevention of Hypersensitivity Reactions to Paclitaxel, a Pilot Study|Étude Pilote DEXEL-RH: Comparaison de Deux schémas Posologiques de DEXaméthasone en prévention Des Réactions d'Hypersensibilité au paclitaXEL|DEXEL-RH|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01797991||70744|
NCT01798277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NERG-02|Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia|Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed)|VeTAMed|Newmarket Electrophysiology Research Group Inc|No|Withdrawn|April 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||January 2015|January 26, 2015|February 20, 2013||No|Low Enrolment|No||https://clinicaltrials.gov/show/NCT01798277||70722|
NCT01799499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE-TURBT-DR-PRO|A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|NMIBC TURBT HG|UroGen Pharma Ltd.||Withdrawn|March 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|N/A|No|||August 2015|August 30, 2015|February 21, 2013||No|Change in the company clinical trials priority|No||https://clinicaltrials.gov/show/NCT01799499||70630|
NCT01799902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-11-VES-01|Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)|Belgian Observational Study to Evaluate Storage and Voiding Symptoms Improvement in Male Subjects With Lower Urinary Tract Predominant Storage Symptoms (Overactive Bladder Syndrome) Being Treated With Solifenacin in Monotherapy or Combination|VENICE|Astellas Pharma Inc|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Male|18 Years|N/A|No|Non-Probability Sample|Male patients in Belgium with lower urinary tract predominant storage symptoms (Overactive        Bladder Syndrome) being treated with solifenacin in monotherapy or combination.|December 2013|December 18, 2013|February 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01799902||70599|
NCT01798797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAGE-HF|Integrated Diagnostic for Heart Failure|Integrated Diagnostic for Heart Failure||Medtronic|No|Completed|August 2013|July 2015|Actual|July 2015|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with heart failure who have been implanted with an ICD or a CRT-D wirless device        for at least 3 months|September 2015|September 21, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01798797||70684|
NCT01798810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-1-0588|Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery|Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery (OXYGEN Study)|OXYGEN|Major Extremity Trauma Research Consortium|Yes|Recruiting|June 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01798810||70683|
NCT01793662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLAST2012|Norwegian Laparoscopic Aortic Surgery Trial|Norwegian Laparoscopic Aortic Surgery Trial|NLAST|Oslo University Hospital|No|Recruiting|February 2013|January 2023|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|N/A|N/A|No|||April 2015|April 20, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793662||71077|
NCT01794104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130080|Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas|A Phase I Trial of Weekly Indenoisoquinoline LMP400 in Adults With Relapsed Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|120 Years|No|||July 2015|October 3, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794104||71043|
NCT01794117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130071|Anakinra for Inflammatory Pustular Skin Diseases|A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|110 Years|No|||September 2015|March 10, 2016|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794117||71042|
NCT01794143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRADE|A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes|Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study|GRADE|GRADE Study Group|Yes|Recruiting|May 2013|||August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|5000|||Both|30 Years|N/A|No|||February 2016|February 9, 2016|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794143||71040|
NCT01795157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/859|Computer Based Assessment and Treatment|Computer Based Assessment and Treatment|COMBAT|Norwegian University of Science and Technology|No|Completed|September 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|255|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795157||70962|
NCT01796860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS AFO|Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis|The Impact of Ankle Foot Orthosis (AFO) on Gait Recovery in Select Individuals With Multiple Sclerosis (MS)||University of Texas Southwestern Medical Center|Yes|Terminated|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|60 Years|No|||August 2015|August 3, 2015|February 18, 2013||No|Modifications were made to protocol, new IRB pending|No|May 13, 2015|https://clinicaltrials.gov/show/NCT01796860||70831|
NCT01796873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0021-01|Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention|Clopidogrel Resistance and Platelet Reactivity in Hispanic Females Undergoing Percutaneous Coronary Intervention||University of Arizona|No|Recruiting|January 2012|October 2013|Anticipated|June 2013|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Female|45 Years|N/A|No|Non-Probability Sample|Females, age ≥ 45 years, with Acute Coronary Syndrome (ACS), undergone a percutaneous        coronary intervention and currently treated with clopidogrel will be enrolled. The        subjects' race and ethnicity will be self -reported and Hispanic ethnicity by self-report        of having both parents of Hispanic/Latino descent.|February 2013|February 21, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796873||70830|
NCT01797159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12127|Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer|"A Phase II Trial of Hippocampal-Sparing Cranial Irradiation (PCI) for Small-Cell Lung Cancer (SCLC)"||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|100 Years|No|||March 2016|March 8, 2016|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01797159||70808|
NCT01797484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHZ-KARD-01-2013|Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia|Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia|RIMINI-Pilot|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|July 2013|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797484||70783|
NCT01797120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0102|Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI|Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy|PrE0102|PrECOG, LLC.|Yes|Active, not recruiting|May 2013|February 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797120||70811|
NCT01797133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|647/2555(EC1)|A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization|A Comparative Study of ID Fellow-based Pre-authorization VS. Pharmacist-based Pre-authorization in Reducing Antibiotic Consumptions and Hospital Expenditures|DUE|Siriraj Hospital|Yes|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|984|||Both|15 Years|N/A|No|||February 2016|February 19, 2016|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01797133||70810|
NCT01798017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004|Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh|Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh||Gynuity Health Projects|Yes|Completed|November 2012|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1738|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|December 8, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798017||70742|
NCT01798576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28498|An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure|Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens||Hoffmann-La Roche||Active, not recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|282|||Both|18 Years|N/A|No|Probability Sample|Treatment-experienced patients with chronic hepatitis C receiving re-treatment with        Pegasys plus ribavirin or regimens containing direct-acting antivirals (DAAs)|March 2016|March 1, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798576||70699|
NCT01798901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11130|AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia|Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2013|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|3 Years|N/A|No|||August 2015|August 6, 2015|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798901||70676|
NCT01799161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110847|Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer|Phase 1 Study of the Combination of gp96-Ig Cell Based Lung Cancer Vaccine With Suppression of Adenosinergic Pathways With Theophylline and Oxygen for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients With Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Disease Who Have Failed Palliative Therapy.||University of Miami|Yes|Withdrawn|December 2014|||April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|February 22, 2013|No|Yes|Insufficient funding|No||https://clinicaltrials.gov/show/NCT01799161||70656|
NCT01799720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elena García-García|Oxidized Omega-3 Supplements With Different Oxidation|Effect of Omega-3 Dietary Supplements With Different Oxidation Levels in the Lipidic Profile of Women: a Randomized Controlled Trial|GPTPASPAD|Universidad Miguel Hernandez de Elche|Yes|Completed|October 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|71|||Female|25 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|February 19, 2013|No|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01799720||70613|
NCT01800201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817179|Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)|Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)|Heartstrong|University of Pennsylvania|Yes|Active, not recruiting|March 2013|July 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1500|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800201||70577|
NCT01799915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1408|Natural History Study of Synucleinopathies|Natural History Study of Synucleinopathies||New York University School of Medicine|Yes|Recruiting|June 2011|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|800|Samples With DNA|Blood Sample for DNA processing|Both|18 Years|N/A|No|Non-Probability Sample|Primary autonomic disorders are a group of diseases that usually begin in adulthood with        the inability to stand because of dizziness, lightheadedness and fainting. Symptoms are        the result of a dysfunction in the autonomic nerves that regulate blood pressure and heart        rate, and are either related to the accumulation of abnormal protein deposits and a        primary neurodegenerative process (like Parkinson's disease, pure autonomic failure,        dementia with Lewy bodies and multiple system atrophy), secondary to genetic abnormalities        (dopamine-beta-hydroxylase deficiency), an autoimmune process (autoimmune ganglionopathy),        or because of a direct injury to the nerves involved in buffering blood pressure        fluctuations (acquired baroreflex failure).|November 2015|November 11, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799915||70598|
NCT01793402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD_Preterm#1|Vitamin D Status and the Adequacy of Vitamin D Intake in Early Preterm Infants|Adequacy of Vitamin D Intake and Vitamin D Status in Early Preterm Infants||Children's Hospital Medical Center, Cincinnati|No|Completed|October 2010|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|N/A|1 Week|Accepts Healthy Volunteers|Probability Sample|All infants born at or less than 32 weeks postmenstrual age admitted to the Newborn        Intensive Care Unit at University of Cincinnati Medical Center were eligible. Intake of        vitamin D and serum 25-hydroxyvitamin-D concentrations were assessed during stay in the        Newborn Intensive Care Unit.|April 2013|April 17, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793402||71097|
NCT01794156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119587|Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder|Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder||Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine|No|Recruiting|September 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||February 2013|February 14, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01794156||71039|
NCT01800058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaPr-RTCTC-01/PI 197|Prognostic Value of the Levels of CTCs in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.|Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.||Hospital Universitario de la Princesa|No|Not yet recruiting|March 2013|April 2016|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|65|Samples Without DNA|Prospective analysis of biological material from samples of peripheral blood (PB) of      patients diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III,      treated with 3D-CRT, IMRT dose escalation (with androgen deprivation (DA))      The sampling of peripheral blood (PB) for detection of CTCs in three treatment periods:        -  Before starting any treatment-DA initially neoadjuvant        -  Prior to the start of RT (DA after neoadjuvant)        -  At the end of RT (1-3 months) The analysis-quantification of CTCs obtained in these           phases, will correlate with treatment outcomes in terms of biochemical failure (BF)           according to the criteria of Phoenix 2006 and overall survival and metastasis-free to           identify potential prognostic value. Likewise determinations are compared before and           after CTCs DA and RT to evaluate the effect of such treatments on modular quantifying           CTCs (predictive value).|Male|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III,        treated with 3D-CRT, IMRT dose escalation (with androgen deprivation (DA))|February 2013|February 25, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01800058||70588|
NCT01800071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/13/001|A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma|A Cancer Research UK (CR-UK) Phase Ib Trial to Determine the Safety, Tolerability and Immunogenicity of Extended Schedule Vaccination With MVA-EBNA1/LMP2 in Patients With Epstein Barr Virus Positive (EBV+) Nasopharyngeal Carcinoma (NPC).||Cancer Research UK|No|Active, not recruiting|March 2013|||March 2017|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800071||70587|
NCT01794676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIU03-07|Genetic Evaluation of Families With Endocrine Cancers|A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers|MEN1|Jersey Shore University Medical Center|Yes|Enrolling by invitation|March 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|25|Samples With DNA|Approximately 10 ml of blood will be drawn from each participant. Tumor samples will be      obtained from any prior surgeries, if available.|Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals belonging to families observed with MEN1 mutation related cancers.|July 2013|July 8, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794676||70999|
NCT01794923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491010|Topical Ibuprofen for Delayed Onset Mulscle Soreness|Placebo-controlled, Double-blind Evaluation of the Efficacy and Safety of Ibuprofen 5% Topical Gel for the Treatment of Delayed-onset Muscle Soreness of the Elbow Flexor Muscles||Pfizer|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|205|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794923||70980|
NCT01795170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03481|Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients|Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine|NOEL|University of British Columbia|No|Withdrawn|April 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|3 Months|3 Years|No|Non-Probability Sample|Infants with pyridoxine-dependent epilepsy resulting from ATQ deficiency.|September 2014|September 26, 2014|February 18, 2013||No|The study couldn't be initiated as we did not secure funding.|No||https://clinicaltrials.gov/show/NCT01795170||70961|
NCT01795183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMISUL06155|Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia|The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study|ESCAPE|Sanofi|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|316|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795183||70960|
NCT01796886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01426-37|Performance Evaluation of Pupillary Reactivity in Monitoring of Brain-damaged Patients in Intensive Care|Performance Evaluation of Pupillary Reactivity in Monitoring of Brain-damaged Patients in Intensive Care||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|February 2013|November 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01796886||70829|
NCT01797172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39783.015.12|Is Treatment of the Intervertebral Disc More Effective at Short-term Than the Nerve Root in Patients With a Neck Hernia?|Percutaneous Cervical Nucleoplasty vs. Pulsed Radio Frequency in Patients With Contained Cervical Disc Herniation; a Double-blind Randomized Clinical Trial||St. Anna Ziekenhuis, Geldrop, Netherlands|No|Recruiting|October 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01797172||70807|
NCT01797497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0578|Intervention to Increase Parent-provider Communication During Referrals|Parent-Provider Partnerships for Referral Communication|P3RC|University of Colorado, Denver|No|Active, not recruiting|March 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|97|||Both|N/A|17 Years|No|||February 2016|February 11, 2016|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797497||70782|
NCT01797510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008958|Feasibility Study for a Web Based Health Coaching Program|Mayo-Sessions Clinical Trial||Mayo Clinic|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797510||70781|
NCT01797731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10137|Conventional Alignment System Versus Surgical Navigation System in Total Knee Arthroplasty|Conventional Tibial Extramedullary Alignment System Versus a Hand-Held, Surgical Navigation System for Tibial Component Placement in Total Knee Arthroplasty: A Randomized, Controlled Trial||Hospital for Special Surgery, New York|Yes|Completed|November 2011|August 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|N/A|N/A|No|||August 2014|August 25, 2014|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797731||70764|
NCT01797744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/816|Vestibular Rehabilitation for Strokepatients With Dizziness|Vestibular Rehabilitation for Strokepatients With Dizziness - a Randomized Controlled Trial.||Lund University|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||March 2015|March 30, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797744||70763|
NCT01798316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0409|IV Acetaminophen for Postoperative Analgesia|IV Acetaminophen for Postoperative Analgesia After Laparoscopic Cholecystectomy||Northwell Health|No|Terminated|March 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|February 5, 2013|Yes|Yes|Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT01798316||70719|
NCT01798303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14792|A Study of LY2940094 in Participants With Alcohol Dependency|Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence||Eli Lilly and Company|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|21 Years|65 Years|No|||December 2014|December 9, 2014|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798303||70720|
NCT01798589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD 12 P1 401|Bioequivalence of Ethylenediamine Dihydrochloride Study|Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations||Allerderm|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798589||70698|
NCT01798914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-139|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder|Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder||Mannkind Corporation||No longer available|October 2008|May 2015|Actual|April 2015|Actual|Phase 3|Expanded Access|N/A|||||||Both|N/A|N/A|No|||January 2016|January 19, 2016|February 19, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01798914||70675|
NCT01799187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010YT|Research of Revascularization in Immature Teeth With Periapical Periodontitis|Randomized Controlled Research of Revascularization in Immature Permanent Teeth With Periapical Periodontitis||Sun Yat-sen University|Yes|Recruiting|July 2012|July 2021|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|190|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||July 2014|July 19, 2014|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01799187||70654|
NCT01796717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-WDH-201205001|Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia|Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|March 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||August 2012|February 14, 2016|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796717||70842|
NCT01796964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-006|Efficacy and Safety Study of ESBA1008 Versus EYLEA®|A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration||Alcon Research|No|Completed|March 2013|August 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|50 Years|N/A|No|||January 2016|January 11, 2016|February 20, 2013|Yes|Yes||No|January 11, 2016|https://clinicaltrials.gov/show/NCT01796964||70823|
NCT01796093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC&PJ-Dig-Iva-2009-2012|Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function|Comparison of Digoxin and Ivabradine in Heart Failure With Preserved Systolic Function.|DIGvsIVA|Cocco, Giuseppe, M.D.|Yes|Completed|April 2008|February 2012|Actual|February 2012|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|42|||Both|60 Years|78 Years|No|Probability Sample|Patients with ischemic heart disease and heart failure with preserved systolic function,        dyspnea grade III NYHA. Either in sinus rhythm (and possible paroxismal atrial        fibrillation) or with permanent atrial fibrillation.|February 2013|February 19, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01796093|4 Months|70890|
NCT01793415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL1201|Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)|Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)||PharmaLundensis AB|No|Recruiting|February 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|60 Years|No|||February 2013|February 14, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01793415||71096|
NCT01794455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR5642|Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression|Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression||Vanderbilt University|No|Terminated|May 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|1|||Both|60 Years|N/A|No|||June 2015|June 1, 2015|February 12, 2013|No|Yes|Enrollment difficulties|No||https://clinicaltrials.gov/show/NCT01794455||71016|
NCT01793909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0062|Type 2 Diabetes and Exercise Function in Single Leg Exercises|Role of Vascular Function: Oxygen Delivery vs Oxygen Utilization in the Exercise Impairment in Type 2 Diabetes||University of Colorado, Denver|Yes|Recruiting|June 2012|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01793909||71058|
NCT01794936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3321|Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate Surgery|VTI Doppler Probe For Robotic Surgery||Columbia University|Yes|Terminated|August 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|9|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|February 9, 2013||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01794936||70979|
NCT01789307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01647|Lactose, Sucrose & Corn Syrup Tolerance|Lactose: A Unique Carbohydrate Enabling Homeostatic Regulation of Blood Glucose & Insulin||University of British Columbia|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|16|||Male|19 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01789307||71411|
NCT01819181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN TAVI|Women's INternational Transcatheter Aortic Valve Implantation Registry|Women's INternational Transcatheter Aortic Valve Implantation Registry|WINTAVI|Society for Cardiovascular Angiography and Interventions|Yes|Recruiting|March 2013|March 2019|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|N/A|No|Non-Probability Sample|Consecutive female patients with severe symptomatic Aortic Stenosis who are deemed        eligible for TAVI by a multi-disciplinary team in participating sites according to local        policy.|December 2013|December 3, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819181|5 Years|69123|
NCT01789879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNG-NNRTI PK study|A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy|A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women||University of Nebraska|No|Active, not recruiting|June 2013|||April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789879||71367|
NCT01820013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGP-LC12|Single Centre Blinded Randomized Controlled Trial Evaluating the Effectiveness of Two Pelvic Support Garments|Management of Antenatal Pelvic Girdle Pain Study (MAPS): a Single Centre Blinded Randomized Trial Evaluating the Effectiveness of Two Pelvic Support Garments|MAPS|University of Plymouth|Yes|Completed|November 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01820013||69059|
NCT01787786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1207|Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels|Defining and Predicting the Ideal Infliximab Pharmacokinetic Profile Associated With Treatment Efficacy in Patients With Inflammatory Bowel Disease|OPTIMIZE|University of Western Ontario, Canada|No|Withdrawn||September 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Whole Blood|Both|18 Years|75 Years|No|Non-Probability Sample|50 patients with Crohn's Disease and 50 patients with Ulcerative Colitis from 10 centres        (Canada, United States, Netherlands and Spain).|December 2015|December 1, 2015|February 6, 2013||No|Unable to align the study questions with a complementary trial|No||https://clinicaltrials.gov/show/NCT01787786||71527|
NCT01787799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2072|EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)|EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)|EVOLVE II QCA|Boston Scientific Corporation|No|Completed|March 2013|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 16, 2013||No||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01787799||71526|
NCT01820351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics Committee 023/11|Assessment of Thigh Muscle After a Stretching Program|BICEPS FEMORIS AND VASTUS LATERALIS MUSCLE ARCHITECTURE AFTER A CHRONIC STRETCHING PROGRAM||Universidade Federal do Rio de Janeiro||Completed|February 2011|||November 2011|Actual|N/A|Interventional|Primary Purpose: Basic Science|||||||Male|17 Years|25 Years||||March 2013|March 25, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820351||69033|
NCT01820364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818X2102|LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma|Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma|LOGIC|Array BioPharma||Completed|November 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820364||69032|
NCT01820637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2049|Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project|Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent|MAJESTIC|Boston Scientific Corporation|No|Active, not recruiting|July 2013|March 2017|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01820637||69011|
NCT01820650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001|A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System|A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System||ConforMIS, Inc.|No|Recruiting|February 2013|March 2025|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with osteoarthritis of the knee|May 2015|May 29, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01820650||69010|
NCT01820936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101204|A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765|Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765||Janssen Research & Development, LLC|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|52|||Both|18 Years|55 Years|No|||July 2014|July 14, 2014|March 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01820936||68988|
NCT01788917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H39_09|Effects of Supplementation With Linseed Oil on Blood Lipids in Vegetarians|Effects of Supplementation With Linseed Oil on Blood Lipids and Fatty Acid Profile in Plasma and Erythrocyte Lipids in Vegetarians||University of Jena|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01788917||71441|
NCT01797289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52823P|Prevalence of Pulmonary Embolism in Patients With Syncope|The Prevalence of Pulmonarym Embolism in Patients With the First Episode of Syncope|PESY|University of Padova|Yes|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|600|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797289||70798|
NCT01797601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra-CT: 2006-002244-29|Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application|Insulinsensitivität Des Menschlichen Zentralnervensystems: Kernspintomographische Untersuchung Mit Intranasaler Gabe Von Insulin||University Hospital Tuebingen|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01797601||70774|
NCT01797913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-CJH|The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer|The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer||Fudan University||Completed|August 2008|||February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797913||70750|
NCT01798121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHP-Aplisol-02|Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)|A Randomized, Double-blind, Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard Tuberculin Purified Protein Derivative (PPD-S2) for Detection of Tuberculosis in Subjects With a Confirmed Diagnosis of Tuberculosis.|02|JHP Pharmaceuticals LLC|No|Not yet recruiting|February 2013|July 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798121||70734|
NCT01798134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TANDEM 2012-001 OUS|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma|MIRACLE I|CeloNova BioSciences, Inc.|Yes|Completed|December 2012|March 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01798134||70733|
NCT01798459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009-12-SHA|The Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.|A Double Blind Randomized Crossover Study of the Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.||Shalvata Mental Health Center|Yes|Recruiting|February 2013|May 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01798459||70708|
NCT01798472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1188-31/1|Hip Fractures Treated With Uncemented Arthroplasties|Cemented Versus Uncemented Arthroplasty in Elderly Patients With Displaced Femoral Neck Fractures: a Randomized Controlled Trial|HUA|Stockholm South General Hospital|No|Recruiting|November 2009|November 2018|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|140|||Both|65 Years|N/A|No|||January 2015|January 15, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798472||70707|
NCT01788618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG REDUC|Cancer and Disorders of Cognitive Functions and Quality of Life: "Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"|Cancer and Disorders of Cognitive Functions and Quality of Life: "Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"||Centre Francois Baclesse|No|Recruiting|July 2012|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|168|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788618||71464|
NCT01818609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|step-reduction|Study of Inactivity on Metabolism of Elderly Muscles|Influence of Reduce Daily Step Count on Muscle Protein Metabolism in Older Persons||McMaster University|Yes|Completed|September 2011|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01818609||69167|
NCT01818882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/XB-01|Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department|Evaluation of the Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department: a Randomized Study|VSCAN-DYSP|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|April 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01818882||69146|
NCT01819454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-EER Restech|The Diagnostics of Extraesophageal Reflux With the Restech System|The Diagnostics of Extraesophageal Reflux With the Restech System in Patients With Chronic Rhinosinusitis||University Hospital Ostrava|No|Recruiting|August 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|90|||Both|18 Years|60 Years|No|||January 2015|January 27, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819454||69102|
NCT01819467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301-1|A Trial to Reduce Adhesions Following a Primary Cesarean Section|A Randomized Controlled Trial to Reduce Adhesions Following a Primary Cesarean Section||South East Area Health Education Center, Wilmington, NC|No|Recruiting|June 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|750|||Female|12 Years|N/A|No|||February 2015|February 27, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819467||69101|
NCT01819480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16376|Efficacy and Safety of TORS for SCCA|A Single Arm Study of Efficacy and Functional Quality of Life in Patients Treated With Transoral Robotic Surgery for Oropharyngeal and Supraglottic Squamous Cell Carcinoma||University of Virginia|Yes|Recruiting|March 2013|||September 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819480||69100|
NCT01820338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204-2009|Extension Family Lifestyle Intervention Project (E-FLIP for Kids)|Extension Family Lifestyle Intervention Project (E-FLIP for Kids)|E-FLIP|University of Florida|Yes|Completed|July 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|314|||Both|8 Years|12 Years|No|||March 2015|March 19, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820338||69034|
NCT01787812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJRR-2013|California Joint Replacement Registry|California Joint Replacement Registry|CJRR|California Joint Replacement Registry|No|Recruiting|July 2011|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Californians, 18+ years of age, receiving hip or knee replacement surgery in California.|July 2013|July 2, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01787812|5 Years|71525|
NCT01787825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capso Vision SV-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||March 4, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787825||71524|
NCT01787838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clark_Merck_2.4.2013|Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting|A Quality Improvement Study to Improve Pneumococcal Vaccination Rates Through Targeted Health Education for Patients in an Ambulatory Pre-surgical Testing Setting||Carilion Clinic|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|2509|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 11, 2014|February 4, 2013||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01787838||71523|
NCT01788111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS-ID 294|Incidence, Diagnosis and Treatment of Neck and Back Pain in Helicopter Pilots.|Incidence, Diagnosis and Treatment of Neck and Back Pain in Helicopter Pilots.||Helse Stavanger HF|Yes|Active, not recruiting|January 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|325|||Both|20 Years|60 Years|No|||November 2014|November 18, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788111||71503|
NCT01788423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111007504|Evaluating Hearing Aid Service Delivery Models|Evaluating Hearing Aid Service Delivery Models||Indiana University|Yes|Recruiting|November 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|55 Years|79 Years|No|||February 2016|February 22, 2016|October 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788423||71479|
NCT01788696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036503|Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects|Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)||Duke University|No|Completed|June 2012|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|80 Years|No|||June 2015|June 11, 2015|February 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01788696||71458|
NCT01788904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARAMIS 2013|Plasma i-FABP as Predictor for Irreversible Bowel Ischemia|Plasma i-FABP as Predictor for Irreversible Bowel Ischemia After Interventional Re-vascularization in Patients With Acute Mesenteric Ischemia|FARAMIS|University Hospital Regensburg|No|Recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|Samples With DNA|Blood plasma, blood serum, EDTA blood|Both|18 Years|N/A|No|Non-Probability Sample|Tertiary care clinic|December 2013|December 11, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788904||71442|
NCT01797302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100034|Vitamin D and Vascular Health in Children|Vitamin D and Vascular Function in Obese Children||University of Pittsburgh|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|252|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797302||70797|
NCT01797614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108062RC|Intra-abdominal Pressures During the Spontaneous Breathing Trial|Measuring the Change of Intra-abdominal Pressures of the Intensive Care Unit Patients During the Spontaneous Breathing Trial|IAP_SBT|National Taiwan University Hospital|No|Recruiting|January 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Adult patients with endotracheal intubation and are preparing for weaning assessment|February 2013|February 20, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797614||70773|
NCT01797926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116799|Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions|An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in Healthy Adult Male and Female Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797926||70749|
NCT01798147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRT-TACE-CCC-Mainz-1|Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).|Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).||Johannes Gutenberg University Mainz|Yes|Recruiting|February 2011|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01798147||70732|
NCT01789632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00067750|Impact of Platelet Rich Plasma Over Alternative Therapies in Patients With Lateral Epicondylitis|Impact of Platelet Rich Plasma Over Alternative Therapies With LateralEpicondylitis (IMPROVE): A Multicenter, Randomized Trial Comparing Autologous Whole Blood vs. Dry Needle Tendon Fenestration of Pain and Quality of Life in Patients With Lateral Epicondylitis.|IMPROVE|University of Michigan|Yes|Recruiting|January 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|20|||Both|20 Years|N/A|No|||December 2015|December 14, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01789632||71386|
NCT01818375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-277-SDR|Goal Directed Fluid Therapy and Postoperative Ileus|Goal-directed Fluid Therapy and Postoperative Ileus After Elective Laparoscopic Colorectal Surgery Using an Enhanced Recovery Program: a Randomized Controlled Trial||McGill University Health Center|No|Completed|February 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|128|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818375||69185|
NCT01819194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5282|Contact Lens Comfort Relative to Meibomian Gland Status|||Johnson & Johnson Vision Care, Inc.|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|64|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|March 24, 2013|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01819194||69122|
NCT01819493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DK094108-01A1|Parents and Children Together Preventing Diabetes (PACT PD)|Parents and Children Together Preventing Diabetes|PACT PD|Wake Forest School of Medicine|No|Recruiting|March 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|72|||Both|8 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 28, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819493||69099|
NCT01818921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-211|An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome|Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension||Zafgen, Inc.|No|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|17|||Both|16 Years|65 Years|No|||December 2013|December 17, 2013|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818921||69143|
NCT01818934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2006.144|Ultrasound Screening for Developmental Dysplasia of the Hip in Newborns|Ultrasound Screening for Developmental Dysplasia of the Hip in the Neonate: The Effect on Treatment Rate and Prevalence of Late Cases||University of Bergen|Yes|Completed|January 1988|March 2009|Actual|June 1990|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|11925|||Both|N/A|20 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818934||69142|
NCT01819766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exact Sciences 2013-01|Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease|Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study|OCEANIA|Exact Sciences Corporation|No|Recruiting|March 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|440|Samples With DNA|Residual samples may be archived for further research. Clinical data and samples will be      kept in a manner that preserves anonymity of the subject. Specimens will be stored in a      commercial biorepository contracted by Exact Sciences or at Exact Sciences and may be used      for future research.|Both|18 Years|84 Years|No|Non-Probability Sample|Subjects who have diagnosed IBD and are undergoing a colorectal cancer surveillance        program. Also, have either a histopathological diagnosis of high grade dysplasia or        colorectal cancer resulting from colonoscopy preceding enrollment or for whom a        surveillance colonscopy is indicated.|December 2015|December 1, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01819766||69078|
NCT01819779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-LDV-102|Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)|Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects||Hanlim Pharm. Co., Ltd.|No|Recruiting|March 2013|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01819779||69077|
NCT01820026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infection and Cirrhosis|Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis|Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria||University of Roma La Sapienza|Yes|Recruiting|December 2012|June 2015|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01820026||69058|
NCT01820039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FertiScreen|FertiScreen: an Online Application to Improve the Quality of Fertility Care|FertiScreen: an Online Application to Improve the Quality of Fertility Care||Radboud University|No|Recruiting|June 2013|||May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|152|||Both|18 Years|37 Years|No|||March 2013|December 13, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01820039||69057|
NCT01820052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-DM-67|A Randomized Trial of Oral Iron Therapy in Fibromyalgia|A Double-blind , Randomized, Placebo-controlled Trial of Oral Iron Therapy in Fibromyalgia||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Active, not recruiting|April 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820052||69056|
NCT01820325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120D2204|Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer|A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology|BASALT-2|Novartis|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820325||69035|
NCT01819792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2011-843-0005|Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia|Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy|LAMVIRE|Centre Hospitalier Universitaire, Amiens|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|115|||Both|18 Years|85 Years|No|||July 2015|July 28, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819792||69076|
NCT01788462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00074675|Egrifta Replacement and Sleep Disordered Breathing|Egrifta Replacement and Sleep Disordered Breathing||Johns Hopkins University|No|Suspended|May 2012|||January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood|Both|18 Years|75 Years|No|Non-Probability Sample|Men and women with HIV infection and central lipohypertrophy about to start tesamorelin        therapy will be recruited from the Endocrinology Clinic at the Johns Hopkins Outpatient        Center. Physicians and members of the clinical staff will identify eligible men and        briefly introduce the study to them. Patients will be offered a phone number for the Johns        Hopkins Sleep Disorders Center to call if they are interested in learning more about the        research study.|August 2015|August 31, 2015|February 1, 2013||No|Lack of funding.|No||https://clinicaltrials.gov/show/NCT01788462||71476|
NCT01788124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|macomb0001|A Prospective Trial Comparing Metal to Plastic Speculums for Patient Comfort|A Randomized Prospective Trial Comparing Metal to Plastic Speculums for Patient Comfort|GYN|St. John Health System, Michigan|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|160|||Female|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women greater than 18 years of age presenting for routine speculum exam|February 2013|February 7, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01788124||71502|
NCT01788436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100911|A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers|An Exploratory Study to Measure and Contrast Implicit and Explicit Learning Performance in Patients With Stable Schizophrenia and Young and Elderly Healthy Subjects||Janssen Research & Development, LLC|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|51|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|November 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01788436||71478|
NCT01788709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.32|PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation|PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study||American University of Beirut Medical Center|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|200|||Both|18 Years|80 Years|No|||January 2013|June 23, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788709||71457|
NCT01788722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16625|Regulatory Post Marketing Surveillance Study in Korea|Visanne® (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea||Bayer|No|Recruiting|July 2013|June 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3750|||Female|N/A|N/A|No|Non-Probability Sample|Women desiring treatment for endometriosis using Visanne (dienogest 2mg)|March 2016|March 18, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788722||71456|
NCT01789164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G189AP-S2|Measure of Cerebrovascular Dysfunction After TBI With fNIRS|Measure of Cerebrovascular Dysfunction After Truamatic Brain Injury With Functional Near Infrared Spectroscopy||Uniformed Services University of the Health Sciences|No|Recruiting|January 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Males and females (military health care beneficiaries and non military health care        beneficiaries) between 18 and 60 years who have a diagnosis of TBI and are symptomatic        with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched        non-TBI volunteers.|December 2015|December 30, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789164||71422|
NCT01789762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P001|Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process|Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process|EFFIPAP|Etablissement Français du Sang|Yes|Recruiting|May 2013|May 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|840|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789762||71376|
NCT01788631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005|A Phase II Trial of Regadenoson in Sickle Cell Anemia|A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia||Dana-Farber Cancer Institute|Yes|Recruiting|May 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|70 Years|No|||March 2016|March 24, 2016|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788631||71463|
NCT01788345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|445-12|Prospective Trial of the Bilevel Positive Airway Pressure (by Boussignac) in Emergency Department of Non-invasive Patients Presenting With Acute Hypercapnic Respiratory Failure|Prospective Trial of the Bilevel Positive Airway Pressure (by Boussignac) in Emergency Department of Non-invasive Patients Presenting With Acute Hypercapnic Respiratory Failure|Boussignac|Vygon GmbH & Co. KG|No|Active, not recruiting|February 2013|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Anticipated|44|||Both|18 Years|90 Years|No|||February 2013|February 7, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788345||71485|
NCT01788852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 139|HPV in Adolescents|Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|27|Samples With DNA|Cervical and anal pap smears specimens will be used for HPV typing. Blood will be collected      for STI and immune response to HPV/HIV testing|Both|12 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 60 sexually active adolescents (perinatally and behaviorally HIV-infected        adolescents, HIV negative adolescents) aged 12-24 will be recruited from the HIV-NAT and        TRC Anonymous Clinic|March 2015|March 30, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788852||71446|
NCT01789086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-3967|A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years|A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years||Novo Nordisk A/S|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|12 Years|17 Years|No|||May 2014|May 28, 2014|February 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789086||71428|
NCT01789099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001852-20|A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.|A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.|UV1-hTERT2012L|Ultimovacs AS|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789099||71427|
NCT01789320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS1001-101|Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis|Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis||Clearside Biomedical, Inc.|No|Completed|February 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789320||71410|
NCT01789333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4157|Higher Irradiance in Keratoconus Ectasia|Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross- Linking at Higher Irradiances in Patients With Keratoconus or Ectasia||Columbia University|No|Recruiting|August 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789333||71409|
NCT01789346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-EV3|Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars|||Cutera Inc.|No|Completed|February 2013|||July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789346||71408|
NCT01789359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBAnthoUrine|Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding|Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding||Atlantic Food and Horticulture Research Center|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2012|February 8, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789359||71407|
NCT01819207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1492MF|Evaluation of the Coagulation Profile by Thromboelastography in Bariatric Patients|||Western Galilee Hospital-Nahariya|Yes|Not yet recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819207||69121|
NCT01819220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0077|Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome|||Yonsei University|No|Completed|April 2009|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01819220||69120|
NCT01818960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-103|Revascularization Strategies for ST Elevation Myocardial Infarction Trial: The ASSIST-MI Trial|Revascularization Strategies for ST Elevation Myocardial Infarction Trial||St. Michael's Hospital, Toronto|Yes|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01818960||69140|
NCT01819233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12G.616|Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy|A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients|CAREFOR|Thomas Jefferson University|No|Recruiting|March 2013|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819233||69119|
NCT01819506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0799-R|Patient Targeted Upper Extremity Rehabilitation After Stroke|Patient-Targeted Upper Extremity Rehabilitation After Stroke|TARG|VA Office of Research and Development|No|Recruiting|March 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|89 Years|No|||October 2015|October 28, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01819506||69098|
NCT01787487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0737|Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm|Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm||M.D. Anderson Cancer Center|No|Recruiting|March 2013|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|105|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787487||71549|
NCT01787500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0748|Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers|A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies||M.D. Anderson Cancer Center|No|Recruiting|February 2013|||February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|77|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787500||71548|
NCT01788475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-031|Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery|A Randomized, Pilot Study of the Efficacy and Safety of Ozurdex Steroid Implants in Post-Vitrectomized Eyes in Patients With Diabetic Macular Edema||Lahey Clinic|No|Withdrawn|December 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|February 7, 2013|Yes|Yes|Unable to recruit study participants, study withdrawn by Investigator|No||https://clinicaltrials.gov/show/NCT01788475||71475|
NCT01788735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF|Unexplained Infertility Among Asthmatic and Atopic Patients|Unexplained Infertility Among Asthmatic and Atopic Patients||Bispebjerg Hospital|Yes|Recruiting|December 2011|October 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|396|Samples Without DNA|whole blod, serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|young healthy wemon that are unexplained infetile and have asthma, atopic ezcema or        allergy|February 2013|February 8, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788735||71455|
NCT01788930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1227|Aspirin Resistance and Sleep Apnea|Obstructive Sleep Apnea and Aspirin Resistance in Type-2 Diabetic Patients|AREAS|University Hospital, Grenoble|No|Recruiting|February 2013|||February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|286|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788930||71440|
NCT01789463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/03|Physiotherapy and Capsulitis|Physiotherapy Versus Self Rehabilitation After Shoulder Dilatation for Primary Idiopathic Capsulitis||Hopital Foch|No|Active, not recruiting|April 2010|June 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||January 2013|February 11, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01789463||71399|
NCT01789749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/12/WMEAD/139|Soft Coagulation for the Prevention of Adenoma Recurrence|Soft Coagulation for the Prevention of Adenoma Recurrence After Endoscopic Mucosal Resection (EMR) of Large Sessile Colonic Polyps: A Multicentre, Randomized Trial.|SCAR|Western Sydney Local Health District|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|398|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01789749||71377|
NCT01790022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METALL 2012|Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)|Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study|METALL|Saratov State Medical University||Active, not recruiting|July 2012|||March 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2013|February 9, 2013|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01790022||71356|
NCT01790035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404101|Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer|A Phase I and Randomized Controlled Phase II Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer|LGG|Washington University School of Medicine|No|Recruiting|August 2014|October 2021|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790035||71355|
NCT01790594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-15|Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation|Optimization of NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|February 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|55 Years|No|||September 2015|September 15, 2015|February 11, 2013|Yes|Yes|Slow accrual within enrollment time period: projected accrual goal not achieved.|No||https://clinicaltrials.gov/show/NCT01790594||71312|
NCT01788358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14801|Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension|Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension||Bayer|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|508|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|February 7, 2013|Yes|Yes||No|July 21, 2015|https://clinicaltrials.gov/show/NCT01788358||71484|
NCT01788878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDEL-1211|Cancer of the Upper Aero-digestive Tract and Future Socioprofessional|Cancer of the Upper Aero-digestive Tract and Future Socioprofessional|CARDEL|Centre Oscar Lambret|No|Recruiting|February 2014|August 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|55 Years|No|||January 2013|March 6, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01788878||71444|
NCT01788644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036242|Early Child Care and Risk of Obesity|Nurture: Early Child Care and Risk of Obesity|Nurture|Duke University|No|Active, not recruiting|February 2013|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|saliva, fecal|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Mothers/infant dyads in the Durham, NC area|February 2016|February 2, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788644||71462|
NCT01788865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URT-001|Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction|Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA™) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study|UVENTA|Samsung Medical Center|Yes|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|20 Years|80 Years|No|||February 2013|February 7, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788865||71445|
NCT01789112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-032|Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizer III System in Patients With Heart Failure|Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizer III System in Patients With Heart Failure||RWTH Aachen University||Recruiting|May 2012|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|90 Years|No|||September 2015|September 22, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789112||71426|
NCT01789658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU-OM-01|Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation|A Randomized Controlled Trial of Cryotherapy for Prevention and Reduction of Severity of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.||Uppsala University|No|Recruiting|October 2012|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|4 Years|18 Years|No|||December 2015|December 3, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01789658||71384|
NCT01789944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK095676-01|Parent Partnership Project|Peer Counseling in Family-Based Pediatric Overweight Treatment||Seattle Children's Hospital|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|7 Years|11 Years|No|||May 2015|May 19, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789944||71362|
NCT01818427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11152002 IND 15117|PreHospital Air Medical Plasma Trial|Prehospital Air Medical Plasma (PAMPer) Phase III Multicenter, Prospective, Randomized, Open-label, Interventional Trial A Four Year Multicenter Open Label Randomized Trial|PAMPer|University of Pittsburgh|Yes|Recruiting|May 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|90 Years|No|||September 2015|September 30, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818427||69181|
NCT01818622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911678|Virtual Darkness as Additive Treatment in Mania|Virtual Darkness as Additive Treatment in Mania- a Randomized Controlled Trial|VATMAN|Helse Fonna|Yes|Completed|February 2012|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01818622||69166|
NCT01818635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-0663|To Investigate the Effect of Montelukast on Behavior Problems in Children With Asthma|Phase 4 Study of to Investigation the Effect of Montelukast on Behavior Problems in Children With Asthma||Fatih University|Yes|Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Months|60 Months|Accepts Healthy Volunteers|Probability Sample|We planned to include who who treated for asthmatic children and healthy controls in the        study.|August 2015|August 12, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01818635|3 Months|69165|
NCT01818648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008505|Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome|Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition||Mayo Clinic|No|Withdrawn|March 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||January 2014|January 10, 2014|February 28, 2013|Yes|Yes|Study was withdrawn by PI due to decision to study a different medication.|No||https://clinicaltrials.gov/show/NCT01818648||69164|
NCT01791036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5231-B|Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair|Postoperative Analgesia Produced by Adductor Canal (Distal Femoral Artery Compartment) Block Is Not Inferior to Femoral Nerve Block In Outpatient Arthroscopic Anterior Cruciate Ligament Repair||University Health Network, Toronto|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|50 Years|No|||March 2015|March 2, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791036||71278|
NCT01787175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18HS017186-03|VA Integrated Medication Manager|Veterans Affairs Integrated Medication Manager|IMM|University of Utah|No|Completed|October 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|N/A||1|Actual|166|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Aim 1: VA providers Aim 2: VA or non-VA physicians, nurse practitioners and physician        assistants|February 2013|February 5, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01787175||71573|
NCT01819246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011798|High Yield Intraoperative, Autologous Platelet Apheresis|High Yield Intraoperative, Autologous Platelet Apheresis-Optomizing Transfusion Practice In Cardiac Surgery||Duke University|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01819246||69118|
NCT01791348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|d2test_1234|The Test-retest Effect of the "d2 Test of Attention".|The Test-retest Effect of the "d2 Test of Attention" - a Test for Concentration and Performance.||Herlev Hospital|Yes|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|22 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01791348||71254|
NCT01787149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHEN1201|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis||TSH Biopharm Corporation Limited|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|20 Years|N/A|No|||October 2013|June 10, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787149||71575|
NCT01787513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/237|Cognitive Bias Modification (CBM) Via Imagery and Internet Cognitive Behavioural Therapy (iCBT) for Depression|A Randomised Controlled Trial Comparing Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder Plus a Cognitive Bias Modification Intervention (OxIGen)on Symptoms of Depression and Negative Interpretation Bias.||St Vincent's Hospital, Sydney|Yes|Completed|February 2013|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|65 Years|No|||August 2014|August 10, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787513||71547|
NCT01789476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845 CLIN2003|A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery|A Single-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of CR845 Dosed in Patients With Pain Following Bunionectomy Surgery||Cara Therapeutics, Inc.|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|February 8, 2013|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01789476||71398|
NCT01789489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/12|3D Ultrasound - Based Hysteroscopy Versus Virtual Hysteroscopy|Contribution of 3D Sonohysterography and Virtual Hysteroscopy in Exploration of the Uterine Cavity in Comparison to the Diagnostic Hysteroscopy.||Hopital Foch|No|Recruiting|July 2010|April 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|69|||Female|18 Years|45 Years|No|||February 2013|February 8, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01789489||71397|
NCT01788748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRB-E2VER02|Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae|Evaluation of Fractional Bipolar Radiofrequency, and Bipolar Radiofrequency Potentiated by Infrared, in Monotherapy or Combined, for the Treatment of Striae||Candela France|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 30, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788748||71454|
NCT01788943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nAChR-PET-quit|Nicotine Receptor Levels and Smoking Cessation|||University of Pennsylvania|Yes|Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788943||71439|
NCT01789177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0055|Use of Disposable Spirometer for Recovery of Pulmonary Function|Use of Disposable Spirometer for Recovery of Pulmonary Function by Peak Expiratory Flow Measurement Following Exploratory Laparotomy||University of North Carolina, Chapel Hill|No|Completed|January 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789177||71421|
NCT01790321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSF_Zn_school|Water-based Zinc Efficacy Trial in Beninese Shool Children|Efficacy Study of Water as Fortification Vehicle for Zinc for Improving Zinc Status in Primary Schools Children in the Municipality of Natitingou, North of Benin.||Swiss Federal Institute of Technology|Yes|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|278|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790321||71333|
NCT01797341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0330-B|Prograf-Advagraf Cross Over Conversion Study|Prograf/Advagraf Conversion Study in Kidney Pancreas Transplant Recipients||University Health Network, Toronto|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||July 2014|September 17, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797341||70794|
NCT01788059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900939|The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital|The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital||Emdadi Kamyab Hospital|Yes|Completed|January 2013|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 26, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01788059||71507|
NCT01788670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hidroxitirosol/FIS/1|Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol|Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 1. Evaluating the Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol (DOPET).||Parc de Salut Mar|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788670||71460|
NCT01788683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSI2012-RCT01|Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Non-retracted Supraspinatus Tendon Tears||Regenerative Sciences, LLC|No|Recruiting|February 2013|March 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01788683||71459|
NCT01789125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA03131301A1|Smoking Termination / Anxiety Reduction Treatment (ST/ART)|Augmenting Smoking Cessation With Transdiagnostic CBT for Smokers With Anxiety|START|University of Houston|Yes|Recruiting|March 2012|May 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789125||71425|
NCT01789372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOGAFF-001|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation||Danderyd Hospital|Yes|Completed|December 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|||Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic. All participants should have been on usual treatment (medication,        cardio version or ablation) for at least three months.|February 2013|February 11, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01789372||71406|
NCT01789385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DİLEKPARKİNSON|Anesthesia for Deep Brain Stimulation|Anesthesia for Deep Brain Stimulation for the Treatment of Parkinsons Disease||Diskapi Teaching and Research Hospital|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|19 Years|85 Years|No|||February 2013|May 19, 2014|February 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01789385||71405|
NCT01789671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SafewayFoundationSaelens-01|Peer Counseling in Family-Based Treatment for Childhood Obesity|Peer Counseling in Family-Based Treatment for Childhood Obesity|EPICH|Seattle Children's Hospital|Yes|Completed|September 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|7 Years|11 Years|No|||May 2015|May 19, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01789671||71383|
NCT01789957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-112E|Extension Study for 2993-112|An Open-Label Extension Study of Protocol 2993-112 to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated With Metformin Alone||AstraZeneca|No|Completed|September 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|225|||Both|16 Years|75 Years|No|||January 2015|February 23, 2015|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789957||71361|
NCT01790516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-439|Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer|A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer||Georgetown University|Yes|Terminated|May 2012|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2013|September 26, 2014|June 21, 2012|No|Yes|low accruals--2 patients were enrolled in over a year|No|June 3, 2014|https://clinicaltrials.gov/show/NCT01790516||71318|
NCT01818661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008988|Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech|Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech||Mayo Clinic|Yes|Recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818661||69163|
NCT01818947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OGB-IRE-2012/1|Gefitinib Usage and Outcomes in Routine Treatment|A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment||AstraZeneca|No|Completed|June 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|157|||Both|18 Years|N/A|No|Non-Probability Sample|hospital clinic|January 2014|January 22, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01818947||69141|
NCT01787188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL3-12-02|Study of Meloxicam Capsules to Treat Osteoarthritis Pain|A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix™ Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip||Iroko Pharmaceuticals, LLC|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|403|||Both|40 Years|N/A|No|||March 2015|March 9, 2015|February 6, 2013|Yes|Yes||No|February 6, 2015|https://clinicaltrials.gov/show/NCT01787188||71572|
NCT01791361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101120|Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe|Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe||Amgen|No|Completed|September 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|439|||Both|18 Years|N/A|No|Probability Sample|Oncologists satisfying all of the physician eligibility criteria will be eligible to        participate in the medical records review study. From each eligible oncologist, medical        records from 3 or more patients who satisfy all the patient inclusion criteria will be        obtained.|October 2015|October 23, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01791361||71253|
NCT01787162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-393 ex 11/12|Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases|Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases||Medical University of Graz|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples With DNA|Samples with DNA will be retained for later examinations at the Biobank, in case that the      patient agrees (extra patient information).      The blood samples are taken only during routine tests.|Both|18 Years|95 Years|No|Probability Sample|patients with myeloproliferative disorders|September 2015|September 7, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01787162||71574|
NCT01788150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-12-002|Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System|Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)|DIRECT II|Svelte Medical Systems, Inc.|Yes|Active, not recruiting|January 2013|May 2019|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788150||71500|
NCT01788449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101852|Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance|Association of Antibiotic Measures and Control of Bacterial Resistance||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2005|February 2007|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|335|||Both|N/A|N/A|No|Non-Probability Sample|Intensive Care Unit (ICU)|February 2013|February 12, 2013|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01788449||71477|
NCT01789788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28436|A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.||Hoffmann-La Roche||Completed|March 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789788||71374|
NCT01789775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40174|Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea|||Galderma R&D||Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|February 8, 2013||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01789775||71375|
NCT01790048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211066|Whey Permeate Study|Comparison of a Novel Ready-to-use Supplementary Food (RUSF) With Whey Permeate to Standard Peanut/Soy RUSF for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomised, Double-blinded, Clinical Effectiveness Trial||Washington University School of Medicine|Yes|Recruiting|February 2013|February 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1800|||Both|6 Months|59 Months|No|||February 2013|February 8, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790048||71354|
NCT01790607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2745IVU007|An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment|An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|February 2013|||November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790607||71311|
NCT01788072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOXT-10-2013|INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders|INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders (ASD)|INOXT|Anagnostou, Evdokia, M.D.|Yes|Recruiting|June 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|45 Years|No|||February 2016|February 9, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788072||71506|
NCT01798537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401-12-RMB CTIL|Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections|Simplified Selective Digestive Tract Decontamination for the Prevention of ICU Infections in the Setting of High-level Antibiotic Resistance|SDDICU|Rambam Health Care Campus|Yes|Not yet recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2400|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01798537||70702|
NCT01798849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8892-001|A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)|A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892||Merck Sharp & Dohme Corp.|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798849||70680|
NCT01788891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 149|Second-line Therapy|TASER-Pediatrics: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children|TASER-P|The HIV Netherlands Australia Thailand Research Collaboration|No|Active, not recruiting|January 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood and hair will be used for therapeutic drug monitoring (TDM). Blood drawn at every      visit will be used to assess CD4 count, viral load, and other basic chemistry test panel. If      necessary, drug resistant tests will also be carried out on the blood samples.|Both|N/A|18 Years|No|Non-Probability Sample|HIV-positive children <18 years old who are have switched to or treated with second-line        ART at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD)        sites.|March 2015|March 27, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788891||71443|
NCT01789138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARTH12115T|Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia|Randomized Controlled Trial of Situated Optimal Adherence Intervention Estonia (sOAI Estonia) Among Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia||University of Tartu|No|Completed|January 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|519|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 8, 2013||No||No|December 31, 2015|https://clinicaltrials.gov/show/NCT01789138||71424|
NCT01789398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-01 / BF2.649|Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)|Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks|HARMONY IV|Bioprojet|No|Completed|September 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789398||71404|
NCT01789411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC MEC 2008-210|The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study|The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study|AtheroRemoIVUS|Erasmus Medical Center|No|Active, not recruiting|November 2008|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Arterial blood samples|Both|21 Years|N/A|No|Probability Sample|Patients with acute coronary syndrome or stable angina pectoris, referred for percutaneous        coronary intervention or coronary angiography|February 2013|February 11, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789411||71403|
NCT01799837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057641|Norepinephrine Transporter Availability in PTSD|Kinetic Modeling of Norepinephrine Transporter Availability in PTSD||Emory University||Completed|June 2012|July 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|9|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799837||70604|
NCT01800110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-13|Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk|Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 25, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01800110||70584|
NCT01791049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0098|TD-1607 SAD Study in Healthy Subjects|A Randomized, Double−Blind, Placebo−Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide−Cephalosporin Heterodimer Gram−Positive Antibiotic, in Healthy Subjects||Theravance Biopharma Antibiotics, Inc.|No|Completed|April 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791049||71277|
NCT01791062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAREKT-DE-2011-12|Safety and Efficacy Study of HYTOP® in the Treatment of Focal Chondral Defects.|Safety and Efficacy of a Novel, Cell-free Cartilage Repair Construct in the Treatment of Focal Chondral Defects Involving the Femoro-tibial Compartment of the Knee Joint.||TRB Chemedica AG|No|Recruiting|February 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|50 Years|No|||November 2015|November 6, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791062||71276|
NCT01790802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERA201201|Laser Intervention in Early Age-Related Macular Degeneration Study|A Multi-centre, Randomized Trial Into the Safety and Efficacy of Nanosecond Microsurgical Laser Intervention in Early Age-related Macular Degeneration|LEAD|Center for Eye Research Australia|Yes|Active, not recruiting|November 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|292|||Both|50 Years|95 Years|No|||February 2016|February 17, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01790802||71296|
NCT01791387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258AAU02T|1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC|Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study|DILIGENCE-1|Auckland District Health Board|Yes|Active, not recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 1, 2015|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791387||71251|
NCT01791400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-70|Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache|Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache||Isfahan University of Medical Sciences|Yes|Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01791400||71250|
NCT01787526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|Intravenous High Dose Iron in Blood Donors|High Dose Intravenous Iron in Blood Donors With Iron Deficiency: a Randomized, Controlled Trial|IronWoMan|Medical University of Graz|No|Recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787526||71546|
NCT01787851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 65827-1|Study of the Acute Effects of Triheptanoin in Heart Failure|Assessment of the Clinical Effects of Triheptanoin Oil to Target Cardiac Anaplerosis in Congestive Heart Failure- Acute Study|ACETO-TCA|University of Texas Southwestern Medical Center|No|Recruiting|February 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787851||71522|
NCT01788137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWOG0002|A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients|A Prospective , Multicenter, RandomizedPhase III Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients||Sun Yat-sen University|Yes|Recruiting|January 2008|December 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT01788137||71501|
NCT01788163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00074|Asia Pacific and Russia Diagnostic Study for EGFR Testing|A Diagnostic Study to Determine the Prevalence of EGFR Mutations in Asian and Russian Patients With Advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma Histologies|IGNITE|AstraZeneca|No|Active, not recruiting|February 2013|July 2017|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3500|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 7, 2013|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01788163||71499|
NCT01790061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT-CN-121123|Standardized Fecal Microbiota Transplantation for Ulcerative Colitis|Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation in Patients With Moderate to Severe Ulcerative Colitis||The Second Hospital of Nanjing Medical University|Yes|Recruiting|November 2012|June 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|70 Years|No|||November 2014|November 21, 2014|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01790061||71353|
NCT01789528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00023|A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers|A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers.||AstraZeneca||Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|April 2, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01789528||71394|
NCT01790334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32488|Effects of Different Modes of Ventilation and Head Position on Size of Vena Jugular Interna|Comparing the Size of the Vena Jugular Interna Under Spontaneous Ventilation and Different Mechanical Ventilation Modes When Head is in Neutral and 30 Degree Lateral Position:Clinical Trial|USG-IJV|Istanbul University|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|80 Years|No|Probability Sample|30 ASA status I-II patients between 18-80 years old undergoing elective abdominal surgery        under endotracheal intubation will be included in this random, prospective, clinical        study.|February 2013|August 28, 2013|February 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01790334|1 Day|71332|
NCT01790347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gestational weight gain|Physical Exercise Controls Gestational Weight Gain|The Role of a Supervised Physical Exercise Program as a Alternative on the Control of Maternal Gestational Weight Gain||Technical University of Madrid|Yes|Completed|September 2007|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2350|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|March 13, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01790347||71331|
NCT01790360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1585|STAR - Seek, Test, and Retain. Linkages for Black HIV+, Substance-Using MSM|Seek, Test, and Retain. Linkages for Black HIV+, Substance-Using Men Who Have Sex With Men.|STAR|Columbia University|No|Recruiting|July 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790360||71330|
NCT01788657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 63:2012|iCBT for Depression - Standard Versus Condensed Treatment Material|Internet-based Cognitive Behavior Therapy for Depression With Standard Treatment Material Compared to a Condensed Version|KONRAD|Örebro County Council|No|Not yet recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01788657||71461|
NCT01798862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121212|Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles|The Effect of Endometrial Injury on IVF Outcome Parameters in Patients With Failed IVF Cycles||National and Kapodistrian University of Athens|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|25 Years|42 Years|No|||September 2015|September 8, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798862||70679|
NCT01798836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030675|Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF|Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF||National and Kapodistrian University of Athens|No|Terminated|February 2013|February 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|25 Years|44 Years|No|||August 2015|August 4, 2015|February 20, 2013||No|Obtained results were not good. Protocol was proved ineffective.|No||https://clinicaltrials.gov/show/NCT01798836||70681|
NCT01799122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:047|Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Stress Urinary Incontinence|Randomized Clinical Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence||University of Manitoba||Not yet recruiting||||February 2017|Anticipated|Phase 3|Interventional|Primary Purpose: Treatment|1||||||Female|25 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|February 22, 2013||||No||https://clinicaltrials.gov/show/NCT01799122||70659|
NCT01799382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13001-Trisolini|Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens|Mutational Analysis of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Specimens in Patients With Advanced Non-small Cell Lung Cancer: a Randomized Trial of Rapid On-site Evaluation||Maggiore Bellaria Hospital, Bologna|No|Completed|February 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|126|||Both|18 Years|85 Years|No|||October 2014|October 5, 2014|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01799382||70639|
NCT01799395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13002-Trisolini|Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer|Prevalence, Incidence and Predictors of Central Airway Obstruction in Patients With Advanced Lung Cancer||Maggiore Bellaria Hospital, Bologna|No|Terminated|February 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|85 Years|No|Probability Sample|Patients with advanced lung cancer undergoing treatment and follow-up at the Oncology        Units of the Azienda USL di Bologna (government structure that manages several public        hospitals that "cover" a 800.000 inhabitants area)|September 2014|September 26, 2014|February 23, 2013||No|Staff constraints made it impossibile to enroll consecutive patients, making the sample not    representative of the true cancer population|No||https://clinicaltrials.gov/show/NCT01799395||70638|
NCT01799616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0148|Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease|||University Hospital, Clermont-Ferrand||Recruiting|January 2013|March 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|60 Years|No|||February 2013|February 25, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799616||70621|
NCT01800123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14|EtCO2 Monitoring in Acute Self-poisoning|Continuous EtCO2 Monitoring in Acute Self Poisoned Patients Admitted in an Emergency Department|CAPNOTOX|University Hospital, Grenoble|No|Recruiting|March 2012|||November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over 18y/o admitted in the ED for acute self poisoning.|February 2013|February 25, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800123||70583|
NCT01790828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831078|Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A|Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha 'Registered' In Subjects With Hemophilia A||Pfizer|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|42|||Both|N/A|N/A|No|Non-Probability Sample|Hemophilia A|July 2015|July 21, 2015|February 11, 2013|No|Yes||No|July 21, 2015|https://clinicaltrials.gov/show/NCT01790828||71294|
NCT01790841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54|DF4 Master Study (Safety and Efficacy Study)|Master Study of the BIOTRONIK DF4 System||Biotronik SE & Co. KG|No|Active, not recruiting|February 2013|May 2016|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|237|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard ICD/CRT-D indication who are referred to the hospital.|June 2015|June 22, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01790841||71293|
NCT01791374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110251|Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ|A Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab in Japanese Subjects||Amgen|No|Completed|November 2012|March 2015|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|20 Years|100 Years|No|||February 2016|February 26, 2016|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01791374||71252|
NCT01787877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0064-12-ZIV|Inflammatory Biomarkers as Tool in Diagnosis and Management of Patients With Ischemic Stroke|Inflammatory Biomarkers as Additional Tool to Neuroimaging in the Diagnosis and Management of Patients With Ischemic Stroke||Ziv Hospital|No|Not yet recruiting|February 2013|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|85 Years|No|Probability Sample|Patients with CVA reporting to the Hospital Emergency Room|February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787877||71520|
NCT01788176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HBR10T|The Use of Zoledronic Acid to Complex Regional Pain Syndrome|Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient.|Aclasta|University of Sao Paulo General Hospital|No|Not yet recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|October 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788176||71498|
NCT01787201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU4261|The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers|The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers||Liberty University|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01787201||71571|
NCT01787539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-COMB-0254/275/2012-MUL|The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer|The Role of Postoperative Chemotherapy Cycles in the Combined Modality Therapy of Gastric Cancer With Perioperative Chemotherapy and Surgery in Pathological Responders|STOPEROPCHEM|Medical University of Lublin|Yes|Recruiting|February 2013|February 2022|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787539||71545|
NCT01787864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0336|Prevalence of Dysplasia of the Gastric Cardia|Prevalence of Dysplasia of the Gastric Cardia||University of North Carolina, Chapel Hill|No|Active, not recruiting|February 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|170|Samples With DNA|Esophageal and gastric cardia biospies|Both|18 Years|80 Years|No|Non-Probability Sample|This study will consist of a cross-sectional arm, as well as a prospective longitudinal        arm, and will include patients who are undergoing ablative therapy at UNC. The        cross-sectional arm will consist of patients who have undergone ablative therapy for        Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence        of BE since their first ablation. Concurrently enrolled will be a prospective longitudinal        arm which will consist of patients prior to their first ablation procedure. The        prospective cohort will be followed for 12 months after initial treatment or longer if BE        is not yet clear 6 months after the initial treatment.|February 2016|February 16, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787864||71521|
NCT01789190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/01093|Regular Physical Exercise Extends Honeymoon Phase in Type 1 Diabetes Subjects|Observational Study: Regular Physical Exercise Extends Honeymoon Phase in Type 1 Diabetes Subjects|Honeymoon|University Hospital A Coruña|Yes|Terminated|January 2011|February 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|Samples With DNA|Whole blood|Both|7 Years|30 Years|No|Non-Probability Sample|19 subjects from 26 with recent onset of type 1 diabetes completed the 2 years study in        the Endocrinology Service of the University Hospital Complex of A Coruña (Spain).        The mean age of group A was 21.9±4.2 years and included 8 individuals, 5 men and 3 women        diagnosed at the moment of onset by hyperglycaemia + ketoacidosis (n=4), ketoacidosis        (n=2) or hyperglycaemia (n=2). The mean age of group S was 23.3±2.2 years and included 11        individuals, 7 men and 4 women diagnosed at the moment of onset by hyperglycaemia +        ketoacidosis (n=3), ketoacidosis (n=7) or hyperglycaemia (n=1).|February 2013|February 7, 2013|February 5, 2013||No|The study has concluded normally|No||https://clinicaltrials.gov/show/NCT01789190|24 Months|71420|
NCT01789203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612-0114|Ciprofloxacin for Prevention of BK Infection|Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients||The Methodist Hospital System|No|Recruiting|January 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789203||71419|
NCT01789216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH1020090|Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)|Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)|PAIN|Major Extremity Trauma Research Consortium|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|495|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789216||71418|
NCT01789515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/538-31/1|Defunctioning Stoma and Postoperative Morbidity|Diverting Stoma and Postoperative Morbidity After Low Anterior Resection for Rectal Cancer Within an Enhanced Recovery After Surgery,ERAS, Program||Karolinska Institutet|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|287|||Both|18 Years|90 Years|No|Non-Probability Sample|Rectal cancer|March 2014|March 11, 2014|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01789515||71395|
NCT01789801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/RGG-01|A Randomized Study Evaluating the Role of Ultra-sound Guidance When Drawing Radial Arterial Blood Samples|A Randomized Study Evaluating the Role of Ultra-sound Guidance When Drawing Radial Arterial Blood Samples|ECHO-PARDIF|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01789801||71373|
NCT01790074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPA 2010|Trigger Point Therapy in Cervicogenic Headache|MANUAL TREATMENT OF ACTIVE TRIGGER POINTS IN THE STERNOCLEIDOMASTOID MUSCLE IN PATIENTS WITH CERVICOGENIC HEADACHE: A PILOT RANDOMIZED CLINICAL TRIAL||Universidad Rey Juan Carlos|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|No|||February 2013|February 12, 2013|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01790074||71352|
NCT01790373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3852|Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence|Suubi+Adherence: Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence||Columbia University|No|Recruiting|February 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|736|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790373||71329|
NCT01790659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-21|Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama|A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama||U.S. Army Medical Research and Materiel Command|Yes|Recruiting|May 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Years|N/A|No|||July 2015|July 10, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790659||71307|
NCT01788410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-002071|MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine|MRI-Guided Cryoablation of Head, Neck and Spine Nerves and Facets Using the Advanced Multimodality Image Guided Operating(AMIGO) Suite||Brigham and Women's Hospital|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Potential subjects must be 18 years of age and will be selected among patients who have a        pain related to facet joint disease, nerve degeneration or compression. Subjects must        benefit from a minimally invasive treatment option.|January 2016|January 11, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788410||71480|
NCT01799642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00262|Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis|Qualitative Descriptors of Dyspnea During Exercise in Cystic Fibrosis|CF_Dyspnea|University of British Columbia|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|50|||Both|19 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The CF patients will be recruited from the St. Paul's Hospital Adult CF Clinic. Healthy        control participants will be recruited from the Vancouver area.|November 2015|November 19, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799642||70619|
NCT01799135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004|Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)|Feasibility Study of the Utility of Pulmonary Dynamic Contrast Enhanced MRI for Assessment of Tumor Response and Lung Injury and for Treatment Planning for Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|April 2012|April 2019|Anticipated|April 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01799135||70658|
NCT01799408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPA-2012|Intra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis|The Effect of Intra-articular Injection of Betamethasone Acetate/Betamethasone Sodium Phosphate at the Knee Joint on the Hypothalamic-pituitary-adrenal Axis: a Case Controlled Study||The Nazareth Hospital, Israel|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with osteoarthritis of the knee and had not been onsteroids for at least 3 months|February 2013|February 23, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799408||70637|
NCT01799629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2121 110|Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial|Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial||King Faisal Specialist Hospital & Research Center|No|Recruiting|March 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|1 Month|Accepts Healthy Volunteers|||January 2016|January 22, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01799629||70620|
NCT01799850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPNA 02-037A|The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle|The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle||East Tennessee State University|No|Completed|March 2002|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|No|||February 2013|February 25, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01799850||70603|
NCT01790815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUAC mères|Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers|Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers of Children < 5 Years Old|MUAC|Alliance for International Medical Action|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|6 Months|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children present in the inpatient malnutrition treatment unit and paediatric service of        the Mirriah district hospital aged between 6-59 months old        Children aged between 6-59 months old in the two villages of the Mirriah district, Niger;        where the community phase of the study was conducted|December 2013|December 8, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01790815||71295|
NCT01787214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|walnuts and glucose|Walnuts and Glucose Variability|The Effect of Walnuts on Glucose Variability in Adults With Type-2 Diabetes Mellitus: a Dose-response Metabolic Feeding Study||Loma Linda University|Yes|Terminated|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|40 Years|70 Years|No|||March 2014|March 17, 2014|February 1, 2013||No|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT01787214||71570|
NCT01791075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 10-0631-B|Comparing Endoglide to Endoserter for DSAEK Graft Insertion|Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With the Endoserter for Insertion of the Donor Graft in Descemets Stripping Endothelial Keratoplasty (DSAEK)||University Health Network, Toronto|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791075||71275|
NCT01788540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12013|Intralipid for Recurrent Miscarriage|The Role of Intralipid in Natural Killer Cell Positive Cases With Recurrent Miscarriages Undergoing IVF/ICSI Cycles: a Double Blind Randomized Controlled Trial||Woman's Health University Hospital, Egypt|No|Recruiting|February 2013|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 31, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788540||71470|
NCT01788488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008835|Procalcitonin Use in Pneumonia Patients in the Critical Care Setting|Impact of Measuring Serum Procalcitonin Levels on Duration of Antimicrobial Therapy in Critical Care Patients With Suspected Pneumonia||Mayo Clinic|No|Completed|February 2013|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01788488||71474|
NCT01788501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCP_001|Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease|Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients||Seoul National University Hospital|No|Recruiting|November 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|N/A|18 Years|No|||November 2015|November 17, 2015|November 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01788501||71473|
NCT01788514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11028|Combining Entertainment & Influenza Education for Pediatric Patients|Combining Entertainment & Education Into an Age Appropriate Intervention Geared Toward Increasing Influenza Vaccination of Pediatric Patients in Underserved Communities||Winthrop University Hospital|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01788514||71472|
NCT01788956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLS STP-9100002|Comparison of Central Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter|Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter vs Central Venous Oxygen Saturation, Measured by a CO-Oximeter.||Mespere Lifesciences Inc.|No|Active, not recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Study subjects will consist of patients admitted either to the Medical Surgical ICU or the        Cardiac Surgery Recovery Unit at University Hospital. The four groups will comprise        patients with the following diagnoses: i) sepsis +/- septic shock, ii) post cardiac        surgery low output syndrome requiring inotropic/vasopressor therapy, iii) cardiogenic        shock post myocardial infarction, and iv) hypoxemic respiratory failure.|September 2015|September 25, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788956||71438|
NCT01789502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-1210-034|Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage|Are Fully Covered Metal Stents Superior to Plastic Stents for Preoperative Biliary Decompression in Malignant Distal Bile Duct Obstruction?||Inje University|Yes|Completed|January 2012|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|20 Years|N/A|No|||August 2015|August 2, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01789502||71396|
NCT01789541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/9A|Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?|Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation|TABLAS|Karolinska Institutet|No|Completed|February 2013|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|327|||Both|18 Years|N/A|No|Probability Sample|Patients with atrial fibrillation (cases) or AV-nodal reentry tachycardia (controls)|January 2016|January 19, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01789541||71393|
NCT01789814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PraCloBiv2013CK|Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation|The Effect of Prasugrel as Compared to Clopidogrel on Platelet Function Immediately Following the Termination of Intravenous Bivalirudin in Patients Undergoing Percutaneous Coronary and Structural Cardiac Intervention||Tufts Medical Center|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|No|||July 2014|July 22, 2014|February 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789814||71372|
NCT01790087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANX-188-05|ANX-188 Thorough QT/QTc Study in Healthy Volunteers|A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers||Mast Therapeutics, Inc.|Yes|Completed|February 2013|June 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790087||71351|
NCT01790672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydroxytyrosol/FIS/2|Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects|Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 2. To Establish the Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects||Parc de Salut Mar|No|Completed|May 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790672||71306|
NCT01790685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00079951|Ozurdex for Retinal Vein Occlusion Study (ORVO Study)|Ozurdex for Retinal Vein Occlusion Study (ORVO Study)|ORVO|Johns Hopkins University|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|February 8, 2013|Yes|Yes||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01790685||71305|
NCT01790958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH 1009|Microcurrent Stimulation to Treat Macular Degeneration|An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases||Retina Institute of Hawaii|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|50|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with retinal disease such as Age-Related Macular Degeneration, STargardt's        Disease, and Retinitis Pigmentosa|February 2013|February 11, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790958||71284|
NCT01798225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20RR017696-06|Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population|The Relationships Between Periodontal Disease and Type 2 Diabetes Mellitus in the Gullah Population and the Effects of Mechanical Periodontal Therapy and Systemic Antibiotics on the Glycemic Control||Medical University of South Carolina|No|Completed|December 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|13 Years|N/A|No|||December 2007|February 21, 2013|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798225||70726|
NCT01796015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.598|Intracranial Hypertension and Optic Nerve Sheath Diameter|Intracranial Hypertension Detection Using Optic Nerve Sheath Diameter Measurement in Children|DENO|Hospices Civils de Lyon|Yes|Recruiting|April 2011|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|227|||Both|2 Months|16 Years|No|||February 2016|March 24, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01796015||70896|
NCT01796028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000530-19|Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer|A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE®+Metformine Placebo Versus TAXOTERE®+Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.|TAXOMET|Centre Antoine Lacassagne|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||November 2015|November 13, 2015|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01796028||70895|
NCT01799863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAV011_12|Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis|Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis||Fundação Altino Ventura|Yes|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799863||70602|
NCT01796340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-2-009|Cue Exposure Training for Overweight Children|Cue Exposure Training for Overweight Children||Maastricht University Medical Center|Yes|Terminated|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|12 Years|18 Years|No|||October 2014|October 13, 2015|February 20, 2013||No|Insufficient number of participants|No||https://clinicaltrials.gov/show/NCT01796340||70871|
NCT01800136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.662|Analgesic Effect of Non Invasive Stimulation : Comparison of rTMS and tDCS Efficacy|Non-invasive Cortical Stimulation for Pharmacoresistant Neuropathic Pain: rTMS Versus tDCS|NI-MCS|Hospices Civils de Lyon|Yes|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||November 2013|November 4, 2013|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01800136||70582|
NCT01796002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro-CHOP Study|Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma|PHASE 3 MULTI-CENTER RANDOMIZED STUDY TO COMPARE EFFICACY AND SAFETY OF ROMIDEPSIN CHOP (Ro-CHOP) VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA||The Lymphoma Academic Research Organisation|Yes|Recruiting|January 2013|July 2024|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|80 Years|No|||September 2015|September 4, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01796002||70897|
NCT01796314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 255 07|Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life|Impact of a Therapeutic Educational Programme for Alzheimer's Disease Patients and Their Caregiver in Community Dwelling, on the AD Patient's Quality of Life|THERAD|University Hospital, Toulouse|No|Recruiting|January 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|170|||Both|50 Years|N/A|No|||August 2015|August 24, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796314||70873|
NCT01796327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471046|A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers|A Phase 1, Single Dose, Fixed Sequence Study To Estimate The Absolute Bioavailability Of Dacomitinib (PF-00299804) By Comparing Oral To Intravenous Administration In Healthy Volunteers||Pfizer|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|February 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01796327||70872|
NCT01790568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.047|Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant|Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant||University of Michigan Cancer Center|Yes|Recruiting|December 2014|July 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790568||71314|
NCT01788189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No. 2012-001891-13|Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas|Lenalidomide in Conjunction With Methotrexate, Leucovorin, Cytarabine and Rituximab for the Treatment of Relapsed or Refractory CD20-positive Aggressive Lymphomas: an Open-label, Multicenter Phase I/II Trial|LeMLAR|University Hospital, Essen|No|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01788189||71497|
NCT01787552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2116|A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF|A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis||Novartis|No|Active, not recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787552||71544|
NCT01788553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-102246|Study Of Remission In Patients Treated For Generalized Anxiety Disorder|An Observational Study of Remission in Patients Treated for Generalized Anxiety Disorder in Primary and Specialized Care in Belgium.||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|March 2006|March 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|750|||Both|18 Years|N/A|No|Probability Sample|Patients treated with generalized anxiety disorder in primary and specialized care in        Belgium.|July 2009|February 8, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01788553||71469|
NCT01788969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00014259|Serotonergic Modulation of Motor Function in Subacute and Chronic SCI|Serotonergic Modulation of Motor Function in Subacute and Chronic SCI||Rehabilitation Institute of Chicago|No|Active, not recruiting|June 2005|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||September 2015|September 8, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788969||71437|
NCT01789229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 260/2003|Tumor Bank for Tissue Samples|Establishment of a Tissue Sample Bank in the Field of Gynaecological Oncology||Medical University of Vienna|Yes|Recruiting|September 2003|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|10000|Samples With DNA|Universal tumor bank|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients/people. Minimum age 18 years Characteristics: Recruited at the        Medical University Vienna or at one of the facilities cooperating with the Vienna Med.        University|September 2015|September 28, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789229||71417|
NCT01789827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1274|Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy|Interleukin-2 Imaging as a Guide to Cancer Immunotherapy (Ipilimumab or Pembrolizumab) in Advanced Melanoma: A Pilot Study||Mayo Clinic|Yes|Active, not recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|February 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789827||71371|
NCT01789840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPH-P3-12-01|Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia|Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia||Merit Medical Systems, Inc.|Yes|Recruiting|July 2013|May 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Male|50 Years|79 Years|No|||October 2015|October 20, 2015|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789840||71370|
NCT01790100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-135-101|A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C||Alios Biopharma Inc.|No|Completed|February 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||November 2013|June 23, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790100||71350|
NCT01790113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arthrex 003|Arthrex Eclipse™ Shoulder Prosthesis|A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease||Arthrex, Inc.|No|Recruiting|January 2013|October 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|21 Years|N/A|No|||February 2016|February 4, 2016|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790113||71349|
NCT01790386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coramed 01-144|Equivalency Study of the TEG and CORA Hemostasis Systems|Equivalency Study of the CORA(R) and TEG(R) 5000 Systems||Coramed Technologies LLC|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|465|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|For surgical group, and consented patient 18 years of age or over, going through a heart        surgical procedure.        For Reference Ranges group, helathy subjects 18 years of age or over, not taking        medications, having conditions or undergoing treatments that would affect blood        hemostasis.|December 2013|December 16, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790386||71328|
NCT01790724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13146|Regulating Efficacy and Wellness in Diabetes|Social Cognitive and Neuropsychological Influences on Physical Activity Behavior in Type II Diabetes|REWinD|University of Illinois at Urbana-Champaign|No|Completed|January 2013|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790724||71302|
NCT01791244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200136-560|A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device|A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device|RebiQoL|Merck KGaA||Active, not recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791244||71262|
NCT01798264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-01|Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes|A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus||Intarcia Therapeutics||Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|30 Years|70 Years|No|||April 2013|April 5, 2013|February 20, 2013|No|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT01798264||70723|
NCT01798550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063210|Enoxaparin Dosing in Obesity|Evaluation of Enoxaparin Dosing in Hospitalized Morbidly Obese Patients at an Academic Medical Center||Emory University|No|Recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798550||70701|
NCT01800162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815013|RCT for Women With a Persisting Pregnancy of Unknown Location|Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location -- a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy||University of Pennsylvania|Yes|Recruiting|February 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|18 Years|N/A|No|||February 2013|February 25, 2013|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800162||70580|
NCT01796600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.710|Assessment of Distal Limbs Fractures With Cone-Beam CT Newtom 5G|Assessment of Distal Limbs Fractures With Cone-Beam CT Newtom 5G|FRADICOBE|Hospices Civils de Lyon|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|43|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01796600||70851|
NCT01796613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMC0313|Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy|Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy|Ring-Plus|Institute of Tropical Medicine, Belgium|Yes|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01796613||70850|
NCT01796626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-M22-ResurFX-12-01|Clinical Evaluation of M22 ResurFX 1565nm Module|Clinical Evaluation of M22 ResurFX 1565nm Module||Lumenis Ltd.|No|Completed|December 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|February 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796626||70849|
NCT01796639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400ACN02|Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China|Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China|REACH|Novartis|Yes|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1500|||Both|18 Years|75 Years|No|Probability Sample|male and female kidney transplantation patients with living-donor grafts, > 18 years of        age|June 2014|June 17, 2014|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01796639||70848|
NCT01791413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-55-13|Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas|||Mahidol University|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|40 Years|No|||August 2013|August 23, 2013|February 10, 2013||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01791413||71249|Small sample size
NCT01791426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810|A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye|A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye||Bausch & Lomb Incorporated|No|Withdrawn|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|February 4, 2013||No|Adjustment of company focus due to acquision by Valeant Pharmaceuticals|No||https://clinicaltrials.gov/show/NCT01791426||71248|
NCT01791439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-201-SDR|Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese|Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese.||Royal Victoria Hospital, Canada|No|Recruiting|January 2013|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01791439||71247|
NCT01788527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0037-A|Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial|Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial|CONCEPTT|Mount Sinai Hospital, Canada|Yes|Recruiting|March 2013|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Female|18 Years|40 Years|No|||February 2016|February 11, 2016|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01788527||71471|
NCT01788800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221012|Physical Activity and Cognitive Behavioural Therapy in Panic Disorder|The Influence of Physical Activity on the Effect of Cognitive Behavioural Therapy, Neurobiological Parameters and Information Processing in Patients With Panic Disorder With/Without Agoraphobia||Charite University, Berlin, Germany|No|Completed|January 2009|May 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|75 Years|No|||May 2013|May 15, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01788800||71450|
NCT01788761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pROBIOTICS11|The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants|The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants||Rockford Memorial Hospital||Enrolling by invitation|July 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|14 Days|No|||November 2014|November 29, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01788761||71453|
NCT01788982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1209|Nintedanib(BIBF1120) in Thyroid Cancer|A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|143|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788982||71436|
NCT01789554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUMBA2013|The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR|The Response to Urgent Mobile Message for Bystander Activation (RUMBA) Trial - The Use of Mobile Phone Positioning for Dispatch of Bystanders to Out of Hospital Cardiac Arrest.|RUMBA|Karolinska Institutet|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|600|||Both|8 Years|N/A|No|||September 2014|September 10, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789554||71392|
NCT01789567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAE00807|Engager Direct Aortic Clinical Study|Engager Direct Aortic Clinical Study: Medtronic Engager™ Transcatheter Aortic Valve Implantation System Via Direct Aortic Approach||Medtronic Cardiovascular|Yes|Completed|May 2013|June 2015|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789567||71391|
NCT01790126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103305|The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer|The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer||Aragon Pharmaceuticals, Inc.|No|Recruiting|March 2013|January 2020|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Male|18 Years|N/A|No|||March 2016|March 18, 2016|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790126||71348|
NCT01790399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENTIMAG-1213|IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER|IDENTIFICATION OF SENTINEL NODE(S) BY SENTIMAG® /SIENNA+ IN BREAST CANCER: FEASIBILITY STUDY|SENTIMAG|Centre Oscar Lambret|No|Active, not recruiting|January 2013|July 2014|Anticipated|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|115|||Female|18 Years|N/A|No|||August 2013|March 5, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790399||71327|
NCT01790698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFECT-FP7305340|Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).|Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection|INFECT|Karolinska Institutet|No|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Bacterial isolates, whole blood, plasma, tissue|Both|18 Years|N/A|No|Probability Sample|Hospitalized patients with NSTI|September 2015|September 1, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01790698|3 Months|71304|
NCT01791595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/12/004|A Phase I Trial of AZD3965 in Patients With Advanced Cancer|A Cancer Research United Kingdom Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer||Cancer Research UK|No|Recruiting|February 2013|||November 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791595||71235|
NCT01799421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEURISK|Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy|Predictive Models of Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy.|NEURISK|Asociación para el Fomento de la Investigación y el Desarrollo Integral de la Oncología|No|Active, not recruiting|October 2011|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-hematologic cancer that will start chemotherapy treatment.|October 2015|October 26, 2015|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01799421||70636|
NCT01796054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1398|Stress Free Now, a Mind-body Reduction Program for Nurses|Effectiveness of a Mind-body Stress Reduction Program for Nurses: A Randomized Controlled Study|SFN-Nurses|The Cleveland Clinic|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|360|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01796054||70893|
NCT01796041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12111|Intraoperative Imaging of Breast Cancer With Indocyanine Green|A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery|ICG|University of Pennsylvania|Yes|Recruiting|July 2011|February 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796041||70894|
NCT01796353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CopenHeart-SF|Effects of a Comprehensive Sexual Rehabilitation Programme in Heart Patients|A Randomized Clinical Trial of a Comprehensive Sexual Rehabilitation Programme Versus Usual Care in Male Patients With Impaired Sexual Function and Ischemic Heart Disease or Implantable Cardioverter Defibrillator|CopenHeartSF|Rigshospitalet, Denmark|No|Recruiting|February 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|154|||Male|18 Years|N/A|No|||November 2015|November 3, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796353||70870|
NCT01796899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0007|Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers|A Randomized, Single-center, Open-label, 5-way Crossover, Single-dose Bioavailability/Bioequivalence Comparison of Brivaracetam Oral Tablets (10 mg, 50 mg,75 mg, and 100 mg) and Brivaracetam Intravenous Bolus Injection (100 mg) in Healthy Volunteers||UCB Pharma|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796899||70828|
NCT01787565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X9001016|Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland|Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland||Pfizer|No|Terminated|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|86|||Both|18 Years|N/A|No|Non-Probability Sample|Members of the Terveystalo health insurance scheme presenting with a new episode of low        back pain|February 2014|February 12, 2014|January 22, 2013||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01787565||71543|
NCT01787903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2012INCONTROL01|The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA|The Effects of Real-time Continuous Glucose Monitoring on Glycemia and Quality of Life in Patients With Type 1 Diabetes Mellitus and Impaired Hypoglycemia Awareness|INCONTROL|VU University Medical Center|No|Active, not recruiting|February 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787903||71519|
NCT01787916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LIDO|52 Week Trial of Liraglutide in Type 1 Diabetes|Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.|LIDO|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|50 Years|No|||March 2014|March 17, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787916||71518|
NCT01788202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090260|Patients With Positive Urine Cocaine Metabolites Undergoing General Anesthesia|An Observational, Prospective Study in Patients With Positive Urine Cocaine Metabolites Undergoing Surgery for General Anesthesia||Rutgers, The State University of New Jersey|No|Terminated|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|60 Years|No|Non-Probability Sample|subjects requiring urgent surgeries for acute abdomen, orthopedic trauma and maxillary        facial trauma cases.|September 2014|September 25, 2014|February 5, 2013||No|unable to enroll patients|No||https://clinicaltrials.gov/show/NCT01788202||71496|
NCT01789021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1206-BA|Analytical Performance Evaluation of Blood Glucose Monitoring Systems- Investigator Sponsored Contour® XT Comparator Study - Ulm Germany|Analytical Performance Evaluation of Blood Glucose Monitoring Systems|IDT-1206-BA|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|N/A|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|June 17, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789021||71433|
NCT01789034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Besta-2012-01|Difficult Intubation With Glidescope Video Laryngoscope|Incidence and Predictors of Difficult Intubation Adopting an Institutional Algorithm Glidescope Based: a Cohort Study||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Recruiting|June 2011|June 2013|Anticipated|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2600|||Both|16 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing neurosurgical procedures eligible for intubation in a tertiary        neurosurgical centre|February 2013|February 11, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789034||71432|
NCT01788774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-RISP-2011-01|Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths|Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder|PRISMA-1|Rovi Pharmaceuticals Laboratories|Yes|Completed|April 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|No|||October 2014|October 6, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788774||71452|
NCT01788995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28355|BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer|A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer||Hoffmann-La Roche||Recruiting|October 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed ovarian cancer (epithelial ovarian cancer, fallopian tube        carcinoma or primary peritoneal carcinomas) with indication for carboplatin/paclitaxel        chemotherapy in combination with Avastin|March 2016|March 1, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788995||71435|
NCT01789255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00355|Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies|A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation||National Cancer Institute (NCI)|Yes|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|75 Years|No|||June 2014|October 13, 2015|February 7, 2013|Yes|Yes||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01789255||71415|
NCT01789853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00010421|Very Intensive Early Walking in Stroke|Improving the Delivery of Intensive Gait Training in the Clinical Setting to Augment Community Ambulation|VIEWS|Rehabilitation Institute of Chicago|Yes|Completed|October 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01789853||71369|
NCT01789866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01306|DHA & Lutein and fMRI Brain Mapping in Healthy Children|Dynamic Roles of Dietary Docosahexaenoic Acid (DHA) and Lutein in Brain Function in Healthy Children||University of British Columbia|No|Completed|September 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|69 Months|78 Months|Accepts Healthy Volunteers|Non-Probability Sample|school-age children differentiated by intake of DHA and lutein|April 2015|April 14, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01789866||71368|
NCT01790139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0584|Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles|Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles||Asan Medical Center|No|Completed|February 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|84|||Both|20 Years|N/A|No|||March 2014|March 24, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790139||71347|
NCT01790412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Technical University of Madrid|Gestational Diabetes: the Prevention|Gestational Diabetes. The Rol of Exercise in the Prevention||Technical University of Madrid|Yes|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|257|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 11, 2013|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790412||71326|
NCT01790711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT-CN-121025|Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus|The Efficiency of Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus||The Second Hospital of Nanjing Medical University|Yes|Enrolling by invitation|October 2012|June 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||November 2014|November 21, 2014|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01790711||71303|
NCT01821170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/16|Cognitive Remediation in ADHD Children : Comparison Between Three Therapeutic Strategies : Cognitive Remediation With a Virtual Classroom Software and Methylphenidate and Supportive Psychotherapy||RECOGNITA|University Hospital, Bordeaux|No|Recruiting|April 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Both|7 Years|11 Years|No|||January 2015|January 12, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821170||68970|
NCT01800149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.2013.POST-EXT.PROED|Healing of Post-ext Sites Using Bovine Bone Mineral: a CBCT and Histologic RCCT|Healing of Post-extraction Sites Using Bovine-bone Mineral: a CBCT and Histologic Randomized Controlled Clinical Study||Proed|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||December 2014|December 1, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800149||70581|
NCT01796067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project FIT|Families Improving Together (FIT) for Weight Loss|Families Improving Together (FIT) for Weight Loss||University of South Carolina|Yes|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|520|||Both|11 Years|16 Years|No|||November 2015|January 12, 2016|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01796067||70892|
NCT01796080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAF_V1.1 (05.07.2012)|The Effect of Simulated Obstructive Apnoea and Hypopnoea on Heart Rhythm in Patients With Paroxysmal Atrial Fibrillation|The Effect of Simulated Obstructive Apnoea and Hypopnoea on Heart Rhythm in Patients With Paroxysmal Atrial Fibrillation||University of Zurich|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|45|||Both|18 Years|75 Years|No|||December 2013|December 20, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796080||70891|
NCT01796366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1953-4013|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|64 Years|No|||August 2013|August 20, 2013|February 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01796366||70869|
NCT01796652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.BAV.0.05.05/374|Home Treatment of Acute Pancreatitis|A Randomized Controlled Trial of Home Monitoring Versus Hospitalization in Mild Non-Alcoholic Acute Interstitial Pancreatitis||Bezmialem Vakif University|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|No|Probability Sample|Mild acute non-alhololic patients managed in home.|February 2013|February 21, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796652|30 Days|70847|
NCT01796912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1880|Lipoprotein Apheresis in Refractory Angina Study|Clinical Outcomes, Perfusion and Vascular Function in Patients With Refractory Angina and Raised Lipoprotein (a), Treated With Lipoprotein Apheresis||Imperial College London|Yes|Completed|February 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||February 2013|February 15, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01796912||70827|
NCT01787591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0344|Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome|Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome||Ohio State University|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787591||71541|
NCT01787929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-10|Displaced Femoral Neck Fracture in Elderly Patient. Should Cement be Used for Hip Hemiarthroplasty ?|Cemented Versus Uncemented Hemiarthroplasty for Displaced Femoral Neck Fracture in Elderly Patient : a Randomized Prospective Trial|PIH|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|70 Years|N/A|No|||February 2013|February 7, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01787929||71517|
NCT01788215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 00034479|Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome|The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome|MI-PCOS|University of Rochester|Yes|Completed|November 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|August 11, 2011|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01788215||71495|This study was underpowered due to reduced enrollment. Targeted enrollment was 40 and actual enrollment was 10.
NCT01788228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116861|Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure||GlaxoSmithKline||Completed|March 2013|February 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|February 25, 2016|January 31, 2013|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01788228||71494|
NCT01788826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH01|Prophylactic Mesh to Reduce The Incidence of Ventral Hernia|Randomized Clinical Trial to Evaluate the Use of a Prophylactic Polypropylene Mesh To Reduce the Incidence of Ventral Hernias in Colorectal Surgery||Henares University Hospital|Yes|Active, not recruiting|June 2009|September 2013|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|112|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788826||71448|
NCT01788787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1112|Ask Advise Connect (AAC) Harris Heath CPRIT|Implementation of an Automated EMR System to Connect Smokers in a Safety Net Healthcare System With Smoking Cessation Treatment||M.D. Anderson Cancer Center|No|Recruiting|April 2013|||April 2049|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5212|Samples With DNA|Saliva sample to test for cotinine.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Harris Health System Community Health Clinics|October 2015|October 21, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788787||71451|
NCT01789580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0153|MOD&JEU: Moderators of Online Gambling, How Effective?|Moderators of Online Gambling, How Effective? Experimental, Controlled and Randomized Study.|MOD&JEU|Nantes University Hospital||Recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|485|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789580||71390|
NCT01789593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4001|A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes|A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|29|||Both|18 Years|64 Years|No|||June 2015|June 11, 2015|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789593||71389|
NCT01789606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4371008|Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet|Ibuprofen 600 mg Immediate Release/Extended Release (IR/ER) Caplet Self-Selection, Safety and Compliance Study||Pfizer|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|712|||Both|12 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 25, 2014|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789606||71388|
NCT01820286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002294|Positive Psychology for Mood Disorders|Trial of a Positive Psychology Intervention to Reduce Suicide Risk in Patients With Mood Disorders|PPBPAD|Massachusetts General Hospital|No|Enrolling by invitation|March 2013|January 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820286||69038|
NCT01791257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicroRNA in SAH|MicroRNA Diagnostics in Subarachnoid Hemorrhage|MicroRNA Expression in Cerebrospinal Fluid From Patients Suffering Subarachnoid Hemorrhage With and Without Delayed Cerebral Ischemia||Rigshospitalet, Denmark|Yes|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|50|Samples With DNA|Group 1+2: Cerebrospinal fluid 1-2 ml a day for 8 days drawn in each patient from external      ventricular drain Gropu 3: Cerebrospinal fluid 2 ml drawn from patients undergoing spinal      anesthesia before injection of local anesthetic.|Both|18 Years|N/A|No|Non-Probability Sample|Group 1+2: Patients admitted to Neurointensive Department in Rigshospitalet. Group 3:        Patients undergoing spinal anesthesia for orthopedic surgery in Bispebjerg Hospital.|April 2014|April 7, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791257|3 Months|71261|
NCT01821768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209143|Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy|A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound||Washington University School of Medicine|No|Recruiting|April 2013|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|460|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01821768||68924|
NCT01821781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301135|Immune Disorder HSCT Protocol|A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime||Washington University School of Medicine|No|Recruiting|March 2013|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||January 2016|January 9, 2016|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821781||68923|
NCT01799889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-0102|Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies|A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies||Gilead Sciences|No|Recruiting|March 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|385|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799889||70600|
NCT01800175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-13-001|Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug|||Ocular Therapeutix, Inc.|No|Active, not recruiting|February 2013|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01800175||70579|
NCT01796691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOCLAplan02|The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)|Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.|BOCLA-Mort|Ruhr University of Bochum|No|Completed|January 2009|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|600|||Both|18 Years|N/A|No|Probability Sample|Patients following coronary stenting if informed consent was obtained|February 2013|February 24, 2013|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01796691||70844|
NCT01796925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT2012-02|Targeted Hypoglossal Neurostimulation Study #2|Clinical Study of the aura6000™ Targeted Hypoglossal Implantable Neurostimulation (THN) Sleep Therapy System|THN2|ImThera Medical, Inc.|No|Completed|February 2013|September 2014|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796925||70826|
NCT01796938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0641|Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects|Open, Non-randomized, Sequential Group Comparison to Investigate the Pharmacokinetics, Safety, and Tolerability of 100 mg SPM 927 in Male and Female Subjects With Renal Impairment Including Subjects Requiring Dialysis Compared With Male and Female Healthy Subjects Following Single-dose Administration||UCB Pharma|No|Completed|June 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2013|October 17, 2014|February 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01796938||70825|
NCT01796379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9378|High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia|High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia|HITTS|Oslo University Hospital|No|Recruiting|February 2013|December 2035|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|January 22, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796379||70868|
NCT01796665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-12-005|A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris||Perrigo Company|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1180|||Both|12 Years|40 Years|No|||September 2013|September 23, 2013|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796665||70846|
NCT01796678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 14386-05|Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial|Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial||Children's Hospital & Research Center Oakland|Yes|Completed|September 2000|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|3 Years|21 Years|No|||July 2013|July 29, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796678||70845|
NCT01797848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-047|Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients|A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4|COMMAND-Asia|Bristol-Myers Squibb|No|Withdrawn|June 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797848||70755|
NCT01797861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLACE|Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy|A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC)|PLACE|Radboud University|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797861||70754|
NCT01787942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R974/83/2012|Investigating Abnormal Lipid Layer Thickness in Blepharoplasty Patients|Investigating Abnormal Lipid Layer Thickness and Other Objective Dry Eye Parameters in Patients Seeking Blepharoplasty, and How They Change After Blepharoplasty||Singapore National Eye Centre|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|21 Years|90 Years|No|||February 2013|August 15, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01787942||71516|
NCT01788241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT-MP-003|TweeSteden Mild Stenosis Study|A Psycho-biochemical Perspective on Non-significant Coronary Artery Disease: a Prospective Cohort Study of Classic and Novel Risk Markers.|TWIST|University of Tilburg|No|Active, not recruiting|January 2009|April 2025|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|547|Samples With DNA|Serum, DNA, leukocyte differentiation, high-sensitive C-reactive protein, fibrinogen|Both|20 Years|N/A|No|Probability Sample|All patients who have received coronary angiography or computed tomography at the        TweeSteden Hospital Tilburg are being screened since January 2009.|October 2015|October 6, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01788241||71493|
NCT01788254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKP243|Open Label Study for the Functional Characterization of Drug Metabolism and Transport|Open Label Study for the Functional Characterization of Drug Metabolism and Transport|IKP243|University Hospital Tuebingen|No|Completed|January 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|144|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01788254||71492|
NCT01788566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14789|A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer|A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Active, not recruiting|March 2013|December 2015|Anticipated|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788566||71468|
NCT01789619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016||Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients|Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients||UMC Utrecht|No|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|75 Years|No|Probability Sample|Patients with severe atopic dermatitis, who can not be treated adequately with Cycloporin        A because of side effects and/or non-responsiveness.|May 2015|May 28, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789619||71387|
NCT01789008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC/12-01|Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease.|Interest of Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Didease in Alcoholic Patients in Weaning.|FIBR-OH|Rennes University Hospital|Yes|Recruiting|February 2013|||February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2013|February 8, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789008||71434|
NCT01789242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMyC 11MM02|A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis|A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis||Academic Myeloma Consortium|No|Recruiting|February 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01789242||71416|
NCT01789294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ped-LNH|Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia|CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL.||Azienda Policlinico Umberto I|Yes|Recruiting|November 2008|March 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|270|||Both|6 Months|18 Years|No|||November 2008|February 8, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01789294||71412|
NCT01790737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101424|First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02|A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma|FMG-MM02|Kuopio University Hospital|Yes|Active, not recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||July 2015|August 5, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01790737||71301|
NCT01820000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00032804|Efficacy of Non Contrast DWI(Diffusion Weighted Imaging) Imaging Compared to DMR-DE|Prospective Study to Obtain Preliminary Data to Determine the Efficacy of Non Contrast DWI Imaging Compared to CMR-DE||University of Michigan|Yes|Active, not recruiting|December 2009|July 2016|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820000||69060|
NCT01820910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG39|This is a Phase 2 Trial of First-line Doxycycline to Treat Ocular Adnexal Marginal Zone Lymphoma|International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitoring and Antibiotic Re-treatment at Infection Re-occurrence in Patients With Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)||International Extranodal Lymphoma Study Group (IELSG)||Recruiting|March 2013|September 2023|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820910||68990|
NCT01790971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0460-A|Spinal Morphine for Patients With Obstructive Sleep Apnea|Low Dose Spinal Morphine for Patients With Obstructive Sleep Apnea (OSA) Undergoing Total Hip Arthroplasty (THA)||University Health Network, Toronto|No|Recruiting|September 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||July 2015|July 20, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790971||71283|
NCT01820598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AGIR-04|Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients|Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device|StimobII|AGIR à Dom|Yes|Recruiting|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01820598||69014|
NCT01820897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTIPROPH-625|Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation|Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation. Randomized Controlled Trial.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|75 Years|No|||March 2015|March 25, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820897||68991|
NCT01821469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EssaiClinique_"BIP-ED"|Functional Correlates of Bipolar Disorders and Effects of the Psychoeducation. an fMRI Study|Functional Correlates of Bipolar Disorders and Effects of the Psychoeducation. Assessment by Functional and Anatomic Neuroimaging.|BIP-ED|University Hospital, Grenoble|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01821469||68947|
NCT01821495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-01|Study of DC-CIK to Treat NPC|A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Staging Ⅱ-Ⅲ of Nasopharyngeal Carcinoma||Guangxi Medical University|Yes|Not yet recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821495||68945|
NCT01821508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMS|Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus|Prospective, Open,Randomized, Unicenter Study Comparing Roux-en-Y Gastric Bypass With the Best Clinical Treatment Regarding Improvement of Microvascular Complications of Type 2 Diabetes Mellitus in Obese Patients.||Hospital Alemão Oswaldo Cruz|Yes|Recruiting|March 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821508||68944|
NCT01800188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-171|Glucose Metabolism During Hemodialysis|Glucose Metabolism During Hemodialysis||Rigshospitalet, Denmark|No|Completed|February 2013|||September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Serum of blood specimens will be retained for analysis at the end of the study|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with ESRD undergoing chronic hemodialysis/hemodiafiltration and with a normal        fasting glucose|November 2013|November 18, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800188||70578|
NCT01796704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM120018CTIL|Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index With the Clinical Evaluation|Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index (Calculated From Physiological Parameters) With the Clinical Evaluation||Clalit Health Services|No|Not yet recruiting|February 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population is composed of adults both genders:        healthy subjects visiting for administrative cause healthy subject during acute illness        patients with chronic conditions|October 2012|February 21, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01796704||70843|
NCT01797224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0023|OTIS Autoimmune Diseases in Pregnancy Project|Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project||University of California, San Diego|Yes|Recruiting|March 2012|December 2022|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who reside in the United States or Canada.|January 2016|January 26, 2016|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01797224||70803|
NCT01797237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH OD 14|Outcome Comparison Between PFNA and InterTAN|Outcome Comparison Between PFNA and InterTAN in Intertrochanteric Fractures||Chinese PLA General Hospital|No|Recruiting|October 2012|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||February 2015|February 4, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797237||70802|
NCT01797575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0046|N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder|A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009)|SMRI-Bipolar|The University of Texas Health Science Center, Houston|No|Recruiting|January 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||December 2015|December 19, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01797575||70776|
NCT01797874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-09-060-002|Pazopanib Maintenance for SCLC|Phase II Study of Pazopanib Maintenance for SCLC||Samsung Medical Center|Yes|Recruiting|June 2013|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|N/A|No|||April 2015|April 14, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797874||70753|
NCT01797887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEDA-Trial|Ayurvedic Versus Conventional Counseling in Mothers With Burnout-Syndrome|Diet and Lifestyle Modification in Mothers With Burnout-Syndrome: Ayurvedic Versus Conventional Standard Counseling - A Randomized Controlled Clinical Pilot Study|VEDA|Charite University, Berlin, Germany|Yes|Completed|May 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|18 Years|50 Years|No|||December 2014|December 22, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797887||70752|
NCT01787955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0879|Impact of Braun Anastomosis on Reduction in Delayed Gastric Emptying Following Pancreaticoduodenectomy|||Yonsei University|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|80 Years|No|||February 2015|February 24, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787955||71515|
NCT01788267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.678|Bone Microarchitecture in Young Cystic Fibrosis Patients|Evaluation of the Bone Microarchitecture in a Young Cystic Fibrosis Patients Using High-Resolution Peripheral Quantitative Computed Tomography||Hospices Civils de Lyon|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|38|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01788267||71491|
NCT01788280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI60947|Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab|Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab||University of Utah|Yes|Not yet recruiting|June 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788280||71490|
NCT01788813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116958|To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies|A Randomized, Double Blind, Placebo-controlled Study to Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies||GlaxoSmithKline|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||August 2014|October 16, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788813||71449|
NCT01789268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0012|Impact of Respiratory Pathogens in Infants|Impact of Respiratory Virus Infections and Bacterial Microbiome Shifts on Lymphocyte and Respiratory Function in Infants Born Prematurely or Full Term||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2013|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||Anticipated|280|||Both|N/A|3 Years|No|||October 2015|October 29, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789268||71414|
NCT01789281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2X01B|Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.|An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment||Novartis||Recruiting|May 2013|September 2022|Anticipated|September 2022|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|N/A|N/A|No|||March 2016|March 4, 2016|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789281||71413|
NCT01790425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD IRB # 319719|Randomized Controlled Trial Comparing Water vs. Air Method for Performing Colonoscopy in Adult Female Subjects|Randomized Controlled Trial Comparing Water vs. Air Method for Performing Colonoscopy in Adult Female Subjects||University of California, Davis|Yes|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|80 Years|No|||February 2013|February 11, 2013|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01790425||71325|
NCT01790438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12143|A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes|A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study|IMAGINE 6|Eli Lilly and Company|Yes|Completed|March 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|630|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790438||71324|
NCT01820299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101839|Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer|Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer||Medical University of South Carolina|Yes|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820299||69037|
NCT01820312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136191|A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure|A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure||University of Arkansas|No|Terminated|January 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 21, 2013|Yes|Yes|Due to low enrollment.|No||https://clinicaltrials.gov/show/NCT01820312||69036|
NCT01820884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-GYN/EC-02|The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma|The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial|EC-02|Huazhong University of Science and Technology|Yes|Recruiting|November 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|50 Years|No|||March 2013|March 26, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820884||68992|
NCT01821183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|c.b.1.1|Strength and Strength-ratio of Hip Rotator Muscles at Soccer Players|Strength and Strength-ratio of Hip Rotator Muscles at Soccer Players Compared to Non-soccer Players||University Hospital, Basel, Switzerland|Yes|Completed|April 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|soccer club of Sarnen, Switzerland Residents of Sarnen and Basel, Switzerland|August 2013|August 5, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821183||68969|
NCT01821482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-01|A Study of DC-CIK to Treat Hepatocellular Carcinoma|A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Hepatocellular Carcinoma||Guangxi Medical University|Yes|Not yet recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821482||68946|
NCT01821209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLING2013|A Study of Intra-operative Autologous Retropubic Urethral Sling on Urinary Control After Robot Assisted Radical Prostatectomy|A Randomized Study of Intra-operative Autologous Retropubic Urethral Sling on Urinary Control After Robot Assisted Radical Prostatectomy|Sling|University of California, San Francisco|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Male|45 Years|75 Years|No|||May 2015|May 26, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821209||68967|
NCT01821222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-086KU|Wired Mothers - Use of Mobile Phones to Improve Maternal and Neonatal Health in Zanzibar|Mobile Phones as a Health Communication Tool to Improve Maternal and Neonatal Health in Zanzibar||University of Copenhagen|Yes|Completed|February 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2550|||Female|14 Years|45 Years|No|||March 2013|March 28, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821222||68966|
NCT01796392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600-0012|Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)|Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema|LIBERATE|Pulmonx, Inc.|Yes|Recruiting|July 2013|December 2020|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|183|||Both|40 Years|75 Years|No|||February 2016|February 29, 2016|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796392||70867|
NCT01796951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR5137|Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers|Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers||Vanderbilt University|No|Recruiting|February 2013|||August 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|38|||Male|35 Years|90 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796951||70824|
NCT01797250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0308|Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly) NEO/PEDS|Neonatal and Pediatric Studies Using a Bedside Respiratory Patient Monitoring System With the Functional Patient Monitoring PCBA-1||Medtronic - MITG|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|12|||Both|1 Month|18 Years|Accepts Healthy Volunteers|Probability Sample|The study population will include male and female pediatric and neonatal patients who meet        the specified sensor weight requirements with an existing intra-arterial line, typically        found in hospital intensive care areas. Subjects of all racial and ethnic backgrounds may        be included in the studies.|December 2013|December 5, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797250||70801|
NCT01798433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12-039|STRATEGY for Left Main Coronary Bifurcation Lesion II|A Prospective, Multi-center, Randomized Study to Evaluate the Optimal Strategy for Side Branch Treatment in Patients With Left Main Coronary Bifurcation Lesion|STRATEGY-II|Samsung Medical Center|Yes|Recruiting|February 2013|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|700|||Both|20 Years|N/A|No|||October 2014|October 19, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01798433||70710|
NCT01798446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1301-124-461|A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus|A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus||Seoul National University Hospital|No|Recruiting|February 2013|December 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||February 2013|May 23, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01798446||70709|
NCT01788306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA030351|Project OOPEN: Opioid Overdose Prevention, Education and Intervention|A Trial to Prevent Opioid Overdose: E.D. Based Intervention & Take-home Naloxone|OOPEN|University of Washington|Yes|Active, not recruiting|January 2013|April 2021|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|518|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788306||71488|
NCT01789060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01-047|p-AKT Expression on Clinical Outcomes in Malignant Lymphoma|The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study||Samsung Medical Center|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|262|Samples Without DNA|paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT|Both|17 Years|90 Years|No|Non-Probability Sample|Patients with malignant lymphoma who are treated in a tertiary hospital in Korea (Samsung        Medical Center)|February 2013|February 7, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789060||71430|
NCT01789073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-146|Preoperative Oral Immunonutrition for Patients With Pancreatic Cancer Undergoing Elective Surgery - Effect on Complications and Length of Hospital Stay|Randomized, Controlled Trial Investigating the Effect of Preoperative Oral Immunonutrition on Complications and Length of Hospital Stay After Elective Surgery for Pancreatic Cancer||University of Copenhagen|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|35|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789073||71429|
NCT01819155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF59-TIV-SEN-01|Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa|Assessment of the Immunogenicity and Safety of an MF59™- Adjuvanted Trivalent Influenza Vaccine and a Non-adjuvanted Trivalent Influenza Vaccine Among Children in Senegal||PATH|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|296|||Both|6 Months|71 Months|Accepts Healthy Volunteers|||June 2013|October 18, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819155||69125|
NCT01819168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102026-E|Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing|||Far Eastern Memorial Hospital|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30|||Female|20 Years|99 Years|No|Probability Sample|We will perform a retrospective study to review the data of bladder diary, urodynamic        studies and clinical data of patients who underwent tolterodine SR treatment once per day        for 12 weeks in Department of Obstetrics & Gynecology in National Taiwan University        Hospital and Far Eastern Memorial Hospital.|February 2016|February 22, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01819168||69124|
NCT01819441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peking University|Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients|Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial|APPROVE|Peking University First Hospital|Yes|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|40 Years|85 Years|No|||October 2015|October 22, 2015|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819441||69103|
NCT01789047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-DYSK|Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease|Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease|TOP-DYSK|Rush University Medical Center|Yes|Recruiting|March 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|30 Years|90 Years|No|||October 2015|October 26, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789047||71431|
NCT01819753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSAPCNL|Assessment of the Effects of Access Count in Percutaneous Nephrolithotomy on Renal Functions by Technetium-99M-Dimercaptosuccinic Acid Scintigraphy|||TC Erciyes University||Completed|June 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|20 Years|60 Years|No|||March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01819753||69079|
NCT01820065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003|Long-term Evaluation of Single-piece ACrysof IOL Implantation on Development of Posterior Capsule Opacification|A Long-term Evaluation of Single-piece Hydrophobic Acrylic Intraocular Lens Implantation on the Development of Posterior Capsule Opacification||Iladevi Cataract and IOL Research Center||Completed|June 2005|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|390|||Both|40 Years|75 Years|No|Non-Probability Sample|Patients undergoing phacoemulsification for age-related uncomplicated phacoemulsification|March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820065||69055|
NCT01820611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMET.CR.US19|Arcos Revision Stem: Evaluation of Clinical Performance|Arcos Revision Stem: Evaluation of Clinical Performance||Biomet, Inc.|No|Enrolling by invitation|February 2013|February 2021|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients who had a revision to a total hip replacement        using the Arcos Revision Stem Hip System.|January 2016|January 6, 2016|March 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01820611||69013|
NCT01820624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3912|Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.||Case Comprehensive Cancer Center|Yes|Active, not recruiting|April 2013|||October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01820624||69012|
NCT01820923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.04|Transcranial Brain Stimulation in Vegetative State Patients|Study on the Use of Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation to Promote Diagnosis, Prognosis and Innovative Rehabilitation in Patients in Vegetative and Minimally Conscious State.||IRCCS San Camillo, Venezia, Italy|Yes|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01820923||68989|
NCT01821196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210313|Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma|Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma||St. Olavs Hospital|No|Active, not recruiting|December 2012|December 2017|Anticipated|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|N/A|N/A|No|||May 2015|May 12, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821196||68968|
NCT01789151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucosamine|99m-Technetium- Glucosamine in Arthritis|99mTc-labelled D-Glucosamine in the Evaluation of Disease Activity in Patients With Degenerative and Inflammatory Rheumatic Conditions||University of Sydney||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|90 Years||||December 2014|December 2, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789151||71423|
NCT01796405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-050|Clofarabine for Langerhans in Pedi|Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis||Dana-Farber Cancer Institute|Yes|Withdrawn||||October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||August 2015|August 24, 2015|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796405||70866|
NCT01797588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYGHTKA-01|Pain After Total Knee Arthroplasty: A Trial Examining Combined Adductor-canal Nerve Block and Periarticular Infiltration Versus Adductor Canal Nerve Block Versus Periarticular Infiltration|Pain After Total Knee Arthroplasty: A Randomized Controlled Trial Examining the Effectiveness of a Combined Adductor-canal Peripheral Nerve Block With Periarticular Infiltration Versus Adductor-canal Nerve Block Alone Versus Periarticular Infiltration Alone.||North York General Hospital|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797588||70775|
NCT01797900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-HN-002|The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT|Phase 2 Study of Inductive Plus Concurrent Chemoradiation Versus Concurrent Plus Adjuvant Chemoradiation for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT||Chinese Academy of Medical Sciences|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|70 Years|No|||September 2014|September 9, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797900||70751|
NCT01798095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHP-03|Equivalence Study of Specificity of PPD|A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol®) in Comparison With a Reference Standard|03|JHP Pharmaceuticals LLC|No|Not yet recruiting|February 2013|July 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|152|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798095||70736|
NCT01798108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15522|Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases|A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases||Bayer|No|Completed|August 2001|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|30 Years|N/A|No|||February 2013|February 22, 2013|January 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01798108||70735|
NCT01798719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPINUT3|Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease|Low Glycemic Index Mediterranean Diet Effect on Moderate or Severe Non-alcoholic Fatty Liver Disease|Nutriepa|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|Yes|Completed|February 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01798719||70689|
NCT01798732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012|PIO Laser Sclerectomy IOP SLT Sclerectomy|Effect of Selective Laser Trabeculoplasty on the Intraocular Pressure Nycthemeral Rhythm.|PIO laser SPNP|University Hospital, Grenoble|No|Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01798732||70688|
NCT01788839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-249|Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma|Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma||Memorial Sloan Kettering Cancer Center||Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|blood draw is optional|Female|18 Years|N/A|No|Non-Probability Sample|Women for both the premenopausal and postmenopausal cohorts diagnosed with stage 0-III        breast cancer or any aggressive lymphpoma will be recruited from breast cancer and        lymphoma clinics.|January 2016|January 4, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788839||71447|
NCT01818869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0542C00002|To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects|A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects||AstraZeneca|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01818869||69147|
NCT01788579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI2851|Women Initiating New Goals of Safety|Project WINGS: Women Initiating New Goals of Safety|WINGS|Columbia University|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|209|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 26, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788579||71467|
NCT01788592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-02|Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)|Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice||Asan Medical Center|No|Completed|January 2003|October 2013|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5097|||Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients amenable to percutaneous coronary intervention with drug eluting        stents|December 2014|December 8, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01788592|1 Year|71466|
NCT01803789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2-KiWI|Single Versus Double Kirschner Wires for Intramedullary Fixation of Metacarpal V Fractures|Single Versus Double Kirschner Wires for Intramedullary Fixation of Metacarpal V Fractures|1-2-KiWI|University Medicine Greifswald|No|Recruiting|May 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803789||70303|
NCT01804296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003248 Part 2|rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2|A Randomized, Double-Blinded, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents||Mayo Clinic|Yes|Enrolling by invitation|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|21 Years|No|||February 2015|February 9, 2015|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804296||70264|
NCT01800344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0392-A|The Effect of a New Supraglottic Airway With Built-in Cuff Pressure Indicator|The Effect of a New Supraglottic Airway With Built-in Cuff Pressure Indicator on Postoperative Pharyngolaryngeal Adverse Events: A Prospective, Randomized Trial||University Health Network, Toronto|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|170|||Both|18 Years|65 Years|No|||February 2013|February 25, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01800344||70566|
NCT01800578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1044/2001|Awareness During Blended Anaesthesia|Relationships Between Bispectral Index (BIS), Implicit Memory Dream Recall and MAC in Blended Anaesthesia||Catholic University of the Sacred Heart|No|Completed|September 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|70 Years|No|Probability Sample|patients undergoing elective major abdominal surgery|February 2013|February 25, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01800578||70548|
NCT01800838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2411|Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma|Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures||Case Comprehensive Cancer Center|Yes|Completed|April 2013|May 2015|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01800838||70528|
NCT01801072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00064523|Seizure Prophylaxis in Aneurysm Repair|Seizure Prophylaxis in Aneurysm Repair|SPAR|University of Michigan|No|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801072||70510|
NCT01801410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4001|Induction With Foley OR Misoprostol (INFORM) Study|Induction of Labour in Pre-eclamptic Women: a Randomised Trial Comparing the Foley Balloon Catheter With Oral Misoprostol|INFORM|University of Liverpool|Yes|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Female|18 Years|N/A|No|||December 2015|December 11, 2015|February 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01801410||70485|
NCT01801969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hovedtraume|Return to Work and QOL Following TBI. Impact of Rehabilitation Service.|Return to Work and QOL Following TBI. Impact of Rehabilitation Service.||University of Aarhus|No|Active, not recruiting|February 2013|December 2016|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|653|||Both|18 Years|64 Years|No|Non-Probability Sample|Individuals suffering from severe TBI (GCS<9) from the Danish Head Trauma Database|March 2016|March 17, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01801969||70442|
NCT01801982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481283|A Non-Interventional Follow Up Study For Subjects Who Received Sildenafil for Persistent Pulmonary Hypertension of the Newborn (PPHN)|A Follow Up Investigation For Patients Completing Study A1481276 To Investigate Developmental Progress 12 And 24 Months Following Completion Of Sildenafil Treatment||Pfizer|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|1|||Both|N/A|1 Year|No|Non-Probability Sample|Pediatric patients who took part in study A1481276 following PPHN treatment with IV        sildenafil|December 2014|December 2, 2014|January 8, 2013|No|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01801982||70441|Results at Month 24 were not reported as the participant lost to follow-up after Month 12.
NCT01801995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA190313|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2013|||||N/A|N/A|N/A||||||||||||||December 8, 2014|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801995||70440|
NCT01802216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A119016|Kidney and Periodontal Disease Study|Kidney and Periodontal Disease Study|KAPD|University of California, San Francisco|Yes|Enrolling by invitation|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|51|||Both|20 Years|75 Years|No|||May 2015|May 14, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01802216||70423|
NCT01802827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARKAR236|Ventilator Associated Tracheobronchitis in the First 14 Days in ICU|||University of Thessaly|Yes|Completed|June 2009|June 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|236|Samples Without DNA|blood, sputum|Both|18 Years|85 Years|No|Non-Probability Sample|ICU patients ventilated > 48hours|February 2013|February 28, 2013|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01802827||70376|
NCT01802476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481015|A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)|A Phase 1, Single Dose, Fixed Sequence, 2-Period Cross-Over Absolute Oral Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of PD-0332991||Pfizer|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|February 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01802476||70403|
NCT01802489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amiloride 02|Amiloride Clinical Trial In Optic Neuritis|A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis|ACTION|University of Oxford|Yes|Active, not recruiting|February 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|55 Years|No|||March 2013|February 3, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802489||70402|
NCT01789450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPE|Nipple-Areola Complex Sensitivity After the Section of Periareolar Dermis in Breast Reduction|||Universidade Federal de Pernambuco|Yes|Not yet recruiting|June 2013|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789450||71400|
NCT01789723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-FUS-12-102|Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn|An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (Pralatrexate)||Spectrum Pharmaceuticals, Inc|No|Withdrawn|March 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789723||71379|
NCT01789736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG286-CS202|A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days|A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components||Aerie Pharmaceuticals|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|234|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|February 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789736||71378|
NCT01789983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1226|Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy|Feasibility of an Evidence-based Walking Program in a Sample of Cancer Patients >60 Years of Age Undergoing Cytotoxic Chemotherapy|WWE|UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|October 2012|December 2017|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|29|Samples Without DNA|Whole Blood Sample|Both|60 Years|N/A|No|Non-Probability Sample|Colon, lung and breast cancer patients age 60 and above who are beginning chemotherapy or        chemoradiation treatment.|October 2015|October 29, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789983||71359|
NCT01790269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKcells Gilenya®-treated MS|Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod|Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial||Charite University, Berlin, Germany|No|Recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|64 Years|No|Non-Probability Sample|Definite diagnosis of Relapsing-Remitting Multiple Sclerosis according to the 2010 revised        McDonald criteria (Polman et al., 2011)|January 2016|January 20, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790269||71337|
NCT01790282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2 luteal support in ICSI|Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT|Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial||Mansoura Integrated Fertility Center|Yes|Not yet recruiting|March 2013|December 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|39 Years|No|||February 2013|February 12, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790282||71336|
NCT01802970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-099|Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients|Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients||Baylor Research Institute|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802970||70365|
NCT01802983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013670808|The Prognostic Assessment of Extubation in Aged Patients With Multiple Organ Dysfunction Syndrome|Key Technology Research of the Comprehensive Treatment of Multiple Organ Dysfunction Syndrome||Chinese PLA General Hospital|Yes|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1|||Both|60 Years|N/A|No|Probability Sample|All subjects were selected from among inpatients who were hospitalized between Jan 2009        and May 2013 in the Respiratory Intensive Care Unit(RICU),Surgical Intensive Care        Unit(SICU) and Emergency Intensive Care Unit(EICU).|February 2013|March 1, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802983||70364|
NCT01803490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0076-12-NHR|Bacterial Colonization of Suction Drains Following Spine Surgery|Bacterial Colonization of Suction Drains Following Spine Surgery||Western Galilee Hospital-Nahariya|No|Recruiting|January 2013|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing elective or emergent spine surgery in the normal course of activity at        the Western Galilee Hospital spine surgery unit.|December 2015|December 9, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01803490||70325|
NCT01803776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANIC|Physical Activity and Nutrition in Children Study|Physical Activity and Diet Intervention Study to Improve Health and Wellbeing of Children|PANIC|University of Eastern Finland|No|Active, not recruiting|October 2007|November 2022|Anticipated|November 2022|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|512|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01803776||70304|
NCT01804062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0394|Respiration Rate V2.0 in Healthy Volunteers|Evaluation of Respiration Rate Parameters in Healthy Volunteers Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0||Medtronic - MITG|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer subjects with no significant medical problems|July 2015|July 14, 2015|February 20, 2013||No||No|July 14, 2015|https://clinicaltrials.gov/show/NCT01804062||70282|
NCT01804335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0710|CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)|Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects With Early Stage Cutaneous T-Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|February 2013|||March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|March 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804335||70261|
NCT01804049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-019-12S|Metformin and Muscle in Insulin-resistant Older Veterans|Metformin and Muscle in Insulin-resistant Older Veterans|M&M|VA Office of Research and Development|Yes|Active, not recruiting|April 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|120|||Both|65 Years|N/A|No|||February 2016|February 24, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01804049||70283|
NCT01804309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FANTON-Ebc|Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer|Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer||National Institute of Oncology, Hungary|Yes|Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|||Female|18 Years|N/A|No|Non-Probability Sample|Clinical stage T1-2(≤ 5cm)N0M0 primary unilateral invasive breast cancer patients|October 2015|October 5, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804309||70263|
NCT01804322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM77RW2S|Standardized Educational Plan for Epilepsy Patients With Comorbidities|Comprehensive Information Imparted to Patients With Epilepsy and Comorbidity and Decreased Prevalence of Adverse Treatment Effects. The EDU-COM Study.|EDU-COM|San Gerardo Hospital|Yes|Completed|February 2009|September 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804322||70262|
NCT01800357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-007|Efficacy and Safety of Mildronate for Acute Ischemic Stroke|Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial||Xijing Hospital|Yes|Recruiting|January 2013|August 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||January 2013|February 25, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800357||70565|
NCT01800591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817128|UPHS Weight Loss Study|UPHS Weight Loss Study: Evaluating Methods to Use Health Benefits Design to Encourage Employee Weight Loss||University of Pennsylvania|No|Completed|April 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|4||Actual|201|||Both|18 Years|70 Years|No|||December 2013|May 4, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01800591||70547|
NCT01801696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC24945(1)|Parent-delivered Massage for Children With Autism|Phase 2 Study of the Parent-delivered Massage Treatment Protocol for Children With Autism||Western Oregon University|No|Active, not recruiting|September 2012|February 2016|Anticipated|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|2 Years|5 Years|No|||December 2015|December 8, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01801696||70463|
NCT01802229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002|Prevention of Umbilical Port-site Hernia After Laparoscopic Cholecystectomy Using a Prosthetic Mesh Versus Simple Suture|||Hospital General Universitario Elche||Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|106|||Both|18 Years|90 Years|No|||February 2013|February 28, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802229||70422|
NCT01802502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-201302.01|Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation|Explorative PK Study Comparing 600 mg Rifampicin i.v. With 750 mg and 900 mg Rifampicin Oral in Tuberculous Meningitis Patients|REMOVER|Universitas Padjadjaran|Yes|Completed|June 2013|April 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||June 2014|June 15, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802502||70401|
NCT01802801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP12122007|Intra- and Interobserver Agreement in the Assessment of Human Embryos|Intra-and Inter-observer Agreement in the Morphological Assessment of Human Embryos||University Hospital, Gasthuisberg||Completed|December 2007|August 2009|Actual|July 2009|Actual|N/A|Observational|N/A||1|Actual|50|||Both|N/A|3 Days|Accepts Healthy Volunteers|Probability Sample|embryos of IVF/ICSI patients|February 2013|February 28, 2013|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01802801||70378|
NCT01802814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IntReALL SR 2010|International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010|International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group||University Hospital of Berlin|Yes|Recruiting|May 2014|||April 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1242|||Both|N/A|17 Years|No|||August 2015|August 25, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01802814||70377|
NCT01802840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01|Soy Fiber Improves Weight Loss and Lipid Profile|Soy Fiber Improves Weight Loss And Lipid Profile In Overweight And Obese Adults: A Randomized Controlled Trial||Zhejiang University|Yes|Completed|March 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|39|||Both|19 Years|39 Years|No|||February 2013|February 28, 2013|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01802840||70375|
NCT01803087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1104-PR-0062|Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients|A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.|ADO pMDI|Chiesi Farmaceutici S.p.A.|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|12 Years|18 Years|No|||March 2013|March 1, 2013|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01803087||70356|
NCT01803360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NERI-OA-2013|Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.|A Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy of Neridronate 100 mg -4 i.v. Infusions- in Patients With Painful Osteoarthritis of the Knee With Bone Marrow Lesions.||ASST Gaetano Pini-CTO||Recruiting|March 2013|September 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803360||70335|
NCT01790308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13450149260|Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function|Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients||Sun Yat-sen University|Yes|Enrolling by invitation|February 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||February 2013|February 11, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01790308||71334|
NCT01790581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCC12-09-16|Balance Training vs. Balance Training w/ STARS|Balance Training vs. Balance Training w/ STARS||University of North Carolina, Charlotte|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|35 Years|No|||December 2014|December 23, 2014|February 8, 2013||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01790581||71313|
NCT01789996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.089|The Six Minute Walk Test: Influence of Patient Effort on Results and Interpretation|Alternative Instruction in Six Minute Walk Test|fast vs far|Inova Health Care Services|No|Recruiting|June 2010|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|90 Years|No|||March 2015|March 23, 2015|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01789996||71358|
NCT01790009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAV-AGE01|Influence of Age on the Absorption and Metabolism of Cocoa Flavanols|Influence of Age on the Absorption and Metabolism of Cocoa Flavanols||University of Reading|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790009||71357|
NCT01790295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1809|Ruxolitinib Prior to Transplant in Patients With Myelofibrosis|Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|February 2013|February 2021|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|70 Years|No|||October 2014|October 21, 2014|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790295||71335|
NCT01803503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR01/08/13|Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors|Phase II Randomized Study of Docetaxel With or Without Low-dose, Short Course Sunitinib in the Treatment of Advanced Solid Tumors||National University Hospital, Singapore|No|Recruiting|May 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||June 2015|June 17, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803503||70324|
NCT01803516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-013|QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser|Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser||Memorial Sloan Kettering Cancer Center||Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the Dermatology Division and/or Radiation Oncology, Plastic and        Reconstructive Surgery Department(s) and the Breast Cancer Survivorship Program will be        identified by the Nurse Practitioners of the survivorship program or by clinicians in        these departments for the study.|February 2016|February 11, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803516||70323|
NCT01800383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096987-01A1|Cerebral GABA and Fear Conditioning in PTSD|||Mclean Hospital||Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|93|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be between the ages of 20 and 50 years. These will include 31 subjects        meeting DSM-IV criteria for PTSD, 31 trauma-exposed healthy subjects, and 31 healthy        comparison (HC) subjects without any trauma exposure.|March 2016|March 14, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01800383||70563|
NCT01800903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP235|Safety and Performance of a New Coating for Urinary Intermittent Catheters|Clinical Study Investigating Safety and Performance of a New Coating for Urinary Intermittent Catheters in Healthy Volunteers||Coloplast A/S|Yes|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|36|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 27, 2014|February 22, 2013||No||No|November 29, 2013|https://clinicaltrials.gov/show/NCT01800903||70523|
NCT01804348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-32.2-1|AL-SENSE 1-Step - Determination of Product Specificity|AL-SENSE 1-Step - Determination of Product Specificity|ROM|Common Sense|No|Not yet recruiting|April 2013|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Anticipated|150|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|March 4, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01804348||70260|
NCT01800370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007753|The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men|The Effect of Mixed Exercise and Metabolic Stress Upon Pituitary Secretion in Relationship to Age in Healthy Men: a Pilot Study||Mayo Clinic|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|40|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01800370||70564|
NCT01800604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43605-B|Power Over Pain (POP) Study|Psychological Treatment of Disability-Related Pain: Efficacy and Mechanisms|POP|University of Washington|No|Recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01800604||70546|
NCT01800877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVATION|Optimal Vasopressor Titration|Optimal Vasopressor Titration Pilot Randomized Controlled Trial|OVATION|Clinical Evaluation Research Unit at Kingston General Hospital|Yes|Completed|April 2013|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|17 Years|N/A|No|||April 2015|April 14, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800877||70525|
NCT01801098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-interval prior TAVI|Electrophysiologic HV-interval as a Predicor for Permanent Pacemaker Implantation After TAVI|Electrophysiologic HV-interval as a Predicor for Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation With a Self-expanding Bioprosthesis||Heinrich-Heine University, Duesseldorf|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic aortic valve stenosis screened for TAVI will be enrolled in this        study.|November 2013|November 12, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01801098||70508|
NCT01801111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28673|A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment|AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT||Hoffmann-La Roche||Active, not recruiting|June 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801111||70507|
NCT01802242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5015-C|Tumor TARGET Prostate Cancer|Tumor Targeted Radiotherapy for Patients With Localized Prostate Cancer||University Health Network, Toronto|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01802242||70421|
NCT01802515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010407|A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment|Atomoxetine Treatment for Opioid Maintained Cocaine Users||Yale University|Yes|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|65 Years|No|||December 2014|December 15, 2014|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802515||70400|
NCT01803100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036470|Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms|Study of the Temporal Profile and Bi-directional Transmission of Microorganisms Between Patients and Environmental Surfaces.||Duke University|No|Completed|January 2013|October 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|Samples Without DNA|Swabs from nares, oropharynx, axillae, peri-rectal. Fecal specimens|Both|18 Years|N/A|No|Non-Probability Sample|The cohort will be selected from hospitalized inpatients who are admitted into        freshly-cleaned patient rooms and provides consent to participate in this study.|October 2015|October 23, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803100||70355|
NCT01803113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0144-01|Sofia hCG FIA Field Study|Sofia hCG FIA Field Study||Quidel Corporation|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|975|Samples Without DNA|Leftover urine specimens may be retained to be used for further product testing.|Female|N/A|N/A|No|Non-Probability Sample|Any female of childbearing potential being screened for pregnancy|March 2013|March 11, 2013|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803113||70354|
NCT01803373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100987|A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants|A Phase I, Open-label, Randomized, 3-way Crossover Study in 3 Panels of Healthy, Adult Subjects to Assess the Relative Bioavailability of TMC207 Following Single-dose Administration of Two Pediatric Formulations Using a 100 mg Tablet Formulation as the Reference, With and Without Food.||Janssen Infectious Diseases BVBA|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803373||70334|
NCT01803607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-076|Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)|A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate||Merck Sharp & Dohme Corp.|Yes|Terminated|March 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Female|60 Years|N/A|No|||December 2014|December 30, 2014|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803607||70316|
NCT01790880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74374|Enhancing Written Communication in Persons With Aphasia|Enhancing Written Communication in Persons With Aphasia: A Clinical Trial||Rehabilitation Institute of Chicago|No|Active, not recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790880||71290|
NCT01791114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-193|The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans|||The University of Texas Medical Branch, Galveston|No|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791114||71272|
NCT01791127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G110221|Safety and Performance Study of the Siello S Pacing Lead||SIELLO|Biotronik, Inc.|Yes|Active, not recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1800|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigators' general patient        population according to the inclusion and exclusion criteria.|January 2016|January 5, 2016|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791127|5 Years|71271|
NCT01790854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLESS Study|BLeeding Events and Maintenance DoSe of PraSugrel|Bless Study (BLeeding Events and Maintenance DoSe of PraSugrel)|BLESS|Careggi Hospital|Yes|Recruiting|November 2012|October 2014|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|74 Years|No|||February 2013|February 12, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01790854||71292|
NCT01790867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2013|||||N/A|N/A|N/A||||||||||||||December 5, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790867||71291|
NCT01791088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1169|Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Pharmacodynamic Study of Sirolimus in Older Children and Adults With Advanced Solid Malignancies||University of Chicago|No|Active, not recruiting|June 2012|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Years|N/A|No|||July 2015|July 16, 2015|February 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791088||71274|
NCT01791101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP0511|Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.|Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.|ITP0511|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|September 2013|November 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791101||71273|
NCT01803243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB-Spine-1315-2|Spine Biomechanics During Gait Following Lower Extremity Treatment in Different Patient Groups|The Measurement of Spine Dynamics During Gait for the Quantification of Intervention Outcomes in Patients With Different Pathologies||University Children's Hospital Basel|No|Recruiting|July 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|45|||Both|10 Years|18 Years|No|||March 2016|March 24, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803243||70344|
NCT01803256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB-Spine-1315-1|Possibilities and Limitations of a New Method for the Measurement of Spine Dynamics During Gait|The Measurement of Spine Dynamics During Gait for the Quantification of Intervention Outcomes in Patients With Different Pathologies||University Children's Hospital Basel|No|Completed|April 2013|January 2016|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|30|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Scoliosis patients: Patients attending the Orthopedic Department at UKBB for scoliosis        treatment.        Healthy controls: Middle and high school students in the Basel area.|March 2016|March 24, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803256||70343|
NCT01803802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 HD051676|Effects of Early Abuse on Adult Intimate Relationships|Effects of Early Abuse on Adult Intimate Relationships||University of Texas at Austin|No|Completed|April 2005|August 2014|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|148|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01803802||70302|
NCT01803815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA - CEDOC/FCT|Evaluation of Antihypertensive Drugs in OSA Patients|Evaluation of Antihypertensive Drugs in Patients With Obstructive Sleep Apnea|ADOSA|Universidade Nova de Lisboa|No|Completed|April 2010|April 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|369|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients, male and women, aged above 18 years, that attended a first visit at        CHLN Hospital Sleep Unit, located in Lisbon, were enrolled.|October 2014|October 31, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803815||70301|
NCT01801137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/23|The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium|A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy|AFINIVEST|Hopital Foch||Recruiting|June 2011|||January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||July 2012|February 26, 2013|February 12, 2013||||No||https://clinicaltrials.gov/show/NCT01801137||70505|
NCT01800617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT303-2|A Study of T3 Therapy in Patients With Hypothyroidism|Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients||Ipe, LLC|Yes|Completed|March 2013|||July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||July 2014|July 1, 2014|February 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800617||70545|
NCT01800890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP234|Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy|Investigating the Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy||Coloplast A/S|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|31|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|February 22, 2013||No||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01800890||70524|
NCT01801124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B702|EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair|Evaluation of the Safety and Efficacy of EXPAREL® When Infiltrated Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Unilateral Abdominal Hernia Repair|702|Pacira Pharmaceuticals, Inc|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|75 Years|No|||July 2013|July 2, 2013|February 26, 2013|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT01801124||70506|
NCT01801423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NS080639-01|Sickle Cell Disease - Stroke Prevention in Nigeria Trial|Primary Prevention of Strokes in Nigerian Children With Sickle Cell Disease Affiliated Titles: Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial|SPIN|Vanderbilt University|Yes|Active, not recruiting|February 2013|September 2020|Anticipated|September 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|5 Years|12 Years|No|||October 2015|October 22, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01801423||70484|
NCT01801436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013843|A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma|A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan||Johnson & Johnson Taiwan Ltd|No|Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||March 2013|March 28, 2013|February 27, 2013|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT01801436||70483|
NCT01802255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECSEVO-LT-011|Sevoflurane- Safety in Long-term Sedation Procedures|Study of the Safety of Administration of Sevoflurane for Long-term Critically Ill Patients Sedation Undergoing Mechanical Ventilation. Prospective, Controlled, Randomized, Multicenter, Clinical Trial.||Fundación para la Investigación del Hospital Clínico de Valencia|Yes|Recruiting|March 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|February 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802255||70420|
NCT01802853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28438|A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers|Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability and Pharmacokinetics of RO6811135, Following Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Subjects.||Hoffmann-La Roche||Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01802853||70374|
NCT01803646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-12-01|AM-101 in the Treatment of Acute Tinnitus 2|Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2|TACTT2|Auris Medical, Inc.|No|Active, not recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803646||70314|
NCT01803932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterveneDV-CI|Evaluation of a Male-focused Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting|Evaluation of a Male-focused Primary Prevention Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting: A Cluster Randomized Controlled Trial in Cote d'Ivoire||London School of Hygiene and Tropical Medicine|No|Completed|September 2008|March 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|601|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 1, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01803932||70292|
NCT01804153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULPURO-2010-01|Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)|Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Mesenchymal Stem Cells Use Derived From Adipose Tissue (ASC) for the Local Feminine Stress Urinary Incontinence|HULPURO|Instituto de Investigación Hospital Universitario La Paz||Recruiting|September 2012|April 2014|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2013|March 1, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01804153||70275|
NCT01791140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25630|BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer|Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)||Hoffmann-La Roche||Completed|March 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|65 Years|N/A|No|Probability Sample|Elderly patients (</= 65 years of age) with newly diagnosed metastatic colorectal cancer        starting first-line treatment with Avastin in combination with fluoropyrimidine-based        chemotherapy|March 2016|March 1, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791140||71270|
NCT01791153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA28119|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis|A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS||Hoffmann-La Roche||Active, not recruiting|July 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|251|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791153||71269|
NCT01791465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121342|Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults|Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy||Vanderbilt University|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791465||71245|
NCT01791452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042-12-ZIV|Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study|||Ziv Hospital||Not yet recruiting||||February 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|80 Years|No|Probability Sample|400 subjects will be enrolled and informed consent obtained. After clinical evaluation,        subjects will undergo liver ultrasound, non-invasive liver elastography (Fibroscan) and        standard biochemical evaluation including glucose, insulin, TG, HDL, LDL, leptin,        adiponectin and TNF-alpha. They will then be divided into 2 groups: NAFLD, and NAFLD with        fibrosis (NASH). In addition a cohort of healthy volunteers will also be studied. LAL        activity in dry blood spots (DBS) will be measured using the substrate        4-methylumbelliferyl palmitate. LAL activity will be measured by measuring total lipase        activity and lipase activity in the presence of Lalistat2.|February 2013|February 13, 2013|February 10, 2013||||No||https://clinicaltrials.gov/show/NCT01791452||71246|
NCT01787227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDP-736-272|A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel|A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection||Luminex Molecular Diagnostics|No|Completed|January 2015|||September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1500|Samples With DNA|Nasopharyngeal swab|Both|N/A|N/A|No|Probability Sample|Clinical specimens collected from patients with clinical signs and symptoms of respiratory        tract infection who are either hospitalized, admitted to emergency departments or visiting        outpatient clinics.|March 2016|March 1, 2016|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787227||71569|
NCT01787240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001241|Neurobiological Bases of Placebo Response in Major Depressive Disorder|Neurobiological Bases of Placebo Response in Major Depressive Disorder||Massachusetts General Hospital|Yes|Recruiting|September 2014|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||April 2015|April 6, 2015|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01787240||71568|
NCT01803009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210009869|Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool|Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool|CRC-RAT|Indiana University|No|Completed|November 2012|October 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|50 Years|75 Years|No|||April 2014|April 1, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01803009||70362|
NCT01803022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tropique|Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer|Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer||LEO Pharma|No|Completed|November 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|419|||Both|18 Years|N/A|No|Probability Sample|Men or women aged 18 years or more with on-going cancer and recent diagnosis of Venous        Thromboembolism, treated with Low Molecular Weight Heparin before entry into the study|September 2013|September 18, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803022||70361|
NCT01803282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-296-0101|Safety and Tolerability Study in Solid Tumors|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors||Gilead Sciences|No|Recruiting|March 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|313|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01803282||70341|
NCT01803529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066-03|Deep Friction Massage for Intercostal Pain in Patients With Heart Disease|Standard Heat-pack With or Without Deep Friction Massage for Intercostal Pain in Patients With Heart Disease||St. Olavs Hospital|No|Completed|October 2003|October 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||January 2016|January 18, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803529||70322|
NCT01804361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT-2012-DH-HS-01|Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes|Efficacy and Safety Study of Haporine-S in Subjects With Moderate to Severe Dry Eye, A Multicenter, Investigator(Assessor)Blind, Parallel Design, Non-inferiority Phase III Trial||DH Bio Co., Ltd.|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|20 Years|N/A|No|||July 2015|July 20, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01804361||70259|
NCT01800643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Busulfan-2013|Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation|Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation||Hospital Israelita Albert Einstein|Yes|Recruiting|March 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||December 2014|December 2, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800643||70543|
NCT01800682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018658|A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants|A Single-Dose, Open-Label, Randomized, Crossover Dose-Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 25, 50, and 100 mg ULTRAM ER Under Fasted Conditions in Healthy Adult Subjects||Janssen Research & Development, LLC|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 26, 2013|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01800682||70540|
NCT01801150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-DM-SAHS-2012|CPAP in Diabetes Type 2 Patients With Sleep Apnea|Effect Of Nasal CPAP On Glycemic Control In Patients With Poorly Controlled Type 2 Diabetes And Sleep Apnea-Hypopnea Syndrome|DM-SAHS|Hospital Universitario La Paz|No|Completed|October 2011|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01801150||70504|
NCT01801449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130086|Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)|A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|3 Months|N/A|No|||May 2015|December 10, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801449||70482|
NCT01801709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-09|Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy|A Phase I/II, Open Labeled, Monocentric Study of Direct Intracranial Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human ARSA cDNA to Children With Metachromatic Leukodystrophy.|TG-MLD|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|March 2013|April 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|6 Months|5 Years|No|||January 2014|January 28, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01801709||70462|
NCT01802008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-25203|Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times|Comparison of Adenoma Detection and Miss Rates at Colonoscopy Associated With a Six-minute Withdrawal Time vs a Three-minute Withdrawal Time||Stanford University|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802008||70439|
NCT01802528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0924|Clinical Effectiveness of Obturator Externus Muscle Injection in Chronic Pelvic Pain Patients|||Yonsei University|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|23|||Both|20 Years|75 Years|No|Non-Probability Sample|The study population was defined as chronic pelvic pain patients with a localized        tenderness on inferolateral side of the pubic tubercle corresponding to obturator foramen        who received OE muscle injection with local anesthetic for their pain treatment.|February 2013|February 27, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802528||70399|
NCT01802541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031217|Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism|Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism||Zhejiang University|Yes|Completed||||February 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|127|||Both|40 Years|70 Years||||February 2013|February 28, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802541||70398|
NCT01803659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6195-2012-01-00-HKI|Effect of Small Daily Doses of B-carotene on Breast Milk Retinol|Effect of Small Daily Doses of B-carotene or Vitamin A on Breast Milk Retinol Concentration in Lactating Filipino Women.||University of California, Davis|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803659||70313|
NCT01803672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102009189|Effectiveness of an Integrated Programme in Promoting the Regular Physical Activity Among Childhood Cancer Survivors|Effectiveness of an Integrated Adventure-Based Training and Health Education Programme in Promoting the Adoption and Maintenance of Regular Physical Activity Among Childhood Cancer Survivors||The University of Hong Kong|Yes|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Both|9 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803672||70312|
NCT01790893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 117497|Treatment for Presumed Ocular Histoplasmosis|Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)|HANDLE|Retina Associates of Kentucky|No|Recruiting|March 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790893||71289|
NCT01790906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-SR-001|Renal Sympathetic Denervation for Patients With Chronic Heart Failure|Safety and Effectiveness Study of Percutaneous Catheter-base Renal Sympathetic Denervation for Patients With Chronic Heart Failure|RSD4CHF|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|January 2013|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 9, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790906||71288|
NCT01790919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH094535-01A1|Improving Depression Outcome by Enhancing Memory for Cognitive Therapy|Improving Depression Outcome by Enhancing Memory for Cognitive Therapy||University of California, Berkeley|Yes|Completed|February 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01790919||71287|
NCT01791166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/49|Immuno-humoral Rejection Markers in Pulmonary Transplant|Humoral Rejection - Diagnostic Markers in Pulmonary Transplant.|RHUM-TP|Hopital Foch||Recruiting|February 2011|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|100|||Both|18 Years|N/A||||October 2010|February 12, 2013|February 12, 2013||||No||https://clinicaltrials.gov/show/NCT01791166||71268|
NCT01791179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042125|Carolina Alcohol and Drug Resources|Carolina Alcohol and Drug Resources|CADRE|Duke University|Yes|Recruiting|February 2013|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|690|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791179||71267|
NCT01791192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2205|Study of FTY720 in Patients With Uveitis|A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis||Novartis|No|Withdrawn|November 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||April 2014|April 15, 2014|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791192||71266|
NCT01787253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-05|Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)|Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)||Örebro University, Sweden|No|Recruiting|November 2010|December 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|125|Samples With DNA|Biopsies and blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from clinic (endoskopimotagningen) at Örebro University        Hospital.|February 2013|February 6, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01787253||71567|
NCT01787578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobetirome-CLIN-006|Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)|A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD)||Oregon Health and Science University|Yes|Withdrawn|April 2013|February 2014|Actual|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|64 Years|No|||February 2014|February 12, 2014|February 6, 2013|No|Yes|revisions to original study protocol underway|No||https://clinicaltrials.gov/show/NCT01787578||71542|
NCT01803269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1726|Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer|A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer||University of Chicago|No|Active, not recruiting|January 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803269||70342|
NCT01803828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOGITO|REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs|Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A|RECOGITO|University of Roma La Sapienza||Recruiting|May 2014|March 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|164|||Both|35 Years|75 Years|No|||July 2014|July 7, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803828||70300|
NCT01804075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1-M-185|Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal|Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS).|NAS|Eastern Maine Medical Center|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|31|||Both|N/A|28 Days|No|||September 2014|September 9, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01804075||70281|
NCT01800656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDL-001|Assessing Endoloop-assisted Polypectomy in Patients With Antiplatelet Therapy|Endoloop-assisted Colorectal Polypectomy or "Ligate and Let go" in Patients With Long-term Antiplatelet Therapy||Hospital Danilo I Cetinje|Yes|Completed|January 2004|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||February 2013|February 27, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800656||70542|
NCT01800409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12NE539|Abdominal Functional Electrical Stimulation Training and Its Effect on Mechanical Insufflation-Exsufflation|Abdominal Functional Electrical Stimulation Training and Its Effect on Mechanical Insufflation-Exsufflation||NHS Greater Glasgow and Clyde|No|Recruiting|February 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|N/A|No|||February 2013|February 27, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01800409||70561|
NCT01801189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H001|Preoperative Pain Control in Gastric Bypass Surgery Patients|A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 300 mg Will Improve Pain Control in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass (Bariatric Surgery)||Legacy Health System|No|Completed|February 2013|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01801189||70501|
NCT01801202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-HS 805nm-12-01|Clinical Evaluation of LightSheer Duet 805nm HS Handpiece|Clinical Evaluation of LightSheer Duet 805nm HS Handpiece||Lumenis Ltd.|No|Completed|February 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|April 28, 2015|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801202||70500|
NCT01800916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP236|Safety and Performance of New 1-piece Ostomy Product|Investigating the Safety and Performance of New 1-piece Ostomy Product Concepts Compared With SenSura 1-piece in Subjects With an Ileostomy||Coloplast A/S|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|65|||Both|18 Years|N/A|No|||April 2014|October 31, 2014|February 22, 2013||No||No|April 27, 2014|https://clinicaltrials.gov/show/NCT01800916||70522|
NCT01801163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0404|A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)|A Phase Ib Study of Stereotactic Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)||Indiana University||Withdrawn|February 2012|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|February 25, 2013|No|Yes|Trial had no patients accrued while open|No||https://clinicaltrials.gov/show/NCT01801163||70503|
NCT01801176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01188-33|Peripheral Primitive Fibromatosis|Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression|WS-RT Fibro|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|May 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801176||70502|
NCT01801462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-162|Simulation-based Ultrasound Training to Improve Patient Comfort and Decrease the Need for Re-examination. A Randomized Trial.|Simulation-based Ultrasound Training to Improve Patient Comfort and Decrease the Need for Re-examination. A Randomized Trial.||Rigshospitalet, Denmark|No|Completed|March 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01801462||70481|
NCT01801722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502008|Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease|Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.|NT-proBNP|Lund University|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|75|||Both|65 Years|N/A|No|Non-Probability Sample|Patients aged 65 years and older with a registered diagnosis of COPD.|February 2013|February 28, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801722||70461|
NCT01802021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1967A3|Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients|Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy|QSYQT|Chang Gung Memorial Hospital|Yes|Recruiting|May 2009|February 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|75 Years|No|||April 2009|February 28, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802021||70438|
NCT01803126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-024|A Proposed Study of Atherosclerotic Plaques in Leg Arteries|A Proposed Study of Atherosclerotic Plaques in Leg Arteries||Southwest Regional Wound Care Center|No|Active, not recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|No|Probability Sample|Subject with vascular disease or diabetes.|May 2015|May 27, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01803126||70353|
NCT01803386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIM-002-2011-4|Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography|Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography||Skulpt, Inc.|Yes|Completed|January 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALS Patients|July 2015|July 21, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803386||70333|
NCT01803399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112166|A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers|A Phase I, Randomized, Partially Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (PDF112166)||GlaxoSmithKline|No|Withdrawn|August 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|February 28, 2013|No|Yes|Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not    seen that changed the risk: benefit profile and led to a termination|No||https://clinicaltrials.gov/show/NCT01803399||70332|
NCT01804179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16447|Colorectal Cancer Awareness, Research, Education and Screening (CARES)|Colorectal Cancer Awareness, Research, Education and Screening (CARES)||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|February 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|514|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804179||70273|
NCT01790620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRAKI 00-2012|Impact of CVVHD With Increased Adsorption Membranes in Septic Acute Kidney Injury|Impact of a Continuous Dialysis Technique Associated With Increased Adsorption Membranes in Severe Septic Patients With Acute Kidney Injury.||Hospital Universitari de Bellvitge|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790620||71310|
NCT01790932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-438|BKM120 For Triple Negative Breast Cancer|A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2013|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790932||71286|
NCT01791205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28552|ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis|A Multi-Center Observational Study on the Use of Biologic Drugs as Monotherapy or Combination With DMARDs in Patients With Rheumatoid Arthritis in Italian Clinical Practice||Hoffmann-La Roche||Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|304|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis who have received at least one cycle of therapy with a        biologic drug in monotherapy or in combination with DMARDs|November 2015|November 2, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791205||71265|
NCT01791504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-100-0085|Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu® Surgical Adhesive|A Clinical Investigation for a Randomized Study Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques Plus TissuGlu® and No Drains (Test) During Abdominoplasty||Cohera Medical, Inc.|No|Completed|March 2013|November 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 3, 2013|December 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791504||71242|
NCT01791517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5230|Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions|Clinical and Laboratory Evaluation of Three Contact Lens Materials With Four Contact Lens Solutions||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|269|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791517||71241|
NCT01791478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 12101|BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer|A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|April 2013|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||July 2015|July 31, 2015|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791478||71244|
NCT01791491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-144|Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients|A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant||Bristol-Myers Squibb|Yes|Recruiting|May 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|12 Years|17 Years|No|||January 2016|February 25, 2016|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791491||71243|
NCT01787266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGQ2013|Symptoms and Function During and After Pregnancy|Symptoms and Function During and After Pregnancy||Oslo University Hospital|No|Recruiting|January 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women in week 32 - 36|February 2013|February 7, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01787266||71566|
NCT01787279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19522|An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B|Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-negative Chronic Hepatitis B||Hoffmann-La Roche||Completed|January 2006|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787279||71565|
NCT01787292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0956-W|Effects of Exercise Intervention on Aging-related Motor Decline|Effects of Exercise Intervention on Aging-related Motor Decline (AGING)|EIAMD|VA Office of Research and Development|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01787292||71564|
NCT01803841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOTRI|Korea Transradial Coronary Intervention Prospective Registry (KOTRI)|Korea Transradial Coronary Intervention Prospective Registry (KOTRI)|KOTRI|Yonsei University|No|Completed|February 2013|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7300|||Both|19 Years|N/A|No|||July 2015|July 14, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01803841||70299|
NCT01804374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERIO|Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma|A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma|SERIO|Italian Sarcoma Group|Yes|Completed|June 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804374||70258|
NCT01800396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41768.081.12|Milk Ingredients and Resistance Against E-coli-induced GastroEnteritis (MIRAGE)|A Randomized, Placebo-controlled, Double Blind Volunteer Study Into the Effect of Milk Ingredients on Gastroenteritis Caused by an Attenuated E.Coli.|MIRAGE|NIZO Food Research|Yes|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01800396||70562|
NCT01800630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-12-001|Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas|An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas||InnoPharmax Inc.|No|Active, not recruiting|April 2013|March 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|37|||Both|20 Years|N/A|No|||January 2016|January 20, 2016|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01800630||70544|
NCT01800669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS020640-01A1|Computer-Supported Management of Medical-Legal Issues Impacting Child Health|Computer-Supported Management of Medical-Legal Issues Impacting Child Health|CHICA-MLP|Indiana University|No|Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|N/A|36 Months|No|||March 2016|March 1, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800669||70541|
NCT01801748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|490/2555(EC3)|The Natural History of Wheat Hypersensitivity in Thai Children|The Natural History of Wheat Hypersensitivity in Thai Children||Mahidol University|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Both|1 Year|15 Years|No|||April 2015|April 7, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801748||70459|
NCT01801761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-3555b|A Simplified Questionnaire to Detect OSA in COPD Patients|A Simplified Screening Questionnaire to Detect the Existence of Severe Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease Patients||Chang Gung Memorial Hospital|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|40 Years|90 Years|No|Probability Sample|develop group : previous COPD cohort study validation group : consecutive COPD patient        from outpatients clinics|December 2012|February 23, 2016|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01801761||70458|
NCT01801475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD070795-01A1|How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women|Prevention of Neonatal Abstinence Syndrome|Zofran_PK|Stanford University|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|100|||Female|18 Years|45 Years|No|||May 2015|May 28, 2015|January 28, 2013||No||No|January 23, 2015|https://clinicaltrials.gov/show/NCT01801475||70480|Since the neonate was not given a dose of study medication (ondansetron) directly it was not possible to estimate the volume of distribution in the neonate.
NCT01801735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL3-12-03|Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip|A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix™ Capsules in Subjects With Osteoarthritis of the Knee or Hip||Iroko Pharmaceuticals, LLC|No|Completed|March 2013|August 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|600|||Both|40 Years|N/A|No|||April 2015|April 24, 2015|February 21, 2013|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01801735||70460|
NCT01802034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012648|Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)|Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)|RENAL AID|The Rogosin Institute|No|Recruiting|February 2013|August 2022|Anticipated|August 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|Blood, urine, tissue|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from The Rogosin Institute, NewYork Presbyterian Hospital and        affiliated institutions.|February 2016|February 26, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01802034|10 Years|70437|
NCT01802268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E8-3328|Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients|Outcomes of Planned Conversion From Tacrolimus to Sirolimus-based Immunosuppressive Regimen in de Novo Kidney Transplant Recipients||Hospital do Rim e Hipertensão|Yes|Completed|February 2008|October 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01802268||70419|
NCT01802281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN-24P01|Study of Uterine Prolapse Procedures - Randomized Trial|A Randomized Trial of Vaginal Surgery for Uterovaginal Prolapse: Vaginal Hysterectomy With Native Tissue Vault Suspension vs. Mesh Hysteropexy Suspension|SUPeR|NICHD Pelvic Floor Disorders Network|Yes|Active, not recruiting|April 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|180|||Female|21 Years|N/A|No|||July 2015|July 14, 2015|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802281||70418|
NCT01803139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMRT-02|Long Term Results of the Canadian Breast IMRT Study|Long Term Outcomes of a Multicentre Controlled Clinical Trial of Breast Irradiation Using Intensity-Modulated Radiation Therapy|IMRT-FU|Sunnybrook Health Sciences Centre|No|Not yet recruiting|April 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|358|||Female|20 Years|N/A|No|||March 2013|March 1, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01803139||70352|
NCT01803152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110462|Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma|A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine Pre-Treatment For Children And Adults With Sarcoma||University of Miami|Yes|Recruiting|July 2012|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|1 Year|N/A|No|||February 2016|February 4, 2016|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803152||70351|
NCT01804192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20080514001|Is Acupoints Sensation Necessary for Acu-TENS to Elicit Physiological Changes in Healthy Subjects?|Is Acupoints Sensation Necessary for Acu-TENS to Elicit Physiological Changes in Healthy Subjects?|Acu-TENS|The Hong Kong Polytechnic University|Yes|Recruiting|February 2013|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|36|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 2, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01804192||70272|
NCT01790633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 38B|Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests|Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests As a Tool for Screening and Access to Care Among At-Risk Populations|OPTISCREEN-III|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Yes|Active, not recruiting|March 2013|October 2013|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790633||71309|
NCT01790646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCCB 2012-02|Learning and Performance of Glidescope® Videolaryngoscope Intubation|Learning and Performance of Glidescope® Videolaryngoscope Intubation in Anesthesiologists Trained in Direct Laryngoscopy: a "in Vivo" Study||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Yes|Recruiting|September 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|16 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|elective neurosurgical patients from a tertiary neurosurgical centre|February 2013|February 12, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01790646||71308|
NCT01791218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101071|Surgical Pulmonary Vein Isolation Efficiency Study|Concomitant Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation Patients Undergoing Elective Coronary Artery Bypass Grafting and Aortic Valve Replacement for Aortic Stenosis: a Prospective Study|FIN-PVI|Kuopio University Hospital|Yes|Terminated|November 2012|September 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|February 12, 2013||No|Not enough patients for study arms|No||https://clinicaltrials.gov/show/NCT01791218||71264|
NCT01791530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVeM|International Multicenter Study of Ventilator Associated Tracheobronchitis.|International Multicenter Study of Ventilator Associated Tracheobronchitis.|TAVeM|Corporacion Parc Tauli|No|Completed|September 2013|September 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|||Both|18 Years|N/A|No|Probability Sample|10-20 consecutive admissions with a predictive duration of intubation and mechanical        ventilation > 48h.|August 2015|August 4, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791530||71240|
NCT01791543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000304|Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia|Early Feasibility Study of Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia That Has Failed Conventional Radiofrequency Ablation||Brigham and Women's Hospital|No|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791543||71239|
NCT01787305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210010962|Pilot Study of Gut Commensals in Antiphospholipid Syndrome|Longitudinal Study of the Fecal Microbiome in Persistently Anti-β2 Glycoprotein-I Positive Individuals and Patients With Antiphospholipid Syndrome||Yale University|Yes|Active, not recruiting|February 2013|January 2017|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|16|Samples With DNA|Whole Blood Serum Stool DNA?|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Yale New Haven Hospital and affiliated outpatient clinics Hospital for Special Surgery and        affiliated outpatient clinics|March 2016|March 14, 2016|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01787305||71563|
NCT01787604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR|Study of Aortic Root Reimplantation Procedure|Superiority Trial of Aortic Root Reimplantation Procedure Versus Aortic Valve Reimplantation Procedure|STAR|Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01787604||71540|
NCT01804114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH11-297|Continuous Local Anesthetic Infusion Following Hernia Repair|Continuous Preperitoneal Infusion of Local Anesthetic Via Pain Pump for Laparoscopic Ventral Hernia Repair||NorthShore University HealthSystem Research Institute|Yes|Completed|March 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|19 Years|N/A|No|||November 2015|November 5, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01804114||70278|
NCT01804387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeSLA study|Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study|Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study|TeSLA|Korea University|Yes|Recruiting|May 2011|May 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2013|March 3, 2013|December 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804387||70257|
NCT01800929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP5433|Evaluation of Performance and Usability of N6 in the Paediatric Population|Evaluation of Performance and Usability of N6 in the Paediatric Population||Cochlear, Asia Pacific|No|Recruiting|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01800929||70521|
NCT01801774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si234/2012|Efficacy Comparison Study of Steroids to Control Post-operative Inflammation|Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification||Mahidol University|Yes|Recruiting|May 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801774||70457|
NCT01802047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-SD-0678-12-CTIL|Impact of Different Electric Pumping Modalities on Milk Volume Production in Mothers of Preterm Infants|Milk Volume Production in Mothers of Preterm Infants: Electric Pumping Modalities||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|August 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|250|||Female|18 Years|60 Years|No|||August 2013|August 20, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01802047||70436|
NCT01802294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Griffin39|Sinovuyo Caring Families Project - Pilot Trial|Sinovuyo Caring Families Project - Pilot Randomised Controlled Trial of a Parenting Program to Reduce Child Behavior Problems in Xhosa Children Ages 3 to 8 in South Africa|SCFP|University of Cape Town|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01802294||70417|
NCT01802307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054478|Focal Therapy for Prostate Cancer|Focal Therapy for the Treatment of Organ Confined Prostate Cancer||University of Maryland|Yes|Not yet recruiting||March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|45 Years|N/A|No|||February 2013|February 27, 2013|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802307||70416|
NCT01802554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG031090|Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention|Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention||University of California, San Diego|Yes|Completed|April 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|55 Years|N/A|No|||February 2014|February 20, 2014|February 20, 2013||No||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01802554||70397|
NCT01802567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC008|Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer|A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer||Spectrum Health Hospitals|Yes|Active, not recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|13 Months|N/A|No|||March 2015|March 10, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01802567||70396|
NCT01802866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4429-202|Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride|A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|SEATTLE|Acucela Inc.||Active, not recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|55 Years|N/A|No|||July 2015|July 16, 2015|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802866||70373|
NCT01803711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OmegaDVS|Omega 3 FA Supplements as Augmentation in the Treatment of Depression|A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.||University of Connecticut Health Center|Yes|Terminated|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 28, 2013|Yes|Yes|Lack of recruitment and no resources|No||https://clinicaltrials.gov/show/NCT01803711||70309|
NCT01804205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MgRoc 60|Magnesium Sulphate and Rocuronium in Patients Over 60|Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study||Instituto Nacional de Cancer, Brazil|No|Completed|September 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|64|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 2, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01804205||70271|
NCT01804218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01-BCM-01|Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma|||Invion, Inc.|Yes|Active, not recruiting|March 2013|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2015|October 31, 2015|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804218||70270|
NCT01803945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJFF AVE8112 MAD PD|A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease|A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease||Michael J. Fox Foundation for Parkinson's Research|Yes|Terminated|January 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|35 Years|70 Years|No|||April 2015|October 2, 2015|February 26, 2013|Yes|Yes|First milestone was not met.|No||https://clinicaltrials.gov/show/NCT01803945||70291|
NCT01803958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA trial|Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study|BREAST CANCER WITH LOW RISK OF LOCAL RECURRENCE: PARTIAL AND ACCELERATED RADIATION WITH THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3DCRT) VS. STANDARD RADIOTHERAPY AFTER CONSERVING SURGERY (PHASE III STUDY||Regione Emilia-Romagna|Yes|Recruiting|April 2007|June 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3302|||Female|49 Years|85 Years|No|||November 2014|November 18, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803958||70290|
NCT01800513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGFRSC EMBX 2013|Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure|EVAULATION OF IMPLANTATION AND PREGNANCY AFTER ENDOMETRIAL INJURY VIA ENDOMETRIAL PIPELLE BIOPSY IN THE CYCLE PRIOR TO IVF: A RANDOMIZED, SINGLE-BLINDED, CONTROLLED TRIAL.|EMBX/IVF|Shady Grove Fertility Reproductive Science Center|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|254|||Female|18 Years|37 Years|No|||February 2013|February 25, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01800513||70553|
NCT01790945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVER Study|Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography|Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography|DIVER|Retina Institute of Hawaii|No|Not yet recruiting|February 2013|August 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|(n=500) A large population will need to be screened to find 100-150 patients with diabetic        eye disease|February 2013|February 12, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01790945||71285|
NCT01791556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR# 1591|Clinic-based ART Diagnostic Evaluation|Clinic-based ART Diagnostic Evaluation|CLADE|Walter Reed Army Institute of Research (WRAIR)|Yes|Active, not recruiting|January 2010|August 2014|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|820|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01791556||71238|
NCT01791569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0303|Pulse Oximetry- Evaluating Sensor Off- PCBA-1|Sensor Off Studies Using a Bedside Respiratory Patient Monitoring System With the Multi-Functional Patient Monitoring PCBA-1||Medtronic - MITG|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy, Well Perfused subjects|December 2013|December 5, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01791569||71237|
NCT01787331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#125513|A Phase II Study of Itraconazole in Biochemical Relapse|Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse||University of California, San Francisco|Yes|Recruiting|November 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787331||71561|
NCT01787344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG-11-02|Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy|Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of "Botulax®" Versus "Botox®" in Children With Cerebral Palsy||Hugel|Yes|Completed|March 2012|August 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|2 Years|10 Years|No|||April 2015|May 1, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01787344||71560|
NCT01787643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC702|Standing Behavior After Installation of Height-Adjustable Desks|Adoption of Standing Behavior After Installation of Height-Adjustable Desks||USDA Grand Forks Human Nutrition Research Center|No|Completed|January 2013|August 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787643||71537|
NCT01787318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 1208010682|Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes|Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes|IPCL|Yale University|Yes|Recruiting|January 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|12 Years|40 Years|No|||January 2014|January 14, 2014|January 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787318||71562|
NCT01787617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC11038 ARTIIS|Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men|Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men|ARTIIS|Pennington Biomedical Research Center|No|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|113|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01787617||71539|
NCT01787630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoHarm1|To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy|Initiating Phase II-III Study to Evaluate the Technique and Effects of Separating the Prostate From the Rectum With Hyaluronic Acid During Radiotherapy|NoHarm|Umeå University|No|Recruiting|January 2010|December 2014|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|75 Years|No|||February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787630||71538|
NCT01800422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12B09|Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer|Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer||Northwestern University|Yes|Active, not recruiting|June 2013|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|February 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800422||70560|
NCT01800695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-356|Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme||AbbVie|No|Recruiting|April 2013|February 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|196|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800695||70539|
NCT01800708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Cataract Surgery With Intracameral Triamcinolone in Infants|The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery||Fundação Altino Ventura|No|Completed|January 2010|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|6 Weeks|2 Years|No|||August 2013|August 13, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800708||70538|
NCT01801488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#238810|Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm|Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm||State University of New York - Upstate Medical University|No|Terminated|November 2011|||March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|5|Samples With DNA|Tissue samples of intracranial arterial-venous malformations (AVM) or aneurysm and blood      samples.|Both|18 Years|89 Years|No|Probability Sample|Patients admitted to University Hospital.|February 2013|November 24, 2015|December 12, 2012||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01801488||70479|
NCT01801501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKI-FGF23-012|Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients|Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients||University of Chile|Yes|Recruiting|January 2012|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Venous blood samples will be obtained. Serum samples will be extracted, with elimination of      other material. Serum will be stored at -20ºC until determination of FGF-23 by ELISA      technique.|Both|15 Years|89 Years|No|Probability Sample|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock.        Pregnant women and transplanted patients are excluded.|February 2014|February 23, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801501|1 Month|70478|
NCT01801514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCT DL|Applications of Dual-Energy Computed Tomography|Applications of Dual-Energy Computed Tomography||Philips Healthcare|Yes|Completed|November 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|337|||Both|N/A|N/A|No|||November 2014|November 10, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801514||70477|
NCT01802333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00490|Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia|A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2013|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|784|||Both|18 Years|60 Years|No|||November 2015|March 23, 2016|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802333||70414|
NCT01802593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0169-12-WOMC|Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure|Phase 4, Open Label Multicenter Randomized Controlled Trial. Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator Failure|WITHDRAW|Wolfson Medical Center|Yes|Terminated|February 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|18 Years|No|||December 2015|December 21, 2015|December 24, 2012|Yes|Yes|lack of budget and failure to reach milestones|No||https://clinicaltrials.gov/show/NCT01802593||70394|
NCT01802060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0449|Accuracy of SPD Persona LH Assay When Compared to Ultrasound Observed Ovulation and Other Indices of Ovulation|Accuracy of SPD Persona LH Assay When Compared to Ultrasound Observed Ovulation and Other Indices of Ovulation||SPD Development Company Limited|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|Samples Without DNA|Urine samples Serum samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|General Public|November 2014|November 27, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01802060||70435|
NCT01802320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00487|Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery|A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation||National Cancer Institute (NCI)||Active, not recruiting|March 2013|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802320||70415|
NCT01802580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021783|Using an Internet Study to Improve Adherence for Psoriasis Patients|Using an Internet Study to Improve Adherence for Psoriasis Patients||Wake Forest School of Medicine|No|Active, not recruiting|October 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01802580||70395|
NCT01802879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2402B|Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator|An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment||Novartis|No|Active, not recruiting|June 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|N/A|No|||February 2016|February 3, 2016|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01802879||70372|
NCT01792791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038254|Post-traumatic Arthritis Associated With Joint Injury|Assessment of Biomarkers Associated With Joint Injury and Subsequent Post-Traumatic Arthritis||Duke University|No|Active, not recruiting|October 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Adults that are at least 18 years old and had a unilateral closed intra articular fracture        of the knee that requires surgery.|August 2015|February 19, 2016|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01792791||71144|
NCT01803971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/13|Cardiac Arrest and Intra Osseous Infusion|Obtaining Vascular Access (Venous or Intraosseous) During Cardiac Arrest in Out-of-hospital Care: Delays and Failure Risk Factors|ACCIO|University Hospital, Bordeaux|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01803971||70289|
NCT01791231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013624|A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers|An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-28431754 in Healthy Male Subjects Following a Single Oral Dose Administration of 14C-JNJ-28431754||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791231||71263|
NCT01787682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0503|Nutritional and Functional Changes in Heart Failure|Metabolic and Functional Changes in Relation to Nutritional Status in Chronic Heart Failure||Texas A&M University|No|Recruiting|December 2012|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|46|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787682||71534|
NCT01788020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECWM-1|Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia|Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia||University of Ulm|Yes|Recruiting|November 2013|December 2022|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01788020||71510|
NCT01788033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-189/10|Effects of XOMA 052 on Insulin Production in Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes|LATE STAGE|University of Zurich|Yes|Completed|September 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|No|||February 2014|February 10, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01788033||71509|
NCT01787656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USA-MCI GON-1.01|A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus|A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus||University of South Alabama|No|Recruiting|January 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|Samples With DNA|De-idetified samples of gynecologic fluid, mucus, and blood|Female|50 Years|N/A|No|Probability Sample|Women with an adenxal mass or suspicion of ovarian, fallopian tube, or primary peritoneal        cancer|January 2016|January 8, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787656||71536|
NCT01787968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI083563|Congenital Transmission of Lineages I and II of Trypanosoma Cruzi|Congenital Transmission of Lineages I and II of Trypanosoma Cruzi||Tulane University School of Public Health and Tropical Medicine|No|Completed|April 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28348|Samples With DNA|Plasma, blood with guanidine, dry spots on filter papers|Female|18 Years|N/A|No|Non-Probability Sample|Women delivering in participating hospitals.|February 2015|February 4, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01787968||71514|
NCT01787981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIA-CF-068|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2013|||||N/A|N/A|N/A||||||||||||||July 3, 2014|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01787981||71513|
NCT01787994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815441|Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy|A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV|MazF|University of Pennsylvania|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|January 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787994||71512|
NCT01788007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMQC 1220|Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.|A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.||Taro Pharmaceuticals USA|No|Completed|January 2013|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|443|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|February 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01788007||71511|
NCT01788293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVI - HR|Fluid Management Based on Pleth Variability Index (PVI) Monitoring During High-risk Surgery|Fluid Management Based on Pleth Variability Index (PVI) Monitoring During High-risk Surgery||Hospital Regional de Presidente Prudente|Yes|Recruiting|February 2013|February 2015|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|90 Years|No|||February 2013|February 26, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01788293||71489|
NCT01800435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCTnr. 2010-022668-11|A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor|Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover Study|BPATXAS|Oslo University Hospital|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800435||70559|
NCT01800448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011763-01H|Variability Analysis During Weaning and Extubation in Critically Ill Patients|Cardiopulmonary Monitoring, Skin Conductance and Variability Analysis During Weaning and Extubation in Critically Ill Patients|NM3|Ottawa Hospital Research Institute|No|Completed|June 2012|June 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|ICU Patients|March 2014|March 17, 2014|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01800448||70558|
NCT01800942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC1282|Prevention of Bacterial Infections in Newborn|Prevention of Bacterial Infections in the Newborn by Pre-delivery Administration of Azithromycin (AZI): a Placebo-controlled Randomized Trial|PregnAnZI|Medical Research Council Unit, The Gambia|Yes|Completed|February 2013|August 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|829|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800942||70520|
NCT01801228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001264-22|Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects|Swedish, Multicentered, Randomized Study of Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis Regarding Efficacy and Side Effects||Region Skane|Yes|Withdrawn|February 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|70 Years|No|||January 2016|January 14, 2016|February 26, 2013|No|Yes|difficulties to include patients|No||https://clinicaltrials.gov/show/NCT01801228||70499|
NCT01801241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPP-12-245|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2013|||||N/A|N/A|N/A||||||||||||||March 13, 2013|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801241||70498|
NCT01801527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/02749-02764|Telehealth System to Improve Quality of Life in Breast Cancer Survivors|E-Cuidate: Effectiveness of a Telerehabilitation System in Women Breast Cancer Survivors||Universidad de Granada|Yes|Completed|March 2012|July 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|65 Years|No|||May 2015|May 11, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801527||70476|
NCT01802346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-10-3|Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer|A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy||University of Southern California|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|19 Years|N/A|No|||October 2015|October 24, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802346||70413|
NCT01802892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116610|Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)|An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)||GlaxoSmithKline|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|November 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01802892||70371|
NCT01803165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|541-12-EP|Lower Extremity Regional Anesthesia and Infrainguinal Bypass Grafting|Lower Extremity Regional Anesthesia and Infrainguinal Bypass Grafting||University of Nebraska|No|Withdrawn|May 2013|May 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|19 Years|N/A|No|Non-Probability Sample|Patients 19 years of age and older who are candidates to undergo infrainguinal bypass        grafting for the treatment of peripheral vascular disease.|December 2014|December 1, 2014|February 26, 2013||No|Inadequate patient population|No||https://clinicaltrials.gov/show/NCT01803165||70350|
NCT01803412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD115501|A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in US and Canadian Subjects With Duchenne Muscular Dystrophy.||BioMarin Pharmaceutical|No|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|67|||Male|5 Years|N/A|No|||February 2016|February 26, 2016|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803412||70331|
NCT01803685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVM-125R|Nationwide Treatment Survey of Intracranial Arteriovenous Malformation in China|A Nationwide Treatment Survey of Intracranial Arteriovenous Malformation: a Multicenter Retrospective and Prospective Register Study in China|NTSIAVMC|Beijing Tiantan Hospital|Yes|Recruiting|February 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All the patients that diagnosed of intracranial AVM by DSA/CT/MRI|March 2013|March 1, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803685|6 Months|70311|
NCT01803698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20PiccVall|Management of Gestational Weight Gain by Family Physicians: Seeking Congruence With Guidelines|MANAGEMENT OF GESTATIONAL WEIGHT GAIN BY FAMILY PHYSICIANS: SEEKING CONGRUENCE WITH GUIDELINES||Nova Scotia Health Authority|No|Not yet recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|530|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|April 23, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803698||70310|
NCT01804504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5186272761903|Nutrition Education on the Metabolic Syndrome of Subjects Who Are Frequently Eating Out|Survey on Eating Out Behavior and Dietary Structure in Urban Chinese Citizens and the Effect of Nutrition Education||Second Military Medical University|No|Enrolling by invitation|March 2013|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|78|||Both|30 Years|60 Years|No|||March 2013|March 5, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01804504||70248|
NCT01804478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091793|Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg|Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg||University of California, San Diego|No|Completed|May 2005|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 4, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01804478||70250|
NCT01793129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0051|Preemie Hypothermia for Neonatal Encephalopathy|A Randomized Trial of Targeted Temperature Management With Whole Body Hypothermia For Moderate And Severe Hypoxic-Ischemic Encephalopathy In Premature Infants 33-35 Weeks Gestational Age.||NICHD Neonatal Research Network|Yes|Recruiting|May 2015|October 2020|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|33 Weeks|35 Weeks|No|||March 2016|March 2, 2016|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793129||71118|
NCT01793142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1781047|Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice|Post Marketing Surveillance For General Drug Use To Assess The Safety And Efficacy Profile Of Viviant In Usual Practice.||Pfizer|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Female|20 Years|N/A|No|Non-Probability Sample|Postmenopausal osteoporosis and osteopenia patients|March 2016|March 12, 2016|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793142||71117|
NCT01791582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0304|Pulse Oximetry- Evaluating Resp Rate- PCBA-1|Respiration Rate Parameter Studies in Healthy Volunteers Using a Bedside Respiratory Patient Monitoring System With the Multi-Functional Patient Monitoring PCBA-1||Medtronic - MITG|No|Completed|October 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Subjects|December 2013|December 5, 2013|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01791582||71236|
NCT01787669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwitchDMO|Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema|A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)|SwitchDMO|University of Sydney|No|Recruiting|June 2013|December 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787669||71535|
NCT01787695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02235|UVA 1 Phototherapy for Vitiligo|||University of British Columbia||Recruiting|February 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|19 Years|N/A|No|||June 2015|June 30, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787695||71533|
NCT01788319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55194|Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm)|Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm) in Open Angle Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Completed|February 2013|June 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||February 2013|June 22, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01788319||71487|
NCT01788605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMTC-supp001|Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation|Prospective, Single-arm Phase 2 Trial to Evaluate Efficacy and Safety of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies||The Catholic University of Korea|No|Recruiting|August 2014|February 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|65|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01788605||71465|
NCT01800955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1347/2012|Effectiveness of Resistive Capacitive Diathermy in Patients Affected by Knee Osteoarthritis|The Effectiveness of Resistive Capacitive Diathermy in Patients Affected by Knee Osteoarthritis: a Sham-controlled Study||Catholic University of the Sacred Heart|No|Completed|August 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01800955||70519|
NCT01801254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00043988|Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior|Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior||University of Rochester|No|Completed|February 2013|February 2015|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801254||70497|
NCT01801787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/123/12|Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia|The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia||Charite University, Berlin, Germany||Recruiting|March 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801787||70456|
NCT01802073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22591|Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects|Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects|PSC|Stanford University|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|1 Year|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802073||70434|
NCT01802918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116787|Single Dose Escalation Study of GSK2838232 in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects||GlaxoSmithKline|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|February 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01802918||70369|
NCT01802931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117016|GSK239512 DDI Study|An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512||GlaxoSmithKline|No|Completed|January 2013|May 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|January 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01802931||70368|
NCT01802606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091217|Factors Related to Infection Prevention After Tension-free Inguinal Hernia Repair|Department of Pharmacy, Xijing Hospital|infection|Xijing Hospital|Yes|Completed|January 2010|November 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|||Both|16 Years|18 Years|No|Probability Sample|e recruited 1200 patients with inguinal hernia undergoing inguinal hernioplasty in the six        hospitals|February 2013|February 27, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01802606||70393|
NCT01802905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA POG 01|Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies|Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies||British Columbia Cancer Agency|No|Completed|June 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|N/A|No|||February 2013|February 4, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802905||70370|
NCT01803178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-SCC-0574|The Effect of Plant Sterols on Vascular Function|The Effect of Plant Sterols on Vascular Function||Unilever R&D|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|240|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2013|October 25, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803178||70349|
NCT01803425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116290|Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka|Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix™) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka||GlaxoSmithKline||Withdrawn|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|6 Weeks|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Sri Lankan infants aged 6 weeks and above and children|September 2013|September 5, 2013|February 28, 2013|No|Yes|Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it    was concluded GSK will submit local PSURs.|No||https://clinicaltrials.gov/show/NCT01803425||70330|
NCT01800539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00023642|Improving Services and Outcomes for Children With Autism Spectrum Disorder (ASD)|Improving Part C Services and Outcomes for Under-resourced Children With ASD||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|February 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Months|42 Months|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01800539||70551|
NCT01800812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARDOU PHRC R 2002|Effects of OM-174 in Adult Patients With Solid Tumors|Phase One Study With Direct Individual Benefit: Effects of OM-174 in Adult Patients With Solid Tumors.|OM-174|Centre Hospitalier Universitaire Dijon||Completed|March 2007|||January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label||||27|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01800812||70530|
NCT01800526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117090|A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease|A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease|NACinSCD|Puget Sound Blood Center|Yes|Enrolling by invitation|March 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|January 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800526||70552|
NCT01800799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL007|Urinary NGF as A Biomarker for Acute Bacterial Cystitis|Use of Urinary Nerve Growth Factor as A Biomarker to Determine Complete Resolution of Bladder Inflammation After Acute Bacterial Cystitis in Women||Buddhist Tzu Chi General Hospital|No|Recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Female|20 Years|90 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01800799||70531|
NCT01821443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12105/12-02|A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)|A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed Primarily With Stereotactic Radiosurgery (SRS)||University of California, San Francisco|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821443||68949|
NCT01821456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|!SZINF2|Cologne Cohort of Neutropenic Patients (CoCoNut)|The Cologne Cohort of Neutropenic Patients (CoCoNut) - a Non-interventional Cohort Study Assessing Risk Factors, Interventions, and Outcome of Immunosuppressed Patients With or Without Opportunistic Infections|CoCoNut|University Hospital of Cologne|Yes|Recruiting|January 1995|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients developing neutropenia after receiving chemotherapy for any kind of malignant        disease, treated in the University Hospital of Cologne|March 2013|March 26, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01821456||68948|
NCT01787357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015514|A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)|A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Four-Way Crossover Study Evaluating ECG Intervals in Healthy Adults Receiving a Single, Oral Dose of JNJ-28431754 at Therapeutic and Supra-Therapeutic Doses||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 11, 2013|February 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01787357||71559|
NCT01787370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flow-MEC|Mainz Registry of Flow-mediated Constriction|Mainz Registry of Flow-mediated Constriction||Johannes Gutenberg University Mainz|No|Recruiting|September 2009|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing coronary angiography for the suspect of coronary artery        disease.|February 2016|February 23, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787370|2 Years|71558|
NCT01787383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-64|A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities|A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities||LEO Pharma|No|Completed|February 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|February 6, 2013|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01787383||71557|
NCT01787396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL011|Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d|A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes||LG Life Sciences||Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|433|||Both|20 Years|N/A|No|||April 2015|April 1, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787396||71556|
NCT01822002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment of PC-BPPV|Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo|Randomized Controlled Trials for Treatment of Benign Paroxysmal Positional Vertigo|PC-BPPV|Chonbuk National University|Yes|Recruiting|February 2013|February 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|10 Years|90 Years|No|||March 2013|March 29, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822002||68906|
NCT01817829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPPALP|Oral Paracetamol as Preemptive Analgesia for Labor Pain|Oral Paracetamol as Preemptive Analgesia for Labor Pain||Ain Shams University|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|40 Years|No|||March 2013|March 21, 2013|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817829||69227|
NCT01788046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120230|20120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis||Amgen|Yes|Completed|March 2013|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||April 2015|May 1, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01788046||71508|
NCT01788332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIN|Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)|A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer|PIN|Velindre NHS Trust|Yes|Recruiting|January 2014|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01788332||71486|
NCT01801540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-095|The Effects of L-arabinose in a Meal in Healthy Men|The Effects of L-arabinose in a Meal on Glucose Metabolism in Healthy Men||University of Copenhagen|Yes|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|17|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801540||70475|
NCT01801553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IoNS-UCL-Hidalgo-01|Study of the Efficacy of Manual Therapy for a Subgroup of Acute Non-specific Low Back Pain|A Randomized Controlled Double Blind Study on the Pragmatic Application of a Clinical Prediction Rule in Primary Care to Treat Low Back Pain Patients With a Brief Spinal Manipulation Intervention: a Validation Study||Université Catholique de Louvain|Yes|Terminated|May 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|55 Years|No|||June 2014|June 24, 2014|February 23, 2013||No|problem of recruitment (not enough patients)|No||https://clinicaltrials.gov/show/NCT01801553||70474|
NCT01801800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0410|Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage Patients|Speckle Tracking Assessment of Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage and Impact on Neurologic Outcome (SPLASH)|SPLASH|Nantes University Hospital|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|15 Years|85 Years|No|Non-Probability Sample|Severe Aneurysmal subarachnoid haemorrhage|May 2014|May 9, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01801800|2 Months|70455|
NCT01801813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0416|Risk Factors of Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery (Cranioscore).|Observational Study of Risk Factors of Neuro-critical Care Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery : a Prospective Validation of the Cranioscore.|Cranioscore|Nantes University Hospital|No|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|795|||Both|15 Years|85 Years|No|Non-Probability Sample|Patients undergoing neuro-surgery for a brain tumor|March 2016|March 24, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01801813|2 Months|70454|
NCT01802086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SormlandCC|Emla-Cream as Pain Relief During Pneumococcal Vaccination|Emla-Cream as Pain Relief During Pneumococcal Vaccination||Sormland County Council, Sweden|Yes|Recruiting|May 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|72|||Both|2 Months|4 Months|No|||September 2015|September 28, 2015|October 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802086||70433|
NCT01795625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFS-201201|OneTouch® Verio™Pro+ Blood Glucose Monitoring System Clinical Accuracy Study in China|A Multi-centre, Open Clinical Evaluation to Determine Professional Clinical Accuracy Comparing the OneTouch® Verio™Pro+ Blood Glucose Results With the YSI 2300 Analyzer.||Johnson & Johnson Medical, China|Yes|Completed|August 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of at least 240 diabetic subjects (type 1 or type 2)        study-wide at two clinical sites.|February 2013|February 18, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795625||70926|
NCT01803191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPROST|Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy|Randomized Controlled Clinical Trial of Efficacy of Fosfomycin Versus Ciprofloxacin as Antibiotic Prophylaxis Prior to Ultrasound Guided Transrectal Prostate Biopsy|BIPROST|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|No|Active, not recruiting|August 2012|June 2015|Anticipated|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|470|||Male|18 Years|85 Years|No|||March 2014|March 11, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01803191||70348|
NCT01803438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cryo-FIRST|Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation|Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.||Medtronic Atrial Fibrillation Solutions|Yes|Recruiting|June 2014|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803438||70329|
NCT01803451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-28-01|Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass|The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery|GLP-1|Cedars-Sinai Medical Center|Yes|Active, not recruiting|November 2005|December 2020|Anticipated|December 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01803451||70328|
NCT01803724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUC-0003|Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome|Comparison Between Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome Patients||Pontificia Universidad Catolica de Chile|No|Not yet recruiting|May 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients meeting Rome III criteria for IBS.|March 2013|March 1, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803724||70308|
NCT01803984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/19|MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction|MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction|MIBRAIN|University Hospital, Bordeaux|No|Recruiting|March 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a clearly defined migraine (as per IHS criteria) who are aged 30 and        older, are able to fluently speak French, do not have a major psychiatric disease or major        anxiety disorder which would not allow to perform a MRI imaging, and who are willing to        participate.|January 2015|January 13, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803984||70288|
NCT01803997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC216|Pink and Dude Chef|Pink and Dude Chef Afterschool Cooking Program: Improving Food Knowledge and Skills in Middle School Students||USDA Grand Forks Human Nutrition Research Center|No|Completed|August 2012|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01803997||70287|
NCT01801059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07104|Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer|Patient Activation To Increase Colon Cancer Screening (THE CHAT STUDY)||Ohio State University Comprehensive Cancer Center|Yes|Completed|September 2007|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|284|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 14, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801059||70511|
NCT01801046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L-11-8|Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia|HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia||University of Southern California|Yes|Recruiting|March 2013|April 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||August 2015|August 29, 2015|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801046||70512|
NCT01801358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2203|A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma|A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma||Array BioPharma|No|Terminated|August 2013|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 21, 2013|Yes|Yes|The trial was terminated for scientific reasons.|No||https://clinicaltrials.gov/show/NCT01801358||70489|
NCT01822015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.588|Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia||Thomas Jefferson University|Yes|Recruiting|March 2013|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822015||68905|
NCT01821742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS ID 121440|Echocardiography in Kids Intensive Care Decision Support|Echocardiography in Kids Intensive Care Decision Support - is Focused Echocardiography Superior to Pressure Derived Measurements at Predicting Fluid Responsiveness in Critically Ill Children?|ECHOKIDS|Imperial College London|No|Recruiting|March 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|16 Years|No|Non-Probability Sample|Shocked children on PICU|March 2013|March 29, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01821742||68926|
NCT01821755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID0032|Effectiveness of a Foster Parent Intervention: Results of a Trial|Development, Implementation and Evaluation of a Foster Parent Intervention|PVO|Vrije Universiteit Brussel|No|Active, not recruiting|January 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01821755||68925|
NCT01818115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-10-001|Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.|A Prospective, Multi-Center, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the Hydrus Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery.|Hydrus II|Ivantis, Inc.|No|Active, not recruiting|January 2011|November 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|80 Years|No|||August 2014|August 21, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01818115||69205|
NCT01818128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_flexion|The Pretreatment of a Left-sided Double-lumen Tube to Prevent Its Misplacement to the Right Mainstem Bronchus|||Seoul National University Hospital||Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1540|||Both|20 Years|85 Years|No|||May 2015|May 20, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01818128||69204|
NCT01817842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1DA028710|Study of Mobile Phone Support for the DC Tobacco Quitline|Comparative Effectiveness of Web-based Mobile Support for the DC Tobacco Quitline||Truth Initiative|Yes|Completed|July 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|803|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817842||69226|
NCT01818089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-116|Monitoring of Lung Sounds of Patients With Pneumonia|Monitoring of Lung Sounds of Patients With Pneumonia||RWTH Aachen University|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with ambulant aquired pneumonia|September 2015|September 22, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01818089||69207|
NCT01818102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_CT window|CT Window Setting to Select Double-lumen Tube Size|||Seoul National University Hospital||Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|228|||Both|20 Years|85 Years|No|||May 2015|May 20, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01818102||69206|
NCT01818895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 018-13|Terminal Weaning of Mechanical Ventilation or Extubation in Anticipation of Death in the Intensive Care Unit|Terminal Weaning of Mechanical Ventilation or Extubation in Anticipation of Death in the Intensive Care Unit: Impact on Relatives, Care Givers and the Dying Process - A Prospective, Multicenter, Observational Study|ARREVE|Centre Hospitalier Departemental Vendee|No|Completed|April 2013|May 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|458|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted in ICU with end of life decision to withdraw invasive mechanical        ventilation after at least 48 hours of ICU stay|July 2015|July 9, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818895||69145|
NCT01801566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1129-9956|Effectiveness of the Single Implant-retained Mandibular Overdenture Treatment|Effectiveness of the Single Implant-retained Mandibular Overdenture Treatment: Radiographic Evaluations, Patient's Satisfaction, and Oral-health-related Quality of Life|SIOver|Universidade Federal de Goias|Yes|Completed|April 2013|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|45 Years|N/A|No|||March 2016|March 14, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801566||70473|
NCT01802359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100836|A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction|Post-Marketing Surveillance of Bravonto in Korea||Janssen Korea, Ltd., Korea|No|Terminated|November 2011|May 2012|Actual|May 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|379|||Male|19 Years|N/A|No|Non-Probability Sample|Participants diagnosed with erectile dysfunction and prescribed mirodenafil on demand.|November 2015|November 30, 2015|February 28, 2013||No|This prodect will be transferred to another company.|No||https://clinicaltrials.gov/show/NCT01802359||70412|
NCT01802619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121025-8|Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass.|Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass: A Double Blind Randomized Controlled Trial.||Xijing Hospital|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|212|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802619||70392|
NCT01795911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-008 (Substudy Part C)|Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin|A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects|D-LITE|Bristol-Myers Squibb|No|Completed|March 2013|September 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795911||70904|
NCT01795924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT12-US-AML-a|Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome|An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients With Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|AML/MDS|Biosuccess Biotech Co., Ltd.|Yes|Recruiting|January 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|75 Years|No|||February 2013|July 8, 2013|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795924||70903|
NCT01795937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.61|Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin|Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin in Healthy Male and Female Subjects (Open-label, Fixed-sequence)||Boehringer Ingelheim||Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|February 20, 2013||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01795937||70902|
NCT01795898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015268|An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain|Efficacy, Safety and Quality of Life Outcome of Fentanyl Transdermal Patch (Durogesic-D-Trans) Among Filipino Patients With Osteoarthritis and Chronic Low Back Pain||Janssen Pharmaceutica|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|18 Years|65 Years|No|||June 2013|June 10, 2013|February 19, 2013|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01795898||70905|
NCT01791933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2013-01|The Evaluation of the Effectiveness of CAM Treatments for Lumbar and Cervical Spine Pain Patients Due to Spinal Disease|The Evaluation of the Effectiveness of CAM Treatments for Lumbar and Cervical Spine Pain Patients Due to Spinal Disease : Prospective, Observational Study||Jaseng Hospital of Korean Medicine|Yes|Completed|February 2013|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|N/A|N/A|No|Probability Sample|Consecutive patient sampling within lumbar and cervical spine pain patients due to spinal        disease.|October 2013|October 29, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01791933||71209|
NCT01792232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01831|Effects of Co-Exposure to Air Pollution and Allergen|Effect of Exposure to Allergens and Air Pollution on Lung Function and Immunity||University of British Columbia|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|18|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|November 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01792232||71187|
NCT01792518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.89|MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin|A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)||Boehringer Ingelheim||Completed|February 2013|December 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|February 14, 2013||||No||https://clinicaltrials.gov/show/NCT01792518||71165|
NCT01804231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGPC-3|Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer|A Prospective Study of Hybrid PET/MRI in the Evaluation of Men With Suspected Prostate Cancer Recurrence Following Definitive Local Therapy|IGPC-3|Lawson Health Research Institute|No|Active, not recruiting|April 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Male|19 Years|100 Years|No|||January 2016|January 19, 2016|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01804231||70269|
NCT01804491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252-2006-130228|Motion Analysis in Patients With Hallux Rigidus|Motion Analysis in Patients With Hallux Rigidus Before and After Different Types of Surgery||University Hospital Heidelberg|No|Completed|October 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort||7|Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with osteoarthritis in the first metatarso-phalangeal joint (hallux rigidus)|March 2013|March 1, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804491||70249|
NCT01801644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bladder Cancer-001|Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer|Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer||Barmherzige Brüder Vienna|No|Completed|April 2007|February 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01801644||70467|
NCT01801891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASGARD2013|Surface NeuroMuscular Electrical Stimulation in the Treatment of Chronic Venous Leg Ulcers|Surface NeuroMuscular Electrical Stimulation in the Treatment of Chronic Venous Leg Ulcers: A Randomised Controlled Trial of the "VASGARD" Device||Mid Western Regional Hospital, Ireland|Yes|Completed|May 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801891||70448|
NCT01821794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130091|Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B|Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF Versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2013|December 2017|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 27, 2016|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821794||68922|
NCT01817855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2550C00002|To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients|A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD||AstraZeneca||Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817855||69225|
NCT01817868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16368|Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients|Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis||Bayer|No|Recruiting|January 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|76|||Both|18 Years|N/A|No|Non-Probability Sample|Adult haemophilia patients already on treatment with commercially available recombinant        FVIII products.|March 2016|March 3, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01817868||69224|
NCT01818388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDC-1978|COOL-ARREST Pilot Study to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest|A Multicenter, Prospective, Single Arm Observational Trial to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest|COOL-ARREST|ZOLL Circulation, Inc., USA|Yes|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Subjects that have experienced an out-of-hospital cardiac arrest.|July 2015|July 27, 2015|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818388||69184|
NCT01818401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_100|Medico-economic Interest of the Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During the Poses of Complete Prosthesis of Knee GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About a Medical Device.|Medico-economic Interest of the Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During the Poses of Complete Prosthesis of Knee GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About a Medical Device.|MY Knee|Nantes University Hospital|No|Active, not recruiting|March 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818401||69183|
NCT01818908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPH-HLH-001|Trial of DA-EPOCH Regimen for NHL With HLH|Clinical Study of Dose-adjusted EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|June 2012|April 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|15 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 23, 2013|March 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818908||69144|
NCT01801826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0726|A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device|A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines Utilizing Optimized Algorithms With the Cryo-Touch IV Device||MyoScience, Inc|No|Completed|January 2013|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|61|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects, male or female, age 30 - 65 with forehead and/or glabellar lines deemed        significant per protocol inclusion criteria.|March 2013|March 23, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01801826||70453|
NCT01802099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD085-11|Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines|Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines: Multicenter, Randomized Controlled Trial (NUTRIREA-2)|NUTRIREA2|Centre Hospitalier Departemental Vendee|Yes|Active, not recruiting|March 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2854|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802099||70432|
NCT01795092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008A058574|A Study Assessing the Impact of Dermatology Consultation in Patients Presenting With Possible Cellulitis|A Randomized-controlled Study to Assess the Impact of Dermatology Consultations on Reducing Admissions for Patients Presenting to Internal Medicine Clinics for Possible Cellulitis||Massachusetts General Hospital|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795092||70967|
NCT01795339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00002|A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients||AstraZeneca||Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|47|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|February 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01795339||70948|
NCT01803217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-010|Evaluation of Pacemaker Algorithms to Avoid Unnecessary Right Ventricular Pacing|AV-Hysteresis Versus Mode Switch to AAI (MVP) for the Avoidance of Unnecessary Right Ventricular Pacing|ADVANTAGE|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|November 2007|December 2015|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803217||70346|
NCT01803230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creatine in Children|Creatine Supplementation on Cognition in Children|Effects of Creatine Supplementation on Cognitive Function in Children||University of Sao Paulo|No|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||February 2013|March 1, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803230||70345|
NCT01803464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15HD071397-01|Effect of Botox and Vibration on Bone in Children With Cerebral Palsy|Effect of Botox and Vibration on Bone in Children With Cerebral Palsy||University of Delaware|Yes|Completed|March 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803464||70327|
NCT01803737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12110211|Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults|Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults||University of Pittsburgh|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|No|||January 2014|January 3, 2014|February 28, 2013||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01803737||70307|
NCT01804010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0114|Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers|||Asan Medical Center|No|Completed|May 2007|November 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|February 27, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01804010||70286|
NCT01804517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT|Impact of a Nurse for Migraine Management: the IMPACT Project|Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic|IMPACT|Notre-Dame Hospital, Montreal, Quebec, Canada|No|Active, not recruiting|February 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients followed at the migraine clinic at the Notre-Dame Hospital in Montreal|May 2015|May 25, 2015|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01804517|1 Year|70247|
NCT01801371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM6|68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma|Diagnostic Performance and Evaluation Efficacy of Brain 68Ga-BNOTA-PRGD2 PET/CT in Pre-surgery Glioma Patients|GRGDG|Peking Union Medical College Hospital|Yes|Recruiting|October 2012|December 2015|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 1, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01801371||70488|
NCT01801384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014028|Voucher Based Incentives to Treat Pregnant Smokers|Phase 2 Study of the Efficacy of Voucher-Based Incentives to Treat Pregnant Smokers||University of Vermont|No|Active, not recruiting|April 2006|||May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|166|||Female|18 Years|45 Years|No|||March 2013|March 26, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801384||70487|
NCT01801657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009CB522109|The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults|The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|February 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|serum|Both|18 Years|80 Years|No|Non-Probability Sample|Adults with non-CF bronchiectasis diagnosed by High Resolution CT(HRCT) attending the        out-patient clinics of First Affiliated Hospital of Guangzhou Medical        University,Guangzhou,Guangdong,China|March 2014|March 11, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801657||70466|
NCT01801904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACER|A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer|A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer|PACER|National Cancer Institute, Naples|No|Active, not recruiting|December 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01801904||70447|
NCT01801917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312X2205|Efficacy and Tolerability of BAF312 in Patients With Polymyositis|A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis||Novartis|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801917||70446|
NCT01821521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGSPT_L20PK|Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects|A Randomized, Open Label, Single-dose, 2x2 Crossover Study to Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects|S-Pantoprazole|Ahn-Gook Pharmaceuticals Co.,Ltd|No|Not yet recruiting|June 2013|||August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 29, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01821521||68943|
NCT01817543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM003|A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers||Cytomedix|Yes|Active, not recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|385|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817543||69249|
NCT01817556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9601_Gas_IV|A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.|A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis||Dong-A ST Co., Ltd.|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Both|20 Years|75 Years|No|||November 2013|November 5, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817556||69248|
NCT01817569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5550C00001|Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)|Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)||AstraZeneca||Recruiting|February 2011|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3100|||Both|N/A|N/A|No|Non-Probability Sample|Patients are eligible to be included in the study if they meet all of the following        criteria:        The patient who is diagnosed with Type 2 Diabetes Mellitus and who is naive patient with        Byetta.        The patient follows the PI of Byetta.|March 2016|March 11, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817569||69247|
NCT01818141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICO003785HE|Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin|An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin||Hartford Hospital|No|Recruiting|August 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818141||69203|
NCT01818414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF-112778|Same-day Dilapan-S With Adjunctive Misoprostol|Dilapan-S With Adjunctive Misoprostol for Same-day Second Trimester Dilation and Evacuation: A Randomized Trial|DAM|University of Pittsburgh|No|Terminated|October 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 12, 2014|March 21, 2013||No|Concerns for safety|No||https://clinicaltrials.gov/show/NCT01818414||69182|
NCT01818154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7257|Validation of a New Hand Held Light Emitting Diode Device for the Determination of Minimal Erythema Dose (MED)|Validation of a New Hand Held Light Emitting Diode (LED) Device for the Determination of Minimal Erythema Dose (MED) for Narrowband Ultraviolet B.||Henry Ford Health System|No|Suspended|May 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 25, 2013|March 20, 2013|Yes|Yes|Under evaluation for need for further enrollment|No||https://clinicaltrials.gov/show/NCT01818154||69202|
NCT01794871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400ACN03T|The Histological Analysis in Renal Transplantation Patients With Deterioration of Graft Function|||Shanghai Zhongshan Hospital|No|Recruiting|May 2012|August 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|graft biopsy after kidney transplantation|Both|18 Years|N/A|No|Probability Sample|Maintenance living donor renal transplant recipients|February 2013|February 20, 2013|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01794871||70984|
NCT01795352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OES-XXX-2012/1|Retrospective Study in a NSCLC M+ p|Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain|Ca_Pulmon|AstraZeneca|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|187|||Both|18 Years|N/A|No|Non-Probability Sample|All patients recently diagnosed with advanced EGFR mutated NSCLC (both newly or with        recurrent disease , without previous treatment for metastatic disease) from April 2010 to        December 2011 will be included as study population.|October 2013|October 29, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795352||70947|
NCT01795638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-28-07|Sodium Supplementation and Growth in Very Low Birth Weight Infants|Impact of Early Postnatal Sodium Supplementation on Weight Gain in Very Low Birth Weight Infants|SSALT|Children's Hospital Medical Center, Cincinnati|Yes|Terminated|October 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|53|||Both|N/A|8 Days|No|||February 2013|February 18, 2013|February 13, 2013|Yes|Yes|The unit's standard nutrition practices change which impacted our methodology.|No||https://clinicaltrials.gov/show/NCT01795638||70925|
NCT01803477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0085-1000|Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm|A Seamless Phase 1/2 Exploratory Multi-centre, Investigator-blind, Dose Escalation Study (Study Part 1), Followed by a Randomised, Intra-subject, Active Controlled Efficacy Study of Different Ingenol Mebutate Formulations Applied to the Forearm for 2 Consecutive Days (Study Part 2)||LEO Pharma|No|Completed|February 2013|December 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803477||70326|
NCT01803750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-031|Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations|Building a Network of Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations||Memorial Sloan Kettering Cancer Center||Terminated|February 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be primary care providers (PCPs) in the NYC Queens. Brooklyn ,Bronx and        Staten Island, borough neighborhoods that serve large Latino populations.|February 2015|February 19, 2015|February 28, 2013||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01803750||70306|
NCT01804244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101181|A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants|An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects||Janssen Pharmaceutical K.K.|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804244||70268|
NCT01800825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher (DDD# 601465)|Clindamycin to Reduce Preterm Birth in a Low Resource Setting|Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial||Christiana Care Health Services|Yes|Active, not recruiting|July 2013|April 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1726|||Female|13 Years|N/A|No|||October 2015|October 6, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01800825||70529|
NCT01801085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-TR116581|Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens|The Impact of Nursing and Pharmacy Care Between Xeloda® and 5-Fluoruracil Regimens in the Management of Colorectal Cancer (CRC) in Hong Kong||Chinese University of Hong Kong|No|Recruiting|October 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Colorectal patients who were newly prescribed to receive either the XELOX or the FOLOFX4        chemotherapy regimen will be identified from the colorectal clinic.|February 2014|February 11, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01801085||70509|
NCT01801397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Psy-Rheu_2011/1|A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)|||University of Zurich||Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|35 Years|No|||March 2014|March 25, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801397||70486|
NCT01801956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-428-12|The MILE Study: A Motivational, Individual and Locally Anchored Exercise Intervention in 30-49 Year Olds.|The MILE Study: A Motivational, Individual and Locally Anchored Exercise Intervention Among 30-49 Year-olds With Low Levels of Cardiorespiratory Fitness. A Randomised Controlled Study in Primary Care.|MILE|University of Aarhus|Yes|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|30 Years|49 Years|Accepts Healthy Volunteers|||October 2013|February 5, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01801956||70443|
NCT01801670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30121|Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study|A Phase IV Study Of The Impact Of Vorinostat On Cellular Signaling And Cytokine Production In Cutaneous T-Cell Lymphoma Patients With Pruritus||Boston University|No|Withdrawn|January 2015|January 2015|Anticipated|January 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood Samples Skin biopsies|Both|18 Years|85 Years|No|Non-Probability Sample|Subjects with CTCL-mycosis fungoides type treated at Boston Medical Center and that have,        independent of this study, already agreed to start vorinostat according to the        stand-of-care guidelines.|January 2015|January 26, 2015|February 25, 2013||No|Enrollment was too slow, so no participants were ever enrolled.|No||https://clinicaltrials.gov/show/NCT01801670||70465|
NCT01789424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swallsed|Valuation of Swallowing in Patient Sedated for Gastroenteric Endoscopic Procedure|Valuation of Airway Protection (Swalling) in Patient Sedated for Gastroenteric Endoscopic Procedure|SwallSed|Ospedale San Raffaele|No|Completed|May 2012|December 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Patient sedated for gastroenteric endoscopic examination|March 2015|March 13, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01789424||71402|
NCT01821807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDPH 26Q26A|Comparison of Two Spinal Needles Regarding Postdural Puncture Headache|Postdural Puncture Headache After Spinal Anesthesia for Cesarean Section, Two Different Needles.||Adiyaman University Research Hospital|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|256|||Female|18 Years|40 Years|No|Probability Sample|Pregnant female patients between 18-40 years old undergoing cesarean section in Adiyaman        University Research Hospital, Turkey.|January 2014|January 17, 2014|March 27, 2013||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01821807||68921|We have planned to enroll 150 patients in the Atraucan group, but the circumstances forced us to finish the recruitment at 110.
NCT01817881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-BBH-AKM/MMA-Exerg|Investigation of the Accuracy of Temporal Artery Thermometers|Investigation of the Accuracy in the Use of Temporal Artery Thermometers for Non-invasive Temperature Measurement||Bispebjerg Hospital|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|385|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department University Hospital|June 2013|June 18, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817881||69223|
NCT01790256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cereve CIP-003|Comparison of Two Temperatures to Treat Insomnia|A Multi-center Prospective, Blinded, Randomized Crossover Study to Compare the Cerêve Sleep System at Two Different Temperatures in Primary Insomnia Patients||Cereve, Inc.|Yes|Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|22 Years|N/A|No|||May 2015|May 5, 2015|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790256||71338|
NCT01795105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-KOA-1101n|ABF Tourette's Disorder PMS|Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the "New Drug Re-Examination"||Korea Otsuka Pharmaceutical Co.,Ltd.|Yes|Recruiting|June 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|6 Years|18 Years|No|Probability Sample|Pediatric patients 6 to 18 years of age with Tourette's Disorder according to the approved        product market authorization|February 2013|February 17, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01795105||70966|
NCT01795118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-HS 1060nm-11-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||February 17, 2013|January 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795118||70965|
NCT01802658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/06-P|Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)|Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled|DBMZol|Nantes University Hospital|Yes|Recruiting|November 2012|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|No|||January 2016|January 12, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01802658||70389|
NCT01802957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHTF IR Ethiopia|Health Facility Networking for Maternal Health|Health Facility Networking for Maternal Health||Harvard School of Public Health|Yes|Completed|March 2013|December 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10787|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01802957||70366|
NCT01804023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13-125|Biomarkers of Protocol Compliance and Product Adherence|Comparison of Objective Biomarkers of Protocol Compliance and Product Adherence With Classic Markers of Compliance and Adherence||CONRAD|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, non-pregnant, HIV-uninfected women|October 2013|October 29, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804023||70285|
NCT01804257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMITTER 3.0 PSY|Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study|Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (EMITTER 3.0 PSY)|EMITTER3PSY|Proteus Digital Health, Inc.|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|28|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|February 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804257||70267|
NCT01804283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CmiR-001|Effects of Ischemic Postconditioning on MicroRNAs in Double Valve Replacement|Effects of Ischemic Postconditioning on Expression of Apoptosis-related MicroRNAs and Genes in Human Double Valve Replacement||Central South University|Yes|Not yet recruiting|March 2013|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|8|||Both|20 Years|N/A|No|||March 2013|March 3, 2013|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01804283||70265|
NCT01804270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003248 Part 1|rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1|A Randomized, Double-Blinded, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents||Mayo Clinic|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|21 Years|No|||February 2015|February 9, 2015|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804270||70266|
NCT01800331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03175|Text2bHealthy: Using Innovative Methods in Childhood Obesity Treatment|Text2bHealthy: Enhancing Adherence to Childhood Obesity Treatment Through the Use of Innovative Methods||University of British Columbia|No|Terminated|March 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|10 Years|16 Years|No|||May 2015|May 8, 2015|February 18, 2013||No|My post-doctoral fellow did not return from her mat leave and I have no other students to take    on this project.|No||https://clinicaltrials.gov/show/NCT01800331||70567|
NCT01800552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVWUS-001|Ultrasound Detection of Peripheral IV Infiltration|Ultrasound Detection of Peripheral IV Infiltration||ivWatch, LLC|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers (18 years or older) that were friends, family members, or        employees of ivWatch, LLC participated in this study.|February 2013|February 25, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01800552||70550|
NCT01800565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULH|First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty|Urinary LH in the Diagnosis of Precocious Puberty||Kaplan Medical Center|Yes|Recruiting|June 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|65|||Both|3 Years|9 Years|No|||February 2013|February 25, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01800565||70549|
NCT01800851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0146|Calorimetry, Insulin Resistance and Energy Metabolism Study to Understand the Risk of Obesity in Kidney Transplanted Patients|Calorimetry, Insulin Resistance and Energy Metabolism Study to Understand the Risk of Obesity in Kidney Transplanted Patients|CALIMERO|University Hospital, Clermont-Ferrand||Completed|January 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01800851||70527|
NCT01800864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003834|Leptin Biology in Adipose Tissue|Leptin Biology in Adipose Tissue||Mayo Clinic|No|Recruiting|August 2011|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800864||70526|
NCT01801683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mef01326|Evidence Based Medicine in General Practice|Application of Evidence Based Medicine in General Practice|EBMINGP|University of Split|No|Completed|January 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|98|||Both|N/A|N/A|No|||May 2015|May 27, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01801683||70464|
NCT01801943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalkCog-MCI|Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment|Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment||Pennington Biomedical Research Center|No|Recruiting|February 2013|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Anticipated|80|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 6, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801943||70444|
NCT01802203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA-003|trūFreeze® Spray Cryotherapy Patient Registry|trūFreeze® Spray Cryotherapy Patient Registry||CSA Medical, Inc.|No|Recruiting|April 2013|December 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are being treated using the trūFreeze® spray cryotherapy device for the        removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary        or gastrointestinal (GI) setting.|February 2016|February 1, 2016|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802203|5 Years|70424|
NCT01802463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S130213|Study on Ocular Blood Flow and the Orbital Cerebrospinal Fluid Pressure in Glaucoma|Correlation Between Ocular Blood Flow and the Optic Nerve Sheath Diameter in Patients With Primary Open-angle Glaucoma||Universitaire Ziekenhuizen Leuven|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|197|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary clinic care|January 2013|January 31, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01802463||70404|
NCT01789437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAMETER-001|Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.|Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.||Università degli Studi di Brescia|Yes|Completed|June 2011|January 2013|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|20 Years|N/A|No|||February 2013|February 8, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789437||71401|
NCT01789710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040194|Contingency Management for Smoking Cessation in Homeless Smokers|Contingency Management for Smoking Cessation in Homeless Smokers||Duke University|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789710||71380|
NCT01789684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 1102|Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients|A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients|SCUSF 1102|University of South Florida|Yes|Recruiting|February 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|3780|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01789684||71382|
NCT01789697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034182|Text Message Study|Using Mobile Phone Text Messaging and E-mailing to Decrease Anxiety, Pain, Follow-up Visits and Improve Reporting of Surgical Site Infection After Spine Surgery: A Double-Blind Randomized Trial||Duke University|Yes|Active, not recruiting|September 2012|||December 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|194|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01789697||71381|
NCT01789970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/3103|Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 30 to 90 mg Every 12 Hours for Relief of Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time||Teva Pharmaceutical Industries|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|623|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01789970||71360|
NCT01790243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0006-01|LEVANT 2 Safety Registry|A Prospective, Multicenter, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry)||C. R. Bard|No|Active, not recruiting|February 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01790243||71339|
NCT01790529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-19/12|Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis|Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis||University Hospital, Basel, Switzerland|Yes|Active, not recruiting|February 2013|July 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5000|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01790529||71317|
NCT01790542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2011:166|Assessment of Complementary Feeding of Canadian Infants|Assessment of Complementary Feeding of Canadian Infants|Infant Feeding|University of Manitoba|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Actual|87|||Both|N/A|6 Months|Accepts Healthy Volunteers|||July 2014|May 27, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01790542||71316|
NCT01790555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEEL-2012-04|Perioperative Δ9-THC for Postsurgical Pain|The Analgesic Efficacy of Perioperative Δ9-THC (Namisol®) in Patients Undergoing Major Abdominal Surgery: A Randomized, Double Blinded, Placebo-controlled, Parallel Design|NamiSur|Radboud University|Yes|Recruiting|July 2013|April 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|October 22, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01790555||71315|
NCT01802385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S4 0296-01|Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis|Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis|ASTRO-CM|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802385||70410|
NCT01803763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/10|Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients|Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients||University Hospital Inselspital, Berne|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|70 Years|No|||April 2014|April 14, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803763||70305|
NCT01804036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBNet-193532-1|Two Contrasting Interventions for Sleep Management|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management||University of Utah|No|Active, not recruiting|March 2013|July 2015|Anticipated|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|17 Years|40 Years|No|||April 2015|April 27, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01804036||70284|
NCT01795144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1517|Incretin Regulation of Insulin Secretion in Monogenic Diabetes|Incretin Regulation of Insulin Secretion in Monogenic Diabetes||University of Chicago|No|Recruiting|January 2014|December 2020|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|February 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01795144||70963|
NCT01795378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2012-0478|Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation|HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY|DNKI-II|Asan Medical Center|Yes|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|17 Years|N/A|No|||December 2015|December 29, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795378||70945|
NCT01795391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCED|Comparison of Two New Generations Dressings in Intensive Care Unit|Comparison Between Two New Generation Dressings in the Prevention of Intravascular Catheter Related Complications in Intensive Care Units|Advanced|University Hospital, Grenoble|Yes|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|685|||Both|18 Years|N/A|No|Probability Sample|Patients hospitalised in the Medical ICU and requiring an intravascular device during        hospitalisation (peripheral or central)|January 2014|January 20, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795391||70944|
NCT01795651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0143|Identification of Take Home Message in Lecture Based Learning|Identification of Take Home Message in Lecture Based Learning: a Randomize Controlled Trial|T-REX 2|University Hospital, Clermont-Ferrand||Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Observational|N/A||1|Actual|77|||Both|18 Years|N/A|No|Non-Probability Sample|French juniors|October 2013|October 8, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01795651||70924|
NCT01791673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYEMUST-3|Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients|Efficacy and Safety of Circular Cyclocoagulation Using High Intensity Focused Ultrasound With EYEOP1 Device in Glaucoma Patients. Prospective Multicenter Clinical Trial.||EyeTechCare|Yes|Completed|November 2012|June 2014|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2013|June 15, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791673||71229|
NCT01791686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1135-01|Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease|A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease||Celldex Therapeutics|Yes|Terminated|January 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|4 Years|N/A|No|||March 2014|March 6, 2014|January 29, 2013|No|Yes|Portfolio prioritization due to slow enrollment and variable spectrum of potential complement    abnormalities in DDD patients.|No||https://clinicaltrials.gov/show/NCT01791686||71228|
NCT01792882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBC PRT0008|Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples|Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples|GBCPRT0008|Global BioClinical|No|Enrolling by invitation|February 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|100|Samples With DNA|Surplus Surgical Tissues      Tissue procurement will involve the collection of tissues snap frozen in liquid nitrogen.      Tissues will include tumors and histologically normal (uninvolved) areas (>2cm from tumor)      of tissue. A tumor tissue sample is required; a normal tissue sample should be provided if      available.      Individual samples will be collected in weights (sizes) approximately 100-200 mg or larger.      Research tissues sample collection will only be performed on surplus (discard) tissues not      required for patient diagnosis and will never interfere with clinical diagnosis.      Blood Samples      Blood samples will be collected from consented subjects prior to surgery and will involve      the collection of up to 20 ml of whole blood into appropriate blood collection tubes and      freezing them.|Both|18 Years|90 Years|No|Probability Sample|Subjects diagnosed with one of the cancer indications listed below and scheduled to        undergo surgical tumor resection|January 2016|January 6, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01792882||71137|
NCT01793194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00047720|Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings|Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings: A Randomized Pilot Study||Johns Hopkins University|No|Recruiting|February 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|45 Years|No|||February 2013|February 26, 2013|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793194||71113|
NCT01793454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36048|Hyperoxic Oxidative Stress During Abdominal Surgery|Comparing the Effect of Hyperoxic and Conventional Fraction of Inspired Oxygen on Oxidative Stress During Abdominal Surgery.||Istanbul University|Yes|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|60 Years|No|||April 2015|April 8, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793454||71093|
NCT01793701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6883|Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer|A Phase I/II, Multi-centre Dose Escalation Study of Simultaneous Boost Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer|DEPICT|Queen Mary University of London|No|Recruiting|July 2010|||July 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|18 Years|N/A|No|||October 2014|October 23, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793701||71074|
NCT01793181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201149311|Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study|Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study||St. Erik Eye Hospital|No|Active, not recruiting|January 2013|November 2014|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|Samples Without DNA|Blood sample of vitamin D|Both|50 Years|90 Years|No|Non-Probability Sample|Consecutive patients with central retinal vein occlusion diagnosed at St Eriks Eye        Hospital|October 2014|October 2, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793181||71114|
NCT01793948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0365|Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer|A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer||Indiana University|Yes|Active, not recruiting|April 2013|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|75 Years|No|||March 2016|March 14, 2016|February 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01793948||71055|
NCT01753245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRR-ANT-2012-01|Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.|CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS VULGARIS, WITH OR WITHOUT ARTHRITIS, TREATED WITH ANTI-TNF IN REAL CLINICAL PRACTICE. ANALYSIS OF THE INFLUENCE OF METABOLIC SYNDROME ON TREATMENT EFFICACY.||Hospital Universitario Reina Sofia|No|Active, not recruiting|December 2012|June 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples With DNA|whole blood, serum, plasma.|Both|18 Years|80 Years|No|Non-Probability Sample|-Moderate-to-severe psoriasis treated >1 ys with anti-TNFalpha drugs at Reina Sofia        University Hospital|March 2014|March 12, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753245||74178|
NCT01785927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES.no. 18/2554|The Safety of Tuberculosis Treatments by Oral Inhalation|Clinical Trial Phase I of Antituberculosis Dry Powder Aerosols||Prince of Songkla University|Yes|Not yet recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785927||71669|
NCT01785940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103329|Continuous Interscalene Block for Same Day Discharge Following Total Shoulder Arthroplasty|Evaluation of Ultrasound Guided Continuous Interscalene Block for Same Day Discharge Following Total Shoulder Arthroplasty - An Open Label Feasibility Study||Lawson Health Research Institute|No|Recruiting|February 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785940||71668|
NCT01752972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-006-CT|Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic|Effect of Spirulina on the Levels of Zinc, Vitamin E and Linoleic Acid in the Palm Skin Extracts of People With Prolonged Exposure to Arsenic||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01752972||74199|
NCT01786499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3888-2|The Effect of Relaxation Response on Provider Burnout|||Allina Health System|No|Not yet recruiting|June 2013|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2013|February 6, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786499||71625|
NCT01786785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008442|Optical Measurement of Cerebral Hemodynamics in Children With Acute Arterial Ischemic Stroke|Optical Measurement of Cerebral Hemodynamics in Children With Acute Arterial Ischemic Stroke: A Pilot Study||Children's Hospital of Philadelphia|No|Recruiting|February 2012|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|74|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children (2-18 y.o.) presenting at the Children's Hospital of Philadelphia with a        confirmed arterial ischemic stroke|September 2015|September 28, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786785||71603|
NCT01754129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-895|Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa|Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)|GREENFIELD|AbbVie|No|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|99 Years|No|Non-Probability Sample|Adult patients already on treatment with DUODOPA® according local DUODOPA® product label        (treatment of advanced levodopa-responsive Parkinson's disease with severe motor        fluctuations and hyper/dyskinesia when available combinations of PD medicinal products        have not given satisfactory results) and according to specific reimbursement criteria will        be offered the opportunity to enroll in this study.|January 2016|January 8, 2016|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01754129||74110|
NCT01797952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 1201|A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation|A Randomized Double Blind Placebo Controlled Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation|mucositis|All India Institute of Medical Sciences, New Delhi|No|Not yet recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|108|||Both|10 Years|70 Years|No|||July 2015|July 28, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01797952||70747|
NCT01798212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PlicatorLinz|Prospective Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.|A Prospective Multi Center Case Controlled Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.||Krankenhaus Barmherzige Schwestern Linz|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01798212||70727|
NCT01791699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOX.AFABL.9.5.2012|Moxonidine for Prevention of Post-ablation AFib Recurrences|Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)||G.Gennimatas General Hospital|Yes|Completed|August 2012|April 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|25 Years|80 Years|No|||May 2014|May 4, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791699||71227|
NCT01791985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/23/2011|AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)|A Single Arm Phase IIa Study (With Combination SRI) to Assess the Safety & Efficacy of AZD4547 in Combination With Either Anastrozole or Letrozole in ER+ Breast Cancer Patients Who Have Progressed on Treatment With Anastrozole or Letrozole|RADICAL|Imperial College London|Yes|Recruiting|July 2012|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|25 Years|N/A|No|||June 2015|June 22, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791985||71205|
NCT01795664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2012-94|Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients|A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Seretide® Evohaler (Supplied by Allen & Hanburys, UK) and a Generic Salmeterol/Fluticasone HFA pMDI (Manufactured by Cipla Ltd, India) on Functional Respiratory Imaging Parameters in Asthmatic Patients.||FLUIDDA nv|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01795664||70923|
NCT01795677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAK ALLO STUDY|JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis|JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study||French Innovative Leukemia Organisation|Yes|Recruiting|December 2012|December 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|69 Years|No|||March 2016|March 15, 2016|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01795677||70922|
NCT01792583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/9022|The Nuvigil and Provigil Pregnancy Registry|The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry||Teva Pharmaceutical Industries|Yes|Recruiting|June 2009|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Registry is designed for open enrollment of all patients who meet the inclusion        criteria. The function and activities of the Nuvigil/Provigil Pregnancy Registry will be        publicized through direct mailings to obstetricians and pharmacists. Known prescribers        identified from marketing sources will be targeted for Registry awareness. A toll-free        phone line will be established for patient enrollment and a website containing information        about the Registry for both physician and patient recruitment will be available. The        Registry will be posted on the FDA website for pregnancy registries, with a direct link to        a Nuvigil/Provigil Registry website. For ongoing awareness, information on the Registry        will be included in the prescribing information and in the Medication Guides distributed        by the pharmacist at the time of dispensing. In addition, patient support groups or        condition-related sources of information may be targeted to raise patient awareness of the        Registry.|March 2016|March 1, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01792583|12 Months|71160|
NCT01792596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212E25704|Satiety Effects of Protein and Fiber Added to Pasta|Satiety Effects of Protein and Fiber Added to Pasta||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01792596||71159|
NCT01792895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A04-12|Different Types of Manual Therapy Techniques in Patients With Chronic Neck Pain|Is Better the One Type of Manual Therapy Than Others for to Treat the Patients With Chronic Neck Pain? : A Randomized Clinical Trial|CNP|Universidad Rey Juan Carlos|Yes|Completed|January 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||October 2013|October 21, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792895||71136|
NCT01793207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCS001|Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population|Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population||Cairo University|No|Completed|December 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|316|Samples With DNA|10cc blood sample and tissue biopsies from colorectal lesions when present.|Both|18 Years|85 Years|No|Probability Sample|Patients refered to Kasr-Alaini endoscopy unit and National cancer institute endoscopy        department for colonoscopy.|May 2015|May 4, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793207||71112|
NCT01793467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036598|Transplantation and the Use of Raltegravir in HIV-Infected Patients|Solid Organ Transplantation and the Use of Raltegravir in HIV-Infected Patients: An Observational Study of Pharmacokinetics, Safety, Tolerability and Efficacy||Duke University|No|Recruiting|October 2012|||October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|13 Years|80 Years|No|Non-Probability Sample|HIV positive patients, awaiting or listed for organ transplantation, currently taking        Raltegravir|August 2015|August 3, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793467||71092|
NCT01793714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00903-40|Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques|Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques|MALTA|Rennes University Hospital|Yes|Recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with brain tumor involving MRI realization|March 2016|March 21, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793714|1 Day|71073|
NCT01793727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000023363|Infant Glidescope® Learning Curve|Learning Curve of the Infant Glidescope® Cobalt Video Laryngoscope in Anesthesiology Residents||The Hospital for Sick Children|Yes|Completed|July 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|18 Months|Accepts Healthy Volunteers|||December 2013|December 2, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793727||71072|
NCT01795209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1207-162-005|Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision|Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity|RVOFV|Seoul National University Bundang Hospital|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795209||70958|
NCT01752673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23231|The Visualization of Uncertainty in Clinical Diagnostic Reasoning for Pulmonary Embolism|The Visualization of Uncertainty in Clinical Diagnostic Reasoning for Pulmonary Embolism: a Randomized Controlled Trial.||University of Calgary|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|24 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01752673||74222|
NCT01752686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Severance_BR_01|A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer|A Phase III Trial of Carboplatin as Adjuvant Chemotherapy Versus Observation in Triple Negative Breast Cancer With Pathologic Residual Cancer After Neoadjuvant Chemotherapy: POST-Neo Adjuvant Study||Severance Hospital|Yes|Not yet recruiting|March 2013|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|587|||Female|20 Years|N/A|No|||December 2012|December 21, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01752686||74221|
NCT01753232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-DALI-MONET-01-D|Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter|Non-interventional Study: Safety and Efficacy of the DALI LDL-adsorber and MONET-lipoprotein Filter|LINET|Fresenius Medical Care Deutschland GmbH|No|Completed|May 2012|August 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|Hypercholesterolemic patients from free-standing private apheresis centres and one        hospital department|September 2015|September 3, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753232||74179|
NCT01753219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onli|Onstep Versus Lichtenstein, the Onli Trial.|Effect of Suture for Mesh Fixation on Pain and Other Complications in Patients Undergoing Inguinal Hernia Repair: a Double-blind, Randomized Study Comparing the Lichtenstein With the Onstep Technique - the ONLI Trial.|Onli|Herlev Hospital|No|Completed|March 2013|August 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753219||74180|
NCT01753505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0549|Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients|||Yonsei University|No|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|40 Years|N/A|No|||February 2014|February 17, 2014|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753505||74158|
NCT01753817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0016 CTIL|Assessment of Radial Artery Patency Following Catheterization With a 7F Sheath|Observational Study of Radial Artery Patency Following Catheterization With a 7F Sheath||Jaffe, Ronen, M.D.|No|Not yet recruiting|January 2013|January 2015|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Two-hundred subjects who have previously undergone transradial cathetrization between the        years 1999 and 2012 with a 7F sheath will be identified in the Lady Davis Carmel Medical        Center Catheterization laboratory computerized database.|December 2012|December 26, 2012|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01753817||74134|
NCT01794650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West-Walker2|Guidelines for Post-exercise Dietary Intake in T1DM|The Metabolic and Glycaemic Responses to Changes in the Glycaemic Index of the Meal Consumed After Performing Evening Exercise in Type 1 Diabetes Mellitus||Northumbria University|Yes|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|50 Years|No|||November 2013|November 14, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794650||71001|
NCT01794663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN305-102|Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function|A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function||Opsona Therapeutics Ltd.|Yes|Recruiting|October 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|351|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794663||71000|
NCT01799096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRRH003|Effects of the Sugar Sucrose on Bodyweight and Energy Intake Over 28 Days in Obese Women|Effects of the Sugar Sucrose on Bodyweight and Energy Intake Over 28 Days in Obese Women||University of Hull|No|Completed|September 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|41|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799096||70661|
NCT01799109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-2012CQ|Lung Function of Asthmatic Children by Nebulized MgSO4|Lung Function Changes of Mild to Moderate Asthmatic Children Treated by Nebulized MgSO4||Chongqing Medical University|No|Completed|November 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|4 Years|10 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01799109||70660|
NCT01791712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KJWW367/53|Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal|Enhanced Vascular Endothelial Growth Factor and Pro-inflammatory Cytokine Clearances With On-line Hemodiafiltration Versus High-flux Hemodialysis in Sepsis-related Acute Kidney Injury Patients||Chulalongkorn University|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01791712||71226|
NCT01791725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-DS201|A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia|A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia|DS201|Transition Therapeutics Ireland Limited|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|45 Years|No|||December 2015|December 22, 2015|February 6, 2013|No|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01791725||71225|
NCT01791998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1017|Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer|A Pilot Study to Evaluate Magnet Resonance Thermal Imageguided Interstital Thermal Therapy for Focal Ablation of Breast Cancer||University of Chicago|No|Withdrawn|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|N/A|N/A|No|||October 2014|October 14, 2014|February 12, 2013|No|Yes|Funding was time sensitive and expired. No subjects enrolled.|No||https://clinicaltrials.gov/show/NCT01791998||71204|
NCT01792310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN-001-1203|A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours|A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval®) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma||Lipopharma Therapeutics SL|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01792310||71181|
NCT01792609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMO1208M18202|MIMO Clinical Trial|Minimize Implants Maximize Outcomes (MIMO) Clinical Trial|MIMO|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|January 2013|June 2018|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|10 Years|18 Years|No|||February 2015|February 4, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01792609||71158|
NCT01793480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004609-26|Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.|Phase IIIb Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.|EQUIMETH2|Laboratoires Bouchara-Recordati|No|Recruiting|December 2011|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793480||71091|
NCT01793740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035303|Cognitive Rehabilitation in Sickle Cell Disease|Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study||Duke University|No|Completed|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|8 Years|16 Years|No|||August 2014|August 19, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793740||71071|
NCT01793961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5331|Effects of Chronic Intake of Cannabis on Contrast Sensitivity|Effects of Chronic Intake of Cannabis on Contrast Sensitivity||University Hospital, Strasbourg, France||Not yet recruiting|February 2013|||July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|108|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793961||71054|
NCT01794481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.070|Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy|Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy||University of Michigan Cancer Center|Yes|Completed|January 2010|March 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794481||71014|
NCT01794715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2013-1|Ultrasound by Nurses in Heart Failure Patients|Is Routine Ultrasound Examination Performed by Nurses Useful in Heart Failure Patients at a Outpatient Clinic||Levanger Hospital|Yes|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|62|||Both|N/A|N/A|No|||January 2014|January 13, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01794715||70996|
NCT01783379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN AKF 12.05|Pharmacokinetics of Micafungin in Patients Intensive Care Unit|Pharmacokinetics of Micafungin (Mycamine ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|MIMIC|Radboud University|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|blood samples for pharmacokinietic analysis will be collected|Both|18 Years|N/A|No|Non-Probability Sample|All patients receiving micafungin for the treatment or suspicion of an invasive fungal        infection will be included. At least 20 patients will be included to obtain 16 evaluable        patients. If recruitment of 20 patients is achieved within one year, more patients can be        included. A formal sample size cannot be performed for several reasons but the sample size        is rather based on the general assumption that 16 patients are sufficient to have a        descriptive PK approach.|April 2014|April 29, 2014|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01783379||71865|
NCT01783392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16245|Peripheral Electrical Stimulation for the Treatment of Overactive Bladder|Peripheral Electrical Stimulation for the Treatment of Overactive Bladder|PESTOB|Sheffield Teaching Hospitals NHS Foundation Trust||Completed|March 2013|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01783392||71864|
NCT01783405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00137|Cardiovascular Disease in FH Heterozygous|Cardiovascular Disease in FH Heterozygous||Sociedad Española de Arteriosclerosis|Yes|Recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|1100|||Both|30 Years|70 Years|No|Non-Probability Sample|Heterozygous FH from the Lipid Units of the Sociedad Española de Arteriosclerosis (Spanish        Atherosclerosis Society)|June 2014|June 7, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01783405||71863|
NCT01752985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV202-010|Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease|A Double-Blind, Placebo-Controlled, Randomized, Two-stage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) Who Have Residual Macroalbuminuria Despite Treatment With an Inhibitor of the Renin-Angiotensin System||Bristol-Myers Squibb|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|89|||Both|18 Years|85 Years|No|||August 2015|August 18, 2015|December 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01752985||74198|
NCT01753544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-ESD-2012|Endoscopic Submucosal Dissection Using a Thulium Laser|Endoscopic Submucosal Dissection Using a Thulium Laser: Preliminary Results of a New Method for Treatment of Gastric Epithelial Neoplasia||Soonchunhyang University Hospital|Yes|Completed|October 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|ESD specimen will be examined by a experienced pathologist.|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients are diagnosed with gastric epithelial neoplasia in a private clinic and        referred to our hospital for endoscopic resection.|November 2015|November 16, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753544||74155|
NCT01753843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brief Delay in Cord Clamping|Brief Delay in Cord Clamping and Neurobehaviour in Preterms|A Randomised Controlled Trial to Evaluate the Role of Brief Delay in Cord Clamping in Preterm Neonates (34-36weeks) on Short Term Neurodevelopmental Outcome||Lady Hardinge Medical College|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 4, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01753843||74132|
NCT01753856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14592|Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis|Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Female|55 Years|89 Years|No|||September 2015|September 11, 2015|December 18, 2012|Yes|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01753856||74131|
NCT01753518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003183|A Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure|A Randomized Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure||Mayo Clinic|No|Completed|November 2012|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|December 5, 2012|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01753518||74157|The data are limited by the lack of diversity, and there may be racial or genetic differences in wound healing confounding the results. This trial was not powered for postoperative wound complications.
NCT01753531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-199|Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B|A Multicenter Performance Evaluation for the Ultra Influenza A&B Test Using Nasal Swabs||Sekisui Diagnostics, LLC|Yes|Completed|November 2012|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|677|Samples With DNA|Nasal swab specimens|Both|3 Months|N/A|No|Non-Probability Sample|Subjects presenting with symptoms suggestive of influenza virus infection will be enrolled        from geographically diverse CLIA Waived Intended Users (Physicians office laboratories,        clinics or equivalents)|June 2013|June 20, 2013|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01753531||74156|
NCT01753830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35GA1203|Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis|A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane® Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee||Q-Med AB|No|Terminated|December 2012|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|40 Years|80 Years|No|||August 2014|August 4, 2014|December 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01753830||74133|
NCT01784419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-001|Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients|Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients||University of California, San Francisco|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Anticipated|30|||Both|6 Years|N/A|No|||October 2014|October 17, 2014|February 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784419||71785|
NCT01795404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-NA-549-CTIL|A Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for Cancer Survivors.|A Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for Cancer Survivors - Effects on Quality of Life, Psychological Measures,Physical Symptoms, and Biological Measurements.|IBSR|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|90 Years|No|||February 2013|February 17, 2013|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01795404||70943|
NCT01795417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP200 3.25 MHZ RF|Safety and Efficacy of XP200 Radiofrequency Treatment of Wrinkles|Safety and Efficacy of Non-invasive Dermatologic Procedure With XP200 Radiofrequency for the Primary Treatment of Wrinkles and Rhytids||BTL Industries Ltd.|No|Completed|August 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795417||70942|
NCT01795430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12391|Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma|A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma||City of Hope Medical Center|Yes|Withdrawn|July 2013|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Months|40 Years|No|||January 2015|January 7, 2015|February 18, 2013|No|Yes|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01795430||70941|
NCT01794897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11120013|Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia|Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia||University of Pittsburgh|Yes|Enrolling by invitation|February 2013|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|156|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|February 22, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01794897||70982|
NCT01792349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12NE530|Increasing Physical Activity in Stroke Survivors Using STARFISH|Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Feasibility Study||NHS Greater Glasgow and Clyde|No|Recruiting|February 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01792349||71178|
NCT01792622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481296|Patient Reported Outcomes in Pulmonary Arterial Hypertension|Patient Reported Outcomes in Pulmonary Arterial Hypertension|PROPAH|Pfizer|No|Withdrawn|July 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pulmonary arterial hypertension|July 2013|July 31, 2013|February 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01792622||71157|
NCT01792635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731003|A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus|A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Terminated|December 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|65 Years|No|||July 2014|July 2, 2014|December 20, 2012|No|Yes|The study was terminated prematurely on 16 May 2014 due to a safety concern.|No||https://clinicaltrials.gov/show/NCT01792635||71156|
NCT01792908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T11230S|Kinesio Tape Effects on Ankle Proprioception|Has Kinesio Tape Effects on Ankle Proprioception? A Randomized Clinical Trial||University Rovira i Virgili|Yes|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792908||71135|
NCT01792323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPHER-Clamp|Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations|Subcutaneous Insulin Absorption Following Bolus Administrations With an Insulin Pump - Comparison of Bolus Administrations With Different Bolus Durations||Medical University of Graz|Yes|Completed|August 2011|January 2014|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|60 Years|No|||February 2014|February 25, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792323||71180|
NCT01792336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130076|Transcranial Magnetic Stimulation for Focal Hand Dystonia|Gamma Frequency Transcranial Magnetic Stimulation in Dystonia||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|62|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792336||71179|
NCT01792921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0576-12|Effectiveness of a Cognitive-functional (Cog-Fun) Intervention for Children With ADHD|COG FUN Intervention for ADHD||Hadassah Medical Organization|No|Not yet recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|||Both|7 Years|10 Years|No|Probability Sample|Children age 7-10 years diagnosed with ADHD|February 2013|February 14, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01792921||71134|
NCT01793220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOAPSS1|Economic and Clinical Outcomes of Attendance in Psychosis Services Using SMS.|Economic and Clinical Outcomes of Attendance in Psychosis Services Using SMS: The ECO APSS Randomized Controlled Trial|ECO APSS|King's College London|No|Not yet recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793220||71111|
NCT01794494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVENCE-1|Prospective Observation Study of Cost Effectiveness of Interventions for Critical Ischemia|Prospective Observation Study of Cost Effectiveness of Interventions for Critical Ischemia|PROVENCE|Sahlgrenska University Hospital, Sweden|No|Active, not recruiting|November 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Patients with critical limb ischemia coming to the for vascular department in the western        region of Sweden.|May 2015|May 18, 2015|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01794494|2 Years|71013|
NCT01794520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-367|Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma||AbbVie|No|Active, not recruiting|October 2012|August 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|October 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794520||71011|
NCT01794728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.115|How the Elderly Live With Pain in Heart Failure|How the Elderly Live With Pain in Heart Failure|HELP-HF|Thomas Jefferson University|No|Completed|July 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|60 Years|N/A|No|Non-Probability Sample|Men and women age 60 or greater hospitalized with acute decompensated heart failure.|November 2015|November 2, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01794728||70995|
NCT01794741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 4007|3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis|Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|February 2013|||November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|4 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 22, 2015|February 15, 2013|Yes|Yes||No|March 22, 2015|https://clinicaltrials.gov/show/NCT01794741||70994|
NCT01795235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16391|Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones|Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones||University of Virginia|No|Recruiting|December 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|6|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01795235||70956|
NCT01794962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU2012|"Cognitive Functional Therapy" vs. Manual Therapy for Non-specific Low Back Pain|Classification Based "Cognitive Functional Therapy" vs. Manual Therapy for a Subgroup of Patients With Chronic NSLBP, Classified as Having a "Flexion Pattern"||Spine Centre of Southern Denmark|No|Recruiting|October 2012|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2013|February 16, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01794962||70977|
NCT01794975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIMI 2|Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline|Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline - a PET Study in Healthy Human Subjects|AIMI2|University of Turku|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794975||70976|
NCT01783431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101838|Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma||Medical University of South Carolina|Yes|Terminated|October 2012|November 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2014|October 1, 2015|January 25, 2013|Yes|Yes|The study was terminated early due to low accrual.|No||https://clinicaltrials.gov/show/NCT01783431||71861|
NCT01753557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A12|Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C|A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naïve or Relapsed After Previous Treatment||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|65 Years|No|||August 2015|August 17, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753557||74154|
NCT01783912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0604|Helping Those With Mental Illness Quit Smoking|Preparing Those With Significant and Persistent Mental Illness to Quit Smoking||University of Wisconsin, Madison|Yes|Completed|December 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|99 Years|No|||January 2016|January 29, 2016|January 22, 2013||No||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01783912||71824|
NCT01784185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPU-DIMPA-WUM12(1)|Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling|Development and Evaluation of Clinical Utility of Virtual Bronchoscopy (VB)-Based System for Bronchoscopic Navigation, Mediastinal Mapping and Transbronchial Aspiration of Mediastinal Lesions.|VB/EBUS-TBNA|Medical University of Warsaw|No|Recruiting|January 2013|April 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01784185||71803|
NCT01784432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 0150.0.135.000-10|Effects of Low-level Laser Therapy on Global Gene Expression of Young Males Submitted to Physical Strength Training|Effects of Low-level Laser Therapy on Global Gene Expression of Young Males Submitted to Physical Strength Training||Universidade Federal de Sao Carlos|Yes|Completed|January 2011|September 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||February 2013|February 3, 2013|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01784432||71784|
NCT01784731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDU1|User Charges for General Practitioner Services in Denmark|Brugerbetaling i Almen Praksis (In Danish: User Charges for General Practitioner Services)||University of Southern Denmark|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients enrolled with a general practitioner clinic|March 2013|March 11, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784731||71761|
NCT01795443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/AD-03|Lumbar Proprioception in Lower Back Pain Patients Versus Healthy Subjects : a Comparative Study on the Effects of Low- and High-frequency Muscle Vibrations|Lumbar Proprioception in Lower Back Pain Patients Versus Healthy Subjects : a Comparative Study on the Effects of Low- and High-frequency Muscle Vibrations|Vibrioception|Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|12||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795443||70940|
NCT01794910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1136-5605|A Randomized Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training|A Randomized Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training on Improving Muscle Strength of Women After Vaginal or Cesarean Delivery|PFMT|University of Sao Paulo|No|Completed|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|297|||Female|35 Years|45 Years|No|||February 2013|February 19, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01794910||70981|
NCT01793493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente).|Effects of Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia: a Randomized Controlled Trial (Allena-Mente).|Allena-Mente|Fondazione Golgi Cenci|Yes|Completed|March 2011|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|70 Years|75 Years|No|||August 2015|August 14, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793493||71090|
NCT01793753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000231|Effect of Propofol on Internal Anal Sphincter Pressure During ARM|||Massachusetts General Hospital||Recruiting|October 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|2 Years|6 Years|No|Non-Probability Sample|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal        manometry including propofol per standard of care|February 2013|February 14, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01793753||71070|
NCT01793974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008065|Genetics of Latent Autoimmune Diabetes in Adults|A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults|LADA|Children's Hospital of Philadelphia|No|Recruiting|July 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|Whole blood, plasma, serum|Both|25 Years|N/A|No|Non-Probability Sample|The recruitment will be carried out at several adult diabetes clinics across the United        States.|October 2015|October 8, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01793974||71053|
NCT01793766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000191|Non-invasive Brain Modulation for Weight Maintenance|Neurobehavioral Contribution to Weight Loss Maintenance: an Interdisciplinary Experimental Study With Noninvasive Brain Modulation||Massachusetts General Hospital|Yes|Terminated|May 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|55 Years|No|||December 2015|December 3, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01793766||71069|
NCT01793987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWR001|Coblation in Endoscopic Sinus Surgery|The Effect of Coblation on Blood Loss in Endoscopic Sinus Surgery: A Randomized Controlled Trial||Western University, Canada|No|Not yet recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|70 Years|No|||February 2013|February 14, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793987||71052|
NCT01794195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0145|Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking|Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking||University Hospital, Clermont-Ferrand||Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|63|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01794195||71036|
NCT01794208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXGP24201|Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®|A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing ICSI Treatment||Glycotope GmbH|No|Completed|January 2013|June 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|240|||Female|18 Years|37 Years|No|||June 2014|June 23, 2014|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01794208||71035|
NCT01794221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1290443|The Role of 2-octyl Cyanoacrylate in Prevention of Recurrent Adhesions After Circumcision|The Role of 2-octyl Cyanoacrylate in Prevention of Recurrent Adhesions After Circumcision|Circ glue|Children's Mercy Hospital Kansas City|No|Recruiting|November 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|336|||Male|N/A|7 Years|No|||January 2016|January 27, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794221||71034|
NCT01794754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2265-3|Occupational Therapy and Surgery in Carpometacarpal Osteoarthritis|May Occupational Therapy Delay the Need for Surgery in Carpometacarpal Osteoarthritis: A Randomised Controlled Trial.||National Resource Center for Rehabilitation in Rheumatology|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794754||70993|
NCT01794988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR059674-03|Can Therapy Alter CNS Processing of Chronic Pain: A Longitudinal Study|Can Therapy Alter CNS Processing of Chronic Pain: A Longitudinal Study||University of Vermont|No|Recruiting|July 2010|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794988||70975|
NCT01795001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55133|The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy|The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|330|Samples With DNA|Non-interventional study on corneal endothelium, anterior eye chamber fluid and      paraffin-embedded corneal tissue, using molecular techniques to identify and characterise      the molecular players involved in the pathogenesis of FECD.|Both|N/A|N/A|No|Probability Sample|Patients with Fuchs' Endothelial Corneal Dystrophy (FECD), normal control patients, and        patients with non-Fuchs edematous corneas; in university hospital setting.|December 2015|December 7, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01795001||70974|
NCT01795807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGEA 001-12|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2013|||||N/A|N/A|N/A||||||||||||||February 19, 2013|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795807||70912|
NCT01792141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH 1010|Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment|The Use of Fluorescein-Indocyanine Green Angiography in Patients With Diabetic Macular Edema to Identify Areas of Increased Leakage and Provide Targeted Focal Laser Treatment.||Retina Institute of Hawaii|No|Completed|January 2011|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Clinically Significant Macular Edema|February 2013|February 12, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792141||71194|
NCT01783184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-ANA01|Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms|Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms||Vascutek Ltd.|No|Active, not recruiting|June 2012|October 2018|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Probability Sample|Abdominal Aortic Aneurysm (AAA)|December 2014|December 9, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783184||71880|
NCT01783418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3550|Mindfulness-based Intervention for Teenagers With Cancer|A Randomized, Wait-list Controlled Clinical Trial: the Effects of a Mindfulness-based Intervention on Quality of Life, Sleep and Mood in Adolescents With Cancer.||St. Justine's Hospital|No|Completed|August 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|15|||Both|12 Years|18 Years|No|||December 2015|December 7, 2015|January 29, 2013||No||No|September 24, 2015|https://clinicaltrials.gov/show/NCT01783418||71862|Major recruitment and retention issues leading to very small number of subjects recruited and analyzed.Small sample leading to underpowered study and uninterpretable data
NCT01783665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13332|The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis|The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis||University of Kansas Medical Center|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|21 Years|80 Years|No|||February 2016|February 8, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783665||71843|
NCT01783678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0124|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects||Gilead Sciences|Yes|Completed|January 2013|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|275|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|January 31, 2013|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01783678||71842|
NCT01783639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRION™ Pivotal Study (WISE)|Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting|The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting|WISE|Gardia Medical|Yes|Completed|February 2013|April 2015|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|No|||June 2015|July 26, 2015|January 13, 2013||No||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01783639||71845|
NCT01783938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-064|Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)|An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma||Bristol-Myers Squibb|No|Active, not recruiting|April 2013|April 2017|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|January 21, 2016|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783938||71822|
NCT01784198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00070|Determination of Protein Requirements in Pregnancy|Determination of Protein Requirements in Healthy Pregnant Women Using Indicator Amino Acid Oxidation Technique||University of British Columbia|Yes|Completed|April 2011|March 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|20|||Female|19 Years|35 Years|No|||April 2014|April 8, 2014|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01784198||71802|
NCT01784211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14183|A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes|The Pharmacokinetic and Pharmacodynamic Intra-subject Variability of LY2605541 and the Effect of Exercise on LY2605541 Pharmacokinetics in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|76|||Both|18 Years|65 Years|No|||November 2013|November 27, 2013|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01784211||71801|
NCT01784445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP 2013|Post ERCP Pancreatitis Prevention in Average Risk Patients|Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial||University Hospital Rijeka|No|Completed|June 2013|February 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01784445||71783|
NCT01791738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 10-1138|Acetabular Shell Positioning Using Patient Specific Instruments|Comparison of Acetabular Shell Position Using Patient Specific Instruments vs. Standard Surgical Instruments: A Randomized Clinical Trial||The Cleveland Clinic|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|85 Years|No|||July 2015|July 9, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791738||71224|
NCT01795690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOM TAR|Clinical Tumor Anemia Registry (TAR)|Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia|TAR|iOMEDICO AG|No|Completed|December 2011|February 2016|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1018|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with malignant diseases starting anti-anemic treatment|December 2014|February 26, 2016|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01795690||70921|
NCT01795703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017062|A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel|A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy||Janssen Research & Development, LLC|Yes|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Male|20 Years|N/A|No|||November 2015|November 3, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795703||70920|
NCT01793246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT_2012_lung_01|Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung|Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy: Discrete Pulmonary Lesions and Acute Rejection in Transplanted Lungs|BREATH|Mauna Kea Technologies|No|Active, not recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are 18 years of age or older with a clinical indication for a Bronchoscopic        procedure for:          -  Discrete Lung Lesions          -  Surveillance or Symptoms of Acute Rejection in Lung Transplants|November 2015|November 4, 2015|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793246||71109|
NCT01793506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter-01|Novel Testing Procedures|Novel Testing Procedures for Detection of Primary Humoral Immunodeficiency||Medical College of Wisconsin|No|Not yet recruiting|April 2016|June 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|1 Year|80 Years|No|Non-Probability Sample|Male or female, 1 year to 80 years of age|January 2016|January 25, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01793506||71089|
NCT01793779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2013-CS01|Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness|Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness in Experienced Resistance Trained Individuals.||Metabolic Technologies Inc.|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793779||71068|
NCT01794767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparin2012|Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children|Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children||University of Florence|No|Suspended|January 2013|August 2016|Anticipated|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|52|||Both|2 Years|14 Years|No|||October 2015|October 28, 2015|January 29, 2013||No|difficult recruiting|No||https://clinicaltrials.gov/show/NCT01794767||70992|
NCT01794234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28346|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues|Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice||Hoffmann-La Roche||Terminated|August 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B initiated on therapy with Pegasys|March 2016|March 1, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794234||71033|
NCT01794507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-901|A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy|A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Therapy||AbbVie|No|Recruiting|November 2012|January 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794507||71012|
NCT01795248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM-TREAT|The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes|The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|July 2012|||August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795248||70955|
NCT01795508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFI 2505|Parent Management Training, Oregon|The Effect of Parent Management Training, Oregon, in Denmark|PMTO|The Danish National Centre For Social Research|No|Recruiting|January 2013|December 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|3 Years|12 Years|No|||August 2014|August 15, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795508||70935|
NCT01795794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor034612ctil|Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC|||Soroka University Medical Center|No|Not yet recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|12 Years|N/A|No|||February 2013|February 26, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01795794||70913|
NCT01792440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220084152|The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis|The Sputum Colour Chart as a Predictor of Lung Inflammation, Proteolysis and Damage in Non-cystic Fibrosis Bronchiectasis||Universitaire Ziekenhuizen Leuven|No|Completed|September 2009|December 2012|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|80|Samples With DNA|induced sputum cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|non-cystic fibrosis bronchiectasis|February 2013|February 19, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792440||71171|
NCT01783444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001Y2201|A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.|Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.|BOLERO-6|Novartis|Yes|Active, not recruiting|February 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|317|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783444||71860|
NCT01783691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-SCD1|Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)|A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease||NKT Therapeutics|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||June 2015|June 25, 2015|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01783691||71841|
NCT01783704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00046956|Improving Community Ambulation After Hip Fracture|Improving Community Ambulation After Hip Fracture|CAP|University of Maryland|Yes|Recruiting|June 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783704||71840|
NCT01783652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|catch_it_2013|Adapted and Translated, Adolescent Depression, Internet Intervention|Adaptation of a U.S. Internet Tool to Prevent Depression and Addiction in Hong Kong Adolescents||The University of Hong Kong|No|Active, not recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|138|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783652||71844|
NCT01783925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16469|Eylea Regulatory Post Marketing Surveillance(rPMS)|Eylea Regulatory Post Marketing Surveillance in Korea||Bayer|No|Recruiting|April 2014|March 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3600|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with wet age-related macular degeneration(wAMD) who are decided to        receive EYLEA (VEGF Trap Eye) treatment|March 2016|March 18, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783925||71823|
NCT01784237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB101-77|A Novel Anterior Rhinoscopic Scoring Scale to Predict Nasal Insertability Before Transnasal Endoscopy|Comparison Between an Anterior Rhinoscopic Scoring Scale With the Sniff Test to Predict Nasal Insertability Before Transnasal Endoscopy: A Prospective, Randomized, Controlled Study||Buddhist Tzu Chi General Hospital|No|Recruiting|September 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|233|||Both|18 Years|65 Years|No|||February 2013|February 2, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01784237||71799|
NCT01784224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010346|A Comparison of the Blom Low Profile Voice Inner Cannula and the Passy-Muir One-Way Tracheotomy Tube Speaking Valve on Voice Production, Speech Intelligibility, and Biomechanical Swallowing Behavior|A Comparison of the Blom Low Profile Voice Inner Cannula and the Passy-Muir One-Way Tracheotomy Tube Speaking Valve on Voice Production, Speech Intelligibility, and Biomechanical Swallowing Behavior||Yale University|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01784224||71800|
NCT01784757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104003|Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer|A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer|ARAFOR|Orion Corporation, Orion Pharma|No|Active, not recruiting|March 2013|July 2016|Anticipated|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Male|18 Years|N/A|No|||January 2016|January 13, 2016|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784757||71759|
NCT01784770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661208|Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)|Zithromac Iv Special Investigation For Legionella Infection.|RESCUE-L|Pfizer|No|Active, not recruiting|March 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A0661208 prescribes the Zithromac IV.|March 2016|March 23, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784770||71758|
NCT01792648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM2222|Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome|Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome||Children's Hospital & Research Center Oakland|No|Recruiting|April 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01792648||71155|
NCT01792934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-073|Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases|A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.|ORCHESTRA|VU University Medical Center|Yes|Recruiting|December 2012|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|478|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01792934||71133|
NCT01795716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMTN-1.0|Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body|Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||May 2015|May 16, 2015|February 6, 2013||No||No|March 16, 2014|https://clinicaltrials.gov/show/NCT01795716||70919|
NCT01794000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13038|A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.||Eli Lilly and Company|Yes|Terminated|April 2013|December 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|341|||Both|2 Years|17 Years|No|||February 2016|February 25, 2016|February 14, 2013|Yes|Yes|The study is being terminated for lack of efficacy.|No||https://clinicaltrials.gov/show/NCT01794000||71051|
NCT01794247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGLIDIT-12|Intrathecal Magnesium for Same-day-surgery|Intrathecal Magnesium Associated to Lidocaine Decreases the Incidence of the Transitory Neurologic Syndrome Following Same-day-surgery|MAGLIDIT|Hospital General de Ciudad Real|Yes|Terminated|April 2013|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|80 Years|No|||March 2014|March 7, 2014|February 15, 2013||No|low recruitment rate|No||https://clinicaltrials.gov/show/NCT01794247||71032|
NCT01794533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18050|Effect of Fentanyl on the Rate of Anesthesia|Analgesic Efficacy of a Combination of Fentanyl and Lidocaine for Maxillary Infiltration in Teeth With Irreversible Pulpitis||Islamic Azad University, Tehran|Yes|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||February 2013|February 16, 2013|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794533||71010|
NCT01795820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHIFT-OVER|Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor|Platelet Aggregation During Pharmacological Shift From Clopidogrel to Ticagrelor in Patients With Acute Coronary Syndrome|SHIFT-OVER|University Magna Graecia||Completed|November 2012|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|50|||Both|18 Years|80 Years|No|||February 2013|February 18, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01795820||70911|
NCT01795547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14724A|Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia|A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|February 18, 2013|Yes|Yes||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01795547||70932|
NCT01795014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVP0002|Correlation of Orbital Cerebrospinal Fluid Pressure and Retinal Venous Outflow in Primary Open-angle Glaucoma|Analysis of the Relationship Between Optic Nerve Sheath Diameter and the Spontaneous Venous Pulsation in Primary Open-angle Glaucoma||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|January 2013|February 15, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01795014||70973|
NCT01792154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH 1011|Measuring Corneal Cells With Specular Microscopy|Specular Photomicrograpic Assessment of the Effect of Anti-VEGF Intravitreal Injections on Corneal Thickness and Endothelial Cell Density and Morphology||Retina Institute of Hawaii|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects of either gender with an age greater than 50 years of age who have been receiving        intraocular Anti-VEGF medication every month for at least the past 3 months.|February 2013|February 12, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792154||71193|
NCT01792167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CE001677|Multi-Site Evaluation of Second Step|Multi-site Evaluation of Second Step: Student Success Through Prevention (Second Step - SSTP) in Preventing Bullying and Sexual Violence|SSTP|University of Illinois at Urbana-Champaign|No|Active, not recruiting|September 2009|October 2014|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4089|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01792167||71192|
NCT01792453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10012013|240 mL Water Drink Study|MRI Quantification of Gastric and Small Bowel Liquid Volumes Before and After Ingestion of the Standard Oral Solid Delivery 240 mL Water Drink||University of Nottingham|No|Completed|February 2013|May 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792453||71170|
NCT01783457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsychEd-FEP|e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis|e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis||Basque Health Service|No|Completed|January 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|45 Years|No|||January 2016|January 25, 2016|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01783457||71859|
NCT01784263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002061|Schema, Emotion, and Behavior Therapy for Children|Treatment of Autism Symptoms in Children (TASC): Initial RCT With Active Control|SEBASTIEN|University of California, Los Angeles|Yes|Recruiting|March 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Years|13 Years|No|||January 2016|January 26, 2016|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01784263||71797|
NCT01783951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1+DC CIK- G|Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer|||Capital Medical University|No|Recruiting|February 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783951||71821|
NCT01783964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-110|Elacytarabine Mass Balance Study in Healthy Volunteers|An Open-Label, Single-Dose Study Designed to Assess the Mass Balance Recovery of an Intravenous Microdose of [14C]-Elacytarabine in Healthy Male Subjects||Clavis Pharma|No|Completed|February 2013|June 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783964||71820|
NCT01784250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON000|Efficacy of Clonidine and Propranolol in Dentistry (AAA)|Efficacy of Clonidine and Propranolol Versus Placebo for the Control of Anxiety During Surgical Procedures in Dentistry||CES University|Yes|Recruiting|August 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|14 Years|40 Years|No|||February 2013|February 2, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01784250||71798|
NCT01784458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0004|Clinical Significance of Intra-abdominal Hypertension in Surgical Patients With Severe Sepsis|Observational Study of Relationship Between Intra-abdominal Hypertension and Severe Sepsis in Surgical Patients||University of Ulsan|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to surgical intensive care unit with severe sepsis|February 2013|February 3, 2013|February 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01784458|2 Months|71782|
NCT01785043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAED001|Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users|Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users: A Randomized, Open-label, Parallel-group and Active Controlled Trial|LAED001|Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|March 2013|September 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|45 Years|65 Years|No|||September 2015|September 14, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01785043||71737|
NCT01792661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-072|Navigating the Challenges of Chronic Kidney Disease|Navigating the Challenges of Chronic Kidney Disease|CKD|The Cleveland Clinic|Yes|Active, not recruiting|February 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|209|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792661||71154|
NCT01792011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Institute of LLT|Accuracy of the Pleth Variability Index to Predict Fluid Responsiveness in Liver Transplantation|Accuracy and Utility of the Pleth Variability Index as a Predictor of Fluid Responsiveness During the Dissection and Anhepatic Phase of Liver Transplantation||Inonu University|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792011||71203|
NCT01792024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1841|MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer|PHASE II EVALUATION OF MR-GUIDED LASERINDUCED INTERSTITIAL THERMAL THERAPY (LITT) FOR PROSTATE CANCER||University of Chicago|No|Active, not recruiting|January 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Male|45 Years|N/A|No|||March 2016|March 1, 2016|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792024||71202|
NCT01795027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCCGPS|Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer|A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer|CAPITAL|Sun Yat-sen University|No|Recruiting|September 2011|June 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|724|||Both|18 Years|70 Years|No|||November 2015|November 1, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01795027||70972|
NCT01795261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD075050-01|Healthy Beginning Initiative|Comparative Effectiveness of Congregation and Clinic Based Approaches to Prevention of Mother to Child Transmission of HIV|HBI|University of Nevada, Reno|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|5400|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and their male partners who are 18 years and older and attend one of the 40        churches in the Enugu state of Nigeria will be eligible to participate in the study. All        participation is voluntary.|November 2015|November 30, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01795261||70954|
NCT01795521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22113-08113|LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC|LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial|LungTech|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|August 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795521||70934|
NCT01795534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jan 13|Beetroot Juice as a Potential Ergogenic Aid During Exercise in Hypoxia|Beetroot Juice as a Potential Ergogenic Aid During Exercise in Hypoxia||Bangor University|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 18, 2013||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01795534||70933|
NCT01795560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-13|Follow up by US Following Hospitalization With Periappendicular Abscess Refusing to be Operated on Within a Few Weeks.|US Follow-up After Appendicitis Attack.||Hillel Yaffe Medical Center|Yes|Enrolling by invitation|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients diagnosed in the last 10 years suffering from periappendicular abcess.|February 2013|February 19, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795560||70931|
NCT01795573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17263|Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease|Phase I Trial of Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease||H. Lee Moffitt Cancer Center and Research Institute|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|February 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01795573||70930|
NCT01795833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1999|Diabetes Prevention Using SMS Technology|A Pragmatic and Scaleable Strategy Using Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK||Imperial College London|Yes|Active, not recruiting|April 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2178|||Both|18 Years|74 Years|No|||February 2016|February 22, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01795833||70910|
NCT01791816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL112736-01A1|Mechanisms of Vasovagal Syncope|Mechanisms of Vasovagal Syncope||New York Medical College|Yes|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|14 Years|29 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01791816||71218|
NCT01791829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2012-LUMINA|A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer|A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer|LUMINA|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|July 2013|||March 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Specimens will be used to determine Ki67 status by IHC and subsequent testing for DNA/RNA.|Female|55 Years|N/A|No|Probability Sample|This is a multicentre, single-arm prospective cohort study evaluating risk of IBTR        following BCS in a group of women postulated to be at low risk for recurrence. Subjects        will be followed for 10 years and will be assessed for recurrent disease, new primary        cancer and survival. The primary outcome is IBTR|March 2016|March 18, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791829||71217|
NCT01792180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nr. 60-61900-98-449|The Senior Step Study How Elderly Help Themselves Maximally Forward|The Senior Step Study: How Elderly Help Themselves Maximally Forward|SSS|Radboud University|No|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|70 Years|N/A|No|||January 2014|January 21, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792180||71191|
NCT01792193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studie 139/12|Gut-derived Neuropeptides in Cerebrospinal Fluid of Patients With Parkinson's Disease and Healthy Controls|Quantitative Analysis of Gut-derived Neuropeptides in Cerebrospinal Fluid (CSF) of Patients With Parkinson's Disease and Healthy Controls||Saarland University|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|CSF and serum samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease|March 2016|March 16, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01792193||71190|
NCT01792466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007021|RCT of the Double Wire Technique With or Without Transpancreatic Sphincterotomy for Difficult Common Bile Duct Cannulation|A Randomized Controlled Trial of the Double Wire Technique With or Without Transpancreatic Sphincterotomy for Difficult Common Bile Duct Cannulation||Mayo Clinic|No|Recruiting|February 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792466||71169|
NCT01784003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7972W|Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development|Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development||VA Eastern Colorado Health Care System||Recruiting|June 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Study 1: Non-amputee Study 2: Unilateral transtibial amputee Study 3: Unilateral        transtibial amputee Study 4: Non-amputee Study 5: Unilateral transtibial amputee|December 2015|December 24, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01784003||71817|
NCT01783509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGMD Nat Hx|Limb Girdle Muscular Dystrophy (LGMD) Natural History|Longitudinal Assessment and Genetic Understanding of Limb-Girdle Muscular Dystrophy||Carolinas Healthcare System|No|Recruiting|November 2011|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood|Both|6 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of GENETICALLY CONFIRMED LGMD|February 2015|February 2, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01783509|20 Years|71855|
NCT01783977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 092|Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|April 2013|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|209|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01783977||71819|
NCT01783990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN268201200023C|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol|BABY HUG|National Heart, Lung, and Blood Institute (NHLBI)|No|Enrolling by invitation|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|158|Samples With DNA|Stored blood and urine|Both|24 Months|18 Years|No|Probability Sample|All subjects enrolled in the BABY HUG Follow-Up I Study who participated for at least 24        months are eligible for the Follow-Up Study II.|January 2013|February 4, 2013|February 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783990||71818|
NCT01784783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44357-A|Home-based Partner Education and Testing (HOPE) Study|HIV Testing and Educating Male Partners to Improve Maternal and Infant Outcomes: Home-based Partner Education and Testing (HOPE) Study|HOPE|University of Washington|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|601|||Both|14 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784783||71757|
NCT01785056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000052|IVIG Treatment in Systemic Sclerosis|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis||Georgetown University|Yes|Recruiting|April 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01785056||71736|
NCT01785069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410XL-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2012|||||N/A|N/A|N/A||||||||||||||April 6, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785069||71735|
NCT01793532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130070|Study of [11C]DPA-713 for Temporal Lobe Epilepsy|Assessment of [11C]DPA-713 in Temporal Lobe Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793532||71087|
NCT01792947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUE2013-1|Percutaneous Electroneurostimulation of Dermatome T6 for Appetite Reduction and Weight Loss in Morbidly Obese Patients|Percutaneous Electroneurostimulation of Dermatome T6 for Appetite Reduction and Weight Loss in Morbidly Obese Patients||Hospital General Universitario Elche|Yes|Completed|June 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01792947||71132|
NCT01793233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE11C1|Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas|Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma||Children's Oncology Group|Yes|Recruiting|June 2013|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|205|Samples With DNA|blood|Female|N/A|29 Years|No|Non-Probability Sample|Female patients newly diagnosed with lymphoma. This includes but is not limited to Hodgkin        Lymphoma, Burkitts Lymphoma, Diffuse Large B Cell Lymphoma, and Anaplastic Large Cell        Lymphoma|December 2015|December 3, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793233||71110|
NCT01794806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIOWA-OG-001|Efficacy of Socket Grafting for Alveolar Ridge Preservation|Efficacy of Socket Grafting for Alveolar Ridge Preservation: A Randomized Controlled Trial||University of Iowa|Yes|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01794806||70989|
NCT01795040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEGA-Study|Efficacy of Omega-3/Omega-6 Fatty Acids in Pre-school Children at Risk for ADHD|Efficacy of a Supplementary Balanced Diet With Omega-3/ Omega-6 Fatty Acids Among 3-6 Year Olds With Symptoms of ADHD||University of Cologne|No|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|6 Years|No|||April 2014|April 14, 2014|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01795040||70971|
NCT01795274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHOENIX-01|Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial|Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial|PHOENIX-01|University Hospital Heidelberg|Yes|Not yet recruiting|April 2013|April 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795274||70953|
NCT01795287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kaakinen001|Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture|Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture: A Single-center Randomized, Controlled Trial.||University of Oulu|No|Recruiting|March 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01795287||70952|
NCT01795586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17169|A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients|A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|February 2013|December 2016|Anticipated|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|February 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01795586||70929|
NCT01795846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12L3330001|Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis and/or Asthma.|||Ankara University|No|Not yet recruiting|March 2013|March 2014|Anticipated|January 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will included adult patients with moderate/severe perennial allergic        rhinitis and mild/moderate asthma who were monosensitized to house dust mites or        sensitized to at least 2 different allergens including house dust mites. No patient will        previously had been performed allergen immunotherapy.|February 2013|February 28, 2013|February 20, 2013||||No||https://clinicaltrials.gov/show/NCT01795846|3 Months|70909|
NCT01791842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.648|TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE|TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.|TOCIDYS|Hospices Civils de Lyon|Yes|Recruiting|February 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791842||71216|
NCT01791855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261008|PF-04634817 Renal Impairment Study|A Phase 1, Single Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04634817||Pfizer|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|26|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01791855||71215|
NCT01791868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100148|Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.|Randomized and Multicenter Study Assessing the Efficacy of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.|VALSE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791868||71214|
NCT01793090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-12-92|EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment|Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect||Bambino Gesù Hospital and Research Institute|No|Active, not recruiting|January 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|20 Years|No|||April 2014|April 23, 2014|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01793090||71121|
NCT01793103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002P0001762|Brigham and Women's Rheumatoid Arthritis Sequential Study|Brigham and Women's Rheumatoid Arthritis Sequential Study|BRASS|Brigham and Women's Hospital|No|Recruiting|March 2003|March 2028|Anticipated|March 2028|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|Samples With DNA|whole blood, serum, DNA|Both|18 Years|N/A|No|Non-Probability Sample|Adults 18 years or older with Rheumatoid Arthritis|July 2015|July 29, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793103|15 Years|71120|
NCT01784042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 12-075|Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue|Effect of Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue and Systemic Biomarkers of Breast Cancer Risk||Milton S. Hershey Medical Center|Yes|Not yet recruiting|March 2013|March 2018|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2080|||Female|30 Years|55 Years|No|||November 2013|November 12, 2013|January 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01784042||71814|
NCT01784055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800001-001|NeoChord TACT Post-Market Surveillance Registry|Post-Market Surveillance Registry for the NeoChord DS1000||NeoChord|No|Active, not recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|126|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Grade 3+ or 4+ mitral valve regurgitation who are candidates for surgical        mitral valve repair or replacement|December 2015|December 19, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01784055|1 Year|71813|
NCT01783717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-217|Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage|Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage||Huashan Hospital|Yes|Recruiting|December 2012|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|55 Years|No|||October 2013|October 20, 2013|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01783717||71839|
NCT01783730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-983|Special Investigation in Rheumatoid Arthritis Patient Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents|Special Investigation in Japanese Rheumatoid Arthritis Patients Who Have no Previous Use of DMARDs and Biological Agents||AbbVie||Completed|February 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|166|||Both|16 Years|99 Years|No|Non-Probability Sample|Rheumatoid Arthritis patients showing rapid progression of structural damage of the        joints, who have no prior history of treatment with disease-modifying anti-rheumatic drugs        or biological agents.|October 2015|October 14, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01783730||71838|
NCT01783743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00043444|Identification of TT Cases by Community Treatment Assistants: An Assessment|Identification of TT Cases by Community Treatment Assistants: An Assessment|SIMBA|Johns Hopkins University|Yes|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|36|||Both|15 Years|N/A|No|||February 2015|February 4, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01783743||71837|
NCT01784016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmokingPETD2-3fMRI|Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers|Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers||Mclean Hospital||Withdrawn|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|January 30, 2013|No|Yes|Technical complications.|No||https://clinicaltrials.gov/show/NCT01784016||71816|
NCT01784471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-1|Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms|A Pilot Study to Assess the Use of the Magic Foot in the Improvement of Subjective and Objective Parameters in Subjects With Foot Symptoms as a Result of Diabetes or Peripheral Vascular Disease.|MF|Yaffa Golan, Ltd.|No|Recruiting|November 2012|June 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 3, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01784471||71781|
NCT01784484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0058-12-ZIV|Screening for Liver Fibrosis by Using Non-invasive Methods ( Fibro Scan) in Patients With Elevated Liver Enzymes|Screening for Liver Fibrosis by Using Non-invasive Methods ( Fibro Scan) in Patients With Elevated Liver Enzymes||Ziv Hospital|Yes|Not yet recruiting|February 2013|||January 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients with abnormal liver enzymnes who attend the liver clinic|February 2013|February 3, 2013|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01784484||71780|
NCT01784796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 12-413|Mindful Hearts Study|Mindfulness Based Stress Reduction for Women at Risk for Cardiovascular Disease||VA Office of Research and Development|No|Recruiting|July 2013|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|138|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784796||71756|
NCT01784497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PostTransplant Quality of life|Health Related Quality of Life Assessment In Egyptian Recipients After Living Donor Liver Transplantation|||Ain Shams University|Yes|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|60 Years|No|Non-Probability Sample|patients who will undergo LDLT In Ain Shams Center For Organ Transplantation (ASCOT) in        the next 6 months.|October 2014|October 12, 2014|February 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01784497||71779|
NCT01784809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5608|The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders|Multimedia HIV/STI Prevention for Drug-Involved Female Offenders|Project WORTH|Columbia University|No|Completed|November 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|306|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 25, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784809||71755|
NCT01794546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5781|Integrated Care for Pediatric Obesity Using Telehealth|Integrated Care for Pediatric Obesity Using Telehealth||Children's Hospital Boston|No|Completed|February 2013|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|10 Years|17 Years|No|||July 2015|July 27, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794546||71009|
NCT01794780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BCN01|A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator|A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator||Novartis||Recruiting|February 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|10000|||Both|N/A|N/A|No|||January 2015|January 2, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794780||70991|
NCT01792960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0869|Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy|||Yonsei University|Yes|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples With DNA|serum, whole blood, DNA|Both|13 Years|N/A|No|Non-Probability Sample|familial hypertrophic cardiomyopathy patients and their relatives|February 2014|February 17, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01792960|2 Years|71131|
NCT01792973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PapilloV|HPV Infection and Cervical Lesions in HIV Infected Women in Thailand: A Prospective Study|HPV Infection and Cervical Lesions in HIV Infected Women in Thailand|PapilloV|Institut de Recherche pour le Developpement|Yes|Active, not recruiting|February 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|884|Samples With DNA|Cervical secretions|Female|18 Years|N/A|No|Non-Probability Sample|HIV-infected women followed in the PHPT cohort|January 2016|January 26, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01792973||71130|
NCT01794819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-ARK-01/10|Usefulness of C-reactive Protein Testing in Acute Cough|The Usefulness of Point-of-care-testing for C-reactive Protein in Lower Respiratory Tract Infection or Acute Cough||Northern State Medical University|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|179|||Both|18 Years|N/A|No|||February 2013|February 16, 2013|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01794819||70988|
NCT01795053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|playtrainingADHD|Effects of Playtraining in ADHD Preschoolers on ADHD Symptoms and Play Persistence and Intensity|Randomized Controlled Trial to Evalualte Effects of Playtraining as Manualized in THOP, a Modulized German ADHD Manual, in 3 to 6 Year Old Children With a Diagnosis of ADHD on ADHD Symptoms and Play Persistence and Intensity||University of Cologne|Yes|Recruiting|February 2012|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|6 Years|No|||April 2014|April 14, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01795053||70970|
NCT01795872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16401|Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis|BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis||Bayer|No|Completed|September 2013|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|278|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01795872||70907|
NCT01791881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG-06-01|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm|Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." In Essential Blepharospasm Running Parallel With Phase I Study||Hugel|No|Completed|April 2008|July 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|75 Years|No|||February 2013|February 13, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791881||71213|
NCT01791894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0015|Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma|An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma||Stanford University||Completed|April 2013|November 2015|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01791894||71212|
NCT01795859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-15|First Time Use of SD-809 in Huntington Disease|A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease|First-HD|Teva Pharmaceutical Industries|Yes|Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01795859||70908|
NCT01792492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H28135|The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study|The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study||Boston Medical Center|No|Active, not recruiting|June 2009|November 2013|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Tertiary hospital setting Urban hospital|February 2013|February 13, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01792492||71167|
NCT01792778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGHT IV Pilot Study|RIGHT IV Pilot Study|Post-Market Study Comparing the Clinical Performance Two Blood Control Safety Peripheral Intravenous Catheters: A Pilot Study|RIGHT IV|Smiths Medical, ASD, Inc.|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|February 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01792778||71145|
NCT01796470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-0103|Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies|A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies||Gilead Sciences|No|Active, not recruiting|June 2013|March 2016|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01796470||70861|
NCT01796483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.712|EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PD|Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson|EEGDBSNAd|Hospices Civils de Lyon|Yes|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01796483||70860|
NCT01796496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-1|Manipulative Therapy Techniques to Treat Chronic Low Back Pain|Short-term Effect of Manipulative Therapy Techniques in People With Chronic Low Back Pain: A Randomized Controlled Trial.||Universidad de Almeria|No|Completed|March 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|25 Years|55 Years|No|||November 2013|October 3, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01796496||70859|
NCT01783756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO-US B09|Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis|Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab||Jonsson Comprehensive Cancer Center|Yes|Recruiting|June 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01783756||71836|
NCT01784302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4347|The Effect of Antacids and Multivitamins on Raltegravir|A 3 Arm, 5 Phase Study to Determine the Effect of Divalent and Monovalent Metal Containing Antacids and Multivitamins on the Pharmacokinetics of Raltegravir in Healthy Volunteers||University of Liverpool|Yes|Completed|April 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01784302||71794|
NCT01784029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC12-09-345|Treatment Study of Vitamin D Deficiency in Adolescents|Comparison of Two Standard High-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents: Associations of Vitamin D Repletion With Changes in Markers of Musculoskeletal, Cardiometabolic, and Immune Function||Montefiore Medical Center|Yes|Completed|February 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|183|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01784029||71815|
NCT01784276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-CRX10-09-0486-2|Dental Fear Among Children With Autism Spectrum Disorders|A PILOT AND FEASIBILITY STUDY OF ELECTRONIC SCREEN MEDIA TO REDUCE DENTAL FEAR AMONG CHILDREN WITH AUTISM SPECTRUM DISORDER||Children's Hospital Boston|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|80|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||February 2013|February 2, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01784276||71796|
NCT01784510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3696|Two or Six cm From Pylorus at Laparoscopic Sleeve Gastrectomy|||Mansoura University||Completed||||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|73|||Both|18 Years|65 Years||||February 2013|February 5, 2013|February 2, 2013||||No||https://clinicaltrials.gov/show/NCT01784510||71778|
NCT01784523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11179|Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients|A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.||Hospital for Special Surgery, New York|Yes|Terminated|February 2013|February 2020|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|60 Years|No|||October 2015|October 16, 2015|February 3, 2013|Yes|Yes|low recruitment rate exacerbated by manufacturing shortage and price increase of    hydroxychloroquine.|No||https://clinicaltrials.gov/show/NCT01784523||71777|
NCT01784822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-013|Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair|Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair||Cook||Active, not recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|21 Years|N/A|No|Non-Probability Sample|Patients from University of Tennessee, Duke University and Cleveland Clinic|September 2015|September 15, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784822||71754|
NCT01784835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-02|Early Exposure to OMT Prevents Long LOS|||European Institute for Evidence Based Osteopathic Medicine||Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|32 Weeks|37 Weeks|Accepts Healthy Volunteers|||February 2013|February 4, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784835||71753|
NCT01794026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWMRIGASTADENO|Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients|Use of Diffusion Weighted Magnetic Resonance Imaging to Stage Gastric Adenocarcinoma Patients Preoperatively||Bezmialem Vakif University|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794026||71049|
NCT01793792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL11002|Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)|Pivotal Study of the Microvention, Inc Neurovascular Self-Expanding Retrievable Stent System LVIS|LVIS|Microvention-Terumo, Inc.|Yes|Completed|July 2013|January 2016|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|18 Years|75 Years|No|||January 2016|January 10, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793792||71067|
NCT01794793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2412|Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.|An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment||Novartis|No|Recruiting|June 2013|July 2024|Anticipated|July 2024|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|February 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01794793||70990|
NCT01794559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNSR011|Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression|A Prospective, Double Blind, Randomized, Multicenter Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Patients With a Primary Diagnosis of a Depressive Disorder Versus Treatment as Usual.||CNS Response|Yes|Recruiting|March 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1922|||Both|18 Years|65 Years|No|||March 2014|March 10, 2014|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794559||71008|
NCT01795300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINOCCHIO|Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial.|Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial.|PINOCCHIO|University Hospital Heidelberg|Yes|Not yet recruiting|March 2013|February 2016|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795300||70951|
NCT01795599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005276-34|Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination|Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination||Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2013|August 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|198|||Female|18 Years|N/A|No|||August 2014|August 29, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795599||70928|
NCT01795885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF12-22|Trial of the Effect of "16 and Pregnant" on Teen Girls' Attitudes About Pregnancy|Can "16 & Pregnant" Change Teens' Attitudes About Teen Pregnancy? A Randomized Controlled Trial||University of Michigan|No|Active, not recruiting|November 2012|April 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|153|||Female|15 Years|18 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01795885||70906|
NCT01791907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 304-12|Effect of Structured Nutrition Education in Type 1 Diabetes|Effect of Structured Education in Advanced Carbohydrate Counting or Healthy Food Choices With Low Glycemic Index in Type 1 Diabetes||Göteborg University||Active, not recruiting|February 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|216|||Both|20 Years|70 Years|No|||January 2016|January 7, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01791907||71211|
NCT01797354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Groupe support 22-007|Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment|Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment||Université Libre de Bruxelles|Yes|Completed|July 2011|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|260|||Female|18 Years|N/A|No|||September 2015|September 3, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01797354||70793|
NCT01792206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81890|Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease|EFFECT OF PARICALCITOL (ZEMPLAR) ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE||Scott and White Hospital & Clinic|No|Active, not recruiting|September 2009|February 2013|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|70 Years|No|||February 2013|February 12, 2013|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01792206||71189|
NCT01799577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEHGynobs-4|Comparison of 2-Dimensional and 3-Dimensional Laparoscopic Visions|Comparison of 2-Dimensional and New Generation 3-Dimensional Laparoscopic Visions In An Experimental Model||Bagcilar Training and Research Hospital|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|24|||Both|25 Years|60 Years|No|Probability Sample|Medical doctors|December 2013|December 31, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01799577||70624|
NCT01796210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 2012-046B|Prediction of Hemodynamic Reactivity During Suspension Laryngoscopy Using Analgesia/Nociception Index (ANI)|Prediction of Hemodynamic Reactivity During Suspension Laryngoscopy Using Analgesia/Nociception Index (ANI): an Observational Study||Hôpital Edouard Herriot|Yes|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients underoing suspension laryngoscopy performed on general anesthesia|June 2013|June 6, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01796210||70881|
NCT01797016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059-12-ZIV|Platelet Leukocyte Aggregates in Acute Cardiac Syndrome vs Healthy Volunteers|Comparing Blood Count Test Measures to Flow Cytometry in Healthy Patients to Acute General Syndrome Patients||Ziv Hospital|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|67 Years|Accepts Healthy Volunteers|Probability Sample|Acute Myocardial Infact|November 2014|November 13, 2014|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01797016||70819|
NCT01797029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-CE-01|A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh|A Randomized, Double-Blind, Placebo-Controlled Trial on the Clinical Efficacy and Safety of a Single Dose of Trivalent Seasonal Live-Attenuated Influenza Vaccine(LAIV) Among Children Aged 24 Through 59 Months in Bangladesh||PATH|Yes|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1761|||Both|24 Months|59 Months|Accepts Healthy Volunteers|||July 2014|May 15, 2015|February 20, 2013||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01797029||70818|
NCT01785121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-Wii|Increasing Exercise Capacity of Patients With Heart Failure by Wii Gaming|Increasing Exercise Capacity of Patients With Heart Failure by Wii Gaming (HF-Wii) A Randomized Controlled Trial|HF-Wii|Linkoeping University|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785121||71731|
NCT01785134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT20110061|Effects of Different Surgical Methods to Treat Obesity|Metabolic Effects of Different Surgical Methods to Treat Obesity|DEOSH|Karolinska Institutet|No|Completed|May 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Female|18 Years|70 Years|No|||September 2014|September 28, 2014|January 30, 2013||No||No|September 19, 2014|https://clinicaltrials.gov/show/NCT01785134||71730|
NCT01785147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-01 / BP1.4979|Efficacy and Safety of BP1.4979 in Smoking Cessation|Randomized Placebo Controlled Trial Assessing the Efficacy and Safety of BP1.4979 in Smoking Cessation||Bioprojet|Yes|Completed|February 2013|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|219|||Both|18 Years|65 Years|No|||January 2015|January 20, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785147||71729|
NCT01784549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTEST TRIAL RF-2009-1530324|Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease|A Multi-center Phase II Randomized Study of Customized Neoadjuvant Therapy Versus Standard Chemotherapy in Non-small Cell Lung Cancer (NSLC) Patients With Resectable Stage IIIA (N2) Disease (CONTEST-TRIAL)|CONTEST|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Yes|Recruiting|July 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||November 2014|November 23, 2014|February 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01784549||71775|
NCT01784562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16097|Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial|EAS|Bayer||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|80 Years||||January 2016|January 5, 2016|February 4, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01784562||71774|
NCT01784848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEP2013_HAS|GAstric Bypass to Treat obEse Patients With steAdy hYpertension|Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.|GATEWAY|Hospital do Coracao|No|Recruiting|January 2013|October 2015|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01784848||71752|
NCT01784861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303150|VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors|A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors||Washington University School of Medicine|No|Recruiting|May 2013|June 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|71|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784861||71751|
NCT01784289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_09/0941|Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity|Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophies According to Fat Mass and Glucose Metabolism|IL-7norm|University Hospital, Lille|No|Completed|June 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|126|Samples With DNA|Wholeblood and tissue bank|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with lipodystrophy : Endocrinology Departments of Lille , Amiens, Caen, Rouen and        Reims University hospitals.        Obese (diabetics and non diabetics) and normal weight patients : Endocrinology -        Metabolism, Endocrine Surgery and Nutrition Departments, Lille University Hospital|June 2015|June 17, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01784289||71795|
NCT01784536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-12-03|Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers|Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail|DDI|The Medicines Company|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01784536||71776|
NCT01785862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00498 TA 3 01|Ibuprofen Lozenge in Acute Sore Throat Pain|Study of Efficacy and Safety of V0498 Versus Placebo in Acute Sore Throat Pain.||Pierre Fabre Medicament||Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|427|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785862||71674|
NCT01794312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT4020-PIII-12/11|Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer|Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer||Laboratoires Thea|Yes|Recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|95 Years|No|||March 2016|March 8, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01794312||71027|
NCT01794325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4786/12|Transradial and Transfemoral Coronary Angiography by EXPERienced operaTors|Transradial and Transfemoral Approach by EXPERienced Operators in Daily rouTine (EXPERT): a Randomized, Non-inferiority Trial|EXPERT|Instituto de Cardiologia do Rio Grande do Sul|No|Completed|February 2013|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||September 2014|September 16, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794325||71026|
NCT01794286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1LM010512|Improving Childhood Immunization|Improving Childhood Immunization Compliance Using Electronic Health Records|ImmProve|Johns Hopkins University|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|107|||Both|28 Years|40 Years|No|||February 2013|February 15, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01794286||71029|
NCT01794299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-AIR-007|Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor||Kiadis Pharma|Yes|Active, not recruiting|March 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|23|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794299||71028|
NCT01795066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0856|Endoscopic Ultrasound-guided Fine Needle Biopsy With 25-gauge Biopsy Needles for Solid Pancreatic Masses|||Yonsei University|No|Recruiting|March 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|59|||Both|20 Years|N/A|No|||May 2014|May 26, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01795066||70969|
NCT01795950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX-PH-101|Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)|A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH||United Therapeutics|Yes|Terminated|April 2013|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|75 Years|No|||February 2016|February 15, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01795950||70901|
NCT01793116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0049|Generic Database of Moderate Preterm Infants|Time Limited Observational Study of the Moderately Preterm Infant (29 0/7 - 33 6/7 Weeks)||NICHD Neonatal Research Network|No|Completed|March 2012|February 2014|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7057|||Both|29 Weeks|33 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Moderately preterm infants born at 29 0/7 weeks to 33 6/7 weeks—both inborn and outborn        but admitted prior to 72 hours at NRN centers will be included in this study.|July 2015|July 21, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793116|11 Weeks|71119|
NCT01798160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRT-TACE-HCC-Mainz-1|Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).|Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).||Johannes Gutenberg University Mainz|Yes|Completed|February 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01798160||70731|
NCT01798173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HILLON HORS AOI 2008|Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients|CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients|CIRCE|Centre Hospitalier Universitaire Dijon||Recruiting|June 2008|||December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|35 Years|N/A|No|||February 2013|February 22, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01798173||70730|
NCT01798485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-14|A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC|A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma|Galaxy 2|Synta Pharmaceuticals Corp.|Yes|Terminated|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|696|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01798485||70706|
NCT01796223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1271|Effects of Systematic Patient Feedback on Therapy Outcome|Effects of Systematic Patient Feedback on Therapy Outcome and Dropout: A Randomized Controlled Study on Adult Out-patients at a Community Mental Health Centre.||Norwegian University of Science and Technology|No|Recruiting|December 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01796223||70880|
NCT01793155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAUH 01|Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial|Respiratory Muscle Strength, Functional Capacity and Subjective Outcome - Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial||Aalborg Universitetshospital|No|Completed|November 2012|December 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793155||71116|
NCT01785394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLET-12-13|POLlinosis and Exhaled Breath Temperature|Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy|POLET|Association Asthma, Bulgaria|Yes|Active, not recruiting|February 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|55 Years|No|||February 2013|February 6, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785394||71710|
NCT01785381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS recherche 2012820690007|RCT: Added Value of Coordinator for the Management of Hip Fracture Patients|Randomized Controlled Trial: Added Value of Coordinator for the Management of Hip Fracture Patients in a Network of Public Hospitals in Brussels.||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|December 2012|December 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|128|||Both|50 Years|N/A|No|||February 2013|February 5, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785381||71711|
NCT01785628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-296|The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease|||China Medical University Hospital|Yes|Completed|August 2010|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|N/A|No|||August 2013|August 20, 2013|June 24, 2011||No||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01785628||71692|
NCT01785355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients|Periodontal Disease, Inflammation, Nutritional Status And Anaemia Response To Erythropoietin In Chronic Haemodialyzed Patients - The Impact Of Treatment For Periodontal Disease|PAROHEM|Anemia Working Group Romania|Yes|Recruiting|September 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|85 Years|No|||January 2015|January 14, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01785355||71713|
NCT01785368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/PR-01|Referral Guidelines for Imaging Exams: Impact on Exam Relevance and Associated Delays|Implementing Referral Guidelines for Imaging Exams Requested Via the Emergency Department: Impact on Exam Relevance and Associated Delays|RIU|Centre Hospitalier Universitaire de Nīmes|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|8549|||Both|N/A|N/A|No|||March 2015|March 25, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01785368||71712|
NCT01785615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. 1988|Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin|Interactions of Thrombogenic, Lipogenic, and Inflammatory Markers in Women With the Metabolic Syndrome - Effect of Atorvastatin|PINK|University of Rochester|Yes|Active, not recruiting|November 2004|April 2013|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01785615||71693|
NCT01786733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012 / 226|Behavioral Activation - From Inpatient to Outpatient Services|Psychotherapy in the Transition From Acute Psychiatric Inpatient Wards to Outpatient Services - A Randomized Controlled Trial of Behavioral Activation vs. Supportive Therapy||Uppsala University|Yes|Active, not recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|60 Years|No|||December 2015|December 23, 2015|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01786733||71607|
NCT01794338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-12-02A|The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients|A Randomized, Prospective, Double Blind Clinical Trial of Non-cross-linked Porcine Dermis vs. Bioabsorbable Synthetic Mesh for the Repair of Abdominal Wall Defects in At-risk Patients||Carolinas Healthcare System|Yes|Recruiting|November 2012|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794338||71025|
NCT01794832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS|Severe Aortic Stenosis in Patients Referred for Valve Surgery|A Prospective Longitudinal Study of Severe Aortic Stenosis in Elderly and Outcome of Aortic Surgery.|SAS|Oslo University Hospital|No|Recruiting|February 2010|June 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Serum, myocardial biopsi|Both|18 Years|N/A|No|Non-Probability Sample|Inclusion: Patients above 18 years with symptomatic AS referred to preoperative        examination will be included. Patients will undergo standard investigations with regard to        assessment of the clinical indication for operation|April 2014|April 2, 2014|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01794832|1 Year|70987|
NCT01794845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090467|Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma|Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma||University of Miami|Yes|Recruiting|May 2013|||May 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||February 2016|February 3, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794845||70986|
NCT01798823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/160/12/KE|Exercise-induced Bronchoconstriction in School Children|Exercise-induced Bronchoconstriction in School Children - Prevalence, Environmental/Individual Risk Factors and Its Mechanism||Medical Universtity of Lodz|Yes|Recruiting|February 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1200|Samples With DNA|-  exhaled breath condensate sample        -  blood sample (5 ml sample): tryptase, lipoxin A4 serum levels        -  blood sample also will be taken before and after challenge together with exhaled breath           condensate sample in order to detect markers of inflammation (such as IL-1a, IL-2,           IL-5, IL-6, IL-8, IL-9, IL-12p70, IL-13, IL-17, IL-22, MCP1, TLR2, MIP1a, PDGFBB,           TIMP2, TNFalfa, CRP, TGF-b1, TSLP- ELISA and cysteinyl leukotrienes, LTB4,           PGE2-HPLC/mass spectrometry).|Both|6 Years|18 Years|No|Probability Sample|school-children screened for EIB during PE lesson|February 2013|February 22, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01798823||70682|
NCT01796249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 2012-052B|Prediction of Immediate Postoperative Pain Using Analgesia/Nociception Index (ANI)|Prediction of Immediate Postoperative Pain Using Analgesia/Nociception Index (ANI): an Observational Study||Hôpital Edouard Herriot|Yes|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients underoing surgical procedures performed on general anesthesia|August 2013|August 26, 2013|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01796249||70878|
NCT01799811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVG1201.000-M|Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization|Prospective, Multicenter, Primary Below the Knee Bypass Evaluation With CryoVein® Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia|LIMBSAVE|CryoLife, Inc.|No|Enrolling by invitation|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|During the Study follow-up period, a patient may present with an event requiring an open      surgical revision, surgical explant or limb amputation on the (allograft) recipient limb. At      the time of related planned intervention a tissue sample of the affected area of the      allograft may be obtained and, if so, will placed into 10% buffered formalin solution and      returned to CryoLife for histologic analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open        peripheral arterial revascularization.|August 2015|August 7, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01799811||70606|
NCT01799824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1403-HHID-202|Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis|Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults||Anterios Inc.|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|No|||November 2013|November 15, 2013|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01799824||70605|
NCT01795612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12007|Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase|Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase|APAC|University Hospital, Limoges|No|Recruiting|March 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Female|18 Years|75 Years|No|||November 2012|March 26, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795612||70927|
NCT01797939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1302-192-107|Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients|Predictive Factors of Response to Proton Pump Inhibitor Treatment in Patients With Gastroesophageal Reflux Disease Symptoms||Seoul National University Bundang Hospital|No|Completed|July 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|197|||Both|16 Years|85 Years|No|Non-Probability Sample|Even the patients complain GERD symptoms such as heartburn and acid regurgitation the        final diagnosis could be erosive reflux disease(ERD), non-erosive reflux disease (NERD)        and even functional heartburn (FH).|February 2013|February 22, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01797939||70748|
NCT01798784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1AG043844-01|Habit Formation for Adherence to Statin Use and LDL Reduction|Testing Behavioral Economic Interventions to Improve Statin Use and Reduce CVD Risk||University of Pennsylvania|Yes|Enrolling by invitation|July 2013|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|800|||Both|18 Years|N/A|No|||November 2012|May 29, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798784||70685|
NCT01799317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-05|How Bone is Made in Children Receiving Dialysis|Regulation of Bone Mineralization in Renal Osteodystrophy||University of California, Los Angeles|Yes|Recruiting|March 2009|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|21 Years|No|||February 2013|February 22, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01799317||70644|
NCT01796769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-FFPO-01|Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study|Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients||Fédération Française de Pneumologie|Yes|Recruiting|February 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|936|||Both|18 Years|78 Years|No|||September 2014|September 4, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01796769||70838|
NCT01796782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-002|QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer|A Prospective, Randomized, Open-label, Phase II Study of QYHJ Granules Versus Xeloda in the Second-line Treatment of Patients With Metastatic Pancreatic Cancer||Fudan University|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|December 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01796782||70837|
NCT01793168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-10-014|Rare Disease Patient Registry: Coordination of Rare Diseases at Sanford|Coordination of Rare Diseases at Sanford|CoRDS|Sanford Health|No|Recruiting|July 2010|||December 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|None Retained|Biospecimen collection capability anticipated in 2014.|Both|N/A|N/A|No|Non-Probability Sample|English speakers, globally|November 2015|November 17, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793168|100 Years|71115|
NCT01793428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-19|Capillary Lactate and Transfusion Needs|Predictive Abilities for Transfusion Needs of Capillary Lactate Measure in Emergency for Injured Normotensive Patients||University Hospital, Grenoble|No|Completed|August 2011|||February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Adults admitted in vital emergency unit due to severe trauma based on a local severity        score.        Patients are normotensive|April 2015|April 2, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793428||71095|
NCT01786161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 002617|Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients|Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients|CIV|Massachusetts General Hospital|No|Recruiting|September 2013|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01786161||71651|
NCT01785641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA56/006|Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients|Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients||Chulalongkorn University|Yes|Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|300|||Both|15 Years|75 Years|No|||February 2013|February 6, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01785641||71691|
NCT01785654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0142|Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU|Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU|REVECOL|University Hospital, Clermont-Ferrand||Not yet recruiting|March 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Defined population|February 2013|February 5, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01785654||71690|
NCT01785888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00070|Europe-Japan Diagnostic Study for EGFR Testing|A Diagnostic Study of European and Japanese Advanced NSCLC Patients to Evaluate Suitable Sample Types for EGFR Testing,|ASSESS|AstraZeneca|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1311|Samples With DNA|Tumour samples (biopsy or citology) Blood (plasma) samples|Both|18 Years|N/A|No|Probability Sample|-  Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who are newly             diagnosed, have not received any local or systemic chemotherapy. Locally advanced             patients should not be eligible for curative treatment (including surgery and             chemoradiotherapy).          -  Patients who have newly diagnosed locally advanced (stage IIIA/B) NSCLC who are not             eligible for curative treatment (including surgery and chemoradiotherapy) or             metastatic NSCLC and have not received systemic chemotherapy. Previous or planned             palliative radiotherapy is allowed.          -  Patients who have had surgical resection with or without adjuvant chemotherapy and             have experienced recurrent disease.|January 2015|January 7, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01785888||71672|
NCT01785875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120231|20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD|A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis||Amgen|Yes|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|891|||Both|18 Years|100 Years|No|||December 2015|December 19, 2015|February 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01785875||71673|
NCT01786135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN19A-002|A Safety Study of SGN-CD19A for B-Cell Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma||Seattle Genetics, Inc.|No|Active, not recruiting|February 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|12 Years|N/A|No|||November 2015|December 2, 2015|February 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01786135||71653|
NCT01786421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlcoholTG_SFG_2013|Diurnal Triglyceridemia in Relation to Alcohol Intake|Observational Study of Diurnal Triglyceridemia in Relation to Alcohol Intake||Sint Franciscus Gasthuis|No|Completed||||December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|273|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Subjects were healthy volunteers or patients with hyperlipidemia or a known medical        history of cardiovascular diseases, type 2 diabetes mellitus participating in several        clinical studies with the same protocol, aimed to investigate factors influencing        postprandial lipemia|February 2013|February 5, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01786421||71631|
NCT01786434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1737|Fentanyl in Colonoscopy|Routine Versus on Demand Administration of Fentanyl in Colonoscopy: A Multi-centre Randomized Controlled Trial|FEKOL|Sorlandet Hospital HF|No|Active, not recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01786434||71630|
NCT01786746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073545|Adapting Cognitive Behavioral Therapy (CBT) for Chinese Americans|Cognitive Behavioral Therapy (CBT)||Claremont McKenna College|Yes|Completed|June 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786746||71606|
NCT01787006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEOPARD II|Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer|Definitive Radiochemotherapy With 5-FU / Cisplatin Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer: a Phase II Study||University of Schleswig-Holstein|Yes|Recruiting|September 2011|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01787006||71586|
NCT01797666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-081|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited|No|Completed||||September 2008|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797666||70769|
NCT01798511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NTA/9|Oral Refeeding IntOlerance After Nasogastric Tube Feeding (ORION)|A Randomized Controlled Trial of Oral Refeeding Intolerance After Nasogastric Tube Feeding|ORION|University of Auckland, New Zealand|No|Not yet recruiting|April 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|82|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01798511||70704|
NCT01796262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-00-11|The Effects of DHA on Attention Deficit and Hyperactivity Disorder|The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder|DADA|IRCCS Eugenio Medea|No|Completed|June 2012|June 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|6 Years|14 Years|No|||August 2015|August 28, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01796262||70877|
NCT01800084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/LS-01|Impact of Reconstruction Method (ASIR, FBP) Used in CT on Bone SPECT/CT Image Quality|Impact of Reconstruction Method (Adaptive Statistical Iterative Reconstruction, Filtered Back Projection) Used in Computed Tomography on Bone Single-Photon- Emission-Computed-Tomography/Computed-Tomography Image Quality|AsirTest|Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01800084||70586|
NCT01792505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19814|Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma|A Phase I Trial of Surgical Resection Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate With Imiquimod for Patients With Malignant Glioma||Cedars-Sinai Medical Center|Yes|Active, not recruiting|October 2009|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|July 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01792505||71166|
NCT01792245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02854|Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand|Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial||University of British Columbia|No|Recruiting|February 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|N/A|No|||June 2015|June 30, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01792245||71186|
NCT01792531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2012|The More & Less Study: A Trial Testing Different Treatment Approaches to Obesity in Preschoolers|The More & Less Study: A Randomized Controlled Trial Testing Different Treatment Approaches to Obesity in Preschoolers|M&L|Karolinska Institutet|No|Recruiting|January 2013|December 2020|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|4 Years|6 Years|No|||February 2016|February 23, 2016|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792531||71164|
NCT01799798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1574|Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab|TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB|OI-AK|University of Cologne|No|Completed|February 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|11 Years|No|||January 2015|January 26, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01799798||70607|
NCT01800305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1209EPO|PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual|A Randomized, Positive-controlled, Single-dose, Dose-escalation Phase I Trial to Evaluate Safety & Tolerability, and Explore the Pharmacokinetics and Pharmacodynamics Profile of Pegylated rhEPO in Male Healthy Individual||Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|August 27, 2015|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01800305||70569|
NCT01793441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28420|A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders|A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)||Hoffmann-La Roche||Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Male|18 Years|45 Years|No|||March 2016|March 1, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793441||71094|
NCT01785680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211096|Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone|Conducting Research on Moderate Acute Malnutrition in Humanitarian Emergencies Integrated Management of MAM and SAM in Sierra Leone With Ready to Use Theraputic Foods (RUTF)||Washington University School of Medicine|Yes|Recruiting|January 2013|January 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1800|||Both|6 Months|59 Months|No|||February 2013|February 4, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01785680||71688|
NCT01786460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-05|Brain Injury Biomarkers in the General Population|||Banyan Biomarkers, Inc|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|800|Samples Without DNA|Whole blood, serum, plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers who meet eligibility criteria|February 2013|February 7, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786460||71628|
NCT01786759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFBA|Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion|Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion||Shanghai Jiao Tong University School of Medicine|No|Recruiting|October 2012|July 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|28 Days|No|||February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786759||71605|
NCT01786148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055077|Music for Health Project|An Audio Music Self-Management Program to Improve ART Adherence in Rural GA|MFH|Emory University|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01786148||71652|
NCT01786447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-04a|Biomarkers of Brain Injury: Magnitude and Outcome of Mild and Moderate TBI|||Banyan Biomarkers, Inc|No|Terminated|April 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|111|Samples Without DNA|Whole blood, serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who present to the health care facility with either Traumatic Brain Injury (GCS        9-15) or isolated extracranial orthopedic injury within 4 hours of injury|February 2013|February 8, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786447||71629|
NCT01783080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYSPI5908|Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning|Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning||New York State Psychiatric Institute|Yes|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||January 2013|January 31, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01783080||71888|
NCT01787071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENICE|Fluid Challenges in Intensive Care|How do we Administer Fluids in the ICU?|FENICE|European Society of Intensive Care Medicine|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2304|||Both|18 Years|N/A|No|Non-Probability Sample|criticallyill patients receiving fluid challenge|August 2014|August 19, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787071||71581|
NCT01794572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-2012-04|Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse|Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.|TOMMY|Institut Cancerologie de l'Ouest|Yes|Recruiting|January 2013|October 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|65 Years|No|||November 2015|November 6, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794572||71007|
NCT01794585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A120032-2|Virtual Reality (VR) Treatment for Balance Problems in Traumatic Brain Injury (TBI)|Home-Based Virtual Reality (VR) Treatment for Chronic Balance Problems in Adults With Traumatic Brain Injury||Craig Hospital|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|64 Years|No|||January 2016|January 27, 2016|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01794585||71006|
NCT01794858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00828|Therapeutic Hypothermia for Severe Acute Pancreatitis|Therapeutic Hypothermia for Severe Acute Pancreatitis: A Clinical Model for "Suspended Inflammation"||New York University School of Medicine|Yes|Withdrawn|June 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||March 2016|March 10, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794858||70985|
NCT01798524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HES-ONS|Kidney Allograft Recipients in England - an Observational Cohort Study|An Observation Cohort Study of Kidney Allograft Recipients in England by Data Linkage Analysis|KARE|University Hospital Birmingham NHS Foundation Trust|No|Completed|November 2011|||February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|19688|||Both|N/A|N/A|No|Non-Probability Sample|All kidney allograft recipients transplanted at an English transplant centre between April        2001 and March 2012|February 2013|February 21, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01798524||70703|
NCT01799343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-139|Water Immersion and Changes in the Fetoplacental Circulation|Water Immersion and Changes in the Fetoplacental Circulation. A Case-Control Study With the Case as it's Own Control.||Hvidovre University Hospital|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 23, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01799343||70642|
NCT01795079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-p-001996|Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury|Boston-Harvard Burn Injury Model System: Cortical Modulation With Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury||Spaulding Rehabilitation Hospital|Yes|Recruiting|January 2013|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01795079||70968|
NCT01795313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050422|Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod|Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod||University of Pittsburgh|Yes|Recruiting|August 2012|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Months|21 Years|No|||December 2015|December 17, 2015|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01795313||70950|
NCT01795326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00127|Physician Survey on Monitoring of Patients Treated With Quetiapine|Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL® (Quetiapine Fumarate) Tablets and SEROQUEL® (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU||AstraZeneca|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||8|Actual|800|||Both|N/A|N/A|No|Non-Probability Sample|A sample of physicians who were targeted to receive the metabolic educational materials        and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL®        XR.|January 2014|January 27, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01795326||70949|
NCT01791920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG-11-01|To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines|Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of "Botulax®" Compared to Botox Inj. in Patients With Moderate to Severe Glabellar Lines||Hugel|No|Completed|August 2011|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01791920||71210|
NCT01791946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-186H|Binocular Treatment of Amblyopia Before and After Strabismus Surgery|Binocular Treatment of Amblyopia Before and After Strabismus Surgery||Massachusetts Eye and Ear Infirmary|No|Enrolling by invitation|January 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|60 Years|No|||October 2015|October 20, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01791946||71208|
NCT01791959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|046466|The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis||National Nutrition and Food Technology Institute|Yes|Completed|March 2012|January 2013|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|70 Years|No|||February 2013|February 12, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01791959||71207|
NCT01792258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53/12|Procedures and Follow-up of Percutaneous Tracheostomy in Intensive Care Unit|Procedures, Complications and Follow-up of Percutaneous Tracheostomies in Intensive Care Unit||University of Genova|Yes|Recruiting|June 2012|January 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|82 Years|No|Non-Probability Sample|Criticall ill patients requiring percutaneous tracheostomy in intensive care unit|February 2016|February 2, 2016|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01792258||71185|
NCT01792271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2602|Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis|Novel Therapies for Muco-Obstructive Lung Diseases: Sustained Effects of Hypertonic Saline on Mucociliary Clearance and Clinical Tolerability in Subjects With Chronic Bronchitis||University of North Carolina, Chapel Hill|Yes|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|80 Years|No|||September 2015|September 9, 2015|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01792271||71184|
NCT01792284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14184|A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus|A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study|IMAGINE 7|Eli Lilly and Company|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792284||71183|
NCT01792544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUIRB-021780|Clinical Reminders in Test Reports to Improve Guideline Compliance|||VA Palo Alto Health Care System|No|Active, not recruiting|July 2011|July 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|N/A|N/A|No|||December 2013|December 2, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01792544||71163|
NCT01792557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEAH06021301|Crystallized Phenol Versus Transposition Flaps for Treatment of Pilonidal Disease: A Prospective Study|Crystallized Phenol Application Versus Transposition Flaps for Treatment of Sacrococcygeal Pilonidal Disease: A Prospective Randomized Study||S.B. Konya Education and Research Hospital|No|Active, not recruiting|March 2013|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792557||71162|
NCT01792804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1400|Staphylococcus Aureus Bacteremia Antibiotic Treatment Options|Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection|SABATO|University of Cologne|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792804||71143|
NCT01792817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-US-01|Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache|Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache|CH|ElectroCore LLC|Yes|Completed|February 2013|October 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|February 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792817||71142|
NCT01756833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051170|Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial|Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)|N-TA^3CT|University of Maryland|Yes|Recruiting|May 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|248|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01756833||73904|
NCT01786174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000313|Gilenya in Amyotrophic Lateral Sclerosis (ALS)|Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)||Massachusetts General Hospital|Yes|Completed|August 2013|May 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 4, 2013|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01786174||71650|
NCT01786473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01BHR11|Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism|A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism||Laboratoires Besins International|No|Recruiting|December 2012|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Male|18 Years|68 Years|No|||February 2013|February 6, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01786473||71627|
NCT01786486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL03562|AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol||ACPR|St. Jude Medical|Yes|Completed|August 2009|||December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|204|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation|January 2014|January 24, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01786486|4 Years|71626|
NCT01787019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Age of Oral Feeding|Initiation of Oral Feeding at 30 Versus 33 Weeks Postmenstrual Age|||The University of Texas Health Science Center, Houston|No|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|7 Weeks|No|||June 2015|June 17, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01787019||71585|
NCT01783054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101826|Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas|Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas||Medical University of South Carolina|Yes|Terminated|July 2012|||October 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2015|February 8, 2016|September 10, 2012||No|Study terminated due to low accrual|No|October 7, 2015|https://clinicaltrials.gov/show/NCT01783054||71890|
NCT01783067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1430|Zinc and Iron Bioavailability From Biofortified Pearl Millet|Zinc and Iron Bioavailability From Bio-fortified Pearl Millet||University of Colorado, Denver|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|18 Months|36 Months|Accepts Healthy Volunteers|||December 2013|December 11, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01783067||71889|
NCT01783093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0269|Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Sickle Cell Anemia|An Evaluation of Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Patients With Sickle Cell Anemia: A Retrospective Data Review||Ohio State University|No|Completed|December 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|Patients records will be extracted from the complete medical record at OSUMC|January 2013|January 31, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01783093||71887|
NCT01783106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royal_Liverpool|Antibiotics and Hydroxychloroquine in Crohn's|A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease|APRiCCOT|Royal Liverpool University Hospital|Yes|Recruiting|January 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01783106||71886|
NCT01797393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIC-001|"Air Assisted"Water Injection Colonoscopy in Experienced Endoscopists|"Air Assisted"Water Injection Colonoscopy in Experienced Endoscopists||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|600|||Both|18 Years|80 Years|No|||February 2013|February 21, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01797393||70790|
NCT01797653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP_V1.0 (01.11.2012)|Randomized-controlled Trial (RCT) on CPAP-withdrawal and Microvascular Function in OSA|The Effects of CPAP-withdrawal on Microvascular Function in Patients With Obstructive Sleep Apnea: A Randomized-controlled Trial||University of Zurich|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|75 Years|No|||December 2013|December 20, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01797653||70770|
NCT01799356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asicioglu03|Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials|||Istanbul Bakirkoy Maternity and Children Diseases Hospital||Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1303|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|February 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01799356||70641|
NCT01799369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSRG-001|Surgical Apgar Score in Clinical Practice: a Pilot Study|Surgical Apgar Score in Clinical Practice: a Pilot Study|SAS|London Surgical Research Group|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|143|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01799369||70640|
NCT01795365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV Active surveillance|Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer|||Centre Hospitalier Universitaire Vaudois|No|Recruiting|December 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|75 Years|No|||June 2014|June 6, 2014|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01795365||70946|
NCT01792219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201215061|Interprofessional Collaboration in Health Care and Outcomes in Nursing Homes|The Effectiveness of Learning to Collaborate Interprofessionally on Healthcare Processes and Outcomes in Nursing Homes: a Cluster Randomized Controlled Trial in Primary Care.|IPCIHC|Universiteit Antwerpen|Yes|Active, not recruiting|January 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 12, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01792219||71188|
NCT01791647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000102011|Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome|Myo-inositol Versus Metformin: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome||Catholic University of the Sacred Heart||Recruiting|June 2011|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01791647||71231|
NCT01791660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLVSC-ZA-001|Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System|Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System||Dermatology, Laser & Vein Specialists of the Carolinas|No|Recruiting|August 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01791660||71230|
NCT01791972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-302|Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)|A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)||Teva Pharmaceutical Industries|No|Completed|March 2013|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|50 Years|No|||May 2015|May 21, 2015|February 12, 2013|Yes|Yes||No|May 1, 2015|https://clinicaltrials.gov/show/NCT01791972||71206|
NCT01792297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-255|The Effect of Bovine Colostrum Supplementation in Older Adults|The Effect of Bovine Colostrum Supplementation in Older Adults||University of Saskatchewan|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 10, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01792297||71182|
NCT01792570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS03/2012|DRV/r + RPV QD: Efficacy and Toxicity Reduction|Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.||Ospedale L. Sacco – Polo Universitario|No|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01792570||71161|
NCT01792843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_26|Cognitive Phenotypes in Parkinson's Disease|Cognitive Phenotypes in Parkinson's Disease: Anatomical and Functional Correlates|CogPhenoPark|University Hospital, Lille|Yes|Completed|January 2013|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|158|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Parkinson's disease, according to international criteria, irrespective of        their disease stage or their current antiparkinsonian medication|December 2015|December 1, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01792843||71140|
NCT01792856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-486|Coaching Intervention for Patients With Early Psychosis|Randomized Controlled Trial on Recovery-oriented Coaching Intervention for Patients With Early Psychosis||The University of Hong Kong|No|Not yet recruiting|February 2013|August 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|25 Years|64 Years|No|||February 2013|February 14, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01792856||71139|
NCT01792869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_TOE3_2013|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2013|||||N/A|N/A|N/A||||||||||||||July 8, 2015|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01792869||71138|
NCT01792830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056365|Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients|Prospective Study Aim to Determine the Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Cardiac Surgery Patients With Perioperative Hyperglycemia|CABG-D/C|Emory University|Yes|Completed|October 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|175|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|August 14, 2012||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01792830||71141|The study had participants from other states who lived more than 50 miles away from the hospitals and did not return for their post-operative care or 12 week follow up. Some subjects preferred to complete follow ups via phone and no blood was drawn.
NCT01793935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI #: 12T-001|Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia|Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study||University of Pittsburgh|Yes|Recruiting|April 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793935||71056|
NCT01756846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82310-97-12154|Impact on Management of the HEART Risk Score in Chest Pain Patients|Cost-effectiveness Study of the HEART Score in the Management of Patients With Chest Pain Presenting in the Emergency Room|HEART-Impact|UMC Utrecht|Yes|Completed|July 2013|March 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|3666|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01756846||73903|
NCT01752699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH|Methadone in Post-Herpetic Neuralgia Pain|Methadone in Post-Herpetic Neuralgia Pain|NPH|University of Sao Paulo|Yes|Completed|January 1998|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01752699||74220|
NCT01786187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA164515|The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer|Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience|SES|Michigan State University|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|74|||Both|21 Years|N/A|No|||January 2015|January 11, 2015|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01786187||71649|
NCT01786772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT12-16517|Neuromuscular Consequences of Knee Arthroscopy|Neuromuscular Consequences of Knee Arthroscopy||Creighton University|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|65 Years|No|||December 2015|December 10, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01786772||71604|
NCT01787032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.7|Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects|Relative Bioavailability of Single Oral Dose of BI 113608 When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole or Voriconazole in Healthy Male Subjects (an Open-label, Randomised, Three-period Cross-over Trial)||Boehringer Ingelheim||Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 30, 2013||||No||https://clinicaltrials.gov/show/NCT01787032||71584|
NCT01787045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EarlyPTProtocol1|Early Physical Therapy in Patients With Sepsis|Effect of Early Physical Activity on Skeletal Muscle Signaling Pathways Controlling Protein Turnover in Patients With Sepsis.|EARTH-ICU|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|February 2013|November 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|85 Years|No|||November 2015|November 16, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01787045||71583|
NCT01787058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060756|Evaluation of the Dubai Cares WASH in School Initiative|Monitoring and Evaluation Framework of the Dubai Cares' WASH in School Initiative||Emory University|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10308|||Both|6 Years|14 Years|Accepts Healthy Volunteers|Probability Sample|Primary school students attending public schools in the Koulikoro, Sikasso, Bamako, and        Mopti regions of Mali|March 2015|March 11, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01787058||71582|
NCT01753804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-DMD-01|A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.|A Prospective Natural History Study of Progression of Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy.||BioMarin Pharmaceutical|No|Active, not recruiting|September 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Blood sampling at 4 time points (first visit then once a year). Urinalysis sampling at 4      time points (first visit then once a year).|Male|3 Years|18 Years|No|Non-Probability Sample|Subjects diagnosed with DMD resulting from a mutation in the DMD gene which is confirmed        by a state of the art DNA diagnostic technique covering all DMD gene exons|June 2015|June 4, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01753804||74135|
NCT01799603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100854|A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435|A Single-dose, Open-label, Randomized, Two-way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of TMC435 in Japanese Healthy Adult Male Subjects||Janssen Research & Development, LLC|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|February 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01799603||70622|
NCT01795131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09033|Vitamin B12 Supplementation During Pregnancy|Role of Vitamin B12 Supplementation During Pregnancy and Postpartum to Reduce Nutritional Anemia and Improve Immunity in Bangladeshi Women and Their Infants||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|February 2010|December 2013|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|120|||Both|22 Years|35 Years|Accepts Healthy Volunteers|||July 2009|April 2, 2014|February 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01795131||70964|
NCT01807260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|stepwise0946|Stepwise Shock Wave Lithotripsy in Pediatric Urolithiasis|STEPWISE SHOCK WAVE LITHOTRIPSY IN PEDIATRIC UROLITHIASIS: A COMPARATIVE STUDY.||TC Erciyes University|No|Completed|March 2008|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|12 Months|16 Years|No|||March 2013|March 6, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01807260||70036|
NCT01807273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01619-3|Time Up and go in Hemiplegic Patients|Quantification of Biomechanical Parameters of Functional Task Time Up and Go in Hemiplegic Patients|TUG|Centre d'Investigation Clinique et Technologique 805|No|Completed|March 2013|November 2014|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|60 hemiplegic out patients|January 2014|February 3, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807273||70035|
NCT01814423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-CQ|Pharmacokinetic Study of Multi-dose Chloroquine|Pharmacokinetic Study of Multi-dose Chloroquine||Bandim Health Project|No|Completed|April 2013|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|9 Years|No|||March 2014|March 10, 2014|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01814423||69487|
NCT01808092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4281C00001|A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia|A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults||AstraZeneca|Yes|Completed|April 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|859|||Both|18 Years|90 Years|No|||January 2016|January 25, 2016|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808092||69972|
NCT01815814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104644|Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy|Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy||Stanford University|No|Completed|November 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|1 Year|3 Years|No|||May 2015|July 4, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815814||69382|
NCT01815515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12113|Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer|Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer.||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|March 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Male|18 Years|N/A|No|||June 2014|June 16, 2014|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815515||69405|
NCT01815801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1301-066-459|Effect of Mechanical Ventilation on the Incidence of Pneumothorax After Subclavian Vein Catheterization|||Seoul National University Hospital|No|Recruiting|March 2013|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|334|||Both|20 Years|80 Years|No|||March 2013|March 20, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815801||69383|
NCT01815255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 133|TDF Long Term Study|Efficacy and Safety Evaluation of TDF-based Regimen in Thai HIV-infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|December 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|None Retained|Phlebotomy will be for safety evaluation and will be drawn according to the schedule of      visit.|Both|8 Years|18 Years|No|Non-Probability Sample|HIV-infected children who are currently taking or are changing to tenofovir-(TDF) based        regimen|March 2015|March 26, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01815255||69425|
NCT01816893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P001233|Hypoglycemia and Autonomic Nervous System Function|Hypoglycemia and Autonomic Nervous System Function|HypoANS|Brigham and Women's Hospital|Yes|Recruiting|January 2005|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|260|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 20, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816893||69299|
NCT01815775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI05-PR-LEGARS|Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery|Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery||Centre Hospitalier Universitaire, Amiens|No|Completed|March 2006|July 2009|Actual|July 2008|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|20 Years|N/A|No|||March 2013|March 19, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815775||69385|
NCT01815788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-17|Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid|Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid.|TEO FIRST|Centre Hospitalier Universitaire de Nice|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Both|60 Years|N/A|No|||March 2013|July 28, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815788||69384|
NCT01817361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DE017360-01A2|Oral Health and People With Systemic Sclerosis|Oral Health and People With Systemic Sclerosis||University of Alabama at Birmingham|No|Completed|October 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|210|||Both|18 Years|85 Years|No|Non-Probability Sample|adults with systemic sclerosis|March 2013|March 22, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01817361||69263|
NCT01816568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mütf4|The Comparison of Single Incision Laparoscopic Appendectomy and Three Port Laparoscopic Appendectomy|The Comparison of Single Incision Laparoscopic Appendectomy and Three Port Laparoscopic Appendectomy||Maltepe University|Yes|Completed|February 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816568||69324|
NCT01817322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AKR09T|Kidney Graft Function Under the Immunosuppression Strategies|Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients|MyLowCsA|Samsung Medical Center|Yes|Completed|June 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01817322||69266|
NCT01815229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301037|Role of Neutrophil Activation|Sore Throat Secondary to Endotracheal Intubation: the Role of Neutrophil Activation||Washington University School of Medicine|No|Recruiting|March 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients requiring endotracheal itubation|December 2015|December 8, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815229||69427|
NCT01815242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06 / ADAPT TN|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer|ADAPT|West German Study Group|Yes|Active, not recruiting|June 2013|May 2020|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Female|18 Years|75 Years|No|||June 2015|June 18, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815242||69426|
NCT01814202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTM.2012.002|Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea|A Double-blind, Randomized, Placebo-controlled Clinical Trial (Pilot Phase) to Evaluate the Efficacy of a Medical Nutrition Product, PTM202, in Children With Acute Diarrhea||PanTheryx, Inc.|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|6 Months|5 Years|No|||October 2013|October 4, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814202||69504|
NCT01814215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2129|Keys to Healthy Family Child Care Homes|The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|April 2013|April 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Months|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814215||69503|
NCT01813929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0693|Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes|Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes|MeT1|University of Colorado, Denver|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|59 Years|No|||September 2015|September 30, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01813929||69525|
NCT01814228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Casilino0001, 0002|Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope|Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope||Policlinico Casilino ASL RMB|No|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||November 2015|November 9, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814228||69502|
NCT01813292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URT-Bone-001|Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine|Comparative Study of Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV + Men Being Given Tenofovir With FTC, Emtricitabine (TRUVADA®), or Without (VIREAD®), as Part of Their Antiretroviral Therapy.||Hopital Lariboisière|No|Active, not recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|||Male|18 Years|55 Years|No|Non-Probability Sample|HIV+ male patients treated by TRUVADA® or VIREAD® for more than 60 months.|September 2015|September 30, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813292||69574|
NCT01813305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTC1-01|CSTC1 for Diabetic Foot Ulcers Phase II Study|A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers||Charsire Biotechnology Corp.|No|Recruiting|March 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|N/A|No|||January 2016|January 26, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813305||69573|
NCT01807598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMPD0016|Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia|A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)||Stanford University||Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807598||70010|
NCT01807572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK080760-01|Relation of Consummatory and Anticipatory Food Reward to Obesity|Relation of Consummatory and Anticipatory Food Reward to Obesity||Oregon Research Institute|Yes|Completed|June 2009|July 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|Samples With DNA|All DNA samples will be stored at the Sequencing and Genomics lab of the University of      Colorado. Only authorized staff will have access to remove the DNA samples for analysis. The      DNA samples will be analyzed in this lab using standard DNA procedures. Data will be kept on      the password protected server for a period of six months. After six months, the data will be      destroyed. The DNA samples will be stored with a unique identification number, connected to      a code list accessed only by our research team. Once the analysis has been completed, the      saliva sample will be destroyed by soaking it in bleach. This will remove all DNA. In      addition, by the end of the study the code list connecting subject numbers with DNA numbers      will be destroyed. No individual samples, analyzed results, or any other individual data      will be shared with other researchers.|Both|14 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be 140 lean adolescents at risk for obesity (by virtue of having two        obese parents) and 40 lean adolescents with two lean parents. Participants will range in        age from 14-16 and be recruited from high schools.|September 2015|September 29, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807572||70012|
NCT01807585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-11101-01|VenaSeal Sapheon Closure System Pivotal Study|Randomized Control Trial Comparing VenaSeal Sapheon Closure System With Radiofrequency Ablation|VeClose|Sapheon, Inc.|Yes|Active, not recruiting|March 2013|September 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|244|||Both|21 Years|70 Years|No|||April 2015|April 2, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807585||70011|
NCT01814722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-266|Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)|Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens||Merck Sharp & Dohme Corp.|No|Terminated|November 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|HIV patients at academic and community-based practices in the United States|September 2015|September 7, 2015|March 18, 2013|No|Yes|The trial was terminated early due to slow recruitment.|No|October 6, 2014|https://clinicaltrials.gov/show/NCT01814722||69464|
NCT01814696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-002181|The Effect of the MedSentry System on Medication Adherence|The Effect of the MedSentry System on Medication Adherence for Patients With Congestive Heart Failure: A Pilot Study||Massachusetts General Hospital|No|Terminated|March 2013|August 2014|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|March 18, 2013||No|Slow enrollment and reached number needed for analysis.|No||https://clinicaltrials.gov/show/NCT01814696||69466|
NCT01815554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133N110006|Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia|Long-term Follow-up of Patients With Ventilatory Dependent High Tetraplegia Managed With Diaphragmatic Pacing Systems||Craig Hospital|No|Enrolling by invitation|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|All individuals implanted with DPS since 2003 who are being followed at one of the 6        collaborating study sites, including individuals who undergo DPS implantation during the        funding cycle through October of 2014. Currently, there are approximately 60 individuals        who comprise the existing clinical cohort of eligible participants. Individuals who are        implanted during the funding cycle also will be eligible for study inclusion.|July 2015|July 27, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815554||69402|
NCT01816087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287/2012|Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians|Study AGE - Part 2 (Active Geriatric Evaluation for General Practitioner), Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians||University of Lausanne|No|Completed|May 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|86|||Both|70 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816087||69361|
NCT01816074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0189|Sequencing Treatments for Mothers With ADHD and Their At - Risk Children|Sequencing Treatments for Mothers With ADHD and Their At - Risk Children|TMF|Seattle Children's Hospital|Yes|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Female|21 Years|50 Years|No|||November 2014|November 18, 2014|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816074||69362|
NCT01816607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-2013/152|Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness|Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness|OxyTarget|University Hospital, Akershus|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood, rectal cancer tissue, normal tissue, lymph nodes|Both|18 Years|N/A|No|Non-Probability Sample|Rectal cancer patients referred to radical surgery, with or without preoperative        chemoradiotherapy.|June 2015|June 22, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816607||69321|
NCT01817114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000023324|Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling|Chronic Remote Ischemic Conditioning Following Primary Percutaneous Intervention for ST-Elevated Myocardial Infarction|CRIC-RCT|The Hospital for Sick Children||Recruiting|March 2013|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817114||69282|
NCT01816906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiaBSmart-01|Development and Testing of a New Generation of Diabetic Footwear|Development of a New Generation of DIABetic Footwear Using an Integrated Approach and SMART Materials|DiaBSmart|Staffordshire University|Yes|Active, not recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|No|||November 2015|November 22, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816906||69298|
NCT01817075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL1034|Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant|Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)||Children's Oncology Group|Yes|Recruiting|November 2013|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|450|||Both|2 Months|21 Years|No|||February 2016|February 22, 2016|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817075||69285|
NCT01813578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norrbacka 2009|Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study|Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study||Karolinska University Hospital|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813578||69552|
NCT01809678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT006948|Yoga as a Complementary Therapy for Smoking Cessation|Efficacy of Yoga as a Complementary Therapy for Smoking Cessation||The Miriam Hospital|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809678||69850|
NCT01809691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1216|S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer|A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer|S1216|Southwest Oncology Group|Yes|Recruiting|March 2013|||July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1486|||Male|18 Years|N/A|No|||November 2015|December 8, 2015|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809691||69849|
NCT01813617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SweMyoNet 1|Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis|Outcome of Muscle Function and Disease Activity in Patients With Recent Onset Polymyositis and Dermatomyositis - a 1-year Follow-up Register Study||Karolinska University Hospital|No|Completed|September 2010|||June 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|18 Years|N/A|No|Non-Probability Sample|All patients diagnosed with polymyositis or dermatomysitis at the Karolinska University        Hospital 2003-2010.|March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813617|12 Months|69549|
NCT01813630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3002_TS_III (Version 1.2)|A Clinical Study to Assess the Efficacy and Safety of DA-3002|Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome||Dong-A ST Co., Ltd.|No|Recruiting|February 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|2 Years|12 Years|No|||August 2013|August 12, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01813630||69548|
NCT01814787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK092717|Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes|Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes||Indiana University|No|Recruiting|October 2013|July 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|1400|||Both|10 Years|18 Years|No|||February 2016|February 22, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814787||69459|
NCT01814800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMA-003|Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)|An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)||ADMA Biologics, Inc.|No|Completed|February 2014|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|2 Years|75 Years|No|||February 2015|February 20, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814800||69458|
NCT01813890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101093|A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy||Janssen-Cilag International NV|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|80 Years|No|||December 2014|December 31, 2014|March 15, 2013|Yes|Yes||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01813890||69528|
NCT01807871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-113|Treatment of Smoking Lapses and Relapses|Treatment of Smoking Lapses and Relapses||University of Vermont|No|Completed|March 2013|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|842|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807871||69989|
NCT01815294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100961|A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer|A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.||Janssen Research & Development, LLC|No|Completed|May 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01815294||69422|
NCT01815528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cat-Ovar_2011|Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer|Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes||Charite University, Berlin, Germany|Yes|Completed|March 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||February 2015|February 17, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01815528||69404|
NCT01815008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL105897-PARes-I|Pharmacogenomics of Antiplatelet Response - I|PHARMACOGENOMICS OF ANTI-PLATELET RESPONSE - I|PARes-I|Johns Hopkins University|Yes|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Both|45 Years|75 Years|No|||September 2014|September 5, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815008||69442|
NCT01815268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC75-EXT|High-Dose Influenza Vaccine in Nursing Homes|High Dose Influenza Vaccination and Morbidity & Mortality in U.S. Nursing Homes||Insight Therapeutics, LLC|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|823|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 14, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01815268||69424|
NCT01815827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28134|A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers|An Open-label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers||Hoffmann-La Roche||Completed|June 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|62|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815827||69381|
NCT01816360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AromaYoga|Aromatherapy and Yogatherapy for Hot Flashes|The Effects of Olfactory Aromatherapy and Yogatherapy Breathing Exercises on the Quality of Life, Stress Levels, Coping Strategies and Hot Flashes Intensity and Frequence in Climacteric Women||University of Sao Paulo|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|108|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01816360||69340|
NCT01816373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 3591/11/009|Non-invasive Negative Pressure Treatment for Pectus Excavatum|Efficacy Evaluation of the Non-invasive Negative Pressure Treatment for Pectus Excavatum||University of Sao Paulo|Yes|Active, not recruiting|March 2013|April 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Years|35 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01816373||69339|
NCT01816633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM002|Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers||Cytomedix|Yes|Active, not recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|380|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816633||69319|
NCT01816321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143201316398|Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial|Corifollitropin Alfa Followed by Hp-HMG Versus Recombinant FSH in Young Poor Ovarian Responders. A Multicentre Randomized Controlled Clinical Trial|COMPORT|Universitair Ziekenhuis Brussel|No|Recruiting|March 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|39 Years|No|||August 2015|August 5, 2015|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01816321||69343|
NCT01816334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201|Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica|Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica|TéAGS|University Hospital, Grenoble|Yes|Completed|January 2013|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816334||69342|
NCT01816347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-61-11|Evaluation of Pre-deployment Device-to-artery Relative Axial Motion in Coronary Catheterizations|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|18 Years|80 Years||Probability Sample|Patients undergoing routine PCI|March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816347||69341|
NCT01816620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POEMS-01|Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome|An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome||Peking Union Medical College Hospital|No|Active, not recruiting|March 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||November 2014|November 29, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816620||69320|
NCT01813357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-491/12|Does Rosuvastatin Delay Progression of Atherosclerosis in HIV|Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial||Bayside Health|Yes|Recruiting|March 2013|January 2017|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||July 2014|July 12, 2014|December 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01813357||69569|
NCT01808846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001006251|Neural Functioning of Feeding Centers in Obese Youth|Neural Functioning of Feeding Centers in Obese Youth||Yale University|No|Recruiting|July 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|116|Samples Without DNA|Serum|Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinic patients of Dr. Caprio at the Yale Pediatric Obesity Clinic who have undergone oral        glucose tolerance testing (OGTT) and found to be insulin resistant or sensitive and/or        previous research subjects who were found to be insulin resistant or sensitive and who        agreed to be contacted for other studies will be contacted.|March 2015|March 3, 2015|October 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01808846||69914|
NCT01809093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-954|A Research Study to Determine Levels of Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.|Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes|PEDF|Wills Eye|No|Completed|March 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|Samples Without DNA|The level of TSP1 and PEDF in the vitreous and plasma.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus who are undergoing pars plana vitrectomy for any reason|February 2015|February 2, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809093||69895|
NCT01809431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0486|Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants|Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants||University of North Carolina, Chapel Hill|Yes|Completed|May 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01809431||69869|
NCT01814462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_ASIC+CPAP_121/2012|Impact of CPAP Therapy in Obstructive Sleep Apnea on Parameters of Nocturnal Pulse Wave Analysis|Impact of CPAP Therapy in Obstructive Sleep Apnea on Parameters of Nocturnal Pulse Wave Analysis||Wissenschaftliches Institut Bethanien e.V|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01814462||69484|
NCT01814267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 12 07|Medico-economical Assessment of Telemedicine During Chronic Diabetes-related Foot Wound Management||AIRPEDIA|University Hospital, Grenoble|Yes|Active, not recruiting|March 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814267||69499|
NCT01814436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FourthMMU2013|Revitalization of Immature Permanent Teeth With Necrotic Pulps Using SHED Cells|Revitalization of Young Immature Permanent Teeth With Necrotic Pulps Using Autologous Stem Cells From Human Exfoliated Deciduous Teeth||Fourth Military Medical University|Yes|Recruiting|February 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|7 Years|12 Years|No|||March 2013|March 16, 2013|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01814436||69486|
NCT01814735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03TW008726-01|Substituting Brown Rice For White Rice: Effect On Diabetes Risk Factors In India|Substituting Brown Rice For White Rice: Effect On Diabetes Risk Factors In India||Harvard School of Public Health|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814735||69463|
NCT01814748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-028|A Study of the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Completed|May 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|44 Years|No|||September 2015|September 24, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814748||69462|
NCT01814189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-045|Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment|Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|65 Years|No|||July 2013|July 28, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814189||69505|
NCT01814709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28617|A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects||Genentech, Inc.||Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01814709||69465|
NCT01815034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-083|Trancutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations|Transcutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations: a Joint Quality Initiative Pilot From Cardiac Electrophysiology and Anesthesiology|TCO2|The Cleveland Clinic|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing catheter ablation for artial fibrillation or ventricular tachycardia|March 2013|August 18, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01815034||69440|
NCT01815541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0008|Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study|Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study||Centre Hospitalier Universitaire, Amiens|No|Completed|March 2013|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01815541||69403|
NCT01816100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039-13-EP|The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients|The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients: A Multimodal Neuroimaging Investigation|remapping|University of Nebraska|Yes|Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6|||Both|19 Years|65 Years|No|||December 2015|December 11, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01816100||69360|
NCT01816113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC051|Phase Ia Study of ChAd63/MVA PvDBP|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP||University of Oxford|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01816113||69359|
NCT01816386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuARP|Acupuncture Trial for Post Anaesthetic Recovery and Postoperative Pain|Acupuncture Randomized Trial for Post Anaesthetic Recovery and Postoperative Pain - a Pilot Study||Ludwig-Maximilians - University of Munich|No|Completed|June 2012|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Female|18 Years|N/A|No|||January 2015|January 12, 2015|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01816386||69338|
NCT01816399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-9-2003b|New Vectorcardiogram Analysis a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG|Spacial Relation of QRS-T Vectocardiogram is a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing routine coronary angiography|March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816399||69337|
NCT01816646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0903|Intravesical Cidofovir for Hemorrhagic Cystitis|Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2013|||September 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816646||69318|
NCT01816919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-09-0075-CTIL|Characterization of Head and Neck Malignant Tumors Using an Electronic Nose|Characterization of Head and Neck Malignant Tumors Using an Electronic Nose|HNeNose|Carmel Medical Center|Yes|Completed|November 2010|September 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|July 30, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816919||69297|
NCT01817387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMHK23SCH|Enhancing Motivation in Recent Onset Schizophrenia|Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia|PRIME|University of California, San Francisco|No|Recruiting|July 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|14 Years|30 Years|No|||December 2015|December 1, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01817387||69261|
NCT01817140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2012-06-06|Assessment of Mandibular Bone Invasion With MRI Using SWIFT|Assessment of Mandibular Bone Invasion With Magnetic Resonance Imaging (MRI) Using Sweep Imaging Fourier Transformation (SWIFT)||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|April 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of oral cancer with clinical or imaging findings suggestive of        maxillofacial or mandibular bone invation|May 2015|May 28, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817140||69280|
NCT01810029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1HL100386-01|A Trial of Stress Reduction in the Secondary Prevention of Coronary Heart Disease in Blacks|A Randomized Controlled Trial of Stress Reduction in the Secondary Prevention of Coronary Heart Disease in African Americans|CCR|Maharishi University of Management|Yes|Active, not recruiting|October 2009|May 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|56|||Both|N/A|N/A|No|||April 2012|March 11, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01810029||69823|
NCT01809730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02513|Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients|Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients||New York University School of Medicine|No|Withdrawn|May 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|CV biomarkers - inflammatory, metabolic, hypercoagulable and platelet.|Both|21 Years|N/A|No|Probability Sample|This pilot, observational study is designed to identify and follow orthopedic surgical        patients meeting specific high-risk criteria for postoperative cardiovascular events. All        normal standard of care will be maintained. Patients will be observed from Pre-Admission        Testing (PAT) visit through hospital discharge.|November 2015|November 16, 2015|March 11, 2013||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01809730||69846|
NCT01810276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601291|Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury|The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy That Sustain Traumatic Intracranial Hemorrhage|PUNCH|Christiana Care Health Services|Yes|Terminated|June 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|November 7, 2012||No|Patient population not available|No||https://clinicaltrials.gov/show/NCT01810276||69805|
NCT01810289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|START-ART|The "START" (a Streamlined ART Initiation Strategy) Study|The "START" (a Streamlined ART Initiation Strategy) Study|START-ART|University of California, San Francisco|No|Enrolling by invitation|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12500|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810289||69804|
NCT01813955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Papaverine schizophrenia|Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia|PDE Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia||University of Copenhagen|No|Terminated|June 2011|June 2013|Actual|May 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|5|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 19, 2011||No|Patient recruitment insufficient|No||https://clinicaltrials.gov/show/NCT01813955||69523|
NCT01815086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 100472|Radioimmunoimaging of Light Chain (AL) Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4||University of Tennessee|No|Completed|December 2008|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|21 Years|90 Years|No|||September 2013|September 17, 2013|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815086||69437|
NCT01814241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0900|Mechanisms of Desensitization During Peanut Oral Immunotherapy|Mechanisms of Desensitization During Peanut Oral Immunotherapy|PnOIT4|University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|April 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|4 Years|12 Years|No|||June 2015|June 16, 2015|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814241||69501|
NCT01814449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120224.1.1|Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer|Department of Breast Surgery And Department of Nuclear Medicine, Fudan University Shanghai Cancer Center,||Fudan University|Yes|Recruiting|March 2012|May 2014|Anticipated|February 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|Samples With DNA|Each patient underwent diagnostic core-needle biopsy on the primary site at baseline. A      therapeutic surgery or a second core-needle biopsy on the primary site was planned in a      subset of patients after at least 3 months of primary letrozole therapy. Both biopsy and      surgical samples of primary tumors were routinely embedded in paraffin wax and cut to 3- to      5-mm thickness and dried overnight for immunohistochemistry testing.Immunohistochemistry      staining for HIF-1-alpha and Ki67 were performed on 3- to 5-mm serial sections on coated      slides.|Female|60 Years|90 Years|No|Probability Sample|Postmenopausal women who had ER-a-positive breast cancer at stages II-IV and had never        received prior endocrine therapy were considered eligible for this study.|March 2013|March 19, 2013|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01814449|6 Months|69485|
NCT01815021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCS 009|A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients|A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.|AMCS009|Amorphical Ltd.|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01815021||69441|
NCT01814761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-AP-EYE-AGN-001|A Study of Bimatoprost 0.01% in the Clinical Setting||APPEAL-Taiwan|Allergan|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|312|||Both|20 Years|N/A|No|Non-Probability Sample|Subjects with primary open-angle glaucoma or ocular hypertension|September 2015|September 28, 2015|March 18, 2013|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01814761||69461|
NCT01815840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28295|A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas|A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas||Hoffmann-La Roche||Active, not recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815840||69380|
NCT01815307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1208|Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||October 2014|October 21, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01815307||69421|
NCT01816412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD02-LDCB|LEVANT Japan Clinical Trial|A Prospective, Multicenter, Single Blind, Randomized, Controlled Japanese Population Trial Comparing MD02-LDCB Versus Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries||C. R. Bard|Yes|Active, not recruiting|March 2013|June 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|100 Years|No|||October 2015|October 6, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01816412||69336|
NCT01816425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thermoplastic Denture Base|Comparison Between Cobalt-chromium Partial Dentures and Thermoplastic Partial Dentures|Comparison Between Cobalt-chromium Partial Dentures and Thermoplastic Partial Dentures: Random Clinical Trial|Flex|University of Sao Paulo|No|Active, not recruiting|February 2012|July 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 22, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816425||69335|
NCT01816659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1150|An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin|An Open-Labeled Pilot Study of Biomarker Response in Patients With Colorectal Cancer or Endoscopically Non-Resectable Adenomas Following Short-Term Exposure to Metformin Extended Release (ER)||M.D. Anderson Cancer Center|Yes|Terminated|May 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3|||Both|18 Years|75 Years|No|||August 2014|November 16, 2015|March 20, 2013|No|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01816659||69317|
NCT01816672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM001|Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.|A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers||Cytomedix|No|Recruiting|April 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816672||69316|
NCT01816945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207010574|The Momba Mobile Application-based Community|The Momba Mobile Application-based Community|MOMBA|Yale University|No|Completed|April 2013|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|47|||Female|18 Years|45 Years|No|||January 2016|January 6, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01816945||69295|
NCT01816958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_1293|Neuromodulation to Facilitate the Effect of Ketamine|Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.|TMS/ketamine|The Neuroscience Center, LLC|Yes|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|patients within my own clinic, suffering with chronic emotional and/or somatic pain|March 2013|March 20, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01816958||69294|
NCT01816932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-13-41|Home or Office Visit for the Insertion of Implantable Birth Control|Home or Office Visit for Insertion of Etonogestrel Implant: A Pilot Study||Case Western Reserve University|No|Active, not recruiting|June 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816932||69296|
NCT01817426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02MA|Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission|Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study|STOP IT|Copenhagen University Hospital at Herlev|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01817426||69258|
NCT01813383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celiac disease and HLA-DQ2.2|Clinical Relevance of Typing HLA-DR7-DQ2|Clinical Relevance of Typing HLA-DR7-DQ2|HLA|Corporacion Parc Tauli|Yes|Completed|January 2010|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|92|||Both|N/A|18 Years|No|Probability Sample|Celiac disease patients who have been diagnosed in a Hospital by a Pediatrician.|March 2013|March 14, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813383||69567|
NCT01809717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13412|Multiple Myeloma and Exercise|Modulating The Toxicity And Efficacy Of High Dose Chemotherapy For Multiple Myeloma Through An Intervention To Increase Lean Body Mass||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01809717||69847|
NCT01809457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S01 / UW 11-177|Effectiveness of Dental Trauma Educational Poster to Secondary Students|Effectiveness of Educational Poster to Secondary Students Regarding Knowledge of Emergency Management of Dental Trauma - A Cluster Randomised Controlled Trial||The University of Hong Kong|No|Completed|March 2011|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|671|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01809457||69867|
NCT01810042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|임상20120178|Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab|A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration||Pusan National University Hospital|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|50 Years|N/A|No|||March 2014|March 9, 2014|March 11, 2013||No||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01810042||69822|Small number of cases, high rate of follow-up loss. Technical problem with measuring caliber of choroidal new vessels.
NCT01814839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTRSC-001|A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers||Alnylam Pharmaceuticals|No|Completed|March 2013|May 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814839||69455|
NCT01814852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENO-006B-MR|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' for Patients With Erectile Dysfunction|A Prospective, Randomized, Double Blind With Sham Control, Clinical Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction||Initia|No|Completed|December 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|80 Years|No|||May 2015|May 11, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814852||69454|
NCT01814865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212082BCA2004|Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer|Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer||British Columbia Cancer Agency|No|Withdrawn|May 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Female|18 Years|N/A|No|||December 2013|December 19, 2013|March 13, 2013||No|Funding was not acquired|No||https://clinicaltrials.gov/show/NCT01814865||69453|
NCT01815047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1201002753|Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy|Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy||Cornell University|Yes|Active, not recruiting|December 2012|May 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|85|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01815047||69439|
NCT01815320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-US|CE-US in Renal Transplantation|A PILOT, EXPLORATIVE STUDY TO IDENTIFY CONTRAST-ENHANCED ULTRASOUND (CE-US) PATTERNS THAT CHARACTERIZE ACUTE ALLOGRAFT REJECTION AND OTHER CAUSES OF ACUTE ALLOGRAFT DYSFUNCTION IN RENAL TRANSPLANT RECIPIENTS||Mario Negri Institute for Pharmacological Research|No|Completed|April 2011|September 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01815320||69420|
NCT01814774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRU2011|A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm|||Allergan|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with cervical dystonia or blepharospasm previously treated with Xeomin® and        BOTOX®.|June 2014|June 4, 2014|March 18, 2013|No|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT01814774||69460|
NCT01815567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060043|DETECT and Retinal Outcomes in Hypertension|The Effects of Blood Pressure on Cognitive Function: Examining the Use of Bedside Neuropsychological Testing During Acute Hypertensive Events||Emory University|No|Recruiting|November 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Emergency department patients that meet the inclusion/exclusion criteria.|December 2015|December 15, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01815567||69401|
NCT01815853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCCGPS2|Pre-operative Chemoradiotherapy or Chemotherapy Following Surgery and Adjuvent Chemotherapy in Patients With Gastric Cancer|||Sun Yat-sen University|No|Recruiting|July 2012|||June 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|18 Years|70 Years|No|||March 2013|March 21, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815853||69379|
NCT01816126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2013|One-or Two Person Technique and Quality Performance of Colonoscopy|||Valduce Hospital|Yes|Recruiting|February 2013|||May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|50 Years|80 Years|No|Non-Probability Sample|colon cancer screening population|March 2013|March 18, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01816126||69358|
NCT01816139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-05812|Multicenter Study to Evaluate Safety and Efficacy of WC3011 in Postmenopausal Women|A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women||Warner Chilcott|No|Completed|February 2013|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|576|||Female|35 Years|N/A|No|||February 2015|February 24, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816139||69357|
NCT01816438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFED N°100|A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia|A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia in Intestinal Inflammatory Diseases||Hôpital Edouard Herriot|No|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|pathological lesion slides|Both|18 Years|80 Years|No|Probability Sample|In France more than 40000 persons are concerned with a high risk of cancer because of        ulcerative colitis for example|August 2015|August 17, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816438|4 Years|69334|
NCT01816685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041457|Effect of CPAP on Postoperative Delirium|The Effect of Peri-operative Continuous Positive Airway Pressure (CPAP) on Postoperative Delirium in a Population at High-risk for Obstructive Sleep Apnea (OSA)||Duke University||Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|135|||Both|50 Years|N/A|No|||August 2015|August 4, 2015|March 20, 2013|Yes|Yes||No|June 28, 2015|https://clinicaltrials.gov/show/NCT01816685||69315|
NCT01816971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1725|Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma|Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy||University of Chicago|No|Active, not recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816971||69293|
NCT01817166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2012/ET-01|Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome|Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.|D-Lay-MS|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|July 2013|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|316|||Both|18 Years|56 Years|No|||January 2016|January 18, 2016|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817166||69278|
NCT01817439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 1|Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF|The Effect of Intravenous vs. Oral Administration of Amiodarone on the Incidence Rate of Phlebitis Among Patients With Recent Onset of Atrial Fibrillation (AF)||Western Galilee Hospital-Nahariya|No|Not yet recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817439||69257|
NCT01809119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UROUSP - 005|Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy|Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy||University of Sao Paulo|Yes|Recruiting|December 2012|February 2015|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809119||69893|
NCT01810081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.MAR.0.01.02/AEK/73|Gallstones and Concomitant Gastric Helicobacter Pylori Infection|Study of Relationship Between Gallstones and Concomitant Gastric Helicobacter Pylori Infection||Marmara University|Yes|Not yet recruiting|March 2013|June 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|94|||Both|18 Years|80 Years|No|Non-Probability Sample|Ninety-four patients with symptomatic gallstones undergoing laparoscopic cholecystectomy        were enrolled for the study.|March 2013|March 11, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01810081||69820|
NCT01810302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-2013|Safety Study of Nicardipine to Treat Cerebral Vasospasm|Intraventricular Nicardipine for the Treatment of Cerebral Vasospasm: Prospective Pilot Study||University of Florida|Yes|Terminated|August 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|March 11, 2013|Yes|Yes|Unable to secure drug.|No|August 18, 2014|https://clinicaltrials.gov/show/NCT01810302||69803|This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done.
NCT01810315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-124|Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity|Influence of Female Reproductive Cycle and Menopause on Cervicovaginal Tissue Susceptibility to HIV-1 Infections and Tenofovir 1% Gel Activity||CONRAD|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|40|||Female|21 Years|89 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810315||69802|
NCT01810328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|482-2012|A Validation of a Genomics Based Prognostic in Severe Trauma|Validation of a Genomics Based Prognostic in Severe Trauma||University of Florida|No|Recruiting|October 2013|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810328||69801|
NCT01810588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205012383|Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) for Haplo-Cord Transplantation|A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)||Weill Medical College of Cornell University|Yes|Recruiting|August 2012|October 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810588||69781|
NCT01814501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11131|Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab|A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2013|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814501||69481|
NCT01814878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016636|A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain|A Randomized, Active-Controlled, Parallel Group, Double-Blind Study to Compare the Efficacy and Safety of Tramadol HCl/Acetaminophen ER and IR in Subjects Who Complain of Moderate to Severe Postoperative Pain||Janssen Korea, Ltd., Korea|No|Completed|November 2009|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|320|||Both|25 Years|80 Years|No|||June 2013|June 18, 2013|March 18, 2013|Yes|Yes||No|March 30, 2013|https://clinicaltrials.gov/show/NCT01814878||69452|
NCT01814475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022052-23 GITMO - MF2010|Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis|Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis|GITMO-MF2010|Gruppo Italiano Trapianto di Midollo Osseo|Yes|Recruiting|July 2011|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 2, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814475||69483|
NCT01814813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A071101|Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery|A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)||Alliance for Clinical Trials in Oncology|Yes|Recruiting|May 2013|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814813||69457|
NCT01815073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02049715|Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine|A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine||Changchun Keygen Biological Products Co., Ltd.|Yes|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|497|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815073||69438|
NCT01815866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|484-2012|Cough-Generated Aerosols of NTM in Cystic Fibrosis|Cough-Generated Aerosols of Nontuberculous Mycobacteria in Patients With Cystic Fibrosis||University of Florida|Yes|Completed|April 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|5|Samples Without DNA|Sputum cultures|Both|8 Years|75 Years|No|Probability Sample|Specialialty Clinics, Pulmonary|October 2015|October 13, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815866||69378|
NCT01816451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRJ-2010|Physiologic Adaptations to Interval and Continuous Running at Low Volume and Vigorous Intensity Over 14-Weeks.|Physiological Responses to Constant-load (Continuous) vs. Variable-intensity (Interval) During 14 Weeks of Supervised Aerobic Exercise on Active Men.||University of Trás-os-Montes and Alto Douro|Yes|Completed|March 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|35|||Male|25 Years|32 Years|No|||April 2014|April 10, 2014|March 14, 2013||No||No|June 15, 2013|https://clinicaltrials.gov/show/NCT01816451||69333|
NCT01816698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZS01167262|Effects and Safety of Taurine Granule on Blood Pressure in Prehypertensive|A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of TAURINE GRANULE and Placebo on Blood Pressure in Prehypertensive.|ESTAB|Third Military Medical University|Yes|Completed|December 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|25 Years|75 Years|No|||November 2015|November 23, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816698||69314|
NCT01816984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1972|PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer||University of Chicago|No|Active, not recruiting|May 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816984||69292|
NCT01817179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-Effects of FES/PwP|Functional Electrical Stimulation for Hemiplegic Cerebral Palsy|Effects of Functional Electrical Stimulation Neuroprosthesis in Children With Hemiplegic Cerebral Palsy||Children's Hospital Medical Center, Cincinnati|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|6 Years|17 Years|No|||March 2013|January 27, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817179||69277|
NCT01817452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06 / ADAPT HER2+/HR-|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol|ADAPT|West German Study Group|Yes|Recruiting|March 2014|August 2020|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817452||69256|
NCT01817465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9701_PPI_IV|A Study to Demonstrate the Efficacy and Safety of Motilitone®|A Multi-centers, Randomized, Double-blinded, Parallel Study Study to Evaluate the Efficacy and Safety of Motilitone® in Patients With Functional Dyspepsia.||Dong-A ST Co., Ltd.|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|389|||Both|20 Years|N/A|No|||January 2015|January 25, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01817465||69255|
NCT01817478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0093-12-ZIV|The Influence of Hospital Environment on Eyes Infections in Medical Staff|||Ziv Hospital||Recruiting|January 2013|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817478||69254|
NCT01810068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mans-01-2013|Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function|Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study.||Mansoura University|Yes|Completed|January 2013|April 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|262|||Male|50 Years|N/A|No|||May 2015|May 8, 2015|March 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810068||69821|
NCT01809769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMG-KOA-1.1|Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis|Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial||Cellular Biomedicine Group Ltd.|Yes|Completed|March 2013|December 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|40 Years|70 Years|No|||March 2014|March 19, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809769||69843|
NCT01809795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-4400|The Health Effects of a Blueberry Enriched Diet on Obese Children|The Health Effects of a Blueberry Enriched Diet on Obese Children: A Feasibility Study|Wild Blueberry|Children's Hospital Medical Center, Cincinnati|No|Completed|March 2013|December 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|12 Years|17 Years|No|||December 2014|December 16, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01809795||69841|
NCT01810341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12002|SynapDx Autism Gene Expression Analysis Study (STORY)|SynapDx Autism Spectrum Disorder Gene Expression Analysis Study|STORY|SynapDx|No|Completed|March 2013|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|880|Samples With DNA|Peripheral blood|Both|18 Months|60 Months|No|Probability Sample|Children 18 months to less than 60 months referred to a developmental evaluation center        for evaluation of a possible developmental disorder.|December 2014|December 15, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810341||69800|
NCT01810601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|noharabei-1|Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates|Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates|ET|Ain Shams Maternity Hospital|Yes|Completed|September 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||March 2013|March 25, 2013|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810601||69780|
NCT01810614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13493|A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)|A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)||University of Kansas Medical Center|No|Completed|February 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810614||69779|
NCT01814514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90166|Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation|Early Intra Ocular- Pressure Control Using Aqueous Suppressive Agents After Ahmed Glaucoma Valve Implantation||hahid Beheshti University of Medical Sciences|No|Recruiting|January 2011|||March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01814514||69480|
NCT01814527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSM-2012-1059|High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions|High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions||East Carolina University|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|40 Years|No|||February 2015|February 9, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814527||69479|
NCT01815099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEF003523.3|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder: Substudy #2||Hartford Hospital|No|Recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815099||69436|
NCT01815606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405581|Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm|Randomized Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm||Florida Hospital|Yes|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|51|||Both|19 Years|89 Years|No|||January 2014|January 8, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01815606||69398|
NCT01815580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT-Peru|HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women|HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru|SABES?|Fred Hutchinson Cancer Research Center|No|Recruiting|July 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01815580||69400|
NCT01815593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-30872571|The Value of Enhanced External Counterpulsation Treatment to Erectile Dysfunction|||First Affiliated Hospital, Sun Yat-Sen University||Enrolling by invitation|April 2013|April 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|80 Years|No|Probability Sample|Men with erectile dysfunction in GuangDong province|March 2013|March 21, 2013|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01815593||69399|
NCT01816152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG034157|Methodology Issues in a Tailored Light Treatment for Persons With Dementia|Phase 1 Methodology Issues in a Tailored Light Treatment for Persons With Dementia||Rensselaer Polytechnic Institute|No|Recruiting|December 2010|April 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01816152||69356|
NCT01816477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008050|Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient After Minimally Invasive Repair|A Prospective, Randomized, Controlled Trial of Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient After Minimally Invasive Repair||Mayo Clinic|No|Recruiting|April 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816477||69331|
NCT01816724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT/URO/2013/546|Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia|Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia||Corporacion Parc Tauli|No|Completed|March 2013|April 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|129|||Both|60 Years|N/A|No|Probability Sample|Men older than 60 years old suffering from nocturia (one or more voidings overnight)        without exclusion criteria|March 2013|June 16, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816724||69312|
NCT01816711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFVD2012|Vitamin D Levels in Frail Elderly Patients With a Hip Fracture|Vitamin D Levels in Frail Elderly Patients With a Hip Fracture||University of Aarhus|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|447|||Both|65 Years|N/A|No|Probability Sample|Cases were frail elderly admitted with a hip fracture to the Orthopaedic Ward at Aarhus        University Hospital in the period: 18th of January 2010 to the 1st of October 2012.        Controls were frail elderly, without hip fracture in the previous ten years, admitted to        the Geriatric Ward at Aarhus University Hospital in the period: 18th of January 2010 to        the 1st of October 2012.|April 2013|April 4, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816711||69313|
NCT01816997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 2011-10-005IA|The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose|The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2012|December 2022|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|160|||Both|35 Years|70 Years|No|||November 2013|November 15, 2013|December 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01816997||69291|
NCT01817192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-120888|Adjuvant Chemotherapy in Patients With High Risk Stage I Non-squamous Non-Small Cell Lung Cancer|A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I Non-Squamous Non-Small Cell Lung Cancer Identified as High Risk by the Pervenio™ Lung RS Assay||Encore Clinical|Yes|Active, not recruiting|May 2013|||April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01817192||69276|
NCT01817205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR-13-01|Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma|A Pilot Study on the Feasibility of Combined Chemoembolization and Adjuvant Systemic Hyperthermia for Palliative Treatment of Unresectable Hepatocellular Carcinoma(HCC)||Chinese University of Hong Kong|Yes|Recruiting|March 2013|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2013|July 27, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817205||69275|
NCT01817491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1298|Low Fat Vegan Diet or American Heart Association Diet Impact on Cardiovascular Risk in Obese Hypercholesterolemic 9-18 y.o.|Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese Hypercholesterolemic Children/Adolescents: A Four Week Randomized Trial||The Cleveland Clinic|Yes|Active, not recruiting|March 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|9 Years|18 Years|No|||September 2013|September 18, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817491||69253|
NCT01809782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Two-stage liver|Cognitive Outcome After Two-stage Liver-Operation|Post-operative Cognitive Dysfunction (POCD) and Delirium in Patients Undergoing Two-stage Liver Operation - a Pilotstudy|2-StaLi|Charite University, Berlin, Germany|No|Recruiting|March 2013|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult female and male patients undergoing two stage liver-operations|March 2016|March 2, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01809782||69842|
NCT01809496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7067W|Hearing Aids, Counseling and the Significant Other|Auditory Rehabilitation From the Perspective of the Significant Other||VA National Center for Rehabilitative Auditory Research|No|Terminated|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|March 6, 2013||No|Funding ended|No||https://clinicaltrials.gov/show/NCT01809496||69864|
NCT01811160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INPRF_144|Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics|Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics||Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|No|Completed|October 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|No|||March 2013|March 12, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01811160||69737|
NCT01810094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-0910|Minimally Invasive Reduction and Fixation of Thoracolumbar Fractures|Prospective Observational Study of Minimally Invasive Fixation of Thoracolumbar Fractures With the Fracture Fixation System S4, Performed With the Fracture Reduction Instrumentation FRI (FRIFIX)|FRIFIX|Aesculap AG|Yes|Active, not recruiting|February 2013|November 2016|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients|January 2016|January 15, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01810094||69819|
NCT01811472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908A2216|Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease||Novartis|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|74 Years|No|||January 2016|January 5, 2016|March 12, 2013|Yes|Yes||No|September 8, 2015|https://clinicaltrials.gov/show/NCT01811472||69713|
NCT01810354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0004|PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN|PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN: Does Increasing the Dose Increase the Tissue Concentration?||Women and Infants Hospital of Rhode Island|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 22, 2014|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810354||69799|
NCT01810367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-CJH|ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC|ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in First Line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Stage II Randomized Controlled Trials||Fudan University|Yes|Completed|December 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810367||69798|
NCT01814332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09S-NIMH-002|Analyzing Female Trauma Exposed Responses to a Medication|CRF Receptor Antagonist for PTSD and Related Sleep Disturbances in Women|AFTER|VA Office of Research and Development|Yes|Completed|March 2013|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|65 Years|No|||January 2015|January 14, 2015|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814332||69494|
NCT01815112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07-PR-MEYER1|Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging|Benefit of MRI and 18F-FDG PET Imaging in the Early Diagnosis of Alzheimer-like Dementia||Centre Hospitalier Universitaire, Amiens|No|Terminated|February 2008|April 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|5||Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 9, 2015|March 18, 2013||No|Administrative re-organization of the department. Referent physician left the hospital.|No||https://clinicaltrials.gov/show/NCT01815112||69435|
NCT01815333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0926|Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging|Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging||M.D. Anderson Cancer Center|No|Recruiting|July 2013|||July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815333||69419|
NCT01815346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1054|Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG|A Phase I-II Study of Acupuncture for the Treatment of Chronic, Taxane-Induced Peripheral Neuropathy in Breast Cancer Survivors||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2014|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815346||69418|
NCT01815359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-289|ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis|ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis|ICARuS|Memorial Sloan Kettering Cancer Center||Recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|220|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815359||69417|
NCT01815619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409832|Comparison of On-Site Verus Off-Site Evaluation of Cholangioscopy-Guided Biopsies of the Bile Duct|Comparison of On-Site Verus Off-Site Evaluation of Cholangioscopy-Guided Biopsies of the Bile Duct||Florida Hospital|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|66|||Both|18 Years|89 Years|No|||November 2015|November 24, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01815619||69397|
NCT01815632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTiMuS|Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)|Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)|ACTiMuS|North Bristol NHS Trust|Yes|Recruiting|January 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||August 2013|January 29, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815632||69396|
NCT01815879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORE|Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project|Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project|MORE|Sarah Cannon|No|Active, not recruiting|December 2012|||June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colorectal liver metastases in the USA treated with 90Y resin microsphere        radioembolization|March 2013|March 20, 2013|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01815879||69377|
NCT01815892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG1234|The Use of Furosemide in Patients on Dialysis|The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis||St. Michael's Hospital, Toronto|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|51|||Both|N/A|N/A|No|||December 2015|December 2, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815892||69376|
NCT01816165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0649|Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes|Role of Lipotoxicity in Insulin Resistance, Vascular, and Mitochondrial Dysfunction in Type 1 Diabetes|AcT1|University of Colorado, Denver|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816165||69355|
NCT01816464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatFlu_HIVneg_preg+nonpreg|Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women|Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Non-pregnant HIV-Uninfected Women: An Open Label Trial||University of Witwatersrand, South Africa|Yes|Completed|September 2013|April 2014|Actual|February 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|150|||Female|18 Years|39 Years|No|||January 2015|January 9, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816464||69332|
NCT01816737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC13191-12CTIL|Fetal Blood Flow Response to Partial Occlusion by External Compression|||Meir Medical Center||Not yet recruiting|March 2013|||October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women|March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816737||69311|
NCT01817010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1121|Strength and Function Following Total Hip Arthroplasty|Strength and Function Following Total Hip Arthroplasty||University of Colorado, Denver|No|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|50 Years|75 Years|No|||November 2015|November 24, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817010||69290|
NCT01817231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVitaminD|Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women|Vitamin D Status and Breast Cancer in Saudi Arabian Women: Case Control Study||University of Arizona|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|240|Samples Without DNA|serum for vitamin D levels|Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Saudi Arabian women receiving care at King Fahd Women's clinic in Saudi Arabia during the        summer of 2009.|March 2013|March 22, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01817231||69273|
NCT01817218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002247-20|Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers|Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting|PRP-2012|Basque Health Service|Yes|Completed|June 2013|April 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||July 2015|July 22, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01817218||69274|
NCT01813474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081BC00001|Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies|A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|March 2013|July 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|N/A|No|||September 2014|September 11, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01813474||69560|
NCT01813487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB110E_PI_PS|Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E|Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy in Patients Who Have Been Treated With HB110E Hepatitis B DNA Vaccine||Genexine, Inc.|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|60 Years|No|||December 2013|December 26, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813487||69559|
NCT01809509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Pilot Study on Molecular Quantitation and Sequencing of Endometrial Cytokines Gene Expression and Their Effect on the Outcome of In-vitro Fertilization (IVF) Cycle|A Prestudy of Impact of Cytokines and Gene Expression on Outcome of IVF||Cairo University|No|Enrolling by invitation|January 2012|November 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Female|23 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|those under going IVF using standard protocol|March 2013|March 9, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01809509||69863|
NCT01810653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12052|A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation|A Double-blind, Randomized, Uninational, Multicenter, Two Parallel Groups, Active Controlled Study to Compare the Effect of the Treatment With Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation||Bayer|No|Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|97|||Both|6 Months|15 Years|No|||August 2015|August 12, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810653||69776|
NCT01811485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237A1303|Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy|CLMF237A1303|Novartis|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|171|||Both|20 Years|74 Years|No|||February 2015|February 4, 2015|March 12, 2013||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01811485||69712|
NCT01811706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121107|Dalfampridine and Gait in Spinocerebellar Ataxias|Therapeutic Effect of Dalfampridine on Gait Incoordination in Spinocerebellar Ataxias- A Randomized, Double-blinded, Placebo-controlled, Crossover Clinical Trial||University of Florida|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|March 6, 2013|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01811706||69695|
NCT01811719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC 555|Enhanced Nurse Home Visitation to Prevent Intimate Partner Violence|An Enhanced Nurse Home Visitation Program To Prevent Intimate Partner Violence||Portland State University|No|Completed|January 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|238|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01811719||69694|
NCT01806051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-12-00178|A Pilot Study on Diurnal Variation|A Pilot Study on the Diurnal Variation in PKU Patients With Kuvan||Children's Hospital Los Angeles|No|Terminated|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label|2||Anticipated|10|||Both|4 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806051||70129|
NCT01806350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0912|Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors|A Pilot Randomized Control Trial to Evaluate Pelvic Floor Muscle Training for Urinary Incontinence Among Gynecologic Cancer Survivors||New Mexico Cancer Care Alliance|Yes|Completed|November 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|30 Years|N/A|No|||March 2013|March 6, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806350||70106|
NCT01805778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000032746|Preventing Cardiac Sequelae in Pediatric Cancer Survivors|Novel Approaches to the Prediction, Diagnosis and Treatment of Cardiac Late Effects in Survivors of Childhood Cancer: A Multi-centre Observational Study|PCS2|The Hospital for Sick Children|No|Recruiting|December 2012|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1190|Samples With DNA|The study will retain plasma for biomarker and genomic analysis. The study will also retain      saliva for those patient who are unable or unwilling to provide a blood specimen for genomic      analysis.|Both|N/A|18 Years|No|Non-Probability Sample|Patients will be recruited from pediatric oncology centres across Ontario, Canada        (SickKids in Toronto, McMaster Children's Hospital in Hamilton, Children's Hospital of        Eastern Ontario in Ottawa, and London Health Sciences Centre in London)|May 2015|May 19, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805778||70150|
NCT01805791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMPL-004-03|A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis||Hutchison Medipharma Limited||Terminated|March 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|75 Years|No|||March 2014|May 3, 2015|March 4, 2013|Yes|Yes|Interim futility analysis results|No||https://clinicaltrials.gov/show/NCT01805791||70149|
NCT01814891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zambia II|Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children|Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children||University of Wisconsin, Madison|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|143|||Both|57 Months|88 Months|Accepts Healthy Volunteers|||March 2013|March 19, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01814891||69451|
NCT01814904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E14|Dose-finding Study of MCI-196|A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy With a Calcium-based Phosphate Binder, in Paediatric Subjects With Chronic Kidney Disease Stage 5 on Dialysis and With Hyperphosphataemia||Mitsubishi Tanabe Pharma Corporation|Yes|Terminated|April 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|2 Years|18 Years|No|||May 2015|May 25, 2015|March 18, 2013||No|This study has been terminated because of insufficient patient recruitment.|No||https://clinicaltrials.gov/show/NCT01814904||69450|
NCT01815372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPEDI|Ultrasound-guided Nerve Blocks for the Sciatic and Saphenous Nerves: Characteristics of the Single Penetration Dual Injection (SPEDI) Technique|Ultrasound-guided Nerve Blocks for the Sciatic and Saphenous Nerves: Characteristics of the Single Penetration Dual Injection (SPEDI) Technique||Bispebjerg Hospital|No|Completed|October 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01815372||69416|
NCT01815398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6586|Cognitive Skills Training for Homeless Youth|Cognitive Skills Training to Improve Vocational Outcome in Homeless Youth||New York State Psychiatric Institute|No|Active, not recruiting|July 2012|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|22 Years|No|||January 2016|January 5, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01815398||69414|
NCT01815645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/01469-7 (FAPESP)|Contingency Management Treatment for Crack Addiction - Study With Brazilian Population|Evaluating the Efficacy of Including Contingency Management to Standard Ambulatory Treatment for Crack Addiction - A Randomized Controlled Trial||Federal University of São Paulo|Yes|Active, not recruiting|May 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815645||69395|
NCT01815905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1206/160-005|Effect of U-Health Service in Stroke Patients|U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia||Seoul National University Bundang Hospital|Yes|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|No|||March 2014|March 3, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01815905||69375|
NCT01815918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11007|The Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Replacement|The Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Replacement||Hospital for Special Surgery, New York|No|Completed|February 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|90 Years|No|||March 2013|March 19, 2013|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815918||69374|
NCT01815931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-032013|Hemolysis in Blood Samples in the ER|||University Hospital, Geneva|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2800|||Both|16 Years|N/A|No|Non-Probability Sample|All adult (> 16 y) patients admitted in the emergency departement during the study period|November 2013|November 8, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815931||69373|
NCT01816178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUIRB-1|Using a Voice Output Communication Aid to Facilitate Language Development in Young Children With ASD|Using a Voice Output Communication Aid to Facilitate Language Development in Young Children With Autism Disorders||University of South Alabama|No|Completed|February 2004|August 2005|Actual|August 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01816178||69354|
NCT01816191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN307-PK-001|An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride|An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride||Ventrus Biosciences, Inc|No|Active, not recruiting|February 2013|September 2013|Anticipated|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||July 2013|August 19, 2013|March 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816191||69353|
NCT01816490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THISTLE|THISTLE - The HIV-HCV Silibinin Trial|A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS)|THISTLE|University of Zurich||Completed|April 2013|December 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||September 2013|March 4, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01816490||69330|
NCT01807481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2011-10-131|Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD|A Prospective,Single-arm,Multicenter Study to Evaluate the Efficacy and Safety of Mircera in Peritoneal Patients Who Already Had Been Treated With ESA||Samsung Medical Center|No|Recruiting|March 2013|August 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|101|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807481||70019|
NCT01807754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00069294|Simulated Screening Study for Breast Imaging|Simulated Screening Study of Combined Digital X-Ray, Ultrasound and Photoacoustic Breast Imaging||University of Michigan|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|160|||Female|30 Years|80 Years|No|||July 2015|July 31, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01807754||69998|
NCT01808027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1313/74|Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Evaluation of the Methods and Management of Acute Coronary Events: 3. Investigating Variation in Hospital Acute Coronary Syndrome Outcomes||University of Leeds|Yes|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5555|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Consented patients with acute coronary syndrome were recruited from acute Trusts in        England. These hospitals have been selected because of their diverse population        demographics, different acute coronary syndrome care pathways and established track record        for good data collection. Specifically these hospitals represent both teaching hospitals        and community hospitals - but more importantly include a wide range of patient types.        Mortality tracked through the UK statistics authority, and primary and secondary endpoints        tracked locally and transferred through the secure NHS net to a central database.|March 2013|March 7, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808027|12 Months|69977|
NCT01817504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.714|Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure|Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure|DESYRE|Hospices Civils de Lyon|Yes|Recruiting|August 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|118|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01817504||69252|
NCT01808508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007964|Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome|Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome|TRIO|Children's Hospital of Philadelphia|Yes|Completed|September 2010|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|8 Years|20 Years|No|||December 2015|January 8, 2016|March 7, 2013|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01808508||69940|This preliminary study was limited by the small sample size, and the few children with Down Syndrome but normal breathing during sleep.
NCT01810926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBG_361.11|T&B Depletion Non Malignant|A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies||Bambino Gesù Hospital and Research Institute|Yes|Recruiting|September 2011|October 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|130|||Both|N/A|64 Years|No|||March 2013|March 12, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01810926||69755|
NCT01811186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN12-KR-403|An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)|An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With Targin® in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)||Mundipharma Korea Ltd|No|Completed|December 2012|June 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|261|||Both|20 Years|80 Years|No|||July 2015|July 7, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811186||69735|
NCT01810939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-301|A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)|A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia|OPAL|Relypsa, Inc.|No|Completed|February 2013|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|March 12, 2013|Yes|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01810939||69754|
NCT01811173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMAP|Comprehensive-Care for Multimorbid Adults Effectiveness Study|The Clalit Comprehensive-Care for Multimorbid Adults Project|CCMAP|Meir Medical Center|Yes|Active, not recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1800|||Both|18 Years|95 Years|No|||February 2013|April 28, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811173||69736|
NCT01806363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTECHL12I_1|Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone|A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.||HanAll BioPharma Co., Ltd.|Yes|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806363||70105|
NCT01806389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00080884|A Study of Breastfeeding in Buprenorphine Maintained Women|Lactation Among Buprenorphine Maintained Women: A Pilot Study||Johns Hopkins University|No|Completed|February 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Maternal urine, plasma and breast milk INnfant plasma|Female|18 Years|41 Years|No|Non-Probability Sample|Five buprenorphine maintained women who deliver and infant and desire to breastfeed|February 2013|February 29, 2016|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01806389||70103|
NCT01806337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL-2003-1|CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma|Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation||University of Göttingen|Yes|Completed|July 2003|February 2011|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|70 Years|No|||March 2013|March 6, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01806337||70107|
NCT01806038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042998|Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge|The Effect of Pharmacist-Provided Counseling Combined With Outpatient Dispensing at Hospital Discharge on the Incidence of Post-Discharge Drug-Related Problems and Healthcare Utilization||Duke University|No|Completed|March 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|44|||Both|18 Years|N/A|No|||April 2014|November 11, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806038||70130|
NCT01815385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-12-428|Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants|Early Life Exposure to Polycyclic Aromatic Hydrocarbons: Metabolic Perturbations and Epigenetic Biomarkers||Montefiore Medical Center|No|Recruiting|March 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Maternal blood sample Cord blood sample Infant saliva Peripheral blood sample from enrolled      patients at 12 and 24 months of age|Both|N/A|72 Hours|Accepts Healthy Volunteers|Probability Sample|Mother-baby pairs will be recruited.|September 2015|September 21, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815385||69415|
NCT01806584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVG01-SRM003|An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access|A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access||Shire|Yes|Terminated|March 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||October 2015|November 25, 2015|March 5, 2013|Yes|Yes|Development of SRM003 was discontinued based on portfolio prioritization.|No|October 16, 2015|https://clinicaltrials.gov/show/NCT01806584||70088|Study was discontinued early due to Sponsor decision.
NCT01815658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-15-2013|"Bio-logical" Carbon Fiber Intramedullary Nail Biomechanical Test and Preliminary Clinical Results|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Probability Sample|Patients presenting with broken humerus|March 2013|March 19, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01815658||69394|
NCT01815944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMMC883.11|Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose|Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose||University of Malaya|Yes|Completed|December 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|85 Years|No|||March 2013|March 19, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815944||69372|
NCT01807195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0922|Acute Renal Injury Associated Contrast in Intensive Care Unit Patients|||Yonsei University|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|886|||Both|N/A|N/A|No|Non-Probability Sample|RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) categorization and the        existing classification method were used to compare their predictive value for acute renal        damage related to contrast media.|June 2014|June 5, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807195||70041|
NCT01807780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2011 UGSAN|Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel|||University of Roma La Sapienza||Active, not recruiting|September 2012|||December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|310|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01807780||69996|
NCT01808274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve|Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve|CENTERA|Edwards Lifesciences|Yes|Active, not recruiting|February 2013|December 2018|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|N/A|No|||November 2014|November 18, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808274||69958|
NCT01808287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07|Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study|Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve|SAPIEN3|Edwards Lifesciences|Yes|Active, not recruiting|January 2013|June 2019|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|75 Years|N/A|No|||June 2015|June 12, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808287||69957|
NCT01808300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMPT-1|Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.|A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers||Unimed Pharmaceuticals|No|Completed|February 2013|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|42|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2013|August 21, 2013|March 3, 2013||Yes||||https://clinicaltrials.gov/show/NCT01808300||69956|
NCT01808768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID IIT- 000373|Ocular Allergy Treatment Practical Impact Trial|To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)|(OAT-PIT)|Starx Research Center, LLC|No|Recruiting|April 2013|November 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2013|May 29, 2013|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808768||69920|
NCT01804764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX/001137-23/12/2010|Lotta Alla Sepsi Ospedaliera - Fighting Hospital Sepsis|Educational and Organizational Intervention's Effect on Severe Sepsis and Septic Shock Management Out of Intensive Care Units: Medical Wards and Emergency Departments||University of Milano Bicocca|Yes|Recruiting|June 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All the Emergency Department out-patients and the Medical Wards in -patients presenting        with suspected svere sepsis or septic shock|February 2013|March 4, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804764||70228|
NCT01808261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104615|POC in Patients With Ischaemic Stroke|Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients||GlaxoSmithKline|Yes|Terminated|May 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|90 Years|No|||October 2014|February 26, 2015|February 14, 2013|Yes|Yes|This study was terminated for futility.|No||https://clinicaltrials.gov/show/NCT01808261||69959|
NCT01805362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-API-03|RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough|RAS Blockade at Bedtime Versus on Awakening for the Prevention of Aldosterone Breakthrough|IRAB2|Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|106|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805362||70182|
NCT01810393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28589|A Study of Patient Preference for Subcutaneous Versus Intravenous Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Herceptin for at Least 3 Years|An Open-label, Randomized, Multicenter Phase III Study in Patients With HER2-positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab||Hoffmann-La Roche||Active, not recruiting|June 2013|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810393||69796|
NCT01811524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07042|The Etiology and Progression of Brain Tumors|The Etiology and Progression of Brain Tumors - Molecular Genetic Changes and Heredity||Tampere University Hospital|No|Completed|September 1983|March 2012|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2000|Samples With DNA|Paraffin-embedded and frozen brain tumor tissue|Both|1 Month|85 Years|No|Non-Probability Sample|Glioma and meningioma patients|March 2013|March 18, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811524||69709|
NCT01811758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmokeBreak2|Culturally Specific Interventions: African American Smokers|Culturally Specific Interventions and Acculturation in African American Smokers|SB2|University of Miami|No|Completed|August 2011|April 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811758||69691|
NCT01811771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-12041|Oral Cholera Vaccine Delivery in Rural Bangladesh|Impact Evaluation of Oral Cholera Vaccination in a Rural Setting Using the National Immunization System of Bangladesh|ROCV|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|August 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60000|||Both|1 Year|N/A|Accepts Healthy Volunteers|||September 2012|October 12, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811771||69690|
NCT01812057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041334|Dexamethasone for Post-cesarean Delivery Pain|Dexamethasone as an Analgesic Adjunct for Post-cesarean Delivery Pain Relief||Duke University|No|Recruiting|December 2012|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|104|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812057||69668|
NCT01806649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551691411|BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy|A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy||Prince of Songkla University|Yes|Recruiting|January 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|N/A|N/A|No|||October 2015|October 19, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01806649||70083|
NCT01806662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0737|Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis|Randomized Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis Who Have Sub-optimal Response to Prior Therapy||Rockefeller University|No|Active, not recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806662||70082|
NCT01806402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130104|Evaluation of OCT Measurements|Evaluation of the Precision and Accuracy of OCT Measurements in Retinal and Glaucoma Patients||Optovue|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will have retina pathology or glaucoma.|January 2014|January 20, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806402||70102|
NCT01806623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0561023|The Study Of Fluconazole For Vulvovaginal Candidiasis|A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis.||Pfizer|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Female|18 Years|80 Years|No|||December 2014|December 1, 2014|January 28, 2013|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01806623||70085|
NCT01806636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0014|Post Market Observational, Prospective, Multi-center Study|Post Market Observational, Prospective, Multi-center Registry Using the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) System||PneumRx, Inc.|No|Recruiting|May 2013|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|All adult patients diagnosed with homogeneous or heterogeneous emphysema who are        appropriate for Coil treatment based on the CE-Mark Approved IFU and who have been        scheduled for treatment with the RePneu procedure will be eligible to participate in the        Registry. If they agree and sign a consent form, they will then become study participants.|May 2015|May 27, 2015|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01806636|5 Years|70084|
NCT01806597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2312|Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis|GESTURE|Novartis|No|Active, not recruiting|June 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|205|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806597||70087|
NCT01806610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPS804A2204|Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease|A Randomized, Placebo-controlled Trial of BPS804 on Safety and Tolerability in Patients With Late-stage Chronic Kidney Disease||Novartis|No|Withdrawn|August 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||October 2013|October 30, 2013|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01806610||70086|
NCT01815125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOF2013|Ondansetron for Pediatric Mild Traumatic Brain Injury|Ondansetron for Pediatric Mild Traumatic Brain Injury; a Pilot Randomized Controlled Trial.||St. Justine's Hospital|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|8 Years|17 Years|No|||February 2014|September 28, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815125||69434|
NCT01807208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034650|PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction|PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction||Duke University|No|Completed|March 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|192|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01807208||70040|
NCT01806935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01547-36|Xerotic Dermatitis in Aged People|||Pierre Fabre Medicament|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|442|||Both|70 Years|N/A|No|||February 2013|September 25, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806935||70061|
NCT01806948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_GO_017|Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting|||Seoul National University Hospital|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Female|N/A|N/A|No|||March 2016|March 19, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806948||70060|
NCT01808040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11109|A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer|A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer||University of Wisconsin, Madison|Yes|Suspended|November 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||July 2015|July 9, 2015|January 16, 2013|No|Yes|protocol modifications|No||https://clinicaltrials.gov/show/NCT01808040||69976|
NCT01808326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116586|A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia|A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia||GlaxoSmithKline|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|N/A|No|||April 2015|June 4, 2015|February 21, 2013||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01808326||69954|
NCT01804530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX119-01|Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors||Plexxikon|No|Recruiting|August 2013|August 2021|Anticipated|February 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804530||70246|
NCT01804777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-017|Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes|ENaC as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes||University of New Mexico|Yes|Terminated|March 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|9|||Both|18 Years|80 Years|No|||September 2014|September 26, 2014|March 1, 2013|Yes|Yes|Currently closed for data analysis.|No||https://clinicaltrials.gov/show/NCT01804777||70227|
NCT01805063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-SS-0049|Effect of Fire Suppression and Emergency Duties on Vascular Function|Effect of Fire Suppression and Emergency Duties on Vascular Function in Firefighters||University of Edinburgh|Yes|Recruiting|February 2012|||August 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Plasma and urine samples|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be healthy, non-smoking, whole-time firefighters working within Lothian and        Borders Fire and Rescue Service|March 2013|March 4, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805063||70205|
NCT01805089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-305|Melatonin Versus Placebo in Breast Cancer|A Randomized Trial of Oral Melatonin Supplementation in Breast Cancer Survivors||Dana-Farber Cancer Institute|Yes|Completed|October 2006|July 2009|Actual|July 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|95|||Female|18 Years|N/A|No|||February 2015|March 3, 2015|March 4, 2013|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT01805089||70203|
NCT01810952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27172|The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients|The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients|GIH|Baylor College of Medicine|No|Recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2013|March 12, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810952||69753|
NCT01811212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00554|Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer|Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy||National Cancer Institute (NCI)|No|Suspended|May 2013|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 12, 2013|Yes|Yes|Scheduled interim monitoring|No||https://clinicaltrials.gov/show/NCT01811212||69733|
NCT01816503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015778|Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study|High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study||Janssen Korea, Ltd., Korea|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|636|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who are admitted to a study center during the study period and are receiving a        strong oral long-acting opioid analgesic but deemed to control pain insufficiently.|March 2013|March 20, 2013|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816503||69329|
NCT01816750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/P/031|Cardiac GSI Feasibility Study|Pilot Study to Assess the Feasibility and Diagnostic Performance of Computed Tomographic Coronary Angiography Using Cardiac Gemstone Spectral Imaging (Cardiac GSI) in Patients With High-risk of Significant Coronary Artery Disease and Myocardial Scar||Plymouth Hospitals NHS Trust|No|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|70|||Both|50 Years|N/A|No|||October 2015|October 30, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01816750||69310|
NCT01817244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A102065_2013|A Long Term Effect of Collaborative Care on Depression Treatment in a Community Dwelling Elderly|||National Clinical Research Coordination Center, Seoul, Korea||Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||March 2016|March 9, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01817244||69272|
NCT01811498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-352|Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM|Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme||Northwell Health|Yes|Recruiting|February 2013|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|March 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01811498||69711|
NCT01812330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130118 CR|Efficacy and Safety Study of Ticagrelor|The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|January 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|80 Years|No|||March 2015|June 23, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812330||69647|
NCT01806688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:036|Effect of Snacks on Appetite Control|A Randomized, Controlled, Cross-over Study of the Effect of Snacks on Appetite Control||St. Boniface General Hospital Research Centre|No|Active, not recruiting|June 2013|December 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|6||Anticipated|38|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806688||70080|
NCT01806675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARIMG0002|18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy|Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis||Stanford University||Recruiting|March 2013|March 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806675||70081|
NCT01806987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R305A120391|A Test of the Kids in Transition to School (KITS) Program in Disadvantaged Neighborhoods|A Randomized Efficacy Trial of the Kids in Transition to School (KITS) Program to Improve School Readiness of Children in Disadvantaged Communities|KITS-PN|Oregon Social Learning Center|No|Recruiting|March 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|4 Years|6 Years|No|||April 2015|April 21, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01806987||70057|
NCT01806974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0172|Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium|Multicenter, Prospective Study, on the Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on: - Healthy and Pathological Periodontium - The Level of Expression of Some Markers of Inflammation and Periodontal Pathogenic Bacteria in Periodontal Sulci and Periodontal Pockets|ParoPAR|Nantes University Hospital|No|Terminated|December 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 6, 2013||No|as the recruitment rate was very low, a futility study was conducted and it was decided to    discontinue inclusions|No||https://clinicaltrials.gov/show/NCT01806974||70058|
NCT01806311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAMCAO12I_1|Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg|An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers||HanAll BioPharma Co., Ltd.|Yes|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806311||70109|
NCT01806324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-040XC-US-001|A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects|||HanAll BioPharma Co., Ltd.|No|Completed|April 2012|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806324||70108|
NCT01807520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2313|Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Longterm Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis|TRANSFIGURE|Novartis|No|Active, not recruiting|June 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807520||70016|
NCT01807494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCO.2012.05|Direct Anterior Versus Posterior Total Hip Arthroplasty Surgical Approaches|Direct Anterior Versus Posterior Total Hip Arthroplasty Surgical Approaches||New Lexington Clinic|No|Active, not recruiting|November 2012|February 2023|Anticipated|February 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||October 2015|October 5, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01807494||70018|
NCT01807507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1016|Clinical Verification Evaluation of VeinViewer® Device|Clinical Verification Evaluation of VeinViewer® Device||Christie Medical Holdings, Inc.|No|Completed|October 2011|July 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|January 2014|January 30, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807507||70017|
NCT01807767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0457|Myfortic in High MELD Liver Transplantation|Prospective Evaluation of the Efficacy and Safety of Zortress (Everolimus)/Myfortic (Enteric Coated Mycophenolate Sodium) Conversion in High MELD Liver Transplantation||University of Colorado, Denver|No|Completed|March 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|70 Years|No|||August 2015|August 7, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807767||69997|
NCT01808313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115812|Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)|An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)||GlaxoSmithKline||Completed|December 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|18 Years|75 Years|No|||April 2015|April 27, 2015|February 28, 2013|No|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01808313||69955|
NCT01808339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117156|To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma|A Randomised, Repeat-dose, Placebo-controlled, Three-way Crossover, Double Dummy Study to Evaluate and Compare the Efficacy of Fluticasone Furoate Inhalation Powder Delivered Via the Single Strip Dry Powder Inhaler When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic Subjects||GlaxoSmithKline|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|70 Years|No|||September 2014|September 18, 2014|February 21, 2013||No||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01808339||69953|
NCT01808352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 073|HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)|Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities||HIV Prevention Trials Network|No|Completed|August 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|225|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|January 20, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01808352||69952|
NCT01808521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-Acetylcysteine in TTP|A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura|A Pilot Study of N-acetylcysteine in Suspected Thrombotic Thrombocytopenia Purpura|NACinTTP|Puget Sound Blood Center|Yes|Enrolling by invitation|May 2013|March 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01808521||69939|
NCT01808534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0403|Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors|Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors||Indiana University|No|Terminated|February 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 6, 2013|Yes|Yes|Due to Low Accrual|No|June 11, 2015|https://clinicaltrials.gov/show/NCT01808534||69938|
NCT01804543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US- 259-0140|Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy|Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy||Westside Medical Associates of Los Angeles|No|Recruiting|June 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subject with chest pain or equivalence (atypical chest pain, shortness of breath, or        fatigue)|March 2013|March 4, 2013|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804543||70245|
NCT01804790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 23 - UCGI 23|Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer|- Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer|Néofirinox|UNICANCER|Yes|Recruiting|January 2012|January 2022|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804790||70226|
NCT01805076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011104|MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer|Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer||Alliance for Clinical Trials in Oncology|No|Recruiting|February 2014|||September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|536|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01805076||70204|
NCT01805102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioIncept LLC-2|Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome|Preimplantation Factor (PIF): Biomarker Detection in Maternal Blood - Correlation With Live Birth.|PIFBlood1|BioIncept LLC|No|Enrolling by invitation|September 2012|||August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|maternal blood|Female|18 Years|N/A|No|Non-Probability Sample|Women followed during pregnancy in perinatal centers|March 2013|March 5, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805102||70202|
NCT01811511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORC-MS-CKJA|Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome|||Chonbuk National University Hospital|Yes|Completed|March 2013|February 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811511||69710|
NCT01817283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACTRIP12|Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders|Study of Triptolide Woldifiion T Cell Immune Activation and Inflammation Biomarkers in HIV-infected Immunological Non-responders|CACTrip12|Peking Union Medical College|Yes|Recruiting|January 2013|March 2015|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||March 2013|March 22, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817283||69269|
NCT01812343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-2011|Value of Ankle Pressure Index After Maximal Exercise Tests|Mesure de l'Index de Pression Systolique de Cheville après Test d'Effort Maximal.|VICTOR|University Hospital, Angers|Yes|Recruiting|September 2009|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|880|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 17, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01812343||69646|
NCT01817257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON1037-11|Anticoagulation Length in Cancer Associated Thrombosis|A Feasibility Study to Inform the Design of a Randomised Controlled Trial to Identify the Most Clinically and Cost Effective Length of Anticoagulation With Low Molecular Weight Heparin In the Treatment of Cancer Associated Thrombosis|ALICAT|Cardiff University|Yes|Not yet recruiting|March 2013|February 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|16 Years|N/A|No|||March 2013|March 20, 2013|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817257||69271|
NCT01817270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02038506|Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine|A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine||Changchun Keygen Biological Products Co., Ltd.|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|368|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||October 2013|October 14, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01817270||69270|
NCT01806714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056103-002|Text Reminders to Immunize in a Managed Care Organization|Text Reminders to Immunize in a Managed Care Organization|TRIO|University of Rochester|No|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806714||70078|
NCT01806701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH097769|Brain Response to Treatment for Pediatric PTSD|Biomarkers of Clinical Response to Cognitive Treatment of PTSD in Youth||Stanford University|Yes|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01806701||70079|
NCT01807000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD555-104|Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects||Shire|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 22, 2014|March 6, 2013|No|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT01807000||70056|
NCT01807234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00075486|Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine|Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)|KSPN|Johns Hopkins University|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807234||70038|
NCT01806961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP848-AKEx-1209|Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.|Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.||Spirig Pharma Ltd.|No|Terminated|January 2013|September 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with complete clinical clearance (i.e. no previously existing AK-lesion present)        at the end of the trial SP848-AK-1101 or Non- Responder who withdrew from the trial        prematurely.|December 2015|December 14, 2015|March 6, 2013||No|sponsor decision|No|December 14, 2015|https://clinicaltrials.gov/show/NCT01806961||70059|
NCT01807533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103075RB|A Family-Centered Intervention Program for Preterm Infants: Effects and Their Biosocial Pathways|A Family-Centered Intervention Program for Preterm Infants: Effects and Their Biosocial Pathways||National Taiwan University Hospital|No|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|N/A|7 Days|No|||October 2013|October 31, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01807533||70015|
NCT01807793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR013001-01A1|Targeted Management Intervention for African-American Men With TIA or Stroke|Targeted Management Intervention for African-American Men With TIA or Stroke.|TEAM|Case Western Reserve University|No|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|76|||Male|22 Years|64 Years|No|||January 2016|January 27, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807793||69995|
NCT01808053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008639|Assessment of the BodyGuardian Remote Monitoring Platform in Elderly Healthy Subjects|Assessment of the BodyGuardian Remote Monitoring Platform in Elderly Healthy Subjects||Mayo Clinic|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy older adults living at an independent living center.|January 2014|January 6, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808053||69975|
NCT01808066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12X226|GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs|GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs||CogCubed, Corp|Yes|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|5 Years|12 Years|No|||August 2014|August 26, 2014|March 6, 2013||No||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01808066||69974|Technical difficulties resulting from firewall at school affected set up time and therefore facility of use.
NCT01808079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN09B1|Gene Analysis in Studying Susceptibility to Wilms Tumor|OBSERVATIONAL: A Genome-Wide Association Study in Wilms Tumor||Children's Oncology Group|No|Active, not recruiting|November 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|We currently have 1300 DNA samples from Wilms tumor cases, primarily from recruitment from        oncology clinics over the last decade. We are further identifying Wilms tumor survivors >        1000 for targeted recruitment. However, if there is any shortfall, we will use additional        US and/or IWTGC cases and we are fully confident that at least 2000 cases for the        replication will be available.|August 2015|August 14, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808079||69973|
NCT01808573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA-NER-1301|A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting|A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting|NALA|Puma Biotechnology, Inc.|Yes|Recruiting|March 2013|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808573||69935|
NCT01804582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054913|The Family VOICE Study|The Family VOICE Study (Value, Information, Community Support, and Experience): A Randomized Trial of Family Navigator Services Versus Usual Care for Care of Young Children Treated With Antipsychotic Medication||University of Maryland|Yes|Enrolling by invitation|May 2013|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|1 Year|12 Years|No|||December 2015|December 8, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01804582||70242|
NCT01808547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-303-004|Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects|A Randomized Double-Masked Study to Compare the Ocular Safety,Tolerability,and Efficacy of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects||InSite Vision||Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|268|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808547||69937|
NCT01804556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0197|The Effects of the Myofascial Trigger Point Injections on Pain and Sleep Disturbance in Patients With Nocturnal Leg Cramps With Trigger Points on Gastrocnemius Muscle|||Yonsei University|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|80 Years|No|||January 2015|January 26, 2015|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01804556||70244|
NCT01804569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|moxa201097603|The Effects of Self-Moxibustion Therapy on Subjective Physical Symptoms and Health-related Quality of Life of the Elderly. The Effects of Self-Moxibustion Therapy|The Effects of Self-Moxibustion Therapy on Subjective Physical Symptoms and Health-related Quality of Life of the Elderly.|moxa|Pusan National University School of Medicine|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|70|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||September 2013|September 8, 2013|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01804569||70243|
NCT01804803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAMONDS-I|DIgital Assisted MONitoring for DiabeteS - I|A Telemedicine-based Intervention Study Involving Real-time and Anywhere Transmission of Blood Glucose Data to a Decision Supported Software-assisted Server With Web-based Analysis of Data and Medical Feedback on Metabolic Control.|DIAMONDS|University of Bari|Yes|Recruiting|May 2013|July 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||August 2013|August 2, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01804803||70225|
NCT01805115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-005|Misoprostol Administration Before Operative Hysteroscopy|A Randomized Comparison of Oral, Sublingual and Vaginal Misoprostol Administration in Premenopausal Women Before Operative Hysteroscopy||CHA University|No|Completed|March 2013|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Female|18 Years|55 Years|No|||December 2014|December 24, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805115||70201|
NCT01816204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539-2012|Therapist Assisted Online Treatment for Anxiety|Therapist Assisted Online Treatment for Anxiety|TAO-anxiety|University of Florida|No|Enrolling by invitation|July 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|35 Years|No|||October 2014|October 14, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01816204||69352|
NCT01817023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-HN-003|The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT|Multicenter Phase III Study of Intensity-modulated Radiotherapy Alone Compared to Intensity-modulated Radiotherapy Combined Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma||Chinese Academy of Medical Sciences|Yes|Recruiting|April 2013|April 2018|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|590|||Both|18 Years|70 Years|No|||September 2014|September 9, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817023||69289|
NCT01817036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCX2-EW-R-10-VD|Vitamin D Intervention Trial in Healthy Chinese|Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study：A Pilot Study||Chinese Academy of Sciences||Completed|January 2013|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|75|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817036||69288|
NCT01817296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4093|Klinefelter Fertility Preservation|Klinefelter Syndrome: Are we Missing the Optimal Time for Fertility Preservation?||Children's Hospital Boston|Yes|Completed|March 2013|||April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|12 Years|25 Years|No|||May 2014|May 14, 2014|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01817296||69268|
NCT01817517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHM IRB NA_00073086|Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome|Phase 1 Study of Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome||Johns Hopkins University|Yes|Recruiting|March 2014|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|N/A|No|||August 2015|August 31, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817517||69251|
NCT01817530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-813|Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)|A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids||AbbVie|No|Completed|January 2013|December 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|571|||Female|18 Years|51 Years|No|||December 2015|December 16, 2015|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817530||69250|
NCT01806740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-057|DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC|Phase IV Study of DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC|DCE-MRI|Guerbet|No|Active, not recruiting|March 2013|June 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|37|||Both|20 Years|N/A|No|||February 2016|February 10, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01806740||70076|
NCT01807052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST10B2|Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas|Observational - Tissue Factor Expression in Bone Sarcomas||Children's Oncology Group|No|Recruiting|November 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|34|||Both|N/A|39 Years|No|Non-Probability Sample|Tissue samples from patients with osteosarcomas obtained from the CHTN that participated        in either study P9754 clinical trial for patients with non-metastatic osteosarcoma or        AOST0121 clinical trial for patients with metastatic or recurrent osteosarcoma|November 2015|November 16, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807052||70052|
NCT01807039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KARIM FN Brno|Mortality Following Surgery for Proximal Femoral Fractures|Mortality Following Surgery for Proximal Femoral Fractures|HipMo|Brno University Hospital|No|Completed|December 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|isolated fracture of proximal femur indicated for surgery|January 2015|May 31, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807039||70053|
NCT01807286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0215|Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis|A Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis||M.D. Anderson Cancer Center|No|Terminated|January 2014|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 6, 2013|Yes|Yes|Sponsor requested termination|No||https://clinicaltrials.gov/show/NCT01807286||70034|
NCT01807013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LapSon|Evaluating Ultrasound, Elastometry, Minilaparoscopy and Histology for the Diagnosis of Compensated Liver Cirrhosis.|Prospective Study to Evaluate the Diagnostic Value of B-mode Ultrasound, Elastometry and Minilaparoscopic Guided Liver Biopsy for the Diagnosis of Compensated Liver Cirrhosis.||University Hospital Erlangen|No|Recruiting|February 2011|August 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|patients with suspected chronic liver disease|January 2016|January 20, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01807013||70055|
NCT01807026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15107|A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease|A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease||Eli Lilly and Company|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807026||70054|
NCT01807221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14564|Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone|A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone|ARTS-HF|Bayer|Yes|Completed|June 2013|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1058|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807221||70039|
NCT01807546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-09|Oral Rigosertib for Squamous Cell Carcinoma|A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma||Onconova Therapeutics, Inc.|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807546||70014|
NCT01807559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN009|SoundBite Hearing System 24 Month Multi Site Patient Use Study|SoundBite Hearing System 24 Month Multi Site Patient Use Study||Sonitus Medical Inc|No|Recruiting|March 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|All trial subjects are individuals who are already currently using SoundBite Hearing        System for treatment of their SSD or CHL and were enrolled in the SoundBite Hearing System        Long Term Multi Site Patient Use Study (Protocol CLN0006). Participants are willing to        participate in this study.|May 2013|May 2, 2013|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807559||70013|
NCT01807845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 1-Version 1.|Bioavailability of Vitamin D Encapsulated in Casein Micelles, Compared to Its Bioavailability in a Synthetic Emulsifier Currently Used for Supplementation and Enrichment.||VD|Rambam Health Care Campus|No|Recruiting|January 2013|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807845||69991|
NCT01807806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC Subcontract No 10150.003.0|Safety and Effectiveness Study: Role Playing Game for Friends and Family of Service Members|Safety and Effectiveness Study: Interactive Game-Based System for Psychological Health Education|RPG|University of Southern California|No|Completed|March 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|65|||Both|18 Years|86 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01807806||69994|
NCT01808365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114991|N. Meningitidis Carriage Study|Neisseria Meningitidis Carriage Study||GlaxoSmithKline||Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1000|Samples With DNA|Throat swab|Both|5 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects aged between 5 and 24 years attending a school or university in the        Philippines.|April 2014|July 30, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808365||69951|
NCT01815281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GONDOLAPILOTA|Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.|Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease|GONDOLAPILOTA|IRCCS San Raffaele|No|Recruiting|July 2013|April 2015|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01815281||69423|
NCT01808560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF005|Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery|Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery||TearScience, Inc.|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|55 Years|85 Years|No|||February 2015|February 4, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808560||69936|
NCT01805128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-04|Exploration of the Social Cognition in Adolescents With a Dissociative Disorder or Autism Spectrum|EXPLORATION OF THE SOCIAL COGNITION IN ADOLESCENTS WITH A Dissociative Disorder OR AUTISM SPECTRUM||Centre Hospitalier Universitaire de Nice|No|Completed|January 2013|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2013|May 27, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01805128||70200|
NCT01805141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNCVX0003|Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer|Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer||Stanford University|No|Recruiting|August 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 12-15 cervical cancer patients are referred for radiation each year.|March 2015|March 30, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01805141||70199|
NCT01804816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-580|Acupuncture on Cardiac and Autonomic Function in Human Heart Failure|Acupuncture on Cardiac and Autonomic Function in Human Heart Failure||The Cleveland Clinic|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||March 2016|March 2, 2016|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804816||70224|
NCT01805648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPOzyq120725|Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP|A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia||Peking Union Medical College|Yes|Recruiting|February 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|70 Years|No|||March 2013|March 4, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01805648||70160|
NCT01816789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDROS-01-13|Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles|Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization||Andros Day Surgery Clinic|No|Recruiting|March 2013|December 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|40 Years|No|||January 2015|January 27, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816789||69307|
NCT01817049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAIRC&Y-mar2013|The Effect of a Behavioural Intervention on Injury Prevention Program Adherence in Female Youth Soccer|Examining the Effect of a Behavioural-based Intervention on Injury Prevention Program Adherence in Canadian Female Youth Soccer Players||University of Calgary|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|214|||Female|11 Years|16 Years|No|||May 2015|May 28, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817049||69287|
NCT01813253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE766-A-J302|Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer|A Randomized, Open-label, Japan-Korea Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy Versus Irinotecan Monotherapy as Second Line Treatment in Subjects With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer||Kuhnil Pharmaceutical Co., Ltd.|Yes|Recruiting|March 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|N/A|No|||September 2015|September 8, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813253||69577|
NCT01813266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hepcvirusscreeningtrial|Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors|Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors.|TPEGHCVS|Intermountain Health Care, Inc.|No|Not yet recruiting|May 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|6000|Samples With DNA|Hepatitis C virues enzyme immunosorbent assay screening; if positivie follow up testing|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|residents of Salt Lake County, Utah with pre-stratification to equalized sex, age, and        ethnic similarity.|March 2013|March 13, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813266|3 Months|69576|
NCT01813227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 3596 (CAR-531)|A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531|A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531||Hackensack University Medical Center|Yes|Active, not recruiting|April 2013|April 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813227||69579|
NCT01817348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121001R|Effect of Combined Intra-articular Injection of Lidocaine Plus Physiotherapy in Treatment of Frozen Shoulder|Effect of Combined Intra-articular Injection of Lidocaine Plus Physiotherapy in Treatment of Frozen Shoulder||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|January 2013|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||March 2013|March 20, 2013|January 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817348||69264|
NCT01807312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211070RIC|The Application of CO2 Insufflations in Routine Colonoscopy Examination for Duration in Toilet After Examination Compared With Air Insufflations|||National Taiwan University Hospital|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|120|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807312||70032|
NCT01807325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB8317|RNA Sequencing of Solid and Cystic Lesions of the Pancreas|RNA Sequencing of Solid and Cystic Lesions of the Pancreas||Oregon Health and Science University|Yes|Enrolling by invitation|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|pancreas biopsies|Both|18 Years|N/A|No|Probability Sample|adult, nonpregnant patients referred for endoscopic ultrasound to evaluate solid or cystic        lesion of the pancreas.|October 2014|October 14, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807325||70031|
NCT01807299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD_Omega_Exercise|The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit Hyperactivity Disorder in Children|The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit|AOE|Federal University of São Paulo|Yes|Recruiting|May 2011|May 2015|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|68|||Male|7 Years|14 Years|No|||March 2013|March 7, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807299||70033|
NCT01807247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01487-34|Short Effects of a Rehabilitation Session on Gait in Patients With CNS|Evaluation of the Short Effects of a Rehabilitation Session on Gait Parameters in Patients With a Lesion of the Central Nervous System||Centre d'Investigation Clinique et Technologique 805|No|Completed|February 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|The population includes patients with various lesions of central nervous system such as        post-stroke patients with hemiparesis, patients with spinal cord injury and patients with        mutiple sclerosis.|March 2013|February 3, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807247||70037|
NCT01807858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68/16.Oct.2012|The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants|The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants||Dr. Sami Ulus Children's Hospital|Yes|Recruiting|October 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|400|||Both|N/A|30 Days|Accepts Healthy Volunteers|||March 2013|March 7, 2013|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01807858||69990|
NCT01807819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-2013|The Determination of Important Mechanical Patterns of Left Ventricular Efficiency-MV02 Study|The Determination of Important Mechanical Patterns of Left Ventricular Efficiency-MV02 Study|DIMPLE|University of Florida|No|Recruiting|August 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age or older who are referred to our adult cardiovascular heart        failure clinics for evaluation of heart failure or LV dysfunction|November 2015|November 19, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807819||69993|
NCT01807832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-LF-0695-CTIL|The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.|The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|N/A|N/A|No|||March 2013|March 7, 2013|March 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807832||69992|
NCT01815502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVL Fontan|Study of Effects of Sildenafil on Patients With Fontan Heart Circulation|Response to Sildenafil in Patients With Fontan Physiology, A Pressure-volume Loop Analysis||Medical University of South Carolina|No|Recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|3 Years|40 Years|No|||February 2013|March 19, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815502||69406|
NCT01814995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-CAI117789|Motivational Support and Meal Preparation Training to Reduce Vascular Risk After Gestational Diabetes|Combining Motivational Support, Meal Preparation Training, and a Tapering Course of Meal Replacements To Achieve Vascular Risk Reduction in Women With a Gestational Diabetes History (MoMM)|MoMM|McGill University Health Center|No|Completed|January 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Female|18 Years|55 Years|No|||September 2014|September 10, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814995||69443|
NCT01804829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|988|Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.|A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients||Biotest Pharmaceuticals Corporation|Yes|Active, not recruiting|June 2013|May 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|80|||Both|18 Years|80 Years|No|||January 2016|January 15, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804829||70223|
NCT01804842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCRM104|Randomized, Crossover Study to Assess the Effect of EFB0027 on Plasma Glucose and PK in Subjects With T2DM|A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus||Elcelyx Therapeutics, Inc.|No|Completed|November 2012|June 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|70 Years|No|||August 2014|August 20, 2014|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804842||70222|
NCT01815489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-001|Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis|Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis||Carolinas Healthcare System|No|Completed|July 2011|May 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Peripancreatic fluid, pancreatic tissue, blood sample, stool sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults over 18 years of age with a diagnosis of necrotizing pancreatitis and concern for        superinfection of the pancreas related to their condition.|May 2014|May 22, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01815489||69407|
NCT01805414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031605|Breakfast Nutrition and Inpatient Glycemia|The Effect of a Targeted Breakfast Intervention on Inpatient Glycemic Control||Duke University|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|237|||Both|18 Years|N/A|No|||February 2013|October 11, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805414||70178|
NCT01816061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0637-R|Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS|Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS|COMPASS|VA Office of Research and Development|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01816061||69363|
NCT01816295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14396|A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy|A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men||Eli Lilly and Company|Yes|Completed|May 2013|April 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|715|||Male|18 Years|N/A|No|||November 2015|November 24, 2015|March 19, 2013|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01816295||69345|
NCT01816022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFEX 11.15|Myeloproliferative Neoplasms and Bone Structure|Myeloproliferative Neoplasms and Bone Structure||University of Southern Denmark|No|Recruiting|March 2012|March 2015|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|125|Samples With DNA|Blood samples to compare groups and to look for endocrine abnormalities|Both|18 Years|N/A|No|Probability Sample|Danish patients with CMPN|March 2013|March 20, 2013|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01816022||69366|
NCT01816828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCO150GP|Intervention Research to Reduce HIV Sexual Transmission Among HIV Positive Men Who Have Sex With Men|A Small Group Intervention to Reduce HIV Sexual Transmission Risk Behaviour Among HIV Positive Men Who Have Sex With Men: Gay Poz Sex (GPS)||Ryerson University|Yes|Recruiting|March 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Male|18 Years|N/A|No|||October 2015|October 26, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01816828||69304|
NCT01813851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0487|Effect of Intradialytic Physical ACTIvity in Addition to a NUTritional Support on Protein Energy Wasting and Physical Functioning in Chronic Hemodialysis Patients ("ACTINUT" Study)|Effect of Intradialytic Physical ACTIvity in Addition to a NUTritional Support on Protein Energy Wasting and Physical Functioning in Chronic Hemodialysis Patients ("ACTINUT" Study), Multicenter, Randomized, Controlled Open Label Trial Study Multicenter, Prospective, Randomized Study|ACTINUT|Nantes University Hospital|No|Terminated|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813851||69531|
NCT01814150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1AGP1234|The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel|The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy||Meir Medical Center|No|Not yet recruiting|April 2013|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Metastatic cancer from lung, breast, gastric, prostate, and bladder origin,        treated with docetaxel based chemotherapy|March 2013|March 22, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01814150||69508|
NCT01808651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14596|A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing|A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder||Eli Lilly and Company|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|20 Years|N/A|No|||October 2015|October 22, 2015|March 7, 2013|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01808651||69929|
NCT01804647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN-E-002|Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease|A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Multiple Sclerosis Patients (RRMS - SPMS - PPMS - CIS) as Assessed by PCR and ELISA in Blood|LOMBARD|GeNeuro Innovation SAS|No|Completed|November 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|58|Samples Without DNA|Plasma, serum and PBMC|Both|18 Years|60 Years|No|Non-Probability Sample|Patients coming to the Hospital for regular visits.|March 2015|March 16, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804647||70237|
NCT01808625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9756-LZ-CTIL|Hyperbaric Oxygen Stimulation for Patients With Brain Malignancies After Radiation Therapy.|Hyperbaric Oxygen Stimulation for Patients With Brain Malignancies After Radiation Therapy.||Sheba Medical Center||Not yet recruiting|March 2013|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|76|||Both|18 Years|70 Years|No|||March 2013|March 7, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01808625||69931|
NCT01808638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atu027-I-02|Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)|A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA|Atu027-I-02|Silence Therapeutics GmbH|Yes|Completed|March 2013|January 2016|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|84 Years|No|||March 2016|March 10, 2016|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01808638||69930|
NCT01805219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01411-42|Global Positioning Satellite and Accelerometry to Assess Human Locomotion (ACTI GPS)|Assessment of Human Locomotion and Energy Expenditure Using Global Positioning Satellite and Accelerometry|ActiGPS|University Hospital, Angers|Yes|Recruiting|February 2013|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy subjects|February 2016|February 11, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01805219||70193|
NCT01805232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|artesunate and malaria|Intravenous Artesunate and Malaria|Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan|IVAS|University of Khartoum|No|Recruiting|March 2013|July 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|1 Year|80 Years|No|||March 2013|March 4, 2013|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01805232||70192|
NCT01805466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2009-1591573|Effects on Organ Damage and Surgical Outcome of a New Cardiopulmonary Pass System (EVADO)|A New Cardiopulmonary By-pass System That Minimizes Haemodilution, Hemolysis and Systemic Inflammation. Effects on Organ Damage and Surgical Outcome|EVADO|IRCCS San Raffaele|Yes|Completed|October 2012|July 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|85 Years|No|||February 2013|February 19, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01805466||70174|
NCT01805700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B091217|Effects of Acute Intake of Caffeinated Beverages in Type 1 Diabetes|Effects of Acute Intake of Caffeine Enhanced Energy Drinks on Blood Glucose, Some Physiological Parameters and Cognitive Performance in Patients With Type 1 Diabetes|REDBULL|The Royal Bournemouth Hospital|No|Completed|January 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|20|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805700||70156|
NCT01805960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONVERT-AF Version5 22.01.2013|Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF|Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study|CONVERT-AF|University Hospital, Basel, Switzerland|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2016|January 19, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805960||70136|
NCT01806194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212196|Empowering Rural African American Women and Communities to Improve Diabetes Outcomes|Empowering Rural African American Women and Communities to Improve Diabetes Outcomes|EMPOWER|East Carolina University|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|19 Years|75 Years|No|||January 2016|January 19, 2016|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01806194||70118|
NCT01806207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35GA0301|Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis|A Double-blind, Randomized, Multi-centre Study of the Efficacy and Safety of a Single Intra-articular Injection With Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis||Q-Med AB|No|Completed|February 2003|||April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|50 Years|N/A|No|||March 2013|March 6, 2013|March 5, 2013||||No||https://clinicaltrials.gov/show/NCT01806207||70117|
NCT01806480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST2013|The Effectiveness of Proactive Telephone Support Provided to Breastfeeding Mothers of Preterm Infants|The Effectiveness of Proactive Telephone Support Provided to Breastfeeding Mothers of Preterm Infants - a Randomized Controlled Trial||Uppsala University|No|Active, not recruiting|March 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|493|||Both|N/A|36 Weeks|Accepts Healthy Volunteers|||January 2016|January 4, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806480||70096|
NCT01806831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU 12-33-009|Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment|Efficacy and Safety of Biocellulose Sheet From Coconut Juice Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment||Chulalongkorn University|Yes|Completed|September 2012|June 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806831||70069|
NCT01817400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1414|Mediators of Abnormal Reproductive Function in Obesity (MARO)|Mediators of Abnormal Reproductive Function in Obesity|MARO|University of Colorado, Denver|Yes|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|10|||Female|18 Years|60 Years|No|||March 2015|March 12, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01817400||69260|
NCT01817413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD&I 3968, UoL000590|Comparison of Two Dental Techniques Used to Treat Teeth Which Have Become Infected or Painful Following Trauma|Revascularisation Versus Mineral Trioxide Aggregate in the Management of Non-Vital Immature Permanent Incisors in a Young Population: A Randomised Controlled Trial (Pilot Study)||University of Liverpool|No|Completed|February 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|7 Years|25 Years|No|||December 2015|December 9, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01817413||69259|
NCT01813942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302013RINC|Platform for Medical Information Extraction From Incomplete Data|Platform for Medical Information Extraction From Incomplete Data||National Taiwan University Hospital|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with liver cancer|October 2013|October 25, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01813942||69524|
NCT01813331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/12|ALERT-HF: Adherence to Guidelines in the Treatment of Patients With Chronic Heart Failure|ALERT-HF:Adherence to Guidelines in the Treatment of Patients With Chronic Heart Failure|ALERT-HF|Federico II University||Completed|November 2012|February 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|660|||Both|65 Years|N/A|No|Probability Sample|Chronic Heart Failure patients older than 65 years, consecutively referred to the A.R.C.A        Campania Cardiologists in the pertaining healthcare districts|March 2013|March 13, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01813331|3 Months|69571|
NCT01813344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBL-CISL-1|Hyper-CVAD Treatment in Lymphoblastic Lymphoma|The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma|LBL-CISL-1|Ajou University School of Medicine|Yes|Recruiting|January 2012|||June 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult lymphoblast lymphoma patients treated with hyper-CVAD regimen in Korea|March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813344||69570|
NCT01807351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWC_REC_5522|Progression From Impaired Fasting Glucose to Type 2 Diabetes Mellitus Among Subjects With and Without Hypertension in Primary Care Setting|Progression From Impaired Fasting Glucose to Type 2 Diabetes Mellitus Among Subjects With and Without Hypertension in Primary Care Setting|IFG to DM|Kowloon Hospital, Hong Kong|Yes|Completed|July 2012|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10000|||Both|18 Years|N/A|No|Non-Probability Sample|We included all subjects with impaired fasting glucose results from Jan 2002 to Dec 2007.        Most of the subjects are hypertension patients visiting 6 general outpatient clinics        located in Sham Shui Po, Wong Tai Sin, Yau Mei Tei in Kowloon, Tsuen Wan in New        territories of Hong Kong. Minority of subjects had blood taken for other reasons. All the        laboratory results and dispensing records in the selected study centres are computerized        and accessible from 2002. The reasons of consultation are coded by attending doctors by        International Classification of Primary Care (ICPC-2). The ICPC-2 coding rate and quality        are generally satisfactory(22). Locally the study centre ICPC-2 coding rate is over 99% in        all consultations.|March 2013|March 7, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807351||70029|
NCT01808690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1528|EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes|Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes|EMERALD|University of Colorado, Denver|Yes|Recruiting|March 2013|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|19 Years|No|||December 2015|December 9, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808690||69926|
NCT01808703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ12-02|Clinical Trial of PeriZone PerioPatch in Subjects With Chronic Periodontitis|||MIS Implant Technologies, Ltd|No|Recruiting|March 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808703||69925|
NCT01807624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-06|Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)|The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers||St. Renatus, LLC|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807624||70008|
NCT01807637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138159|Transcranial Direct Current Stimulation for Improving Gait Training in Stroke|Using Transcranial Direct Current Stimulation to Jump Start Gait Training in Chronic Stroke Patients||University of Arkansas|Yes|Recruiting|March 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|30 Years|N/A|No|||October 2015|October 28, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807637||70007|
NCT01807897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-12S|Oxygen Versus PAP for Treatment of Sleep Apnea in Chronic Heart Failure|Oxygen Versus PAP for Treatment of Sleep Apnea in Chronic Heart Failure|OPTIMAL-HF|VA Office of Research and Development|Yes|Recruiting|June 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|161|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807897||69987|
NCT01808664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364498-3|Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests|Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests: Randomized Clinical Trial||University of California, Davis|Yes|Completed|April 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|61|||Both|N/A|N/A|No|||May 2015|May 19, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01808664||69928|
NCT01804660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN-E-003|Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population|A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Normal Population as Assessed by PCR and ELISA in Blood|CONTROL|GeNeuro Innovation SAS|No|Completed|October 2012|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|Serum, plasma and PBMC.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Blood donors coming for regular blood draw in the center of transfusion.|January 2014|January 27, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804660||70236|
NCT01804920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1600|D-Serine Treatment For Tardive Dyskinesia|D-SERINE TREATMENT FOR TARDIVE DYSKINESIA||Herzog Hospital|Yes|Recruiting|January 2013|||January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||August 2015|August 23, 2015|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01804920||70216|
NCT01805245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0333|Mindfulness: a Novel Approach for the Management of Diabetes-related Distress|Mindfulness: a Novel Approach for the Management of Diabetes-related Distress||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|30 Years|N/A|No|||July 2015|August 10, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01805245||70191|
NCT01804894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPU-TEAMScreen|Do Common Physical Tests Predict Injury or Performance|Field Tests and Their Correlation With Injury and Performance|TEAM|High Point University|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|359|||Both|18 Years|23 Years|Accepts Healthy Volunteers|Non-Probability Sample|college age, varsity, division 1 athletes|March 2015|March 31, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804894|3 Years|70218|
NCT01804907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032846|Feasibility of Non-pharmacological Insomnia Therapy in People Living With HIV|||Duke University|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||April 2015|April 17, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804907||70217|
NCT01805479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT107574|Exercise Training in Depressed Traumatic Brain Injury Survivors|Exercise Training in Depressed Traumatic Brain Injury Survivors||Virginia Commonwealth University|Yes|Withdrawn|February 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|14 Years|65 Years|No|||December 2015|December 18, 2015|March 1, 2013||No|Unable to enroll participants. Sponsor requested study closure.|No||https://clinicaltrials.gov/show/NCT01805479||70173|
NCT01805713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210M22861|Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung|Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Blood, Urine, BALF and Sputum.|Both|6 Months|N/A|No|Non-Probability Sample|Infants with Cystic Fibrosis Diagnosed by Newborn Screen.        Subjects with Cystic Fibrosis => 8 Years of Age.|June 2015|June 1, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805713||70155|
NCT01805973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013VSAS001|Surviving Aneurysm Surgery: A Pilot Study on Exercise Training in Abdominal Aortic Aneurysm Patients|Surviving Aneurysm Surgery: A Pilot Randomised Controlled Trial on Exercise Training in Abdominal Aortic Aneurysm Patients|SAS|University Hospital of South Manchester NHS Foundation Trust|No|Not yet recruiting|June 2013|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805973||70135|
NCT01806220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcmscsp180/06|Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis|Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis|EGFR|Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|24|||Both|20 Years|80 Years|No|||March 2015|March 18, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01806220||70116|
NCT01806506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBN N N403 3882 33|Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity|Randomized Clinical Trial Comparing Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity and Underlying Metabolic and Hormonal Abnormalities||Medical University of Warsaw|No|Active, not recruiting|November 2008|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|60 Years|No|||January 2013|March 6, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01806506||70094|
NCT01807416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.2013.Piemonte.PROED|Bone Dimensional Changes at Different Implant-to-abutment Connections: a 1-year Clinical and Radiological Study|Bone Dimensional Changes at Different Implant-to-abutment Connections: a 1-year Clinical and Radiological Study||Proed|No|Active, not recruiting|March 2013|September 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|90 Years|No|||January 2014|January 27, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807416||70024|
NCT01813968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2613|Ischemic Postconditioning in Cardiac Surgery|Ischemic Postconditioning in Cardiac Surgery|IPICS|Oslo University Hospital|Yes|Recruiting|January 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|20 Years|N/A|No|||October 2015|October 13, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813968||69522|
NCT01813370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-225|A Registry for Patients Treated on the Clinical Trial TAX 3503|A Registry for Patients Treated on the Clinical Trial TAX 3503 (A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy)||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|19|Samples With DNA|Serum PSA evaluations Serum testosterone levels|Male|18 Years|N/A|No|Non-Probability Sample|Patients who are presently on TAX3503 and undergoing followup for evidence of progressive        disease will be approached by their study physicians at their local sites to enter the        registry. No other patient will be approached or recruited. Some sites that were part of        the TAX3503 study are unable to open this registry at their site. In order to minimize the        number of participants whose information might be lost, Memorial Sloan-Kettering Cancer        Center (MSKCC) will inform these sites that they may refer their participants to MSKCC for        this registry.|August 2014|May 18, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813370|36 Months|69568|
NCT01814254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-11|Comparison of Body Hydration State in Hemodialysis Patients|Comparison of Body Hydration State in Hemodialysis Patients With the Hydra 4200 and ZOE (100 and 5 kHZ) Bioimpedance Devices||Renal Research Institute|No|Terminated|July 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|80 Years|No|Probability Sample|Hemodialysis clinics|February 2016|February 22, 2016|March 15, 2013||No|Change of Institutional Affiliation & Funding|No||https://clinicaltrials.gov/show/NCT01814254||69500|
NCT01807364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 10032|Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia|Evaluation of Cardiovascular Risk Profile in Adult Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency Diagnosed During Childhood|cardiohcs|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|180|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood and        controls|April 2015|April 23, 2015|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01807364||70028|
NCT01807650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-12|Oleogel-S10 in Wound Healing of Skin Graft Donor Sites|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split Thickness Skin Graft Donor Sites|BSG-12|Birken AG|No|Completed|March 2013|September 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01807650||70006|
NCT01804972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFO2013|Efficacy of Patient Centred Information for Vascular Disease|Efficacy of Patient Centred Information for Vascular Disease||Mid Western Regional Hospital, Ireland|Yes|Completed|May 2013|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804972||70212|
NCT01805297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-12-01|Aflibercept Injection for Proliferative Diabetic Retinopathy|Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy||University of Oklahoma|No|Active, not recruiting|March 2013|April 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805297||70187|
NCT01808144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-307|Lesinurad and Febuxostat Combination Extension Study in Gout|A Long-Term Extension Study of Lesinurad in Combination With Febuxostat for Subjects With Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat||Ardea Biosciences, Inc.|Yes|Active, not recruiting|March 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||January 2015|January 27, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808144||69968|
NCT01808157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT327-2005|A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis|A Phase II Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of CT327 Topical Ointment (0.05% and 0.5% w/w) Compared to Vehicle, in Subjects With Mild or Moderate Atopic Dermatitis and at Least Moderate Pruritus||Creabilis SA|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|188|||Both|12 Years|N/A|No|||November 2015|November 24, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808157||69967|
NCT01808417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-179|NRI-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer|Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2013|||December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808417||69947|
NCT01804933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|伦审[2012]326号|Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function|||First Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|July 2012|August 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|65 Years|No|||March 2013|March 4, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804933||70215|
NCT01804946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-ER-001|Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza|Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza||Materia Medica Holding|No|Completed|February 2011|October 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|60 Years|No|||March 2013|June 1, 2015|March 4, 2013||No||No|April 13, 2015|https://clinicaltrials.gov/show/NCT01804946||70214|
NCT01805271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIRAD|Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy|Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy||UNICANCER|Yes|Recruiting|March 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1984|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01805271||70189|
NCT01805258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/NACO-1/2006-07|Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB|Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.|"NVP"|All India Institute of Medical Sciences, New Delhi|No|Completed|June 2007|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|60 Years|No|||March 2013|March 25, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805258||70190|
NCT01805726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM235|Sedation During Bronchoscopy:Dexmedetomidine vs Alfentanil|Success of Sedation During Bronchoscopy: Comparison of the Effects of Dexmedetomidine, Alfentanil and Local Anesthesia||Saint-Joseph University|Yes|Completed|February 2013|November 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|80 Years|No|||November 2014|November 22, 2014|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01805726||70154|
NCT01806259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCtrial|Ketorolac in Breast Cancer Surgery|Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.|KBCt|Université Catholique de Louvain|Yes|Recruiting|February 2013|August 2018|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||December 2014|December 1, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01806259||70113|
NCT01805986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12115|Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner|Investigation of Grey Matter Pathology Using Ultra High Field (7T) MRI Scanner||University of Nottingham|No|Enrolling by invitation|March 2013|February 2015|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients studied will be those with known MS. For purposes of comparison as described        previously, we will also seek to include healthy volunteers.|May 2013|May 16, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805986||70134|
NCT01806233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3534123123|Lu's Acupuncture and Moxibustion Treatment on Stroke|Lu' Acupuncture and Moxibustion Treatment on Ischemic Stroke|LAMTS|Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|March 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|70 Years|No|||September 2015|October 18, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01806233||70115|
NCT01806246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2159|A Rehabilitation Program for Adolescents With Chronic Fatigue Syndrome|An Integrative Approach Based Psychoeducation, Heart Rate Variability Coherence Biofeedback and Elements of, Pacing Cognitive Behavior Therapy||St. Olavs Hospital|No|Completed|February 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|13 Years|18 Years|No|||October 2015|October 22, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01806246||70114|
NCT01806519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTU_SG_5|Motor_Control_Neck_SSED|A Motor Control Intervention of Patients With Forward Head Posture and Persistent Neck Pain - A Single System Experimental Design With 12 Month Follow-up||Luleå Tekniska Universitet|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|3|||Both|20 Years|50 Years|No|||March 2013|March 6, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806519||70093|
NCT01806844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Copernicus I|Prehospital Cerebral Oxygenation During Cardiopulmonary Resuscitation (CPR)|Cerebral Oxygenation During Resuscitation and Post-resuscitation Phase||Hasselt University|No|Active, not recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|16 Years|N/A|No|Non-Probability Sample|pre-hospital cardiac arrest|February 2016|February 18, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806844||70068|
NCT01806857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001274|Clinical Trial Nuedexta in Subjects With ALS|The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)||Center for Neurologic Study, La Jolla, California,|No|Active, not recruiting|April 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806857||70067|
NCT01807143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST10B1|Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma|Observational - Gene Discovery in Osteosarcoma||Children's Oncology Group|No|Completed|January 2010|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|Samples With DNA|tissue|Both|N/A|N/A|No|Non-Probability Sample|Osteosarcoma|March 2016|March 4, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807143||70045|
NCT01807702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 654-10|13C-Pyruvate Breath Test|13C-Pyruvate Breath Test Pilot Study|PBT|University of Florida|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807702||70002|
NCT01807975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/56|Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome|||Hopital Foch||Recruiting||||September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|90|||Both|18 Years|N/A|No|||May 2011|March 7, 2013|March 7, 2013||||No||https://clinicaltrials.gov/show/NCT01807975||69981|
NCT01813994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0889|Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer|||Yonsei University|No|Recruiting|February 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|70 Years|No|||February 2014|May 26, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01813994||69520|
NCT01814280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERIS1|Reducing Medication Errors on Basis of an Individual Risk Assessment|Differentiated Intervention Aimed at Reducing Medication Errors on Basis of an Individual Risk Assessment - a Pilot Study|MERIS1|University of Aarhus|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 27, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01814280||69498|
NCT01813669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039087|Integrative Coping Group for Children|Treatment of Psychosomatic Pain in Youth (ToPSY): A Pilot Study|ToPSY|Duke University|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|12 Years|No|||August 2014|August 19, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01813669||69545|
NCT01807663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01280-43|Validation of a Dynamic Evaluation Tool in Respiratory Failure|Validation of a Dynamic Evaluation Tool in Respiratory Failure by Ambulatory Inductance Plethysmography|TELERESP|Centre d'Investigation Clinique et Technologique 805|No|Terminated|November 2012|June 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 25, 2014|February 26, 2013||No|Healthy volonteers study results show that the device is not enough reliable|No||https://clinicaltrials.gov/show/NCT01807663||70005|
NCT01805310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12020453|Pre-operative Bowel Preparation Prior to Minimally Invasive Sacral Colpopexy|Pre-operative Bowel Preparation Prior to Minimally Invasive Sacral Colpopexy||University of Pittsburgh|No|Recruiting|February 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805310||70186|
NCT01808170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05081985|Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve|Effect of Laparoscopic Ovarian Cystectomy of Endometrioma Versus Cyst Deroofing on Ovarian Reserve as Determined by Anti-mullerian Hormone and Antral Follicle Count: a Prospective Randomized Study.||Ain Shams University|Yes|Completed|March 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|122|||Female|18 Years|35 Years|No|||March 2015|March 25, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808170||69966|
NCT01808430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-12-001|Powered Echelon Device in VATS Surgery|Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEX™ Powered ENDOPATH® Stapler: a Prospective European Multicenter Study||Ethicon Endo-Surgery (Europe) GmbH|Yes|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for VATS lobectomy for histologically confirmed Non-Small Cell Lung        Cancer (NSCLC) or scheduled for VATS wedge resection for undiagnosed pulmonary nodule or        metastasis from colorectal cancer (CRC) in accordance with their institution's        Standard-of-care (SOC).|February 2015|February 11, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808430|6 Weeks|69946|
NCT01805284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/788|Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia|Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia|UGENT_LIMOP|University Ghent|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01805284||70188|
NCT01805518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOEL 2011|Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals|9 wk, Randomized, 2-blind, Placebo-controlled, 2X2 Cross-over Phase 1 Study of 25 mg of Scelectium Tortuosum (as Zembrin®) in Aged Normals to Find Effects on Mental, Emotional and Cognitive Safety Measures and Cytokines.||Woodbury, Michel, M.D.|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|20|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01805518||70170|
NCT01805739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multi Modal Cardiac Imaging|Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation|Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation (TAVI)||Heinrich-Heine University, Duesseldorf|No|Recruiting|January 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|patients with aortic valve stenosis screened for TAVI|February 2016|February 10, 2016|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805739|12 Months|70153|
NCT01805492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRI-03-03|Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal|Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal||Windber Research Institute|No|Completed|January 2000|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|422|||Both|21 Years|N/A|No|||March 2013|March 4, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01805492||70172|
NCT01805505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-EH-01-2012-01|Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound|Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound||IVI Madrid|No|Terminated|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|346|||Female|18 Years|49 Years|No|||August 2015|February 24, 2016|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805505||70171|
NCT01806883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110701|Evaluation of the Effects of Rehabilitation Using the "Wii" on Upper Limb Kinematics in Chronic Stroke Patients.|Evaluation of the Effects of Rehabilitation Using the "Wii" on Upper Limb Kinematics in Chronic Stroke Patients.|WII|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2013|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806883||70065|
NCT01806896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241016|Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease|A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease||Pfizer|Yes|Completed|September 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|70 Years|No|||February 2015|February 17, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806896||70064|
NCT01806532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000561|Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study|Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study||Massachusetts General Hospital|No|Recruiting|January 2008|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Blood samples will be drawn and plasma stored for future potential biomarker studies.|Both|18 Years|N/A|No|Non-Probability Sample|Adult intensive care patients requiring mechanical ventilation who have been on the        ventilator for more than 24 hours.|June 2014|June 11, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806532||70092|
NCT01806870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062730|Immune Enhancement for Immunological Non-responders to ART|Immune Enhancement for Immunological Non-responders to ART|IMMUNE|Emory University|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|21 Years|N/A|No|||March 2016|March 3, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806870||70066|
NCT01807156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061422|Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer|Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer||Emory University|Yes|Terminated|March 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|March 6, 2013|Yes|Yes|Primary endpoint not met|No||https://clinicaltrials.gov/show/NCT01807156||70044|
NCT01807429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390284|Is Analgesic Effect of Low Dose Ketamine-midazolam the Same as Morphine|Comparing Low Dose IV Ketamine-midazolam Versus IV Morphine Regarding ED Pain Control in Patients Sustaining Closed Limb Fracture(s)||Isfahan University of Medical Sciences|Yes|Completed|December 2012|February 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807429||70023|
NCT01808235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039035|Oral Health Intervention Pilot Study for Individuals With Memory Problems|Developing a Caregiver-assisted Oral Health Intervention for Individuals With Memory Problems||Duke University|No|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|60 Years|N/A|No|||December 2015|December 23, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808235||69961|
NCT01814488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004008-37 Gandalf-01|A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia|A Phase II Multicentre Open-label Study on Allogeneic Stem Cell Transplantation From Unrelated, Cord-blood and Family Haploidentical Donors in Patients With Active Acute Leukemia|Gandalf-01|Gruppo Italiano Trapianto di Midollo Osseo|Yes|Active, not recruiting|July 2013|October 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|70 Years|No|||September 2015|September 2, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814488||69482|
NCT01814826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15009|Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older|A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older||Millennium Pharmaceuticals, Inc.|No|Recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|60 Years|N/A|No|||January 2016|January 29, 2016|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01814826||69456|
NCT01808183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-10-13B|Pediatric Supracondylar Humerus Fracture NIRS Study|Near Infrared Spectroscopy for the Evaluation of Pediatric Forearm Compartment Perfusion After Supracondylar Humerus Fracture||Carolinas Healthcare System|Yes|Recruiting|February 2012|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|17 Years|No|Non-Probability Sample|Children presenting to the Levine Children's Hospital / CMC Emergency Department with        displaced supracondylar fractures.|February 2016|February 14, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808183||69965|
NCT01805557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_VERAL12|Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.|Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.|FIL_VERAL12|Fondazione Italiana Linfomi ONLUS|No|Recruiting|February 2013|February 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805557||70167|
NCT01808677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11-1193|Reirradiation Registry Study|Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2012|||June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or        without chemotherapy at UT MD Anderson Cancer Center in Houston, Texas.|January 2016|January 20, 2016|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808677|5 Years|69927|
NCT01804673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005440|A Study to Evaluate the Safety and Tolerability of Fentanyl Iontophoretic Transdermal System (Fentanyl-ITS) in the Management of Post-Surgery Pain|Global Assessment of Treatment With IONSYS and Its Handling by Patients, Doctors and Nursing Staff in the Management of Acute Moderate to Severe Post-Surgery Pain in Hospitalised Patients||Janssen-Cilag G.m.b.H|No|Terminated|March 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|174|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|March 4, 2013|No|Yes|The study was prematurely discontinued since study medication was no longer available.|No|May 1, 2013|https://clinicaltrials.gov/show/NCT01804673||70235|The study was prematurely discontinued after enrolling 184 of 200 planned participants because the study medication was no longer available.
NCT01806012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05022013|Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy|Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy: a Randomized, Single-Blinded Study Comparing the Efficacy to the Routine Procedure||University Hospital Tuebingen|Yes|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|N/A|No|||March 2013|March 5, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01806012||70132|
NCT01806272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-12-01|Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis|A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|March 2013|August 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||March 2013|March 27, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806272||70112|
NCT01805999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13122012SCS|Ispaghula and Colonic Water Content|Effect of Ispaghula on Colonic Water Content||University of Nottingham||Active, not recruiting|March 2013|March 2016|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805999||70133|
NCT01806922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210006RIB|Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke|Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke : A Pilot Study||National Taiwan University Hospital|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|80 Years|No|||February 2014|February 9, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806922||70062|
NCT01807169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-05|Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel|Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel: the "MEDOC"Study.|MEDOC|Centre Hospitalier Universitaire de Nice|Yes|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01807169||70043|
NCT01807442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002729|Positive Psychology to Improve Cardiac Health Behaviors|Developing a Positive Psychology Intervention to Improve Cardiac Health Behaviors: Qualitative Research Phase|PEACE|Massachusetts General Hospital|No|Completed|March 2013|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01807442||70022|
NCT01807455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1206|An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine|An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine||Q-Med AB|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|25 Years|45 Years|No|||December 2015|December 16, 2015|March 6, 2013||No||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01807455||70021|
NCT01807715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|﻿352286|Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion|Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion||University of California, Davis|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|202|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women seeking first trimester surgical abortion|December 2015|December 2, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807715||70001|
NCT01808001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0030-B|Simulation Team Training and Critical Event Checklist Use for Optimizing the Management of Critical Perioperative Events in an Ambulatory Surgical Facility|Critical Event Checklist Use for Management of Critical Events in Ambulatory Surgery|CEC|Women's College Hospital|No|Active, not recruiting|June 2013|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Health care professionals|February 2013|November 15, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01808001||69979|
NCT01817153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRO-2012-04|Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.|Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.|HyStOON|Centre Hospitalier Régional d'Orléans|No|Recruiting|November 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 26, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817153||69279|
NCT01813435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRI-12-001, 02EU11|GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation|Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use||ECRI bv|Yes|Active, not recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16000|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813435||69563|
NCT01813448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-CL-3001|A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects||Astellas Pharma Inc|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|36|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|March 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813448||69562|
NCT01813461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0016|Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects|A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of Isavuconazole After a Single Oral Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 15, 2013|March 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813461||69561|
NCT01813682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eoitopia|Effect of Iron-fortified TPN on Preterm Infants Anemia|Effect of Iron-fortified TPN on Preterm Infants Anemia||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|September 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|118|||Both|N/A|3 Days|No|||March 2013|March 20, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813682||69544|
NCT01813695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0853|Preemptive Genotyping and Pain Management|Preemptive Genotyping of Children and Adolescents at Risk for Surgery and Subsequent Pain Management||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|March 2013|April 2021|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|748|Samples With DNA|Saliva Blood|Both|6 Years|21 Years|No|Non-Probability Sample|Pediatric patients scheduled for scoliosis and pectus excavatum surgeries.|February 2016|February 4, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813695||69543|
NCT01813981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COFF2011|The Effect of High and Low Roasted Coffee on Vascular Response|The Effect of High and Low Roasted Coffee on Vascular Response||University of Reading|Yes|Completed|May 2011|January 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|19|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813981||69521|
NCT01808456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFH20132015|Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.|Phase IV, Pilot, Randomized, Investigator-blinded, Study to Evaluate the Reactogenicity and Immunogenicity of Standard-dose Versus High-dose Inactivated Influenza Vaccine After Kidney, Heart and Lung Transplantation.||Inova Health Care Services|No|Recruiting|October 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|70 Years|No|||September 2015|September 3, 2015|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808456||69944|
NCT01836367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0026|Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp|An Investigator-Initiated Study to Assess the Degree of Irritation After a Second Cycle of Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp||Icahn School of Medicine at Mount Sinai|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 30, 2013|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836367||67808|
NCT01804686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100955|A Long-term Extension Study of PCI-32765 (Ibrutinib)|A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study||Janssen Research & Development, LLC|No|Enrolling by invitation|September 2013|December 2019|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804686||70234|
NCT01804959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-SScGI|Clinical Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease|A Proof-of-concept Double-blind Randomized Placebo-controlled Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease||Singapore General Hospital|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01804959||70213|
NCT01806025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0093-CTIL|Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients|Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients|Hp-in-CF|Carmel Medical Center|No|Completed|April 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|142|Samples Without DNA|Peripheral blood serum|Both|N/A|60 Years|No|Non-Probability Sample|Patients diagnosed with CF|January 2015|January 2, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806025||70131|
NCT01806285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP0001|Sample Collection to Evaluate an Investigational Instrument for the Detection of Respiratory Viruses in Nasopharyngeal Swabs|||GenMark Diagnostics|No|Completed|February 2013|November 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|205|Samples With DNA|Nasopharyngeal swabs|Both|N/A|N/A|No|Probability Sample|Children and adults of any age suspected of having respiratory infection with onset of        symptoms and fever within 5 days of sample collection.|December 2015|December 23, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01806285||70111|
NCT01806298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-011|An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)|Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)||Merck KGaA||Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806298||70110|
NCT01806545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF01-SRM003|An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access|A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access||Shire|Yes|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|March 5, 2013|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01806545||70091|
NCT01838070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAF85|Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)|Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)||Sanofi|No|Active, not recruiting|April 2013|May 2016|Anticipated|November 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|626|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who have received AVAXIM 160U (Hepatitis A Vaccine) according to Summary of        Product Characteristics (SmPC)|December 2015|December 3, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838070||67678|
NCT01807182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2643.00|Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma|Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Recruiting|July 2013|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807182||70042|
NCT01807468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0113061|Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors|Haploidentical Stem Cell Transplantation Followed by NK Cell Infusion in Patients With High-risk Solid Tumors Who Failed Autologous Stem Cell Transplantation||Samsung Medical Center|Yes|Active, not recruiting|May 2013|December 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|21 Years|No|||November 2015|November 19, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01807468||70020|
NCT01807728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12090536|Training Programs to Improve Outcomes for Individuals With Spinal Cord Injury|Training Programs to Improve Outcomes for Individuals With Spinal Cord Injury||University of Pittsburgh|No|Recruiting|August 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|680|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01807728||70000|
NCT01807741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-4181|Asenapine for Bipolar Depression|Asenapine for Bipolar Depression||University of Cincinnati|Yes|Recruiting|September 2013|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807741||69999|
NCT01808014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0920|The Analgesic Effect of Nefopam on the Fentanyl Based PCA (Patient-controlled Analgesia) After Lumbar Spinal Surgery|||Yonsei University|Yes|Recruiting|February 2013|June 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01808014||69978|
NCT01813396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012075RB|Prediction of Functional Disability and Clinical Trial in Subjects With Stiff Shoulders|Prediction of Functional Disability and Randomized Clinical Trial in Subjects With Stiff Shoulders: Joint Mobility, Range of Motion, Muscle Stiffness, and Shoulder Physical Activity||National Taiwan University Hospital|Yes|Recruiting|December 2011|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Both|N/A|N/A|No|||October 2013|October 31, 2013|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01813396||69566|
NCT01813409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR-RCR|Rheumatology Clinical Registry|American College of Rheumatology Clinical Registry|RCR|American College of Rheumatology|No|Recruiting|August 2009|||December 2015|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|820|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Rheumatology patients|August 2014|August 29, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01813409|1 Year|69565|
NCT01814046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130093|Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma|Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|May 2019|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|16 Years|75 Years|No|||November 2015|February 20, 2016|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814046||69516|
NCT01814059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130094|Sirolimus for Eosinophil-Associated Gastrointestinal Disorders|A Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal Disorders||National Institutes of Health Clinical Center (CC)||Terminated|March 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||May 2015|December 8, 2015|March 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01814059||69515|
NCT01813721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110146|Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.|Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.||Amgen|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1007|||Both|18 Years|N/A|No|Probability Sample|Eligible subjects will have NHL, breast or lung cancer and be due to initiate one of the        permitted standard dose chemotherapy regimens listed in the protocol (those with a        documented intermediate FN risk of 10-20%). Subjects will be prospectively and        sequentially identified by approximately 150-200 investigators during their clinics        distribututed in 11 countries.|January 2015|January 28, 2015|January 8, 2013||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01813721||69541|
NCT01804699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03189|Canadian National ARVC Registry|Canadian National Arrhythmogenic Right Ventricular Cardiomyopathy|ARVC Registry|University of British Columbia|No|Enrolling by invitation|January 2013|August 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|If the participant consents to the biobanking arm of the study an additional blood sample      (Please see the ARVC Lab Manual for details) will be collected at baseline and stored for      subsequent analysis. These analyses may include measurement of serum Troponin T, NT-pro-BNP,      C-reactive protein and other biomarkers to determine their association with the progression      of disease; both in terms of cardiac structure (i.e. change in right ventricular volume) and      electrical substrate (i.e. number of ICD shocks) over time.|Both|2 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be identified from centers that form the Canadian Genetics Heart Rhythm        (CGHR) Network of Inherited Heart Rhythm Clinics across Canada 25        (http://www.heartrhythmresearch.ca/).|December 2015|December 2, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804699|3 Years|70233|
NCT01836380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOA26752611|Regular Swimming, Vascular Function, and Arthritis|Effects of Swimming Exercise and Cycling Exercise Interventions on Vascular Function, Inflammation and Pain in Middle-aged and Older Adults With Osteoarthritis.|OA|University of Texas at Austin|No|Completed|January 2013|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|90 Years|No|||March 2015|March 25, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836380||67807|
NCT01836393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU Ortho Plai|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 14% of Plai (Plaivana®) to Placebo Gels|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 14% of Plai (Plaivana®) to Placebo Gels|OA knee Plai|Khon Kaen University|Yes|Completed|January 2013|April 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|120|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 5, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01836393||67806|
NCT01805531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16398|Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication|Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention|SAFARI|Bayer|No|Completed|April 2013|March 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|425|||Both|18 Years|N/A|No|Non-Probability Sample|Patients more than 18 years old, with a diagnosis of non-valvular atrial fibrillation,        treated to prevent stroke or non-central nervous system systemic embolism, who switch from        VKA to Xarelto due to issues with VKA|April 2015|April 28, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805531||70169|
NCT01805752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD075075-01|Optimizing Integrated PMTCT Services in Rural North-Central Nigeria|Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial||Vanderbilt University|No|Active, not recruiting|March 2013|June 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|N/A|No|||December 2015|December 14, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805752||70152|
NCT01836692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_DOG07_136|Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study|Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study||Christie Hospital NHS Foundation Trust|No|Recruiting|April 2014|April 2021|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01836692||67783|
NCT01837199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP/726|MTZ Plus AMX in the Treatment of Smokers and Non-smokers|Clinical and Microbiological Effects of Adjunctive Metronidazole Plus Amoxicillin in the Treatment of Generalized Chronic Periodontitis: Smokers Versus Non-Smokers.||University of Guarulhos|Yes|Completed|July 2011|||December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|35 Years|75 Years|No|||April 2013|April 17, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01837199||67744|
NCT01806558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004900|Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions|Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions|MBI/US|Mayo Clinic|No|Active, not recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Female|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806558||70090|
NCT01806571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1284|Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression||Mayo Clinic|Yes|Recruiting|July 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|69 Years|No|||March 2016|March 14, 2016|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806571||70089|
NCT01806909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130081|Intranasal AD4-H5-VTN as an Adenovirus Vaccine|Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01806909||70063|
NCT01838356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH085740|Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft|Intracranial Atherosclerosis and Predictors of Post-CABG Depression|NOAHS|Yale University|No|Recruiting|September 2012|||February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|40 Years|N/A|No|Non-Probability Sample|The study population for this study will be drawn from cardiac surgery patients at a        university-based hospital who will undergo coronary artery bypass graft (CABG) surgery.|April 2013|April 23, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01838356||67656|
NCT01838616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503/60|Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.|Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus Oxycodone/Naloxone PR in Non-opioid Pre-treated Subjects With Uncontrolled Severe Chronic Low Back Pain With a Neuropathic Pain Component.||Grünenthal GmbH|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|367|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 19, 2013||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01838616||67636|
NCT01838629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090833B27|the Effect of Universal Salt Iodization on Thyroid Diseases|||Hangzhou Center of Disease Control and Prevention||Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|12438|Samples With DNA|The participants were invited to local community health center before 8:00 am after 8-hour      fasting overnight. Firstly, each participant provided 10 ml spot urine samples. Then, 5 ml      venous blood was collected using vacuum blood collection tube.|Both|6 Years|86 Years|Accepts Healthy Volunteers|Probability Sample|This study was conducted in Hangzhou, Zhejiang Province, China, which locates at east of        China. This city covers eight districts and five counties. There are 8.7 millions        residents in Hangzhou city; 73.25% of them living in urban areas, 26.75% in rural areas.        This study was designed to be representative of the civilian from Hangzhou and collected        information on demographic characteristics, health status, iodine intake and thyroid        disease.|May 2013|May 4, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838629|1 Year|67635|
NCT01838369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-BI-505-02|A Phase II Study of BI-505 in Smoldering Multiple Myeloma|A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma||BioInvent International AB|No|Terminated|March 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 25, 2015|March 26, 2013||No|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT01838369||67655|
NCT01838941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPGDN001|Betaine and Peroxisome Biogenesis Disorders|A Pilot, Open Label Trial Assessing the Safety and Efficacy of Betaine in Children With Peroxisome Biogenesis Disorders.||McGill University Health Center|No|Recruiting|March 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||August 2013|August 7, 2013|March 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838941||67612|
NCT01838642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130108|Ponatinib for Advanced Medullary Thyroid Cancer|A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|March 2013|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|April 20, 2013|Yes|Yes|Recruiting halted prematurely and will not resume. New study to open soon.|No|February 18, 2016|https://clinicaltrials.gov/show/NCT01838642||67634|
NCT01838655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130124|Nitisinone for Type 1B Oculocutaneous Albinism|A Pilot Study of Nitisinone in the Treatment of Oculocutaneous Albinism, Type 1B||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|November 26, 2015|April 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838655||67633|
NCT01839253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0422|The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery|||Yonsei University|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|75|||Both|18 Years|29 Years|No|||March 2014|March 31, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01839253||67588|
NCT01839266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0034|Prognostic Factors for Acute Pulmonary Embolism in Critically Ill Patients|||Yonsei University|No|Completed|November 2011|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|34 Years|N/A|No|Non-Probability Sample|patients with acute pulmonary embolism(PE) (diagnosed by CT) treated in the hospital with        IV unfractionated heparin|April 2013|April 21, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01839266||67587|
NCT01813422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120153|GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound|A Randomized, Double-Blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization.|GLAGOV|Amgen|Yes|Active, not recruiting|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|970|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813422||69564|
NCT01813708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-716-0107|Intensive Life-Style Intervention in Type 2 Diabetes Patients|The Effectiveness of an Intensive Life-Style Intervention Compared to an Collaborative Educational Intervention On Metabolic Control, and Its Impact on Weight, Physical Activity, Quality of Life, Self-Efficacy in Type 2 Diabetes Patients||Coordinación de Investigación en Salud, Mexico|Yes|Completed|November 2004|December 2007|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2012|March 20, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01813708||69542|
NCT01805050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAGL|Case Study: HAGL-lesion (HAGL:Humeral Avulsion Glenohumeral Ligament)|Arthroscopically Repair of the Anterior Instability of the Shoulder Due an HAGL - Lesion - A Case Serie||Schulthess Klinik|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who underwent surgical repair of the anterior instability due an HAGL lesion        at the Schulthess Klinik and have been performed surgery by Dr. M. Flury, Dr. H.-K.        Schwyzer or Dr. Ph. Frey|August 2014|August 8, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805050||70206|
NCT01814345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1077|Her 2 Testing in Indian Patients With Gastric Cancer|"An Observational Study to Determine the Incidence of of Her 2 Positivity in 100 Consecutive Gastric Cancers"||Tata Memorial Hospital|Yes|Recruiting|February 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|100 consecutive Gastric Cancer|July 2013|July 10, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01814345||69493|
NCT01814293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10271|Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)|Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)||University of California, San Francisco|No|Withdrawn|May 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|18 Years|No|||May 2015|May 13, 2015|March 13, 2013|No|Yes|loss of funding. No data was collected.|No||https://clinicaltrials.gov/show/NCT01814293||69497|
NCT01814306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLMA-100|Supreme LMA and Proseal LMA in Prone Anesthetized Patient|Comparison of the Effectiveness Between the LMA SupremeTM and the LMA ProsealTM for Airway Management in Patient Undergoing Elective Orthopaedic Surgery in Prone Position|SPLMA|Prince of Songkla University|Yes|Enrolling by invitation|October 2011|June 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|100|||Both|N/A|15 Years|Accepts Healthy Volunteers|||March 2013|March 15, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01814306||69496|
NCT01814319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Re-Prosper HF|Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure|Initial Study on the Use of Probenecid as a Positive Inotrope for the Treatment of Systolic Heart Failure in Stable NYHA Class II to IV Patients|ReProsperHF|University of Cincinnati|Yes|Completed|March 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||August 2015|August 24, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814319||69495|
NCT01804985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4203|De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia|A Trial of De-escalation and Stopping Treatment in Chronic Myeloid Leukaemia Patients With Excellent Responses to Tyrosine Kinase Inhibitor Therapy|DESTINY|University of Liverpool|Yes|Active, not recruiting|December 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01804985||70211|
NCT01804998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENORITA 2013|Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy|Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy and Stomach Preserving Surgery in Early Gastric Cancer||National Cancer Center, Korea||Recruiting|March 2013|December 2022|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|580|||Both|20 Years|80 Years|No|||March 2016|March 23, 2016|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804998||70210|
NCT01836094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS 13-208|Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity|Beneficial Effects of Methylene Blue on Human Cognitive and fMRI Measures||The University of Texas Health Science Center at San Antonio|Yes|Completed|August 2013|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2016|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836094||67828|
NCT01805544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16409|Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication|Satisfaction and Quality of Life in Patients With a Diagnosis of DVT (Deep Venous Thrombosis) Who Take Rivaroxaban|SATORI|Bayer|No|Completed|May 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|Patients more than 18 years old, with a diagnosis of acute DVT treated with VKA with        issues, who switch from VKA to Xarelto|November 2015|November 19, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805544||70168|
NCT01836055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI-2011-33|Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist|Comparing Lesion Contrast With Both Magnevist and Gadavist and Understanding the Cerebral Perfusion Patterns of Patients With Multiple Sclerosis (MS) Using Magnetic Resonance Imaging (MRI)||Wayne State University|Yes|Terminated|January 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|19|||Both|20 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|Fifty-four subjects will be recruited in this study including 18 RRMS patients, 18 CIS        patients and 18 control subjects. Patients will be recruited by physicians affiliated with        the Detroit Medical Center (DMC), Oakland Hospital in Detroit, MI and other local        hospitals and physicians. Patients with prior known neurological disorders other than MS        or substances abuse, with contraindication to MRI such as pacemaker, pregnancy, other        non-MR compatible implanted device as well as with moderate to severe kidney disease that        have impaired ability to filter the contrast agents will be excluded from the study. Brain        MRI scans will be obtained once at entry as we will be running a cross sectional study.        Controls will be recruited from the university environment in Detroit and the surrounding        areas.|December 2014|December 8, 2014|April 8, 2013||No|The study didn't have sufficient flow of subjects (discontinued by the Sponsor)|No||https://clinicaltrials.gov/show/NCT01836055||67831|
NCT01805765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QE-2458-1|Qing'E Formula Therapy on Menopausal Symptoms|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial on the Effects of Chinese Medicine Formula (Qing'E) on Menopausal Symptoms||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Female|40 Years|60 Years|No|||March 2013|March 4, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01805765||70151|
NCT01837511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109937|Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients|Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients||GlaxoSmithKline||Completed|August 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|377|||Both|N/A|N/A|No|Non-Probability Sample|Previously collected samples and data of patients with pathologically proven stage I, II        and III NSCLC.|April 2013|April 18, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01837511||67721|
NCT01837498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH13-031|Reversal of Neuromuscular Blockade in Thoracic Surgical Patients|Reversal of Neuromuscular Blockade in Thoracic Surgical Patients||NorthShore University HealthSystem Research Institute|No|Recruiting|February 2013|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|90 Years|No|Probability Sample|240 patients presenting for elective thoracic surgical procedures with an expected        duration greater than 45 minutes will be enrolled in this study. The study is designed as        a "before and after" investigation of sugammadex (data will be collected on 120        consecutive patients before sugammadex is approved by the FDA for clinical care in the        United States (neostigmine used), and on 120 consecutive patients after sugammadex is        approved). In addition, after data on 120 patients reversed with neostigmine is collected,        the data will be analyzed to compare patients with residual block (train-of four < 0.9)        and without residual block (TOF </= 0.9)|September 2014|September 23, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01837498||67722|
NCT01837823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1507|YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering|YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01837823||67697|
NCT01838083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD13560|Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus|A Double-blind, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two New Insulin Glargine Formulations Using the Euglycemic Clamp Technique in Subjects With Type 1 Diabetes Mellitus||Sanofi|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|64 Years|No|||August 2013|August 9, 2013|April 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838083||67677|
NCT01838096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cera-001|Alumina Matrix Composite Ceramic Bearing Total Hip Arthroplasty in Patients Younger Than 30 Years|||Seoul National University Bundang Hospital|No|Active, not recruiting|March 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|15 Years|30 Years|No|||May 2015|May 18, 2015|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838096||67676|
NCT01838382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0871|Pain Characteristics After Total Laparoscopic Hysterectomy|||Yonsei University|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|20 Years|80 Years|No|||January 2014|January 12, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01838382||67654|
NCT01838694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVXCpn001|Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.|||Invion, Inc.|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||September 2015|September 4, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838694||67630|
NCT01838707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1976|Postoperative Epidural Analgesia in Spine Fusion Surgery|Postoperative Epidural Analgesia in Spine Fusion Surgery||Assiut University||Completed|December 2007|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|No|||April 2013|April 24, 2013|April 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838707||67629|
NCT01838668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS305|An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis||Biogen|No|Active, not recruiting|March 2013|October 2019|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|55 Years|No|||October 2015|October 2, 2015|April 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838668||67632|
NCT01838954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW-1281571|Short-wave Diathermy in Patients With Osteoarthritis of the Hand|The Effect of Short-wave Diathermy in Patients With Osteoarthritis of the Hand: A Randomized, Double Blinded, Placebo Controlled Trial||Medical University of Vienna|No|Recruiting|March 2012|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01838954||67611|
NCT01838967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_IDCV_1301|A Drug Interaction Study of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Cilnidipine 10 mg and Valsartan 160 mg After Oral Administration in Healthy Male Volunteers||IlDong Pharmaceutical Co Ltd|No|Completed|April 2013|October 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|54|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01838967||67610|
NCT01839279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAN-QT-1006|A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial|A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial|TQT|Acorda Therapeutics|Yes|Completed|April 2013|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|April 22, 2013|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01839279||67586|
NCT01813734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-103|Ponatinib in Advanced NSCLC w/ RET Translocations|A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations||Massachusetts General Hospital|Yes|Recruiting|September 2013|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813734||69540|
NCT01805349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-01|Study of Association Between Digital Osteoarthritis and Lower Limb Osteoarthritis|Study of the Association Between Digital Osteoarthritis and Lower Limb Osteoarthritis (Knee and Hip) in Terms of Severity and Evolution - Khoala Group Ancillary Project / Cohort Khoala|Khoala|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|March 2013|March 2015|Anticipated|March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|860|||Both|40 Years|75 Years|No|||March 2013|March 5, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805349||70183|
NCT01805817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cuzuncakmak1907|Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality|Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality||Istanbul Training and Research Hospital|Yes|Recruiting|December 2012|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|5|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805817||70147|
NCT01814007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA13-001|Multiple Treatment Study|SAFETY EVALUATION OF MULTIPLE COOLSCULPTING TREATMENTS||Zeltiq Aesthetics|No|Completed|March 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|October 14, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01814007||69519|
NCT01814020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOB015B/Final 30-Aug-2012|An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)|||Moberg Derma AB||Completed|December 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|N/A|||||||Both|18 Years|70 Years||||June 2013|September 19, 2014|March 15, 2013||||No||https://clinicaltrials.gov/show/NCT01814020||69518|
NCT01814033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRU1|Use of the LRU Pillow in the Acute Setting Following Total Knee Arthroplasty|Use of the LRU Pillow in the Acute Setting Following Total Knee Arthroplasty|LRU|Newton-Wellesley Hospital|No|Not yet recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|80 Years|No|||October 2015|October 8, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814033||69517|
NCT01805323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-OZU-12-001|A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema|||Allergan|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|101|||Both|N/A|N/A|No|Non-Probability Sample|Patients with macular edema|April 2014|April 28, 2014|March 5, 2013|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01805323||70185|
NCT01805336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A000000166-37|Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality|Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality|SEPREV|University Hospital, Caen|No|Recruiting|March 2013|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|60|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01805336||70184|
NCT01836432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0505|Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer|A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer|PILLAR|NewLink Genetics Corporation|Yes|Active, not recruiting|May 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|302|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836432||67803|
NCT01836445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA035145-01|Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men|Efficacy of Internet-based HIV Prevention|KIU!|Northwestern University|Yes|Active, not recruiting|May 2013|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|901|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836445||67802|
NCT01836341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-279|Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation|A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation||Memorial Sloan Kettering Cancer Center||Withdrawn|April 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836341||67810|
NCT01836705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TES13519|Effect of SAR302503 on ECG Activity in Patients With Solid Tumors|Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors||Sanofi|No|Completed|May 2013|May 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836705||67782|
NCT01836354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0699|Discharge Educational Strategies for Reduction of Vascular Events|Discharge Educational Strategies for Reduction of Vascular Events|DESERVE|New York University School of Medicine|Yes|Recruiting|August 2012|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836354||67809|
NCT01836952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11621|Sweet Cheeks: How Early Nutrition Affects Oral Microbiota Populations and Disease Incidence|Sweet Cheeks: How Early Nutrition Affects Oral Microbiota Populations and Disease Incidence||University of Illinois at Urbana-Champaign|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|Samples With DNA|Oral swabs of tongue and cheeks. Bacterial DNA to be extracted, no human DNA will be      extracted|Both|N/A|7 Months|Accepts Healthy Volunteers|Non-Probability Sample|Full term infants born via vaginal delivery|June 2015|June 12, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836952||67763|
NCT01837225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0633-CE|ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging Device|ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging Device||University Health Network, Toronto|No|Enrolling by invitation|September 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|Punch biopsies of healthy and cancerous breast tissue will be acquired from the surgical bed      and from the ex-vivo samples.|Female|18 Years|N/A|No|Non-Probability Sample|The study will be conducted at the Princess Margaret Hospital in Toronto, Canada. Patients        undergoing lumpectomy or mastectomy procedures to remove breast tumours will be recruited        to participate.|December 2015|December 9, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01837225||67743|
NCT01837524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003988|The KP Personal Shopper: A Pilot to Improve the Impact of Dietary Advice|||Kaiser Permanente|No|Completed|June 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|55|||Both|18 Years|64 Years|No|||January 2014|January 27, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837524||67720|
NCT01837264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-11-003|Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma|Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma Study Protocol|Magellan MAR01|Arteriocyte, Inc.|Yes|Active, not recruiting|January 2013|June 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837264||67740|
NCT01837836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC-49/2012|Effect of Health Education on Water Handling Practices in Rural Pondicherry|Effect of Health Education on Water Handling Practices in Rural Pondicherry||Sri Manakula Vinayagar Medical College and Hospital|No|Not yet recruiting|April 2013|||April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|980|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837836||67696|
NCT01837849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHNTU-2010-28|A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine|Comparative Effects of Recombinant Human Brain Natriuretic Peptide and Dobutamine on Acute Decompensated Heart Failure Patients With Different Blood BNP Levels||Nantong University|Yes|Completed|January 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|No|Probability Sample|Patients with acute decompensated heart failure who required hospitalization|April 2013|April 18, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01837849||67695|
NCT01838109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSMN-01|Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery|Multicenter, Prospective Randomized Controlled Trial Evaluating Postoperative Oral Nutritional Supplementation for the Patients Who Received Major Gastrointestinal Surgery||Seoul National University Hospital||Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|20 Years|80 Years|No|||September 2013|May 25, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01838109||67675|
NCT01838395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-8040.01|Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients|A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA||BioLineRx, Ltd.|Yes|Active, not recruiting|April 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|April 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838395||67653|
NCT01838681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14570A|Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment||H. Lundbeck A/S|No|Active, not recruiting|June 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|2193|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|April 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838681||67631|
NCT01838980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MCU-IL-0412|Evaluation of the Motus GI CleanUp System During Screening Colonoscopy|Evaluation of the Motus GI CleanUp System During Screening||Motus GI Medical Technologies Ltd|Yes|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|15|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||April 2014|February 18, 2016|April 21, 2013||No||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01838980||67609|
NCT01838993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 2013011|Inhalation of Lidocaine Before Intubation|The Effect of Ultrasonic Nebulizer Delivered Lidocaine on Circulatory Responses During Tracheal Intubation and Postoperative Sore Throat||New Taipei City Hospital|Yes|Recruiting|January 2013|||May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|65 Years|No|||April 2013|April 23, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01838993||67608|
NCT01834820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-01|Epinephrine, Dexamethasone, and Hypertonic Saline in Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety|Pilot Study: Epinephrine, Dexamethasone, and Hypertonic Saline in Children With Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|120|||Both|2 Months|24 Months|No|||July 2015|July 4, 2015|January 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834820||67926|
NCT01835314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0315|Compassionate Use of Stiripentol in Dravet Syndrome|Compassionate Use of Stiripentol in Dravet Syndrome||University of Colorado, Denver||Available||||||N/A|Expanded Access|N/A|||||||Both|1 Year|21 Years||||March 2016|March 17, 2016|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835314||67888|
NCT01808755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMannose UTIs|D Mannose in Recurrent Urinary Tract Infections|Recurrent Urinary Tract Infections in Adult Women: a Pilot Study With Oral D Mannose||IRCCS Policlinico S. Matteo|Yes|Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|22 Years|75 Years|No|||April 2014|April 25, 2014|March 7, 2013||No||No|April 1, 2013|https://clinicaltrials.gov/show/NCT01808755||69921|
NCT01804751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hx2ck2|Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China|||West China Second University Hospital|No|Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|N/A|N/A|No|Non-Probability Sample|Chinese women who fulﬁlled a research deﬁnition of preeclampsia, and who were admitted to        participating obstetric centres|June 2013|August 24, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804751||70229|
NCT01805570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID STUDY 2|Rapid Activity of Platelet Inhibitor Drugs Study 2|Rapid Activity of Platelet Inhibitor Drugs Study (RAPID 2)||Careggi Hospital|Yes|Completed|November 2012|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805570||70166|
NCT01805583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2109-31/5|Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders|SAFARI-Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders|SAFARI|Karolinska Institutet|No|Completed|March 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|352|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01805583||70165|
NCT01805596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTC-18129|Effect of Ticagrelor on Endothelial Function|Effect of Ticagrelor on Endothelial Function||Lawson Health Research Institute|No|Recruiting|April 2013|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805596||70164|
NCT01805830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP_C301|Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy|Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM|T2DM|Handok Pharmaceuticals Co., Ltd.|No|Completed|May 2012|September 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01805830||70146|
NCT01814540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264294|Bovine Milk Oligosaccharide Study|Pilot Study: Tolerability of Feeding Different Doses of Bovine Milk Oligosaccharides for Modifying Gastrointestinal Function in Healthy Individuals|BMO|University of California, Davis|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01814540||69478|
NCT01814553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.167|ADAM-Afatinib Diarrhea Assessment and Management|A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)||Boehringer Ingelheim||Completed|April 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 4, 2013||||No||https://clinicaltrials.gov/show/NCT01814553||69477|
NCT01836068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1331|Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals|Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|July 2013|July 2021|Anticipated|July 2020|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836068||67830|
NCT01836718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-50064|Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation|An Assessment of Intrahepatic HCV RNA Levels at the Time of Liver Transplantation in Patients With HCV Receiving Antiviral Therapy While on the Liver Transplant Waiting List Compared to Those Not Currently Receiving Therapy||Schiano, Thomas D., MD|No|Active, not recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|20|Samples With DNA|Whole blood, serum, liver explant tissue and hilar lymph nodes will be obtained for testing.      With subject consent, any unused specimens will be retained indefinitely for use in future      research either related or unrelated to this study, which may include genetic testing.|Both|18 Years|80 Years|No|Probability Sample|Patients with Chronic Hepatitis C on the Mount Sinai Recanati/Miller Transplantation        Institute's Liver Transplant Waiting list may be eligible for participation|November 2014|November 17, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836718||67781|
NCT01836965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42565EP|Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders|Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders||Milton S. Hershey Medical Center|No|Recruiting|March 2013|July 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01836965||67762|
NCT01837238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Reserach Institute|Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients|Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients||University of Illinois at Urbana-Champaign|Yes|Active, not recruiting|November 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|30 Years|80 Years|No|||December 2015|December 1, 2015|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01837238||67742|
NCT01837251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.21 / ENGOT ov-18|Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer|A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer||AGO Research GmbH|Yes|Active, not recruiting|May 2013|November 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|682|||Female|18 Years|N/A|No|||August 2015|August 25, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837251||67741|
NCT01837277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SevereHIV|Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients|||Fundação Bahiana de Infectologia||Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837277||67739|
NCT01837537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0399|Respiration Rate V2.0 in a Hospital Setting|Evaluation of Respiration Rate Parameters in a Hospital Population Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0||Medtronic - MITG|No|Completed|March 2013|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Volunteer subjects from a hospital setting on the general care floor or general surgical        care floor|November 2013|November 4, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01837537||67719|
NCT01837862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMC1411|A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas|A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas||Northwell Health|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|1 Year|21 Years|No|||October 2015|October 14, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837862||67694|
NCT01838122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HbA1C-PCOS|Prevalence of HbA1C in Women With PCOS|Prevalence of HbA1C in Different Categories of Obesity in Women With PCOS'A Propective Randomized Control Study|WHI|Southern Cross Fertility Centre|Yes|Active, not recruiting|April 2013|November 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|15 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|This population will have subjects with diagnosis of PCOS,by Rotterdam criteria regardless        of complain(s)|April 2013|April 18, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01838122||67674|
NCT01838408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008184|Evaluation of Proposed EZ2go Complete Bowel Cleansing System|Randomized, Single Blinded Study of Proposed EZ2go Complete Bowel Cleansing System: Evaluation of Its Safety, Efficacy and Patient Tolerance Compared to LOSO Prep, an Over the Counter Laxative Kit for Colonoscopy Bowel Preparation||Borland-Groover Clinic|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01838408||67652|
NCT01838720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20130406|Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage|Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial||RenJi Hospital|Yes|Recruiting|April 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|15 Years|80 Years|No|||August 2014|August 12, 2014|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01838720||67628|
NCT01839006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|supranormal|Clinical Significance of Supranormal Differential Renal Function in the Recovery of Hydronephrosis|Clinical Significance of Supranormal Differential Renal Function in the Recovery of Unilateral Hydronephrosis After Surgery: Long-term Results||Seoul National University Hospital|Yes|Completed|June 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|N/A|18 Years|No|Non-Probability Sample|patients with unilateral UPJO pediatric patients who underwent dismembered pyeloplasty and        preoperative HN in USG and supranormal renal function in DTPA renography|April 2013|April 21, 2013|June 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01839006||67607|
NCT01839019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3099003|Safety and Tolerability Study With Single Ascending Doses of ODM-102|Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males||Orion Corporation, Orion Pharma|Yes|Completed|April 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01839019||67606|
NCT01835626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#122011|Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma|A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck||University of California, San Francisco|Yes|Recruiting|May 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835626||67864|
NCT01805375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/12/003|A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies|A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies||Cancer Research UK|No|Recruiting|April 2013|||September 2017|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805375||70181|
NCT01805609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-030|Training Model to Advance Support of the Family as a Caregiving System in the Inpatient Oncology Setting|Training Model to Advance Support of the Family as a Caregiving System in the Inpatient Oncology Setting||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805609||70163|
NCT01805843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-311 ex 10/11|Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia|Pulmonary Vascular Changes in Patients With Chronic Myeloid Leukemia With Second-line Therapy Dasatinib vs. Nilotinib||Medical University of Graz|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|Samples with DNA will be retained for later examinations at the Biobank, in case that the      patient agrees (extra patient information). The blood samples are taken only during routine      tests.|Both|18 Years|95 Years|No|Probability Sample|patients with chronic myeloid leukemia under second-line therapy with dasatinib or        nilotinib,|September 2015|September 7, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01805843||70145|
NCT01805804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2012|Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients|Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker||Medical University of Silesia|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01805804||70148|
NCT01835847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G24062|An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression|Tipepidine for Adolescent Depression||Chiba University||Completed|April 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|10 Years|18 Years|No|||May 2014|May 22, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01835847||67847|
NCT01836081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0687|Respirophasic Carotid Artery Peak Velocity Variation as a Predictor of Fluid Responsiveness in Patients With Coronary Disease|||Yonsei University|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|20 Years|N/A|No|||April 2013|April 18, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01836081||67829|
NCT01837004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HL11341001A1|Cognitive Regulation Training and Exercise|Cognitive Regulation Training and Exercise (CORTEX) Trial|CORTEX|University of Illinois at Urbana-Champaign|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|133|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||March 2014|December 8, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01837004||67759|
NCT01837303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1341|chemQbiosciences:Manual Liquid Based Cytology|chemQbiosciences:Manual Liquid Based Cytology||University of North Carolina, Chapel Hill|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|76|||Female|18 Years|N/A|No|Non-Probability Sample|76 healthy women presenting for standard pap smear screening|April 2013|December 3, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01837303||67737|
NCT01836731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEHPP|Impact Evaluation of Community-Based Health Programs in Rwanda|Health Impact Evaluation of the "Community-Based Environmental Health Promotion Programme" in Rwanda|CBEHPP|Georgetown University|No|Active, not recruiting|April 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|8718|||Both|N/A|5 Years|No|||February 2016|February 10, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836731||67780|
NCT01836744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-2012-024|Survival Rate of Dental Implants Placed in Sinus Lift Performed With Two Different Grafts|Survival Rate of Dental Implants Placed in Sinus Lift Performed With Two Different Grafts||Grupo de Investigação: Cirurgia Oral, Peridontologia, Implantologia|Yes|Recruiting|March 2013|March 2022|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 13, 2016|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836744||67779|
NCT01836978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-454-SDR|Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy|Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy: Combining Physical Exercise to Stress Reduction Strategies and Nutritional Supplementation||McGill University Health Center|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|85 Years|No|||March 2016|March 17, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01836978||67761|
NCT01836991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-ADGC|D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer|Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||April 2013|April 22, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836991||67760|
NCT01838135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00509|WheelSeeU Feasibility Study|Wheelchair Self-efficacy Enhanced Training Program to Improve Wheelchair Use in Older Adults||University of British Columbia|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|55 Years|N/A|No|||December 2015|December 2, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01838135||67673|
NCT01838421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paediatric tube size|Correlation of the Paediatric Tracheal Tube Size|Correlation of the Paediatric Tracheal Tube Size With the Known Formulas for the Calculation of the Size||Charite University, Berlin, Germany|No|Completed|January 2011|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3000|||Both|N/A|11 Years|No|Non-Probability Sample|Children under the age of 12 who underwent surgery in the Charité - University Medicine        Berlin, Campus Virchow - Klinikum in the years 2011/12|April 2013|April 19, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01838421||67651|
NCT01838434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A051201|Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|July 2013|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|April 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838434||67650|
NCT01838733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:015|Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery|Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery||University of Manitoba|No|Recruiting|April 2014|||May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|65 Years|85 Years|No|Probability Sample|Age >65 High-risk non-cardiac surgery (aortic aneurysm repair, hepatic resection,        pancreatectomy, colon resection)|February 2015|February 23, 2015|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01838733||67627|
NCT01839032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041316|Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy|A Phase II Study of Cisplatin With Intravenous and Oral Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemotherapy With Oral Vinorelbine and Cisplatine for Locally Advances Non-small Cell Lung Cancer||Pierre Fabre Medicament|Yes|Completed|May 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|75 Years|No|||April 2013|April 19, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01839032||67605|
NCT01834833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110601 - PHRQ1104|Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient|Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient.|CHIC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2013|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|326|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01834833||67925|
NCT01835080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.038|Obstructive Sleep Apnea in Pulmonary Arterial Hypertension (OSA in PAH)|Effect of Pulmonary Arterial Hypertension Treatment on Obstructive Sleep Apnea|OSA in PAH|Inova Health Care Services|No|Terminated|April 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosis of Group 1 PAH Either lack of treatment for PAH or sub-optimally treated PAH|June 2014|June 27, 2014|April 10, 2013||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01835080||67906|
NCT01835327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1398|Cerebral Oxygen Monitoring During Surgery and Recovery After Surgery in Patients Having Lung Surgery|Cerebral Oximetry and Recovery Following Thoracic Surgery||Icahn School of Medicine at Mount Sinai|No|Suspended|September 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anticipated inclusion is all patients scheduled for thoracic surgery at Mount Sinai        Hospital by the aforementioned surgeons Dr. Flores and Dr. Kaufman. Exclusion criteria        will be those patients who (1) do not speak English, (2) are less that the age of 18 years        old, (3) are currently prisoners, (4) do not display the capacity to consent to the trial        and (5) who are unwilling to complete the study. Screening for exclusion criteria will        occur primarily in the pre-operative setting under the guidance of Drs. Flores and Kaufman        and will be reviewed by the Research Coordinator and acting anesthesiologist on the day of        surgery.|March 2016|March 16, 2016|April 16, 2013||No|new PI to be appointed and project will be resubmitted for review|No||https://clinicaltrials.gov/show/NCT01835327||67887|
NCT01805388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130054H|Comparison of Tissue in Regenerative Endodontic Procedures and Apexification|Comparison of Tissue Formation in Regenerative Endodontic Procedures and Apexification||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|February 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 28, 2013|Yes|Yes|Lack of pediatric recruitment ability|No||https://clinicaltrials.gov/show/NCT01805388||70180|
NCT01805622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICS cRCT|Educational Program to Increase Colorectal Cancer Screening: a Cluster Trial|Efficacy to Effectiveness Transition of an Educational Program to Increase Colorectal Cancer Screening|EPICS|Morehouse School of Medicine|No|Recruiting|August 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|7200|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805622||70162|
NCT01805856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ito-RCT1|Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery|Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery|Ito-RCT1|Ito Hospital|No|Completed|November 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2164|||Both|10 Years|90 Years|No|||March 2013|March 5, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805856||70144|
NCT01806064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105RC101|A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma|A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma||Tracon Pharmaceuticals Inc.|Yes|Recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01806064||70128|
NCT01806077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-A2012-04|Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors|Demonstration of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Antiplatelet Effect of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors||Tufts Medical Center|Yes|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806077||70127|
NCT01835860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-12-81|Prostatic Artery Embolization for Benign Prostatic Hyperplasia|||Regina Qu'Appelle Health Region||Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|N/A|N/A|No|||April 2013|May 4, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01835860||67846|
NCT01836107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2027|Adaptation and Validation of a Score From English to Spanish for Evaluating Quality of Clinical Notes|Cross-cultural Adaptation and Validation of a Score for Evaluating Quality of Inpatient Clinical Notes||Hospital Italiano de Buenos Aires|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|N/A||1|Actual|38|||Both|N/A|N/A|No|Non-Probability Sample|Clinical notes (admission notes, progress notes and discharge summaries) will be included        in the study following the original research.|April 2013|March 22, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01836107||67827|
NCT01837589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N° ID RCB : 2009-A00292-55|Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis|Evaluation of the Bone Mineralization by Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis : Validation Study|TOMODENS|Hôpital Necker-Enfants Malades|No|Recruiting|January 2012|June 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|5 Years|N/A|No|||April 2013|April 18, 2013|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01837589||67715|
NCT01836406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0485|Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy|||Yonsei University|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Both|20 Years|65 Years|No|||February 2014|February 17, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836406||67805|
NCT01836419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0711|The Clinical Efficacy of Laryngeal Mask Airway in Elderly Patients: Comparison With Young Adults|||Yonsei University|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|85 Years|No|||February 2014|February 17, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836419||67804|
NCT01837290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA12/166|Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery|The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery||Baskent University|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|65 Years|95 Years|No|||January 2015|January 26, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837290||67738|
NCT01837550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HörNet VGR|Educational Program for Hearing Aid Users With Internet Support|A Randomized, Controlled Trial of the Short-term Effects of Complementing an Educational Program for Hearing Aid Users With Internet Support||Sodra Alvsborgs Hospital|Yes|Completed|April 2013|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|74|||Both|20 Years|80 Years|No|||April 2013|September 12, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837550||67718|
NCT01838148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL VIII|Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia|BASEL VIII Trial - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia|BASEL VIII|University Hospital, Basel, Switzerland|No|Recruiting|May 2004|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|4000|Samples Without DNA|EDTA, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients presenting with suspected exercise-induced myocardial ischemia        referred for rest/ergometry myocardial perfusion SPECT.|March 2016|March 3, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01838148||67672|
NCT01838161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0026-P4S|Improving Adolescent Vaccination in Appalachian Kentucky|Project INSPIRE: Improving Adolescent Vaccination in Appalachian Kentucky|INSPIRE|University of Kentucky|No|Completed|April 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|551|||Both|11 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01838161||67671|
NCT01838447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAMINDINCHD-01|Prevention of Vitamin D Deficiency Following Pediatric CHD Surgery: a Phase II Dose Evaluation Randomized Controlled Trial Comparing Usual Care With a High Dose Pre-operative Supplementation Regimen Based on the Institute of Medicine Daily Upper Tolerable Intake Level|Prevention of Post-Cardiac Surgery Vitamin D Deficiency in Children With Congenital Heart Disease: A Pilot Dose Evaluation Randomized Controlled Trial|HICCUPS 2|Children's Hospital of Eastern Ontario|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|36 Weeks|17 Years|No|||January 2016|January 26, 2016|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01838447||67649|
NCT01838746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAGS-1|CRAGS (Coronary aRtery diseAse in younG adultS)|Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients Aged < 50 Years: a Multicenter Study|CRAGS|University of Turku|No|Active, not recruiting|April 2013|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2000|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients aged < 50 years who underwent CABG or PCI from 2005 to 2012 will be collected        from multiple institutions.|May 2015|May 27, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01838746||67626|
NCT01838759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEUN 2013-31-26/02|Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia|Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia||Zonguldak Karaelmas University|No|Completed|February 2013|September 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|58|||Both|18 Years|65 Years|No|Probability Sample|Patients admitted to Bulent Ecevit University Hospital with the presentation of        hyponatremia|October 2014|October 30, 2014|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01838759|6 Months|67625|
NCT01839045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dtectDx-Breast-001|Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification|Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept||Provista Diagnostics, Inc|Yes|Active, not recruiting|March 2013|August 2014|Anticipated|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples Without DNA|At each visit, 35mL or 2 1/2 tablespoons of blood will be drawn from your arm.|Female|25 Years|49 Years|No|Non-Probability Sample|Primary Care Clinics|June 2014|June 6, 2014|April 5, 2013||||No||https://clinicaltrials.gov/show/NCT01839045|6 Months|67604|
NCT01834846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090486|Impact of Perivascular Tissue on Endothelial Function in Coronary Artery Bypass Grafting|Impact of Perivascular Tissue on Endothelial Function and Vessel Structure in Vein Grafts Used for Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Trial.|IMPROVE-CABG|Norwegian University of Science and Technology|Yes|Recruiting|May 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834846||67924|
NCT01835093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G24061|An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Tipepidine for ADHD||Chiba University||Completed|April 2013|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Years|17 Years|No|||February 2014|February 19, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835093||67905|
NCT01835925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285|Rectal Cancer Consortium|Rectal Cancer Consortium: BrUOG 285: A Comprehensive Program to Identify Therapeutic Targets and Develop Targeted Agents for Testing With Total Neoadjuvant Treatment for Stage II-III Rectal Cancer BrUOG= Brown University Oncology Research Group||Brown University|Yes|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Tissue specimen from diagnosis from rectal cancer|Both|18 Years|N/A|No|Non-Probability Sample|Patients with stage II or III rectal cancer (adenocarcinoma)|April 2014|April 30, 2014|April 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835925||67841|
NCT01805401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-11/42|tDCS Applied to the OFC: Effects on Decision-Making and Impulse Control|Modulating Decision-Making and Impulse Control With Transcranial Direct Current Stimulation (tDCS) Over the Orbitofrontal Cortex (OFC): A Randomized and Sham-Controlled Study||Douglas Mental Health University Institute|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01805401||70179|
NCT01805635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/23/13/KE|PF and FeNO and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases|Evaluation of the Relationship Between the Parameters of Pulmonary Function (PF) and the Concentration of Fractional Exhaled Nitric Oxide (FeNO) and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases||Medical Universtity of Lodz|Yes|Recruiting|February 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|5500|Samples With DNA|IgE specific allergen antibodies|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with allergic diseases, healthy children.|September 2013|September 6, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01805635||70161|
NCT01806116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hematology-01|Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation|Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation|DFMBHSCT|The First Affiliated Hospital of Soochow University||Active, not recruiting|September 2009|May 2014|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Years|65 Years|No|||March 2013|March 11, 2013|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806116||70124|
NCT01806090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCP|Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding|Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding||Chinese University of Hong Kong|No|Recruiting|February 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806090||70126|
NCT01806376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBYN-Ⅰ-01|A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics|A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|March 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|70 Years|No|||March 2013|March 7, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01806376||70104|
NCT01836120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTH103|A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer|A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer||Hebei Tumor Hospital|Yes|Active, not recruiting|April 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||April 2013|April 18, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836120||67826|
NCT01837329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46356|Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer|A Phase I Study of Tetrathiomolybdate (TM) in Combination With Carboplatin and Pemetrexed in Chemo-Naive Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer||University of Rochester|Yes|Recruiting|November 2013|September 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837329||67735|
NCT01836757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|msm2012|Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage|The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte|msm|G.Papanikolaou Research Group|Yes|Recruiting|September 2012|October 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|40 Years|N/A|No|||April 2013|April 17, 2013|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836757||67778|
NCT01836770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kambin|Epidural Contrast Flow Patterns of TESI Using the Inferior-Anterior Position as the Final Needle Tip Position.|Epidural Contrast Flow Patterns of Transforaminal Epidural Steroid Injections Using the Inferior-Anterior Position as the Final Needle Tip Position.||George Washington University|Yes|Recruiting|August 2010|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|George Washington Spine and Pain Center patients.|April 2013|April 17, 2013|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01836770||67777|
NCT01837563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0605|Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer|Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Terminated|September 2006|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Female|18 Years|N/A|No|Non-Probability Sample|Women with locally-advanced breast cancer, with or without metastatic disease, meeting        inclusion criteria (and giving informed consent for participation) receiving systemic        therapy at DHMC will be enrolled. Breast size and epithelial integrity of the skin surface        can limit the ability to deliver effective imaging exams, adn these individual        characteristics need be determined in each individual patient. Women with pacemakers or        other implanted electronic devices will not be allowed into the study because of potential        for electrical interference with proper operation during an imaging session.|September 2015|September 28, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837563||67717|
NCT01837576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1016|An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris|||LEO Pharma|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||April 2013|July 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837576||67716|
NCT01838460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM WS 12|Sublingual Nicotine Tablets Compared With Swedish Snus|Elevated Dose of Sublingual Nicotine Tablets Compared With Swedish Snus. Nicotine Pharmacokinetics and Subjective Effects of Single Doses.||Contract Research Organization el AB|No|Completed|May 2012|February 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838460||67648|
NCT01838772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA010|HCV Treatment in HIV Co-Infected Patients in Asia|Effectiveness and Tolerability of Hepatitis C Treatment in HIV Co-infected Patients in Routine Care Services in Asia: A Pilot Model of Care Project||amfAR, The Foundation for AIDS Research|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|188|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01838772||67624|
NCT01837875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IQAN|Intervention to Improve Quality of Life in African American Lupus Patients|Intervention to Improve Quality of Life for African-AmericaN Lupus Patients (IQAN)|IQAN|Medical University of South Carolina|Yes|Active, not recruiting|April 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837875||67693|
NCT01837888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02687|WheelSee Feasibility Study|A Feasibility Study to Evaluate and Refine a Manual Wheelchair Training Program That is Enhanced for Self-efficacy(WheelSee): A Pilot Controlled Trial||University of British Columbia|No|Completed|November 2011|August 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837888||67692|
NCT01839058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1559-13|Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?|Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?||Queen's University|No|Active, not recruiting|October 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with non cardiac chest pain as diagnosed by cardiologist or other physician.        Healthy Volunteers will include anyone in the Kingston area who fulfils Inclusion and        Exclusion criteria.|May 2014|May 20, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01839058||67603|
NCT01839071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-077|Influence of Vasculary Inflammation on Development of Diabetes|Influence of Vasculary Inflammation on Development of Diabetes||RWTH Aachen University|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|109|||Both|18 Years|90 Years|No|||November 2013|June 24, 2014|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01839071||67602|
NCT01834859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234|Weight Loss Maintenance and Compensatory Mechanisms Activated With a Very-low Calorie Diet|How to Optimize Weight Loss Maintenance After a Very-low Calorie Diet?||Norwegian University of Science and Technology|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834859||67923|
NCT01834872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arenal - 001|Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation|Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation||Instituto de Investigación Sanitaria Gregorio Marañón|No|Active, not recruiting|September 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||June 2013|June 11, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01834872||67922|
NCT01835106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3650|Efficacy of an Epidural Versus a Fascia Iliaca Compartment Catheter After Hip Surgery|A Prospective, Randomized, Double-blind, Placebo-controlled, Crossover Trial of Epidural Analgesia Versus a Surgically-placed Fascia Iliaca Compartment Catheter for Postoperative Pain After Periacetabular Osteotomy||Children's Hospital Boston||Recruiting|April 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|15 Years|35 Years|No|||April 2013|April 17, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835106||67904|
NCT01835340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01191021|Breath Gas Measurement of Propofol During Anesthesia in Patients With Endourological Procedures|Study to Estimate Central Propofol Effect by Measuring Exhaled Propofol Concentrations in Patients||University of Luebeck|No|Recruiting|October 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 17, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01835340||67886|
NCT01835353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-13|High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)||University of Patras|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|74 Years|No|||September 2013|September 20, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01835353||67885|
NCT01835652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00276|The Effects of Exercise in Parkinson's Disease|The Effects of Exercise in Parkinson's Disease.|PET|Pacific Parkinson's Research Centre|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|40 Years|70 Years|No|||May 2015|May 8, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835652||67862|
NCT01805661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10-002|Adductor Canal Block With Posterior Capsular Injection for Total Knee Replacement|Assessment of Early Ambulation and Participation in Rehabilitation Program in Patients Receiving Continuous Adductor Canal Block With Ultrasound Guided Posterior Capsular Knee Injection vs Continuous Femoral Nerve Block With Tibial Nerve Block Following Total Knee Replacement.||Saint Francis Care|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||January 2015|March 16, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805661||70159|
NCT01816308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_DIAL-F|Cognitive Impairment in Atrial Fibrillation|Mild Cognitive Impairment (MCI) in Patients With Atrial Fibrillation (AF), Trajectories of the Progression of MCI and Factors Associated With the Progression|DIAL-F|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|July 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|888|||Both|50 Years|75 Years|No|Non-Probability Sample|Detail study information will be provided to the patients and written informed consent        will be obtained from the each patient or family member before enrolling in the study.        Consenting patients will be evaluated and the appropriate treatment strategy for managing        arrhythmia will be independently determined by the physicians at the participating        centers. Patients undergoing catheter ablation for AF will be included in the study group        and those determined to stay on AAD will form the control group.|September 2015|September 3, 2015|March 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816308|2 Years|69344|
NCT01806129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1Q11|Reproductive Health Program in Patients With Cancer|EROS: Engendering Reproductive Health Within Oncologic Survivorship||Eastern Cooperative Oncology Group||Not yet recruiting|November 2013|||November 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|612|||Female|18 Years|55 Years|No|||October 2013|October 7, 2013|February 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806129||70123|
NCT01806103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007305|Antimicrobial Stewardship for Primary Care Pediatricians|Reducing Inappropriate Prescribing of Antibiotics by Primary Care Clinicians|PARTI|Children's Hospital of Philadelphia|No|Completed|June 2010|December 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|N/A|N/A|No|||March 2013|March 5, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806103||70125|
NCT01807065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12367|Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer|Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer||City of Hope Medical Center|Yes|Active, not recruiting|June 2013|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807065||70051|
NCT01837017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMSC-2012|Project FARMS: Fall Risk Reduction in Multiple Sclerosis|Project FARMS: Fall Risk Reduction in Multiple Sclerosis|FARMS-1|University of Illinois at Urbana-Champaign|No|Completed|June 2012|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|50 Years|75 Years|No|||November 2014|November 23, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01837017||67758|
NCT01837030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00023612|Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding|Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding||Medical University of South Carolina|Yes|Recruiting|March 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||March 2013|April 17, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01837030||67757|
NCT01837316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116592|A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma|A Randomized, Double-blind, Placebo-controlled Cross-over Study to Determine the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg Combination Administered in the Morning in Adult Patients With Asthma||GlaxoSmithKline|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||September 2014|September 22, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837316||67736|
NCT01838174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06APR2012|A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis|A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis|ACTHAR|University of Texas Southwestern Medical Center|No|Recruiting|May 2013|April 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||March 2014|March 27, 2014|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838174||67670|
NCT01808105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL06|Growth and Tolerance of Infants Fed Infant Formulas|Growth and Tolerance of Young Infants Fed Infant Formulas||Abbott Nutrition|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|424|||Both|N/A|5 Days|Accepts Healthy Volunteers|||May 2014|May 30, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808105||69971|
NCT01838785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-4149A|Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects|Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects||Chang Gung Memorial Hospital|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|April 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838785||67623|
NCT01808586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2982|Facet Versus Trigger Point Injections for Chronic Neck Pain|Facet Versus Trigger Point Injection for Management of Chronic Muscular Neck Pain: A Randomized Clinical Trial and Creation of a Clinical Prediction Algorithm||Lawson Health Research Institute|No|Recruiting|May 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|43|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808586||69934|
NCT01804595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N015454-00|A Randomized Control Trial of Sun Protection Interventions for Operating Engineers|A Randomized Control Trial of Sun Protection Interventions for Operating Engineers||University of Michigan|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|357|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01804595||70241|
NCT01804855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSCUH-2013-1158|Effectiveness of a Smartphone App for Adolescent Obesity Management|An Investigation of the Clinical Effectiveness of Adolescent Weight-management Delivered Via a Portable Device||Children's University Hospital, Ireland|No|Recruiting|February 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804855||70221|
NCT01805167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-06|Electrophysiological Study of Interindividual Differences in Speech-understanding Among Cochlear Implant Patients|Electrophysiological Study of Interindividual Differences in Speech-understanding Among Cochlear Implant Patients||Centre Hospitalier Universitaire de Nice|Yes|Recruiting|February 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2013|March 5, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01805167||70197|
NCT01805154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60046199|Advance Cardiac Resynchronization Therapy (CRT) Registry|Registry That Aims to Understand the Definition Used and Treatment Options Utilized by Clinicials for CRT Non-responders||St. Jude Medical|No|Enrolling by invitation|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|HF patients with St. Jude Medical CRT devices|October 2015|October 22, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01805154|30 Months|70198|
NCT01805427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXTATIC|Antiretroviral Therapy and Extreme Weight|Extreme Weights and Antiretroviral Therapy Individual Concentrations|EXTATIC|Hopital Lariboisière|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|140|||Both|18 Years|80 Years|No|Non-Probability Sample|HIV-infected patients aged 18 years and older, treated with either efavirenz, atazanavir,        or darunavir for at least 4 weeks and under stable treatment regimen|December 2013|December 5, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805427||70177|
NCT01805921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV001|RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.|A Phase I Study to Assess Safety and Immunogenicity of a New Respiratory Syncytial Virus (RSV) Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Simian Adenovirus (PanAd3-RSV) and Modified Vaccinia Virus Ankara (MVA-RSV)||ReiThera Srl|Yes|Active, not recruiting|May 2013|September 2018|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805921||70139|
NCT01813318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-Acamprosate in Autism|Study of Acamprosate in Autism|Double-Blind Placebo-Controlled Study of Acamprosate in Autism||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|5 Years|17 Years|No|||February 2016|February 10, 2016|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813318||69572|
NCT01805869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130033|Tooth and Tissue Sample Collection During Wisdom Teeth Removal|Diagnosis and Treatment of Patients in Need of Third Molar Removal and Oral Specimen Acquisition||National Institutes of Health Clinical Center (CC)||Recruiting|November 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|16 Years|50 Years|No|||August 2015|October 28, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805869||70143|
NCT01805882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130066|Combination Therapy for Chronic Hepatitis C Infection|A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients||National Institutes of Health Clinical Center (CC)||Completed|January 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|237|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805882||70142|
NCT01816880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wellderly Immune Antibodies|Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort|Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort (HSC# 004789)||Scripps Translational Science Institute|No|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|Blood sample of approximately 20mL|Both|90 Years|N/A|No|Non-Probability Sample|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior        to enrollment in this sub-study|October 2015|October 14, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816880||69300|
NCT01806415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304126|Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers|A Double Blind, Randomized, Single Dose, Placebo Controlled Study of the Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers||Washington University School of Medicine|Yes|Completed|May 2013|September 2015|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01806415||70101|
NCT01807910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER stress|ER Stress in NAFLD|Phospholipid Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease||Vanderbilt University|No|Withdrawn|October 2013|April 2018|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|0|||Female|30 Years|60 Years|No|||October 2013|October 22, 2013|March 5, 2013|No|Yes|The study was not funded|No||https://clinicaltrials.gov/show/NCT01807910||69986|
NCT01807338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0031-002|A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease|A Follow-up Study on Safety and Tolerability and Pharmacodynamic Effect, of Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Who Have Previously Been Treated With sNN0031, Using an Implanted Catheter and a SynchroMed® II Pump||Newron Sweden AB|No|Completed|August 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|N/A||1|Actual|11|||Both|30 Years|75 Years|No|Non-Probability Sample|Patients diagnosed with idiopathic PD of moderate severity who have completed        participation in study sNN0031-001.|October 2014|October 8, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807338||70030|
NCT01837901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST_2|Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa|Transkorneale Elektrostimulation Zur Therapie Bei Retinitis Pigmentosa - Eine Prospektive, Randomisierte, Einfach Blinde Folgestudie||Okuvision GmbH|No|Completed|July 2011|February 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01837901||67691|
NCT01837342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5061|Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery|Multicenter Randomized Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery.|SIGMOIDITE|University Hospital, Strasbourg, France|Yes|Recruiting|November 2012|November 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||April 2013|April 17, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01837342||67734|
NCT01808391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPEL version 3.0 - AEEI|A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)|A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease||Associations for Establishment of Evidence in Interventions|Yes|Active, not recruiting|March 2013|September 2017|Anticipated|May 2014|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Among 1,200 patients to be registered at the website database, the first 900 continuously        registered patients will be then assigned to the clinical follow-up cohort, and the        remaining 300 patients to the routine angiographic follow-up cohort.|April 2015|April 6, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01808391|36 Months|69949|
NCT01808378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULPOFT-2010-01|Stem Cells Treatment for Bilateral Limbic Associated Keratopathy (HULPOFT)|Phase IIa Clinical Trial to Study the Feasability and Security of the Expanded Autologous Stem Cells (ASC) From Lipoaspirate in the Bilateral Limbic Associated Keratopathy Treatment|HULPOFT|Instituto de Investigación Hospital Universitario La Paz|Yes|Recruiting|February 2013|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||September 2012|March 7, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01808378||69950|
NCT01804608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL001|Kinematics of Lower Limb, Pain and Function of the Women With Patellofemoral Pain Syndrome|Kinematics of Lower Limb, Pain and Function of the Women With Patellofemoral Pain Syndrome Who Underwent Two Types Treatment: Randomized Clinical Trial||University of Nove de Julho|Yes|Completed|March 2013|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|30 Years|No|||January 2016|January 22, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01804608||70240|
NCT01804621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811285|RCT to Examine the Effects of Scanning|An RCT to Examine the Effects of Scanning; a Major Step on the Path Towards Population Intervention||University of Pennsylvania|No|Completed|April 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|15824|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||December 2012|March 4, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01804621||70239|
NCT01804868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV005|Web Tutorial Based on Case Vignettes for Teaching Literature Critical Assessment to Nursing Students|Efficacy of a Web Tutorial Based on Case Vignettes for Teaching Literature Critical Assessment to Nursing Students: a Randomized Controlled Trial||Assistance Publique - Hôpitaux de Paris|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|506|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|April 17, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804868||70220|
NCT01805180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5010|Evaluation of the Spectra Optia PMN Cell Collection Procedure|A Controlled Evaluation of the Spectra Optia® Apheresis System's Granulocyte / Polymorphonuclear (PMN) Cell Collection Procedure|PMNC|Terumo BCT|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 27, 2015|March 1, 2013|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01805180||70196|The Full Analysis Set included 32 subjects who completed both procedures of the cross-over study design presented here. Two subjects did not meet pre-defined criteria for evaluable and 30 subjects were included in the Evaluable Analysis Population.
NCT01805193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SS/0078|Myocardial Blood Flow by 15O Water PET|Validation of Computed Tomography Myocardial Perfusion Imaging Using Quantification of Myocardial Blood Flow by Positron Emission Tomography With 15O-water||University of Edinburgh|No|Recruiting|December 2012|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with suspected coronary heart disease|March 2013|March 4, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01805193||70195|
NCT01805440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Utah|Placebo-Controlled Study of Uridine for Adolescent Bipolar Depression|Placebo-Controlled Study of Uridine for Adolescent Bipolar Depression: a Magnetic Resonance Spectroscopy Study||University of Utah|Yes|Active, not recruiting|August 2013|May 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|13 Years|21 Years|No|||February 2016|February 17, 2016|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805440||70176|
NCT01805674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTROCALVI|Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women|Study to Evaluate the Changes in Quality of Life in Menopausal Women After the Administration of Soy Isoflavones Combined With Magnolia Extract|ESTROCALVI|Rottapharm Spain|No|Completed|March 2013|October 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Female|45 Years|59 Years|No|Non-Probability Sample|The study will be conducted in patients with typical mild to mderate vasomotor symptoms        and psycho symptoms such as mood changes, or sleep, anxiety / depression, which do not        require specific drug treatment.|November 2014|November 4, 2014|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01805674||70158|
NCT01806181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02504|NEXT (Nutrition and EXercise During Adjuvant Treatment) Study|Nutrition and Exercise During Adjuvant Treatment (NEXT) Study Implementation of a Physician-referred Exercise and Healthy Eating Intervention as Supportive Care in Breast Cancer Survivors|NExT|University of British Columbia|Yes|Active, not recruiting|August 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|184|||Female|19 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01806181||70119|
NCT01817127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216198|Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study|Functional Deconstruction of Human Milk Oligosaccharides and Lipids||University of California, Davis|No|Active, not recruiting|April 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|395|Samples With DNA|Breast milk, blood, saliva, urine, stool, epidermal skin cells|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women and women diagnosed with gestational diabetes mellitus or type 2        diabetes mellitus.|February 2016|February 3, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01817127||69281|
NCT01816594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120F2203|NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer|NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer|NeoPHOEBE|Novartis|Yes|Completed|September 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816594||69322|
NCT01816867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-T1-08|Laparoscopic and Open Ventral Hernia Repair Using the Intramesh T1|Laparoscopic and Open Ventral Hernia Repair Using the Intramesh T1: a Prospective, Multicenter Registry||be Medical|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a ventral hernia|May 2015|May 21, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816867|12 Months|69301|
NCT01806428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208249|Activated Protein C and Microcirculation|THE Activated Protein C (aPC) TREATMENT IMPROVES MICROCIRCULATION IN SEVERE SEPSIS/ SEPTIC SHOCK SYNDROME||Università Politecnica delle Marche|No|Completed|July 2009|August 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours        of the onset of sepsis|October 2013|October 20, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806428||70100|
NCT01806727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60LIFT|Lifestyle Intervention for Treatment of Diabetes|Lifestyle Intervention for Treatment of Diabetes|LIFT Diabetes|Wake Forest School of Medicine|Yes|Active, not recruiting|April 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|21 Years|N/A|No|||December 2014|March 27, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806727||70077|
NCT01807923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-809-103|A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|TRAFFIC|Vertex Pharmaceuticals Incorporated|Yes|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|559|||Both|12 Years|N/A|No|||June 2015|August 1, 2015|March 4, 2013|Yes|Yes||No|August 1, 2015|https://clinicaltrials.gov/show/NCT01807923||69985|
NCT01837043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-057|Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function|A Randomized Trial of Early Conversion From Calcineurin Inhibitors (CNI) to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function||Nair, Vinay, D.O.|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||April 2015|April 13, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837043||67756|
NCT01808118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-375|Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis||AbbVie|No|Active, not recruiting|May 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|740|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808118||69970|
NCT01808404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43AT006952|Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help|Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help (Phase 1)||Contextual Change LLC|Yes|Completed|February 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 27, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808404||69948|
NCT01808599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG38|This Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma|A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)||International Extranodal Lymphoma Study Group (IELSG)|No|Recruiting|December 2013|December 2025|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808599||69933|
NCT01808612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14595|A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing|A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder||Eli Lilly and Company|No|Completed|March 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|513|||Both|20 Years|N/A|No|||April 2015|April 24, 2015|March 7, 2013|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01808612||69932|
NCT01804634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12106|A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors|A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Bone Marrow Transplantation for High-risk Solid Tumors||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|40 Years|No|||March 2013|March 18, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804634||70238|
NCT01804881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0225|Effect of Managing Problematic Eating Behaviours With Dietary Management on Chronic Disease Self-management|Effect of Beyond the Fork on Chronic Disease Self-management: a Pilot RCT||University of Toronto Practice Based Research Network|No|Completed|March 2013|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|70 Years|No|||June 2014|June 4, 2014|March 2, 2013||No||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01804881||70219|Small sample size is limitation and was affected by small number recruited due to some participants declining participation due to being unable to come in for the day/time group program was offered and some participants dropped out during the study.
NCT01805206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215610|Prediction of NEC With Urinary iFABP|An Assessment of Urinary Intestinal Fatty Acid Binding Protein as a Early Predictor of Necrotizing Enterocolitis||Loma Linda University|Yes|Withdrawn|November 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|2 Days|No|||May 2015|May 13, 2015|March 4, 2013||No|PI left institution prior to receiving funding|No||https://clinicaltrials.gov/show/NCT01805206||70194|
NCT01805453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120105|Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma|Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial|ASTER|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2013|November 2016|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01805453||70175|
NCT01805687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTX 082-04-01|Single Dose Bronchodilatory Study in Asthma|A Single-Center, Open-Label, Single-Dose Evaluation of the Duration and Extent of Bronchodilation Following Administration of Zileuton CR 1200 mg in Subjects With Stable, Chronic Asthma||Cornerstone Therapeutics Inc.||Completed|March 2013|||June 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|55 Years|No|||August 2014|August 22, 2014|March 5, 2013|No|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01805687||70157|
NCT01805934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk2013-01|Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection|Quadruple Therapy With Furazolidone Versus Dual Therapy With High Doses of Amoxicillin as Rescue Regimens for Helicobacter Pylori Infection||Shanghai Jiao Tong University School of Medicine|No|Completed|May 2012|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01805934||70138|
NCT01805947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5216 POSITAG|Lifestyle Modification Program for Patients With Chronic Pain Conditions|Process-outcome-study in the Context of a Lifestyle Modification Program for Patients With Chronic Pain Conditions|POSITAG|Universität Duisburg-Essen|No|Completed|January 2013|September 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|75 Years|No|Non-Probability Sample|200 patients with pain condition admitted to the lifestyle modification program|September 2015|September 3, 2015|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01805947||70137|
NCT01806493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fasting|Fat Mass Estimation in Overweight and Obesity|Body Composition Evaluation in Overweight and Obesity||University of Roma La Sapienza|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|103|||Both|20 Years|45 Years|No|Probability Sample|Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and        less than 35 kg/m2, were eligible for the study.|March 2013|March 6, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01806493||70095|
NCT01813643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100000-068941|A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis|A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment||Central South University|Yes|Terminated|July 2012|August 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|65 Years|No|||February 2015|February 2, 2015|August 19, 2012|Yes|Yes|Effects of aripiprazole was not obvious and showed adverse reaction obviously|No||https://clinicaltrials.gov/show/NCT01813643||69547|
NCT01813656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100000-068942|An Study of Aripiprazole in the Treatment of Methamphetamine Dependence|A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence||Central South University|Yes|Terminated|September 2012|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|19 Years|65 Years|No|||February 2015|February 2, 2015|November 28, 2012|Yes|Yes|Aripiprazole arm had obvious adverse reactions,especially akathisia.|No||https://clinicaltrials.gov/show/NCT01813656||69546|
NCT01817374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-021|Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy|A Pilot Study Evaluating Quantitative Volume Contrast Enhanced Ultrasound (VCEUS) Imaging for Determining Early Breast Cancer Response to Neoadjuvant Chemotherapy||University of Alabama at Birmingham|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Female|19 Years|N/A|No|||February 2016|February 5, 2016|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817374||69262|
NCT01813604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB-RRC-PR-12028|Immunogenicity of Inactivated and Live Polio Vaccines|Phase III Clinical Trial to Assess the Immunogenicity of a Sequential Dose of Fractional Inactivated Polio Vaccine (f-IPV) and Oral Polio Vaccine (OPV)||Centers for Disease Control and Prevention|Yes|Completed|November 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|1206|||Both|6 Weeks|7 Weeks|Accepts Healthy Volunteers|||March 2013|January 7, 2014|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813604||69550|
NCT01813903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL10433|Family Welfare Pilot Intervention Study|Family Welfare Pilot Intervention Study at Finnish Welfare Clinics|HYPE|National Institute for Health and Welfare, Finland|Yes|Completed|April 2013|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813903||69527|
NCT01817101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIET|Dietary Supplement for the Prevention of Cognitive Decline in a Very Elderly Population.|Field Trial With Omega-3 Fatty Acid Supplementation for the Prevention of Cognitive Decline in a Very Elderly Population||Clinica Universidad de Navarra, Universidad de Navarra|No|Active, not recruiting|January 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|170|||Both|75 Years|N/A|Accepts Healthy Volunteers|||January 2013|July 16, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817101||69283|
NCT01813916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804039R|Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis|Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis||National Taiwan University Hospital|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|30|||Both|40 Years|75 Years|No|||March 2013|March 14, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01813916||69526|
NCT01808443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306PLA-001|Efficacy of Laser Versus Cryotherapy in the Treatment of Warts|Cryotherapy Versus Laser for the Treatment of Nongenital Cutaneous Warts: A Randomized Controlled Clinical Trial||The 306 Hospital of People's Liberation Army|Yes|Not yet recruiting|March 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808443||69945|
NCT01807611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPNK1|KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy|KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies||St. Jude Children's Research Hospital|No|Recruiting|April 2013|April 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|N/A|21 Years|No|||December 2015|December 9, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01807611||70009|
NCT01807884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMYLASPI|Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients|Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients: a Pilot Trial|AMYLASPI|University Hospital, Bordeaux|Yes|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01807884||69988|
NCT01808131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-306|Lesinurad and Allopurinol Combination Extension Study in Gout|A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol||Ardea Biosciences, Inc.|Yes|Active, not recruiting|February 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|85 Years|No|||July 2015|July 31, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808131||69969|
NCT01821612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A021101|Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer|Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|May 2013|||July 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821612||68936|
NCT01821898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27999|Eosinophilic Esophagitis Clinical Therapy Comparison Trial|Eosinophilic Esophagitis Clinical Therapy Comparison Trial||Baylor College of Medicine|No|Recruiting|March 2013|March 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|17 Years|No|||December 2015|December 16, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821898||68914|
NCT01817699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKDR-001|Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients|A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients|CANDLE-KIT|CANDLE-KIT Trial Study Group|Yes|Enrolling by invitation|April 2013|September 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|246|||Both|20 Years|79 Years|No|||February 2015|February 2, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817699||69237|
NCT01817972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-GAME01|Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease|A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathioprine in the Change in Mean SES-CD (Simple Endoscopic Scores-Crohn's Disease) Scores in the Treatment of Active, Moderate to Severe Crohn's Disease||Gastroenterology Research of America|No|Not yet recruiting|March 2013|November 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|70 Years|No|||March 2013|March 21, 2013|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817972||69216|
NCT01819363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPOT-01|Relationship Between Pleural Elastance and Effectiveness of Pleurodesis on Recurrent Malignant Pleural Effusion|Relationship Between Pleural Elastance and Effectiveness of Pleurodesis on Recurrent Malignant Pleural Effusion||Grupo de Pesquisa em Pleura e Oncologia Toracica|No|Recruiting|February 2012|January 2016|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with malignant pleural effusion diagnosed by pleural fluid cytology and / or        pleural biopsy|March 2013|March 24, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01819363||69109|
NCT01819675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1211-178-001|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding|Effect of rTMS Over Primary Motor Cortex on Gamma-aminobutyric Acid A (GABAA)-[18F]Flumazenil Binding: A Positron Emission Tomography (PET) Study||Seoul National University Bundang Hospital|No|Terminated|March 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 19, 2013||No|After doing some preliminary analysis, investigators will decide whether to go or stop.|No||https://clinicaltrials.gov/show/NCT01819675||69085|
NCT01819688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120704|Surgical Stress After Laparoscopic Compared to Open Liver Resection|Surgical Stress Induced Insulin Resistance and Cytokine Response After Laparoscopic Compared to Open Liver Resection||Sir Run Run Shaw Hospital|Yes|Completed|August 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|52|||Both|18 Years|70 Years|No|||March 2013|March 22, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01819688||69084|
NCT01819350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPM-UFPB|In Vivo Study of Sucrose and Liquid Oral Pediatric Medicines of Long-term Effect on Dental Biofilm pH|Avaliação in Vivo do Potencial cariogênico e Erosivo de Bebidas e Medicamentos pediátricos líquidos Intra-orais|SPMedicines|Federal University of Paraíba|No|Completed|August 2011|August 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||March 2013|March 24, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819350||69110|
NCT01819662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHR-CS-012-032|Optimised Pacing Program|Stratified Management of Patients With Pacemakers|OPT-pace|University of Leeds|Yes|Recruiting|August 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|2100|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819662||69086|
NCT01819909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jackins|Effectiveness Study of Postoperative Rotator Cuff Repair Rehabilitation|Prospective Randomized Trial of Rotator Cuff Repair Postoperative Rehabilitation: Jackins' Exercises Versus Pulleys||Orthopedic Institute, Sioux Falls, SD|No|Active, not recruiting|November 2008|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|December 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01819909||69067|
NCT01807130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042120|Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)|Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)|AMERICA-HF|Duke University|Yes|Terminated|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||August 2014|December 9, 2014|March 5, 2013||No|We observed a very high referral rate for patients with HF in the Duke Health System,    eliminating the need for an automated referral process.|No||https://clinicaltrials.gov/show/NCT01807130||70046|
NCT01806805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091104|Efficacy Trial of Zonisamide for Myoclonus Dystonia|Comparative Study of the Efficiency of Zonisamide in Myoclonus Dystonia: A Monocentric , Randomized in Cross Over and Double Blind Study Versus Placebo Study|EpsilonZêta|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||April 2015|April 23, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806805||70071|
NCT01807091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7910|Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome||University of Washington|No|Recruiting|May 2013|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807091||70049|
NCT01807104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091819|Total Hip Arthroplasty (THA) Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach|Prospective Randomized Single Center Clinical Evaluation of THA Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach||Barrett, William, M.D.|No|Active, not recruiting|January 2010|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01807104||70048|
NCT01819012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160052|Effect of Isoflurane on Tissue Doppler Imaging of Mitral Annulus During Cardiac Surgery|Effect of Isoflurane on Tissue Doppler Imaging of Mitral Annulus During Cardiac Surgery||Konkuk University Medical Center|Yes|Completed|March 2013|March 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|65 Years|No|||March 2015|March 19, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819012||69136|
NCT01819285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30891|Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer|Phase III Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH Agonist Therapy) in Previously Untreated Patients With Nonmetastatic Asymptomatic Carcinoma of the Prostate||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1990|September 2010|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|985|||Male|N/A|80 Years|No|||March 2013|March 22, 2013|March 18, 2013||||No||https://clinicaltrials.gov/show/NCT01819285||69115|
NCT01819558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-WT1/IPC 2011-006|Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy|Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches|ALLO-WT1|Institut Paoli-Calmettes|Yes|Completed|March 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01819558||69094|
NCT01821027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015511|A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers|A Open-Label, Single Sequence Study to Assess the Pharmacokinetics and Pharmacodynamics of Simvastatin Alone and of Simvastatin in Combination With JNJ-28431754 in Healthy Adult Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821027||68981|
NCT01821911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-5|The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use|Phase 4 Study of Speeda® Rabies Vaccine for Human Use||Beijing Center for Disease Control and Prevention|No|Completed|July 2012|December 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10500|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|January 19, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821911||68913|
NCT01817712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|589|Veterans Individual Placement and Support Towards Advancing Recovery|CSP #589 - Veterans Individual Placement and Support Towards Advancing Recovery|VIP-STAR|VA Office of Research and Development|Yes|Active, not recruiting|December 2013|October 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|541|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817712||69236|
NCT01818011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116266|A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects|A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects||GlaxoSmithKline|No|Terminated|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|February 14, 2013|No|Yes|Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not    seen that changed the risk: benefit profile and led to a termination|No||https://clinicaltrials.gov/show/NCT01818011||69213|
NCT01818297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1666|Subcutaneous Nerve Stimulation for Failed Back Surgery Syndrome (FBSS) Patients|SubQStim Pivotal Study: A Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Nerve Stimulation. Protocol 1666|SubQStim|MedtronicNeuro|No|Suspended|April 2013|March 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|22 Years|N/A|No|||March 2016|March 1, 2016|March 21, 2013|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01818297||69191|
NCT01818817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarGal2|Ultrasound Paravertebral Block in Breast Surgery.|Single Injection, Ultrasound Guided Paravertebral Block for Anesthesia in Breast Surgery.||Campus Bio-Medico University|Yes|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|20|||Female|18 Years|90 Years|No|Non-Probability Sample|Patient candidate for minor breast surgery.|September 2011|March 23, 2013|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01818817||69151|
NCT01818557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0719|Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes|Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes: A Randomized, Non-Inferiority Pilot Study|GLIMPSE|The University of Texas Health Science Center, Houston|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|286|||Female|18 Years|55 Years|No|||June 2015|June 18, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818557||69171|
NCT01818570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AROS-002|A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus|A Single-center, Randomized, Double-blind, Cross-over Trial in Healthy Volunteers Investigating the Local Efficacy and Safety of a Single Intra-luminal Administration of PPC-5650 on Reflux Pain and Hyperalgesia During Multimodal Stimulation of the Esophagus||Aalborg Universitetshospital|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01818570||69170|
NCT01818830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGHHN2013001|Amino Acids Expression Profiling of Patients With Sepsis|Amino Acids Expression Profiling of Patients With Sepsis||Chinese PLA General Hospital|Yes|Active, not recruiting|March 2012|||May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The inpatients were included who were in the intensive care units (ICU) of the Department        of Respiratory Disease, the Emergency Department, and the Department of Surgery of the        Chinese People's Liberation Army General Hospital from March 2012.|March 2013|March 23, 2013|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01818830||69150|
NCT01819116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-020|Organ Donor Tissue Oxygen Saturation as a Predictor of Number of Organs to Transplant Per Donor|Tissue Oxygen Saturation During Management of the Deceased by Neurological Criteria Organ Donor as a Predictor of Number of Organs to Transplant Per Donor||The Cleveland Clinic|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|15 Years|N/A|No|Non-Probability Sample|DNC Organ Donor managed by Lifebanc|March 2014|January 26, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01819116||69128|
NCT01819129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3853|Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes|Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes|onset® 2|Novo Nordisk A/S|No|Completed|September 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|881|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819129||69127|
NCT01819922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731008|Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Assess The Effect Of PF-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects||Pfizer|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|February 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01819922||69066|
NCT01820208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS- AH-01|Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis|Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial.||Institute of Liver and Biliary Sciences, India|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820208||69044|
NCT01820221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138350|Sutures vs. Staples Skin Closure After C-section in Obese Patients|Staples Compared With Subcuticular Suture for Skin Closure After Cesarean Delivery in Obese Patients||University of Arkansas|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2250|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820221||69043|
NCT01820494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJ85|Nutritional Management of Infants With Chronic Diarrhea|Nutritional Management of Infants With Chronic Diarrhea||Abbott Nutrition|No|Completed|October 2000|November 2002|Actual|November 2002|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|N/A|12 Months|No|||March 2013|March 27, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820494||69022|
NCT01820507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 12/85|Extubation Failure Prevention in High Risk Patients by High-flow Conditioned Oxygen Therapy vs. Standard Oxygen Therapy|Prevention of Post-extubation Respiratory Failure in High Risk Patients by High-flow Conditioned Oxygen Therapy Versus Standard Oxygen Therapy||Althaia Xarxa Assistencial Universitària de Manresa|No|Terminated|March 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|95 Years|No|||January 2015|January 29, 2015|March 26, 2013||No|Slow recruitment, interim analysis|No||https://clinicaltrials.gov/show/NCT01820507||69021|
NCT01807689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS Biomarker Development Study|Salivary Biomarkers for Sjögren's Syndrome Detection|Salivary Biomarkers for Sjögren's Syndrome Detection - A Multi-Center Study||University of California, Los Angeles|Yes|Enrolling by invitation|April 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|420|Samples With DNA|Saliva|Both|18 Years|N/A|No|Probability Sample|All enrolled subjects must be classified as having both oral and ocular sicca symptoms,        without another autoimmune/connective tissue disease. All enrolled subjects, who are also        being evaluated as part of their clinical care, using the standard diagnostic tests of the        AECG criteria of 2002, will meet the ARC criteria.|December 2015|December 3, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01807689||70003|
NCT01807117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8212|PET-MRI in Diagnosing Patients With Colon or Rectal Cancer|Evaluation of PET-MRI in Initial Staging of High Grade Rectal Cancer Patients and in the Follow up of Colorectal Cancer Patients.||Case Comprehensive Cancer Center|Yes|Completed|April 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|22 Years|N/A|No|||November 2015|November 25, 2015|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807117||70047|
NCT01807377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731021|Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects|A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects||Pfizer|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01807377||70027|
NCT01819298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH - 2011 - C25|Bacterial Colonization in COPD in View of CAT Under ICS+LABA Therapy|The Influence on Airway Bacteria Colonization in Chronic Obstructive Pulmonary Disease by the Combination of Inhaled Corticosteroid and Long-acting β2 Agonist||Far Eastern Memorial Hospital|Yes|Completed|March 2011|June 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|17|||Both|20 Years|N/A|No|Probability Sample|COPD under ICS+LABA combination therapy and FEV1<80% and FEV1/FVC<70%|March 2013|March 22, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819298||69114|
NCT01819597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS079477-01A1|Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis|EDAS (Surgical) Revascularization for Symptomatic Intracranial Arterial Stenosis|ERSIAS|University of California, Los Angeles|Yes|Recruiting|March 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|30 Years|80 Years|No|||December 2014|December 1, 2014|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819597||69091|
NCT01821053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-1-13|Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus|Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus||Odense University Hospital|Yes|Completed|June 2013|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|Samples With DNA|whole blood serum plasma urine|Female|18 Years|45 Years|No|Probability Sample|pregnant women with pregestational type 1 diabtes are included when they show up for their        first outpatient pregnancy visit around the 9th weeks gestation.|October 2014|October 15, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821053||68979|
NCT01821352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_OL_001|Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia Obesity Laser on the Reduction of Circumference of the Hips, Waist and Upper Abdomen for Individuals With a Body Mass Index (BMI) of 30 to 40 kg/m2||Erchonia Corporation|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 7, 2015|March 27, 2013|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01821352||68956|
NCT01820117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIGHT|Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation|Brain Integrity in Survivors of Hodgkin Lymphoma (HL) Treated With Thoracic Radiation||St. Jude Children's Research Hospital|No|Recruiting|March 2013|April 2019|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|392|Samples Without DNA|Blood (5 ml) will be collected, frozen and stored for future serum biomarker assays.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|SJLIFE is an institutional initiative to establish a lifetime survivor cohort to study        physical and behavioral health outcomes in adult survivors of childhood cancer. This        protocol includes individuals diagnosed and treated with a malignancy during childhood at        SJCRH since 1962, who are now 10 or more years from diagnosis and over 18 years of age.        The current study will recruit participants from the SJLIFE cohort who received thoracic        radiation as part of their treatment for Hodgkin lymphoma.        Potentially eligible comparison group participants will be recruited from the relative or        friend population who accompany any After Completion of Therapy (ACT) or SJLIFE patient        for follow-up at SJCRH.|September 2015|September 28, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820117||69051|
NCT01820130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-12-047-FR-SC|Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure|Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure|TAME-HF|St. Jude Medical|Yes|Withdrawn|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|February 22, 2013||No|end of inclusion period without patient enrolled|No||https://clinicaltrials.gov/show/NCT01820130||69050|
NCT01821326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk0831|Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding|Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding||Shanghai Jiao Tong University School of Medicine||Completed|June 2002|||January 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|339|||Both|18 Years|89 Years|No|Probability Sample|Patients who underwent CE in Shanghai Renji Hospital ( China )from June 2002 to January        2012 for OGIB|March 2013|March 29, 2013|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01821326||68958|
NCT01818024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116343|A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers|A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|11||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01818024||69212|
NCT01818310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-T2DM-CLI|Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia|Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)|DIALEG|University Hospital Ostrava|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01818310||69190|
NCT01818583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK-01|Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter|Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter||Diakonhjemmet Hospital|Yes|Recruiting|March 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01818583||69169|
NCT01818843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DapingH 021|The Safety and Adverse Reaction Study of Neonatal to Inhaled Carbon Monoxide|Phase 1 Study of Inhaled Carbon Monoxide on the Effectiveness of Neonatal Pulmonary Hypertension|CO|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Enrolling by invitation|April 2012|December 2013|Anticipated|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|1 Month|Accepts Healthy Volunteers|||April 2012|March 26, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01818843||69149|
NCT01819142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM004|AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers||Cytomedix|Yes|Active, not recruiting|April 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01819142||69126|
NCT01819389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE12-019|Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance|Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|October 2012|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|October 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01819389||69107|
NCT01819402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO FAT|Pioglitazone Decreases Visceral Fat Metabolism|Effects of Pioglitazone on Visceral Fat Metabolic Activity||Kurume University|Yes|Recruiting|March 2012|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|58 Years|Accepts Healthy Volunteers|||March 2013|March 24, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819402||69106|
NCT01819714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP/2012/JD|Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease|Evaluation of the Impact of Care Based on Sensory Support for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease|SensiCare|Centre Hospitalier Universitaire de Nīmes|No|Completed|June 2013|February 2015|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01819714||69082|
NCT01819727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-301|An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165|A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety & Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165|Prism301|BioMarin Pharmaceutical|Yes|Completed|May 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||November 2015|November 25, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819727||69081|
NCT01819376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOBFB|Use of Facebook as a Motivating Factor in a Weight-reduction Program for Obese and Overweight Adolescents|Use of Facebook as a Motivating Factor in a Weight-reduction Program for Obese and Overweight Adolescents.||Hospital San Jose Tec de Monterrey|No|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|26|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819376||69108|
NCT01819701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF11263|L-carnitine and Coenzyme Q10 in Relation to the Oxidative Stress, Antioxidant Enzymes Activities, Inflammation, and the Risk of Coronary Artery Disease|||Taichung Veterans General Hospital|Yes|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|47|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01819701||69083|
NCT01819935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951163|Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia|Clinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin||Pfizer|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|5271|||Both|18 Years|90 Years|No|Non-Probability Sample|National database of inpatient admissions between January 1, 2002 and Septmeber 30, 2010|December 2013|December 12, 2013|February 28, 2013|No|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01819935||69065|Results for 'time to intubation' was reported and not 'time to extubation' due to change in planned analysis.
NCT01819948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phytomed|Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™|Pilot Clinical Trial to Assess Changes in Biomarkers of Cancer Related to Inflammation in Women With Stage 0-IIIA Breast Cancer and Without Evidence of Disease Who Were Given the PhytoMed™ Complement.||Phytogen Medical Foods S.L.|No|Completed|June 2012|||December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01819948||69064|
NCT01820234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201018315-1|Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event|Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event||University of California, Davis|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 25, 2013|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01820234||69042|
NCT01807988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/488|Internetbased Relapse Prevention for Partially Remitted Depression|Regional Study of Internet-based Relapse Prevention as an Adjunct to Partially Successful Antidepressant Medication|ISAK|Örebro County Council|No|Recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|264|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807988||69980|
NCT01807390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120321-01H|Perspectives of Receiving Open Versus Minimally Invasive Surgery|Perspectives for Receiving Open Versus MIS (PROMIS) - Patients' Perspectives on Surgical Treatment of Lung and Esophageal Cancer|PROMIS|Ottawa Hospital Research Institute|No|Recruiting|July 2012|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at the Ottawa Hospital General Campus who are surgical candidates for lung or        esophageal cancer over the age of 18.|July 2015|July 29, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01807390||70026|
NCT01807403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081203|Comparison of DBS Targets in Obsessive-compulsive Disorder|Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder.|PRESTOC2|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|October 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|60 Years|No|||April 2015|April 27, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01807403||70025|
NCT01807676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0520|Prospective, Randomized Clinical Trial Evaluating the ETView Double-Lumen Tube|Prospective, Randomized Clinical Trial Evaluating the ETView Double-Lumen Tube||University of Zurich||Completed|March 2013|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||April 2014|April 25, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807676||70004|
NCT01807936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2VS3E|Esophagectomy:Three-field Versus Two-field Lymphadenectomy|A Phase Ⅲ Study of Three-field Versus Two-field Lymphadenectomy For Middle or Lower Third Intrathoracic Esophageal Cancer||Fudan University|No|Recruiting|February 2013|December 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807936||69984|
NCT01819610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1SPR11001|Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures|A Single Arm, Open Label Study to Compare the Pharmacokinetics, Safety, and Efficacy of SPRIX (Intranasal Ketorolac Tromethamine) in 12 to 17 Year Old Patients vs. Adult Patients (18-64 Years) Undergoing Open Surgical Procedures||Luitpold Pharmaceuticals|Yes|Completed|February 2013|August 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|12 Years|64 Years|No|||July 2015|July 6, 2015|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819610||69090|
NCT01819844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000993|Inpatient Closed-loop Glucose Control|Subcutaneous Continuous Glucose Monitoring and Intravenous Dosing of Insulin and Dextrose for Automated Glycemic Control in the Inpatient Setting||Massachusetts General Hospital|Yes|Active, not recruiting|March 2013|October 2015|Anticipated|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|80 Years|No|||September 2015|September 10, 2015|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819844||69072|
NCT01821924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000643|Role of Stress Cardiac MRI in Predicting Adverse Clinical Events in Patients With Known or Suspected Ischemic Heart Disease|||Brigham and Women's Hospital||Active, not recruiting|January 2012|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|21 Years|N/A|No|Non-Probability Sample|Patients above the age of 21 who are clinically referred for stress cardiac MRI.|March 2013|March 29, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821924||68912|
NCT01821937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.52|Pharmacokinetics of Faldaprevir of Soft Capsule|Pharmacokinetics of Single and Multiple Oral Doses of 120 mg and 240 mg BI 201335 in Healthy Chinese Volunteers||Boehringer Ingelheim||Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|March 25, 2013||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01821937||68911|
NCT01821339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043568|Pelvic Ring Injury|Does Residual Displacement On Standard Radiographic Views Correlate With Pelvic Ring Injury Clinical Outcome?||Duke University|Yes|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Urgent care patients. Patients coming to the ER with a Pelvic ring Fx|January 2015|October 15, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821339||68957|
NCT01818037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002|Long-term Postoperative Outcomes After Bilateral Congenital Cataract Surgery in Eyes With Microphthalmos|A Long-term Postoperative Outcome After Bilateral Congenital Cataract Surgery in Eyes With Microphthalmos||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2003|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|1 Month|24 Months|No|Non-Probability Sample|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract        surgery between January 2003 and June 2008.|March 2013|March 25, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818037||69211|
NCT01818323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001654-25|Phase I Trial: T4 Immunotherapy of Head and Neck Cancer|Phase I Trial: T4 Immunotherapy of Head and Neck Cancer||King's College London|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01818323||69189|
NCT01818336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQ-2010-001|Evaluation of Skin Testing Reagents for Penicillin Allergy|Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral Challenge With Amoxicillin||AllerQuest LLC|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|481|||Both|2 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 10, 2013|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818336||69188|
NCT01819987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HomeTech healthy lifestyle|HomeTech Healthy Lifestyle Program for Mothers With Young Children|Home-based & Technology-centered Childhood Obesity Prevention for Mothers With Young Children||University of California, San Francisco|No|Active, not recruiting|January 2014|March 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 14, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819987||69061|
NCT01811784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-12053|Community Intervention to Prevent Nipah Spillover|A Community Intervention Trial Utilizing Behavior Change to Reduce the Risk of Nipah Spillover Through Date Palm Sap in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|7752|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||July 2012|March 24, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811784||69689|
NCT01820572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-116|A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based|Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression||Bristol-Myers Squibb|No|Recruiting|March 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820572||69016|
NCT01820585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-210|Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia|Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia: a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|528|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|March 26, 2013||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01820585||69015|
NCT01819961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fo-Lap|Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery|Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery||Sir Run Run Shaw Hospital|No|Not yet recruiting|April 2013|December 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|85 Years|No|||March 2013|March 27, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01819961||69063|
NCT01819974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERIS2|Effect of Medication Reviews Performed in High Risk Patients|Effect of Medication Reviews in Hospitalized High-risk Patients - a Randomised Controlled Trial||University of Aarhus|No|Recruiting|April 2013|May 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 27, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819974||69062|
NCT01820546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR06|Cancer Stem Cells in Multiple Myeloma|Flow Cytometric Definition and Prognostic Effects of Multiple Myeloma Cancer Stem Cells||Ankara University|No|Completed|January 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|Samples With DNA|Bone Marrow|Both|18 Years|N/A|No|Non-Probability Sample|New Diagnosed or Relapsed Multiple Myeloma Patients|January 2016|January 4, 2016|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820546||69018|
NCT01820559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-209|Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine|Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine: a Doubleblind,Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|April 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|452|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 26, 2013||No||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01820559||69017|
NCT01820845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVI2013|Accuracy of Pleth Variability Index (PVI) in Children|Accuracy of Pleth Variability Index (PVI) in Predicting Response to Intravenous Fluid Load During Scoliosis Surgery in Children|PVI|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2012|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|2 Years|18 Years|No|Probability Sample|Children undergoing scoliosis surgery|December 2012|December 3, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01820845||68995|
NCT01820858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-GYN/EC-01|The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma|A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma|EC-01|Huazhong University of Science and Technology|Yes|Recruiting|November 2012|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|65 Years|No|||March 2013|March 26, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01820858||68994|
NCT01808482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116702|A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis||GlaxoSmithKline|Yes|Terminated|March 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|September 17, 2015|March 7, 2013||No|GSK confirmed misrepresentation of preclinical data that supported the rationale for    GSK2618960 in MS. This decreased benefit assessment for MS|No||https://clinicaltrials.gov/show/NCT01808482||69942|
NCT01807949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-809-104|A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|TRANSPORT|Vertex Pharmaceuticals Incorporated|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|563|||Both|12 Years|65 Years|No|||September 2015|September 2, 2015|March 4, 2013|Yes|Yes||No|August 1, 2015|https://clinicaltrials.gov/show/NCT01807949||69983|
NCT01807962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10-213|Local Injection Under US Control in GTPS.|A Randomised Double Blind Controlled Trial of Injection of Local Anaesthetic and Corticosteroid Under Ultrasound Control in the Greater Trochanteric Pain Syndrome.||University Hospital, Geneva|Yes|Recruiting|November 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01807962||69982|
NCT01808196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0106|Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD|A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|5 Years|21 Years|No|||December 2015|December 7, 2015|January 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808196||69964|
NCT01808209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-40|Clinical Performance of Stenfilcon A Versus Filcon II 3|Clinical Performance of Stenfilcon A Versus Filcon II 3||Coopervision, Inc.|No|Completed|January 2013|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|February 14, 2013||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT01808209||69963|
NCT01808469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0101-01_|First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers|A Randomized, Double Blind, Placebo-controlled, Pharmacokinetics/Pharmacodynamics-guided, Phase I Study in Healthy Volunteers Given Escalating, Single Intravenous Doses of NI-0101 in the Absence and Then in the Presence of a Systemic Lipopolysaccharide Challenge.|NI-0101-01|NovImmune SA|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01808469||69943|
NCT01820143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-P104-099|Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety|A Phase 1, Randomized, Open-Label, Four-Period Crossover, Multiple-Dose, Single-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety Following Administration of Oral Doses of 10, 20 and 40 mg of Ilaprazole and 40 mg of Esomeprazole in Healthy Subjects||Il-Yang Pharm. Co., Ltd.|No|Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2005|March 25, 2013|March 25, 2013||||||https://clinicaltrials.gov/show/NCT01820143||69049|
NCT01820156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090212TNHRP|Diagnosis of Patients With Low or Intermediate Suspicion of SAHS or With Comorbidity: Standard Laboratory Polysomnography Compared With Three Nights of Home Respiratory Polygraphy.|Diagnosis, Cost and Therapeutic Decision-Making of Home Respiratory Polygraphy for Patients Without High Suspicion of OSA or With Comorbidity - Hospital Polysomnography in Comparison With Three Nights of Home Respiratory Polygraphy||Hospital Clinic of Barcelona||Completed|February 2012|June 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|56|||Both|18 Years|75 Years|No|||September 2013|March 23, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01820156||69048|
NCT01820442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1006|Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects||US WorldMeds LLC|No|Completed|March 2013|January 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||July 2014|July 29, 2014|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820442||69026|
NCT01820767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENPARIC-2011-01|Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients|Paricalcitol Action on Parameters of Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease Stage Vd Carriers Tunneled Hemodialysis Catheters|SENPARIC|Hospital El Bierzo|No|Completed|August 2012|March 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820767||69001|
NCT01821950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P002600B|Evaluation of Yoga for Substance Use Risk Factors in a School Setting|Evaluation of Yoga for Substance Use Risk Factors in a School Setting||Brigham and Women's Hospital|No|Active, not recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|283|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01821950||68910|
NCT01821625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032013-020|Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C|Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C|SQUELCH-C|University of Texas Southwestern Medical Center|No|Recruiting|April 2013|||April 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2013|August 15, 2013|March 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821625||68935|
NCT01818050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21604|Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaduct™)|Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaduct™)||Stanford University|Yes|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818050||69210|
NCT01818349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSC-44059|Impact of Training on Gait and Strength in Stroke Survivors|Gait Performance and Lower-limb Muscle Strength Improved in Both Upper-limb and Lower-limb Isokinetic Training Programs in Individuals With Chronic Stroke||Université de Montréal|No|Completed|March 2002|December 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01818349||69187|
NCT01819740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT/URO/2013/PROSTATE|Analysis of a New Biomarker for Prostate Cancer Diagnosis||HEM|Corporacion Parc Tauli||Not yet recruiting|April 2013|||April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|||Male|45 Years|75 Years|No|Non-Probability Sample|Men with clinical or laboratory suspected of prostate cancer attends in Parc Tauli        Universitary Hospital.|March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01819740||69080|
NCT01811537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-01-149-17122-59685|Safety and Efficacy Study of a New Device for Making Neochordae in Mitral Valve Repair|Phase II Study of Using a New Device (Neochordameter) in Making Artificial Chordae for Mitral Valve Repair||Tehran University of Medical Sciences|Yes|Enrolling by invitation|August 2012|August 2014|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||March 2013|March 12, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811537||69708|
NCT01811238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN12-KR-401|An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of TARGIN(R) (Oxycodone/Naloxone) in Korean Patients With Spinal Disorders|TALENT|Mundipharma Pte Ltd.|No|Recruiting|September 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|237|||Both|20 Years|80 Years|No|||March 2013|March 12, 2013|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01811238||69731|
NCT01811550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11110979|Study of Procoagulation Markers in Stroke Patients|Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)|I-SPOT|Temple University|Yes|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|315|Samples With DNA|Whole blood and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be selected from participants in the SHINE trial.|August 2015|August 24, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811550||69707|
NCT01820247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IT1|Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission|Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission||Jinling Hospital, China|No|Recruiting|December 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|75 Years|No|||March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820247||69041|
NCT01820260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0105-1012|Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis||LEO Pharma|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|315|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820260||69040|
NCT01820273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRD-Study|Changes in Incretine Response and Glycemic Control After Gastric Bypass Surgery in Type 2 Diabetic Patients Versus Healthy|Study of Incretine Response and Glycemic Control: Pre Diet, After Conventional Weight Loss and in the Early Postoperative Phase After Gastric Bypass in T2D-patients.||Lund University|No|Recruiting|April 2013|August 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Bloodsamples|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|female obese (BMI>35)patients accepted for bariatric surgery (lap gastric bypass). 10        patients with type 2 diabetes(T2D) 6 10 matched controls without T2D.|September 2013|September 23, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820273||69039|
NCT01812356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11-088|The Concomitant Cryomaze Procedure Using Nitreous Oxide Cryoprobe: Comparison With Argon Based Cryoprobe|Study of Cryomaze Procedure Using Nitrous Oxide Versus Argon Gas||Samsung Medical Center||Recruiting|March 2013|March 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|70 Years|No|||March 2013|May 18, 2015|March 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01812356||69645|
NCT01812369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/119/HP|Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer|Randomized Phase III Study of Gemcitabine/Cisplatine (GC) Versus High-dose Intensity Methotrexate, Vinblastine, Doxorubicine and Cisplatin (HD-MVAC) in the Perioperative Setting for Patients With Locally Advanced Transitional Cell Cancer of the Bladder|VESPER|University Hospital, Rouen|Yes|Recruiting|March 2013|August 2021|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||September 2015|September 28, 2015|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01812369||69644|
NCT01820871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-DM|Self-Management Using Smartphone Application for Type2 DM in Real siTuation (SMART-DM)|A Pilot Study of Self Management Using Application for Chronic Disease Care in Real siTuation (SMART) - DM||Inje University|No|Completed|November 2012|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|69 Years|No|||November 2013|November 26, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820871||68993|
NCT01821157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP/611|Flapless Esthetic Crown Lengthening for the Treatment of Excessive Gingival Display|Open-flap Versus Flapless Esthetic Crown Lengthening: 12-month Clinical Outcomes of a Randomized Controlled Clinical Trial||University of Guarulhos|Yes|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|21 Years|35 Years|No|||March 2013|March 29, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821157||68971|
NCT01808248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0151|Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3|A Phase 2, Open-Label Study of Sofosbuvir in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3||Gilead Sciences|No|Completed|February 2013|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|March 1, 2013|Yes|Yes||Yes|September 5, 2014|https://clinicaltrials.gov/show/NCT01808248||69960|
NCT01808495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-101002-F|Function and Modulation of Fibulin-1 Assembly in Nucleus of Corneal Fibroblasts|||Far Eastern Memorial Hospital|Yes|Active, not recruiting|August 2012|August 2015|Anticipated|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5|||Both|20 Years|N/A|No|Non-Probability Sample|The original cell sources were collected from the donors with more than 20 years old        following penetrating keratoplasty. After successfully amplified from the residual corneal        rim following penetrating keratoplasty in the previous projects, human corneal fibroblasts        (HCFs) were reserved in liquid nitrogen tank and were thawed for this study under in vitro        cultivation and application.|August 2015|August 10, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01808495||69941|
NCT01808742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0602|Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device|A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines Utilizing Optimized Algorithms With the Cryo-Touch III Device||MyoScience, Inc|No|Completed|November 2012|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects, male or female, age 30 - 65 with forehead and/or glabellar lines deemed        significant per protocol inclusion criteria.|March 2015|March 23, 2015|March 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01808742||69922|
NCT01808222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061518|FACBC for Recurrent Prostate Cancer|Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence||Emory University|Yes|Active, not recruiting|November 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Male|18 Years|99 Years|No|||January 2016|January 14, 2016|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808222||69962|
NCT01808716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UFRN 176/10|Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage|Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage: Randomized Double-blind Placebo-controlled Study||Universidade Federal de Sao Carlos||Completed|February 2011|June 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Male|25 Years|35 Years|No|||March 2013|March 7, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01808716||69924|
NCT01804712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121451|Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy|A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy||University of California, San Diego|Yes|Recruiting|July 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||August 2015|August 21, 2015|March 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804712||70232|
NCT01820455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI-TRA-10-020|MRSA in a Trauma Population: Does Decolonization Prevent Infection?|Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection?||University of Tennessee|No|Completed|January 2012|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01820455||69025|
NCT01820780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110128|Early Care After Discharge of HF Patients|Usefulness of a Short-time But Very Early Specialized Follow-up After Hospitalization for Acute Heart Failure: a Randomized Controlled Trial.|ECAD-HF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|534|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820780||69000|
NCT01821040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOD3501|A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR|A Randomised, Multi-centre, Double-blind, Active-controlled, Parallel Group Study to Assess the Efficacy and Safety of Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR) in Subjects Suffering From Polymyalgia Rheumatica (PMR).||Mundipharma Research Limited|No|Terminated|March 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|50 Years|N/A|No|||April 2015|April 9, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01821040||68980|
NCT01821963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0977|Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)|Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation||M.D. Anderson Cancer Center|No|Terminated|April 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|69 Years|No|||February 2015|February 23, 2015|March 27, 2013|Yes|Yes|Low referral rate due to new therapeutic options.|No|February 23, 2015|https://clinicaltrials.gov/show/NCT01821963||68909|
NCT01817725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangGungMH 101-3594A3|Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study|||Chang Gung Memorial Hospital|Yes|Active, not recruiting|March 2013|February 2016|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|80 Years|No|||February 2015|February 3, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817725||69235|
NCT01819415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR-10059|Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD|||Maisonneuve-Rosemont Hospital|No|Completed|February 2011|February 2013|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|50 Years|N/A|No|||April 2013|April 28, 2013|March 24, 2013|Yes|Yes||No|April 28, 2013|https://clinicaltrials.gov/show/NCT01819415||69105|
NCT01819428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV120101-201|NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma|A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations||National OncoVenture|No|Terminated|March 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|March 14, 2013||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01819428||69104|
NCT01811225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS018|Smoking, Sex Hormones, and Pregnancy|Smoking, Sex Hormones, and Pregnancy||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|204|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01811225||69732|
NCT01811004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-GS-HH01|Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis|||Cynosure, Inc.|No|Completed|September 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01811004||69749|
NCT01811251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0132|Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery|Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery|DEXA-PG-HD|University Hospital, Clermont-Ferrand||Not yet recruiting|March 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|85 Years|No|||March 2013|March 12, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01811251||69730|
NCT01811563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043737|Total Knee Arthroplasty: Functional and Clinical Outcomes|Clinical and Functional Outcomes Following Total Knee Replacement Using Two Different Implants||Duke University|Yes|Active, not recruiting|February 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|85 Years|No|||February 2016|February 9, 2016|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811563||69706|
NCT01811576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1106-GHD-201|Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency|A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency||Teva Pharmaceutical Industries|Yes|Completed|March 2013|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|23 Years|65 Years|No|||February 2016|February 26, 2016|March 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01811576||69705|
NCT01812070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7957|Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)|Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Randomized Trial||Fred Hutchinson Cancer Research Center|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812070||69667|
NCT01812083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SelcukU|Interleukin-1 Receptor Antagonist Gene Polymorphism and Adverse Pregnancy Outcome in Turkish Women|Interleukin-1 Receptor Antagonist Gene Polymorphism and Adverse Pregnancy Outcome in Turkish Women|IRAGPAAOITW|Selcuk University|Yes|Completed|January 2004|February 2005|Actual|June 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|156|Samples With DNA|Whole blood|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women between 18-35 years of age with single gestation and with ≥20 on-crowded        teeth excluding third molars were included in this study. Subjects were divided into        normal birth (NB) and PLBW groups on the basis of their pregnancy outcome. Women who        delivered an infant with a birth weight of more than 2500 g after 37 weeks of gestation        were placed in the NB group. Women who delivered infants whose birth weight was below 2500        g or before 37 weeks of gestation were placed in the PLBW group.|March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812083||69666|
NCT01812616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA1208 Part B|A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients|A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma||GW Research Ltd|No|Active, not recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812616||69626|
NCT01812629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH72|Nutritional Management of Children With Chronic Diarrhea|Clinical Management of Children With Chronic Diarrhea||Abbott Nutrition|No|Completed|July 1997|June 1999|Actual|June 1999|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|9 Months|No|||March 2013|March 14, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812629||69625|
NCT01812876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009ZX09502-030-01|A Registry Study on Shenqifuzheng（a Chinese Medicine Injection）Used in Hospitals in China|A Registry Study on Shenqifuzheng（a Chinese Medicine Injection）Used in Hospitals in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|None Retained|Eligibility criteria Patients who will use Shenqifuzheng injection in selected hospitals.|Both|18 Years|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 30000 Patients using        Shenqifuzheng injection from 2013 to 2014 in more than 30 hospitals.|April 2013|April 15, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812876|14 Days|69606|
NCT01812889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0077|Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463|A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2013|May 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01812889||69605|
NCT01835028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-57745|Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study)|Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study Phase III)||Laval University|No|Recruiting|June 2002|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|320|Samples Without DNA|Blood sample (lithium-heparin, EDTA), Tissue (explanted aortic valves)|Both|21 Years|90 Years|No|Probability Sample|patients with moderate to severe aortic stenosis and Low Fow Low Gradiwnt , with Low and        preserved Ejection Fraction wil be selected at primary care clinic|October 2015|October 30, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835028||67910|
NCT01835236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 22/10|Trastuzumab & Pertuzumab Followed by T-DM1 in MBC|A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|July 2013|November 2019|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01835236||67894|
NCT01835249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303M30341|Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure - an Ancillary Study to SPRINT|Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure||University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|June 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|600|||Both|55 Months|N/A|No|||September 2015|September 25, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835249||67893|
NCT01808729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1601|CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium|The CAUSE Trial: Genomics of Extreme Trait-Coronary Artery Disease Cells and Fibromuscular Dysplasia Using Induced Pluripotent Stem Cell-Derived Endothelial Cells||Icahn School of Medicine at Mount Sinai|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|34|Samples With DNA|DNA from leukocytes, plasma, fibroblasts and fibroblast-derived cell lines|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible subjects will be recruited from the clinical care areas of Mount Sinai Hospital,        including outpatient clinics and the catheterization laboratory. Subjects will either have        a confirmed diagnosis of FMD, early onset CAD, or other rare vascular disease as outlined        above. Healthy controls will also be selected as age- and gender- matched persons without        these disorders, ideally healthy related siblings if available.|November 2013|November 4, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808729||69923|
NCT01804725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0284|Study of Bicycle Seat Effects on Male Perineal Blood Flow|Phase 1: To Compare Perineal Artery Occlusion in Road and Stationary Models. Phase 2: To Test Different Seats for Perineal Arterial Occlusion.||University of Illinois at Chicago|Yes|Enrolling by invitation|August 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Male|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers will be recruited from the general population. Recruitment will be done using        oral presentation, meetings, advertisement flyers.Participants will be avid cyclists and        will not be at risk of undue influence( i.e UIC students).|May 2015|May 26, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01804725||70231|
NCT01805011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.08.INF|Study on Normal Ranges of Lipids in Breast Milk of Healthy Mothers|||Nestlé||Completed|July 2011|||May 2012|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy mothers|September 2011|March 4, 2013|March 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01805011||70209|
NCT01805024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-I-015|Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)|Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)|CALLISTO|Santhera Pharmaceuticals||Recruiting|December 2014|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|5 Years|16 Years|No|||September 2015|September 29, 2015|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805024||70208|
NCT01821066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481026|A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers|A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study Of The Effect Of Multiple Doses Of Tamoxifen On PD-0332991 Pharmacokinetics In Healthy Male Volunteers||Pfizer|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821066||68978|
NCT01821079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731014|A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers||Pfizer|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821079||68977|
NCT01821638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1064|Brain Alterations and Cognitive Impairment in Older Adults With Heart Failure|Brain Alterations and Cognitive Impairment in Older Adults With Heart Failure||University of Wisconsin, Madison|No|Recruiting|April 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|47|||Both|65 Years|85 Years|No|Non-Probability Sample|Older adults with heart failure|October 2015|October 9, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01821638||68934|
NCT01818362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU005|A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1|A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1||University of Oxford|Yes|Completed|April 2013|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01818362||69186|
NCT01818596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0112|Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment|A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment||Gilead Sciences|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|252|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 22, 2013|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01818596||69168|Enrollment in Cohort 2 (treatment-naive) was low, which affects the interpretation of the data.
NCT01817738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9104-004|Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer|A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-Derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients With Metastatic Castrate-refractory Prostate Cancer||CureVac AG|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Male|18 Years|N/A|No|||December 2013|December 19, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01817738||69234|
NCT01817751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14816|Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma|Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma||Virginia Commonwealth University|Yes|Recruiting|April 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817751||69233|
NCT01811017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO_MGH_TB|Clinical Evaluation of 755nm Alexandrite Laser Versus Nanosecond 755nm Alexandrite|||Cynosure, Inc.|No|Withdrawn|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||February 2014|February 3, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01811017||69748|
NCT01811264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPA Study|Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer|Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer||Northwestern University|No|Recruiting|December 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|280|||Female|21 Years|N/A|No|||October 2015|October 13, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01811264||69729|
NCT01811589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H1221|Guided Application of Ventricular Catheters|Randomized Controlled Multi-center Trial Comparing the Ventricular Catheter Location Between Instrument Guided and Freehand Placement.|GAVCA|Aesculap AG|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|N/A|N/A|No|||January 2015|January 26, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811589||69704|
NCT01811797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENO-03-ICH|Safety and Efficacy Associated With Treating Erectile Dysfunction Patients With Low Intensity Shockwaves by Renova|A Prospective, Randomized, Double Blind With Sham Control, Clinical Study to Assess the Safety and Efficacy Associated With Treating Patients Suffering From Erectile Dysfunction With Low Intensity Shockwaves by Renova||Initia|No|Terminated|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Male|20 Years|80 Years|No|||May 2015|May 11, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811797||69688|
NCT01811810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22812|Proton Therapy for High Risk Prostate Cancer|Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|March 2013|||April 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|75 Years|No|||December 2015|December 14, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811810||69687|
NCT01812096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ5201|Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China|Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China.|MM|The First Affiliated Hospital of Soochow University||Active, not recruiting|May 2014|June 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812096||69665|
NCT01812382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117151|Retapamulin Microdialysis Feasibility Study|A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers||GlaxoSmithKline|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812382||69643|
NCT01812642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014818|A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia|A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|20 Years|55 Years|No|||March 2014|March 16, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812642||69624|
NCT01839292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE4-10-009|ComVi and D-type Stent in Malignant GOO|A Newly Designed Conformable Uncovered Versus Covered Self-expandable Metallic Stent for Palliation of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Multicenter Study||Ajou University School of Medicine|Yes|Completed|April 2010|||August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|89|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01839292||67585|
NCT01835041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 57112|CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer|A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|April 2013|||January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835041||67909|
NCT01835262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/09/VA01|Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department|Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study||Maimonides Medical Center|No|Completed|April 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|January 29, 2016|April 12, 2013||No||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01835262||67892|This was a single center study in which patients were enrolled as a convenience. There was the potential for unblinding as some participants exhibited ketamine specific reactions such as nystagmus.
NCT01804738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/01149|Investigating Inter-individual Variability in Glycemic and Insulin Responses|Investigating Inter-individual Variability in Glycemic and Insulin Responses||Singapore Institute for Clinical Sciences|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|75|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01804738||70230|
NCT01805037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12H09|Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas|A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas||Northwestern University|Yes|Recruiting|March 2013|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805037||70207|
NCT01821651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOR-1|Use of Standardized Diagnostic Imaging Data for Image Fusion in the Hybrid Operating Room|Use of Standardized Diagnostic Imaging Data (Computertomography, Angiography, Echocardiography) for Image Fusion in the Hybrid Operating Room||University of Zurich|Yes|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|140|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01821651||68933|
NCT01810705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPA-AML2012-01|GRASPA Treatment for Patients With Acute Myeloblastic Leukemia|A Multicenter, Open, Randomized, Controlled Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA (L-asparaginase Encapsulated in Red Blood Cells) Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Elderly Patients, Unfit for Intensive Chemotherapy|ENFORCE|ERYtech Pharma|Yes|Recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|123|||Both|65 Years|85 Years|No|||March 2016|March 17, 2016|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01810705||69772|
NCT01817764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114930|A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD||GlaxoSmithKline|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|707|||Both|40 Years|N/A|No|||May 2014|July 10, 2014|March 21, 2013|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01817764||69232|
NCT01810965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSM 2012-A01392-41|Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis|Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study.|SAIFER|Rennes University Hospital|No|Recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810965||69752|
NCT01810978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128/01.10.2012|Synbiotics in Infants With Cyanotic Congenital Heart Disease|Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease||Dr. Sami Ulus Children's Hospital|No|Completed|October 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|3 Months|No|||May 2013|May 7, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810978||69751|
NCT01810991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-1440-BK-HID1|Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser|||Cynosure, Inc.|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|85 Years|No|||July 2015|July 29, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01810991||69750|
NCT01811030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO_SCARS_RG06|Evaluation of the 755nm Alexandrite Laser for the Treatment of Scars|||Cynosure, Inc.|No|Completed|June 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|85 Years|No|||July 2015|July 29, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01811030||69747|
NCT01811290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-BMD|A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis|A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis|MS-BMD|Simnad, Virginia, M.D.|No|Recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|44|||Both|21 Years|N/A|No|Non-Probability Sample|Men and women aged 21 or older diagnosed with a relapsing form of multiple sclerosis.        Minimum age was defined due to the limitations of site's current Dexa bone scan software        in scanning any person under 21 years of age. A total of 44 subjects are planned to be        randomized, with an estimated 10% screening failure or early termination, leaving an        estimated 40 subjects completing this study. Racial composition of the regional population        (Puget Sound of the Pacific Northwest, USA) from which study candidates will be recruited        over-represents Caucasian individuals, and thus this pilot study may not be balanced for        race.|May 2015|May 20, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01811290||69727|
NCT01811823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIV_HIV_TB|Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults|Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults|TIV_HIV_TB|University of Witwatersrand, South Africa|No|Recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|360|||Both|18 Years|55 Years|No|||August 2014|August 11, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01811823||69686|
NCT01812421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-036-01|A Nested Case-control Study on the Secondary Prevention of Ischemic Stroke and TIA by Hypertension Health Education Protocol (HHEP): The Post-Stroke Preventive Trial|||Guangzhou University of Traditional Chinese Medicine||Recruiting|April 2013|||April 2015|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812421||69641|
NCT01812395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEAH07031301|Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?|Is Superior Laryngeal Nerve Really Safe During Thyroidectomy Using Ultrasonic Dissector.||S.B. Konya Education and Research Hospital|No|Recruiting|March 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812395||69642|
NCT01812655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109422|Comparison of Virtual Reality and Passive Distraction on Burn Wound Care Pain in Adolescents|Comparison of Virtual Reality and Passive Distraction on Burn Wound Care||University of Arkansas|Yes|Terminated|June 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|30|||Both|10 Years|17 Years|No|||August 2013|August 5, 2013|March 13, 2013|Yes|Yes|Early termination of study due to fewer subjects available than expected resulting in small    sample size.|No|March 27, 2013|https://clinicaltrials.gov/show/NCT01812655||69623|Early termination of study due to fewer subjects available than expected resulting in small sample size.
NCT01835054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP#102737|Determinants of the Progression and Outcome of Mitral Regurgitation|Determinants of the Progression and Outcome of Mitral Regurgitation-PROGRAM STUDY|PROGRAM|Laval University|No|Recruiting|December 2008|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|Samples With DNA|Fasting blood sample (serum, lithium-heparin, EDTA) and white cells - Tissue (explanted      mitral valves)|Both|21 Years|N/A|No|Probability Sample|Cohort will be selected at primary care clinic|October 2015|October 30, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835054||67908|
NCT01835535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN02-001|Continued Safety and Performance of the TIVUS System|Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Renal Denervation in Patients With Resistant Hypertension||Cardiosonic|No|Active, not recruiting|August 2013|December 2016|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||March 2014|March 25, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01835535||67871|
NCT01835548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT0102.1004|NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder||Neos Therapeutics, Inc|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|6 Years|12 Years|No|||January 2015|January 30, 2015|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835548||67870|
NCT01835275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000969|Audio-enhanced Analgesia in Healthy Subjects|Audio-enhanced Analgesia in Healthy Subjects||Massachusetts General Hospital|No|Completed|June 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01835275||67891|
NCT01835834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-159|Clinical Study on Zirconia Bridges|||University of Siena|No|Active, not recruiting|January 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||July 2014|July 4, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01835834||67848|
NCT01821365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009CB522100|End Tidal Carbon Dioxide Monitoring for Evaluating Changes of PaCO2 After Noninvasive Mechanical Ventilation in COPD|End Tidal Carbon Dioxide Monitoring for Evaluating Changes of Arterial Carbon Dioxide After Noninvasive Mechanical Ventilation in Chronic Obstructive Pulmonary Disease||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|March 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|40|||Both|40 Years|85 Years|No|Non-Probability Sample|Patients with a COPD exacerbation who admitted to the respiratory department of First        Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China|April 2013|April 4, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821365|2 Days|68955|
NCT01821378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050303|Lurasidone Low-Dose - High-Dose Study Study|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects With Schizophrenia||Sunovion|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|412|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|March 22, 2013|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01821378||68954|
NCT01821677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-05-002|A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema|A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adult Patients With Diabetic Macular Edema||Ampio Pharmaceuticals. Inc.|Yes|Completed|February 2013|January 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 2, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821677||68931|
NCT01821690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210009885|Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression|Brain Research in Aggression and Irritability Network (BRAIN): Building Evidence-Based Approaches to Managing Traumatic Brain Injury||Indiana University|Yes|Recruiting|May 2013|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|70 Years|No|||August 2015|August 30, 2015|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821690||68930|
NCT01818063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12G.376|Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer|An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer||Thomas Jefferson University|Yes|Suspended|April 2013|||April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||October 2015|October 12, 2015|March 21, 2013|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01818063||69209|
NCT01810198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONSERVE|Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization|Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life|CONSERVE|MDDX LLC|Yes|Active, not recruiting|December 2012|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|1500|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01810198||69811|
NCT01818856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC-TEL-2012-1|Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir|Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir in HIV/HCV-co-infected Patients Under Treatment for Genotype 1 Chronic Hepatitis C.||Hospitales Universitarios Virgen del Rocío|Yes|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|65 Years|No|||April 2013|April 19, 2013|December 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01818856||69148|
NCT01810718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GITMO Protocol Nilotinib-cGVHD|Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD|Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD.|Nilo-cGVHD|Gruppo Italiano Trapianto di Midollo Osseo|Yes|Completed|November 2011|August 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|64 Years|No|||September 2015|September 2, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01810718||69771|
NCT01810731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-6393|Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya|A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Standard Dose Quadrivalent Inactivated Influenza Vaccine, and Double Dose Quadrivalent Inactivated Influenza Vaccine in HIV-Infected and HIV-Uninfected Pregnant Women in a Malaria-Endemic Area of Rural Western Kenya||Centers for Disease Control and Prevention|Yes|Withdrawn|April 2014|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Female|13 Years|49 Years|No|||April 2014|April 8, 2014|March 12, 2013||No|Scientific review positive from 3 manufacturers; internal committees did not support due to    deploying new flu vaccines in HIV+ pregnant women in Kenya.|No||https://clinicaltrials.gov/show/NCT01810731||69770|
NCT01811056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006|Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion|Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion||Gynuity Health Projects|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|401|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01811056||69745|
NCT01811277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOX-S-1 BTC|SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer|Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer||Peking University|No|Recruiting|July 2010|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||July 2010|March 13, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811277||69728|
NCT01820078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALIFE-2011-01|Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)|Effect of Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study): a Randomized Study|PALIFE|Fundación Renal Iñigo Alvarez De Toledo|No|Terminated|May 2012|December 2013|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|July 30, 2012||No|Recruitment not reached|No||https://clinicaltrials.gov/show/NCT01820078||69054|
NCT01811836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211114|Zinc Resistant Starch Project|The Effect of Resistant Starch Consumption on Zinc Hemostasis in Malawian Children at Risk for Zinc Deficiency||Washington University School of Medicine|Yes|Recruiting|March 2013|March 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|36 Months|60 Months|Accepts Healthy Volunteers|||March 2013|March 12, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01811836||69685|
NCT01811849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-102|Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes|A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration||Biodel||Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|70 Years|No|||March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811849||69684|
NCT01811862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-038|Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients|Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients: A Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|21 Years|N/A|No|||February 2016|February 18, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811862||69683|
NCT01812109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102010-133|Near-Infrared Spectroscopy for Pediatric Acute Scrotum and Testicular Torsion|Near-Infrared Spectroscopy for Pediatric Acute Scrotum and Testicular Torsion|NIRS|University of Texas Southwestern Medical Center|No|Recruiting|May 2011|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|750|||Male|1 Month|21 Years|No|||March 2013|March 13, 2013|January 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812109||69664|
NCT01812122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMS_SU_Gliptin|Effects of Vildagliptine and Glimepiride on Glucose Variability|Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS||Seoul National University Hospital|Yes|Completed|March 2013|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|75 Years|No|||November 2015|November 19, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812122||69663|
NCT01812434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001M76094 PART A|Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients|Evaluation of Phosphodiesterase-5 Inhibition on Endothelial Function in Heart Transplant Recipients||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|October 2010|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812434||69640|
NCT01812694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913055|Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix|Lifestyle Interventions for Expectant Moms (LIFE-Moms Phoenix)-Phoenix||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Female|18 Years|N/A|No|||May 2015|June 2, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812694||69620|
NCT01812668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-185|Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer|Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812668||69622|
NCT01812681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.4.İSM.4.06.68.49|Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities|Is Higher Cord Blood 25(Oh)-Vitamin D Level Preventive For Any Morbidity Including Rds, Pda, Nec, Bpd And Rop In Preterm Infants||Dr. Sami Ulus Children's Hospital|No|Completed|October 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|81|||Both|N/A|5 Days|No|Non-Probability Sample|Premature infants|August 2014|August 12, 2014|March 14, 2013||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01812681||69621|
NCT01812928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122010SUR|Diclofenac Suppository to Control Pain During Flexible Cystoscopy|Phase 2 Study of Diclofenac Suppository to Control Pain During Flexible Cystoscopy|DUF|Aga Khan University|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 14, 2013|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812928||69602|
NCT01834794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32243|Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders|Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834794||67928|
NCT01834807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28540|A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis|Retrospective Study on the Use of Biologicals in Monotherapy in Rheumatoid Arthritis||Hoffmann-La Roche||Completed|April 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|180|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis who are currently receiving a biologic agent in        monotherapy (corticosteroids and/or non-steroidal anti-inflammatory drugs are permitted)|March 2016|March 1, 2016|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01834807||67927|
NCT01835301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IntraStent|Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation|Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation||Medstar Research Institute|No|Active, not recruiting|November 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 40 subjects will be enrolled in the study, with 20 patients who previously        received BMS > 3 years ago and 20 patients who previously received DES > 3 years ago|August 2014|August 8, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01835301||67889|
NCT01835561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-CP-009|Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males|A Phase 1, Open‐Label, Two‐Part Study to Evaluate the Pharmacokinetics of Pomalidomide (CC‐4047) in Hepatically Impaired Male Subjects||Celgene|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835561||67869|
NCT01835574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA033672|Cambodia Integrated HIV and Drug Prevention Implementation Program|Cambodia Integrated HIV and Drug Prevention Implementation Program|CIPI|University of California, San Francisco|Yes|Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1200|||Female|18 Years|N/A|No|||July 2014|July 2, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01835574||67868|
NCT01835587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-AML-002|Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Phase 1/2 Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects With Acute Myelogenous Leukemia and Myelodysplastic Syndromes After Allogeneic Hematopoietic Stem Cell Transplantation||Celgene|No|Active, not recruiting|July 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835587||67867|
NCT01821391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29112|Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses|Multi-centre, Randomized, Investigator-blind, Intra-individual Active and Vehicle-controlled Study, Comparing Metvix Natural Daylight Photodynamic Therapy Versus Metvix Conventional Photodynamic Therapy in Subjects With Actinic Keratosis|COMET2|Galderma|No|Completed|July 2013|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821391||68953|
NCT01821664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2012-0583|Vascular Graft Infections|Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy|VASGRA|University of Zurich||Recruiting|May 2013|March 2023|Anticipated|March 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a vascular surgery at the University hospital will be included in the        study.|May 2015|May 5, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01821664|10 Years|68932|
NCT01818076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL023|Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines|||Revance Therapeutics, Inc.||Terminated|February 2013|December 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|311|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|March 20, 2013|Yes|Yes|Sponsor decision to terminate study (not due to safety reasons)|No||https://clinicaltrials.gov/show/NCT01818076||69208|
NCT01810445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210092-9|Endoscopic Subsurface Optical Imaging for Cancer Detection|Endoscopic Subsurface Optical Imaging for Cancer Detection||University of California, Davis|Yes|Completed|January 1999|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Probability Sample|Patients already scheduled to undergo a bladder surgery at UCDMC.|March 2013|March 11, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01810445||69792|
NCT01810211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NovaSEU|The Most Effective Intervention for Reducing Posterior Shoulder Tightness Acutely in the Post-operative Population|The Most Effective Intervention for Reducing Posterior Shoulder Tightness Acutely in the Post-operative Population: A Double Blinded Randomized Control Trial.||Nova Southeastern University|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|September 24, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01810211||69810|
NCT01810224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAFFITI|Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial|Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial|GRAFFITI|Onze Lieve Vrouw Hospital|No|Recruiting|March 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|90 Years|No|||March 2013|March 11, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01810224||69809|
NCT01810458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63-2013|Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)|Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency||University of Florida|No|Recruiting|October 2013|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Liver tissue and whole blood.|Both|18 Years|70 Years|No|Non-Probability Sample|Pulmonary clinic, hepatology clinic, and the Alpha-1 Antitrypsin Tissue and Data Bank.|January 2016|January 28, 2016|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810458||69791|
NCT01810744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-FANI-2012|Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma|Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma|BEVACAPI|Centre Georges Francois Leclerc|No|Recruiting|May 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|98|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810744||69769|
NCT01810757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3973|Study of Weekly Radiotherapy for Bladder Cancer|A Multicentre Randomised Phase II Study of HYpofractionated Bladder Radiotherapy With or Without Image Guided aDaptive Planning|HYBRID|Institute of Cancer Research, United Kingdom|Yes|Recruiting|April 2014|January 2025|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01810757||69768|
NCT01810770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15397|Radium-223 Dichloride (Ra-223 Cl2) Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis|A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis||Bayer|No|Recruiting|March 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|234|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810770||69767|
NCT01811602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02473|Gynecological Pelvic Floor Muscle Training|The Efficacy of Pelvic Floor Muscle Training in Gynecological Cancer Survivors: A Pilot Study||University of British Columbia|No|Recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|19 Years|65 Years|No|||April 2015|April 10, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811602||69703|
NCT01820689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUJM|Tympanometric Analysis in Cleft Palate|Tympanometric Analysis in Post Surgical Individuals With Cleft Palate||Centro de Diagnostico Auditivo de Cuiaba|Yes|Completed|January 2012|November 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|1 Year|N/A|No|||March 2013|March 26, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01820689||69007|
NCT01820962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC06-2-003|Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients|Concentrated Citrate Locking to Reduce the Incidence of Central Venous Catheter-related Infections and Thrombosis: a Randomized Phase III Study in a Hematological Patient Population||Maastricht University Medical Center|No|Terminated|July 2006|July 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|212|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|March 12, 2013|Yes|Yes|Because the inclusion rate was lower than expected.|No||https://clinicaltrials.gov/show/NCT01820962||68986|
NCT01820663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRH-424|Dietary Intervention With the Modified Atkins Diet in Stroke Rehabilitation|Dietary Intervention in Stroke Recovery in the Acute Rehabilitation Setting With the Modified Atkins Diet.||Burke Rehabilitation Hospital|No|Completed|March 2012|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|99 Years|No|||February 2016|February 22, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01820663||69009|
NCT01812135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-1001-II-02|Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants|A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants||Sinovac Biotech Co., Ltd|Yes|Withdrawn|September 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|0|||Both|6 Months|11 Months|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 13, 2013||No|Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was    elected to be used for the efficacy Phase III study.|No||https://clinicaltrials.gov/show/NCT01812135||69662|
NCT01812148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maisonneuve Rosemont Hospital|Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)|Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)||Maisonneuve-Rosemont Hospital|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|19|||Both|N/A|N/A|No|Non-Probability Sample|Patients suffering of peritoneal mesotheliomas undergoing cytoreductive surgery and HIPEC|March 2013|March 15, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01812148||69661|
NCT01821235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/210|Evaluation of Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers|A Single Centre, Single-blind, Randomized, Two-part, 6-way Cross-over Study to Investigate the Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers.|DRUG13-GABA|University Hospital, Ghent|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821235||68965|
NCT01821534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-128|Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification|||Allergan|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|March 2014|March 28, 2014|March 25, 2013||No||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01821534||68942|
NCT01812941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-212|Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients|Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients||University of South Alabama|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|50|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812941||69601|
NCT01812954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO-GOE|Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis|||Technische Universität Dresden|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1000|||Both|16 Years|65 Years|No|Probability Sample|patients with moderate-to-severe psoriasis, who require systemic treatment to adequately        control the disease|March 2013|July 1, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812954||69600|
NCT01808807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101110-F|Factors Influencing Cesarean Section Rate: Does the Audit Still Work?|Factors Influencing Cesarean Section Rate: Does the Audit Still Work?||Far Eastern Memorial Hospital|No|Completed|December 2012|||April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|4000|||Female|15 Years|47 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women who delivered in a medical center will be included retrospectively in this        study|March 2013|August 16, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01808807||69917|
NCT01808820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120750|Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects|Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects||University of Miami|Yes|Recruiting|July 2013|||July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|100 Years|No|||February 2016|February 4, 2016|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808820||69916|
NCT01808833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 12-22|Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy|A Pilot Trial of Frailty Assessment in Older Adults (Age 70 >) Requiring Concurrent Chemotherapy Plus Radiation Therapy for Cancer (CTRC# 12-22)||The University of Texas Health Science Center at San Antonio|Yes|Terminated|February 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|4|||Both|70 Years|N/A|No|Non-Probability Sample|Age >70 years undergoing concurrent standard of care chemotherapy plus radiation therapy.|January 2014|January 28, 2014|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01808833||69915|
NCT01835067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number: 2012-004078-24|Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration|Intravitreal Tissue Plasminogen Activator (tPA) And Perfluoropropane (C3F8) for the Treatment of Neovascular Age-related Macular Degeneration With Associated Submacular Haemorrhage (TAPAS): a Multi-centre, Randomized, Double-masked, Sham-controlled, Factorial, Feasibility Study|TAPAS|King's College Hospital NHS Trust|No|Recruiting|September 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|55|||Both|50 Years|N/A|No|||January 2016|January 22, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835067||67907|
NCT01836133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28282|An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)|Efficacy and Safety of erLotinib (Tarceva® ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT||Hoffmann-La Roche||Completed|May 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced or metastatic adenocarcinoma non-small cell lung cancer,        with ECOG performance status of 0-1|March 2016|March 1, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836133||67825|
NCT01836146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202|International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension||EnligHTN III|St. Jude Medical|Yes|Completed|April 2013|September 2015|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||October 2014|October 19, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836146||67824|
NCT01835288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0023|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene||Stanford University||Not yet recruiting|May 2013|||May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835288||67890|
NCT01835600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMV-312|Suspension of Mechanical Ventilation in Ureteroscopic Lithotripsy Under General Anesthesia|||Chinese Medical Association|Yes|Not yet recruiting|April 2013|November 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|80 Years|No|||April 2013|April 11, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01835600||67866|
NCT01817777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116086|An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes|A Pharmacy Based Open Study to Evaluate Whether Pack Size Affects Compliance for Subjects Diagnosed With Diabetes Type II Who Are Established on Metformin Treatment||GlaxoSmithKline|No|Terminated|May 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||May 2014|September 25, 2014|March 21, 2013||No|It's no longer feasible to continue to recruit patients into the study as severe recruitment    difficulties have been experienced since the study start|No|September 25, 2014|https://clinicaltrials.gov/show/NCT01817777||69231|
NCT01817790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01619|Assessment of Fluticasone Propionate on Ocular Allergy Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy of Once-Daily Fluticasone Propionate Aqueous Nasal Spray 200mcg for 14 Days on Ocular Symptoms Associated With Seasonal Allergic Rhinitis||GlaxoSmithKline|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|626|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2013|March 6, 2014|March 21, 2013|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01817790||69230|
NCT01809886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-PED-2010-01CT|Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial|Reversal With Sugammadex (BRIDION ®) From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial of Efficacy and Safety|SUGAPED-01|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|No|Completed|October 2011|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|2 Years|11 Years|No|||March 2014|March 5, 2014|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809886||69834|
NCT01810237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS001|Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy|Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy||Nova Scotia Health Authority|No|Withdrawn|March 2013|September 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|70 Years|No|||February 2015|February 4, 2015|February 28, 2013||No|No patients recruited|No||https://clinicaltrials.gov/show/NCT01810237||69808|
NCT01810497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLASTICA-001|Analysis of Postoperative Bandage Use Protocols in Otoplasty|Analysis of the Influence of Different Protocols of Postoperative Elastic Bandage Use in the Results of Otoplasty||University of Campinas, Brazil|No|Completed|May 2012|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|10 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01810497||69788|
NCT01810471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407- 05_130307|External Ankle Supports - 3D Motion Analysis|||University Hospital Heidelberg|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01810471||69790|
NCT01810484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-133|Feasibility Study: Evaluation of the Treatment of Striae Using Ultherapy® in Combination With Laser Treatment|Feasibility Study: Evaluation of the Ulthera® System in Combination With 70W Alma Pixel CO2 Fractional Ablative Laser for Improvement of Abdominal Striae||Ulthera, Inc|No|Completed|January 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|14|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810484||69789|
NCT01810796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRanTrop|Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial|Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial||Hadassah Medical Organization|Yes|Not yet recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810796||69765|
NCT01811043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038873|Improving Biopsy Experiences Study for Women|Improving Biopsy Experiences Study for Women|IBEST|Duke University|No|Active, not recruiting|August 2012|March 2019|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|243|||Female|21 Years|N/A|No|||May 2015|May 28, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811043||69746|
NCT01819805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100722|A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen|Evaluation of the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol HCl (75mg)/Acetaminophen (650mg) Extended Release Tablet: Multicenter, Open Label, Prospective, Observational Study||Janssen Korea, Ltd., Korea|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1065|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with chronic non-malignant pain taking tramadol hydrochloride and acetaminophen|December 2014|December 31, 2014|February 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01819805||69075|
NCT01821287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0638|Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease|Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|75|Samples With DNA|whole blood|Both|N/A|12 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants with Single Ventricle Congenital Heart Disease (CHD) being treated at CCHMC and        Healthy newborns recruited from CCHMC and private practices|April 2014|April 11, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01821287||68961|
NCT01821300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009233|Down Syndrome Metabolic Health Study|Cardiometabolic Risk and Obesity in Adolescents With Down Syndrome||Children's Hospital of Philadelphia|No|Recruiting|February 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|250|Samples Without DNA|Blood serum will be retained.|Both|10 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from primary care and speciality clinics, Trisomy 21        events, T21 interest groups, and referrals.|November 2015|November 4, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821300||68960|
NCT01820975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-067|Manipulation of Dietary Protein and the Anabolic Response|The Manipulation of Dietary Protein Intake on the Anabolic Response in Healthy Young Men|PRO-ADAPT|Maastricht University Medical Center|No|Completed|April 2013|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|28|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|March 15, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01820975||68985|
NCT01821248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1201|A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis|A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)||Kansai Hepatobiliary Oncology Group|Yes|Recruiting|March 2013|February 2019|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||October 2014|October 22, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01821248||68964|
NCT01820949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380/12|Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients|Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients|PBM|Johann Wolfgang Goethe University Hospitals|Yes|Completed|January 2013|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|110000|||Both|18 Years|N/A|No|Non-Probability Sample|all surgical patients over a period of 24 months at 4 hospitals|September 2015|September 4, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820949||68987|
NCT01821261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAEBBA0004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2014|||||N/A|N/A|N/A||||||||||||||April 9, 2015|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821261||68963|
NCT01821833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1211|Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel|A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome||New Mexico Cancer Care Alliance|Yes|Recruiting|February 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821833||68919|
NCT01821547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2012/09|New Methods to Measure the Immune Response to Hepatitis B Vaccine|Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors||University of Oxford|No|Recruiting|March 2013|||November 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01821547||68941|
NCT01821820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0064|Pistachios, Performance, Metabolomics|Influence of Pistachios on Performance and Exercise-induced Inflammation, Oxidative Stress, and Immune Dysfunction in Athletes: a Metabolomics-based Approach.||Appalachian State University|No|Completed|March 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821820||68920|
NCT01817582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813|Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca|A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax® Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)||Bausch & Lomb Incorporated|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|40 Years|N/A|No|||August 2014|August 20, 2014|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817582||69246|
NCT01817595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBG star study|Evaluation of Iphone Technology in Diabetes Treatment|Evaluation of Iphone Technology in Diabetes Treatment||Endocrine Research Society|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|43|||Both|18 Years|80 Years|No|||December 2014|December 3, 2014|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817595||69245|
NCT01817608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107589|Weaning From Mechanical Ventilation in the ICU|Weaning From Mechanical Ventilation in the ICU||Loyola University|No|Completed|September 2004|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Probability Sample|ICU patients receiving mechanical ventilation|March 2013|March 20, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01817608||69244|
NCT01835886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183-12|Study to Assess Stairs as an Outcome Measure in Individuals With Pulmonary Disease|Study to Assess if Ability to Ascend and Descend Stairs Within 30 Seconds Will Prove to be a Reliable and Valid Outcome Measure in Individuals With Pulmonary Disease|TSCT|Beth Israel Medical Center|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|29|||Both|18 Years|90 Years|No|||May 2015|May 5, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01835886||67844|
NCT01835899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305.2|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d.for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)||Boehringer Ingelheim||Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|April 9, 2013||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01835899||67843|The study was prematurely completed as per protocol after 2 of the originally planned 4 dose groups ie., 1 mg BI 1015550 and 6 mg BI 1015550 because of higher than expected drug exposure.
NCT01835912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009|Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m|Chronic vs. Acute Ingestion of Sodium Citrate: a Randomised Placebo Controlled Cross-over Trial for Swimming a 200 Metres in Well-trained Swimmers Age 13-17||Brock University|Yes|Completed|September 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|10|||Male|13 Years|17 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|April 10, 2013||No||No|March 19, 2014|https://clinicaltrials.gov/show/NCT01835912||67842|
NCT01836484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007697|Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma|Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma|MAPPING|Barts & The London NHS Trust|Yes|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|Samples With DNA|Lymph node tissue samples|Female|18 Years|N/A|No|Non-Probability Sample|150 women with histologically confirmed endometrial or cervical carcinoma.|January 2016|January 21, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01836484||67799|
NCT01835613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR/BIOM|Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.|Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.||Osservatorio Epidemiologico GISEA|No|Recruiting|January 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|75 Years|No|||April 2013|April 18, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01835613||67865|
NCT01835873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|492|The Effect of Intravenous Prehydration on the Hemodynamic Status of Healthy Parturients Undergoing Spinal Anesthesia for Cesarean Delivery|Comparative Study of the Effect of 6% Hydroxyethyl Starch 130/0.42 vs Lactated Ringer's Preload on the Hemodynamic Status of Parturients Undergoing Spinal Anesthesia for Elective Cesarean Delivery. Arterial Pulse Contour Analysis (FloTrac/VigileoTM) is Employed for Continuous Monitoring of Maternal Hemodynamic Parameters||Attikon Hospital||Completed|March 2011|||January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01835873||67845|
NCT01810185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDN in IBD|Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease|Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease||Santa Barbara Cottage Hospital|No|Withdrawn|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 19, 2014|March 11, 2013||No|Low patient enrollment|No||https://clinicaltrials.gov/show/NCT01810185||69812|
NCT01809899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4295-033|Enhanced Consent for Symptom Provocation Research|Risks and Outcomes of Enhanced Consent in Symptom-provocation Research||Georgetown University|No|Completed|April 2009|August 2014|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01809899||69833|
NCT01809912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1102_001|Safety Study of MG1102 in Patients With Solid Tumors|A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MG1102 IN PATIENTS WITH SOLID TUMORS||Green Cross Corporation|Yes|Terminated|November 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2014|November 25, 2015|October 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809912||69832|
NCT01810523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817212|Stories to Educate Patients With Ankle, Foot, and Knee Injuries|Comparative Effectiveness of Descriptive Versus Narrative Emergency Department Discharge Instructions for Patient Education on Unnecessary Testing for Ankle, Foot and Knee Injuries||University of Pennsylvania||Not yet recruiting|March 2013|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|March 12, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01810523||69786|
NCT01810510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000028|Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading|Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading||Massachusetts General Hospital|Yes|Recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810510||69787|
NCT01810783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14644B|Brexpiprazole in Patients With Schizophrenia|Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|July 2013|||December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|65 Years|No|||January 2016|January 18, 2016|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810783||69766|
NCT01811303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSSL SSID P12-06545|Effects of Added D-fagomine on Glycaemic Responses to Sucrose|Effects of Added D-fagomine on Glycaemic Responses to Sucrose||Bioglane|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|June 28, 2013|March 12, 2013||No||No|April 3, 2013|https://clinicaltrials.gov/show/NCT01811303||69726|
NCT01811316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2013-1-23|A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis|A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis||Sunstar Americas|No|Completed|March 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|62|||Both|18 Years|65 Years||||October 2015|October 6, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811316||69725|
NCT01821586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-200-005|Modified ORS Solution for Severely Malnourished Children|Optimisation of Oral Rehydration Solution and Evaluation of the Efficacy of Benefiber(Partially Hydrolyzed Guar Gum) Containing Modified Oral Rehydration Solution in the Treatment of Severely Malnourished Children With Watery Diarrhoea||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|April 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|189|||Both|6 Months|36 Months|No|||January 2006|March 29, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821586||68938|
NCT01821573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110136 / AOM11223|Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients|Double Blind Randomized Controlled Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength of These Muscles During Locomotion in Chronic Hemiparetic Patients|FOLOTOX|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821573||68939|
NCT01821560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817101|Baclofen Effects in Cigarette Smokers|Baclofen Effects on Brain and Behavior in Cigarette Smokers|BAC|University of Pennsylvania|No|Recruiting|March 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821560||68940|
NCT01821846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3929|Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus|A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza®) in Subjects With Type 2 Diabetes Mellitus in Korea||Novo Nordisk A/S|No|Enrolling by invitation|November 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3600|||Both|N/A|N/A|No|Non-Probability Sample|Victoza® will be prescribed and titrated by the physician.|November 2015|November 24, 2015|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821846||68918|
NCT01817647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-2013|PREDICS Study: PCT Reveals Early Dehiscence in Colorectal Surgery|PREDICS Study: Procalcitonin Reveals Early Dehiscence in Colorectal Surgery|PREDICS|University of Roma La Sapienza|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|504|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing all different kinds of colorectal surgery (from right colectomies to        low anterior resection), in elective setting, either for cancer or benign disease (ex        diverticular disease) with an anastomosis being performed (ileo-colic, colo-colic, or        colo-rectal)|September 2014|September 26, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817647|2 Years|69241|
NCT01817621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399055-1|Body Image and Self-Care in HIV-Infected MSM|Body Image and Self-Care in HIV-Infected MSM|BUILD|Massachusetts General Hospital|Yes|Recruiting|February 2013|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|69|||Male|18 Years|65 Years|No|||April 2015|April 6, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01817621||69243|
NCT01817634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/334|ω3 LCPUFAs for Healthy Growth and Development of Infants and Young Children in Southwest Ethiopia|ω3 Long-chain Polyunsaturated Fatty Acids for Healthy Growth and Development of Infants and Young Children in the Gilgel Gibe Hydroelectric Dam Area, Ethiopia.|OME³Jim|University Ghent|No|Active, not recruiting|November 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|320|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817634||69242|
NCT01817907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2009P001862|The Effects of Trazodone on Sleep Apnea Severity|The Effects of Trazodone on the Severity of Obstructive Sleep Apnea||Brigham and Women's Hospital|No|Recruiting|March 2013|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|70 Years|No|||September 2013|September 25, 2013|November 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817907||69221|
NCT01817920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-091237|Integrated Interdisciplinary Program for Fall Prevention in Hospitalized Patients|||Changhua Christian Hospital||Completed|January 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|3000|||Both|18 Years|85 Years|No|||March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817920||69220|
NCT01835639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009753|Vitamin D Supplementation in Glomerular Disease|Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease||Children's Hospital of Philadelphia|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|5 Years|30 Years|No|||February 2016|February 29, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01835639||67863|
NCT01836458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKAE609A2201|A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection|An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection||Novartis|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|25|||Both|20 Years|60 Years|No|||February 2016|February 3, 2016|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836458||67801|
NCT01836471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2214|A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients|A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy||Novartis||Completed|May 2013|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|345|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836471||67800|
NCT01836783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amnio-12|Bone Augmentation Techniques in Extraction Sockets|A Prospective Study of Bone Augmentation Techniques in Extraction Sockets||University of Alabama at Birmingham|No|Active, not recruiting|January 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 7, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836783||67776|
NCT01809613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009020|Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease|Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease||Mayo Clinic|No|Recruiting|March 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|90 Years|No|Probability Sample|Patients approved and scheduled to undergo the clinical procedure of Deep Brain        stimulation.|January 2016|January 15, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809613||69855|
NCT01809626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001379|Proton MRS Study of SSRI-Zolpidem Interactions|Proton MRS Study of SSRI-Zolpidem Interactions||Mclean Hospital|No|Completed|May 2010|December 2012|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|21 Years|40 Years|No|||March 2013|March 12, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809626||69854|
NCT01809925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012126|Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, 2-treatment, 3-period Crossover Design Study of the Efficacy and Tolerability of Psyllium 6.8 g Provided as Sugarfree Metamucil® Fiber Supplement Powder Versus Placebo on Satiety in Healthy Volunteers||Procter and Gamble|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|October 27, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809925||69831|
NCT01809938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH01|Does Adding Milk to Tea Delay Gastric Emptying?|Gastric Emptying of Tea With Milk, Compared With Tea Without Milk. Does Milk Delay Gastric Emptying?|GETEAM|Guy's and St Thomas' NHS Foundation Trust|No|Completed|November 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 24, 2013|March 7, 2013|Yes|Yes||No|August 25, 2013|https://clinicaltrials.gov/show/NCT01809938||69830|
NCT01810822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUSP-LIM25-0002|Sex-specific Association With Kidney Disease|Sex-specific Associations of Variants in the Regulatory Regions of NADPH Oxidase-2 (CYBB) and Gluthatione Peroxidase 4 (GPX4) Genes With Kidney Disease in Type 1 Diabetes.||University of Sao Paulo General Hospital|Yes|Completed|May 1994|October 2012|Actual|May 1994|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|1396|Samples With DNA|Whole Blood|Both|11 Years|N/A|No|Probability Sample|Three cohorts pf type 1 diabetic patients were used for the present study. The first one        is a Brazilian cohort with 451 patients recruited in diabetes/endocrinology departments of        three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre        (RS), Brazil between October 2004 and October 2012. The second one is a French/Belgium        cohort with 501 patients recruited from both countries between November 1998 to December        2000. The third cohort is a French/Belgium cohort with 444 patients recruited from both        countries between May 1994 to April 1995.|March 2013|March 13, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810822||69763|
NCT01810809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0255/10|Hip Viscosupplementation: What is the Best Dosage?|Hip Viscosupplementation: What is the Best Dosage?|Hip VS|University of Sao Paulo General Hospital|No|Recruiting|April 2013|November 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|40 Years|N/A|No|||September 2013|September 10, 2013|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810809||69764|
NCT01819519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-DD-12-005|Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus|Development and Evaluation of a Clinic-Based Screening and Brief Intervention for Changing Behaviors Related to Cytomegalovirus Transmission in Pregnant Women|CDC/CMV|Women and Infants Hospital of Rhode Island|Yes|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|223|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819519||69097|
NCT01820377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008:060|The Aboriginal Youth Mentorship Program|Northern Lights Physical Activity Program for Management of Type 2 Diabetes Early in Life: Aboriginal Youth Mentorship Program|AYMP|University of Manitoba|No|Active, not recruiting|October 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820377||69031|
NCT01820390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1837|Optimizing DBS Electrode Placement and Programming|Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.||University of Colorado, Denver|Yes|Withdrawn|March 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects will be recruited from the population of patients undergoing DBS surgery at the        University of Minnesota Medical Center, for the treatment of (1) Parkinson's disease, or        (2) essential tremor.|February 2014|February 18, 2014|January 14, 2013||No|Funding discontinued.|No||https://clinicaltrials.gov/show/NCT01820390||69030|
NCT01820676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004|iUni G2+ Prospective Study|A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2+ Unicompartmental Knee Resurfacing Device||ConforMIS, Inc.|No|Recruiting|July 2013|July 2027|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with knee osteoarthritis|June 2015|June 18, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01820676||69008|
NCT01821599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCA-9090|Comparative Study Between Two Physiotherapy Protocols Conventional X Accelerated in Individuals Undergoing Reconstruction of the Anterior Cruciate Ligament.|Comparative Study Between Two Physiotherapy Protocols Conventional X Accelerated in Individuals Undergoing Reconstruction of the Anterior Cruciate Ligament.||University of Sao Paulo|Yes|Completed|January 2013|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|45 Years|No|||December 2014|April 12, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01821599||68937|
NCT01821872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7258|Paracetamol CSF Pharmacokinetics Study|A Single Centre Prospective Randomised Study to Investigate the Cerebrospinal Fluid (CSF) Pharmacokinetics of Intravenous Paracetamol in Humans||Barts & The London NHS Trust|Yes|Completed|May 2011|November 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|80 Years|No|||April 2013|April 2, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821872||68916|
NCT01821859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005859|Abraxane/Bevacizumab|A Phase II Evaluation of Abraxane Plus Bevacizumab for the Treatment of Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||OHSU Knight Cancer Institute|Yes|Terminated|January 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||July 2013|July 18, 2013|March 27, 2013|Yes|Yes|Terminated due to low enrollment|No|April 1, 2013|https://clinicaltrials.gov/show/NCT01821859||68917|
NCT01817660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVERPAR Trial|Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial|Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial|OVERPAR|Boston Medical Center|Yes|Recruiting|February 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|35 Years|N/A|No|||March 2016|March 8, 2016|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01817660||69240|
NCT01817946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMDIR-001|Myotubular Myopathy Genetic Testing Study|Myotubular Myopathy Genetic Testing Study||Cure CMD|No|Recruiting|March 2013|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples With DNA|saliva, whole blood, or other source|Both|N/A|N/A|No|Non-Probability Sample|The study will be composed of individuals registered in the CMDIR who have been clinically        diagnosed with XLMTM but do not have an XLMTM diagnosis confirmed by genetic testing.|September 2015|September 21, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01817946||69218|
NCT01818232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-108-NRM|Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects|A Phase 1, Open-label, Nonrandomized, Single Dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-LX4211, Following Oral Administration, in Healthy Male Subjects|AME|Lexicon Pharmaceuticals||Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01818232||69196|
NCT01817933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-100410|Integrated Rehabilitation Program for Fractures|||Changhua Christian Hospital||Completed|July 2010|July 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817933||69219|
NCT01818245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12152|A Study of LY2605541 in Healthy Participants and in the Elderly|Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541||Eli Lilly and Company|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 25, 2013|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01818245||69195|
NCT01818206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8750|Bacteriophage Effects on Pseudomonas Aeruginosa|Bacteriophages Effects on Pseudomonas Aeruginosa Presents in Sputum of Cystic Fibrosis (CF) Patients|MUCOPHAGES|University Hospital, Montpellier|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Both|6 Years|N/A|No|||September 2013|September 4, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818206||69198|
NCT01818219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/12|Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro-regulation of Respiration|Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro Regulation of Respiration|RegAIN|University Hospital, Angers|No|Terminated|February 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|February 28, 2013||No|Only half recruitment : restrictive respiratory mechanics group not achievable for technical    problems|No||https://clinicaltrials.gov/show/NCT01818219||69197|
NCT01805895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000718|A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients|Minocycline in Acute Cerebral Hemorrhage (MACH) Trial|MACH|Georgia Regents University|Yes|Recruiting|February 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01805895||70141|
NCT01805908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2011-PETRA|Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)|Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer|PETRA|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|November 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01805908||70140|
NCT01836159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-059C|iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic|iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic||St. Michael's Hospital, Toronto|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|85 Years|No|||November 2015|November 16, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836159||67823|
NCT01836497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62|SD01 Master Study (Safety and Efficacy Study)|SD01 Master Study (Safety and Efficacy Study)||Biotronik SE & Co. KG|No|Active, not recruiting|May 2013|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard ICD/CRT-D (cardiac resynchronization therapy plus defibrillator)        indication|October 2015|October 7, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01836497||67798|
NCT01836796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0056|Metabolic Effects of Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes|Metabolic Effects of Dietary Supplementation With Lactobacillus Reuteri DSM 17938 - a Randomised Placebo Controlled Proof-of-concept Study in Type 2 Diabetes||Vastra Gotaland Region|No|Completed|May 2012|July 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|46|||Both|50 Years|75 Years|No|||October 2013|October 24, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836796||67775|
NCT01809639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFU Procuss|Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion|Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study||Wake Forest School of Medicine|Yes|Active, not recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|44 Years|No|||December 2014|December 9, 2014|March 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01809639||69853|
NCT01810250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE Registry|Endurant for Challenging Anatomy: Global Experience Registry|EVAR Treatment With the Endurant Stent Graft of Challenging Anatomy in Experienced Hands, the Real World Experience|EAGLE|Catharina Ziekenhuis Eindhoven|No|Recruiting|November 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Probability Sample|Patients with abdominal aortic aneurysms (AAAs) with challenging anatomy defined by having        one or more of the following measurements:          -  Proximal necks 5 - 10mm in combination with < 60 degrees infrarenal AND < 45 degrees             suprarenal angulation          -  Proximal necks 10 - 15mm in combination with 60 degrees - 75 degrees infrarenal AND <             60 degrees suprarenal angulation OR in combination with < 75 degrees infrarenal AND             45 degrees - 60 degrees suprarenal angulation          -  Proximal necks > 15mm in combination with 75 degrees - 90 degrees infrarenal AND < 75             degrees suprarenal angulation OR in combination with < 90 degrees infrarenal AND 60             degrees - 75 degrees suprarenal angulation|April 2012|March 11, 2013|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810250|5 Years|69807|
NCT01819818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100810|A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients|Korea Post-Marketing Surveillance of Invega Sustenna||Janssen Korea, Ltd., Korea|No|Recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Participants with schizophrenia and prescribed with paliperidone palmitate for acute or        maintenance treatment.|March 2016|March 8, 2016|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819818||69074|
NCT01820091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-FUS-12-103|Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®|An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)||Spectrum Pharmaceuticals, Inc|No|Withdrawn|April 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820091||69053|
NCT01820702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Contract 22126/08/NL/VJ (SAG)|Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation|Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation or the Appliance of Definite Combined Training Program to Counteract Effects of Bed Rest (Acronym: SAG Study)|SAG|DLR German Aerospace Center||Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01820702||69006|
NCT01820988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-3-006|MaSS - Maastricht Sarcopenia Study|Cross-sectional Study on the Identification and Characterization of Community-dwelling Older People With Sarcopenia|MaSS|Maastricht University Medical Center|No|Completed|May 2013|December 2015|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|247|Samples With DNA|Blood sample.|Both|65 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|Community-dwelling older people|April 2015|January 18, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01820988||68984|
NCT01821274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN307-DERM-002|A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design|A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects, Using a Cumulative Irritant Patch Test Design||Ventrus Biosciences, Inc|No|Active, not recruiting|March 2013|September 2013|Anticipated|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|August 19, 2013|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821274||68962|
NCT01817985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-281-0112|A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment||Gilead Sciences|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|March 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01817985||69215|
NCT01817998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-048|Atrial Fibrillation (AF) and Physical Exercise|Role of Physical Exercise in Patients With Atrial Fibrillation.|EXAF|Hvidovre University Hospital|No|Completed|November 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817998||69214|
NCT01821885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011111013|Effectiveness of Spirometry as a Motivational Tool to Quit Smoking|Effectiveness of Spirometry and the Report of Spirometric Test Results by a Primary Care Physician on Smoking Cessation Rate in Adult Smokers: a Randomized Controlled Trial.|ESPIMOAT|Basque Health Service||Completed|April 2012|January 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|335|||Both|40 Years|80 Years|No|||January 2015|January 26, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821885||68915|
NCT01817673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creatine & kidney|Creatine Supplementation on Kidney Function in Resistance-trained Individuals|||University of Sao Paulo|No|Completed|July 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|46|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|March 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817673||69239|
NCT01817959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0211|Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation|A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation|REP0211|Dompé Farmaceutici S.p.A|No|Active, not recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|42|||Both|18 Years|70 Years|No|||July 2015|July 30, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01817959||69217|
NCT01818258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1092|IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children|IMPAACT 1092: Phase IV Evaluation Of The Steady State Pharmacokinetics Of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1-Infected Children||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Enrolling by invitation|October 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Months|36 Months|No|||October 2015|October 26, 2015|January 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818258||69194|
NCT01818271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hr2013:086|Effects of a Community-based Group Rehabilitation Program for Dynamic Balance and Mobility Post Stroke|Phase 1 Study of the Effects of a Community-based Group Rehabilitation Program for Dynamic Balance and Mobility; as an Alternate to Out-patient Rehabilitation Post Stroke;||University of Manitoba|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|55 Years|70 Years|No|||March 2013|December 18, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818271||69193|
NCT01818505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URIC|The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome|The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome|URIC|National Taiwan University Hospital|Yes|Recruiting|March 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|210|Samples Without DNA|serum|Both|20 Years|N/A|No|Non-Probability Sample|General population|April 2014|April 11, 2014|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818505||69175|
NCT01806155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|734/2555(EC2)|Prevalence of Post-craniotomy Headache in Siriraj Hospital|Prevalence of Post-craniotomy Headache in Siriraj Hospital||Mahidol University|No|Recruiting|March 2013|October 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient undergoing major craniotomy|August 2013|August 16, 2013|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01806155||70121|
NCT01806168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01578|rTMS in the Treatment of PTSD|The Role of Fast or Slow Repetitive Transcranial Magnetic Stimulation as Adjunct Therapy in Civilian Post-Traumatic Stress Disorder||University of British Columbia|No|Recruiting|September 2013|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|27|||Both|19 Years|70 Years|No|||September 2015|September 9, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806168||70120|
NCT01836172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW2012-YJP002|YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus|Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus||Han Wha Pharma Co., Ltd.|Yes|Recruiting|April 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|136|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836172||67822|
NCT01836510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA100|Selection of Potential Predictors of Worsening Heart Failure|Selection of Potential Predictors of Worsening Heart Failure|BioDetectHFIV|Biotronik SE & Co. KG|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Population of subjects with an indication for ICD and/or CRT-D implantation according to        current guidelines|January 2016|January 5, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01836510||67797|
NCT01836809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15024|Nesiritide and Renal Function After the Total Artificial Heart|The Impact of Nesiritide on Renal Function After Implantation of the Total Artificial Heart and Left Ventricular Assist Devices||Virginia Commonwealth University|Yes|Terminated|April 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 17, 2013|Yes|Yes|Futility for enrollment|No|July 7, 2014|https://clinicaltrials.gov/show/NCT01836809||67774|Enrollment closed. Total Artificial Hearts (TAH) are rarely done as advances with Left Ventricular Assist Devices have improved. We were unable to meet enrollment goal based on the funding timeline due to the lack of TAH's for comparison to LVAD.
NCT01809951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANID-1101|Isomil Post Marketing Observational Study|A Prospective, Open-label, Post-marketing Observational Study to Document the Use of Soy-based Infant Formula With Low Chain Polyunsaturates (LCP) in Infants With Symptoms Suggestive to Cow's Milk Allergy||Indonesia University|No|Recruiting|August 2011|July 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2250|||Both|6 Months|12 Months|No|Non-Probability Sample|Infants with symptoms suggestive adverse reactions to cow's milk protein|March 2013|March 11, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01809951||69829|
NCT01809964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1401-LCL-203|Clinical Trial to Evaluate ANT-1401 in Crow's Feet|Clinical Trial to Evaluate ANT-1401 in Subjects With Lateral Canthal Lines||Anterios Inc.|No|Completed|March 2013|October 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|109|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809964||69828|
NCT01810536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFLOWCF|High Flow Nasal Oxygen for Children With Cystic Fibrosis Presenting With Respiratory Failure - a Randomized Controlled Study|High Flow Nasal Oxygen for Children With Cystic Fibrosis Presenting With Respiratory Failure - a Randomized Controlled Study|HIFLOWCF|University of Sao Paulo|No|Not yet recruiting|April 2013|May 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|17 Years|No|||March 2013|March 11, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01810536||69785|
NCT01820104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130301|Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study|Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males||Xijing Hospital|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|March 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01820104||69052|
NCT01820403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK081714|Portion Size Effects on Body Weight:Free Living Setting|Portion Size Effects on Body Weight: Free Living Setting||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|233|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820403||69029|
NCT01820715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3030_DN_I (Version 3.4)|A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain|A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain||Dong-A ST Co., Ltd.|No|Completed|June 2010|||April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|70 Years|No|||August 2013|August 12, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01820715||69005|
NCT01820728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3801_CA_III (Version 4.0)|A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®|A Phase III Clinical Study for the Comparison Evaluation of DA-3801 and Gonal-F® in Infertile Female Patients With Chronic Anovulation Syndrome||Dong-A ST Co., Ltd.|No|Completed|January 2007|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|20 Years|38 Years|No|||March 2013|March 26, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01820728||69004|
NCT01820741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||March 28, 2013|March 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820741||69003|
NCT01821001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007353|Vaginal Bromocriptine for Treatment of Adenomyosis|Vaginal Bromocriptine for the Treatment of Adenomyosis||Mayo Clinic|No|Active, not recruiting|March 2013|June 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|25 Years|55 Years|No|||March 2016|March 15, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01821001||68983|
NCT01818544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16359|Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY85-8501 in Patients With Non-Cystic Fibrosis Bronchiectasis||Bayer|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01818544||69172|
NCT01818284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0579|Plerixafor for Stem Cell Mobilization in Normal Donors|Plerixafor for Stem Cell Mobilization in Normal Donors||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2013|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818284||69192|
NCT01817686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01381|Study of Default Options in Advance Directives|Default Options in Advance Directives for Veterans With Serious Illnesses: A Randomized Clinical Trial||Philadelphia Veterans Affairs Medical Center|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|62|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01817686||69238|
NCT01818752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005|Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)|A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma|CLARION|Onyx Pharmaceuticals|Yes|Active, not recruiting|March 2013|February 2019|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|882|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818752||69156|
NCT01819064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atropine in infants|Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants|Do Small Doses of Atropine Cause Bradycardia in Young Children||State University of New York at Buffalo|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|N/A|2 Years|No|Probability Sample|Children less than 2 yrs of age, weighing less than 15Kg coming to Women and Children's        hospital of Buffalo for elective surgery.|August 2013|August 1, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01819064||69132|
NCT01806467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210107|Validation of a New Method to Measure Cardiac Output: Comparison With Thermodilution|Continuous Thermodilution, Transpulmonary Thermodilution and Pressure Recording Analytical Method for Cardiac Output Measurement During Hemodynamic Instability: a Prospective Clinical Study||Università Politecnica delle Marche|No|Completed|August 2011|May 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|hemodynamic instability|March 2013|March 6, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01806467||70097|
NCT01806142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-C10-08-053|Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome|Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome|MCT|Laval University|No|Completed|February 2011|February 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Male|18 Years|60 Years|No|||March 2013|March 6, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806142||70122|
NCT01806441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-125-05-06|Impact of a Short-Term High Fat or Low Fat Diet on Intestinal Genes Expression Involved in the Cholesterol and Fatty Acid Metabolism|Impact of a Short-Term High Fat Diet Versus A Short-Term Low Fat Diet on Expression of the Key Intestinal Genes Involved in the Cholesterol and Fatty Acid Metabolism Pathways|DGENES|Laval University|No|Completed|February 2009|December 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01806441||70099|
NCT01806753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0661|Performance of Endoscopic Submucosal Dissection According to the Sedation Method|||Yonsei University|Yes|Completed|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|20 Years|80 Years|No|||January 2014|January 28, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806753||70075|
NCT01806766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPECCC|Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings|Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings in Primary Cementless Total Hip Arthroplasty in the Same Patients||Ewha Womans University|No|Completed|January 1998|December 2012|Actual|January 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806766||70074|
NCT01810263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1112-069-007|The Efficacy of Intensive Nutritional Supplement in Patient With Stroke|The Efficacy of Intensive Nutritional Supplement in Patient With Stroke: a Prospective Randomized Controlled Trial||Seoul National University Bundang Hospital|Yes|Terminated|May 2012|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||July 2015|July 1, 2015|February 1, 2013||No|The study does not seem to provide benefits to patients.|No|May 18, 2015|https://clinicaltrials.gov/show/NCT01810263||69806|
NCT01819532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046760|Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks|Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants <33 Weeks: A Randomized Controlled Trial||Johns Hopkins University|No|Recruiting|September 2011|June 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|15 Years|50 Years|No|||March 2013|March 22, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01819532||69096|
NCT01819545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10ZR1425800|The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease|Shanghai Mental Health Center||Shanghai Mental Health Center|Yes|Recruiting|January 2012|December 2015|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|300|Samples With DNA|Plasma miRNA107 and BACE1mRNA are to be retained.|Both|60 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|the subjects were collected from Shanghai Mental Health Center, Shanghai Jiao Tong        University School of Medicine (Alzheimer's Disease and Related Disorders Center, ADRDC)        and the of Shanghai Changning district, Huangpu district and Putuo district.|February 2014|February 16, 2014|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819545||69095|
NCT01820416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808718|The Effect of Low-Level Laser Stimulation on Hearing Thresholds|The Effect of Low-Level Laser Stimulation on Hearing Thresholds||University of Iowa|No|Terminated|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|75 Years|No|||March 2013|March 25, 2013|March 25, 2013||No|Analysis showed no clinically or statistically significant effects|No||https://clinicaltrials.gov/show/NCT01820416||69028|
NCT01820754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038093|Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)|Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer|TOP1201 IPI|Duke University|Yes|Recruiting|March 2013|November 2020|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|November 25, 2015|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820754||69002|
NCT01821014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000132|Satellite-supplementation of Medical Outreach Clinics: a Feasibility Study|Satellite-supplementation of Medical Outreach Clinics: a Feasibility Study||Mayo Clinic|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|144|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01821014||68982|
NCT01821313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00197|CASH- Children Active to Stay Healthy|Effects of High Intensity Interval Exercise on Inflammation and Endothelial Function in Children & Adolescents With Obesity|CASH|Nationwide Children's Hospital|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821313||68959|
NCT01819103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WM/0431|Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Evaluation of the Methods and Management of Acute Coronary Events-4: Investigating Variation in Hospital Acute Coronary Syndrome Outcomes||University of Leeds|No|Completed|March 2011|March 2013|Actual|February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5555|Samples With DNA|Blood, Urine|Both|18 Years|N/A|No|Non-Probability Sample|A total of 5555 consented patients were recruited from acute Trusts in England.|April 2013|April 3, 2013|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01819103|12 Months|69129|
NCT01818778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Queens-Baycrest 65|The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes|The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes|VolCogStim|Queen's University|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01818778||69154|
NCT01818791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD069427-03|Enhancing Quality Interventions Promoting Healthy Sexuality|Enhancing Quality Interventions Promoting Healthy Sexuality|EQUIPS|RAND|No|Active, not recruiting|July 2012|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|960|||Both|10 Years|14 Years|No|||May 2015|May 5, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01818791||69153|
NCT01818804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20120076|The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis|The Effect of n-3 Polyunsaturated Fatty Acids on Risk Markers for Cardiovascular Disease and Inflammation in Patients With Psoriatic Arthritis||Aalborg Universitetshospital|Yes|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|145|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01818804||69152|
NCT01819090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012- A01394-39|Optimizing Communication During Ventilation|Optimizing Communication During Nasal Mechanical Ventilation|PHONOVNI|Centre d'Investigation Clinique et Technologique 805|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||October 2015|February 12, 2016|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01819090||69130|
NCT01818518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0022|Neonatal Outcome by Reason for Delivery|Neonatal Outcome by Reason for Delivery - A Prospective, Observational Study||Mednax Center for Research, Education and Quality|No|Active, not recruiting|July 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1290|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All babies from singleton pregnancies delivering in each of the involved hospitals who        delivered at less than 32 weeks of gestation and who are stillborn, who die in the        delivery room and who are cared for in the Neonatal Intensive Care Unit (NICU) will be        included.|March 2016|March 11, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818518||69174|
NCT01818531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00023002|Adductor Canal Block for Medial Compartment Knee Arthroplasty|Evaluation of Ultrasound-Guided Adductor Canal Blockade for Postoperative Analgesia Following Robotic Medial Unicompartmental Knee Replacement||Wake Forest Baptist Health|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|85 Years|No|||May 2015|May 26, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01818531||69173|
NCT01818765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-2013-208|A Pilot Study of Interventricular Septal Puncture for Cardiac Resynchronization Therapy to Treat Heart Failure|Left Ventricular Endocardial Pacing Through the Ventricular Septum|LV-CONSEPT|Oxford University Hospitals NHS Trust|Yes|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01818765||69155|
NCT01819077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMR-RS|TMMR (Total Mesometrial Resection) Register Study|Register Study: TMMR and Therapeutic Lymphadenectomy According to M.Hoeckel for Treatment of Cervical Cancer FIGO IB-IIA|TMMR-RS|University Hospital, Essen|No|Recruiting|March 2013|March 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE.|May 2015|May 26, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01819077|5 Years|69131|
NCT01806818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EPAC-201|Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients|A Phase 2, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Compare Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients||Hanmi Pharmaceutical Company Limited|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|98|||Both|20 Years|60 Years|No|||August 2013|August 22, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01806818||70070|
NCT01806454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hx2ck1|Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China|Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China: a Multi-center, Prospective Random Trial||West China Second University Hospital||Recruiting|October 2013|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|11000|||Female|N/A|N/A|No|||April 2014|August 24, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01806454||70098|
NCT01806779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042699|Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers|Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers|ConNic5|Duke University|Yes|Completed|March 2013|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|376|||Male|18 Years|65 Years|No|||October 2015|December 14, 2015|March 6, 2013|Yes|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01806779||70073|
NCT01806792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_RSNPM_301|Post-menopausal Women Osteoporosis(Phase III)|For 4 Months, the Multi Center, Double Blinded, Randomized, Active Controlled, Comparative Clinical Study to Assess the Efficacy and the Safety to Improvement Effect of Vit.D of Risenex Plus M Tablet in Patients With In Post-menopausal Women Osteoporosis||Hanlim Pharm. Co., Ltd.|No|Completed|November 2009|March 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Female|N/A|N/A|No|||March 2013|March 6, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01806792||70072|
NCT01807078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222-D-2013|Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients|Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial|CHOLESS|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||March 2013|March 6, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01807078||70050|
NCT01819259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037792|Nicotine, Non-Smokers With and Without ADHD, and Genetics Study|Nicotine, Non-Smokers With and Without ADHD, and Genetics Study|NNSG|Duke University|No|Recruiting|January 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01819259||69117|
NCT01819272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCRM105|Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus||Elcelyx Therapeutics, Inc.|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|240|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|March 19, 2013|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01819272||69116|
NCT01819571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0056|Pulse Pressure Variation for Prediction of Fluid Responsiveness in Coronary Artery Disease Patients With Diastolic Dysfunction|||Yonsei University|Yes|Completed|January 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|66|||Both|20 Years|N/A|No|||February 2014|February 17, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01819571||69093|
NCT01819584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9794-KM-CTIL|Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism|Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism||Sheba Medical Center|No|Not yet recruiting|April 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|N/A|No|Probability Sample|The study will include conservatively treated CHI patients who are in remission for at        least one year|March 2013|March 24, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01819584||69092|
NCT01819831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120263|A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall|A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall||Loma Linda University|No|Recruiting|March 2013|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|98 Years|No|||January 2016|January 27, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819831||69073|
NCT01820429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCORPA|Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease|Residual Platelet Activity Despite Aspirin Utilization in Patients With Non ST Elevation Acute Coronary Syndromes: Comparison Between the Acute and Chronic Phases||University of Sao Paulo General Hospital|Yes|Completed|December 2009|April 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|70 patients diagnosed with non ST acute coronary syndrome (unstable angina and myocardial        infarction without ST elevation), with up to 48 hours of evolution from the onset of        symptoms.|March 2013|March 25, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01820429||69027|
NCT01817335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13128|Psycho-Educational Program in Increasing Knowledge and Satisfaction and Decreasing Distress in Younger Patients With Cancer Receiving Treatment|Pilot Study of Psycho-Educational Group for Young Adults (YA) on Treatment: Impact on Knowledge, Distress, and Satisfaction||City of Hope Medical Center|Yes|Completed|August 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|30 Years|No|||May 2015|May 29, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01817335||69265|
NCT01814371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS021736|Individualized vs. Household MRSA Decolonization|Individualized vs. Household Eradication of MRSA in Households With Children|HOME2DS|Washington University School of Medicine|Yes|Enrolling by invitation|April 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|N/A|N/A|No|||December 2014|December 8, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814371||69491|
NCT01814605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0060-A|Sciatic Nerve Block Using the Subgluteal Space Approach: A Comparison With the Infragluteal Approach|Ultrasound-guided Sciatic Nerve Block Using the Subgluteal Space Injection Approach: A Comparison With the Infragluteal Approach||University Health Network, Toronto|No|Completed|June 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|85 Years|No|||March 2013|March 15, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01814605||69473|
NCT01814618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1567|Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery|Trial of Directed High-dose Nasal Steroids on Residual Olfactory Dysfunction in Patients With Chronic Rhinosinusitis Following Endoscopic Sinus Surgery||University of North Carolina, Chapel Hill|No|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|84 Years|No|||March 2013|March 18, 2013|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814618||69472|
NCT01814956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0813|Different Lipid Emulsions in Acute Lung Injury Patients|Prospective, Randomized, Controlled, Double-blind, Parallel-group, Mono-center, Explorative Phase IV Trial on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion Versus a Standard Soybean-oil Based Lipid Emulsion in Patients With Acute Lung Injury||B. Braun Melsungen AG|No|Terminated|March 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|March 18, 2013||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01814956||69446|
NCT01816243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009925|An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain|Evaluation Study of Efficacy and Safety of TTS-Fentanyl in Chronic Non-Malignant Pain||Janssen-Cilag Ltd.,Thailand|No|Completed|April 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|March 19, 2013|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01816243||69349|Some limitations of this study were non randomization and uncontrolled design.
NCT01816256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPN 12-01|Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms|Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms||University Health Network, Toronto|No|Recruiting|May 2013|||March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|N/A|N/A|No|||January 2016|January 7, 2016|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01816256||69348|
NCT01817062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoNec|Neonates With Very Low Birth Weight and Surgery Therapy of Acute Abdomen|Retrospective Analysis of Intraoperative Volume Administration in Neonates Without Congenital Malformations With Very Low Birth Weight and Acute Abdomen.|NeoNec|Charite University, Berlin, Germany|No|Completed|January 2001|March 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|89|||Both|N/A|4 Weeks|No|Probability Sample|Neonates with very low birth weight and surgery therapy of acute abdomen|May 2013|May 7, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817062||69286|
NCT01814137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-4003|A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily|A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)|BOOST®|Novo Nordisk A/S|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 15, 2013|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01814137||69509|Due to the highly selected trial population randomised in this trial (N=40), the results should be interpreted with caution.
NCT01815463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00919|Non-Invasive Prediction of Colorectal Neoplasia|Non-Invasive Prediction of Colorectal Neoplasia|NIPCON|Philadelphia Veterans Affairs Medical Center|No|Terminated|August 2006|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2282|Samples With DNA|Stool Urine Saliva Blood Tissue|Both|18 Years|85 Years|No|Probability Sample|Greater than average risk for colorectal neoplasia|November 2013|February 6, 2015|March 18, 2013||No|Local PI was not able to submit the annual review renewal in time, thus terminated, still    active in Detroit but not recruiting.|No||https://clinicaltrials.gov/show/NCT01815463||69409|
NCT01815203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH2013a|Caffein Consumption and Response Inhibition|Does Caffeine Consumption Improve Response Inhibition to Food Cues?||Uppsala University|No|Completed|March 2013|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|21|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815203||69429|
NCT01815216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH2013b|Effect of Gastric Bypass Surgery on Brain Responses|The Effects of Bariatric Surgery on Impulsivity and Attentional Bias to Food Cues||Uppsala University|No|Suspended|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|48|||Female|18 Years|65 Years|No|||June 2015|June 1, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815216||69428|
NCT01803581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYS004-0013|A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice|A Randomized, Controlled, Investigator-blinded, Comparative Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice||Oystershell NV|No|Enrolling by invitation|February 2013|||May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|N/A|No|||March 2013|March 1, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01803581||70318|
NCT01803594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264254|Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism|Postprandial Modulation of HDL Metabolism|HDL|University of California, Davis|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803594||70317|
NCT01803919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-SUR-2011-68|Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients|Multicentric, Controlled, Randomized Clinical Trial to Assess the Efficacy and Cost-effectiveness of Urinary Catheters With Silver Alloy Coating Versus Conventional Catheters in Spinal Cord Injured Patients|ESCALE|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|November 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|742|||Both|18 Years|N/A|No|||March 2013|September 10, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803919||70293|
NCT01804140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28560|A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)|Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib||Genentech, Inc.||Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|662|None Retained|Formalin-fixed paraffin-embedded (FFPE) tumor samples|Both|18 Years|N/A|No|Probability Sample|Patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or        multiple myeloma|February 2016|February 1, 2016|February 26, 2013||No||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01804140||70276|
NCT01800721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA031030|Social Networks and Prevention|A Randomized Controlled Trial to Train Black MSM as Peer Health Educators for HIV Testing and Prevention|SNAP|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|July 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|April 22, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800721||70537|
NCT01800734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBonadonna artificial pancreas|Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study|Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study.||Azienda Ospedaliera Universitaria Integrata Verona|No|Recruiting|October 2012|February 2015|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|65 Years|No|||August 2012|November 18, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01800734||70536|
NCT01813500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI and IBD|Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients|Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients||Boston Medical Center|Yes|Recruiting|October 2011|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Serum, stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Crohn's Disease and Ulcerative Colitis or healthy controls.|January 2015|January 28, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01813500||69558|
NCT01813773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THE A.C.T. STUDY|Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study|Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study|ACT|Ophthalmic Consultants of Long Island|No|Recruiting|March 2013|March 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|February 25, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01813773||69537|
NCT01813786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO-CAPHST-07|Clinical and Histological Evaluation of the 755nm Alexandrite Laser With Handpiece for the Treatment of Scars|||Cynosure, Inc.|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|85 Years|No|||February 2014|February 7, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813786||69536|
NCT01813799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-9801|Study of DA-9801 to Treat Diabetic Neuropathic Pain|Phase 2 Clinical Study to Evaluate DA-9801 Tablet's Effectiveness and Safety and to Decide Optimal Volume for Neuropathic Pains With Diabetic Neuropathy Patients as the Target||Dong-A ST Co., Ltd.|No|Recruiting|November 2011|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|20 Years|70 Years|No|||August 2013|August 12, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813799||69535|
NCT01816035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7900|Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery|Thrombokinetic Studies of Ado-Trastuzumab Emtansine||University of Washington|No|Recruiting|June 2014|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816035||69365|
NCT01816048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO12810|NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis|A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone||University of Wisconsin, Madison|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|N/A|No|||October 2015|October 9, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816048||69364|
NCT01814163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP 09-02|Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab|Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology|ANGIOMET|Spanish Lung Cancer Group|Yes|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-small cell lung cancer advanced unresectable, metastatic or recurrent,        non-squamous and untreated with chemotherapy|March 2013|March 18, 2013|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01814163||69507|
NCT01813279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01228-33|Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis|Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis||Assistance Publique Hopitaux De Marseille|Yes|Completed|November 2012|March 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01813279||69575|
NCT01813591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTHAR|A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines|A Randomized, Open-Label, Parallel Two-Arm Study Evaluating the Efficacy of H.P. Acthar Injection Gel in the Treatment of Adults With Intractable Chronic Migraine||Dent Neuroscience Research Center|No|Active, not recruiting|April 2013|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||August 2014|August 19, 2014|March 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813591||69551|
NCT01813864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015125|Linking Services to Patient Needs for Improved Patient Outcomes (CASPAR)|Linking Services to Patient Needs for Improved Patient Outcomes (CASPAR)|CASPAR|Treatment Research Institute|No|Completed|August 2004|July 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|352|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01813864||69530|
NCT01813877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDOPA12-000939|Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma|Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma F-DOPA PET/CT||University of California, Los Angeles|No|Recruiting|September 2012|September 2019|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|360|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|March 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813877||69529|
NCT01814644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003436|Interactive Mobile Messaging for Weight Control Among the Underserved|Tailored Rapid Interactive Mobile Messaging (TRIMM) for Weight Control Among the Underserved|TRIMM|Johns Hopkins Bloomberg School of Public Health|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|124|||Both|21 Years|65 Years|No|||January 2015|January 14, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01814644||69470|
NCT01815710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCO150GP|Best Strategies for Implementation of Clinical Pathways in Emergency Department Settings|Best Strategies for Implementation of Clinical Pathways in Emergency Department Settings||Children's Hospital of Eastern Ontario|No|Enrolling by invitation|January 2013|November 2016|Anticipated|July 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|6400|||Both|3 Months|17 Years|No|Non-Probability Sample|Community hospitals in a variety of local health integration networks across Ontario (very        high to low volume).|March 2016|March 2, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815710||69390|
NCT01816815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14723|Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days||Bayer|No|Completed|November 2011|January 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|73|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816815||69305|
NCT01813240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0727-11-HMO|Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement|||Hadassah Medical Organization|No|Not yet recruiting|May 2013|||April 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|444|||Both|18 Years|65 Years|No|||March 2013|March 15, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813240||69578|
NCT01814657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00029750|Optimizing Patient Analgesic Experience During IVF|Optimizing Patient Analgesic Experience During IVF||University of Alberta|No|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|308|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01814657||69469|
NCT01812707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI12361|Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥100 mg/dL (≥2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy||Sanofi|Yes|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|20 Years|75 Years|No|||August 2015|August 21, 2015|March 14, 2013|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01812707||69619|
NCT01815723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP187-301|Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis|A Randomised, Double Blind, Double Dummy, Active Comparator and Placebo Controlled Confirmative Non-inferiority Trial of FP187 Compared to Fumaderm® in Moderate to Severe Plaque Psoriasis||Forward-Pharma GmbH||Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815723||69389|
NCT01815736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0109|Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects|A Phase 3, Open-Label Study to Evaluate Switching From a TDF-containing Combination Regimens to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-suppressed, HIV-1 Positive Subjects||Gilead Sciences|Yes|Active, not recruiting|April 2013|February 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1439|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815736||69388|
NCT01803633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264297-2|Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2|Effects of Dairy Fat on Postprandial Inflammation- Phase 2||University of California, Davis|No|Active, not recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803633||70315|
NCT01800461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120844-01H|Occupational Performance Coaching for Stroke Survivors|Occupational Performance Coaching for Stroke Survivors: A Novel Patient-centered Intervention to Improve Participation in Personally Valued Activities||Ottawa Hospital Research Institute|No|Completed|February 2013|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01800461||70557|
NCT01800747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-Pediatrics|Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics)|Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics)|DAP|Asociacion Colaboracion Cochrane Iberoamericana|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|2 Years|14 Years|No|||June 2015|June 23, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800747||70535|
NCT01800968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042633|Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)|Functional Impact of GLP-1 for Heart Failure Treatment|FIGHT|Duke University|Yes|Completed|April 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01800968||70518|
NCT01801267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043098|Third Ventriculostomy Versus Shunt for Children With Hydrocephalus|A Randomized Controlled Trial of Endoscopic Third Ventriculostomy Versus Ventricular Shunt for Children With Communicating Hydrocephalus||Duke University|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|1 Year|18 Years|No|||March 2016|March 7, 2016|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801267||70496|
NCT01813513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-004|Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)|A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|March 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813513||69557|
NCT01813526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH75|Infants With Protein Sensitive Colitis|Evaluation of an Elemental Formula in Infants With Protein Sensitive Colitis||Abbott Nutrition|No|Completed|November 1999|February 2001|Actual|February 2001|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|53|||Both|N/A|6 Months|No|||March 2013|March 15, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813526||69556|
NCT01813812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA6034_Gas_III (Version 4.3)|A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis||Dong-A ST Co., Ltd.|No|Recruiting|October 2010|||August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|492|||Both|20 Years|75 Years|No|||March 2013|March 20, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813812||69534|
NCT01814670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-BTXC-12-001|Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines|||Allergan|No|Completed|March 2013|October 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|60 Years|No|||July 2015|August 5, 2015|March 18, 2013|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01814670||69468|
NCT01814176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0229-B|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope in Patients With at Least One Difficult Intubation Risk Factor||University Health Network, Toronto|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814176||69506|
NCT01814098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016381|An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms|Escitalopram in the Long-term Treatment of Major Depressive Disorder With Associated Anxiety Symptom|Lexapro|Xian-Janssen Pharmaceutical Ltd.|No|Completed|July 2009|November 2011|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|318|||Both|18 Years|65 Years|No|||May 2014|May 30, 2014|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814098||69512|
NCT01814384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 12_0100|Medico-economic Study of Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During Knee Arthroplasty GMK ®.|Medico-economic Study of Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During Knee Arthroplasty GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About Medical Device.||Nantes University Hospital|No|Active, not recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01814384||69490|
NCT01814631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409829|Endoscopic Ultrasound (EUS) Processor Comparison|Prospective Comparison of Two EUS Processors for Imaging of the Pancreas||Florida Hospital|No|Withdrawn|March 2013|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|19 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreas will        be included.|January 2014|January 8, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814631||69471|
NCT01815450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI1100-202|BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris|||Braintree Laboratories|No|Completed|February 2013|||November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|369|||Both|12 Years|45 Years|No|||January 2015|January 26, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815450||69410|
NCT01816555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101813|Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma|Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II||Medical University of South Carolina|Yes|Terminated|January 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|N/A|No|||August 2014|July 20, 2015|February 6, 2013||No|Study closed due to low accrual.|No||https://clinicaltrials.gov/show/NCT01816555||69325|
NCT01816802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-009|Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment|MERGE: MulticEnter ReGistry With Eeva|MERGE|Progyny, Inc.|No|Active, not recruiting|February 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Female|N/A|N/A|No|Non-Probability Sample|Patients undergoing in vitro fertilization treatment who provide informed consent and use        Eeva in their treatment cycle.|March 2015|March 25, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816802|12 Months|69306|
NCT01817309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLPS|Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis|Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis||Chinese University of Hong Kong|No|Active, not recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|90 Years|No|||February 2015|February 4, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01817309||69267|
NCT01813838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003120-21|GFM-Acadesine: A Phase I-II Trial of Acadesine|GFM-Acadesine: A Phase I-II Trial of Acadesine in IPSS High and Int-2 SMD, LAM With 20-30% Marrow Blasts and Chronic Myelomonocyticleukemia Type 2 Not Responding to Azacitidine or Decitabine for at Least 6 Courses or Relapsing After a Response|GFM-Acadesine|Groupe Francophone des Myelodysplasies|Yes|Suspended|June 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|March 12, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813838||69532|
NCT01814111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-SR-082|Renal Sympathetic Denervation in Patients With Hypertension and Paroxysmal Atrial Fibrillation|Safety and Effectiveness Study of Percutaneous Catheter-based Sympathetic Denervation of the Renal Arteries in Patients With Hypertension and Paroxysmal Atrial Fibrillation|RSDforPAF|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|July 2012|June 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2013|March 15, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01814111||69511|
NCT01812447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-03434|Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function|A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema|EMPROVE|Spiration, Inc.|Yes|Recruiting|June 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|40 Years|N/A|No|||March 2016|March 4, 2016|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812447||69639|
NCT01809444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010-doxy|Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy|The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial||Sun Yat-sen University|Yes|Recruiting|November 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|60 Years|No|||December 2013|December 7, 2013|December 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01809444||69868|
NCT01809704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-03267|Clinical Validation of New OCT System|Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study||Topcon Medical Systems, Inc.|No|Completed|February 2013|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that are Normal, or shows signs of Glaucoma or Retinal Ocular Pathology.|January 2014|January 22, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809704||69848|
NCT01816269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cu1959|Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection|Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection|Scaling and Hp|Goztepe Training and Research Hospital|No|Enrolling by invitation|March 2013|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|70 Years|No|Non-Probability Sample|Eligible population with H.pylori infection and result of treatment based on presence of        dental scaling.|March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816269||69347|
NCT01812967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Milk Components Study|Mechanism of Action of Milk and Its Components on Glycemic Control in Healthy Young Men|||University of Toronto||Completed||||September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Prevention|||Actual|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||March 2013|March 15, 2013|March 13, 2013||||No||https://clinicaltrials.gov/show/NCT01812967||69599|
NCT01804426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-12-221|Hair Cortisol Level as a Predictor of PTSD Development|Hair Cortisol Level as a Predictor of PTSD Development||Shalvata Mental Health Center|No|Suspended|March 2013|November 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|-  Blood        -  Saliva        -  Hair|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 men and women arriving at Meir medical center Emergency department, as a result of a        traumatic civil event.|November 2014|November 18, 2014|February 28, 2013||No|Lack of funding.|No||https://clinicaltrials.gov/show/NCT01804426||70254|
NCT01800474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PT1209|A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice|A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice||Q-Med AB|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|582|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient aiming to perform one or more of the following aesthetic procedures:          1. Pulsed-dye laser therapy          2. Laser-assisted hair removal          3. Non-ablative laser resurfacing          4. Dermal filler injection          5. Vascular access|February 2015|February 27, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01800474||70556|
NCT01800981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW2012-12-12|Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care|Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care (SOC) Protocol MW2012-12-12||MediWound Ltd|No|Not yet recruiting|March 2013|||July 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|53|||Both|10 Years|61 Years|No|Probability Sample|Adults and children who had participated and completed study MW2004-11-02 (previous phase        3 study) will be contacted. Patients who will agree to participate in the study will be        invited to the clinic for a one day visit for assessments.|February 2013|February 27, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01800981||70517|
NCT01801280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL 080A DE 20 T|Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept®|Single Center, Open Label, Cross-over Study in Maintenance Renal Transplant Patients to Evaluate the Bioavailability of CellCept® (Mycophenolate Mofetil) in Comparison to Myfortic® (Enteric Coated Mycophenolate Sodium) With/Without the Proton Pump Inhibitor Pantozol® (Pantoprazole).||Charite University, Berlin, Germany|No|Recruiting|January 2012|December 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801280||70495|
NCT01801293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-0109|A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806|A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806||Gilead Sciences|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01801293||70494|
NCT01813539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARGX-110-1201|Phase 1b Study of ARGX-110 in Patients With Advanced Malignancies|A Phase I Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70||arGEN-X BVBA|No|Recruiting|February 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|54|||Both|18 Years|N/A|No|||January 2015|January 25, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01813539||69555|
NCT01813552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-006|To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)|A Phase I, Randomized, Open-label Study to Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|March 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813552||69554|
NCT01814683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL 1301|IMPROV (Improving the Radical Cure of Vivax Malaria)|Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens||University of Oxford|Yes|Recruiting|July 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|2075|||Both|6 Months|N/A|No|||June 2015|June 11, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814683||69467|
NCT01815749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12224|Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma|Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|September 2013|||September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01815749||69387|
NCT01815762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RandBCM|Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients|Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients|BUST|Grigore T. Popa University of Medicine and Pharmacy|No|Completed|March 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815762||69386|
NCT01817088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/07|Sub-thalamic Nucleus Stimulation in Parkinson Disease|Sub-thalamic Nucleus Stimulation in Parkinson Disease: Comparison of a Two-steps Electrophysiological Approach Under Local and General Anesthesia and a One-step Approach Under General Anesthesia|PARKEO|University Hospital, Bordeaux|Yes|Recruiting|March 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|70 Years|No|||November 2014|November 12, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817088||69284|
NCT01814969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRT-COI-01|Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer.|Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|March 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||May 2015|May 4, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814969||69445|
NCT01815190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-040-f-S|IgA-positive Versus IgA-negative Immune Complex Vasculitis|Retrospective Analysis of Frequency of Systemic Involvement in IgA-positive Cutaneous Immune Complex Vasculitis Versus IgA-negative Cutaneous Immune Complex Vasculitis||University Hospital Muenster|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients of the department of dermatology in Muenster with histologically proven        leukocytoclastic vasculitis in files in last 10-20 years|November 2015|November 30, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815190||69430|
NCT01816009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN09 - LB / DATIPO|Treatment of the Infections on Osteo-articular Prostheses by 6 Versus 12 Weeks of Antibiotherapy|Multicentric Study, of Non Inferiority, Randomized, Opened, to Evaluate the Two Durations Effectiveness of Antibiotherapy (6 Weeks Versus 12 Weeks) in the Treatment of Osteo-articular Prostheses Infections, With Prosthetic Change (in 1 Time or 2 Long Times) or Not (Articular Washing)|DATIPO|University Hospital, Tours|No|Active, not recruiting|November 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01816009||69367|
NCT01811615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHCMA-CHM-BUH-RHS-00633|Efficacy of New Alcohol Free Mouthrinses|A Clinical Study to Investigate the Efficacy of New Alcohol Free Mouthrinses||University of Witten/Herdecke|No|Completed|February 2010|||February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01811615||69702|
NCT01811875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF07|Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A|Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A||Bio Products Laboratory|No|Recruiting|June 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||February 2015|March 30, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811875||69682|
NCT01812161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15002738313766868351|Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome|Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome||Huazhong University of Science and Technology|Yes|Recruiting|September 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|28 Years|No|||February 2016|February 21, 2016|December 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01812161||69660|
NCT01809106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio CERP|RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.|RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.|CERP|Mario Negri Institute for Pharmacological Research|No|Completed|April 2011|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|518|||Both|18 Years|N/A|No|||October 2015|November 20, 2015|March 8, 2013||No||No|October 20, 2015|https://clinicaltrials.gov/show/NCT01809106||69894|
NCT01808885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622CLEQ1585-1|Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.|A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.|MSREPAIR|Trophos|Yes|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01808885||69911|
NCT01812980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatFlu_HIVpos_nonpregnant|Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women|Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV- Infected Women: An Open Label Trial.||University of Witwatersrand, South Africa|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|105|||Female|18 Years|39 Years|No|||December 2013|December 10, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812980||69598|
NCT01804439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 12_153R|Risk Factors in the Initial Presentation of Specific Cardiovascular Disease Syndromes|Cardiovascular Risk Factors in the Initial Presentation of Specific Cardiovascular Disease Syndromes: a CALIBER Proposal Using Linked GPRD-MINAP-HES Data||University College, London|No|Completed|January 1997|March 2010|Actual|March 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2240000|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include all patients aged ≥30yrs old, registered in CPRD        practices in England consenting to data linkage, with at least 1 year of up-to-standard        pre-study follow-up and no history of any of the CVD endpoints considered. Follow-up for        endpoints will commence on the earliest date on which a patient fulfils the criteria,        within the period between 1st January 1997 and 25th March 2010.|March 2013|March 3, 2013|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01804439|10 Years|70253|
NCT01800773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31806|Written Exposure Therapy for Posttraumatic Stress Disorder|Written Exposure Therapy for Post Traumatic Stress Disorder: A Randomized Noninferiority Trial|WET|Boston University|Yes|Recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01800773||70533|
NCT01801306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-12-04-006261|A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy|A New Multi-parameter Monitoring System Applying Near Infrared Spectroscopy and Indocyanine Green to Detect Cerebrovascular Events in Patients With Subarachnoid Hemorrhage||NeMoDevices AG|Yes|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|75 Years|No|||June 2014|June 17, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801306||70493|
NCT01801319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-07|A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression|A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression||St. Jude Medical|No|Active, not recruiting|June 2011|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|70 Years|No|||November 2015|November 17, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801319||70492|
NCT01801579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01036-37|Reproducibility of Ankle Brachial Index After Maximal Exercise|Reproducibility of the Ankle-Brachial Index Measurements After a Maximal Exercise|RICATEM|University Hospital, Angers|Yes|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|health volunteers over 18 years old|February 2016|February 11, 2016|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01801579||70472|
NCT01814410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER0006|Interactive Effects of IV Ethanol and IV Nicotine|A Laboratory Study on the Interactive Effects of IV Ethanol and IV Nicotine on Subjective Effects and Cognition||Yale University|No|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|50|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01814410||69488|
NCT01816581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1043/2010|Oral Oxycodone After Major Cardiac Surgery|Prospective, Randomized Clinical Pilot Study: Oral Opiate Targin In Treatment Of Postoperative Pain After Major Cardiac Surgery||Medical University of Vienna|No|Completed|July 2011|March 2013|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||March 2014|March 25, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01816581||69323|
NCT01813825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVMC 104|A Single Site Prospective, Non-randomized Study of Partial Breast Intracavitary Brachytherapy Devices to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.|||St. Vincent's Medical Center|No|Recruiting|November 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|300|||Female|45 Years|N/A|No|Non-Probability Sample|Females, with Breast Cancer Tis, T1,N0,M0. Negative Surgival Margens|March 2013|March 14, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01813825|7 Years|69533|
NCT01811355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378164-3|Mexiletine for the Treatment of Muscle Cramps in ALS|Mexiletine for the Treatment of Muscle Cramps in ALS||University of California, Davis|No|Active, not recruiting|May 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|89 Years|No|||January 2016|January 18, 2016|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811355||69722|
NCT01811329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264297-1|Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1|Effects of Dairy Fat on Postprandial Inflammation- Phase 2||University of California, Davis|No|Active, not recruiting|August 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811329||69724|
NCT01811342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348788|Continuous Hemoglobin Evaluation|Evaluation of the Masimo Continuous Hemoglobin Monitor With Polar Plot Methodology||University of California, Davis|No|Active, not recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective surgery.|June 2015|June 30, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01811342||69723|
NCT01812460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-085|Progressive Resistance Training of the Extensor Muscle of the Thigh in COPD-patients Hospitalized With an Exacerbation|Progressive Resistance Training of the Extensor Muscle of the Thigh in COPD-patients Hospitalized With an Exacerbation||Frederikssunds Hospital, Denmark|Yes|Withdrawn|December 2012|November 2013|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|N/A|N/A|No|||October 2013|October 25, 2013|March 14, 2013||No|The Study had to stop due to organizational changes in Nordsjællands Hospital|No||https://clinicaltrials.gov/show/NCT01812460||69638|
NCT01812473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML8949|Plasma Protein Binding Characteristics of Voriconazole|Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients.||Universitaire Ziekenhuizen Leuven|No|Completed|February 2013|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|Samples With DNA|Plasma and serum samples are obtained to determine the albumin and alpha-1-acid-glycoprotein      level.|Both|2 Years|N/A|No|Probability Sample|Patients admitted to the intensive care unit|March 2013|March 3, 2015|March 1, 2013||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01812473||69637|Relatively small data set.Only adult ICU patients.No data are available for plasma albumin concentrations above 40 g/liter.
NCT01812720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1287|Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant|A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)|CARAMEL 2|Mayo Clinic|No|Active, not recruiting|August 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812720||69618|
NCT01808859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biodex2013|Tourniquet and Quadricepsforce|The Effect of Tourniquet Use During Total Knee Arthroplasty Surgery on the Postoperative Loss of Quadricepsforce||Region Skane|No|Completed|February 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|41 Years|80 Years|No|||November 2014|November 5, 2014|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01808859||69913|
NCT01808872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-043652|Clinical Performance Evaluation of AQT90 FLEX BNP and NT-proBNP|Clinical Sensitivity and Specificity Study of AQT90 FLEX BNP and NT-proBNP||Radiometer Medical ApS|No|Completed|March 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|569|Samples Without DNA|Samples are retained only for this study (troubleshooting purposes).|Both|21 Years|N/A|No|Non-Probability Sample|Subjects 21 years of age or older with heart failure|May 2014|May 2, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808872||69912|
NCT01809743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42049.060.12|Regadenoson and Adenosine|Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve||Catharina Ziekenhuis Eindhoven|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|100|||Both|18 Years|80 Years|No|||November 2013|November 11, 2013|December 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809743||69845|
NCT01809756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41938.015.12|The Effect of Caphosol® on the Development of Esophagitis in Small Cell Lung Cancer (SCLC) Patients Treated With Concurrent Chemo/Radiotherapy|The Effect of Caphosol® on the Development of Esophagitis in Small Cell Lung Cancer (SCLC)Patients Treated With Concurrent Chemo/Radiotherapy A Prospective Study of Caphosol + Standard of Care Versus Standard of Care|CARACTER|Amphia Hospital|No|Not yet recruiting||December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||March 2013|March 11, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01809756||69844|
NCT01804166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100938|A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)|A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)||Janssen Scientific Affairs, LLC|No|Recruiting|March 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|N/A|N/A|No|||March 2016|March 11, 2016|February 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804166||70274|
NCT01800487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramathibodi_silymarin|The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs|The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs||Ramathibodi Hospital|No|Completed|January 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|February 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01800487||70555|
NCT01800760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136010|Probiotics to Improve Women's Health|Probiotics to Improve Women's Health||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01800760||70534|
NCT01800994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-HAL-EL-32|Prospective evAluatIon foR Inhalation Devices Study|Multicenter, Prospective, Observational, Non Interventional Clinical Trial to Assess the Asthma and COPD Treatment by Inhalation Devices|P A I R|Elpen Pharmaceutical Co. Inc.|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|750|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Asthma and COPD treated by inhalation devices|August 2014|August 18, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01800994||70516|
NCT01801007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL12001|Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms|Pivotal Study of the MicroVention Flow Re-Direction Endoluminal Device (FRED) Stent System in the Treatment of Intracranial Aneurysms|FRED|Microvention-Terumo, Inc.|Yes|Active, not recruiting|July 2013|August 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|22 Years|75 Years|No|||December 2015|December 17, 2015|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801007||70515|
NCT01794078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037605|A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude|A Randomized, 4-Sequence, Double-Blind Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude|GQ02|Duke University||Completed|September 2013|December 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|92|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|February 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01794078||71045|
NCT01794377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBELIX|Influence of Muscle Strength on the Energy Cost of Walking in Obese Subjects|Influence of Muscle Strength on the Energy Cost of Walking in Obese Subjects|OBELIX|Centre Hospitalier Universitaire de la Réunion|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|40 Years|No|||July 2014|July 24, 2014|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794377||71022|
NCT01794598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5132|Preliminary Study Examining Heart Failure Patients Responses to Depression Education|HF-ACTION Depression Education Substudy||Duke University|No|Terminated|May 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|270|||Both|18 Years|N/A|No|||February 2013|September 19, 2014|February 17, 2012||No|Terminated|No||https://clinicaltrials.gov/show/NCT01794598||71005|
NCT01815476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380-2012|The Prone Breast Radiation Therapy Trial|A Multicentre Randomized Controlled Clinical Trial for the Reduction of Acute Skin Reaction in Adjuvant Breast Radiation in Large Breasted Women Using a Prone Technique - The Prone Breast Trial||Toronto Sunnybrook Regional Cancer Centre|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|378|||Female|N/A|N/A|No|||January 2016|January 11, 2016|March 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01815476||69408|
NCT01816841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08095|Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care|The Role of Direct Visual Fluorescence in Oral Examination||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|November 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|283|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816841||69303|
NCT01816854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-HERO-07|Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent|Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent||be Medical|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who suffer from intermittent claudication and critical limb ischemia (TASC A, B        and C lesions).|July 2015|July 15, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01816854|12 Months|69302|
NCT01811082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010MMXX2CoA006|Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia|Randomized Head-to-Head Comparison of Coenzyme A Capsule and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial.||Zhejiang University|Yes|Completed|July 2010|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|75 Years|No|||March 2013|March 14, 2013|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01811082||69743|
NCT01811641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-ING-MDEG|Methyl-Donors and EpiGenetics in The Gambia|Epigenesis in Humans: Can Maternal Methyl-donor-deficient Diets Induce Epigenetic Alterations in Their Offspring?|MDEG|Medical Research Council|No|Completed|January 2009|December 2015|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|166|Samples With DNA|blood, buccal swab, hair follicles|Both|N/A|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women of reproductive age in rural Gambia and their infants|March 2016|March 21, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811641||69700|
NCT01811654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01020|Effectiveness Trial for Evaluating IAHA for PFPS|A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome|PFPS|New York University School of Medicine|Yes|Recruiting|April 2013|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|40 Years|No|||October 2015|October 5, 2015|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811654||69699|
NCT01811069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p-002632|Effect of Body Positioning on Upper Airway Patency During Induction of Anesthesia in Obese Patients|Effect of Body Positioning on Upper Airway Patency During Induction of Anesthesia in Obese Patients||Massachusetts General Hospital|Yes|Not yet recruiting|April 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|65 Years|No|Probability Sample|Fifteen patients with BMI limited in the range of 30 kg/ m2 to 50 kg/ m2, between 18-65        years of age meeting ASA physical status classification I-III requiring general anesthesia        for elective surgery|March 2013|March 13, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811069|1 Day|69744|
NCT01811888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKAPAIN|Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.|Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.||Parc de Salut Mar|No|Recruiting|January 2013|December 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|177|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with knee osteoarthritis scheduled for total knee artheroplasty.|October 2015|October 21, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811888||69681|
NCT01812174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01|On-X Heart Valve - 17mm Aortic and 23mm Mitral|On-X Heart Valve - 17mm Aortic and 23mm Mitral||On-X Life Technologies, Inc.|Yes|Recruiting|January 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||September 2015|September 4, 2015|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812174||69659|
NCT01812486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50809|Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer|Dose De-escalation to the Elective Nodal Sites, the Swallowing Apparatus and Neck Soft Tissues for Head and Neck Cancer: Multi-centre, Randomized Phase III Trial Using Image-guided Intensity-modulated Radiotherapy (IG-IMRT)||Universitaire Ziekenhuizen Leuven|No|Completed|May 2008|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01812486||69636|
NCT01812733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN9513|Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives|An Observational Study of Quality of Life, Resource Use and Costs Associated With Treatment of Severe Pain - a Comparison of a Combination of Oxycodone and Naloxone (Targiniq) Versus Oxycodone and Laxatives||Mundipharma AB|No|Completed|June 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|The patients have severe pain treated with opioids and will be enrolled at different        clinics in Sweden|August 2015|August 6, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812733||69617|
NCT01813032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-SS-0085|Comparison of Vascular Function in Emergency Service Professionals|Comparison of Vascular Function in Emergency Service Professionals|FIRECOP|University of Edinburgh|Yes|Recruiting|April 2012|||April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Plasma and urine.|Male|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be healthy, non-smoking, whole-time firefighters working within Lothian and        Borders Fire and Rescue Service and age- and sex-matched police officers who are also        healthy and non-smokers working within Lothian and Borders Police Force.|March 2013|March 14, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813032||69594|
NCT01812993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES03_2013|Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea|Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea (Reverse-STEAL): A Multicenter Randomized Study|Reverse-STEAL|Technische Universität Dresden|Yes|Recruiting|March 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2015|February 10, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812993||69597|
NCT01813006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/899(REK)|Effect of Omega-3 Fatty Acid on Endothelial Function|Effect of Omega-3 Polyunsaturated Fat on Endothelial Function and Inflammatory Parameters in Familial Hypercholesterolemia - a Double Blind, Placebo-controlled Crossover Study||Nordlandssykehuset HF|No|Not yet recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||March 2013|March 14, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813006||69596|
NCT01813019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2225|Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy||Novartis|Yes|Completed|February 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813019||69595|
NCT01804452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4RTNI|4 Repeat Tauopathy Neuroimaging Initiative|Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration|4RTNI|University of California, San Francisco|No|Recruiting|January 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|Samples With DNA|Plasma, serum, urine, cell lines and cerebrospinal fluid will be retained by study      investigators.|Both|45 Years|90 Years|No|Probability Sample|Subjects with a diagnosis of PSP or CBD|December 2015|December 1, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01804452||70252|
NCT01800500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 165309|Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers|Exploring Current Smokers' Interest in Using Smokeless Tobacco Products Smokeless Tobacco Substitution for Cigarettes||Roswell Park Cancer Institute|No|Terminated|September 2011|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|February 20, 2013||No|Difficulty accruing|No||https://clinicaltrials.gov/show/NCT01800500||70554|
NCT01800786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAM|Memory Consolidation in Obstructive Sleep Apnea|Memory Consolidation in Obstructive Sleep Apnea||Brigham and Women's Hospital|No|Recruiting|August 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 26, 2013|February 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01800786||70532|
NCT01793870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117058|A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies|A Four Way Crossover Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies||GlaxoSmithKline|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01793870||71061|
NCT01793883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA51-350-201|Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza|A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection|Igloo|Biota Scientific Management Pty Ltd|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|639|||Both|18 Years|64 Years|No|||September 2015|September 17, 2015|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793883||71060|
NCT01794611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36049|Different Types Of Laryngoscopes During Routine Intubation in Adult Patients|Comparison Of C-MAC Videolaryngoscopy, Kingsvision Videolaryngoscopy and Macintosh Laryngoscopy During Routine Intubation in Adult Patients||Istanbul University|Yes|Completed|February 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|80 Years|No|||February 2013|April 1, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01794611||71004|
NCT01794624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00070364|Biobehavioral Pain Management in TMD|Biobehavioral Pain Management in TMD|TMD|Johns Hopkins University|Yes|Recruiting|April 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|60 Years|No|||March 2014|March 10, 2014|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01794624||71003|
NCT01794884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|glncardio001|Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery|Intravenous Supplementation of Glutamine Preoperatively for Cardiac Function and Recovery Improvement in Adult Accepting Cardiosurgery: A Randomized, Double-Blinded, Placebo-Controlled Trial||Southeast University, China|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01794884||70983|
NCT01816282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bleeding Control|The Use of Fibrin Sealant to Reduce Bleeding After Total Knee Replacement|||University of Milan|No|Completed|March 2011|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|62|||Both|N/A|N/A|No|||March 2013|March 22, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01816282||69346|
NCT01810835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URT-Liver-001|Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.|Prevention of Hepatitis B Virus (HBV) Mother-to-child Transmission (MTCT): Impact of Serovaccination in Lariboisiere Hospital, Paris, France.||Hopital Lariboisière|No|Completed|November 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|28|||Female|18 Years|45 Years|No|Non-Probability Sample|This monocentre, observational study will include pregnant women whom HBV-DNA is > 105        IU/mL and who are not currently treated for HBV hepatitis.|December 2013|December 5, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810835||69762|
NCT01811368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#233|Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma||University of California, Davis|Yes|Recruiting|March 2013|January 2016|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|75 Years|No|||July 2014|July 11, 2014|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811368||69721|
NCT01811667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vasca-LM|Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations|Clinical Study on Efficacy and Safety of the mTor Rapamycin Inhibitor Found in the Complex Vascular Malformations|vasca-LM|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|70 Years|No|||October 2015|October 8, 2015|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01811667||69698|
NCT01811628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1051|Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers|Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2013|||July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants recruited through referrals from community health agencies.|November 2015|November 3, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01811628||69701|
NCT01812187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30374|Designing a Mobile App for Veterans With Substance Use Problems|Development of an Interactive, Adaptable and Transportable Treatment for Veterans With Substance Use Disorders||Michael Debakey Veterans Affairs Medical Center|No|Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01812187||69658|
NCT01812499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55141|Common Causes of Blood Transfusion Events in a University Hospital: Analysis of Incident Reports|Common Causes of Blood Transfusion Events in a University Hospital: Analysis of Incident Reports.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2013|||February 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|131|||Both|N/A|N/A|No|Non-Probability Sample|All patients in a university hospital which experienced a transfusion event|February 2013|March 13, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01812499||69635|
NCT01812746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIND-014-004|A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer||BIND Therapeutics||Active, not recruiting|April 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||August 2015|August 3, 2015|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01812746||69616|
NCT01809158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11T-013|Minocycline for Schizophrenia|A Double-blind Randomized Placebo-controlled Trial of Adjuvant Therapy With Minocycline for Schizophrenia||Addis Ababa University|Yes|Recruiting|April 2013|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|64 Years|No|||July 2014|July 8, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809158||69890|
NCT01813071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 008|Safety Study of Live Shigella Vaccine in Bangladeshi Adults and Children|A Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation, Age-Descending Study to Assess the Safety and Tolerability of Live Attenuated, Oral Shigella WRSS1 Vaccine in Bangladeshi Adults and Children||PATH|Yes|Active, not recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|87|||Both|5 Years|39 Years|Accepts Healthy Volunteers|||August 2015|December 16, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813071||69591|
NCT01809132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AA021893-01|Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis|Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2013|||December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|21 Years|70 Years|No|||June 2015|June 23, 2015|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809132||69892|
NCT01809470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-VG-001|Metabolic Response to Playing Video Games|Metabolic Response to Playing Video Games||University College, London|No|Recruiting|February 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|72|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2013|April 8, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809470||69866|
NCT01809483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB0201/IIC5D11/16095/2012|Comparison Between Bandage Contact Lens and Pressure Patching for The Erosion Area and Pain Scale in Corneal Erosion Patients|Comparison Between Bandage Contact Lens and Pressure Patching for The Erosion Area and Pain Scale in Corneal Erosion Patients||Udayana University|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|17 Years|55 Years|No|||March 2013|March 8, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809483||69865|
NCT01804465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#12557|A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer|A Randomized Phase 2 Trial of Immediate vs. Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy||University of California, San Francisco|Yes|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|18 Years|N/A|No|||July 2015|July 21, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804465||70251|
NCT01793376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-208-1|Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)|Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)||Given Imaging Ltd.|No|Active, not recruiting|February 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|videos of colon Crohn's disease subjects who have undergone the Colon 2 CE procedure will        be included.|March 2015|March 11, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793376||71099|
NCT01793597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0095|Platelet Reactivity After CABG|Platelet Activation, Reactivity, and Inflammation After Coronary Bypass Surgery In Patients Treated With Ticagrelor or Clopidogrel||University of Vermont|No|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|Samples Without DNA|Platelets and leukocytes will be evaluated acutely. Plasma will be stored for cytokine and      chemokine analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute coronary syndrome who based on clinical indications require urgent        CABG. CABG is scheduled for clinical indications within 48 hours. Previous treatment with        clopidogrel or ticagrelor.|September 2015|September 20, 2015|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01793597||71082|
NCT01793610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-12|Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD|A Randomized, Double-Blind, Dose Response Phase 2 Pilot Study of Manualized MDMA-Assisted Psychotherapy in Subjects With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|April 2013|November 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|23|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01793610||71081|
NCT01794390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJ1201|Handling Inhalers - Technique Error Comparison (HI-TEC)|Critical Errors in Pulmojet and Other Devices|HI-TEC|Research in Real-Life Ltd|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|431|||Both|18 Years|75 Years|No|Probability Sample|Patients from a representative UK primary care asthma and COPD population|October 2015|October 25, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01794390|1 Month|71021|
NCT01794403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110491|Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer|A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer|HEAT|University of Miami|Yes|Recruiting|March 2013|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Male|35 Years|85 Years|No|||February 2016|February 3, 2016|February 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794403||71020|
NCT01801865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2850|Clinical Use of a New Neonatal MRI System|Clinical Use of a New Neonatal MRI System||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|700|||Both|N/A|N/A|No|||September 2014|September 23, 2014|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01801865||70450|
NCT01802125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B9|Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas|Observational - SNP Array Analysis of Undifferentiated Sarcomas||Children's Oncology Group|No|Recruiting|February 2013|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|49|Samples Without DNA|tissue|Both|N/A|N/A|No|Non-Probability Sample|Undifferentiated sarcomas from ARST0332|November 2015|November 5, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802125||70430|
NCT01810003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2012-143|Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)|Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation in Men and Women With Metabolic Syndrome|n3|Laval University|No|Active, not recruiting|March 2013|December 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|170|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01810003||69825|
NCT01810016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2012-004|NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma|Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated.||Ludwig Institute for Cancer Research|No|Active, not recruiting|March 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810016||69824|
NCT01810549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 303/12|Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake Study|Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake Study. A Randomized, Double-blind, Single Dose of Anakinra, Placebo-controlled, Cross-over Proof-of-concept Study.||University of Zurich|No|Completed|March 2013|||December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2013|December 16, 2014|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01810549||69784|
NCT01811095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01-M10-13B|A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing|A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing||McGill University|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|27|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 11, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811095||69742|
NCT01811381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0669-I|Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease|Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's Disease||VA Office of Research and Development|Yes|Recruiting|January 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|80|||Both|55 Years|90 Years|No|||February 2016|February 17, 2016|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811381||69720|
NCT01812226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU31235|Alcohol Biomarkers in Post-Liver Transplant Patients|Alcohol Biomarkers in Post-Liver Transplant Patients||Northwestern University|No|Completed|March 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|214|Samples With DNA|Blood samples collected to detect PEth levels.|Both|18 Years|N/A|No|Non-Probability Sample|Transplant center patients|November 2015|November 3, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01812226||69655|
NCT01812512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-230|Telehealth Self Management for CHF|Communication Skills Training for Heart Failure Self-Management in Telehealth|TSM-CHF|VA Office of Research and Development|No|Withdrawn|November 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|55 Years|85 Years|No|||November 2014|November 25, 2014|September 12, 2012||No|Never funded.|No||https://clinicaltrials.gov/show/NCT01812512||69634|
NCT01811901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130214|Reduction of In-hospital Delays in Stroke Thrombolysis: SITS-WATCH|Reduction of In-hospital Delays in Stroke Thrombolysis: SITS-WATCH|SITS-WATCH|SITS International|Yes|Recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3000|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811901||69680|
NCT01812200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTT-1.0|Antithrombotic Triple Therapy in Humans|A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects||Medical University of Vienna|Yes|Completed|October 2012|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01812200||69657|
NCT01812213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV4-04|Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)|Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)|NAV4-04|Navidea Biopharmaceuticals|No|Active, not recruiting|March 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|55 Years|N/A|No|||October 2014|October 24, 2014|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812213||69656|
NCT01812525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|453/12|Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations|Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3%||Hôpital de L'Enfance|Yes|Recruiting|March 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Weeks|24 Months|No|||March 2015|March 17, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812525||69633|
NCT01813084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STN001|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729|A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma||Respivert Ltd|No|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813084||69590|
NCT01809184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1956-4014|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects||Novo Nordisk A/S|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|84|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01809184||69888|
NCT01809197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-056|Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution|Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution||Alcon Research|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|387|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|March 8, 2013|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01809197||69887|
NCT01808911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/090/HP|Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)|Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)|CREHA|University Hospital, Rouen|Yes|Recruiting|May 2012|November 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01808911||69909|
NCT01808924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11080592|Muscle Insulin Resistance In Aging|Muscle Insulin Resistance In Aging|MIRAGE|University of Pittsburgh|Yes|Recruiting|December 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|120|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 8, 2013|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808924||69908|
NCT01809171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s55283|Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients|Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients||Universitaire Ziekenhuizen Leuven|No|Terminated|October 2013|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|March 8, 2013||No|Inclusion problems|No||https://clinicaltrials.gov/show/NCT01809171||69889|
NCT01793389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-Dis-002|Platelet Rich Fibrin in the Treatment of Localized Gingival Recessions|Platelet Rich Fibrin in the Treatment of Localized Gingival Recessions: Split-mouth Randomized Clinical Trial||Ege University|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 14, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01793389||71098|
NCT01793623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050391|Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery and Tissue Banking|Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery and Tissue Banking||University of Pittsburgh|No|Recruiting|February 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|(1) myocardial tissue (2) DNA|Both|18 Years|N/A|No|Non-Probability Sample|Subjects are patients of UPMC Cardiothoracic Surgery who are having standard of care open        heart surgery|January 2016|January 4, 2016|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01793623||71080|
NCT01793896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondecyt 1130284|Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue|Mitochondrial Biogenesis, Reduction of Muscle Oxidative Damage and Improvement in Adipose Tissue Functional Profile, Account for the Beneficial Effects of Exercise and Healthy Diets||University of Chile|Yes|Recruiting|July 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|115|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01793896||71059|
NCT01794091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrotic Index in Diabetics|Detection of Diffuse Scar in Patients With Diabetes|Comprehensive Stress-Perfusion Cardiac MRI Assessment of Diabetic Cardiomyopathy: Prognostic Role of the Fibrotic Index||Brigham and Women's Hospital|Yes|Not yet recruiting|August 2013|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|50|||Both|40 Years|75 Years|No|||February 2013|February 15, 2013|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01794091||71044|
NCT01801605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/053/HP|Repetitive Transcranial Magnetic Stimulation in Irritable Bowel Syndrome|Does Repetitive Transcranial Magnetic Stimulation (rTMS) Reduce Rectal Hypersensitivity in Patients With IBS ?||University Hospital, Rouen|Yes|Completed|August 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 28, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01801605||70470|
NCT01802398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 HL111033-01A1|Improving Syncope Risk Stratification in Older Adults|Improving Syncope Risk Stratification in Older Adults|SRS|Oregon Health and Science University|No|Recruiting|April 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3700|Samples Without DNA|Serum samples will be collected for standardized cardiac biomarker testing. Samples will be      split into two aliquots for testing and long-term storage. Aliquots in long-term -80˚C      storage will be used for future studies of novel tests.|Both|60 Years|N/A|No|Non-Probability Sample|Emergency Departments (ED)|October 2015|October 14, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802398||70409|
NCT01802671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS-PI12-02710|Efficacy Study of Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain|Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain: A Randomized Clinical Trial|POETS|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Not yet recruiting|April 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|20 Years|65 Years|No|||February 2013|February 28, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802671||70388|
NCT01810848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORT|Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity|Pilot Study of the Impact of Viscosupplementation Therapy With Hylan G-F 20 (Single Injection) on Exercise Tolerance - Implications for Patients With Cardiovascular Risk|CORT|OhioHealth|No|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|40 Years|70 Years|No|||March 2015|March 24, 2015|March 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810848||69761|
NCT01811108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.12|Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer|Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively (From 1/7/2009) and Prospectively (up to 31/12/2013) as First Line Treatment for Patients With Locally Advanced or Metastatic Colorectal Cancer (With or Without KRAS Mutation). Assessment of Toxicity, Compliance and Survival of Patients.||Hellenic Oncology Research Group|No|Completed|July 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|670|||Both|18 Years|N/A|No|Probability Sample|Clinics for cancer prevention|October 2014|October 23, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01811108||69741|
NCT01811940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6698|Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence|Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence|TACT2|New York State Psychiatric Institute|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|60 Years|No|||October 2015|October 26, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811940||69677|
NCT01811914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKGMTTE4|Focused TTE for Hemodynamic Instable High Risk Patients|Intraoperative Focused TTE - Impact on High Risk Patients´ Management in Hemodynamic Instabilities||Philipps University Marburg Medical Center|No|Completed|March 2013|March 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811914||69679|
NCT01811927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1210|The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent|The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent (BIOHELIX-II)|BIOHELIX-II|Biotronik AG|Yes|Terminated|March 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811927||69678|
NCT01813045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/R/CAR/22|Angiogenesis and Fibrosis in Myocardial Infarction|The Identification of In Vivo Angiogenesis and Fibrosis in Myocardial Infarction Using Positron Emission Tomography.||University of Edinburgh|Yes|Recruiting|April 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|Samples Without DNA|Blood samples will be taken, and the serum frozen and stored for further analysis pending      ethical approval.|Both|40 Years|N/A|No|Non-Probability Sample|40 patients in total , recruited from cardiology inpatient wards or outpatient clinics.|March 2015|March 17, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01813045||69593|
NCT01813097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664C00011|Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer|||Chinese PLA General Hospital|Yes|Completed|February 2008|||March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|N/A|N/A|No|Probability Sample|Subject number: <<60>>|February 2008|March 15, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813097||69589|
NCT01808898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/BWH/NO75|Role of Intrauterine Cornual Block in Combination With Direct Cervical Block in Outpatient Endometrial Ablation|Randomized Double-blind Placebo Controlled Trial to Assess the Role of Intrauterine Cornual Block (ICOB) in Combination With Direct Cervical Block in Outpatient Endometrial Ablation|ICOB|University of Birmingham|No|Completed|February 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01808898||69910|
NCT01809145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-LF-0683-CTIL|Testing Hypersensitivity to Metals in Sarcoidosis Patients by Applying the MELISA Test.|Testing Hypersensitivity to Metals in Sarcoidosis Patients With Occupational Exposure, Using the MELISA Test.||Tel-Aviv Sourasky Medical Center|No|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|N/A|N/A|No|||March 2013|March 10, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01809145||69891|
NCT01809522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Posterior Reconstruction|Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy?|Does the Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy? A Multicenter Randomized Controlled Trial. A Phase III Open-label Prospective International Multicenter Randomized Controlled Study for the Evaluation of the Efficacy of PRR, in Patients Subjected to RALP, Measured in Terms of Early Recovery of the Continence.|PRR|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Recruiting|January 2013|||March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Male|18 Years|80 Years|No|||March 2013|March 12, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01809522||69862|
NCT01810380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14644A|Brexpiprazole in Patients With Acute Schizophrenia|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia||H. Lundbeck A/S|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|465|||Both|18 Years|65 Years|No|||February 2015|February 5, 2015|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810380||69797|
NCT01810640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012002002|Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors|Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study|PPB|Rutgers, The State University of New Jersey|No|Terminated|February 2013|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|6|||Both|N/A|N/A|No|||May 2015|May 11, 2015|March 11, 2013||No|Complications encountered with biopsy in first 6 patients|No||https://clinicaltrials.gov/show/NCT01810640||69777|
NCT01801020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-107-12CTIL|Different Modes of Temperature Measurement in the Emergency Department|Different Modes of Temperature Measurement in the Emergency Department||HaEmek Medical Center, Israel|Yes|Withdrawn|March 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|January 14, 2013||No|The investigator left the organization|No||https://clinicaltrials.gov/show/NCT01801020||70514|
NCT01801033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130058|Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism|Effects of Pharmacologic Block of Type-1 Deiodinase on Thyroid Hormone Action and on the Circulating Levels of T3 in Hypothyroid Patients||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||November 2013|December 11, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01801033||70513|
NCT01801332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETI HAA|Intensive Enteral Nutrition and Acute Alcoholic Hepatitis|Intensive Enteral Nutrition in Association With Corticosteroids in Severe Acute Alcoholic Hepatitis: a Multicenter, Randomized, Controlled Trial||Erasme University Hospital|Yes|Completed|February 2010|||February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|75 Years|No|||February 2013|February 27, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801332||70491|
NCT01801345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12-048|The Effect of Fatigue on the Clinical Performance|The Effect of Fatigue on the Clinical Performance of Experienced Physicians: A Simulation Study||NorthShore University HealthSystem|No|Completed|August 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|13|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01801345||70490|
NCT01802138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILC_IIT_03|A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma|A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma||Seoul National University Hospital|No|Recruiting|February 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|21 Years|No|||November 2015|November 17, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01802138||70429|
NCT01802151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177-2012|Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults|Evaluation of Bacillus Subtilis R0179 in Capsules on Gastrointestinal Survival, Transit Time, Gastrointestinal Symptoms, and General Wellness in Healthy Young Adults||University of Florida|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|83|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|February 20, 2013||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01802151||70428|
NCT01802710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008111005|Clinical Improvement and in Quality of Life-Functional Dyspepsia-|Influencia Del Tratamiento psicológico Combinado Con el médico en la mejoría clínica y de la Calidad de Vida en Los Pacientes Con Dispepsia Funcional||Hospital Galdakao-Usansolo|No|Completed|March 2009|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|158|||Both|18 Years|80 Years|No|||February 2013|February 28, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01802710||70385|
NCT01802723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-16|Dose Ranging Study|A Dose Ranging Study of the Safety and Efficacy of LIPO-202 Healthy Patients With Subcutaneous Fat in the Periumbilical Area|RESET|Neothetics, Inc|No|Completed|February 2013|October 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|472|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802723||70384|
NCT01810562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4403 001|SlagSens (Effect of Tactile Stimulation After Stroke)|Study on Effect of Tactile Stimulation on Reduced Sensibility of the Affected Extremities After Stroke.||Vestre Viken Hospital Trust|Yes|Recruiting|March 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|56|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01810562||69783|
NCT01810861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851148|Serotype Distribution and Antibiotic Sensitivity of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey: Multi-centered, Retrospective Laboratory Trial|Serotype Distribution And Antibiotic Susceptibility Of Streptococcus Pneumoniae Causing Invasive Diseases In Children And Adults: A Laboratory- Based Multicenter Retrospective Study-secondary Data Collection Study||Pfizer|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|700|Samples Without DNA|Blood, CSF and/or other sterile body areas (catheter, pleural fluid, parasynthesis fluid,      pericardial fluid, synovial fluid, BAL)|Both|N/A|N/A|No|Non-Probability Sample|Pneumococcal isolates that are obtained from the blood, CSF and/or other sterile body        areas (catheter, pleural fluid, parasynthesis fluid, pericardial fluid, synovial fluid,        BAL) with the aim of routine laboratory diagnosis from the pediatric patients that are        younger than 18 years old (≤18), who are accepted to the pediatric clinic with the        diagnosis of meningitides, bacteremia - sepsis or pneumonia, will be included in the        trial.        S.pneumoniae isolates that meet the inclusion criteria and that are obtained from the        invasive clinical samples of the adult patients that are over 18 years old (>18) and        applied to the hospital are included in the trial.|December 2015|December 14, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810861||69760|
NCT01811394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAC-01|Ion Irradiation of Sacrococcygeal Chordoma|Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma|ISAC|Heidelberg University|Yes|Recruiting|January 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 5, 2015|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01811394||69719|
NCT01811407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9010|Impacts of Public Announcements of Goals and Outcomes on Goal Completion (Commit to Steps)|Impacts of Public Announcements of Goals and Outcomes on Goal Completion||University of Michigan|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01811407||69718|
NCT01811979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69/04.01.2012|Efficacy of Oral Sucrose and Topical Anesthetics to Reduce Pain During Eye Examination for Retinopathy of Prematurity|Efficacy of Oral Sucrose and Topical Anesthetics to Reduce Pain During Eye Examination||Dr. Sami Ulus Children's Hospital|No|Completed|April 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|N/A|3 Months|No|||May 2013|May 7, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811979||69674|
NCT01812811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35522|Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes|Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes||University of Aarhus|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|22|||Both|30 Years|75 Years|No|Non-Probability Sample|Type 2 diabetes patients recruited from out patient clinic|December 2013|December 10, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812811||69611|
NCT01811680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG DSRB_D_2012/00571|An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill System (VASST) for Hemiparetic Gait Rehabilitation|A Phase 1 Study of "An Exploratory Feasibility Clinical Study on a Variable Speed and Sensing Treadmill System (VASST) for Hemiparetic Gait Rehabilitation in Subacute Stroke Patients."|VASST|Tan Tock Seng Hospital|No|Completed|August 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||January 2015|January 2, 2015|March 5, 2013||No||No|September 12, 2014|https://clinicaltrials.gov/show/NCT01811680||69697|There were technical limitations due to Gaitrite walkway malfunction midway in the trial leading to unreliable cadence results. Step length results were not affected.
NCT01812759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0982|Fentanyl for Breakthrough Pain in the Emergency Department|A Randomized Controlled Double-Blind Trial of Fentanyl Nasal Spray (Lazanda) Plus Hydromorphone Demand PCA Versus Placebo Nasal Spray Plus Hydromorphone Demand PCA for Treatment of Breakthrough Cancer Pain in the Emergency Department||M.D. Anderson Cancer Center|Yes|Suspended|January 2014|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|March 14, 2013|Yes|Yes|Sponsor preparing an amendment|No||https://clinicaltrials.gov/show/NCT01812759||69615|
NCT01812772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-370|The Effect of Ureteric Stent Tethers on Patient Symptoms and Urinary Infection|The Effect of Ureteric Stent Tethers on Patient Symptoms, Stent Bacterial Colonization and Urinary Tract Infection||St. Michael's Hospital, Toronto|No|Terminated|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||February 2014|May 19, 2015|March 14, 2013||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01812772||69614|
NCT01812239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0019|Vaginal Progesterone in Twins With Short Cervix|Vaginal Progesterone to Prevent Early Preterm Birth In Twin Pregnancy With Short Cervix. Double-Blind, Placebo-Controlled, Randomized Clinical Trial||Mednax Center for Research, Education and Quality|Yes|Withdrawn|March 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|March 12, 2013|Yes|Yes|inability to retain study drug with comparable placebo.|No||https://clinicaltrials.gov/show/NCT01812239||69654|
NCT01809535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS97-CT9-10|Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|A Randomized Controlled Trial of Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding||Kaohsiung Veterans General Hospital.|Yes|Completed|January 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|20 Years|80 Years|No|||March 2013|March 9, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01809535||69861|
NCT01812785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feverstudy|Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara|Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara||Swiss Tropical & Public Health Institute|No|Completed|January 2008|December 2011|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1010|||Both|2 Months|10 Years|No|Probability Sample|Consecutive patients aged 2 months to 10 years presenting at the outpatient clinic of        Amana district hospital in Dar es Salaam, and at the outpatient clinic of St-Francis        designated-district hospital in Ifakara, Kilombero District.|March 2013|March 14, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812785||69613|
NCT01813058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00003400|Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?|The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?||Children's Hospital Boston|Yes|Recruiting|January 2013|October 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|10 Years|21 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01813058||69592|
NCT01809808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA0890|A Prospective Study of Outcome After Therapy for Acromegaly|A Prospective Study of Outcome After Therapy for Acromegaly||Columbia University|No|Recruiting|September 2003|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|Serum and blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects newly diagnosed with acromegaly or who have previously undergone surgery for        acromegaly are invited to participate.|May 2015|May 13, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01809808||69840|
NCT01810406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK - 1013037|Epidural Volume Extension During a Combined Spinal-Epidural Technique for Labor Analgesia.|A Randomized Controlled Trial of Epidural Volume Extension During a Combined Spinal-Epidural Technique for Labor Analgesia.||IWK Health Centre|Yes|Completed|March 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||April 2014|April 22, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810406||69795|
NCT01801618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12276 2PICAM|National Evaluation of PI-based 2nd Line Efficacy in Cambodia|National Evaluation of PI-based 2nd Line Efficacy in Cambodia||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|February 2013|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|Plasma HIV RNA and cDNA|Both|18 Years|N/A|No|Non-Probability Sample|All HIV-1 infected adults receiving a PI-based 2nd line regimen in one of the 13        participating national program ARV treatment sites.|February 2013|February 28, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01801618|6 Months|70469|
NCT01801631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF2009-70|Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital|Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital|Diacourse|UMC Utrecht|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|201|||Both|N/A|N/A|No|||July 2014|July 25, 2014|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01801631||70468|
NCT01802411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-322|Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy||Pacira Pharmaceuticals, Inc|Yes|Completed|December 2012|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|February 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802411||70408|
NCT01801878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1206-158-005|Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts|Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts||Seoul National University Hospital|No|Not yet recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|10|||Female|40 Years|60 Years|No|||May 2015|May 19, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801878||70449|
NCT01802697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-HMedIdeS-01|Safety Study on IdeS in Healthy Volounteers|A Phase i Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects||Hansa Medical AB|Yes|Completed|February 2013|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802697||70386|
NCT01802996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGIC-301|Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury|A Randomized, Controlled, Multi-center Collaborative Study to Evaluate the Efficacy of Magnesium Isoglycyrrhizinate Injection in the Prevention of Antineoplastic Chemotherapy Related Acute Liver Injury|MAGIC|Cttq|No|Recruiting|March 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2040|||Both|18 Years|75 Years|No|||October 2013|October 29, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01802996||70363|
NCT01802736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THRiVE- ASK|Alcohol Use and Risky Sexual Behaviors Among HIV Infected Subjects in Kampala Uganda|Alcohol Consumption and Alcohol Reduction Intervention Among HIV Infected Persons in a Large Urban HIV Clinic in Uganda|ASK|Makerere University|No|Active, not recruiting|February 2013|March 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|510|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01802736||70383|
NCT01810575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13311|Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction|A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction||Warner Chilcott|No|Terminated|February 2013|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Male|40 Years|N/A|No|||August 2014|August 8, 2014|February 27, 2013|Yes|Yes|Re-assessment of study|No||https://clinicaltrials.gov/show/NCT01810575||69782|
NCT01810874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STELLA|STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer|STELLA Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes|STELLA|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|June 2012|April 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Female|N/A|N/A|No|||April 2015|April 28, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810874||69759|
NCT01811121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-697|MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS|Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional|RESECT|Hospices Civils de Lyon|Yes|Recruiting|February 2013|August 2019|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||February 2013|March 12, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01811121||69740|
NCT01811420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cariesremoval09|Chemomechanical Caries Removal Using Papain Gel|Chemomechanical Caries Removal Using a Papain-Based Gel: A Randomized Clinical Trial|CMCR09|University of Nove de Julho|Yes|Completed|March 2009|March 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||March 2013|March 12, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01811420||69717|
NCT01811433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Masimo 27353|Halo Index and Adaptive Alarm Thresholds During Routine PACU Inpatient Care: "Normal" vs. "Non-normal" Recovery|Halo Index and Adaptive Alarm Thresholds During Routine PACU Inpatient Care: "Normal" vs. "Non-normal" Recovery|Halo|University of Vermont|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting for surgery with a planned inpatient stay of 24 hours or greater.|September 2014|September 18, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811433||69716|
NCT01813110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRONOVA|Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation|Effects of a Prescription Omega-3 Fatty Acid Concentrate in a Placebo-controlled Trial of Human Endotoxemia|PRONOVA|Penn State University|Yes|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813110||69588|
NCT01813123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ3409|A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls|A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls||Columbia University|No|Active, not recruiting|March 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|788|||Female|13 Years|14 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01813123||69587|
NCT01812252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2661.00|Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant|Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)|ICT-HCT|Fred Hutchinson Cancer Research Center|No|Recruiting|April 2013|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812252||69653|
NCT01813136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAZOTHYR|Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma|A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma||Centre Leon Berard|Yes|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813136||69586|
NCT01811953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.8|Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together|Bioequivalence of Empagliflozin/Metformin Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed and Fasted Conditions (an Open-label, Randomised, Single-dose, Crossover Study)||Boehringer Ingelheim||Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|March 13, 2013||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01811953||69676|
NCT01811966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKGMVolume|Preoperative Volume Substitution in Elective Surgery Patients|Preoperative Volume Substitution in Fasting Patients Undergoing Elective Surgery - Impact on Hemodynamic Stability During Anesthesia||Philipps University Marburg Medical Center|No|Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01811966||69675|
NCT01812798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12LP3.7|Canadian Peanut Thresholds Study|Disease Management: Canadian Peanut Thresholds Study||McMaster University|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|7 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812798||69612|
NCT01809548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIES001|Preterm Infants on Early Solid Foods|Early Introduction of Solid Foods in Preterm Infants: Effects on Growth, Atopy and Neurodevelopment|PIES-Project|Medical University of Vienna|Yes|Recruiting|October 2013|July 2020|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|N/A|3 Months|No|||September 2015|September 22, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01809548||69860|
NCT01809821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRBCRFG-150213-EMG|Sleep to Lower Elevated Blood Pressure|Sleep to Lower Elevated Blood Pressure: A Randomised Controlled Trial|SLEPT|University College Hospital Galway|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809821||69839|
NCT01808937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032007021|Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository|Immunologic and Genetic Profiles in Subsets of Morphea Patients|MAC|University of Texas Southwestern Medical Center|No|Recruiting|May 2007|||January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|serum, WBC, tissue|Both|N/A|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment from clinic visits as well as from regional and national referrals.|December 2014|December 2, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01808937|6 Years|69907|
NCT01810133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ko-MoSkaU|Evaluation of Co-morbidity Scales|Retrospective Data Analysis: Evaluation of Co-morbidity Scales in Peri-operative Medicine|Ko-MoSkau|Charite University, Berlin, Germany|No|Completed|January 2006|March 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|230034|||Both|N/A|100 Years|No|Probability Sample|All patients undergoing general anesthesia between January 2006 and December 2011|October 2015|October 16, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810133||69816|
NCT01810146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0022|Characterization of the Digestive Functions and the Enteric Nervous System in Obesity. Investigations of Relationships With Metabolism Disorders (EnteroNeurObesity)|Characterization of the Digestive Functions and the Enteric Nervous System in Obesity. Investigations of Relationships With Metabolism Disorders(EnteroNeurObesity)||Nantes University Hospital||Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01810146||69815|
NCT01810432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14626|Study of Food on Evacetrapib (LY2484595) in Healthy Participants|Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects||Eli Lilly and Company|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|86|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810432||69793|
NCT01810107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006H|Study to Evaluate the Efficacy of Optical Imaging to Evaluate the Anatomy of the Developing Pediatric Vocal Fold|Study to Evaluate the Efficacy of Optical Imaging to Evaluate the Anatomy of the Developing Pediatric Vocal Fold||Massachusetts Eye and Ear Infirmary|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|||Both|1 Month|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 1 month to 18 (and adults >18) undergoing laryngoscopy and bronchoscopy for        airway evaluation where the patients will be already scheduled for general anesthesia with        intravenous catheter placement as part of standard routine.|October 2015|October 27, 2015|October 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01810107||69818|
NCT01810120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBG_359.11|Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT|Phase I/II Study of Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Family Donor After TCR Alfa Beta Negative Selection in Pediatric Patients Affected by Hematological Disorders||Bambino Gesù Hospital and Research Institute|Yes|Recruiting|September 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Months|20 Years|No|||March 2013|March 12, 2013|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01810120||69817|
NCT01802424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71 FRIENDS|FRIENDS as an Indicative Prevention Program in Norway|The FRIENDS-program as Indicative Prevention for Children and Adolescents With Symptoms of Anxiety and Depression||Uni Research|No|Completed|February 2012|December 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Both|8 Years|15 Years|No|||December 2015|December 4, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01802424||70407|
NCT01802684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VELVET C12-1|OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer|OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.|VELVET|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Active, not recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01802684||70387|
NCT01802437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110M05542|An Adaptive Treatment Strategy for Adolescent Depression|An Adaptive Treatment Strategy for Adolescent Depression|PTAD|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|45|||Both|12 Years|17 Years|No|||March 2016|March 15, 2016|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01802437||70406|
NCT01803542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0951-C|Stereotactic Radiotherapy (SBRT) of Lung Metastasis|Lung Stereotactic Radiation Therapy for Patients With Non-small Cell Lung Cancer and Other Cancers||University Health Network, Toronto|No|Recruiting|March 2006|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01803542||70321|
NCT01810887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100323|A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants|A Study to Evaluate the Pharmacokinetics and Safety of Oral Single-Dose JNS011 Tablet in Combination With Low-Dose Ritonavir Capsule in Healthy Japanese Adult Males||Janssen Pharmaceutical K.K.|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810887||69758|
NCT01810900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ABCL002|To Assess the Anti-adhesive Effect and Safety of Protescal|To Assess the Anti-adhesive Effect and Safety of Protescal Following Laparoscopic Surgery||LG Life Sciences|No|Terminated|September 2012|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|20 Years|N/A|No|||November 2014|March 9, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01810900||69757|
NCT01811134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.689|Flow Diverter Stent for Endovascular Treatment of Unruptured Saccular Wide-necked Intracranial Aneurysms|Multicenter Randomized Study for Medico-economic Evaluation of Embolization With Flow Diverter Stent in the Endovascular Treatment of Unruptured Saccular Wide-necked Intracranial Aneurysms|EVIDENCE|Hospices Civils de Lyon|Yes|Recruiting|November 2012|November 2017|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01811134||69739|
NCT01811693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBP001|Field Administration of Stroke Therapy-Blood Pressure Lowering|The Field Administration of Stroke Therapy-Blood Pressure Lowering Pilot Trial|FAST-BP|University of California, Los Angeles|Yes|Recruiting|April 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|40 Years|80 Years|No|||June 2015|June 2, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811693||69696|
NCT01812824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC21510|Study of Virtual Patient Advocate for Preconception Care for African American Women|Using Innovative Communication Technology to Improve the Health of Young African American Women|"Gabby"|Boston Medical Center|No|Completed|February 2011|January 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812824||69610|
NCT01808950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP848-nBCC-1104|Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)|Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)||Spirig Pharma Ltd.|No|Terminated|January 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01808950||69906|
NCT01812538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-011|A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects|A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects||Hospira, Inc.|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812538||69632|
NCT01808963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|389048|Evaluation of Respiratory Heast Loss as a Physiologic Patient Monitor for Acute Care Medicine|Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine||University of California, Davis|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patient undergoing elective surgery requiring arterial pressure monitoring.|January 2015|January 27, 2015|March 7, 2013||No||No|July 17, 2013|https://clinicaltrials.gov/show/NCT01808963||69905|
NCT01809210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00070|Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer|A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)|SELECT-3|AstraZeneca|No|Completed|April 2013|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|99 Years|No|||March 2016|March 4, 2016|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809210||69886|
NCT01809561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC13186-12CTIL|Telomeres Evaluation in Endometriosis|Telomeres Evaluation in Endometriosis||Meir Medical Center|Yes|Not yet recruiting|May 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|whole blood, endometrial tissue biopsy, lesion of endometriosis|Female|15 Years|60 Years|No|Non-Probability Sample|women facing surgical treatment|February 2013|April 7, 2013|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01809561|6 Weeks|69859|
NCT01809574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225-12-MMC|The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease|The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease||Meir Medical Center|No|Recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|60 patients that will refer to the pulmonary outpatient or inpatients department for        evaluation due to ILD will be included|October 2013|April 8, 2015|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01809574||69858|
NCT01809834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-57|Evaluation of Stenfilcon A Versus Etafilcon A|Evaluation of Stenfilcon A Versus Etafilcon A||Coopervision, Inc.|No|Completed|November 2012|November 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|46|||Both|17 Years|N/A|No|||June 2014|June 26, 2014|January 17, 2013||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01809834||69838|One participant temporarily discontinued after 12-hour visit. (Primary outcome 1 and 4,1-week visit, n=43)
NCT01810159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034266|Integrated Collaborative Care for Substance Use Disorders|Integrated Collaborative Care for Substance Use Disorders|SUMMIT|RAND|No|Recruiting|June 2014|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01810159||69814|
NCT01810419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03055|Ultrasound Estimation of Spleen Size|Estimation of Spleen Size With Hand Held Ultrasound||University of British Columbia|Yes|Completed|March 2013|March 2014|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|N/A|N/A|No|||July 2014|July 16, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01810419||69794|
NCT01815671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-1|Evaluate the Safety and Diagnostic Advantages of Tilt Down Verses Standard Horizontal Colonoscopy Positioning|The Effect of Body Positioning for Colonoscopy in Women: Randomized, Study of Left Lateral Tilt Down Versus Left Lateral Horizontal Positioning|CTDTTIE|Specialists in Gastroenterology, LLC|No|Terminated|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|173|||Female|18 Years|90 Years|No|||February 2014|February 4, 2014|March 18, 2013||No|Increased number of oxygen desaturation in tilt down position|No|June 2, 2013|https://clinicaltrials.gov/show/NCT01815671||69393|Early termination owing to increased incidence of oxygen desaturation in the tilt down group.
NCT01810666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16287|Prophylaxis Versus on Demand Treatment for Children With Hemophilia A|Routine Prophylaxis Treatment Versus On-demand Treatment for Children With Severe Hemophilia A: Comparison of All Bleeding Events in Chinese Hemophilia Patients||Bayer|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|2 Years|16 Years|No|||April 2015|April 30, 2015|March 12, 2013|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT01810666||69775|
NCT01810679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120053|Perceval S Aortic Heart Valve Study- North America|Clinical Investigation of the Perceval S Sutureless Heart Valve||Sorin Group USA, Inc.|Yes|Recruiting|April 2013|April 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810679||69774|
NCT01801930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293-12-001|A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer|A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|20 Years|N/A|No|||April 2015|April 3, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01801930||70445|
NCT01802749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-16 -MANGO-OV2b|Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer|Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line|MITO16MANGO2b|National Cancer Institute, Naples|Yes|Recruiting|November 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01802749||70382|
NCT01802164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/12|Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia|Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia: A Randomized Controlled Trial|PerProMe|University Hospital Inselspital, Berne|Yes|Terminated|March 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|February 15, 2013||No|Recruitment problems due to very restricted inclusion criteria|No||https://clinicaltrials.gov/show/NCT01802164||70427|
NCT01802177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02840|Excimer Light for Alopecia Areata|Efficacy and Safety of UVB Excimer Light in Alopecia Areata: A Prospective, Single-Blind Randomized Controlled Trial||University of British Columbia|No|Recruiting|February 2013|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|19 Years|N/A|No|||June 2015|June 30, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01802177||70426|
NCT01802450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASAPOST|Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase|Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment|DASAPOST|PETHEMA Foundation|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802450||70405|
NCT01804088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-023|FORMAT Clinical Study|Clinical Investigation of the Cook Formula™ 535 Iliac Balloon-Expandable Stent||Cook||Active, not recruiting|March 2013|January 2018|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||March 2015|May 5, 2015|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01804088||70280|
NCT01804101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2642.00|Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia|Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality||Fred Hutchinson Cancer Research Center|Yes|Recruiting|April 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01804101||70279|
NCT01810627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-RAD-01|Application of Megavoltage Imaging to Reduce Artifact After Seed Implants|Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma||University of Kentucky|Yes|Not yet recruiting|March 2013|April 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|50 Years|80 Years|No|||March 2013|March 11, 2013|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01810627||69778|
NCT01810913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1216|Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer|Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2013|||May 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|675|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810913||69756|
NCT01811147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106005847|Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI|Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI||The Cleveland Clinic|No|Recruiting|November 2011|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|200|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||July 2015|September 11, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01811147||69738|
NCT01811446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2.00|Evaluation of Muscle Activation Efficiency in Challenging Subjects|Evaluation of Muscle Stimulation Efficiency in Challenging Subjects: A Pilot Study||Niveus Medical, Inc.||Completed|March 2013|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811446||69715|
NCT01811459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.189|Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium|Randomized Controlled Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium : The Haloquet Trial|Haloquet|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|February 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2013|February 9, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811459||69714|
NCT01812551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02A001|Treatment of Low Bone Density in Cystic Fibrosis.|Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.|OSCYF|Istituto Auxologico Italiano|No|Completed|October 2002|July 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|5 Years|30 Years|No|||March 2014|March 5, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812551||69631|
NCT01812577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarGal|Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions|Evaluation of the Analgesic Efficacy of the Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions|TPVB|Campus Bio-Medico University|Yes|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|In this study 40 patients undergoing elective procedure of radiofrequency ablation of        liver lesions are enrolled after written informed consent is obtained.|March 2014|March 18, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01812577||69629|
NCT01809262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.3|Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease|Single Dose Preliminary Dose-ranging and Safety in Patients With COPD||Boehringer Ingelheim||Completed|December 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|36|||Both|40 Years|N/A|No|||May 2014|May 27, 2014|March 8, 2013||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01809262||69882|
NCT01813149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-400|Mechanism and Treatment of Sympathetically Maintained Pain|||The Cleveland Clinic|No|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|75|||Both|18 Years|80 Years|No|||February 2015|February 12, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813149||69585|
NCT01813162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-118|In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products|In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products||CONRAD|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|101|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01813162||69584|
NCT01808976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH100466|Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.|Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.||University of California, San Francisco|Yes|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 26, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808976||69904|
NCT01808989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00001|Clinical Interest of the TcPO2 Technique|Multicentric Study of the Clinical Interest of the TcPO2 Technique|CINEYSOFT|University Hospital, Angers|Yes|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|40 Years|80 Years|No|Non-Probability Sample|Patient with buttock pain and referred for an oximetry exercise test|October 2014|October 17, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01808989||69903|
NCT01809223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902007|A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV|The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia|SHINY|Chengdu Kanghong Biotech Co.,Ltd.|No|Active, not recruiting|August 2012|March 2015|Anticipated|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||March 2014|June 3, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809223||69885|
NCT01814917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E15|Long-term Extension Study of MCI-196|A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Hyperphosphataemia and With Either Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stages 3b to 5 Not on Dialysis||Mitsubishi Tanabe Pharma Corporation|Yes|Terminated|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|2 Years|18 Years|No|||May 2015|May 25, 2015|March 18, 2013||No|This study has been terminated because of insufficient patient recruitment.|No||https://clinicaltrials.gov/show/NCT01814917||69449|
NCT01814930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814909|Adolescent Postpartum Contraceptive Counseling Intervention|Evaluation of a Brief Standardized Postpartum Counseling Intervention's Effect on Repeat Pregnancy Rates Contraceptive Choice/Use/Continuation/Satisfaction in Adolescents|PPCI|University of Pennsylvania|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814930||69448|
NCT01809847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-CLL-X4-054|Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation|Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation(CLL-X4 Trial)||Technische Universität Dresden|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|56 Years|N/A|No|||August 2014|August 20, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01809847||69837|
NCT01809860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0020|A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01809860||69836|
NCT01815411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1962|Effect of Andosan in Patients With Rheumatoid Arthritis|Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA)|Andosan-RA|Oslo University Hospital|No|Not yet recruiting|April 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15|||Both|19 Years|75 Years|No|||March 2013|March 20, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01815411||69413|
NCT01816516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-55215-05220|Healthy Babies Through Infant Centered Feeding|Healthy Babies Through Infant Centered Feeding|HB|Michigan State University|Yes|Completed|February 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|546|||Female|18 Years|N/A|No|||May 2014|May 30, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01816516||69328|
NCT01816529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN307-DERM-001|Topical Safety Study of Topical Diltiazem Hydrochloride|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects Using a Repeat Insult Patch Test Design||Ventrus Biosciences, Inc|No|Active, not recruiting|March 2013|September 2013|Anticipated|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|August 19, 2013|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01816529||69327|
NCT01810692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.514|Preference Tiotropium Respimat Study in COPD|Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|150|||Both|18 Years|N/A|No|Probability Sample|COPD|March 2015|March 16, 2015|March 12, 2013||||No|March 16, 2015|https://clinicaltrials.gov/show/NCT01810692||69773|
NCT01811199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.2011.0024|Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels|Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels||Marmara University|No|Active, not recruiting|February 2011|May 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing thyroidectomy and mastectomy|March 2013|March 12, 2013|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01811199||69734|
NCT01802762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-1.000_NeMo_C001 / MUG|A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury|A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury||NeMoDevices AG|No|Recruiting|January 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01802762||70381|
NCT01802775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-E-U210|Edoxaban in Peripheral Arterial Disease|A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention|ePAD|Daiichi Sankyo Inc.|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|February 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01802775||70380|
NCT01802190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8640|Prevalence of POU4F3 and SLC17A8 Mutations|Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.||University Hospital, Montpellier|No|Terminated|March 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|Samples With DNA|Samples with DNA|Both|18 Years|N/A|No|Probability Sample|Deafness patients|April 2015|July 20, 2015|July 24, 2012||No|No convincing results|No||https://clinicaltrials.gov/show/NCT01802190||70425|
NCT01803295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-4M-CS-0002-0|Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC|Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|OPTIMA|UroGen Pharma Ltd.|No|Recruiting|June 2013|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|21 Years|N/A|No|||November 2015|November 29, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01803295||70340|
NCT01803880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-2012-02|Mechanical Debridement vs. Radiofrequency-Based Debridement to Treat Articular Cartilage Legions With Partial Meniscectomy in the Knee|A Prospective, Double Blinded, Multicenter, Randomized, Controlled Trial to Evaluate Mechanical Debridement vs. Radiofrequency-Based Debridement in the Treatment of Articular Cartilage Lesions|ACT|Smith & Nephew, Inc.|Yes|Recruiting|March 2013|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01803880||70296|
NCT01803893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioIncept LLC-1|Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome|Preimplantation Factor (PIF): Prognostic Value of a Non-invasive Embryo Viability Biomarker Detection in Culture Media Followed by Single Embryo Transfer - Correlation With Live Birth.|PIF-SET1|BioIncept LLC|No|Enrolling by invitation|September 2012|||August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|embryo culture media|Female|18 Years|N/A|No|Probability Sample|Infertile women attending IVF center who undergo in vitro fertilization in order to        achieve pregnancy.|March 2013|March 1, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803893||70295|
NCT01811992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00057130|Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma|A Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-Stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma||University of Michigan|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||December 2013|December 5, 2013|February 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811992||69673|
NCT01812005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12106|Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|May 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812005||69672|
NCT01812265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5281003|Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Crossover Study To Investigate The Effects Of Pf-06305591 On Cold Pain In Healthy Male Subjects||Pfizer||Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01812265||69652|
NCT01812278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7859|Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)|Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|2637|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812278||69651|
NCT01812564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF012|Use of Platelet Rich Plasma in the Management of Acute Hamstring Muscle Strain Injury|Clinical Utilization of Growth Factors Preparations in the Management of Acute Hamstring Muscle Strain Injury||Aspetar|No|Completed|November 2009|October 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Male|18 Years|50 Years|No|||January 2015|January 13, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01812564||69630|
NCT01809275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QBECO-01|Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease|A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease||Qu Biologics Inc.|Yes|Active, not recruiting|March 2013|May 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809275||69881|
NCT01809288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130090|Identifying Risk for Diabetes and Heart Disease in Women|Identifying Risk for Diabetes and Heart Disease in Women: A Study of African-American, African and White Federal Employees and Contractors||National Institutes of Health Clinical Center (CC)||Recruiting|February 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|360|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01809288||69880|
NCT01812837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|282150|The Use of Microneedles in Photodynamic Therapy|||University of California, Davis||Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 18, 2014|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812837||69609|
NCT01812850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-024-CERES-D|Effects of the Continuous Wear of Invisalign® Trays on the Temporomandibular Joints and Orofacial Muscular Complex|Effects of the Continuous Wear of Invisalign® Trays on the Temporomandibular Joints and Orofacial Muscular Complex||Université de Montréal|Yes|Not yet recruiting|April 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|12 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are recruited from the Department of Orthodontics of the University of Montreal|April 2013|April 3, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812850||69608|
NCT01813175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.1.C.A|Color Synbiotics Study|Randomised, Controlled, Double-blind Exploratory Study to Investigate the Effect of Specific Synbiotics Mixtures on Gut Microbiota Composition in Healthy Infants.||Danone Asia Pacific Holdings Pte, Ltd.|No|Active, not recruiting|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|289|||Both|43 Days|65 Days|Accepts Healthy Volunteers|||September 2015|September 14, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813175||69583|
NCT01809002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG-CP-007|Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair|A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance® Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities|RECON|AxoGen, Inc|No|Recruiting|June 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||January 2016|January 24, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809002||69902|
NCT01809236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902008|Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion|An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)|FALCON|Chengdu Kanghong Biotech Co.,Ltd.|No|Active, not recruiting|May 2012|March 2014|Anticipated|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809236||69884|
NCT01809249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donar Safety|Causes of Disqualification of Egyptian Potential Living Liver Donors|||Ain Shams University|Yes|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|potential living liver donors|March 2013|March 9, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01809249|3 Months|69883|
NCT01815684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0049|A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects|A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects||Astellas Pharma Inc|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|March 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01815684||69392|
NCT01815138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-098-3|Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS|A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS||University of Connecticut Health Center|Yes|Recruiting|March 2013|December 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|March 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815138||69433|
NCT01816217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8977|Difficult Intubation in Intensive Care|Comparison of Difficult Intubation Rates Using McGrath Mac Video Laryngoscope vs Standard Macintosh Laryngoscope in Critically Ill Patients - a Prospective Interventional Study||University Hospital, Montpellier|No|Terminated|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|March 13, 2013||No|The interim analysis has shown a significative difference between the two groups of patients.|No||https://clinicaltrials.gov/show/NCT01816217||69351|
NCT01816230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P#03.01.020|Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies||Gamida Cell ltd|Yes|Recruiting|April 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 15, 2016|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816230||69350|
NCT01815996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407-2012|Identify Clinical Conditions That Increase Circulating DNA Levels|Identify Clinical Conditions That Increase Circulating DNA Levels|BARDA II|University of Florida|No|Recruiting|October 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|130|Samples With DNA|4-5 ml of blood will be processed and the plasma will be divided into 150 μl aliquots|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Seeking healthy volunteers, pregnant women, patients who recently suffered a heart attach        or pulmonary embolism, and patiebts with autoimmune disease. Patients who are health        individuals will also be asked to participate.|November 2015|November 19, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01815996||69368|
NCT01815957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-069 MICRO Study|Impact of Ranolazine on Coronary Microcirculatory Resistance|Impact of Ranalozine on Coronary Microcirculatory Resistance- A Prospective Single Center Study to Evaluate the Effect of Ranalozine in Microcirculatory Resistance (MICRO Study)||University of New Mexico|No|Recruiting|May 2012|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815957||69371|
NCT01802788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-054-EU-PV|5 Year Observation of Patients With PORTICO Valves|International Long-term Follow-up Study of Patients Implanted With a Portico™ Valve|PORTICO-1|St. Jude Medical|Yes|Recruiting|April 2013|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1050|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are candidates for implantation of a St Jude Medical Portico replacement        aortic heart valve, or have been implanted with with a St. Jude Medical Portico valve as        part of a previous investigational device trial|October 2015|October 20, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01802788||70379|
NCT01803035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-109-04|A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo|A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo||Lytix Biopharma AS|No|Completed|February 2013|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|2 Years|N/A|No|||April 2014|April 25, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01803035||70360|
NCT01803854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|585|Gulf War Era Cohort and Biorepository|CSP # 585 - Pilot Study: Gulf War Era Cohort and Biorepository|CSP# 585|VA Office of Research and Development|No|Active, not recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|One EDTA tube of blood will be collected from participants. All specimens will be processed      and stored at the VA Central Biorepository (VACB) for use in future research. One vial of      buffy coat containing the DNA will be stored. One aliquot of plasma will also be extracted      for storage from all samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Veterans who served in the military in 1990-1991 without regard to actual deployment.|March 2016|March 24, 2016|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01803854||70298|
NCT01803867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM22-MS-1004|An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis|A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)|M22|Acorda Therapeutics|Yes|Completed|March 2013|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|70 Years|No|||February 2015|February 26, 2015|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01803867||70297|
NCT01804400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2212|A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber|A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber||Novartis|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|188|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01804400||70256|
NCT01811732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-3341-302|Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections||Melinta Therapeutics, Inc.|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|660|||Both|18 Years|N/A|No|||July 2014|July 16, 2015|March 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01811732||69693|
NCT01812018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-SAR-001|Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma|An Open-label, Single-arm, Phase II Study to Assess the Efficacy and Safety of Endostar® (Recombinant Human Endostatin Injection) Plus Gemcitabine and Docetaxel in Treatment of Soft Tissue Sarcoma Patients With Pulmonary Metastases||Chinese Academy of Medical Sciences|No|Recruiting|November 2012|October 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2013|March 13, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812018||69671|
NCT01812291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 01GI1107|Evaluation of a Stepped Care Approach to Manage Depression in Diabetes|Efficacy of a Stepped Care Approach to Manage Depression in Diabetic Patients and Putative Inflammatory Mechanisms Between Diabetes and Depression|Ecce_homo|Forschungsinstitut der Diabetes Akademie Mergentheim|Yes|Completed|February 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812291||69650|
NCT01812304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-01|Theoretical Compared With hands-on Training of Vaginal Breech Management|Objective Structured Assessment of Technical Skills Evaluation of Theoretical Compared With hands-on Training of Shoulder Dystocia Management: a Randomized Controlled Trial.||Ruhr University of Bochum|No|Completed|October 2011|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|172|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 10, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01812304||69649|
NCT01812317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-SS-0086|Effect of Real-fire Training on Vascular Function|Effect of Real-fire Training on Vascular Function|FIREPROOF|University of Edinburgh|Yes|Recruiting|April 2012|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01812317||69648|
NCT01814592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-2012-359|Comparison Between Two Coronally Positioned Flap With Connective Tissue|Comparison of Two Bilaminar Techniques for Root Covering of Miller´s Recessions Class I and II: A Blind, Randomized Controlled Clinical Trial||Universidad El Bosque, Bogotá|Yes|Enrolling by invitation|March 2013|August 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|20 Years|60 Years|No|||March 2013|March 23, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01814592||69474|
NCT01809587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/026612|IQP-PO-101 for the Regulation of Bowel Movement Frequency|Open Label Study to Assess the Safety and Efficacy of IQP-PO-101 in Regulating Bowel Movement Frequency||InQpharm Group|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01809587||69857|
NCT01809873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035154|Sustainable Financial Incentives To Improve Prescription Practices For Malaria|Sustainable Financial Incentives To Improve Prescription Practices For Malaria||Duke University|Yes|Completed|September 2012|March 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Actual|14862|||Both|N/A|N/A|No|||March 2015|March 9, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809873||69835|
NCT01810172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2013-293|Digital Air Leak Monitoring for Patients Undergoing Lung Resection|Digital Air Leak Monitoring for Patients Undergoing Lung Resection: A Randomized Controlled Clinical Trial||Nova Scotia Health Authority|No|Recruiting|April 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01810172||69813|
NCT01814566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009ZX09502-030-02|Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China|Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|None Retained|Eligibility criteria Patients who will use DanshenDuofensuanyan injection in selected      hospitals.|Both|N/A|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 30000 Patients using        DanshenDuofensuanyan injection from 2013 to 2014 in more than 20 hospitals|March 2013|May 13, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814566|14 Days|69476|
NCT01814579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01423-FB|Vaginal Cuff Closure Time Using Unidirectional Barbed Suture in Robotic Hysterectomy|Vaginal Cuff Closure Time Using Unidirectional Barbed Suture in Robotic Hysterectomy, a Randomized Controlled Trial||University of Tennessee|No|Enrolling by invitation|July 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||March 2013|March 25, 2013|March 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01814579||69475|
NCT01815177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulder01|Arthroscopic Rotator Cuff Repair: Suture Anchors Versus Arthroscopic Transosseous Fixation|Advantages of Arthroscopic Rotator Cuff Repair With Transosseous Suture Technique. A Prospective Randomized Controlled Trial||University of Milan|No|Completed|March 2013|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815177||69431|
NCT01815970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00591|Does Pulmonary Rehabilitation Improve Breathing of COPD Patients|Does Pulmonary Rehabilitation Reduce Neuromechanical Uncoupling of the Respiratory System in COPD|PR-COPD|University of British Columbia|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|40 Years|80 Years|No|||November 2015|November 16, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01815970||69370|
NCT01815697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81070488|The Effect of Enhanced External Counterpulsation Treatment to Lower Urinary Tract Symptoms|||First Affiliated Hospital, Sun Yat-Sen University||Not yet recruiting|April 2013|March 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|90 Years|No|Probability Sample|Men complaining lower urinary tract symptoms were enrolled|March 2013|March 21, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01815697||69391|
NCT01815983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|367729|Video-Assisted Laryngoscopy Education|Does Video-Assisted Self Review Help Students Learn a New Skill Faster?||University of California, Davis|No|Recruiting|February 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|78 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01815983||69369|
NCT01814397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.101|Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients|Prospective Pilot Study to Determine the Effect of Aromatase Inhibitor-induced Estrogen Depletion on Evoked Pain Threshold and Psychosocial Factors in Breast Cancer Patients||University of Michigan Cancer Center|Yes|Completed|July 2009|February 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Baseline: whole blood for DNA, serum, plasma 3 month: serum, plasma 6 month: serum|Female|21 Years|N/A|No|Non-Probability Sample|Postmenopausal women with ER positive early stage breast cancer who are starting AI        therapy|July 2014|July 7, 2014|March 15, 2013||No||No|June 5, 2014|https://clinicaltrials.gov/show/NCT01814397||69489|
NCT01816763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-030|Effective Screening for Pain Study|Effective Screening for Pain Study|ESP|VA Office of Research and Development|No|Recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|500|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01816763||69309|
NCT01816776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Respicardia CR-1005|Respicardia, Inc. Pivotal Trial of the remedē System|A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea||Respicardia, Inc.|Yes|Active, not recruiting|March 2013|December 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|173|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01816776||69308|
NCT01803048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407388572|Predicting Cognitive and Emotional Health From Neurocircuitry Following TBI|A Model for Predicting Cognitive and Emotional Health From Structural and Functional Neurocircuitry Following Traumatic Brain Injury||University of Arizona||Recruiting|February 2013|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|180|||Both|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|One hundred eighty participants aged 20-45, including 150 adults with documented mild TBI        and 30 healthy controls (HC) will participate in this study. Participants in the TBI group        will include 30 individuals who will be tested at two weeks post-TBI; 30 individuals who        will be tested at one month post-TBI; 30 individuals who will be tested at three months        post-TBI; 30 individuals who will be tested at six months post-TBI; and 30 individuals who        will be tested at 12 months post-TBI. Participants will be recruited from the local area        of Boston, MA, via IRB-approved flyers and advertisements placed in newspapers, on the        radio and within vehicles of the local public transport system (e.g. buses and subway        cars).|January 2016|January 29, 2016|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803048||70359|
NCT01803308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB12-9200-101|A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection|A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naïve HCV Infected Adults||INC Research|Yes|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|60 Years|No|||August 2014|December 8, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01803308||70339|
NCT01803321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-AI-0504|Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)||Regeneron Pharmaceuticals|Yes|Completed|November 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|4 Years|20 Years|No|||February 2013|February 28, 2013|February 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01803321||70338|
NCT01803555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFS-AS-306|Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®|A 12-Week Efficacy and Safety Evaluation of Budesonidel/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|June 2013|July 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|605|||Both|12 Years|N/A|No|||August 2014|August 1, 2014|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803555||70320|
NCT01803568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/882|Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU|Skeletal Muscles, Myokines and Glucose Metabolism|MyoGlu|Oslo University Hospital|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|31|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01803568||70319|
NCT01804413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB6961|Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency|Effects of Pegvisomant-Priming With the Glucagon Stimulation Test in Assessing GH and Cortisol Reserve in Adults: a Randomized Proof-of-Concept Pilot Study||Oregon Health and Science University|No|Recruiting|March 2011|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Both|21 Years|55 Years|No|||October 2013|October 23, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01804413||70255|
NCT01811745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-175|Physical Exercise and Jaques-Dalcroze Eurhythmics: Effects on Physical and Cognitive Functions, and Falls in Seniors|Physical Exercise and Jaques-Dalcroze Eurhythmics: Effects on Physical and Cognitive Functions, and Falls in Seniors (EPHYCOS Study)|EPHYCOS|University Hospital, Geneva|No|Active, not recruiting|February 2013|August 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|65 Years|N/A|No|||December 2014|December 3, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01811745||69692|
NCT01812031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOL09-PR-MEYER|Benefits Study of Respiratory-gated PET Acquisition in Lung Disease|Benefits Study of a Respiratory Gating Protocol for Positron Emission Tomography: Application on the Lungs|PneumoTEP|Centre Hospitalier Universitaire, Amiens|No|Completed|August 2009|February 2015|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|103|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01812031||69670|
NCT01812044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033000|Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery|Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery||Duke University||Completed|March 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|57|||Both|1 Year|7 Years|No|||December 2014|December 15, 2014|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01812044||69669|
NCT01809015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCM-2010EPI01|Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme|A Study Programme for the Evaluation of Oral Anticoagulation Therapy With Vitamin K Antagonists|thrombEVAL|Johannes Gutenberg University Mainz|Yes|Active, not recruiting|January 2011|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|In cohort A, patients of regular medical care are enrolled in the area of        Rhineland-Palatinate, Germany. Treatment and management of oral anticoagulation therapy        with vitamin K antagonists is performed within primary (ambulatory) care system.        In cohort B, patients are treated with oral anticoagulation in a specialized        telemedicine-based coagulation service in the area of Rhinehesse, Germany.|May 2014|May 14, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809015||69901|
NCT01814943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5040N00007|The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users|The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users||AstraZeneca|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|39000|||Both|50 Years|84 Years|No|Non-Probability Sample|Patients aged 50-84 yrs who had a first prescription of low-dose ASA (75-300mg/day) for        secondary cardiovascular or cerebrovascular prevention in 2000-2007 in The Health        Improvement Network database in the UK. Patients had to be enrolled with their PCP        (Primary Care Physician) for at least 2 years and have a health contact in the year prior.        Patients with use of aspirin ever recorded in the database before start of follow-up as        well as patient with cancer or alcohol abuse were excluded. Individuals were followed up        until the earliest occurrence of one of the following endpoints; first recorded diagnosis        of uncomplicated peptic ulcer, canser, alcohol abuse or alcohol related disease, reaching        the age of 85 years old, date of last practice data collection, death or end of follow-up        ( 30 September 2011).Patient records were manually reviewed to validate cases.|June 2013|June 17, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01814943||69447|
NCT01815164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M71-09|Effect of Hypnotherapy and Educational Intervention in Irritable Bowel Syndrome|Effect of Hypnotherapy and Educational Intervention on Brain Response to Visceral Stimulus Perception in the Irritable Bowel Syndrome||University Hospital, Linkoeping|No|Completed|August 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 20, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01815164||69432|
NCT01815424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921174|A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel-group Study Of The Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Asian Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|266|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01815424||69412|
NCT01815437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU100|Evaluating Vitamin D Content in Mushrooms|Evaluation of Vitamin D in a Mushroom Supplement||Boston Medical Center|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|80|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2013|January 11, 2016|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01815437||69411|
NCT01813565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130135|The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.|The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.||Asan Medical Center|Yes|Recruiting|March 2013|December 2016|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|20 Years|N/A|No|||December 2015|December 29, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01813565||69553|
NCT01814124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207-116|Conservative Management of Femoroacetabular Impingement|Therapeutic Effectiveness of Manual Therapy Plus Exercise for Femoroacetabular Impingement of the Hip: a Randomized Controlled Clinical Trial Pilot Study||High Point University|No|Completed|March 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|No|||February 2016|February 24, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01814124||69510|
NCT01814982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012997|An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury|An Open-Label, Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-17299425 in Patients With Traumatic Brain Injury||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|August 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||April 2013|April 30, 2013|March 18, 2013||No|reprioritization of company activities|No||https://clinicaltrials.gov/show/NCT01814982||69444|
NCT01816542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-2013-PT-BA|Evaluation of Irritancy/Allergic Sensitivity to Natural Personal-care Products by Patch Tests|Dermatologically Tested - Patch Tests - to Assess the Irritancy/Allergic Sensitivity of the Natural Personal-care Products Developed by "Mother's Choice".||Mother's Choice Ltd|Yes|Not yet recruiting|June 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01816542||69326|
NCT01803061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WebCan|Use of Computer-based Patient-reported Data to Assess Long Term and Late Effects of Head and Neck Cancer at the Point-of-care|Use of Computer-based Patient-reported Data to Assess Long Term and Late Effects of Head and Neck Cancer at the Point-of-care||Danish Cancer Society|No|Completed|September 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|N/A|N/A|No|||March 2015|March 5, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01803061||70358|
NCT01803074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-002|Study to Evaluate a HIV Drug for the Treatment of HIV Infection|Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects|HIV|Bristol-Myers Squibb|No|Completed|March 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|13||Actual|107|||Both|18 Years|55 Years|No|||January 2015|February 6, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803074||70357|
NCT01803334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322259|Impact of Marking Surgical Incision on Patient's Abdomen|Impact of Marking Surgical Incision Size and Location on the Patient's Abdomen During Preoperative Counseling in Minimally Invasive Gynecologic Surgery. A Randomized Control Trial.||Florida Hospital|No|Recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|54|||Female|18 Years|89 Years|No|||February 2013|March 1, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01803334||70337|
NCT01803347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001178-28|Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells|Multicentre,Randomized,Comparative,Add-on,Into Two Parallel Groups Clinical Trial to Evaluate Efficacy and Safety of Autologous Mesenchymal Stem Cells Derived From Expanded Adipose Tissue (ASC), for Treatment of Complex Perianal Fistulizing Disease in Patients Without IBD.|FISPAC|Instituto de Investigación Hospital Universitario La Paz|Yes|Recruiting|February 2013|March 2015|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01803347||70336|
NCT01803906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB5754|Tissue Sample Study for Mitochondrial Disorders|Tissue Study for Mitochondrial Disorders||Columbia University|No|Recruiting|February 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6900|Samples With DNA|Any type of tissue could be submitted, however, generally blood, urine, buccal cell (cheek),      and muscle are sent.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of all ages, race, gender with known or suspected mitochondrial disorders and        their carrier relatives (if requested).|May 2015|May 5, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01803906||70294|
NCT01804127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 13-01|Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL|Interim PET/CT Guided Cycle Numbers of R-CHOP in Patients With Diffuse Large B-cell Lymphoma: a Exploratory Phase II Study Study||Fudan University|No|Recruiting|February 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|196|||Both|18 Years|80 Years|No|||March 2013|March 2, 2013|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01804127||70277|
NCT01812590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ex-Panc|Acute Exercise and Pancreatic Endocrine Function|||Rigshospitalet, Denmark||Completed|January 2013|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|30 Years|70 Years|No|||January 2014|January 30, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812590||69628|
NCT01812603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA1208 Part A|A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma|A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma||GW Research Ltd|No|Active, not recruiting|September 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812603||69627|
NCT01812863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-14957|Pain Management in Children Undergoing Supracondylar Humerus Fracture Repair|Pain Management in Children Undergoing Supracondylar Humerus Fracture Repair: Can a Local Supraclavicular Block Improve Their Postoperative Outcome?||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|July 2012|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|46|||Both|2 Years|10 Years|No|||July 2015|December 9, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812863||69607|
NCT01813747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN10-DS-MS2|Mandible and Sub-mandible Using the 1440nm Wavelength Laser and Hand Piece|||Cynosure, Inc.|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||February 2014|February 3, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813747||69539|
NCT01813760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-AFF-UL-09|Treatment of Periorbital and Perioral Wrinkles With the Applications of the Iluminage Diode Laser|||Cynosure, Inc.|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|35 Years|60 Years|No|||March 2014|March 25, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01813760||69538|
NCT01814358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thomas whey 01|Whey Protein Effects on Gycemic Control and Vascular Function|Effects of Pre-meal Whey Protein Ingestion on Daily Glycemic Control and Oxidative Stress Mediated Postprandial Inflammation and Vascular Dysfunction Evoked by Consumption of a High-glycemic Meal||University of California, Los Angeles|No|Withdrawn|March 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814358||69492|
NCT01814072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH NIDDK R01DK097364-01|Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity|Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity|Opt-IN|Northwestern University|Yes|Recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|32||Anticipated|560|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01814072||69514|
NCT01814085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016300|A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression|A Single-arm, Open-label, Multi-center Study to Investigate Efficacy and Safety of Lexapro on Acute Treatment of Severe Depression||Xian-Janssen Pharmaceutical Ltd.|No|Completed|February 2010|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|225|||Both|18 Years|65 Years|No|||January 2014|January 2, 2014|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01814085||69513|
NCT01830868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-410|A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410)|An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Observational Study of the Use of Zonisamide (ZNS) in the Adjunctive Treatment of Adult Patients With Partial Onset Seizures Treated With One Antiepileptic Drug (AED) as Baseline Medication|ZOOM|Eisai Inc.|No|Active, not recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitals, medical practices across several European countries.|April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830868||68228|
NCT01830855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971009|A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years|A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years||Pfizer|Yes|Completed|April 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3597|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830855||68229|
NCT01831115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL V|Basics in Acute Shortness of Breath EvaLuation (BASEL V) Study|Basics in Acute Shortness of Breath EvaLuation (BASEL V) Study|BASEL V|University Hospital, Basel, Switzerland|No|Active, not recruiting|April 2006|July 2017|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|EDTA, Plasma and Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with acute dyspnea to the emergency department.|March 2016|March 3, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01831115||68209|
NCT01832259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI63129|A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection|A Neoadjuvant, Randomized, Phase II Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection||University of Utah|Yes|Recruiting|August 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||February 2016|February 10, 2016|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832259||68123|
NCT01831986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-9-10|Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders|Addition of Both Pregnenolone and L-theanine to Ongoing Antipsychotic Treatment for Schizophrenia and Schizoaffective Disorders: an 8-week, Randomized, Double-blind, Placebo-controlled Multicenter Study||Sha’ar Menashe Mental Health Center|Yes|Enrolling by invitation|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||December 2013|December 4, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01831986||68143|
NCT01832272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1206/158-004|Reinflation After Early Tourniquet Release in Total Knee Arthroplasty|The Effects of Tourniquet Reinflation After Early Tourniquet Release in Total Knee Arthroplasty||Seoul National University Hospital|Yes|Recruiting|February 2013|January 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|40 Years|90 Years|No|||May 2014|May 18, 2014|February 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01832272||68122|
NCT01832285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120241|Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients|Effect of Fluvoxamine Augmentation on Cognitive Function , Aggressive Behavior , Clinical Symptoms and mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) in Medicated Schizophrenia Patients||Sha’ar Menashe Mental Health Center|Yes|Recruiting|December 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||January 2013|April 22, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01832285||68121|
NCT01832545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICO-FY013|Aquatic Exercise Program for Knee Osteoarthritis|The PICO Project: Aquatic Exercise for Knee Osteoarthritis in Overweight and Obese Individuals|PICO|Technical University of Lisbon|No|Completed|November 2011|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|65 Years|No|||April 2013|April 15, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832545||68101|
NCT01832779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300104|Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy (POEM)|POEM|University of Florida|No|Recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Those subjects with Achalasia who have been referred for the POEM treatment for their        Achalasia.|March 2016|March 9, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01832779||68083|
NCT01833936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-12-00389|E-Stim and Achilles Tendon Repair Study|The Use of Electrical Stimulation on Muscle Cross Sectional Area and Muscle Fascicle Length Following Postoperative Achilles Tendon Repair|E-Stim|Orthopedic Foot and Ankle Center, Ohio|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833936||67994|
NCT01832662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.07.MET|Coffee Polyphenols Antioxidants|Coffee Antioxidant Efficacy in Humans||Nestlé|No|Completed|March 2011|June 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832662||68092|
NCT01834638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-765|Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)|Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855||AbbVie|No|Terminated|March 2013|November 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|268|||Both|20 Years|66 Years|No|||October 2014|October 27, 2014|April 16, 2013|Yes|Yes|Study endpoint in preceding base study M10-855 not met.|No||https://clinicaltrials.gov/show/NCT01834638||67940|
NCT01834651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-IST20|A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases|A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases||Cedars-Sinai Medical Center|No|Recruiting|April 2013|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||October 2015|October 7, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834651||67939|
NCT01830829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JALYN|JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)||Queen's University|No|Terminated|April 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Male|45 Years|N/A|No|||October 2014|October 21, 2014|April 10, 2013||No|Difficulty in enrolling particpants|No||https://clinicaltrials.gov/show/NCT01830829||68231|
NCT01831076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0627.cc|Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors|Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.||University of Colorado, Denver|Yes|Active, not recruiting|April 2002|August 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|50 Years|N/A|No|||November 2015|November 9, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831076||68212|
NCT01834144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:136|The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial|The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial|VIGOR|University of Manitoba|Yes|Recruiting|May 2013|September 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|70|||Both|15 Years|45 Years|No|||March 2015|March 18, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01834144||67978|
NCT01834118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVC-001|Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension|Reintervention After Previous Renal Denervation in Non-responding Patients With Severe Hypertension|RETREAT|Cardiovascular Center Frankfurt|No|Recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients with treatment-resistant hypertension, who already underwent renal denervation        with no therapeutic avail.|June 2013|July 11, 2014|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834118|1 Year|67980|
NCT01834131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL114197|Hypertension Control Program in Argentina (HCPIA)|Comprehensive Approach for Hypertension Prevention and Control in Argentina||Tulane University Health Sciences Center|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1888|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 13, 2014|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01834131||67979|
NCT01834690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-0582C|Uses of Immunosuppression Therapy in Patients With Liver Transplantation|Trends of Immunosuppression Therapy and Their Effectiveness in Patients With Liver Transplantation||Chang Gung Memorial Hospital|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|314|None Retained|no biospecimens are to be retained|Both|20 Years|N/A|No|Non-Probability Sample|Study subjects: Patients who had liver transplantation in Kaohsiung Chang Gung Memorial        Hospital|February 2015|February 15, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01834690||67936|
NCT01825291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2000|Sleep-disordered Breathing in Postmenopausal Women|Sleep-disordered Breathing in Postmenopausal Women and CPAP Treatment||Turku University Hospital||Active, not recruiting|January 1999|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|80 Years|No|Probability Sample|Clinical sample of patients with sleep apnea|November 2015|November 11, 2015|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01825291||68653|
NCT01825304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC110-92|The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation|the Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation||Nanjing Medical University|Yes|Recruiting|October 2011|June 2013|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2011|April 4, 2013|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825304||68652|
NCT01825317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX-KOR1|Effect of NeuroAD on Alzheimer Patients|Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients||Neuronix Ltd|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|60 Years|90 Years|No|||April 2014|April 17, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825317||68651|
NCT01831141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSKP|Long Term Outcome of Congenital Solitary Kidney|Renal Outcome in Children With Congenital Solitary Kidney: a Longitudinal Prognostic Study|CSKP|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|June 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|18 Years|No|Non-Probability Sample|Children aged 0 - 18 years, diagnosed with a CSK (defined as a single functioning kidney        documented and confirmed by DMSA Scan.).        Subjects will be enrolled from 1st June 2010 to 30th Jume 2013 at the Paediatric        Nephrology Department of the Sant'Orsola Malpighi Hospital, the follow-up of each subject        will continue for 10 years.|April 2013|April 11, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831141||68207|
NCT01831128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACE 001|French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS)|Prospective Multicentre Observational French Cohort Study of Patients With Heart Failure and Central Sleep Apnoea Requiring Adaptive Servo-Ventilation (PaceWave, AutoSet CS) Treatment|FACE|ResMed|No|Recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Heart Failure Patients with Central Sleep Apnea|September 2014|September 1, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01831128||68208|
NCT01831388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-261|Breath Training Exercise for the Reduction of Chronic Dyspnea|Breath Training Exercise for the Reduction of Chronic Dyspnea: a Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|19 Years|N/A|No|||August 2015|August 19, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01831388||68189|
NCT01831648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081216|Establishment of Reference Values for Insulin-like Growth Factor 1 (IGF1) in the General Population|An Open, Prospective, National, Multicenter, Non Randomised, Study Based on Healthy Volunteers for Establishing Normative Data for IGF1 in the General Population|VARIETE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|924|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01831648||68169|
NCT01831661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-VIN-183|Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition|A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition||IPCA Laboratories Ltd.|Yes|Completed|December 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831661||68168|
NCT01831999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA030480-01A1|Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients|Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients||Treatment Research Institute|No|Active, not recruiting|June 2012|April 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01831999||68142|
NCT01832792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxGSH1|Guided Self-help for Binge Eating|Guided Self-help for Binge Eating||Oxford Health NHS Foundation Trust|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|102|||Both|17 Years|N/A|No|||November 2013|November 18, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832792||68082|
NCT01833091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Artificial Night|Creating an Artificial Night on Physiological Changes in Preterm Infants|||Mashhad University of Medical Sciences||Completed|April 2012|October 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|30 Weeks|34 Weeks|Accepts Healthy Volunteers|||March 2013|April 12, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833091||68059|
NCT01833104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReSource|Plasticity of the Compassionate Brain|A Longitudinal Study on the Trainability of Socio-affective and Cognitive Functions and Abilities.||Max Planck Institute for Human Cognitive and Brain Sciences|No|Active, not recruiting|January 2013|May 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|330|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01833104||68058|
NCT01833390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagniXene-087550-01|MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects|Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation|HXe-VENT|Xemed LLC|No|Completed|September 2011|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|58|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2015|March 10, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833390||68036|
NCT01833676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901.11|To Compare Effect of Sevoflurane Versus Desflurane on the Return of Swallowing Reflexes in the Elderly|To Compare Effect of Sevoflurane Versus Desflurane on the Return of Protective Airway Reflexes in the Elderly Population||University of Malaya|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|60 Years|85 Years|No|||December 2013|December 4, 2013|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01833676||68014|
NCT01830738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/VL-03|Laparoscopic Hysterectomy Via a Single Port, Peri-umbilical Technique Versus a Conventional Laparoscopic Technique|Laparoscopic Hysterectomy Via a Single Port, Peri-umbilical Technique Versus a Conventional Laparoscopic Technique : a Prospective, Randomized, Multicenter Study Evaluating the Length of Hospital Stay|HOT|Centre Hospitalier Universitaire de Nīmes|No|Terminated|February 2014|April 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|April 10, 2013||No|Inclusion curve too poor.|No||https://clinicaltrials.gov/show/NCT01830738||68238|
NCT01834339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00069761|EVPOME Versus AlloDerm in Subjects Reconstructed With Large Defect Mandibular Resection|A Randomized, Parallel-Group (Autogenous EVPOME Versus AlloDerm Without Incorporation of Keratinocytes) Study in Subjects Reconstructed With Large Defect Mandibular Resection in Need of Vestibuloplasty for Dental Rehabilitation|Large Defect|University of Michigan|Yes|Recruiting|September 2013|August 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834339||67963|
NCT01834352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1289|Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy|WOIT|University of North Carolina, Chapel Hill|Yes|Withdrawn|November 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|45 Years|No|||March 2014|March 21, 2014|April 12, 2013|Yes|Yes|Concern for cross contamination in weighing tree nuts in facility with peanuts|No||https://clinicaltrials.gov/show/NCT01834352||67962|
NCT01831596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030110|Evaluation of a Novel Post-Surgical Dressing|Evaluation of a Novel Post-Surgical Dressing||Spiracur, Inc.|No|Active, not recruiting|June 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01831596||68173|
NCT01831609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-089-013|Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer|Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer||Samsung Medical Center|Yes|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Pleural fluid, ascites, fine needle aspirations, other body fluids (i.e. CSFs)prospectively.      Primary cultures, Xenografts.|Both|N/A|N/A|No|Non-Probability Sample|1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare        cancer|January 2016|January 3, 2016|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01831609||68172|
NCT01833897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6535|NMDA Antagonists in Bipolar Depression|NMDA Antagonists in Bipolar Depression||New York State Psychiatric Institute|No|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||September 2015|September 28, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833897||67997|
NCT01834456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-125|Comprehensive Care of Children With Medical Complexity|Comprehensive Care of Children With Medical Complexity: Piloting an Innovative Model||Seton Healthcare Family|Yes|Active, not recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|450|||Both|N/A|17 Years|No|||November 2015|November 30, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01834456||67954|
NCT01834430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NLY059|Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting|Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting||Nanjing PLA General Hospital||Completed|February 2010|||February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|60 Years|No|||April 2013|April 15, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01834430||67956|
NCT01834443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVS-Therapy|Therapeutic Effects of Galvanic Vestibular Stimulation (GVS) on Spatial Neglect|Therapeutic Effects of Galvanic Vestibular Stimulation (GVS) on Spatial Neglect|GVS|Schoen Clinic Bad Aibling|No|Recruiting|May 2011|March 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01834443||67955|
NCT01830686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 13005|Metabolic Effects of Short Term Sugarcane Bagasse Supplementation|Metabolic Effects of Short Term Sugarcane Bagasse Supplementation|BROWNIE|Pennington Biomedical Research Center|No|Completed|April 2013|December 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|23|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830686||68242|
NCT01830907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|First Hospital of JLU|Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002|Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002- A Prospective, Randomized Clinical Trial||First Hospital of Jilin University|No|Completed|January 2012|March 2013|Actual|February 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|85 Years|No|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830907||68225|
NCT01834677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039288|Translational Research Evaluating Neurocognitive Memory Processes|Translational Research Evaluating Neurocognitive Memory Processes|TREC-MP|Duke University|No|Completed|April 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|76|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects are able to contact the study team. The depressed ECT cohort will be referred to        study team.|December 2015|December 1, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01834677||67937|
NCT01830673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA-2012-SCIT|Regulatory T-cells After Subcutaneous Immunotherapy|Investigation of T-regulatory Cells After Subcutaneous Immunotherapy|RTCAS|Johann Wolfgang Goethe University Hospitals|No|Completed|October 2011|October 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|68|Samples Without DNA|serum|Both|7 Years|28 Years|No|Non-Probability Sample|Patients aged 7-28 years of age with house grass pollen allergy|July 2014|July 24, 2014|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01830673||68243|
NCT01831414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00246-51|Effect of Immersion Level on Respiratory Function of Spinal Cord Injury Patients During Balneotherapy|Etude Pilote évaluant l'Effet du Niveau d'Immersion Sur la Fonction Respiratoire Des Patients tétraplégiques bénéficiant de balnéothérapie|BALNEORESPI|Centre d'Investigation Clinique et Technologique 805|No|Completed|June 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831414||68187|
NCT01831674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-VIN-184|Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition|A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fed Condition||IPCA Laboratories Ltd.|Yes|Completed|December 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831674||68167|
NCT01831401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12080DB-SW|A Study Investigating the Effect of Patient Pelvic Positioning and Method of Acetabular Component Insertion on Acetabular Component Inclination During Total Hip Arthroplasty (THA)|A Randomised Controlled Study Investigating the Effect of Patient Pelvic Positioning and Method of Acetabular Component Insertion on Acetabular Component Inclination During Total Hip Arthroplasty (THA).||Musgrave Park Hospital|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|9||Actual|270|||Both|16 Years|100 Years|No|||March 2016|March 20, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01831401||68188|
NCT01832298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-101|Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor|Phase I Study of Simmitecan Hydrochloride for Injection in Patients With Advanced Solid Tumor：Tolerability and Pharmacokinetics||ShangHai HaiHe Pharmaceutical|No|Active, not recruiting|December 2012|September 2016|Anticipated|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|65 Years|No|||March 2016|March 18, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832298||68120|
NCT01832571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391449|SCOPE: Strategies to Combine PrEP With Prevention Efforts|Open Label Prospective Study of Strategies to Combine Pre-Exposure Prophylaxis (PrEP)With Prevention Efforts|SCOPE|FHI 360|No|Withdrawn|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 11, 2013|April 3, 2013|Yes|Yes|Study is closed early due to withdrawal of funding. No study procedures were implemented.|No||https://clinicaltrials.gov/show/NCT01832571||68099|
NCT01832558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2012-002175-34|The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)|||Medical University of Vienna||Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832558||68100|
NCT01833403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211M23881|Metabolomic Analysis of Hepatic Insulin Resistance|Metabolomic Analysis of Hepatic Insulin Resistance||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|April 10, 2013||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01833403||68035|
NCT01833689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0549|Glycaemic Index of Foods in Healthy Volunteers|Glycaemic Index Testing of Carbohydrate Containing Foods Using a Standardised Method|GI|Imperial College London|Yes|Recruiting|June 2013|March 2023|Anticipated|March 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833689||68013|
NCT01833962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-3708|A Retrospective Study of Actifuse Synthetic Bone Graft Versus Other Bone Graft Substitutes in Patients Requiring Lumbar Fusion|A Retrospective Study of Actifuse Synthetic Bone Graft Versus Other Bone Graft Substitutes in Patients Requiring Lumbar Fusion||OrthoGeorgia|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All study patients will be extracted from our current patient population. A total of 50        patients treated with Actifuse and 50 patients treated with other synthetic bone grafting        substitutes|April 2015|April 20, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833962||67992|
NCT01833949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBC-2013-HR|Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume|This Prospective Longitudinal Cohort Study Included Infertile Women With PCOS Unresponsive to Clomiphene Citrate Treatment, Who Underwent Either Unilateral (ULOD) or Bilateral (BLOD)Laparoscopic Diathermy||KBC Split|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Female|25 Years|35 Years|No|||April 2013|April 13, 2013|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833949||67993|
NCT01834196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038240|Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging|Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging|SWEPT|Duke University|No|Terminated|August 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|April 15, 2013|No|Yes|No active study enrollment for a 2 years.|No||https://clinicaltrials.gov/show/NCT01834196||67974|
NCT01825694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA031301|An Integrated Treatment for Comorbid PTSD and Substance Abuse in Adolescents|An Integrated Treatment for Comorbid PTSD and Substance Abuse in Adolescents||University of California, Los Angeles|No|Recruiting|April 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|13 Years|19 Years|No|||June 2013|June 25, 2013|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01825694||68622|
NCT01830621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO23|BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma|A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma||Canadian Cancer Trials Group|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||April 2015|March 16, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830621||68247|
NCT01826903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034166|Perinatal Depression Treatment and Child Development|Perinatal Depression Treatment and Child Development: A Follow-Up of the Thinking Healthy Programme||Duke University|No|Completed|July 2012|October 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|964|||Both|6 Years|7 Years|No|Probability Sample|The study population includes children of women who participated in the Thinking Healthy        Programme and children of women who were eligible for participation in the Thinking        Healthy Programme but who screened negative for depression at the time.|April 2015|April 17, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01826903||68531|
NCT01827215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD006213|Randomized Control Trial of a Virtual Patient Advocate for Preconception Care|Using Innovative Communication Technology to Improve the Health of Young African American Women||Boston Medical Center|No|Recruiting|September 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|530|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827215||68507|
NCT01827228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP1DA034989|Transmission Reduction Intervention Project|Preventing HIV Transmission by Recently-Infected Drug Users|TRIP|National Development and Research Institutes, Inc.|No|Enrolling by invitation|April 2013|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3000|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01827228||68506|
NCT01834157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F5-2012-305495-OT2|Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis|The "DeSScipher" Project - to Decipher the Best Treatment for Systemic Sclerosis - Observational Trial 2: Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis||University of Pecs|No|Recruiting|April 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|160|||Both|N/A|N/A|No|Probability Sample|The study population is adult and juvenile systemic sclerosis patients from the EUSTAR        cohort (MEDSonline database) and the jSScWG cohort.|December 2015|December 21, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01834157|12 Months|67977|
NCT01834469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2083|Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients|Feasibility Study of the (Intravenously Injected) Indocyanine Green (ICG) Imaging of Tumoral Implants in Patients With Peritoneal Carcinomatosis From Ovarian Carcinoma|OV-AP-ICG-IV|Jules Bordet Institute|Yes|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|October 14, 2014|April 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834469||67953|
NCT01834482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068726|Modified Atkins Diet Plus KetoCal for Adult Epilepsy|A Randomized, Open-label Evaluation of KetoCal® in Initial Combination With the Modified Atkins Diet for the Dietary Management of Intractable Adult Epilepsy.||Johns Hopkins University|No|Recruiting|March 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|100 Years|No|||October 2015|October 1, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01834482||67952|
NCT01834703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR-13-02|Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids|Randomized Controlled Trial of Uterine Artery Embolization (UAE) Versus High-Intensity-Focused-Ultrasound (HIFU) for Treatment of Patients With Uterine Fibroids||Chinese University of Hong Kong|Yes|Recruiting|May 2009|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|30 Years|47 Years|No|||February 2015|February 3, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01834703||67935|
NCT01830920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-003|A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)|A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)||Thrasos Innovation, Inc.|Yes|Active, not recruiting|May 2013|December 2015|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|85 Years|No|||November 2015|November 2, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830920||68224|
NCT01831427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-326-0101|Evaluating the Safety, Pharmacokinetics and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis|A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis||Gilead Sciences|Yes|Completed|March 2013|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||February 2015|February 26, 2015|April 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831427||68186|
NCT01830881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 9064|Evaluation of Oral Midazolam in First-trimester Surgical Abortions|An Evaluation of Oral Midazolam for Anxiety and Pain in First-trimester Surgical Abortion: a Randomized Controlled Trial||Oregon Health and Science University|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Female|18 Years|65 Years|No|||April 2014|April 2, 2014|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830881||68227|
NCT01830894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9889-SH-CTIL|Feasibility Study of New MRI Protocol in Assessing Early Blood Brain Barrier Disruption (BBBD)in Related to Delay Brain Edema|Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding|BBBD|Sheba Medical Center|No|Not yet recruiting|April 2013|June 2014|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|80 Years|No|||March 2013|April 10, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830894||68226|
NCT01832025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUSDM10665|Comparison of Incidence Between Two Techniques|Comparison of the Intraoperative, Postoperative Complications and Patient's Discomfort Involving External and Internal Maxillary Sinus Floor Elevation Techniques With Simultaneous Implant Placement: a Randomized Clinical Trial||Tufts University School of Dental Medicine|No|Recruiting|March 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832025||68140|
NCT01831687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/11-VIN-414|Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition||IPCA Laboratories Ltd.|Yes|Completed|December 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831687||68166|
NCT01832012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGUCPR1|Basic Life Support Cardiopulmonary Resuscitation Refresher in MS2 at St George's University|Practical Skill Retention in Medical Students: Improving Cardiopulmonary Resuscitation With Hands-On Practice||Windward Islands Research and Education Foundation|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|175|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832012||68141|
NCT01832805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/392|Theta Burst Study Ghent|The Effects of Thetaburst Stimulation in Treatment Resistant Unipolar Depressed Patients|TBS Ghent|University Hospital, Ghent|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832805||68081|
NCT01832818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01|Post-Market Study Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System|A Prospective, Feasibility, Multi-Center Nonrandomized Clinical Trial Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System||Pioneer Surgical Technology, Inc.|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832818||68080|
NCT01833117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-021|Efficacy and Safety Study of FID 119515A|A Randomized, Observer-Masked, Efficacy and Safety Study of FID 119515A in Dry Eye||Alcon Research|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|April 12, 2013||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01833117||68057|
NCT01833702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037857|Use of a Mobile-based App for SCD Patients|Use of a Mobile-based Pain Assessment Application for SCD Patients|SMART|Duke University|No|Recruiting|January 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|12 Years|N/A|No|Non-Probability Sample|Patients experiencing pain or patients with sickle cell disease|August 2015|August 17, 2015|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01833702||68012|
NCT01834209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100946|A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|Open-Label Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Subjects With Metastatic Castration-Resistant Prostate Cancer||Janssen Research & Development, LLC|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834209||67973|
NCT01834222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851143|Post Market Surveillance to Observe Safety of Prevenar13™ in Adults|Post Marketing Surveillance To Observe Safety Of Prevenar 13 In Adults||Pfizer|No|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Korean adults aged 18 years and older who receive Prevenar13™ in a routine clinical        setting|February 2016|February 9, 2016|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834222||67972|
NCT01825109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09070|Improving Rotavirus Vaccine Immune Response|Improving the Immune Response to Rotavirus Vaccine||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|July 2010|December 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Both|1 Month|45 Years|Accepts Healthy Volunteers|||December 2009|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825109||68667|
NCT01834768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11020|EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety|Study of the Safety of Eplerenone in Cyclosporine A-treated Transplant Recipients|EpleCsAT|CHU de Reims|Yes|Recruiting|February 2013|December 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01834768||67930|
NCT01825421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nCD64 ABX NICU - 01|A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64|A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64||Yale University|No|Withdrawn|October 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|5 Months|No|||July 2015|July 14, 2015|April 2, 2013||No|No funding obtained|No||https://clinicaltrials.gov/show/NCT01825421||68643|
NCT01826305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09642|Independent Exercise Compared With Formal Rehabilitation Following Primary Total Knee Replacement|Independent Exercise Compared With Formal Rehabilitation Following Primary Total Knee Replacement||University of California, San Francisco||Recruiting|July 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826305||68576|
NCT01826916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/5|EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema|EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema||Dyax Corp.|Yes|Completed|November 2003|January 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Both|10 Years|N/A|No|||April 2013|April 4, 2013|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01826916||68530|
NCT01826942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-UP-13-01|Scar Prevention Using Fractional Carbon Dioxide Laser Treatment|Scar Prevention Using Fractional Carbon Dioxide Laser Treatment||Lumenis Ltd.|No|Terminated|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|April 4, 2013|Yes|Yes|Cooperation stooped with PI|No||https://clinicaltrials.gov/show/NCT01826942||68528|
NCT01827254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181211|Sutent Rechallenge In mRCC Patients|Etude Resume (Retraitement Sunitinib Rein Metastatique)|RESUME|Pfizer|Yes|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|mRCC patients treated with sunitinib in first line and rechallenged with sunitinib in 3rd        and 4th line|April 2015|April 28, 2015|March 25, 2013||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01827254||68504|
NCT01834170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC 92-1|EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer|EUS-guided Intratumoral Gemcitabine Therapy in Locally Advanced Unresectable Pancreatic Cancer: A Phase 1 Study||University of Tehran|Yes|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|No|||December 2014|December 1, 2014|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01834170||67976|
NCT01834716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002817|Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study|Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study/ 18F-AV-45-A14 - CLINICAL EVALUATION OF FLORBETAPIR F 18 (18F-AV-45) Sponsor of 18F-AV-45-A14: Avid Radiopharmaceuticals||Mayo Clinic|Yes|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834716||67934|
NCT01832038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0009|Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures|A Multi-center, Open-label, Uncontrolled, Long-term, Extension Study to Evaluate the Safety and Efficacy of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Partial-onset Seizures With or Without Secondary Generalization||UCB Pharma|No|Active, not recruiting|March 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|473|||Both|16 Years|70 Years|No|||March 2016|March 8, 2016|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832038||68139|
NCT01832324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005998|Molecular Basis of Food Allergy|Molecular Basis of Food Allergy and Food Tolerance||Children's Hospital of Philadelphia|No|Recruiting|January 2011|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1300|Samples With DNA|DNA, sera and PBMC|Both|4 Months|75 Years|Accepts Healthy Volunteers|Probability Sample|Food Allergy (Both IgE and Non-IgE Mediated) Atopic Controls Healthy controls|December 2015|December 3, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01832324||68118|
NCT01831154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106219|The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery|The Effect of Intraoperative Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery||James A. Haley Veterans Administration Hospital|Yes|Completed|May 2010|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|37|||Both|21 Years|N/A|No|||April 2013|April 10, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831154||68206|
NCT01831167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-JBZ-Tefflon|Effect of Dynamic Light Application on Performance of ICU Nurses|Effect of Dynamic Light Application on Performance of ICU Nurses|Tefflon|Jeroen Bosch Ziekenhuis|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01831167||68205|
NCT01832584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC-04|Effect of Red Grape Cells (RGC) Powder Consumption on Measures of Aerobic Fitness and Mood|A Double-blind, Randomized, Placebo Controlled Study of the Effect of Red Grape Cells (RGC) Powder Consumption on Measures of Aerobic Fitness, Body Composition and Mood||Fruitura Bioscience Ltd.|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 13, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832584||68098|
NCT01832311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108-1080229-0142|Protein Profile of Immunoregulatory Factors in Diabetic Cataract|Protein Profile of Immunoregulatory Factors in Diabetic Cataract||University of Zagreb|No|Completed|January 2009|December 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|61|||Both|N/A|N/A|No|||April 2013|April 10, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01832311||68119|
NCT01833130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-CM-12-545|Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)|||Allergan|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|No|||September 2015|September 18, 2015|April 12, 2013|Yes|Yes||No|September 18, 2015|https://clinicaltrials.gov/show/NCT01833130||68056|
NCT01833143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-222|Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D|A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833143||68055|
NCT01833416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013027692|Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients|Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients||Hospital do Rim e Hipertensão|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Probability Sample|All male and female de novo kidney transplant recipients|March 2015|March 20, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01833416||68034|
NCT01833429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|907/2011|Autonomic Dysfunction in Resistant Hypertension|Circadian Autonomic Disturbances in Resistant Hypertension With and Without White-coat Phenomenon|RH|University of Campinas, Brazil|No|Completed|September 2011|December 2012|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|44|||Both|30 Years|60 Years|No|Probability Sample|Forty-four resistant hypertension subjects, regularly followed up at the cardiovascular        clinical pharmacology out-patients' clinic, and who complied with pharmacological        prescription for hypertension, were recruited to participate in this transversal and        observational study.|February 2012|April 12, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01833429|10 Months|68033|
NCT01824576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSI 5R44NS054372|Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion|Physiological Effects of Intrathoracic Pressure Regulation in Patients With Decreased Cerebral Perfusion Due to Brain Injury or Intracranial Pathology||Advanced Circulatory Systems|No|Recruiting|April 2013|||July 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824576||68708|
NCT01825148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUNMC-EX-BCM-2012|GLP-1 Receptor Targeting in Diabetic and Healthy Individuals|Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4|GLP-1-CPOP|Radboud University|Yes|Completed|December 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|blood samples|Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 Diabetes patients and healthy volunteers responding to advertisment|November 2014|November 27, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01825148||68664|
NCT01824810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00027|Whiplash-associated Disorders - Needling Treatments Pilot Study|A Pilot Case Randomized Control Study Analysing the Effectiveness of 3 Needling Techniques: Intramuscular Stimulation, Neural Prolotherapy, and Myofascial Release in the Treatment of Chronic Whiplash Associated Disorder.||University of British Columbia|No|Recruiting|June 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|32|||Both|19 Years|75 Years|No|||August 2015|August 24, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824810||68690|
NCT01825122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVSC001|Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction|||Invion, Inc.|No|Completed|March 2014|August 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825122||68666|
NCT01825135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXJ012|Electrical Stimulation to Strengthen Muscles in the Lower Legs in Patients Requiring Prolonged Mechanical Ventilation|Electrical Stimulation to Strengthen the Quadriceps Muscles in Patients Requiring Prolonged Mechanical Ventilation||RML Specialty Hospital|No|Recruiting|March 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825135||68665|
NCT01825434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 454/2008|Effect of Yogurt With Polydextrose,L Acidophilus and B Lactis in Chronic Constipation|Effect of Yogurt Containing Polydextrose, Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis HN019: a Randomized, Double-blind, Controlled Study in Chronic Constipation||University of Campinas, Brazil|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|No|||January 2013|April 2, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01825434||68642|
NCT01826682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0039UG|Physiotherapy in Exacerbation Chronic Obstructive Pulmonary Disease|Physiotherapy Program Intervention in Exacerbation of Chronic Obstructive Pulmonary Disease.||Universidad de Granada|Yes|Recruiting|March 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01826682||68548|
NCT01826695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0040UG|Neurodynamic Intervention in Fibromyalgia|Study of the Effectiveness of a Neurodynamic Intervention in Women With Fibromyalgia.|FM|Universidad de Granada|Yes|Recruiting|January 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||December 2014|December 9, 2014|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01826695||68547|
NCT01826929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USI-10-66|Effectiveness New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based|Effectiveness of a New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based on a Multifactorial Intervention: The PROPRESE Randomized Controlled Trial.|PROPRESE|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Recruiting|January 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|30 Years|80 Years|No|||April 2013|April 9, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01826929||68529|
NCT01827605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_FLAZ-12|A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed Follicular Lymphoma (FL)|A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed Follicular Lymphoma (FL) Aged 18-65 Years||Fondazione Italiana Linfomi ONLUS|No|Recruiting|January 2012|April 2019|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|265|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827605||68477|
NCT01830725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20120020H|Purine Metabolism Enzyme SNP to Uric Acid Production|Relationship of Purine Metabolism Enzyme Single-Nucleotide Polymorphisms to Uric Acid Production and Response to Xanthine Oxidase Inhibitors||Keesler Air Force Base Medical Center|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|DNA will be banked for future studies as allowed by patient consent|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients for either the gout/hyperuricemia group or the control group will be recruited at        the time of their evaluation in either the Internal Medicine (IM) Clinic or IM Specialties        Clinic.|January 2016|January 1, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830725||68239|
NCT01830699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20120016H|Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis|Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis||Keesler Air Force Base Medical Center|Yes|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2014|July 13, 2014|April 6, 2013||No||No|May 10, 2014|https://clinicaltrials.gov/show/NCT01830699||68241|
NCT01830712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3864|A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors|A Long-Term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors. A Retrospective Follow-up Assessment to F7HAEM/USA/3/USA and F7HAEM/USA/4/USA||Novo Nordisk A/S|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|15|||Both|N/A|N/A|No|Non-Probability Sample|Haemophilia patients with inhibitors who had EOS during their participation in        F7HAEM/USA/3/USA or F7HAEM/USA/4/USA (NCT01561391).|April 2014|April 14, 2014|April 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01830712||68240|
NCT01830933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150B-0158|Breast Cancer Risk Reduction: A Patient Doctor Intervention|Breast Cancer Risk Reduction: A Patient Doctor Intervention|BreastCARE|University of California, San Francisco|Yes|Completed|June 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1235|||Both|40 Years|74 Years|No|||August 2014|August 14, 2014|April 10, 2013||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01830933||68223|
NCT01831180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00022675|A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women|A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women: II-Scalp & Blood Flow 2012||Wake Forest School of Medicine|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|50|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Selected from the Wake Forest University Health Sciences Dermatology clinics and        responders to Institutional Review Board (IRB) approved advertising|December 2015|December 9, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01831180||68204|
NCT01831700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/10/386|Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lisinopril/Hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition||IPCA Laboratories Ltd.|Yes|Completed|October 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831700||68165|
NCT01832337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|伦研批第E201215号|Limb Remote Ischemic Preconditioning for Heart and Intestinal Protection During Laparoscopic Colorectal Surgery|||Sixth Affiliated Hospital, Sun Yat-sen University||Recruiting|October 2012|||May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|120|||Both|40 Years|N/A|No|||April 2013|April 11, 2013|March 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832337||68117|
NCT01823484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112233|Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill|Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill||Zhongda Hospital||Recruiting|January 2012|||May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||January 2014|January 13, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01823484||68792|
NCT01823497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP4155|Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit|Parent/Nurse Controlled Analgesia for Post-Operative Pain Management in Neonates: A Preliminary Randomized Controlled Trial|PNCA|Medical College of Wisconsin|No|Active, not recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|70 Days|No|||September 2015|September 1, 2015|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823497||68791|
NCT01832831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00035833|Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy|||University of Michigan||Active, not recruiting|May 2010|||September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Male|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|December 2014|December 3, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832831||68079|
NCT01824056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3626A|The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography|The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)||Chang Gung Memorial Hospital|Yes|Completed|August 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|20 Years|80 Years|No|||November 2013|November 10, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01824056||68748|
NCT01824589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSI W81XWH-11-1-0542|Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury|Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology||Advanced Circulatory Systems|No|Terminated|August 2012|||August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|1|||Both|15 Years|N/A|No|||February 2015|February 12, 2015|March 29, 2013|Yes|Yes||No|August 25, 2014|https://clinicaltrials.gov/show/NCT01824589||68707|
NCT01824303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-100-202|Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis|A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension||Allergan|Yes|Terminated|March 2013|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|March 31, 2013|Yes|Yes|This study was terminated early due to company decision.|No|October 23, 2015|https://clinicaltrials.gov/show/NCT01824303||68729|Due to technical issues with the patient electronic diary used for the collection of the outcome measures data, as well as the small evaluable sample size and large variability, the efficacy data should be interpreted with caution.
NCT01825161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-12-002|The Epidemiology, Process and Outcomes of Spine Oncology (EPOSO)|The Epidemiology, Process and Outcomes of Spine Oncology|EPOSO|AOSpine International|No|Recruiting|August 2013|July 2018|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with metastatic spine disease|January 2016|January 13, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01825161||68663|
NCT01825486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I050309|Balance and Gait Characteristics to Predict Accidental Falls in Community-dwelling Stroke Elderly|||Changhua Christian Hospital||Completed|August 2005|July 2007|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|65 Years|N/A|No|Non-Probability Sample|first-ever stroke patients were retrieved from the Inpatient department and followed-up        regularly in the Outpatient department when they are discharged|April 2013|April 4, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825486||68638|
NCT01825447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4981002|A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users|A Randomized, Single-Dose, Placebo-Controlled, Double-Blind, 3-Way Crossover Study to Determine the Relative Abuse Potential of Intravenous Oxycodone Hydrochloride Alone or in Combination With Intravenous Naltrexone Hydrochloride in Opioid Experienced Non-Dependent Subjects||Pfizer|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|89|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825447||68641|
NCT01825460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-326|Manual Therapy to Treat Acute Whiplash Injury|Short-Term Effects of a Manual Therapy Protocol||Universidad de Almeria|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|50 Years|No|||May 2013|September 22, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01825460||68640|
NCT01825707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-103|AME Study of [14C]-YH4808 in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-YH4808 Following Single Oral Dose Administration in Healthy Male Subjects||Yuhan Corporation|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825707||68621|
NCT01826019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE-4|Heart Outcomes Prevention and Evaluation 4|Heart Outcomes Prevention and Evaluation 4 (HOPE-4)|HOPE-4|Hamilton Health Sciences Corporation|Yes|Recruiting|August 2014|August 2020|Anticipated|August 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|9500|||Both|50 Years|N/A|No|||February 2016|February 26, 2016|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01826019||68597|
NCT01826409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WKP-FG7070-001|Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes|||Chonbuk National University Hospital|Yes|Completed|March 2008|||September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|20 Years|75 Years|No|||August 2013|August 28, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01826409||68568|
NCT01826955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2712-2012|Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen Saturation|Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen|rSO2pneumo|Gachon University Gil Medical Center|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|20 Years|70 Years|No|Probability Sample|Patient who undergoing laparosopic or open gastrectomy patients who have respiratory and        cardiovascular disorders were excluded|December 2015|December 22, 2015|February 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01826955|5 Days|68527|
NCT01827267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA-NER-4201|Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer|A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations||Puma Biotechnology, Inc.|No|Active, not recruiting|May 2013|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827267||68503|
NCT01831219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PROTO-01|ROBODOC® CLINICAL TRIALS: LONG-TERM FOLLOW-UP|A Follow-Up Study of Subjects Enrolled in the Pin-Based (IDE G920035) and Pinless (IDE G000071) ROBODOC® Surgical System Clinical Trial||Curexo Technology Corporation|No|Enrolling by invitation|April 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects included in this study will have been enrolled in either the IDE G920035 or the        IDE G000071 Clinical Trial and will have completed the follow-up requirements to those        trials.|February 2015|February 2, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831219||68201|
NCT01831193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-793|Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease|Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease||Instituto Nacional de Cardiologia Ignacio Chavez||Completed|February 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831193||68203|
NCT01831206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|438/55|Collagen Cross-linking in Infectious Keratitis Trial|Collagen Cross-linking in Infectious Keratitis Trial||Chulalongkorn University|Yes|Completed|March 2013|December 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|6 Years|N/A|No|||April 2013|May 1, 2015|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01831206||68202|
NCT01831440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKX10022|Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging|The Influence of Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging：A Comparative Longitudinal Study||Nanjing Medical University|No|Recruiting|January 2011|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01831440||68185|
NCT01831713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH DOP08|Pulmonary Blood Flow Measurements in CHF Patients|Evaluation of Pulmonary Blood Flow Patterns Using Transthoracic Doppler in Patients With Congestive Heart Failure||Echosense Ltd.|No|Terminated|September 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|CHF patients admitted to the cardiology telemetry unit and to the CCU|August 2012|July 14, 2015|April 11, 2013||No|Changing staff|No||https://clinicaltrials.gov/show/NCT01831713||68164|
NCT01831726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258AUS26|Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET|SIGNATURE|Novartis|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|100 Years|No|||March 2016|March 20, 2016|April 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831726||68163|
NCT01831739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13020130|Genomic Research in Sarcoidosis|Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol|GRADS Sarc|University of Pittsburgh|Yes|Completed|May 2013|September 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Actual|368|Samples With DNA|Serum, plasma, urine, stool, BAL fluid.|Both|18 Years|85 Years|No|Non-Probability Sample|Subjects will be prescreened for predefined clinical phenotypes of sarcoidosis. Those who        meet initial criteria and ERS/ATS criteria for a sarcoidosis diagnosis will be recruited        and phenotyped by questionnaire, physical exam, research chest CT exam, pulmonary function        tests, and blood and urine tests with a total recruitment goal of 400.        A subset of participants who have suspected pulmonary sarcoidosis, but who have not        undergone a biopsy, will be recruited so that material may be obtained during their        clinically indicated biopsy. If a diagnosis of sarcoidosis is confirmed, they will be        enrolled and followed. If an alternative diagnosis is made, they will not undergo any        further testing.        Participants who cannot be classified within the clinical phenotypes based on data from        the initial visit will not continue in the study. Recruitment of participants with defined        clinical phenotypes will be monitored and ongoing recruitment goals adjusted to achieve        overall study objectives.|January 2016|January 11, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831739||68162|
NCT01823237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062538|Effect of Increasing Motor Cortex Inhibition on Task Specific Dystonia|Effect of Increasing Motor Cortex Inhibition on Task Specific Dystonia||Emory University|No|Recruiting|February 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|15|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01823237||68811|
NCT01823770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8917|Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome|Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study||University Hospital, Montpellier|Yes|Recruiting|December 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2013|April 2, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823770||68770|
NCT01823757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHTCPHARMACY1|Pharmaceutical Care in VA Nursing Home|The Impacts of Pharmaceutical Cares on the Elderly in a VA Nursing Home.||Taichung Veterans General Hospital|No|Active, not recruiting|April 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|65 Years|N/A|No|Probability Sample|Resident from a Veteran nursing home and willing to receive the pharmaceutical care by        pharmacists.|August 2014|August 27, 2014|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823757||68771|
NCT01824043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUBRAHV|Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage|Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy||Hospital Regional de São José - Dr. Homero de Miranda Gomes|No|Recruiting|March 2013|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||April 2013|April 1, 2013|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01824043||68749|
NCT01824849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUmedTY1|Total Versus Partial Arytenoidectomy in Bilateral Vocal Fold Paralysis|The Comparison of Voice and Swallowing Parameters After Endoscopic Total and Partial Arytenoidectomy Using Medially Based Mucosal Advancement Flap Technique for Bilateral Abductor Vocal Fold Paralysis: A Randomized Trial||Hacettepe University|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||April 2013|April 4, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824849||68687|
NCT01824862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM2021/11-B|Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema|Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Oedema, With and Without Centre Involvement||Hospital Juarez de Mexico|Yes|Completed|January 2013|July 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|60|||Both|30 Years|85 Years|No|Probability Sample|target population were type 2 diabetics, from Mexico City and its metropolitan area, and        available population were type 2 diabetics who attended an Ophthalmology service from a        general hospital in Mexico City, from September 2011 to May 2012|July 2013|July 10, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01824862|1 Day|68686|
NCT01824823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1311|Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence|A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence||Eastern Cooperative Oncology Group||Terminated|July 2013|||March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|April 2, 2013|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01824823||68689|
NCT01824836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1Z11|A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)|A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)||Eastern Cooperative Oncology Group|Yes|Recruiting|May 2013|||January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1000|||Female|18 Years|N/A|No|||September 2014|May 7, 2015|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01824836||68688|
NCT01825720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0347|Effect of Glucose-Insulin-Potassium on Hyperlactatemia in Patients Undergoing Valvular Heart Surgery|||Yonsei University|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|20 Years|80 Years|No|||October 2013|October 10, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01825720||68620|
NCT01825733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0122|Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery|||Yonsei University|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|196|||Both|20 Years|65 Years|No|||February 2014|February 17, 2014|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01825733||68619|
NCT01826032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-E1|Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment|Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment||Hospital Clinic of Barcelona|Yes|Completed|November 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|65 Years|N/A|No|||January 2015|January 21, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01826032||68596|
NCT01822028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-056-102|Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®|A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor® (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca® (Miglustat) in Healthy Subjects||Actelion|No|Completed|March 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01822028||68904|
NCT01826708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8688|Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations|Development of a Technique to Identify New Genes by Studying and Cloning the Breakpoints of de Novo Apparently Balanced Chromosomal Translocations in Patients Presenting With Syndromic Psychomotor Retardation||University Hospital, Montpellier|Yes|Active, not recruiting|October 2011|April 2015|Anticipated|January 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|N/A|N/A|No|||April 2013|December 30, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01826708||68546|
NCT01826968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung Recruitment in Cesareans|Alveolar Recruitment Maneuver During Cesarean Section Improves Lung Compliance|Phase 2 Study of the Alveolar Recruitment Maneuver in Cesarean Section|CSRecGHPyr|General Hospital Of Pyrgos|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|42 Years|No|||November 2013|June 22, 2015|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01826968||68526|
NCT01827644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117313|Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers|A Single Center, Randomized, Open-Label, Sequential, Single Dose, 4-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Two Prototype Formulations of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers||GlaxoSmithKline|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827644||68474|
NCT01822249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBGC&RS_12_003|Phase 2 Study of EPI-743 for Treatment of Rett Syndrome|A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome||Edison Pharmaceuticals Inc|No|Completed|January 2013|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|N/A|18 Years|No|||August 2015|August 3, 2015|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822249||68887|
NCT01831453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dr. Amr Elkhouli 1962|Omega-3 and Quality of Life in Recurrent Aphthous Stomatitis Patients|Therapeutic Effect of Systemic Omega-3 Polyunsaturated Fatty Acids On Quality of Life in Patients Suffering From Recurrent Aphthous Stomatitis Unresponsive to Topical Therapy.||October 6 University|No|Active, not recruiting|April 2012|May 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|13 Years|70 Years|No|||April 2013|April 10, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01831453||68184|
NCT01822730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100000-068943|A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis|A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis||Central South University|Yes|Completed|February 2013|May 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|19 Years|65 Years|No|||February 2015|February 2, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822730||68850|
NCT01823016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100976|A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma||Janssen Research & Development, LLC|Yes|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823016||68828|
NCT01823250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100055|Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial|Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial|CIFFTA|University of Miami|No|Completed|January 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|14 Years|17 Years|No|||December 2015|December 15, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01823250||68810|
NCT01823263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepPartialJCCB2013|Metabolic and Cognitive Parameters Following Partial Sleep Deprivation|Metabolic and Cognitive Effects of Sleep Deprivation||Uppsala University|No|Recruiting|April 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Male|20 Years|28 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01823263||68809|
NCT01823510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0208|Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients|Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients||Icahn School of Medicine at Mount Sinai|No|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|March 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823510||68790|
NCT01823523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOMFS-Orthognathic|Orthognathic Surgery and Postoperative Antibiotic Use|Orthognathic Surgery and Postoperative Antibiotic Use||Atlantic Center for Oral and Maxillofacial Surgery|Yes|Recruiting|June 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823523||68789|
NCT01823536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P20E1|Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose|A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine||Novartis|No|Completed|May 2013|June 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|465|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|March 28, 2013|Yes|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01823536||68788|
NCT01824316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012E0508|A Comparison of Management Strategies of Asthma in Pregnancy|A Comparison of Management Strategies of Asthma in Pregnancy||Ohio State University||Completed|January 2013|March 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|88 Years|No|Non-Probability Sample|Physicians-in-training and attending physicians in Emergency Medicine, Family Medicine,        Internal Medicine, Obstetrics/Gynecology, and Pulmonary/Critical Care Medicine at the Ohio        State University Werner Medical Center|April 2013|April 3, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01824316||68728|
NCT01825187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302-1|Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias|Prospective Randomized Controlled Trial Comparing Resident Performance and Clinical Outcomes With Two Different Polypropylene Meshes for Laparoscopic Inguinal Hernias||South East Area Health Education Center, Wilmington, NC|No|Not yet recruiting|April 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|511|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 26, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01825187||68661|
NCT01825174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213-2006-130321|Overweight Children - Musculoskeletal Consequences|Musculoskeletal Consequences of Pediatric Overweight - Efficiency of Different Interventions on Health, Motor and Psychosocial Development in Overweight and Obese Children||University Hospital Heidelberg|No|Completed|June 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|137|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825174||68662|
NCT01825473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16220|Study of Erythromycin in GER-Associated Apnea of the Newborn|Study of Erythromycin in GER-Associated Apnea of the Newborn|SEGAN|University of Virginia|No|Recruiting|September 2012|June 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 2, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01825473||68639|
NCT01825759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West China Hospital|Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function|The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function||West China Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||March 2013|April 5, 2013|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825759||68617|
NCT01826045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT2012-BL-PGA-01|Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia|A Multi-center, Randomized, Double Blind, Placebo Control, Parallel Design, Phase 2a Trial to Evaluate the Efficacy and Safety of PGA (Poly-gamma Glutamic Acid) for the Fertile Women With Cervical Intraepithelial Neoplasia 1 (CIN1)|PGA|BioLeaders Corporation|Yes|Completed|June 2013|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|49 Years|No|||January 2016|January 28, 2016|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01826045||68595|
NCT01822041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-509-006|14C-ARN-509 Microtracer Label AME and Absolute BA Study|14C-ARN-509 Microdose Absolute Bioavailability and Microtracer Absorption, Metabolism, and Excretion Study in Healthy Volunteers||Aragon Pharmaceuticals, Inc.|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822041||68903|
NCT01822288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101080-F|The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder|The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder||Far Eastern Memorial Hospital|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|40 Years|70 Years|No|||February 2016|February 22, 2016|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01822288||68884|
NCT01826721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB10-0987-AE|Impact of an E-learning Tool on Patient Satisfaction, Knowledge and Medication Adherence in Solid Organ Transplantation: A Randomized Controlled Trial|Impact of an E-learning Tool on Patient Satisfaction, Knowledge and Medication Adherence in Solid Organ Transplantation: A Randomized Controlled Trial||University Health Network, Toronto|No|Completed|May 2011|March 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|246|||Both|N/A|N/A|No|||April 2013|April 3, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01826721||68545|
NCT01827280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Galvus_2013|Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women|Acute and Short-term Chronic Effects of Galvus (Vildagliptin) on Endothelial Function and Oxidative Stress on Recently Diagnosed Type 2 Diabetic Obese Women: the Role of Intestinal Peptides During Lipid Overload||Rio de Janeiro State University|Yes|Not yet recruiting|April 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|19 Years|50 Years|No|||April 2013|April 4, 2013|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827280||68502|
NCT01827293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-067|Promethazine vs. Lorazepam for Treatment of Vertigo|Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial||hahid Beheshti University of Medical Sciences|Yes|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|65 Years|No|||June 2013|June 13, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01827293||68501|
NCT01828164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0018-0031|The Effect of Ultrasound on Orthodontic Tooth Movement|The Effect of Ultrasound on Orthodontic Tooth Movement||SmileSonica Inc.|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828164||68434|
NCT01822743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111007|Osteopathy and Obstructive Sleep Apnea Syndrome II|A Single Blind Cross Over Trial to Compare Osteopathic Compression of Pterygopalatine Node to Sham in Patients With Obstructive Sleep Apnea Syndrome and in Healthy Subjects|OSTEOSAOSII|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822743||68849|
NCT01822470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209009531|Small Intestinal Bacterial Overgrowth: A Prospective Registry|Small Intestinal Bacterial Overgrowth: A Prospective Registry|SIBO|Indiana University|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|DNA will be kept from patients jejunal aspirate and mucosal biopsy. In addition, patient      serum will be kept|Both|18 Years|90 Years|No|Non-Probability Sample|a. All adult patients who are undergoing small bowel aspiration for suspected SIBO        regardless etiology|October 2015|October 23, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822470|1 Year|68870|
NCT01823549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0240|Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients|Use of Nutritional Supplements and CAM (Complementary and Alternative Medicine) by Prostate and Breast Cancer Patients Undergoing Radiotherapy||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2011|||September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Men with clinically localized prostate cancer that have chosen external beam irradiation        or brachytherapy or a combination for their treatment and women with localized breast        cancer who are scheduled to begin external beam radiation therapy as a component of their        primary or adjuvant therapy.|October 2015|October 29, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823549||68787|
NCT01823562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12125|Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery|Dietary Fruit Bioactives and Prostate Cancer||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2012|||August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|56|||Male|N/A|N/A|No|||September 2015|September 4, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01823562||68786|
NCT01823783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8948|Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy|Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction : Potential Links and Targeted Pharmacotherapy in Duchenne Muscular Dystrophy (DMD).||University Hospital, Montpellier|No|Recruiting|November 2012|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|2 Years|15 Years|Accepts Healthy Volunteers|||March 2013|March 29, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823783||68769|
NCT01824342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080585|Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer||Amgen||Completed|January 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|N/A|No|||February 2015|February 19, 2015|April 1, 2013|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01824342||68726|
NCT01824069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULPVAS-2011-01|Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy|Phase IIa Clinical Trial to Safety of Treatment in Critical Ischemia Nonrevascularizable Lower Limb by Mesenchymal Stem Cells|HULPVAS|Instituto de Investigación Hospital Universitario La Paz|Yes|Recruiting|April 2013|October 2014|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||April 2013|April 3, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824069||68747|
NCT01824329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00000769|Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer|Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer|SPARC|University of Michigan|Yes|Completed|June 2006|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01824329||68727|
NCT01824602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-204|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double-blind, Fixed Multiple Dose, Randomised, Placebo-controlled,Multicentre Clinical Trial.||Bial - Portela C S.A.|No|Terminated|February 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|N/A|No|||August 2013|February 26, 2014|March 28, 2013||No|Due to a slow recruitment rate|No|April 8, 2013|https://clinicaltrials.gov/show/NCT01824602||68706|
NCT01824615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT99076|Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma|Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma||Cathay General Hospital|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|80 Years|No|||April 2013|April 7, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01824615||68705|
NCT01825525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE0075|Safety of the Colonoscope Magnetic Imaging Device (ScopeGuide®) in Patients With Implantable Cardiac Devices|Safety of the Colonoscope Magnetic Imaging Device (ScopeGuide®) in Patients With Implantable Cardiac Devices||Cambridge University Hospitals NHS Foundation Trust|Yes|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|80 Years|No|||April 2013|April 5, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825525||68635|
NCT01825499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VON001|Vermont Oxford Network Very Low Birth Weight Database|Vermont Oxford Network Very Low Birth Weight Database of Infants 401 to 1500 Grams or 22 to 29 Weeks Gestational Age at Birth|VON VLBW|Vermont Oxford Network|No|Recruiting|January 1990|December 2040|Anticipated|December 2040|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60000|||Both|N/A|28 Days|No|Non-Probability Sample|Infants who are 401 to 1500 grams birth weight or 22 to 29 weeks gestational age and who        are admitted to Vermont Oxford Network member centers within 28 days of birth without        first going home|December 2015|December 7, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01825499|1 Year|68637|
NCT01825512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEEP-2|Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients|Multicentre, Randomised, Open Label, Non-inferiority Active-controlled Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Paediatric Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies||Consorzio per Valutazioni Biologiche e Farmacologiche|Yes|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|344|||Both|1 Month|17 Years|No|||December 2013|December 11, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825512||68636|
NCT01825746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUFM0001|Goal Setting for Health Behavior and Psychosocial Issues in Primary Care|My Own Health Report (MOHR): A Pragmatic Evaluation to Enhance Primary Care Based Goal Setting and Evidence-Based Support for Health Behavior and Psychosocial Issues Through Meaningful Use of Patient-Centered Data and Tools|MOHR|Virginia Commonwealth University|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3591|||Both|18 Years|75 Years|No|||May 2015|May 12, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01825746||68618|
NCT01826058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KROG 1316|Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression|Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord: Prospective Phase II Study||Samsung Medical Center|Yes|Recruiting|October 2012|August 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|20 Years|N/A|No|||November 2014|November 27, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826058||68594|
NCT01822054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133540|Childhood Body Composition and Brain Structure and Function|Childhood Body Composition and Brain Structure and Function||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|January 2012|January 2017|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|27|||Both|8 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal weight or obese children (age 8-10 years)|September 2015|September 9, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01822054||68902|
NCT01822067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134776|Effects of Maternal Body Composition on Offspring Brain Structure and Function|Effects of Maternal Body Composition on Offspring Brain Structure and Function||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|August 2012|May 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|17 Days|Accepts Healthy Volunteers|Non-Probability Sample|Full term neonates born from obese or lean mothers enrolled in the Glowing study        (IRB#110889)|September 2015|September 9, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01822067||68901|
NCT01822301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100585|Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort|Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort|BTI Plus Up|University of Pittsburgh|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01822301||68883|
NCT01822522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00740|Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus|Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection||National Cancer Institute (NCI)|No|Recruiting|June 2013|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822522||68866|
NCT01826981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0122|Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection|A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection||Gilead Sciences|No|Completed|April 2013|May 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|362|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826981||68525|
NCT01826994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3-015|Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome|Incremental Value of Heart-type Fatty Acid-Binding Protein (H-FABP) in Evaluating Patients Presenting With Symptoms Possibly Matching Acute Coronary Syndrome in Primary Care|RAPIDA|Maastricht University Medical Center|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826994||68524|
NCT01827917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-6|The Protection Effect of Speeda® Rabies Vaccine for Human Use|Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level||Beijing Center for Disease Control and Prevention|No|Completed|February 2013|December 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|January 19, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01827917||68453|
NCT01828671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOYT-2013|A Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals|A Double-Blind, Randomized, Controlled Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals.|SOYT-2013|University of Manitoba|No|Completed|December 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828671||68396|
NCT01823289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014362|An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections|Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections||Xian-Janssen Pharmaceutical Ltd.|No|Completed|June 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|80 Years|No|||April 2013|April 12, 2013|March 12, 2013|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01823289||68807|
NCT01823029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-AT1|Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia||CD-AT1|Jinling Hospital, China|No|Completed|November 2012|November 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|387|||Both|18 Years|75 Years|No|||November 2013|November 26, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01823029||68827|
NCT01823276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-43 HC|Effect of Tyrosine on Behavioral, Physiological and Nutritional Status During Survive, Evade, Resist, Escape (SERE) School|Effect of Tyrosine on Behavioral, Physiological and Nutritional Status During Survive, Evade, Resist, Escape School||United States Army Research Institute of Environmental Medicine|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|73|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823276||68808|
NCT01823796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0041G|Risk of Falls in Patients With Fibromyalgia|Assessment of Balance and Risk of Falls in Women With Fibromyalgia|FM|Universidad de Granada|Yes|Completed|March 2013|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women with fibromyalgia. Fibromyalgia is a chronic condition characterised by chronic        pain, fatigue, sleep disorders and psychological disturbances.|December 2014|December 9, 2014|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823796||68768|
NCT01824082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phantom Pain Treatment (DoD)|Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study|Treating Intractable Post-Amputation Phantom Limb Pain With Ambulatory Continuous Peripheral Nerve Blocks|DoD-PLP-Tx|University of California, San Diego|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824082||68746|
NCT01824641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T113E4|Physiologic Assessment of Thrombus Aspiration in Acute ST-segment Elevation Myocardial Infarction Patients|The Randomized Physiologic Assessment of Thrombus Aspiration in Patients With Acute ST-segment Elevation Myocardial Infarction Trial|PATA-STEMI|Clinical Centre of Serbia|Yes|Recruiting|September 2012|November 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|19 Years|90 Years|No|||April 2013|April 2, 2013|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824641||68703|
NCT01824628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.316|Comparison of the QT/QTc Interval Between an Outpatient HIV-Infected Population on Antiretroviral Therapy and Two Large HIV-Negative Cohorts|Comparaison Des Intervalles QT/QTc Entre Une Population HIV Positive Ambulatoire Sous thérapie antirétrovirale et Une Population Ambulatoire HIV négative|QTVIE|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|March 2013|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|160|Samples With DNA|10 mL whole blood in a purple Vacutainer EDTA tube|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is being conducted within the Centre hospitalier de l'Université de Montréal        (CHUM). The recruited population was identified from the CHUM ambulatory care HIV clinic        and an ECG registry composed of outpatient HIV negative subjects who were scheduled for a        one-day surgery. The HIV positive outpatients on antiretroviral therapy will be recruited        prospectively from March 2013 through August 2013. The outpatient HIV negative cohort will        be recruited retrospectively according to a 10:1 ratio.|November 2013|November 25, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824628||68704|
NCT01824875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2211|Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors|A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors||Eastern Cooperative Oncology Group|Yes|Active, not recruiting|May 2013|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824875||68685|
NCT01825538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0435|Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases|Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases||Ohio State University|Yes|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|93|||Both|18 Years|88 Years|No|Non-Probability Sample|Patients with COPD or pulmonary fibrosis|July 2014|July 24, 2014|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01825538||68634|
NCT01825772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jan1|Clinical and Radiographic Outcomes of Dental Implant Therapy|Clinical and Radiographic Outcomes of Dental Implant Therapy||Göteborg University|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|596|||Both|55 Years|85 Years|No|Probability Sample|The register of the Swedish Social Insurance Agency was searched for subjects scheduled        for treatment with dental implants in 2003/2004. In a first group, subjects between 65 and        75 years old in 2003 were identified and from this pool of about 23.000 individuals, 3.000        subjects were randomly selected. In a second group, all subjects in the age of 45-60 years        were identified (n=1716)from the same register. Thus, the total study population in the        present project included 4716 subjects.|February 2014|February 3, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825772||68616|
NCT01826071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-15150|Comparison of Three Treatments for Lower Extremity Apophysitis|Comparison of Three Treatments for Lower Extremity Apophysitis||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|October 2012|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|8 Years|17 Years|No|||March 2013|April 5, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01826071||68593|
NCT01822080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13390|Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients|A Multicenter Study to Investigate the Efficacy and Safety of Daily Oral Administration of 2 mg Dienogest Tablets (Visanne/SH T00660AA) for the Treatment of Endometriosis in Chinese Patients: a Double-blind, Randomized, Placebo-controlled, Parallel Group Phase Over 24 Weeks Followed by an Open-label, Single-group Follow up Over 28 Weeks||Bayer|No|Completed|March 2013|November 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|45 Years|No|||November 2015|November 24, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01822080||68900|
NCT01822314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-12-B01|Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer|Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer " ETNA (Evaluating Treatment With Neoadjuvant Abraxane)|ETNA|Fondazione Michelangelo|Yes|Active, not recruiting|April 2013|October 2025|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|632|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822314||68882|
NCT01822535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01374|Body Temperature in Persons With Tetraplegia When Exposed to Cold|Core Temperature During Cold Exposure in Persons With Tetraplegia||James J. Peters Veterans Affairs Medical Center|No|Completed|July 2011|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|March 21, 2013|Yes|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT01822535||68865|Did not assess cognitive performance a third time, after Tcore in the group with tetraplegia had returned to baseline levels.Study had a small sample size, and only included males.
NCT01827657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117380|Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects|A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)||GlaxoSmithKline|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|31|||Both|18 Years|74 Years|No|||April 2014|May 8, 2014|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827657||68473|
NCT01828424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 12-262|Prediction of Postoperative Pain by Measuring Nociception at the End of Surgery|Prediction of Postoperative Pain by Measuring Nociception at the End of Surgery|PREPOP|University Hospital, Geneva|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|patients scheduled for elective gynaecological intraperitoneal surgery (laparascopy,        laparoscopic hysterectomy, vaginal hysterectomy, abdominal hysterectomy) under general        anesthesia|December 2015|December 2, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01828424||68414|
NCT01832350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVP923|Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease|Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Active, not recruiting|December 2012|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|55 Years|90 Years|No|||January 2016|January 27, 2016|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832350||68116|
NCT01832363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagniXene-112397|Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI|Single-Session Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI|HXe-BT|Xemed LLC|Yes|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2014|March 10, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832363||68115|
NCT01823302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9601A1-4000|Effect of a New Growing-up Milk on Growth and Nutrient Adequacy in Children With Picky-eating Behaviors|Effect of a New Growing-up Milk on Growth and Nutrient Adequacy in Children With Picky-eating Behaviors||Nestlé|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|30 Months|60 Months|No|||March 2013|March 28, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01823302||68806|
NCT01823575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHS_URST|Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction|Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research||Asan Medical Center|Yes|Active, not recruiting|March 2013|September 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|20 Years|80 Years|No|||March 2013|April 2, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823575||68785|
NCT01823809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2011.084|Non-invasive and Invasive Assessment of Coronary Artery Disease|Assessment of Coronary Artery Disease With Multi-Slice Computed Tomography Combined With Stress Cardiac Magnetic Resonance Imaging Compared to Coronary Angiography Combined With Fractional Flow Reserve Trial|COMFORT|University Medical Center Groningen|No|Recruiting|November 2011|||December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01823809||68767|
NCT01823822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-182|Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa|Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa||University Hospital, Geneva|No|Completed|June 2008|April 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|40 Years|No|||March 2013|April 2, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823822||68766|
NCT01824355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2012-010-01|Performance of an Investigational Blood Glucose Monitoring System|Performance of the Ninja 3 Plus Blood Glucose Monitoring System||Ascensia Diabetes Care|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|113|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 1, 2013|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01824355||68725|
NCT01824368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEC-TH|Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.|FOTOAFERESIS EXTRACORPÓREA EN EL TRASPLANTE HEPÁTICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESIÓN|FEC-TH|Red de Terapia Celular|Yes|Active, not recruiting|April 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824368||68724|
NCT01824394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|reMARQable|nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation|reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation||Biosense Webster, Inc.|No|Active, not recruiting|March 2013|September 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824394||68722|
NCT01824888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUC-001-EN1500|Efficacy of JUC as Hand Rub Evaluated by Using European Standard 1500|The Effectiveness and Efficacy of Using JUC Antimicrobial Spray for Controlling the Infection Transmission|JUC|The Hong Kong Polytechnic University|Yes|Completed|June 2012|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01824888||68684|
NCT01824901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2512|Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer|A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer||Eastern Cooperative Oncology Group|Yes|Completed|September 2013|April 2015|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|25 Years|N/A|No|||February 2016|February 1, 2016|April 2, 2013|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01824901||68683|
NCT01825200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC11|Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age|Comparison of the Safety of Flublok® Versus Licensed Inactivated Influenza Vaccine in Healthy, Medically Stable Adults ≥ 50 Years of Age||Protein Sciences Corporation|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2640|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|March 11, 2013|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01825200||68660|Rash, urticaria, swelling and edema were self-reported by subjects and most were not observed by investigators. Review by independent experts indicated that 42 of 52 subject-reported events did not represent Type 1 (IgE-mediated) hypersensitivity.
NCT01825551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-01-54-17265|The Effect of GCSF in the Treatment of ALS Patients|The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013||Tehran University of Medical Sciences|Yes|Completed|November 2012|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||November 2013|November 10, 2013|March 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825551||68633|
NCT01825564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZNG-SLU-450126, 22201|Comparison of RightSpot pH Indicator & RightLevel pH Detector With X-Ray Verification for FT or G-Tube Placement|Comparison of the RightSpot pH Indicator & RightLevel pH Detector With the Gold Standard of Radiographic Verification of Feeding Tube Placement & Gastrostomy Tube Replacement||St. Louis University|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the patients presenting to the Emergency Department for        replacement of G-Tube or patients residing in the ICU that require placement of feeding        tubes for enteral nutrition.|February 2016|February 4, 2016|February 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825564||68632|
NCT01825785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060221|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass||Amgen|No|Completed|October 2007|July 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|January 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825785||68615|
NCT01825798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-10-2012|Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)|Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)|MET|Anagnostou, Evdokia, M.D.|Yes|Active, not recruiting|April 2013|March 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|6 Years|17 Years|No|||February 2016|February 9, 2016|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01825798||68614|
NCT01822093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-2011-02|Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT|Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation|ASPIRE|Cell Medica Ltd|Yes|Recruiting|December 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|16 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01822093||68899|
NCT01822327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA009378|Treating Cocaine Abuse: A Behavioral Approach|Treating Cocaine Abuse: A Behavioral Approach||University of Vermont|No|Active, not recruiting|December 2007|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|124|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01822327||68881|
NCT01822548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005399-32|Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes|Randomized, Open Label, Two Parallel Arms, Intervention Trial Comparing the Effect of DPP-IV Inhibitor Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number in Patients With Type 2 Diabetes in Metformin Failure||Azienda Ospedaliero-Universitaria di Parma|Yes|Not yet recruiting|April 2013|September 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|35 Years|N/A|No|||March 2013|March 28, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822548||68864|
NCT01822834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRR|Bronchiectasis Research Registry|||COPD Foundation||Recruiting|January 2008|||December 2050|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients over the age of 18 with non-CF Bronchiectasis and/or Nontuberculosis Mycobacteria        (NTM).|February 2015|February 19, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822834|20 Years|68842|
NCT01823107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESO-001|Feasibility Study of Meso BioMatrix Device for Breast Reconstruction|Meso BioMatrix Acellular Peritoneum Matrix Breast Reconstruction Feasibility Trial||Kensey Nash Corporation|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|21 Years|N/A|No|||September 2015|September 3, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823107||68821|
NCT01828177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|172-7451-201|An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea|A Multicenter Randomized Evaluator-Blinded Vehicle-Controlled Parallel Group Evaluation of Twice Daily PDI-320 in Comparison to Its Monads in Adults With Rosacea||PreCision Dermatology, Inc.|No|Active, not recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828177||68433|
NCT01832051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Her2.4|Clinical Value of 89Zr-trastuzumab PET|HER2-PET as a Diagnostic Tool in Breast Cancer Patients With a Clinical Dilemma||University Medical Center Groningen|No|Completed|March 2013|October 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01832051||68138|
NCT01832064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26610|Active Living Tool Kit for Chronic Conditions|Development of a Mailed Chronic Disease Self-Management Program||Stanford University|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|255|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832064||68137|
NCT01823601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC-04201301|Behavioral Management and Psychological Well-Being|A Cognitive-Behavioral Program Of Emotional Management and Feeling Of Psychological Well-Being||Centro de Estudos em Medicina Comportamental|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|April 2, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01823601||68783|
NCT01823835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29642|A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|||Genentech, Inc.||Recruiting|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|141|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823835||68765|
NCT01823588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nurse led|Nurse-led Reminder Program for the Prevention of Cardiovascular Diseases|Efficacy of a Nurse-led Reminder Program for the Management of the Risk Factors for Cardiovascular Diseases in Hypertensive Patients: a Randomized Controlled Trial||Università degli Studi 'G. d'Annunzio' Chieti e Pescara|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|203|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01823588||68784|
NCT01823848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enema Randomization|A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children|A Randomized Controlled Trial of Three Types of Enemas Used to Treat Functional Constipation in Children||Children's Hospital Los Angeles|No|Not yet recruiting|April 2013|July 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||March 2013|March 30, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01823848||68764|
NCT01824108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WALLIS-2008|Wallis Interspinous Dynamic Stability System for Lumbar Disc Herniation: a Prospective Study|Effectiveness of Wallis Interspinous Dynamic Stability System for Lumbar Disc Herniation: a Prospective Randomised Controlled Study||Guangdong General Hospital|No|Completed|July 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||March 2013|March 31, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01824108||68744|
NCT01824667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAS/1213|Effect of B-GOS on GI Discomfort in Healthy Adults|Double-blind, Placebo Controlled, Randomised, Multicentered, of Parallel Design Study to Determine the Effect of B-GOS on GI Discomfort in Healthy Adults||Clasado Limited|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|November 26, 2013|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01824667||68701|
NCT01824654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.333|Enhanced Guidance for Endovascular Repair of Abdominal Aortic Aneurysm|Endovascular Repair of Abdominal Aortic Aneurysm: Enhanced Guidance by Elastic Registration Between CT-Scanner and Fluoroscopy|AAA 2D/3D II|Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|April 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|N/A|N/A|No|||March 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824654||68702|
NCT01824914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20121231|Airway Evaluation by McGrath Videolaryngoscope|Comparison of Cormack-Lehane Score in Sedation and Anesthesia Condition by McGrath Videolaryngoscope||Huazhong University of Science and Technology|Yes|Completed|April 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|97|||Both|15 Years|65 Years|No|||November 2014|November 6, 2014|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824914||68682|
NCT01825213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000042|Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT|Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT||Massachusetts General Hospital|No|Not yet recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825213||68659|
NCT01826110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00033154|PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers|"[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls"||Johns Hopkins University|No|Recruiting|September 2013|May 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01826110||68591|
NCT01826123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343/12|Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study|Point-of-Care Testing - A Prospective, Randomized, Controlled Multicenter Study of Efficacy in Coagulopathic Cardiac Surgery Patients|MultiPOC|Goethe University|Yes|Active, not recruiting|July 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Both|18 Years|99 Years|No|||February 2016|February 23, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01826123||68590|
NCT01825811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-TGC(S)-01-2|Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis|A Single-blind, Randomized, Parallel-group, Multi-center Phase 2 Study to Determine the Efficacy and Safety of TissueGene-C Mixed With Fibrin-glue in Patients With Degenerative Arthritis||Kolon Life Science|Yes|Completed|October 2012|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825811||68613|
NCT01826097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1236|Improving Sensitivity of Urine Cytology for Bladder Cancer|Non-Invasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer||Johns Hopkins University|Yes|Recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|1||Anticipated|20|||Male|18 Years|80 Years|No|||April 2013|April 3, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01826097||68592|
NCT01822340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-HM10560A-201|Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients|A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)|HM10560A|Hanmi Pharmaceutical Company Limited|Yes|Completed|October 2011|February 2016|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|72|||Both|23 Years|60 Years|No|||February 2016|February 17, 2016|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822340||68880|
NCT01822561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEEC-10722|Eplerenone for Central Serous Chorioretinopathy|Eplerenone for Central Serous Chorioretinopathy: A Pilot Study||Tufts Medical Center|Yes|Recruiting|May 2013|||April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2014|December 3, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822561||68863|
NCT01822847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-16583|Physiological Response of Cortisol to Cardiac Catheterization|Physiological Response of Cortisol to Cardiac Catheterization||Creighton University|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|24|||Both|20 Years|90 Years|No|Non-Probability Sample|30 males and females, age 20-90 years who are scheduled for elective cardiac        catheterization procedure.|February 2015|February 24, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822847||68841|
NCT01822860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16628|Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function|The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study||Creighton University|Yes|Withdrawn|March 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|19 Years|N/A|No|||March 2015|March 24, 2015|March 28, 2013|Yes|Yes|Study subjects were not able to be recruited|No||https://clinicaltrials.gov/show/NCT01822860||68840|
NCT01823120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/18|Text Message Intervention to Reduce Repeat Self-harm|Text Message Intervention to Reduce Repeat Self-harm in Patients Presenting to the Emergency Department||University of Dublin, Trinity College|Yes|Terminated|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|March 26, 2013||No|Resignation of critical volunteer staff and lack of funding|No||https://clinicaltrials.gov/show/NCT01823120||68820|
NCT01831752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZY001|Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2|Performance Evaluation of a Non-Invasive Glucose Monitor (Spectral Data Acquisition) as Compared to CGM Data Acquired by the iPro2||William Sansum Diabetes Center|No|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|9|||Both|12 Years|75 Years|No|Non-Probability Sample|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently        using insulin to treat their diabetes.|November 2014|November 17, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01831752||68161|
NCT01831765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3852|Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes|Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes|onset® 1|Novo Nordisk A/S|No|Completed|August 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1290|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831765||68160|
NCT01832623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.688|Vitamin D, Bones, Nutritional and Cardiovascular Status|Are Bone, Nutritional and Cardiovascular Status of French Children and Adolescents, Correlated With Their Vitamin D Status?|VITADOS|Hospices Civils de Lyon|Yes|Recruiting|February 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01832623||68095|
NCT01823614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2041679|Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools|Epidemiological Study of the Co-receptor Tropism of HIV-1 Subtype A Spread in the Russian Federation Among naïve and ART-experienced Patients Using V3-based Genotyping Tools|CoTrAST|Central Institute of Epidemiology, Moscow, Russia|No|Completed|November 2012|December 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Actual|943|Samples With DNA|plasma peripheral blood mononuclear cells|Both|18 Years|N/A|No|Probability Sample|primary care clinic|February 2014|February 4, 2014|March 30, 2013||No||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01823614||68782|
NCT01823861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MarieStopes|Mobile Technology for Improved Family Planning||MOTIF|Marie Stopes International|No|Active, not recruiting|May 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|500|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01823861||68763|
NCT01823874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44218-G|Firsthand ID for Pain Control|The 3D Immersive Display: Validation of a Virtual Reality Technique for Pain Control|ID|University of Washington|No|Completed|April 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823874||68762|
NCT01824680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0149|Effect of a Physical Activity Program on the Hormonal Regulation of Food Intake|Effect of a 3 Months Physical Activity Program on the Hormonal Regulation of Food Intake by Intense Physical Activity in Overweight Adolescents|APHRO|University Hospital, Clermont-Ferrand||Suspended|October 2012|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|18 Years|No|||April 2013|April 2, 2013|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824680||68700|
NCT01824095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Standard Process - 2013|Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain|Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain: a Multisite Randomized Controlled Trial|ASP|Logan University, Inc.|Yes|Terminated|January 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|50 Years|No|||January 2016|January 22, 2016|April 1, 2013||No|Unable to recruit enough subjects to attain the minimum sample size.|No||https://clinicaltrials.gov/show/NCT01824095||68745|
NCT01824381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA/GH|Use of the Amniotic Membrane in Large Wound Epithelialization|Use of the Amniotic Membrane in Large Wound Epithelialization. Phase I Clinical Trial.|MA/GH|Red de Terapia Celular|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01824381||68723|
NCT01825239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12070339|Virtual LV Lead Navigation in Patients With Ischemic Cardiomyopathy|Virtual Left Ventricular Lead Navigation in Patients With Ischemic Cardiomyopathy||University of Pittsburgh|No|Withdrawn|April 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|April 2, 2013||No|Problems with execution|No||https://clinicaltrials.gov/show/NCT01825239||68657|
NCT01825252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH089128|Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)|Prevention of HIV Infection in High-Risk Social Networks of African American MSM|C3|Medical College of Wisconsin|No|Active, not recruiting|August 2011|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|960|||Male|18 Years|N/A|No|||November 2015|November 6, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825252||68656|
NCT01824927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBCS001|Pain Expression in the Perioperative Period of Cataract Surgery|Pain Expression in the Perioperative Period of Cataract Surgery||Evidence Based Cataract Study Group||Recruiting|January 2013|||May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|150|||Both|50 Years|85 Years|No|||April 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824927||68681|
NCT01825226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6117001|Helen Keller International's Enhanced-Homestead Food Production Program in Burkina Faso|THE IMPACT OF THE ENHANCED HOMESTEAD FOOD PRODUCTION PROGRAM ON CHILD HEALTH|EHFP|International Food Policy Research Institute|No|Active, not recruiting|February 2010|June 2017|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1763|||Both|3 Months|12 Months|No|||August 2015|August 24, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01825226||68658|
NCT01822119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAS5484|Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System)|Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System). A Multicentre, Open, Prospective Clinical Investigation. 3 Months Investigation With a 6 Months Follow-up||Cochlear Bone Anchored Solutions|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|March 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822119||68897|
NCT01822106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC2-011|Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD)|||China Medical University Hospital|No|Recruiting|February 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|75 Years|No|||March 2013|March 27, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01822106||68898|
NCT01822574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008219|Comparison of Three Surgical Techniques to Achieve Patella Symmetry During Resection|Effect of Surgical Technique on Resection Symmetry of the Patella in Total Knee Arthroplasty||Mayo Clinic|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|99 Years|No|||February 2016|February 3, 2016|March 18, 2013||No||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01822574||68862|
NCT01822873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036248|Study on Visual Function Impairments in Dry Age-related Macular Degeneration|Evaluation of Visual Function Impairments in Patients With Early Dry Age-related Macular Degeneration||Duke University|No|Recruiting|March 2013|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|210|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be identified from patients of the Duke Eye Center presenting for        ophthalmologic consultation. Patients with dry AMD are routinely available from this        clinic and will be the primary study group.|August 2015|August 3, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822873||68839|
NCT01823133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GSCL001|Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects||LG Life Sciences|Yes|Completed|April 2013|August 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01823133||68819|
NCT01823367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207009188|Encourage Healthy Families|Primary Prevention of Diabetes in Children and Mothers at Increased Risk: Encourage Healthy Families.|Encourage|Indiana University|No|Active, not recruiting|December 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|8 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01823367||68801|
NCT01832727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001|Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma||Onyx Pharmaceuticals|No|Active, not recruiting|May 2013|October 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832727||68087|
NCT01831466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921082|Tofacitinib Ointment For Chronic Plaque Psoriasis|A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.||Pfizer|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|476|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|March 28, 2013|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01831466||68183|Efficacy results for participants in the severe population were not reported since this was considered an exploratory population.
NCT01831479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWJ1276001|Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers|||Severance Hospital||Completed|August 2011|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01831479||68182|
NCT01832389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PiSAH|Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage|Does a PiCCO-controlled Advanced Haemodynamic Monitoring Improve the Outcome After Aneurysmal Subarachnoid Haemorrhage?|PiSAH|Technische Universität München|Yes|Recruiting|March 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|80 Years|No|||July 2015|July 21, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01832389||68113|
NCT01833208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 223912|Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T|Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients||Roswell Park Cancer Institute|Yes|Recruiting|July 2013|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||November 2015|November 24, 2015|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833208||68050|
NCT01824134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09-008|Aloe Vera on Irradiated Breast Tissue|A Phase III Double Blind Study on the Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue||John D. Archbold Memorial Hospital|No|Recruiting|October 2012|October 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|N/A|No|||April 2013|April 3, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824134||68742|
NCT01824420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL008|Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome|Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy||Buddhist Tzu Chi General Hospital|No|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|65 Years|No|||April 2014|April 3, 2014|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824420||68720|
NCT01824953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010393|Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years|Significance of Helicobacter Pylori Infection and Pepsinogen Levels on the Prognosis of Atrophic Gastritis - Observational Study||Konkuk University Medical Center|No|Completed|January 2010|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|3328|Samples Without DNA|Serum for Helicobacter pylori antibody and pepsinogen levels Gastric biopsy for the      diagnosis of intestinal metaplasia, atrophy, inflammatory cells, Helicobacter pylori, and      the presence of gastric neoplasm if any.|Both|18 Years|90 Years|No|Non-Probability Sample|Asymptomatic Korean adults who underwent serum PG tests, H. pylori serology, and upper        gastrointestinal endoscopy on the same day at our center.|August 2013|August 15, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824953|3 Years|68679|
NCT01824407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN12-DERM02|A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers|A Double-Blind, Multi-center, Randomized, Sham-Controlled, Parallel Group Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers||SANUWAVE, Inc.|Yes|Recruiting|March 2013|||April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|22 Years|N/A|No|||March 2014|March 4, 2014|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824407||68721|
NCT01825590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053-11|Effects of Simple Sodium Alignment on Clinical Outcomes|Effects of Simple Sodium Alignment on Short-, Medium- and Long-term Clinical and Laboratory Outcome Measures||Renal Research Institute|No|Completed|May 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|148|||Both|18 Years|88 Years|No|Probability Sample|All subjects on hemodialysis|February 2016|February 23, 2016|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01825590||68630|
NCT01825577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23014|Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.|Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.||St. Louis University|Yes|Terminated|November 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|65 Years|95 Years|No|||March 2015|March 26, 2015|March 13, 2013||No|Administrative Reasons|No||https://clinicaltrials.gov/show/NCT01825577||68631|
NCT01825824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-1205-001-005|Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm|Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm||Korea Cancer Center Hospital|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825824||68612|
NCT01831362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT006328-01A1|Dismantling Mindfulness|Dismantling Mindfulness: Contributions of Attention vs. Acceptance||Brown University|Yes|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|65 Years|No|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01831362||68191|
NCT01822353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS21813030112|The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults|The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk and Nut Allergy in Adults||Helsinki University Central Hospital|No|Recruiting|January 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|50 Years|No|||March 2015|March 17, 2015|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01822353||68879|
NCT01822366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039770|Randomized Controlled Trial of Trauma-focused CBT in Tanzania and Kenya|Improving Health Outcomes by Preventing HIV/STD Risk||Duke University|Yes|Active, not recruiting|August 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|7 Years|13 Years|No|||November 2015|November 6, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822366||68878|
NCT01831934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-18615|Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)|Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease||Stanford University|No|Completed|September 2010|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|13 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|March 19, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01831934||68147|
NCT01832220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13010343|Genomic Research in Alpha-1 Antitrypsin Deficiency|Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Alpha-1 Protocol|GRADS Alpha-1|University of Pittsburgh|Yes|Completed|May 2013|September 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|140|Samples With DNA|Serum, plasma, urine, stool, BAL fluid.|Both|40 Years|80 Years|No|Non-Probability Sample|The GRADS Alpha-1 Study will enroll approximately 200 participants over two years. An        ancillary application to SPIROMICS will request data from 50 PiMM subjects, all (estimate        10) PiMZ subjects, and any (estimate 1) PiZZ subjects. The remainder of the participants        (N=~150) will be recruited through nine GRADS clinical sites.        Potential participants are invited to participate through the Alpha-1 Foundation Research        Registry by email, telephone, mailings, or website per Registry protocols and procedures.        Additionally, participants are recruited at the clinical centers by invitations to        participate through flyers, websites and mailings and by physician referrals. Other        recruitment protocols approved by the local institutional review board for human research        are allowed.|January 2016|January 11, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832220||68126|
NCT01832493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOCR|Sensor Optimization of Cardiac Resynchronization Therapy Response|Sensor Optimization of CRT Response|SOCR|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|March 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01832493||68105|
NCT01832506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200095-003|A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors|A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors||Merck KGaA|No|Completed|April 2013|October 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||April 2015|April 17, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01832506||68104|
NCT01832740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nighttime sleep-tSOS-Young|Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Younger, Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Younger, Healthy Subjects||Charite University, Berlin, Germany|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832740||68086|
NCT01832753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009578|Treatment Trial of Subclinical Hypothyroidism in Down Syndrome|Levothyroxine Treatment and Cardiometabolic Outcomes in Adolescents With Down Syndrome||Children's Hospital of Philadelphia|Yes|Recruiting|January 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|20 Years|No|||November 2015|November 4, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832753||68085|
NCT01832077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-WDF-Telemedicine|Uptake of Telemedicine System Trial in Rual Canton|The Impact of Telemedicine System to the Diagnosis and Treatment of Diabetes Retinopathy in Rural Canton||Sun Yat-sen University|Yes|Active, not recruiting|April 2013|August 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|5000|||Both|40 Years|90 Years|No|Probability Sample|age > 40y, diagnosed (Diabetes Retinapathy)DR, 10% normal patients|May 2013|May 20, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832077|1 Year|68136|
NCT01832090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110607|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||October 13, 2014|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832090||68135|
NCT01832103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7145-018|The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)|A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Withdrawn|August 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|75 Years|No|||September 2013|September 23, 2013|April 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01832103||68134|
NCT01832909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS43|The Measured Energy Value of Walnuts in the Human Diet|Macronutrient Absorption From Walnuts: The Measured Energy Value of Walnuts in the Human Diet||USDA Beltsville Human Nutrition Research Center|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|18|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832909||68073|
NCT01833520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0952|Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma|Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2013|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|15 Years|N/A|No|||October 2015|October 16, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833520||68026|
NCT01833819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.BAV.0.05.05/346|Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy|Opioid-free Total Intravenous Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy; Comparison With Propofol, Remifentanil Infusions||Bezmialem Vakif University|No|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|60 Years|No|||November 2013|November 12, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833819||68003|
NCT01833247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford Epilepsy IRB 21989|Lactic Acidosis During and After Seizures|||Stanford University|No|Enrolling by invitation|July 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|75 Years|No|Non-Probability Sample|Age range will be 18-75, men and women, all ethnic backgrounds to be eligible. Eligible        population will be determined by who gets admitted to the epilepsy monitoring unit with a        history of generalized tonic-clonic seizures.|April 2013|April 12, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01833247||68047|
NCT01824433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFPWMDD|Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression|A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder||Capital Medical University|Yes|Recruiting|March 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|50 Years|80 Years|No|||July 2015|July 27, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824433||68719|
NCT01824693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT1221|Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia|A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)||Children's Oncology Group|Yes|Suspended|June 2013|||June 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|145|||Both|3 Months|18 Years|No|||January 2016|January 19, 2016|April 2, 2013|Yes|Yes|early relapse data in one arm|No||https://clinicaltrials.gov/show/NCT01824693||68699|
NCT01824966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRCC|Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma|Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior|SRCC|University Hospital, Gasthuisberg|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|From our prospectively built database we retrieved all adenocarcinoma from 1990 till 2009        who underwent primary surgery with R0 resection. Seven hundred seventy-nine patients were        included for further analysis. Pathology reports mentioning signet ring cells (n = 82)        were reviewed by our pathologist and, after confirmation, tumors were classified into two        groups according to WHO criteria (>50% SRC or <50% SRC). The remaining 697 ADC patients        served as control group.|April 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824966||68678|
NCT01824979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA76|Pilairo Lab Market Research|Pilairo Lab Market Research||Fisher and Paykel Healthcare|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824979||68677|
NCT01824940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004205|SHINE Sanitation, Hygiene, Infant Nutrition Efficacy Project|Sanitation, Hygiene, Infant Nutrition Efficacy Project|SHINE|Johns Hopkins Bloomberg School of Public Health|Yes|Active, not recruiting|November 2012|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|5272|||Female|15 Years|49 Years|No|||September 2015|September 28, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01824940||68680|
NCT01830634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I050507|Lower-limb Strength and Flexibility Program on Prevention of Recurrent Falls in the Community-dwelling Elderly|||Changhua Christian Hospital||Completed|June 2005|July 2006|Actual|January 2006|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|107|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830634||68246|
NCT01825837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-205|Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder|Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder||Bial - Portela C S.A.|No|Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|N/A|N/A|No|||February 2014|February 26, 2014|April 1, 2013||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01825837||68611|
NCT01826136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_Acapella|Effect of Vibratory Expiratory Pressure on Pulmonary Function After Lung Resection Surgery|||Seoul National University Hospital|No|Completed|January 2013|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|65 Years|No|||May 2014|May 13, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826136||68589|
NCT01826149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160053|Propofol Effects on Mitral Valve Annular Velocity|The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia||Konkuk University Medical Center|No|Recruiting|April 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|65 Years|No|||August 2015|August 13, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01826149||68588|
NCT01831375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA098966-07|Cancer Prevention and Care Among Aged|Health Care Partners in Cancer Prevention and Care Among Aged||Case Western Reserve University|No|Recruiting|January 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|500|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 17, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831375||68190|
NCT01831622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005246-38|Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder|Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder||University of Oslo|Yes|Completed|June 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|131|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831622||68171|
NCT01831947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE09T|Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.|Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)|RABIMO|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|April 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|N/A|No|||April 2013|April 11, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831947||68146|
NCT01831960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171-7151-202|An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris|An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris||Intrepid Therapeutics, Inc.|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|12 Years|N/A|No|||March 2015|March 27, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831960||68145|
NCT01832233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB12-73|Prairie Renal Denervation Study|Prairie Renal Denervation Study||Regina Qu'Appelle Health Region|No|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01832233||68125|
NCT01832519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001InfantMRI|Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF|MRI Predictors of Infection, Inflammation, and Structural Lung Damage in CF (Cystic Fibrosis)|MRIinfantCF|Children's Hospital Medical Center, Cincinnati|No|Recruiting|February 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|serum|Both|6 Months|52 Months|No|Non-Probability Sample|CF infants 6 to 12 months or CF infants 24 to 36 months or non-CF controls between 6        months to 52 months scheduled for clinical MRI and willing to have contrast.|September 2015|September 25, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832519||68103|
NCT01833364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1021-F6A|Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation|A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment||University of Kentucky|Yes|Completed|April 2013|September 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|40 Years|75 Years|No|||March 2016|March 8, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01833364||68038|
NCT01832636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001 -"IMAGINE"|Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy|Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy (IMAGINE)|IMAGINE|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|October 2013|February 2016|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|2 Months|5 Years|No|||April 2013|November 26, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01832636||68094|
NCT01833533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-002|A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection|A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)|PEARL-IV|AbbVie|Yes|Completed|March 2013|September 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|70 Years|No|||September 2015|September 4, 2015|February 27, 2013|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01833533||68025|
NCT01833260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Music|Music and Perceived Rate of Exertion|Influence of a Distractive Auditory Stimulus on the Rate of Exertion During Pulmonary Rehabilitation Sessions||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|May 2013|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|45 Years|90 Years|No|||July 2014|July 17, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833260||68046|
NCT01833546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200592-002|A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer|A Japanese Single Center, Open-label, Phase I Trial of TH-302 Given Intravenously to Subjects With Solid Tumors as Monotherapy or to Subjects With Advanced Pancreatic Cancer in Combination With Gemcitabine||Merck KGaA|No|Completed|April 2013|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833546||68024|
NCT01824446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-109|AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SSP-004184 Following a Single Oral Dose in Healthy Male Subjects||Shire||Completed|April 2013|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|April 1, 2013|No|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01824446||68718|
NCT01824459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOX-DGCA|S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Diffuse Gastric Adenocarcinoma Patients|A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients||Sun Yat-sen University|No|Recruiting|April 2013|April 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|446|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824459||68717|
NCT01824706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-PMK-1201|Prospective, Multicenter Observational Study Evaluating the Long Term Safety of the Custombone Implant|A Prospective, Multicenter Observational Study Evaluating the Long Term Safety in Terms of Explantation Rate and Number of Infections of the Custom-made Bioceramic Implant CustomBone™|CUSTOMBONE|Codman & Shurtleff|Yes|Active, not recruiting|December 2012|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|N/A|No|Probability Sample|All patient implanted with the Custombone prosthesis|February 2016|February 9, 2016|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01824706|2 Years|68698|
NCT01834404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000948|Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients|Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients||Mayo Clinic|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|March 27, 2013|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01834404||67958|
NCT01834417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_0009|Preliminary Study Leading to Prevention of Pressure Ulcers by the Use of an On-board Device : Ergonomic Assessment of Wheelchair-seat Pressures in Spinal Cord Injured (SCI) Patients ( PRESDIE)|Preliminary Study Leading to Prevention of Pressure Ulcers by the Use of an On-board Device : Ergonomic Assessment of Wheelchair-seat Pressures in Spinal Cord Injured (SCI) Patients|PRESDIE|Nantes University Hospital||Recruiting|April 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01834417||67957|
NCT01825265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0758 Phase II|Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Phase II, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Withdrawn|November 2005|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|April 2, 2013|Yes|Yes|Study did not progress to second phase.|No||https://clinicaltrials.gov/show/NCT01825265||68655|
NCT01825278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10678|Evaluation of a Respiratory Monitor in Surgical Patients With a BMI>35|The Evaluation of a Respiratory Monitor in Surgical Patients With a BMI >35 Undergoing Elective Surgery Under General Anesthesia||Tufts Medical Center|No|Active, not recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Obese surgical patients|April 2015|April 2, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01825278||68654|
NCT01830647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28411|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum|Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum||Hoffmann-La Roche||Active, not recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic cancer of the colon and/or rectum|March 2016|March 1, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830647||68245|
NCT01830660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR-TPOP1|A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers|A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 3, 2015|December 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01830660||68244|
NCT01830842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043890|Acute and Chronic Nicotine Modulation of Reinforcement Learning|Acute and Chronic Nicotine Modulation of Reinforcement Learning|NicLearning|Duke University|Yes|Recruiting|February 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|October 1, 2015|April 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01830842||68230|
NCT01831102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1260|Adiponectin and Ethnic Differences in Insulin Resistance|Adiponectin as an Independent Determinant of Ethnic Differences in Insulin Resistance||University of Colorado, Denver||Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|April 2013|April 9, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01831102||68210|
NCT01831973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC388.3|A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients|An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma||Taiwan Liposome Company|No|Recruiting|October 2012|||July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||April 2013|April 10, 2013|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831973||68144|
NCT01832246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20122012|Endoscopic Ultrasonographic Staging and Conventional Endoscopic Staging for Depth of Invasion for Early Gastric Cancer|Prospective Study of Endoscopic Ultrasonographic Staging and Conventional Endoscopic Staging for Depth of Invasion and Endoscopic Tumor Size Estimation for Early Gastric Cancer||Seoul National University Hospital|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|560|||Both|20 Years|80 Years|No|Probability Sample|patients with early gastric adenocarcinoma is prospectively enrolled at Seoul National        University Hospital.|November 2014|November 17, 2014|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01832246||68124|
NCT01831635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B12/24|Myeloproliferative Neoplasms: an In-depth Case-control Study|Myeloproliferative Neoplasms: an In-depth Case-control Study|MOSAICC|Queen's University, Belfast|No|Recruiting|April 2013|June 2015|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|300|Samples With DNA|Venous blood sample (up to 12 ml) - whole blood, DNA Saliva (2ml) Dried Blood spots (500 µl)      Toe-nails (2 great toe-nail clippings)|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Hematology clinic Primary Care clinic Non-blood relatives/ friends of cases|April 2013|April 23, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01831635||68170|
NCT01832532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001Pilot 2GLP|A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks|Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||August 2015|August 3, 2015|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832532||68102|
NCT01832766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0359|The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes|The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes||University of Colorado, Denver|Yes|Terminated|June 2005|May 2011|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|13|||Both|18 Years|50 Years|No|||August 2015|August 18, 2015|March 25, 2013||No|Unable to find subjects with schizophrenia that were using only cannabis|No|June 30, 2014|https://clinicaltrials.gov/show/NCT01832766||68084|early termination as recruitment of subjects with only cannabis use was difficult leading to small number of subjects analyzed
NCT01833052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZL-01-TAVI|CLaret Embolic Protection ANd TAVI - Trial||CLEAN-TAVI|University of Leipzig||Active, not recruiting|April 2013|June 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 2, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833052||68062|
NCT01833065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000080|Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation|A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period||Ferring Pharmaceuticals|No|Terminated|April 2013|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 12, 2013|Yes|Yes|Terminated due to a distribution issue with the trial medication|No|July 17, 2015|https://clinicaltrials.gov/show/NCT01833065||68061|Due to the early termination of the study, outcomes were presented only for descriptive purposes.
NCT01833078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817283|Ghrelin Repeated Dose Study|Ghrelin in Frail Elderly Subcutaneous Repeated Dose Study|GRD|University of Pennsylvania|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|70 Years|N/A|No|||September 2015|September 9, 2015|April 11, 2013|Yes|Yes||No|September 12, 2014|https://clinicaltrials.gov/show/NCT01833078||68060|
NCT01833221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-159|Reinnervation of Facial Muscles After Lengthening Temporalis Myoplasty|Study of the Reinnervation of Facial Muscles After Lengthening Temporalis Myoplasty|FacialReinn|University Hospital, Caen|No|Recruiting|April 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|6 Years|70 Years|No|||April 2014|April 8, 2014|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833221||68049|
NCT01833234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford Epilepsy IRB 20523|Epilepsy Impact Scale|Questionnaire Development for a Comprehensive Scale to Measure the Impact of Epilepsy on Life.||Stanford University|No|Enrolling by invitation|July 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the Stanford Epilepsy Center who have had a seizure in the past year and agree        to participate.|April 2013|April 12, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01833234||68048|
NCT01832935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-123|Cost Effectiveness of Glargine Insulin Versus NPH Insulin|Cost Effectiveness of Glargine Insulin Versus NPH Insulin in Diabetic Patients in Iran||Tehran University of Medical Sciences|Yes|Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|200|||Both|18 Years|65 Years|No|||April 2013|April 15, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832935||68071|
NCT01833884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 09-02|Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic|Hodgkin's Lymphoma: Prognostic Value of the Kinetic of Decrease of 5 Cytokines Concentration During Treatment|CYTOKINES_LH|Centre Henri Becquerel|No|Recruiting|April 2010|January 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01833884||67998|
NCT01823224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380250|A Prospective, Randomized, Double Blind, Comparative-effectiveness Study Comparing Perioperative Administration of Oral Versus Intravenous Acetaminophen for Laparoscopic Cholecystectomy|A Prospective, Randomized, Double Blind, Comparative-effectiveness Study Comparing Perioperative Administration of Oral Versus Intravenous Acetaminophen for Laparoscopic Cholecystectomy||Defense and Veterans Center for Integrative Pain Management|No|Recruiting|February 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|220|||Both|18 Years|N/A|No|||May 2014|December 31, 2014|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823224||68812|
NCT01853267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRCOMS0513|Perianal Abscess Packing Randomized ControlledTrial Pilot Study|A Randomized Controlled Trial Evaluating the Requirement for Post-operative Packing of Perianal Abscesses||Imperial College London|Yes|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2013|May 20, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853267||66515|
NCT01853280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000379|L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults|L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial||Massachusetts General Hospital|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||December 2015|December 23, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853280||66514|
NCT01853553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1440|Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney||University of Colorado, Denver|No|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|79 Years|No|||November 2015|November 30, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01853553||66493|
NCT01853800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16886|Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet|Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects||Bayer|No|Completed|May 2013|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01853800||66474|
NCT01854307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1475/REK vest|The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements|The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements||Haukeland University Hospital|No|Terminated|May 2013|||August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Male|18 Years|N/A|No|||January 2016|January 21, 2016|May 13, 2013|No|Yes|Low inclusion rate|No||https://clinicaltrials.gov/show/NCT01854307||66435|
NCT01854320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK095069|Acceptance-based Behavioral Treatment for Obesity: Maintenance and Mechanisms|Acceptance-based Behavioral Treatment for Obesity: Maintenance and Mechanisms|MYH-II|Drexel University||Active, not recruiting|July 2012|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01854320||66434|
NCT01854580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Witt|Evaluation of an Integrated Care Project|Evaluation of an Integrated Care Project of the Statutory Health Insurance Techniker Krankenkasse [Evaluation Des Integrierten Versorgungsangebots Der Techniker Krankenkasse]|ediva|Charite University, Berlin, Germany|No|Enrolling by invitation|March 2013|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3960|||Both|12 Years|N/A|No|Non-Probability Sample|Insured people of the statutory health insurance Techniker Krankenkasse in Germany|August 2015|August 13, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01854580||66414|
NCT01855399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-412|Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes|Technologically Enhanced Coaching (TEC):A Program for Improving Diabetes Outcomes|VA-TEC|VA Office of Research and Development|No|Recruiting|September 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|4||Anticipated|609|||Both|18 Years|99 Years|No|||December 2015|December 11, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855399||66351|
NCT01855685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1XCGD.01|Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)|A Phase I/II, Non Randomized, Multicenter, Open-label Study of g1xcgd (Lentiviral Vector Transduced cd34+ Cells) in Patients With X-linked Chronic Granulomatous Disease|CGD|Genethon|No|Recruiting|February 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|24 Months|N/A|No|||January 2016|February 1, 2016|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855685||66329|
NCT01830946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2011.7210|Nighttime Macronutrient Choice and Combined Resistance and High-intensity Interval Training|The Effect of Nighttime Macronutrient Choice and Combined Resistance and High-Intensity Interval Training on Body Composition, Cardiovascular Health, Resting Metabolism, Appetite and Strength in Overweight and Obese Adults||Florida State University|No|Completed|September 2011|November 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830946||68222|
NCT01830959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFS-1|Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)|Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)|REFS|University of Cincinnati|Yes|Active, not recruiting|April 2013|October 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830959||68221|
NCT01826279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110172B|Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery|Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.||University of Aarhus|No|Active, not recruiting|May 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Female|25 Years|60 Years|No|||May 2013|January 29, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826279||68578|
NCT01822444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-16|ANGIOPREDICT. ICORG 12-16, V3|Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|November 2012|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|224|||Both|18 Years|N/A|No|Non-Probability Sample|All patients from the intent-to-treat population with aCRC or mCRC, (incurable with any        conventional multimodality approach) and who fulfil all inclusion and exclusion criteria.|December 2014|March 16, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822444||68872|
NCT01822704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20130209001|Whole Body Vibration in Chronic Stroke|Application of Vertical Whole Body Vibration in Stroke Patients: Neuromuscular Effects, and Clinical Efficacy||The Hong Kong Polytechnic University|Yes|Recruiting|March 2013|May 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822704||68852|
NCT01822717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIDGES- ST09 49|Nonvisual Foot Inspection for People With Visual Imapirment|Nonvisual Foot Inspection for People With Visual Impairment||Case Western Reserve University|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822717||68851|
NCT01823003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sbrt_lung_fff2012|Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases|Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases|sbrtlungfff|Institut Català d'Oncologia|No|Recruiting|June 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01823003||68829|
NCT01852981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/14119-4|Evaluation Study of Interventions for Physical Activity Promotion in Primary Health Care in Brazil.|Evaluation Study of Interventions for Physical Activity Promotion in Primary Health Care/Health Family Strategy in Brazil.|PACTIVEM|University of Sao Paulo|Yes|Completed|February 2011|October 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|157|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01852981||66537|
NCT01852994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Testosterone|Exercise Training and Testosterone Replacement in Heart Failure Patients|Exercise Training and Testosterone Replacement in Heart Failure Patients||University of Sao Paulo General Hospital|Yes|Completed|July 2009|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|39|||Male|18 Years|65 Years|No|||May 2013|March 3, 2016|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01852994||66536|
NCT01854125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingPLAGH1|Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites|Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites||Nanjing PLA General Hospital|Yes|Enrolling by invitation|May 2013|||January 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||May 2013|May 14, 2013|May 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854125||66449|
NCT01854138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCI-1333|Evaluating Advantages of Prevena After Hip and Knee Arthroplasty|Evaluating the Efficacy of the Prevena Incision Management System in Patients Undergoing Total Knee and Hip Arthroplasty||ProMedica Health System|No|Completed|January 2014|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|200|||Both|18 Years|85 Years|No|||May 2015|May 4, 2015|May 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854138||66448|
NCT01854346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KONTAKT|Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders|Genotype and Behavioral Effects of Social Skills Training in Children and Adolescents With High-functioning Autism Spectrum Disorders, a Randomized Controlled Trial (RCT) and Multicenter Study.|KONTAKT-RCT|Karolinska Institutet|No|Recruiting|August 2012|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|288|||Both|8 Years|17 Years|No|||May 2015|May 6, 2015|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01854346||66432|
NCT01854606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COEB071X2103|Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma|An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma|COEB071X2103|Novartis|No|Active, not recruiting|December 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|May 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01854606||66412|
NCT01854619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-1212-1|Photodynamic Therapy for the Treatment of Chronic Rhinosinusitis|Photodisinfection for the Treatment of Chronic Rhinosinusitis||Ondine Biomedical Inc.|No|Recruiting|May 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854619||66411|
NCT01854086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC130009-13CTIL|Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday|Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.|CONTINUITY|Meir Medical Center|No|Not yet recruiting|September 2013|||February 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Female|40 Years|90 Years|No|Non-Probability Sample|Patients with osteoporosis,who been treated in Endocrinology Clinic of Medical Center|May 2013|May 12, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01854086|1 Day|66452|
NCT01854099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFORMANCE|Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens|Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens|PERFORMANCE|University of Florida|No|Withdrawn|January 2014|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|May 11, 2013|Yes|Yes|Investigator decided not to open study.|No||https://clinicaltrials.gov/show/NCT01854099||66451|
NCT01854112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No. 101115-E|Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma|||Far Eastern Memorial Hospital||Enrolling by invitation|November 2012|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Female|37 Years|37 Years|No|Probability Sample|T-cell lymphoma|May 2013|August 5, 2014|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01854112||66450|
NCT01854333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EvaluationADOS&ADI-R|The Swedish Versions of ADOS and ADI-R: Psychometric Validation|The Swedish Versions of ADOS and ADI-R: Psychometric Validation||Karolinska Institutet|Yes|Completed|January 2011|November 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|50|||Both|N/A|N/A|No|||June 2015|June 23, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01854333||66433|
NCT01854918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120138|Open Label Study of Long Term Evaluation Against LDL-C Trial-2|A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145-2|OSLER-2|Amgen|Yes|Active, not recruiting|April 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3681|||Both|18 Years|85 Years|No|||September 2015|October 1, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854918||66388|
NCT01854931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG034956-02|Community Dissemination of Tai Ji Quan|Translating an Effective Fall Prevention Program Into a Community-Based Practice||Oregon Research Institute|No|Recruiting|May 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01854931||66387|
NCT01854944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-09-219|PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia|||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|September 2013|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|No|||January 2016|January 5, 2016|May 7, 2013|No|Yes||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01854944||66386|
NCT01855698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMATO0213|PENELOPE Observational Study|Clinical Practice in the Prophylaxis and Treatment of Arterial and Venous Thromboembolism in Patients With hEmatological NEoplasms and LOw PlatElets (PENELOPE Observational Study)||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Withdrawn|June 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Because this study is designed to provide as wide a picture of the different clinical        management strategies in unselected patients with hematologic neoplasms, inclusion        criteria are set deliberately wide.        All consecutive subjects that present to the centre and satisfy the inclusion criteria        will be considered as potential candidates for enrolment.        There is no age limit for including the patients in the study.|May 2014|May 13, 2014|May 14, 2013||No|Ethics Committee did not approve the statistical design.|No||https://clinicaltrials.gov/show/NCT01855698||66328|
NCT01855711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3B20032|Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)|A Four-week, Open, Multicenter Study to Assess the Safety and Efficacy of 1 mg Once Daily (QD) of GR68755 in Female Subjects With Severe Diarrhea-predominant Irritable Bowel Syndrome (IBS) Who Have Frequent Bowel Urgency||GlaxoSmithKline|No|Completed|September 2003|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|20 Years|64 Years|No|||January 2011|May 16, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855711||66327|
NCT01856010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM10-1221-01|Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia|Short-term Efficacy and Cognitive Side Effects of Acute Electroconvulsive Therapy (ECT) for Agitation and Aggression in Dementia||Pine Rest Christian Mental Health Services|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|||Both|50 Years|N/A|No|Non-Probability Sample|Individuals age 50 or older that have been diagnosed with dementia and associated        agitation and aggression and have already been referred for ECT.|February 2015|February 13, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01856010||66304|
NCT01856023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12PLK02|HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma|Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma|PROCLIVITY 02|Prometheus Laboratories|Yes|Terminated|May 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|May 10, 2013||No|A shift in the melanoma treatment landscape adversely affected accrual & early closure|No||https://clinicaltrials.gov/show/NCT01856023||66303|
NCT01834495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENS-ILIAC|Efficacy of Balloon-Expandable Stent Versus Self-Expandable Stent for the Atherosclerotic ILIAC Arterial Disease|Phase 4 Study of Efficacy of Balloon-Expandable Cobalt Chromium SCUBA Stent Versus Self-Expandable Stent COMPLETE-SE Nitinol Stenting for the Atherosclerotic ILIAC Arterial Disease: Prospective, Multicenter, Randomized, Controlled Trial||Korea University Guro Hospital|Yes|Recruiting|October 2012|August 2015|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|20 Years|85 Years|No|||April 2013|April 17, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01834495||67951|
NCT01834508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-07|3E Extension Study|A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study|3E Ex|Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|65 Years|No|||June 2014|June 17, 2014|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01834508||67950|
NCT01834521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCOURAGE2-2012|Web-based Screening and Tailored Support|Web-based Screening and Tailored Support for Breast Cancer Patients at the Onset of the Survivorship Phase|ENCOURAGE|University Medical Center Groningen|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|128|||Female|18 Years|N/A|No|||February 2015|February 2, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01834521||67949|
NCT01826292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363700-3|The Association Between Anesthetic and Surgical Practices and Patient Length of Stay in the Post Anesthesia Care Unit|The Association Between Anesthetic and Surgical Practices and Patient Length of Stay in the Post Anesthesia Care Unit||University of California, Davis|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|None Retained|Cross-sectional cart review|Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent an anesthetic administered by an anesthesiologist in the University        of California Davis main operating rooms and were transferred to the main post anesthesia        care unit between January 1, 2012 and March 31, 2012.|January 2014|January 21, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826292||68577|
NCT01856179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H42-KK|Supplementation of Land-based Stearidonic Acid (SDA)-Rich Oils in Humans|Accumulation of n-3 Long-chain (LC)-PUFA by Supplementation of SDA-rich Echium Oil in Humans Depending on Age, Gender and Physiological Stage||University of Jena|Yes|Completed|March 2011|April 2012|Actual|August 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|78|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01856179||66291|
NCT01822236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-123|Craniosacral Therapy to Treat Chronic Low Back Pain|Effectiveness of a Craniosacral Therapy Program on Disability, Quality of Life, Autonomic Nervous System and Oxidative Stress Indicators in Chronic Low Back Pain: a Randomized Controlled Clinical Trial||Universidad de Almeria|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|25 Years|60 Years|No|||March 2015|March 23, 2015|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01822236||68888|
NCT01856413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT 987|A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant|An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study|ZEUS|Biotest|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|49|||Both|18 Years|75 Years|No|||March 2015|March 24, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856413||66273|
NCT01852513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 12-1812|Allergic Rhinitis Changes the Sinus Microbiome|Allergic Rhinitis Changes the Sinus Microbiome||University of Chicago|No|Recruiting|January 2013|June 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|55 Years|No|||May 2013|May 10, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852513||66573|
NCT01853020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211011055|Cannabinoids and Cerebellar-Motor Functioning|Cannabinoids and Cerebellar-Motor Functioning||Yale University|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|42|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|March 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01853020||66534|
NCT01852747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0023|Comparison of Actifuse ABX and Local Bone in Spinal Surgery|Actifuse ABX and Local Bone Have Comparable Outcomes to Local Bone in Instrumented Multi-Level Adult Spinal Deformity Patients||Ohio State University|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||June 2013|June 6, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01852747||66555|
NCT01853566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH and men|Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old|Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old||Universidade Federal do Rio de Janeiro|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|13|||Male|50 Years|70 Years|No|||August 2014|August 31, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01853566||66492|
NCT01853852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115806|A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects|A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects||Amicus Therapeutics||Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|14|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01853852||66470|
NCT01853865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPAL|Follow-up of Endometrial Cancer Patients|Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit?|OPAL|Odense University Hospital|No|Recruiting|May 2013|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01853865||66469|
NCT01854151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01122|Promoting Safe Use of Pediatric Liquid Medications|Promoting Safe Use of Pediatric Liquid Medications: A Health Literacy Approach||New York University School of Medicine|Yes|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|N/A|8 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01854151||66447|
NCT01854892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006978|The RELIEF Study - Researching the Effectiveness of Lumbar Interventions for Enhancing Function|The RELIEF Study - Researching the Effectiveness of Lumbar Interventions for Enhancing Function||Ohio University|Yes|Recruiting|April 2013|August 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|3||Anticipated|162|||Both|18 Years|45 Years|No|||May 2013|May 20, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01854892||66390|
NCT01854905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-OPH-DE-015|An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy|||Allergan|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients consulting with ophthalmologist for possible LASIK|January 2014|January 28, 2014|May 14, 2013||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01854905||66389|
NCT01855165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHF42013|The Role of Clinical Pharmacist in Management of DDIs in CHF Patients|The Role of Clinical Pharmacist's Intervention in Management of Clinically Relevant Drug-drug Interactions in Patients With Chronic Heart Failure||The University Clinic of Pulmonary and Allergic Diseases Golnik|No|Recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|N/A|N/A|No|||May 2013|May 15, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01855165||66369|
NCT01854632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-SEN-01|Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal|A Randomized, Double-Blind, Placebo-Controlled Trial of the Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal||PATH|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1761|||Both|24 Months|71 Months|Accepts Healthy Volunteers|||February 2014|June 1, 2015|May 13, 2013||No||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01854632||66410|
NCT01855438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD302305|Increasing Communication About Live Donor Kidney Transplant|Increasing Communication About Live Donor Kidney Transplant: A Proof of Concept||Virginia Commonwealth University|No|Active, not recruiting|May 2013|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855438||66348|
NCT01855672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-13-001|Occipital Nerve Stimulation in the Treatment of Migraine|A Multicenter, Randomized, Controlled, Double-Blind, Proof-of-Concept Study Assessing the Safety and Effectiveness of a Signal Generator Device (NMS EBox) for the Treatment of Chronic Migraine|Verona|Ethicon, Inc.|No|Terminated|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|8 Years|65 Years|No|||June 2013|July 15, 2013|May 14, 2013||No|Business strategic decision not related to safety.|No||https://clinicaltrials.gov/show/NCT01855672||66330|
NCT01855724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 37/12|Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer|Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)||Hellenic Cooperative Oncology Group|No|Recruiting|June 2013|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855724||66326|
NCT01855256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.035 H²O|Treatment of Hyperhidrosis With Oxybutynin|Treatment of Hyperhidrosis With Oxybutynin: a Randomized Controlled Double Blind Against Placebo|H²O|University Hospital, Brest|Yes|Completed|June 2013|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855256||66362|
NCT01855503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 1210010985|Breast Cancer Molecular Analysis Protocol|Breast Cancer Molecular Analysis Prior to Investigational Therapy|MAP-IT|Yale University|No|Recruiting|May 2013|||May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Biopsies of metastatic cancer|Both|N/A|N/A|No|Probability Sample|Metastatic Breast Cancer|May 2013|May 13, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855503||66343|
NCT01826006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASER-AMI P/915/CE/2012|THE LASER-AMI STUDY - Excimer Laser Versus Manual Thrombus Aspiration in Acute Myocardial Infarction|A Randomized Comparison of Excimer LASER vs Manual Thrombus Aspiration for the Prevention of No-reflow During Primary Percutaneous Coronary Intervention of St-elevation Myocardial Infarction(LASER-AMI Study)|LASER-AMI|Catholic University of the Sacred Heart|Yes|Recruiting|April 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01826006||68598|
NCT01822483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080|A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)|A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)|AUC-MPA|Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|75 Years|No|||April 2015|April 1, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822483||68869|
NCT01856439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS1/001/09|Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease|A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.||Oxford BioMedica|Yes|Active, not recruiting|May 2011|May 2022|Anticipated|May 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|N/A|N/A|No|||June 2014|June 9, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856439||66271|
NCT01852526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1510|Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Lumbar-spine Fusion|Clinical Trial (Phase II, Therapeutic Explorative) of the Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Fusion-surgery in the Lumbar Spine: a Prospective, Randomised, Monocenter Pilotstudy|D-Rod|University of Cologne|Yes|Terminated|March 2013|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|30 Years|N/A|No|||September 2015|September 15, 2015|May 8, 2013||No|device failure|No||https://clinicaltrials.gov/show/NCT01852526||66572|
NCT01852539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-13-045|Dexmedetomidine for Laryngeal Mask Airway Insertion|Optimal Dose of Dexmedetomidine for Laryngeal Mask Airway Insertion During Propofol Induction||Ajou University School of Medicine|Yes|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|60 Years|No|||April 2014|April 20, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01852539||66571|
NCT01852760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO103563|Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound|Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound||Lawson Health Research Institute|No|Completed|September 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Consecutive adult patients with IBD attending outpatient IBD clinics at the University of        Western Ontario teaching hospitals and patients admitted to hospital with severe UC will        be included for endoscopic ultrasound assessment.|October 2015|October 1, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01852760||66554|
NCT01856426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDP239X2201|Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects|Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects||Enanta Pharmaceuticals|No|Completed|June 2013|October 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856426||66272|
NCT01853033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-048|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis|A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122||AbbVie|No|Completed|July 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|75 Years|No|||June 2014|June 3, 2014|May 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01853033||66533|
NCT01853046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16653|Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment|A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group||Bayer|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|May 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01853046||66532|
NCT01853293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-000727|Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons|Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons||Mclean Hospital|No|Withdrawn|March 2014|||September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|60 Years|No|||October 2015|October 6, 2015|May 10, 2013|No|Yes|Grant was not funded|No||https://clinicaltrials.gov/show/NCT01853293||66513|
NCT01853579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/11|The TRUST Study - Depression Substudy|Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression|TRUST|University Hospital Inselspital, Berne|Yes|Recruiting|March 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|65 Years|N/A|No|||November 2015|November 12, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01853579||66491|
NCT01853878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116389|A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor|GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer|PEARL|GlaxoSmithKline||Active, not recruiting|June 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||July 2015|February 4, 2016|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853878||66468|
NCT01853813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005048-46|First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer|First-line FOLFIRI and Bevacizumab in Patients With Advanced Colorectal Cancer Prospectively Stratified According to Serum LDH|CENTRAL|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Completed|May 2013|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01853813||66473|
NCT01853826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.55|An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)||Boehringer Ingelheim||Active, not recruiting|July 2013|January 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|481|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 13, 2013||||No||https://clinicaltrials.gov/show/NCT01853826||66472|
NCT01853839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.602|Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients|Treatment Adherence to JNC 7(Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 7th Report) Guidelines in Cardiovascular (CV)-Risk Patients Across the Middle East - the Impact of Ramadan Fasting on Achieving Treatment Goals in Daily Practice||Boehringer Ingelheim||Completed|October 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1674|||Both|18 Years|N/A|No|Non-Probability Sample|Hypertensive patients wih at least one CV risk factor|July 2015|July 15, 2015|May 13, 2013||||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01853839||66471|
NCT01854385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44912-B|Sumatriptan as Treatment for Post-traumatic Headache|Sumatriptan as Treatment for Moderate to Severe Post-Traumatic Headache|TWIST|University of Washington|Yes|Recruiting|June 2013|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854385||66429|
NCT01854658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003007-00|Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)|A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo||Pearl Therapeutics, Inc.|Yes|Completed|July 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1618|||Both|40 Years|80 Years|No|||July 2015|July 7, 2015|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854658||66408|
NCT01854359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130088|Idebenone for Primary Progressive Multiple Sclerosis|Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2013|August 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2015|October 10, 2015|May 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854359||66431|
NCT01854645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003006-00|Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)|A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control||Pearl Therapeutics, Inc.|Yes|Completed|May 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|2103|||Both|40 Years|80 Years|No|||July 2015|July 7, 2015|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854645||66409|
NCT01855191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC Lung|SDC for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation|Standardized Data Collection (SDC) for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation (SDC Lung).|SDC lung|Maastricht Radiation Oncology|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|864|||Both|18 Years|N/A|No|Non-Probability Sample|All patients planned for curatively intended radiotherapy or postoperative radiotherapy.|October 2015|October 13, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01855191||66367|
NCT01855451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 12.01|Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma|TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma|HPVOropharynx|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Recruiting|June 2013|June 2021|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855451||66347|
NCT01855789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28776|A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis|A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY||Hoffmann-La Roche||Active, not recruiting|November 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|718|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855789||66321|
NCT01855802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT-GG-P|Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma|Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma||Democritus University of Thrace|No|Recruiting|April 2013|October 2013|Anticipated|September 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|70|||Both|25 Years|67 Years|No|Non-Probability Sample|Greek Medical Council Members|May 2013|May 13, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01855802||66320|
NCT01856062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|379303-1|Ovulation Induction With Clomiphene Citrate and Dexamethasone|Ovulation Induction With Clomiphene Citrate and Dexamethasone||San Antonio Military Medical Center|No|Recruiting|May 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|40 Years|No|||February 2014|February 27, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01856062||66300|
NCT01822262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYGDWK-01|Contrastive Study for Minimally Invasive Cholecystolithotomy With Gallbladder Reservation and Laparoscopic Cholecystectomy|All the Phases Study Will be Operated by the Department of Hepatobiliary Surgery, The Affiliated Hospital of Guiyang Medical College||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|January 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 6, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01822262||68886|
NCT01823042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS-2|The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)|A Randomized, Controlled, Open-label Study to Assess the the Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD).||Jinling Hospital, China|No|Recruiting|October 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2013|March 28, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01823042||68826|
NCT01823055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Karolinska Institutet|Safety and Efficacy of a Transvaginal Suture Capturing Mesh Device|Safety and Efficacy of a Transvaginal Suture Capturing Mesh Device: The Nordic Uphold LITE Trial||Karolinska Institutet|Yes|Completed|January 2012|||March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Female|18 Years|N/A|No|||March 2013|April 2, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01823055||68825|
NCT01852292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120H2201|Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy|Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)||Novartis|Yes|Active, not recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852292||66590|
NCT01852552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2009-1578270|Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement|Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement|CCQ|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Active, not recruiting|December 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients undergoing TAVI or AVR for AS at participating centers during the        period of enrollment|May 2015|May 7, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852552|12 Months|66570|
NCT01852565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115679|Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).|An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).||GlaxoSmithKline|Yes|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|May 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852565||66569|
NCT01852578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/12.02|Cabazitaxel in Relapsed and Metastatic NSCLC|A Pilot Phase II Trial of Cabazitaxel in Patients With Metastatic NSCLC Progressing After Docetaxel-based Treatment||Hellenic Oncology Research Group|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852578||66568|
NCT01852773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11-5736|Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury|Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury|TEVAR|Scripps Health|Yes|Enrolling by invitation|May 2013|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|||Both|18 Years|N/A|No|Non-Probability Sample|Trauma patients with blunt aortic injury (BAI)|February 2014|May 18, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01852773||66553|
NCT01853007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD301152|Communicating About Choices in Transplantation|Communicating About Choices in Transplantation (COACH)|COACH|Virginia Commonwealth University|No|Active, not recruiting|June 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|158|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01853007||66535|
NCT01853059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092896|Functional Outcomes Following Anal Cancer Treatment|Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus|FOFACT|Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|176|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under the care of the anal cancer multidisciplinary team in Addenbrookes,        Cambridge and Christie Hospital, Manchester|May 2013|May 13, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853059||66531|
NCT01853306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-695|A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors||AbbVie|No|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|March 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01853306||66512|
NCT01853319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16754|Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy|An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy|REGARD|Bayer|No|Active, not recruiting|July 2013|June 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01853319||66511|
NCT01853592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130098|Gadofosveset Trisodium for Heart Imaging Studies|A Pilot Dosing Study for Gadofosveset Trisodium (Ablavar) for Coronary Magnetic Resonance Angiography (MRA)||National Institutes of Health Clinical Center (CC)||Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01853592||66490|
NCT01853605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410CA-002|NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study|||Allergan|No|Terminated|April 2003|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3811|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|May 13, 2013|No|Yes|The study was discontinued following product approval.|No|July 16, 2015|https://clinicaltrials.gov/show/NCT01853605||66489|
NCT01854164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ilhwa-FG-001|Efficacy and Safety of Hydrolyzed Ginseng Extract on Impaired Fasting Glucose|An 8 Weeks, Randomized, Double-blind, Placebo-controlled Clinical Trial for Anti-diabetic Effects of Hydrolyzed Ginseng Extract||Chonbuk National University Hospital|Yes|Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854164||66446|
NCT01854372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-53|Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.|Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. A Phase 2, Multi-Center, Open Label Study (CTRC# 11-53)||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|June 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2013|December 9, 2013|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854372||66430|
NCT01854684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 228112|Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery|A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease||Roswell Park Cancer Institute|No|Recruiting|February 2014|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854684||66406|
NCT01854671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF13-10|Investigating the Effect of a Prenatal Family Planning Counseling Intervention Led by Community Health Workers on Postpartum Contraceptive Use Among Women in the West Bank|Investigating the Effect of a Prenatal Family Planning Counseling Intervention Led by Community Health Workers on Postpartum Contraceptive Use Among Women in the West Bank||Planned Parenthood League of Massachusetts|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|176|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854671||66407|
NCT01854957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESEMS|MEsenchymal StEm Cells for Multiple Sclerosis|MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis|MESEMS|University of Genova|Yes|Recruiting|July 2012|September 2014|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|50 Years|No|||May 2013|May 13, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01854957||66385|
NCT01855425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6K0377|Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose|Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose|CBCT-ENT|Carestream Health, Inc.|No|Completed|September 2012|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|80 Years|No|Non-Probability Sample|Invitation to Volunteer extended to any patient presenting with the following conditions        who will be scheduled for a standard of care Medical CT:        Chronic sinusitis with and without polyps CerebroSpinal Fluid (CSF) leak Chronic Otitis        Media Cochlear Implant Otospongiosis Otosclerosis Pulsatile Tinnitus Cholesteatoma        superior semicircular canal dehiscence|September 2013|November 24, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855425||66349|
NCT01855464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKW-TCH-2013-001|Wedge Resection or Parietal Pleurectomy for the Treatment of Recurrent Pneumothorax (WOPP)|Pulmonary Wedge Resection Plus Parietal Pleurectomy (WRPP) Versus Parietal Pleurectomy (PP) for the Treatment of Recurrent Primary Pneumothorax|WOPP|Wuerzburg University Hospital|Yes|Recruiting|November 2013|May 2020|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Both|15 Years|40 Years|No|||February 2016|February 26, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01855464||66346|
NCT01823380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8987|Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype|Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype||University Hospital, Montpellier|No|Completed|September 2012|September 2015|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|127|||Both|18 Years|95 Years|No|||September 2015|December 4, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823380||68800|
NCT01822275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00053043|Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme|Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme|GCC 1224|University of Maryland|Yes|Recruiting|May 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01822275||68885|
NCT01822496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00737|Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Recruiting|November 2013|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|234|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822496||68868|
NCT01822756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-144|An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors|A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors||Incyte Corporation|No|Active, not recruiting|April 2013|December 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822756||68848|
NCT01822769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00005391|Cardiopulmonary Rehabilitation for Adolescents and Adults With Congenital Heart Disease|Cardiopulmonary Rehabilitation for Adolescents and Adults With Congenital Heart Disease||Children's Hospital Boston|No|Active, not recruiting|April 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||August 2015|August 4, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822769||68847|
NCT01823068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-09-089-01|Vandetanib in Advanced NSCLC With RET Rearrangement|A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement||Samsung Medical Center|Yes|Recruiting|April 2013|July 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823068||68824|
NCT01856231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038130|Lifestyle Physical Activity for People With COPD|Lifestyle Physical Activity for People With COPD||University of Michigan|No|Recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|55 Years|N/A|No|||June 2015|June 8, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01856231||66287|
NCT01852591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16727|Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant|Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma|PCV13|H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|February 2013|October 2016|Anticipated|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852591||66567|
NCT01852786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Contraception|The Effect of Hormonal Contraception on Female|Metabolic, Androgen, Blood Coagulation Parameters and Female Sexual Function in Relation to Oral Contraceptive Use and Androgen Receptor Polymorphisms in Healthy Lithuanian Women|HORMCONTRA|Lithuanian University of Health Sciences|Yes|Active, not recruiting|February 2013|February 2016|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|340|Samples With DNA|1. Lipidogram, glycemia;        2. Hormonal analyses by radioimmunoassay method ׃ total testosterone (T), free           testosterone (FT), sex hormone binding globulin (SHBG), dehidroepiandrosterone sulphate           (DHEAs), thyrotropin hormone (TSH), free thyroxine (FT4);        3. Blood coagulation test׃ clotting time according to Ovren, fibrinogen, aPTT.        4. Total blood picture test;        5. Androgen receptor (AR) polymorphism test.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|340 healthy Lithuanian women age 18- 40 years with regular menstruale cycle (22- 35 days)        presenting for routine gynecologic concern or contraception purposes.|May 2013|May 13, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01852786||66552|
NCT01853072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-067|Nepafenac Once Daily for Macular Edema - Study 1|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery||Alcon Research|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|881|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853072||66530|
NCT01853631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31970 SAGAN|Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)|Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)|SAGAN|Baylor College of Medicine|Yes|Recruiting|February 2014|February 2032|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|75 Years|No|||November 2015|November 25, 2015|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01853631||66487|
NCT01853332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P000424|Physical Health in Midlife: Influences of Adversity and Relationships Over Time|Physical Health in Midlife: Influences of Adversity and Relationships Over Time||Beth Israel Deaconess Medical Center|No|Completed|January 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|227|Samples Without DNA|Serum and plasma are stored to be analyzed for biomarkers related to metabolic syndrome.|Both|35 Years|55 Years|No|Non-Probability Sample|Approximately 165 former participants and 250 new participants will take part in this        study at Beth Israel Deaconess Medical Center (and Judge Baker Children's Center). The new        sample will include 250 African American and Black Caribbean midlife men and women with        the goal of recruiting 80% as couples. A total of 415 people will take part in this study        at all study sites. Spouses and long-term significant others (with bonuses to couples for        joining) will be encourage to also participate in the study. Targeting couples in this way        will be parallel for the community and longitudinal samples|January 2015|January 12, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01853332||66510|
NCT01853618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130120|Tremelimumab With Chemoembolization or Ablation for Liver Cancer|A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Stereotactic Body Radiation Therapy (SBRT) or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|99 Years|No|||October 2015|January 5, 2016|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01853618||66488|
NCT01854177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#23992|Differentiating the Effects of Substance P and Beta-endorphin|Differentiating the Effects of Substance P and Beta-endorphin in the Perception of Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Dartmouth-Hitchcock Medical Center|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Both|50 Years|90 Years|No|||January 2014|January 30, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854177||66445|
NCT01854398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0021|The Effect of Continuous Positive Airway Pressure on Diastolic Function in Patients With Obstructive Sleep Apnea|||Yonsei University|Yes|Recruiting|May 2013|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||February 2014|February 4, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01854398||66428|
NCT01854697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-774|A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before|A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)|MALACHITE 1|AbbVie|No|Completed|March 2013|July 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|311|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|April 8, 2013||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01854697||66405|
NCT01854970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/08|Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux|Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux|PHARO|University Hospital, Bordeaux|No|Completed|May 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01854970||66384|
NCT01855204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUH-rad|Low Tube Voltage Computed Tomographic (CT) Urography Using Low Concentration Iodine Contrast Agent|Low Tube Voltage Computed Tomographic (CT) Urography Using Low Concentration Iodine Contrast Agent: a Comparison Study With Conventional CT Urography||Seoul National University Hospital|Yes|Recruiting|April 2013|April 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|64|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|April 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855204||66366|
NCT01855737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-GZH1|The Study of Warfarin Maintenance Dose in Chinese Patients|Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients|WADCH|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|June 2013|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Samples with DNA frozen in -80℃|Both|18 Years|N/A|No|Non-Probability Sample|Chinese Han population who need to use Warfarin and older than 18 years old.|June 2013|June 2, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01855737||66325|
NCT01855750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102118|A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma||Janssen Research & Development, LLC|Yes|Recruiting|September 2013|June 2020|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855750||66324|
NCT01823692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-75|Evaluating Validity of Ultrasonography in Determining Distal Radius Fracture Reduction|Study of Accuracy of Ultrasonography in Determining the Adequacy of Distal Radius Fracture Reduction||Isfahan University of Medical Sciences|Yes|Completed|September 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|184|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2013|April 2, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01823692||68776|
NCT01823965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLOMD|Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment|||Poitiers University Hospital||Recruiting||||December 2013|Anticipated|Phase 2|Interventional|N/A|1||||||Both|18 Years|79 Years||||March 2013|April 3, 2013|March 27, 2013||||No||https://clinicaltrials.gov/show/NCT01823965||68755|
NCT01822509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00739|Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant|A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation||National Cancer Institute (NCI)|No|Recruiting|April 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|113|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822509||68867|
NCT01822782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/LB-01|Abnormal Vaginal Flora and Vaginal Lesions at Delivery: is There a Relationship?|Abnormal Vaginal Flora and Vaginal Lesions at Delivery: is There a Relationship?||Centre Hospitalier Universitaire de Nīmes|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1100|||Female|15 Years|45 Years|No|Non-Probability Sample|The study population consists of all consecutive women meeting inclusion/exclusion        criteria and delivering at the Nîmes University Hospital, France during an inclusion        period of 6 months.|March 2015|March 25, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822782||68846|
NCT01823081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91128|Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|January 2013|||June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|March 28, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01823081||68823|
NCT01823315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-GYN/GTN-01|Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia|A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia|GTN-01|Huazhong University of Science and Technology|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|60 Years|No|||March 2013|March 29, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01823315||68805|
NCT01853098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151|A Pilot Study of Positive Affect Training|Effect of a Novel Mindfulness Based Loving Kindness Meditation on Positive and Negative Affect||Boston University|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853098||66528|
NCT01852799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138MMY2074|A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma|A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed Multiple Myeloma(MM)||Shanghai Changzheng Hospital|Yes|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||July 2015|July 6, 2015|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01852799||66551|
NCT01853644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00073756|Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|TIVO|Northwestern University|Yes|Recruiting|May 2013|October 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|110 Years|No|||November 2015|November 1, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853644||66486|
NCT01853345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-406|iCAT for Recurrent/Refractory/HR Solid Tumors|Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors||Dana-Farber Cancer Institute|No|Completed|August 2012|||September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|Samples With DNA|Blood samples, tumor samples|Both|N/A|30 Years|No|Non-Probability Sample|Pediatric patients with recurrent, refractory or high risk solid tumors|February 2015|February 9, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01853345|99 Years|66509|
NCT01853904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2296|Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage|Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage||University of Oklahoma|No|Completed|July 2012|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01853904||66466|
NCT01854190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINEX 02|Obstructive Sleep Apnea and Endothelial Function in Patients With Resistant Hypertension|Evaluation of Obstructive Sleep Apnea and Endothelial Function in Resistant Hypertension Patients||Rio de Janeiro State University|Yes|Completed|July 2012|May 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Hypertensive patients, from the Hypertension Clinic of UERJ|February 2013|May 12, 2013|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01854190|2 Days|66444|
NCT01854411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI09048|Study of Analgesics Drug and Human Milk Transfer in Mature Milk, to Avoid Breastfeeding Cessation Without Scientific Probes|Ibuprofen and Ketoprofen Concentrations in Human Mature Milk. PK Study in Breastmilk AOR-10127 "Antalait" Study|ANTALAIT|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2011|November 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples Without DNA|human breast milk|Female|18 Years|49 Years|No|Non-Probability Sample|Lactarium, Maternal care, Consultant of Lactation|April 2015|April 20, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854411||66427|
NCT01854710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-204-407|QT/QTc Study of 2 Doses of ADASUVE®|Thorough QT/QTc Study of 2 Doses of ADASUVE® in Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01854710||66404|
NCT01854996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291020|Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion|A Phase I, Randomized, Single-Dose Study To Determine The Relative Bioavailability Of Capsule Vs Oral Dispersion And The Effect Of Food On The Pharmacokinetics Of Orally Administered PF-05089771 As Capsule In Healthy Volunteers||Pfizer|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|May 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01854996||66382|
NCT01854983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0693|Significance of Fluorescence Colposcopy With Autofluorescence Imaging for Cervical Cancer|Clinical Trial to Access Significance of Fluorescence Colposcopy With Autofluorescence Imaging for the Screening of Cervical Cancer||Asan Medical Center|Yes|Not yet recruiting|May 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Female|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|tertiary center|May 2013|May 14, 2013|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854983||66383|
NCT01855217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40732.100.12|Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade|Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade|MOS|St. Antonius Hospital|Yes|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 16, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01855217||66365|
NCT01855477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35781.041.11|CPCT-02 Umbrella Biopsy Protocol|Development of a Platform for Next-generation DNA Sequencing Based Personalized Treatment for Cancer Patients: Protocol to Obtain Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer (CPCT - 02 Biopsy Protocol)|CPCT-02|UMC Utrecht|Yes|Recruiting|August 2011|||August 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|2500|||Both|18 Years|N/A|No|||February 2014|February 23, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855477||66345|
NCT01855243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CairoU teaching hospital|Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM|Premix 70/30 Insulin Plus Supplemental Lunch Insulin in Comparison to Basal Plus Prandial Supplemental Scale and Sliding Scale Insulin in Hospitalized Patients With Type 2 Diabetes||Cairo University|No|Active, not recruiting|March 2010|June 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|65|||Both|18 Years|64 Years|No|||May 2013|May 13, 2013|May 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01855243||66363|
NCT01824524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018070|A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer|An Open-Label Study to Evaluate the Single Dose Pharmacokinetic Profile and Safety of OROS® Hydromorphone in Chinese Subjects With Cancer Who Are Not Opioid Tolerant||Xian-Janssen Pharmaceutical Ltd.|No|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||August 2014|August 14, 2014|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824524||68712|
NCT01822795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD12133|Lung Volume Reduction Coil Treatment in Emphysema.|Cost-effectiveness of Lung Volume Reduction Coil Treatment in Emphysema.|STICREVOLENS|CHU de Reims|Yes|Active, not recruiting|March 2013|December 2019|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822795||68845|
NCT01823094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393991|CTP Imaging of Lung Cancer|CTP (Computed Tomography Perfusion) Imaging of Lung Cancer|CTPLC|University of California, Davis|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|patients with non small cell lung cancer who are planned to receive systemic therapy|January 2016|January 22, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823094||68822|
NCT01823328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 13-3601|Ketamine Versus Etomidate for Rapid Sequence Intubation|Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation||Minneapolis Medical Research Foundation|Yes|Completed|September 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823328||68804|
NCT01852305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27/2/2013|Obstructive Sleep Apnea in Bariatric Surgical Patients|Would A New Pathway Managing Obstructive Sleep Apnea in Bariatric Surgical Patients Be Safe and Cost-effective?||University Health Network, Toronto|No|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|316|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01852305||66589|
NCT01852318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301065MINB|Pregabalin for the Treatment of Uremic Pruritus|A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus||National Taiwan University Hospital|No|Not yet recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 13, 2014|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852318||66588|
NCT01852838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9716-NP-CTIL|The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer|The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer||Sheba Medical Center|No|Recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|95 Years|No|Non-Probability Sample|The population will include a total of 70 participants, 50 of which currently suffer from        lung cancer, and have not yet begun any form of medical treatment whilst the remaining        group consists of 20 individuals who have been defined as high-risk patients for lung        cancer by the Research and Detection Unit for Thoracic malignancies at the Sheba Medical        Center, Tel Hashomer, Israel.|February 2014|February 20, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852838||66548|
NCT01852812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-520|Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)|A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|87|||Both|1 Year|15 Years|No|||July 2015|July 29, 2015|May 9, 2013|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01852812||66550|
NCT01853371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients|The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients in Jeddah, 2013, A Pilot Study||King Abdulaziz University|Yes|Completed|June 2013|||November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|65 Years|No|||November 2014|November 24, 2014|May 7, 2013||No||No|May 11, 2014|https://clinicaltrials.gov/show/NCT01853371||66507|
NCT01853891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0315|Dim Light at Night in Patients With Obstructive Sleep Apnea|Effects of Sleeping With Dim Light at Night in Patients With Obstructive Sleep Apnea||Ohio State University|Yes|Recruiting|April 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|47|||Both|18 Years|60 Years|No|Non-Probability Sample|Adult subjects age 18-60 who have been diagnosed with OSA based on polysomnography (PSG)        with an AHI of >10 episodes per hour.|September 2014|September 23, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853891||66467|
NCT01853917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0503|Evaluation of Barriers to Postpartum Care in HIV Infected Women|Evaluation of Barriers to Postpartum Care in HIV Infected Women||The University of Texas Health Science Center, Houston|No|Completed|January 2012|November 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Female|18 Years|65 Years|No|Non-Probability Sample|HIV infected pregnant women|December 2014|December 2, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01853917||66465|
NCT01853930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0849-R|Translation of Eye Movement Reading Training to Clinical Practice|Translation of Eye Movement Reading Training to Clinical Practice||VA Office of Research and Development|No|Recruiting|January 2014|June 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|55 Years|N/A|No|||February 2016|February 4, 2016|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01853930||66464|
NCT01854203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiECRCT-2013003|Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC|Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma|NPC|Sun Yat-sen University|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||July 2013|July 28, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01854203||66443|
NCT01854723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-029B|Comparison Study of Insulin Glargine and NPH Insulin|Basal Insulin Therapy in Patients With Insulin Resistance: A 6 Month Comparison of Insulin Glargine and NPH Insulin||Providence Health & Services|No|Enrolling by invitation|April 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|N/A|85 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854723||66403|
NCT01855230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM-024/II/STA-04|Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)||Asmacure Ltée|Yes|Completed|August 2013|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|N/A|No|||December 2014|December 15, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01855230||66364|
NCT01855490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201009520|Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes|A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta ®) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes||Yale University|No|Recruiting|January 2012|October 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|56 Years|No|||May 2013|May 15, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01855490||66344|
NCT01855009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066|Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program|A Comparative Effectiveness Research Study Comparing Changes in Body Composition and Parent Ratings of Quality of Life in 5-19 Year Olds as a Function of Participation in One of Four Versions of the Good NEWS 4 Kids Program (GN4K)||Integrative Health Technologies, Inc.|No|Recruiting|May 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|200|||Both|5 Years|19 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01855009||66381|
NCT01855269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/Feb 2012|Lactobacillus Reuteri Versus Herbal Drop in the Treatment of Infantile Colic: a Prospective Study|A Prospective Randomized Controlled Study: Lactobacillus Reuteri Versus Herbal Drop in the Treatment of Infantile Colic||Dr. Sami Ulus Children's Hospital|Yes|Completed|April 2012|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|74|||Both|N/A|3 Months|No|||May 2013|May 15, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855269||66361|
NCT01855516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2013-001|Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin|Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin: Comparison of a 2 Times Per Day Versus a 3 Times Per Day Dosage.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855516||66342|
NCT01822808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-AHEF|Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure|A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction|B-AHEF|University of Cape Town|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822808||68844|
NCT01822821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-269|Pain Control After Cardiac Surgery Using Intravenous Acetaminophen|||The Cleveland Clinic|No|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|80 Years|No|||October 2015|October 7, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822821||68843|
NCT01823627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-322|Pulmonary Disease in a Psychiatric Inpatient Population|Pulmonary Disease in a Psychiatric Inpatient Population, a Screening Study||Psykiatrien Syd|No|Enrolling by invitation|March 2013|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|All inpatients in the general psychiatric wards in Psyciatrien Syd, Region Zealand|April 2013|April 2, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01823627||68781|
NCT01823887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01|Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study|Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study|ANTHEM-HF|Cyberonics, Inc.|Yes|Completed|July 2012|June 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823887||68761|
NCT01823900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWJ1276|Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers|A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers||Severance Hospital||Completed|January 2012|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01823900||68760|
NCT01824121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032011|Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism|Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|40 Years|N/A|No|||March 2013|March 31, 2013|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01824121||68743|
NCT01852825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8237-009|MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)|A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis||Merck Sharp & Dohme Corp.|No|Completed|November 2013|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|May 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852825||66549|
NCT01853085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/038|A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons|||Allergan|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1830|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open-angle glaucoma or ocular hypertension|May 2015|May 12, 2015|May 10, 2013|Yes|Yes||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01853085||66529|
NCT01852851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03527|Employment and Arthritis: Making it Work|Employment and Arthritis: Making it Work: A Randomized Controlled Trial Evaluating an On-line Program to Help People With Inflammatory Arthritis Remain Employed|MIW|University of British Columbia|No|Recruiting|June 2013|June 2023|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|526|||Both|18 Years|59 Years|No|||February 2015|February 3, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01852851||66547|
NCT01853358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLI-NK/IPC 2012-003|Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation|Phase I of Infusion of Selected Donor NK Cells After HLA Identical Allogeneic Stem Cell Transplantation Prepared With Reduced Intensity Conditioning - DLI-NK/IPC 2012-003|DLI-NK|Institut Paoli-Calmettes|Yes|Recruiting|April 2013|March 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|70 Years|No|||March 2016|March 4, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01853358||66508|
NCT01853397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-137-LP-H|Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method|An Evaluation of the Safety and Effectiveness of Treatment of Adipose Tissue With the Liposonix System (Model 2) Using a New Treatment Method||Valeant Pharmaceuticals|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|May 8, 2013|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01853397||66505|
NCT01853657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCS|Kumasi Cohort Study|Efficacy of First and Second Line ART in HIV Patients Treated at the Komfo Anokye Teaching Hospital, Kumasi|KCS|Bernhard Nocht Institute for Tropical Medicine|No|Active, not recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3000|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01853657||66485|
NCT01853683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/02E|Is Interval Appendectomy Necessary?|Interval Appendectomy in Children, is it Really Necessary? A Randomized, Noninferiority Trial||Children's Hospital of Eastern Ontario|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|18 Years|No|||September 2015|September 23, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01853683||66483|
NCT01853943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pertini-02|Hand Grip Test and Transradial Coronary Procedures|Hand Grip Test After Transradial Percutaneous Coronary Procedures|HANGAR|Ospedale Sandro Pertini, Roma|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|107|||Both|18 Years|N/A|No|Non-Probability Sample|Stable patients who undergo elective percutaneous transradial coronary procedures|March 2015|March 2, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853943||66463|
NCT01853956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116937|Bioequivalence Trial of Alprazolam 0.25 mg Tablets|Open,Two-period, Two-treatment, Two-sequence, Cross-over, Randomized Trial of Single Doses of Two Oral Preparations With 0.25 mg of Alprazolam (Zamoprax® GlaxoSmithKline México, S.A. de C.V. vs. Tafil® 0.25mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01853956||66462|
NCT01826162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-079|Short Chain Fatty Acid Metabolism and Energy Metabolism|The Effects of Differential Short Chain Fatty Acid Availability on Human Substrate and Energy Metabolism||Maastricht University Medical Center|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2013|September 14, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01826162||68587|
NCT01854216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0718|Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects|Parallel Group Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Repeated Dose Treatment With Rotigotine Continuous Delivery System (5 cm^2/2.25 mg, 10 cm^2/4.5 mg, 20 cm^2/9 mg) in Japanese and Caucasian Healthy Subjects||UCB Pharma|No|Completed|December 2002|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|October 17, 2014|May 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01854216||66442|
NCT01854424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11026|Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS|Involvement of Fibrocytes in Repair Processes During Acute Respiratory Distress Syndrome (Validation Study-2)|IFRA2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|84|Samples With DNA|Patients or relatives will be informed of the study. The samples (Bronchoalveolar lavage      fluid -BALF-and blood samples) will be obtained in current care and stored in an authorized      center of biological resources (CRB Bichat- DC 2009-940)|Both|18 Years|N/A|No|Non-Probability Sample|Mechanically Ventilated patients after Sepsis, infectious pneumonia, trauma or        postoperative complications.|December 2015|December 21, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854424||66426|
NCT01854437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1391|The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients|||Shiraz University of Medical Sciences|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 1|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|hemodialysis patients|May 2013|May 12, 2013|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01854437|4 Months|66425|
NCT01854450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120902|Evaluation of Asymmetrical Lateral Decubitus for Rotation of Occipitoposterior Fetal Position|Evaluation of Asymmetrical Lateral Decubitus for Rotation of Occipitoposterior Fetal Position During Labor : EVADELA Multicentre Randomized Trial|EVADELA|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2013|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Female|18 Years|N/A|No|||May 2015|May 19, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854450||66424|
NCT01854736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-24|Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate|Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate||ALK-Abelló A/S|No|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01854736||66402|
NCT01855022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2AIT16621-B|A Trial to Reduce Readmissions Using Motivational Interviewing and Interactive Voice Response|A Hospital-based Intervention Using Motivational Interviewing and Interactive Voice Response to Reduce Readmissions in Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial||Asante Health System|No|Completed|June 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|512|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01855022||66380|
NCT01855035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Find-AF randomised|Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring|A Prospective, Randomised, Controlled Study to Determine the Detection of Atrial Fibrillation by Prolonged and Enhanced Holter Monitoring as Compared to Usual Care in Stroke Patients||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Active, not recruiting|May 2013|November 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|60 Years|N/A|No|||September 2014|September 18, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01855035||66379|
NCT01823146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39-2013|Oxytocin's Effect on Socioemotional Aging|Oxytocin and Aging: Neuro-Behavioral Effects on Social Cognition and Prosocial Behavior||University of Florida|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|106|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 25, 2013|Yes|Yes||No|June 24, 2015|https://clinicaltrials.gov/show/NCT01823146||68818|
NCT01825031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN43622374|Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy|Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial|REALITY|Medical Research Council|Yes|Active, not recruiting|June 2013|March 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1800|||Both|5 Years|N/A|No|||May 2015|May 21, 2015|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01825031||68673|
NCT01825044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.001|Copenhagen Head Injury Ciclosporin (CHIC) Study|An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT® (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)|CHIC|NeuroVive Pharmaceutical AB|Yes|Recruiting|April 2013|April 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||November 2015|November 23, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01825044||68672|
NCT01825057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034243|Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units|Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|1200|||Both|18 Years|100 Years|No|||October 2015|October 5, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01825057||68671|
NCT01823341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO4|Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children|Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children|PSO4|In Home Closed Loop Study Group|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|97|||Both|3 Years|14 Years|No|||August 2015|August 31, 2015|March 29, 2013|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01823341||68803|Only selected participants prone to nocturnal hypoglycemia and only tested one continuous glucose sensor. Participants didn't know if system was active before activation so could not observe what would happen if the participants knew it was.
NCT01823640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHRVI|Experimental Human Rhinovirus Infection|Experimental Human Rhinovirus Infection, a Randomized Placebo-controlled Pilot Study|EHRVI|Radboud University|Yes|Completed|March 2013|June 2014|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|March 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823640||68780|
NCT01823913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0081|Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers|||Severance Hospital||Completed|July 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01823913||68759|
NCT01824147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/13|ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry|ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry||Goethe University|No|Completed|August 2013|August 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|Patients following cardiac surgery and a antiaggregatory therapy with aspirin|February 2016|February 23, 2016|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01824147||68741|
NCT01852617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U48DP001948-01|A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay|A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay||Institute for Clinical Effectiveness and Health Policy|No|Completed|October 2011|August 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6858|||Female|12 Years|49 Years|No|||January 2015|January 29, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01852617||66565|
NCT01852643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390548|Spreader Graft and Lateral Crural Overlay Technique in Rhinoplasty|Determine and Compare the Finding of Rhinomanometry Before and After Treatment in Two Ways of Rhinoplasty Surgery (Spreader Graft and Lateral Crural Over Lapping)||Isfahan University of Medical Sciences|No|Completed|February 2012|December 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||May 2013|May 13, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852643||66563|
NCT01852864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H0311/2|Degarelix Before Radical Prostatectomy|A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy||University of Cambridge|No|Recruiting|July 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Male|18 Years|80 Years|No|||December 2014|December 15, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01852864||66546|
NCT01853111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001539|Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants|Biomarker-guided Withdrawal of Immunosuppression in Recipients of Vascularized Composite Tissue Transplants||Brigham and Women's Hospital|No|Recruiting|March 2014|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853111||66527|
NCT01853150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-022|Repetitive Transcranial Magnetic Stimulation for Freezing of Gait|Repetitive Transcranial Magnetic Stimulation for Freezing of Gait||Dongtan Sacred Heart Hospital|No|Recruiting|April 2013|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||August 2015|August 3, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853150||66524|
NCT01853163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-Gd64/001|Long-Term Retention of Gadolinium in Bone|Exploratory Evaluation of the Potential for Long-term Retention of Gadolinium in the Bones of Patients Who Have Received Gadolinium Based Contrast Agents According to Their Medical History||Ecron Acunova GmbH|No|Recruiting|May 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|350|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853163||66523|
NCT01853176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064693|Exparel vs. Standard Bupivicaine for Abdominoplasty|Is Liposomal Injection Bupivacaine (Exparel) Superior to Standard Bupivacaine for Abdominoplasty? A Randomized Controlled Trial||Emory University|No|Terminated|May 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|May 10, 2013|Yes|Yes|required documentation too onerous|No|October 29, 2014|https://clinicaltrials.gov/show/NCT01853176||66522|Trial terminated prior to any meaningful patient accrual so no analysis performed.
NCT01853670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167-08|Adaptive Radiation Therapy for Head & Neck Cancer Patients|Kilovoltage Conebeam Imaging Based Adaptive Radiation Therapy for Head & Neck Patients Treated With Intensity Modulated Radiation Therapy|IGRT|Beth Israel Medical Center|No|Completed|August 2009|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||September 2014|March 27, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01853670||66484|
NCT01825850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GBCL001|Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects||LG Life Sciences|No|Completed|June 2013|March 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825850||68610|
NCT01825863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-BDTAP-APP|Ultrasound-guided Abdominal Wall Nerve Blockade in Laparoscopic Surgery for Acute Appendicitis.|Optimal Postoperative Pain Management by Ultrasound-guided Abdominal Wall Nerve Blockade in Laparoscopic Surgery for Acute Appendicitis - a Randomised Controlled Trial.|BD-TAP APP|Bispebjerg Hospital|Yes|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01825863||68609|
NCT01826175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000225|Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study|Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study||Massachusetts General Hospital||Terminated|May 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|47|||Both|18 Years|79 Years|No|||June 2014|June 27, 2014|April 1, 2013|Yes|Yes|The study was terminated mutually by the sponsor and PI due to extremely low enrollment over    the past year.|No||https://clinicaltrials.gov/show/NCT01826175||68586|
NCT01822158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS PSPH N 002|Vaginal Delivery Debrief Checklist to Improve Team Communication|Vaginal Delivery Debrief: A Nursing Research Study|VDD|Providence Health & Services|No|Enrolling by invitation|May 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01822158||68894|
NCT01822132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALKIIT-KOR-034|Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade|Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade||Oregon Health and Science University|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|62|||Both|18 Years|55 Years|No|||April 2015|April 24, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01822132||68896|
NCT01822145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICTICDS01|A Feasibility Study on Prediction of an ICD Shock by ICD-derived Data|PREDICTion of Implantable-Cardioverter Defibrillator Shock Study|PREDICT-ICDS|Princess Margaret Hospital, Hong Kong|No|Recruiting|March 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|ICD recipients with documented cardiac arrest, ventricular tachycardia or ventricular        fibrillation|September 2015|September 3, 2015|March 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822145||68895|
NCT01854463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSHH2011-64|The Effect of Vitamin D Supplementation in Type 2 Diabetes|The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes|VD2000|Chuncheon Sacred Heart Hospital|Yes|Completed|December 2011|February 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|30 Years|69 Years|No|||May 2013|May 9, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01854463||66423|
NCT01854749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1- ESCC -CJH|S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study|S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study||Fudan University|Yes|Completed|November 2011|||December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01854749||66401|
NCT01854762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PregnantHIV|Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection|Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study|PregnantHIV|Fundação Bahiana de Infectologia|No|Recruiting|March 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||March 2015|March 5, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01854762||66400|
NCT01822899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116134|A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD||GlaxoSmithKline|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|717|||Both|40 Years|N/A|No|||April 2014|May 1, 2014|March 28, 2013|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01822899||68837|
NCT01823393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9026|Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure|Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure|HEPAVALV|University Hospital, Montpellier|No|Recruiting|January 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823393||68799|
NCT01823679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0016|Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin|A Phase II Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin||Stanford University||Terminated|March 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|March 29, 2013|Yes|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT01823679||68777|
NCT01825382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMOTE-T1D|Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study|Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study|REMOTE-T1D|University of Colorado Denver School of Medicine Barbara Davis Center|Yes|Completed|December 2012|November 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01825382||68646|
NCT01823354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8964|Executive Dysfunction in Restless Legs Syndrome: Clinical Correlates and Outcome After Therapeutic Management|Executive Dysfunction in Restless Legs Syndrome: Determination of Clinical Correlates and Outcome After Therapeutic Management||University Hospital, Montpellier|Yes|Recruiting|November 2012|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|140|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||March 2013|April 2, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01823354||68802|
NCT01823926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|valdecirtese2|Asthma and Quantifying Delivery Of Radio Labeled Aerosol|Quantifying Delivery Of Radio Labeled Aerosol During Noninvasive Ventilation To Stable Moderate And Severe Asthmatics: A Randomized, Cross-Over Clinical Trial||Universidade Federal de Pernambuco|Yes|Completed|October 2011|August 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|60 Years|No|||December 2012|March 30, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01823926||68758|
NCT01824160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120188|Pulmonary Artery Repair With Covered Stents|Pulmonary Artery Repair With Covered Stents|PARCS|Johns Hopkins University|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|7 Years|75 Years|No|||February 2016|February 15, 2016|April 1, 2013|No|Yes||No|February 15, 2016|https://clinicaltrials.gov/show/NCT01824160||68740|
NCT01852630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS- SBP-01|Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure|A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.||Institute of Liver and Biliary Sciences, India|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2013|May 23, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01852630||66564|
NCT01852656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12010936|Effectiveness of Influenza Vaccine Reminder Systems|The Effectiveness and Cost of Different Methods of Reminders for Annual Influenza Immunization Among Adults With Asthma and Chronic Obstructive Pulmonary Disease||Kaiser Permanente|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|12255|||Both|19 Years|64 Years|No|||May 2013|May 9, 2013|October 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01852656||66562|
NCT01853124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0045|Emergency Department Probiotic Treatment of Pediatric Gastroenteritis|Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial||University of Calgary|Yes|Recruiting|October 2013|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|886|||Both|3 Months|48 Months|No|||December 2014|December 1, 2014|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853124||66526|
NCT01853384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-032|Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers|A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU)||Healthpoint|Yes|Terminated|November 2013|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|May 8, 2013|Yes|Yes|based on outcome of trial NCT01656889.|No||https://clinicaltrials.gov/show/NCT01853384||66506|
NCT01853189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAsPed-1|Effectiveness of Osteopathic Manipulative Treatment in Pediatric Asthma||OMT|European Institute for Evidence Based Osteopathic Medicine|No|Not yet recruiting|November 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|5 Years|14 Years|No|||April 2014|April 24, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853189||66521|
NCT01825330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX - US4|Effect of NeuroAD on the Cognitive Function of Alzheimer Patients|Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients||Neuronix Ltd|No|Active, not recruiting|October 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|60 Years|90 Years|No|||October 2015|October 8, 2015|March 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825330||68650|
NCT01853410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103661|Peripheral Stimulation Device to Improve Coronary Flow Reserve in Coronary Artery Disease|Peripheral Stimulation Device to Improve Coronary Flow Reserve in Coronary Artery Disease|PERCCAD|Lawson Health Research Institute|No|Completed|July 2013|October 2015|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01853410||66504|
NCT01853423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC TSC01|Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream|Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream||Le Bonheur Children's Hospital|No|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|3 Years|45 Years|No|||September 2015|September 2, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853423||66503|
NCT01826188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0196-12-MMC|Combined THC and CBD Drops for Treatment of Crohn's Disease|Combined THC and CBD Drops for Treatment of Crohn's Disease, a Phase II Double Blind Placebo Controlled Trial||Meir Medical Center|No|Recruiting|March 2013|||March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|85 Years|No|||April 2013|February 23, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826188||68585|
NCT01822171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSPH-002-Pharm|Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients|Multi-Disciplinary Discharge Counseling and MTM Services After Discharge for Heart Failure Patients|MTM|Providence Health & Services|No|Terminated|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|January 7, 2013||No|Unable to enroll and study intended patient population.|No||https://clinicaltrials.gov/show/NCT01822171||68893|
NCT01822392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108008914|On-line Treatment for Conduct Problems|||Yale University|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|6 Years|12 Years|No|||February 2015|February 4, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01822392||68876|
NCT01822379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #6121|Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo|Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo||Henry Ford Health System|Yes|Withdrawn|May 2010|July 2012|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||March 2013|March 27, 2013|May 12, 2010||No|This study was never initiated.|No||https://clinicaltrials.gov/show/NCT01822379||68877|
NCT01822587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21392|Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving|Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity and Use||Medical University of South Carolina|Yes|Recruiting|September 2013|||June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822587||68861|
NCT01822886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_GEMRO|Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients.|Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients.|FIL_GEMRO|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|January 2013|September 2017|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822886||68838|
NCT01823159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERETI|Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study|Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study|CERETI|University Hospital of Mont-Godinne|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01823159||68817|
NCT01824212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCHAne001|Recognizing Ventricular Fibrillation From an Area of a Mobile Phone|Recognizing Ventricular Fibrillation From an Area of a Mobile Phone||North Karelia Central Hospital|No|Completed|November 2013|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with severe dysrhytmia and the necessity to an implantable cardioverter        defibrillator (ICD)|March 2016|March 22, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01824212||68736|
NCT01855373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL049|Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements|A Randomized, Double-blind, Placebo-controlled Study Comparing the Healthy Levels of Blood Sugar and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplementation Versus Placebo||Supplement Formulators, Inc.|No|Active, not recruiting|July 2012|January 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Anticipated|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855373||66353|
NCT01823653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-130-LP-H|Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound|A Study to Investigate the Safety and Efficacy of Treatment of Subcutaneous Adipose Tissue in the Thighs Using the Liposonix System (Model 2)||Valeant Pharmaceuticals|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|March 29, 2013|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01823653||68779|
NCT01833325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1206-EY01|Proton Radiation Therapy for Macular Degeneration|A Pilot Study to Assess the Safety of Proton Therapy for Subfoveal Neovascularization Associated With Age-Related Macular Degeneration||University of Florida|Yes|Recruiting|May 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|N/A|No|||March 2016|March 3, 2016|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833325||68041|
NCT01833611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETV HR-96-23|Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT|Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase||National Cheng-Kung University Hospital|Yes|Active, not recruiting|September 2008|May 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||April 2013|April 14, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01833611||68019|
NCT01852370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOLT+BMT|Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases|Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors|BOLT+BMT|University of Pittsburgh|Yes|Recruiting|June 2013|August 2022|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|5 Years|40 Years|No|||December 2015|December 1, 2015|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852370||66584|
NCT01824719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-5-6-1|A Registry Study on Reduning（a Chinese Medicine Injection）Used in Hospitals in China|a Study of Clinical Safety Monitoring and the Mechanism of Anaphylactic Reaction Used Reduning(a Chinese Medicine Injection)in Hospitals in China||China Academy of Chinese Medical Sciences|Yes|Recruiting|January 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|3000|||Both|1 Month|80 Years|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 3000 Patients using Reduning        injection from January to March 2013 in hospitals.|April 2013|April 2, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01824719|15 Days|68697|
NCT01852877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA030796|Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois|Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois||University of Illinois at Chicago||Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Blood serum|Both|18 Years|N/A|No|Non-Probability Sample|Detainees in Cook County Jail, prisoners in the Illinois Department of Corrections|June 2015|June 30, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852877||66545|
NCT01853137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAMA-18-2-2013|Fixed Lingual Mandibular Growth Modificator|A Prospective Controlled Evaluation of Class II Division 1 Malocclusions Treated With Fixed Lingual Mandibular Growth Modificator (FLMGM)|FLMGM|Damascus University|No|Completed|May 2009|December 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|11 Years|16 Years|No|||May 2013|May 10, 2013|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853137||66525|
NCT01825616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_0355|Vitamin D2, Muscle Damage, NASCAR Pitcrew|Influence of 6-weeks Supplementation With Vitamin D Portobello Mushroom Powder on Muscle Function and Performance, Innate Immune Function, and Exercise-induced Muscle Damage and DOMS in NASCAR Pit Crew Members||Appalachian State University|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|33|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825616||68628|
NCT01826201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-02|Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis|A Phase 2a, Randomized, Blinded, Paired Psoriasis Lesion, Comparative, Placebo-controlled Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Epidermal Administrations of MOL4239 in Adults With Plaque Psoriasis||Moleculin, LLC|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|72 Years|No|||December 2014|December 22, 2014|March 21, 2013|Yes|Yes||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01826201||68584|
NCT01825603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470-12|ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery|A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers||University of Nebraska|Yes|Recruiting|April 2013|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|19 Years|N/A|No|||May 2013|May 7, 2013|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825603||68629|
NCT01822405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT-OXI-2009|Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen|Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen|ORT-OXI-2009|Hospital Universitario de Canarias||Recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01822405||68875|
NCT01822613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJM716X2103|Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)|A Phase Ib/II, Open-label Study of LJM716 in Combination With BYL719 Compared to Taxane or Irinotecan in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)||Novartis|No|Active, not recruiting|July 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822613||68859|
NCT01822938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12006 / TICAA'DOM|Follow-up of Patients' Physical Activity in Post-hospitalization|Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring.|TICAA'DOM|University Hospital, Limoges|No|Recruiting|March 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|84|||Both|18 Years|N/A|No|||December 2012|March 19, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822938||68834|
NCT01823172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009929|Second Echelon Node Study With Methylene Blue|Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue||Mayo Clinic|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01823172||68816|
NCT01822600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER-98-239|The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia|The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood||National Cheng-Kung University Hospital|Yes|Completed|January 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|91|||Both|39 Years|83 Years|No|||March 2013|March 27, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01822600||68860|
NCT01822912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0006|Heart Failure Management Program Versus Usual Care|Evaluation of a Skilled Nursing Facility Heart Failure Disease Management Program Versus Usual Care||University of Colorado, Denver|No|Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1400|||Both|N/A|N/A|No|||March 2016|March 23, 2016|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01822912||68836|
NCT01822925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9801-DN-001|Study of DA-9801 to Treat Diabetic Neuropathy|A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy||Dong-A ST Co., Ltd.|Yes|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|128|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01822925||68835|
NCT01823991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17089|COGNUTRIN in Breast Cancer Survivors|Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|40 Years|70 Years|No|||March 2016|March 3, 2016|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823991||68753|
NCT01824758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESM 0538|Effect of Esmolol on Pain Due to Rocuronium|The Effect of Esmolol on Pain Due to Rocuronium Injection Pain||Etlik Zubeyde Hanim Womens' Health and Teaching Hospital|Yes|Not yet recruiting|April 2013|May 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2013|April 4, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824758||68694|
NCT01825070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE10-01-12554|Montmorency Cherry Juice and Uric Acid Metabolism|The Influence of Tart Montmorency Cherries on Indices of Uric Acid Metabolism||Northumbria University|Yes|Completed|March 2012|March 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01825070||68670|
NCT01825083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00068533|The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl|The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl||Northwestern University|No|Withdrawn||March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|64 Years|No|||May 2014|May 7, 2014|January 31, 2013||No|Change in personnel|No||https://clinicaltrials.gov/show/NCT01825083||68669|
NCT01855152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant RP-PG-0608|Improving Well-being and Health for People With Dementia|An Optimized Person Centred Intervention to Improve Quality of Life for People With Dementia Living in Care Homes. A Cluster Randomized Controlled Trial.|WHELD|King's College London|Yes|Not yet recruiting|August 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|N/A|N/A|No|||May 2013|May 13, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855152||66370|
NCT01833013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9113|Infertility and Endometriosis Cohort|Infertility and Endometriosis : a Prospective Cohort Study|EndoFertil|University Hospital, Montpellier|No|Recruiting|April 2013|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Female|18 Years|41 Years|No|||April 2013|January 8, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833013||68065|
NCT01833312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuroHYP-1|Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke|EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke|EuroHYP-1|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|July 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01833312||68042|
NCT01833338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METcUMCG 2010.266|Non-invasive and Invasive Plaque Characterisation|Coronary Artery Plaque Characterisation With Non-invasive Multi-Slice Computed Tomography and Invasive Intravascular Ultrasound and Optical Coherence Tomography in Patients With Acute Coronary Syndromes Without ST-segment Elevation||University Medical Center Groningen|No|Terminated|June 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|March 4, 2013||No|The study was terminated based on an included stopping rule in the study protocol|No||https://clinicaltrials.gov/show/NCT01833338||68040|
NCT01833351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12680|Evaluation of Intravenous Ascorbic Acid|Pharmacokinetic Evaluation of Intravenous Ascorbic Acid||University of Kansas Medical Center|Yes|Completed|May 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833351||68039|
NCT01833624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00078-35|Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula|Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial|NUTRI_REA|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|June 2012|November 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833624||68018|
NCT01852383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6143R|Duloxetine Treatment in Elderly With Dysthymia|An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder||New York State Psychiatric Institute|Yes|Completed|January 2006|March 2013|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|60 Years|95 Years|No|||February 2014|April 1, 2014|May 8, 2013|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT01852383||66583|
NCT01825629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-321-15/03/2013|Multidisciplinary Therapy in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome|Benefits of a Multidisciplinary Therapy in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome: a Randomized Clinical Trial||Universidad de Almeria|No|Completed|April 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|65 Years|No|||December 2013|December 9, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01825629||68627|
NCT01852890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310772|Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I|Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I||University of Iowa|Yes|Recruiting|January 2014|February 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852890||66544|
NCT01852903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11CIHE|Comparative Bioavailability of Two Forms of Vitamin C|A Randomized, Double-blind, Placebo-controlled Crossover Study Comparing the Bioavailability of Two Forms of Vitamin C in Plasma and Leukocytes Over 24 Hours.||NBTY, Inc.||Completed|May 2011|||July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|40|||Both|18 Years|60 Years||||May 2013|May 9, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852903||66543|
NCT01852916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013: 040|NHFOV Versus NCPAP to Prevent Exubation Failure|Nasal High Frequency Oscillatory Ventilation (NHFOV) Versus Nasal Continuous Positive Airway Pressure (NCPAP) Ventilation: a Pilot Trial||University of Manitoba|No|Suspended|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|7 Days|No|||August 2015|August 3, 2015|April 17, 2013||No|Poor recruitment rate|No||https://clinicaltrials.gov/show/NCT01852916||66542|
NCT01826214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2203|Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia|A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia||Novartis|Yes|Completed|May 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826214||68583|
NCT01825876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14616|A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects||Eli Lilly and Company|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|April 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825876||68608|
NCT01825889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14620|A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants|Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function||Eli Lilly and Company|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|April 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825889||68607|
NCT01823419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1401|Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds|Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds||University of North Carolina, Chapel Hill|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|70|None Retained|No biospecimens will be collected.|Both|7 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|7-9 year olds|March 2013|March 29, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01823419||68797|
NCT01823432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAV_Risks|Genetic Risks for Bicuspid Aortic Valve Disease|Genetic Risks for Bicuspid Aortic Valve Disease||The University of Texas Health Science Center, Houston|No|Recruiting|March 2012|||November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|400|Samples With DNA|Genomic DNA from whole blood Genomic DNA from saliva Aortic valve tissue preserved in      RNALater|Both|18 Years|N/A|No|Non-Probability Sample|Adults at least 18 years old with unicuspid or bicuspid aortic valves|November 2015|November 30, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01823432|10 Years|68796|
NCT01823718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/7-M|Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes|||Nantes University Hospital|Yes|Active, not recruiting|February 2007|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|12 Months|N/A|No|||March 2013|November 14, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823718||68774|
NCT01824004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHH-MO-03|Postoperative Chemoradiotherapy With S-1 in Gastric Cancer|A Phase II Study of Adjuvant S-1/Cisplatin Chemotherapy Followed by S-1-based Chemoradiotherapy in Advanced Gastric Cancer||Chonnam National University Hospital|Yes|Completed|April 2009|June 2012|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|19 Years|N/A|No|||April 2013|April 3, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824004||68752|
NCT01823406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00060967|Tissue-Specific Metabolic Reprogramming in Diabetic Complications|Tissue-Specific Metabolic Reprogramming in Diabetic Complications. Glycemic Clamp Studies to Determine the Real Time Synthesis Rates of Glucose Derived Metabolites in Individuals With Type 1 Diabetes and Healthy Controls.|DP3|University of Michigan|No|Recruiting|May 2012|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01823406||68798|
NCT01824225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NihonU-2|Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration|Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration||Nihon University|No|Completed|March 2013|March 2015|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||October 2015|October 5, 2015|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01824225||68735|
NCT01823705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exilis-1|Gastric Electrical Stimulation (GES) for the Treatment of Obesity|Gastric Electrical Stimulation (GES) for the Treatment of Obesity|GES|Medtronic Corporate Technologies and New Ventures|Yes|Active, not recruiting|March 2013|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|64 Years|No|||September 2015|September 9, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823705||68775|
NCT01824771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013232|Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients|||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|75 Years|No|Probability Sample|This study was carried out in Surgical Intensive Care Unit (SICU) of the first affiliated        hospital, Sun Yat-sen University.The project has been approved by Ethics Committee of Sun        Yat-sen University. All the subjects have signed written informed consent.|March 2015|March 5, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824771|1 Day|68693|
NCT01824784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-03273|TopQ Cut-Off Determination Study|TopQ Cut-off Determination Study||Topcon Medical Systems, Inc.|No|Completed|February 2013|November 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sujects that have no known ocular pathologies|October 2014|October 21, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824784||68692|
NCT01825408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2377|Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis|A Randomized Cohort Trial Evaluating Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis||University of North Carolina, Chapel Hill|No|Recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|March 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825408||68644|
NCT01855139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16851|Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism|Belgian Real Life Non-interventional Study (NIS) on Xarelto® in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)|BOX-AF|Bayer|No|Completed|July 2013|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory or hospitalized patients coming from the cardiology clinic of the participating        hospitals|December 2015|December 14, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855139||66371|
NCT01855412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-0001-P|Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes|LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD)|LIBERTY|Cardiovascular Systems Inc|No|Active, not recruiting|May 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1204|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been determined by their physician to require endovascular device        treatment for their PAD.|December 2015|February 3, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01855412||66350|
NCT01833026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0997|COPD Assessment and Management Bundle Versus Usual Care|Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD||University of Illinois at Chicago|No|Active, not recruiting|March 2013|December 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|122|||Both|40 Years|N/A|No|||December 2015|December 4, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833026||68064|
NCT01833039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101862|An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma||Janssen Biotech, Inc.|No|Active, not recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833039||68063|
NCT01833910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816764|A Mannequin Study to Assess Various CPR Training Methods Using a Student Population|A Mannequin Study to Assess Various CPR Training Methods Using a Student Population||University of Pennsylvania|No|Completed|October 2012|October 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|December 8, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833910||67996|
NCT01824732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-5-6-2|A Registry Study on Tanreqing（a Chinese Medicine Injection）Used in Hospitals in China|a Study of Clinical Safety Monitoring and the Mechanism of Anaphylactic Reaction Used Tanreqing(a Chinese Medicine Injection)in Hospitals in China||China Academy of Chinese Medical Sciences|Yes|Recruiting|January 2013|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|3000|||Both|1 Month|80 Years|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 3000 Patients using        Tanreqing injection from January to March 2013 in hospitals.|April 2013|April 2, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01824732|15 Days|68696|
NCT01825005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4-008|Predicting Outcome in Cervix Carcinoma: a Prospective Study|Predicting Outcome in Cervix Carcinoma: a Prospective Study|POCER|Maastricht Radiation Oncology|Yes|Suspended|February 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|90|||Female|18 Years|N/A|No|Non-Probability Sample|All patients with cervical cancer can be included in the study.|December 2014|January 27, 2016|March 12, 2013||No|logistics|No||https://clinicaltrials.gov/show/NCT01825005|5 Years|68675|
NCT01824472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814153|Understanding the Sleep Apnea/Insomnia Interaction|Understanding the Sleep Apnea/Insomnia Interaction: a CPAP/Sham-CPAP Trial||University of Pennsylvania|Yes|Recruiting|March 2013|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824472||68716|
NCT01824485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0199/11|Comparison of Two Application Regimens for Viscosupplementation|Best Effect of Viscosupplementation With Hyaluronic Acid and Triamcinolone in Patients With Knee Osteoarthritis. Prospective Randomized Study Between Two Different Applications Regimens||University of Sao Paulo General Hospital|Yes|Completed|March 2013|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|40 Years|N/A|No|||September 2013|January 5, 2015|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01824485||68715|
NCT01822197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00044|Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients|Pilot Trial of Phototherapy for Acute Depression in Hospitalized CF Patients|PHOTO|Nationwide Children's Hospital|No|Completed|March 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|N/A|No|||June 2015|June 15, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822197||68891|
NCT01824992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeesPharm_RHI|Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections|a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection||Lee's Pharmaceutical Limited||Completed|March 2011|September 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Female|30 Years|65 Years|No|||April 2013|April 4, 2013|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01824992||68676|
NCT01822951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVE-AT-0412|Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)|Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease|DAT|Ever Neuro Pharma GmbH|Yes|Withdrawn||December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||October 2015|October 23, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01822951||68833|
NCT01822184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-090|Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)|A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)||Shire|No|Active, not recruiting|January 2013|March 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Genotyping of the iduronate-2-sulfatase gene will be required ONLY for those patients who      have not had a previous genotyping sample analysis performed at the selected diagnostic      laboratory.|Male|2 Years|18 Years|No|Probability Sample|Male MPS II patients between 2<18 years of age at time of informed consent|May 2015|May 13, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01822184||68892|
NCT01822964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCCTAVI-II|Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II|||Hasselt University|Yes|Recruiting|March 2013|December 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|N/A|N/A|No|||March 2013|April 2, 2013|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01822964||68832|
NCT01822977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000180|The Impact of Proton Pump Inhibitors on the Fecal Microbiome|The Impact of Proton Pump Inhibitors on the Fecal Microbiome and Their Relationship to Clostridium Difficile Infection||Mayo Clinic|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 18, 2014|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822977||68831|
NCT01823198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0819|Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies|Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies||M.D. Anderson Cancer Center|No|Recruiting|June 2013|||June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|7 Years|65 Years|No|||February 2016|February 23, 2016|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01823198||68814|
NCT01823445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM2013|Xylitol Disk Use in Adults With Dry Mouth|XyliMelts Ability to Reduce Mutans Streptococci in Adults With the Perception of Dry Mouth||University of Washington|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 1, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01823445||68795|
NCT01823458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC4 AG039115 - 03|Behavioral Economics Incentives for Health Management|Evaluation of Behavioral Economics Patient Incentive Strategies for Health Management||University of Southern California|No|Enrolling by invitation|April 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|64 Years|No|||March 2013|March 29, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01823458||68794|
NCT01824238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-050|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)|A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|80 Years|No|||May 2015|May 18, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824238||68734|
NCT01823731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCNCS-13-700|A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index|||National Cancer Center, Korea|Yes|Enrolling by invitation|January 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Female|20 Years|N/A|No|Non-Probability Sample|-  ovarian cancer, tubal cancer, primary peritoneal cancer, mesothelioma, pseudomyxoma             peritonei          -  Debulking operation|June 2013|June 4, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01823731||68773|
NCT01824537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-MOP-125949|Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study|Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples|TRAP-HPV|McGill University|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824537||68711|
NCT01825096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p00622|Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism|Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems||Mclean Hospital|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|12 healthy subjects will be recruited for the study will be recruited from the general        population|April 2015|April 27, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01825096||68668|
NCT01825395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0567|Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome|Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)|3 4-DAP|University of Colorado, Denver||Available|July 2004|March 2050|Anticipated|February 2050|Anticipated|Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 22, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01825395||68645|
NCT01854866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soundny Biotech|Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion|Phase II Study of Tumor Cell-derived Microparticles Used as Vectors of Chemotherapeutic Drugs to Treat Malignant Ascites and Pleural Effusion||Huazhong University of Science and Technology|No|Enrolling by invitation|May 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2013|September 28, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01854866||66392|
NCT01854879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||May 15, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854879||66391|
NCT01855984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-6767|Tocotrienols for School-going Children With ADHD|Tocotrienols Supplementation in School Going Children With Attention Deficit/Hyperactivity Disorder(ADHD) - A Randomized Controlled Trial|TOCAT|Penang Medical College|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Years|12 Years|No|||June 2013|June 13, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01855984||66306|
NCT01833637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00064629|Electronic Patient Reported Symptom Assessment|Electronic Patient Reported Symptom Assessment: A Pilot Study Introducing Advanced Care Planning and Palliative Care to Hospitalized Women With Advanced Gynecologic, Breast, Thoracic, or Gastrointestinal Malignancies.||Northwestern University|Yes|Completed|October 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Female|18 Years|N/A|No|||July 2015|July 13, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01833637||68017|
NCT01833650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-HCS-89|The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer|A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer||Cyprus University of Technology|Yes|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|120|||Both|N/A|N/A|No|||December 2015|December 8, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833650||68016|
NCT01833663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XH-WXK-001|Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women|Multi-site, Randomized, Opened and Controlled Comparison Study on the Effectiveness and Safety of Solifenacin Succinate Tablets and Solifenacin Succinate Tablets + Estrogen for Overactive Bladder in the Post-menopausal Women|OAB|Peking Union Medical College Hospital|Yes|Completed|October 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|75 Years|No|||March 2014|March 19, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833663||68015|
NCT01833923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-I-01|A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics|A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics|ALTN|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Completed|May 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01833923||67995|
NCT01825642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00005063|Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer|Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer||University of Michigan|Yes|Completed|September 2006|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|140|||Male|18 Years|N/A|No|||April 2013|April 1, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01825642||68626|
NCT01825018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00019160|Social Network Intervention to Engage Out-of-Care PLH Into Treatment|Social Network Intervention to Engage Out-of-Care PLH Into Treatment||Medical College of Wisconsin|No|Enrolling by invitation|May 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01825018||68674|
NCT01825343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0005-13|Preventable Paediatric Trauma - Retrospective Analysis|Preventable Paediatric Trauma - Retrospective Analysis||Ziv Hospital|Yes|Active, not recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|None Retained|We are looking retrospectively at data already stored on the hospital database. We have no      human subjects and will only analyse hospital records. We will not be contacting patients.|Both|N/A|18 Years|No|Non-Probability Sample|Identify from the Trauma database all patients assessed at Ziv Medical Centre with Trauma,        consult their medical notes and document the exact injury, the mechanism of injury, the        circumstances, whether the child was alone or supervised, the nature and complications of        the injury, treatment required and short and long term progress and disability.|April 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825343||68649|
NCT01822210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StOlav2205|Botulinum Toxin for Stomach Cancer Treatment|Botulinum Toxin (BOTOX) for Stomach Cancer Treatment||St. Olavs Hospital|Yes|Recruiting|January 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01822210||68890|
NCT01825902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1279|18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma|A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients||Mayo Clinic|Yes|Active, not recruiting|March 2013|||January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|9|||Both|7 Years|N/A|No|||March 2016|March 15, 2016|April 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825902||68606|
NCT01825915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaHoST protocol (v2)|Feasibility of a Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy|Feasibility of a Randomised Controlled Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy|LaHoST|Medway NHS Foundation Trust|No|Active, not recruiting|September 2010|May 2013|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|54 Years|No|||April 2013|April 5, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01825915||68605|
NCT01823185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STGUD005|Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy|Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis||Dammam University|Yes|Recruiting|March 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01823185||68815|
NCT01823744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.07.NIHS|Harmonized Micronutrient Project|A New Strategy to Analyze Gene-Nutrient Interaction in Children and Adolescents||Nestlé|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|146|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01823744||68772|
NCT01824030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6261/13|FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty|FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty|FORZA|Catholic University of the Sacred Heart||Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01824030||68750|
NCT01824277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT2012-53|DCI: A Community Based Pre-cardiac Surgery Diabetes Care Project|Diabetes Cardiac Surgery Initiative (DCI): A Community Based Pre-cardiac Surgery Diabetes Care Project||St. Boniface General Hospital Research Centre|No|Recruiting|October 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01824277||68731|
NCT01824290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10609|A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)|A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension||Eli Lilly and Company|Yes|Recruiting|February 2014|December 2022|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|134|||Both|6 Months|18 Years|No|||February 2016|February 19, 2016|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824290||68730|
NCT01824017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12044|Validation of an RLIP76 Assay in Humans|Validation of RLIP76 Assay and Exploratory Study of RLIP76 Correlation Among Patients With Type 2 Diabetes and Metabolic Syndrome||City of Hope Medical Center|Yes|Active, not recruiting|December 2012|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01824017||68751|
NCT01824251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-09/C-01|Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.|NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.||Nihon Pharmaceutical Co., Ltd|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|100 Years|No|||October 2014|January 17, 2016|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824251||68733|
NCT01824264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIK066A2202|Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes|A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Evaluate Change in HbA1c After 12 Weeks Monotherapy With 7 Doses of LIK066 Compared With Placebo or Sitagliptin in Patients With Type 2 Diabetes||Novartis|No|Withdrawn|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|0|||Both|18 Years|75 Years|No|||April 2014|April 2, 2014|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824264||68732|
NCT01824550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0836|Home Exercise Intervention in Persons With Multiple Sclerosis|Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis|HOMS|University of Illinois at Chicago|Yes|Recruiting|August 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|54|||Both|18 Years|70 Years|No|||June 2015|June 10, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824550||68710|
NCT01854853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6394|Brazilian HIV/Sexually Transmitted Infection (STI) Prevention for Adolescents With Mental Health Disorder|Brazilian HIV/Sexually Transmitted Infection (STI) Prevention for Adolescents With Mental Health||New York State Psychiatric Institute|Yes|Recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|13 Years|24 Years|No|||October 2015|October 5, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01854853||66393|
NCT01855646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044212|Improved Patient Handoffs to Prevent Sentinel Events|Patient Acuity Score With Improved Patient Handoffs to Prevent Sentinel Events||Duke University|No|Completed||January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|4344|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855646||66332|
NCT01855997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV28855|A Study to Collect Blood Biomarker Samples From Patients With Chronic Hepatitis B Who Received Treatment With Pegasys (Peginterferon Alfa-2a) +/- Nucleos(t)Ide Analogue|A Phase 4, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBE-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2A 40KD (PEG-IFN) +/- Nucleos(t)Ide Analogue||Hoffmann-La Roche||Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1398|Samples With DNA|Whole blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B who received therapy with Pegasys +/- nucleos(t)ide        analogue|December 2015|December 1, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01855997||66305|
NCT01833377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT12345678|Effect of Consumption of Caraway on Treatment of Obesity|Caraway Intake as a Sustainable Dietary Practice: Impact on Overweight & Obese Women||University of Malaya|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01833377||68037|
NCT01834742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1006-01/2011 (OUT)|Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects|Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects|OUT|Norgine|No|Completed|April 2011|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|161|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834742||67932|
NCT01834755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-03|Physical and Psychological Profiles Associated With Patient's Preference for ESRD Treatment|Physical and Psychological Evaluation of Patients Reaching End Stage Renal Disease : Effects on the Choice of Renal Replacement Therapy||Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|80|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01834755||67931|
NCT01825941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEDNET3|Diphenhydramine for Acute Migraine|Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.||Montefiore Medical Center|Yes|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|374|||Both|21 Years|64 Years|No|||March 2015|March 19, 2015|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825941||68603|
NCT01825928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100000-068944|An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence|A Multiple-Center, Randomized, Double-Blind Study of Paliperidone Extended-Release Tablets for Treatment of Methamphetamine Dependence||Central South University|Yes|Completed|February 2013|July 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|65 Years|No|||February 2015|February 2, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825928||68604|
NCT01826227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-017|Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer: A Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Female|19 Years|N/A|No|||December 2015|December 17, 2015|April 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826227||68582|
NCT01822678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-203|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|December 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|March 28, 2013||No||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01822678||68854|
NCT01822691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17280|Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)|A Phase II Study to Determine the Safety and Efficacy of INCB024360 in Patients With Myelodysplastic Syndromes||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 2013|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|December 14, 2015|March 28, 2013|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01822691||68853|The study was closed prior to meeting the overall survival criteria.
NCT01822626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|reggioemilia2013|Pediatrician-lead Motivational Counselling to Control BMI in Overweight Children: a RCT in Primary Care|Pediatrician-lead Motivational Counselling to Control BMI in Overweight Children: a RCT in Primary Care||Azienda Unità Sanitaria Locale Reggio Emilia|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|372|||Both|4 Years|7 Years|No|||April 2013|April 2, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822626||68858|
NCT01822639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116798|A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study|An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822639||68857|
NCT01822418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01112012|Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)|Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)|AGOPSYCH|Central Institute of Mental Health, Mannheim|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|60 Years|No|||March 2013|March 27, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01822418||68874|
NCT01822431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-Z0001|A Comparison Between Pupillometry, Heart Rate Variability and Metaiodobenzylguanidine Scintigraphy for the Diagnosis of Early Diabetic Autonomic Neuropathy in Type 1 Diabetes|||AHEPA University Hospital|Yes|Enrolling by invitation|June 2011|||June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|20 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients: outpatient diabetes clinic of AHEPA university hospital Controls: residents of        Thessaloniki area|March 2013|April 1, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01822431||68873|
NCT01822652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31493 GRAIN|3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN|AUTOLOGOUS ACTIVATED T-CELLS TRANSDUCED WITH A 3rd GENERATION GD-2 CHIMERIC ANTIGEN RECEPTOR AND iCASPASE9 SAFETY SWITCH ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA (GRAIN)|GRAIN|Baylor College of Medicine|Yes|Active, not recruiting|August 2013|October 2030|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|N/A|N/A|No|||December 2015|December 24, 2015|March 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01822652||68856|
NCT01822665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1901106|Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics|A Study to Investigate the Gastrointestinal Safety of OTC Analgesics in Healthy Volunteers by Endoscopic Examination||GlaxoSmithKline|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|February 13, 2014|March 28, 2013||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01822665||68855|
NCT01853527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2167b|Myocardial Ischemia in Non-obstructive Coronary Artery Disease|Myocardial Ischemia in Non-obstructive Coronary Artery Disease|MicroCAD|University of Bergen|No|Active, not recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|Samples With DNA|Blood and urin test for biobank|Both|30 Years|N/A|No|Probability Sample|The study population include 132 patients with symptomatic angina pectoris and        non-obstructive coronary artery disease detected by CT-coronary angiography|December 2014|December 2, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01853527||66495|
NCT01853540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130075|Sildenafil for PNTM Infection|Sildenafil in Patients With Pulmonary Nontuberculous Mycobacterial Infection||National Institutes of Health Clinical Center (CC)||Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853540||66494|
NCT01853787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|898CEC|Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study|Acute Bronchodilation and Bronchial Inflammation: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients. Stretching of Airways and Nitric Oxide in Bronchodilation, SANOB Study|SANOB|University of Milan|Yes|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|49|||Both|45 Years|90 Years|No|||July 2015|July 9, 2015|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01853787||66475|
NCT01854060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDF-1083-2011|Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of Young Adults.|Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of 440,822 Young Adults.||Medical Corps, Israel Defense Force|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|440822|||Both|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of Israeli men and women aged 18-39 years who served in        active military service (mandatory and career service) between the years 2005-2011|May 2013|May 14, 2013|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01854060||66454|
NCT01854073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFHSR-5-2013|Hyoscine Butyl Bromide for Management of Prolonged Labor|Use of Hyoscine Butyl Bromide for Management of Prolonged Labor in Nulliparous Women, A Randomized Controlled Trial||Ain Shams University|Yes|Recruiting|February 2014|March 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|35 Years|No|||April 2014|April 17, 2014|May 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01854073||66453|
NCT01824563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-RCA-01-2013|Benefits of the HiResolutionTM Bionic Ear System in Adults With Low-Frequency Hearing|Benefits of the HiResolutionTM Bionic Ear System in Adults With Low-Frequency Hearing.||Advanced Bionics AG|Yes|Recruiting|June 2013|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|100 Years|No|Probability Sample|individuals with severe-to-profound hearing loss|January 2016|January 5, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01824563||68709|
NCT01824797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044248|Bone Metabolism After Bariatric Surgery|Determining Changes in Bone Metabolism After Bariatric Surgery in Postmenopausal Women||Duke University|No|Enrolling by invitation|May 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Serum will be collected from the subjects preoperatively and 12 months postoperatively. The      serum will be used at the completion of the study to run enzyme-linked immunosorbent assay      (ELISA) to determine biochemical changes in their bone metabolism.|Female|40 Years|N/A|No|Non-Probability Sample|Postmenopausal females scheduled to undergo Roux-en-Y gastric bypass or Sleeve        Gastrectomy.|June 2015|January 19, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824797||68691|
NCT01854593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-NAPN-23170|Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy|Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy||Nihon University|Yes|Completed|May 2012|March 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|69|||Both|N/A|N/A|No|||June 2014|June 11, 2014|May 13, 2013||No||No|December 29, 2013|https://clinicaltrials.gov/show/NCT01854593||66413|
NCT01855178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00895-XP|Pediatric Seizure Movement Bed Alarm|Pediatric Seizure Alarm: A Pilot Study to Establish Efficacy Parameters|PedsBedAlarm|Le Bonheur Children's Hospital|No|Completed|October 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|136|||Both|N/A|70 Years|No|Non-Probability Sample|Approximately 200 children and young adults will be enrolled in the study. Patients will        be recruited from the population of children and young adults being admitted to the        Epilepsy Monitoring Unit at LeBonheur Children's Hospital for evaluation of ongoing        seizure disorders.|September 2015|September 2, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01855178||66368|
NCT01856283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhilosoPhy34 CAMN107EIT11T|Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells|An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment||Niguarda Hospital|No|Recruiting|March 2013|June 2019|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856283||66283|
NCT01856296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01738-35|A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies|WINTHER: A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies|WINTHER|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|April 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856296||66282|
NCT01834183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-084|Tivozanib + Gemcitabine in Metastatic RCC|A Phase II and Biomarker Study of Tivozanib With Gemcitabine Addition Upon Progression in Patients With Metastatic Refractory Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Withdrawn|June 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 12, 2013|Yes|Yes|Sponsor Aveo has withdrawn support for this trial.|No||https://clinicaltrials.gov/show/NCT01834183||67975|
NCT01834729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006090|Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions|Effect of Stress and a Alpha-1 Antagonist on Anorectal Functions||Mayo Clinic|No|Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834729||67933|
NCT01822223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-LL-001|A Study to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments to Promote Tissue Healing|A Controlled, Double-Blind, Randomized, Parallel-Arm, Clinical Trial to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments for Enhanced Oral Mucosal Healing||University of Alabama at Birmingham|No|Completed|November 2010|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2013|September 16, 2014|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01822223||68889|
NCT01826240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6592|Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior|Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior: A Treatment Development Study||New York State Psychiatric Institute|No|Completed|March 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||April 2013|December 3, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01826240||68581|
NCT01822457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 LO 1896|Effect of Nike FuelBand on Exercise and Function in Claudicants; a Randomised Controlled Trial|Effect of Nike FuelBand on Exercise and Function in Claudicants; a Randomised Controlled Trial||Imperial College London|No|Active, not recruiting|August 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|40 Years|80 Years|No|||September 2015|September 11, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01822457||68871|
NCT01822990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABGPINO150613|Circulating Anti-Beta2-glycoprotein Antibodies and Endothelial Dysfunction|Influence of Circulating Anti-beta2-glycoprotein I Antibodies on the Endothelial Function and NO Metabolism in Peripheral Arterial Disease Patients.||Hospital Universitario Getafe|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|Serum samples of all the subjects included.|Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Cases: Male patients with intermittent claudication due to peripheral arterial disease        after haemodynamic confirmation of the disease by Doppler and treadmill exercise testing.        No previous history of autoimmune disease.        Controls: Healthy male subjects with normal results on vascular examination and no        cardiovascular risk factors, who were not in receipt of any pharmacological treatment,        matched by age within two years with PAD patients.|March 2013|March 28, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01822990|12 Months|68830|
NCT01823211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KVO-2|Profitability Trial in Primary Preventive Implantable Cardioverter-defibrillator Recipients|Heart Rate Variability, Microvolt T-wave Alternans and Cardiac Magnetic Resonance Imaging Analysis in Primary Preventive ImplantablE Cardioverter-defibrillator Recipients Profitability Trial - HAPPIER Trial|HAPPIER|University Hospital Ostrava|No|Recruiting|March 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|360|||Both|18 Years|90 Years|No|Non-Probability Sample|Heart-failure clinic,primary care clinic|December 2015|December 3, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01823211|36 Months|68813|
NCT01823471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52579|I-Scan For Colon Polyp Detection In HNPCC|High Definition Endoscopy Versus Virtual Chromoendoscopy In The Detection Of Colonic Polyps In HNPCC||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2010|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|March 29, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01823471||68793|
NCT01829022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCNCS-13-MAR|Multi-center Prospective Study on E-NOTES for Myomectomy With Traction of Multidirectional Sutures|Multi-center Prospective Study on Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy With Traction of Multidirectional Sutures|E-NOTES|National Cancer Center, Korea|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Female|20 Years|N/A|No|Non-Probability Sample|Patients with myoma which are surgically candidate at educational hospitals|June 2014|June 24, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01829022||68369|
NCT01838187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIBG Expanded Access (NDP)|Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma|An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma||Children's Hospital Medical Center, Cincinnati||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Months|N/A||||December 2015|December 16, 2015|April 8, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01838187||67669|
NCT01829750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0329-18|Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)|Phase 2 Study of Intracoronary Infusion of Cardiac Progenitor Cells in Patients With Univentricular Heart Disease||Okayama University|Yes|Active, not recruiting|April 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|N/A|20 Years|No|||October 2014|April 21, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829750||68313|
NCT01830062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACS NIRS|Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium|Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium||Medstar Research Institute|No|Recruiting|November 2013|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01830062||68289|
NCT01830322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CPI-613-024|Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer|A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer||Cornerstone Pharmaceuticals, Inc.|No|Withdrawn|January 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|No|||August 2013|August 13, 2013|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830322||68270|
NCT01830335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-167|Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress|The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress||Brock University|No|Active, not recruiting|April 2013|December 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01830335||68269|
NCT01835119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk14|Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies|Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies||Erzincan Military Hospital|Yes|Recruiting|January 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Female|N/A|N/A|No|||April 2013|April 17, 2013|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835119||67903|
NCT01835132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130102|Gevokizumab for Active Scleritis|Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|March 2013|July 2016|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 16, 2013|Yes|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01835132||67902|
NCT01835366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_DAMF_001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2012|||||N/A|N/A|N/A||||||||||||||July 1, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835366||67884|
NCT01835379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815-999-09-010|Study of Oasis Ultra in Diabetic Foot Ulcers|A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers||Healthpoint|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|April 16, 2013|Yes|Yes||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01835379||67883|
NCT01835392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259980|Neuroprotective Effects of Remote Ischemic Preconditioning During Infant Cardiac Surgery|Neuroprotective Effects of Remote Ischemic Preconditioning During Infant Cardiac Surgery||Nemours Children's Clinic|No|Recruiting|September 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|6 Months|No|||October 2014|August 31, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835392||67882|
NCT01835665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR12-09098|Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations|An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations||University of California, San Francisco|No|Active, not recruiting|March 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|30 Years|N/A|No|||April 2015|April 6, 2015|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835665||67861|
NCT01835678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC2012LINA|Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.|Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes||University of Erlangen-Nürnberg Medical School|No|Completed|October 2012|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|70 Years|No|||April 2014|April 9, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01835678||67860|
NCT01836848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH-NIRS-001|Non-invasive Measuring of Cerebral Perfusion After Severe Brain Injury With Near-infrared-spectroscopy and ICG|Continuous, Non-invasive Monitoring of Cerebral Oxygenation and Perfusion Using Near-infrared Spectroscopy With Indocyanine Green Perfusion Measurement in Patients With Traumatic Brain Injury, Intracerebral or Subarachnoid Hemorrhage||University of Cologne|No|Not yet recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|80 Years|No|||April 2013|April 17, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836848||67771|
NCT01836588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX-CUR|New Gentle Biopsy Method of Cervix Lesions Using Superficial Curettage/Protocol ID: CX-CUR|||Charite University, Berlin, Germany||Enrolling by invitation|March 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|300|||Female|18 Years|80 Years|No|||April 2013|April 17, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01836588||67791|
NCT01856244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSN-0613|Stability and Balance in Locomotion Through Exercise|Sensorimotor Treadmill Training to Improve Gait and Balance in Parkinson's Disease|StaBLE|University of Erlangen-Nürnberg|No|Recruiting|June 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01856244||66286|
NCT01856257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-16|Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen|Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation (CTOT-16)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|July 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|May 14, 2013|Yes|Yes|Safety concern:disparity in rejection rates between investigational versus control arm    (stopping rule not met).|No||https://clinicaltrials.gov/show/NCT01856257||66285|
NCT01852357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15AT007226|An Evaluation of Neurofeedback Efficacy in Adults With ADHD|A Placebo-Control Evaluation of Neurofeedback Efficacy in Adults With ADHD||University of North Carolina, Wilmington|Yes|Recruiting|April 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01852357||66585|
NCT01827137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-288|WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation|A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827137||68513|
NCT01828281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-CPAP|Effects of CPAP on Visceral Fat Thickness|A Randomized Controlled Study on the Effects of Continuous Positive Airway Pressure (CPAP) on Visceral Fat Thickness, Carotid Intima-media Thickness and Adipokines in Patients With Obstructive Sleep Apnoea Syndrome (OSAS)||Chinese University of Hong Kong|No|Completed|February 2012|August 2015|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|20 Years|80 Years|No|||October 2015|October 15, 2015|April 8, 2013||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01828281||68425|
NCT01828294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17005|Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis|Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis|SIMM|St. Louis University|Yes|Terminated|October 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|November 1, 2011|Yes|Yes|Study stopped by sponsor due to difficulty enrolling at site|No||https://clinicaltrials.gov/show/NCT01828294||68424|
NCT01828307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033411-01A1|Exercise: Addressing Stress in Relapse Prevention for Substance Use Disorders|||St. Louis University|Yes|Enrolling by invitation|April 2013|September 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|55 Years|No|||October 2015|October 23, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01828307||68423|
NCT01828775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13193|Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment|Integration of Palliative Care for Cancer Patients on Phase I Trials||City of Hope Medical Center|Yes|Recruiting|September 2014|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|480|||Both|21 Years|N/A|No|||September 2015|September 28, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828775||68388|
NCT01828788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0151|Postoperative Rehabilitation After Cardiac Surgery in Patients at Risk of Respiratory Complications. Effects of a Continuous Bi-laterosternal Infusion of Ropivacaine Through Multihole Catheters|Postoperative Rehabilitation After Cardiac Surgery in Patients at Risk of Respiratory Complications. Effects of a Continuous Bi-laterosternal Infusion of Ropivacaine Through Multihole Catheters.|BLS-Sterno|University Hospital, Clermont-Ferrand||Recruiting|September 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||September 2013|September 24, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828788||68387|
NCT01837914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02721|Maxillary Expansion Treatment of Pediatric OSA|Maxillary Expansion Treatment of Pediatric Obstructive Sleep Apnea||University of British Columbia|No|Recruiting|May 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|10 Years|No|||April 2015|April 7, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837914||67690|
NCT01838798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/CR-02|Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients|Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients|NeuroPsy Réa|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients hospitalized in the ICU, intubated and        ventilated for at least 48 hours.|November 2015|November 18, 2015|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01838798||67622|
NCT01829763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000600-42|Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb|Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb||Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2013|November 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829763||68312|
NCT01839084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-051|PaNeX: Partial Nephrectomy Under Xenon|Impact of Xenon-anesthesia on the Renal Function After Partial Nephrectomy - PaNeX: Partial Nephrectomy Under Xenon:a Pilot Study|PaNeX|RWTH Aachen University|No|Completed|July 2013|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01839084||67601|
NCT01830348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC127-2012-01|Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers|A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus|STRIDE 1|Derma Sciences, Inc.|No|Active, not recruiting|February 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|422|||Both|18 Years|N/A|No|||June 2015|November 18, 2015|March 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830348||68268|
NCT01834885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2327|A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation||Novartis|No|Withdrawn|December 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||November 2013|November 8, 2013|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834885||67921|
NCT01835405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-LBF001-05-1|LiquiBand Versus Dermabond Versus Sutures for Closure of Surgical Wounds|||Advanced Medical Solutions (Plymouth) Ltd||Recruiting|February 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835405||67881|
NCT01835418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9529148100|Bedtime Administration of Amlodipine Versus Lisinopril|Bedtime Administration of Amlodipine Versus Lisinopril: a Randomized Trial|BAVLART|Allina Health System|Yes|Not yet recruiting|April 2013|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|75 Years|No|||April 2013|April 18, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01835418||67880|
NCT01835691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12861|Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease|Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease||University of Kansas Medical Center|No|Completed|October 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01835691||67859|
NCT01835951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI/2012/028|Individual Versus Grouped Debriefing Approaches in Anaesthesia Crisis Simulation-Based Training. What Impact On The Technical Score ?|Individual Versus Grouped Debriefing Approaches in Anaesthesia Crisis Simulation-Based Training. What Impact On The Technical Score ?|DEBRIEF-SIM|Centre Hospitalier Universitaire de Besancon|No|Completed|March 2013|October 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01835951||67839|
NCT01836601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00006501|Nighttime Communication Study|The Effect of a Family-Centered Nighttime Communication Bundle on Shared Mental-Model Building, Safety, and Patient Experience||Children's Hospital Boston|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1334|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01836601||67790|
NCT01837121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-WDF-SMS|a Trial of Using SMS Reminder Among Diabetic Retinopathy Patients in Rural China|a Randomized Controlled Trail to Determine the Impact of a SMS Reminder Among Diabetic Retinopathy Patients in Rural China|SMS|Sun Yat-sen University|Yes|Active, not recruiting|April 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|5000|||Both|N/A|N/A|No|||April 2013|April 17, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01837121||67750|
NCT01856270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44274-B|Amitriptyline to Prevent Headache After Traumatic Brain Injury|Amitriptyline to Prevent Headache After Traumatic Brain Injury||University of Washington|Yes|Recruiting|April 2013|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|60 Years|No|||May 2015|May 26, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856270||66284|
NCT01856036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUM-CRYOABLATION|Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers|CHUM-CRYOABLATION: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers||John Wayne Cancer Institute|No|Terminated|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|April 18, 2013|Yes|Yes|PI left institute and contacted IRB to close study.|No||https://clinicaltrials.gov/show/NCT01856036||66302|
NCT01856049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007176|Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients|Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients||Mayo Clinic|No|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Female|N/A|N/A|No|||December 2015|December 16, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856049||66301|
NCT01828047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-214-SDR|Sublingual Microcirculation and Postoperative Ileus|Correlation Between Sublingual Microcirculation and Postoperative Ileus Symptoms in Patients Undergoing Colorectal Surgery - a Pilot Study||McGill University Health Center|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing elective colorectal surgery with an Enhanced Recovery Program (ERP)|March 2015|March 16, 2015|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01828047||68443|
NCT01828060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS8914|Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population|Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population.||Natural Immune Systems Inc||Completed|April 2013|||August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828060||68442|
NCT01828580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-65-001|Safety and Performance Evaluation of the AutoLap System|Safety and Performance Evaluation of the AutoLap System - a Feasibility Study||M.S.T. Medical Surgery Technology LTD.|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|36|||Both|18 Years|75 Years|No|||December 2014|December 30, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01828580||68403|
NCT01837641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15082|A Study of LY3002813 in Participants With Alzheimer's Disease|A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease||Eli Lilly and Company|No|Active, not recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 8, 2015|April 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01837641||67711|
NCT01828567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-288|Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?|Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?|ACTIVATE|VA Office of Research and Development|No|Enrolling by invitation|October 2014|August 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|450|||Both|N/A|N/A|No|||November 2015|November 4, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828567||68404|
NCT01837602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13111|cMet CAR RNA T Cells Targeting Breast Cancer|Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|4||Anticipated|15|||Both|N/A|N/A|No|||December 2015|December 14, 2015|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837602||67714|
NCT01837615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39583.018.12|Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis|Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Patients With Ulcerative Proctitis|Photopill|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|January 2013|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837615||67713|
NCT01839123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-2012-Aim1|Evaluation of Limb Health Associated With a Prosthetic Vacuum Socket System|Prosthetic Socket System: Pilot Assessment||Ohio Willow Wood||Recruiting|April 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01839123||67598|
NCT01838811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 30.01|Applying Speed of Processing Training to Individuals With Traumatic Brain Injury|Applying Speed of Processing Training (SPT) to Individuals With TBI|SPTTBI|Kessler Foundation|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01838811||67621|
NCT01838473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMWS03|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Swedish 'Snus' in Regular Snus Users|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users.|SMWS03|Contract Research Organization el AB|No|Completed|May 2004|April 2005|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01838473||67647|
NCT01838486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/12|Bladder Thermal Distention for Patients With Interstitial Cystitis / Painful Bladder Syndrome|Bladder Thermal Distention for Patients With Interstitial Cystitis / Painful Bladder Syndrome|IC|Assaf-Harofeh Medical Center|No|Recruiting|June 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838486||67646|
NCT01834898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA 10/2010|Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery|Phase 4 Study, Open, Observational, to Evaluate the Safety and Tolerability of Hydrochloride Controlled-release Oxycodone in Moderate and Severe Postoperative Pain in Oncologic Head and Neck Surgery.||Instituto Nacional de Cancer, Brazil|Yes|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|83|||Both|18 Years|70 Years|No|Probability Sample|Patients on postoperative head and neck oncologic surgery which moderate to severe pain|April 2013|April 16, 2013|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834898||67920|
NCT01834911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-10,830|Effect of Tetrabenazine on Stroop Interference in HD|Effect of Tetrabenazine on Stroop Interference in Huntington Disease||New York Medical College|No|Recruiting|March 2013|||January 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834911||67919|
NCT01835145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00821|Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye|Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|July 2013|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|69|||Both|18 Years|N/A|No|||January 2016|March 24, 2016|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835145||67901|
NCT01835964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16723|Biobehavioral Mechanisms of Glucose Variability|Biobehavioral Mechanisms of Glucose Variability||University of Virginia|No|Completed|April 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|21 Years|65 Years|No|||February 2014|February 18, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01835964||67838|
NCT01835730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE0139-PT-CL-0001|Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus|Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus||PhaseBio Pharmaceuticals Inc.|No|Completed|April 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||October 2014|October 13, 2014|March 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835730||67856|
NCT01835743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_HP_001|Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia HP Scanner (HPS) Laser on Chronic Heel Pain||Erchonia Corporation|No|Completed|February 2012|May 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|April 17, 2013|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT01835743||67855|
NCT01836211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-DIA-2010-18|High-Sensitivity Troponin T and Coronary Computed Tomography Angiography for Rapid Diagnosis of Emergency Chest Pain|High-Sensitivity Troponin T and Coronary Computed Tomography Angiography for Rapid Diagnosis of Emergency Chest Pain: a Randomized Controlled Study|TRUE|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Terminated|September 2011|June 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|101|||Both|18 Years|90 Years|No|||April 2013|April 11, 2013|November 23, 2012||No|low recruitment|No||https://clinicaltrials.gov/show/NCT01836211||67819|
NCT01836549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-036|Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors|A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma||Pediatric Brain Tumor Consortium|Yes|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|12 Months|21 Years|No|||October 2014|October 27, 2014|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836549||67794|
NCT01836562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00105|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism. It is Self Funded (Patients' Own Funding) Clinical Trial|BMCA|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01836562||67793|
NCT01837134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telemedical coaching|Telemedical Coaching for Weight Loss|TeleLifestyleCoaching Study - Telemedical Coaching for Weight Loss|Fit|West German Center of Diabetes and Health|No|Completed|May 2013|April 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01837134||67749|
NCT01836900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STING|Endoscopic Treatment of Recurrent Upper GI Bleeding: OTSC [Over the Scope Clip] Versus Standard Therapy|Endoscopic Treatment of Recurrent Upper GI Bleeding From Gastroduodenal Ulcers: OTSC [Over the Scope Clip] Versus Standard Therapy|STING|Kliniken Ludwigsburg-Bietigheim gGmbH|No|Recruiting|March 2013|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01836900||67767|
NCT01856309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102023|Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003|A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)|SIRROUND-LTE|Janssen Research & Development, LLC|Yes|Enrolling by invitation|August 2013|April 2020|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|2033|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856309||66281|
NCT01827800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0033|New Media Obesity Treatment in Community Health Centers|New Media Obesity Treatment in Community Health Centers||Duke University|Yes|Active, not recruiting|June 2013|October 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|21 Years|N/A|No|||January 2016|January 25, 2016|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01827800||68462|
NCT01828333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swiss TPH P 001-01-12|Malaria Treatment With Injectable ArteSunate|Treatment of Severe Malaria - An Operational Comparative Study Between Quinine and Artesunate for the Treatment of Severe Malaria in Hospitals and Health Centers of Kinshasa and Lower Congo|MATIAS|Swiss Tropical & Public Health Institute|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|350|||Both|2 Months|N/A|No|Non-Probability Sample|Patients diagnosed with severe malaria will be enrolled in four hospitals and five health        centers located in four health zones of the Democratic Republic of the Congo, three rural        and one urban.|September 2013|September 12, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01828333||68421|
NCT01837927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237ABR01|Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 μg o.d.) Using Tiotropium (5 μg o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.||Novartis||Suspended|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|40 Years|N/A|No|||January 2014|January 13, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837927||67689|
NCT01828801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10017|Pinnacle Metal-on-Metal 522 Post-Market Surveillance Study|Cross-Sectional, Multi-Center Evaluation of 8 Year Metal Ion Trends for Pinnacle MoM System Used in Primary Hip Arthroplasty||DePuy Orthopaedics|No|Active, not recruiting|March 2013|July 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||9|Anticipated|300|Samples With DNA|Whole blood and serum samples are retained.|Both|N/A|N/A|No|Non-Probability Sample|Patients that have undergone a total hip arthroplasty with the Pinnacle Metal-on-Metal        device within the past 8 years.|May 2015|December 17, 2015|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828801||68386|
NCT01838213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK S-08901b|Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients|Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology|ESCAPE|Vestre Viken Hospital Trust|No|Completed|February 2009|||December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|760|Samples Without DNA|Bacterial cultures|Both|18 Years|N/A|No|Non-Probability Sample|Patients living in Eastern Norway who have an urine submitted for culturing to the        Department of Medical Microbiology, Vestre Viken Hospital Trust, which covers an area of        about 450.000 inhabitants.        All patients with an bacteria producing ESBL were eligible while patients without ESBL        producing bacteria were randomly sampled.|October 2015|October 21, 2015|April 18, 2013||No||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01838213||67667|Publication of results:"High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085889
NCT01838499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5440C00001|Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa|A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa||AstraZeneca|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|April 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838499||67645|
NCT01838850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8635-SIT-11-01|Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy|A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg||Daiichi Sankyo Korea Co., Ltd.|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|344|||Both|20 Years|75 Years|No|||September 2014|October 2, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01838850||67619|
NCT01834924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1423|Improving Communication of Medication Instructions to Parents|Dissemination of a Health Literacy Intervention to Improve Provider-Patient Communication of Medication Instructions and Decrease Outpatient Pediatric Medication Errors||New York University School of Medicine|No|Recruiting|May 2010|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|17500|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834924||67918|
NCT01839097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-BEL-12-104|Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)|Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839097||67600|
NCT01839110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817785|Targeting the Right Ventricle in Pulmonary Hypertension|A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction||University of Pennsylvania|Yes|Recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839110||67599|
NCT01835431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3816|A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus|A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|362|||Both|1 Year|17 Years|No|||January 2016|January 26, 2016|April 16, 2013|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT01835431||67879|
NCT01835704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-Dnr-2012-446-31M-2|Health-economic Evaulation of Interventional Pain Mangement|Health-economic Evaluation of Interventional Pain Management Among Patients With Chronic Pain||Eques Indolor AB|No|Active, not recruiting|January 2008|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|300|||Both|15 Years|99 Years|No|Non-Probability Sample|Patients with pain of more then 6 months duration|January 2016|January 19, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01835704||67858|
NCT01835717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 45-65/FPM 2012|Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population|Cross-sectional Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population||Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Active, not recruiting|April 2013|April 2020|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2500|Samples With DNA|serum; white cells|Both|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cognitive normal men and woman aged 45-65 years|March 2015|March 11, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01835717||67857|
NCT01835756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_LBP_01|Study of Low Level Laser Therapy to Treat Low Back Pain|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Low Back Pain Clinical Study||Erchonia Corporation|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||November 2015|December 31, 2015|April 17, 2013|Yes|Yes||No|July 9, 2015|https://clinicaltrials.gov/show/NCT01835756||67854|
NCT01835769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_TMJ_001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||July 10, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835769||67853|
NCT01835977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013249|Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer|Multi-Center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer||Clinical Research Office of the Endourological Society|Yes|Enrolling by invitation|June 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Male|50 Years|100 Years|No|||April 2015|October 19, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01835977||67837|
NCT01836224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Sepsis-01|Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit|A Prospective Open Label Randomized Non Inferiority Trial to Compare the Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit.||Institute of Liver and Biliary Sciences, India|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|70 Years|No|||December 2013|May 23, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01836224||67818|
NCT01836237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E - 24807|The Use of Wound Protector in Whipple's Procedure With Intrabiliary Stent|The Use of Wound Protectors to Prevent Surgical Site Infection for Whipples (Pancreatoduodenectomy) With Intrabiliary Stents: A Randomized Controlled Trial.||University of Calgary|Yes|Recruiting|February 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836237||67817|
NCT01836575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3E-BL-O027-PS2|Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2|Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2|PS2|Instituto Nacional de Cancer, Brazil|Yes|Completed|April 2008|December 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01836575||67792|
NCT01837147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03CA168450-01|Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)|Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk||University of California, San Diego|No|Active, not recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 27, 2014|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01837147||67748|
NCT01838044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081296|Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component|A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Concomitant Administration Of Celecoxib And Pregabalin Compared With Celecoxib Monotherapy, In Patients With Chronic Low Back Pain Having A Neuropathic Component||Pfizer|Yes|Terminated|October 2013|June 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|April 15, 2013|Yes|Yes|Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational    feasibility. Study was not terminated for reasons of safety/efficacy.|No||https://clinicaltrials.gov/show/NCT01838044||67680|
NCT01855763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metformin in gdm & t 2 dm|Metformin Treatment in Gestational Diabetes and Noninsulin Dependent Diabetes in Pregnancy in a Developing Country|Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country|migdm&t2dm|Dow University of Health Sciences|Yes|Active, not recruiting|December 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|20 Years|46 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855763||66323|
NCT01855776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRG10NOV002|A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees|A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees||Duke-NUS Graduate Medical School|No|Completed|May 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|800|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01855776||66322|
NCT01856322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130126|Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer|Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|April 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 14, 2013|Yes|Yes|The trial was prematurely closed due to lack of accrual.|No|March 25, 2015|https://clinicaltrials.gov/show/NCT01856322||66280|
NCT01856335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130127|Exercise Education for Adults With Seizure Disorders|Increasing Self-Efficacy and Outcome Expectations For Exercise in Adults With Epilepsy: An Educational Motivation Intervention - E-MOVE||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01856335||66279|
NCT01828086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCJM112X2101|Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis|A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients||Novartis|No|Completed|June 2013|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828086||68440|
NCT01828320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD071065-01A1|Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence|Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence||University of California, Berkeley|Yes|Recruiting|March 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Female|10 Years|18 Years|No|||December 2014|December 15, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828320||68422|
NCT01837355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 12/129/1B|Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis|Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)|MoHuM-1|Cantonal Hospital of St. Gallen|Yes|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|6 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01837355||67733|
NCT01837628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/13|Reducing Urethral Pain During Urodynamic Test - Comparison Between Lidocaine Gel and Paraffin Oil|Reducing Urethral Pain During Urodynamic Test - Comparison Between Lidocaine Gel and Paraffin Oil||Assaf-Harofeh Medical Center|No|Recruiting|February 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837628||67712|
NCT01837953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120689-01H|Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial|Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial||Ottawa Hospital Research Institute|No|Active, not recruiting|November 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01837953||67687|
NCT01837940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/309|Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population|Efficacy of a Dietary Supplementation With Lactobacillus Reuteri DSM 17938 for Digestive Health in an Elderly Population||Örebro University, Sweden||Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01837940||67688|
NCT01838200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2012-003|A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma|A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma||Ludwig Institute for Cancer Research|No|Recruiting|April 2013|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|March 2, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01838200||67668|
NCT01838824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4607-A-3|Applying Speed of Processing Training to Individuals With Multiple Sclerosis|Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis|SPTMS|Kessler Foundation|No|Active, not recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||November 2014|November 24, 2014|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01838824||67620|
NCT01838863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB# 12-1349|Control of Major Bleeding After Trauma Study|A Prospective, Randomized Comparison of Fresh Frozen Plasma Versus Standard Crystalloid Intravenous Fluid as Initial Resuscitation Fluid|COMBAT|Denver Health and Hospital Authority|Yes|Recruiting|April 2014|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838863||67618|
NCT01839136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 03332812.0.0000.5440|Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial|Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial||University of Sao Paulo|Yes|Terminated|May 2013|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|40 Years|No|||June 2014|June 30, 2014|April 21, 2013|||Low pregnancy rates in both groups|No||https://clinicaltrials.gov/show/NCT01839136||67597|
NCT01835158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00820|Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer|Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|July 2013|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835158||67900|
NCT01835171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00804|Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer|Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2013|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835171||67899|
NCT01835444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82310-97-12094|A Multicenter Research on the Effects of Substitution of Hospital Ward Care From Medical Doctors to Physician Assistants|Worthy Assistants: Does Substituting Hospital Ward Care From Medical Residents to Physician Assistants Result in Cost Savings?||Radboud University|No|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|2382|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital Ward Care: all patients (age 18 years or older) admitted to a hospital ward will        be included in the study.|May 2015|May 13, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01835444||67878|
NCT01836263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F5-2012-305495-OT1|Prevention and Treatment of Digital Ulcers in Systemic Sclerosis|||University of Florence|No|Recruiting|April 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|420|||Both|N/A|N/A|No|Probability Sample|The study population are adult and juvenile systemic sclerosis patients from the EUSTAR        cohort (MEDSonline database), the VEDOSS cohort and the jSScWG cohort|April 2013|April 24, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836263|24 Months|67816|
NCT01836614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC 2012-0674|Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients|Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients||Children's Hospital Medical Center, Cincinnati|Yes|Withdrawn|January 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|15 Years|No|||March 2016|March 7, 2016|April 8, 2013|Yes|Yes|Study was closed due to recommendations of performing a PK study first.|No||https://clinicaltrials.gov/show/NCT01836614||67789|
NCT01836874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100585|A Study of Prophylaxis for Migraine Patients With Topiramate in India|Prophylaxis of Migraine Patients With Topiramate in India (PROMPT-IN)|PROMPT-IN|Janssen-Cilag Ltd.||Completed|May 2007|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|Indian participants experiencing migraine|April 2013|April 17, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01836874||67769|
NCT01836887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSB101118 (2)|The Effects of a Polyphenol-enriched Fruit Drink on Metabolic Health(2)|Fruit Polyphenols: Maximising Knowledge of Their Metabolic Health Benefits and Practical Applications (Phase 2)||King's College London|No|Completed|February 2013|February 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|22|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01836887||67768|
NCT01823666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z11107056811043|Predicting the Conversion From Mild Cognitive Impairment to Dementia|Study on Risk Factors for Prediction of Conversion to Dementia in Patients With Mild Cognitive Impairment|PCMCItoD|Dongzhimen Hospital, Beijing|Yes|Recruiting|September 2012|September 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|plasma|Both|40 Years|85 Years|No|Non-Probability Sample|People with cognitive complaint living in the community.|August 2014|August 27, 2014|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01823666||68778|
NCT01823939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK Study|PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera|Two-Part, Single-Centre Pharmacokinetic Study of iOWH032 in Adult Male and Female Healthy Volunteers, and Adult Males With Cholera|PISCES|PATH|Yes|Completed|May 2013|December 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823939||68757|
NCT01823952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTORS|High Amylose Maize Starch for Treatment of Cholera|Phase 2, Single Centre, Randomized, Double-blind Study Conducted in Adult Males With Acute Dehydrating Diarrhea Due to Cholera With the Aim Being to Select One or More of the Three Fermentable Starches (FS) for an FS-HO-ORS Formulation.|RESTORS|PATH|Yes|Terminated|April 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|N/A||1|Actual|106|Samples Without DNA|Analysis of the sample for starch, short chain fatty acids and faecal microbiota.|Male|18 Years|65 Years|No|Probability Sample|Study Population is 150 adult male patients: 40 each in the HAMS, HAMSA2.5 and HAMSA6 arms        and 30 in the HO-ORS study arm.|February 2014|April 2, 2014|March 27, 2013||No|The study was closed early due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT01823952||68756|
NCT01824173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004000|Muscle Protein Metabolism in Obesity|Regulation of Muscle ATP Synthase Beta Subunit Metabolism in Obesity||Mayo Clinic|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01824173||68739|
NCT01824186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG DSRB 2009/00434|Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy|A Randomized Controlled Trial Comparing Post-operative Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy||National University Hospital, Singapore|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|80 Years|No|||March 2013|March 31, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01824186||68738|
NCT01837056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nuneuveitis|Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis|Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis||National Institute of Health, Korea|Yes|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Both|N/A|N/A|No|Probability Sample|patient with uveitis|April 2013|April 17, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01837056|14 Days|67755|
NCT01837069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMIZE-OS|Risk Factor Control Before Orthopedic Surgery|OPTMIZE-OS: Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery||New York University School of Medicine|Yes|Recruiting|February 2014|January 2018|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|550|||Both|21 Years|N/A|No|||November 2015|November 11, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01837069||67754|
NCT01837654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76/12|Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity|Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity|DO|Assaf-Harofeh Medical Center|No|Recruiting|June 2012|June 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837654||67710|
NCT01837667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L12-20661|Phase I Study of LB-100 With Docetaxel in Solid Tumors|A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors||Lixte Biotechnology Holdings, Inc.|No|Recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2015|June 5, 2015|April 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01837667||67709|
NCT01838239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715313|Development of a Metabolic Assessment Tool for Chronic Kidney Disease|Development of a Metabolic Assessment Tool for Chronic Kidney Disease||University of California, Davis||Completed|June 2008|June 2011|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838239||67665|
NCT01838226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-285|Randomized Controlled Trial of Group Prevention Coaching|Randomized Controlled Trial of Group Prevention Coaching||VA Office of Research and Development|No|Recruiting|August 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838226||67666|
NCT01838512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-008|Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)|Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)|PREAMBLE|Bristol-Myers Squibb|No|Recruiting|June 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with relapsed or refractory MM initiating a new line of therapy that        contains an immunomodulatory drugs (IMiDs), an proteasome inhibitors (PIs), or both.|July 2014|June 22, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838512||67644|
NCT01834963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1207|P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.|Randomised Phase II Study of Postoperative Hepatic Arterial Infusion Chemotherapy (Interferon/Fluorouracil Versus Low-dose Cisplatin/Fluorouracil) for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.||Kansai Hepatobiliary Oncology Group|Yes|Recruiting|March 2013|February 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|20 Years|N/A|No|||October 2014|October 21, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01834963||67915|
NCT01839149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIG-05|TI-001 (Intranasal Oxytocin) for Treatment of Chronic Migraine|A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine||Trigemina, Inc|No|Active, not recruiting|May 2013|January 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01839149||67596|
NCT01839162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLRMB-Pertini1|RAdiation Dose In percutAneuos Coronary Procedures Through TransradIal apprOach Using Dedicated radiatioN Shields|RAdiation Dose In percutAneuos Coronary Procedures Through TransradIal apprOach Using Dedicated radiatioN Shields (The RADIATION Study)|RADIATION|Ospedale Sandro Pertini, Roma|No|Completed|April 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|452|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01839162||67595|
NCT01834937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM019-Registry|ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|BM019-Registry|InSightec|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All consented patients from all participating US sites who receive the commercial ExAblate        procedure during the first year after approval will be included. This study/registry will        examine treatment background information such adverse events, primary cancer type,        treatment frequency, etc., reported in patients undergoing the device procedure for the        first two years of commercial experience.|November 2015|November 30, 2015|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834937|4 Months|67917|
NCT01835782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-Serine2013|Determining the Safety of L-serine in ALS|Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses.||Phoenix Neurological Associates, LTD|Yes|Active, not recruiting|January 2013|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|85 Years|No|||July 2015|July 28, 2015|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835782||67852|
NCT01835990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFT Pilot|Feasibility Study of Geko vs. IPCs in Trauma|Feasibility Study of a Randomized Controlled Trial of a Novel Device vs. Intermittent Pneumatic Compression for Prevention of Venous Thromboembolism in Trauma Patients|GIFT Pilot|Hamilton Health Sciences Corporation|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|December 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01835990||67836|
NCT01836003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHP044|An Intervention to Improve Antenatal Access to CD4 Testing and HAART in Botswana|Programmatic CD4 Testing and HAART Initiation Among HIV-Infected Pregnant Women in Gaborone, Botswana: A Randomized Staged Trial of an Improvement Intervention||Harvard School of Public Health|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|422|||Both|N/A|N/A|No|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01836003||67835|
NCT01836276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12990|Understanding Disparities in Quitting in African American and White Smokers|Understanding Disparities in Quitting in African American and White Smokers||University of Kansas Medical Center|Yes|Active, not recruiting|June 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|449|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836276||67815|
NCT01836627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001CMDwHyperinsufflation|A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy|Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|5 Years|20 Years|No|||September 2015|September 25, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836627||67788|
NCT01823978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-PC-002|Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer|A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)||Bellicum Pharmaceuticals|No|Recruiting|April 2013|May 2016|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||February 2015|February 9, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01823978||68754|
NCT01824199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008053|CYP2C19 Genotype Predictor of Gastric Acid Suppression|CYP2C19 Genotype as a Predictor of Gastric Acid Suppression and Healing of Erosive Esophagitis||Mayo Clinic|No|Active, not recruiting|March 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01824199||68737|
NCT01824498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN914|Dietary Fat, Eicosanoids and Breast Cancer Risk|Dietary Fat, Eicosanoids and Breast Cancer Risk||USDA Grand Forks Human Nutrition Research Center|No|Completed|January 2004|November 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|18|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|April 1, 2013||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01824498||68714|
NCT01824511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS B11-185|Effects of Quitting Study A Test of Pre-clinical Findings|Does Smoking Cessation Increase Anhedonia? A Test of Pre-clinical Findings||University of Vermont|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|287|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01824511||68713|
NCT01837368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tinnitus_T0|Research Project About Psychological Strain, Quality of Life and Emotional Awareness in Patients With Tinnitus|Research Project About Psychological Strain, Quality of Life and Emotional Awareness in Patients With Tinnitus||University of Zurich|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with tinnitus|January 2015|February 4, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01837368||67732|
NCT01837966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-03152|Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients|A Randomized Prospective Placebo-Controlled Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Surgery Patients||New York University School of Medicine|No|Active, not recruiting|January 2013|December 2015|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|April 18, 2013||No||No|December 22, 2014|https://clinicaltrials.gov/show/NCT01837966||67686|
NCT01837979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Down syndrome screening|Down Syndrome Screening Based on Dried Blood Spots and Cell-free Fetal DNA|A Clinical Trial to Explore a New Prenatal Screening and Diagnosis Pattern for Fetal Chromosomal Abnormalities With Dried Blood Spots and Cell-free Fetal DNA.|DBS&CFF|Peking Union Medical College Hospital|Yes|Enrolling by invitation|April 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women with 15-20+6 weeks of gestation|April 2013|April 18, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01837979||67685|
NCT01837992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VanSI_2013|Safety and Efficacy of Primaquine for P. Vivax|Evaluation of Safety and Efficacy of Two Primaquine Dosing Regimens for the Radical Treatment of Plasmodium Vivax Malaria in Vanuatu and Solomon Islands||Menzies School of Health Research|Yes|Not yet recruiting|May 2013|May 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|12 Months|60 Years|No|||November 2013|November 7, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01837992||67684|
NCT01838252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001629|Hyaluronic Acid Gels for Lower Lid Retraction|||University of California, Los Angeles|No|Withdrawn|February 2013|May 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|65 Years|No|||December 2014|December 2, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838252||67664|
NCT01838525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130419-007|Alpha-1-acid Glycoprotein as a Biomarker of Developmental Diagnosing and Monitoring Effectiveness in Sepsis|||Chinese PLA General Hospital|Yes|Recruiting|April 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Between April 2011 and APRIL 2013, inpatients were included who were in the intensive care        units (ICU) of the Department of Respiratory Disease (RICU), the Emergency Department        (EICU), and the Department of Surgery (SICU) of the Chinese People's Liberation Army        General Hospital.|April 2013|April 23, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838525||67643|
NCT01835210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-15072|Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life|Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life||Ann & Robert H Lurie Children's Hospital of Chicago||Completed|August 2012|January 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60|||Both|12 Years|17 Years|No|Non-Probability Sample|Subjects will be recruited from the pediatric dermatology clinic at Ann and Robert H.        Lurie Children's Hospital of Chicago. Teenagers must be between 12 and 17 years old, and        have a diagnosis of acne by a pediatric dermatologist.|January 2016|January 26, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835210||67896|
NCT01835197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7451001|First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects|A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects||Pfizer|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|10||Actual|79|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835197||67897|
NCT01834950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01364-39|Identification of Early Markers of Response and Resistance to Trastuzumab|Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery|HERBIN|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|February 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01834950||67916|
NCT01835184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00808|Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery|Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib||National Cancer Institute (NCI)|Yes|Terminated|May 2013|||September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|April 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01835184||67898|
NCT01835795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 06251612.7.0000.0068|Radial Extracorporeal Shock Wave Treatment (rESWT) of Myofascial Pain Syndrome in Low Back Pain|Prospective, Comparative, Randomized Study of the Effectiveness of Shock Wave Treatment in Myofascial Pain Syndrome in Low Back Pain||University of Sao Paulo|No|Recruiting|January 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 18, 2013|April 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835795||67851|
NCT01836640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13100|Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer|Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|December 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Women or men > age 18 with advanced breast cancer|March 2013|January 6, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836640||67787|
NCT01837160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/R/CAR/23|Angiogenesis and Fibrosis in Aortic Stenosis|The Identification of In Vivo Angiogenesis and Fibrosis in Aortic Stenosis Using Positron Emission Tomography||University of Edinburgh|Yes|Recruiting|April 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|Blood samples will be taken, and the serum frozen and stored for further analysis pending      ethical approval.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50 patients in total, recruited from Cardiology Outpatient Clinics|March 2015|March 17, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01837160||67747|
NCT01837446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390163|Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer|Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan||Isfahan University of Medical Sciences|Yes|Completed|July 2011|October 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01837446||67726|
NCT01837459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001VF|A Research Study for Children About Heart Changes and Obstructive Sleep Apnea (OSA)|Vascular Function in Children With Obstructive Sleep Apnea||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|November 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|260|Samples With DNA|Serum, plasma, tissue|Both|5 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 5-13 years recruited from the community, otolaryngology and sleep disorder        clinics|July 2015|July 29, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01837459||67725|
NCT01837784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13024|Central Hemodynamics|Value of Non-invasively Measured Arterial Stiffness and Central Hemodynamics for Guiding Antihypertensive Treatment in Selected Patient Populations||Luzerner Kantonsspital||Recruiting|April 2013|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients referred for optimization of antihypertensive treatment to Luzerner        Kantonsspital, Switzerland.|April 2013|April 18, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837784||67700|
NCT01837797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14571A|Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment||H. Lundbeck A/S|No|Terminated|April 2013|||May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|129|||Both|65 Years|N/A|No|||February 2016|February 4, 2016|April 4, 2013|Yes|Yes|The study was terminated because of recruitment challenges|No|August 17, 2015|https://clinicaltrials.gov/show/NCT01837797||67699|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.
NCT01824745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12383|Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors|Survivorship Care Planning for At Risk Breast Cancer Survivors||City of Hope Medical Center|Yes|Recruiting|July 2013|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01824745||68695|
NCT01825356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-13-03A|Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus|||OrthoCarolina Research Institute, Inc.|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01825356||68648|
NCT01837082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCHF_D.3874|Iron in Congestive Heart Failure|Randomized, Double-blind, Placebo-controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients With Congestive Heart Failure|iCHF|University of Ulm|Yes|Terminated|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|April 17, 2013||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01837082||67753|
NCT01837381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR-13-03|Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)|A Comprehensive Analysis of Clinical Outcome, Treatment Toxicity and Tumor Response of Transarterial Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)||Chinese University of Hong Kong|Yes|Active, not recruiting|February 2007|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2013|July 27, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01837381||67731|
NCT01837680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-166|Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy|Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes||St. Luke's-Roosevelt Hospital Center|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|March 9, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01837680||67708|
NCT01837693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cervicalscreening_mRNA_p16|Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2|HPV as Primary Screening Test in Cervical Cancer Prevention: From DNA to mRNA? A Randomised Controlled Trial Nested in a Double Testing Study With Long Term Follow up|NTCC2|Azienda Unità Sanitaria Locale Reggio Emilia|No|Not yet recruiting|June 2013|December 2019|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|60000|||Female|25 Years|59 Years|No|||May 2012|April 18, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837693||67707|
NCT01837706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-5120206|The Impact of Emergency Physician Empathy on Litigation Propensity|The Impact of Emergency Physician Empathy on Litigation Propensity||Loma Linda University|Yes|Completed|April 2013|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|437|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Emergency room patients|October 2014|October 1, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837706||67706|
NCT01838551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-003|Treatment for Endogenous Cushing's Syndrome|An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome||Cortendo AB|No|Recruiting|August 2014|November 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838551||67641|
NCT01838876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-76|To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)|A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder||Forest Laboratories|No|Active, not recruiting|May 2013|May 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|347|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838876||67617|
NCT01838889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47847|Exploratory Trial of a Group Psychological Intervention for Postnatal Depression in British Mother's of South Asian Origin|Exploratory RCT of a Group Psychological Intervention for Postnatal Depression in British Mother's of South Asian Origin|ROSHNI-D|Lancashire Care NHS Foundation Trust|No|Completed|March 2011|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Female|16 Years|N/A|No|||December 2014|December 5, 2014|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01838889||67616|
NCT01838538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25396|Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy|||Chinese PLA General Hospital|No|Recruiting|June 2011|||June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|75 Years||||April 2013|April 19, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838538||67642|
NCT01828190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOT- fistulas non-naive|The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers|Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers||Assaf-Harofeh Medical Center|No|Recruiting|March 2013|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01828190||68432|
NCT01835483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-FVL-300|Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test|A Multicenter Clinical Study to Determine the Performance Characteristics of the MassPLEX Factor II and Factor V Leiden Genotyping Test in Patients With Suspected Thrombophilia||Sequenom, Inc.|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|867|Samples With DNA|De-identified banked genomic DNA|Both|18 Years|N/A|No|Probability Sample|Patients with suspected thrombophilia|January 2014|January 16, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01835483||67875|
NCT01835496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA41-0412|Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease|The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease||ApoPharma|No|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|45 Years|No|||April 2013|July 22, 2015|April 11, 2013||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01835496||67874|
NCT01836016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER in COPD|A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients|Comparison of Conventional Medicine, TCM Treatment and Combination of Both Conventional Medicine and TCM Treatment for Patients With Chronic Obstructive Pulmonary Disease: A Randomized Comparative Effectiveness Research Trial||Henan University of Traditional Chinese Medicine|Yes|Not yet recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|80 Years|No|||April 2013|April 11, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01836016||67834|
NCT01835457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS_concmed_controlled|Concentration/Meditation Limits Inflammation|Concentration/Meditation as a Novel Means to Limit Inflammation: a Randomized Controlled Pilot Study||Radboud University|Yes|Completed|February 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2013|July 22, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01835457||67877|
NCT01836653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATOM|Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases|Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer|ATOM|EPS Corporation|Yes|Recruiting|May 2013|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||January 2016|January 20, 2016|April 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836653||67786|
NCT01836666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-Dnr-2012-446-31M-1|Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management|Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management||Eques Indolor AB|No|Recruiting|January 2008|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|500|||Both|15 Years|99 Years|No|Non-Probability Sample|Patients referred to a specialized interventional pain management clinic in northen sweden|January 2016|January 19, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836666|1 Year|67785|
NCT01836913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPECT|Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer|Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer|RESPECT|University Medical Center Groningen|No|Completed|May 2009|April 2014|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically proven esophageal carcinoma who are planned for curative high        dose radiotherapy with or without chemotherapy, with or without surgery.|March 2016|March 22, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836913||67766|
NCT01837173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECLNI-MC2013|Multicentric Retrospective Review of Extracapsular Lymph Node Involvement After Esophagectomy|Can Extracapsular Lymph Node Involvement be a Tool to Fine-tune UICC TNM 7th Edition for Esophageal Carcinoma?|ECLNI-MC|University Hospital, Gasthuisberg|No|Enrolling by invitation|March 2013|November 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Multicentric cohort study, patient chart analysis Since several high volume European        institutions have published their results on patients with extracapsular lymph node        involvement, we plan a pooling of their 'raw' data regarding type of treatment, histology,        extracapsular LNI and (disease-free) survival.|April 2013|April 17, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01837173||67746|
NCT01837186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMPY2013|Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)|Incidence, Risk Factors and Outcome of Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)||University Hospital, Gasthuisberg|No|Completed|January 2012|March 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive pneumonectomies for Non Small Cell Lung Cancer (NSCLC) from the University        Hospital Leuven from 1996 till 2012|April 2013|April 22, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01837186||67745|
NCT01837472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390506|Probiotics in the Treatment of Irritable Bowel Syndrome|Evaluating The Effects of Probiotics on Symptoms of Patients With Irritable Bowel Syndrome||Isfahan University of Medical Sciences|No|Completed|April 2012|April 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|65 Years|No|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837472||67724|
NCT01837485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15010101882058|Probiotics in the Treatment of Irritable Bowel Syndrome|Evaluation of the Effects of Lactol Probiotic in Comparison With Placebo on Symptoms of Irritable Bowel Syndrome||Islamic Azad University, Najafabad Branch|No|Completed|August 2011|March 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|No|||April 2013|April 18, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837485||67723|
NCT01825369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FinemanCarnitine|Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow|Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow|L-carn|University of California, San Francisco|Yes|Recruiting|December 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Months|12 Months|No|||January 2015|January 12, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01825369||68647|
NCT01825655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2012-003|Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching|Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study||Virginia Commonwealth University|No|Recruiting|September 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|73|||Both|6 Years|18 Years|No|||February 2016|February 19, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01825655||68625|
NCT01826253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-D37-VOL.13|Observational Study of Oxygen Delivery During a Fractional Fluid Expansion|Observational Study of Oxygen Delivery During a Fractional Fluid Expansion|OR|University Hospital, Caen|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Mechanically ventilated patients after elective cardiac surgery with oesophageal Doppler        for cardiac output monitoring and arterial and venous central line|May 2013|June 13, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01826253||68580|
NCT01837108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43234.091.13|Eplerenone and Extracellular Adenosine Formation|Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo|eplerenone01|Radboud University|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|January 8, 2014|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837108||67751|
NCT01837719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-511|Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat|A Randomized, 5-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Following a Light Meal, the Relative Bioavailability of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Under Fasted Conditions, and the Effect of Food on the Bioavailability of Atazanavir in the Fixed Dose Combination|Atazanavir|Bristol-Myers Squibb|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|64|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|April 18, 2013|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01837719||67705|
NCT01837394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-029|Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy|Ultrasound-guided Block of the Saphenous Nerve and Obturator Nerve, Posterior Branch, for Postoperative Pain Management After Ambulatory Knee Arthroscopy||Bispebjerg Hospital|No|Completed|August 2012|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01837394||67730|
NCT01838265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120698|Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management|A Randomized Two-Arm Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management: The MGM Trial|MGM|University of Miami|Yes|Withdrawn|August 2012|||August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Biopsy tumor tissue, blood and urine samples for correlative studies (circulating tumor      cells (CTC), free-circulating DNA (fcDNA) and single nucleotide polymorphisms (SNPs)|Male|35 Years|75 Years|No|Non-Probability Sample|Low risk male patients with early stage T1 - T2a prostate adenocarcinoma, based on a        digital rectal exam palpation. Patients must also have less than three positive cores with        < 50% of a single core; and Gleason score 3 + 3 = 6 or less.|December 2014|December 5, 2014|April 18, 2013||No|Unlikely to Accrue|No||https://clinicaltrials.gov/show/NCT01838265||67663|
NCT01838564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-321|The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology|The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology||Dana-Farber Cancer Institute|No|Completed|November 2004|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|104|||Both|2 Years|25 Years|No|||April 2013|April 26, 2013|April 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01838564||67640|
NCT01838902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1321|Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers|Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia|PRINOGAM|Medical Research Council Unit, The Gambia|Yes|Completed|August 2013|October 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|467|||Both|12 Months|N/A|Accepts Healthy Volunteers|||September 2015|March 15, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01838902||67615|
NCT01839188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI02C|Spanish Mixed HEXA/PENTA/HEXA Schedule|A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.||Sanofi Pasteur MSD|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|385|||Both|46 Days|76 Days|Accepts Healthy Volunteers|||December 2014|December 11, 2014|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01839188||67593|
NCT01839175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HXM01C|Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination|A Phase III Open-label Randomised Study to Evaluate the Immunogenicity and Safety of the Concomitant Administration of a New Hexavalent DTaP-IPV-HepB-PRP-T Combined Vaccine (Hexavalent Vaccine) Given at 2, 3, and 4 Months of Age With a Meningococcal Serogroup C Conjugate (MenC) Vaccine Given at 2 and 4 Months of Age||Sanofi Pasteur MSD|No|Completed|April 2013|February 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|46 Days|76 Days|Accepts Healthy Volunteers|||May 2015|May 29, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01839175||67594|
NCT01828203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHI-1005|Minocycline in Acute Spinal Cord Injury (MASC)|Phase III Study of Minocycline in Acute Spinal Cord Injury||Rick Hansen Institute|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|16 Years|N/A|No|||October 2014|October 29, 2014|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828203||68431|
NCT01836029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRXP-A202|Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||VentiRx Pharmaceuticals Inc.|Yes|Active, not recruiting|July 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836029||67833|
NCT01836042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS100-PAS|Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort|Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent System In Conjunction With Cataract Surgery: Extended Follow-up of the Premarket Cohort||Glaukos Corporation|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|108|||Both|N/A|N/A|No|Non-Probability Sample|Extended follow-up of subjects previously enrolled in Glaukos Study GC-003|May 2015|May 18, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836042||67832|
NCT01836315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:123|Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section|Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section||University of Manitoba|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Serum|Female|18 Years|45 Years||Probability Sample|We will undertake a prospective cohort study to examine the levels of circulating        inflammatory cytokines in obese and non-obese parturients undergoing elective cesarean        section and correlate them with the rate of postoperative wound infections. We will        recruit 20 patients in each arm of the study.|December 2013|December 6, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836315||67812|
NCT01835470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-365|Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan|A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics||Bristol-Myers Squibb|No|Active, not recruiting|August 2013|December 2018|Anticipated|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|17 Years|No|||February 2016|March 11, 2016|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835470||67876|
NCT01829139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-MULTI|Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones|A Prospective Multicenter Comparative Study for Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones||Soon Chun Hyang University|No|Recruiting|March 2012|December 2021|Anticipated|February 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|We randomized patients (>18 years of age) who underwent therapeutic endoscopic biliary        sphincterotomy and/or balloon dilation for the complete clearance of their bile duct        stones.|April 2013|April 8, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01829139|2 Years|68360|
NCT01829152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARHF-0319|Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure|Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure||Verizon Wireless|No|Active, not recruiting|December 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829152||68359|
NCT01836926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mansoura oncology centre|Short Term Outcomes of Laparoscopic Intersphincteric Resection for Low Rectal Cancer|Short Term Outcomes of Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer:A Multicentric Randomized Controlled Trial|ISR|Mansoura University|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01836926||67765|
NCT01836939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1881|Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT||Icahn School of Medicine at Mount Sinai|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836939||67764|
NCT01829633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29144/3/LT|Anatomic and Clinical Long-term Follow-up of Conservatively Treated Rotator Cuff Tears|Anatomic and Clinical Long-term Follow-up of Conservatively Treated Rotator Cuff Tears||Martina Hansen's Hospital|Yes|Enrolling by invitation|March 2012|July 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with a symptomatic full-thickness rotator cuff tear in the period 2002        to 2005. All tears were deemed to be repairable at the time of the diagnosis|December 2015|December 18, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829633||68322|
NCT01829932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1443-11|The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study|The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study||Queen's University|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||October 2015|October 13, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829932||68299|
NCT01825954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-201|Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - St. Joseph Mercy Oakland|A Double-Blinded, Randomized, Sham-Controlled, Proof of Concept Study Exploring the Safety and Efficacy of RINCE Technology for the Treatment of Patients With Fibromyalgia|PERRFECT-SJMO|Cerephex Corporation||Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|22 Years|65 Years|No|||September 2015|September 2, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825954||68602|
NCT01825967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/532|Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker|Predictive Value of C-Reactive Protein in Acute Diverticulitis||Corporacion Parc Tauli|No|Not yet recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|All Patients with Acute Diverticulitis|April 2013|April 9, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01825967|30 Days|68601|
NCT01826266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-001|Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban|Phase I Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban|PER977-P1|Perosphere, Inc.|Yes|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|83|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826266||68579|
NCT01825980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBZF961X2201|Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients|Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients|CBZF961X2201|Novartis|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|N/A|N/A|No|||March 2015|March 11, 2015|April 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825980||68600|
NCT01837732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K110702|Effectiveness of Relational Touch in Painful Elderly|Effectiveness of Relational Touch in the Management of Chronic Pain in Institutionalized Elderly|EFFITOUREL|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|65 Years|N/A|No|||May 2014|May 19, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01837732||67704|
NCT01837745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01569-34|Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?|Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?|ESTIMABL2|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|April 2013|October 2020|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|750|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837745||67703|
NCT01838005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1676|Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services|Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services||University of North Carolina, Chapel Hill|No|Completed|April 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|433|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01838005||67683|
NCT01838018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8777|Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)|Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)||Oregon Health and Science University|No|Recruiting|April 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|12|||Both|7 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The PKAN group consists of individuals in the United States diagnosed with PKAN.|October 2015|October 23, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838018||67682|
NCT01838278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vojta-2013|Effectiveness of Vojta Therapy in Motor Development of Preterm Children|Effectiveness of Vojta Therapy in Motor Development of Preterm Children||Universidad de Murcia|Yes|Enrolling by invitation|January 2013|December 2014|Anticipated|March 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|1 Month|18 Months|Accepts Healthy Volunteers|||May 2013|May 6, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01838278||67662|
NCT01838291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA35-PM|Active Drug Surveillance Program of Ferriprox Use|Active Drug Surveillance Program of Ferriprox Use||ApoPharma|No|Completed|June 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|294|||Both|N/A|N/A|No|Non-Probability Sample|Apporximately 300 patients who have recently started treatment with treatment with        Ferriprox (less than one month prior to enrolment) or who are naive to Ferriprox        treatment.|April 2013|April 19, 2013|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838291||67661|
NCT01835002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESOLA|Transcorneal Electrical Stimulation - Multicenter Safety Study|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicenter Safety Study of the Okustim ® System||Okuvision GmbH|No|Completed|September 2012|August 2015|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|80 Years|No|||September 2015|September 7, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01835002||67912|
NCT01835223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 229112|Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery|Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma||Roswell Park Cancer Institute|Yes|Recruiting|July 2013|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01835223||67895|
NCT01834976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pchd biomarker in okayama|Cardiac Biomarker in Pediatric Heart Disease|Observational Study of Cardiac Biomarker During Perioperative Management in Pediatric Heart Disease||Okayama University||Completed|November 2012|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|Samples With DNA|serum,urine|Both|N/A|18 Years|No|Non-Probability Sample|pediatric patients who receive surgery for congenital heart disease under 18 years old|December 2015|December 27, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834976||67914|
NCT01834989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-078|Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I|Effect of Training and Local Infusion of Insulin-like Growth Factor-I and Training on Tendon Structure in Patients With Patellar Tendinopathy|IGF-I|Bispebjerg Hospital|No|Recruiting|April 2013|January 2017|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|50 Years|No|||July 2015|July 28, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01834989||67913|
NCT01828216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|amb_hosp_OSA|Ambulatory Versus Conventional Approach Diagnosing OSA|A Randomized Controlled Study Assessing the Role of an Ambulatory Approach Versus the Conventional Approach in Managing Suspected Obstructive Sleep Apnoea Syndrome||Chinese University of Hong Kong|No|Recruiting|January 2013|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|260|||Both|18 Years|80 Years|No|||April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01828216||68430|
NCT01835808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POST-IT|Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease|Observational Study of the Evaluation of FFR in the Treatment of Coronary Artery Disease|POST-IT|Portuguese Society of Cardiology|Yes|Completed|March 2012|November 2014|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|918|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive CAD patients submitted to coronary angiography and in which coronary lesions        are to be evaluated with pressure-wire (FFR functional evaluation).|May 2015|May 22, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01835808|1 Year|67850|
NCT01835821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-158|Clinical Study of Porcelain-fused and IPS e.Max CAD Crowns|A Clinical Evaluation of Hand-veneered, Porcelain-fused NobelProcera(TM) Crown Shaded Zirconia and NobelProcera(TM) Full Contour Crown IPS e.Max CAD on Molars||University of Siena|No|Active, not recruiting|March 2010|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|70 Years|No|||July 2014|July 4, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01835821||67849|
NCT01828684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00047263|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine.||University of Utah|No|Completed|March 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||February 2014|February 9, 2014|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828684||68395|
NCT01836289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052668|High-dose Cyclophosphamide for Severe Refractory Crohn Disease|High-dose Cyclophosphamide for Severe Refractory Crohn Disease||Johns Hopkins University|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 1, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836289||67814|
NCT01836302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:138|Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study)|Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study)||University of Manitoba|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|16|||Both|18 Years|80 Years|No|Probability Sample|Adult patients admitted to the Intensive Care Unit with Septic Shock|December 2013|December 6, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01836302||67813|
NCT01828944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU961|Olive Oil Polyphenols, Vitamin D, Docosahexaenoic Acid (DHA) and Locomotor Function (PolivD3)|Olive Oil Polyphenols, Vitamin D and Docosahexaenoic Acid (DHA) Synergistic Effects on Locomotor Function|PolivD3|Lesieur|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|149|||Female|57 Years|79 Years|Accepts Healthy Volunteers|||January 2015|April 28, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828944||68375|
NCT01829386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00067651|Non-Heme Iron Load Quantification in the Brain on MRI in Patients With Hemorrhagic Stroke|Non-Heme Iron Load Quantification in the Brain on MRI in Patients With Hemorrhagic Stroke||University of Michigan|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|85 Years|No|||February 2016|February 3, 2016|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829386||68341|
NCT01829399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2373|Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic|Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic||University of North Carolina, Chapel Hill|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|March 25, 2013|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01829399||68340|Originally this was designed as a crossover study. However, there was a very strong crossover effect which invalidated the results from the second series of injections. Therefore, we have only analyzed the data from the first visit.
NCT01829659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS Brilinta AZ|The ACS Ethnicity Platelet Function Study|The ACS Ethnicity Platelet Function Study||Medstar Research Institute|No|Recruiting|May 2013|||February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Thirty African American patients with documented acute coronary syndrome who agree to        participate in this clinical study and who sign an informed consent will be enrolled.        Race determination will be based on a patient's self-report, but patients enrolled in the        trial must also report that all four of their grandparents were of the same race as        theirs. Other races (Asian, Native American, etc) will be excluded from this study.|August 2014|August 8, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829659||68320|
NCT01829646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54731|Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology|Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology. A Prospective, Non-commercial and Mono-centric Study.||Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 15, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01829646||68321|
NCT01825993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR TAP 2013|RANDOMISED STUDY OF EPIDURAL VS MPCA MORPHINE VS TAPP IN LAPAROSCOPIC SIGMOIDECTOMY|RANDOMISED STUDY ABOUT POTSOTERATORY PAIN CONTROL IN LAPAROSCOPIC SIGMOIDECTOMY|2013/004|Corporacion Parc Tauli|No|Not yet recruiting|April 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|225|||Both|18 Years|90 Years|No|||April 2013|April 5, 2013|March 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01825993||68599|
NCT01855932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00078810|Enlighten: An Adaptive Technology Weight Loss Intervention|Enlighten: An Adaptive Technology Weight Loss Intervention||Northwestern University|Yes|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||September 2013|September 20, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01855932||66310|
NCT01855945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V129_01|Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.|Phase I Multi-center, Observer-Blind, Randomized, Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to < 65 Years and Elderly ≥ 65 Years and Older.||Novartis|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|627|||Both|3 Years|92 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|April 2, 2013|Yes|Yes||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01855945||66309|
NCT01837758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVVH-Multiplate|Monitoring Platelet Function During Continuous Hemodialysis|Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device||Goethe University|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients in an intensive care unit with the need for a renal replacement therapy-|October 2013|October 1, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837758||67702|
NCT01837771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13008|Epiphrenic III Pilot Trial|Uni- or Biventricular Pacing and Diaphragmatic Stimulation for Severe Heart Failure (Epiphrenic III Pilot Trial)||Luzerner Kantonsspital||Recruiting|April 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01837771||67701|
NCT01838031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z111107058811025|Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study|Randomized Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study||Peking Union Medical College Hospital|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|1000|||Female|18 Years|42 Years|No|||November 2013|November 25, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01838031||67681|
NCT01839201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEOEC RKEB/IKEB 2830-2008|The Effect of Preoperative Suggestions on Perioperative Dreams and Dream Recalls|Guiding Dreaming During Anaesthesia by Means of Communication Through Suggestions. What Influences Our Suggestions? What do Our Suggestions Influence?|dream|University of Debrecen|Yes|Completed|November 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|270|||Both|19 Years|75 Years|No|||April 2013|April 25, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01839201||67592|
NCT01839214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-201-064|A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis|A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis||Vascular Biogenics Ltd. operating as VBL Therapeutics|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01839214||67591|
NCT01839240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0111|Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia|Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)||University of Chicago|No|Active, not recruiting|June 2012|December 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839240||67589|
NCT01835015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-074|Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration|A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration||Alcon Research|No|Completed|May 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|50|||Both|55 Years|90 Years|No|||February 2016|February 24, 2016|April 16, 2013|No|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01835015||67911|
NCT01827696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effect of American Ginseng on Exercise-induced Muscle Soreness|Effect of American Ginseng on Exercise-induced Muscle Soreness||Lawson Health Research Institute|Yes|Completed|May 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 1, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827696||68470|
NCT01835509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12136|Group Intervention to Increase Physical Activity in Childhood Cancer Survivors|Group Intervention to Increase Physical Activity in Childhood Cancer Survivors||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|8 Years|12 Years|No|||February 2014|February 24, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01835509||67873|
NCT01835522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beth_IsraelMC 058-09|A Survey of Sexual Function in Schizophrenic Patients|A Survey of Sexual Function in Schizophrenic Patients||Beth Israel Medical Center|No|Withdrawn|July 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|Beth Israel Medical Center outpatient behavioral and mental health clinic|August 2015|August 3, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01835522||67872|
NCT01828515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082012-082|Vilazodone for Corticosteroid-Induced Memory Impairment|Vilazodone for Corticosteroid-Induced Memory Impairment||University of Texas Southwestern Medical Center|No|Completed|December 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01828515||68408|
NCT01828437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYRIPREDIS|Addition of Pyridoxine to Prednisolone in Infantile Spasms|Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial||Lady Hardinge Medical College||Recruiting|March 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|3 Months|36 Months|No|||April 2013|April 9, 2013|April 7, 2013||||No||https://clinicaltrials.gov/show/NCT01828437||68413|
NCT01828463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL000928|Dose Response Study of Nitisinone in Alkaptonuria|An International, Multicentre, Randomised, Open-label, No-treatment Controlled, Parallel-group, Dose-response Study to Investigate the Effect of Once Daily Nitisinone on 24-hour Urinary Homogentisic Acid Excretion in Patients With Alkaptonuria After 4 Weeks Treatment.|SONIA1|University of Liverpool|Yes|Completed|May 2013|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828463||68412|
NCT01828489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO-DBH-AML2012|Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years|NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years|AML2012|Vastra Gotaland Region|Yes|Recruiting|March 2013|March 2023|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|N/A|18 Years|No|||April 2013|January 23, 2014|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01828489||68410|
NCT01836328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RATIOMTD-010810|Conversion From Parenteral to Oral Methadone.|Prospective Randomized Simple Blinded Study Comparing Two Conversion Ratios From Parenteral to Oral Methadone in Patients With Cancer Pain.|RATIOMTD|L'Hospitalet de Llobregat|Yes|Completed|August 2011|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|44|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836328||67811|
NCT01836679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM204|Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer|A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer||Chipscreen Biosciences, Ltd.|No|Completed|April 2013|December 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01836679||67784|
NCT01829178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-03-33-18878|Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma|Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity||Tehran University of Medical Sciences|Yes|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||May 2015|May 11, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01829178||68357|
NCT01829165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21206|Brain Imaging of rTMS Treatment for Depression|A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI||Stanford University|No|Recruiting|September 2012|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01829165||68358|
NCT01829958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-028|Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy|Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||January 2016|January 5, 2016|April 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01829958||68297|
NCT01829984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-057|Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers|A Comparison of Strategies for Injection Teaching: Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers||Memorial Sloan Kettering Cancer Center||Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|51|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All breast cancer medical oncology clinics at MSKCC will serve as recruitment clinics for        the proposed study. Nurses will notify the PI of any patient due to start adjuvantadjuvant        or neoadjuvant treatment when the regimen includes pegfilgrastim.|September 2015|September 3, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829984||68295|
NCT01829971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX34-101|A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection|A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection||Mirna Therapeutics, Inc.|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|November 23, 2015|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829971||68296|
NCT01830283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-8|The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination|Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination||Beijing Center for Disease Control and Prevention|No|Enrolling by invitation|April 2013|April 2018|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50000|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||April 2013|May 27, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01830283||68273|
NCT01825668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:019|Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy|Effect of a Plant Sterol-Fortified Low-fat Milk Product on Plasma Lipid Levels of Humans in Relation to Different Infant Feeding Practices and Later Life Cholesterol Metabolism||University of Manitoba|Yes|Active, not recruiting|March 2013|June 2016|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|February 2, 2016|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01825668||68624|
NCT01825681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13236|Life Enhancing Activities for Family Caregivers|Life Enhancing Activities for Family Caregivers (LEAF)|LEAF|University of California, San Francisco|No|Recruiting|October 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01825681||68623|
NCT01856192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00959|Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma|Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|August 2013|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|345|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856192||66290|
NCT01838577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08114|Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study|Genetics of EGFR Mutation Study (GEM): a Translational Study of the EORTC Lung Group.|GEM|European Organisation for Research and Treatment of Cancer - EORTC|No|Recruiting|September 2013|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Case cohort: Patients with proven EGFR mutation in exons 18-21 from tumor material.        Control cohort: Patients known to be somatic EGFR "wild-type," i.e. no mutation detected        in exons 18-21 from tumor material.|January 2016|January 21, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838577|3 Years|67639|
NCT01838915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/284|Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection|Gut Microbiota, Bacterial Translocation, Immune Activation and Endothelial Dysfunction in HIV Infection|MicroVIH|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Yes|Completed|June 2011|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 2, 2013|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838915||67614|
NCT01838928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FU 002|Minimum Effective Concentration of Bupivacaine in Ultrasound-guided Axillary Brachial Plexus Block|Minimum Effective Concentration of Bupivacaine in Ultrasound-guided Axillary Brachial Plexus Block||Federal University of São Paulo||Completed|August 2010|June 2012|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|46|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01838928||67613|
NCT01839227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0039|Post-operative Cognitive Dysfunction and the Change of Regional Cerebral Oxygen Saturation in Elderly Patients Undergoing Spinal Surgery|||Yonsei University|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|87|||Both|65 Years|85 Years|No|||January 2015|January 27, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01839227||67590|
NCT01827371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0021|Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®|A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|435|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|December 17, 2015|April 4, 2013|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01827371||68495|
NCT01827384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130105|NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors|Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||July 2015|September 15, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827384||68494|
NCT01827709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54730|Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma|Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma. A Prospective, Non-commercial and Mono-centric Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 15, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01827709||68469|
NCT01827943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-08|Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer|Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer|VESTOR|Institut Bergonié|No|Active, not recruiting|June 2009|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01827943||68451|
NCT01828528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-0026-ZB-CTIL|Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease in Diabetic Patients|The Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease in Diabetic Patients: Pre- and Post-Surgical Evaluation Utilizing Non-invasive Measures||Sheba Medical Center|No|Not yet recruiting|April 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Whole blood, Liver tissue|Both|20 Years|80 Years|No|Non-Probability Sample|30 diabetic patients with NAFLD (diagnosed by ultra sound) undergoing Roux-en-Y gastric        bypass (RYGB) or sleeve gastrectomy (SG) at Surgery C department at Sheba Medical Center,        Israel.|April 2013|April 7, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01828528||68407|
NCT01828476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081214|Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer|A Phase II Study of ABT-263/Abiraterone (Arm A) or ABT-263/Abiraterone and Hydroxychloroquine (Arm B) in Patients With Metastatic Castrate Refractory Prostate Cancer (CRPC) and Progression Following Chemotherapy and Abiraterone||Rutgers, The State University of New Jersey|No|Completed|June 2013|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828476||68411|
NCT01828710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-2103-GC|Myo-inositol on Human Semen Parameters|Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles||AGUNCO Obstetrics and Gynecology Centre|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|62|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828710||68393|
NCT01828723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSVF0001|Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells|A Phase One, Open Label, Single Arm Study to Demonstrate the Safety of Antria Cell Preparation Process During Facial Fat Grafting Assisted With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)||Antria|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828723||68392|
NCT01828931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151/2012|Lifestyle Intervention for Diabetes and Weight Management in Psychosis|Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With Psychosis|Healthy LIFE|Centre for Addiction and Mental Health||Active, not recruiting|December 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||January 2015|January 8, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01828931||68376|
NCT01829425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT007171|Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy|Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy|Hyp-hOP|University of New Mexico|Yes|Recruiting|March 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|182|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829425||68338|
NCT01829438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6MWT|Influence of Music on 6 Minutes Walking Distance in Healthy Children|Influence of a Distractive Auditory Stimulus on 6 Minute Walking Test in Healthy Children||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|June 2010|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|97|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829438||68337|
NCT01829412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMY-MRI-08|Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma|Comparison of Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) With Skeletal X-Ray and MRI of the Spine for the Assessment of Bone Disease in Multiple Myeloma|MMY-MRI-08|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|July 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|80 Years|No|||April 2013|April 9, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829412||68339|
NCT01829997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB3D012012|Assessment of nanOss Bioactive 3D in the Posterolateral Spine|A Prospective, Post-Market Assessment Of NanOss Bioactive 3D in the Posterolateral Spine||Pioneer Surgical Technology, Inc.|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829997||68294|
NCT01830296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDHTRKTN13|Intravenous Remifentanil Plus Morphine or Morphine Alone for Postthoracotomy Pain|COADMINISTRATION OF INTRAVENOUS REMIFENTANIL AND MORPHINE FOR POSTTHORACOTOMY PAIN; COMPARISON WITH IV MORPHINE ALONE||Cukurova University|No|Completed|May 2011|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|59 Years|No|||April 2013|April 10, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01830296||68272|
NCT01855620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK6606|The Effect of Body Mass Index on Etonogestrel Hormone Levels in Women Using the Single-rod Contraceptive Implant|The Effect of Body Mass Index on Etonogestrel Levels in Women Using the Single-rod Contraceptive Implant|Eto BMI|Columbia University|No|Completed|December 2012|March 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|52|Samples With DNA|Whole blood|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is English or Spanish-speaking women ages 15-45 years old at the New        York Presbyterian Hospital's Title X Family Planning Clinic and the Columbia University        Medical Center's Department of Obstetrics and Gynecology Family Planning Practice who have        been using the etonogestrel contraceptive implant for at least the six months prior to        their visit.|April 2014|April 11, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855620||66334|
NCT01856218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX003-CL201|An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With MPS 7|An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)||Ultragenyx Pharmaceutical Inc|Yes|Active, not recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|5 Years|30 Years|No|||January 2015|January 15, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856218||66288|
NCT01852279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12NE574|BCI and FES for Hand Therapy in Spinal Cord Injury|Brain Computer Interface Control of Functional Electrical Stimulation for a Hand Therapy in Tetraplegic Patients||NHS Greater Glasgow and Clyde|No|Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||May 2013|May 13, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01852279||66591|
NCT01838343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218-12|Efficacy of Ultrasound to Guide Management During a Rapid Response Event|Efficacy of Ultrasound to Guide Management During a Rapid Response Event||Beth Israel Medical Center|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01838343||67657|
NCT01838590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0138|Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection|A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.||Gilead Sciences|No|Completed|March 2013|August 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 15, 2013|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01838590||67638|
NCT01838603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-Dnr-2012-446-31M-3|Patient Experience of Interventional Pain Management. Qualitative Study|Patient Experience of Interventional Pain Management. Qualitative Study||Eques Indolor AB|No|Recruiting|April 2013|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic pain|January 2016|January 19, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01838603||67637|
NCT01827072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-10/C-01|Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.|NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy.||Nihon Pharmaceutical Co., Ltd|No|Completed|April 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|100 Years|No|||October 2014|January 17, 2016|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01827072||68518|
NCT01827397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN41CT1.1.2|Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine|Phase 1 Randomised, Single-centre, Observer-blind, Placebo-controlled Trial of Safety and Immunogenicity of EN41-UGR7C HIV Vaccine Candidate Administered Intramuscularly in Healthy Female Volunteers||PX'Therapeutics|Yes|Completed|April 2013|February 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827397||68493|
NCT01827410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH10|High Agreement Between the Danish Ventral Hernia Database and Hospital Files in Region Zealand|High Agreement Between the Danish Ventral Hernia Database and Hospital Files in Region Zealand||University Hospital Koge|No|Completed|October 2010|February 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|408|||Both|18 Years|N/A|No|Non-Probability Sample|Hernia repairs performed in Region Zealand and registered in the Danish Ventral Hernia        Database during the study period|April 2013|April 8, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827410||68492|
NCT01827423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-SCCA|Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava|Squamous Cell Carcinoma Antigen as a Marker of Sinonasal Inverted Papilloma||University Hospital Ostrava|No|Completed|January 2000|January 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01827423||68491|
NCT01827722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORION|Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion|Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein|ORION|Valley Retina Institute|No|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827722||68468|
NCT01827956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-24|Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms|Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours|FCRVADS|Institut Bergonié|Yes|Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|N/A||1|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|Squamous cell carcinomas of the upper aero-digestive tract recurrent or metastatic.|April 2013|April 9, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01827956||68450|
NCT01828762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040420100005|Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy|Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy|DC-TC|Cellular Biomedicine Group Ltd.|Yes|Completed|December 2012|||December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||April 2013|December 20, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828762||68389|
NCT01828502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 1201|Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer|Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer||University of South Florida|Yes|Withdrawn|October 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|2 Years|12 Years|No|||October 2014|October 28, 2014|March 28, 2013||No|The study was closed due to poor accrual. No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT01828502||68409|
NCT01828970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/43|Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients|Glycemic Control Assessed by Continuous Glucose Monitoring in Hemodialyzed Patients With Diabetes Mellitus Treated Via the Basal-Bolus Detemir-Aspart Insulin Regimen: A Pilot Study|GlyCEDIA|Centre Europeen d'Etude du Diabete|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|83 Years|No|||April 2013|April 9, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01828970||68373|
NCT01829191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1561AD|Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control)|Controlling Myopia Progression With Soft Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|April 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|April 8, 2013|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT01829191||68356|
NCT01828697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Highlow|Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy|Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2013|January 2019|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|50 Years|No|||January 2016|January 6, 2016|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828697||68394|
NCT01828957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-009|Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants|Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem® Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants||Medipost Co Ltd.|Yes|Active, not recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|14 Days|No|||April 2015|April 7, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828957||68374|
NCT01829451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uoulu|Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Endometrial Ablation|Autocrosslinked Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Bipolar Radiofrequency Endometrial Ablation: a Randomised, Controlled and Double Blind Study||University of Oulu|No|Completed|January 2011|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Female|35 Years|52 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01829451||68336|
NCT01829464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_303|TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes||Takeda|Yes|Terminated|May 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|April 9, 2013|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT01829464||68335|
NCT01829672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-174 ex 12/13|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Prospective Study||Medical University of Graz|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829672||68319|
NCT01829685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-06|Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy|A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study|Dragon-Ex|Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|March 2013|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|65 Years|No|||June 2014|June 17, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829685||68318|
NCT01826864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002177|Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma|Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection||Jonsson Comprehensive Cancer Center|Yes|Recruiting|August 2011|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|75 Years|No|||October 2015|October 28, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826864||68534|
NCT01855386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375-2012|The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes|Non-Alcoholic Fatty Liver Disease in Gestational Diabetes - An Opportunity for Prevention of Type 2 Diabetes Mellitus?||University of Florida|No|Recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|190|||Female|18 Years|50 Years|No|Probability Sample|-  a pregnant female          -  age between 18-50 years.|November 2015|November 25, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01855386||66352|
NCT01855633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-019|Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke|Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke||Dongtan Sacred Heart Hospital|No|Recruiting|April 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01855633||66333|
NCT01855971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESXF|Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)|Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)||Parc de Salut Mar|No|Completed|June 2013|October 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|40 Years|No|||February 2016|February 10, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855971||66307|
NCT01826526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCL-0112|Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%|Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device||Radboud University|Yes|Recruiting|June 2013|September 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|80 Years|No|||November 2014|November 11, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01826526||68559|
NCT01826539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen8652|A Comparison of Dorsal Branch of the Digital Nerve Versus Dorsal Digital Nerve for Finger Pulp Reconstruction|||The Second Hospital of Tangshan|Yes|Completed|January 2011|September 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|71|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 5, 2013|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826539||68558|
NCT01826799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICUnoise|Noise in the Intensive Care Unit|Noise in the Intensive Care Unit and Its Influence on Sleep Quality: a Nationwide Survey in Dutch Intensive Care Units||Jeroen Bosch Ziekenhuis|Yes|Completed|April 2013|December 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|100 Years|No|Non-Probability Sample|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours        ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to        understand Dutch are eligible.|January 2016|January 13, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01826799||68539|
NCT01827085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN2012/015|Time to Intubation (TTI) of Obese Patients. A Comparison Macintosh Laryngoscope and Stortz Video Laryngoscope|Time to Intubation in Obese Patients. A Comparison Between Macintosh Laryngoscope and Stortz Video Laryngoscope|TTI|Örebro University, Sweden|No|Recruiting|May 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|60 Years|No|Probability Sample|In-patients from the University hospital of Orebro who will go through planned surgery|September 2014|September 10, 2014|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827085||68517|
NCT01827436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009844|Asymmetrical Gait Training After Pediatric Stroke|Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia||Children's Hospital of Philadelphia|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|5 Years|17 Years|No|||January 2016|January 4, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827436||68490|
NCT01827982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101083|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study To Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827982||68448|
NCT01827969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-58|Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy|Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy|USF|Institut Bergonié|Yes|Terminated|December 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Female|18 Years|N/A|No|||April 2013|April 9, 2013|November 6, 2012||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01827969||68449|
NCT01828736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVH-CT 02|Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma|Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression|CVH-CT02|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|No|Active, not recruiting|February 2004|||May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||April 2013|April 8, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01828736||68391|
NCT01828983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0087|Telephone Support During Overseas Deployment for Military Spouses|Telephone Support During Overseas Deployment for Military Spouses||Memphis VA Medical Center||Active, not recruiting|April 2011|March 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01828983||68372|
NCT01829204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L13-054|Prospective Data Bank Creation to Study Vaginal Conditions|A Prospective Longitudinal Data Bank Creation to Study Vaginal Conditions With a Novel Diagnostic Approach|CRIPB-13-002|Texas Tech University Health Sciences Center|Yes|Recruiting|April 2013|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|550|||Female|21 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients willing to participate, and give informed consent, and Asymptomatic,        non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or        recurrent vulvovaginal condition who attend our clinical offices for their annual        well-woman physical examination.        2—Non-pregnant women ages 21 to 75 years being evaluated for any gynecological        vulvovaginal condition.        Pregnant women ages 21 to 75 years who are both asymptomatic and healthy Pregnant women        ages 21 to 75 who have any gynecological vulvovaginal condition|October 2015|October 21, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829204|12 Months|68355|
NCT01830309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_102|Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects|Clinical Study to Evaluate Food-Effect on Pharmacokinetics and Pharmacodynamics of Single Oral Dose of CJ-12420 in Healthy Male Subjects||CJ HealthCare Corporation|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01830309||68271|
NCT01829698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trendful-TAU-001|Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC|Evaluate the Efficacy And Safety Of TUDCA Compare UDCA In The Treatment Of Cholestatic Liver Disease-PBC by A Randomized,Double-Blind,Double Dummy,Parallel-Controlled,Multicenter Trial and The Consecutive Treatment By TUDCA||Beijing Trendful Kangjian Medical Information Consulting Limited Company|Yes|Completed|August 2009|February 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|70 Years|No|||March 2014|March 21, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829698||68317|
NCT01829711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130106|Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia|A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia||MedImmune LLC|Yes|Recruiting|April 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|N/A|N/A|No|||March 2016|March 15, 2016|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829711||68316|
NCT01826344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD001|The Vascutek Custom Fenestrated Anaconda Post-Market Surveillance Study|||Vascutek Ltd.|No|Terminated|June 2010|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|628|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a short infrarenal neck of <15mm or juxta-renal abdominal aortic aneurysms        who, in the opinion of the treating physician, are anatomically suitable for the        AnacondaTM Custom Fenestrated Stent Graft and for whom a customised medical device is        required.|December 2015|December 8, 2015|April 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826344|5 Years|68573|
NCT01826617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-13008|Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome|Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA)||St. Luke's Medical Center, Philippines|Yes|Completed|December 2010|December 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||5|Anticipated|400|||Male|18 Years|N/A|No|Non-Probability Sample|This is a cross-sectional study prospectively collecting data from all patients who had        their first Transrectal ultrasound (TRUS) prostate biopsy at the Stone and Prostate        Treatment Center of St. Luke's Medical Center-Quezon City . Data will be collected        uniformly for the purpose of building a clinical care prostate biopsy database. The        indication for prostate biopsy is either a suspicious DRE findings or elevated PSA level        (>4.0ng/ml) or both.|April 2015|April 5, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01826617|1 Year|68552|
NCT01827189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cpc32813|Staffing Patterns of Comprehensive Primary Care Practices|Evaluation of the Comprehensive Primary Care Initiative|cpc|Mathematica Policy Research, Inc.|No|Enrolling by invitation|October 2012|August 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Medicare patients enrolled in traditional Medicare who receive the majority of their        Evaluation and Management visits from one of the study practices.|September 2015|September 28, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01827189||68509|
NCT01827202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-Nr. 011/2012|RAS Quantification in Patients With Aliskiren or Candesartan|Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL)|RASQAL|Medical University of Vienna|Yes|Completed|December 2012|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|24|||Both|18 Years|99 Years|No|||March 2016|March 14, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827202||68508|
NCT01852604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-005|Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)|A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|Yes|Completed|March 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|143|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852604||66566|
NCT01826552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT2356401|Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent|Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent|ORIENT|Seoul National University Bundang Hospital|Yes|Recruiting|September 2013|December 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|375|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|March 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826552||68557|
NCT01826565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPPark|Comparison of Two Insertion Technique of I-gel|Comparison of Two Insertion Technique of I-gel: Standard Versus 90-degree Rotation|I-gel90|Seoul National University Hospital|Yes|Not yet recruiting|May 2013|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|80 Years|No|||May 2013|May 3, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01826565||68556|
NCT01826812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082755|Impairment of Reading Ability in Dry Eye Patients|Functional Impairment of Reading Ability in Dry Eye Patients and Effects of Sustained Reading on the Ocular Surface||Johns Hopkins University|No|Completed|April 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|Samples With DNA|Tears|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known dry eye as well as normal healthy control subjects with no ocular        surface diseases will be recruited from the Ocular Surface Diseases and Dry Eye Clinic as        well as Glaucoma Clinic of the Wilmer Eye Institute.|February 2016|February 24, 2016|April 4, 2013||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01826812||68538|
NCT01826825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Culley_01|Preoperative Cognitive Screening of Elderly Surgical Patients|Preoperative Cognitive Screening of Elderly Surgical Patients||Brigham and Women's Hospital|No|Completed|May 2013|August 2015|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|200 patients over the age of 65 that have provided informed consent will be randomly        assigned to either the mini-cog or the clock in the box cognitive screen.|September 2015|September 3, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01826825||68537|
NCT01827098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM-00066353|A Clinical Study to Compare Two Revascularization Protocols to Treat Non-vital Teeth With Incomplete Root Formation|A Randomized Controlled Clinical Trial of Regenerative Protocols to Treat Immature Necrotic Teeth||University of Michigan|Yes|Recruiting|October 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|25 Years|No|||February 2016|February 12, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01827098||68516|
NCT01827111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1157|Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma|Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Recruiting|April 2013|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|12 Years|70 Years|No|||March 2016|March 23, 2016|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827111||68515|
NCT01827995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDuo2013|Simplified Medical Abortion in Rural India|||Karolinska Institutet|Yes|Completed|April 2013|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|731|||Female|18 Years|N/A|No|||August 2014|August 13, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01827995||68447|
NCT01828008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-004|Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas||CIK|Chinese PLA General Hospital|Yes|Not yet recruiting|April 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|90 Years|No|Probability Sample|the patients with CD20-positive Lymphomas|January 2013|April 9, 2013|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01828008|5 Years|68446|
NCT01828229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2009-082|Consequences of Human Inactivity|Consequences of Human Inactivity||Rigshospitalet, Denmark|Yes|Completed|January 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828229||68429|
NCT01829243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026392|Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial|Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial||Duke University|No|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|N/A|65 Years|No|||August 2014|August 27, 2014|April 9, 2013|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT01829243||68352|
NCT01829503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-099|Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed AML||University of Pittsburgh|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|60 Years|N/A|No|||January 2016|January 14, 2016|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829503||68332|
NCT01828749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-13-19E|Pelvic CT Imaging in Blunt Abdominal Trauma|Pelvic CT Imaging in Blunt Trauma: Limiting Low Yield Radiation Exposure in Carefully Selected Adult and Pediatric Patients||Carolinas Healthcare System|No|Completed|February 2013|March 2015|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|230|||Both|3 Years|60 Years|No|Probability Sample|3-60 years of age evaluated for blunt trauma with a GCS of >14 Order of CT abdomen and        pelvis imaging|December 2015|December 21, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01828749||68390|
NCT01829477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_309|Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes||Takeda|Yes|Terminated|July 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|April 9, 2013|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT01829477||68334|
NCT01829490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB034|Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults|Phase I Trial to Evaluate the Safety and Immunogenicity of a ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy BCG Vaccinated Adults||University of Oxford|Yes|Active, not recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01829490||68333|
NCT01829724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130110|Cerebral Palsy and the Study of Brain Activity During Motor Tasks|Near-infrared Spectroscopy and Electroencephalography to Assess and Train Cortical Activation During Motor Tasks||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|February 2025|Anticipated|February 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|320|||Both|3 Months|N/A|Accepts Healthy Volunteers|||September 2015|March 1, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829724||68315|
NCT01829217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-086|Sunitinib in Never-Smokers With Lung Adenocarcinoma|A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity||Dana-Farber Cancer Institute|Yes|Recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829217||68354|
NCT01829230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1561AF|Myopia Progression After Ceasing Myopia Control Contact Lens Wear|Myopia Progression After Ceasing Myopia Control Contact Lens Wear||Johnson & Johnson Vision Care, Inc.|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|April 8, 2013|Yes|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01829230||68353|
NCT01829737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913107|Malaria Transmission Studies in Mali|Epidemiologic Studies of Plasmodium Falciparum Gametocytemia and Transmission-blocking Immunity in Kenieroba, Mali||National Institutes of Health Clinical Center (CC)||Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|650|||Both|6 Months|65 Years|Accepts Healthy Volunteers|||January 2015|August 26, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829737||68314|
NCT01826357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hsu2013-TMU-JIRB 201302002|Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age|Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age.||Taipei Medical University WanFang Hospital|Yes|Recruiting|March 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Female|13 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|Women had been fulfilled with whole anthropometric measurements, clinic and biochemical        survey about cardiovascular study.|November 2013|November 5, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826357||68572|
NCT01826630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 2012H0327|A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema|A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis.||TopMD Skin Care, Inc.|Yes|Terminated|July 2013|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|4|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|February 20, 2013||No|Difficulty enrolling patients|No||https://clinicaltrials.gov/show/NCT01826630||68551|
NCT01826877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000577|Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer|A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma||Jonsson Comprehensive Cancer Center|Yes|Recruiting|December 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826877||68533|
NCT01835938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5189|Clinical Investigation of Erlotinib as an HCV Entry Inhibitor|Dose Finding and Early Efficacy Study of Erlotinib in Treatment of Chronic Hepatitis C Virus infection_proof of Concept Study||University Hospital, Strasbourg, France|Yes|Not yet recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||June 2014|June 14, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01835938||67840|
NCT01855958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0013|Motor Cortex Plasticity and the Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST) in Osteoarthritis Pain|Primary Motor Cortex Plasticity and the Bottom up Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST)in Osteoarthritis Chronic Pain||Hospital de Clinicas de Porto Alegre|Yes|Completed|February 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|N/A|No|||August 2015|August 19, 2015|May 8, 2013||No||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01855958||66308|
NCT01856205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG607|Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis|A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal||University of Liverpool|Yes|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|1 Year|14 Years|No|||May 2013|May 18, 2013|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01856205||66289|
NCT01826578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jrlee01|Single Port Myomectomy Versus Conventional Myomectomy|Prospective Randomized Controlled Trial to Analyze the Benefits of Single Port Laparoscopic Myomectomy in the View of Cosmetics and Patient Satisfaction|SM|Seoul National University Hospital|Yes|Not yet recruiting|May 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01826578||68555|
NCT01827449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:039|Hypothermia Rewarming With Distal Limb Warming|Hypothermia Rewarming Effectiveness of Distal Limb Warming With Either Fluidotherapy or Warm Water Immersion||University of Manitoba|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827449||68489|
NCT01827462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03192011-7599|Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages|Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages||Stanford University|No|Active, not recruiting|October 2007|May 2016|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|April 4, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01827462||68488|
NCT01827761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258|Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258|Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258||Brown University|Yes|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer Clinics|May 2014|May 9, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827761||68465|
NCT01827774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-015|Soft Tissue Graft for Repair of Pelvic Organ Prolapse|A Post-Market Study of Surgisis® Soft Tissue Graft for Repair of Pelvic Organ Prolapse|POP|Cook||Recruiting|March 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01827774||68464|
NCT01827735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092737|Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2|Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D)|DILT1D|Cambridge University Hospitals NHS Foundation Trust|No|Completed|March 2013|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|50 Years|No|||June 2015|June 22, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827735||68467|
NCT01827748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA120928|Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position|Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position||Adventus Technology|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 11, 2013|March 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827748||68466|
NCT01828268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|META-HA-001-2013|Metabolomics Fingerprinting and Metabolic Dynamis After HIV Infection|Metabolic Fingerprintings and Metabolic Dynamics After HIV Infection:Impact of Metabolic Changes and Anti-Retroviral Therapy, Life Style and Clinical Conditions||Sichuan Academy of Medical Sciences|Yes|Recruiting|March 2013|March 2020|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Plasma from peripheral blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruit 100 HIV-infected individuals from community HIV Clinic and/or Transmitted Disease        Hospital of Chengdu|August 2015|August 9, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828268||68426|
NCT01828242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Empowerment for DM|The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control|The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control|EDMID|SEAMEO Regional Centre for Food and Nutrition|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|84|||Both|18 Years|55 Years|No|||June 2015|June 30, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01828242||68428|
NCT01828255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1212|IOP Patterns in Fast Versus Slow Visual Field Progression Patients|A Single Center, Case-control, Open Label Study Assessing Intraocular Pressure Patterns in Patients With Primary Open-angle Glaucoma Experiencing Fast Versus Slow Visual Field Progression||Sensimed AG|No|Terminated|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|40 Years|89 Years|No|||May 2014|May 12, 2014|April 5, 2013||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT01828255||68427|
NCT01829516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin|The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers|The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers||University of California, San Francisco|Yes|Active, not recruiting|May 2013|November 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829516||68331|
NCT01828996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-SW-001|Shocking Therapy for Chronic Pelvic Pain Syndrome|Shocking Therapy for Pelvic Pain: Evaluation of Shock Wave Therapy to Treat Chronic Pelvic Pain in Men|CPPS|Mount Sinai Hospital, Canada|No|Enrolling by invitation|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|65 Years|No|||August 2014|April 10, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01828996||68371|
NCT01830036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007|RehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation|RehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation|RehaSleep|RWTH Aachen University|No|Active, not recruiting|June 2011|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|1300|||Both|18 Years|N/A|No|Non-Probability Sample|Treatment as part of the routine diagnostics using 2-channel polygraphic|September 2015|September 22, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01830036|12 Months|68291|
NCT01830049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJU2013024|Differential Plasma MicroRNA Profiles in ED and Normal Erectile Function in Older Males|||Nanjing Medical University||Recruiting|March 2013|August 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|||Male|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Group I: older males came to our clinic for diagnosis and treatment of ED. Group II: older        males came to our clinic for physical examination and the erectile function was normal.        Group III: young males came to our clinic for physical examination and the erectile        function was normal.|April 2013|April 10, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01830049||68290|
NCT01830010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKRP203A2105|A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies|A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies||Novartis|No|Recruiting|June 2013|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01830010||68293|
NCT01830023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-28|Vitality Trial - Sampling Examination Data|||RWTH Aachen University|No|Completed|May 2009|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|2019|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients who are examined in the department of cardiology, university hospital Aachen|September 2015|September 22, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01830023||68292|
NCT01826370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.94|Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus|A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Terminated|May 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|678|||Both|18 Years|N/A|No|Non-Probability Sample|Filipino type 2 DM patients|September 2014|September 17, 2014|April 4, 2013||||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01826370||68571|
NCT01826383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|York HPRC 2013-004|Improving Parental Soothing by Video|Improving Parental Soothing by Video: A Randomized Controlled Trial||York University|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|5 Months|20 Months|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826383||68570|
NCT01826656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsteoporosisTrial|Bone Healing in Healthy and Post-menopausal Osteoporotic Women|A Clinical/Real Time Model of Intramembranous Jawbone Healing in Post-menopausal Osteoporotic and Non-osteoporotic Women. A Pilot Study.||University College, London|No|Recruiting|May 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01826656||68550|
NCT01826669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Chest Wall Muscle Stretching and Acute Effects in Chronic Obstructive Pulmonary Disease|Chest Wall Muscle Stretching and Acute Effects on Volume Variation of Thoracoabdominal Wall and Electromyographic Activity in Chronic Obstructive Pulmonary Disease||Universidade Federal de Pernambuco|Yes|Completed|May 2011|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|N/A|No|||April 2013|April 3, 2013|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01826669||68549|
NCT01826890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0012|Neurally Adjusted Ventilatory Assist in Adults at Risk of Delayed Weaning From Mechanical Ventilation|A Randomised Feasibility Study Examining Neurally-adjusted Ventilatory Assist (NAVA) in Patients at High Risk of Prolonged Ventilatory Failure During Recovery From Critical Illness.|RESTUS|King's College Hospital NHS Trust|Yes|Recruiting|May 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|92|||Both|18 Years|N/A|No|||April 2013|June 26, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01826890||68532|
NCT01836198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14586|The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream|Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|April 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836198||67820|
NCT01855659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-HAL-EL-36|A Single-center Study to Assess Peak Inspiratory Flow (PIF) in Different Stages' COPD Patients by Using the In-check Method.|A Single-center Study to Assess Peak Inspiratory Flow (PIF) in Different Stages' COPD Patients by Using the In-check Method.|INSPIRE|Elpen Pharmaceutical Co. Inc.|No|Completed|June 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|210|||Both|50 Years|90 Years|No|Non-Probability Sample|COPD patients belonging in Stages II, II, IV|May 2013|December 2, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855659||66331|
NCT01852331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-274|Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia|The Herbal Medicine Peony-Glycyrrhiza Decoction (PGD) as an Adjunctive Therapy to Treat Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia: a Double-blind, Randomized, Placebo-controlled Study|PGD-RCT|The University of Hong Kong|Yes|Completed|January 2013|November 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|60 Years|No|||May 2015|May 6, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01852331||66587|
NCT01852344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AA020297|Behavioral Differences in Effortful Control|Behavioral Differences in Effortful Control|BDEC|University of Michigan|No|Active, not recruiting|June 2012|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852344||66586|
NCT01826838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 255|Study of Dasatinib, Androgen Deprivation Therapy and Radiation|A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer|BrUOG PR255|Brown University|Yes|Withdrawn|January 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||June 2015|June 9, 2015|July 24, 2012|Yes|Yes|Lack of patients|No||https://clinicaltrials.gov/show/NCT01826838||68536|
NCT01827124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams U|Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption|||Ain Shams University|Yes|Recruiting|April 2013|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||April 2013|October 7, 2013|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827124||68514|
NCT01827475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBNet119536|Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting|Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting||Stony Brook University|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|April 4, 2013||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01827475||68487|Small sample size, single center, short follow up
NCT01827488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ViaDor SR01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||June 30, 2013|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827488||68486|
NCT01828554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS 12903|Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight|Pilot Study Evaluating Pharmacokinetic Parameters of Capecitabine Dosing in Patients With Advanced Cancer and Elevated Body Mass Index||University of Wisconsin, Madison|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828554||68405|
NCT01828021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAH22-02|Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer|A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH||MacroGenics|Yes|Recruiting|March 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||January 2016|March 14, 2016|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828021||68445|
NCT01828034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004|First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma|A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828034||68444|
NCT01829009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-887-13/14-1|Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women|Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women||National Institute of Medical Sciences and Nutrition, Salvador Zubiran|Yes|Withdrawn||||April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|70 Years|N/A|No|||April 2015|April 20, 2015|April 2, 2013||No|Financial issues|No||https://clinicaltrials.gov/show/NCT01829009||68370|
NCT01828541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDRR H133A120024|Hypnosis for Pain and Itch Following Burn Injuries|A Randomized Controlled Trial of Hypnosis for Pain and Itch Following Burn Injuries||University of Washington|No|Recruiting|May 2013|September 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01828541||68406|
NCT01829620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01477|Military Continuity Project|Military Continuity Project (MCP): A Suicide Prevention Study|MCP|University of Washington|Yes|Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01829620||68323|
NCT01833728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0023|A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy|||Yonsei University|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|65 Years|No|||February 2014|February 17, 2014|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01833728||68010|
NCT01833741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEAR|A Study of LUMIGAN® RC in the Clinical Setting|||Allergan|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1137|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|April 15, 2013|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01833741||68009|
NCT01834014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATOM Exploratory study|Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases|An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer|ATOM ES|EPS Corporation|Yes|Recruiting|May 2013|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||January 2016|January 20, 2016|April 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834014||67988|
NCT01834573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|runIBD|Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.|Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.||Technische Universität München|No|Completed|April 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||December 2013|December 22, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01834573||67945|
NCT01832948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121201E-mCRC|Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer|Study of Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer and Efficacy Prediction||Zhejiang Cancer Hospital|No|Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||April 2013|April 11, 2013|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01832948||68070|
NCT01831271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI: 2009/1756-31/4|Neck-specific Training or Prescribed Physical Activity for Patients With Cervical Radiculopathy|Interventions for Patients With Cervical Radiculopathy- Neck-specific Training With a Cognitive Behavioural Approach Compared With Prescribed Physical Activity in a Prospective Randomised Controlled Trial||Karolinska University Hospital|Yes|Active, not recruiting|August 2010|August 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01831271||68197|
NCT01831284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA-0774|Correlates and Consequences of Increased Immune Activation in Injection Drug Users|Correlates and Consequences of Increased Immune Activation in Injection Drug Users||Rockefeller University|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|201|Samples Without DNA|Sigmoidoscopy with biopsy|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Group 1: HIV-uninfected, active IDU defined as a minimum of 3 injections of heroin per        week (N=48)        Group 2: Non-injecting controls defined as no lifetime use of injection drugs and no        illicit non-injection opiate or cocaine for at least 3 years (N=48)        Group 3: Former injectors of heroin with/without other agents will be recruited and        followed after approximately 1 month (N=48) and 3 months (N=48) from the time of last        injection.        All groups will be matched for age, sex, and race/ethnicity. Groups 1 and 3 will be        matched for Hepatitis C status and HCV RNA levels. Group 1 subjects will be studied twice;        at baseline, at 1-2 months to assess stability of findings. Group 2 will be studied once;        Group 3 will be studied at 1 and 3 months after ceasing injections.|November 2014|November 4, 2014|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01831284||68196|
NCT01830595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-006|Lactoferrin Treatment in HIV Patients|Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients||Minneapolis Medical Research Foundation|Yes|Recruiting|September 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||December 2015|December 21, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830595||68249|
NCT01830608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-240912|Risk Factors for Drusen Progression|||Medical University of Vienna||Withdrawn|January 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|50 Years|N/A|No|Non-Probability Sample|300 male and female patients with age-related macular degeneration|April 2015|April 7, 2015|April 10, 2013||No|Could not find a Sponsor for the study|No||https://clinicaltrials.gov/show/NCT01830608||68248|
NCT01831830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01308|Evaluation of the Veterans' In-home Program|Evaluation of the Veterans' In-home Programs for Veterans With TBI and Families|VIP|Philadelphia Veterans Affairs Medical Center|No|Completed|October 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831830||68155|
NCT01831843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|php2|Effect of Breathing Circuits on Intraoperative Body Temperature||BT|Seoul National University Hospital|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|111|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 15, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01831843||68154|
NCT01831856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F373280 CA 2 01|Efficacy and Safety Study of F373280|Efficacy and Safety Study of F373280 for Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation and Chronic Heart Failure. International, Multicentric, Randomised, Double-blind, Placebo Controlled Study.||Pierre Fabre Medicament||Recruiting|April 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831856||68153|
NCT01832194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN_BTX|Use of Botox to Treat Scrotal Pain|Use of Botox to Treat Scrotal Pain||Mount Sinai Hospital, Canada|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|65 Years|No|||April 2013|August 28, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832194||68128|
NCT01832961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/C0346|Acute Effects of a Flutter Device in COPD|Acute Effects of a Flutter Device on Airways Resistance in Chronic Obstructive Pulmonary Disease (COPD)|AEFLUC|Imperial College London|No|Recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|21 Years|90 Years|No|||April 2013|July 12, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01832961||68069|
NCT01832974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-C-0046|Possible New Therapy for Advanced Cancer|A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma||INSYS Therapeutics Inc||Terminated|December 2012|September 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|9|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|September 11, 2012|No|Yes|Business decision by the sponsor during Phase 1.|No||https://clinicaltrials.gov/show/NCT01832974||68068|
NCT01820520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE11-09|Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery|Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery||Asociación para Evitar la Ceguera en México|No|Recruiting|January 2013|||September 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||March 2013|March 27, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820520||69020|
NCT01820533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005437-2|Survey of Smokers Treated in the Emergency Department (ED) on Ownership and Usage of Cell Phones|Survey of Smokers Treated in the ED on Ownership and Usage of Cell Phones||Yale University|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|775|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be current patients in the Yale New Haven Hospital Emergency Department who        were previously identified as smokers.|August 2014|August 21, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820533||69019|
NCT01821131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:012|Flax Muffins and Cholesterol Lowering|A Dose Response, Randomized, Controlled, Double-blind, Cross-over Trial to Determine the LDL Cholesterol Lowering Effect of Ground Flaxseed in Adults With Above Optimal Plasma LDL Concentrations||St. Boniface General Hospital Research Centre|No|Active, not recruiting|January 2014|March 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|76|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821131||68973|
NCT01820481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN-901X-P2|Safety and Efficacy of WIN-901X in Asthma|Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients||Whanin Pharmaceutical Company|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|209|||Both|20 Years|79 Years|No|||December 2013|December 5, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820481||69023|
NCT01820793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120202|Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli|Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli.|FOXICOLI|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|May 2013|April 2016|Anticipated|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820793||68999|
NCT01820806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-105|Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects|Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects Following a Single Oral Administration of [14C] GLPG0634||Galapagos NV|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 5, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820806||68998|
NCT01828918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-2012-03-02 (II)|Biomarkers for the Early Diagnosis, Prediction, Prognosis for Colorectal Cancers|Kaohsiung Medical University Hospital||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|20 Years|90 Years|No|||June 2012|April 10, 2013|January 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828918||68377|
NCT01829126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F5-2012-305495-OT5|Development and Prevention of Severe Heart Disease in Systemic Sclerosis|||Second University of Naples|No|Recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|765|||Both|N/A|N/A|No|Probability Sample|The study population are adult and juvenile SSc patients from the EUSTAR cohort        (MEDSonline database) and the jSScWG cohort|November 2013|November 7, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829126|1 Year|68361|
NCT01829373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG1006|Lung Cancer Vaccine Plus Oral Dietary Supplement|Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived β-Glucan||University of Kentucky|Yes|Completed|October 2011|February 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|N/A|No|||April 2013|April 10, 2013|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829373||68342|
NCT01833442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipq0704/10br|Randomized Controlled Meditation Trial for Treating OCD|Randomized Controlled Meditation Trial for Treating OCD Comparing Kundalini Yoga Meditation Versus the Relaxation Response||University of Sao Paulo|Yes|Active, not recruiting|March 2011|August 2013|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||April 2013|April 17, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01833442||68032|
NCT01833715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03/13|Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy|Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy||Universidad de Valparaiso|Yes|Recruiting|March 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|70 Years|No|||April 2013|April 16, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01833715||68011|
NCT01834261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293408|Brain Dynamics of Oxytocin|Computational Modeling of Oxytocin in the Regulation of Trust||Stony Brook University|Yes|Recruiting|April 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834261||67969|
NCT01831011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-008|Mildronate for Acute Ischemic Stroke|Efficacy and Safety of Mildronate for Acute Ischemic Stroke: a Randomized, Double-blind, Active-controlled Phase II Multicenter Trial||Xijing Hospital|Yes|Completed|July 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|80 Years|No|||April 2013|April 10, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01831011||68217|
NCT01831024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIG-001|Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia|Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer||Target Health Inc.|Yes|Active, not recruiting|July 2013|December 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Female|18 Years|N/A|No|||May 2015|May 11, 2015|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831024||68216|
NCT01833559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDMTEST-5010-00|Impact of Blood Glucose at the First Trimester of Pregnant Women With Gestational Diabetes on Maternal and Fetal Outcomes and Metabolic Disorders: a Multi-central Prospective Cohort Study|Impact of Blood Glucose at the First Trimester of Pregnant Women With Gestational Diabetes on Maternal and Fetal Outcomes and Metabolic Disorders: a Multi-central Prospective Cohort Study||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|June 2012|August 2021|Anticipated|May 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01833559||68023|
NCT01834079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00104|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease. It is Self Funded (Patients' Own Funding) Clinical Trial|OND|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01834079||67983|
NCT01831323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUR-SUDD 2012|Evaluation of the Metabolome in Diverticular Disease|Evaluation of the Metabolome in Diverticular Disease and Effects of Probiotic Mixture VSL#3 vs Fibers, Rifaximin and Mesalazine on the Metabolome in Diverticular Disease of the Colon||S.Eugenio Hospital|No|Recruiting|December 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|40|Samples Without DNA|urine and stools|Female|18 Years|N/A|No|Probability Sample|Women with first diagnosis of uncomplicated symptomatic diverticular disease|October 2014|October 16, 2014|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01831323||68193|
NCT01832701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.38.MET|Coffee, Exercise, and Oxidative Stress|Coffee and Oxidative Stress During Exercise in Healthy Humans||Nestlé|No|Completed|March 2012|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|24|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832701||68089|
NCT01833572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIRES0081|Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC|A Single-arm, Phase II Study of Preoperative Gefitinib for Stage II-IIIa NSCLC With Activating EGFR Mutation||Fudan University||Recruiting|May 2013|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833572||68022|
NCT01833585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRIRAJR015533013|Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells|Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells||Mahidol University|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||September 2015|September 28, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01833585||68021|
NCT01821144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008602 QM|A School-based Education Programme to Reduce Salt Intake in Children and Their Families|A School-based Education Programme to Reduce Salt Intake in Children and Their Families (School-EduSalt)|School-EduSalt|Queen Mary University of London|No|Recruiting|March 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|840|||Both|9 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 26, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01821144||68972|
NCT01821092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.2013.Don Bosco.PROED|Dimensional Changes of Peri-implant Facial Bone|Horizontal and Vertical Dimensional Changes of Peri-implant Facial Bone Following Placement of T3 Implants: a 1-year Cone Beam Computed Tomography Study||Proed|No|Active, not recruiting|March 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||March 2013|May 5, 2014|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01821092||68976|
NCT01821105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0375|2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer|A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer.||Ohio State University Comprehensive Cancer Center|Yes|Completed|March 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 9, 2012|Yes|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT01821105||68975|
NCT01821118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951024|Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy|A Phase 2, Randomized, Double Blind Placebo Controlled Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of Pf-04360365 (Ponezumab) In Adult Subjects With Probable Cerebral Amyloid Angiopathy||Pfizer|No|Completed|June 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|55 Years|90 Years|No|||March 2016|March 7, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821118||68974|
NCT01832597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RetroBENDA|Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders|A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, As Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders||Gruppo Italiano Studio Linfomi|Yes|Completed|November 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|109|||Both|18 Years|N/A|No|Probability Sample|All patients with relapsed or refractory chronic lymphoproliferative disorders treated        with Bendamustine +/- Rituximab|April 2013|April 12, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832597||68097|
NCT01832844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0096|Effects of Control Scan for Presumed Difficult Epidural Infiltrations (ECHORACHIS)|Effects of Scan Control for Presumed Difficult Epidural Infiltrations: a Monocentric, Prospective, Randomized, Controlled, Simple Blind Trial|ECHORACHIS|Nantes University Hospital|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|80|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01832844||68078|
NCT01833156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS5NL|Validation of the MoistureMeterD in Local Edema by Histamine|A Clinimetric Research to Test the Validity of the MoistureMeterD, Conducted by the Local Edema (Urticaria Acuta) Into the Administering of Intradermal Histamine.||Nij Smellinghe Hosptial|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 9, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01833156||68054|
NCT01832870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIPIPI 2013|Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer|Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer||Prostate Oncology Specialists, Inc.|Yes|Active, not recruiting|April 2013|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||May 2015|May 4, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832870||68076|
NCT01833169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120ZUS40|BKM120 for Patients With PI3K-activated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors|SIGNATURE|Novartis|No|Active, not recruiting|March 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833169||68053|
NCT01833182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOLHH0196-09|The Effectiveness of a Fall Prevention Program|The Effectiveness of a Fall Prevention Program|ADL|Washington University School of Medicine|Yes|Completed|May 2010|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|129|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833182||68052|
NCT01833455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW-PVC-2012-0510|Premature Ventricular Contractions (PVCs) and Blood Pressure Control|The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs||University of Wisconsin, Madison|No|Recruiting|February 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|66|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01833455||68031|
NCT01833468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foot-SpA|Functional Limitations Due To The Foot Involvement In Spondyloarthritis|FUNCTIONAL LIMITATIONS DUE TO the FOOT INVOLVEMENT IN SPONDYLOARTHRITIS||Vakif Gureba Training and Research Hospital|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|30|||Both|18 Years|70 Years|No|Probability Sample|patients with SpA and foot pain|April 2013|April 16, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01833468||68030|
NCT01830556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETMET study|Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck|Cetuximab 5-FU and Cisplatin or Carboplatin Versus Cetuximab With Paclitaxel and Carboplatin Treatment of Metastatic Squamous Cell Carcinoma of Head and Neck|CETMET|Karolinska University Hospital|Yes|Recruiting|November 2011|November 2015|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2013|May 19, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830556||68252|
NCT01831037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137855|The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study|The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study|ROLFH|University of Arkansas|Yes|Withdrawn|July 2015|December 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Serum, plasma, PBMC for DNA isolation|Both|18 Years|70 Years|No|Probability Sample|Patients with chronic hepatitis C or B, with cirrhosis, with successful antiviral        treatment no earlier than January 2010 (retrospective component), or planned to start        antiviral treatment by the time of recruitment|January 2015|January 27, 2015|April 2, 2013||No|Unable to obtain funding|No||https://clinicaltrials.gov/show/NCT01831037||68215|
NCT01834326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00065554|Phase II Clinical Trial of Intraoral Grafting of Human Tissue Engineered Oral Mucosa|A Randomized, Parallel-group (Autogenous ex Vivo Produced Oral Mucosa Equivalent (EVPOME) vs. Palatal Oral Mucosa (POM) Safety and Efficacy Study in Subjects Requiring Additional Keratinized Oral Mucosa for Dental Rehabilitation With Endosseous Dental Implants|Small Defect|University of Michigan|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834326||67964|
NCT01834625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004532|Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement|Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement||Mayo Clinic|No|Recruiting|April 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|25|||Both|60 Years|N/A|No|||January 2016|March 14, 2016|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834625||67941|
NCT01831050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1460|Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine|A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs)||Fidec Corporation|Yes|Completed|May 2013|December 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|9||Anticipated|1420|||Both|5 Weeks|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01831050||68214|
NCT01831063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alberta Children's Hospital|A Simulation-based Intervention for Caregivers of Children With Seizures|Simulation for Family Centered Care: Improving Caregivers Skills, Self-Efficacy and Quality of Life Using a Practice-Until-Perfect Simulation Intervention for Seizure Management in the Home Environment||University of Calgary|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|61|||Both|N/A|17 Years|No|||April 2013|April 12, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01831063||68213|
NCT01831895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALM-FIM_US, CRD0152, G130013|Controlling and Lowering Blood Pressure With The MOBIUSHD™|CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHD™ - A Prospective Multicenter Safety Study|CALM-FIM_US|Vascular Dynamics, Inc.|Yes|Recruiting|May 2013|June 2018|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|April 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831895||68150|
NCT01831908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-2013-03|The "Know Your Numbers" Program in Atahualpa|The "Know Your Numbers" Program in Atahualpa - An Interventional Study Aimed to Reduce Cardiovascular Diseases and Stroke Burden in Rural Coastal Ecuador.||Hospital Clínica Kennedy|No|Recruiting|February 2014|August 2018|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|95 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831908||68149|
NCT01833286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACE+RFA VS. Re-resection|TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma|Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Re-resection for Recurrent Hepatocellular Carcinoma|TACE-RFA|Sun Yat-sen University|Yes|Not yet recruiting|July 2013|July 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||April 2013|April 12, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01833286||68044|
NCT01821729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-051|Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer|Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Proton Beam for Locally Advanced Pancreatic Cancer||Massachusetts General Hospital|Yes|Recruiting|July 2013|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821729||68927|
NCT01820832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calcitriol-MP-1|Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD|Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD||Huashan Hospital|Yes|Not yet recruiting|March 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2013|March 28, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01820832||68996|
NCT01821703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15051|A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Multiple Oral Dosing in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|March 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01821703||68929|
NCT01821716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-PR-PRI-196|Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract|Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract to Determine the Biological Activity in HEP Units.||Laboratorios Leti, S.L.|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|18 Years|60 Years|No|||March 2013|May 22, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821716||68928|
NCT01821976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W8XWH-10-2-0090|Transtibial Amputation Outcomes Study|Transtibial Amputation Outcomes Study (TAOS): Comparing Transtibial Amputation With (Ertl) and Without a Tibia-fibula Synostosis Procedure|TAOS|Major Extremity Trauma Research Consortium|Yes|Recruiting|March 2013|June 2022|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|60 Years|No|||September 2015|September 1, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821976||68908|
NCT01832376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/773|Treatment of Calcific Tendinitis by Ultrasound-guided Needle Lavage|Treatment of Calcific Tendinitis by Ultrasound-guided Needle Lavage - a Multicenter, Randomized and Sham Controlled Study (KALK Study)||Martina Hansen's Hospital|Yes|Active, not recruiting|June 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832376||68114|
NCT01832610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-PAS-03|Post- Approval Study on Patients Who Received a HeartWare HVAD® During IDE Trials|A Multi Center, Post Approval Study Providing Continued Evaluation and Follow-up on Patients Who Received a HeartWare® Ventricular Assist System During IDE Trials for the Treatment of Advanced Heart Failure|HW-PAS-03|HeartWare, Inc.|No|Active, not recruiting|January 2013|January 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|115|||Both|18 Years|N/A|No|Probability Sample|The patient population consists of patients who were at risk of death from refractory,        advanced heart failure and implanted with a HeartWare® Ventricular Assist System under IDE        G070199.        Patients must have participated as a study patient in a prior HeartWare trial under IDE        G070199, and been implanted with the HeartWare® System|July 2015|July 31, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832610||68096|
NCT01832857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CPI-613-023|Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients|An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients||Cornerstone Pharmaceuticals, Inc.|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832857||68077|
NCT01832883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rebiscan-002|Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|Pediatric Vision Scanner 4 (PVS4)||Rebiscan, Inc.||Completed|December 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|78|||Both|3 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children presenting for ophthalmic exam at eye clinic.|April 2013|April 11, 2013|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01832883||68075|
NCT01833754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110227|Study of Romosozumab (AMG 785) Administered to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis|A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis||Amgen|No|Completed|April 2013|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 14, 2014|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833754||68008|
NCT01833767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-12|Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma|Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma||Western Regional Medical Center|No|Withdrawn|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 14, 2013|Yes|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01833767||68007|
NCT01833780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBS PCR .CTIL|Effectiveness of Intrapartum Group B Streptococcus (GBS) Polimerase Chain Reaction Reaction (PCR) Screening|||The Baruch Padeh Medical Center, Poriya||Not yet recruiting|May 2013|||December 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|||||Female|18 Years|45 Years|No|Probability Sample|Unknown GBS pregnant women|April 2013|April 17, 2013|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833780|2 Years|68006|
NCT01834027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 40925|The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy|The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy||Penn State University|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|56|||Female|18 Years|75 Years|No|||August 2014|August 5, 2014|November 30, 2012||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01834027||67987|
NCT01830790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042897|Effects of Sildenafil on Choroidal Thickness in AMD|Effects of Sildenafil on Choroidal Thickness in Age-Related Macular Degeneration||Duke University|Yes|Terminated|March 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 27, 2015|April 10, 2013|Yes|Yes|Inadequate support to complete recruitment/data analysis.|No|April 29, 2015|https://clinicaltrials.gov/show/NCT01830790||68234|Study was terminated early due to inadequate support to complete recruitment/data analysis.
NCT01832181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0129-A|MiTy Kids (Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial)|Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial (MiTy Kids)||Mount Sinai Hospital, Canada||Recruiting|April 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Female|18 Years|45 Years|No|Non-Probability Sample|Offspring of women with type 2 diabetes who participated in the MiTy trial during        pregnancy.|March 2016|March 14, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01832181||68129|
NCT01832675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0056-22-21|Clinical Trial With Bupivacaine Lozenges as Local Anaesthesia Under Upper Gastrointestinal Endoscopy|New Bupivacaine Lozenge as Topical Anesthesia Compared to Lidocaine Pharyngeal Spray Before Upper Gastrointestinal Endoscopy in Unsedated Patients||Hvidovre University Hospital|Yes|Completed|March 2012|January 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|80 Years|No|||April 2013|April 12, 2013|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01832675||68091|
NCT01829529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000405-23|Antibiotic Prophylaxis - Amoxicillin|Susceptibility Changes Among Oral Microorganisms Following Single Dose Antibiotic Prophylaxis||Karolinska University Hospital|No|Recruiting|September 2013|March 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829529||68330|
NCT01829776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9257|Pilot Study of Free From Falls Program in Multiple Sclerosis|Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis|FFF|Oregon Health and Science University|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|89 Years|No|||November 2014|November 3, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829776||68311|
NCT01830075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12-143#12.17.0161|The Life InSight Application Study (LISA)|The Life InSight Application Study: the Role of an Assisted Structured Reflection on Life Events and Ultimate Life Goals to Improve Quality of Life of Cancer Patients|LISA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|153|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830075||68288|
NCT01831570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K110301|DIGItal Cohort Osteoarthritis Design|Prospective 6 Years Follow up of Patients With Hand Osteoarthritis|DIGICOD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2013|September 2022|Anticipated|September 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|35 Years|N/A|No|||November 2015|November 19, 2015|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01831570||68175|
NCT01831583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01|Assessment of PPG & PAT to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea|Assessment of a New Photoplethysmographic (PPG) Method and a Pulse Arrival Time Method to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in a Sleep Laboratory||Sotera Wireless, Inc.|No|Not yet recruiting|May 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|15|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 9, 2013|March 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831583||68174|
NCT01832454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00160|Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years|Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial|BMCP2|Chaitanya Hospital, Pune|Yes|Recruiting|March 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|3 Years|15 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01832454||68108|
NCT01832467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL019|Cetuximab Rechallenge Study|A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy||Chinese University of Hong Kong|No|Recruiting|April 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01832467||68107|
NCT01826396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIHeilongjiang-001|Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer|Comparison of Standard and High Dose Irinotecan Based on UGT1A1 Genotype, 5-fluorouracil, and Leucovorin (FOLFIRI) for First-line Treatment of Locally Advanced Colon Cancer: a Prospective Phase II Clinical Study||Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences||Recruiting|April 2013|December 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||April 2013|April 4, 2013|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826396||68569|
NCT01833858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol100|Human Chorionic Gonadotrophin in an Antagonist Protocol|The Role of Low Dose HCG in Improving the Quality of Antagonist Protocol in Patient Undergoing ICSI|HCG|Cairo University|No|Completed|August 2013|January 2015|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|40 Years|No|||February 2015|February 1, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01833858||68000|
NCT01834092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-085|Study of the Glycocalyx in Abdominal Aortic Aneurysm|Measurement of the Endothelial Function in Patients With a Abdominal Aortic Aneurism.|Endo_eAAA|Rigshospitalet, Denmark|No|Recruiting|April 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01834092||67982|
NCT01821404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005438-20|Atorvastatin Before Prostatectomy and Prostate Cancer|The Impact of Atorvastatin on Prostate Cancer - a Randomized, Pre-surgical Clinical Trial|ESTO1|Tampere University Hospital|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|160|||Male|40 Years|80 Years|No|||January 2016|January 12, 2016|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821404||68952|
NCT01817803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0013|A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)|||Yonsei University|No|Withdrawn|March 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|20 Years|75 Years|No|||February 2014|February 17, 2014|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01817803||69229|
NCT01817816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-061203|Early Injection of Botulinum Toxin on Motor Function and Gait Pattern in Stroke Patients|||Changhua Christian Hospital||Completed|January 2009|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|45 Years|75 Years|No|||November 2015|November 3, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01817816||69228|
NCT01832896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/IST-5|Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema|A Multicenter, Open-Label Study to Assess the Tolerability and Safety of a Single, Subcutaneous Administration of Ecallantide in Children and Adolescents With Hereditary Angioedema||Winthrop University Hospital|No|Recruiting|August 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|16 Years|No|||September 2014|September 23, 2014|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832896||68074|
NCT01833195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-C-00003|Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing|Outcomes AlloMap Registry Study: the Clinical Long-term Management and Outcomes of Heart Transplant Recipients With Regular Rejection Surveillance Including Use of AlloMap Gene-expression Profiling Testing|OAR|CareDx|No|Recruiting|March 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|RNA isolated from peripheral blood mononuclear cells (PBMC)|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Heart transplant patients|April 2015|April 20, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833195|5 Years|68051|
NCT01833793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16314|Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice|Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion|MARILIA|Bayer|Yes|Completed|February 2013|May 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who have been prescribed Mirena for contraception.|September 2015|September 10, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01833793||68005|
NCT01833481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12009|THA Kinematics and Sound for Subjects Implanted Using Various Surgical Approaches|In Vivo Determination of THA Kinematics and Sound for Subject Implanted Using Various Surgical Approaches|THA|The University of Tennessee Knoxville|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|30|||Both|40 Years|85 Years|No|Non-Probability Sample|Patients implanted with a direct-anterior surgical approach will be provided by Dr.        William Barrett of Valley Orthopedic Associates in Renton, WA.        Patients implanted with an anterior-lateral surgical approach will be provided by Dr. of        Steven J. MacDonald of the London Health Sciences Center, London, Ontario.        Patients implanted with a posterior-lateral approach will be provided by Dr. David F.        Dalury of Towson Orthopaedic Associates, Inc. in Towson, MD.|October 2014|October 31, 2014|April 11, 2013||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01833481||68029|
NCT01834274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_310|Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes||Takeda|Yes|Terminated|June 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|April 12, 2013|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No|March 27, 2015|https://clinicaltrials.gov/show/NCT01834274||67968|
NCT01834287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pasos Hacia La Salud|Pasos Hacia La Salud - Physical Activity Intervention for Latinas|Promoting Physical Activity in Latinas Via Interactive Web-Based Technology||University of California, San Diego|No|Completed|December 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01834287||67967|
NCT01834586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRB 2012|Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications|Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)|OUCH|Brown, Theodore R., M.D., MPH|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01834586||67944|
NCT01830803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HowRU/we/1|Reliability of howRU and howRwe Questionnaires|Reliability of howRU and howRwe Questionnaires||Medical Research Foundation, The Netherlands|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients visiting a general practice will be asked to participate. We will select patients        based on their scores on the howRU and howRwe questionnaires. We will aim to include at        least 90 patients: a minimum of 30 patients with diabetes, 30 COPD patients and 30 persons        without these diseases.|April 2015|April 10, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830803||68233|
NCT01830816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16015|Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment|Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|September 2013|November 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|April 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01830816||68232|
NCT01832688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300662|Assessment of the Nutritional Status of Pregnant Women and Optimization of Prenatal Care Services|Assessment of the Nutritional Status of Pregnant Women in Zinder, Niger and Optimization of Prenatal Care Services||University of California, Davis|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2306|Samples Without DNA|Blood and urine sample for assessment of nutritional status|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women residing in participating villages|November 2015|November 30, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01832688||68090|
NCT01833273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESSTINI_A|Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA|Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA|DESSTINI_A|Stony Brook University|Yes|Active, not recruiting|July 2010|May 2014|Anticipated|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|79 Years|No|||April 2014|April 8, 2014|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01833273||68045|
NCT01829282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3294930|Eban II: Intervention for HIV Sero-Discordant Couples|Implementing Eban II: An Evidence-Based Intervention for HIV Sero-Discordant Couples||University of California, Los Angeles|Yes|Recruiting|July 2012|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829282||68349|
NCT01829542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB2UReading|Dose-dependent Effects of Blueberry Polyphenols on Endothelial Function in Healthy Individuals|Dose-dependent Effects of Blueberry Polyphenols on Endothelial Function in Healthy Individuals|BB2|University of Reading|No|Completed|May 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|11|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829542||68329|
NCT01830088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BudFam2|Family Based Treatment of Depressed Adolescents (AHUS)|Family-based Treatment of Depressed Adolescents: An Empirical Study With Norwegian Adolescents in Specialty Mental Health Care|BudFam2|University Hospital, Akershus|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|13 Years|17 Years|No|||October 2013|October 5, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01830088||68287|
NCT01829789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA034301|Individual vs. Group Community Reinforcement Training to Help Parents of Substance-using Treatment-refusing Youth|Group Community Reinforcement Training for Parents of Treatment-Elusive Youth|POP|Oregon Research Institute|No|Active, not recruiting|April 2013|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829789||68310|
NCT01830361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-MIDOKI-052|Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML|A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML|MIDOKIT|Technische Universität Dresden|Yes|Recruiting|April 2012|September 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01830361||68267|
NCT01830374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12090001548|Bulimia Nervosa: A Biobehavioral Study (The Eating Disorder Study)|Weight Suppression, Dieting, and Bulimia Nervosa: A Biobehavioral Study|TEDS|Drexel University|No|Recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|132|||Female|18 Years|45 Years|No|Non-Probability Sample|Participants will be recruited from local university counseling centers and eating        disorder centers.|February 2016|February 8, 2016|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01830374||68266|
NCT01821417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-11|Performance of MicroTextured Dental Implants|A Randomized Clinical Trial to Assess the Performance of MicroTextured Dental Implants With or Without a Machined Collar||University of Alabama at Birmingham|No|Active, not recruiting|May 2011|October 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 14, 2014|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01821417||68951|
NCT01821430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000669|Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids|Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin||Georgetown University|Yes|Active, not recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|65 Years|No|||February 2016|February 11, 2016|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01821430||68950|
NCT01813188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCBO-PS|Clinical Trial Based on the Use of Mononuclear Cells From Autologous Bone Marrow in Patients With Pseudoarthrosis|Phase II Clinical Trial of Tissue Engineering Based on the Use of Mononuclear Cells From Autologous Bone Marrow Seeded on Porous Tricalcium Phosphate Biomaterial in Patients With Pseudoarthrosis||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Completed|April 2011|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||March 2014|March 11, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01813188||69582|
NCT01813201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIC-0911|Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects|A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects|TIC|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Active, not recruiting|March 2011|March 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Male|18 Years|N/A|No|||March 2014|March 12, 2015|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813201||69581|
NCT01821989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|moos80|Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate|Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate.||Mooselmokadem||Not yet recruiting|June 2013|||January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Both|N/A|28 Days|Accepts Healthy Volunteers|||May 2014|May 8, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01821989||68907|
NCT01809314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21420|An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients Receiving Chemotherapy|HUNGARIAN NON-INTERVENTIONAL STUDY TO OBSERVE THE TREATMENT OF SYMPTOMATIC ANAEMIA IN CANCER PATIENTS RECEIVING CHEMOTHERAPY AND NEORECORMON||Hoffmann-La Roche||Completed|April 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|645|||Both|18 Years|N/A|No|Probability Sample|Patients with anemia due to malignancies|February 2016|February 1, 2016|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809314||69878|
NCT01809600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISL-1203|Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults|Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL|RBL|Gachon University Gil Medical Center|No|Recruiting|February 2013|August 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|55|||Both|20 Years|N/A|No|Non-Probability Sample|patients who were treated with Burkitt's or Burkitt-like high-grade B-cell lymphoma in        Republic of Korea|March 2013|March 11, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809600||69856|
NCT01833494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA1302|A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia|A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia||Kissei Pharmaceutical Co., Ltd.||Completed||||August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A||||April 2015|April 22, 2015|April 12, 2013||||No||https://clinicaltrials.gov/show/NCT01833494||68028|
NCT01833507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000675|Physical Activity and Health Outcomes|Relationship Between Physical Activity and Health Outcomes in Overweight and Obese Medically Complex Adults, a Randomized Trial|PAHO|Mayo Clinic|No|Completed|April 2013|April 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833507||68027|
NCT01833806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM018|A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain||InSightec|No|Recruiting|September 2013|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01833806||68004|
NCT01834040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00102|Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy|Study Safety and Efficacy of of AUTOLOGOUS Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) for the Patient With Duchenne Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial|BMMNC|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|20 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01834040||67986|
NCT01830569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55183|Impact of an Evidence-based Electronic Decision Support System on Diabetes Care|Feasibility and Impact of an Evidence-based Electronic Decision Support System on Diabetes Care in Family Medicine: a Cluster Randomized Controlled Trial||Katholieke Universiteit Leuven|No|Not yet recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|618|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830569||68251|
NCT01834365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKhomaini|Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly|Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial||Indonesia University|No|Active, not recruiting|October 2012|May 2013|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|188|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 16, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01834365||67961|
NCT01834378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAVIP-1204|Diabetes Prevention in Clinical Practice.|Diabetes Prevention in Primary Health Care With Special Emphasis on Physical Activity.|DIAVIP|Göteborg University||Not yet recruiting|June 2016|April 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2000|||Both|20 Years|85 Years|No|||January 2016|January 7, 2016|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834378||67960|
NCT01834391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-010185|Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients|Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients||Mayo Clinic|No|Active, not recruiting|March 2013|December 2015|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|220|Samples With DNA|Urine|Both|65 Years|N/A|No|Probability Sample|Geriatric traumatic injury patients that were admitted to Saint Marys Hospital.|February 2015|February 2, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01834391||67959|
NCT01831869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012GSF11824|Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism|The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study||Shandong Provincial Hospital|Yes|Active, not recruiting|April 2013|April 2022|Anticipated|April 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|60 Years|No|||May 2015|May 18, 2015|April 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01831869||68152|
NCT01831882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26529|Identifying Biological Markers for Severe Depression|Identifying Biological Markers for Severe Depression||Stanford University|No|Recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|We will be retaining biospecimens including, whole blood, serum, hair and saliva tissues      samples.|Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inpatient hospitals, outpatient clinics, community.|August 2014|August 21, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831882||68151|
NCT01829555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-043-2|A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management|A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management||University of Connecticut Health Center|Yes|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|15 Years|21 Years|No|||November 2014|November 6, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829555||68328|
NCT01829802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-14|RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients|A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen|ARTE|The Huesped Foundation|No|Recruiting|May 2014|May 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829802||68309|
NCT01829815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5108|Impact of a Parenting Program in Liberia to Improve Parenting, Education, and Health Outcomes for Children in Liberia|Impact Evaluation of a Parenting Program to Improve Parenting, Education, and Health Outcomes for Young Children in Liberia||International Rescue Committee|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829815||68308|
NCT01830114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CheckupAndChoicesPilot|A Web App for Patients With Alcohol and Drug Use Problems in Primary Care|A Web App for Patients With Alcohol and Drug Use Problems in Primary Care||Behavior Therapy Associates, LLP|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01830114||68285|
NCT01830101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-Patel-01|A Phase III Study of Re-Irradiation in Recurrent Glioblastoma|A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma||AHS Cancer Control Alberta|Yes|Withdrawn|February 2014|November 2017|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|March 14, 2016|March 13, 2013||No|This study will not be proceeding due to lack of funding from anticipated sources|No||https://clinicaltrials.gov/show/NCT01830101||68286|
NCT01826422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHA/EPA in Dunchenne|Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients|Effect of Eicosapentaenoic Fatty Acid(EPA)and Docosahexaenoic Fatty Acids(DHA) Supplementation in the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy||Coordinación de Investigación en Salud, Mexico|Yes|Enrolling by invitation|March 2013|December 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|70|||Male|6 Years|18 Years|No|||January 2016|January 26, 2016|April 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826422||68567|
NCT01812902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UROUSP - 006|Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy|Prospective Randomized Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy|LFD|University of Sao Paulo|Yes|Recruiting|May 2012|December 2014|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Male|18 Years|70 Years|No|||March 2013|March 15, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01812902||69604|
NCT01813214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN28305|The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma|Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy||Georgetown University|Yes|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01813214||69580|
NCT01809028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407129|A RT Evaluating the Number of Passes Required for Diagnositc Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions|A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block Diring EUS-FNA of Solid Pancreatic Mass Lesions||Florida Hospital|Yes|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|62|||Both|19 Years|89 Years|No|||February 2014|February 17, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01809028||69900|
NCT01809301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPSI-1479|Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions|A Single-Dose, Randomized, Open-Label, Crossover, Comparative Bioavailability Study of TRIA-662 500 mg Immediate-Release Tablets and NIASPAN 1000 mg Extended-Release Tablets in Healthy Male and Female Volunteers Under Fed Conditions||Cortria Corporation|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809301||69879|
NCT01809327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100034|A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise|A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise||Janssen Research & Development, LLC|Yes|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1186|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|March 8, 2013|Yes|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01809327||69877|
NCT01834053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00106|Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.|Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial|BMACHC|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|35 Years|44 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01834053||67985|
NCT01834300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1008/1|The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)|The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, β-cell Function and Triglyceride Kinetics in Patients With Non-alcoholic Fatty Liver Disease (NAFLD).||University of Liverpool|Yes|Active, not recruiting|February 2009|June 2015|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||September 2014|September 16, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01834300||67966|
NCT01834599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoubertHMR2013/04|Could the Cerebral Oximetry be a Good Technology to Measure Placental Oxygenation?|Could the Cerebral Oximetry (NIRS) be a Good Technology to Measure Placental Oxygenation in Pregnant Woman?||Maisonneuve-Rosemont Hospital|No|Not yet recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Female|N/A|N/A|No|Non-Probability Sample|healthy pregnant woman at term gestation in labour|April 2013|April 15, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834599||67943|
NCT01833871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol200|The Use of Doppler to Diagnose Myometrial Masses|Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses|3D|Cairo University|No|Recruiting|February 2013|December 2013|Anticipated|October 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|120|||Female|20 Years|60 Years|No|||April 2013|April 15, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01833871||67999|
NCT01830582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-019|Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer|Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|100|||Both|21 Years|N/A|No|||November 2015|November 5, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830582||68250|
NCT01832441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00108|Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus.|Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus. It is Self Funded (Patients' Own Funding) Clinical Trial|BMACD|Chaitanya Hospital, Pune|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832441||68109|
NCT01828827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-824 CL-003|Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects|A Phase 1, Randomized, Balanced, Single-Dose, Two-Treatment, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects|CL-003|Global Alliance for TB Drug Development|No|Completed|March 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828827||68384|
NCT01829256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044811|Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)|Simultaneous Risk Factor Control Using Telehealth to SlOw Progression of Diabetic Kidney Disease (STOP-DKD)|STOP-DKD|Duke University|No|Active, not recruiting|May 2014|May 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|285|||Both|18 Years|75 Years|No|||August 2015|January 20, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829256||68351|
NCT01829269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 759|French Attitude Registry in Case of ICD Lead Replacement|French Attitude Registry in Case of ICD Lead Replacement|FRAGILE|French Cardiology Society|No|Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Centers are hospitals recruiters French public or private, authorized to ask        defibrillators and who agreed to participate in the study. A cardiologist referral will be        designated for each hospital.        Patients with a defibrillator will be recruited during their hospitalization for change        probe. Patients will receive full information about the purpose and conduct of the study.|February 2015|February 12, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829269|2 Years|68350|
NCT01829568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00792|Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma|A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|June 2013|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2015|January 12, 2016|April 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01829568||68327|
NCT01829828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100835|The Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management|To Evaluate the Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management; Multicenter, Cross-sectional Study||Janssen Korea, Ltd., Korea|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|587|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients admitted for cancer pain management|April 2013|April 8, 2013|April 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01829828||68307|
NCT01829841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-II-MRCC|A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer|A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|May 2011|June 2014|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829841||68306|
NCT01829854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG423-12HTM|To Investigate the Incidence of Obstructive Sleep Apnoea in Patient Undergoing Open Heart Surgery|Unrecognised Obstructive Sleep Apnoea In Cardiac Surgery Patient In The Asian Population||University of Malaya|Yes|Recruiting|June 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|45 Years|N/A|No|Probability Sample|Patient undergoing open heart surgery and is more than 45 years old . These patient are        also required to stay in hospital for more than 5 days .|April 2013|April 10, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829854||68305|
NCT01830127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.30|BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3|A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection||Boehringer Ingelheim||Completed|April 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|March 22, 2013||||No|October 20, 2015|https://clinicaltrials.gov/show/NCT01830127||68284|Because the company decided to stop the DBV development program, analyses for this trial were limited to the basic requirement for efficacy, and only the primary endpoint and secondary endpoint were analyzed.
NCT01830140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-081|A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|July 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|466|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|April 10, 2013|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01830140||68283|
NCT01830387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041869|Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy|Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy||Duke University|No|Active, not recruiting|April 2013|April 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|March 21, 2016|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830387||68265|
NCT01826435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043793|Improving Medication Adherence in Hypertensive Patients|Improving Medication Adherence in Hypertensive Patients|HTNmobile|Duke University|No|Withdrawn|January 2014|May 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|18 Years|75 Years|No|||January 2014|January 24, 2014|April 4, 2013||No|Collaborator was not clear on how best to proceed with this project.|No||https://clinicaltrials.gov/show/NCT01826435||68566|
NCT01812915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J In 2013-1|Comparison of Tapered- vs. Cylindrical-shaped Tube Cuffs Pressure Alteration With Nitrous Oxide|Comparison of Tapered- vs. Cylindrical-shaped Tube Cuffs Pressure Alteration With Nitrous Oxide Diffusion Under General Anesthesia||DongGuk University|No|Completed|January 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|28|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01812915||69603|
NCT01808781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17263|The Effect of Home-based Velocity Training in Individuals With Total Knee Replacement|The Effect of Home-Based High-Velocity Training on Muscle Strength and Power, Functional Performance, and Physical Activity Behavior in Individuals With Total Knee Arthroplasty.|TKR|Texas Woman's University|Yes|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01808781||69919|
NCT01809041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZuo-POCD-1|Comparison of Intravenous Anesthetics to Volatile Anesthetics on Postoperative Cognitive Dysfunction|Comparison of Total Intravenous Anesthesia With Sevoflurane-based Balanced Anesthesia on Postoperative Cognitive Dysfunction in Elderly Patients for Major Elective Intra-abdominal Surgery||Sun Yat-sen University|No|Recruiting|March 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|684|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01809041||69899|
NCT01809353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100982|To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacokinetics and Safety of JNJ-54452840 Following Single Intravenous Doses to Healthy Japanese and Caucasian Subjects||Janssen Research & Development, LLC|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|32|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01809353||69875|
NCT01809366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65/10|Effect of Seminal Plasma Insemination on Pregnancy Rates After IVF-ET|||Assaf-Harofeh Medical Center||Completed|January 2012|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|41 Years|No|||January 2013|March 10, 2013|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01809366||69874|
NCT01833832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130114|Surgery and Heated Chemotherapy for Adrenocortical Carcinoma|Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|May 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|99 Years|No|||December 2015|January 5, 2016|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833832||68002|
NCT01833845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-8020.01|Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C|An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C||BioLineRx, Ltd.|No|Terminated|April 2013|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|April 15, 2013||No|due to failure to recruit subjects|No|July 30, 2014|https://clinicaltrials.gov/show/NCT01833845||68001|
NCT01831336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1215|BIOFLOW-III Belgium Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium||Biotronik Belgium NV|No|Active, not recruiting|January 2013|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|September 2015|September 7, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831336||68192|
NCT01832480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4042013|Trichomonas Vaginalis Repeat Infections Among HIV Negative Women|Trichomonas Vaginalis Repeat Infections Among HIV Negative Women||Tulane University Health Sciences Center|Yes|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1664|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832480||68106|
NCT01834105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81173280|Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1|Study on the Molecular Mechanism of Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome From CLCF1 Interventing on JAK-STAT Signaling Pathways|pop|Fujian Institute Of Trational Chinese Medicine|Yes|Recruiting|January 2012|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|25|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|April 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834105||67981|
NCT01831544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-MVAD-01|A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)|Multi Center, Prospective, Non-Randomized, Single-Arm Trial Evaluating the Clinical Safety and Performance Of the HeartWare MVAD® System For the Treatment of Advanced Heart Failure||HeartWare, Inc.|Yes|Recruiting|July 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|August 21, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01831544||68177|
NCT01831557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-18-2012|The Genetic Basis of the Influence of Dairy Product Intake on Body Measures in Children|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Children from a community sample|April 2013|April 10, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01831557||68176|
NCT01829048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241018|A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia||Pfizer|Yes|Completed|March 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|55 Years|No|||December 2013|December 4, 2013|March 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01829048||68367|
NCT01828840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-10-HMO|A Prospective Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia|A Prospective Double Blind Randomized Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia.||Hadassah Medical Organization||Recruiting|April 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01828840||68383|
NCT01829061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QDL Clinical Studies|Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System|Reproducibility and Method Comparison of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver of the Quo-Test™ A1C System||Quotient Diagnostics Limited|No|Enrolling by invitation|April 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|360|Samples Without DNA|Whole Blood Venous Draw and Capillary Blood - IVD Study|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|From site's patient database|November 2013|November 5, 2013|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829061||68366|
NCT01829295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EY021125-01|Methotrexate and Mycophenolate Mofetil for UVEITIS|First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial|FAST|University of California, San Francisco|Yes|Recruiting|August 2013|August 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|16 Years|N/A|No|||January 2016|January 4, 2016|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829295||68348|
NCT01829594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499/2008|Case Managers to Frail Older People a Randomized Controlled Trial|Case Managers to Frail Older People a Randomized Controlled Trial||Lund University|No|Completed|October 2006|April 2012|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|153|||Both|65 Years|N/A|No|||April 2013|April 9, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829594||68325|
NCT01829867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0031-003|A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.|A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 μg by Intracerebroventricular Infusion||Newron Sweden AB|Yes|Terminated|April 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|55 Years|75 Years|No|||January 2016|January 26, 2016|April 9, 2013||No|Issues with development and supply of infusion system for delivery of IMP. Prolonged approval    process for the clinical study sNN0031-004.|No||https://clinicaltrials.gov/show/NCT01829867||68304|
NCT01830153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CKR13T|RAD001 in Advanced Sarcoma|A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas||Asan Medical Center|No|Completed|April 2010|||January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|17 Years|N/A|No|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830153||68282|
NCT01830413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|stent-2013|Stenting for Symptomatic Intracranial Artery Stenosis Registry in China|Stenting for Symtomatic Intracranial Artery Stenosis Registry in China||Beijing Tiantan Hospital|Yes|Not yet recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with systematic Intracranial artery stenosis for stenting procedure|April 2013|April 18, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830413|12 Months|68263|
NCT01826474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO045-CLIN-01|Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy|A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy||BioMarin Pharmaceutical|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|45|||Male|5 Years|18 Years|No|||June 2015|June 3, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01826474||68563|
NCT01830400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2093-E044-404|A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)|An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Prospective Study Evaluating Retention Rate, Seizure Control and Tolerability of Eslicarbazepine Acetate (ESL) as Adjunctive Treatment to One Baseline Antiepileptic Drug in Adult Patients With Partial-Onset Seizures With or Without Secondary Generalisation||Eisai Inc.|No|Completed|April 2012|June 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|254|||Both|18 Years|N/A|No|Non-Probability Sample|Normal clinical practice setting/ centre.|August 2015|August 18, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01830400||68264|
NCT01826734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-Dacryoliths|Analysis of 86 Dacryoliths at the University Hospital Ostrava|Lacrimal Sac Dacryoliths (86 Samples): Chemical and Mineralogic Analyses||University Hospital Ostrava|No|Completed|January 1994|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|Samples Without DNA|Dacryolits during the DCR procedure.|Both|18 Years|N/A|No|Non-Probability Sample|The study population consisted of patients complaining of lacrimation, with subsequent        detection and extraction of a dacryolit.|April 2013|April 3, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01826734||68544|
NCT01826747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52775|Intrauterine Insemination and Luteal Fase Support|Impact of Luteal Phase Support With Vaginal Progesterone on the Clinical Pregnancy Rate in Intrauterine Insemination Cycles Stimulated With Gonadotrophins: a Prospective Randomized Multicentre Study.||Universitaire Ziekenhuizen Leuven|Yes|Enrolling by invitation|April 2011|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|198|||Female|18 Years|43 Years|No|||November 2012|June 25, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01826747||68543|
NCT01808794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUSDM10551|Comparison of Two Different Membranes|Clinical, Radiographic, and Histological Comparison of Healing After Alveolar Ridge Preservation Using Bone Allograft With Two Different Xenogeneic Membranes||Tufts University School of Dental Medicine|No|Active, not recruiting|January 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|March 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01808794||69918|
NCT01809067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3887-2|The Effects of Lavender Aromatherapy on Reducing Stress and Anxiety During MRI Procedures.|The Effects of Lavender Aromatherapy on the Reduction of Stress and Anxiety During MRI Procedures. A Randomized Study Comparing the Use of Lavender Aromatherapy to no Aromatherapy.||Allina Health System|No|Not yet recruiting|March 2013|January 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01809067||69897|
NCT01809054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1888|Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty|Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty||LifeBridge Health|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|March 8, 2013||No||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01809054||69898|
NCT01809340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100957|The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression|An Exploratory, Blinded, Randomized, Placebo-controlled Study in Subjects With Depressive Disorder to Investigate the Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced (Partial) Symptoms Response||Janssen Research & Development, LLC|No|Terminated|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|80 Years|No|||June 2015|June 29, 2015|March 8, 2013||No|study team decision because of IP supply issue and necessary amendment to protocol|No||https://clinicaltrials.gov/show/NCT01809340||69876|
NCT01809652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remote Implant Support|Feasibility Study of Remote Support for Implantable Pulse Generator (IPG)/Implantable Cardioverter Defibrillator (ICD) Implant|Remote Implant Support||Medtronic Cardiac Rhythm Disease Management|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|37|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01809652||69852|
NCT01809977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-39|Comparison of Partial Removal and Total Removal of the Corneal Epithelium on Keratoconus|Study of Surgical Methods for Keratoconus||Isfahan University of Medical Sciences|Yes|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809977||69827|
NCT01831089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-007-13|Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors||PharmaMar|No|Active, not recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|April 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831089||68211|
NCT01832207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD-224301|Comparison Between Sensory and Motor Transcutaneous Electrical Nervous Stimulation on Electromyographic and Kinesiographic Activity of Patients With Temporomandibular Disorder: a Controlled Clinical Trial|Comparison Between Sensory and Motor Transcutaneous Electrical Nervous Stimulation on Electromyographic and Kinesiographic Activity of Patients With Temporomandibular Disorder: a Controlled Clinical Trial||University of L'Aquila|Yes|Completed|January 2010|February 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832207||68127|
NCT01834664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00109|Safety and Efficacy of Bone Marrow Derived Autologous Cells Treatment of Cerebral Palsy in Subjects Above 15 Years|Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Cerebral Palsy in Subjects Above Years (BMACCP) .It is Self Funded (Patients' Own Funding) Clinical Trial|BMACCP|Chaitanya Hospital, Pune|No|Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01834664||67938|
NCT01834313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCE|Willingness to Pay for Patient-centred Care|Identifying Patients' and Healht Insurers' Preferences Regarding Patient-centred Care by Determining Their Willingness-to-pay for Patient-centred Care||University Medical Center Nijmegen|No|Recruiting|November 2012|October 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|Patient who are under treatment for their fertility problem and underwent at least one        treatment in one of 10 Dutch clinics.        All healthcare purchasers from the 5 large Dutch health insurer companies|July 2013|July 22, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01834313||67965|
NCT01834612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zynex 750|Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM1500) in Healthy Adult Volunteers During a Blood Draw||Zynex Monitoring Solutions|No|Recruiting|January 2013|||July 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01834612||67942|
NCT01831297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-082|Haemodynamic Feasibility Study of Sensors Within a Tilting Table Examination|||RWTH Aachen University|No|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with syncope|November 2013|November 26, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01831297||68195|
NCT01829035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAH Korea Trial|A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC|A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)||National Cancer Center, Korea|No|Recruiting|February 2013|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|338|||Both|20 Years|N/A|No|||July 2015|July 16, 2015|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01829035||68368|
NCT01828853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kabiri-Stripping-HMO-CTIL|Maternal and Neonatal Outcomes After Membrane Sweeping|Maternal and Neonatal Outcomes After Membrane Sweeping|Stripping|Hadassah Medical Organization|No|Not yet recruiting|April 2013|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1200|||Female|17 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|All women presenting to the Maternal-fetal unit who are 37+ weeks gestation|March 2013|April 8, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01828853|1 Month|68382|
NCT01829308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034258-01|SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers|SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers|ST@T|Friends Research Institute, Inc.|No|Recruiting|April 2013|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2168|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829308||68347|
NCT01829321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0974-CL-201|Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis|Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis||Galapagos NV|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||April 2014|April 24, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829321||68346|
NCT01830166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03268|Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate Brachytherapy|FTPC (Focal Therapy for Prostate Cancer): A Pilot Study Using Focal Low Dose Rate Brachytherapy as an Alternative to Active Surveillance and Radical Treatment for Favourable Risk Prostate Cancer.|FTPC|British Columbia Cancer Agency|No|Recruiting|May 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Male|18 Years|N/A|No|||January 2016|January 13, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01830166||68281|
NCT01830426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN261201200049C|Circulating Tumor Cells in Non-Small Cell Lung Carcinoma|Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma|LDx|Epic Sciences|Yes|Completed|November 2012|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|232|Samples With DNA|Cell solution plated onto slides and frozen for storage|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A primary lung cancer bearing population will be studied. Eligible patients will include        those presenting to the specified clinical centers with a tissue confirmed primary lung        cancer or radiographic abnormality deemed highly suspicious for primary lung cancer by        collaborating clinical team, in whom definitive tissue diagnosis is planned. All stages of        primary lung cancer will considered.|January 2016|January 20, 2016|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01830426||68262|
NCT01830439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-824-CL-009|Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)|A Phase 1, Randomized, Balanced, Single-Dose, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects|CL-009|Global Alliance for TB Drug Development|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01830439||68261|
NCT01826487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-020-DMD|Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy|A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy|ACT DMD|PTC Therapeutics|Yes|Active, not recruiting|March 2013|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Male|7 Years|16 Years|No|||October 2014|October 15, 2014|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826487||68562|
NCT01827033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082735|Effects of Meditation|||Johns Hopkins University|No|Terminated|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|55 Years|No|||November 2013|September 14, 2015|March 29, 2013||No|The Principal Investigator is leaving Johns Hopkins.|No||https://clinicaltrials.gov/show/NCT01827033||68521|
NCT01826448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-09|A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma|A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma||Plexxikon|No|Terminated|June 2013|||September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826448||68565|
NCT01826461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|172-0151-202|An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age||PreCision Dermatology, Inc.|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|151|||Both|3 Months|17 Years|No|||May 2014|May 27, 2014|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826461||68564|
NCT01827306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR01|Effectiveness of Biofreeze® on Shoulder Pain and In-office Exercise Performance|Effectiveness of Biofreeze® on Shoulder Pain and In-office Exercise Performance: A Preliminary Pilot Study|BFShld01|Sport and Spine Rehab Clinical Research Foundation|No|Completed|March 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|64 Years|No|||January 2016|January 11, 2016|April 2, 2013|No|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01827306||68500|
NCT01809080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-095109|Intern Health Study|Investigation Into the Interaction Between Genes and Stress in the Etiology of Depression in Interns||University of Michigan|No|Enrolling by invitation|May 2007|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4380|Samples With DNA|Saliva: DNA collection kits are sent via postal mail and participants are asked to provide a      small sample of saliva.      Blood samples (up to 50 mL via venopuncture): whole blood and serum will be assessed.      Hair: The total diameter taken from the scalp's posterior vertex will be about 3 mm, which      is about half of the diameter of pencil (approximately 100 hair strands with a minimum of 50      mg of hair for a 3-cm segment).|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical internship is an attractive model to bypass some limitations of previous studies.        Internship is well chronicled as a time of high stress (Butterfield 1988; Addison et al        2004). Interns are faced with long work hours, sleep deprivation, loss of autonomy and        extreme emotional situations (Shanafelt & Habermann 2002). Many physicians recall        internship as among the most stressful years of their lives (Duffy 2005). The stress of        internship is often uncontrollable, unpredictable and chronic; features that are        particularly linked to the development of depression (Kendler et al 2003; Cryan et al        2004). Several studies have estimated the point prevalence of depression among interns at        28%-37% (Valko & Clayton 1975; Reuben 1985; Cohen et al 2006), in contrast to a point        prevalence of 5% in general population (Murphy et al 2000). There is also evidence that        physicians have underlying personality traits that predispose to depression (McDonough        1990; Hojat et al 1999).|March 2013|March 8, 2013|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01809080||69896|
NCT01809405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCNCS-12-685|Validation of Sexual Function Scale in Female Cancer|||National Cancer Center, Korea|No|Recruiting|December 2012|December 2016|Anticipated|February 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1130|||Female|18 Years|N/A|No|Probability Sample|About 1130 adult women living in Korea|March 2014|March 18, 2014|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01809405|3 Weeks|69871|
NCT01809418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|keePAP-1.0|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||March 22, 2016|March 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809418||69870|
NCT01809379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPAC-OV1|Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer|Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial||Ruhr University of Bochum|Yes|Completed|February 2013|September 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Female|18 Years|80 Years|No|||October 2014|October 12, 2014|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01809379||69873|
NCT01809392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hematology-02|Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|||The First Affiliated Hospital of Soochow University||Active, not recruiting|January 2013|December 2015|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 10, 2013|January 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01809392||69872|
NCT01809990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPOCD1|Internet-delivered CBT for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study||Karolinska Institutet|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|12 Years|17 Years|No|||June 2014|June 27, 2014|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01809990||69826|
NCT01818973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6901061|Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer|||Sun Yat-sen University|Yes|Recruiting|March 2013|March 2020|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|March 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01818973||69139|
NCT01831921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60LaComunidad|Latinos Combating Diabetes|Latinos Combatiendo la Diabetes (Latinos Combating Diabetes)|La Comunidad|Wake Forest School of Medicine|No|Recruiting|April 2013|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|225|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831921||68148|
NCT01832987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SXT8469|Pharmacokinetic Parameters of Co-trimoxazole|Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis||University Medical Center Groningen|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|64 Years|No|||September 2014|September 15, 2014|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832987||68067|
NCT01833000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9048|NIRS and Doppler to Predict NEC in Risk Neonates|Assessment of Splanchnic Oxygenation and Circulation in Neonates at Risk for Necrotizing Enterocolitis Using NIRS and Doppler|NeoNIRS|University Hospital, Montpellier|No|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|69|||Both|N/A|28 Days|No|||April 2013|April 11, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01833000||68066|
NCT01833598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0656|Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis|The Efficacy of Ultrasound Guided Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01833598||68020|
NCT01831310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canturkz1|Nutrition for Colorectal Cancer Patients and Neutrophil Functions|Effects Of Standard And/Or Glutamine Dipeptide And/Or Omega-3 Fatty Ascid-Supplemented Parenteral Nutrition On Neutrophil Functions, Interleukin-8 Level And Length Of Stay-A Double Blind,Controlled, Randomized Study||Kocaeli University|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|36|||Both|50 Years|70 Years|No|||April 2013|April 10, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01831310||68194|
NCT01828593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH6001|Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy|Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.||Entera Health, Inc|No|Completed|April 2013|September 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|103|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 8, 2013||No||No|February 9, 2016|https://clinicaltrials.gov/show/NCT01828593||68402|
NCT01828814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre|Different Strategies for Preventing Severe Acute Malnutrition in Niger|Different Strategies for Preventing Severe Acute Malnutrition in Niger: a Pragmatic Trial||Epicentre|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||7|Actual|7836|||Both|6 Months|24 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children 6 to 24 months|March 2013|April 8, 2013|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01828814||68385|
NCT01829334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 06-203|Cost-effectiveness of Four Methods in Preventing Fissure Caries in Permanent Teeth|A Comparative Study on the Cost-effectiveness of Four Methods in Preventing Fissure Caries in Permanent Teeth||The University of Hong Kong|No|Completed|June 2006|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|329|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829334||68345|
NCT01829581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter Analysis OAC-ICH|geRman-widE mulTicenter Analysis of oRal Anticoagulation-associated intraCerebral hEmorrhage|German-wide Multicenter Analysis of Oral Anticoagulant-associated Intracerebral Hemorrhage|RETRACE|University of Erlangen-Nürnberg Medical School|No|Completed|September 2011|January 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1205|||Both|18 Years|N/A|No|Probability Sample|Patients with oral anticoagulation (INR>1.4) associated intracerebral hemorrhage|February 2014|February 25, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829581||68326|
NCT01826513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA13245678|AutoSet for Her Clinical Trial Protocol|AutoSet for Her Clinical Trial Protocol||ResMed|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|50 Years|No|||November 2012|August 3, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826513||68560|
NCT01826760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wenzhouMC 023|Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure|Study of 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure Using Artificial Neural Network||Wenzhou Medical University|Yes|Completed|April 2010|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|583|||Both|19 Years|87 Years|Accepts Healthy Volunteers|Probability Sample|The patients were collected who were diagnosed with ACLF at the First Affiliated Hospital        of Wenzhou Medical College. Patients with ACHBLF were included in the study. ACHBLF was        defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated        within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection.        Patients with evidence of non-B hepatitis virus, alcohol abuse, autoimmune, toxic or other        causes that might lead to liver failure, past or current hepatocellular carcinoma, liver        transplantation, or serious diseases in other organ systems were excluded.        Informed consent was obtained from each patient included in the study and the research        protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou        Medical College.|April 2013|April 3, 2013|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01826760||68542|
NCT01827319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMR1201.001-M|Cardiogenesis Transmyocardial Revascularization Registry|A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction|ANGINA RELIEF|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.|No|Completed|May 2013|June 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who meet the eligibility criteria and undergo TMR at the selected centers        will be provided an opportunity to participate.|July 2015|July 27, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827319|30 Days|68499|
NCT01827046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICH02|Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III|Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III|MISTIE III|Johns Hopkins University|Yes|Recruiting|December 2013|September 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827046||68520|
NCT01827007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS469/E6/05|Assessment of Fluid Responsiveness by Elevation of PEEP in Patients With Septic Shock|Assessment of Fluid Responsiveness by Elevation of PEEP in Patients With Septic Shock||Helsinki University Central Hospital|No|Completed|January 2008|February 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||April 2013|April 4, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01827007||68523|
NCT01827332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20991|Effect of Oxytocin on Craving and Therapy Response|Effect of Oxytocin on Craving and Therapy Response in Marijuana-dependent Individuals||Medical University of South Carolina|No|Active, not recruiting|March 2013|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827332||68498|
NCT01827930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-07|Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response|Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year|MIM|Institut Bergonié|Yes|Recruiting|July 2009|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|268|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01827930||68452|
NCT01817894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-139|Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism|Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism||Bispebjerg Hospital|No|Completed|January 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||November 2013|November 29, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01817894||69222|
NCT01818479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI61077|Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies|Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies||University of Utah|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|70 Years|No|||December 2015|December 16, 2015|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818479||69177|
NCT01818440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130092|Fluoroscopy or 3-D Roadmap Imaging Software for Liver Tumor Treatment|Prospective Randomized Trial Comparing Navigation With 3D Roadmap vs. Conventional Angiography During Transarterial Embolization||National Institutes of Health Clinical Center (CC)||Completed|February 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|8|||Both|18 Years|99 Years|No|||September 2015|December 31, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01818440||69180|
NCT01809665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61|ProMRI PROVEN Master Study|Master Study for the MRI Compatibility of the Solia S and Solia T Pacing Lead, the Linoxsmart ProMRI and Linoxsmart ProMRI DF4 ICD (Implantable Cardioverter-defibrillator) Lead and the Corox ProMRI OTW Coronary Sinus Lead in Combination With the Ilesto/Iforia ICD or the Evia/Entovis Triple Chamber Pacemaker||Biotronik SE & Co. KG|Yes|Completed|June 2013|September 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|174|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigator's general patient        population according to the inclusion and exclusion criteria.|March 2016|March 1, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01809665||69851|
NCT01818986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102012-026|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)|Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)||University of Texas Southwestern Medical Center|Yes|Recruiting|August 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2015|May 7, 2015|March 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818986||69138|
NCT01818999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102012-020|Ixabepilone and SBRT For Metastatic Breast Cancer|A Phase II Trial Of Ixabepilone and Stereotactic Body Radiation Therapy (SBRT) For Patients With Triple Negative Metastatic Breast Cancer||University of Texas Southwestern Medical Center|Yes|Terminated|August 2013|December 2023|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|99 Years|No|||October 2015|October 23, 2015|March 6, 2013|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01818999||69137|
NCT01818687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E16|Safety and Tolerability Study of MCI-196|A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Chronic Kidney Disease Stages 3b to 5 and With Hyperphosphataemia Not on Dialysis||Mitsubishi Tanabe Pharma Corporation|Yes|Terminated|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|2 Years|18 Years|No|||May 2015|May 25, 2015|March 18, 2013||No|This study has been terminated because of insufficient patient recruitment.|No||https://clinicaltrials.gov/show/NCT01818687||69161|
NCT01832714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI-W81XWH-12-C-0205|Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event|Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event|NKI-RIF1|Neuro Kinetics|No|Recruiting|September 2013|November 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|||Both|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The Investigational Group includes Service Members (SM) who had been diagnosed with an        mTBI. The Control Group consists of SM who do not have clinical symptoms consistent with        mTBI. There will be 90 participants in each group, for a target total of 180 study        participants.|September 2014|September 25, 2014|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832714||68088|
NCT01833299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACE-Sorafenib|Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Recruiting|January 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||April 2013|April 12, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01833299||68043|
NCT01834066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00101|Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.|Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial|mdp|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Years|25 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01834066||67984|
NCT01828346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-0087|Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy|A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy||TetraLogic Pharmaceuticals|No|Active, not recruiting|June 2013|November 2015|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828346||68420|
NCT01828606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS6NL|Comparative Trial to Monitor Interface Pressure in Relation to Volume Change in Leg Lymphoedema|Randomised Controlled Trial to Compare the Influence of Sub-bandage Pressure on Percentage Volume Reduction of Leg Lymphoedema||Nij Smellinghe Hosptial|No|Completed|April 2013|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||February 2014|February 7, 2015|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828606||68401|
NCT01829074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13RT001|Predictive Value of Subjective and Objective Measurement Tools for Extraesophageal Reflux|||Respiratory Technology Corporation||Enrolling by invitation|April 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients presenting to the Otolaryngology practices of the co-investigators with certain        symptoms consistent with Laryngopharyngeal reflux: hoarseness, globus sensation, and/or        recurrent throat clearing for more than 3 months|April 2013|April 10, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01829074||68365|
NCT01829880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLNIK_PKT1|Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure|Impact of Body Composition Changes and Cachexia on Bisoprolol and Ramipril Pharmacokinetics and Renal Function Estimation in Patients With Chronic Heart Failure||The University Clinic of Pulmonary and Allergic Diseases Golnik||Recruiting|October 2011|August 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic heart failure who attend internal medicine outpatient clinic|April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829880||68303|
NCT01826773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardioPET™ P-02|CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects|A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects With Coronary Artery Disease||Fluoropharma, Inc.|No|Completed|March 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|29|||Both|30 Years|N/A|No|||November 2015|November 25, 2015|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826773||68541|
NCT01827020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mukadder|Effect of Ketamine Addition to Lidocaine in Rhinoplasty|Effect of Ketamine Addition to Lidocaine for Postoperative Pain Management in Rhinoplasty||Inonu University|Yes|Completed|January 2013|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|50 Years|No|||April 2013|April 8, 2013|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827020||68522|
NCT01827059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 42568.018.12|Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE|A Randomized Placebo Controlled Trial to Analyze Changes in Pulmonary Arterial Pressures at Peak Exercise in Congenital Heart Disease Patients With Exercise-induced Pulmonary Arterial Hypertension Before and After Treatment With Bosentan, Compared to Placebo|BICYCLE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|October 2013|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827059||68519|
NCT01827345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-2013|Vitamin D as a Supplement Against Falls in Elderly Study|Effects of Vitamin D Supplementation on Fall Risk and Functional Outcomes in Older Adults With Insufficient Vitamin D Levels: A Pilot Study|D-SAFE|University of Florida|Yes|Recruiting|April 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827345||68497|
NCT01827670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01685|Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|April 5, 2013|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01827670||68472|
NCT01827683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOT-Fibro|Hyperbaric Oxygen and Fibromyalgia: Randomised Prospective Clinical Trial|The Effect of Hyperbaric Oxygen on Patients Suffering From Chronic Pain Syndrome (Fibromyalgia)||Assaf-Harofeh Medical Center|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|45 Years|65 Years|No|||April 2013|April 8, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01827683||68471|
NCT01818492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0501-04|A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis|A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis||NovImmune SA|Yes|Recruiting|January 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|18 Years|No|||February 2016|March 3, 2016|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818492||69176|
NCT01818674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDF2010-2014|Microclinic Social Network Behavioral Health Trial in Jordan|Microclinic Social Network Behavioral Health Trial for Obesity and Metabolic Risk Factor Control in Jordan||Microclinic International|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01818674||69162|
NCT01818700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP12-KR-401|An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of NORSPAN® (Buprenorphine) in Korean Patients With Spinal Disorders (NOBLE)|NOBLE|Mundipharma Korea Ltd|Yes|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|245|||Both|20 Years|80 Years|No|||October 2015|October 1, 2015|October 18, 2012||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT01818700||69160|
NCT01827553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014476-21|Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy|Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone|CONKO-007|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|March 2013|April 2022|Anticipated|April 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|830|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827553||68481|
NCT01827566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-2012-GS|Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet|Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial With a Cross-over Design to Assess the Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet||Università degli Studi di Brescia|No|Active, not recruiting|July 2012|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|26|||Both|18 Years|65 Years|No|||December 2014|December 5, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827566||68480|
NCT01827826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184802-16|Call-2-Health: Preventing Type II Diabetes|Translating the Diabetes Prevention Project (DPP) in a Health Maintenance Organization (HMO) Setting|C2H|Group Health Cooperative|Yes|Completed|July 2010|June 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|47|||Both|40 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01827826||68460|
NCT01827839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116796|Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster|Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster||GlaxoSmithKline||Completed|June 2013|November 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|96|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827839||68459|
NCT01828099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2301|LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer|A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer||Novartis|Yes|Recruiting|July 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828099||68439|
NCT01828359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALOS-401|The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.|An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy||Hanmi Pharmaceutical Company Limited|No|Completed|August 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|20 Years|N/A|No|||April 2013|April 9, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828359||68419|
NCT01828879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017833|An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis|The Efficacy and Safety of Tacrolimus Ointment in Adult Patients With Moderate to Severe Atopic Dermatitis||Janssen-Cilag Ltd.,Thailand|No|Completed|November 2007|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828879||68380|
NCT01829087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ES01|Botulinum Toxin A to Treat Flexion Contracture After Total Knee Arthroplasty|Botulinum Toxin A to Treat Flexion Contracture After Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Study||Rothman Institute Orthopaedics|No|Recruiting|August 2012|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829087||68364|
NCT01826500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/12-16 - VARITI-5|VARITI-5 : Study of Variations of Serum ITIH5 in Women During the Genital Life and in Pathological Situations|VARITI-5 : Study of Variations of Serum ITIH5 in Women During the Genital Life and in Pathological Situations.|VARITI-5|Rennes University Hospital|No|Recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|175|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patients with embryo transfer fresh or frozen          -  Patients from an IVF cycle,          -  Patients supported surgically for endometriosis or          -  donors|December 2015|December 17, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01826500||68561|
NCT01834534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH096699|Telemonitoring Enhanced Support for Depression Self Management|Telemonitoring Enhanced Support for Depression Self Management||University of Michigan|Yes|Recruiting|September 2013|August 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|21 Years|N/A|No|||January 2016|January 25, 2016|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01834534||67948|
NCT01826786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100975|The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers|The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|43|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|April 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01826786||68540|
NCT01830751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMRIS 12-02|Limiting Trunk Flexion as a Self-treatment for Low Back Pain|Influencing Diurnal Variation in Disc Hydration as a Treatment for Non-specific Low Back Pain|RST|Liberty Mutual Research Institute for Safety|No|Active, not recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|30 Years|60 Years|No|||March 2016|March 3, 2016|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01830751||68237|
NCT01827358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0065|Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial|Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|April 2014|April 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|126|||Both|N/A|24 Months|No|||October 2015|March 17, 2016|April 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827358||68496|
NCT01831232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2674.00|Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)||Fred Hutchinson Cancer Research Center|No|Completed|May 2013|||February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|74 Years|No|||March 2015|March 3, 2015|April 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831232||68200|
NCT01818739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12114|Lymph Node Mapping in Patients With Endometrial Cancer|Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|18 Years|85 Years|No|||February 2016|February 8, 2016|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01818739||69157|
NCT01818167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microdermis-100|An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.|A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa||Henry Ford Health System|No|Recruiting|March 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|13 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01818167||69201|
NCT01818180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/19|Urell and Pregnancy|Effect of URELL(Cranberry Vaccinium Macrocarpon)Consumption on the Prevalence of Recurrent Urinary Tract Infection and Asymptomatic Bacteriuria During Pregnancy.||Hopital Foch|No|Terminated|May 2010|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator)|2||Actual|11|||Female|18 Years|40 Years|No|||March 2013|March 21, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01818180||69200|
NCT01818193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/60|Neurological Complications - Pulmonary Transplant|||Hopital Foch||Recruiting|June 2012|||September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|patients enregistered in the waiting list for lung transplant|March 2013|March 21, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01818193||69199|
NCT01818453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01-0025|Can Genetics Predict Treatment Response to a Computerized Self-help Program for Depression?|Genetic Predictors of Response to a Computerized Self-help Program for Depression||University of Texas at Austin|Yes|Completed|March 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|55 Years|No|||November 2015|November 6, 2015|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01818453||69179|
NCT01818466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57171|Anterior Tibiotalar Arthrodesis With Blade Plate Fixation|Anterior Tibiotalar Arthrodesis With Blade Plate Fixation in Treatment of Post-traumatic Arthritis Secondary to Pilon Fracture||University of Utah|No|Enrolling by invitation|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who have previously undergone tibiotalar arthrodesis using an anterior approach        with blade-plate fixation for tibiotalar arthritis secondary to injury to the articular        surface of the distal tibia.|December 2015|December 18, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01818466||69178|
NCT01827241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR11-0264|Colonoscopy Database|Outcome of Colonoscopy Screening and Surveillance||M.D. Anderson Cancer Center|No|Recruiting|September 2011|||December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Chart review from participants receiving colonoscopy at UT MD Anderson Cancer Center in        Houston, Texas from 02/01/2009 - 12/31/2020.|October 2015|October 13, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01827241||68505|
NCT01827579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/11/0519|Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)|Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant|ICAT|University College, London|Yes|Recruiting|July 2014|July 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|16 Years|N/A|No|||November 2015|November 30, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827579||68479|
NCT01827592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000079|26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation|A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks||Ferring Pharmaceuticals|No|Terminated|April 2013|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|376|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 5, 2013|Yes|Yes|Terminated due to a distribution issue with the trial medication|No|July 17, 2015|https://clinicaltrials.gov/show/NCT01827592||68478|Due to the early termination of the study, outcomes were presented only for descriptive purposes.
NCT01827852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28306|AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung|AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung||Hoffmann-La Roche||Active, not recruiting|March 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1107|||Both|18 Years|N/A|No|Probability Sample|Patients with inoperable advanced, metastatic or recurrent predominantly non-squamous        adenocarcinoma non-small cell lung cancer|March 2016|March 1, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01827852||68458|
NCT01827865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/11-VIN-413|Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|November 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827865||68457|
NCT01828112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2303|LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib|A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib||Novartis|Yes|Recruiting|June 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828112||68438|
NCT01828866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZ / NISPA / BSI / WM04|Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients|From Feasibility to Efficacy: the Use of EMDR to Reduce Craving and Drinking Behaviour in Alcohol Dependent Outpatients - A Multiple Baseline Study and Randomized Controlled Trial (RCT)||IrisZorg|No|Active, not recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828866||68381|
NCT01829100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChuDep2009|Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression|The Function of Avoidance in Depressed Behavior and a Pilot of Transdiagnostic Behavioral Activation Therapy||Rutgers University|Yes|Completed|September 2009|June 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|895|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01829100||68363|
NCT01829347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-210|Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure|A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure||Vital Therapies, Inc.|Yes|Terminated|April 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 8, 2013|Yes|Yes|Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and    the VTI-210 study has been terminated.|No||https://clinicaltrials.gov/show/NCT01829347||68344|
NCT01829607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES-HFPEF|Functional Electrical Stimulation of Peripheral Muscles in Heart Failure With Preserved Left Ventricular Ejection Fraction|||Attikon Hospital||Completed|January 2011|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829607||68324|
NCT01830465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOLLREC3|VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma|Phase II Study of VELCADE in Combination With Rituximab in Patients With Relapsed or Progressed Non Hodgkin's Follicular Lymphoma||Gruppo Italiano Studio Linfomi|No|Completed|August 2006|May 2011|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|90 Years|No|||April 2013|April 11, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01830465||68259|
NCT01830478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFL08|Lenalidomide Plus Rituximab (R) in Non Follicular NHL|Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).||Gruppo Italiano Studio Linfomi|No|Active, not recruiting|April 2009|October 2014|Anticipated|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|75 Years|No|||April 2013|April 9, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830478||68258|
NCT01834547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players|Phase I Study About Effects of Caffeine, Methylphenidate, Modafinil and Placebo on Cognitive Performance of Chess Players.|CHESS|Johannes Gutenberg University Mainz|Yes|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|4||Actual|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01834547||67947|
NCT01834560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG25|SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression|Subgenual Cingulate Stimulation in Resistant Depression|CG25|University Hospital, Grenoble|Yes|Recruiting|December 2007|May 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|||Both|30 Years|55 Years|No|Non-Probability Sample|patients suffering from severe depression and referred by the psychiatry department of        french University Hospital|February 2013|April 15, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01834560||67946|
NCT01834781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-Re5|Pulsed Electromagnetic Fields for Multiple Chemical Sensitivity|Transcranial Pulsed Electromagnetic Fields for Multiple Chemical Sensitivity: a Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial||The Danish Research Centre for Chemical Sensitivities|Yes|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|75 Years|No|||April 2014|April 15, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01834781||67929|
NCT01830985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-509-104|A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis|A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs||Vertex Pharmaceuticals Incorporated|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|65 Years|No|||October 2015|October 23, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830985||68219|
NCT01830972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX001-CL202|An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid (ER Tablets + IR Capsules) in Patients With GNE Myopathy|An Open-label Phase 2 Extension Study to Evaluate the Long Term Safety and Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy||Ultragenyx Pharmaceutical Inc|Yes|Active, not recruiting|June 2013|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830972||68220|
NCT01831245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2105-31/2|Right-sided Colon Tumor, Laparoscopic Versus Open Surgery, in an ERAS Protocol|Right-sided Colon Tumor, Laparoscopic and Open Surgery, in an ERAS Protocol||Karolinska Institutet|No|Completed|January 2011|July 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Non-Probability Sample|Right sided colom tumor or large benign adenoids|February 2015|February 19, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01831245|2 Years|68199|
NCT01831778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCSC|Breast Cancer Surveillance Consortium|Breast Cancer Surveillance Consortium Data Resource|BCSC|Group Health Cooperative|No|Completed|January 1994|December 2009|Actual|December 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2345817|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The BCSC pooled database includes data from seven BCSC registries, of which five are        currently active. Information comes from a large study population that is ethnically,        geographically, and socioeconomically diverse. The database currently includes 9 million        mammograms from 2.3 million women interpreted by over 1400 radiologists at 400 facilities.        There are 1.1 million digital mammograms; 660,000 ultrasounds; 180,000 benign and        malignant biopsies; and records of over 155,000 deaths. Over 107,000 women have a breast        cancer diagnosis, of which 83% are first diagnosed in 1994 or later. The data are        collected in the course of routine, clinical care to accurately represent community        practice.|April 2013|April 23, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831778|1 Year|68159|
NCT01831791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114264|A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia|Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia||GlaxoSmithKline|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Male|20 Years|50 Years|No|||August 2014|February 26, 2015|April 11, 2013||No||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01831791||68158|
NCT01819324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Park003382HE|A Lifestyle Intervention for Breast Cancer Survivors|Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors|TTMI|Hartford Hospital|Yes|Completed|April 2011|July 2015|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|173|||Female|18 Years|80 Years|No|||December 2015|December 2, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819324||69112|
NCT01818713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12LMB|Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases|Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases||The Netherlands Cancer Institute|No|Recruiting|October 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01818713||69159|
NCT01818726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ARU02|Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients|Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group||Novartis|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01818726||69158|
NCT01819025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-PC-HH-KHL|Cognitive Behavioral Therapy Treatment of Depression With Smartphone Support|Face-to-face CBT Treatment of Depression With Smartphone Support||Linkoeping University|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||July 2013|February 6, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819025||69135|
NCT01827618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120135H|Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy|An Immunopharmacodynamic Phase 0/I Study of Rapamycin in Patients Undergoing Radical Cystectomy for Bladder Cancer||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|March 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827618||68476|
NCT01827878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/10/387|Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lisinopril/Hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA in Normal, Healthy, Adult, Human Subjects Under Fed Condition.||IPCA Laboratories Ltd.|Yes|Completed|October 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|April 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827878||68456|
NCT01828125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mini-doses glucagon|Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes|A Double-blinded, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Small Subcutaneous Glucagon Dose Against the Conventional 1 mg Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Withdrawn|April 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01828125||68437|
NCT01828372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPUK-12-GenPOPPK-2|Quantification of Drugs and Their Degradation Products|Quantification of Drugs and Their Metabolites in Patients at the Cologne University Hospital||University of Cologne|Yes|Not yet recruiting|May 2013|March 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828372||68418|
NCT01828619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUIH-201303|Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients|The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases||Peking University People's Hospital||Enrolling by invitation|February 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|55 Years|70 Years|No|Probability Sample|The study population is patients with hematologic malignant diseases, who will undergo HLA        matched HSCT.|April 2013|April 9, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828619||68400|
NCT01828632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-08-2011|Effects of Preoperative Respiratory Physical Therapy on Postoperative Respiratory Function After Bariatric Surgery|Effects of Preoperative Respiratory Physical Therapy on Postoperative Respiratory Function in Morbidly Obese Patients Undergoing Bariatric Surgery. A Randomized, Controlled, Clinical Trial||Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|44|||Both|18 Years|60 Years|No|||April 2013|February 4, 2016|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828632||68399|
NCT01830192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47/09 RA CBM|REM (Risk Of Endometrial Malignancy)|REM (Risk Of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy|REM|Campus Bio-Medico University|No|Completed|January 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|741|||Female|45 Years|80 Years|No|||April 2013|April 11, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830192||68280|
NCT01830205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-063|Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment|Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment||Bristol-Myers Squibb|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|58|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|April 10, 2013|Yes|Yes||No|August 19, 2015|https://clinicaltrials.gov/show/NCT01830205||68279|
NCT01830452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL27506.058.09|Less Chronic Pain After Lichtenstein Hernioplasty Using the Self-gripping Parietex Progrip Mesh|Multicentre Randomised Controled Trial Comparing the Effect of a New Self-gripping Lightweight Polyester Mesh and a Normal Sutured Lightweight Polyester Mesh on the Incidence of Chronic Inguinodynia in Lichtenstein Hernioplasty.|HIPPO|Groene Hart Ziekenhuis|No|Recruiting|September 2010|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||April 2013|April 9, 2013|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01830452||68260|
NCT01834248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 227712|DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML||Roswell Park Cancer Institute|Yes|Active, not recruiting|July 2013|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01834248||67970|
NCT01830777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-040|Brentuximab Vedotin + Chemo for AML|Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)||Massachusetts General Hospital|Yes|Recruiting|May 2013|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830777||68235|
NCT01830998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130401|Early Detection of Cognitive Dysfunction in Diabetes|Study of Cognitive Dysfunction and Diabetes||Wuhan General Hospital of Guangzhou Military Command|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|400|None Retained|serum|Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with type 2 diabetes|December 2014|December 9, 2014|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01830998||68218|
NCT01830764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS-ACN06|Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers|An Open-label Safety and Tolerability Study of LTS 0.3% With Red Light Applied to the Backs of Healthy Volunteers||Dermira, Inc.|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 5, 2013|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830764||68236|
NCT01831505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRS-1|Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents|Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System||Presage Biosciences|Yes|Active, not recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01831505||68180|
NCT01831492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-217 ex 12/13|Effects of Zeolite + Dolomite on Performance and Acidosis|Effects of Dietary Zeolite + Dolomite on Performance, Exercise-induced Acidosis, Oxidative Stress, Inflammation and Intestinal Barrier Dysfunction in Trained People||Green Beat|Yes|Completed|April 2013|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|56|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01831492||68181|
NCT01831804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115760|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863|Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer||GlaxoSmithKline|No|Recruiting|June 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|7||Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|February 4, 2016|April 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01831804||68157|
NCT01832402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1169|Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea||M.D. Anderson Cancer Center|Yes|Active, not recruiting|June 2013|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832402||68112|
NCT01819337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactate1|The Influence of Preoperative Cardiopulmonary Capacity on the Perioperative Lactate Level|The Influence of Preoperative Cardiopulmonary Capacity Mesured in MET's (Metabolic Equivalents) on the Perioperative Lactate Level||University of Witten/Herdecke|No|Completed|March 2013|August 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1502|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing elective/urgent or emergency surgery|September 2013|September 15, 2013|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01819337||69111|
NCT01819649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-DK-PILOT-PRECISE|Selenium in the Prevention of Cancer|Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population|DK PRECISE|Odense University Hospital|Yes|Completed|November 1998|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|491|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|January 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01819649||69087|
NCT01819038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chula|Early Renal Replacement Therapy and the Outcome of Acute Kidney Injury||EarlyRRT|Chulalongkorn University|Yes|Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||December 2015|January 26, 2016|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819038||69134|
NCT01819051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOE - 131|Pilot Study to Evaluate Plasma Treatment of Onychomycosis|A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Onychomycosis||Moe Medical Devices||Completed|March 2013|||March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01819051||69133|
NCT01819623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-830-13/14-1|Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment|Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment||National Institute of Medical Sciences and Nutrition, Salvador Zubiran|No|Withdrawn||||March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|60 Years|N/A|No|||April 2015|April 20, 2015|March 11, 2013||No|Financial issues (no participants enrolled)|No||https://clinicaltrials.gov/show/NCT01819623||69089|
NCT01819311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH097931|Attention Bias Modification Training for Child Anxiety CBT Nonresponders|Attention Bias Modification Training for Child Anxiety CBT Nonresponders||Florida International University|Yes|Recruiting|April 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|8 Years|16 Years|No|||February 2016|February 1, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01819311||69113|
NCT01827631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116416|Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects|Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects||GlaxoSmithKline|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01827631||68475|
NCT01827891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-12|Remote Ischemic Preconditioning and Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Stent Implantation|Remote Ischemic Preconditioning and Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Stent Implantation|REPAIR|Beijing Anzhen Hospital|Yes|Active, not recruiting|March 2012|June 2013|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|310|||Both|18 Years|80 Years|No|||April 2013|April 9, 2013|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01827891||68455|
NCT01828138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9-5510|Hypertension and Urine Protease Activity in Preeclampsia|HUPP-study -Hypertension and Urine Protease Activity in Preeclampsia|HUPP|Odense University Hospital|Yes|Completed|May 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|35|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828138||68436|
NCT01828385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAGF-01M|Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex|Effect of Magnesium Sulfate on the Reversal of Neuromuscular Blockade With Sugammadex: a Prospective, Randomized Double-blind Trial||Universidade Federal do Rio de Janeiro|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||January 2015|January 17, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828385||68417|
NCT01828892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120819|Glue Application in the Treatment of Low-Output Fistulas|A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas|FG-treatment|Jinling Hospital, China|Yes|Recruiting|March 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01828892||68379|
NCT01829906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|321|Suboptimal Weight Loss After Gastric Bypass Surgery|Evaluation of the Efficacy of Two Lifestyle Interventions for Suboptimal Weight Loss After Gastric Bypass Surgery||Norwegian University of Science and Technology|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01829906||68301|
NCT01829919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N30-005|Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women|Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women|N30-005|Noven Therapeutics|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|40 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|April 9, 2013|No|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01829919||68300|
NCT01830218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBAAMA 2011|Obstetric Anesthesia and Analgesia Month Attributes in Czech Republic|A National Survey on Obstetric Anesthesia and Analgesia Care in Czech Republic|OBAAMA|Charles University, Czech Republic|Yes|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1940|||Female|N/A|N/A|No|Non-Probability Sample|Women in labor|April 2013|April 11, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01830218||68278|
NCT01830231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Secavin-12|Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)|A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium||Associació per a la Recerca Oncologica, Spain|Yes|Recruiting|October 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|372|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01830231||68277|
NCT01830543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100758|A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention|An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention|PIONEER AF-PCI|Janssen Scientific Affairs, LLC|Yes|Active, not recruiting|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2127|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01830543||68253|
NCT01831817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01591|Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity|A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|March 23, 2015|April 11, 2013|Yes|Yes||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01831817||68156|
NCT01831258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-SA13-01|Comparison Study of the ICON™ CPAP Series With and Without SensAwake™|||Fisher and Paykel Healthcare||Completed|March 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||October 2014|October 14, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01831258||68198|
NCT01832415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCOURAGE (GINECO-OV123)|First Line Ovarian Cancer Treatment - Cohort Study|Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy|ENCOURAGE|ARCAGY/ GINECO GROUP|No|Completed|April 2013|March 2016|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Female|18 Years|N/A|No|Non-Probability Sample|• Patients with epithelial ovarian cancer, fallopian tube or peritoneal with treatment        receiving Bevacizumab (Avastin ®) in first-line therapy|March 2016|March 15, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01832415|36 Months|68111|
NCT01832649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PEF-2011-98|Exercise as an Adjunctive Treatment for Cocaine Dependent Patients|Effectiveness of an Exercise Program in the Treatment of Cocaine Dependence||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|January 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|60 Years|No|||April 2013|April 12, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01832649||68093|
NCT01832922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13067|BR in Patients With CLL With Comorbidities and/or Renal Dysfunction|A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|April 2013|April 2018|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01832922||68072|
NCT01820195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC-18043|N-Acetyl Cystein and Contrast Nephropathy|The Effect of N-Acetyl Cystein in Preventing Contrast Induced Nephropathy: A Double Blind Double Dummy Randomized Controlled Trial||Imam Khomeini Hospital|Yes|Recruiting|March 2013|November 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|549|||Both|18 Years|80 Years|No|||March 2013|March 27, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01820195||69045|
NCT01819636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-2|Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile|Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile||Neptune|Yes|Completed|March 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|162|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01819636||69088|
NCT01819883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002517|Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly|Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly||Massachusetts General Hospital|No|Recruiting|April 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|52|Samples Without DNA|Whole blood, serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty-two study subjects will be studied: 1) patients with active acromegaly, and 2)        healthy controls. Study subjects with acromegaly will be prescribed treatment for        acromegaly by their healthcare providers, and this study will not interfere in anyway with        clinical care and will not provide surgery, medications or other forms of clinical care.|March 2016|March 9, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01819883||69069|
NCT01819857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO4|Droperidol and Cardiac Repolarization|The Influence of Droperidol on Cardiac Repolarization. A Double-blind, Ondansetron-controlled Study.||Medical University of Gdansk|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|75|||Male|18 Years|60 Years|No|||August 2013|August 5, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01819857||69071|
NCT01819870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125HPS12006|Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg|A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|April 2013|August 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2013|March 29, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01819870||69070|
NCT01827904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET002|ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors|A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects||InSightec|Yes|Active, not recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|22 Years|N/A|No|||February 2016|February 16, 2016|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827904||68454|
NCT01828151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbosco5|Noninvasive Positive Airway Pressure Ventilation and Risk of Facial Pressure Ulcers|Noninvasive Positive Airway Pressure Ventilation and Risk of Facial Pressure Ulcers in Patients With Acute Respiratory Failure||Ospedale S. Giovanni Bosco|No|Completed|December 2009|March 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|170|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to our high dependency unit for an episode of acute respiratory failure        and treated with noninvasive ventilation.|April 2013|April 5, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01828151||68435|
NCT01828398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke_tDCS|tDCS and Robotic Therapy in Stroke|||University Hospital of Ferrara|Yes|Completed|November 2011|November 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||January 2014|January 15, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01828398||68416|
NCT01828645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cho+whey protein safety|Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein|Residual Gastric Volume Measured by Upper Digestive Endoscopy 2h After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein. A Controlled, Randomized Clinical Trial||Federal University of Mato Grosso do Sul|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Both|18 Years|80 Years|No|||April 2013|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01828645||68398|
NCT01829893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP-FITAM-104|PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination|Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects||Korea University Anam Hospital|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2011|April 8, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829893||68302|
NCT01833975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00103|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury . It is Self Funded (Patients' Own Funding) Clinical Trial|SCI|Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01833975||67991|
NCT01834235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1201|A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer|A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX||Precision Biologics, Inc|No|Recruiting|April 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01834235||67971|
NCT01833988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013p000561|The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas|The Summer Camp Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population at the Clara Barton Diabetes Camps||Massachusetts General Hospital|Yes|Active, not recruiting|April 2013|December 2014|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|12 Years|20 Years|No|||March 2014|March 11, 2014|April 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01833988||67990|
NCT01834001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130119|Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy|Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|February 2021|Anticipated|February 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|190|||Male|18 Years|99 Years|No|||November 2015|December 15, 2015|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01834001||67989|
NCT01831518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHCIT1|Predicting Response to CRT Using Body Surface ECG Mapping|Evaluation of a Novel Method of Non-surface Electrocardiographic Mapping in Predicting Clinical, Structural and Neurohormonal Responses in Patients Undergoing Cardiac Resynchronization Therapy.||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|July 2014|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01831518||68179|
NCT01831531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-Shanghai7|Study of S-1 in Combination With Radiotherapy in Esophageal Cancer|Phase II Study of S-1 in Combination With Radiotherapy in Esophageal Squamous Cell Carcinoma||Fudan University|Yes|Active, not recruiting|March 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01831531||68178|
NCT01832116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMOT imaging|89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients|89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g|MMOT|University Medical Center Groningen|Yes|Completed|March 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01832116||68133|
NCT01832129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRG_VB12_CM|Vitamin B12 Acceptance and Biomarker Response Study|Acceptance and Biomarker Response With Oral vs. Intramuscular Supplementation of Vitamin B12 in Primary Care||University Hospital, Basel, Switzerland|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01832129||68132|
NCT01832155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga4OA|Yoga for Managing Knee Osteoarthritis in Older Women: a Feasibility Study|A Pilot Study Testing a Hatha Yoga Exercise Program in Older Women With Knee Osteoarthritis||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|36|||Female|65 Years|86 Years|No|||April 2015|April 3, 2015|April 4, 2013||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01832155||68131|Limitations: Small sample size without blinding. Strengths: Randomized controlled design, data collection at multiple time points and the use of a yoga expert panel to design the yoga program specifically for older women with knee osteoarthritis.
NCT01832168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFRALP001|Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy|A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.||MiMedx Group, Inc.|No|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|45 Years|70 Years|No|||March 2015|March 16, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01832168||68130|
NCT01832428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00107|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke.|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke. It is Self Funded (Patients' Own Funding) Clinical Trial|BMACS|Chaitanya Hospital, Pune|No|Recruiting|September 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01832428||68110|
NCT01820819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10003|Is Access to Liver Transplantation Similar in Alcoholic or Not Patients?|Is Access to Liver Transplantation Similar in Alcoholic or Not Patients? A Prospective Cohort Study|TRANSALC|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2012|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients aged over 18 admitted to medical or hepato gastroenterology        departments of the hospitals selected in three French area with liver cirrhosis|December 2015|December 15, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01820819||68997|
NCT01819896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-009|Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices|Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices||Deutsches Herzzentrum Muenchen|No|Completed|February 2013|January 2015|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Recipients of implantable pacemakers or defibrillators|February 2015|February 12, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01819896||69068|
NCT01820468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01715|Adapting a Model for Veterans on a Psychiatric Inpatient Unit|Adapting a Critical Time Intervention Model for Veterans on a Psychiatric Inpatient Unit||VA Connecticut Healthcare System|Yes|Withdrawn|July 2013|March 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|January 9, 2015|March 25, 2013||No|This study was terminated before any participants were enrolled due to unforseen problems with    participant enrollment and study design.|No||https://clinicaltrials.gov/show/NCT01820468||69024|
NCT01820169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001551|Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG|Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG||Hoffmann-La Roche||Terminated|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|20 Years|N/A||||February 2013|May 11, 2015|March 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01820169||69047|
NCT01820182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023341-29|Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule|Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule in Patients With Obscure Digestive Bleedings||Hôpital Edouard Herriot|Yes|Completed|January 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Both|18 Years|90 Years|No|||October 2010|March 28, 2013|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01820182||69046|
NCT01828411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056/10|Cerebral Perfusion Monitoring With Transpharyngeal Ultrasonography|Monitoring the Brain in On-pump Cardiovascular Surgery: The Role of Transpharyngeal Ultrasonography as a Non-invasive Adjunct to Assess Cerebral Perfusion|TP-Echo|University Hospital Inselspital, Berne|No|Recruiting|April 2013|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|32|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery at the University Hospital Bern.|February 2016|February 9, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01828411||68415|
NCT01828658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM0913|Randomized Bioimpedance vs Clinical Methods in Guiding Ultrafiltration in Hemodialysis Patients|Bioimpedance Versus Clinical Methods in Guiding Ultrafiltration in Hemodialysis Patients: a Randomized Trial|BIAHD|Grigore T. Popa University of Medicine and Pharmacy|No|Completed|July 2008|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||October 2013|October 13, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01828658||68397|
NCT01828905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S041/2012|Cerament Treatment of Fracture Defects|A Prospective, Multicenter, Randomized Study Investigating the Use of CERAMENT™/BONE VOID FILLER as Bone Graft Substitute in Tibia Plateau Fractures|CERTiFy|Johannes Gutenberg University Mainz|No|Recruiting|April 2013|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01828905||68378|
NCT01829113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 229|Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer|Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)|Spruce|SCRI Development Innovations, LLC|No|Active, not recruiting|July 2013|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01829113||68362|
NCT01829360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC012824|Accelerating Word Learning in Children With Language Impairment|Interactive Book Reading to Accelerate Word Learning by Children With SLI||University of Kansas Medical Center|No|Recruiting|March 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|104|||Both|5 Years|6 Years|No|||January 2016|January 28, 2016|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01829360||68343|
NCT01841424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-571|CO-OP Trial: Community-based Outreach on Obesity in Pregnancy|CO-OP Trial: Community-based Outreach on Obesity in Pregnancy: Using Community-based Participatory Research to Modify Dietary Interventions to Prevent Excessive Weight Gain During Pregnancy in Obese and Under-resourced Women|CO-OP|University of Missouri, Kansas City|Yes|Recruiting|June 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841424||67421|
NCT01841437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS100-PAR|Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry|Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry||Glaukos Corporation|No|Active, not recruiting|September 2013|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive subjects in whom implantation of the iStent is attempted at selected clinical        sites|March 2016|March 23, 2016|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841437|36 Months|67420|
NCT01841658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGA_FASUPPLEMENT_EPIGEN|Folic Acid Supplementation in Women of Child Bearing Age|Effect of Obesity and Folic Acid Supplementation on Gene-specific DNA Methylation in Women of Reproductive Age|FASUPP|University of Georgia|No|Active, not recruiting|April 2013|May 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841658||67403|
NCT01842347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT|Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)|Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)||Medical College of Wisconsin|Yes|Withdrawn|August 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Months|N/A|No|||December 2013|December 12, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842347||67351|
NCT01850108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCNC BMT 12108|Non-Myeloablative Conditioning and Bone Marrow Transplantation|A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|May 2013|November 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850108||66757|
NCT01842594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120306M|A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma|A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Terminated|August 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|75 Years|No|||October 2015|October 5, 2015|December 19, 2012||No|Most patients completed only the primary objective (PET) and not went throught the secondary    outcome (efficacy phase) of 8wks period.|No|June 8, 2015|https://clinicaltrials.gov/show/NCT01842594||67332|
NCT01842607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115661|A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects|MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA115588 or MEA115575 Trials||GlaxoSmithKline|Yes|Completed|May 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|651|||Both|12 Years|N/A|No|||February 2016|February 4, 2016|April 25, 2013|Yes|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT01842607||67331|
NCT01842880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-41-10-2|MicroRNAs as Biomarkers in Patients With Chagas Disease|Validation of MicroRNAs as Biomarkers for Determining Patients Prognosis With Chagas Disease||Hospital Sao Rafael|No|Completed|January 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Plasma, Serum, Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Tertiary Hospital|February 2015|February 19, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01842880||67310|
NCT01843192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-12-001|Powered Echelon Device in VATS Surgery|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures||Ethicon Endo-Surgery|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with suspected or confirmed NSCLC, scheduled for VATS lobectomy or wedge        resection in accordance with their institution's SOC|March 2015|May 21, 2015|April 19, 2013|Yes|Yes||No|March 6, 2015|https://clinicaltrials.gov/show/NCT01843192||67286|
NCT01851993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02-M16-13B Ondansetron|Inhaled Ondansetron & Dyspnea|Effects of Inhaled Ondansetron on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction||McGill University|No|Completed|June 2013|December 2014|Actual|September 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851993||66613|
NCT01851226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130415-3|Effect of Different Length of Time for Trainees to Attempt Cannulation on Success Rate of Selective Cannulation During hands-on ERCP Training|Effect of Different Length of Time for Trainees to Attempt Cannulation on Success Rate of Selective Cannulation During hands-on ERCP Training|ERCP|Fourth Military Medical University|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|256|||Both|18 Years|90 Years|No|||April 2014|April 1, 2014|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01851226||66671|
NCT01852214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2011-184|Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes|A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease||University of Florida|Yes|Completed|February 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|74 Years|No|||October 2015|October 1, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852214||66596|
NCT01849991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-11-0203|Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic|Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic||The University of Texas Health Science Center, Houston|Yes|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|N/A|3 Months|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849991||66766|
NCT01850004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-406|Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response|Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE|DASFREE|Bristol-Myers Squibb|Yes|Recruiting|October 2013|November 2021|Anticipated|November 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|79|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850004||66765|
NCT01839981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 57113|CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|July 2013|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839981||67532|
NCT01840189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2218|Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes|Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes||Haukeland University Hospital|Yes|Active, not recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840189||67516|
NCT01852201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO23329|POSITIVE Stroke Clinical Trial|POSITIVE: PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy||Medical University of South Carolina|Yes|Recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|80 Years|No|||September 2015|October 1, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852201||66597|
NCT01849367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC13052|Trial of Bilateral tDCS for Depression|||The University of New South Wales|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01849367||66814|
NCT01849380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST T-01|Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer|Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer||Shandong University|Yes|Not yet recruiting|June 2013|June 2018|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|70 Years|No|||May 2013|May 6, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849380||66813|
NCT01841229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetaG|Effect of Ginseng on Glycemic Control|Effect of Ginseng on Glycemic Control: A Systematic Review and Meta-analysis of Controlled Trials to Provide Evidence-based Clinical Recommendations||St. Michael's Hospital, Toronto|Yes|Active, not recruiting|October 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|N/A||1|Actual|770|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Diabetic (type 1 & type 2) Pre-diabetic Hypertensive Healthy|May 2013|May 22, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841229||67436|
NCT01841216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR02|EMG Activation of Gluteal Musculature During Exercises With and Without Resistance|EMG Activation of Gluteal Musculature and Perceived Exertion During Therapeutic Exercises With and Without Thera-Band® Resistance|GlutEMG02|Sport and Spine Rehab Clinical Research Foundation|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|April 23, 2013||No||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01841216||67437|
NCT01841671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV002ABMG|Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine|A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines|IPV002ABMG|University of Chile|Yes|Active, not recruiting|April 2013|June 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|570|||Both|7 Weeks|9 Weeks|Accepts Healthy Volunteers|||April 2014|May 19, 2014|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841671||67402|
NCT01841684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-042|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)|A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Merck Sharp & Dohme Corp.|No|Terminated|June 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841684||67401|
NCT01842035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA 12D05|Heart Rate Response to Regadenoson and Sudden Cardiac Death|Heart Rate Response to Regadenoson and Sudden Cardiac Death||University of Alabama at Birmingham|Yes|Enrolling by invitation|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|19 Years|80 Years|No|||June 2015|June 18, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01842035||67374|
NCT01842048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120305D|Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases|||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|152|||Both|21 Years|80 Years|No|||November 2015|November 15, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842048||67373|
NCT01850121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-11-04 amended 2002-01-08|Remicade in the Treatment of Patients With Active Ankylosing Spondylitis|Remicade in the Treatment of Patients With Active Ankylosing Spondylitis||Göteborg University|No|Completed|January 2003|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|Samples Without DNA|Serum samples|Both|18 Years|60 Years|No|Non-Probability Sample|Patients with active ankylosing spondylitis with BASDAI>4|May 2013|May 8, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01850121||66756|
NCT01850420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRID-201|A Study of IMC-1 In Patients With Fibromyalgia|A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia||Innovative Med Concepts, LLC|No|Completed|May 2013|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|70 Years|No|||March 2015|March 25, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850420||66733|
NCT01850433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDD-P|Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD)|Internet-based Cognitive Behavior Therapy for Body Dysmorphic Disorder: A Pilot Study||Karolinska Institutet|No|Active, not recruiting||||March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850433||66732|
NCT01850706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-060A|UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation|Evaluation of Urinary Nerve Growth Factor as an Objective Tool to Assess Therapeutic Outcome in Patients With Detrusor Overactivity Undergoing Treatment With Sacral Neuromodulation||Northwell Health|No|Active, not recruiting|August 2011|||September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects over 18 years of age will be screened for eligibility relative to patient        inclusion and exclusion criteria. If eligible to enroll, the nature and purpose of this        study will be explained to the subject with a witness present. The subject will review and        sign the written Informed Consent Form indicating informed consent and voluntary        participation in the study. A copy of the consent form including all risks and benefits to        research subjects is attached as a separate document.|October 2015|October 19, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850706||66711|
NCT01850979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307/09|Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops|Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study||University of Sao Paulo General Hospital|No|Completed|February 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|60 Years|No|||May 2013|May 9, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01850979||66690|
NCT01850992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20892-01|Reproductive Aging and Obstructive Sleep Apnea|Reproductive Aging and Obstructive Sleep Apnea||Los Angeles Biomedical Research Institute|No|Withdrawn|May 2013|August 2015|Actual|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|0|||Male|30 Years|70 Years|No|||January 2016|January 8, 2016|May 7, 2013|No|Yes|This study is non-funded study and experienced difficulty in recruitment.|No||https://clinicaltrials.gov/show/NCT01850992||66689|
NCT01851538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2011-029|The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients|Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis|Bio-SHiFT|Erasmus Medical Center||Recruiting|August 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood (EDTA plasma, citrate plasma, serum, DNA) and urine samples are taken at the day of      inclusion and at follow-up visits, which will be performed every 3 months, until the end of      the scheduled follow-up, or until the patient dies. The maximum total number of samples per      patient is 11 (in patients with 30 months follow-up).|Both|18 Years|N/A|No|Non-Probability Sample|Chronic heart failure patients visiting the outpatient clinic.|January 2016|January 25, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851538||66648|
NCT01851733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305148|MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme|A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme||Washington University School of Medicine|No|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851733||66633|
NCT01851746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB2013|A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer|A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer||Wuhan University|No|Active, not recruiting|March 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Boold,Urine|Female|18 Years|70 Years|No|Probability Sample|residents of a certain town|May 2013|May 9, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851746||66632|
NCT01852006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI MUHC 3234|Abdominal Binding in Chronic Obstructive Pulmonary Disease|Abdominal Binding: a Novel Intervention to Relieve Dyspnea and Improve Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease?||McGill University|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|N/A|No|||August 2015|August 24, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01852006||66612|
NCT01849718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEST-704171|Nacadia Effect Study (NEST)|Nacadia Effect Study - Studying the Effect of Garden Therapy in Relations to People Suffering From Stress|NEST|University of Copenhagen|No|Active, not recruiting|August 2013|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|80|||Both|20 Years|60 Years|No|Probability Sample|The project has agreed with a number of surrounding municipalities that they refer        participants of both genders who are 20-60 years of age to the project through the        rehabilitation institutions 'Incita' and 'Væksthuset', WHO are external collaborators        Affiliated with the local job centers. Furthermore, local citizens can through their own        doctor / psychiatrist or if they are customers at the Insurance Company 'TopDanmark', join        the project. They will be provided with detailed information about the project, the target        group and the triage procedure.|December 2015|December 18, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849718||66787|
NCT01840202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S140213|Ocular Blood Flow in Glaucoma Patients - the Leuven Eye Study|Correlation Between Submacular and Peripapillary Choroidal Tissue and Ocular Blood Flow in Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|770|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Tertiary referral center|January 2013|May 28, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840202||67515|
NCT01851694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817585|Beta-cell Response to Incretin Hormones in Cystic Fibrosis|Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis||University of Pennsylvania|Yes|Recruiting|May 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851694||66636|
NCT01851967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-002340|Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans|Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans||Massachusetts General Hospital||Recruiting|September 2014|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851967||66615|
NCT01848847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9598|Relationship Between Bladder Distention and Hysteroscopy Application|The Impact of Bladder Distention on Execution of Diagnostic Hysteroscopy Procedure; a Randomised Controlled Trial.||Namik Kemal University|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|102|||Female|17 Years|55 Years|No|||July 2013|October 28, 2013|April 10, 2013||No||No|July 26, 2013|https://clinicaltrials.gov/show/NCT01848847||66854|difficulties in introduction of hysteroscopy
NCT01849107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTR_SB_2013|Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity|||Asan Medical Center||Recruiting|April 2013|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|20 Years|N/A|No|||May 2013|May 5, 2013|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01849107||66834|
NCT01849393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTECH|Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents|Incentives and Technology Survey 2013: Evaluation of Acceptance of Incentive-Based Adherence Programs and Electronic Medication Monitoring Among HIV-Positive Adolescents||St. Jude Children's Research Hospital|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|16 Years|24 Years|No|Non-Probability Sample|HIV-positive adolescents between the ages of 16 and 24 years who are currently undergoing        treatment with antiretrovirals at St. Jude's HIV clinic.|December 2013|December 12, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849393||66812|
NCT01849341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROFLU2011|Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily|Clinical Trial Phase III Blind, Parallel Group to Analyze Differences in the Safety of Roflumilast Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily|ROFLU2011|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|July 2012|July 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|105|||Both|18 Years|80 Years|No|||July 2015|July 7, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849341||66816|
NCT01841450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS100-PAS2|Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery|A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery||Glaukos Corporation|Yes|Recruiting|July 2013|December 2023|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|22 Years|N/A|No|||June 2015|June 3, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841450||67419|
NCT01841463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1446A-05/72/12|Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation|An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation||Piramal Enterprises Limited|No|Suspended|August 2013|March 2016|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|April 17, 2013|No|Yes|Sponsor decision not related to patient safety|No||https://clinicaltrials.gov/show/NCT01841463||67418|
NCT01849081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000688|Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver|Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)||Massachusetts General Hospital|Yes|Not yet recruiting|July 2016|July 2018|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849081||66836|
NCT01849094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-MIL-1|Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone|||The Alfred|No|Completed|May 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01849094||66835|
NCT01849601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acotec-01|Effectiveness and Safety Study of Peripheral Balloon Dilatation Catheter in Percutaneous Transluminal Angioplasty(PTA) Procedure|A Prospective, Multicenter and Single-arm Target Value Clinical Study on the Efficacy and Safety of Peripheral Balloon Dilatation Catheter in PTA Procedure||Acotec Scientific Co., Ltd|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|80 Years|No|||November 2012|March 19, 2015|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01849601||66796|
NCT01849848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011004|Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma|A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma||SymBio Pharmaceuticals||Completed|November 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|79 Years||||January 2015|January 21, 2015|April 17, 2013||||No|December 26, 2014|https://clinicaltrials.gov/show/NCT01849848||66777|
NCT01849861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|idosos01|Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone|Cardiopulmonary Capacity In Different Quartiles Ranges Of Reference For Serum Thyroid Stimulating Hormone (TSH): Sectional Evaluation And Effect Of The Use Of Methimazole In Elderly Population||Universidade Federal do Rio de Janeiro|No|Recruiting|September 2011|September 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 10, 2013|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849861||66776|
NCT01850134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL18|Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.|Evaluation of a Nutritional Supplement for People With Type 2 Diabetes (T2DM).||Abbott Nutrition|No|Withdrawn|June 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|March 2, 2015|May 7, 2013||No|Funding|No||https://clinicaltrials.gov/show/NCT01850134||66755|
NCT01850147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-2013-041|Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen|Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen||Chinese Academy of Medical Sciences||Recruiting|March 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01850147||66754|
NCT01850446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-ER-003|Comparative Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza|Comparative Parallel-group Randomized Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza||Materia Medica Holding|No|Recruiting|May 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||August 2015|August 31, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01850446||66731|
NCT01850719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4418.100.13|Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients|Cost-effectiveness of Early Surgery Versus Conservative Treatment With Optional Delayed Meniscectomy in Older Patients. A Randomized Controlled Trial.|ESCAPE|Onze Lieve Vrouwe Gasthuis|No|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|402|||Both|45 Years|70 Years|No|||April 2015|April 20, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850719||66710|
NCT01842425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-LCD2|Changes in Body- and Liver-composition During Low Calorie Diet in Morbidly Obese|Changes in Body- and Liver-composition During Low Calorie Diet in Morbidly Obese||Uppsala University|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Two serum samples from each patient at each examination. Biopsies of subcutananeous fat and      visceral fat, approximately 1 mililiter each, taken during laparoscopic gastric bypass      surgery|Female|20 Years|60 Years|No|Probability Sample|Morbidly obese females awaiting laparoscopic gastric bypass surgery|April 2013|April 29, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842425||67345|
NCT01842737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRoGReSS-PS|PRoGReSS-PS: Patient Response to GRraded Sensory Stimulation: A Pilot Study|PRoGReSS-PS: Patient Response to GRraded Sensory Stimulation: A Pilot Randomized Controlled Trial|PRoGReSS-PS|Palmer College of Chiropractic|Yes|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|21 Years|65 Years|No|||April 2014|April 14, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01842737||67321|
NCT01842711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTA01-010|Cumulative Irritation Patch Test|Exclusive Cumulative Irritation Patch Test (21 Day) With Challenge Patch Application||Chattem, Inc.|Yes|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|224|||Both|16 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Approximately 240 subjects will be enrolled in the trial so that at least 200 subjects        will complete the trial. Subjects who meet all of the inclusion criteria and none of the        exclusion criteria will be eligible to enroll into the trial.|April 2013|April 29, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842711||67323|
NCT01842724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/149|Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Study|Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Randomized Study.||Oslo University Hospital|No|Recruiting|August 2014|||August 2017|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|70 Years||||May 2015|May 23, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842724||67322|
NCT01842984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300009673|Decreasing Loneliness in Older Adults|Increasing Social Competence and Social Integration of Older Adults Experiencing Loneliness|I-SOCIAL|Tel Aviv University|No|Recruiting|March 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 16, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842984||67302|
NCT01842997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEPI-001|Safety of H1N1 Influenza Vaccination in Pregnant Women|A Stratified and Controlled Clinical Trial With Split-virion, Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Pregnant Women||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|122|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842997||67301|
NCT01850043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreanTSTtrends|The Epidemiology of TST Change in Korea|The Trend of Tuberculin Skin Test in Korea||Asan Medical Center|No|Completed|May 2005|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|5552|||Male|18 Years|29 Years|Accepts Healthy Volunteers|Non-Probability Sample|A term of whole military conscripts per year|December 2013|December 11, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01850043||66762|
NCT01850342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-FMBC-01-01-13|Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence|Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence Via Endoscopically-Assisted Administration of Fat Tissue Micrografts Enriched by Autologous Adipose-Derived Regenerative Cells||Burnasyan Federal Medical Biophysical Center|No|Enrolling by invitation|May 2013|December 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|75 Years|No|||May 2013|May 8, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850342||66739|
NCT01848301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12060201|Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation|Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation||University of Pittsburgh|Yes|Active, not recruiting|September 2012|September 2020|Anticipated|September 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848301||66894|
NCT01848574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10067|Satisfaction Understanding of Patients and Relatives in Emergency Room|Satisfaction Understanding of Patients and Relatives in Emergency Room|SUPER4|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1816|||Both|18 Years|N/A|No|||August 2015|September 24, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01848574||66874|
NCT01848834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-012|Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)|A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Active, not recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|297|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01848834||66855|
NCT01849120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003690|NIRS Predict Low Cardiac Output State in Neonates and Infants in Cardiac Surgery|Does Near Infrared Spectroscopy Predict Low Cardiac Output State in Neonates and Infants Following Cardiac Surgery for Congenital Heart Disease?||Mayo Clinic|No|Active, not recruiting|May 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|N/A|3 Years|No|||April 2015|April 21, 2015|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849120||66833|
NCT01849133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S65/500|Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy|Randomized Clinical Trial: Comparison Between Quadrantectomy Followed by External Fractionated Radiotherapy and Quadrantectomy Associated With Intraoperative Radiotherapy in Women >= 48 Years of Age Affected by Early-stage Breast Carcinoma.|ELIOT|European Institute of Oncology|No|Completed|November 2000|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1305|||Female|48 Years|75 Years|No|||May 2013|May 5, 2013|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01849133||66832|
NCT01848561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-282|A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)|A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)||AbbVie|No|Recruiting|April 2013|April 2027|Anticipated|April 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|8250|||Both|18 Years|N/A|No|Probability Sample|Adult patients with moderately to severely active Ulcerative Colitis (UC) who have been        prescribed HUMIRA according to the local label and adult patients being prescribed and        treated with IMM (6-mercaptopurine or azathioprine) with no concurrent biologic use.|March 2016|March 7, 2016|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848561||66875|
NCT01849588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-213|Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C|A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C||Massachusetts General Hospital|No|Recruiting|May 2013|September 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849588||66797|
NCT01850160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-12 HTA|Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension|Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial||Farma de Colombia SA|No|Completed|April 2013|May 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|70 Years|No|||March 2015|January 25, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850160||66753|
NCT01849822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16384|Providing Brain Control of Extracorporeal Devices to Patients With Quadriplegia|A Feasibility Study of the Ability of the Neural Prosthetic System to Provide Direct Brain Control of Extracorporeal Devices in Patients With Quadriplegia Due to High Spinal Cord Injury||California Institute of Technology|Yes|Active, not recruiting|February 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|2|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|April 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849822||66779|
NCT01849835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tongji10us|A Test of the Comparison Between Trans-rectal and Trans-perineal Biopsy of Prostate||RCT|Shanghai 10th People's Hospital|Yes|Recruiting|January 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Male|N/A|80 Years|No|||May 2014|May 4, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01849835||66778|
NCT01851018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03-90|Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment|Match Pair Analysis Study, Comparing Toxicities Between 2 Treatment Regiments Including Neo-adjuvant Hormonal Therapy Plus Hypofractionated RT With HDR Brachytherapy Boost Compare to Our Current Clinical Standard Approach at CHU de Quebec|HyBraFi|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|May 2012|July 2018|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|95 Years|No|||May 2013|May 8, 2013|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01851018||66687|
NCT01851239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0002|Venous Thromboembolism Prophylaxis in Medical and Surgical ICUs in a Single University Hospital|||Yonsei University|No|Completed|February 2013|April 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|1000|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|ICU admitted patients who are indicated for VTE prophylaxis.|May 2014|May 2, 2014|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01851239||66670|
NCT01851252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVPG-BB-EX-513|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||March 17, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851252||66669|
NCT01850758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSI2013-RCT01|Regenexx™ SD Versus Exercise Therapy for ACL Tears|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears||Regenerative Sciences, LLC|No|Recruiting|May 2013|May 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850758||66707|
NCT01851525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Therapeutic Outcomes Using Contact Force Handling During Atrial Fibrillation Ablation|Therapeutic Outcomes Using Contact Force Handling During Atrial Fibrillation Ablation|TOUCH AF|Southlake Regional Health Centre|No|Recruiting|June 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|19 Years|N/A|No|||April 2014|April 22, 2014|May 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851525||66649|
NCT01851720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00071159|Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage|Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage||Johns Hopkins University||Recruiting|July 2012|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||May 2013|May 8, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851720||66634|
NCT01843010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSYY-2013-04-23|Effect of Parecoxib on the Change of Shoulder Pain Threshold After Gynecological Laparoscopies|Effect of Parecoxib on the Change of Shoulder Pain Threshold After Gynecological Laparoscopies||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Female|18 Years|65 Years|No|||February 2014|February 15, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01843010||67300|
NCT01843270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0004|Appropriate Laryngeal Mask Airway Size in Patients With Overweight: A Comparison of the Actual Body Weight and Ideal Body Weight|||Yonsei University|No|Completed|November 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|20 Years|70 Years|No|||January 2014|September 25, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01843270||67280|
NCT01848249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK093770-01A1|Deceased Donor Biomarkers and Recipient Outcomes|Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes|DDS|Yale University|No|Active, not recruiting|May 2010|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1679|Samples Without DNA|((A)) Urine Samples: At time of deceased donor nephrectomy ((B)) Perfusates: At time of      initiation and stopping of machine perfusion|Both|N/A|N/A|No|Probability Sample|The population from which our Deceased-Donor Cohort will be selected is all potential        deceased organ donors located in the regions serviced by our participating organ        procurement organizations (OPOs).        The recipient cohorts will be defined by the deceased donors enrolled in the study, and        thus, the study population for this group is all recipients of kidneys from deceased organ        donors procured in the regions serviced by our participating OPOs.|January 2016|January 5, 2016|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01848249||66898|
NCT01848262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:054|ECALMIST Versus InSurE in Preterm Infant < 32 Weeks,Multicenter, Multinational RCT|ECALMIST (Early CPAP And Large Volume Minimal Invasive Surfactant Therapy) Versus InSurE (Intubate, Surfactant, Extubate) in Preterm Infants With Respiratory Distress Syndrome (RDS): Prospective Randomised Control Clinical Trial|ECALMIST|University of Manitoba|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|24 Weeks|31 Weeks|No|||February 2014|February 9, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848262||66897|
NCT01848587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111001|Trial of Acupuncture Pelvic and Low Back Pain in Pregnancy (Medical and Economical Assessment)|Trial of Acupuncture Pelvic and Low Back Pain in Pregnancy (TAPPP)|GAME|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|N/A|No|||June 2014|May 12, 2015|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01848587||66873|
NCT01848860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211051DIC|Absorbable Mesh Pleurodesis in Thoracoscopic Treatment of Spontaneous Pneumothorax|Thoracoscopic Bullectomy With Absorbable Mesh Coverage of the Staple Line Versus Thoracoscopic Bullectomy Only for the Treatment of Primary Spontaneous Pneumothorax: a Single-blind, Parallel-group, Prospective, Randomized Controlled Trial||National Taiwan University Hospital|Yes|Recruiting|May 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|204|||Both|15 Years|50 Years|No|||July 2015|July 5, 2015|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01848860||66853|
NCT01848886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-116|Neurological Complications Comparing Endoscopically vs. Open Harvest of the Radial Artery|Endoscopic Versus Open Radial Artery Harvest and Mammario-radial Versus Aorto-radial Grafting in Patients Undergoing Coronary Artery Bypass Surgery (The 2x2 Factorial Designed Randomised NEO Trial)|NEO|Rigshospitalet, Denmark|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||February 2015|February 28, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01848886||66851|
NCT01840293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 09-07|Breast Cancer Proteomics and Molecular Heterogeneity|Breast Cancer Proteomics and Molecular Heterogeneity||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|February 2013|||February 2023|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|1780|||Female|18 Years|N/A|No|Non-Probability Sample|All newly diagnosed breast cancer patients, recurrent and stage IV metastatic breast        cancer patients.|October 2015|October 23, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840293||67508|
NCT01849614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1239|Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart|Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|99 Years|No|Non-Probability Sample|Women with left-sided breast cancer|October 2015|October 9, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849614||66795|
NCT01848821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001903/1|The Effect of OASIS Ultra on Critical Sized Wound Healing|Pilot Study of the Effect of OASIS Ultra on Critical Sized Wound Healing||Massachusetts General Hospital|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|100 Years|No|||September 2015|September 29, 2015|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848821||66856|
NCT01850173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAT-VIB01|Whole Body Vibration in Chronic Obstructive Pulmonary Disease|Effects of Whole Body Vibration Training in Severe Chronic Obstructive Pulmonary Disease Patients||Hospital de Mataró|No|Completed|February 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|55 Years|85 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01850173||66752|
NCT01850186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-15|Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma|Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma||Centre Hospitalier Universitaire de Nice|No|Completed|February 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||February 2015|February 13, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01850186||66751|
NCT01849354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T17/2013|Operative Treatment of Endometriosis Patients in Turku University Hospital||ProEndo|Turku University Hospital|No|Recruiting|January 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Blood and urine samples. Peritoneal fluid, helthy peritoneum, endometriosis tissue and      endometrium samples.|Female|N/A|50 Years|No|Probability Sample|Endometriosis patients to be operated in Turku university hospital 2013-2015. The control        group consists of patients who will be operated because of an adnexal finding other than        endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization        will be recruited to the control group.|May 2013|May 3, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01849354|3 Years|66815|
NCT01850732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-03|Screening of Abdominal Aortic Aneurysms Among Male Patients With TIA Symptoms|Screening of Abdominal Aortic Aneurysms Among Male Patients With TIA Symptoms||North Karelia Central Hospital|No|Completed|May 2013|||June 2014|Actual|N/A|Interventional|Primary Purpose: Screening|1||||||Male|N/A|N/A||||June 2014|June 25, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850732||66709|
NCT01841281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD105573|L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels|Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level||University of California, Davis|Yes|Recruiting|August 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||January 2015|January 5, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841281||67432|
NCT01851031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|houjia|A New Surgical Approach to Treat Medial or Low Condylar Fractures|A New Surgical Approach to Treat Medial or Low Condylar Fractures:The Minor Parotid Anterior Approach||West China College of Stomatology|Yes|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|56 Years|No|||May 2013|May 8, 2013|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01851031||66686|
NCT01841827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-033|The Headache Inducing Effects of Cilostazol on Migraine Patients|The Headache Inducing Effects of Cilostazol on Migraine Patients||Danish Headache Center|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|14|||Both|18 Years|60 Years|No|||June 2014|June 5, 2014|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01841827||67390|
NCT01851265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081AC00001|D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours|A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|July 2013|December 2016|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|35|||Both|18 Years|130 Years|No|||January 2016|January 26, 2016|May 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851265||66668|
NCT01842438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03979|A Couple Support Intervention for Prostate Cancer|Psychosexual Support Following Prostate Cancer Surgery: Feasibility and Outcomes of a Couple-based Intervention||University of Stirling|Yes|Active, not recruiting|October 2012|August 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|136|||Both|N/A|N/A|No|||December 2014|December 2, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842438||67344|
NCT01842451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-135-105|A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C|A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842451||67343|
NCT01842750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_RADIO_101|The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study|The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study|BRAD|Christie Hospital NHS Foundation Trust|No|Recruiting|August 2013|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Male|18 Years|N/A|No|||June 2014|July 29, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01842750||67320|
NCT01851681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-060-CERES-P|Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants|Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants: a Randomized Clinical Trial||Université de Montréal|No|Recruiting|July 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|75 Years|No|||July 2015|July 3, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851681||66637|
NCT01851915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS2010/013|Cognitive Behavioral Therapy and Interpersonal Psychotherapy as Treatment for Major Depressive Disorder|Randomized Trial of Treatment of Depression With Interpersonal Psychotherapy and Cognitive Behavioral Therapy|CIPPS|Linkoeping University|No|Recruiting|January 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||May 2013|May 10, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01851915||66619|
NCT01851980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-370-MUHC|Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness|Effects of Inhaled Furosemide on Breathlessness During Exercise in the Presence of External Thoracic Restriction: A Dose-Reponse Study||McGill University|No|Not yet recruiting|April 2016|September 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851980||66614|
NCT01848327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120415|Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis|A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.||University of Miami|No|Recruiting|February 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|59 Years|No|||January 2016|January 6, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01848327||66892|
NCT01848600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV003|Impact of a Limitation Section on the Meta-analysis Results' Interpretation|Impact of a Limitation Section on the Meta-analysis Results' Interpretation: a Randomized Controlled Trial|ILMARI|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|April 2013|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|N/A|N/A|No|||January 2013|April 17, 2014|February 25, 2013||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01848600||66872|
NCT01848613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST162.05|Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC|Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study.|VIVOS|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|October 2012|August 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01848613||66871|
NCT01848873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUSA-amlodipine|Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine|Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension and Hyperhomocysteinemia ：a Double-blind Randomized Controlled Trial||Shenzhen Ausa Pharmed Co.,Ltd|Yes|Recruiting|January 2013|August 2013|Anticipated|August 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|756|||Both|18 Years|75 Years|No|||May 2013|May 7, 2013|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01848873||66852|
NCT01840059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012HS001B|Renal Denervation in Heart Failure With Preserved Ejection Fraction|A Randomised Controlled Trial Investigating the Effect of Transcatheter Renal Sympathetic Denervation on Symptoms and Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction.|RDT-PEF|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|85 Years|No|||September 2015|September 14, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840059||67526|
NCT01840306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-15|Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15, V2|Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|October 2012|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|330|||Female|18 Years|N/A|No|Non-Probability Sample|-  HER2 positive breast cancer:Female patients with newly diagnosed (including             metastatic) HER2 positive breast cancer.          -  HER2 negative breast cancer:Female patients with newly diagnosed HER2 negative breast             cancer.|February 2016|February 15, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840306||67507|
NCT01849627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9141B|Eat Well for Life: A Weight Loss Maintenance Study|Eat Well for Life: A Weight Loss Maintenance Study||University of Tennessee|Yes|Active, not recruiting|August 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|345|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01849627||66794|
NCT01849874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-162-311|A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer|||Array BioPharma|Yes|Recruiting|June 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849874||66775|
NCT01840826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS019700|Reducing Hospital Readmissions in Patients With Depressive Symptoms|Reducing Hospital Readmission Among Medical Patients With Depressive Symptoms|RED-D|Boston Medical Center|Yes|Recruiting|February 2013|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01840826||67467|
NCT01850745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMAR-MSP-CHC|Multidisciplinary Support Program in Chronic Hepatitis C|Evaluation of a multidìsciplinary Support Program in the Adherence and Efficacy of Peginterferon Alfa-2a and Ribavirin Therapy in Chronic Hepatitis C.||Parc de Salut Mar|No|Completed|January 2003|January 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|447|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic hepatitis C virus infection (CHC)|May 2013|May 7, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850745||66708|
NCT01850459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001- ERK in Autism|Extracellular Signal-Related Kinase Biomarker Development in Autism|Extracellular Signal-Related Kinase Biomarker Development in Autism|ERK|Children's Hospital Medical Center, Cincinnati|No|Recruiting|January 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|288|Samples Without DNA|For the ERK activation assay, about 5 mL of whole blood is layered onto 3 mL Histopaque in a      15 mL centrifuge tube, and centrifuged. The lymphocyte-containing cell layer is removed and      transferred for washing. After a second wash, cells are resuspended and rested. They are      then stimulated by addition of phorbol myristate acetate and sample aliquots are removed at      short intervals, fixed and permeabilized. Fixed, permeabilized cells are stained by addition      of Alexafluor488-labeled monoclonal antibody to phospho-ERK in the dark for 30 min. Washed,      resuspended cells are analyzed in a Coulter flow cytometer.|Both|3 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects with autism will be recruited through the clinic population at Cincinnati        Children's Hospital Medical Center. Recruitment of subjects will be conducted by notifying        via, IRB approved electronic and paper ads, individuals with autistic disorder, their        families, treating clinicians and agencies throughout the referral base of CCHMC and those        within our existing clinical services, residential facilities, schools and group homes for        the developmentally disabled.|March 2014|March 5, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850459||66730|
NCT01850472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001786|Brain Mechanisms of Emotion and Motivation: A Mind-Body Study|Brain Mechanisms of Emotion and Motivation: A Mind-Body Study|MIDAS|Mclean Hospital|No|Recruiting|March 2013|December 2017|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|April 2015|April 6, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01850472||66729|
NCT01850485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 745|Microcirculatory Perfusion in Patients With Coma After Out-of-hospital Cardiac Arrest|Microcirculatory Perfusion as Measured by Sublingual SDF Imaging and NIRS in Patients With Coma After Out-of-hospital Cardiac Arrest Treated With Mild Therapeutic Hypothermia (TH) or Not Treated With Mild-TH||Medical Centre Leeuwarden|No|Completed|February 2012|May 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|No|Probability Sample|patients after out of hospital cardiac arrest|June 2015|June 22, 2015|April 23, 2012||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01850485||66728|Relative small sample size Large inter individual variability in microvascular reactivity
NCT01841840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.7712|The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke|The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke||Florida State University|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|11|||Both|40 Years|80 Years|No|||April 2013|April 24, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841840||67389|
NCT01841866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA246521|Laryngeal Mask Airway Removal During Deep Anesthesia in Children|Does Laryngeal Mask Airway Removal During Deep Anesthesia Reduce Postoperative Sore Throat in Children?||Prince of Songkla University|Yes|Not yet recruiting|May 2013|October 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|456|||Both|6 Years|12 Years|No|||April 2013|April 26, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841866||67387|
NCT01842126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103NS103|Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)|Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy||Biogen|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|April 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01842126||67367|
NCT01842139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0545|Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission|Randomized Phase I Study Combining Suppression of T Regulatory Cells With WT1 Vaccine Therapy for AML Patients in Complete Remission||University of Chicago|No|Active, not recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|85 Years|No|||June 2015|June 22, 2015|July 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01842139||67366|
NCT01842763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-08|French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders|French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders|NGO|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients suffering from refractory chronic headache disorders (chronic migraine, cluster        headache, chronic paroxysmal hemicranias, SUNCT syndrome (Short-lasting Unilateral        Neuralgiform headache attacks with Conjunctival injection and Tearing), hemicrania        continua, cervicogenic headache disorders) according to ICHD-II|March 2016|March 18, 2016|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842763||67319|
NCT01843036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017478_Amd6|Durham Connects Evaluation II|Second RCT Evaluation of the Durham Connects Nurse Home Visiting Program||Duke University|Yes|Active, not recruiting|August 2013|March 2017|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1650|||Both|N/A|6 Months|No|||August 2015|August 5, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843036||67298|
NCT01843322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/720|Endoleak Repair Guided by Navigation Technology|Endoleak Repair Guided by Navigation Technology||Norwegian University of Science and Technology|No|Recruiting|April 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||November 2015|November 25, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843322||67276|
NCT01852175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2011-143|Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease|A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease||University of Florida|Yes|Completed|January 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|74 Years|No|||August 2014|May 26, 2015|May 8, 2013||No||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01852175||66599|
NCT01848314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42766.041.12|The Effect of Renal Denervation on Renal Flow in Humans|The Effect of Renal Denervation on Renal Flow in Humans||UMC Utrecht|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01848314||66893|
NCT01839526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL19110|A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease|A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease||Sanofi|No|Recruiting|May 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Male|5 Years|25 Years|No|||February 2016|February 18, 2016|April 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839526||67567|
NCT01839786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP14|Evaluation of Lung Doppler Signals in Pulmonary Hypertension|Evaluation of Lung Doppler Signals in Pulmonary Hypertension||Echosense Ltd.|No|Recruiting|May 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients suspected of PHTN|April 2013|March 14, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01839786||67547|
NCT01840072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140815|China Antihypertensive Trial in Acute Ischemic Stroke|Inner Mongolia Stroke Project|CATIS|Tulane University Health Sciences Center|Yes|Active, not recruiting|August 2009|September 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4071|||Both|22 Years|N/A|No|||November 2014|November 13, 2014|April 13, 2013||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01840072||67525|
NCT01840085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC127-2012-05|Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use|Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")|STRIDE 5|Derma Sciences, Inc.|No|Active, not recruiting|June 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|November 2, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840085||67524|
NCT01840098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-63-13|Leucine and Beta-hydroxy-beta-methylbutyrate (HMB) as Anabolic Nutrients After 36 Hours of Fasting|Leucine and Beta-hydroxy-beta-methylbutyrate (HMB) as Anabolic Nutrients After 36 Hours of Fasting||University of Aarhus|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|8|||Male|20 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 4, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840098||67523|
NCT01849406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASTER|Effect of Nasal Steroids in Snoring Intensity|A Randomized Crossover Trial of the Effect of Nasal Steroids in Snoring Intensity||University of Athens|Yes|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||September 2013|September 12, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01849406||66811|
NCT01849887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR3-07521|Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke|Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke||University of California, Irvine|No|Withdrawn|January 2016|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|May 6, 2013|Yes|Yes|Study was never started|No||https://clinicaltrials.gov/show/NCT01849887||66774|
NCT01841060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2008-34|Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive|Assessment of the Effectiveness of Local Ablathermy Radio Frequency (RF) Bronchial Tumors Primitive Stage IA Non-surgical Patients. Phase II Multicenter National|PARF2008|Institut Bergonié|No|Completed|November 2008|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|43|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01841060||67449|
NCT01841294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11077|NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery|NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery||Maisonneuve-Rosemont Hospital|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2012|April 25, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01841294||67431|
NCT01841528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDUIVF001|Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome|Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial|FreFro-PCOS|Shandong University|Yes|Active, not recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1180|||Female|20 Years|34 Years|No|||April 2014|April 14, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01841528||67413|
NCT01841853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Livslots Angered|RCT of Health-promoting Intervention for Older Foreign-born Adults|Livslots Angered - A Randomized Controlled Trial of a Community-based Health-promoting and Disease-preventive Program for Older Foreign Born Adults||Göteborg University|No|Active, not recruiting|August 2012|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01841853||67388|
NCT01842165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBMNLUMEN|177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs|The LuMEn Trial: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.|LUMEN|Jules Bordet Institute|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842165||67365|
NCT01842191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOMS|Efficacy of Fish Oil in Multiple Sclerosis|Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b|EFOMS|Coordinación de Investigación en Salud, Mexico|No|Completed|May 2010|December 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|No|||May 2013|May 20, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842191||67363|
NCT01842178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRH-OLE:2013|Endometrial Scratching in In Vitro Fertilization Cycles With Oocyte Donation|Randomized Prospective Study of Endometrial Injury in In Vitro Fertilization Cycles With Oocyte Donation||Centro de Infertilidad y Reproducción Humana|No|Withdrawn|April 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Female|21 Years|50 Years|No|||February 2016|February 25, 2016|April 25, 2013||No|Principal investigator retired from the project|No||https://clinicaltrials.gov/show/NCT01842178||67364|
NCT01843049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ESO_FU_01|Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer|Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial||Fudan University|Yes|Recruiting|January 2013|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||April 2013|April 26, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01843049||67297|
NCT01843335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/359/REKnord|Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair|Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair||Norwegian University of Science and Technology|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|All patients in follow-up after endovascular implantation of abdominal aortic prothesis,        Central Norway|March 2016|March 15, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843335||67275|
NCT01849328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-492|Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air|||Rauscher, Gregory E., M.D. PA|No|Recruiting|May 2013|||May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with breast cancer, biopsy confirmed, ages above 18. vs. Healthy women without        breast cancer.|November 2013|November 18, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849328||66817|
NCT01849575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPVIZA version 20121204|Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention|Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme (VIP) and Ordinary Care.|VIPVIZA|Umeå University|No|Recruiting|April 2013|April 2020|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3200|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849575||66798|
NCT01852227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO23524|ADAPT A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke|ADAPT A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke||Medical University of South Carolina|Yes|Completed|June 2013|||March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|This is a chart review of clinical data for patients who have been treated for stroke with        either direct aspiration or stent retrievers. This review will be conducted at MUSC and        SUNY Buffalo, SUNY Stonybrook, Swedish Medical Center, Vanderbilt University, Erlanger        Health System, and West Virginia University School of Medicine. Each participating group        will submit for approval at their individual institution.|April 2013|December 14, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852227||66595|
NCT01839539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-01|Study of DC-CIK to Treat Colorectal Cancer|Phase Ⅱ Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage Ⅲ Colorectal Cancer||Guangxi Medical University|Yes|Recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01839539||67566|
NCT01839552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-CA-12|An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.|An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids.|FCNS|James Graham Brown Cancer Center|Yes|Withdrawn|October 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|April 10, 2013|Yes|Yes|Site chose to close due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT01839552||67565|
NCT01839799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03213|A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma|A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2013|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01839799||67546|
NCT01839812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001638|Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery|Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery||Mayo Clinic|No|Completed|March 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|N/A|365 Days|No|||June 2014|June 13, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839812||67545|
NCT01839825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109-2012-GES-0001|Comparative Study of QuietCare|Randomized Comparative Study of QuietCare (Motion Sensor System) in Elderly Subjects Living in Assisted/ Independent Living Facilities||National Center for Geriatrics and Gerontology, Japan|Yes|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|202|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 25, 2014|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01839825||67544|
NCT01840332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0 /29.08.2012|Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer|Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer||University of Tartu|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01840332||67505|
NCT01840618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-336E|Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents|Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|February 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|50|Samples Without DNA|Blood|Female|13 Years|21 Years|Accepts Healthy Volunteers|Probability Sample|Girls with PCOS, with and without sleep apnea. Ages 13-21.|June 2015|June 24, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01840618||67483|
NCT01840605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-284-19|A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)||Mitsubishi Tanabe Pharma Corporation|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|303|||Both|7 Years|15 Years|No|||September 2015|September 17, 2015|April 23, 2013||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01840605||67484|
NCT01841073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FermCarb|Effect of Fermentable Carbohydrate on Glucose Homeostasis|Effect of Fermentable Carbohydrate on Glucose Homeostasis and Weight Management in Subjects With Prediabetes|FermCarb|Imperial College London|No|Recruiting|March 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|93|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01841073||67448|
NCT01841086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUP-SPG3-101|Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation|A Randomized, Open-label, Single Dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Sarpogrelate HCl CR Tablets Compared With Sarpogrelate HCl IR Tablets in Healthy Male Subjects||Korea United Pharm. Inc.||Completed|September 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01841086||67447|
NCT01841307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11080|Cromolyn Detection of Silent Aspiration|Development and Validation of Test for Gastro-esophageal Reflux and Aspiration||University of California, San Francisco|No|Recruiting|June 2014|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01841307||67430|
NCT01841047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2008-42|Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma|Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma|TOMOREP|Institut Bergonié|Yes|Active, not recruiting|January 2009|December 2019|Anticipated|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01841047||67450|
NCT01841879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA140304|Mumbai Worksite Tobacco Control Study|Mumbai Worksite Tobacco Control Study||Harvard School of Public Health|No|Active, not recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6880|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841879||67386|
NCT01841892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA032778-01A1|The Therapeutic Workplace Intervention in Community Settings|The Therapeutic Workplace Intervention in Community Settings||University of Maryland, Baltimore County|No|Not yet recruiting|April 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|65 Years|No|||April 2013|April 24, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841892||67385|
NCT01842204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/234|Evaluation of the Efficacy of Electromagnetic Therapy on Postoperative Surgical Pain After Uni- and Bilateral Inguinal Hernia Repair.|Evaluation of the Efficacy of Electromagnetic Therapy on Postoperative Surgical Pain After Uni- and Bilateral Inguinal Hernia Repair.|ELEFANT|University Hospital, Ghent|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842204||67362|
NCT01842464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternGalileeH|Sacro-Spinous Ligaments Anterior Apical Anchoring|Sacro-Spinous Ligaments Anterior Apical Anchoring for Needle-Guided Mesh in Advanced Pelvic Organ Prolapse||Western Galilee Hospital-Nahariya|Yes|Completed|September 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|44|||Female|35 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female patients suffering advanced pelvic organ prolapse with anterior predominance and        apical supportive defect, reffered to mesh reconstruction.|June 2015|June 17, 2015|April 24, 2013|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01842464||67342|
NCT01842776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20129159|Care Transitions in Renal Disease Patients|Care Transitions in Renal Disease Patients|CT|Fresenius Medical Care North America|No|Recruiting|March 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3300|||Both|18 Years|N/A|No|Probability Sample|Adult hemodialysis patients|April 2013|April 25, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842776||67318|
NCT01843062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00065|Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer.|A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer|ASTRA|AstraZeneca|No|Recruiting|August 2013|March 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|130 Years|No|||March 2016|March 23, 2016|March 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843062||67296|
NCT01843075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-9252|Evaluating Liraglutide in Alzheimer's Disease|Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)|ELAD|Imperial College London|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|206|||Both|50 Years|85 Years|No|||February 2016|February 15, 2016|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843075||67295|
NCT01843348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE44|12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients|12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certican® Based Regimen Either in Combination With Cyclosporin A or Tacrolimus|ATHENA|Novartis|Yes|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|617|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01843348||67274|
NCT01843361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meves-clopi-01|Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study|Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.|Bo-CRISP|Ruhr University of Bochum|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|159|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an acute ischemic stroke admitted to our stroke unit and treated with        clopidogrel|April 2013|April 26, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843361||67273|
NCT01843751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0226|Dane County Drug Court Study for Addicted Offenders|Health Promotion and Public Safety: Community-based Collaborative Services to Addicted Offenders||University of Wisconsin, Madison|No|Enrolling by invitation|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01843751||67243|
NCT01843257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01843257|Effects of Alcohol After Bariatric Surgery|Pharmacokinetics and Pharmacological Effects of Alcohol After Bariatric Surgery|RBA|Washington University School of Medicine|Yes|Recruiting|April 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A||7|Anticipated|88|Samples With DNA|Blood and plasma|Female|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Bariatric surgery clinic|March 2016|March 1, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843257||67281|
NCT01843556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2022-J081-003|A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males|A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals||Eisai Inc.||Completed|December 2012|June 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|65 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 17, 2014|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01843556||67258|
NCT01839305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485/2011|Effects of Hydrotherapy on Physical Function and Quality of Life of Women With Fibromyalgia|Effects of Hydrotherapy on 3D Scapular Kinematics, Electromyography, Pain, Quality of Life, Balance and Cardiorespiratory Variables in Women With Fibromyalgia||Universidade Federal de Sao Carlos|No|Completed|July 2011|March 2014|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839305||67584|
NCT01839565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR_QSP|Quadrilateral Surface Plate (QSP) Focused Registry|A Prospective and Retrospective Multicenter Registry for Surgeon-based Evaluation of the "Quadrilateral Surface Plate" Used for Acetabular Fractures||AO Clinical Investigation and Documentation|No|Active, not recruiting|October 2012|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Probability Sample|The increasing number of acetabular fractures in elderly individuals with osteoporosis has        added new technical challenges to surgical management. A common group of fracture patterns        in this population is the anterior wall or column often with an associated posterior        hemitransverse.        These injuries frequently also include quadrilateral surface comminution which can make        both reduction and stabilization more difficult. The 3.5 mm quadrilateral surface plate        was developed to provide a more effective way to deal with these issues, for example, a        way to deal with the quadrilateral surface enbloc for reduction, allowing buttress        stabilization, which is independent of bone density.|January 2016|January 5, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01839565|24 Months|67564|
NCT01840111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033975|Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)|Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments||Duke University|No|Completed|December 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|67|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840111||67522|
NCT01840891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORO2013|Secondary Lactose Intolerance Due to Chronic Norovirus Infection|Secondary Lactose Intolerance Due to Chronic Norovirus Infection in Renal Transplant Recipients||University of Zurich|Yes|Completed|April 2013|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01840891||67462|
NCT01840631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-214|A Trial To Study The Effects Of Group Versus Individual Dietary Counseling In Pediatric Obesity|A Randomized Controlled Trial To Study The Effects Of Group Versus Individual Dietary Counseling In Pediatric Obesity||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Years|17 Years|No|||June 2015|June 24, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01840631||67482|
NCT01840839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nap-tSOS-aged|Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Slow Wave Sleep in Older Adults||Charite University, Berlin, Germany|Yes|Completed|October 2013|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01840839||67466|
NCT01841099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI_CT_2013/0016|Mesalamine in Environmental Enteropathy|Randomised Placebo-controlled Trial of a Gut Immunomodulatory Agent (Mesalamine) to Tackle Environmental Enteropathy in Acutely Malnourished Children: A Pilot Study.||KEMRI-Wellcome Trust Collaborative Research Program|Yes|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|1 Year|5 Years|No|||July 2014|July 10, 2014|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01841099||67446|
NCT01841320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030776|Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial|Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial|VISTA|Johns Hopkins University|Yes|Recruiting|October 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Male|18 Years|N/A|No|||March 2015|March 30, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841320||67429|
NCT01841541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.03RS|The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan|Triage Plus for TB: Improving Community‐Based Provision for TB in Africa. The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan|Triage-Plus|Liverpool School of Tropical Medicine|Yes|Completed|January 2009|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|380|||Both|14 Years|N/A|No|||April 2013|April 25, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841541||67412|
NCT01841905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900,421-477|Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease|Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease|Scope|Rhode Island Hospital|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|55 Years|80 Years|No|Probability Sample|Individuals between the ages of 55 and 80 years old, and who have two risk factors for AD        (subjective memory complaints as ascertained on a standardized questionnaire and a        positive family history for the disease).|January 2016|January 18, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841905||67384|
NCT01842477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-12|Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing|Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing in Patients With Delayed Consolidation After Long Bone Fracture Requiring Graft Apposition or Alternative Orthobiologics|OrthoCT1|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01842477||67341|
NCT01842789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0021|Post Market Evaluation of Acessa With TAG|Post Market Evaluation of the Acessa System With Targeting Animation Guidance (TAG)|TAG|Halt Medical, Inc|No|Terminated|April 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|18|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|April 17, 2013||No|Results to date adequately demonstrated user preference and recovery time. Time to target    (Part II) was not studied. .|No||https://clinicaltrials.gov/show/NCT01842789||67317|
NCT01842802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-NIF-ABDM02|Clinical Investigation of Non Invasive Fat Reduction|||Cynosure, Inc.|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|20 Years|60 Years|No|||March 2014|March 25, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01842802||67316|
NCT01843088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00106|Trial of Mannitol Cream for Pain Relief After a Long Run|Randomized Trial of Mannitol Cream for Pain Relief After a Long Run|PainCream|University of British Columbia|Yes|Completed|May 2013|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|19 Years|74 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01843088||67294|
NCT01843374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4880C00003|Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma|A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma|Tremelimumab|MedImmune LLC|Yes|Active, not recruiting|May 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|564|||Both|18 Years|99 Years|No|||January 2016|January 7, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843374||67272|
NCT01843387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-DN001|Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy|A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes||Mesoblast, Ltd.|Yes|Completed|July 2013|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|85 Years|No|||September 2015|September 24, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01843387||67271|
NCT01844063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Third Affiliated Hospital|Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure|Clinical Comparison of Safety and Efficacy of Allogeneic Umbilical-Cord and Bone Marrow-derived Mesenchymal Stem Cells Transplantation for HBV-related Liver Failure||Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|July 2013|January 2019|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|65 Years|No|||July 2013|July 4, 2013|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01844063||67219|
NCT01844310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACT1215-01|Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection|Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection in China||Peking Union Medical College|Yes|Not yet recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||April 2013|April 26, 2013|August 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01844310||67200|
NCT01843569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|In Vitro maturation|In Vitro Maturation (IVM) of Human Oocytes|In Vitro Maturation (IVM) of Human Oocytes|IVM|Northwell Health|No|Active, not recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|25 Years|42 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843569||67257|
NCT01839578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.724|Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances|Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances|RCA-SHA|Hospices Civils de Lyon|No|Recruiting|May 2013|April 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839578||67563|
NCT01839838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04113|APBI Proton Feasibility and Phase II Study|A FEASIBILITY AND PHASE II TRIAL OF ACCELERATED PARTIAL BREAST IRRADIATION USING PROTON THERAPY FOR WOMEN WITH STAGE IA-IIA BREAST CANCER||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2013|April 2024|Anticipated|April 2024|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|57|||Female|50 Years|N/A|No|||January 2016|January 22, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01839838||67543|
NCT01840358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJ-3638|Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes|Evaluation of the Frequency of Hypoglycemia at Initiation of Insulin Pump Therapy in Children With Type 1 Diabetes||St. Justine's Hospital|No|Recruiting|April 2013|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|N/A|18 Years|No|||April 2013|April 25, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01840358||67503|
NCT01840683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-I-H-1202|HELP Therapy for Dry AMD|An Open-label, Single Center Study to Evaluate the Efficacy and Safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a Treatment for Non-exudative (Dry) Age-related Macular Degeneration (AMD)|HELPuc|B.Braun Avitum AG|No|Active, not recruiting|May 2013|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|50 Years|90 Years|No|||November 2014|November 11, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01840683||67478|
NCT01840384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT.01.2012|Efficacy Study of Multiple Micro Nutrients Supplementation|Longitudinal Study on the Effect of Multiple Micro Nutrients Supplementation on Haemoglobin Level of 8 to 22-month-old Indonesian Children.|Babytop|PT. Sari Husada|No|Not yet recruiting|July 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|239|||Both|8 Months|10 Months|Accepts Healthy Volunteers|||April 2013|April 23, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840384||67501|
NCT01840696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062632|Phase Analysis and Obstructive CAD on Rubidium PET|Regional and Global Left Ventricular Mechanical Dyssynchrony in the Diagnosis of Obstructive Coronary Artery Disease on Rest and Regadenoson Stress Rubidium Myocardial Perfusion PET||Emory University|No|Withdrawn|October 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|90 Years|No|||May 2014|May 29, 2014|April 16, 2013|Yes|Yes|PI leaving facility|No||https://clinicaltrials.gov/show/NCT01840696||67477|
NCT01840319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRB1810005|Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)|Retrospective Observational Study Of Patients Previously Treated With Tigecycline In ICU And Included In The Previous French Prospective Observational Study||Pfizer|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|156|||Both|18 Years|N/A|No|Non-Probability Sample|- Patients which has already been enrolled in the previous study protocol initial WYETH        3074A1-4448 then Pfizer B1811030|October 2013|June 27, 2014|April 22, 2013||No||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01840319||67506|As this was an observational study therefore, no randomization and control groups were included. This limitation did not allow the comparison of tigecycline treatment.
NCT01840644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090351|Validity and Reliability of Perceived Exertion Rating Scale in Children With Brain Damage|Validity and Reliability of Perceived Exertion Rating Scale in Children With Traumatic Brain Injury, Cerebral Palsy and Typically Developed||Alyn Pediatric & Adolecent Rehabilitation Center|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|25|||Both|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children post severe TBI Children with CP TD control|June 2015|June 22, 2015|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01840644||67481|
NCT01840852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-1|Sleep and Cytokines During Acute Diverticulitis|the Effects of Inflammatory Cytokines on Sleep During Acute Diverticulitis||Herlev Hospital|Yes|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|Samples Without DNA|plasma|Both|18 Years|75 Years|No|Probability Sample|16 x Acute uncomplicated diverticulitis (Hansen and stock stage 1) patients aged 18-75        years managed by antibiotic treatment at Herlev Hospital.|February 2014|February 24, 2014|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01840852||67465|
NCT01841112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.4|Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|65|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|April 24, 2013||||No||https://clinicaltrials.gov/show/NCT01841112||67445|
NCT01841125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADD_E_2010|Escitalopram for the Treatment of Depression in Alzheimer's Disease|A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease|Escitalopram|Konkuk University Medical Center|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|50 Years|N/A|No|||August 2014|August 12, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01841125||67444|
NCT01841333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1558.cc|PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant|A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse||University of Colorado, Denver|Yes|Recruiting|April 2013|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841333||67428|
NCT01841554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1-2|Cardioband With Transfemoral Delivery System|Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitation||Valtech Cardio Ltd|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|March 10, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841554||67411|
NCT01841918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPO AVIAN FLU Vaccine-V02-2|Safety and Immunogenicity of Live Attenuated Influenza H5N2|Phase II Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers||Mahidol University|Yes|Completed|January 2013|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01841918||67383|
NCT01842490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA|Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery|Can Serum Biomarker of Plaque Vulnerability be Identified Through the Contrast-enhanced Ultrasound of Carotid Artery||Kyunghee University Medical Center|Yes|Completed|May 2010|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|serum|Both|N/A|N/A|No|Non-Probability Sample|The patients were selected from those who admitted due to chest pain and underwent carotid        duplex ultrasound examination at KyungHee university medical center, Seoul, South Korea.|April 2013|August 22, 2014|March 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01842490||67340|
NCT01842503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73CT-2-03|Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent|A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects|SPAD|Laboratorio Farmaceutico Ct S.r.l.|No|Recruiting|November 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|21 Years|65 Years|No|||September 2015|September 28, 2015|December 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842503||67339|
NCT01842815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN12-PICO-SK|Evaluation of the 755nm Alexandrite for Unwanted Tattoos|||Cynosure, Inc.|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||February 2016|February 16, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01842815||67315|
NCT01839383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJFH-EC/2013-020|The Effects of Different Dialysate Calcium Concentration|The Effects of Different Dialysate Calcium Concentration on Mineral-bone Metabolism in Chinese Patients on Maintenance Hemodialysis||Beijing Friendship Hospital||Not yet recruiting|June 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||April 2013|April 29, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839383||67578|
NCT01839630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16608|Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China|Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients|SUCCESS|Bayer|No|Active, not recruiting|May 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Unresectable HCC patients and be candidates for concomitantly systemic therapy with        sorafenib + TACE. Considering the local practice and possible clinical benefits, sorafenib        should not be initiated later than 7 days after the 3rd TACE course. No prior tartgeted        therapy.|March 2016|March 14, 2016|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01839630||67559|
NCT01844076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 11-099|Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma|Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:||Milton S. Hershey Medical Center|Yes|Recruiting|March 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|March 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844076||67218|
NCT01843283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR013755-01|Meaningful Activity Intervention for Persons With Mild Cognitive Impairment|Meaningful Activity Intervention for Persons With Mild Cognitive Impairment||Indiana University|Yes|Active, not recruiting|July 2012|December 2017|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|72|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843283||67279|
NCT01839851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-13-0047-CTIL|Hair Cortisol in Asthma or Allergic Rhinitis Treated With Topical Corticosteroids|Evaluation of Hair Cortisol in Patients With Asthma or Allergic Rhinitis Treated With Topical (Inhaled or Intranasal) Corticosteroids||Meir Medical Center|No|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Hair|Both|18 Years|N/A|No|Non-Probability Sample|Adults with asthma or allergic rhinitis requiring treatment with topical corticosteroids        (inhaled corticosteroids or intranasal glucocorticoids), presenting to the Meir Medical        Center Allergy and Immunology clinic.|October 2013|March 9, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839851||67542|
NCT01840345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC in Chronic Pain|The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain|The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain||Virginia Commonwealth University|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840345||67504|
NCT01840670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-123-FC|Central Venous and Abdominal Pressures and the Inferior Vena Cava|Influence of Central Venous and Abdominal Pressures on the Inferior Vena Cava Shape and Size||Catholic University of the Sacred Heart|No|Recruiting|May 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery|August 2013|August 6, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840670||67479|
NCT01840124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11026|Uterine Leiomyoma Treatment With Radiofrequency Ablation|Uterine Leiomyoma Treatment With Radiofrequency Ablation|ULTRA|University of California, San Francisco|Yes|Active, not recruiting|July 2013|||June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840124||67521|
NCT01840371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0012|Randomized Controlled Study for Analyzing Clinical Benefit of Pain Focused Sedation With Combination of Fentanyl and Propofol During Endoscopic Retrograde Cholangiopancreatography (ERCP)|||Yonsei University|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|220|||Both|20 Years|N/A|No|||June 2014|June 2, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01840371||67502|
NCT01840709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP.PSYCHO|Effectiveness Study of Psychotherapy in Systemic Lupus Erythematosus|Effectiveness Study of Brief Group Psychoanalytic Psychotherapy (BGPP) to Improve Quality of Life in Patients With Systemic Lupus Erythematosus.|PSYCHO|Federal University of São Paulo|No|Active, not recruiting|August 2010|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|80|||Female|18 Years|N/A|No|||January 2014|January 8, 2014|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01840709||67476|
NCT01840657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMDIR-002|Myotubular Myopathy Event Study|Prospective Study of Adverse Event Rates in Males With X-Linked Myotubular Myopathy|MTMES|Cure CMD|No|Active, not recruiting|April 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Male|N/A|N/A|No|Non-Probability Sample|Participants for the MTM Event study will be recruited from 2 sources:          -  the Centronculear Myopathy Natural History Study and          -  the Congenital Muscle Disease International Registry (CMDIR)|October 2015|January 26, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01840657||67480|
NCT01840865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nap-tSOS-young|Effects of Brain Stimulation During Daytime Nap on Memory Consolidation in Younger, Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Daytime Slow Wave Sleep in Younger, Healthy Subjects||Charite University, Berlin, Germany|Yes|Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01840865||67464|
NCT01841593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 051|A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers|A Two Way Cross Over Pharmacokinetic (PK) Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers||St Stephens Aids Trust|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|April 16, 2013||No||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01841593||67408|
NCT01841931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/09/VA05|Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients|Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients||Maimonides Medical Center|No|Recruiting|February 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|January 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841931||67382|
NCT01841567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxB Po01|Post Market Clinical Follow-up Study|A Multi-centre, Post CE-mark, Open Investigation to Evaluate the Performance of a Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip or Knee Arthroplasty|MxB Po01|Molnlycke Health Care AB|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|45 Years|N/A|No|||December 2013|September 26, 2014|April 23, 2013||No||No|April 16, 2014|https://clinicaltrials.gov/show/NCT01841567||67410|
NCT01841580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R980/89/2012|Proteomic Profiles in Trabeculectomy Patients|Long-term Observation of Tear Proteomic Profiles and Ocular Surface in Trabeculectomy Patients Before and After Surgery||Singapore National Eye Centre|No|Recruiting|November 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|21 Years|99 Years|No|Non-Probability Sample|120 patients will be recruited for this study|January 2013|November 16, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841580||67409|
NCT01842516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCB01-0371-12-1-02|Multiple Ascending Dose Study for LCB01-0371|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, and Population Pharmacokinetics of LCB01-0371 in Healthy Male Subjects.||LegoChem Biosciences, Inc|No|Completed|March 2013|December 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01842516||67338|
NCT01842828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMUL201208b|UK-Czech E-cigarette Study|E-Cigarettes as an Addition to Multi-component Treatment for Tobacco Dependence: A Pilot Study|(SUKCES)|Queen Mary University of London|No|Recruiting|December 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01842828||67314|
NCT01843413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8312|Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases|Dose Escalation for Larger Brain Metastases: Phase I/II Study||Case Comprehensive Cancer Center|Yes|Recruiting|July 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843413||67269|
NCT01839396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120075|Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease|Implantable Neurostimulator for the Treatment of Parkinson's Disease|INTREPID|Boston Scientific Corporation|Yes|Recruiting|April 2013|July 2021|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|310|||Both|22 Years|75 Years|No|||December 2015|March 17, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839396||67577|
NCT01844349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corus 6028-2|Nutritional Transition in the Maghreb and Prevention of Obesity and Non-communicable Diseases|Understanding the Nutritional Transition in the Maghreb to Contribute to the Prevention of Obesity and Non-communicable Diseases|Obe-Maghreb|Institute of Research for Development, France|No|Completed|March 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|8218|||Both|6 Months|49 Years|No|Probability Sample|Residents of the region of the capital city|May 2013|May 4, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844349||67197|
NCT01839318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01336|Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses|Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses Using Ring Mire Projection||Alcon Research|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|44 Years|No|||May 2014|May 21, 2014|April 22, 2013|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01839318||67583|
NCT01839864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRI Promotora Trial|Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial|Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial|FMRIMetSynd|Family Medicine Residency of Idaho|Yes|Not yet recruiting|September 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01839864||67541|
NCT01839877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 1201 DEBIRI|Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study|Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study||Federation Francophone de Cancerologie Digestive|Yes|Recruiting|May 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||April 2013|March 3, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01839877||67540|
NCT01840137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00051581|Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer|||University of Michigan|Yes|Recruiting|June 2012|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01840137||67520|
NCT01840397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wolf-6|Neuromarker S-100B as Diagnostic Tool|Elevated Levels of S-100B and Neuron-specific Enolase (NSE) in Spine Surgery: A Comparison of Serum Levels With Surgery for Long-bone Fractures|SpineSurgery|Medical University of Vienna|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|serum levels of the biomarkers S-100B and NSE are measured|Both|18 Years|N/A|No|Non-Probability Sample|Patients with spine fractures undergoing spine surgery for fracture stabilization|November 2013|November 20, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840397||67500|
NCT01840410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002G2301|Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization.|A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to VEGF-driven Choroidal Neovascularization.||Novartis|No|Completed|September 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|12 Years|N/A|No|||March 2016|March 2, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840410||67499|
NCT01841398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHARA- Trial|South Asian HeArt Risk Assessment Project - Trial (SAHARA-Trial)|South Asian HeArt Risk Assessment Project - Trial|SAHARA|McMaster University|No|Recruiting|June 2012|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|330|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01841398||67423|
NCT01841138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GastroKMBColEl|Changes of Serum Electrolytes During Bowel Prep With PEG 3350 + Ascorbic Acid - a Prospective Study|Changes of Serum Electrolytes During Bowel Prep With PEG 3350 + Ascorbic Acid - a Prospective Study||Klinik Bogenhausen|No|Recruiting|July 2010|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an indicaton for colonoscopy|April 2013|April 23, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01841138||67443|
NCT01840878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-2|Validation of Actigraph Measured Sleep During Acute Diverticulitis|Accuracy of Actigraph Measured Sleep Compared to Polysomnography During Acute Uncomplicated Diverticulitis||Herlev Hospital|Yes|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|75 Years|No|Probability Sample|16 x Acute uncomplicated diverticulitis (Hansen and stock stage 1) patients aged 18-75        years managed by antibiotic treatment at Herlev Hospital.|February 2014|February 24, 2014|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01840878||67463|
NCT01841372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13610|A Virtual Reality Intervention to Improve Weight Maintenance|A Virtual Reality Intervention (Second Life) to Improve Weight Maintenance||University of Kansas Medical Center|No|Active, not recruiting|September 2013|July 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|21 Years|65 Years|No|||October 2015|October 28, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841372||67425|
NCT01841606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03634|The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries|The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries Under Spinal Anesthesia: A Randomized Controlled Trial||University of British Columbia|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|57|||Female|19 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01841606||67407|
NCT01841944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/14890|Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction|Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality|OMEMI|Oslo University Hospital|Yes|Recruiting|November 2012|November 2019|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1400|||Both|70 Years|82 Years|No|||October 2014|April 24, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01841944||67381|
NCT01841957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Immediate Simultaneous Bilateral Cataract Surgery|Immediate Simultaneous Bilateral Cataract Surgery: A Prospective, Case-controlled Clinical Trial in the United States|ISBCS|Panhandle Eye Group, LLP|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|30 Years|100 Years|No|||October 2015|October 27, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01841957||67380|
NCT01842217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41 608.042.12|Validation of [18F]FES for Imaging of Brain Estrogen Receptors|Validation of [18F]FES for Imaging of Brain Estrogen Receptors||University Medical Center Groningen|Yes|Recruiting|November 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|12|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842217||67361|
NCT01842230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142HPS13001|Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine|A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine After Oral Administration in Healthy Volunteers|CKD-345 DDI|Chong Kun Dang Pharmaceutical|No|Completed|April 2013|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842230||67360|
NCT01842243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CD016|Effect of Septal Versus Apical Pacing- a Comparative Study Using Cardiac MRI|Multiparametric CMR Assessment of Apical Versus Septal Pacing Study|MAPS|University Hospital of South Manchester NHS Foundation Trust|Yes|Recruiting|February 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|85 Years|No|||January 2013|April 29, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842243||67359|
NCT01843101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040413|Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study|Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study||Medical University of Vienna|Yes|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843101||67293|
NCT01843400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16472|Regorafenib Post-marketing Surveillance|Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer||Bayer|No|Recruiting|April 2013|March 2021|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|||Both|N/A|N/A|No|Non-Probability Sample|Patients with unresectable, metastatic or recurrent colorectal cancer|March 2016|March 18, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843400||67270|
NCT01843127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0165|A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.|A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period||Gilead Sciences|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||March 2014|March 28, 2014|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843127||67291|
NCT01839409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A001359-32|Biological Rhythms and Vestibular System|Biological Rhythms and Vestibular System|REHAB_Rn'V|University Hospital, Caen|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|96|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839409||67576|
NCT01839422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00351-40|Imaging of New Learning in Severe Alzheimer's Disease Patients|Functionnal Magnetic Resonnance Imaging (fMRI)Study of Cerebral Substrates of New Musical and Pictorial Learning in Alzheimer Patients|INCAS|University Hospital, Caen|Yes|Recruiting|January 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839422||67575|
NCT01839669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140928|The CurePPaC Study - Analysing Non-surgical Treatment Strategies to Cure Pes Planovalgus Associated Complaints|The CurePPaC Study - Analysing Non-surgical Treatment Strategies to Cure Pes Planovalgus Associated Complaints||Bern University of Applied Sciences|No|Recruiting|July 2013|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||March 2016|March 8, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01839669||67556|
NCT01844362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|utx-ld|Uterus Transplantation From Live Donor|Prospective Case Series of Human Uterus Transplantation From Live Donor|utx|Sahlgrenska University Hospital, Sweden|Yes|Active, not recruiting|September 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01844362||67196|
NCT01844375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB050|A Trial of Preoperative CHO Drinks on Postoperative Walking Capacity in Colorectal Surgery|A Randomized Controlled Trial of Preoperative Carbohydrate Drinks on Postoperative Walking Capacity in Colorectal Surgery.||Siriraj Hospital|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01844375||67195|
NCT01839591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-01-ASMN|Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa|Treatment of Bronchial Severe Asthma With Bronchial Thermoplasty. Assessment of Efficacy and Safety of Treatment, Study of Effects on Neuronal and Chemosensitive Component of the Bronchial Mucosa Pre and Post Treatment|BT-ASMN|Arcispedale Santa Maria Nuova-IRCCS|No|Recruiting|March 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839591||67562|
NCT01839890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEBSI-01|Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction|Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction After Bare Metal Stent Insertion|PEBSI-01|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|202|||Both|18 Years|N/A|No|||July 2014|February 5, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01839890||67539|
NCT01839903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA156699|System Based Tracking and Treatment for Emergency Patients Who Smoke: STTEPS|System Based Tracking and Treatment for Emergency Patients Who Smoke: STTEPS|STTEPS|The Miriam Hospital|No|Recruiting|July 2011|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|692|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839903||67538|
NCT01840930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50687|Cohort of Children With Severe Cerebral Palsy|Longitudinal Study of a Children Population With Bilateral Severe Cerebral Palsy: Incidence and Evolution of Orthopaedic Complications and Pain Related With These Complications.|CPCohort|Hospices Civils de Lyon|No|Recruiting|September 2009|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|385|||Both|2 Years|10 Years|No|Non-Probability Sample|Children aged from 2 to 10 years, with severe cerebral palsy: who do not acquire the        ability to walk.|January 2016|January 19, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01840930||67459|
NCT01841177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000032365|Evaluating Precision of Therapy - Milrinone|Evaluating Precision of Therapy - Milrinone||The Hospital for Sick Children|No|Recruiting|April 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|18 Years|No|||December 2014|December 19, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841177||67440|
NCT01841190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsd1509|Prognostic Evaluation Of Severe Sepsis And Septic Shock. Procalcitonin Versus Delta Sofa|PROGNOSTIC EVALUATION OF SEVERE SEPSIS AND SEPTIC SHOCK. PROCALCITONIN VERSUS DELTA SOFA||Hospital Sao Domingos|Yes|Recruiting|May 2012|||January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|128|||Both|18 Years|N/A|No|Probability Sample|Adult patients with severe sepsis and septic shock admitted to a multidisciplinary ICU|March 2013|April 25, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841190||67439|
NCT01840904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-3|Subjective Sleep and Fatigue During and After Acute Diverticulitis|Subjective Sleep Quality and Fatigue During and After Acute Uncomplicated Diverticulitis||Herlev Hospital|Yes|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|Samples Without DNA|plasma|Both|18 Years|75 Years|No|Probability Sample|16 x Acute uncomplicated diverticulitis (Hansen and stock stage 1) patients aged 18-75        years managed by antibiotic treatment at Herlev Hospital.|February 2014|February 24, 2014|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01840904||67461|
NCT01841346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JoPCR1-12-12-12|The First Jordanian PCI Registry: Events at 1 Year|The First Jordanian Percutaneous Coronary Intervention (PCI) Registry|JoPCR1|Jordan Collaborating Cardiology Group|Yes|Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with acute coronary syndrome and stable coronary syndromes undergoing        PCI.|March 2015|March 31, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841346|1 Year|67427|
NCT01841359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joslin 08-34|Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery|Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery||Joslin Diabetes Center|No|Recruiting|June 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|21 Years|65 Years|No|||May 2014|May 6, 2014|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841359||67426|
NCT01841385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilates2012|Effects of Pilates on Respiratory Mechanics|Influence of Application of the Pilates Method on Pulmonary Function, Thoracic Mobility and Respiratory Muscle Strength||Universidade Metodista de Piracicaba|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841385||67424|
NCT01841619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-9351|IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus|Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus||University of California, Irvine|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2015|July 14, 2015|April 21, 2013|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01841619||67406|
NCT01842295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110153|Bariatric Surgery and Sperm Quality|Bariatric Surgery, Nutrition, and Sperm Quality of Adult Obese Men on Childbearing Age : A Multicentric Cohort Study|BARIASPERM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2013|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|46|||Male|18 Years|50 Years|No|||April 2015|April 20, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01842295||67355|
NCT01842256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142HPS13002|Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.|A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin After Oral Administration in Healthy Volunteers|CKD-345|Chong Kun Dang Pharmaceutical|No|Completed|April 2013|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842256||67358|
NCT01842269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223KTP12003|Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients|Open Label, Randomized, Multi-center, Phase 4 Trial to Evaluate the Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) Versus My-Rept® Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination With Tacrolimus for 26 Weeks in Kidney Transplant Patients|My-Rept_KT_P4|Chong Kun Dang Pharmaceutical|No|Completed|January 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|20 Years|N/A|No|||August 2015|August 18, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842269||67357|
NCT01842282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00065177|Amlexanox for Type 2 Diabetes and Obesity|Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics||University of Michigan|No|Active, not recruiting|April 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|59 Years|No|||January 2016|January 8, 2016|April 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01842282||67356|
NCT01843426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro19770|Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan|Diagnostic Image Quality and Safety of Low-Volume, Low-Concentration, Iso-Osmolar Contrast Medium in the Computed Tomographic Workup of Patients Considered for TAVR||Medical University of South Carolina|No|Active, not recruiting|February 2013|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|90 Years|No|||April 2015|April 16, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01843426||67268|
NCT01843439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1205-083-410|Effects of Multidisciplinary Interventions in Elderly Asthma Patients With Risk of Acute Exacerbation|||Seoul National University Hospital|No|Active, not recruiting|June 2012|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|360|||Both|65 Years|N/A|No|||April 2013|April 26, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843439||67267|
NCT01839435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0031|Feasibility of Outpatient Appendectomy for Acute Appendicitis|PROSPECTIVE EVALUATION OF OUTPATIENT APPENDECTOMY FOR NON COMPLICATED ACUTE APPENDICITIS: Intention-to-treat Study|APPENDAMBU|Centre Hospitalier Universitaire, Amiens|No|Recruiting|April 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839435||67574|
NCT01849432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH070730-01A2|Study of Brain Circuitry in Anxiety Disorders|Probing Amygdalo-Cortical Circuitry in Anxiety Disorders||Mclean Hospital|No|Completed|December 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Boston metropolitan area|May 2013|May 7, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01849432||66809|
NCT01839604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5660C00001|A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma|A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma||AstraZeneca|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|March 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839604||67561|
NCT01840423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3112001|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.|NOCIFIM|Orion Corporation, Orion Pharma|Yes|Completed|May 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|101|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840423||67498|
NCT01840436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11M10MURT|Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer|A Randomized Controlled Study Evaluating the Effect of MUCIPLIQ Versus Placebo on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering of Upper Aerodigestive Tract Carcinomas|MUCIPLIQ|Organ, Tissue, Regeneration, Repair and Replacement|Yes|Recruiting|March 2013|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|105|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840436||67497|
NCT01840956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PRO-V003|Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease||Humacyte, Inc.|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840956||67457|
NCT01840969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0467|Association of Carotid Arterial Circumferential Strain With Left Ventricular Function and Hemodynamic Compromise During Off-pump Coronary Artery Bypass Surgery|||Yonsei University|No|Completed|September 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|20 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective multivessel off-pump coronary artery bypass surgery|April 2013|April 25, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01840969||67456|
NCT01840722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA033866-02|Brief Intervention for Rural Women at High Risk for HIV/HCV|Brief Intervention for Rural Women at High Risk for HIV/HCV|WISH|University of Kentucky|No|Recruiting|April 2013|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01840722||67475|
NCT01840735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-234-0117|Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis||Gilead Sciences|No|Completed|May 2013|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01840735||67474|
NCT01841203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YARADI|Dual Point-of-care Test for the Diagnosis of Yaws|Evaluation of a Rapid Dual Point-of-care Assay for Targeting Antibiotic Treatment for Yaws Eradication: a Prospective Descriptive Study|YARADI|Lihir Medical Centre|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|703|||Both|2 Years|15 Years|No|Non-Probability Sample|Patients will be recruited from Lihir Island villages in April 2013. This community has        been described previously. We will conduct community-based surveys and we invited children        aged 1 - 15 years suspected to have yaws by clinical examination to participate in the        study. All children for whom a parent or guardian gives written informed consent will be        included consecutively|November 2014|November 14, 2014|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841203||67438|
NCT01840917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-4|Heart Rate Variability During Acute Diverticulitis|Heart Rate Variability in the Course of Acute Uncomplicated Diverticulitis||Herlev Hospital|Yes|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|Samples Without DNA|plasma|Both|18 Years|75 Years|No|Probability Sample|16 x Acute uncomplicated diverticulitis (Hansen and stock stage 1) patients aged 18-75        years managed by antibiotic treatment at Herlev Hospital|February 2014|February 24, 2014|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01840917||67460|
NCT01841151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KITE|Neurofeedback and Working Memory Training for Children and Adolescents With ADHD|Does Neurofeedback and Working Memory Training Improve Core Symptoms of ADHD in Children and Adolescents? A Comparative, Randomized and Controlled Study.|KITE|Karolinska Institutet|No|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|220|||Both|9 Years|17 Years|No|||May 2015|May 6, 2015|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01841151||67442|
NCT01842308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1185|Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)||Mayo Clinic|No|Suspended|June 2013|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|April 25, 2013|Yes|Yes|Accrual to dose level 3 (56 mg/m2 Carfilzomib; 100 mg/m2 Melphalan) has been met.|No||https://clinicaltrials.gov/show/NCT01842308||67354|
NCT01842555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R16-3560|Photodynamic Therapy (PDT) Oncology Registry|Photodynamic Therapy (PDT) Oncology Registry|PDT Registry|Main Line Health|No|Recruiting|November 2012|||November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Each participating center will need to describe its own mechanism for patient        identification and eligibility screening.|January 2016|January 7, 2016|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842555|3 Years|67335|
NCT01842529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT13-01|Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery|Botulinum Toxin Injection in Epicardial Fat Pads Can Prevent Recurrences of Atrial Fibrillation After Cardiac Surgery: Randomized Pilot Study||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2014|January 30, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842529||67337|
NCT01842542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-03014-000|Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset|An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.||Neuronetics|No|Completed|December 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|50 Years|No|||October 2015|October 26, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01842542||67336|
NCT01842841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-091|Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease|A Multicenter, Open-label Extension Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease||Shire|No|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|N/A|No|||September 2015|November 9, 2015|April 11, 2013|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01842841||67313|
NCT01843114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-280113|Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects|Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects||Medical University of Vienna|Yes|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843114||67292|
NCT01843166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102186|Vaginal Estrogen With Pessary Treatment|Use of Vaginal Estrogen With Pessary Treatment of Pelvic Organ Prolapse and Urinary Incontinence||Lawson Health Research Institute|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|No|||April 2013|April 25, 2013|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01843166||67288|
NCT01843179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-302|Sulindac for Patients With AML|A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission||Massachusetts General Hospital|Yes|Withdrawn|January 2014|||January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|60 Years|N/A|No|||October 2014|October 1, 2014|April 22, 2013|Yes|Yes|Lack of Funding|No||https://clinicaltrials.gov/show/NCT01843179||67287|
NCT01839448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/VC-01|Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation|Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation|DG Post-Partum|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|The study population is composed of pregnant women consulting before 24 weeks of        amenorrhea and who have at least one of the following risk factors: age > 35 years; body        mass index > 25; a family history of type 2 diabetes; a history of gestational diabetes or        macrosomia.|February 2016|February 5, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839448||67573|
NCT01839695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10086370DOCRev1C|Safety and Efficacy of Valiant Mona LSA Stent Graft System|Valiant Mona LSA Stent Graft System Early Feasibility Study||Medtronic Endovascular|No|Active, not recruiting|April 2013|February 2019|Anticipated|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 11, 2013|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01839695||67554|
NCT01849445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arthritis Research UK 20100|Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study|Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study (TRIO-Physio)|TRIO-Physio|University of Edinburgh|No|Recruiting|September 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|16 Years|N/A|No|||May 2015|May 26, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849445||66808|
NCT01839617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICESP|Study Comparing Early and Late Nutrition in Cancer Patients Undergoing Abdominal Surgery|Early Versus Late Parenteral Nutrition in Cancer Patients Undergoing Abdominal Surgery|PaNCS|Instituto do Cancer do Estado de São Paulo|Yes|Recruiting|May 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|335|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839617||67560|
NCT01840163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01CA163233|A Trial of a Comprehensive Breast Cancer Treatment Patient Decision Tool|Individualizing Decision Quality for Patients With Breast Cancer: A RCT of a Comprehensive Breast Cancer Treatment Patient Decision Tool||University of Michigan|Yes|Recruiting|February 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|444|||Female|21 Years|84 Years|No|||January 2016|January 4, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01840163||67518|
NCT01840748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F5-2012-305495-OT4|Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis|||University of Paris 5 - Rene Descartes|No|Recruiting|April 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|960|||Both|N/A|N/A|No|Probability Sample|The study population are adult and juvenile systemic sclerosis patients from the EUSTAR        cohort (MEDSonline database) and the juvenile systemic sclerosis working group cohort|April 2013|April 23, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01840748|2 Years|67473|
NCT01841476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL-3|Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers|POL6326 - A Phase I, Open, Single Intravenous Infusion Dose, Pharmacokinetic and Pharmacodynamic Study in Healthy Volunteers Who Are Volunteering as Haematopoietic Stem Cell (HSC) Donors||Polyphor Ltd.|Yes|Completed|February 2012|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01841476||67417|
NCT01841632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISOT-I|Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation|Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium||University Hospital Regensburg|Yes|Recruiting|April 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841632||67405|
NCT01841164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-Type 4 KI_Cfa|A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma|A Study of the Effects of the Selective CysLT1 Antagonist Montelukast on Bronchoconstriction and Airway Inflammation Induced by Inhalation of Leukotriene E4 in Subjects With Asthma|E-Type|Karolinska University Hospital|No|Recruiting|May 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|55 Years|No|||April 2013|April 23, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01841164||67441|
NCT01841970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HET-12-001|Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids|Multi-Center, Prospective Study of the Safety and Efficacy of the HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids||Medtronic - MITG|No|Completed|April 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|N/A|No|||June 2015|June 1, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841970||67379|
NCT01841983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19OH008861|Project A: Integrated Approaches to Improving the Health and Safety of Health Care Workers|Project A: Integrated Approaches to Improving the Health and Safety of Health Care Workers||Harvard School of Public Health|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|9500|||Both|N/A|N/A|No|||May 2015|May 6, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841983||67378|
NCT01841996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1111-1|Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients|A Phase 1 Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study of the Safety, Absorption and Systemic Pharmacokinetics of ME1111 Topical Agent Applied to All Toenails of Adult Moderate to Severe Onychomycosis Patients for 28 Days||Meiji Seika Pharma Co., Ltd.|No|Completed|March 2013|||August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||December 2013|December 15, 2013|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841996||67377|
NCT01842321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADUSEIME02|Abiraterone Acetate in Molecular Apocrine Breast Cancer|A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer|AMA|UNICANCER|No|Active, not recruiting|July 2013|July 2018|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842321||67353|
NCT01842568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISION Cardiac Surgery|Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery|Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery||Population Health Research Institute|No|Recruiting|May 2013|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone cardiac surgery who are at least 18 years of age.|March 2016|March 15, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01842568||67334|
NCT01842854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-41-10|Galectin-3 as a Biomarker in Patients With Chagas Disease|Validation of Galectin-3 as a Biomarker for Determining Patients Prognosis With Chagas Disease||Hospital Sao Rafael|No|Completed|January 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Plasma, Serum, Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Tertiary Hospital|October 2015|October 9, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01842854||67312|
NCT01843140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST|Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry|Fertility Information Research Study||University of California, San Diego|No|Recruiting|May 2011|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Dried blood spots|Female|18 Years|44 Years|No|Probability Sample|Young women ages 18-44 who have been diagnosed with cancer or exposed to cancer treatment|June 2015|June 4, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01843140||67290|
NCT01843153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sciatic block|Continuous Versus Intermittent Sciatic Block for Total Knee Arthroplasty|Continuous Versus Intermittent Sciatic Block Combined With a Continuous Femoral Block for Patients Undergoing Total Knee Arthroplasty: a Prospective, Randomized Trial.||Kreiskrankenhaus Dormagen|No|Completed|April 2013|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||April 2013|March 30, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01843153||67289|
NCT01843452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV 20080214|Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal|Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal||Centre Hospitalier Universitaire Vaudois|No|Recruiting|December 2012|June 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843452||67266|
NCT01843465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-CRYO-001|Cryoablation of AF: Improving the Use of the Achieve Catheter|Improving the Assessment of Pulmonary Vein Disconnection With the Achieve Catheter During Atrial Fibrillation Cryoablation||Clinique Pasteur|No|Completed|April 2013|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|90 Years|No|Non-Probability Sample|Consecutive patients undergoing cryoablation of atrial fibrillation using the Achieve        catheter to document pulmonary vein disconnection.|October 2013|October 18, 2013|April 26, 2013||No||No|August 10, 2013|https://clinicaltrials.gov/show/NCT01843465||67265|
NCT01851499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Normast-2013|Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain|Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Study||Danish Pain Research Center|No|Completed|May 2013|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851499||66651|
NCT01851512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3803_HCG_I|A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803|Single-Blind, Randomized, Comparative, Phase I Study to Evaluate the Tolerability, Safety, and Pharmacokinetic Characteristics of Human Chorionic Gonadotropin Between Two Recombinant hCG Products, DA-3803 Injection and Ovidrel Liquid Injection, in Healthy Subjects||Dong-A ST Co., Ltd.|No|Completed|May 2010|April 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851512||66650|
NCT01849679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0407|Post Extubation Dysphagia|The Effect on Time After Extubation on Aspiration Risk||University of Wisconsin, Madison|Yes|Recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Intubated inpatients 18 years and older at the University of Wisconsin Hospital Trauma and        Life Support Center.|December 2014|May 29, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849679||66790|
NCT01840150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-040|Nanoscale Artificial Nose in Monitoring Response and Detecting Recurrence After Surgery or Radiation Therapy in Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Single-center Study to Evaluate the Feasibility of a Novel NA-NOSE for Monitoring Response to and Detecting Recurrence After Surgery or Radiation in Early Stage Lung Cancer||Fox Chase Cancer Center|No|Recruiting|August 2012|||November 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840150||67519|
NCT01839942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGChirIPOM|Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)|Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)|SGChirIPOM|Cantonal Hospital of St. Gallen|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|348|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after laparoscopic repair of a ventral hernia (including recurrent hernias)|February 2014|February 17, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01839942||67535|
NCT01840462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52120-165|Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]|A National, Multicenter, Non-interventional, Prospective, Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia (Dysport®)|CDNISLongterm|Ipsen|No|Active, not recruiting|July 2012|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|373|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from cervical dystonia|November 2015|November 30, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840462||67495|
NCT01840475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52120-174|Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]|International, Multicenter, Non-interventional, Prospective, Longitudinal Study to Investigate the Effectiveness of Botulinum Toxin A (Dysport®) Injections in Patients Suffering From Post-stroke Arm Spasticity With Respect to Early, Medium or Late Start of Treatment.||Ipsen|No|Recruiting|March 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|25 Years|N/A|No|Non-Probability Sample|Patients suffering from post-stroke arm spasticity registered with Neurological clinics,        Rehab centers with BoNT out-patient clinics and neurological practices.|February 2016|February 5, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840475||67494|
NCT01840761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010B030700029|Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine|Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine||Guangzhou University of Traditional Chinese Medicine|Yes|Recruiting|July 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01840761||67472|
NCT01848288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-006|Intra-Operative Metrics With CENTURION® and INFINITI® Vision Systems|Intra-Operative Metrics and Clinical Outcomes After Cataract Surgery With the CENTURION® Vision System and the INFINITI® Vision System||Alcon Research|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|112|||Both|55 Years|N/A|No|||March 2015|March 18, 2015|May 1, 2013|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01848288||66895|
NCT01840943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100654|A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX® Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy||Xian-Janssen Pharmaceutical Ltd.|No|Terminated|June 2013|August 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|March 18, 2013||No|the study was terminated due to medication supply issue from current manufacturer|No|May 22, 2015|https://clinicaltrials.gov/show/NCT01840943||67458|The study was terminated early as the total number of participants treated in this study was low and only descriptive analysis was used for efficacy and safety evaluation.
NCT01841411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microbiology2013|Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis|Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis||Minia University|Yes|Recruiting|March 2013|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01841411||67422|
NCT01841645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT2013|CLA Metabolism and Effects on Human Health|Conjugated Linoleic Acid (CLA) Depletion-repletion: Metabolism and Bioactivity in Humans||Universidade Federal do Rio de Janeiro|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|29|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01841645||67404|
NCT01842009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000384|Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients|Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients||Spaulding Rehabilitation Hospital|No|Active, not recruiting|July 2013|||December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|85 Years|No|||December 2014|December 15, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01842009||67376|
NCT01842022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB-0413|The Effect of the Glycemic Load of Meals on the Cognition and Mood of Older Adults|The Effect of the Glycemic Load of Meals on the Cognition and Mood of Older Adults With Differences in Glucose Tolerance||Swansea University|Yes|Completed|September 2011|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|155|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01842022||67375|
NCT01842334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001707|D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation (DCS)|D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation|DCS|Mclean Hospital|No|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842334||67352|
NCT01842581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFHE4044|The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy|A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy||Valeant Pharmaceuticals International, Inc.|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842581||67333|
NCT01842867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-41-10-1|Syndecan-4 as a Biomarker in Patients With Chagas Disease|Validation of Syndecan-4 as a Biomarker for Determining Patients Prognosis With Chagas Disease.||Hospital Sao Rafael|No|Completed|January 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Plasma, Serum, Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Tertiary Hospital|October 2015|October 9, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01842867||67311|
NCT01851005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-RP|Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients|Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients|CSUHAPM|Chosun University Hospital|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 18, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01851005||66688|
NCT01851213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMI-001-NGS-500|FoundationOne™ Test Registry Study|A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test|FMI Registry|Foundation Medicine|No|Active, not recruiting|March 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|510|||Both|18 Years|N/A|No|Non-Probability Sample|This Pilot Study will aim to enroll approximately 500 patients from a total of 40 oncology        centers in the US over a 1-year time period. Any patient for whom the treating physician        has ordered the FoundationOne test is eligible for inclusion in the study. In order to        capture real-world treatment patterns, site recruitment will aim to include approximately        80% of sites (and 80% of patients) from the community oncology setting. Enrollment will be        competitive and each site will be capped at a maximum of 15 patients.|December 2015|December 14, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01851213|1 Year|66672|
NCT01849471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP2013|Socioeconomic Aspects Before and After Radiation Therapy in Patient With Prostate Cancer|Evaluation of Socioeconomic Aspects Before and After Primary Radiation Therapy (Percutaneous or Interstitial or Combined Percutaneous and Interstitial) in Patients With Prostate Cancer|ECOPRO|University of Erlangen-Nürnberg Medical School|No|Recruiting|April 2013|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|60|||Male|18 Years|N/A|No|Non-Probability Sample|Men with prostata cancer that receive primary radiation therapy|May 2013|May 3, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01849471||66806|
NCT01840176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0101|Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy|Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy||University of North Carolina, Chapel Hill|No|Active, not recruiting|May 2013|December 2014|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 8, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840176||67517|
NCT01840449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52030-240|Somatuline Predictive Factors in Acromegaly and NET|Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)|SOPRANo|Ipsen|No|Active, not recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|152|||Both|18 Years|N/A|No|Non-Probability Sample|Clinics and private practitioners who treat acromegaly and/or NET subjects with Somatuline        Autogel® 60, 90 or 120 mg.|September 2015|September 29, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840449||67496|
NCT01840488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-55-58064-002|BN83495 Phase I in Post-menopausal Women|A Phase I Dose Escalation Study To Determine The Optimal Biological Dose Of BN83495 - An Oral Steroid Sulphatase Inhibitor - In Postmenopausal Women With Oestrogen-Receptor Positive Breast Cancer Whose Disease Progressed After Prior Therapy For Locally Advanced/Metastatic Disease||Ipsen|No|Completed|April 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||April 2013|April 23, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840488||67493|
NCT01840774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43929|Modifying Virtual Reality Analgesia With Low-Dose Pain Medication|Modifying Virtual Reality Analgesia With Low-Dose Pain Medication||University of Washington|Yes|Recruiting|April 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|April 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01840774||67471|
NCT01840982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCF2_2010_MC_2|The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male|A Randomized, Crossover Clinical Trial, The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male||Chonbuk National University Hospital|Yes|Completed|October 2010|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Male|19 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01840982||67455|
NCT01842360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV130-SLG-001|Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)|Randomized Double-blind Placebo-controlled Prospective, Parallel, Multicentre Clinical Trial of Bacterial Vaccine Administered by Sublingual Mucosa in Subjects With COPD for Efficacy and Safety Evaluation and Immunomodulatory Response|MV130|Inmunotek S.L.|No|Recruiting|April 2013|May 2017|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|35 Years|85 Years|No|||February 2016|February 24, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842360||67350|
NCT01842373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41491|Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing|A Double-Blind, Randomized, Split-Face Comparison Trial on Topical Anesthetic Agents Prior to Fractional Skin Resurfacing||Milton S. Hershey Medical Center|Yes|Not yet recruiting|July 2013|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842373||67349|
NCT01839773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107CS-3|A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy|A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum|DREAM|Daehwa Pharmaceutical Co., Ltd.|No|Completed|March 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Both|20 Years|N/A|No|||August 2015|August 9, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01839773||67548|
NCT01869855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDH-KSA|A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage|Use of Subperiosteal Drainage Versus Subdural Drainage in Chronic Subdural Hematomas Treated With Burr-Hole Trepanation: a Randomized Controlled Trial||Kantonsspital Aarau||Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01869855||65246|
NCT01840046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-05|Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata|Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe Alopecia Areata Resistant to Conventional Systemic Treatment|IL2|Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2012|November 2013|Anticipated|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||March 2013|April 24, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840046||67527|
NCT01840267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0090|The Effect of Pneumoperitoneum on Intracranial Pressure in Pediatric Laparoscopic Surgery: Ultrasonographic Measurement of Optic Nerve Sheath Diameter|||Yonsei University|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Both|N/A|9 Years|No|Non-Probability Sample|pediatric patients undergoing laparoscopic surgery under general anesthesia|September 2013|September 25, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840267||67510|
NCT01840280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONKOIRI01|A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Irinotecan Utilized in Mono- or Combination Therapy for the Treatment of Advanced Colorectal Carcinoma.||Onkovis GmbH|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|350|||Both|N/A|N/A|No|Probability Sample|Patients treated in practices, clinics, hospitals|October 2015|October 26, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01840280||67509|
NCT01870596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01097|Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia|Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML||National Cancer Institute (NCI)||Active, not recruiting|May 2013|||January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||December 2014|January 5, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870596||65189|
NCT01870895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-702|A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)|A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|577|||Female|20 Years|64 Years|No|||October 2015|October 9, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870895||65166|
NCT01870908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGR03|Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients|Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings||Astellas Pharma Inc|No|Completed|August 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|664|||Both|N/A|N/A|No|Non-Probability Sample|Patients with rheumatoid arthritis who have been treated with biological agents|October 2015|October 2, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870908||65165|
NCT01871194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSE|An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).|An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®) for the Prevention of Stroke in Patients With Atrial Fibrillation (AF), Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales.|ROSE|Drug Safety Research Unit, Southampton, UK|Yes|Recruiting|May 2013|April 2016|Anticipated|January 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients prescribed rivaroxaban or an alternative anticoagulant in the secondary care        hospital setting in England and Wales for the prevention of stroke in patients with AF,        the treatment of DVT or PE, or the prevention of recurrent DVT and PE.|January 2016|January 25, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01871194|12 Weeks|65143|
NCT01851707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-04|A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone|A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of Duvelisib With Background Methotrexate in Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone|ASPIRA|Infinity Pharmaceuticals, Inc.|Yes|Completed|April 2013|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|322|||Both|18 Years|70 Years|No|||April 2015|April 13, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851707||66635|
NCT01873742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Tilden|The STIC Norway RCT Study: Using Feedback in Psychotherapy.|The STIC Online Feedback System in Psychotherapy Process-outcome Research: A Multi-site, Multi-modality, International RCT-study.|STICNorway|Modum Bad|Yes|Recruiting|June 2013|December 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01873742||64948|
NCT01873755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-443|Addressing Barriers to Physical Activity in Inner-City Schoolchildren With Asthma|Addressing Barriers to Physical Activity in Inner-City Schoolchildren With Asthma||Montefiore Medical Center|No|Enrolling by invitation|October 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|250|||Both|7 Years|12 Years|No|||June 2013|June 10, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01873755||64947|
NCT01869790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prandial bolus coverage|Evaluation of Fats on Postprandial Glucose Control|Development of "Fat" Bolus for Coverage of Higher Fat Meals.|Nabucco|Joslin Diabetes Center|Yes|Enrolling by invitation|June 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2014|September 20, 2014|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01869790||65251|
NCT01840995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0078|The Effect of Stellate Ganglion Block on Intracranial Pressure Predicted by Ultrasonographic Assessment of Optic Nerve Sheath Diameter|||Yonsei University|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|35|||Both|20 Years|70 Years|No|Non-Probability Sample|Patients who were scheduled to receive stellate ganglion block at our pain management        clinic|January 2015|January 26, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01840995||67454|
NCT01841008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-12|Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control|Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study||Centre Hospitalier Universitaire de Nice|No|Terminated|December 2011|June 2014|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||June 2014|September 4, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01841008||67453|
NCT01841762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-401|Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument|A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument||Actelion|No|Active, not recruiting|April 2013|May 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841762||67395|
NCT01841775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIGAT-RJ IFNα2b|Interferon α 2b Pharmacovigilance Study|Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro)||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Completed|May 2009|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|70 Years|No|||April 2013|April 24, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01841775||67394|
NCT01841242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108096|Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation|Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation|CHLOVIS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|April 2013|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2276|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841242||67435|
NCT01841489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-0111|A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics|A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics||Gilead Sciences|No|Completed|May 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|April 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01841489||67416|
NCT01841736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00831|Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors|Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors||National Cancer Institute (NCI)|Yes|Suspended|June 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||December 2015|March 24, 2016|April 24, 2013|Yes|Yes|Other - Accrual reached, sample size may increase|No||https://clinicaltrials.gov/show/NCT01841736||67397|
NCT01841749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2007-40|Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast|Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study|CINNAMOME|Institut Bergonié|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|231|||Female|18 Years|N/A|No|||April 2013|April 23, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01841749||67396|
NCT01842087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2010|The Effects of Fiber Fortified Foods to the Diets of Chronic Kidney Disease Patients|An Investigation Into Pulse Fiber Fermentation and Nitrogen Excretion in Patients With Chronic Renal Failure||University of Florida|Yes|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|N/A|No|||April 2013|April 26, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01842087||67370|
NCT01842672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC 542|Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia|A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma|MITCL|New York Medical College|No|Recruiting|March 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|N/A|30 Years|No|||April 2015|April 29, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842672||67326|
NCT01842945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01138394|Internet Based Cognitive Behavior Therapy for Procrastination: A Randomized Controlled Trial|Internet Based Cognitive Behavior Therapy for Procrastination: A Randomized Controlled Trial||Stockholm University|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842945||67305|
NCT01843231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41936|Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone|A Randomized Controlled Multicenter Feasibility Study of an IncisionLEss Operating Platform for Primary ObeSiTy vs. Diet-exercise Alone: The MILEPOST Study|MILEPOST|USGI Medical|No|Active, not recruiting|September 2013|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|60 Years|No|||April 2015|April 1, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01843231||67283|
NCT01869868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIU2012/310-31|Neurobiological Changes When Treating Depression With Electroconvulsive Therapy - a Longitudinal Observational Study|Neurobiological Changes and Clinical Outcome When Treating Depression With Electroconvulsive Therapy.||Linkoeping University|No|Recruiting|December 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with depression referred for ECT.|April 2015|April 28, 2015|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01869868|3 Months|65245|
NCT01870128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-54/ 12.06.2009|Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial|Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|No|||June 2013|June 3, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870128||65225|
NCT01870336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-2013|Combination of Lateral Foot Orthoses and Knee Brace for Treatment of the Knee Osteoarthritis|Combination of Lateral Foot Orthoses and Knee Brace for Treatment of the Medial Knee Osteoarthritis||Laval University|Yes|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|22|||Both|40 Years|N/A|No|||March 2016|March 3, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01870336||65209|
NCT01871220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-2012-036|Periimplant Mucosa Dynamics Around Divergent and Concave Atlantis Abutment Transition Profiles|||University of Iowa|No|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871220||65141|
NCT01871519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-03|Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs|A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures|EVOLVE|Medtronic Spinal and Biologics|No|Active, not recruiting|May 2013|October 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|65 Years|N/A|No|||January 2016|January 6, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871519||65118|
NCT01870557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36777|Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)|Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)|Diabone|University of Aarhus|No|Completed|March 2013|May 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|197|Samples Without DNA|Serum Plasma EDTA Plasma Heparin Urine|Both|50 Years|N/A|No|Probability Sample|200 Diabetes Mellitus patients. 100 with type 1 diabetes and 100 with type 2 diabetes. Of        the 100 type 2 diabetes patients half should be treated with insulin (n=50) and the other        half treated with other oral antidiabetics and not insulin.|May 2015|May 27, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01870557||65192|
NCT01870570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBE019|Determination of Glycaemic Index and Insulinaemic Index Values of 6 Food Products in 3 Separate Research Centers|Determination of Glycaemic Index and Insulinaemic Index Values of 6 Cereal Products in 3 Separate Research Centers||Mondelēz International, Inc.|No|Completed|June 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|48|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870570||65191|
NCT01870583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI#12-07-248|Comparison of Surgical Skin Preps During Cesarean Deliveries|Comparison of Surgical Skin Preps During Cesarean Deliveries||Montefiore Medical Center|Yes|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1404|||Female|13 Years|50 Years|No|||August 2014|August 21, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870583||65190|
NCT01871493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14833|A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants|A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871493||65120|
NCT01871506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001036|Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial|Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial||Massachusetts General Hospital|Yes|Recruiting|September 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|295|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871506||65119|
NCT01871753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiRT study|The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria|The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria|BiRT|Erasme University Hospital|Yes|Recruiting|January 2014|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01871753||65100|
NCT01871987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0003|Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers|Pharmacokinetic Study of FK949E -A Pharmacokinetic Study in Healthy Male Volunteers to Investigate the Effect of Food on the Pharmacokinetics of FK949E||Astellas Pharma Inc|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871987||65082|
NCT01840527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-488|Utility of Novel BRAF Test for Melanoma|Exploring the Utility of a Novel BRAF Test in Patients With Melanoma||Massachusetts General Hospital|No|Recruiting|May 2013|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|Peripheral blood lymphocytes (PBLs); Plasma; Tumor Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients being treated at Massachusetts General Hospital, Dana-Farber Cancer Institute and        Beth Isreal Deaconess Medical Center|March 2016|March 20, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840527||67490|
NCT01840540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009298|MSC for Occlusive Disease of the Kidney|Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis||Mayo Clinic|No|Active, not recruiting|April 2013|April 2017|Anticipated|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|80 Years|No|||October 2015|October 8, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840540||67489|
NCT01840787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18801|A Pilot Study on the Use of a Sensory Panel to Assess Comfort Between Three Different Contact Lenses|A Pilot Study on the Use of a Sensory Panel to Assess Comfort Between Three Different Contact Lenses|NAISMITH|University of Waterloo|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|63|||Both|17 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|April 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840787||67470|
NCT01841502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF UMCN 12.02|Interaction Between Paroxetine and Telaprevir|The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX)|ROLEX|Radboud University|No|Terminated|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|3|||Both|18 Years|65 Years|No|||October 2014|October 27, 2014|April 2, 2013||No|Telaprevir will not be used in NL, no more inclusions are expected.|No||https://clinicaltrials.gov/show/NCT01841502||67415|
NCT01842412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/395/REK midt|The Initial Effect of Training on Mitochondrial Function in Patients With Intermittent Claudication|The Initial Effect of Training on Mitochondrial Function in Patients With Intermittent Claudication||Norwegian University of Science and Technology|No|Completed|April 2013|May 2014|Actual|March 2014|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|muscle tissue|Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient clinic, vascular surgery, Trondheim, Norway|January 2015|January 20, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842412||67346|
NCT01842698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPVéchoguidé|Ultrasound-guided PVB|Feasibility of the Use of Ultrasound-guided Paravertebral Catheterisation for the Analgesic Management of Thoracotomy|BPV échoguidé|Centre Jean Perrin|No|Terminated|April 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2014|March 19, 2014|February 14, 2013||No|The study was stopped because there was a technical problem with the ultrasound used in the    trial.|No||https://clinicaltrials.gov/show/NCT01842698||67324|
NCT01842100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMHRC99 - 15 RC/B/121|To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy|To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy||The University of Hong Kong|Yes|Completed|September 1999|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2193|||Female|N/A|N/A|No|||April 2013|April 24, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01842100||67369|
NCT01842958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 10/09|Straumann Roxolid Multi-Center Study|A Randomized, Controlled, Multi-center Clinical Study Evaluating the Crestal Bone Level Changes of Straumann BL Ø 3.3 mm NC SLActive RXD Implants Compared to Straumann BL Ø 4.1 mm RC SLActive RXD Implants for Single Tooth Replacement.||Institut Straumann AG|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842958||67304|
NCT01842386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130082|Rituximab for Anti-cytokine Autoantibody-Associated Diseases|Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|February 2013|January 2025|Anticipated|January 2025|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842386||67348|
NCT01842399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130078|Resveratrol and Cardiovascular Health in the Elderly|Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial||National Institutes of Health Clinical Center (CC)||Recruiting|February 2013|September 2018|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|300|||Both|50 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842399||67347|
NCT01842685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216/12|Bladder Thermal Distention for Patients With Refractory Overactive Bladder|Bladder Thermal Distention for Patients With Refractory Overactive Bladder|OAB|Assaf-Harofeh Medical Center|No|Recruiting|April 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01842685||67325|
NCT01839500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28934|EVIDENCE: A Non-Interventional Study of Treatment and Clinical Outcomes in Chinese Patients With Gastric Cancer|A NON-INTERVENTIONAL, REGISTRY STUDY FOR CHINESE GASTRIC CANCER PATIENTS WITH HER2 STATUS: CLINICAL AND PATHOLOGICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES||Hoffmann-La Roche||Recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1600|||Both|18 Years|N/A|No|Probability Sample|Patients with gastric or gastro-oesophageal junction cancer|March 2016|March 1, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839500||67569|
NCT01839513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 2013-021B|Prediction of Hemodynamic Reactivity During General Anesthesia Using Analgesia/Nociception Index (ANI)|Prediction of Hemodynamic Reactivity During Desflurane/Remifentanil General Anesthesia Using Analgesia/Nociception Index (ANI)||Hôpital Edouard Herriot|Yes|Completed|May 2013|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients underoing ear-nose-throat or orthopedic lower limb surgery performed on        desflurane/remifentanil general anesthesia|November 2013|November 1, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839513||67568|
NCT01870154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/1443|Effectiveness of an Intervention for Prevention and Treatment of Burnout in Primary Care|Effectiveness of an Intervention for Prevention and Treatment of Burnout in Primary Health Care Professionals|EDESPROAP|Gerencia de Atención Primaria, Madrid|No|Completed|March 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 4, 2013|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01870154||65223|
NCT01870141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-2212 Ago, 29 2012|Psychological Distress and Type 2 Diabetes|Glycaemic Control, Body Weight and Psychological Distress in Type 2 Diabetes: The Role of Self-Efficacy|COPEST|Azienda Ospedaliera Universitaria Integrata Verona|Yes|Recruiting|October 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|75 Years|No|||March 2013|June 3, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01870141||65224|
NCT01870349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-2009-51|A Comparison of Inflammatory Mediators Surrounding Titanium or Zirconium Implant Abutments|Evaluation of Pro-inflammatory Mediators Around Astra Tech Dental Implant Abutments Following a Minimum of 6 Months of Clinical Function||University of Iowa|No|Completed|December 2010|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|46|Samples Without DNA|Gingival crevicular fluids|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, dental clinic patients|June 2013|June 3, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870349||65208|
NCT01870609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-202|Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma|COMMAND|Verastem, Inc.|Yes|Terminated|September 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 29, 2013|Yes|Yes|Interim analysis-DSMB stated good safety profile but lack of efficacy|No||https://clinicaltrials.gov/show/NCT01870609||65188|
NCT01871779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALPAINCLAUD2011|Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease|The Effect of Different Forms of Exercise on Both the Clinical, Systemic and Local Biological Responses in Intermittent Claudication||Flinders University|No|Completed|October 2010|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|N/A|N/A|No|||June 2013|June 4, 2013|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01871779||65098|
NCT01870921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00087|Brilinta DaYu Study|A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)|DaYu|AstraZeneca||Completed|June 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2004|||Both|18 Years|130 Years|No|||October 2015|October 12, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870921||65164|
NCT01871207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA-EVA|Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy||UVA-EVA|Università degli Studi di Brescia|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Case: type 2 diabetic patients with PDR who had to undergo vitrectomy during the period        May 2011-January 2012 at the Unit of Ophthalmology, A.O. Civil Hospital and University of        Brescia.        Control: non-diabetic patients who underwent vitrectomy for macular hole or pucker.|June 2013|June 5, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871207||65142|
NCT01871766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMS13|Treatment of Rhabdomyosarcoma With Chemotherapy, Radiation Therapy (Proton Beam), and Surgery|Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy||St. Jude Children's Research Hospital|No|Recruiting|June 2013|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|N/A|21 Years|No|||January 2016|January 25, 2016|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871766||65099|
NCT01872000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVMP2013|Binocular Vision in Monocular Pseudophakia|A Prospective Randomised Controlled Trial to Assess Improved Binocular Visual Function in Young Patients Undergoing Monocular Cataract Surgery With a Bifocal Intraocular Lens.|BVMP|University of Oxford|No|Recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|No|||February 2016|February 19, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01872000||65081|
NCT01841268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240869|Skin Lipid Profiles in Term and Preterm Infants|Skin Lipid Profiles in Term and Preterm Infants||University of California, Davis|No|Active, not recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Blood, epidermal skin cells, breast milk|Both|N/A|4 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Newborn infants in the NICU at UCDMC. 20 neonates will be enrolled, 5 in each of the        following gestational age categories: 23-27 weeks, 28-32 weeks, 33-36 weeks, >36 weeks.        Infants will be involved in the study from enrollment until 4 weeks of age or until        discharge, whichever comes first.|December 2015|December 2, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841268|4 Weeks|67433|
NCT01840501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101337|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants|A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-Doses of JNJ-42721458 in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|18||Actual|108|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840501||67492|
NCT01840514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1982|Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.|Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.||Mansoura University||Recruiting|December 2012|September 2015|Anticipated|April 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|60 Years|No|Probability Sample|recipient of living donor liver|October 2013|October 4, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840514|1 Day|67491|
NCT01841034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-13|Impact of an Antioxidant Alimentary Complement on Sperm Data|Evaluation of a 6 Months Treatment of Conceptio (EA) on Sperm Data in Infertile Men With Oligoasthenozoospermia||Centre Hospitalier Universitaire de Nice||Recruiting|September 2011|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|N/A|No|Probability Sample|Any patient receipt within the framework of the care of an infertility in the pole ORG,        whatever is the étiologie and the type of treatment proposing and presenting during at        least two spermogrammes an oligospermie and\or an asthénospermie.|February 2013|April 25, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01841034||67451|
NCT01841255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06108|UMOX™: A New Device for Preoxygenation|UMOX™: A New Device for Preoxygenation||Maisonneuve-Rosemont Hospital|Yes|Completed|September 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|April 25, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01841255||67434|
NCT01842113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifaximin and Nutrition|Quality of Life and Nutritional Improvements in Cirrhotic Patients|Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.||Tampa General Hospital|No|Terminated|April 2013|||May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|April 11, 2013||No|PI Initiated study - PI left facility|No||https://clinicaltrials.gov/show/NCT01842113||67368|
NCT01872663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patricia2013|Influence of Different Physical Therapy Resources Application After Reduction Stomach Surgery|Influence of Different Physical Therapy Resources Application After Abdominal Surgery||Universidade Metodista de Piracicaba|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|140|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872663||65030|
NCT01842971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 2012-843-0028|ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis|Associating Liver Partition and Portal Vein Ligation (ALPPS) for Potentially Resectable Liver Metastasis From Colorectal Cancer: Prospective Evaluation of the Early Two-stage Hepatectomy by the Simon's Methods||Centre Hospitalier Universitaire, Amiens|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842971||67303|
NCT01872962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-022-01|Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|November 2013|November 2020|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|476|||Both|18 Years|65 Years|No|||June 2013|March 16, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872962||65007|
NCT01843244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15097|Plethysmography as a Useful Intraoperative Monitor|Plethysmography as a Useful Intraoperative Monitor||University of Virginia|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patient scheduled for surgery that will have both an arterial catheter and a pulmonary        artery catheter as standard of care|April 2013|April 29, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01843244||67282|
NCT01843530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER-1272-0058-I|Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema|Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema||Technische Universität München|No|Recruiting|November 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843530||67260|
NCT01843543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU_9405|Examining Bladder Control Using Mindful Based Approach|Assessing the Therapeutic Effect of Mindfulness-based Stress Reduction Intervention in Women With Urgency Incontinence Using Advanced Brain Imaging||Oregon Health and Science University|No|Active, not recruiting|April 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Female|40 Years|85 Years|No|||October 2014|October 16, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843543||67259|
NCT01873807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIE-ALL-2013|HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL|An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia|HITA|Nanfang Hospital of Southern Medical University|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|65 Years|No|||October 2015|October 7, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873807||64943|
NCT01870947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5811|Assisted Exercise in Obese Endometrial Cancer Patients|REWARD (Revving-Up Exercise for Sustained Weight Loss by Altering Neurological Reward and Drive): A Pilot Study of Assisted Exercise in Obese Endometrial Cancer Patients||Case Comprehensive Cancer Center|Yes|Recruiting|September 2011|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870947||65162|
NCT01870960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PP-01|Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties|Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties|EMDOGAIM|Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2013|September 2017|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|14|||Both|45 Years|N/A|No|||March 2016|March 18, 2016|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870960||65161|
NCT01870362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prob-gracetpaul_01|Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis|Improvement of Periodontal Health and Reduction in Periodontal Plaque Micro-flora Using a Probiotic Lozenge in Patients With Chronic Periodontitis||CD Pharma India Pvt. Ltd.|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|25 Years|60 Years|No|||July 2014|July 22, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870362||65207|
NCT01870934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH3D01|3D Camera - Telemedical Foot Ulcer Treatment|A Feasibility Study on the Development of 3D Optic Ulcer Camera||Odense University Hospital|Yes|Recruiting|January 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|90 Years|No|Non-Probability Sample|Diabetic foot ulcers patients|October 2013|October 28, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870934||65163|
NCT01871246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062912|Acute Exacerbation of COPD and Physical Activity - Preliminary Study|Acute Exacerbation of COPD and Physical Activity - Preliminary Study||University of Michigan|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|55 Years|N/A|No|Non-Probability Sample|People with COPD, who have had an exaccerbation in the last year who live in the greater        Ann Arbor area and their family members.|June 2013|December 8, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871246||65139|
NCT01871532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700623_535|Low-dose Gonal-f® in Ovulation Induction|A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction|LoGo|Merck KGaA|No|Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|37 Years|No|||February 2015|February 18, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871532||65117|
NCT01872273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC026|Blood Cell Response to Exercise|Blood Cell Response to Exercise||USDA Grand Forks Human Nutrition Research Center|No|Recruiting|February 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese adults with Metabolic Syndrome|November 2015|November 20, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01872273||65060|
NCT01872026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7991-CL-1003|Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis|ASP7991 Clinical Pharmacological Study -Examination of Pharmacokinetics and Pharmacodynamics in Chronic Kidney Disease Patients Undergoing Hemodialysis||Astellas Pharma Inc|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Both|20 Years|75 Years|No|||July 2013|July 8, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872026||65079|
NCT01872286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|capsule-1|Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2|A Double-center Randomized Head-to-head Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2||Changhai Hospital|Yes|Completed|November 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|53|||Both|18 Years|70 Years|No|||February 2014|February 28, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872286||65059|
NCT01871935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuRe-002|Atropine Effects in Anaesthesia With Sufentanil vs. Remifentanil|Comparison of the Effects of Atropine on Haemodynamics and Tissue Oxygenation in Anaesthesia With Propofol and Sufentanil Versus Propofol and Remifentanil||University Medical Center Groningen|No|Recruiting|June 2013|June 2014|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01871935||65086|
NCT01840800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-063|USG Nerve Blocks for ACL Reconstruction|Ultrasound Guided Nerve Block Combinations for Anterior Cruciate Ligament Reconstruction; Femoral, Saphenous and Obturator (Posterior Branch)Nerves.||Bispebjerg Hospital|Yes|Completed|February 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01840800||67469|
NCT01841021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17343|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841021||67452|
NCT01841814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-Dr.DAMAJ/PACCOU|Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy|Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.|LYMPHOS|Centre Hospitalier Universitaire, Amiens|No|Active, not recruiting|April 2013|June 2014|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||April 2013|April 24, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01841814||67391|
NCT01871948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184|Effective Communication for Preventing and Responding to Oncology Adverse Events|Effective Communication for Preventing and Responding to Oncology Adverse Events|CanComm|University of Massachusetts, Worcester|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|21 Years|80 Years|No|||December 2013|December 12, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01871948||65085|
NCT01872429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-102034-E|Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients|||Far Eastern Memorial Hospital|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|401|||Both|20 Years|N/A|No|Non-Probability Sample|Dialysis patients, including referred cases, from the tertiary-care medical center in        northern Taiwan.|April 2013|June 6, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872429||65048|
NCT01872975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP-B-51/RTOG-1304|Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery|A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy||NSABP Foundation Inc|Yes|Recruiting|August 2013|August 2028|Anticipated|July 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1636|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01872975||65006|
NCT01872676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1144-0316|Immediate Effects of Upper Thoracic Manipulation on Skin Surface Temperature of T3 Vertebral Region and Biceps Brachii Muscle|||Universidade Metodista de Piracicaba|No|Completed|January 2011|December 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872676||65029|
NCT01873248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOTATATE12-001920|Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients|Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients||University of California, Los Angeles|No|Active, not recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873248||64986|
NCT01873508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28738|A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers|A Single-center, Open Label, Randomized Cross-over Study to Compare 3 Modified-release Formulations With Different Release Profiles of RO4917523 Along With a Reference Intravenous Microdose Infusion||Hoffmann-La Roche||Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873508||64966|
NCT01873820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07EAHT|Tolerance of Two Forms of Vitamin C in Acid-sensitive Adults|A Randomized, Double-blind, Crossover Study Comparing the Tolerance of Two Forms of Vitamin C in Acid Sensitive Adults||NBTY, Inc.|No|Completed|March 2008|||June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|75 Years||||June 2013|June 6, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01873820||64942|
NCT01871233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-401|An Extended Access Program for Perampanel|An Extended Access Program for Perampanel||Eisai Inc.||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Years|70 Years||||February 2016|March 21, 2016|June 4, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01871233||65140|
NCT01871545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0214|Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)|Evaluation of HCC Response to Systemic Therapy With Quantitative MRI||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|June 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871545||65116|
NCT01871805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28761|A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer|A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib||Hoffmann-La Roche||Active, not recruiting|September 2013|May 2017|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|May 28, 2013|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT01871805||65096|
NCT01872013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7991-CL-1002|Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects|Randomized, Double-blinded, Placebo-controlled, Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects||Astellas Pharma Inc|No|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872013||65080|
NCT01871792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRINCIPLE-II|Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction|Preventive Effect of the PRetreatment With pItavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention (PRINCIPLE-II Study)||Gachon University Gil Medical Center|Yes|Not yet recruiting|June 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|404|||Both|19 Years|N/A|No|||June 2013|June 4, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01871792||65097|
NCT01843023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA033391-01A1|Extended Release Naltrexone for Opioid-Dependent Youth|Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth||Friends Research Institute, Inc.|Yes|Recruiting|June 2013|January 2019|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|15 Years|21 Years|No|||September 2015|September 10, 2015|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843023||67299|
NCT01871480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIK plus gefitinib|CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer|An Open-label, Randomized, Controlled Study of Gefitinib Plus Autologous Cytokine-Induced Killer Cell Immunotherapy（CIK）Versus Gefitinib Alone As Second Or Third-Line Treatment in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer||Kunming Medical University|Yes|Terminated|May 2013|May 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||December 2013|December 26, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871480||65121|
NCT01841515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00134031|Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug|Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis||University of Ulsan|Yes|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|N/A|No|||May 2013|May 9, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841515||67414|
NCT01841788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012006|Evaluation of Experimental Heat Patch|Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches||Chattem, Inc.|Yes|Completed|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841788||67393|
NCT01841801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012007|Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches|Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches||Chattem, Inc.|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|157|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01841801||67392|
NCT01871961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-MTX.15/HF|Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient|Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery||medac GmbH||Completed|October 2012|May 2013|Actual|February 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|16 Years|N/A|No|||March 2015|March 13, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871961||65084|
NCT01871974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0001|Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder|Phase I Study of FK949E - Multiple Dose Study of Non-Elderly Adult Patients With Major Depressive Disorder (MDD)||Astellas Pharma Inc|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|16|||Both|20 Years|64 Years|No|||June 2013|June 5, 2013|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871974||65083|
NCT01872416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20120926A|A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer|A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer: Single Center, Single-arm Study||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|October 2012|May 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872416||65049|
NCT01872689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB28547|A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis|A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS||Hoffmann-La Roche||Recruiting|October 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|484|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872689||65028|
NCT01873261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-PI-3750|NIV NAVA Versus NIV-PS in Pediatric Patients - Pilot Study|Neurally Adjusted Ventilatory Assist (NAVA) Versus Pressure Support in Pediatric Acute Respiratory Failure - Pilot Study|NINAVAPed|Hospital Universitario La Paz|No|Recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|1 Month|18 Years|No|Non-Probability Sample|Children from 1 month to 18 years admitted to the PICU with moderate/severe acute        respiratory failure minimally sedated/agitated|June 2013|June 7, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01873261||64985|
NCT01873521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-PI-3751|Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure|A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol|NiNAVAped|Hospital Universitario La Paz|Yes|Recruiting|February 2014|December 2016|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Both|1 Month|18 Years|No|||April 2014|April 15, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873521||64965|
NCT01873534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX-C-402|A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD|A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)||FerruMax Pharmaceuticals, Inc.|No|Terminated|June 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|June 5, 2013|Yes|Yes|Unable to recruit patients meeting the inclusion criteria|No||https://clinicaltrials.gov/show/NCT01873534||64964|
NCT01869621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-383|Study of Metformin Pharmacogenetics in Twins|The Relation Between Heritability and the Trough Concentration of Metformin in Plasma Under Steady-state in Twins||University of Southern Denmark|No|Completed|April 2013|October 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869621||65264|
NCT01869894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0204|A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction|||Yonsei University||Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|73|||Both|20 Years|N/A|No|||September 2015|September 29, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01869894||65243|
NCT01870622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036974|Confirmation of Correct Tracheal Tube Placement in Newborn Infants - a Randomized Control Trial|Confirmation of Correct Tracheal Tube Placement in Newborn Infants - a Randomized Control Trial||University of Alberta|Yes|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|100|||Both|N/A|120 Days|No|||December 2014|December 17, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01870622||65187|
NCT01870375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905M65804|Longitudinal Studies of Brain Structure and Function in MPS Disorders|Longitudinal Studies of Brain Structure and Function in MPS Disorders||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|September 2009|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|||Both|6 Years|25 Years|No|Non-Probability Sample|Patients who have a verified diagnosis of MPS I, II, IV, VI or VII, aged 6-25 years.|March 2016|March 9, 2016|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01870375||65206|
NCT01870388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14600|A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease|A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction||Eli Lilly and Company|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|June 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870388||65205|
NCT01870401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0005-01|Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries(Lutonix BTK Trial)||C. R. Bard|Yes|Recruiting|May 2013|September 2019|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870401||65204|
NCT01870648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSO1026396|Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan|Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in Emergency Departments in Pakistan|OSEP|University of Calgary|Yes|Recruiting|May 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|868|||Both|6 Months|59 Months|No|||September 2014|September 25, 2014|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870648||65185|
NCT01870661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035-13|Ultrasound Guided Peripheral Intravenous Catheter Insertion in the Hospitalized Patient: Long vs. Short Axis Placement|Ultrasound Guided Peripheral Intravenous Catheter Insertion in the Hospitalized Patient: Long vs. Short Axis Placement||Beth Israel Medical Center|No|Withdrawn|May 2013|May 2014|Actual|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|June 3, 2013||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01870661||65184|
NCT01870674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH12852-101|Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects|A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects||Yuhan Corporation|Yes|Completed|August 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|127|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01870674||65183|
NCT01870973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|root canal versus no treatment|Effect of Root Canal Treatment (Versus no Treatment) for Patients With Tooth Infections and Toothaches|Effect on Initial Endodontic Treatment on Postoperative Pain in Symptomatic Teeth With Pulpal Necrosis||Ohio State University|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 4, 2013||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01870973||65160|
NCT01870986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5381001|Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects||Pfizer|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|210|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870986||65159|
NCT01872065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-1001|Safety and Tolerability Study of ARC-520 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers||Arrowhead Research Corporation||Completed|July 2013|November 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872065||65076|
NCT01871831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1326-IU|Assessment of Blood Glucose Monitoring Systems - Evaluation of Oxygen Dependency|Prüfung Von Blutzuckermesssystemen - Bewertung Der Sauerstoffabhängigkeit|IDT-1326-IU|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|N/A|||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|January 13, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01871831||65094|
NCT01871558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AFR07|Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin|Randomized, Open-label, SU-controlled Study of 24-week Duration to Compare Metformin/Vildagliptin + Basal Insulin Versus Metformin/SU + Basal Insulin in T2DM Patients Starting Basal Insulin After Failing Metformin/SU|ADDONIS|Novartis|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 4, 2013||No||No|February 22, 2016|https://clinicaltrials.gov/show/NCT01871558||65115|
NCT01871571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R-12-2|Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer|Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer||University of Southern California|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871571||65114|
NCT01872507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0374-12|BioFeedBack Breathing Training Influence Cardiac Autonomic Nervous System in Children With Cerebral-Palsy.|The Effect of Breathing Biofeedback Training to Influence the Function of the Cardiac Autonomic Nervous System at Rest and in Activity in Children With Cerebral Palsy.||Hadassah Medical Organization|Yes|Not yet recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|11 Years|No|||June 2013|June 5, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01872507||65042|
NCT01843296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392022|Effects of Addition of Magnesium Sulfate in Spinal Anesthesia on Sensory-Motor Blocks and Postoperative Pain in Lumbar Disk Herniation Surgery|Comparison of the Effects of Three Methods of Intrathecal Bupivacaine; Bupivacaine-Fentanyl and Bupivacaine-Fentanyl-Magnesium Sulfate on Sensory-Motor Blocks and Postoperative Pain in Patients Undergoing Lumbar Disk Herniation Surgery||Isfahan University of Medical Sciences|Yes|Completed|November 2012|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|105|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 30, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01843296||67278|
NCT01843309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPHYRO-628|Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B|Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||Terminated|May 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|80 Years|No|||July 2015|July 2, 2015|April 26, 2013||No|Not possible to complete the sample within the estimated time by the use of new antifungals|No||https://clinicaltrials.gov/show/NCT01843309||67277|
NCT01872247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apoptosis2013|Effect of Ovarian Stimulation With r-hLH/r-hFSH,r-hFSH and hMG in Reducing Apoptosis Rate in Cumulus Cells of Patients Undergoing ICSI|A Pilot Study on the Effect of Ovarian Stimulation With r-hLH/r-hFSH, r-hFSH and hMG in Reducing Apoptosis Rate in Cumulus Cells of Patients Undergoing ICSI||Centro di Biologia della Riproduzione, Palermo, Italy|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Female|30 Years|45 Years|No|Probability Sample|Infertile women after 2 years of failed spontaneous conception|May 2013|June 5, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01872247||65062|
NCT01872442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASA-PegIFN|Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase|||Poitiers University Hospital||Active, not recruiting|October 2013|||October 2018|Anticipated|Phase 2|Interventional|N/A|2||||||Both|18 Years|65 Years||||December 2014|December 11, 2014|May 14, 2013||||No||https://clinicaltrials.gov/show/NCT01872442||65047|
NCT01872221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12TETE01|Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study|Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study|STEMRI|Institut Claudius Regaud|No|Recruiting|May 2013|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2015|May 26, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01872221||65064|
NCT01872715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10233|Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea|Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea||Galderma Laboratories, L.P.|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|25 Years|70 Years|No|||January 2016|January 20, 2016|March 15, 2013|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT01872715||65026|
NCT01872234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADIT-ASIA|MADIT ASIA Cardiac Resynchronization Trial|MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA)|MADIT-ASIA|Boston Scientific Corporation|Yes|Terminated|February 2014|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|May 31, 2013||No|The study encountered significant difficulties in patient enrollment.|No||https://clinicaltrials.gov/show/NCT01872234||65063|
NCT01872988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF12045|Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma|Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma||Taichung Veterans General Hospital|Yes|Terminated|September 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|20 Years|N/A|No|||September 2014|September 3, 2014|January 30, 2013||No|Difficult in patient enrollment|No||https://clinicaltrials.gov/show/NCT01872988||65005|
NCT01873274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3-009|Comparative Study Menaquinone-7|Comparative Study of Three Delivery Systems of Menaquinone-7||Maastricht University Medical Center|No|Completed|April 2012|May 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|107|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01873274||64984|
NCT01873547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-04SCI-III|Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China|Different Efficacy Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Chronic Spinal Cord Injury in China|SCI-III|General Hospital of Chinese Armed Police Forces|Yes|Recruiting|June 2012|December 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|65 Years|No|||June 2013|June 6, 2013|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873547||64963|
NCT01869881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCM009|Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)|Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes||Yuhan Corporation|No|Active, not recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|166|||Both|20 Years|N/A|No|||July 2014|July 8, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869881||65244|
NCT01870167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric- PEG|Antibiotic Prophylaxis for PEG in Children|Antibiotic Prophylaxis for Percutaneous Endoscopic Gastrostomy (PEG) in Children: a Randomised Controlled Trial.||Azienda Policlinico Umberto I|Yes|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|1 Month|18 Years|No|||May 2013|June 4, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01870167||65222|
NCT01870635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSO1026252|Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan|Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in Emergency Departments in Pakistan|OWEP|University of Calgary|Yes|Recruiting|May 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|602|||Both|6 Months|59 Months|No|||September 2014|September 25, 2014|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870635||65186|
NCT01870687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AG-E-4|Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS|Prospective, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Randomized Clinical Trial to Proof Efficacy and Safety of 20 mg (2 Tablets of 10 mg) VAC BNO 1095 FCT in Patients Suffering From Cyclic Mastodynia and PMS||Bionorica SE|No|Recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|45 Years|No|||February 2014|February 11, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01870687||65182|
NCT01870700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no one|Lactobacillus Reuteri in Adult With Functional Chronic Constipation|The Effect of Lactobacillus Reuteri Supplementation to Adult With Functional Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial||Catholic University, Italy|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01870700||65181|
NCT01871012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKRPLA2013|The Assessment of Postoperative Recovery in Elder Diabetic Patients|The Assessment of the Management of Intraoperation and Postoperative Quality of Recovery for Total Knee Replacement in Elder Diabetic Patients|TKRDM2013|Chinese PLA General Hospital|Yes|Recruiting|June 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Female|65 Years|90 Years|No|Probability Sample|All the participants are more than 65 years with knee osteoarthritis, who will undergo        selective total uniknee replacement.Participants(n=150)in diabetes mellitus(DM)group have        been diagnosed DM more than three years without severe nervous system        complications.participants(n=150)in non diabetes mellitus (NDM)haven't been diagnosed        diabetes mellitus.|October 2013|October 15, 2013|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871012|7 Days|65157|
NCT01871259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sleeposa|Clinical Predictors of Apnea-hypopnea During Propofol Sedation|Clinical Predictors of Apnea-hypopnea During Propofol Sedation in Patients Undergoing Spinal Anaesthesia|sleeposa|Samsung Medical Center|Yes|Terminated|November 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|29|||Male|40 Years|70 Years|No|Non-Probability Sample|We expected a correlation coefficient of ~0.5 in this study, which meant that for a level        of significance of 5% and a power of 80%, we required 29 analyzable subjects. Based on a        predicted exclusion rate of 15%, 34 patients were included.|June 2013|June 5, 2013|June 4, 2013||No|Finished|No||https://clinicaltrials.gov/show/NCT01871259||65138|
NCT01871584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydro-Prep, CLPR-200-0101|A Post Marketing Study of Angel of Water™ for Colon Cleansing as Preparation for Colonoscopy|A Prospective, Single Center, Single-blinded, Randomized Study, of the Angel of Water™ for Colon Cleansing as Preparation for Colonoscopy||novoGI|No|Recruiting|June 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|160|||Both|18 Years|80 Years|No|||June 2013|June 4, 2013|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871584||65113|
NCT01872078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5320C00001|A Study of AZD4901 in Females With Polycystic Ovary Syndrome|A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome||AstraZeneca|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|67|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|May 23, 2013|No|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01872078||65075|
NCT01872039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-PD-2012001|Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients|A Multi-center, Randomized and Controlled Phase IV Study on the Efficacy and Safety of Two Dose Adjustment Regimens of Nicardipine Injection for Hypertensive Emergency||Astellas Pharma Inc|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872039||65078|
NCT01872052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-AFL-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||January 13, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872052||65077|
NCT01839331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-003-A|A Efficacy and Safety Study of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee||Ampio Pharmaceuticals. Inc.|Yes|Completed|March 2013|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|329|||Both|40 Years|85 Years|No|||August 2014|March 2, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839331||67582|
NCT01872260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2107|Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer|A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer||Novartis|No|Recruiting|October 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872260||65061|
NCT01871740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ausa-CSPPT-CKD|CSPPT- Chronic Kidney Diseases Study|Enalapril Maleate and Folic Acid Tablets for Prevention of Chronic Kidney Diseases in Patients With Hypertension: a Double-blind Randomized Controlled Trial|CSPPT-CKD|Shenzhen Ausa Pharmed Co.,Ltd|Yes|Withdrawn|May 2008|August 2014|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|45 Years|75 Years|No|||January 2016|January 18, 2016|May 29, 2013||No|The sponsor and the PIs both agreed that the CSPPT-CKD should be a sub-study of the CSPPT    insted of an independent randomized trial.|No||https://clinicaltrials.gov/show/NCT01871740||65101|
NCT01873001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101970|A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873001||65004|
NCT01873014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|head2012neck|the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake|the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake||Tianjin Medical University Cancer Institute and Hospital|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||May 2012|February 14, 2016|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01873014||65003|
NCT01873287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-302955, CIHR-287347|Predicting Persistent Postconcussive Problems in Pediatrics (5P)|Predicting Persistent Postconcussive Problems in Pediatrics: A Clinical Prediction Rule Derivation and Validation Study|5P|Children's Hospital of Eastern Ontario|No|Completed|August 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3063|||Both|5 Years|17 Years|No|Non-Probability Sample|Subjects presenting to one the nine participating Canadian pediatric hospitals (IWK Health        Sciences Centre (NS), CHU Sainte-Justine (PQ), Montreal Children's Hospital (PQ),        Children's Hospital of Eastern Ontario (ON), The Hospital for Sick Children (ON),        Children's Hospital of Western Ontario (ON), Children's Hospital of Winnipeg (MB),        Stollery Children's Hospital (AB) and Alberta Children's Hospital (AB)) EDs after        sustaining a head injury.|January 2016|January 27, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873287||64983|
NCT01873560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-2-1306-020|Influence of FFR on the Clinical Outcome After Percutaneous Coronary Intervention|Influence of Fractional Flow Reserve (FFR) on the Clinical OutcomEs of PERcutaneouS Coronary Intervention (PCI): A ProspECTIVE, Multicenter FFR Registry|PERSPECTIVE|Inje University|Yes|Recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients who diagnosed obstructive coronary artery disease and treated by DES with FFR        examination at the index procedure|March 2016|March 7, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873560|2 Years|64962|
NCT01869634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS RFA _Asmuth:TMC114HIV2029|Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART|Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART||University of California, Davis|No|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 1, 2013|June 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869634||65263|
NCT01869907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMON|Effect of Minocycline on Pain Caused by Nerve Damage|Effect of Minocycline on Neuropathic Pain|EMON|Ziekenhuis Oost-Limburg|Yes|Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||January 2015|January 24, 2015|May 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869907||65242|
NCT01870180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013MGD|EyeBag Effectiveness in Meibomian Gland Dysfunction|Investigating the Efficacy of the MGDRx EyeBag in Patients With Meibomian Gland Dysfunction Related Evaporative Dry Eye|MGD|Aston University|No|Completed|May 2013|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01870180||65221|
NCT01870999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-05-244|A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot|An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|64 Years|No|||December 2013|December 3, 2013|June 4, 2013|No|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01870999||65158|
NCT01871025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/4025|Early Incentive and Mobilization During COPD Exacerbation|Early Incentive and Mobilization During COPD Exacerbation|TIME|Parc de Salut Mar|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|45 Years|N/A|No|||October 2015|October 22, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871025||65156|
NCT01871272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-41-1411|Knee Arthroscopy Cohort Southern Denmark (KACS)|Knee Arthroscopy Cohort Southern Denmark (KACS)|KACS|University of Southern Denmark|No|Completed|February 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|491|||Both|18 Years|N/A|No|Probability Sample|Patients assigned for arthroscopy on suspicion of a meniscus tear in the period from        February 1st 2013 to January 31st 2014 will be consecutively recruited to the KACS cohort        from 4 different hospitals (Lillebaelt Hospital - Kolding and Vejle and Odense University        Hospital - Odense and Svendborg) in the Region of Southern Denmark.|June 2015|June 29, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871272||65137|
NCT01871285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3409-204|Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film|An Evaluation of the Tolerability of Switching Subjects on Chronic Around-the-Clock (ATC) Opioid Therapy to Buprenorphine HCl Buccal Film||Endo Pharmaceuticals|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|60 Years|No|||January 2016|January 4, 2016|June 4, 2013|Yes|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01871285||65136|
NCT01871597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0041|Pulmonary Artery Energy Sealing for VATS Procedure|Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing for VATS Procedure||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|December 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01871597||65112|
NCT01871818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110116|A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients|A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis.|REHABMUSCLE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||June 2015|June 23, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01871818||65095|
NCT01872338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-134|Mindfulness-Based Cognitive Therapy for Suicide Prevention|Mindfulness-Based Cognitive Therapy for Preventing Suicide in Military Veterans|MBCT-S|VA Office of Research and Development|Yes|Enrolling by invitation|December 2013|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01872338||65055|
NCT01872325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0379-01H|Improving Cardiac Arrest Diagnostic Accuracy of Emergency Medical Dispatchers|Improving the Cardiac Arrest Diagnostic Accuracy of 9-1-1 Emergency Medical Dispatchers||Ottawa Hospital Research Institute|Yes|Suspended|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1400|||Both|16 Years|N/A|No|Probability Sample|All patients with out-of-hospital cardiac arrest|October 2015|October 21, 2015|May 9, 2013||No|Slow accrual and insufficient funding|No||https://clinicaltrials.gov/show/NCT01872325||65056|
NCT01872299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7/2007-2013, No. 241558|Studies Investigating Co-morbidities Aggravating Heart Failure|Studies Investigating Co-morbidities Aggravating Heart Failure|SICA-HF|Charite University, Berlin, Germany|Yes|Active, not recruiting|March 2010|September 2016|Anticipated|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2000|Samples With DNA|Whole blood, serum, plasma, DNA, biopsies from fat and muscle.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and controls will be recruited from hospitals' outpatients' departments and/or        via advertisements; in-patients are permitted if clinically stable.|October 2015|October 28, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01872299|4 Years|65058|
NCT01872312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0033|Spiration IBV® Valve System and Spiration Airway Sizing Kit|The Humanatarian Use of the Spiration IBV® Valve System and Spiration Airway Sizing Kit for Use in Patients at The Ohio State University Medical Center.||Ohio State University|Yes|Recruiting|March 2012|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|65 Years|No|||February 2014|February 7, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01872312||65057|
NCT01872533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11009|Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)|Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)|SLEEP HIGH|Pennington Biomedical Research Center|No|Completed|July 2011|May 2013|Actual|September 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01872533||65040|
NCT01839344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13A-1334|Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.|Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function.||Bastyr University|No|Completed|May 2013|March 2015|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|75 Years|No|||February 2014|March 16, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839344||67581|
NCT01872455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX13|Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients|EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS||Federico II University|Yes|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2012|June 5, 2013|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872455||65046|
NCT01872702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1305|Targeted Chemo-elimination (TCE) of Malaria|Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia|TME|University of Oxford|No|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8000|||Both|6 Months|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872702||65027|
NCT01873027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICVD1225|OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON|OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON (OPINION)|OPINION|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|829|||Both|20 Years|85 Years|No|||August 2014|August 11, 2014|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01873027||65002|
NCT01873300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001806|Endoscopic Myotomy for the Treatment of Achalasia (Motility Disorder) of the Esophagus - POEM Procedure|Endoscopic Esophageal Myotomy for the Treatment of Achalasia|POEM|Massachusetts General Hospital|Yes|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||April 2015|April 8, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873300||64982|
NCT01873573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17316|Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection|Randomized Controlled Trial of Endoscopic Dilation With or Without Triamcinolone Injection in Patients With Non-malignant Radiation or Anastomotic Esophageal Strictures||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01873573||64961|
NCT01873586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSX-US-2012-1|OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion|Efficacy and Safety of OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion||Integra LifeSciences Corporation|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873586||64960|
NCT01869647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01H50118322|Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone|Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone||Yale University|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|201|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01869647||65262|
NCT01869660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMS-S|Shared Decision Making for Patients With First-admission Schizophrenia|Shared Decision Making for Patients With First-admission Schizophrenia: a Randomized Controlled Trial||Yokohama City University|No|Completed|June 2013|October 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|16 Years|65 Years|No|||August 2015|December 29, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869660||65261|
NCT01869920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/02609_PI12/02020|Effectiveness of an Educational Intervention to Maintain Exclusive Breastfeeding|Effectiveness of an Educational Group Intervention in Primary Care to Maintain Exclusive Breastfeeding. Cluster Randomised Clinical Trial. PROLACT Study.|PROLACT|Gerencia de Atención Primaria, Madrid|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|432|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869920||65241|
NCT01870414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-6567|Electromyographic Analysis And Body Balance In The Use Of Athletes After Cryotherapy By Immersion Ankle|Electromyographic Analysis And Body Balance In The Use Of Athletes After Cryotherapy By Immersion Ankle||University of Sao Paulo|Yes|Completed|March 2012|June 2013|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01870414||65203|
NCT01870726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2204|Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma|A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma||Novartis|No|Recruiting|January 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|N/A|No|||September 2015|December 26, 2015|June 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870726||65179|
NCT01870739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2224|A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension|A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension||Novartis|No|Completed|October 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870739||65178|
NCT01871038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111725|Rotarix Vaccine Effectiveness|A Case-Control Study to Assess the Effectiveness of Rotarix Vaccine (RV1)||Children's Hospital Medical Center, Cincinnati|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2268|Samples Without DNA|Stool specimen|Both|N/A|5 Years|No|Non-Probability Sample|Children who are an inpatient or a patient of the Emergency Department with symptoms of        acute gastroenteritis.|June 2013|June 4, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01871038||65155|
NCT01871298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL6402|Drug User Internet and Mobile Tech Use|Exploratory Study of Drug User Health-related Internet and Mobile Technology Use||Columbia University|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|212|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871298||65135|
NCT01871311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0039|A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors|A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab||Georgetown University|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871311||65134|
NCT01871610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-4313A|Amyloid Accumulation After Mild Traumatic Brain Injury|Amyloid Accumulation After Mild Traumatic Brain Injury||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|November 2012|October 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|40|||Both|30 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 3, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871610||65111|
NCT01872585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K02DA023504|Program for Caregivers Involved With Mental Health Services|Feasibility Study of a Mentalization-based Parenting Program for Female Caregivers Involved in Mental Health Services.||Yale University|Yes|Recruiting|April 2012|||June 2014|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01872585||65036|
NCT01872559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209013095|3 Dimensional Sonography Imaging|3D Sonographic Volumetric Analysis of Ovarian Follicles.||Weill Medical College of Cornell University|No|Recruiting|December 2012|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|45 Years|No|Non-Probability Sample|In Vitro fertilization patients and donor egg patients of the Ronald O. Perelman and        Claudia Cohen Center for Reproductive Medicine who at the day of monitoring (having an        ultrasound and blood work drawn) have an estradiol level greater than 2000pg/ML.|December 2014|December 18, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01872559||65038|
NCT01872546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYTOPSO|Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy|||Poitiers University Hospital||Recruiting||||January 2014|Anticipated|Phase 2|Interventional|N/A|1||||||Both|18 Years|N/A||||March 2013|June 5, 2013|March 27, 2013||||No||https://clinicaltrials.gov/show/NCT01872546||65039|
NCT01839357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16320|Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter|An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter|X-TRA|Bayer|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839357||67580|
NCT01839370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16666|Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus|Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus||University of Virginia|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|65 Years|No|||February 2014|February 18, 2014|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839370||67579|
NCT01872468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/90845|Effectiveness of a Structured Intervention to Reduce the Progression of Chronic Kidney (RENAP Study)|Effectiveness of an Structured Intervention in Patients With Chronic Kidney Failure to Reduce the Progression of the Illness.|RENAP|Gerencia de Atención Primaria, Madrid|Yes|Completed|September 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|269|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01872468||65045|
NCT01872481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv195|Effects of Repetitive Transcranial Magnetic Stimulation in the Treatment of Phantom Limb Pain in Landmine Victims: ANTARES|Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients Victims of Landmines With Phantom Limb Pain|ANTARES|Fundación Cardiovascular de Colombia|Yes|Completed|June 2013|October 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2013|February 4, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872481||65044|
NCT01872728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.774|Facial Block for Outpatient Rhinoplasty Analgesia|Efficacy of Facial Block for Outpatient Rhinoplasty Analgesia|FABLORA|Hospices Civils de Lyon|No|Active, not recruiting|June 2013|December 2014|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872728||65025|
NCT01873040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS021492-01|Vaccine Social Media Randomized Intervention Trial|Randomized Intervention Trial to Evaluate a Vaccine Social Media Website|VSMRCT|Kaiser Permanente|No|Enrolling by invitation|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|2000|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873040||65001|
NCT01873313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/ANAES/01|Blood Levels of Local Anaesthetic in Knee Arthroplasty|Blood Levels of Local Anaesthetic in Knee Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Knee Arthroplasty|BLOCKS|Golden Jubilee National Hospital|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Up to 20 blood samples per patient|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing elective knee joint replacement where they will be receiving the        Caledonian technique|June 2013|June 10, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873313||64981|
NCT01873599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41160EP|Impact of an Online Positive Affect Journaling Intervention|Impact of an Online Positive Affect Journaling Intervention||Milton S. Hershey Medical Center|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|21 Years|80 Years|No|||July 2014|July 9, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873599||64959|
NCT01873612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PropDexHVRVolunteers|Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers|||Karolinska University Hospital|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01873612||64958|
NCT01869673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORALMASK|A Comparison of the Face Mask and Oral Mask Ventilation After Nasal Surgery|A Comparison of the Face Mask and Oral Mask Ventilation After Nasal Surgery.||Diskapi Teaching and Research Hospital|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|45 Years|No|||May 2013|April 1, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01869673||65260|
NCT01869686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120351|Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose|An Open-label Study to Evaluate the Concentration of Denosumab in Seminal Fluid After a Single Subcutaneous Injection in Healthy Men||Amgen|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|May 31, 2013|No|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT01869686||65259|
NCT01869933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-10X-102|Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X|An Open Label Phase I Placebo Controlled, Dose Escalation Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X||OcuCure Therapeutics, Inc.|Yes|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869933||65240|
NCT01870713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150CTSX001|Proteomics Study of Gastric Bypass Surgery to Treat Type 2 Diabetes Mellitus|Serum Proteomics Research in Bypassing Surgery to Treat Type 2 Diabetes in China||No. 150 Central Hospital of the Chinese People Liberation Army||Active, not recruiting|October 2010|October 2013|Anticipated|October 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples With DNA|whole blood, serum, urine|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|all patients are recruited from No. 150 Central Hospital of PLA|June 2013|June 4, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870713|1 Year|65180|
NCT01871324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0560-12-HMO-CTIL|The Efficacy of Group Therapy in Ultra-Orthodox Jewish Young Men Diagnosed With Type One Diabetes|||Hadassah Medical Organization|No|Withdrawn|September 2013|||September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Male|18 Years|30 Years|No|||March 2015|March 22, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871324||65133|
NCT01871337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UI_MS_HMO|Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS)|A Clinical Trial for the Efficacy of Paula Method ( Circular Muscle Exercise) in Women With Multiple Sclerosis Who Suffer From Urinary Incontinence|UI-MS|Hadassah Medical Organization|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||December 2012|September 20, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871337||65132|
NCT01871623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4416A3|One-Piece Le Fort I Osteotomy Versus Segmental Le Fort I Osteotomy|Stability of One-Piece Le Fort I Osteotomy Versus Segmental Le Fort I Osteotomy: A Prospective Study||Chang Gung Memorial Hospital|No|Recruiting|April 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||March 2013|June 3, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01871623||65110|
NCT01871844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/09/2984/02|ITF2984 Repeated Doses Study in Healthy Volunteers|A Within Group, Randomised, Phase I, Repeated Doses, Placebo and Octreotide Controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Incremental Doses of ITF2984|MAD|Italfarmaco|No|Completed|January 2012|May 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|46|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01871844||65093|
NCT01872091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-3579|Analysis of Neuromuscular, Circulatory and Biomechanical Responses After Cryotherapy by Immersion of the Forearm|||University of Sao Paulo|Yes|Recruiting|May 2013|May 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 14, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01872091||65074|
NCT01872845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0206|A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT|||Yonsei University|No|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|740|||Both|20 Years|80 Years|No|||February 2014|February 4, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872845||65016|
NCT01872832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-104|Single and Multiple Dose Study in Japanese Subjects|A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RDEA3170 in Healthy Male Japanese Subjects||Ardea Biosciences, Inc.|No|Completed|June 2013|November 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|46|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|June 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01872832||65017|
NCT01839916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1191|Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies||University of Chicago|No|Recruiting|April 2013|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|14 Years|75 Years|No|||January 2016|January 6, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839916||67537|
NCT01839929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-KT-02|A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF|A Multicenter, Open-label, Single-arm, Non-inferiority Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF® in Stable Kidney Transplant Patients Converted From a PROGRAF® Based Immunosuppressive Regimen|PeACE|Astellas Pharma Inc|No|Completed|September 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|20 Years|N/A|No|||April 2013|April 30, 2013|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01839929||67536|
NCT01872494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|local anaesthetic|The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation|Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation||Guangzhou General Hospital of Guangzhou Military Command|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|70 Years|No|||May 2014|May 1, 2014|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01872494||65043|
NCT01872741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiniPT Trial|Minipterional Versus Pterional Craniotomy|Prospective Randomized Study Comparing Clinical, Functional and Aesthetics Results of "Classical" Pterional and Minipterional Craniotomies.||University of Sao Paulo General Hospital|No|Active, not recruiting|October 2010|July 2013|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|90 Years|No|||June 2013|June 4, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872741||65024|
NCT01873625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-RA-001|Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis|Resurfacing Articular Cartilage With Mesenchymal Stem Cells Transplantation in Patients With Knee Joint Osteoarthritis Affected by Rheumatoid Arthritis: Randomized Triple Blind Clinical Trial Phase II/III (ACRCT)||Royan Institute|Yes|Completed|October 2009|December 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|10 Years|65 Years|No|||August 2009|June 7, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873625||64957|
NCT01869699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-ICUFever|Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults|Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: a Randomized Controlled Trial|ICUFeverAPAP|University of California, San Francisco|Yes|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869699||65258|
NCT01869946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/ANAES/02|Blood Levels of Local Anaesthetic in Hip Arthroplasty|Blood Levels of Local Anaesthetic in Hip Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Hip Arthroplasty|BLAST|Golden Jubilee National Hospital|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Up to 10 blood samples per patient|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing elective hip joint replacement where they will be receiving the        Caledonian technique|June 2013|June 4, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869946||65239|
NCT01869972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUvar-01|Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia|Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia||Hamilton Health Sciences Corporation|No|Completed|May 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|32|||Both|4 Years|N/A|No|Non-Probability Sample|Metabolic and/or PKU clinic|December 2015|December 10, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869972||65237|
NCT01870440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRVA-2013-Ozurdex-16.2|TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema|TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema||Northern California Retina Vitreous Associates|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01870440||65201|
NCT01871350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0504|Nutrition Intervention During Chemotherapy|Effects of Chemotherapy and Nutritional Intervention on Gut Function and Metabolism in Cancer||Texas A&M University|No|Recruiting|April 2013|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871350||65131|
NCT01871636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVKendo2013|ESD Versus EMR for Treatment of Early Barrett`s Adenocarcinoma|Water-jet Assisted Endoscopic Submucosal Dissection (ESD) Versus Endoscopic Mucosal Resection (EMR) for Treatment of Early Barrett`s Adenocarcinoma||Evangelisches Krankenhaus Düsseldorf|No|Completed|December 2012|August 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01871636||65109|
NCT01871857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH|7% Hypertonic Saline for Acute Bronchiolitis|7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial|HS|Le Bonheur Children's Hospital|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|6 Weeks|2 Years|No|||June 2013|June 8, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01871857||65092|
NCT01872104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT-R-01|Safety and Efficiency of Photodynamic Therapy for Rectal Cancer|Longterm Outcome of Photodynamic Therapy Compared With Chemotherapy Alone in Patients With Advanced Rectal Cancer|PDT-R-01|Central South University|Yes|Suspended|August 2013|August 2016|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|75 Years|No|||June 2013|June 5, 2013|June 5, 2013||No|Modifying the clinnicaltrials|No||https://clinicaltrials.gov/show/NCT01872104||65073|
NCT01872117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-3596|Assessment of Temperature by Infrared Thermography and Blood Conduction Velocity by Doppler After Applying Shortwave Diathermy and Microwave - Correlations With Cardiovascular and Hemodynamic Parameters|Assessment of Temperature by Infrared Thermography and Blood Conduction Velocity by Doppler After Applying Shortwave Diathermy and Microwave - Correlations With Cardiovascular and Hemodynamic Parameters||University of Sao Paulo|Yes|Recruiting|May 2013|May 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 14, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01872117||65072|
NCT01872572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG1-CLINSC101|Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD|A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers|SC101|Regado Biosciences, Inc.|Yes|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|June 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01872572||65037|
NCT01872351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1410|Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder|Assessment of Chronic Fatigue Syndrome as a Mitochondrial Disorder||Columbia University|Yes|Withdrawn|November 2011|November 2012|Actual|November 2012|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|20 Years|70 Years|No|Non-Probability Sample|Twelve CFS male and female patients between the ages of 20-70 years will be recruited to        participate in this pilot study. Subjects will be eligible to participate if they meet the        criteria for CFS of the Centers for Disease Control and Prevention (CDC). These include        persistent, unexplained fatigue for at least 6 months, concurrent with four of the        following: impaired memory/concentration, sore throat, new headaches, unrefreshing sleep,        muscle pain, multi-joint pain, tender lymph nodes, and post-exertional malaise. Subjects        will be screened for eligibility; the study will be explained and a verbal consent will be        given over the telephone. If the subject agrees, they will be sent a questionnaire        assessing their clinical and fatigue status prior to starting ENT and their present        clinical and fatigue status, as well as their compliance to ENT.|April 2015|April 9, 2015|June 5, 2013|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT01872351||65054|
NCT01872364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05123|Dominican Republic Mission Cost Analysis|A Material Cost-Minimization Analysis for Hernia Repairs and Minor Procedures During a Surgical Mission in the Dominican Republic||Washington University School of Medicine|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|110|||Both|N/A|N/A|No|Probability Sample|Patients presenting to the Institute of Latin American Concern Center for surgical        procedure, previously screened by local healthcare workers.|December 2013|December 16, 2013|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872364||65053|
NCT01872598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB09004|A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease|A Multicenter, Double-blind, Placebo-controlled, Randomised, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease||AB Science|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|396|||Both|50 Years|N/A|No|||June 2013|June 6, 2013|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872598||65035|
NCT01873144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-437|High Flow Therapy vs Hypertonic Saline in Bronchiolitis|High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial||Ministry of Health, Spain|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|6 Months|No|||June 2013|June 5, 2013|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873144||64993|
NCT01872858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jianhuifu2013|Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)|||Huashan Hospital||Recruiting|November 2010|November 2015|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872858||65015|
NCT01839643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVM-01001|Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women|Phase 1 Study of Assessment of Local Absortion of a Non-steroidal Antiinflammatory Drug (NSAID), Inhibitor of Cyclooxygenase 2 (COX-2) Meloxicam, Through a Vaginal Ring and Its Effect on Ovarian Cycle in Fertile Women||Laboratorios Andromaco S.A.|Yes|Completed|December 2012|July 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|13|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01839643||67558|
NCT01839656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS3A|A Study to Assess the Safety and Pharmacokinetics of IONIS SMNRx in Infants With Spinal Muscular Atrophy|A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of IONIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy||Ionis Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2013|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|210 Days|No|||December 2015|December 31, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839656||67557|
NCT01873053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KR-KHNMC-OA02|A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee|A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee||Kyunghee University Medical Center|No|Completed|April 2013|August 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|35 Years|80 Years|No|||November 2015|November 20, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01873053||65000|
NCT01872754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090803|Study Comparing the Use of Remifentanil Versus Propofol for Performing Bronchial Fibroscopy|Randomized and Single Blind Study Comparing Remifentanil Sedation Versus Propofol for Performing Bronchial Fibroscopies Under Intravenous Anesthesia|REVPRO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872754||65023|
NCT01873326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-074|Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors|Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873326||64980|
NCT01873352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADCA01|Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation|Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation (ERADICATE--AF) Trial|ERADICATE--AF|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2013|February 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873352||64978|
NCT01873638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5200630|Comparing Minilaparotomy and Laparoscopic Cholecystectomy as a Day Surgery Procedure|||Kuopio University Hospital||Completed|February 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||June 2013|June 7, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01873638||64956|
NCT01873651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delta III|Longterm Outcome of the Delta III Inverse Prosthesis|The Reverse Delta III Total Shoulder Prosthesis - Longerm Results in 98 Patients||Schulthess Klinik|No|Withdrawn|October 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||August 2014|August 8, 2014|June 5, 2013||No|The study has been withdrawn due to too few patients|No||https://clinicaltrials.gov/show/NCT01873651||64955|
NCT01869712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0100604024|PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies|Using Partially Randomized Patient Preference Research Model for Evaluation the Therapeutic Effect of Non-pharmaceutical Therapies: Protocol for a Feasibility Study||Beijing University of Chinese Medicine|Yes|Recruiting|July 2013|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|20 Years|60 Years|No|||October 2013|October 15, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01869712||65257|
NCT01869959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12708|A Study of LY2405319 in Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2405319 With 28 Days of Subcutaneous Injections in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|April 2009|December 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|47|||Both|18 Years|75 Years|No|||May 2013|May 31, 2013|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01869959||65238|
NCT01870219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turgut Ozal Medical Center|Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy|The Effects of Sevoflurane or Ketamine on QTc Interval During Electroconvulsive Therapy||Inonu University|Yes|Completed|February 2012|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||June 2013|June 5, 2013|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870219||65218|
NCT01870193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSH-Aging|Glutathione and Fuel Oxidation in Aging|Glutathione and Fuel Oxidation in Aging||Baylor College of Medicine|No|Recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|Samples With DNA|Breath, blood and muscle tissue|Both|21 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|April 2014|April 4, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870193||65220|
NCT01870427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRVA-2013-Newton-4-01|NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions|NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions|NEWTON|Northern California Retina Vitreous Associates|No|Active, not recruiting|June 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01870427||65202|
NCT01871051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-4414|Risk Factors For Postoperative Respiratory Complications After Anesthesia|Risk Factors For Postoperative Respiratory Complications After Anesthesia||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|September 2007|December 2013|Anticipated|March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|16000|||Both|N/A|18 Years|No|Non-Probability Sample|All patients who receive an anesthetic in participating institutions who are under 18        years of age and where an anesthetic record is generated will be included in the overall        statistics for each center|June 2013|June 4, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871051||65154|
NCT01871649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_ 42670_PsA_Golimumab|Initial Treatment With Golimumab in Early PsA|A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871649||65108|
NCT01871662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEG-SIL-2-02|Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C|A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon® SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C|HEPASIL|Rottapharm|Yes|Withdrawn|August 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|45 Years|No|||March 2015|March 4, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01871662||65107|
NCT01871870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.001|Artificial Pancreas Control System in an Outpatient Setting|Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in an Outpatient (Hotel) Setting.||Legacy Health System|No|Completed|May 2013|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|60 Years|No|||May 2015|May 13, 2015|May 29, 2013|Yes|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01871870||65091|
NCT01872130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-239|Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins|Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Dermatology clinics at MSKCC|January 2016|January 4, 2016|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872130||65071|
NCT01872143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/10 (Ethical Committee)|Non-invasive Brain Stimulation for the Treatment of Psychiatric Disorders|Non-invasive Brain Stimulation for the Treatment of Psychiatric Disorders||Federico II University|Yes|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||June 2013|June 3, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01872143||65070|
NCT01872377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120384-01H|Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer|Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnife® Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer||Ottawa Hospital Research Institute|Yes|Recruiting|July 2013|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|80 Years|No|||November 2015|November 23, 2015|October 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01872377||65052|
NCT01872611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-071|Nepafenac Once Daily for Macular Edema - Study 2|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery||Alcon Research|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|819|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872611||65034|
NCT01872884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSTROKE|Sedation Versus General Anesthesia for Endovascular Therapy in Acute Stroke - Impact on Neurological Outcome|Sedation Versus General Anesthesia for Endovascular Therapy in Acute Stroke - Impact on Neurological Outcome|ANSTROKE|Sahlgrenska University Hospital, Sweden|Yes|Recruiting|June 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872884||65013|
NCT01872897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA1202|Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients|A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Tablets or Placebo Tablets||Reckitt Benckiser Healthcare (UK) Limited|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||January 2014|January 8, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872897||65012|
NCT01872871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.4.İSM.4.06.68.49/231|The Efficacy of Paracetamol in Reducing Pain During Ophthalmological Examination for Retinopathy of Prematurity: a Prospective Randomised Trial|||Dr. Sami Ulus Children's Hospital|No|Recruiting|January 2013|January 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|3 Months|No|||June 2013|June 6, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872871||65014|
NCT01873170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11120183|Quantification of Immune Cells in Women Using Contraception (CHIC II)|Quantification of Immune Cells in Women Using Contraception|CHIC-II|University of Pittsburgh|Yes|Recruiting|August 2013|June 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|275|Samples With DNA|whole blood, plasma archive, vaginal swabs, serum|Female|18 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women, age 18-34 years, who are HIV negative and non-pregnant.|February 2016|February 8, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873170||64991|
NCT01839955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8512|Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer|A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|September 2013|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839955||67534|
NCT01872793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIVA02|Validation of BIVA for Nutritional Assessment in Cirrhotic Patients|Validation of Bioelectrical Impedance Vector Analysis for Nutritional Assessment in Patients With Cirrhosis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|January 2010|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|70 Years|No|Non-Probability Sample|The participants will be recruited from the Gastroenterology Department of a tertiary care        setting.|September 2015|September 29, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01872793||65020|
NCT01873066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN04|Closing the Loop 24/7 in Adolescents With Type 1 Diabetes|An Open-label, Single-centre, Randomised, Two-period Crossover Study to Assess the Efficacy, Safety and Utility of Automated Closed-loop Glucose Control, Day and Night Over 7 Days (Phase 1) and 21 Days (Phase 2) in Comparison With Continuous Subcutaneous Insulin Infusion Combined With Continuous Glucose Monitoring in the Home Setting in Children and Adolescents T1D|DAN04|University of Cambridge|Yes|Active, not recruiting|July 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|10 Years|18 Years|No|||July 2015|November 14, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873066||64999|
NCT01873339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115678|Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects|An Open-label, Single-sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of Darapladib (SB-480848) in Healthy Subjects||GlaxoSmithKline|Yes|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873339||64979|
NCT01873079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP-PPI ver. 2|PPI for Prevention of Post-sphincterotomy Bleeding|Prevention of Delayed Post-sphincterotomy Bleeding by High Dose Proton Pump Inhibitor||The University of Hong Kong|No|Recruiting|April 2013|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873079||64998|
NCT01873664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRF-2010-0017278|Functional Magnetic Resonance Imaging Study of Jaw-tapping Movement on Memory Function|Brain Activity During Jaw Tapping Movement in Healthy Subjects and Mild Cognitive Impairment Patients Using Functional Magnetic Resonance Imaging||Kyunghee University Medical Center|Yes|Recruiting|May 2009|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Female|50 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 7, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01873664||64954|
NCT01869725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212736|Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors|Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors||University of Iowa|Yes|Recruiting|April 2013|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|112|||Both|2 Years|N/A|No|||August 2015|August 3, 2015|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869725||65256|
NCT01869738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-10|MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction|MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction|MASTER-II|InspireMD|Yes|Terminated|June 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 28, 2013|Yes|Yes|low enrollment rate|No||https://clinicaltrials.gov/show/NCT01869738||65255|
NCT01869985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EPAC-102|Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers|A Randomized, Open-label, Single Dose, 3-sequence and 3-period Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|August 2013|January 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 8, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869985||65236|
NCT01869998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0040|Implication of Left veNtricle Vortex Flow Guided aNticOagulation Therapy for preVenting Apical Thrombus Formation In Patients With Acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION Study|||Yonsei University|No|Recruiting|February 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|85|||Both|30 Years|90 Years|No|Probability Sample|Patients with acute anterior wall myocardial infarction showing akinetic or dyskinetic        apical wall motion abnormalities on an initial transthoracic echocardiogram|February 2014|February 4, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01869998||65235|
NCT01870453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MassGH-001|Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease|Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease||Massachusetts General Hospital|Yes|Recruiting|October 2013|April 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 study participants with mild-to-moderate AD who are scheduled to have elective        noncardiac, nonneurologic, nonvascular surgery will be recruited at MGH. Surgeons will        first introduce the study to patients at their preoperative surgical clinic visit. If a        patient expresses interest in the study, and with permission of the surgeon, the patient        will then be contacted by study staff at his/her PATA preoperative evaluation and medical        optimization clinic visit. Recruitment, screening, and enrollment will then occur at the        patient's PATA clinic visit.|February 2014|February 6, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870453||65200|
NCT01870206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Birmex-ECA-01-2013|Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns|Phase III Immunogenicity, Safety, Poliovirus Excretion and Acceptance of Vaccination OPV (Vero Cells) in Newborns Mexicans||Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.|Yes|Recruiting|June 2013|January 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|320|||Both|N/A|2 Weeks|No|||September 2013|September 27, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01870206||65219|
NCT01871064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCE50498|Residual Curarization and Its Incidence at Tracheal Extubation in China|Residual Curarization and Its Incidence at Tracheal Extubation in China|RECITE-China|Peking University First Hospital|Yes|Completed|December 2012|September 2015|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1571|||Both|18 Years|N/A|No|Probability Sample|Adults 18 years of age or older scheduled to undergo an elective open abdominal or        laparoscopic surgical procedure for an anticipated duration of less than four hours will        be approached for participation in the study.|November 2015|November 9, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871064||65153|
NCT01871675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HEMREF 34|Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies|An Open-label, Phase Ib Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia||SCRI Development Innovations, LLC|No|Active, not recruiting|May 2013|May 2018|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871675||65106|
NCT01842893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYL/24019/008|Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer|Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer|ETHYFYL|Ethypharm|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||April 2013|May 2, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01842893||67309|
NCT01871883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRPV1SenSk|TRPV Expression in Subjects With Sensitive Skin|Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome.||Universidad Autonoma de San Luis Potosí|No|Enrolling by invitation|May 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01871883||65090|
NCT01872156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOMAMFYC11/2012|Effectiveness of an Intervention in Primary Care to Promote Smoking Cessation in Pregnant Women|Effectiveness of an Intervention in Primary Care to Promote Smoking Cessation in Pregnant Women: Cluster Randomized Controlled Trial.|GESTABAC|Gerencia de Atención Primaria, Madrid|Yes|Active, not recruiting|December 2013|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 8, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01872156||65069|
NCT01839461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-2973|Pharmacogenetic Morphine Spine Study|Personalizing Perioperative Morphine Analgesia for Adolescents Undergoing Major Spine Surgeries||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|July 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|De-identified study subjects' genetic information and their responses to pain and pain      medications, side-effects will be included in a study database. No patient identifiers will      be included in the database and there will be a confidential (access limited to      investigators only) code or link between the database and other information about the      participant|Both|10 Years|18 Years|No|Non-Probability Sample|Children ages 10 to 18, inclusive, years scheduled for spinal surgical procedures.|February 2016|February 4, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839461||67572|
NCT01839708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK083934-01A2|Mothers in Motion Program to Prevent Weight Gain in WIC Mothers (MIM)|Mothers in Motion Program to Prevent Weight Gain in Overweight/Obese WIC Mothers (MIM)|MIM|Michigan State University|Yes|Active, not recruiting|September 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|620|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01839708||67553|
NCT01840007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-17|Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma|Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma||Centre Hospitalier Universitaire de Nice|No|Recruiting|August 2011|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2013|April 23, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840007||67530|
NCT01873183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-439-32M|Perioperative Fluid Management in Morbidly Obese Patients|Perioperative Fluid Management With Transthoracic Echocardiography and Pulse-contour Device in Morbidly Obese Patients||Umeå University|No|Completed|January 2011|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||June 2013|March 13, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01873183||64990|
NCT01840215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S16022013|Study on the Impact of Ocular Anesthetic Procedures in Ocular Blood Flow|Impact of Topical, Retrobulbar and General Anesthesia in Ocular Blood Flow||Universitaire Ziekenhuizen Leuven|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|240|||Both|18 Years|N/A|No|Probability Sample|primary care setting|February 2013|May 28, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840215||67514|
NCT01839682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siegel-1|Evaluation of Outcomes of DFine StabiliT Kyphoplasty in Vertebral Compression Fractures Due to Osteoporosis|Prospective, Single Arm, Open Label Post-Market Pilot Study to Evaluate the StabiliT Vertebral Augmentation System Treat Vertebral Compression Fractures Due to Osteoporosis||Cedars-Sinai Medical Center|No|Completed|June 2009|July 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|50 Years|90 Years|No|Non-Probability Sample|Patients evaluated for vertebral compression fracture in clinic|April 2013|April 25, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01839682||67555|
NCT01839968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-117|Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel|||University Hospital, Geneva||Completed|September 2011|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute coronary syndrome who received a loading dose of prasugrel within 6        and 24h.|August 2014|August 18, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839968||67533|
NCT01873092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00493|AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients|AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients||VA New York Harbor Healthcare System|No|Active, not recruiting|May 2003|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|N/A|No|Non-Probability Sample|Veteran patients with chronic obstructive pulmonary disease|June 2013|June 5, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873092||64997|
NCT01873105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00019092|The CARS Study: Communicating About Readiness (for Discharge)|The CARS Study: Communicating About Readiness (for Discharge)||Marquette University|No|Recruiting|March 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01873105||64996|
NCT01873365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200089|A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above|Physician-practice Based Cohort Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Japan||GlaxoSmithKline||Completed|June 2013|February 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|448|||Both|60 Years|N/A|No|Non-Probability Sample|Japanese adults, male or female, greater than or equal to sixty years of age, presenting        with HZ at the participating sites.|April 2015|April 16, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873365||64977|
NCT01873378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GnRHa hysteroscopic myomectomy|GnRH Agonist Pretreatment in Hysteroscopic Myomectomy|Surgical Effects of GnRH Agonist Pretreatment on Cold Loop Hysteroscopic Myomectomy.||Azienda Ospedaliera S. Maria della Misericordia|No|Completed|January 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|55 Years|No|||August 2015|August 10, 2015|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01873378||64976|
NCT01870011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0208|A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Renal Protection During Deceased Brain Dead Donor Kidney Transplantation - A Prospective, Randomized Trial|||Yonsei University|No|Recruiting|October 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|192|||Both|20 Years|69 Years|No|||July 2014|July 24, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870011||65234|
NCT01870024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110123|Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus|Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients|LORACLOFT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|522|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870024||65233|
NCT01870232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103294|Evaluation of Use of Ultrasound for Greater Palatine Nerve Block and Inferior Alveolar Nerve Blocks: An Open Label Feasibility Study|EVALUATION OF USE OF ULTRASOUND FOR GREATER PALATINE NERVE BLOCK AND INFERIOR ALVEOLAR NERVE BLOCKS: AN OPEN LABEL FEASIBILITY STUDY||Lawson Health Research Institute|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||August 2015|August 31, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870232||65217|
NCT01870245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-975-002|A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers|A Phase 1 Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 Administered Intravenously to Healthy Volunteers||Achaogen, Inc.||Terminated|May 2013|||June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 28, 2013|May 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870245||65216|
NCT01870492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19978|Improving Patient Access to Stroke Therapy Study|Improving Patient Access to Stroke Therapy Study|IMPACT|Medical College of Wisconsin|No|Suspended|January 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients presenting with an acute ischemic stroke (AIS) or transient ischemic attack (TIA)        and meet all of the inclusion and none of the exclusion criteria.|November 2015|November 6, 2015|June 3, 2013||No|Principle Investigator is relocating to a new institution|No||https://clinicaltrials.gov/show/NCT01870492||65197|
NCT01870284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13650|Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis|SPIRIT A1|Eli Lilly and Company|Yes|Withdrawn|July 2014|April 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|June 3, 2013|Yes|Yes|Due to unexpected operational issues outside of Lilly's control the study has been closed|No||https://clinicaltrials.gov/show/NCT01870284||65213|
NCT01870466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-004|Pharmacodynamic Drug Interaction Between Cilostazol and Statins|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacodynamic Drug Interaction Between Cilostazol and Statins in Healthy Male Volunteer|SMCCPT-100|Samsung Medical Center|No|Completed|June 2012|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|63|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01870466||65199|
NCT01870479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120118|Music & Cancer - Live Music During Chemotherapy|Music & Cancer - Live Music During Chemotherapy. Randomized Study of the Effect of Live Music During Chemotherapy Treatment||University of Southern Denmark|Yes|Recruiting|May 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|105|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01870479||65198|
NCT01870752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02813|Ovarian Tissue Transplantation|Autologous Orthotopic Transplantation of Previously Cryopreserved Ovarian Tissue||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|June 2013|||June 2018|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|10|||Female|18 Years|45 Years|No|||January 2016|January 22, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01870752||65177|
NCT01871363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-027|Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer|Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer||Chinese Academy of Medical Sciences|No|Recruiting|October 2012|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||June 2013|June 3, 2013|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01871363||65130|
NCT01842906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLEEP-AID|Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)|Randomized Controlled Trial for Assessment of a Novel Non-Pharmacologic Intervention for Decrease in Altitude Illness|SLEEP-AID|Stanford University|Yes|Completed|October 2013|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|219|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01842906||67308|
NCT01842646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17302|Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)|A Phase II Study Evaluating the Oral Smoothened Inhibitor PF-04449913 in Patients With Myelodysplastic Syndrome (MDS)||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01842646||67328|
NCT01843205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA035481|Buspirone as a Candidate Medication for Methamphetamine Abuse|Buspirone as a Candidate Medication for Methamphetamine Abuse||University of Kentucky|No|Recruiting|April 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843205||67285|
NCT01842919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-64|Dance and Huntington Disease|||Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|May 2013|||February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|April 25, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01842919||67307|
NCT01843478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00071156|The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling|A Test of an Intervention to Improve Pap Testing Among Women With HIV||Johns Hopkins University|No|Enrolling by invitation|October 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|111|||Female|18 Years|N/A|No|||April 2013|April 26, 2013|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843478||67264|
NCT01843491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC.2012.0006|A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents|A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa)|AdBa|U.S. Army Medical Research and Materiel Command|No|Withdrawn|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 22, 2013|Yes|Yes|Did not go forward with study.|No||https://clinicaltrials.gov/show/NCT01843491||67263|
NCT01843504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0723|Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy|The Clinical, Biomechanical, and Tissue Regenerating Effects of a Single Platelet-rich Plasma Injection for the Treatment of Chronic Patellar Tendinopathy: a Randomized Controlled Trial|PRP|University of Wisconsin, Madison|No|Enrolling by invitation|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843504||67262|
NCT01839474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ7954|CPAP Survival Study in Ghana|Clinical Trial Evaluating the Difference in Mortality Rates in Children in Ghana Receiving CPAP Versus Those Who Do Not||Columbia University|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2200|||Both|1 Month|5 Years|No|||February 2016|February 1, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839474||67571|
NCT01839721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.7.06.09|Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation|Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|December 2006|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|246|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01839721||67552|
NCT01839734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-071|Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy|LAMBCHOP-Lubiprostone Activity Among the MicroBiota of the Colon in HIV in Opposing Permeability: A Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy|LAMBCHOP|Ruth M. Rothstein CORE Center|No|Active, not recruiting|June 2013|June 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839734||67551|
NCT01840020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1206|BAR-trial: Bioavailability of Ethanol Following Bariatric Surgery|Changes in Bioavailability of Ethanol Following Bariatric Surgery||Norwegian University of Science and Technology|Yes|Recruiting|September 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|blood samples|Both|18 Years|60 Years|No|Non-Probability Sample|persons eligible for bariatric surgery in the Obesity policlinic, St Olavs Hospital,        Trondheim, Norway|October 2015|October 21, 2015|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01840020||67529|
NCT01839994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT/BT/SBRT-COI-02|Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer|Phase III Clinical Trial on Conventionally Fractionated Conformal Radiotherapy (CF-CRT) Versus CF-CRT Combined With High-dose-rate Brachytherapy or Stereotactic Body Radiotherapy for Intermediate and High-risk Prostate Cancer.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Not yet recruiting|June 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Male|18 Years|80 Years|No|||April 2013|April 24, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839994||67531|
NCT01873391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|co2 vs h2o|Pain in Diagnostic Hysteroscopy|Pain in Diagnostic Hysteroscopy: a Multivariate Analysis.||Azienda Ospedaliera S. Maria della Misericordia|Yes|Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|603|||Female|18 Years|80 Years|No|||February 2014|February 5, 2014|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01873391||64975|
NCT01873677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US02|Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis|A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis||Maruho North America Inc.|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|537|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873677||64953|
NCT01869751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55296|The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?|The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?||Universitaire Ziekenhuizen Leuven|No|Suspended|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|serum, urine|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with known or newly diagnosed chronic slow-transit constipation necessitating        treatment with prucalopride (Resolor®, Shire) according to current treatment guidelines|December 2014|December 2, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869751||65254|
NCT01870037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ION 03-OAB|Phase 1 Study in Subjects With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer|Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB (Overactive Bladder Syndrome and Detrusor Overactivity)|OAB|Ion Channel Innovations|Yes|Recruiting|September 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870037||65232|
NCT01870050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cookderm 01|Dapsone Prurigo Study|A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis||John H. Stroger Hospital|No|Not yet recruiting|September 2013|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870050||65231|
NCT01870063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLUTROT|Comparision of FIBTEM and Blood-loss|||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|71|||Both|18 Years|90 Years|No|Probability Sample|Patient with full sternotomy|August 2014|August 5, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870063|1 Week|65230|
NCT01870258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-8037|Myocardial Infarction Prediction|Prediction of Acute Myocardial Infarction With Artificial Neural Networks in Patients With Nondiagnostic Electrocardiogram||Shiraz University of Medical Sciences|Yes|Completed|January 2011|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1100|||Both|40 Years|72 Years|No|||June 2013|June 4, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01870258||65215|
NCT01870076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1253|The Effect of Healing Touch on Sleep|Effectiveness of Healing Touch on Sleep, Pain, Anxiety, Anesthesia Emergence, Satisfaction and Cost of Care in Surgical|Sleep7|Shriners Hospitals for Children|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|5 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 7, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01870076||65229|
NCT01870505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-027|BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer|A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|56|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|June 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870505||65196|
NCT01841697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-026|Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.|Yes|Completed|June 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|642|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|April 24, 2013|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01841697||67400|
NCT01870791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11122|Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer|Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma||University Hospitals, Leicester|Yes|Suspended|May 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 28, 2013||No|Interim analysis|No||https://clinicaltrials.gov/show/NCT01870791||65174|
NCT01870765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-4442|Safety Study of Non-invasive Ventilation Versus High-flow Oxygen in Patients With Hypoxemic Respiratory Failure Undergoing Fiberoptic Bronchoscopy.|Prospective Randomised Study on the Safety of Non-invasive Ventilation Versus High-flow Oxygen in Patients With Hypoxemic Respiratory Failure Undergoing Fiberoptic Bronchoscopy.||Universitätsklinikum Hamburg-Eppendorf||Completed|July 2013|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870765||65176|
NCT01870778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2301|Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients|RELAX-AHF-2|Novartis|Yes|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6800|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870778||65175|
NCT01871376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC|Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation|Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation|EPIC|Hawaii Pacific Health|No|Active, not recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|25 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01871376||65129|
NCT01871389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D3|Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects|||Texas Tech University|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|31|||Both|18 Years|60 Years|No|Non-Probability Sample|bariatric surgery|May 2014|May 7, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871389||65128|
NCT01871402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000-0551-304|A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)||Therapeutics, Inc.|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||January 2014|February 13, 2015|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871402||65127|
NCT01842659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 2011|Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes|Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes|DASIRUWIBE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2013|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01842659||67327|
NCT01842932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-09-257|Usefulness Of Flospan As A Premedication For Colonoscopy|Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial||Ajou University School of Medicine|Yes|Recruiting|December 2009|December 2015|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 25, 2014|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01842932||67306|
NCT01843218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2008-07|Erectile Rating During the Treatment of Rectal Cancers Localized|Erectile Rating During the Treatment of Rectal Cancers Localized. Exploratory Study|METEORR|Institut Bergonié|Yes|Terminated|March 2008|December 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01843218||67284|
NCT01840033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-02|A Monocenter Prospective Study to Evaluate the Efficacy of Peripherally Inserted Central Catheter to Tunnelled Central Catheter With Cuff in Home Parenteral Nutrition for Long-term Used.|A Monocenter Prospective Study to Evaluate the Efficacy of Peripherally Inserted Central Catheter to Tunnelled Central Catheter With Cuff in Home Parenteral Nutrition for Long-term Used: the PICCnut Study.|PICCNUT|Centre Hospitalier Universitaire de Nice|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|122|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840033||67528|
NCT01840241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0419|Effect of Sodium Bicarbonate on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass (OPCAB)|||Yonsei University|No|Recruiting|April 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|162|||Both|20 Years|N/A|No|||February 2014|February 17, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840241||67512|
NCT01840254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0490|Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial|||Yonsei University|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Female|20 Years|65 Years|No|||February 2014|February 5, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840254||67511|
NCT01840553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICOL121|Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing|A Randomized Assessor-blinded Multicenter International Study Investigating Efficacy Patients Acceptance Safety and Tolerability of Sodium Phosphate Tablets Compared to Split Dose Polyethylene Glycol for Colon Cleansing Prior to Colonoscopy||Laboratoires Mayoly Spindler|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|461|||Both|18 Years|75 Years|No|||November 2013|March 21, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01840553||67488|
NCT01840566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-117|High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma|A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center||Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01840566||67487|
NCT01840813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMU911|Intraumbilical Misoprostol in Retained Placenta|Intra-umbilical Injection of Misoprostol Versus Normal Saline in the Management of Retained Placenta: Intrapartum Placebo-controlled Trial||Hawler Medical University||Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|15 Years|45 Years|No|||November 2013|November 1, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01840813||67468|
NCT01851460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130117|Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease|Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients With Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|January 2030|Anticipated|January 2030|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851460||66654|
NCT01873690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103696|Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)|A Randomized Controlled Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on Reducing Urinary Tract Infection||Lawson Health Research Institute|No|Terminated|November 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|360|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|June 3, 2013||No|Due to the low recruitment rate and the large number lost to follow-up|No||https://clinicaltrials.gov/show/NCT01873690||64952|
NCT01873703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI-003|Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome|A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS)||MEI Pharma, Inc.|Yes|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873703||64951|
NCT01869764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98113|Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer|A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|November 2013|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869764||65253|
NCT01869777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99113|Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia|INVESTIGATING THE PROGNOSTIC IMPORTANCE OF BIOELECTRICAL IMPEDANCE PHASE ANGLE IN ADULTS TREATED FOR NEWLY DIAGNOSED ACUTE LEUKEMIA||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|July 2013|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|102|||Both|N/A|N/A|No|||September 2015|September 22, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869777||65252|
NCT01870271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot-DCPT|Pilot-Study Developmentally Adapted Cognitive Processing Therapy for PTSD in Adolescents and Young Adults With a History of CSA and/or CPA|Pilotstudie Developmentally Adapted Cognitive Processing Therapy für Jugendliche Und Junge Erwachsene Mit Posttraumatischer Belastungsstörung Nach Sexualisierter Und /Oder körperlicher Gewalt (Pilot DCPT)|Pilot-DCPT|Goethe University|No|Recruiting|November 2012|July 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|21 Years|No|||June 2013|June 3, 2013|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01870271||65214|
NCT01841710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816980|Genetic Variability in Taste Perception|Genetic Variability in Taste Perception||Monell Chemical Senses Center|No|Completed|December 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|90|Samples With DNA|Saliva|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|One hundred women who were previously enrolled in the study entitled "Efficacy of Bitter        Blockers on Taste Acceptance in Pediatric Populations," Protocol #809789; will be        recruited for the current study|March 2016|March 14, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01841710||67399|
NCT01841723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00826|Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia|A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia||National Cancer Institute (NCI)||Recruiting|April 2013|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|January 25, 2016|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01841723||67398|
NCT01870804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|472013|Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)|Impact of Early High-dose Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury in Unselected Patients With Non- ST Elevation Acute Coronary Syndromes Scheduled for Early Invasive Strategy.|PRATO-ACS-2|Centro Cardiopatici Toscani|Yes|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|760|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01870804||65173|
NCT01871077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPH156-0612/I|Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.|Phase I Clinical Trial to Assess the Safety and Tolerability of the Ophthalmic Solution PRO-156 Over the Ocular Surface of Ophthalmologically Healthy Volunteers.||Laboratorios Sophia S.A de C.V.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871077||65152|
NCT01871090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60047158|Remote Device Interrogation In The Emergency Department|Remote Device Interrogation In The Emergency Department|REMEDY|St. Jude Medical|No|Completed|September 2013|July 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01871090||65151|
NCT01842620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117219|OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.|Oral Bioavailability Study Comparing OXEMET™ 1000 mg Coated Tablets Containing Metformin Hydrochloride With 1000 mg of the Reference Product (GLAFORNIL™) Administered as Two 500 mg Tablets, Through a Randomized, Single-dose, Open Label, Balanced, 2-way Crossover Study in Healthy Volunteers Under Fasting Conditions.OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.||GlaxoSmithKline|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|25|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842620||67330|
NCT01842633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202172|Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache|A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache||GlaxoSmithKline|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|282|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01842633||67329|
NCT01843517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022603|Endogenous Pain Facilitation and Inhibition in Postpartum Women|Endogenous Pain Facilitation and Inhibition in Postpartum Women||Wake Forest School of Medicine|No|Recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy women 10-14 days postpartum following term vaginal delivery, who are breast        feeding and age- and race- matched healthy, nonpregnant women, either nulliparous or at        least 1 year beyond delivery.|December 2015|December 8, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01843517||67261|
NCT01839487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-109-202|PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer|A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer|HALO-109-202|Halozyme Therapeutics|Yes|Active, not recruiting|April 2013|June 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|279|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01839487||67570|
NCT01839747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-307|Evaluation of PET/MRI in Children With Cancer|Evaluation of PET/MRI in Children With Cancer||Massachusetts General Hospital|Yes|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|3 Years|18 Years|No|||April 2015|April 7, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01839747||67550|
NCT01839760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-EPI-001|Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients|Prospective Study to Evaluate Viral Shedding Patterns and Clinical Outcomes of Hospitalized Adult Influenza Patients||Crucell Holland BV|No|Completed|December 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized adult patients with laboratory-confirmed influenza A or B|August 2014|August 21, 2014|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01839760||67549|
NCT01840579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-011|Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)|A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.|No|Active, not recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|20 Years|N/A|No|||January 2016|January 7, 2016|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01840579||67486|
NCT01840592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-259|Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib|Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib||Memorial Sloan Kettering Cancer Center||Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01840592||67485|
NCT01870882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL001|Attention Training for Opioid-maintained Cocaine Users|Attention Training for Opioid-maintained Cocaine Users||Yale University|Yes|Completed|June 2013|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|No|||July 2015|July 15, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870882||65167|
NCT01871181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026522|US-guided Ilioinguinal Blocks Versus Local Infiltration|The Short and Long-term Effects of Ultrasound-guided Ilioinguinal and Iliohypogastric Nerve Block on Postoperative Pain Control Following Open Inguinal Hernia Repair||University of Alberta|No|Active, not recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 24, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871181||65144|
NCT01871467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-5001-1|Sargramostim for Myeloid Dendritic Cell Deficiency|Sargramostim for Myeloid Dendritic Cell Deficiency - Phase I||Johns Hopkins University|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|May 20, 2015|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871467||65122|
NCT01871727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7777-G000-302|A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma|A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma||Eisai Inc.|No|Active, not recruiting|May 2013|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||December 2015|January 27, 2016|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871727||65102|
NCT01851473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913482|Interactions Between Intravenous Cocaine and Acetazolamide or Quinine|Pharmacodynamic and Pharmacokinetic Interactions Between Intravenous Cocaine and Acetazolamide or Quinine||National Institutes of Health Clinical Center (CC)||Completed|October 2012|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|May 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851473||66653|
NCT01851486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0393-12-RMB.CTIL|The Relationships Between the Noradrenergic, Opioid and Pain System|||Rambam Health Care Campus|Yes|Not yet recruiting|May 2013|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01851486||66652|
NCT01873417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS403|Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States|A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules|MANAGE|Biogen|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|May 9, 2013|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01873417||64973|
NCT01873716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000895|Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque|Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque -- A Pilot Study|BRIGHT-CEA|Massachusetts General Hospital|No|Completed|May 2013|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873716||64950|
NCT01873729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000696|An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.|An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.||Massachusetts General Hospital|No|Active, not recruiting|November 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|55 Years|No|||March 2016|March 14, 2016|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873729||64949|
NCT01870089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmartCare/PS-NIV|SmartCare Driven Pressure Support-Non Invasive Ventilation Feasibility Study|Clinical Evaluation of an Automated Knowledge-based Computer Driven System (SmartCare/PS-NIV) Designed to Automatically Adapt Pressure Support Level and Expiratory Cycling During Non Invasive Ventilation, a Feasability Study.||University of Lausanne Hospitals|No|Recruiting|May 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 7, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01870089||65228|
NCT01870297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14347|A Study of LY3025876 in Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Both|21 Years|70 Years|No|||January 2015|January 21, 2015|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01870297||65212|
NCT01842061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00518|Everyday Activity Supports You (EASY) Pilot Study|Everyday Activity Supports You (EASY) Pilot Study|EASY-Pilot|University of British Columbia|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Female|55 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01842061||67372|
NCT01842074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110147|Desensitization With Bortezomib Before a Living Kidney Donation|Desensitization With Bortezomib Before a Living Kidney Donation|VELDON|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01842074||67371|
NCT01871103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTS1306017|The Dorsal Homodigital Island Flap Based on the Dorsal Branch of the Digital Artery: A Review of 171 Cases|||The Second Hospital of Tangshan|Yes|Completed|January 2006|March 2013|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|173|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2007|June 5, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871103||65150|
NCT01844739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC006|A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel|A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers||Novan, Inc.|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844739||67167|
NCT01845896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.20/reva13.02|Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis|Rehabilitation in MS: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis||Hasselt University|Yes|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 3, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845896||67078|
NCT01845909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-SOS|Sudden Cardiac Death - Screening Of Risk Factors|Sudden Cardiac Death: Evaluation of a New Strategy to Identify Young Adults at Risk|SCD-SOS|University of Coimbra|No|Recruiting|February 2012|||May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|12 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment will include mainly university students but also young adults involved in        sport practice (professional, semi-professional and amateur athletes) or in other        activities (sales, industry, etc). This way, the places for sample collection will the        university departments or technical schools, students associations and other places that        gather university students, shopping centers, gyms, sports venues, factories in the city        surroundings. Information collection in these places will be performed under the        authorization of proper entities.|April 2013|May 2, 2013|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01845909||67077|
NCT01845870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIJMUGHE|Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria|Study Whether Serum 1,25-dihydroxyvitamin D Levels Could be an Indicator for Dysfunction of Renal Tubules|DM|Tianjin Medical University General Hospital|No|Completed|February 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|162||Blood samples were collected after an overnight fast to evaluate glycosylated hemoglobin      A1c（HbA1c）, hemoglobin (Hb), serum albumin (ALB), serum creatinine (SCR), serum urea      nitrogen (BUN), uric acid (UA), serum calcium (Ca), serum phosphate (P), serum alanine      transferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP),      serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Urine albumin, calcium and phosphate      of 24 hour were also evaluated.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with T2DM were recruited from the general hospital of Tianjin Medical University        in China .|April 2013|June 5, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01845870||67080|
NCT01845883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001589|Perceptual Decision Making Under Conditions of Visual Uncertainty|Perceptual Decision Making Under Conditions of Visual Uncertainty||University of California, Los Angeles|No|Recruiting|April 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01845883||67079|
NCT01846260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZGS2013021|Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients|Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients|CONCEPT|General Hospital Groeninge||Completed|April 2013|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Probability Sample|The study population consist of newly diagnosed cancer patients of all ages (≥18 years),        presenting with a solid tumour (lung, gastro-intestinal, GIST, urological, prostate,        breast, sarcoma or gynecological cancer) or hematologic malignancy, in an early or        advanced stage, eligible for systemic treatment (radiotherapy, chemotherapy,        radiochemotherapy, radiobiotherapy, anti-hormonal or targeted therapy) with curative        intent.|March 2016|March 21, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846260||67050|
NCT01847144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF111|MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes|MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2|Mastermind|NIHR Exeter Clinical Research Facility|No|Completed|April 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|143|||Both|19 Years|79 Years|No|||October 2015|October 13, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01847144||66983|
NCT01847131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R015532021|Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction|Effectiveness of Oxymetazoline Added on Intranasal Steroid in the Treatment of Allergic and Nonallergic Rhinitis With Persistent Nasal Obstruction||Mahidol University|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2015|January 3, 2015|April 14, 2013||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01847131||66984|Further studies with larger numbers of subjects and longer period of follow-up would probably have led to significant differences between both treatment groups in NPIF, Rcq scores and the possible rebound nasal congestion or other adverse events.
NCT01847677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICO-1205|Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin|A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer|NOVA|Grupo Español de Investigación en Cáncer de Ovario|No|Active, not recruiting|April 2013|June 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|N/A|No|||June 2015|June 17, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847677||66942|
NCT01845779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epitope-HPV01|Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal|Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal|Epitopes-HPV01|Centre Hospitalier Universitaire de Besancon|No|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|4|||Both|18 Years|N/A|No|||April 2013|May 2, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01845779||67087|
NCT01845792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1489.cc|Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer|Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.||University of Colorado, Denver|Yes|Recruiting|July 2013|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|95 Years|No|||December 2015|December 3, 2015|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845792||67086|
NCT01847053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-1208|Bioavailability Study of Cinnamon in Healthy Subjects|A Single-Center, Partial Double-Blind, Randomized, Four-Treatment Crossover Bioavailability Study of Cinnamon in Healthy Subjects||McCormick and Company, Inc.|Yes|Completed|January 2013|April 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847053||66990|
NCT01847313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1-2012-01|The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease|Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease||University College Dublin|Yes|Active, not recruiting|April 2013|November 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|75 Years|No|||June 2015|June 5, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01847313||66970|
NCT01847326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1554|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer|Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.||University of Chicago|No|Recruiting|March 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01847326||66969|
NCT01847872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1327|IPV Clinical Trial - The Gambia|A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes|IPV|Medical Research Council Unit, The Gambia|Yes|Completed|July 2013|July 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|1504|||Both|9 Months|10 Months|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01847872||66927|
NCT01847885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0131-CSP-000|Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System|A Randomized, Double-Blinded, Placebo-Control Multicenter Pivotal Study of the Smartpatch Peripheral Nerve Stimulation (PNS) System for the Treatment of Chronic Post-Stroke Shoulder Pain||SPR Therapeutics, LLC|Yes|Suspended|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|21 Years|N/A|No|||May 2015|May 10, 2015|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847885||66926|
NCT01847573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-DMD-01|Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy|A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy||Akashi Therapeutics|Yes|Suspended|May 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|54|||Male|6 Years|20 Years|No|||February 2016|February 3, 2016|May 2, 2013|Yes|Yes|All dosing suspended temporarily|No||https://clinicaltrials.gov/show/NCT01847573||66950|
NCT01847833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p001007|Advanced MRI Applications Development|Advanced MRI Applications Development||Massachusetts General Hospital|No|Recruiting|January 2014|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A||Non-Probability Sample|Patients with brain tumors or tumors affecting the brain.|July 2015|July 8, 2015|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847833||66930|
NCT01847846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA07052013|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||September 24, 2014|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847846||66929|
NCT01844453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3216|Local Endometrial Injury in Fresh Embryo Transfer Cycles|Impact of Local Endometrial Injury on Implantation Rates in Fresh Embryo Transfer Cycles|LEI|McGill University|No|Not yet recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|360|||Female|36 Years|44 Years|No|||April 2013|April 29, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844453||67189|
NCT01844466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38/3-10-2011|Correlation of Visual and Motor Deficits in Stroke Patients|||University of Ioannina|No|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|80 Years|No|||May 2015|May 26, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01844466||67188|
NCT01844752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC201|A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne|A Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled, Parallel Group, 3-arm Study Comparing the Efficacy, Tolerability and Safety of 2 Concentrations of NVN1000 Gel and Vehicle Gel Twice Daily in the Treatment of Acne Vulgaris.||Novan, Inc.|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|153|||Both|12 Years|40 Years|No|||January 2014|January 10, 2014|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844752||67166|
NCT01845025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258D2416|Study of Safety of Foradil in Patients With Persistent Asthma|A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.||Novartis|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|11700|||Both|12 Years|N/A|No|||February 2016|February 3, 2016|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845025||67145|
NCT01845324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011-13|Fetal Heart Interventricular Septum in Fetuses of Diabetic Mothers|Relation Between Fetal Heart Interventricular Septum Size and Gestational Diabetes Mellitus Control. a Prospective Trial||Hillel Yaffe Medical Center|No|Not yet recruiting|May 2013|June 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|All consequtive pregnant women with Diabetes Mellitus - Gestational and non Gestational|April 2013|April 30, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01845324||67122|
NCT01845922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKM refeeding|The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer|The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer||University of Copenhagen|No|Recruiting|May 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 5, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01845922||67076|
NCT01846273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2412|Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy.|A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV|EVEREST II|Novartis|No|Active, not recruiting|August 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01846273||67049|
NCT01846585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23501|Treatment for Insomnia During Pregnancy|The Effectiveness of Non-Pharmacological Treatment for Insomnia During Pregnancy||Stanford University|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Female|18 Years|N/A|No|||May 2014|May 12, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846585||67025|
NCT01846845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-2012-Aim3|Evaluation of a Novel Transfemoral Prosthetic Socket System|Prosthetic Socket System: Pilot Assessment||Ohio Willow Wood||Recruiting|March 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846845||67005|
NCT01846858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001538|Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy|Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy||Mayo Clinic|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|31|Samples Without DNA|10 vaginal tissue specimens from each group of energy modality will be compared and      analyzed. Tissue from the specimen side of the hysterectomy will be sent (after marking the      most distal edge with a marker) for pathological evaluation such that the vaginal length is      not compromised.|Female|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for a robotic hysterectomy for benign indications|December 2014|December 17, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846858||67004|
NCT01847157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202016RIB|Transcranial Direct Current Stimulation Combined Sensory Modulation Intervention in Chronic Stroke Patients|The Effect of the Transcranial Direct Current Stimulation Combined Sensory Modulation Intervention on Upper Extremity Functional Rehabilitation in Patients With Chronic Stroke||National Taiwan University Hospital|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|80 Years|No|||February 2016|February 16, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01847157||66982|
NCT01847170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000353|Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease|||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|May 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847170||66981|
NCT01847378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISII|Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias|EPIcardial and Endocardial Mapping and Ablation Using Contact Force Catheter in Chagasic Patients With Sustained Ventricular Tachycardia|EPICONTAC-VT|Federal University of São Paulo|No|Recruiting|June 2013|August 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Probability Sample|Chagasic patients with symptomatic documented ventricular tachycardia|October 2014|October 17, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847378||66965|
NCT01847391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-279-0102|A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects|A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects||Gilead Sciences|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01847391||66964|
NCT01847365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESOLAUK13|TES for the Treatment of RP|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicentre Safety Study of the Okustim® System|TESOLAUK|University of Oxford|Yes|Completed|April 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|March 10, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847365||66966|
NCT01847924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLC901-1|NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects|NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects : a Pilot Double Blind, Placebo-controlled Randomized Trial on Efficacy and Safety (NEURITES) Study|NEURITES|National University Hospital, Singapore|No|Recruiting|March 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|85 Years|No|||May 2013|May 7, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01847924||66923|
NCT01846507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH12-00822|Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding|Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding||Nationwide Children's Hospital|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|10 Years|19 Years|No|||June 2015|June 17, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846507||67031|
NCT01846780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44588|Treadmill Pilot Study (Invasive Pressure Measurements in PTS)|The Effect of PTA & Stenting on Intravenous Pressure in Deep Venous Obstructive Disease Before, After and During Ambulation on a Treadmill - Pilot Study.||Maastricht University Medical Center|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|24|Samples With DNA|Blood samples for possible future research|Both|18 Years|85 Years|No|Probability Sample|Patients at our specialized venous outpatient clinic in our tertiary centre|October 2015|October 20, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846780||67010|
NCT01843647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV06|Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients|Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|April 2013|February 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2014|July 14, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843647||67251|
NCT01847898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-SPI-S-06-134-01|Study on the Treatment of Osteoporotic Vertebral Fractures Using Vertebral Body Stenting|Study to Evaluate the Clinical Performance of the VBS System for the Treatment of Osteoporotic Vertebral Fractures in a Multicenter, Randomized, Controlled Setting||Synthes GmbH|No|Active, not recruiting|September 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||September 2015|September 24, 2015|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01847898||66925|
NCT01847911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1336|Self-directed Video Versus Instructor-based Neonatal Resuscitation Training|Self-directed Video Versus Instructor-based Neonatal Resuscitation Training of Novice Providers. A Controlled Blinded Randomized Non-inferiority Multicenter Study||Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|252|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01847911||66924|
NCT01843608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSMSCCMYEJ1|Effect of Combined Exercise Post-treatment Intervention in Lean Mass Recovery in Breast Cancer Survival.|Effect of Combined Training Post-treatment Intervention in Lean Body Mass Recovery in Breast Cancer Survival. A Randomised Controlled Trial.|WIM1|Universidad Politecnica de Madrid|No|Recruiting|February 2013|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|75 Years|No|||November 2013|November 22, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843608||67254|
NCT01843582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T81/2012|A Study to Determine the Location of the Blind Spot and the Macula-disc Centre Distance on a Fundus Photograph|A Study to Develop Both a Novel Method for Evaluating the True Size of a Retinal Object on Fundus Photographs and a New Reaction-time Based Method for Studying the Visual Field on Healthy Volunteers||Turku University Hospital|No|Completed|May 2013|November 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|May 2013|February 26, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843582|1 Day|67256|
NCT01843595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1548|Rethinking Eating and FITness for Men|Efficacy Trial of the REFIT (Rethinking Eating and FITness) Weight Loss Intervention for Men|REFIT|University of North Carolina, Chapel Hill|No|Completed|July 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|October 20, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843595||67255|
NCT01845038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-12-003|Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma|A Prospective, Multicenter, Randomized, Double-Masked, Multi-Arm Feasibility Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension||Ocular Therapeutix, Inc.|No|Completed|April 2013|July 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01845038||67144|
NCT01845051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-01|Is There a Comorbidity Between Migraine and Allergic Rhinitis?|||Baskent University|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Migraine patients attending neurology clinic and healthy subjects|May 2013|May 1, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845051||67143|
NCT01845350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-M2-2013|Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients|Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients||Siberian Branch of the Russian Academy of Medical Sciences|No|Recruiting|October 2012|October 2015|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||April 2013|April 29, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01845350||67120|
NCT01845363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cefa01|Antibiotic Prophylaxis in Bariatric Surgery With Cefazolin: Concentration in Adipose Tissue|Antibiotic Prophylaxis in Bariatric Surgery With Continuous Infusion of Cefazolin: Determination of Concentration in Adipose Tissue||Universidade Federal de Pernambuco|No|Completed|June 2011|May 2012|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|No|||April 2013|April 29, 2013|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845363||67119|
NCT01845610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSWAKA|Randomized Controlled Trial in South Africa Comparing the Efficacy of Complementary Food Products on Child Growth|Randomized Controlled Trial in South Africa Comparing the Efficacy of Complementary Food Products on Child Growth|TSWAKA|North-West University, South Africa|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||May 2015|May 6, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01845610||67100|
NCT01846598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301038RIND|48 Hours After Surgery Shower Patient's Wound Infection Rate, Pain Score, Patient Satisfaction and Cost.|Comparison of 48 Hours After Surgery That Shower and Non-shower Patient's Wound Infection Rate, Pain Score, Patient Satisfaction and Cost.||National Taiwan University Hospital|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|444|||Both|241 Months|N/A|No|Probability Sample|adult (minimum age> 20 years; maximum age are not limit) postoperative 48 hours suture not        opened the line and remove the drainage tube of the wound (clean or clean contaminated        wounds; the wound category 1,2)|April 2014|April 13, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846598|14 Days|67024|
NCT01846871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-069|Tivozanib for Recurrent Glioblastoma|A Phase II Study of Tivozanib in Recurrent Glioblastoma||Massachusetts General Hospital|Yes|Active, not recruiting|June 2013|May 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846871||67003|
NCT01846884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opal|Specimen Stability Study|Urine Sample Processing Study:Analysis of Fresh Versus Frozen Urine Samples From Critically Ill Subjects||Astute Medical, Inc.|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Both|21 Years|N/A|No|Non-Probability Sample|Critically-ill adult subjects at risk for acute kidney injury.|May 2013|May 15, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01846884||67002|
NCT01847690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2216|Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure|Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal||Haukeland University Hospital|Yes|Active, not recruiting|June 2013|March 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 29, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01847690||66941|
NCT01847703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/361-31/1|Robotic Versus Abdominal Surgery for Endometrial Cancer|Randomized Trial Comparing Robotic and Abdominal Surgery for High Risk Endometrial Cancer|RASHEC|Karolinska Institutet|No|Recruiting|April 2013|April 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|75 Years|No|||March 2015|March 16, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847703||66940|
NCT01847404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116480|Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions|An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fasting Conditions||GlaxoSmithKline|No|Completed|May 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847404||66963|
NCT01847417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116498|Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions|An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fed Conditions||GlaxoSmithKline|No|Completed|May 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847417||66962|
NCT01847976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120543-02H|Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer|A Phase 2 Trial Exploring the Clinical and Correlative Effects of Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer|OTT12-05|Ottawa Hospital Research Institute|Yes|Active, not recruiting|August 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Female|19 Years|N/A|No|||December 2015|December 11, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01847976||66919|
NCT01847989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13-1661|Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers|A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers||Novo Nordisk A/S|No|Completed|January 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01847989||66918|
NCT01847963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-10-KR- 1301|A Clinical Study to Evaluate the Efficacy of Two Siddha Drugs Sindhuvallathy Mezhugu and Kalladaippu Kudineer for Kidney Stones|Standardization and Clinical Evaluation of Siddha Formulations for Urolithiasis /Kalladaippu.|SVMKK|Tamil Nadu Dr.M.G.R.Medical University|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|80 Years|No|||December 2014|December 30, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01847963||66920|
NCT01843686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-11-004|Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns|Use of Autologous Platelet Rich Plasma (PRP) Gel as an Adjunct to the Treatment of Deep 2nd and 3rd Degree Burns||Arteriocyte, Inc.|Yes|Recruiting|April 2013|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|86 Years|No|||March 2016|March 11, 2016|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843686||67248|
NCT01847339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-183|A Study of Epidural Bupivacain-soaked Absorbable Gelatin Sponge on Post-operative Pain in Lumbar Laminectomy|||The Cleveland Clinic|No|Recruiting|April 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|80 Years|No|||March 2014|March 4, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847339||66968|
NCT01847625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-011|Safe Traction During Ongoing Lead Extraction Procedure (STOP)|Safe Traction During Ongoing Lead Extraction Procedure|STOP|Deutsches Herzzentrum Muenchen|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|N/A||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians experienced in pacemaker or defibrillator electrode extraction|July 2013|July 3, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01847625||66946|
NCT01843894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-101-C001|A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye|A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye||R-Tech Ueno, Ltd.|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|80 Years|No|||August 2014|August 20, 2014|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843894||67232|
NCT01847950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConstiFOS|Effects of scFOS on Stool Frequency in People With Functionnal Constipation|Randomized, Placebo-controlled Double-blind Study to Evaluate the Effects of Fructo-oligosachharides on Increase of Stool Frequency in Constipated People||Syral|No|Recruiting|November 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01847950||66921|
NCT01847586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215/2012|Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease|Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease|TMS-AD|Centre for Addiction and Mental Health|Yes|Recruiting|April 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|56|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847586||66949|
NCT01847599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01300-39|Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib|Implementation of a Therapeutic Educational Program Applicated to Adherence of Patients Treated by Capecitabine Alone or in Combination With Lapatinib|ProMETheX|Centre Jean Perrin|No|Recruiting|September 2011|May 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01847599||66948|
NCT01847612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 2013-843-0003|Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy|Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study|CAMFIB|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|132|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01847612||66947|
NCT01843621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13227|A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children|A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 ("A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series||U.S. Army Medical Research and Materiel Command|Yes|Completed|February 2005|February 2009|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843621||67253|
NCT01844167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302023RINB|The Effect of Noxipoint Therapy Versus Physical Therapy With TENS on Chronic Neck Pain|The Effect of Noxipoint™ Therapy Versus Physical Therapy With Transcutaneous Electrical Never Stimulation on Chronic Cervical Pain||National Taiwan University Hospital|Yes|Completed|April 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|20 Years|70 Years|No|||December 2014|December 1, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01844167||67211|
NCT01844778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2403|Ease of Use and Microbial Contamination of TIP vs Nebulised TIS and Nebulised Colistimethate|An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With TIS and Nebulized Colistimethate for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis||Novartis|No|Completed|August 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|6 Years|N/A|No|||February 2016|February 22, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844778||67164|
NCT01844791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCZ103-206|An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase IIa Exploratory Study of OCZ103-OS in Combination With Platinum-Gemcitabine Based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients||Oncozyme Pharma Inc.|Yes|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844791||67163|
NCT01845064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMA-Clin-199-2013-001|A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients|A Double-Blinded, Placebo-Controlled, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof of Concept of DM199 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||DiaMedica USA Inc.|Yes|Completed|April 2013|November 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|98|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01845064||67142|
NCT01845077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.8|Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets|Relative Bioavailability of Two Newly Developed Extended Release FDC Tablet Strengths (5mg/1000mg and 2.5 mg/750 mg) of Linagliptin/Metformin Extended Release Compared With the Free Combination of Linagliptin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|April 30, 2013||||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01845077||67141|
NCT01845376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB035|Local or Regional or General Anesthesia for Hernia Repair: a Randomized Controlled Trial|Postoperative Clinical Outcomes and Inflammatory Markers After Inguinal Hernia Repair With Local or Spinal or General Anesthesia: A Randomized Trial||Siriraj Hospital|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01845376||67118|
NCT01845623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMID001A2201|A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma||Novartis|No|Withdrawn|August 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845623||67099|
NCT01846286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0642|Neuropathic Pain in Head and Neck Cancer|Molecular Epidemiology of Neuropathic Pain in Head and Neck Cancer||M.D. Anderson Cancer Center|No|Recruiting|October 2012|||October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood specimen|Both|18 Years|N/A|No|Non-Probability Sample|For AIM 1: Squamous cell carcinoma of the head and neck patients for whom genome-wide        (730,525 SNPs) and pain data are available; AIM 2: Newly diagnosed and previously        untreated patients with locoregional (excludes Stage IVc) squamous cell carcinoma of the        head and neck recruited at the Head and Neck Center at MD Anderson; AIM 3: Populations        from AIM 1 & 2.|November 2015|November 9, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846286||67048|
NCT01846299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002G2302|To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema|A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravtitreal Injections in Patients With Visual Impairment Due to VEGF-driven Macular Edema||Novartis|No|Completed|October 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|12 Years|N/A|No|||November 2015|November 16, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846299||67047|
NCT01846611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100983|A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Janssen Research & Development, LLC|Yes|Recruiting|October 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|670|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846611||67023|
NCT01847430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116722|Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder|Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Challenge Dose of GSK Biologicals' Hepatitis B Virus Vaccine, Engerix™-B Kinder (SKF103860), in 15-16 Years Old Adolescents, Vaccinated in Infancy With Engerix™-B Kinder||GlaxoSmithKline||Completed|July 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|303|||Both|15 Years|16 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|May 2, 2013|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01847430||66961|
NCT01847443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01705|Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations|A Pharmacokinetic Study Comparing Two Nicotine Gum Formulations in a Single Dose Design||GlaxoSmithKline|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|March 6, 2014|May 2, 2013||No||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01847443||66960|
NCT01847716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13IC0457|Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension|Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension||Imperial College London|Yes|Recruiting|October 2013|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|93|Samples With DNA|Muscle biopsy and blood specimens will be retained by Imperial College and are subject to      thier restrictions ad regulations|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinics at Royal Brompton and Hammersmith hospital|February 2016|February 16, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01847716||66939|
NCT01848002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13-1662|Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers|A Randomized, Placebo-Controlled, Double-Blind, Multi-dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers||Novo Nordisk A/S|No|Completed|May 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01848002||66917|
NCT01848015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG5003|Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer|Prediction of Recurrence in Advanced Gastric Cancer After Radical Resection by Circulating Tumor Cells （CTCs）||Peking University||Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Probability Sample|The patients with advanced gastric cancer accepted radical resection(D2)|May 2015|May 17, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848015||66916|
NCT01843699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1341/06|Topiramate Trial for Pathological Gamblers|Double-blind Placebo Controlled Topiramate Trial for Pathological Gamblers||University of Sao Paulo||Completed|June 2009|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|21 Years|65 Years|No|||April 2013|April 30, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01843699||67247|
NCT01843946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rulid-2011|Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome|||The Catholic University of Korea||Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|||Male|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|75|April 2013|April 30, 2013|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01843946||67228|
NCT01843959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREC008|Abu Dhabi Diabetes and Obesity Study|Abu Dhabi Diabetes and Obesity Study (ADOS) - A Study on the Aetiology and Associated Risk Factors of Patients With Obesity/Diabetes Within the Emirati Population.||Imperial College London Diabetes Centre||Recruiting|March 2013|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|5 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Imperial College London Diabetes Centre, Abu Dhabi.|April 2013|April 7, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01843959||67227|
NCT01847638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT-2013|Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery|Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery|QD|Discover Vision Centers|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01847638||66945|
NCT01843634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 63137|Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia|A Pilot Study to Evaluate the Safety and Preliminary Evidence of a Therapeutic Effect of ODSH (2-0, 3-0, Desulfated Heparin) in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia||Cantex Pharmaceticals|Yes|Completed|August 2013|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||August 2015|March 22, 2016|April 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843634||67252|
NCT01843673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11639|Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer|Image-Guided Adaptive Radiotherapy for Head And Neck Cancer: Patient Image Acquisition||Virginia Commonwealth University|Yes|Active, not recruiting|January 2009|July 2016|Anticipated|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|21 Years|N/A|No|||February 2016|February 19, 2016|April 26, 2013||No||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01843673||67249|
NCT01844206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL3857|Two Dose Epidural Morphine for Post-cesarean Analgesia|Two Dose Epidural Morphine for Post-cesarean Analgesia||Columbia University|No|Terminated|June 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|45 Years|No|||November 2015|November 19, 2015|April 29, 2013|Yes|Yes|Slow recruitment of subjects|No|October 16, 2015|https://clinicaltrials.gov/show/NCT01844206||67208|
NCT01843868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLG SC03|Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP|A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP.||Australasian Leukaemia and Lymphoma Group|Yes|Not yet recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|130|||Both|18 Years|N/A|No|||April 2013|April 28, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01843868||67234|
NCT01843881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007667|The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass|The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass||Mayo Clinic|No|Completed|March 2012|December 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|April 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843881||67233|
NCT01844193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJO-NMES-12|Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients|A 12-Month Prospective, Post-Market Study of Early Postoperative Compex® Rehab NMES Use in Total Knee Arthroplasty Patients||Orthopaedic Research Foundation|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|45 Years|75 Years|No|||March 2015|March 4, 2015|January 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844193||67209|
NCT01845636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6577|Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil|Olfactory Deficits in Mild Cognitive Impairment as a Predictor of Improved Cognition on Donepezil||New York State Psychiatric Institute|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|55 Years|95 Years|No|||August 2015|August 27, 2015|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845636||67098|
NCT01845935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/15|Cryoablation of Venous Vascular Malformations|Cryoablation of Venous Vascular Malformations Located in Soft Tissues|CRYOMAV|University Hospital, Bordeaux|Yes|Active, not recruiting|April 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01845935||67075|
NCT01846312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4074|An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes|The Longitudinal Diabetes Biomarker Study: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes||Novo Nordisk A/S|No|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Blood sampling for biomarkers. A portion of each sample collected will be tested for five      different islet autoantibodies (presence and precise titers). The remaining portion of each      sample will be coded and then assessed for autoantibody isotypes, phenotyping of peripheral      blood mononuclear cells (PBMC), and profiling of cytokines, and pharmacogenetic markers.|Both|4 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Subjects who are at risk for developing T1D either by genetic testing or due to family        history and identified with one or more islet autoantibodies).|September 2015|September 22, 2015|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846312||67046|
NCT01846325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|046401|The Effects of Administration of Combined Docosahexaenoic Acid and Vitamin E Supplements on Spermatogram and Seminal Plasma Oxidative Stress in Infertile Men With Asthenozoospermia|||National Nutrition and Food Technology Institute||Completed|December 2013|May 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|180|||Male|20 Years|45 Years|No|||June 2015|June 14, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846325||67045|
NCT01846624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0022|Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia||Stanford University||Recruiting|June 2013|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|60 Years|N/A|No|||September 2013|September 14, 2013|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846624||67022|
NCT01846637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013|Two or Five cm From Pylorus During Laparoscopic Sleeve Gastrectomy|Comparative Study Between Two and Five cm Resection During Laparoscopic Sleeve Gastrectomy||Mansoura University||Completed|June 2010|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||May 2013|May 2, 2013|February 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01846637||67021|
NCT01846910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:118|Prepare to Quit - A Clinical Trial to Help People Quit Smoking in a Community Dental Clinic Setting|Prepare to Quit - A Randomized Clinical Trial to Help People Quit Smoking in a Community Dental Clinic Setting||University of Manitoba|No|Recruiting|October 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846910||67001|
NCT01846923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51657MoH|B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals|Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major||Aghia Sophia Children's Hospital of Athens|Yes|Active, not recruiting|October 2010|||February 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Both|18 Years|60 Years|No|||May 2013|May 1, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01846923||67000|
NCT01855048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL200-1A|A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers||Intron Biotechnology, Inc.|Yes|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01855048||66378|
NCT01855282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-MSPREIT|Assessment of an Intervention to Prevent Obesity and Diabetes in Latino Farm Workers|Pasos Saludables: A Pilot Intervention to Prevent Obesity and Diabetes Among Latino Farm Workers|Pasos|University of California, Davis|No|Completed|April 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|254|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01855282||66360|
NCT01847183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA019671|Evaluation of an School-based Alcohol Prevention Program for Middle School Students|Evaluation of an Intranet-Based Alcohol Prevention Program in Middle School|AlcoholINET|Oregon Research Institute|No|Active, not recruiting|November 2012|June 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2300|||Both|12 Years|16 Years|No|||January 2016|January 25, 2016|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01847183||66980|
NCT01847456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB 997 A01 WP7|Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity|Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity||University Hospital Tuebingen||Completed|April 2013|||November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 20, 2013|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01847456||66959|
NCT01855815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-CA-1600|Hemolung RAS Registry Program|HL-CA-1600, Hemolung RAS Registry. A Retrospective Registry Involving Voluntary Reporting of De-identified, Standard of Care Data Following the Commercial Use of the Hemolung Respiratory Assist System (RAS)||Alung Technologies|No|Enrolling by invitation|April 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|99|||Both|18 Years|99 Years|No|Non-Probability Sample|Severe COPD or ARDS|December 2015|December 28, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855815||66319|
NCT01855828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305012136|Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer|Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer||Yale University|Yes|Recruiting|September 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855828||66318|
NCT01856075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanofi-EFFECT-AF|Effectiveness Study of Atrial Fibrillation|Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation|EFFECT-AF|La-ser Europe Limited|Yes|Completed|October 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|1015|||Both|18 Years|N/A|No|Non-Probability Sample|This is an international observational multicentre study to be conducted in the following        four countries: Germany, Spain, Italy and USA. Patients will be will be recruited from        cardiology clinics, both hospital and non-hospital based, depending on particulars of        treatment pathway of ppAF patients in each country.|September 2015|September 7, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01856075||66299|
NCT01843712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HabeatWP31|Eating in the Absence of Hunger and Caloric Compensation in Preschool Children, Link With Parental Feeding Practices|Study of Eating in the Absence of Hunger and of Caloric Compensation in French Children, and of Their Relationships With Parental Feeding Practices|HabEatWP31|Centre des Sciences du Goût et de l'Alimentation|Yes|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|236|||Both|2 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population was composed of 236 children aged 2 to 7 years-old|April 2013|April 30, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01843712||67246|
NCT01843972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.1|Safety of Single Rising Doses and Relative Bioavailability of BI 691751|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 691751 in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Design (Part I) and Investigation of Relative Bioavailability of BI 691751 Given as Tablet and Oral Solution to Healthy Male Subjects in an Open, Randomised, Single-dose, Single Period Parallel Group Design (Part II).||Boehringer Ingelheim||Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|10||Actual|81|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 29, 2013||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01843972||67226|
NCT01872767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-0003|Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure|Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure Admitted in Liver Specialty ICU (Intensive Care Unit)- An Observational Study||Institute of Liver and Biliary Sciences, India|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|522|||Both|18 Years|65 Years|No|Probability Sample|Tertiary Care Center.|November 2014|May 23, 2015|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01872767||65022|
NCT01872780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-101|Identification of Null Allelic Variant of CYP2C8 In A Korean Population|The Effect of CYP2C8 E274Q, a Novel 23452 G>T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population||Inje University|No|Completed|August 2008|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01872780||65021|
NCT01843660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016117|An Efficacy and Safety Study of Tramadol Hydrochloride-Paracetamol in Treatment of Moderate to Severe Acute Neck-Shoulder Pain and Low Back Pain|The Clinical Efficacy and Safety Study of Tramadol Hydrochloride - Paracetamol Tablets in the Treatment of Moderate to Severe Acute Neck-shoulder Pain and Low Back Pain in Orthopaedics Outpatient or Emergency Setting||Xian-Janssen Pharmaceutical Ltd.|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1059|||Both|18 Years|65 Years|No|||June 2013|June 18, 2013|April 26, 2013|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01843660||67250|Results are reported for 'number of participants who required additional dosage administration' instead of 'time to achieve analgesic effect' due to change in planned analysis.
NCT01844518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-301|Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)|A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)||Bristol-Myers Squibb|Yes|Active, not recruiting|June 2013|March 2019|Anticipated|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|187|||Both|2 Years|17 Years|No|||February 2016|February 23, 2016|April 29, 2013|Yes|Yes||No|February 23, 2016|https://clinicaltrials.gov/show/NCT01844518||67184|
NCT01843907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-118|Patient Participation in Prevention of Loss of Functions|Cross-sectorial Patient Participation in Prevention of Loss of Functions in Older Short-stay Medical Patients||Herlev Hospital|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01843907||67231|
NCT01844479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00059211|Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer|Multi-material, Layer, and Density Insoles for a Patient-specific Approach to Shear and Pressure Reduction in the Treatment and Prevention of Diabetes-related Foot Ulcer||University of Michigan|No|Completed|December 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01844479||67187|
NCT01844492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13020304|Improving Patient and Family Centered Care in Advanced Critical Illness|Improving Patient and Family Centered Care in Advanced Critical Illness|PARTNER|University of Pittsburgh|Yes|Recruiting|April 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01844492||67186|
NCT01844765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2203|Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.|A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib|Dialog|Novartis|Yes|Active, not recruiting|August 2013|October 2020|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Both|1 Year|18 Years|No|||January 2016|January 25, 2016|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844765||67165|
NCT01845649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-08112|Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia|A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women With Dyspareunia||Warner Chilcott|No|Completed|April 2013|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|550|||Female|35 Years|N/A|No|||February 2015|February 24, 2015|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845649||67097|
NCT01845662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-13-ZIV|Non-traumatic Rupture of the Spleen. Can Splenectomy be Applied Selectively?|Non-traumatic Rupture of the Spleen. Can Splenectomy be Applied Selectively?||Ziv Hospital|No|Active, not recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|1 Year|N/A|No|Non-Probability Sample|Patients in Ziv Hospital referred to the surgical department with acute onset abdominal        pain or CT findings of splenic rupture without a history of trauma|April 2013|April 29, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01845662||67096|
NCT01845948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND789|Effectiveness of a Parental Training Programme to Enhance Parent-child Relationship and Reduce Harsh Parenting Practices and Parental Stress in the Preparation of Children for Transition to Primary School|Effectiveness of a Parental Training Programme to Enhance Parent-child Relationship and Reduce Harsh Parenting Practices and Parental Stress in the Preparation of Children for Transition to Primary School: A Randomized Controlled Trial||The University of Hong Kong|Yes|Completed|March 2009|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|142|||Both|N/A|N/A|No|||April 2013|April 30, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01845948||67074|
NCT01845961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15912|Effect of Galantamine on Short-term Abstinence|Repurposing Cholinesterase Inhibitors for Smoking Cessation||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|107|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845961||67073|
NCT01846338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB1010505|The Effect of「GTT-EGCG」on Acne Women|The Effect of「GTT-EGCG」on Acne Women||National Yang Ming University|Yes|Enrolling by invitation|October 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846338||67044|
NCT01846351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC270608|Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes|Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.||New England Retina Associates|Yes|Completed|July 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|16|||Both|58 Years|90 Years|No|Non-Probability Sample|age-related macular degeneration|May 2013|May 1, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846351||67043|
NCT01846650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPTB-1.1|A Bioequivalence Study of Capecitabine Tablets|A Bioequivalence Study of Capecitabine Tablets in Patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 28, 2013|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846650||67020|
NCT01846663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFHE4043|The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy||Valeant Pharmaceuticals International, Inc.|Yes|Recruiting|April 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846663||67019|
NCT01846936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE1012-001|Disconnection Technique With a Bronchial Blocker for Improving Lung Deflation|A Randomized, Prospective Trial Comparing Double-lumen Tube and Bronchial Blocker With or Without Modified Disconnection Technique||Ajou University School of Medicine|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|16 Years|N/A|No|||June 2015|June 22, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01846936||66999|
NCT01855295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00036763|Protein Supplementation in Dialysis Patients|Protein Supplementation in Dialysis Patients||University of Utah|No|Completed|November 2009|||December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01855295||66359|
NCT01855308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD 307021|Single Site Robotic Cholecystectomy in Non Selected Patients|Single Site Robotic Cholecystectomy in Non Selected Patients|SSRC|University of California, Davis|No|Enrolling by invitation|January 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are referred to the surgery program with non-emergency gallbladder        disease, for which cholecystectomy is indicated, will be given the opportunity to        participate. Referred patients typically come from the primary care setting. The        demographic composition of the study population will depend in the patient referred to the        program.|May 2013|May 15, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855308||66358|
NCT01855529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000227-40|ROPI Study : Ropivacaine Interest in Postsurgical Pain After Mastectomy|ROPI Study: Evaluation of the Interest of Ropivacaine Streaming in Postoperative Pain After Mastectomy.|ROPI|Centre Jean Perrin|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855529||66341|
NCT01855841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemin_AP|Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis|Prevention of Post-ERCP Acute Pancreatitis by Heme-oxygenase Activation Through the Administration of Hemin : a Prospective, Randomized Double Blind Controlled Trial||Erasme University Hospital|No|Recruiting|April 2012|May 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|284|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01855841||66317|
NCT01856088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scitech 004|DESTINY TRIAL (Inspiron x Biomatrix)|Stents Coated With the Biodegradable Polymer on Their Abluminal Faces and Elution of Sirolimus Versus Biolimus Elution for the Treatment of de Novo Coronary Lesions - Destiny Trial||Scitech Produtos Medicos Ltda|Yes|Active, not recruiting|May 2013|February 2018|Anticipated|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|December 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01856088||66298|
NCT01856101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO2012-01|Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy|A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.|BEZ235|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|February 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|December 10, 2012||No|Novartis decided to stop the marketing of BEZ235|No||https://clinicaltrials.gov/show/NCT01856101||66297|
NCT01843725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mom1-AD12|Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers|Modulation of Metabolic Index in Tailoring Treatment of Incurable Metastatic ColoRectal Cancer (CRC) Program 1.|MOMENTUM1|Jules Bordet Institute|No|Active, not recruiting|September 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||September 2015|March 4, 2016|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01843725||67245|
NCT01843738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI64498|Radiation Use During Vemurafenib Treatment|||University of Utah|Yes|Not yet recruiting|August 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843738||67244|
NCT01872520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-Pharmacy-001|Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study|Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study||Peking University Third Hospital|Yes|Completed|June 2012|September 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30180|||Both|N/A|N/A|No|Non-Probability Sample|Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in china(including        the inpatient and the outpatient(only in some hospitals which can get the information))|October 2015|October 26, 2015|April 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01872520|2 Weeks|65041|
NCT01844804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5371001|A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study of PF-06438179 and Infliximab Sourced From US and EU Administered to Healthy Volunteers||Pfizer|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|146|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844804||67162|
NCT01844219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-059-001|Accuracy of Pre-existing Risk Scoring Models for Predicting Acute Kidney Injury in Patients Who Underwent Aortic Surgery Using a Gray Zone Approach|Accuracy of Pre-existing Risk Scoring Models for Predicting Acute Kidney Injury in Patients Who Underwent Aortic Surgery Using a Gray Zone Approach||Samsung Medical Center|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|375|||Both|N/A|N/A|No|Non-Probability Sample|Those who underwent elective or emergency aortic surgery in Samsung Medical Center during        between 2004 and 2010.|December 2013|December 24, 2013|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01844219||67207|
NCT01844232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arbaclofen OS440-3003|One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity|A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity||Osmotica Pharmaceutical Corp.|Yes|Completed|April 2013|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|70 Years|No|||May 2015|May 14, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844232||67206|
NCT01844505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-067|Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)|A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma||Bristol-Myers Squibb|Yes|Active, not recruiting|May 2013|October 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|915|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844505||67185|
NCT01845675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEPNET|Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor|||Peking Union Medical College Hospital||Recruiting|April 2013|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845675||67095|
NCT01845974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5387|Atrial Pressure Electrophysiology Pilot Study|Atrial Pressure Electrophysiology Pilot Study: Comparison of High vs. Low Flow Catheters During Radiofrequency Catheter Ablation (RFCA) for Atrial Fibrillation (AF).|APES|Advocate Health Care|Yes|Suspended|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 1, 2013||No|Interim evaluation of data after internal safety report from sponsor.|No||https://clinicaltrials.gov/show/NCT01845974||67072|
NCT01845987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100950|A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis||Janssen Pharmaceutical K.K.|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|20 Years|N/A|No|||October 2015|October 26, 2015|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845987||67071|
NCT01854229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAS-01|Prometra Post-Approval Study|A Prospective, Non-randomized, Open-label, Multicenter Study to Evaluate the Long-term Safety of the Prometra Programmable Pump System||Flowonix Medical|No|Recruiting|June 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|22 Years|N/A|No|||February 2016|February 2, 2016|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854229||66441|
NCT01854476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SionM1|Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze|A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopan™) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis.||Sion Microtec Ltd.|No|Recruiting|October 2013|August 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854476||66422|
NCT01854489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifabupre|Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine|Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-phase Cross-over Study in Healthy Subjects.||Turku University Hospital|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01854489||66421|
NCT01854775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0106|Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children|A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children||Gilead Sciences|Yes|Active, not recruiting|May 2013|December 2021|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|6 Years|17 Years|No|||December 2015|December 21, 2015|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854775||66399|
NCT01856114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0043|Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Buccal Tablets (FBT) for Exercise Induced Breakthrough Dyspnea||M.D. Anderson Cancer Center|Yes|Recruiting|May 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856114||66296|
NCT01855542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0059|The Aim of This Investigation is to Compare the Influence of 0.9% Saline and Plasmalyte Solution on Acid-base Balance and Electrolytes in Healthy Patients Undergoing Major Spine Surgeries.|||Yonsei University|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01855542||66340|
NCT01855555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0688|The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI/CT in One Korean University Hospital: Prospective Study|||Yonsei University|No|Completed|November 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2948|||Both|N/A|18 Years|No|Non-Probability Sample|Children requiring sedation for MRI/CT|January 2015|January 18, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855555||66339|
NCT01852435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-001|R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B|A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B||Ruijin Hospital|Yes|Recruiting|May 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|16 Years|80 Years|No|||September 2015|September 29, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852435||66579|
NCT01852708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-014-NPT|Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood|Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood||Natera, Inc.|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|The mother and biological father (if available) will be asked to provide a blood sample.      There will be 4 tubes collected from the mother (approximately 3 tablespoons) and 1 tube      collected from the father (2 teaspoons).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|October 2015|October 15, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01852708||66558|
NCT01856348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHA-11-VID/FOL-01|Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers|Effects of Vitamin D3 (1,25 Dihydroxyvitamin D3) on Pharmacokinetics and Absorption of Folic Acid and Fexofenadine in Healthy Volunteers||University of Zurich|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856348||66278|
NCT01872806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC azM/UM NL44004.068.13|Electrophysiological Reactivity Due to Mobile Phone Radiation|Radiation Meter Controlled Electrophysiological Reactivity (EEG and ECG) Due to Mobile Phone Radiation.||Maastricht University Medical Center|Yes|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|93|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01872806||65019|
NCT01872819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8003|Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay|Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay||University of Washington|No|Active, not recruiting|July 2013|||April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01872819||65018|
NCT01847651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOLA-Merz WMDH P39937|Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate|LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial||Imperial College London|Yes|Completed|August 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||May 2013|October 21, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847651||66944|
NCT01847937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-85-13|Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy|Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy||Aarhus University Hospital|Yes|Recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|145|Samples Without DNA|Blood sample less then 250ml to determine Hba1c (blood glucose level).|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|In the 3 year course of the study it is expected to include 90 diabetics with and without        neuropathy, 10 patients with hereditary axonal neuropathy and 10 patients with        demyelinated neuropathy, as well as 35 healthy control subjects. This amounts to a total        of 145 subjects.|January 2016|January 4, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01847937||66922|
NCT01844245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH B-RFA 2013-001|Endobiliary RFA for Unresectable Malignant Biliary Strictures|Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial||Eastern Hepatobiliary Surgery Hospital|No|Recruiting|May 2013|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01844245||67205|
NCT01844258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China3|Modified Surgical Techniques for Pediatric Cataract Treatment|Modified Surgical Techniques for Pediatric Cataract Treatment||Sun Yat-sen University|Yes|Completed|March 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|1 Month|24 Months|No|||December 2015|December 21, 2015|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01844258||67204|
NCT01844544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC130061-13CTIL|Drug Related Problems Among Patients With Femoral Neck Fractures in an Orthopedic Ward|Identification and Characterization of Drug Related Problems Among Patients With Femoral Neck Fractures in an Orthopedic Ward||Meir Medical Center|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|||Both|64 Years|N/A|No|Non-Probability Sample|Patients over the age of 65 after a femoral neck fracture that are hospitalized in the        orthopedic department at "Meir" medical center|February 2014|February 24, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844544|7 Days|67182|
NCT01844817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 184|Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer|A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel Combined With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial)|Rainier|SCRI Development Innovations, LLC|No|Completed|August 2013|March 2016|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844817||67161|
NCT01845090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMHLANFGF23|The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23|Compared the Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 With Calcium Carbonate in Hemodialysis Patients||Camillians Saint Mary's Hospital Luodong|Yes|Recruiting|August 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|May 1, 2013|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845090||67140|
NCT01845389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-2013|Comparative Study Between Continuous Epidural Anesthesia And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter|Comparative Study Between Continuous Epidural Anesthesia Using Standard Epidural Catheter And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter In Geriatric Patients Undergoing TURP||Theodor Bilharz Research Institute|No|Completed|June 2013|January 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Male|60 Years|N/A|No|||March 2016|March 9, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01845389||67117|
NCT01853696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0424|Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty|Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty||Cornea Research Foundation of America|Yes|Completed|March 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|167|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|May 8, 2013||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01853696||66482|
NCT01853969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101131|Typing Proficiency Following Carpal Tunnel Release|Typing Proficiency Following Carpal Tunnel Release||Vanderbilt University|No|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|20 Years|70 Years|No|Non-Probability Sample|Vanderbilt Hand & Upper Extremity Center Outpatient Clinic|September 2015|September 15, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01853969||66461|
NCT01854502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IArpalahti2008|Family-based Counseling Models for Young Children|Organizing Family-based Health Promotion for Young Children in Public Dental Service||University of Turku|Yes|Completed|January 2008|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|804|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 11, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01854502||66420|
NCT01854788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uniko2010.01|3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis|A Comparative Study of Three Airway Clearance Techniques With Different Autonomy Degrees in Non Cystic Fibrosis Bronchiectasis: Randomized Cross-over Trial.||Hospital Clinic of Barcelona|No|Completed|September 2010|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01854788||66398|
NCT01855061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35198.041.11|Biomarker Development for Response Prediction by DNA Mutational Analysis|Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions|CPCT-01|UMC Utrecht|Yes|Recruiting|May 2011|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Histological biopsies Blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with a metastatic solid tumor who are eligible for (standard of care) treatment        with irinotecan.|February 2014|February 23, 2014|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01855061||66377|
NCT01852448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009589|Genetics of Insulin and Incretins in Cystic Fibrosis|Evaluation of the Enteroinsular Axis in Cystic Fibrosis||Children's Hospital of Philadelphia|Yes|Recruiting|May 2013|June 2021|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|2 Years|N/A|No|Probability Sample|Patients with Cystic Fibrosis age >2 yrs|February 2016|February 3, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852448||66578|
NCT01856374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0052|Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study|||Yonsei University|No|Recruiting|August 2011|April 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|N/A|No|||May 2013|May 16, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01856374||66276|
NCT01853241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00031000JHU|Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy|Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy in Patients With Suspected Small Bowel Disease||Johns Hopkins University|No|Terminated|May 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to our center for anterograde augmented enteroscopy for the assessment        of suspected small disease|May 2013|May 13, 2013|May 10, 2013||No|SE system by Spirus Medical withdrawn from market in 2011|No||https://clinicaltrials.gov/show/NCT01853241||66517|
NCT01856361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301013462|Ramipril for the Treatment of Oligospermia|Ramipril for the Treatment of Oligospermia: A Double-Blind Randomized Control Trial||Weill Medical College of Cornell University|Yes|Recruiting|July 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01856361||66277|
NCT01873118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANCC2013-01|READI (Readiness Evaluation And Discharge Interventions) Study|READI (Readiness Evaluation And Discharge Interventions): Implementation as a Standard Nursing Practice for Hospital Discharge|READI|Marquette University|No|Recruiting|January 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|24000|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01873118||64995|
NCT01873131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001538|A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn|Preventing Growth of Hemangioma Tumors in Newborn: A Prospective Randomized Clinical Study||Massachusetts General Hospital|No|Recruiting|February 2011|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|126|||Both|N/A|3 Months|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01873131||64994|
NCT01843920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11095 Gas Duration|The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble|A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Scleral Buckling and Pneumatic Retinopexy.||Wills Eye|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01843920||67230|
NCT01843933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112009471|Detecting Post-Operative Respiratory Depression in Children|Detecting Post-Operative Respiratory Depression in Children: Are Our Current Standards Good Enough?||Yale University|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|211|||Both|1 Year|20 Years|No|||January 2016|January 26, 2016|March 29, 2013||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01843933||67229|
NCT01844531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.6|Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets|Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)||Boehringer Ingelheim||Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|April 29, 2013||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01844531||67183|
NCT01844830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 3-04|Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients|A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients||St. Renatus, LLC|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|3 Years|17 Years|No|||May 2015|May 27, 2015|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844830||67160|
NCT01845103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLT1101.003-M|The PEARL 8.0 Post-Approval Study|Post-Approval Study of the PEARL 8.0 Handpiece for Transmyocardial Revascularization (TMR) With the Cardiogenesis Holmium:YAG Laser System||Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.|No|Terminated|September 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|A minimum of two and a maximum of five study sites will be selected for participation. The        sites (surgeons) will be selected first from those that participated in the PEARL Study        TMR 05-001. If additional sites are required, selection will be made for the sites        (surgeons) to be familiar with TMR and thoracoscopic surgery. Sites will be asked to offer        all patients eligible for stand-alone thoracoscopic TMR, who meet the inclusion/exclusion        criteria, the opportunity to participate in the current study.|August 2015|August 28, 2015|April 30, 2013||No|Due to the product being discontinued|No|August 28, 2015|https://clinicaltrials.gov/show/NCT01845103||67139|
NCT01845402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091125|Chronic Kidney Disease in Teenagers With Congenital Cardiac Disease|The Prevalence of Chronic Kidney Disease at Adolescence in Patients With Congenital Cardiac Disease, Having Undergone Corrective Surgery During Childhood|PRECARDIO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2013|May 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|sample of blood and urine|Both|10 Years|15 Years|No|Non-Probability Sample|Patients 10 to 15 years old with congenital cardiac diseases|February 2016|February 23, 2016|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01845402||67116|
NCT01845415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13AP011|Intervention to Prevent Fall Injuries to Young Children in the Home|A Community-Based Intervention to Prevent Fall Injuries to Young Children in the Home||University of Guelph|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|100000|||Both|16 Years|75 Years|No|||December 2015|December 21, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01845415||67115|
NCT01853982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-009|Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia|A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia||Cubist Pharmaceuticals LLC|No|Terminated|July 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 13, 2013|Yes|Yes|Terminated to focus on a larger study within the clinical development program.|No|April 19, 2015|https://clinicaltrials.gov/show/NCT01853982||66460|This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia.
NCT01853995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLMGM: Mechanism of Correction|Mechanism of Class II Correction With Fixed Lingual Mandibular Growth Modificator (FLMGM)|Class II Division 1 Malocclusions Treated With Fixed Lingual Mandibular Growth Modificator (FLMGM): The Mechanism of Sagittal Occlusal Correction|FLMGM|Damascus University|Yes|Completed|May 2009|December 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|11 Years|16 Years|No|||March 2014|March 21, 2014|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853995||66459|
NCT01854242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300312|Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease|Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease: A New Comorbidity or Secondary Consequence||University of Florida|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Glycogen storage disease (GSD) type I is an autosomal recessive disorder of glycogen        metabolism that affects approximately 1 in 100,000 live births (1). Mutations of the genes        that encode glucose 6-phosphatase [type Ia] (2) and glucose 6-phosphate translocase [type        Ib] (3) have been isolated. Diagnosis is usually suspected in infants with fasting        hypoglycemia, lactic acidosis, hyperlipidemia, and hepatomegaly. Other features include        stomatitis, growth retardation, osteopenia and hyperuricemia.|December 2014|December 22, 2014|May 10, 2013||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01854242||66440|
NCT01855321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174-2010|Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes|Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes||University of Florida|No|Completed|August 2010|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|30 Years|65 Years|No|||June 2015|June 25, 2015|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01855321||66357|
NCT01855880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.005.01|Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients|Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)|AbGn-168H|AbGenomics B.V Taiwan Branch|No|Completed|May 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|75 Years|No|||April 2015|April 22, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855880||66314|
NCT01855568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-006|Methotrexate Treatment for Ectopic Pregnancy|Comparison of Two-dose and Single-dose Methotrexate Protocol for Ectopic Pregnancy: a Randomized Controlled Trial||CHA University|No|Completed|May 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Female|19 Years|55 Years|No|||January 2016|January 21, 2016|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855568||66338|
NCT01855854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-036|Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH|A Phase II, Prospective Study for Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression or Positive FISH as Second-line Treatment||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|May 2013|November 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||April 2015|July 14, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855854||66316|
NCT01856400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-053|Ventricular Arrhythmias in Uremic Cardiomyopathy|Understanding the Molecular Basis of Ventricular Arrhythmias in Uremic Cardiomyopathy||Northwell Health|Yes|Completed|January 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|36|Samples With DNA|blood vessel tissue sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hemodialysis Patients Uremic Patients Diastolic dysfunction|January 2014|January 31, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856400||66274|
NCT01852461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|685.114A|Perfusion Index Variability in Respiratory Distress Syndrome|Perfusion Index Variability in Preterm Infants Treated With Two Different Natural Surfactants for Respiratory Distress Syndrome||Dr. Sami Ulus Children's Hospital|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|N/A|3 Days|Accepts Healthy Volunteers|||May 2013|May 10, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01852461||66577|
NCT01852474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-p-000629|Effects of Transcranial Direct Current Stimulation (tDCS) and Motor Learning in Children With Cerebral Palsy (CP)|Effects of tDCS in Cortical Plasticity and Motor Learning in Children With Cerebral Palsy||Spaulding Rehabilitation Hospital|No|Recruiting|May 2013|||January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|8 Years|18 Years|No|||March 2015|March 4, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852474||66576|
NCT01852955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00078104|Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery|Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery||Northwestern University|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Female|18 Years|70 Years|No|||February 2016|February 16, 2016|May 9, 2013|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT01852955||66539|
NCT01853228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102071|A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia||Janssen Research & Development, LLC|Yes|Recruiting|October 2013|December 2019|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|1 Month|18 Years|No|||March 2016|March 21, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01853228||66518|
NCT01853488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010‐13|Bone Strength After Spinal Cord Injury|Impact of Spinal Cord Injury on Bone Strength in Paralysed Extremities.||Swiss Paraplegic Centre Nottwil|No|Completed|October 2010|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|273|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the Swiss Paraplegic Centre Nottwil (in-patient or out-patient).|November 2015|November 25, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01853488||66498|
NCT01873404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103NS201|BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy|SPRINT|Biogen|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||April 2015|August 27, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873404||64974|
NCT01844271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uninove|Low Level Laser Therapy in Muscle Fatigue and Muscle Recovery|Low Level Laser Therapy in Muscle Fatigue and Muscle Recovery After Exercise: What is the Ideal Dose?|LLLT|University of Nove de Julho|No|Completed|May 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|28|||Male|18 Years|35 Years|No|||December 2014|December 4, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01844271||67203|
NCT01844557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0195|Testing Accountability in Patient Adherence|Testing Accountability in Patient Adherence||M.D. Anderson Cancer Center|Yes|Recruiting|May 2013|||May 2017|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|225|||Both|18 Years|N/A|No|Non-Probability Sample|Head and neck cancer patients receiving radiation therapy at MDACC clinics.|October 2015|October 13, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844557||67181|
NCT01844843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T121E4|Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES|Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months|DISCOVERY123|Terumo Europe N.V.|Yes|Active, not recruiting|January 2014|March 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844843||67159|
NCT01844856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-008|Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections|IGNITE1|Tetraphase Pharmaceuticals, Inc.|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|541|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 29, 2013|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01844856||67158|
NCT01845116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omegaven 04-10-18B|Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Use of a Fish Oil-Based Intravenous Lipid Emulsion (Omegaven®) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury||Carolinas Healthcare System|Yes|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|18 Years|No|||June 2014|June 26, 2014|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845116||67138|
NCT01845428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0789|Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome|Assessment of the Efficacy of Lipid-lowering Agents to Limit Lipid Oxidation and Activation of the Clotting System in Patients With the Nephrotic Syndrome: a Pilot Study.|OxLDL|University of North Carolina, Chapel Hill|No|Recruiting|May 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|70 Years|No|||March 2016|March 5, 2016|April 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845428||67114|
NCT01854515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391387|Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients|||Isfahan University of Medical Sciences||Recruiting|March 2012|||September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|65 Years|No|||May 2013|May 14, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854515||66419|
NCT01854801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100120|Evaluation of a Specialized Therapeutic Care of Patients Presenting an Intolerance Attributed to Electromagnetic Fields|Evaluation of a Specialized Therapeutic Care of Patients Presenting an Idiopathic Environmental Intolerance Attributed to Electromagnetic Fields|IEI-CEM|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2012|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01854801||66397|
NCT01855594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN302|Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain|Double Blind, Randomized Placebo-controlled Clinical Study Evaluating the Efficacy of Lithium Carbonate in the Treatment of Neuropathic Pain of Patients With Spinal Cord Injury||China Spinal Cord Injury Network|Yes|Completed|May 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01855594||66336|
NCT01856127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VII-IT-09|Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?|A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction||Thomas Jefferson University|No|Recruiting|January 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856127||66295|
NCT01856387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zekai Tahir Burak|The Effect of neutrophil-to Lymphocyte Ratio in Preeclampsia- Eclampsia|the Predictive Value of neutrophil-to Lymphocyte Ratio on Preeclampsia- Eclampsia||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|May 2013|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|600|None Retained|whole blood, serum, white cells|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|first trimester pregnant|May 2013|March 16, 2014|May 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856387||66275|
NCT01856153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-044|Maximizing the Anti-inflammatory Effects of Strawberry Bioavailability|Maximizing the Anti-inflammatory Effects of Strawberries: Understanding the Influence of Strawberry Anthocyanin Bioavailability in the Context of Meals||Institute for Food Safety and Health, United States|No|Active, not recruiting|July 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01856153||66293|
NCT01856166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9147|PIEB-PCEA Versus CEI-PCEA for Labor Analgesia in Nulliparous|Programmed Intermittent Epidural Bolus Coupled With PCEA (PIEB-PCEA) Versus Continuous Epidural Infusion Coupled With PCEA (CEI-PCEA) for Labor Analgesia in Nulliparous: Effects on Labor Outcomes|PIEB|University Hospital, Montpellier|No|Recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Female|18 Years|44 Years|No|||May 2013|January 8, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01856166||66292|
NCT01852487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pumpkin0912|Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia|||Dream Plus||Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 10, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852487||66575|
NCT01852500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-Plac 01|Are Newborns Conscious of the Placebo Effect? Result From an RCT in Osteopathy|||European Institute for Evidence Based Osteopathic Medicine||Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|29 Weeks|37 Weeks|Accepts Healthy Volunteers|||May 2013|May 9, 2013|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852500||66574|
NCT01844947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUCOG III|Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract|An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract|VINSOR|Karolinska University Hospital|Yes|Recruiting|June 2012|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|80 Years|No|||June 2015|June 26, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01844947||67151|
NCT01852721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-213 A1|Effects of the Mediterranean Diet on Cardiovascular Risk Profile in Men and Women (ALIMED)-Part 2|Gender Differences in Response to the Mediterranean Diet-Part 2||Laval University|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Both|25 Years|50 Years|No|||September 2013|September 5, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01852721||66557|
NCT01853501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|973 Project No. 2010CB945 104|Effects of ADSC Therapy in Women With POF|Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure||Nanjing University|Yes|Enrolling by invitation|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Female|20 Years|39 Years|No|||November 2013|November 4, 2013|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853501||66497|
NCT01873157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI 190|Bortezomib in Late Antibody-mediated Kidney Transplant Rejection|Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)|BORTEJECT|Medical University of Vienna|Yes|Active, not recruiting|December 2013|February 2017|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||March 2016|March 14, 2016|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01873157||64992|
NCT01844024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tasksharing PAC|Task Sharing to Improve Post Abortion Care at District Health Care Level- Trial in Uganda|Task Sharing to Improve Post Abortion Care at District Health Care Level- Trial in Uganda||Karolinska Institutet|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1010|||Female|15 Years|N/A|No|||August 2014|August 27, 2014|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01844024||67222|
NCT01844284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-301|AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population|A Clinical Evaluation of AVJ-301 (Absorb™ BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population|ABSORB JAPAN|Abbott Vascular|Yes|Active, not recruiting|April 2013|May 2019|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Both|20 Years|N/A|No|||December 2015|December 3, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844284||67202|
NCT01852669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS001|Adjunct Inversion for Lower Pole Stone|A Prospective, Randomized, Double Blind, Controlled Study Comparing Extracorporeal Shock Wave Lithotripsy (ESWL) With and Without Simultaneous Adjunct Controlled Inversion Therapy in the Treatment of Lower Pole Caliceal Stone||Monash University|No|Completed|January 2002|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|75 Years|No|||April 2015|April 17, 2015|May 2, 2013||No||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01852669||66561|
NCT01844570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEADER|Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research|Levamlodipine Maleate (Xuanning) or Amlodipine Besylate (Norvasc) for Treatment of Hypertension: A Comparative Effectiveness Research|LEADER|Peking University First Hospital|No|Active, not recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|45 Years|N/A|No|Probability Sample|100 eligible sites(including primary care clinic and tertiary hospitals) over the country        will participate. Each center will collect patients who fit the recruitment standard in        chronological order.|April 2013|April 30, 2013|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01844570||67180|
NCT01844583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14015|Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib|Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas||Millennium Pharmaceuticals, Inc.||Active, not recruiting|July 2013|March 2015|Anticipated|November 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844583||67179|
NCT01853202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1220|EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial|EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial|EXPECT|University of Vermont|Yes|Completed|March 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|79 Years|No|||December 2014|December 3, 2014|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01853202||66520|
NCT01853462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNF-123-BAL-SPR|Rehabilitation Study Comparing Two Exercise Programs for Ankle Sprains|Comparison of Two Exercise Programs -Proprioceptive Neuromuscular Facilitation and Balance- for the Rehabilitation of Ankle Sprains.||Aristotle University Of Thessaloniki|Yes|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|No|||October 2015|October 26, 2015|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853462||66500|
NCT01845129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPH_01EO0801|Impact of Transcranial Direct Current Stimulation of the Motor Cortex on Language Functions in Residual Aphasia|Impact of Transcranial Direct Current Stimulation of the Motor Cortex on Language Functions in Residual Aphasia|StimRAph|Charite University, Berlin, Germany|No|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|80 Years|No|||April 2013|April 30, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845129||67137|
NCT01853436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC 2012.04.01|Impact of Acellular Dermal Matrix in Reduction of Surgical Complexity of Breast Reconstructions With Implants|Impact of Acellular Dermal Matrix in Reduction of Surgical Complexity of Breast Reconstructions With Implants||LifeCell|No|Recruiting|March 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01853436||66502|
NCT01855581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0923|The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI/CT in One Korean University Hospital: Retrospective Study|||Yonsei University|No|Recruiting|November 2012|October 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3739|||Both|N/A|18 Years|No|Non-Probability Sample|Children requiring sedation for MRI/CT|May 2013|May 13, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855581||66337|
NCT01855867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUAD|HIV Non-Occupational Post-Exposure Prophylaxis|A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|QUAD|Fenway Community Health|Yes|Recruiting|May 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855867||66315|
NCT01855360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWHAMY1|Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy|An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy.||Brigham and Women's Hospital|No|Active, not recruiting|June 2013|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||January 2016|January 11, 2016|March 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01855360||66354|
NCT01855893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/00203|Auto-acupressure: Effectiveness for Diminishing Neck Pain of Benign Origin|Effectiveness of the Auto-acupressure for Diminishing Neck Pain of Benign Origin||Gerencia de Atención Primaria, Madrid|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01855893||66313|
NCT01856140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-RM-SGChung-ASC-01|Treatment of Tendon Injury Using Mesenchymal Stem Cells|Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study|ALLO-ASC|Seoul National University Hospital|No|Recruiting|May 2013|April 2014|Anticipated|January 2014|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|19 Years|90 Years|No|||November 2013|November 22, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01856140||66294|
NCT01844388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10077X-001|A Study to Compare a New Eye Drop Formulation With Refresh Contacts®|||Allergan|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|365|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 25, 2014|April 29, 2013|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01844388||67194|
NCT01844401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-102|Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma|Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|April 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|4 Years|11 Years|No|||November 2013|November 13, 2013|April 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844401||67193|
NCT01844700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-403A|1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain|1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain||Northwell Health|Yes|Terminated|July 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Both|13 Years|18 Years|No|||January 2016|January 6, 2016|April 29, 2013|No|Yes|very slow recruitment, no sufficient results|No|August 19, 2015|https://clinicaltrials.gov/show/NCT01844700||67170|
NCT01844960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1592|Laparoscopic Single Incision -Vs- Multiple Incision Gastric Band Surgery|A Prospective Double Blinded Randomised Control Trial Comparing Laparoscopic Single Incision Versus Multiple Incision Adjustable Gastric Band Surgery in Patients With Morbid Obesity|SIMIS|King's College Hospital NHS Trust|No|Completed|November 2011|October 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||April 2013|September 1, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01844960||67150|
NCT01845233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1142(REK)|Monitoring of Non-invasive Ventilation|Monitoring of Non-invasive Ventilation||Oslo University Hospital|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic hypoventilation treated with long term mechanical ventilation|August 2014|August 22, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01845233||67129|
NCT01845532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0101|Analgesic Effect of Trigger Point Injection and EMLA for Shoulder Pain in Laparoscopic Hysterectomy|||Yonsei University|No|Completed|April 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|75|||Female|20 Years|70 Years|No|||February 2014|February 4, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845532||67106|
NCT01852734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-2013|Uterine Fibroid Embolization- Long Term Follow up and Technical Perspectives|Uterine Fibroid Embolization- Long Term Follow up and Technical Perspectives||Odense University Hospital|Yes|Recruiting|November 2013|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|52 Years|No|||September 2015|September 17, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01852734||66556|
NCT01852968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301M26901|Hippocampal Metabolism and Function in Patients With Type 1 Diabetes|Hippocampal Metabolism and Function in Patients With Type 1 Diabetes||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|blood smaple will be drawn measurement of blood glucose, HgbA1C, insulin and hormone levels|Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|University of Minnesota Endocrine Clinic, univeristy of Minnesota community and a registry        of volunteers maintained by the investigators.|February 2016|February 22, 2016|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852968||66538|
NCT01873430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000629-30|The Sun Protective Effect of Melatonin|The Sun Protective Effect of Melatonin: a Randomized, Placebo-controlled, Double-blind Study on Healthy Volunteers||Herlev Hospital|No|Completed|May 2013|August 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|22|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873430||64972|
NCT01852682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA1303|A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia|||Kissei Pharmaceutical Co., Ltd.||Completed||||March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A||||November 2014|November 11, 2014|May 7, 2013||||No||https://clinicaltrials.gov/show/NCT01852682||66560|
NCT01852942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111M06585|Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV|Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|September 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852942||66540|
NCT01852929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1944|Sleep Apnea and Visual Perceptual Skill Learning|The Effect of Sleep Apnea on Sleep Dependent Learning Using the Visual Discrimination Task.||University of North Carolina, Chapel Hill|No|Completed|November 2009|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|50 Years|No|||May 2013|May 13, 2013|April 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852929||66541|
NCT01853475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_13_002|Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State|Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS Formulation in the Fasted State in Healthy Volunteers||Medicines for Malaria Venture|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|May 10, 2013|Yes|Yes||No|March 27, 2015|https://clinicaltrials.gov/show/NCT01853475||66499|
NCT01853449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02-M16-13B Fentanyl|Inhaled Fentanyl Citrate & Dyspnea|Effects of Inhaled Fentanyl Citrate on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction||McGill University|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|14|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853449||66501|
NCT01853709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT-END-DIG-2012|Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients|Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized Controlled Trial||Corporacion Parc Tauli|No|Not yet recruiting|May 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01853709||66481|
NCT01855074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014845|An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders|Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone||Janssen-Cilag Ltd.|No|Completed|November 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|March 22, 2013|Yes|Yes||No|May 27, 2013|https://clinicaltrials.gov/show/NCT01855074||66376|The planned sample size was not reached and a high dropout rate of participants was observed. Due to the high number of protocol violations, analysis was performed as intention-to-treat instead of per protocol as was planned.
NCT01855087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R875|Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes|A Study of Safety and Efficacy of Sitagliptin Added to Insulin Therapy in the Treatment of Type 2 Diabetes in Kanagawa|ASSIST-K|Kanagawa Physicians Association||Completed||||March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|20 Years|N/A||Non-Probability Sample|One-thousand Japanese patients with type 2 diabetes|May 2013|May 13, 2013|May 10, 2013||||No||https://clinicaltrials.gov/show/NCT01855087||66375|
NCT01848093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160/08|Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation|Molekularbiologische Eigenschaften Des Sputums während Einer Pulmonalen COPD Exacerbation|mucinCOPDex|Philipps University Marburg Medical Center|No|Enrolling by invitation|December 2008|July 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|15|Samples Without DNA|sputum|Both|18 Years|75 Years|No|Probability Sample|COPD patients Stadium 2-3 during pulmonary exacerbation|May 2013|May 6, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848093||66910|
NCT01855607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL2664|Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy|Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial||Columbia University|No|Recruiting|August 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855607||66335|
NCT01855906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103307|The Impact of Total Knee Arthroplasty Surgical Technique on Coronal Plane Motion and PatelloFemoral Articulation|The Impact of Total Knee Arthroplasty Surgical Technique on Coronal Plane Motion and PatelloFemoral Articulation||Lawson Health Research Institute|No|Withdrawn|September 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||March 2016|March 9, 2016|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855906||66312|
NCT01855919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14376|A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain|Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan||Eli Lilly and Company|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|458|||Both|20 Years|79 Years|No|||June 2015|June 26, 2015|May 14, 2013|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01855919||66311|
NCT01845246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM-COL-MC-12|Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin|Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin.||Parc de Salut Mar|No|Recruiting|January 2012|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01845246||67128|
NCT01845259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1 antipsychotics|Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?|Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial|GREAT|Psychiatric Centre Rigshospitalet|Yes|Active, not recruiting|April 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|April 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845259||67127|
NCT01845545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoN-J18102012|Study of Effect of Microfinance on Under 5 Health in Rural India|A Feasibility and Pilot Study of the Effects of Microfinance on Under 5 Mortality and Nutrition, Amongst the Very Poor in India||University of Nottingham|Yes|Recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|800|||Both|N/A|5 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01845545||67105|
NCT01845558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS651/12|Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise|Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise - a Randomized, Two-stage, Double-blind, Placebo-controlled Cross-over Trial|2012-005003-40|Mucos Pharma GmbH & Co. KG|Yes|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01845558||67104|
NCT01845831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063642|Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes|Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes||Emory University|Yes|Active, not recruiting|August 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|280|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845831||67083|
NCT01845207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-123314|Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions|Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions||Jewish General Hospital|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Tissue specimens|Both|70 Years|N/A|No|Non-Probability Sample|In-patients and out-patients referred for surgical or transcatheter aortic valve        replacement.|April 2015|April 1, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01845207|1 Year|67131|
NCT01845220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81276|Prevention of Alcohol Intolerance|||Johns Hopkins University|No|Active, not recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845220||67130|
NCT01845519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 121775|Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors|Feasibility of a Technology-based Intervention to Reach Inactive Breast Cancer Survivors and Objectively Track Step Activity.||UNC Lineberger Comprehensive Cancer Center|No|Completed|July 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|90|||Female|40 Years|70 Years|No|||December 2013|May 28, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01845519||67107|
NCT01840228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301148|Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor|Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor|PAL|Washington University School of Medicine|Yes|Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01840228||67513|
NCT01854021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wuhan university|Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer|Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer||Wuhan University||Recruiting|May 2013|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|50 Years|70 Years|No|||May 2013|May 16, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01854021||66457|
NCT01853215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-04|Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum|A Follow-Up Volunteer Study Evaluating Intraosseous Vascular Access Infusion in the Sternum Using the EZ-IO T.A.L.O.N.Intraosseous System.||Vidacare Corporation|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 9, 2013|May 9, 2013|No|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01853215||66519|
NCT01854528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-862|A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults|A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon a-2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE-II)|MALACHITE II|AbbVie|No|Completed|June 2013|July 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|65 Years|No|||November 2015|January 14, 2016|May 13, 2013||No||No|November 24, 2015|https://clinicaltrials.gov/show/NCT01854528||66418|
NCT01853722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-150-0002|A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers|A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers||Deacon Biosciences, Inc.|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853722||66480|
NCT01854008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WALURB-01|Urban Walking Circuits|Improving Physical Activity in Patients With Severe Chronic Obstructive Pulmonary Disease With Urban Walking Circuits||Hospital de Mataró|No|Completed|April 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|82|||Male|50 Years|85 Years|No|||May 2013|May 12, 2013|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01854008||66458|
NCT01854255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPAC-GA01|Intraperitoneal Aerosol Chemotherapy in Gastric Cancer|Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial|PIPAC-GA01|Ruhr University of Bochum|No|Recruiting|November 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01854255||66439|
NCT01855113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-031-CERES-D|COMPARISON OF THE PERCEPTION OF PAIN BETWEEN ORTHODONTIC TREATMENT WITH Invisalign ® AND TREATMENT WITH BRACKETS|COMPARISON OF THE PERCEPTION OF PAIN BETWEEN ORTHODONTIC TREATMENT WITH Invisalign ® AND TREATMENT WITH BRACKETS||Université de Montréal|No|Not yet recruiting|June 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|12 Years|30 Years|No|Non-Probability Sample|Patients are recruited from the Department of Orthodontics at the University of Montreal.|March 2013|May 13, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01855113||66373|
NCT01854840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10069|Betamethasone and Severity of Hyaline Membrane Disease|Betamethasone and Severity of Hyaline Membrane Disease in the Newborn Premature|b-Mhyalines|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Plasma samples will be collected. The effect of covariates as genetic polymorphism for      CYP3A4, CYP3A5 and P-glycoprotein will be tested to explain the variability of placental      transfer|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women (at one-term >27 PMA) that received at least a first injection of Celesten        in the prevention of hyaline membrane disease|December 2015|January 5, 2016|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01854840||66394|
NCT01855334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK096189|L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD|A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease|LAST-D|Brigham and Women's Hospital|Yes|Withdrawn|September 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|No|||January 2015|January 6, 2015|May 14, 2013|Yes|Yes|change of funding and redesign before trial initiated|No||https://clinicaltrials.gov/show/NCT01855334||66356|
NCT01855347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-NICU/NIRS|Evaluation of Abdominal Tissue Oxygenation in Premature Infants Using Near Infrared Spectroscopy|Evaluation of Abdominal Tissue Oxygenation in Premature Infants Using Near Infrared Spectroscopy||Brigham and Women's Hospital|No|Not yet recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|3 Weeks|No|Non-Probability Sample|Preterm infants (Premature Infants) from 32 to 36 weeks of post menstrual age hospitalized        in the Neonatal Intensive Care Unit (NICU) at Brigham and Women's Hospital.|August 2015|August 23, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855347|3 Months|66355|
NCT01844141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC11022013|Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy|Effectiveness of the Lavage With 70% Alcohol Plus 0.5% Chlorhexidine Compared to 70% Alcohol for Chemical Matricectomy in the Surgical Treatment of Ingrown Toenails||Universidad Complutense de Madrid|Yes|Recruiting|January 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2013|April 30, 2013|February 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844141||67213|
NCT01844414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10000358|UCLA-Amity Parolee Health Promotion Study|Health Promotion Coaching/Vaccine for Homeless Parolees||University of California, Los Angeles|Yes|Completed|February 2010|May 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|600|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01844414||67192|
NCT01843816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tragus-wall|The Effect of Body Shape on Tragus-Wall Measurement|The Effect of Body Shape on Tragus-Wall Measurement||Vakif Gureba Training and Research Hospital|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|465|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects between 18-65 ages who have no disorder that may disturb posture or erect        position (inflammatory diseases, kyphosis, scoliosis, joint deformities)|September 2013|September 30, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01843816||67238|
NCT01844115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-07|Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder|A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.||Forest Laboratories|No|Completed|April 2013|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|415|||Both|18 Years|70 Years|No|||February 2015|February 27, 2015|April 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844115||67215|
NCT01844128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0257-12mmc|The Effect of Weight Loss on Ovarian Reserve|||Meir Medical Center|Yes|Recruiting|May 2013|||April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|43 Years|No|Non-Probability Sample|Overweight women with infertility|April 2013|June 10, 2013|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01844128|1 Year|67214|
NCT01845844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28713|Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab|Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial)|ROTATE|Southeast Retina Center, Georgia|No|Recruiting|April 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845844||67082|
NCT01846221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL4101|Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain|Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia|Clon/Fent|Columbia University|No|Recruiting|October 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846221||67053|
NCT01846533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212080RINC|Osteoprosis in Type 2 Diabetic Patients- a Cohort Study|Osteoprosis in Type 2 Diabetic Patients- a Cohort Study||National Taiwan University Hospital|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1200|Samples Without DNA|CBC/DC & BCS|Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|type 2 diabetic patients|July 2015|July 28, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846533||67029|
NCT01845805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12138|A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)|A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|October 2013|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01845805||67085|
NCT01845818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-990|Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium|Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium|SPACTIVE|AbbVie|No|Active, not recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|50 Years|No|Probability Sample|Patients with Ankylosing Spondylitis and Psoriatic Arthritis followed in university or        peripheral hospitals or peripheral private practices with experience in Ankylosing        Spondylitis and Psoriatic Arthritis care.|January 2016|January 25, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01845818||67084|
NCT01846156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52103|New Magnesium Sulphate Protocol for Pre-eclampsia|The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial||Cairo University|Yes|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|240|||Female|18 Years|42 Years|No|||August 2014|August 21, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846156||67058|
NCT01846169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUN-12-2011-004|Study to Improve Healthy Eating for At-Risk Older Adults|Healthy Eating for At-Risk Older Adults (HERO)||Boston Medical Center|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|101|||Both|55 Years|N/A|No|||August 2014|August 21, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846169||67057|
NCT01852695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122173|Family Integrated Care in the NICU|A Family Integrated Care Model For The Neonatal Intensive Care Unit: A Cluster Randomised Controlled Trial|FICare|Mount Sinai Hospital, Canada|No|Active, not recruiting|March 2013|December 2015|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|720|||Both|N/A|33 Weeks|No|||October 2015|October 19, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01852695||66559|
NCT01854034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-484|Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR|Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR||Massachusetts General Hospital|Yes|Recruiting|July 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|May 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854034||66456|
NCT01854268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32-2013|Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults|Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults||University of Florida|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|May 10, 2013|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01854268||66438|
NCT01854541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMRTP|Visual Management for the Radiotherapy Process|Visual Management for the Radiotherapy Process|VMRTP|Maastricht Radiation Oncology|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|10000|||Both|N/A|N/A|No|Non-Probability Sample|All patients treated with radiotherapy|April 2015|April 9, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01854541|3 Months|66417|
NCT01854554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0097|Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)|A Prospective Phase II Randomized Trial to Compare Intensity Modulated Proton Radiotherapy (IMPT) vs. Intensity Modulated Radiotherapy (IMRT) for Newly Diagnosed Glioblastoma (WHO Grade IV)||M.D. Anderson Cancer Center|Yes|Recruiting|May 2013|||May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854554||66416|
NCT01854814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAIN|The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients|The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study|MAIN|Nanfang Hospital of Southern Medical University||Recruiting|July 2013|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Both|16 Years|70 Years|No|||October 2015|October 8, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01854814||66396|
NCT01854567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-AB006|P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies|A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment||Mesoblast, Ltd.|Yes|Recruiting|February 2013|July 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|N/A|65 Years|No|||March 2016|March 15, 2016|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854567||66415|
NCT01847547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.157|Comparative Effectiveness of Oral Anticoagulants|Comparative Effectiveness of Oral Anticoagulants: A Cohort Study||Boehringer Ingelheim||Completed|April 2013|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|5982|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age and older with non-valvular AF initiating oral anticoagulation        therapy|April 2014|June 3, 2014|April 18, 2013||||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01847547||66952|These first data are limited by small sample size, short follow up, few events resulting in wide confidence intervals. No comparative conclusions are possible. After the feasibility analysis future analysis will increase patient numbers and follow up
NCT01847560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.177|Anticoagulant Utilization Pattern|A Description of Warfarin and NOAC Utilization Patterns Including Initiation, Switching, and Discontinuation||Boehringer Ingelheim||Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age and older with non-valvular AF at risk for stroke treated with        oral anticoagulation|March 2016|March 8, 2016|April 18, 2013||||No||https://clinicaltrials.gov/show/NCT01847560||66951|
NCT01855126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG042602|Individually Tailored Lighting System to Improve Sleep in Older Adults|Individually Tailored Lighting System to Improve Sleep in Older Adults||Rensselaer Polytechnic Institute|No|Recruiting|March 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01855126||66372|
NCT01844726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU77430|Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness|Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals||Northwestern University|No|Completed|May 2013|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844726||67168|
NCT01844999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-363|Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks|Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks||Dana-Farber Cancer Institute|Yes|Recruiting|September 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|625|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01844999||67147|
NCT01845272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CCA_101|Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate|Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers.|CCA|CJ HealthCare Corporation|No|Active, not recruiting|April 2013|August 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01845272||67126|
NCT01844713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00069552|Evaluation of Sun Protection Education for Kidney Transplant Recipients|Evaluation of Sun Protection Education for Kidney Transplant Recipients||Northwestern University|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|153|||Both|18 Years|85 Years|No|||July 2014|July 30, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844713||67169|
NCT01844973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US05|Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients|||Maruho North America Inc.|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844973||67149|
NCT01844986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0818C00001|Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.|SOLO-1|AstraZeneca|Yes|Active, not recruiting|August 2013|January 2022|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|397|||Female|18 Years|130 Years|No|||February 2016|February 23, 2016|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844986||67148|
NCT01845857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07212010-6585|A National Study of the Chronic Disease Self-Management Program|A National Study of the Chronic Disease Self-Management Program||Stanford University|No|Completed|August 2010|April 2013|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1170|||Both|18 Years|N/A|No|||August 2010|April 30, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01845857||67081|
NCT01846234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salt|Sodium Intake in Multiple Sclerosis|Effect of Sodium Intake in Multiple Sclerosis Disease Activity|SALT|Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia|No|Completed|November 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|Samples Without DNA|Blood, urine|Both|18 Years|50 Years|No|Non-Probability Sample|A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were        recruited from the MS clinic at FLENI by attending neurologists. A second group of 52        relapsing-remitting MS patients was recluted later.|October 2013|October 21, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846234||67052|
NCT01846247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version3 25April08|A Very Early Rehabilitation Trial|A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.|AVERT|Neuroscience Trials Australia|Yes|Completed|June 2006|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2014|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846247||67051|
NCT01846806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00570|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy||New York University School of Medicine|Yes|Terminated|September 2012|March 2016|Actual|March 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 1, 2013|No|Yes|PI no longer at NYUMC|No||https://clinicaltrials.gov/show/NCT01846806||67008|
NCT01846182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-016-12F|Research Examining Gulf War Illness in Our Nations Service Members|RCT of Duloxetine & Pregabalin for the Treatment of Gulf War Illness in Veterans|REGIONS|VA Office of Research and Development|Yes|Recruiting|June 2015|July 2020|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|43 Years|70 Years|No|||December 2015|December 2, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846182||67056|
NCT01846195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zynex500|Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Adult Patients During a Blood Draw||Zynex Monitoring Solutions|No|Recruiting|September 2012|||August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01846195||67055|
NCT01846208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 04-1271|Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy|Oral Desensitization to Egg With Subsequent Induction of Sustained Unresponsiveness for Egg-Allergic Children Using Baked Egg or Egg Oral Immunotherapy (OIT)|CoFAR7|Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|July 2013|September 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|3 Years|16 Years|No|||February 2016|February 25, 2016|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846208||67054|
NCT01846520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08176|Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers|A Randomized Trial of a Family Caregiver Palliative Care Intervention||City of Hope Medical Center|Yes|Recruiting|October 2013|||October 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846520||67030|
NCT01853735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0077|Enteral Feeding in the Post-Injury Open Abdomen|||Denver Health and Hospital Authority|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|||Both|18 Years|98 Years|No|Probability Sample|All patients requiring an open abdomen following trauma will be prospectively followed.|October 2015|October 20, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01853735||66479|
NCT01853748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-048|T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)|A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)||Dana-Farber Cancer Institute|Yes|Recruiting|May 2013|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01853748||66478|
NCT01853514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-020|Fresh Fruit and Vegetable Purchasing Behavior|Assessing Consumer Behavior Regarding the Purchasing of Fresh Produce in Low-income Population||Institute for Food Safety and Health, United States|No|Active, not recruiting|February 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|510|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Low income equal or less than 250% above the poverty level.|October 2015|October 5, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01853514||66496|
NCT01854281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1929/12|Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure|Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure||University Hospital, Motol|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|47|||Both|19 Years|N/A|No|Probability Sample|Adult scuba divers with either a previously diagnosed patent foramen ovale (PFO) or after        a catheter-based PFO closure. Consecutive divers that undergo a simulated dive in        hyperbaric chamber will be recruited.|October 2013|October 28, 2013|May 10, 2013||No||No|July 8, 2013|https://clinicaltrials.gov/show/NCT01854281||66437|
NCT01854047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI12544|An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma||Sanofi|Yes|Completed|June 2013|April 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|776|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854047||66455|
NCT01854827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P007 PRIME|Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia|A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia|PRIME|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|120 Days|No|||September 2014|August 27, 2015|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854827||66395|
NCT01855100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16852|Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)|Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto® Following an Acute Deep Vein Thrombosis (DVT)|BOX-DVT|Bayer|No|Completed|July 2013|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory or hospitalized patients coming from the vascular diseases clinic of the        participating hospitals|December 2015|December 14, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01855100||66374|
NCT01847274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-30-5011-C|A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer|A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.||Tesaro, Inc.|Yes|Active, not recruiting|June 2013|October 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|490|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847274||66973|
NCT01848106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG1-CLIN310|A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI|A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention|Regulate|Regado Biosciences, Inc.|Yes|Terminated|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3232|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|May 2, 2013|Yes|Yes|Clinical Hold|No||https://clinicaltrials.gov/show/NCT01848106||66909|
NCT01847807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS2304|The Organ Protection of Astragalus in Subjects With Metabolic Syndrome|The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome||LanZhou University|Yes|Completed|January 2011|||June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|80 Years|No|||October 2015|October 7, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847807||66932|
NCT01847820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-ROM-001|Clinical Evaluation of the AmniSure ROM Test|Clinical Evaluation of the AmniSure ROM Test||QIAGEN Gaithersburg, Inc|No|Recruiting|August 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|240|||Female|18 Years|50 Years|No|Non-Probability Sample|The study population will be women presenting with signs, symptoms or suspicion of        membrane rupture at 11 to 42 weeks gestation.|December 2015|December 17, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847820||66931|
NCT01845012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00307-36|Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis|Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis|HDQ200|Association Pour L'utilisation Rein Artificiel Région Lyonnaise|No|Terminated|July 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|April 11, 2013||No|Study has been prematurely halted because of failure of patient recruitment.|No||https://clinicaltrials.gov/show/NCT01845012||67146|
NCT01845285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 001|A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System|A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients With Severe Aortic Stenosis|DISCOVER|Direct Flow Medical, Inc.|Yes|Recruiting|March 2013|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|71 Years|N/A|No|Non-Probability Sample|The Direct Flow Medical Transcatheter Aortic Valve System is intended for use in patients        with severe aortic valve stenosis who require replacement of their native aortic valve but        are extreme risk candidates for open surgical replacement. This is in accordance with the        product Intended Use in the commercial Instructions for Use.|February 2016|February 23, 2016|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845285|3 Years|67125|
NCT01845571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.12.2011|Retinal Detachment - Demographic and Clinical Survey|Long-term Anatomic and Funcional Succes After Surgery in Eyes With Retinal Detachment||Medical University of Vienna|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|400|Samples Without DNA|vitreous body samples and blood plasmsa for evaluation of cytocines levels.|Both|18 Years|N/A|No|Non-Probability Sample|People will be selected from the surgery database of Ass.Prof.PD.Dr. Stefan Sacu and Prof.        Dr. Michael Georgopoulos from the Medical University of Vienna.|December 2015|December 11, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01845571||67103|
NCT01847105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-GHS Comfort Study|Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions|Assessing Patient Comfort in Silicone Hydrogel Contact Lenses When Cleaned and Stored in Two Different Multi-Purpose Disinfecting Solutions||Hom, Milton M., OD, FAAO|No|Enrolling by invitation|June 2013|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 25, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01847105||66986|
NCT01847118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-63-001|A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors|A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|April 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|74 Years|No|||July 2014|March 22, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847118||66985|
NCT01846793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX02-0022|Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)|Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart||Nymox Corporation|No|Recruiting|April 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Male|45 Years|N/A|No|||April 2014|April 1, 2014|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846793||67009|
NCT01847066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMA 013-001|Epidermal Delivery of Ani-Aging Ingredients|Fractional Erbium 2940nm Laser & Impact US for Trans-Epidermal Delivery of Cosmetic Anti-Aging Ingredients for Wrinkles, Acne Scars and Pigmented Skin: A Randomized Split Face & Dorsal Hand Side by Side Study||Alma Lasers Inc.|No|Enrolling by invitation|May 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|21|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01847066||66989|
NCT01847079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 38603.078.11|Procalcitonin to Guide Obtaining Bloodcultures in the ICU Intensive Care Infection Score|Procalcitonin to Guide Obtaining Bloodcultures in the ICU. Intensive Care Infection Score.|ProBIC/ICIS|Erasmus Medical Center|Yes|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1130|||Both|18 Years|N/A|No|||October 2014|October 13, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01847079||66988|
NCT01853761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-001|Microcurrent and Aerobic Exercise Effects on Abdominal Fat|Microcurrent and Aerobic Exercise Effects on Abdominal Fat||Escola Superior de Tecnologia da Saúde do Porto|Yes|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|45|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01853761||66477|
NCT01846117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHPD 186153|Once-Daily Oral Dose of BeneFlax to Healthy Older Adults|Once-Daily Oral Dose of BeneFlax to Healthy Older Adults|MOD|University of Saskatchewan|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||August 2013|January 6, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846117||67061|
NCT01846130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-191|Preserving Muscle Mass and Function in Bedridden Older Adults|Preserving Muscle Mass and Function in Bedridden Older Adults|EBR|The University of Texas Medical Branch, Galveston|Yes|Recruiting|January 2013|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Anticipated|96|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01846130||67060|
NCT01846143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15832|Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies|Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59)|Mel59|University of Virginia|Yes|Active, not recruiting|May 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846143||67059|
NCT01853774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA162393-02|Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations|Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations||Arizona State University|No|Recruiting|April 2012|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1840|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01853774||66476|
NCT01846468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHW090X2101|An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction|A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction||Novartis|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|205|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846468||67034|
NCT01846741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epilepsy (E)-37|VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)|VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia|E-37|Cyberonics, Inc.|No|Completed|July 2013|August 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||October 2015|October 26, 2015|April 15, 2013|No|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01846741||67013|The small sample size and the absence of randomization did not allow conclusions about whether the AutoStim alone, or the combination of AutoStim and traditional VNS therapy modes, or some other factor was a cause of the observed beneficial effects.
NCT01846754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302037RINC|Prevalence of Fatigue in Hemodialysis Patients|Prevalence of Fatigue and Its Related Factors in Hemodialysis Patients||National Taiwan University Hospital|Yes|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|Samples Without DNA|human blood: 5c.c.|Both|20 Years|90 Years|No|Non-Probability Sample|ESRD patients receiving regular hemodialysis thrice or twice per week|April 2014|April 17, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846754||67012|
NCT01854294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALS 001|GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)|GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)|GALS|Genervon Biopharmaceuticals, LLC|No|Completed|August 2013|July 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01854294||66436|
NCT01847859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2013-2|Pocket-size Ultrasound by Nurses in Cardiothoracic Post-operative Patients|Feasibility and Reliability of Routine Ultrasound Examination Performed by Nurses in Cardiothoracic Post-operative Patients||Levanger Hospital|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|59|||Both|N/A|N/A|No|||January 2014|January 13, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847859||66928|
NCT01843842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-ER-007|Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children||Materia Medica Holding|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|3 Years|18 Years|No|||April 2013|August 25, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01843842||67236|
NCT01844154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204059RIC|Fracture and Fall Prevention in Elderly With Osteoporosis|Fracture and Fall Prevention in Elderly With Osteoporosis: Long-term Follow up||National Taiwan University Hospital|Yes|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|osteopenia (-2.5 < t-score < -1.0) or osteoporosis (t-score <-2.5)|March 2016|March 2, 2016|October 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01844154||67212|
NCT01843829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/VCC/0009|A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer|A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer|NeoSCOPE|Velindre NHS Trust|Yes|Recruiting|October 2013|May 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01843829||67237|
NCT01845337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005282-12|Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine|Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno|TOFFEE|University of Edinburgh|Yes|Not yet recruiting|June 2013|||August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|May 1, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845337||67121|
NCT01845597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAKO-03|Survivorship and Outcomes of Robot Assisted Medial Partial Knee Replacement|Survivorship and Outcomes of Robotically Assisted Medial UKA||Northwest Surgical Specialists, Vancouver|No|Active, not recruiting|April 2013|May 2021|Anticipated|May 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|145|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who underwent a MAKOplasty procedure by the investigating surgeon and received a        medial MCK onlay implant.|October 2015|October 8, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845597||67101|
NCT01845298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC114HIV4076|Immune Activation and Drug Absorption in HIV-Infected Patients|||Drexel University||Not yet recruiting|June 2014|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|21 Years|45 Years|No|||May 2014|May 1, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845298||67124|
NCT01845311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT4000|ReZolve2 Clinical Investigation|RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold|RESTORE II|REVA Medical, Inc.|Yes|Active, not recruiting|April 2013|September 2018|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01845311||67123|
NCT01845584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-08/E-01|Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.||Nihon Pharmaceutical Co., Ltd|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|20 Years|N/A|No|||October 2014|June 11, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01845584||67102|
NCT01846819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00843|Factors Associated With End Stage Liver Disease|Factors Associated With End Stage Liver Disease||New York University School of Medicine|Yes|Terminated|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients experiencing cirrhosis of the liver|March 2016|March 1, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846819||67007|
NCT01846832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100981|A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection|A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection||Janssen-Cilag International NV|Yes|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|232|||Both|18 Years|70 Years|No|||October 2015|October 16, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846832||67006|
NCT01846546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-TBI 10JC|Cerebrospinal Fluid Endostatin/Collagen XVIII Concentrations in Patients With Severe Traumatic Brain Injury|Dynamic Changes of Cerebrospinal Fluid Endostatin Concentrations in Patients With Severe Traumatic Brain Injury.||Shanghai Sixth People's Hospital|No|Completed|October 2006|April 2008|Actual|October 2007|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Cerebrospinal fluid|Both|16 Years|82 Years|No|Probability Sample|Of the 30 patients with severe TBI, twenty were male and ten were female. The patients'        age ranged from 16 to 82 years, with mean age of 51.1 years. The mechanisms of trauma        included motor vehicle collisions, falls, heavy strikes (patients who were hit by heavy        objects such as bricks, sticks, or falling objects) and assaults. Types of lesions, as        evidenced by radiologic and neurologic symptoms or signs, included cerebral        contusions/lacerations, intracranial hematomas, brain stem injury and diffuse axonal        injury.|April 2013|May 1, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846546|6 Months|67028|
NCT01846559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17062|The Antiplatelet and Immune Response Trial|Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|June 27, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846559||67027|
NCT01846572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUB-Neuro-2013-clopi|Clopidogrel Response in Acute Ischemic Stroke|Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke. The Bochumer CRISP Study|Bo-CRISP|Ruhr University of Bochum|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|159|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an acute ischemic stroke admitted to our hospital and treated with        clopidogrel|April 2013|May 2, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846572||67026|
NCT01847664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIT-4/DIV|Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis|A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis||Dr. Falk Pharma GmbH|Yes|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|375|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847664||66943|
NCT01847092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5610C00001|A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria|An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria||Ardelyx|No|Completed|May 2013|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|80 Years|No|||September 2015|September 18, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847092||66987|
NCT01847352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0710|Iron Status and Hypoxic Pulmonary Vascular Responses|Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous Iron||University of Oxford|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847352||66967|
NCT01853254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV17590|A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials|An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols||Hoffmann-La Roche||Completed|September 2003|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|272|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|May 10, 2013|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01853254||66516|
NCT01846767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13CGLU|Exogenous Glucose Oxidation Breath Test|Study of the Metabolism of 13C Labelled Glucose to 13CO2 in Human Breath|EGOBT|National University of Ireland, Galway, Ireland|No|Completed|April 2012|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|46|||Male|35 Years|82 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846767||67011|
NCT01846481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-13-0004|A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse|A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects|RBP-8000|Indivior Inc.|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846481||67033|
NCT01846494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042419|Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)|Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)|CARE-Hep C|Duke University|Yes|Active, not recruiting|April 2013|May 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|113|Samples Without DNA|Plasma, serum, and urine|Both|N/A|N/A|No|Non-Probability Sample|Hepatitis C positive subjects previously exposed to BMS 986094 and Hepatitis C positive        subjects not previously exposed to BMS 986094.|March 2015|March 12, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846494|5 Years|67032|
NCT01847040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0105|Deployment Related Mild Traumatic Brain Injury (mTBI)|Deployment Related Mild Traumatic Brain Injury (mTBI): Incidence, Natural History, and Predictors of Recovery in Soldiers Returning From OIF/OEF||The Defense and Veterans Brain Injury Center|No|Enrolling by invitation|September 2009|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cohort of soldiers returning to Fort Bragg and Fort Carson returning from deployment to        Iraq and Afghanistan. National Guard and Army Reservists serving on Active Duty will also        be included.|May 2013|May 1, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847040||66991|
NCT01847287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TST5|A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years|A Prospective, Observational, Single-blinded, Longitudinal Study of Natalizumab Effect on Brain Atrophy and Disability in Multiple Sclerosis Patients Over 5 Years.|TST|University at Buffalo|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|65 Years|No|Non-Probability Sample|Multiple Sclerosis - relapsing remitting|May 2013|May 6, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847287||66972|
NCT01847300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bchRFADA13012|cSBI-M for Young Military Personnel|Computerized Screening and Brief Intervention for Young Military Personnel||Children's Hospital Boston|No|Withdrawn|September 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|0|||Both|18 Years|25 Years|No|||May 2013|March 18, 2015|May 2, 2013||No|not funded|No||https://clinicaltrials.gov/show/NCT01847300||66971|
NCT01847014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-402|Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument|AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument|SYMPHONYext|Actelion|No|Terminated|September 2013|May 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|May 2, 2013|Yes|Yes|Protocol-defined criterion of macitentan availability achieved.|No||https://clinicaltrials.gov/show/NCT01847014||66993|
NCT01847027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-162|Exercise and NutraStem (NT-020): Effects on Stem Cells|Phase 2 Study of the Effect of a Nutritional Supplement and Exercise on Human Stem Cells||University of North Texas Health Science Center|No|Active, not recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||December 2014|May 26, 2015|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847027||66992|
NCT01843855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000161|The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass|The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass||Mayo Clinic|No|Completed|June 2011|September 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Both|20 Years|65 Years|No|||December 2013|December 3, 2013|April 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01843855||67235|
NCT01844180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2952POU004|A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|RESTORE|Ono Pharmaceutical Co. Ltd|No|Completed|April 2013|||July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|200|||Female|18 Years|65 Years|No|||January 2016|January 26, 2016|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844180||67210|
NCT01844440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/25|Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD|Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD.|HRM RTSIO|University Hospital, Bordeaux|Yes|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|75 Years|No|||July 2014|July 1, 2014|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01844440||67190|
NCT01844427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000520|Memantine Monotherapy for Executive Dysfunction and ADHD|Memantine Monotherapy for Executive Dysfunction and ADHD: A Pilot Study||Massachusetts General Hospital|No|Withdrawn|July 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|45 Years|No|||September 2013|September 23, 2013|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844427||67191|
NCT01850498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1663|Epilepsy Motion Sensing|Motion Sensing Study in Epilepsy Patients||MedtronicNeuro|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with epilepsy referred to epilepsy monitoring unit.|May 2013|May 6, 2013|November 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01850498||66727|
NCT01850511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001362|The Effect of Nasal Hair on Nasal Obstruction|The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction||Mayo Clinic|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 20, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01850511||66726|
NCT01851044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11031|The Effect of Platelet Rich Plasma on Lateral Epicondylitis|The Treatment of Lateral Epicondylitis: the Effect of Platelet Rich Plasma on Healing -- A Randomized Controlled Double-Blinded Trial||University of Tampere|No|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01851044||66685|
NCT01851278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA- 3131- AR|Effectiveness Intraarticular Corticosteroid|Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose||Federal University of São Paulo|Yes|Recruiting|April 2013|April 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2013|May 9, 2013|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01851278||66667|
NCT01852032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221183|Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis|Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis||University of California, Davis|No|Active, not recruiting|November 2010|November 2017|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|112|||Female|35 Years|N/A|No|||December 2015|December 8, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01852032||66610|
NCT01852019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-CAN-13-01|Cangrelor Prasugrel Transition Study|A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.||The Medicines Company|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|12|||Both|18 Years|75 Years|No|||May 2015|May 27, 2015|May 6, 2013|Yes|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01852019||66611|
NCT01852240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perio&ED|Periodontal Disease as a Risk Indicator for Erectile Dysfunction - A Cross-sectional Study on 100 Patients|||Medical University of Vienna||Recruiting|May 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|In the present cross-sectional study 100 male patients with ED will be included. Patients        who visit the urological department (Rudolfstiftung) for ED-treatment will be asked to        participate.|May 2014|May 12, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01852240||66594|
NCT01848340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117008|An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects|An Open Label, Non-Randomized, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Placebo-Controlled, Randomized Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects||ViiV Healthcare|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|May 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01848340||66891|
NCT01848639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCHEMIST|ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial|ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b|ALCHEMIST|University Hospital, Brest|Yes|Recruiting|June 2013|June 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|825|||Both|18 Years|N/A|No|||September 2015|January 13, 2016|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848639||66869|
NCT01848652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.032 - MYLY|Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.|Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.|MYLY|University Hospital, Brest|Yes|Terminated|October 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|May 3, 2013||No|The laboratory's partner on this study decides to terminate the contract with the CHRU Brest,    because of the difficulty of the recruitment.|No||https://clinicaltrials.gov/show/NCT01848652||66868|
NCT01848912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120564-01H|Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)|Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)|THRRIVES|Ottawa Hospital Research Institute|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|Samples Without DNA|blood serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with an expected prolonged period of neutropenia completing bone marrow        transplant (including both allogeneic and autologous) or induction chemotherapy|October 2015|October 21, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01848912||66849|
NCT01849224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCNCS-13-723|Randomized Trial of Exercise on Lower Extremity Edema After Lymphadenectomy in Gynecologic Cancer|Randomized Trial of Pelvic and Lower Extremity Exercise in Patients Who Underwent Pelvic Lymphadenectomy With Lower Extremity Edema-related Symptoms||National Cancer Center, Korea|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849224||66825|
NCT01849705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-298|Melanocortin 4 Receptor Mutations and Obesity-associated Diseases|Mutations in the Melanocortin 4 Receptor and Obesity-associated Diseases|Mc4Obes|University of Copenhagen|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|226|Samples With DNA|Whole blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women aged 18-70 years|May 2013|May 6, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849705||66788|
NCT01837095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL-7|Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer|A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer||Polyphor Ltd.|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|55 Years|No|||February 2016|February 25, 2016|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01837095||67752|
NCT01836835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/465|Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian|Case-cohort Validation Study of Pregnancy Unique Questionnaire of Emesis (PUQE) in Norwegian|PUQE-N|Haukeland University Hospital|No|Completed|May 2013|January 2015|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|69|||Female|16 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hyperemesis patients; recruited from university hospital clinic (normally 60 patients        admitted during 12 months)        Control paitients recruited from primary care/private practice out-patient gynaecologists|March 2015|March 27, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01836835|9 Months|67772|
NCT01844622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-39-H-08|Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying|Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying||Mt. Sinai Medical Center, Miami|Yes|Recruiting|December 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|500|||Both|12 Years|N/A|No|||May 2013|May 8, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844622||67176|
NCT01844635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APBMT AAWG-01|Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA|A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia||Nagoya University|Yes|Recruiting|May 2012|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|N/A|69 Years|No|||April 2015|April 14, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844635||67175|
NCT01844895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-174 Substudy-2|Methotrexate-Inadequate Response Autoinjector Device Sub Study|Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|MTX-IR|Bristol-Myers Squibb|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|April 5, 2013|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01844895||67155|
NCT01845168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120034|Prevention of Gastric Ulcer Bleeding by Using "Computer-alert" in General Practice|Prevention of Peptic Ulcer Bleeding Related to the Use of NSAIDs and Aspirin by Using "Computer-alert" - a Randomized Study in General Practice||Odense University Hospital|Yes|Recruiting|April 2013|April 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 28, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01845168||67134|
NCT01845493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0056|Sulforaphane Supplementation in Atopic Asthmatics|Sulforaphane Supplementation in Atopic Asthmatics|brasma|University of North Carolina, Chapel Hill|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|No|||March 2016|March 7, 2016|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845493||67109|
NCT01845766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0710|Effects of Early Exercise Rehabilitation on Long-term Functional Recovery in Patients With Severe Sepsis|||Yonsei University|No|Recruiting|February 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|220|||Both|20 Years|N/A|No|||April 2013|May 1, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845766||67088|
NCT01850199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINEDiE|Intelligent and Educational System for Gestational Diabetes Management|||Corporacion Parc Tauli|No|Enrolling by invitation|January 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Female|18 Years|46 Years|No|||January 2014|January 28, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01850199||66750|
NCT01850212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-104-0423|A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects|A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects||Gilead Sciences|No|Completed|February 2013|October 2014|Actual|October 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|476|||Both|50 Years|N/A|No|Probability Sample|Study population of ≥ 50 year old male subjects and post-menopausal female subjects|October 2014|October 30, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01850212||66749|
NCT01851070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-RA001|A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor|A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor.||Mesoblast, Ltd.|Yes|Recruiting|May 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||June 2015|November 24, 2015|April 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851070||66683|
NCT01851304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKMPON-013|Metabolic Effect of New Foods Through Gut-brain Axis|Checking Melanoidins and Bitter Compound Satiating Efficiency Through Evaluation of Human Gut-brain Response to Novel-food Ingestion|CHECKMATE|Federico II University|Yes|Completed|September 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851304||66666|
NCT01851564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74570|RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage|Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study.|SOV|University College, London|Yes|Recruiting|August 2012|February 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|136|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01851564||66646|
NCT01851772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRP-0010|Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer|Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer||Xoft, Inc.|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|N/A|N/A|No|||July 2015|July 17, 2015|May 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851772||66630|
NCT01848119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-01|Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery?|Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery? A Randomised, Double-blind, Placebo Controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|May 2013|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|204|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848119||66908|
NCT01852253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31262.042.10|Implant Surface Decontamination With 2 % Chlorhexidine in Peri-implantitis Treatment|Clinical and Microbiological Evaluation Implant Surface Decontamination With 2% Chlorhexidine in the Surgical Treatment of Peri-implantitis; a Double Blind Controlled Randomized Clinical Study||University Medical Center Groningen|No|Completed|March 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|N/A|N/A|No|||May 2013|May 10, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01852253||66593|
NCT01852266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 285|Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|October 2013|||July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|51|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||July 2015|July 10, 2015|May 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852266||66592|
NCT01848353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20 MD000528-RP2|Financial Incentives to Exercise for Adolescents|Incentivizing Behavior: Promoting More Physical Activity in American Indian Youth|MOVE|University of Oklahoma|No|Recruiting|May 2013|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|8||Anticipated|185|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01848353||66890|
NCT01848925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGSC-003|Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients|A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE™ at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.||Prolong Pharmaceuticals|No|Completed|May 2013|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|N/A|No|||December 2014|December 2, 2014|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01848925||66848|
NCT01848938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisareNorr301811|Treatment of Stress Urinary Incontinence Via Smartphone|Treatment of Stress Urinary Incontinence Via Smartphone||Umeå University|No|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Female|18 Years|N/A|No|||May 2015|May 28, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01848938||66847|
NCT01849185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc120213ctil|Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia|||Meir Medical Center|No|Not yet recruiting|May 2013|March 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01849185||66828|
NCT01849198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMMneck|Accelerometry at the Neck: Comparison With m. Adductor Pollicis Stimulation|||Kreiskrankenhaus Dormagen|No|Recruiting|April 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2013|March 30, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01849198||66827|
NCT01849497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120348|Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen|A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a Prefilled Syringe or a Prefilled Autoinjector/Pen||Amgen|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|80 Years|No|||September 2015|September 11, 2015|April 1, 2013|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT01849497||66804|
NCT01849731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0096-2010|Effectiveness of Two Interventions in Patients With Low Educational Level With Diabetes to Reduce Inequalities in Self-care Behavior|||Andalusian School of Public Health|No|Completed|February 2011|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|184|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849731||66786|
NCT01836861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-05|IPI-145 ADME and Absolute Bioavailability Study|A Phase 1, Open-Label Study of the Absorption, Distribution, Metabolism and Excretion of 14C-Labeled IPI-145 and the Absolute Bioavailability of IPI-145 in Healthy Subjects||Infinity Pharmaceuticals, Inc.|No|Completed|March 2013|May 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836861||67770|
NCT01837407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen8871|Reconstruction of a Neurocutaneous Defect of the Proximal Phalanx With a Heterodigital Arterialized Nerve Pedicle Flap|||The Second Hospital of Tangshan|Yes|Completed|March 2008|March 2013|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|9|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||June 2011|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837407||67729|
NCT01844323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481022|A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract|A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study In Healthy Volunteers To Estimate The Effect Of Active Pharmaceutical Ingredient Particle Size And Lubrication On The Bioavailability Of A Single 125 Mg Dose Of Palbociclib (PD-0332991) Administered Under Fasted Conditions||Pfizer|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|April 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844323||67199|
NCT01844336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR003|PBASE System Idiopathic Rhinitis Clinical Investigation|||Chordate Medical|No|Completed||||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|65 Years|No|||September 2014|September 8, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01844336||67198|
NCT01844921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_02|High Resolution Optical Imaging of the Esophagus Using the Nvision Volumetric Laser Endomicroscopy (VLE™) Imaging System|High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging System||NinePoint Medical|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and females >18 years of age undergoing esophagogastroduodenoscopy (EGD).|May 2013|May 16, 2013|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844921||67153|
NCT01844908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2013.032|Electroacupuncture for Postoperative Ileus After Laparoscopic Rectal Cancer Surgery|Can Electroacupuncture Prevent Prolonged Ileus After Laparoscopic Surgery for Mid and Low Rectal Cancer? A Prospective Study With Matched Historical Controls||Chinese University of Hong Kong|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||February 2014|February 10, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01844908||67154|
NCT01845506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2166|The Application of a Wireless Sensor Technology for Vital Statistics in CHILDREN AND ADULTS|||Lawson Health Research Institute|No|Not yet recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01845506||67108|
NCT01845753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LS-DK-02|Molecular Screening for Lynch Syndrome in Denmark|Molecular Screening for Lynch Syndrome in Denmark||Vejle Hospital|No|Active, not recruiting|October 2012|October 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5000|||Both|N/A|N/A|No|Non-Probability Sample|All colorectal cancer patients in Denmark|November 2015|November 25, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845753||67089|
NCT01849900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70315|Preconception Reproductive Knowledge Promotion (PREKNOP)|Efficacy Study of the Preconception Reproductive Knowledge Promotion Intervention|PREKNOP|Calvin College|Yes|Active, not recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||January 2015|January 24, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01849900||66773|
NCT01849913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCDE-12345|Laser Therapy on Neck Pain in Adolescents|Evaluation of the Effect of Low-level Laser Therapy on Neck Pain In Adolescents|Cervicalgia|University of Nove de Julho|Yes|Recruiting|February 2013|January 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|75|||Both|14 Years|20 Years|No|||May 2013|May 8, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01849913||66772|
NCT01851577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-EngagingFathers|Engaging Fathers in Home Visitation|Engaging Fathers in Home Visitation: Incorporation of a Coparenting Intervention|FF Project|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|45 Years|No|||May 2013|May 15, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851577||66645|
NCT01851785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AR059615-03|African American Preference for Knee Replacement: A Patient-Centered Intervention|Behavioral & Social Science Research on Understanding and Reducing Health Disparities|ACTION|University of Pennsylvania|No|Active, not recruiting|July 2010|June 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|340|||Both|50 Years|N/A|No|||December 2015|December 4, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851785||66629|
NCT01852045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-120|Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients|||Allergan|Yes|Recruiting|June 2013|August 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|8 Years|17 Years|No|||March 2016|March 9, 2016|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852045||66609|
NCT01852058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-121|A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity|||Allergan|Yes|Recruiting|September 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|8 Years|19 Years|No|||March 2016|March 9, 2016|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852058||66608|
NCT01852071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 15440|Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)|Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)||University of California, Los Angeles|Yes|Recruiting|May 2013|September 2018|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Month|N/A|No|||January 2016|January 13, 2016|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852071||66607|
NCT01852084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|761|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||September 23, 2014|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852084||66606|
NCT01848392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 - A00819 - 32|Extrapulmonary Effects of Cystic Fibrosis on Physical Activity of Adult Patients.|Extra Pulmonary Determinants of Physical Activity in Adults With Cystic Fibrosis.|MUCO-DAP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2013|December 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with CF cared at Cochin adult CF centre, Paris|April 2015|April 20, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848392||66887|
NCT01848366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-034|Biowave Overactive Bladder Trial|Biowave Overactive Bladder (OAB) Trial|OAB|William Beaumont Hospitals|No|Active, not recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848366||66889|
NCT01848665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEL 073.3|The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress|The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress||Brock University||Active, not recruiting|May 2013|December 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848665||66867|
NCT01848691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capnia CoSense Award 12.8062|Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis|Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis||Children's Hospital & Research Center Oakland|No|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848691||66866|
NCT01848951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287.13.FB|Comparison of Epidural and TAP Block in Abdominal Surgery|Comparison of Epidural Analgesia With Bilateral Dual TAP Infiltration Block With Liposomal Bupivacaine in Patients With Major Abdominal Surgery||University of Nebraska|Yes|Recruiting|February 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|19 Years|N/A|No|Probability Sample|Adult subjects undergoing major abdominal surgery|November 2015|November 30, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01848951||66846|
NCT01849211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diffmask|Influence of Neuromuscular Block on Mask Ventilation|Influence of a Neuromuscular Block on Face Mask Ventilation Conditions During Induction of Anaesthesia||Kreiskrankenhaus Dormagen|No|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|18 Years|N/A|No|||April 2013|March 30, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01849211||66826|
NCT01850030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-563|A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization|A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I)|Lotus I|Abbott|No|Active, not recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1066|||Female|19 Years|41 Years|No|||July 2015|July 1, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01850030||66763|
NCT01850056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acotec-02|AcoArt Ⅰ / SFA China|Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure (AcoArt I Study)||Acotec Scientific Co., Ltd|Yes|Active, not recruiting|April 2013|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||December 2015|January 4, 2016|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01850056||66761|
NCT01837420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-201-079|A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis|A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis||Vascular Biogenics Ltd. operating as VBL Therapeutics|No|Completed|November 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|194|||Both|18 Years|75 Years|No|||March 2015|March 26, 2015|December 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01837420||67728|
NCT01844648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH004-3|Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients|A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints||NeuroHealing Pharmaceuticals Inc.|No|Completed|April 2013|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|N/A|No|||April 2014|December 8, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844648||67174|
NCT01844661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2008-000364-16|Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.|Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors.||Hospital Infantil Universitario Niño Jesús, Madrid, Spain|No|Completed|January 2013|January 2016|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|6 Months|75 Years|No|||February 2016|February 18, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844661||67173|
NCT01844934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 3963-2 IRB|Impact of Prehabilitation in Total Knee Replacement|Impact of Prehabilitation in Total Knee Arthroplasty: Outcomes and Healthcare Service Utilization||Allina Health System|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|N/A|No|||January 2016|January 6, 2016|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01844934||67152|
NCT01845181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2012-163|"First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers|Randomized, Double Blind, Placebo Controlled "First-in-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-680 in Male Healthy Volunteers||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|April 2013|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01845181||67133|
NCT01845194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWINS-II-v1.9|Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics|Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics (TWINS II)||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|December 2009|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|117|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01845194||67132|
NCT01849640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR#1877|Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity|Active Surveillance for P. Falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia||Armed Forces Research Institute of Medical Sciences, Thailand|Yes|Suspended|December 2012|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|February 27, 2013||No|Poor efficacy of DHA-piperaquine due to likely drug resistance.|No||https://clinicaltrials.gov/show/NCT01849640||66793|
NCT01851083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-13-0038|Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury|A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)||The University of Texas Health Science Center, Houston|Yes|Recruiting|August 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|5 Years|17 Years|No|||February 2016|February 29, 2016|May 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851083||66682|
NCT01850823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71209805|Clinical Equivalence Study of Mometasone Nasal Spray|||Actavis Inc.|No|Completed|February 2013|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|875|||Both|12 Years|N/A|No|||August 2014|August 18, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01850823||66702|
NCT01850771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSI2013-RCT02|Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy|A Single-Blinded, Randomized Controlled Trial of Regenexx™ PL-Disc Versus Steroid Epidurals for Treatment of Lumbar Radiculopathy||Regenerative Sciences, LLC|No|Active, not recruiting|May 2013|May 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|September 30, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850771||66706|
NCT01850784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/2013|High Energy Formula Feeding in Infants With Congenital Heart Disease|High Energy Formula Feeding in Infants With Congenital Heart Disease||Dr. Sami Ulus Children's Hospital|Yes|Recruiting|February 2013|October 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|6 Months|No|||May 2013|May 8, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850784||66705|
NCT01851057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD073115|Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial|Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|2 Years|12 Years|No|||February 2015|February 16, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01851057||66684|
NCT01851356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130100|Brain Inflammation in Major Depressive Disorder Background|Brain Inflammation In Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|November 6, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851356||66662|
NCT01851590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334/13/03/01/2012|Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis|Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial||Helsinki University Central Hospital|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 24, 2015|May 8, 2013||No||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01851590||66644|Relatively short treatment period for the toenail onychomycosis (9 months).Patients with total dystrophic onychomycosis (46%) - the most difficult subtype to treat - may not have been amenable to monotherapy with a topical antifungal treatment.
NCT01851798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRNMMC IRB#384867|Evaluation of Sleep Disordered Breathing Following Ambulatory Surgery|Postoperative Home Sleep Test Changes in Ambulatory Surgical Patients With and Without Obstructive Sleep Apnea: A Prospective Clinical Trial||Walter Reed National Military Medical Center|Yes|Terminated|April 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|203|||Both|18 Years|85 Years|No|Non-Probability Sample|ambulatory orthopedic surgery patients presenting to Walter Reed National Military Medical        Center|December 2015|December 14, 2015|May 8, 2013||No|Staffing changes precluded sleep study interpretation|No||https://clinicaltrials.gov/show/NCT01851798||66628|
NCT01848418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR - 10050|Conception of an ICF Core Set for Systemic Sclerosis|Conception of an ICF Core Set for Systemic Sclerosis|SCISCIF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2013|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female aged 18 and older with a diagnosis of ScS made according to ACR and/or        Leroy et Medsger criteria|August 2015|August 25, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848418||66886|
NCT01848132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRCAP-GELTAMO12|Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.|Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|127|||Both|18 Years|70 Years|No|||November 2015|November 3, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848132||66907|
NCT01848379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS017507GI|White Blood Cell Signaling and Defense Mechanisms in Patients With Diabetes Mellitus Type 2 and Periodontitis|Human Polymorphonuclear Neutrophil (PMN) Cytosolic Signaling and Effector Functions in Patients With Diabetes Mellitus Type 2 and Periodontitis|DMS|Zentrum fuer Zahn-, Mund- und Kieferheilkunde|Yes|Active, not recruiting|January 2012|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01848379||66888|
NCT01849237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RuMCeSS|Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia|Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia.||National Research Center for Hematology, Russia|No|Recruiting|December 2012|May 2015|Anticipated|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|17 Years|75 Years|No|||May 2013|May 8, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01849237||66824|
NCT01849484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPSPA2013|Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy|Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area|HIPPO-SPARE 01|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|March 2013|April 2021|Anticipated|April 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849484||66805|
NCT01850329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB- 980425|A Parental Educational Intervention to Facilitate Informed Consent for Pediatric Procedural Sedation in the Emergency Department|A Parental Educational Intervention to Facilitate Informed Consent for Pediatric Procedural Sedation in the Emergency Department||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|December 2009|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|N/A|18 Years|No|||May 2013|May 7, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01850329||66740|
NCT01837433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XinqiaoH-001|Short-term Prednisone to Treat STA Study(SPTSS)|Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis|STA|Xinqiao Hospital of Chongqing|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01837433||67727|
NCT01844674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28396|A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies|A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy||Hoffmann-La Roche||Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|18|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844674||67172|
NCT01844687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study Number CBD-001|Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana|Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana||National Institute on Drug Abuse (NIDA)|No|Not yet recruiting|May 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|36|||Both|18 Years|50 Years|No|||May 2013|May 21, 2013|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844687||67171|
NCT01849926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UiO_IMUTI|Ibuprofen Versus Mecillinam for Uncomplicated Cystitis|Ibuprofen Versus Mecillinam for Uncomplicated Cystitis in Adult, Non-pregnant Women|IMUTI|University of Oslo|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|440|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|December 11, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01849926||66771|
NCT01849419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-120-B|Effects of MDMA on Social and Emotional Processing|Effects of MDMA on Social and Emotional Processing||University of Chicago|No|Completed|July 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|65|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|April 23, 2013|No|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01849419||66810|Behavioral measures may not have been obtained at optimal times to detect oxytocin effects. Placebo and oxytocin nasal spray formulations differed slightly. Other potential limitations are the selection of participants, or the doses administered.
NCT01850537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0171|Prospective Study To Assess The Safety and Efficacy of the PROW LIF Procedure|Prospective Study To Assess The Safety and Efficacy of the PROW LIF Procedure||NLT Spine|No|Not yet recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||May 2013|May 6, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01850537||66724|
NCT01850836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS in Rehab of aphasia|Dual Hemisphere rTMS for Rehabilitation of Post Stroke Aphasia|Treatment of Aphasic Stroke Patients With rTMS||Assiut University|No|Completed|December 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01850836||66701|
NCT01851317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00243|The Relationship Between Patients' Head Position and ETT Intracuff Pressure|The Relationship Between Patients' Position and Endotracheal Tube Intracuff Pressure in Pediatric Population||Nationwide Children's Hospital|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|N/A|17 Years|No|Non-Probability Sample|Patients undergoing otolaryngological surgery with cuffed endotracheal tube|May 2015|May 7, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851317||66665|
NCT01851330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0108|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|Yes|Completed|May 2013|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|647|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|May 3, 2013|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01851330||66664|
NCT01851603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1186|Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects|Phase I, Single-center, Inpatient, Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Oral Doses of AVL-3288 (Anvylic-3288) Healthy Subjects.|AVL3288|University of Colorado, Denver|Yes|Recruiting|June 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851603||66643|
NCT01851811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000359|Correlation Between CPAP Compliance and Food Intake Timing|To Examine the Correlation Between Continuous Positive Airway Pressure (CPAP) and the Timing of Last Meal Before Bed Time.|TLMECC|Hackensack University Medical Center|No|Completed|October 2008|February 2009|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|50|||Both|21 Years|N/A|No|Probability Sample|Patients in the HUMC who are diagnosed with sleep apnea will be determined through        screening charts.|February 2014|February 2, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851811||66627|
NCT01852097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0210|An Online Intervention to Address Barriers to IBD Medication Adherence|A Pilot Randomised Controlled Trial to Determine the Feasibility, Acceptability and Effectiveness of a CBT Based Online Intervention to Address Practical and Perceptual Barriers to Medication Adherence in Inflammatory Bowel Disease.||University College, London|Yes|Not yet recruiting|May 2013|January 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2013|May 10, 2013|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01852097||66605|
NCT01848145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CLL 18|Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia|Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial||SCRI Development Innovations, LLC|No|Active, not recruiting|July 2013|September 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848145||66906|
NCT01848158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24849 Academic Enrichment Fund|Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit|Safety, Feasibility & Effectiveness of Acupuncture as an Adjunct to Pharmacologic Treatment for Sedation and Analgesia in Mechanically Ventilated PICU Patients - A Pilot Study||Seattle Children's Hospital|Yes|Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|6 Months|17 Years|No|||November 2015|November 17, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848158||66905|
NCT01848704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV 007|Impact of "Spin" on the Interpretation of Results of Randomized Trials in the Field of Cancer|Impact of "Spin" on the Interpretation of Results of Randomized Trials in the Field of Cancer|SPIIN|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|300|||Both|N/A|N/A|No|||April 2013|July 26, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01848704||66865|
NCT01848717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANS_MINTLIFT_1101|Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold|A Single‐Center, Single Arm, Pre-post Test Design, Open Clinical Study to Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold||Chung-Ang University Hospital||Recruiting|November 2012|||December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|20 Years|N/A|No|||May 2013|May 3, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848717||66864|
NCT01848431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-HTC Verson 1-3|Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer|Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer||University of Zurich|Yes|Not yet recruiting|May 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Blood analysis|Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for defect reconstruction with free flaps and a preoperative hematocrit        of 28 % or below|December 2014|December 4, 2014|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01848431||66885|
NCT01848964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00219-36|Analyzing Stump-socket Interface Pressure to Improve Gait in Above-knee Amputee|Peut-on améliorer la Marche de l'amputé fémoral en Guidant la Correction prothétique Par l'Analyse Des Pressions Dans l'emboîture ?||University Hospital, Grenoble|Yes|Completed|April 2013|March 2015|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01848964||66845|
NCT01848977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1302-016-462|Comparison of Two Devices Using Near-infra Red Spectroscopy During a Vascular Occlusion Test|Comparison of Two Devices Using Near-infra Red Spectroscopy for the Measurement of Tissue Oxygenation During a Vascular Occlusion Test (INVOS® Versus Inspectra™)||Seoul National University Hospital|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|20|||Both|26 Years|41 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|April 7, 2013||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01848977||66844|
NCT01849250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00859|Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors|A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2013|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|64|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849250||66823|
NCT01838304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817166|Probability Ramp Control of Propofol for EGD|A Prospective, Randomized Comparison of Depth of Sedation With Propofol Titrated by Probability Ramp Control to Control by Anesthesia Providers During Esophagogastroduodenoscopy (EGD)||University of Pennsylvania|Yes|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2013|May 21, 2013|April 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838304||67660|
NCT01838317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072012-036|A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas|A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas||University of Texas Southwestern Medical Center|Yes|Recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|April 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01838317||67659|
NCT01849653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOVS-CTG2013|Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing|Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing: Concurrence in Non-Clinical Settings vs. Clinical Settings|SOVS-CTG|University of California, San Francisco|No|Active, not recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3500|Samples With DNA|Residual vaginal swab specimens collected with the APTIMA® Vaginal Swab Specimen Collection      Kit.|Female|16 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This will be a multicenter trial involving approximately 3500 women ages 16-75 from        different geographic areas in North America and from populations having different        prevalences of Ct and GC. Women will be either healthy women having routine exams, or        women being evaluated specifically for STDs (symptomatic and asymptomatic). Sites will        include Family Planning, Ob/Gyn and STD clinics. The possibility of using a college        student health clinic and a military clinic will be explored if it proves feasible to        obtain a large enough number of participants during the project's planned duration.|June 2015|June 26, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01849653||66792|
NCT01849939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0150|Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia|Reduced Intensity Conditioning Allogeneic Transplantation for CLL With Preemptive MDR Management (ICLL 03 RICAC-PMM)|RICAC|University Hospital, Clermont-Ferrand||Recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|70 Years|No|||May 2013|May 8, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01849939||66770|
NCT01850225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped ABI|Feasibility Study of Auditory Brainstem Implant in Young Children|A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients||House Research Institute|No|Withdrawn|October 2013|September 2017|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|5 Years|No|||October 2013|March 17, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850225||66748|
NCT01850524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16014|IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma|A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2013|February 2021|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|701|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850524||66725|
NCT01850797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-556/2011|Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)|Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)|RASUNOA|University Hospital Heidelberg|No|Completed|January 2012|August 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|353|||Both|18 Years|N/A|No|Non-Probability Sample|patients suffering from acute ischemic stroke or intracranial hemorrhage while being anti        coagulated. Only patients taking new oral anticoagulants will be included.|August 2015|August 15, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850797||66704|
NCT01850810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL17|Evaluation of a Nutritional Product for People With Type 2 Diabetes|Evaluation of a Nutritional Product for People With Type 2 Diabetes (T2DM)||Abbott Nutrition|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01850810||66703|
NCT01851109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DP001142-01|Prevention of Ovarian Cancer in Women Participating in Mammography|Prevention of Ovarian Cancer in Women Participating in Mammography||Fred Hutchinson Cancer Research Center|No|Completed|July 2008|December 2015|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|458|||Female|35 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01851109||66680|
NCT01851122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-11-0299|The Effect of the Amino Acid L-Theanine on Alertness and Vigilance|The Effect of the Amino Acid L-Theanine on Alertness and Vigilance||The University of Texas Health Science Center, Houston|Yes|Completed|November 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 7, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01851122||66679|
NCT01851096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-5422-CLN1-007|Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma|A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.||Esanex Inc.|No|Active, not recruiting|March 2013|May 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2015|November 19, 2015|May 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851096||66681|
NCT01851343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130077|Bone Marrow Stromal Cells for Inflammatory Bowel Diseases|An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the Treatment of Moderate to Severe Inflammatory Bowel Disease||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|November 2019|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 18, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851343||66663|
NCT01851616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 298/12/1|Oral Glucosestimulation After Gastric Bypass Surgery|Oral Glucosestimulation After Gastric Bypass Surgery||University Hospital, Basel, Switzerland|Yes|Completed|January 2013|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Female|18 Years|45 Years|No|||May 2013|May 9, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851616||66642|
NCT01851824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28397|A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY||Hoffmann-La Roche||Completed|August 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|9|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|May 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851824||66626|
NCT01851837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no grant|Response Of Weight And Lipid Profile To Exercise Time In Sedentary Overweight/Obese Middle-Aged And Older Women|Response Of Weight And Lipid Profile To Exercise Time In Sedentary Overweight/Obese Middle-Aged And Older Women||P.L.Shupik National Medical Academy of Post-Graduate Education|Yes|Completed|September 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 10, 2013|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01851837||66625|
NCT01851850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067|Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial|Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial||Rabin Medical Center|No|Not yet recruiting|May 2013|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|30 Years|80 Years|No|||January 2013|May 10, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01851850||66624|
NCT01852110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7622-012|Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)|A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease||Merck Sharp & Dohme Corp.|No|Active, not recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|830|||Both|55 Years|85 Years|No|||March 2016|March 24, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01852110||66604|
NCT01848171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130328|Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism|Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism||Shandong Provincial Hospital|Yes|Active, not recruiting|July 2013|July 2023|Anticipated|July 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|40 Years|75 Years|No|||November 2014|November 19, 2014|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848171||66904|
NCT01848444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 12009|Levels of Contaminants in Human Milk|Evaluation of Different Chemical Substances in the Milk of Breastfed Infant|Conta-Lait|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|187|Samples Without DNA|4*200 ml of breastmilk homogenizated and frozen -18° Celsius in the milk bank|Female|18 Years|N/A|No|Non-Probability Sample|Lactating women given their milk to a milk bank|October 2015|October 8, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01848444||66884|
NCT01848730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNV2197944/201|Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia|A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia||Convergence Pharmaceuticals|No|Completed|April 2013|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|85 Years|No|||January 2014|October 29, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848730||66863|
NCT01848743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gilead IN-US-174- 0190|Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation|Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation|HBSAE|Kaohsiung Veterans General Hospital.|Yes|Recruiting|April 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|75 Years|No|||September 2014|September 12, 2014|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01848743||66862|
NCT01849263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00887|Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma|Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2013|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849263||66822|
NCT01849510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIME2013|Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost|Efficacy of Dose Intensified Radiotherapy of Spinal Metastases of Solid Tumors by Dose Increased, Homogeneous Radiation of Vertebral Body and Simultaneous Application of Stereotactic Boost.|SPIN-MET|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|March 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|155|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01849510||66803|
NCT01837810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384409|Safety Study of Post Tonsillectomy Ibuprofen Use in Adults|NSAID Post-Tonsillectomy Hemorrhage: A Randomized, Double-Blinded Controlled Noninferiority Trial||Brooke Army Medical Center|Yes|Recruiting|April 2013|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|810|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01837810||67698|
NCT01838057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X9001010|Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting|Evaluation of the Clinical and Economic Impact of Pfizer's painPRIMER Program in the Treatment of Low Back Pain in a Primary Care Setting||Pfizer|No|Terminated|June 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|103|||Both|18 Years|N/A|No|Probability Sample|Patients with low back pain|April 2015|April 15, 2015|April 15, 2013|No|Yes|The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated    for reasons of either safety or efficacy.|No||https://clinicaltrials.gov/show/NCT01838057||67679|
NCT01838330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00052609|Effects of High Dietary Fiber Supplementation on Uremic Retention Molecules and Inflammation in Diabetic Chronic Kidney Disease|Effects of High Dietary Fiber Supplementation on Uremic Retention Molecules and Inflammation in Diabetic CKD||University of Utah|Yes|Recruiting|June 2012|||June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|90 Years|No|||December 2013|December 9, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01838330||67658|
NCT01849666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28398|A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY||Hoffmann-La Roche||Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|2|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849666||66791|
NCT01850251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTOHMB-13|Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture|Randomized Controlled, Pilot Study to Assess the Effect of a High Protein and Calorie Nutritional Supplementation Enriched Hydroxymethylbutyrate and Vitamin D on Muscle Strength and Function in Patients With Hip Fracture.||Hospital Clinic of Barcelona|No|Terminated|June 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Both|65 Years|N/A|No|||August 2015|August 18, 2015|May 3, 2013||No|Recruiting problems.|No||https://clinicaltrials.gov/show/NCT01850251||66746|
NCT01850264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDZNRW_KA_002_KJG|Quartet™ Bad Oeynhausen Trial|Quartet™ Bad Oeynhausen Trial|QUOTA|Heart and Diabetes Center North-Rhine Westfalia|No|Recruiting|March 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||March 2015|March 30, 2015|December 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01850264||66745|
NCT01850238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXON CO 18700|Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease|A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability & Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension||Axon Neuroscience SE|Yes|Completed|May 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|85 Years|No|||October 2015|October 9, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850238||66747|
NCT01851135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0130|Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1|Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1|NF1-QDV|Nantes University Hospital|No|Recruiting|May 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|8 Years|59 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01851135||66678|
NCT01851369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130118|TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas|A Phase I Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|February 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|120 Years|No|||October 2015|February 5, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851369||66661|
NCT01851629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2013|Walking Adaptability Post-Spinal Cord Injury|Adaptive Walking Responses Critical for Effective Community Ambulation Post-Incomplete Spinal Cord Injury||University of Florida|Yes|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01851629||66641|
NCT01851863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJYYXHNK-001|Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia|Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia: A Randomized Comparison of Different Prescribing Behaviors||RenJi Hospital|Yes|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|262|||Both|18 Years|75 Years|No|||November 2014|February 10, 2015|May 4, 2013||No||No|April 13, 2014|https://clinicaltrials.gov/show/NCT01851863||66623|
NCT01852123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High-STEACS|High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome|High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome: A Randomized Controlled Trial|High-STEACS|University of Edinburgh|Yes|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|23800|||Both|N/A|N/A|No|||March 2015|March 17, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01852123||66603|
NCT01848756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-5422-CLN1-008|Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers|A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers.||Esanex Inc.|No|Terminated|April 2013|June 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|May 3, 2013|No|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT01848756||66861|
NCT01848990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Halo-117-403|CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)|CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)||Halozyme Therapeutics|No|Active, not recruiting|March 2013|August 2015|Anticipated|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|456|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|April 29, 2013|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT01848990||66843|
NCT01849003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-279-0110|Study of the Effect of GS-6615 in Subjects With LQT-3|An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome||Gilead Sciences|No|Completed|May 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|65 Years|No|||November 2014|November 13, 2014|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849003||66842|
NCT01849276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 11H03|Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML|A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia||Northwestern University|Yes|Active, not recruiting|July 2013|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849276||66821|
NCT01849289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3587|A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™: ONCE)|BEGIN™|Novo Nordisk A/S|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|833|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|May 6, 2013|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01849289||66820|
NCT01849523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot WIN-2013|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study (Pilot WIN-study).|WIN|University Medical Center Groningen|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01849523||66802|
NCT01849744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-4718-101|Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies|A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies||Verastem, Inc.|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849744||66785|
NCT01830244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCC12.01|IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer|Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer|Neonab|Barwon Health|No|Active, not recruiting|April 2013|June 2020|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01830244||68276|
NCT01830257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-7|Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)|Phase 4 Study of MR and APDT Vaccine|AEFI|Beijing Center for Disease Control and Prevention|No|Enrolling by invitation|April 2013|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 11, 2013|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01830257||68275|
NCT01830491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-CPG-401|Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients|Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial||Hanmi Pharmaceutical Company Limited|No|Completed|March 2009|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|20 Years|80 Years|No|||April 2013|April 9, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01830491||68257|
NCT01830504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-748|A Multicenter Phase II Pilot Open Label|A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers|BKM120|Hospices Civils de Lyon|Yes|Recruiting|April 2013|January 2017|Anticipated|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||April 2013|August 25, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01830504||68256|
NCT01849952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12160|Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas|Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood, tumor tissue, cerebrospinal fluid.|Both|18 Years|N/A|No|Non-Probability Sample|Patients seen in the clinic who are going to be treated with surgery, radiation and        medical therapy for gliomas will be eligible for the study.|February 2016|February 4, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849952||66769|
NCT01849965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC127-2012-02|Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers|A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus|STRIDE 2|Derma Sciences, Inc.|No|Active, not recruiting|April 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|633|||Both|18 Years|N/A|No|||June 2015|November 18, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849965||66768|
NCT01849978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044422|Enhancing Exercise in Breast Cancer Survivors|Enhancing Exercise in Breast Cancer Survivors||Duke University|No|Completed|May 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|81|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849978||66767|
NCT01850576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-PA-12-231|Project TEACH-Kenya|Project Tailoring Effective And Community-based HIV Interventions in Kenya|TEACH|North Bronx Healthcare Network|No|Withdrawn|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|May 2, 2013||No|We did not receive proper funding to complete this study|No||https://clinicaltrials.gov/show/NCT01850576||66721|
NCT01850589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001|Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice|Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice||Northwell Health|Yes|Terminated|March 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|April 8, 2013||No|Use of bupropion with counseling works better to help patients quit smoking.|No|March 26, 2014|https://clinicaltrials.gov/show/NCT01850589||66720|
NCT01850550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2|Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care|Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care|KL2|Milton S. Hershey Medical Center|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 29, 2013||No||No|May 7, 2015|https://clinicaltrials.gov/show/NCT01850550||66723|This was a pilot study. No other limitations noted.
NCT01850563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12129|A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases|A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|May 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850563||66722|
NCT01851148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIOST-1|Clinical Effectiveness of Osteopathic Manipulative Treatment in Chronic Migraine|Clinical Effectiveness of Osteopathic Manipulative Treatment Versus Sham Therapy and Usual Care in Chronic Migraine: 3 Armed RCT||European Institute for Evidence Based Osteopathic Medicine|Yes|Completed|March 2010|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|60 Years|No|||August 2013|August 31, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851148||66677|
NCT01851408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480157|Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma|Phase 2 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)|No|Withdrawn|April 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|April 14, 2015|May 9, 2013|No|Yes|No progression of Phase 1 trial to Phase 2.|No||https://clinicaltrials.gov/show/NCT01851408||66658|
NCT01851382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130128|Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research|Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research||National Institutes of Health Clinical Center (CC)||Completed|April 2013|February 2015|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|29|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|February 5, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851382||66660|
NCT01851876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/20|Endometrial Injury and Single Embryo Transfer|Endometrial Injury May Increase the Clinical Pregnancy Rate in Normoresponders Underwent Long Agonist Protocol Intracytoplasmic Sperm Injection Cycles With Single Embryo Transfer||Karadeniz Technical University|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 11, 2013|April 26, 2013||No||No|May 11, 2013|https://clinicaltrials.gov/show/NCT01851876||66622|No limitations.
NCT01852136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-11-NEXXT01|Clinical Evaluation of BD NEXT Pen Needle|Clinical Evaluation of the BD NEXT (Extra Thin Wall Pen Needles) Compared to the Currently Marketed Pen Needles||Becton, Dickinson and Company|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|217|||Both|35 Years|80 Years|No|||January 2015|January 28, 2015|May 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01852136||66602|
NCT01848184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPCOV0293|A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch|A Multicentre Prospective Study in Patients Undergoing Ventral Hernia Repair by Open Approach With Intraperitoneal Positioning Using Parietex™ Composite Ventral Patch - Panacea Study.|Panacea|Medtronic - MITG|Yes|Active, not recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848184||66903|
NCT01850667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-1201-001-004|Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma|Phase II Multicenter Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Toxicity and Outcome||Korea Cancer Center Hospital|No|Active, not recruiting|January 2012|April 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850667||66714|
NCT01848457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009967|Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy|Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma||Children's Hospital of Philadelphia|No|Recruiting|April 2013|November 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|24|||Both|1 Year|30 Years|No|||December 2015|December 14, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01848457||66883|
NCT01848470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG400549-1-02|Multiple Ascending Doses Study of CG400549|Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers||CrystalGenomics, Inc.|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01848470||66882|
NCT01848483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059987|Living Well Project for Persons With AIDS|The Living Well Project: Early Palliative Care and Motivational Interviewing (MI) for Persons With AIDS||Emory University|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01848483||66881|
NCT01848769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0902-PR-0013|Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old|A Single-dose, Open-Label, 2-Way Cross-Over, Clinical Pharmacology Study Of Chf 1535 50/6 HFA pMDI (Fixed Combination Of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6 µg) Using The Aerochamber Plus™ Spacer Device Versus The Free Combination Of Beclomethasone HFA pMDI And Formoterol HFA pMDI Available On The Market Using The Aerochamber Plus™ Spacer Device In Asthmatic Children|PAED1|Chiesi Farmaceutici S.p.A.|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|5 Years|11 Years|No|||May 2013|May 7, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848769||66860|
NCT01849016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC trial|N-Acetylcysteine in Patients With Sickle Cell Disease|N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain|NAC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|April 2013|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Both|12 Years|N/A|No|||February 2016|February 1, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849016||66841|
NCT01850680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU13402|Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate||Sanofi|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|61|||Both|20 Years|65 Years|No|||January 2014|January 27, 2014|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01850680||66713|
NCT01851928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3621|Validation of a Nutrition Screening Tool|The Validation of Two Inpatient Adult Nutrition Screening Tools in Cancer Care - a Prospective Study||Royal Marsden NHS Foundation Trust|Yes|Completed|July 2011|March 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be approached for consideration and recruitment to the study in a stratified        manner in order to proportionately represent the diagnostic groups admitted to The Royal        Marsden NHS Foundation Trust as inpatients. Patients will be approached sequentially from        the list until the required number of patients are recruited for that particular        diagnoses. Recruitment for particular diagnostic groups may take place over a number of        days until the required number of patients is recruited. The same procedure will be        repeated, with a newly generated list, for all selected diagnostic groups in a random        order. This methodology will aim to capture patients who have been newly diagnosed,        patients with established disease, patients newly admitted and those who have been        inpatients for anumber of days or weeks.|May 2013|May 8, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01851928||66618|
NCT01829945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-129-05-02|Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome (SMB48)|Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome.||Laval University|No|Completed|October 2009|February 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|30|Samples With DNA|Serum Plasma Intestinal tissue|Male|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|community sample|April 2013|April 10, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01829945||68298|
NCT01830517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-AMO-401|Diurnal Variation in Hypertensive Stroke Patients|Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients||Hanmi Pharmaceutical Company Limited|No|Completed|August 2007|February 2012|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|35 Years|85 Years|No|||April 2013|April 11, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01830517||68255|
NCT01830530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09F102|HIGH Altitude CArdiovascular REsearch in the ANDES|HIGH Altitude CArdiovascular REsearch in the ANDES|HIGHCARE-A|Istituto Auxologico Italiano|No|Completed|May 2012|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||February 2013|April 9, 2013|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01830530||68254|
NCT01849692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-001|ESBA1008 Microvolume Study|A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration||Alcon Research|No|Completed|June 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|107|||Both|50 Years|N/A|No|||January 2016|February 25, 2016|May 6, 2013|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT01849692||66789|
NCT01850615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-4049|Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes|Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes|onset® 3|Novo Nordisk A/S|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850615||66718|
NCT01850862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UFRN 530/11|Progressive Collective-exercise Program on the Knee Osteoarthritis|||Universidade Federal do Rio Grande do Norte||Completed|June 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|80 Years|No|||May 2013|May 15, 2013|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01850862||66699|
NCT01850849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0083-1011|Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream|A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream||LEO Pharma|No|Completed|May 2013|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|23|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850849||66700|
NCT01851395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130131|Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue|A Pilot Study of Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|72|||Both|18 Years|100 Years|No|||December 2015|January 5, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851395||66659|
NCT01848782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV006|Impact of Adding a Limitation Section in Abstract of Systematic Review|Impact of Adding a Limitation Section in Abstract of Systematic Review on Interpretation by Readers: a Randomised Controlled Trial|ILMARI 2|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|300|||Both|N/A|N/A|No|||April 2013|September 8, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848782||66859|
NCT01849029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43091-G|Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women|Cognitive Processing Intervention for HIV/STI and Substance Use Among Native Women||University of Washington|Yes|Recruiting|October 2013|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01849029||66840|
NCT01849757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ruh/westerncan/primestudy|Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%|Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%||University of Saskatchewan|No|Not yet recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|7000|||Both|50 Years|90 Years|No|||May 2013|May 8, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849757||66784|
NCT01849770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43708-A|Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)|A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS)|MX-ALS-001|University of Washington|Yes|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 6, 2013|Yes|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT01849770||66783|
NCT01851187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y207858|Effect of Perinatal Emotional Management on Maternal Emotion and Delivery Outcomes|A Randomized Control Study of Prenatal Emotion Management on Maternal Emotion and the Delivery Outcomes||First People's Hospital of Hangzhou|Yes|Completed|September 2008|December 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200|||Female|22 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 10, 2013|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851187||66674|
NCT01851902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20130012H|PREdicting Atrial Fibrillation or Flutter|PREdicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF)"|PREDATE-AF|Keesler Air Force Base Medical Center|No|Active, not recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|360|||Both|18 Years|N/A|No|Non-Probability Sample|The PREDATE AF trial is a prospective, single arm, open-label, single center clinical        study to evaluate the incidence of AF in patients that are suspected to be at high risk of        having AF, as defined by a modified CHA2DS2-VASc score.|January 2016|January 1, 2016|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01851902||66620|
NCT01848795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRRB/30/10|EndoBarrier Versus Intragastric Balloon in Obese Diabetic Patients|Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes.||The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|No|Recruiting|May 2013|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||March 2015|March 23, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848795||66858|
NCT01849549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/191/HP|Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage|Anatomical Clinical Correlations. Neuropsychological and Brain Medical Imaging Study in Brain Damaged Subjects.|CORAC|University Hospital, Rouen|No|Recruiting|May 2013|January 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01849549||66800|
NCT01849562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH102-007|Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects|A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection||Achillion Pharmaceuticals|Yes|Completed|April 2013|April 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|April 18, 2013|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01849562||66799|
NCT01851200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-12-GCT01|Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors|Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial.||Fondazione Michelangelo|Yes|Recruiting|May 2013|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||August 2015|August 11, 2015|April 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01851200||66673|
NCT01848028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVDP-085-07|PsoBest - The German Psoriasis Registry|Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|January 2008|July 2026|Anticipated|December 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||15|Anticipated|3500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with plaque-type psoriasis or psoriatic-arthritis starting the first systemic        treatment with authorized atipsoriatic drugs in Germany.|October 2015|October 9, 2015|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01848028|10 Years|66915|
NCT01826331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034041|Incentives for Participation Versus Outcomes|Incentives for Participation Versus Outcomes for Population Cessation of Smoking||University of Rhode Island|Yes|Active, not recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|880|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826331||68574|
NCT01850017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16150|Study of Dexmedetomidine in Spine Surgery|Prospective Randomized Double Blind Study of Intraoperative Dexmedetomidine and Postoperative Pain Control in Patients Undergoing Multi-level Thoraco-lumbar Spine Surgery||University of Virginia|No|Terminated|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|April 30, 2013||No|No effect seen at interim analysis|No||https://clinicaltrials.gov/show/NCT01850017||66764|
NCT01850277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-NP-0021-47/1378/13|Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study|Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study|Pilot-CRAfT|Institute of Cardiology, Warsaw, Poland|No|Recruiting|October 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850277||66744|
NCT01850290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-277|Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)|Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)||Baylor Research Institute|No|Recruiting|May 2013|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|50 Years|No|Non-Probability Sample|Traumatic Brain Injury patients in Inpatient Rehabilitation|January 2016|January 15, 2016|May 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01850290||66743|
NCT01850602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA1301|A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia|||Kissei Pharmaceutical Co., Ltd.||Completed||||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|20 Years|N/A||||November 2014|November 11, 2014|May 7, 2013||||No||https://clinicaltrials.gov/show/NCT01850602||66719|
NCT01850628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP DP-1|NSABP Biospecimen Discovery Project|NSABP Biospecimen Discovery Project||NSABP Foundation Inc|No|Recruiting|July 2013|February 2020|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|fresh tumor tissue and blood samples|Female|18 Years|N/A|No|Non-Probability Sample|Women with locally advanced, HER2-positive breast cancer from selected sites in the United        States|February 2016|February 1, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01850628||66717|
NCT01850875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EC1010A|Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain|Localized and Generalized Musculoskeletal Pain: Psychobiological Mechanisms and Implications for Treatment (LOGIN) - Subgroups Characterized by Psychological Trauma, Mental Comorbidity, and Psychobiological Patterns and Their Specialized Treatment - Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain|LOGIN - EMDR|University Hospital Heidelberg|No|Active, not recruiting|May 2013|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01850875||66698|
NCT01848808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2012-076|The Effect of Wobenzym PS on Inflammation|The Effect of Wobenzym PS on Inflammation|WO|Laval University|No|Completed|April 2013|March 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848808||66857|
NCT01851642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2007|Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs|The Role of Conformational Diseases on Macrophage Function||University of Florida|No|Recruiting|September 2007|December 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|April 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01851642||66640|
NCT01849536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/20|Corneal Biomechanics and Continuous IOP Monitoring Using Soft Contact Lenses in Glaucomatous Patients|Corneal Biomechanics and Continuous IOP Monitoring Using Soft Contact Lenses in Glaucomatous Patients|BIOLENS|University Hospital, Bordeaux|Yes|Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|40 Years|N/A|No|||November 2013|November 21, 2013|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01849536||66801|
NCT01850368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-1209-001-007|Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion|Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion||Korea Cancer Center Hospital|No|Active, not recruiting|October 2012|March 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|20 Years|N/A|No|||March 2016|March 2, 2016|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01850368||66737|
NCT01852162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2011-112|Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy|Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel||University of Florida|Yes|Completed|February 2012|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|80 Years|No|||March 2015|March 10, 2015|May 8, 2013||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01852162||66600|
NCT01848223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T56/2013|The Quality of Life in Late Menopause|The Quality of Life in Late Menopause. A Seventeen Years Follow-up Study.|QoL|Turku University Hospital|No|Recruiting|November 2012|December 2016|Anticipated|May 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|64|||Female|64 Years|82 Years||Non-Probability Sample|community sample of the area of Turku|May 2013|May 2, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848223||66900|
NCT01848236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adams VitD 01|Effects of Vitamin D Insufficiency in Man|Effects of Vitamin D Insufficiency in Man||University of California, Los Angeles|No|Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848236||66899|
NCT01848522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 10043|Creation and Setting up of Therapeutic Programs, Interprofessional Communication, Patients' Education and Counseling|Creation and Setting up of Therapeutic Programs, Interprofessional Communication, Patients' Education and Counseling: a Qualitative Study in 3 Physical Therapy and Rehabilitation Departments|EMCIQUAL|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2012|July 2014|Actual|January 2014|Actual|N/A|Observational|N/A||1|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|In each of 3 centers, we will evaluate :          -  13 healthcare professionals          -  8 patients          -  1 hospital executives|July 2014|July 25, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01848522||66878|
NCT01849315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12F011|Effects of Physical Activity on Disease Risk Factors|Effects of an Empirically-Based Physical Activity Intervention on Chronic Disease Risk Factors in Children||Ohio University|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|13|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849315||66818|
NCT01849783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208755|Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma|Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy||University of Iowa|Yes|Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|65 Years|85 Years|No|||November 2014|November 18, 2014|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849783||66782|
NCT01850381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBD 002|Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease|GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease|GAP-PD|Genervon Biopharmaceuticals, LLC|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|30 Years|N/A|No|||August 2015|August 17, 2015|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850381||66736|
NCT01843764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDT-ClearTZ1|Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections|Efficacy of Plasmodium Falciparum Specific Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Infections After Antimalarial Treatment||Karolinska University Hospital|Yes|Completed|June 2009|June 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|Samples With DNA|Whole capillary blood collected for Rapid Diagnostic tests, microscopy and PCR|Both|6 Months|59 Months|No|Probability Sample|Children with fever visiting primary health care units in malaria endemic area|May 2013|May 2, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01843764||67242|
NCT01826604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22591|Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section|The Effect of a Barrier Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section|Alexis|St. Louis University|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|300|||Female|14 Years|50 Years|No|||September 2015|September 8, 2015|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01826604||68553|
NCT01827501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOM|Avoidance of Delirium in Older Patients After Major Non-cardiac Surgery|Can Perioperative Goal Directed Hemodynamic Management Reduce the Incidence of Delirium in Older Patients After Major Non-cardiac Surgery?|ADOM|Technische Universität München|No|Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|70 Years|N/A|No|||November 2015|November 8, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827501||68485|
NCT01830270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPEC-GC|Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer|Preoperative Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel (Intensified PET) in Patients With Locally Gastric Cancer : a Phase II Proof-of-concept Study.|IPEC-GC|Centre Hospitalier Universitaire de Besancon|Yes|Terminated|May 2011|May 2019|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||January 2016|February 23, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01830270||68274|
NCT01826318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH_SIP_2007|Stress Coping Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation|Impact of a Stress Coping Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation: A Randomized Controlled Trial||University Hospital, Basel, Switzerland|No|Completed|December 2007|May 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|124|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 3, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01826318||68575|
NCT01850316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00481|Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy|A Phase II Study for the Treatment of Unresectable or Medically Inoperable Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy (SBRT) in British Columbia||British Columbia Cancer Agency|No|Recruiting|July 2013|August 2020|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850316||66741|
NCT01850303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1201|MODEL (Maintenance Versus Observation After inDuction Chemotherapy in Non-progressing Elderly Patients With Advanced Non-small Cell Lung Cancer)|Phase III Study Comparing Maintenance With Pemetrexed or Gemcitabine to a Surveillance in Elderly Patients (70 Years Old and More) With a Advanced Non Small Cell Lung Cancer Controlled by Induction Chemotherapy.||Intergroupe Francophone de Cancerologie Thoracique|Yes|Recruiting|May 2013|December 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|70 Years|89 Years|No|||March 2016|March 9, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01850303||66742|
NCT01850901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-540|Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension|Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial|SYMPATHY|UMC Utrecht|Yes|Recruiting|May 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01850901||66696|
NCT01850888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS107|MIBG for Refractory Neuroblastoma and Pheochromocytoma|131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Refractory Neuroblastoma and Pheochromocytoma||Masonic Cancer Center, University of Minnesota|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|N/A|No|||January 2016|January 21, 2016|March 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850888||66697|
NCT01851655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-2008|Anterior Cruciate Ligament Reconstruction and Plyometric Exercise|The Effect of Plyometric Exercise Intensity on Function & Articular Cartilage Metabolism After ACL Reconstruction||University of Florida|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|15 Years|30 Years|No|||September 2014|September 17, 2014|April 25, 2013||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT01851655||66639|
NCT01851668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12063|Preterm Infant Transport Stress (PremiTranS) Study|Preterm Infant Transport Stress (PremiTranS) Study - A Feasibility Study of the Impact of Inter-hospital Transport on the Preterm Infant|PremiTranS|University of Nottingham|No|Recruiting|June 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Blood and urine|Both|N/A|3 Months|No|Non-Probability Sample|Hospital born preterm infants|February 2016|February 25, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01851668||66638|
NCT01851889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-010|Optimizing Continuous-flow Left Ventricular Assist Device Settings and Identification of Pump Malfunction - A Comparative Study of Echocardiography and Invasive Hemodynamics|||Rigshospitalet, Denmark||Completed|April 2013|October 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|All heart failure patients with CF-LVAD at University Hospital of Copenhagen,        Rigshospitalet.|October 2015|October 26, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01851889||66621|
NCT01848496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPGO0015|Clinical Trial of Two Techniques for Gingival Displacement|A Double-blind Randomized Clinical Trial of Two Techniques for Gingival Displacement||Federal University of Pelotas|No|Completed|January 2012|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01848496||66880|
NCT01850069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16714|The Use of Near Infrared Spectroscopy (NIRS) to Estimate Intracranial Pressure (ICP)|The Use of Near Infrared Spectroscopy (NIRS) to Estimate Intracranial Pressure (ICP)||University of Virginia|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|59|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients in the ICU with intracranial hypertension, being monitored with an arterial        catheter and intraranial pressure monitor|April 2015|April 13, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01850069||66760|
NCT01850355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000661|An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|An Open-label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders||Massachusetts General Hospital|No|Recruiting|July 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|17 Years|No|||February 2016|February 26, 2016|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850355||66738|
NCT01850940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OASIS|Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia|Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia - A Multi-center Prospective Cohort Study|OASIS|Beijing Friendship Hospital|Yes|Completed|January 2013|May 2015|Actual|September 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|98|Samples Without DNA|plasma|Both|18 Years|70 Years|No|Probability Sample|The study population of this study will be patients with established cirrhosis and        hyponatremia.|July 2015|July 27, 2015|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850940||66693|
NCT01846676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221-2010|Clinical Trial to Assess the ACE Program for Rehabilitation in Hearing Loss|Clinical Trial to Assess the Active Communication Education Program for Rehabilitation in Patients With Hearing Loss Users of Hearing Aids||University of Chile|Yes|Enrolling by invitation|October 2012|||October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|65 Years|N/A|No|||May 2013|May 29, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01846676||67018|
NCT01849042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMEO-AD 14394A|Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease|A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.|ROMEO-AD|Konkuk University Medical Center|Yes|Recruiting|January 2013|August 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|50 Years|90 Years|No|||August 2014|August 12, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849042||66839|
NCT01849796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148-10|Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain|Transcranial Stimulation (TDCS) For The Treatment of Neuropathic Facial Pain.|TDCS|Beth Israel Medical Center|No|Terminated|October 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 27, 2012|Yes|Yes|Investigators moved to other institutions|No||https://clinicaltrials.gov/show/NCT01849796||66781|
NCT01849809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2010-001|Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD|Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder||Butler Hospital|No|Active, not recruiting|February 1993|||August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|65 Years|No|||May 2013|May 6, 2013|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01849809||66780|
NCT01850953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225/2012|Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia|Evaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment||Centre for Addiction and Mental Health|Yes|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01850953||66692|
NCT01851447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130112|Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy|Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients With a Fragile Sarcolemmal Muscular Dystrophy||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|March 2, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01851447||66655|
NCT01843777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1004-P|Applying the Use of Motivational Tools to Auditory Rehabilitation|Applying the Use of Motivational Tools to Auditory Rehabilitation||VA Office of Research and Development|No|Active, not recruiting|November 2013|September 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|89 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01843777||67241|
NCT01827514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-MM-619-CTIL|Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens|Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens|EPO-CAN|Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|January 2013|January 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|Samples Without DNA|Retrospective part: prepared slides from already taken preparations (specimens from      Biopsy/Bone Marrow tests) will serve as the basis for that part of the work - samples      without available DNA.      Prospective part: fresh material samples will be taken from biopsies in the operating room      from Biopsy/Bone Marrow tests and will be used to prapare the slides for the study tests.      There is an available DNA before slide staining.|Both|18 Years|N/A|No|Non-Probability Sample|Adults with one of listed above types of cancer.|April 2013|April 4, 2013|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01827514||68484|
NCT01826591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22305|Diet X Genotype Study|Do Genotype Patterns Predict Weight Loss Success for Low Carb vs. Low Fat Diets?||Stanford University|No|Active, not recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|609|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01826591||68554|
NCT01850654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12170|Ohio Colorectal Cancer Prevention Initiative|Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome|OCCPI|Ohio State University Comprehensive Cancer Center|No|Recruiting|December 2012|September 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|5000|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01850654||66715|
NCT01850641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA1304|A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia|||Kissei Pharmaceutical Co., Ltd.||Completed||||December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A||||November 2014|November 11, 2014|May 7, 2013||||No||https://clinicaltrials.gov/show/NCT01850641||66716|
NCT01849055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14708|A Multiple Dose Study of LY3023703 in Healthy Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849055||66838|
NCT01850394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 01-53-06|Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement|Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.||Mahidol University|Yes|Completed|January 2010|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|50 Years|N/A|No|||October 2013|October 24, 2013|May 2, 2013||No||No|May 9, 2013|https://clinicaltrials.gov/show/NCT01850394||66735|
NCT01850407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.02.054|Preparing Caregivers for the Child Sexual Abuse Examination: Are Informational Leaflets Helpful?|Preparing Caregivers for the Child Sexual Abuse Examination: Are Informational Leaflets Helpful?||Hackensack University Medical Center|Yes|Completed|August 2007|July 2008|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|37|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 1, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850407||66734|
NCT01851161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12806|Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy|Pulmonary Tumor Motion Reduction and Improved Breathing Reproducibility by Prone Patient Positioning in Radiation Therapy||Virginia Commonwealth University|Yes|Terminated|May 2010|September 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|General radiotherapy patient population during either the consultation or the simulation        process. The possible participant will be contacted by either of the investigators or the        study coordinator. Eligibility will be evaluated by observing the simulation data        collected for each patient clinically, including any pretreatment fluoroscopy, digital        simulation radiographs, cone beam CT, conventional or four-dimensional CT scans. Only        clinical data will be used to assess eligibility. No extra imaging will be performed on a        patient solely for the purpose of assessing eligibility.|September 2015|September 16, 2015|April 26, 2013||No|Data analysis completed|No||https://clinicaltrials.gov/show/NCT01851161||66676|
NCT01848197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJTC0001|Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer|An Open, Randomized, Parallel-group, Multicenter Clinical Study to Evaluate Efficacy and Safety of Paclitaxel Every 2 Weeks Compared Weekly in Adjuvant Treatment of Breast Cancer|PATEN|Taizhou Hospital||Not yet recruiting|May 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|18 Years|70 Years|No|||May 2013|May 6, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848197||66902|
NCT01848210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN01/12|Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency|Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT.||Takeda|No|Completed|May 2013|September 2015|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|398|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01848210||66901|
NCT01848509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00713-40|Telemedicine for Sleep Apnea Patients|A Telemedicine System for the Follow-up of Patients With SAS|Respir@dom|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2013|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|201|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01848509||66879|
NCT01849302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/6|The Effect of Beverages Varying in Protein Quantity on Appetite and Energy Intake|The Acute Effect of Beverages Varying in Macro-nutrient Content on Subjective Appetite Ratings and ad Libitum Energy Intake in Healthy Subjects||Lund University|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 6, 2016|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01849302||66819|
NCT01846013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMSUMMA|Increasing Workplace Physical Activity in Sedentary Office Workers|Increasing Workplace Physical Activity in Sedentary Office Workers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846013||67069|
NCT01846364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEEI06.33|DIM as a Treatment for Thyroid Disease|Diindolymethane: Anti-proliferation Agent in Thyroid Disease—Non-surgical Protocol||The New York Eye & Ear Infirmary|No|Terminated|November 2006|September 2011|Actual|August 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|65 Years|No|||April 2013|April 30, 2013|April 30, 2013||No|Lack of sufficient enrollment|No||https://clinicaltrials.gov/show/NCT01846364||67042|
NCT01846689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E130426|An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease|An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease||Targeted Medical Pharma|Yes|Not yet recruiting|June 2013|September 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846689||67017|
NCT01846949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDUS|Surveillance Study for HCC (ALDUS)|Study for Clinical Significance of Use of AFP, AFP-L3 and DCP Versus US Alone in Surveillance for HCC|ALDUS|ALDUS Study Group|No|Not yet recruiting|May 2013|October 2020|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|None Retained|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with compensated cirrhosis.|May 2013|May 1, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01846949||66998|
NCT01847196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QD-155|Angel® Catheter Early Feasibility Clinical Study|A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism||BiO2 Medical|Yes|Terminated|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|May 2, 2013|Yes|Yes|IDE approval received for larger Pivotal Study|No|February 18, 2015|https://clinicaltrials.gov/show/NCT01847196||66979|Due to the small number of patients, analysis is descriptive only.
NCT01847209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001915|Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions|Percutaneous Image Guided Video Assisted Thoracic Surgery (VATS) Resection of Lung Lesions||Brigham and Women's Hospital|No|Active, not recruiting|April 2013|December 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847209||66978|
NCT01847469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP0039|Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence|Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence||Yale University|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|65 Years|No|||September 2015|September 8, 2015|January 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847469||66958|
NCT01847729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0498|OPAL: "Opiates and PhArmacoLogy"|A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil.|OPAL|Nantes University Hospital|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|354|Samples With DNA|Collecting 2 EDTA tubes of 5 mL (blood)|Both|18 Years|N/A|No|Non-Probability Sample|The study deals with patients on OST precsribed to treat opiate dependence; the OST may be        methadone, buprenorphine (+/- naloxone) or a morphine-based drug.        The total group of patients to be inclued is estimated at 384 patients. Of these patients,        200 will take part in the ancillary study.        The number of recruitment centers foreseen allows this objective to be met in 6 months.        Those participating in this study will not be able to participate in another study        (notably in order to avoid drug interactions).|March 2016|March 24, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01847729||66938|
NCT01844089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029944|The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures|The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures: A Multi-Site Longitudinal Study An Initiative Under the East African Women's Health Network (EAWoHNet)||Duke University|Yes|Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|57|||Female|18 Years|N/A|No|Probability Sample|Any woman who recently delivered by either vaginal or cesarean delivery who experiences        postpartum hemorrhage.|February 2015|February 12, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844089||67217|
NCT01826851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 00044181|Parasternal Nerve Block in Cardiac Patients|Parasternal Intercostal Nerve Block in Post-Cardiac Surgery Patients: A Randomized, Controlled Trial of Extended-release Liposomal Bupivacaine (Exparel) Versus Placebo||University of Rochester|No|Recruiting|March 2013|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01826851||68535|
NCT01848535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABRnr42438|Effect of GOS Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults|Effect of Galacto-Oligosaccharides Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults : a Proof of Principal Study|GOS|Wageningen University|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01848535||66877|
NCT01849068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-B13-04-1195|Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study|Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study|EZEmRNA|Laval University|No|Recruiting|June 2013|December 2015|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|60 Years|No|||August 2015|August 24, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01849068||66837|
NCT01848548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLN Airway Trial|Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study|Superior Laryngeal Nerve Block For Airway Anesthesia Efficacy Study||Wake Forest Baptist Health|No|Recruiting|April 2013|December 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|95|||Both|18 Years|80 Years|No|Probability Sample|Scheduled Surgery Patients who require an awake intubation|December 2015|December 31, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01848548||66876|
NCT01851174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRMC 12-25|Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer|A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel in the First Line Treatment of Surgically Unresectable/Metastatic Pancreatic Cancer||Western Regional Medical Center|No|Terminated|February 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|February 15, 2013|Yes|Yes|PI Leaving Site|No||https://clinicaltrials.gov/show/NCT01851174||66675|
NCT01845441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-10|Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions|A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm.||University Hospital Case Medical Center|Yes|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|18 Years|85 Years|No|||April 2013|May 1, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845441||67113|
NCT01845688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiSTCSM-2011|Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy|Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study||Shanghai University of Traditional Chinese Medicine|No|Active, not recruiting|November 2011|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845688||67094|
NCT01846000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLTMD 40455|Low-level Laser Therapy on Temporomandibular Disorder|Evaluation of Effect of Low-level Laser Therapy on Adolescents With Temporomandibular Disorder||University of Nove de Julho|Yes|Recruiting|February 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|75|||Both|15 Years|18 Years|No|||April 2013|April 30, 2013|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01846000||67070|
NCT01846026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1392-13 (REK)|Ulcerative Colitis and Vitamin D Supplementation|Immunomodulating and Clinical Effects of Vitamin D on Remission Induction in Patients With Moderate and Severe Ulcerative Colitis, Undergoing Treatment With Infliximab.||University Hospital of North Norway|Yes|Withdrawn|April 2013|December 2016|Anticipated|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 30, 2013||No|At the planned study start new treatment guidelines for this disease with new drugs were    implemented in clinical practice.|No||https://clinicaltrials.gov/show/NCT01846026||67068|
NCT01846039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLXC-AP-ND-001|JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose|A Prospective, Open-label Study of the Safety and Efficacy of JUVÉDERM VOLUMA® to Enhance the Aesthetic Appearance of the Asian Nose||Allergan|Yes|Completed|April 2013|August 2014|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|May 1, 2013||No||No|September 11, 2015|https://clinicaltrials.gov/show/NCT01846039||67067|
NCT01846377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29172|Video Games for Obesity and Diabetes Prevention-Diab & Nano|Video Games for Obesity and Diabetes Prevention: Efficacy Trial|G4H-DiabNano|Baylor College of Medicine|Yes|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|444|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846377||67041|
NCT01846975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BREAK|Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday|A Phase IV, Open Label Study Introducing a Single IV Treatment With Abatacept in Patients With Rheumatoid Arthritis Currently Receiving Weekly Injections of SC Abatacept to Simulate a Holiday or Patient Vacation|A-BREAK|Cantonal Hospital of St. Gallen|Yes|Completed|May 2013|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01846975||66996|
NCT01846962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric-EoE|Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis|COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS)||Azienda Policlinico Umberto I|No|Recruiting|November 2012|June 2013|Anticipated|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|6 Months|18 Years|No|||November 2012|May 3, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846962||66997|
NCT01847222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGHV-005|An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.|An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.||Prolong Pharmaceuticals|No|Terminated|May 2013|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|2|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|April 23, 2013||No|Terminated due to completion of competing study.|No||https://clinicaltrials.gov/show/NCT01847222||66977|
NCT01847482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOL-ARREST JP|Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients in Japan|COOL-ARREST JP: A Multicenter, Prospective, Single-arm Interventional Trial to Evaluate Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients||ZOLL Circulation, Inc., USA|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|80 Years|No|||June 2014|June 30, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01847482||66957|
NCT01847742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1No:4|EMDR Intervention for Psychological Trauma Among Syrian Refugees|EMDR Treatment for Psychological Trauma Among Syrian Refugees in Kilis, Randomized Controlled Trial.||Istanbul Sehir University|Yes|Recruiting|April 2013|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||August 2013|August 7, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01847742||66937|
NCT01848041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVL-1201-001|Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis|A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis||RevitaLid Inc.|No|Completed|May 2013|February 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848041||66914|
NCT01844102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|416416|Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia|Evaluation of the Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia||FHI 360|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|500|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|April 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01844102||67216|
NCT01827150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-030-CERES-D|The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve|The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve||Université de Montréal|Yes|Recruiting|June 2013|April 2014|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2013|July 22, 2013|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01827150||68512|
NCT01827163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002|Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer|The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827163||68511|
NCT01827176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094/2556(EC4)|Clinical Characteristic of Recurrent Acute Rhinosinusitis in Children|Clinical Characteristic of Recurrent Acute Rhinosinusitis in Children||Mahidol University|Yes|Completed|March 2013|September 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|94|||Both|N/A|15 Years|No|Non-Probability Sample|The patients from pediatric allergy clinic will be selected.|September 2014|September 8, 2014|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01827176||68510|
NCT01827787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-077|Eribulin in HER2 Negative Metastatic BrCa|A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes||Dana-Farber Cancer Institute|Yes|Recruiting|June 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01827787||68463|
NCT01850693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRF 2010-0023504|Assessment of Coronary Artery Disease in Stroke Patients|Prevalence and Characteristics of Coronary Atherosclerosis in Stroke Patients Using Coronary CT Angiography|ACADIS|Seoul National University Hospital|Yes|Completed|July 2006|June 2015|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|1657|||Both|30 Years|N/A|No|Non-Probability Sample|Stroke patients on the basis of TOAST classification|May 2013|November 8, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01850693|5 Years|66712|
NCT01850966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRM01T|Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis|Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis||Eisai Inc.|No|Recruiting|September 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1108|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals and clinics in Japan|April 2015|April 7, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01850966||66691|
NCT01850082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|588|Randomized Endo-Vein Graft Prospective|CSP #588 - Randomized Endo-Vein Graft Prospective (REGROUP) Trial|REGROUP|VA Office of Research and Development|Yes|Recruiting|September 2013|October 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1150|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01850082||66759|
NCT01850095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1622/11|The Influence of Peripheral Androgen Conversion at Women Adult Acne|The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.||Federal University of São Paulo|Yes|Recruiting|March 2012|January 2015|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|60|||Female|26 Years|44 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01850095||66758|
NCT01848275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN- RDN Strategy|Full Length Versus Proximal Renal Arteries Ablation|The Clinical Efficacy Comparison of Two Renal Sympathetic Denervation Strategies ---- Full Length Versus Proximal Renal Arteries Ablation||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|March 2011|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||May 2013|May 6, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848275||66896|
NCT01851421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130097|Fat Metabolism and Melanocortin 3 Receptors in African Americans|Fat Metabolism and Function Altering Polymorphisms in MC3R||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|400|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01851421||66657|
NCT01851434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130104|Natural History of Optic Neuritis|Natural History of Optic Neuritis||National Institutes of Health Clinical Center (CC)||Suspended|March 2013|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01851434||66656|
NCT01845454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2603|A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy|A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)|DOSE|CSA Medical, Inc.|No|Terminated|April 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|April 25, 2013|No|Yes|poor enrollment and study design|No||https://clinicaltrials.gov/show/NCT01845454||67112|
NCT01845701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A60041|Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon|Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon||University of Yaounde 1|Yes|Completed|March 2010|April 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|720|||Both|6 Months|120 Months|No|||May 2015|May 27, 2015|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01845701||67093|
NCT01846390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY15|Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma|A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma||Canadian Cancer Trials Group|Yes|Recruiting|May 2013|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|March 22, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846390||67040|
NCT01846403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002|Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test in an Assisted Fertility Setting|Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test to Replace Sequential Serum hCG Testing in an Assisted Fertility Setting||Gynuity Health Projects|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|50|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846403||67039|
NCT01846702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14530|A Study of LY3084077 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3084077 in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|54|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846702||67016|
NCT01846988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001APAP|Comparing Auto-adjustable Positive Airway Pressure to Continuous Positive Airway Pressure in Children With Sleep Apnea|Efficacy of Auto-adjustable Positive Airway Pressure (APAP) in Pediatric Patients With Obstructive Sleep Apnea (OSA).||Children's Hospital Medical Center, Cincinnati|No|Recruiting|October 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|20 Years|No|||September 2015|September 25, 2015|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846988||66995|
NCT01847235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OD_OA|Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial|The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial||Seoul National University Hospital|Yes|Recruiting|May 2013|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||June 2015|June 24, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01847235||66976|
NCT01847495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5443|Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis|Prospective Evaluation of Low-dose Irinotecan and Cyberknife® Stereotactic Body Radiotherapy in the Treatment of Patients With Colorectal Cancer and Limited Liver Metastasis||Advocate Health Care|Yes|Recruiting|October 2013|October 2025|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01847495||66956|
NCT01847755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMC-TBI-001|Hyperbaric Treatment of Traumatic Brain Injury (TBI)|Phase 1-2 Study of Hyperbaric Treatment of Traumatic Brain Injury|TBI|Jupiter Medical Center|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847755||66936|
NCT01848054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX219-007|Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence|A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence||Orexo AB|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|May 2, 2013|Yes|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01848054||66913|
NCT01843790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS-100-CS-4002|A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease|A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease||La Jolla Pharmaceutical Company|No|Completed|June 2013|September 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|April 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843790||67240|
NCT01849146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00858|WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme|Phase I Study of AZD1775 (MK-1775) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)|No|Recruiting|August 2013|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||February 2016|March 23, 2016|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01849146||66831|
NCT01849159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-HYP-01|Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema|Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema||Federal Research Clinical Center of Federal Medical & Biological Agency, Russia|Yes|Recruiting|March 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|75 Years|No|||October 2015|October 26, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01849159||66830|
NCT01827540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBR 652-1-110|Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam|A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam||Tobira Therapeutics, Inc.|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|March 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01827540||68482|
NCT01827527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 422234|Magnetic Resonance & Optical Spectroscopy Validation|Development and Validation of 31P Magnetic Resonance and Optical Spectroscopy for the Characterization of ATP in Whole Body Human Applications||Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Recruiting|March 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adult volunteers|January 2016|January 14, 2016|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01827527||68483|
NCT01844037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1002|OneShot Renal Denervation Registry|Renal Denervation Using the OneShot Ablation System||Medtronic Endovascular||Terminated|July 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844037||67221|
NCT01844050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06DZ19728-2|Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms|||Shanghai University of Traditional Chinese Medicine|Yes|Completed|September 2008|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||May 2013|May 21, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01844050||67220|
NCT01851941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 0406127 007|A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer|||Seoul National University Hospital|No|Completed|October 2004|||June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|75 Years|No|||May 2013|May 8, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01851941||66617|
NCT01851954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clarith_VLBW|Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)|Pharmacokinetic Study of Clarithromycin in Premature Infants With Safety Evaluation||Seoul National University Hospital|Yes|Terminated|February 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|N/A|1 Month|No|||November 2014|November 17, 2014|April 12, 2013||No|declined enrollment|No||https://clinicaltrials.gov/show/NCT01851954||66616|
NCT01850914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-52-31M|Vascular Risk Factors in INPH-patients|Vascular Risk Factors, Subclinical and Manifest Vascular Disease in Patients With Idiopathic Normal Pressure Hydrocephalus||Umeå University|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|860|||Both|60 Years|85 Years|No|Probability Sample|Cases are all INPH-patients who underwent surgery 2008-2010 and are registered in the        Swedish National Register of Hydrocephalus. Controls were found in the Swedish population        indox of Umeå, and were indivdually matched to cases according to age and sex.|May 2013|May 27, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01850914||66695|
NCT01850927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSRG-002|Perioperative Reduction of Inapparent Myocardial Injury|Effect of Remote Ischemic Preconditioning on Subclinical Myocardial Injury in Major Abdominal Surgery: a Randomised Controlled Trial|PRIME|London Surgical Research Group|No|Active, not recruiting|June 2013|March 2017|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|84|||Both|45 Years|N/A|No|||March 2016|March 5, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01850927||66694|
NCT01852149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLPR-005|Mitralign Percutaneous Annuloplasty First in Man Study|Mitralign Percutaneous Annuloplasty First in Man (FIM) Study||Mitralign, Inc.|No|Completed|August 2009|September 2015|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01852149||66601|
NCT01845714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT-KC-VSQOL3|Impact of Keratoconus, Cross-linking and Cross-linking Combined With Topo-guided Photorefractive Keratectomy on Self-reported Quality of Life. A Three-year Update.|Impact of Keratoconus, Cross-linking and Cross-linking Combined With Topo-guided Photorefractive Keratectomy on Self-reported Quality of Life. A Three-year Update.||Democritus University of Thrace||Completed|April 2009|October 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|45 Years|No|||April 2013|May 1, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01845714||67092|
NCT01846052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHM-001|Clinical and Genetic Characterization of Individuals With Achromatopsia|Clinical and Genetic Characterization of Individuals With Achromatopsia||Applied Genetic Technologies Corp|No|Recruiting|June 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|DNA samples will be stored at the DNA testing laboratory for additional testing for      mutations in other genes that may be causally related to achromatopsia.|Both|6 Years|N/A|No|Non-Probability Sample|Individuals with a clinical diagnosis of achromatopsia|December 2015|December 28, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01846052||67066|
NCT01846416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28625|A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR"|A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer||Genentech, Inc.||Active, not recruiting|May 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846416||67038|
NCT01846429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17136|Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain|A Phase I/II Study of Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|September 2013|May 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|May 1, 2013|No|Yes|Drugs unavailable. Study did not progress to Phase 2.|No||https://clinicaltrials.gov/show/NCT01846429||67037|
NCT01846715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL010|Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease|A Phase 1, Open-Label Safety and Delivery Optimization Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Chronic Kidney Disease (CKD)||Tengion|No|Terminated|April 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||December 2014|December 10, 2014|April 30, 2013|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01846715||67015|
NCT01847261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #12-226|Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults|A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown in Healthy Older Adults||Solae, LLC|No|Recruiting|April 2013|April 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Male|55 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01847261||66974|
NCT01851551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA00005|Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL|A Phase I/II Study of Rituximab Plus Vincristine Sulfate Liposomes Injection in the Treatment of Relapsed or Refractory Aggressive Non Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc|No|Completed|September 2001|April 2005|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01851551||66647|
NCT01847248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPA12B-sepsis-biomarker|HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis|||Changhai Hospital|Yes|Completed|May 2011|October 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|118|Samples Without DNA|Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Continuous patients with sepsis, severe sepsis, SIRS after major orthopedics surgery and        healthy volunteers|November 2013|November 22, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01847248||66975|
NCT01847508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHILOS+|PHILOS Augmented - a Multicenter Randomized Controlled Trial|A Multicenter Randomized Controlled Trial to Investigate the Treatment Outcome of PHILOS Screw Augmentation Compared to PHILOS Without Augmentation in Older Adult Patients With Proximal Humerus Fractures||AO Clinical Investigation and Documentation|Yes|Recruiting|October 2013|May 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01847508||66955|
NCT01847521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroproteckOpenLabel|Effects of the Anti-inflammatory Flavonoid Luteolin on Behavior in Children With Autism Spectrum Disorders|||Attikon Hospital||Completed|December 2011|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|4 Years|10 Years|No|||May 2013|May 2, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847521||66954|
NCT01847768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AADCRC-UC-01|Human Rhinovirus Infection and Airway Remodeling Mediators|Comparison of Airway Remodeling Mediators Following Experimental Human Rhinovirus Infection in Subjects With Mild to Moderate Asthma, and in Healthy, Non-asthmatic Control Subjects (AADCRC-UC-01)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Terminated|April 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|2|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|May 1, 2013|No|Yes|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT01847768||66935|
NCT01848067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.128|Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer|A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone||Thomas Jefferson University|Yes|Recruiting|August 2013|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Male|18 Years|N/A|No|||November 2015|November 6, 2015|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01848067||66912|
NCT01843803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 12-280|Improving Patient-centered Care Using an Inventory|Developing a Patient Inventory to Facilitate Patient-centered Care Delivery||VA Office of Research and Development|Yes|Recruiting|December 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|167|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01843803||67239|
NCT01849172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAI24B01|Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition|Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition —a Multicenter Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Female|40 Years|55 Years|No|||December 2014|December 21, 2014|May 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849172||66829|
NCT01836185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14621|A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment|Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment||Eli Lilly and Company|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|48|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01836185||67821|
NCT01836523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9211-3919|The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes|The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial|ADJUNCT ONE™|Novo Nordisk A/S|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|1398|||Both|18 Years|75 Years|No|||June 2015|June 9, 2015|April 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01836523||67796|
NCT01827813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProstatBX|Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies|Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies||TC Erciyes University|No|Completed|June 2007|February 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|74|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01827813||68461|
NCT01828073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1097|Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants|Raltegravir Pharmacokinetics and Safety in Neonates||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|April 2011|||August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|45|||Female|N/A|N/A|No|Non-Probability Sample|This study will enroll two cohorts: Cohort 1 will enroll HIV-infected pregnant women and        their full-term infants, and Cohort 2 will enroll HIV-infected pregnant women and their        low birth weight infants.|February 2016|February 1, 2016|April 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01828073||68441|
NCT01852188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 20638|Intrapartum Study of Sterile and Clean Gloves|A Comparison of Sterile and Non-sterile Gloves for the Incidence of Chorioamnionitis During Labor: a Randomized Controlled Trial||Medical University of South Carolina|No|Recruiting|May 2011|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|470|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01852188||66598|
NCT01844869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41443/1103 Study|An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate|An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors||Teva Pharmaceutical Industries|No|Completed|July 2013|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01844869||67157|
NCT01844882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-CKD-2013|The Effects of Dietary Fiber in CKD: A Systematic Review and Meta-analysis|The Effects of Dietary Fiber on Uremic Retention Solutes in CKD: A Systematic Review and Meta-analysis||St. Michael's Hospital, Toronto|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|patients with Chronic Kidney Disease (CKD)|November 2014|November 20, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844882||67156|
NCT01845142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ViDImmun|Immunologic Action of a Single Dose Cholecalciferol|Immunologic Functions of a Single Dose of 100.000 I.U. Cholecalciferol (Vitamin D3)|ViDImmun|Charite University, Berlin, Germany|Yes|Completed|February 2013|April 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01845142||67136|
NCT01845727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-CL-TF001|Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia|Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia|Anfoleish|Drugs for Neglected Diseases|No|Active, not recruiting|February 2014|September 2016|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|No|||February 2016|February 17, 2016|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01845727||67091|
NCT01845740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-115-04|Phase Ib Study of SC Milatuzumab in SLE|A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)||Immunomedics, Inc.|No|Recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|April 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01845740||67090|
NCT01846065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055208|Tobacco Craving and Triggers in Persons With Schizophrenia|||University of Maryland|No|Recruiting|September 2013|May 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|55 Years|No|Probability Sample|This study will include: current smokers with a DSM-IV diagnosis of schizophrenia or        schizoaffective disorder. Participants with schizophrenia will be considered on a stable        medication regimen if they have received their current antipsychotic medication(s) for at        least 6 weeks and the same dose for at least 30 days.|June 2015|June 5, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01846065||67065|
NCT01846078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si343/2012|Accuracy of Holladay 2 Formula in the Absence of Lens Thickness|Accuracy of Holladay 2 Formula Using IOLMaster Parameters in the Absence of Lens Thickness||Mahidol University||Completed|June 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|143|||Both|44 Years|89 Years|Accepts Healthy Volunteers|||April 2013|May 2, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846078||67064|
NCT01846728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0149|Effects of Estrogen Deficiency on Energy Expenditure|Ovarian Function and Facultative Thermogenesis||University of Colorado, Denver|Yes|Recruiting|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01846728||67014|
NCT01847001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI9158|Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy|A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer||Columbia University|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|April 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847001||66994|
NCT01851759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing005|Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction|A Random, Double-blind, Placebo- Controlled and Dose-finding, Multi-center, Phase II Clinical Trial of Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction||Xijing Hospital|Yes|Not yet recruiting|October 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|40 Years|75 Years|No|||May 2013|May 7, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01851759||66631|
NCT01847534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC RC AD 003|Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial|Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial||Australian and New Zealand Intensive Care Research Centre|No|Recruiting|February 2014|July 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|16 Years|N/A|No|||October 2015|October 13, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01847534||66953|
NCT01847781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004486-41|PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency|PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency|PNEUMOCELL|Karolinska University Hospital|Yes|Completed|May 2013|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01847781||66934|
NCT01847794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG5002|HER2 Positive CTC in Advanced Gastric Cancer|Clinical Significance of HER2 Positive Circulating Tumor Cells(CTCs) in the Peripheral Blood of Patients With Advanced Gastric Cancer|AGC-HER2CTC|Peking University||Not yet recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01847794||66933|
NCT01848080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-217-S1|A Randomized, Non-inferiority Clinical Trial of CVA Telerehabilitation Treatments - TelePhysioTaiChi|A Tai Chi Based Exercise Program Provided Via Telerehabilitation Compared to During Home Visits in Persons Post-Stroke Who Have Returned Home Without Intensive Rehabilitation: A Randomized, Non-inferiority Clinical Trial||Université de Sherbrooke|No|Recruiting|June 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|45 Years|N/A|No|||April 2015|April 20, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01848080||66911|
NCT01848626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI 04|Study With Advanced Vaginal Tactile Imager|Study With Advanced Vaginal Tactile Imager||Artann Laboratories|No|Completed|April 2013|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|22|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult females, presenting to the urogynecological office for a vaginal examination with        normal pelvic floor organs, referred to gynecologic examination due to pelvic organ        prolapse concern or earlier diagnosed with pelvic organ prolapse, will be considered        eligible as volunteers to be enrolled in the clinical studies.|July 2014|July 14, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01848626||66870|
NCT01848899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02409|Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography|The Assesment of Thrombotic Markers Utilizing Ionic Versus Non-Ionic Contrast During Coronary Angiography and Intervention (AToMIC) Trial||New York University School of Medicine|No|Completed|February 2013|November 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|104|||Both|18 Years|N/A|No|||October 2015|November 11, 2015|April 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01848899||66850|
NCT01849458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tornier 2013-1|BioFiber Scaffold Post-Market Observational Study|BioFiber and BioFiber-CM Absorbable Biologic Scaffold for Soft Tissue Repair and Reinforcement Post-Market Surveillance Clinical Study||Tornier, Inc.|No|Active, not recruiting|June 2013|December 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Orthopedic referral clinic|November 2015|November 4, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01849458||66807|
NCT01836536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA-CELL|Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients|Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment|AVA-CELL|Center Eugene Marquis|No|Completed|September 2012|August 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|August 18, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01836536||67795|
NCT01836822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPU-DIMPA-WUM13(1)|Bronchoscopic Sampling Techniques in Sarcoidosis|Diagnostic Accuracy of Different Bronchoscopic Sampling Techniques in Patients With Mediastinal Lymph Node Enlargement Suspected of Sarcoidosis||Medical University of Warsaw|No|Recruiting|March 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|80 Years|No|||February 2014|February 11, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01836822||67773|
NCT01844596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1056|Optimizing Linkage and Retention to Hypertension Care in Rural Kenya|Optimizing Linkage and Retention to Hypertension Care in Rural Kenya||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|April 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1800|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844596||67178|
NCT01844609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42338|China Obstetrics and Gynecology Journal Club|An English Language Obstetrics and Gynecology Journal Club to Improve Medical English in China: A Randomized Controlled Trial|COG-JOCS|Milton S. Hershey Medical Center|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 24, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01844609||67177|
NCT01844297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACT1215|Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy|Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection||Peking Union Medical College|Yes|Not yet recruiting|May 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|65 Years|No|||April 2013|April 26, 2013|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01844297||67201|
NCT01845155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTR-TC-02|Neuro-Music-Therapy for Patients With Chronic Tinnitus - a Controlled Clinical Trial|Neuro-Music-Therapy for Patients With Chronic Tinnitus - a Controlled Clinical Trial||German Center for Music Therapy Research||Completed|March 2006|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|April 24, 2013||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT01845155||67135|
NCT01845467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRCP-ChiRhoClin-JHMI|Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis|Efficacy of Secretin Assisted Dynamic MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis(AIP)|S-MRCP|Johns Hopkins University|Yes|Recruiting|February 2013|April 2014|Anticipated|February 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|90 Years|No|Non-Probability Sample|A total of 100 patients with suspicion of Auto Immune Pancreatitis will be identified from        the multidisciplinary pancreatic cancer clinic at Johns Hopkins and from the Pancreatitis        clinic of the Division of Gastroenterology, Johns Hopkins Hospital. The patients will be        managed as part of standard of care.|April 2013|April 30, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01845467||67111|
NCT01845480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSU-CHE-SRO-WWCT|The Wildcat Wellness Coaching Trial|The Wildcat Wellness Coaching Trial: Home-based Obesity Prevention and Health Promotion in Children and Adolescents||Kansas State University|No|Recruiting|August 2012|May 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Female|8 Years|13 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01845480||67110|
NCT01846091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0979|Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer|Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck||Mayo Clinic|Yes|Recruiting|April 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846091||67063|
NCT01846104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-23|Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|RVEc|U.S. Army Medical Research and Materiel Command|No|Completed|May 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|4|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01846104||67062|
NCT01846442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-210|Topical DHEA Against Vaginal Atrophy|Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)||EndoCeutics Inc.|No|Completed|June 2007|October 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|218|||Female|40 Years|75 Years|No|||February 2016|February 19, 2016|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846442||67036|
NCT01846455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-08-0003|Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects|Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers||Indivior Inc.|No|Completed|August 2012|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|August 20, 2013|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01846455||67035|
NCT01859429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP-332-026|Stepped Care - Optimising Psycho-oncological Care Provision by Structured Screening and Diagnosis|Stepped Care - Optimising Psycho-oncological Care Provision by Structured Screening and Diagnosis|STEPPEDCARE|University of Leipzig|No|Active, not recruiting|April 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859429||66043|
NCT01859702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-235|Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients|Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients||Alcon Research|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|May 20, 2013||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01859702||66023|
NCT01859715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1692|Emergency Department (ED) Drug Interaction in Emergency Department Patients|Hepatic Cytochrome Drug Interactions in Emergency Department Patients||University of Colorado, Denver|No|Completed|June 2012|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|502|||Both|18 Years|95 Years|No|||May 2013|May 21, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01859715||66022|
NCT01869075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-2006|Toronto Thromboprophylaxis Patient Safety Initiative|Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial|TOPPS|Sunnybrook Health Sciences Centre|No|Completed|July 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|6||Actual|1895|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|April 3, 2013||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT01869075||65306|
NCT01869088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-120402|TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma|Phase Ⅲ Trial of Transcatheter Arterial Chemoembolization(TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)||Sun Yat-sen University|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||May 2013|May 30, 2013|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01869088||65305|
NCT01869348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-071|IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial|IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial|IMPACT|The University of Texas Medical Branch, Galveston|No|Active, not recruiting|June 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|55 Years|79 Years|Accepts Healthy Volunteers|||September 2014|December 1, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01869348||65285|
NCT01866124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACF0213|MAM'Out Project - Evaluation of Multiannual and Seasonal Cash Transfers to Prevent Acute Malnutrition|MAM'Out Project - Evaluation of Multiannual and Seasonal Cash Transfers to Prevent Acute Malnutrition|MAM'Out|Action Contre la Faim|No|Completed|May 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1278|||Both|N/A|12 Months|No|||October 2015|October 9, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01866124||65532|
NCT01858116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABY-025-MI105|PET Study of Breast Cancer Patients Using [68Ga]ABY-025|An Exploratory Study to Evaluate [68Ga]ABY-025 for PET Imaging of HER2 Expression in Subjects With Metastatic Breast Cancer||Biomedical Radiation Sciences|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01858116||66143|
NCT01858402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 09/06|Paracetamol Versus Dipyrone After Pediatric Lower Abdominal Surgery in Children With Spinal Anesthesia|The Efficacy of Intravenous Paracetamol Versus Dipyrone for Postoperative Analgesia After Day-case Lower Abdominal Surgery in Children With Spinal Anesthesia: a Prospective Randomized Double-blind Study||Baskent University|Yes|Completed|December 2009|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858402||66121|
NCT01858129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0090-11-BNZ|Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn|Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn in Infants Born at >34 Weeks Gestation: A Prospective, Randomized, Double Blind, Placebo Controlled Study.||Bnai Zion Medical Center|No|Recruiting|March 2012|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|N/A|6 Hours|No|||January 2015|January 28, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01858129||66142|
NCT01866410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01085|Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer|Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866410||65510|
NCT01858077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR 10341|Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial|Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB™ Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME™ or XIENCE Xpedition™) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.|AIDA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Active, not recruiting|August 2013|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1850|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01858077||66146|
NCT01858090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA08/48|Intrathecal Levobupivacaine With Opioids for Caesarean Section|Comparison of Intrathecal Levobupivacaine Combined With Sufentanil, Fentanyl, or Placebo for Elective Caesarean Section: A Prospective, Randomized, Double-blind, Controlled Study||Baskent University|Yes|Completed|January 2009|January 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|93|||Female|19 Years|40 Years|No|||May 2013|May 20, 2013|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858090||66145|
NCT01866982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREMOD|The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants|The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants|PREMOD|Sharp HealthCare|Yes|Active, not recruiting|August 2013|December 2017|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 10, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866982||65466|
NCT01867281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-01-119-20728|The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases|The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases||Tehran University of Medical Sciences|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|90 Years|No|||June 2014|June 28, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867281||65443|
NCT01858064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013000956|Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging|Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging||Massachusetts General Hospital|No|Withdrawn|April 2015|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|No|||April 2015|April 27, 2015|May 16, 2013|Yes|Yes|Competing Departmental Studies|No||https://clinicaltrials.gov/show/NCT01858064||66147|
NCT01859455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGT209X2105|Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins|A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers||Novartis|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859455||66041|
NCT01860053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2030-09|A Behavioral Intervention to Decrease Vomiting and Improve Weight Loss in Post-Operative Laparoscopic Adjustable Gastric Banding (LAGB) Patients|||The Miriam Hospital||Suspended|May 2009|||February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||May 2013|May 19, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01860053||65996|
NCT01860066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2328|A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation||Novartis|No|Withdrawn|December 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||November 2013|November 8, 2013|April 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01860066||65995|
NCT01860027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOMRD|Eye Movements and Reading Disabilities|Reliability of Clinical Eye Movement Tests as Screening Devices for Reading Disabilities|EOMRD|Scripps Health|Yes|Terminated|December 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1|||Both|7 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with reading disorders, eye movement disorders or control (normal reading and        eyemovements)between the ages of 7 and 13 are eligible for the study.|December 2013|May 18, 2015|May 20, 2013||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01860027||65998|
NCT01868061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB28689|A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication||Hoffmann-La Roche||Active, not recruiting|July 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1068|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868061||65383|
NCT01868555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1790|Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects|A Randomised, Double-blind, Single Centre, Placebocontrolled, Parallel Group, Multiple s.c. Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Two SIAC Preparations and Two Insulin 454 (SIBA) Preparations in Healthy Japanese Male Subjects||Novo Nordisk A/S|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868555||65345|
NCT01859117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA-002-DFU-001|Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU|A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer||Celgene|Yes|Active, not recruiting|May 2013|October 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|80 Years|No|||October 2015|October 22, 2015|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859117||66066|
NCT01859130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2012-10K|Zimmer POLAR - Total Knee Arthroplasty (TKA)|Persona Outcomes Led Assessment Research in Total Knee Arthroplasty||Zimmer, Inc.|No|Recruiting|April 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859130||66065|
NCT01868542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3994|A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)|A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea||Novo Nordisk A/S|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868542||65346|
NCT01868776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|buffered anesthetic toothache|Effect of Buffered Numbing Solution on Patients With Toothaches|Effect of Buffered Lidocaine on the Success of the Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis||Ohio State University|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|May 30, 2013||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01868776||65328|
NCT01868789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-12-00397|Weightbearing Assessment of Tarsal Instability|In-Vivo Physiologic Weight-Bearing Assessment of Tarsal Instability: Three-Dimensional Cone-Beam Computed Tomography Analysis|WBCT|Orthopedic Foot and Ankle Center, Ohio|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|23|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868789||65327|
NCT01865604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS_cVMR|Impact of tDCS on Cerebral Autoregulation|||Charite University, Berlin, Germany|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01865604||65572|
NCT01865838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seprafilm in Thyroidectomy|A Study Into the Effect of Seprafilm in Open Total Thyroidectomy|A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.||National Cancer Centre, Singapore|Yes|Terminated|May 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Both|21 Years|75 Years|No|||April 2015|April 23, 2015|May 14, 2013||No|safety issue|No||https://clinicaltrials.gov/show/NCT01865838||65554|
NCT01857271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-233|Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer|EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III NSCLC Patients With EGFR Mutations (EVENT Trial)|EVENT|Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|November 2013|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|May 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01857271||66207|
NCT01857869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117014|Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults|Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults||GlaxoSmithKline||Completed|May 2013|December 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857869||66162|
NCT01857882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1027-CE|Decision Support Workshop for Breast Reconstruction|Breast Reconstruction Decision Workshop Pilot RCT (Randomized Controlled Trial)|DSW|University Health Network, Toronto|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Female|18 Years|79 Years|No|||June 2015|June 16, 2015|May 6, 2013||No||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01857882||66161|
NCT01858415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC210118_S, rev. 01|Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles|Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles and Rhytides||Pollogen|No|Active, not recruiting|April 2013|||December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 11, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01858415||66120|
NCT01858714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK092374|Environmental and Acceptance-Based Innovations for Weight Loss Maintenance||ENACT|Drexel University|Yes|Active, not recruiting|September 2011|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|297|||Both|18 Years|70 Years|No|||October 2014|October 3, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01858714||66097|
NCT01857856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCC2012007|PHOspholamban RElated CArdiomyopathy STudy - Intervention|PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomatic PLN-R14del Carriers)|i-PHORECAST|University Medical Center Groningen|Yes|Recruiting|May 2013|December 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|65 Years|No|||December 2015|December 1, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01857856||66163|
NCT01888120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001|Patient Registry of Intrathecal Ziconotide Management(PRIZM)|Patient Registry of Intrathecal Ziconotide Management (PRIZM): An Open-Label, Long Term, Multi-Center, Observational Study of PRIALT® (Ziconotide) Solution, Intrathecal Infusion, in Patients With Severe Chronic Pain|PRIZM|Jazz Pharmaceuticals|No|Recruiting|July 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Up to 140 patients will be enrolled at approximatley 50 sites in the United States.|June 2015|June 18, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888120|18 Months|63845|
NCT01858675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01310-41|Biomarkers Correlation With Volemia|Predictive Value of Biomarkers on Volemia, Extra and Intra Vascular Varation and Hydroelectrolytic Disorders in Different ICU Patients|ENVOL|ThermoFisher Scientific Brahms Biomarkers France|No|Completed|March 2012|December 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01858675||66100|
NCT01858896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP00055308|GLP-1 and Hypoglycemia|Hypoglycemia Associated Autonomic Dysfunction||University of Maryland|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858896||66083|
NCT01867515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1020-R|Spectral Dynamics and Speech Understanding by Hearing Impaired People|Spectral Dynamics and Speech Understanding by Hearing Impaired People||VA Office of Research and Development|No|Enrolling by invitation|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|None Retained|None collected|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|December 2015|December 15, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01867515||65425|
NCT01859767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-672-01|Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.|An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.||Molecular NeuroImaging|No|Active, not recruiting|April 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 14, 2014|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859767||66018|
NCT01860040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-04|Neoadjuvant Chemo for NSCLC|Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer||Western Regional Medical Center|No|Terminated|April 2013|April 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|May 17, 2013|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT01860040||65997|
NCT01860079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the EDAP PCI trial|Early Discharge After Primary Percutaneous Coronary Intervention|Early Discharge After Primary Percutaneous Coronary Intervention: A Prospective Randomized Multi-center Trial (the EDAP PCI Trial)|EDAPPCI|Acibadem University|Yes|Recruiting|May 2013|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|N/A|N/A|No|||January 2015|January 13, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01860079||65994|
NCT01860300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapienza Università di Roma|Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus|Multicentre, Randomised, Double-blinded, Placebo-controlled Trial of Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus|AntibioTICS|University of Roma La Sapienza|Yes|Recruiting|March 2013|May 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|3 Years|16 Years|No|||December 2014|December 1, 2014|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01860300||65977|
NCT01860313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|573974/2008-0|Mental Health Training for Elementary Teachers Through Tele-education and Its Impact on the School Atmosphere|Mental Health Training for Elementary Teachers Through Tele-education and Its Impact on the School Atmosphere||University of Sao Paulo|No|Completed|January 2010|July 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|213|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 19, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01860313||65976|
NCT01868802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC KET-DRT-01-2013|Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population|Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population||American British Cowdray Medical Center|Yes|Recruiting|September 2013|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2015|March 13, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01868802||65326|
NCT01860274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-06|Meshed Safen Graft Patency Trial|Randomized Prospective Comparison of Patency in Safen Vein Graft to the Diagonal Branch Under 1.5 mm||Cardiochirurgia E.H.|Yes|Not yet recruiting|May 2013|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||May 2013|May 21, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860274||65979|
NCT01868321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRoVENT|Practice of Ventilation in Critically Ill Patients Without ARDS|Practice of Ventilation in Critically Ill Patients Without Acute Respiratory Distress Syndrome - An International Observational Study|PRoVENT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1030|||Both|18 Years|N/A|No|Probability Sample|Intubated and ventilated ICU-patients.|April 2015|April 25, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01868321||65363|
NCT01869101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TET2013-001|Prospective Observational Study Assessing Treatment and Outcomes of Patients With Prediabetes|A Multicenter, 26-Week, Prospective Observational Study in Adult Patients With Prediabetes Assessing Patient Treatment and Outcomes in Community-Based Clinical Practice||Tethys Bioscience, Inc.|No|Not yet recruiting|June 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|560|Samples Without DNA|Serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|U.S.-based primary care practices|May 2013|May 30, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869101||65304|
NCT01869361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00533|Indomethacin for Tocolysis|Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis||MetroHealth Medical Center|Yes|Not yet recruiting|November 2015|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Female|16 Years|50 Years|No|||September 2015|September 23, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869361||65284|
NCT01869582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Safer Births|Safer Births - Reducing Perinatal Mortality|Safer Births - New Knowledge and Innovations to Decrease Perinatal Mortality and Morbidity Worldwide||Helse Stavanger HF|Yes|Recruiting|April 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20000|||Both|N/A|N/A|No|||February 2016|February 23, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01869582||65267|
NCT01865591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITV-CL-0001|Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension|A Clinical Trial for the Assessment of Safety and Efficacy of the UltraSOUND Mediated InTerVentional Treatment of Resistant Hypertension|SoundITV|Sound Interventions, Inc.|No|Recruiting|April 2012|||July 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||May 2013|May 30, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01865591||65573|
NCT01857284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009L05707|Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis|A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical Trial to Investigate Safety and Efficacy of Tauroursodeoxycholic Acid Capsules in Treatment of Adult Primary Biliary Cirrhosis||Beijing Friendship Hospital|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|70 Years|No|||May 2013|May 16, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857284||66206|
NCT01858454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-012|Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy|A Randomized Controlled Trial of Hand-assisted Laparoscopic Myomectomy Versus Abdominal Myomectomy: Surgical Outcomes and Patient Satisfactions||CHA University|No|Terminated|March 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|70 Years|No|||April 2015|April 15, 2015|May 17, 2013|Yes|Yes|The study enrollment is not enough|No||https://clinicaltrials.gov/show/NCT01858454||66117|
NCT01858935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-L02-s0201-001|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects||Nitto Denko Corporation|Yes|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|56|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858935||66080|
NCT01858688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-056|A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer|A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|June 2013|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858688||66099|
NCT01888133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 2012-12|Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients|Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients||Joslin Diabetes Center|Yes|Terminated|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|April 2, 2013||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01888133||63844|
NCT01888406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15DK092768-O1A1|Binge Eating Self-help Treatment for University Students|Targeting Binge Eating to Prevent Weight Gain in College Students|BEST4US|Wesleyan University|Yes|Active, not recruiting|January 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01888406||63823|
NCT01859195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS-ES-ID-11941|Monoclonal Antibody-based Multipurpose Microbicides|Monoclonal Antibody-based Multipurpose Microbicides|Project WIND|The Miriam Hospital|No|Active, not recruiting|May 2013|July 2016|Anticipated|September 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females who are 18-45 years old, HIV negative or unknown (self report), non-pregnant and        not intending to get pregnant (self report), and report vaginal sex with a man in the past        12 months.|October 2015|October 5, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01859195||66060|
NCT01859156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2713|End-Tidal Carbon Dioxide as a Measure of Carboxyhemoglobin in Carbon Monoxide Poisoning|End-Tidal Carbon Dioxide as a Measure of Carboxyhemoglobin in Carbon Monoxide||Minneapolis Medical Research Foundation||Completed|October 2006|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department at an urban county hospital.|October 2014|October 28, 2014|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01859156||66063|
NCT01859169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT-B-01|Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma|Longterm Outcome of Photodynamic Therapy Compared With Biliary Drainage Alone in Patients With Unresectable Cholangiocarcinoma||Central South University|Yes|Suspended|June 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|30 Years|70 Years|No|Probability Sample|Patients with bile duct cancer|May 2013|May 17, 2013|May 10, 2013||No|Modifying the clinnicaltrials|No||https://clinicaltrials.gov/show/NCT01859169||66062|
NCT01859182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01014|Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery|A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers||National Cancer Institute (NCI)||Withdrawn|January 2013|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|September 8, 2014|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859182||66061|
NCT01859780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-246|Visual Distraction as a Means of Enhancing Child Resistance|Visual Distraction as a Means of Enhancing Child Resistance|VDCR|Michigan State University|No|Completed|August 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|229|||Both|2 Years|54 Months|Accepts Healthy Volunteers|||April 2015|April 6, 2015|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859780||66017|
NCT01860586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HsuPVR13|Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.|A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy||Wills Eye|No|Active, not recruiting|June 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860586||65955|
NCT01860599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB132171|Effects of Aerobic Exercise in Patients With Pre-diabetes|The Effect of Controlled Aerobic Exercise on Endothelial Dysfunction and Vascular Reactivity in Patients With Pre-diabetes: A Crossover Pilot Study||Baystate Medical Center|No|Completed|March 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|20 Years|70 Years|No|||July 2014|July 16, 2014|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01860599||65954|
NCT01860612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-001|Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects|Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects||Clinical Research Consultants, Inc.|No|Recruiting|October 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|460|||Both|22 Years|N/A|No|||March 2016|March 18, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860612||65953|
NCT01860326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2114|Evaluate the Pharmacokinetics, Safety, and Tolerability of DEB025 in Subjects With Hepatic Impairment Compared to Healthy Subjects|An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of DEB025 in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects With Normal Liver Function||Novartis||Completed|March 2011|||September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860326||65975|
NCT01860339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS055903|Growth and Development of the Striatum in Huntington's Disease|Growth and Development of the Striatum in Huntington's Disease|Kids-HD|University of Iowa|No|Recruiting|July 2005|||August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|400|Samples With DNA|Biospecimens are collected and retained for both case and control participants for genetic      testing purposes. Specimens are either a single sample of 1-2 teaspoons of blood drawn from      the arm or 1 teaspoon of saliva via collection device.      Biospecimens will be tested for the number of CAG repeats in the Huntingtin Gene. Each      sample obtained will be coded with a randomly assigned number and never linked with personal      identifiers. The results from the genetic analysis will be sent directly to the data manager      on the project, who is the ONLY research member with access to this data. This person has no      direct contact with study participants.|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young people ages 6-18 years old who have a parent or grandparent that has been diagnosed        with Huntington's Disease|June 2015|June 6, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01860339||65974|
NCT01860352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00051786|Effects of Fish Oil on the Colon Mucosa|Phase Ib Study of the Effects of Omega-3 Supplementation on Fatty Acid Metabolism in the Colon||University of Michigan|Yes|Active, not recruiting|May 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01860352||65973|
NCT01860287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIRB-130197|The Effects of Buprenorphine on Responses to Verbal Tasks|The Effects of Buprenorphine on Responses to Verbal Tasks||University of Chicago|Yes|Recruiting|September 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|May 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01860287||65978|
NCT01860534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-039|"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"|"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"||The University of Texas Medical Branch, Galveston|Yes|Completed|July 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|December 8, 2015|May 20, 2013||No||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01860534||65959|
NCT01860833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGOG1|NSAID Treatment in Knee Osteoarthritis|EFFECTS OF NSAIDs ON CLINICAL OUTCOMES, SYNOVIAL FLUID CYTOKINE CONCENTRATION AND SIGNAL TRANSDUCTION PATHWAYS IN KNEE OSTEOARTHRITIS|NSKO|University of Cantanzaro|Yes|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|90|||Both|50 Years|85 Years|No|||May 2013|May 22, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860833||65936|
NCT01856686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brain Proteins|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|BrainProtein|Spanish Foundation for Neurometrics Development|Yes|Completed|December 2013|July 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|64|||Both|7 Years|13 Years|No|||August 2014|August 30, 2014|May 14, 2013|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01856686||66252|
NCT01856946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203853|Effect of Vitamin D Supplementation on Oral Glucose Tolerance Among Obese Adolescents|Effect of 4,000 IU Vitamin D3 Supplementation on Oral Glucose Tolerance Among Vitamin D Deficient Obese Adolescent||University of Missouri-Columbia|No|Recruiting|May 2013|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|9 Years|19 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01856946||66232|
NCT01857297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-ASU-12-82|A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older).||bioCSL PTY LTD|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 14, 2014|May 12, 2013|No|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01857297||66205|
NCT01856907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP13-009|Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM|A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM||Woman's|Yes|Recruiting|September 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Female|18 Years|42 Years|No|||February 2016|February 23, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856907||66235|
NCT01856920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130095|GI-6207 for Advanced Medullary Thyroid Cancer|A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|37|||Both|18 Years|100 Years|No|||October 2015|January 21, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856920||66234|
NCT01856933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263|BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)|BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study||Brown University|Yes|Completed|May 2013|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|January 8, 2013|Yes|Yes||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01856933||66233|
NCT01857518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01466-37|Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study|Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study.|ADODEP|Centre Hospitalier St Anne|No|Recruiting|August 2013|March 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857518||66188|
NCT01857531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041533|Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate|Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate|Ganaxolone|Duke University|Yes|Completed|June 2013|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|No|||September 2014|September 5, 2014|May 16, 2013|Yes|Yes||No|August 13, 2014|https://clinicaltrials.gov/show/NCT01857531||66187|
NCT01857544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-1313|Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy|Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)||Tennessee Retina|No|Active, not recruiting|June 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857544||66186|
NCT01858727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESM0606|The Effect of Preoperative Warming on Postoperative Hypothermia|The Effect of Preoperative Warming on Postoperative Hypothermia in TURP Surgery||Etlik Zubeyde Hanim Womens' Health and Teaching Hospital|Yes|Active, not recruiting|May 2013|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01858727||66096|
NCT01858974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZARI-NK-2013-01|Fast Identification of Pathogen in the Setting of Pneumonia Using Multiplex PCR|Identification of Microbes Through Detection of Pathogen Specific DNA Using Multiplex PCR as a Point of Care Diagnostic Tool in the Setting of Pneumonia||University of Göttingen|No|Completed|June 2013|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples With DNA|aspiration samples from the respiratory system (tracheal secretion sample, BAL) containing      microbial DNA|Both|18 Years|90 Years|No|Non-Probability Sample|patients will be recruited from two intensive care units of the university hospital.|February 2014|February 18, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858974||66077|
NCT01858428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-1397|Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon|ILLUMENATE Pivotal: ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon|ILLUMENATE|Spectranetics Corporation|Yes|Active, not recruiting|June 2013|July 2020|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858428||66119|
NCT01858701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01335|Visual Performance Investigation of Two Toric Soft Contact Lenses|Visual Performance Investigation of Two Toric Soft Contact Lenses|CARDINAL|Alcon Research|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|May 17, 2013|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01858701||66098|
NCT01887899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plasticity in Alzheimer's|Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type|Influence of Transcranial Direct-current Stimulation on Cortical Plasticity in Patients With Dementia of the Alzheimer Type||Charite University, Berlin, Germany|No|Recruiting|May 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|50 Years|80 Years|No|||March 2016|March 15, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01887899||63862|
NCT01888146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH2AT007788-01|Pain Program for Active Coping & Training|Collaborative Care for Chronic Pain in Primary Care|PPACT-UH2|Kaiser Permanente|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01888146||63843|
NCT01859221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1301-OL01|Radiotherapy for Oligometastatic Prostate Cancer|Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer||University of Florida|Yes|Recruiting|May 2013|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859221||66059|
NCT01859481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601015|Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study|A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura)||Pfizer|No|Completed|March 2000|March 2002|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|971|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859481||66039|
NCT01859468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCS010|A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures|A Prospective, Randomized, Parallel, Double-blind, Active Controlled Pilot Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) Versus Placebo on Functional Outcome and Radiographic Healing Time of Distal Radius Fractures||Amorphical Ltd.|No|Terminated|June 2013|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|50 Years|90 Years|No|||March 2015|March 30, 2015|May 19, 2013||No|Low Recruitment|No||https://clinicaltrials.gov/show/NCT01859468||66040|
NCT01859494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2012-009-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||March 21, 2016|May 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859494||66038|
NCT01860365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-09-0024-CTIL|Measuring Concerns of Cancer Patients Referred to Complementary Medicine Treatment Integrated Within Oncology Service|Measuring Concerns and Needs of Cancer Patients Referred to Complementary Medicine Treatment Integrated Within the Oncology Service||Carmel Medical Center|Yes|Recruiting|July 2009|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|980|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860365||65972|
NCT01860625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-001|A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects|||Icure Pharmaceutical Inc.||Completed|April 2013|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01860625||65952|
NCT01860638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28347|A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma|A Double-blind, Placebo-controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Beyond Compared to Addition of Placebo, Following First Progression of Disease (PD1) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab||Hoffmann-La Roche||Recruiting|August 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|298|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01860638||65951|
NCT01856465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6115-A|Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery|Role of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Pre and Post bAriatric Surgery||University Health Network, Toronto|No|Recruiting|June 2013|August 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Liver biopsy and stool samples|Both|18 Years|N/A|No|Probability Sample|NAFLD is the hepatic manifestation of the metabolic syndrome, and the prevalence is 74-98%        in morbidly obese individuals. The aim of this study is to examine the role of intestinal        microbiota (IM) in non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients        undergoing Roux-en-Y gastric bypass surgery. Alterations of the human gut flora        (intestinal microbiota) will be determined before and after surgery in realtion with the        change of liver histology.|November 2014|November 25, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856465||66269|
NCT01860547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYBID1|Effects of Berries and Berry Fractions on Metabolic Diseases|The Effect of the Bioactives of Sea Buckthorn and Bilberry on the Risk of Metabolic Diseases||University of Turku|No|Completed|June 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|110|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01860547||65958|
NCT01860846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-338|Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey|Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey|IDEA|AbbVie|No|Completed|May 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|65 Years|No|Probability Sample|Crohn's disease patients who at time of entry are receiving anti-Tumor Necrosis Factors as        it is prescribed in the normal clinical setting and according to approved Summary of        Product Characteristics (SmPC) for this disease.|February 2016|February 17, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860846||65935|
NCT01856699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuSPect-CAA|Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy|Observational Study on the Prognostic Relevance of Supratentorial Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy|SuSPect-CAA|Ludwig-Maximilians - University of Munich|No|Recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|whole blood, serum, plasma, CSF|Both|55 Years|N/A|No|Non-Probability Sample|hospital based|May 2013|May 15, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856699||66251|
NCT01856959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-2013CQ|Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4|Response of Asthmatic Children's Lung Function to Nebulized Magnesium Sulfate After Acetylcholine Provocation Test: a Clinical Trail||Chongqing Medical University|No|Completed|November 2011|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|330|||Both|4 Years|16 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856959||66231|
NCT01857908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI Correlative Study|A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone|||University Health Network, Toronto||Completed|June 2012|||November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Male|N/A|N/A|No|Non-Probability Sample|Patients receiving Abiraterone Acetate for Castrate Resistant Prostate Cancer|June 2015|June 19, 2015|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01857908||66159|
NCT01857557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24702|Evaluation of an Aerobic Exercise Program in Migraine Management|Evaluation of an Aerobic Exercise Program in Migraine Management||University of Calgary|No|Recruiting|August 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857557||66185|
NCT01857895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200016|Feasibility Study of Exenatide by Continuous Subcutaneous Infusion|An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects||GlaxoSmithKline|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857895||66160|
NCT01858142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012940|Helping Parents to Decide Whether They Want to be With Their Child During Anesthesia Induction|Preparing Parents to be Present for Their Child's Anesthesia Induction: A Randomized Control Effectiveness Trial|PPDT|IWK Health Centre|No|Completed|June 2013|||August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|2 Years|10 Years|No|||March 2016|March 18, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01858142||66141|
NCT01858155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C17 MEL P1|Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors|Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors||C17 Council|Yes|Recruiting|May 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|9|||Both|2 Years|18 Years|No|||January 2016|January 26, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01858155||66140|
NCT01858441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005036-28|Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate|Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate|ABIGENE|Centre Antoine Lacassagne|No|Recruiting|April 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|330|||Male|18 Years|90 Years|No|||November 2015|November 13, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01858441||66118|
NCT01858987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-08|Stapler vs. LigaSure in Elective Hepatic Resection|Stapler vs. LigaSure for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH II - A Randomized Controlled Trial|CRUNSH II|Heidelberg University|Yes|Recruiting|November 2011|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858987||66076|
NCT01859260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGHCPAPCKD|Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease|Using CPAP to Prevent Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease||University of South Florida|No|Not yet recruiting|June 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|125|||Both|19 Years|N/A|No|||May 2013|May 17, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01859260||66056|
NCT01858948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK097599-01A1|SGA-induced Metabolic Syndrome in Bipolar Youth|Risk and Protective Factors for SGA-induced Metabolic Syndrome in Bipolar Youth||University of Cincinnati|Yes|Recruiting|July 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|10 Years|17 Years|No|||August 2015|August 21, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858948||66079|
NCT01858961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.37|Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients|A Phase III, Randomised, Open Label, Active-controlled Study of an Interferon-free Regimen of BI 207127 in Combination With Faldaprevir and Ribavirin Compared to Telaprevir in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive Patients With Chronic Genotype 1b Hepatitis C Virus Infection||Boehringer Ingelheim||Withdrawn|May 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||January 2014|January 22, 2014|May 17, 2013||||No||https://clinicaltrials.gov/show/NCT01858961||66078|
NCT01859234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCGABR40641|89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma|Evaluation of VEGF Expression With 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma; a Feasibility Study||University Medical Center Groningen|No|Recruiting|May 2013|||May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859234||66058|
NCT01859520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gazi University 01/2011-110|Swim up and Gradient Methods Used in Assisted Reproduction Techniques on DNA Fragmentation of Spermatozoa|The Effect of Swim up and Gradient Methods Used in Assisted Reproduction Techniques on DNA Fragmentation of Spermatozoa||Gazi University|No|Completed|July 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|65|||Male|20 Years|45 Years|No|||May 2013|May 21, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01859520||66036|
NCT01859793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-50600|Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy|A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin||Medical College of Wisconsin|No|Active, not recruiting|June 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Both|21 Years|70 Years|No|||October 2015|October 9, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859793||66016|
NCT01859507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ramzy9501|Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm|Study of the Effectiveness and Safety of Clostridium Botulinum Type A Neurotoxin Complex Injection in the Perineal Muscles in Resistant Cases of Vaginismus|VginsmsBOTOX|Cairo University|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Female|16 Years|44 Years|No|||April 2015|April 9, 2015|May 19, 2013|Yes|Yes||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01859507||66037|
NCT01860092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-02|New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System|New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System||Second Sight Medical Products|Yes|Recruiting|January 2014|||August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|53|||Both|25 Years|N/A|No|Non-Probability Sample|Age 25 years or older; both males and females; with severe to profound retinitis        pigmentosa; with bare or no light perception in both eyes or with retinal response to        electrical stimulation; with previous history of useful form vision|May 2015|May 28, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860092||65993|
NCT01860105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-157-12-01|Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation|Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Open-label, Randomized, Cross-over Evaluation: The AMPHORE Study|AMPHORE|The Medicines Company|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01860105||65992|
NCT01860378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010045|Vouchers to Promote Tdap Vaccination|Retail Pharmacy Vouchers to Promote Tdap Vaccination for Adults Living With Infants||Children's Hospital of Philadelphia|No|Completed|July 2013|March 2015|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|149|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860378||65971|
NCT01856764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-DERM_203|Topical Roflumilast in Adults With Atopic Dermatitis|A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity||Takeda|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||June 2015|June 11, 2015|May 14, 2013||No||No|March 11, 2015|https://clinicaltrials.gov/show/NCT01856764||66246|
NCT01856777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6003|Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy|Evaluating the Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy After Early Medical Abortion||Gynuity Health Projects|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|600|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01856777||66245|
NCT01856478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.161|LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy|A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy||Boehringer Ingelheim||Recruiting|May 2013|December 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 15, 2013||||No||https://clinicaltrials.gov/show/NCT01856478||66268|
NCT01856491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1868|Safety and Performance Study of the RELIANCE 4-Front Passive Fixation Lead|RELIANCE 4-FRONT™ Passive Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study||Boston Scientific Corporation|No|Active, not recruiting|December 2013|November 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|167|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856491||66267|
NCT01860560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-HFR2013001Reg|Non-Inferiority Trial of Acute HFT Versus nCPAP|Effect of High Flow Nasal Cannula (Flowrest®) on Mild-Moderate Sleep Disordered Breathing: A Non-Inferiority Study Versus Nasal Continuous Positive Airway Pressure (CPAP) Therapy||Vapotherm, Inc.|No|Completed|May 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860560||65957|
NCT01860573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0089|Neurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants|||Women and Infants Hospital of Rhode Island|Yes|Active, not recruiting|November 2008|March 2016|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|N/A|18 Hours|No|||March 2015|March 17, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01860573||65956|
NCT01856452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1110212-2|Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer|Phase II Study of Comparison of Sentinel Lymph Node Biopsy Guided by The Multimodal Method of Indocyanine Green Fluorescence, Radioisotope and Blue Dye Versus the Radioisotope in Breast Cancer||National Cancer Center, Korea|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|86|||Female|20 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 14, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01856452||66270|
NCT01856712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0702|Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence|Pharmacotherapeutic Intervention to Improve Treatment Engagement Among Alcohol-dependent Veterans After Hospital Discharge||University of Wisconsin, Madison|No|Recruiting|May 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856712||66250|
NCT01856972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00096|Does the Addition of Manual Therapy Techniques Increase Gastrocnemius/Soleus Length More Than Stretching Alone?|Does the Addition of Manual Therapy Techniques Increase Gastrocnemius/Soleus Length More Than Stretching Alone?||Nationwide Children's Hospital|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|12 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 10, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856972||66230|
NCT01857921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0511|Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery|||Yonsei University|No|Recruiting|December 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|376|||Both|20 Years|80 Years|No|||February 2014|February 4, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857921||66158|
NCT01858168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-115|Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma|Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy||Massachusetts General Hospital|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858168||66139|
NCT01858467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-27|Supreme LMA and Endotracheal Intubation Use in Caesarean Section|Supreme LMA Versus Endotracheal Intubation in General Anaesthesia for Elective Caesarean Section- a Randomised Controlled Trial||QuanZhou Women and Children's Hospital|Yes|Not yet recruiting|May 2013|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|920|||Female|18 Years|50 Years|No|||May 2013|May 26, 2013|April 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01858467||66116|
NCT01858480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 04C 010|Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure|Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure||RiboCor, Inc.|No|Terminated|July 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|90 Years|No|||January 2016|January 12, 2016|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858480||66115|
NCT01859273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011702|Adherence Enhancement for Renal Transplant Patients|Adherence Enhancement for Renal Transplant Patients||Medical University of South Carolina|No|Recruiting|September 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||May 2013|May 17, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859273||66055|
NCT01859845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00077615|Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma|Melanoma Simulation Model With Smartphone Devices: Training Physicians to Perform Opportunistic Surveillance for Early Detection of Melanoma||Northwestern University|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 30, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01859845||66012|
NCT01859559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIV-RCT-ED|Evaluate Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Peripheral Intravenous Access|A Randomized Controlled Trial To Compare The Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Placement of Peripheral Intravenous Access Lines in Emergency Department Patients||George Washington University|No|Completed|August 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1189|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859559||66033|
NCT01859247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM 657|Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study|Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study||University of New Mexico|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|8|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859247||66057|
NCT01859533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams Uni|Positive End Expiratory Pressure With A T-piece Resuscitator For Near-Term and Term Infants With Respiratory Distress|Positive End Expiratory Pressure With A T-piece Resuscitator (Neopuff) For Near-Term and Term Infants With Respiratory Distress: A Randomized, Controlled Trial||Ain Shams University|No|Completed|November 2011|May 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|N/A|2 Days|No|||May 2013|May 20, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859533||66035|
NCT01859806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatic anastomosis|Isolated Roux Loop Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy|Isolated Roux Loop Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy|PD|Mansoura University|No|Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||January 2011|May 20, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01859806||66015|
NCT01860118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18NS082132|LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease|LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease||University of Alabama at Birmingham|No|Recruiting|January 2013|January 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|Whole blood samples and urine|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Neurology clinic|September 2015|October 12, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01860118||65991|
NCT01856504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICTORY|Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY|Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY: A Prospective Multicenter Study|VICTORY|MDDX LLC|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|18 Years|N/A|No|Probability Sample|Consenting adult patients ≥18 years of age, Suspected but without known prior history of        CAD, Not actively taking heart rate lowering agents at least 48 hours prior to study        (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)|March 2015|March 31, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856504|1 Day|66266|
NCT01857037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.655|Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI|Detection and Localization of Prostate Cancer Local Recurrences After Radiation Therapy Using Histoscanning™ and Multiparametric MRI|HISTO-RAD|Hospices Civils de Lyon|No|Completed|May 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Male|18 Years|N/A|No|||April 2011|February 26, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01857037||66225|
NCT01857024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB06009|Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia|Renvela® Post-Marketing Observational Study to Monitor the Clinical Use in Adult Hyperphosphataemic Chronic Kidney Disease Patients Not On Dialysis With Serum Phosphorus ≥1.78 mmol/L||Sanofi|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|210|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult Chronic Kidney Disease (CKD) patients not on dialysis with serum phosphorus ≥ 1.78        mmol/L.|March 2015|March 19, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857024||66226|
NCT01856725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_684|MPP Programming Study|Evaluation of Programming Strategies for MultiPoint™ Pacing in Cardiac Resynchronization Therapy Patients||St. Jude Medical|Yes|Completed|May 2013|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856725||66249|
NCT01856985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010|Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation|The Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered Buccally or Sublingually at 78-84 Days Gestation: Two Pilot Studies||Gynuity Health Projects|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 9, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01856985||66229|
NCT01856998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROP-001-CP3|Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery|Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared With Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surgery|PropofolTE|Fresenius Kabi|No|Completed|May 2013|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|64 Years|No|||February 2014|February 20, 2014|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01856998||66228|
NCT01857310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAZST|Folic Acid and Zinc Supplementation Trial (FAZST)|Folic Acid and Zinc Supplementation Trial: A Multi-center, Double-blind, Block-randomized, Placebo-controlled Trial|FAZST|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|June 2013|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2400|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857310||66204|
NCT01857570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43482.091.13|Volume CT of the Wrist and Carpus After Trauma|Volume CT of the Wrist and Carpus After Trauma: A Pilot Study|VuisT|Radboud University|No|Completed|June 2013|May 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|All consecutive patients who enter the emergency or radiology department of the Radboud        University Nijmegen Medical Centre for suspicion on fractures of the wrist and study are        eligible for this study.|May 2015|May 13, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01857570||66184|
NCT01857583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J306|Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs|Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs||Daiichi Sankyo Inc.|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|80|||Both|20 Years|N/A|No|||February 2015|February 25, 2015|May 16, 2013|No|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01857583||66183|
NCT01858506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFSD_I-ACE|Diabetes Lifestyle Assessment and Educational Tools|Development and Evaluation of Lifestyle Assessment and Educational Tools for Diabetic People With Limited Literacy|I-ACE|Sheba Medical Center|No|Active, not recruiting|August 2014|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|64 Years|No|||February 2016|February 4, 2016|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01858506||66113|
NCT01858181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEN-001|Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies|A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies||Mentrik Biotech, LLC|No|Not yet recruiting|January 2015|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|May 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858181||66138|
NCT01858493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA-AGE2 dossier28835|Continence Across Continents to Upend Stigma and Dependency|Phase 3 Cluster Randomised Trial Testing the Efficacy of a Continence Promotion Intervention to Improve Urinary Symptoms and Quality of Life, and Reduce Stigma and Falls in Older Community-dwelling Women With Untreated Incontinence|CACTUS-D|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|No|Recruiting|May 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|65 Years|N/A|No|||February 2015|February 3, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01858493||66114|
NCT01858740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2660.00|Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children|A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2013|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||October 2015|October 29, 2015|May 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858740||66095|
NCT01859858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1227|A Prospective Evaluation of the Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors.|A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2013|June 2020|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|N/A|No|||October 2014|October 6, 2014|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859858||66011|
NCT01860170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-083|Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis|A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)||Spectrum Health Hospitals||Recruiting|April 2012|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|28|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01860170||65987|
NCT01859546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/311074-0|SMS Reminders to Improve the on Time Vaccination Rates Among Children in Pakistan|Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates for Children in Pakistan||Aga Khan University|No|Recruiting|March 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|N/A|18 Weeks|Accepts Healthy Volunteers|||May 2013|May 20, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01859546||66034|
NCT01859819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-157|Treatment for Advanced B-Cell Lymphoma|Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma|REBOOT|New York Medical College|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|3 Years|31 Years|No|||April 2015|April 29, 2015|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859819||66014|
NCT01860131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 201200877|Self-Management and Educational Support in Extremely Obese Patients Awaiting Bariatric Care|Evaluating Self-Management and Educational Support in Extremely Obese Patients Awaiting Multidisciplinary Bariatric Care|EVOLUTION|University of Alberta|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|660|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01860131||65990|
NCT01860391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000060585|Silver and Fluoride Salivary Levels After the Application of Silver Fluoride|Salivary Levels of Fluoride and Silver 7 Days After Treatment With Diammine Silver Fluoride||Universidad Peruana Cayetano Heredia|No|Completed|December 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|6|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860391||65970|
NCT01860651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOUNG-WEB|Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease|Patient Empowerment: Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease for Better Quality of Treatment||Hvidovre University Hospital|Yes|Recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Both|10 Years|17 Years|No|||March 2015|March 17, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860651||65950|
NCT01860664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F2012-05|Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis|Phase 2 EFFICACY AND SAFETY OF HYDROCORTISONE OPHTHALMIC OINTMENT - VERSUS PLACEBO IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS||Koffler Vision Group|No|Active, not recruiting|May 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860664||65949|
NCT01856790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211011156|Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes|Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes||Yale University|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|40 Years|No|||January 2015|January 20, 2015|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01856790||66244|
NCT01857050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC130210-12CTIL|Assessment of International Normalized Ratio (INR) Prolongation in Patients Treated Simultaneously With Warfarin and Cephalosporins|Assessment of INR Prolongation in Patients Treated Simultaneously With Warfarin and Antibiotics From the Cephalosporins Family,Observational Retrospective Study.||Meir Medical Center|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|236|||Both|18 Years|N/A|No|Non-Probability Sample|Warfarin-treated patients who were hospitalized for any reason in the department of        internal medicine and were treated with antibiotics from the Cephalosporins group during        their hospitalization.|February 2014|February 24, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857050||66224|
NCT01857362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.NTBC-004|Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.|A Study to Evaluate the Bioequivalence of Orfadin Capsules 20 mg Compared to Orfadin Capsules 10 mg. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers.||Swedish Orphan Biovitrum|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|May 16, 2013|No|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01857362||66200|
NCT01857349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L13-016|Efficacy of Surgical Preparation Solutions in Knee Surgery|Efficacy of Surgical Preparation Solutions in Knee Surgery||Texas Tech University Health Sciences Center|No|Enrolling by invitation|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857349||66201|
NCT01856738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44622.029.13|Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease|Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.|CHEVAL|VU University Medical Center|Yes|Recruiting|November 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|168|||Both|40 Years|N/A|No|||December 2015|December 28, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856738||66248|
NCT01856751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGA-TEM|Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa|Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa Concentrate in Patients With Acquired Haemophilia and in Patients With Haemophilia A With Inhibitors|Thrombus|Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus|No|Recruiting|April 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|this data is not applicable|Both|18 Years|N/A|No|Non-Probability Sample|60 patients with acquired haemophilia 20 patients with congenital haemophilia A with        inhibitor|December 2015|December 17, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856751||66247|
NCT01857011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAPA UNIFESP 01|Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty|Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial|ISAPA|Federal University of São Paulo|Yes|Recruiting|April 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Female|18 Years|55 Years|No|||March 2015|March 6, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01857011||66227|
NCT01857323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-308|Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)|A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter||Teva Pharmaceutical Industries|No|Completed|May 2013|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|317|||Both|4 Years|N/A|No|||May 2015|May 19, 2015|May 15, 2013|Yes|Yes||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01857323||66203|
NCT01857596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1P-104-1000|Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety|A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder|PURPLE|S1 Biopharma, Inc.|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|25 Years|50 Years|No|||October 2014|October 26, 2014|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857596||66182|
NCT01857609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPI|Clinical Trial to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin|The Cross-Over Study to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Korean Men.|MPI|Seoul National University Hospital|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01857609||66181|
NCT01857622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J307|Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment|Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment (SRI)||Daiichi Sankyo Inc.|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|93|||Both|20 Years|N/A|No|||January 2015|January 15, 2015|May 16, 2013|No|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01857622||66180|
NCT01859013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304M31241|Topiramate in Adolescents With Severe Obesity|BMI Reduction With Meal Replacements + Topiramate in Adolescents With Severe Obesity||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|June 2013|December 2017|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|12 Years|17 Years|No|||February 2016|February 24, 2016|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859013||66074|
NCT01858753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-B-003|Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars|A Phase II, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars||Fibrocell Technologies, Inc.|No|Active, not recruiting|May 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858753||66094|
NCT01858766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-0102|Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-naive Subjects With Chronic HCV Infection|A Phase 2, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-naive Subjects With Chronic HCV Infection||Gilead Sciences|No|Completed|April 2013|July 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|14||Actual|378|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858766||66093|
NCT01859000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057675|Family-Based Drug Services for Young Disaster Victims|Family-Based Drug Services for Young Disaster Victims|Katrina|University of Miami|No|Completed|January 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||May 2013|May 16, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01859000||66075|
NCT01859871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R39OT22059|Evaluation of a Website on Living Kidney Donation for Hispanics|Evaluation of a Culturally Competent Website on Living Kidney Donation for Hispanics||Northwestern University|Yes|Completed|May 2013|September 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|123|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01859871||66010|
NCT01860183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMerkur|Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis|Comparison of 3g Versus 2g Mycophenolate Mofetil in Combination With Tacrolimus on Progression of Chronic Histology Changes in Kidney Transplant Recipients||Clinical Hospital Merkur|No|Recruiting|May 2013|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A||||January 2014|January 29, 2014|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01860183||65986|
NCT01859832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-016|Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay|Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay||Lawson Health Research Institute|No|Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|None Retained|Collected blood samples will be discarded immediately following testing|Both|18 Years|80 Years|No|Non-Probability Sample|All participants enrolled in this study will be undergoing renal transplantation and will        have already been consented to the study entitled, "A Comparison of Effects of Standard        Dose vs Low Dose Advagraf with IL-2 Receptor Antibody Induction, MMF and Steroids, With or        Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function,        and Immune Response."|August 2015|August 31, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01859832||66013|
NCT01860144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG2001|An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer|||Peking University|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|metastatic colorectal cancer patients accept bevacizumab|May 2015|May 17, 2015|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01860144|2 Years|65989|
NCT01860157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/2011|Deep rTMS for Treatment-Resistant Late-life Depression|A Randomized Controlled Study of H1-Coil rTMS for Treatment-Resistant Late-Life Depression|rTMS|Centre for Addiction and Mental Health|No|Recruiting|June 2013|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|85 Years|No|||January 2016|January 8, 2016|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01860157||65988|
NCT01860677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-001567|Cranial Electrotherapy Stimulation (CES) to Treat PTSD|Cranial Electrotherapy Stimulation (CES) to Treat PTSD: Identifying Metrics of Efficacy Using Brain Imaging|CES-fMRI-PTSD|Mclean Hospital|No|Recruiting|May 2010|May 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|21 Years|40 Years|No|||May 2013|May 22, 2013|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860677||65948|
NCT01856517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011PPRC01TURC|Upregulation of Alpha-1 Receptors Upon Septic Shock?|Up Regulation of Alpha-1 Receptors Upon Septic Shock ?|CATACHOC|Direction Centrale du Service de Santé des Armées|Yes|Recruiting|August 2013|||August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01856517||66265|
NCT01856530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31668|Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder|Effect of Oxytocin on Pro-Social Behavior in Social Anxiety Disorder||Boston University|Yes|Completed|July 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Male|18 Years|N/A|No|||August 2014|August 12, 2014|May 10, 2013|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01856530||66264|
NCT01857063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-519|Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)|A Phase III, Double-Blind, Randomized, Placebo-Controlled Cross-over Clinical Trial to Study the Efficacy and Safety of MK-0476 in Japanese Pediatric Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|10 Years|15 Years|No|||February 2016|February 19, 2016|May 16, 2013|Yes|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01857063||66223|
NCT01857375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-029|A Study of Improved Efficacy, Safety and Compliance to Administer Insulin in Pen vs. Vial and Syringe|A Study of Improved Efficacy, Safety and Compliance to Administer Insulin in Pen vs. Vial and Syringe||Northwell Health|Yes|Completed|October 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults newly begun on insulin therapy during their hospital stay.|May 2013|May 20, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857375||66199|
NCT01857700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1961|Economic Compensation to Increase Demand for Voluntary Medical Male Circumcision|Compensation for Transport Costs and Lost Wages Associated With Voluntary Medical Male Circumcision (VMMC) Uptake: an Intervention to Increase VMMC Demand Among Older Men in Nyanza Province|CTT-VMMC|University of North Carolina, Chapel Hill|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1504|||Both|25 Years|49 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01857700||66174|
NCT01857674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00141-44|Evaluation of Laryngeal Ultrasonography Performance in Predicting Major Post Extubation Laryngeal Edema in Intensive Care Patients|Evaluation of Laryngeal Ultrasonography Performance in Predicting Major Post Extubation Laryngeal Edema in Intensive Care Patients|ECHOLPE|Centre Hospitalier Universitaire de Besancon|No|Recruiting|May 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All Adults were admitted to the surgical (20 beds) and medical (20 beds)intensive care        unit of besançon University Hospital.|May 2013|August 1, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857674||66176|
NCT01857687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH CT-FFR WSS TPF|Evaluation of FFR, WSS, and TPF Using CCTA|Noninvasive Evaluation of Ischemia Causing Coronary Stenosis, Wall Shear Stress, and Total Plaque Force Using Coronary CT Angiography (CCTA) and Physics-based Analytic Model Derived From Conservation of Energy||Seoul National University Hospital||Recruiting|May 2013|||May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|patients with coronary artery stenosis|November 2013|November 26, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857687||66175|
NCT01857336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03|G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation|Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation||Peking University People's Hospital|Yes|Withdrawn|March 2013|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|14 Years|60 Years|No|||May 2015|May 13, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857336||66202|
NCT01857635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TpCO2-NIV|Use of TpCO2 (Transcutaneous CO2 Measurement) as PaCO2 Predictor During NIV in Case of Acute Hypercapnic Respiratory Failure|Use of TpCO2 (Transcutaneous CO2 Measurement)as PaCO2 Predictor During Non Invasive Ventilation (NIV) in Case of Acute Hypercapnic Respiratory Failure|TpCO2-NIV|University of Lausanne Hospitals|No|Completed|February 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care unit patients equipped with an arterial line and requiring non invasive        ventilation because of acute hypercapnic respiratory failure|June 2015|June 7, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857635||66179|
NCT01857648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/14119-5|Physical Activity Promotion in the Brazilian Primary Health Care Using Community Health Workers Counseling|Physical Activity Promotion in the Brazilian Primary Health Care Using Community Health Workers Counseling||University of Sao Paulo|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|176|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857648||66178|
NCT01857934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB2012|Therapy for Children With Advanced Stage Neuroblastoma|Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma||St. Jude Children's Research Hospital|No|Recruiting|May 2013|June 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|18 Years|No|||October 2015|October 6, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857934||66157|
NCT01857947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTAPE01|Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER|Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room|UTAPE BPCO|ThermoFisher Scientific Brahms Biomarkers France|No|Completed|March 2013|December 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|370|||Both|40 Years|N/A|No|||December 2014|December 2, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857947||66156|
NCT01858194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B 12-02-395-05|REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation|REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation|RESET-VT|Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|March 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|202|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|March 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858194||66137|
NCT01859286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0655|Improving Signout Accuracy and Information Delivery in the Emergency Department|Improving Transfer of Care Accuracy and Information Delivery in the Emergency Department|SAID-ED|The University of Texas Health Science Center, Houston|No|Completed|February 2012|||May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|321|||Both|N/A|N/A|No|Non-Probability Sample|ED Physicians. We looked at the amount of errors due to signout that ED Physicians commit        with standard signout procedure and then with a revised signed out process|May 2013|May 17, 2013|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01859286||66054|
NCT01859572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN-CS-0001|Observational Study of Ischaemic Stroke|A Non-interventional Observational Study to Document the Clinical Course of Patients Following Ischaemic Stroke and to Establish a Pool of Patients for Future Trials in the Ischaemic Stroke Setting|OSIS|ReNeuron Limited|No|Active, not recruiting|February 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|The group consists of consenting patients who survive the first 7 days following their        first ischaemic stroke in participating stroke units|December 2015|December 18, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01859572||66032|
NCT01860417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TerCel005|Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)|Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure|Disc_allo|Red de Terapia Celular|Yes|Active, not recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||September 2015|September 26, 2015|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01860417||65968|
NCT01856543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-069|Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation|Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|143|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856543||66263|
NCT01856803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-08|Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis|Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies||Peking University People's Hospital|Yes|Recruiting|October 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|60 Years|No|||November 2015|November 9, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856803||66243|
NCT01857388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00362|School-Based Mental Health Program Implementation in Uganda|Implementing a School-based Mental Health Prevention Program in Ugandan Schools||New York University School of Medicine|Yes|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|79|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01857388||66198|
NCT01858285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X10-04-0197|Genetics of Severe Early Onset Epilepsies|Genetics of Epilepsy and Related Disorders||Children's Hospital Boston|No|Recruiting|November 2010|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|DNA from whole blood or saliva|Both|N/A|N/A|No|Non-Probability Sample|Epilepsy|February 2015|February 2, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01858285||66130|
NCT01858571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-63/2013|Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies|Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study||All India Institute of Medical Sciences, New Delhi|Yes|Active, not recruiting|October 2013|February 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|108|||Both|5 Years|18 Years|No|||January 2016|January 27, 2016|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01858571||66108|
NCT01857986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HST-AG-07|Evaluating Air Leak Detection in Intubated Patients|A Study to Evaluate Air Leak Detection Above the Endotracheal Cuff in Intubated Patients Using the AnapnoGuard 100 System||Hospitech Respiration|No|Completed|September 2013|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|76|||Both|18 Years|N/A|No|||June 2015|August 4, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857986||66153|
NCT01857661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/03001-2|The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial|The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial||University of Sao Paulo|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|June 25, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857661||66177|
NCT01857960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcKNOW|Attitudes and Knowledge of Acne in Mexican Adolescents|Survey About Knowledge and Attitudes Regarding Acne in Mexican Adolescents||Universidad Autonoma de San Luis Potosí|No|Recruiting|May 2012|March 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|12 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community high schools and colleges.|December 2014|December 1, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857960||66155|
NCT01858207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG3B0121|Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient|Combine Chemoembolization and Radiofrequency Ablation Versus Radiofrequency Ablation Monotherapy for Patients With Unilobar Hepatocellular Carcinoma of 3.1 to 7 cm: A Randomized Controlled Trial||Chang Gung Memorial Hospital|No|Recruiting|January 2012|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|May 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01858207||66136|
NCT01858220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheba-9180-2011|IS There a Correlation Between Sypmtoms of Gastroparesis and the Duration of Video Caspule Retention in the Stomach|Open Prospective Single Center Study for the Determination of Correlation Between Video Capsule Period of Retention in the Stomach and Symptoms of Gastroparesis||Sheba Medical Center|No|Recruiting|January 2013|January 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient undergoing small bowel video capsule examination for any indication|February 2014|February 24, 2014|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01858220||66135|
NCT01858519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPP-12-01|Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy|A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors||AbbVie|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Serum specimens for subsequent assay for antibodies to HEV and other selected porcine      viruses|Both|2 Years|99 Years|No|Non-Probability Sample|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT) and        patients with chronic disease not receiving any PERT.|March 2016|March 1, 2016|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858519||66112|
NCT01858779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-ER-KYP|Know Your Pulse Post Stroke-Measurement of Peripheral Pulse for Detection of Atrial Fibrillation After Ischemic Stroke|Know Your Pulse Post Stroke - Peripheral Pulse Taking to Detect Paroxysmal Atrial Fibrillation After Ischemic Stroke||University of Erlangen-Nürnberg Medical School|No|Recruiting|May 2013|October 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke without the history of atrial fibrillation|May 2013|May 31, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01858779||66092|
NCT01859026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17361|A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation|A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859026||66073|
NCT01859325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130141|Therapeutic Vaccine for HIV|A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2013|January 2030|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|May 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859325||66051|
NCT01859299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130072|Intestinal Bacteria and Ocular Inflammatory Disease|Microbiome and Ocular Inflammatory Disease||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|65|||Both|18 Years|N/A|No|||July 2015|October 3, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859299||66053|
NCT01859585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU-0001|Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion|Comparing the Efficacy of Parecoxib and Ketorolac as Preemptive Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion||Prince of Songkla University|Yes|Completed|March 2011|March 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|96|||Both|18 Years|80 Years|No|||May 2013|May 21, 2013|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859585||66031|
NCT01860196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_IT_009|Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy|A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy|ATHETOID_CD|Seoul National University Hospital||Not yet recruiting|June 2013|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|20 Years|N/A|No|||December 2013|December 5, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860196||65985|
NCT01856582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2344|CD34+ Stem Cell Infusion to Augment Graft Function|Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|October 2010|October 2022|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|35 Years|No|||January 2016|January 26, 2016|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856582||66260|
NCT01856595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4801003|PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients|A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus||Pfizer|No|Completed|May 2013|March 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|117|||Both|18 Years|70 Years|No|||January 2015|January 29, 2015|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01856595||66259|
NCT01856842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-ANGIO-12|Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy|Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy. A Randomized Trial of Interlock™ Fibered IDC™ Occlusion System vs. Nester Coils||St. Michael's Hospital, Toronto|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856842||66240|
NCT01860716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/02877|Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.|Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant: a Prospective, Randomised Double-blind Study.||Aragon Institute of Health Sciences|Yes|Not yet recruiting|May 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|68 Years|No|||May 2013|May 22, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01860716||65945|
NCT01860729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-022|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)|A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Merck Sharp & Dohme Corp.|No|Completed|May 2013|August 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|589|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860729||65944|
NCT01856829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKO-PC_01|Effect of Omega-3 Phospholipids on Perceptual-cognitive Training|Effect of Omega-3 Phospholipids on Attentional Abilities and Perceptual-cognitive Training||Université de Montréal|Yes|Recruiting|May 2013|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01856829||66241|
NCT01860404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10227|BCAA's in Sports-related Concussion|Head Injury Treatment With Healthy and Advanced Dietary Supplements (HIT HEADS): A Randomized, Placebo-controlled, Double-blinded, Therapeutic Exploratory Clinical Trial of Branched Chain Amino Acids (BCAA's) in the Treatment of Sports-related Concussion|HIT HEADS|Children's Hospital of Philadelphia|No|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|50|||Both|14 Years|34 Years|No|||February 2016|February 5, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860404||65969|
NCT01860690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHCG1|BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success|BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success|BHCG|Meir Medical Center|No|Recruiting|November 2011|February 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|May 22, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01860690||65947|
NCT01860703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA37-1111|Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects|A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects||ApoPharma|No|Completed|November 2012|July 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|May 6, 2013|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01860703||65946|
NCT01856816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102010527|Effect of Meal Patterning on Carotenoid Absorption From Vegetables|Effect of Meal Patterning on Carotenoid Absorption From Vegetables|S26|Purdue University||Completed|May 2011|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856816||66242|
NCT01857076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2012-01|Surgical Treatment in Diabetic Patients With Grade 1 Obesity|Surgical Treatment in Diabetic Patients With Grade 1 Obesity||Hospital Sirio-Libanes|No|Completed|February 2013|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|25 Years|65 Years|No|||May 2013|August 18, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01857076||66222|
NCT01857089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaPAS-DCIC-1204|Characterization of Sitting Postures in Healthy Subjects|Characterization of Sitting Postures in Healthy Subjects|CaPAS|University Hospital, Grenoble|Yes|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01857089||66221|
NCT01857102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5363|Toric Eye Strain and Stability Study|||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857102||66220|
NCT01858584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STDMG2013|Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate|Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate||Federico II University|Yes|Recruiting|February 2013|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|N/A|12 Months|No|||May 2013|May 29, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01858584||66107|
NCT01858844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEST COMPRESSION TECHNIQUE|Chest Compression Technique in Infants|EVALUATION OF THE EFFECTS OF MANUAL CHEST COMPRESSION TECHNIQUE IN INFANTS WITH PULMONARY ATELECTASIS- Clinical CONTROLLED TRIAL||Hospital Sirio-Libanes|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|N/A|24 Months|Accepts Healthy Volunteers|||May 2013|May 16, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01858844||66087|
NCT01859052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH1K23NS078345-01|Diet and Migraine Study|Diet and Migraine Study||Johns Hopkins University|No|Terminated|July 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|32|||Female|19 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|May 10, 2013||No|Study team was unable to effectively conduct the study.|No||https://clinicaltrials.gov/show/NCT01859052||66071|
NCT01857973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP273|Overnight Closed Loop Study in U.S.|In-Clinic Feasibility Study to Observe the Overnight Closed Loop System|OCL|Medtronic Diabetes|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|67|||Both|22 Years|75 Years|No|||August 2015|August 25, 2015|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857973||66154|
NCT01858233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBEP|The IBEP Study: an Intervention for Lifestyle Modification in Women With Gestational Diabetes|The IBEP Study: a Randomized Control Trial of an Educational Intervention for Lifestyle Modification in Women With Gestational Diabetes.|IBEP|University of Pennsylvania|No|Completed|November 2012|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Female|18 Years|45 Years|No|||December 2015|December 3, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01858233||66134|
NCT01858246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJPSMH01|A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge|A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge||Ninewells Hospital|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|85 Years|No|||March 2016|March 22, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01858246||66133|
NCT01858532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-352|Study Of Diabetic Nephropathy With Atrasentan|A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan|SONAR|AbbVie|Yes|Recruiting|May 2013|November 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4148|||Both|18 Years|85 Years|No|||January 2016|January 20, 2016|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858532||66111|
NCT01858792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115030|A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies|Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients With Higher Disease Activity (Anti-dsDNA Positive and Low Complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies||GlaxoSmithKline|Yes|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|N/A||2|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who were anti-dsDNA positive and had low C3 and/or C4 at baseline (Low        C+anti-dsDNA Population) Subjects with baseline SELENA SLEDAI score >= 10 (SS >=10        Population)|May 2013|May 16, 2013|December 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858792||66091|
NCT01859039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CHI 0659|Safety of Nasal Influenza Immunisation in Egg Allergic Children|Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study|SNIFFLE|Imperial College London|Yes|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|282|||Both|2 Years|17 Years|No|Non-Probability Sample|Children and young people with egg allergy between 2-17 years old|May 2015|May 27, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859039||66072|
NCT01859312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130121|Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia|A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|99 Years|No|||December 2015|December 24, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859312||66052|
NCT01859598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORBIT|Observational Registry for Basal Insulin Treatment Study (ORBIT)|A Prospective, Observational Registry Study Focusing on the Real World Use, Effectiveness and Safety of Initial Basal Insulin Regimen in Type 2 Diabetic Patients Uncontrolled by Oral Antidiabetic Drugs in China||The George Institute for Global Health, China|No|Recruiting|December 2011|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients meet the following criteria, either from in-patient or out-patient department,        will have chance to be enrolled in this study.|May 2013|May 20, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01859598|6 Months|66030|
NCT01859884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00055356|Optimizing Kidney Transplant Informed Consent|Optimizing Kidney Transplant Patients' Informed Consent for Increased Risk Donors||Northwestern University|Yes|Completed|October 2013|November 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|288|||Both|21 Years|N/A|No|||November 2015|November 18, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01859884||66009|
NCT01860430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-084|A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer|A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer||University of Pittsburgh|Yes|Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860430||65967|
NCT01860755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIPRC-PT-conc-01|Effects of Physiotherapy in Individuals With Persistent Symptoms Following Concussion|Physiotherapy Treatment (Including Vestibular Rehabilitation) Compared to Rest in Individuals With Persistent Symptoms of Dizziness, Neck Pain and/or Headache Following Sport-related Concussion.|PTConc|Sport Injury Prevention Research Centre|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|12 Years|30 Years|No|||May 2013|May 23, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860755||65942|
NCT01856608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012B0233|Assessing the Team SA Instrument in Measuring the Effectiveness of Communication Across Disciplines During ICU Rounds|Assessing the Utility of the Team SA Instrument in Measuring the Effectiveness of Communication Across Disciplines During ICU Rounds||Ohio State University|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|240|||Both|17 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Daily census rosters of the MICU and 8ICU nursing units will be reviewed for occupancy. At        8am on survey days occupied beds will be tallied (up to 39 beds). Beds occupied by a        non-MICU service patient and those with active DNR-CC orders will be excluded. From the        remaining patients, ten bed numbers will be randomly selected for review. Randomization        will be stratified by MICU service sub-unit (MICU 40, MICU 90, 8ICU). If fewer than ten        patients are eligible on an assigned survey day, all patients in the ICU on that day will        be surveyed.|July 2013|September 15, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01856608||66258|
NCT01857154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064|A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate|A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate||Integrative Health Technologies, Inc.|No|Recruiting|May 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|160|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01857154||66216|
NCT01857427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0214|A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities|A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities||Ohio State University|Yes|Recruiting|August 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|70 Years|No|Probability Sample|care clinics|September 2014|September 23, 2014|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857427||66195|
NCT01856556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX1074-C-101|Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers|A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers||Naurex, Inc|Yes|Completed|May 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|May 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01856556||66262|
NCT01856569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801362|Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy|Assial - Anti Tnf Treatment In Ankylosing Spondylitis: An Observational Cohort Study In Italy|ASSIAL|Pfizer|No|Completed|July 2013|December 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|152|||Both|18 Years|N/A|No|Probability Sample|ankylosing spondylitis|January 2016|January 8, 2016|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01856569||66261|
NCT01857401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0073|Development of a Novel Human In Vitro Sarcoidosis Model|Development of a Novel Human In Vitro Sarcoidosis Model||Ohio State University|No|Recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|primary care clinic|September 2014|September 2, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01857401||66197|
NCT01857414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Condi2-37747|Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI|Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Multinational Multicentre Randomised Controlled Clinical Study|CONDI2|University of Aarhus|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|4300|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857414||66196|
NCT01857999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCOR 2993/07/008|Losartan in Decompensated Heart Failure|Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial||InCor Heart Institute|Yes|Completed|September 2008|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||March 2011|May 17, 2013|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857999||66152|
NCT01858259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F5-2012-305495-OT3|Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis|Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis||Charite University, Berlin, Germany|Yes|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1372|||Both|N/A|N/A|No|Probability Sample|The study population are adult and juvenile SSc patients from the EUSTAR cohort        (MEDSonline database) and the jSScWG cohort|August 2014|August 12, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01858259|12 Months|66132|
NCT01858272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00000431|Preliminary Testing of New Treatment for Chronic Leg Wounds|Phase I Trial to Evaluate the Safety of H5.020CMV.PDGF-b and Limb Compression Bandage for the Treatment of Venous Leg Ulcer (Trial A)||University of Pennsylvania||Completed|September 2004|June 2009|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||November 2009|May 20, 2013|May 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858272||66131|
NCT01858545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL2011-002-I|A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers|An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers Resistant to Standard of Care: A Prospective, Randomized Controlled Trial||ACell Inc.|No|Terminated|May 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||March 2016|March 17, 2016|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01858545||66110|
NCT01858558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1343|Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma|Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2013|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||June 2015|June 26, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858558||66109|
NCT01858805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-EC|Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer|Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Both|18 Years|N/A|No|Probability Sample|This prospective, single-institution study conducted at the University Hospital        Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially        considered resectable.|November 2014|November 17, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01858805||66090|
NCT01859897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|okayama-1692|A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan|A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan|CAVI-J|Okayama University|Yes|Recruiting|June 2013|||June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|40 Years|74 Years|No|Non-Probability Sample|primiary care clinic and hospital|June 2014|June 25, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01859897|5 Years|66008|
NCT01860209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRS-SASinHD|Effect of Intermittent Hemodialysis on Sleep Apnea Syndrome in End Stage Renal Disease Patients|Effect of Intermittent Hemodialysis on Sleep Apnea Syndrome and Its Correlation to Nocturnal Rostral Fluid Shift, in End Stage Renal Disease Patients|SASinHD|Centre Hospitalier Universitaire Vaudois|Yes|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01860209||65984|
NCT01860443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONIS SA12I1294|Telepsychiatry to Improve the Management of Adolescent Depression in Primary Care|Telepsychiatry-Based Collaborative Program to Improve the Management of Adolescent Depression in Primary Care Clinics in the Araucanía Region, Chile: A Randomized Controlled Trial||University of Chile|No|Terminated|June 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|13 Years|19 Years|No|||October 2015|October 31, 2015|May 18, 2013||No|Because there are enough data to present the conclusions|No||https://clinicaltrials.gov/show/NCT01860443||65966|
NCT01860742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBMNCASTOR|Randomized Phase III of PRRT Versus Interferon|Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b|CASTOR|Jules Bordet Institute|No|Not yet recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860742||65943|
NCT01857167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUOLI2013011|Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients|||Zhejiang University||Completed|June 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|185|||Both|35 Years|80 Years|No|||March 2015|March 11, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01857167||66215|
NCT01857180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med Student Lap Curriculum|Comprehensive Laparoscopic Curriculum for Medical Students|Introduction of a Comprehensive Training Curriculum in Laparoscopic Surgery for Medical Students: a Randomized Trial.||St. Michael's Hospital, Toronto|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|24|||Both|N/A|N/A|No|||November 2015|November 16, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857180||66214|
NCT01857440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0073|The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study|The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study|FLIPR|Ohio State University|No|Active, not recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Age 18 or older with diagnosed glaucoma of known severity Controls: Matched to        Cases on age, sex, and race.|October 2014|October 21, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857440||66194|
NCT01857115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-561|Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)|A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS|wCCyd|Stichting Hemato-Oncologie voor Volwassenen Nederland||Recruiting|April 2013|July 2017|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|65 Years|N/A|No|||March 2015|March 24, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01857115||66219|
NCT01857128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382094-2|Pilonidal Disease Wound Healing Study|A Prospective Randomized Open-Label Study Examining the Efficacy of Drawtex® Hydroconductive Wound Dressing and Negative Pressure Wound Therapy in Pilonidal Cystectomy Wounds Healing by Secondary Intention - A Pilot Study||Walter Reed National Military Medical Center|No|Recruiting|March 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||May 2013|May 17, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01857128||66218|
NCT01857141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0904|Comparative Study on the Effects of Epidural Dexmedetomidine on Heart Rate Variability During General Anesthesia in Patients Undergoing Gastrectomy|||Yonsei University|No|Completed|February 2012|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|38|||Both|40 Years|70 Years|No|||February 2014|February 4, 2014|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01857141||66217|
NCT01858012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 10-00922|Insulin Resistance in HCV Infection|Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos||University of California, San Francisco|No|Recruiting|May 2008|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|serum samples for analysis|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Latinos with and without HCV infection|May 2015|May 29, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858012||66151|
NCT01858298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|usp|Conservative Versus Non-conservative Treatment for Severe Dental Caries|Conservative Versus Non-conservative Treatment for Severe Dental Caries in Preschool Children and Its Impact on Oral Health-related Quality of Life, Anthropometric Measures, Space Loss and Anxiety: a Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|December 2013|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|3 Years|5 Years|No|||May 2015|May 26, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01858298||66129|
NCT01858311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0113|Nutrition Blood Outcomes Following Tocotrienol N2B|HUMAN BLOOD OUTCOMES FOLLOWING TOCOTRIENOL SUPPLEMENTATION - NUTRITION PHASE IIB|NIIB|Ohio State University|Yes|Active, not recruiting|March 2013|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Blood Draw|Both|N/A|N/A|No|Non-Probability Sample|Stroke survivors within 6 months of clinical presentation for ischemic stroke or TIA event|October 2015|October 20, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01858311||66128|
NCT01858597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010dong|Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus|Endocrine Fibroblast Growth Factor 19 and 21 Regulate the Insulin Resistance State in Gestational Diabetes Mellitus||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|155|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|university hospital|April 2015|April 13, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858597||66106|
NCT01858610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT4|Drug Interaction Between Irbesartan and Hydrochlorothiazide|||Damanhour University|Yes|Completed|March 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01858610||66105|
NCT01858818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZI 1119/4-1|Project 4: Acute Effects of Alcohol on Learning and Habitization in Healthy Young Adults|Project 4: Acute Effects of Alcohol on Learning and Habitization in Healthy Young Adults|LeAD_P4|Technische Universität Dresden|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Male|18 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|random sampling of representative sample of 18 year old men in the area of Dresden|February 2015|February 11, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01858818||66089|
NCT01858831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116441|Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension|Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -||GlaxoSmithKline|No|Completed|April 2012|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01858831||66088|
NCT01859338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13777|MRI, Cone Beam CT, and Fan Beam CT in Detecting Soft Tissue in Patients With Prostate and Lung Cancer Undergoing Radiation Therapy|Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning||Virginia Commonwealth University|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01859338||66050|
NCT01859611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriActive+RF-ElEn-022013|TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides|Clinical Study to Evaluate the Performance of TriActive+ RF for the Non-Invasive Treatment of Wrinkles and Rhytides||El. En. SpA|No|Completed|May 2013|May 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|May 10, 2013||No||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01859611||66029|
NCT01859624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034177|Albuterol in Individuals With Late Onset Pompe Disease (LOPD)|A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy||Duke University|No|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|May 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859624||66028|
NCT01859637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP06-401|Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia|Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia||Sandoz|No|Terminated|May 2011|September 2015|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||November 2015|November 4, 2015|May 8, 2013||No|Study no longer necessary to be continued.|No||https://clinicaltrials.gov/show/NCT01859637||66027|
NCT01859910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lid margin VS Cataract Surgery|Compression of the Lid Margin Increase Microbial Contamination Risk of Patients Undergoing Cataract Surgery|Compression of the Lid Margin Increase Microbial Contamination Risk of Patients Undergoing Cataract Surgery||Orbis||Completed|October 2011|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|306|||Both|60 Years|90 Years|No|||May 2013|May 20, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01859910||66007|
NCT01859923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-12-233|A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis|Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|August 2013|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|N/A|17 Years|No|||February 2016|February 12, 2016|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859923||66006|
NCT01859936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POMB|Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment|Randomized Multicenter Trial Assessing if Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Will Change Primary Treatment|POMB|Karolinska University Hospital|No|Completed|February 2008|April 2013|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|440|||Both|18 Years|56 Years|No|||May 2013|May 27, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859936||66005|
NCT01860222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2012-002-12|Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma|A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2011|December 2016|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||May 2013|May 21, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01860222||65983|
NCT01860456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIKlet-2012-M1.5|TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study|Tyrosine Kinase Inhibitors of BCR/ABL: Pharmacokinetic and Pharmacogenetic Study in Patients Affected by Chronic Myeloid Leukemia. Evaluation of Efficacy and Tolerability|TIKlet|University of Pisa|Yes|Recruiting|May 2013|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|412|Samples With DNA|Whole blood, plasma, DNA|Both|18 Years|80 Years|No|Non-Probability Sample|Patients affected by CML from Hematology Units|May 2013|May 18, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01860456||65965|
NCT01860469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeshVanco|Reducing Mesh Infections in Open Hernia Repairs|Does Soaking Synthetic Mesh in Vancomycin Solution Reduce Mesh Infections in Open Hernia Repairs?||University of Saskatchewan|Yes|Not yet recruiting|June 2013|||June 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||May 2013|May 18, 2013|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01860469||65964|
NCT01860482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243GERD13003|The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD|An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen||Chong Kun Dang Pharmaceutical|No|Completed|April 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|20 Years|N/A|No|||September 2015|September 22, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860482||65963|
NCT01860495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahmedgamal|Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane|Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Modified Perforated Membrane Barriers in Localized Intrabony Defects (An in Vivo Study)|MPM|Al-Azhar University|Yes|Completed|March 2012|December 2012|Actual|May 2012|Actual|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|31 Years|51 Years|Accepts Healthy Volunteers|Probability Sample|Fifteen non-smoking patients (8 males and 7 females) who were 31 to 51 years of age at the        time of baseline examination (mean age 33.8 ± 6.1) with severe chronic periodontitis        (Armitage 1999) participated in this prospective, randomized and blinded clinical trial.        The subjects were recruited consecutively from the list of patients seeking care for        periodontal problems at the Department of Periodontology of the Faculty of Dental        Medicine, Al Azhar University, Cairo, Egypt, between March 2012 to December 2012. The        experimental protocol was approved by the Ethical Committee of El Azhar University (OMD -        45 - 2012). Research procedures were explained to all patients and they agreed to        participate in the study and signed the appropriate informed consent form of Al Azhar        University.|May 2013|May 21, 2013|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01860495|6 Months|65962|
NCT01856855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121218006|Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)|RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer||University of Alabama at Birmingham|Yes|Recruiting|February 2013|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|19 Years|N/A|No|||March 2016|March 11, 2016|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01856855||66239|
NCT01856868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD0113|Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)|An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.||University of California, Davis||Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|60 Years|No|||August 2013|August 23, 2013|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856868||66238|
NCT01856881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100018|Multiple Ascending Dose Study in Subjects With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes||Amgen|No|Terminated|March 2013|March 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|March 25, 2013|Yes|Yes|This study was terminated on August 29th, 2014 due to a business decision by the Sponsor. The    study was not terminated due to a safety reason.|No||https://clinicaltrials.gov/show/NCT01856881||66237|
NCT01857193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2106|Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer|A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer||Novartis|No|Recruiting|September 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857193||66213|
NCT01857206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_31|Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age|A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.||Novartis|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2055|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|May 16, 2013|No|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01857206||66212|
NCT01857453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002803-16|Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas|National, Multicentric, Prospective Phase II Study Estimating the Interest of a Dose Decrease for Radiation Therapy Associated With a Carboplatine and Etoposide Based Chemotherapy for the Treatment of Standard Risk Adult Medulloblastomas|RSMA2010|Central Hospital, Nancy, France|Yes|Recruiting|April 2013|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857453||66193|
NCT01857752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSEYE0003|Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala|Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala||Stanford University||Recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|N/A|21 Years|No|||June 2015|June 30, 2015|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01857752||66171|
NCT01857765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02077|Breast Augmentation Rehabilitation Program|How Rehabilitation Affects the Time to Pain-free Living After Endoscopic Transaxillary Subpectoral Breast Augmentation||University of British Columbia||Withdrawn|May 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 10, 2014|May 9, 2013||No|The resident in charge of the project has graduated so we decided to close this study|No||https://clinicaltrials.gov/show/NCT01857765||66170|
NCT01857778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1990|Breast Tissue Before And After Breastfeeding Or The Use Of A Breast Pump|||Foundation for Maternal Infant and Lactation Knowledge|Yes|Completed|August 2011|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Lactating women.|October 2011|May 16, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857778||66169|
NCT01857713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-001-02|Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device|A Multi-Center, Non-Randomized, Prospective Study of the Reza Band™ Upper Esophageal Sphincter (UES) Assist Device for the Treatment of Esophagopharyngeal Reflux||Somna Therapeutics, L.L.C.|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 16, 2013||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01857713||66173|
NCT01857726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVT_TACE/TACI|Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion|A Randomized Open Label Pilot Study Comparing Transarterial Chemoembolization Versus Transarterial Chemoembolization/Transarterial Chemoinfusion Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion||Seoul National University Hospital|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||November 2014|November 26, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857726||66172|
NCT01858324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-025|Evaluation of Educational Tools for Pregnant Women|Evaluation of Educational Tools Concerning Hypertension in Ambulatory Pregnant Women, Compared With Usual Antenatal Care||Université de Sherbrooke|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|247|||Female|18 Years|N/A|No|||December 2014|December 2, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01858324||66127|
NCT01858337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL28886.081.09|Mum Can I Have Vegetables Again? Development of Vegetable Preferences|Mum Can I Have Vegetables Again? Development of Vegetable Preferences.|VaVo|Wageningen University|Yes|Completed|February 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|101|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||May 2013|May 16, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01858337||66126|
NCT01858623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT5|Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide||PKLH|Damanhour University|Yes|Completed|February 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|May 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858623||66104|
NCT01858636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL06818|Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device||SEAL PM|St. Jude Medical|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|235|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that will be included in the study will be indicated for the procedure according        to the Instructions for Use. Physicians should carefully select patients based on the IFU        including a consideration of all warnings and precautions.|November 2014|November 17, 2014|May 14, 2013||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01858636||66103|
NCT01859078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14609|A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants|Effect of Baricitinib on the Pharmacokinetics of Digoxin in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01859078||66069|
NCT01859091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA13-004|Pilot Study on the Submental Area|Pilot Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis||Zeltiq Aesthetics|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 14, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01859091||66068|
NCT01859065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 15 11 10|"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"|"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"||Bronx-Lebanon Hospital Center Health Care System|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|323|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 17, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859065||66070|
NCT01859351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/90-001|Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours|A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors||Wilex|No|Terminated|July 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|April 23, 2013|No|Yes|Study terminated for business reasons|No||https://clinicaltrials.gov/show/NCT01859351||66049|
NCT01859650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17245|Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients|Lung HeXeRT: Advanced Proton, Hyperpolarised 3-helium and 129-xenon Magnetic Resonance Imaging for Lung Cancer Radiotherapy Planning and Evaluation|HeXeRT|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with NSCLC attending Weston Park Hospital, Sheffield, UK.|March 2016|March 18, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01859650||66026|
NCT01860235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMLA2012|EMLA Topical Anesthetic During Scaling and Root Planing|Topical Intrapocket Anesthesia With Prilocaine and Lidocaine as Alternative to Injectable Anesthesia During Scaling and Root Planing - A Randomized Clinical Trial||Franciscan University Center|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||May 2013|May 18, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01860235||65982|
NCT01860768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2XY-ED-001|Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection|Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection||Central South University|Yes|Recruiting|May 2013|April 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Alll patients presenting to the Second Xiangya Hospital of Central South Unversity        Emergency Department with acute chest pain.|May 2013|May 24, 2013|May 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01860768||65941|
NCT01856621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106008 EudraCT 2012-003782-18|Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus|Pharmacokinetic Study Comparing Two Salmeterol Fluticasone Propionate Device-metered Dry Powder Inhalers, Salmeterol/Fluticasone Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; a Randomised, Doubleblind,Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856621||66257|
NCT01856634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-12-232|Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis|Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|July 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|N/A|17 Years|No|||February 2016|February 12, 2016|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01856634||66256|
NCT01856660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA12060259|Bitter Taste and Weight Loss in Women|Bitter Taste Phenotype as an Adjunct to Behavioral Weight-loss Intervention in Women||Rutgers University|No|Active, not recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856660||66254|
NCT01860781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R092670-SCH-4008|The Effect of Paliperidone Palmitate in Schizophrenia|The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study|sustenna|Seoul National University Hospital|Yes|Completed|August 2011|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 6, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860781||65940|
NCT01860794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBC09-074|Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease|Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease||Bundang CHA Hospital|No|Recruiting|May 2013|February 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01860794||65939|
NCT01856647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUG-0799|Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects|A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)||Rockefeller University|No|Terminated|February 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1|Samples Without DNA|Fat Biopsy|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Obesity and psoriasis are characterized by infiltration of inflammatory cells (leukocytes)        in SAT and skin, respectively. We expect that SAT in obese psoriasis subjects will have        infiltrating inflammatory leukocytes because of obesity, and that these infiltrating        leukocytes might be different and/or increased in numbers by the pathology of psoriasis|December 2015|December 18, 2015|May 14, 2013||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01856647||66255|
NCT01857219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002574|A Brain Imaging Study of Fibromyalgia|A Brain Imaging Study of Fibromyalgia||Massachusetts General Hospital|No|Recruiting|January 2013|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01857219||66211|
NCT01857232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN10016|Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy|Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy||Acacia Pharma Ltd|Yes|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|343|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857232||66210|
NCT01857791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-083|Efficacy of a Clinic-based, Multi- Disciplinary, Pediatric Weight Management Program|Efficacy of a Clinic-based, Multi- Disciplinary, Pediatric Weight Management Program|REWARD Teens|University of Vermont|No|Recruiting|January 2011|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|12 Years|18 Years|No|||September 2015|September 9, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857791||66168|
NCT01858025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-075|Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma|A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal||Massachusetts General Hospital|Yes|Recruiting|July 2013|||July 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858025||66150|
NCT01858051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001071|Vitamin D Status in Lower Extremity Joint Replacement Surgery Patients|Bolus vs. Divided Cholecalciferol Dosing to Optimize Perioperative Vitamin D Status for Joint Replacement Surgery||Massachusetts General Hospital|Yes|Not yet recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01858051||66148|
NCT01858649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEV-ONCO2012|Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.|Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI|BEV-ONCO2012|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|May 2013|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01858649||66102|
NCT01858662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CET-ONCO2012|Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors|Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|January 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01858662||66101|
NCT01867723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2008.547|Improving Symptom Management for Cancer Patients and Their Caregivers Through Internet|Improving Symptom Management for Cancer Patients and Their Caregivers Through Internet Support: A Randomized Clinical Trial||Oslo University Hospital|No|Completed|April 2012|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|560|||Both|18 Years|90 Years|No|||October 2015|October 27, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01867723||65409|
NCT01867736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1102|BIOLUX P-II First-in-Man Study to Compare the Passeo-18 Lux DRB Against POBA in Infrapopliteal Arteries|BIOTRONIK's - First in Men Study of the Passeo-18 LUX Drug Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Subjects Requiring Revascularization of Infrapopliteal Arteries (BIOLUX P-II).|BIOLUX P-II|Biotronik AG|Yes|Completed|July 2012|July 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01867736||65408|
NCT01858857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAP2013|Geriatric Psychiatry and Pharmacovigilance|Pharmacovigilance in Gerontopsychiatric Patients|GAP|Hannover Medical School|Yes|Recruiting|May 2013|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|65 Years|N/A|No|Non-Probability Sample|All inpatients meeting the Inclusion/Exclusion criteria, treated at one of the geriatric        psychiatry study sites (one university hospital and four primary care clinics), should be        screened.|May 2013|May 27, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01858857||66086|
NCT01859364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913484|Tobacco Cessation: Treatment Delivery and Predictors of Outcome|Tobacco Cessation:Treatment Delivery and Predictors of Outcome||National Institutes of Health Clinical Center (CC)||Withdrawn|April 2013|March 2023|Anticipated|March 2023|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|October 23, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859364||66048|
NCT01859663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1303003665|Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome|Baseline Assessment of Dietary Intake and Physical Activity in Women With Polycystic Ovary Syndrome (PCOS)||Cornell University|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|80|Samples With DNA|Whole blood and urine samples|Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|New York State. Must be between 18-38 years, with a BMI of 18.5 kg/m2 or higher.|January 2016|January 26, 2016|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859663||66025|
NCT01859949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENASG-0021-007|Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)|Long Term Study Of Pnu-180307 For Short Children Born Small For Gestational Age (Sga) Without Epiphyseal Closure (Extension Of The Study 307-met-0021-002)||Pfizer|No|Completed|October 2002|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|4 Years|8 Years|No|||February 2016|February 16, 2016|April 17, 2013||No||No|February 16, 2016|https://clinicaltrials.gov/show/NCT01859949||66004|
NCT01859962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-201|Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C|A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a)||Presidio Pharmaceuticals, Inc.|No|Completed|May 2013|December 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859962||66003|
NCT01859975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1127|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||August 28, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859975||66002|
NCT01859988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1021|Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|No|Completed|May 2013|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|380|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859988||66001|
NCT01860248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMS 4341|Vapocoolant Spray Effectiveness On Arterial Puncture Pain: Randomized Double Blind Placebo-Controlled Trial|Topical Alkane Vapocoolant Spray Effectiveness On Arterial Puncture Pain Reduction In Emergency Department: Randomized Double Blind Placebo-Controlled Trial||Tehran University of Medical Sciences|Yes|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|80|||Both|14 Years|N/A|No|||July 2013|July 16, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01860248||65981|
NCT01860807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA035054-01|Trial of Ibudilast for Methamphetamine Dependence|Randomized Trial of Ibudilast for Methamphetamine Dependence|IBUD ph II|University of California, Los Angeles|Yes|Recruiting|July 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860807||65938|
NCT01865578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/037/12|Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis|||Charite University, Berlin, Germany||Completed|April 2012|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01865578||65574|
NCT01865825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009305|Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?|PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?||Mayo Clinic|No|Enrolling by invitation|March 2013|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients with GERD that have been currently diagnosed with erosive esophagitis at        endoscopy, at Mayo Clinic Rochester, Minnesota|March 2016|March 15, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01865825||65555|
NCT01866111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP3089C017|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension||SK Life Science|Yes|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|437|||Both|18 Years|70 Years|No|||August 2015|August 21, 2015|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866111||65533|
NCT01856894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCODHC|Serum Anti-Mullerian Hormone (AMH) Levels in Overweight and Obese Adolescent Girls With Polycystic Ovaries|Is Serum Anti-Mullerian Hormone (AMH) Level Associated With Body Weight, Glycemic and Lipidemic Markers in Adolescent Girls With Polycystic Ovaries?||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|||Female|12 Years|20 Years|Accepts Healthy Volunteers|Probability Sample|The diagnosis of Polycystic ovary syndrome was made in the presence of ;oligo- and/or        anovulation,clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries.        Clinical hyperandrogenism was defined by the presence of hirsutism, acne, or the presence        of androgenic alopecia , biochemical hyperandrogenemia was defined as a serum level of        total testosterone higher than 2.60 nmol/L, body mass index (BMI) was calculated as weight        in kilograms divided by the square of height in meters. The patients were classified as        obese with BMI ≥ 25 kg/m2 , adolescent patients were diagnosed 2 years after menarche in        order to avoid the misdiagnosis of transitory functional hyperandrogenism and menstrual        disorders during puberty.|February 2014|February 16, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01856894||66236|
NCT01857492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000033|tDCS for the Management of Chronic Visceral Pain in Patients With Chronic Pancreatitis|tDCS for the Management of Chronic Visceral Pain in Patients With Chronic Pancreatitis|tDCS|Beth Israel Deaconess Medical Center|No|Withdrawn|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|May 16, 2013||No|Inactive|No||https://clinicaltrials.gov/show/NCT01857492||66190|
NCT01857466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-017|Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix|Additional Benefit of Hemostatic Sealant in Preserving Ovarian Reserve During Laparoscopic Ovarian Cystectomy: a Randomized Controlled Trial||CHA University|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|45 Years|No|||June 2014|June 24, 2014|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857466||66192|
NCT01857479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/708/Res/181|A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis|||Postgraduate Institute of Medical Education and Research|Yes|Completed|May 2013|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|12 Years|65 Years|No|||August 2015|August 4, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01857479||66191|
NCT01858038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002618|Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis|Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis||Massachusetts General Hospital|No|Recruiting|May 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|May 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01858038||66149|
NCT01858350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1AT005699|Comparison of the Effectiveness of CAM Therapies in Pediatric Patients Undergoing Sedation|Comparison of the Effectiveness of Complementary and Alternative Medicine (CAM) Therapies in Pediatric Patients Undergoing Medical Resonance Imagining (MRI) Studies||Wayne State University|Yes|Completed|August 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|471|||Both|1 Year|12 Years|No|||May 2013|May 16, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01858350||66125|
NCT01858363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP 1360|CVI Drug Coated Balloon European Randomized Clinical Trial|Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter||Spectranetics Corporation|Yes|Active, not recruiting|November 2012|June 2019|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01858363||66124|
NCT01868074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209787|Study of Changes in the Feet With Pregnancy|Enhancing Women's Health Through Assessing Foot Plasticity With Pregnancy||University of Iowa|No|Active, not recruiting|May 2013|August 2014|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01868074||65382|
NCT01868334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-1U01IP000662-01|SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM|A Vaccination SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM|SOP|University of Pittsburgh|No|Active, not recruiting|April 2013|December 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|596|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01868334||65362|
NCT01858870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACO-EXP|Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication|Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication||Instituto de Investigacion Sanitaria La Fe|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|860|||Both|18 Years|N/A|No|Probability Sample|The study is designed to collect data from patients with epilepsy, aged 18 years with        partial onset seizures (Partial Crisis) treated with Lacosamide as routine clinical        practice in Spain. Lacosamide must have been used for the treatment of Partial Crisis for        at least 12 months. We intend to collect data from approximately 860 patients in 13        Spanish centers.|December 2012|May 20, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01858870||66085|
NCT01868048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS1315|Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.|A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.||GW Research Ltd|No|Not yet recruiting||||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|711|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|May 30, 2013||Yes||||https://clinicaltrials.gov/show/NCT01868048||65384|
NCT01859104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001535|Feasibility of Use of BariCare App in Pre-transplant Population|Feasibility and Efficacy of Engagement Modules for Renal and Liver Transplant Candidates||Mayo Clinic|No|Suspended|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|May 17, 2013||No|App to be used in study needs revision.|No||https://clinicaltrials.gov/show/NCT01859104||66067|
NCT01859377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00498 TA 1 01|Evaluation and Comparison of Systemic Exposure to Ibuprofen After Single Oromucosal Versus Oral Administrations|||Pierre Fabre Medicament||Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859377||66047|
NCT01859390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1557|Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis|A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients|AquADEKs-2|University of Colorado, Denver|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|10 Years|N/A|No|||August 2015|August 26, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859390||66046|
NCT01859403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASDNUTRIMOVE13|Nutrigenomics: Personalizing Weight Loss for Obese Veterans|Nutrigenomics: Personalizing Weight Loss for Obese Veterans||University of California, San Diego|No|Completed|November 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 22, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859403||66045|
NCT01859416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBA-2013(1)|Effects of Oral Nutritional Supplements in Nursing Home Residents|Effects of Oral Nutritional Supplements in Nursing Home Residents||University of Erlangen-Nürnberg Medical School|No|Completed|March 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|87|||Both|65 Years|N/A|No|||May 2013|May 17, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01859416||66044|
NCT01859689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003235|Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer|A Phase II Study of Targeted Brachytherapy for Low Risk Prostate Cancer Patients||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|March 2012|||September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|April 4, 2013||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01859689||66024|
NCT01860001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3828|Incidence of Postoperative Ketosis and Metabolic Acidosis|Incidence of Postoperative Ketosis and Metabolic Acidosis|POKACID|Royal Marsden NHS Foundation Trust|No|Recruiting|October 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|hospital patients seen in pre-operative assessment clinic|May 2013|May 20, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860001||66000|
NCT01860508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-PEM-WJL|A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers|Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research||Fudan University|Yes|Recruiting|February 2013|||February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|70 Years|N/A|No|||July 2013|July 4, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860508||65961|
NCT01869569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012026|Effect of Pregabalin in Patients With Radiation-Induced Peripheral Neuropathic Pain|Effect of Pregabalin in Patients With Radiation-Induced Peripheral Neuropathic Pain: A Randomized Double-blind Placebo-controlled Trial||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|February 2013|February 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01869569||65268|
NCT01866423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-13-1|Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer||University of Southern California|Yes|Terminated|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||July 2015|July 6, 2015|May 28, 2013|Yes|Yes|Not progressing toward scientific goals|No||https://clinicaltrials.gov/show/NCT01866423||65509|
NCT01866436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMBRER186|Educational Study of Multimedia in Surgical Skills Training in Colorectal Surgery|The Role of Multimedia in Cognitive Surgical Skill Acquisition in Open and Laparoscopic Colorectal Surgery||University of Sheffield|No|Completed|October 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|59|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01866436||65508|
NCT01858103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-503|BMN 110 US Expanded Access Program|A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA||BioMarin Pharmaceutical||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||March 2014|March 31, 2014|May 15, 2013||Yes||||https://clinicaltrials.gov/show/NCT01858103||66144|
NCT01866696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID051313|Computer Assisted Implant Surgery and Immediate Loading|Computer Assisted Implant Surgery and Immediate Loading With Full-arch Screw Retained Prosthesis||Università degli Studi di Sassari|No|Completed|April 2006|June 2012|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|39 Years|78 Years|No|||May 2013|May 28, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01866696||65488|
NCT01858389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471047|A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer|Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC||Pfizer|No|Completed|July 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858389||66122|
NCT01857245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034086-01, 2011-555|Intensive Models of HCV Care for Injection Drug Users|Intensive Models of HCV Care for Injection Drug Users||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|July 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|May 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01857245||66209|
NCT01866683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184.583|Yoga Effects on Heart Rate Variability and Electroencephalography|Effects of Yoga on Heart Rate Variability, Electroencephalography, Quality of Life and Salivary Cortisol of Healthy Adult Subjets||University of Sao Paulo|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01866683||65489|
NCT01857830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1039|The Relaxation vs. Retreat Study|The Effect of a Short Term Meditation Retreat on Markers of Cellular Stress and Aging|R&R|University of California, San Francisco|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|96|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01857830||66165|
NCT01857804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|olivier1|Surgical Treatment of Peri-implantitis|Surgical Treatment of Peri-implantitis With and Without Adjunctive Use of Antibiotics : a Controlled and Randomized Clinical Study||Göteborg University|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857804||66167|
NCT01857817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT1-SYS-601|Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer|A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer||Vicus Therapeutics||Active, not recruiting|June 2013|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01857817||66166|
NCT01867749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH086682-03|Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss|Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss||Brown University|Yes|Completed|June 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|50 Years|No|||January 2016|January 12, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01867749||65407|
NCT01859754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM5-28|Octagam 5% Versus Comparator Post Marketing Trial|Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events||Octapharma|Yes|Recruiting|May 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 years old with Primary Immune Deficiency Syndrome PID receiving marketed        IVIG as treatment|September 2015|September 2, 2015|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859754||66019|
NCT01887184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 07-212|Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy|A Study to Assess Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy||The University of Hong Kong|No|Completed|January 2009|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||October 2014|October 24, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01887184||63917|
NCT01887457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_DOG06_172|Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy|PIVOTAL: Pharmacological Individualisation of VOriconazole Therapy for AntifungaL Treatment|PIVOTAL|Christie Hospital NHS Foundation Trust|Yes|Suspended|September 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 7, 2013||No|Transfer of management of study|No||https://clinicaltrials.gov/show/NCT01887457||63896|
NCT01887730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL/81/6.05.00/2012|Hand Hygiene Intervention Study in Finnish Garrison|Can Intensified Hand Hygiene Decrease Morbidity and Lost Service Days in a Garrison|VirusFight|National Institute for Health and Welfare, Finland|No|Active, not recruiting|January 2012|December 2016|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|1120|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01887730||63875|
NCT01887743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G130069PTZ-BT|Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study|The Effect of Obesity on the Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD||Children's Mercy Hospital Kansas City|Yes|Recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||March 2014|January 5, 2015|June 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887743||63874|
NCT01887964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112012-CR|Effect of Resistant Starch (Type-4) on Metabolic Syndrome|Dietary Fiber Intervention in Hutterite Population of South Dakota With and Without Signs of Metabolic Syndrome||South Dakota State University|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|86|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01887964||63857|
NCT01888237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si111/2013|High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication|Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients||Mahidol University|No|Completed|May 2013|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888237||63836|
NCT01888211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC/2003/8/13|Effect of Omega 3 Fatty Acids on Vascular Function|Effect of Omega 3 Fatty Acid Supplementation on Endothelial Function, Endogenous Fibrinolysis and Platelet Activation in Patients With a Previous Myocardial Infarction||University of Edinburgh|No|Completed|December 2004|June 2009|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|N/A|No|||June 2013|June 24, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01888211||63838|
NCT01888224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618-10|Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|June 2011|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|June 25, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888224||63837|
NCT01888549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0103|Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial|||Yonsei University|Yes|Recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|19 Years|70 Years|No|||August 2015|August 18, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888549||63812|
NCT01889095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-03-33-15600|Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients|||Tehran University of Medical Sciences||Completed|July 2011|July 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Both|25 Years|65 Years|No|||June 2013|June 27, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889095||63770|
NCT01889082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14857|Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment|Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment|SPARKRVA|Virginia Commonwealth University|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|25 Years|No|||December 2014|December 16, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01889082||63771|
NCT01889329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR- 11005|Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for SAM Children|Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for the Treatment of Children With Severe Acute Malnutrition||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|465|||Both|6 Months|59 Months|No|||June 2015|July 26, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889329||63752|
NCT01865201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009001|Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis|Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis in Patients With Nasopharyngeal Carcinoma After Radiotherapy||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Completed|March 2009|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01865201||65602|
NCT01865227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRG12-2-16|Obesity Surgery, Counseling, and Psychological Well-Being|Impact of Counseling on Obesity Surgery Outcomes and Psychological Functioning: A Randomized Clinical Trial in 2 Arab Countries||American University of Sharfah|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865227||65601|
NCT01860976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-332|Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis|A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis|ASTRAEA|Bristol-Myers Squibb|No|Active, not recruiting|June 2013|July 2017|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2015|March 11, 2016|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860976||65925|
NCT01888159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEvsTSinAMH|Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve|||Karlstad Central Hospital|No|Not yet recruiting|September 2013|||September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|25 Years|45 Years|No|||June 2013|June 25, 2013|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01888159||63842|
NCT01888432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2307|Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants|A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants and Long Term Extension to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants in Japan.||Novartis|Yes|Recruiting|September 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888432||63821|
NCT01887860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10232c|Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50|Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)||Galderma Laboratories, L.P.||Completed|December 2012|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887860||63865|
NCT01888705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UERJ-DPOC-01|Complexity of the Airflow in COPD|Complexity of the Airflow at Different Levels of Bronchial Obstruction of COPD.||Rio de Janeiro State University|No|Recruiting|March 2010|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||6|Anticipated|90|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The control group will consist of healthy subjects, nonsmokers, who had no episode of        respiratory infection thirty days before the examinations.        The group of patients with COPD will be comprised of individuals treated at the Department        of Pneumology (Hospital Universitário Pedro Ernesto), at different levels of airflow        obstruction.|June 2013|June 27, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01888705|1 Day|63800|
NCT01888991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR kids_26570|Substrate Oxidation Does Not Affect Short Term Food Intake in Healthy Boys and Men|Substrate Oxidation Does Not Affect Short Term Food Intake in Healthy Boys and Men.||University of Toronto|No|Completed|December 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|30|||Male|9 Years|29 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01888991||63778|
NCT01890122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322MET_303|Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|September 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|651|||Both|18 Years|75 Years|No|||December 2015|December 8, 2015|June 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01890122||63691|
NCT01889849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN 003/2009|Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers|Comparative Pharmacokinetics and Pharmacodynamics, and Safety of Two Products Containing Recombinant Human Interferon Alpha-2 Conjugated to Polyethylene Glycol in Healthy Volunteers - Phase 1.||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 28, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889849||63712|
NCT01889862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-302|Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU|A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)|Prism302|BioMarin Pharmaceutical|Yes|Active, not recruiting|July 2013|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889862||63711|
NCT01890135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH3TR000959-01|Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication|A Phase II Clinical Trail to Assess the Safety and Effects of ZD4054 (Zibotentan) on Exercise Induced Calf Muscle Perfusion in Patients With Intermittent Claudication (Rutherford II or III).||University of Virginia|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|44|||Both|40 Years|N/A|No|||February 2014|February 11, 2014|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890135||63690|
NCT01887470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-KR-004|2 Regimens of Lactulose for Colonoscopy Preparation in Adults|A Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of 2 Regimens of Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults||Cumberland Pharmaceuticals|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|June 21, 2013|Yes|Yes||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01887470||63895|
NCT01887483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF_2013|Vetal Laban Intervention Trial Assessing Bowel Symptoms|A Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 Month Consumption of Vetal Laban Including L. Acidophilus on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for IBS|KF_2013|Danisco|No|Terminated|March 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|May 27, 2013||No|Slow recruitment, high drop-out|No||https://clinicaltrials.gov/show/NCT01887483||63894|
NCT01887717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-104|Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein|A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)|YES-P|BTG International Inc.|Yes|Recruiting|June 2013|December 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|N/A|No|||July 2015|December 10, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887717||63876|
NCT01887756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTR-Motion|Research Online Tele-Rehabilitation Program in People After a Stroke Living at Home|Research and Clinical Aspects of the Project Study of Home Based Tele-Rehabilitation Program for Patients With Stroke||Clalit Health Services|No|Terminated|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|20 Years|80 Years|No|||June 2013|February 18, 2014|June 12, 2013||No|Halted before intervention due to approval of service.|No||https://clinicaltrials.gov/show/NCT01887756||63873|
NCT01887977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T17/2012|Computational Modeling for Prediction of Acoustic Changes in Vowel Production Due to Orthognathic Surgery|Computational Modeling for Prediction of Acoustic Changes in Vowel Production|PUMA|Turku University Hospital|No|Recruiting|March 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01887977||63856|
NCT01888250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|671/09|Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|August 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|June 25, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888250||63835|
NCT01888536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJ7-401|A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis|A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis||Yungjin Pharm. Co., Ltd.|No|Completed|February 2013|February 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|20 Years|75 Years|No|||December 2015|December 19, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888536||63813|
NCT01888575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5040N00008|Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy|Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention||AstraZeneca|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|35604|||Both|50 Years|84 Years|No|Non-Probability Sample|This is a pharmacoepidemiology study using data from The Health Improvement Network (THIN)        primary care database in the UK. Patients aged 50-84 years with evidence of ischemic heart        disease or cerebrovascular disease, who were new users of low-dose ASA (75-300 mg/day) and        who had received at least two low-dose ASA prescriptions for the secondary prevention of        cardiovascular disease or cerebrovascular disease between 2000 and 2007 were identified        from THIN. .|May 2014|May 9, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01888575||63810|
NCT01889368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|329493-4|Effect of a Grape Seed Extract (GSE) on Insulin Resistance|Effect of a Grape Seed Extract (GSE) on Insulin Resistance||University of California, Davis|No|Recruiting|November 2012|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Both|20 Years|70 Years|No|||June 2013|June 25, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01889368||63749|
NCT01889342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SveJoh 1|Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial.|Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial.||Modum Bad|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889342||63751|
NCT01889355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAFPGM01|User Study for Enhanced Meter Feature|User Study for the Evaluation of an Enhanced Meter Feature Using an AgaMatrix BGMS||AgaMatrix, Inc.|No|Completed|January 2014|March 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|September 1, 2015|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889355||63750|
NCT01865240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008/12|Renal Denervation for Resistant Hypertension|Renal Denervation for Resistant Hypertension|RDNP-2012-01|Baker IDI Heart and Diabetes Institute|No|Active, not recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865240||65600|
NCT01861002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2011-002|A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML|A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|1 Year|21 Years|No|||July 2014|July 29, 2014|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861002||65923|
NCT01889264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-042011-088|Methionine Metabolism in Enterally Fed Pediatric Sepsis|Methionine Metabolism in Enterally Fed Critically Ill Children||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Blood samples.|Both|1 Month|19 Years|No|Non-Probability Sample|Septic pediatric patients: A total of 45 critically ill children age 1 month-19 years with        diagnosis of sepsis, as defined by the International Sepsis Consensus Conference.|June 2013|June 21, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889264||63757|
NCT01888718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|671/10|Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra ® (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2011|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|June 26, 2013|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888718||63799|
NCT01888744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/010|Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist|The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial|Avanti|Universitair Ziekenhuis Brussel|No|Completed|September 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|39 Years|No|||June 2013|June 27, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01888744||63797|
NCT01889836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN / 001 / 2013|Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos|Brazil's Conjugated Vaccine Project Against Meningococcal C. Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01889836||63713|
NCT01889563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD6VS12|Physical Training and Heart Rate Variability in COPD|Potential Effects of 6 vs 12-weeks of Physical Training on Cardiac Autonomic Function and Functional Capacity in COPD||Universidade Federal de Sao Carlos|No|Completed|May 2006|June 2013|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|32|||Both|45 Years|80 Years|No|||November 2013|November 21, 2013|June 25, 2013||No||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01889563||63734|
NCT01886508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00270426|A Multicentre Trial of Nerve-Spring Radical Hysterectomy vs. Radical Hysterectomy for Cervical Cancer|||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|July 2013|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Female|17 Years|60 Years|No|||May 2013|July 19, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01886508||63969|
NCT01886716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA021151|Retraining Attention to Treat Alcohol Dependence and Social Anxiety|Cognitive Bias Modification: A Novel Intervention for Alcohol Dependence and Social Anxiety|AMP|University of Cincinnati|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|115|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01886716||63953|
NCT01886729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 11/18/146|Effect of Time Shift of Transcranial Direct Current Stimulation (tDCS) for Treatment of Acute Tinnitus|||University Hospital, Antwerp||Recruiting|April 2012|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label|2||||||Both|18 Years|50 Years||||June 2013|June 25, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886729||63952|
NCT01887210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD074846-01|A Pilot Gaming Adherence Program for Youth Living With HIV|A Pilot Gaming Adherence Program for Youth Living With HIV||Rhode Island Hospital|Yes|Recruiting|September 2012|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|14 Years|26 Years|No|||May 2015|May 5, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887210||63915|
NCT01887496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARICOMP|Varicella-related Hospitalizations in Turkey|The Epidemiology and Economic Impact of Varicella Related Hospitalization in Turkey (VARICOMP Study)|VARICOMP|Eskisehir Osmangazi University|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1800|||Both|N/A|18 Years|No|Non-Probability Sample|0-18 years old hospitalized children due to varicella and -related complications|June 2013|June 26, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01887496||63893|
NCT01888003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130117001|The Benefits of a Preoperative Anemia Management Program|The Benefits of a Preoperative Anemia Management Program|PAMP|University of Alabama at Birmingham|Yes|Terminated|April 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|19 Years|80 Years|No|||May 2015|May 26, 2015|March 20, 2013||No||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01888003||63854|
NCT01887990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F120307001|Treatment of Suicidal Ideation With Intravenous Ketamine Infusion|Treatment of Suicidal Ideation With Intravenous Ketamine Infusion||University of Alabama at Birmingham|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|18|||Both|19 Years|N/A|No|||June 2015|June 17, 2015|August 7, 2012|No|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01887990||63855|short term followup small sample size
NCT01888263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|672/09|Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|August 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|June 25, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888263||63834|
NCT01888562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404024|Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma|A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study||Washington University School of Medicine|No|Withdrawn|January 2016|July 2023|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|June 25, 2013|No|Yes|Could not obtain an IDE on the FGFR2 assay|No||https://clinicaltrials.gov/show/NCT01888562||63811|
NCT01888588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5040N00006|Risk of Uncomplicated Peptic Ulcer in the General Population|Risk of Uncomplicated Peptic Ulcer in the General Population||AstraZeneca|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4000|||Both|40 Years|84 Years|No|Non-Probability Sample|The study is conducted using The Health Improvement Network database in the UK. Patients        aged 40-84 years between January 1997 and December 2005 with a registration status of        permanent or deceased, who were enrolled for at least 2 years with a GP and had 1 year of        electronic prescription history. Patients with a code for cancer, peptic ulcer (both        uncomplicated and complicated), upper GI bleeding, oesophageal varices, Mallory-Weiss        disease, alcohol abuse, liver disease, or coagulopathies before beginning date were        excluded from the source population. All patients in the study population were followed up        until the end of the study period (December 2005), or until they reached the age of 85,        died, met any of the exclusion criteria (including receiving a diagnosis of complicated        peptic ulcer disease), or received a diagnosis of uncomplicated peptic ulcer        disease.Patient records were manually reviewed to validate cases.|July 2014|July 14, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01888588||63809|
NCT01888874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-203 (DARWIN1)|Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone|DARWIN1|Galapagos NV|Yes|Completed|July 2013|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|599|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888874||63787|
NCT01888887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10236|Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser: 200 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation||Galderma Laboratories, L.P.|No|Completed|December 2012|||February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01888887||63786|
NCT01888900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130150|New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C|Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Completed|May 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888900||63785|
NCT01889108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU_HM13949|Feasibility Study of SPEEDI|Feasibility Study of Supporting Play, Exploration, & Early Development Intervention (SPEEDI) for Infants Born Preterm|SPEEDI|Virginia Commonwealth University|No|Completed|July 2012|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||June 2013|June 27, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01889108||63769|
NCT01889121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE_Methadone|Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers|Retrospective Analysis of the Utility Formal Psychosocial Support in Enhancing the Outcome of Pregnancies in Opiate-addicted Pregnant Women in Agonist Maintenance Programs|HOPE|Children's Hospital Medical Center, Cincinnati|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|113|||Female|N/A|N/A|No|Non-Probability Sample|Opiate abusing pregnant women who received their prenatal care through Good Samaritan        Faculty Medical Center and were getting methadone maintenance therapy|June 2013|June 26, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889121||63768|
NCT01889654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5543|Anti-nucleosome B Lymphocytes in Lupus|Analysis of Frequency and Phenotype of Anti-nucleosome B Lymphocyte in Systemic Lupus||University Hospital, Strasbourg, France||Not yet recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|lupus patient and healthy volunteers|January 2014|January 14, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889654||63727|
NCT01889667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-D-009|Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With T2DM Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin||Oramed, Ltd.|Yes|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|70 Years|No|||October 2014|March 26, 2015|June 19, 2013|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01889667||63726|
NCT01889381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00067257|Human Craniomaxillofacial Allotransplantation|Human Craniomaxillofacial Allotransplantation||Johns Hopkins University|Yes|Recruiting|August 2012|August 2026|Anticipated|August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||March 2016|March 8, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889381||63748|
NCT01865253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087/12|Renal Denervation for Complicated Hypertension|Renal Denervation for Complicated Hypertension (RDNP-2012-03)|RDNP-2012-03|Baker IDI Heart and Diabetes Institute|No|Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865253||65599|
NCT01861028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002|Study Comparing Fit of the iTotal Versus Standard Total Knee Implants|Study Comparing Fit of the iTotal Versus Standard Total Knee Implants||ConforMIS, Inc.|No|Recruiting|February 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving either a standard total knee implant or an iTotal patient-specific        total knee implant|June 2015|June 18, 2015|March 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861028||65921|
NCT01889277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-J03|Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy|A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy||Mitsubishi Tanabe Pharma Corporation|No|Completed|July 2013|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|20 Years|75 Years|No|||January 2015|January 26, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889277||63756|
NCT01888445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0304|A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug|ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia||Astellas Pharma Inc|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|130|||Both|20 Years|75 Years|No|||October 2014|October 15, 2014|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01888445||63820|
NCT01888757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|718/09|Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|September 2010|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|June 26, 2013|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888757||63796|
NCT01889290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELZH12|Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients|Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation|RELZH12|University of Zurich|Yes|Recruiting|February 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01889290||63755|
NCT01890447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116964|Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation|Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation, in Italy and Spain||GlaxoSmithKline||Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged 18 years and above who are either contacts of newborns (aged ≤ 6 months) or        expecting mothers in their last trimester of pregnancy or their partners, who will be in        close contact with the newborn.|February 2016|February 25, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01890447||63666|
NCT01886989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-12-52|Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes|Postprandial Effects of Polyphenol-rich Cocoa Beverage on Glucose, Insulin, Lipids, Oxidative Stress and Inflammation in Type 2 Diabetic Patients||Oklahoma State University|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|18|||Both|21 Years|60 Years|No|||December 2014|December 22, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01886989||63932|
NCT01887002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2952POU005|Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)|RESTORE|Ono Pharmaceutical Co. Ltd|No|Terminated|June 2013|||January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Female|18 Years|65 Years|No|||January 2016|January 26, 2016|June 24, 2013|Yes|Yes|The study was terminated due to slow accrual of subjects.|No||https://clinicaltrials.gov/show/NCT01887002||63931|
NCT01887197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1 HL108929-01 (B)|Repeatability and Response Study of Absorptive Clearance Scans|Repeatability and Response Study of Absorptive Clearance Scans||University of Pittsburgh|Yes|Recruiting|June 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887197||63916|
NCT01887223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNRVMT-RS|Transconjunctival Needling Revision Versus Medical Treatment|Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Treatment in Encapsulated Blebs: a 12-month Prospective Study||University of Sao Paulo General Hospital|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||June 2013|June 26, 2013|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887223||63914|
NCT01887236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-38-13|The Effect of Exercise Training Programs: Step and Stability Ball on Balance and Obstacle Avoidance in Older People|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|45|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 23, 2013|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01887236||63913|
NCT01887769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20824|Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis||BAT-SCAN|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Yes|Recruiting|May 2012|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|40 Years|80 Years|No|Probability Sample|Lung cancer patients, at diagnosis, following in oncology clinic|March 2016|March 14, 2016|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01887769||63872|
NCT01888016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manifa|Effectiveness of Fascial Manipulation in Rotator's Cuff Surgery Patients|Effectiveness of Fascial Manipulation in Early Rehabilitation Treatment of Rotator's Cuff Surgery Patients. A Randomized Trial.||Istituto Ortopedico Rizzoli|No|Completed|June 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||August 2015|November 18, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888016||63853|
NCT01888289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-101|Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 40 mg of Roche Laboratories Inc., Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|July 2001|September 2001|Actual|August 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2001|June 26, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888289||63832|
NCT01888276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 225 02|Words Generation in Compulsives Gamblers and Parkinson's Disease Patients|Study of Words Generation in Compulsives Gamblers and Healthy Volunteers: Comparison With a Study of Parkinson's Disease Patients|FLUENCE|University Hospital, Toulouse|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|37|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01888276||63833|
NCT01888913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130158|Patient Perspectives and Doctor Visits|Patient Perspectives and Simulated Clinical Interactions||National Institutes of Health Clinical Center (CC)||Completed|June 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|338|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 12, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01888913||63784|
NCT01889134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-722/2009|OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism|Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate||Wroclaw Medical University|No|Completed|January 2009|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|112|||Both|25 Years|N/A|No|||June 2013|June 25, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01889134||63767|
NCT01889420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1304|Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma||New Mexico Cancer Care Alliance|Yes|Terminated|July 2014|July 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|June 26, 2013|No|Yes|Low accrual|No|July 3, 2015|https://clinicaltrials.gov/show/NCT01889420||63745|Low accrual led to early termination; only one subject was enrolled.
NCT01889407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDA20130517|Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients|Idarubicin Overcomes Multidrug Resistant-1(MDR1) Induced Chemoresistance With Higher Induction Remission Rate and Remission Quality Than Daunorubicin in de Novo Acute Myeloid Leukemia Patients||Nanfang Hospital of Southern Medical University|Yes|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|94|Samples With DNA|Bone marrow|Both|14 Years|60 Years|No|Probability Sample|• Patients aged 16 to 60 years are eligible. Patients must be chemo-naïve, i.e. not have        received any prior chemotherapy (except hydrea) for AML. They could have received        transfusion, hematopoietic growth factors or vitamins. Temporary measures such as pheresis        or hydrea (0.5 to 5g daily or more for up to 3 days) are allowed|July 2013|April 18, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889407|3 Years|63746|
NCT01889394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB 234/05|Primary Wound Closure Using a Limberg Flap Versus Secondary Wound Healing Following Pilonidal Sinus Excision|Primary Wound Closure Using a Limberg Flap Versus Secondary Wound Healing Following Pilonidal Sinus Excision: Short-term Results of a Randomized Controlled Multicenter Trial||Kantonsspital Liestal|Yes|Active, not recruiting|January 2006|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889394||63747|
NCT01889693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaMSA-Atherosclerosis|Imaging of Atherosclerosis With 68Ga-MSA|Identification of Vascular Inflammatory Image Using a 68Ga-MSA(Gallium-68 Neomannosyl Human Serum Albumin) in Patients With Atherosclerotic Lesions||Korea University|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 patients with acute coronary syndrome, 20 patients with chronic stable angina and 20        control subjects wihout coronary artery disease of the Cardiovascular Center at Korea        University Guro Hospital|August 2013|August 23, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889693||63724|
NCT01865266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP-YYT-003|The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia|The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia||Shanghai Minhang Central Hospital|Yes|Not yet recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||May 2013|May 29, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865266||65598|
NCT01865279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1718|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec|A Randomised, Double-blind, Placebo-controlled Single Dose, Dose Escalation Trial With Insulin 454 in Healthy Male Subjects, Followed by a Two-period Cross-over Trial With Insulin 454 and Insulatard® in Male Subjects With Type 1 and Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|December 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|May 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865279||65597|
NCT01888770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOCH|The Effect of Preeclampsia and Gestational Hypertension on Offspring Cardiovascular Health|The Effect of Preeclampsia and Gestational Hypertension on Offspring Cardiovascular Health|EPOCH|University of Oxford|No|Recruiting|August 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|Samples With DNA|Whole blood, serum, plasma|Both|N/A|6 Months|No|Non-Probability Sample|Study population is drawn from infants delivered in the OUH hospital trust to normotensive        or hypertensive pregnancies. The mothers of these infants form a secondary study cohort.|July 2013|December 2, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01888770||63795|
NCT01889550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIIP|Use of eHealth in Communication With Patients About Prenatal Diagnosis|Use of eHealth in Communication With Patients About Prenatal Diagnosis. An Intervention Study Carried Out in a Highly Specialised Unit for Obstetrics|HIIP|Odense University Hospital|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|1150|||Female|18 Years|50 Years|No|||October 2014|October 15, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01889550||63735|
NCT01890161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXP1275-201|A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma|A Phase IIa Randomized Double-blind Placebo-controlled Two-way Cross-over Trial of the Effects of Repeat Doses of 50 mg AXP1275 Daily on the Asthmatic Response to a Pulmonary Allergen Challenge in Adults With Mild-to-Moderate Atopic Asthma||Axikin Pharmaceuticals, Inc.|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|64 Years|No|||January 2016|January 8, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890161||63688|
NCT01886521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37238|Use of Lumbar Drain to Remove Clots in Patients Admitted to the Neuro-ICU After Subarachnoid Hemorrhage.|Use of Lumbar Drain Versus Ventricular Drain to Remove Clots in Patients Admitted to the Neuro-ICU After Subarachnoid Hemorrhage (a Randomized Trial).||Odense University Hospital|No|Recruiting|August 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 19, 2014|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01886521||63968|
NCT01886742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1653|Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients|Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients||University of Colorado, Denver|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|75 Years|No|||December 2015|December 9, 2015|February 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886742||63951|
NCT01886534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-638|Caregiver Enhanced Assistance and Support for the Elderly Heart Failure Patient at Hospital Discharge (CEASE-HF)|A Randomized Controlled Trial of Enhanced Caregiver Support Versus Usual Care for Managing Older Heart Failure Patients at Hospital Discharge|CEASE-HF|McMaster University|Yes|Recruiting|September 2012|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Anticipated|120|||Both|60 Years|N/A|No|||June 2013|June 25, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886534||63967|
NCT01886755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0069|Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis|||Aghia Sophia Children's Hospital of Athens|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|6 Months|36 Months|No|||February 2016|February 20, 2016|June 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01886755||63950|
NCT01887015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0157|Optiflow® to Prevent Post-Extubation Hypoxemia afteR Abdominal Surgery (the OPERA Trial)|Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial|OPERA|University Hospital, Clermont-Ferrand||Completed|June 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|220|||Both|19 Years|N/A|No|||March 2015|March 26, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887015||63930|
NCT01887509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005|Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology|Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology|TRaMA|IHU Strasbourg|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01887509||63892|
NCT01887522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003005-10 Phase II|Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults|Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma|VINILO|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|May 2013|May 2019|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Months|20 Years|No|||June 2013|June 24, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01887522||63891|
NCT01887782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179/2012|Randomized Controlled Trial of Conventional vs Theta Burst rTMS|A Randomized Controlled Study of Conventional Versus Theta Burst Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder|HFL vs TBS|Centre for Addiction and Mental Health|Yes|Recruiting|September 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01887782||63871|
NCT01888315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symplicity Extension|Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity|Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation on Different Organ Systems in Patients With Increased Sympathetic Activity||University Hospital, Saarland|No|Recruiting|January 2011|January 2021|Anticipated|January 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01888315||63830|
NCT01888302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1243|Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery|Pilot Trial of Sirolimus, Gemcitabine and Cisplatin for Patients With High Risk for Cholangiocarcinoma Recurrence||Mayo Clinic|Yes|Recruiting|September 2013|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01888302||63831|
NCT01888601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0279|TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)|TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)|TRACERx|University College, London|Yes|Recruiting|April 2014|April 2023|Anticipated|April 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|842|Samples With DNA|tissue, blood, plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|Stage I-IIIA NSCLC eligible for primary surgery|March 2016|March 8, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01888601||63808|
NCT01889147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDR1220|Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)|A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).||TNO|Yes|Completed|June 2013|October 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|4|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889147||63766|
NCT01889433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-016-3|An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C|An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C||Biocad|No|Active, not recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|70 Years|No|||November 2015|November 12, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889433||63744|
NCT01889706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTiT1DM|Metformin Therapy in Type 1 Diabetes Mellitus.|Application of Metformin as Adjuvant Therapy in Overweight and Obese Patients With Type 1 Diabetes Mellitus.||Poznan University of Medical Sciences|No|Recruiting|January 2009|February 2014|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|60 Years|No|Non-Probability Sample|200 Caucasian patients with type 1 diabetes admitted to the Department of Internal        Medicine and Diabetology, Poznan University of Medical Sciences in years 2009-2014,        treated with intensive insulintherapy.|June 2013|June 26, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889706||63723|
NCT01889992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339-12-FB|Cardiac Allograft Remodeling and Effects of Sirolimus|Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression|CAR|University of Nebraska|No|Recruiting|April 2013|April 2016|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|110|||Both|19 Years|70 Years|No|||June 2013|June 26, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01889992||63701|
NCT01890005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2013-05|Low Dose Aspirin for the Prevention of Preeclampsia|Low Dose Aspirin Between 13 and 16 Weeks of Pregnancy for the Prevention of Preeclampsia. Double Blind, Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Not yet recruiting|July 2013|January 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|476|||Female|N/A|N/A|No|||June 2013|June 28, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890005||63700|
NCT01889303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCSC G-02|Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer|Phase II Clinical Trial of Docetaxel Plus Cisplatin as Adjuvant Chemotherapy and Concurrent Chemoradiotherapy Versus FOLFOX6 as Adjuvant and 5-FU/CF as Chemoradiotherapy in Patients of Locally Advanced Gastric Cancer After Radical Surgery||Wuhan University|No|Recruiting|May 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|70 Years|No|||December 2014|December 11, 2014|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01889303||63754|
NCT01888783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOT_CRPS2013|Two Measures of Tactile Acuity in CRPS Type I Patients|Comparison of Two Measures of Tactile Acuity in CRPS Type I Patients , Patients With a Neuropathy of the Median Nerve and Healthy Controls.||Ruhr University of Bochum|No|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|August 1, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888783||63794|
NCT01888796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-025|Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus|Effect of Linagliptin Therapy on Myocardial Diastolic Function in Patients With Type 2 Diabetes Mellitus|Diast Dysfkt|RWTH Aachen University|Yes|Terminated|September 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|50 Years|N/A|No|||February 2015|February 6, 2015|June 20, 2013||No|bad recruitment of suitable participants, just 8 patients in one year|No||https://clinicaltrials.gov/show/NCT01888796||63793|
NCT01889017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V 1.0 22/05/2013|Generic Immunosuppressive Drugs After Lung Transplantation|Generic Immunosuppressive Drugs After Lung Transplantation - a Crosssectional Observational Study by Patient Questionnaire||Hannover Medical School|No|Recruiting|July 2013|September 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|patients after lung transplantation (single, double or combined) with an immunosuppressive        therapy with tacrolimus or ciclosporin|June 2013|July 15, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889017||63776|
NCT01889875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Graesallergi|Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen|Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen||Bispebjerg Hospital|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|40|||Both|18 Years|70 Years|No|||June 2013|June 26, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889875||63710|
NCT01890187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-OCT-GA-2010-2|Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium|Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium||Carl Zeiss Meditec, Inc.|Yes|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|85|||Both|50 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|June 2013|June 27, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890187||63686|
NCT01890486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 95300|The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen|The Prospective Collection, Storage and Reporting of Data on Patients||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|May 2001|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|120 Years|No|Non-Probability Sample|patients who are not on a specific "treatment research protocol" but who are nevertheless        receiving "standard of care" dose intensive therapy and either an allogeneic or autologous        bone marrow transplant|September 2014|September 22, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890486|1 Year|63663|
NCT01890499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029966|Prospective Controlled Trial On Clear Feeds Versus Low Residue Diet After Surgery In Elective Colorectal Surgery Patients|PROSPECTIVE RANDOMIZED CONTROLLED TRIAL ON CLEAR FEEDS VERSUS LOW RESIDUE DIET AFTER SURGERY IN ELECTIVE COLORECTAL SURGERY PATIENTS.||Cedars-Sinai Medical Center|Yes|Completed|November 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890499||63662|
NCT01886768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB101-101|Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy|Double Versus Single Pledget Method of Nasal Anesthesia for Transnasal Endoscopy: A Randomized Prospective Control Study||Buddhist Tzu Chi General Hospital|No|Recruiting|September 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|212|||Both|18 Years|65 Years|No|||June 2013|June 22, 2013|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01886768||63949|
NCT01887028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0158|Impacts of Intraperitoneal Pressure and CO2 Gas on Surgical Peritoneal Environment|A Single-blind, Randomized Study to Compare Impacts of Intraperitoneal Pressure (8mmHg Versus 12 mmHg) and CO2 Gas (Cool, Dry CO2 Gas Versus Warmed; Humidified Co2 Gas) on Surgical Peritoneal Environment During Laparoscopic Surgery||University Hospital, Clermont-Ferrand||Recruiting|July 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|80|||Female|45 Years|75 Years|No|||November 2013|November 4, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887028||63929|
NCT01887262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPASS|Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS|Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS (COMPASS) Trial|COMPASS|Seoul National University Hospital|Yes|Recruiting|July 2013|July 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|138|||Both|20 Years|75 Years|No|||June 2014|June 17, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887262||63911|
NCT01887535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101620|A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects||Janssen Research & Development, LLC|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|70|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887535||63890|
NCT01888029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plasticity in MCI|Influence of tDCS on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)|Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)||Charite University, Berlin, Germany|No|Recruiting|May 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|50 Years|80 Years|No|||March 2016|March 15, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888029||63852|
NCT01888042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-00979-14|Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer|Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis|POORTOR|Gustave Roussy, Cancer Campus, Grand Paris|No|Terminated|July 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888042||63851|
NCT01888653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 6688|Attention-Bias Modification Treatment for PTSD|Attention-Bias Modification Treatment for PTSD||Research Foundation for Mental Hygiene, Inc.|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|No|||May 2015|May 4, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888653||63804|
NCT01888640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM01-FAST2012|Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)|Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation|FAST|University of Iowa|Yes|Recruiting|May 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Female|18 Years|70 Years|No|||June 2015|June 2, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888640||63805|
NCT01888614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-41|Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study|Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study||University Hospital Case Medical Center|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with sickle cell disease who are 18 years of age or older. Patients presenting        for follow up at the outpatient sickle cell clinic. Patients who are capable of following        simple instructions. Patients who are able and willing to provide informed consent.|June 2013|June 25, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01888614||63807|
NCT01888627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCESS-II|Integrated Care in Psychotic Disorders With Severe Mental Illness|Integrated Care in Patients With a Psychotic Disorder Fulfilling Definition of Severe Mental Illness (ACCESS-II Study)|ACCESS-II|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|May 2007|December 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|12 Years|N/A|No|||July 2015|July 13, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01888627||63806|
NCT01889719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC-0803|A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR|Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)||Rockefeller University|Yes|Completed|January 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889719||63722|
NCT01889732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2013-05-060|A Gray Zone Approach of Rotational Thromboelastometry for Predicting Postoperative Bleeding in Cardiac Surgical Patients|The Effectiveness Evaluation of Rotational Thromboelastometry(ROTEM) for Predicting Postoperative Bleeding in Cardiac Surgical Patients Using a Gray Zone Approach : A Preliminary Retrospective Study||Samsung Medical Center|Yes|Recruiting|June 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|elective cardiac surgical patient age 20-80years|June 2013|June 26, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01889732||63721|
NCT01890018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817167|Partners and Alerts: A Study of Social Forces in Medication Adherence|Partners and Alerts: A Study of Social Forces in Medication Adherence||University of Pennsylvania|No|Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|5||Actual|178|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01890018||63699|
NCT01890304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68-2013|Longitudinal Study of Traumatic Brain Injury (TBI) in (University of Florida) UF Athletes|Diffusion Tensor Imaging (DTI) Compared to Serum Biomarkers and Standard Clinical Measures of Concussion in Female and Male Collegiate Athletes: a Longitudinal Survey Across the College Years.|GATOR TBI|University of Florida|No|Enrolling by invitation|July 2013|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|750|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890304||63677|
NCT01890317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZLCOOL1|Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction|Randomized Pilot Study of Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction|SHOCK-COOL|University of Leipzig|No|Active, not recruiting|August 2012|March 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||November 2015|November 11, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890317||63676|
NCT01890616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1312|Constipation and Gut Transit in DMD Patients|Constipation and Gut Transit in Duchenne Muscular Dystrophy Patients||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2013|||October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||June 2013|June 27, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890616||63653|
NCT01890629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL012|Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)|A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on Glucose Variability(MAGE, Glucose SD) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d., or Glimepiride 2mg q.d. With Metformin 500-1,000mg q.d. in Patients With Type 2 Diabetes|STABLE|LG Life Sciences|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|20 Years|70 Years|No|||March 2015|March 12, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890629||63652|
NCT01889901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/13E|Enhancing Physical Activity Levels in Children With Epilepsy|Enhancing Physical Activity in Children With Epilepsy: Impacts on Health and Quality of Life||Children's Hospital of Eastern Ontario|No|Completed|December 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|8 Years|14 Years|No|||March 2016|March 2, 2016|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01889901||63708|
NCT01889576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDS BE-02-RG-219|The Effect of Magnesium on Early Post-transplantation Glucose Metabolism|The Effect of Magnesium Supplements on Early Post-transplantation Glucose Metabolism: a Randomized Controlled Trial.||University Hospital, Ghent|No|Completed|January 2010|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889576||63733|
NCT01889589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYCHFUS2010|NYC Heart Follow-Up Study 2010|Baseline 24 Hour Urine Collection in Population-based Sample of NYC Adults|HFUS|New York City Department of Health and Mental Hygiene||Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1775|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|NYC adult population|June 2013|June 27, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889589||63732|
NCT01889888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-FMBC-01-02-13|Effectiveness and Safety of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures|Effectiveness and Safety of Endoscopically-Assisted Submucosal Administration of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures||Burnasyan Federal Medical Biophysical Center|No|Enrolling by invitation|June 2013|May 2015|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|75 Years|No|||June 2013|June 26, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889888||63709|
NCT01890460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-041|Evaluation of Liver Disease With Elastography Measurements in Patients Undergoing Liver Transplant Surgery|Quantitative Evaluation of Liver Disease With Liver Elastography Measurements Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine in Patients Undergoing Liver Transplant Surgery|SupersonicOR|Baylor Research Institute|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing a liver transplant surgery|January 2016|January 21, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890460||63665|
NCT01890512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1897|INGENIO MRI/ FINELINE II Pacing System Data Collection in Patients Undergoing MRI|INGENIO MRI/ FINELINE II ImageReadyTM Pacing System Data Collection in Patients Undergoing Magnetic Resonance Imaging|INFINITE-MRI|Boston Scientific Corporation|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients implanted with a ImageReady pacemakers according to standard medical guidelines        in the investigational site or referral centers|May 2014|January 11, 2016|June 25, 2013||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01890512||63661|
NCT01886547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURA-2013|2013 Annual National Digital Rectal Exam (DRE) Day Study|2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection||St. Luke's Medical Center, Philippines|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|925|||Male|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Filipino males ages 40 or older|April 2015|April 5, 2015|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01886547|1 Year|63966|
NCT01886781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N10-08-270|Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome|Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome||University of Stellenbosch|Yes|Completed|January 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|June 18, 2013||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01886781||63948|
NCT01887041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 - mtachezy|Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer|Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice|BYPAPA|Universitätsklinikum Hamburg-Eppendorf|Yes|Terminated|January 2010|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|90 Years|No|||February 2016|February 5, 2016|June 24, 2013||No|Recruiting problems|No||https://clinicaltrials.gov/show/NCT01887041||63928|
NCT01887249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1007/106-001|15-day Sequential Therapy for Helicobacter Pylori Infection in Korea|Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea||Seoul National University Bundang Hospital|No|Completed|May 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|287|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887249||63912|
NCT01887795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yang-1970|Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study|||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01887795||63870|
NCT01887808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10232b|Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30|Cetaphil Dermacontrol Oil Control Moisturizer SPF 30- 100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)||Galderma Laboratories, L.P.|No|Completed|December 2012|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01887808||63869|
NCT01888328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-102|Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 40 mg of Roche Laboratories Inc., Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2001|June 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2001|June 26, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888328||63829|
NCT01889160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5200C00001|Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels|A Phase I Single-blind, Randomised, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AZD4721 Solution After Single Ascending Doses, and to Compare the Oral Bioavailability of Single Doses of Solution and Suspension in Healthy Subjects||AstraZeneca|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889160||63765|
NCT01888926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130163|The Effects of Repetitive Paired Associative Stimulation in Dystonia|Investigating the Plastic Effects of Repetitive Paired Associative Stimulation (rPAS) in Dystonia||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|24|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01888926||63783|
NCT01889459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-CTOPCI-ER2013|Japanese CTO PCI Expert Registry|Patient Registry of Percutaneous Coronary Intervention (PCI) for Chronic Total Occlusion (CTO) by Japanese Experts||Kurashiki Central Hospital||Recruiting|July 2013|December 2027|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|19000|||Both|20 Years|N/A|No|Probability Sample|Patients who underwent PCI for CTO lesions by Japanese certified operators|July 2013|July 1, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889459||63742|
NCT01889472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNB-003|Impact of Interface With/Without Oral Appliance of Sleep Apnea Treatment|Impact of Nasal Mask/Oronasal Mask on Compliance to Treatment With Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea||Laval University|No|Recruiting|June 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01889472||63741|
NCT01889745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_0361|A Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.|A Phase I Clinical Study, Randomized, Single-blind,Placebo-controlled, Multiple Doses, Dose Escalation Study fo the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.|HX-1171|Biotoxtech Co., Ltd|Yes|Temporarily not available||||||N/A|Expanded Access|N/A|||||||Male|20 Years|40 Years||||June 2013|June 20, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01889745||63720|
NCT01889758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 Grant|Pharmacokinetic Studies of Tacrolimus in Transplant Patients|Pharmacokinetic Studies of Tacrolimus in Transplant Patients|PK|University of Cincinnati|No|Completed|June 2013|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889758||63719|
NCT01890031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R44HL097506-01|Interactive Cholesterol Advisory Tool|The Interactive Cholesterol Advisory Tool|ICAT|University of Rochester|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 18, 2012||No||No|July 1, 2015|https://clinicaltrials.gov/show/NCT01890031||63698|
NCT01890330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:006|Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome|Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome|METCO-2013|University of Manitoba|No|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|100|||Both|20 Years|75 Years|No|||March 2016|March 8, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01890330||63675|
NCT01890343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-010|Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.|A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.||Avid Radiopharmaceuticals|No|Completed|September 2009|April 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|34|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 16, 2014|June 27, 2013|No|Yes||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01890343||63674|
NCT01889628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00403|Study to Determine Ethnic Differences in the Glycaemic Response to Nutritional Formula Drinks|Ethnic Differences in the Glycaemic Response and Glycaemic Index to Liquid-based Nutritional Formulas Between Chinese, Malays and Indians in Singapore||Clinical Nutrition Research Centre, Singapore|No|Completed|June 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|52|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01889628||63729|
NCT01889641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5504|IL-26 and Systemic Lupus Erythematosus|Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique||University Hospital, Strasbourg, France|No|Not yet recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patient and healthy volunteers|January 2014|January 14, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889641||63728|
NCT01890174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-OCT-DR-2010-2|Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation|Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation||Carl Zeiss Meditec, Inc.|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|50 Years|N/A|No|Non-Probability Sample|Primary care clinic|June 2013|June 27, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890174||63687|
NCT01890473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-366|Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe|Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe||Bristol-Myers Squibb|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 27, 2013|No|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01890473||63664|
NCT01886560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU2|Low Dose Doxycycline in the Treatment of Corneal Burn|Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn||Sun Yat-sen University|Yes|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||June 2013|August 7, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01886560||63965|
NCT01886573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01186|Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery|Genome-Wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-Treatment With 5-Azacytidine and Entinostat||National Cancer Institute (NCI)||Terminated|June 2013|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|May 15, 2015|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886573||63964|
NCT01886820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV4-02|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology||Navidea Biopharmaceuticals|No|Active, not recruiting|June 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|290|||Both|21 Years|N/A|No|||July 2015|July 24, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886820||63945|
NCT01886794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-114|Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse|Role of Hormonal Status on Vascularization and Vaginal Tissue in Women With Pelvic Organ Prolapse||The University of Texas Medical Branch, Galveston|Yes|Recruiting|June 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|30|||Female|21 Years|70 Years|No|||August 2015|August 24, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886794||63947|
NCT01886807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apneic Oxygenation|The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial|The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial||University of Texas Southwestern Medical Center|No|Completed|June 2013|May 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|482|||Both|1 Year|17 Years|No|||October 2015|October 14, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01886807||63946|
NCT01887054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045495|Freezing of Gait in Parkinson's Disease|Effect of Visuospatial Training Tasks on Freezing of Gait in Parkinson's Disease|FOG|Duke University|No|Recruiting|June 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01887054||63927|
NCT01888055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plasticity in healthy adults|Influence of tDCS on Cortical Plasticity in Healthy Older Adults|Influence of Transcranial Direct-current Stimulation on Cortical Plasticity in Healthy Older Adults||Charite University, Berlin, Germany|No|Recruiting|May 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888055||63850|
NCT01888068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPGDx_Protocol1|Comparison of Bioimpedance Body Composition Device Measurements|Comparison of Bioimpedance Body Composition Device Measurements: Predicate (EFG®) Versus Candidate (Vitality Analyzer™)||IPGDx, LLC||Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|None Retained|None acquired or retained|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Self declared healthy subjects aged 18 to 99|July 2013|July 31, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888068||63849|
NCT01888666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tecc01/2013|Comparison Between Rapid and Slow Palatal Expansion: Evaluation of Periodontal Indices|||University of L'Aquila||Completed|January 2013|||August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|6 Years|10 Years|No|Probability Sample|patients attending the division of orthodontics of Department MeSVA, University of        L'Aquila, Italy|August 2013|August 14, 2013|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01888666||63803|
NCT01888679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229/12|Influence of Head Positioning on the Movement of the Endotracheal Tube|Influence of Head Positioning on the Movement of the Endotracheal Tube||University of Lausanne Hospitals|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|16 Years|N/A|No|||June 2013|June 27, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01888679||63802|
NCT01860261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF IRB 12-09153|Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV|Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV|SEA|University of California, San Francisco|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|50 Years|N/A|No|||January 2015|January 16, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01860261||65980|
NCT01889446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001197|The Effects of the Food Preservative Propionic Acid in Post-prandial Metabolism|Pilot Study to Study the Effects of the Food Preservative Calcium Propionate on Postprandial Hormonal and Metabolic Milieu|Walnut|Brigham and Women's Hospital|Yes|Recruiting|August 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889446||63743|
NCT01856673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-UV-JHU-2013-001|Evaluation of Two Community-based Mental Health Interventions for Violence-Displaced Afro-Descendants in Colombia.|Evaluation of Two Mental Health Interventions Based on the Community for Violence-Displaced Afro-Descendants in Colombia.|ACOPLE|Universidad del Valle, Colombia|Yes|Completed|June 2012|June 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|521|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 14, 2013||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01856673||66253|This study will include a subsequent follow-up to assess middle-term effects of the interventions. The proportion of participants lost to follow-up represents a limitation. The low male participation in the study did not allow for a gender subgroup.
NCT01886872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01220|Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2013|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|523|||Both|65 Years|N/A|No|||December 2015|March 18, 2016|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886872||63941|
NCT01857258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0116|Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction|Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction||Ohio State University|No|Active, not recruiting|May 2013|April 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01857258||66208|
NCT01857505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000158|Hip Replacement in a High Volume Community Hospital: Effect on Length of Stay and Hospital Cost|Introduction of the Direct Anterior Approach to Hip Replacement Into a High Volume Community Hospital: Effect on Length of Stay and Hospital Cost||Anne Arundel Health System Research Institute|No|Withdrawn||||January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|0|||Both|40 Years|90 Years|No|Probability Sample|Patients who have undergone primary uncemented hip replacement at our institution (Anne        Arundel Medical Center) through either a posterior approach or direct anterior approach on        a fracture table utilizing the identical post operative protocol.|December 2014|December 17, 2014|May 10, 2013||No|Funding|No||https://clinicaltrials.gov/show/NCT01857505||66189|
NCT01857843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2009-0032|Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome|||Yonsei University|No|Completed|November 2009|January 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|160|||Both|20 Years|N/A|No|||February 2014|February 4, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01857843||66164|
NCT01889940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPELMA|Effectiveness of Psycho-emotional Support in Acute Spinal Cord Injury. ESPELMA Project|Effectiveness of Psycho-emotional Support in Acute Spinal Cord Injury. ESPELMA Project.|ESPELMA|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|February 2012|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|15 Years|N/A|No|||June 2015|June 15, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01889940||63705|
NCT01889914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004602-19|TReatment by Insulin Continuous Infusion in Type 2 DIAbetes|Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments|TRICIDIA2|Centre Hospitalier Universitaire Dijon|No|Recruiting|January 2012|September 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01889914||63707|
NCT01890538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2013/174|Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo|Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial||Kocaeli University|Yes|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890538||63659|
NCT01890551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5203078|Kine-Mri in Patellofemoral Instability|Dynamic Kine-mri in Patellofemoral Instability in Adolescents- an Aid in the Diagnosis|Knee- MRI 2012|Kuopio University Hospital|No|Completed|January 1998|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01890551||63658|
NCT01887067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2012-038|Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus|Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus|HTN2DM|Pamela Youde Nethersole Eastern Hospital|Yes|Recruiting|June 2013|June 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||October 2014|October 28, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887067||63926|
NCT01887301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP10114|Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients|An Open Label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics and Tolerability of a Single Oromucosal Dose of 4 Sprays of Sativex(Containing 10.8 mg Delta-9-tetrahydrocannabinol [THC] and 10 mg Cannabidiol [CBD]) in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function.||GW Pharmaceuticals Ltd.|No|Completed|July 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 3, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887301||63908|
NCT01887275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gyb61641947|A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B|Medical Ozone Versus Conventional Interferon-α Treatment of Patients With Chronic Hepatitis B —A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B||Nanfang Hospital of Southern Medical University|Yes|Completed|March 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|439|||Both|12 Years|60 Years|No|||October 2012|June 25, 2013|June 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887275||63910|
NCT01887288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRMC 13-05|Capecitabine With Digoxin for Metastatic Breast Cancer|Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment||Western Regional Medical Center|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887288||63909|
NCT01887548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130618|Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Crohn's Patients|Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Patients With Crohn's Disease||Jinling Hospital, China|Yes|Active, not recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|65 Years|No|||June 2013|June 24, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887548||63889|
NCT01888341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-129|Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 20 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 20 mg of Roche Laboratories Inc., Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2002|June 26, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888341||63828|
NCT01859741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59R5-003|A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)|A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)|PINNACLE|OncoMed Pharmaceuticals, Inc.|Yes|Recruiting|May 2013|April 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||September 2015|February 26, 2016|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01859741||66020|
NCT01889784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13573013.1.0000.5504|Acute Effect of Phototherapy With Light Emitting Diode (LED) on Muscle and Pulmonary Oxygen Consumption on Diabetes Mellitus|Evaluation of Acute Effect of Phototherapy With Light Emitting Diode (LED) on Muscle and Pulmonary Oxygen Consumption in Patients With Diabetes Mellitus||Universidade Federal de Sao Carlos|No|Recruiting|August 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01889784||63717|
NCT01890044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11-5786|Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients|Consortium of Leaders in the Study Of Traumatic Thromboembolism (CLOTT): A Multicenter Registry for Determining the Comparative Effectiveness of Risk Assessment, Prophylaxis, Surveillance, and Treatment of Venous Thromboembolism in Trauma Patients|CLOTT|Scripps Health|Yes|Enrolling by invitation|August 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the hospital for the care of traumatic injuries who have a moderate        to highest level of VTE risk.|November 2015|November 20, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890044|30 Days|63697|
NCT01890057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0280|The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients|||Severance Hospital|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|44|||Both|20 Years|N/A|No|||February 2014|February 2, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890057||63696|
NCT01890356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC12499|Maintenance Transcranial Electrical Stimulation for Depression|A Study of Transcranial Electrical Stimulation (TES) as a Maintenance Treatment for Depression||The University of New South Wales||Recruiting|June 2013|||June 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890356||63673|
NCT01888939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130169|Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children|Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01888939||63782|
NCT01889173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F104|Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults|A Single-Dose, Open-Label, Randomized, Parallel-Design Study Of The Comparative Pharmacokinetics And Safety Of TNX-102 2.8 mg SL Tablets (With Potassium Phosphate) At 2.8 mg, TNX-102-B 2.8 mg SL Tablets (With Sodium Phosphate) At 2.8 mg, TNX-102-C 2.8 mg SL Tablets (With Trisodium Citrate) At 2.8 mg, And Cyclobenzaprine 5 mg Oral Tablets In Healthy Adults||Tonix Pharmaceuticals, Inc.|No|Completed|June 2013|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889173||63764|
NCT01886885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00061111|Mindfulness Based Chronic Pain Management: A Pilot Study|The Efficacy of Mindfulness-Based Chronic Pain Management: A Pilot Study|MBCPM|University of Utah|No|Completed|January 2013|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants are 18 years of age and older, English speaking, in chronic pain for 3 months        or more,and willing to participate in the 13 sessions.|June 2013|June 25, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01886885||63940|
NCT01887613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG001|Specified Drug Use-Results Survey of Regnite|Specified Drug Use-Results Survey of Regnite||Astellas Pharma Inc|No|Recruiting|October 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patients with moderate to severe idiopathic restless legs syndrome|September 2015|September 18, 2015|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887613||63884|
NCT01887106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1205-CL-101|First-in-Human Single and Multiple Dose of GLPG1205|Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects||Galapagos NV|No|Completed|June 2013|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 13, 2013|June 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01887106||63923|
NCT01887366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1380-COA-201|Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects|A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/Week or 300 mg/Week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects||Teva Pharmaceutical Industries||Completed|June 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|208|||Both|18 Years|60 Years|No|||October 2015|October 12, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887366||63903|
NCT01887600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0608|Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis|A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|ALPS|Astellas Pharma Inc|Yes|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887600||63885|
NCT01889680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FC-8|Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer|A Randomized Phase II Trial of Induction Regimen With mFOLFOX6 and Ziv-aflibercept for First-line Therapy of Metastatic Colorectal Cancer Followed by Continuation Regimen With 5-FU/LV Alone or With Ziv-aflibercept Until Disease Progression||NSABP Foundation Inc|No|Withdrawn|November 2014|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889680||63725|
NCT01889602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDEC|Characterizing and Predicting Drug Effects on Cognition|Characterizing and Predicting Drug Effects on Cognition||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889602||63731|
NCT01889615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMA K70 Dual PETOvac|Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer|Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer|Dual PETOvac|Odense University Hospital|No|Not yet recruiting|August 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Tissue samples from the ovarian cancer and metastasis|Female|18 Years|N/A|No|Non-Probability Sample|Ovarian cancer|June 2013|June 27, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889615|5 Years|63730|
NCT01890213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045976|Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer|A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer||Duke University|No|Recruiting|November 2013|November 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|June 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01890213||63684|
NCT01890525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL109711-01|PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER) Specific Aim 3b|PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER), Specific Aim 3b|PROMISE-SAFER|Kaiser Permanente|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|45 Years|N/A|No|Non-Probability Sample|PROMISE study patients|March 2015|March 20, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01890525||63660|
NCT01886586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10110050|Retaining Cognition While Avoiding Late-Life Depression|RECALL: Retaining Cognition While Avoiding Late-Life Depression|RECALL|University of Pittsburgh|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|136|||Both|60 Years|N/A|No|||January 2016|January 6, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886586||63963|
NCT01887314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF01-12-69|Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy|Multicenter, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Activity of a Ginger (Zingiber Officinale) Food Supplement in the Management of Nausea in Patients Receiving Highly Emetogenic Treatments and Standard Anti-emetogenic Therapy.||Helsinn Healthcare SA|Yes|Completed|June 2013|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887314||63907|
NCT01887561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-04|Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial|PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS||Kanto CML Study Group|Yes|Recruiting|November 2012|||December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 24, 2013|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887561||63888|
NCT01887821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07MA|Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam|A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam||Oxford University Clinical Research Unit, Vietnam|No|Recruiting|March 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|3 Years|N/A|No|||June 2014|June 25, 2014|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887821||63868|
NCT01860014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306/29 March 2010|Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage|Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage||Dr. Sami Ulus Children's Hospital|No|Completed|March 2010|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|1 Week|No|||May 2013|May 20, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01860014||65999|
NCT01890681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039195|Baby NAP SACC Intervention Study|Preventing Obesity in Infants and Toddlers in Child Care||Duke University|Yes|Recruiting|August 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|960|||Both|3 Months|N/A|Accepts Healthy Volunteers|||January 2015|February 9, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890681||63648|
NCT01886651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO ALL92 study HDM TPMT|The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia|The Influence of Thiopurine Methyltransferase Activity on Bone Marrow- and Hepato-toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia||Rigshospitalet, Denmark|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|411|Samples With DNA|whole blood stored for a subset of patients|Both|1 Year|15 Years|No|Probability Sample|The study cohort was based on patients enrolled in the NOPHO ALL92 protocol, where 97% of        all eligible patients were included.        Participation in this study was on the basis of TPMT status that was randomly missing.|June 2013|June 21, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886651||63958|
NCT01860521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUL 4022|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Second Trimester Voluntary Termination of Pregnancy Analgesia: a Randomized Study.||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|N/A|No|||August 2013|August 19, 2013|May 13, 2013||No||No|June 10, 2013|https://clinicaltrials.gov/show/NCT01860521||65960|
NCT01860820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103618|The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema|The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema||Lawson Health Research Institute|No|Enrolling by invitation|June 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860820||65937|
NCT01887392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-229|Gaining Optimal Osteoporosis Assessments in Long-Term Care (GOAL)|The Evaluation of a Multifaceted, Knowledge Translation Education Intervention in Long-Term Care and Its Ability to Facilitate the Uptake of Osteoporosis Canada 2010 Clinical Practice Guidelines, Across Ontario LTC Homes|GOAL|McMaster University|No|Recruiting|June 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|N/A|N/A|No|||September 2015|September 22, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887392||63901|
NCT01870115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant Protocol Number 13-59|Melatonin-Micronutrients for Osteopenia Treatment Study|Phase 1 Study of Combination Strontium, Melatonin and Nutritional Co-factors on Bone Health and Quality of Life in Postmenopausal Women With Osteopenia|MOTS|Duquesne University|No|Active, not recruiting|August 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870115||65226|
NCT01870323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13019|The Social Media and Activity Research in Teens Trial|The Social Media and Activity Research in Teens Trial|SMART|University of Illinois at Urbana-Champaign|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|13 Years|15 Years|No|||March 2014|December 8, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01870323||65210|
NCT01889966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2196851|VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension|Vasoreactivity Testing With Intravenous Sildenafil in Patients With Precapillary Pulmonary Hypertension (Treatment Optimisation Study)|SIL-REACT|Kerckhoff Heart Center|No|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||April 2015|April 26, 2015|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01889966||63703|
NCT01889979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-09|Tramadol for Labour Analgesia in Low Risk Primiparous Women|Tramadol for Labour Analgesia in Low Risk Primiparous Women. Double Blind, Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|October 2012|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|N/A|N/A|No|||July 2013|July 7, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889979||63702|
NCT01889927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11AR13|INSPIRE-CF: an Alternative Physiotherapy Model for Children With Cystic Fibrosis|INSPIRE-CF: A Randomised Controlled Trial Investigating the Clinical and Economic Benefits of an Alternative Model of Physiotherapy Care for Children With Cystic Fibrosis|INSPIRE-CF|Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|6 Years|15 Years|No|||April 2015|April 23, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01889927||63706|
NCT01890200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-700-02-01|The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)|A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection||TCM Biotech International Corp.|No|Withdrawn|June 2015|June 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|65 Years|No|||January 2016|January 11, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890200||63685|
NCT01890252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECL00005|Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema|Prospective, Randomized Crossover Study Of The Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema||EyeYon Medical|Yes|Not yet recruiting|July 2013|April 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01890252||63681|
NCT01890265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-067|Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis||FibroGen|Yes|Recruiting|June 2013|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|40 Years|80 Years|No|||December 2015|December 16, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890265||63680|
NCT01890564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00783|Modes of Ventilation During Laparoscopic Bariatric Surgery|||Nationwide Children's Hospital|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|14 Years|20 Years|No|Non-Probability Sample|Bariatric surgery patients|March 2014|March 31, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890564||63657|
NCT01887080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-002|Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program|Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program in Patients With Acute Myocardial Infarction||Escola Superior de Tecnologia da Saúde do Porto|Yes|Completed|September 2012|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|40 Years|75 Years|No|||January 2014|January 29, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01887080||63925|
NCT01887574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002688|Renal Mass Registry|Renal Mass Registry||Mayo Clinic|No|Recruiting|June 2013|June 2053|Anticipated|June 2053|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5000|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01887574||63887|
NCT01887834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302|Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome|The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Severe Irritable Bowel Syndrome|IBS|The Canadian College of Naturopathic Medicine|Yes|Completed|June 2013|July 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|64 Years|No|||March 2015|March 10, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01887834||63867|
NCT01888081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-MEL-13|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma|Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma||Angimmune LLC|Yes|Recruiting|February 2014|||December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01888081||63848|
NCT01888094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0159|SUBclavian Central Venous Catheters Guidance and Examination by UltraSound|SUBclavian Central Venous Catheters Guidance and Examination by UltraSound : a Randomized Controlled Study Versus Landmark Method|SUBGEUS|University Hospital, Clermont-Ferrand||Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888094||63847|
NCT01889485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12-224|Screening and Access to Health Care for Vascular Disease|Screening and Access to Health Care for Vascular Disease in Urban and Suburban Patient Populations||NorthShore University HealthSystem|No|Active, not recruiting|April 2013|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|255|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer subjects age 55 and over who sign informed consent will be enrolled in three        separate neighborhoods in the Chicago area (North, South, West).|April 2015|April 14, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889485||63740|
NCT01889771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0757|A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline|A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline||University of Colorado, Denver|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1495|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889771||63718|
NCT01890395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-294|Bioenergetics in Surgical Patients|Bioenergetics in Surgical Patients||University of South Alabama|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|19 Years|80 Years|No|||January 2016|January 27, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890395||63670|
NCT01886430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES|Effects of Low-frequency Electrical Stimulation in Patients With Advanced HF|Effects of Low-frequency Electrical Stimulation in Sympathetic Nerve Activity and Peripheral Vasoconstriction in Patients With Advanced HF||University of Sao Paulo General Hospital|No|Completed|May 2009|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||April 2013|December 2, 2015|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01886430||63975|
NCT01886664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Des vs Sevo PRS|Comparison of PRS According to Inhalation Agent During LDLT|||Seoul National University Hospital||Completed|December 2012|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01886664||63957|
NCT01890668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0379|Efficacy Assessment of Osteopathic Manipulative Treatment in the Suboptimal Breastfeeding Behaviour|Efficacy Assessment of Early Osteopathic Manipulative Treatment (OMT) in the Management of Suboptimal Breastfeeding Behaviour in Healthy Newborns. A Prospective Monocentric Randomized Double-blinded Study.|NEOSTEO|Nantes University Hospital|No|Recruiting|July 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|N/A|4 Days|No|||September 2013|September 20, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01890668||63649|
NCT01886638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248-13|Determining the Effect of Abacavir on Platelet Activation|Determining the Effect of Abacavir on Platelet Activation in Virologically Suppressed HIV Positive Men: an Open Label Interventional Study||Bayside Health|No|Completed|August 2013|October 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||May 2015|May 21, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01886638||63959|
NCT01887119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133031|Aldosterone Antagonism and Microvascular Function|Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome||Maastricht University Medical Center|No|Recruiting|October 2013|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|June 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887119||63922|
NCT01887132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130164|A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism|A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism||National Institutes of Health Clinical Center (CC)||Terminated|June 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|5|||Both|24 Months|50 Months|No|||December 2015|December 19, 2015|June 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887132||63921|
NCT01888172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WeightWatchersOnline|Weight Watchers Online|Weight Watchers Online|WWO|The Miriam Hospital|No|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01888172||63841|
NCT01888458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0008|Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)|Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation|MycaCOORD|Nantes University Hospital|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||June 2015|June 5, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888458||63819|
NCT01887873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT150611|Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy|An Open Two-center Study Evaluating the Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy in Patients With Open Angle Glaucoma and Cataract||Croma-Pharma GmbH|No|Recruiting|July 2012|||October 2014|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||June 2013|July 29, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01887873||63864|
NCT01887886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28758|A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation|A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION||Hoffmann-La Roche||Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887886||63863|
NCT01864031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 12-02|The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study|The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study Using Linked Electronic Health Records||University College, London|Yes|Active, not recruiting|January 1997|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2240000|||Both|30 Years|N/A|No|Non-Probability Sample|The cohort used in the present study was drawn from patients registered with GPRD general        practices in England that consented to data linkage (approx. 5% of the UK population). We        used an open cohort design, where participants joined the cohort when they met the        inclusion criteria at any point between 1st January 1997 and 25th March 2010 (the last        GPRD data submission). Patients were included in cohort if they were aged ≥ 30 years, had        at least one year of electronic health record data which met GPRD data quality standards,        and had no record indicating any cardiovascular disease prior to study entry. Patients        were followed up until the date of an initial presentation of one of our cardiovascular        endpoints or were censored on the date of leaving the practice/last data submission from        their practice. Patients who died before 1st January 2001 were excluded as cause-specific        mortality data was not available for them (this approach is adopted in the Prospective        Studies Collaboration).|May 2013|May 28, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01864031||65692|
NCT01890291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIC-I02|Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.|Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea|Immuncell-LC|Green Cross Cell Corporation|No|Completed|June 2013|February 2016|Actual|January 2016|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|230|||Both|20 Years|80 Years|No|Probability Sample|This long term follow-UP study is observation about the Immuncell-LC Groups' and        'Non-treatment Groups' in patient undergo curative resection (PEIT, RFA or Operation) for        Hepatocelluar Carcinoma in Korea.|March 2016|March 4, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890291|3 Years|63678|
NCT01890590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-235|A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma|A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Recruiting|July 2013|June 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890590||63655|
NCT01890226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00067447|A Mobile Personal Health Record for Behavioral Health Homes|A Mobile Personal Health Record for Behavioral Health Homes|mPHR|Emory University|Yes|Recruiting|November 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01890226||63683|
NCT01890239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B143201213985|The Effectiveness of the Care Programme for the Last Days of Life|Improving End-of-life Care in Acute Geriatric Hospital Wards Using the Care Programme for the Last Days of Life: a Cluster Randomized Controlled Trial|PLaDays|End-of-Life Research Group|No|Recruiting|September 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890239||63682|
NCT01890577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110243|Study of South African Dialysis Patients|An Observational Study of South African Dialysis Patients Treated With Aranesp||Amgen|No|Terminated|April 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients receiving dialyis at South African study centres and having received at        least one dose of Aranesp|May 2015|May 14, 2015|April 18, 2013||No|Study was terminated due to slow enrolment with no reasonable expectation of attaining a    meaningful sample size|No|March 31, 2015|https://clinicaltrials.gov/show/NCT01890577||63656|
NCT01887327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-204|Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates With Hyperbilirubinemia|A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates|JASMINE_204|InfaCare Pharmaceuticals Corporation|No|Recruiting|September 2013|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|72 Hours|No|||January 2016|January 14, 2016|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887327||63906|
NCT01887340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01615-38|Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma|Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma|SEMITEP|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|June 2013|June 2026|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|271|||Male|18 Years|N/A|No|||February 2016|February 5, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887340||63905|
NCT01887353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024475|The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure|A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion|RAD HF|Intermountain Health Care, Inc.|No|Terminated|June 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||April 2015|July 15, 2015|June 24, 2013|Yes|Yes|Difficultly in enrolling|No|April 9, 2015|https://clinicaltrials.gov/show/NCT01887353||63904|
NCT01858883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-116|Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors|Official Title: A Phase 1B/2 Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors||Incyte Corporation|No|Active, not recruiting|June 2013|June 2016|Anticipated|February 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858883||66084|
NCT01859143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-VA-FLUMIST-1156|Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults||MedImmune LLC|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|May 17, 2013|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01859143||66064|
NCT01859442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H1002/12c|The Effect of Cancer Therapies and Exercise on Mitochondrial Energetics and Fitness|Phase 1 Study of Mitochondrial Energetics After Long Course Chemoradiotherapy and a Short Term Exercise Programme in Locally Advanced Rectal Cancer Patients - A Randomized Controlled Trial.||Aintree University Hospitals NHS Foundation Trust|Yes|Completed|January 2012|October 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|N/A|No|||September 2013|May 5, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01859442||66042|
NCT01859728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAMBIT201201|GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer|GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer|GAMBIT|Barretos Cancer Hospital|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01859728||66021|
NCT01890369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B13122012 GEM BMS|Modulation of Muscle Protein Metabolism by Essential Amino Acids|Modulation of Muscle Protein Metabolism by Essential Amino Acids|Aj1B|University of Nottingham|Yes|Recruiting|April 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|32|||Male|65 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890369||63672|
NCT01886924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034558|Computer MI for Tobacco Quitline Engagement in Smokers Living With HIV|Computer-based MI to Engage Smokers Living With HIV in Tobacco Quitline Treatment|MI-HIV|Butler Hospital|No|Recruiting|February 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01886924||63937|
NCT01887145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM-CTSRCT-2|Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome|Endoscopic Versus Open Carpal Tunnel Release: 10 to 15 Years Follow-up of a Randomized Controlled Trial||Region Skane|Yes|Completed|September 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|25 Years|60 Years|No|||May 2015|May 5, 2015|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887145||63920|
NCT01886898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.23.INF|Synbiotics and Growth|Growth of Infants Fed Starter Formula Containing Oligo-saccharides and the Probiotics Bifidobacterium & Lactobacillus||Nestlé|No|Completed|June 2007|October 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|311|||Both|N/A|14 Days|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01886898||63939|
NCT01887379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS 03/10|Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions)|Characterisation of Gastric Residence of a Furosemide-containing New Gastric Retention System by Means of MMM Measurement and Determination of Pharmacokinetics, Pharmacodynamics and Safety||LTS Lohmann Therapie-Systeme AG|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887379||63902|
NCT01887912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-014|Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection|Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection||Sanofi|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|15000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887912||63861|
NCT01888185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHersheyMC-40726|Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)|Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease||Milton S. Hershey Medical Center||Recruiting|December 2012|||July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|230|Samples With DNA|Whole blood, serum, plasma, white blood cells, urine, cerebral spinal fluid (CSF), tissue|Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinical patients and community volunteers|September 2015|September 22, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01888185||63840|
NCT01888484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCGAM-01|Study of Octanorm Subcutaneous IG in Patients With PID|Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases||Octapharma|Yes|Recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|2 Years|75 Years|No|||August 2015|August 27, 2015|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01888484||63817|
NCT01887626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00076|Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.|An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer||AstraZeneca|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01887626||63883|
NCT01864057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCR 12-004047; NECHR 208|Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants|Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants||Mayo Clinic|No|Completed|January 2012|September 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 23, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01864057||65690|
NCT01886612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-NMES-DVT-333|A Comparison of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression in Terms of Lower Limb Blood Flow|A Comparison of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression in Terms of Lower Limb Haemodynamics||National University of Ireland, Galway, Ireland|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886612||63961|
NCT01889953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00077483|EUS-Guided Biliary Drainage in Patients With Inoperable Malignant Distal Biliary Obstruction and Failed ERCP: a Prospective Feasibility Multicenter Trial|EUS-Guided Biliary Drainage in Patients With Inoperable Malignant Distal Biliary Obstruction and Failed ERCP: a Prospective Feasibility Multicenter Trial||Johns Hopkins University|Yes|Completed|December 2012|January 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|80 Years|No|||January 2015|May 22, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01889953||63704|
NCT01886833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROVAS 01|Causes of Rotavirus Vaccine Failure in Zambian Children|An Observational Study to Evaluate Causes of Rotavirus Vaccine Failure in Zambian Children in the Context of Routine Immunization Services||Centre for Infectious Disease Research in Zambia|No|Recruiting|April 2013|July 2017|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|420|Samples With DNA|Blood samples for immunogenicity testing will be analyzed in batches.      Stool samples for rotavirus extraction will also be stored and analyzed in batches.|Both|6 Weeks|15 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted at Kamwala health facility in Lusaka where the Maternal Child        Health (MCH) and antiretroviral therapy (ART) clinics as well as the CIDRZ Kamwala        Research Unit are co-located. Kamwala has a catchment population of over 10,000 with        approximately 30 new infants presenting to MCH each month with 6-14 week (DPT-HiB-Hep)        immunisation rates above 95%. Mother-infant pairs will be approached during the initial        visit to MCH by the study clinic assistant or peer counsellor with information about this        study in the local language of choice. Those generally interested will be invited to the        research clinic which is close by, for more detailed information during which motivated        mothers will be recruited and taken through the written informed consent process by the        study nurse. For illiterate participants, an independent, literate individual will witness        and validate the informed consent process.|June 2013|June 22, 2013|June 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01886833|42 Months|63944|
NCT01879904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081202|Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy|Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy|DISSECMUC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|85 Years|No|||June 2013|September 17, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879904||64477|
NCT01888692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2006;089|To Evaluate the Impact of PET/CT on Radiation Treatment Planning in Relation to Changes in GTV in Stage 3 NSCLC|A Prospective Observational Study to Evaluate the Impact of PET/CT Simulation on Radiation Treatment Planning in Relation to Changes in GTV in Locally Advanced Non-small Cell Lung Cancer||University of Manitoba||Terminated|April 2007|December 2010|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|Pathologically proven NSCLC Clinical stage III A (inoperable) or stage IIIB where there is        intent to pursue radical curative RT/chemo, staged with conventional imaging as outlined        in standard work up section|June 2013|June 25, 2013|June 18, 2013||No|Poor accural|No||https://clinicaltrials.gov/show/NCT01888692||63801|
NCT01888952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 13-0013|Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)|Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|April 7, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888952||63781|
NCT01889186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-982|A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion|A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion||AbbVie|Yes|Active, not recruiting|June 2013|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889186||63763|
NCT01889199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB #12-001780|Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women|Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women||University of California, Los Angeles|No|Recruiting|April 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|59|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01889199||63762|
NCT01889212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-19-12|Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC|Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC||University of Aarhus|No|Terminated|April 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|November 13, 2014|June 3, 2013||No|Due to technical problems|No||https://clinicaltrials.gov/show/NCT01889212||63761|
NCT01890083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH097847|A Health Intervention to Prevent Depression Hepatitis C Patients|An Exercise Intervention to Prevent Interferon-Induced Depression in Hepatitis C||University of Texas Southwestern Medical Center|No|Terminated|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|65 Years|No|||October 2015|October 23, 2015|June 5, 2013||No|Lack of eligible patients due to introduction of new drugs for Hepatitis C|No||https://clinicaltrials.gov/show/NCT01890083||63694|
NCT01890382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Pro Elderly Study|Protein Intake and Resistance Training in Aging|Effect of Protein Intake Associated With Resistance Training in Elderly Frail Individuals.||University of Sao Paulo|No|Not yet recruiting|October 2013|October 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Both|60 Years|N/A|No|||June 2013|July 1, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890382||63671|
NCT01886950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52091|Evolution of Bone Histomorphometry and Vascular Calcification Before and After Renal Transplantation|A Prospective Observational Study to Investigate the Natural History of Bone Histomorphometry and Vascular Calcification in Dialysis-dependent Patients Before and After Renal Transplantation.||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2010|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Bone biopsy Serum samples A. epigastrica inferior|Both|18 Years|N/A|No|Non-Probability Sample|end stage renal disease patients able to consent|December 2012|June 21, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01886950||63935|
NCT01887158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGOP0613|Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection|Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial.|PEGOP|Ospedale Santa Maria delle Croci||Completed|July 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||June 2014|June 15, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01887158||63919|
NCT01886911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Davidson-GWB|Games & Well-Being Study|Neural Correlates of Video Game Based Training to Foster Mindfulness and Prosocial Skills in Adolescents|GWB|University of Wisconsin, Madison|No|Completed|June 2013|May 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|192|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||June 2015|September 30, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01886911||63938|
NCT01887405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX-A-01|Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext|Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext; the HEJ-study|HEJ|ALK Nordic A/S, Danmark Filial|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|91|||Both|16 Years|N/A|No|||June 2013|June 24, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01887405||63900|
NCT01887639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NAR-XXX-2013/1|Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial|Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial: PANTHER Study|PANTHER|AstraZeneca|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Non-Probability Sample|Individuals between 18 and 75 years old that have non-psychotic unipolar major depression        and have not been treated for the current episode.|July 2015|July 29, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01887639|12 Weeks|63882|
NCT01887925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BreastCaCTx_circadian|The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy|The Effects of Per3, Clock Polymorphism on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy.||Seoul National University Hospital|Yes|Completed|February 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|Samples With DNA|whole blood, serum|Female|18 Years|70 Years|No|Non-Probability Sample|university hospital, oncology clinic|November 2015|November 27, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01887925||63860|
NCT01887678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1301|Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee|Multi-center Double-blind Randomized Controlled Trial to Evaluate Effectiveness and Safety of Co-administered Traumeel® / Zeel® Intra-articular Injections vs Placebo in Patients With Moderate-to-Severe Pain With Osteoarthritis of the Knee|MOZArT|Biologische Heilmittel Heel GmbH|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|287|||Both|45 Years|80 Years|No|||March 2015|March 10, 2015|June 14, 2013|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01887678||63879|
NCT01888510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15032|CT in Diagnosing Patients With Lung Cancer|Comparison of Conventional Free Breathing CT, 4D CT, and Integrated Active Breath Hold CT Image Acquisition for Lung Cancer||Virginia Commonwealth University|Yes|Recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888510||63815|
NCT01888471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_22OB|Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.|Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.||Novartis|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3033|Samples With DNA|Maternal and cord serum aliquots will be retained.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 18 years or older attending for antenatal care or delivery at 1        academic hospital centers in the Johannesburg area and the antenatal clinics serving that        hospital centers.|April 2015|April 28, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888471||63818|
NCT01889004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC-2013|The Neural Mechanisms of Anesthesia and Human Consciousness|The Neural Mechanisms of Anesthesia and Human Consciousness (LOC-2013)|LOC-2013|University of Turku|No|Completed|February 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01889004||63777|
NCT01890642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443133-1|The Use of Jet Injection Lidocaine for Blood Draws in Young Children|Use Of The Needle Free Jet-Injection System With Buffered Lidocaine (J-Tip) For The Treatment Of Pain During Venipuncture For Blood Draws In Young Children||Medical College of Wisconsin|Yes|Completed|July 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|205|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|June 24, 2013||No||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01890642||63651|
NCT01890655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E05|Extension Study of MT-1303|A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study||Mitsubishi Tanabe Pharma Corporation|Yes|Active, not recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|60 Years|No|||August 2015|August 24, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890655||63650|
NCT01890278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005|Phase II Trial of Conventional Versus IMRT Whole Brain Radiotherapy for Brain Metastases|Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases||Good Samaritan Hospital Medical Center, New York|No|Recruiting|June 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890278||63679|
NCT01890603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS17832|Enhancing Complex Care Through an Integrated Care Coordination Information System|Ambulatory Safety and Quality Program: Improving Management of Individuals With Complex Healthcare Needs Through Health It||Care Management Plus|Yes|Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|60000|||Both|18 Years|90 Years|No|||June 2013|July 1, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01890603||63654|
NCT01887093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC(No. 81270255)|The Influence of Walking at Different Times of Day on Blood Lipids and Inflammatory Markers|The Influence of Regular Walking at Different Times of Day on Blood Lipids and Inflammatory Markers in Sedentary Patients With Coronary Artery Disease||The First Affiliated Hospital with Nanjing Medical University|Yes|Completed|September 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|330|||Both|40 Years|80 Years|No|||June 2013|June 26, 2013|June 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01887093||63924|
NCT01879683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-100-105|A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions|A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis||Allergan|No|Completed|July 2013|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||November 2015|November 13, 2015|June 10, 2013|No|Yes||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01879683||64494|
NCT01888354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0210|Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations|Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations||The University of Texas Health Science Center, Houston|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|No|||September 2014|September 14, 2014|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888354||63827|
NCT01888367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA-02-CD-005|Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery|A Randomized, Blinded, Placebo and Standard of Care Controlled Efficacy, Safety, and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|445|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888367||63826|
NCT01889498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|954|Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery|A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair|AZATAAR|Liverpool Heart and Chest Hospital NHS Foundation Trust|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01889498||63739|
NCT01889797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0401|Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|PrE0401|PrECOG, LLC.|Yes|Active, not recruiting|December 2013|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01889797||63716|
NCT01890070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM 06/12/2011 n° prot. 32064|Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet|Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet - A Cross Over Interventional Study||University of Rome Tor Vergata|No|Recruiting|May 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|28||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01890070||63695|
NCT01890096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMOR_HDR Monotherapy RCT|A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer|A Randomized Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer||Sunnybrook Health Sciences Centre|No|Active, not recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|174|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01890096||63693|
NCT01886443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPITL safety|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study|CAPITL|Universitaire Ziekenhuizen Leuven|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||June 2013|September 24, 2014|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886443||63974|
NCT01886703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACREC 26059|Feasibility of a Walking Program for Cancer Survivors Receiving Radiation Therapy|Feasibility of a Supported Walking Program for Breast and Head-and-Neck Cancer Survivors Receiving Adjuvant Radiation Therapy|PEDWAY|University of Alberta|Yes|Completed|June 2013|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01886703||63954|
NCT01886963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101106A|A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair|A Randomized, Prospective, Double-Blind Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps and Reducing Wound Complications After Complex Ventral Hernia Repairs||Carolinas Healthcare System|Yes|Recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|122|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886963||63934|
NCT01887418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QST-13-002|Pharmacokinetic Study of Testosterone Enanthate|3 Arm Open-label Randomized Multidose Study of Pharmacokinetics, Safety & Tolerability of Testosterone Enanthate Administered Subcutaneously Via an Auto-injector Device or Intramuscular Testosterone Enanthate in Hypogonadal Adult Males||Antares Pharma Inc.|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Male|18 Years|75 Years|No|||September 2015|September 23, 2015|June 17, 2013|No|Yes||No|July 20, 2015|https://clinicaltrials.gov/show/NCT01887418||63899|
NCT01887652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-03-12|Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks|Individualization of Controlled Ovarian Stimulation Using Anti-mullerian Hormone as a Biomarker of Ovarian Response Maximizes the Beneficial Effects of Treatment and Minimizes Complications and Risks.||ANDROFERT - Clinica de Andrologia e Reproducao Humana|No|Completed|March 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|N/A|No|||June 2014|June 24, 2014|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887652||63881|
NCT01887665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12116|Enhancing Early-Phase Care for Primary Care Patients With Unhealthy Substance Use|Enhancing Early-Phase Care for Primary Care Patients With Unhealthy Substance Use||Brandeis University|Yes|Completed|August 2013|March 2016|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01887665||63880|
NCT01888198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC 13-116|Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment|Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment||Memorial Sloan Kettering Cancer Center||Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|The patients at MSKCC will be identified and recruited from the existing patient        population in the Interventional Radiology Service in the Department of Radiology. At all        other participating sites, patients meeting eligibility criteria will be identified by the        site investigators that have received the referral for consideration of renal mass        ablation. Participation in ARMOR may involve retrospective data collection only, combined        retrospective and prospective data collection, or prospective data collection|March 2016|March 15, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01888198|24 Months|63839|
NCT01888497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451178|Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers|A Phase 3 Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Single-dose, Clinical Trial to Assess the Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers||Pfizer|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|59|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888497||63816|
NCT01864551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH 097-05-061|Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder|Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders|OCTLPODEPWBD|Tri-Service General Hospital|No|Completed|August 2008|September 2012|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|15 Years|50 Years|No|||May 2013|May 24, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01864551||65652|
NCT01864564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121008004|Early Gestational Diabetes Screening in the Gravid Obese Woman|Early Gestational Diabetes Screening in the Gravid Obese Woman|EGGO|University of Alabama at Birmingham|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1160|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864564||65651|
NCT01864577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01UDEACx2013|Negative Pleural Suction for Tube Thoracostomy in Patients With Chest Trauma|Efficacy of Negative Pleural Suction in Tube Thoracostomy for Patients With Penetrating and/or Blunt Chest Trauma: a Randomized Clinical Trial||Universidad de Antioquia||Completed|March 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|15 Years|N/A|No|||May 2013|May 24, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01864577||65650|
NCT01887587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00020384|Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia|Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia||Medical College of Wisconsin|Yes|Terminated|October 2013|August 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 5, 2013|No|Yes|SAE- risk of overall protocol treatment outweighs benefits|No||https://clinicaltrials.gov/show/NCT01887587||63886|
NCT01886599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-033|Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease|Open-Label, Parallel Group, Multiple-Dose Study to Evaluate the Pharmacokinetics and Safety of Asunaprevir in Subjects With Renal Function Impairment||Bristol-Myers Squibb|No|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 8, 2013|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886599||63962|
NCT01886846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EskisehirOU 4.6.2008/41|Plasma Adiponectin Levels and Relations With Cytokines in Children With Acute Rheumatic Fever|||Eskisehir Osmangazi University|No|Completed|July 2008|||August 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|87|||Both|5 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|acute rheumatic fever and by comparing results with that of healthy|June 2013|June 22, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01886846|1 Month|63943|
NCT01888107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004993|Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder|Maintenance of Clinical Response With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder||Janssen-Cilag S.p.A.|No|Completed|January 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|347|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888107||63846|
NCT01889225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-DK076771-Aim1A|Obesity and Mortality|||University of Alabama at Birmingham||Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||19|Actual|311982|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|U.S. based prospective cohorts of adults|August 2014|August 21, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01889225||63760|
NCT01889238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-11|Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer|A Phase 2, Single Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor Positive, Triple Negative Breast Cancer||Medivation, Inc.||Active, not recruiting|June 2013|May 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|June 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889238||63759|
NCT01889524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|valdecir tese normais|Radioaerossol Pulmonary Deposition Using Mesh in Normal Subjects|RADIOAEROSSOL PULMONARY DEPOSiTION USING MESH AND JET NEBULIZERS DURING NONINVASIVE VENTILATION IN NORMAL SUBJECTS: A RANDOMIZED CROSSOVER CLINICAL TRIAL||Universidade Federal de Pernambuco|Yes|Completed|January 2012|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|June 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889524||63737|
NCT01889810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUB: B12/35; HSC: 12117MMcK-AS|Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study|Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in People at High Risk of Type 2 Diabetes and Cardiovascular Disease (The DIR Study)||Queen's University, Belfast|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889810||63715|
NCT01890408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111101|Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity.|Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity|ROPIHEP|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|75 Years|No|||June 2014|June 25, 2014|June 14, 2013||No|promoter decision|No||https://clinicaltrials.gov/show/NCT01890408||63669|
NCT01887431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71156|Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump|Telecare in Adults With Type 1 Diabetes Mellitus Treated by Insulin Pump - A Randomized Controlled Trial||Assuta Hospital Systems|Yes|Active, not recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|22 Years|N/A|No|||January 2016|January 4, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01887431||63898|
NCT01887444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00163-42|Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic|The Benefit of Using the Lactobacillus Reuteri Probiotic as a Supplement in the Treatment of Newborn Colic|PROBIOC|BioGaia AB|No|Withdrawn|October 2013|September 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|3 Months|No|||September 2015|September 16, 2015|June 20, 2013||No|Never started|No||https://clinicaltrials.gov/show/NCT01887444||63897|
NCT01888848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDAHNRC-2013-1|Effects of Blueberry on Cognition and Mobility in Older Adults|Effects of Dietary Blueberry Supplementation on Cognition and Mobility in Healthy Older Adults||USDA Human Nutrition Research Center on Aging|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01888848||63789|
NCT01888809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC-01|Building Healthy Children|Building Health Children: Randomized Controlled Trial (RCT) Evaluation|BHC|University of Rochester|No|Recruiting|August 2007|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1100|||Female|12 Years|23 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01888809||63792|
NCT01888822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MarPic63|Antibiotic Prophylaxis in Laparoscopic Cholecystectomy|Ciprofloxacin, Ampicillin-sulbactam and Placebo Prophylaxis in Laparoscopic Cholecystectomy. A Randomized Controlled Study||University of Roma La Sapienza|No|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01888822||63791|
NCT01888835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034527|Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)|Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up||San Francisco Department of Public Health|Yes|Recruiting|August 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|69 Years|No|||February 2016|February 19, 2016|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888835||63790|
NCT01889030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAR-XXX-2013/1|Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention|Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention. RISK Study|RISK|AstraZeneca|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|516|||Both|18 Years|N/A|No|Non-Probability Sample|Patients older than 18 years old, without known vascular disease (primary prevention)        under follow-up by the investigator, whose medical records were initiated during the past        3 years and have completed their baseline assessment of CV risk|July 2014|July 23, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01889030|1 Day|63775|
NCT01864590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Of Antioquia|Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol|Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol - A Randomized Trial||Universidad de Antioquia|No|Terminated|June 2011|June 2013|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|13 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 24, 2013|May 19, 2013||No|After the Interim analyses, with the higher than expected closure rate, the investigators saw    that continuing the trial would not offer different results|No||https://clinicaltrials.gov/show/NCT01864590||65649|
NCT01864863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-BOTAN-101|To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers|An Open-label, Randomized, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|April 2013|||May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01864863||65628|
NCT01888380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paediatric virtopsy|The Paediatric Virtual Autopsy Trial|Post-mortem Cross-sectional Imaging With Guided Biopsy; A Comparative Study With Conventional Autopsy in Foetuses, Neonates, Infants and Children||University of Zurich|No|Recruiting|January 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|N/A|16 Years|No|||December 2015|December 3, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01888380||63825|
NCT01888393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-809-010|Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects|A Phase 1, Open Label Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects||Vertex Pharmaceuticals Incorporated|Yes|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01888393||63824|
NCT01886859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00888|Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|April 2013|||December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|December 17, 2015|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886859||63942|
NCT01886625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41466.042.12|Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)|Single-port Thoracoscopic Sympathicotomy for Treatment of Complex Regional Pain Syndrome Type I, a Feasibility Study.||University of Groningen|Yes|Withdrawn|August 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|March 24, 2013||No|No local inclusions|No||https://clinicaltrials.gov/show/NCT01886625||63960|
NCT01888965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTK1258AUS16T|Maintenance Dovitinib for Colorectal and Pancreas Cancer|A Pilot Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients With Colorectal and Pancreas Cancers||Georgetown University|Yes|Terminated|October 2013|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|June 26, 2013|Yes|Yes|Adverse Event issues.|No||https://clinicaltrials.gov/show/NCT01888965||63780|
NCT01889251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-12-075|A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion|A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection||Alcon Research|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|251|||Both|20 Years|N/A|No|||November 2015|November 2, 2015|June 26, 2013|No|Yes||No|September 30, 2015|https://clinicaltrials.gov/show/NCT01889251||63758|
NCT01889511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15CA176595|Text Messaging to Improve Adherence to Oral Chemotherapy Agents|Text Messaging to Improve Adherence to Oral Chemotherapy Agents||Michigan State University|Yes|Completed|June 2013|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|75|||Both|21 Years|N/A|No|||September 2015|September 17, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01889511||63738|
NCT01889823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX1|Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.|||Radboud University|Yes|Completed|June 2013|December 2014|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889823||63714|
NCT01890109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120180|Randomized, Parallel-group, Double-blind, Placebo-controlled, Study to AMG 334 in Women With Hot Flashes|Randomized, Stratified, Parallel-group, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 334 in Women With Hot Flashes Associated With Menopause||Amgen|No|Completed|May 2013|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Female|45 Years|65 Years|No|||October 2014|November 11, 2014|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890109||63692|
NCT01890148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3551C00003|Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069|An Explorative Investigation to Study the Relationship and Distribution of Neutrophils in Bronchial Mucosal Tissue, Induced Sputum and Blood After Administration of 45 mg BD AZD 5069 for 4 Weeks to Patients With Moderate Persistent Neutrophilic Asthma||AstraZeneca|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|June 17, 2013||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01890148||63689|
NCT01890434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15962|Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)|Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis|GadaCAD 2|Bayer|No|Recruiting|August 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890434||63667|
NCT01886677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA161263-01A1|Improving Energy Balance in Men With Prostate Cancer|Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer||University of Alabama at Birmingham|No|Completed|September 2012|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|19 Years|N/A|No|||December 2014|March 4, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01886677||63956|
NCT01886690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11002X-002|A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery|||Allergan|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|June 24, 2013|Yes|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01886690||63955|
NCT01886937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6415|Studying the Effects of Phentermine on Eating Behavior|The Quantification of Ingestive Behavior||New York State Psychiatric Institute|No|Recruiting|July 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|48|||Both|18 Years|60 Years|No|||June 2013|June 24, 2013|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886937||63936|
NCT01887691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000187 ASMF 80-PA-12|Sleep Effectiveness and Insulin and Glucose Homeostasis|Sleep Effectiveness and Insulin and Glucose Homeostasis||Beth Israel Deaconess Medical Center|No|Active, not recruiting|October 2012|December 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01887691||63878|
NCT01887704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERBRCAL|Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion|Effect of Rotational Atherectomy on Balloon-resistant Calcified Coronary Lesion the During a Long-term Follow-up Study||Capital Medical University|Yes|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|80 Years|No|||June 2013|June 25, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01887704||63877|
NCT01887938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-MLD-071|Open-Label Extension Study Evaluating Safety and Efficacy of HGT-1110 in Patients With Metachromatic Leukodystrophy|An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy||Shire|Yes|Enrolling by invitation|May 2013|October 2023|Anticipated|October 2023|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|N/A|13 Years|No|||November 2015|November 16, 2015|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01887938||63859|
NCT01887951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB 2013/044/C|Penthrox Versus Tramadol for SCDF|Clinical Evaluation of Penthrox (Methoxyflurane)and Tramadol for the Singapore Emergency Ambulance Service|PENTRA|Singapore General Hospital|No|Completed|February 2014|October 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|380|||Both|16 Years|N/A|No|||November 2015|November 17, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01887951||63858|
NCT01887171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1633|Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus|A Randomized Study of Effect of Preimplantation Portal Vein and Hepatic Artery Liver Flushing With Tacrolimus on Ischemia-reperfusion Injury, Allograft Dysfunction and Liver Histology|PATAC|Republican Scientific and Practical Center for Organ and Tissue Transplantation|Yes|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|69 Years|No|||November 2014|November 3, 2014|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01887171||63918|
NCT01888523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14971|Stress Management for Cancer Survivors|Stress Management for Cancer Survivors Using a Technologically Adapted Psychosocial Intervention: A Randomized Trial Determining the Effect of Expressive Writing on Psychoneuroimmunology Based Outcomes||Virginia Commonwealth University|Yes|Completed|February 2014|January 2016|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|21 Years|N/A|No|||January 2016|January 20, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888523||63814|
NCT01888861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|916423|Effect of Alpha-lipoic Acid on Biochemical Markers and Important Outcomes in Patients Admitted to Intensive Care Units|Evaluating the Effect of Alpha Lipoic Acid on Biochemical Markers, Length of Stay and Other Important Outcomes in Patients Admitted to Intensive Care Units.||Shiraz University of Medical Sciences|Yes|Recruiting|February 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01888861||63788|
NCT01889069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28881|A Study to Evaluate Safety, Efficacy and Pharmacokinetics of MabThera/Rituxan (Rituximab) in Patients With Diffuse Large B Cell Lymphoma or Follicular Lymphoma|A Single Arm, Multicenter, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)||Hoffmann-La Roche||Active, not recruiting|July 2013|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|June 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01889069||63772|
NCT01889056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOPERF CH12|Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans|||University of Zurich||Active, not recruiting|February 2013|December 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01889056||63773|
NCT01889043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53536|Monitoring of Non-invasive Ventilation During Sleep in ALS|Monitoring of Non-invasive Ventilation During Sleep in ALS||Universitaire Ziekenhuizen Leuven|No|Completed|January 2012|||September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Amyotrophic lateral sclerosis patients, which are followed at the Neuromuscular Reference        Centre UZ Leuven, in need for NIV treatment|December 2015|December 11, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01889043||63774|
NCT01889316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0197|Performance Comparison of a New Fetal/Maternal Monitor With an FDA-cleared Method|Performance Comparison of a New Fetal/Maternal Monitor With an FDA-cleared Method||University of Arizona|No|Completed|April 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|75|||Female|18 Years|50 Years|No|||February 2014|February 24, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01889316||63753|
NCT01864603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH|Sustainable East Africa Research in Community Health|Sustainable East Africa Research in Community Health|SEARCH|University of California, San Francisco|Yes|Active, not recruiting|April 2013|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|334512|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01864603||65648|
NCT01888419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTPS 1-10-72-76-13|Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer|A Prospective, Randomized Study of the Possible Pain Relieving and Scar Tissue Modifying Properties of Lipotransplantation in a "Post Breast Therapy Pain Syndrome" Setting||Aarhus University Hospital|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|80 Years|No|||February 2016|February 12, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01888419||63822|
NCT01888731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|717/09|Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|August 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|June 26, 2013|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888731||63798|
NCT01879410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114951|A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD||GlaxoSmithKline|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|700|||Both|40 Years|N/A|No|||July 2014|July 24, 2014|June 13, 2013|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01879410||64515|
NCT01887847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI 2006-01|Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge|A Randomized, 2 Way Crossover, Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablets ( Pharmaceutical Productions Inc.) Versus COMMIT Smoking Lozenge ( GLAXOSMITHKLINE) in Healthy Smoking Volunteers||Pharmaceutical Productions Inc.|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01887847||63866|
NCT01888978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-384|Molecularly Tailored Therapy for Pancreas Cancer|A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer||Georgetown University|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01888978||63779|
NCT01889537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43329-K|Low Dose Ketamine VR Analgesia During Burn Care Procedure|Low Dose Ketamine to Enhance VR Analgesia During Painful Burn Care Procedure.|VRK|National Institute of General Medical Sciences (NIGMS)|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3|||Both|18 Years|85 Years|No|||October 2015|October 13, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01889537||63736|
NCT01890421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15961|Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)|Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis|GadaCAD 1|Bayer|No|Active, not recruiting|July 2013|February 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|432|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890421||63668|
NCT01886456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.1.2013_KEK ZH 2012-0422|IOP Lowering Effect of PLT Versus SLT in Naiv OAG Patients|Effect of Patterned Laser Trabeculoplasty on Intraocular Pressure Compared to Selective Laser Trabeculoplasty in Treatment Naiv Patients Suffering From Open-angle Glaucoma or Ocular Hypertension||University of Zurich||Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886456||63973|
NCT01886469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLD100-102|A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.||Ironshore Pharmaceuticals and Development, Inc||Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|17 Years|No|||September 2014|October 2, 2014|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886469||63972|
NCT01886976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-008|Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138|Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas|CART-138|Chinese PLA General Hospital|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01886976||63933|
NCT01886482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|high protein diet in childhood|Effect of High Protein Diet on Cardiovascular Diseases Risk Factors Among Overweight and Obese Children|||Isfahan University of Medical Sciences|Yes|Completed|September 2011|September 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|50|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886482||63971|
NCT01886495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|high protein diet in children|Effect of High Protein Diet on Adiponectin and Inflammation Among Overweight and Obese Children|High Protein Diet , Adiponectin and Inflammatory Factors||Isfahan University of Medical Sciences|Yes|Completed|September 2011|September 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|50|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886495||63970|
NCT01863719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0082|Aerosolized and Intravenous Colistin in Healthy Adults|A Phase 1, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Aerosolized Colistimethate Sodium After Multiple Doses Administered Separately or in Combination With Intravenous Colistimethate Sodium in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|August 2013|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863719||65716|
NCT01863069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-037|Avonex®: Safety, Blood Levels and Effects|A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers|C-851|Trio Medicines Ltd.|No|Completed|January 2001|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|77|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|May 20, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01863069||65766|
NCT01872390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK7103|Start TB Patients on ART and Retain on Treatment (START Study)|Start TB Patients on ART and Retain on Treatment: Combination Intervention Package to Enhance Antiretroviral Therapy Uptake and Retention During TB Treatment in Lesotho|START|Columbia University|No|Active, not recruiting|April 2013|March 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|407|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01872390||65051|
NCT01863979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0514-12|New Causes and Predictors for the Development of Atrial Fibrillation and Its Complications|New Causes and Predictors for the Development of Atrial Fibrillation and Its Complications||Rambam Health Care Campus|No|Completed|January 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the Rambam health care campus between 1.1.2007 and 31.12.2011        with the primary diagnosis with Acute Atrial Fibrillation and were 18 years old or older        at the time of diagnosis, will be included in this historical prospective study|May 2013|May 23, 2013|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01863979||65696|
NCT01873196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-016-Malawi|Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi|Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi|FAQR-Malawi|Tufts University||Completed|July 2013|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|6811|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2015|February 2, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01873196||64989|
NCT01873222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICVD1311|OPtical Frequency Domain Imaging Versus INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging|OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging||Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|20 Years|85 Years|No|||February 2016|February 16, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01873222||64988|
NCT01873443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 1.3|Long-Term Efficacy and Safety of CT-P10 in Patients With RA|An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1||Celltrion|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|75 Years|No|||May 2015|November 25, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01873443||64971|
NCT01873456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CES1|Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?|Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?|CES|Copenhagen University Hospital at Herlev|No|Completed|January 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 31, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01873456||64970|
NCT01864746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG78/BIG 1-13/NSABP-B-54-I|A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery|Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"|PENELOPE-B|German Breast Group|Yes|Recruiting|November 2013|November 2023|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01864746||65637|
NCT01865006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCTF-2013-01|Phoniatric Evaluation and Comparison of Patients Who Underwent Sutureless Thyroidectomy With Vessel Closure Devices and Conventional Total Thyroidectomy With Suture|Phoniatric Evaluation and Comparison of Patients Who Underwent Sutureless Thyroidectomy With Vessel Closure Devices and Conventional Total Thyroidectomy With Suture||Istanbul University||Recruiting|May 2013|||April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent to total thyroidectomy.|May 2013|May 26, 2013|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865006||65617|
NCT01865019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1981|Pressure Controlled Versus Volume Controlled Mechanical Ventilation During Anesthesia for Living Donor Liver Transplantation Recipients|||Mansoura University|No|Recruiting|April 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|living donor liver transplantation recipients|May 2013|May 26, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01865019|7 Days|65616|
NCT01886157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11C.554|Treatment of Trigger Finger With Steroid Injection Versus Steroid Injection and Splinting|Treatment of Trigger Finger With Steroid Injection Versus Steroid Injection and Splinting: A Randomized Controlled Trial||The Philadelphia & South Jersey Hand Center|No|Active, not recruiting|May 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886157||63996|
NCT01864889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-005|Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19|Clinical Study of Chimeric CD(Cluster of Differentiation)19 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|CART19|Chinese PLA General Hospital|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|5 Years|90 Years|No|||January 2016|January 26, 2016|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01864889||65626|
NCT01861262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 506 03|StO2 Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning|Percentage of Oxygen Saturation of Haemoglobin in Tissues (StO2) Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning|IMACS|University Hospital, Toulouse|No|Completed|April 2013|February 2014|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|300|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861262||65903|
NCT01861548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBZ-MEiN-/8/2//2006|Polish Mother and Child Cohort Study (REPRO_PL) - Follow up of the Children.|Polish Mother and Child Cohort Study (REPRO_PL).Follow up of the Children.|REPRO_PL|Medical Universtity of Lodz|Yes|Completed|January 2007|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|479|Samples With DNA|blood, urine, hair, saliva|Both|N/A|24 Months|Accepts Healthy Volunteers|Probability Sample|Investigators include into the study children delivered from women observed starting from        between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not        expected to be finished as spontaneous abor-tion. All women with the serious chronic        diseases specified in study protocol such as diabetes, hypertension, nephrop-athy,        epilepsy and cancer are excluded from the study. The same refers to suspicion of serious        child malformations known to exist at the inclusion into the study.|May 2013|May 21, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01861548||65881|
NCT01862159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2012/039|Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery|Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery||University Hospital Orebro|No|Completed|May 2007|May 2013|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25038|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing bariatric surgery in Sweden|May 2013|May 23, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01862159|30 Days|65835|
NCT01862484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH09680|Neuroimaging of Diet in ADHD: Phase I|Neuroimaging of Diet and Medication in the Treatment of ADHD|FTF|The University of Texas Health Science Center at San Antonio|Yes|Completed|May 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|9 Years|12 Years|No|||March 2015|March 10, 2015|May 17, 2013||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01862484||65810|
NCT01862757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130130|Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance|Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance||National Institutes of Health Clinical Center (CC)||Completed|May 2013|March 2015|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|13|||Female|18 Years|70 Years|No|||March 2015|March 14, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862757||65790|
NCT01862731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130099|Muscle Strength Loss and Its Effect on Knee Cap Motion in Volunteers With Anterior Knee Pain|Vasti Control of Patellofemoral Kinematics in Patients With Chronic Patellofemoral Pain||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|February 2020|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|November 11, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862731||65792|
NCT01863082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/15649-4|Resistant Hypertension and Physical Activity Performed in a Heated Pool|Effects of Training in a Heated Pool in Patients With Refractory Hypertension|HAR|University of Sao Paulo|Yes|Recruiting|November 2011|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|28|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01863082||65765|
NCT01872169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BS03|Investigating Prevalence of Disordered Eating in Children With GI Disorders|Investigating the Prevalence of Disordered Eating in Children and Adolescents Attending the Great Ormond Street Gastroenterology Clinic||Great Ormond Street Hospital for Children NHS Foundation Trust||Not yet recruiting|July 2013|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|300|||Both|5 Years|17 Years|No|||June 2013|June 3, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01872169||65068|
NCT01872182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MELS-301|Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome|A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome||Hanmi Pharmaceutical Company Limited|No|Recruiting|May 2013|August 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|64 Years|No|||March 2014|March 7, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01872182||65067|
NCT01872195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK Vest 2012/560|Effects of Checklists in Surgical Care - a Study on Complications, Death and Quality of Patient Administrative Data|Effects of Checklists in Surgical Care - a Study on Morbidity, Mortality and Data Quality||Haukeland University Hospital|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21000|||Both|N/A|N/A|No|||June 2015|June 10, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01872195||65066|
NCT01873495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057844|Omacetaxine for Consolidation and Maintenance|Omacetaxine for Consolidation and Maintenance in Patients Age ≥ 55 With AML in First Remission: A Pilot Study||Emory University|Yes|Recruiting|May 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|55 Years|N/A|No|||October 2015|October 6, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873495||64967|
NCT01863940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002299|Continuous Infusion of Local Anesthetic for Post-operative Pain Control in Ukraine|||Massachusetts General Hospital|Yes|Suspended|August 2013|June 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|12 Years|65 Years|No|||October 2015|October 7, 2015|May 23, 2013||No|Political unrest in study country|No||https://clinicaltrials.gov/show/NCT01863940||65699|
NCT01863953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-082|A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension|||Allergan|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|112|||Both|40 Years|N/A|No|||January 2015|January 16, 2015|May 24, 2013|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT01863953||65698|
NCT01872910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14852|A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal|Evaluation of the Acute Analgesic Efficacy of a Single Dose of LY3023703 in Patients With Postsurgical Dental Pain: A Parallel, Double-Blind, Randomized, Placebo and Positive Control Study||Eli Lilly and Company|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|January 7, 2014|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872910||65011|
NCT01872923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI 101/06 Extension|Dose Escalating Study for Amphinex-based PCI of Bleomycin.|Dose Escalating Study to Evaluate the Tolerability, Efficacy and Safety of Amphinex 0.125 mg/kg or Lower in Amphinex-based PCI of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies.||PCI Biotech AS|No|Completed|January 2012|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01872923||65010|
NCT01872936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-205|Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection|Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection||Santaris Pharma A/S|No|Active, not recruiting|June 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2014|November 17, 2014|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872936||65009|
NCT01873469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-PETra-2013|Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme|Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme||Technische Universität Dresden|No|Recruiting|July 2013|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|99|Samples With DNA|fresh tumour pieces, blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with the diagnosis of glioblastoma multiforme|March 2016|March 7, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01873469||64969|
NCT01873768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOS-16735|Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement|A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty||Miller Orthopedic Specialists|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|90 Years|No|||March 2016|March 18, 2016|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873768||64946|
NCT01869803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU# 99213|Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia|Compassionate Use of Gemtuzumab Ozogamicin (Mylotarg) for Treatment of Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL)||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|August 2013|||August 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01869803||65250|
NCT01869816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD(CTRP3,PRGL)|CTRP3 and Progranulin in Patients With Coronary Artery Disease|||Korea University||Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|362|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Acute coronary syndrome (ACS) patients, who were admitted to the coronary care units of        the Division of Cardiology at Guro Hospital in Korea University Medical Center.        Control subjects were recruited from the participants for a routine health check-up in the        Health Promotion Center of Korea University Guro Hospital.|June 2013|June 2, 2013|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01869816||65249|
NCT01860989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKAE609X2202|A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection|An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection||Novartis|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Both|20 Years|60 Years|No|||September 2015|September 8, 2015|May 21, 2013|No|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01860989||65924|
NCT01861015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-013|Vasopressin Versus Epinephrine in Myomectomy|Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial||CHA University|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|75 Years|No|||January 2016|January 21, 2016|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861015||65922|
NCT01861561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125/2556(EC2)|Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children|Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children|Low/highIVCY|Mahidol University|Yes|Recruiting|May 2013|November 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|15 Years|No|||March 2016|March 15, 2016|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01861561||65880|
NCT01861574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 15330|Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception|TMS Effects on Pain Perception||Medical University of South Carolina|No|Completed|February 2005|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|123|||Both|18 Years|60 Years|No|||April 2012|May 21, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01861574||65879|
NCT01861860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-37811002 / 2012-A00696-37|OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA|OPtimized Stenting Using IVUS in Long lEsion: Rationale for Simplified criteriA|OPERA|Centre Chirurgical Marie Lannelongue|No|Recruiting|October 2012|October 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01861860||65857|
NCT01861873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210982|Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases|Phase 2 Study: Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases||University of Aarhus|Yes|Not yet recruiting|August 2013|March 2016|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861873||65856|
NCT01861899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC12-004_PL_C|Treatment of Sacroiliac Dysfunction With SI-LOK® Sacroiliac Joint Fixation SI-SI-LOK|Treatment of Sacroiliac Dysfunction With SI-LOK® Sacroiliac Joint Fixation System||Globus Medical Inc|No|Recruiting|May 2013|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|55|||Both|21 Years|70 Years|No|Non-Probability Sample|Patients will be screened according to inclusion/exclusion criteria and will be selected        for the treatment using the SI-LOK® system|February 2016|February 10, 2016|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861899||65854|
NCT01862172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 486 03|Focal Cortical Atrophy After Myocardial Internal Capsule|FOCAL CORTICAL ATROPHY AFTER MYOCARDIAL INTERNAL CAPSULE: CORRELATION FRACTION ANISOTROPY BEAM PYRAMID AND DISABILITY|ACFI|University Hospital, Toulouse|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|90 Years|No|||August 2015|August 24, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01862172||65834|
NCT01863043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501174|Aspiration of Residual Gastric Contents|Routine Aspiration of Residual Gastric Contents in Very Low Birth Weight Infants||University of Florida|No|Recruiting|September 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|N/A|3 Days|No|||February 2016|February 16, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863043||65768|
NCT01863056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SitstandstudyCaldrea2012|The Effect of Sit-Stand Workstations on Physical Activity in Sedentary Office Workers|The Effect of Sit-Stand Workstations on Physical Activity in Sedentary Office Workers: A Randomized Crossover Trial||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|January 2012|July 2013|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 22, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01863056||65767|
NCT01862744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130115|Imaging Studies of Cognitive Impairment in Parkinson s Disease|Neural Correlates of Cognitive Impairment in Parkinson Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2013|February 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|76|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 4, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862744||65791|
NCT01873794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0864|Treating Cancer-Related Fatigue Through Systematic Light Exposure|Treating Cancer-Related Fatigue Through Systematic Light Exposure||Icahn School of Medicine at Mount Sinai|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|54|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873794||64944|
NCT01862328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15010|Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors|A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|May 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01862328||65822|
NCT01863732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2305E1|Extension in AS: Sustainability of Benefits, Safety and Tolerability|An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis|MEASURE 1 ext|Novartis|Yes|Active, not recruiting|November 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863732||65715|
NCT01863745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A1201|Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment|An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment||Novartis|No|Active, not recruiting|June 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||October 2015|October 12, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863745||65714|
NCT01872637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0432|Improving Function, Participation and Function After Acute Hospitalization in Older Adults|Improving Activity, Participation And Function After Acute Hospitalization In Older Adults With Multiple Chronic Conditions: Phase II Randomized Controlled Trial||University of Colorado, Denver|No|Active, not recruiting|June 2011|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872637||65032|
NCT01862588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201314159|Renal Resistive Index and Cardiac Output Changes During Resuscitation Predict the Occurrence of Acute Kidney Injury in Septic Shock Patients|Clinical Study of Renal Resistive Index and Hemodynamic Parameters Changes Caused by Fluid Resuscitation to Predict the Occurrence of Acute Kidney Injury in Septic Shock Patients|CORRI|Zhongda Hospital|No|Recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|For every enrolled patient,we will collect 5ml blood plasma for renal function examination,      and this point will fully informed and approved by the Ethic Committee.|Both|18 Years|90 Years|No|Probability Sample|Critical ill patients diagnosed with septic shock who required a fluid resuscitation.|January 2014|January 14, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01862588||65803|
NCT01863147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010Wze052|Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|55 Years|70 Years|No|||August 2015|August 15, 2015|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863147||65760|
NCT01873781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTH-200912|A Pilot Study Simulating Multifocal Intraocular Lenses in Healthy Subjects|||Medical University of Vienna||Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|young healthy subjects|August 2013|August 28, 2013|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01873781||64945|
NCT01869829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045657|PEACE: Pediatric Antifungal Comparative Effectiveness|International Pediatric Fungal Network: Multi-Center Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis|PEACE|Duke University|Yes|Recruiting|July 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|120 Days|18 Years|No|Probability Sample|Pediatric patients with invasive candidiasis|September 2015|October 27, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869829|5 Years|65248|
NCT01882387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2012-02|Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation|Phase II Evaluation of the Efficacy of TXA127 (Angiotensin 1-7) to Reduce Acute Graft-vs.-Host Disease in Adults Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation||US Biotest, Inc.|Yes|Withdrawn|December 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|June 17, 2013|Yes|Yes|Change in drug product development strategy|No||https://clinicaltrials.gov/show/NCT01882387||64286|
NCT01882400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-12|Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy|Évaluation Multidimensionnelle de la réponse au Traitement de l'ostéoporose spontanée et Induite Par Les corticostéroïdes à l'Aide d'un Bisphosphonate à Administration Orale Chez Des Malades Porteurs d'Une Dystrophie Musculaire sévère.||Université de Sherbrooke|Yes|Completed|May 2001|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|5 Years|18 Years|No|||October 2013|October 31, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882400||64285|
NCT01861275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/2013|Cerebral Palsy and Sleep Apnea in North Part of Finland|Obstructive Sleep Apnea as a Risk Factor for Cerebral Palsy, a Prospective Study||University of Oulu|Yes|Recruiting|April 2013|November 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|residents of Oulu university hospital area. consecutive patient sampling|May 2013|May 22, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861275|6 Months|65902|
NCT01861041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSTAT|Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy.|Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy.|TURP|Diskapi Yildirim Beyazit Education and Research Hospital|No|Not yet recruiting|May 2013|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|52|||Male|50 Years|85 Years|No|||May 2013|May 21, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861041||65920|
NCT01861288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DER-SBIO|Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease|Development of a New Algorithm to Determine the Activity of Disease: Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With IBD.||Herlev Hospital|No|Enrolling by invitation|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|Feces|Both|N/A|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study includes adult and pediatric patients with and without IBD who, as part of an        ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children:        colonoscopy).|March 2015|March 17, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01861288||65901|
NCT01861301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00937|Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma|A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma||National Cancer Institute (NCI)||Terminated|January 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2015|December 21, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861301||65900|
NCT01861587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR18682|Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain|Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain||Medical University of South Carolina||Completed|October 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|500|||Both|18 Years|75 Years|No|||January 2014|October 1, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01861587||65878|
NCT01861600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9055A1-3001|Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas|Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas||Nestlé|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|375|||Both|N/A|14 Days|Accepts Healthy Volunteers|||May 2013|May 21, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01861600||65877|
NCT01861886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16972|The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women|A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505® Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception||Bayer|No|Completed|January 2013|September 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|73|||Female|21 Years|44 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|February 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861886||65855|
NCT01862185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-PCTQ1|The Effect of Semi-quantitative Procalcitonin Assay to The Adequacy of Empirical Antibiotics and Mortality in Septic Patients|Pengaruh Pemeriksaan Procalcitonin Semikuantitatif Terhadap Adekuasi Terapi Antibiotik Empirik Awal Dan Mortalitas Pada Pasien Sepsis||Indonesia University|Yes|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|205|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862185||65833|
NCT01862198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2012-1819-0002|The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent|Pilot Study on the Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent||Inje University|Yes|Completed|September 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A|No|||November 2013|November 29, 2013|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01862198||65832|
NCT01862510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZUBM12133|Detection of Celiac Disease in Patients With Hypothyroidism|Detection of Celiac Disease in Patients With Hypothyroidism||University of Vermont|No|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with hypothyroidism who take thyroid replacement therapy|December 2014|December 5, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862510||65808|
NCT01862770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913050|Effect of Lung Cancer Diagnoses on Family Behaviors|Impact of a Patient's Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk Information and Receptivity to Quit Smoking||National Institutes of Health Clinical Center (CC)||Completed|December 2012|February 2016|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|55 Years|No|||February 2016|February 26, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862770||65789|
NCT01863368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-040|Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining|Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining||Alcon Research|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 23, 2013||No||No|June 17, 2015|https://clinicaltrials.gov/show/NCT01863368||65743|
NCT01863706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Misoprostol for PPH|Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage|Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage||Hormozgan University of Medical Sciences|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|10 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863706||65717|
NCT01871896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoSurgery|Endoscopic Surgery for Bariatric Revision After Weight Loss Failure|Apollo OverStitch for Bariatric Surgery Revision After Weight Loss Failure||University of California, San Francisco|No|Recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 9, 2014|May 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01871896||65089|
NCT01871909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0286|Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients|Validation of LBNP Model of Human Hemorrhage in Trauma Patients||University of Colorado, Denver|No|Enrolling by invitation|October 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|31 Days|89 Years|No|Non-Probability Sample|Trauma patients|December 2015|December 3, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01871909||65088|
NCT01862341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FON-JOLIE-PPH-2012-01|The Effect of Milk Powder With Fiber and Probiotics on Digestive Habits and General Health Well-being of Selected Filipino Mothers.|The Effect of Milk Powder With Fiber and Probiotics on Digestive Habits and General Health Well-being of Selected Filipino Mothers.||Fonterra Research Centre||Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Female|21 Years|35 Years|No|||August 2013|August 6, 2013|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01862341||65821|
NCT01862354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-00017214-14 2013/9|Analgesic Effect Between TAP Block and Continuous Wound Infusion in Abdominoplasty Surgery|Comparative Analgesic Effect Between Continuous Wound Infusion and Transverse Abdominal Plan Block for Abdominoplasty Surgery||University Hospital of Liege|No|Recruiting|June 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|70 Years|No|||December 2015|December 2, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01862354||65820|
NCT01872624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0150|Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema|Bone-marrow Derived Mesenchymal Stromal Cells Associated With One-way Endobronchial Valves in Patients With Pulmonary Emphysema: Safety Study||Hospital de Clinicas de Porto Alegre|No|Completed|May 2013|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01872624||65033|
NCT01862302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALPCARD-2013|Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium|Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium: A Randomized Placebo-Controlled Pilot Study|HALPCARD|McMaster University|Yes|Active, not recruiting|August 2013|July 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01862302||65824|
NCT01862315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-066|Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)|A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|86|||Both|21 Years|N/A|No|||February 2016|February 3, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862315||65823|
NCT01863160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEP - 001 - IL|Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-escalating Study to Assess Safety, Tolerability and Pharmacokinetics of 0.1% and 1.0% ZEP-3 Cream, Administered Topically in Healthy Volunteers.||Shulov Innovate for Science Ltd. 2012|Yes|Completed|July 2013|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|February 19, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01863160||65759|
NCT01863459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDX-COMORB-1|Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity|Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity||Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada|No|Recruiting|April 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863459||65736|
NCT01863433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-TIV-13-84|A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years||bioCSL PTY LTD|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|May 23, 2013|No|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01863433||65738|
NCT01863446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002568|Effects of Light on Melatonin and Contractions in Pregnant Women|Effects of Light on Melatonin and Contractions in Pregnant Women||Brigham and Women's Hospital|No|Recruiting|May 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863446||65737|
NCT01885910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-000508|Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel|Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment||Derm Research, PLLC|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|12 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|June 21, 2013|No|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01885910||64015|
NCT01882413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-RES-012-001|A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal||REVEAL|Allergan|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|204|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with planned cataract removal surgery|November 2015|November 2, 2015|June 18, 2013||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01882413||64284|
NCT01882725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_HPBC_001_ZANG|Study of Low Level Laser Light Therapy to Improve Blood Circulation in People With Chronic Heel Pain|An Evaluation of the Effect of the Erchonia HP Scanner (HPS) Laser on Increasing Blood Circulation in Individuals With Chronic Heel Pain||Erchonia Corporation|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|July 12, 2015|June 17, 2013|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT01882725||64260|
NCT01882738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039-13-HYMC|Effect of Maternal BMI on Measurement of Cervical Length|Effect of Maternal BMI on Accuracy of Measurement of Cervical Length During the 3rd Trimester of Pregnancy||Hillel Yaffe Medical Center|No|Not yet recruiting|July 2013|July 2015|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|All pregnant women in 2nd or 3rd trimester who attend routine ultrasound exam|June 2013|June 18, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01882738||64259|
NCT01861054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0210|Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients|A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery||Dompé Farmaceutici S.p.A|Yes|Terminated|February 2013|March 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|April 18, 2013|Yes|Yes|Enrollment target not reached|No||https://clinicaltrials.gov/show/NCT01861054||65919|
NCT01861314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00999|Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia|Phase I Study of The Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|May 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861314||65899|
NCT01861327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO2|The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures|The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures||Hospital Israelita Albert Einstein|No|Active, not recruiting|April 2012|May 2016|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|120|||Both|N/A|N/A|No|||September 2015|September 1, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01861327||65898|
NCT01861340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1340|Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma|Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|May 2014|April 2016|Anticipated|August 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861340||65897|
NCT01861613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HBV-001|Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students|||Peking University||Completed|September 2009|||November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2040|||Both|16 Years|30 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01861613||65876|
NCT01861626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00057 CA 1 01|Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects|||Pierre Fabre Dermatology||Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861626||65875|
NCT01861912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDREC2013109H(R1)|Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma|Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study|ACTION|Guangdong General Hospital|Yes|Enrolling by invitation|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|75 Years|No|||June 2013|June 4, 2013|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861912||65853|
NCT01861925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-LS900-TOPO-01|Study of Clinical Performance of Corneal Topography Measurement Using an Optical Biometer|Lenstar LS 900 Topography||Haag-Streit AG|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers recruited at University Hospital|May 2014|May 13, 2014|May 21, 2013||No||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01861925||65852|
NCT01862211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.663|Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort|POLYGEN DEFI-ALPHA : Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort|Polygen|Hospices Civils de Lyon|No|Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|7 Years|N/A|No|||December 2015|December 14, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862211||65831|
NCT01862224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100963|A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Janssen Research & Development, LLC|Yes|Terminated|July 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|May 2, 2013|Yes|Yes|The study was stopped due to lack of efficacy in a study conducted in a similar    population,38518168ARA2002-NCT01679951.|No||https://clinicaltrials.gov/show/NCT01862224||65830|
NCT01862783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913074|Collection of Biological Material From Pregnant Women in a Malarial Region|In-Vitro Evaluation of Anti-Adhesion Activity by Antibodies to Pregnancy Malaria Vaccine Candidates||National Institutes of Health Clinical Center (CC)||Terminated|February 2013|March 2016|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|2500|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862783||65788|
NCT01870817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34769|Home Jejunostomy Feeding Following Esophagectomy/Gastrectomy|A Pilot Study Investigating the Effect of Post-operative Home Jejunostomy Feeding on Quality of Life and Nutritional Parameters in Patients With Oesophago-gastric Cancer||University Hospitals, Leicester|Yes|Completed|July 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01870817||65172|
NCT01862523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mucosal potentials in the nose|Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls|Unraveling the Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls by Measuring Mucosal Potentials in the Nose.||Universitaire Ziekenhuizen Leuven|Yes|Completed|February 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01862523||65807|
NCT01862536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-12F|Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease|Tadalafil for Pulmonary Hypertension Associated With Chronic Lung Disease|TADA-PHILD|VA Office of Research and Development|Yes|Recruiting|October 2013|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|85 Years|No|||December 2015|December 8, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01862536||65806|
NCT01862796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913096|Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals|Is Non-Adherence Unique to Weight-Loss? Predictors of Adherence to a Heart-Healthy Diet in Lean vs. Obese Individuals||National Institutes of Health Clinical Center (CC)||Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|February 4, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862796||65787|
NCT01862367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1841-3868|Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study|Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study|mentor™6|Novo Nordisk A/S|No|Enrolling by invitation|May 2013|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|This observational study will enroll patients with congenital FXIII A-subunit deficiency        for whom the decision to treat with rFXIII has been made and who are willing to provide        informed consent (or patient's legally acceptable representative (LAR) consent, if        applicable).|January 2016|January 21, 2016|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01862367||65819|
NCT01872403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAH20120906|Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung|Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|October 2012|December 2017|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872403||65050|
NCT01862861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medimix Pharm-02|Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study|Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study|REVERT|Medimix Specialty Pharmacy, LLC|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Female|30 Years|65 Years|No|Non-Probability Sample|Peri-menopausal or post-menopausal women between the age of 30 and 65 years of age.|July 2014|July 30, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862861||65782|
NCT01863849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluvalAB-H-YL2013|Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection|Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 μgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.||Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|119|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863849||65706|
NCT01862835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000047|Impact of Estradiol Addback|Impact of Estradiol Addback on Somatostatin Rebound in Older Men||Mayo Clinic|No|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|60|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01862835||65784|
NCT01862848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medimix Pharm-01|Topical Compounded Pain Creams And Pain Perception (TOPCAPP)|Topical Compounded Pain Creams And Pain Perception (TOPCAPP)|TOPCAPP|Medimix Specialty Pharmacy, LLC|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|285|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants with neuropathic or nociceptive chronic pain who are between 18 and 65 years        of age prescribed a combination compounded topical analgesic.|June 2015|June 12, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862848|12 Weeks|65783|
NCT01863498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12120535|Prospective Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA|Prospective Randomized Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA|Pectus epi PCA|Children's Mercy Hospital Kansas City|No|Recruiting|May 2013|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|12 Years|17 Years|No|||January 2016|January 27, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01863498||65733|
NCT01863472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF20/13 Version 03|Catheter Ablation of Drug-refractory Persistent Atrial Fibrillation With the HeartLight(TM) Laser Balloon in Comparison With Irrigated Radiofrequency Current Ablation|Catheter Ablation of Drug-refractory Persistent Atrial Fibrillation With the HeartLight(TM) Laser Balloon in Comparison With Irrigated Radiofrequency Current Ablation||Cardioangiologisches Centrum Bethanien|No|Active, not recruiting|June 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01863472||65735|
NCT01863485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM082-CA-I-001|Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China|Phase 1 Safety, Tolerability, and Pharmacokinetic Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China||AnewPharma|No|Active, not recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863485||65734|
NCT01882179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0533|Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size|MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)|MINIMISE-STEMI|University College, London|Yes|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882179||64302|
NCT01882192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR113798|Family Planning to Promote Regular Physical Activity|Family Planning to Promote Regular Physical Activity: A Randomized Controlled Trial||University of Victoria|Yes|Recruiting|June 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|6 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01882192||64301|
NCT01861067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-014|LESS-TLH Versus LESS-LAVH|A Randomized Comparison of Laparoendoscopic Single-site (LESS) Hysterectomies: Total Laparoscopic Hysterectomy (TLH) Versus Laparoscopically Assisted Vaginal Hysterectomy (LAVH)||CHA University|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Female|18 Years|75 Years|No|||April 2015|April 15, 2015|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861067||65918|
NCT01861353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK74/2012|Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children|Randomized Controlled Trial of the Effect of Cranberry-lingonberry Juice on the Occurrence of Urinary Tract Infections, the Gut Microbiota, and the Uropathogenic Escherichia Coli||University of Oulu|No|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|260|||Both|1 Year|16 Years|No|||December 2014|December 1, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861353||65896|
NCT01861366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MuMs07|Implementation of Nutritional Guidelines and Effects in Nursing Home Residents|Clinical Outcome in Nursing Home Residents After Implementation of Nutritional Guidelines||Uppsala University|Yes|Completed|May 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|101|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 22, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861366||65895|
NCT01861639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP1P003|Stability of rTMS on Cognition and Brain Networks on Healthy Subjects.|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cognition and Brain Networks in Healthy Subjects in 2 Sessions 15 Days Apart||Qualissima||Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|8||Anticipated|101|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01861639||65874|
NCT01861652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388140|Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study|The Use of the Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study||Walter Reed National Military Medical Center|No|Withdrawn|July 2013|||January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|June 12, 2015|May 21, 2013|Yes|Yes|sponsor withdrew support|No||https://clinicaltrials.gov/show/NCT01861652||65873|
NCT01861938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0419-12-HMO|Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients|Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients||Hadassah Medical Organization|No|Not yet recruiting|June 2013|||December 2014|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||December 2012|May 23, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01861938||65851|
NCT01862237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.699|Type II Diabetes Influence on Left Ventricular Remodeling and Outcomes in Patients Undergoing Aortic Valve Replacement Surgery.|Does Type II Diabetes Influence Prognosis and Left Ventricular Remodeling in Patients With Aortic Valve Stenosis Referred for Aortic Valve Replacement ?|DIAPASON|Hospices Civils de Lyon|No|Recruiting|December 2012|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862237||65829|
NCT01870830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-088B|Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude|Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude||University of Zurich|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|50|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870830||65171|
NCT01871116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12128|POWER-remote Weight Loss Program in Early Stage Breast Cancer|A Randomized Study Evaluating the Effect of a Remote-Based Weight Loss Program (POWER-remote) on Biomarkers in Women With Early Stage Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|July 2013|July 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871116||65149|
NCT01871415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YC28036|A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLUS METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY||Hoffmann-La Roche||Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871415||65126|
NCT01871428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YC28037|A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy|A MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS ITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY||Hoffmann-La Roche||Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871428||65125|
NCT01871688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0906/077-010|Pelvic Floor Rehabilitation for Gynecological Cancer Patients|Neuromodulation System for Pelvic Floor Dysfunction Based on the Myo-neurophysiological Assessment for Gynecological Cancer Patients||Seoul National University Bundang Hospital|No|Recruiting|April 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||June 2013|June 4, 2013|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01871688||65105|
NCT01873235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P30DK090868-02|PKD Clinical and Translational Core Study|The Baltimore Polycystic Kidney Disease Clinical and Translational Core Study||University of Maryland|No|Recruiting|March 2013|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Plasma, serum,urine, and DNA will be collected at the baseline visit and stored in a      biorepository.|Both|18 Years|N/A|No|Non-Probability Sample|Adults with diagnosed Polycystic Kidney Disease|December 2015|December 1, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01873235|4 Years|64987|
NCT01873482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042492|Traditional African Healing Ceremony in a U.S. Population|Traditional African Healing Ceremony in a U.S. Population||Duke University||Completed|May 2014|||May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|17|||Both|25 Years|65 Years|No|||October 2014|October 31, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01873482||64968|
NCT01862874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-122|Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)|A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1100|||Male|16 Years|26 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862874||65781|
NCT01869842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0070|Randomized Controlled Study of the Traditional Percutaneous Coronary Intervention and Intervention Using Optical Coherence Tomography of Incomplete Stent Adhesion and Extent of the Formation of Neointima by Resolute Zotarolimus-eluting Stent Insertion|||Yonsei University|No|Recruiting|December 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|115|||Both|20 Years|N/A|No|||May 2013|June 4, 2013|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869842||65247|
NCT01862601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT1202|JetTouch Injection System to Deliver Saline Into the Bladder Wall of Healthy Volunteers|Study to Evaluate the Safety and Performance of the JetTouch Needle-Free Endoscopic Injection System to Deliver Saline Into the Bladder Wall of Healthy Subjects||American Medical Systems|Yes|Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862601||65802|
NCT01864070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1205|Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease|Phase I Study of TheraSphere and Everolimus Among Patients With Neuroendocrine Tumors and Liver Only or Liver Dominant Disease||M.D. Anderson Cancer Center|No|Withdrawn|May 2014|||May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01864070||65689|
NCT01863212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSF008786|The Role of the FTO Gene in Reward System Activation in Obese and Healthy Subjects|Investigating the Role of the FTO Gene in Reward System Activation During Visual Presentation of Food Images With fMRI Technique|FTO|Uppsala University|Yes|Recruiting|September 2010|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|500|||Both|18 Years|37 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01863212||65755|
NCT01863173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-3502|Effect of Metoprolol on Thalassemia Cardiomyopathy|The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study||Shiraz University of Medical Sciences|Yes|Completed|January 2012|December 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|13 Years|25 Years|No|||May 2013|May 22, 2013|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01863173||65758|
NCT01864304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000068|Fat Distribution and Glucose Metabolism in Williams Syndrome|Characterization of Fat Distribution and Glucose Metabolism in Individuals With and Without Williams Syndrome||Massachusetts General Hospital|No|Completed|December 2013|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|24|||Both|14 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults with Williams Syndrome (WS), and "control" individuals without WS.|March 2016|March 10, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01864304||65671|
NCT01863823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmeritekUsa|The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication|Director of Research Division||Ameritek USA|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|350|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 28, 2013|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863823||65708|
NCT01863836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-20913|Study on the Influence of Fluoroscopy in the Diagnosis of Peripheral Lung Lesions With Endobronchial Ultrasound Guidance|Randomized Trial of Fluoroscopy Use for Radial Endobronchial Ultrasound-guided Biopsy of Peripheral Lung Lesions||Laval University|No|Recruiting|April 2013|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|115|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01863836||65707|
NCT01882426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1206|Care Path for the Management of Ulcerative Colitis|A Cluster Randomized Controlled Trial of a Care-Path for the Management of Ulcerative Colitis|CONSTRUCT|University of Western Ontario, Canada|No|Terminated|May 2014|May 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882426||64283|
NCT01861080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005|Korean Registry of Target Organ Damages in Hypertension|Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives|KorHR|Dongtan Sacred Heart Hospital|Yes|Recruiting|May 2013|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|30 Years|N/A|No|Non-Probability Sample|Korean patients with incident hypertensive, who visited university hospital|August 2015|August 4, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01861080|36 Months|65917|
NCT01861379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-008|The Role of Ghost Ileostomy in Laparoscopic Rectal Resection|The Role of Ghost Ileostomy in Laparoscopic Rectal Resection|GILRR|University of Roma La Sapienza|No|Completed|January 2007|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|90 Years|No|||May 2013|May 21, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861379||65894|
NCT01861392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-3618|Analisys of Neuromuscular Response, Postural Balance and Quality of Life of Diabetics Type 2 After Sensory-motor Training: Blind Random Controled Clinical Trial|Analisys of Neuromuscular Response, Postural Balance and Quality of Life of Diabetics Type 2 After Sensory-motor Training: Blind Random Controled Clinical Trial||University of Sao Paulo|Yes|Not yet recruiting|May 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|64 Years|No|||May 2013|May 22, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861392||65893|
NCT01861665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004010977|Marcaine Use in Laparoscopic Gynecological Surgery|A Comparative Trial of Marcaine Administration in Laparoscopic Gynecologic Surgery Using Either a Pre- or Post-operative Injection.|Marcaine|Weill Medical College of Cornell University|No|Terminated|June 2010|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|May 21, 2013||No|Investigator no longer recruiting subjects.|No||https://clinicaltrials.gov/show/NCT01861665||65872|
NCT01861951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS001|A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma|A Randomized Phase II Trial Comparing Pazopanib With Doxorubicin as First Line Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma|EPAZ|Hannover Medical School|No|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|N/A|No|||September 2015|February 23, 2016|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01861951||65850|
NCT01870518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BN006|Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI|Neurocognitive Effects of Bilateral Subthalamic Nucleus Versus Globus Pallidus Interna Deep Brain Stimulation in Parkinson's Disease Patients With Mild Cognitive Impairment|DBS|St. Joseph's Hospital and Medical Center, Phoenix|No|Terminated|April 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|21 Years|N/A|No|||February 2016|February 9, 2016|May 1, 2013|No|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01870518||65195|
NCT01871441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.127|Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes||Thomas Jefferson University|Yes|Active, not recruiting|May 2013|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871441||65124|
NCT01871701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNSQT|Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs|Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin||Seoul National University Hospital|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01871701||65104|
NCT01861717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KELD-ESS-0413|A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.|A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity||John Wayne Cancer Institute|No|Completed|May 2013|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|75 Years|No|||September 2015|March 14, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861717||65868|
NCT01862016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2009-04|Early Spontaneous Breathing in Acute Respiratory Distress Syndrome|Early Spontaneous Breathing in Acute Respiratory Distress Syndrome|BiRDS|University Hospital, Angers|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01862016||65845|
NCT01862653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0053|Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder|Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder||United States Naval Medical Center, San Diego|Yes|Completed|February 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01862653||65798|
NCT01862614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Buffered Articaine|Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.|A Prospective Randomized, Double-blind Study of the Anesthetic Efficacy of Buffered Articaine as a Primary Buccal Infiltration of the Mandibular First Molar.||Ohio State University|No|Completed|April 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults between the age of 18-65 years.|April 2015|April 20, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862614||65801|
NCT01863225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-009|Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia|A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia||Resverlogix Corp|No|Terminated|May 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|13|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01863225||65754|
NCT01864083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-177|FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients|FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Female|21 Years|N/A|No|||October 2015|October 5, 2015|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01864083||65688|
NCT01864096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAST 01|The Metformin Active Surveillance Trial (MAST) Study|A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study|MAST|University Health Network, Toronto|Yes|Recruiting|October 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|408|||Male|18 Years|79 Years|No|||March 2016|March 4, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01864096||65687|
NCT01864317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-220213|Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging|Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging||Medical University of Vienna|Yes|Not yet recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01864317||65670|
NCT01882452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEST-UK|A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression|A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression|MEST|Medical Research Council|Yes|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|May 12, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882452||64281|
NCT01865318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1740|Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes|A Single Centre, Open-Label, Multiple Dose Trial Examining the Pharmacodynamic Characteristics of Insulin 454 Under Single-Dose and Steady-State Conditions in Male Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|September 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|69 Years|No|||October 2015|October 21, 2015|May 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865318||65594|
NCT01861093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130116|Safety Study of Cord Blood Units for Stem Cell Transplants|A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|November 2037|Anticipated|November 2037|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|No|||February 2016|February 20, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861093||65916|
NCT01861405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.02|Neurococognitive and Functioal Assessment of Patients With Brain Metastases|Neurocognitive and fMRI Activation Changes Observed at Baseline and After Whole Brain Radiation vs. Radiosurgery for Patients With Cerebral Metastases: a Prospective Case-control Analysis.||Thomas Jefferson University||Recruiting|March 2013|||March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with brain metastases will be referred through the department of Neurosurgery and        Radiation-oncology at Thomas Jefferson University Hospital. Healthy subjects will        recruited through postings distributed around the hospital and university bulletin boards        and through an advertisement in a local newspaper.|December 2014|December 16, 2014|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861405||65892|
NCT01870531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800-20100046|Korean Transient Ischemic Attack eXpression Registry|Transient Ischemic Attacks in Korean: Hospital-based, Multi-center Prospective Registry|KTX registry|Seoul National University Boramae Hospital|No|Completed|July 2010|August 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|40 Years|N/A|No|Probability Sample|University Hospitals|June 2015|June 6, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01870531|90 Days|65194|
NCT01861678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCUMC-D1108013|Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection|Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients||Yokohama City University Medical Center|No|Active, not recruiting|July 2006|September 2017|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|20 Years|N/A|No|||August 2013|August 4, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861678||65871|
NCT01871129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13046M|The Effects of Dexmedetomidine to Postoperative Awakening and Extubation-related Changes in Blood Pressure|The Effects of Postoperative Dexmedetomidine Sedation to Haemodynamics During Extubation||Tampere University Hospital|Yes|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|60 Years|90 Years|No|||July 2015|July 10, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871129||65148|
NCT01871142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4002H|Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance|Double-Blind, Placebo Controlled Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance in Healthy Adult Humans||Colorado State University|No|Completed|March 2013|June 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|May 29, 2013|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01871142||65147|
NCT01872208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PRO-V002|Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With Peripheral Arterial Disease|A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial Disease||Humacyte, Inc.|Yes|Active, not recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||April 2015|April 2, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01872208||65065|
NCT01872650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIPEUS|A Trial to Assess the Effect and Safety of the C-Qur™ Film|A Randomized, Controlled, Clinical Trial to Assess the Effect and Safety of the C-Qur™ fiLm, an antI-adhesive Barrier for the PrevEntion of sUrgical adhesionS|CLIPEUS|University Medical Center Nijmegen|Yes|Recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01872650||65031|
NCT01872949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 04654-C|C-Pulse® System European Multicenter Study|C-Pulse System eurOPean mulTicenter Study, Implantable cOuNterpulsation System in patIents With Moderate to Severe Heart Failure|OPTIONS HF|Sunshine Heart Inc.|No|Active, not recruiting|May 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|A patient population of up to 50 patients with moderate to severe heart failure refractory        to optimal medical therapy, who are implanted with the C-Pulse System as clinically        appropriate, will be enrolled into the Study|March 2016|March 3, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01872949||65008|
NCT01861730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-015-404/ IMPAACT P1113|Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants|Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants|C-015-404|Aeras|Yes|Enrolling by invitation|July 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|229|||Both|64 Days|196 Days|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861730||65867|
NCT01862029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130123|Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals|An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2015|January 14, 2016|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862029||65844|
NCT01862042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11183|Palliative Care in Spinal Muscular Atrophy (SMA) 1|Evaluation of Palliative and Supportive Care for Spinal Muscular Atrophy (SMA) Type 1 Patients|ASI1|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2012|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|N/A|1 Year|No|||December 2015|December 8, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01862042||65843|
NCT01862627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye011|Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy|Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy But Without Optic Disc Pit Nor High Myopia||Kyorin University|No|Completed|December 2004|||April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|11|||Both|10 Years|95 Years|No|Probability Sample|The patients with macular retinoschisis and detachment associated with normal tension        glaucoma|August 2014|August 18, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01862627||65800|
NCT01863238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-770-115|An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis|An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis||Vertex Pharmaceuticals Incorporated|No|Active, not recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|95|||Both|6 Years|11 Years|No|Non-Probability Sample|Pediatric patients with CF who are 11 years of age or younger at the time of initiation of        treatment with ivacaftor and are receiving or planning to receive commercially-available        ivacaftor in the United States (US)|July 2015|July 28, 2015|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863238||65753|
NCT01863537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC5642|Using Multimedia Technologies to Disseminate an HIV Prevention|Using Multimedia Technologies to Disseminate an HIV Prevention Program for Couples||Columbia University|No|Completed|May 2007|June 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|253|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01863537||65730|
NCT01863186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-3003-1|Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal|Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)||US WorldMeds LLC|Yes|Completed|June 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|603|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863186||65757|
NCT01863199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28727|Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)|A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).|Liberty|Retinal Consultants of Arizona|No|Active, not recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||October 2015|October 28, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863199||65756|
NCT01863251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202009750|Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia|Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia||Yale University|No|Completed|May 2013|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863251||65752|
NCT01863511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUF-01|Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure|Primary Mode of Therapy in Acute Decompensated Heart Failure:Comparison Between Usual Care Plus Tolvaptan and Ultrafiltration.|TUF|The Christ Hospital|Yes|Completed|May 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||February 2015|January 27, 2016|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01863511||65732|
NCT01863524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc130152ctil|Screening for Abdominal Aortic Aneurysm Using a Portable Transthoracic Echocardiography Among Patients With Acute Coronary Syndrome|Screening for Abdominal Aortic Aneurysm Using a Portable Transthoracic Echocardiography (TTE) Among Patients With Acute Coronary Syndrome in Intensive Cardiac Care Unit.||HaEmek Medical Center, Israel||Recruiting|May 2013|||July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|65 Years|N/A|No|Probability Sample|Patients over 65 years old with ACS admitted in Intensive Cardiac Care Unit, who will be        examined by TTE.|July 2015|July 21, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01863524||65731|
NCT01864330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-28102012|Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome|Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome||Medical University of Vienna|Yes|Completed|May 2013|September 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01864330||65669|
NCT01883661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BM/2013/MS/01|Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)|Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial||Chaitanya Hospital, Pune|Yes|Recruiting|June 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01883661||64188|
NCT01870102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW330SR-1002(Ver1.1.)|Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects|A Randomized, Open Label, Cross-over, Phase 1 Trial to Investigate the Pharmacokinetics in Multi-dose and the Food Effect in Single-dose of Pelubiprofen IR and Pelubiprofen SR in Healthy Male Volunteers||Daewon Pharmaceutical Co., Ltd.||Completed||||August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||||||Male|20 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01870102||65227|
NCT01870310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLOMOUC 1|Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction.|Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.||University Hospital Olomouc|No|Recruiting|June 2012|June 2016|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2013|June 3, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01870310||65211|
NCT01870544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tufts Obesity Study|Does Weight Loss Surgery and Probiotic Supplementation Lead to a "Lean" Gut Microbiota?|Does Weight Loss Surgery and Probiotic Supplementation Lead to a "Lean" Gut Microbiota?||Tufts Medical Center|Yes|Completed|September 2013|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01870544||65193|
NCT01870843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100826|A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom|Improving Quality of Life and Social Functionality With Escitalopram in the Treatment of Major Depressive Disorder With Anxiety Symptom||Xian-Janssen Pharmaceutical Ltd.|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|261|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870843||65170|
NCT01871922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retro-002|Atropine-effect During Propofol/Remifentanil Induction|Evaluation of the Effects of the Addition of Atropine During Propofol/Remifentanil Induction of Anesthesia on Hemodynamics, Microvascular Blood Flow and Tissue Oxygenenation in Patients Undergoing Ophthalmic Surgery||University Medical Center Groningen|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01871922||65087|
NCT01861132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NexValid13|Validation of a Non-invasive Hemodynamic Monitor (NexFin) in Pregnant Women|Validation of Non-invasive Monitoring of Blood Pressure and Cardiac Output in Healthy Pregnant Women During Cesarean Section||Oslo University Hospital|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|50 Years|No|Probability Sample|Healthy singleton pregnancies at term scheduled for cesarean delivery under spinal        anesthesia|February 2014|February 10, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861132||65913|
NCT01861145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032936|Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea|Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea||University of Alberta|No|Withdrawn|May 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|17 Years|No|||December 2015|December 17, 2015|May 21, 2013||No|Unable to sufficiently enroll or collect follow-up|No||https://clinicaltrials.gov/show/NCT01861145||65912|
NCT01861444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25581|An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)|National, Multicenter, Observational Study Evaluating Prevalence, Virological and Clinical Characteristics of Chronic Hepatitis Delta in Romania and Assess Efficacy of Peg-interferon Alfa-2a Treatment in Patients With Chronic Hepatitis D (CHD)||Hoffmann-La Roche||Active, not recruiting|March 2011|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B, and then those who are positive for anti-HDV Ab and        treated with Pegasys|October 2014|October 20, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01861444||65889|
NCT01862380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111005|Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.|Evaluation of Adrenocortical Functions by Insulin Tolerance Test and Sodium Depletion in Women With Nonclassical Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Comparison With Healthy Volunteers.|EVAF-21|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862380||65818|
NCT01862393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0081.0.186.000-07|Stimulus Phase Duration on Discomfort and Electrically Induced Torque of Quadriceps Femoris|The Influence of Stimulus Phase Duration on Discomfort and Electrically Induced Torque of Quadriceps Femoris||Universidade Cidade de Sao Paulo||Completed|August 2008|||December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|38|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01862393||65817|
NCT01862640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-12-283|A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|July 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|420|||Both|55 Years|90 Years|No|||February 2016|February 9, 2016|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862640||65799|
NCT01862887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631035|A Study to Investigate the Effect of PH-797804 on QTc Interval|A Phase 1, Randomized, Placebo-And Positive-Controlled Crossover Study To Determine The Effect Of A Single-Dose Of PH-797804 On QTc Interval In Healthy Volunteers||Pfizer|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01862887||65780|
NCT01862900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-017A|Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions|Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.|OX40 Breast|Providence Health & Services|No|Recruiting|February 2013|February 2023|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862900||65779|
NCT01864135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/180/2012|Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging and Biomarkers|Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging|IMPROD|Turku University Hospital|No|Completed|March 2013|November 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|175|||Male|40 Years|85 Years|No|||January 2016|January 20, 2016|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01864135||65684|
NCT01863862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGBRJG0113|Organ Preservation in Elderly Patients With Rectal Cancer|Organ Preservation in Elderly Patients With Rectal Cancer: a Prospective Observational Study||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Recruiting|August 2012|January 2016|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|70 Years|N/A|No|||May 2013|May 23, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01863862||65705|
NCT01863875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2154|Language Proficiency and Quality of Life After Receiving Cochlear Implantation as a Child|Assessment of Listening, Speech, and Language Proficiency, and of Experienced Quality of Life in People Who Have Received Cochlear Implants as Children.||Oslo University Hospital|Yes|Recruiting|January 2013|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|530|||Both|18 Months|50 Years|No|Non-Probability Sample|All people in Norway that have received Cochlear Implants as a child.|October 2014|October 29, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863875||65704|
NCT01864109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-068|Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma|A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|83|||Both|1 Year|40 Years|No|||January 2016|January 21, 2016|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864109||65686|
NCT01864343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STATIM-Pilot|Target Temperature Management In Myocardial Infarction - A Pilot Study|Target Temperature Management In Myocardial Infarction - A Pilot Study||Medical University of Vienna|No|Completed|September 2011|May 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||May 2013|May 24, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01864343||65668|
NCT01883674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLC-021742|Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.|Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.|PRO|Université de Sherbrooke|No|Completed|May 2012|December 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Male|65 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01883674||64187|
NCT01870856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-005|Lid Wiper Epitheliopathy Trial|Evaluation of Lid Wiper Epitheliopathy With and Without Daily Disposable Contact Lenses||Alcon Research|No|Terminated|July 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|187|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|June 4, 2013|Yes|Yes|Primary efficacy was not demonstrated in Stage 1|No|October 24, 2014|https://clinicaltrials.gov/show/NCT01870856||65169|
NCT01870869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410CAXL-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2013|||||N/A|N/A|N/A||||||||||||||April 21, 2015|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01870869||65168|
NCT01871155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF-01|Effect of Nutri-jelly on Quality of Life in Head and Neck Cancer Patients|Efficacy Study of Nutri-jelly Intake on Quality of Life in Head and Neck Cancer Patients Undergoing Radiotherapy||Dental Innovation Foundation Under Royal Patronage|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|35 Years|85 Years|No|||June 2013|June 4, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01871155||65146|
NCT01871168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002507|Continuous TAP Blocks - Pain & Plasma LA Levels|Continuous Transversus Abdominis Plane Blocks for Patients Undergoing Major Abdominal Surgery: A Prospective, Controlled, Randomized, Double-blind Trial||University of Alberta|No|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||August 2015|August 11, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871168||65145|
NCT01871454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-RAD-13-Pentoxifylline|Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers|Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary NSCLC Using Stereotactic Ablative Radiotherapy in Patients Previously Treated With Thoracic Radiation||James Graham Brown Cancer Center|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01871454||65123|
NCT01871714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-014|Phenotypic Properties in Individuals Affected With XLHED|Phenotypic Properties in Individuals Affected With X-linked Hypohidrotic Ectodermal Dysplasia: Symptoms and Facial Recognition|ECP-014|Edimer Pharmaceuticals|No|Completed|May 2013|September 2013|Actual|July 2013|Actual|N/A|Observational|N/A||3|Actual|30|Samples With DNA|Genetic tests will be carried out in a subset of subject in order to confirm XLHED status.|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|XLHED affected males and females and unaffected female controls|November 2013|November 25, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01871714||65103|
NCT01865370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISFSP-HL-KOCHUJANG|Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects|||Chonbuk National University Hospital|Yes|Completed|November 2011|April 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 27, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865370||65590|
NCT01865383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1111|Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania|Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania||University of North Carolina, Chapel Hill|No|Active, not recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2623|||Both|15 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865383||65589|
NCT01861158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44DA026658-02A1|Online Parent Training for Children With Behavior Disorders|Online Parent Training for Children With Behavior Disorders: Phase II|PW2|Family Works Incorporated|No|Recruiting|September 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|450|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 7, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861158||65911|
NCT01861171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clinex01|Effect of Green Tea in Obese Pre-hypertensive Women|Effect of Green Tea on Adiposity, Metabolic Profile, Blood Pressure and Endothelial Function in Obese Pre-hypertensive Women||Rio de Janeiro State University|No|Completed|July 2010|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|28 Years|59 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861171||65910|
NCT01861457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nozin|Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic|Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer®||Medical University of South Carolina|No|Completed|January 2013|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|May 20, 2013|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01861457||65888|
NCT01862068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 10017|Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)|Neutrophils Function and Identification of Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis).|NeutroVasc|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2012|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|300|Samples Without DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|GPA (Granulomatosis with polyangiitis) patients and MPA ( Microscopic Polyangiitis) with        an active disease at inclusion|December 2015|December 21, 2015|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01862068||65841|
NCT01862419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817822|An Electronic Alert System for In-Hospital Acute Kidney Injury|An Electronic Alert System for In-Hospital Acute Kidney Injury: A Randomized, Controlled Trial||University of Pennsylvania|Yes|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2393|||Both|18 Years|N/A|No|||April 2014|March 13, 2015|May 16, 2013||No||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01862419||65815|
NCT01862406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSC-CEPSH-649-322600|The Impact of Generic Labels on Compliance|The Impact of Generic Labels on Consumption Dosage and Medication Compliance||Universidade Federal de Santa Catarina|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|101|||Both|18 Years|80 Years|No|||August 2013|August 7, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01862406||65816|
NCT01862666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_01|A Comparison of Volumetric Laser Endomicroscopy (VLE) and Endoscopic Mucosal Resection (EMR) in Patients With Barrett's Dysplasia or Intramucosal Adenocarcinoma|||NinePoint Medical|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Endoscopic Mucosal Resection (EMR). With this technique, the mucosa is resected by injecting      a liquid in the submucosal space, after which the thus created pseudopolyp can be resected      using a snare and electrocoagulation. The histological processing of the ex-vivo EMR      specimen will be carried out according to hospital standards|Both|18 Years|N/A|No|Non-Probability Sample|Patients with either suspected or confirmed Barrett's-associated dysplasia or intramucosal        adenocarcinoma presenting for endoscopy likely requiring EMR.|March 2014|June 17, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01862666||65797|
NCT01862679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12RE153|Randomised Study of High-flux Haemodialysis and Haemodiafiltration|Single Blind, Prospective, Randomised Comparative Study of High-flux Haemodialysis and Haemodiafiltration||NHS Greater Glasgow and Clyde|No|Recruiting|May 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|May 22, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862679||65796|
NCT01862692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD064870|Web-based Parenting Intervention for Mothers of Infants At-Risk for Maltreatment (Baby-Net)|Web-based Parenting Intervention for Mothers of Infants At-Risk for Maltreatment|Baby-Net|Oregon Research Institute|No|Completed|August 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01862692||65795|
NCT01863550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1A11|Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma||Eastern Cooperative Oncology Group||Recruiting|November 2013|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|756|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863550||65729|
NCT01862926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBHIPF004|Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD|A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease|RECITAL|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|November 2014|||November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|80 Years|No|||May 2015|May 6, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862926||65777|
NCT01863563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 4 September 2012|Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy|Hemostatic Control After Adenotonsillectomy- Open Label QuikClot Study.||Eastern Virginia Medical School|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|2 Years|17 Years|No|||August 2014|August 20, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01863563||65728|
NCT01863888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS13539|Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis|Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis|TERI-DYNAMIC|Sanofi|No|Completed|October 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863888||65703|
NCT01864122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8141|Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death||WHI|Tufts University|No|Completed|January 2007|||October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|2448|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Womens' Health Initiative Observational Study|May 2014|May 21, 2014|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01864122||65685|
NCT01864902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-006|Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33|Clinical Study of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Acute Myeloid Leukemias|CART33|Chinese PLA General Hospital|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|90 Years|No|||January 2016|January 26, 2016|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01864902||65625|
NCT01883349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13566|Cognitive Impairment and Imaging Correlates in End Stage Renal Disease|Cognitive Impairment and Imaging Correlates in End Stage Renal Disease||University of Kansas Medical Center|No|Recruiting|March 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|30 Years|70 Years|No|Non-Probability Sample|The study population will include patients from the renal transplant waiting list at        University of Kansas Medical Center. They will be tested before renal transplant and 3        months after renal transplantation.|August 2015|August 10, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01883349||64212|
NCT01883362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412AUS23|Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML|A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia|RADIUS|Novartis||Recruiting|February 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2016|March 20, 2016|March 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883362||64211|
NCT01864265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreCePRA|Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain|Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)|PreCePRA|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|July 2013|June 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864265||65674|
NCT01864525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370955-3|Effects of Octanoic Acid for Treatment of Essential Voice Tremor|||Syracuse University|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||April 2015|April 17, 2015|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864525||65654|
NCT01864798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB‐BCTL‐ 20119167|A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer|A Pre‐Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer|D-Beyond|Jules Bordet Institute|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864798||65633|
NCT01865058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLG-PET 10.06|The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.|The Use of 18 F-FDG Positron Emission Tomography (PET) in the Early Response Evaluation of Diffuse Large B-cell Lymphoma.||Odense University Hospital|No|Recruiting|June 2011|August 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosis of Diffuse Large B-cell lymphoma|May 2013|May 26, 2013|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01865058||65613|
NCT01865071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110026|Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer|Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer||Odense University Hospital|No|Recruiting|September 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01865071||65612|
NCT01861470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6650|REDEXAM - Reducing Painful Eye Examinations in Preterm Infants|Reducing Painful Eye Examinations in Preterm Infants|REDEXAM|Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|November 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples Without DNA|Urine|Both|N/A|56 Days|No|Probability Sample|Preterm infants <1500g or <32 weeks gestation|October 2015|October 7, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861470||65887|
NCT01861743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13020402|Multimodal Analgesia Versus Routine Care Pain Management|Multimodal Analgesia Versus Routine Care Pain Management for Minimally Invasive Spine Surgery: A Prospective Randomized Study|MMA|Rush University Medical Center|No|Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01861743||65866|
NCT01862055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 10010-NI09032|Acute Preoperative Stress and Hypotension After Spinal Anesthesia. SAS for "Salivary Amylase and Stress "|Effect of Acute Preoperative Stress Assessed With Salivary Amylase on the Severity of Maternal Hypotension After Spinal Anesthesia for Planned Cesarean Section|SAS|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|79|Samples Without DNA|Salivary samples|Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women undergoing planned cesarean section|March 2015|March 6, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01862055||65842|
NCT01862432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-097|Immediate Skin-to-skin Contact After C-section|Immediate Skin-to-skin Contact After Caesarean Delivery to Improve Neonatal|CALIN|Université de Sherbrooke|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01862432||65814|
NCT01862913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDECYT Nº11121637|Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression|Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression in Primary Care Clinics in Santiago, Chile (YPSA-M): A Randomized Controlled Trial|YPSA-M|University of Chile|No|Active, not recruiting|June 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|15 Years|19 Years|No|||October 2015|October 31, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862913||65778|
NCT01862952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/211|Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy|Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy|Video-EEG|University Hospital, Ghent|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01862952||65775|
NCT01862965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PredEver first|Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus|Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study -|PredEver first|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|October 2012|July 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01862965||65774|
NCT01862939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS7309-A-U101|A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus|A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862939||65776|
NCT01863264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460111-3|The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants|A Pilot Study on The Effects of Cold Liquids on the Pharyngeal Swallow in Preterm Infants With Dysphagia.||Winthrop University Hospital|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|N/A|43 Weeks|No|||December 2015|December 29, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863264||65751|
NCT01863901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0709|Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device|A Prospective, Non-Randomized, Unblinded Study Evaluating the Treatment With the Cryo-Touch III Device for Upper Limb Spasticity||MyoScience, Inc|No|Completed|April 2013|October 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863901||65702|
NCT01864356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-03|A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)|A Randomized, Double Blind, Multi-Center, Placebo Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Doses Of NT100 Following IVF In Women With A History Of Repeated IVF Failures (Thrive-IVF)|Thrive-IVF|Nora Therapeutics, Inc.|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Female|21 Years|38 Years|No|||November 2014|November 18, 2014|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864356||65667|
NCT01864369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 126118|Canadian e-Platform to Promote Behavioral Self-Management in Chronic Heart Failure: CHF-CePPORT|Canadian e-Platform to Promote Behavioral Self-Management in Chronic Heart Failure: CHF-CePPORT|CHF-CePPORT|University Health Network, Toronto|Yes|Recruiting|September 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|298|||Both|18 Years|N/A|No|||May 2013|June 18, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01864369||65666|
NCT01864616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCD-060|The Impact of Vitamin D on Disease Activity in Crohn's Disease|||University of Saskatchewan||Not yet recruiting|July 2013|||March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|16 Years|70 Years|No|||May 2013|May 24, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864616||65647|
NCT01864629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00061119|Optimizing Postpartum Contraception in Women With Preterm Births|Optimizing Postpartum Contraception in Women With Preterm Births||University of Utah|No|Active, not recruiting|April 2013|December 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|362|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01864629||65646|
NCT01864915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED 1578-13 HOOKEY|Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule|Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule||Queen's University|Yes|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|60|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01864915||65624|
NCT01883700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-028|Acute Vascular Response To Meals Varying In Glycemic Index And Glycemic Load|Variability of Acute Response to Equicaloric Test Meals Varying in Glycemic Index and Glycemic Load on Postprandial Glycemia, Arterial Stiffness and Blood Pressure in Healthy Adults|HILO|St. Michael's Hospital, Toronto|No|Active, not recruiting|August 2010|September 2013|Anticipated|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01883700||64185|
NCT01864044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC07|Prospective Observational Lymphoedema Intensive Treatment||POLIT|Thuasne||Completed|September 2009|||March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|306|||Both|18 Years|N/A|No|Probability Sample|All consecutive adult patients hospitalized with a clinical diagnosis of unilateral stage        II-III upper or lower limb lymphoedema of any etiology and an indication for intensive        decongestive therapy (IDT) were enrolled.|May 2013|May 23, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01864044||65691|
NCT01864278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0004-01|Lutonix Global SFA Registry|A Prospective, Global Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the LUTONIX Drug Coated PTA Dilatation Catheter||C. R. Bard|No|Active, not recruiting|December 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|691|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital patients (global registry)|November 2015|November 23, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864278|2 Years|65673|
NCT01864538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-413|A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma|A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma||Threshold Pharmaceuticals|No|Active, not recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864538||65653|
NCT01864811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFO-V4072/2012|Effect of Baby-CIMT in Infants Younger Than 12 Months|The Efficacy of Constraint Induced Movement Therapy for Babies (Baby-CIMT) in Infants Below 12 Month With Risk of Developing Unilateral Cerebral Palsy, a Study Protocol of a Randomized Controlled Trial|B-CIMT|Karolinska Institutet|No|Completed|September 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|3 Months|8 Months|No|||March 2016|March 7, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864811||65632|
NCT01860859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-03-204|Suture of UTerus and Ultrasound Repair Evaluation|Randomized Controlled Trial Comparing Three Techniques of Uterine Closure on the Myometrium Thickness Evaluated With Ultrasound Six Months After a Primary Cesarean|SUTURE|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|81|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01860859||65934|
NCT01861483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1205|Vessel Resection and Reconstruction of Biliary Tract Cancers|Resection and Reconstruction of Major Vessels in Biliary Tract Cancers||Kansai Hepatobiliary Oncology Group|Yes|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|All patients who underwent vessel resection and reconstruction in biliary tract cancer        after 1990 will be included for analysis.|June 2014|June 29, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01861483||65886|
NCT01861496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiPlaCis/P1/002|Phase I Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours|Phase I Dose-escalating Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours|LiPlaCis|LiPlasome Pharma|Yes|Recruiting|April 2013|June 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01861496||65885|
NCT01861756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTH87963|The Diabetes Medication Choice Cards Trial in Greece|The Diabetes Medication Choice Cards Trial in Greece||Aristotle University Of Thessaloniki||Completed|May 2013|August 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|204|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861756||65865|
NCT01861769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 2011-03-01|Implementation of Evidence-based Psychotherapy for PTSD|Implementation of Evidence-based Psychotherapy for PTSD: An Empirical Investigation of Post-workshop Consultation in Treatment Fidelity and Patient Outcomes||Ryerson University|No|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861769||65864|
NCT01862445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC1013|Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients|A Retrospective Study to Assess the Efficacy and Safety of Chlorambucil Plus Rituximab as Front-line Therapy in Elderly and/or Unfit Patients Affected by B-cell Chronic Lymphocytic Leukemia||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The GIMEMA Chronic Lymphocytic Leukemia Working Party promotes an observational,        retrospective, multicenter study on safety and efficacy of Chl-R administered front-line        to treat elderly and/or unfit pts affected by B-CLL.|February 2015|February 23, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01862445||65813|
NCT01862705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|449272-1|Using fMRI to Determine if Cerebral Hemodynamic Responses to Pain Change Following Thoracic Spine Manipulation in Individuals With Mechanical Neck Pain|Using fMRI to Determine if Cerebral Hemodynamic Responses to Pain Change Following Thoracic Spine Manipulation in Individuals With Mechanical Neck Pain||OSF Healthcare System|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|24|||Both|18 Years|60 Years|No|||May 2015|May 12, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01862705||65794|
NCT01862718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130079|Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms|Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms||National Institutes of Health Clinical Center (CC)||Recruiting|February 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|84 Years|No|||December 2015|February 5, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862718||65793|
NCT01863277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0130-12|Safety Study of Melatonin in Stroke Patients|A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.||Wolfson Medical Center|No|Not yet recruiting|July 2013|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||April 2013|May 24, 2013|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863277||65750|
NCT01864161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIANCA79|Endovenous Versus Liposomal Iron in CKD|||Federico II University|Yes|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2013|July 23, 2014|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01864161||65682|
NCT01864148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215MS201|Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex|SYNERGY|Biogen|Yes|Active, not recruiting|August 2013|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|419|||Both|18 Years|58 Years|No|||January 2016|January 7, 2016|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864148||65683|
NCT01864642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW IRB 2012-1102|Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects|A Study of the Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP)in Un-medicated Confirmed Ocular Hypertensive (OHT) or Glaucoma Suspect Subjects|OMT4OHT|University of Wisconsin, Madison|No|Completed|July 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|90 Years|No|||August 2014|August 14, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01864642||65645|
NCT01864655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH2TR000967-01|Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease|A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease||Yale University|Yes|Completed|July 2013|||March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|50 Years|90 Years|No|||June 2014|June 12, 2014|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864655||65644|
NCT01864668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130519|the Influence of Tidal Volume to Lung Strain|the Influence of Different Tidal Volume to Lung Strain of ARDS Patients||Zhongda Hospital|No|Recruiting|June 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|85 Years|No|Probability Sample|Critical patients diagnosed with acute respiratory distress syndrome|May 2013|February 8, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864668||65643|
NCT01884987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRN2013|Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study|Phase II Study of Monosialotetrahexosylganglioside for Cerebral Radiation Necrosis||Fudan University|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients must have undergone definitive RT for histologically confirmed NPC years before.        They were required to have at least two consecutive magnetic resonance imaging (MRI) study        supporting the diagnosis of CRN with an interval of 3-4 months, with the second MRI        showing progressive disease compared with the first MRI. The necrotic mass shown on MRI        must be measured in two dimensions in order to define the response to treatment. Other        radiologic studies were also required to support the non-existence of local or regional        recurrence, distant metastasis. Patients must have undergone mental status examinations        and had progressive neurologic symptoms or signs. In addition, they were required to have        a Karnofsky performance status of at least 70 and were supposed to live more than 6        months.|January 2014|January 6, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884987|1 Year|64086|
NCT01863784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101336|A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function|An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function||Janssen Research & Development, LLC|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863784||65711|
NCT01863797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2007/65-31/2|Trial on Early Induction Versus Expectant Management of Nulliparous Women With a Prolonged Latent Phase|||Karolinska Institutet||Completed|June 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Female|16 Years|45 Years|No|||May 2013|May 23, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01863797||65710|
NCT01863810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW21052_P3|Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain|Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain||KunWha Pharmaceutical Co., Ltd.|No|Not yet recruiting|August 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|394|||Both|20 Years|N/A|No|||May 2013|May 28, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863810||65709|
NCT01864824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21ES021895-01|Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial|Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial|EPI-Air|Harvard School of Public Health|Yes|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01864824||65631|
NCT01865084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15122|A Study of Tadalafil for Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy||Eli Lilly and Company|Yes|Terminated|September 2013|March 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|227|||Male|7 Years|14 Years|No|||February 2016|February 25, 2016|May 24, 2013|Yes|Yes|The study is being terminated for lack of efficacy|No||https://clinicaltrials.gov/show/NCT01865084||65611|
NCT01865097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0494-12|Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease|Pilot Study of Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease||Rambam Health Care Campus|No|Enrolling by invitation|June 2013|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|N/A|No|||November 2014|November 5, 2014|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01865097||65610|
NCT01860872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-CF MRI|Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)|Study of Cardiac MRI to Assess Pulmonary Perfusion and Pulmonary Hemodynamics in Patients With Cystic Fibrosis Study (Pilot 3)||Children's Hospital Medical Center, Cincinnati|No|Recruiting|April 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|Samples With DNA|serum|Both|5 Years|60 Years|No|Non-Probability Sample|Cystic Fibrosis and Non-CF Controls|September 2015|September 25, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01860872||65933|
NCT01861184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100090090|Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)|A Study of Pneumococcal Carriage in Hospitalised Patients With Lower Respiratory Tract Infections||Royal Liverpool and Broadgreen University Hospitals NHS Trust|Yes|Completed|January 2013|November 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|Samples With DNA|Blood samples Nasal wash samples Nasopharyngeal swabs (where nasal wash not possible) Urine      samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the hospital with Lower Respiratory Tract Infection|May 2013|May 8, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861184||65909|
NCT01861197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-09-070-002|Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer|||Samsung Medical Center|No|Recruiting|March 2013|||January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|20 Years|N/A|No|||May 2013|May 22, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861197||65908|
NCT01861782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor0356-12ctil|Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With RA|Comparison Between Dead Sea Solar and Water Treatment to "Sulfur Pool" and Medicinal Mud Treatment in Patients With Rheumatoid Arthritis||Soroka University Medical Center|No|Active, not recruiting|June 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|May 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01861782||65863|
NCT01862081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27802|A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer|||Genentech, Inc.||Recruiting|July 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|196|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01862081||65840|
NCT01863290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301011280|Linking Former Inmates to Primary Care|Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care||Yale University|No|Recruiting|May 2013|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Former inmates; released from state or federal prisons.|January 2016|January 6, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863290||65749|
NCT01863303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R201206DCAPC|Epidemiological Study of Colorectal Cancer in WuHan|Epidemiological Study of Colorectal Cancer in WuHan||Wuhan Pu-Ai Hospital|Yes|Active, not recruiting|June 2012|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|Samples With DNA|Blood sample or neoplasm from high risk group|Both|40 Years|74 Years|No|Non-Probability Sample|Coulp of this study from a chemical industry Zone of Wuhan with a long history,seriously        polluted environment， which has few data of CRC epidemiology.        HanYang Areo has been choosen as Control for its non-industry environment|May 2013|May 24, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863303||65748|
NCT01863576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037.0.009.000-10|Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy|Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy: a Randomized Controlled Clinical Trial||Evandro Chagas Institute of Clinical Research|No|Recruiting|March 2013|April 2014|Anticipated|January 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|85 Years|No|||May 2013|May 23, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863576||65727|
NCT01863589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112299|Drug Use Investigation for HEPSERA (Adefovir) Tablet|Drug Use Investigation for HEPSERA (Adefovir) Tablet||GlaxoSmithKline||Completed|February 2005|July 2012|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|436|||Both|N/A|N/A|No|Probability Sample|Subjects with chronic hepatitis B or hepatic cirrhosis B who are confirmed of hepatic        function abnormality with continuous re-proliferation of hepatitis B virus while treated        with lamivudine|May 2013|May 23, 2013|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01863589||65726|
NCT01863602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112728|Special Drug Use Investigation for LAMICTAL® (Long Term)|Special Drug Use Investigation for LAMICTAL (Long Term)||GlaxoSmithKline||Active, not recruiting|April 2009|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|Adult (>=15 to <65 years) and pediatric (>=2 to <15 years) subjects with epilepsy with the        following seizure type who use lamotrigine tablets          -  Partial seizures          -  Tonic-clonic seizures          -  Generalized seizures of Lennox-Gastaut syndrome|August 2015|August 10, 2015|October 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01863602||65725|
NCT01863615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116615|Bioequivalence Study for an Isotretinoin|Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Crossover, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences With Meal (Breakfast) Study||GlaxoSmithKline||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01863615||65724|
NCT01863914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-2314-B-006-045|Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula|Effect of Rosuvastatin in the Mobilization of Endothelial Progenitor Cells and Graft Vascular Function Following Creation of Arteriovenous Fistula in Diabetic Patients With Chronic Renal Failure||National Cheng-Kung University Hospital|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 25, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01863914||65701|
NCT01864421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13023|Physiological Effects of Deferred Cord Clamping|Delivery Room and Postnatal Assessment of the Physiological Effects of Deferred Cord Clamping on the Newborn: A Feasibility Study|DoppCord|University of Nottingham|No|Recruiting|May 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Umbilical Cord and Blood|Both|N/A|24 Hours|No|Non-Probability Sample|The study will recruit babies born at or after 32 weeks with no antenatal or perinatal        risk factors that may necessitate the need for resuscitation beyond normal thermal        management in the delivery room.|February 2016|February 25, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864421||65662|
NCT01864681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012XLC07|Combination of Metformin With Gefitinib to Treat NSCLC|A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer|CGMT|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Active, not recruiting|May 2013|July 2017|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|75 Years|No|||January 2016|January 30, 2016|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01864681||65642|
NCT01864694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL081380|Improving Dietary Behavior Through Tailored Messages|Improving Dietary Behavior Through Tailored Messages||Boston Medical Center|No|Completed|November 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1224|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01864694||65641|
NCT01884233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA033196|Cell Phone Technology Targeting ART Adherence and Drug Use|Cell Phone Technology Targeting ART Adherence and Drug Use|TXT-CBT|University of California, Los Angeles|Yes|Active, not recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01884233||64144|
NCT01864291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-028H|Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects|Study of the Nucleus 24 Auditory Brainstem Implant in Pediatric Non-Neurofibromatosis Type 2|ABI|Massachusetts Eye and Ear Infirmary|Yes|Recruiting|May 2013|November 2022|Anticipated|November 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Months|17 Years|No|||October 2015|October 15, 2015|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864291||65672|
NCT01865110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL R2 Elderly|R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL|Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma||The Lymphoma Academic Research Organisation|Yes|Recruiting|November 2013|March 2024|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|633|||Both|60 Years|N/A|No|||November 2015|November 12, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865110||65609|
NCT01860885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN1-2012-1219|Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure|Study of Hospital-wide Critical Respiratory Events Requiring Naloxone in a Pediatric Institution||Children's Hospital Medical Center, Cincinnati|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|95|||Both|N/A|N/A|No|Non-Probability Sample|All patients who required rescue with naloxone between June 2006 and June 2012; identified        based upon an automated trigger report generated from the hospital's risk management        database for any dispensation of naloxone from the hospital pharmacy|May 2013|May 21, 2013|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01860885||65932|
NCT01860898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005334|A Phase I Study of iPS Cell Generation From Patients With COPD|A Phase I Study of iPS Cell Generation From Patients With COPD||Mayo Clinic|No|Active, not recruiting|September 2009|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860898||65931|
NCT01861210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00043714|Couples HIV Counseling and Testing for Male Couples in the United States|Couples HIV Counseling and Testing for Male Couples in the United States|CVCT|Emory University|No|Completed|September 2010|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|216|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861210||65907|
NCT01861509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC 2012-4|BP-C1 in Metastatic Breast Cancer Patients|Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer: A Phase I(D) Study||Meabco A/S|Yes|Recruiting|June 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Female|18 Years|80 Years|No|||November 2014|November 17, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01861509||65884|
NCT01861795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-7261-201-RD|Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Invasive Ventilatory Support|An Oligo-center Observational Study to Collect Data in Preterm Neonates Born at or Above 27+0 Weeks of Gestational Age Who Are Sufficiently Stable on Non-Invasive Ventilatory Support||Takeda|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|27 Weeks|36 Weeks|No|Non-Probability Sample|Preterm neonates on non-invasive ventilatory support in a hospital setting.|August 2014|August 20, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01861795||65862|
NCT01862107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130140|Cerebrospinal Fluid Collection and Repository Storage|Cerebrospinal Fluid Collection and Repository Storage||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|April 2063|Anticipated|July 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|2 Years|100 Years|No|||February 2016|March 10, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862107||65839|
NCT01863004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYSF001A1|Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin|Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin|Dysferlin|University Hospital, Basel, Switzerland|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01863004||65771|
NCT01863654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117012|Bioequivalence Study of Montelukast 5 mg Chewable|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations of Chewable Tablets of Montelukast 5 mg (Product of GlaxoSmithKline México, S.A. de C.V. vs. Singulair™, Merck Sharp & Dohme de México, S.A. de C.V.) in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863654||65721|
NCT01863667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-027|A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)|A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication||Merck Sharp & Dohme Corp.|Yes|Terminated|July 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 23, 2013|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01863667||65720|The study was terminated based on business decisions only, and not due to any unexpected safety or efficacy concerns.
NCT01863628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120508|Recognition and Early Intervention on Prodrome in Bipolar Disorders|Recognition and Early Intervention on Prodrome in Bipolar Disorders: a Longitudinal Prospective Study of the Offspring of Parents With Bipolar Disorder||Guangzhou Psychiatric Hospital|Yes|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|10 Years|25 Years|No|||March 2015|March 14, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01863628||65723|
NCT01863641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1910354604|The Effect of Calcitriol on Progress and Activity of Lupus Nephritis|The Effect of Calcitriol on Progress and Activity of Lupus Nephritis||Guilan University of Medical Sciences|Yes|Recruiting|April 2013|April 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||May 2013|May 28, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01863641||65722|
NCT01864174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-206|Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes|A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adults Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||Bristol-Myers Squibb|No|Active, not recruiting|June 2013|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|553|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864174||65681|
NCT01864408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0332|Interactive Web-Based Tool for Pelvic Organ Prolapse: Impact on Patient Understanding and Provider Counseling|Interactive Patient and Provider Counseling on Pelvic Organ Prolapse: Do Patients Better Understand and Do Providers Better Counsel|iPad|University of North Carolina, Chapel Hill|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 23, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01864408||65663|
NCT01864434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130180/2012017|In Vivo Kinematics Comparison of Stryker or Zimmer Total Knee Arthroplasty|In Vivo Comparison of Kinematics for Patients Implanted With Either a Stryker or a Zimmer Posterior Cruciate Retaining Total Knee Arthroplasty||The University of Tennessee Knoxville|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|50|||Both|40 Years|70 Years|No|Non-Probability Sample|Participants will be patients of Dr. Harold E. Cates of Tennessee Orthopaedic Clinics and        must have been implanted with either a Stryker Triathlon CR TKA or Zimmer PCR TKA|May 2015|May 22, 2015|May 16, 2013||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01864434||65661|
NCT01864707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-Fatigue-13|Acupuncture or MBSR for Patients With Fatigue and MS|Randomized Controlled Trial on the Efficacy of Acupuncture and the Efficacy of Mindfulness-Based Stress Reduction (MBSR) in Patients With Multiple Sclerosis Suffering From Fatigue|MS-Fatigue|Charite University, Berlin, Germany|No|Completed|April 2013|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01864707||65640|
NCT01864954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA140310-01A2|Web and Phone Intervention to Maintain Postpartum Tobacco Abstinence|Web and Phone Intervention to Maintain Postpartum Tobacco Abstinence|StayQuit|Oregon Research Institute|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|62|||Female|18 Years|60 Years|No|||September 2015|September 29, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01864954||65621|
NCT01864382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-FIS-2012-04|"Core Stability" Exercises to Improve Sitting Balance in Stroke Patients|Effects of the Inclusion of Exercises "Core Stability" in the Treatment of Inpatient Physiotherapy to Improve Balance in Post-stroke Patients Sitting in Subacute Phase. Randomized Clinical Trial.|Fisionet|Universitat Internacional de Catalunya|Yes|Completed|October 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2014|September 15, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864382||65665|
NCT01864395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-143|Clinical and Chemical Outcomes Following Cardiac Surgery: The Post-Operative Effects of MUF|Clinical and Chemical Outcomes Following Cardiac Surgery: The Post-Operative Effects of Modified Ultrafiltration (On-line MUF) and Off-line (MUF)|MUF|University of Saskatchewan|No|Not yet recruiting|July 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|80 Years|No|||May 2013|May 22, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01864395||65664|
NCT01864928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28677|Rapid Evaluation for Stroke Outcomes Using Lytics in Vascular Event (RESOLVE) Registry and Implementation Quality Improvement Study|Reperfusion in Acute Stroke - Creating the Clinical Decision-Making Tool (RESOLVE)|RESOLVE|Saint Luke's Health System|No|Enrolling by invitation|July 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients|November 2015|November 16, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01864928|90 Days|65623|
NCT01864941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01153|Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients|Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients||University of British Columbia|Yes|Active, not recruiting|May 2013|May 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2015|August 7, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01864941||65622|
NCT01878110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC COMB Pilot Study|Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania|Treatment Development Study of the COMB Model of Trichotillomania||American University||Completed|January 2013|||January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01878110||64614|
NCT01878123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-110-01|Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis|A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis||Amplimmune||Completed|April 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|No|||August 2014|August 12, 2014|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01878123||64613|
NCT01864837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMCIRB-2013-01|Evaluation on the Availability of Tongue Diagnosis System|Availability of Tongue Diagnosis System for Assessing Tongue Coating Thickness of Patients With Functional Dyspepsia: Study Protocol for Comparative Trial With Conventional Method||Korea Health Industry Development Institute|No|Recruiting|February 2013|November 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|60 patients with functional dyspepsia which be considered to appear the various aspects of        tongue coating in traditional Korean medicine(TKM).|May 2013|May 24, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864837||65630|
NCT01865123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT110413|A RCT of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans|A Randomized Controlled Trial of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans||United States Department of Defense|Yes|Recruiting|June 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865123||65608|
NCT01865136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC 1|Post-abortion Care and Contraceptive Counselling by Midwives or Physicians|Post-abortion Care and Contraceptive Counselling by Midwives or Physicians - a Randomized Controlled Trial in Kisumu, Western Kenya||Karolinska Institutet|Yes|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|979|||Female|15 Years|60 Years|No|||February 2016|February 22, 2016|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01865136||65607|
NCT01860911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005173|Plasma Triglyceride Extraction by The Muscle|Regulation of the Plasma Triglyceride Extraction in Muscle in Insulin Resistance||Mayo Clinic|No|Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01860911||65930|
NCT01861223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11-087-007|Afatinib Plus Nimotuzumb for NSCLC|A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI||Samsung Medical Center|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|N/A|No|||February 2014|February 23, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861223||65906|
NCT01861236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000036|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina|FAST AR|Ferring Pharmaceuticals|No|Active, not recruiting|March 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Male|18 Years|100 Years|No|Non-Probability Sample|200 patients with Advanced Prostate Cancer that receive Firmagon therapy in the context of        usual clinical practice|October 2015|October 29, 2015|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01861236|3 Years|65905|
NCT01861522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-284-20|The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|473|||Both|7 Years|15 Years|No|||November 2015|November 10, 2015|May 19, 2013||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01861522||65883|
NCT01861821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-158|Analgesic Efficacy of a Multiport Versus Uniport Flexible Catheter for Labor Epidural Analgesia|Prospective, Controlled, Randomized, Blinded, Single-center Study of the Clinical Efficacy and Outcomes of a Multiport Versus Uniport Flexible Catheter for Epidural Analgesia During Labor and Delivery||Baylor Research Institute|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|650|||Female|18 Years|45 Years|No|||August 2015|August 5, 2015|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861821||65860|
NCT01862120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101106|Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes|Induction of Regulatory T Cells for the Treatment of Recently Diagnosed Type 1 Diabetes: Dose Finding Study of the Lowest Active Dose of IL-2 in Children|DFIL2-Child|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2013|March 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|24|||Both|7 Years|14 Years|No|||September 2015|September 21, 2015|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01862120||65838|
NCT01862978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTSVKNEUROL001|Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke|Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke|Heparinas|University Hospital, Martin|No|Recruiting|May 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||August 2013|August 14, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862978||65773|
NCT01863316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0023|The Comparison of the Clinical Efficacy Between I-gel and LMA-Supreme, the Two Most Recently Developed Supraglottic Airway Devices, in Infants|||Yonsei University||Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|N/A|1 Year|No|||May 2013|May 22, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863316||65747|
NCT01863329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0006|Comparison of Optic Nerve Sheath Diameter on Retrobulbar Ultrasound Before and After Drainage of Cerebrospinal Fluid in Patient With Hydrocephalus|||Yonsei University|No|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|38|||Both|20 Years|N/A|No|Non-Probability Sample|patient with hydrocephalus|May 2013|May 24, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863329||65746|
NCT01863342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0127|Influence of Central Sensitization on Efficacy of Patient-controlled Epidural Analgesia in Osteoarthritis Patients Undergoing Total Knee Replacement|||Yonsei University|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|98|||Both|20 Years|80 Years|No|Non-Probability Sample|osteoarthritis patients undergoing total knee replacement|May 2013|May 22, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863342||65745|
NCT01863355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0176|Comparison of Analgesic Efficacy and Occurrence of Emesis Among Different Background Infusion and Bolus Administration Regimens of Fentanyl Based Intravenous Patient-controlled Analgesia in Patients After Laparoscopic Assisted Gastrectomy - a Randomized Blind Study -|||Yonsei University|No|Recruiting|May 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|20 Years|70 Years|No|||May 2013|May 22, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863355||65744|
NCT01863927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9726-AD-CTIL|The Effect of Ventilated Vest on Thermoregulation During Exercise in Hot Environment|The Effect of Ventilated Vest on Thermoregulation During Exercise in Hot||Sheba Medical Center|No|Not yet recruiting|November 2014|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Male|21 Years|28 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863927||65700|
NCT01864187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morbid Obesity|Pharmacokinetics of Dexmedetomidine in Morbid Obesity|A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01864187||65680|
NCT01864200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTG-PR005-002|Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation|A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® Versus Placebo With Rescue Treatment for Copperhead Snake Envenomation|Copperhead RCT|BTG International Inc.|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|12 Years|N/A|No|||March 2016|March 21, 2016|May 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01864200||65679|
NCT01864447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS M13-219|Exercise Training After an Acute Blood Clot|An Exercise Training and Behavioral Weight Loss Program After an Acute Blood Clot: TRAIN ABC|TRAIN ABC|University of Vermont|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|79 Years|No|||December 2014|December 3, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01864447||65660|
NCT01864720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC103664|Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients|A Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients : Efficacy and Cost-Effectiveness.|Stepped Care|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|September 2013|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864720||65639|
NCT01864967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-001|Carbon Dioxide Infusion:Clinical and Histological Appraisal in Chronic Wounds|Carbon Dioxide Infusion:Clinical and Histological Appraisal in Chronic Wounds||Institute of Assistance in Plastic Surgery, Sao Paulo|No|Completed|March 2007|August 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|10|||Both|49 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|10 patients with chronic wounds on both lower limbs|January 2013|May 23, 2013|November 23, 2008||No||No||https://clinicaltrials.gov/show/NCT01864967||65620|
NCT01864980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bleeding SpHb-001|Intra-operative Monitoring of Blood Loss|Monitoring of Intraoperative Blood Loss: Benefit of Continuous Noninvasive Haemoglobin Monitoring?||University Medical Center Groningen|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|No|Probability Sample|30 adult patients scheduled for surgery associated with undetected, i.e., difficult to        reliably monitor intraoperative blood loss|May 2015|May 26, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864980||65619|
NCT01865292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1719|Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes|A Randomised, Double-Blind, Single Dose, Six-Period Cross-over Dose Response Trial Comparing the Pharmacodynamics and Pharmacokinetics of Insulin 454 With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes||Novo Nordisk A/S|No|Completed|August 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|69 Years|No|||October 2015|October 16, 2015|May 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865292||65596|
NCT01874587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-RdC-ORL-Th|Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma|Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia|ARTIX|Center Eugene Marquis|Yes|Recruiting|July 2013|January 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01874587||64883|
NCT01864850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC ELAN-RT|Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC|Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma|GORTEC-ELAN-RT|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Recruiting|June 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|70 Years|N/A|No|||March 2015|March 23, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864850||65629|
NCT01865162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maes 002|Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study|Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study|KGDinGBM|Mid-Atlantic Epilepsy and Sleep Center, LLC|No|Recruiting|January 2013|May 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865162||65605|
NCT01860924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006106|Vigorous Exercise for Depressed Smokers|Supervised, Vigorous Intensity Exercise Intervention for Depressed Female Smokers||Mayo Clinic|No|Completed|May 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860924||65929|
NCT01860937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-052|T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia|A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia||Memorial Sloan Kettering Cancer Center||Recruiting|May 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|26 Years|No|||February 2016|February 8, 2016|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01860937||65928|
NCT01861249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS12593|Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)|A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)||Sanofi|Yes|Terminated|July 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|May 21, 2013|Yes|Yes|The study was early terminated due to slow recruitment. Not linked to any safety concern.|No||https://clinicaltrials.gov/show/NCT01861249||65904|
NCT01861535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI293|Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia|Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia|PITVIN|Medical University of Graz|Yes|Recruiting|June 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|90 Years|No|||January 2016|January 12, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861535||65882|
NCT01861808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2315118|Prognostic Value of Biochemical Markers in Cerebrospinal Fluid for Functional Outcome of Spinal Cord Injured Patients|Investigation on the Prognostic Value of Biochemical Markers in the Cerebrospinal Fluid for the Functional Outcome of Spinal Cord Injured Patients||Azienda Usl di Bologna|No|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2015|March 2, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01861808||65861|
NCT01862458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12120552|Empyema Treated With tPA & DNAse|Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema||Children's Mercy Hospital Kansas City|No|Withdrawn|January 2016|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|17 Years|No|||January 2016|January 27, 2016|May 17, 2013|Yes|Yes|funding difficulty|No||https://clinicaltrials.gov/show/NCT01862458||65812|
NCT01862471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-NMES-DVT-012|Neuromuscular Electrical Stimulation Versus Intermittent Pneumatic Compression for Blood Flow|Improved Lower Limb Haemodynamics Using Neuromuscular Electrical Stimulation (NMES); Potential Novel DVT Prophylaxis||National University of Ireland, Galway, Ireland|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862471||65811|
NCT01862991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05132013-108659|Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services|Protocol Title: Reducing Complications and Patient Barriers in Second Trimester Abortion: Pre-Operative Effects of Mifepristone (POEM) on Dilatation and Evacuation Services|POEM|Stanford University|Yes|Active, not recruiting|July 2013|February 2017|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|102|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862991||65772|
NCT01863381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMST02802|Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement|Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement: Continuous Intracranial Pressure Monitoring Subprotocol||LifeBridge Health|No|Completed|September 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863381||65742|
NCT01863394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUAC À L'ÉCHELLE|Evaluation of Two Community Based Screening Strategies for Severe Acute Malnutrition in Children 6-59 Months in Mirria District, Niger|Evaluation of Two Community Based Screening Strategies for Severe Acute Malnutrition in Children Aged 6-59 Months in the Mirria District, Niger|MàLÉ|Alliance for International Medical Action|Yes|Completed|May 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|4429|||Both|6 Months|59 Months|No|||July 2014|July 14, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01863394||65741|
NCT01863680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200113_001|Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel|Open-label, Single-arm, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of COL-1620 8% Vaginal Progesterone Gel for Luteal Phase Support in In-vitro Fertilization and Embryo Transfer (IVF/ET) Cycles in Japanese Women||Merck KGaA|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Female|20 Years|45 Years|No|||November 2015|November 16, 2015|May 23, 2013||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01863680||65719|This study was not a randomized controlled study and did not included an active control arm, however it was designed to allow for comparison with historical IVF-ET data from Japan.
NCT01863693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28570|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)|AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER||Hoffmann-La Roche||Active, not recruiting|May 2013|August 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Female|18 Years|N/A|No|Probability Sample|Patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube,        or primary peritoneal cancer undergoing first-line treatment with chemotherapy and Avastin|March 2016|March 1, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863693||65718|
NCT01864213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00771|Efficacy of Ametop Cream in Reducing Pain of Local Anesthetic Infiltration|The Efficacy of Topical Amethocaine Gel in Reducing the Pain of Local Anesthetic Infiltration Prior to Neuraxial Anesthesia in Non-labouring Pregnant Women: A Randomized Controlled Trial|Ametop|University of British Columbia|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|78|||Female|19 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01864213||65678|
NCT01863966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-AchaWater|Hot Water Drinking Therapy in Achalasia|Efficacy and Safety Study of Hot Water Drinking Therapy in Achalasia Patients|AHW|Peking Union Medical College Hospital|Yes|Recruiting|March 2010|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2013|May 23, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01863966||65697|
NCT01864226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28845|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.||Hoffmann-La Roche||Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|44|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01864226||65677|
NCT01864460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1030-R|Improving Autonomic Function and Balance in Diabetic Neuropathy|Improving Autonomic Function and Balance in Diabetic Neuropathy|IMABIN|VA Office of Research and Development|No|Recruiting|November 2013|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Male|30 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01864460||65659|
NCT01864473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Management of Vaginal Fistula by Kshar Sutra, a Minimally Invasive Treatment|Single Case Study of Vaginal Fistula Managed by Kshar Sutra, a Minimal Invasive Treatment.|Bhagandar|Government Ayurved College and Hospital|No|Completed|October 2010|January 2013|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|42 Years|42 Years|Accepts Healthy Volunteers|||June 2013|June 1, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01864473||65658|
NCT01864733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0152|Multimodal Approach of Undernutrition in Chronic Heart Failure|Multimodal Approach of Undernutrition in Chronic Heart Failure : a Controlled, Randomized Trial|NUTRICARD|University Hospital, Clermont-Ferrand||Not yet recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01864733||65638|
NCT01864993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1876/2012|Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity|Glutox Trial. Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity: a Double Blind Crossover Controlled Trial|Glutox|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|March 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|150|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01864993||65618|
NCT01865305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1738|Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes|A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix® 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|September 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|59|||Male|18 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|May 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865305||65595|
NCT01886417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906|Auditory Verbal Hallucinations in Schizophrenia|Electromyography Study of Lip Muscles During Auditory Verbal Hallucinations Without Subvocalization in Patients With Schizophrenia|HAV|University Hospital, Grenoble|No|Completed|October 2009|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|in- and out-patients|March 2015|March 9, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886417||63976|
NCT01864876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA-0784|The Effects of GLA (5 mcg) on Human Volunteers|A Randomized, Single-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Single Administration of 5 mcg GLA in Healthy Volunteers||IDRI|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|May 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01864876||65627|
NCT01865149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0022|Comparison of Optic Nerve Sheath Diameter on Retrobulbar Ultrasonography Before and After Drainage of Cerebrospinal Fluid in Pediatric Patient With Hydrocephalus|||Yonsei University|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|38|||Both|1 Year|19 Years|No|Non-Probability Sample|patient with hydrocephalus|May 2013|May 26, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01865149||65606|
NCT01865175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP ASF1|A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron|A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron||Milton S. Hershey Medical Center|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|May 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865175||65604|
NCT01865188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2320|Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension|An 8-week Randomized, Double-blind, Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Essential Hypertension||Novartis|Yes|Withdrawn|April 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865188||65603|
NCT01860950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019694|Effects of Transcranial Direct Current Stimulation on Pain Perception|Effects of Transcranial Direct Current Stimulation on Pain Perception|tDCS-CBT|Medical University of South Carolina|No|Recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|240|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860950||65927|
NCT01860963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW-16467|Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls|Prevalence of Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls|ADIBD|Stanford University|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|310|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01860963||65926|
NCT01861834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND107300|Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage|A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage||Georgetown University||Available||||||N/A|Expanded Access|N/A|||||||Both|2 Months|18 Years||||January 2014|November 11, 2015|May 22, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01861834||65859|
NCT01861847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2905|7-Keto DHEA for the Treatment of PTSD|7-Keto DHEA for the Treatment of PTSD||Humanetics Corporation|Yes|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|64 Years|No|||October 2015|October 7, 2015|May 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861847||65858|
NCT01862133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDA# 93.719|Aspiring to Awesome- Patient Preference Privacy Selections in EMR|Aspiring to Awesome- Patient Preference Privacy Selections in EMR||Indiana University|No|Completed|August 2013|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|April 2015|April 10, 2015|May 15, 2013||No||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01862133||65837|We could not separate the anonymous post-study provider survey results and comments by provider type because the numbers within the physicians and nurses were sufficiently small that anonymity could have been lost.
NCT01862146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCA INJURY|Arterial Remodeling in Smokers|Response-to-injury in Patients Undergoing Transradial Coronary Angiography: Arterial Remodeling in Smokers|TCA|Heinrich-Heine University, Duesseldorf|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|all subjects who underwent an TCA (trans radial catheterisation)|June 2014|June 3, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862146||65836|
NCT01862497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052012-029|Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension|Mechanism of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension and Hemodialysis Controls: A Case Control Study and Crossover Trial Comparing Carvedilol and Prazosin Hydrochloride||University of Texas Southwestern Medical Center|No|Recruiting|January 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||December 2014|December 2, 2014|May 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862497||65809|
NCT01863017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13155|Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome|Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation- Induced Modulation of Hyperphagia in Prader-Willi Syndrome||University of Kansas Medical Center|No|Recruiting|April 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01863017||65770|
NCT01863030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phasix|A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery|A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery||University of Kentucky|Yes|Active, not recruiting|May 2013|August 2016|Anticipated|August 2015|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patents with ventral hernias that meet eligibility criteria.|December 2014|December 23, 2014|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01863030||65769|
NCT01868724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ruby|Identification and Validation of Biomarkers of Acute Kidney Injury Recovery|Identification and Validation of Biomarkers of Acute Kidney Injury Recovery||Astute Medical, Inc.|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|362|||Both|21 Years|N/A|No|Non-Probability Sample|Adult ICU Patients with AKI|September 2014|March 12, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01868724||65332|
NCT01869010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIBA 1237|Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection|||Hospital Italiano de Buenos Aires|No|Completed|January 2010|April 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without HIV infection followed at Hospital Italiano de Buenos Aires,        university-affiliated tertiary-care community hospital|May 2013|May 31, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01869010||65311|
NCT01869257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-SSI 09|Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery|Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery||University of Milano Bicocca|Yes|Completed|May 2009|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|85 Years|No|||May 2013|May 30, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01869257||65292|
NCT01869270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905M66723|Gene Therapy for Tay-Sachs Disease|Gene Therapy for Tay-Sachs Disease (Phase 1: Natural History Data Gather)||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2010|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4|||Both|N/A|N/A|No|Non-Probability Sample|Any person, living or dead, who has been diagnosed with a hexosaminidase deficiency        disease|December 2014|December 3, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01869270||65291|
NCT01865500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUcar|Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations|||Ataturk University|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|40 Years|90 Years|No|||May 2013|May 30, 2013|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865500||65580|
NCT01865708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethanol Lock, Safety|Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children|Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children||Children's Healthcare of Atlanta|No|Completed|July 2013|June 2015|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|6 Months|17 Years|No|||August 2015|August 17, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01865708||65564|
NCT01865981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CA04|Investigating Hereditary Cardiac Disease by Reprogramming Skin Cells to Heart Muscle|Cellular Reprogramming as a Tool to Characterise the Cellular Electrophysiology of Familial Arrhythmia|CLUE|University of Dundee|No|Active, not recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|5|None Retained|Skin biopsies will be extracted and used to derive fibroblasts. These will be retained and      reprogrammed to iPS cells (also to be retained). Derived cell lines are not considered a      tissue under the UK Human Tissue Act|Both|18 Years|N/A|No|Non-Probability Sample|Arrhythmic patients participating in the Familial Arrhythmia Network Scotland (FANS)|January 2016|January 18, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01865981||65543|
NCT01865994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S108/2012|Correlation of Estimated Continuous Cardiac Output (esCCO) and TEE in Pediatric Cardiac Surgery|Study to Examine the Correlation of 'Estimated Continuous Cardiac Output' (esCCO) With Transesophageal Echocardiography (TEE) in Pediatric Cardiac Surgery||Heidelberg University|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|44|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric patients (0-18 yrs) scheduled for elective cardiac surgery|December 2014|December 2, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865994||65542|
NCT01866007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100969|A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants|Phase 1, Open-label, Randomized, Parallel Study to Assess the Pharmacokinetic Comparability of 2 Formulations and to Evaluate Pharmacokinetic Comparability of Guselkumab (CNTO1959) Delivered by 2 Different Devices in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|May 2013|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|141|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866007||65541|
NCT01868295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD-UdeM-EE-2013a|The Effect of Nocturnal Wear of Dentures on Sleep and Oral Health Related Quality of Life|The Effect of Nocturnal Wear of Dentures on Sleep and Oral Health Related Quality of Life: a Randomized Cross-Over Trial||Université de Montréal|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868295||65365|
NCT01868308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817085|Screening To Obviate Preterm Birth|Screening To Obviate Preterm Birth|STOP|University of Pennsylvania|No|Completed|January 2013|June 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|589|Samples With DNA|A vaginal swab will be collected during the patients clinical admission exam by a nurse.|Female|N/A|N/A|No|Non-Probability Sample|All pregnant women presenting to the perinatal evaluation center at the Hospital of the        University of Pennsylvania with preterm labor symptoms will be approached for the study.|December 2015|December 22, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868308||65364|
NCT01866839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130144|Preventing Stem Cell Transplant Complications With a Blood Separator Machine|Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|192|||Both|2 Years|80 Years|No|||February 2016|March 9, 2016|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866839||65477|
NCT01866852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913113|Expansion of Childhood Relationship Study to Young Adult Romantic Relationships|The Formation of Healthy, Stable Romantic Relationships During Young Adulthood: A Developmental and Dyadic Perspective||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866852||65476|
NCT01866566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-9|The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination|Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination||Beijing Center for Disease Control and Prevention|No|Recruiting|June 2013|January 2016|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1800|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||May 2013|June 25, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866566||65498|
NCT01867411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913485|Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity|Multimodal Neuroimaging Genetic Biomarkers of Nicotine Addiction Severity||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867411||65433|
NCT01867671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN050AD|Peanut Oral Immunotherapy in Children|Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)|IMPACT|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|146|||Both|12 Months|48 Months|No|||November 2015|November 9, 2015|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867671||65413|
NCT01867957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1109_P1_v1.2|Efficacy and Safety of Anthrax Vaccine, GC1109|A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men||Seoul National University Hospital||Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 3, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867957||65391|
NCT01867931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39721.068.12|Epithelial Damage in GERD|Characterisation of Esophageal Epithelial Damage in Patients With Non-erosive Reflux Disease (NERD) and Erosive Esophagitis (EE): Role of Epithelial Permeability||Maastricht University Medical Center||Completed|April 2013|October 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with EE and patients with NERD referred to the GI-outpatient clinic of the        University Hospital Maastricht with an indication for diagnostic gastroscopy, as well        healthy volunteers will be asked to participate in the study.|February 2015|February 19, 2015|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01867931||65393|
NCT01868217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81100653|A Retrospective Study to Investigate Prevalence of Capsular Bag Distention Syndrome and Its Influencing Factors|||Evidence Based Cataract Study Group||Completed|January 2013|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|239|||Both|45 Years|90 Years|No|Probability Sample|Patients Who Underwent Cataract Surgery at Eye and ENT Hospital of Fudan University,        Xuhui, Shanghai, China|May 2013|May 30, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01868217||65371|
NCT01868269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2011-02|Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)|Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome||Institut Curie|Yes|Recruiting|February 2013|||February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|6 Months|8 Years|No|||January 2016|February 11, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01868269||65367|
NCT01868490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215-3-2552|The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells|Phase 1 Study of The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells.||Siriraj Hospital|Yes|Recruiting|April 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|8 Years|60 Years|No|||April 2015|April 8, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868490||65350|
NCT01866371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817019|High Resolution Retinal Imaging|High Resolution Retinal Imaging|AOSLO|University of Pennsylvania|No|Recruiting|May 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals age 7 and older will be recruited for purposes of this study. Adults must have        the capacity to give informed consent. Subjects age 7 to 17 will need parent/guardian        consent to participate in the study. Subjects aged 7 to 17 will need to assent to        participate in the study. We will recruit subjects with both normal (disease-free) retinas        and subjects with retinal degenerations including Leber's Congenital Amaurosis,        Stargardt's Dystrophy, retinitis pigmentosa, age-related macular degeneration,        Choroideremia, Geographic Atrophy, etc. Subjects will not be excluded based on ethnic or        racial background; we expect that enrollment will be split evenly between males and        females.|December 2014|December 12, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866371||65513|
NCT01867242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS050|Methods Project 4: Clinical Trial|PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT Part of "MODELS FOR TOBACCO PRODUCT EVALUATION||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867242||65446|
NCT01868997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED01RV|Teprotumumab Treatment in Patients With Active Thyroid Eye Disease|A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease||River Vision Development Corporation|Yes|Active, not recruiting|April 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|75 Years|No|||March 2015|September 18, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868997||65312|
NCT01869517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91138|Myoring Versus Keraring Implantation for Keratoconus|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|May 2013|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2|||23|||Both|20 Years|40 Years||||June 2013|June 1, 2013|May 22, 2013||||No||https://clinicaltrials.gov/show/NCT01869517||65272|
NCT01869504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFH1|A Feasibility and Safety Study of the Use of a Dedicated Ballooned Intercostal Drain|A Feasibility and Safety Study of the Use of a Dedicated Ballooned Intercostal Drain||Sherwood Forest Hospitals NHS Foundation Trust|No|Recruiting|February 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|N/A|No|||February 2014|February 5, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01869504||65273|
NCT01865513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPULAR|POPULAR: POst-operative PULmonary Complications After Use of Muscle Relaxants in Europe|POPULAR: POst-operative PULmonary Complications After Use of Muscle Relaxants in Europe - A European Prospective Multicenter Observational Study|POPULAR|European Society of Anaesthesiology|No|Completed|June 2014|August 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Patients undergoing any in-hospital surgical procedure under general or regional        anaesthesia|October 2015|October 13, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865513||65579|
NCT01865721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16359|Optimizing the Use of Entonox® During Screening Colonoscopy|Optimizing the Use of Entonox® During Screening Colonoscopy: an Open Randomised Controlled Trial||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|60 Years|75 Years|No|||July 2014|July 17, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01865721||65563|
NCT01865734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-13-02|Comparison of Usual Podiatric Care and Early Physical Therapy for Plantar Heel Pain|Comparison of Usual Podiatric Care and Early Physical Therapy for Plantar Heel Pain: A Randomized Clinical Trial||Des Moines University|Yes|Enrolling by invitation|December 2013|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|60 Years|No|||February 2015|February 16, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865734||65562|
NCT01865747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-308|A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma|A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy|METEOR|Exelixis|Yes|Active, not recruiting|June 2013|August 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865747||65561|
NCT01866345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment|Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment in the Mandibular Anterior Region||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|August 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||February 2014|February 12, 2014|May 28, 2013||No|Cannot find subjects to particpate|No||https://clinicaltrials.gov/show/NCT01866345||65515|
NCT01866358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wanglan|Intraosseous Infusion for Neonatal Asphyxiated Resuscitation|Intraosseous Infusion for Neonatal Asphyxiated Resuscitation||Third Military Medical University|Yes|Completed|May 2013|May 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|28 Weeks|42 Weeks|No|||November 2014|November 13, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01866358||65514|
NCT01858376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0381|Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans|Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans|Capros|Ohio State University|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|May 9, 2013||No||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01858376||66123|
NCT01866267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUDS_GSK117335|Switching Undetectables to Selzentry|A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry®-Containing Regimen, Switching Them to Once-daily Selzentry® (600mg qd) Plus the Same 2 NRTIs Previously Administered|SUDS|St. Hope Foundation|Yes|Completed|January 2013|June 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|No|||November 2014|November 18, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01866267||65521|
NCT01866904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CMC-DUM-2013/1|Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients|TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients|TIGRIS|AstraZeneca|No|Active, not recruiting|June 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10570|||Both|50 Years|N/A|No|Probability Sample|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous        MI with their most recent MI occurring 1 to 3 years prior to enrollment and at least one        additional risk factor for atherothrombotic events|March 2016|March 3, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866904||65472|
NCT01867164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100569|A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis|A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)||Janssen-Cilag, S.A.|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|75 Years|No|||November 2013|November 1, 2013|May 29, 2013|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT01867164||65452|
NCT01867177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP2012|Community-based Interventions to Increase HIV Testing and HIV Care Utilization|Community-based Interventions to Increase HIV Testing and HIV Care Utilization||Kaiser Permanente|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 18, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867177||65451|
NCT01867424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130145|Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer|Pilot Study of Eovist (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|25|||Male|18 Years|99 Years|No|||December 2015|December 31, 2015|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867424||65432|
NCT01867268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2137|Effect of Acetazolamide & Position in CSF Leakage and Collection and Wound Dehiscence|Evaluating the Effect of Acetazolamide Administration and Prone Positioning Following Lumbosacral Spinal Surgery in Preventing Cerebro Spinal Fluid Leakage and Collection and Wound Dehiscence in Children.||Tehran University of Medical Sciences|Yes|Recruiting|October 2012|September 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|144|||Both|N/A|18 Years|No|||April 2015|April 17, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867268||65444|
NCT01867944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000738|Perineal Self-Acupressure|A Randomized Controlled Trial of Perineal Self-Acupressure for Chronic Constipation||University of California, Los Angeles|No|Completed|June 2013|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867944||65392|
NCT01865539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB00558|Efficacy of Foot Orthotics in Veterans With Chronic Lower Back Pain|Efficacy of Foot Orthotics in Veterans With Chronic Lower Back Pain||Canandaigua VA Medical Center|Yes|Recruiting|May 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01865539||65577|
NCT01866943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-253|Role of Topical Tranexamic Acid in Total Hip Arthroplasty|Role of Topical Tranexamic Acid in Total Hip Arthroplasty|TXA|Northwell Health|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866943||65469|
NCT01869283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-4456|Effectiveness of Physical Therapy Treatments of Myofascial Trigger Points in Subjects With Neck Pain|||University of Sao Paulo|Yes|Not yet recruiting|May 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|59 Years|No|||May 2013|May 30, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869283||65290|
NCT01865526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIS|Efficacy of the 6-point Diet|Effects of the 6-point Diet on the Metabolic Control, the Compliance and the Nutritional Status of CKD Patients Stage 3b-5|PIS|Federico II University|No|Completed|March 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2012|May 30, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865526||65578|
NCT01865760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-138-13|Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia|Incidence of Medical and Nutritional Complications After Bariatric Surgery, Especially Focusing on Assessment and Treatment of Severe Hypoglycemia||University of Aarhus|No|Recruiting|June 2013|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2013|June 3, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01865760||65560|
NCT01866020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DipA|Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients|Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients - a Prospective Clinical Trial in the Department of Intensive Care, University Medical Center Hamburg-Eppendorf (UKE)|DipA|Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2013|January 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|85|||Both|18 Years|N/A|No|Probability Sample|adult patients|May 2015|May 28, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01866020||65540|
NCT01866033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101359|A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants|An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866033||65539|
NCT01866956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MH094092|Computerized Screening for Comorbidity in Adolescents With Substance or Psychiatric Disorders|Computerized Screening for Comorbidity in Adolescents With Substance or Psychiatric Disorders||Center for Psychological Consultation|No|Not yet recruiting|March 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|11 Years|17 Years|No|Non-Probability Sample|adolescents aged 13-18 seeking psychiatric treatment at a rural mental health clinic|February 2016|February 1, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866956||65468|
NCT01867710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100916|Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy|A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients||Janssen Pharmaceutica N.V., Belgium|Yes|Active, not recruiting|July 2013|July 2018|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|164|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867710||65410|
NCT01858909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-172|Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock|Phase III, Prospective, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock||Aragon Institute of Health Sciences|Yes|Not yet recruiting|May 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01858909||66082|
NCT01866280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-01|Sleep Timing and Energy Balance|Effect of Sleep Timing, Independent of Duration, on Food Intake and Metabolic Control of Energy Balance||St. Luke's-Roosevelt Hospital Center|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|5|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01866280||65520|
NCT01866293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-240|Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma|A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866293||65519|
NCT01868763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FitMeFit|TeleLifestyleCoaching for Weight Loss|TeleLifestyleCoaching Use of Telemedicine for Weight Loss and Care of Weight Associated Illnesses|FitMeFit|West German Center of Diabetes and Health|No|Completed|August 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868763||65329|
NCT01867190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 15069|Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia|An Open-label Single Arm Phase 2 Proof of Concept Study to Assess the Efficacy and Safety of ASCT01 in Patients With Critical Limb Ischemia|CLI|Lifecells, LLC.|Yes|Recruiting|May 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||September 2014|September 12, 2014|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867190||65450|
NCT01867203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYPstatin001|Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|December 2012|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|25 Years|80 Years|No|Non-Probability Sample|Patients treated with statin drugs|May 2013|May 29, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867203|6 Months|65449|
NCT01867437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130136|Effects of RM-493 on Energy Expenditure in Obese Individuals|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, 2-Period Crossover Study to Evaluate the Effect of RM-493 on Energy Expenditure in Obese Subjects||Rhythm Metabolic, Inc.|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867437||65431|
NCT01868282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103681|Study of Pain Management Techniques Following Anterior Cruciate Ligament Repair Surgery|Comparison of Efficacy and Safety of Perihamstring Local Anesthetic Injection to Obturator Nerve Block When Combined With Subsartorial Saphenous Block for Anterior Cruciate Ligament Repair. A Randomized Double Blinded Study.||Lawson Health Research Institute|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|105|||Both|16 Years|60 Years|No|||August 2015|August 31, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01868282||65366|
NCT01867970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42580.068.12|Interactive Tool to Support Self-management Through Lifestyle Feedback, Aimed at Physical Activity of COPD/DM Patients|RCT It's LiFe! to Evaluate the Effectiveness of the Monitoring and Feedback Tool and the Corresponding Counseling Protocol (Self-management Support Program) to be Executed by Practice Nurses in Primary Care|RCTIt'sLiFe!|Maastricht University Medical Center|No|Completed|April 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|240|||Both|40 Years|70 Years|No|||April 2015|April 9, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867970||65390|
NCT01866059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Root Caries Cork|Treatment of Root Caries in an Older Irish Population.|Randomised Controlled Clinical Trial to Compare Restorative Materials in the Treatment of Root Caries in an Older Irish Population.||University College Cork|Yes|Active, not recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866059||65537|
NCT01863095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA035358|An Exercise App to Reduce Young Adults' MJ Use|Use of Exercise to Reduce Young Adult Marijuana Use: There is an App for That||State University of New York at Buffalo|Yes|Completed|October 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|25 Years|No|||January 2016|January 29, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01863095||65764|
NCT01863108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 11 19|Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma|Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma|GeniusVac-Mel4|University Hospital, Grenoble|Yes|Recruiting|June 2013|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01863108||65763|
NCT01867450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913101|Study of Lung Health Among Workers Exposed to Diesel Exhaust|A Cross-Sectional Molecular Epidemiology Study of Occupational Exposure to Diesel Exhaust and Biomarkers in China||National Institutes of Health Clinical Center (CC)||Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|115|||Both|18 Years|70 Years|No|||November 2015|January 16, 2016|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01867450||65430|
NCT01867463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913109|Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine|Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali||National Institutes of Health Clinical Center (CC)||Completed|March 2013|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|350|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|May 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867463||65429|
NCT01867697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nordic 8|Nordic 8 - A Phase II Trial|Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial||Odense University Hospital|No|Recruiting|May 2012|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|180|||Both|18 Years|80 Years|No|||January 2015|January 20, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01867697||65411|
NCT01868009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116669|DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)|RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|287|||Both|40 Years|N/A|No|||December 2013|January 16, 2014|May 30, 2013|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01868009||65387|
NCT01868503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0027|Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer|Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells||Stanford University|Yes|Terminated|July 2013|July 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 30, 2013|Yes|Yes|Protocol modification|No||https://clinicaltrials.gov/show/NCT01868503||65349|
NCT01868516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5214-23-CRD-003|Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder|||Targacept Inc.|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1635|||Both|18 Years|N/A|No|||August 2014|May 11, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868516||65348|
NCT01869322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sling vs. Splint|Acute Management of Humeral Shaft Fractures: Sling vs. Splint|||Oregon Health and Science University|No|Recruiting|May 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869322||65287|
NCT01865786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-276-0101|A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication|A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication Nested in the Antiretroviral Pregnancy Registry||Gilead Sciences|No|Recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Female|N/A|N/A|No|Non-Probability Sample|Number of Subjects and Subject Selection: 400 HIV-1 uninfected women who are exposed to        FTC/TDF for PrEP during pregnancy stratified into 200 who decide to continue and 200 who        choose to discontinue FTC/TDF for PrEP. A propensity score-matched comparison group of        equal size (400 women) of HIV-positive pregnant women taking antiretrovirals.        All evaluable subjects enrolled into the APR who fulfill the inclusion criteria for the        target cohort will be selected. Every year at the time of building the annual report for        this study, a propensity score matched comparison group will be selected on a 1:1 ratio        among all pregnant women on antiretrovirals.|February 2016|February 18, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01865786||65558|
NCT01867476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.075EXP|Adherence Monitoring For Substance Abuse Clinical Trials|||California Pacific Medical Center Research Institute||Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Normals|May 2013|May 29, 2013|January 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867476||65428|
NCT01867489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201214929|A Qualitative Study Into How Patients Deal With Chemotherapy-related Side Effects at Home|A Qualitative Study Into How Patients With Cancer Deal With Chemotherapy-Related Side Effects at Home||Universitaire Ziekenhuizen Leuven|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients treated with chemotherapy|November 2014|November 17, 2014|May 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01867489||65427|
NCT01869049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Spleen|The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia|A Study on the Alteration of Macrophage Function in the Spleen Tissue From Patients With Primary Immune Thrombocytopenia (ITP): a Multicenter, Perspective, Clinical Trial|ITP|Shandong University|Yes|Recruiting|November 2012|||September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|The biospecimens were retained for PCR, western blotting and FACS analysis.|Both|15 Years|75 Years|No|Probability Sample|Chinese Adult with primary immune thrombocytopenia|April 2013|May 30, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869049||65308|
NCT01869062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSY01|Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography|Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography|SonR-ECHO|LivaNova|Yes|Active, not recruiting|June 2013|June 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|328|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869062||65307|
NCT01858922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30993 TXCH-HD-12A|Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A|Immune Reconstitution and Biomarker Identification in Patients With Newly Diagnosed Low and Intermediate Risk Hodgkins Lymphoma Receiving Chemotherapy With or Without Radiation Therapy: TXCH-HD-12A|TXCH-HD-12A|Baylor College of Medicine|Yes|Recruiting|December 2012|March 2019|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||September 2015|September 8, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01858922||66081|
NCT01866891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.744|Effects of Physical Activity on the Microcirculation in Hemodialysis Patients|Effects of Regular Perdialytic Physical Activity on the Peripheral Microcirculation in Chronic Hemodialysis Patients|ACTIVDIAL|Hospices Civils de Lyon|Yes|Recruiting|April 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|July 29, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01866891||65473|
NCT01869556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-05|Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress|Comparison of Intravenous Ergonovine With Intramuscular Carboprost, Both in Combination With Oxytocin Infusion, During Cesarean Section for Failure to Progress in Labor: A Double-blinded Placebo-controlled Randomized Controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Female|14 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869556||65269|
NCT01865565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yeh CN001|Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy|A Trial for Surgical Treatment in Patients With Initially Locally Unresectable Advanced GIST Without Metastasis During Therapy With Imatinib||Chang Gung Memorial Hospital|Yes|Recruiting|April 2012|December 2019|Anticipated|April 2018|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Histologically verified GIST and exon genotype.|Both|18 Years|N/A|No|Non-Probability Sample|The study will be conducted in four branch hospitals of Chang Gung Memorial Hospital,        Taiwan including Keelung, Linkou, Cha-Yi, and Kaoshung, respectively. To target 50        patients; 90% patients with response after imatinib treatment; 10% patients without        response; compare the result with historical data.|May 2013|May 28, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01865565||65575|
NCT01867502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ABR05T|Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes|A 12-week Study to Compare the Effects of Vildagliptin Versus Glibenclamide on Glycemic Variability After a Sub Maximal Exercise Test in Patients With Type 2 Diabetes Inadequately Controlled With Metformin.|DIABEX-VILDA|Hospital de Clinicas de Porto Alegre|No|Recruiting|April 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01867502||65426|
NCT01866670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00896312.0.0000.5393|Effect of the Nursing Intervention "Spiritual Support"|Effect of the Nursing Intervention "Spiritual Support" in the Level of Spirituality and Clinical Parameters in Women With Breast Cancer: a Randomized Clinical Trial||University of Sao Paulo|Yes|Recruiting|March 2013|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|25|||Female|18 Years|N/A|No|||May 2013|May 30, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01866670||65490|
NCT01869296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-02-CWUGM|The Effect of Endoscopy Water Pump Flow Rates on Successful Unsedated Colonoscopy by Water Immersion Method: a Randomized Controlled Trial|The Effect of Endoscopy Water Pump Flow Rates on Successful Unsedated Colonoscopy by Water Immersion Method: a Randomized Controlled Trial||Gadjah Mada University||Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|132|||Both|18 Years|N/A|No|||June 2013|June 1, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01869296||65289|
NCT01869309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015|Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor|Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy|HEIGHTEN|LifeBridge Health|No|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||December 2013|November 20, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869309||65288|
NCT01868737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10/09/035|Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature Infants|The Use of Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature and Very-low Birth Weight Infants||University of Stellenbosch|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|184|||Both|25 Weeks|34 Weeks|Accepts Healthy Volunteers|||June 2013|July 19, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868737||65331|
NCT01866644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC400|Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation|Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation||Instituto de Investigacion Sanitaria La Fe|Yes|Active, not recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|214|||Both|18 Years|95 Years|No|||July 2015|July 21, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01866644||65492|
NCT01868022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117360|Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling|Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling||GlaxoSmithKline|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868022||65386|
NCT01868750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16544|Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia|A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy||University of Virginia|Yes|Recruiting|May 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|53|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868750||65330|
NCT01863758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-21|Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A|Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A||Octapharma|Yes|Completed|August 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|66|||Male|18 Years|N/A|No|||January 2015|January 20, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863758||65713|
NCT01869036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82/12|Use of Caudal Anesthesia Supplemented With Morphine in Children Undergoing Renal Surgery|Use of Caudal Anesthesia Supplemented With Morphine in Children Undergoing Renal Surgery - Prospective Study||Shaare Zedek Medical Center|No|Completed|July 2012|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|2 Months|12 Years|No|||November 2013|December 3, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01869036||65309|
NCT01865552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB4-G11-NHV|Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects|A Randomised, Single-blind, Three-part, Two-period, Two-sequence, Single-dose, Cross-over Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Etanercept (SB4, EU Sourced Enbrel® and US Sourced Enbrel®) in Healthy Male Subjects||Samsung Bioepis Co., Ltd.|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|6||Actual|138|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865552||65576|
NCT01866657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCMC-CEROX-01|Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery|NIRS-Based Cerebral Oximetry Monitoring in Elderly Thoracic Surgical Patients Undergoing Single Lung Ventilation Procedures: A Single Center, Prospective, Randomized Controlled Pilot Study Assessing the Clinical Impact of NIRS-Guided Intervention||University Hospital Case Medical Center|Yes|Not yet recruiting|June 2013|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||May 2013|May 28, 2013|May 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866657||65491|
NCT01868035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/007|Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP|Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-line CHOP||GlaxoSmithKline|Yes|Completed|May 2000|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|May 30, 2013|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01868035||65385|
NCT01865032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-19|Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis|Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States||U.S. Army Medical Research and Materiel Command|No|Completed|June 2013|April 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|Samples With DNA|dental broach samples in lysis buffer|Both|18 Years|N/A|No|Probability Sample|Dermatology clinic|September 2014|September 5, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01865032||65615|
NCT01843985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YLDZH-OS-1|Observational Study of Survival Outcomes of Stage IV Cancer Patients|Observational Study of Survival Times of Stage IV Cancer Patients||Cure Cancer Worldwide Corporation|No|Not yet recruiting|June 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|N/A||5|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|April 2013|April 27, 2013|April 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01843985||67225|
NCT01843998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO#00019812|Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)|Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)||Medical College of Wisconsin|Yes|Withdrawn|February 2014|December 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01843998||67224|
NCT01866605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2008.074|A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients|A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients||Melbourne Health|No|Completed|July 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|70 Years|No|||February 2009|May 30, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866605||65495|
NCT01866618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2013-01|Natural Cycle In Vitro Fertilization|Natural Cycle In Vitro Fertilization||Reproductive Medicine Associates of New Jersey|No|Active, not recruiting|April 2013|October 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|850|||Female|18 Years|50 Years|No|||November 2015|November 16, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01866618||65494|
NCT01866085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-013|AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence|Randomised Clinical Trial to Evaluate Efficacy of AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence||Jewish General Hospital|Yes|Recruiting|June 2012|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Male|18 Years|N/A|No|||May 2013|May 30, 2013|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866085||65535|
NCT01866098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK093924-01A1|Naltrexone for Antipsychotic-Induced Weight Gain|Naltrexone for Antipsychotic-Induced Weight Gain|NTX|Yale University|Yes|Recruiting|May 2013|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|75 Years|No|||May 2015|May 5, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01866098||65534|
NCT01866969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13158|Quality of Life in Caregivers of Hospitalized Older Patients With Cancer|Physical, Emotional and Social Stressors and Their Impact on Quality of Life of Caregivers of Hospitalized Older Adults With Cancer||City of Hope Medical Center|Yes|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|211|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866969||65467|
NCT01861964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBIXOS001|Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora|Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora|XOS|University of California, Los Angeles|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01861964||65849|
NCT01869530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012436|TARGet Kids!: Measuring Nutrition in Young Preschool Children in the Primary Care Practice Setting||TARGet Kids!|The Hospital for Sick Children|No|Recruiting|July 2008|||June 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children are recruited from 9 large pediatric and family medicine primary care practices        in Toronto, Ontario, Canada.|November 2015|November 16, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869530|10 Years|65271|
NCT01865773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFR13|HFR Cartridge and Inflammation|Role of HFR Cartridge in the Removal of Mediators of Inflammation and P-cresol in Hemodialysis Patients|HFR|Federico II University|No|Completed|January 2011|September 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|May 28, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01865773||65559|
NCT01862549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205012350|Adapting DBT for Children With DMDD: Pilot RCT|Adapting Dialectical Behavior Therapy for Children With Disruptive Mood Dysregulation Disorder: Pilot Randomized Clinical Trial||Weill Medical College of Cornell University|Yes|Active, not recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|7 Years|12 Years|No|||December 2015|December 27, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01862549||65805|
NCT01862809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913103|Cigarette Smoking and Oral Microbiota|The Effect of Smoking on Oral Microbiota||National Institutes of Health Clinical Center (CC)||Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|N/A|||Anticipated|50|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||November 2015|December 15, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01862809||65786|
NCT01863407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZY 001|Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation||Beijing Bozhiyin T&S Co., Ltd.|Yes|Recruiting|April 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|75 Years|No|||May 2013|May 28, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863407||65740|
NCT01863121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/04/13/503|Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis|A Prospective Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis||Sir Ganga Ram Hospital|No|Recruiting|May 2013|November 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient of cirrhosis Age between 18 - 75 years|May 2015|May 19, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01863121||65762|
NCT01863992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00979|The Quality of Life and Direct Financial Costs Associated With Home Ventilation of Children: A Prospective Study|The Quality of Life a Direct Financial Costs Associated With Home Ventilation of Children: A Prospective Study||University of British Columbia|No|Completed|September 2013|February 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|90|||Both|1 Year|17 Years|No|Non-Probability Sample|Children receiving home ventilation for chronic illness or disease|March 2015|March 5, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863992||65695|
NCT01869543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346123|Asthma and Indoor-air: Reducing Exposures|Benefits of High Efficiency Filtration to Children With Asthma|AIRE|University of California, Davis|No|Active, not recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|4||Anticipated|200|||Both|6 Years|12 Years|No|||December 2014|December 3, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01869543||65270|
NCT01866072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/01/13/455|Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure|A Prospective Evaluation of the Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure|ACLF|Sir Ganga Ram Hospital|No|Recruiting|May 2013|January 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Acute severe viral hepatitis or acute on chronic liver failure|June 2013|June 3, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866072||65536|
NCT01867255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005860|Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels|Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass||Mayo Clinic|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867255||65445|
NCT01864759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICOVIR5-2|Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma|Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma||Institut Català d'Oncologia|Yes|Recruiting|January 2013|June 2015|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01864759||65636|
NCT01864772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC ELAN-FIT|Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC|Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment|GORTEC-ELANFIT|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|70 Years|N/A|No|||March 2015|March 23, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01864772||65635|
NCT01865045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2012|Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients|Pharmacogenetics of Vinorelbine in Malignant Pleural Mesothelioma Patient||Istituto Clinico Humanitas|No|Recruiting|November 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|Samples Without DNA|tissue|Both|N/A|N/A|No|Probability Sample|Malignant pleural mesothelioma patients treated with vinorelbine as a second or later line        chemotherapy with at least an objective response evaluation.|July 2015|July 2, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865045||65614|
NCT01844011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 2011-56|Promoting Fetal Movement Monitoring: Improving Birth Outcomes|Promoting Fetal Movement Monitoring: Improving Birth Outcomes||Mercy Medical Center|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01844011||67223|
NCT01867216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14797|A Study of Multiple Doses of LY2922470 in Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of LY2922470 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|70|||Both|18 Years|70 Years|No|||January 2014|January 28, 2014|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867216||65448|
NCT01867229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-gyneco-001|Breast Cancer and Chemo-amennorhea|Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.|chemo-ameno|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|October 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Female|N/A|N/A|No|Non-Probability Sample|pre-menauposal breast cancer treated with chemotherapy|May 2013|May 31, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867229||65447|
NCT01861106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130132|Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|6 Years|70 Years|No|||January 2016|February 3, 2016|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861106||65915|
NCT01866384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.466|Targeted Temperature Management After Intracerebral Hemorrhage|Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage||Thomas Jefferson University|Yes|Recruiting|September 2012|||September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|May 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866384||65512|
NCT01866397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDOFOVIR_CVVH|Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration|Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration||Medical University of Vienna|No|Completed|March 2002|March 2002|Actual|March 2002|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Male|18 Years|75 Years|No|||June 2013|June 4, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866397||65511|
NCT01867983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA031147|Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines|Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines||Alere Wellbeing|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|2550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 6, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867983||65389|
NCT01867996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116073|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)|To Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) Co-administered With EFAVIRENZ||GlaxoSmithKline|Yes|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867996||65388|
NCT01861990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA2013|Valproic Acid in Childhood Progressive Brain Tumors|Valproic Acid for Children With Recurrent and Progressive Brain Tumors||Medical University of South Carolina|Yes|Withdrawn|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|N/A|No|||May 2015|May 21, 2015|May 22, 2013||No|Feasibility of the trial was proven to be absent.|No||https://clinicaltrials.gov/show/NCT01861990||65847|
NCT01862276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1206|Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma|Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma||Kansai Hepatobiliary Oncology Group|Yes|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|All patients who underwent hepatic lobectomy between 2000 and 2010 for intrahepatic        cholangiocarcinoma, and did not undergo adjuvant chemotherapy will be included for        analysis.|June 2014|June 29, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01862276||65826|
NCT01866046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR013628-02|Rapid HIV Testing and Counseling in High Risk Women in Shelters|Rapid HIV Testing and Counseling in High Risk Women in Shelters||The University of Akron|Yes|Completed|January 2013|March 2015|Actual|October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|98|||Female|N/A|N/A|No|||March 2015|March 24, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866046||65538|
NCT01862250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIE-CLON_2012|Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia|Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia|HIE|Johns Hopkins University|Yes|Not yet recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|35 Weeks|42 Weeks|No|||May 2013|May 23, 2013|April 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01862250||65828|
NCT01862263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AMX01|Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Compare the Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Insulin.|VIDA|Novartis|Yes|Recruiting|May 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862263||65827|
NCT01866995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHCL-01-15052013|Efficacy Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)|Phase 3 Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men.||The Clinic of Men's Health and Couple Longevity, Russia||Recruiting|May 2013|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Male|20 Years|60 Years|No|||May 2013|May 29, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866995||65465|
NCT01867008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-CI422-2012|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||December 3, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867008||65464|
NCT01862822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11 016|Position of Children During Urine Collection: Evaluation Study|Position of Children During Urine Collection: Evaluation Study|PUCES|University Hospital, Limoges|No|Recruiting|May 2013|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1360|||Both|2 Months|36 Months|No|||December 2012|May 30, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862822||65785|
NCT01863134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 P05C 023 27|Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up|||Medical University of Silesia|Yes|Completed|January 2005|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|140|||Both|21 Years|75 Years|No|||August 2013|August 19, 2013|May 18, 2013|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01863134||65761|
NCT01863420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2012B22|The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer|Phase II Clinical Trial: The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy (BMS-IMRT) on Reduction Acute Hematologic Toxicity in Gastric and Rectal Cancer Patients Treated With Concurrent Chemotherapy and IMRT|IMRT|Chinese Academy of Medical Sciences|Yes|Recruiting|November 2012|October 2015|Anticipated|October 2014|Anticipated|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|58|None Retained|There is two study groups. Group A consists of 33 rectal cancer patients as designed. Group      B consists of 25 gastric cancer patients as designed.|Both|18 Years|75 Years|No|Probability Sample|II/III rectal cancer and gastric cancer patients|May 2013|May 28, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01863420|1 Month|65739|
NCT01864005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00053|A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS|A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)|HouYi|AstraZeneca|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|May 24, 2013||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT01864005||65694|(1) Sample size was relatively small. (2) Study duration with 6 weeks seemed limited. (3) Sampling time-points seemed relatively scarce, such as missing the time point for 1-hour and 4-hour after loading dose.
NCT01864239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0326|The Medicines Advice Service Evaluation|The Medicines Advice Service: A Randomised Controlled Trial of a Pharmacy-based Telephone Intervention to Support Patients Taking Medication for a Long-term Condition||University College, London|Yes|Completed|November 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|677|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01864239||65676|
NCT01864486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4M|Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy|Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy (Title in France: Compensation of Vision With the Intelligent Retinal Implant System (IRIS V1) in Patients With Retinal Dystrophy)|IRIS-1|Pixium Vision SA|Yes|Recruiting|April 2013|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|25 Years|N/A|No|||March 2016|March 8, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01864486||65657|
NCT01864499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DINO-NEURO|Perioperative Evaluation of Intracranial Hypertension by Ultrasound Measurement of Variations in the Diameter of the Sheath of the Optic Nerve in the Excision of a Tumor or Biopsy Supratentorial Brain|||Poitiers University Hospital||Not yet recruiting||||May 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||May 2013|May 24, 2013|May 14, 2013||||No||https://clinicaltrials.gov/show/NCT01864499||65656|
NCT01864512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-eltrombopag|Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment|A Prospective, Multicenter Study on the Alteration of Different Immune Parameters in ITP Patients Receiving Eltrombopag Treatment.||Shandong University|Yes|Recruiting|March 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|The biospecimens were retained for PCR, western blotting and FACS analysis.|Both|18 Years|75 Years|No|Probability Sample|Chinese chronic primary immune thrombocytopenia (ITP) adult subjects who have not        responded to or have relapsed after previous treatment for ITP, including first line        therapy and /or splenectomy.|June 2013|June 17, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01864512||65655|
NCT01864785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xblzh2013|Comparison of Posterior Fixation Alone and Combined With Articular Process Fusion in Thoracolumbar Burst Fractures|Posterior Fixation Alone Versus Posterior Fixation Combined With Articular Process Fusion in Thoracolumbar Burst Fractures||Jinling Hospital, China|Yes|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||June 2013|June 12, 2013|May 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864785||65634|
NCT01869114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.587|Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy|A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy||Thomas Jefferson University|Yes|Recruiting|July 2013|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869114||65303|
NCT01852396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-020|The Retroclavicular Approach for Regional Anesthesia|Ultrasound-Guided Brachial Plexus Regional Anesthesia by the Novel Retroclavicular Approach : A Feasibility Study||Université de Sherbrooke|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01852396||66582|
NCT01852409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG6001|Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites|Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.||Peking University|No|Recruiting|May 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||May 2013|May 19, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852409||66581|
NCT01868529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1876|Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus|A Randomised, Single Centre, Double-blind, Two-Period Cross-over, Multiple Dose Trial Comparing the Pharmacodynamic Response of Insulin 454 With Insulin Glargine at Steady-State Conditions in Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|69 Years|No|||September 2015|September 24, 2015|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868529||65347|
NCT01861431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4402|Evaluating a Microfinance Intervention for High Risk Women in Mongolia|Evaluating a Microfinance Intervention for High Risk Women in Mongolia||Columbia University|No|Completed|April 2010|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|107|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|March 17, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861431||65890|
NCT01867684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12CP391|Positive PsychoTherapy in Acquired Brain Injury (ABI) Rehabilitation|Brief Positive Psychotherapy After Acquired Brain Injury: A Pilot Randomised Controlled Trial|PoPsTAR|NHS Greater Glasgow and Clyde|No|Completed|July 2013|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01867684||65412|
NCT01869023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCANOGAR2012-JA3|Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma|Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma.||Instituto Nacional de Cancerologia de Mexico|No|Active, not recruiting|November 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01869023||65310|
NCT01862289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110904|Prevalence of Hyperventilation Syndrome in Difficult Asthma|Prevalence of Hyperventilation Syndrome in Difficult Asthmatics Uncontrolled Despite a Daily Maximal Doses of Inhaled Treatment|PRESH|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01862289||65825|
NCT01862562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCUMC-D1108015|Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients Who Were 75 Years Old or Over||Yokohama City University Medical Center|No|Active, not recruiting|August 2008|August 2017|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|75 Years|N/A|No|||November 2013|November 24, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01862562||65804|
NCT01867307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.66|Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls|An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls||Boehringer Ingelheim||Completed|June 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|May 21, 2013||||No||https://clinicaltrials.gov/show/NCT01867307||65441|
NCT01867541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intraOP_OCT_1|Intra-operative Measurements to Predict the Position of the Intraocular Lens Post-operatively|Predictability of the IOL Position Using an Intra-operative OCT||Vienna Institute for Research in Ocular Surgery|No|Completed|December 2010|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|21 Years|N/A|No|Probability Sample|patients who are sceduled for cataract surgery|May 2013|May 29, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01867541||65423|
NCT01867294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC09C8|Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab|A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients||Academic and Community Cancer Research United|Yes|Active, not recruiting|August 2012|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|February 11, 2016|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867294||65442|
NCT01867528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCH-95-150513|Comparison of Laparoscopic Surgery Versus Open Surgery in the Treatment of Adhesive Small Bowel Obstruction|Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial||Helsinki University Central Hospital||Recruiting|July 2013|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||102|||Both|18 Years|95 Years||||March 2015|March 16, 2015|May 26, 2013||||No||https://clinicaltrials.gov/show/NCT01867528||65424|
NCT01867762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101807|An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ 49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease||Janssen Research & Development, LLC|Yes|Completed|September 2013|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|211|||Both|40 Years|80 Years|No|||September 2015|September 10, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867762||65406|
NCT01867775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052/2012|Mirtazapine for Sleep Disorders in Alzheimer's Disease|Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study||Brasilia University Hospital|No|Recruiting|May 2012|May 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||May 2013|June 3, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867775||65405|
NCT01863771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100937|A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.|A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Pharmaceutical K.K.|No|Completed|April 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|70 Years|No|||February 2016|February 19, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01863771||65712|
NCT01864018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1382|Ixazomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma|Phase 1/2 Trial of MLN9708 in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma||Mayo Clinic|No|Recruiting|August 2013|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||November 2015|January 6, 2016|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01864018||65693|
NCT01864252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120541|Investigation Into the Role of GTN & RIPC in Cardiac Surgery|The Effect of Remote Ischaemic Preconditioning and Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass Surgery Patients (ERIC-GTN Study)|ERIC-GTN|University College, London|Yes|Recruiting|January 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01864252||65675|
NCT01868828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD VS VCD Clinical Protocol|A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma|A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.||Peking University People's Hospital|No|Recruiting|May 2013|May 2017|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|65 Years|No|||June 2013|June 4, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01868828||65325|
NCT01868841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-039|123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System|123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging||Aspire Foundation|No|Completed|December 2013|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868841||65324|
NCT01866215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Lausanne|Effects of Exercise on Fructose Metabolism|Effects of Exercise on Fructose Metabolism|FruEx2|University of Lausanne|No|Completed|May 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01866215||65525|
NCT01866228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:085|Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes|Impact of Treatment Consultation Recordings on Cancer Patient Outcomes: A Prospective, Parallel, Randomized Controlled Trial||University of Manitoba|No|Recruiting|June 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|327|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01866228||65524|
NCT01852422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP protocol 01|Location and Anatomic Characterization of the Sacrospinous Ligaments in Women With Pelvic Organ Prolapse|||Pop Medical Solutions||Completed|June 2013|||September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|21 Years|80 Years|No|Non-Probability Sample|Women with pelvic organ prolapse 21-80 years old|October 2013|October 27, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01852422||66580|
NCT01869335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/13|A Study Comparing ex Vivo MRI Versus Radiography of Breast Specimens|A Randomized Study Comparing ex Vivo MRI Versus Radiography of Breast Specimens in Evaluating Tumor-free Margins After Surgical Resection of Breast Microcalcifications||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Not yet recruiting|May 2013|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|260|||Female|18 Years|80 Years|No|||May 2013|June 4, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01869335||65286|
NCT01865851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5558|Comparison of the Classic Face Mask Versus NuMask for Preoxygenation|Comparison of the Classic Face Mask Versus NuMask for Preoxygenation||Nimmagadda, Usharani, M.D.|Yes|Recruiting|May 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865851||65553|
NCT01865864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-057|Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Changes of Blood Pressure Between Day and Night|Changes In Diurnal Blood Pressure Pattern In Obstructive Sleep Apnea (OSA) Patients After CPAP Therapy||Northwell Health|Yes|Terminated|July 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2|||Both|18 Years|N/A|No|Probability Sample|Obstructive sleep apnea patients age over 18 years|May 2013|May 28, 2013|December 26, 2008|No|Yes|Difficulty Recruiting subjects|No||https://clinicaltrials.gov/show/NCT01865864||65552|
NCT01866137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsyCo|Copeptin During a Standardized Psychological Stress Test|Copeptin During a Standardized Psychological Stress Test|PsyCo|University Hospital, Basel, Switzerland|No|Completed|March 2013|February 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|7.5 ml of EDTA blood, 7.5 ml of serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults|September 2014|September 8, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01866137||65531|
NCT01861418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasWU|Effects of Lumbopelvic Manipulation on Neuromuscular Activity of Back & Hip Muscles in Adults With Chronic Low Back Pain|Effects of Lumbopelvic Manipulation on Neuromuscular Activity of Back and Hip Muscles in Adults With Chronic Low Back Pain||Texas Woman's University|Yes|Recruiting|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|55|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01861418||65891|
NCT01861691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCUMC-D1108014|Randomized Controlled Trial Between Laparoscopic and Open Surgery in Transverse and Descending Colon Cancer Patients|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Transverse and Descending Colon Cancer Patients||Yokohama City University Medical Center|No|Active, not recruiting|August 2008|October 2017|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|20 Years|N/A|No|||November 2013|November 24, 2013|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861691||65870|
NCT01861977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009|Healthy Habits Program for High Cardiovascular Risk Patients: Randomized Controlled Clinical Trial|Healthy Habits Program for High Cardiovascular Risk Patients: Randomized Controlled Clinical Trial. Effectiveness of a Program Using Cognitive Behavioral Therapy to Improve Healthy Habits in a Population With Cardiovascular Disease.||Hospital Italiano de Buenos Aires|Yes|Active, not recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|45 Years|80 Years|No|||December 2015|December 1, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01861977||65848|
NCT01866735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00019937|Early Mobility for the Critically Injured Burn Patient|Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient||Wake Forest School of Medicine||Suspended|May 2013|May 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|May 21, 2013||No|Results from trial in another population lead investigators to determine study outcome may not    reach statistical significance. Suspended for futility.|No||https://clinicaltrials.gov/show/NCT01866735||65485|
NCT01866709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPS-001|Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia|A Phase 4, Single-center, Prospective, Double-blind, Placebo-controlled, Randomized Study to Investigate the Safety and Efficacy of Sodium Polystyrene Sulfonate (SPS) in Subjects With Hyperkalemia.||ZS Pharma, Inc.|Yes|Terminated|May 2013|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|May 28, 2013|Yes|Yes|Risk/benefit determination showed study revealed negative safety issues.|No|August 20, 2014|https://clinicaltrials.gov/show/NCT01866709||65487|Due to the high frequency of adverse events in the SPS group, the independent Data Monitoring Committee (iDMC) recommended termination of the study.
NCT01866722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS B12-268|Not Quite Ready to Quit|A Test of Two Clinical Methods to Prompt a Quit Attempt Among Smokers||University of Vermont|No|Active, not recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|560|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01866722||65486|
NCT01867567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBandage|Early Bandage Removal Post-Cesarean Delivery|Early Bandage Removal Post-Cesarean Delivery||Ziv Hospital|Yes|Completed|August 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|320|||Female|18 Years|44 Years|No|||December 2015|December 29, 2015|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01867567||65421|
NCT01867580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS.2011.ULTA.04|A Prospective, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds|A Prospective, Randomized, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds||KCI USA, Inc.|Yes|Active, not recruiting|May 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867580||65420|
NCT01867554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-06|Research and Characterization of New Genes Involved in Intellectual Disability|Recherche et caractérisation de Nouveaux gènes impliqués Dans la déficience Intellectuelle.|GeneDefi|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|December 2012|||December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8500|Samples With DNA|DNA RNA Plasma Urines|Both|N/A|N/A|No|Non-Probability Sample|-  2500 patients with intellectuel disability          -  5000 parents or unaffected sibs          -  1000 affected sibs|October 2012|June 3, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01867554||65422|
NCT01867788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS082157|Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2|Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2|HBS2|Brigham and Women's Hospital|No|Active, not recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|76|Samples With DNA|Whole blood, plasma, CSF, RNA, DNA|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Two tertiary care centers.|January 2016|January 11, 2016|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867788|36 Months|65404|
NCT01868100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.762|Financial Distress in Patients With Advanced Cancer|Preliminary Study of Financial Distress and Quality of Life in Patients With Advanced Cancer|DIFIC|Hospices Civils de Lyon|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|144|||Both|18 Years|N/A|No|||June 2013|September 2, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868100||65380|
NCT01868087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13730|Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study|Impact Advanced Recovery® for Radical Cystectomy (RC) Patients||University of Kansas Medical Center|No|Active, not recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Male|40 Years|90 Years|No|||February 2016|February 1, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868087||65381|
NCT01868347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI-20686|Obese Patient During RARP: the Role of a Preemptive Ventilator Strategy to Contrast Pneumoperitoneum and Trendelenburg Position|The Obese Patient in the Urologic Robotic Surgery: the Role of a Preemptive Ventilator Strategy and Partitioning to Contrast Pneumoperitoneum and Trendelenburg Position|OPERA|University of Turin, Italy|No|Recruiting|February 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|80 Years|No|||May 2013|June 5, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01868347||65361|
NCT01868568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1959|Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes|A Randomised, Double-blind, Multiple Period Cross-over Trial Comparing Insulin 454 and Insulin Aspart Fixed Combination Products With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared to Biphasic Insulin Aspart 30 (NovoMix® 30) in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|55|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868568||65344|
NCT01869127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIP48039353950|Study to Test Whether Shoes Protect Children Against Hookworm Infection on Pemba Island, Zanzibar|Shoes for Kids on the Island of Pemba (SKIP): A Pragmatic, Cluster Randomised Controlled Trial to Test if Shoes Reduce Hookworm Infection and Transmission in School-aged Children on Pemba Island, Zanzibar|SKIP|Bird, Christopher|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1056|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||June 2013|June 1, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01869127||65302|
NCT01869140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFEC-001|the Hypoalgesic Effect of Spinal Manual Therapy|the Hypoalgesic Effect of Spinal Manual Therapy on an Healthy Population: a Randomized Clinical Trial||Institut Franco Europeen de Chiropratique|Yes|Not yet recruiting|November 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 4, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01869140||65301|
NCT01865929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LundKK|Minimally Invasive Benign Hysterectomy|Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy||Region Skane|No|Recruiting|January 2010|December 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|25 Years|N/A|No|||May 2013|May 30, 2013|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01865929||65547|
NCT01865344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK sør-øst 2013/196|Skin Conductance Fluctuations Per Sec and NRS to Monitor Pain|A Pilot Study for the PainMonitor During Standardized Painful Stimuli and no Stimuli to Calculate the Sensitivity and Specificity and Thereby the Accuracy of the Monitor||Oslo University Hospital|Yes|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult cardiac patients prior to, during, and after anesthesia for surgery. The proposed        pilot study will be conducted at the Acute Clinic, Rikshospitalet - Oslo University        hospital, Oslo, Norway.|December 2013|December 3, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865344||65592|
NCT01865357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/33|Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI|Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI:"SCI-COG" Study|SCI-COG|University Hospital, Bordeaux|No|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865357||65591|
NCT01865799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-276-0105|A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA|A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA||Gilead Sciences|No|Recruiting|May 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|This prospective case series is composed of every subject in the database that is exposed        to FTC/TDF or its components for any indication.        Additionally, 200 physicians who prescribe FTC/TDF for a PrEP indication will be randomly        sampled from the same source.|January 2016|January 4, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01865799||65557|
NCT01865812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-205|Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis|A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis||Intercept Pharmaceuticals|Yes|Active, not recruiting|November 2013|October 2016|Anticipated|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865812||65556|
NCT01865877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNN 35/12|Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study|Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)|ReMePARK|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Yes|Recruiting|August 2012|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|Samples With DNA|Serum and/or saliva|Both|20 Years|95 Years|No|Non-Probability Sample|Subjects diagnosed with idiopathic or genetic Parkinson's disease attending any of the        participant sites in Mexico.|March 2015|March 23, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865877|2 Years|65551|
NCT01865890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-016|Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients|Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients||Northwell Health|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Hemodialysis patients who are taking plavix daily|May 2013|May 30, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01865890||65550|
NCT01861704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000.000.004.858|Post-market Study to Capture Information Regarding Performance of Lyric2|Post-market Study to Capture Information Regarding Performance of Extended Wear Hearing Aid Lyric2 Compared to Lyric||Phonak AG, Switzerland|No|Completed|April 2011|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|177|||Both|18 Years|90 Years|No|||April 2014|April 16, 2014|March 21, 2013|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01861704||65869|
NCT01862003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0136|Phase I/II Trial of Antagonism of HER in GI Cancer|AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer|PANTHER|University College, London|Yes|Recruiting|May 2014|May 2018|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01862003||65846|
NCT01866748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9928-4048|Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866748||65484|
NCT01867047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037620|ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients|Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients||Duke University|No|Recruiting|June 2013|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|February 9, 2016|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867047||65461|
NCT01867021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_22|Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above|A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above||Novartis|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2902|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|May 29, 2013|Yes|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT01867021||65463|
NCT01867034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5516|Soluble Receptors for Advanced Glycation End-Products and PCI|Soluble Receptors for Advanced Glycation End-Products to Predict the Type of Stent Implant||University of Saskatchewan|No|Recruiting|March 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|40 Years|80 Years|No|||March 2012|May 29, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867034||65462|
NCT01868126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-002|Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Santen Inc.|No|Completed|May 2013|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|91|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868126||65378|
NCT01867801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNCI|Portuguese Registry on Interventional Cardiology|Portuguese Registry on Interventional Cardiology|PRIC|Portuguese Society of Cardiology|No|Recruiting|January 2002|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|99 Years|No|Probability Sample|All adult patients admitted to Portuguese hospitals for percutaneous coronary intervention|September 2015|October 22, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01867801|5 Years|65403|
NCT01868113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS1259|Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial|Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial|ICS|Makerere University|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|1010|||Both|2 Months|59 Months|No|||April 2015|October 25, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868113||65379|
NCT01868373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM H31389|Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea|Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea||Baylor College of Medicine|No|Enrolling by invitation|February 2013|February 2022|Anticipated|February 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868373||65359|
NCT01868360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB65110|Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea|Subconjunctival Aflibercept Injection for Corneal Neovascularization||University of Utah|Yes|Terminated|June 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 15, 2013|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01868360||65360|
NCT01868581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1985|Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Crossover, Glucose Clamp Trial to Test for Bioequivalence Between Two Insulin 454 Formulations, With or Without Buffer, and Between Two SIAC Formulations, With or Without Buffer, in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868581||65343|
NCT01868854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Incich-2013-Dp-0012|Risk Assessment of Peritoneal Dialysis Failure Based on Catheter Tip Location.|Risk Assessment of Peritoneal Dialysis Failure Based on Catheter Tip Location. Multicentric Study.|TIP-DP|Instituto Nacional de Cardiologia Ignacio Chavez|No|Enrolling by invitation|March 2013|April 2014|Anticipated|December 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|30|||Both|14 Years|N/A|No|Non-Probability Sample|Patients with chronic renal failure 5d: who are initiating peritoneal dialysis in any form|May 2013|June 4, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01868854|7 Days|65323|
NCT01868867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH086152|New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression|New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression||Center for Psychological Consultation|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|13 Years|18 Years|No|||February 2016|February 1, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868867||65322|
NCT01869400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OvaYond|An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer|An Observational, Multicenter, Open-label Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer|NIS-OvaYond|PharmaMar, Spain|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|180|||Female|18 Years|N/A|No|Probability Sample|hospitales and medical practices in Germany|March 2016|March 24, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01869400||65281|
NCT01866540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-tonsilsv2 Version 2|Immune Response To Intranasal Influenza Vaccination|The Systemic And Local Immune Response To Intranasal Influenza Vaccination||University of Bergen|No|Active, not recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|2 Years|59 Years|Accepts Healthy Volunteers|||June 2015|June 6, 2015|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866540||65500|
NCT01869595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSM/TG Test and Treat Study|Thai MSM/TG Test and Treat Study|Prospective Study of Study to Evaluate the Feasibility of Universal HIV Testing and Antiretroviral Treatment Regardless of CD4 Count Using the Test and Treat Strategy Among Men Who Have Sex With Men and Transgender Women in Thailand||Thai Red Cross AIDS Research Centre|Yes|Recruiting|November 2012|November 2020|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|men who have sex with men and transgender women in Thailand|November 2015|November 2, 2015|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01869595|2 Years|65266|
NCT01865331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1788|Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Single-dose, Parallel Group Trial With Insulin 454 and SIAM 50 in Healthy Male Japanese Subjects||Novo Nordisk A/S|No|Completed|December 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|May 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865331||65593|
NCT01866150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28642|A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Rheumatoid Arthritis: A Comparison of the Effectiveness of Biologic Monotreatment and Biologic and Methotrexate (MTX) Combination Treatment||Hoffmann-La Roche||Completed|April 2013|March 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|476|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis with an inadequate response to at least 2 DMARD        treatments, one of which includes methotrexate, who are being treated with first-line        biologic therapy|September 2015|September 1, 2015|May 21, 2013||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01866150||65530|
NCT01866163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-1001|LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris|LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris||LEO Pharma|No|Completed|June 2013|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|426|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866163||65529|
NCT01866449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-GBM (XRP6258)|Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme|Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -||University of Ulm|Yes|Recruiting|October 2013|August 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01866449||65507|
NCT01866462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProCo Metformin|Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin|A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance||NuMe Health|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|10|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866462||65506|
NCT01867060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HASTE-2|Using a Personal Heart Rhythm Monitor to Diagnose Paroxsymal Atrial Fibrillation in the Community|Using a Personal Heart Rhythm Monitor (PHRM) to Diagnose Paroxsymal Atrial Fibrillation (PAF) in the Community - Substudies to Investigate Biomarkers to Detect PAF and to Monitor the Progression of Frequent Atrial Premature Beats to PAF||University of Surrey|Yes|Recruiting|May 2013|October 2015|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|900|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867060||65460|
NCT01867320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130135|Raltegravir for HAM/TSP|Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|January 7, 2016|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867320||65440|
NCT01867333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130146|Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer|A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Male|18 Years|100 Years|No|||November 2015|December 15, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867333||65439|
NCT01868386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16604|Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate|Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial||University of Virginia|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|52|||Male|18 Years|N/A|No|||November 2015|November 20, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01868386||65358|
NCT01868139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-31|Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)|A Phase II, Multi-Center Study of Interventional Spray Cryotherapy for Early-Stage Esophageal Cancer (ICE-CANCER)|ICE-CANCER|University of Maryland|Yes|Terminated|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|March 30, 2013|Yes|Yes|insufficient accrual|No||https://clinicaltrials.gov/show/NCT01868139||65377|
NCT01868607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOT_UZA_2013|Reliability of Different FOT Devices to Measure the Human Respiratory Impedance|Comparison of the Reliability of Different Devices to Measure Lung Function With the Forced Oscillation Technique||University Hospital, Antwerp|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult subjects and patients with obstructibve lung disease|February 2014|February 6, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868607||65341|
NCT01868893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28979|An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia|An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia||Genentech, Inc.||Approved for marketing|August 2013|January 2014|Actual|January 2014|Actual|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2015|November 2, 2015|May 29, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01868893||65320|
NCT01869166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-007|Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)|Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors|CART-EGFR|Chinese PLA General Hospital|Yes|Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 27, 2015|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01869166||65299|
NCT01868594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-SU-003|Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus||Materia Medica Holding|No|Recruiting|May 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01868594||65342|
NCT01868880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|calo03|Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing|Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator.||Policlinico Casilino ASL RMB|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|95 Years|No|||November 2015|November 9, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01868880||65321|
NCT01869153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD-308519|Monitoring Growth of Preterm Infants|Monitoring Growth of Preterm Infants||University of California, Davis|No|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Preterm infants of gestational age < 32w at birth, or <1750 weight at birth.|November 2015|November 30, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869153||65300|
NCT01865916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00502|2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation|2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial||University of British Columbia|No|Active, not recruiting|April 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|278|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01865916||65548|
NCT01865955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02|Comparison Between Palpatory and Preprocedural Ultrasound Guided Techniques on Performance of Spinal Anesthesia|Comparison Between Palpatory and Preprocedural Ultrasound Guided Techniques on Performance of Spinal Anesthesia in Term Parturients Undergoing Elective Caesarian Section- A Randomized Control Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865955||65545|
NCT01861119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-020|Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars|Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial||CHA University|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|75 Years|No|||May 2013|May 22, 2013|May 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01861119||65914|
NCT01865630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3007-ETP|Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage|Phase I Safety, Blood Brain Barrier Permeability and Potential Efficacy of Etanercept for Aneurysmal Subarachnoid Hemorrhage||St. Michael's Hospital, Toronto|Yes|Not yet recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865630||65570|
NCT01865903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/830/REK sør-øst D|Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)|Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer; Incidence, Development and Impact on Quality of Life, Adverse Effects and Survival.|LEKS|Oslo University Hospital|No|Terminated|June 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|17|Samples With DNA|Bloodsamples for biobank|Both|18 Years|N/A|No|Probability Sample|About 250 new cases of lung cancer are diagnosed in Oslo every year. About 200 of these        belong to the defined catchment area for the present study. Approximately 150 patients are        expected to be in a palliative setting. Based on the number of new referrals to OUS        Ullevål in 2011, about 60-80 patients with NSCLC will be starting first line palliative        chemotherapy every year. A sample size of 110 patients is planned for this study Cohort 2,        which gives an enrolment period of about 2 years In Cohort 1 another 50 patients.|May 2013|July 13, 2015|May 8, 2013||No|To Low recruitment and competing studies|No||https://clinicaltrials.gov/show/NCT01865903||65549|
NCT01866176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG2007-097-A4|Effects of a New Knee Brace for Treatment of the Knee Osteoarthritis|Effects of a New Knee Brace for Treatment of the Knee Osteoarthritis on the Medial Knee Loading During Gait||Laval University|Yes|Completed|October 2011|August 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|24|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 5, 2014|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01866176||65528|
NCT01866475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-16|Continuous Intraosseous Vascular Access Over 48 Hours|A Study to Determine the Safety of Continuous Intraosseous Vascular Access Over a Period of 48 Hours||Vidacare Corporation|No|Recruiting|November 2014|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866475||65505|
NCT01866488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1027-01|The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor|The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor: A Double-Blinded, Randomized Controlled Trial||University of Arizona|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|No|||August 2015|August 14, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01866488||65504|
NCT01867814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0133-CTIL|Arterial and Plethysmographic Waveforms Variables as Predictors of Hemodynamic Response to Pneumoperitoneum|Clinical Trial for Evaluation of Arterial and Plethysmographic Waveform Variations as Predictors of Hemodynamic Response to Pneumoperitoneum During Laparoscopic Surgery|SPV-PnP|Carmel Medical Center|Yes|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01867814||65402|
NCT01867593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-018|MET-PET for Newly Diagnosed Glioblastoma|Pilot Study of MET-PET (L-[Methyl]-11C Methionine Positron Emission Tomography) to Evaluate for Treatment Response After Chemoradiation Therapy for Newly-diagnosed Glioblastoma||Massachusetts General Hospital|Yes|Recruiting|January 2014|||December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867593||65419|
NCT01867827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON997-11|Real-time fMRI Neurofeedback for Treatment of Parkinson's Disease|Real-time fMRI Neurofeedback for Treatment of Parkinson's Disease||Cardiff University||Completed|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||March 2015|March 9, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867827||65401|
NCT01867840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-07|Role of ASICs in Human Inflammatory Pain|Study of the Role of Acid Sensing Ion Channels (ASICs) in Human Inflammatory Pain||Centre Hospitalier Universitaire de Nice||Recruiting|November 2012|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|20|||Both|N/A|N/A|No|Probability Sample|(osteoarthritis, chondrocalcinosis, gouty arthritis, rheumatoid arthritis)|March 2016|March 18, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01867840||65400|
NCT01868152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Predictive opioid|The Realtime Detection for Prediction of Opioid Analgesic|Study of Prediction of Opioid Analgesic||Huazhong University of Science and Technology|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|131|||Female|20 Years|65 Years|No|Probability Sample|Chinese female patients receiving elective surgery under general anesthesia|March 2016|March 19, 2016|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868152||65376|
NCT01868399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120080|Pilot Survey of Dengue Fever in Solomon Islands|Pilot Survey of Dengue Fever in Solomon Islands||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1400|Samples Without DNA|Remaining samples will be provided to the BioBank for the studies of other infectious      diseases pathogens.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Residents of Solomon Islands          -  people who understand the purpose of the study          -  people who agree to sign the informed consent|February 2016|February 22, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01868399|1 Month|65357|
NCT01868620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 030 03|Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.|Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.|IONTO-CXL|University Hospital, Toulouse|Yes|Recruiting|May 2013|May 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868620||65340|
NCT01869413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP-342559|Tranexamic Acid During Cystectomy Trial (TACT)|Tranexamic Acid During Cystectomy Trial (TACT)|TACT|Ottawa Hospital Research Institute|Yes|Recruiting|June 2013|December 2018|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|354|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869413||65280|
NCT01865422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01548-35|French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL)|French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL)|PC-QOL|Assistance Publique Hopitaux De Marseille|No|Completed|May 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|N/A|17 Years|No|||August 2014|August 29, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865422||65586|
NCT01865643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-03|A Comparison of Two GlideScope Intubation Techniques|A Comparison of Two GlideScope Intubation Techniques - Effect on Hemodynamic Changes and Injury Rate||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865643||65569|
NCT01865656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHTF IR India|A Skills and Drills Intervention for Emergency Obstetrics and Neonatal Care at First Referral Units of North Karnataka|Skills and Drills Intervention for Improving Emergency Obstetric and Neonatal Care in Select First Referral Units in Northern Karnataka||Harvard School of Public Health|No|Completed|July 2013|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15018|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865656||65568|
NCT01865968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HA-4009|Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults|Phase IV Trial to Compare the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) With One- or Two-dose Regimen and Live Attenuated HAV With One-dose Regimen in Chinese Young Adults, and to Evaluate the Immunogenicity of a Booster Dose.||Sinovac Biotech Co., Ltd|No|Completed|October 2008|September 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|239|||Both|16 Years|25 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865968||65544|
NCT01869374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6427|Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults|Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy|MSTvsEST|New York State Psychiatric Institute|Yes|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|90 Years|No|||September 2015|September 24, 2015|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869374||65283|
NCT01869387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRISOL-MARTINA-2013|Respiratory Muscle Function in COPD Exacerbations|Improvement of Respiratory Muscle Function With Noninvasive Ventilation in Exacerbated COPD Patients Presenting Hypercapnic Respiratory Failure Without Acidosis||Parc de Salut Mar|No|Not yet recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|40 Years|80 Years|No|||May 2013|May 31, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01869387||65282|
NCT01865617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2639.00|Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia|Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor||Fred Hutchinson Cancer Research Center|Yes|Recruiting|May 2013|||April 2029|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01865617||65571|
NCT01866761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHK_OU-RN605|Relationship Analysis Between Periodontal Disease and Atherosclerosis in Japanese Medical Cooperation Services|Analysis of the Relationship Between Periodontal Disease and Atherosclerosis Within a Local Cooperation System of Japanese Medical Services|RAPA-JMCS|Okayama University|No|Completed|November 2008|||January 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples Without DNA|blood|Both|N/A|N/A|No|Non-Probability Sample|This clinical study was performed by the local clinics which belonged to Tokyo Medical        Practitioners Association, Tokyo Dental Practitioners Association, and Chiba Medical        Practitioners Association. 37 patients (with lifestyle-related diseases under consultation        in either of 16 medical clinics), and 79 periodontal patients (not undergoing treatment at        a medical clinic,) were enrolled. The subjects constituted a broad cross-section of the        local society. Medical treatment at an internal medicine clinic and clinical periodontal        treatment including periodontal surgery at a dental clinic were performed on all the        subjects. Twenty-six patients dropped out of the study and medical treatment and        periodontal treatment were provided to the remaining 90 subjects (mean ages: 59.2 ± 12.3        yrs).|May 2013|May 27, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01866761|2 Years|65483|
NCT01866189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 252 01|Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke|Assessment of Hypoxic Tissues in Acute Ischemic Stroke With 18F-FMISOnidazole PET and Comparison With MRI : A Prospective Multicenter Study|STROKE F-MISO|University Hospital, Toulouse|Yes|Not yet recruiting|September 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|85 Years|No|||June 2015|June 10, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01866189||65527|
NCT01866202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00105|Study of Circulating and Tumor Biomarkers in Breast Cancer Patients|||National University Hospital, Singapore|Yes|Recruiting|March 2012|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|21 Years|N/A|No|Probability Sample|Patients being treated with Breast Cancer at National University Hospital (Singapore)|December 2013|December 10, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01866202||65526|
NCT01866501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06|Follow-Up Study Validating a Blended Technique|A Follow-up Study Validating a Blended Technique for Identifying the Proximal Humerus Intraosseous Vascular Access Insertion Site||Vidacare Corporation|No|Completed|May 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866501||65503|
NCT01867853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10286|Volume Responsiveness Before SBT Predicts the Outcome of Mechanical Ventilation Weaning in Critically Ill Patients|Volume Responsiveness Before Spontaneous Breath Trial Predicts the Outcome of Mechanical Ventilation Weaning in Critically Ill Patients|weaning|Southeast University, China|Yes|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The patients were mechanically ventilated and ready to undergo a spontaneous breathing        trial (SBT) with a T-piece|June 2013|June 3, 2013|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867853|6 Months|65399|
NCT01867346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903323|Early Markers of Cognitive Change and Alzheimer s Disease|Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology||National Institutes of Health Clinical Center (CC)||Completed|March 2003|January 2015||June 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 3, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867346||65438|
NCT01867359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903326|The Genetic Characterization of Dementia|The Genetic Characterization of Dementia||National Institutes of Health Clinical Center (CC)||Suspended|March 2003|December 2016||December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867359||65437|
NCT01867372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903328|Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes|Early Markers of Alzheimer's Disease in BLSA Participants: Structural and Functional Brain Changes||National Institutes of Health Clinical Center (CC)||Terminated|March 2003|December 2016||December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|300|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2014|October 23, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01867372||65436|
NCT01868412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH15101075|Resin Salve Versus Honey Treatment in Wound Care|Comparison of Resin Salve and Medical Honey in Wound Care in Vascular Surgery Patients - A Prospective, Randomized and Controlled Clinical Trial||Kuopio University Hospital|No|Completed|May 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|100 Years|No|||January 2016|January 15, 2016|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01868412||65356|
NCT01868633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210765|Dexamethasone for Post Cesarean Delivery Analgesia|The Effect of a Single Intraoperative Dose of Dexamethasone in Combination With Intrathecal Morphine for Post Cesarean Delivery Analgesia||University of Iowa|Yes|Completed|March 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|52|||Female|18 Years|50 Years|No|||May 2015|May 26, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868633||65339|
NCT01868425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0538|ACL Repair and Multimodal Analgesia|ACL Repair and Multimodal Analgesia||University of Wisconsin, Madison|Yes|Recruiting|April 2013|April 2015||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|55 Years|No|||August 2014|August 7, 2014|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01868425||65355|
NCT01868438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-017-12|Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers|Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers||Medicines for Malaria Venture|No|Completed|May 2013|January 2014|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868438||65354|
NCT01869192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0824.cc|Phase II Trial for Large ER-Negative Breast Cancers|Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial.||University of Colorado, Denver|Yes|Active, not recruiting|March 2003|September 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869192||65297|
NCT01869179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG042526|Community Choirs To Promote Healthy Aging; Community of Voices Chorus|Community Choirs To Promote Healthy Aging And Independence Of Older Adults||University of California, San Francisco|No|Recruiting|February 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|450|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01869179||65298|
NCT01869426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSLcolics13|Impact of Probiotic Preparation VSL#3 on Infants Colics|Impact of VSL#3 on Infants Colics as Assessed by Average Crying Time||Policlinico Hospital|No|Recruiting|June 2013|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|N/A|90 Days|No|||April 2015|April 30, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869426||65279|
NCT01865435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01655-38|IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE|IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE||Assistance Publique Hopitaux De Marseille|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|N/A|27 Days|No|||September 2015|September 29, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865435||65585|
NCT01865942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-050|Surgical Spinal Decompression of Metastatic Spinal Cord Compression, Minimal Access Versus Open Surgery|Surgical Spinal Decompression of Metastatic Spinal Cord Compression, Minimal Access Versus Open Surgery. A Randomized Clinical Trial.||Rigshospitalet, Denmark|Yes|Not yet recruiting|June 2013|October 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01865942||65546|
NCT01866254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13527|Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries|Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries||University of Kansas Medical Center|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866254||65522|
NCT01866579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0041|Early Retinal Nerve Fiber Layer Change of Ethambutol Optic Neuropathy by Optical Coherence Tomography|||Yonsei University|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|20 Years|70 Years|No|Probability Sample|patients who diagnosed with primary lung tuberculosis|May 2014|May 19, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866579||65497|
NCT01866592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817552|Vascular Inflammation in Psoriasis - Extension Study|Vascular Inflammation in Psoriasis - Extension Study|VIP-E|University of Pennsylvania|Yes|Active, not recruiting|April 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866592||65496|
NCT01869608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005|Postpartum Screening of Type 2 Diabetes|Can we Screen Type 2 Diabetes on the 2nd Day After Delivery in Women Who Had Gestational Diabetes Mellitus?|Tot ou tard|Université de Sherbrooke|No|Active, not recruiting|April 2014|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|145|||Female|18 Years|45 Years|No|||January 2016|January 4, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01869608||65265|
NCT01866774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4415|Evaluation of Fecal Calprotectin Screening and a Gastroenterology Questionnaire for Triaging Children With Chronic Abdominal Pain and/or Diarrhea Referred to a Pediatric Gastroenterology Service|Evaluation of Fecal Calprotectin Screening and a Gastroenterology Questionnaire for Triaging Children With Chronic Abdominal Pain and/or Diarrhea Referred to a Pediatric Gastroenterology Service - A Randomized, Controlled Trial||Queen's University|Yes|Terminated|May 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|15|||Both|5 Years|17 Years|No|||October 2015|October 22, 2015|January 3, 2013||No|Primary Investigator (AJN) left institution|No||https://clinicaltrials.gov/show/NCT01866774||65482|
NCT01866787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074-OJ3|Study on Baroreceptor Function in Relation to Orthostatic Blood Pressure Regulation After Hip Surgery|Baroreceptor Function and Inflammation in Relation to Orthostatic Intolerance During Early Mobilization After Elective Hip Arthroplasty||Rigshospitalet, Denmark|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood samples for Hemoglobin measurement and plasma for inflammatory markers.|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective unilateral hip arthroplasty at Frederiksberg Hospital.|January 2015|January 15, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01866787||65481|
NCT01867073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG01/04/11|A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours|||National University Hospital, Singapore|No|Active, not recruiting|May 2011|May 2015|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples|Both|21 Years|N/A|No|Non-Probability Sample|The study will enroll patients from the extension cohort an ongoing phase I study of        OPB51602, to study the tumour response in selected tumour types, as a proof of concept.|May 2013|May 27, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01867073||65459|
NCT01867086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 110|Salvage Ovarian FANG™ Vaccine + Carboplatinum|Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105||Gradalis, Inc.|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867086||65458|
NCT01867866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-102|Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone|A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone||Taiho Oncology, Inc.|No|Active, not recruiting|June 2013|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867866||65398|
NCT01868165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P40221|Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)|Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)||Imperial College London|No|Completed|June 2013|February 2016|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|335|||Both|80 Years|N/A|No|Non-Probability Sample|UK Primary care|May 2014|February 17, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868165||65375|
NCT01868178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 935/2007|Relationship Between Bispectral Index (BIS) and Spectral Entropy (SpEn) During Desflurane Anaesthesia|Relationship Between Bispectral Index (BIS) and Spectral Entropy (SpEn) During Desflurane Anaesthesia||Catholic University of the Sacred Heart|Yes|Completed|September 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Female|30 Years|60 Years|No|Probability Sample|female patients, aged 30-60 years , scheduled for minor elective surgery lasts between 1        and 3 hours were enrolled.|May 2013|May 30, 2013|November 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01868178||65374|
NCT01867879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-103|Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|No|Completed|June 2013|April 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|May 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01867879||65397|
NCT01868191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOE_2013_SB|Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)|Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months.||Diabetes Schwerpunktpraxis|No|Not yet recruiting|July 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|75 Years|No|||May 2013|May 30, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01868191||65373|
NCT01868451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-034|Brentuximab Vedotin Combined With AVD Chemotherapy and Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma|A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|May 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|60 Years|No|||February 2016|February 8, 2016|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868451||65353|
NCT01868906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-FMISO-PET-06-1413|FMISO-PET in Brain Tumors and SCS Effect|Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation|FMISOPETSCS|Dr. Negrin University Hospital|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|75 Years|No|||February 2014|February 26, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01868906||65319|
NCT01868919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIPLEP.PUC.CHILE|Triple P to Improve Behaviour in Children|Implementation Research of a Parenting Intervention to Improve Behaviour in Children in Primary Care|TriplePChile|Pontificia Universidad Catolica de Chile|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|87|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01868919||65318|
NCT01868932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWICS|Treating Wheezing in Children With Hypertonic Saline (TWICS)|Treating Wheezing in Children With Hypertonic Saline (TWICS)|TWICS|Queen's University|Yes|Withdrawn|October 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|6 Years|No|||January 2014|November 12, 2015|May 28, 2013||No|Funding declined. Study never initiated.|No||https://clinicaltrials.gov/show/NCT01868932||65317|
NCT01868945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-24-HyD|Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3|Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3|D-DOSE|DSM Nutritional Products, Inc.|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|59|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01868945||65316|
NCT01869439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV12CL-0003 Revision 09|Measuring Wounds Found on the Outside of the Body Surface|Utilizing Visual and Thermal Images for the Measuring and Monitoring of External Wounds||Wound Vision|No|Active, not recruiting|May 2013|July 2014|Anticipated|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869439||65278|
NCT01865448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNK-DHA-2013-01|Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment|Study to Assess the Effects of DHA (Docosahexaenoic Acid) on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment||Protein Supplies SL|Yes|Active, not recruiting|May 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||June 2013|October 28, 2014|May 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01865448||65584|
NCT01865669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-04|In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity|In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 17, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865669||65567|
NCT01865682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALB-1215|Effect of Ankle-foot Orthoses Trim Line Modifications on Ankle and Knee Motion and Force.|Effects of Varying Trim Lines of Solid Ankle-foot Orthoses on Ankle and Knee Kinematics and Kinetics During Stance Phase.||Southern California Institute for Research and Education|No|Active, not recruiting|December 2012|June 2016|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study seeks to recruit younger, healthy (non-pathological) individuals over 18 years        of age.|July 2015|July 14, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865682||65566|
NCT01866332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP2013/02075-8|Effectiveness of the Addition of the Kinesio Taping Method to Conventional Physical Therapy Treatment in Patients With Chronic Nonspecific Low Back Pain|Effectiveness of the Addition of the Kinesio Taping Method to Conventional Physical Therapy Treatment in Patients With Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial||Universidade Cidade de Sao Paulo|No|Completed|June 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|60 Years|No|||January 2015|January 14, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866332||65516|
NCT01866631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR08/30/10|Using National University Cancer Institute of Singapore (NCIS) Registry to Measure Time Trends in Quality of Care for Breast Cancer Patients in a National Cancer Centre|||National University Hospital, Singapore|No|Recruiting|December 2010|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Female|21 Years|N/A|No|Non-Probability Sample|To retropsectively review the NCIS registry of females diagnosed with breast cancer in        years 2002 to 2008 with regards to clinical quality indicators as published by the        European Sociaty of Breast Cancer Oncologists (Eur J Can 2010; 46:2344-2356). We will        extract data from a pre-existing breast cancer registry which belongs to NCIS, looking at        data which includes the following:(1) Completeness of clinical and imaging diagnostic        work-up(2) Completeness of prognostic and predictive characterization(3) Multidisciplinary        discussion(4) Appropriate surgical approach(5) Appropriate post-operative radiation(6)        Avoidance of over-treatment(7) Appropraiet hormonal therapy(8) Appropriate chemotherapy        and other medical therapy(9) Staging, counselling, follow-up and rehabilitative procedures|December 2013|December 8, 2013|October 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01866631||65493|
NCT01865396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/865|Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.|Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.|IPaC|University Ghent|No|Recruiting|April 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01865396||65588|
NCT01865409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B 30 FTH 0 20 00 00 / 1503|Effect of Kangaroo Care on Heart Rate Variability|Does Kangaroo Care Effects on Heart Rate Variability in Neonates||Fatih University|Yes|Recruiting|June 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|32 Weeks|35 Weeks|No|||September 2014|September 7, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865409||65587|
NCT01866527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003.07|Selective Ultrasound Screening for DDH 1991-2006|Selective Ultrasound Screening for Developmental Hip Dysplasia: Effect on Management and Late Detected Cases. A Prospective Survey During 1991-2006.||University of Bergen|Yes|Completed|January 1991|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81564|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All infants born at the maternity unit at Haukeland University Hospital from January 1991        through December 2006 were included. The hospital provides the only delivery unit for the        city and suburbs of Bergen and a large rural area within the Hordaland County. It serves a        population of approximately 400 000 inhabitants, predominantly ethnic Norwegians. The        annual birth rates varied from 4723 to 6010.        Minimum observation time was 5,5 years.|May 2013|May 28, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01866527||65501|
NCT01866800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0111-13|The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI|Reducing Acute Kidney Injury in TAVI Patients (REDUCE Trial)|REDUCE-AKI|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|65 Years|N/A|No|||September 2013|September 10, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01866800||65480|
NCT01866813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-52-1|Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints|Feasibility And Efficacy Of An Internet-Delivered Cognitive Training Program For Breast Cancer Survivors With Cognitive Complaints||University of Aarhus|Yes|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Female|40 Years|N/A|No|||May 2013|January 9, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01866813||65479|
NCT01866826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130062|Rifaximin for Chronic Immune Activation in People With HIV|A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|January 2013|May 2018|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|September 24, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866826||65478|
NCT01867099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valley 12.0032|Ten-year Outcomes After AF Ablation|Long-term Outcome After Initially Successful Catheter Ablation of Atrial Fibrillation by Pulmonary Vein Isolation: a Ten-Year Cohort Study||Valley Health System|No|Completed|December 2002|December 2012|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|445|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients who underwent PVI ablation for drug refractory AF over a 10 year period and were        free of AF for one year after last ablation procedure|December 2014|December 13, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867099|10 Years|65457|
NCT01867112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-26-13|Physical Activity for Improving Quality of Life and Reducing Frailty in Advanced Age|Physical Activity for Improving Quality of Life and Reducing Frailty in Advanced Age: Individually Tailored Program vs the General Guidelines Recommended by Offical Health Organizations.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 29, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867112||65456|
NCT01867398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913125|Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders|The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder||National Institutes of Health Clinical Center (CC)||Terminated|April 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|320|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01867398||65434|
NCT01867892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2212|A Phase II Study of Locally Advanced Pancreatic Cancer|A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|June 2013|May 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|20 Years|70 Years|No|||May 2013|May 27, 2013|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01867892||65396|
NCT01867905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01716|Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock|The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.||University of British Columbia|No|Recruiting|June 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|361|Samples With DNA|Blood cultures|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (age > 18) who present to the emergency department with severe        sepsis/septic shock .|November 2015|November 16, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867905||65395|
NCT01868204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPMATOBE3002|Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder|Pharmacogenetic Study of Neurofunctional Brain Areas Related to Food Craving in Obese Patients With Binge Eating Disorder Treated With Topiramate||Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|Yes|Not yet recruiting|June 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|Samples With DNA|Genomic DNA will be extracted from 5 ml of peripheral blood using standard method.|Both|18 Years|50 Years|No|Probability Sample|This will be a single-center study that will seek to recruit 60 obese subjects with binge        eating disorder who started taking Topiramate. Eligible male or female subjects, from or        referred to, the Eating Disorder Clinic will be invited to participate in the study.        Obesity will be defined as having a body mass index ≥ 30 kg/m2.|May 2013|June 3, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868204||65372|
NCT01868984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-468|Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis|The Use of Intravascular Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis: A Randomized Study|PaciFIST-1|Englewood Hospital and Medical Center|No|Terminated|May 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|September 14, 2015|May 29, 2013|Yes|Yes|catheters no longer available - difficult to recruit subjects|No||https://clinicaltrials.gov/show/NCT01868984||65313|
NCT01869244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/13/03/02/2013|WOODCAST Hand Resting Splint - Study of User Experience|User Experience From WOODCAST 2mm Hand Resting Splint||Onbone Oy|No|Enrolling by invitation|May 2013|October 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients whos treatment involves a hand resting splint. Finnish language skills (written        and spoken).|May 2013|April 28, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869244||65293|
NCT01868646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-SU-004|Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus||Materia Medica Holding|No|Recruiting|May 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|190|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01868646||65338|
NCT01868659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201002794|Diagnostic Time-Out: A Randomized Clinical Trial of a Checklist to Improve Diagnostic Accuracy|Diagnostic Time-Out: A Randomized Clinical Trial of a Checklist to Improve Diagnostic Accuracy||University of Iowa|No|Completed|April 2010|May 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|114|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868659||65337|
NCT01868958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058267|DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy|Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy||Emory University|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|26|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients at the Emory Orthopaedics & Spine Center suffering signs and symptoms of cervical        myelopathy and with evidence of radiographic cervical cord compression with or without        abnormal spinal cord signal intensity secondary to spondylosis.|July 2015|July 14, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01868958||65315|
NCT01868971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDPR100|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||October 9, 2013|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868971||65314|
NCT01869205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCR2013-0368|The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients|The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients||Asan Medical Center|Yes|Recruiting|March 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||December 2013|December 16, 2013|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01869205||65296|
NCT01869452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Platform|Platform Therapeutic Education in Heart Failure and Coronary Disease|Telephonic Platform of Follow up, Therapeutical Education and Coordination in Secondary Prevention in Patients With Heart Failure and Coronary Disease|METISCARDIO|Resicard|No|Completed|May 2010|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|555|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01869452||65277|
NCT01865461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00197-38|Evaluation of MRI Sequences in Hepatic Overload|Evaluation of MRI Sequences in Hepatic Overload.|HEPAT_MR|Rennes University Hospital|Yes|Recruiting|June 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with or suspected clinically to be with a hepatic overload pathology (hepatic        iron and/or fat overload)|January 2016|January 25, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01865461||65583|
NCT01865695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16190|Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase|Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Terminated|May 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|16 Years|N/A|No|||March 2015|March 10, 2015|May 21, 2013||No|Lack of participant enrolment|No||https://clinicaltrials.gov/show/NCT01865695||65565|
NCT01866917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-11-397|Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women|Effectiveness of Transversus Abdominis Plane Block in Reducing Immediate Postoperative Pain in Obese Women After Laparoscopic or Robotic Gynecologic Procedures||Montefiore Medical Center|Yes|Recruiting|April 2013|||April 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866917||65471|
NCT01866930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-032|Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV|Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV|DIMENSION|Bristol-Myers Squibb|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01866930||65470|
NCT01866514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07|Proximal Humerus Site for Anesthesia|A Study Evaluating Use of the Proximal Humerus Intraosseous Vascular Access Site for Anesthesia Patient Positioning||Vidacare Corporation|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|June 5, 2014|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866514||65502|
NCT01867125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB28688|A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication||Hoffmann-La Roche||Active, not recruiting|July 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1081|||Both|18 Years|75 Years|No|||October 2015|October 1, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867125||65455|
NCT01867138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|563|Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin|Clinical Outcome of Newborn Infants With Suspected Nosocomial Coagulase-negative Staphylococcal Sepsis Treated With Cefazolin or Vancomycin. A Non-inferiority, Randomized, Controlled Trial||Hospital Italiano de Buenos Aires|Yes|Completed|March 2007|January 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|N/A|4 Months|No|||May 2013|May 31, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867138||65454|
NCT01866865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913134|Adaptation to Living With a BRCA1/2 Mutation|Adaptation to Living With a BRCA l/2 Mutation in Carriers and Their Partners||National Institutes of Health Clinical Center (CC)||Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|460|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01866865||65475|
NCT01867645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPNM|The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis|The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial|CIPNM|Medical University of Vienna|No|Terminated|December 2004|April 2011|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|80 Years|No|||May 2013|May 29, 2013|May 23, 2013||No|The trial was terminated early due to futility in reaching the primary endpoint.|No||https://clinicaltrials.gov/show/NCT01867645||65415|
NCT01867918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1392 REK South East C|LOTCOL Study: Local Treatment of Colo-rectal Liver Met|A Randomized Study With Palliative Chemotherapy With or Without Local Treatment of Liver Metastases in Patients With Colo-rectal Cancer|LOTCOL|Oslo University Hospital|No|Recruiting|May 2013|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01867918||65394|
NCT01867606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1267|Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery|MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients||Mayo Clinic|No|Active, not recruiting|October 2013|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||June 2015|July 15, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867606||65418|
NCT01867619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0595 Phase II|Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients|A Phase II Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain||M.D. Anderson Cancer Center|No|Withdrawn|February 2006|||February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|May 29, 2013||No|Phase I study did not progress to Phase II.|No||https://clinicaltrials.gov/show/NCT01867619||65417|
NCT01868230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 DK097011-01|Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women|||University of Massachusetts, Amherst|No|Recruiting|January 2014|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|333|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01868230||65370|
NCT01868464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0033|Challenge Model for Assessment of Human TB Immunity|Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|November 19, 2015|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01868464||65352|
NCT01868685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2207|Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients|An Exploratory, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of BYM338 on Muscle in Patients Requiring Prolonged Mechanical Ventilation||Novartis|Yes|Withdrawn|April 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|N/A|N/A|No|||January 2015|January 6, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01868685||65335|
NCT01868698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-8004|Effects of High Voltage Electrical Stimulation, Shortwave Diathermy and Kinesiotherapy on Arterial Blood Flow in the Lower Limbs of Diabetic Women|||University of Sao Paulo|Yes|Completed|January 2009|January 2012|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Female|40 Years|90 Years|No|||May 2013|May 30, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868698||65334|
NCT01868711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6806R|Psychological Mindedness as a Predictor of Success in Cognitive Behavior Therapy for Depression|Psychological Mindedness as a Predictor of Success in CBT for Depressed Patients||New York State Psychiatric Institute|No|Recruiting|July 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01868711||65333|
NCT01868672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1808|Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial|Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial||University of North Carolina, Chapel Hill|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 1, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01868672||65336|
NCT01869478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002496|Feasibility Study of IV rtPA vs. Primary Endovascular Therapy for Acute Ischemic Stroke|Endovascular Arterial Reperfusion vs. Intravenous ThromboLYsis for Acute Ischemic Stroke (EARLY): A Randomized Pilot Study of Ultra-early (&lt;2 Hours) and Early (2-4.5 Hours) Reperfusion Therapy|EARLY|Mayo Clinic|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869478||65275|
NCT01869491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA1210|Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study|A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease||Reckitt Benckiser Healthcare (UK) Limited|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1107|||Both|18 Years|65 Years|No|||May 2014|May 12, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01869491||65274|
NCT01869218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1025.cc|Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy|Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy in Patients With Advanced Malignancies||University of Colorado, Denver|Yes|Active, not recruiting|November 2012|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples With DNA|Tumor tissue, whole blood|Both|18 Years|N/A|No|Non-Probability Sample|-  Patients with advanced solid or hematological malignancy that is resistant to             standard therapy or for which no standard therapy is available.          -  Patients who are considered for early phase clinical trials in which an             investigational agent is used either alone or in combination with chemotherapy or             radiation.          -  Patients with a primary or metastatic tumor lesion that is amenable to biopsy or             resection|February 2016|February 2, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01869218||65295|
NCT01869231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17070401|Evaluating the Efficacy of Current Treatments for Reducing Postoperative Ileus|||Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo|Yes|Completed|April 2010|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|360|||Both|18 Years|90 Years|No|||May 2013|June 4, 2013|May 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01869231||65294|
NCT01869465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESIUPT2013|Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis|Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial|ESIUPT|Makerere University|No|Active, not recruiting|October 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1277|||Both|10 Years|17 Years|No|||June 2013|June 1, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01869465||65276|
NCT01865474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-0212|Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus|DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus||Dexa Medica Group|No|Recruiting|May 2013|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|25 Years|65 Years|No|||November 2015|November 25, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01865474||65582|
NCT01865487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-035-456|A Phase I/IIa Safety & Immunogenicity of AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)|A Phase I/IIa Double-Blind, Randomized, Placebo-controlled Dose-Finding Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults With and Without Latent Tuberculosis Infection||Aeras|Yes|Completed|August 2013|November 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|98|||Both|18 Years|50 Years|No|||January 2016|January 4, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01865487||65581|
NCT01866306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-218|A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)|A Dose-Finding and Longitudinal Biomarker Study of Rhinovirus Challenge in Healthy Volunteers and Mild-Moderate Asthmatics to Evaluate the Safety and Use of a Human Rhinovirus Preparation in Developing High Dimensionality Phenotypes ("Handprints") for Asthma||Merck Sharp & Dohme Corp.|No|Completed|October 2013|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01866306||65518|
NCT01866319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-006|Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)|A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|August 2013|March 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|834|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|May 28, 2013|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT01866319||65517|
NCT01866241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUST-17-2012|Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage|Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage||Mbarara University of Science and Technology|Yes|Completed|November 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1140|||Female|18 Years|38 Years|No|||September 2014|September 5, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866241||65523|
NCT01866553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NordDutchCML009|Nilotinib Plus Pegylated Interferon-α2b in CML|A Phase II, Single Arm, Multicenter Study of Nilotinib in Combination With Pegylated Interferon-α2b in Patients With Suboptimal Molecular Response or Stable Detectable Molecular Residual Disease After at Least Two Years of Imatinib Treatment (NordDutchCML009)||VU University Medical Center|Yes|Recruiting|April 2013|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01866553||65499|
NCT01866878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-13|Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.|Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.|FINGER|Centre Hospitalier Universitaire de Nice|No|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01866878||65474|
NCT01867385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130142|The Physiology of Fatigue in Patients With Chronic Liver Disease|The Physiology of Fatigue in Patients With Chronic Liver Disease||National Institutes of Health Clinical Center (CC)||Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|N/A|||Actual|12|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01867385||65435|
NCT01867151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS2013|Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome|Effetto Della Dieta Priva di Glutine in Soggetti Con BMS||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Recruiting|May 2013|March 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||May 2013|May 31, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01867151||65453|
NCT01867658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO12-102|Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery|A Prospective Multi-Center Clinical Study to Evaluate the Safety of Progel® Pleural Air Leak Sealant in Video Assisted and Robotic Assisted Thoracotomy Surgery||C. R. Bard|No|Completed|June 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01867658||65414|
NCT01867632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-073-PED|Acellular Dermal Matrix in Primary Furlow Palatoplasty|Does Acellular Dermal Matrix Reduce Fistula Rate in Primary Furlow Palatoplasty||McGill University Health Center|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|70|||Both|3 Months|3 Years|No|Non-Probability Sample|Children who present to the Montreal Children's Hospital with a cleft palate (Veau II-IV)        that undergo surgical repair between the age of 3 months and 3 years.|March 2016|March 18, 2016|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01867632||65416|
NCT01868243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAWA2013|Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively|Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study|DAWA|Hospital Ana Nery|Yes|Terminated|August 2013|October 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|64 Years|No|||September 2015|September 14, 2015|May 28, 2013||No|because a significant decrease of viable candidates for the study.|No|June 24, 2015|https://clinicaltrials.gov/show/NCT01868243||65369|
NCT01868256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PAP-2011-07|Safety of Early Discharge Following Low Risk Myocardial Infarction|Safety of a Early Discharge Strategy in Patients With Low-risk ST-segment Elevation Myocardial Infarction Treated With Primary Coronary Intervention: a Randomized Controlled Trial|EDAMI|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|January 2012|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1558|||Both|18 Years|90 Years|No|||May 2013|May 30, 2013|November 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01868256||65368|
NCT01868477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2421|Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.|An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome.||Novartis|No|Recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01868477||65351|
NCT01875016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRASH|CRyo-Ablation to Treat Patients With HOCM.|Endocardial Catheter CRyo-Ablation of Septal Hypertrophy for Hypertrophic Obstructive Cardiomyopathy|CRASH|Shaare Zedek Medical Center|No|Not yet recruiting|June 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01875016||64850|
NCT01875367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2012-07|A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).|Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC) Who Have Received Intravenous Trastuzumab at Least 4 Months and Without Disease Progression|ChangHER-SC|Spanish Breast Cancer Research Group|No|Recruiting|September 2013|May 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||December 2013|December 16, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875367||64824|
NCT01875380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-13-01|Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer|A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)|REFRAME|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Active, not recruiting|June 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875380||64823|
NCT01875692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-051|Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?|Culture Versus Genomics: Study of Oropharyngeal and Tracheal Flora in Intubated Patients. Can we Better Understand the Development of Ventilator-Acquired Pneumonia (VAP) and Predict Its Causing Pathogen(s)?||University Hospital, Geneva|No|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|286|||Both|18 Years|N/A|No|Non-Probability Sample|ICU adult patients intubated in the last 24h for a condition that will probably require        more than 3 days of mechanical ventilation.|December 2014|December 2, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01875692||64800|
NCT01875705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28885|A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875705||64799|
NCT01875991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090176|Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept|An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept||Amgen|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||April 2015|May 1, 2015|June 10, 2013|Yes|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01875991||64777|
NCT01876771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX-LUT-001|A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours|An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours|NAP|AHS Cancer Control Alberta|No|Recruiting|April 2014|April 2023|Anticipated|April 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|14 Years|90 Years|No|||April 2015|November 16, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876771||64717|
NCT01876485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-426|Point-of-care Health Literacy and Activation Information to Improve Diabetes Care|Point-of-care Health Literacy and Activation Information to Improve Diabetes Care||VA Office of Research and Development|Yes|Recruiting|July 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|284|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876485||64739|
NCT01877252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRITISCH132105|Registry of First-line Treatments in Patients With Critical Limb Ischemia|National Registry Investigating the Effectiveness of Different First-line Treatment Strategies in Patients With Critical Limb Ischemia|CRITISCH|St. Franziskus Hospital|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1200|||Both|18 Years|N/A|No|Probability Sample|The target population consists of patients suffering from critical limb ischemia lasting        more than 2 weeks|November 2014|November 18, 2014|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01877252|2 Years|64680|
NCT01905644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/VL-01|Verifying Post-delivery Anal Sphincter Integrity Using Perineal Ultrasound: Impact on Immediate Care|Verifying Anal Sphincter Integrity in the Delivery Room Using a Specific Perineal Ultrasound: Impact on Immediate Care and Postpartum Anal Incontinence Rates in Mothers Undergoing Vaginal Birth|OASIS 2|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|276|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905644||62503|
NCT01906905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC13053|A Comparative Trial of TMS Approaches to Treating Depression|A Comparative Trial of TMS Approaches to Treating Depression||The University of New South Wales|No|Recruiting|June 2013|||July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Both|18 Years|N/A|No|||December 2014|December 2, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906905||62406|
NCT01878032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130154|Color Vision as a Measure for Inherited Retinal Diseases|Color Vision as an Outcome Measure for Clinical Trials of Inherited Retinal Degenerations||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|233|||Both|5 Years|N/A|No|||March 2015|April 11, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878032||64620|
NCT01873976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL109090-01A1|Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)|Cardiac Biomarkers in Pediatric Cardiomyopathy||Wayne State University|Yes|Recruiting|June 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|480|Samples Without DNA|Plasma, Serum|Both|N/A|20 Years|No|Non-Probability Sample|Pediatric cases of dilated and hypertrophic cardiomyopathy will be recruited at 11        pediatric cardiology centers in the US and Canada.|October 2015|October 9, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873976||64930|
NCT01873989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105008492|Testosterone Replacement for Male Opioid Agonist Maintained Patients|Testosterone Replacement for Male Opioid Agonist Maintained Patients||Yale University|No|Recruiting|April 2012|September 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|50 Years|No|||January 2014|January 13, 2014|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873989||64929|
NCT01874223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23346|Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Stanford University|No|Not yet recruiting|June 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with IPF as defined by ATS guidelines|June 2013|June 6, 2013|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874223||64911|
NCT01874470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allegro-HTN|Renal Denervation by Allegro System in Patients With Resistant Hypertension|Renal Denervation by Allegro System in Patients With Resistant Hypertension||Shanghai AngioCare Medical|Yes|Recruiting|May 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||December 2013|December 11, 2013|June 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874470||64892|
NCT01874210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51367|Study on Colonic Fermentation in Chronic Kidney Disease Patients|Study on Colonic Fermentation in Chronic Kidney Disease Patients||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|75|Samples Without DNA|Fecal sample, serum|Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated with renal replacement therapy, i.e. hemo- or peritoneal dialysis for        more than 3 months|December 2014|December 2, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874210||64912|
NCT01874730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038567|KOREAN Enhanced RecOvery Strategy for Colorectal Surgery|KOREAN Enhanced RecOvery Strategy for Colorectal Surgery|KEROS|Duke University|No|Terminated|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|101|||Both|45 Years|80 Years|No|||August 2015|August 5, 2015|June 4, 2013|No|Yes|Very slow accrual because sites have few open colorectal surgery|No||https://clinicaltrials.gov/show/NCT01874730||64872|
NCT01874444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN2447|Verify the Effectiveness rTMS Using MEG|Verify the Effectiveness rTMS Using MEG|rTMS|Seoul National University Hospital|Yes|Active, not recruiting|May 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|28|||Both|18 Years|70 Years|No|||December 2013|November 18, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01874444||64894|
NCT01875419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0256|Non-invasive Brain Stimulation and Cognitive Processing in Depression|||University College, London|Yes|Recruiting|July 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2015|February 2, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01875419||64820|
NCT01875029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Back Pain_tDCS|tDCS Effects on Chronic Low Back Pain|The Effects of Transcranial Direct Current Stimulation (tDCS)Combined With Back School in Subjects With Chronic Low Back Pain. Randomised Control Trial Study.||University Hospital of Ferrara|Yes|Completed|January 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||January 2014|January 15, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01875029||64849|
NCT01875718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM104|A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)|A Randomized, Double-blind, Placebo-controlled Parallel-group Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UC1010 Administered Subcutaneously, Single-dosing in Healthy Women (Part 1) and Multiple Dosing in PMDD Women (Part 2) - Phase I/II Study||Umecrine Mood AB||Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|146|||Female|18 Years|45 Years||||January 2015|January 19, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01875718||64798|
NCT01875731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE 67-2012|Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine|Efficacy of BPS (Bacterial Pneumonia Score) Guided Antibiotic Use in Children With Community Acquired Pneumonia on Reducing Antibiotic Use as Compared to Standard Care Practice (Current Guidelines for CAP) in the Era of Pneumococcal Vaccine||Hospital General de Niños Pedro de Elizalde|Yes|Completed|July 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|65|||Both|3 Months|5 Years|No|||April 2015|April 16, 2015|June 10, 2013||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01875731||64797|
NCT01876004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP UNIFESP 0772/11|Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy|Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy||Federal University of São Paulo|No|Completed|September 2011|June 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||June 2013|June 10, 2013|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876004||64776|
NCT01876251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8641016|A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer|Phase 1b Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer||Pfizer|No|Terminated|November 2013|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|June 10, 2013|No|Yes|The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014    development. There were no safety/efficacy concerns behind the decision.|No||https://clinicaltrials.gov/show/NCT01876251||64757|
NCT01876264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERT2013|Crohn's Extent of Resection Trial|Crohn's Extent of Resection Trial (CERT): A Randomised Controlled Trial Comparing Anastomotic Disease Recurrence Following 2cm Versus 10cm Resection Margins for Patients With Ileocolic Crohn's Disease|CERT|Oxford University Hospitals NHS Trust|No|Recruiting|June 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|16 Years|80 Years|No|||July 2013|July 7, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876264||64756|
NCT01876498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brief MHQ1|Registry of Patient With M. Dupuytren and Validation of the Brief MHQ|Buildup of a Registry of Patient With M. Dupuytren and Validation of the Brief Michigan Hand Questionnaire||Schulthess Klinik|No|Active, not recruiting|August 2013|September 2017|Anticipated|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|patients with M.Dupuytren with Xiapex injection or surgery|October 2014|October 13, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876498|3 Years|64738|
NCT01876511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1365|Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors|Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2013|October 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|171|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876511||64737|
NCT01876784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4203C00011|Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.|VERIFY|AstraZeneca|No|Active, not recruiting|September 2013|May 2017|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|130 Years|No|||March 2016|March 18, 2016|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876784||64716|
NCT01877018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/01994|Colorectal Cancer Screening in Primary Care|Effectiveness of an Electronic Alert Into the Primary Care Medical Health Record to Increase Participation in a Population Colorectal Cancer Screening Program.|COLO-ALERT|Jordi Gol i Gurina Foundation|No|Completed|September 2010|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|41042|||Both|50 Years|69 Years|No|||March 2014|March 27, 2014|June 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01877018||64698|
NCT01877044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123050|Long-term Effects of Arabinoxylans on Intestinal Barrier Function|The Effects of Long-term Arabinoxylan Administration on Intestinal Barrier Function and Innate Immunity||Maastricht University Medical Center|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01877044||64696|
NCT01905904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ulkü_2|Sevoflurane in Electroconvulsive Therapy|The Comparision of Different Doses of Sevoflurane for Induction of General Anesthesia in Electroconvulsive Therapy||Inonu University|No|Completed|March 2013|June 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|60 Years|No|||July 2013|July 22, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905904||62483|
NCT01905917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The STARS Study|The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study|The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study: A Randomized Controlled Trial|STARS|National University, Singapore|No|Recruiting|November 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||March 2016|March 21, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905917||62482|
NCT01907191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-06-001|Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy|Comparison of Bupivacaine to Liposomal Bupivacaine for Ultrasound Guided Periarticular Hip Infiltration for Postoperative Analgesia After Hip Arthroscopy.||Saint Francis Care|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|June 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907191||62384|
NCT01907204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinusitis001|Evaluation of Inhaled Treatment in Sinusitis|Evaluation of Inhaled Corticosteroid Treatment in Sinusitis||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|July 2013|January 2014|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|70 Years|No|||January 2014|January 24, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01907204||62383|
NCT01878045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913151|Mechanisms of Diabetic Kidney Disease in American Indians|Determinants of Diabetic Nephropathy in American Indians||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2013|January 2035|Anticipated|December 2022|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|November 3, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878045||64619|
NCT01874002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12_186|Prospective Registry to Asses the Long-term Safety and Performance of the Combo Stent|Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry|REMEDEE Reg|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|June 2013|March 2019|Anticipated|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|The registry population consists of consecutive patients in whom a treatment with a Combo        stent in the setting of routine clinical care is attempted.|December 2015|December 29, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874002|5 Years|64928|
NCT01874015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-GI-003|Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease|Transplantation of Bone Marrow Mesenchymal Stem Cell in Moderate to Severe Fistulizing Crohn's Disease||Royan Institute|Yes|Recruiting|February 2013|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|December 3, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874015||64927|
NCT01874236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300164|Validity and Reliability of Diagnostic Findings of SI Joint Blocking|VaReFi Validity and Reliability of Diagnostic Findings of SI Joint Blocking|VaReFi|SI-BONE, Inc.|No|Terminated|June 2013|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|28|||Both|21 Years|75 Years|No|||March 2015|March 20, 2015|May 30, 2013||No|study design under review|No||https://clinicaltrials.gov/show/NCT01874236||64910|
NCT01874249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAFLD|Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease|Randomized Clinical Trial to Detect Advanced Fibrosis by Non-invasive Methods in Subjects With Non-alcoholic Fatty Liver Disease||Fundación Clínica Médica Sur|Yes|Active, not recruiting|July 2012|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|5||Anticipated|594|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||June 2013|July 2, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01874249||64909|
NCT01874483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|71|||Both|20 Years|70 Years|No|||January 2016|January 26, 2016|June 7, 2013||||No||https://clinicaltrials.gov/show/NCT01874483||64891|
NCT01874496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-05|Iron Absorption From GDS Capsules|Iron Absorption Mechanism From a Slow Release Iron Capsule Using the Gastric Delivery System||Swiss Federal Institute of Technology|No|Completed|May 2013|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|4|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01874496||64890|
NCT01874743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 043 CESAR|Rosuvastatin to Decrease Residual Immune Activation in HIV Infection|Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRétroviraux)|CESAR|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Yes|Recruiting|March 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2012|June 11, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01874743||64871|
NCT01875068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002913|A Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants|Implementing a Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants||Mayo Clinic|No|Recruiting|July 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01875068||64846|
NCT01875081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-BD-CT-P-002|REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)|Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient.||Pharmicell Co., Ltd.||Completed|November 2012|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|20 Years|70 Years|No|||March 2016|March 16, 2016|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875081||64845|
NCT01875770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPTURE|Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)|Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)|CAPTURE|Johns Hopkins University|No|Active, not recruiting|January 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|115|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who have been enrolled in the following three trials will be included in the        study:        A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple        Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein        Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal        vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with        intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and        the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach        (RELATE)"|April 2015|April 1, 2015|June 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875770||64794|
NCT01875393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1201 PCM304|Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy for Localized Prostate Cancer|Study of the Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer|PCM304|Steba Biotech S.A.|No|Completed|May 2013|March 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Male|18 Years|N/A|No|||April 2015|April 27, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875393||64822|
NCT01875744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/2013|Polyethylene Glycol for Childhood Constipation|||Medical University of Warsaw|No|Recruiting|June 2013|||November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|1 Year|18 Years|No|||November 2013|November 1, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01875744||64796|
NCT01876277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890-PSY-13|Body Image Issues in Boys Being Treated at the Royal Marsden|What Are the Psychosocial Implications of Body Image Issues in Adolescent Males With Cancer?||University of Surrey|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7|||Male|13 Years|21 Years|No|Non-Probability Sample|Adolescent males who have been treated for cancer at the Royal Marsden Hospital within the        past 5 years.|May 2014|May 20, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876277||64755|
NCT01876524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tRNS01072013|tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients|Transcranial Random Noise Stimulation in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients|tRND&SUDs|Spanish Foundation for Neurometrics Development|Yes|Completed|July 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|60 Years|No|||October 2014|October 16, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876524||64736|
NCT01876537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZHKB-2015|Hardware Wound Healing In Surgical Treatment Of Sacrococcygeal Pilonidal Sinus Disease|Phase 1 STRENGTHENING OF THE SACROCOCCYGEAL FASCIA IN THE SURGICAL TREATMENT OF PILONIDAL SINUS DISEASE|HWHPSD|Voronezh N.N. Burdenko State Medical Academy|Yes|Active, not recruiting|January 2011|||June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||June 2013|June 11, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876537||64735|
NCT01876550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUPC 1106|A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.|A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban® Cream (Mupirocin Calcium Cream, 2%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions.||Taro Pharmaceuticals USA|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|696|||Both|18 Months|N/A|No|||June 2014|June 9, 2014|June 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01876550||64734|
NCT01876563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17112|the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes|||Tehran University of Medical Sciences|Yes|Enrolling by invitation|August 2012|July 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|60 Years|No|||June 2013|June 10, 2013|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876563||64733|
NCT01877031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-607|Virtual Reality With Ultrasound Versus Ultrasound For Central Line Insertion|Needle Guidance With Virtual Reality Augmented Ultrasound Versus Ultrasound Guidance Alone For Central Line Insertion: A Randomized Trial.||Lawson Health Research Institute|No|Recruiting|April 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|192|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01877031||64697|
NCT01877577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDVitD-42012|Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D|Supplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.||University of California, San Francisco|No|Completed|April 2012|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877577||64655|
NCT01906671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-MP formulation|Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid|Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia.||Rigshospitalet, Denmark|Yes|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|18 Years|No|||March 2015|March 19, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906671||62424|
NCT01906697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92--02-48-6933|The Effect of RF Turbinoplasty in Polypoid Change of Middle Turbinates|The Effect of RF Turbinoplasty Versus Two Other Methods in Management of Polypoid Change of Middle Turbinates: A Randomized Trial.||Tehran University of Medical Sciences|No|Active, not recruiting|May 2011|October 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01906697||62422|
NCT01877824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDU001|Study of Fast-track Surgery in Hernia Repair and Laparoscopic Cholecystectomy|Consequences of Fast-track Training in Surgery in Denmark in Selected Operative Skills.||University of Aarhus|No|Completed|March 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|35|||Both|20 Years|70 Years|No|||June 2013|June 11, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01877824||64636|
NCT01878058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5302-CE|Identifying Prostate Brachytherapy Seeds Using MRI|Identifying Prostate Brachytherapy Seeds Using MRI||University Health Network, Toronto|No|Active, not recruiting|October 2012|September 2016|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|18 Years|N/A|No|||June 2015|June 16, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01878058||64618|
NCT01874275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VECTTOR DMD2012|Duchenne Muscular Dystrophy Clinical Trial|Double-blind, Randomized, Placebo-controlled Study of VECTTOR Treatment for Duchenne Muscular Dystrophy|DMD|Alan Neuromedical Technologies, LLC|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|8 Years|20 Years|No|||April 2015|April 14, 2015|June 7, 2013|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01874275||64907|
NCT01874262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CV-1301|A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction|A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction - SUPPORT|SUPPORT|AstraZeneca|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|174|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 29, 2013||No||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01874262||64908|
NCT01874509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFP 285651|Randomized Controlled Trial of a Minimal Versus Extended Internet-based Intervention for Problem Drinkers|Randomized Controlled Trial of a Minimal Versus Extended Internet-based Intervention for Problem Drinkers||Centre for Addiction and Mental Health|No|Active, not recruiting|June 2013|March 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01874509||64889|
NCT01874782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03534|Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury|Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury||University of British Columbia|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||August 2015|August 20, 2015|February 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874782||64868|
NCT01874756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303010802|The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia|The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia|Beta|Indiana University|Yes|Recruiting|June 2013|June 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Male|18 Years|60 Years|No|||February 2016|February 22, 2016|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874756||64870|
NCT01874769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-22|Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|RDEB|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|30|Samples With DNA|All patients will have a blood sample of 5 ml on EDTA, 10 ml on heparin and 5 ml on dry tube      collected for genomic DNA extraction to identify or verify COL7A1 mutations: mutation      screening of the patients will be performed to identify COL7A1 mutations on both alleles. 2)      HLA genotyping: patients selected on the clinical and molecular criteria will be      HLA-genotyped by PCR to determine the likelihood of an immune response to the type VII      collagen wild-type protein. A 5-mm punch skin biopsy performed under local anaesthesic will      be undertaken during visit 1 for diagnostic purposes .The consequences of COL7A1 mutations      on collagen VII protein expression will be determined, if not performed previously. Two      additional 5-mm punch skin biopsies will be taken from different areas from up to 10      patients during the second visit. Keratinocytes and fibroblasts will be expanded and stored      in vapor-phase liquid-nitrogen.|Both|7 Years|65 Years|No|Non-Probability Sample|Adults and children with RDEB|December 2013|December 17, 2013|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01874769||64869|
NCT01875094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212M25581|Self-Management in Stroke Survivors|Promoting Self-Management in Stroke Survivors Using Health IT||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|40 Years|80 Years|No|||January 2016|January 15, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01875094||64844|
NCT01875107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301M26861|Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients|Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|August 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 10, 2014|June 3, 2013||No|Time constraints of primary investigator.|No||https://clinicaltrials.gov/show/NCT01875107||64843|
NCT01875406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-416|a Diagnostic SIJ Injection Following a Composite of 3 Diagnostic Tests and a Pain Referral Diagram|Diagnosis of Sacroiliac Joint Pain: Predictive Value of a Diagnostic SIJ Injection Following a Composite of 3 Diagnostic Tests and a Pain Referral Diagram||The Cleveland Clinic|No|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|18 Years|90 Years|No|||July 2015|July 29, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01875406||64821|
NCT01876303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPI10N5|Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma|Genetic Epidemiology of Ewing's Sarcoma||Children's Oncology Group|No|Recruiting|December 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|1650|Samples With DNA|saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a diagnosis of Ewing Sarcoma meeting other criteria.|November 2015|November 16, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876303||64753|
NCT01876290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/14|Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting|Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?|Loop-NVPO|Hopital Foch|No|Completed|May 2013|March 2015|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01876290||64754|
NCT01877057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133001|Protected Pea Protein Extract and Satiety Hormone Release|Assessment of the Effects of Gastric Degradation-protected Pea Protein Extract on Mucosal Satiety Hormone Release by Human Duodenal Tissue||Maastricht University Medical Center|Yes|Completed|March 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01877057||64695|
NCT01876797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyeong-Seok Lim|PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males|A Single Dose, Open-label, One Sequence, 2-period, Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Adult Subjects||Asan Medical Center|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876797||64715|
NCT01877850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPn1351|Utility of a Weaning Protocol in ICU|Non Pharmacological Randomized Clinical Trial Designed to Evaluate the Difference of the Duration of Weaning Process From the Ventilator Between Protocol-driven Weaned Patients and Clinical-driven Weaned Patients.|WEAN|Università degli Studi di Brescia|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|N/A|N/A|No|Probability Sample|difficult to wean patients|April 2015|April 22, 2015|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01877850||64634|
NCT01906229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|959521891|Lung and Systemic Inflammation in the Critically Ill Patient|Acute Pulmonary and Systemic Inflammation in Mechanically Ventilated Intensive Care Patients||Rigshospitalet, Denmark|Yes|Recruiting|July 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|18|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care unit|February 2016|February 23, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906229||62458|
NCT01899183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic Cough and GERD|Surgery in Chronic Cough GERD Related|Effectiveness of Anti-reflux Surgery for the Cure of Chronic Cough Associated With Gastro-oesophageal Reflux Disease|CCGERD|University of Bologna|No|Completed|January 1995|January 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|GERD and Chronic Cough (< 8 weeks).|July 2013|July 10, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899183||62997|
NCT01874028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-001PK|A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients|A Phase 1 Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson's Disease.||Univar BV|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|6 Years|90 Years|No|||September 2014|September 18, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874028||64926|
NCT01874795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071/2011|Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure|Effect of Ganglionar Transcutaneous Electrical Nerve Stimulation on Central Arterial Pressure in Healthy Young Population||University of Brasilia|Yes|Completed|March 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01874795||64867|
NCT01875133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0088|Patients With Chronic Obstructive Pulmonary Disease At Altitude|Effect of Altitude on Exercise Performance of Patients With Chronic Obstructive Lung Disease||University of Zurich|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|50|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01875133||64841|
NCT01874522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-104|Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI|A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI||Taiho Oncology, Inc.|No|Completed|July 2013|November 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874522||64888|
NCT01875471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5305|Clinical Evaluation of Two Daily Disposable Contact Lenses|Clinical Evaluation of Two Daily Disposable Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|279|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|June 7, 2013|Yes|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01875471||64817|
NCT01875809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDN-Cathecholamines-1|Impact of Catecholamine Spill-over on Outcome After RDN and EP Ablation|Impact of Patient-specific and Procedural Characteristics Like Catecholamine Spill-over on the Long-term Outcome After Renal Denervation and EP Ablation|RDN-Cath-1|University of Witten/Herdecke|No|Recruiting|March 2013|||February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|None Retained|Blood for measurement of catecholamines.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing renal denervation or EP Ablation with informed consent fulfilling all        inclusion criteria and None of the exclusion criteria.|June 2013|June 11, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01875809||64791|
NCT01875120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.327.12 (8428-F)|Study to Evaluate Anxiety Sensitivity and Somatic Symptoms as Risk Factors for PONV|Prospective Observational Study to Evaluate Somatic Symptom Load and Anxiety Sensitivity as Risk Factors for Postoperative Nausea and Vomiting (PONV)|somPONV|Johannes Gutenberg University Mainz|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Female|18 Years|75 Years|No|Non-Probability Sample|Female patients in a universitary hospital who are scheduled for elective surgery in        general anesthesia (planned interventions in general surgery, orthopedia, traumatology,        gynecology, neurosurgery (except intracranial interventions)and who present with an        increased risk to experience postoperative nausea and vomiting.|November 2013|November 8, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875120||64842|
NCT01906268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0338|Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants|Attentional Bias Modification Treatment (ABMT) as Adjuvant Therapy for Anxiety Disorder Patients Resistent to Antidepressants: A Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre||Recruiting|July 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01906268||62455|
NCT01906281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joan01|Influence of Adipocytokines in Osteoarthritis|Adipocytokines Influence on Clinical and Ultrasonographic Inflammatory Activity in Patients With Knee Osteoarthritis||Hospital Parc Taulí, Sabadell|Yes|Recruiting|July 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|105|Samples With DNA|First we analyze the blood and articular fluid adipocytokines. If we can define a subset of      patients characterized by a pattern of adipocytokines, genetic analysis will be performed      later.|Both|50 Years|80 Years|No|Probability Sample|patients over 50 years who were referred for rheumatology for symptomatic knee        osteoarthritis.|November 2013|November 7, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01906281||62454|
NCT01875445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013InositolTTM|Inositol in Trichotillomania|A Double-Blind, Placebo-Controlled Study of Inositol in Trichotillomania||University of Chicago|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875445||64819|
NCT01875458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815570|Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use|Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects||University of Pennsylvania|No|Recruiting|May 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Anticipated|500|Samples With DNA|Saliva will be collected from online participants and DNA analysis will be performed.      Blood and tissue samples will be collected from in-person participants. DNA and RNA analysis      will be performed.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults who either have ever taken bisphosphonates (see list under Key Words) and/or who        have ever had an atypical femur fracture or bisphosphonate related osteonecrosis of the        jaws (BRONJ) or both. Also healthy volunteers.|May 2013|December 8, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875458||64818|
NCT01875757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001152-19|Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life|Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life|VitDBR2012|Hospital Universitari Vall d'Hebron Research Institute||Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|718|||Both|N/A|19 Days|No|||September 2015|September 1, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01875757||64795|
NCT01876056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT_CAPRCT_120310|Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis|A Randomized Controlled Trial of Brief Culturally Adapted CBT for Schizophrenia in Pakistan||Pakistan Association of Cognitive Therapists|Yes|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||October 2014|October 27, 2014|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01876056||64772|
NCT01876017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BMCRF/2013//01|Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of of Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Chronic Renal Failure Patients. It is Self Funded (Patients' Own Funding) Clinical Trial||Chaitanya Hospital, Pune|No|Recruiting|September 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|June 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01876017||64775|
NCT01876030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyGait-HMO-CTIL|Comparison of Different Treatment Methods for Gait Rehabilitation of Sub-Acute Post Stroke Patients With Dropped Foot|||Hadassah Medical Organization||Recruiting|June 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2013|November 3, 2013|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01876030||64774|
NCT01876810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082/2012|Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction|Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction||Centre for Addiction and Mental Health|Yes|Completed|February 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|19 Years|65 Years|No|||March 2016|March 10, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01876810||64714|
NCT01877291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-FMUSP 147-13|Young Smokers Have Impaired Airway Defense|Young Smokers Have Impaired Airway Defense That is Not Associated With Pulmonary Function||University of Sao Paulo|Yes|Completed|April 2012|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|72|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy nonsmokers and smokers aged between 18 and 35 y.o. that were recruited from the        Faculdade de Medicina da Universidade de São Paulo|June 2013|June 14, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877291||64677|
NCT01877304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKITA|Effect of Drug Targeting Nebulization on Lung Deposition|Effect of Drug Targeting Nebulization on Lung Deposition||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01877304||64676|
NCT01877278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11262|Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis: Double Blinded, Randomized Clinical Trial|Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis Patients: a Double Blinded, Randomized Clinical Trial||University of Messina|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|40 Years|N/A|No|||January 2015|January 22, 2015|June 11, 2013||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01877278||64678|
NCT01877564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138647|A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women|A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women||University of Arkansas|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|45 Years|65 Years|No|||March 2016|March 16, 2016|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877564||64656|
NCT01906918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC|Application of Remote Ischemic Preconditioning in Patients Undergoing Open Heart Surgeries|Evaluation of Remote Preconditioning on Heart Resistance to Ischemia and Reperfusion Injury||University of Campinas, Brazil|No|Recruiting|August 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2013|November 27, 2013|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906918||62405|
NCT01874288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO-101|Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL|A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)|DI-Leu16-IL2|Alopexx Oncology, LLC|Yes|Recruiting|July 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874288||64906|
NCT01874535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD A and B|Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy|The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis||Chang Gung Memorial Hospital|Yes|Recruiting|June 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|15 Years|80 Years|No|||November 2015|November 1, 2015|November 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01874535||64887|
NCT01874808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAITALS-C12-13|From Movement Preparation to Gait Execution in ALS|From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches|GAITALS|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|June 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational|N/A||3|Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALS patients with motor deficit with or without postural instability|March 2013|August 7, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01874808||64866|
NCT01875484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB518603|Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling|Impact of Circulating miR-126 on Left Ventricular Remodeling and Clinical Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention. The PMIR-miR-126 Study.|PMIR-miR-126|Qilu Hospital|Yes|Completed|February 2012|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1200|Samples With DNA|Blood Samples: serum, plasma, RNA, DNA, microRNAs, CD34+ cells|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing primary PCI for STEMI|July 2015|July 28, 2015|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875484||64816|
NCT01875822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06T-773|Open-label Study of Curcumin C-3 Complex in Schizophrenia|Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia||Woodbury, Michel, M.D.|Yes|Completed|June 2009|May 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||April 2013|June 9, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01875822||64790|
NCT01876069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02-018|Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer|Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Endoscopic Ultrasonography-guided Sampling of Suspected Unresectable Pancreatic Cancer||Samsung Medical Center|Yes|Not yet recruiting|June 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|65|||Both|18 Years|80 Years|No|||June 2013|June 8, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01876069||64771|
NCT01876615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-109|Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac|A Randomized, Open-Label, Single-dosing and Cross-over Clinical Trial to Investigate the Safety and Pharmacokinetic Drug-Drug Interaction of YH4808 and Diclofenac in Healthy Male Volunteers||Yuhan Corporation|No|Completed|July 2013|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|49|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876615||64729|
NCT01906528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-07970|Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium|The Pharmacodynamics of Mivacurium in Males and Females: A Study in Human Volunteers||University of California, San Francisco|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906528||62435|
NCT01876043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2011-02|Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial|Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial|APLIPO|Institut Bergonié||Terminated|February 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01876043||64773|
NCT01876576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.247|The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy|The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy||Thomas Jefferson University|No|Completed|April 2012|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|175|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876576||64732|
NCT01876589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANISH|Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study|Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: a Randomized H215O PET/CT Study|VANISH|VU University Medical Center|No|Recruiting|June 2013|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876589||64731|
NCT01876602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK088800|Test of an Intervention to Increase Physical Activity Among School Children|Feeling States and Heart Rates; A Translational Study||University of California, Irvine|No|Active, not recruiting|April 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876602||64730|
NCT01877863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-25253|The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients|The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients||University of Calgary|Yes|Completed|May 2013|||December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01877863||64633|
NCT01877876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00524E|Assessing the Accuracy of the RevK Sensor|Assessing the Accuracy of the RevK Sensor for Non-Invasive Hemoglobin Monitoring||University of California, San Francisco|No|Completed|June 2013|June 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|8|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing spine surgery|June 2015|June 8, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01877876||64632|
NCT01877590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze029|Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|November 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|66|||Both|40 Years|70 Years|No|||August 2015|August 19, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877590||64654|
NCT01878084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOGLASS-STDF#116|Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction|Phase I/II Trial of Alveolar Bone Engineering Using Bioactive Glass (Sol-Gel) Immediately After Premolar Extraction in Patients Requiring Orthodontic Treatment||Alexandria University|Yes|Active, not recruiting|October 2013|May 2018|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|9 Years|16 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01878084||64616|
NCT01906502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1217|24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population|A Prospective, Open Label Study to Assess the 24-hour IOP Pattern Recorded With SENSIMED Triggerfish® in a Healthy Population||Sensimed AG|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|115|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906502||62437|
NCT01874301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.05.NRC|Probiotics and Gut Health|Evaluation of Changes in Gut Transit Time and Gastrointestinal Symptoms Following the Consumption of a Probiotic Food Product in Adults With Constipation||Nestlé|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01874301||64905|
NCT01874548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-0620A3|MR Metabolic Biomarkers for Cervical Cancer|Magnetic Resonance Study on Metabolism Biomarkers for Cervical Cancer.||Chang Gung Memorial Hospital|No|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Tumor tissue will be collected during the operation or biopsy and will be store in liquid      nitrogen within 5 minutes removal from body. Standard dual phase tissue extraction will be      performed for tumor and cell samples for high resolution MRS analysis.|Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients in a tertiary referral center.|February 2015|February 8, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874548||64886|
NCT01874821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.005|Adhesive Capsulitis and Dynamic Splinting|Adhesive Capsulitis and Dynamic Splinting: a Randomized, Controlled Trial||Dynasplint Systems, Inc.|No|Terminated|January 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|June 7, 2013|No|Yes|Unrelated to trial|No||https://clinicaltrials.gov/show/NCT01874821||64865|
NCT01875159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI 01|Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm|Pilot Study of Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm||American SIDS Institute|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|33 Weeks|37 Weeks|No|||March 2015|March 16, 2015|June 3, 2013||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT01875159||64839|
NCT01875146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vyc|Effects of High-intensity Interval Training in Combination With Side-alternating Whole-body Vibration|Effects of High-intensity Interval Training in Combination With Side-alternating Whole-body Vibration||University of Zurich||Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|33|||Male|18 Years|35 Years|No|||December 2013|January 6, 2014|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01875146||64840|
NCT01875497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E26-103.011/2012|Effect of Vitis Vinifera Extract on Oxidative Stress, Inflamatory Biomarkers and Hormones in High Trained Subjects|Effect of Vitis Vinifera Extract on Oxidative Stress, Inflammatory Biomarkers and Hormones in High Trained Subjects After Resting and Intensive Physical Activity.||Rio de Janeiro State University|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|55|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875497||64815|
NCT01905436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107185|Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia|DOLF-LIBERIA|Washington University School of Medicine|No|Recruiting|March 2012|September 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|15600|Samples Without DNA|Study procedures include collection of finger prick blood that will be tested for      microfilaremia and for serology testing (antigenemia and antibody testing). Investigators      will also collect skin snips (small superficial skin biopsies) to detect Onchocerca      microfilariae, and stool samples to detect parasitic worm eggs indicative of STH infections.      All assays will be performed in Liberia (filarial serology tests, MF smears, stool      examinations).|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study populations are people who live in areas of Liberia that are co-endemic for        lymphatic filariasis and onchocerciasis.|December 2015|December 11, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01905436||62519|
NCT01876082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2011-03|PAZOPANIB Efficacy and Tolerance in Desmoids Tumors|PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial|DESMOPAZ|Institut Bergonié|Yes|Recruiting|July 2012|July 2019|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01876082||64770|
NCT01877655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-CL-1004|A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|HELIOS|Astellas Pharma Inc|Yes|Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877655||64649|
NCT01876823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6277R|Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment|Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment||New York State Psychiatric Institute|No|Completed|April 2006|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|90 Years|No|||September 2013|October 23, 2014|June 5, 2013|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01876823||64713|The inclusion criteria required all patients to have an MMSE of 24 or higher, which may have lowered the conversion rate to dementiasmall sample sizecognitive improvement may have been due in part to combined es-citalopram and memantine
NCT01876836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016||Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications|Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications|C-LMA|Diskapi Yildirim Beyazit Education and Research Hospital|Yes|Not yet recruiting|July 2013|September 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|120|||Both|19 Years|70 Years|No|||June 2013|June 11, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876836||64712|
NCT01875783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-17|OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits|Diabetic Macular Edema Found by OCT Utilization at Non-ophthalmic Diabetes Care Visits|DME FOUND|Joslin Diabetes Center|No|Recruiting|April 2014|January 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|380|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01875783||64793|
NCT01875796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA031937A|Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders|Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders||Louisiana State University and A&M College|Yes|Recruiting|June 2013|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01875796||64792|
NCT01877070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-076|Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies|Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies||Memorial Sloan Kettering Cancer Center||Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|401|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from outpatient clinics at both the Urology Service at        Memorial Sloan-Kettering Cancer Center (MSKCC). Patients may also be contacted by e-mail        (securely using MSKSecure) or by mail.|February 2016|February 25, 2016|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877070||64694|
NCT01877083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-209|Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung|A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung||Eisai Inc.|Yes|Recruiting|April 2013|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877083||64693|
NCT01877317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIT-653820|Study of SelfFit Mobile Medical App for Hearing Loss Diagnostics and Hearing Device Fitting / Fine Tuning|Study of SelfFit App for Hearing Loss Diagnostics Based on Threshold Measurements Through In-situ Audiometry and Adjustment of Hearing Device Amplification Parameters in Agreement With Prescriptive Formulas as NAL-NL1,DSL-i/o|SelfFit|Two Pi Signalprocessing Applications GmbH|Yes|Active, not recruiting|May 2013|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01877317||64675|
NCT01876316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-166|The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover Trial to Compare Moxifloxacin Induced QT Interval Prolongation in Japanese and Korean Healthy Subjects||Inje University|No|Completed|November 2011|January 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|40|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01876316||64752|
NCT01877603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze030|The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes|The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|200|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|From July 2013 to Dec 2013, a total of 200 Chinese Han newly diagnosed type 2 diabetic        patients were selected. They had been referred to our hospital and were aged 40～70 years.        During the same period, 50 healthy subjects (all from medical staff in our hospital) were        selected as control subjects.|June 2015|June 12, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877603||64653|
NCT01877889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101974|A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers|A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects||Janssen-Cilag International NV|No|Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|June 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877889||64631|
NCT01908062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0055|Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study|Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study|CHOICES|Oregon Health and Science University|Yes|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|100 Years|No|||October 2015|October 13, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908062||62317|
NCT01878097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01CE001675|Evaluation of Green Dot a Primary Prevention Intervention|Green Dot Across the Bluegrass: Evaluation of a Primary Prevention Intervention||University of Kentucky|Yes|Completed|November 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|104575|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|March 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01878097||64615|
NCT01874067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-GLOVES v2 26.7.13|C-GLOVES: the Effectiveness of Compression Gloves in Arthritis|C-GLOVES: an Evaluation of the Effectiveness of Compression Gloves in Arthritis: a Feasibility Study|C-GLOVES|University of Salford|No|Completed|October 2013|March 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|100 Years|No|Non-Probability Sample|Rheumatology Occupational Therapy and Hand Therapy out-patient departments|March 2016|March 1, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874067||64923|
NCT01898923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON101CLCT02|Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers|Randomized Controlled Study to Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers|WH-1|Oneness Biotech Co., Ltd.|Yes|Recruiting|September 2012|September 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|20 Years|80 Years|No|||November 2015|November 23, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01898923||63016|
NCT01874561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1011-TQT-108|Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization|A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men||Teva Pharmaceutical Industries|No|Completed|May 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|May 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874561||64885|
NCT01874574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrthoTU-01|Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee|Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial||Thammasat University|Yes|Completed|January 2011|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|80 Years|No|||April 2014|April 21, 2014|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874574||64884|
NCT01874834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA 09-1344|Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust|Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust With Moderate Exercise in Healthy Adults|DEPOZ|Environmental Protection Agency (EPA)|No|Completed|August 2010|January 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01874834||64864|
NCT01905449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaskinsA185|Ultrasound Biofeedback for Speech Sound Disorders|Biofeedback and Speech Disorders||Yale University|No|Recruiting|May 2013|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|8 Years|50 Years|No|||December 2015|December 30, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905449||62518|
NCT01905761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMP Lifestyle Medicine Program|UMP Lifestyle Medicine Program|UMP Lifestyle Medicine Program||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|February 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients are adults with obesity (BMI > 30) seen at our Lifestyle Medicine program in        weight management at the University of Minnesota|September 2015|September 17, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905761||62494|
NCT01905774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0089-10-EMC|Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox|Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox||HaEmek Medical Center, Israel|No|Completed|March 2011|August 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|36|||Both|1 Year|45 Years|No|Probability Sample|Patients with Thalassemia Major or Intermedia treated by Iron chelators or by blood        transfusions without treatment with iron chelators|August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01905774||62493|
NCT01905163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01391-42|Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients|Prospective Study Assessing the Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinomatosis of Ovarian Origin, Tubal or Primary Peritoneal, in Chemosensitive Patients Treated by Neoadjuvant Chemotherapy.|CILOVE|Centre Jean Perrin|No|Recruiting|July 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Female|18 Years|N/A|No|||July 2015|August 7, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01905163||62540|
NCT01905735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLSGB-01|A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis|A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .||Healthcare Homoeo Charitable Society|Yes|Recruiting|August 2013|February 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|60 Years|No|||August 2013|August 1, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905735||62496|
NCT01905748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-09-EMC|Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine|Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine, Laboratory Investigations in Steady State and During Migraine Attack||HaEmek Medical Center, Israel|Yes|Recruiting|August 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|15|||Both|5 Years|20 Years|No|||August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01905748||62495|
NCT01877668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921091|Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis|OPAL BROADEN|Pfizer|Yes|Active, not recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877668||64648|
NCT01876628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4C-4078|Adjunctive Clindamycin for Cellulitis: C4C Trial.|A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis|C4C|University Hospitals Bristol NHS Foundation Trust|Yes|Active, not recruiting|October 2013|January 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|January 7, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876628||64728|
NCT01876849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAN|An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus|An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|December 2003|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|275|||Both|30 Years|75 Years|No|||January 2015|February 23, 2015|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876849||64711|
NCT01876862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORVACS 012|Towards HIV Functional Cure|A Pilot Study Evaluating the Maintenance of Viral Suppression After 24 Weeks of Therapeutic Interruption in Chronically HIV-1 Infected Patients With a Low Circulating HIV-DNA Reservoir|ULTRASTOP|Objectif Recherche Vaccins SIDA|Yes|Completed|September 2013|July 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|70 Years|No|||September 2015|September 28, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01876862||64710|
NCT01877330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISNB001|Optimal Location of Local Anesthetic Injection for Ultrasound Guided Interscalene Block|Intraplexus vs Extraplexus Injection of Local Anesthetic for Interscalene Block for Patients Undergoing Arthroscopic Shoulder Surgery||University of California, San Francisco|No|Recruiting|January 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|No|||May 2015|May 30, 2015|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01877330||64674|
NCT01877616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-Sleep-2013|Sleep Disorders and Their Cardiovascular Correlates in Atahualpa.|Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases||Hospital Clínica Kennedy|No|Completed|June 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|650|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 24, 2013|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01877616||64652|
NCT01877629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-060-104|Study in Healthy Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Formulations of ACT-129968|A Single-center, Open-label, Two-period, Two-treatment, Crossover, Single-dose Study in Healthy Female and Male Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of ACT-129968||Actelion|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877629||64651|
NCT01908075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04312|Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|REACH Fostair vs Seretide - Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|REACH|Research in Real-Life Ltd||Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|194723|||Both|18 Years|80 Years|No|Non-Probability Sample|All patients are diagnosed with asthma or COPD and aged between 18-80 years with all 61-80        year olds being non-smokers only|July 2013|July 24, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908075||62316|
NCT01904188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-033F|Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?|Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?||Michigan State University|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|None Retained|No specimens will be retained after analysis by study investigators. Prior to being sent to      the laboratory they will be retained in frozen state until there is a large enough quantity      to batch run specimens.|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients who undergo evaluation for suspected sepsis who have peripheral blood        cultures and urine samples obtained and patient characteristics recorded. Those that have        other bodily fluids in addition will also be included.|March 2016|March 15, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904188||62614|
NCT01904201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST007_03|Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People|QuantiFERON® Monitor Test to Evaluate Immune Function in HIV Infected and Uninfected Control Study Subjects|QFM|QIAGEN Gaithersburg, Inc|Yes|Terminated|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|57|Samples With DNA|A portion of the study blood sample collected for the HIVVR test will be banked for future      HIV research using the HIVVR test. Specifically, this future research will involve the HIVVR      test for additional cell associated markers relating to HIV pathogenesis including (for      example) other markers of activation and senescence, apoptosis (programmed cell death) and      chemokine receptors (for HIV tropism).|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive Anti-retroviral drug naïve (never on treatment, or for the last 60 days or        greater off or treatment), n=30.        HIV positive successful HAART for the last 24 months (or greater) with two undetectable        plasma viral load within the last 12 months, n=30        HIV positive on HAART for the last 24 months (or greater) with latest plasma viral load        >200, n=30        HIV negative|July 2014|July 7, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01904201||62613|
NCT01904461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HemORL-DCIC-1211|HemORL: Monocentric, Prospective, Comparative Study on the Use of a Haemostatic Vacuum Device During Tonsillectomy in Children|Monocentric, Prospective, Comparative and Randomised Study on the Use of a Haemostatic Vacuum Device During Tonsillectomy in Children|HemORL|University Hospital, Grenoble|Yes|Recruiting|October 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|74|||Both|3 Years|15 Years|No|||January 2015|January 12, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01904461||62594|
NCT01904474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/DTP-PIC/0769/2012|E-therapeutic Program for Obese Adolescents|Internet Based Intervention Program for Obese Adolescents and Their Families(NEXT.STEP)||Hospital de Santa Maria, Portugal||Completed|April 2013|August 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|116|||Both|12 Years|18 Years|No|||November 2015|November 16, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01904474||62593|
NCT01898936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transplant heads|Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses|A Randomized Half-side Comparative Trial of Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic Therapy in Organ Transplant Recipients With Multiple Actinic Keratoses of the Scalp or Forehead||Oslo University Hospital|No|Recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01898936||63015|
NCT01899196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP 52 PIECVIH|Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients|EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS|ANRS EP 52|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01899196||62996|
NCT01905176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEETTinCY|Management of Patients With HF by Using Educational or Educational & Telephone or Telephone Interventions and Support in Cyprus|The Effectiveness of Multiple Nursing Interventions, for Promoting Heart Failure Self-care, on Patients' Quality of Life and Heart Failure Outcomes: A Randomized Control Trial.|MEETTinCY|Cyprus University of Technology|No|Recruiting|April 2010|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|300|||Both|N/A|N/A|No|||July 2013|July 22, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01905176||62539|
NCT01905462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114101|Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK|Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix in the United Kingdom||GlaxoSmithKline|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1046|||Female|15 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 15 to 25 years, residing in UK, exposed to Cervarix and whose data is        recorded in the CPRD GOLD.|September 2013|September 26, 2013|July 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905462||62517|
NCT01905189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01612-41|Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension|Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension|RETRIEVE|University Hospital, Caen|Yes|Recruiting|July 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905189||62538|
NCT01876901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2010-08|Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)|Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial.|CASCADOR|Institut Bergonié|Yes|Recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01876901||64707|
NCT01906021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130178|Study of New Software Used During Ablations|Prospective Pilot Observational Study Examining Cone Beam CT and CT Thermometry During Ablations||National Institutes of Health Clinical Center (CC)||Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|99 Years|No|||January 2016|February 12, 2016|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01906021||62474|
NCT01906034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFU-2.104|Effects of a Fall Preventive Exercise Program on Intrinsic Fall Risk Factors in Healthy Older Adults.|Effects of a Fall Preventive Exercise Program on Intrinsic Fall Risk Factors in Healthy Older Adults.||University of Potsdam|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01906034||62473|
NCT01906294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5050000|IMS® DIAREG Diabetes Registry|Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus||IMS HEALTH GmbH & Co. OHG|No|Recruiting|August 2013|September 2023|Anticipated|September 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12000|||Both|18 Years|N/A|No|Probability Sample|Patients with Type 2 Diabetes Mellitus|July 2015|July 17, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01906294|10 Years|62453|
NCT01906307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJPC-501-CS-5001|A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome|A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome||La Jolla Pharmaceutical Company|No|Terminated|March 2014|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 17, 2013|No|Yes|Corporate decision|No||https://clinicaltrials.gov/show/NCT01906307||62452|
NCT01877941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 12-10139|Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time|Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time|esCCO|University of California, San Francisco|No|Completed|December 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|39|||Both|19 Years|N/A|No|||December 2014|December 30, 2014|December 5, 2012|No|Yes||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01877941||64627|
NCT01876329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20130010H|Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients|Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients||Keesler Air Force Base Medical Center|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the Internal Medicine and Internal Medicine Specialty        Clinics at one academic community hospital.|May 2015|May 11, 2015|June 9, 2013||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01876329||64751|
NCT01906710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHMEA-39435|the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes|The Effect of Patient Centered Medication Reconciliation, Medication Review and Discharge Counseling With Information Transfer in Hospitalized Patients on Clinical and Economic Parameters: a Multicentre, Before-after Study.|PITH|Dutch Society of Outpatient Pharmacies|No|Recruiting|January 2013|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|N/A|No|||July 2013|July 21, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906710||62421|
NCT01906970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClampArt-ES2|Clinical Experimental Study 2|Clinical Experimental Study 2, to Further Investigate the Measurement Accuracy, Glucose Control Quality, Safety, Handling and Functionality of ClampArt® and Its Influence on Pharmacodynamic Parameters in Glucose Clamps||Profil Institut für Stoffwechselforschung GmbH|No|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906970||62401|
NCT01906944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004223|Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain|Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial||Mayo Clinic|No|Recruiting|January 2012|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01906944||62403|
NCT01877096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1377|Motivational Interviewing for Colonoscopy|Motivational Interviewing for Colonoscopy: A Feasibility and Pilot Study||Icahn School of Medicine at Mount Sinai|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|57|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877096||64692|
NCT01907503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maillefert PHRC R 2004|Adaptation of Locomotor Activity in Patients Suffering From Hip OA - Analysis of This Adaptation as a Prognostic Criterion for Future Disease Progression|||Centre Hospitalier Universitaire Dijon|No|Recruiting|February 2008|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907503||62360|
NCT01907516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-118|Managing Diabetes in Pregnancy Using Cell Phone/Internet Technology|Managing Diabetes in Pregnancy Using Cell Phone/Internet Technology||Hawaii Pacific Health|No|Completed|February 2009|June 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|July 22, 2013||No||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01907516||62359|Selection bias towards English speaking, educated, and technology savvy women, a 25% drop out rate, a high rate of glucose reporting compliance in the control system, and technical problems when Confidant first started which were quickly resolved.
NCT01908088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-skin-003|Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa|Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane for Mitten Hand Deformity in Patients With Epidermolysis Bullosa||Royan Institute|Yes|Completed|July 2010|July 2013|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|5 Years|25 Years|No|||February 2010|July 24, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908088||62315|
NCT01904214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2129|A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function|||Novartis|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|16|||Both|18 Years|70 Years|No|||June 2015|June 2, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904214||62612|
NCT01904227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rivierduinen 2012|Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT)|A Randomized Controlled Study of the Efficacy of an Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT) for a Population of Borderline Patients (Young Adults/Adults: 18 - 40), Compared With Standard Outpatient DBT.|REDBT|Rivierduinen, Centre for Personality disorders Jelgersma|Yes|Active, not recruiting|February 2012|April 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|40 Years|No|||November 2014|November 9, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01904227||62611|
NCT01904487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO#10100519|Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence|Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence||University of Pittsburgh|No|Terminated|April 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|July 16, 2013|No|Yes|Interim analysis do not support the hypothesis that alcoholics (vs. matched controls) will    have altered Tiagabine-induced GABA release|No||https://clinicaltrials.gov/show/NCT01904487||62592|
NCT01895010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA2013|Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE|Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE||Fudan University|Yes|Recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01895010||63316|
NCT01876134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210055RIC|The Diagnostic Role of Cystein-rich Protein 61 (Cyr61) in Acute Kidney Injury: Correlation With the Harmonic Analysis of Arterial Pressure Pulse Waves.|The Diagnostic Role of Cystein-rich Protein 61 (Cyr61) in Acute Kidney Injury: Correlation With the Harmonic Analysis of Arterial Pressure Pulse Waves.||National Taiwan University Hospital|No|Active, not recruiting|April 2013|||June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Urine|Both|20 Years|80 Years|No|Probability Sample|All consecutive incident adult patients undergoing elective cardiac surgery (including        coronary artery bypass graft, valve surgery, and correction of congenital heart diseases)|June 2013|June 10, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876134|1 Week|64766|
NCT01876394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COIL|Comparison of Dietary Fats on Vascular Parameters|Acute Effects of Dietary Fats on Postprandial Vascular Function in Healthy Individuals: Pilot Double Blind, Randomized, Controlled Trial|COIL|St. Michael's Hospital, Toronto|No|Recruiting|June 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01876394||64746|
NCT01876667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRS stroke study|An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke|An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke||Kaiser Permanente|No|Active, not recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|85 Years|No|||July 2015|July 20, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01876667||64725|
NCT01876680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIU-001|The Effects of Two Different Home-exercise Programmes on Women Suffering Long Term Neck/Shoulder Muscle Pain|The Effects (Pain, Function, Biochemistry and Psychological Factors) of Two Different Home-exercise Programmes on Women Suffering Long Term Nack/Shoulder Muscle Pain||Linkoeping University|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Female|20 Years|60 Years|No|||June 2013|June 10, 2013|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01876680||64724|
NCT01876914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #9361|Pilot Study of OCT Versus Fluorescein Angiography in DME|Pilot Study of OCT Versus Fluorescein Angiography in Diabetic Macular Edema in Eyes With Good and Poor Macular Capillary Perfusion|OCT and DME|Oregon Health and Science University|No|Active, not recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|||Both|18 Years|N/A|No|Probability Sample|Individuals 18 years of age and older presenting to the Retina Service within the        Department of Ophthalmology at the Casey Eye Institute of Oregon Health & Science        University with signs and symptoms of DME will be evaluated for enrollment into this        study. This pilot study has a planned enrollment target sample size of 28 subjects with        DME. However, up to 35 subjects will be recruited as it is possible that after subjects        sign the consent form they may not meet all eligibility criteria.|April 2015|April 21, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01876914||64706|
NCT01877122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS1-1004|Comparative Study of Safety and Efficacy of Heavyweight and Partially Absorbable Mesh in Inguinal Hernia Repair|||Samyang Biopharmaceuticals Corporation|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|50|||Male|20 Years|85 Years|No|||June 2015|June 24, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01877122||64690|
NCT01877382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS3032-A-U101|A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas||Daiichi Sankyo Inc.|No|Recruiting|July 2013|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877382||64670|
NCT01877395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRV04|Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults||Sanofi|No|Completed|June 2013|September 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|342|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877395||64669|
NCT01874379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M•TIJRP|'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients|Investigating the Effect of the 'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients.|M•TIJRP|Saint Clare's Health System|No|Recruiting|December 2012|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01874379||64899|
NCT01906515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|doctor19|Impact of SpHb Monitoring on Transfusion|Continuous and Noninvasive Hemoglobin Monitoring Reduces Red Blood Cell Transfusion During Neurosurgery: A Prospective Cohort Study||Cairo University|Yes|Completed|February 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|15 Years|60 Years|No|||January 2014|January 24, 2014|July 13, 2013||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01906515||62436|
NCT01907243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91--02-48-6933|The Role of Spreader Flaps in Preventing of Nasal Obstruction|The Role of Spreader Flaps in Preventing of Nasal Obstruction in Primary Rhinoplasty: A Randomized-controlled Trial.||Tehran University of Medical Sciences|No|Completed|May 2011|April 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01907243||62380|
NCT01907256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-01-48-20912|Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty|Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty A Randomized Trial||Tehran University of Medical Sciences|No|Completed|December 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|No|||January 2014|January 17, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01907256||62379|
NCT01907230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-962|Entecavir for Biological Agents Associated HBV Reactivation in Rheumatoid Arthritis Patients|Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients: a Randomized Controlled Trial||Taipei Veterans General Hospital, Taiwan|No|Not yet recruiting|July 2013|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|20 Years|90 Years|No|||July 2013|July 18, 2013|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01907230||62381|
NCT01874613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T97/2011|Clinical Study of FRC Implant to Treat Skull Bone Defects|Clinical Study of Skull Defect Reconstruction With Patient-specific Fibre-reinforced Composite Implant|Cranio-2|Turku University Hospital|No|Active, not recruiting|January 2013|December 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|N/A|No|||February 2015|February 18, 2015|November 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01874613||64881|
NCT01907737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0546/11|Combined Brain and Peripheral Nerve Stimulation for Stroke|Combined Brain and Peripheral Nerve Stimulation to Enhance Beneficial Effects of Functional Electrical Stimulation on Hand Motor Function After Stroke||University of Sao Paulo General Hospital|Yes|Recruiting|July 2013|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|4||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907737||62342|
NCT01907750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biliary_TCvsTA|Transcystic Versus Transanastomotic Tube Drainage in Right Lobe LDLT|Transcystic Versus Transanastomotic Biliary Drainage Tubes in Living Donor Liver Transplantation. A Prospective Randomized Trial.||Mansoura University|Yes|Recruiting|January 2009|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|180|||Both|2 Years|70 Years|No|||February 2016|February 28, 2016|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01907750||62341|
NCT01875224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-303|Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression|Open-Label, Randomized Comparison of NODAT in Renal Transplant Patients Receiving a Nulojix (Belatacept) Regimen Versus Standard Therapy Immunosuppression||University of Arizona|Yes|Not yet recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|65 Years|No|||June 2013|June 7, 2013|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875224||64835|
NCT01875562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PME of Qishe|A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy|A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|May 2012|November 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2400|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|December 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01875562||64810|
NCT01905202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP404|The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus|Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus||Effexus Pharmaceutical|Yes|Enrolling by invitation|April 2013|||April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905202||62537|
NCT01905215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116969|Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Men||GlaxoSmithKline||Completed|July 2013|March 2015|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|128|||Male|18 Years|44 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|July 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905215||62536|
NCT01876407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-LAS-2012-04|Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer|||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876407||64745|
NCT01904708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9202|Moderate Intensity Exercise and Phenylketonuria|The Effects of an Acute Bout of Moderate Intensity Exercise on Plasma Amino Acids in Subjects With Phenylketonuria||Oregon Health and Science University|No|Terminated|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|2|||Male|14 Years|17 Years|No|||October 2014|October 15, 2014|May 31, 2013||No|Current design not able to measure the outcomes anticipated.|No||https://clinicaltrials.gov/show/NCT01904708||62575|
NCT01904721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-084|A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)|||Allergan|Yes|Completed|August 2013|January 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|244|||Male|18 Years|49 Years|No|||February 2016|February 23, 2016|July 18, 2013|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01904721||62574|
NCT01904968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Piard PHRC K 2011|Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis|||Centre Hospitalier Universitaire Dijon||Withdrawn|December 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Colon cancers in patients living the Cote D'or area|July 2013|July 17, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01904968||62555|
NCT01876927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST151.01|Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer|A Randomised Phase Ii Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox) Regimen In Patients With Locally Advanced Resectable Gastric Cancer|GastroDOC|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|September 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01876927||64705|
NCT01877148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkinson_tDCS_rehabilitation|Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease|Effects of Transcranial Direct Current Stimulation Associated With Physical Therapy on Motor Rehabilitation in Parkinson´s Disease Patients||Universidade Federal de Pernambuco|Yes|Completed|January 2010|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|80 Years|No|||June 2013|May 14, 2015|June 11, 2013||No||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01877148||64688|
NCT01877135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-LAZ-001|Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients|Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients|AIN3|French Society of Coloproctology|No|Recruiting|August 2013|June 2019|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|Samples Without DNA|A liquid phase anal smear|Both|18 Years|N/A|No|Non-Probability Sample|patients consulting a proctologist in primary care or in hospital|September 2013|March 4, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877135||64689|
NCT01877408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICIRC SA|A Randomized Controlled Trial of Open Surgical vs. Rapid, Minimally-invasive Voluntary Adult Male Circumcision|A Randomized Controlled Trial of Open Surgical vs. Rapid, Minimally-invasive Voluntary Adult Male Circumcision||Simunye Primary Health Care|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 7, 2014|June 11, 2013||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01877408||64668|
NCT01874158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8115|DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women|DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women||Tulane University Health Sciences Center|Yes|Completed|November 2012|April 2014|Actual|April 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples With DNA|1 vaginal swab collected at screening for In-pouch 3 vaginal swabs collected at enrollment,      PCR, gram stain, and future microbiome study At each of 3 follow-up visits, 3 vaginal swabs,      PCR, In-pouch, and future microbiome study At the 4th follow-up visit, 4 vaginal swabs, PCR,      In-pouch, gram stain, and future microbiome study.      All swabs, except at screening, are self-collected.|Female|18 Years|N/A|No|Non-Probability Sample|English speaking HIV- women over the age of 18 who are TV positive|June 2014|June 20, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874158||64916|
NCT01906723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UpnFree-HMO-CTIL|Evaluation of the Effectiveness of a Novel Gait Trainer in Increasing the Functionality of Motor Impaired Patients: Pilot Study|Evaluation of the Effectiveness of a Novel Gait Trainer in Increasing the Functionality of Motor Impaired Patients: Pilot Study||Hadassah Medical Organization||Completed|August 2013|||August 2014|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Actual|4|||Both|18 Years|100 Years|No|||July 2013|January 4, 2016|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906723||62420|
NCT01906736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-ChilTip 1060nm-13-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||July 15, 2015|July 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906736||62419|
NCT01906957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGNEX-2|Cognition and Exercise Training|Cerebral Oxygenation, Cardiac Output,Cognitive Function, and Exercise Training in Patients With Metabolic Syndrome, Coronary Heart Disease and Chronic Heart Failure.|COGNEX-2|Montreal Heart Institute|Yes|Recruiting|September 2013|October 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906957||62402|
NCT01878136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13011803|Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage|Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage||Rush University Medical Center|Yes|Withdrawn|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|June 12, 2013|Yes|Yes|Time constraints|No||https://clinicaltrials.gov/show/NCT01878136||64612|
NCT01874093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP1050035|THE IMPACT- 24Bt Post rtPA TRIAL (IMPlant Augmenting Cerebral Blood Flow Trial 24 Hours From Stroke Onset, Post IV-rtPA)|A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Safety and Effectiveness of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke|IMPACT-24Bt|BrainsGate|No|Recruiting|May 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|85 Years|No|||September 2015|October 19, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01874093||64921|
NCT01907529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBMUFH-101|A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer|A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)|TENDENCY|Hebei Medical University Fourth Hospital|No|Not yet recruiting|August 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|70 Years|No|||July 2013|July 22, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907529||62358|
NCT01874639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0156|Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study (HEPACOLL)|Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study||University Hospital, Clermont-Ferrand||Recruiting|June 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||July 2015|July 30, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01874639||64879|
NCT01874873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-01-IIA|A Phase II Study of Anlotinib in MTC Patients|Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma|ALTN/MTC|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Active, not recruiting|April 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|70 Years|No|||January 2015|January 6, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01874873||64861|
NCT01874886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431587-AZ-29944|Cannabis Effects on Brain Morphology in Aging|Effects of Heavy Adolescent Cannabis Use on Brain Morphology in Aging|CAN|University of California, Los Angeles|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be a community sample within the Los Angeles area. They will be recruited        from the greater Los Angeles area using flyer postings in various areas of Los Angeles.        Also, flyers will be posted in the Alzheimer's Disease Research Center at UCLA and the        Longevity Center at UCLA as well as across the UCLA campus.|December 2015|December 1, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01874886||64860|
NCT01875237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0501|Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene|A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies||M.D. Anderson Cancer Center|No|Recruiting|December 2013|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875237||64834|
NCT01875250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130153|Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer|A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Male|18 Years|100 Years|No|||November 2015|December 15, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875250||64833|
NCT01875263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-COL-2013-06|Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.|Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Terminated|May 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|June 7, 2013||No|Not participants inclusion|No||https://clinicaltrials.gov/show/NCT01875263||64832|
NCT01875575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 08/11|Oral Glucose Stimulation in Normal-weight and Obese Volunteers|Oral Glucose in Normal-weight and Obese Volunteers||University Hospital, Basel, Switzerland|No|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01875575||64809|
NCT01875588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130149|Thinking and Memory Problems in People With HIV|Screening and Recruitment for HIV-associated Neurocognitive Disorders (HAND) Studies and an Evaluation of HIV-associated Neurocognitive Disorders in Virologically Controlled Patients||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|December 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|600|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01875588||64808|
NCT01875601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130152|NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors|A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|May 2013|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|2 Years|25 Years|No|||November 2015|November 17, 2015|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875601||64807|
NCT01875614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875614||64806|
NCT01905514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMA-13-002|ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients|ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients|PRIMA|Seoul National University Hospital||Enrolling by invitation|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|15 Years|70 Years|No|||May 2015|May 24, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905514||62513|
NCT01876940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2013-15391|Comparison of Fiberoptic Intubation With Fiberoptic Intubation Through an Air-Q Intubating Laryngeal Airway in Infants and Small Children|A Randomized Comparison of Free-handed Fiberoptic Intubation Compared With Fiberoptic Intubation Through an Air-QTM Intubating Laryngeal Airway in Children Less Than Two Years of Age: Does Operator Experience Affect Time to Successful Tracheal Intubation?||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|N/A|2 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01876940||64704|
NCT01877161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1206-158-003|Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types|Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types||Seoul National University Bundang Hospital||Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|March 11, 2013||No||No|January 23, 2014|https://clinicaltrials.gov/show/NCT01877161||64687|
NCT01876368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2318|Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan|A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan||Novartis|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 9, 2013|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01876368||64748|
NCT01876381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-12-007|A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration||Otsuka Pharmaceutical Co., Ltd.|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|80 Years|No|||July 2014|July 31, 2014|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01876381||64747|
NCT01877694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1301|Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis|A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis|BACTOvation™|NovaBay Pharmaceuticals, Inc.|No|Completed|June 2013|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|1 Year|N/A|No|||May 2015|May 26, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877694||64646|
NCT01877954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02511|Qvar vs FP in Pediatrics|Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients — a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population||Research in Real-Life Ltd|Yes|Completed|February 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2654|||Both|5 Years|11 Years|No|Non-Probability Sample|Asthma patients who initiate ICS therapy as one of:        HFA-BDP pMDI FP pMDI|June 2013|June 13, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877954||64626|
NCT01877421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-14|A Double-Blind, Randomized, Controlled, Dose Escalation Clinical Trial of an Antiplaque Chewing Gum - Phase 1 Safety and Tolerability and Phase 2a Safety, Tolerability, and Proof of Concept in a Gingivitis Population|A Double-Blind, Randomized, Controlled, Dose Escalation Clinical Trial of an Antiplaque Chewing Gum - Phase 1 Safety and Tolerability and Phase 2a Safety, Tolerability, and Proof of Concept in a Gingivitis Population|APCG|U.S. Army Medical Research and Materiel Command|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Anticipated|137|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877421||64667|
NCT01877434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-201-31M|Reversed TESS Shoulder Artroplasty|The TESS Reverse Shoulder Arthroplasty: Effect of Arm Lengthening and Early Scapular Notching at Three Years Follow-up|RTESS|Sundsvall Hospital|No|Completed|October 2007|June 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|60 Years|88 Years|No|Probability Sample|Patients undergone reversed shoulder arthroplasty at Sundsvall hospital, Sweden between        2007-2012|June 2013|June 11, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877434||64666|
NCT01877681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011111099|Reference Nurse Program for Pressure Ulcers in Primary Care|Chronic Wounds Reference Nurse and Telematic Interconsultation Program for Pressure Ulcers in Primary Care: Evaluation of Effectiveness and Cost Reduction||Basque Health Service|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|16 Years|90 Years|No|||April 2015|April 15, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877681||64647|
NCT01874691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI11B02-A|China Acute Myocardial Infarction Registry|China Acute Myocardial Infarction Registry|CAMIRegistry|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Probability Sample|Eligible patients admitted within 7 days of acute ischemic symptoms and diagnosed acute        ST-elevation or non ST-elevation myocardial infarction.|January 2016|January 26, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01874691|2 Years|64875|
NCT01877915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101940|A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure|A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure|COMMANDER HF|Janssen Research & Development, LLC|Yes|Recruiting|September 2013|May 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5000|||Both|18 Years|95 Years|No|||March 2016|March 8, 2016|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877915||64629|
NCT01873833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-12-10|Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer|Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen||University of Southern California|No|Recruiting|July 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||June 2015|June 8, 2015|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873833||64941|
NCT01873846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||September 22, 2014|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873846||64940|
NCT01874106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|916425|Effect of Anti-inflammatory Diet on Inflammatory, Oxidative and Nutritional Markers in Hemodialysis Patients|Effect of Anti-inflammatory Diet on Inflammatory, Oxidative and Nutritional Markers in Hemodialysis Patients||Shiraz University of Medical Sciences|Yes|Completed|October 2012|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|85 Years|No|||January 2014|January 7, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874106||64920|
NCT01874119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-MISP-50440, 23432|Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma|Phase 2B Double-blind Placebo-controlled Crossover Study Evaluating the Efficacy of Intravenous Fosaprepitant for Chemotherapy-induced Nausea and Vomiting (CINV) Associated With High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Metastatic Renal Cell Carcinoma|HD IL-2/Emend|St. Louis University|No|Terminated|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|90 Years|No|||January 2016|January 19, 2016|June 6, 2013|Yes|Yes|Enrollment issues|No||https://clinicaltrials.gov/show/NCT01874119||64919|
NCT01874340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457B2203|Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis|A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis||Novartis|Yes|Terminated|June 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|55 Years|No|||May 2015|May 14, 2015|May 28, 2013|Yes|Yes|Study terminated early based upon development of another anti-IL17 fully human monoclonal    antibody with better potential for treating MS patients|No|April 13, 2015|https://clinicaltrials.gov/show/NCT01874340||64902|Due to early termination this trial was not powered for efficacy no statistical analysis was performed
NCT01874600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-0421|Seizure Detection and Warning System for Epilepsy Patients|A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients||Brain Sentinel|No|Recruiting|July 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|225|||Both|2 Years|99 Years|No|||January 2016|January 11, 2016|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874600||64882|
NCT01875276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04412|Evaluating the Need for New Rhinitis Treatment|Evaluating the Need for a New Combination Nasal Spray in the Treatment of Seasonal Rhinitis|MEDA|Research in Real-Life Ltd|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|21203|||Both|N/A|N/A|No|Non-Probability Sample|Patients will have seasonal rhinitis: defined as hay fever/rhinitis diagnosis during the        hay fever season period and will be receiving therapy during the hay fever season|June 2013|June 7, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875276||64831|
NCT01874899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPNI-3|Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical Leads|Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical Leads|RestoreSensor|Justin Parker Neurological Institute|No|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||August 2015|August 31, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874899||64859|
NCT01874912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO(IRISIN)|Human Irisin Concentration in Sarcopenia|||Korea University|Yes|Completed|November 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|406|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients in Korean Sarcopenic Obesity Study (KSOS), an prospective observational cohort        study designed to examine the prevalence of sarcopenia and sarcopenic obesity in Korean        adults and to evaluate their effects on metabolic disorders and health outcomes.|June 2013|June 7, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01874912||64858|
NCT01875926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0171-1.3/13|ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers|Phase I, Single-centre, Open-label Study to Evaluate the Pharmacokinetics of ALX-0171, Administered by Oral Inhalation or Intravenously, in Healthy Male Volunteers||Ablynx|No|Completed|June 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01875926||64782|
NCT01876160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-6220|Analysis of Sensory and Motor Thresholds During Transcutaneous Electrical Stimulation in Different Sexes and Ages|||University of Sao Paulo|Yes|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|86|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 8, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01876160||64764|
NCT01905228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I137-101|A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas|A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas||Incuron|No|Recruiting|July 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905228||62535|
NCT01905241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-652|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||July 22, 2013|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905241||62534|
NCT01905501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Versione 02.01.2013|Sevoflurane Protective Effect on Ischemia-reperfusion Injury. Multicenter, Randomized Controlled Trial|Sevoflurane Protective Effect on Ischemia-reperfusion Injury in Patients Undergoing Reconstructive Plastic Surgery With Microsurgical Flap. Multicenter, Randomized Controlled Trial.||Regina Elena Cancer Institute||Recruiting|February 2013|February 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Female|18 Years|75 Years|No|||November 2014|November 5, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905501||62514|
NCT01905540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-111|A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)|A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of SSP-004184AQ (Magnesium Salt) to SSP-004184SS (Disodium Salt) Each Administered as a Single Dose and as Two Doses of SSP-004184 (Free Acid) in Healthy Adult Subjects||Shire|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|July 18, 2013|No|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01905540||62511|
NCT01905553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-113|The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects|A Phase 1, Open-label, Randomized, 2-period, Crossover, Exploratory Study to Investigate the Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects||Shire|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|July 18, 2013|No|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01905553||62510|
NCT01877187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12115|Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer|Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2013|||May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877187||64685|
NCT01876693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si041/2013|A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy|A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy in Medical Practice||Mahidol University|Yes|Recruiting|May 2013|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01876693||64723|
NCT01876706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP12911|UroLift System TOlerability and ReCovery When Administering Local Anesthesia|L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia|LOCAL|NeoTract, Inc.|No|Active, not recruiting|April 2013|September 2018|Anticipated|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Male|50 Years|N/A|No|||October 2015|October 22, 2015|May 6, 2013|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01876706||64722|
NCT01877707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE/0462|Near Patient Microbial Testing in Cystic Fibrosis|A Home-based, Rapid and Quantitative Test for Bacterial Respiratory Infections in Patients With Cystic Fibrosis, to Reduce Admissions and Hospital Stay Length and to Improve Healthcare Outcomes.||Papworth Hospital NHS Foundation Trust|Yes|Completed|January 2013|June 2014|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|17 Years|N/A|No|||February 2016|February 16, 2016|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01877707||64645|
NCT01873872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBIOTIC|Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics|Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics||St. Vincent's East, Birmingham, Alabama|No|Recruiting|July 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2013|March 26, 2014|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873872||64938|
NCT01874145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-MS-303|Safety and Tolerability of Glatiramer Acetate|An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis|GLACIER|Teva Pharmaceutical Industries|No|Completed|June 2013|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|209|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|June 6, 2013|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01874145||64917|
NCT01874704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0154|Comparison of Biomarkers of Stress in Emergency Physicians Working a 24-hour Shift or a 14-hour Night Shift - the JOBSTRESS Randomized Trial|Comparison of Biomarkers of Stress in Emergency Physicians Working a 24-hour Shift or a 14-hour Night Shift - the JOBSTRESS Randomized Trial|JOBSTRESS|University Hospital, Clermont-Ferrand||Completed|April 2010|September 2011|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Actual|19|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 7, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01874704||64874|
NCT01877928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMED-079-12|Post-extubation Boussignac CPAP System in Adults With Moderate to Severe Obstructive Sleep Apnea|Use of the Boussignac CPAP System Immediately Following Extubation to Improve Lung Function in Adults With Moderate to Severe Obstructive Sleep Apnea||Queen's University|Yes|Recruiting|June 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877928||64628|
NCT01873859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sbcvrc-43-891128|Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media|Incidence of Lactic Acidosis After Coronary Angiography and Angioplasty in Diabetic Patients on Continued Metformin Therapy With Normal Renal Function.||hahid Beheshti University of Medical Sciences|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|166|||Both|N/A|N/A|No|||May 2014|May 16, 2014|June 5, 2013||No||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01873859||64939|unable to follow patient's creatinine and acidosis for more than 48 hr.
NCT01874366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11187/77/13|Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187||Piramal Enterprises Limited|No|Recruiting|June 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|May 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874366||64900|
NCT01874652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007-13-BNZ|Assessment of Safety & Efficacy of Light Weight Breast Implant|Assessment of Safety & Efficacy of Light Weight Breast Implant||Bnai Zion Medical Center|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|November 2, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01874652||64878|
NCT01874925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSLED002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2013|||||N/A|N/A|N/A||||||||||||||August 31, 2013|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874925||64857|
NCT01874938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15007|A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer|A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer||Eli Lilly and Company|No|Completed|August 2013|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|May 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874938||64856|
NCT01874353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00002|Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy|Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy||AstraZeneca|Yes|Active, not recruiting|September 2013|June 2020|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|297|||Female|18 Years|130 Years|No|||November 2015|November 27, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874353||64901|
NCT01874626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST0225-US-010-001|Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain|A Randomized, Double-blind, Placebo-controlled, Multi-dose, Pivotal Study to Determine the Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain.||Strategic Science & Technologies, LLC||Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|16 Years|N/A|No|||January 2014|January 23, 2014|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874626||64880|
NCT01875939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W 771/2349-101|Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers|Phase-I Randomized, Open Label, Crossover Food-Effect and Absolute Bioavailability Study of WCK 2349 and WCK 771 in Healthy Adult Human Volunteers||Wockhardt|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875939||64781|
NCT01875627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-353|Satiety Study of a Carbohydrate Meal to a Highly Viscous Gel Meal|Comparing the Satiety Scores of a Carbohydrate Meal to a Meal of Equal Volume in Which Half of the Volume is Replaced With a Highly Viscous Gel.|InGel|St. Michael's Hospital, Toronto|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|June 9, 2013|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01875627||64805|
NCT01875640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1360|Decision Support for Parents Receiving Information About Child's Rare Disease|Decision Support for Parents Receiving Information About Child's Rare Disease|DSD DST|University of Michigan|No|Recruiting|June 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|45|||Both|N/A|6 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01875640||64804|
NCT01876446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 225612|Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer||Roswell Park Cancer Institute|Yes|Recruiting|August 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876446||64742|
NCT01905839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130167|A Study of Movement Disorders Using the QMAT At-Home Testing Device|A Longitudinal Study Assessing the Pathophysiology of Movement Disorders Utilizing the QMAT at Home Testing Device||National Institutes of Health Clinical Center (CC)||Terminated|June 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|18 Years|90 Years|No|||April 2015|April 21, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905839||62488|
NCT01906814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanghs20130507|Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation|Three Cycles Versus Six Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Randomized Control Study||Sun Yat-sen University|Yes|Recruiting|January 2013|December 2023|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|N/A|N/A|No|||December 2015|December 9, 2015|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906814||62413|
NCT01907048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16167|Patient and Physician Knowledge of Key Safety Messages|Xarelto (Rivaroxaban) - Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages||Bayer|No|Recruiting|September 2014|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Physicians of various specialties; patients treated in primary care and specilized        clinical practices.|March 2016|March 15, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01907048||62395|
NCT01876966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018409|Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine|A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects|DDI Coartem|Janssen Pharmaceutica N.V., Belgium|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01876966||64702|
NCT01877174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM-2013-01|MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)|MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)||Silk Road Medical|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|24|Samples With DNA|The inline filter of the MICHI(TM) NPS+f System may contain debris that is released from the      lesion during carotid stenting. It is the objective of the study to determine the volume and      characteristics of the debris.|Both|N/A|N/A|No|Non-Probability Sample|Patients who are booked for a routine stenting of the Internal Carotid Artery (bifurcation        may be involved) using the MICHI(TM) NPS+f System, at vascular surgery departments or        interventional radiology departments|September 2014|September 2, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01877174||64686|
NCT01877200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4071|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh|DiabCare Asia|Novo Nordisk A/S|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2092|||Both|18 Years|N/A|No|Non-Probability Sample|People treated for at least a year are eligible for the study. The selection of the        patients will be done randomly by the individual physician involved in the study.|January 2015|January 20, 2015|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877200||64684|
NCT01877447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aF3_cF4_F32|Comparison of Two tDCS Protocols for the Treatment of Major Depressive Disorder|Comparison of Two Transcranial Direct Current Stimulation (tDCS) Protocols for the Treatment of Major Depressive Disorder: a Randomized, Double-blinded, Controlled Clinical Trial.||University of Sao Paulo|Yes|Completed|July 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|89 Years|No|||December 2013|December 13, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01877447||64665|
NCT01877460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26942|Sodium Alginate in Chocolate Milk, Satiety and Glycemic Control|The Effects of Isovolumetric Preloads of Sodium Alginate-enriched Chocolate Milk on Glycemia, Subjective Appetite and Food Intake in Healthy Young Men||University of Toronto|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|24|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01877460||64664|
NCT01877473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHS 12.0031|Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF|||Valley Health System|No|Withdrawn|May 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||June 2014|June 16, 2014|May 26, 2013||No|No enrollment|No||https://clinicaltrials.gov/show/NCT01877473||64663|
NCT01873911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRNLDN6707|Neurobehavioral Phenotypes in MPS III|Characterizing the Neurobehavioral Phenotype(s) in MPS III||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2010|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|2 Years|12 Years|No|Non-Probability Sample|Twenty children who have been diagnosed with MPS III type A or type B. Ten age-matched        children (as controls) who have been diagnosed with MPS I (Hurler syndrome), who in the        past have undergone hematopoietic cell transplantation, and who have been        clinically-determined to have low cognitive function.|November 2014|November 19, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01873911||64935|
NCT01877967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8AA.N04022|Investigating the Effect of Dietary Supplement VSL#3 on Cognition and Mood in Healthy Older Adults|A Randomised Double-blind Placebo-controlled Trial Investigating the Effect of Dietary Supplement VSL#3 on Memory, Attention, Executive Function and Mood in Healthy Older Adults.||University of Dublin, Trinity College|Yes|Active, not recruiting|May 2013|July 2015|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01877967||64625|
NCT01873885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1046-PT-CL-0002|Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension|Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension||PhaseBio Pharmaceuticals Inc.|Yes|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|80 Years|No|||April 2014|April 8, 2014|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01873885||64937|
NCT01873898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REX-OUS-2027-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2013|||||N/A|N/A|N/A||||||||||||||April 28, 2014|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01873898||64936|
NCT01874717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0155|Midazolam Sedation in Dentally Anxious Patients|Conscious Sedation With Midazolam in Dentally Anxious Patients: Effect of the Administration Route (Oral Versus Intravenous Administration)||University Hospital, Clermont-Ferrand||Completed|June 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|8 Years|60 Years|No|||June 2013|June 10, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01874717||64873|
NCT01874132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVD-2009-EX|Study of the Long-term Effects of Exercise on Heath Indicators in Older People|A Randomised Longitudinal Study of Exercise Prescription for Older Adults: Mode and Intensity to Induce the Highest Cardiovascular Health-related Benefits||University of Trás-os-Montes and Alto Douro|Yes|Completed|May 2011|September 2014|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|90|||Male|65 Years|79 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874132||64918|
NCT01874964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-R01DA027211|Trial of Methadone Maintenance Versus Methadone Detox in Jail|A Randomized Trail of Continues Methadone Maintenance Versus Detoxification in Jail||The Miriam Hospital|Yes|Active, not recruiting|June 2010|May 2014|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|No|||December 2010|June 7, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01874964||64854|
NCT01875289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOB-Studie EK 25-387 ex 12/13|Efficacy of a Modified Obturator Nerve Block Technique|||Medical University of Graz||Completed|July 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875289||64830|
NCT01875302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH-001|Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions|Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions||nSpire Health, Inc.|No|Completed|February 2013|May 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|40 Years|75 Years|No|Non-Probability Sample|COPD Subjects|June 2013|June 17, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01875302||64829|
NCT01875315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0295|Comparative Effectiveness of Stress Tests|EXACT-COST: Exercise CMR's Accuracy for Cardiovascular Stress Testing-Comparative Effectiveness of Stress Tests|EXACT-COST|Ohio State University|Yes|Recruiting|September 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01875315||64828|
NCT01874951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000371|Low-Dose Naltrexone for Depression Relapse and Recurrence|Randomized, Proof-Of-Concept Trial of Augmentation of Anti-depressants by Low Dose and Ultra-Low Dose Naltrexone for Patients With Breakthrough Symptoms of Major Depressive Disorder on Antidepressant Therapy||Massachusetts General Hospital|No|Completed|June 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|May 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874951||64855|
NCT01875653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CA-P01|Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma|Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma||Caladrius Biosciences, Inc.|Yes|Active, not recruiting|October 2014|June 2022|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875653||64803|
NCT01875666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1214|Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib|Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|September 2013|March 2018|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Female|18 Years|N/A|No|||October 2015|October 7, 2015|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875666||64802|
NCT01876173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-214|Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator|Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator||McMaster University|No|Completed|June 2012|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Actual|82|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01876173||64763|
NCT01876186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212143RINB|Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients|Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study||National Taiwan University Hospital|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|N/A|No|||July 2015|July 5, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876186||64762|
NCT01905267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0689|Mindfulness Intervention to Study the Neurobiology of Depression|Mindfulness Intervention to Study the Neurobiology of Depression|MIND|University of Illinois at Chicago|No|Active, not recruiting|March 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|12 Years|18 Years|No|||March 2016|March 22, 2016|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01905267||62532|
NCT01906606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#231-1112|Effectiveness of Parenting Programs on Child Development and Maternal Well-being in Rural Uganda|Effectiveness of Parenting Programs on Child Development and Maternal Well-being in Rural Uganda||McGill University|No|Completed|January 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|360|||Both|12 Months|36 Months|No|||March 2016|March 17, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01906606||62429|
NCT01905878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|halflifeDLBS1033|Biological Half Life of DLBS1033 in Healthy Volunteers|Biological Half Life of DLBS1033 in Healthy Volunteers||Indonesia University|Yes|Recruiting|June 2013|December 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01905878||62485|
NCT01877720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV-NAVA Physiologic Study|Physiologic Comparison Between NIV-NAVA and PS in Preterm Infants|Physiologic Comparison Between Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) and Pressure Support (PS) in Preterm Infants||Seoul National University Hospital|Yes|Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|3 Months|No|||November 2015|November 18, 2015|June 5, 2013||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01877720||64644|
NCT01877746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRC-ICIT-01|CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)|RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY IMMUNOSUPPRESSION TRIAL)||St. Anne's University Hospital Brno, Czech Republic|No|Recruiting|January 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|234|||Both|18 Years|65 Years|No|||June 2013|June 11, 2013|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01877746||64642|
NCT01877733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1678|Effective Rehabilitation of Patients Operated With Total Knee Arthroplasty|Effective Rehabilitation of Patients Operated With Total Knee Arthroplasty||Norwegian University of Science and Technology|No|Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|75 Years|No|||February 2016|February 8, 2016|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01877733||64643|
NCT01877980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S021/2013|Ultrasound and Pediatric Endotracheal Tube Size|Prediction of Uncuffed Endotracheal Tube Size in a Pediatric Population by Sonographic Measurements at Various Structures of the Airway Compared to Age-related Formulas and Little-finger Diameters|SoTu2|Heidelberg University|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|101|||Both|N/A|6 Years|No|Non-Probability Sample|Children scheduled for elective surgery|December 2014|December 2, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01877980||64624|
NCT01873924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Batten Study|Clinical and Neuropsychological Investigations in Batten Disease|Clinical and Neuropsychological Investigations in Batten Disease||University of Rochester|No|Recruiting|August 2004|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|whole blood, buccal epithelial cells|Both|1 Year|40 Years|No|Non-Probability Sample|Individuals diagnosed with any form of Batten disease are eligible to take part in this        study.|December 2015|December 21, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01873924|10 Years|64934|
NCT01874171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMRCT0034|Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC|Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma|De-ESCALaTE|University of Warwick|Yes|Recruiting|October 2012|September 2019|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874171||64915|
NCT01874405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPEDNA-2013-1|Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy|Effectiveness of Deferasirox Therapy on Comprehensive Management of Iron Overload in Adult and Pediatric Transfusion-dependent Patients: a Long Term Retrospective Study||Second University of Naples|Yes|Completed|March 2003|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|80|||Both|2 Years|N/A|No|Probability Sample|Adult and pediatric transfusion- dependent patients (male and female) with different        underlying cronic anemias who received iron chelation therapy with deferasirox during the        observational study period and underwent at least 2 cardiac MRI scans at the Pozzuoli        site.        All consecutive patients visited at the participating sites starting from March 2003 to        October 2012 will be entered in this observational study (chart review) provided all the        inclusion an no exclusion criteria are met.|June 2013|June 6, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01874405||64897|
NCT01874418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAM|Biomarker Study to Diagnose Alzheimer's Disease|Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease|ADAM|Seoul National University Hospital|Yes|Recruiting|March 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01874418||64896|
NCT01874665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-12-202|A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor|Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy|GIST|Ariad Pharmaceuticals||Active, not recruiting|June 2013|May 2016|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874665||64877|
NCT01874678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYTG0904|A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer|A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer||TTY Biopharm|No|Completed|March 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|74 Years|No|||January 2016|January 10, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01874678||64876|
NCT01874977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0047102|Trial of a Physical Activity Intervention for RA Fatigue|Randomized Controlled Trial of a Physical Activity Intervention for RA Fatigue||University of California, San Francisco|No|Active, not recruiting|November 2013|March 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01874977||64853|
NCT01874990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preeclampsia &salt sensitivity|Increased Salt Sensitivity of Ambulatory Blood Pressure in Women With a History of Severe Preeclampsia|||University Hospital, Geneva|No|Completed|December 2009|December 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|June 6, 2013|April 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874990||64852|
NCT01875328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9011|Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial|Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial|STEP TO IT|Oregon Health and Science University|Yes|Recruiting|May 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|21 Years|N/A|No|||April 2015|April 20, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01875328||64827|
NCT01876199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC2359|Targeted Screening of At-Risk Adults for Acute HIV-1 Infection|Targeted Screening of At-Risk Adults for Acute HIV-1 Infection|AHI|University of Oxford|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|522|||Both|18 Years|29 Years|No|||August 2014|August 1, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876199||64761|
NCT01876212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-048|Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma|A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma||University of Pittsburgh|Yes|Recruiting|November 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876212||64760|
NCT01875952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Informed Consent:552 / 306|Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)|Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach|HIV/TB|Instituto Nacional de Salud Publica, Mexico|No|Active, not recruiting|May 2010|June 2013|Anticipated|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|60 Years|No|||June 2013|June 11, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01875952||64780|
NCT01875965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4707A3|IAN Injury After BSSO in Oral Clefts|Inferior Alveolar Nerve Injury After Bilateral Sagittal Split Osteotomy in Oral Clefts||Chang Gung Memorial Hospital|Yes|Not yet recruiting|June 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|16 Years|N/A|No|Non-Probability Sample|recruit patients with nonsyndromic CLP (age, >16 for females, >18 for males), who will        undergo Dal Pont type BSSO as a part of the correction of their dentofacial deformities,        from Chang Gung Craniofacial Center, Taoyuan.|February 2013|June 10, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01875965|24 Months|64779|
NCT01876979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC# 33082|Arch Bars vs. IMF (Intermaxillary Fixation) Screws: Cost Effectiveness|Erich Arch Bars vs. IMF Screws for Placement of Maxillomandibular Fixation: Which is More Cost Effective in the Operating Room Setting?||Christiana Care Health Services|No|Terminated|July 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|70 Years|No|||April 2015|April 29, 2015|June 11, 2013||No|Extended study duration|No||https://clinicaltrials.gov/show/NCT01876979||64701|
NCT01905592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-30-5010-C|A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients|A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients|BRAVO|Tesaro, Inc.|Yes|Recruiting|October 2013|February 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905592||62507|
NCT01905605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2182|Phosphatidylcholine Supplementation in Infants|Phosphatidylcholine Supplementation in Infants With Diminished Sensory Gating||University of Colorado, Denver|Yes|Not yet recruiting|October 2016|January 2031|Anticipated|June 2030|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|162|||Both|N/A|7 Weeks|Accepts Healthy Volunteers|||March 2016|March 23, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905605||62506|
NCT01905891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JG05012013|Nanocytology Test to Evaluate Skin Cancer in High Risk Patients|Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients||Northwestern University|Yes|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905891||62484|
NCT01877486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR Cryo PVI|PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide|Pulmonary Vein Isolation Using Cryoablation Alone in Paroxysmal Atrial Fibrillation Patients Converted From Persistent Atrial Fibrillation With Dofetilide|ABLATE|University of Rochester|No|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred for catheter ablation of AF|January 2016|January 18, 2016|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01877486||64662|
NCT01877499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2013/33|Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration?|Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration? Feasibility Study in Preparation of the Convective Transport Study (CONTRAST II)||VU University Medical Center|No|Active, not recruiting|May 2013|||June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|Patients treated with hemodialysis or hemodiafiltration recruited at dialysis units in 6-7        hospitals in the Netherlands|June 2015|June 2, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01877499||64661|
NCT01877759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BM/2013/LS/01|A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis|Role of Bone Marrow Derived Autologous Stem Cells + Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Liver Cirrhosis||Chaitanya Hospital, Pune|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877759||64641|
NCT01877993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-CAS|The Effect of Autonomic Function on Coronary Vasomotion|The Association of Acetylcholine-induced Coronary Artery Spasm With the Blood Pressure Level||Korea University|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2169|||Both|N/A|N/A|No|Non-Probability Sample|A total of 5,304 consecutive patients in the CAS registry of the Cardiovascular Center at        Korea University Guro Hospital|August 2013|August 23, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877993|5 Years|64623|
NCT01878006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130061|Mu Opioid Receptor Genes, Remifentanil, and Pain Sensitivity|OPRM1 A118G SNP Effect on Striatal Dopamine Response to an IV Opiate||National Institutes of Health Clinical Center (CC)||Recruiting|April 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Anticipated|120|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||August 2015|October 29, 2015|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878006||64622|
NCT01873937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1967|Analgesic Effects of LED Light on Temporomandibular Disorders.|COMPARATIVE CLINICAL STUDY OF LIGHT ANALGESIC EFFECT ON TEMPOROMANDIBULAR DISORDER (TMD) USING RED AND INFRARED LED-THERAPY|LED/TMD|University of Sao Paulo|No|Completed|April 2009|December 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01873937||64933|
NCT01874184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9026|Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer|Diet, Exercise and Estrogen Metabolites Study (DEEM)|DEEM|University of Washington|No|Completed|October 2013|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|17|||Female|35 Years|65 Years|No|||January 2016|January 15, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874184||64914|
NCT01874197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B120176|Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic|Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic Aneurysms: An Investigator-Initiated Study|B-TEVAR|University of Washington|Yes|Recruiting|August 2012|August 2023|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874197||64913|
NCT01874431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16243|Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy|ARTS-DN|Bayer|Yes|Completed|June 2013|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|823|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874431||64895|
NCT01875042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/11|Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis|Does Transcutaneous Electrical Nerve Stimulation (TENS) Affect Pain and Function in Patients With Osteoarthritis of the Knee? ETRELKA, a Randomised Controlled Trial|ETRELKA|University Hospital Inselspital, Berne|Yes|Completed|December 2012|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01875042||64848|
NCT01875055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:118|Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU|A Pilot Trial to Assess the Feasibility and Efficacy of Treating Post-Cardiac Surgery Cerebral Desaturation in the Intensive Care Unit|NIRS ICU|University of Manitoba|No|Recruiting|May 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2013|August 12, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01875055||64847|
NCT01874392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 17-2010-765|Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp|Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) and Technosphere® Insulin Inhalation System From MannnKind Corp.||William Sansum Diabetes Center|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|65 Years|No|||October 2015|October 19, 2015|May 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874392||64898|
NCT01875003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB28183|A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication||Hoffmann-La Roche||Recruiting|August 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|12 Years|17 Years|No|||March 2016|March 1, 2016|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875003||64851|
NCT01875341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005972-01H|Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.|Resistant Hypertension in Patient With Diabetic Nephropathy: Role of Sleep Apnea and Associated Sympathetic Hyperactivity.|SAS|Ottawa Hospital Research Institute|No|Completed|December 2004|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01875341||64826|
NCT01875354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PHX-01-NU-02|A Prospective Study Investigating the Effects of a Novel Weight Management Program|A Prospective, Randomized, Blinded, Controlled Study Investigating the Effects of a Novel Body Weight Management Program Over 90-days and Weight Maintenance at One Year.||Pharmanex|Yes|Completed|May 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01875354||64825|
NCT01875679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC2013|Comprehensive Surgical Coaching|Surgical Coaching -Using Error Debriefing, Behavioral Modeling and Error Recognition to Enhance Surgical Skill||St. Michael's Hospital, Toronto|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01875679||64801|
NCT01875978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-036|Effect of Phytosterols on Nonalcoholic Fatty Liver Disease|Clinical Study of Phytosterols for Insulin-like Growth Factor-1 and Endothelial Progenitor Cell Levels in Patients With Nonalcoholic Fatty Liver Disease||China Medical University Hospital|Yes|Completed|October 2012|July 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|40|||Both|25 Years|80 Years|No|||May 2014|May 12, 2014|June 3, 2013||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01875978||64778|The sample size of this study is small amountAbdominal ultrasound related nonalcoholic fatty liver disease diagnosis is not compatible completely
NCT01876225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0033-CTIL|Evaluating Pain and Discomfort Associated With Cervical Punch Biopsy|Evaluating Pain and Discomfort Associated With Cervical Punch Biopsy||Carmel Medical Center|No|Recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|65 Years|No|||June 2013|May 18, 2014|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01876225||64759|
NCT01876238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12112|Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer|Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|May 2013|June 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876238||64758|
NCT01876472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD_2011_11_15|Differences in Music Perception Skills Between Child, Teen and Adult Cochlear Implant Recipients|Differences in Music Perception Skills Between Child, Teen and Adult Cochlear Implant Recipients||University of Zurich|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|||Both|3 Years|70 Years|No|Non-Probability Sample|Healthy CI recipients that receive their regular follow-ups in the ENT-clinic of the        Zurich University Hospital.|May 2013|June 10, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876472||64740|
NCT01877239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801357|Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria|A Multicenter Non-interventional Study To Observe The Safety And Efficacy Of Etanercept (Enbrel (Registered)) In Patients With Moderately Active Rheumatoid Arthritis In Every Day Clinical Practice In Austria||Pfizer|No|Recruiting|December 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with moderately active RA that are treated with Etanercept will be studied. All        patients enrolled should meet the usual prescribing criteria for Etanercept as per the        Austrian SmPC and should be entered into the study at the investigator's discretion.|March 2016|March 9, 2016|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877239||64681|
NCT01905618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13353|Tobacco Treatment Medical Education in 10 Medical Schools|RCT for Smoking Cessation in 10 Medical Schools|MSQuit|University of Massachusetts, Worcester|Yes|Completed|July 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905618||62505|
NCT01905631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onset Dermatologics|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||September 20, 2013|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905631||62504|
NCT01906190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201104|Persistence of Immune Response After Vaccination With Influenza Vaccine|Persistence Study of Immune Response After Vaccination With Influenza Vaccine in Healthy Population||Centers for Disease Control and Prevention, China|Yes|Completed|August 2011|July 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|207|||Both|12 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 19, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01906190||62461|
NCT01906203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0163|Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance|Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance|IMPETRAIL|University Hospital, Clermont-Ferrand||Completed|May 2013|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 25, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906203||62460|
NCT01877512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/12|GH and Cardiovascular Risk Factors|Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration||VU University Medical Center||Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|20 Years|65 Years|No|||May 2014|May 6, 2014|June 11, 2013||||No||https://clinicaltrials.gov/show/NCT01877512||64660|
NCT01873950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-011D|Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects||Food and Drug Administration (FDA)|Yes|Completed|May 2013|December 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|May 22, 2013|No|Yes||No|March 16, 2015|https://clinicaltrials.gov/show/NCT01873950||64932|
NCT01873963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL111459-01|Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)|Genotype-Phenotype Associations in Pediatric Cardiomyopathy||Wayne State University|Yes|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric cases of dilated, hypertrophic or restrictive cardiomyopathy and select        relatives will be enrolled at 11 pediatric cardiology centers in the US and Canada.|October 2015|October 9, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01873963||64931|
NCT01878019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130143|Brain Response to Pain Control in People With Chronic Pain|Mechanisms of Pain Control in Chronic Pain Patients||National Institutes of Health Clinical Center (CC)||Recruiting|May 2013|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|December 2, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878019||64621|
NCT01874457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN/002/2008|Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)|A Serological Study of Measles, Mumps and Rubella in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) in Health Centers Where a Phase III Study Should be Conducted||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Completed|May 2008|August 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|150|Samples With DNA|Whole blood|Both|12 Months|24 Months|Accepts Healthy Volunteers|Probability Sample|Children 12-23 months and 29 days old, in the routine of PNI in health units in the city        of Rio de Janeiro.|June 2013|June 13, 2013|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874457||64893|
NCT01907269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110928001|A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care|Activating Patients to Reduce OsteoPOrosiS|APROPOS|University of Alabama at Birmingham|Yes|Active, not recruiting|August 2013|March 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|5065|||Female|55 Years|N/A|No|||December 2015|December 28, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01907269||62378|
NCT01907555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLIVIER-FAIVRE PHRC N 2012|Clinical, Molecular and Physiopathological Study of Cohen Syndrome and Cohen-like Syndromes|||Centre Hospitalier Universitaire Dijon|No|Withdrawn|May 2013|||May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|N/A|N/A|No|Probability Sample|Cohen syndrome|July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907555|1 Day|62356|
NCT01904760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUSSIRB-2012006|Dexmedetomidine to Prevent Agitation After Free Flap Surgery|The Effect of Dexmedetomidine on Agitation and Delirium in Patients After Free Flap Reconstructive Surgery||Peking University|Yes|Completed|June 2013|||November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|80 Years|No|||November 2014|November 5, 2014|June 27, 2013||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01904760||62571|
NCT01904266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028824|Paravertebral Blocks for Breast Cancer Surgery|Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial||University of Alberta|No|Recruiting|May 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|80 Years|No|||November 2015|November 24, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01904266||62608|
NCT01905566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2012-02|Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation|Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta||Asan Medical Center|Yes|Completed|September 2013|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905566||62509|
NCT01905579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC 123|Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.|Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.||The Eye Center and The Eye Foundation for Research in Ophthalmology|No|Completed|March 2013|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|10 Years|80 Years|No|||August 2014|August 29, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905579||62508|
NCT01904773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3032C00001|Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder|A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder||AstraZeneca|No|Completed|August 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|12 Years|17 Years|No|||March 2015|March 11, 2015|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904773||62570|
NCT01906398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maes 001|Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy|Evaluation of the Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy: a Pilot Study.|KD|Mid-Atlantic Epilepsy and Sleep Center, LLC|No|Recruiting|January 2013|May 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2014|December 12, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906398||62445|
NCT01879449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110470VU|Prevalence of Spasticity in Veterans Living in a Long-term Care Facility|Prevalence of Spasticity in Veterans Living in a Long-term Care Facility||Vanderbilt University|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nursing home residents|January 2016|January 25, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879449||64512|
NCT01879462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116973|A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects|A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults||GlaxoSmithKline|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879462||64511|
NCT01880203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEETMAC|Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study|Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study|SWEETMAC|Centre Francois Baclesse|Yes|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|140|||Both|18 Years|N/A|No|||October 2014|September 29, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880203||64454|
NCT01880437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28852|A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome|A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)||Hoffmann-La Roche||Terminated|September 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|June 11, 2013|Yes|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01880437||64436|This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.
NCT01879943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003|Capsule Versus Conventional Colonoscopy in Patient Following Colorectal Surgery|Capsule Versus Conventional Colonoscopy in Patient Following Colorectal Surgery||IHU Strasbourg|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|85 Years|No|||March 2016|March 17, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01879943||64474|
NCT01907152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43997.081.13|Increase Protein Intake in Elderly|Increase Protein Intake in Elderly||Wageningen University and Research Centre|No|Completed|September 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|106|||Both|55 Years|N/A|No|||May 2014|May 15, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907152||62387|
NCT01907165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308038|Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide|A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma||Washington University School of Medicine|No|Recruiting|October 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|July 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907165||62386|
NCT01908023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/271|Exercise and Radiotherapy, a Good Combination?|Exercise and Radiotherapy, a Good Combination? A Pilot Study of Group Exercise for Patients With Breast Cancer||Norwegian University of Science and Technology|No|Completed|May 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|80 Years|No|||January 2014|January 28, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908023||62320|
NCT01908036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FITBIT2|Use of a Monitor in ME/CFS|||New York CFS Association|Yes|Recruiting|July 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 CFS patients|July 2013|July 24, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908036||62319|
NCT01907438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISF-1702/12|Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells|Identification of the Transformation Potential of Normal Estrogen Exposed BRCA1 (Breast Cancer Susceptibility Gene 1) and BRCA2 (Breast Cancer Susceptibility Gene 2) Heterozygous Epithelial Breast Cells Due to Irradiation||Hadassah Medical Organization|Yes|Not yet recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|||Female|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|human breast tissue samples will be obtained from risk-reducing mastectomy in healthy        premenopausal women with BRCA1 and BRCA2 mutations. Tissues from premenopausal women        undergoing esthetic breast surgery with no family history of breast or ovarian cancers        also will be obtained.|July 2013|July 24, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907438|7 Days|62365|
NCT01907451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Casillas PHRC IR 2009|Long-Term Effects Of An Early Individualised Retraining Programme On Walking Ability In Patients Following Hemiplegic Stroke||letswalk|Centre Hospitalier Universitaire Dijon||Terminated|May 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|85 Years|No|Probability Sample|patients hospitalized in the Physical Medicine and Rehabilitation (PMR) units of Dijon and        Besançon CHU, and the Functional Rehabilitation Centres of Divio (Dijon) and Bregille        (Besançon)|July 2013|July 24, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907451||62364|
NCT01904123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0358|A Phase I Trial of WP1066 in Patients With Central Nervous System (CNS) Melanoma and Recurrent Glioblastoma Multiforme (GBM)|A Phase I Trial of WP1066 in Patients With Central Nervous System (CNS) Melanoma and Recurrent Glioblastoma Multiforme (GBM)||M.D. Anderson Cancer Center|Yes|Not yet recruiting|May 2016|||May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904123||62619|
NCT01904136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0708|NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies|A Phase I/II Clinical Trial of Natural Killer (NK) Cells Administration to Prevent Disease Relapse for Patient With High-risk Myeloid Malignancies Undergoing Haploidentical Stem-cell Transplantation||M.D. Anderson Cancer Center|No|Recruiting|April 2014|||April 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|2 Years|65 Years|No|||February 2016|February 22, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904136||62618|
NCT01904175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041936|Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant|Registry Study of T Cell Depleted Allogeneic Non-Myeloablative Stem Cell Transplant Recipients||Duke University|No|Recruiting|August 2013|July 2030|Anticipated|July 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic stem cell transplant|December 2015|December 3, 2015|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01904175|1 Year|62615|
NCT01896076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0244|The Caudal Space in Children: Ultrasound Evaluation|||Yonsei University|No|Completed|June 2013|March 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|300|||Both|N/A|7 Years|No|Probability Sample|Patients aged 0 - 84 months who were scheduled to undergo elective urological surgery.        This investigation was conducted at a single tertiary medical center (Severance Hospital),        Seoul, Republic of Korea.|July 2014|July 24, 2014|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01896076||63234|
NCT01896427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292037|Comparing Pain and Swelling After Surgical Extraction of Mandibular Third Molar in Dexamethasone Injection and Without Corticosteroid Methods|||Isfahan University of Medical Sciences|Yes|Recruiting|April 2013|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|75|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 6, 2013|June 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896427||63207|
NCT01896700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3055|Methylphenidate to Improve Balance and Walking in MS|Methylphenidate to Improve Balance and Walking in MS||Oregon Health and Science University|Yes|Recruiting|July 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|65 Years|No|||October 2015|October 13, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896700||63186|
NCT01907789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0340|Prophylactic Salpingectomy With Delayed Oophorectomy|Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study||M.D. Anderson Cancer Center|No|Recruiting|August 2013|||August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|Samples With DNA|Blood (about 2 tablespoons) drawn to measure CA125 and HE4 levels.|Female|30 Years|47 Years|Accepts Healthy Volunteers|Non-Probability Sample|Woman who have a mutation (genetic change) in one of the BRCA genes and are at high risk        for developing ovarian cancer.|December 2015|December 11, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01907789||62338|
NCT01904006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVISEV-003AGR|Human Embryo Group Culture vs. Standard Single Drop Culture|Evaluation and Development of a New in Vitro Embryo Group Culture at Low Oxygen Tension at the Embryology Laboratory|AGRUPADO|IVI Sevilla|No|Active, not recruiting|July 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|182|||Female|18 Years|38 Years|No|||February 2016|February 23, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904006||62628|
NCT01905280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0330|Ridge Preservation Comparing 2 Membranes|Ridge Preservation Comparing the Clinical and Histologic Healing of a PTFE Non-resorbable Membrane Versus an Acellular Dermal Matrix Allograft Plus a Facial Overaly Bovine Xenograft.||University of Louisville|No|Not yet recruiting|September 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01905280||62531|
NCT01904812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Besancenot PHRC N 2010|Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus||EQUAL|Centre Hospitalier Universitaire Dijon||Active, not recruiting|December 2011|||January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|356|||Both|18 Years|75 Years|No|||July 2013|July 17, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01904812||62567|
NCT01904825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonnin PHRC IR 2006|Use of Sentinel Cells for the Development of Molecular Tests to Control the Quality of Cryopreservation|||Centre Hospitalier Universitaire Dijon||Withdrawn|September 2006|August 2009|Actual|August 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A||Probability Sample|Only patients of the CHU Dijon and Strasbourg|July 2013|July 19, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01904825|1 Day|62566|
NCT01906138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1106|An Open Label Study Assessing the 24-hour Intraocular Pressure Pattern in PAC and PACG Patients, Before and After Laser Peripheral Iridotomy|A Prospective, Open Label Study Assessing the 24-hour Intraocular Pressure Pattern Monitored by SENSIMED Triggerfish® in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After Laser Peripheral Iridotomy||Sensimed AG|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01906138||62465|
NCT01905293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DK091492|Individual Differences in Children's Susceptibility to Overeating|Individual Differences in Children's Susceptibility to Overeating||University of Pennsylvania|No|Completed|May 2011|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|50|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||June 2013|July 18, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01905293||62530|
NCT01879956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT Schizophrenia_1|Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia|Randomized Controlled Trial for the Evaluation of the Efficacy of Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Refractory Schizophrenia|OTSchizo|University of Sao Paulo|Yes|Recruiting|February 2012|September 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||June 2013|June 17, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01879956||64473|
NCT01880450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-551|Project Prepared: Risks, Roles and Relationships|Longitudinal Intervention Study to Prepare Early Adolescents for Middle Adolescence, Specifically Focusing on Improving Sexual Health Outcomes|Prepared|Albert Einstein College of Medicine of Yeshiva University|No|Completed|May 2009|December 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|397|||Both|12 Years|14 Years|No|||January 2015|January 12, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01880450||64435|
NCT01880424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-103-307|A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|D5630C00001|AstraZeneca|No|Completed|July 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1722|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880424||64437|
NCT01906879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304017MINB|Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection|Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial||National Taiwan University Hospital|Yes|Recruiting|June 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1620|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 31, 2016|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906879||62408|
NCT01906892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH/K003364/1|Creative Practice as Mutual Recovery|Creative Practice as Mutual Recovery: Connecting Communities for Mental Health and Wellbeing||Royal College of Music|Yes|Completed|November 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|8||Actual|150|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906892||62407|
NCT01907464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8751|Bone Loss in Patients With Anorexia Nervosa|Physiopathology of Bone Loss in Young Patient With Anorexia Nervosa||University Hospital, Montpellier|No|Recruiting|September 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|320|||Female|14 Years|38 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907464||62363|
NCT01907698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catarina Castro|Effect of Vaginal Intercourse on Spontaneous Labour at Term|Effect of Vaginal Intercourse on Spontaneous Labour at Term- A Randomized Trial||Hospital de Santa Maria, Portugal|Yes|Completed|April 2009|||June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|123|||Female|18 Years|N/A|No|Probability Sample|Pregnant women attending to antenatal appointment in our Obstetric Unit|July 2013|July 22, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01907698||62345|
NCT01907490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-004|Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation|A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.||Hatchtech Pty Ltd|No|Completed|March 2013|December 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|6 Months|17 Years|No|||August 2015|August 25, 2015|July 22, 2013|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01907490||62361|
NCT01907724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-007|Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)|A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907724||62343|
NCT01904149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-TRA-04|Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride|A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain Following Abdominal Hysterectomy|DAVID lap|Menarini Group|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|606|||Female|18 Years|75 Years|No|||February 2016|February 4, 2016|July 17, 2013||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01904149||62617|
NCT01896089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPD6172013|Regional Kidney Paired Donor Exchange in Sensitized Patients|Prospective, Multicenter, Observational Registry Study to Determine if Enrollment in a Regional Kidney Paired Donor Exchange Program Improves the Overall Rate of Kidney Transplantation in Sensitized Patients, and Sensitized Patients Undergoing Desensitization Treatments.||BiologicTx, LLC|Yes|Recruiting|December 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 250 renal transplant candidates at 6 transplantation centers in the United        States (northwest) will participate.|August 2014|August 1, 2014|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896089|24 Months|63233|
NCT01896102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD-102|A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)|A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)||bluebird bio||Active, not recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Male|N/A|17 Years|No|||June 2015|August 11, 2015|March 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896102||63232|
NCT01906047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCFB chronic pollution|Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis|Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis||Universitaire Ziekenhuizen Leuven|No|Completed|June 2006|April 2013|Actual|October 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|189|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with a HRCT diagnosis of bronchiectasis and do not have a diagnosis of cystic        fibrosis. They also need to have typical bronchiectatic disease (recurrent infections and        sputum).|July 2013|July 18, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01906047|6 Years|62472|
NCT01896440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric ondansetron QTc|Heart Safety Study of Ondansetron in Children Receiving Chemotherapy|The Effects of Ondansetron on Myocardial Repolarization in Children Receiving Chemotherapy||University of Oklahoma|Yes|Withdrawn|October 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|18 Years|No|||October 2013|October 4, 2013|July 1, 2013|Yes|Yes|FDA did not approve|No||https://clinicaltrials.gov/show/NCT01896440||63206|
NCT01896713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-2009|The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer|To Determine if MultiSpectral 3 Tesla MRI Can Provide Added Value in the Detection of Significant Cancers in Patients o n Active Surveillance for Prostate Cancer||Sunnybrook Health Sciences Centre|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|81|||Male|18 Years|N/A|No|||July 2013|July 8, 2013|January 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896713||63185|
NCT01896726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14601|A Study of Baricitinib and Birth Control Pills in Healthy Females|The Effects of Multiple Doses of Baricitinib on the Pharmacokinetics of a Single Dose of an Oral Contraceptive in Healthy Female Subjects||Eli Lilly and Company|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896726||63184|
NCT01904565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSA_HYPROSAR1|Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma|A Phase I/II Study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma|HYPROSAR|Kantonsspital Aarau|Yes|Recruiting|February 2014|December 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01904565||62586|
NCT01907841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPCEIMD001|The Effect of Ischemic Pre-Conditioning on the Rate of Recovery Following Exercise-Induced Muscle Damage|The Effect of Ischemic Pre-Conditioning on the Rate of Recovery Following Exercise-Induced Muscle Damage: a Randomized Control Trial||St Mary's University College|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01907841||62334|
NCT01904786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU22484|Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy|Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy||St. Louis University|Yes|Withdrawn|April 2014|November 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|8 Hours|No|||January 2015|July 1, 2015|July 17, 2013|No|Yes|Lack of enrollment of suitable candidates|No||https://clinicaltrials.gov/show/NCT01904786||62569|
NCT01904799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benaim PHRC N 2012|Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study||Casper|Centre Hospitalier Universitaire Dijon|No|Recruiting|December 2014|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|290|||Both|18 Years|80 Years|No|||January 2015|July 15, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01904799||62568|
NCT01904838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006453 -2|The Healing Context in CAM: Instrument Development and Initial Validation - Calibration Study|The Healing Context in Complementary and Alternative Medicine (CAM): Instrument Development and Initial Validation - Calibration Study|HEAL2|University of Pittsburgh|Yes|Completed|September 2012|November 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|1650|||Both|18 Years|N/A|No|Non-Probability Sample|Local clincal sample is persons receiving treatment at UPMC clinics or UPMC Center for        Integrative Medicine.        Internet sample is persons reporting current or past year conventional or integrative        medicine treatment.|November 2015|November 30, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904838||62565|
NCT01904851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052012-093|Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes|Multi-Center Registry Comparing Stent and Non-Stent Based Interventional Outcomes for Patients With Peripheral Arterial Disease|XLPAD|University of Texas Southwestern Medical Center|Yes|Recruiting|January 2013|January 2033|Anticipated|January 2033|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|2174|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diagnosed peripheral arterial disease who underwent endovascular        intervention, and received either a stent or non-stent based treatment.|July 2015|July 15, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904851|12 Months|62564|
NCT01905306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTGIS1|Randomized Controlled Trial of Full-Arch Rehabilitation|Clinical Evaluation of Immediate Loading Full Arch Rehabilitation Made With Methodology for Computer Guided Implant Planning With Software Polyvalent vs Free Hand Implants Placement||University of Siena|No|Active, not recruiting|January 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||July 2013|July 18, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905306||62529|
NCT01905319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARLA 0475;DARLA 0500|Juvenile Idiopathic Arthritis in Children in Estonia.|Juvenile Idiopathic Arthritis in Children in Estonia - an Epidemiological and Clinical Investigation.||University of Tartu|No|Completed|January 1998|December 2002|Actual|December 2000|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|162|Samples Without DNA|Sera and plasma.|Both|1 Month|15 Years|No|Probability Sample|During years 1998-2000, 162 newly-diagnosed juvenile idiopathic arthritis cases from 14        counties of Estonia, were included to the study, among them 76 boys and 86 girls.|July 2013|July 18, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905319||62528|
NCT01880216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bemiparin|Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT|A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment of Acute Deep Vein Thrombosis (DVT)||Berlin-Chemie AG Menarini Group|No|Completed|June 2013|May 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|100 Years|No|||February 2016|February 3, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880216||64453|
NCT01881750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11022010-7151|Pivotal Response Group Treatment for Parents of Young Children With Autism|Pivotal Response Group Treatment for Parents of Young Children With Autism||Stanford University|No|Active, not recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|6 Years|No|||June 2013|June 17, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01881750||64335|
NCT01880697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_33S|Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults||Novartis|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 31, 2013|June 12, 2013||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01880697||64416|
NCT01880970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.20.INF|Effect of Starter Formula on Infection Prevention|Effect of Starter Formula With Synbiotics on Prevention of Gastro-intestinal Infections and All Infections With Fever in Full Term Infants||Nestlé|No|Completed|October 2008|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|477|||Both|N/A|12 Months|Accepts Healthy Volunteers|||July 2014|October 20, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01880970||64395|
NCT01907178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-06-002|Postoperative Pain Management in Hospital and Following Discharge From Hospital.|Assessment of Postoperative Pain Management in Patients Undergoing Total Knee Arthroplasty Immediately After Surgery and Following Discharge From Hospital.||Saint Francis Care|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients treated at Saint Francis Hospital undergoing total knee replacement|October 2015|October 29, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01907178||62385|
NCT01907711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV/AS|Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.|Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome.|AV/AS|Hospital Vall d'Hebron|Yes|Recruiting|February 2013|October 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01907711||62344|
NCT01895478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210394|Adaptation of the Pediatric Asthma Control & Communication Instrument (PACCI) in a Pediatric Emergency Department|||Rhode Island Hospital|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|77|||Both|1 Year|17 Years|No|||July 2013|July 9, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895478||63280|
NCT01895491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM206RY-VM01|Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer|An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer|VM206RY|Reyon Pharmaceutical Co., Ltd.|Yes|Completed|March 2011|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Female|20 Years|N/A|No|||October 2013|January 20, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01895491||63279|
NCT01908049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROB-VIH|Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in HIV Infection.|Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in HIV Infection.||Parc de Salut Mar|No|Recruiting|August 2012|September 2013|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01908049||62318|
NCT01906320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-0034/08-1|Effects of a High Intensity Resistance Training in Muscular Strength, Agility, and Body Composition of Anorexia Nervosa Restricting Type Patients|||Universidad Europea de Madrid|Yes|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Female|12 Years|16 Years|No|||July 2013|July 19, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906320||62451|
NCT01906541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-CGD|Gene Therapy for X-CGD|A Phase I/II Gene Therapy Trial for X-CGD With a SIN Gammaretroviral Vector||Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|July 2013|December 2019|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01906541||62434|
NCT01906749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27/06/13|Colchicine for Acute Coronary Syndromes|Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial.|COACS|Maria Vittoria Hospital|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|90 Years|No|||July 2013|July 23, 2013|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906749||62418|
NCT01896739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VACL004|A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants|A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2,4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined Administered Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.||LG Life Sciences|No|Completed|August 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|289|||Both|N/A|6 Months|Accepts Healthy Volunteers|||July 2013|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896739||63183|
NCT01896999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01275|Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|January 2014|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896999||63164|
NCT01907854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4059|Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin|Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin|LIRA-SWITCH™|Novo Nordisk A/S|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907854||62333|
NCT01907867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-008|Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin|An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers||MerLion Pharmaceuticals GmbH|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907867||62332|
NCT01904292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA28118|A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis|A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS||Hoffmann-La Roche||Recruiting|August 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|1 Year|17 Years|No|||March 2016|March 1, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904292||62606|
NCT01904617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025-11|Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas|A Randomized Controlled Trial on the Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas||MemorialCare Health System|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|300|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01904617||62582|
NCT01904864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE15929|Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia|A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.|BESTIRON|University of Texas Southwestern Medical Center|No|Recruiting|July 2013|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Months|48 Months|No|||July 2013|July 17, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904864||62563|
NCT01905020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-04|Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes|An Open-label, Randomized, Three-way, Multicenter Study to Compare the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Overnight Glucose Levels at Home in Adolescents and Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|12 Years|N/A|No|||October 2014|October 18, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01905020||62551|
NCT01905033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-056|Molecular Diagnosis and Risk Stratification of Sepsis|Molecular Diagnosis and Risk Stratification of Sepsis|MARS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|January 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7500|Samples With DNA|Whole blood, plasma, RNA, DNA.|Both|18 Years|N/A|No|Probability Sample|In 3-4 years all patients> 18 years in the Intensive Care Units of the AMC Amsterdam and        UMC Utrecht will be included in the study with the exemption of elective cardiac surgery        patients with an uncomplicated stay.|August 2013|August 21, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01905033|1 Year|62550|
NCT01905332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00352|Preschool Literacy Screening: Validating a 5 Question Survey Using the GRTR-R and the Efficacy of Literacy-promoting Interventions|Preschool Literacy Screening: Validating a 5 Question Survey Using the GRTR-R and Evaluation of the Efficacy of Literacy-promoting Interventions.||Nationwide Children's Hospital|No|Withdrawn|July 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|0|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905332||62527|
NCT01905345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGPOT|Influence of Consecutive Strength- and Endurance Regimes on the Myonuclear Domain and Satellite Cell in the M. Vastus Lateralis of Old Healthy Men|||University of Zurich||Recruiting|August 2013|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|45|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|June 2, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905345||62526|
NCT01881451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00921|Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer|Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer||British Columbia Cancer Agency|No|Recruiting|August 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|The collection of archival tumour blocks from the time of prior surgery/biopsy and any newly      obtained biopsies (newly obtained biopsies are optional) will be used to construct a tumour      tissue microarray (TMA). The TMA will be assessed using multi-parameter staining for LC3A/B      (autophagy), EF5 (hypoxia) and cleaved caspase 3 (apoptosis).|Both|19 Years|N/A|No|Non-Probability Sample|Eligible participants with recurrent or metastatic clear cell ovarian cancer will be        approached for study participation at the time of their visit with their treating        oncologist (medical oncologist, radiation oncologist or gynecologic oncologist).|January 2016|January 4, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01881451||64358|
NCT01881464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0006-CTIL|Anti TNF α Improves Endothelial Dysfunction in IBD Patients|Anti TNF α Improves Endothelial Dysfunction in IBD Patients||Carmel Medical Center|No|Recruiting|May 2014|June 2018|Anticipated|June 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|CRP, CBC,Serum for future metabolomics perpus.|Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|IBD Patients.|June 2013|May 15, 2014|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01881464||64357|
NCT01881243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REOX|Reoxygenation After Cardiac Arrest (REOX Study)|Reoxygenation After Cardiac Arrest (REOX Study)|REOX|The Cooper Health System|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|Samples Without DNA|This research will measure biomarkers of oxidative stress (isoprostanes and isofurans) on      plasma samples.|Both|18 Years|N/A|No|Probability Sample|Adult patients resuscitated from cardiac arrest|December 2015|December 11, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881243||64374|
NCT01881256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BabyGrow1 Study|The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants|The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants|BabyGrow|University College Cork|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|N/A|34 Weeks|No|Non-Probability Sample|Preterm infants admitted to Cork University Maternity Hospital Neonatal Unit|June 2013|June 18, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881256||64373|
NCT01881958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0224-13-HMO-CTIL|The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.|||Hadassah Medical Organization|No|Not yet recruiting|August 2013|||August 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|45 Years|No|||June 2013|June 19, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01881958||64319|
NCT01881971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100503|Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center|Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo|SPARC|University of Pittsburgh|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||September 2014|May 26, 2015|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01881971||64318|
NCT01881984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13050530|Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation|Use of Glycerol Phenylbutyrate (Ravicti™) as a Chaperone to Stabilize Enzyme in Patients With MCAD Deficiency Due to the Common MCAD 985A>G (K304E) Mutation||University of Pittsburgh|Yes|Completed|June 2013|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881984||64317|
NCT01907477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dalle PHRC IR 2009|Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients|||Centre Hospitalier Universitaire Dijon||Completed|August 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|500|||Both|14 Years|N/A|No|||July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907477||62362|
NCT01907217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA/2007/5|Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression|A Randomised Controlled Trial of Standard Bilateral Electroconvulsive Therapy Versus High-dose Unilateral Electroconvulsive Therapy for Severe Depression|EFFECT-Dep|St Patrick's Hospital, Ireland|Yes|Completed|May 2008|April 2015|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|June 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907217||62382|
NCT01895504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoAssist|ColoAssist vs. MEI|ColoAssist vs. Magnetic Guided Colonoscopy - a Randomized Controlled Trial||Sorlandet Hospital HF|No|Completed|April 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|475|||Both|55 Years|66 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01895504||63278|
NCT01895517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIUC1312|CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）|Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Active, not recruiting|June 2013|March 2021|Anticipated|March 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|18471|||Female|30 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01895517||63277|
NCT01895777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.106|Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)|Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age||Boehringer Ingelheim||Recruiting|September 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|N/A|17 Years|No|||March 2016|March 21, 2016|July 4, 2013||||No||https://clinicaltrials.gov/show/NCT01895777||63257|
NCT01896063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wangqiang888|Sedative and Hypnotic Effects Induced by EA|EA Induces Sedative and Hypnotic Effects by Detecting BIS Value and MRI.||Xijing Hospital|Yes|Completed|September 2011|May 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|45|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 17, 2014|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01896063||63235|
NCT01906762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|389456|Comparing the Analgesic Effect of Intravenous Acetaminophen and Morphine on Patients With Renal Colic Pain Reffering to the Emergency Department: A Randomized Controlled Trial|Comparing the Effect of Intravenous Morphine and Injectable Acetaminophen on Renal Colic Patients Presenting to the Emergency Department: A Randomized Controlled Trial||Isfahan University of Medical Sciences|Yes|Completed|July 2012|April 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|124|||Both|15 Years|80 Years|No|||July 2013|July 20, 2013|July 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906762||62417|
NCT01906996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC01|Proximal Row Carpectomy Versus Four Corner Fusion|Comparison of Subjective, Radiological and Functional Results After Proximal Row Carpectomy and Four Corner Fusion||Schulthess Klinik|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|114|||Both|18 Years|N/A|No|Non-Probability Sample|patients with a post-traumatic wrist osteoarthritis, who are treated with a proximal row        carpectomy or a four corner fusion|February 2014|February 26, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906996||62399|
NCT01906983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0159-13-RMBCTIL|Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound|Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound||Rambam Health Care Campus|No|Recruiting|July 2013|||August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|All trauma patients 18 and up admitted to Rambam Medical Center with diagnosis of blunt        splenic trauma.|August 2015|August 25, 2015|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01906983|3 Months|62400|
NCT01904045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEL-1235_REN-0176-I|PEL-1235_REN-0176-I|A Multicentre, Prospective, Non-Interventional Study to Assess the Intra-patient Variability of Tacrolimus Once and Twice Daily After Kidney Transplantation|Pelicon|Technische Universität München||Recruiting|May 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|176|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient clinic|March 2016|March 16, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01904045||62625|
NCT01904058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-201|Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis|CLARITY|Shire|Yes|Completed|August 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904058||62624|
NCT01904591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIantiox1|The Effects of Anti-oxidants on Clinical Outcomes and Radiological Features of Chronic Spinal Cord Injury: A Pilot Study|||McMaster University|No|Recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01904591||62584|
NCT01904604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR6|Peanut Epicutaneous Phase II Immunotherapy Clinical Trial|Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|September 2013|February 2018|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|4 Years|25 Years|No|||December 2015|December 31, 2015|July 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904604||62583|
NCT01904630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1707|Sequencing to Identify Gene Variants in Familial Colorectal Cancer|Exom-sekvensering for å Identifisere høyrisiko Genvarianter i en Familie Predisponert for Colorectal Cancer||Norwegian University of Science and Technology|No|Recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|10|Samples With DNA|Blood samples for DNA sequencing|Both|20 Years|N/A|No|Non-Probability Sample|A specific family showing increased risk for CRC|January 2016|January 20, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01904630||62581|
NCT01905930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA-PCM-1101|Post-Approval Clinical Trial of the PCM® Cervical Disc|A Prospective, Randomized, Multi-Center, Post-Approval Clinical Trial Evaluating the Long-Term (7 Year) Safety and Effectiveness of the PCM® Cervical Disc||NuVasive|No|Completed|April 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|65 Years|No|||May 2015|May 19, 2015|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905930||62481|
NCT01905943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28543|A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia|A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Recruiting|November 2013|October 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|950|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905943||62480|
NCT01905046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A211102|Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer|Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1,1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women||Alliance for Clinical Trials in Oncology|Yes|Recruiting|August 2013|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Female|25 Years|55 Years|No|||June 2015|June 12, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905046||62549|
NCT01905657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-010|Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)|A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|August 2013|March 2019|Anticipated|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1034|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905657||62502|
NCT01905670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBR-02494|Safety and Performance of Electrodes Implanted in the Left Ventricle|Multicenter, Prospective Evaluation of Safety and Performance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy|SELECT-LV|EBR Systems, Inc.|Yes|Active, not recruiting|July 2013|February 2020|Anticipated|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|75 Years|No|||February 2015|May 20, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905670||62501|
NCT01880996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0112-DG-CTIL|Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies|The Effect of Tai-chi/Qi-gong on Quality of Life (QOL), Sleep, and Fatigue in Patients With Gynecological Malignancies||Sheba Medical Center|No|Withdrawn|August 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||June 2015|June 10, 2015|May 30, 2013||No|The deparment failed to detect patients that were willing to participate in this study|No||https://clinicaltrials.gov/show/NCT01880996||64393|
NCT01878240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-37813003/2012A01258-35|Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac|Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac|SCOPE1|Centre Chirurgical Marie Lannelongue|Yes|Recruiting|May 2013|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01878240||64604|
NCT01878253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIU2012-12E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||December 18, 2015|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878253||64603|
NCT01899209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-REST|Surgical Treatment of Obstructed Defecation Syndrome|Obstructed Defecation Caused by Rectal Intussusception and Rectocele:STARR Versus Laparoscopic Ventral Rectopexy|PRO-REST|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|August 2013|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01899209||62995|
NCT01899508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045175|Virtual Reality for Osteoarthritis Knee Pain Pilot|Virtual Reality for Osteoarthritis Knee Pain Pilot|VROA|Duke University|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|85 Years|No|||January 2016|January 13, 2016|June 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899508||62972|
NCT01906931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187_13|Ambulatory Oxygen for ILD|Effective Delivery of Ambulatory Oxygen in Interstitial Lung Disease - a Crossover Trial.||The Alfred|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906931||62404|
NCT01895231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-BD-02|A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors|A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-Deficient Blood Donors||Pharmacosmos A/S|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|March 1, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895231||63299|
NCT01895244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST MOMA|Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis|Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation|AST-MOMA|University Hospital Tuebingen|Yes|Recruiting|September 2012|September 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895244||63298|
NCT01905475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL6326-POL-006|CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)|CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction|CATCH-AMI|Polyphor Ltd.|Yes|Active, not recruiting|July 2013|June 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||July 2015|November 24, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905475||62516|
NCT01895790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00080955|Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer|Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients: A Prospective Pilot Study||Johns Hopkins University|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|80 Years|No|||February 2016|February 29, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01895790||63256|
NCT01895803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 0047-13|The Factors That Inhibit Women Who Smoke to do Pap Smear Test|To Find Factors That Inhibit Women Who Smoke to do Pap Smear Test||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2013|October 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|smoking woman 18-60 years old|June 2013|July 7, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01895803||63255|
NCT01907815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01354|Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations||National Cancer Institute (NCI)|No|Suspended|October 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 22, 2013|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01907815||62336|
NCT01907828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-0009|A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence|A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence|RDN + AF|St. Jude Medical||Recruiting|July 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907828||62335|
NCT01903993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28753|A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"|A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH DOCETAXEL IN PATIENTS WITH NON&#8722;SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE [POPLAR]||Hoffmann-La Roche||Active, not recruiting|August 2013|February 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903993||62629|
NCT01907282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1MH088546-0110|Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis|Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis||University of California, Los Angeles|No|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|12 Years|35 Years|No|||July 2013|July 18, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01907282||62377|
NCT01904071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/09/VA09|Ultrasound Guided Pain Control Versus Standard Treatment in Emergency Department HIP Fracture Patients|Ultrasound Guided Femoral (3 in 1) Nerve Block Versus Ultrasound Guided Fascia Iliacus Compartment Block Versus Standard Treatment for Pain Control in Patients With Hip Fractures in the Emergency Department||Maimonides Medical Center|No|Completed|October 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|July 17, 2013||No||No|December 26, 2013|https://clinicaltrials.gov/show/NCT01904071||62623|
NCT01904331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|686317|Breast Cancer Long-term Outcome of Cardiac Dysfunction|Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy|BLOC|University Medical Center Groningen|No|Recruiting|June 2013|November 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|700|Samples With DNA|EDTA-plasma, Heparin-Lithium plasma, Serum, Frozen whole blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients are selected in primary care practices in the Northern part of the        Netherlands.        Controls are randomly selected in the same primary care clinics as participants.|December 2015|December 2, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01904331|1 Day|62603|
NCT01904643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0024|Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)||Stanford University|Yes|Recruiting|February 2014|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904643||62580|
NCT01905397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045975|Negative Pressure Wound Therapy to Reduce Surgical Site Infection|Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery||Duke University|Yes|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|126|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905397||62522|
NCT01905059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12286MOBIDIP|Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa|Multicenter, International, Prospective, Phase III, Randomized, Superiority Trial Comparing Two Maintenance Strategies With Mono or Bi-therapy of Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment Over a Period of 96 Weeks in Africa (Dakar, Bobo Dioulasso, Yaounde)|MOBIDIP|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|February 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||April 2015|December 8, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01905059||62548|
NCT01906463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bonithon PHRC N 2010|Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments|Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments: Côte d'Or, Martinique, Guadeloupe and French Guyana Analysis of Their Impact on Vascular Risk Factors and the Management of CVA|INDIA|Centre Hospitalier Universitaire Dijon|No|Recruiting|July 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patient from CHU Dijon , CHU Point-à-Pitre and CHU Fort-de-France,CHU Guyane|July 2013|July 17, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01906463||62440|
NCT01882010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487-12-FB|Leukine (Sargramostim) for Parkinson's Disease|Leukine (Sargramostim) for Parkinson's Disease||University of Nebraska|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|32|||Both|35 Years|85 Years|No|||January 2015|January 9, 2015|June 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01882010||64315|
NCT01895270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA035325|Improving Buprenorphine Detoxification Outcomes With Isradipine|Improving Buprenorphine Detoxification Outcomes With Isradipine||University of Arkansas|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01895270||63296|
NCT01895530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIC 0391.0.203.000-09|Impact of Probiotics in Modulation of Intestinal Microbiota|Impact of Probiotics in Modulation of Intestinal Microbiota of Patients Undergoing a Resection Colonic||Federal University of Minas Gerais|Yes|Completed|July 2010|May 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|33|||Both|N/A|N/A|No|||July 2013|July 5, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01895530||63276|
NCT01899495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11494|Blood Pressure Response to Sodium in the Diet|D1 and AT1 Receptor Interaction in Human Hypertension: Sodium Sensitivity of Blood Pressure||University of Virginia|No|Recruiting|January 2005|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01899495||62973|
NCT01895257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The SIR-step trial|Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer|A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Cancer Which Are Controlled After Induction Systemic Therapy||Universiteit Antwerpen|Yes|Recruiting|August 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|99 Years|No|||December 2015|December 8, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01895257||63297|
NCT01906333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43302.068.13/METC 13-3-003|Elevated FFA and Skeletal Muscle Lipid Content|Effects of Acute Elevation of Circulating Fatty Acids on Skeletal Muscle Lipid Accumulation and Metabolism in Healthy Lean Young Men||Maastricht University Medical Center|Yes|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906333||62450|
NCT01905787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0128-11-EMC|Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study|Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study. Clinical and Genetic Characteristics of Sickle Cell Anemia (SCA) Patients in Three Different Communities.||HaEmek Medical Center, Israel|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||4|Anticipated|300|||Both|1 Year|40 Years|No|Non-Probability Sample|Group 1 - Emek group - (EMC): 100 patients will be included in the study, including        Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be        included).        Group 2 - Dana group - (DMC): 50 patients will be included in the study. Group 3 -        Schneider group - (ShMC): 50 patients will be included in the study. Group 4 - Detroit        group - (WYUMC): 100 patients will be included in the study, Homozygous SCA patients and        Sickle Cell β Thalassemia Patients (β0 and β+) will be included).|August 2015|August 30, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905787||62492|
NCT01907035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSICCAPAD 2012|Anxiety-depressive Disorder in Primary Care and Cognitive-behavioral Treatment|Improving Anxiety-depressive Disorder in Primary Care Applying a Cognitive-behavioral Treatment, Applied by Psychologists.|PSICCAPAD|Basque Health Service|Yes|Recruiting|August 2012|December 2015|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|75 Years|No|||July 2013|July 23, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907035||62396|
NCT01904253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-201|A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy|An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based Chemotherapy||Taiho Oncology, Inc.|No|Terminated|July 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 12, 2013||No|The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed    an imbalance of PFS between the two arms|No||https://clinicaltrials.gov/show/NCT01904253||62609|
NCT01904084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/555|Volar Locked Plating vs Bridging External Fixation in Distal Radius Fracture|A Randomized, Prospective Comparison of Volar Locked Plating Versus Hoffman II Bridging External Fixation in Patients With Dislocated Distal Radius Fractures, AO/OTA Type A.||Haukeland University Hospital|Yes|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||January 2016|January 27, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01904084||62622|
NCT01904357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-1202|Pediatric Cefazolin PK Study|USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System in Pediatric Subjects of 10-12 Years (Inclusive) Scheduled for Surgery||B. Braun Medical Inc.|Yes|Completed|March 2013|September 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|10 Years|12 Years|No|||March 2014|March 19, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01904357||62601|
NCT01904344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_NXT_SLEEP|Clinical Validation of New Breathing Sensors in Patients With Respiratory Insufficiency|NXT_SLEEP: the Development of a Next Generation Sleep Monitoring Platform|NXT_SLEEP|University Hospital, Antwerp|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01904344||62602|
NCT01905371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044966|Amphetamine-Enhanced Stroke Recovery|Amphetamine-Enhanced Stroke Recovery||Duke University|No|Completed|April 2001|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|July 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905371||62524|
NCT01905384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 130331|Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction|Randomized Controlled Trial Comparing Covered Versus Uncovered Metal Stents for Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction||Vanderbilt University|No|Enrolling by invitation|April 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01905384||62523|
NCT01905683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3071_1|Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy|Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy||Merz Pharmaceuticals GmbH|Yes|Active, not recruiting|August 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|370|||Both|2 Years|17 Years|No|||March 2016|March 22, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905683||62500|
NCT01905358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29031|The Knee Usual Care Evaluation Study|Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study|KUCE|Hospital for Special Surgery, New York|No|Terminated|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|30 Years|80 Years|No|Non-Probability Sample|Hospital for Special Surgery knee osteoarthritis patients|March 2014|March 17, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905358|5 Years|62525|
NCT01905956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/010013|Safety and Efficacy of IQP- AK-102 in Reducing Body Weight|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of IQP- AK-102 in Reducing Body Weight in Overweight and Obese Subjects||InQpharm Group|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|February 10, 2016|July 19, 2013||No||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01905956||62479|
NCT01881789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPZ003|Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma||Onyx Pharmaceuticals|Yes|Active, not recruiting|August 2013|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881789||64332|
NCT01881776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10142|Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week|Continuous Interscalene Block in Patients Having Outpatient Rotator Cuff Repair Surgery: a Prospective Randomized Trial||St. Luke's-Roosevelt Hospital Center|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|71|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|May 5, 2014|February 26, 2013||No||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01881776||64333|1. It was difficult to keep three different groups blinded. 2. The resting and mobilization highest/worst NRS pain scores were ignored and only the highest pain scores of the postoperative days 1, 2, 3, and 7 were recorded.
NCT01882023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anfmri40|Comparing Neural Responses to Food Images in EDNOS Patients and Healthy Controls Using fMRI|Comparing Neural Responses to Explicit and Subliminal Food Images in EDNOS Patients and Healthy Controls Using fMRI|ANfMRI|Uppsala University|No|Recruiting|May 2011|November 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples With DNA|Whole blood|Female|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Half of the cohort are patients recruited from the eating disorder clinic. All subjects in        the study are adolescent females residing in the Uppsala area.|December 2014|December 2, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01882023||64314|
NCT01905488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0056|Perioperative Changes of Cognitive Function According to Jugular Vein Insufficiency in Robot-assisted Prostatectomy|||Yonsei University|No|Completed|May 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|50|||Male|56 Years|78 Years|No|Non-Probability Sample|Patients who were over 50 years old with ASA class I or II, scheduled for robot-assisted        laparoscopic prostatectomy|July 2013|July 18, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905488||62515|
NCT01899521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULM-038-12S|Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics|Alcohol Abuse, Oxidative Stress, and Zinc Deficiency in Lung Disease|ExZACTO|VA Office of Research and Development|Yes|Recruiting|May 2013|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|60 Years|No|||February 2016|February 10, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01899521||62971|
NCT01895543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000081|Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation|A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation|Echo 3|Ferring Pharmaceuticals|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|411|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895543||63275|
NCT01895556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSG09-Thornton|Information About HIV Transmission and Circumcision on Subsequent Sexual Behavior, and the Demand for Circumcision|A Study of the Effect of Information About the Relationship Between HIV Transmission and Circumcision on Subsequent Sexual Behavior, and the Demand for Circumcision Among Circumcised and Uncircumcised Men in Malawi, Africa.||University of Michigan||Completed|August 2008|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|1200|||Both|25 Years|40 Years|No|||July 2013|July 3, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01895556||63274|
NCT01895816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRHRC-9026|Herbal Tonic Fertile Supplement(ZO2C5)|Phase 3 of Study on Effects of New Herbal Mixture on Men Infertility|(ZO2C5)|Islamic Azad University of Tabriz|Yes|Completed|June 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|1||Actual|1|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01895816||63254|
NCT01907009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL-CAP|A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).|A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).|MEL-CAP|Barts & The London NHS Trust|Yes|Recruiting|January 2013|September 2017|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Male|18 Years|N/A|No|||July 2013|September 7, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907009||62398|
NCT01906554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-1066-001|Plasma and Urine TMAO Formation and Changes to Oxidized LDL After Ingestion of Different Amounts of Egg|Determining Whether or Not Egg Ingestion Increases Concentrations of Trimethylamine N-oxide (TMAO) in Plasma and Urine and Activates LDL Oxidation in Humans||University of North Carolina, Chapel Hill||Completed|October 2012|July 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 20, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01906554||62433|
NCT01907295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092860|National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension|National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension|NAIAD|University of Cambridge|Yes|Recruiting|February 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3600|Samples With DNA|All subjects will have a sample of blood taken for next generation genetic sequencing (up to      their entire genome). Samples will be sequenced to identify novel genetic mutations      associated with PAH. This blood sample will be taken once during the study|Both|16 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with idiopathic, anorexigen-induced or heritable PAH relative who has a        family member diagnosed with idiopathic, anorexigen-induced, or heritable PAH|January 2016|January 5, 2016|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01907295|5 Years|62376|
NCT01907308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1502.cc|Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma|A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen||University of Colorado, Denver|Yes|Withdrawn|February 2014|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|July 16, 2013|Yes|Yes|Sponsor's decision to terminate the study|No||https://clinicaltrials.gov/show/NCT01907308||62375|
NCT01907581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quenot PHRC IR 2012|Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU.|Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU. Prospective, Multi-centre Cohort Study|IVOIRE|Centre Hospitalier Universitaire Dijon||Recruiting|June 2013|||April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1400|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907581||62354|
NCT01904669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0128|Internet-based Study of Fertility and Early Pregnancy (PEEPS)|Prospective Evaluation of the Elements of Pregnancy Study|PEEPS|Ohio State University|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|161|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are looking for women ages 18-44 who are planning a pregnancy and have been trying to        conceive for <3 months. Women must have reliable daily access to the Internet. The woman        and her male partner may not have any known fertility problems.|October 2015|October 26, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01904669||62578|
NCT01904383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.147|PMS of Trazenta on the Long-term Use as Add-on Therapy|Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Active, not recruiting|July 2013|September 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|3000 patients with type 2 Diabetes Mellitus|February 2016|February 17, 2016|July 8, 2013||||No||https://clinicaltrials.gov/show/NCT01904383||62600|
NCT01905098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H35B11-Phase1|Complementary and Alternative Medicine Sauna Detoxification Study: Phase I|Complementary and Alternative Medicine Sauna Detoxification Study: A Phase I Randomized 2-Arm Study to Determine the Impact of Hyperthermia Intervention Protocol on Serum Polychlorinated Biphenyls (PCBs) in Healthy Human Adults.||Bastyr University|Yes|Terminated|July 2013|April 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|1|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905098||62545|
NCT01905111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300.15|A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer|An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours||Boehringer Ingelheim||Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||September 2014|September 3, 2014|July 12, 2013||||No||https://clinicaltrials.gov/show/NCT01905111||62544|
NCT01906476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH095753-01A1|Stepped Telemental Health Care Intervention for Depression|Stepped Telemental Health Care Intervention for Depression||Northwestern University|Yes|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906476||62439|
NCT01906489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0007|20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)||Akebia Therapeutics|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|82 Years|No|||November 2014|November 12, 2014|July 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906489||62438|
NCT01906216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHDD-001|Sorafenib Chemoembolization Evaluation Controlled Trial|Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial|SELECT|Fourth Military Medical University|No|Recruiting|September 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01906216||62459|
NCT01878305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS2344|Neuromonitoring of Hepatic Encephalopathy|Frontal Electroencephalogram Variables Are Associated With Outcome and Stage of Hepatic Encephalopathy in Acute Liver Failure||Helsinki University|No|Completed|December 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|All acute liver failure patients meeting the inclusion criteria, referred to the intensive        care unit of the Surgical Hospital of Helsinki, Finland, for evaluation for the need of a        liver transplant. The total study size was set to twenty patients, and recruitment was        continued until the set number was met.|June 2013|June 12, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01878305||64599|
NCT01878318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28204|A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs|Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs||Hoffmann-La Roche||Withdrawn|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01878318||64598|
NCT01878552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Policlinico-07|Energy Load in Patients With Acute Respiratory Distress Syndrome (ARDS)|Energy Load During Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome (ARDS)||Policlinico Hospital|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|ARDS patients|April 2015|April 27, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878552||64580|
NCT01882036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908M70742|Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus|The Effects of Roux-en-Y Gastric Bypass on Mitochondrial Dysfunction and Type 2 Diabetes Mellitus||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||May 2015|May 4, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01882036||64313|
NCT01878565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-009|The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion|The Treatment With Nucleoside Analogues in Combination With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion: a Phase I/II, Single-blind, Randomized, GM-CSF-controlled Trial||Beijing 302 Hospital|Yes|Recruiting|June 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||July 2013|July 23, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878565||64579|
NCT01905826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130157|Natural History Study of GATA2 Deficiency and Related Disorders|The Natural History of GATA2 Deficiency and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|January 2040|Anticipated|March 2028|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|2 Years|N/A|No|||December 2015|December 15, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905826||62489|
NCT01906346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033364-01|Impact of a Non-Drug Choice on Cocaine Reinforcement|Impact of a Non-Drug Choice on Cocaine Reinforcement||University of Kentucky|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|8|||Both|21 Years|45 Years|No|||June 2015|June 30, 2015|July 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01906346||62449|
NCT01905800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/980|BPPV Treatment in Biaxial Rotational Chair|Randomized Multicenter Study of Benign Paroxysmal Positional Vertigo Treatment in Biaxial Rotational Chair||Haukeland University Hospital|Yes|Recruiting|August 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|350|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01905800||62491|
NCT01905813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 40093-102|Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies|A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies||Incyte Corporation|No|Active, not recruiting|June 2013|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905813||62490|
NCT01906060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0151|Blind Intubation Through The Self-Pressurised Disposable Air-Q Laryngeal Intubation Mask: An International Multicentre Trial|||University of Zurich||Recruiting|July 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|85 Years|No|||September 2015|September 14, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01906060||62471|
NCT01906788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMAQUINE STUDY|The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy|THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY||Kilimanjaro Clinical Research Institute|Yes|Recruiting|May 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|250|||Both|3 Years|17 Years|No|||July 2013|July 23, 2013|July 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01906788||62415|
NCT01907568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-1|Understanding Hallucinations (Part I)|Understanding Hallucinations (Part I) - Phenomenology and Cognition|UH-1|UMC Utrecht|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||10|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We aim to include subjects of each of the following diagnostic groups, both with and        without psychotic symptoms:          1. patients with schizophrenia spectrum disorders          2. patients with borderline personality disorder (BPD)          3. patients with hearing impairment          4. patients with visual loss          5. patients with Parkinson's disease (PD)          6. patients with Alzheimer's disease (AD)          7. patients with Lewy Body dementia (DLB)          8. patients with post-traumatic stress disorder (PTSD)          9. patients with delirium         10. healthy individuals|July 2013|July 22, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01907568||62355|
NCT01907880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011349-01H|The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer|A Randomized, Double-blind, Placebo-controlled, Phase IV Trial Evaluating the Palliative Benefit of Either Continuing Pamidronate or Switching to Second-line Zoledronic Acid in Breast Cancer Patients With High-risk Bone Metastases.|ER11-03|Ottawa Hospital Research Institute|Yes|Completed|August 2012|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|74|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907880||62331|
NCT01907893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METRC - TCCS|Improving Activity and Quality of Life Following Orthopaedic Trauma: The Trauma Collaborative Care Study (TCCS)|Improving Activity and Quality of Life Following Orthopaedic Trauma: The Trauma Collaborative Care Study (TCCS)|TCCS|Major Extremity Trauma Research Consortium|No|Active, not recruiting|July 2013|September 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|60 Years|No|||April 2015|April 16, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01907893||62330|
NCT01907321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-2011|Cough and Swallow Rehab Following Stroke|Cough and Swallow Rehabilitation Following Stroke||University of Florida|No|Completed|January 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|50 Years|85 Years|No|||October 2015|October 14, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907321||62374|
NCT01907334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-2013|Dose-Response of Salmeterol in Children|Dose-response of Salmeterol Delivered by Advair Diskus in Children: Bioassay by Methacholine Challenge Using Oscillometry as the Endpoint||University of Florida|No|Completed|August 2013|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|10|||Both|4 Years|11 Years|No|||October 2014|October 6, 2014|June 28, 2013|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT01907334||62373|
NCT01907347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEREH-13-022|Prognosis Value of Bioimpedance Analysis (BIA) Phase Angle at Admission in Intensive Care Unit (ICU) Patients|PHASE ANGLE PROJECT|PAP|University Hospital, Geneva|No|Recruiting|March 2013|July 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized in medical and surgical intensive care units.|July 2013|July 18, 2013|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01907347||62372|
NCT01904019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.E16|Comparison of ARPE Prosthesis With the Literature|Trapezia-metacarpal Arthroplasty: Comparison of ARPE Prosthesis With the Literature||Biomet, Inc.|No|Active, not recruiting|April 2013|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|patients with trapezio-metacarpal arthritis Eaton Stage of trapezio-metacarpal arthritis :        Stage II - IV|November 2015|November 23, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01904019||62627|
NCT01904279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA28117|A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis|AN PHASE Ib, OPEN LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS||Hoffmann-La Roche||Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|1 Year|17 Years|No|||March 2016|March 1, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904279||62607|
NCT01905969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIAST-NJBMR-12|Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy|Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1|NJBMR|Iwate Medical University|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|Samples With DNA|Archived paraffin blocks|Both|N/A|N/A|No|Non-Probability Sample|This is a retrospective study. Data analyses are based on archived record and materials of        gastric cancer patients whose treatment was curative surgery followed by adjuvant        chemotherapy with S-1.|March 2015|March 24, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905969||62478|
NCT01905982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAT 2013|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV; part2|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy on Dyspnoea, Activity and Parasympathetic Activities in Patients With COPD III-IV||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|50 Years|75 Years|No|||September 2015|September 2, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905982||62477|
NCT01905423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103313|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis|DOLF-Indo|Washington University School of Medicine|No|Active, not recruiting|May 2011|December 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|21000|Samples Without DNA|Study procedures include collection of finger prick blood that will be tested for      microfilaremia and for serology testing (antigenemia and antibody testing). We will also      collect stool samples to detect STH infections.      All assays will be performed in Indonesia (filarial serology tests, MF smears, stool      examinations).|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study populations are people who live in areas of Indonesia that are endemic for        lymphatic filariasis.|December 2015|December 11, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01905423||62520|
NCT01905722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036851|Development of Novel Therapies for NIDDM|Development of Novel Therapies for NIDDM: Technology Development for Mitochondrial Substrate Oxidation at 3 Tesla and 7 Tesla||Duke University|No|Recruiting|October 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|July 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905722||62497|
NCT01905696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041312|The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia|The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow Under Hypoxic and Normoxic Conditions||Duke University|No|Active, not recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|April 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905696||62499|
NCT01906684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFMS:QP1-2013|Comprehensive Analysis of Relapse in Multiple Sclerosis|Comprehensive Analysis of Relapse in Multiple Sclerosis||Tanner Foundation for Multiple Sclerosis|No|Not yet recruiting|August 2013|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||July 2013|July 31, 2013|July 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01906684||62423|
NCT01882062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-62|Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease||TRIHEP2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|February 24, 2016|June 18, 2013||No||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01882062||64311|
NCT01882075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/17|Closed-loop Fluid Administration System: Pilot Study to Evaluate Feasibility|Automated Administration of Fluid Administration Thanks to Hemodynamic Parameters and Cardiac Output During General Anesthesia||Hopital Foch|No|Terminated|June 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||December 2014|March 25, 2015|June 18, 2013||No|Dysfonction of the device|No||https://clinicaltrials.gov/show/NCT01882075||64310|
NCT01878812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200188|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra® (2013/2014 Season) in Adults 18 Years of Age and Older||GlaxoSmithKline||Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 8, 2015|June 13, 2013|Yes|Yes||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01878812||64560|
NCT01878825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200190|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|June 13, 2013|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01878825||64559|
NCT01906567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zekai tahir burak heavy metal|İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels?|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2013|December 2013|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Anticipated|90|None Retained|maternal whole blood maternal hair umbilical whole blood|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women with preeclampsia|July 2013|August 4, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01906567|6 Months|62432|
NCT01906775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIT in ICD patients|Sub-threshold Pacing to Prevent Pacemaker-induced Ventricular Tachycardia|Sub-threshold Ventricular Back-up Pacing to Prevent Pacemaker-induced Ventricular Tachycardia||Johannes Gutenberg University Mainz|No|Completed|June 2003|May 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|550|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having an implanted ICD for secondary prevention of ventricular tachyarrhythmias.        Patients are routinely under follow-up for device interrogation in our outpatient device        department.        Patients with identified pacemaker-induced ventricular tachycardia were selected and after        two or more episodes of VT, the ventricular back-up pacing was reprogrammed to a        sub-threshold level.|July 2013|July 23, 2013|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906775||62416|
NCT01906593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201301|A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly|A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older||Centers for Disease Control and Prevention, China|Yes|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community||2|Actual|536812|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Beijing subjects aged 60 years or older, at the time of routine visit to a participating        clinic or hospital for annual influenza vaccination.|March 2013|July 20, 2013|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906593|1 Year|62430|
NCT01907022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-Ti-CDC01-RELAX|Combined rTMS and Relaxation in Chronic Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) in Combination With Relaxation Therapy in Patients With Chronic Tinnitus|RELAX|University of Regensburg|No|Completed|July 2013|October 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||March 2015|March 11, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01907022||62397|
NCT01907386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.101|Abdominal Aortic Aneurysm Follow-up After Endovascular Repair by Non-invasive Vascular Elastography|Abdominal Aortic Aneurysm Follow-up After Endovascular Repair by Non-invasive Vascular Elastography|AAA-Elasto|Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|January 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907386||62369|
NCT01904032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204197|Sunshine 2 Study for Women With Diabetes|Vitamin D Supplement to Women With Type 2 Diabetes||Loyola University|Yes|Recruiting|September 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|21 Years|N/A|No|||March 2016|March 8, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904032||62626|
NCT01904305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robinson-2010-01|Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Bronchoscopic Findings|Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Macroscopic Examination of Bronchoscopic Findings in Critically Ill Surgical Patients||University of Cincinnati|No|Completed|January 2011|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Standard lavage specimens collected as part of standard of care and submitted for laboratory      evaluation|Both|18 Years|80 Years|No|Non-Probability Sample|Physicians working in the Surgical Intensive Care Unit|July 2013|July 17, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01904305||62605|
NCT01904318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-PDF-70-1|A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer|A Dose Block-randomized, Doubled, Placebo-controlled, Single Dose, Dose-escalation Clinical Phase I Study to Evaluate the Safety, Pharmacokinetics and Food|PDF inhibitor|IlDong Pharmaceutical Co Ltd|No|Completed|July 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|56|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01904318||62604|
NCT01907906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-0080|Inactivation of Whole Blood With Mirasol|Inactivation of Whole Blood With Mirasol : Performance in Red Blood Cells in Healthy Volunteers|IMPROVEII|Terumo BCTbio|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 20, 2013|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01907906||62329|
NCT01905072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK096488-01A1|Preventing Childhood Obesity Through Early Guidance|Preventing Childhood Obesity Through Early Feeding and Parenting Guidance||Arizona State University|Yes|Active, not recruiting|October 2012|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|N/A|40 Years|No|||January 2015|January 12, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01905072||62547|
NCT01905085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133331|Energy Expenditure Methodology Infant|Energy Expenditure Methodology Infant||Arkansas Children's Hospital Research Institute|Yes|Completed|November 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|3 Months|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy infants|September 2015|September 8, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905085||62546|
NCT01897831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002 H L 0153|Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|PIP-SBT|Xiangbei Welman Pharmaceutical Co., Ltd|Yes|Enrolling by invitation|August 2011|November 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||September 2012|July 9, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897831||63100|
NCT01897844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/13/2984/03|A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers|A Two-part Phase I Study in Male Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Repeated Incremental Doses of ITF2984. Part A is Double-Blind, Randomized, Subcutaneous Administration. Part B is Open Label, Continuous Infusion.|14 days MAD|Italfarmaco|No|Completed|May 2013|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897844||63099|
NCT01898130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 12C06|Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy|A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy||Northwestern University|Yes|Recruiting|October 2013|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898130||63077|
NCT01905995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG EEG Munich|Basal Ganglia Local Field Potentials in Gait and Speech|Recording of Gait and Speech Related Neurophysiological Parameters With an Implantable Bi-directional Deep Brain Stimulation System in Parkinson's Disease||Ludwig-Maximilians - University of Munich|No|Recruiting|July 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|40 Years|75 Years|No|Probability Sample|Patients with advanced Parkinson's disease|July 2013|July 22, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905995||62476|
NCT01906008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0323|Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients|Phase II, Randomized, Placebo-Controlled Study of Minocycline for Reducing Symptom Burden in Patients With Colorectal Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|November 2013|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906008||62475|
NCT01906255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-276-0104|Seroconversions, Resistance, Adverse Events and Drug Adherence Among Subjects Taking Truvada® for PrEP: A Case Control Study|Seroconversions, Resistance, Adverse Events and Drug Adherence Among Subjects Taking Truvada® for PrEP: A Case Control Study||Gilead Sciences|No|Recruiting|October 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|7000|||Both|18 Years|N/A|No|Non-Probability Sample|Seven thousand (7000) HIV-1 negative adults (any sex/gender, including transgender) who        are participating in observational or clinical studies on FTC/TDF for PrEP|February 2016|February 25, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01906255||62456|
NCT01882088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ION RAMS|Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD|Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease|OGIG-130-1|Russian Academy of Medical Sciences|No|Recruiting|April 2012|August 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||June 2013|June 20, 2013|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01882088||64309|
NCT01878331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/13|Long-term Study to Evaluate Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants|Long-term, Prospective, Cohort Study to Evaluate Safety and Efficacy of Two Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants for Removable Prosthesis in Patients With Edentulous Mandibles||Institut Straumann AG|No|Active, not recruiting|June 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|Male or female patient ≥ 18 years of age who were provided with an implant supported        over-denture in the mandible in the course of the core study (CR 04/07).|March 2016|March 2, 2016|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01878331||64597|
NCT01906073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFCP-2|Nasal Fentanyl for Chronic Cancer Pain|An Open Label, Cross-over, Randomized Controlled Multicenter Phase III Study Comparing Standard Oral SR-morphine by the Clock Medications With Self-controlled Nasal Fentanyl for Chronic Cancer Pain Requiring Opioids|NFCP-2|Norwegian University of Science and Technology|Yes|Recruiting|September 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01906073||62470|
NCT01906086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|legume consumption in adults|Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults|Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among First Degree Relatives of Diabetic Patients||Isfahan University of Medical Sciences|Yes|Completed|September 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|26|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01906086||62469|
NCT01906099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|legume intake and CVD risks|Effects of Legume Intake on Cardiovascular Risk Factors Among Adults at Risk for Diabetes|||Isfahan University of Medical Sciences|Yes|Completed|September 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|26|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01906099||62468|
NCT01906359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A005/11|Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers|The Acute Effects of Triacylglycerol Structure of Dietary Fats on Gut Hormones and Haemostatic Markers in Subjects With Type 2 Diabetes Mellitus||Malaysia Palm Oil Board|No|Completed|September 2012|March 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|23|||Both|30 Years|60 Years|No|||October 2015|October 9, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01906359||62448|
NCT01906580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011030D|Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B|Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B||Beijing 302 Hospital|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|16 Years|60 Years|No|||August 2015|August 14, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01906580||62431|
NCT01906801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-56-25|Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine|||Ramathibodi Hospital|Yes|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|50 Years|N/A|No|||November 2014|November 4, 2014|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906801||62414|
NCT01907399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonnotte PHRC IR 2010|Study of Immune Response in Obesity and Type 2 Diabetes||IMMUNOBEDIA|Centre Hospitalier Universitaire Dijon||Recruiting|September 2010|||September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907399||62368|
NCT01907633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102051|An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide|Post-Authorization Safety Study: Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide||Janssen Research & Development, LLC|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|15000|||Both|2 Years|N/A|No|Non-Probability Sample|Patients with exposure to domperidone, proton pump inhibitor, and metoclopramide|May 2015|May 18, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907633||62350|
NCT01907919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|private practice|Pilot Study,Diode Laser 808 nm Supported Direct Pulp Capping in Permanent Teeth|Diode Laser-Assisted Direct Pulp Capping In Permanent Teeth|Laser in DPC|Yazdanfar, Iraj, M.D.||Completed|July 2011|||August 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|||Both|12 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study was carried out on 10 patients, aged between 12 and 40 years, with an average        age of 26 years, who underwent conservative treatment for deep caries of permanent teeth        (2 anterior and 8 posterior).|July 2013|July 24, 2013|July 12, 2013||||No||https://clinicaltrials.gov/show/NCT01907919|12 Months|62328|
NCT01907945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNWT|Healthy Networks Water Treatment Study|Healthy Networks Water Treatment Study|HNWT|University of California, San Francisco|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907945||62326|
NCT01904903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 28685|Cardiac Safety Study in Patients With HER2 + Breast Cancer|SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function|SAFE-HEaRt|Washington Hospital Center|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|120 Years|No|||December 2015|December 7, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904903||62560|
NCT01904916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.45677.041.13|CPCT-05 Biopsy Protocol Patient Selection|Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection)||UMC Utrecht|Yes|Recruiting|January 2014|||August 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2014|February 23, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904916||62559|
NCT01904890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54CA153499 Sub7323|AANCART Research Project on Lay Health Workers and Asian Americans|Asian American Network for Cancer Awareness, Research, and Training (AANCART): The National Center for Reducing Asian American Cancer Health Disparities Research Project on Lay Health Workers and Asian Americans|AANCARTLHW|University of California, San Francisco|No|Completed|March 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|994|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01904890||62561|
NCT01897857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0209|Influence of DM on Artery Blood Flow and Complications After Radial Artery Cannulation|||Yonsei University|No|Completed|July 2013|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|80|||Both|20 Years|60 Years|No|||March 2016|March 9, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01897857||63098|
NCT01898143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpiroErgoGalileo-2013|Cardiorespiratory Response During Whole Body Vibration Training in Patients With Chronic Lung Disease|Cardiorespiratory Response During Whole Body Vibration Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Interstitial Lung Disease (ILD)||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|10|||Both|20 Years|75 Years|No|||February 2016|February 23, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01898143||63076|
NCT01898390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSEURO|TRANSEURO Open Label Transplant Study in Parkinson's Disease|An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation With Fetal Ventral Mesencephalic Tissue in Patients With Parkinson's Disease|TRANSEURO|University of Cambridge|Yes|Enrolling by invitation|May 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|68 Years|No|||December 2014|December 17, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898390||63057|
NCT01898377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-1301|Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children|Open-label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Children With Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-host Disease||Seoul National University Hospital|No|Recruiting|August 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|N/A|21 Years|No|||May 2015|May 26, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01898377||63058|
NCT01898637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009527|A Simple Clinical Tool to Help Diagnose Pulmonary Embolism: Phase 1|A Simple Clinical Tool to Help Diagnose Pulmonary Embolism: Phase 1||Mayo Clinic|No|Enrolling by invitation|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|August 16, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01898637||63038|
NCT01878630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13KQ0904B|Telemedical Interventional Management in Heart Failure II||TIM-HF II|Charite University, Berlin, Germany|Yes|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878630||64574|
NCT01878344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ozaydin290|Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention|Effects of N-acetyl Cysteine on Major Cardiac and Cerebral Events in Patients Undergoing Primary Percutaneous Coronary Intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy|EASE-PRM-PCI|Suleyman Demirel University|No|Recruiting|January 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|85 Years|No|||October 2015|October 17, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878344||64596|
NCT01878357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC Belu|Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine|Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial||Indonesia University|Yes|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1488|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 23, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01878357||64595|
NCT01905852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130168|Use of Cardiac-MRI to Predict Results for People With Severe Aortic Stenosis|Utilization of Cardiac Magnetic Resonance Imaging to Predict Clinical Outcomes of Patients With Severe Aortic Stenosis||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||April 2014|October 9, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905852||62487|
NCT01906112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17_2013RC_IN305|Role of Surgery for the Primary in Patients With Breast Cancer Stage IV.|Role of Surgery for the Primary in Patients With Breast Cancer Stage IV - A Prospective Randomized Multicenter Controlled Trial||National Cancer Institute, Thailand|Yes|Withdrawn|August 2013|August 2019|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|July 15, 2013||No|Low accrual and no further funding.|No||https://clinicaltrials.gov/show/NCT01906112||62467|
NCT01906125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481020|A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product|A Phase 1, Open-Label 3 Sequence 3 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Establish The Bioequivalence Of The Phase 1/2 And Phase 3 Formulation To Palbociclib ICH Formulation Under Fasted Conditions||Pfizer|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|73|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|July 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01906125||62466|
NCT01906372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13050507|Acthar in Treatment of Refractory Dermatomyositis and Polymyositis|Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis||University of Pittsburgh|No|Active, not recruiting|September 2013|May 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01906372||62447|
NCT01906385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 12-02|Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma|A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906385||62446|
NCT01907594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6769|Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers|Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers||New York State Psychiatric Institute||Not yet recruiting|August 2013|||July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|50|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907594||62353|
NCT01907607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2013-01|Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib|Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study|CYCLIGIST|Institut Bergonié|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907607||62352|
NCT01907620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sagot PHRC IR 2007|Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia.|||Centre Hospitalier Universitaire Dijon||Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|120|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907620||62351|
NCT01907074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-063|Quantitative Liver Function Tests Using Cholates|Quantitative Liver Function Tests Using Cholates||Baylor Research Institute|Yes|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Probability Sample|Enrolled from Baylor University Medical Center and Liver Consultants of Texas Clinic|January 2016|January 15, 2016|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907074||62393|
NCT01907412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HD058529-02|Trial of Transition to Parenthood Program for Couples|Trial of Transition to Parenthood Program for Couples|FF2|Feinberg, Mark, Ph.D.|No|Active, not recruiting|June 2008|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907412||62367|
NCT01907425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Callier PHRC N 2012|Prenatal Molecular Characterisation by CGH+SNP-ARRAY of Supernumerary Marker Chromosomes and de Novo Apparently Balanced Reciprocal Translocations||compass|Centre Hospitalier Universitaire Dijon||Recruiting|July 2013|||March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|225|||Both|N/A|N/A|No|||July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907425||62366|
NCT01907646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients|Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients: a Randomized Trial||Catholic University of the Sacred Heart|No|Completed|April 2009|August 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Female|27 Years|81 Years|No|||July 2013|July 24, 2013|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01907646||62349|
NCT01907932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01727|Estimation of Spleen by Residents With VScan|Estimation of Spleen Size by Medical Residents With Hand Carried Ultrasound||University of British Columbia|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|N/A|N/A|No|||October 2014|October 9, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907932||62327|
NCT01907958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINPRADIA|Management of Albuminuria in Hypertensive Diabetics|A Multicentre Study to Evaluate the Management of Microalbuminuria in Hypertensive Patients With Type 2 Diabetes: Improving Clinical Practice|CLINPRADIA|Medpharmgene, Inc.|No|Recruiting|April 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|280|Samples With DNA|urine whole blood|Both|18 Years|N/A|No|Probability Sample|18 years and older Uncontrolled blood pressure Type 2 diabetes|July 2013|July 24, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01907958|3 Months|62325|
NCT01907971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VentriPoint in Ebstein anomaly|Assessment of Left and Right Ventricular Function in Patients With Ebstein Anomaly With Different Echocardiographic Methods|Left Ventricular Function in Ebstein Anomaly: Assessment by 3D Echocardiography and Speckle Tracking. Assessment and Validation of the Right Ventricle by VentriPoint Method.||University Children's Hospital, Zurich|Yes|Completed|August 2013|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|11 Years|80 Years|No|Probability Sample|Ebstein anomaly patients of the Zurich Area followed by primary care center|March 2014|May 26, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907971||62324|
NCT01897233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-809-011|Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|No|Completed|July 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|6 Years|11 Years|No|||December 2015|December 1, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897233||63146|
NCT01906242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPGO016|Hygiene Protocol of Complete Dentures|Hygiene Protocols for Cleaning Complete Dentures||Federal University of Pelotas|No|Completed|April 2013|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|40|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01906242||62457|
NCT01905150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119005|Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer|Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer||Bruckner Oncology|No|Recruiting|July 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905150||62541|
NCT01898416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-JB-558-CTIL|Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors|A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS.||Tel-Aviv Sourasky Medical Center|No|Recruiting|June 2013|December 2026|Anticipated|December 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01898416||63055|
NCT01898663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-DC/CIK|DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma|Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma: a Phase Ⅰ/Ⅱ Study||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898663||63036|
NCT01898403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL0010|Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma|Testing the Efficacy of Indocyanine Green Imaging ( ICG-SPY ) in the Identification of Sentinel Lymph Nodes ( SLN ) in Patients With Malignant Melanoma||Stanford University|Yes|Active, not recruiting|June 2013|||August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|21 Years|85 Years|No|||July 2014|July 28, 2014|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898403||63056|
NCT01898650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208086|MRI for Non-invasive Evaluation of Brain Stress|MRI for Non-invasive Evaluation of Brain Stress||Washington University School of Medicine|No|Recruiting|December 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|N/A|18 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01898650||63037|
NCT01899222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHFC 02|Assessment of Prototype Hand-Held Fundus Camera|Assessment of Prototype Hand-Held Fundus Camera||University of Rochester|No|Recruiting|April 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899222||62994|
NCT01878383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 11-0070|Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture|Device Trial: Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture||University of Alabama at Birmingham|Yes|Recruiting|January 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12500|||Female|19 Years|N/A|No|Probability Sample|Pregnant and non-pregnant women|March 2016|March 13, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878383||64593|
NCT01878864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC004PDS|Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning|Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning||Hvidovre University Hospital|Yes|Terminated|November 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||April 2015|April 1, 2015|April 19, 2013||No|Too slow patient inclusion and superior effect of the injection|No||https://clinicaltrials.gov/show/NCT01878864||64556|
NCT01878877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-140|Update Prevalence of Chronic Pain in Hong Kong|Update Prevalence of Chronic Pain Among Hong Kong Adult Population: Change Over the Last Decade||The University of Hong Kong|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1570|||Both|18 Years|N/A|No|Probability Sample|The telephone interview will be conducted every weekday evening between 6pm and 9 pm by        trained interviewers from Public Opinion Programme (POP) of the University of Hong Kong.        Telephone number will be selected randomly from all households in Hong Kong.|September 2013|September 15, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01878877||64555|
NCT01907061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-157|Acute Renal Failure Post Liver Transplantation|Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress||Baylor Research Institute|Yes|Completed|July 2007|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|71 Years|No|||January 2016|January 12, 2016|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01907061||62394|
NCT01907360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLD200-102|Phase I/II Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining Pk of 2 MR Formulations of MPH in Adolescent/Pediatric With ADHD|Phase I/II Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the PK Effects of up to 2 Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With Attention-Deficit Hyperactivity Disorder||Ironshore Pharmaceuticals and Development, Inc|Yes|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|6 Years|17 Years|No|||September 2014|September 30, 2014|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907360||62371|
NCT01907373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704|Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers|Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers||Central South University|Yes|Completed|August 2009|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01907373||62370|
NCT01906619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2_009_10|Respiratory Physiology in Children With Febrile Seizures.|Investigation of the Respiratory Physiology of Children With and Without Febrile Seizures During Febrile Illness.||Charite University, Berlin, Germany|No|Recruiting|July 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|3 Months|5 Years|No|Non-Probability Sample|Children with febrile illness between 3 months and 5 years of age with a body temperature        of >38.0 during the monitoring period.|July 2013|July 23, 2013|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906619||62428|
NCT01906827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zekai tahir burak- p wave|P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2013|June 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|The pregnant women with intrahepatic cholestasis who admitted our clinic|July 2013|March 16, 2014|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01906827||62412|
NCT01907087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-201|A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease|A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease||BioMarin Pharmaceutical|Yes|Active, not recruiting|September 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|3 Years|16 Years|No|||January 2015|January 5, 2015|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907087||62392|
NCT01907100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.93|Nintedanib (BIBF 1120) in Mesothelioma|Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma||Boehringer Ingelheim||Recruiting|September 2013|September 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|397|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 22, 2013||||No||https://clinicaltrials.gov/show/NCT01907100||62391|
NCT01904396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carnitine001|Identification of Carnitine-Responsive Cardiomyopathy|Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.|C001|University Health Network, Toronto|No|Not yet recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01904396||62599|
NCT01907659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX RED-001|Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections|Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections||University of Rochester|Yes|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|21 Years|N/A|No|||June 2014|June 30, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01907659||62348|
NCT01904877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11914|Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC)|Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC) Version 1.0 Dated 10/15/12|MP3|Vanderbilt University|No|Enrolling by invitation|March 2013|March 2017|Anticipated|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|3760|Samples With DNA|HIV RNA will be extracted from plasma and the HIV PR and RT genes will be amplified by a      one-step RT-PCR using TaKaRa One Step RNA PCR Kit . The quality of sequences will be      evaluated using Sequence Scanner v1.0, and the sequences will be cleaned and assembled by      Sequencher (Gene Codes Corporation, Ann Arbor, MI,USA).|Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|subjects selected are living or working in Beijing China|June 2015|June 2, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904877|1 Year|62562|
NCT01897259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0566|Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study|Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study||Christine M. Kleinert Institute for Hand and Microsurgery|No|Recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||July 2013|July 9, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01897259||63144|
NCT01897493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14619|A Study of Evacetrapib and Digoxin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897493||63126|
NCT01897506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201920|Assessing Risk of Food Insecurity Within Households of Children With Food Allergy|Assessing Risk of Food Insecurity Within Households of Children With Food Allergy||Arkansas Children's Hospital Research Institute|No|Enrolling by invitation|June 2013|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|650|||Both|1 Year|17 Years|No|Non-Probability Sample|Families with children who have allergy appointments at Arkansas Children's Hospital        between 1-17 years of age. We will recruit 325 families with patients in the food allergy        group and 325 families with patients in the without food allergy group.|June 2015|June 22, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897506||63125|
NCT01903954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28302|A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection||Hoffmann-La Roche||Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903954||62632|
NCT01904513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102881|Investigating the Effects of Probiotic Yogurt on Reducing the Levels of Environmental Toxins Among School Children in Mwanza, Tanzania|Investigating the Effects of Probiotic Yogurt on Reducing the Levels of Environmental Toxins Among School Children in Mwanza, Tanzania|PDTX|Western University, Canada|No|Completed|December 2012|August 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01904513||62590|
NCT01904526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009133|PK/PD Comparison of Guanfacine ER and IR|Pharmacokinetic/Dynamic (PK/PD) Comparison of Guanfacine Extended Release (ER) and Immediate Release (IR) in Smokers||Yale University|Yes|Active, not recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01904526||62589|
NCT01904539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-103|Hepatic Impairment Trial of Obeticholic Acid|An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)||Intercept Pharmaceuticals|Yes|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|May 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904539||62588|
NCT01898949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10031|Stimulation of Diet-Induced Thermogenesis by Cold-Exposure|BAT&DIT: Stimulation of Diet-Induced Thermogenesis by Cold-Exposure|BAT&DIT|Pennington Biomedical Research Center|No|Completed|November 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01898949||63014|
NCT01899235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110015|The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study|The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study|EXPEL|Aalborg Universitetshospital|No|Terminated|May 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||March 2014|March 15, 2014|July 11, 2013||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01899235||62993|
NCT01882673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034312|Motivating Quitline Use Among Smokers in Treatment for Substance Use Disorders|Brief Computer Intervention to Motivate Quitline Use for Smokers in SUD Treatment|MI-SUD|Butler Hospital|No|Recruiting|August 2012|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01882673||64264|
NCT01878643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20033799|Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit|Pilot Study of the Effects of Inhaled Antibiotic on Bacterial Resistance||Stony Brook University|No|Completed|December 2001|December 2002|Actual|December 2002|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878643||64573|
NCT01878656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chung-Ang University Hospital|Comparison of Emergence Agitation Between Sevoflurane and Desflurane Anesthesia After Orthognathic Surgery|||Chung-Ang University Hospital||Completed|April 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|144|||Both|18 Years|60 Years|No|||April 2014|April 4, 2014|June 12, 2013||No||No|April 4, 2014|https://clinicaltrials.gov/show/NCT01878656||64572|
NCT01878890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2011-01|Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.|Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.|ESCALE|Institut Bergonié||Active, not recruiting|June 2011|December 2015|Anticipated|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2015|March 3, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01878890||64554|
NCT01906151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1306|IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI|A Prospective, Open Label Study Assessing the 24-hour Intraocular Pressure Pattern Monitored by SENSIMED Triggerfish® in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After Laser Peripheral Iridotomy||Sensimed AG|No|Withdrawn|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01906151||62464|
NCT01906411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAD|Dopaminergic Function and Food Reward|||University Hospital Tuebingen|No|Completed||||March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|36|||Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|May 2015|May 28, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01906411||62444|
NCT01906632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMC|Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy|||Capital Medical University|No|Recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||October 2015|October 13, 2015|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906632||62427|
NCT01906840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interventional|Role of Turmeric on Oxidative Modulation in ESRD Patients|Evaluate the Effects of Turmeric on Oxidative Stress Markers in HD Patients||Shiraz University of Medical Sciences|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906840||62411|
NCT01907113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.12|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial||Boehringer Ingelheim||Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|75 Years|No|||July 2014|July 11, 2014|July 15, 2013||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01907113||62390|
NCT01907126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH094188|HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence|HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence||Brown University|Yes|Completed|September 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01907126||62389|
NCT01907997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0342|Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy|||Yonsei University|Yes|Completed|July 2013|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|20 Years|65 Years|No|||June 2015|June 5, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907997||62322|
NCT01905137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-2013|Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain|Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain||Boston Urogynecology Associates|No|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905137||62542|
NCT01904656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08168|CBPR Strategies to Increase Colorectal Cancer Screening in Ohio Appalachia|Community-Based Participatory Research(CBPR)Strategies in Increasing Colorectal Cancer(CRC)Screening in Participants in Ohio Appalachia||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2009|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4320|||Both|51 Years|75 Years|No|||February 2015|February 5, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01904656||62579|
NCT01904409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNLC2131|Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis|A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis||Valeant Pharmaceuticals International, Inc.|Yes|Completed|June 2013|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|420|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904409||62598|
NCT01905709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-507|Fecal Microbiota Transplantation for C Diff Infection|Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)||Englewood Hospital and Medical Center|No|Recruiting|July 2013|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01905709||62498|
NCT01897870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGA-1|The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.|The Effect of a Home-based Community Pharmacist-led Medication Management Program (HomeCoMe-program) Complementary to an In-hospital Medication Reconciliation Program on Drug-related Problems Post-discharge: A Prospective Cohort Study.|HomeCoMe|Zorggroep Almere|No|Completed|November 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01897870||63097|
NCT01897519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-958|A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery|A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery||AbbVie|Yes|Terminated|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|56|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|May 10, 2013|Yes|Yes|Topline results from study M13-796 showed an overall lack of efficacy. There were no safety    concerns.|No||https://clinicaltrials.gov/show/NCT01897519||63124|
NCT01904734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VETSCLOMIDPHX|Clomid in Men With Low Testosterone With and Without Prior Treatment|A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone||Phoenix VA Health Care System|No|Recruiting|October 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Male|30 Years|70 Years|No|||October 2015|October 20, 2015|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904734||62573|
NCT01904981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0843|Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)|||Yonsei University|Yes|Recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|90 Years|No|||July 2014|July 24, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01904981||62554|
NCT01879917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005317-39|Liraglutide in Newly Onset Type 1 Diabetes.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.|NewLira|Hvidovre University Hospital|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|40 Years|No|||November 2013|November 28, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01879917||64476|
NCT01882894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFO Trial|Efficacy of a Custom Temporary Foot Orthosis for Plantar Fasciitis Treatment|Efficacy of a Custom Temporary Foot Orthosis for Plantar Fasciitis Treatment: A Randomized Controlled Trial.||University of Puget Sound|Yes|Not yet recruiting|September 2013|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882894||64247|
NCT01882907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AKR05T|Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes|An Open-label, Randomized, Active-controlled Study to Compare the Effect of 16 Weeks Treatment With Vildagliptin to Pioglitazone as add-on Therapy to Metformin in Type 2 Diabetic Patients Inadequately Controlled With Metformin Monotherapy||Pusan National University Hospital|Yes|Completed|December 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|June 3, 2013||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01882907||64246|
NCT01905865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913162|The Role of Uncertainty in Coping: The Experience of Parents of Children With Undiagnosed Medical Conditions|The Role of Uncertainty in Coping Efficacy: The Experience of Parents of Children With Undiagnosed Medical Conditions||National Institutes of Health Clinical Center (CC)||Completed|June 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01905865||62486|
NCT01906164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8176-501|Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers||Alios Biopharma Inc.|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01906164||62463|
NCT01906424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETI201307|Restoring Arm and Hand Function With Non-invasive Spinal Stimulation|Restoring Arm and Hand Function With Non-invasive Spinal Stimulation||NeuroEnabling Technologies, Inc.|Yes|Active, not recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|July 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01906424||62443|
NCT01906645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eIRB 6208|Care Transitions Innovation (C-TraIn)|Care Transitions Innovation (C-TraIn): Study of a Multi-component Transitional Care Intervention for Uninsured and Low-income Publicly Insured Adults||Oregon Health and Science University|No|Completed|November 2010|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|382|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01906645||62426|
NCT01906853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG12/01|Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction|A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in Infants|MIS BAIR|Murdoch Childrens Research Institute|No|Recruiting|July 2013|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1438|||Both|N/A|10 Days|Accepts Healthy Volunteers|||April 2015|April 6, 2015|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01906853||62410|
NCT01906866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU_CH_7911|Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities|A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities||Neurim Pharmaceuticals Ltd.|Yes|Recruiting|October 2013|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|17 Years|No|||October 2015|December 27, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906866||62409|
NCT01904097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120128|Functional Neuroimaging in Fibromyalgia Patients Receiving tDCS|Study of the Brain With Optic Functional Neuroimaging in Patients With Chronic Pain Using Transcranial Direct Current Stimulation||Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|65 Years|No|||July 2013|July 17, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01904097||62621|
NCT01904422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidad de los Andes|Periodontal Treatment in Non-controlled Type 2 Diabetes Mellitus Patients. Clinical Trial|Evaluation of the Effectiveness of Intensive Periodontal Treatment as Compared to Conventional Periodontal Treatment on the Level of Glycosylated Hemoglobin in Patients With Decompensated Type 2 Diabetes Mellitus: Randomized Clinical Trial|FONIS12I2106|Universidad Los Andes, Chile|Yes|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|30 Years|N/A|No|||December 2015|December 15, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01904422||62597|
NCT01904110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_RSNM_401|To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women|For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women(Phase IV)||Hanlim Pharm. Co., Ltd.|No|Recruiting|December 2012|June 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Female|19 Years|N/A|No|||July 2013|July 17, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01904110||62620|
NCT01896960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-273-SDR|ET50 With Fentanyl for Post Caesarean Section Spinal Hypotension|The Time Required to Remain Sitting After Spinal Anesthesia With Fentanyl for 50% of Patients to Not Experience Hypotension.|ET-50-Fent|McGill University Health Center|No|Recruiting|July 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|50 Years|No|||June 2014|June 20, 2014|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896960||63167|
NCT01896973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.CP.0.1|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)||HistoSonics, Inc.|Yes|Active, not recruiting|July 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|50 Years|N/A|No|||February 2016|March 17, 2016|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896973||63166|
NCT01907542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00544|A Trial Comparing Stapled Versus Monocryl Sutured Skin Closure for Elective Open Colectomy|A Randomized Controlled Trial Comparing Stapled Versus Monocryl Sutured Skin Closure for Elective Open Colectomy.||National University Hospital, Singapore|Yes|Recruiting|June 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|21 Years|N/A|No|||July 2013|July 22, 2013|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01907542||62357|
NCT01898156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8962-002|Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer|Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma||Kyowa Hakko Kirin Korea Co., Ltd.|No|Active, not recruiting|July 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|20 Years|N/A|No|||August 2015|August 6, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01898156||63075|
NCT01904994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL2708|Link4Health: A Combination Strategy for Linkage and Retention, Swaziland|LINK4HEALTH: A Combination Approach to Linkage and Retention for HIV (Human Immunodeficiency Virus) Infected Individuals in Swaziland|L4H|Columbia University|No|Active, not recruiting|August 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2201|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01904994||62553|
NCT01904240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12102401-IRB01|Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease|Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease||Rush University Medical Center|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rush University Movement Disorders Clinic|November 2014|November 11, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01904240||62610|
NCT01904552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant: 390553|Accuracy of ERCLMDs in Teeth With Apical Periodontitis|Influence of Apical Periodontitis on the Accuracy of Three Electronic Root Canal Length Measurement Devices: An In Vivo Study|ERCLMDs|Isfahan University of Medical Sciences|Yes|Completed|September 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 17, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01904552||62587|
NCT01905527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200136-567|Adherence Trial With MS LifeLines ® Services|A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)||EMD Serono|No|Terminated|July 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|306|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who have been prescribed to Rebif® treatment by their treating physicians will be        observed.|January 2015|January 30, 2015|July 18, 2013|No|Yes|The study was terminated as per the Sponsor's decision.|No||https://clinicaltrials.gov/show/NCT01905527||62512|
NCT01904747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481021|Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption|A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Effect Of Food On The Bioavailability Of Palbociclib||Pfizer|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904747||62572|
NCT01879709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01TW008289|Yoga as Cognitive Remediation in Schizophrenia|The Impact of Yoga Supplementation on Cognitive Function Among Indian Outpatients With Schizophrenia||Dr. Ram Manohar Lohia Hospital|Yes|Active, not recruiting|August 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|258|||Both|18 Years|60 Years|No|||May 2015|May 31, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879709||64492|
NCT01880151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-71|Neuroelectrical Biomarkers for Alzheimer's Disease Stages|NEw approacheS for The dIagnosis of AlzeiMer's diseAse Through neuroElectrical Changes in the Brain|ESTIMATE|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|90|||Both|70 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880151||64458|
NCT01906177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GK5|SE Asia Vanguard PS Multi-center Study|A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System||Biomet, Inc.|No|Recruiting|July 2012|July 2022|Anticipated|July 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|No|Probability Sample|Total 300 cases        each site of 6 sites delegated to enroll 50 cases each|February 2016|February 18, 2016|January 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01906177||62462|
NCT01906437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-443|Cardiac Fibrosis by CMR in Patients With Cancer|Non-invasive Detection of Cardiac Fibrosis After Administration of Doxorubicin-based Chemotherapy in Patients With Lymphoma Using Cardiac Magnetic Resonance||Massachusetts General Hospital|No|Recruiting|March 2013|November 2019|Anticipated|November 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906437||62442|
NCT01907672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVT68|The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level|The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level: a Cluster Randomized Trial|GhanaCommRDT|Ghana Health Services|No|Completed|August 2011|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|4748|||Both|6 Months|N/A|No|||July 2013|July 22, 2013|September 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01907672||62347|
NCT01907984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5481-1/2013/EKU|Diclofenac Administered Before Skull Operations Reduces the Severity of Headache After the Intervention|Preoperatively Administered Single Dose Diclofenac Reduces the Intensity of Acute Postcraniotomy Headache and Decreases Postoperative Analgesic Requirements- a Randomized, Controlled Trial||University of Debrecen|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||July 2013|July 22, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01907984||62323|
NCT01907685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD6295|Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors|An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Advanced Solid Tumors||Sanofi||Completed|June 2006|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|75 Years|No|||July 2013|July 22, 2013|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907685||62346|
NCT01904435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 203|Cetuximab, Paclitaxel, Carboplatin And Radiation For Esophageal, Gastroesophageal Junction And Gastric Cancer|BrUOG-E/G-203 CETUXIMAB, PACLITAXEL, CARBOPLATIN AND RADIATION FOR ESOPHAGEAL, GASTROESOPHAGEAL JUNCTION AND GASTRIC CANCER||Brown University|Yes|Completed|January 2005|September 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|May 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904435||62596|
NCT01904448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0664|Auditory Brainstem Implantation in Young Children|An Early Feasibility Study of the Safety and Efficacy of the Nucleus 24 Auditory Brainstem Implant in Children With Cochlear or Cochlear Nerve Disorders Not Resulting From Neurofibromatosis Type II||University of North Carolina, Chapel Hill|Yes|Recruiting|September 2012|April 2023|Anticipated|April 2023|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Months|17 Years|No|||April 2014|April 5, 2014|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904448||62595|
NCT01905410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-VVZ149-01|Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection|A Randomized, Double-blind, Single and Multiple Ascending Dose Escalation, Placebo-controlled Clinical Trial to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection in Healthy Male Volunteers|P1_VVZ149IV|Vivozon, Inc.|No|Completed|July 2013|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|66|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2013|December 24, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01905410||62521|
NCT01896986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV girls 5year followup|HPV Vaccination in Special Risk Groups: 5 Year Follow-up|HPV Immunisation Protecting Special Risk Group Patients From Cervical Cancer: 5 Year Follow-up Post-vaccination||Murdoch Childrens Research Institute|No|Active, not recruiting|March 2012|December 2013|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Female|16 Years|30 Years|No|Non-Probability Sample|In 2007 we began a clinical audit of the 'special risk patients' within two subgroups        (PRD&IBD). From April 2007- March 2010 there were 64 special risk female participants        including 38 PRD patients of which 28 had juvenile idiopathic arthritis (JIA). The other        subgroups included: 14 IBD; 10 paediatric cancer; 1 SOTR (solid organ transplant        recipient) and 1 CRD (Chronic Renal Disease). The median age at the first dose of 4vHPV        vaccine administration was 14.7 years [range 11.8 to 24.7].        The overall results were good with all participants showing at least some level of        antibody protection against HPV.        Long-term follow-up will help determine the requirement for booster vaccine doses,        including those patients treated with combination immunosuppressive therapies.|July 2013|July 8, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01896986||63165|
NCT01897246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0363|Computer Assisted Planning of Corrective Osteotomy for Distal Radius Malunion|Computer Assisted Planning of Corrective Osteotomy for Distal Radius Malunion||Christine M. Kleinert Institute for Hand and Microsurgery|No|Completed|September 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01897246||63145|
NCT01907802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01338|Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction|A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction||National Cancer Institute (NCI)||Active, not recruiting|August 2013|||July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|July 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907802||62337|
NCT01903967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50834|Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)|Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)|PITUIGENE|Hospices Civils de Lyon|No|Active, not recruiting|September 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|240|Samples With DNA|Pituitary tumour DNA may be extracted from frozen or paraffin-embedded tumours.|Both|18 Years|85 Years|No|Probability Sample|Patients presenting a pituitary tumour, including PRL, GH, ACTH and LH/FSH, operated on by        transsphenoidal route between 1990 and 2008 with at least 5 years of follow-up|January 2016|January 19, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903967||62631|
NCT01907763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOTB07_AST_III_2012|Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients|A 12-week, Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients||SK Chemicals Co.,Ltd.|Yes|Terminated|January 2013|||October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|194|||Both|15 Years|N/A|No|||January 2016|January 26, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01907763||62340|
NCT01907776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1100-CL-101|Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ME1100 Inhalation Solution (Arbekacin Inhalation Solution) Administered to Healthy Volunteers||Meiji Seika Pharma Co., Ltd.|No|Completed|July 2013|||December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|July 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01907776||62339|
NCT01903980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epipericardial Fat Necrosis|Epipericardial Fat Necrosis: A Misdiagnosed Condition|Epipericardial Fat Necrosis: A Misdiagnosed Condition|epipericardial|Hospital Sirio-Libanes|Yes|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients from the emergency department of SIrio-Libanes Hospital who performed a chest CT        due to any reason|July 2013|July 17, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903980|2 Years|62630|
NCT01904578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|treatment|The Efficacy of Acupressure on Sleep Quality in Menopausal Women|The Effect of Acupressure on Sleep Quality in Menopausal Women||Mashhad University of Medical Sciences|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Female|41 Years|65 Years|No|||February 2010|July 21, 2013|July 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01904578||62585|
NCT01905254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE IRB 2742|Transient Elastography in Autoimmune Hepatitis|Prospective Comparison of Transient Elastography and Mini-laparoscopic Guided Liver Biopsy in Autoimmune Hepatitis||Universitätsklinikum Hamburg-Eppendorf|No|Completed|August 2007|January 2013|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|34|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|July 1, 2013||No||No|December 7, 2014|https://clinicaltrials.gov/show/NCT01905254||62533|
NCT01905007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH-09-087|Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation|"Test-No Test" Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)|TNT-ICD|The Cooper Health System|Yes|Recruiting|December 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|February 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01905007||62552|
NCT01879436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0053-13-MMC|The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells|The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells||Meir Medical Center|Yes|Recruiting|November 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|N/A||2|Anticipated|100|Samples With DNA|Placentae will be collected and used in cell culture experiments for a week. Their proteins      and RNA will be analyzed.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women Age 18-45. Pregnant (6-9 weeks) and non pregnant women.|April 2013|April 13, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879436||64513|
NCT01879722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-063_104|Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects||Takeda|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|June 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01879722||64491|
NCT01880190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301|A Comparative Study of Volume Replacement With HES 130/0.4 Versus Ringer's Lactate (RL) Regarding Their Effects on Inflammatory Biomarkers (Cytokines and Matrix Metalloproteinases) Responses to Major Abdominal Surgery.|Volume Replacement With HES 130/0.4 Attenuates Inflammatory Response to Major Abdominal Surgery Compared to Ringer's Lactate (RL); the Effect on Cytokines and Matrix Metalloproteinases||Attikon Hospital||Completed|December 2008|||April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|47|||Both|18 Years|76 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880190||64455|
NCT01879930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075/08|Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study|Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study||University Hospital Inselspital, Berne|Yes|Terminated|November 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|N/A|No|||March 2015|March 4, 2015|June 13, 2013||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01879930||64475|
NCT01906450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1688|STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.|STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.||Universidad del Valle, Colombia||Active, not recruiting|May 2013|January 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 19, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01906450||62441|
NCT01906658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC01-ALS-01|A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis|A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis||Mallinckrodt|No|Active, not recruiting|July 2013|December 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||April 2014|April 4, 2014|July 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01906658||62425|
NCT01907139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-M07-072|Comparative Efficacy Research of Robot-Assisted Therapy With and Without Constraint-Induced Therapy in Stroke Rehabilitation|Comparative Efficacy Research of Robot-Assisted Therapy With and Without Constraint-Induced Therapy in Stroke Rehabilitation: Does the Combined Therapy Improve Outcomes Compared With Monotherapy?||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Active, not recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|80 Years|No|||August 2014|August 6, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01907139||62388|
NCT01908010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-080|Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors||AbbVie|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|55 Years|90 Years|No|||December 2013|December 9, 2013|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908010||62321|
NCT01904682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-07|Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs|A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System||Onconova Therapeutics, Inc.|No|Active, not recruiting|July 2013|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01904682||62577|
NCT01905124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-241UV|Safety &Efficacy of CF101 to Subjects With Uveitis|A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis||Can-Fite BioPharma|No|Not yet recruiting|January 2017|October 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|July 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01905124||62543|
NCT01904162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-005|Effect of Age and Gender on the PK and Tolerability of Finafloxacin|Determination of the Effect of Age and Gender on the Pharmacokinetics and Tolerability of a Single Dose of Finafloxacin-HCL in Healthy Volunteers||MerLion Pharmaceuticals GmbH|No|Completed|February 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 17, 2013|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01904162||62616|
NCT01896414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00052080|Metabolic Actions of Omega-3 Fatty Acids|Metabolic Actions of Omega-3 Fatty Acids on Inflammation and Adipocyte Lipolysis in the Metabolic Syndrome||University of Maryland|Yes|Recruiting|July 2014|April 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896414||63208|
NCT01904695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81202846|Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study|Causal Inference Research of Resistant Hypertension Treatment With Recipe of Removing Both Phlegm and Blood Stasis in a Real World Study||China Academy of Chinese Medical Sciences|Yes|Recruiting|August 2013|December 2015|Anticipated|April 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01904695||62576|
NCT01897532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.22|Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)|CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk||Boehringer Ingelheim||Recruiting|July 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|8000|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 9, 2013||||No||https://clinicaltrials.gov/show/NCT01897532||63123|
NCT01897545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDAFA-030|Combined Treatment of Arterial Hypertension and Atrial Fibrillation|The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Atrial Fibrillation and Arterial Hypertension||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|April 2012|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||October 2013|October 8, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897545||63122|
NCT01879527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSP-2|Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve|A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis||Medical University of Vienna|Yes|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|50 Years|No|||May 2015|May 8, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879527||64506|
NCT01880502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_Belviq_1301|Pharmacokinetic Study of Belviq in Adult Korean Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study (Phase I) to Evaluate the Tolerability and Pharmacokinetics of Belviq in Adult Korean Volunteers||IlDong Pharmaceutical Co Ltd|No|Completed|June 2013|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880502||64431|
NCT01880749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02808, CRAD001CUS205T|Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas|Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas||New York University School of Medicine|Yes|Recruiting|June 2013|||June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|51|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01880749||64412|
NCT01880242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1207|BIOFLOW-III Canada Satellite Registry|Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada||Biotronik Canada Inc|No|Recruiting|April 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|January 2015|January 31, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880242||64451|
NCT01881269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0409|Respiration Rate Monitoring During Transitions|Assessment of Respiration Rate Monitoring During Transitions From Spontaneous to Controlled Ventilation||Medtronic - MITG|No|Completed|June 2013|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer subjects from a hospital population, who are scheduled to undergo surgery        requiring general anesthesia|November 2013|November 4, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881269||64372|
NCT01881490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImageKids|ImageKids Study: Developing the Pediatric Crohn's Disease Intestinal Damage Score (PECDID) & the Pediatric MRE-Based Activity Index (P-MECAI)|Investigator Initiated Study: Developing the Pediatric Crohn's Intestinal Damage Score (PECDID Score) and the Pediatric MRE Based Activity Index (P-MECAI)||Shaare Zedek Medical Center|Yes|Recruiting|January 2013|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|5 Years|18 Years|No|||May 2015|May 19, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01881490||64355|
NCT01902602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAB10-2012|Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia|Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia|HAB|Herrmann Apparatebau GmbH|No|Not yet recruiting|August 2013|June 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples|Both|45 Years|N/A|No|Non-Probability Sample|All patients which fulfill the mentioned criterias.|August 2013|August 12, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902602||62735|
NCT01902888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAA 12-01|Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm|Retrospective Evaluation of the GORE® VIABAHN® Endoprosthesis for a Popliteal Artery Aneurysm Indication|PAA 12-01|W.L.Gore & Associates|No|Terminated|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who had popliteam aneurysm and were treated with GORE® VIABAHN® Endoprosthesis        between January 1, 2002 and December 31, 2010.|June 2015|June 17, 2015|July 16, 2013|No|Yes|Closed due to internal and external factors.|No|May 19, 2015|https://clinicaltrials.gov/show/NCT01902888||62714|Early termination of study. No subject analysis done
NCT01903837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK3831-302|A Study of ALKS 3831 in Adults With Schizophrenia|A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine||Alkermes, Inc.|Yes|Completed|June 2013|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|309|||Both|18 Years|50 Years|No|||April 2015|April 7, 2015|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903837||62641|
NCT01899690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063849|Antibiotics and Tissue Expanders in Breast Reconstruction|Impact of Prophylactic Perioperative Antibiotic Administration on Surgical Site Infections Following Implant-based Breast Reconstruction.||Emory University|No|Suspended|June 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|238|||Female|18 Years|N/A|No|||February 2016|February 6, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899690||62958|
NCT01881204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.21.NRC|Hesperidin and Bone Health in Postmenopausal Women|Hesperidin and Bone Health in Postmenopausal Women|Hesperidin|Purdue University|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|12|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881204||64377|
NCT01881217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16182|First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors||Bayer|No|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|63|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881217||64376|
NCT01880411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBPEKVPI001|Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine|Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL||HealthBanks Biotech Co., Ltd.||Active, not recruiting|June 2013|June 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|45 Years|No|||June 2013|June 14, 2013|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880411||64438|
NCT01881191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ-2013-10958|Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months|Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study|GZA|University at Buffalo|No|Completed|June 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples With DNA|Serum to be retained.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|MS patients from the Baird MS Center, The Jacobs Neurological Institute, Department of        Neurology, State University at Buffalo, NY, USA who are also taking Aubagio as their        disease modifying therapy.        Healthy controls from the general population.|February 2016|February 11, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881191||64378|
NCT01878994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/02220|Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children|Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial|NEREU|Jordi Gol i Gurina Foundation|No|Recruiting|January 2013|December 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01878994||64546|
NCT01879007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-AACL006|Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)|Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)||LG Life Sciences||Completed|January 2006|||March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01879007||64545|
NCT01879540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_44S|Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad®) in Healthy Adults ≥65 Years of Age||Novartis|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 24, 2014|June 13, 2013||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01879540||64505|
NCT01879553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_34S|Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Agrippal®) in Healthy Adults||Novartis|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 10, 2014|June 13, 2013||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01879553||64504|
NCT01880034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0324|Availability of Lipid Emulsion to Regional Anesthesia Programs at US Academic Anesthesia Departments|Availability of Lipid Emulsion to Regional Anesthesia Programs at US Academic Anesthesia Departments||University of Wisconsin, Madison|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|N/A||1|Actual|18|||Both|N/A|N/A|No|Non-Probability Sample|Regional Anesthesia Section heads at academic anesthesia institutions.|December 2014|October 1, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880034||64467|
NCT01880255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057/2013|rTMS for Working Memory Deficits in Schizophrenia|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Working Memory Deficits in Schizophrenia and Effects on Brain Structure||Centre for Addiction and Mental Health|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|59 Years|No|||September 2015|September 15, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880255||64450|
NCT01880268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR BMERDC NeuroRehab10201|Wireless Brain-computer-interface-controlled Neurorehabilitation System for Patients With Stroke|Evaluating the Effectiveness of Wireless Electroencephalogram-based Brain-computer-interface-controlled Neurorehabilitation System in Patients With Stroke||China Medical University Hospital|No|Recruiting|July 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|80 Years|No|||February 2015|February 3, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880268||64449|
NCT01880281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/13|Effect of the Diet on Urinary Excretion of Alpha-ketoglutarate|Effect of a Meat Versus Vegetarian Diet in 12 Healthy Volunteers on the Excretion of Alpha-ketoglutarate Measured in 24-hours Urine||Centre Hospitalier Universitaire Vaudois|No|Completed|June 2013|July 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880281||64448|
NCT01881009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G130115|Medtronic Minimed Overnight Closed-Loop System|Nocturnal Closed-Loop Control Using An ePID (Enhanced Proportional Integral Derivative) Algorithm On An Android Platform With Remote Monitoring In A Closely Monitored Camp Setting: The OCL Camp Study||Stanford University|Yes|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|10 Years|35 Years|No|||March 2015|March 5, 2015|June 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881009||64392|
NCT01881282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002125|A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids|A Comparative Clinical Research on Therapeutic Effect and Safety of Compound Carraghenates Cream Versus Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids||Xian-Janssen Pharmaceutical Ltd.|Yes|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|16 Years|75 Years|No|||February 2014|February 27, 2014|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01881282||64371|
NCT01881503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-454|Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia|Expanded Access Protocol for the Treatment Use of HBOC-201||Englewood Hospital and Medical Center|No|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||December 2015|December 21, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881503||64354|
NCT01881516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM2013－F|Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue（CRF）|Randomized, Double-Blind, Placebo-Controlled, Stage II Trial of Acupuncture For Lung Cancer Patients With Cancer Related Fatigue（CRF）||Fudan University|Yes|Not yet recruiting|July 2013|||July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01881516||64353|
NCT01903226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPREK|Intervention Study to Assess the Effects of Moderate and High Intensity Aerobic Training on Physical Capacity and Activity Level in Persons With Incomplete Spinal Cord Injury|High Intensity Aerobic Training in Persons With Incomplete Spinal Cord Injury||Sunnaas Rehabilitation Hospital|Yes|Recruiting|January 2013|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01903226||62688|
NCT01903512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT010713|Arthrocentesis and Temporomandibular Joint Disorders a Conservative Alternative to Surgical Treatments|||Università degli Studi di Sassari|No|Completed|November 2010|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|25 Years|62 Years|No|Non-Probability Sample|A total of 30 patients with TMJ internal derangement and pain with history of failed        conservative management were selected. 70% had anteriorly displaced discs (AD), and 30        complained of other disorders (osteophytes, signs of soft tissues inflammmation, TMJ        structure alterations).|July 2013|July 16, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01903512||62666|
NCT01903525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042012-055|DHA For The Treatment of Pediatric Concussion Related to Sports Injury|Docosahexaenoic Acid (DHA) For The Treatment of Pediatric Concussion Related to Sports Injury||University of Texas Southwestern Medical Center|No|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Years|18 Years|No|||December 2015|December 30, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01903525||62665|
NCT01903538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211/2010BO1_2|Interference With Cognitive Control by Transcranial Direct Current Stimulation|||University Hospital Tuebingen||Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01903538||62664|
NCT01903824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26401/1111|Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects|A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 μg) Following Single-Dose Administration to Healthy Subjects||Teva Pharmaceutical Industries|No|Completed|August 2013|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|July 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903824||62642|
NCT01903551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTurin|Loco-regional Analgesia for Post-operative Pain Management in Cardiac Surgery|Phase 3 Study of Post-operative Pain Management With Loco-regional Analgesia in Minithoracotomy for Cardiac Surgery. A Randomized Controlled Trial||University of Turin, Italy|No|Recruiting|May 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||December 2014|December 6, 2014|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01903551||62663|
NCT01903863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040223|The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity|Prospective, Randomized Pilot Study of Prophylactic Fresh Frozen Plasma Administration During Neonatal-Pediatric Extracorporeal Membrane Oxygenation.||Duke University|No|Recruiting|July 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|N/A|18 Years|No|||December 2015|December 22, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903863||62639|
NCT01878214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110075|Promoting Smoking Cessation in Carpenters|Effective Communication Strategies for Promoting Smoking Cessation in Carpenters||Washington University School of Medicine|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|442|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 3, 2014|May 22, 2013||No||No|November 25, 2014|https://clinicaltrials.gov/show/NCT01878214||64606|Messages were based on feedback from a small sample that over-represented young workers; messages may not have been applicable to all union members. Intervention reach was low; only 42% of intervention participants reporting receiving postcards.
NCT01880957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1826-F|PET and MRI Brain Imaging of Bipolar Disorder|Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging||Stony Brook University|No|Recruiting|August 2012|||May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|76|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|June 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01880957||64396|
NCT01881737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08092011-8246|A Study of Pregnenolone in the Treatment of Individuals With Autism|An Open-Label Pilot Study of Pregnenolone in the Treatment of Individuals With Autism||Stanford University|Yes|Completed|July 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|45 Years|No|||December 2015|December 2, 2015|November 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01881737||64336|
NCT01878747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES02|Healthcare Provider Behavior and Children's Perioperative Distress|Healthcare Provider Behavior and Children's Perioperative Distress||University of California, Irvine|Yes|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1920|||Both|2 Years|14 Years|No|||February 2016|February 17, 2016|February 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01878747||64565|
NCT01879020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-E02|Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects|A Randomised Double-blind, Placebo-controlled, Ascending-dose, Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Adult Male Subjects||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|61|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01879020||64544|
NCT01879813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stress and cognition study|The Effect of a Phospholipid Drink on Cognitive Performance Under Acute Stress|A Randomised, Double-blind, Parallel Groups, Placebo-controlled 6 Weeks Human Intervention Study Investigating the Effect of a Phospholipid Drink on Cognitive Performance||University of Leeds|No|Completed|October 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01879813||64484|
NCT01879228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818014|Effect of Chronic Incretin-based Therapy in Cystic Fibrosis|A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis||University of Pennsylvania|Yes|Recruiting|June 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879228||64528|
NCT01879241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAS-ALS|Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance||University of Ulm|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879241||64527|
NCT01880515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEPR-BIBW2992|Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW 2992|Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992||Instituto Nacional de Cancerologia de Mexico|Yes|Recruiting|December 2010|March 2014|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01880515||64430|
NCT01881048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0104.cc|Window of Opportunity Study Targeting the Inflammatory Milieu|Window of Opportunity Study Targeting the Inflammatory Milieu of Pregnancy Associated Breast Cancer||University of Colorado, Denver|Yes|Active, not recruiting|August 2009|August 2017|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Female|18 Years|50 Years|No|||February 2016|February 2, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881048||64389|
NCT01881061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-US-2010|Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit|||University of Athens|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Probability Sample|ICU population|June 2013|June 18, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881061||64388|
NCT01880762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02920|Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions|Research Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions||New York University School of Medicine|No|Active, not recruiting|January 2013|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with Multiple Myeloma and that are referred for PET CT imaging.|November 2015|November 11, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01880762||64411|
NCT01880775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKabanPrilocain|Discharge Conditions of Spinal Anesthesia With Heavy Prilocaine-Fentanyl and Heavy Bupivacaine-Fentanyl|The Comparison of the Discharge Conditions and Efficacy of Spinal Anesthesia With Heavy Prilocaine-Fentanyl and Heavy Bupivacaine-Fentanyl in Outpatient Minor Perianal Surgery||Diskapi Teaching and Research Hospital|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|70 Years|No|||March 2012|June 2, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01880775||64410|
NCT01881022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCF-092013|An Internet-based Psychosexual Intervention for Couples Following Treatment for Breast Cancer|An Evaluation of an Internet-based, Psychosexual Intervention for Couples Following Treatment for Breast Cancer: A Phase I Trial|IPSIC|Sunnybrook Health Sciences Centre|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|80 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01881022||64391|
NCT01881295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301013174|Bioavailability of Potassium From Potatoes and Potassium Gluconate|Bioavailability of Potassium From Potatoes and Potassium Gluconate|Potato|Purdue University|No|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|9||Anticipated|35|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881295||64370|
NCT01881802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Study of Opioid Immunosuppressive Effects|||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Enrolling by invitation|March 2013|||June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|The refrigerator - 80 degrees|Both|18 Years|55 Years|No|Non-Probability Sample|Guangzhou Psychiatric Hospital|June 2013|June 19, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01881802||64331|
NCT01881529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0108|A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma|A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma||Gilead Sciences|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|29|Samples Without DNA|-  5 mL blood draw for LOXL2 testing        -  2 Punch Skin Biopsies (one near the scleroderma lesion, the other from normal skin)|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with documented diagnoses of scleroderma will be enrolled into one of two        cohorts, depending upon the subject's diagnosis|April 2014|April 16, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01881529||64352|
NCT01881542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0157-12-EMC|Standard 24-hour Urine Protein vs Shorter Period for Diagnosis of Pre-eclampsia|Comparison of the Standard 24-hour Urine Protein With Shorter Collection Periods for the Diagnosis of Preeclampsia|PET and urine|HaEmek Medical Center, Israel|Yes|Recruiting|June 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|307|||Female|18 Years|55 Years|No|Non-Probability Sample|pregnant women admitted for assessment of suspected preeclampsia|December 2015|December 29, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01881542||64351|
NCT01903239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11D.479|Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas|Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas||Thomas Jefferson University|Yes|Active, not recruiting|November 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|179|||Both|N/A|N/A|No|||February 2016|February 4, 2016|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01903239||62687|
NCT01903850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA 005|TruFreeze™ Airway Obstruction: TAO STUDY|A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - "TAO" STUDY)|TAO|CSA Medical, Inc.|Yes|Withdrawn|July 2013|September 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 16, 2013|Yes|Yes|Withdrawn for business reasons|No||https://clinicaltrials.gov/show/NCT01903850||62640|
NCT01903876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000472|A Web-based Bystander Education Program|Preventing Violence Against Women: A Web-based Approach|RealConsent|Emory University|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|743|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2013||No||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01903876||62638|
NCT01899729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8400-201|A 12-week Dose-Ranging Trial in Patients With Moderate to Sever Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Sever Plaque Psoriasis|8400-201|Idera Pharmaceuticals, Inc.|No|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|70 Years|No|||July 2013|October 16, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01899729||62955|
NCT01899742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116960|The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium|DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium||GlaxoSmithKline|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|497|||Both|40 Years|N/A|No|||January 2016|January 28, 2016|July 11, 2013|Yes|Yes||No|January 11, 2016|https://clinicaltrials.gov/show/NCT01899742||62954|
NCT01881997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001068|Pain Management in ED for Incision and Drainage of Abscess|Randomized Controlled Trial of the Use of Intramuscular Fentanyl for the Incision and Drainage of Abscess in the Emergency Department||University of California, Los Angeles|No|Withdrawn|June 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|April 1, 2011||No|IRB modifications made study impractical.|No||https://clinicaltrials.gov/show/NCT01881997||64316|
NCT01881438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100940|An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment|Oral Fluoroquinolones and the Risk of Retinal Detachment||Janssen Research & Development, LLC|No|Completed|January 2000|May 2013|Actual|December 2012|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Actual|119924|||Both|N/A|N/A|No|Non-Probability Sample|Participants with exposure to oral fluoroquinolones|June 2013|June 18, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881438||64359|
NCT01878500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069579|Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI|Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI||Johns Hopkins University|Yes|Enrolling by invitation|September 2012|September 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|7 Years|No|||June 2013|June 12, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878500||64584|
NCT01878760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRICOT|APRICOT: Anaesthesia PRactice In Children Observational Trial|APRICOT: Anaesthesia PRactice In Children Observational Trial - European Prospective Multicenter Observational Study: Epidemiology of Severe Critical Events in Paediatric Anaesthesia|APRICOT|European Society of Anaesthesiology|No|Completed|March 2014|April 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30000|||Both|N/A|15 Years|No|Non-Probability Sample|Children from birth to 15 years included admitted for an inpatient or outpatient procedure        under general anaesthesia with or without regional analgesia or admitted for a diagnostic        procedure under general anaesthesia (such as endoscopy, radiology…) or admitted        out-of-hours for emergency procedures|October 2015|October 12, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01878760||64564|
NCT01879566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2012_0393|Effect of Catheter-based Radiofrequency Ablation Therapy in Patient With Therapy-resistant Hypertension and Sleep Apnea Syndrome|Effect of Catheter-based Radiofrequency Ablation Therapy of the Renal Sympathetic-Nerve System for Patient With Sleep Apnea Syndrome and Therapy Resistant Hypertension||University of Zurich||Recruiting|May 2013|July 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with therapy-resistant arterial hypertension and sleep apnea syndrome|May 2015|May 27, 2015|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01879566||64503|
NCT01880060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK071664-02|Tailored Worksite Weight Control Programs|Tailored Worksite Weight Control Programs||Virginia Polytechnic Institute and State University|No|Completed|March 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1790|||Both|18 Years|N/A|No|||July 2013|July 13, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880060||64465|
NCT01879254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s50928|Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD).|Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Severe Treatment Refractory Obsessive Compulsive Disorder (OCD).||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2008|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients that have received DBS for OCD will be included in this study.|January 2016|January 26, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879254||64526|
NCT01880788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMM-AMD-107|Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD|Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).||Sequenom, Inc.|No|Completed|November 2012|August 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|152|Samples With DNA|Buccal cells|Both|30 Years|N/A|No|Probability Sample|Patients seen for routine visits at the offices of Vitreous Retina Macula Consultants of        New York.        Enrollment will include 150 subjects: 50 will be selected based on diagnosis of CNV        secondary to CSC 50 will be selected based on diagnosis of CSC without neovascularization        and 50 selected based on diagnosis of CNV secondary to advanced AMD.|September 2015|September 17, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01880788||64409|
NCT01880801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-12-LND|Immunoglobulins Anti Platelets In Breast Milk Of Maternal ITP|IMMUNOGLOBULINS ANTI PLATELETS IN BREAST MILK OF MATERNAL ITP||Laniado Hospital|Yes|Not yet recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|22|||Both|18 Years|40 Years|No|Probability Sample|Lactating women diagnosed with ITP|February 2012|June 18, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01880801||64408|
NCT01881308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA2012-1/ver3_1|Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis|REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design|ARCTIC REWIND|Diakonhjemmet Hospital|No|Recruiting|June 2013|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|360|||Both|18 Years|80 Years|No|||February 2015|February 10, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881308||64369|
NCT01881035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCH Heart Station 10|Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy|Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy|TreatDialRDN|Turku University Hospital|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01881035||64390|
NCT01881568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANEX1|Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA|Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.|TRANEX1|Hospital Universitario La Paz|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01881568||64349|
NCT01882049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE#G100290|Use of Adjustable Gastric Band in Adolescents|Use of the REALIZE™ Adjustable Gastric Band (Model 2200-X) in Adolescents||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|May 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|12 Years|18 Years|No|||March 2015|March 20, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882049||64312|
NCT01903889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10385|Male Engagement in PMTCT Services|Promoting Constructive Male Engagement to Increase Use of Prevention of Mother to Child Transmission (PMTCT) Services||FHI 360|No|Completed|January 2013|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3806|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903889||62637|
NCT01899755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116987|A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability, Immunogenicity, and Pharmacodynamics of GSK2800528 in Healthy Subjects.||GlaxoSmithKline|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|May 1, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899755||62953|
NCT01899768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117270|GSK2339345 Hypertussive Challenge Study|A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients With Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler||GlaxoSmithKline|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899768||62952|
NCT01900028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00007|To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours|A Non-randomised, Open-label, Sequential, Three-part, Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation, and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|October 2013|December 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|85|||Both|18 Years|130 Years|No|||March 2016|March 15, 2016|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900028||62932|
NCT01878773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5229-CE|Prostate Delineation: High Quality Volume CT|Prostate Delineation During Radiation Treatment Planning for Prostate Cancer: Comparison of High Quality Volume Computerized Tomography With Conventional Tomography and Magnetic Resonance Imaging||University Health Network, Toronto|No|Recruiting|October 2012|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01878773||64563|
NCT01878487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0906/85|Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention|INtra-Vascular Ultrasound Study of Export Thrombectomy in ST Elevation Myocardial Infarction Myocardial Infarction|INVEST-MI|Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01878487||64585|
NCT01879280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100387|Effect of Craniotomy on Temporalis Function|||Vanderbilt University|No|Withdrawn|May 2010|May 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|April 29, 2010||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01879280||64524|
NCT01879826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laser|Pediatric Laser Acupuncture and Renal Biopsy|Efficacy of Laser Therapy as an Adjuvant Treatment During Kidney Biopsies to Decrease Anxiety and Pain.||University of California, San Francisco|Yes|Active, not recruiting|July 2013|June 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|7 Years|25 Years|No|||November 2015|November 30, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879826||64483|
NCT01880307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39202.078.12|Infliximab Top-down in Pediatric Crohn|Infliximab Top-down Study in Kids With Crohn's Disease|ITSKids|Erasmus Medical Center|No|Terminated|January 2013|||December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|3 Years|17 Years|No|||July 2015|July 1, 2015|June 7, 2013||No|Not enough study subjects|No||https://clinicaltrials.gov/show/NCT01880307||64446|
NCT01879800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207748|One-Day Acceptance and Commitment Training Intervention in Primary Care Patients|One-Day Acceptance and Commitment Training Intervention in Primary Care Patients||University of Iowa||Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|No|||August 2015|August 13, 2015|May 30, 2013||No||No|June 3, 2015|https://clinicaltrials.gov/show/NCT01879800||64485|
NCT01880021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12735|Synthetic Mesh Explant Study|Characterization of Explanted Hernia Meshes From Human Subjects: A Prospective Study||Washington University School of Medicine|No|Recruiting|March 2008|||March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from study investigators' patient population.|June 2015|June 1, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01880021||64468|
NCT01880541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-71|Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer|Assessment of Cognitive Function After Surgery in Two Types of Anesthesia (General Anesthesia Hypnosedation or Traditional) in Patients Operated for Breast Cancer|HYPNOSEIN|Institut Bergonié|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|50|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01880541||64428|
NCT01880814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23MH093491|Using SMART Experimental Design to Personalize Treatment for Child Depression|Using SMART Experimental Design to Personalize Treatment for Child Depression||Massachusetts General Hospital|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|7 Years|14 Years|No|||December 2015|December 28, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01880814||64407|
NCT01881074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287-2011|Periodontal Treatment Response in Type II Diabetic Patients|The Influence of Periodontal Treatment on Gingival Inflammatory Response of the Type II Diabetic Patient||University of Florida|No|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|70 Years|No|||January 2016|January 21, 2016|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01881074||64387|
NCT01881555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.725|Functional Testing Underlying Coronary Revascularisation|FUnctional Testing Underlying Coronary REvascularisation.|FUTURE|Hospices Civils de Lyon|Yes|Recruiting|May 2013|November 2020|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1728|||Both|18 Years|N/A|No|||December 2013|August 8, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01881555||64350|
NCT01881581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDCPChina001|Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS|A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS||Centers for Disease Control and Prevention, China|Yes|Recruiting|June 2013|August 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Anticipated|56|||Both|18 Years|50 Years|No|||June 2013|June 19, 2013|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01881581||64348|
NCT01881594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEL-001|Stimulation of Efferent Loop Prior to Ileostomy Closure|||Hospital Universitario Virgen de la Arrixaca|No|Completed|January 2012|||September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01881594||64347|
NCT01881815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR-001-B|Swab Sample Collection for the Detection of Bacterial Proteases|Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay||Systagenix Wound Management|Yes|Completed|June 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|N/A||1|Actual|141|None Retained|Swabs will be tested on day on collection. Test is destructive. No swabs will be retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult subjects (greater than 18 years old), presenting at participating clinical sites        with wounds of different etiologies, who are willing to provide informed consent and who        meet the inclusion / exclusion criteria, will be prospectively enrolled|June 2013|July 4, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01881815||64330|
NCT01881828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DX-17-2013-506|Metformin Therapy for Overweight Adolescents With Type 1 Diabetes|A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes||T1D Exchange Clinic Network Coordinating Center|Yes|Active, not recruiting|September 2013|December 2014|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|12 Years|19 Years|No|||October 2014|October 22, 2014|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881828||64329|
NCT01903564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0362|Fetal and Neonatal Magnetophysiology|Fetal and Neonatal Magnetophysiology||University of Wisconsin, Madison|No|Suspended|March 2014|February 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|We plan to study a total of 125 subjects. Twenty-five will be pregnant women with        uncomplicated pregnancies; 100 will be pregnant women with pregnancies complicated by        fetal arrhythmia or a condition that puts the fetus at risk of fetal arrhythmia. We refer        to these cases as "high-risk" due to the presence of or risk of arrhythmia to the fetus.        The pregnant mothers will be age 18 or older. They will be studied as early as 15 weeks'        gestation and may be asked to return about once every 4 weeks, if their physician        determines that additional fMCG studies are necessary.|September 2014|September 17, 2014|July 11, 2013|Yes|Yes|IRB suspension|No||https://clinicaltrials.gov/show/NCT01903564|1 Year|62662|
NCT01900041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU20040_4002_1|A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss|Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2)||Merz Pharmaceuticals GmbH|No|Completed|April 2012|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Female|18 Years|45 Years|No|||December 2013|December 11, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01900041||62931|
NCT01881477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICUPT|Effect of Therapeutic Modalities on the Physical Fitness and Functional Capacity in Critical Patient|Effect of Therapeutic Modalities on the Physical Fitness and Functional Capacity in Critical Patient|ICUPT|CES University|No|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01881477||64356|
NCT01881763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-127|Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression|Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia||Northwell Health|No|Recruiting|June 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|May 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881763||64334|
NCT01878786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIRPCRAD001AUS183T|A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys|A Pilot Study Comparing the Safety and Efficacy of Zortress (Everolimus) With Low Dose Tacrolimus to Early Conversion to Calcineulin Inhibitor-Free Regimen and Mycophenolic Acid With Standard Dose Tacrolimus in Recipients of ECD/DCD Kidneys|Evered|Georgetown University|Yes|Recruiting|June 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878786||64562|
NCT01878227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010MMXX2CoA007|Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia|Randomized Head-to-Head Comparison of Coenzyme A Capsule and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial.||Zhejiang University|Yes|Completed|July 2010|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|75 Years|No|||June 2013|June 11, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01878227||64605|
NCT01879059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIA-1200428|The Effects of Altering Physical Activity on Cardiometabolic Health|The Effects of Altering Physical Activity on Endothelial Function, Glycemic Control, and the Blood Flow Response to an Oral Glucose Tolerance Test.|PIA|University of Kansas Medical Center|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|19 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|January 24, 2012||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01879059||64541|
NCT01879267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2009-0119|Exercise Effects in Huntington's Disease|Exercise Effects in Huntington's Disease||University of Zurich|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|30 Years|60 Years|No|||December 2014|December 15, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01879267||64525|
NCT01879579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03713|Mobile Insulin Titration Intervention|The Mobile Insulin Titration Intervention (MITI) Study: Innovative Chronic Disease Management of Diabetes|MITI|New York University School of Medicine|Yes|Completed|June 2013|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|70 Years|No|||September 2015|September 15, 2015|June 13, 2013||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01879579||64502|
NCT01880073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202012213|FemVue and Tubal Patency|Use of FemVue for Assessment of Tubal Patency as Compared to Laparoscopic Chromopertubation||Weill Medical College of Cornell University|No|Recruiting|May 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|45 Years|No|||December 2015|December 8, 2015|May 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01880073||64464|
NCT01880086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornell-1301013472|Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration|Clomiphene Citrate for the Treatment of Opioid-Induced Androgen Deficiency: Randomized Controlled Clinical Trial||Weill Medical College of Cornell University|Yes|Recruiting|August 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Male|18 Years|65 Years|No|||September 2013|September 5, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01880086||64463|
NCT01880047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116862|Safety and Efficacy of Eltrombopag at Escalated Doses|Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg||Weill Medical College of Cornell University|Yes|Recruiting|February 2013|February 2016|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|12 Years|N/A|No|||June 2013|June 17, 2013|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880047||64466|
NCT01880294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100891|A Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia|CONSIST- Constipation Symptoms Observational Study: A Multicenter, Cross-Sectional Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia|CONSIST|Johnson & Johnson Pte Ltd|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|461|||Both|18 Years|N/A|No|Non-Probability Sample|Asian participants diagnosed with chronic constipation using the Asian        Neurogastro-enterology and Motility Association diagnostic tool.|February 2015|February 6, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880294||64447|
NCT01880554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2010-29|Ultrasound Liver Intraoperative Imaging With SonoVue®|Clinical Utility of Contrast-enhanced Intraoperative Ultrasound in Surgery of Colorectal Liver Metastases. Phase II Clinical Trial.|ULIIS|Institut Bergonié|Yes|Recruiting|June 2011|December 2021|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|57|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01880554||64427|
NCT01881100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No sponsor ID|Randomized Trial on Resin Infiltration in Deciduous Teeth|Randomized Clinical Trial on Resin Infiltration Versus Fluoride Varnish Treatment of Early Smooth-surface Caries Lesions in Deciduous Teeth|infiltration|Medical University of Warsaw|No|Completed|January 2011|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Months|71 Months|Accepts Healthy Volunteers|||June 2013|June 16, 2013|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01881100||64385|
NCT01881087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LevoBupi-003|Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy|Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy: A Double Blind, Randomized Clinical Trial Comparing Three Low Doses|levobupi|Fundacion Clinica Valle del Lili|Yes|Completed|June 2006|July 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|64 Years|No|||June 2013|June 19, 2013|June 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881087||64386|
NCT01881321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130108|Use of Motivational Interviewing to Increase Contraception Use Among Young Women|Use of Motivational Interviewing to Increase Contraception Use Among Young Women: a Randomized Control Trial|MI RCT|University of Chicago|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|15 Years|29 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881321||64368|
NCT01882101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTNS trial|Comparison of PTNS and Biofeedback for Fecal Incontinence|Comparison of Posterior Tibial Nerve Stimulation and Biofeedback for Fecal Incontinence: Prospective Randomized Controlled Trial||Seoul National University Hospital|No|Not yet recruiting|January 2014|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||November 2013|November 10, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882101||64308|
NCT01881841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRKnightR34PA-13-078|Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking|Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking||Children's Hospital Boston|No|Recruiting|January 2015|August 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|14 Years|20 Years|No|||August 2015|August 14, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01881841||64328|
NCT01903577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robotic Ergonomics|Comparative Ergonomic Analysis of Robotic Versus Laparoscopic Surgery|Comparative Ergonomic Analysis of Robotic Versus Laparoscopic Surgery||Washington University School of Medicine|No|Recruiting|September 2012|||December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01903577||62661|
NCT01892800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-shelly|Right Side of Heart Function After Lung Surgery|The Pulmonary Vascular / Right Ventricular Response to Lung Resection||University of Glasgow|No|Active, not recruiting|August 2013|August 2015|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Blood Endo-bronchial aspirate|Both|16 Years|N/A|No|Non-Probability Sample|Prospective observational cohort study in 25 patients presenting for lobectomy for        resection of primary lung cancer|October 2014|October 30, 2014|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892800||63486|
NCT01878513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-252B|Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis|Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis||Northwell Health|No|Recruiting|September 2009|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|264|||Both|18 Years|60 Years|No|||October 2015|October 24, 2015|June 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878513||64583|
NCT01878539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCIII-11/02285|Oral Anticoagulation and Self-management|Oral Anticoagulation and Self-management: Analysis of the Factors That Determine the Feasibility of Using Self-testing and Self-management in Primary Care||Osakidetza|No|Recruiting|June 2012|December 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|333|||Both|16 Years|N/A|No|||June 2013|June 14, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878539||64581|
NCT01879033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-219E|Endothelial Function in Obese Adolescents|Effect Of Obesity And Hyperglycemia on Endothelial Function in Inner City Bronx Adolescents||Montefiore Medical Center|No|Recruiting|March 2011|January 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01879033||64543|
NCT01879592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202349|Molecular Phenotyping of Asthma in Sickle Cell Disease|Molecular Phenotyping of Asthma in Sickle Cell Disease|MoP-ASC|Nemours Children's Clinic|No|Recruiting|June 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|100|Samples With DNA|Blood (RBC, WBC, DNA), urine, and saliva|Both|6 Years|20 Years|No|Non-Probability Sample|Three groups of 30 children each will be studied: Group 1, children with asthma and sickle        cell disease; Group 2, children with sickle cell disease but without asthma; Group 3,        control group of 30 African American children with asthma but without sickle cell disease        ; Group 4, healthy control group of 25 African American children with no chronic disease.        All children are seen at Nemours Children's Clinics in Jacksonville FL, Orlando FL, or        Wilmington DE.|September 2015|September 10, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879592||64501|
NCT01879293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze028|Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease|Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease:A Randomized, Double-Blind, Placebo-Controlled Study||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|40 Years|70 Years|No|||August 2015|August 15, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01879293||64523|
NCT01880099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012154|A Study to Help People Quit Smoking.|Cholinergic Enhancement as a Treatment for Nicotine Addiction||Yale University|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|55 Years|No|||January 2016|January 8, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880099||64462|
NCT01880528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1221|Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer|A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung||Mayo Clinic|Yes|Active, not recruiting|May 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|January 7, 2016|June 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01880528||64429|
NCT01880827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002689-10|Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery|The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve|GIP-PET|Turku University Hospital|Yes|Recruiting|January 2013|January 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01880827||64406|
NCT01881360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS-GFD-013|Efficacy of a Gluten-free Diet for the Treatment of Fibromyalgia|Comparison Between a Gluten-free Diet and a Hypocaloric Diet for the Treatment of Patients With Fibromyalgia and Celiac-type Symptoms||Universidad de Granada|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|75 Years|No|||December 2014|December 1, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881360||64365|
NCT01881633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISU-002|A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers||ISU Abxis Co., Ltd.||Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01881633||64344|
NCT01881347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32036|Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus|Randomized Crossover Study of The Effects of Resveratrol on Endothelial Function in Subjects With Type 2 Diabetes Mellitus||Boston University|No|Recruiting|June 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|21 Years|75 Years|No|||July 2014|July 15, 2014|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881347||64366|
NCT01881334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045700|Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants|A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation||Duke University||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|65 Years||||February 2016|February 4, 2016|June 17, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01881334||64367|
NCT01878370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-2013|Audit and Feedback for Primary Care: a Cluster-randomized Trial|Optimizing Audit and Feedback for Primary Care - Testing Scalable Approaches to Providing Feedback Reports, a Cluster-randomized Trial||Sunnybrook Health Sciences Centre|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|177|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878370||64594|
NCT01899781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-003812-CTIL|Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon|Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon||HaEmek Medical Center, Israel|No|Not yet recruiting|August 2013|||January 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|13 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899781||62951|
NCT01899794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008|Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.|Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence||Jewish General Hospital|Yes|Completed|October 2007|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|N/A|No|||July 2013|July 11, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01899794||62950|
NCT01893697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPT_2013_01|The Influence of Posture on Airway Diameter, Resistance and Airflow Distribution in Healthy Subjects|The Influence of Posture on Airway Diameter, Resistance and Airflow Distribution in Healthy Subjects||University Hospital, Antwerp|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects|May 2015|May 27, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893697||63417|
NCT01893944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07694812.7.0000.5501|Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer|Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer||Universidade do Vale do Paraíba|Yes|Completed|January 2013|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|40 Years|70 Years|No|||February 2014|February 14, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01893944||63398|
NCT01878266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-BT002|Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children|Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma||Children's Cancer Hospital Egypt 57357|Yes|Recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|119|||Both|2 Years|18 Years|No|||January 2016|January 11, 2016|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01878266||64602|
NCT01878526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD therapy in scleroderma|Gastroesophageal Reflux Treatment in Scleroderma|The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis|GERD-SSc|Khon Kaen University|Yes|Recruiting|June 2013|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||September 2015|September 17, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878526||64582|
NCT01879319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120356|Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen|A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.||Amgen|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|80 Years|No|||November 2015|November 19, 2015|June 13, 2013|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT01879319||64522|
NCT01879332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-118|A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers||Bial - Portela C S.A.|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|June 13, 2013|Yes|Yes||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01879332||64521|
NCT01879046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0394|Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells|Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells|ARTHROSTEM|Nantes University Hospital|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01879046||64542|
NCT01879605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v57e4nbn|Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery|Preoperative Bowel Preparation Versus no Preparation Before Spinal Surgery: a Randomised Clinical Trial||Oslo University Hospital|Yes|Completed|December 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|15 Years|N/A|No|||June 2013|June 17, 2013|June 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01879605||64500|
NCT01879345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-113|A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers|A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE TOLERABILITY AND PHARMACOKINETICS OF TWO SINGLE AND MULTIPLE HIGH DOSE REGIMENS OF BIA 2-093 IN HEALTHY VOLUNTEERS||Bial - Portela C S.A.|No|Completed|October 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|June 13, 2013||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01879345||64520|
NCT01879631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.IMU.0.05.05-11|Efficacy of Radial Keratotomy in the Optical Rehabilitation of Mild to Moderate Keratoconus Cases|Efficacy of Radial Keratotomy in the Optical Rehabilitation of Mild to Moderate Keratoconus Cases||Nisa Hastanesi|No|Completed|July 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|36|||Both|18 Years|N/A|No|Probability Sample|mild to moderate keratoconus cases|June 2013|June 17, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01879631||64498|
NCT01879644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF-HC|Neurofeedback Study ADHD|||Philipps University Marburg Medical Center|No|Recruiting|January 2011|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|7 Years|11 Years|No|||March 2014|March 7, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01879644||64497|
NCT01879839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uni-koeln-1547|Effect of a Pre-interventional Diet on Renal Function After Administration of Contrast Agent in Patients at Risk|Phase 4 Study of Effect of a Pre-interventional Calorie Restriction on Renal Function After Administration of Contrast Agent in Patients at Risk|CR_KMN|University of Cologne|Yes|Recruiting|July 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879839||64482|
NCT01879852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00060374|Muscle Weakness and Post-traumatic Knee OA|Muscle Weakness and Post-traumatic Knee OA||University of Florida|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|15 Years|35 Years|No|||September 2014|September 17, 2014|June 13, 2013||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01879852||64481|Difficulty with subject recruitment due to concomitant injury with meniscal tear
NCT01880346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066261|Comparison of Absorption of Vitamin D in Cystic Fibrosis|Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil||Emory University|Yes|Completed|October 2013|October 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|59 Years|No|||November 2015|November 19, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880346||64443|
NCT01880567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0090|Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)|A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)||M.D. Anderson Cancer Center|No|Recruiting|July 2013|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880567||64426|
NCT01880320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18240|Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris|A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris||Galderma R&D|No|Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|503|||Both|12 Years|N/A|No|||October 2014|October 8, 2014|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01880320||64445|
NCT01881113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100-0002|A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Aciex Therapeutics, Inc.|No|Completed|June 2013|||October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|10 Years|N/A|No|||April 2015|April 30, 2015|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881113||64384|
NCT01881126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LUM-12-021|An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|June 17, 2013|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01881126||64383|
NCT01881646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPE|Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery||POPE|Karolinska University Hospital|No|Enrolling by invitation|June 2013|December 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|60 Years|75 Years|No|||November 2014|November 10, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01881646||64343|
NCT01881607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040830|An Integrated Intervention to Reduce Secondhandsmoke in Children|Respiratory Symptoms, Asthma and Passive Smoking in Children: Effectiveness of an Integrated Individual, Family, and School-based Intervention|RESPIR·NET|Institut Català d'Oncologia|No|Completed|May 2006|September 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1779|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01881607||64346|
NCT01881620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2009-70|PET Enhanced CT Scan Performance in Cancer|PET / Enhanced CT Scan Performance in Cancer (Positron Emission Tomography Combined With Computed Tomography or Vascular Contrast CT Scan). COMBI TEP Study|COMBITEP|Institut Bergonié|Yes|Completed|March 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|109|||Both|18 Years|N/A|No|||April 2013|June 17, 2013|November 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01881620||64345|
NCT01881854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cranio-sleep-melatonin|Sleep Wake and Melatonin Pattern in Craniopharyngioma|Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls||Rigshospitalet, Denmark|No|Active, not recruiting|November 2011|September 2015|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated for craniopharyngioma with surgery and some also irradiation|October 2014|October 29, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01881854||64327|
NCT01882114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetS1306/2007|Metabolic Syndrome and Atrial Fibrillation|Impact of Metabolic Syndrome on Atrial Fibrillation Outcomes||University of Roma La Sapienza|Yes|Recruiting|November 2007|December 2030|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|After overnight fasting and supine rest for at least 10 minutes, blood was withdrawn from      the antecubital vein. Serum was divided into aliquots and stored at -80°C.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prospective single-center study included 896 consecutive patients with NVAF who referred        to our center for monitoring and management of antithrombotic therapies of the Department        of Internal Medicine and Medical Specialties of Sapienza-University of Rome between        November 2007 and April 2013.|June 2013|June 17, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01882114||64307|
NCT01892241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATFSHBVD|Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA|||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2010|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|16 Years|60 Years|No|||September 2013|September 28, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01892241||63528|
NCT01893424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0658-12-HMO-CTIL|Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol)|Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoid Combination (Δ9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD) In 1:1 Ratio)||Hadassah Medical Organization|Yes|Completed|August 2013|January 2015|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01893424||63438|
NCT01894789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130105-01H|Ticagrelor vs Clopidogrel Effect on MFR in CAD Population|ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study|PATH|Ottawa Heart Institute Research Corporation|Yes|Completed|March 2013|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01894789||63333|
NCT01878279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21397|HSV Oral Reactivation in Children|Longitudinal Study to Evaluate the Frequency of HSV-1 Oral Reactivation in Children in Dar es Salaam, Tanzania||Dartmouth-Hitchcock Medical Center|No|Completed|September 2008|||July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|For this Pilot study, we will enroll 20 HIV-infected and 10 HIV-uninfected children|June 2013|June 12, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01878279||64601|
NCT01878292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-21|Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder|VLZ-MD-21|Forest Laboratories|No|Recruiting|July 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|495|||Both|12 Years|17 Years|No|||December 2015|December 17, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878292||64600|
NCT01878838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-AVO1|The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.|A Prospective Randomized Controlled Clinical Trial Comparing the Intra-operative Effects, Safety, Efficacy and Performance of Two Commercially Available Laser Systems in Patients Undergoing Femtosecond Laser-Assisted Cataract Surgery.||Hoopes Vision|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|22 Years|N/A|No|||August 2015|August 18, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01878838||64558|
NCT01878799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130159|Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV|An Open Label Trial to Assess Safety, Tolerability, and Efficacy of the Fixed Dose Combination of GS-7977 and GS-5885 in HCV Genotype 1 Subjects Coinfected With HIV||National Institutes of Health Clinical Center (CC)||Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||September 2014|September 24, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878799||64561|
NCT01879618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301091|Use Of Fragmin In Hemodialysis|"a Phase Iiib Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study"||Pfizer|No|Active, not recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|85 Years|No|||February 2016|February 15, 2016|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879618||64499|
NCT01879878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POUDER|Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]|Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]|POUDER|Heidelberg University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879878||64479|
NCT01879865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex-PKPD/01|Dexmedetomidine PKPD Modeling and the Influence of Auditory Stimulation on Dexmedetomidine Effect|Development of a Pharmacokinetic/Pharmacodynamic Model of Dexmedetomidine, and the Effect of Repeated Auditory Stimulation on Pharmacodynamics of Dexmedetomidine.||University Medical Center Groningen|No|Completed|June 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879865||64480|
NCT01880593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0365|Ketamine Plus Lithium in Treatment-Resistant Depression|Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment-Resistant Depression||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|21 Years|65 Years|No|||April 2015|April 2, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880593||64424|
NCT01880333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADRE|Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy|Phase 2/3 Study of the Modified Atkins Diet in Young Children With Refractory Epilepsy||Lady Hardinge Medical College|Yes|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|9 Months|3 Years|No|||June 2013|July 9, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880333||64444|
NCT01880580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC-001|Cone Beam CT for Breast Imaging|Cone Beam CT for Breast Imaging: A Pilot Study||Koning Corporation|Yes|Completed|July 2006|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|76|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard        mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone        beam CT scanner specifically designed to image the breast.        Group II includes forty (40) women, who have had abnormalities detected by physical exam        or an imaging modality and are also scheduled for breast biopsy of the index lesion, will        also undergo a CBCT of the breast(s), prior to biopsy.|June 2013|June 18, 2013|June 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01880580||64425|
NCT01882127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-009|All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|Clinical Study on All-Trans Retinoic Acid (ATRA) Combining High-dose Dexamethasone Versus High-dose Dexamethasone Alone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|February 2013|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||June 2013|June 17, 2013|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01882127||64306|
NCT01885312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA021502-2|Tailored Mobile Text Messaging to Reduce Problem Drinking|Tailored Mobile Text Messaging to Reduce Problem Drinking||Northwell Health|Yes|Recruiting|February 2014|August 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885312||64061|
NCT01885611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS_PGH_2013_003|Virgin Coconut Oil Oral Supplementation for Leprosy Patients|The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study||Philippine Dermatological Society|Yes|Recruiting|June 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|26|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01885611||64038|
NCT01885884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13020507|Supportive Care Intervention-Pancreas|A Pilot Trial of an Embedded Collaborative Model of Supportive Care for Pancreatic Cancer|SCI-P|University of Pittsburgh|No|Active, not recruiting|July 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01885884||64017|
NCT01886131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 388 02|Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder|Subthalamic Nuclei (STN) Local Field Potentials to Investigate Motor Control During REM Sleep Behaviour Disorder (TCSP) Secondary to Idiopathic Parkinsons Disease (PD)|RevesParkNST|University Hospital, Toulouse|No|Terminated|June 2013|July 2014|Actual|June 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|3|||Both|35 Years|70 Years|No|||November 2015|November 25, 2015|June 20, 2013||No|Recruitment|No||https://clinicaltrials.gov/show/NCT01886131||63998|
NCT01886404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209-13-FB|EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients|Efavirenz Pharmacokinetics and Pharmacogenomics in Older HIV-infected Patients|EFV|University of Nebraska|No|Completed|December 2013|August 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|30|||Both|50 Years|N/A|No|Non-Probability Sample|HIV Infected Older than 50 years Of Age and Taking Efavirenz as Part of The Antiretroviral        regimen|December 2014|December 2, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01886404|12 Months|63977|
NCT01893437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28751|A Study of RO6799477 in Healthy Volunteers|A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.||Hoffmann-La Roche||Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893437||63437|
NCT01890707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00062431|Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery|A Comparison of the Effect of Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery||Northwestern University|No|Recruiting|June 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01890707||63646|
NCT01890993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4077|Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe|Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe||Novo Nordisk A/S|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|952|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients with type 2 diabetes initiated on liraglutide or a DPP-4 inhibitor        and primarily managed in primary care with 12 (+/-2) months of available data will be        included in this study. Only data derived from patients receiving either therapy in        accordance with license indications will be included and analyzed.|May 2015|May 20, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890993||63624|
NCT01879072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1202|Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)|Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT (BMT CTN #1202)||Medical College of Wisconsin|Yes|Recruiting|June 2013|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1750|Samples With DNA|10mL serum for Proteomic studies for all 1500 patients at the following time points:      pre-transplant, days 7, 14, 21, 28, 42, 56, and 90.      Gene Expression studies will include the following:        -  PAXgene Lysates-source whole blood RNA (15 ml blood) for 240 patients collected on days           21, 56, and 90.        -  CytoChex tube for Immunophenotyping (4-5 mL blood) collected on days 21, 56, and 90.|Both|N/A|N/A|No|Non-Probability Sample|All U.S. Allogeneic Transplant Donors and Recipients weighing 20 or more kg may        participate in the collection of samples.|December 2015|December 28, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879072|2 Years|64540|
NCT01879098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 70-2013|The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation|Evaluation of the Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation in Healthy, Middle-aged Adults: a Randomized, Double-blinded, Placebo-controlled Study||University of Florida|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|155|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879098||64538|
NCT01879371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335.2|Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate|Relative Bioavailability of Ibuprofen From a Fixed Dose Combination (FDC) Tablet of Ibuprofen 400 mg and Caffeine 100 mg Compared to a Tablet of Ibuprofen 400 mg and a Tablet of Ibuprofen Lysinate 400 mg Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Study)||Boehringer Ingelheim||Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|June 13, 2013||||No||https://clinicaltrials.gov/show/NCT01879371||64518|
NCT01879085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI# 12-104|Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma|Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma|GemTax|University of Pittsburgh|Yes|Recruiting|June 2013|December 2020|Anticipated|June 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01879085||64539|
NCT01879657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117289|68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors|68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors||Radio Isotope Therapy of America|Yes|Recruiting|March 2013|August 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|April 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879657||64496|
NCT01880125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJ4-101|Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination|Clinical Trial to Compare the Pharmacokinetics Profile of YJAT Sustained Release Tablet and ULTRACET® Immediate Release Tablet After Oral Administration to Healthy Male Subjects||Yungjin Pharm. Co., Ltd.|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880125||64460|
NCT01880112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23256|Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.|Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.||West Virginia University|No|Withdrawn|June 2011|June 2013|Anticipated|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Female|18 Years|N/A|No|||June 2013|June 17, 2013|June 29, 2011|Yes|Yes|There is no longer need for this study.|No||https://clinicaltrials.gov/show/NCT01880112||64461|
NCT01884779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12260 EDIRAPHIS|Prevalence of Histoplasmosis in HIV + Patients With a Rapid Diagnostic Test in West Indies|Histoplasmosis in the Guiana Shield and the French West Indies: Evaluating Prevalence in HIV + Patients With a Rapid Diagnostic Test Using an ELISA Capture Method for the Detection of Histoplasma Antigens in Blood and Urine.|EDIRAPHIS|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|August 2013|October 2015|Anticipated|July 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|727|Samples Without DNA|Urine, serum and Histoplasma capsulatum var. capsulatum strains|Both|18 Years|N/A|No|Non-Probability Sample|Adult (aged 18 or over), seen while hospitalized or in outpatient awaiting        hospitalization, HIV1 or HIV2 infection confirmed by techniques validated in France and in        Suriname, either before the episode considered, or discovered concomitantly, and        presenting at least one of the three followings items: an alteration of their general        condition (with a grade 1 according to the WHO Performance Status scale) and/or a fever        and/or symptoms suggestive of an infectious syndrome.|October 2014|October 22, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01884779|90 Days|64102|
NCT01880840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 442|Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR|Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|June 2013|August 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|6 Months|5 Years|No|||April 2014|June 9, 2015|June 17, 2013|Yes|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01880840||64405|
NCT01880853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-breast-screening|Ultrasound and Mammography for Screening Breast Cancer in Chinese Women|||Peking Union Medical College Hospital|Yes|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|47709|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 7, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880853||64404|
NCT01881880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8904|Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging|Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging||University Hospital, Montpellier|No|Recruiting|December 2012|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|750|||Female|40 Years|N/A|No|||June 2013|January 8, 2015|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01881880||64325|
NCT01878396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOV2011/35|Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors|Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF|CMCBRAF|Istituto Oncologico Veneto IRCCS|No|Recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Whole blood.|Both|18 Years|N/A|No|Probability Sample|Primary care clinic|February 2016|February 24, 2016|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878396||64592|
NCT01878669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ozaydin289|Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention|Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention|EASE-PCI|Suleyman Demirel University|No|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|460|||Both|18 Years|85 Years|No|||October 2015|October 17, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01878669||64571|
NCT01878916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HcyMPN|Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs|Plasma Cobalamin, Folate, Pyridoxine and Homocysteine Levels and Thrombosis in Patients With Philadelphia-chromosome-negative Myeloproliferative Neoplasms||Istanbul University|No|Completed|January 2003|June 2004|Actual|June 2004|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Between January and June 2003, thirty-one new or formerly diagnosed MPN patients who        consecutively visitted our clinic, as well as 40 age and sex matched healthy controls were        enrolled in this study.|June 2013|June 14, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01878916|12 Months|64552|
NCT01879150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc-cyclaplex001-il|Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity|Single Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of CyclaPlex Implant and Tools for Correction of First Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity|CO001|Meir Medical Center|No|Recruiting|June 2013|September 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|75 Years|No|||June 2013|June 13, 2013|September 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01879150||64534|
NCT01879163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB028|Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults|A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Guérin (BCG) Vaccinated Adults||University of Oxford|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879163||64533|
NCT01879423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115207|The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects|A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.||GlaxoSmithKline|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|September 5, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879423||64514|
NCT01879696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10000|Double Blinded, Randomized Clinical Trial of the Twin Star ECSPRESS Monitoring System for the Reduction of the Incidence of Fasciotomy|Double Blinded Study for the Reduction of the Incidence of Fasciotomy|ECSPRESS|Twin Star Medical, Inc.|Yes|Not yet recruiting|June 2013|June 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|44 Years|No|||June 2013|June 13, 2013|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879696||64493|
NCT01894529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09/1313|Immunological Biomarkers in Patients With Acute Ischemic Stroke|Clinical Implications of a Panel of Immunological Biomarkers in Patients With Acute Ischemic Stroke||Hospital Clinic of Barcelona|No|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|132|Samples Without DNA|Whole blood, serum and plasma.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum        severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis and        age-matched subjects free of acute neurological injury.|April 2015|April 28, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01894529||63353|
NCT01901757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MERO-102|Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers|An Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of HCP1201 Tablet in Healthy Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01901757||62800|
NCT01902017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123790|Investigations of Mechanisms and Treatment in Post-traumatic Joint Contractures|Randomized, Double Blind, Placebo Controlled Trial of Ketotifen in Patients With Elbow Fractures or Dislocations|Ketotifen|University of Calgary|No|Recruiting|June 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|152|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01902017||62780|
NCT01878578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-106|The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients|||Bial - Portela C S.A.|No|Terminated|November 2002|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|65 Years|No|||February 2014|February 26, 2014|June 12, 2013||No|prematurely terminated due to impossibility of recruiting the planned number of patients by    the study centre.|No||https://clinicaltrials.gov/show/NCT01878578||64578|
NCT01878591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1865|Can Ultrasound Predict Labor Outcome in Operative Vaginal Deliveries?|Can Ultrasound Predict Labor Outcome in Operative Vaginal Deliveries?||Helse Stavanger HF|Yes|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Nulliparous women with a singleton live fetus in cephalic presentation at term (≥ 37        weeks) with prolonged active second stage and a clinical decision to expedite delivery by        vacuum due to poor progression|May 2015|May 19, 2015|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01878591||64577|
NCT01879384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08-PR-DEVAUCHELLE|Monitoring of Bone Free Flaps With Microdialysis|Feasibility of Monitoring of Bone Free Flaps With Microdialysis Catheter Directly Positioned in Bone Tissue|MTM|Centre Hospitalier Universitaire, Amiens|No|Recruiting|February 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2013|June 17, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879384||64517|
NCT01879124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KidneyTX-UZLEUVEN-RI|Resistive Index Measurements After Kidney Transplantation|Correlation Between Renal Vascular Resistive Index, Renal Allograft Histology and Outcome||Universitaire Ziekenhuizen Leuven|No|Completed|March 2004|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|346|||Both|18 Years|N/A|No|Probability Sample|All de novo renal allograft recipients transplanted at the University Hospitals Leuven        between March 2004 and October 2007|June 2013|June 12, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879124||64536|
NCT01879358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORT OUT VII|Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent|Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention|SORT OUT VII|Odense University Hospital|Yes|Active, not recruiting|November 2012|February 2019|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2314|||Both|N/A|N/A|No|||April 2015|April 13, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01879358||64519|
NCT01879891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK049779-14|Exercise Intensity, Metabolic Rate and Insulin Sensitivity|||University of Alabama at Birmingham||Active, not recruiting|May 1995|||August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|44|||Female|19 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879891||64478|
NCT01883765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHO 1448/2-1|Efficacy of Neurofeedback Training in Adults With ADHD|Efficacy of a Neurofeedback Treatment in Adults With ADHD: a Double-blind Randomized Placebo-controlled Study||University Hospital Tuebingen||Recruiting|February 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|60 Years|No|||June 2013|June 18, 2013|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01883765||64180|
NCT01883986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 12-141|Supportive Care for Patients Newly Diagnosed With Lung Cancer|Palliative Care Interventions for Outpatients With Newly Diagnosed Lung Cancer||VA Office of Research and Development|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||February 2016|February 10, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883986||64163|
NCT01880359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1219|AF CRT +/- Nimorazole in HPV/p16 NEG HNSCC|A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of HPV/p16 Negative Squamous Cell Carcinoma of the Head and Neck.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|July 2014|December 2020|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880359||64442|
NCT01881659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC 12-27|Cervical Cancer Screening With Human Papillomavirus Testing|Multicentric Study of Cervical Cancer Screening and Triage With Human Papillomavirus (HPV) Testing|ESTAMPA|International Agency for Research on Cancer|Yes|Recruiting|June 2013|September 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50000|Samples With DNA|Three cervical samples will be collected at entry (one dry and two liquid-based). Sample      retaining or discharge will depend on HPV test (done in first liquid sample) results. If HPV      positive (and 2% of HPV negatives): 1) the dry sample will be used for the E6 protein strip      test, 2) the first liquid sample remains will be used for liquid-based cytology and the      p16/ki67 test and, 3) 10 aliquots from the second liquid sample will be stored. If HPV      negative: 1) the dry sample will be stored for the E6 strip test until the end of the study.      Testing will be done based on evidence towards usefulness in primary screening, 2) two      aliquots from the first liquid sample will be stored and, 3) the second liquid sample will      be discharged. At initial colposcopy, a cervical sample (6 aliquots) and a 10mL blood sample      (serum, plasma and buffy-coat) will be collected and stored. All stored samples will be used      for testing of triage techniques, either currently available or develop in the near future.|Female|30 Years|64 Years|No|Non-Probability Sample|This is a multicentric study to be carried out in countries across the Latin American        region. At each site, a census of all women 28-64 years of age residents of the selected        area will be done previously to the start of the study. All women will then be invited        using different approaches to the local health centers where screening is to happen.|June 2013|April 2, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881659||64342|
NCT01885052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913156|Evaluation of National Cancer Institute Young Adult Stop-Smoking Program|NCI Young Adult Smoking Cessation Evaluation||National Institutes of Health Clinical Center (CC)||Completed|June 2013|May 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|4432|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||May 2015|February 11, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885052||64081|
NCT01878149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0025|Retrospective Multicenter Clinical Evaluation of Complications for Single or Multilevel VEO® Lateral Access and Interbody Fusion System and eXtreme Lateral Interbody Fusion (XLIF®) Subjects|Retrospective Multicenter Clinical Evaluation of Complications for Single or Multilevel VEO® Lateral Access and Interbody Fusion System and eXtreme Lateral Interbody Fusion (XLIF®) Subjects||Baxano Surgical, Inc.|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 40 subjects will be enrolled across the participating sites; 20 subjects who        have been treated with the VEO® lateral system and 20 who have been treated with the XLIF®        system. Consecutive subjects at the participating sites that meet all of the inclusion        criteria and none of the exclusion criteria will be eligible for study participation until        the enrollment target is reached.|August 2014|August 11, 2014|June 11, 2013||No||No|May 30, 2014|https://clinicaltrials.gov/show/NCT01878149||64611|
NCT01882140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-4821|The Use of Electrical Stimulation by Capacitive Field in the Repair of Skin Burns and Quality of Life|The Use of Electrical Stimulation by Capacitive Field in the Repair of Skin Burns and Quality of Life: a Double-blind Randomized Controlled Clinical Trial||University of Sao Paulo|Yes|Not yet recruiting|June 2013|February 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|64 Years|No|||June 2013|June 17, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01882140||64305|
NCT01878409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652|Study of Sexuality in Parkinson Disease|Study of Sexuality in Parkinson Disease|Sex-PD|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|January 2010|November 2012|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|244|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed as having idiopathic PD were recruited from four Italian Movement        Disorders Clinics|June 2013|June 14, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01878409|1 Day|64591|
NCT01878422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST153.01|Sequential Treatment Strategy for Metastatic Colorectal Cancer|SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS BEVACIZUMAB WITH OR WITHOUT CETUXIMAB AS SECOND-LINE THERAPY|ITACa|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Active, not recruiting|November 2007|March 2016|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|350|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878422||64590|
NCT01878682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VibraTip® SSFHC/002|A Study to Evaluate the Performance of VibraTip® by Different Clinical Users|A Study to Evaluate the Performance of the VibraTip® Product by Different Community Medical Practitioners Compared to an Expert Validation by a Diabetologists.||Tameside Hospital NHS Foundation Trust|No|Not yet recruiting|September 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients will be recruited while attending Tameside Hospital NHS Foundation Trust Diabetes        Clinic for a routine 12 month diabetes check up|June 2013|June 14, 2013|June 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01878682||64570|
NCT01878929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-13-06|The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions|The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions: A Double Blind Randomized Control Trial.|SCIT|University Hospital Case Medical Center|No|Recruiting|April 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|245|||Both|5 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 12, 2013|May 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01878929||64551|
NCT01879176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095/2013|Cytokine Removal in Cardiopulmonary Bypass Patients|EFFECT OF CYTOKINE REMOVAL IN CARDIOPULMONARY BYPASS PATIENTS USING THE CYTOSORB ™ FILTER|CytoSorb|Medical University of Vienna|No|Completed|August 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01879176||64532|
NCT01901471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.754|Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock|Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock|CLOTILDE|Hospices Civils de Lyon|Yes|Withdrawn|September 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01901471||62822|
NCT01901484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012162|Schistosoma Mansoni Morbidity in Children Aged 1-5 Years|Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines.||Makerere University|No|Completed|December 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901484||62821|
NCT01902810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-205|Protective Effects of Propranolol in Adults|Protective Effects of Propranolol in Adults Following Major Burn Injury: A Safety and Efficacy Trial||The University of Texas Medical Branch, Galveston|Yes|Recruiting|July 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902810||62720|
NCT01878604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP50469|Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia|The Study of Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia||Central South University|No|Not yet recruiting|July 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|25|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|Homozygous Familial Hypercholesterolemia|June 2013|June 13, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878604||64576|
NCT01878617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJMB12|A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma|A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma||St. Jude Children's Research Hospital|Yes|Recruiting|June 2013|December 2026|Anticipated|June 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|350|||Both|3 Years|21 Years|No|||February 2016|February 15, 2016|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878617||64575|
NCT01878851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moti-Kot-HMO-CTIL|Characterization of Blood Drawn From the Pulp of Primary Molar Undergoing Pulpotomy or Pulpectomy.|||Hadassah Medical Organization|No|Recruiting|September 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|3 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children undergoing pulpotomy during regular dental treatment|August 2015|August 18, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01878851||64557|
NCT01879137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARGO 2013|Copeptin After Arginine Infusion in Polyuria-Polydipsia Syndrome|Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study''||University Hospital, Basel, Switzerland|No|Recruiting|June 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40||Serum EDTA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults Patients with polyuria-polydipsia syndrome|June 2013|April 20, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879137||64535|
NCT01879670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012HSB002B|Partial Left Ventricular Support in Advanced Heart Failure|Partial Left Ventricular Support in Advanced Heart Failure||Royal Brompton & Harefield NHS Foundation Trust|No|Terminated|June 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2|Samples Without DNA|Plasma samples|Both|18 Years|80 Years|No|Probability Sample|Patients will be selected from advanced heart failure clinics at two tertiary heart        hospitals with large cardiac transplantation and mechanical circulatory support        programmes.|October 2015|October 27, 2015|June 11, 2013||No|Withdrawal of CircuLite Synergy from clinical use|No||https://clinicaltrials.gov/show/NCT01879670||64495|
NCT01880619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment of USS|Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms|A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms||Mansoura University|Yes|Completed|January 2013|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|131|||Both|20 Years|50 Years|No|||August 2015|November 23, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880619||64422|
NCT01880866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI|(-)-Epicatechin and Pulmonary Arterial Hypertension|An Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension||University of California, San Francisco|No|Withdrawn|July 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880866||64403|
NCT01884272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-126|NSAID Drug Interaction Study|A Phase 1 Study to Evaluate the Potential Two-Way Pharmacokinetic Interaction Between Lesinurad and Naproxen and Between Lesinurad and Indomethacin in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|June 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884272||64141|
NCT01881867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITN12-03|CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)||Fred Hutchinson Cancer Research Center||Recruiting|September 2013|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881867||64326|
NCT01878448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-02-II|A Phase II Study of Anlotinib in STS Patients|Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma|ALTN/STS|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||Active, not recruiting|April 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|70 Years|No|||January 2015|January 6, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01878448||64588|
NCT01878435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1053900|Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya|Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya|m-SIMU|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|2800|||Both|N/A|5 Weeks|Accepts Healthy Volunteers|||November 2014|November 10, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01878435||64589|
NCT01878695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.396|Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer|Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer|NAC|Thomas Jefferson University|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01878695||64569|
NCT01878708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-165|A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma|A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma||Dana-Farber Cancer Institute|Yes|Terminated|July 2013|September 2018|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|No|||August 2015|August 7, 2015|May 23, 2013|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01878708||64568|
NCT01878942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 279/12|Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study|Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study||University Hospital, Basel, Switzerland|Yes|Completed|June 2013|December 2014|Actual|February 2014|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01878942||64550|
NCT01879189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81670|PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk|PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk Using a Web-based Breast Cancer Screening Decision Aid Tool||University of Pennsylvania|No|Not yet recruiting|September 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1500|||Female|39 Years|48 Years|Accepts Healthy Volunteers|||June 2013|June 26, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879189||64531|
NCT01902290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120141|Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility||Amgen|No|Terminated|May 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|May 22, 2013|Yes|Yes|The decision to stop the study was due to a lack of observed efficacy in a pre-specified    interim analysis. The decision was not related to safety concerns.|No||https://clinicaltrials.gov/show/NCT01902290||62759|
NCT01902537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100894|An Observational Study to Evaluate the Quality of Life in Korean Female Participants With Chronic Constipation|Health Related Quality of Life in Female Patients With Chronic Constipation||Janssen Korea, Ltd., Korea|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|||Female|N/A|N/A|No|Non-Probability Sample|Korean female participants with chronic constipation, having received treatment previously        for constipation. Participants who have visited Constipation Clinic of AMC or Department        of Gastrointestinal for constipation therapy will be selected.|July 2013|July 15, 2013|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902537||62740|
NCT01902550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102301|A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants|A Randomized, Double-Blind, 2-Period Crossover Study to Evaluate the Effect of Single Dose JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Subjects||Janssen Research & Development, LLC|Yes|Not yet recruiting|July 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 15, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01902550||62739|
NCT01879111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-GX-1004|Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback|Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback: Randomized Controlled Trial|DEPSCREEN-INFO|Universitätsklinikum Hamburg-Eppendorf|No|Completed|October 2011|May 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|4151|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879111||64537|
NCT01879397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-797|Pilot Study of Ultrasonic Determined Carotid Plaque Composition|Ultrasonic Mapping of Carotid Plaque Composition|UMP|The Cleveland Clinic|No|Enrolling by invitation|May 2013|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|55|Samples Without DNA|Carotid plaque removed during Carotid Endarterectomy (CEA) for subjects in the CEA Cohort      will be collected and processed for production of histology slides.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People 40 years old or older who are scheduled for a CEA for atherosclerotic plaque        removal within the carotid artery will be considered for enrollement in the CEA Cohort        (anticipated enrollment of 50). A small number of people 40 years old or older with no CEA        scheduled and no prior carotid intervention will be enrolled into the Normal Cohort        (anticipated enrollment of 5).|February 2016|February 24, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01879397||64516|
NCT01880879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-HOPE|A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment|A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease|Pro-HOPE|Kinhely Bio-tech Co.,Ltd.|Yes|Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|80 Years|No|||January 2013|June 20, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01880879||64402|
NCT01880892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-010052|Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy|Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy||Mayo Clinic|No|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880892||64401|
NCT01881152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRUa2-2010-013|Effectiveness of a Public Campaign to Increase Stroke Awareness in Reducing Prehospital Delay|Cluster Randomized Controlled Trial to Assess the Effectiveness of a Population-based Educational Campaign on Stroke Symptom Recognition in Reducing Pre-hospital Delay||Azienda Ospedaliero-Universitaria di Parma|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1772|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01881152||64381|
NCT01881139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150CTSX002|Impact of Exercise Training on Cardiac Function in Man|Effects of Exercise Training on Cardiac Function and Lipid Metabolism in Mem 18-22 Year Old||No. 150 Central Hospital of the Chinese People Liberation Army|Yes|Completed|December 2012|May 2013|Actual|May 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|46|||Male|18 Years|22 Years|No|||June 2013|June 17, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01881139||64382|
NCT01881373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA 2011-68001-30335|Children's Healthy Living Program|Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region|CHL|University of Hawaii|No|Recruiting|April 2011|March 2016|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5000|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881373||64364|
NCT01881386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0536 CCR3939|Lactate Imaging as a Tumour Biomarker|Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response||Institute of Cancer Research, United Kingdom|No|Recruiting|September 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|90|||Both|18 Years|80 Years|No|Probability Sample|Primary care clinic|February 2016|February 3, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881386||64363|
NCT01881672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRE|Syndrome and Aspiration Pneumonia in Intensive Care|Syndrome and Aspiration Pneumonia in Intensive Care|SPIRE|Centre Hospitalier Departemental Vendee|No|Active, not recruiting|November 2012|September 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Patients hospitalized in ICU for coma (define by Glasgow score < 8) and under mechanical        ventilation. Suspicion of bacterial inhalation pneumonia will be confirme by a protected        distal sampling during a flexible bronchoscopy.|September 2015|September 25, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01881672||64341|
NCT01878734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00261|Zambia Micronutrient Powder Trial Effectiveness Study|MNP Pilot Study for Development of a Micronutrient Powder Home Fortification Program to Combat Anaemia Among Children 6-23 Months in Zambia||University of British Columbia|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|631|||Both|6 Months|11 Months|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01878734||64566|
NCT01878968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-06|Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?|Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?||Jewish Hospital, Cincinnati, Ohio|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200|||Both|65 Years|N/A|No|||January 2016|January 4, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01878968||64548|
NCT01878721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14824|Positron Emission Tomography of Infection and Vasculitis|Positron Emission Tomography of Infection and Vasculitis (PETU)|PETU|Turku University Hospital|No|Recruiting|January 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|117|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of Turku University Hospital|June 2013|June 14, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01878721||64567|
NCT01878955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH-123|The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients|Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines||Izmir Katip Celebi University|No|Active, not recruiting|February 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|primary care clinic|February 2016|February 22, 2016|May 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878955||64549|
NCT01879475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT001|Safety and Performance of 032-11 Haemostat in Cardiac and Thoracic Aortic Surgery|Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat With FLOSEAL® Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery.||Medtrade|Yes|Recruiting|June 2013|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01879475||64510|
NCT01879488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AeroVent-01|Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879488||64509|
NCT01879735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-CSar humane 244|Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT|Hepatic Transport of Conjugated Bile Acids in Humans Quantified by 11C-cholylsarcosine PET/CT||University of Aarhus|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|February 4, 2015|June 11, 2013||No||No|January 19, 2015|https://clinicaltrials.gov/show/NCT01879735||64490|
NCT01879748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP1012-PK-10002|A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline|A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects||Teva Pharmaceutical Industries|No|Completed|June 2013|November 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01879748||64489|
NCT01902056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0330|Implant Placement and Simultaneous Soft Tissue Grafting With Single or Double Layers of Acellular Dermal Matrix|Implant Placement and Simultaneous Soft Tissue Grafting With Single or Double Layers of Acellular Dermal Matrix: A Randomized, Controlled Clinical Tria.||University of Louisville|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01902056||62777|
NCT01902303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTL - 2013-06-0161|Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores|Evaluation of Cold Sore Treatments on UV Induced Cold Sores||Beech Tree Labs, Inc.|No|Completed|July 2013|February 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|July 15, 2013|Yes|Yes||No|February 14, 2016|https://clinicaltrials.gov/show/NCT01902303||62758|
NCT01902563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE-O-prot|Osteopathic Approach Into Neonatology Ward: the NE-O Model|Osteopathic Approach Into Neonatology Ward: the NE-O Model||European Institute for Evidence Based Osteopathic Medicine||Available||||||N/A|Expanded Access|N/A|||||||Both|29 Weeks|40 Weeks||||May 2014|May 16, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01902563||62738|
NCT01903148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEN-AEE-2011-01|Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations|ANEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NOT ON DIALYSIS PATIENTS AFTER THE ERBP WORKING GROUP RECOMMENDATIONS|ACERCA|Fundación Senefro|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|455|||Both|18 Years|N/A|No|Non-Probability Sample|Adults patients with anemia secondary to chronic kidney disease (CKD) not on dyalisis.|November 2013|November 8, 2013|July 12, 2013||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01903148||62694|
NCT01903434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14623|A Study of Evacetrapib (LY2484595) in Healthy Participants|A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions||Eli Lilly and Company|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|July 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903434||62672|
NCT01878903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW-13-166|Electronic Visual Analogue Scale in Acute Postoperative Pain|Prospective Comparative Study of Electronic Visual Analogue Scale and Verbal Numerical Rating Scale in Acute Post-operative Pain.||The University of Hong Kong|No|Completed|April 2013|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted at the population of Hong Kong.|January 2014|January 21, 2014|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01878903||64553|
NCT01883479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH096748|Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression|Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression.|HM2|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|December 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|450|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01883479||64202|
NCT01883492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GH2|A Prospective Multi-center Study on Total Hip Arthroplasty With E1|A Prospective Multi-center Randomized Study on Total Hip Replacement With E1||Biomet, Inc.|Yes|Active, not recruiting|March 2013|May 2024|Anticipated|May 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Female|20 Years|75 Years|No|||January 2015|September 8, 2015|January 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883492||64201|
NCT01880138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0192|Effect of Animated Cartoon for Prevention of Emergence Agitation in Children Aged 1.5 - 5 yr After General Anesthesia|||Yonsei University|No|Recruiting|June 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|17 Months|5 Years|No|||June 2013|June 13, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01880138||64459|
NCT01880606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-IBD2012|Endomicroscopy in Primary Sclerosing Cholangitis Related Inflammatory Bowel Disease Surveillance|Probe-based Confocal Laser Endomicroscopy in Colonoscopic Surveillance of Patients With Primary Slerosing Cholangitis Related Inflammatory Bowel Disease (PSC-IBD)|pCLE-PSC-IBD|Karolinska University Hospital|No|Completed|August 2011|June 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|69|Samples With DNA|whole blood, serum, tissue|Both|18 Years|75 Years|No|Probability Sample|Eighty patients with PSC and IBD included in annual surveillance with colonoscopy with        routine biopsy regime will be included in the study.|April 2015|April 24, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880606|1 Year|64423|
NCT01880918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETROPRESS, CLPR-43-11-01|A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing|Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417||novoGI|No|Recruiting|October 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who underwent a laparoscopic or open Low Anterior resection with the        creation of an anastomosis using the ColonRing in routine clinical practice.|June 2013|June 16, 2013|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01880918||64399|
NCT01880931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0239|The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation in Normotensive and Hypertensive Patients|||Severance Hospital|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Female|50 Years|N/A|No|||April 2015|April 8, 2015|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01880931||64398|
NCT01881165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01491|Cranberry on Urinary Tract Infections|A Randomized, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate in Preventing Recurrent Urinary Tract Infections in Adult Women||University of British Columbia|No|Withdrawn|September 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|June 17, 2013||No|Sponsor declined funding|No||https://clinicaltrials.gov/show/NCT01881165||64380|
NCT01881399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004|Fluorescence Versus Intraoperative Cholangiography in the Visualization of Biliary Tree Anatomy|Fluorescence Cholangiography Versus Conventional Intraoperative Cholangiography for Visualization of Biliary Tract Anatomy : a Prospective, Controlled Study|FLARIOC|IHU Strasbourg|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|February 26, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881399||64362|
NCT01881685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#12018|Fetal Intrapartum Heart Rate FHR/ECG Study|Fetal Intrapartum Heart Rate FHR/ECG Study||Mindchild Medical Inc.|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|1) umbilical cord arterial and venous blood; 2)placenta for pathological evaluation.|Female|18 Years|N/A|No|Non-Probability Sample|Women in labor who are having their fetus' heart rate monitored continuously|September 2014|September 16, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01881685|1 Day|64340|
NCT01881698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1426/2013|Evaluation of Platelet Function in Pregnancy With Multiple Electrode Aggregometry|Multiple Electrode Aggregometry and Platelet Function in Pregnancy|MULPP|Medical University of Vienna|No|Recruiting|October 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients above the age of majority|October 2013|October 10, 2013|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881698|7 Months|64339|
NCT01881893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 123251|Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial|Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial|ACHD-CARE|University Health Network, Toronto|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01881893||64324|
NCT01879995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0120|Phenylketonuria and Hyperphenylalaninemia Nutrition Study|Nutrition Status of Adult and Adolescent Patients With Classical Phenylketonuria (PKU) and Hyperphenylalaninemia||University of Zurich||Completed|June 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with phenylketonuria or hyperphenylalaninemia, in treatment at the participating        centres|February 2016|February 5, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01879995||64470|
NCT01880229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0659-01|Physical Activity Monitoring in Frailty and Falling|Phase II STTR: Portable Device for Telecare Monitoring of Elderly People||BioSensics|No|Completed|August 2012|July 2014|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|123|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pima County Arizona elders aged 65+ will be recruited from the Arizona Center on Aging        affiliated geriatrics clinics.|July 2015|July 27, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880229|6 Months|64452|
NCT01880463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001332|Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)|Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)||Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 17, 2016|June 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01880463||64434|
NCT01879761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0491|Immune Resolution After Staphylococcus Aureus Bacteremia|||University of Chicago|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Isolated monocytes from whole blood for HLA-DR measurement. Serum and plasma for cytokine      measurements|Both|18 Years|N/A|No|Non-Probability Sample|Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.|December 2015|December 16, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879761||64488|
NCT01879969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDM 06/06/13|Computer Assisted Orthognathic Surgery. Facial Asymmetry|||Università degli Studi di Sassari|No|Completed|December 2009|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|54 Years|No|||June 2013|June 18, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01879969||64472|
NCT01879982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00725-38|PSYCHE (Personalised Monitoring SYstems for Care in Mental Health)|A Personal Wearable and Interactive System for Monitoring and Multivariable Physiological Assessment to Predict Mood Changes: a Pilot Study With Cyclothymic and Rapid Cycling Bipolar Subjects|PSYCHE|University Hospital, Strasbourg, France|No|Recruiting|May 2013|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|65 Years|No|Non-Probability Sample|Individuals with cyclothymia or with rapid cycling BD will be recruited in the general        population via ads in newspapers and universities (psychology, medical, and arts        departments, for instance) and in clinical populations (patients from the investigators).|June 2013|June 13, 2013|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01879982||64471|
NCT01902316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deng01|Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus|Clinical Verification for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides||Beijing Institute of Technology|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|389|||Both|35 Years|72 Years|Accepts Healthy Volunteers|Non-Probability Sample|university hospital, plasma samples of physical examination, faculties and staff of a        certain university|July 2013|July 17, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902316||62757|
NCT01902849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TICC|Anesthetic Technique on Immune Response in Colorectal Cancer|The Influence of Anesthetic Technique on Interleukin Plasma Level in Colorectal Cancer Surgery - TIVA vs Inhalation Anesthesia|T-IL-Co-ReCa|Iuliu Hatieganu University of Medicine and Pharmacy|No|Completed|February 2012|August 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|70|Samples Without DNA|The collected blood samples are centrifuged at 2500 rpm / min for 10 minutes and the      resulting plasma is stored at -70 °|Both|18 Years|N/A|No|Probability Sample|patient with colorectal neoplasms|March 2014|March 9, 2014|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01902849|1 Day|62717|
NCT01903460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-302|Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome|IMAGO|Shire|Yes|Completed|August 2013|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|12 Months|18 Years|No|||June 2015|November 2, 2015|July 16, 2013||No||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01903460||62670|
NCT01903785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01154-A009|Salbutamol, Pharmacogenetics and Breathing Mechanics|The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance||University of British Columbia|No|Active, not recruiting|May 2013|June 2016|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|70|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01903785||62645|
NCT01880164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2108|Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity|Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity Associated With Low Grade Scoliosis: A Prospective Pilot Study to Evaluate Disease Burden and Longitudinal Study Feasibility|HEO|International Spine Study Group Foundation|No|Enrolling by invitation|June 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|||Both|40 Years|75 Years|No|Non-Probability Sample|Adult spinal deformity patients|January 2016|January 18, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880164||64457|
NCT01880632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28733|Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma|A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma|Neo-Classic|Shanghai Zhongshan Hospital|Yes|Recruiting|July 2013|August 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|June 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01880632||64421|
NCT01880944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1304-199-003|Evaluation of Usefulness of Contrast Enhanced MRI in Evaluation of Spine Trauma: Prospective Study|Evaluation of Usefulness of Contrast Enhanced MRI in Evaluation of Spine Trauma: Prospective Study||Seoul National University Bundang Hospital|No|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|19 Years|N/A|No|Non-Probability Sample|300 patients that fulfilled the following criteria|July 2013|July 1, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880944|2 Months|64397|
NCT01881178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nopalea|The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein|The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein (NOPALEA)|NOPALEA|University of Bridgeport|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|287|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||June 2013|December 29, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881178||64379|
NCT01881412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-231928-N|Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma|Optimizing Discharge After Emergency Department Visits for Children With Uncontrolled Asthma||Rhode Island Hospital|Yes|Recruiting|August 2012|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|143|||Both|3 Years|12 Years|No|||October 2015|November 5, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881412||64361|
NCT01881711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDxDev-SCMP-2013|ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study|An Operator-Blinded Study of the Efficacy of ShuntCheck-Micro-Pumper, a Non-Invasive Diagnostic Procedure, in Detecting Ventricular Shunt Patency or Occlusion and in Predicting Clinical Outcome in Children and Adolescents Presenting to Emergency Departments and Neurosurgery Clinics||NeuroDx Development|Yes|Recruiting|May 2013|September 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|6||Anticipated|400|||Both|35 Months|29 Years|No|||June 2015|June 22, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881711||64338|
NCT01881906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fdaaa|Exercise in Advanced Stage Lung Cancer Patients|"EXHALE" A Randomized Clinical Trial Comparing the Effects of a 12 Week Supervised Exercise Intervention Versus Usual Care for Advanced Stage Lung Cancer Patients.|EXHALE|Rigshospitalet, Denmark|No|Recruiting|February 2012|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|216|||Both|18 Years|N/A|No|||June 2013|November 4, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01881906||64323|
NCT01878162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPacific_Davenport1|Work Injury Prevention in Law Enforcement Officials|Effectiveness of an Exercise-based Work Injury Prevention Program in Law Enforcement Officials||University of the Pacific|No|Suspended|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|108|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01878162||64610|
NCT01879787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS_mCIMT_MP_Stroke|Effects of tDCS Combined With mCIMT or Mental Practice in Poststroke Patients|Impact of Transcranial Direct Current Stimulation (tDCS)on the Effects of Mental Practice and Modified Constraint-induced Movement Therapy (mCIMT)in the Rehabilitation of Chronic Stroke Patients||Universidade Federal de Pernambuco|Yes|Completed|January 2011|December 2014|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|84|||Both|40 Years|80 Years|No|||May 2014|April 10, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879787||64486|
NCT01880008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0073|Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma|An Exploratory Study of Quantitative [18F]FLT-PET and Advanced MRI as Early Indicators of Treatment Response and Molecular Markers for Cell Proliferation in Patients With Glioblastoma Following Subtotal Resection||Washington University School of Medicine|No|Completed|April 2008|August 2012|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with WHO grade III or IV glioma|June 2013|June 13, 2013|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01880008||64469|
NCT01879202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSP|Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis|Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.|MS|Medical University of Vienna|Yes|Recruiting|December 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|November 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01879202||64530|
NCT01879215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817841|T1Rho MRI Evaluation of Patellofemoral Changes After Tibial IM Nailing|Patella Femoral Changes Following Tibial Nailing: Does Approach Matter?||University of Pennsylvania|Yes|Recruiting|June 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|50 Years|No|||June 2013|May 20, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01879215||64529|
NCT01879501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRG11MAY005|Living Successfully With Chronic Eye Diseases|Living Successfully With Chronic Eye Diseases: the 'Living Successfully With Low Vision' (LSLV) Program - a Randomized Controlled Trial of a Self-management Program for Low Vision|ADAPT-LAH|Singapore Eye Research Institute|Yes|Recruiting|January 2013|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|45 Years|75 Years|No|||June 2013|June 14, 2013|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01879501||64508|
NCT01880983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7202|Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))|7202 Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC)||University of Alabama at Birmingham||Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|whole blood for lymphoblast transformation|Both|7 Years|N/A|No|Non-Probability Sample|Erythropoietic Protoporphyria|September 2015|September 14, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01880983||64394|
NCT01881230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-MBC-001|Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)|A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer|tnAcity|Celgene|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|191|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881230||64375|
NCT01902862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010342|An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma|Pilot Study With Bortezomib in Combination With Rituximab Standard Therapy in Patients With Relapsed or Refractory Follicular Lymphoma and at Least 2 Previous Therapies||Janssen-Cilag G.m.b.H|No|Terminated|February 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||March 2014|March 31, 2014|June 7, 2013|Yes|Yes|Recruitment too slow|No||https://clinicaltrials.gov/show/NCT01902862||62716|
NCT01903161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|delayed RIPC|Effect of Delayed Remote Ischemic Preconditioning on Myocardial Injury|Effect of Delayed Remote Ischemic Preconditioning on Myocardial Injury in Patients Undergoing Cardiac Valve Replacement Surgery|RIPC|Seoul National University Hospital|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|80 Years|No|||June 2015|June 7, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01903161||62693|
NCT01903174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0004|Study of AeroForm Tissue Expander for Breast Reconstruction|AeroForm Patient Controlled Tissue Expansion for Breast Reconstruction|ASPIRE|AirXpanders, Inc.|Yes|Completed|June 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|70 Years|No|||March 2014|March 21, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01903174||62692|
NCT01880177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00068783|Developing a COPD Case Finding Methodology for Primary Care|A Study Designed to Develop and Validate a New Screening Measure for Identifying Undiagnosed At-Risk COPD Cases||University of Michigan|Yes|Recruiting|February 2013|||May 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|109|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited through multiple clinic settings, i.e., pulmonology        clinics, internal medicine clinics, and primary care/family medicine clinics.|June 2013|June 17, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01880177||64456|
NCT01880372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSU130106|The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy|Pilot Study: The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy|ALA-TPD|Ferris State University|No|Recruiting|September 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880372||64441|
NCT01880385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25168|Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer|Efficacy & Safety of Bevacizumab as Neoadjuvant Treatment in Patients With Locally Advanced Inflammatory Breast Cancer, a Pilot Study.|Beva|Association Tunisienne de lutte Contre le Cancer|Yes|Recruiting|March 2011|April 2017|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|75 Years|No|||June 2013|June 14, 2013|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01880385||64440|
NCT01880645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0163|Selective Image Guided Resection of Axillary Lymph Nodes|Feasibility of Selective Image Guided Resection of Cytologically Documented Axillary Lymph Node Metastases||M.D. Anderson Cancer Center|No|Completed|March 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01880645||64420|
NCT01880905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0031-13-MMC|The Length of Uteroovarian Ligament and the Risk of Ovarian Torsion|||Meir Medical Center|No|Not yet recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Female|16 Years|45 Years|No|||April 2013|June 18, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01880905||64400|
NCT01881425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN005|InnFocus MicroShunt Versus Trabeculectomy Study|A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShuntTM Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma|IMS|InnFocus Inc.|Yes|Recruiting|June 2013|July 2019|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|857|||Both|40 Years|85 Years|No|||February 2016|February 16, 2016|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01881425||64360|
NCT01881724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK466711|Impact of Sleep Education Program on Glycemic Control in Hong Kong Chinese Type 2 Diabetic Patients|Impact of Sleep Education Program on Glycemic Control in Hong Kong Chinese Type 2 Diabetic Patients||Chinese University of Hong Kong|No|Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|65 Years|No|||June 2013|June 19, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01881724||64337|
NCT01878201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-L201|A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension||Boryung Pharmaceutical Co., Ltd|Yes|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|20 Years|70 Years|No|||September 2014|September 5, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01878201||64607|
NCT01881919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC12-019|Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial|A Double-Blind, Cross-Over, Placebo-Controlled Study Evaluating the Effect of Quercetin 500 mg Tablets on Blood Uric Acid in Healthy Males||University of Leeds||Completed|February 2013|November 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|22|||Male|19 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01881919||64322|
NCT01878175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1033-P|Functional Movement Retraining After Hip Replacement|Functional Movement Retraining After Hip Arthroplasty in Veterans: Pilot Study|FMR-THA|VA Office of Research and Development|No|Active, not recruiting|May 2014|February 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|N/A|No|||January 2016|January 15, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01878175||64609|
NCT01878188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-BLAD-01|Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma|Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma||BioCancell Ltd.|No|Recruiting|February 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01878188||64608|
NCT01878461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US03|Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis|A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center PhaseIII Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis||Maruho North America Inc.|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|542|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01878461||64587|
NCT01880489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034661|Multicomponent Intervention to Reduce Sexual Risk and Substance Use|Multicomponent Intervention to Reduce Sexual Risk and Substance Use||Hunter College|Yes|Recruiting|June 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01880489||64432|
NCT01880736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4060|A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes|A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|June 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|458|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|June 14, 2013|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01880736||64413|
NCT01880710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sj-268|Total Versus Subtotal Abdominal Hysterectomy|Randomized Clinical Trial of Total Versus Subtotal Abdominal Hysterectomy||Nykøbing Falster County Hospital|No|Completed|August 2012|February 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|319|||Female|18 Years|N/A|No|||September 2014|September 24, 2014|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880710||64415|
NCT01880476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Labarge-13-377|Interprofessional Community-Based Diabetes Intervention for Older Adults|Feasibility, Acceptability and Effects of an Interprofessional Community-Based Health Promotion Intervention on Self-Management in Older Adults With Type 2 Diabetes and Comorbid Chronic Conditions: A Pilot Study||McMaster University|No|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|65 Years|N/A|No|||May 2015|May 7, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01880476||64433|
NCT01880723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1123-01|Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis|Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels||University of Arizona|No|Completed|May 2009|January 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|June 15, 2013|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01880723||64414|
NCT01902589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0058-10-EMC|Resistance of Helicobacter Pylori to Antibiotics in Children|Resistance of Helicobacter Pylori to Antibiotics in Children||HaEmek Medical Center, Israel|No|Completed|December 2010|October 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|1 Year|18 Years|No|Probability Sample|Our research group will conclude 100 children in the ages of 1-18 years, evaluated for        recurrent abdominal pain, iron deficiency anemia, failure to thrive by an upper endoscopy,        biopsy specimens taken for a rapid urease test, for histology, for culture and for        antibiotic susceptibility testing.|August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01902589||62736|
NCT01902875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ0001|Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy|Preconditioning Chemotherapy Combined With Cytokine Induced Killer Cell Immunotherapy in Advanced Non Small Cell Lung Cancer||Jinling Hospital, China|Yes|Recruiting|June 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|70 Years|No|Probability Sample|Primary non small cell lung cancer patients with pathology diagnosis.|July 2013|July 16, 2013|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01902875||62715|
NCT01903187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204|EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension|Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension|EnligHTN-IV|St. Jude Medical|Yes|Active, not recruiting|October 2013|November 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|July 9, 2013|Yes|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01903187||62691|Enrollment ended early due to a sponsor decision unrelated to safety. The 2 treatment group subjects are being followed up through 3 years. The 2 sham group subjects were exited after their 1 month visit. Due to these reasons, data is limited.
NCT01903200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0002|Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder|Phase I Study of FK949E - Multiple Dose Study of Elderly Adult Patients With Major Depressive Disorder||Astellas Pharma Inc|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|16|||Both|65 Years|80 Years|No|||July 2013|July 17, 2013|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903200||62690|
NCT01903213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIK002|Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis|Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis||Astellas Pharma Inc|No|Recruiting|March 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Chronic renal failure with Hyperphosphatemia receiving Peritoneal dialysis|March 2016|March 23, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903213||62689|
NCT01880671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine2013/657-32|Evaluation of a New Treatment for Migraine Attacks|Undersökning av ny Behandlingsmetod Vid migränanfall||Karolinska University Hospital|No|Completed|May 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|55 Years|No|||March 2014|March 31, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01880671||64418|
NCT01880684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1437|Validation of Capnography as a Predictor of Cardiac Output Change as Measured by FloTrac|Validation of Capnography as a Predictor of Cardiac Output Change as Measured by FloTrac||Montreal Heart Institute|No|Completed|March 2013|December 2013|Actual|September 2013|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of 18 years old or more presenting for cardiac or aortic surgery at the Montreal        Heart Institute.|April 2014|April 3, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01880684||64417|
NCT01880398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2468|Management of Fistula in Ano by Kshar Sutra, Para Surgical Procedure.|Case Study of Fistula in Ano Managed by Kshar Sutra, Para Surgical Procedure|Bhagandar|Government Ayurved College and Hospital|No|Completed|June 2011|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Female|48 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Government Ayurved Hospital|December 2013|December 23, 2013|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01880398||64439|
NCT01880658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU03|Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer|Phase II Clinical Trial: Capecitabine Maintenance Therapy in Colorectal Cancer Patients With Stage IIIC and R0-R1 Resected Stage IV|CAMCO|Sun Yat-sen University|Yes|Recruiting|June 2013|May 2019|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||July 2013|February 8, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01880658||64419|
NCT01881932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00053394|Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)|Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients||University of Maryland|Yes|Terminated|February 2013|April 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|19|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|March 13, 2013|No|Yes|The PI has moved to another institution, which resulted in significant changes in the study    design and study title.|No|April 21, 2015|https://clinicaltrials.gov/show/NCT01881932||64321|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.
NCT01881945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00273-52|Validation of Study in Respiratory Physiology and it Interactions|Validation of Tools Studying Respiratory Physiology and it Interaction With Swallowing and Cardiac Physiology.|ValApPhI|University Hospital, Grenoble|No|Recruiting|September 2008|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01881945||64320|
NCT01878474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-01|Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, First Time-in-humans Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Escalating Doses of TA-8995 in Healthy Subjects||Mitsubishi Tanabe Pharma Corporation|No|Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01878474||64586|
NCT01878981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAF 2011|Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China|Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China||Johnson & Johnson Medical, China|No|Active, not recruiting|June 2011|April 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|80 Years|No|Probability Sample|A minimum of 150 subjects in the catheter ablation arm ,75 paroxysmal AF patients and 75        persistent AF patients, and 300 subjects in the drug treatment arm ,150 paroxysmal AF        patients and 150 persistent AF patients.|June 2013|June 13, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01878981||64547|
NCT01879514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDC12010114|Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath|Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|January 2010|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||June 2013|June 13, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01879514||64507|
NCT01879774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Characterisation of Neuropsychological and Motoric Performance in Patients With Hyponatremia|Characterisation of Neuropsychological and Motoric Performance in Patients With Hyponatremia||University of Cologne|No|Recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01879774||64487|
NCT01884506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEKZH-2013-0110|Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume|Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume||Swiss Federal Institute of Technology|Yes|Completed|June 2013|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|64|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884506||64123|
NCT01884519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200160|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older|Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above||GlaxoSmithKline||Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|June 13, 2013|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01884519||64122|
NCT01883791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032733-01A1|Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings|Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings|SBIRT in MH|University of California, Los Angeles|Yes|Recruiting|March 2013|August 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1080|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01883791||64178|
NCT01884792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208M18741|Effects of Standing on Glycemia in Prediabetic Adults|Acute Effects of Standing on Glycemia in Prediabetic Adults: A Pilot Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2013|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884792||64101|
NCT01885065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF-02|Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients|Efficacy Study of Novel Edible Gel-based Artificial Saliva in Xerostomic Cancer Patients||Dental Innovation Foundation Under Royal Patronage|No|Completed|July 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|35 Years|80 Years|No|||June 2013|June 19, 2013|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01885065||64080|
NCT01885078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14060|An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis|A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis|RA-BEYOND|Eli Lilly and Company|Yes|Recruiting|June 2013|March 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3073|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885078||64079|
NCT01885403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 12-117|Acute Congestive Heart Failure|Non-Invasive Pulmonary Monitoring in Patients With Cardiogenic Pulmonary Congestion and Edema|AcuteCHF|RWTH Aachen University|No|Recruiting|June 2013|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885403||64054|
NCT01885923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAREPS 2.0|A RCT Study in Schizophrenia Relapse Prevention|Prospective, Randomized, Open, Controlled Study With Information and Telecommunication Technology-aided Relapse Prevention Program in Schizophrenia.||Prague Psychiatric Center|No|Active, not recruiting|August 2012|December 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|60 Years|No|||July 2013|July 10, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01885923||64014|
NCT01886209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-509-010|Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects|An Open-Label, Phase 1 Study to Examine the Pharmacokinetic Interactions Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886209||63992|
NCT01882231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SAR 1275|Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma|Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|March 2013|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|13 Years|N/A|No|||January 2015|January 30, 2015|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882231||64298|
NCT01882166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/600|Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment|Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment||St. Olavs Hospital|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|38 Years|No|||July 2014|July 21, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882166||64303|
NCT01877785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV28916|A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers||Genentech, Inc.||Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|June 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877785||64639|
NCT01874847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT-127046|PLAY GAME: Post-concussion Syndrome in Youth - Assessing the GABAergic Effects of Melatonin|PLAY GAME: Post-concussion Syndrome Affecting Youth: GABAergic Effects of Melatonin. A Randomized Double-blind Placebo-controlled Trial of MELATONIN|PLAYGAME|University of Calgary|Yes|Recruiting|September 2013|September 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|8 Years|19 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874847||64863|
NCT01874860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-OHN-GI-13|Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients|Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients||James Graham Brown Cancer Center|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874860||64862|
NCT01884753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102021-F|Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.|Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.||Far Eastern Memorial Hospital|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Female|20 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with lower urinary tract symptoms|February 2016|February 22, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884753|12 Weeks|64104|
NCT01883778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00057136|Evaluating Patient and Physician Cost Knowledge in the Emergency Department|Do Providers and Consumers Know the Cost of Common Tests and Procedures Delivered in the Emergency Department?||University of Utah|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|512|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There will be two distinct study populations in this study. The first population will        consist of physicians from Emergency Medicine. There are 51 Emergency Medicine physicians        at the University of Utah (27 attending, 24 residents); there are 138 board-certified        Emergency Medicine physicians in the EPIC group therefore a projected provider cohort of        n=90 (about 50% of 189) is anticipated. The only exclusion criterion for physicians is        they do not practice in one of the above-mentioned provider groups.        The second population will consist of patients presenting to the University Utah Emergency        Department who are determined by the attending physicians to be mentally and physically        competent to complete the questionnaire (n=450). Included in this cohort are all English        speaking patients who are eighteen years of age and older, who are deemed psychologically        and medically stable by the ED care provider, are not prisoners, and were not brought in        by EMS.|December 2014|December 1, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01883778||64179|
NCT01883999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBE 12-04|Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis|Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms||W.L.Gore & Associates|Yes|Recruiting|October 2013|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||June 2015|June 25, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883999||64162|
NCT01883206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 12/0161|CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response|Long Term Antibody Response to CMV gB Vaccine in Patients Requiring Liver or Renal Transplant.||University College, London|No|Enrolling by invitation|September 2013|September 2016|Anticipated|August 2015|Anticipated|Phase 2|Observational|Observational Model: Cohort||1|Anticipated|120|Samples With DNA|Serum,Lymphocytes.|Both|18 Years|N/A|No|Non-Probability Sample|The patients will be those that received vaccine or placebo in the Phase II Immunogenicity        Trial Of Cytomegalovirus Glycoprotein B Vaccine In Allograft Candidate Recipients Study        (CTA ref no 20363/0238/001-0010; REC (Research Ethics Committee)ref no 5476; UCL        (University College London) sponsor no 05/009).|May 2015|May 26, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883206||64223|
NCT01883505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612-003|A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612|A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612|ND0612-003|NeuroDerm Ltd.|No|Recruiting|December 2013|September 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|N/A|No|||March 2014|March 18, 2014|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01883505||64200|
NCT01883518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-01-2013|Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma|Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma|ADCVCTAST|Petrov Research Institute of Oncology|No|Recruiting|June 2013|||September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01883518||64199|
NCT01884012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 2012-0538|Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension|||University of Zurich|No|Recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|85 Years|No|||October 2015|October 2, 2015|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01884012||64161|
NCT01884298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIISO-021|Effect of Different Anesthetic Techniques for Isolated Systolic Hypertensive Patients of Abdominal Surgery on Postoperative Hospital Stay and Morbidity|Effect of Different Anesthetic Techniques for Isolated Systolic Hypertensive Patients of Abdominal Surgery on Postoperative Hospital Stay and morbidity---a Prospective, Randomized Study||Peking University First Hospital|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|180|||Both|50 Years|70 Years|No|||June 2013|June 21, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884298||64139|
NCT01884311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIG03|Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases|A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam®VF in Primary Immunodeficiency Diseases|SCIG03|Bio Products Laboratory|No|Recruiting|August 2015|March 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|2 Years|75 Years|No|||February 2016|February 23, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884311||64138|
NCT01884532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11012|ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study|Cross-Sectional, Multi-Center Evaluation of 6 Year Metal Ion Trends for ASR-XL Total Hip Replacement System||DePuy Orthopaedics|No|Active, not recruiting|May 2013|July 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|150|Samples With DNA|Whole blood and serum samples are retained|Both|N/A|N/A|No|Non-Probability Sample|Patients that have undergone a total hip arthroplasty with the ASR-XL Metal-on-Metal        device that are currently 2 to 6 years post-operative.|May 2015|December 17, 2015|June 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884532||64121|
NCT01885689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13130|Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission|Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission||City of Hope Medical Center|Yes|Recruiting|January 2014|||December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|70 Years|No|||December 2015|December 7, 2015|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885689||64032|
NCT01885676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI-01D-EC/12/ALO|Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia|A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.||Biotechnology Institute IMASD||Not yet recruiting||||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||24|||Both|18 Years|65 Years|No|||June 2013|June 24, 2013|June 19, 2013||||No||https://clinicaltrials.gov/show/NCT01885676||64033|
NCT01885936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046020|Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy|A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy||Duke University|No|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885936||64013|
NCT01883050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004546|Application for Self-Monitoring of Cardiovascular Risk|Application for Self-Monitoring of Cardiovascular Risk||Mayo Clinic|No|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|100 Years|No|||September 2015|September 30, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01883050||64235|
NCT01883310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOCT_MS_cerebellar tDCS|Task-oriented Circuit Training Combined With Cerebellar Transcranial Direct Current Stimulation in Multiple Sclerosis Subjects|The Effects of a Task-oriented Circuit Training Combined With Cerebellar Transcranial Direct Current Stimulation on Locomotor Function, Balance and Mobility in Multiple Sclerosis Subjects||University Hospital of Ferrara|Yes|Not yet recruiting|May 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883310||64215|
NCT01886183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC005|Effects of Training in a Virtual Environment in Chronic Stroke Patients|Effects of Training in a Virtual Environment on the Motor Function, Cognition, Postural Control and Gait in Chronic Stroke Patients: A Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Recruiting|August 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01886183||63994|
NCT01876758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6599|Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy|Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy||New York State Psychiatric Institute|No|Active, not recruiting|September 2012|July 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01876758||64718|
NCT01876992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046072|Function of Metformin at the Cellular Level and Best Dosing for Children and Adults With DM or Pre-DM|Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children||Johns Hopkins University|Yes|Terminated|January 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5|||Both|10 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 2, 2013||No|All investigators/co-investigators relocating to other institutions.|No||https://clinicaltrials.gov/show/NCT01876992||64700|
NCT01877811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXDX-105-01|Study of RXDX-105 (RET and BRAF Inhibitor) in Patients With Advanced Solid Tumors|An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors||Ignyta, Inc.|No|Recruiting|June 2013|April 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877811||64637|
NCT01875198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0138|Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer|||Yonsei University|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||February 2014|February 4, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01875198||64836|
NCT01882374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2012-01|Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation|Phase II Evaluation of the Efficacy of TXA127 (Angiotensin 1-7) to Reduce Acute Graft-vs-Host Disease in Adults Undergoing Double Umbilical Cord Blood Transplantation||US Biotest, Inc.|No|Withdrawn|December 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|June 17, 2013|Yes|Yes|Change in drug product development strategy|No||https://clinicaltrials.gov/show/NCT01882374||64287|
NCT01882959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF_META|Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis|Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis||Turku University Hospital|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|374|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with chronic neck or low back pain.|June 2013|June 20, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882959||64242|
NCT01885559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62401-PKD-TN (IND)|HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B|Polycystic Kidney Disease-Treatment Network|HALT-PKD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2006|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|486|||Both|15 Years|64 Years|No|||February 2015|February 25, 2015|June 17, 2013|Yes|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01885559||64042|
NCT01885572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pfm 12k001 TiLOOP Bra|National, Multicenter PMS Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With TiLOOP Bra|National, Multicenter Post-market Surveillance Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)|PRO-BRA|Pfm Medical Mepro Gmbh|Yes|Recruiting|November 2013|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|267|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885572||64041|
NCT01882920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89/10|Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)|Cytoreductive Surgery With Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) - Goal Directed Therapy vs. Standard Fluid Therapy. Prospective Randomized Study||Regina Elena Cancer Institute|No|Recruiting|June 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01882920||64245|
NCT01882933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.761|D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma|GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.|GASTRICHIP|Hospices Civils de Lyon|Yes|Recruiting|May 2013|May 2023|Anticipated|May 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|322|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01882933||64244|
NCT01884025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-187|Get Moving and Get Well - Pilot Study|Get Moving and Get Well: A Behavioral Activation Program for Veterans With SMI|GMGWP|VA Office of Research and Development|No|Active, not recruiting|June 2013|May 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01884025||64160|
NCT01883219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-201304-K2|TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Tyrosine Kinase Inhibitor Therapy Based on Molecular Monitoring of BCR/ABL Transcript Levels in Allogeneic Hematopoietic Stem Cell Transplant Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia||Nanfang Hospital of Southern Medical University|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|14 Years|65 Years|No|||June 2013|June 23, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01883219||64222|
NCT01884545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039569|Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease|Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease||Duke University|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884545||64120|
NCT01884831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USMA01082012|The Study of the Effectiveness of Tissue Equivalent on the Basis of Cultured Cells to Heal Skin Blemishes|Phase 2 The Use of Tissue-equivalent Based on Cultured Cells for Healing Skin Blemishes|SETES|Ural Medical University|Yes|Not yet recruiting|February 2014|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|1|||Both|18 Years|70 Years|No|||December 2013|December 10, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884831||64098|
NCT01884844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSADYI13-15|Vitamin D Supplementation for Bipolar Depression|Randomized Double-Blind Placebo-Controlled Pilot Study of Vitamin D Supplementation for the Treatment of Bipolar Depression||University of Massachusetts, Worcester|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||May 2015|December 10, 2015|June 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884844||64097|
NCT01885104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18127|Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)|Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation||Bayer|No|Completed|April 2013|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|75 Years|No|||February 2015|February 20, 2015|June 19, 2013|No|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT01885104||64077|
NCT01885117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78_11S|Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above|A Phase III, Open Label, Single Arm, Multi Center Study to Evaluate Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus (Fluvirin®) in Healthy Adults||Novartis|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 10, 2014|June 19, 2013||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01885117||64076|
NCT01885364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2013-05-003-001|Esmolol Pretreatment on Pain During Injection of Propofol|Esmolol Pretreatment on Pain During Injection of Propofol||Kyungpook National University|Yes|Completed|June 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|19 Years|60 Years|No|||February 2016|February 4, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885364||64057|
NCT01885377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8820 PV-JN-1|SWESS: The SWedish Exercise Shoulder Study in Primary Care for Patients With Subacromial Pain|SWESS: The SWedish Exercise Shoulder Study in Primary Care for Patients With Subacromial Pain - a Randomized Clinical Trial|SWESS|Linkoeping University|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|30 Years|67 Years|No|||March 2016|March 8, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885377||64056|
NCT01885702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-005584-33|Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI|Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI||Radboud University|No|Active, not recruiting|October 2010|June 2016|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885702||64031|
NCT01885962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15409|Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers|Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers|iSHIFTup|University of Virginia|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885962||64011|
NCT01885975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003419|Personality Profile of Patients With Apical Ballooning Syndrome|Personality Profile of Patients With Apical Ballooning Syndrome (ABS)||Mayo Clinic|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted among participants in the Mayo Clinic Apical Ballooning        Registry. These patients were prospectively diagnosed with Apical Ballooning Syndrome at        the time of presentation with their acute illness, and consented to participation in a        registry. They are residents of Olmsted County, and the surrounding regions for which the        Mayo Clinic serves as a tertiary care center. Enrollment in the registry requires        satisfaction of standard criteria for the diagnosis of ABS and includes the administration        of a standardized questionnaire. Subjects have agreed to participate in yearly follow up        questionnaires about their health status.|February 2015|February 13, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885975||64010|
NCT01883063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRx-001|Distal Radius Fracture - Treatment Comparison|PATIENT OUTCOME COMPARISON OF INTRAMEDULLARY LOCKED NAILING VERSUS NONOPERATIVE MANAGEMENT OF EXTRA-ARTICULAR AND MINIMALLY DISPLACED INTRA-ARTICULAR DISTAL RADIUS FRACTURES IN THE ELDERLY||Sonoma Orthopedic Products, Inc.|Yes|Terminated|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 12, 2015|June 14, 2013|Yes|Yes|Low Enrollment|No||https://clinicaltrials.gov/show/NCT01883063||64234|
NCT01882218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0262|Direct Peritoneal Resuscitation Plus Conventional Resuscitation|A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer||University of Louisville|No|Recruiting|September 2012|March 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||June 2013|June 17, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882218||64299|
NCT01877525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105473|Resect and Discard Approach to Diminutive Colonic Polyps|"Resect and Discard" Approach to Diminutive Colonic Polyps: Real World Applicability Amongst Both Academic and Community Gastroenterologists|RD|Washington University School of Medicine|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|618|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or        routine surveillance indications were prospectively enrolled between October 2011 and        October 2012. Written informed consent was obtained from all patients.|June 2013|June 11, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877525||64659|
NCT01877551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306105|Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance|Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance||Washington University School of Medicine|Yes|Recruiting|September 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877551||64657|
NCT01882153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11232011-8727|Evaluating Parent Delivered Interventions for Children With Autism|||Stanford University||Recruiting|February 2010|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Months|17 Years|No|||December 2015|December 2, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882153||64304|
NCT01882946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWBio 050012|Safety and Efficacy Study of DCVax-Direct in Solid Tumors|A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS||Northwest Biotherapeutics|Yes|Active, not recruiting|June 2013|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01882946||64243|
NCT01883232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0298|The Efficacy of Analgesic Buffering With Sodium Bicarbonate for the Pediatric Dental Patient|The Efficacy of Analgesic Buffering With Sodium Bicarbonate for the Pediatric Dental Patient||University of Colorado, Denver|Yes|Withdrawn|August 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|May 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883232||64221|
NCT01882686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54606|Efficacy of a Classification Based 'Cognitive Functional Therapy' in Nurses With Non Specific Chronic Low Back Pain|Efficacy of a Classification Based 'Cognitive Functional Therapy' in Nurses With Non Specific Chronic Low Back Pain - a Series of Case-controls||Katholieke Universiteit Leuven|No|Active, not recruiting|December 2012|April 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01882686||64263|
NCT01883804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1408|Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes|Open Label Pilot Study of the Effect of Methyldopa on MHC-II Antigen Presentation in Type 1 Diabetes||University of Colorado Denver School of Medicine Barbara Davis Center|No|Recruiting|June 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|46 Years|No|||August 2015|August 24, 2015|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883804||64177|
NCT01883570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPER-11-120-D(1)|Improving Search Strategy for Identifying Urgent Conditions on the Chest X-ray|Improving Search Strategy for Identifying Urgent Conditions on the Chest X-ray. (Original Title in French: Améliorer la stratégie de Recherche et l'Identification Des Conditions Urgentes Sur Une Radiographie Pulmonaire: Impact de l'Utilisation d'un Logiciel Interactif de Lecture systématique)||Université de Montréal|No|Recruiting|June 2013|August 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 20, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883570||64195|
NCT01884324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29862|Randomized Clinical Trial of Early Delivery in Fetal Gastroschisis vs. Routine Care|Early Delivery in Fetal Gastroschisis: a Randomized Controlled Trial of Elective Early Delivery Versus Routine Obstetrical Care||Baylor College of Medicine|Yes|Recruiting|June 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Female|16 Years|50 Years|No|||January 2016|January 8, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884324||64137|
NCT01884337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-158|Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery|A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery||Bristol-Myers Squibb|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884337||64136|
NCT01884038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-LT-301|Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients|A Single Center, Randomized, Double-Blind, Parallel Placebo-Controlled Study of the Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients||United Therapeutics|Yes|Withdrawn|June 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|75 Years|No|||June 2013|June 20, 2013|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884038||64159|
NCT01884350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-220|Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)|Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)|AEGEAN|Bristol-Myers Squibb|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1112|||Both|18 Years|N/A|No|||October 2015|December 21, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884350||64135|
NCT01884363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000803|Walnut Consumption, Endothelial Function, and Biomarkers|Walnut Consumption, Endothelial Function, and Plasma Adipokines in Subjects With Diabetes or Coronary Disease: a Pilot Trial||Brigham and Women's Hospital|No|Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|30 Years|N/A|No|||March 2016|March 16, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884363||64134|
NCT01884558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0051|A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin||Astellas Pharma Inc|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 20, 2013|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884558||64119|
NCT01884571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064218|Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)|A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS)|NIPALS2013|Emory University|Yes|Completed|October 2013|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884571||64118|
NCT01884857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA1264349|Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 50 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fasting Conditions||IPCA Laboratories Ltd.|Yes|Completed|April 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884857||64096|
NCT01885130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10232a|Patch Test Skin Irritation/Sensitization of Cetaphil Daily Advance Ultra Hydration Lotion|100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)||Galderma Laboratories, L.P.|No|Completed|December 2012|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885130||64075|
NCT01885390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-03|Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension|ROX CONTROL HTN Registry: To Evaluate the ROX Coupler in Patients With Resistant or Uncontrolled Hypertension||ROX Medical, Inc.|Yes|Recruiting|March 2014|June 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||September 2015|September 28, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885390||64055|
NCT01882465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5360|Corneal Staining Associated With Daily Disposable Beauty Contact Lenses|Corneal Staining Associated With Daily Disposable Beauty Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Terminated|August 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|35|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882465||64280|
NCT01882478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006030|Cryotherapy -BEATS-RF Ablation Trial|CryoSpray Ablation for Barrett's Esophagus After Treatment Failure With Serial RadioFrequency Ablation||Mayo Clinic|No|Enrolling by invitation|June 2013|June 2020|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|patients with persistent BE with HGD or IMCA despite 2 or more serial RF ablation        treatment sessions in a cohort of patients undergoing endoscopic therapy.|December 2015|December 15, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882478||64279|
NCT01885988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-IT-74|Nebivolol Effects on Endothelial Function and Erectile Function|Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction.|NEB-ED|The Miriam Hospital|No|Recruiting|March 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Male|25 Years|65 Years|No|||June 2013|June 21, 2013|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885988||64009|
NCT01882244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2013-04-17|Remotely Deployed TBI Study|Remotely Deployed Training for Cognitive Impairment Associated With TBI|RD|VA Northern California Health Care System|No|Recruiting|June 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|85|||Both|24 Years|65 Years|No|||December 2015|December 2, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01882244||64297|
NCT01882439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921125|Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor|OPAL BEYOND|Pfizer|Yes|Active, not recruiting|August 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|390|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882439||64282|
NCT01877538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-01|Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System|"[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy Adults"||University of Aarhus|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Observational|Time Perspective: Cross-Sectional||1|Actual|7|||Male|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|7 healthy male volunteers is included in this study.|February 2016|February 22, 2016|June 11, 2013||No||No|May 31, 2015|https://clinicaltrials.gov/show/NCT01877538||64658|
NCT01877798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSS|Venoarterial PCO2 Difference /Arteriovenous O2 Content Difference Ratio as Goal of Early Septic Shock Therapy|Venoarterial PCO2 Difference /Arteriovenous O2 Content Difference Ratio as Goal of Early Severe Sepsis and Septic Shock Therapy||Peking Union Medical College Hospital|No|Not yet recruiting|June 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877798||64638|
NCT01878071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIOB01|The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study|The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study||University of Iowa||Completed|June 2012|||June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects in maintenance dental care with at least one rough surface titanium oral implant        in function|May 2014|May 19, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01878071||64617|
NCT01882985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 10-11|Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients|A Phase II Study to Evaluate the Effects of Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients||University of California, Irvine|Yes|Recruiting|December 2010|June 2021|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|21 Years|N/A|No|||January 2014|January 30, 2014|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882985||64240|
NCT01883531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-204|Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years|A Randomised, Multicentre, Double-blind, Placebo-controlled, Crossover Trial Determining the Efficacy of Dry Powder Mannitol in Improving Lung Function in Subjects With Cystic Fibrosis Aged Six to Seventeen Years||Pharmaxis|No|Completed|June 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|6 Years|17 Years|No|||October 2015|October 12, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01883531||64198|
NCT01883544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1007-US-HV-102|Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects|A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple IV Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects||Alexion Pharmaceuticals|No|Completed|June 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883544||64197|
NCT01883245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orofacial pain_tDCS|Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain|Effects of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Orofacial Pain Unresponsive to Conventional Treatment. A Randomized Controlled Trial.||University Hospital of Ferrara|Yes|Terminated|May 2013|February 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|March 18, 2014|June 18, 2013||No|We decided to stopped the study because we have difficulties in recruiting subjects phase.|No||https://clinicaltrials.gov/show/NCT01883245||64220|
NCT01883557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|773-34682|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||June 26, 2013|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883557||64196|
NCT01884051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO1 HL108800|Hormonal, Metabolic, and Signaling Interactions in PAH|Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension||Vanderbilt University|No|Recruiting|September 2012|September 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2120|Samples With DNA|We plan to collect the following samples on all subjects:      DNA, RNA, white cells, plasma, serum, urine      We plan to collect the following samples on selected subjects:      Skin biopsy|Both|N/A|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort 1 subjects will be recruited from our adult and pediatric pulmonary vascular        disease clinics. Cohort 2-healthy controls will be recruited form patients families and        the general public in middle Tennesssee.|July 2015|July 20, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01884051||64158|
NCT01884064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608M91226|Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia|Multiple Sessions of Low-frequency Repetitive Transcranial Magnetic Stimulation in Focal Hand Dystonia: Clinical and Physiological Effects||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|21 Years|75 Years|No|||October 2015|October 2, 2015|June 20, 2012|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01884064||64157|In this preliminary study, there were subjects with different types of hand dystonia and large range of symptom duration. An ideal study would have sufficient n to be able to stratify subjects within various groups.
NCT01883817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0199|Effect of Omega-3 Fatty Acid on Cortical Function in ADHD|Docosahexaenoic Acid Augmentation of Cortical Attention Networks in ADHD||University of Cincinnati|Yes|Recruiting|September 2013|September 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|15 Years|No|||August 2015|October 22, 2015|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883817||64176|
NCT01884584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00053609|Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer|Assessment of Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer||Emory University|Yes|Active, not recruiting|June 2012|March 2017|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|June 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884584||64117|
NCT01884597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4929S|Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)|Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively|PEARL2|Hawaii Pacific Health|No|Completed|November 2010|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|25 Years|95 Years|No|||August 2014|August 20, 2014|June 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01884597||64116|
NCT01884870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 01187012.2.0000.0068|Silent Ureteral Stone: Impact on Renal Function and Kidney Anatomy|The Impact of Silent Ureteral Stone on Renal Function and Kidney Anatomy: a Prospective Analysis||University of Sao Paulo|No|Recruiting|November 2012|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884870||64095|
NCT01885143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.01-2013-GES-0001|A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe Essential|A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe Essential||GE Healthcare|No|Completed|August 2013|June 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Female|40 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the site's population of women recalled for further workup        due to abnormalities found on screening Full-field digital Mammography exam.|December 2014|December 1, 2014|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01885143||64074|
NCT01885416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRICHIP-2|Impact of Dairy Products on Postprandial Inflammation|The Impact of Dairy Products on Postprandial Inflammation in Obese Males||Agroscope Liebefeld-Posieux Research Station ALP|Yes|Completed|January 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|21|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885416||64053|
NCT01882777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6239|Evaluation of a Project to Distribute Water Filters and Cookstoves in Western Rwanda|ASSESSING THE IMPACT OF WATER FILTERS AND IMPROVED COOK STOVES ON DRINKING WATER QUALITY AND INDOOR AIR POLUTION: A RANDOMISED CONTROLED TRIAL IN RWANDA||London School of Hygiene and Tropical Medicine|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|566|||Both|N/A|N/A|No|||June 2013|June 18, 2013|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01882777||64256|
NCT01883037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CF007B|Comparing Laboratory Blood Glucose Results With HemoCue Glucose 201 RT|To Compare the Clinical Accuracy of Glucose Measurement During Oral Glucose Tolerance Test Using Two Methods: i) Laboratory Standard Technique, ii) HemoCue Glucose 201 RT System|CFRD|Royal Brompton & Harefield NHS Foundation Trust|Yes|Completed|June 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|||Both|16 Years|N/A|No|Non-Probability Sample|The first 70 consecutive adult CF patients, without cystic fibrosis related diabetes, who        are 16 years of age and over, attending annual review at the Royal Brompton Hospital from        June 2013, are eligible for the study.|November 2014|November 12, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883037||64236|
NCT01882790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTN-CAS|The Prevalence of Coronary Spasm in Hypertensive Patients Treated With Antihypertensive Medication|The Association of Acetylcholine-induced Coronary Artery Spasm With the Blood Pressure Level in Hypertensive Patients Treated With Blood Pressure Lowering Drugs||Korea University|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1933|||Both|N/A|N/A|No|Non-Probability Sample|A total of 5,304 consecutive patients in the CAS registry of the Cardiovascular Center at        Korea University Guro Hospital|August 2013|August 23, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01882790|5 Years|64255|
NCT01883089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Craving and Drinking|Ambivalence Model of Craving: Re-examining the Drinking-craving Relationship|Ambivalence Model of Craving: Re-examining the Drinking-craving Relationship||University of South Florida|Yes|Recruiting|January 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01883089||64232|
NCT01883323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TILs-002-MEL|Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma|Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma||University Health Network, Toronto|Yes|Recruiting|June 2013|December 2023|Anticipated|June 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883323||64214|
NCT01883336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE HH Endoscopy PV3879|Long Term Follow up of Small Non-inflammatory Pancreatic Cysts|Long Term Follow up of Small Non-inflammatory Pancreatic Cysts - a Retrospective Multicenter Study.||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|January 2011|October 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Patients with non-inflammatory pancreatic cystic lesions up to 3 cm in diameter referred        to the University Hospital Hamburg Eppendorf, Israelitic Hospital Hamburg, Sana Klinikum        Lichtenberg, Berlin and Krankenhaus Märkisch-Oderland,Strausberg.|January 2016|January 7, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883336||64213|
NCT01877265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14594|A Study of LY2605541 in Healthy Participants|Assessment of the Impact of Monomethoxy Polyethylene Glycols on the Pharmacokinetics and Glucodynamics of Single Doses of LY2605541 in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877265||64679|
NCT01882751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Komistek 2|In Vivo Comparison of Knee Kinematics for Subjects Implanted With Either a ConforMIS or Traditional Knee Implant|In Vivo Determination & Comparison of Knee Kinematics for Subjects Implanted With Either a Personalized ConforMIS or Traditional Knee Implant||ConforMIS, Inc.|No|Recruiting|June 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|40 Years|70 Years|No|Non-Probability Sample|Patients who are at least 6 month post-op with a ConforMIS knee replacement or a standard        total knee replacement who meets the inclusion/exclusion criteria|May 2015|May 29, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01882751||64258|
NCT01882998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD070767|Primary HIV Prevention in Pregnant and Lactating Ugandan Women|PRIMARY HIV PREVENTION IN PREGNANT AND LACTATING UGANDAN WOMEN: A RANDOMIZED TRIAL|PRIMAL|University of California, San Francisco|No|Active, not recruiting|February 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1230|||Both|15 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882998||64239|
NCT01882699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-004|30 Days in Home Use and Home Use Patterns Over 6 Months|A Multi-center, Prospective, Non-randomized Study to Determine Durability of Effectiveness of the Cerêve Sleep System Following 30 Days in Home Use and Home Use Patterns Over 6 Months||Cereve, Inc.|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|22 Years|N/A|No|||May 2015|May 5, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882699||64262|
NCT01882712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40191|Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema|||Galderma R&D|No|Withdrawn||||September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01882712||64261|
NCT01882972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205243|Strength for Health|Safety and Efficacy of Home-based Resistance Training in Colorectal Cancer Survivors||Loyola University|No|Withdrawn|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|June 18, 2013||No|investigator left Loyola|No||https://clinicaltrials.gov/show/NCT01882972||64241|
NCT01883830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kinect_study|Xbox in the Rehabilitation of Chronic Traumatic Brain Injury|"Feasibility and Efficacy of Virtual Reality With Xbox Kinect in the Rehabilitation of Cronic Traumatic Brain Injuries: a Randomized Controlled Trial".||University Hospital of Ferrara|Yes|Recruiting|April 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01883830||64175|
NCT01884077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209102|Total vs. Reverse Shoulder Replacement: Pain Relief Two Years After Surgery|Total vs. Reverse Shoulder Replacement: a Prospective Randomized Trial||Washington University School of Medicine|No|Enrolling by invitation|November 2012|November 2022|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|70 Years|95 Years|No|||December 2015|December 7, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01884077||64156|
NCT01884090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD062565|Youth Empowerment Solutions for Positive Youth Development|Youth Empowerment Solutions for Positive Youth Development (YES) Also Known as Genesee County Afterschool Study (GCAS)|YES|University of Michigan|No|Recruiting|June 2011|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|816|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01884090||64155|
NCT01884376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-009|Clinical Study for the Treatment of Peripheral Nerve Defects With Neuromaix|Klinische Interventionsstrategie Zur überbrückenden Behandlung Peripherer Nervendefekte Mit Neuromaix|PeRepair|RWTH Aachen University|Yes|Completed|July 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||June 2015|June 17, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884376||64133|
NCT01884610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/06/143|Study on the Impact of Stem Cell Donation and Bone Marrow Harvesting on Unrelated Donors|Multi Centre Controlled Study on the Impact of Stem Cell Donation Either After Mobilisation With Granulocyte Colony Stimulating Factor or Bone Marrow Harvest on Unrelated Bone Marrow Donors.||University College, London|Yes|Completed|September 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Fixed ( methanol/acetic acid ) chromosome preparations solution and genomic DNA.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Donors of peripheral blood stem cells, who have agreed to participate in the study|May 2013|June 19, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884610||64115|
NCT01884883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAILLEFERT 2010|Evaluation of a Distraction-rotation Knee Unloader Brace in Patients With Medial Knee Osteoarthritis.|Evaluation of a Distraction-rotation Knee Unloader Brace in Patients With Medial Knee Osteoarthritis.|ORFEVRE|Centre Hospitalier Universitaire Dijon||Completed|May 2010|||December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|40 Years|75 Years|No|||June 2013|June 21, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884883||64094|
NCT01885156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90200_3028_1|Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris||Merz Pharmaceuticals, LLC|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|12 Years|17 Years|No|||March 2015|March 26, 2015|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885156||64073|
NCT01885169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-4621|LAIV (Flumist®) Administration in CF Patients|Safety of Live-attenuated Influenza Vaccine (LAIV, Flumist®) in Patients With Cystic Fibrosis (CF)||McGill University Health Center|No|Active, not recruiting|August 2013|December 2015|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|170|Samples Without DNA|nasal swabs|Both|2 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients with CF followed in clinics in the provinces of Quebec and British        Columbia|September 2014|September 15, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885169||64072|
NCT01885728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27485|Immune-modulation Effects of an Arginine Rich Nutritional Supplement in Surgical Patients|A Randomized, Controlled Study Evaluating the Immune-Modulatory Effects of Perioperative Administration of Arginine Rich Nutritional Supplements With Mass Cytometry in Patient Undergoing Surgery||Stanford University|No|Recruiting|July 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|No|||August 2013|August 19, 2013|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01885728||64029|
NCT01885429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.32.NRC|Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis|The Effect of a Leucine 'Spike' of a Sub-optimal Protein Dose on Acute Muscle Protein Synthesis||McMaster University|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01885429||64052|
NCT01882257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00051504|Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury|Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury||University of Michigan|No|Active, not recruiting|October 2011|February 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882257||64296|
NCT01882491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052162|Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand|A Phase 2 Proof-of-concept Study of Gevokizumab in Subjects With Inflammatory Erosive Osteoarthritis of the Hand||XOMA (US) LLC|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882491||64278|
NCT01882504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052170|Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum|An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum||XOMA (US) LLC|No|Completed|May 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882504||64277|
NCT01883102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002235|The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream|The Effect of Ablation of Epidermal Nerve Fibers Using 0.1% Capsaicin Cream on Spontaneous Cutaneous Burning Pain, Tactile Hyperalgesia, and Thermal Hyperalgesia: A Controlled, Masked Trial With an N of 1||Mayo Clinic|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|1|||Female|39 Years|N/A|No|||June 2013|June 19, 2013|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01883102||64231|
NCT01883076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008521|Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome|Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome||Mayo Clinic|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|18 Months|No|||March 2016|March 11, 2016|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01883076||64233|
NCT01877837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001894|Stem Cell Transplantation for Sickle Cell Anemia|Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old||Hackensack University Medical Center|Yes|Recruiting|June 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|30 Years|No|||August 2015|August 21, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877837||64635|
NCT01882764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMPL-004-04|A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis|A Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis With Clinical Remission or Response From Induction Therapy. (NATRUL-4)|NATRUL-4|Hutchison Medipharma Limited|No|Terminated|June 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||May 2015|May 3, 2015|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882764||64257|
NCT01883011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N09642|A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke|Randomized, Double Blind, Placebo Controlled, Two Parallel Group Study to Evaluate the Efficacy and Safety of Piracetam, 12 g Intravenous (IV) Infusion Within 7 Hour (h) Post Stroke Onset, Followed by 12 g/d for 4 Weeks (IV Ampoules, Oral Solution) and 4.8 g/d for 8 Weeks (Tablets) in Adult Subjects With an Acute Ischemic Middle Cerebral Artery Stroke||UCB Pharma|Yes|Terminated|August 1998|July 2001|Actual|July 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|571|||Both|50 Years|N/A|No|||August 2013|August 28, 2013|June 18, 2013||No|This study was terminated after a pre-specified interim analysis. Please see Detailed Study    Description for further information.|No||https://clinicaltrials.gov/show/NCT01883011||64238|
NCT01883024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00495-40|Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.|Prospective Study, Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.|IPRA|Rennes University Hospital|Yes|Completed|June 2013|September 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01883024||64237|
NCT01883258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280-2012|Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes|Mechanisms of Cardiovascular Dysfunction and Effect of Aerobic Exercise Training in Adults With Type 2 Diabetes||University of Florida|No|Recruiting|May 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|118|||Both|30 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883258||64219|
NCT01883583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUH-rad2|Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney|Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney for Evaluation of Effectiveness of Perfusion Parameter in Assessment of Allograft Nephropathy||Seoul National University Hospital|Yes|Recruiting|June 2013|December 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|20 Years|70 Years|No|||November 2013|November 5, 2013|June 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883583||64194|
NCT01883596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPS-02|Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in Children.|Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.||Sinaloa Pediatric Hospital|No|Recruiting|October 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|1 Month|18 Years|No|||December 2015|December 7, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883596||64193|
NCT01883609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC055|A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S|A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone.||University of Oxford|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883609||64192|
NCT01883843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke_tDCS_TOCT|Efficacy of TOCT and (tDCS) for Gait Improvement in Patients With Chronic Stroke|Efficacy of a Task-oriented Circuit Training Associated With Transcranial Direct Current Stimulation (tDCS) for Gait Improvement in Chronic Stroke Patients . A Randomized Controlled Trial||University Hospital of Ferrara|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01883843||64174|
NCT01884402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-PEG-2010-01|Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4|Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.|OPTIM|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|October 2010|August 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|770|Samples With DNA|Whole blood|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with chronic hepatitis C genotype 1 and 4 mono-or co-infected with HIV who meet        the selection criteria described.|September 2014|September 3, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884402||64131|
NCT01884623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004967-38|Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer|Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation|ELAN-UNFIT|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|June 2013|June 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|70 Years|N/A|No|||February 2016|February 5, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884623||64114|
NCT01884389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES121956|Randomized Trial of an HIV Navigation Program for Early Palliative Care|Randomized Trial of an HIV Navigation Program for Early Palliative Care||Case Western Reserve University|Yes|Active, not recruiting|June 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|179|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01884389||64132|
NCT01884636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0052|A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate|A Phase 1, Open- Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate||Astellas Pharma Inc|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 20, 2013|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884636||64113|
NCT01885182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN10-CN-303|Targin Cancer Pain|A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets 5/2.5mg, 10/5mg, 20/10mg or 40/20mg Compared to Oxycodone PR 5mg, 10mg, 20mg or 40mg in Subjects With Moderate to Severe, Chronic Cancer Pain||Mundipharma (China) Pharmaceutical Co. Ltd|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885182||64071|
NCT01885195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162AUS11|MEK162 for Patients With RAS/RAF/MEK Activated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors|SIGNATURE|Array BioPharma|No|Active, not recruiting|October 2013|||October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|100 Years|No|||February 2016|February 11, 2016|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01885195||64070|
NCT01885442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TryCYCLE|TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients|TryCYCLE (Critical Care Cycling to Improve Lower Extremity Strength): A Prospective Pilot Study of the Safety and Feasibility of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients|TryCYCLE|McMaster University|Yes|Completed|September 2013|January 2015|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01885442||64051|
NCT01885715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1208/168-009|Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium|Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium||Seoul National University Hospital|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Actual|112|||Both|19 Years|69 Years|No|||June 2014|June 12, 2014|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01885715||64030|
NCT01886001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16396|Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections|Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections||University of Virginia|No|Active, not recruiting|November 2012|July 2013|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|N/A|7 Days|No|||June 2013|June 20, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01886001||64008|
NCT01886222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJNS001|Randomized Controlled Trial of Long-term Mild Hypothermia for Severe Traumatic Brain Injury|A Multi-center, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Long-term Mild Hypothermia in Adult Patients With Severe Traumatic Brain Injury|LTH-Ⅰ|RenJi Hospital|Yes|Recruiting|July 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||December 2015|December 13, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01886222||63991|
NCT01886235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 231512|Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery|A Pilot Study of Feasibility of Performing Intravital Microscopy in Melanoma Patients||Roswell Park Cancer Institute|Yes|Active, not recruiting|September 2013|||June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886235||63990|
NCT01882530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130505A-32|Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.|Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.|OCTOPUS|Rennes University Hospital|No|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|1000|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882530||64275|
NCT01882803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-06|A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)|A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)||Infinity Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2013|January 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882803||64254|
NCT01884181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-1056B|Accelerated Diffusion MRI for Diagnosis of Hungtington Disease|Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease||Chang Gung Memorial Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Healthy Controls:             The healthy controls will be recruited from the local community, or the neurological             clinic. The cognitive performance will be evaluated by Mini-Mental State Examination             (MMSE). A complete physical and neurological examination will be performed.          2. Huntington Disease:        Patients with Huntington Disease will be referred from the department of neurology in        ChangGung Memorial Hospital, LinKou. Established diagnosis will be made by a neurological        examination and genetic assessment of CAG expansion in the Htt gene. The severity and        progression of the disease will be assessed by the Unified Huntington's Disease Rating        Scale (UHDRS) (18). The cognitive performance will be evaluated by Mini-Mental State        Examination (MMSE). The inclusion criteria are the following:|February 2014|February 19, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884181||64148|
NCT01883375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:024|Dignity Talk: Helping Palliative Care Patients and Families Have Important Conversations|Dignity Talk: a Novel Palliative Care Intervention for Patients and Their Families|DTalk|University of Manitoba|No|Recruiting|March 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883375||64210|
NCT01883388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM-NOVEL-211-2012|NovellusDx Cancer Early Detection Blood Test- Clinical Trial|Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol||NovellusDx|No|Suspended|June 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy subjects and subjects with primary / relapsed lung cancer|October 2014|October 6, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01883388||64209|
NCT01874041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1144-0809|Effect of Massage Therapy and Occlusal Splint Therapy on the Electromyographic Activity and Mandibular Range of Motion in Individuals With Temporomandibular Disorder|||University of Nove de Julho|Yes|Completed|January 2010|December 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01874041||64925|
NCT01883869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0374-F6A|Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor|XANTHIPPE: Examining the Effect of Ticagrelor on Platelet Activation, Platelet-Leukocyte Aggregates, and Acute Lung Injury in Pneumonia|XANTHIPPE|University of Kentucky|Yes|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01883869||64172|
NCT01884129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCHNSCC01|Prognostic Value of CTC in HNSCC Patients|Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer|CTCHNSCC01|Chang Gung Memorial Hospital|Yes|Terminated|June 2012|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|None Retained|Blood samples were drawn by standard procedure, stored in EDTA-coating tubes in 4 degree      temperature, then sent for CTCs counting and analysis.|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Locally advanced or recurrent/metastatic head and neck cancer|February 2013|December 9, 2015|June 10, 2013||No|participants are no longer being examined or treated|No||https://clinicaltrials.gov/show/NCT01884129|12 Months|64152|
NCT01883271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551-2012|Effect of Aerobic Interval Training on Cardiovascular Function in Aging|Effect of Aerobic Interval vs. Continuous Exercise Training on Cardiovascular Function in Aging||University of Florida|No|Recruiting|May 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|125|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883271||64218|
NCT01883284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8870|Action of Epigenetic Modifiers in Cystic Fibrosis Treatment|Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients|Mod2EpiCF|University Hospital, Montpellier|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|39|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883284||64217|
NCT01883622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GES03|Glucose Variability in Pregnancy Complicated by Diabetes|Glucose Fluctuations During Gestation: an Additional Tool for a Better Monitoring of Pregnancy Complicated by Diabetes||University of Padova|Yes|Completed|January 2004|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient pregnant women enrolled at three Italian diabetes clinics (Padua, Pisa and        Florence)|June 2013|June 18, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883622||64191|
NCT01883635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46413|Exercise Intervention for Cancer Survivors and Caregivers|Dyadic Exercise Intervention for Cancer Survivors and Caregivers||University of Rochester|Yes|Completed|May 2013|August 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|June 5, 2013||No||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01883635||64190|First, this was a pilot, Phase I trial, and hence had a limited sample size. This study was conducted in a single geographic region. Finally, we analyzed only two time points: baseline and post-intervention.
NCT01884116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0060|Comparison of NSAID Patch Given in Monotherapy and NSAID Patch in Combination With Transcutaneous Electric Nerve Stimulation, Heating Pad, or Topical Capsaicin in the Treatment of Patients With Myofascial Pain Syndrome of the Upper Trapezius: A Pilot Study|||Yonsei University|No|Completed|March 2011|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|100|||Both|20 Years|N/A|No|||June 2013|June 18, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01884116||64153|
NCT01884909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA1264351|Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fed Conditions||IPCA Laboratories Ltd.|Yes|Completed|April 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884909||64092|
NCT01885221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA033422|A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree)|A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation||Oregon Research Institute|No|Recruiting|September 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885221||64068|
NCT01884896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA1264350|Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fasting Conditions||IPCA Laboratories Ltd.|Yes|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884896||64093|
NCT01885741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPBS-001|Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy|A Prospective, Open-Label, Single-Arm, Single-Site, Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy.||McMaster University|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|N/A|No|||April 2015|April 7, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885741||64028|
NCT01886014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|placebo_oxy|The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers|The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers Using a Double-blind Design||Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01886014||64007|
NCT01886248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antithrombin-III|Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation|Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation||Seoul National University Hospital|No|Active, not recruiting|June 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|N/A|65 Years|No|||May 2015|November 17, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01886248||63989|
NCT01882270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2846|Third Molar Clinical Trials: Pericoronitis Studies|Pericoronitis; Oral and Systemic Inflammation||University of North Carolina, Chapel Hill|No|Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|115|Samples Without DNA|GCF samples. biofilm samples serum samples|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar        with adjacent 2nd molar with recommended treatment being removal of 3rd molars.|February 2014|February 6, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882270||64295|
NCT01882517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL_2010_024|Lipid-lowering Effect of Plant Stanol Yogurt|The Cholesterol Lowering Efficacy of Plant Stanol Ester Yoghurt in a Turkish Population||Raisio Group|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882517||64276|
NCT01882543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQX-1125-201|Efficacy and Safety of AQX-1125 in IC/BPS|A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway|LEADERSHIP|Aquinox Pharmaceuticals, Inc.|No|Completed|June 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|75 Years|No|||November 2015|November 20, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882543||64274|
NCT01883440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOcoldSY2013|Glucose Oxidase as Treatment Against Common Cold|A Placebo Controlled Study With a Nasal Spray Containing Glucose Oxidase, Aiming to Induce a Faster Recovery From an Episode of Common Cold||Umeå University|Yes|Completed|January 2013|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|April 23, 2013||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01883440||64205|Viral samplings were made in order to exclude persons with no viral infection and persons with influenza. Most common Colds are due to Rhinoviruses, Parainfluenza and Coronaviruses. These persons were included in the Groups with significant findings.
NCT01875185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00079522|Hormones Inflammation and Thrombosis|Hormones Inflammation and Thrombosis|HIT2|Johns Hopkins University|No|Recruiting|December 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|June 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875185||64837|
NCT01884194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTB_0305_outcome|Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging|Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging||Charite University, Berlin, Germany|No|Completed|November 2013|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|80|||Both|N/A|50 Years|No|Non-Probability Sample|pediatric patients with retinoblastoma|December 2015|December 28, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01884194||64147|
NCT01884207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCOT_03_05|Multiparametric Characterization of Orbital Tumors by MRI|||Charite University, Berlin, Germany||Completed|May 2013|December 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|patients with orbital tumors|December 2015|December 22, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01884207||64146|
NCT01884727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1675|Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans|A Randomized, Cross-Over Clinical Trial to Evaluate the Acute Effects of ASEA on Energy Expenditure and Fat Oxidation in Humans||University of North Carolina, Chapel Hill|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884727||64106|
NCT01874054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-016|Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma|A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)||Seattle Genetics, Inc.|No|Active, not recruiting|June 2013|December 2017|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01874054||64924|
NCT01874314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0079|Effects of SQ109 on QTc Interval in Healthy Subjects|Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|March 20, 2014|May 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874314||64904|
NCT01883882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43641-B|Pilot Trial of Opioid Taper Support|Pilot Randomized Trial of Opioid Taper Support|POTS|University of Washington|Yes|Active, not recruiting|June 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883882||64171|
NCT01884142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ergoreflex|Effects of Exercise Training on Mechanoreflex and Metaboreflex Control in Heart Failure Patients|Effects of Exercise Training on Mechanoreflex and Metaboreflex Control of Muscle Sympathetic Nerve Activity in Heart Failure Patients||University of Sao Paulo General Hospital|No|Active, not recruiting|March 2008|October 2013|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|30 Years|65 Years|No|||June 2013|September 5, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01884142||64151|
NCT01884155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBStroke|Allogeneic Umbilical Cord Blood Therapy for Stroke|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Patients With Stroke||Bundang CHA Hospital|No|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||January 2014|January 8, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884155||64150|
NCT01883297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TILs-001-DC|"Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||University Health Network, Toronto|Yes|Recruiting|January 2015|December 2023|Anticipated|June 2023|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883297||64216|
NCT01883648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Byrd AD-001|Study to Evaluate Coconut Oil for Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, 6 Month Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects With Mild to Moderate Alzheimer's Disease||University of South Florida|Yes|Recruiting|June 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|55 Years|90 Years|No|||August 2015|September 16, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01883648||64189|
NCT01883856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16051|Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves|Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves||University of Virginia|No|Recruiting|February 2012|June 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|80 Years|No|||December 2014|December 15, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883856||64173|
NCT01884103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CE002175|Field Triage of Older Adults Who Experience Traumatic Brain Injury|Field Triage of Older Adults Who Experience Traumatic Brain Injury||University of Rochester|No|Active, not recruiting|June 2013|May 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Emergency Medical Service (EMS) providers who transport injured older adult patients to        any of the participating Emergency Departments in Rochester, NY.|December 2015|December 21, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01884103||64154|
NCT01884922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003005-10 Phase I|Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults|PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA|VINILO|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|May 2013|May 2019|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Months|20 Years|No|||January 2016|January 31, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884922||64091|
NCT01885208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3624|Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)|SUSTAIN™ 3|Novo Nordisk A/S|No|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|813|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885208||64069|
NCT01884935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS328|PK and PD Study of Natalizumab in Pediatric Subjects With RRMS|A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)||Biogen|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|17 Years|No|||January 2015|January 15, 2015|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884935||64090|
NCT01885234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM-HAS120008|Aerobic Training in Pregnant Women With Gestational Diabetes and Chronic Hypertension|Aerobic Training Effect in Pregnant Women With Gestational Diabetes and Chronic Hypertension: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Completed|December 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|9|||Female|20 Weeks|27 Weeks|Accepts Healthy Volunteers|||December 2015|December 21, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01885234||64067|
NCT01885468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1106|X-Ray Verified Accuracy of the proGAV Verification Instrument|X-Ray Verified Accuracy of the Aesculap - Miethke proGAV Adjustable Shunt Pressure Setting Verification Instrument|X-AMIN|Aesculap, Inc.|No|Recruiting|May 2013|||September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Probability Sample|Hydrocephalus patients implanted with proGAV shunt requiring adjustment|March 2015|March 5, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01885468||64049|
NCT01885455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF 01414|Improving Resection Rates Among African Americans With NSCLC|Improving Resection Rates Among African Americans With NSCLC||Wake Forest NCORP Research Base|Yes|Recruiting|January 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|No|||February 2016|February 8, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01885455||64050|
NCT01885754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20878|Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer|Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer.||Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Yes|Recruiting|February 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|56|Samples Without DNA|Quadriceps Biopsy|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with NSCLC|March 2016|March 14, 2016|February 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01885754||64027|
NCT01885767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTF001|Neurofibromatosis (NF) Registry Portal|Neurofibromatosis (NF) Registry Portal Funded by Children's Tumor Foundation||The Children's Tumor Foundation|No|Recruiting|June 2012|June 2050|Anticipated|June 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||3|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Patients affected with NF1, NF2, or Schwannomatosis|January 2016|January 26, 2016|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01885767|50 Years|64026|
NCT01886027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU-022413B3E|Stress Management for Irritable Bowel Syndrome|Stress Management for Irritable Bowel Syndrome||Wayne State University|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|70 Years|No|||May 2015|May 5, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01886027||64006|
NCT01886261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111274/ 121378|Validation of Objective Measures of Place-Based Physical Activity|Validation of Objective Measures of Place-Based Physical Activity||University of California, San Diego|No|Completed|September 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Validation Study: We will be recruiting 40 primarily Spanish speaking, adults from various        community locations throughout San Diego County.        Usability Testing:        Recruiting research staff member from the SDSU Fe en Accion research study to participate        in usability testing.        Added Value Cohort: Fe en Accion Participants of the Fe en Accion cohort.|December 2014|December 3, 2014|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01886261||63988|
NCT01882283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10205345-A2|Effects of Black Tea Intake on Serum Lipids|Effects of Black Tea Intake on Serum Lipids in Mildly Hypercholesterolemic Adults A Randomized Diet-controlled Crossover Trial||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2002|||April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|57|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882283||64294|
NCT01883401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE1015|Chronic Effects of Freeze-Dried Strawberry Beverage on Cardiovascular Risk Factors|Chronic Effects of Freeze-dried Strawberry Beverage on Cardiovascular Risk Factors in Subjects With Abdominal Adiposity and Dyslipidemia.||Oklahoma State University|Yes|Completed|April 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|60|||Both|19 Years|72 Years|No|||June 2013|June 19, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01883401||64208|
NCT01875510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.4.İSM.4.06.68.49/144|The Influence of Fish-oil Lipid Emulsions on Neonatal Morbidities|The Effect of Fish-oil Lipid Emulsions on Neonatal Cholestasis and Retinopathy of Prematurity||Dr. Sami Ulus Children's Hospital|No|Completed|January 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|N/A|3 Days|No|||June 2014|June 5, 2014|May 31, 2013||No||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01875510||64814|The limitation of our study is that participants are mostly above 1000 grams. It was a single center study and DHA levels were not measured.
NCT01884220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDN6706|Wolman/CESD Natural History Chart Review and Longitudinal Follow-Up|A Historical Chart Review and Longitudinal Follow-Up of Identified Patients With Wolman Disease or Cholesteryl Ester Storage Disease, Lysosomal Acid Lipase Deficiency||Children's Hospital Medical Center, Cincinnati|No|Completed|November 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|4|None Retained|No biospecimens will be collected specifically for this study. However, participants are      encouraged to send left over biopsy material to the study site for analysis at a later date.|Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited initially from the PIs patient population. Other physicians may        refer their patients to this study for inclusion.|July 2015|July 27, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01884220||64145|
NCT01904929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASILLAS TML 400m 2013|The 400m-walk-test for Stable Coronary Patients|Evaluation of the Psychometric Properties of the 400m-walk-test at a Self-selected Speed (400m WT) for Stable Coronary Patients|TML 400 m|Centre Hospitalier Universitaire Dijon|No|Recruiting|June 2013|||June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|65|||Both|55 Years|N/A|No|||July 2013|July 17, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01904929||62558|
NCT01904942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUCOROY PHRC K 2010|Study of Hepatocellular Carcinoma in Cirrhotic Patients|Study of Hepatocellular Carcinoma in Cirrhotic Patients|CIRCE ProSpec|Centre Hospitalier Universitaire Dijon||Completed|October 2008|||June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|600|||Both|35 Years|70 Years|No|Probability Sample|patient|July 2013|July 17, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01904942||62557|
NCT01904955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faivre PHRC K 2010|Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort|||Centre Hospitalier Universitaire Dijon||Completed|September 2010|||February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|598|||Both|N/A|N/A|No|Probability Sample|patients with adenocarcinoma of the colon or rectum|July 2013|December 10, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01904955|1 Day|62556|
NCT01883687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-0546C|Functional Nasal Surgery at the Time of Le Fort I Osteotomy: A Prospective, Single-blind, Randomized Trial|Functional Nasal Surgery at the Time of Le Fort I Osteotomy: A Prospective, Single-blind, Randomized Trial||Chang Gung Memorial Hospital|Yes|Not yet recruiting|June 2013|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|N/A|No|||April 2013|June 19, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01883687||64186|
NCT01883895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0805|Exercise-induced Hypoaglesia After Comparative Forms of Exercise|Exercise-induced Hypoaglesia After Comparative Forms of Anaerobic Training in Healthy Adults||University of Wisconsin, Madison|Yes|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01883895||64170|
NCT01884168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMCEI|Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy|Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy||Capital Medical University|No|Recruiting|March 2013|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|The malignant tumor patients present with malignant cavity effusion and can receive DC-CIK        immunotherapy.|January 2016|January 27, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884168||64149|
NCT01884415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPATOTRAS|Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis|Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation||Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|89|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884415||64130|
NCT01884649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEAH-1|Fetuin A in Hashimoto Thyroiditis|Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis||Istanbul Medeniyet University|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||2|Actual|97|||Both|20 Years|N/A|No|Probability Sample|Patients ≥ 20 years of age being followed up at the outpatient clinics of the Internal        Medicine Department in Medeniyet University Goztepe Training and Research Hospital and        fulfilling the below mentioned criteria were included in the study|June 2013|June 21, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01884649|1 Day|64112|
NCT01884948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omegaven - Zurich|Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection|A Randomized, Double-blind Study of the Effects of Omega-3 Fatty Acids (Omegaven™) on Outcome After Major Liver Resection||University of Zurich|Yes|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01884948||64089|
NCT01884961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST172.03|Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2|Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response|IL2HD|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884961||64088|
NCT01885247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-746|4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice|4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice|OBALPA|Hospices Civils de Lyon|No|Not yet recruiting|June 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|40 Years|75 Years|No|Non-Probability Sample|Patients with Obstructive Chronic BronchoPneumopathy (OCBP) stage ≥ 2|June 2013|June 19, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01885247||64066|
NCT01885481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1304-199-001|Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone|Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone in Patients With Spinal Pain: a Prospective, Randomized, Double-blind Study||Seoul National University Bundang Hospital|No|Completed|October 2013|April 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|600|||Both|19 Years|N/A|No|||May 2015|May 20, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885481||64048|
NCT01885793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00107|Cuff Pressure in Patients: Manometer vs Invasive Pressure Monitoring Setup|||Nationwide Children's Hospital|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|220|||Both|N/A|N/A|No|Non-Probability Sample|Surgical patients that require endotracheal intubation.|February 2015|February 24, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885793||64024|
NCT01886040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102058-E|Factors Affecting the Prognosis of Patients With Endometrial Cancer|||Far Eastern Memorial Hospital||Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|20 Years|99 Years|No|Non-Probability Sample|the cases with endometrial cancer|February 2016|February 22, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886040||64005|
NCT01886053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTDQ04104-CTF|A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|A Phase II Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|189|||Both|18 Years|70 Years|No|||June 2013|June 19, 2013|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01886053||64004|
NCT01886274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine_tDCS|Does tDCS is Effective in the Prophylactic Treatment of Migraine|Transcranial Direct Current Stimulation in the Visual Cortex of Migraine Patients: Neurophysiological and Clinical Implications||Universidade Federal de Pernambuco|Yes|Recruiting|October 2012|October 2014|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01886274||63987|
NCT01886287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17410|P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome|Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|December 2013|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|June 21, 2013|Yes|Yes|Slow accrual|No|January 6, 2015|https://clinicaltrials.gov/show/NCT01886287||63986|This study was closed early due to slow accrual. There were no evaluable participants at 6 months for the planned Progression Free Survival measure.
NCT01883128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA135089|FOcal RECurrent Assessment and Salvage Treatment|An Evaluation of a Novel Imaging Based Complex Diagnostic and Therapeutic Pathway Intervention for Men Who Fail Radiotherapy for Prostate Cancer.|FORECAST|University College London Hospitals|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|177|||Male|18 Years|N/A|No|||January 2014|January 2, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883128||64229|
NCT01883141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSPOT|Left Ventricular MultiSpot Pacing for CRT (iSPOT)|Left Ventricular MultiSpot Pacing for CRT (iSPOT)|iSPOT|Medtronic Bakken Research Center|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01883141||64228|
NCT01875835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMUOCT-STEMI|Evaluation of Neointimal Coverage of EES and BMS After Implantation in STEMI Patients by Optical Coherence Tomography|Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography|NeoCover|Harbin Medical University|No|Recruiting|June 2013|December 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2013|June 25, 2013|June 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01875835||64789|
NCT01875848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-184|Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain|Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain|Bup|VA Office of Research and Development|Yes|Active, not recruiting|December 2013|July 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875848||64788|
NCT01883921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS1-13-002|Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)|Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data in Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)||AxelaCare Health Solutions, LLC|No|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|7 Years|N/A|No|Non-Probability Sample|Any patient who is aged 7 years or greater at time of enrollment; who is on Ig therapy,        have been on or is between doses of Ig therapy, or is being considered to be prescribed Ig        therapy; provides informed consent for participation; and who has been determined to be        eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration with        the patient's prescribing physician. Subjects will be recruited from the practices of        participating physicians.|January 2016|January 4, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01883921||64168|
NCT01883934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FREDS|Frozen Embryo Donation Study|Increasing the Use of Donated Embryos: A Demonstration|FREDS|Boston IVF|No|Completed|September 2011|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|3568|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01883934||64167|
NCT01883947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-494-32M|Effects of Touch Massage in the Sub-acute Phase After Stroke|Touch Massage in the Sub-acute Phase After Stroke - Does it Have Impact on General Health and Independence?|MEST|Umeå University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|N/A|No|||May 2015|May 26, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01883947||64166|
NCT01883960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1732B|A Longitudinal Study of Motor Control and Brain Images in Patients With Brain Damage|A Longitudinal Study of Motor Control and Brain Images in Patients With Brain Damage: Clinical Measures and Multimodel Imaging Studies||Chang Gung Memorial Hospital|Yes|Completed|September 2010|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|||Both|6 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|CP and CVA, and healthy children, and adults|June 2011|February 10, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01883960||64165|
NCT01904500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040497|Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida|Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida||University of Pittsburgh||Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 15, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01904500||62591|
NCT01875900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-399 ex 12/13|Instructor-led Simulation Training Versus Self-directed Simulator Training During Simulated Neonatal Resuscitation|Instructor-led Simulation Training Versus Self-directed Simulator Training During Simulated Neonatal Resuscitation - A Randomized Controlled Trial||Medical University of Graz|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|38|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01875900||64784|
NCT01883908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00053319|Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer|A Pilot Randomized Controlled Trial to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer.|GCC1229|University of Maryland|Yes|Terminated|December 2012|February 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|4|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|March 13, 2013|No|Yes|The project is terminated due to that fact that the PI has moved to another institution and    there are no resources to keep the study open in either institution.|No|April 21, 2015|https://clinicaltrials.gov/show/NCT01883908||64169|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.
NCT01884454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSAR01|SLEEP AND OSA ON REPRODUCTIVE FUNCTION IN MEN|EFFECTS OF SLEEP LOSS AND OBSTRUCTIVE SLEEP APNEA SYNDROME ON REPRODUCTIVE FUNCTION IN MEN|PSAR01|Federal University of São Paulo|Yes|Completed|June 2013|September 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|60|||Male|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inclusion Criteria:          -  men          -  There is no discrimination of economic class          -  Age between 25 and 50          -  BMI 30 kg/m2          -  No prior neurological, psychiatric or use of psychotropic medication          -  OSA (moderate and severe apnea hypopnea index > 15)        Exclusion Criteria:          -  smokers          -  addiction          -  Individuals with another sleep disorder|February 2016|February 2, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01884454||64127|
NCT01884428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2010-003|Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma|Phase I, Prospective, Open-label, Multi-centric, Dose Finding Trial of Combination of IGEV and Panobinostat Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma||Istituto Clinico Humanitas|No|Recruiting|July 2011|December 2015|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||January 2014|January 28, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01884428||64129|
NCT01884662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N110008VWalking|Virtual Walking for Neuropathic Pain in Spinal Cord Injury|Virtual Walking for Reducing Spinal Cord Injury-Related Neuropathic Pain||University of Alabama at Birmingham|No|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01884662||64111|
NCT01885507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0127|Mechanical Ventilation in Brain-injured Patients|Duration of Mechanical Ventilation and Mortality Among Brain-injured Patients - a Before-after Evaluation of a Quality Improvement Project|BI-VILI|Nantes University Hospital|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|560|||Both|18 Years|N/A|No|Non-Probability Sample|Structural coma.|January 2015|February 19, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885507||64046|
NCT01885520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-EPT-PK-02|Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg|A Randomized,Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg After Oral Administration in Healthy Adult Male Subjects.|eperisone|Navipharm Corporation|No|Completed|July 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01885520||64045|
NCT01885806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 15388913.6.0000.5149|Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease|Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study||Federal University of Minas Gerais|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|85 Years|No|||June 2013|June 24, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01885806||64023|
NCT01885494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF008E|AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A|AFF008E:Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE® PD01A Applied During AFF008 in Patients With Parkinson's Disease.||Affiris AG|Yes|Completed|June 2013|||February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|Samples With DNA|Analyzing patients' DNA (isolated out of whole blood) for polymorphisms in genes/regions      like REP1 or alpha-synuclein to correlate results with the progression rate of the disease.|Both|41 Years|66 Years|No|Non-Probability Sample|Only participants of AFF008 will be offered participation in AFF008E.|August 2015|August 14, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01885494||64047|
NCT01885780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Prospective Evaluation of the Effectiveness of the Femtosecond Laser-assisted Refractive Astigmatic Keratotomy.|Phase IV Study_Prospective Evaluation of the Effectiveness of the Femtosecond Laser-assisted Refractive Astigmatic Keratotomy Following the Cataract Surgery.||Technolas Perfect Vision GmbH|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|40 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 30, 2014|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01885780||64025|
NCT01882296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGSPT_PD|Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects|A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects|AGSPT_PD|Ahn-Gook Pharmaceuticals Co.,Ltd|Yes|Not yet recruiting||||September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|June 19, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882296||64293|
NCT01882309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-016|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||March 19, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882309||64292|
NCT01882556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0808-16319|Early Use of Botulinum Toxin in Spasticity Post Stroke.|Is it Clinically Effective to Treat Arm Flexor Spasticity, With Botulinum Toxin - Type A (BoNTA) and Physiotherapy, as Soon as Signs of Abnormal Muscle Activity Are Observed?|EUBoSS|Sandwell & West Birmingham Hospitals NHS Trust|No|Completed|January 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882556||64273|
NCT01882816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-070|Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer|A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882816||64253|
NCT01883115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILTelescopic|A Prospective Study Comparing Telescopic vs. Balloon Dissection in Single Incision Laparoscopic Inguinal Herniorraphy (SILTELESCOPIC)|A Prospective Study Comparing Telescopic vs. Balloon Dissection in Single Incision Laparoscopic Inguinal Herniorraphy (SILTELESCOPIC)|SILTelescopic|The Sydney Hernia Specialists Clinic|Yes|Recruiting|February 2013|April 2015|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|102|||Both|16 Years|86 Years|No|Probability Sample|All eligible patients referred with inguinal/femoral hernias from February 2013 will be        enrolled into the study|April 2014|April 3, 2014|June 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01883115|12 Months|64230|
NCT01882842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12GY005|A Study to Assess if Scratching the Lining of the Womb Prior to IVF Treatment Increases the Chances of Pregnancy|The Efficacy of Endometrial Biopsy on the Outcome of In Vitro Fertilization (IVF) /Intra-Cytoplasmic Sperm Injection (ICSI) Treatment (Endoscratch): A Feasibility Pilot Study||Nottingham University Hospitals NHS Trust|No|Recruiting|February 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|49 Years|No|||June 2013|June 18, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01882842||64251|
NCT01882855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03729|Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy|Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy||New York University School of Medicine|Yes|Withdrawn|December 2012|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|Blood samples|Both|18 Years|70 Years|No|Non-Probability Sample|At least fifty subjects will be included in this study, including screening failures.        There will be an equitable inclusion of both men and women in this study. Subjects must be        between the ages of 18 and 70 to participate in this study. There is no restriction on        race or ethnicity in this study. An effort will be made to recruit a diverse sample of        participants.|March 2016|March 10, 2016|May 1, 2013||No|Dr. Sigal no longer with NYUMC|No||https://clinicaltrials.gov/show/NCT01882855||64250|
NCT01883713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 12-015|Study of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilution in Heart Surgery Patients|A Prospective Analysis of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilutional Anemia in Patients Undergoing Heart Surgery||St. Michael's Hospital, Toronto|Yes|Recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Plasma will be retained for analysis of plasma erythropietin, hepcidin and and      nitrate/nitrite levels|Both|18 Years|65 Years|No|Non-Probability Sample|heart surgery with cardiopulmonary bypass|November 2014|November 20, 2014|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883713||64184|
NCT01883726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-1267C|Comparison of Two Nasoalveolar Molding Techniques in Complete Unilateral Cleft Lip Patient|Comparison of Two Nasoalveolar Molding Techniques in Complete Unilateral Cleft Lip Patient|NAM|Chang Gung Memorial Hospital|Yes|Enrolling by invitation|May 2010|July 2013|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|3 Months|No|||April 2013|June 19, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01883726||64183|
NCT01876342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27/2013|TEP Versus Open Repair of Sportsman's Hernia|Total ExtraPeritoneal (TEP) Versus Open Minimal Suture Repair for Treatment of Sportsman's Hernia/Athletic Pubalgia: A Randomized Multi-center Trial|sports hernia|Kuopio University Hospital|No|Recruiting|June 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||August 2015|August 17, 2015|June 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01876342||64750|
NCT01883739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 00037475|Randomised Controlled Trial to Investigate the Effect of Parental Presence at Intensive Care Unit to Ward Transfer Bedside Rounds on Parental Anxiety and Children's Safety|Randomised Controlled Trial to Investigate the Effect of Parental Presence at Intensive Care Unit to Ward Transfer Bedside Rounds on Parental Anxiety and Children's Safety||University of Alberta|No|Completed|June 2013|||July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01883739||64182|
NCT01876888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physiotherapy & Rehabilitation|Turkish Cultural Adaptation, Validation and Reliability Study of MedRisk Instrument|Turkish Version of MedRisk Instrument for Measuring Patient Satisfaction With Physical Therapy Care: Its Cultural Adaptation, Validation and Reliability Study||Hacettepe University|No|Completed|April 2011|March 2013|Actual|September 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|317|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients from various regions in Turkey who were receiving outpatient physiotherapy        programs.|June 2013|June 12, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01876888|15 Days|64708|
NCT01877109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-056|Samsung Medical Center-Lymphoma Cohort Study-II|Prospective Observation Cohort Study of Malignant Lymphoma Patients|SMC-LCS-II|Samsung Medical Center|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|1. Serum        2. Tissue specimen        3. DNA from peripheral blood mononuclear cells|Both|19 Years|N/A|No|Probability Sample|Newly visited lymphoma patients at the Samsung Medical Center|June 2013|June 10, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01877109|5 Years|64691|
NCT01876121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX-05|Celecoxib Japan Observational Study for the Patients With Acute Pain|Celecoxib Japan Observational Study for the Patients With Acute Pain||Astellas Pharma Inc|No|Completed|July 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|784|||Both|N/A|N/A|No|Non-Probability Sample|Patients with traumatic pain, post-surgical pain and tooth extract pain|September 2014|September 4, 2014|June 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01876121||64767|
NCT01885273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRS001|Is Pressurized Irrigation an Effective Alternative to Swabbing for Wound Cleansing?|A Multicenter, Prospective, Randomised Controlled Trial to Compare the Pressurized Irrigation Method With Conventional Practice of Swabbing for Wound Cleansing||Prince of Wales Hospital, Shatin, Hong Kong|No|Completed|April 2008|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|256|||Both|14 Years|75 Years|No|||June 2013|June 20, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885273||64064|
NCT01885533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110269|Post-Radioiodine Graves' Management: The PRAGMA-Study|POST-RADIOIODINE GRAVES' MANAGEMENT|PRAGMA|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|March 2013|December 2015|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|750|||Both|18 Years|N/A|No|Probability Sample|Adult patients with a history of Graves' disease treated with radioiodine|October 2015|October 7, 2015|February 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01885533||64044|
NCT01884441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2010-002|Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Study With Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Before High Dose Chemotherapy With Autologous Hematopoietic Stem Cells Transplant||Istituto Clinico Humanitas|No|Recruiting|July 2011|July 2016|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01884441||64128|
NCT01884675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115811|Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.|A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).|AMBER I|GlaxoSmithKline|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|80 Years|No|||October 2015|November 12, 2015|June 20, 2013|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01884675||64110|
NCT01884688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138826|UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma|A Phase II Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma||University of Arkansas|Yes|Recruiting|April 2013|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884688||64109|
NCT01884701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVO-031|Accessing Peripheral Occluded LesiOns II (APOLO-II)|Accessing Peripheral Occluded LesiOns II (APOLO-II)|APOLO-II|EndoCross Ltd.|No|Active, not recruiting|June 2013|||December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Both|21 Years|N/A|No|||March 2015|March 11, 2015|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884701||64108|
NCT01886339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/117/1031|SNIF (Sniff Nasal Inspiratory Force) Reference Values Of Mediterranean Population|SNIF (Sniff Nasal Inspiratory Force) REFERENCE VALUES OF MEDITERRANEAN POPULATION.|SNIF REF V|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|June 2010|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|February 2014|February 21, 2014|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01886339||63982|
NCT01882322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-LT-01|A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects|A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Advagraf® (Modified Release Tacrolimus, Once Daily) After Using Prograf® (Tacrolimus Twice Daily) in de Novo Liver Transplant Recipients|Maple|Astellas Pharma Inc|No|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|20 Years|65 Years|No|||November 2015|November 4, 2015|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01882322||64291|
NCT01886300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27807|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam|A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating Sustained Response in Subjects With HBeAg Positive Chronic Hepatitis B Receiving Therapy With Pegasys (Peginterferon Alfa-2a) in Vietnam||Hoffmann-La Roche||Terminated|September 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|Patients with HBeAg-positive chronic hepatitis B treated with Pegasys|November 2015|November 2, 2015|June 21, 2013||No|Due to out-of-date design and non-compliance.|No||https://clinicaltrials.gov/show/NCT01886300||63985|
NCT01886313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-07-01|Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve|A DOUBLE BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP EVALUATION OF CIVAMIDE (ZUCAPSAICIN) 0.01% AND VEHICLE NASAL SPRAYS IN THE TREATMENT OF POSTHERPETIC NEURALGIA OF THE TRIGEMINAL NERVE||Winston Laboratories|No|Terminated|March 2014|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|21 Years|80 Years|No|||December 2015|December 7, 2015|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886313||63984|
NCT01882829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0389|Nuedexta in Treatment-Resistant Major Depression|Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression||Icahn School of Medicine at Mount Sinai|No|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882829||64252|
NCT01883154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|loe135673ctil|The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome|The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome||Meir Medical Center|No|Not yet recruiting|September 2013|September 2023|Anticipated|September 2017|Anticipated|N/A|Observational|N/A||4|Anticipated|160|Samples With DNA|placental tissue ,fetal cord blood and maternal blood.|Both|N/A|N/A|No|Non-Probability Sample|Samples from pregnancies complicated with IUGR, Gestational and pre gestational Diabetes,        placentas from IVF pregnancies and from normal pregnancies. We intend to assess these        factors in placental tissue, in cord blood and maternal blood.|June 2013|June 19, 2013|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01883154||64227|
NCT01883414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-136 Avram|Feasibility Study: Evaluation of the Ulthera® System for Improvement of Surgical Scars.|Feasibility Study: Evaluation of the Ulthera® System for Improvement of Surgical Scars.||Ulthera, Inc|No|Terminated|June 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|June 18, 2013|Yes|Yes|Lack of resources to manage trial; lack of efficacy.|No||https://clinicaltrials.gov/show/NCT01883414||64207|
NCT01883427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GObarn2013|Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children|Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms||Umeå University|No|Completed|October 2012|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|3 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 23, 2013||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01883427||64206|We wanted 200 Children but only 40 fulfilled the study, which make the results hard to evaluate.
NCT01886391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179-09-FB|Health Behavior-Related Outcomes With Diaphragmatic Breathing Retraining in Heart Failure Patients|Health Behavior-Related Outcomes With Diaphragmatic Breathing Retraining in Heart Failure Patients||University of Nebraska|Yes|Withdrawn|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|0|||Both|19 Years|N/A|No|||January 2014|January 7, 2014|June 17, 2013||No|Major changes in study required new IRB application and approval|No||https://clinicaltrials.gov/show/NCT01886391||63978|
NCT01883167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-105|RDEA3170 and Febuxostat Drug Interaction Study|A Phase 1 Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Febuxostat in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|June 2013|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|21|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01883167||64226|
NCT01885897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS023|IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT|IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|November 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885897||64016|
NCT01876095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM-NHR study|Discontinuing Inappropriate Medication in Nursing Home Residents|Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial||University of Groningen|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1027|||Both|N/A|N/A|No|||December 2015|December 9, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876095||64769|
NCT01875913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F24176-101|The Power of Curiosity: Leveraging Curiosity to Motivate People to Complete Health Risk Assessments|The Power of Curiosity||Harvard University|No|Enrolling by invitation|June 2013|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|25000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 10, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875913||64783|
NCT01876420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT10093773DOC|The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study|The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study||Medtronic Cardiovascular|No|Active, not recruiting|October 2013|September 2016|Anticipated|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||October 2015|October 29, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01876420||64744|
NCT01876147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxfordVA2013|Visual and Functional Assessment in Low Vision Patients|A Randomised Crossover Study to Assess the Usability of Two New Vision Tests in Patients With Low Vision, and Relationship of the Measures to Daily Living Tasks.||University of Oxford|No|Active, not recruiting|June 2013|December 2016|Anticipated|March 2016|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with low vision attending outpatient clinics in Oxford Eye Hospital.|March 2016|March 16, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876147||64765|
NCT01884740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202012214|Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22|Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age||Weill Medical College of Cornell University|Yes|Recruiting|June 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|21 Years|No|||March 2016|March 16, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884740||64105|
NCT01884714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10AP033|Diabetes Risk Assessment Study|New and Innovative Bioanalytical Tools to Assess Lifestyle Recommendations for Managing Type-2 Diabetes|DRA|University of Guelph|No|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 19, 2014|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884714||64107|
NCT01884974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0060-CTIL|A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.|A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.|PH-MPD1|Carmel Medical Center|Yes|Recruiting|July 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|patients diagnosed with Myeloproliferative disease and followed up at the Carmel        Hematology Unit|June 2015|June 15, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01884974||64087|
NCT01885260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 449884-CS2|Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes|A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin||Ionis Pharmaceuticals, Inc.|No|Completed|July 2013|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|75 Years|No|||November 2013|November 21, 2014|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885260||64065|
NCT01886066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0257-C|Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer|Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer: A Prospective Trial|EndoSLN|University Health Network, Toronto||Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01886066||64003|
NCT01886079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0194|The Effects of Dexmedetomidine on Postoperative Renal Function in Valvular Heart Surgery|||Yonsei University||Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|90 Years|No|||June 2013|June 20, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01886079||64002|
NCT01886326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912008773|Eating Peanuts for Health|Peanut Consumption and Human Weight Management||Purdue University|Yes|Completed|February 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|196|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01886326||63983|
NCT01885832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-SVF-OA-002-2013|Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis|Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis||Translational Biosciences|Yes|Withdrawn|June 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|June 18, 2013||No|per sponsor decision|No||https://clinicaltrials.gov/show/NCT01885832||64021|
NCT01882569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24014|Optimization of Time-of-Flight Mass Cytometry (CyTOF) Analysis for Evaluation of Immune Changes Following Surgery|Detection of Immune Changes as a Result of Surgical Trauma in Human Back Surgery Subjects: Optimization of CyTOF Analysis||Stanford University|No|Active, not recruiting|May 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Generally healthy patients undergoing back surgery|June 2013|June 18, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882569||64272|
NCT01882582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25292|Evaluation of Immune Signaling Networks in Healthy Human Volunteers|Evaluation of Immune Signaling Networks in Healthy Human Volunteers||Stanford University|No|Active, not recruiting|August 2012|January 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Study population consists of a community sample.|June 2013|June 18, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882582||64271|
NCT01886352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/089|Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).|Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).|IPLA|University Hospital, Ghent|No|Recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01886352||63981|
NCT01882335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant # 0064-03|Saving Brain in Uganda and Burkina Faso|Saving Brains In Uganda And Burkina Faso (PROMISE Saving Brains)||Makerere University|Yes|Enrolling by invitation|April 2013|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|600|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||April 2013|August 1, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882335||64290|
NCT01882595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nebu Tracheo|Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient|Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|January 2009|September 2011|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|9|||Both|18 Years|80 Years|No|||June 2013|June 18, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882595||64270|
NCT01882608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107-2012|Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders|Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders|PATH-MOD|Sunnybrook Health Sciences Centre|No|Enrolling by invitation|October 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|14 Years|N/A|No|||April 2015|April 20, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882608||64269|
NCT01882660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44048.018.13|Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study|Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study|DECO|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|88|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01882660||64265|
NCT01883193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1672|Women First: Preconception Maternal Nutrition|Women First: Preconception Maternal Nutrition|WF|University of Colorado, Denver|Yes|Active, not recruiting|August 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|5760|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01883193||64224|
NCT01882881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE 107|Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors|Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors|CAS|Penn State University|No|Active, not recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|48|||Both|30 Years|70 Years|No|||January 2016|January 20, 2016|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01882881||64248|
NCT01885351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCRCS-302259|An Interactive Preventive Health Record to Increase Colorectal Cancer Screening|An Interactive Preventive Health Record to Increase Colorectal Cancer Screening|MyCRCS|Virginia Commonwealth University|No|Recruiting|August 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|832|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01885351||64058|
NCT01876641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304715|Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib|Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib|ML28604|University of Iowa|Yes|Recruiting|October 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01876641||64727|
NCT01876875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cataldi13|n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis|Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial.|PSO|Federico II University|Yes|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||October 2008|June 11, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01876875||64709|
NCT01876433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004805-29|Beta 3 Agonist Treatment in Heart Failure|Beta 3 Agonist Treatment in Heart Failure|Beat-HF|Rigshospitalet, Denmark|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876433||64743|
NCT01876719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR08.001|AR08 for Treatment of ADHD in Children|A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Proof-of-Concept Study of AR08 in the Treatment of Attention Deficit Hyperactivity Disorder in Children (Ages 6 - 17)||Arbor Pharmaceuticals, Inc.|No|Completed|June 2013|February 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|122|||Both|6 Years|17 Years|No|||November 2015|November 10, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876719||64721|
NCT01884467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210M21603|Gentamicin Bladder Instillation Trial|Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization||Gillette Children's Specialty Healthcare|No|Recruiting|May 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|16 Years|N/A|No|||April 2015|April 8, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01884467||64126|
NCT01874327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000607|Biomarkers of Developmental Trajectories and Treatment in Autism Spectrum Disorder (ASD)|Joint Engagement in Infants at Risk for ASD: Integrating Treatment With Biomarkers|BabyJ|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|72|||Both|12 Months|21 Months|No|||May 2014|November 16, 2014|October 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01874327||64903|
NCT01885819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-SVF-AR-002-2013|Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis|Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis||Translational Biosciences|Yes|Withdrawn|June 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|June 18, 2013||No|per sponsor decision|No||https://clinicaltrials.gov/show/NCT01885819||64022|
NCT01885000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29107|Patient-Reported Outcome Of Facial Erythema (PROOF)||PROOF|Galderma||Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885000||64085|
NCT01885286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAPSHCS-00434|Pilot Trial of Novel Circumcision Device|Simple Circumcision Device: Proof-of-Concept for a Single-visit, Adjustable Device to Facilitate Safe Adult Male Circumcision||VA Puget Sound Health Care System|Yes|Completed|September 2011|October 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 24, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885286||64063|
NCT01885546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAFPGM02|Accuracy Study for Enhanced Meter Feature|Accuracy Study for the Evaluation of Obtaining an Enhanced Meter Feature Using an AgaMatrix BGMS||AgaMatrix, Inc.|No|Completed|July 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|133|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|July 6, 2015|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01885546||64043|
NCT01886365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3388|Computerized Tight Glycemic Control in Cardiac Surgery|Perioperative Glycemic Control With a Computerized Algorithm vs. Conventional Glycemic Control in Cardio-surgical Patients Undergoing Cardiopulmonary Bypass With Blood Cardioplegia||Universitätsklinikum Hamburg-Eppendorf|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01886365||63980|
NCT01886378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX007-CL201|An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)|An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)||Ultragenyx Pharmaceutical Inc|Yes|Active, not recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Months|N/A|No|||December 2015|December 15, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886378||63979|
NCT01886092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1212-081-451|Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus|Verification of the Usefulness of the Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Tinnitus|rTMS|Seoul National University Hospital|Yes|Enrolling by invitation|May 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|70 Years|No|||September 2015|October 28, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01886092||64001|
NCT01883752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES01|Goal Directed Fluid Management Based on Non-invasive Monitoring|Goal-Directed Fluid Management Based on Non- Invasive Monitoring of Pulse Oximeter-Derived Pleth Variability Index||University of California, Irvine|Yes|Completed|July 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01883752||64181|
NCT01884493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC1-002|Electrophysiological Investigation and rTMS Intervention of Ambulatory Central Processing of Freezing of Gait in Parkinson's Disease|||China Medical University Hospital||Withdrawn|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|20 Years|85 Years|No|||January 2014|August 6, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884493||64124|
NCT01885598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-259|Eliquis Regulatory Post Marketing Surveillance|Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation||Bristol-Myers Squibb|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Non-Probability Sample|Patients visiting outpatient department of hospital|January 2016|January 14, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01885598||64039|
NCT01885325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD055451|Multi-component Intervention to Increase Physical Activity in Preschool Children|Multi-component Intervention to Increase Physical Activity in Preschool Children|SHAPES|University of South Carolina|No|Completed|August 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|708|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885325||64060|
NCT01885338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 2013-020208|N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia|Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia|NACSZ|VA Greater Los Angeles Healthcare System|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|June 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01885338||64059|
NCT01883466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMU-12-14031|Health Effects of Biodiesel Exhaust Exposure|Cardiovascular Effects of Exposure to 100% Biodiesel Exhaust in Man|BD100|Umeå University|No|Completed|September 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|19|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01883466||64203|
NCT01875172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA089510-01A2|Bupropion for Smoking Cessation in Pregnancy|Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion||Watching Over Mothers & Babies Foundation|Yes|Completed|October 2001|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|April 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875172||64838|
NCT01886170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817693|Using Patient Feedback to Improve Communication Regarding Glycemic Control to Patients With Diabetes|Using Patient Feedback to Improve the Ways we Communicate Information Regarding Glycemic Control to Patients With Poorly Controlled Diabetes||University of Pennsylvania|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01886170||63995|
NCT01877642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-204-402|ADASUVE-Lorazepam Drug-Drug Interaction|ADASUVE®-Lorazepam Drug-Drug Interaction Study|204-402|Alexza Pharmaceuticals, Inc.|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|June 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01877642||64650|
NCT01877902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-PEM-2013-06|Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System|STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|October 2011|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|190|||Both|N/A|N/A|No|Probability Sample|It will be included all patients diagnosed CPNMm participating centers to initiate        treatment with pemetrexed in 1st line (either induction or maintenance.|April 2014|December 4, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877902||64630|
NCT01876732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-024|Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients|Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients||Northwell Health|Yes|Completed|June 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|132|||Both|18 Years|90 Years|No|||September 2014|September 5, 2014|May 14, 2013||No||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01876732||64720|There were too few patients with MMA levels over 800 to determine sensitivity.
NCT01876953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12393|Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia|Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients||City of Hope Medical Center|Yes|Recruiting|September 2013|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01876953||64703|
NCT01876654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TruMatch01|Evaluation of the TruMatch® System in Knee Prosthetic Surgery|Evaluation of the TruMatch® Personalized Solutions System in Knee Prosthetic Surgery||University of Milan|No|Completed|June 2013|November 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|80 Years|No|||February 2016|February 16, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876654||64726|
NCT01885013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST174.04|Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients|Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients|MYME|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Completed|September 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Female|18 Years|75 Years|No|||December 2015|December 31, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885013||64084|
NCT01875861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 08-375|Monitoring and Management for Metabolic Side Effects of Antipsychotics|Monitoring and Management for Metabolic Effects of Antipsychotics|AMMP|VA Office of Research and Development|No|Active, not recruiting|January 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|103|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01875861||64787|
NCT01875874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-212|Safety and Efficacy of ELAD to Treat Acute Liver Failure (ALF)|An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)||Vital Therapies, Inc.|Yes|Terminated|October 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 5, 2013|Yes|Yes|Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and    the VTI-212 study has been terminated.|No||https://clinicaltrials.gov/show/NCT01875874||64786|
NCT01876355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cat1.1|The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients|The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients CATAPRES (Confusion and Alpha-Two Agonist Prescription Randomised Efficacy Study)|CATAPRES|Deventer Ziekenhuis|Yes|Not yet recruiting|January 2018|April 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876355||64749|
NCT01885299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSSearch Patient Registry|RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT|Multi-Institution Registry of SRS/SBRT Procedures||The Radiosurgery Society|No|Enrolling by invitation|March 2012|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|25000|||Both|N/A|N/A|No|Non-Probability Sample|Any patients who have a SRS/SBRT procedure|September 2014|July 29, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885299|20 Years|64062|
NCT01882621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM1-0324|Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients|A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients.||Sun Yat-sen University|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||July 2015|July 1, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01882621||64268|
NCT01882634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP041192|Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care|Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care|BarcelonAAA|Consorci d'Atenció Primària de Salut de l'Eixample|Yes|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1010|||Male|60 Years|N/A|No|||November 2014|November 5, 2014|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882634||64267|
NCT01882868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11885|A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan|A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen||Sanofi|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|20 Years|N/A|No|||November 2015|November 12, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882868||64249|
NCT01884259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_HNO 2|Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN|Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck|HNO-2|Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Recruiting|May 2013|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2015|July 9, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01884259||64142|
NCT01885039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913137|Breast Tissue Study of Breast Diseases Among Women in Hong Kong|Characterization of Molecular Subtypes of Breast Cancer and Their Relationships With Known Breast Cancer Risk Factors Among Chinese Women in Hong Kong - A Pilot Study||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|200|||Female|18 Years|100 Years|No|||February 2016|March 9, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885039||64082|
NCT01885585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-222|Eliquis Regulatory Post Marketing Surveillance (rPMS)|Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention||Bristol-Myers Squibb|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|19 Years|N/A|No|Non-Probability Sample|Primary care clinic Patients must be ≥19 years of age, at risk for venous thrombosis, and        have elected to undergo total hip replacement arthroplasty or total knee replacement        arthroplasty will be included in this study|February 2016|February 5, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01885585||64040|
NCT01886118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-12-24|A Trial Evaluating Autologous Endometrial Co-Culture Versus Conventional Medium in the Treatment of Infertility|A Randomized Trial Evaluating Autologous Endometrial Co-Culture Versus Conventional Medium in the Treatment of Infertility|OvoGEN|OVO R & D|Yes|Completed|March 2013|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|207|||Female|18 Years|38 Years|No|||December 2015|December 23, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01886118||63999|
NCT01884805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 483 03|Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)|Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)|HyperVOPTICA|University Hospital, Toulouse|No|Recruiting|March 2013|July 2016|Anticipated|February 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01884805||64100|
NCT01884818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thoracic|Thoracic Spine Manipulation for Patients With Thoracic Spine Pain|The Effect of Manipulation for Thoracic Spine Pain and Mobility, and Reliability of Used Mobility Measurements.||University of Jyvaskyla|No|Recruiting|August 2011|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|55 Years|No|||March 2016|March 18, 2016|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01884818||64099|
NCT01875523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2102|PK of Serelaxin in Severe Renal Impairment and ESRD|A Single Dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Serelaxin in Patients With Severe Renal Impairment or End-Stage Renal Disease on Hemodialysis Compared to Matched Healthy Control Subjects|CRLX030A2102|Novartis|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01875523||64813|
NCT01885624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB08/HS/R1|Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers|Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers||Theramab LLC|Yes|Completed|November 2011|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 2, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885624||64037|
NCT01885949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-073|Tivozanib + Enzalutamide in Adv Prostate Cancer|Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|June 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01885949||64012|
NCT01886144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402877|Effects of Bracing on Knee Osteoarthritis (OA)|Effectiveness of Decompressive and Stabilizing Knee Bracing in Individuals With Unicompartment Knee Osteoarthritis||Stony Brook University|No|Completed|July 2013|||May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|35 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who are currently living with Knee OA of one leg|May 2014|May 9, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01886144||63997|
NCT01885637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-016|DOMUS: A Trial of Accelerated Transition From Oncological Treatment to Continuing Palliative Care at Home|DOMUS: A Randomized Controlled Clinical Trial of Accelerated Transition From Oncological Treatment to Continuing Palliative Care at Home|DOMUS|Rigshospitalet, Denmark|No|Enrolling by invitation|June 2013|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|340|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01885637||64036|
NCT01876459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5330|Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.|Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.|AlphaLewyMa|University Hospital, Strasbourg, France||Recruiting|April 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|265|||Both|45 Years|N/A|No|||June 2013|June 17, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01876459||64741|
NCT01876745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-4030|A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan|A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan||Novo Nordisk A/S|No|Enrolling by invitation|October 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|All patients with GT, who are enrolled in this study and to whom activated recombinant        human factor VII (NovoSeven®) is administered in the study period, shall be included.|December 2015|January 21, 2016|May 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01876745||64719|
NCT01877005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIJAK|A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|HIJAK|The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|July 2013|May 2017|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877005||64699|
NCT01877343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300055|Developing a Non-invasive Cardiac Functional Health Status Measurement Device|Developing a Non-invasive Cardiac Functional Health Status Measurement Device to be Used in a Critical Population of Adults and Children With Heart Failure.||University of Florida|No|Terminated|June 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|7 Years|74 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 15, 2013||No|Challenges associated with study enrollment due to stress test, study terminated|No|February 20, 2015|https://clinicaltrials.gov/show/NCT01877343||64673|Early termination due concerns for severity of stress test on high risk patients. Only control and post-transplant groups had enrollment. Statistical analysis cannot be performed.
NCT01877356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|study B300201215548|Comparative Study Between Bilateral and Unilateral Spinal Anaesthesia|Unilateral Versus Bilateral Spinal Anesthesia in Day Case Procedures: Difference in Block Characteristics, Micturition Quality and Discharge Time||University Hospital, Antwerp|Yes|Terminated|December 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|60 Years|No|||April 2015|April 23, 2015|March 29, 2013||No|intermittent evaluation of results: high incendence of complications|No||https://clinicaltrials.gov/show/NCT01877356||64672|
NCT01877369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-1309-FAVHF-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2013|||||N/A|N/A|N/A||||||||||||||January 20, 2016|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01877369||64671|
NCT01875536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS_Physical Therapy_stroke|rTMS and Conventional Physical Therapy After Stroke|Efficacy of Coupling Repetitive Transcranial Magnetic Stimulation and Conventional Physical Therapy to Reduce Upper Limb Spasticity in Stroke Patients||Universidade Federal de Pernambuco|Yes|Completed|November 2011|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|75 Years|No|||June 2013|June 11, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01875536||64812|
NCT01875549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-014-002|Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent|Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a Large Cell Niti-S (LCD) Stent||Samsung Medical Center|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01875549||64811|
NCT01875887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cui_owen|Treatment of Bilateral Maxillofacial Post-traumatic Deformities|Application of Surgery Planning Software, Rapid Prototyping Model and Preshaped Titanium Plates in Treatment of Bilateral Maxillofacial Post-traumatic Deformities||West China Hospital|Yes|Completed|May 2008|April 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Male|18 Years|53 Years|Accepts Healthy Volunteers|Probability Sample|patients with Bilateral maxillofacial Post-traumatic Deformities|June 2013|June 7, 2013|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01875887||64785|
NCT01885026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1138-31/1|Substance-focused SBI as a Complement to Internet-based Psychiatric Treatment: RCT|Substance-use Focused Screening and Brief Intervention as a Complement to Internet-based Psychiatric Treatment for Depression, Panic Disorder or Social Phobia: A Randomized Controlled Trial|eScreeniPsy|Karolinska Institutet||Recruiting|July 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|15 Years|N/A|No|||August 2015|August 31, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885026||64083|
NCT01886105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1322|Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma|Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|65 Years|No|||February 2015|February 3, 2015|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01886105||64000|
NCT01883180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-201304-K1|ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis|Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|June 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|14 Years|65 Years|No|||September 2015|September 1, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01883180||64225|
NCT01883453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOcoldU&B2013|A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold|A Double Blinded Clinical Study Aiming to Shorten an Episode of Common Cold When the Treatment is Started at the Onset of an Episode of Common Cold||Umeå University|Yes|Completed|January 2013|September 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|October 9, 2015|April 23, 2013||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01883453||64204|Too few virus positive persons in order to get significant results. Local side effects were mild and about the same as in the placebo Group. Influensa season and few rhinovirus infections.
NCT01884766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 352/12|Copeptin in Childhood Epilepsy|Prospective Study on Copeptin in Childhood Epilepsy|EpiCop|University Hospital, Basel, Switzerland|Yes|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|350|Samples Without DNA|Serum|Both|N/A|5 Years|No|Non-Probability Sample|Children below six years presenting at the emergency unit of one tertiary university        children's hospital|November 2015|November 23, 2015|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01884766||64103|
NCT01885858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCH-IADB 2012-2013|Measuring Ethnic Disparities in Family Planning Services in Peru|Quality of Health Services in Indigenous Communities in Peru||Universidad Peruana Cayetano Heredia|No|Completed|September 2012|October 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|351|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 11, 2013|June 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01885858||64019|
NCT01885871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-LPS03|Laser Removal of Age (Sun) Spots on Hands|Safety and Efficacy of Cutera Picosecond Q-Switched Nd:YAG Laser in the Treatment of Solar Lentigines||Cutera Inc.|No|Completed|June 2013|August 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||October 2015|October 9, 2015|June 21, 2013|Yes|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01885871||64018|
NCT01882361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816019|Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone|Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone||University of Pennsylvania|Yes|Active, not recruiting|June 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01882361||64288|
NCT01882647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000-0551-305|A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)||Therapeutics, Inc.|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01882647||64266|
NCT01885663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBABI|UCB Therapy in Acquired Brain Injury|Umbilical Cord Blood Therapy for Patients With Acquired Brain Injury||Bundang CHA Hospital|No|Active, not recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|5 Years|15 Years|No|||August 2013|August 8, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885663||64034|
NCT01885091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K.I.S.S|Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage|Kinerase® Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage||Menarini (Thailand) Limited|No|Completed|December 2012|||March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|35 Years|65 Years|No|||June 2013|June 23, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01885091||64078|
NCT01886196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-256|Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women|Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women||University of Saskatchewan|Yes|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|90|||Female|65 Years|N/A|Accepts Healthy Volunteers|||March 2013|December 1, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01886196||63993|
NCT01882205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50565|Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis|Endoscopic Screening for Dysplasia in Patients With Longstanding Ulcerative Colitis: Classical Chromo-endoscopy Versus NBI , FICE and EPK-i.||Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2008|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|6||Anticipated|402|||Both|18 Years|N/A|No|||April 2012|June 17, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01882205||64300|
NCT01885650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0565|The Addition of Non-Invasive Ventilation To Airway Clearance Techniques In Adults With Cystic Fibrosis|Non-Invasive Ventilation (NIV) For Positive Pressure Support. A Randomised Cross-Over Trial To Evaluate The Short-Term Effects of NIV As An Adjunct To Airway Clearance Techniques in Adults With Cystic Fibrosis.|NIV|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|N/A|No|||February 2016|February 2, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01885650||64035|
NCT01877213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110602|Coaching of Diabetic Patients After Hospital Discharge|Coaching of Difficult Diabetic Patients by a Care Coordinating Team After Hospital Discharge|SORTIDIAB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01877213||64683|
NCT01877226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015466|Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants|An Open-Label, Sequential Treatment Study to Assess the Single and Multiple Dose Pharmacokinetics of a New Tapentadol Prolonged-Release 250 mg Formulation in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|June 11, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01877226||64682|
NCT01877772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0211|Trephination in Arthroscopic Cuff Repair: a Prospective Randomized Controlled|Trephination in Arthroscopic Cuff Repair: a Prospective Randomized Controlled||Ottawa Hospital Research Institute|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01877772||64640|
NCT01874080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-208|Bioequivalence Study|Bioequivalence Study of the Fixed Dosed Combination of 5 mg Saxagliptin and 1000 mg Metformin Extended Release Tablet Manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico Relative to the Fixed Dosed Combination Tablet Manufactured in Mt. Vernon, Indiana and Bioequivalence Study of the Fixed Dosed Combination of 5 mg Saxagliptin and 500 mg Metformin Extended Release Tablet Manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico Relative to the Fixed Dosed Combination Tablet Manufactured in Mt. Vernon, Indiana Administered to Healthy Subjects Under Fed Conditions||AstraZeneca|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|April 21, 2015|June 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01874080||64922|
NCT01884480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK17|Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD|A Retrospective Analysis of Renal Function, Tac Dose Adjustments and CYP3A5 Pharmacogenetics in Stable Renal Transplant Recipients Converted From Tac BID to Tac OD||St. Michael's Hospital, Toronto|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|60|||Both|18 Years|95 Years|No|Non-Probability Sample|500 stable renal transplant recipients|November 2014|November 18, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01884480||64125|
NCT01876108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1392/3/11- 589|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-alcoholic Fatty Liver Disease||Tehran University of Medical Sciences|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2013|July 4, 2013|June 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01876108||64768|
NCT01885845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.7|Excellent BRASSS-V Drape™ Versus Indirect Measurement Protocol for Measurement of Postpartum Blood Loss|A Comparison of the Excellent BRASSS-V Drape™ and an Indirect Blood Measurement Protocol for the Measurement of Blood Loss During Third Stage of Vaginal Delivery||Gynuity Health Projects|No|Completed|November 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|900|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01885845||64020|
NCT01882348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000777/MGH|Changing Pediatric Office Systems Nationally to Address Parental Tobacco Use|Changing Pediatric Office Systems Nationally to Address Parental Tobacco Use||Massachusetts General Hospital|No|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01882348||64289|
NCT01884285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4620C00001|AZD8186 First Time In Patient Ascending Dose Study|A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014||AstraZeneca|No|Recruiting|July 2013|November 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|180|||Both|18 Years|130 Years|No|||February 2016|February 26, 2016|June 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01884285||64140|
NCT01883973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27630|MER Versus MRI Guidance DBS in Parkinson's Disease|Randomized Study of Deep Brain Stimulation (DBS) Implantation Using A Microelectrode-Guided Technique Versus DBS Implantation Using MRI Guidance Alone||Baylor College of Medicine|No|Recruiting|May 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|30 Years|79 Years|No|Non-Probability Sample|Adult patients between the ages of 30 and 79 Diagnosis of idiopathic Parkinson's disease|June 2013|June 20, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01883973||64164|
NCT01884246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 3048110484|Improving Heart Health in Appalachia|Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors|HeartHealth|University of Kentucky|Yes|Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01884246||64143|
NCT01891799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL0661|Swaziland Safe Generations|Situkulwane Lesiphephile-Safe Generations: Improving Approaches to Antiretroviral Therapy for HIV-Positive Pregnant Women||Columbia University|No|Active, not recruiting|August 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|4200|None Retained|50 microliters of capillary blood will be drawn via heelstick or finger prick phlebotomy      from infants using filter paper. Blood will be collected from infants at 6mos of age to      conduct DNA PCR HIV testing, specifically for this study.|Female|18 Years|N/A|No|Non-Probability Sample|The target population for the PMTCT Options Evaluation is all HIV+ pregnant women not on        ART at their first ANC visit at the 10 study facilities. A total of approximately 2600        mother-infant pairs (2600 HIV positive women + 2600 of their HIV exposed babies) will be        observed.|January 2016|January 28, 2016|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891799||63562|
NCT01892306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F32MH098490-01|Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder|Transdiagnostic Treatment for Anxiety and Bipolar I Disorder||Massachusetts General Hospital|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892306||63523|
NCT01892943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHON HCR|Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey|||Santhera Pharmaceuticals||Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|306|||Both|N/A|N/A|No|Non-Probability Sample|patients with genetically confirmed diagnosis of LHON|May 2014|May 14, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892943||63475|
NCT01893216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPsySex|Risk Factors of Psychiatric Disorders and Sexual Dysfunction in Infertile Men|Study of Possible Interactions Between Psychiatric Disorders and Sexual Dysfunction in Infertile Men||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|April 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1500|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|male outpatients visiting the Centre of Reproduction at First Affiliated Hospital of Sun        Yat-sen University|July 2013|July 5, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893216||63454|
NCT01892917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1217|BIOFLOW-III Hungary Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Hungary||Biotronik Hungária Kft.|No|Recruiting|September 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|September 2015|September 9, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01892917||63477|
NCT01893190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EG-01-1962-02|Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage|NEWTON TRIAL - Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage|NEWTON|Edge Therapeutics Inc|Yes|Completed|September 2013|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893190||63456|
NCT01893203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13073 / Q257|Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL)|Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL)|2013-002108-15|Joint Authority for Päijät-Häme Social and Health Care|Yes|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893203||63455|
NCT01923233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-017-HCC|In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer|Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma||Immunovative Therapies, Ltd.|Yes|Withdrawn|November 2013|June 2015|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 12, 2013||No|change to ITL-022-HCC-BKK-VAX+S|No||https://clinicaltrials.gov/show/NCT01923233||61156|
NCT01923246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHI 2006/100|Development of IVR and WEB Alcohol Interventions|Development of IVR and WEB Alcohol Interventions||Region Skane|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|1672|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 13, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923246||61155|
NCT01923259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNI-P0-653|Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition|Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fed State||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2010|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|August 13, 2013|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923259||61154|
NCT01923545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3031_NP_II|Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia|Multi-Center, Randomized, Open, Phase II Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy|PEG-G-CSF|Dong-A ST Co., Ltd.|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|70 Years|No|||September 2014|September 29, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923545||61133|
NCT01923558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNI-P0-652|Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition|Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fasting State||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2010|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|August 13, 2013|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923558||61132|
NCT01924130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20452|School Breakfast Policy Initiative Study|Increasing Breakfast Consumption and Decreasing Childhood Obesity Among Low-income, Ethnically Diverse Youth.|SBPI|Temple University|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|7 Years|16 Years|No|||April 2015|April 2, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01924130||61088|
NCT01924104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJH2013|Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.|Effects of Low Dose Aspirin and Low Molecular Weight Heparin Cotreatment, Alone and/or in Combination on Implantation and Clinical Pregnancy Rates in Repeated Implantation Failures in IVF Cycle.||Jeevan Jyoti Hospital|Yes|Recruiting|August 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|400|||Female|19 Years|35 Years|No|||August 2013|August 15, 2013|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924104||61090|
NCT01924117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2902/2010UAEMéx|Genotypification and Predisposing Factors in Human Papilloma Virus Infection|Genotypification and Predisposing Factors in Human Papilloma Virus Infection and Its Association With the Carbohydrate Antigen (CA-125) Tumoral Marker|HPV|Materno-Perinatal Hospital of the State of Mexico|No|Completed|February 2011|October 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|129|||Female|15 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 15, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924117||61089|
NCT01894867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC13247-12CTIL|Magnesium in Liver Cirrhosis|Magnesium Deficiency in Cirrhotic Patients||Meir Medical Center||Not yet recruiting|August 2013|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2013|July 11, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01894867||63327|
NCT01891136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2298|Oral Peanut Immunotherapy for Peanut Allergic Patients|Pilot Study: Oral Peanut Immunotherapy for Peanut Allergic Patients|PnOIT|University of North Carolina, Chapel Hill|Yes|Completed|April 2004|December 2014|Actual|November 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|1 Year|16 Years|No|||June 2015|June 24, 2015|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891136||63613|
NCT01891123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT0508|Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy|An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patients.||Sun Yat-sen University|Yes|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2015|December 8, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01891123||63614|
NCT01891565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001|Stroke Inpatients Rehabilitation Reinforcement of Activity|Stroke Inpatients Rehabilitation With Accelerometer-based Feedback Reinforcement of Activity||University of Ibadan|Yes|Not yet recruiting|July 2013|July 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891565||63580|
NCT01891578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-04/2010|Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation|Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation Using a Nonmyeloablative Preparative Regimen and Post-transplant Cyclophosphamide, in Patients With Poor Prognosis Lymphomas||Istituto Clinico Humanitas|No|Active, not recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lymphoma (any histology)|June 2013|June 28, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01891578||63579|
NCT01891825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAAT|Persistent Atrial Fibrillation Ablation Trial|Persistent Atrial Fibrillation Ablation Trial|PAAT|Eastbourne General Hospital|Yes|Suspended|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|June 29, 2013||No|Internal protocol review|No||https://clinicaltrials.gov/show/NCT01891825||63560|
NCT01891591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39/08|Assessment of Nutritional Status After Gastric Bypass Surgery|Assessment of Nutritional Status and Vitamin Deficiencies in Obese Subjects After Gastric Bypass Surgery||University of Lausanne|No|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Female|18 Years|65 Years|No|Non-Probability Sample|16 female obese subjects on a waiting list for gastric bypass bariatric surgery|June 2013|July 2, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01891591||63578|
NCT01891552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACETUX01|Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab|Observational Study on Second Line Treatment of Colorectal Liver Metastases (KRas wt) by Hepatic Intra-arterial Chemoembolization With Dc Beads 70-150 μm Microspheres Preloaded With Irinotecan 200 Mgr Plus Systemic Cetuximab|TACETUX|International Group of Endovascular Oncology|Yes|Completed|May 2013|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|70 Years|No|Non-Probability Sample|primary care clinic|May 2015|May 12, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891552|12 Months|63581|
NCT01891812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK6900|Nitrous Oxide Analgesia Vaso-occlusive Crisis|Nitrous Oxide for Analgesia in Sickle Cell Vaso-occlusive Crisis||Columbia University|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|8 Years|18 Years|No|||July 2015|July 27, 2015|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01891812||63561|
NCT01892098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD054630|Zinc and Bone Turnover Study in Adolescent Females|Supplemental Zinc and Bone Turnover in Early Pubertal Females||University of Georgia|Yes|Completed|February 2007|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|147|||Female|9 Years|11 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01892098||63539|
NCT01892618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-012642-22|Pneumococcal Vaccine in Untreated CLL Patients|A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia||Karolinska University Hospital|Yes|Completed|August 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01892618||63499|
NCT01892930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 212712|Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery|Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma||Roswell Park Cancer Institute|Yes|Active, not recruiting|July 2013|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892930||63476|
NCT01892956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-ZH-658|Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals|Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals||Tel-Aviv Sourasky Medical Center|No|Recruiting|April 2013|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Blood count, lipids, liver functions, CBP Stool sample for intestinal microbiota|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Israeli residents and visitors|July 2013|March 26, 2014|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892956||63474|
NCT01892969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A120253|Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)|Coagulation and Fibrinolysis in a Pediatric Insulin Titration Trial|CAF-PINT|University of California, San Francisco|Yes|Recruiting|October 2012|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Blood Samples|Both|N/A|18 Years|No|Non-Probability Sample|Patients Enrolled in the Half Pint Trial to study the efficacy of Tight Glycemic control        using Insulin on reducing organ failure and mortality among children with Heart and Lung        Failure with Hyperglycemia|December 2015|December 22, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892969||63473|
NCT01893229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120509|Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania|Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase||Guangzhou Psychiatric Hospital|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|65 Years|No|||March 2015|March 14, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893229||63453|
NCT01893242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC28504|A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)|A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE THE RISK OF END STAGE RENAL DISEASE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ALERENAL STUDY)||Hoffmann-La Roche||Withdrawn|December 2013|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893242||63452|
NCT01893528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2009-HV-1304|Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers|||Regeneron Pharmaceuticals|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01893528||63430|
NCT01923571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2241985|Blood Glucose Concentration & Craniotomy|Blood Glucose Concentration During Craniotomy: Epidemiology and Relationship With Postoperative Infections||University of Roma La Sapienza|Yes|Recruiting|April 2013|||June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|53|||Both|18 Years|85 Years|No|Non-Probability Sample|at least 28 patients in each group|June 2014|June 24, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923571||61131|
NCT01923818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-TRACE|Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events|Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke|TRACE|Xijing Hospital|Yes|Not yet recruiting|September 2013|April 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|3700|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923818||61112|
NCT01923831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0385|Comparison of the Effect of Magnesium Sulfate and Dexamethasone on Postoperative Sore Throat After Spinal Surgery in Prone Position With Tracheal Intubation: a Double-blind, Randomized, Noninferiority Clinical Trial|||Yonsei University|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|146|||Both|20 Years|65 Years|No|||March 2015|March 11, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01923831||61111|
NCT01924442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517-FS|ROOBY Trial Follow-up Extension|CSP #517-FS - ROOBY Trial Extension (Randomized on Pump and Off Pump Bypass Surgery: Long Term Follow-up)||VA Office of Research and Development|No|Active, not recruiting|October 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2130|||Both|18 Years|N/A|No|Non-Probability Sample|To be eligible for the ROOBY trial, subjects were elective or urgent Coronary Artery        Bypass only procedure candidates|December 2015|December 23, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01924442||61064|
NCT01924416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16005|Lung Cancer Information Study (LCIS-R01)|A Decision Aid With Health-Related Quality of Life (HRQL) Assessment to Reduce Costs in the Treatment of Non-Small Cell Lung Cancer (NSCLC)|LCIS-R01|University of Virginia|Yes|Recruiting|September 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|196|||Both|N/A|N/A|No|||December 2014|December 11, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01924416||61066|
NCT01924429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1186|Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation|Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation||Icahn School of Medicine at Mount Sinai|No|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|55 Years|No|||August 2013|August 15, 2013|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924429||61065|
NCT01890850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200158|Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants|Risk Factors Associated With Pertussis Among Infants Less Than One-year of Age||GlaxoSmithKline||Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1|||Both|N/A|1 Year|No|Non-Probability Sample|Infants less than one-year of age born between 2005 and 2010 in a U.S. commercially        insured population contained within the optum propertity database|July 2015|July 20, 2015|June 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01890850||63635|
NCT01891149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1880|Ultrasonographic and Hormonal Characteristics of Malawian Women With and Without Obstetric Fistula|Ultrasonographic and Hormonal Characteristics of Malawian Women With and Without Obstetric Fistula||University of North Carolina, Chapel Hill|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|112|||Female|18 Years|45 Years|No|Probability Sample|We will be enrolling 100 Malawian women with obstetric fistula and 10 Malawian women        without obstetric fistula.|February 2015|February 3, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891149||63612|
NCT01890824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0297F|Fat Metabolism Following Chemotherapy in Breast Cancer|The Effect of Chemotherapy on Fat Metabolism and Digestion and Function in Breast Cancer Patients.||Texas A&M University|No|Terminated|August 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|5|Samples With DNA|Urine, adipose tissue, serum, plasma|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with breast cancer will be recruited when visiting a medical or cancer clinic in        and outside the surrounding area of College Station. Cancer patients and healthy subjects        will also be recruited by responding to distributed flyers in the community in the College        Station area; for example in hospital/clinic waiting areas, clinic rooms and bulletin        boards at Scott & White and the CSMC or any other hospital. Other general recruitment        material in relation to the nutrition research that the research group performs at Texas        A&M can be placed on bulletin boards at Scott & White and the CSMC.|February 2016|February 1, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890824||63637|
NCT01890837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100CPT5|Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)|Effect of Daikenchuto (TU 100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome||Tsumura USA|No|Completed|August 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890837||63636|
NCT01891370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11060|Median Study for Biochemical Serum Markers in First Trimester of Pregnancy|||PerkinElmer, Wallac Oy|No|Completed|July 2013|September 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|200|Samples Without DNA|Serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women in first trimester of pregnancy coming to antenatal assessment|September 2015|September 25, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891370||63595|
NCT01891617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15DK082800-XFG|Exercise Effects on Insulin, Gut Peptides, and Appetite|The Exercise Effects on Appetite and Gut Peptides While on High-fat Diet|XFG|University of Michigan|No|Completed|November 2010|March 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 28, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891617||63576|
NCT01891344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-338-017|A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)|A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)|ARIEL2|Clovis Oncology, Inc.|No|Recruiting|September 2013|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|480|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891344||63597|
NCT01891357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM07 (Neo-PREDICT-HER2)|Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer|A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer||West German Study Group|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|75 Years|No|||August 2015|August 6, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01891357||63596|
NCT01891604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jamesfriel2013|Study the Safety and Efficacy of Probiotics Use in Premature Infants|||University of Manitoba|Yes|Terminated||||December 2016|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment|||Anticipated|50|||Both|N/A|2 Days|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891604||63577|
NCT01892137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-62|Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%|Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%||LEO Pharma|No|Completed|July 2013|May 2014|Actual|March 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|June 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892137||63536|
NCT01892111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2013|Physical Activity and ARTs|Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial|SETART|University of Modena and Reggio Emilia||Not yet recruiting|October 2013|June 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|42 Years|No|||June 2013|June 28, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01892111||63538|
NCT01892319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-4016|An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry|An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Levemir® (Insulin Detemir) in Pregnant Women With Diabetes Mellitus||Novo Nordisk A/S|No|Enrolling by invitation|September 2013|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3075|||Female|N/A|N/A|No|Non-Probability Sample|Women with diabetes mellitus, who are pregnant and treated with Levemir® or other        injectable antidiabetic treatment regimens, and who have not changed basal insulin or        other injectable antidiabetic treatment product (for those not treated with basal insulin)        4 weeks prior to and following conception will be included in the Diabetes Pregnancy        Registry.|March 2016|March 3, 2016|June 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892319||63522|
NCT01892332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0257|The Effective Concentration of Lidocaine With Fentanyl in Lumbar Epidural Anesthesia for Transurethral Resection of Prostate(TURP) in Elderly Patients|||Yonsei University|No|Completed|June 2013|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Male|65 Years|85 Years|No|||July 2014|July 24, 2014|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892332||63521|
NCT01892631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|txt4flujab|Text Messaging Reminders for Influenza Vaccine in Primary Care|A Feasibility Study for a Cluster Randomised Trial of Text Messaging Reminders for Influenza Vaccine in Patients Under 65 in Clinical Risk Groups in English Primary Care.|TXT4FLUJAB|London School of Hygiene and Tropical Medicine|No|Active, not recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|64 Years|No|||October 2015|November 3, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01892631||63498|
NCT01893255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28443|A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Who Are Treated With Tocilizumab||Hoffmann-La Roche||Withdrawn|September 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra in        monotherapy|March 2016|March 1, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893255||63451|
NCT01893541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBONILHA|PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?|PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL||Federal University of São Paulo|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|78 Years|No|||July 2013|July 8, 2013|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893541||63429|
NCT01893554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 288|Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|June 2013|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|75|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||March 2016|March 15, 2016|July 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01893554||63428|
NCT01893801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT 12-001|Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)|A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)||Pancreatic Cancer Research Team|Yes|Recruiting|May 2013|August 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893801||63409|
NCT01923844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|surf_pi_co_1|Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide|Effects of Bolus Surfactant Therapy on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants With Severe Respiratory Distress Syndrome||Ege University|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|48|||Both|N/A|1 Day|No|||August 2013|August 15, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923844||61110|
NCT01923857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-104|Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function||Repros Therapeutics Inc.|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|26|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923857||61109|
NCT01924143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105|TD-9855 Mass Balance Study|An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924143||61087|
NCT01923870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-105|Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function|An Open Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Hepatic Function||Repros Therapeutics Inc.|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923870||61108|
NCT01924156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-DC/CIK-RCC|DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma|Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924156||61086|
NCT01924169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0371|Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)|A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924169||61085|
NCT01924728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRSPelvicenter|Efficacy of Magnetic Stimulation for Stress Urinary Incontinence|A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Effects of Transpelvic Magnetic Stimulation (Using QRS®-1010 PelviCenter) in Patients With Stress Urinary Incontinence.||QRS Asia Sdn Bhd|Yes|Completed|September 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|21 Years|N/A|No|||February 2016|February 19, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924728||61042|
NCT01890863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200260|ROTAHALER Device Optimization Study|An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 Mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 Mcg) Delivered Via the DISKUS Inhaler||GlaxoSmithKline|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890863||63634|
NCT01890876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN5029|Altitude, Exercise and Glucose Metabolism in Pre-diabetic Men|Altitude-dependent Effects of Concentric and Eccentric Exercise on Glucose Metabolism in Pre-diabetic Men||Universitaet Innsbruck|No|Enrolling by invitation|June 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|32|||Male|50 Years|65 Years|No|||July 2013|July 4, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890876||63633|
NCT01891656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA029010-01|Motivational Assessment Program to Initiate Treatment|In-Person VS. Computer Interventions for Increasing Probation Compliance|MAPIT|University of North Texas Health Science Center|No|Active, not recruiting|June 2012|February 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01891656||63573|
NCT01891630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1588|Observational Assessment of Baseline Asthma Control in African-American Children|Observational Assessment of Baseline Asthma Control as a Susceptibility Factor for Air Pollution Health Effects in African-American Children With Moderate-severe Asthma (Teen AIRE Study)|TeenAire|University of North Carolina, Chapel Hill|No|Completed|July 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|25|||Both|12 Years|17 Years|No|Non-Probability Sample|We will enroll a maximum of 60 African-American children with moderate-to-severe        persistent asthma in which half of the cohort will have well-controlled asthma and the        other half will have poorly-controlled asthma (defined by NHLBI guidelines). Participants        will be of both genders, ages 12-17 years old, and live within a convenient driving        distance from the study site located within the UNC Pediatric Pulmonary and UNC Pediatric        Allergy and Immunology Subspecialty clinics at Rex Hospital located in Raleigh, NC.|September 2015|September 2, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891630||63575|
NCT01891643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-006 (Biomarker Substudy)|PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)|A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma||Bristol-Myers Squibb|No|Active, not recruiting|September 2013|July 2020|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891643||63574|
NCT01891864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP15-302|Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel|A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Etanercept (GP2015) and Enbrel® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|EGALITY|Sandoz|Yes|Completed|June 2013|March 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|531|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01891864||63557|
NCT01891877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT in Football|Sickle Cell Trait in Football Players|Is Sickle Cell Trait as Benign as is Usually Assumed?||University of South Florida|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|Buccal swabs will be collected from each participant.|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of adult males who currently or formerly played high school        or college football and know that they carry sickle cell trait.|October 2014|October 17, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891877||63556|
NCT01891851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014773|A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers|Phase I, Open-label Trial in Healthy Subjects to Evaluate the Drug-drug Interaction Between Ritonavir at Steady-state and TMC435350, a Viral Protease Inhibitor Against Hepatitis C Virus, After the First and the Last Dose of a Multiple Dosing Regimen||Tibotec Pharmaceuticals, Ireland|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891851||63558|
NCT01892410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10235|Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash|100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-Occlusive Patch)||Galderma Laboratories, L.P.|No|Completed|December 2012|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|July 1, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01892410||63515|
NCT01892670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2279|Storage Temperature and Quality of Leucoreduced Whole Blood|Storage Temperature and Quality of Leucoreduced Whole Blood|BFF|Haukeland University Hospital|No|Active, not recruiting|March 2013|June 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892670||63495|
NCT01891838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/15|Mode of Ventilation and Bleeding During Transsphenoidal Surgery|Transsphenoidal Surgery for Pituitary Adenomas: Influence of the Ventilation Mode on Intraoperative Bleeding|Vent-Hyp|Hopital Foch|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01891838||63559|
NCT01892124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44890-G|Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms|Healthy Hearts, Healthy Minds||University of Washington|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01892124||63537|
NCT01892345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-NMO-301|A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)||Alexion Pharmaceuticals|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892345||63520|
NCT01892982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD072069|Improving Preterm Outcomes by Safeguarding Maternal Mental Health|Improving Preterm Outcomes by Safeguarding Maternal Mental Health||Boston Medical Center|Yes|Recruiting|June 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|325|||Both|N/A|64 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01892982||63472|
NCT01893827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02263|Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care|Randomized, Open-label Clinical Trial of Extended-Release vs. Oral Naltrexone for Alcohol Treatment in Primary Care.|X-ON|New York University School of Medicine|No|Recruiting|June 2014|September 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|60 Years|No|||October 2015|October 26, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893827||63407|
NCT01893840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-FO-01|Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg|Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg||Otivio AS|No|Active, not recruiting|August 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|30 Years|90 Years|No|||October 2013|October 30, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01893840||63406|
NCT01893866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291041|A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects|An Open-Label, Randomized, Phase 1, Single-Dose Crossover, Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects||Pfizer|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893866||63404|
NCT01893567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10243|Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%|Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%||Galderma Laboratories, L.P.|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2014|September 3, 2014|June 26, 2013|Yes|Yes||No|June 11, 2014|https://clinicaltrials.gov/show/NCT01893567||63427|
NCT01893580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLUCA|Perioperative Rehabilitation in Operation for Lung Cancer|Perioperative Rehabilitation in Operation for Lung Cancer|PROLUCA|Rigshospitalet, Denmark|Yes|Terminated|May 2012|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|June 20, 2013||No|Due to low recruiment rate, the study design is chanced to a feasibility study|No||https://clinicaltrials.gov/show/NCT01893580||63426|
NCT01893814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAB/029911|Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort|||Probi AB|No|Recruiting|April 2013|||May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|N/A|12 Weeks||||July 2013|July 2, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893814||63408|
NCT01923597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fapesp-2013|Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.|A Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Green Tea on Albuminuria in Patients With Diabetic Nephropathy and Use of Maximum Dose of ACE-I and / or Angiotensin II Receptor Blocker.||University of Campinas, Brazil|Yes|Completed|November 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||August 2013|March 22, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923597||61129|
NCT01923610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RisVac02 boost|Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B|Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B||Hospital Clinic of Barcelona|No|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923610||61128|
NCT01923883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUSFNA20130574|Comparison of EUS-Guided Fine Needle Aspiration Technique|Comparison of EUS-guided Fine Needle Aspiration Technique: Negative-pressure Suction With Syringe vs. Capillary Sampling With Stylet Slow-pull Technique||Asan Medical Center|No|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|51|||Both|20 Years|N/A|No|||August 2013|August 15, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01923883||61107|
NCT01924754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINI|Gardasil Immunogenicity With Needle-Free Injection|Gardasil Immunogenicity With Needle-Free Injection|GINI|University of California, San Francisco|No|Recruiting|January 2014|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|150|||Female|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is only for women; the study is focused on the safety and immunogenicity of the        HPV vaccine in women. Separate studies will be done in men if the dosing regimens in        Groups II or III are shown to be non-inferior to the standard regimen.|April 2014|April 8, 2014|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924754||61040|
NCT01924767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients||Boehringer Ingelheim||Completed|July 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|70 Years|No|||July 2014|July 3, 2014|August 9, 2013||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01924767||61039|
NCT01924455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK094818|HBV-HIV Coinfection Research Network|HBV-HIV Coinfection Research Network||Virginia Commonwealth University|Yes|Recruiting|April 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|80 Years|No|Non-Probability Sample|HBV-HIV coinfection|December 2015|December 10, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924455||61063|
NCT01924468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913483|Brain Networks and Addiction Susceptibility|The Impact of Genetic Variation In Nicotinic Cholinergic Receptors on Functional Brain Networks Underlying Addiction Susceptibility||National Institutes of Health Clinical Center (CC)||Recruiting|July 2013|December 2018|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|January 6, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924468||61062|
NCT01891383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMS# 12lO9006|Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel|Endophenotypes of Dementia Associated With Traumatic Brain Injury in Retired Military Personnel||Uniformed Services University of the Health Sciences|No|Recruiting|July 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|50 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|Subjects for this study will be recruited from the Armed Forces Retirement Home (AFRH) in        Washington, DC and the Veterans Home of California- Yountville. Up to 150 AFRH residents        from both the independent living and the assisted living facilities will be invited to        take the screening questionnaire and enroll in the study.|December 2015|December 30, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891383||63594|
NCT01891669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4481001|A Study Of PF-06263507 In Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors||Pfizer|No|Terminated|August 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|June 10, 2013|No|Yes|The study was terminated on June 23, 2015 due to the company's change in prioritization for    the portfolio and is not due to any safety concerns.|No||https://clinicaltrials.gov/show/NCT01891669||63572|
NCT01891916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/11|Effect Of Lactobacillus GG on Atopic March|Preventive Effect of Lactobacillus GG on Atopic Manifestation in Children With Cow's Milk Allergy||Federico II University|No|Recruiting|October 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|N/A|12 Months|No|||July 2013|July 15, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891916||63553|
NCT01891890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066541|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|COPE|Emory University|No|Active, not recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|5 Years|16 Years|No|||January 2016|January 15, 2016|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891890||63555|
NCT01891903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPAS52424166|to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish|TO TRANSLATE AND VALIDATE THE ToPAS (TORONTO PSORIATIC SCREENING QUESTIONNAIRE) FOR THE SCREENING OF PSORIATHIC ARTHRITIS PATIENTS IN DERMATOLOGY CLINICS|spanishTopas|Reumatologia Integral LTDA|Yes|Recruiting|May 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|60|||Both|16 Years|N/A|No|Non-Probability Sample|PATIENTS WITH PSORIASIS ASESSED IN THE DERMATOLOGY CLINIC|June 2013|June 28, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01891903|20 Days|63554|
NCT01892163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIVS1007|Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone|A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 μg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema|OZDRY|Moorfields Eye Hospital NHS Foundation Trust|Yes|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|July 3, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01892163||63534|
NCT01892150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj-Eucerin02|Histologic Response to UVA and UVB Exposure During the Use of Sunscreen|Histologic Response to UVA and UVB Exposure During the Use of Sunscreen With Anti-inflammatory and Anti-oxidant Properties - A Pilot Study||Mahidol University|Yes|Completed|March 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|2|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01892150||63535|
NCT01892384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.18|Safety and Tolerability of BI 409306 in Patients With Schizophrenia|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Patients With Schizophrenia (Randomized, Parallel-group, Double-blind, Placebo-controlled Study)||Boehringer Ingelheim||Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|No|||July 2015|July 21, 2015|July 1, 2013||||No||https://clinicaltrials.gov/show/NCT01892384||63517|
NCT01892397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-067|Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma|Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma||Memorial Sloan Kettering Cancer Center||Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892397||63516|
NCT01892683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExhaledPropofolPK|Breath Monitoring of Propofol (Observational Study)|Breath Monitoring of Propofol in Patients Undergoing Anesthesia for Surgical Procedures(Observational Study)||Ludwig-Maximilians - University of Munich|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Blood plasma|Both|18 Years|N/A|No|Non-Probability Sample|Study persons undergo general anesthesia for elective routine surgery at the hospital of        the University of Munich (Klinikum der Universität München)|November 2013|November 11, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892683||63494|
NCT01892358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034957|Preventing Bacterial and Viral Infections Among Injection Drug Users|Preventing Bacterial and Viral Infections Among Injection Drug Users||Butler Hospital|Yes|Recruiting|September 2013|April 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|75 Years|No|||August 2015|November 10, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892358||63519|
NCT01892371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1047|AC220 With 5-Aza or Low Dose Cytarabine|Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|November 2013|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892371||63518|
NCT01892644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2139|Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome|Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.|DefeHEMY|Haukeland University Hospital|No|Recruiting|May 2013|March 2015|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892644||63497|
NCT01892657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.US10093|Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test|Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)||Galderma Laboratories, L.P.|No|Completed|March 2008|August 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|128|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2008|July 23, 2013|July 1, 2013||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01892657||63496|
NCT01893593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Young Hearts, Strong Starts|Young Hearts, Strong Starts|A Cluster Randomized Trial of the Implementation of the NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents||RTI International|No|Completed|November 2011|October 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|3 Years|11 Years|No|||August 2014|August 13, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893593||63425|
NCT01894438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD-0098|Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease|Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Non-alcoholic Fatty Liver Disease.||Harokopio University|No|Recruiting|April 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894438||63360|
NCT01894087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R49CE002099|Safety & Prevention Outcomes Study|A Brief Prescription Opioid Overdose Intervention in an Emergency Department|SPOS|University of Michigan|No|Completed|April 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|204|||Both|18 Years|60 Years|No|||July 2015|July 24, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894087||63387|
NCT01894399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EMSI-102|Study to Evaluate a Pharmacokinetic of HM61713 (BI 1482694) in Healthy Male Subjects|Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 (BI 1482694) Tablet in Healthy Korean, Japanese and Caucasian||Hanmi Pharmaceutical Company Limited|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|59|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894399||63363|
NCT01894412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE-I-13|Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers||Hanwha Chemical|No|Active, not recruiting|July 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 13, 2014|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894412||63362|
NCT01924182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1664 - CONVERT-TDD|Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects|Post-market Study Evaluating a Treatment Conversion to Low Dose Intrathecal Morphine From Conventional Medical Management for Maintenance of Pain Control and Improvement of Opioid-related Side Effects. (CONVERT Targeted Drug Delivery [TDD])|CONVERT-TDD|MedtronicNeuro|No|Terminated|October 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 13, 2013||No|Amendment changes were significant enough to warrant a new study.|No|December 21, 2015|https://clinicaltrials.gov/show/NCT01924182||61084|Due to the small sample size (only 1 IT Group and 0 CMM Group participants completed the primary outcome assessment), statistical tests cannot be performed and conclusions cannot be made on any of the original study objectives.
NCT01924195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-03-II|Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Completed|August 2013|October 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924195||61083|
NCT01924481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00023752|Effects of a Cocoa Shot on the Human Brain|Effects of a Cocoa Shot on the Human Brain||Wake Forest School of Medicine|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|6|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924481||61061|
NCT01924494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GITEP|Gastro Intestinal Tele Endoscopy Project|Gastrointestinal Tele-Endoscopy Project: Synchronous Tele-Endoscopy - A Clinical Feasibility Study of Implementation of EndoAlpha Platform in Gastrointestinal Endoscopy.||Bispebjerg Hospital|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing elective gastrointestinal endoscopy procedures|August 2013|August 15, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01924494||61060|
NCT01891175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAESAREANFENI|Prevention of Maternal Hypotension During Elective Caesarean Section Performed With Spinal Anaesthesia, Through Intermittent Pneumatic Compression System in the Lower Extremities|Prevention of Maternal Hypotension During Elective Caesarean Section Performed With Spinal Anaesthesia, Through Intermittent Pneumatic Compression System in the Lower Extremities.||Parc de Salut Mar|No|Completed|May 2013|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01891175||63610|
NCT01891396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cingal 13-01|Cingal Study for Knee Osteoarthritis|A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee||Anika Therapeutics, Inc.|Yes|Completed|June 2013|September 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|368|||Both|40 Years|75 Years|No|||December 2014|December 29, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891396||63593|
NCT01892722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2311|Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis|Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis||Novartis|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|10 Years|17 Years|No|||October 2015|October 2, 2015|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892722||63491|
NCT01893034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAIT|Trial for Femoroacetabular Impingement Treatment|A Randomised Controlled Trial of Surgical Versus Non-surgical Treatment of Femoroacetabular Impingement|FAIT|University of Oxford||Recruiting|July 2013|July 2017|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||December 2013|December 2, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01893034||63468|
NCT01892176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB/2010/00223|Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease|Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease||National University Hospital, Singapore|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Months|N/A|No|||July 2013|July 8, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892176||63533|
NCT01892436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2306E1|Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis|A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis|FUTURE 1 ext|Novartis||Active, not recruiting|September 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892436||63513|
NCT01892423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04SPR.US10044|Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion|Daily Advance Cetaphil Moisturizing Lotion: Human Repeat Insult Patch Test||Galderma Laboratories, L.P.|No|Completed|August 2006|||September 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|146|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|July 1, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892423||63514|
NCT01893021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1084|Family Planning Knowledge, Attitudes, and Practices of Postpartum Malawian Women|Family Planning Knowledge, Attitudes, and Practices of HIV+ and HIV- Postpartum Malawian Women||University of North Carolina, Chapel Hill|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|634|||Female|18 Years|45 Years|No|Probability Sample|Our study population will be a sample of 210 HIV+ and 420 HIV- postpartum Malawian women.|February 2015|February 3, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01893021||63469|
NCT01892995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMC-385833-1|Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial|Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial|LDK-SI|Brooke Army Medical Center|No|Not yet recruiting|June 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|53|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 13, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01892995||63471|
NCT01893268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28621|An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice|Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.||Hoffmann-La Roche||Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|277|||Both|65 Years|N/A|No|Probability Sample|Patients aged over 65 years with non-squamous non-small cell lung cancer|March 2016|March 1, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893268||63450|
NCT01893281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14980|The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel|The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel||Eli Lilly and Company|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Male|18 Years|N/A|No|||October 2014|October 21, 2014|July 2, 2013|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01893281||63449|
NCT01893619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|immunoprop|Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome|Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome|immunoprop|New York CFS Association|Yes|Recruiting|June 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|60 Years|No|Probability Sample|Fukuda criteria and Canadian consensus criteria will be the diagnosis criteria for patient        selection|July 2013|July 24, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893619||63423|
NCT01893853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC12038|Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)|Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)|APEX|Pennington Biomedical Research Center|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01893853||63405|
NCT01894724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-1.0|Targeted Hypothermia During Cardiac Surgery|Targeted Cerebral Hypothermia During Cardiac Surgery: A Feasibility Trial||NeuroSave Inc.|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01894724||63338|
NCT01894100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0807|Shoe Lifts for Leg Length Inequality in Adults With Knee or Hip Symptoms|Defining and Correcting Limb Length Inequality in Adults With Knee or Hip Symptoms||University of North Carolina, Chapel Hill|No|Completed|July 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|55 Years|N/A|No|||April 2015|April 1, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894100||63386|
NCT01894425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/SD-01|Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation|Study of the Role of Infection by Human Papillomavirus (HPV) in the Success Rate of Pregnancies Achieved Via Medically Assisted Procreation|PAPILLO-PMA|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|May 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|Samples With DNA|Samples collected (semen and cervical smears) will be sent to the Virology Laboratory of the      Hôpital St-Eloi, CHU Montpellier, for analysis. After analysis, the remains of viral DNA      will be banked for future studies on the Papilloma Virus.|Both|18 Years|60 Years|No|Non-Probability Sample|The study population consists of couples under care for infertility in the participating        centers. Gamete donations are not included.|May 2015|October 26, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01894425||63361|
NCT01923909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATF02092012|Comparison of IA Platelet Rich Plasma Injections With IA Steroid Injections in Treatment of Primary Knee Osteoarthritis|Comparison of Intra-articular Platelet Rich Plasma Injections With Intra-articular Steroid Injections in the Treatment of Primary Osteoarthritis of the Knee : A Randomized Control Trial|Articular|King Hamad University Hospital, Bahrain|Yes|Recruiting|April 2013|January 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923909||61105|
NCT01924208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tons2|Tonsillar Cytokine Expression After Allergen and/or Virus Intervention|T Cell and Interferon Expression in Tonsils After Sublingual Immunotherapy and/or Nasal Live Attenuated Influenza Vaccine|Tons2|Turku University Hospital|Yes|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|180|||Both|4 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 12, 2013|August 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924208||61082|
NCT01924221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RER CRT|Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy|Study of Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy|RER-CRT|Johns Hopkins University|No|Active, not recruiting|December 2011|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Heart Failure Patients with currently approved indications for implantation of cardiac        resynchronization therapy defibrillator|September 2015|September 1, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924221||61081|
NCT01891929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01676-37|Cognitive Remediation and Sheltered Employment in Schizophrenia|Specific Cognitive Remediation for Schizophrenia (RECOS) and Sheltered Employment: a Multicentre Controlled Randomized Trial.|RemedRehab|Hôpital le Vinatier|Yes|Recruiting|July 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|50 Years|No|||February 2016|February 2, 2016|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891929||63552|
NCT01891409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC-0139-01|Use of the Shang Ring Circumcision Device in Boys Below 18 Years Old in Kenya|Use of the Shang Ring Device in All Four Childhood Age Groups in the African Population||EngenderHealth|Yes|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Male|1 Month|17 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891409||63592|
NCT01923415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101971|A Non-drug Study Profiling Cutaneous Lupus|Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus||Janssen Research & Development, LLC|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|29|Samples With DNA|Blood from participants with discoid lupus erythematosus (DLE), subacute cutaneous lupus      erythematosus (SCLE), and active systemic lupus erythematosus (SLE) with cutaneous      involvement.|Both|18 Years|70 Years|No|Non-Probability Sample|Participants have CLE (either DLE or SCLE) or SLE with cutaneous manifestations|September 2014|September 11, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01923415||61142|
NCT01893047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47585|Effect of Music on Breastmilk|Effect of Quiet or Listening to Music While Breastfeeding on the Production and Lipid and Sodium Content of the Milk||University of Rochester|No|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01893047||63467|
NCT01893333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSRH_Cxca|The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer|The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer|NSRHCXCA|Asan Medical Center|Yes|Recruiting|March 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|146|||Female|18 Years|70 Years|No|||July 2013|July 2, 2013|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01893333||63445|
NCT01892696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CvDVPPIVC|Effects of Inspiratory Flow Waveforms on Preload|Effects of Inspiratory Flow Waveforms on Arterial Pulse Pressure Variation and Inferior Vena Cava Distensibility in Mechanically Ventilated Patients.||Military Hospital of Tunis|Yes|Recruiting|May 2013|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|N/A|N/A|No|||July 2013|July 1, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892696||63493|
NCT01892709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 12-12-408|Titration of Intravenous Hydromorphone|Titration of Intravenous Hydromorphone in Adult Emergency Department Patients With Pain||Montefiore Medical Center|No|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|286|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|June 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892709||63492|
NCT01893008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43194.041.13|Preoperative Inspiratory Muscle Training in Esophageal Resection|Preoperative Inspiratory Muscle Training to Prevent Postoperative Pneumonia in Patients Undergoing Esophageal Resection|PREPARE|UMC Utrecht|No|Recruiting|September 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01893008||63470|
NCT01893294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1241|Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer|Phase I Trial of Intra-tumoral Gemcitabine Therapy for Locally Advanced Pancreatic Carcinoma||Mayo Clinic|Yes|Terminated|April 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|January 7, 2016|July 2, 2013|No|Yes|Funding discontinued; all patients off study|No||https://clinicaltrials.gov/show/NCT01893294||63448|
NCT01893606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liujunkang|Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment|Multicenter Randomized Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for Irritable Bowel Syndrome With Diarrhea (IBS-D) Treatment||Third Military Medical University|Yes|Recruiting|April 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01893606||63424|
NCT01894113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBB2010|Prospective, Randomised Multicenter Study Comparing the Efficacy of Transbronchial Forceps Biopsy With Cryobiopsy to Diagnose Interstitial Lung Disease.|Prospective, Randomised Multicenter Study Comparing Transbronchial Forceps Biopsy With Cryobiopsy in Interstitial Lung Disease|TRABIS|University Hospital Tuebingen|No|Completed|January 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|382|||Both|18 Years|N/A|No|||May 2015|May 2, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894113||63385|
NCT01921712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0010P|A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients|A Phase I, 2-Part, Single-dose, Placebo and Active-Controlled, Dose-ranging, Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Pulmatrix Inc.|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|38|||Both|40 Years|80 Years|No|||March 2014|March 17, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921712||61273|
NCT01894711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-4-075|Real World Efficiency of Trastuzumab in Early Breast Cancer|Real-world Use and (Cost)-Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer||Maastricht University Medical Center|Yes|Completed|May 2010|May 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2684|||Both|N/A|N/A|No|Probability Sample|All patients diagnosed with invasive stage I-III breast cancer in the years 2005, 2006 and        2007 in the participating 5 hospitals.        That is, no distant metastasis at the time of the primary diagnosis|July 2013|July 9, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894711||63339|
NCT01894945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.06b|Dual Time Point PET in Lymphoma|||Odense University Hospital|No|Recruiting|March 2012|July 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed NHL and HL|July 2013|July 9, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01894945||63321|
NCT01924507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bedsidesleep|Bedside Sleep Medicine|Intensive Cared Bedside Sleep Medicine||Associação Fundo de Incentivo à Pesquisa|No|Recruiting|August 2013|December 2015|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924507||61059|
NCT01924520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0009|Oral Multiple-dose Study in Patients With Major Depressive Disorder|Phase I Study of FK949E - Phase I Oral Multiple-dose Study in Patients With Major Depressive Disorder||Astellas Pharma Inc|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|32|||Both|20 Years|64 Years|No|||August 2013|August 14, 2013|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924520||61058|
NCT01924533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081BC00004|Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer|A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy||AstraZeneca|Yes|Active, not recruiting|September 2013|December 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|99 Years|No|||January 2016|January 22, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924533||61057|
NCT01924546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065861|Study of Dehydration and Cognition in Pupils in Zambia|Cognitive Effects of Drinking Water and Improving Hydration Status Among Schoolchildren in Zambia||Emory University|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|292|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924546||61056|
NCT01924780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEMOS1|NEMOS in Normal Volunteer and JIA Study|Evaluation of the Anti-inflammatory Potential of NEMOS® Transcutaneous Vagus Nerve Stimulation Device in Patients With Juvenile Idiopathic Arthritis||Astrid Lindgren Children´s Hospital|Yes|Enrolling by invitation|August 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924780||61038|
NCT01925040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKG-DT-01/2011-SOCO-CLIN|Comparison of 2 Different Resin Based Filling Materials in Posterior Teeth - a Multicenter Study|Clinical Investigation of a New Nanohybrid Resin Composite Venus Pearl in Class 2 Cavities- a Multi-center Study||Heraeus Kulzer GmbH|No|Recruiting|June 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925040||61018|
NCT01922869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21072|An Acute Human Intervention With Flavonoid to Investigate Absorption, Metabolism and Excretion|An Acute Flavonoid Intervention Study to Examine Influences of Genotype and Phenotype on Flavonoid Absorption, Metabolism and Excretion|COB|University of East Anglia|No|Recruiting|July 2013|September 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|240|||Both|18 Years|77 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01922869||61184|
NCT01892189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-063_102|Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults|A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period, Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults||Takeda|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|June 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892189||63532|
NCT01892449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0287|Comparison of Different Inspiratory to Expiratory Ratios on Respiratory Mechanics and Oxygenation in Robot-assisted Laparoscopic Radical Prostatectomy With Steep Trendelenburg Position and Pneumoperitoneum|||Yonsei University|Yes|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|80|||Male|20 Years|90 Years|No|||May 2014|May 22, 2014|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892449||63512|
NCT01924013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039072|Maternal Vitamin D for Infant Growth (MDIG) Trial|Randomized Placebo-controlled Trial of Maternal Vitamin D Supplementation During Pregnancy and Lactation to Improve Infant Linear Growth in Dhaka, Bangladesh.|MDIG|The Hospital for Sick Children|Yes|Recruiting|March 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|1300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924013||61097|
NCT01923688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104182|Preventing Hypoglycemia|Prevention of Hypoglycemia and Insulin Errors in Barnes-Jewish Hospital Inpatients||Washington University School of Medicine|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|390|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 19, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923688||61122|
NCT01924000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-56059|Minoxidil 1% for Eyebrow Enhancement|Minoxidil 1% for Eyebrow Enhancement: A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study||Mae Fah Luang University Hospital|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 20, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924000||61098|
NCT01924286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRI_001|Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone|Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone|Pred-ART|University of Cape Town|Yes|Recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924286||61076|
NCT01924299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14607|A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants|The Effect of Ketoconazole or Fluconazole on the Pharmacokinetics of Baricitinib in Healthy Subjects||Eli Lilly and Company|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924299||61075|
NCT01924572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Term Pilot Study|Placental Transfusion in Term Infants: A Pilot Study|Placental Transfusion in Term Infants Placed Skin-to-Skin: A Pilot Controlled Trial||University of Rhode Island|No|Completed|July 2010|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924572||61054|
NCT01893632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6740|Gabapentin Treatment of Benzodiazepine Dependence|Gabapentin Treatment of Benzodiazepine Dependence||New York State Psychiatric Institute|No|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|June 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893632||63422|
NCT01893307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0825|Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT)|Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|August 2013|||August 2023|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893307||63447|
NCT01893320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0099|Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome|A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Recruiting|July 2013|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|60 Years|N/A|No|||February 2016|February 24, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893320||63446|
NCT01893879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0028|Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema|Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients|PCTTPL|Stanford University||Terminated|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|July 2, 2013||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01893879||63403|
NCT01894451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-147|Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy|Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy||Dana-Farber Cancer Institute|Yes|Recruiting|June 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|21 Years|N/A|No|||January 2016|January 19, 2016|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894451||63359|
NCT01894464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0207|The Early Truancy Prevention Project|The Early Truancy Prevention Project|ETPP|Duke University|No|Completed|August 2013|July 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|N/A|N/A|No|||March 2016|March 7, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01894464||63358|
NCT01921725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-156|The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing|The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing||Bio-medical Carbon Technology Co., Ltd.||Completed|May 2013|||August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|20 Years|85 Years|No|||August 2013|August 9, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921725||61272|
NCT01894958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-FXS-001|A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome||Neuren Pharmaceuticals Limited|Yes|Completed|January 2014|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Male|12 Years|45 Years|No|||October 2015|October 29, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894958||63320|
NCT01894971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-25|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|The Effect of Thermal Damage of Ligasure® to Destroy Cornual Portion of Fallopian Tube Tissue||Samsung Medical Center|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01894971||63319|
NCT01891201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/00791|Intrapartum Oxytocin Administration Affects Primitive Neonatal Reflexes|||Puerta de Hierro University Hospital|No|Completed|March 2011|June 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|N/A|4 Days|No|Non-Probability Sample|Maternity ward of a terciary Hospital|June 2013|June 27, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891201|6 Months|63608|
NCT01891435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9070/09|The Antipyretic Efficacy of Oral and Intravenous Paracetamol and Intramuscular Diclofenac in Patients Presenting With Fever.|A Randomized Controlled Clinical Trial on the Antipyretic Efficacy of Oral Paracetamol, Intravenous Paracetamol and Intramuscular Diclofenac in Patients Presenting With Fever to Emergency Department||Hamad Medical Corporation||Completed|January 2010|April 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|434|||Both|14 Years|75 Years|No|||June 2013|June 28, 2013|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891435||63590|
NCT01924247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090/13|Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims|Prospective Randomized Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims With Minor or no Residual Deficits||University Hospital Inselspital, Berne|Yes|Active, not recruiting|November 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01924247||61079|
NCT01924260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#240|Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer|Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer||University of California, Davis|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924260||61078|
NCT01925079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-lipid-2013|Intensive Education on Lipid Management|A Randomized and Controlled Study About the Impact of Intensive Education on Lipid Management in Patients With Acute Coronary Syndrome in China||Shanghai Zhongshan Hospital|No|Not yet recruiting|August 2013|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2568|||Both|18 Years|N/A|No|||August 2013|August 18, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925079||61015|
NCT01924793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181-2-06|An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection|An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection|PIV|Ansun Biopharma, Inc.|Yes|Active, not recruiting|August 2013|||August 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|N/A|No|||May 2015|May 19, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924793||61037|
NCT01924806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WW-2013-02|A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention|A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention|WoundWand|Smith & Nephew, Inc.|No|Terminated|December 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|August 13, 2013||No|Lower than anticipated accrual rate and desire to reassess overall study strategy|No||https://clinicaltrials.gov/show/NCT01924806||61036|
NCT01923428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5612C00001|The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Ardelyx|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|371|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923428||61141|
NCT01923129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00029210|Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery|Prospective Study Investigating Optimal Duration of Indwelling Urinary Catheter Following Infraperitoneal Colorectal Surgery and Role of Postoperative Alpha Blockade||Cedars-Sinai Medical Center|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923129||61164|
NCT01924325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-ADANCE|Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events|Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design|ADANCE|Xijing Hospital|Yes|Not yet recruiting|January 2014|July 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|10000|||Both|18 Years|80 Years|No|||August 2013|August 13, 2013|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924325||61073|
NCT01924312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR141892|Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease|Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease|MCI/CVD|University of Kentucky|Yes|Recruiting|May 2013|August 2017|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|55 Years|N/A|No|||February 2015|February 15, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01924312||61074|
NCT01924585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1042-SAGE|Surgery in Persons of Older Age|Prospective Observational Study of Patients Aged >=60 Years Undergoing Major Gastrointestinal Surgery With 1 Year Follow-up|SAGE|Imperial College London|Yes|Recruiting|December 2012|July 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Preoperative serum and urine sample.|Both|60 Years|N/A|No|Non-Probability Sample|Patients aged 60 years or more, undergoing elective colorectal surgery (laparoscopic or        open).|August 2012|March 25, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924585||61053|
NCT01924598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC/13/0267|Pilot Study of Deep Brain Stimulation for Severe Anorexia Nervosa|Hungry for Reward : A Pilot Investigation of the Ethics, Practice and Neural Basis of Deep Brain Stimulation to the Nucleus Accumbens in Severe Intractible Anorexia Nervosa.||University of Oxford|Yes|Recruiting|July 2013|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Female|20 Years|65 Years|No|||December 2015|December 8, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01924598||61052|
NCT01924845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701-301|BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)|A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease||BioMarin Pharmaceutical|Yes|Recruiting|March 2014|||June 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924845||61033|
NCT01924858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117155|A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.|An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects||GlaxoSmithKline|No|Terminated|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|August 15, 2013||No|Study objectives met so study concluded earlier than planned hence we terminated the study.|No||https://clinicaltrials.gov/show/NCT01924858||61032|
NCT01924832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV111|BG00012 Regional Absorption Study|Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BG00012 (Dimethyl Fumarate) When Delivered to Different Regions of the Gastrointestinal Tract in Healthy Subjects||Biogen|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01924832||61034|
NCT01893892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0018|Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms|Double-blind, Randomized, Placebo-controlled Two-period Crossover Study to Assess the Effect of Levocarnitine on Vismodegib-associated Muscle Spasms||Stanford University|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|26|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893892||63402|
NCT01894126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K12HD001264-14UNGER|Mobile Phone Messaging to Improve Women's and Children's Health (Mobile WACh) in Kenya|Mobile Phone One Way Short Message Service (SMS) Versus SMS Dialogue for Women's and Child Health (Mobile WaCH) in Kenya: A Randomized Control Trial|Mobile WACh|University of Washington|No|Active, not recruiting|July 2013|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Female|14 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 27, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894126||63384|
NCT01894139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.C02.2012|An Optimized Programming of Healthy Children (APPROACH)|An Optimized Programming of Healthy Children (APPROACH) - The Most Favourable Dietary Protein:Carbohydrate Ratio During Pregnancy in the Context of New Nordic Diet||Copenhagen University Hospital at Herlev|Yes|Recruiting|November 2013|December 2025|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|390|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894139||63383|
NCT01925664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40 MC 00203|Doula Support for Young Mothers: A Randomized Trial|Doula Support for Young Mothers: A Randomized Trial||University of Chicago|No|Completed|January 2001|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|248|||Female|14 Years|21 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01925664||60971|
NCT01925885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU-1302010649|Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)|Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)|FIRMAT-PAF|Indiana University|Yes|Terminated|September 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|August 5, 2013||No|•Terminated: recruiting or enrolling participants has halted prematurely and will not resume;    participants are no longer being examined or treated|No||https://clinicaltrials.gov/show/NCT01925885||60954|
NCT01922011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-006|Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)|A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms||Cubist Pharmaceuticals LLC|Yes|Recruiting|September 2013|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|1 Year|17 Years|No|||February 2016|February 24, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922011||61250|
NCT01921985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190/11|Terlipressin Administration in Patients Undergoing Major Liver Resection|Terlipressin Administration in Patients Undergoing Major Liver Resection: a Prospective Randomized Blinded Trial||University Hospital Inselspital, Berne|Yes|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921985||61252|
NCT01922258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-12-284|Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|September 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|55 Years|90 Years|No|||February 2016|February 9, 2016|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922258||61231|
NCT01924559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00000982|Comparison of Airway Intubation Devices When Using a Biohazard Suit|Comparison of Airway Intubation Devices When Using a Biohazard Suit: A Feasibility Study||Lehigh Valley Hospital|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|37|||Both|18 Years|126 Years|No|||March 2016|March 22, 2016|August 6, 2013||No||No|October 6, 2015|https://clinicaltrials.gov/show/NCT01924559||61055|Limitations described in associated reference
NCT01924819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0407GR|Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma|A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer|TOPGEAR|Australasian Gastro-Intestinal Trials Group|Yes|Recruiting|September 2009|December 2020|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|752|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924819||61035|
NCT01917045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSOPCA-021|Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia|Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia --- a Double Blind Randomized Study||Peking University First Hospital|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|180|||Female|20 Years|50 Years|No|||August 2013|August 3, 2013|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917045||61632|
NCT01917058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL0950|A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata|A Randomized Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata||Columbia University|Yes|Withdrawn|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||July 2014|July 23, 2014|August 2, 2013|Yes|Yes|Unfortunately we did not receive funding and therefore were not able to begin the trial.|No||https://clinicaltrials.gov/show/NCT01917058||61631|
NCT01925365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREC 09/12|Health Benefits of Whole Grain Oats in Population at Risk of Cardio-metabolic Disease|Hypocholesterolaemic and Prebiotic Effects of a Whole-grain Oat-based Breakfast Cereal in a Cardio-metabolic 'at Risk' Population||University of Reading|Yes|Completed|May 2009|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|23 Years|64 Years|Accepts Healthy Volunteers|||August 2013|August 15, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925365||60994|
NCT01923714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-53534|Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms|Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms in Belgian Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with OAG that require topical therapy for intraocular pressure lowering and that        were scheduled to switch current therapy to preservative-free DTFC|December 2012|August 13, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923714||61120|
NCT01923701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007011164|Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk|Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk||Weill Medical College of Cornell University|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|12 Years|25 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01923701||61121|
NCT01924338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB-NIRMR-001|Validation of a Method to Measure Soft Tissue Thickness Using Near Infrared Laser Light|Validierung Der Bestimmung Der Gewebedicke Mit Hilfe Von Licht im Infrarotbereich||University of Luebeck|No|Recruiting|September 2013|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924338||61072|
NCT01924611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 134/04|Two Years Survival Rate of Class II ART Restorations in Primary Molars Using Two Ways to Avoid Saliva Contamination|Two Years Survival Rate of Class II ART Restorations in Primary Molars Using Either Rubber Dam or Cotton Rolls.||Federal University of Paraíba|No|Completed|September 2004|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|6 Years|7 Years||||August 2013|August 15, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924611||61051|
NCT01924871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deep extubation in CAUH|Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia|||Chung-Ang University Hospital||Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|20 Years|60 Years|No|||April 2014|April 4, 2014|August 12, 2013||No||No|April 4, 2014|https://clinicaltrials.gov/show/NCT01924871||61031|
NCT01925131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1312|S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia|S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)||Southwest Oncology Group|No|Recruiting|April 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925131||61011|
NCT01925144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14603|A Study of Baricitinib and Omeprazole in Healthy Participants|Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Absorption of Baricitinib in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925144||61010|
NCT01925105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-162|Comprehensive Geriatric Assessment - Can it Improve Quality of Life|Comprehensive Geriatric Assessment - Can it Improve Quality of Life||Örebro County Council|No|Active, not recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01925105||61013|
NCT01925118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1305-6130491|Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2|Phase II Study of Irradiated Donor Lymphocyte Infusion Plus High-dose Interleukin-2 in Patients With Metastatic Malignant Melanoma and Renal Cell Carcinoma||Seoul National University Hospital|No|Recruiting|August 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||August 2013|May 23, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01925118||61012|
NCT01925092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-CH-0170|Mifepristone in Children With Refractory Cushing's Disease|An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease||Corcept Therapeutics|Yes|Withdrawn|August 2013|||December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Years|17 Years|No|||July 2014|July 31, 2014|August 8, 2013|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01925092||61014|
NCT01925378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110917-01|A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia|A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA||The University of Texas Health Science Center, Houston|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||June 2015|June 18, 2015|April 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925378||60993|
NCT01925391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120451|The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops|The Measurement of Intraocular Pressure in Nonglaucomatous Children Under Nitrous Oxide/02/Topical Anesthesia and Sevoflurane/Nitrous Oxide/Topical Anesthesia|IOP|University of Miami|Yes|Completed|January 2013|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|75|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01925391||60992|
NCT01925651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-B 01|Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer|Randomized Clinical Trial of the Impact of the Use of Bolus in the Treatment of Post Mastectomy Radiotherapy for Breast Cancer||AC Camargo Cancer Center|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|54|||Female|18 Years|N/A|No|||January 2014|January 24, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925651||60972|
NCT01925898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87/13|A Randomized, Clinical Trial of Oral Midazolam Versus Oral Ketamine for Sedation During Laceration Repair.|A Randomized, Clinical Trial of Oral Midazolam Versus Oral Ketamine for Sedation During Laceration Repair.||Assaf-Harofeh Medical Center|No|Recruiting|August 2013|July 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|10 Years|No|||August 2013|January 20, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01925898||60953|
NCT01922024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURETIS LRT55 Study - V 6.0|Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application|Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples Using the Curetis Unyvero LRT55 Application|LRT55|Curetis AG|No|Recruiting|June 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|Bronchial lavage (BAL) Tracheal aspirate (TA)|Both|18 Years|N/A|No|Non-Probability Sample|Suspicion of lower respiratory tract infection in hospitalized subjects.|February 2016|February 29, 2016|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01922024||61249|
NCT01921998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_DOG05_99|Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|BioACT|Christie Hospital NHS Foundation Trust|No|Suspended|October 2013|||November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood samples will be collected to analyse for biomarkers CK18 and FLT 3 Ligand.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Lymphoma or sarcoma identified to receive out-patient chemotherapy with an        anticipated febrile neutropenia rate of less than 20%.|February 2015|February 3, 2015|August 9, 2013||No|Trial has been suspended due to lack of resource and staff|No||https://clinicaltrials.gov/show/NCT01921998||61251|
NCT01922271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237ADE02|Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study)|FAST|Novartis|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|40 Years|N/A|No|||December 2014|December 19, 2014|August 9, 2013||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01922271||61230|
NCT01916798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 300|Intralipid Therapy for Women 35-40 Years With Positive Natural Killer Cells Undergoing Intracytoplasmic Sperm Injection (ICSI)|Intravenous Intralipid Therapy Among Women Aged 35-40 Years With Positive Peripheral Blood Natural Killer Cells Undergoing in Vitro Fertilization-Embryo Transfer: A Randomized Controlled Trial.||Cairo University|No|Recruiting|May 2013|February 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|35 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01916798||61651|
NCT01913418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 102-2320-B-039-024-|Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance|Clinical Efficacy and Serum Proteomic Profiling of Traditional Chinese Medicine, Suan-Zao-Ren Tang, for Sleep Disturbance During Methadone Maintenance: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial||China Medical University, Taiwan|Yes|Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|20 Years|N/A|No|||March 2014|March 16, 2014|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01913418||61909|
NCT01913093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000033923|N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors|N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors|N-PhenoGENICS|The Hospital for Sick Children||Recruiting|July 2013|||July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|DNA samples obtained via blood, saliva and buccal sample collection.|Both|8 Years|20 Years|No|Non-Probability Sample|Childhood leukemia survivors|May 2015|May 21, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913093||61934|
NCT01913106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000601|HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer|Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease||The Methodist Hospital System|Yes|Active, not recruiting|June 2007|December 2028|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|N/A|N/A|No|||January 2016|March 15, 2016|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913106||61933|
NCT01913379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0006|Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole|A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|41|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913379||61912|
NCT01923727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-2012|Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer|A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer|IAB2M|ImaginAb, Inc.|No|Recruiting|August 2013|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|38|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|August 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01923727||61119|
NCT01923740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-397|A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)|A Clinical Evaluation of Absorb™ BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population|ABSORB CHINA|Abbott Vascular|Yes|Active, not recruiting|July 2013|July 2019|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|480|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01923740||61118|
NCT01924026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039726|Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study|Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia (MHP)/Phenylketonuria (PKU) With Phenylalanine Levels Between 360 and 600 µmol/L Caused by Phenylalanine Hydroxylase (PAH) Deficiency.||The Hospital for Sick Children|No|Completed|September 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Those with mild form of PKU known as mild hyperphenylalaninemia (MHP) and their unaffected        siblings who fulfill the inclusion and exclusion criteria.|February 2016|February 13, 2016|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01924026||61096|
NCT01924351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056720|HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)|A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis||University of Maryland|Yes|Recruiting|February 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924351||61071|
NCT01924624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHXMU-013|Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma|Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma.: a Randomized Controlled Trial||The First Affiliated Hospital of Xiamen University|No|Recruiting|July 2013|December 2019|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|75 Years|No|||July 2013|August 15, 2013|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01924624||61050|
NCT01924884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052186|Surgical Site Infection Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy at Initial Closure|Surgical Site Infection (SSI) Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy (NPWT) at Initial Closure||Johns Hopkins University|No|Enrolling by invitation|July 2013|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All patients greater than or equal to 18 years of age undergoing intra-abdominal surgery        at Johns Hopkins Hospital by Dr. Frederic Eckhauser. Both men and women and members of all        races and ethnic groups are eligible.|August 2013|August 16, 2013|August 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924884||61030|
NCT01925157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14848|A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)|A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis||Eli Lilly and Company|No|Completed|August 2013|September 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|43|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925157||61009|
NCT01925417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001|Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea|A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study|PUNCH CD|Rebiotix Inc.|No|Completed|August 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|August 15, 2013|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01925417||60990|Small sample size (n=34) limits extrapolation of results to a larger population.
NCT01925430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA06082013|The Evaluation of a New Sleep Algorithm|The Evaluation of a New Sleep/Wake State Algorithm||ResMed|Yes|Completed|November 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers who are employees within a medical device company|May 2014|May 1, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925430||60989|
NCT01925404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0692-AM02|Promoting Physical Activity In High Poverty Neighborhoods|Promoting Physical Activity In High Poverty Neighborhoods||RAND|Yes|Recruiting|June 2013|July 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|5760|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925404||60991|
NCT01925690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033769|Development of a Motivational Intervention to Improve Treatment Adherence in MS|Development of a Motivational Intervention to Improve Treatment Adherence in MS|MIMS|University of Missouri, Kansas City|No|Completed|February 2013|September 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925690||60969|
NCT01925677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055955|Robotic Single Port Donor Nephrectomy|Use of the Intuitive Surgical da Vinci® Single-Site™ With Instruments and Accessories for Single-Port Laparoscopic Nephrectomies||University of Maryland|No|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|January 27, 2015|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925677||60970|
NCT01921491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU005|DHACM vs Other Commercially Available Treatments|DHACM vs Other Commercially Available Treatments||MiMedx Group, Inc.|No|Completed|August 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||October 2015|December 11, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921491||61290|
NCT01921738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mnts-o77|The Effect of Azithromycin in the Treatment of Chronic Periodontitis|The Effects of Systemic and Locally Azithromycin Adjunct to Scaling and Root Planning on Clinical and Microbiological Periodontal Indices in Moderate to Severe Chronic Periodontitis||Isfahan University of Medical Sciences|Yes|Completed|May 2012|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|No|||August 2013|August 10, 2013|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921738||61271|
NCT01922635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8967|Validation Lymphoqol|Validation of Metrological Properties of Questionnaire of Quality of Life LYMPHOQOL|0|University Hospital, Montpellier|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|170|||Both|6 Years|25 Years|No|||August 2013|August 12, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922635||61202|
NCT01922284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2059|Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses|A Phase I Clinical Trial Investigating Immunisation Strategies Using DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses|UKHVCSpoke003|Imperial College London|Yes|Recruiting|June 2013|June 2015|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01922284||61229|
NCT01922596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3_UG_12|Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain After TKA|Effect of Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain in Patients With Severe Pain After Total Knee Arthroplasty||University Hospital, Gentofte, Copenhagen|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|85 Years|No|||January 2014|January 9, 2014|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922596||61205|
NCT01913119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-059|A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma|A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell|Ro-ENKTL|Samsung Medical Center|Yes|Completed|July 2013|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|79 Years|No|||July 2013|July 29, 2013|July 19, 2013||||No||https://clinicaltrials.gov/show/NCT01913119||61932|
NCT01912846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRPD1C0011|An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients|An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients||Chang Gung University|No|Recruiting|January 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|462|||Both|20 Years|95 Years|No|||July 2015|July 27, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01912846||61953|
NCT01913678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B307|The Effect of Dairy Fat and Inulin on Fasting Induced Adipose Factor (FIAF) Blood Concentrations|The Effect of Dairy Fat and Inulin on Fasting Induced Adipose Factor (FIAF) Blood Concentrations|FIAF|University of Copenhagen|No|Active, not recruiting|July 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|20|||Male|23 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913678||61889|
NCT01923753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACACIA-01|A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis|A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis||Actegy Ltd.|Yes|Active, not recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|43|||Both|16 Years|N/A|No|||January 2016|January 18, 2016|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923753||61117|
NCT01923766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTCAT2|Cytotoxic T Cells to Prevent Virus Infections|Adoptive Transfer of Cord Blood T Cells to Prevent and Treat CMV, EBV and Adenovirus Infections After Transplantation||Children's Research Institute|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||August 2015|August 26, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923766||61116|
NCT01924039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055/2013|Brief Motivational Enhancement Therapy for Concurrent Disorders|Brief Motivational Enhancement Therapy for Individuals With Psychotic Disorders and Concurrent Substance Use Disorders||Centre for Addiction and Mental Health|No|Terminated|June 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|16 Years|65 Years|No|||December 2014|December 16, 2014|August 7, 2013||No|Not enough study participants|No||https://clinicaltrials.gov/show/NCT01924039||61095|
NCT01924637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3889|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|64 Years|No|||October 2014|October 15, 2014|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924637||61049|
NCT01924650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631040|A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804|A Randomized, Open Label, Single Dose, 6 Treatment, 4-way Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Three Different Particle Sizes of PH-797804 Tablet With and Without the Solubilizing Agent Sodium Lauryl Sulphate (SLS)||Pfizer|No|Withdrawn|March 2014|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924650||61048|
NCT01924897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ONC11S|Preop CPET Testing and Exercise Training in Colorectal Patients|An Investigation Into the Role of Cardiopulmonary Exercise Testing and Pre-operative Exercise Training in Patients Undergoing Major Surgery for Colorectal Cancer||University of East Anglia|Yes|Not yet recruiting||||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924897||61029|
NCT01925170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1337-05 Part B|Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts|Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer||Mayo Clinic|No|Completed|April 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|1638|||Female|40 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 30, 2014|August 15, 2013|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01925170||61008|
NCT01925443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1146-7109|Effects of Low Power Laser Therapy on Muscle Performance Isokinetic Pre-exercise in Individuals With Diabetes Mellitus Type II|||University of Nove de Julho|Yes|Suspended|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|70 Years|No|||December 2015|December 2, 2015|June 8, 2013||No|technical problems with equipment from the main outcome|No||https://clinicaltrials.gov/show/NCT01925443||60988|
NCT01921478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25271|A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis|Retrospective, Multi-center, Observational Study of Daily Practice Patterns and Outcomes of the Management of Rheumatoid Arthritis Patients Without Documented Erosions Treated With RoACTEMRA in Belgium||Hoffmann-La Roche||Completed|August 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|77|||Both|18 Years|N/A|No|Probability Sample|Retrospective survey of medical records from patients with moderate to severe rheumatoid        arthritis treated with RoActemra/Actemra (tocilizumab) who did not have documented        erosions at the start of RoACTEMRA treatment .|August 2013|August 9, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921478||61291|
NCT01921504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2013-006|Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial|Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial||Kyunghee University Medical Center|Yes|Recruiting|August 2013|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|75 Years|No|||August 2013|August 9, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921504||61289|
NCT01922037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28528|An Observational Study in Patients With Asthma Initiating Treatment With Xolair (Omalizumab)|A Prospective Observational Study To Evaluate Predictors of Clinical Response To Omalizumab||Hoffmann-La Roche||Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|807|Samples With DNA|Blood samples|Both|12 Years|N/A|No|Probability Sample|Patient's with moderate to severe asthma initiating treatment with omalizumab|March 2016|March 1, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922037||61248|
NCT01921751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1201|High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer||Radiation Therapy Oncology Group|Yes|Recruiting|August 2013|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|346|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921751||61270|
NCT01890720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130010|Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section|Use of Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section in Women With BMI >=30||Odense University Hospital|No|Recruiting|September 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|948|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890720||63645|
NCT01922297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090438|Juvenile Offender HIV Prevention and Drug Abuse Services|Juvenile Offender HIV Prevention and Drug Abuse Services|Day Treatment|University of Miami|No|Completed|January 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01922297||61228|
NCT01922310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-01-2012|Communication Regarding Organ and Tissue Donation in Intensive Care|Communication With Families Regarding Organ and Tissue Donation After Death in Intensive Care Study|COMFORT|NSW Organ and Tissue Donation Service|Yes|Recruiting|May 2013|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|400|||Both|N/A|N/A|No|||October 2015|October 18, 2015|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01922310||61227|
NCT01922609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1075/13|Prediction of Carotid Occlusion Intolerance by Transcranial Doppler Evaluation in Patients Undergoing Carotid Artery Stenting With Proximal Flow Arrest Protection System.|Prediction of Carotid Occlusion Intolerance by Transcranial Doppler Evaluation in Patients Undergoing Carotid Artery Stenting With Proximal Flow Arrest Protection System.||University Hospital, Motol|No|Recruiting|May 2013|||August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|19 Years|N/A|No|Probability Sample|Adult patients with carotid artery stenosis indicated for carotid artery stenting with the        use of proximal flow arrest protection device.|August 2013|August 11, 2013|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922609||61204|
NCT01922622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM 4(qqqq)07/05/13|Minimum Effective Intrathecal Dose of Local Anaesthetic With Fentanyl for Fractured Neck of Femur(Dose Finding Study).|Determination of the Initial Minimum Effective Dose of 0.5% Bupivacaine With 20mcg of Fentanyl Via a Spinal Catheter for Operative Fixation of Fractured Neck of Femur.||Cork University Hospital|Yes|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|||Both|60 Years|N/A|No|Non-Probability Sample|patients with fractured neck of femur undergoing surgical repair of their fracture|February 2015|February 2, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922622||61203|
NCT01912612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.044|Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain|A Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients With Chronic Pain||University of Michigan Cancer Center|No|Recruiting|August 2013|July 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|132|||Female|25 Years|110 Years|No|||November 2015|November 23, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912612||61971|
NCT01912625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01357|Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Suspended|October 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 29, 2013|No|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01912625||61970|
NCT01913444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-12-00147|Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO|Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation||Children's Hospital Los Angeles|Yes|Withdrawn|July 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|30 Days|No|||January 2015|January 10, 2015|July 29, 2013|Yes|Yes|Unable to enroll patients into study.|No||https://clinicaltrials.gov/show/NCT01913444||61907|
NCT01913132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2013/322|PICO Above Incisions After Vascular Surgery|PICO Versus Standard Dressing Above Groin Incisions After Vascular Surgery - a Prospective Randomized Trial||Skane University Hospital||Recruiting|November 2013|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01913132||61931|
NCT01913431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETV_HB_IV|Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B|A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B||Dong-A ST Co., Ltd.|Yes|Recruiting|July 2013|||June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|65 Years|No|||July 2013|July 30, 2013|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01913431||61908|
NCT01924364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12030255|Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using TGI Device|Structural Fat Grafting for Craniofacial Trauma: Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using the Tissue Genesis Cell Isolation System™ (CIS) Device|AFIRM-TGI|University of Pittsburgh|Yes|Active, not recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|December 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924364||61070|
NCT01924052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-141|CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load|CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load||Danish Headache Center|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|18 Years|65 Years|No|||August 2013|August 14, 2013|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01924052||61094|
NCT01892514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN-13|Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head|Combined Treatment of Early and Advanced Osteonecrosis of the Femoral Head With Core Decompression and Grafting With Demineralized Bone Matrix (DBM) or Homologous Lyophilized Bone Chips (LBC) Together With Platelet-rich-fibrin (PRF) and Concentrated Bone Marrow (CBM)|AVN-13|Istituto Ortopedico Rizzoli|No|Recruiting|April 2013|April 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|60 Years|No|||April 2014|March 7, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01892514||63507|
NCT01892527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2012-001|Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects|A Single-Arm Phase II Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects With Locally Advanced or Metastatic Colorectal Cancer With Wild-Type KRAS||Istituto Clinico Humanitas|Yes|Active, not recruiting|March 2013|March 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|80 Years|No|||February 2016|February 15, 2016|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01892527||63506|
NCT01892813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N32-FY13Q2-S0-P00723|Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers|Tailored Tobacco Intervention||University of Iowa|No|Not yet recruiting|July 2013|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 3, 2013|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892813||63485|
NCT01892826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC8851|Frozen Blastocyst Transfer in Natural Cycle|Cryopreserved Thawed Blastocyst Transfer in Natural Cycle With or Without hCG Administration||Universitair Ziekenhuis Brussel|No|Completed|February 2009|March 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|17 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892826||63484|
NCT01893125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNV2197944/202|Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy|A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy||Convergence Pharmaceuticals|No|Completed|August 2013|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|80 Years|No|||October 2014|October 29, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893125||63461|
NCT01893450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA19508091|Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment|Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Terminated|June 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|45 Years|No|||July 2013|July 2, 2013|June 28, 2013||No|Efficacy demonstrated on a preliminary analysis|No||https://clinicaltrials.gov/show/NCT01893450||63436|
NCT01925456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813672|Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder|Validation of Instruments for Pragmatic Clinical Trials for Overatcive Bladder|PfizerOABLUT|University of Pennsylvania|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|75|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|December 8, 2014|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925456||60987|
NCT01925703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0551|Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure|Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure||University of North Carolina, Chapel Hill|No|Completed|April 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||May 2014|August 12, 2015|May 30, 2013|No|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01925703||60968|
NCT01922050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1013|A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis|Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis||LEO Pharma|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|324|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922050||61247|
NCT01894217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029836|Statin Therapy to Improve Medication Adherence|Pilot Study: Statin Therapy to Improve Medication Adherence||Duke University|No|Completed|May 2011|April 2014|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894217||63377|
NCT01922323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-140|Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors|Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors||Baylor Research Institute|No|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Each subject will provide samples of urine and blood at specific timepoints as outlined in      the protocol|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be comprised of living liver donors.|February 2015|February 9, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922323||61226|
NCT01891032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0261|Assessment of Acute Renal Injury During Partial Nephrectomy Using Neutrophil Gelatinase-associated Lipocalin (NGAL): Prospective Comparative Study Between Open, Video-assisted Minilaparotomy, Laparoscopic, and Robotic-assisted Laparoscopic Surgery|||Yonsei University|No|Completed|June 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|160|||Both|20 Years|N/A|No|Non-Probability Sample|1. the adult patients with open partial nephrectomy          2. the adult patients with laparoscopic partial nephrectomy          3. the adult patients with VAMS partial nephrectomy, 4: the adult patients with robotic             partial nephrectomy|July 2014|July 24, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01891032||63621|
NCT01891292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP 172, 10/11|Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy|A Phase 2 Study of the Efficacy of Antioxidant Therapy Compared With Enalapril in Slowing the Progression of Sickle Nephropathy in Children||The University of The West Indies|Yes|Not yet recruiting|July 2013|September 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|2 Years|18 Years|No|||June 2013|June 27, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01891292||63601|
NCT01922934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM3469|A Toolbox Approach to Obesity Treatment in Primary Care|A Toolbox Approach to Obesity Treatment in Primary Care|Toolbox|Denver Health and Hospital Authority|No|Active, not recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|80 Years|No|||November 2015|November 1, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922934||61179|
NCT01922947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA032808-01A1|Motivational Interviewing Integrated With Social Network Counseling for Teens|Motivational Interviewing Integrated With Social Network Counseling for Teens||Virginia Commonwealth University|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|14 Years|18 Years|No|||December 2015|December 4, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01922947||61178|
NCT01923220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO-ARD-01-2012|Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis|An Open-Label, Randomized Study to Evaluate the Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis In Breast Cancer Patients Undergoing Radiation Therapy.|ARD|HealOr|No|Not yet recruiting|September 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Female|18 Years|N/A|No|||August 2013|August 12, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01923220||61157|
NCT01913145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040412|Comparison Study of Lay Person Finger Stick Versus Blood Draw|Usability and HbA1c Method Comparison Study Using Lay Person Micro-Blood Specimens||Home Access Health Corporation|Yes|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|128|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|March 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913145||61930|
NCT01913457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP018/25388|Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients|Evaluation of Lung Doppler Signals in Pediatric and Adult Patients||Echosense Ltd.|Yes|Recruiting|July 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The study targets to enroll 200 patients (see inclusion criteria): 100 patients will be        children without cardiopulmonary diseases, 50 patients will be children undergoing heart        catheterization, 50 patients will be adults undergoing heart catheterization|July 2013|January 21, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01913457|1 Day|61906|
NCT01913743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINDSETS - TOS|The Effects of Mindsets on the Brain's Response to Food Cues|The Effects of Mindsets on the Brain's Response to Food Cues|MINDSETS|The Miriam Hospital|No|Recruiting|July 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|35|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The recruited sample will include both males and females between the ages of 25-55 years        with BMIs between 25-40. This age range reflects the modal ages for obese participants        presenting for behavioral weight loss, and individuals with BMIs greater than 40 typically        do not fit comfortably within the scanner bore. As with previous studies at the WCDRC, all        participants will be weight stable (defined as within +/- 5 lbs. for the past two months).|July 2013|July 30, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01913743||61884|
NCT01913704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMC16/CZ/12|Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers|A Randomised Controlled Double Blind Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers in Conjunction With Standard Best Practice||Inotec AMD Limited|No|Recruiting|October 2012|October 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01913704||61887|
NCT01913717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S768/113|Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion|Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion||European Institute of Oncology|No|Active, not recruiting|January 2014|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Male|18 Years|N/A|No|||February 2015|January 21, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913717||61886|
NCT01913730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-MMY-2084|Maintenance Therapy With Subcutaneous Bortezomib|A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY||Stichting Hemato-Oncologie voor Volwassenen Nederland|No|Recruiting|November 2013|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|216|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01913730||61885|
NCT01892267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00079056|Self-Propelled Versus Standard Percutaneous Endoscopic Gastrojejunostomy(PEG-J); RCT|Comparison Outcomes and Complications of Self-Propelled vs. Standard Percutaneous Endoscopic Gastrojejunostomy (PEG-J); a Randomized Single Blind Clinical Trial||Johns Hopkins University|Yes|Suspended|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2015|January 22, 2015|July 1, 2013||No|We had problems with the PEG-J tube being studied|No||https://clinicaltrials.gov/show/NCT01892267||63526|
NCT01892540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE15112|PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer|Positron Mammographic Imaging (PMI)||Case Comprehensive Cancer Center|Yes|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892540||63505|
NCT01892839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEY0026APR|Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis|Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis||Palo Alto Veterans Institute for Research|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|85 Years|No|||July 2015|July 9, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892839||63483|
NCT01892852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuCIPN|Acupuncture for Chemotherapy-induced Peripheral Neuropathy|Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study||Pusan National University Hospital|No|Recruiting|June 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01892852||63482|
NCT01892865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-113|Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency|Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency||VA Office of Research and Development|No|Active, not recruiting|August 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1500|||Both|N/A|N/A|No|||July 2015|July 24, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892865||63481|
NCT01893138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003|Autologous Muscle Derived Cells for Female Urinary Sphincter Repair|A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence||Cook||Recruiting|October 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|267|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893138||63460|
NCT01893463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004|Prospective Evaluation of the iTClamp50 to Provide Temporary Wound Closure|Prospective Study to Evaluate the Safety and Effectiveness of the iTClamp50 to Provide Temporary Wound Closure||Innovative Trauma Care Inc.|No|Withdrawn|August 2013|||December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Pre-hospital or emergency department patients requiring wound closure for hemorrhage        control|December 2013|December 18, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893463||63435|
NCT01893476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258837|A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management|Tailored Implementation for Chronic Diseases.|TICD-COPD|Medical Universtity of Lodz|No|Completed|September 2013|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|540|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893476||63434|
NCT01890772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1217|Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1|A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus||Southern California Institute for Research and Education|No|Withdrawn|August 2013|||October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890772||63641|
NCT01893723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_51|Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery|Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery : Multicenter Randomized Clinical Trial|AIVOC-ANI|University Hospital, Lille|No|Terminated|June 2012|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|37|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 18, 2013||No|Changes of usual clinical practices|No||https://clinicaltrials.gov/show/NCT01893723||63415|
NCT01893970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44360|SWIFT Study in the ED|Social Work Intervention for Adults With Mild Traumatic Brain Injury: SWIFT Pilot Study|SWIFT|University of Washington|No|Recruiting|April 2013|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01893970||63396|
NCT01893710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric PD Biopsy Study|International Pediatric Peritoneal Biopsy Study|International Pediatric Peritoneal Biopsy Study in Children on PD and Healthy Controls||Heidelberg University|No|Recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Parietal ond omental peritoneal membrane specimen will be collected in all groups|Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|See below eligibility data|July 2015|July 29, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893710|3 Years|63416|
NCT01925716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-1303|Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids|A Randomized Double Blind Controlled Crossover Trial to Assess the Effects of Dietary Oils on Fasting Lipoprotein Lipids||ACH Food Companies, Inc.|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01925716||60967|
NCT01921764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA08|Implementation of Physical Exercise at the Workplace (IRMA08) - Healthcare Workers|Implementation of Physical Exercise at the Workplace (IRMA08) - Healthcare Workers|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|September 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|67 Years|Accepts Healthy Volunteers|||January 2014|January 26, 2014|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01921764||61269|
NCT01894542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/572-14|A Study of the Effects of Intake of Two Cod Protein Fractions on Glucose Homeostasis and Inflammation in Overweight and Obese Adults|An 8 Week Study to Compare the Effects of Water Soluble and Non-water Soluble Cod Proteins on Glucose Homeostasis and Inflammatory Markers in Overweight and Obese Adults|FISK3-2|University of Bergen|No|Active, not recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894542||63352|
NCT01894802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100092|Cortical Recording and Stimulating Array Brain-Machine Interface|A Sensorimotor Microelectrode Brain-Machine Interface for Individuals With Tetraplegia|CRS-BMI|University of Pittsburgh|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|22 Years|70 Years|No|||December 2015|December 14, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894802||63332|
NCT01891006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120163|Intervention for Postpartum Infections Following Caesarean Section|Intervention for Postpartum Infections Following Caesarean Section - a Randomized Controlled Trial|APIPICS|Odense University Hospital|No|Active, not recruiting|May 2011|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01891006||63623|
NCT01891019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-147|Thalidomide in the Treatment of Chronic Plaque Psoriasis.|Thalidomide in the Treatment of Chronic Plaque Psoriasis.||Wake Forest School of Medicine|No|Completed|April 2003|June 2009|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891019||63622|
NCT01891279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0260|Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?|The Use of Elemental Formula in Neonates Post Small Bowel Resection: Improved Success to Wean From Total Parenteral Nutrition?||The University of Texas Health Science Center, Houston|No|Recruiting|November 2011|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|40|||Both|N/A|1 Year|No|||March 2014|March 28, 2014|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01891279||63602|
NCT01913158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-13-002|Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in the Treatment of Symptomatic Internal Hemorrhoids||G & W Laboratories Inc.|No|Active, not recruiting|October 2013|June 2014|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913158||61929|
NCT01913171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULA 233401|Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression|Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression||Helsinki University|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|53|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01913171||61928|
NCT01913782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-ER-101-143|The Impact of Epidural Steroid Analgesia on Functional MRI for Patients With LBP|The Impact of Epidural Steroid Analgesia on Functional MRI for Patients With Low Back Pain||National Cheng-Kung University Hospital|Yes|Recruiting|October 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|None Retained|fMRI image|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who first visited in our pain clinic for low back pain with root sign will be        included in this study.|August 2013|August 5, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01913782||61881|
NCT01913756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-340857|Dairy Products and Metabolic Syndrome|||Norwegian University of Life Sciences||Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|153|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913756||61883|
NCT01913769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-102032-F|Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan|Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan: Correlation Between Radiotherapy Dose Distribution, Myocardial Perfusion, Cardiac Function, Serum Biomarkers and Clinical Prognosis.||Far Eastern Memorial Hospital|Yes|Active, not recruiting|July 2013|July 2016|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Venous blood sampling|Both|20 Years|80 Years|No|Non-Probability Sample|Patients with thoracic malignancy who scheduled further locoregional RT.|July 2013|July 30, 2013|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913769||61882|
NCT01893983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-083|Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans|Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans|COACH|VA Office of Research and Development|Yes|Recruiting|October 2015|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01893983||63395|
NCT01893996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09816|Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease|Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease||University of California, San Francisco|Yes|Recruiting|July 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893996||63394|
NCT01894256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00006|Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment||AstraZeneca|No|Active, not recruiting|November 2013|April 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|57|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|July 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894256||63374|
NCT01894269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sysucc-HCC010|Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication|Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial||Sun Yat-sen University|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2013|July 20, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894269||63373|
NCT01894568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13422|A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment|A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naïve Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|July 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|392|||Both|20 Years|N/A|No|||September 2015|September 3, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894568||63350|
NCT01894828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutri01|Nutritional Supplementation in Patients With no Signs of Malnutrition|The Effect of Nutritional Supplementation in Cancer Patients With no Clinical Signs of Malnutrition||MedSource Polska|Yes|Recruiting|April 2011|||August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|July 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894828||63330|
NCT01890759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA70|Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation|Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Aged 9 to 23 Months in India and in the Russian Federation||Sanofi|No|Active, not recruiting|June 2013|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|300|||Both|9 Months|17 Months|Accepts Healthy Volunteers|||February 2016|February 3, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890759||63642|
NCT01890785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-123|Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers|A Phase 1, Open-label, Randomized, 3-period Crossover Study Evaluating the Relative Bioavailability of SPD489 When the Contents Are Emptied Into a Soft Food and Orange Juice in Healthy Adult Subjects||Shire|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|June 27, 2013|No|Yes||No|March 14, 2014|https://clinicaltrials.gov/show/NCT01890785||63640|
NCT01890798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117402|Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol|A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study||GlaxoSmithKline|No|Withdrawn|January 2014|July 2015|Anticipated|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|5 Years|N/A|No|||March 2014|March 20, 2014|June 27, 2013|Yes|Yes|Rights for the further development of drisapersen have been transferred to Prosensa. Therefore    this study has been cancelled before enrollment.|No||https://clinicaltrials.gov/show/NCT01890798||63639|
NCT01891045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OQ45-11-1|Impact of Online Patient Feedback (OQ) to Therapist|Addiction Treatment Dropout Prevention - Impact of Online Patient Feedback (OQ-45.2) to Therapist||Oslo University Hospital|Yes|Recruiting|July 2011|July 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|16 Years|26 Years|No|||June 2013|June 27, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01891045||63620|
NCT01891305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMT-VT-1161-CL-003|A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis||Viamet|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||October 2014|December 22, 2014|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891305||63600|
NCT01894230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044989|Genetically Guided Statin Therapy|Genetically Guided Statin Therapy to Improve Medication Adherence||Duke University|No|Recruiting|July 2013|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|375|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894230||63376|
NCT01894243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00005|Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment||AstraZeneca|No|Recruiting|March 2014|August 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|July 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894243||63375|
NCT01893957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143-1024|Effects of Electrical Stimulation on Blood Circulation and Sensibility Tactil in Lymphadenectomy|Evaluation of the Effects of High Voltage Electrical Stimulation in the Floe Blood and Tactile Sensitivity of Women Undergoing Axillary Lymphadenectomy||University of Sao Paulo|Yes|Recruiting|August 2012|September 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01893957||63397|
NCT01894815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELECT-TDCS|Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial|Escitalopram and Transcranial Direct Current Stimulation in Major Depressive Disorder: a Double-blind, Placebo-controlled, Randomized, Non-inferiority Trial|ELECT-TDCS|University of Sao Paulo|Yes|Recruiting|October 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894815||63331|
NCT01890733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-CL-02|InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Efficacy and Safety of InSpace™ Device in Comparison to Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.||OrthoSpace Ltd.|No|Terminated|September 2012|September 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|40 Years|95 Years|No|||September 2012|October 14, 2015|June 27, 2013||No|Very low recruitment rate|No||https://clinicaltrials.gov/show/NCT01890733||63644|
NCT01890746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117146|A Safety and Efficacy Study of Eltrombopag in Subjects With AML|A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy||GlaxoSmithKline|Yes|Active, not recruiting|September 2013|March 2017|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890746||63643|
NCT01892280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11|Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study|Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study||Joslin Diabetes Center|Yes|Active, not recruiting|November 2013|August 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|310|||Both|13 Years|17 Years|No|||February 2016|February 22, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892280||63525|
NCT01892293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP-0011-002|CT Antigen TCR-Engineered T Cells for Myeloma|A Phase I/IIa, Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in Patients With Relapsed or Progressive Disease in Multiple Myeloma||Adaptimmune|No|Recruiting|September 2013|April 2031|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892293||63524|
NCT01891526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-338|Single Dose of 9-cis-retinoic Acid in Hepatic Patients|The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency||University Hospital, Gentofte, Copenhagen|Yes|Completed|December 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|Serum and urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 patients with hepatic disease and 10 controls|June 2013|June 28, 2013|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01891526||63583|
NCT01891786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE/0437|Coronary Heart Disease Risk in Type 2 Diabetes|A Randomised Control Trial (RCT) to Investigate the Effectiveness of a Selfmanagement Intervention and Personalised Genetic Risk Information to Reduce Risk of Coronary Heart Disease in Patients With Type 2 Diabetes.|CORDIA|City University, London|Yes|Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|312|||Both|25 Years|74 Years|No|||November 2015|November 18, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891786||63563|
NCT01892072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k0113011-2013VEGF|VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway|VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway|HCC|First Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|October 2012|March 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces      individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial.      Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.|Both|16 Years|80 Years|No|Non-Probability Sample|hepatocellular carcinoma patients underwent surgical therapy|July 2013|July 10, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892072||63541|
NCT01913470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062895|Study of Losartan in the Treatment of NAFLD in Children|A Pilot Study of Losartan in the Treatment of Pediatric NAFLD||Emory University|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|12 Years|19 Years|No|||December 2015|December 8, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913470||61905|
NCT01924078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metronomic Therapy|Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer|Capecitabine Metronomic Chemotherapy Combined With Aromatase Inhibitors in Postmenopausal Hormone-receptor-positive Breast Cancer||Fudan University|Yes|Recruiting|October 2010|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||August 2013|August 14, 2013|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924078||61092|
NCT01924091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME-02B|PK/PD of Single Dose Dapivirine Vaginal Film|Comparison of the Pharmacokinetics and Pharmacodynamics of Single Dose Dapivirine Vaginal Gel and Film Formulation||International Partnership for Microbicides, Inc.|No|Not yet recruiting|September 2013|||September 2014|Anticipated|Phase 1|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Prevention|2||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 13, 2013|August 13, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01924091||61091|
NCT01914107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPM-ward|Real-time Cancer Pain Assessment and Intervention|A Randomized, Controlled Clinical Study: Assess and Intervene Cancer Pain of Advanced Malignant Tumor Patients in Real-Time, Using the Real-time Cancer Pain Assessment and Intervention System Based on Cloud Computing Concept.||Sun Yat-sen University|No|Recruiting|March 2012|June 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||August 2015|August 26, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01914107||61857|
NCT01894282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBI001|Mind Body Intervention for Chronic Lower Back Pain|Mind Body Intervention for Chronic Lower Back Pain: A Pilot Study||Canandaigua VA Medical Center|No|Recruiting|July 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|69 Years|No|||February 2015|February 3, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894282||63372|
NCT01894295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-03-27-18831|Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects|||Tehran University of Medical Sciences||Recruiting|June 2012|September 2013|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|96|||Both|22 Years|52 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894295||63371|
NCT01894581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1420|Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women|Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women||University of Colorado, Denver|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||January 2015|February 23, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894581||63349|
NCT01894841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-026|Veterans Coping Long-term With Active Suicide|Veterans Coping Long-Term With Suicide|CLASP-VA|VA Office of Research and Development|No|Recruiting|February 2014|September 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894841||63329|
NCT01890811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0294|Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function|Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function||Texas A&M University|No|Withdrawn|June 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|55 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|June 27, 2013||No|Recruitment challenges|No||https://clinicaltrials.gov/show/NCT01890811||63638|
NCT01891058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130331|Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED|A Randomized, Controlled Comparison of Electrical Versus Pharmacological Cardioversion for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter (RAFF)|RAFF-2|Ottawa Hospital Research Institute|Yes|Recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|468|||Both|16 Years|N/A|No|||April 2015|April 20, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01891058||63619|
NCT01891071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LVR-01|Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis|Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis||Ottawa Hospital Research Institute|Yes|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|35|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891071||63618|
NCT01891084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKMI003.3|The Benefit and Harm of Fever Suppression by Antipyretics in Influenza|A Randomized Controlled Trial on the Effect of Fever Suppression by Antipyretics on Influenza||The University of Hong Kong|No|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01891084||63617|
NCT01891318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7312|Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study|Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study||Case Comprehensive Cancer Center|Yes|Recruiting|July 2013|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891318||63599|
NCT01891539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBDOX01|Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma|Observational Prospective Study on Chemoembolization Using Doxorubicin Drug-eluting Bead in Patients With Unresectable Hepatocellular Carcinoma|DEBDOX|International Group of Endovascular Oncology|Yes|Recruiting|May 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|primary care clinic|April 2015|April 16, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891539|12 Months|63582|
NCT01894555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL105897-PARes-II|Pharmacogenomics of Antiplatelet Response - II (PARes-II)|Pharmacogenomics of Antiplatelet Response - II|PARes-II|Johns Hopkins University|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|33|||Both|45 Years|75 Years|No|||September 2014|September 5, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894555||63351|
NCT01892085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-00071|Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants|Adequate Breast Milk for Improved Health of Very Low Birth Weight Preterm Infants||University of Florida|No|Recruiting|November 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01892085||63540|
NCT01892592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-12SSidn-06-H|Discovering Healthcare Innovations to Address Disparities in Stroke (DIADS)|Discovering Healthcare Innovations to Address Disparities in Stroke|DIADS|Kaiser Permanente|No|Active, not recruiting|June 2013|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3698|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01892592||63501|
NCT01892605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-IRB-970391|The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy|The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|April 2009|December 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|18 Years|No|||July 2013|July 1, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01892605||63500|
NCT01892566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL117349|Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV|Using mHealth to Respond Early to Acute Exacerbations of COPD in HIV (mREACH)|mReach|Johns Hopkins University|Yes|Recruiting|September 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|100 Years|No|||February 2016|February 22, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892566||63503|
NCT01892579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-NIA|Reducing Agitation in People With Dementia: the Customized Activity Trial|Reducing Agitation in People With Dementia: the Customized Activity Trial|TAP|Johns Hopkins University|Yes|Recruiting|November 2013|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892579||63502|
NCT01892904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16114|Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea|A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [β-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhea for 24 Weeks||Bayer|No|Completed|July 2013|August 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Female|20 Years|N/A|No|||September 2015|September 8, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01892904||63478|
NCT01923792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH002a|ToleroMune House Dust Mite Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|105|||Both|18 Years|64 Years|No|Non-Probability Sample|Subjects previously randomised in study TH002 and completed all dosing visits and the PTC|May 2014|May 14, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01923792||61114|
NCT01923805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1128|Vitagel Revision Total Knee Arthroplasty|A Prospective Randomized Evaluation of a Collagen/Thrombin Autologous Platelet Hemostatic Agent During Revision Knee Arthroplasty||The Cleveland Clinic|No|Recruiting|April 2013|||March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||August 2013|August 14, 2013|July 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923805||61113|
NCT01924377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCH-01|Characterization and Elimination of Mother Rotors|Characterization and Elimination of Mother Rotors - A Mechanism-targeted Approach for Catheter Ablation of Atrial Fibrillation|CENTRA-AF|Maria Cecilia Hospital|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|85 Years|No|||August 2013|December 3, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01924377||61069|
NCT01894594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-12-13|Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease|Alkali Therapy in Subjects With Sickle Cell Disease (SCD) - Evaluation of Efficacy, Safety, and Beneficial Effects||University Hospital Case Medical Center|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|July 9, 2013|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894594||63348|
NCT01894854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Furlong Evolution_EW|RSA Study of Furlong Evolution With and Without Collar|Evaluation of the Furlong Evolution Uncemented Hip Prosthesis With Special Emphasize on the Use of Collared Design or Not. A Prospective, Randomized Study Evaluated by RadioStereometric Analysis (RSA) and DXA.||Region Skane|No|Active, not recruiting|October 2012|October 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||November 2014|November 24, 2014|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894854||63328|
NCT01891097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUP-005|Combined Electroacupuncture and Auricular Acupuncture for Persistent Insomnia|Combined Electroacupuncture and Auricular Acupuncture for Persistent Insomnia: A Randomized Controlled Trial of Dose-Response Effect||The University of Hong Kong|No|Recruiting|July 2012|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|224|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01891097||63616|
NCT01891110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-26|Prevention of Orthostatic Hypotension With Electric Stimulation in Persons With Acute SCI|Prevention of Orthostatic Hypotension With Electric Stimulation in Persons With Acute SCI||Swiss Paraplegic Centre Nottwil|No|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01891110||63615|
NCT01891331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMT-VT-1161-CL-004|A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection)|A Phase 2a, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis||Viamet|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|65 Years|No|||March 2014|December 22, 2014|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891331||63598|
NCT01922479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00265|Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure|Pilot RAndomized Controlled Trial of FerrIC CarboxymaltosE in ASIAns With Heart Failure (the PRACTICE-ASIA-HF) Study|PRACTICEASIAHF|National University Hospital, Singapore|Yes|Recruiting|September 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|90 Years|No|||January 2015|January 15, 2015|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922479||61214|
NCT01923363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13044|PK/PD of High Dose Pip/Tazo in Obese Patients|Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin/Tazobactam in Obese Patients||Loma Linda University|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|44|||Both|18 Years|89 Years|No|||March 2016|March 1, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01923363||61146|
NCT01923376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401550|Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)|Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)|HELP|New York Methodist Hospital|Yes|Withdrawn|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||May 2015|May 9, 2015|July 25, 2013|Yes|Yes|Not enough staff to collect data|No||https://clinicaltrials.gov/show/NCT01923376||61145|
NCT01923948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2013-001-09|Preoperative Pain Control in Liver Surgery Patients|A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2014|February 21, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923948||61102|
NCT01923961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSA0113|Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration|Impact of an Increased Sodium Chloride Concentration in the Infusion Fluid of Predilution Hemodiafiltration on the Removal of Protein-Bound Uremic Toxins||EXcorLab GmbH|No|Recruiting|August 2013|November 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|8|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01923961||61101|
NCT01896596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRSG 12-03|Hepatitis B Vaccination in Infants|A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age|Infanrix|Public Health England|No|Recruiting|July 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|300|||Both|2 Months|3 Months|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01896596||63194|
NCT01896882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA - 120109|Dietary Sodium Restriction in Hemodialysis Patients|Effects of Dietary Sodium Restriction in Hemodialysis Patients: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Enrolling by invitation|March 2012|August 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||February 2012|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896882||63173|
NCT01897142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2341001|A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects||Pfizer|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|49|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|June 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897142||63153|
NCT01897155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH_AP-UC-2012|Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.|Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.||Pontificia Universidad Catolica de Chile|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2013|July 8, 2013|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01897155||63152|
NCT01897415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08212|Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer|Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897415||63132|
NCT01897727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080821012|Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment|Randomized Controlled Trial of Spironolactone Versus Standard of Care Blood Pressure Treatment on the Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension||University of Alabama at Birmingham|No|Completed|January 2009|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|19 Years|80 Years|No|||December 2013|December 13, 2013|July 9, 2013||No||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01897727||63108|Unanticipated enrollment challenges led to small numbers of participants analyzed.Open-label study design may have prevented a placebo effect.An outlier in AHI was present in the control group.
NCT01897168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135180|Bone Mineral Content in Healthy Children|Bone Mineral Content in Healthy Children||Arkansas Children's Hospital Research Institute|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Serum and urine may be collected from study participants.|Both|5 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children|November 2015|November 11, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01897168||63151|
NCT01924962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK 1-2011|Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries|A Randomized Comparison of Recanalisation With Implantation of Cypher Sirolimus Eluting Coronary Stents and Medical Therapy|REVASC|Heart Center Bad Krozingen|No|Recruiting|August 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01924962||61024|
NCT01924975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-line study|Saphenous Vein Cannulation in Infants and Small Children|Ultrasound-image Guided Versus Traditional Landmark Technique for Saphenous Vein Cannulation in Infants and Small Children||University of Iowa|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|102|||Both|N/A|4 Years|No|||January 2015|January 20, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924975||61023|
NCT01924949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0125|Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection|An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Nosocomial Genotype 1 HCV Infection||Gilead Sciences|No|Completed|July 2013|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|August 14, 2013|Yes|Yes||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01924949||61025|
NCT01925261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPX-100|A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees||OrthoTrophix, Inc|Yes|Active, not recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|120|||Both|25 Years|75 Years|No|||May 2015|May 11, 2015|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925261||61001|
NCT01925248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|474534-1|Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?|Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?||University of California, Davis|Yes|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|70 Years|No|||November 2015|November 30, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01925248||61002|
NCT01925508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-021083|Evaluation of a Physical Therapy Protocol on Quality of Life Musculoskeletal Pain and Anxiety in Women With Preeclampsia|Evaluation of a Physical Therapy Protocol on Quality of Life, Musculoskeletal Pain and Anxiety in Women With Preeclampsia||University of Sao Paulo|No|Active, not recruiting|July 2012|October 2013|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|60|||Female|N/A|N/A|No|Probability Sample|The population will be recruited in the infirmary of the high-risk pregnancy Hostptal das        Clinicas of Ribeirao Preto|July 2012|August 15, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01925508||60983|
NCT01921608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-07|Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV|One-Arm, Open Label, Prospective Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV.|RMC-07|Ministry of Health, Rwanda|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1001|||Male|21 Years|49 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|February 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01921608||61281|
NCT01921621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AANA Copernicus Bankart - 1|Proficiency Based Training in Surgery - Employing An Arthroscopic Bankart Repair|The Copernicus Initiative - The Study of Proficiency Based Training in Arthroscopic Surgery||Arthroscopy Association of North America|Yes|Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|44|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 27, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921621||61280|
NCT01921894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVED-P|Vitamin D and Severe Asthma Exacerbations|A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations|SAVED-P|University of Pittsburgh|Yes|Recruiting|August 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|6 Years|14 Years|No|||August 2013|August 9, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921894||61259|
NCT01921907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD17137|Evaluation of a Topical Treatment for Actinic Keratosis|Phase 2 Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study||Assuta Hospital Systems||Completed|July 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|30 Years|90 Years|No|||February 2015|March 9, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01921907||61258|
NCT01922804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2vita|Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification|Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification|K2vita|University of Aarhus|No|Active, not recruiting|July 2013|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01922804||61189|
NCT01923090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_12-098|Finasteride, Dutasteride and Insulin Action|An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers.|FIND-IT|University of Birmingham|No|Recruiting|August 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923090||61167|
NCT01922518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulStMary-RVP|Impact of Right Ventricular Pacing Determined by Electrocardiography|Impact of Right Ventricular Pacing Determined by Electrocardiography; Prospective Randomized Trial|RVpacing|Seoul St. Mary's Hospital|No|Recruiting|March 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01922518||61211|
NCT01922817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012DM07|DPP4inhibitors in Type 1 Diabetes|DPP4 Inhibitors in Type 1 Diabetes||University of Dundee|Yes|Recruiting|September 2012|||April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|14|||Both|18 Years|65 Years|No|||August 2013|August 12, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01922817||61188|
NCT01922830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-OS-196-CTIL|Probiotics and Microbiota in Bariatric Surgery|Probiotics and Microbiota in Bariatric Surgery||Tel-Aviv Sourasky Medical Center|No|Recruiting|October 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2014|March 24, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922830||61187|
NCT01923662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1039-R|A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes|Exploiting Selective Recruitment to Prolong Standing After SCI||VA Office of Research and Development|No|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01923662||61124|
NCT01923675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EY0021242|Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation|Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation||University of Washington|No|Not yet recruiting|September 2013|December 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|240|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923675||61123|
NCT01923974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO-2013|The Analgesic Effects of Melatonin|The Analgesic Effects of Melatonin: A Randomized, Placebo-controlled, Double-blinded Study on Healthy Volunteers||Herlev Hospital|Yes|Completed|August 2013|August 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|36|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01923974||61100|
NCT01923987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-1208-001-002|Short Course Radiotherapy and Biochemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis|Multicenter Phase II Study of Short Course Radiotherapy Followed by Biochemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis||Korea Cancer Center Hospital|No|Recruiting|August 2012|August 2019|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01923987||61099|
NCT01924273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2013-9337|Novel Treatment for Port Wine Stain Birthmarks|Novel Treatment for Port Wine Stain Birthmarks||University of California, Irvine|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924273||61077|
NCT01896297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.173|Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function|A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy||Boehringer Ingelheim||Completed|July 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|July 8, 2013||||No||https://clinicaltrials.gov/show/NCT01896297||63217|
NCT01896609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV05012012|Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population|A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)|Quadritherapy|MinaPharm Pharmaceuticals|Yes|Recruiting|June 2013|June 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|50 Years|No|||July 2013|July 10, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01896609||63193|
NCT01896622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130160|The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers|The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|July 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|March 8, 2016|July 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896622||63192|
NCT01896895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3074_1|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid|Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naïve Subjects With Blepharospasm||Merz Pharmaceuticals GmbH|No|Recruiting|November 2013|October 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896895||63172|
NCT01897181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2013-0455|Central Auditory Processing and the Use of Hearing Aids|Evaluation of the Central Auditory Processing in Patients (Elder Than 45 Years Old) With Bilateral Sensorineural Hearing Loss and the Change of the Central Auditory Processing Ability by the Use of Hearing Aids (CAPHA)|CAPHA|Asan Medical Center|No|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|27|||Both|45 Years|N/A|No|||February 2016|February 14, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01897181||63150|
NCT01924741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPPS registry|Registry of Major Liver Resections Including ALPPS and Other Liver Resections in Two Stages|International Registry to Assess Outcomes of Major Liver Resections Requiring Two Interventions Including the New Operation Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS)|ALPPSREG|University of Zurich|No|Enrolling by invitation|August 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primarily non-resectable liver tumors|July 2014|July 30, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924741|5 Years|61041|
NCT01925274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151005|A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer|A Randomized Phase 2 Study Of PF-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With Kras And NRAS Wild Type Metastatic Colorectal Cancer||Pfizer|No|Terminated|November 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 15, 2013|Yes|Yes|Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no    safety or efficacy issues that contributed to this decision.|No||https://clinicaltrials.gov/show/NCT01925274||61000|
NCT01925521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-KOA-1301i|OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.|A phase1,Randomized,Double-blind,Placebo-controlled,Two-part,Sequential Ascending Single and Multiple Dose Study to Investigate the Safety, Tolerability and the PK and PD Profile of OPS-2071 in Healthy Male Korean Subjects|OPS-2071Ph1|Korea Otsuka Pharmaceutical Co.,Ltd.|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|96|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01925521||60982|
NCT01925534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-OF13-01|Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation|Pilot Study of Optiflow as a NIV Rest Therapy|OPTINIV|Tufts Medical Center|No|Recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925534||60981|
NCT01925768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-006|Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis|A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis||Celgene|Yes|Active, not recruiting|September 2013|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925768||60963|
NCT01921569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLATEP001|Micronized Dehydrated Human Amniotic Membrane Suspension in the Treatment of Lateral Epicondylitis|Micronized Dehydrated Human Amniotic Membrane (dHACM) Suspension in the Treatment of Lateral Epicondylitis.||MiMedx Group, Inc.||Terminated|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 18, 2013||No|Study closed by sponsor|No||https://clinicaltrials.gov/show/NCT01921569||61284|
NCT01921920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9584C00010|Prilosec Bioequivalence Study in Healthy Volunteers|An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck||AstraZeneca|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|August 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921920||61257|
NCT01922492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHUH_AIT_1|Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.|Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.||Seoul National University Hospital|Yes|Active, not recruiting|May 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|80 Years|No|||November 2015|November 17, 2015|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922492||61213|
NCT01922505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1308-214-108|Eradication Rates of Helicobacter Pylori and Its Affecting Factors|The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years||Seoul National University Bundang Hospital|No|Completed|January 2003|May 2013|Actual|May 2013|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2500|||Both|16 Years|92 Years|No|Non-Probability Sample|H. pylori positive patient|August 2013|August 11, 2013|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922505|4 Weeks|61212|
NCT01922531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC001|Defining Axonal Injury in Children With Mild Traumatic Brain Injury|Defining Axonal Injury in Children With Mild Traumatic Brain Injury||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|59|Samples With DNA|Whole blood and serum|Both|11 Years|16 Years|No|Non-Probability Sample|Patients presenting to a Pediatric Emergency Department|August 2013|August 13, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922531||61210|
NCT01923402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJRT-CSD0906|Development of Biomarkers of Effect From Chronic Tobacco Usage|Development of Biomarkers of Effect From Chronic Tobacco Usage: A Clinical Study Examining Metabolic Profiling, Inflammation, and Oxidative Stress||R.J. Reynolds Tobacco Company|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|120|Samples With DNA|Blood, urine, buccal cells, and saliva|Male|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study target population included smokers (SMK), moist snuff consumers (MSC), and        non-tobacco consumers (NTC), in generally good health, as determined by the Investigator.        Exclusive tobacco smokers: n=40        Moist Snuff consumers: n=40        Non-tobacco consumers: n=40|February 2016|February 17, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01923402||61143|
NCT01915355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 13D.230|Pulsed Dye Laser Treatment of Onychomycosis|Pulsed Dye Laser Treatment of Onychomycosis||Thomas Jefferson University|Yes|Recruiting|July 2013|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01915355||61761|
NCT01915680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYGRI Yoga Study 13.04|Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions|Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions||Glaucoma Associates of New York|No|Completed|June 2013|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma Practice and Yoga Studios|December 2013|December 23, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01915680||61736|
NCT01915966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICE-MUT-02-1933-2013|Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients|Randomized Clinical Trial of a Ginger and Cardamom Gelatin Compared to a Camomile and Lemon Juice Infusion in Control of Xerostomy in Terminally Ill Patients||Fundacio Salut i Envelliment UAB|No|Completed|April 2013|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|No|||February 2014|February 10, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915966||61714|
NCT01916239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBAS-CSIC-2|Pomegranate Extract Supplementation in Colorectal Cancer Patients|Phase I-II Study of Pomegranate Extract Formulations in Colorectal Cancer Patients: Metabolic and Gene Expression Profiling in Tumoral and Normal Colon Tissues|POMEcolon|National Research Council, Spain|No|Completed|June 2012|April 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01916239||61693|
NCT01916252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM2012MENOS65|Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old|A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 (MEL-200) Versus Busulfan-melphalan (BUMEL), and Consolidation With VRD-GEM in Patients Under 65 Years Old With Newly-diagnosed, Symptomatic Multiple Myeloma|GEM2012MENOS65|PETHEMA Foundation|Yes|Recruiting|September 2013|May 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916252||61692|
NCT01916512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFINITY|Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia|Investigation of Relationship Between Cholesteryl Ester Transfer Protein Deficiency and Carotid/Coronary Atherosclerosis in Patients With Hyperalphalipoproteinemia|INFINITY|Osaka University|No|Recruiting|February 2012|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples Without DNA|serum and plasma|Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We will explain about this study with the attached leaflet to the male and female        examinees at the age of 40 and above who undergo annual health check up at Hiraga General        Hospital in Akita Prefecture and obtain written consent to participate in the study. The        written consents will be stored. The participant information will be made anonymous with        sequential ID numbers. However the comparative lists of each participant and ID number        will be stored in the locked shelf in case of disclosure requests from participants in        future. The above will be conducted at Hiraga hospital and the samples will be sent to and        measured to collect data in Osaka University. The analysis of data will be done at Osaka        University and Akita University.|August 2013|April 14, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01916512||61672|
NCT01896310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013SDU-QILU-G01|New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy|New Classification of Gastric Pit Patterns and Vessel Architecture Using Probe-based Confocal Laser Endomicroscopy||Shandong University|Yes|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|272|Samples With DNA|endoscopic biopsies will be taken at suspicious lesions|Both|18 Years|80 Years|No|Non-Probability Sample|Prospective patients scheduled for pCLE examination at Qilu Hospital, Shandong University|May 2014|May 9, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01896310||63216|
NCT01896323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-223-CP-003|CC-223 and Ketoconazole Drug-Drug Interaction Study|An Open-Label, Two-Period, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Single Dose Pharmacokinetics of CC-223 in Healthy Adult Male Subjects||Celgene|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896323||63215|
NCT01896635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCUS|Faecal Microbiota Transplantation in Ulcerative Colitis|Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety|FOCUS|The University of New South Wales||Active, not recruiting|November 2013|August 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01896635||63191|
NCT01896648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120021266|Sexual Dysfunction in Type 2 Diabetic Women|Sexual Dysfunction in Type 2 Diabetic Women: Study on Prevalence and on Risk||University of Pavia|No|Recruiting|June 2013|June 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|306|Samples Without DNA|The following parameters will be assessed:      Blood: ematology, glycated hemoglobin, fasting plasma glucose, fasting plasma insulin, total      cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, urea,      transaminases, electrolytes, homocysteine, high sensitivity C-reactive protein (hs-CRP),      metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules      (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen Activator Inhibitor-1      (PAI-1).      Urine: complete urinalysis, 24-hour microalbuminuria|Female|18 Years|N/A|No|Probability Sample|Type 2 diabetic women|July 2013|July 6, 2013|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01896648||63190|
NCT01896908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA - 120437|Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction|Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Preserved Ejection Fraction: a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Enrolling by invitation|March 2013|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896908||63171|
NCT01897194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00059288|Using EEG to Study Coma in the Neurocritical Care Unit|A Wireless EEG Patch Device for Continuous Electrographic Monitoring and Study of Coma in the Neurocritical Care Unit||University of Utah|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Neuro Critical Care Patients|December 2014|December 9, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897194||63149|
NCT01925300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_BCS_101|Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin|A Randomized, Open-label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Bisoprolol and Rosuvastatin in Healthy Adult Volunteers||CJ HealthCare Corporation|No|Enrolling by invitation|July 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 18, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925300||60998|
NCT01924988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120110|Prostate Embolization for Benign Prostatic Hyperplasia|Prostate Embolization for Benign Prostatic Hyperplasia||Georgetown University|No|Recruiting|August 2013|January 2019|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|50 Years|90 Years|No|||December 2015|December 15, 2015|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924988||61022|
NCT01925287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EA1334AHS1|Oral Bioavailability of Curcumin From Micronized Powder and Liquid Micelles in Healthy Young Women and Men|Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain||University of Hohenheim|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|23|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 15, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01925287||60999|
NCT01925547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0315679-HS3|Micellar Curcumin and Metabolic Syndrome Biomarkers|Effect of Micellar Curcumin on Inflammation and Lipid Metabolism Markers||University of Hohenheim|No|Completed|July 2013|October 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01925547||60980|
NCT01925560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13359|Tolerance and Utilization of Agave Inulin in Healthy Adults|Tolerance and Utilization of Agave Inulin in Healthy Adults||University of Illinois at Urbana-Champaign|No|Completed|January 2013|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01925560||60979|
NCT01925781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16684|e-Cigarettes Versus NRT Gum for Smoking Cessation|e-Cigarettes Versus Nicotine Replacement Therapy for Smoking Cessation||Creighton University|No|Terminated|August 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|19 Years|N/A|No|||December 2015|December 10, 2015|August 16, 2013|Yes|Yes|IND required|No|December 10, 2015|https://clinicaltrials.gov/show/NCT01925781||60962|
NCT01925794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA 2012-01|The PzF Shield Trial|COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term Dual Anti-Platelet Therapy||CeloNova BioSciences, Inc.|Yes|Active, not recruiting|August 2013|February 2020|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|296|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925794||60961|
NCT01921946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FMS-CT-116|To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin|A Phase Ⅰ Study to Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|August 2013|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|October 20, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921946||61255|
NCT01922544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT1|EP-Catheter Guided CS-Lead Implantation|Conventional Versus EP-Catheter Guided Implantation of Coronary Sinus Lead in Patients Undergoing Cardiac Resynchronization Therapy||University of Cologne|Yes|Completed|August 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|120|||Both|18 Years|N/A|No|Probability Sample|Patients with symptomatic heart failure and reduced left ventricular ejection fraction.        Asynchronic contraction of left and right ventricle was reflected by QRS duration > 120 ms        in left precordial leads.|August 2013|August 13, 2013|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922544||61209|
NCT01922843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2MD-7H-2B|A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis|A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis|2MD-7H-2B|Deltanoid Pharmaceuticals|Yes|Completed|September 2013|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922843||61186|
NCT01922856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-24|Challenge Study of an ETEC Vaccine|A Phase 2b Controlled Efficacy Study of Intradermally Delivered ETEC Fimbrial Tip Adhesin Vaccine Against Experimental Challenge With ETEC H10407 in Healthy Adult Volunteers||U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|September 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922856||61185|
NCT01922219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6127|Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression|Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression||New York State Psychiatric Institute|No|Completed|December 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922219||61234|
NCT01922232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00240|MRI and Bladder Cancer Chemotherapy|Pilot Study of Role of MRI in Neoadjuvant Chemotherapy for Bladder Cancer||New York University School of Medicine|Yes|Withdrawn|August 2013|July 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically confirmed muscle invasive urothelial carcinoma of the bladder        with clinical stage T2-T4a N0/X M0 disease who are candidates for cisplatin-based        neoadjuvant chemotherapy and subsequent radical cystectomy|October 2014|October 1, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922232|1 Year|61233|
NCT01915082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI003|Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation|A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation|AZI003|Universitaire Ziekenhuizen Leuven|No|Completed|September 2013|||October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||September 2013|November 10, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01915082||61782|
NCT01915342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMV07-2013-1010|Developing Optimal Focal Muscle Vibration for Improving Spasticity|Optimization of Physical Focal Stimulation Parameters for Improving Spasticity and Identification of Neurophysiological Mechanism||Seoul National University Hospital||Completed|August 2013|September 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 8, 2014|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01915342||61762|
NCT01916811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130114|Load Quantitative MRI Study of Incipient LBP Patients.|Load Quantitative MRI Study of Incipient LBP Patients.||Central South University|Yes|Recruiting|January 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|60|||Female|18 Years|27 Years|Accepts Healthy Volunteers|Probability Sample|young female nurse|August 2013|August 5, 2013|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01916811||61650|
NCT01917071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Karasmatched|The Effect of Directional Specific Thoracic Spine Mobilization on Cervical Spine Pain|The Effect of Directional Specific Thoracic Spine Mobilization on Cervial Spine Pain.||Chatham University|Yes|Completed|August 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|July 27, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917071||61630|
NCT01916538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0081|Anorexia Nervosa Genetics Initiative|Anorexia Nervosa Genetics Initiative|ANGI|University of North Carolina, Chapel Hill|No|Recruiting|June 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|13000|Samples With DNA|The blood sample participants provide will be used to identify biological characteristics      and other biological "markers." Some analyses will include genetic analyses which are      measured using DNA and can look at places in DNA, and others can analyze most of the genome.      Other analyses measure a large number of proteins. Still others assess the messenger      substance (called RNA) that transfers information from DNA to protein. Investigators plan to      store the blood specimens and data indefinitely.      Investigators will be collecting DNA to permit immediate and future genetic analyses and      analyses of immune, endocrine, and proteins. All blood will be biobanked indefinitely to      allow for assays that may become available in the future analyses.|Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a lifetime diagnosis of anorexia nervosa|October 2015|October 7, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01916538||61670|
NCT01896661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07572112.7.0000.5327|Effect of Antihypertensive Agents Over Sleep Apnea|The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial||Hospital de Clinicas de Porto Alegre|No|Recruiting|December 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|40 Years|N/A|No|||April 2015|April 16, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896661||63189|
NCT01896921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056162|Switch to Maraviroc + Integrase Inhibitor|Switch to Maraviroc and Integrase Strand Transfer Inhibitor Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens||University of Maryland|Yes|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01896921||63170|
NCT01897207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG226_02|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer||Cantonal Hospital of St. Gallen|No|Completed|November 2002|October 2011|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||August 2015|August 14, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01897207||63148|
NCT01897454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-570|Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer|A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|November 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897454||63129|
NCT01925313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_BEP_101|A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers|A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers||CJ HealthCare Corporation|No|Completed|December 2012|May 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2012|August 15, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925313||60997|
NCT01925573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056719|Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)|Proposed Pilot Study of Combined Optune+ Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Naive Recurrent Glioblastoma||University of Maryland|Yes|Recruiting|May 2014|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|22 Years|N/A|No|||February 2016|February 1, 2016|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01925573||60978|
NCT01925807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAMO_SI_Group_001|Building Resilience and Attachment in Vulnerable Adolescents|Brief Group Intervention for Adolescents With Mild to Moderate Suicidal Ideation and Their Caregivers: Preliminary Investigation for a Novel Treatment Approach|BRAVA|Children's Hospital of Eastern Ontario|No|Recruiting|February 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|54|||Both|13 Years|17 Years|No|||October 2015|October 6, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01925807||60960|
NCT01925820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205003MPC|Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B|Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B||National Taiwan University Hospital|Yes|Recruiting|January 2013|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|540|||Both|20 Years|70 Years|No|||December 2014|December 3, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925820||60959|
NCT01921647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-108|The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects|The Exploration for Pharmacodynamics and Pharmacokinetic Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects|YH4808-108|Yuhan Corporation|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|95|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921647||61278|
NCT01921660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921660||61277|
NCT01921673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1302|Dovitinib Plus Docetaxel in Gastric Cancer|A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy||Asan Medical Center|No|Completed|August 2013|||August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|74 Years|No|||November 2015|November 26, 2015|August 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01921673||61276|
NCT01922557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012081RC|Thoracic Fluid Content and Acute Lung Injury|The Association of Thoracic Fluid Content and Acute Lung Injury in Liver Transplantation||National Taiwan University Hospital||Completed|January 2011|June 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|65 Years|No|Non-Probability Sample|end stage liver disease patients scheduled for liver transplantation in National Taiwan        University Hospital were enrolled.|August 2013|August 12, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922557||61208|
NCT01914536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-POM-2013-46|A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI|A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI|POMPE 2013|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|July 2013|July 2017|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood an urine samples will be obtained|Both|8 Years|N/A|No|Non-Probability Sample|Adult onset Pompe Patients|August 2013|August 29, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914536||61824|
NCT01914549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914549||61823|
NCT01923116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42802.000.12|Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia|Therapeutic Vaccination Against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men|VACCAIN-T|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|August 2013|February 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Male|18 Years|N/A|No|||December 2015|December 22, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01923116||61165|
NCT01923389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2901009|Multiple Dose Study Of PF-05231023 In Obese Adult Subjects|A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects||Pfizer|No|Terminated|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|4|||Both|21 Years|70 Years|No|||September 2014|September 8, 2014|July 30, 2013|No|Yes|The study was terminated on December 19th, 2013 due to a business decision by the Sponsor. No    safety concerns have been observed in this study.|No|September 8, 2014|https://clinicaltrials.gov/show/NCT01923389||61144|
NCT01916525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verve-139226|Effectiveness of Exercise Cardiac Rehabilitation|Effectiveness of Exercise-based Rehabilitation Program for Patients After Acute Coronary Syndrome|EFEX-CARE|University of Oulu|No|Recruiting|February 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|N/A|No|||August 2013|August 1, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01916525||61671|
NCT01916564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SplitAMBPrep|Split-dose Versus Same-day Reduced-volume PEG-ELS Plus Bisacodyl for Morning Colonoscopy|Efficacy and Tolerability of Split-dose Versus Same-day Administration of Reduced-volume PEG-ELS Plus Bisacodyl for Morning Colonoscopy: a Randomised Trial||University of Malaya|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|303|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01916564||61669|
NCT01912638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trab-Olo-SG|Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Mitomycin C and Provisc in Steroid Induced Glaucoma|Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Mitomycin-C and Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma||National Centre of Ophthalmology named after academician Zarifa Aliyeva|Yes|Enrolling by invitation|July 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|N/A|No|||July 2015|July 18, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912638||61969|
NCT01912820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000886|Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery|A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy||Jonsson Comprehensive Cancer Center|Yes|Recruiting|January 2014|||September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Male|40 Years|75 Years|No|||March 2016|March 4, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912820||61955|
NCT01912833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0788|Study of Exposure to Stress, Postpartum Mood, Adverse Life Events, and Hormonal Function Among Latinas (SEPAH Latina)|Assessing the Association Between Stressful Life Events, Hormonal Dysregulation, and Postpartum Depression Among Lactating Latina Mothers: A Pilot Study|SEPAH|University of North Carolina, Chapel Hill||Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|Samples With DNA|oxytocin, cortisol, and adrenocorticotropic hormone (ACTH)|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Latinas (foreign and U.S.-born)|December 2014|December 5, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01912833||61954|
NCT01896375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH1101|Gutkha Pan Masala Ban Impact Study in Mumbai|Impact of 'Gutkha and Pan Masala Ban' in the State of Maharashtra on Users and Vendors|GPMBan|Tata Memorial Hospital|Yes|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|73|||Both|18 Years|N/A|No|Non-Probability Sample|The study is conducted on those people who were using Gutkha and / or Pan Masala when the        ban was imposed.|July 2013|July 10, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01896375||63211|
NCT01896674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuma1478|Knowledge-based Iterative Model Reconstruction at Low-kilovoltage (kV) Cardiac Computed Tomography (CT)|Value of Knowledge-based Iterative Model Reconstruction at Low-kilovoltage Cardiac 256-slice CT: A Comparison of Filtered Back Projection-, Hybrid-, and Iterative Model Reconstruction||Kumamoto University|No|Completed|May 2012|||January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|21|||Both|45 Years|85 Years|No|Probability Sample|We enroll consecutive patients.|July 2013|July 10, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896674||63188|
NCT01896687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRA-LBP|Trial of Scrambler Therapy or Sham Treatment for Low Back Pain|A Pilot Randomized Trial of Scrambler Therapy or Sham Treatment for Persistent Nonspecific Low Back Pain||Virginia Commonwealth University|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|No|||August 2014|August 29, 2014|May 13, 2013||No||No|August 18, 2014|https://clinicaltrials.gov/show/NCT01896687||63187|
NCT01896934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130360|Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression|Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)||Vanderbilt University|No|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|60 Years|N/A|No|||September 2015|September 11, 2015|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896934||63169|
NCT01896947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAP MR study|3T MRI Versus MR Arthrogram in SLAP Lesions|Three Tesla Magnetic Resonance Imaging Compared to Magnetic Resonance Arthrogram in Diagnosing Superior Labrum Anterior Posterior (SLAP) Lesions||Henry Ford Health System|Yes|Not yet recruiting|September 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|All skeletally mature patients with a suspected SLAP lesion on clinical exam will be        eligible for the study.|July 2013|July 10, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896947||63168|
NCT01925001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-206|Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis|A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease||Sangart|Yes|Withdrawn|October 2013|October 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||October 2013|October 25, 2013|August 14, 2013||No|Sangart ceased operations|No||https://clinicaltrials.gov/show/NCT01925001||61021|
NCT01925339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00070747|Esthetic Outcomes of Immediately Placed Implants Receiving Immediate Provisionalization and Delayed Restoration|||University of Michigan|Yes|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925339||60996|
NCT01925586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304011944|Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)|Atypical Lesions of the Breast: Close Observation vs. Excision|ALCOVE|Yale University|No|Active, not recruiting|August 2013|||August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|40 Years|N/A|No|Probability Sample|Patients presenting to the Breast Clinic at Smilow for evaluation and management of ADH        will be identified. After screening and informed consent, patient demographics and study        specific data points will be obtained by interview and chart review. Patients will then be        randomized to surgical excision or close observation.|August 2015|August 18, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01925586||60977|
NCT01925833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insertion|Adenoma Detection by Polypectomy During Both Insertion and Withdrawal|Comparison of Adenoma Detection by Polypectomy During Both Insertion and Withdrawal Versus Only Withdrawal of Colonoscopy: a Randomized, Controlled Trial||The Catholic University of Korea|Yes|Not yet recruiting|September 2013|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1600|||Both|50 Years|80 Years|No|||August 2013|August 16, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925833||60958|
NCT01921634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoAppy-42383|Endometriosis and the Appendix - Incidence and Pathologic Analysis|Endometriosis and the Appendix: Is Incidence Related to Method of Pathologic Analysis?||Milton S. Hershey Medical Center|No|Not yet recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|51 Years|No|||August 2013|August 9, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01921634||61279|
NCT01921933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCS_TP1070|The Optiflow Patency and Maturation Study|The "OPEN" Study Optiflow PatEncy and MaturatioN|OPEN|Bioconnect Systems, Inc|Yes|Completed|February 2014|January 2016|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921933||61256|
NCT01914263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlliancellsPuRui-01|Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection|Phase 1 Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection||Alliancells-PuRui Biocience Co., Ltd.|Yes|Recruiting|March 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||July 2014|April 15, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01914263||61845|
NCT01915693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCTU030|ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study|Palliative Radiotherapy in Addition to Self-expanding Metal Stent for Improving Dysphagia and Survival in Advanced Oesophageal Cancer: ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study.|ROCS|Velindre NHS Trust|Yes|Not yet recruiting|August 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|496|||Both|16 Years|N/A|No|||July 2013|July 31, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915693||61735|
NCT01914848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPS Trial|Multiprofessional Advance Care Planning and Shared Decision Making for End of Life Care|Multiprofessional Advance Care Planning and Shared Decision-making for End of Life Care MAPS Trial|MAPS|University of Zurich|No|Recruiting|July 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01914848||61800|
NCT01914861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheba-0361-13-AJW-CTIL|Cortisol Diurnal Variation and the Risk for Developing Post Traumatic Stress Disorder|||Sheba Medical Center||Not yet recruiting|July 2013|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Plasma cortisol levels plasma neuropeptide y|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men/Women, age 21-65, who have arrived at the Chaim Sheba Medical Center ER within six        hours of exposure to a traumatic event.|July 2013|July 31, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914861||61799|
NCT01915706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047845|The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants|The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants||Duke University|Yes|Recruiting|September 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915706||61734|
NCT01916577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0388|Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation|Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation||University of Colorado, Denver|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01916577||61668|
NCT01915979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPA-EC-02-2012|Effect of Plasma Rich in Growth Factors in Rotator Cuff Tendinopathy|Role of Biological Therapy in Rotator Cuff Tendinopathy. Effectiveness of Plasma Rich in Growth Factors Regarding Functional Capacity and Pain Compared With the Conventional Treatment Using Steroids||Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias|No|Recruiting|February 2014|||May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|84|||Both|40 Years|70 Years|No|||May 2015|May 4, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01915979||61713|
NCT01915992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01412-41|Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies|Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2013|January 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 29, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01915992||61712|
NCT01916291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propess in PROM or GA<38|Safety and Efficacy of Dinoprostone (Propess) in the Women With Premature Rupture of Membrane or Gestational Age <38|||Seoul National University Hospital||Recruiting|July 2013|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|194|||Female|20 Years|50 Years|No|||August 2013|September 1, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01916291||61689|
NCT01912651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00046677|The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery|The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery||University of Michigan|Yes|Recruiting|July 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01912651||61968|
NCT01916824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066705|Effects of Treatment on Decision-making in Major Depression|Effects of Treatment on Decision-making in Major Depression||Emory University|No|Active, not recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|August 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916824||61649|
NCT01900886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEI-HCC-2010-01|Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C|Prospective Observational Study to Assess Personality Disorders in Prison Populations for Hepatitis C Treatment. "|Perseo|Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria|No|Active, not recruiting|December 2010|December 2013|Anticipated|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|263|Samples With DNA|Whole blood|Both|18 Years|65 Years|No|Non-Probability Sample|The study population will consist of patients with chronic hepatitis C mono-or co-infected        with HIV.|December 2010|July 12, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900886||62867|
NCT01901198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921301|Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers|A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Healthy Volunteers||Beijing Bio-Fortune Ltd.|No|Completed|April 2013|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01901198||62843|
NCT01901406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0094|Change of Retinally-Induced Aniseikonia in Patients With Epiretinal Membrane After Vitrectomy|||Yonsei University|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|20 Years|90 Years|No|Non-Probability Sample|patients with epiretinal membrane who had metamorphopsia or had imparied vision, therefore        planned to undergo vitrectomy|August 2014|August 11, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901406||62827|
NCT01901419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB 1-102-05-049|Nitroglycerin Infusion During Cardiac Surgery|Nitroglycerin Infusion During Rewarming in Cardiac Surgery and Its Effects on Tissue Perfusion and Coagulation||Tri-Service General Hospital|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|20 Years|80 Years|No|||July 2013|July 13, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901419||62826|
NCT01925014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAT|Low vs. Standard Dose CT for Appendicitis Trial|A Multi-institutional Trial Comparing Clinical Outcomes Following Low- vs. Standard-dose Abdominal CT as the First-line Imaging Test in Adolescents and Young Adults With Suspected Acute Appendicitis|LOCAT|Seoul National University Bundang Hospital|Yes|Recruiting|December 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|3000|||Both|15 Years|44 Years|No|||February 2016|February 1, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925014||61020|
NCT01925027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120025|Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study|Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study||Lepu Medical Technology (Beijing) Co.,Ltd|Yes|Recruiting|July 2013|November 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|85 Years|No|||December 2015|December 14, 2015|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01925027||61019|
NCT01925352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIHD|Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease|Phase 2 Study of Adenovirus Hepatocyte Growth Factor for Treatment of Ischemic Heart Disease||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|70 Years|No|||August 2013|August 19, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925352||60995|
NCT01925859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IED-PK01-2013|EryDex Pharmacokinetics in Healthy Volunteers|Pharmacokinetics Study to Measure Plasma Concentrations of Dexamethasone Following EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) Infusion in Healthy Volunteers|EryDex|Erydel|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|May 29, 2015|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925859||60956|
NCT01925599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP101|BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma|Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma||Greater Houston Retina Research|No|Recruiting|July 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole Blood|Both|18 Years|N/A|No|Probability Sample|Patients age > 18 years, diagnosed with choroidal nevi or uveal melanoma|February 2016|February 3, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925599||60976|
NCT01925846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212003RINC|Pseudomonal Type Three Secretion System and Contact Lens Associated Microbial Keratitis|Association of Type Three Secretion System (T3SS) of Pseudomonas Aeruginosa With Pathogenesis of Contact Lens-Associated Microbial Keratitis (CLMK)||National Taiwan University Hospital|No|Recruiting|January 2013|July 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|180|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|In order to understand the pathogenesis of CLMK, especially pseudomonal related CLMK, we        proposed to recruit 180 volunteers who will wear different contact lens materials. We then        collect the used contact lens and analyze 1) the microbiota on the used contact lens; 2)        the bacterial-contact lens adhesion of wild strains, pscC mutant strains (T3SS        needle-comples mutant), cytotoxic strain, and invasive strain P. aeruginosa; 3) the effect        of shearing forces on bacterial-contact lens adhesion; 4) the bacteriocidal effect of        multipurpose solution on different strains of P. aeruginosa.|April 2014|April 14, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925846||60957|
NCT01922245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062951|tDCS and Aphasia Treatment|tDCS and Aphasia Treatment||Hunter College|Yes|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01922245||61232|
NCT01915368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01933|Determining Optimal Post-Stroke Exercise (DOSE)|Determining Optimal Post-Stroke Exercise (DOSE)||University of British Columbia|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|19 Years|N/A|No|||July 2015|July 23, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01915368||61760|
NCT01915381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS|Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities|Improving Adherence Healthy Lifestyle on a Smartphone Based on Complementation Adults With Intellectual Disabilities|APPCOID|University of Malaga|Yes|Active, not recruiting|March 2013|July 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||September 2013|December 3, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01915381||61759|
NCT01915394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TurkNICU-RSV|Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)|Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics; TurkNICU-RSV Study: A Multicentric, Prospective Trial|TurkNICU-RSV|Ankara University|No|Completed|September 2013|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|N/A|90 Days|No|Non-Probability Sample|Hospitalized RSV infected newborn infants in the NICU.|January 2015|January 13, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01915394||61758|
NCT01915407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGD 051|AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction|AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction||Aggredyne, Inc.|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|aspirin naïve subjects over 18|August 2013|August 1, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915407||61757|
NCT01916265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCDiab01|Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages|A Randomised, Single Center, Three-period Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages at Four Different Blood Glucose Concentrations||Profil Institut für Stoffwechselforschung GmbH||Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|6|||Both|18 Years|65 Years|No|||August 2013|February 4, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01916265||61691|
NCT01916278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1215|Safety and Efficacy Study of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine|A Randomized, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine||Q-Med AB|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01916278||61690|
NCT01916304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-9999-401-BE|Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation|A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.||Takeda|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 1, 2013||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01916304||61688|
NCT01916876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT 148.2/2013|Impact of Medical Follow-up Discharge Package|A Randomised Controlled Trial of an Integrated Post-discharge Transitional Care Package for General Medical In-patients in Cape Town, South Africa|RECALL-CT|University of Cape Town|No|Withdrawn|March 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 1, 2013||No|Funding shortage|No||https://clinicaltrials.gov/show/NCT01916876||61645|
NCT01916837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1668|Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer|Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer||Jules Bordet Institute|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|180|Samples Without DNA|This study includes the collection of fresh-frozen tumor biopsies at the time of breast      cancer surgery.|Both|18 Years|N/A|No|Non-Probability Sample|This study includes patients diagnosed with early-stage invasive breast cancer and        operable disease.|August 2013|August 2, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01916837||61648|
NCT01912885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MunickP|Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome|Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome: Randomized Blind Clinical Trial||University of Sao Paulo General Hospital|No|Recruiting|March 2012|April 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|145|||Female|18 Years|N/A|No|||June 2013|July 29, 2013|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01912885||61950|
NCT01912859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NextSteps1|Next Steps: a Community-led Solution to Address Childhood Obesity|Next Steps: a Community-led Solution to Sustaining Healthy Behaviors in Families Addressing Childhood Obesity||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|2 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01912859||61952|
NCT01900899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200088|Study to Evaluate the Persistence of Antibodies After GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children|Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children||GlaxoSmithKline||Active, not recruiting|July 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|173|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2015|February 4, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900899||62866|
NCT01900912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDGOPP1024012|Evaluating the Impact of Community Led Total Sanitation Programs in Mali|Evaluating the Impact of Community Led Total Sanitation in Mali. A Randomized Controlled Trial|CLTS|Universidad Nacional de La Plata|No|Completed|January 2011|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39246|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900912||62865|
NCT01901211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-423|Physical and Social Benefits of Multi-Player Interactive Computer Play Games in Youth With Cerebral Palsy|CP Fit 'n' Fun Project: Physical and Social Benefits of Multi-Player Interactive Computer Play Games in Youth With Cerebral Palsy||Holland Bloorview Kids Rehabilitation Hospital|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|9 Years|19 Years|No|||January 2016|January 11, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01901211||62842|
NCT01901432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/12/2357/45|A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera|A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera||Italfarmaco|No|Recruiting|October 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901432||62825|
NCT01925053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02/2013|Flintstone Foods 1|A Pilot Study on Gastric Layering and Emptying Induced by a Palaeolithic Inspired Meal||Institute of Food Research|Yes|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|4|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925053||61017|
NCT01925066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1206-156-004|Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation|Optimal Two-Stage Phase 2 Study of Efficacy and Pharmacokinetics of Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation||Seoul National University Hospital|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|19 Years|N/A|No|||December 2015|December 16, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925066||61016|
NCT01921686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28604|Morphological Markers of Gastroesophageal Reflux Disease (GERD)|Dilation of Intercellular Spaces as Morphological Markers of Gastroesophageal Reflux Disease (GERD)In Children||Baylor College of Medicine|No|Active, not recruiting|March 2013|December 2016|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|54|Samples Without DNA|Three esophageal biopsy samples|Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children between the ages of 8-18 years scheduled for endoscopy for clinical indication.|December 2015|December 16, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921686||61275|
NCT01921959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDK101926A|Fit Moms in Partners, Children, and Other Members|Effects of Postpartum Weight Loss Intervention on Partner and Offspring Weight||California Polytechnic State University-San Luis Obispo|Yes|Active, not recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Partners of postpartum women|December 2015|December 19, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921959||61254|
NCT01921972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Modul E.2 II|The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease|Competence Network - Dementia (BMBF) "Pharmacological and Psychosocial Treatment" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease|AD-Combi|Charite University, Berlin, Germany|Yes|Completed|November 2004|May 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|50 Years|N/A|No|||August 2013|August 12, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921972||61253|
NCT01914016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMU ELHF109-121|Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop|Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop:Feasibility of Instrumented Gait Analysis in Clinical Practice.||Queen Margaret University|No|Recruiting|September 2013|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|80 Years|No|||April 2015|April 22, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01914016||61864|
NCT01915719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVNICTUS|Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure.|Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure. A Prospective Randomized Clinical Trial.|IVNICTUS|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|August 2013|February 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|374|||Both|18 Years|100 Years|No|||November 2015|November 30, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01915719||61733|
NCT01915732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114543|A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris|A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% Clindamycin as Clindamycin Phosphate and 5% Benzoyl Peroxide) Once Daily Gel Compared With Clindamycin Phosphate Gel (1% Clindamycin as Clindamycin Phosphate) Twice Daily in the Treatment of Mild to Moderate Acne Vulgaris.||GlaxoSmithKline|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1018|||Both|12 Years|45 Years|No|||August 2014|November 20, 2014|April 5, 2013||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01915732||61732|
NCT01915420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSURE ROT|The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions|Postmarketing Surveillance Registry to Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Following Rotational Atherectomy for the Treatment of Complex Coronary Lesions - The ASSURE ROT Registry|ASSURE ROT|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|75 Years|No|Probability Sample|Patients with complex coronary artery lesions|February 2015|February 5, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01915420|3 Years|61756|
NCT01916317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH project 902|Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer|Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer||Tata Memorial Hospital|Yes|Recruiting|December 2011|December 2021|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Female|18 Years|99 Years|No|||November 2015|November 24, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916317||61687|
NCT01916330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHOB-PK1|Development of Pharmacokinetics Model in Pregnancy Women and Fetus|||Seoul National University Hospital||Recruiting|December 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Female|20 Years|50 Years|No|Non-Probability Sample|preterm labor, PPROM in pregnant women from tertiary university hospital|August 2013|November 20, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01916330||61686|
NCT01922336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB2-G11-NHV|Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects|A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects||Samsung Bioepis Co., Ltd.|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|159|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922336||61225|
NCT01922349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.9|Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|August 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|98|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|August 12, 2013||||No||https://clinicaltrials.gov/show/NCT01922349||61224|
NCT01916850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-110-NRM|Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects|A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects||Lexicon Pharmaceuticals||Completed|August 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916850||61647|
NCT01916863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-111-NRM|Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects|A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™ (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods||Lexicon Pharmaceuticals||Completed|August 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916863||61646|
NCT01922973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10619|Effect of Fasting on Ghrelin and Growth Hormone in Healthy Young and Older Adults|Effect of Fasting on Ghrelin and Growth Hormone in Healthy Young and Older Adults||University of Virginia|No|Completed|May 2003|December 2004|Actual|December 2004|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|normal volunteers|August 2013|August 12, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922973||61176|
NCT01912872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AMX02|Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma|Multicentric, Open-label, Randomized, Parallel--group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12- Month Period, in Patients With Severe IgE-mediated Asthma Inadequately Controlled With High Doses of Corticosteroids.|MEXIC|Novartis|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|6 Years|55 Years|No|||March 2016|March 20, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912872||61951|
NCT01913184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKITA continuous|Lung Bioavailability With Continuous or Discontinuous Nebulization|EFFECT OF DRUG TARGETING NEBULIZATION ON LUNG DELIVERY||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|April 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913184||61927|
NCT01900925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC1937|Does Prescriptive Treatment of the Hips Improve Outcomes in Patients With Low Back Pain? A Randomized Controlled Trial|Does Prescriptive Treatment of the Hips Improve Outcomes in Patients With Low Back Pain? A Randomized Controlled Trial|HiLoBaS|Regis University|No|Active, not recruiting|September 2013|June 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01900925||62864|
NCT01901224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001042|Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease|||Brigham and Women's Hospital||Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|40 Years|N/A|No|||January 2015|January 26, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901224||62841|
NCT01901445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0039.0.447.000-11|Quality of Life in Children and Adolescents With Chronic Functional Constipation: Educational Action Effects|Quality of Life in Children and Adolescents With Chronic Functional Constipation: Educational Action Effects||Universidade Federal de Pernambuco|Yes|Recruiting|May 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|11|||Both|6 Years|19 Years|No|||July 2013|July 13, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01901445||62824|
NCT01901718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRI-Subsys-001|An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.|An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray Compared to Actiq® for the Management of Breakthrough Pain in Chronic Pain Patients.||International Clinical Research Institute|No|Terminated|April 2013|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic pain patients who are opioid tolerant and who have failed Actiq® therapy for their        breathrough pain will be prescribed Subsys™ fentanyl sublingual spray for their        breakthrough pain.|September 2014|September 2, 2014|April 25, 2013||No|Enrollment was more challenging than anticipated.|No||https://clinicaltrials.gov/show/NCT01901718||62803|
NCT01901978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007007067-Adipocyte Study|Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents|Study to Investigate Benefits of Weight Loss in Yound Adults and Adolescents||Yale University|No|Active, not recruiting|May 2011|August 2016|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Female|16 Years|32 Years|No|||March 2015|March 3, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01901978||62783|
NCT01913392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGS2012|Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate|Prospective, Clinical Study of the Effect of Bariatric Surgery, Laparoscopic Sleeve Gastrectomy, on the Pharmacokinetics of Immunosuppressive Drugs in the Morbidly Obese, Kidney Transplant Candidate||Maisonneuve-Rosemont Hospital|No|Recruiting|July 2013|||December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913392||61911|
NCT01913405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261204|Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures|A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures||Baxalta US Inc.|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|12 Years|65 Years|No|||March 2016|March 2, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913405||61910|
NCT01925612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-017|Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)|A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP ( Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)||Seattle Genetics, Inc.|No|Recruiting|August 2013|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925612||60975|
NCT01925625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ON07|Early Cancer Detection Test - Lung Cancer Scotland|Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test|ECLS|University of Dundee|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|10000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925625||60974|
NCT01925872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTH-GENE-CR|Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance|The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance|ORETCR|Beijing Tiantan Hospital|No|Enrolling by invitation|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|Samples With DNA|whole blood were retained to extract DNA for genetic sequencing.|Both|25 Years|95 Years|No|Probability Sample|Symptomatic ischemic cerebrovascular disease caused by Intracranial atherosclerotic        atherosclerosis research database; 90 days had a stroke or TIA is defined as symptomatic        Intracranial atherosclerotic atherosclerosis; Stenosis ≥ 50% (MRI or CT angiography);        Intracranial vascular stenosis measured according to the method reported Warfarin aspirin        symptomatic intracranial disease research.|August 2013|January 27, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925872||60955|
NCT01921699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pending|Macrophages Effect on Chemoresistance|Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells||Rambam Health Care Campus||Not yet recruiting|August 2013|||September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|2|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01921699||61274|
NCT01914588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/2012 ComET CBM - PHEBO|Multiparametric Telemonitoring In Elderly People With Chronic Heart Failure|Effectiveness of a Multiparametric Telemonitoring System on Prevention of Hospital Admissions and Mortality In Elderly People With Chronic Heart Failure||Campus Bio-Medico University|Yes|Completed|June 2012|July 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|65 Years|N/A|No|||July 2013|July 31, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01914588||61820|
NCT01914874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-05-02-13|Efficacy of a Mindfulness Meditation Program for Social Anxiety Disorder|Efficacy of an Enhanced Mindfulness-based Intervention for Social Anxiety Disorder: A Pilot Feasibility Randomized Controlled Trial||Hopital Montfort|No|Completed|July 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||June 2015|June 29, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914874||61798|
NCT01915095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0815-R|Enhancement of Hand Motor Function After Cervical Spinal Cord Injury|Enhancement of Hand Motor Function After Cervical Spinal Cord Injury||VA Office of Research and Development|No|Active, not recruiting|February 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01915095||61781|
NCT01915108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj1|Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal|Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia||Yeungnam University College of Medicine|Yes|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|128|||Both|18 Years|65 Years|No|||August 2014|August 21, 2014|July 23, 2013|Yes|Yes||No|July 13, 2014|https://clinicaltrials.gov/show/NCT01915108||61780|
NCT01915745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K120601|Study of Current Practice Evaluating the Efficacy of a Mobile Short Message Service (SMS) on Post-fracture Management.|Evaluation of the Efficacy of a Mobile Phone Short Message Service on Post-fracture Management for Patients Who Consult to the Emergency Department|Ostéo-SMS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|97|||Both|50 Years|N/A|No|||April 2015|October 15, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01915745||61731|
NCT01916005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00056-39|Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis|Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis||Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2013|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|174|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01916005||61711|
NCT01916590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0847|Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control|Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control After Anterior Cruciate Ligament Reconstruction With Patellar Tendon Graft or Allograft||University of Colorado, Denver|No|Terminated|July 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|75 Years|No|||October 2015|October 5, 2015|July 30, 2013|Yes|Yes|lack of patients|No||https://clinicaltrials.gov/show/NCT01916590||61667|
NCT01922362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12-022B|Negative Pressure Drainage System Split-thickness Skin Graft Recipient Sites|The Use of "Negative Pressure Drainage System" for Caring Split-thickness Skin Graft Recipient Sites||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|60 Years|No|||August 2013|August 12, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922362||61223|
NCT01922375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLV_BPH_IV-1|Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia||Dong-A ST Co., Ltd.|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|411|||Male|45 Years|N/A|No|||August 2013|August 11, 2013|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922375||61222|
NCT01912664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH090318 STU00052134|Online Peer Networked Collaborative Learning for Managing Depressive Symptoms|Technology Assisted Intervention for the Treatment and Prevention of Depression|MoodTECH|Northwestern University|Yes|Not yet recruiting|April 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|19 Years|N/A|No|||March 2015|March 19, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912664||61967|
NCT01922986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute_rTMS|Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke|Real vs Sham rTMS Combined With Conventional Therapy in Acute Stroke||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922986||61175|
NCT01913197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-070|Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy|Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy||St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|August 2013|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Male|18 Years|N/A|No|||August 2013|August 1, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913197||61926|
NCT01901458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITZ-003|Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®|Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set|optiMaL|Heinrich-Heine University, Duesseldorf|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901458||62823|
NCT01901731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTC12013|Pelvic Embolisation to Reduce Recurrent Varicose Veins - Primary|A Randomised Controlled Trial Investigating The Use Of Pelvic Vein Embolisation To Reduce Recurrent Varicose Veins Of The Legs In Women With Primary Varicose Veins And Associated Pelvic Venous Reflux.||The Whiteley Clinic|Yes|Not yet recruiting|March 2014|October 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Female|18 Years|N/A|No|||January 2014|January 24, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901731||62802|
NCT01901744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008|Contrast Sensitivity Assessment in Pediatric Cataract Surgery With IOL Implantation|Contrast Sensitivity Assessment in Pediatric Cataract Surgery With IOL Implantation: A Comparison of Preoperative and Early Postoperative Outcomes||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2009|January 2013|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|1 Year|15 Years|No|||July 2013|July 16, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01901744||62801|
NCT01902004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-01 MH097892|Brain Aging and Treatment Response in Geriatric Depression|Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age||University of California, Los Angeles|Yes|Recruiting|October 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|60 Years|N/A|No|||December 2014|December 5, 2014|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01902004||62781|
NCT01914042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-10 RMB|Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica|Prediction of Inter-individual Differences in the Response to Morphine by Psychophysical Assessment of Pain Enhancing and Inhibiting Mechanisms in Patients With Chronic Neuropathic Pain||Rambam Health Care Campus|No|Recruiting|July 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914042||61862|
NCT01914055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo009|Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study.||TOBIAS|Ospedale San Donato|No|Recruiting|July 2013|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01914055||61861|
NCT01925638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14751|Effect of Ketoconazole on the Pharmacokinetics of Refametinib|An Open-label Study in Healthy Male Subjects to Assess the Effect of a Strong CYP3A4 Inhibitor, Ketoconazole, on the Pharmacokinetics of Refametinib||Bayer|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|August 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925638||60973|
NCT01913665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not defined yet|The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation|The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation||Eskisehir Osmangazi University|No|Not yet recruiting|September 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|4 Years|18 Years|No|||August 2013|August 5, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913665||61890|
NCT01914029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-13-RMB CTIL|Immunological Mechanisms of Allergy Immunotherapy|Immunological Mechanisms of Allergy Immunotherapy||Rambam Health Care Campus|No|Recruiting|August 2013|July 2016|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|45 Years|No|Non-Probability Sample|10 volunteers will be enrolled in each group. The study will include seven treatment        groups and one control, total number of participants is 80|August 2013|August 26, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01914029||61863|
NCT01914276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047483|Lymphedema in Endometrial Cancer|A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery||Duke University||Recruiting|October 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|(1) women older than 18 years old, (2) endometrial cancer, (3) suitable candidates for        surgery, (4) scheduled to undergo laparoscopy or robotic-assisted (RA) laparoscopy for        endometrial cancer at Duke University Medical Center (DUMC), (5) no severe physical or        mental comorbidity|August 2015|January 20, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914276||61844|
NCT01914562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-104|Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)|An Open Label Trial to Assess the Effects of Food on the Pharmacokinetic Parameters of Obeticholic Acid (OCA)||Intercept Pharmaceuticals|Yes|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914562||61822|
NCT01914575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914575||61821|
NCT01915121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0479|An Educational Intervention for Patients With Bladder Cancer|An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society||Icahn School of Medicine at Mount Sinai|Yes|Enrolling by invitation|September 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915121||61779|
NCT01915134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejaingCH-npc-03|Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma|A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma||Zhejiang Cancer Hospital|Yes|Recruiting|August 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|362|||Both|18 Years|65 Years|No|||July 2013|December 30, 2014|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01915134||61778|
NCT01915433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302829|Wahls Paleo Diet and Progressive Multiple Sclerosis|Wahls Paleo Diet and Progressive Multiple Sclerosis||University of Iowa|No|Active, not recruiting|July 2013|November 2016|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|30 Years|65 Years|No|||January 2016|January 25, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01915433||61755|
NCT01915758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114730|W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers|A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|August 1, 2013|October 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915758||61730|
NCT01916031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD7081|Appropriate Care of URI (ACURI): Early Head Start|||Columbia University|No|Completed||May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||||||Both|N/A|N/A|No|||August 2013|August 1, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916031||61709|
NCT01916018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11012-IDRCB 2012-A00797-36|Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.|Phenotype and Genotype Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. The Use of Genetic Analysis in the Early Care of Children With Thyroid Dysgenesis|HYPOTYGEN|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|558|||Both|N/A|N/A|No|||January 2016|January 16, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916018||61710|
NCT01922063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR_Ebe01/2009|Physiotherapy Following Disc Surgery: Long Term Follow-up of a RCT|Long Term Follow-up of Comprehensive Physiotherapy Following Disc Herniation Operation: Results of a Randomized Clinical Trial||Medical University of Vienna|No|Completed|July 1996|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|90 Years|No|||August 2013|August 13, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922063||61246|
NCT01922076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01602|WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas|A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas||National Cancer Institute (NCI)|Yes|Suspended|September 2013|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|37 Months|21 Years|No|||March 2016|March 24, 2016|August 12, 2013|No|Yes|Other - pending amendment|No||https://clinicaltrials.gov/show/NCT01922076||61245|
NCT01922674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 HS09860 OlAl|Inguinal Hernia Management: Watchful Waiting vs. Tension-Free Open Repair|Inguinal Hernia Management: Watchful Waiting vs. Tension-Free Open Repair||Creighton University|Yes|Completed|January 1999|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|720|||Male|18 Years|N/A|No|||August 2013|August 13, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922674||61199|
NCT01922687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ruijin2010No.14|Amlodipine Plus/Minus Atorvastatin for Protection of Arteries|Amlodipine Plus/Minus Atorvastatin for Protection of Arteries||Shanghai Institute of Hypertension|Yes|Recruiting|April 2011|December 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|109|||Both|40 Years|75 Years|No|||August 2013|August 12, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01922687||61198|
NCT01922648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01|RSV Observational Study 2|Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Exposure in a Paediatric Population||University of Oxford|No|Completed|June 2013|||April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|35|Samples Without DNA|serum|Both|2 Months|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infants aged 2-4 months inclusive Infants aged 6-12 months inclusive Children aged 3-6        years inclusive|November 2015|November 19, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922648||61201|
NCT01922960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-092|Microcirculatory Assessment in Patients With Trauma and Severe Burns|Microcirculatory Assessment in Patients With Trauma and Severe Burns||University of South Alabama|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|19 Years|80 Years|No|||January 2016|January 27, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01922960||61177|
NCT01923272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-US-07|Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIB|Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of Exercised Induced Bronchoconstriction||ElectroCore LLC|No|Withdrawn|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||August 2013|August 14, 2013|June 5, 2012|Yes|Yes|Similar study being conducted, Sponsor decided to not duplicate study|No||https://clinicaltrials.gov/show/NCT01923272||61153|
NCT01923285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-SMI-2012|A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain|A Prospective, Randomized, Multi-Center, Controlled Clinical Trial to Assess the Safety and Efficacy of the Spinal Modulation™ AXIUM™ Neurostimulator System in the Treatment of Chronic Pain (ACCURATE Trial)|ACCURATE|St. Jude Medical|No|Active, not recruiting|August 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|22 Years|75 Years|No|||January 2016|January 18, 2016|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923285||61152|
NCT01923519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PP-06|Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects|Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects|GENEBRO|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|August 2013|||February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2013|August 13, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923519||61134|
NCT01895023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FujianPH-TRC-130615|Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children|Dexmedetomidine Versus Midazolam Premedication on Emergence Agitation After Strabismus Surgery in Children||Fujian Provincial Hospital|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|156|||Both|2 Years|6 Years|No|||January 2015|January 2, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895023||63315|
NCT01895283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-066|The Effect of Aerobic Exercise, on Fitness and Functional Muscle Strength, in Patients With Muscular Dystrophy|The Effect of a Bike Ergometer Training Program in Patients With Bethlem Myopathy||Rigshospitalet, Denmark|Yes|Active, not recruiting|September 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|8|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01895283||63295|
NCT01895569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120021548|Triple Therapy in Type 2 Diabetic Patients|Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients||University of Pavia|No|Recruiting|June 2013|June 2016|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01895569||63273|
NCT01895855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-VC-200-003|Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination||PaxVax, Inc.|Yes|Completed|September 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|210|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 7, 2014|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895855||63251|
NCT01913691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130173|Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma|Phase II Open-Label Trial of Ipilimumab for Metastatic Merkel Cell Carcinoma||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2014|October 9, 2014|July 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913691||61888|
NCT01914068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0711-25093|The Effects of a 9 Week Exercise Programme on Fitness and Quality of Life in Rectal Cancer Patients After Chemoradiotherapy and Before Surgery|A Pilot Study to Investigate Improvements in Physical Fitness and Quality of Life Resulting From a 9 Week Structured Responsive Endurance Training Programme (SRETP) Following Neoadjuvant Chemoradiotherapy Prior to Elective Rectal Cancer Surgery|SRETP|University Hospital Southampton NHS Foundation Trust.|Yes|Recruiting|August 2013|December 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|46|||Both|18 Years|85 Years|No|||August 2013|August 27, 2013|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01914068||61860|
NCT01914289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2013-002-02|Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients|Comparison of Resection and Radiotherapy in the Prognosis of Intrahepatic Cholangiocarcinoma Patients||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2011|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|17 Years|60 Years|No|||July 2013|August 1, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914289||61843|
NCT01914601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFHU-FBR 0040, MU-R/15.11.04|King Vision and Cervical Spines Movement|Does King Vision® Videolaryngoscope Reduce Cervical Spine Motion During Endotracheal Intubation? A Cross-over Study.||Dammam University|Yes|Completed|January 2014|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914601||61819|
NCT01914887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLPDIG-2010-01|Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis|A Phase I/IIa Clinical Trial to Evaluate Safety and Efficacy of Adipose Tissue-derived Mesenchymal Stem Cells (ASC) on Induction to Remission in Ulcerative Colitis|ALOASCU|Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|June 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01914887||61797|
NCT01914900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT40/10|Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer|Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|June 2012|March 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01914900||61796|
NCT01915147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN2505|A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects|||Mundipharma Research GmbH & Co KG||Completed|July 2013|September 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01915147||61777|
NCT01915446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KISMED-001|Kidney and Intestinal Markers for Early Detection of Organ Injury After Endovascular Aortic Repair|Kidney and Intestinal Markers for Early Detection of Organ Injury After Endovascular Aortic Repair - The KISMED Study|KISMED|University Hospital Regensburg|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Plasma Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing endovascular aortic repair in a University hospital|December 2014|December 17, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915446||61754|
NCT01915459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG-13-01|Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity|A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity||Hugel|Yes|Completed|June 2013|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915459||61753|
NCT01916343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#12-159|Laparoscopic Gynecology Curriculum for Residents|Design of a Comprehensive Evidence-Based Laparoscopy Curriculum for Gynecology Residents||St. Michael's Hospital, Toronto|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|27|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 23, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01916343||61685|
NCT01922089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2228|Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients|A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens|TITRATION|Novartis||Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|498|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|August 12, 2013|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT01922089||61244|
NCT01922102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002F2302|Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|Brilliance|Novartis|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|456|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922102||61243|
NCT01922700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPPER01|Effects of Pepper Gas Exposure in Non-combatant Bystanders.|Pepper Gas Exposure Study||Sheri Kashmir Institute of Medical Sciences|No|Completed|April 2013|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|298|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community based non-combatant individuals exposed to pepper gases while being used on        combatants.|July 2014|July 18, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01922700||61197|
NCT01922713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-8282|Effect of Daily Consumption of Orange Maize on Breast Milk Retinol in Lactating Zambian Women|Effect of Daily Consumption of β-carotene Biofortified Maize on Milk Retinol Concentration in Lactating Zambian Women||University of California, Davis|No|Completed|October 2013|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|149|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922713||61196|
NCT01922661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1908-HV-1240|Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects|||Regeneron Pharmaceuticals|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|No|||June 2014|June 9, 2014|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01922661||61200|
NCT01923584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIPD|A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease|A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease||University of South Florida|No|Active, not recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|40 Years|75 Years|No|||May 2015|May 20, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923584||61130|
NCT01895036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6332|Nalrexone Facilitated Discontinuation of Buprenorphine|||New York State Psychiatric Institute|No|Completed|February 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|49 Years|No|||January 2015|February 9, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01895036||63314|
NCT01895296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230BBE01T|Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome|Exploratory Randomized, Placebo-controlled Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome|CSOM230BBE01T|Universitaire Ziekenhuizen Leuven|No|Completed|September 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|80 Years|No|||July 2013|July 4, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895296||63294|
NCT01895582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110131|Performance of IGRAs for TB Infection Diagnosis in Elderly|Mycobacterium Tuberculosis Infection Diagnosis in Patients Above 75 Years Old/ Performance of Interferon Gamma Releasing Assays (IGRA)|IGRage|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|160|Samples Without DNA|Blood samples|Both|75 Years|N/A|No|Non-Probability Sample|Patients with suspected tuberculosis disease|October 2015|October 6, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01895582||63272|
NCT01895868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-154|Long-terms Effects of Simulation-based Ultrasound Training: A Randomized Trial|||Rigshospitalet, Denmark|No|Completed|July 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|26|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 4, 2014|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01895868||63250|
NCT01914081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA/2012/0002|Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside|Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside||St. Boniface General Hospital Research Centre|Yes|Not yet recruiting|January 2015|November 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||December 2014|December 16, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01914081||61859|
NCT01914302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT6000682013|The Characterization of Blood Volumes of Commercially Available Lancing Devices|Lancing Device Blood Volume Study||Facet Technologies|No|Completed|July 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||8|Actual|64|||Both|18 Years|75 Years|No|Probability Sample|People with diabetes|August 2013|August 1, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914302||61842|
NCT01914614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 13-0560-P3H|A Pilot Study of Working Women and Breast Cancer|A Pilot Study of Working Women and Breast Cancer||University of Kentucky|No|Completed|November 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|22|||Female|18 Years|65 Years|No|Probability Sample|Women diagnosed with a new, primary breast cancer within 3 months of enrollment and who        were employed at the time of diagnosis.|May 2015|May 26, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01914614||61818|
NCT01914627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0741/179|Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis|A Single-centre Randomised, Active-controlled, Observer-blinded, Parallel Group Trial to Evaluate the Efficacy and Safety of a Topical Dimeticone Formulation (Loion®) Compared to 10% Salicylic Acid in the Removal of Scaling in Patients With Chronic Psoriasis Capitis||G. Pohl-Boskamp GmbH & Co. KG|Yes|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2014|November 4, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01914627||61817|
NCT01914913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BMRP/2013//01|Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial||Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914913||61795|
NCT01915160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH096907-01A1|Technology-Based Tools to Enhance Quality of Care in Mental Health Treatment|Technology-Based Tools to Enhance Quality of Care in Mental Health Treatment||Medical University of South Carolina|Yes|Recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||August 2012|April 10, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915160||61776|
NCT01915472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU 130-03|A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer|A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer||Immunomedics, Inc.|No|Not yet recruiting|September 2013|||August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|August 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915472||61752|
NCT01915485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lu177-med|Radiolabeled Molecules for Medullary Thyroid Cancer|The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer||Instituto Nacional de Cancer, Brazil|Yes|Recruiting|August 2013|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915485||61751|
NCT01921517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3408455|Micromechanical Modeling Using Low Magnitude Mechanical Stimulation|Osteoporosis Treatment Response Assessed by Micromechanical Modeling of MRI Data|LMMS|University of Pennsylvania|No|Recruiting|September 2012|August 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921517||61288|
NCT01921777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEIR-3|Effects of Traumeel®S Tablets on Recovery and Inflammatory Immune Response After Repeated Bouts of Exercise|||University of Giessen|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01921777||61268|
NCT01922388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013]19|Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications|Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications: A Prospective, Comparative Multicentre Clinical Study||First Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|August 2013|||December 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||August 2015|August 14, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922388||61221|
NCT01923051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301100001|Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)|Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD): Registry of the Czech Pneumological Society (CPPS) at the Czech Medical Association (CzMA)||Masaryk University|No|Recruiting|August 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|In the following centres, we will be collecting samples with DNA (blood samples): University      Hospital Olomouc, University Hospital Hradec Kralove, University Hospital Motol, University      Hospital Brno.|Both|18 Years|N/A|No|Probability Sample|The COPD registry is a non-interventional multicentre observational prospective database        focusing on the collection and analysis of data on real mortality and morbidity in an        unselected population of COPD patients in long lasting care of individual participating        centres. Each centre covers the population of a certain county. The centres are localized        as to symetrically cover the entire Czech Republic.|August 2015|August 13, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01923051||61170|
NCT01922999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melatonin|Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders|A Randomized, Prospective, Double Blind, Placebo-Controlled Trial of Two Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders||Southeast Renal Research Institute|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922999||61174|
NCT01895881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPPA - 12101906|Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial|Estrogen Therapy as Prevention in the Progression of Aneurysm|EPPA|Rush University Medical Center|No|Recruiting|April 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Female|40 Years|52 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01895881||63249|
NCT01896167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-182|Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow by Hypoxia|Study of Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries by Hypoxia in a Humane Experimental Migraine Model||Danish Headache Center|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01896167||63227|
NCT01896505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-003|A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma|An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients Witn Soft-Tissue or Bone Sarcoma||Karyopharm Therapeutics, Inc|No|Active, not recruiting|July 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|53|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896505||63201|
NCT01897064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6508|The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.|The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.||New York State Psychiatric Institute|Yes|Completed|April 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|55 Years|No|||August 2014|August 14, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01897064||63159|
NCT01914094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2010:390|Pre-habilitation Program for Elective Coronary Artery Bypass Graft Surgery Patients|Pre-habilitation Program for Elective Coronary Artery Bypass Graft Surgery Patients||St. Boniface General Hospital Research Centre|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914094||61858|
NCT01914315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0246-RK-CTIL|Rehabilitation Program in Heart Failure With Preserved Ejection Fraction|Multi-Disciplinary Rehabilitation Program in Recently Hospitalized Patients With Preserved Ejection Fraction Heart Failure||Sheba Medical Center|No|Recruiting|October 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Both|21 Years|N/A|No|||November 2014|November 17, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914315||61841|
NCT01914640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMD/OBDLHT- 0001|The Sex Specific Waist Circumference Cut Off Points to Predict Overweight or Obesity|The Cross Sectional Study to Investigate the Waist Circumference Cut Off Points for the Prediction of Overweight and Obesity of the Turkish Adult Population||TC Erciyes University|No|Completed|March 2003|September 2005|Actual|September 2004|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|4310|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|This cross-sectional study was conducted in 24 provinces from the 7 regions of Turkey.        Turkish adult males and non-pregnant females were randomly enrolled from both the        provincial district centers and villages, considering the demographics, economic, social,        and geographical statuses.|July 2013|July 31, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01914640||61816|
NCT01914653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURE-006|SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction|||Allergan||Completed|June 2013|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914653||61815|
NCT01914666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14949|An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain|Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study||Eli Lilly and Company|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|20 Years|79 Years|No|||December 2015|December 18, 2015|July 31, 2013|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01914666||61814|FAS:all randomized pts who received at least 1 dose of study drug and had at least 1 post-dose BPI pain severity (average pain) score. 1 Naïve group pt received at least 1 dose of study drug but had no post-dose data and not included in FAS.
NCT01914926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/01/VA02|Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter|DiME Study: Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Response: A Prospective Randomized and Double-Blinded Non-Inferiority Trial of Safety and Efficacy|DiME|Maimonides Medical Center|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||May 2014|May 1, 2014|July 11, 2013||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT01914926||61794|
NCT01925469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFC-HSG-1|Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram|A Randomized Controlled Trial of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram||University of Pennsylvania|Yes|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 22, 2013|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925469||60986|
NCT01925729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040386|TransMEM Gas Exchange -- Project 1, Aim 2|Middle Ear Pressure Regulation in Health and Disease -- Gas Supply, Demand and Middle Ear Gas Balance -- Specific Aim 2||University of Pittsburgh|No|Recruiting|October 2013|August 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925729||60966|
NCT01921530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103386|Interbody vs Instrumented Posterolateral Fusion Following Decompression for Lumbar Spinal Stenosis With Degenerative Spondylolisthesis|Interbody Fusion and Decompression Versus Instrumented Posterolateral Fusion and Decompression for Lumbar Spinal Stenosis With Degenerative Spondylolisthesis||The London Spine Centre||Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|50 Years|N/A|No|||March 2016|March 2, 2016|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921530||61287|
NCT01921790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-017-01|Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma|An Open-Label, Uncontrolled, Single Centered Phase Ⅱ Study of Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone (Avastin+ GemAOD) As First-Line Treatment in Patients With Untreated NK/T Cell Lymphoma||Sun Yat-sen University|Yes|Recruiting|August 2013|August 2020|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2013|August 20, 2013|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01921790||61267|
NCT01921803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/380|Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer|Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer: Randomised Trial Comparing Toxicity Between 2 Different Hypofractionated Schedules|Hypofraction|University Hospital, Ghent|No|Recruiting|August 2013|July 2017|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Male|40 Years|80 Years|No|||December 2014|December 4, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01921803||61266|
NCT01922414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Staghorn Laser|Laser Versus Ultrasonic Lithotripsy in Percutaneous Nephrolithotomy for Staghorn Stones|Laser Versus Ultrasonic Lithotripsy in Percutaneous Nephrolithotomy for Staghorn Stones||Mansoura University|Yes|Completed|August 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||August 2015|August 10, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01922414||61219|
NCT01922427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.1.1.H1|Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery|Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Knee Anterior Cruciate Reconstruction Surgery||Revalesio Corporation||Withdrawn||||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||January 2015|April 8, 2015|August 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01922427||61218|
NCT01923337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#234|Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer|Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer||University of California, Davis|Yes|Active, not recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923337||61148|
NCT01923012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-0001|Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis|Phase 2 Study Randomized Placebo Controlled With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis|SCAVIT-K2|Azienda Ospedaliera Sant'Anna|No|Not yet recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|90 Years|No|||May 2014|May 24, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923012||61173|
NCT01923025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28844|A PET Study With RO5545965 in Healthy Male Volunteers|A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography||Hoffmann-La Roche||Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01923025||61172|
NCT01923038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB232|Evaluation of Ventilatory Strategies During Laparoscopic Surgery|Re-expansion of Atelectasis During Laparoscopic Surgery. Recruitment Maneuver vs Positive End-expiratory Pressure: a Randomized Study||Maria Vittoria Hospital|Yes|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|May 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01923038||61171|
NCT01923298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0477-04|Estradiol Levels in Patients Treated With Estring|A Single-arm Phase II Trial to Evaluate Serum Estradiol Levels in Patients With Breast Cancer Treated With Vaginal Estrogen, Estring||University of Arizona|Yes|Recruiting|August 2013|||August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923298||61151|
NCT01923311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-183-0160|Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants|A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects||Gilead Sciences|Yes|Recruiting|August 2013|December 2033|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|90|||Both|N/A|17 Years|No|||August 2015|August 31, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923311||61150|
NCT01923324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project ID 18618|Standard Telephone Consultation for Pain|Physician to Physician Telephone Consultation for Chronic Pain Patients: a Pragmatic Randomized Trial|STC|University of Calgary|No|Completed|July 2005|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923324||61149|
NCT01895608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7614-P|Cognitive Training and Dual-task Ability in Older Adults|Cognitive Training and Dual-task Ability in Older Adults|Cog training|VA Office of Research and Development|No|Completed|July 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|17|||Both|60 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01895608||63270|
NCT01895894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMF2013|Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome|A Prospective, Randomized, Open-label Study Evaluating the Efficacy of Mycophenolate Mofetil in the Prevention of Relapse of Steroid Dependent Nephrotic Syndrome in Children||Seoul National University Hospital|No|Recruiting|September 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|2 Years|24 Years|No|||May 2015|May 29, 2015|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01895894||63248|
NCT01896180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALZ-1101-101|Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost|A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost||Alleanza Pharmaceuticals, Inc.|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896180||63226|
NCT01896518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZII|Novel Methods to Reduce Children's Secondhand Smoke Exposure II|Novel Methods to Reduce Children's Secondhand Smoke Exposure II|EZII|University of Oklahoma|No|Recruiting|June 2013|||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01896518||63200|
NCT01914354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|859869783|Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity T Cell Population|Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity: An Untargeted T Cell Population" (# 859869783).|NKG2D|The Cleveland Clinic|No|Enrolling by invitation|February 2012|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|90|Samples Without DNA|blood/serum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohort of 80 living and deceased donor kidney transplant recipients and 10 healthy        volunteers|July 2013|August 1, 2013|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01914354||61838|
NCT01914692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nova-0426|Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection|Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914692||61812|
NCT01914328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPC 01|Postoperative Pulmonary Complications in Major Abdominal Surgery|Postoperative Pulmonary Complications in Major Abdominal Surgery: Prospective Observational Multicentric Study|PPC|Azienda Ospedaliera S. Maria della Misericordia|Yes|Recruiting|June 2013|January 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Patients Undergoing Major Abdominal Surgery Performed under General Anesthesia|July 2013|July 31, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01914328||61840|
NCT01914341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCIM_MTN04|Short Term Effects of Live Music in Newborn Infants|Short-term Effects of Live Pentatonic Music on Physiological Parameters in Newborns Infants||ARCIM Institute Academic Research in Complementary and Integrative Medicine||Completed|July 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|35 Weeks|N/A|No|||January 2014|January 22, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01914341||61839|
NCT01914679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-201-UM|A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan|A Phase 2 Clinical Trial Evaluating Use of the NeuroPoint Medical Device as a Treatment for Fibromyalgia.|PERRFECT-UM|University of Michigan|No|Terminated|July 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Female|18 Years|65 Years|No|||April 2015|April 3, 2015|July 23, 2013||No|Sponsor terminated the study|No||https://clinicaltrials.gov/show/NCT01914679||61813|
NCT01914939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-1-0543|A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder|A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder||Massachusetts General Hospital|Yes|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Male|18 Years|40 Years|No|||March 2016|March 9, 2016|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914939||61793|
NCT01925742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1236; SIRUL-102531|Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood|PEGASUS: PErsonalized Genomics for Prenatal Aneuploidy Screening USing Maternal Blood|PEGASUS|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|November 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|5600|||Female|19 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925742||60965|
NCT01925755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16627|Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients|Prospective Multicenter Observational Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients|NEURO-XAR|Bayer|No|Completed|July 2013|July 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients ≥ 18 years old with prior stroke or TIA history and who have        never taken anticoagulation treatment regarding AF before and meet criteria of inclusion        and exclusion.|August 2015|August 13, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925755||60964|
NCT01921543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s28650|Deep Brain Stimulation in Treatment Refractory Depression|Electrical Stimulation of the Internal Capsule/Grey Matter and Inferior Thalamic Peduncle for Treatment-refractory Major Depressive Disorder|DBSTRD|Universitaire Ziekenhuizen Leuven|No|Terminated|January 2005|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|7|||Both|18 Years|65 Years|No|||June 2013|July 15, 2015|January 8, 2013||No|Patient inclusion was very tedious and slower than expected. (7 patients in 5 years)|No||https://clinicaltrials.gov/show/NCT01921543||61286|
NCT01921816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-173|A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0)|||The University of Hong Kong||Completed|May 2012|||August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|18 Years|90 Years|No|||December 2014|December 2, 2014|July 31, 2013||||No||https://clinicaltrials.gov/show/NCT01921816||61265|
NCT01922115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1352|The Effect of Anticholinergics on Cognitive Function in the Elderly|The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial|ACE|University of North Carolina, Chapel Hill|No|Completed|June 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Female|50 Years|99 Years|Accepts Healthy Volunteers|||June 2015|October 19, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922115||61242|
NCT01922128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-1101-002|Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration|A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals||MacuCLEAR, Inc.|Yes|Completed|September 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922128||61241|
NCT01922726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBSY03 - RESPIRE|Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients (RESPIRE)|Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients||LivaNova|No|Recruiting|July 2013|June 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1078|||Both|18 Years|N/A|No|Probability Sample|Patient eligible for implantation of a dual-chamber pacemaker (primo-implant, replacement,        upgrade) according to current available guidelines Patient with REPLY 200 DR implantation        performed. Patient who provides signed and dated informed consent according to the local        laws and regulations|November 2015|November 19, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01922726||61195|
NCT01922739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/3104|Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets|A 6-Month, Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time||Teva Pharmaceutical Industries|No|Completed|July 2013|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|183|||Both|18 Years|80 Years|No|||July 2015|July 29, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922739||61194|
NCT01922752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C37440/1108|To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors|An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors||Teva Pharmaceutical Industries|No|Completed|July 2013|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922752||61193|
NCT01923077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTENSIFY|Intensive Statin Therapy in Patients With AMI|Early Intensive Treatment With Statins Improves Left Ventricular Function in Patients With Acute Myocardial Infarction.|INTENSIFY|Svendborg Hospital|Yes|Active, not recruiting|April 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|N/A|N/A|No|||August 2013|August 14, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923077||61168|
NCT01923623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huggi123|The Effect of Nerve Blockades in Addition to General Anesthesia in Surgical Fixation of Ankle Fractures.|The Effect of Combined Popliteal and Saphenous Block in Addition to General Anesthesia in Surgical Fixation of Ankle Fractures: a Prospective Randomized Study||Herlev Hospital|No|Withdrawn|November 2013|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|August 13, 2013||No|Study was redesigned and taken over by a ph.D-student|No||https://clinicaltrials.gov/show/NCT01923623||61127|
NCT01923896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061465|D-cycloserine and Treatment of Feeding Disorders|Use of D-cycloserine to Facilitate Extinction of Food Aversion in Pediatric Populations||Emory University|No|Completed|March 2013|November 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Months|6 Years|No|||October 2014|October 17, 2014|September 18, 2012|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01923896||61106|The sample size was small and analyses were underpowered to detect group differences.
NCT01895348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0291|A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial|||Yonsei University||Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Both|20 Years|60 Years|No|||August 2014|August 26, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01895348||63290|
NCT01895621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUNNEL ALFALIPO|Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial.|The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial.||Istituto Ortopedico Rizzoli|No|Completed|March 2013|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|80 Years|No|||January 2015|June 23, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01895621||63269|
NCT01895634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rev-01|Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)|Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)||Johnson & Johnson K.K. Medical Company|No|Completed|May 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|85 Years|No|||February 2016|February 4, 2016|July 1, 2013||No||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01895634||63268|
NCT01895907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15528|SCOPE and Special Olympics|SCOPE and Special Olympics|SCOPE/SO|Texas Woman's University|No|Completed|May 2010|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|7 Years|N/A|No|Non-Probability Sample|Participating athletes will be recruited through the coaches. Participants recruited under        the TWU collection protocol will be informed that they are being asked to be a subject in        a research study to determine if there is a change in levels of participation in other        areas of life for athletes involved in special olympics.|July 2013|July 10, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01895907||63247|
NCT01895920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS RF001 TRANSBioHIV|Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?||TRANSBioHIV|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|December 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|70 Years|No|||July 2013|September 1, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01895920||63246|
NCT01896193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0119|Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection|A Phase 3b, Multicenter, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Genotype 1 and 3 Chronic HCV Infection.||Gilead Sciences|No|Completed|June 2013|June 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|July 2, 2013|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01896193||63225|
NCT01896206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00808|CNAP Accuracy in the Bariatric Surgery Population|||Nationwide Children's Hospital|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||February 2015|February 25, 2015|June 27, 2013||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01896206||63224|
NCT01924676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501022|Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers|An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Food on Oxycodone Pharmacokinetics Following Oral 40 Mg Doses of PF-00345439 Formulation K and to Estimate Its Relative Bioavailability of Oxycodone Compared to PF-003454390 Formulation X in the Fasted State in Healthy Volunteers||Pain Therapeutics|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01924676||61046|
NCT01924689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVDCNV2|Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies|Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies||BioMed Valley Discoveries, Inc|Yes|Recruiting|October 2013|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01924689||61045|
NCT01924663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyDAKI-01|Viral Illness in Pediatric Critical Care: Incidence Timing & Severity of Associated Heart Dysfunction & Acute Kidney Injury|Viral Illness in the Pediatric Critical Care Setting: the Incidence, Timing and Severity of Associated Myocardial Dysfunction and Acute Kidney Injury.|MyDAKI-01|University of Saskatchewan|No|Recruiting|September 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|60|||Both|N/A|18 Years|No|Probability Sample|Pediatric subjects admitted to the local hospital with a confirmed positive respiratory        viral swab.|January 2015|January 23, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924663||61047|
NCT01924910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061103|A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults|A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Concentrations in Healthy Adults: A Pilot Study||Emory University|No|Active, not recruiting|October 2012|May 2016|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924910||61028|
NCT01925183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVCOBOC-RGT|Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C|Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients|HIVCOBOC-RGT|Medical University of Vienna|Yes|Recruiting|August 2013|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|64 Years|No|||August 2013|August 16, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925183||61007|
NCT01925196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130188|Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation|Natural History and Biomarkers of C9ORF72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|62|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925196||61006|
NCT01925209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338B2203|Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients|Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability of i.v. BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility in Sporadic Inclusion Body Myositis Patients|RESILIENT|Novartis|Yes|Active, not recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|36 Years|85 Years|No|||February 2015|February 11, 2015|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01925209||61005|
NCT01921582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044/2013|A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder|A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder||Centre for Addiction and Mental Health|No|Completed|August 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Female|18 Years|50 Years|No|||March 2015|September 28, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921582||61283|
NCT01921595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0350|Impact of Balanced Slat Colloid HES 130/0.42 on Coagulation Profiles in Patients Undergoing Spinal Cord Tumor Surgery|||Yonsei University|No|Recruiting|August 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|20 Years|N/A|No|||July 2014|July 24, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921595||61282|
NCT01921556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAROL|The Improving Care in Chronic Obstructive Lung Disease Study A Cluster Randomized Trial|The Improving Care in Chronic Obstructive Lung Disease Study: CAROL Improving Processes of Care and Quality of Life of COPD Patients in Primary Care: A Cluster Randomized Trial|CAROL|University of Zurich|No|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|45 Years|85 Years|No|||May 2015|May 27, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01921556||61285|
NCT01921829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040071|Protocolized Diuretic Strategy in Cardiorenal Failure|Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial|ProDiuS|University of Pittsburgh|Yes|Terminated|November 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Male|21 Years|N/A|No|||December 2015|December 7, 2015|July 23, 2013||No|Due to futility due to lower than expected recruitment|No||https://clinicaltrials.gov/show/NCT01921829||61264|
NCT01922141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2370|Aliskiren Study of Safety and Efficacy in Senior Hypertensives|A Randomized, Double-blind, Parallel Group, Active-controlled Study to Compare the Systolic Blood Pressure Lowering Efficacy of Aliskiren, Ramipril and a Combination of Aliskiren and Amlodipine, With an Initial 8-week Evaluation, Followed by a 2-3 Year Follow-up to Compare Long-term Safety of an Aliskiren-based Regimen to a Ramipril-based Regimen in Hypertensive Patients ≥ 65 Years of Age|ASSESS|Novartis|Yes|Withdrawn|May 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|65 Years|N/A|No|||April 2015|April 14, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922141||61240|
NCT01922401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCIRB2013-164|Inverse Ratio Ventilation on Bariatric Operation|Effects of a Changes in Inspiratory to Expiratory Ratio on Respiratory Mechanics and Oxygenation During Laparosopic Bariatric Surgery||Gachon University Gil Medical Center|Yes|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|30|||Both|20 Years|65 Years|No|||August 2015|August 30, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922401||61220|
NCT01923064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chen2013|Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices|A Randomized Study to Compare Effect of Endoscopic Injection of a Mixture of Cyanoacrylate and Lipiodol Versus Cyanoacrylate and Lauromacrogol in Gastric Varices||Shanghai Zhongshan Hospital|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01923064||61169|
NCT01923649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50966|SOMATULINE Autogel 90 mg IN DUMPING SYNDROME|SOMATULINE Autogel 90 mg IN DUMPING SYNDROME||Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2013|August 21, 2013|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923649||61125|
NCT01923350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDEP-GDM GS10F0381L|Avoiding Diabetes After Pregnancy Trial|Increasing Adoption of Early Intervention to Prevent Diabetes After Gestational Diabetes Mellitus|ADAPT|Social & Scientific Systems Inc.|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|140|||Female|18 Years|N/A|No|||August 2013|August 14, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923350||61147|
NCT01923636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120114|Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero|Evaluation of the Prognostic Value of Clinical, Imaging, Immunological and Virological Markers in the Neonatal Period for the Development of Neurosensorial Sequelae at 1 Year in Children Infected by Cytomegalovirus in Utero.|CYMEPEDIA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|April 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|N/A|1 Month|No|||July 2015|July 27, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923636||61126|
NCT01895647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MMHIS060|Effect of Different Electric Muscle Stimulation in Patients With Severe Sepsis and Respiratory Failure|Difference of Muscle Power and Myokine Profile After Upper Limb or Lower Limb Electric Muscle Stimulation in Patients With Severe Sepsis and Acute Respiratory Failure||Mackay Memorial Hospital|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|20 Years|90 Years|No|||April 2015|April 10, 2015|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01895647||63267|
NCT01895933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-SS001|Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel|The Aim of This Study is to Evaluate the Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel Made by D Med||D.med|Yes|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|21 Years|N/A|No|||July 2013|July 21, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01895933||63245|
NCT01896219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 12 29|CTNAV II : Multicentric Evaluation of IMACTIS-CT Navigation System|Multicentric Evaluation of IMACTIS-CT Navigation System||University Hospital, Grenoble|No|Active, not recruiting|September 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|464|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01896219||63223|
NCT01896232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120360|Head-to-Head Study of AMG 416 and Cinacalcet|A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism||Amgen|Yes|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|683|||Both|18 Years|85 Years|No|||February 2016|February 5, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896232||63222|
NCT01896544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001406|Cholecalciferol Supplementation for Sepsis in the ICU|The Effect of Cholecalciferol Supplementation on Vitamin D Status in Sepsis|CSI|Massachusetts General Hospital|Yes|Completed|January 2014|December 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896544||63198|
NCT01896856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1369|Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer|A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2013|September 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896856||63175|
NCT01924390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120278H|Histological Comparison of Ridge Preservation Using Mineralized FDBA Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft|Histological Comparison of Healing Following Tooth Extraction With Ridge Preservation Using Mineralized Freeze Dried Bone Allograft Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft||The University of Texas Health Science Center at San Antonio|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 1, 2014|August 13, 2013||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01924390||61068|
NCT01924403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005083|Perfusion Assessment of Wound Closure Techniques in Primary Total Knee Arthroplasty|Assessment of Wound Closure Techniques in Primary Total Knee Arthroplasty Using SPY Intra-operative Angiography||Mayo Clinic|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 13, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924403||61067|
NCT01924923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBT-01|New Biopsy Technique for Uveal Melanoma|New Biopsy Technique for Uveal Melanoma||Greater Houston Retina Research|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|Samples Without DNA|The eye will be enucleated and histopathologic sections of the sclera will be examined for      extra scleral extension of cells. After the tissues are examined, they will be stored in the      ocular histopathology lab for 10 years.|Both|21 Years|N/A|No|Non-Probability Sample|Patients over 21, diagnosed with uveal melanoma and scheduled to undergo enucleation        surgery. No known metastatis.|March 2015|March 25, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01924923||61027|
NCT01925222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FinIP-carriage13THL|Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage|Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme||National Institute for Health and Welfare, Finland|No|Active, not recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|3900|Samples Without DNA|Nasopharyngeal and oropharyngeal swabs|Both|3 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children vaccinated in infancy in the cluster-randomized Finnish Invasive pneumococcal        Disease (FinIP) Trial (ClinicalTrials.gov Identifier:NCT00861380) during 2009 to 2011 and        their unvaccinated older siblings.|October 2015|October 5, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925222||61004|
NCT01925482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13050158|Trans-Middle-Ear Mucosal Gas Exchange Project 1, Specific Aim 1|Middle Ear Pressure Regulation in Health and Disease: Gas Supply, Demand and Middle-Ear Gas Balance -- Specific Aim 1||University of Pittsburgh|No|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925482||60985|
NCT01921868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCAR-8499|An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia|An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia||University of South Florida|No|Recruiting|August 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921868||61261|
NCT01921881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-385|Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals|||University of Southern Denmark|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921881||61260|
NCT01921842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1861|Child Care Wellness Study on Nutrition and Physical Activity|Promoting Nutrition and Physical Activity in Child Care Centers|CCWS|University of North Carolina, Chapel Hill|Yes|Completed|January 2008|August 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921842||61263|
NCT01921855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13787|Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors|A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors|MATCHBOX|Bayer|Yes|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Male|18 Years|65 Years|No|||August 2014|August 20, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01921855||61262|
NCT01922154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK002|Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma|Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma||Siriraj Hospital|Yes|Completed|February 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01922154||61239|
NCT01922167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC-H-5461|Resistance Exercise Training and Amino Acid Leucine Supplementation in Frail Elderly Women|The Impact of Exercise Training and Leucine Supplementation in Frail Elderly Women With an Exploration Into Mechanistic Explanations||McGill University Health Center|No|Recruiting|November 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Female|65 Years|N/A|No|||April 2015|April 9, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01922167||61238|
NCT01922440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-R13-001|PARADIGHM A Natural History Registry for Patients With Chronic Hypoparathyroidism|PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients With Chronic Hypoparathyroidism|PARADIGHM|Shire|Yes|Recruiting|July 2013|June 2032|Anticipated|June 2030|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|Non-Probability Sample|Patients of any age or gender, with a diagnosis of chronic hypoparathyroidism before        enrollment.|March 2016|March 22, 2016|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01922440|17 Years|61217|
NCT01922453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ritmo-HMO-CTIL|Music and Sounds for ECV|Use of Music and Sounds for the External Cephalic Version of Breech Fetuses Near Term.|RITMO|Hadassah Medical Organization|No|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 11, 2013|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01922453||61216|
NCT01922791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T166/2012|Nutrition and Pregnancy Intervention Study|Placebo-controlled Intervention Study for Maternal and Child Health||Turku University Hospital|No|Recruiting|September 2013|December 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|440|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922791||61190|
NCT01923103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDPDD|Natural Disease Progress of Dupuytren Disease|Natural Disease Progress of Dupuytren Disease|DD|University Medical Center Groningen|No|Active, not recruiting|May 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|230|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Dupuytren Disease who participated in prior studies and patients from the        outpatient clinic|August 2013|August 13, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923103||61166|
NCT01923922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP GBM|CT Perfusion in the Prognostication of Cerebral High Grade Glioma|CT Perfusion in the Prognostication of Cerebral High Grade Glioma||Nova Scotia Health Authority|No|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|15 Years|N/A|No|||January 2016|January 26, 2016|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923922||61104|
NCT01923935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFDA20120110139|Busulfan and Melphalan Conditioning in Multiple Myeloma|A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation||Chonnam National University Hospital|Yes|Recruiting|January 2013|December 2015|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|20 Years|65 Years|No|||August 2013|August 15, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923935||61103|
NCT01924234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS004|Opioid Effects on Swallowing Comparing Younger and Elderly Volunteers|Opioid Effects on Swallowing Comparing Younger and Elderly Volunteers||University Hospital Orebro|Yes|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01924234||61080|
NCT01896557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0136/11|Ranitidin Versus Omeprazole in Patients Taking Clopidogrel|Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study||University of Sao Paulo General Hospital|Yes|Completed|October 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2011|December 2, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01896557||63197|
NCT01896570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ciritical endpoint HH|Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF|The Prognostic Role of Subsequent Atrial Tachycardias Occurring After Atrial Fibrillation Termination: A Prospective Randomized Trial||Johannes Gutenberg University Mainz|No|Completed|June 2009|||March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with persistent AF|July 2013|July 10, 2013|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01896570||63196|
NCT01896869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13108|A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer|A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2013|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896869||63174|
NCT01897129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV AND PREGNANCY|Human Papillomavirus and Pregnancy|Human Papillomavirus and Pregnancy|HPVandPregn|Odense University Hospital|Yes|Recruiting|November 2011|November 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Anticipated|546|Samples With DNA|Biospecimen will be kept in a biobank for a period of 10 years after the end of this      project. The biospecimens will be blood samples, cells collected from the ectocervix,      vaginal microbioma, placental biopsies from prenatal diagnostics or miscarriages.|Female|15 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women in Funen, Denmark|July 2013|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897129||63154|
NCT01897389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102353|A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, 4-Period, 5-Treatment Crossover Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897389||63134|
NCT01897402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-NM-002|Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT™) Compared With a Licensed Vaccine||JN-International Medical Corporation|No|Completed|July 2013|December 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|525|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 9, 2013|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01897402||63133|Three subjects, 1 female and 2 males, received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (outcomes 2 and 3).
NCT01924715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA003|Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study|Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study|CEISTDP|Nova Scotia Health Authority|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1082|||Both|12 Years|90 Years|No|Non-Probability Sample|All Major DSM IV categories included including mood, anxiety, personality, somatoform,        dissociative, eating and psychotic disorders|July 2013|August 15, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01924715||61043|
NCT01924702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATS02EO0801|Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)|Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)||Charité Neurocure AG Flöel|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||February 2015|February 3, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01924702||61044|
NCT01924936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH097836-01|Now Matters Now: An Online Suicide Prevention Program|Pilot Study of Online Interventions for Population-based Suicide|NMN_SSIP|Group Health Cooperative|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|460|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01924936||61026|
NCT01925235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ren-PRO TAVI retro|Analysis of Remote-ischemic Preconditioning Effects on Kidney Function|Remote Ischemic Preconditioning Effects on Kidney Function in Patients Receiving Transcatheter Aortic Valve Implantation|RenPRO-TAVI|University of Cologne|Yes|Completed|March 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|patients with impaired renal function and a high risk of developing contrast        medium-induced acute kidney injury undergoing TAVI|August 2013|August 16, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01925235||61003|
NCT01925495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13050328|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3|Middle Ear Pressure Regulation in Health and Disease/Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3||University of Pittsburgh|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925495||60984|
NCT01922180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-EXAC-CT|Chronic Obstructive Pulmonary Disease: CT Features of Severe Exacerbation|Chronic Obstructive Pulmonary Disease: CT Features of Severe Exacerbation||Erasme University Hospital|No|Completed|July 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|COPD patients followed in our institution (i.e. Erasme University Hospital), who are        admitted for a severe exacerbation episode.|August 2013|August 13, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01922180||61237|
NCT01922193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000089|Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program|A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program||Ferring Pharmaceuticals|No|Completed|October 2013|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Female|20 Years|39 Years|No|||June 2015|June 15, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01922193||61236|
NCT01922466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2012-019|East-West Collaboration Treatment Using Bee Venom Acupuncture and NSAIDs for Chronic Cervicalgia|Clinical Research on the Efficacy and Safety of East-West Collaborative Treatment Using NSAIDs and BV on Chronic Cervical Pain; A Randomized, Controlled, Parallel, Pilot Study||Kyunghee University Medical Center|No|Completed|July 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 20, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01922466||61215|
NCT01922206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH094233|Maternal HIV: Trial to Assist Disclosure to Children|2/2-Maternal HIV: Multisite Trial to Assist Disclosure to Children|TRACK II|Georgia State University|Yes|Recruiting|March 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|440|||Both|N/A|N/A|No|||February 2016|February 9, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01922206||61235|
NCT01922765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|concomitant|Concomitant Therapy of H. Pylori|Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori||The Catholic University of Korea|No|Recruiting|August 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|540|||Both|19 Years|75 Years|No|||February 2014|February 9, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922765||61192|
NCT01922778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0105|Screening for Endometrial Abnormalities in Overweight and Obese Women|Screening for Endometrial Abnormalities in Overweight and Obese Women||St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01922778||61191|
NCT01899443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOAJRS_AU|Improving Services and Outcomes for Joint Replacement Patients|Improving Services and Outcomes for Joint Replacement Patients||South West Sydney Local Health District|No|Active, not recruiting|August 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2200|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing primary total hip or knee replacement in private or public hsopitals        in Australia|May 2015|May 25, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899443||62977|
NCT01899456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5548/12|Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation|A Randomized Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation in Patients After Renal Transplantation|ISAR-denerve|Technische Universität München|No|Completed|July 2013|November 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|85 Years|No|||November 2015|November 3, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899456||62976|
NCT01895192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 175 03|Sperm Morphology by High Magnification in Fertility Men|Assessment of Sperm Morphology by High Magnification (x6000) With Interference Contrast Microscopy in Fertile Men.|FERTIFORT|University Hospital, Toulouse|No|Completed|October 2011|February 2013|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 4, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01895192||63302|
NCT01895205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP-02|Treatment of Women After Severe Postpartum Haemorrhage|A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia|PP-02|Pharmacosmos A/S|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895205||63301|
NCT01895725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-selectin 03-13|Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin|Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin||Medical University Innsbruck|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Plasma samples|Both|30 Years|85 Years|No|Non-Probability Sample|Patients referred to ultrasound examinations of the carotid and/or femoral arteries for        standard indications will be screened for potential inclusion into the study|September 2015|September 22, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01895725||63261|
NCT01895738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:257|WrapAround Care for Youth Injured by Violence|WrapAround Care for Youth Injured by Violence: A Pilot Randomized Control Trial||University of Manitoba|Yes|Completed|November 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|14 Years|24 Years|No|||November 2015|November 25, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01895738||63260|
NCT01896037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL2013|Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels|Omega-3 Supplementation to Increase HDL-c Levels in Those With Tetraplegia||University of Manitoba|No|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896037||63237|
NCT01896362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentroPRR-001|The Healthcare Professionals and the Leishmaniasis|Leishmaniasis: the Healthcare Professionals' Knowledge in Endemic Area||Centro de Pesquisas René Rachou|No|Completed|May 2010|May 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|228|||Both|18 Years|N/A|No|Non-Probability Sample|Nurses, physicians and dentists working in primary care units of the municipality,        community health workers and zoonoses agents tied to health surveillance and veterinarians        working in private veterinary clinics of Divinópolis city, Minas Gerais state, Brazil.|July 2013|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896362||63212|
NCT01910337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR335167|Evaluation of Heart Rate Variability in Third Lower Molars Surgeries|Evaluation of Heart Rate Variability in Third Lower Molars Surgeries||University of Sao Paulo|No|Completed|June 2011|March 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|33|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 patients from the community sample in Dentistry School - University of Sao Paulo|July 2013|July 26, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910337||62145|
NCT01910636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0118|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 2 HCV Infection||Gilead Sciences|No|Completed|February 2013|June 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|20 Years|N/A|No|||March 2015|March 13, 2015|July 23, 2013|Yes|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01910636||62122|
NCT01909362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12246|Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)|Feasibility Study of Biomarker Analysis for Patients With Metastatic Colorectal Cancer||US Oncology Research|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|52|Samples With DNA|Tumor tissue (biopsy or surgery) retrieved within 4 weeks from the date of signing the ICF      and tested as outlined in the protocol:      - FFPE specimen (blocks or cut slides) currently in storage at a pathology lab. Such tissue      may be archival and stored, for no more than 5 years, being obtained at the time for a      standard of care diagnostic or research biopsy.|Both|18 Years|N/A|No|Non-Probability Sample|patients with metastatic colorectal cancer seen within the US Oncology network|February 2014|February 25, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01909362||62219|
NCT01918891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12-004|Center for Stroke Disparities Solution - Community Transitions Intervention|Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)|CSDS|Visiting Nurse Service of New York|Yes|Recruiting|September 2012|August 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|495|||Both|21 Years|N/A|No|||March 2016|March 14, 2016|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918891||61490|
NCT01909934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25006|Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma|A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma||Millennium Pharmaceuticals, Inc.|No|Recruiting|October 2013|May 2020|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909934||62175|
NCT01897428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-BPT-101|PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg|Clinical Trial to Evaluate Pharmacokinetic Characteristics of Belion in Healthy Subjects||Korea University Anam Hospital|No|Completed|April 2011|August 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2011|July 11, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897428||63131|
NCT01897753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281310|Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age|Retrospective Study Of The Influence Of Age At Start Of Growth Hormone (Gh) Treatment On Height Gain In Children Born Small for Gestational Age (SGA)|GH-RAST|Pfizer|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|264|||Both|4 Years|N/A|No|Non-Probability Sample|SGA children treated with GH at least 36 months|January 2014|January 17, 2014|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897753||63106|
NCT01898026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|White Line|Soluble Fibre Enriched CHO Food Study|Development of Palatable Soluble Fibre Containing Carbohydrate Foods and Its Effects on Postprandial Blood Glucose Response in Healthy Individuals||St. Michael's Hospital, Toronto|No|Active, not recruiting|July 2013|January 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|35|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 4, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898026||63085|
NCT01898065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11-080|Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer|Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer|HYPOXProstat|Institut Cancerologie de l'Ouest|No|Completed|June 2012|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||November 2015|November 6, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01898065||63082|
NCT01898078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14017|Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas|An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|July 2013|May 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898078||63081|
NCT01898611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818192|Ghrelin Plus Strength Training in Frail Elderly Study|Ghrelin Plus Strength Training in Frail Elderly Study||University of Pennsylvania|No|Active, not recruiting|July 2013|September 2014|Anticipated|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|16|||Both|70 Years|N/A|No|||August 2014|August 26, 2014|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898611||63040|
NCT01898871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMR6010|Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition|Using Indigenous Foods to Reduce Malnutrition in Children||Centre for Food and Nutrition Research, Yaounde|Yes|Completed|February 2012|December 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|6 Months|59 Months|No|||July 2013|July 10, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898871||63020|
NCT01898884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20629-100|Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects With Friedreich's Ataxia||Shire|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|45 Years|No|||July 2015|July 29, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898884||63019|
NCT01899157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT-HIV001|Nutritional Status Among naïve HIV Infected Patients and HIV Infected Patients Receiving Highly Active Antiretroviral Therapy|Nutritional Status Among naïve HIV-infected Patients and HIV-infected Patients Receiving Highly Active Antiretroviral Therapy|TNT-HIV 001|Thai Red Cross AIDS Research Centre|No|Completed|August 2009|December 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|580|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 580 Thai HIV-infected patients who either did or did not receive treatment with        antiretroviral therapy at The Thai Red Cross AIDS Research Centre, Bamrasnaradura        Infectious Disease Institute, Surat Thani hospital, Khonkaen hospital, Sanpathong hospital        and the Queen Savang Vadhana Hospital at Sri Racha.; These participants will be enrolled        at TRCARC and Bamrasnaradura Infectious Disease Institute for amount 300 HIV infected        patients and 70 HIV infected patients from each 4 region hospital.|July 2013|July 10, 2013|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01899157||62999|
NCT01899144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-202|Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients|A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|61|||Both|4 Years|11 Years|No|||February 2016|February 5, 2016|July 8, 2013|Yes|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01899144||63000|
NCT01895218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP-01|Treatment of Women After Postpartum Haemorrhage|A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage|PP-01|Pharmacosmos A/S|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895218||63300|
NCT01895465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHNEIDER/7329|Improvement in Urine Collection Methods in Children|Improvement in Urine Collection Methods in Children|0244-12-RMC|Rabin Medical Center|No|Not yet recruiting|August 2013|July 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|1 Month|14 Years|No|||July 2013|July 22, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01895465||63281|
NCT01895452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-003EXT2|An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)|A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia||Alkermes, Inc.|No|Enrolling by invitation|July 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895452||63282|
NCT01895751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN-11-CA456|Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome|A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.|CABG-ACS|NHS National Waiting Times Centre Board|Yes|Active, not recruiting|April 2012|June 2019|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|September 23, 2014|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895751||63259|
NCT01896050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009.029|Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer|A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen|LOGRIBMET|University of Michigan Cancer Center|No|Completed|September 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|115|Samples With DNA|Whole blood is being collected at baseline for DNA extraction. Serum is being collected at      baseline and after 3, 6, and 12 months.|Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal women with hormone receptor positive breast cancer who are initiating        therapy with either an aromatase inhibitor or tamoxifen.|December 2014|December 8, 2014|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01896050||63236|
NCT01896388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G25013|Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial|Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial||Chiba University|Yes|Recruiting|June 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|13 Years|18 Years|No|||January 2016|January 26, 2016|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896388||63210|
NCT01896401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-14-003|InSeal Vascular Closure Device Clinical Study Protocol|InSeal Vascular Closure Device Clinical Study Protocol|VCD|InSeal Medical Ltd.|No|Terminated|February 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 6, 2013||No|Initiated a new study with improved device|No||https://clinicaltrials.gov/show/NCT01896401||63209|
NCT01910961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRIP|Impact of Limb Remote Ischemic Preconditioning on Mortality and Quality of Life During Abdominal Aortic Aneurysm Repair|Impact of Limb Remote Ischemic Preconditioning on Mortality, Hospitalization Costs and Quality of Life During Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|August 2013|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|80 Years|No|||July 2013|July 26, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01910961||62097|
NCT01910584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|First-GYN-SYSU-2012|Quality of Life and Sexual Function of the Novasure Endometrial Ablation in Menorrhagia|Prospective Study of the Influence on Quality of Life and Sexual Function of the Novasure Endometrial Ablation in the Treatment of Menorrhagia||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|25 Years|50 Years|No|Non-Probability Sample|100 patients diagnosed menorrhagia scheduled for Novasure endometrial ablation in The        First Affiliated Hospital between November 2012 and November 2015|September 2012|July 25, 2013|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01910584||62126|
NCT01910896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ90011_0028_3|Effectiveness and Safety Study of Overnight Intensive Patch in Scars|A Prospective, Intra-individual Randomized, Observer-blind, Controlled Investigation to Investigate the Effectiveness and Safety of Overnight Intensive Patch (OIP) Over 12 to 24 Weeks in Post Dermatological Surgery Scars||Merz Pharmaceuticals GmbH|No|Completed|October 2013|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01910896||62102|
NCT01910909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-005-001|Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma|Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial|SBRT for HCC|Samsung Medical Center||Recruiting|August 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||August 2014|August 25, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910909||62101|
NCT01909622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDFORT|Trial of Vitamin D Fortified Milk|A Randomized Trial of Milk Fortified With Vitamin D in Colombia||University of Michigan||Active, not recruiting|June 2013|||October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|144 Months|174 Months|No|||July 2014|July 18, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909622||62199|
NCT01910597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552941411|Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors|||Prince of Songkla University|No|Recruiting|August 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01910597||62125|
NCT01897441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02-079|Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer|Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897441||63130|
NCT01897766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281314|Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)|Special Investigation For Genotropin (SGA Long Follow-up)||Pfizer|No|Active, not recruiting|September 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|20 Years|No|Probability Sample|-  A patients who is diagnosed for SGA. (SGA is defined as birth weight and/or length at             least 2 standard deviations (SDs) below the mean for gestational age (<or=-2 SD)).          -  A patient who is SGA and older than 3 years.          -  A patient who has persistent short stature (i.e., remaining at least 2.5 SD below the             mean for chronologic age).|March 2016|March 23, 2016|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897766||63105|
NCT01898039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0419-12-HMO-CTIL|Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients|Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I/II Study.||Hadassah Medical Organization|No|Recruiting|May 2013|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||June 2013|July 10, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898039||63084|
NCT01898338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACSARM|Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia|Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients||Spanish Network for Research in Infectious Diseases|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|99 Years|No|||November 2015|November 30, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01898338||63061|
NCT01898351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alternative Protein Study 791|Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY|Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY||University of Aberdeen|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898351||63060|
NCT01898624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE0004|Specified Drug Use-results Survey of Betanis Tablets|Specified Drug Use-results Survey of Betanis Tablets in OAB Patients With Coexisting Glaucoma||Astellas Pharma Inc|No|Recruiting|December 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|OAB patients with coexisting glaucoma treated with mirabegron|January 2016|January 8, 2016|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898624||63039|
NCT01898897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iuliu Hatieganu University|Influence of Anesthesia Technique on Postoperative Evolution After Urogenital Surgical Interventions|Combined Anesthesia Considerations in Uro-Genital Robot Assisted Laparoscopic Surgeries: Acute Kidney Injury|ROBOTNGAL|Iuliu Hatieganu University of Medicine and Pharmacy|Yes|Recruiting|March 2010|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||July 2013|July 15, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01898897||63018|
NCT01898910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDGP-031|Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation|Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation. A Randomized Comparison||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||July 2013|July 12, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01898910||63017|
NCT01899170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28052013|Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain|Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain|DBSforPain|University of Aarhus|Yes|Recruiting|April 2014|August 2022|Anticipated|August 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||July 2013|November 3, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899170||62998|
NCT01899469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMCRO|Efficiency of Physiotherapy Treatments for Low Back Pain in Senior Women.|Efficiency of Physiotherapy Treatments for Low Back Pain in Senior Women.|LUMCRO|University Rovira i Virgili|Yes|Completed|March 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Female|60 Years|85 Years|No|||July 2013|July 10, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899469||62975|
NCT01903915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07052012|Social Dysfunction and Brain Dysfunction in Patients With Schizophrenia|Resting-state Magnetic Resonance Imaging of Brain in Patients With Schizophrenia Compared With Healthy Controls to Prove the Association Between Social Cognition Dysfunction and Abnormality of Brain Function||Asan Medical Center|Yes|Recruiting|July 2012|April 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients groups will be selected from psychiatric clinic in general hospital - Asan        Medical Center.|July 2013|July 17, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01903915||62635|
NCT01903928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-CL-1003|A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant|An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)||Astellas Pharma Inc|Yes|Completed|May 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||February 2015|February 5, 2015|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903928||62634|
NCT01899807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OQ-CR-001|Bone Reconstruction of the Skull Using a Metal Ceramic Implant After Previously Failed Reconstruction|Cranial Reconstruction With Patient-specific Titanium Mesh/Mosaic-designed Calcium Phosphate-implant - A Multi Center Center, Single Arm, Non-comparative Prospective Case Series||Karolinska University Hospital|No|Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01899807||62949|
NCT01895764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI12-ED-COMARIS|Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)|Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)|COMARIS|University Hospital, Tours|Yes|Completed|March 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01895764||63258|
NCT01900054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-284-18|A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis|||Mitsubishi Tanabe Pharma Corporation|No|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|7 Years|15 Years|No|||September 2015|November 10, 2015|July 3, 2013||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01900054||62930|
NCT01900327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOPA|Neoadjuvant Treatment in Resectable Pancreatic Cancer|Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma|NEOPA|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|February 2014|December 2020|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01900327||62910|
NCT01900587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100456|A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bio-equivalence of a New Tapentadol Extended-Release (TRF) 50-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 50-mg Tablet Under Fasted Conditions in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900587||62890|
NCT01909947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEX 01|Prediction of Extubation Readiness in Extreme Preterm Infants by the Automated Analysis of CardioRespiratory Behavior|Prediction of Extubation Readiness in Extreme Preterm Infants by the Automated Analysis of CardioRespiratory Behavior: the APEX Study||McGill University Health Center|No|Recruiting|September 2013|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|N/A|N/A|No|Non-Probability Sample|Extreme preterm infants who are requiring endotracheal tube mechanical ventilation        (ETT-MV).|September 2015|September 21, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909947||62174|
NCT01910922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|habeat_wp2.3|Effect of Learning on Vegetable Acceptance by Toddlers|Learning Mechanisms of Food Preferences in 2-3 y. o. Toddlers in Nurseries|WP23_HabEat|Centre des Sciences du Goût et de l'Alimentation|Yes|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|160|||Both|17 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 2-3 years olds attending nurseries in Dijon city|July 2013|July 26, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01910922||62100|
NCT01910298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC 2012.06.01|Efficacy of Single Stage Breast Reconstruction|A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice™ Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice™ TM .|ESSBR|LifeCell|Yes|Recruiting|July 2013|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01910298||62148|
NCT01911416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI67198|A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer|A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer||University of Utah|Yes|Withdrawn|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|July 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911416||62062|
NCT01911429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050301|Pediatric Schizophrenia Efficacy and Safety Study|A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia||Sunovion|Yes|Completed|August 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|285|||Both|13 Years|17 Years|No|||January 2016|January 7, 2016|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911429||62061|
NCT01911442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050325|Lurasidone Pediatric Autism Study|A 6-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Irritability Associated With Autistic Disorder||Sunovion|Yes|Completed|August 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|6 Years|17 Years|No|||January 2016|January 27, 2016|July 22, 2013|Yes|Yes||No|November 8, 2015|https://clinicaltrials.gov/show/NCT01911442||62060|
NCT01897805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG0930BXW|A Trial to Evaluate Efficacy of Heart-protecting Musk Pill|A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease||Shanghai Hutchison Pharmaceuticals Limited|No|Active, not recruiting|July 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2700|||Both|18 Years|85 Years|No|||December 2014|December 17, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897805||63102|
NCT01897779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 501|Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|94|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 27, 2014|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897779||63104|
NCT01897792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F101108001|Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma|Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma||University of Alabama at Birmingham|Yes|Terminated|May 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|11|||Both|19 Years|N/A|No|||August 2015|August 4, 2015|July 9, 2013|No|Yes|Study was terminated due to inability to recruit enough patients that meet inclusion criteria.    No analysis will be done.|No||https://clinicaltrials.gov/show/NCT01897792||63103|
NCT01898117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13TNB|Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer|Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer|Triple-B|The Netherlands Cancer Institute|Yes|Recruiting|July 2013|December 2029|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|304|||Both|N/A|N/A|No|||January 2016|January 21, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01898117||63078|
NCT01898364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR12857|Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.|An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.||Sanofi|Yes|Completed|July 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|July 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898364||63059|
NCT01902732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol G1.0.- 16.02.2012|Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures|Bronchoscopic Volume Reduction With Valve Implants After Analysis of Interlobar Fissure Integrity and Measurement of Collateral Ventilation in Patients With Severe, Heterogeneous Emphysema||Heidelberg University||Recruiting|June 2013|||December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||July 2013|July 15, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01902732||62726|
NCT01902992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDPG103ADE01|Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Intraseasonal Specific Short-term Immunotherapy With Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depiquick® Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma|INSIDE|Novartis|Yes|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|12 Years|70 Years|No|||February 2014|November 11, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01902992||62706|
NCT01903005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX219-008|Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence|A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219||Orexo AB|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|668|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|July 9, 2013|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01903005||62705|
NCT01903317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-9554|Evaluation of Vitamin D Levels in Psoriasis Patients|Evaluation of Vitamin D Levels in Psoriasis Patients||University of California, Irvine|No|Withdrawn|June 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|Samples Without DNA|For all Vitamin D level testing in this protocol, the Vitamin D 25-hydroxy level will be      drawn, which involves 0.5mL of blood per draw.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from an outpatient population of subjects with psoriasis from        Dr. Jennifer Soung's clinic at the Gottschalk Medical Plaza at the University of        California, Irvine.|October 2015|October 7, 2015|July 3, 2013||No|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT01903317||62681|
NCT01903330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC1671-H02|ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme|A Randomized, Double-blinded, Placebo-controlled Study of (ERC1671/GM-CSF/Cyclophosphamide)+Bevacizumab vs. (Placebo Injection/Placebo Pill) +Bevacizumab in the Treatment of Recurrent, Bevacizumab naïve Glioblastoma Multiforme Patients||University of California, Irvine|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903330||62680|
NCT01899482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFRH/BD/62673/2009|Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial|Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial|MLDCVI|Technical University of Lisbon|Yes|Completed|July 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|41|||Both|18 Years|65 Years|No|||July 2013|March 23, 2016|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899482||62974|
NCT01903941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPExercise|Anti-inflammatory Effect of Aerobic Exercise in Individual With Increased Cardiovascular Risk|Anti-inflammatory Effect of Aerobic Exercise in Individual With Increased Cardiovascular Risk||Escola Bahiana de Medicina e Saude Publica|Yes|Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|40 Years|70 Years|No|||July 2013|July 17, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01903941||62633|
NCT01899820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI_CT_2013/0017|Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya|Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya|EAPHLNP|KEMRI-Wellcome Trust Collaborative Research Program|Yes|Active, not recruiting|April 2013|July 2015|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|2100|||Both|6 Months|10 Years|No|||October 2013|October 7, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01899820||62948|
NCT01899833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-ECDG-C3|Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)|A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)||Cell>Point LLC|Yes|Enrolling by invitation|February 2014|August 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899833||62947|
NCT01900067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD12-001|Study to Evaluate Safety and Efficacy of Blanket Used to Prevent Anesthesia Induced Hypothermia|An Open-Label, Multicenter, Randomised, Controlled Study to Evaluate the Efficacy and Safety of the BARRIER® EasyWarm Active Self-Warming Blanket Used for Continuous Active Warming to Prevent General Anaesthesia Induced Hypothermia During the Perioperative Surgical Period||Molnlycke Health Care AB|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|271|||Both|18 Years|N/A|No|||December 2014|April 21, 2015|July 8, 2013||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01900067||62929|
NCT01900340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 25/11|Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans|Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans||University Hospital, Basel, Switzerland|Yes|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01900340||62909|
NCT01900600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB# 20110521, HM13782|Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)|Substudy of the the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP; CACZ885M2301)||Virginia Commonwealth University|No|Active, not recruiting|April 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|16|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01900600||62889|
NCT01912391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJM-01|Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder|A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety||Mood and Anxiety Research, Inc|No|Completed|October 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01912391||61988|
NCT01912404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-04|Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy|AH|Conatus Pharmaceuticals Inc.|Yes|Terminated|July 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|N/A|No|||September 2015|September 25, 2015|July 29, 2013|Yes|Yes|Emerging data indicated 25mg may not be adequate in very severe hepatic impairment subjects    despite higher exposures and that additional dose-ranging was needed|No||https://clinicaltrials.gov/show/NCT01912404||61987|
NCT01909960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-IR-11-DR-BALEDENT|Flow MRI in Normal Pressure Hydrocephalus|Benefit of Flow Magnetic Resonance Imaging in the Management of Normal Pressure Hydrocephalus|HydroFlux|Centre Hospitalier Universitaire, Amiens|No|Recruiting|June 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|184|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909960||62173|
NCT01909973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH095907-02|Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment||Medlink|Northwestern University|Yes|Enrolling by invitation|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909973||62172|
NCT01910311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14608|A Study of Baricitinib and Rifampicin in Healthy Participants|The Effect of CYP3A Induction by Rifampicin on the Pharmacokinetics of Baricitinib in Healthy Subjects||Eli Lilly and Company|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910311||62147|
NCT01910948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|omega-3 PUFA|Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients|Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial|PAOPUFAGC|First Hospital of Jilin University|No|Active, not recruiting|June 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|85 Years|No|||July 2013|July 26, 2013|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910948||62098|
NCT01911182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:072|Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea|A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity||University of Manitoba|No|Terminated|October 2011|July 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|N/A|60 Days|No|||February 2015|February 18, 2015|September 22, 2011||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT01911182||62080|
NCT01910688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-600|Use of Radiofrequency Ablation for RGB Salvage|Use of Endoscopically Delivered Radiofrequency Ablation for the Treatment of Ptients Who Have Undergone Roux-en-Y Gastric Bypass and Have Failed to Achieve/ Maintain Satisfactory Excess Body Weight Loss||Medtronic - MITG|No|Completed|July 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910688||62118|
NCT01897467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WiiFit|Effect of a Wii Fit Intervention on Components of Fall Risk in Middle-aged Women|Effect of a Wii Fit Intervention on Balance, Muscular Fitness, and Bone Health in Middle-aged Women||Arizona State University|No|Completed|August 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897467||63128|
NCT01897480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14209|A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations|A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib|Balise|Eli Lilly and Company|No|Active, not recruiting|August 2013|July 2020|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897480||63127|
NCT01898091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101529|Herbal Mouthrinse for Oral Mucositis Study|Randomized Controlled Double-blinded Clinical Trial of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients|OM|Medical University of South Carolina|Yes|Completed|July 2013|June 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|89 Years|No|||September 2015|September 21, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898091||63080|
NCT01898104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-shoRT-R3|Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer|Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperatIve Treatment in Low-moderate Risk Rectal Cancer|V-shoRT-R3|National Cancer Institute, Naples|No|Recruiting|May 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|152|||Both|18 Years|70 Years|No|||November 2015|November 27, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01898104||63079|
NCT01902459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-12-005|EVARREST™ Fibrin Sealant Patch Post-Market Study|A Non-Investigational Post-Market Trial Using EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery|EVARREST™ PMS|Ethicon, Inc.|No|Completed|July 2013|September 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902459||62746|
NCT01902745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075741|Fatigue Reduction Diet|Fatigue Reduction Diet in Breast Cancer Survivors|FRD|University of Michigan|No|Recruiting|November 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|March 25, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01902745||62725|
NCT01902758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM82-13|Drug Combination on Exercise Performance at High Altitude|Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude||University of Montana|No|Completed|August 2013|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 11, 2013||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01902758||62724|
NCT01903018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/64/11|A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00|A Multicenter, Phase II/III Study to Assess Radiation Induced Mucositis in Subjects With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Administered Cisplatin and Radiation With or Without P276-00||Piramal Enterprises Limited|No|Completed|July 2012|September 2014|Actual|March 2014|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903018||62704|
NCT01903031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5316|Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART|Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)||AIDS Clinical Trials Group|Yes|Recruiting|November 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|16 Years|N/A|No|||January 2016|January 29, 2016|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903031||62703|
NCT01903343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013AN01|Repeatability and Reproducibility of the Measurement of Young's Modulus Using Shear Wave Elastography in Volunteers|Repeatability and Reproducibility of the Measurement of Young's Modulus Using Shear Wave Elastography in Volunteers||University of Dundee|No|Not yet recruiting|December 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study of 8 subjects - volunteer medical students. Recruitment: Male medical students at        Ninewells Hospital & Medical School, Dundee.        Male medical students will be e-mailed by the chief investigator.|October 2013|October 28, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903343||62679|
NCT01903603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-4545A3|A Longitudinal Study of Movement and Participation in Patients With Cerebral Palsy|A Longitudinal Study of Movement and Participation in Patients With Cerebral Palsy: a Combined Brain Imaging and Kinematic Analysis||Chang Gung Memorial Hospital|Yes|Recruiting|August 2012|July 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|4 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|CP and healthy children|February 2016|February 15, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903603||62659|
NCT01900093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0600|Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses|An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone||Icahn School of Medicine at Mount Sinai|No|Recruiting|July 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900093||62927|
NCT01900353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CC01|Vertical vs Horizontal Brushing: a Randomized Split-mouth Clinical Trial|Vertical Versus Horizontal Brushing: a Randomized Split-mouth Clinical Trial||University of Milan|No|Completed|October 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|43|||Both|19 Years|24 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900353||62908|
NCT01898169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ-001 LACT|Evaluation of Short-term Safety and Use Patterns of an Electronic Nicotine Delivery System|Evaluation of Plasma Nicotine, Carbon Monoxide, Heart Rate, Craving and Withdrawal After Acute Use of the NJOY King E-Cigarette in the Clinic, Following a One-Week Actual Use Pilot Study||LA Clinical Trials|No|Active, not recruiting|April 2013|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01898169||63074|
NCT01900080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI104344-01A1|Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care|Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care||Brigham and Women's Hospital|Yes|Recruiting|August 2013|January 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|888|||Both|18 Years|N/A|No|||June 2015|June 7, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900080||62928|
NCT01900938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-055|Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP|Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During Endoscopic Retrograde Cholangiopancreatography: a Prospective Randomized Controlled Study||Hanyang University|Yes|Not yet recruiting|September 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|210|||Both|18 Years|90 Years|No|||July 2013|July 16, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01900938||62863|
NCT01900951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-01|Temozolomide as Maintenance Therapy in Small Cell Lung Cancer|Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer||Chinese PLA General Hospital|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||January 2016|January 24, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900951||62862|
NCT01901237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2014-067|Yoga for Adolescent and Young Adult Non-Curative Cancer Patients|Impact of Yoga on Quality of Life for Adolescent and Young Adult Non-Curative Cancer Patients: A Pilot Study||Nova Scotia Health Authority|No|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|15 Years|39 Years|No|||January 2016|January 28, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01901237||62840|
NCT01908725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-09|Lamazym Aftercare Study|A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials|rhLAMAN-09|Zymenex A/S|No|Active, not recruiting|June 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||July 2013|February 9, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01908725||62267|
NCT01908738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-244-12-4-2|Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy|Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy Under Oral Analgesic Drugs; A Randomized Controlled Trial||Mahidol University|Yes|Recruiting|September 2013|August 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908738||62266|
NCT01910610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATEGIC-1 C12- 2|Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer|Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.|STRATEGIC-1|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Recruiting|July 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|474|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01910610||62124|
NCT01910623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL-APL0512|Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia|Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia: a Follow-up Observational Study of Patients Enrolled in the GIMEMA AIDA 0493 and AIDA 200|QOL-APL0512|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Acute promyelocytic patients previously enrolled in the studies GIMEMA AIDA0493 and        AIDA2000|October 2014|October 1, 2014|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01910623||62123|
NCT01909193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1624|CBT vs. ABM vs. for Social Anxiety|Cognitive Behavior Therapy vs. Attention Bias Modification Treatment for Social Anxiety||Hebrew University of Jerusalem|No|Completed|January 2011|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909193||62231|
NCT01897220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT/11506-6|Perioperative Ischemia Versus Perioperative Bleeding During Non-cardiac Surgery in Cardiac Patients|Perioperative Ischemia Versus Perioperative Bleeding During Non-cardiac Surgery in Cardiac Patients : PRAGUE 14 Study|PRAGUE-14|Charles University, Czech Republic|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|||Both|N/A|N/A|No|Probability Sample|Unselected cohort of consecutive patients undergoing non-cardiac surgery in four surgical        clinics of the University Hospital.|July 2013|July 10, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01897220|1 Week|63147|
NCT01901926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salman-0509|Periodontal Treatment and Glycemic Control|Impact of Non Surgical Periodontal Treatment on Glycemic Control in Type II Diabetics||Pakistan Institute of Medical Sciences|Yes|Active, not recruiting|December 2012|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|20 Years|70 Years|No|||July 2013|July 15, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901926||62787|
NCT01901939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24960|Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly|Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly||Palo Alto Veterans Institute for Research|No|Withdrawn|February 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|65 Years|N/A|No|||August 2015|August 3, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01901939||62786|
NCT01897818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-16|Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study|||Centre Hospitalier Universitaire de Nice||Recruiting|July 2013|||July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|July 9, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897818||63101|
NCT01902225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 112516|Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination With Doxorubicin HCl Liposomal (Doxil®) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma||University of California, San Francisco|Yes|Recruiting|April 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|July 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01902225||62764|
NCT01902472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-276-0103|A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)|A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)||Gilead Sciences|No|Recruiting|September 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|One hundred fifty (150) HIV-1 negative adults (any sex/gender, including transgender) and        ≥ 18 years of age who seroconvert while taking FTC/TDF for PrEP.|February 2016|February 18, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902472||62745|
NCT01902485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009|Study of Immediate Start of Progestin Contraceptives in Medical Abortion|Immediate Initiation of Progestin Contraceptives in First Trimester Medical Abortion: A Randomized Controlled Trial|Quickstart|Gynuity Health Projects|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|937|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902485||62744|
NCT01903356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.22|A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea|A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|Korean patients with T2DM|March 2016|March 16, 2016|July 16, 2013||||No||https://clinicaltrials.gov/show/NCT01903356||62678|
NCT01903629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKE-1|Comparative Study of the Magnetic-controlled Capsule Endoscopy Versus Standard Gastroscopy|A Double-center Self-controlled Comparative Study of the Magnetic-controlled Capsule Endoscopy Versus Standard Gastroscopy for Gastric Diseases||Changhai Hospital|Yes|Completed|November 2011|February 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|70 Years|No|||July 2015|July 19, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903629||62657|
NCT01903642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonnotte PHRC IR 2008|Study of the Proteome and Cytokines During Inflammatory Syndromes of Different Etiologies.||Proteome|Centre Hospitalier Universitaire Dijon||Terminated|March 2010|February 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|97|||Both|18 Years|90 Years|No|||July 2013|July 17, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903642||62656|
NCT01897298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01283|Urban Training for COPD Patients|Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial||Centre for Research in Environmental Epidemiology, Spain|Yes|Recruiting|July 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|45 Years|130 Years|No|||January 2016|January 26, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897298||63141|
NCT01899534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00039130|Mental Health E-screening in Pregnant and Postpartum Women|Mental Health E-screening in Pregnant and Postpartum Women||University of Alberta|Yes|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|566|||Female|16 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899534||62970|
NCT01903616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 98-2314-B-182-006-MY3|A Longitudinal Study of Movement and Participation in Life Activities of Young Children With Cerebral Palsy in Taiwan|A Longitudinal Study of Movement and Participation in Life Activities of Young Children With Cerebral Palsy in Taiwan||Chang Gung Memorial Hospital|Yes|Recruiting|July 2009|July 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|3 Months|12 Years|No|Probability Sample|Children with cerebral palsy|February 2016|February 15, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903616||62658|
NCT01897883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NCN-XXX-2013/1|Dyslipidemia Management in Chinese Post Stroke Patients|Dyslipidemia Management in Chinese Post Stroke Patients||AstraZeneca|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Post -ischemic stroke patients within 6-12 months from attack, with age ≥ 18 years old.        Subject ( or his legal representative) must demonstrate his or her willingness to        participate in the survey and comply with its procedures by signing a written consent.        Subjects who are unwilling or unable to provide informed consent will be excluded|July 2015|July 29, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897883||63096|
NCT01898429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12051|Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)|Deep Brain Stimulation for Treatment-Resistant Depression||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|22 Years|70 Years|No|||March 2016|March 12, 2016|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898429||63054|
NCT01900613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216443-10|Niños Sanos, Familia Sana - A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California|Niños Sanos, Familia Sana (Healthy Children/Healthy Family): A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California||University of California, Davis|Yes|Recruiting|April 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900613||62888|
NCT01898962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carter 2005-01|Definitive Therapy for Oligometastatic Solid Malignancies|A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies With Oligometastases||Rocky Mountain Cancer Centers|No|Recruiting|December 2005|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01898962||63013|
NCT01899248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_liver transplantation|The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)|||Seoul National University Hospital||Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|52|||Both|18 Years|65 Years|No|Non-Probability Sample|subjects who were enrolled prospectively in study (ClinicalTrials.gov Identifier        NCT01886664)|May 2014|May 13, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899248||62992|
NCT01899261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-10-326|Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma||Albert Einstein College of Medicine of Yeshiva University||Active, not recruiting|October 2010|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899261||62991|
NCT01909440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-13-2|Resistance Training and Protein Supplementation in Increasing Lean Body Mass for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy|Exercise and Protein Supplementation for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy||University of Southern California|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|32|||Male|50 Years|N/A|No|||June 2015|June 2, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909440||62213|
NCT01909453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162B2301|Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma|A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|COLUMBUS|Array BioPharma|Yes|Active, not recruiting|September 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|900|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909453||62212|
NCT01908192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNR-01-NaBen|Adaptive Phase II Study to Evaluate the Safety & Efficacy of Sodium Benzoate as an Add-on Treatment for Schizophrenia in Adolescents|An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® (Sodium Benzoate), A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents||SyneuRx International (Taiwan) Corp|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|12 Years|16 Years|No|||May 2015|May 18, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908192||62307|
NCT01911520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/207|Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients|Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients.|BRIDION|University Hospital, Ghent|No|Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|40|||Both|18 Years|65 Years|No|||July 2013|July 26, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911520||62054|
NCT01901692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC IRB 2013-0582|Transarterial Chemoembolization Plus Radiotherapy or Sorafenib in Hepatocellular Carcinoma With Major Vascular Invasion|Randomized Phase II Trial Comparing Transarterial Chemoembolization Plus External Beam Radiotherapy Versus Sorafenib in Patients With Hepatocellular Carcinoma With Major Vascular Invasion|START|Asan Medical Center|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|N/A|No|||January 2016|January 20, 2016|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01901692||62805|
NCT01901952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1DK092271-01|Lifestyle Improvement Through Food and Exercise (LIFE)Study|Lifestyle Improvement Through Food and Exercise (LIFE) Study|LIFE|Rush University Medical Center|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|N/A|No|||May 2014|September 3, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901952||62785|
NCT01901965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Contralateral_01|Contralateral Strength-training After Anterior Cruciate Ligament (ACL) Reconstruction|Could Contralateral Quadriceps Strength Training Attenuate the Strength Loss in the ACL-operated Knee?||Schulthess Klinik||Recruiting|May 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01901965||62784|
NCT01902238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET ETHANOL|EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study|EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study|EUS|Asan Medical Center|Yes|Active, not recruiting|July 2013|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2015|March 20, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902238||62763|
NCT01902771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130136|Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors|A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors||University of Miami|Yes|Recruiting|July 2013|||July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|30 Years|No|||January 2016|January 14, 2016|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01902771||62723|
NCT01903044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMI_ 404732/2012-7|Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating|Multicentric Study of the Autologous Bone Marrow-derived Mononuclear Cells Injection for Treatment of the Patients With Critical Lower Extremity Ischemia||Pontifícia Universidade Católica do Paraná|No|Not yet recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||July 2013|June 26, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01903044||62702|
NCT01897012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01272|Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas|A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas||National Cancer Institute (NCI)||Recruiting|July 2013|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897012||63163|
NCT01897584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBIRB2013-127|Effect Inverse Ratio Ventilation on Arterial Oxygenation and Respiratory Mechanics During lapaLAR|Effect of Inverse Ratioventilation on Laparoscopic Low Anterior Resection||Gachon University Gil Medical Center|Yes|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|20 Years|70 Years|No|||August 2015|August 30, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01897584||63119|
NCT01897623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-CAD-02|Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|CAD-AAA|North Karelia Central Hospital|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Primary Purpose: Screening|1||||||Male|N/A|N/A||||December 2014|December 15, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897623||63116|
NCT01899846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPC-PK-005|Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood|A Multi-Center, Non-Randomized Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood of Women With a Singleton Pregnancy and a Previous Singleton Spontaneous Preterm Delivery||Lumara Health, Inc.|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|30|||Female|18 Years|N/A|No|||August 2014|August 14, 2014|July 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899846||62946|
NCT01898182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCDeptofDerma-Kinerase-2013|Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging|A Single Arm, Phase IV, Open-Label, Split-Face Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Photoaging||Makati Medical Center|Yes|Completed|November 2013|September 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|132|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01898182||63073|
NCT01898442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TicagSTEMI|High Ticagrelor Loading Dose in STEMI|Pharmacodynamic Profiles of Ticagrelor in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Different Loading Dosage Regimens||University of Florida|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|80 Years|No|||June 2014|May 26, 2015|July 1, 2013||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01898442||63053|The study was not powered to assess safety or efficacy, which would require larger clinical studies. Although laboratory personnel were blinded to treatment assignment, the study had an open-label design.
NCT01898676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIHSC #13-019D|A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets|An Open Label, Randomized, Four-period, Two-sequence, Fully Replicated, Single-dose, Crossover Study of the Relative Bioavailability of Two Formulations of Extended-release Divalproex Sodium Tablets in Fed Patients With Stable Epilepsy.|Epilepsy|Vince & Associates Clinical Research, Inc.|No|Recruiting|July 2013|December 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|16|||Both|18 Years|55 Years|No|||June 2013|July 9, 2013|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01898676||63035|
NCT01898975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-053-001|A Gray Zone Approach to Stroke Volume Variation Derived From NICOM|Evaluation of Stroke Volume Variation Derived From NICOM as a Predictor of Fluid Responsiveness in Neurosurgical Patients: A Gray Zone Approach||Samsung Medical Center|Yes|Recruiting|June 2013|May 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|||Both|20 Years|80 Years|No|Probability Sample|Patients undergoing neurosurgery under general anesthesia in supine position|July 2013|July 10, 2013|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01898975||63012|
NCT01895322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-12-002|Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis||Otsuka Pharmaceutical Co., Ltd.|No|Completed|July 2013|August 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||November 2015|November 30, 2015|July 4, 2013||No||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01895322||63292|
NCT01899274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000036524|Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes|Assessment of an Electronic Self-Management Tool on Glycemic Control in Teens With Type 1 Diabetes||The Hospital for Sick Children|No|Active, not recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|11 Years|16 Years|No|||April 2014|March 9, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899274||62990|
NCT01920425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311DH|Kinesia HomeView - Home Diary Comparison|Kinesia HomeView - Home Diary Comparison||Great Lakes NeuroTechnologies Inc.||Completed|July 2013|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01920425||61372|
NCT01921283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0347|Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring|||Yonsei University|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|180|||Both|40 Years|70 Years|No|||August 2013|August 8, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01921283||61306|
NCT01908972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12172-MM-231|The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma|The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma||Seoul National University Hospital|Yes|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|9 Months|No|||February 2016|February 15, 2016|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908972||62248|
NCT01910441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AIN03|Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients|A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone|VARIABLE|Novartis|No|Terminated|July 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|July 25, 2013||No|The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors    (CGMS) which were required to assess the primary end-point.|No|September 22, 2015|https://clinicaltrials.gov/show/NCT01910441||62137|
NCT01901705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB1-261|A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis|A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis||China Medical University Hospital|Yes|Recruiting|February 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|65 Years|No|||July 2013|July 16, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01901705||62804|
NCT01901991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R72-A4701-13-S9|Localization of Nonpalpable Breast Lesions|A Randomized Study of Localization of Nonpalpable Breast Lesions - RSL vs WGL||Rigshospitalet, Denmark|Yes|Recruiting|January 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01901991||62782|
NCT01902498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-13324|Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B|Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B||Hamilton Health Sciences Corporation|No|Completed|July 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902498||62743|
NCT01896453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCSBACKPAIN|Brain and Peripheral Electrical Stimulation in Chronic Low Back Pain: a Factorial Design|Treatment of Chronic Non-specific Low Back Pain With Brain and Peripheral Electrical Stimulation: a Factorial, Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|92|||Both|18 Years|65 Years|No|||October 2013|December 3, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01896453||63205|
NCT01896752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R35-A1642-10S7|Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL|Pharmacokinetics: Renal and Hepatic Clearance Following High-Dose Methotrexate in Children With Acute Lymphoblastic Leukemia||Rigshospitalet, Denmark|No|Completed|March 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples With DNA|whole blood for RFC allele determination; serum for determination of concentration of MTX,      clearances, and other pharmacokinetic parameters; urine for determination of concentration      of MTX and clearances, and other pharmacokinetic parameters|Both|N/A|19 Years|No|Non-Probability Sample|All children diagnosed and treated for Acute Lymphoblastic Leukemia, ALL, at        Rigshospitalet during the last two years, i.e. 43 children, and who will receive HD-MTX        during the study period.|July 2013|July 14, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896752||63182|
NCT01897025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIG09may022|Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation|Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation - a Feasibility Study||National University Hospital, Singapore|No|Completed|January 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|21 Years|70 Years|No|||February 2016|February 11, 2016|July 8, 2013||No||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01897025||63162|
NCT01897038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28651|A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma|A Phase Ib, Open-Label Study Evaluating The Safety, Tolerability, and Pharmacokinetics of Onartuzumab Given as a Single Agent and in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)||Hoffmann-La Roche||Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897038||63161|
NCT01897922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3385-2|The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants|The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants||Mead Johnson Nutrition|No|Completed|July 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|348|||Both|N/A|16 Days|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01897922||63093|
NCT01898468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN13-5894|Post-Thoracotomy Closure Study|Post-Thoracotomy Pain Syndrome: A Randomized, Double Blind, Study Comparing Closure Techniques||University Health Network, Toronto|No|Recruiting|June 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01898468||63051|
NCT01897272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0416|Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study|Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective, Randomized Study||Christine M. Kleinert Institute for Hand and Microsurgery|Yes|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|We are looking for patients who are old enough to give informed consent who are preparing        to have nerve decompression with short incision for their carpal tunnel syndrome.|July 2013|July 9, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01897272|6 Months|63143|
NCT01897285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0209-13-U368|A Single Centre, Randomised, Comparative, Blinded Wear Test of Two Adhesives on the AQUACEL® Foam Adhesive Dressing|A Single Centre, Randomised, Comparative, Blinded Wear Test of Two Adhesives on the AQUACEL® Foam Adhesive Dressing||ConvaTec Inc.|No|Completed|May 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 13, 2014|May 10, 2013||No||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01897285||63142|Many dressings detached from the skin when the volunteers were at home/away from the clinic and prior to returning for the assessments. It was therefore not possible for the Investigator to give a rating for several parameters on several volunteers.
NCT01897558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-012|Myocardial Micro-damage in Relation to Active and Passive Fixation Pacemaker Electrodes|Effect of Passive Versus Active Fixation Leads on the Magnitude of Troponin Release After Pacemaker Implantation (PACMAN Trial)|PACMAN|Deutsches Herzzentrum Muenchen|No|Completed|April 2013|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||September 2014|February 12, 2015|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01897558||63121|
NCT01897571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7438-G000-101|An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas|An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas||Epizyme, Inc.|Yes|Recruiting|June 2013|September 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897571||63120|
NCT01898715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR-101-001|Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma|Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma||Millendo Therapeutics, Inc.|No|Recruiting|July 2013|July 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898715||63032|
NCT01899001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818103|Mood and Nutrition Interventions in Polycystic Ovary Syndrome|Improving Psychological Health and Cardiovascular Disease Risk in Women With PCOS|MANI-PCOS|University of Pennsylvania|No|Recruiting|July 2013|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|No|||May 2015|September 17, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899001||63011|
NCT01898689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter Popliteal Volunteer|Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks||University of California, San Diego|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 4, 2013|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898689||63034|
NCT01895595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM 5 R21 AT002556|Guided Imagery Intervention for Obese Latino Adolescents|Guided Imagery Intervention for Obese Latino Adolescents||University of Southern California|Yes|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|51|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895595||63271|
NCT01920984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC96-2628-B-002-032-MY3|Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy|Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy|VL|National Taiwan University Hospital|Yes|Completed|January 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|100|||Both|25 Years|75 Years|No|||January 2004|August 12, 2013|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920984||61329|
NCT01920997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QE-2458-3|Qing'E Formula Therapy on Menopausal Symptoms (Healthy Volunteers Recruitment for Control Study)|||Shanghai University of Traditional Chinese Medicine||Recruiting|August 2013|||October 2013|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|50|||Female|40 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women with normal menstrual cycles aged 40-50|September 2013|September 1, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920997||61328|
NCT01921296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.051|Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients|UMCC 2013.051: Prospective Pilot Study Evaluating the Use of Cyclobenzaprine for Treatment of Sleep Disturbance, Fatigue, and Musculoskeletal Symptoms in Aromatase Inhibitor-treated Breast Cancer Patients||University of Michigan Cancer Center|Yes|Terminated|August 2013|April 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Female|18 Years|N/A|No|||February 2016|February 19, 2016|August 8, 2013|Yes|Yes|Accrual terminated early because of poor accrual|No|November 12, 2014|https://clinicaltrials.gov/show/NCT01921296||61305|The study was closed early for futility. The primary endpoint was not analyzed.
NCT01909752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UbiVac DPV-001|Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC||UbiVac|No|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909752||62189|
NCT01911195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McDonnell RCC|Reconstructing Consciousness and Cognition|Reconstructing Consciousness and Cognition|RCC|University of Michigan|Yes|Active, not recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911195||62079|
NCT01902251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0003|Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients|A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer||Astellas Pharma Inc|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Male|18 Years|N/A|No|||September 2014|September 8, 2014|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902251||62762|
NCT01896115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4009|CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation|Current Steering to Optimize Deep Brain Stimulation|CUSTOM-DBS|Boston Scientific Corporation|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01896115||63231|
NCT01896466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0394|Enhanced Gait and Balance Training|Influence of Neuromodulation on Gait and Balance||University of Wisconsin, Madison|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Anticipated|60|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896466||63204|
NCT01896765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIHKF-7161|Intensive Prevention Program After Myocardial Infarction|Intensive Longterm Prevention Program After Myocardial Infarction in Northwest Germany|IPP|Herzzentrum Bremen|Yes|Recruiting|October 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01896765||63181|
NCT01897311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0295.0.045.000-11|Effect of Modulation of TENS in Pain After Cesarean Section|Hypoalgesic Effect of TENS Modulation in Post-Cesarean Pain: A Clinical Trial Controlled and Randomized.||Universidade Federal do Piauí|No|Completed|August 2011|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|34|||Female|18 Years|42 Years|No|||July 2013|July 10, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01897311||63140|
NCT01897610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILC-IIT-04|Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hcc|Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma||Green Cross Cell Corporation|No|Recruiting|December 2013|January 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||March 2016|March 4, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01897610||63117|
NCT01898481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045101|Triadic Expectations: Decision Making in the Context of Cancer Treatment|Triadic Expectations: Decision Making in the Context of Cancer Treatment||Duke University|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|38|||Both|18 Years|N/A||Non-Probability Sample|Patients with advanced cancer, their friends/family, and oncologists|February 2014|February 5, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898481||63050|
NCT01897961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01302-39|Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation|Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation|PRAM-KT|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|N/A|No|||July 2012|July 10, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01897961||63090|
NCT01897597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1313.9|Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions|An Open-label, Single Dose, Randomised, Crossover Trial in Healthy Male Subjects to Investigate the Relative Bioavailability of Tablet and Oral Solution of Two Doses of BI 144807 and Relative Bioavailability of BI 144807 When Administered as Tablet Under Fed and Fasted Conditions||Boehringer Ingelheim||Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|31|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|July 9, 2013||||No||https://clinicaltrials.gov/show/NCT01897597||63118|
NCT01897896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-16|Alternatives for Reducing Chorea in HD|An Open Label, Long Term Safety Study of SD-809 ER in Patients With Chorea Associated With Huntington Disease|ARC-HD|Teva Pharmaceutical Industries|No|Active, not recruiting|November 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897896||63095|
NCT01897909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHECO|The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana|The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana|HHECO|Bernhard Nocht Institute for Tropical Medicine|No|Active, not recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1100|Samples With DNA|Blood sample, stool sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study will be conducted in the HIV outpatient department of the Komfo Anokye Teaching        Hospital (KATH), Kumasi, Ghana. The HIV treatment centre offers comprehensive care for HIV        patients and regularly attends about 9500 HIV-infected patients.|July 2015|July 22, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01897909||63094|
NCT01898741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU-12-628|Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer|Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer||UMC Utrecht|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 1, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898741||63030|
NCT01895049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR32T|Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria|||Hospital do Rim e Hipertensão||Recruiting|August 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895049||63313|
NCT01895309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB4-G31-RA|A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy||Samsung Bioepis Co., Ltd.|Yes|Completed|June 2013|October 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|596|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01895309||63293|
NCT01895335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS13567|Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients|A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients|TERI-PRO|Sanofi|No|Completed|June 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1001|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895335||63291|
NCT01921322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP270|CEP270 China SAP Study|Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target||Medtronic Diabetes|No|Completed|April 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921322||61303|
NCT01917461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-1001-BV|Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections|Observational, Prospective Study to Evaluate Biomarkers as Indicators of Bacterial or Viral Infection During Acute Infectious Diseases|CURIOSITY|MeMed Diagnostics Ltd.|No|Completed|September 2010|September 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|Samples Without DNA|Blood samples Nasopharyngeal samples|Both|1 Month|N/A|Accepts Healthy Volunteers|Probability Sample|Eligible subjects aged one month of age and older from both genders that attend the        hospital or the emergency room (ER) due to a suspected acute infectious disease or due to        a non-infectious disease (e.g. Trauma).|March 2016|March 6, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01917461||61600|
NCT01910090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAFL439/PRO-00|Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions|Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versus ANTADYS® Flurbiprofen 100 mg Comprimé Pelliculé (One Film-coated Tablet) of (LaboratoireThẻramex 6, Avenue Albert II- BP.59 98007 MONACO Cedex) and PEPCID® (Famotidine) 20 mg Tablets, USP (One Tablet) of (Marathon Pharmaceuticals, LLC USA) in Healthy Subjects Under Fasting Conditions||Pharmaceutical Research Unit, Jordan||Completed|December 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|July 24, 2013|December 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01910090||62163|
NCT01910103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1303-051-472|Comparison of Diagnostic Performance of Digital Breast Tomosynthesis and Ultrasound in Women With Dense Breasts|Comparison of Diagnostic Performance of Digital Breast Tomosynthesis and Ultrasound in Women With Dense Breasts||Seoul National University Hospital|Yes|Completed|June 2013|June 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|825|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing mammography and breast US for screening or diagnostic purpose|May 2015|May 18, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910103||62162|
NCT01920971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2314-B-341-001|Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain|Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Study||Taipei Medical University|Yes|Recruiting|August 2013|July 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|85 Years|No|||August 2013|August 8, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01920971||61330|
NCT01902264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16484|Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception|Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception||Bayer|No|Completed|August 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|34|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902264||62761|
NCT01896128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-394|Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke|Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke||Burke Rehabilitation Hospital|No|Completed|January 2008|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 25, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896128||63230|
NCT01896141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-017|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||March 19, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896141||63229|
NCT01896778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 229812|Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer|Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study||Roswell Park Cancer Institute|Yes|Recruiting|October 2013|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896778||63180|
NCT01897948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6022|The Effects of Feeding Different Levels of Docosahexaenoic Acid to Pre-School Children|The Effects of Feeding Different Levels of Docosahexaenoic Acid to Pre-School Children||Mead Johnson Nutrition|No|Terminated|July 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|3||Actual|18|||Both|3 Years|3 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|July 3, 2013||No|Non-compliance|No||https://clinicaltrials.gov/show/NCT01897948||63091|
NCT01897051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR310037|Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients|Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices|RECOVER|Yonsei University|No|Recruiting|July 2013|June 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|19 Years|75 Years|No|||April 2015|April 19, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01897051||63160|
NCT01897974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00276|Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia|||Nationwide Children's Hospital|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|N/A|18 Years|No|Non-Probability Sample|Patients who are taking anti-seizure medications.|August 2014|August 26, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01897974||63089|
NCT01897935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFAM_PRO_120417|Flare Photometry in Uveitis Patients|||ChromoLogic, LLC|No|Completed|June 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with uveitis seen in the uveitis clinic at the UW Medicine Eye Institute        would be eligible for participation in the uveitis arm of the study (n ≤ 50). Patients        with other, non-inflammatory forms of eye disease will be eligible for the        non-inflammatory arm of the study (n ≤ 50).|April 2014|April 30, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897935||63092|
NCT01898455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPFT001|Intranasal Cooling for Cluster Headache and Migraine|IntraNasal Evaporative Cooling for the Symptomatic Relief of Migraine and Cluster Headache|COOLHEAD|Cumbria Partnership NHS Foundation Trust|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898455||63052|
NCT01898702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPPD-2012-ICS|Clinical Trial on Diabetes Expert Patients Programme|Expert Patients Programme Effectiveness on Diabetes Control. A Controlled Clinical Trial|EPPD-ICS|Jordi Gol i Gurina Foundation|No|Recruiting|May 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|N/A|No|||July 2013|July 21, 2013|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898702||63033|
NCT01899066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanghs20130627|Efficacy Study of Lucentis in the Treatment of Retinoblastoma|Lucentis in the Treatment of Retinoblastoma - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma||Sun Yat-sen University|Yes|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||May 2014|May 10, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899066||63006|
NCT01895114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-263|Assessment of Renal Function in Cirrhotic Patients|Assessment of Renal Function in Cirrhotic Patients -A Comparison of Cystatin C and Creatinine Based Calculations to 125I-iothalamate||Baylor Research Institute|Yes|Recruiting|December 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients from Baylor All Saints Medical Center and Baylor University Medical Center who        have cirrhosis and a stable urine creatinine|July 2015|July 27, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01895114||63308|
NCT01899287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-053|A Randomised Clinical Trial on the Effect of Group Education on Patients With Occupational Hand Eczema|A Randomised Clinical Trial on the Effect of Group Education on Skin-protective Behaviour Versus Treatment as Usual Among Individuals With Newly Notified Occupational Hand Eczema|PREVEX|University of Copenhagen|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|770|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899287||62989|
NCT01899300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90871111|Esophageal Fully Covered Metal Stents in Caustic Strictures Study|A Multi-Center, Prospective, Evaluation of the Use of a Fully Covered Metal Stent (FCMS) for the Treatment of Refractory Benign Esophageal Strictures Caused by Caustic Ingestion||Boston Scientific Corporation|No|Recruiting|March 2015|March 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899300||62988|
NCT01899313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.119-2|A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence|A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence||California Pacific Medical Center Research Institute|No|Recruiting|May 2014|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01899313||62987|
NCT01895062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5iS-009|Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy|Effectiveness and Safety of Continuous Negative External Pressure (cNEP) in Preventing Sedation-Related Respiratory Impairment in Adults Undergoing Colonoscopy||5i Sciences, Inc.|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|80 Years|No|||July 2014|July 11, 2014|March 29, 2013||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT01895062||63312|
NCT01895075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2013|Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study|Evaluation of the Effectiveness of Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|July 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|42 Days|No|||November 2015|November 17, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01895075||63311|
NCT01895088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-P12-020C|A Continuation Study To Monitor The Long Term Safety Of Patients Completing Protocols ACU-P08-020/020A|A Continuation Study To Monitor The Long Term Safety Of The AcuFocus ™ ACI 7000PDT Patients Completing Protocols ACU-P08-020/020A|020C|AcuFocus, Inc.|Yes|Enrolling by invitation|December 2012|May 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential participants must have completed the ACU-P08-020/020A study protocol.|July 2013|July 5, 2013|May 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895088||63310|
NCT01917487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QD04.5.1-25|A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode|A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode||OrSense, Ltd.|No|Active, not recruiting|November 2011|November 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers and oncology patients|September 2013|September 9, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917487||61598|
NCT01920724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-IRB 2010/211.0807|Body Composition in Preschool Children|Body Composition and Dietary Intake in Preschool Children Aged 3-5 Years in Daycare Centers||Mahidol University|No|Completed|November 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|137|Samples Without DNA|Urine samples|Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children in the daycare centers in Nakhon Pathom and Samut Prakarn porvinces will be        screened and categorized into 4 groups, including wasting (BMI for age Z-scores < -2 SD),        normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and        stunting (HAZ < -2 SD). Then, they will be randomly selected to participate in this study.|August 2013|August 8, 2013|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01920724||61349|
NCT01917448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2556|Low Dose Spinal Morphine for Post-video-assisted Thoracoscopic Surgery|Low Dose Spinal Morphine for Post-video-assisted Thoracoscopic Surgery. A Pilot Study||Mahidol University|Yes|Completed|February 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917448||61601|
NCT01895829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1127|Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI|Pilot Feasibility Study of Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI for Primary and Nodal Tumor Imaging in Locally Advanced Head and Neck Squamous Cell Carcinomas||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2013|||September 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895829||63253|
NCT01895842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0012|Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|February 2014|||February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895842||63252|
NCT01896492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ccpnacinovi|Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos.|Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial|NACIPCOS|Woman's Health University Hospital, Egypt|Yes|Completed|January 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 5, 2013|June 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896492||63202|
NCT01897077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042409|The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy|The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy||Johns Hopkins University|Yes|Active, not recruiting|November 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 8, 2013|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897077||63158|
NCT01897337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2012-0076|The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting|The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting||Yonsei University|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|125|||Female|20 Years|60 Years|No|||July 2013|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897337||63138|
NCT01897350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 1953|Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial|||University of Bristol||Completed|July 2013|||December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|85 Years|No|Non-Probability Sample|30 patients will be undergo a CMR scan day 2 following STEMI|October 2014|October 20, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897350||63137|
NCT01898195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02157|Improving Adherence to Smoking Cessation Medication Among PLWHA|Improving Adherence to Smoking Cessation Medication Among PLWHA|HIV|New York University School of Medicine|Yes|Active, not recruiting|March 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898195||63072|
NCT01898208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006920|Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures|Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project||Mayo Clinic|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|743|||Both|N/A|99 Years|No|||February 2016|February 17, 2016|July 8, 2013|No|Yes||No|December 2, 2015|https://clinicaltrials.gov/show/NCT01898208||63071|
NCT01898221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008380|Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation|Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation|VOM-R01|The Methodist Hospital System|Yes|Recruiting|October 2013|December 2020|Anticipated|December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|85 Years|No|||March 2016|March 14, 2016|May 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898221||63070|
NCT01898247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00069024|Use of Simulation-Based Mastery Learning for Thoracentesis to Improve Outcomes|Use of Simulation-Based Mastery Learning for Resident Thoracentesis Training to Improve Patient Outcomes||Northwestern University|No|Recruiting|December 2012|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01898247||63068|
NCT01898728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine gel vs drops|Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial|Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial||McMaster University|No|Active, not recruiting|December 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01898728||63031|
NCT01899014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43466.068.13|18F-choline PET-CT and MRI of Carotid Plaques|Plaque at Risk (ParisK): Molecular Imaging of Plaque Vulnerability Using 18F-choline PET-CT and MRI in Patients With Carotid Artery Atherosclerosis|ParisK|Maastricht University Medical Center|Yes|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899014||63010|
NCT01895127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001292|Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation|Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.||Brigham and Women's Hospital|Yes|Active, not recruiting|November 2013|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|75 Years|No|||June 2015|June 19, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895127||63307|
NCT01899027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553/2013/D|Rosuvastatin for Preventing Complications in Renal Ablation|Adjunctive Rosuvastatin Treatment for prEventing coMplIcationS In Renal Ablation|ARTEMISIA|University of Roma La Sapienza|Yes|Not yet recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|80 Years|No|||July 2013|July 12, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899027||63009|
NCT01899040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-MIG-01|A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache|A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache||Scion NeuroStim|No|Active, not recruiting|August 2013|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|65 Years|No|||February 2016|February 7, 2016|June 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899040||63008|
NCT01899053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C32001|Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Recruiting|July 2013|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899053||63007|
NCT01899326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-230|Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant|Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|December 2012|||March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899326||62986|
NCT01895361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SelG1-00005|Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises|A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises|SUSTAIN|Selexys Pharmaceuticals Corporation|Yes|Active, not recruiting|July 2013|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|174|||Both|16 Years|65 Years|No|||August 2015|August 17, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01895361||63289|
NCT01895374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0320|Clinical Efficacy of Bovine Freeze-dried Amniotic Membrane on Wound Healing in Laser Treatment|A Comparison of the Effects of Bovine Freeze-dried Amniotic Membrane and Hydrocolloid on Epithelialization After Laser Treatments||Seoul National University Hospital|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01895374||63288|
NCT01917201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCH01DV0713|Optimal dRug Eluting steNts Implantation Guided By Intravascular Ultrasound and Optical coheRence tomoGraphy ORENBURG|Prospective, Single-center, Randomized Trial, Intended to Compare of Intravascular Ultrasound and Optical Coherence Tomography Guided Implantation of Different Drug-eluting Stents and Implantation Without Using of Intravascular Visualization|ORENBURG|The Orenburg Regional Clinical Hospital|No|Recruiting|March 2012|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|75 Years|No|||October 2014|October 26, 2014|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01917201||61620|
NCT01917474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Effects of Changes in Dietary Intake and Headache's Attacks|Effects of Changes in Dietary Intake and Headache's Attacks||Federico II University|Yes|Recruiting|July 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|75 Years|No|||November 2014|November 21, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917474||61599|
NCT01917188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024572|Promoting Patient-Centered Care Through a Heart Failure Simulation Study|Promoting Patient-Centered Care Through a Heart Failure Simulation Study|HF SIM|Intermountain Health Care, Inc.|No|Recruiting|November 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917188||61621|
NCT01917435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120254|Video-stylet for Nasotracheal Intubation in Limited Mouth Opening Patient|Nasotracheal Intubation Assisted by a Video-stylet in Limited Mouth Opening Patient||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|January 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 4, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01917435||61602|
NCT01917981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HASTE-1|Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation|Testing the Accuracy of an Intermittent Personal Heart Rhythm Monitor (PHRM) to Detect Prolonged Paroxysmal Atrial Fibrillation (PAF) Against Implantable Devices.||University of Surrey|Yes|Recruiting|September 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01917981||61560|
NCT01896154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fib-P-2012|Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity|A Randomized, Controlled Clinical Study on the Effect of Non-digestible Polysaccharides (NPS) on the Immune Response to Influenza Vaccination in Elderly|Fib-P-2012|Clinical Research Center Kiel GmbH|No|Completed|August 2012|June 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|239|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01896154||63228|
NCT01896479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-401|A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer|A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients|EXAMINER|Exelixis|Yes|Recruiting|December 2014|March 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896479||63203|
NCT01897636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zkx12019|Efficacy and Safety of Endoscopic Ultrasound Guided Fine-needle Injection of Dendritic Cells Vaccination Into Unresectable Pancreatic Cancer||DC|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Not yet recruiting|December 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|July 9, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897636||63115|
NCT01897090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042692|A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease|The Relationship of a "Crohn's Disease Diet" in Reducing Symptoms of Crohn's Disease, Improving Quality of Life, and Decreasing Related Health Care Costs.||Johns Hopkins University|No|Recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||July 2013|July 8, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897090||63157|
NCT01897363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59-2013|Hypoglycemia in Prader-Willi Syndrome|Hypoglycemia in Prader-Willi Syndrome: A Prospective Study||University of Florida|No|Completed|July 2013|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|2 Months|12 Months|No|Non-Probability Sample|Infants with Prader-Willi Syndrome who have not yet started growth hormone therapy|September 2014|September 24, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897363||63136|
NCT01897662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROQ_NUTRIMETAB10|Effect of Nutriose Supplementation on Satiety, Weight Loss and Adiposity in Overweight Subjects|Study of the Consumption of Nutriose on Satiety, Weight Loss and Fat Mass Reducing in Overweight Subjects|ROQ_NUTRIMETAB|Nealth Sarl|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|76|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897662||63113|
NCT01897649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROQ_NUTRIFLORE10|Effect of 15g Daily Consumption of NUTRIOSE on Healthy Volunteers Microbiota.|Effect of 15g Daily Consumption of NUTRIOSE During 2 and 4 Weeks on Healthy Volunteers Microbiota and Digestive Tolerance.|ROQ_NUTRIFLORE|Nealth Sarl|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|60|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897649||63114|
NCT01898767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0935|Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses|Production of Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses: An In Vitro Model System to Study the Mechanisms of Asthma Exacerbation Resolution||University of Wisconsin, Madison|Yes|Recruiting|August 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|whole blood, serum, plasma, DNA, RNA, bronchoalveolar lavage, bronchial brushings|Both|18 Years|55 Years|No|Non-Probability Sample|Subjects with mild asthma from Madison, WI region|October 2015|October 9, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898767||63028|
NCT01898780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOMING|Horizontal Mattress vs. Interrupted Suture in Surgical Techniques of Pancreaticojejunostomy|||Wakayama Medical University|Yes|Enrolling by invitation|June 2013|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|20 Years|N/A|No|||July 2013|July 12, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898780||63027|
NCT01898234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012012|Dialysis Membranes and Hemodynamic Tolerance|Assessment of Subjective and Hemodynamic Tolerance of Different High- and Low-flux Dialysis Membranes in Patients Undergoing Chronic Intermittent Hemodialysis: a Randomized Controlled Trial||Ospedale Regionale di Locarno||Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|95 Years|No|||July 2013|July 9, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01898234||63069|
NCT01898494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3311|Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer|Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer||Eastern Cooperative Oncology Group|Yes|Recruiting|August 2013|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|377|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898494||63049|
NCT01898507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816228|Nicotine Metabolism and Low Nicotine Cigarettes|Nicotine Metabolism and Low Nicotine Cigarettes||University of Pennsylvania|No|Active, not recruiting|September 2013|July 2017|Anticipated|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01898507||63048|
NCT01895400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2013-0165|Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|A Single-center, Prospective, Randomized, Parallel Group, Placebo-controlled Exploratory Study on the Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|REREV|Asan Medical Center|No|Terminated|July 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|N/A|No|||February 2016|February 14, 2016|July 5, 2013||No|Participant enrollment is much delayed. The whole design needs to be revised.|No||https://clinicaltrials.gov/show/NCT01895400||63286|
NCT01899339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-069|Long Term Study Looking at the Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis|Submassive Pulmonary Embolism Treatment With Ultrasound-Accelerated Thrombolysis|SPEAR|Spectrum Health Hospitals|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|80 Years|No|Probability Sample|All patient presenting to the Emergency Department with submassive pulmonary hypertension        over the age of 18.|July 2013|July 12, 2013|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899339||62985|
NCT01899352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCF-TracheoTrial|Procedures, Complications and Follow-up of Tracheostomy in Intensive Care Units.|Procedures, Complications and Follow-up of Tracheostomy in Intensive Care Units - a Prospective Study by Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)||University of Genova|No|Not yet recruiting|January 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|1000|||Both|18 Years|85 Years|No|||July 2013|July 10, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01899352||62984|
NCT01895101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-1251|The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients|The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial||Amphia Hospital|Yes|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|750|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|June 25, 2013||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01895101||63309|
NCT01896245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2013-0039|Laryngeal Injuries After Anesthesia Induction With Three Different Sevoflurane Concentrations (Without Muscle Relaxant)|Laryngeal Injuries After Anesthesia Induction With Three Different Sevoflurane Concentrations (Without Muscle Relaxant)|SEVODosage|University of Rostock|No|Completed|July 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|80 Years|No|||October 2014|October 3, 2014|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01896245||63221|
NCT01896258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jesumania|A Nationwide Survey of Korean Emergency Department Triage Systems and Scales|A Nationwide Survey of Korean Emergency Department Triage Systems and Scales; a First Step Towards Korean Triage and Acuity Scale(KTAS)||Hanyang University||Completed|September 2012|March 2013|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|136|||Both|N/A|N/A|No|Non-Probability Sample|triage officers of 136 emergency centers in Korea|July 2013|July 8, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01896258||63220|
NCT01896271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 012013-041|High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer|A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2013|December 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896271||63219|
NCT01917760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY-2013-222|Pharmacokinetics Study of Gamma-aminobutyric Acid|The Pharmacokinetics of Gamma-aminobutyric Acid in Healthy Volunteers.|GABA-PK|Huashan Hospital|Yes|Completed|July 2013|December 2014|Actual|July 2014|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|12|Samples Without DNA|This is an open-labeled, 3-phase, self-control study. In phase 1, blood is sampled from      volunteers who will take placebo to obtain the baseline value. In phase 2, volunteers will      take a single oral dose of 2000 mg GABA. There are at least 7 days between the two phases.      In phase 3, volunteers will take a repeated oral dose of 2000 mg GABA (thrice daily for      seven days). There are at least 5-7 days between phase 3 and phase 3. In each phase,      individuals will be observed for 24 hours to obtain the complete concentration time curve. 4      ml of blood will be sampled at the following time-point for predose and 0.25, 0.5, 0.75, 1,      1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hour postdose.|Both|19 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Residents of Shanghai|October 2015|October 30, 2015|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01917760||61577|
NCT01917747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLB-001-KL2TR000116|Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators|Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators||University of Kentucky|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|346|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917747||61578|
NCT01918293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-ASTHMA (ADULT)|Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult|Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma) in Adult||Inje University|No|Completed|September 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|75 Years|No|||November 2013|November 26, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918293||61536|
NCT01917708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00069836|Abatacept Reduced Intensity for Non-Malignant Diseases|Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Disease: a Dose Assessment Pilot|Aba NMD|Emory University|Yes|Recruiting|January 2014|January 2020|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|N/A|21 Years|No|||February 2016|February 29, 2016|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917708||61581|
NCT01917994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032057|Text Messaging Intervention to Improve Retention in Care and Virologic Suppression in an Urban HIV-Infected Population|Seek Test Treat Retain Strategies Leveraging Mobile Health Technologies|Connect4Care|University of California, San Francisco|No|Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|230|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917994||61559|
NCT01918267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28388|U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)|||Hoffmann-La Roche||Active, not recruiting|August 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|226|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who participated in the U Act Early study (ML22497)|March 2016|March 1, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918267||61538|
NCT01897324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHC2013|IVF/ICSI Protocols in Poor Responders With Growth Hormone|Which is the Best IVF/ICSI Protocol to be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment ? A Prospective Randomized Study||Woman's Health University Hospital, Egypt|Yes|Completed|July 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|287|||Female|20 Years|45 Years|No|||October 2015|October 19, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897324||63139|
NCT01897675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32294|A Comparison of Techniques for Treating Skin Abscesses|Is Loop Drainage of a Cutaneous Abscess in the Emergency Department as Effective as Incision and Drainage With Packing?|LoopDrainage|Boston Medical Center|Yes|Recruiting|August 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|20 Years|N/A|No|||August 2013|July 22, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897675||63112|
NCT01897688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00059469|A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients|A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients||Northwestern University|No|Recruiting|June 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897688||63111|
NCT01898260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-032|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses||Alcon Research|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|89|||Both|18 Years|45 Years|No|||October 2014|May 8, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898260||63067|
NCT01898273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-13-002|Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma|Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma||Cellectar Biosciences, Inc.|Yes|Terminated|February 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898273||63066|
NCT01897987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-009-FU|Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial|Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial||Medipost Co Ltd.|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|7 Months|7 Months|No|||January 2016|January 6, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01897987||63088|
NCT01899092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2801001|Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C|A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection||Tacere Therapeutics, Inc.|Yes|Recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899092||63004|
NCT01898520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWSP08258|A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years|The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase||GW Research Ltd|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|8 Years|18 Years|No|||January 2015|January 20, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898520||63047|
NCT01898754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14124-SCH|Oligonucleotide Ligation Assay (OLA) Resistance Study|Drug-resistance Testing in Kenya to Improve ART Suppression of HIV Replication|OLA|University of Washington|Yes|Recruiting|May 2013|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|2 Years|N/A|No|||July 2015|July 1, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898754||63029|
NCT01895153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-029|Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome|The Efficacy of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy in Patients With Bladder Pain Syndrome||Samsung Medical Center|No|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|72|||Both|N/A|N/A|No|Probability Sample|Bladder pain syndrome patients have not been treated with hydrodistention.|January 2014|February 12, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01895153||63305|
NCT01895387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FN20130614|Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes|Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes||Yonsei University|Yes|Completed|January 2012|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|39 Years|74 Years|No|||July 2013|July 4, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01895387||63287|
NCT01895660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO11HD068345-01A1|Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)|A Multisite Trial of Pediatric Constraint-Induced Movement Therapy|CHAMP|Virginia Polytechnic Institute and State University|No|Recruiting|April 2013|May 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|135|||Both|2 Years|9 Years|No|||December 2015|December 8, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01895660||63266|
NCT01895946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3610C00007|Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability|A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies|OAK|AstraZeneca|No|Completed|December 2013|July 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01895946||63244|
NCT01896284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMF-AFLI-2013-01|Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor|Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.|MACBETH|Barcelona Macula Foundation|No|Not yet recruiting|July 2013|March 2015|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|50 Years|N/A|No|||July 2013|July 10, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896284||63218|
NCT01896583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7147-CL-0003|A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)||Seldar Pharma, Inc.||Completed|November 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||February 2014|December 22, 2014|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896583||63195|
NCT01917773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305011397|Effect of Octreotide on the Colonic Motility in Pediatric Patients|Effect of Octreotide on the Colonic Motility in Pediatric Patients||Indiana University|Yes|Completed|August 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|1 Year|18 Years|No|||December 2015|December 17, 2015|August 2, 2013|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01917773||61576|
NCT01917721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005|Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease|Phase 2 Study to Assess the Efficacy and Safety of Doxycycline in Preventing Coronary Artery Aneurysm Formation and Progression||Hawaii Pacific Health|No|Not yet recruiting|October 2013|December 2018|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Month|18 Years|No|||August 2013|August 8, 2013|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917721||61580|
NCT01917734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-SAM-2010|Integrated Program for Children With Severe Acute Malnutrition in Madhya Pradesh, India|Evaluation of the Effectiveness of an Integrated Program for the Management of Severe Acute Malnutrition in Children in Madhya Pradesh, India||UNICEF|Yes|Completed|January 2010|October 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2740|||Both|6 Months|59 Months|No|Probability Sample|The detection of children with severe acute malnutrition was ensured in the communities by        frontline workers in the context of monthly growth monitoring and promotion sessions.|August 2013|August 6, 2013|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01917734||61579|
NCT01918852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALTO|S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.|S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines|SALTO|Dutch Colorectal Cancer Group|No|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01918852||61493|
NCT01896531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28341|A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer|A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||Genentech, Inc.||Active, not recruiting|August 2013|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896531||63199|
NCT01896791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0418|Transcranial Direct Current Stimulation (tDCS) in Vasomotor Symptoms of Menopause|Transcranial Direct Current Stimulation (tDCS) in Vasomotor Symptoms of Menopause: Blind Sham Controlled Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|May 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||March 2013|September 16, 2013|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896791||63179|
NCT01896804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 90206|Calcitriol in Preventing Lung Cancer in High-Risk Patients|A Pilot Study of Oral Calcitriol in Patients at High Risk for Lung Cancer||Roswell Park Cancer Institute|Yes|Recruiting|July 2008|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|40 Years|79 Years|No|||November 2015|November 30, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896804||63178|
NCT01898286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010|Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®|Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® in Subjects Who Have Completed Study 1001|DIA-AID 2|Andromeda Biotech Ltd.|Yes|Not yet recruiting|September 2013|January 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|47 Years|No|||July 2013|July 15, 2013|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898286||63065|
NCT01898533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046072|Feasibility of Blood Oxygenation Level-Dependent Contrast (BOLD) Breast MRI Induced by Breath- Holding|A Pilot Study of the Feasibility of Blood Oxygenation Level-Dependent Contrast ( BOLD) Breast MRI Induced by Breath- Holding|BOLD|Duke University|No|Active, not recruiting|September 2013|April 2016|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Female|18 Years|N/A|No|Non-Probability Sample|Female subjects with breast cancer|December 2015|December 7, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898533||63046|
NCT01899079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-00163|A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay|Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.||NanoString Technologies, Inc.|No|Completed|June 2013|July 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|217|Samples With DNA|FFPE breast tumor tissue samples|Female|N/A|N/A|No|Probability Sample|Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women        who meet the entry criteria.|March 2015|March 17, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899079||63005|
NCT01899365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09|An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department|An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department; A Multicenter Prospective Randomized Open Trial The IMPROVED Project|IMPROVED|Centre Hospitalier Princesse Grace|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1800|||Both|65 Years|N/A|No|Probability Sample|patient aged 65 years or over who is not vaccinated against pneumoccocus virus during        consultation with medical emergencies|March 2016|March 4, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899365||62983|
NCT01899378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO109949|Safety and Efficacy of Probiotics in Bangladeshi Infants|Safety and Efficacy of Probiotics in Bangladeshi Infants||Stanford University|Yes|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|160|||Both|1 Month|3 Months|Accepts Healthy Volunteers|||November 2014|November 19, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899378||62982|
NCT01895166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201301|EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs|Diagnostic Value of Endobronchial Ultrasound(EBUS) With a Guide Sheath(GS) for Peripheral Pulmonary Lesions(PPLs) Without Fluoroscopy: a Randomized Controlled Trial||Shanghai Chest Hospital|Yes|Recruiting|July 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2013|July 30, 2013|March 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01895166||63304|
NCT01895179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 13017|Comparison of Time-Restricted Feeding Versus Grazing|Time-Restricted Feeding to Improve Glucose Tolerance and Vascular Condition|TIMED EATING|Pennington Biomedical Research Center||Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01895179||63303|
NCT01895673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43058.000.13|PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA)|The Use of PET-MRI in the Follow-up of RFA and MWA Treated Colorectal Liver Metastases||VU University Medical Center|Yes|Recruiting|June 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Twenty patients with primary CRLM or recurrent liver disease after prior local treatment        of CRLM that have been treated with RFA or MWA and are eligible to undergo MRI-scanning        are included when they have adequate renal function. Patients that do not meet inclusion        criteria for undergoing an MRI scan are excluded.        Patients are recruted by the study coordinators (K Nielsen or HJ Scheffer) when meeting        in- and exclusion criteria from the VU Univeristy medical centre and the Gelderse Vallei        hospital in Ede. All scans will be made in the VU University medical centre.|September 2013|September 30, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01895673||63265|
NCT01895959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ferring-Euflexxa|To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection|Quantifications of Biochemical Changes of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection Using Novel MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) Techniques||University of California, San Francisco|No|Recruiting|August 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|80 Years|No|||September 2015|September 8, 2015|July 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895959||63243|
NCT01895985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|849|Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers|A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers|KRONUS|Bausch & Lomb Incorporated|No|Completed|July 2013|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|20 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895985||63241|
NCT01918345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT2013|Avoiding Diabetes After Pregnancy Trial in Moms|Avoiding Diabetes After Pregnancy Trial in Moms (ADAPT-M): Pilot and Feasibility Study|ADAPT-M|Women's College Hospital|Yes|Recruiting|July 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|225|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01918345||61532|
NCT01918007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHANIA-ENT-01|Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study|Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study||Chania General Hospital ”St. George”|No|Recruiting|June 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|4 Years|10 Years|No|||February 2016|February 1, 2016|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01918007||61558|
NCT01918020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21481|Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs|Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs|SNAP-Ed|University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|796|||Both|8 Years|9 Years|No|||September 2014|September 2, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01918020||61557|
NCT01918306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1287|GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer|A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|September 2013|April 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 25, 2013|Yes|Yes|company stopped production of study drug due to excessive toxicities|No||https://clinicaltrials.gov/show/NCT01918306||61535|
NCT01918566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 298/12|The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity|The Role of Endogenous GLP-1 in Regulating Glucose Stimulated Brain Activity||University Hospital, Basel, Switzerland|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01918566||61515|
NCT01918839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMEDVINCI001|Efficacy and Safety of Injection With VINCI Plus Hyaluronic Acid Filler|Clinical Study to Evaluate the Efficacy and Safety of Injection With VINCI Plus as Compared to Restylane-L in Correction of Nasolabial Fold||D.med|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2014|August 1, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918839||61494|
NCT01918579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05HN|C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting|Efficacy of Point-of-care (POC) C-reactive Protein Testing to Reduce Inappropriate Use of Antibiotics for Acute Respiratory Infections (ARIs) in the Primary Health Care Setting of Hanoi - a Randomized Controlled Trial|CRP|Oxford University Clinical Research Unit, Vietnam|Yes|Recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2000|||Both|6 Years|65 Years|No|||June 2014|June 25, 2014|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918579||61514|
NCT01897103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03123|Platelet Activity in Vascular Surgery for Thrombosis and Bleeding|Platelet Activity in Vascular Surgery|PIVOTAL|New York University School of Medicine|No|Recruiting|June 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|serum, plasma, platelet RNA|Both|21 Years|N/A|No|Probability Sample|Study Population will be selected from the inpatient setting at NYU Medical Center and        Bellevue Hospital as well as the outpatient setting in the Faculty Group Practice.|January 2014|January 23, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897103||63156|
NCT01897116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06613|A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma|A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|June 2013|||January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897116||63155|
NCT01896830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI19 (DFI13360)|Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan|Safety and Immunogenicity of a Clostridium Difficile Toxoid Vaccine Administered to Healthy Adult Subjects Aged 40 to 75 Years in Japan||Sanofi|No|Completed|July 2013|June 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01896830||63177|
NCT01898000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2011-2012|"Triphala" - A New Herbal Mouthwash in Gingivitis|"Triphala" - A New Herbal Mouthwash in Gingivitis: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore||Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|90|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01898000||63087|
NCT01898013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01710|Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans|Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans||Durham VA Medical Center|No|Recruiting|September 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898013||63086|
NCT01898559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816605|Nicotine Metabolism and Little Cigars|Nicotine Metabolism and Little Cigars||University of Pennsylvania|No|Active, not recruiting|December 2012|October 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|197|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01898559||63044|
NCT01898546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/012|Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction|Effect of Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction. Results of a Randomized Study in Patients|POSTRE|Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||January 2013|July 9, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898546||63045|
NCT01898793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401085|Cytokine-induced Memory-like NK Cells in Patients With AML or MDS|A Phase 1 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS|NK|Washington University School of Medicine|No|Recruiting|August 2014|March 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898793||63026|
NCT01898806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5852|Intralesional Steroids in the Treatment of Alopecia Areata|A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata||Columbia University|No|Recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|68|||Both|18 Years|75 Years|No|||September 2015|September 3, 2015|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898806||63025|
NCT01899391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0136-CE|Periperal Blood Lymphocytes During Prostate RT|A Pilot Study of Gamma H2AX DNA Repair Foci Kinetics in Peripheral Blood Lymphocytes During Prostate Cancer Radiotherapy||University Health Network, Toronto|No|Withdrawn|August 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with intermediate-risk prostate cancer|July 2013|July 10, 2013|June 11, 2013||No|Recuritment Challenges|No||https://clinicaltrials.gov/show/NCT01899391||62981|
NCT01895140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322-2012|A Study of Renal Denervation in Patients With Treatment Resistant Hypertension|A Pragmatic Randomized Clinical Evaluation of Renal Denervation for Treatment Resistant Hypertension|PaCE|Sunnybrook Health Sciences Centre|Yes|Terminated|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|June 26, 2013||No|Manufacturer updated device technology.|No||https://clinicaltrials.gov/show/NCT01895140||63306|
NCT01895439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSUJCTC|Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis|Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment||University of Jordan|No|Completed|October 2012|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01895439||63283|
NCT01895413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTM_LESÃO ARTICULAR-461/2010|Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair|Autologous Bone Marrow-derived Mesenchymal Stem Cells Used in the Treatment of Articular Cartilage Injury||Pontifícia Universidade Católica do Paraná|No|Recruiting|September 2012|July 2014|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|65 Years|No|||July 2013|July 10, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01895413||63285|
NCT01895686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-080E|Comparison of Gonioscopy With Cirrus and Visante|Comparison of Visante and Cirrus Optical Coherent Tomography for Assessment of the Anterior Segment|ASOCT|Wills Eye|No|Completed|November 2011|November 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|54|||Both|18 Years|N/A|No|Non-Probability Sample|Phakic patients with open, narrow angle and angle closure glaucoma without prior        intraocular surgery, including laser iridotomy or topical miotic use, were recruited for        this study after Informed Consent was obtained.|December 2012|July 3, 2013|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01895686||63264|
NCT01895972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811|A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension|JUPITER|Bausch & Lomb Incorporated|No|Active, not recruiting|July 2013|May 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|20 Years|N/A|No|||August 2014|August 21, 2014|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895972||63242|
NCT01895712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1227|BIOFLOW-III Israel Satellite Registry|Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada||BIOTRONIK Israel|No|Active, not recruiting|August 2013|December 2015|Anticipated|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic subjects (Diabetic patients type 1 or 2) requiring coronary revascularization        with Drug Eluting Stents (DES).|September 2015|September 7, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01895712||63262|
NCT01896011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAFF 12-0170|Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures|Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures: a Randomized Controlled Trial||University Health Network, Toronto|No|Recruiting|July 2013|December 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|100 Years|No|||November 2015|November 30, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01896011||63239|
NCT01918358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VRCL005|Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg|A Randomized, Open-label, Single Dose Crossover Study to Compare the Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg in Healthy Male Volunteers||LG Life Sciences|No|Completed|December 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918358||61531|
NCT01918371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-OZU-13-598|A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema|||Allergan|No|Completed|August 2013|July 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Received Anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema        (DME)|July 2014|July 17, 2014|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918371||61530|
NCT01910285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 522 03|Remifentanil Versus Sufentanil for Intubation Condition Without Myorelaxant|Comparison of Intubation Conditions After Induction With Propofol Associated With a Dose of Remifentanil or Sufentanil in Surgical Tooth Extraction.|REMIDENT|University Hospital, Toulouse|No|Recruiting|June 2013|September 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|No|||July 2013|July 26, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01910285||62149|
NCT01918033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4117-200|A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)|A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|608|||Both|12 Years|N/A|No|||October 2015|October 19, 2015|August 5, 2013|No|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01918033||61556|
NCT01918319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiPO|Lifestyle in Pregnancy and Offspring|The Effect of Lifestyle Intervention in Pregnancy - Follow-up on the Offspring in Early Childhood.|LiPO|Odense University Hospital|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|157|||Both|30 Months|40 Months|Accepts Healthy Volunteers|||August 2013|August 5, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918319||61534|
NCT01918592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEBIB|PET/MRI and Biomarkers in Bladder Cancer|PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy|ACEBIB|Turku University Hospital|No|Recruiting|August 2013|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|85 Years|No|||November 2015|November 5, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918592||61513|
NCT01918605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OY-111|Protection of Rectum From High Radiation Doses Using a Spacer|Protection of Rectum From High Radiation Doses During Prostate Cancer Low-dose Brachytherapy Using Diluted or Non-diluted DuraSeal as a Spacer||University of Oulu|No|Enrolling by invitation|June 2013|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Male|50 Years|78 Years|No|||November 2015|November 30, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918605||61512|
NCT01897701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX900.PH7.101|A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/2013 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Adjuvant 1||Novavax|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 10, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01897701||63110|
NCT01897714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-M1-12|Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients|An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma||Oncopeptides AB|Yes|Recruiting|July 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01897714||63109|
NCT01896843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130166|Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain|Evaluation of [11C]FPEB, [18C]FPEB, and [11C]SP203 To Image mGluR5 Receptors In Brain||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|February 12, 2016|July 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01896843||63176|
NCT01898299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6662|TDCS for Auditory Hallucinations in Schizophrenia|tDCS for Auditory Hallucinations in Schizophrenia||New York State Psychiatric Institute|No|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898299||63064|
NCT01898312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003703-35|BRCA1/2 and Effect of Mifepristone on the Breast|The Effect of a Progesterone Receptor Modulator on Breast Tissue in Women With BRCA-1 and -2 Mutations - a Placebo Controlled RCT.||Karolinska Institutet|No|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|45|||Female|18 Years|N/A|No|||October 2015|October 23, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01898312||63063|
NCT01898572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-DIABIMCAP|Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals|Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis|DIABIMCAP|Hospital Clinic of Barcelona|No|Active, not recruiting|January 2012|June 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Whole blood, serum, urine|Both|40 Years|74 Years|No|Non-Probability Sample|Primary care area: 3 Primary care centers in the city center of Barcelona (Spain)|June 2014|June 24, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01898572||63043|
NCT01898585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28711|An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma|An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.||Hoffmann-La Roche||Active, not recruiting|October 2013|December 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01898585||63042|
NCT01898819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0195|The Effect of Dexmedetomidine in Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy|||Yonsei University|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|70|||Male|20 Years|80 Years|No|||January 2014|January 23, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898819||63024|
NCT01898832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zekai tahir burak- cholestasis|Il-17 Levels in Intrahepatic Cholestasis of Pregnancy|to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|None Retained|maternal venous ad umbilical cordon blood|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|The pregnant women with intrahepatic cholestasis who admitted our clinic|July 2013|March 16, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898832|12 Months|63023|
NCT01899105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-809-012|A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor|A Phase 1, Randomized, Single-Dose, Open-Label Crossover Study to Investigate the Effect of Food on the Relative Bioavailability of 2 Fixed-Dose Combinations of Lumacaftor and Ivacaftor Tablet Formulations in Healthy Adult Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899105||63003|
NCT01899404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5221-C|MRI FDG PET Imaging Cervix|A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer||University Health Network, Toronto|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|October 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01899404||62980|
NCT01895426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1227|ArcadiusXP L Post Market Clinical Follow-Up|Clinical Follow-up of the ArcadiusXP L Stand Alone Intervertebral Body Fusion Device|ArcadiusXPLPMS|Aesculap AG|No|Active, not recruiting|April 2013|February 2017|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|60 Years|No|Non-Probability Sample|adult patients|January 2016|January 15, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01895426||63284|
NCT01895699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze033|The Effect of Contrast Agent on Endothelial Function in Healthy Men|The Effect of Contrast Agent on Endothelial Function in Healthy Men||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|60|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01895699||63263|
NCT01895998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040933|Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease|Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease||Duke University|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|5 Years|12 Years|No|||December 2014|December 2, 2014|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01895998||63240|
NCT01896024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNSF 100014-134562|Effects of Motive-Oriented Therapeutic Relationship in the Early-Phase Treatment of Borderline Personality Disorder||MOTR|University of Lausanne Hospitals|No|Completed|June 2010|April 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01896024||63238|
NCT01896336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPDEMS1011|Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia|National Study, Phase IV, Single-center, Double-blind, Randomized, Parallel, Controlled by 10 mg Oral Zolpidem, in Evaluating the Efficacy and Safety of Zolpidem 5 mg Sublingual in the Induction and Maintenance of Sleep in Patients With Primary Insomnia||EMS|Yes|Active, not recruiting|February 2013|March 2014|Anticipated|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|64 Years|No|||September 2013|September 23, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01896336||63214|
NCT01896349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP-120288|Interpersonal Psychotherapy for Treatment Resistant Depression|Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression||Hospital de Clinicas de Porto Alegre|No|Recruiting|April 2013|November 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01896349||63213|
NCT01910571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7435/76/12|Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects.||Piramal Enterprises Limited|No|Completed|August 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|July 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910571||62127|
NCT01910324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20043161|Juvenile Detention to Community Life|Facilitating Adolescent Offenders' Reintegration From Juvenile Detention to Community Life (DTC)|DTC|University of Miami|Yes|Completed|April 2006|December 2011|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910324||62146|
NCT01918618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1-044-13|Renal Effects of Levosimendan in Cardiac Surgery Patients|||Charite University, Berlin, Germany||Completed|April 2013|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|92|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery between 2007 and 2011 followed by postoperative        observation on an ICU of the anaesthesiology department of the Charité hospital|August 2013|August 6, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01918618||61511|
NCT01918332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VRCL002|Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia|A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia||LG Life Sciences|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|168|||Both|20 Years|80 Years|No|||December 2014|December 8, 2014|August 5, 2013||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01918332||61533|Withdrawal(discontinuation) leading to smaller number of per-protocol set than full analysis set. The violation of protocol was the criterion of subjects' withdrawal.
NCT01919151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-08172d6.2008.540|Micrometastasis in Gastrointestinal Cancer|The Process of Metastasis in Colorectal Cancer Tumour Biology and Prognostic Factors in Pancreatic Cancer||Oslo University Hospital|No|Recruiting|June 2008|December 2015|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood and bone marrow cells fixated to slides or to cartridge. Some fresh frozen tumor      samples|Both|N/A|N/A|No|Probability Sample|Gastrointestinal cancer patients:          1. patients with suspected adenocarcinoma in the pancreas          2. patients with liver metastases secondary to colorectal cancer|August 2013|August 8, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919151||61470|
NCT01919164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700692_006|A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Different Intra Articular (i.a.) Dosages of Sprifermin in Subjects With Primary Osteoarthritis of the Knee|FORWARD|EMD Serono|Yes|Active, not recruiting|August 2013|May 2019|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|549|||Both|40 Years|85 Years|No|||May 2015|May 28, 2015|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919164||61469|
NCT01897740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481307|Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil|A Local, Single-centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil, Prior To Reimbursement And Availability For Subjects In Russian Federation||Pfizer||Available||||||Phase 4|Expanded Access|N/A|||||||Both|10 Years|30 Years|No|||March 2016|March 24, 2016|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01897740||63107|
NCT01897376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-SIT|Cesarean Skin Incision Trial|The Comparative Effectiveness of Pfannenstiel Versus Vertical Skin Incision in Preventing Wound Complications After Cesarean Delivery in Morbidly Obese Women: a Randomized Clinical Trial.|C-SIT|The University of Texas Health Science Center, Houston|Yes|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01897376||63135|
NCT01898052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orthoTU03|The Efficacy of Periarticular Single Drug Compared With Multimodal Drug Injection in Controlling Pain After TKA|A Comparative Study on the Efficacy of Periarticular Single Anesthetic Drug Compared With Multimodal Drug Injection in Controlling Pain After Total Knee Arthroplasty: A Double Blinded Randomized Controlled Trial|TKA|Thammasat University|Yes|Completed|October 2012|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||March 2014|March 31, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01898052||63083|
NCT01898325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gaucher_Fibroscan_CTIL|Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan|Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan||Rambam Health Care Campus|Yes|Not yet recruiting|August 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01898325||63062|
NCT01898598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28726|A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study To Assess The Efficacy And Safety Of Oral Vismodegib For The Treatment Of Basal Cell Carcinoma Preceding Excision By Mohs Micrographic Surgery||Hoffmann-La Roche||Completed|February 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01898598||63041|
NCT01898845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X1101|A Phase I Study of LEE011 in Asian Patients|A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors||Novartis|Yes|Completed|May 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01898845||63022|
NCT01898858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5546|Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic|Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic|H2PAP|University Hospital, Strasbourg, France|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|October 2014|October 14, 2014|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01898858||63021|
NCT01899131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC 13 AS 177-13-TLV CTIL|A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants|A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2013|June 2016|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||June 2013|March 26, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01899131||63001|
NCT01899118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH-ARO2013|Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer|A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|April 2013|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||July 2013|July 12, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899118||63002|
NCT01899417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001|Costs and Benefits of ConforMIS iTotal® Knee Replacement System Versus Standard Total Knee|Analysis of Procedure-related Costs and Proposed Benefits of the ConforMIS iTotal® Cruciate Retaining Knee Replacement System Versus Standard Total Knee||ConforMIS, Inc.|Yes|Completed|July 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|235|||Both|19 Years|N/A|No|Non-Probability Sample|Patients who have had a Total Knee Replacement performed by the Investigator and are at        least 3 months post surgery.|June 2015|June 18, 2015|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899417||62979|
NCT01899430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120047|Polycystic Ovary Syndrome and Liraglutide|Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome||University Medical Centre Ljubljana|No|Completed|November 2011|April 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|55 Years|No|||July 2013|July 10, 2013|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01899430||62978|
NCT01902446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-201304766|Prehospital Ventilator-Associated Pneumonia Prevention Trial|A Pilot Study of Prehospital Oral Chlorhexidine Gluconate to Prevent Early Ventilator Associated Pneumonia in Intubated Trauma Patients|P-VAPP|University of Iowa|Yes|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|All intubated adult patients transported by air ambulance to the University of Iowa        Hospitals and Clinics in interfacility transport after traumatic injury.|December 2014|December 2, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902446||62747|
NCT01893086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC13-029|Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy|Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy: a Multi-center, Randomized Controlled Trial||CHA University|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|19 Years|52 Years|No|||January 2016|January 26, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893086||63464|
NCT01893905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-CS+SG /301|Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis|Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee||Tedec-Meiji Farma, S.A.|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|45 Years|N/A|No|||November 2015|November 19, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893905||63401|
NCT01894152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-396|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study|Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.|XP China SAS|Abbott Vascular|No|Active, not recruiting|July 2013|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2003|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in        realworld settings in China.|January 2016|January 12, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894152||63382|
NCT01894477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2524.00|Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Randomized Phase II Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2013|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|70 Years|No|||February 2016|February 10, 2016|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894477||63357|
NCT01891734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-122|Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology|Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology||VA Office of Research and Development|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891734||63567|
NCT01893177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A018|Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2013/2014-season Virosomal Subunit Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations||Crucell Holland BV|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893177||63457|
NCT01893775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913148|Antibody Treatment for Advanced Celiac Disease|Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2013|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|100 Years|No|||March 2016|March 16, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01893775||63411|
NCT01894035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16755|Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation|Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost|COMPHI|Bayer|No|Recruiting|September 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III,        for whom the treating physician has chosen to initiate the treatment with inhaled iloprost        using I-Neb as the device for inhalation since 1st of February of 2013.|March 2016|March 1, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894035||63391|
NCT01894308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARC-Testosterone-D1/09/13|A Dose Ranging Study to Examine Testagen® TDS-Testosterone 5%|A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen® TDS-Testosterone 5% in Adult Male Subjects|PARC-T-D|Transdermal Delivery Solutions Corp|Yes|Enrolling by invitation|July 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|75 Years|No|||March 2016|March 10, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894308||63370|
NCT01894321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTGBD1|The Clinical Outcomes of the Percutaneous Cholecystostomy, Supportive Care Versus Cholecystectomy.|The Percutaneous Cholecystostomy is Appropriate as the Ultimate Treatment of Acute Cholecystitis in Critically Ill Patients: a Cross-sectional Study at Single Center.||Cheju Halla General Hospital|No|Completed|January 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|82|||Both|N/A|N/A|No|Non-Probability Sample|From November 2007 to November 2012, patients admitted with acute cholecystitis through        emergency center or out-patient clinic then underwent ultrasonography guided percutaneous        cholecystostomy in Cheju Halla General Hospital were enrolled consecutively.|July 2013|July 3, 2013|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01894321||63369|
NCT01903486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009825|Assessing the Efficacy of Steroid Treatment of Achalasia|A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia||Mayo Clinic|No|Enrolling by invitation|March 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||December 2015|December 30, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01903486||62668|
NCT01903499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212E25808|Satiety Effects of Beef Compared to Beans|Satiety Effects of Beef Compared to Beans||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2013|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01903499||62667|
NCT01899976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Number BI-03-01|X-MAS Biliary Study With Covered Biliary Stent|A Non-Randomized, Multi-Center, Prospective, Single Arm Clinical Study of the X-SUIT NIR® Covered Biliary Metallic Stent for Palliation of Malignant Strictures in the Biliary Tree Via Endoscopic Approach||Medinol Ltd.|No|Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899976||62936|
NCT01899677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14893|The Efficacy of Symbiotic on Cytokines|The Efficacy of Symbiotic Preparation on Cytokines Which Act on Necrotising Enterocolitis Pathogenesis in Very Low Birth Weight Infants||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|N/A|2 Days|Accepts Healthy Volunteers|||August 2014|August 5, 2014|July 1, 2013|Yes|Yes||No|July 13, 2014|https://clinicaltrials.gov/show/NCT01899677||62959|
NCT01900496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1354|Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma|Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2014|June 2019|Anticipated|July 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|16 Years|N/A|No|||July 2015|July 2, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900496||62897|
NCT01900236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI103661|Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV|Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV|iENGAGE|University of Alabama at Birmingham|Yes|Recruiting|December 2013|March 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01900236||62917|
NCT01900483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSD|Brain Functions in Patients Before and After Bariatric Surgery|||University Hospital Tuebingen||Completed||||August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|||Both|25 Years|65 Years||Non-Probability Sample|volunteers pre and post bariatric surgery|November 2015|November 9, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900483||62898|
NCT01901367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PED 1309|ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients|ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|May 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|2 Years|18 Years|No|||July 2013|July 12, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901367||62830|
NCT01901653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRX16-001|SC16LD6.5 in Recurrent Small Cell Lung Cancer|Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer||Stemcentrx|No|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901653||62808|
NCT01901666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-IGF-1 AXIS AND CML|Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission|ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|N/A|No|||July 2013|July 12, 2013|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01901666||62807|
NCT01893346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00014|Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections|A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection||AstraZeneca|Yes|Completed|July 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|3 Months|17 Years|No|||June 2015|June 11, 2015|June 26, 2013|Yes|Yes||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01893346||63444|
NCT01893684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCBA|Dietary Intervention and Varying Physical Activity in Seniors|Effects of a Higher Protein Weight Loss Diet and Exercise on Body Composition, Physical Function, and Fatigue in Overweight Older Women|ugaDIVAS|University of Georgia|No|Active, not recruiting|January 2013|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|65 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|February 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01893684||63418|
NCT01893931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1278|Use of a Brief Phone Call After ED Discharge|Discharge Planning for Older Adults in the Emergency Department: Use of a Brief Phone Call After Discharge to Decrease Return Visits to the Emergency Department and Re-admissions to the Hospital||University of North Carolina, Chapel Hill|No|Recruiting|August 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2170|||Both|65 Years|N/A|No|||January 2015|January 7, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01893931||63399|
NCT01894763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1063-04|Prospective Comparison of Large vs. Small Diameter Esophageal Stents for Palliation of Malignant Dysphagia|Randomized, Prospective Comparison of Large vs. Small Diameter Esophageal Stents for Palliation of Malignant Dysphagia||Mayo Clinic|No|Completed|September 2003|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2013|July 4, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01894763||63335|
NCT01894776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013 0080-01H|A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc|A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc|RIFAMARA|Ottawa Hospital Research Institute|Yes|Completed|June 2013|February 2015|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01894776||63334|
NCT01890967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14853|A Study of LY3015014 in Participants With High Cholesterol|A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia||Eli Lilly and Company|Yes|Completed|June 2013|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|527|||Both|18 Years|80 Years|No|||November 2014|November 25, 2014|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890967||63626|
NCT01893099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-CePO-code 16295|Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma|Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma||Centre Hospitalier Universitaire Vaudois|No|Recruiting|June 2013|June 2017|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||June 2013|July 2, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893099||63463|
NCT01893112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH098675|Reducing HIV Stigma for African American Women|Reducing HIV Stigma to Improve Health Outcomes for African-American Women||University of Washington|Yes|Recruiting|June 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|224|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01893112||63462|
NCT01893515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 4016 13201|The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects||Pronova BioPharma|Yes|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|79 Years|No|||October 2015|October 7, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893515||63431|
NCT01894048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012RC16|Targeted Small Airways Therapy in Persistent Asthma|Targeted Small Airways Therapy in Persistent Asthma|ANDA3|University of Dundee|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894048||63390|
NCT01894334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2006-03|Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection|Mechanism and Early Intervention Research on Acute Lung Injury During Emergence Surgery of Acute Stanford A Aortic Dissection||Beijing Anzhen Hospital|Yes|Active, not recruiting|April 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|220|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|June 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01894334||63368|
NCT01894607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0124|Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy|Feasibility Study of Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy||M.D. Anderson Cancer Center|No|Completed|October 2013|||December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 3, 2013|No|Yes||No|February 17, 2016|https://clinicaltrials.gov/show/NCT01894607||63347|
NCT01899703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117213|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2330672 Administration in Patients With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus||GlaxoSmithKline|No|Completed|March 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899703||62957|
NCT01899716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-438|Exercise and Severe Depression: Clinical and Biological Analysis|Exercise and Severe Depression: Clinical and Biological Analysis||Hospital de Clinicas de Porto Alegre||Completed|January 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||May 2013|December 27, 2013|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01899716||62956|
NCT01900275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 13-0425|Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults|Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults||Denver Health and Hospital Authority|No|Completed|July 2013|||November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|Samples Without DNA|Urine will be collected, centrifuged, and frozen|Both|18 Years|N/A|No|Probability Sample|Critically ill adults admitted to the Denver Health MICU or SICU for either (a) septic        shock or (b) major trauma.|November 2014|November 21, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900275||62914|
NCT01900249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-932348-003|To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca|A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca|DROPS|Rigel Pharmaceuticals|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|206|||Both|18 Years|85 Years|No|||July 2014|July 11, 2014|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900249||62916|
NCT01900262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI2014|Exercise Interventions, Running Biomechanics and Injury in Novice Runners|The Effects of Isolated Strengthening and Functional Training on Strength, Running Mechanics, Postural Control and Injury Prevention in Novice Runners||University of Calgary|No|Active, not recruiting|February 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900262||62915|
NCT01900808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPLICABILITY- TE|Improvement of Transient Elastography Applicability and Diagnostic Accuracy to Identify Significant Fibrosis by Experienced Operators Using the M and XL Probe.|Improvement of Transient Elastography Applicability and Diagnostic Accuracy to Identify Significant Fibrosis by Experienced Operators Using the M and XL Probe.||Parc de Salut Mar|No|Completed|March 2012|December 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|868|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with liver stiffness|July 2013|January 15, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900808||62873|
NCT01900821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRDR-NMD|National Mammography Database|||American College of Radiology|Yes|Recruiting|July 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|8000000|||Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women (primarily, but not exclusively), having mammograms at facilities participating in        the registry|February 2014|February 17, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900821|1 Year|62872|
NCT01900782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2314|Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.|A Randomized, Double-blind, Double-dummy, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis.||Novartis|No|Withdrawn|October 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900782||62875|
NCT01900795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAG2001|An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction|A Phase 2a, Single-Center, Randomized, Double-Blind, Double- Dummy, Placebo- and Active-Controlled Analgesic Study of an Oral Dose of V117957 4.5 mg for the Treatment of Postsurgical Pain Due to Third Molar Extraction||Purdue Pharma LP|Yes|Terminated|July 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|45 Years|No|||December 2013|December 3, 2013|July 12, 2013|Yes|Yes|Terminated early due to administrative reasons not related to safety.|No||https://clinicaltrials.gov/show/NCT01900795||62874|
NCT01901107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIK001|Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients|Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphataemia Receiving Hemodialysis||Astellas Pharma Inc|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1078|||Both|N/A|N/A|No|Non-Probability Sample|Chronic renal failure patients with hyperphosphataemia receiving hemodialysis|March 2016|March 24, 2016|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901107||62850|
NCT01901380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204/12|Cow's Milk Allergy and Functional Gastrointestinal Disorders|Effect of Lactobacillus GG on the Appearance of Functional Gastrointestinal Disorders in Children With Cow's Milk Allergy||Federico II University|No|Recruiting|February 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|||Both|4 Years|6 Years|No|Probability Sample|The study population will be enrolled from a cohort of about 300 children (aged from 4 to        6 yrs) with a history of sure diagnosis of CMA obtained in the first year of life treated        with hypoallergenic formula for at least 6 months and who are already in follow-up at the        Department of Pediatrics of University of Naples "Federico II".|July 2013|July 17, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01901380||62829|
NCT01902199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01422|Tobacco Retraining of Automatic Approach to Treat Individuals With Tobacco Dependence and Severe Concurrent Disorders.|Studying a Novel Intervention, the Tobacco Retraining of Automatic Approach (TRAA), to Treat Individuals With Tobacco Dependence and Severe Concurrent Disorders||University of British Columbia|No|Not yet recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||September 2014|September 29, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902199||62766|
NCT01902212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL16|Evaluation of an Oral Nutrition Supplement|Evaluation of an Oral Nutrition Supplement||Abbott Nutrition|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01902212||62765|
NCT01892228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treat-All HIV Pilot|Pilot Study of Immediate HIV Treatment in Guangxi, China|Pilot Study of Immediate HIV Treatment by Means of "One-stop Service" in Hospital in Guangxi, China||National Center for AIDS/STD Control and Prevention, China CDC|No|Recruiting|July 2012|July 2015|Anticipated|July 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1000|||Both|N/A|N/A|No|||June 2013|May 11, 2015|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01892228||63529|
NCT01894178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31550|Study Examining Parker-Flex Endotracheal Tube for Obese Patients|STUDY EVALUATING THE PARKER-FLEX ENDOTRACHEAL TUBE FOR FIBEROPTIC INTUBATION ON OBESE PATIENTS||Baylor College of Medicine|Yes|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894178||63380|
NCT01894516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-204 (DARWIN2)|Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (DARWIN2)|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone||Galapagos NV|Yes|Completed|July 2013|July 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|287|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894516||63354|
NCT01890980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0289|Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134|Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2013|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890980||63625|
NCT01891474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_Uhealth2|Efficacy and Safety of Voice Inception Technique Based U-healthcare Service in Patients With Type 2 Diabetes Mellitus|An Open, Parallel-group, Randomized, Interventional Study to Compare the Efficacy and Safety of Voice Inception Technique Based U-healthcare Service in Patients With Type 2 Diabetes Mellitus||Seoul National University Bundang Hospital|No|Completed|August 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|70|||Both|60 Years|85 Years|No|||October 2015|October 23, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891474||63587|
NCT01901250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06-18|Xylitol for Caries Prevention in Inner-City Children|Xylitol for Caries Prevention in Inner-City Children||Case Western Reserve University|Yes|Completed|August 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|562|||Both|5 Years|6 Years|No|||July 2014|July 22, 2014|July 12, 2013||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01901250||62839|Nearly half the children moved out of the school district by the time of the exit examination, which made the power of the analysis insufficient to detect the difference between two groups.
NCT01893788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nagoya University|Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy||EARTH|Nagoya University|Yes|Recruiting|April 2013|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||July 2013|July 18, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01893788||63410|
NCT01894347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOKALE|Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)|Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)|LOKALE|Charite University, Berlin, Germany|No|Active, not recruiting|September 2013|December 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|Samples With DNA|Blood, tracheal aspirates|Both|18 Years|N/A|No|Non-Probability Sample|Adult ICU patients with invasive ventilation and colonization or infection with MDR        pathogens|April 2015|April 8, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894347||63367|
NCT01894620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:76|The Effect of rTMS Treatment on Alzheimer's and Sleep Quality|Investigating the Effect of Repetitive Transcranial Magnetic Stimulation as a Treatment for Alzheimer's Disease and on Sleep Quality|rTMS|University of Manitoba|Yes|Recruiting|May 2013|August 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|90 Years|No|||July 2013|July 9, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894620||63346|
NCT01894880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-425ex12/13|Pilot Study: Sectio Bonding/Early Skin-to-skin Contact (SSC) After Caesarean Section|Pilot Study: Sectio Bonding/Early Skin-to-skin Contact (SSC) After Caesarean Section|SSC|Medical University of Graz|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|35|||Female|18 Years|55 Years|No|||April 2015|April 21, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01894880||63326|
NCT01899989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-113|Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer|Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|July 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899989||62935|
NCT01900002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0870|Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C||M.D. Anderson Cancer Center|No|Recruiting|September 2013|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900002||62934|
NCT01900288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13337|Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research|Mobile Technologies Assisting Patients & Family Caregivers in Healthy Living||University of Kansas Medical Center|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|90|||Both|13 Years|N/A|No|||November 2015|November 19, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900288||62913|
NCT01900535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKDC- 11|Evaluation and Comparison of the Efficacy of Triphala Mouthwash and 0.2% Chlorhexidine|A Randomized Clinical Trial to Evaluate and Compare the Efficacy of Triphala Mouthwash With 0.2% Chlorhexidine in Hospitalized Patients With Periodontal Diseases||Tatyasaheb Kore Dental College|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|20 Years|65 Years|No|Probability Sample|The participants were selected from patients admitted to three different medical hospitals        namely Mahatma Gandhi Hospital, New Pargaon, Sub district Government Hospital, Kodoli and        Yeshwant Chavan Hospital, Kodoli|July 2013|July 15, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900535|15 Days|62894|
NCT01900509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BECHEM|Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies||St. Jude Children's Research Hospital|No|Recruiting|August 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|21 Years|No|||March 2016|March 21, 2016|July 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900509||62896|
NCT01900522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-214_102|Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia|A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214||Takeda|No|Terminated|July 2013|December 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|July 11, 2013|No|Yes|Business Decision; No Safety or Efficacy Concerns|No||https://clinicaltrials.gov/show/NCT01900522||62895|
NCT01900834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4099|Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period|An Observational Study Evaluating Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period||Novo Nordisk A/S|No|Completed|July 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|Samples With DNA|Monthly venous blood samples within the first half year and thereafter bi-monthly the rest      of the year. A subgroup of the subjects will also be invited for a visit within a week after      the former visit to assess the variation of the biomarkers within a week. The blood samples      will be assayed for peripheral blood mononuclear cells (PBMC) specificity, phenotype and      function as well as for islet autoantibodies (presence and precise titers), for autoantibody      isotypes and diabetes risk parameters. Finally C-peptide levels and residual beta cell      function will be measured three times during the study after a mix meal tolerance test      (MMTT) in subjects with T1D.|Both|14 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with T1D, T2D and healthy subjects (HS) without personal or first degree family        history of autoimmunity of diabetes. The HS will be mean age-matched with the T1D        subjects.|October 2015|October 29, 2015|June 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900834||62871|
NCT01901146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120283|Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer|A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer|Lilac|Amgen|Yes|Active, not recruiting|April 2013|February 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|827|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01901146||62847|
NCT01901120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE0002|Long-Term Specified Drug Use-results Survey of Betanis Tablets|Long-Term Specified Drug Use-results Survey of Betanis Tablets||Astellas Pharma Inc|No|Active, not recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1263|||Both|N/A|N/A|No|Non-Probability Sample|Patients who administer mirabegron for treatment of urinary urgency, daytime frequency,        and urgency incontinence associated with overactive bladder and also who have no treatment        history of mirabegron.|September 2015|September 9, 2015|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901120||62849|
NCT01901133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0009|Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group|A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MDV3100 in Male Subjects With Mild or Moderate Hepatic Impairment and Normal Hepatic Function||Astellas Pharma Inc|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Male|18 Years|69 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901133||62848|
NCT01901159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28433|A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers|A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects||Hoffmann-La Roche||Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01901159||62846|
NCT01901913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc007418ctil|MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management|MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management||Rabin Medical Center|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|14 Years|25 Years|No|||November 2014|April 15, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01901913||62788|
NCT01893060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16859|Umbilical Cord Care for the Prevention of Colonization|Umbilical Cord Care for the Prevention of Colonization||University of Virginia|No|Recruiting|July 2013|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|N/A|7 Days|No|||August 2013|August 1, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01893060||63466|
NCT01892787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013RC01|Effects of Particle Size in Small Airways Dysfunction|Randomised Controlled Single and Chronic Dosing Crossover Comparison of Extra Fine Particle Formoterol and Coarse Particle Salmeterol in Asthmatic Patients With Persistent Small Airways Dysfunction|MAN03|University of Dundee|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|16 Years|N/A|No|||March 2015|March 4, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892787||63487|
NCT01900106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTLP|A Prospective, Open-label Trial of Two Abacavir/Lamivudine Based Regimen (ABC/3TC + Darunavir/Ritonavir or ABC/3TC + Raltegravir) in Late Presenter naïve Patients (With CD4 Count <200 Cells/µL - Advanced HIV Disease)|||University of Modena and Reggio Emilia||Not yet recruiting|July 2013|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|64 Years|No|||July 2013|July 11, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01900106||62926|
NCT01890694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02496|Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia|Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia||New York University School of Medicine|Yes|Terminated|March 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890694||63647|
NCT01900964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0455|Ridge Preservation Comparing a PTFE Nonresorbable Membrane to a Collagen Membrane|Ridge Preservation Comparing the Clinical and Histologic Healing of a PTFE Non-resorbable vs. a Collagen Membrane With an Intrasocket Mineralized Cancellous Allograft Plus a Facial Overlay Bovine Xenograft.||University of Louisville|No|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 21, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01900964||62861|
NCT01902030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP PCR IA TISSUE-EFFUSION|Evaluation of Performance of An Aspergillus PCR in Tissue and Pleural Effusion Samples of Immunocompromised Patients|Diagnostic Study of Performance of an Aspergillus Specific Polymerase Chain Reaction in Tissue and Pleural Effusion Samples of Immunocompromised Patients for the Diagnosis of Invasive Aspergillosis||Heidelberg University|No|Enrolling by invitation|January 2014|August 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|Samples With DNA|Fungal DNA, no human DNA|Both|18 Years|N/A|No|Non-Probability Sample|-  Immunocompromised individuals with suspicion of harbouring an invasive fungal             infection|December 2015|December 8, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01902030||62779|
NCT01902043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoDiab-VD-151/11|CoDiab-VD: a Population-based Cohort on Quality of Care of Patients With Diabetes in the Canton of Vaud (Switzerland)|CoDiab-VD: a Population-based Cohort on Quality of Care of Patients With Diabetes in the Canton of Vaud (Switzerland)|CoDiab-VD|University of Lausanne Hospitals|No|Active, not recruiting|September 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|519|||Both|18 Years|N/A|No|Probability Sample|Non-institutionalized adult diabetic patients (>18 years, type 1 or 2 diabetes, disease        duration >12 months) who were visiting the pharmacy with a prescription for oral        antidiabetic drugs, insulin, glycemic strips or glucose meter are eligible for this study.|December 2014|December 11, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01902043||62778|
NCT01894061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3313|NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma|A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma||Case Comprehensive Cancer Center|Yes|Recruiting|June 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|22 Years|N/A|No|||March 2016|March 8, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894061||63389|
NCT01894386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200587|Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses|An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison With FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).||GlaxoSmithKline|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|July 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894386||63364|
NCT01890889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065|Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health|A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health|AdBiotech|Integrative Health Technologies, Inc.|Yes|Recruiting|July 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890889||63632|
NCT01894633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-449-08|Study of Whole-brain Irradiation With Chloroquine for Brain Metastases|Phase II Randomized, Double Blind, Placebo Controlled Study of Whole-brain Irradiation With Concomitant Daily-dose Chloroquine for Brain Metastases.|CLQ|Instituto Nacional de Cancerologia de Mexico|No|Terminated|May 2011|January 2013|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|46 Years|61 Years|No|||July 2013|July 3, 2013|June 29, 2013||No|terminated|No||https://clinicaltrials.gov/show/NCT01894633||63345|
NCT01894646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00076249|PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA|PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA||Johns Hopkins University|Yes|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01894646||63344|
NCT01894893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.33.NRC|Atlas of Human Milk Nutrients|Atlas of Human Milk Nutrients||Nestlé|No|Completed|December 2012|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|370|Samples With DNA|1. Mother milk        2. Umbilical cord blood        3. Mother blood        4. Adipose tissue|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Healthy mothers of any ethnicity having decided to exclusively breast-feed their new born        baby from birth up to 4 months of age will be eligible to participate in the study.|January 2016|January 4, 2016|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01894893||63325|
NCT01894906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-8|Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients|A Controlled, Randomized Study to Assess the Quantitative Mass Transfer of Iron From SFP-containing Hemodialysate Under Varying Conditions of Blood and Dialysate Flow Rates, Dialyzer Membrane Types and Dialysate Bicarbonate Concentrations in CKD-HD Patients.||Rockwell Medical Technologies, Inc.|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|June 27, 2013|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01894906||63324|Total iron, TBI, NTBI, and UIBC could not be measured because the ferrozine assay for total iron and transferrin-bound iron was unreliable due to the presence of heparin in the samples, which caused the formation of fibrin strands.
NCT01900015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STERAL/50410|CHANGES IN LIVER STEATOSIS AFTER SWITCHING TO RALTEGRAVIR IN HIV/HCV COINFECTION|CHANGES IN LIVER STEATOSIS AFTER SWITCHING FROM EFAVIRENZ TO RALTEGRAVIR AMONG HIV/HCV-COINFECTED PATIENTS RECEIVING TWO NUCLEOSIDE ANALOGS PLUS EFAVIRENZ: THE STERAL STUDY.||Andaluz Health Service|Yes|Not yet recruiting|November 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900015||62933|
NCT01900561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-116|Optimizing Veteran-Centered Prostate Cancer Survivorship Care|Optimizing Veteran-Centered Prostate Cancer Survivorship Care||VA Office of Research and Development|No|Recruiting|April 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|650|||Male|40 Years|80 Years|No|||March 2016|March 22, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01900561||62892|
NCT01900548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-136-13|Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function.|Effect of Intake of Protein High in Ketogenic Amino Acids (e.g. Leucine) in Elderly Osteopenic Patients. Implications for Muscle, Bone , Metabolism, and Physical Function.||University of Aarhus|No|Completed|January 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|57|||Both|60 Years|85 Years|No|||July 2013|January 4, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01900548||62893|
NCT01901185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110107|Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept|A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept||Amgen|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|May 17, 2013|No|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01901185||62844|
NCT01901172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28902|A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors|||Hoffmann-La Roche||Completed|August 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|61|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901172||62845|
NCT01901393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-020|Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery|A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery||Cumberland Pharmaceuticals|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 12, 2013|Yes|Yes||No|January 18, 2016|https://clinicaltrials.gov/show/NCT01901393||62828|
NCT01892748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITD59/11|Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.|Effects of Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Onset Systemic Lupus Erythematosus.||University of Sao Paulo|Yes|Recruiting|September 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|10 Years|25 Years|No|||July 2013|July 3, 2013|June 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01892748||63490|
NCT01891461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS12-000835|Study to Compare the Addition of Floseal to Our Standard of Care to Control Post Operative Bleeding in TKR|A Prospective, Randomized Study to Compare the Addition of Granules of Gelatine + Thrombin to Our Standard of Care (SOC) to Control Post Operative Bleeding in Total Knee Replacement||Hopital du Sacre-Coeur de Montreal|No|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891461||63588|
NCT01893398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FdG_AD_01|Multistimulation Group Therapy for Alzheimer's Disease|Multistimulation Group Therapy in Mild to Moderate Alzheimer's Disease||Fondazione Don Carlo Gnocchi Onlus||Completed|January 2010|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|65 Years|85 Years|No|||June 2013|July 2, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01893398||63440|
NCT01893411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3070_1|Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy|Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy||Merz Pharmaceuticals GmbH|Yes|Active, not recruiting|June 2013|November 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|311|||Both|2 Years|17 Years|No|||March 2016|March 22, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893411||63439|
NCT01900639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.44378.058.13|Aspirin AM or PM: Effect on Circadian Rhythm of Platelet Reactivity|Effect of Aspirin Intake on Awakening Versus at Bedtime on Circadian Rhythm of Platelet Reactivity in Healthy Subjects||Leiden University Medical Center|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900639||62886|
NCT01900652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14208|A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants|A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib|Chime|Eli Lilly and Company|No|Active, not recruiting|August 2013|July 2018|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900652||62885|
NCT01900366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAL-0809|Pilot Study for Noninvasive Spectroscopic Detection of Adipose Tissue Inflammation in Obesity|Pilot Study for Noninvasive Spectroscopic Detection of Adipose Tissue Inflammation in Obesity||Rockefeller University|No|Active, not recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|15|Samples Without DNA|Adipose tissue|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteer and obese subjects|October 2015|October 26, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900366||62907|
NCT01900626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epidural for Scoliosis|Single vs Double Epidural Catheter Analgesia for Scoliosis Surgery|Single Versus Double Epidural Catheter Technique for Postoperative Analgesia Following Scoliosis Surgery||University of Wisconsin, Madison|No|Terminated|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|11 Years|18 Years|No|||December 2014|October 1, 2015|July 11, 2013||No|Study was unable to meet patient enrollment goals. PI chose to terminate the study early.|No||https://clinicaltrials.gov/show/NCT01900626||62887|
NCT01901263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208125|Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units|Initial and Long-term Evaluation of Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2012|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|306|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Alzheimer's disease or associated disorders and BDSP and hospitalized in a        CBU|July 2015|November 30, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01901263|3 Years|62838|
NCT01901497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIVnebu|Pharmacokinetics of Nebulized Amikacin in Non Invasive Ventilated Healthy Volunteers.|Comparison of Pharmacokinetics of Amikacin Administered by Three Vibrating Mesh Nebulizers in Healthy Volunteers|NIV-NEBU|University Hospital St Luc, Brussels|No|Completed|July 2013|January 2016|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901497||62820|
NCT01894074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00068360|The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes|The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes in Obese, Subfertile Women||University of Michigan|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|35 Years|No|||December 2015|December 3, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01894074||63388|
NCT01894360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117100|A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects|A Randomized, Parallel-Group, Open-Label Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Administered Subcutaneously to Healthy Subjects by Prefilled Syringe or Autoinjector||GlaxoSmithKline|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894360||63366|
NCT01894373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWD301|Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis|Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Psoriasis||Chinese PLA General Hospital|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||June 2013|July 3, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01894373||63365|
NCT01894932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103042RC|MBCGT and Psycho-physiological Stress Regulation Group for Depression and Psycho-physiological Stress Patient|Mindfulness-based Cognitive Group Therapy (MBCGT) and Psycho-physiological Stress Regulation Group for Depression and Psycho-physiological Stress Patient: An Outcome Study||National Taiwan University Hospital|No|Enrolling by invitation|April 2011|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|150|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2013|August 12, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01894932||63322|
NCT01891162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISADRI|Assessment of Socioeconomic Status by Brazil and Quality of Life for Urinary Incontinence in Brazilian Women|Socioeconomic Profile and QUALITY OF LIFE FOR WOMEN WITH AND WITHOUT PELVIC FLOOR DYSFUNCTION||University of Sao Paulo General Hospital|No|Enrolling by invitation|December 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|||Female|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|will be avalueted women who will be postmenopausal, who are not taking hormone therapy in        the last six months. Women with urinary loss, which does not have non-inhibited        contraction of the detrusor proven by urodynamic study. Will be compared with a group of        women without pelvic floor dysfunction confirmed by clinical history and gynecological        examination with the same characteristics in relation to postmenopausal status, all from        the general gynecology outpatient clinic.|August 2013|August 30, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01891162|1 Day|63611|
NCT01900314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00053677|Imaging Biomarkers for TMS Treatment of Depression|Imaging Biomarkers for TMS Treatment of Depression||University of Michigan|No|Active, not recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|45|||Both|22 Years|65 Years|No|||November 2015|November 30, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900314||62911|
NCT01900301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH101359-01|Generalization of Extinction Learning|Cholinergic Decontextualization of Exposure Therapy for Anxiety||University of California, Los Angeles|Yes|Recruiting|August 2013|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|55 Years|No|||December 2015|December 14, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900301||62912|
NCT01900860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130101|Dose-dependent Effects of Vitamin D on Bone Health|Randomized Double-blind Study Investigating Dose-dependent Longitudinal Effects of Vitamin D Supplementation on Bone Health||University of Calgary|Yes|Active, not recruiting|August 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01900860||62869|
NCT01900873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1579-13|Effects of Inspiratory Muscle Training on Dyspnea Perception During Exercise in Patients With COPD|Effects of Inspiratory Muscle Training on Dyspnea Perception During Exercise in Patients With COPD|IMTCOCOPD|Katholieke Universiteit Leuven|Yes|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|90 Years|No|||February 2015|February 2, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01900873||62868|
NCT01900847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0045|Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department|Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department||University of Arizona|No|Recruiting|June 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900847||62870|
NCT01891968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0562|Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation|Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2013|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891968||63549|
NCT01892202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25750|A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis|Efficacy of C.E.R.A for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice||Hoffmann-La Roche||Withdrawn|February 2011|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with chronic kidney disease not on dialysis receiving treatment with Mircera for        chronic renal anemia|February 2016|February 1, 2016|June 27, 2013||No|Investigators lost interest in conducting the trail due to unexplained reasons|No||https://clinicaltrials.gov/show/NCT01892202||63531|
NCT01892774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_Exercise|Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation|Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation|Exercise|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|January 2010|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Chronic asymptomatic long-standing persistent AF|May 2015|May 22, 2015|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892774||63488|
NCT01901679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHO-0807|Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women|A Pilot Study: Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women||Rockefeller University|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|July 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901679||62806|
NCT01892462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCRM400003|Circulating Biomarkers and Ventricular Tachyarrhythmia|Circulating Biomarkers and Ventricular Tachyarrhythmia|LIFEMARKER|Ochsner Health System|Yes|Recruiting|June 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples With DNA|Blood samples will be stored frozen for future analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with cardiomyopathy (left ventricular ejection fraction [LVEF] <=35%) who are        followed at our institution's ICD device clinic will have levels of circulating biomarkers        (hs-CRP, IL-6, TNF-alpha, IL-1, sST2, MMP-1, CICP, CITP) and BNP assessed at three-month        intervals for at least one year. Patients will be excluded from the study if they have had        a recent myocardial infarction or PCI (within three months), or recent hospitalization.        Patients with obvious primary inflammatory conditions (such as lupus and rheumatoid        arthritis) will be excluded. Additionally, significant events (e.g., HF hospitalizations,        revascularization, medication changes, and death) will be tracked at each follow up visit        for further statistical analysis.|October 2015|October 14, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892462||63511|
NCT01894997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-NMES-DVT-334|A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Blood Flow in the Lower Limb|A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Lower Limb Haemodynamics||National University of Ireland, Galway, Ireland|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894997||63317|
NCT01892007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08ET002-01|Evaluation of Cogmed Working Memory Training for Adult Hearing Aid Users|Evaluation of Cogmed Working Memory Training to Improve Cognition, Speech Perception and Self-reported Hearing Abilities for Adult Hearing Aid Users: a Double-blind, Randomised, Active-controlled Trial.|TEACH2|Nottingham University Hospitals NHS Trust|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|62|||Both|50 Years|74 Years|No|||November 2014|November 10, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892007||63546|
NCT01899872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100400|Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.|Acute Effects of Aerobic and Resistance Exercise on Endothelial Function in Patients With Type 1 Diabetes.|EAEEFD|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|December 2011|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|15|||Male|18 Years|45 Years|No|||July 2013|July 11, 2013|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01899872||62944|
NCT01900990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQYKDXFSDYYY|Noninvasive Positive Pressure Ventilation for Difficult Weaning in Tracheotomy Patients|A Randomized Controlled Trial of Noninvasive Positive Pressure Ventilation for Weaning From Mechanical Ventilation in Tracheotomy Patients||Chongqing Medical University|Yes|Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||July 2013|July 13, 2013|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900990||62859|
NCT01900977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 071|Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)|Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa|PopART|HIV Prevention Trials Network|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|52500|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01900977||62860|
NCT01901796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00036912|Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT) Full Trial|Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT): Intervening Early to Improve Maternal and Family Well-being.||University of Alberta|No|Recruiting|January 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901796||62797|
NCT01901770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11115|The Parents in Appalachia Receive Education Needed for Teen Project|The Ohio State University Center for Population Health and Health Disparities Community Awareness, Resources and Education (CARE II): Project 4 The PARENT (Parents in Appalachia Receive Education Needed for Teens) Project|PARENT|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|624|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01901770||62799|
NCT01901783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0331|Ridge Augmentation Without Primary Closure|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Plus a Barrier Membrane With and Without Primary Closure||University of Louisville|No|Not yet recruiting|September 2013|||May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901783||62798|
NCT01894659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130117|Oral Sucrose Versus Glucose for Procedural Pain in Premature Neonates|Oral Sucrose Versus Glucose for Procedural Pain in Premature Neonates||Loma Linda University|Yes|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|93|||Both|N/A|7 Days|No|||March 2016|March 1, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894659||63343|
NCT01894672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-053|BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation|A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894672||63342|
NCT01894919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_28E1|Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28|A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28||Novartis|No|Completed|June 2013|November 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|13||Actual|851|||Both|35 Months|12 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|June 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894919||63323|
NCT01891188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHNX-hNIRS-12-120|Using Near-infrared Spectroscopy (NIRS) Monitor to Noninvasively Evaluate Hepatic Venous Saturation|Using Near-infrared Spectroscopy (NIRS) Monitor to Noninvasively Evaluate Hepatic Venous Saturation||Phoenix Children's Hospital|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|All pediatric patients (0-18yrs) undergoing cardiac catheterization by the participating        interventional cardiologist at Phoenix Children's Hospital will be recruited for this        investigation|June 2013|June 29, 2015|November 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01891188||63609|
NCT01890902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-110-002|Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee|A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee||Imprimis Pharmaceuticals, Inc.||Withdrawn|August 2013|||June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|35 Years|N/A|No|||November 2013|November 8, 2013|June 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01890902||63631|
NCT01894191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalinTCGH-hsieh-03|Comparing the Adenoma Detection Rate With Air Insufflation, Water Immersion and Water Exchange|A Randomized, Controlled Trial Comparing the Adenoma Detection Rate With Air Insufflation, Water Immersion and Water Exchange During Colonoscopy||Dalin Tzu Chi General Hospital|Yes|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|450|||Both|20 Years|80 Years|No|||December 2014|December 28, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01894191||63379|
NCT01894204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.161 - PADIS HTP|Determine the Frequency of a HTPPE in 5 Years (± on 1 Year) After a First Episode of Idiopathic Pulmonary Embolism.|Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study " PADIS HTP "|PADIS-HTP|University Hospital, Brest|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|374|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01894204||63378|
NCT01900574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101676|A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis|A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|Yes|Active, not recruiting|August 2013|August 2023|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|2 Years|17 Years|No|||February 2016|February 26, 2016|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01900574||62891|
NCT01892033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10N17|A Pilot Exercise Study for PTSD in Women Veterans|Aerobic Exercise: Feasibility and Safety Assessment in Women Veterans With PTSD (AESAP)||North Texas Veterans Healthcare System|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|50 Years|No|||September 2014|September 23, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01892033||63544|
NCT01891981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1143|Phase I/II Study of Moxetumomab|Phase I/II Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2013|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891981||63548|
NCT01891695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16766|OPSCC N0 Nodal Control With Reduced IMRT|A Pilot Single Arm Study of Intensity Modulated Radiation Therapy Elective Nodal Dose De-Escalation for HPV-Associated Squamous Cell Carcinoma of the Oropharynx||University of Virginia|Yes|Suspended|June 2013|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|June 24, 2013||No|To allow us to conduct investigations of recent advances in other treatment modalities|No||https://clinicaltrials.gov/show/NCT01891695||63570|
NCT01893073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW-LBP|Mindful Walking in Low Back Pain|Effectiveness of a a Mindful Walking Program in Patients With Chronic Low Back Pain - a Randomized Controlled Trial|MW-LBP|Charite University, Berlin, Germany||Completed|June 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893073||63465|
NCT01893658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006797|Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)|Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)||Mayo Clinic|Yes|Recruiting|June 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893658||63420|
NCT01893918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM147/10|Assessment of Severity and Prognosis in Elderly Patients With COPD and Complex Chronic Comorbidities|Assessment of Severity and Prognosis in Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD) and Complex Chronic Comorbidities||University of Modena and Reggio Emilia|Yes|Recruiting|March 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood sampling for complete blood count, fasting glucose, bilirubin, creatinine, blood urea,      uric acid, electrolytes (magnesium, sodium, potassium, chloride), total cholesterol,      cholesterol high-density lipoprotein (HDL), triglycerides, serum glutamic oxaloacetic      transaminase, serum glutamic pyruvic transaminase, gamma-glutamyl transpeptidase, creatine      phosphokinase, hemoglobin A1c, serum insulin. Urine sampling for microalbuminuria and urine      creatinine. Measurement of arterial blood gas. Blood sampling for biomarkers (NT-proBNP,      high-sensitive C-Reactive Protein, IL-1β, IL-6).|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|100 patients older than 65 years with diagnosis of COPD, current smokers or ex-smokers        with more than 20 pack/years, in stable condition.|July 2013|July 2, 2013|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01893918|3 Years|63400|
NCT01891227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_MBC-6|Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer|Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial|MBC-6|Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Active, not recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||May 2015|May 20, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01891227||63606|
NCT01892501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2012-01|Feasability Study on the Contribution of Guided Puncture With Echoendoscopy|Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy in Evaluation of Hypermetabolic Lymphadenopathy Mediastinum Lower, Rear and Middle, Detected in PET-CT to 18 FDG (PET)|APOGEE|Institut Bergonié|No|Recruiting|January 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01892501||63508|
NCT01899547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0925-0586|Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum|Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum : A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group, Non-Inferiority Clinical Trial|LASRE|Fujian Medical University|Yes|Recruiting|August 2013|December 2021|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1150|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01899547||62969|
NCT01900379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310|PAC-IC-SAOS Obstructive Sleep Apnea Syndrome and Ventricular Function|Impact of the Obstructive Sleep Apnea Syndrome Treatment and Ventricular Function in Heart Failure Patients Undergoing Coronary Artery Bypass Surgery or Other Coronary Reperfusion|PAC-IC-SAOS|University Hospital, Grenoble|Yes|Recruiting|July 2013|April 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|90 Years|No|||March 2016|March 4, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01900379||62906|
NCT01901510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009897|Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep|Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep||Mayo Clinic|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|21|||Both|50 Years|75 Years|No|||March 2015|March 2, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01901510||62819|
NCT01902329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN33A-001|A Safety Study of SGN-CD33A in AML Patients|A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia||Seattle Genetics, Inc.|No|Enrolling by invitation|July 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902329||62756|
NCT01902069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P50AA012870|The Gut-brain Axis in Food Reward and Alcohol Consumption|The Gut-brain Axis in Food Reward and Alcohol Consumption||Yale University|Yes|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|29|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902069||62776|
NCT01894685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36557.041.11|Mesalazine Effects in Sporadic Colorectal Adenoma Patients|Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas||UMC Utrecht|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|50 Years|75 Years|No|||December 2015|December 6, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894685||63341|
NCT01894698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1002-P001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||February 22, 2016|July 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894698||63340|
NCT01891422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGC75|Longitudinal Studies of the Glycoproteinoses|Longitudinal Studies of the Glycoproteinoses||Greenwood Genetic Center|No|Recruiting|August 2009|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|When applicable, plasma, white cells, fibroblasts, urine.|Both|N/A|N/A|No|Non-Probability Sample|Individuals of any age diagnosed with any of the nine glycoproteinoses will be enrolled.|September 2014|September 9, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01891422||63591|
NCT01892254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS-INK|Incretin Effect in PCOS Women|Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom før og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance)||University Hospital, Gentofte, Copenhagen|No|Recruiting|June 2013|August 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01892254||63527|
NCT01891487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATSBROW-001|Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows|Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Eyebrow Hypotrichosis: A Phase 4 Investigator Initiated Study||ATS Clinical Research|No|Completed|May 2013|January 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891487||63586|
NCT01891448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV008|Web-based Tool to Improve Reporting of Randomized Controlled Trials|Impact of an Intervention Using a Web-based Tool to Improve the Reporting of Randomized Controlled Trials|WebCONSORT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|300|||Both|N/A|N/A|No|||May 2013|March 20, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01891448||63589|
NCT01891708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHZL02|VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer|VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer||Huazhong University of Science and Technology|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|peripheral blood|Both|18 Years|75 Years|No|Probability Sample|advanced non small cell lung cancer patients with brain metastatic disease|July 2013|July 2, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01891708|2 Months|63569|
NCT01892488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol-Code: 002/2012|Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD|Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study||Hannover Medical School|Yes|Recruiting|June 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|980|||Both|40 Years|N/A|No|||September 2015|September 25, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892488||63509|
NCT01893671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#6612|Corneal Power, Astigmatism, and Aberration Changes After LASIK|Observational Study of Corneal Power, Astigmatism, and Aberration Changes After LASIK||Oregon Health and Science University||Recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing routine LASIK for the correction of myopia or hyperopia with or        without astigmatism|April 2015|April 21, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893671||63419|
NCT01894750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-02126|Building Skill in Heart Failure Self-care: A Community Based Intervention|Building Skill in Heart Failure Self-Care: A Community Based Intervention||New York University School of Medicine|No|Completed|June 2010|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|50 Years|N/A|No|||April 2015|April 14, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894750||63336|
NCT01891721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-015-12F|Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia|Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia||VA Office of Research and Development|No|Recruiting|November 2013|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|25 Years|65 Years|No|||March 2016|March 17, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01891721||63568|
NCT01899859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-020|Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis|A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH)With Advanced Hepatic Fibrosis||Galectin Therapeutics Inc.|Yes|Completed|July 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|74 Years|No|||June 2014|February 19, 2015|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01899859||62945|
NCT01899885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA-37855|Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course|Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course|AHA|Hvidovre University Hospital|Yes|Completed|June 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899885||62943|
NCT01900678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLIC-USA|A Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System|VLIC-USA: A Single-Center Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System||VytronUS, Inc.|Yes|Completed|June 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||June 2015|June 26, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01900678||62883|
NCT01901276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL3307|Effects of Gastric Acid on Colonic Microbiome|The Effects of Gastric Acid Suppression on the Colonic Microbiome||Columbia University|Yes|Completed|August 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901276||62837|
NCT01901289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004|Zilver® PTX® V Clinical Study|Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study||Cook||Active, not recruiting|August 2013|April 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901289||62836|
NCT01901523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCH/13/SFI/Str|Coordinated Assessment of Notifications of Trials Containing Overt Published Errors|Phase II Study of Response of Medical Journal Editorial Boards to Notification of Serious Discrepancies in Published Clinical Trials in Human Patients.||Imperial College London|Yes|Not yet recruiting|June 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 16, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901523||62818|
NCT01901536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH64125-01A2|Family Foundations Coparenting Pilot Trial|Promotion of Coparenting During Family Formation Period|FF1|Feinberg, Mark, Ph.D.|No|Completed|December 2002|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|497|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901536||62817|
NCT01901549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIRD|Renal Denervation in Patients After Acute Coronary Syndrome|Renal Denervation in Patients After Acute Coronary Syndrome|ACSRD|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01901549||62816|
NCT01902108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON-POBPC|Added Value of Local Clonidine for Spine Postoperative Pain Control, in Addition to Bupivacaine|Randomized Double-blind Trial Comparing the Post-operative Analgesic Efficacy of Local Wound Infiltration With Bupivacaine Alone to Bupivacaine With Clonidine in Posterior Spine Surgeries||St Joseph University, Beirut, Lebanon|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|72 Years|No|||December 2015|December 6, 2015|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01902108||62773|
NCT01902576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2710.00|Chronic GVHD Response Measures Validation|Chronic GVHD Response Measures Validation||Fred Hutchinson Cancer Research Center|Yes|Recruiting|June 2013|||June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|368|Samples With DNA|Whole blood samples (30mL) processed for peripheral blood mononuclear cells (PBMC), plasma,      and granulocytes.|Both|7 Years|99 Years|No|Non-Probability Sample|Patients starting initial or subsequent therapy for chronic Graft vs Host Disease.|November 2015|November 19, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902576||62737|
NCT01890915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAN-12-04|Body Temperature in Persons With Tetraplegia When Exposed to Heat|Core Temperature During Heat Exposure in Persons With Tetraplegia||James J. Peters Veterans Affairs Medical Center|No|Completed|May 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|21|Samples With DNA|Venous blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 subjects with tetraplegia (SCI, C4-T1), ages 18-65 years old and 10 age- and        gender-matched, able-bodied controls will be accepted for participation.|February 2016|February 4, 2016|June 27, 2013||No||No|November 24, 2015|https://clinicaltrials.gov/show/NCT01890915||63630|
NCT01891682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-022012-035|Methionine Metabolism in Parenterally Fed Pediatric Sepsis|Methionine Metabolism in Parenterally Fed Critically Ill Children||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2012|April 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Blood Samples.|Both|1 Month|19 Years|No|Non-Probability Sample|Septic pediatric patients: A total of 45 critically ill children age 1 month-19 years with        diagnosis of sepsis, as defined by the International Sepsis Consensus Conference.|June 2013|June 28, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01891682||63571|
NCT01891942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRD-566|Influence of Trigger Threshold on Controlled Twitch Mouth Pressure|Influence of Trigger Threshold on Controlled Twitch Mouth Pressure||Guangzhou Institute of Respiratory Disease|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|30|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|July 2, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01891942||63551|
NCT01891955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFV-ADI-2013-01|Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial|Alimentation and Diabetes in Lanzarote - ADILAN: a Randomized Cross-over Pilot Trial Comparing a Healthy Diet With Grains and Dairy to a Healthy Diet Without Grains and Dairy in Patients With Type 2 Diabetes|ADILAN|Lund University||Completed|November 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891955||63550|
NCT01891253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIGR_MA|Inert Gas Rebreathing in Ventilated Patients|Feasibility of the Non-invasive Determination of Cardiac Output Using Inert Gas Rebreathing in Ventilated Patients|VIGR|Universitätsmedizin Mannheim|Yes|Recruiting|March 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|ventilated ICU patients|December 2015|December 1, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01891253||63604|
NCT01891266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110084|Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty|Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty: A Randomized Controlled Trial||University of Southern Denmark|No|Not yet recruiting|September 2013|September 2016|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|No|||June 2013|June 27, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01891266||63603|
NCT01891747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC NEU 1308|A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma|A Phase I/II Study of High-dose L-methylfolate in With Combination Temozolomide and Bevacizumab in Recurrent High Grade Glioma.||Vanderbilt-Ingram Cancer Center|Yes|Active, not recruiting|July 2013|March 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|June 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891747||63566|
NCT01891760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABH-Dermagraft-001-09|Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers|A Prospective, Multi-center, Longitudinal, Cohort Study of Dermagraft in Subjects With Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial|LTFU|Shire Regenerative Medicine, Inc.||Completed|May 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891760||63565|
NCT01892215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-08|Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad,|Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad. A Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|October 2012|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|839|||Female|N/A|N/A|No|||June 2013|June 30, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892215||63530|
NCT01892475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPRT/AGE/2010/20|TAKing Steps for Incentives|TAKing Steps for Incentives (TAKSI) - A Randomized Controlled Trial to Motivate and Sustain Physical Activity Using Financial Incentives|TAKSI|Duke-NUS Graduate Medical School|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|314|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892475||63510|
NCT01892761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 1013/02|MPA Pharmacokinetics in Renal Transplantation|THE PROFILE OF MYCOPHENOLIC ACID IN CONSECUTIVE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION:EFFECTS OF TIME AND CALCINEURIN-INHIBITORS||University of Sao Paulo General Hospital|No|Completed|September 2002|June 2005|Actual|March 2003|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|52|||Both|18 Years|65 Years|No|Probability Sample|Renal transplant recipients|June 2013|July 3, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01892761||63489|
NCT01893359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL-004|Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism|A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of LASIK With Cross-linking Performed With the KXL System and Photrexa ZD™ (Riboflavin Ophthalmic Solution) Compared to LASIK Alone for Hyperopia and Hyperopic Astigmatism||Avedro, Inc.|No|Active, not recruiting|August 2013|February 2016|Anticipated|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893359||63443|
NCT01894165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1101-MCD-101|Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects||Alexion Pharma GmbH|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|June 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01894165||63381|
NCT01894503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-0513|Safety and Performance of the Steroid-Releasing S8 Sinus Implant (S8 PK)|A Clinical Evaluation of the Safety and Performance of the Steroid-Releasing S8 Sinus Implant When Used in Post-Sinus Surgery Patients With Recurrent Sinus Polyps||Intersect ENT|Yes|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2015|July 15, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894503||63355|
NCT01890954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16890|Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents|Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents||University of Virginia|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|13 Years|18 Years|No|||January 2016|January 6, 2016|June 27, 2013|No|Yes||No|April 3, 2015|https://clinicaltrials.gov/show/NCT01890954||63627|
NCT01903655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chauvet PHRC IR 2009|Study of the Telomere-telomerase System and the Expression of Candidate Genes in the Leukocytes of Patients With Depressive Disorder: Search for Peripheral Markers of Somatic Stress|||Centre Hospitalier Universitaire Dijon||Recruiting|April 2010|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903655||62655|
NCT01900392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816917|Financial Incentives for Maintenance of Weight Loss|A Randomized Trial of Financial Incentives for Maintenance of Weight Loss||University of Pennsylvania|Yes|Completed|September 2013|February 2016|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|191|||Both|30 Years|80 Years|No|||February 2016|February 2, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01900392||62905|
NCT01900665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15136|Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo|Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo|EXPEDITION 3|Eli Lilly and Company|Yes|Active, not recruiting|July 2013|October 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2100|||Both|55 Years|90 Years|No|||April 2015|April 29, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900665||62884|
NCT01901302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-003|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain||Cubist Pharmaceuticals LLC|Yes|Terminated|July 2013|April 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|July 9, 2013|Yes|Yes|Sponsor decision due to lack of enrollment.|No|April 19, 2015|https://clinicaltrials.gov/show/NCT01901302||62835|Due to difficulties with enrollment, this study was terminated early.
NCT01901809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHH HFpEF 1|Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction|Randomized Evaluation of HFpEF Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial|ROPA-DOP|Johns Hopkins University|Yes|Recruiting|August 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|May 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901809||62796|
NCT01902082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCs in ARDS|Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome|Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome||Shaoxing Second Hospital|No|Recruiting|November 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||July 2013|July 14, 2013|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01902082||62775|
NCT01902095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KhanMK-2012|Clinical Effects of Tooth Powder on Gingivitis|Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis|Toothpowder|Sheikh Zayed Federal Postgraduate Medical Institute|No|Completed|November 2010|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|154|||Both|33 Years|40 Years|Accepts Healthy Volunteers|||May 2013|July 17, 2013|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01902095||62774|
NCT01902121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-178|Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge|A Phase 1, Open-label, Randomized, Crossover Clinical Trial in Healthy Normal Volunteers to Evaluate the Bioequivalence of 30 U TI Inhalation Powder Delivered by Gen2 Inhaler Using One 30 U Cartridge Versus a Combination of 10 U and 20 U Cartridges||Mannkind Corporation|No|Completed|August 2013|August 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902121||62772|
NCT01902381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 29113|CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy|A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|August 2013|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902381||62752|
NCT01902342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CES01|A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir|A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Pharmacokinetic Characteristics of Oseltamivir in Healthy Korean Volunteers|CES1|Seoul National University Hospital|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902342||62755|
NCT01902355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|modifiedSeldinger|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Central Venous Catheterization|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Central Venous Catheterization: Seldinger vs. Modified Seldinger Technique||Seoul National University Hospital|Yes|Completed|July 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|272|||Both|18 Years|80 Years|No|||July 2014|July 2, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902355||62754|
NCT01922570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 07-098|Economics of Diarrhoea in Intensive Care Unit|Economic Investigation of Diarrhoea During Nutritional Support in Intensive Care Unit Patients||University Hospital, Geneva|No|Completed|January 2012|April 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|305|||Both|18 Years|90 Years|No|||August 2013|August 11, 2013|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01922570||61207|
NCT01922882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD074267-01|Maternal HIV Disclosure to School Children: RCT of Family-based Intervention|Maternal HIV Disclosure to School Children: RCT of Family-based Intervention (Amagugu)|Amagugu|University of KwaZulu|Yes|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|465|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2014|December 7, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01922882||61183|
NCT01923142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-FOL1|Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo|Double Blind Within-Subject Controlled Study of Autologous Hair Follicle Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo||Centro Studi Gised|No|Terminated|January 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01923142||61163|
NCT01891214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00144-41|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease|F-IBDQ|Rennes University Hospital|Yes|Active, not recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with definite diagnosis of UC or CD for at least 6 months|March 2016|March 21, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01891214||63607|
NCT01902511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Hepatic Regeneration -001|A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.|||Institute of Liver and Biliary Sciences, India|No|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||February 2016|March 17, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902511||62742|
NCT01893372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0225|Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|October 2013|||October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01893372||63442|
NCT01893385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0160|Vitamin D Supplementation and the Immune Response|Impact of Vitamin D Supplementation on Immune Functions: Study in Subjects Aged Over 65 Years Vaccinated Against Influenza||University Hospital, Clermont-Ferrand||Terminated|June 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|37|||Both|65 Years|85 Years|No|||December 2015|December 22, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01893385||63441|
NCT01903057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065751|Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis|AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole|AZIVAL2|Emory University|Yes|Withdrawn|February 2014|July 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|July 15, 2013||No|As of November 2013, the security situation in rural Northern Mozambique is no longer suitable    for this clinical trial.|No||https://clinicaltrials.gov/show/NCT01903057||62701|
NCT01903070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/0594-LINARI|Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment|EFFECTS OF LINAGLIPTIN ON ACTIVE GLP-1 CONCENTRATIONS IN SUBJECTS WITH RENAL IMPAIRMENT||Profil Institut für Stoffwechselforschung GmbH|No|Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903070||62700|
NCT01903369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tenovus 13/7|Comparison of Intraneural and Extraneural Young's Modulus Using Shear Wave Elastography|Comparison of Intraneural and Extraneural Young's Modulus Using Shear Wave Elastography in Patients Undergoing Regional Anaesthesia||University of Dundee|No|Not yet recruiting|January 2014|January 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|48|||Both|16 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing routine ultrasound-guided regional anaesthesia for elective        orthopaedic surgery at Ninewells Hospital & Medical School, Dundee.|July 2013|July 16, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903369||62677|
NCT01899560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-2012-03 2012-A01160-43|ELASTANCE: Prospective Physiological Study of Lung Elastance in Recruitment and Derecruitment in Early Onset Mechanically Ventilated ARDS Patients|Prospective Physiological Study of Lung Elastance in Recruitment and Derecruitment in Early Onset Mechanically Ventilated Acute Respiratory Distress Syndrome (ARDS)Patients|ELASTANCE|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer||Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|80 Years|No|||April 2014|April 16, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899560||62968|
NCT01899573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3566|Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function|A Study of Percutaneous Left Ventricular Reshaping of Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve LV Function Using the Accucinch® System|LVRESTORESA|Guided Delivery Systems Inc.|No|Active, not recruiting|October 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01899573||62967|
NCT01901003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005171-16|Sedative Premedication: Efficacy On Patient Experience|SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE|PremedX|Assistance Publique Hopitaux De Marseille|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1200|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901003||62858|
NCT01901328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-004|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain||Cubist Pharmaceuticals LLC|Yes|Terminated|August 2013|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|July 9, 2013|Yes|Yes|Sponsor decision due to lack of enrollment.|No|April 19, 2015|https://clinicaltrials.gov/show/NCT01901328||62833|Due to difficulties with enrollment, this study was terminated early.
NCT01901822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0332|Root Coverage Comparing Suturing Techniques|Root Coverage With Acellular Dermal Matrix Using the Coronally Positioned Tunnel Technique Comparing Two Different Suturing Techniques.||University of Louisville|No|Not yet recruiting|September 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901822||62795|
NCT01902615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25313|An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection|Multicenter, Observational, Retrospective Study to Assess the Therapeutic Effectiveness of a Strategy of Induction With Enfuvirtide Within an Optimized Regimen of Antiretroviral Drugs (ARV) in Patients Infected With HIV-1 in Routine Clinical Practice||Hoffmann-La Roche||Completed|January 2001|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|58|||Both|18 Years|N/A|No|Probability Sample|Patients with HIV-1 infection having received induction therapy with Fuzeon and        antiretroviral drugs|March 2016|March 1, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902615||62734|
NCT01902654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joan02|Osteoarthritis Cardiovascular Risk Factors|Prevalence of Cardiovascular Risk Factors Between Patients With Knee or Hand Osteoarthritis||Hospital Parc Taulí, Sabadell|Yes|Recruiting|September 2013|||February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|490|||Both|50 Years|N/A|No|Probability Sample|Patients referred to the rheumatology outpatient for symptomatic hand or knee        osteoarthritis or soft tissue disease. Patients were referred by their primary care        physician, and all patients were visited in primary care assitance.|November 2013|February 9, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01902654||62731|
NCT01902368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000326|Celiac Disease Screening|A Prospective Trial of Celiac Disease Screening||Beth Israel Deaconess Medical Center|No|Terminated|September 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|14|||Both|18 Years|80 Years|No|||July 2015|July 28, 2015|July 15, 2013||No|No funding was obtained.|No||https://clinicaltrials.gov/show/NCT01902368||62753|
NCT01922583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922ATW02T(201302063MIPD)|AUY922 in Patient With Stage IV NSCLC|A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy|NSCLC|National Taiwan University Hospital|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|20 Years|N/A|No|||December 2014|December 25, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01922583||61206|
NCT01922895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW_092012-012|Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis|Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis|NTAH-Mod|University of Texas Southwestern Medical Center|Yes|Recruiting|October 2013|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|130|||Both|21 Years|70 Years|No|||June 2015|June 23, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01922895||61182|
NCT01923155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE|Safety & Effectiveness of Nurse Performed Colonoscopies Under Supervision|Safety & Effectiveness of Nurse Performed Colonoscopies Under Supervision: A Randomized Controlled Study in Asia (NE Study)||Chinese University of Hong Kong||Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|731|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01923155||61162|
NCT01923441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-21|Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth and Adolescents Athletes.|Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth and Adolescents Athletes.||ElMindA Ltd|No|Completed|August 2013|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|||Both|10 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Up to 300 athletes from Nazareth Academy, Deerfield High School and the Deerfield young        warriors program athletes, from both genders, aged 10-19 years|August 2013|April 8, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923441||61140|
NCT01890928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-072010-051|Gluconeogenesis Rates and Its Precursors in Pediatric Sepsis|Gluconeogenesis Rates and Its Source in Critically Ill Adolescents||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2011|October 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|None Retained|Blood and urine samples.|Both|5 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Septic pediatric subjects: A total of 45 critically ill children age 5-19 years with        diagnosis of sepsis, as defined by the International Sepsis Consensus Conference.        Healthy subjects: A total of 30 healthy adolescents 13-19 years matched for age, gender,        Tanner and BMI to serve as controls. A Dexa scan will be obtained to determine lean body        mass.|June 2013|June 27, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01890928||63629|
NCT01890941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1205|A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes|||Kissei Pharmaceutical Co., Ltd.||Completed||||March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study|3||||||Both|20 Years|N/A||||October 2015|October 16, 2015|June 27, 2013||||No||https://clinicaltrials.gov/show/NCT01890941||63628|
NCT01891994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130133|Extended Dosing With Eltrombopag for Severe Aplastic Anemia|Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|May 2020|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|100 Years|No|||March 2016|March 5, 2016|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891994||63547|
NCT01902797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU 1303|Malaria Survey in the Tak Province Refugee Camps|Malaria Survey in the Tak Province Refugee Camps||University of Oxford|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|908|||Both|12 Months|N/A|Accepts Healthy Volunteers|||March 2015|March 12, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01902797||62721|
NCT01902784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040209|The Surrogate Project (Surrogate Storytelling)|Surrogate Project - Aim 2: Pilot Randomized Controlled Trial||University of Pittsburgh|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|115|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902784||62722|
NCT01903382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zirkadianest|Circadian, Weekly and Seasonal Variability of Postoperative Mortality and Morbidity (Zirkadianest)|The Association Between Circadian, Weekly, and Seasonal Effects and Time of Surgery on Postoperative Morbidity and Mortality of Patients (Zirkadianest)||Charite University, Berlin, Germany|No|Completed|January 2006|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|247506|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing general anesthesia between January 2006 and December 2013. They        are followed up until hospital discharge.|November 2014|November 7, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01903382||62676|
NCT01903395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP332-032|Risk-adapted Screening in First-degree Relatives of Patients With Colorectal Cancer|Nurse-led Colon Cancer Risk Counseling for First-degree Relatives to Enhance Use of Colonoscopy|FAMKOL|Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|492|||Both|45 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903395||62675|
NCT01903668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ducoroy PHRC IR 2012|Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis|||Centre Hospitalier Universitaire Dijon||Withdrawn|April 2012|||April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Blood samples used for this study come from a collection being created as part of the        research entitled "The combined determination STREM-1/PCT/CD64 it allows the diagnosis of        sepsis in intensive care" - No. IDRCB 2009 - A00870-57 and led by Professor Sebastian        GIBOT CHU Nancy.|July 2013|July 17, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903668||62654|
NCT01903681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDR1219|Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances|Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances||Neurim Pharmaceuticals Ltd.|Yes|Completed|March 2013|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|2 Years|17 Years|No|||June 2013|April 3, 2014|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903681||62653|
NCT01901029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGFPmrhs|Male Reproductive Health of Floating Population: a Large-Scale Survey in Dongguan|Prevalence of Reproductive Health Problems and Their Social, Psychological and Physical Association Among Men in Floating Population: a Large-Scale Cross-Sectional Study in Dongguan City||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2013|September 2013|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|3100|||Male|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|male workers in several towns of Dongguan city|August 2013|August 9, 2013|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01901029||62856|
NCT01901601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00009282|LALAK for Opacities|Randomized Clinical Trial of OCT-Guided Laser-Assisted Lamellar Anterior Keratoplasty in Adults for Stromal Opacities||Oregon Health and Science University|No|Recruiting|July 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901601||62812|
NCT01901562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3900|Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge|Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge||Columbia University|No|Recruiting|September 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||August 2015|August 30, 2015|July 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901562||62815|
NCT01901575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00800|Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia|Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia|IVPCA|New York University School of Medicine|No|Completed|July 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||May 2015|May 9, 2015|April 16, 2013||No||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01901575||62814|
NCT01901835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13037|Media Diversion in Improving Quality of Life in Patients With Recurrent Gynecologic Cancers Receiving Chemotherapy|The Effects of a Media Diversion on Quality of Life in Patients Receiving Chemotherapy for Recurrent Gynecologic Cancers||University of Wisconsin, Madison|Yes|Recruiting|February 2014|October 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|66|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901835||62794|
NCT01902914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE551268|Effectiveness of P02 Digital Hearing Aids|Effectiveness of NECTEC Model, Body-worn, Digital Hearing Aids and Cost of Screening and Hearing Aids Service in Elders|P02|Khon Kaen University|Yes|Recruiting|October 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|60 Years|90 Years|No|||April 2014|April 17, 2014|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01902914||62712|
NCT01902940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFDN-IBM-2013|Natural History in CCFDN and IBM Syndromes|Retrospective Cohort Study Assessing the Natural Course in Congenital Cataract Facial Dysmorphism Neuropathy Syndrome (CCFDN) and Sporadic and Hereditary Inclusion Body Myopathies (IBM)||Ludwig-Maximilians - University of Munich|No|Completed|June 2013|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|||Both|N/A|N/A|No|Non-Probability Sample|Patients with CCFDN and IBM|August 2015|August 31, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01902940||62710|
NCT01902628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28261|OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Stages 3 & 4 Not on Dialysis|An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERA® (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA).||Hoffmann-La Roche||Active, not recruiting|July 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|437|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease (CKD) not on dialysis with renal anemia (CKD Stages 3        & 4) initiated on Mircera therapy|March 2016|March 1, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902628||62733|
NCT01902901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UM1HG007292-01|Clinical Implementation of Carrier Status Using Next Generation Sequencing|Clinical Implementation of Carrier Status Using Next Generation Sequencing|NextGen|Kaiser Permanente|No|Recruiting|January 2014|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|400|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01902901||62713|
NCT01922908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMCIS|Mesenchymal Stromal Cells for Ischemic Stroke|SAfety of Mesenchymal Stromal Cells for Ischemic Stroke|SAMCIS|The University of Texas Health Science Center, Houston|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|83 Years|No|||December 2015|December 7, 2015|August 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01922908||61181|
NCT01923168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719A2201|Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women|A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer||Novartis|No|Recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|360|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923168||61161|
NCT01923454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK001|Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure|Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure||Siriraj Hospital|Yes|Completed|December 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01923454||61139|
NCT01902277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01535|ICU Delirium: a One-week Snapshot of Burden Across the Eastern UK Region|ICU Delirium: a One-week Snapshot of Burden Across the Eastern UK Region||Papworth Hospital NHS Foundation Trust|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|225|||Both|18 Years|N/A|No|Probability Sample|Adult critically ill patients across eastern UK region|July 2013|July 17, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902277||62760|
NCT01902524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002155|Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain|Evaluation in Efficacy and Safety of Fentanyl-TTS (Durogesic® D-Trans) for Treatment of Chronic Pain||Janssen Korea, Ltd., Korea|No|Completed|October 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|19 Years|N/A|No|||August 2014|August 27, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902524||62741|
NCT01903694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JOUVE PHRC K 2009|Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma|||Centre Hospitalier Universitaire Dijon||Completed|March 2010|||November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|474|||Both|18 Years|N/A|No|||July 2013|May 12, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903694||62652|
NCT01903707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT001|Cognitive Remediation in Schizophrenia|Cognitive Remediation in Schizophrenia: Effects on Brain Structure, Brain Function and Social Outcome.||University of Dublin, Trinity College|No|Recruiting|May 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01903707||62651|
NCT01903083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-026A|Chemoimmunotherapy and Radiation in Pancreatic Cancer|Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.|CRIT|Providence Health & Services|No|Active, not recruiting|July 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|July 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903083||62699|
NCT01899898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMAD|Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy|Phase 2/3 Study of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy|SMAD|Lady Hardinge Medical College|Yes|Active, not recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|2 Years|14 Years|No|||July 2013|July 11, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01899898||62942|
NCT01899911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0024|Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)|Pulse Oximeter Response TO Multiple Levels Of Stable Hypoxia||LifeWatch Services, Inc.|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|23 Years|33 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|July 7, 2013|Yes|Yes||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01899911||62941|Not applicable for this trial.
NCT01900405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPDex|Intranasal Dexmedetomidine Sedation for Pediatric CT Imaging|Intranasal Dexmedetomidine Sedation for Pediatric Computerized Tomography Imaging||University of Sao Paulo|No|Recruiting|April 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|1 Month|15 Years|No|Non-Probability Sample|The University Hospital of University of Sao Paulo is a secondary teaching hospital. The        Pediatric Emergency Department has over 6,000 consultations per month, mainly in children        without underlying diseases. Respiratory diseases are the leading causes of hospital        admission. During the study period, any children presented to the emergency department        with indication for a CT scanning will be recruited for IN dexmedetomidine, respecting the        exclusion criteria displayed below.|July 2013|July 11, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01900405||62904|
NCT01900119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130161|A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia|A Description of the Oral Microbiome of Patients With Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|39|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900119||62925|
NCT01900691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-012|Removal of the Evolution® Esophageal Stent - Fully Covered|Clinical Investigation to Evaluate Removal of the Evolution® Esophageal Stent - Fully Covered|CLARITY|Cook||Recruiting|September 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||December 2015|February 9, 2016|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900691||62882|
NCT01901315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPQ-0782/11|Psychiatric Care Via Videoconferencing|New Information and Communication Technologies in the Delivery of Mental Health Treatment: Psychiatric Care Via Videoconferencing||University of Sao Paulo General Hospital|Yes|Completed|March 2012|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|107|||Both|18 Years|55 Years|No|||July 2013|May 21, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901315||62834|
NCT01901861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005660-98|Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes|Effect of a Single Dose of the DPP-4 Inhibitor on Islet Function After Igestion of a Standardized Mixed Meal in Subjects With Type 2 Diabetes||Lund University|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|12|||Male|20 Years|75 Years|No|||March 2015|December 14, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01901861||62792|
NCT01901874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS 10-08|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||January 6, 2016|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901874||62791|
NCT01901588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00556|Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery|Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery||New York University School of Medicine|No|Active, not recruiting|March 2012|March 2016|Anticipated|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|63|||Both|1 Year|7 Years|No|||February 2016|February 8, 2016|April 17, 2013||No||No|February 8, 2016|https://clinicaltrials.gov/show/NCT01901588||62813|
NCT01902134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-TRA-05|Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride|A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain After Elective Unilateral Total Hip Arthroplasty|DAVID-art|Menarini Group|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|641|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|July 15, 2013||No||No|February 6, 2015|https://clinicaltrials.gov/show/NCT01902134||62771|
NCT01903252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0503|TP05 for the Treatment of Mild to Moderate Active UC|A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/d for the Treatment of Active Ulcerative Colitis|Precision-UC|Tillotts Pharma AG|No|Active, not recruiting|July 2013|April 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01903252||62686|
NCT01902927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVD-20948|Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction|Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction : a Pilot Study|DVD|Laval University||Not yet recruiting|July 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Anticipated|10|||Both|50 Years|80 Years|No|||July 2013|July 16, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01902927||62711|
NCT01903265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F202|BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)|A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia|BESTFIT|Tonix Pharmaceuticals, Inc.|No|Completed|September 2013|November 2015|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903265||62685|
NCT01922921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7866|Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy|Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy||University of Washington|No|Suspended|February 2014|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 1, 2013|Yes|Yes|(temporarily not enrolling patients)|No||https://clinicaltrials.gov/show/NCT01922921||61180|
NCT01923181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3790|Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes|Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|632|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923181||61160|
NCT01923194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000055|Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females|A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate|Compass|Ferring Pharmaceuticals|No|Completed|October 2013|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Female|20 Years|39 Years|No|||August 2015|August 20, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923194||61159|
NCT01923207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-2930-01|A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects|A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects||Dyax Corp.|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|August 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01923207||61158|
NCT01923467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50CA101451|Project Quit: Positive vs. Negative Offers of an Online Stop Smoking Program|Project Quit: Positive vs. Negative Offers of an Online Stop Smoking Program||University of Michigan|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|767|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|May 29, 2015|August 13, 2013||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01923467||61138|
NCT01923480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-12-0012|Dosing Study of Amino Acids in Seriously Ill Patients|Determination of the Optimal Infusion Rate of Amino Acids in Seriously Ill Patients||Baxter Healthcare Corporation|No|Terminated|July 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|16|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01923480||61137|
NCT01903096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP105162012|Treating Emotional Disorders in Primary Care With Psychological Techniques|A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial|PsychPC|Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|1126|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01903096||62698|
NCT01903109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEVI-C30-PVFD-1|Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions||Roxane Laboratories|No|Completed|February 2009|February 2009|Actual|February 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01903109||62697|
NCT01903408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klaus Tschira 00.153.2009|Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment|Prostate and Whole Pelvis Irradiation With Integrated-boost Intensity-modulated Radiotherapy (IMRT) After Neoadjuvant Antihormonal Treatment - a Phase II Trial|PLATIN|Heidelberg University|No|Recruiting|May 2009|September 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Male|2 Years|5 Years|Accepts Healthy Volunteers|||December 2015|December 5, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01903408||62674|
NCT01903421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6122-A|Inhalational Anesthesia and Precipitation of Dementia: is There a Link?|Inhalational Anesthesia and Precipitation of Dementia: is There a Link? A Prospective, Multicenter, Randomized, Controlled Clinical Trial Comparing Two Different Anesthetic Techniques in Elderly Patients||University Health Network, Toronto|No|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|65 Years|N/A|No|||July 2015|July 29, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01903421||62673|
NCT01899586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019806|Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly|Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly|FIT|Duke University|No|Completed|September 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 28, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899586||62966|
NCT01899599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXMab25201|PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer|A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma||Glycotope GmbH|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|N/A|No|||February 2015|February 26, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899599||62965|
NCT01899612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/10|Vaginal Inflammation Markers in Postmenopausal Women With and Without Symptoms of Vaginal Inflammation|Vaginal Cytokines in Postmenopausal Women With Symptoms of Vulvovaginal Irritation||University Hospital Inselspital, Berne|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|16|Samples Without DNA|vaginal lavage, serum|Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects will be recruited at the menopause center, Inselspital Berne.|July 2013|July 10, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01899612||62964|
NCT01900418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2321|Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy|Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|August 2013|May 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|80|||Female|21 Years|99 Years|No|||November 2015|November 30, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900418||62903|
NCT01900717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bedenne PHRC K 2010.|Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)|Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma|Prodige20|Centre Hospitalier Universitaire Dijon||Completed|April 2011|||July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|102|||Both|75 Years|N/A|No|||July 2013|May 12, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900717||62880|
NCT01900704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-DB4-201301|Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4|A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia|DB4|Serenity Pharmaceuticals, Inc.|No|Completed|August 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|891|||Both|50 Years|95 Years|No|||November 2015|November 23, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900704||62881|
NCT01900730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0930|Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter|Randomized Phase II Double Blind Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2014|||August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900730||62879|
NCT01901016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELHIV-13|Relaxation, Depressive Symptoms, Quality of Life, Immunological and Virological Status in People Living With HIV: a Pilot Study|Pilot Study to Determine the Feasibility, Acceptability and Preliminary Effects of Relaxation as a Nursing Intervention for Depressive Symptoms, Quality of Life, Immune Status and Viral Load in People Living With HIV||Université de Montréal|No|Recruiting|June 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901016||62857|
NCT01901055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK096028-02|Diabetes-Obstructive Sleep Apnea Treatment Trial|The Effect of Treatment of Obstructive Sleep Apnea on Diabetes Self Management and Glycemic Control|DOTT|University of Pittsburgh|Yes|Recruiting|July 2013|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01901055||62854|
NCT01902160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01273|Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma||National Cancer Institute (NCI)|No|Completed|September 2013|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902160||62769|
NCT01902173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01320|GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer|Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer||National Cancer Institute (NCI)|No|Suspended|July 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|July 15, 2013|Yes|Yes|Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics|No||https://clinicaltrials.gov/show/NCT01902173||62768|
NCT01901848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-018-12F|CPT and Smoking Cessation|Combined Smoking Cessation and Cognitive Processing Therapy for PTSD||VA Office of Research and Development|No|Recruiting|December 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901848||62793|
NCT01902394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2720|The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses|The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses||Tufts University|No|Completed|June 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|108|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01902394||62751|
NCT01902641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK001|Muscle Relaxation for Short Procedures|Comparing Intubating Conditions and Patient Satisfaction Using Succinylcholine or Low-dose Rocuronium for Rigid Bronchoscopy: A Randomized Study||Dr. Horst Schmidt Klinik GmbH|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01902641||62732|
NCT01902953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02-05|Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)|Prospective, Open-Label, Ex Vivo Comparison Study of Lymphoseek® and Vital Blue Dye (VBD) as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) Patients' Excised Colon w/ Abdominal Lymphatic Bed||Maimonides Medical Center|No|Active, not recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|85 Years|No|||August 2015|August 12, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01902953||62709|
NCT01903278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAWIN-002-2|Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C|Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C||Beijing Kawin Technology Share-Holding Co., Ltd.|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|719|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903278||62684|
NCT01903902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB-ONLY|Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries|The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY)||Gachon University Gil Medical Center|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|19 Years|N/A|No|||July 2013|July 18, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903902||62636|
NCT01923493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tuina-13|Tuina for Patients With Chronic Neck Pain|Chronic Neck Pain: a Randomized Controlled Trial in Patients With Chronic Neck Pain Comparing Tuina vs. no Intervention Waiting List|tuina|Charite University, Berlin, Germany|No|Completed|August 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|No|||February 2015|February 6, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01923493||61136|
NCT01923506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13257|Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery|Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study||City of Hope Medical Center|Yes|Recruiting|October 2013|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|19 Years|N/A|No|||February 2016|February 15, 2016|August 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01923506||61135|
NCT01923779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG002a|ToleroMune Grass Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit||Circassia Limited|No|Completed|May 2013|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|163|||Both|18 Years|65 Years|No|Non-Probability Sample|Subject previously randomised in study TG002 and completed all dosing visits and the PTC|November 2013|November 25, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01923779||61115|
NCT01924065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ozaydin291|Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation|Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods|AFTER-CV|Suleyman Demirel University|No|Recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||October 2015|October 17, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01924065||61093|
NCT01892046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX5422-CLN1-006|Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors|A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.||Esanex Inc.|No|Recruiting|November 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892046||63543|
NCT01902823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-86E|Effect of Cancer Nurse Navigators on Patient Outcomes|Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes||University of Wisconsin, Madison|No|Terminated|November 2011|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 29, 2011||No|Clinicians were not offering the study to eligible potential subjects.|No||https://clinicaltrials.gov/show/NCT01902823||62719|
NCT01902836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-11-06|Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis|Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.||National Polytechnic Institute, Mexico|Yes|Completed|August 2011|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|2 Years|17 Years|No|||July 2013|July 26, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01902836||62718|
NCT01903122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEVI-C30-PVFS-1|Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions||Roxane Laboratories|No|Completed|February 2009|February 2009|Actual|February 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01903122||62696|
NCT01903135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AGIR-02|Prevalence of Obesity Hypoventilation Syndrome|Prevalence of Obesity Hypoventilation Syndrome in Subjects With Obesity Referred to Clinical (Medical Analysis) Laboratories for Regular Follow-up|BIO-OHS|AGIR à Dom|No|Completed|September 2013|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|1004|||Both|18 Years|N/A|No|||March 2015|June 22, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01903135||62695|
NCT01899638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115380|Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.|A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.||GlaxoSmithKline|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01899638||62962|
NCT01903720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APMA-OZU-01-01|A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion||COBALT|Allergan|No|Completed|July 2013|March 2015|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903720||62650|
NCT01903733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871040|Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008|An Open-Label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008||Pfizer||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 16, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01903733||62649|
NCT01903746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quenot PHRC IR 2008|Epidemiology of Septic Shock in Medical or Polyvalent ICU in the North-East Region of France|||Centre Hospitalier Universitaire Dijon||Terminated|October 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1495|||Both|N/A|N/A|No|Non-Probability Sample|Patients in septic shock|July 2013|July 17, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903746||62648|
NCT01900743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGO-SARC-1214|Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma|Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial|REGO-SARC|Centre Oscar Lambret|Yes|Recruiting|June 2013|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01900743||62878|
NCT01901042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|marianan|Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms|Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms. A Randomized, Double-blind, Placebo-controlled Trial||Federal University of Mato Grosso do Sul|Yes|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Male|50 Years|80 Years|No|||July 2013|July 13, 2013|May 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01901042||62855|
NCT01901341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-005|The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain||Cubist Pharmaceuticals LLC|Yes|Terminated|July 2013|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|July 9, 2013|Yes|Yes|Due to difficulties with enrollment, the study was terminated early.|No|April 19, 2015|https://clinicaltrials.gov/show/NCT01901341||62832|Due to difficulties with enrollment, the study was terminated early.
NCT01902186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALBAT|Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir|Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density|RALBAT|University of Turin, Italy|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|80 Years|No|||December 2014|December 2, 2014|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01902186||62767|
NCT01902147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-141-SDR|Postoperative Quality Recovery Scale (PQRS)|Measuring Recovery in Patients Undergoing Major Abdominal, Thoracic, and Arthroplasty Surgery Using an Enhanced Recovery Program.||McGill University Health Center|No|Completed|November 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing elective major abdominal, thoracic, and arthroplasty surgery|September 2015|September 21, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902147||62770|
NCT01902407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001-Dymosa|Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome|Dynamic Computational Modeling of Obstructive Sleep Apnea in Down Syndrome|DYMOSA|Children's Hospital Medical Center, Cincinnati|No|Recruiting|March 2011|August 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|73|||Both|1 Year|21 Years|No|Non-Probability Sample|Children and young adults with Down syndrome and OSA|September 2015|September 25, 2015|May 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902407||62750|
NCT01902667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0186 CCR3992|Preoperative Imaging in Retroperitoneal Sarcoma|Preoperative Imaging in Retroperitoneal Sarcoma|PIRS|Institute of Cancer Research, United Kingdom|No|Recruiting|July 2013|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|80 Years|No|Probability Sample|Patients with retroperitoneal sarcoma randomised for preoperative radiotherapy plus        surgery versus surgery alone.|February 2016|February 3, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01902667||62730|
NCT01902680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 URO 06|Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.|Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.|CURIEFOCALE|Institut Claudius Regaud|No|Recruiting|August 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Male|18 Years|N/A|No|||March 2015|May 26, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902680||62729|
NCT01903590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB-070713|TVT Versus TOT in Urinary Stress Incontinence With No Intrinsic Sphincter Deficiency|PROSPECTIVE RANDOMIZED STUDY COMPARING TVT AND TOT IN FEMALE STRESS URINARY INCONTINENCE WITH NO INTRINSIC SPHINCTER DEFICIENCY||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|70 Years|No|||March 2014|June 28, 2014|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01903590||62660|
NCT01894984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013483|An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia|Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China||Xian-Janssen Pharmaceutical Ltd.|No|Terminated|January 2007|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|640|||Both|18 Years|65 Years|No|Non-Probability Sample|Participant must meet the diagnostic criteria for schizophrenia or schizophreniform        disorder according to Diagnostic and Statistical Manual of Mental Disorders, fourth        edition (DSM-IV)|April 2014|April 22, 2014|July 3, 2013|No|Yes|The study was terminated because of high dropout rate.|No|September 5, 2013|https://clinicaltrials.gov/show/NCT01894984||63318|
NCT01891500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00089105|Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure|Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure||University of Florida|Yes|Not yet recruiting|May 2016|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|N/A|48 Hours|No|||March 2016|March 2, 2016|June 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891500||63585|
NCT01891513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099-2013|ACE Inhibitors Combined With Exercise for Seniors - Pilot Study|Multimodal Intervention to Reduce Cardiovascular Risk Among Hypertensive Older Adults|ACES-P|University of Florida|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|72|||Both|65 Years|N/A|No|||October 2015|October 14, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01891513||63584|
NCT01891773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003859|Improving Pediatric Asthma Care Through Inhaled Steroids in Schools|Improving Pediatric Asthma Care Through Inhaled Steroids in Schools (ISIS)|ISIS|Children's Research Institute|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|48|||Both|5 Years|N/A|No|||September 2014|September 10, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01891773||63564|
NCT01892059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC-13003054|Study of Segmental Renal Artery Clamping During Laparoscopic Partial Nephrectomy|A Randomized Controlled Trial Comparing the Segmental Artery Clamping and Main Renal Artery Clamping During Laparoscopic Partial Nephrectomy||The First Affiliated Hospital with Nanjing Medical University|No|Recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||June 2013|July 2, 2013|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01892059||63542|
NCT01903447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0325|Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment|Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment||University of Illinois at Chicago|Yes|Recruiting|September 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903447||62671|
NCT01903759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sagot PHRC IR 2006|Kinetics of Inflammation Markers in Maternal Plasma: Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes|Kinetics of Inflammation Markers in Maternal Plasma (Interleukins, Matrix Metalloproteinases -MMP): Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes (SPROM) Before 34 Weeks of Amenorrhea (WA) With no Modification in the Usual Therapy.||Centre Hospitalier Universitaire Dijon|No|Terminated|September 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|97|||Female|18 Years|50 Years|No|||July 2013|July 18, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01903759||62647|
NCT01903772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMTCO|Effects of Inspiratory Muscle Training in Chronic Obstructive Pulmonary Disease (COPD)||IMTCO|Klinikum Berchtesgadener Land der Schön-Kliniken|Yes|Recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|40 Years|90 Years|No|||February 2016|February 23, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01903772||62646|
NCT01899625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14613|Motivational Interviewing for Weight Loss With Young Adults|Using Motivational Interviewing to Improve Weight Loss Outcomes With Young Adults|LiveWellRVA|Virginia Commonwealth University|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|25 Years|No|||February 2016|February 25, 2016|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01899625||62963|
NCT01900197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monofer®-NIS-14|Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)|A Non-intervention Trial of the Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)||Pharmacosmos A/S|No|Completed|August 2013|November 2015|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|391|||Both|N/A|N/A|No|Probability Sample|Patients with iron deficiency anemia treated on the doctor's dicretion with Monofer® as        standard treatment according to current practice|February 2016|March 1, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900197|1 Year|62920|
NCT01900132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130165|Electrical Impedance Myography: Exploratory Studies in Healthy People and People With Neuromuscular Disorders|Electrical Impedance Myography: Exploratory Studies in Normal Subjects and Patients With Neuromuscular Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|June 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 1, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900132||62924|
NCT01900158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI A202/12|A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas|A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of PCI of Gemcitabine Followed by Gemcitabine/Cisplatin Chemotherapy in Patients With Locally Advanced Inoperable Cholangiocarcinomas||PCI Biotech AS|No|Recruiting|May 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01900158||62923|
NCT01900171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGC001/1QG1|Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo|A Phase I, Double-blind, Placebo-controlled, Ascending Single-dose, Safety, Tolerability and Pharmacokinetic Study of QGC001 in Healthy Male Subjects.||Quantum Genomics SA|Yes|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|9||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01900171||62922|
NCT01900184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGC001/1QG2|Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects|Part 1: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Ascending Single Dose and Food Influence Study of QGC001 Administered Orally To Healthy Adult Subjects, Part 2: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Ascending Multiple Dose Study of QGC001 Administered Orally To Healthy Adult Subjects.||Quantum Genomics SA|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|69|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01900184||62921|
NCT01900457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01221-40|Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers|Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers||Assistance Publique Hopitaux De Marseille|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|208|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900457||62900|
NCT01900470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 817488|Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease|Community Health Worker Support to Help Patients Control Chronic Disease||University of Pennsylvania|No|Active, not recruiting|July 2013|March 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|212|||Both|N/A|N/A|No|||December 2015|December 2, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900470||62899|
NCT01900756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-U01-NS-079179|Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke|Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke|THRIVES|Medical University of South Carolina|No|Recruiting|September 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900756||62877|
NCT01901614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00009280- PTK|OCT-guided LALAK for KCN|RANDOMIZED CLINICAL TRIAL OF OCT-GUIDED LASER-ASSISTED LAMELLAR ANTERIOR KERATOPLASTY IN ADULTS FOR KERATOCONUS||Oregon Health and Science University|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01901614||62811|
NCT01902719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078591|Achieving Blood Pressure Control Together Study|Family and Community Intervention to Address Hypertension Disparities|ACT|Johns Hopkins University|Yes|Active, not recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|336|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 3, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902719||62727|
NCT01902420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113S432|Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly|Investigation of Prevalence and Clinical Effects of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations With DNA Sequence Analysis in Acromegaly Patients in Turkey|AIP|TC Erciyes University|No|Recruiting|November 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples With DNA|DNA samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|acromegaly patients|July 2013|July 18, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01902420||62749|
NCT01902433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTYM2013|Astym® Compared Eccentric Exercise for Chronic Mid-substance Achilles Tendinopathy|Astym® Treatment Compared With Eccentric Exercise in the Management of Chronic Mid-substance Achilles Tendinopathy: A Multisite a Randomized Controlled Trial||University of Indianapolis|No|Recruiting|August 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|60 Years|No|||October 2015|October 26, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01902433||62748|
NCT01902693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2009|Prospective HIV Chemotherapy Cohort Study|Prospective Observational Study of HIV Positive Individuals on Suppressive HAART With Malignancy Undergoing Chemotherapy||Imperial College London|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|Samples With DNA|Blood Cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited only from Chelsea and Westminster joint HIV oncology clinic|February 2015|September 8, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01902693||62728|
NCT01894490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301/08|Randomized Clinical Trial: Nasoenteric Catheter or Jejunostomy|Randomized Clinical Trial: Nasoenteric Catheter or Jejunostomy as a Route For Nutrition After Major Upper Gastrointestinal Operations||Federal University of Minas Gerais|No|Completed|January 2008|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients with gastrointestinal disorders undergoing major abdominal operations|July 2013|July 9, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01894490||63356|
NCT01894737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-3-023|The Effect of Creatine on Muscle Loss|The Effect of Creatine Supplementation on Muscle Loss During Immobilisation|CML|Maastricht University Medical Center|Yes|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01894737||63337|
NCT01892020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-4058|Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus|A Multi-centre, Randomised, Open-labelled, 2-sequence, 2-period Crossover Trial to Investigate the Efficacy and Safety of Biphasic Insulin Aspart 50 (BIAsp 50) Twice Daily Versus Biphasic Human Insulin 50 (BHI 50) Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|80 Years|No|||June 2015|June 16, 2015|June 28, 2013|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01892020||63545|
NCT01892878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGI-002|Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device|A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device||VG Innovations, LLC|No|Not yet recruiting|July 2013|||July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892878||63480|
NCT01892891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBY-036-002|Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing|A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects|VBY036P1B|Virobay Inc.|Yes|Completed|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|July 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01892891||63479|
NCT01893151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMM-3|Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI|A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI)||Jiangsu Simcere Pharmaceutical Co., Ltd.|Yes|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||July 2013|October 21, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893151||63459|
NCT01893164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JilinU-218-RLi|Comparison of Different Surgical Treatments for Different Scales of Cubital Tunnel Syndrome|Comparison of Simple Decompression Versus Anterior Subcutaneous and Intramuscular Transposition of the Ulnar Nerve for Moderate and Severe Cubital Tunnel Syndrome ：A Randomized Double-blind Control Trial||Jilin University|Yes|Recruiting|July 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|65 Years|No|||July 2013|July 5, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893164||63458|
NCT01893489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ga_MSA_CAD_carotid|Visualization of Carotid Atherosclerosis by 68Ga-MSA|Phase I Study to Evaluated the Safety of Noninvasive Molecular Imaging for the Detection of Inflammation in Carotid Atherosclerotic Lesions by Using Ga-68-NOTA-MSA in Healthy Volunteers and Patients With Coronary Artery Disease||Korea University|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|12|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 23, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893489||63433|
NCT01893736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBFS-1|Professional Breastfeeding Support Intervention|A Randomized Controlled Trial of a Professional Breastfeeding Support Intervention to Increase the Exclusivity and Duration of Breastfeeding||The University of Hong Kong|No|Completed|September 2010|March 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|722|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 12, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01893736||63414|
NCT01899651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77598-01|Detection and Quantification of Neonatal Intraventricular Hemorrhage|Detection and Quantification of Neonatal Intraventricular Hemorrhage|DQNIH|Electrical Geodesics, Inc.|No|Enrolling by invitation|May 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|22|||Both|30 Weeks|34 Weeks|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic We will not specifically exclude or include women or minorities from        the research. We expect that the enrollment will include similar numbers of males and        females. We anticipate that the racial mix of subjects will be broadly typical of their        representation in the North Central Florida area. However, since minorities are seen        disproportionately in the NICU we may find more minority representation in our pilot        group. We have estimated that of our 20 subjects(2 less than the estimated enrollment due        to attrition rate of 10%), 40% (8)will be Hispanic or Latino and 60% non-Hispanic, from        which 40% (8) will be Black or African American, 20% (4) will be Asian and 40% (8) will be        classified as white.|November 2014|August 7, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01899651||62961|
NCT01903798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAHC Clinical Trial|A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis|A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis||Southern California Institute for Research and Education|Yes|Not yet recruiting||||September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|186|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903798||62644|
NCT01899924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12011|Cognitive Assessment by the Mean of Event Related Potentials|Cognitive Assessment of Patients With Brain Injuries by the Mean of Event|PEC|University Hospital, Limoges|No|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|320|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 8, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01899924||62940|
NCT01899937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIFN-CH001-IWG-FMD|Effect of Different Methodologies on Variability of Brachial Artery Flow Mediated Dilation|Effect of Different Methodologies on Reliability of Flow Mediated Dilation as Measurement Tool: Meta-regression Analysis to Determine Minimum Quality Standards||Maastricht University Medical Center|No|Active, not recruiting|June 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|15000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults - varied|July 2013|July 11, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899937||62939|
NCT01899950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003868|Longitudinal Study of Cognition With Niemann-Pick Disease, Type C|Longitudinal Study of Cognition With Niemann-Pick Disease, Type C|NPC|Mayo Clinic|No|Completed|March 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|70|||Both|2 Years|99 Years|No|Probability Sample|Longitudinal observational study of cognition in patients with NPC. Subjects will be        recruited from participants in an observational study currently in progress at NIH, and        from subjects receiving clinical care at Mayo Clinic. Participants will be administered        age-and functionally-appropriate neuropsychological test instruments annually to track        cognitive changes over time, and to link these data to the subjects' scores on the NIH        disability scale.|January 2016|January 4, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01899950||62938|
NCT01900431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT13480|Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis|A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)|SARILNIUSATURN|Sanofi|Yes|Active, not recruiting|October 2013|April 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|July 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01900431||62902|
NCT01900444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC22|Study of a Booster Dose of IMOJEV® Vaccine One Year After Primary Immunization in Healthy Children in South Korea|Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given One Year After Primary Immunization in Healthy Children in South Korea||Sanofi|No|Completed|July 2013|September 2014|Actual|April 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|119|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01900444||62901|
NCT01900769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0077|Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study|Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study||University of Arizona|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01900769||62876|
NCT01901068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1010|MonoMax for Abdominal Wall Closure|A Multicentre, International, Prospective Post-market Clinical Follow-up to Evaluate MonoMax for Abdominal Wall Closure|MULTIMAC|Aesculap AG|No|Completed|February 2013|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients|February 2016|February 9, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01901068||62853|
NCT01901354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0887|Acute Lung Injury Ventilator Evaluation (ALIVE)|Acute Lung Injury Ventilator Evaluation (ALIVE) Trial: Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation in Trauma Patients|ALIVE|University of Wisconsin, Madison|Yes|Recruiting|September 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901354||62831|
NCT01901887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAVO2013|The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study|The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans|BRAVO|Medical University of South Carolina|Yes|Recruiting|March 2014|March 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|300|||Both|18 Years|90 Years|No|||March 2015|March 12, 2015|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901887||62790|
NCT01893645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00755|Pronto-7: Accuracy of Non-invasive Hemoglobin Measurement in Parturients|Pronto-7: Accuracy of Non-invasive Hemoglobin Measurement in Parturients|Pronto-7|University of British Columbia|No|Completed|June 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|71|||Female|19 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean        delivery (either elective or emergency).|September 2014|September 26, 2014|October 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01893645||63421|
NCT01902966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0113|Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)|Effect of a Beta Adrenergic Blockade Combined With Relaxation/Guided Imagery Audio Intervention on Symptom Distress in Women With Advanced, Recurrent Incurable Cervical Cancer - Feasibility Study||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2013|||September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01902966||62708|
NCT01902979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR290928|The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial|The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Randomized Trial|SSPANLI|Mount Royal University|No|Recruiting|September 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|45 Years|N/A|No|||September 2013|September 9, 2013|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01902979||62707|
NCT01903291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS404|Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS|A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate|RESPOND|Biogen|No|Active, not recruiting|August 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|333|||Both|18 Years|N/A|No|Probability Sample|This study will be conducted in male and female patients with relapsing forms of MS who        satisfy the therapeutic indication for dimethyl fumarate (DMF) per the United States        Prescribing Information, and who are suboptimal responders to glatiramer acetate (GA), as        determined by the Prescribing Physician.|August 2015|August 27, 2015|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01903291||62683|
NCT01903304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRGN64|Immunological Impact of High Olive Oil Consumption|Immunological Impact of High Olive Oil Consumption|OOS|Tufts University|No|Completed|May 2011|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|41|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01903304||62682|
NCT01891240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study Protocol v. 8.0 20122013|IMproved PRegnancy Outcome by Early Detection|Personalized Medicine for Pregnant Women: Novel Metabolomic and Proteomic Biomarkers to Detect Pre-eclampsia and Improve Outcome.|IMPROvED|University College Cork|No|Recruiting|November 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|EDTA plasma and serum.|Female|16 Years|N/A|No|Probability Sample|First time, low risk mothers attending antenatal care units. Women will be referred to        IMPROvED through a number of routes including referral by their midwife, obstetrician or        general practitioner and self-referral following exposure to the study through friends,        posters, advertisements, website and news stories. Maternity caregivers in each centre        will provide information about the study to eligible women in early pregnancy.|August 2015|August 21, 2015|May 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01891240||63605|
NCT01892553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acutely2012-A00418-35|Effect of Non Invasive Brain Stimulation on Experimentally Induced Dyspnea (Breathlessness)|Effect of Transcranial Direct Current Stimulation (tDCS) on Acutely Induced Dyspnea in Healthy Volunteers : a Pilot Study|tDCS-Dyspnea|Centre d'Investigation Clinique et Technologique 805|Yes|Completed|July 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01892553||63504|
NCT01893502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00057|Duration of Follow-Up Counselling on Smoking Cessation Outcomes|Smoke Free Randomized Controlled Trial||National University Hospital, Singapore|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|N/A|N/A|No|||July 2013|July 10, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01893502||63432|
NCT01893749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 MH090035-01A1|Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health|Primary Care Internet Based Depression Prevention for Adolescents (Promoting AdolescenT Health-PATH)|CATCH-IT|University of Illinois at Chicago|Yes|Recruiting|February 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1340|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01893749||63413|
NCT01893762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCREASE-2013|Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes|Innate Immune Response to Anaerobe and Aerobe Exercise in Rowing Athletes|INCREASE|UMC Utrecht|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01893762||63412|
NCT01894009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUSKB-43121|Foot Manipulation for Pregnancy Related Pelvic Girdle Pain|Effect of Foot Manipulation for Relief of Pregnancy Related Pelvic Girdle Pain. A Randomised Clinical Trial in Primary Care|PPGP|Vastra Gotaland Region|No|Completed|September 2009|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Female|20 Years|45 Years|No|||July 2013|July 2, 2013|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01894009||63393|
NCT01894022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116457|A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|AMBER II|GlaxoSmithKline|Yes|Completed|January 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01894022||63392|
NCT01903473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB1117|Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)|Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD)||University Hospital of Liege|No|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|35|||Both|18 Years|80 Years|No|||July 2013|July 16, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01903473||62669|
NCT01903811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1304|Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma|A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease||Southwest Oncology Group|Yes|Recruiting|October 2013|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01903811||62643|
NCT01899664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205104|Upper Extremity Surgery in Spinal Cord Injury|Study of the Surgical Treatment of Cervical Spinal Cord Injuries With Nerve Transfers to Restore Upper Extremity and Hand Function||Washington University School of Medicine|No|Recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Nerve tissue specimens will be obtained at the time of surgery for histologic examination      and assessment of nerve tissue quality.|Both|18 Years|60 Years|No|Non-Probability Sample|Any patients with cervical spinal cord injury and upper extremity dysfunction who are        medically stable, residents of the United States, willing and able to be assessed at the        Washington University Multidisciplinary Upper Extremity Surgery in Spinal Cord Injury        clinic are potential participants.|December 2015|December 9, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01899664||62960|
NCT01899963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tele-retinal Referral T.T.T.|Time to Treatment Utilizing a Tele-Retinal Referral System for Wet Age Related Macular Degeneration and Diabetic Macular Edema: A Pilot Study|Time to Treatment Utilizing a Tele-Retinal Referral System for Wet Age Related Macular Degeneration and Diabetic Macular Edema: A Pilot Study||McMaster University|No|Recruiting|November 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|165|||Both|18 Years|N/A|No|Probability Sample|The study population includes patients who are referred from an optometrist either        participating in the teleophthalmology referral system or via conventional fax referrals        with a provisional diagnosis of possible wet AMD or DME to any of the physician        investigators.|March 2016|March 14, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01899963||62937|
NCT01900210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA25885-Sum08-13|Sustainable HIV Risk Reduction Strategies for CJ Systems|Sustainable Disease Risk Reduction Strategies for CJ Systems|DRR|Texas Christian University|No|Completed|August 2008|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1396|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 11, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01900210||62919|
NCT01900223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTB-003|Chronic Pain After Shoulder Arthroplasty|Chronic Pain After Shoulder Arthroplasty: Epidemiology and Risk Factors.||University of Aarhus|No|Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|786|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the Danish Shoulder Arthroplasty Register|January 2014|January 13, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01900223||62918|
NCT01901081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0015B|Feasibility of Implantable Myoelectric Sensors to Control Upper Limb Prostheses|A Feasibility Study to Assess Safety and Functionality of Implantable Myoelectric Sensors for Upper Extremity Prosthetic Control in Transradial Amputees|IMES|The Alfred E. Mann Foundation for Scientific Research|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|May 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01901081||62852|
NCT01901094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011202|Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy|A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy||Alliance for Clinical Trials in Oncology|Yes|Recruiting|February 2014|||January 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2918|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01901094||62851|
NCT01901627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-12-0115|A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis|A Multicenter Registry to Evaluate the Clinical Outcome of Chinese Adult Patients With Active Ankylosing Spondylitis Treated With Adalimumab in the Real World Practice||Peking Union Medical College Hospital|No|Recruiting|April 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a diagnosis of ankylosing spondylitis(any disease duration) who meet        the requirements per the local label for treatment with adalimumab.|July 2013|July 12, 2013|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01901627||62810|
NCT01901640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_EDDL_III|Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction|Phase 3 Study to Evaluate Longterm Safety of Once-a-Day Dosing of Udenafil in the Treatment of Erectile Dysfunction||Dong-A ST Co., Ltd.|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Male|20 Years|N/A|No|||January 2013|July 15, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01901640||62809|
NCT01901900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2302E1|Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.|A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis|REASSURE-E|Novartis|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01901900||62789|
NCT01910766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoQ10|Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome|Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome||Mansoura University|No|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|110|||Female|N/A|N/A|No|||July 2013|July 29, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01910766||62112|
NCT01910779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18/04/13|Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks|Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks (OPTIMA Trial).|OPTIMA|Maria Vittoria Hospital|Yes|Recruiting|May 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|90 Years|No|||July 2013|July 29, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01910779||62111|
NCT01911689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKLMC-2013-001|Magnetic Resonance Imaging Study of Acute Pancreatitis|||Afﬁliated Hospital of North Sichuan Medical College|Yes|Completed|August 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|168|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with AP admitted to our institution between August 2013 and March 2015 were        considered for inclusion in this study. The inclusion criteria for patients in this study        were as follows: (a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c)        three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (d)        abdominal MR examination.|November 2014|August 19, 2015|July 26, 2013|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01911689||62041|Some diseases, such as chronic anemia, diabetes, etc., may lead to iron deposition in pancreas and may lead to change the T2* value.
NCT01911364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1208-PR-0090|Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease|A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|Yes|Active, not recruiting|January 2014|August 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|3686|||Both|40 Years|N/A|No|||March 2015|March 4, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911364||62066|
NCT01911676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303011716|Translational Neuroscience Optimization of GlyT1 Inhibitor|Translational Neuroscience Optimization of GlyT1 Inhibitor|NCATS|Yale University|Yes|Recruiting|August 2013|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911676||62042|
NCT01912261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheEffectsofOral Iron052013|Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients|Phase III Randomized Double Blind Placebo-Controlled Study To Assess The Effects Of FeraMax When Administered Orally Once A Day On Postoperative Fatigue Levels In Patients Following Elective Coronary Artery Bypass Graft Surgery (CABG)||Nova Scotia Health Authority|No|Not yet recruiting|December 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|19 Years|N/A|No|||November 2014|November 6, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912261||61998|
NCT01941459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001780-30|Comparison of Blood Cardioplegia and Custodiol|Comparison of Blood Cardioplegia and Custodiol on Patients Operated for Significant Mitral Valve Innsufisiens. An Prospective, Randomized Two-center Study.||Oslo University Hospital|No|Completed|March 2007|January 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|76|||Both|18 Years|N/A|No|Non-Probability Sample|Between Mars 2007 and December 2009, 80 consecutive patients undergoing elective mitral        valve surgery for mitral regurgitation at Oslo University Hospital Ullevål, Oslo, Norway        and Sahlgrenska University Hospital, Gothenburg, Sweden were included in the study after        informed written consent.|September 2013|September 12, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01941459||59761|
NCT01941758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97413|High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors|A Pilot Single Arm Study of High-Dose Influenza Vaccine Immunogenicity in Patients With Central Nervous System Tumors||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|November 2013|||November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941758||59738|
NCT01934023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214-2012|Effects of Varenicline on Plasticity in Schizophrenia|Effects of Varenicline on Cortical Neuroplasticity and Working Memory in Patients With Schizophrenia and Healthy Controls|VAR-PAS|Centre for Addiction and Mental Health|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934023||60329|
NCT01934036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE_TRIAL1|Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women|Efficacy and Safety of Obex®, a Nutritional Supplement, in Overweight or Obese Women||Catalysis SL|Yes|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|92|||Female|35 Years|60 Years|No|||February 2014|February 24, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01934036||60328|
NCT01930461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO72.12|Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma|A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma||Stallergenes|Yes|Completed|September 2013|August 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|386|||Both|18 Years|50 Years|No|||December 2015|December 17, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01930461||60603|
NCT01931319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baclofen_Dose escalation|Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers|Prevention of Baclofen Withdrawal Syndrome: Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931319||60537|
NCT01912443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28629|Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer|||Sun Yat-sen University|No|Recruiting|August 2013|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Patients with histologically confirmed metastatic colorectal cancer are eligible|April 2014|April 25, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01912443||61984|
NCT01908244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCIM_MTN05|Short-term Effects of Live Music in Preterm Infants|Short-term Effects of Live Pentatonic Music on Physiological Parameters in Preterm Infants - A Randomized Controlled Trial With Crossover Design|MTN05|ARCIM Institute Academic Research in Complementary and Integrative Medicine||Completed|July 2013|||October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|21|||Both|26 Weeks|34 Weeks|No|||July 2013|October 22, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908244||62303|
NCT01908556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAFO-001|Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)|Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol.|PreFace|Institut fuer Frauengesundheit|Yes|Active, not recruiting|February 2009|||December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3545|||Female|18 Years|N/A|No|||February 2009|July 24, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908556||62279|
NCT01909284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMI-13-01-20|Efficacy Study of Acupuncture to Treat Spinal Pain|Pilot Study of Efficacy and Safety of Acupuncture on Patient With Spinal Pain Due to Spondylolithesis||Daegu Catholic University Medical Center|No|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|65 Years|No|||February 2014|February 2, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909284||62225|
NCT01909908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-014|ECM and Blood Components for Wound Healing|Treatment of Chronic Wounds Using Extracellular Matrix-Based Devices and the Patient's Own Blood Components||Cook||Terminated|February 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|July 25, 2013|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01909908||62177|
NCT01909921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001513|Retrospective Medical Record Review of Mind Body Depression Group Participants|Retrospective Medical Record Review of Mind Body Depression Group Participants||Massachusetts General Hospital|No|Active, not recruiting|January 2009|August 2013|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|170|||Both|21 Years|N/A|No|Non-Probability Sample|MGH-Health Center patients who have participated in the Relaxation Response Intervention        for Depression groups.|July 2013|July 24, 2013|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01909921||62176|
NCT01910246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetforminMRI|Cardiovascular Effects of Metformin on Obesity|Cardiovascular Effects of Metformin on Obesity With Subclinical Myocardial Dysfunction||University of California, San Francisco|No|Not yet recruiting|April 2015|||June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|17 Years|No|||March 2015|March 4, 2015|April 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910246||62152|
NCT01910792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30047|Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery|Ultraviolet Light and Vitamin D in Subjects With Fat Malabsorption or After Gastric Bypass Surgery||Boston Medical Center|No|Completed|March 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|64 Years|No|||January 2016|January 11, 2016|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910792||62110|
NCT01910805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108628|Recent GDM Lifestyle Intervention|Lifestyle Intervention for African-American Women: A Pilot Study for Women With a Recent History of Gestational Diabetes (The LIFe Study)|LIFe|Brigham and Women's Hospital|Yes|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|15|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910805||62109|
NCT01911130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000702|Longitudinal Study of Outcomes Measures in ALS Trials|Longitudinal Study Comparing the Responsiveness of Outcomes Measures in ALS Trials||Massachusetts General Hospital|No|Active, not recruiting|July 2013|November 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Adults with ALS|September 2015|September 21, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01911130||62084|
NCT01911351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-296|Nitrous Oxide Use in Minor Procedures|High Concentration Continuous Flow Nitrous Oxide Use for Procedural-induced Pain or Anxiety During Pediatric Minor Procedures||New York City Health and Hospitals Corporation|Yes|Active, not recruiting|July 2013|December 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01911351||62067|
NCT01910818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000988|Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury|Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study||Massachusetts General Hospital|Yes|Recruiting|November 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01910818||62108|
NCT01911143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-1002-BV|A Retrospective, Blinded Validation of a Host-response Based Diagnostics|A Retrospective, Blinded Validation Study to Assess the Accuracy of a Host-response Based Diagnostics for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients With an Acute Febrile Disease|PATHFINDER|MeMed Diagnostics Ltd.|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|600|Samples Without DNA|Serum samples|Both|1 Month|18 Years|No|Probability Sample|The study population will include patients aged 1 month to 18 years of age that were        sampled both during emergency department (ED) visit or during hospitalization stay and        were diagnosed with an acute infectious disease or a non-infectious disease. All samples        are expected to fall into one of the following categories:          1. Patients with an acute bacterial infection          2. Patients with an acute viral infection          3. Patients with an acute mixed co-infection (bacterial and viral)          4. Patients with a non-infectious disease (control group)|March 2016|March 6, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01911143||62083|
NCT01942590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043680|Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy|A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy||Duke University|Yes|Active, not recruiting|September 2013|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942590||59674|
NCT01911702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOModena|Different Fluidic Strategy in Patients With Acute Abdomen : The Sure Volume|MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study||Azienda Ospedaliera - Universitaria di Modena|Yes|Completed|January 2010|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911702||62040|
NCT01911715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0001|A Study to Explore the Routes of Elimination of MDV3100|A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 µCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911715||62039|
NCT01941472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICU2013-1|Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness|||Peking Union Medical College Hospital||Not yet recruiting|September 2013|||August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01941472||59760|
NCT01933789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44023-E/A|Improving Communication About Serious Illness|Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients|ICSI|University of Washington|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|765|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933789||60347|
NCT01933802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TISCHMS-MSCNP-001|Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis|Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis||Tisch Multiple Sclerosis Research Center of New York|Yes|Active, not recruiting|April 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01933802||60346|
NCT01934361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120E2102|Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme|Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme||Novartis|No|Active, not recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934361||60303|
NCT01934673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4066|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia|DiabCare Asia|Novo Nordisk A/S|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1668|||Both|18 Years|N/A|No|Non-Probability Sample|People treated for at least a year are eligible for the study. The selection of the        patients will be done randomly by the individual physician involved in the study.|November 2014|November 28, 2014|August 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934673||60279|
NCT01934686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4070|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia|DiabCare Asia|Novo Nordisk A/S|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1862|||Both|18 Years|N/A|No|Non-Probability Sample|People having been treated for at least a year are eligible for the study. The selection        of the patients will be done randomly by the individual physician involved in the study.|May 2014|May 26, 2014|August 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934686||60278|
NCT01930240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cortria-002|The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers|A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of TRIA-662 (A Hypolipidemic Agent) in Healthy Volunteers|Cortria-002|Cortria Corporation||Completed|November 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930240||60620|
NCT01930708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS408|A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes|A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting|PROTEC|Biogen|No|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1114|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01930708||60584|
NCT01930721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|incision angle of mediolateral|Comparison of Incision Angle of Mediolateral Episiotomy at 40 and 60 Degrees|Comparison of Incision Angle of Mediolateral Episiotomy at 40 and 60 Degrees|IAME|Ain Shams Maternity Hospital|Yes|Recruiting|March 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01930721||60583|
NCT01931332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0202/1|Intrathecal Diamorphine Versus Femoral Nerve Block in Primary Total Knee Arthroplasty|Randomised, Observer Blinded, Controlled Trial of Intrathecal Diamorphine Versus Femoral Nerve Block for Post-operative Analgesia Following Primary Total Knee Arthroplasty||Royal Devon and Exeter NHS Foundation Trust|Yes|Completed|February 2010|July 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|16 Years|N/A|No|||August 2013|August 26, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01931332||60536|
NCT01908270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5421-BO|Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer|Randomized Controlled Trial of Yoga for Menopausal Symptoms in Women With Breast Cancer||Universität Duisburg-Essen|No|Completed|August 2013|February 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|30 Years|65 Years|No|||July 2014|July 30, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908270||62301|
NCT01908283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV13 in SIBDCS|Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease|Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease|PCV13inSIBDCS|University Hospital, Geneva|Yes|Recruiting|April 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908283||62300|
NCT01908309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-3|Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship|Contrast-inDuced nephRotoxicity as Assessed by the Cystatin-modified KIdney Load-to-DAmage RElationship|DrKILDARE|Azienda Sanitaria Locale 9, Grosseto|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|20 Years|90 Years|No|||June 2015|June 22, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908309||62298|
NCT01908829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-012|A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)|A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms|BESIDE|Astellas Pharma Inc|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|3815|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908829||62259|
NCT01909570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS09/1968|eSET Plus Single Embryo Cryotransfer vs Double Embryo Transfer|Randomized Clinical Trial Comparing Elective Single Embryo Transfer Plus Single Embryo Cryotransfer vs Double Embryo Transfer|eSET|University Hospital Virgen de las Nieves|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|194|||Female|18 Years|37 Years|No|||April 2015|April 7, 2015|July 24, 2013||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01909570||62203|Our study could have been complemented by improved embryo selection, using a time-lapse system.Another limitation of our study is that after devitrification, blastocyst culture was not performed.
NCT01909583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:117|Pediatric Cardiac Surgery Pre-operative Counselling Study|Pediatric Cardiac Surgery Pre-operative Counselling Study||University of Manitoba|No|Recruiting|June 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|18 Years|No|||July 2013|February 27, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909583||62202|
NCT01940653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFETA-3|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone|PROFETA-3|Universitair Ziekenhuis Brussel|Yes|Recruiting|November 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|39 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940653||59823|
NCT01910259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0219|MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial|A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.|MS-SMART|University College, London|Yes|Recruiting|December 2014|May 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|440|||Both|25 Years|65 Years|No|||March 2016|March 14, 2016|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01910259||62151|
NCT01941238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE12-002|Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi Dose Injection|Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi-dose Insulin Injection||King Abdullah International Medical Research Center||Completed|July 2013|November 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|142|||Both|14 Years|80 Years|No|Non-Probability Sample|The target population of our study is all patients with type1DM treated at three National        Guard institutiuons in three different cities of Saudi Arabia (Riyadh, Alahsa, Dammam)        with either insulin pump or MDI|April 2015|April 5, 2015|September 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01941238||59778|
NCT01910831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCR 28-2013|Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands|Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands|CCCR28-2013|The Center for Clinical and Cosmetic Research|Yes|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|July 25, 2013|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01910831||62107|
NCT01941771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT nr. 2011-003564-72|Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer|Randomized Phase II Trial of Capecitabine Plus Oral Vinorelbine Day 1 and 8 vs Metronomic Capecitabine Plus Oral Vinorelbine as Treatment of Metastatic Breast Cancer.|XeNa|University of Aarhus|Yes|Recruiting|June 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||December 2014|December 2, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01941771||59737|
NCT01942915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12276102D-Liver Cirrhosis|Umbilical Cord Blood Mononuclear Cells Therapy in Liver Cirrhosis|Safety and Efficacy Investigation of Patients With Liver Cirrhosis by Transplantation of Umbilical Cord Blood Mononuclear Cells||Hebei Medical University|Yes|Active, not recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years|No|||November 2013|November 14, 2013|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942915||59649|
NCT01942018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082967|Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)|Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)||Johns Hopkins University|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01942018||59718|
NCT01942031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN2010/1158-31/2|Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)|An Interventional Study of How Collegial Feed Back to Primary Care Physicians on Detection of Diagnosis and Dispensation of Prescribed Secondary Preventive Drugs Affect Stroke Prevention.||Karolinska Institutet|No|Enrolling by invitation|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||September 2013|September 10, 2013|April 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01942031||59717|
NCT01942278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1229|Better Health Outcomes Through Mentoring and Assessment (BHOMA)|CIDRZ 1229- Better Health Outcomes Through Mentoring and Assessment (BHOMA)|BHOMA|University of North Carolina, Chapel Hill|No|Recruiting|January 2011|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|450000|||Both|N/A|N/A|No|||February 2016|February 10, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942278||59698|
NCT01934049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex-THR|Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty|The Effect of Dexmedetomidine on Postoperative Recovery in Elderly Patients With Femoral Neck Fracture Undergoing Hip Hemi-arthroplasty||Chinese PLA General Hospital|Yes|Recruiting|September 2013|June 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|75 Years|N/A|No|||September 2013|September 7, 2013|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934049||60327|
NCT01934062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00508|Induction Hypotension in Pediatric Population|||Nationwide Children's Hospital|No|Completed|August 2013|August 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|1 Year|8 Years|No|Non-Probability Sample|Surgical patients from Nationwide Children's Hosp.|May 2015|May 14, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934062||60326|
NCT01934374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812148R|Long-Term Effects of Task-Oriented Lower Extremity Strengthening Training|Long-Term Effects of Task-Oriented Lower Extremity Strengthening Training on Functional Connectivity of the Brain, Motor Functions, Physical Activity Level, and Quality of Life in Patients With Subacute Stroke||National Taiwan University Hospital|Yes|Completed|March 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||August 2013|August 29, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01934374||60302|
NCT01930474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2013-105|Analysis of Plasma Tumor DNA in Lung Cancer Patients|Analysis of Mechanism of Resistance to Chemotherapy by Sequencing of Plasma DNA||Seoul National University Hospital||Recruiting|July 2013|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|The non-small cell lung cancer patients who will be or have been treated with chemotherapy        (including target agents)|December 2013|December 3, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01930474||60602|
NCT01931046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTG-REIC-PC003|Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer|A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Subjects With Localized Prostate Cancer (MTG-REIC-PC003)||Momotaro-Gene Inc.|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|80 Years|No|||December 2015|December 28, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931046||60558|
NCT01931657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W2009M|Pretreatment With Mifepristone Prior to Mirena Insertion|Pre-treatment With Mifepristone in Patients With Mirena for Optimizing Bleeding Pattern in Pre-menopausal Women|MiMi|Karolinska Institutet|Yes|Completed|August 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01931657||60511|
NCT01912482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR20132014|Cardiorespiratory Training and Ventilatory Muscle Strength|Chronic Effect of Cardiorespiratory Training on Ventilatory Muscle Strength in Elderly Women: Controlled Trial, Randomized and Double Blind.|RMS|Universidade Gama Filho|Yes|Not yet recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|60 Years|79 Years|Accepts Healthy Volunteers|||January 2015|January 3, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01912482||61981|
NCT01912495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44825.078.13|Dutch Acute HCV in HIV Study (DAHHS)|Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.|DAHHS|Erasmus Medical Center|No|Active, not recruiting|August 2013|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912495||61980|
NCT01908296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0004|Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers|Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults||Astellas Pharma Inc|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908296||62299|
NCT01909063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multinutrient Fortified Juice|A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice|A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice||Boston Medical Center|No|Completed|January 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|180|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909063||62241|
NCT01909297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/188|Comparison of the I-gel, Supreme and Proseal LMA in Paralyzed Patients|Comparison of the I-gel, Supreme and Proseal LMA in Paralyzed Patients Undergoing Gynaecological Laparoscopic Surgery With Oropharyngeal Leak Pressure||Inonu University|No|Completed|May 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|35|||Female|18 Years|60 Years|No|||July 2013|July 25, 2013|June 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01909297||62224|
NCT01909596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-2012|Lateral Wedge Insoles With Arch Support in Knee Osteoarthritis|Does it Exist a Relationship Between Inclination Angle of Foot Orthoses and Varus Angle of the Knee in the Relief of the Knee Osteoarthritis Symptoms?||Laval University|Yes|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|24|||Both|40 Years|N/A|No|||July 2013|July 23, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909596||62201|
NCT01909609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00073478|Parents' Knowledge and Perception of Benefits and Risks Regarding Neonatal Circumcision|||University of Michigan||Recruiting|July 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|680|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909609||62200|
NCT01940939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11ZR1431600|A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation for the Treatment of Cognitive Impairment Such as Working Memory in Schizophrenia|||Shanghai Mental Health Center|Yes|Recruiting|February 2013|||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|49 Years|No|||September 2013|September 9, 2013|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940939||59801|
NCT01940952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-065|Zydena on Cognitive Function of Alzheimer's Disease Patients|Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study||Samsung Medical Center|No|Not yet recruiting|September 2013|||August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|50 Years|90 Years|No|||September 2013|September 9, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940952||59800|
NCT01940926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM07|68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis|Diagnostic Performance and Evaluation Efficacy of 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis|GRGDRA|Peking Union Medical College Hospital|Yes|Recruiting|February 2012|December 2015|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 1, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940926||59802|
NCT01941498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01353|WaveLight® Refractive Myopic Study|A Prospective, Global, Multi-Center Study for the Evaluation of Outcomes on Subjects Undergoing Myopic Treatments Using the WaveLight® Refractive Suite||Alcon Research|No|Completed|September 2013|August 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 10, 2013|Yes|Yes||No|February 1, 2015|https://clinicaltrials.gov/show/NCT01941498||59758|
NCT01941797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro-2011perio-02-fp|Experimental Peri-implant Mucositis in Humans|Experimental Peri-implant Mucositis in Humans||University of Connecticut Health Center|No|Active, not recruiting|September 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941797||59735|
NCT01910532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0336|The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy|The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy||Ohio State University|Yes|Withdrawn|April 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|December 19, 2011|No|Yes|Sponsor discontinued the research|No||https://clinicaltrials.gov/show/NCT01910532||62130|
NCT01910545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTS167-FR02|Phase 1 Study of OTS167 in Patients With Solid Tumors|Phase I, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies||OncoTherapy Science, Inc.|No|Recruiting|August 2013|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910545||62129|
NCT01941784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97513|Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy|Taking Health Realization Into Valued Eating and Exercise (THRIVE): A Feasibility Study of an Intervention to Prevent Weight Gain for Breast Cancer Survivors During Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|November 2013|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Female|18 Years|N/A|No|||December 2015|December 28, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941784||59736|
NCT01942603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1208-MG|Minimal SN Tumor Burden|Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation|Minitub|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|July 2009|||July 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with minimal SN tumor burden|March 2016|March 21, 2016|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942603|5 Years|59673|
NCT01943188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAL0027|Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer|Pilot Study of Local Tumor Irradiation With Autologous T-Cell Infusion for Metastatic Renal Cell Carcinoma||Stanford University||Recruiting|May 2014|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943188||59628|
NCT01943201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS_001|Low Friction Bed Sheet|Does a Low Friction Bed Sheet Optimize the Skin, Resistance and Physiology and Reduce the Risk for Pressure Ulcer?||Swiss Paraplegic Centre Nottwil|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|65 Years|No|||September 2013|September 13, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943201||59627|
NCT01943227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483184|Effect of Alveolar Minute Ventilation on Respiratory Gas Heat Content|Effect of Alveolar Minute Ventilation on Respiratory Gas Heat Content|Tidal Volume|University of California, Davis|No|Recruiting|August 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943227||59625|
NCT01934075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD073681|Development of Mental Health Treatment for Obstetric Fistula Patients in Tanzania|Development of Mental Health Treatment for Obstetric Fistula Patients in Tanzania||Duke University|No|Recruiting|September 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|99 Years|No|||January 2016|January 25, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934075||60325|
NCT01934088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013052044 v.1|Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy|Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program.||Copenhagen University Hospital at Herlev|Yes|Completed|January 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|90 Years|No|||September 2015|September 28, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01934088||60324|
NCT01930487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|The Effects of an Antioxidant Formulation on Ocular Blood Flow|The Effects of an Antioxidant Formulation on Intraocular Pressure, Ocular Perfusion Pressure, Retrobulbar, Retinal Capillary and Choroidal Blood Flow||ScienceBased Health|No|Completed|August 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|47|||Both|30 Years|70 Years|No|||January 2016|January 28, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930487||60601|
NCT01930734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0341-DF-CTIL|Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients|Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic|DoBHF|Sheba Medical Center|No|Not yet recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01930734||60582|
NCT01931033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001548|An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders|An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders||Massachusetts General Hospital|No|Recruiting|October 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|11 Years|17 Years|No|||February 2016|February 26, 2016|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931033||60559|
NCT01931059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-036|Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers|Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers||Northwell Health|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01931059||60557|
NCT01931670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-671|A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||AbbVie|Yes|Active, not recruiting|May 2013|December 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|788|||Female|18 Years|49 Years|No|||January 2016|January 27, 2016|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931670||60510|
NCT01908582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14636|A Study of Evacetrapib and Rifampin in Healthy Participants|Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908582||62277|
NCT01908816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002GFR02|An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.|An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.|ECLIPSE|Novartis|No|Active, not recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|260|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01908816||62260|
NCT01909310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN5155 327/4.10|Head Positions to Open the Airway IV|Head Positions to Open the Upper Airway IV||Medical University Innsbruck|No|Completed|September 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909310||62223|
NCT01909336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIvsSHnh|Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia|Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.||Instituto Tecnologico y de Estudios Superiores de Monterey|Yes|Completed|July 2013|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|153|||Both|3 Months|15 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01909336||62221|
NCT01940393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GACE-01|Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria|Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria||Grupo de Alergología Clínica y Experimental|Yes|Completed|August 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|150|||Both|12 Years|50 Years|No|||February 2014|February 16, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01940393||59843|
NCT01940965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS12809|Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes|An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes||Sanofi|No|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|294|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940965||59799|
NCT01940978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|A Study of Combination Therapy in Children With ADHD|A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD||Sears, Douglas, M.D.|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|6 Years|12 Years|No|||April 2015|April 8, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940978||59798|
NCT01941251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|932012|Navigated αTMS in Treatment-resistant Schizophrenia|Navigated Alpha Frequency Transcranial Magnetic Stimulation (αTMS) in Treatment-resistant Schizophrenia|nTMS_NS|Niuvanniemi Hospital|No|Recruiting|March 2013|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|64 Years|No|||April 2015|April 24, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941251||59777|
NCT01941511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5201001|A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects|A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects||Pfizer|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01941511||59757|
NCT01941524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-14-02215338-09873|Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations|Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant||Poznan University of Medical Sciences|No|Recruiting|September 2013|August 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|2 Days|No|||October 2013|October 18, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01941524||59756|
NCT01941485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01354|WaveLight® Refractive Flap Accuracy Study|A Prospective, Global, Multi-Center Study to Evaluate Longitudinal Flap Accuracy on Subjects Undergoing Myopic Refractive Surgery Using the WaveLight® Refractive Suite||Alcon Research|No|Completed|October 2013|March 2015|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 10, 2013|Yes|Yes||No|February 1, 2015|https://clinicaltrials.gov/show/NCT01941485||59759|
NCT01942291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicamp845/2011|Short-term Effect of Extended-release Niacin on Endothelial Function.|Short-term Effect of Extended-release Niacin With and Without the Addition of Laropiprant on Endothelial Function||University of Campinas, Brazil|Yes|Completed|March 2012|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|20 Years|60 Years|No|||September 2013|September 10, 2013|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942291||59697|
NCT01942577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045553|Microbiome Survey of Preterm Infants|Comprehensive Microbiome Survey of Preterm Infants||Duke University|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 3, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942577||59675|
NCT01942616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910005885|The Development of a Domestic Violence Perpetrator Collusion Measurement Tool|Media, Public Health, and Colluding With Murder: The Development of a Domestic Violence Perpetrator Collusion Measurement Tool.||Yale University|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 10, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01942616||59672|
NCT01942928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-001-colic|Cranial Osteopathy in Infantile Colic|Cranial Osteopathic Manipulative Therapy in Addition to Usual Care in Excessively Crying Infants, Sometimes Called Colic||European School of Osteopathy|Yes|Recruiting|June 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|7 Weeks|No|||February 2015|February 19, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942928||59648|
NCT01943240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pec block|Pectoral Nerve Blockade in Mastectomy|Improvement of Analgesia With Addition of Pectoral Nerve Block to Thoracic Paravertebral Blocks in Unilateral Total Simple Mastectomy||University of New Mexico|No|Recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943240||59624|
NCT01930253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1089|Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation|Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|4 Months|29 Years|No|||August 2013|August 23, 2013|November 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01930253||60619|
NCT01930500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luki-40211|The Effectiveness of Neuropsychological Rehabilitation in Young Dyslexic Adults|The Effectiveness of Neuropsychological Rehabilitation in Young Dyslexic Adults - a Single Blind, Randomized, Controlled Study||Rehabilitation Foundation, Finland|No|Active, not recruiting|November 2012|September 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|35 Years|No|||October 2015|October 21, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01930500||60600|
NCT01930747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013JPM2|Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.|Impact of Deep Neuromuscular Block Versus Inhalation and Total Intravenous Anesthesia (TIVA) on Laparoscopic Surgical Workspace Defined as Insufflated Pneumoperitoneum Volume.|TIVA|AZ Sint-Jan AV|No|Recruiting|April 2013|April 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|90 Years|No|||September 2013|September 19, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01930747||60581|
NCT01931072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-GEN100|Exercise-induced Changes in DNA-methylation|The Effect of Exercise on Maximal Aerobic Capacity, DNA-methylation and Gene Expression in Healthy Elderly Men||Norwegian University of Science and Technology|Yes|Completed|August 2012|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|37|||Male|70 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931072||60556|
NCT01931345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOT|The SPOT Project : Motivational Interviewing in Conjunction With Rapid HIV Testing|The SPOT Project: Effect of Counseling Based on Motivational Interviewing Offered in Conjunction With Rapid HIV Testing on the Occurrence of Unprotected Anal Sex and Its Determinants Among Men Who Have Sex With Men (MSM) in Montreal||Universite du Quebec a Montreal|Yes|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Male|18 Years|N/A|No|||May 2015|May 26, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01931345||60535|
NCT01931358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 306|Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E|Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults||U.S. Army Medical Research and Materiel Command|Yes|Suspended|September 2013|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Anticipated|360|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931358||60534|
NCT01908595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US04|Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis|An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis||Maruho North America Inc.|No|Completed|August 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|480|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908595||62276|
NCT01908842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX219-006 Protocol Amendment 4|Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults|Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments|ISTART|Orexo AB|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|759|||Both|18 Years|65 Years|No|||May 2015|May 5, 2015|July 19, 2013|Yes|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01908842||62258|
NCT01909349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-A-SL-022013|Web-based Aftercare Intervention for Cardiac Patients|Rehabiliation-Aftercare for an Optimal Transfer Into Autonomous Daily Life (RENATA) - an eHealth Intervention Study|RENATA|Jacobs University Bremen gGmbH|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1500|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909349||62220|
NCT01940406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01-001|The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study|The ET and PD Tremor Study - Rainbow Medical Acute Stimulation Evaluation for Tremor Reduction||Rainbow Medical|Yes|Not yet recruiting|October 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||September 2013|September 8, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01940406||59842|
NCT01941537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0766|Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis|Phase II Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) in Subjects With Atopic Dermatitis (AD)||Rockefeller University|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941537||59755|
NCT01941264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6800110|Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial|Community-based Scheduled Screening and Treatment of Malaria in Pregnancy for Improved Maternal and Infant Health: a Cluster-randomized Trial in The Gambia, Burkina Faso and Benin|COSMIC|Royal Tropical Institute|Yes|Active, not recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5400|||Female|16 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941264||59776|
NCT01942044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOtake1|Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)|Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)||Kobe University|No|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|N/A|No|||September 2013|September 10, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01942044||59716|
NCT01942304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study|Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|October 2013|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||January 2015|January 20, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942304||59696|
NCT01942317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20232|The Role of Balneotherapy in Obese Patients With Knee Osteoarthritis|||University of Padua||Not yet recruiting|October 2013|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|74|||Both|50 Years|70 Years|No|||September 2013|September 10, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942317||59695|
NCT01942629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0298-13ctil|Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas|Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas||Rambam Health Care Campus|Yes|Not yet recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|300|||Both|18 Years|75 Years|No|Non-Probability Sample|300 patients, 100 for each group.|September 2013|September 10, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01942629||59671|
NCT01942642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0690|Evaluation of Dry Eye and Meibomian Gland Dysfunction After Cataract Surgery|||Yonsei University|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Both|45 Years|88 Years|No|Probability Sample|Patients scheduled for cataract surgery|September 2013|September 13, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01942642||59670|
NCT01942941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE/0314|Peripheral Vascular Disease and Nerve Stimulation|Prospective Observational Series to Establish the Haemodynamic Efficacy and Tolerability of gekoTM Device in Patients With Lower Limb Vascular Disease|CCLINS|University of Hull|Yes|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01942941||59647|
NCT01943253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hybrid ESD|Water-jet Assisted ESD vs Conventional ESD Technique for Treating Early Gastric Cancer|Water-jet Assisted Endoscopic Submucosal Dissection (ESD) in Comparison to Conventional ESD Technique for Treatment of Early Gastric Cancer||Shanghai Zhongshan Hospital|Yes|Completed|May 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01943253||59623|
NCT01930266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187/11|Young Adults With Life Threatening Cow's Milk Allergy: Risks of Decrease Bone Mineralization and Methods of Calcium Supplementation|||Assaf-Harofeh Medical Center|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|16 Years|30 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01930266||60618|
NCT01930760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013526|Supporting Physicians With Education And Know-how in Identifying and Motivating Overweight Kids|Supporting Physicians With Education And Know-how in Identifying and Motivating Overweight Kids: SPEAK IM OK|SPEAK IM OK|The Hospital for Sick Children|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 25, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01930760||60580|
NCT01931085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1438|Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)|"Compassionate Use of Triclabendazole for the Treatment of Parasites" (Prior to FDA Approval; Expanded Access Program)||University of Colorado, Denver||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|99 Years||||February 2016|February 11, 2016|August 22, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01931085||60555|
NCT01931371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFPERAF|Anal Fistula Plug Versus Endorectal Advancement Flap|An Outcome and Cost Analysis of Anal Fistula Plug Versus Endorectal Advancement Flap in Complex Anal Fistulae|AFPERAF|University of Zurich|Yes|Active, not recruiting|May 2007|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Both|18 Years|90 Years|No|||August 2013|August 22, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01931371||60533|
NCT01931384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-VL-LPSRCT|A Study of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen Embryo Transfer|A Randomized Controlled Comparison of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles||The University of Hong Kong|No|Completed|July 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|450|||Female|18 Years|45 Years|No|||December 2015|December 10, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01931384||60532|
NCT01908868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Trg/PG-2012/12563-601|A Trial of EBUS-TBNA Versus Conventional TBNA in Diagnosis of Sarcoidosis|||Postgraduate Institute of Medical Education and Research|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|130|||Both|15 Years|75 Years|No|||December 2014|December 26, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01908868||62256|
NCT01939574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28676|A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma|An Open-label, Single Arm Study to Explore Whether Potential Image Biomarkers Correlate With Efficacy of Bevacizumab Combined With Conventional Therapy in Newly Diagnosed Glioblastoma||Shandong Cancer Hospital and Institute|Yes|Active, not recruiting|August 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01939574||59906|
NCT01940133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQR309-001|A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309|Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors||PIQUR Therapeutics AG|Yes|Active, not recruiting|January 2014|December 2015|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01940133||59863|
NCT01940146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARC Ltd CLR_13_10|Efficacy and Safety of S0597 in Seasonal Allergic Rhinitis|Efficacy and Safety of Intranasal S0597 in an Environmental Exposure Unit Model of Seasonal Allergic Rhinitis: A Phase 2, Single-center, Randomized, Double-blind, Placebo and Active-controlled Parallel Group Study||Sun Pharma Advanced Research Company Limited|No|Not yet recruiting|November 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|275|||Both|18 Years|65 Years|No|||September 2013|September 6, 2013|September 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01940146||59862|
NCT01941303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Irradiation treatment outcome|Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease|Radical Re-irradiation of Recurrent NSCLC - Analysis of Outcome and Toxicity.||Maastricht Radiation Oncology|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|N/A|N/A|No|Non-Probability Sample|Patients with non-small cell lung cancer undergoing chest irradiation (with chemotherapy)        to a radical dose twice: in the primary and the recurrent setting.|March 2016|March 21, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941303||59773|
NCT01941550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005|Neoadjuvant Chemotherapy With Cabazitaxel|Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy|CLUBNET|RWTH Aachen University|Yes|Suspended|July 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|18 Years|N/A|No|||September 2015|September 24, 2015|July 22, 2013||No|Investigator changed locaction. Amendment pending.|No||https://clinicaltrials.gov/show/NCT01941550||59754|
NCT01941563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6603/1131|A Study of SI-6603 in Patients With Lumbar Disc Herniation|||Seikagaku Corporation|Yes|Active, not recruiting|September 2013|August 2017|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|30 Years|70 Years|No|||August 2015|November 24, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941563||59753|
NCT01941810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98513|Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy|A Pilot Study of Bovine Lactoferrin in Cancer Patients Reporting Taste Disturbances While Receiving Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|February 2014|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941810||59734|
NCT01941823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003555|Effect of Carnitine Deficiency on Myocardial Function in Children Receiving Continuous Renal Replacement Therapy|Assessment of the Effect of Carnitine Deficiency on Myocardial Function in Children Receiving Continuous Renal Replacement Therapy||Children's Research Institute|No|Recruiting|December 2014|July 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|1 Year|17 Years|No|||August 2015|August 26, 2015|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941823||59733|
NCT01942057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19043|Myopia Prevalence in Canadian School Children - a Pilot Study|Myopia Prevalence in Canadian School Children - a Pilot Study|Falcon|University of Waterloo|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|173|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|School children in Waterloo Region|July 2015|July 16, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01942057||59715|
NCT01942343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5505|Akathisia in Post Operative Outpatients Surgery|Etude de l'Effet du dropéridol et de l'Ondansetron Sur l'Incidence de l'Akathisie Post opératoire en Chirurgie Ambulatoire||University Hospital, Strasbourg, France|No|Not yet recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Both|18 Years|65 Years|No|||September 2013|September 12, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942343||59693|
NCT01942369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52014-210|A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months|A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.|DIE-NIS|Ipsen|No|Recruiting|September 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|N/A|No|Non-Probability Sample|Hospital patients who had been diagnosed with DIE, surgically treated and for whom        decision has been made to be treated with a GnRHa post-surgery.|February 2016|February 29, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942369||59691|
NCT01942681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1309|Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride|Multi-institution Study on Efficacy and Safety of Propiverine Hydrochloride for Female Patients With Urge and Stress Urinary Incontinence|FRESH|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|20 Years|N/A|No|||July 2015|July 14, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01942681||59667|
NCT01942954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|labpsicom-001|Health Mobile Cognitive Stimulation in Alcoholics|Executive Functioning in Alcoholics Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial||Universidade Lusófona de Humanidades e Tecnologias|Yes|Active, not recruiting|October 2012|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|75 Years|No|||September 2013|September 10, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01942954||59646|
NCT01942967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013: 055|Impact of Different Modes of Noninvasive Ventilation on Regional Oximetry and Hemodynamics in Premature Newborn|Impact of Different Modes of Noninvasive Ventilation (NCPAP Versus TrPA) on Regional Cerebral and Splanchnic Oximetry as Measured by Near Infrared Spectroscopy (NIRS) and Hemodynamics Using Echocardiography in Premature Newborns||University of Manitoba|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|10|||Both|N/A|2 Months|No|Probability Sample|Newborn infants less than 34 weeks gestational age at birth Requiring CPAP or TrPA as a        mode of respiratory support|August 2015|August 3, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01942967||59645|
NCT01942980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHIToN / IPC 2012-005|Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer|Double-blind Randomized Multicenter Phase III Study Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer.||Institut Paoli-Calmettes|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942980||59644|
NCT01939457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2.4|400mcg Sublingual Misoprostol as First Line Treatment|Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal||Gynuity Health Projects|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|641|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01939457||59915|
NCT01930513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG2010OSA|Exercise Capacity and Daily Physical Activity in Obese Subjects With Treated Obstructive Sleep Apnea|Exercise Capacity and Daily Physical Activity in Obese Subjects With Treated Obstructive Sleep Apnea||West Park Healthcare Centre|No|Completed|November 2010|January 2016|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|Obstructive Sleep Apnea|January 2016|January 4, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01930513||60599|
NCT01930786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-SP-12-001|An Adult Spasticity Registry of OnabotulinumtoxinA Treatment||ASPIRE|Allergan|No|Active, not recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|746|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Muscle Spasticity|January 2016|January 25, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930786||60578|
NCT01931098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160034|Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab|A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2015|September 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|99 Years|No|||December 2015|February 5, 2016|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931098||60554|
NCT01931397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG-12G03|DBS for Home Monitoring in Children With Kidney Transplantation|Novel Use of Dried Blood Spots (DBS)for Home Monitoring in Children With Kidney|DBS|Oregon Health and Science University|No|Completed|July 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|2 Years|21 Years|No|Non-Probability Sample|children who are followed at the Pediatric Kidney Transplant CLinic at OHSU.|April 2015|April 20, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01931397||60531|
NCT01931683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-13|Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)|Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia||Ajou University School of Medicine|Yes|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|No|||October 2014|October 13, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931683||60509|
NCT01931917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFI 2570|The Incredible Years Parents and Babies Program in Denmark|A Randomised Controlled Pilot Trial of The Incredible Years Parents and Babies Program in Denmark||The Danish National Centre For Social Research|No|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|N/A|N/A|No|||May 2015|May 21, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931917||60491|
NCT01939587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2013-93|Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics|A Single-centre, Randomised, Double-blind, Placebo-controlled, 3-way Multiple Dose, Cross-over, "Proof-of-concept" Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate (AMP) Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01939587||59905|
NCT01909076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034252-01|Transforming Opioid Prescribing in Primary Care|Implementing Opioid Risk Reduction Strategies Into Primary Care Practice|TOPCARE|Boston Medical Center|Yes|Completed|January 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909076||62240|
NCT01909323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMALTO|Digestive Tolerance of Maltitol and FOS|Digestive Tolerance and Postprandial Glycaemic and Insulinaemic Responses Evaluation of Different Maltitol/FOS Mixtures in Healthy Adults||Syral||Completed|September 2011|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909323||62222|
NCT01940991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL035|Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines|||Revance Therapeutics, Inc.||Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|No|||December 2013|December 27, 2013|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940991||59797|
NCT01941004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2315|Safety and Efficacy of Fingolimod in MS Patients in China|A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis||Novartis|Yes|Withdrawn|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||October 2015|October 9, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941004||59796|
NCT01940666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-TMU-PCOS-201207025|Presentations of Hyperandrogenic Phenotypes in Taiwanese Women|Clinical and Biochemical Presentations of Distinctive Types of Biochemical Hyperandrogenism in Premenopausal Taiwanese Women||Taipei Medical University WanFang Hospital|No|Completed|September 2012|July 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||5|Actual|649|||Female|13 Years|48 Years|No|Probability Sample|A retrospective review of the medical records of women who visited the Reproductive        Endocrinology Clinic was carried out at the Wan Fang Medical Center at Taipei Medical        University from 2009 and up to 2012. A total of 160 Taiwanese women with hyperandrogenism        (HA) and 165 women without hyperandrogenism (non-HA) were included in the study.|November 2013|November 5, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01940666||59822|
NCT01940679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-13-H|Bioavailability of Encapsulated Omega-3 Fatty Acids|Bioavailability of Encapsulated Omega-3 Fatty Acids||United States Army Research Institute of Environmental Medicine|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940679||59821|
NCT01940692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA01|Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA|TOPICAL AND INTRAVENOUS ADMINISTRATION OF TRANEXAMIC ACID ARE EQUALLY EFFECTIVE IN DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL||Ziekenhuis Oost-Limburg|Yes|Completed|July 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01940692||59820|
NCT01941056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08173|Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus|Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia||City of Hope Medical Center|Yes|Active, not recruiting|January 2014|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|September 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01941056||59792|
NCT01941316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAB CTC 11-001|Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients|Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy||Cancer Research and Biostatistics Clinical Trials Consortium|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941316||59772|
NCT01941329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-RET-2013-05|Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.|Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (PROTEUS)|PROTEUS|Association for Innovation and Biomedical Research on Light and Image|No|Active, not recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941329||59771|
NCT01941836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-008|Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients|A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients With or Without Statin Intolerance||Esperion Therapeutics|No|Completed|September 2013|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|349|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941836||59732|
NCT01942070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ge IDE No. I01210|A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction|Intracoronary Scaffold Assessment a Randomised Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction|ISAR-Absorb MI|Deutsches Herzzentrum Muenchen|Yes|Recruiting|September 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942070||59714|
NCT01942330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006972|Pain and Infection After Transvaginal Colectomy|Prospective Evaluation of a Laparoscopic-Assisted Transvaginal Approach for Colonic Resection|TVC|University of South Florida|Yes|Recruiting|August 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942330||59694|
NCT01942356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130047H|Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor|Evaluation of Closed-loop Titration of the Intravenous Anesthetic Propofol, Sufentanil and Ketamine Guided by BIS Monitor||The University of Texas Health Science Center at San Antonio|No|Completed|September 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942356||59692|
NCT01942993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0427|The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma|The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation||Icahn School of Medicine at Mount Sinai|Yes|Terminated|September 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 11, 2013|Yes|Yes|standard of care has changed|No||https://clinicaltrials.gov/show/NCT01942993||59643|
NCT01942655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS RF002 INTESTIPAX|IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection|ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection|INTESTIPAX|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|70 Years|No|||September 2014|September 1, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01942655||59669|
NCT01942668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXC12-05|A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms|A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus|REPLENISH|TherapeuticsMD|No|Active, not recruiting|September 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|1750|||Female|40 Years|65 Years|No|||October 2015|October 13, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942668||59668|
NCT01939717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST2|A Randomized Controlled Pilot Trial to Determine the Benefit of Set Dancing for People With Parkinson's Disease|A Randomized Controlled Pilot Trial to Determine the Benefit of Set Dancing for People With Parkinson's Disease||University of Limerick|No|Completed|August 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01939717||59895|
NCT01930526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JREB2011-12|Single Leg Cycling in COPD: Knowledge Translation to Pulmonary Rehabilitation|Single Leg Cycling in COPD: Knowledge Translation to Pulmonary Rehabilitation||West Park Healthcare Centre|No|Completed|July 2011|October 2015|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01930526||60598|
NCT01930773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONSIDE TEST|Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)|Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.|ONSIDE TEST|Medical University of Warsaw|No|Recruiting|March 2013|May 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|75 Years|No|||August 2013|August 29, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01930773||60579|
NCT01930825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment outcome NSCLC|Analysis of Treatment Outcome and Toxicity in NSCLC Patients Wither-irradiated to a High Dose for Recurrent Disease.|Radical Re-irradiation of Recurrent NSCLC-analysis of Outcome and Toxicity.||Maastricht Radiation Oncology|No|Completed|February 2013|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|N/A|N/A|No|Non-Probability Sample|Advanced stage non-small cell lung cancer patients.|April 2014|April 7, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01930825||60575|
NCT01930838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-191-13|Complications After Bariatric Surgery - a Clinical Trial|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on a Clinical Trial||University of Aarhus|No|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|400|Samples With DNA|Whole blood Urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|All gastric bypass operated residents in The Central Denmark Region between 2006 and 2011.|September 2013|December 3, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01930838|1 Month|60574|
NCT01931111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gen100sub3|Cardiovascular Risk Factors, Maximal Oxygen Uptake and Sedentariness: an Observational Study|Correlation Between Cardiovascular Risk Factors, Sedentary Behaviors and Maximal Oxygen Uptake in an Elderly Norwegian Population||Norwegian University of Science and Technology|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1600|||Both|70 Years|77 Years|No|Non-Probability Sample|elderly, norwegian|April 2015|April 14, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01931111||60553|
NCT01931124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gen100sub4|High Intensity and Moderate Training and Maximal Oxygen Uptake and Activity Levels|Effect of High Intensity and Moderate Training on Maximal Oxygen Uptake and Activity Levels in an Elderly Norwegian Population||Norwegian University of Science and Technology|Yes|Active, not recruiting|August 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|70 Years|77 Years|No|||August 2015|August 26, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01931124||60552|
NCT01931410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu-05|The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial|||Istanbul Bakirkoy Maternity and Children Diseases Hospital||Completed|June 2013|February 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|618|||Female|18 Years|44 Years|No|||February 2014|February 24, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931410||60530|
NCT01931423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu-06|The Influence of Placental Drainage of Management of the Third Stage of Labor:a Randomized Controlled Study|||Istanbul Bakirkoy Maternity and Children Diseases Hospital||Completed|November 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|485|||Female|18 Years|44 Years|No|||November 2013|March 7, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931423||60529|
NCT01940159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP361-105|A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.||Sunovion|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|50 Years|No|||July 2014|July 3, 2014|September 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01940159||59861|
NCT01940172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-POC-0090-PTL|Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer|A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer||TetraLogic Pharmaceuticals|No|Completed|November 2013|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940172||59860|
NCT01909089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/334|Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour|Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour.||University Hospital, Ghent|No|Recruiting|June 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01909089||62239|
NCT01940718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00076088|Androgen Regulation of Priapism in Sickle Cell Disease|Androgen Regulation of Priapism in Sickle Cell Disease||Johns Hopkins University|No|Not yet recruiting|March 2014|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|50 Years|No|||September 2013|September 11, 2013|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940718||59818|
NCT01941277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0902|Effect of Exercise on Insulin Resistance|Effect of Exercise on Insulin Resistance|EFFORT|Alere San Diego|No|Terminated|August 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3|||Both|18 Years|75 Years|No|||September 2014|September 9, 2014|September 6, 2013||No|funding withdrawn|No||https://clinicaltrials.gov/show/NCT01941277||59775|
NCT01941290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1206|BIOFLOW III Asia Registry|Biotronik-Safety and Performance Registry for an All-comers Diabetic Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice-III Asia||BIOTRONIK Asia Pacific Pte Ltd|No|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|880|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic Subjects requiring coronary revascularization with Drug eluting Stent (DES)|January 2015|September 9, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941290||59774|
NCT01941017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORIE|Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis|Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis||Ain Shams University|No|Completed|April 2009|March 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Female|18 Years|35 Years|No|Non-Probability Sample|Group I : patients with minimal or mild endometriosis (I or II) as proven by laparoscopy        (n=20).        Group II: (control group) patients with tubal obstruction without endometriosis (n=20).|September 2013|September 9, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01941017||59795|
NCT01941342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDR-2014-02|Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy|Evaluation of Preoperative Biliary Drainage on Outcome of Pancreatoduodenectomy: A Multicenter Randomized Controlled Study||Southwest Hospital, China|Yes|Not yet recruiting|January 2014|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|274|||Both|18 Years|70 Years|No|||January 2014|January 13, 2014|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941342||59770|
NCT01941589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0401-OH-CTIL|Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis|Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.||Sheba Medical Center|No|Recruiting|September 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01941589||59751|
NCT01941576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJTUMS-20130903|Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot|Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|September 2013|||September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|18 Years|No|||September 2013|September 9, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941576||59752|
NCT01941862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-2-0181|Depression and Anxiety Reduction Treatment for Suicide|Development and Evaluation of a Brief, Suicide Prevention Intervention Targeting Anxiety and Mood Vulnerabilities|DARTS|Florida State University|No|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|65 Years|No|||September 2015|September 10, 2015|July 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01941862||59730|
NCT01942083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|317-12-001|A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)|||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|June 2013|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|20 Years|75 Years|No|||January 2016|January 28, 2016|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01942083||59713|
NCT01942096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7650|Study of Airway Inflammation in Relation to Exercise in Elite Athletes|Study of Airway Inflammation in Relation to Exercise in Elite Athletes||Universitaire Ziekenhuizen Leuven|No|Completed|December 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|66|Samples With DNA|induced sputum sample nasal fluid venous blood (serum)|Both|14 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Competitive swimmers, competitive indoor athletes and healthy individuals|September 2013|September 9, 2013|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01942096||59712|
NCT01943006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hir-901113|Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis|Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment of Superficial Infusion Thrombophlebitis||Medinova AG|No|Recruiting|May 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|144|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01943006||59642|
NCT01939145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06142013|Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation|A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation||Georgetown University|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 3, 2013|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01939145||59939|
NCT01910454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD069626|Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke|Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke|COSTAR|Washington University School of Medicine|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01910454||62136|
NCT01930799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-NDO-112|Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns|||Allergan|No|Completed|August 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|120|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01930799||60577|
NCT01930812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITNEC-A1|18F-NaF PET Imaging for Bone Scintigraphy|18F- Sodium Fluoride PET Imaging as a Replacement for Bone Scintigraphy||British Columbia Cancer Agency|Yes|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|286|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930812||60576|
NCT01940562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0195-13|Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation|Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation||Rabin Medical Center|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|18 Years|No|||June 2015|June 15, 2015|September 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940562||59830|
NCT01940783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44381.068.13/METC 13-1-054|Assessment of the AB HiFocusTM Mid Scala Electrode Movement Using Cone Beam Imaging Following Cochlea Implantation|Assessment of the AB HiFocusTM Mid Scala Electrode Movement Using Cone Beam Imaging Following Cochlea Implantation|ABMS1|Maastricht University Medical Center|Yes|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940783||59813|
NCT01940796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-239|Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)|Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)||Massachusetts General Hospital|No|Recruiting|October 2013|September 2019|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940796||59812|
NCT01940809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01703|Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery|A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma||National Cancer Institute (NCI)|No|Recruiting|August 2013|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|September 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01940809||59811|
NCT01941121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 593|CCTG 593: Testing and Linkage to Care|CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group||California Collaborative Treatment Group|No|Active, not recruiting|July 2013|July 2016|Anticipated|February 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941121||59787|
NCT01940432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-2|The Efficacy of Electroacupuncture for Treatment of Simple Female Stress Urinary Incontinence: Comparison With Pelvic Floor Muscle Training-a Multicenter Randomized Controlled Trial|The Efficacy of Electroacupuncture for Treatment of Simple Female Stress Urinary Incontinence: Comparison With Pelvic Floor Muscle Training-a Multicenter Randomized Controlled Trial||Shaanxi Hospital of Traditional Chinese Medicine|Yes|Recruiting|March 2014|August 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||September 2013|June 11, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01940432||59840|
NCT01939847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J12129|IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins|IMAGE Study: Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|September 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939847||59885|
NCT01940484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22344|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage V Chronic Kidney Disease Patients on Haemodialysis|An Observational, Non-interventional Cohort Study to Observe the Efficacy and Use of MIRCERA in the Treatment of Chronic Renal Anaemia in Patients With Chronic Kidney Disease Stage V on Haemodialysis||Hoffmann-La Roche||Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|N/A|No|Probability Sample|Patients with Stage V chronic kidney disease on haemodialysis with renal anemia receiving        an erythropoietin|October 2015|October 1, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940484||59836|
NCT01940497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28879|SCHEARLY Study: A Study of the Safety of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Early and Locally Advanced HER2-Positive Breast Cancer|NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER||Hoffmann-La Roche||Active, not recruiting|November 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940497||59835|
NCT01941030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLARITY I|Complete Lesion Assessment With Fractional ffR and IVUS TechnologY|Complete Lesion Assessment With ffR and IVUS TechnologY (CLARITY I)|CLARITY I|Cardiovascular Systems Inc|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||February 2015|June 29, 2015|March 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01941030||59794|
NCT01940731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTQ01458-2-CTF|Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults|A Prospective, Open, Non-controlled, Multi-center Study of Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults.||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Not yet recruiting|October 2013|||March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||September 2013|September 9, 2013|September 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01940731||59817|
NCT01941043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin301-201|A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment|A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment||Cerecor Inc|No|Completed|November 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1357|||Both|18 Years|70 Years|No|||October 2014|October 30, 2014|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941043||59793|
NCT01942122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1442-0212|DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis|Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis||Dexa Medica Group|Yes|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|50 Years|No|||October 2015|October 13, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942122||59710|
NCT01942395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00052649|Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)|Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)||University of Michigan|No|Recruiting|March 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|25|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 13, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01942395||59689|
NCT01942694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DK098245|Vitamin D and Type 2 Diabetes Study|Vitamin D and Type 2 Diabetes Study|D2d|Tufts Medical Center|Yes|Recruiting|October 2013|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2382|||Both|30 Years|N/A|No|||February 2016|February 23, 2016|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01942694||59666|
NCT01941849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0499|Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma|A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma|VIBRaNT|University College, London|Yes|Withdrawn|October 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|September 10, 2013||No|Poor patient accrual|No||https://clinicaltrials.gov/show/NCT01941849||59731|
NCT01942382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100413|A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia|Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Subjects With Schizophrenia||Janssen Pharmaceutical K.K.|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|76|||Both|20 Years|65 Years|No|||September 2013|September 10, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942382||59690|
NCT01943279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUNNS-AFPFY112-RFUMA|Comparison of Telephone Follow-up With In-person Follow-up After Medical Abortion|A Comparison of Remote Follow-up After Medical Abortion Using Telephone and Serum Pregnancy Testing With Standard In-person Follow-up||Women's College Hospital|No|Completed|July 2011|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|139|||Female|16 Years|N/A|No|||December 2014|December 8, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943279||59621|
NCT01943292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-102|Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies|A Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of VS-6063, a Focal Adhesion Kinase Inhibitor, in Japanese Subjects With Non-Hematologic Malignancies||Verastem, Inc.|Yes|Completed|September 2013|||June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||January 2016|January 7, 2016|September 11, 2013|No|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01943292||59620|There were no limitations of the trial.
NCT01909765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Circumcicsion|Two Different Surgical Techniques on Postoperative Circumcision Pain|Comparison of Two Different Circumcision Surgical Technique on Postoperative Pain||Diskapi Yildirim Beyazit Education and Research Hospital|No|Not yet recruiting|July 2013|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|30|||Male|2 Years|14 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909765||62188|
NCT01939158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116892|Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine|Immunogenicity and Safety Study of 1 and 2 Doses of GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Pneumococcal Vaccine Prevenar 13™||GlaxoSmithKline||Active, not recruiting|October 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|900|||Both|12 Months|14 Months|Accepts Healthy Volunteers|||October 2015|February 4, 2016|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939158||59938|
NCT01939444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI-12-001|A Pilot Study of the Bioavailability of Nasal Naloxone|A Pilot Study of the Bioavailability of Nasal Naloxone||Norwegian University of Science and Technology|Yes|Completed|August 2013|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|5|||Male|18 Years|45 Years|No|||January 2015|January 2, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01939444||59916|
NCT01910714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARCH V: U26IHS300286/03|Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth|Adapting and Evaluating an Evidence-Based Intervention to Prevent HIV/AIDS Risk Among Apache Youth||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|267|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910714||62116|
NCT01930552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11470|A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies|A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Aflibercept in Combination With FOLFIRI Administrated Every 2 Weeks in Chinese Patients With Advanced Solid Malignancies||Sanofi|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930552||60596|
NCT01940835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003972|Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes|Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes||Mayo Clinic|No|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Serum, DNA, RNA extraction, brush biopsies from duodenal mucosa, biopsies of small      intestine, stool samples|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 Diabetes, diagnosed within 6 months|January 2016|January 4, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940835||59809|
NCT01941134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF-013-LG|Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery|Impact of Gastric Bypass Surgery on the Pharmacokinetics of Oral Contraceptive Hormones||Johns Hopkins University|No|Recruiting|April 2013|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Female|18 Years|40 Years|No|||February 2016|February 22, 2016|June 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941134||59786|
NCT01941407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-BR110|First Line Metastatic Breast Cancer Treatment (ESMERALDA)|A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER|ESMERALDA|ARCAGY/ GINECO GROUP|Yes|Completed|November 2013|March 2016|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941407||59765|
NCT01941914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA1310|Calcium Electroporation for the Treatment of Keloids|Calcium Electroporation for the Treatment of Keloids||Herlev Hospital|Yes|Recruiting|August 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941914||59726|
NCT01941927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13855|Trametinib With GSK2141795 in BRAF Wild-type Melanoma|Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma||University of California, San Francisco|Yes|Active, not recruiting|September 2013|May 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941927||59725|
NCT01940198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-417 ST|Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia|Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia|REfLecT|Holdsworth House Medical Practice|No|Completed|April 2010|September 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|117|||Both|N/A|N/A|No|Non-Probability Sample|Cohort of HIV-1 positive patients attending Holdsworth House Medical Practice who have        commenced ATV as a component of ART will be identified from review of current database.        Data will be collected retrospectively from patient electronic medical records for HIV-1        positive patients that have commenced ATV from year 2002 - 2008.|September 2013|September 8, 2013|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01940198||59858|
NCT01940211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-HS 1060nm-11-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||November 17, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940211||59857|
NCT01940445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-M22-13-01|Impact of Synergistic Sequential Treatment (SST)|Impact of Synergistic Sequential Treatment (SST) of Fractional Non-ablative and Q-Switched Lasers on Skin Texture||Lumenis Ltd.|No|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|September 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940445||59839|
NCT01940419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-425|Testing of the Drug Tranexamic Acids as Prophylaxis of Bleeding in Benign Surgical Removal of the Uterus|Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial|PeTraH|Hillerod Hospital, Denmark|Yes|Completed|April 2013|October 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|332|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940419||59841|
NCT01940744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walsh992013|Prescriptive Mobilization Versus a Pragmatic Mobilization|The Investigation of a Prescriptively Prescribed Non-Thrust Manipulation Versus a Pragmatically Prescribed Non-Thrust Manipulation for Treatment of Individuals With Low Back Pain: A Randomized Controlled Trial||Walsh University|No|Recruiting|October 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940744||59816|
NCT01941069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009477|School Climate and Children's Behavioral Health|Targeting School Climate and Children's Behavioral Health in Urban Schools|Project Access|Children's Hospital of Philadelphia|No|Recruiting|January 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|379|||Both|8 Years|15 Years|No|||October 2015|October 14, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01941069||59791|
NCT01908517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-50915|Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study|A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase Human Papilloma Viruses (HPV) Vaccine Utilization and Adherence Among Adolescents in Eastern North Carolina.||East Carolina University|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|520|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01908517||62282|
NCT01908751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAITH-2|Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2)|Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2): A Multi-Centre 2x2 Factorial Randomized Trial Comparing Sliding Hip Screws Versus Cancellous Screws AND Vitamin D Versus Placebo on Patient Important Outcomes and Quality of Life in the Treatment of Young Adult (18-60) Femoral Neck Fractures|FAITH-2|McMaster University|Yes|Recruiting|September 2014|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|898|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01908751||62265|
NCT01908985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYEMUST-FLUO|Ocular Fluorophotometry for Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).|Ocular Fluorophotometry to Assess the Aqueous Humor Production for Patients With Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).||EyeTechCare||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||July 2013|June 15, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01908985||62247|
NCT01942109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORNADO KB/202/2013|The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure|The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial|TORNADO|Medical University of Warsaw|No|Recruiting|September 2013|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|August 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01942109||59711|
NCT01909466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-12-298|Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia|An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|July 2013|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|64 Years|No|||June 2015|June 3, 2015|July 24, 2013|Yes|Yes||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01909466||62211|
NCT01909479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-005|A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency|A PHASE 3, MULTICENTER STUDY DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF A LONG ACTING HGH PRODUCT (MOD-4023) IN ADULT SUBJECTS WITH GROWTH HORMONE DEFICIENCY||Opko Biologics|Yes|Active, not recruiting|June 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|189|||Both|23 Years|70 Years|No|||July 2015|July 12, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909479||62210|
NCT01909778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.15|Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis|An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2||Boehringer Ingelheim||Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|July 25, 2013||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01909778||62187|
NCT01909791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol V|Treatment for CI-DME in Eyes With Very Good VA Study|Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity|Protocol V|Diabetic Retinopathy Clinical Research Network|Yes|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|702|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909791||62186|
NCT01910129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-AU-01|Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy|A Randomized, Multi-center, Double-blind, Parallel, Crossover Study of a Non-invasive Neurostimulation to the Vagus Nerve With the gammaCore Device for the Reduction in Frequency of Seizures Associated With Epilepsy.||ElectroCore LLC|No|Terminated|July 2013|October 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|13|||Both|18 Years|70 Years|No|||October 2014|October 21, 2014|July 15, 2013||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01910129||62160|
NCT01910116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC6102F|Efficacy of Shinabro in Hand Osteoarthritis|Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.||Seoul National University Hospital|Yes|Completed|September 2013|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||August 2015|November 16, 2015|July 22, 2013||No||No|February 28, 2015|https://clinicaltrials.gov/show/NCT01910116||62161|
NCT01940302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGU-03|Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes|Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes||Shaoguan University|Yes|Completed|June 2013|March 2014|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|25 Years|75 Years|No|||May 2014|May 8, 2014|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01940302||59850|
NCT01940276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046383|Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer|A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer||Duke University|No|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||October 2015|November 25, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940276||59852|
NCT01940289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTM001|Validation of Algometry for Use in the Human Foot|Validation of Algometry for Use in the Human Foot||Dundee Podiatry Clinic|Yes|Not yet recruiting|January 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|544|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940289||59851|
NCT01942187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6627|A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults|A Comparison of Medication Augmentation and Problem Solving Therapy||New York State Psychiatric Institute|No|Withdrawn|August 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|90 Years|No|||August 2014|March 20, 2015|September 10, 2013|Yes|Yes|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01942187||59705|
NCT01942473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiO2_Ulm|Effects of Automated Adjustment of FiO2 on Cerebral and Arterial Oxygenation in Preterm Infants|Effects of Automated Adjustment of Inspired Oxygen on Fluctuations of Regional Cerebral and Arterial Oxygenation in Preterm Infants With Frequent Desaturations|FiO2-Contr|University of Ulm|No|Completed|August 2012|April 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|N/A|30 Weeks|No|||November 2014|November 25, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01942473||59683|
NCT01942837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-301|Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling|Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing||Dana-Farber Cancer Institute|Yes|Recruiting|September 2013|August 2020|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942837||59655|
NCT01942850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICARS-CGI-Ery01-2013|International Ataxia Rating Scale in Younger Patients|APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)||Erydel|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|63|||Both|6 Years|18 Years|No|Non-Probability Sample|Known patients with ataxia/ataxia telangiectasia|December 2014|December 30, 2014|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942850||59654|
NCT01940705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1260-R|A Simplified Patient-Centered Educational Tool for Improved Hearing-Aid Outcomes|A Simplified Patient Centered Educational Tool for Improved Hearing Aid Outcomes||VA Office of Research and Development|No|Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|468|||Both|50 Years|89 Years|No|||October 2015|October 21, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940705||59819|
NCT01940458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-QS-13-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||July 15, 2015|September 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940458||59838|
NCT01940471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-320-0110|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B||Gilead Sciences|Yes|Active, not recruiting|September 2013|April 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1022|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940471||59837|
NCT01941602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/884|A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery|A Comparative Study of Prophylactic Enoxaparin Routinely Administered Preoperative for Prevention of Venous Thromboembolism in Meningioma Surgery - an Acceptable Risk-benefit Ratio?||St. Olavs Hospital|No|Completed|August 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|979|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having had surgical treatment for intracranial meningioma in Norway (St Olavs        University Hospital, Trondheim, and University Hospital North Norway, Tromsø) and Sweden        (Karolinska University Hospital, Stockholm).|February 2016|February 10, 2016|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01941602||59750|
NCT01941615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.31|Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel|An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subjects||Boehringer Ingelheim||Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|September 10, 2013||||No||https://clinicaltrials.gov/show/NCT01941615||59749|
NCT01941875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032793|Luteal Phase Progesterone in IUI and Gonadotropin Cycles|The Effect of Luteal Phase Support on Pregnancy Rate in Intrauterine Insemination Cycles Following Ovarian Stimulation With Gonadotropins||University of Alberta|No|Recruiting|July 2014|January 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||July 2013|December 31, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01941875||59729|
NCT01908764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-023|Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery|An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery||Alcon Research|No|Withdrawn|November 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|6 Months|12 Years|No|||October 2014|March 4, 2016|July 24, 2013|No|Yes|Management Decision|No||https://clinicaltrials.gov/show/NCT01908764||62264|
NCT01908998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21460|Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals|Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals||Temple University|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|40|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01908998||62246|
NCT01909232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-CFS-TRMD-2|A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)|A Prospective, Double-Blind, Randomized, Parallel-Group, Sham-Controlled Feasibility Trial of Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder||Cervel Neurotech, Inc.|Yes|Completed|July 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||June 2015|June 23, 2015|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909232||62229|
NCT01943019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phamon 001|Linagliptin in Schizophrenia Patients|A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients||Monash University|No|Recruiting|August 2013|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||April 2015|April 17, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01943019||59641|
NCT01943032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 196/2010|Discordant Hormonal Status of Breast Cancer.|Discordant Hormonal Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.||National Cancer Institute, Thailand|No|Completed|April 2011|April 2012|Actual|April 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|105|Samples With DNA|Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes.|Female|25 Years|75 Years|No|Non-Probability Sample|Breast Cancer Patients Stage I,II and III.|September 2013|September 19, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01943032|1 Year|59640|
NCT01909804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-0109|Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection|A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection||Gilead Sciences|No|Completed|June 2013|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|323|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909804||62185|
NCT01909817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-9-2003|A Novel Method for Enhancement of Standard Rest Electrocardiograms (ECG) Provides New Parameters for Early Detection of Coronary Artery Disease (CAD)|||Hillel Yaffe Medical Center|Yes|Active, not recruiting|July 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing routine coronary angiogram|July 2013|July 24, 2013|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01909817||62184|
NCT01910142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8145|Effect of Nutrition on Bone Metabolism as Assessed by 41Ca|The Effect of Nutritional Intervention on Bone Metabolism as Assessed by 41Ca and Modeling; Proof of Concept||TNO|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Female|50 Years|68 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01910142||62159|
NCT01910467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15351|Avoiding Hypotension in Preterm Neonates|Avoiding Hypotension in Preterm Neonates (AHIP) - A Randomised Controlled Study on Near Infrared Spectroscopy Monitoring of Peripheral-muscle and Cerebral Oxygenation With Defined Interventions Versus Routine Monitoring and Treatment in Preterm Neonates|AHIP|Medical University of Graz|No|Recruiting|November 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|98|||Both|N/A|6 Hours|No|||November 2015|November 25, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01910467||62135|
NCT01940575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1010-055-001|Efficacy and Safety Study of SkinPlus-Hyal® to Nasolabial Fold|Clinical Trial to Evaluate the Safety and Efficacy of SkinPlus-Hyal® as Tissue Restorative Biomaterials in the Improvement of Bilateral Nasolabial Fold Wrinkles||Seoul National University Hospital|No|Completed|July 2013|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 6, 2014|September 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01940575||59829|
NCT01940822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001918|Cardiovascular Effects of Energy Drinks in Healthy Adults|Cardiovascular Effects of Energy Drinks in Healthy Adults||Mayo Clinic|No|Recruiting|July 2013|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940822||59810|
NCT01942200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONKOOXA01|A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Oxaliplatin Utilized in Combination Therapy for Adjuvant Treatment of Colon Carcinoma of Stage III After Complete Removal of the Primary Tumor and for Treatment of Metastasizing Colorectal Carcinoma.||Onkovis GmbH|No|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|350|||Both|N/A|N/A|No|Probability Sample|Patients treated in practices, clinics, hospitals|August 2015|August 11, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942200||59704|
NCT01942486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00065178|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine||University of Utah|No|Active, not recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|7 Years|18 Years|No|||May 2015|May 26, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01942486||59682|
NCT01942876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA022445|Preventing Drug Use in Low Income Clinic Populations|Preventing Drug Use in Low Income Clinic Populations|QUIT|University of California, Los Angeles|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|411|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942876||59652|
NCT01939886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSACT 2|Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)|Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)|TRANSACT2|London School of Hygiene and Tropical Medicine|Yes|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|219|||Both|6 Months|10 Years|No|||November 2013|November 27, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939886||59882|
NCT01939899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16017|Phase 2 Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma|An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma||Millennium Pharmaceuticals, Inc.|No|Recruiting|November 2013|March 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939899||59881|
NCT01939912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADENOSINE-PILOT-CIBIEM|Study on Reflex Response During Temporary Stimulation and Inhibition of Chemoreceptors of Carotid Bodies - a Pilot Study|Study on Reflex Response During Temporary Stimulation and Inhibition of Chemoreceptors of Carotid Bodies - a Pilot Study||Noblewell|Yes|Active, not recruiting|August 2013|||March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01939912||59880|
NCT01940224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTH2828/26/06/2013|Evaluation of Preoperative Use of Pregabalin on Postoperative Analgesia After Laparoscopic Colorectal Surgery|Effectiveness of Preemptive Use of Pregabalin on Pain Intensity and Postoperative Morphine Consumption After Laparoscopic Colorectal Surgery||Larissa University Hospital|Yes|Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01940224||59856|
NCT01940510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29042|A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802|An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects||Hoffmann-La Roche||Completed|October 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940510||59834|
NCT01912417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Aerobic Exercise During Hemodialysis|Aerobic Exercise Increases Phosphate Removal During Hemodialysis||Universidade Católica de Pelotas|No|Active, not recruiting|August 2010|January 2014|Anticipated|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|15 Years|90 Years|No|||September 2013|September 4, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912417||61986|
NCT01908218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0583|The Reliability and Validity of the Upper Lip Bite Test to Predict Difficult Laryngoscopy in Korean|||Yonsei University|No|Completed|February 2009|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|344|||Both|20 Years|80 Years|No|Non-Probability Sample|adult patients undergoing general anesthesia with orotracheal intubation|July 2013|July 22, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01908218||62305|
NCT01908205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXY-R07-2013|Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)|Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism|OXY-R|Anagnostou, Evdokia, M.D.|Yes|Active, not recruiting|September 2013|August 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|17 Years|No|||February 2016|February 9, 2016|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908205||62306|
NCT01909011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#199-11|A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder|A Single Blind, Randomized, Sham Controlled Study of Cranial Electrical Stimulation in Bipolar II Disorder||Beth Israel Medical Center|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|85 Years|No|||February 2015|November 19, 2015|July 15, 2013||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01909011||62245|A small sample size.A possible self-selection bias due to extensive time commitment required from the study participants.
NCT01909245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12446|Islet Cell Transplant for Type 1 Diabetes|Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen|TCD|City of Hope Medical Center|Yes|Recruiting|October 2013|July 2021|Anticipated|July 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|68 Years|No|||November 2015|November 10, 2015|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909245||62228|
NCT01909505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saliva Testosterone|Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men|Comparison of Salivary Testosterone With Serum Free Testosterone Done by Equilibrium Dialysis.||Saliva Biomarkers, Inc.|No|Recruiting|June 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Male|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty normal males and 20 male subjects, 25 to 65 years of age.|July 2013|July 24, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909505||62208|
NCT01909219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC split|PMC Split Preparation for Colon Cleansing|A Randomized Controlled Trial Comparing Efficacy and Acceptability of Split and Standard Dose Sodium Picosulphate/Magnesium Citrate for Bowel Cleansing Prior to Colonoscopy: the MAGIC-P Multicenter Study|MAGIC-P|Luigi Sacco University Hospital|Yes|Completed|January 2012|April 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|862|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909219||62230|
NCT01910155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71205502|A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Adults With Acute Bacterial Otitis Externa||Par Pharmaceutical, Inc.|No|Terminated|July 2013|September 2015|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|455|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|July 25, 2013|Yes|Yes|FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for    bioequivalence. Small study size resulted in negative culture rates.|No||https://clinicaltrials.gov/show/NCT01910155||62158|
NCT01910168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE29002|A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis|A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis||Hoffmann-La Roche||Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|36|Samples With DNA|Blood Samples|Both|N/A|N/A|No|Probability Sample|Patients with spinal muscular atrophy|March 2016|March 1, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910168||62157|
NCT01910480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1302|Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects|A Phase 1, Open-Label Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects||Neurocrine Biosciences|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910480||62134|
NCT01911052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05-050-002|The Impact of Telephone and Short Message System Based Education on Bowel Preparation for Colonoscopy|The Impact of Telephone and Short Message System Based Education on Bowel Preparation for Colonoscopy in Health Screened Population||Keimyung University Dongsan Medical Center|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|390|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911052||62090|
NCT01941693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05-0279|A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity|Novel Treatments for Alcohol Dependence: A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity||South West Sydney Local Health District|No|Completed|March 2007|March 2013|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|No|||September 2013|September 9, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01941693||59743|
NCT01941706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026786|Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT|Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT||Emory University|No|Completed|October 2009|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|21 Years|N/A|No|||February 2014|February 11, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01941706||59742|
NCT01941940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28699|A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate and/or Other DMARDS in Patients With Rheumatoid Arthritis|A NATIONAL, OPEN-LABEL, SINGLE-ARM, PHASE IIIB STUDY TO EVALUATE THE EFFICACY OF WEEKLY TOCILIZUMAB SUBCUTANEOUS, ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE AND/OR OTHER DMARDS IN RHEUMATOID ARTHRITIS (RA) PATIENTS.||Hoffmann-La Roche||Recruiting|September 2013|May 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01941940||59724|
NCT01941953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 273/12|Metformin and 5-fluorouracil for Refractory Colorectal Cancer.|Phase II Study of Metformin and 5-fluorouracil in Patients With Advanced Colorectal Cancer Previously Treated With Oxaliplatin and Irinotecan Based Chemotherapy.||Instituto do Cancer do Estado de São Paulo|No|Completed|November 2012|March 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|16 Years|N/A|No|||April 2015|April 6, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01941953||59723|
NCT01942213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJRetina ML28942|Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.|Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients||NJ Retina|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|65 Years|90 Years|No|Probability Sample|Private practice patients referred to retinal specialist for treatment of Neovascular        Age-Related Macular Degeneration|April 2015|April 20, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942213||59703|
NCT01942499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006-WP|Community-Based Maintenance Exercise Program for COPD|A Randomized Controlled Trial of a Post-rehabilitation Community-based Exercise Program for Individuals With COPD||West Park Healthcare Centre|No|Recruiting|November 2012|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|50 Years|N/A|No|||December 2015|December 9, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01942499||59681|
NCT01942512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN12145|Risk Factors for Intracranial Aneurysm Recanalization After Endovascular Treatment.|Evaluation of Risk Factors Associated With Intracranial Aneurysm Recanalization After Endovascular Treatment|ARETA|CHU de Reims|No|Recruiting|November 2013|November 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1275|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular        treatment|August 2014|August 5, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942512||59680|
NCT01942889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8710|Antioxidants and Pulmonary Rehabilitation in COPD Patients|Antioxidants Supplementation Associated With Pulmonary Rehabilitation is it Effective on Muscle Dysfunction and Signaling Pathways Involved in the Myopathy of COPD?|AREB-1|University Hospital, Montpellier|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|64|||Both|40 Years|78 Years|No|||May 2015|May 21, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01942889||59651|
NCT01940237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6397|A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer|||New York State Psychiatric Institute|Yes|Suspended|April 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2014|September 2, 2014|August 28, 2013||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01940237||59855|
NCT01941095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28695|A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|Multicenter, Open-label, Phase IIIb Study to Evaluate the Safety, Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-biologic Disease-modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Active, not recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01941095||59789|
NCT01941355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SheppHeartCABG|Trial of Rehabilitation in Phase 1 After Coronary Artery Bypass Grafting|SheppHeartCABG Shaping Outcomes by Exercise Training and Psycho-education in Phase 1 for Coronary Artery Bypass Grafting Patients|SheppHeart|Rigshospitalet, Denmark|Yes|Completed|September 2013|April 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|60|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01941355||59769|
NCT01908231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0313|Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism|Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism: the Thrombo-Embolism Lactate Outcome Study|TELOS|Azienda Ospedaliero-Universitaria Careggi|No|Completed|December 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|N/A|No|Probability Sample|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals        participating in the study with clinical suspicion of PE will be considered for the study.        We excluded patients with life expectancies of less than 3 months, and patients with first        symptoms 15 day or more before inclusion.        The diagnosis of PE will be established by spiral computed tomography or by lung scan or a        selective pulmonary angiogram.        Patients with proven PE who will give written consent to the use of their medical        information for research purposes will be enrolled in the study.|February 2014|February 15, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908231||62304|
NCT01908530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM0639|Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes|Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes||Imperial College London|No|Recruiting|November 2013|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|September 8, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908530||62281|
NCT01908777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-020|A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma|A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908777||62263|
NCT01909258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/PK|Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods|Comparison and Reproducibility of Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods: Clinical Observation Versus Photography Versus the EOS Imaging System|CRESPEOS|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers 20 to 30 years of age.|October 2015|October 30, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909258||62227|
NCT01909518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013SDU-QILU-G02|Detection of Early Esophageal Squamous Neoplasia|Detection of Early Esophageal Squamous Neoplasia by Using Virtual Chromoendoscopy and Probe-based Confocal Laser Endomicroscopy||Shandong University|Yes|Recruiting|July 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|endoscopic biopsies will be taken at suspicious lesions|Both|50 Years|80 Years|No|Non-Probability Sample|Consecutive patients screened that fulfill the eligibility criteria at Qilu Hospital,        Shandong University will be enrolled into the study|July 2013|July 24, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909518||62207|
NCT01909531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12BN136|Deep Brain Stimulation (DBS) Data Base Study|Deep Brain Stimulation (DBS) Data Base Study||St. Joseph's Hospital and Medical Center, Phoenix|No|Enrolling by invitation|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Parkinson's Disease or Essential Tremor who have undergone either awake or        asleep DBS surgery performed by Francisco A. Ponce, MD|February 2016|February 8, 2016|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01909531||62206|
NCT01909856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sim-palonosetron|The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy|The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|October 2011|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|90 Years|No|||November 2015|December 2, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01909856||62181|
NCT01909492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-089B|Relaxin in Multiple Sclerosis (MS)|Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis||Providence Health & Services|No|Recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Patients will provide blood and cerebrospinal fluid for use in this research.|Female|18 Years|45 Years|No|Non-Probability Sample|Patients with suspected MS undergoing a lumbar puncture for diagnosis, patients with        stable MS willing to participate in the study, and patients without MS having a lumbar        puncture as part of their non-MS disease management will be invited to participate in this        study.|March 2016|March 8, 2016|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909492||62209|
NCT01909830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST153.03|Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients|A Phase II Study to Evaluate Activity and Toxicity of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients||Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01909830||62183|
NCT01910493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMSaude01|Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique|Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique: A Randomized Control Trial|SMSaude|Absolute Return for Kids|No|Completed|November 2011|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1352|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 25, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910493||62133|
NCT01911091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 460196|Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)|Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation in Both Skeletal Muscle and Adipose Tissue|Columbus|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Active, not recruiting|July 2013|August 2018|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|56|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01911091||62087|
NCT01911104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 471035|Exercise Resistance in Type 2 Diabetes|Investigating the Underlying Mechanisms of Exercise Resistance in Individuals With Type 2 Diabetes|RESIST|Translational Research Institute for Metabolism and Diabetes, Florida|No|Recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911104||62086|
NCT01941719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11447|Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures|Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures|DFE|Temple University|No|Suspended|September 2009|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|101|||Both|21 Years|75 Years|No|||January 2013|September 9, 2013|April 4, 2013||No|Analysis of 99 subjects showed no significant benefits of the novel diabetic foot education.|No||https://clinicaltrials.gov/show/NCT01941719||59741|
NCT01941966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 84/2010|A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.|A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.||Instituto do Cancer do Estado de São Paulo||Completed|November 2010|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01941966||59722|
NCT01942226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODE|Investigation on Medical Management of Dry Eye Patients|||National Cheng Kung University|No|Completed|August 2013|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|466|||Both|20 Years|N/A|No|Non-Probability Sample|Participants from a primary care clinic or a tertiary referral center|December 2013|December 6, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942226||59702|
NCT01942239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-CGMS|Real-time Continuous Glucose Monitoring in Very Low Birth Weight Neonates|Real-time Continuous Glucose Monitoring Reduces Duration of Hypoglycemia Episodes in Very Low Birth Weight Neonates||University Hospital, Tours|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|48|||Both|N/A|24 Hours|No|||December 2008|September 12, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942239||59701|
NCT01942525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-07-2013|Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants|Intrauterine Growth Restriction Has an Impact on Amplitude-integrated EEG in Preterm Infants||Medical University of Vienna|No|Active, not recruiting|June 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|156|||Both|23 Weeks|30 Weeks|No|Non-Probability Sample|Retrospectively, children with intrauterine growth restriction (defined as a birth weight        below the 10th percentile) treated at the Neonatal Intensive Care Unit (NICU) of the        Medical University Vienna between 2005 and 2007 were included in the study. Besides IUGR,        inclusion criteria were gestational age between 23+1 and 29+6 weeks and routinely assessed        aEEG measurements. Infants with congenital anomalies and severe asphyxia were excluded.        The control group consists of infants of the same age with normal birth weight (>10th        percentile) in the same study period.|September 2013|September 13, 2013|August 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01942525||59679|
NCT01942863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131106-6|Effect of Water Exchange Method on Single-balloon Enteroscopy|Effect of Water Exchange Method on Intubation Depth and Diagnostic Yield in Patients Undergoing Single-balloon Enteroscopy: a Prospective, Randomized, Controlled, Patient-blind Trial.||Fourth Military Medical University|Yes|Completed|December 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|110|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01942863||59653|
NCT01934660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130194|Links Between Inflammation and Cardiometabolic Diseases|Inflammatory Characterization of Known or Possible Cardiovascular Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|July 2025|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|225|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01934660||60280|
NCT01940757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-CH-01|Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae|An Experimental Infection Study of Dermally-applied Infectious Necator Americanus Hookworm Larvae in Hookworm-naïve Adults||Albert B. Sabin Vaccine Institute|Yes|Recruiting|October 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|September 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01940757||59815|
NCT01941082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28936|A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration|A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration||Hoffmann-La Roche||Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|50 Years|N/A|No|||February 2016|February 1, 2016|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941082||59790|
NCT01912118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43511.058.13|The Medasense Study|Measurement of Nociceptive Index During General Anesthesia in ASA 1‐3 Patients Undergoing Elective Surgery Using the Nociception Level (NoL) Index||Leiden University Medical Center|Yes|Completed|July 2013|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|8||Actual|96|||Both|18 Years|80 Years|No|||April 2015|April 2, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01912118||62009|
NCT01908543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS 2013/1|Iron Deficiency and Hereditary Haemorrhagic Telangiectasia|Iron Deficiency and Hereditary Haemorrhagic Telangiectasia||Imperial College London|No|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||July 2013|May 28, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908543||62280|
NCT01909024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT23013|Pelvic Embolisation to Reduce Recurrent Varicose Veins - Recurrent|A Randomised Controlled Trial Investigating The Use Of Pelvic Vein Embolisation To Reduce Recurrent Varicose Veins Of The Legs In Women With Recurrent Varicose Veins And Associated Pelvic Venous Reflux.||The Whiteley Clinic|Yes|Not yet recruiting|July 2013|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Female|18 Years|N/A|No|||May 2014|May 16, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01909024||62244|
NCT01909037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TILFLEXFY 002|Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis|Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis||Tilman S.A.||Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|45 Years|75 Years|No|||July 2013|June 22, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909037||62243|
NCT01909050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000354|Immune Response in Celiac Disease on In-vitro Gluten Challenge|An In-vitro Gluten Challenge on the Immunologic Response in Celiac Disease.||Beth Israel Deaconess Medical Center|No|Active, not recruiting|February 2013|||January 2015|Actual|N/A|Observational|Time Perspective: Prospective||5|Anticipated|40|Samples With DNA|Duodenal biopsy samples|Both|18 Years|75 Years|No|Non-Probability Sample|Subjects will be selected from patients undergoing a clinically indicated upper endoscopy        at Beth Israel Deaconess Medical Center|June 2015|June 16, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909050||62242|
NCT01909271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK5853|Tailored Approaches to Stroke Health Education|Tailored Approaches to Stroke Health Education|TASHE|Columbia University|Yes|Enrolling by invitation|July 2013|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|266|||Both|34 Years|N/A|No|||February 2015|February 2, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01909271||62226|
NCT01909544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MX-20665|Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD|Muscle Oxygenation and Metabolism in Response to a Localized Fatigue-inducing Exercise in Patients With Chronic Obstructive Pulmonary Disease||Laval University|No|Recruiting|September 2011|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01909544||62205|
NCT01909869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2012-12|A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions|A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)|CREDIT|JW Medical Systems Ltd|Yes|Recruiting|January 2013|March 2018|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|75 Years|No|||July 2013|July 24, 2013|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01909869||62180|
NCT01909843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0171-1.2/13|ALX-0171 Safety Study in Adults With Hyperresponsive Airways|A Phase I, Single-centre, Open Label Study to Evaluate the Potential Occurrence, Reversibility and Prevention of Bronchoconstriction as Individual Response to Escalating Doses Followed by Repeated Doses of ALX-0171, Administered by Oral Inhalation to Adults With Hyperresponsive Airways||Ablynx||Completed|August 2013|||December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|60 Years|No|||January 2014|January 2, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909843||62182|
NCT01910181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28390|A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma|A Phase I Open Label, Multicenter, Multiple-dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAFV600 Mutation-positive Unresectable or Metastatic Melanoma||Hoffmann-La Roche||Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910181||62156|
NCT01910194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LanLyx|Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying|A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication||Profil Institut für Stoffwechselforschung GmbH|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910194||62155|
NCT01910753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12018 APANVADS|Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population|Feasibility Study: Physical Activity Program Associated Wtih Nutrition Therapeutic Education in Head and Neck Cancer Population Treating by Chemotherapy With or Without Radiotherapy.|APANVADS|University Hospital, Limoges|No|Recruiting|May 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01910753||62113|
NCT01911338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACuesta07072013|Inertial Sensors Used to Learn Manipulation|EFFECT OF REAL-TIME FEEDBACK THROUGH INERTIAL SENSORS IN LEARNING POSTEROANTERIOR THORACIC MANIPULATION||University of Malaga|Yes|Completed|February 2012|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|December 3, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911338||62068|
NCT01910727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Together on Diabetes - JHSPH|Together on Diabetes Study: Evaluation of a Pilot Diabetes Prevention and Management Program for American Indian Youth|||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|December 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|10 Years|19 Years|No|||July 2013|January 20, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910727||62115|
NCT01910740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC - 1042680|Mobility in Older People|Optimising Rehabilitation Outcomes in Frail Older Adults: Effects of Increasing the Amount of Physical Activity|MOVE|La Trobe University|Yes|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|198|||Both|60 Years|N/A|No|||April 2015|April 21, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01910740||62114|
NCT01911312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP3.00|Evaluation of Thermal-Aided Muscle Stimulation|||Niveus Medical, Inc.||Recruiting|July 2013|||September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911312||62070|
NCT01941732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-Pilot1|Motor Response to Sildenafil in PD|Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease||Bispebjerg Hospital|No|Completed|November 2003|March 2004|Actual|February 2004|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|80 Years|No|||September 2013|September 10, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941732||59740|
NCT01941979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP-113/2011|A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.|A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy.||Instituto do Cancer do Estado de São Paulo||Recruiting|September 2011|September 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|309|||Both|18 Years|75 Years|No|||October 2014|October 29, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01941979||59721|
NCT01942252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207|COMPLICATIONS RELATED CARBOXYHEMOGLOBIN LEVELS IN SECOND HAND SMOKING PEDIATRIC TONSILLECTOMY PATIENTS|COMPLICATIONS OF SECOND HAND SMOKING IN PEDIATRIC TONSILLECTOMY PATIENTS||Mustafa Kemal University|Yes|Recruiting|August 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inclusion Criteria:        -Patients 1-12 years old scheduled for adenotonsillectomy; written informed consent.|September 2013|September 10, 2013|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942252||59700|
NCT01942265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0033|H7N9 Mix and Match With AS03 and MF59 in Healthy Adults|A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without AS03 and MF59 Adjuvants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|10||Actual|980|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||September 2014|March 3, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942265||59699|
NCT01942538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00820-45|Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia|Study of the Effectiveness of Maintenance rTMS Sessions for 6 Months Versus Placebo in Subjects With Fibromyalgia Responders to 3 Week-rTMS Treatment||Centre Hospitalier Esquirol|No|Recruiting|September 2013|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|78|||Both|18 Years|70 Years|No|||July 2015|August 5, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942538||59678|
NCT01942551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-DT-001|Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride|||Dongkook Pharmaceutical Co., Ltd.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|47|||Male|20 Years|29 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942551||59677|
NCT01930695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013|Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T|Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T|Pre-CRAFT|Biotronik SE & Co. KG|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Failure patients with CRT-D indication according to current ESC guidelines and        permanent atrial fibrillation|January 2015|January 9, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01930695||60585|
NCT01911845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-103|An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine|An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine||AbbVie|No|Completed|April 2013|September 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||August 2015|September 16, 2015|May 13, 2013|No|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01911845||62029|
NCT01912430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120246|Retrospective Data Analysis of VitalCare Targeted Population Management on Scott and White Chronically Ill Beneficiaries|Retrospective Data Analysis of the Impact of Vital Care Targeted Population Management Upon a Matched Cohort of Scott and White Health Plan Beneficiaries||Scott & White Health Plan|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|17559|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01912430||61985|
NCT01908790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075160|Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter|Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter vs Venous Oxygen Saturation From Blood Samples From the Jugular Vein vs Central Venous Oxygen Saturation vs Mixed Venous Oxygen Saturation, Measured by a CO-Oximeter.||Mespere Lifesciences Inc.|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Acute and chronic heart failure patients already receiving right heart catheterization        (RHC) as part of their usual care|September 2015|September 25, 2015|July 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908790||62262|
NCT01908803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-026|Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes|Proof of Concept of Single Application of AL-60371/AL-817 Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes Compared to CIPRODEX® (BID for 7 Days)||Alcon Research|No|Terminated|December 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|6 Months|12 Years|No|||October 2015|October 16, 2015|July 24, 2013|Yes|Yes|Management decision|No|August 24, 2015|https://clinicaltrials.gov/show/NCT01908803||62261|
NCT01909882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Massage therapy|Effect of Family Member's Massage Therapy on the Vital Signs and Glasgow Coma Scale Score|The Effect of Family Members' Massage Therapy on Vital Signs and Glasgow Coma Scale Score of Patients Hospitalized in Intensive Care Unit: A Triple-blinded Randomized Controlled Clinical Trial Study||Baqiyatallah Medical Sciences University|Yes|Completed|August 2007|May 2013|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|1||Actual|180|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2012|July 25, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01909882||62179|
NCT01910233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOB01|Registry of Patients With Acute Dyspnea in the Emergency Department|Prospective Registry for Quality Assurance of Medical Care of Patients With Acute Dyspnea in the Emergency Department||Klinikum Nürnberg|No|Recruiting|May 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the emergency department of the city hospital Nuremberg|March 2015|March 30, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910233|6 Months|62153|
NCT01910519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT HIPC: VAX-010|Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)|Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2013|November 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910519||62131|
NCT01910220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1033-HV-1223|Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)|||Regeneron Pharmaceuticals|No|Completed|August 2013|October 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|125|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910220||62154|
NCT01910506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-106|RDEA3170 AME Study|A Phase 1 Absorption, Metabolism and Excretion Study of [14C]RDEA3170 Orally Administered to Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|August 2013|November 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01910506||62132|
NCT01911117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ER-102-080|Evaluating the Correction of Non-invasive Estimated Continuous Cardiac Output in Cardiac Surgical Patients|Evaluating the Correction of Non-invasive Estimated Continuous Cardiac Output in Cardiac Surgical Patients||National Cheng-Kung University Hospital|Yes|Recruiting|June 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|52|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo cardiac surgery will be included in this study.|July 2013|July 30, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911117||62085|
NCT01911936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJM716X1101|A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors||Novartis|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01911936||62022|
NCT01912248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-143|Acute Effect of Strength Training on Blood Pressure in Cardiac Patients|Acute Effect of Strength Training on Blood Pressure in Cardiac Patients||Bispebjerg Hospital|Yes|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|36|||Both|18 Years|80 Years|No|Probability Sample|12 heart transplant recipients 12 heart failure patients 12 patients with ischemic disease|January 2015|January 26, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912248||61999|
NCT01911325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120D2205|Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients|A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer||Novartis|Yes|Completed|October 2013|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911325||62069|
NCT01911663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGC-CKJ-PC|The Effect of Korean Red Ginseng Supplementation on Glucose Control|The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus||Yonsei University|Yes|Completed|November 2011|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911663||62043|
NCT01941745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhCC10 Study 2013|Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome|Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome||Tufts Medical Center|Yes|Recruiting|October 2013|July 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|88|||Both|24 Weeks|29 Weeks|No|||February 2016|February 23, 2016|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941745||59739|
NCT01941992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOV-HN-1-2012 ROSAM|Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients|Role of SAMITAL® in Prevention and Treatment of Oral Mucositis in Patients Treated With Chemo-radiation (CT/RT)for Head-and-neck Squamous Cell Carcinomas. A Double-blind, Phase 2 Placebo Controlled, Randomized Trial.|ROSAM|Istituto Oncologico Veneto IRCCS||Recruiting|December 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01941992||59720|
NCT01942005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/10|EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients|EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection|EBVER/TMC|University Hospital, Basel, Switzerland|No|Completed|January 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|Samples With DNA|Blutsample|Both|18 Years|N/A|No|Non-Probability Sample|patients who underwent organ transplatation or patients who have a HIV infection|December 2014|December 3, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01942005||59719|
NCT01934335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301763|Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer||University of Iowa|Yes|Recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|99 Years|No|||December 2015|December 14, 2015|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934335||60305|
NCT01934348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH091203|Psychological First Aid for Victims of Crime|Psychological First Aid for Victims of Crime||Medical University of South Carolina|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||August 2013|April 10, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01934348||60304|
NCT01931007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004459|Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis|Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis, A Randomized Placebo Controlled Pilot Study|BMAC|Mayo Clinic|Yes|Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|August 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931007||60561|
NCT01931020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucose versus sucrose in pain|Analgesic Effect of Oral 25% Glucose Versus Oral 24% Sucrose for Pain Relief During Heel Lance in Preterm Neonates|Double Blind Randomised Controlled Trial to Compare the Efficacy of Oral 25% Glucose With Oral 24% Sucrose for Pain Relief During Heel Lance in Preterm Neonates||Lady Hardinge Medical College|Yes|Recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|34 Weeks|37 Weeks|Accepts Healthy Volunteers|||August 2013|August 26, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01931020||60560|
NCT01912131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-120|Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients|Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients||Memorial Sloan Kettering Cancer Center||Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|99|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01912131||62008|
NCT01908257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-127|Lesinurad Interaction Study With Ranitidine|A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|July 2013|November 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908257||62302|
NCT01908569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVISEV-004ROVIC|Application of MACS and Time-lapse Technology in Good-prognosis Patients|Application of MACS (Magnetic-activated Cell Sorting) and Time-lapse Technology (Embryoscope) in Assisted Reproduction Patients With Good Prognosis||IVI Sevilla|No|Recruiting|July 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|200|||Female|18 Years|38 Years|No|||January 2016|January 15, 2016|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908569||62278|
NCT01909557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unict10/1997|Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.|Effect of Supplementation of Antioxidant Substances and Probiotics in HCV Correlated Liver Disease Treated With Interferon and Ribavirin. Studies on Biochemical and Virological Response and on Quality of Life.||University of Catania|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909557||62204|
NCT01909895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK4250|Study of the Effects of Negative Emotions on Endothelial Function|Translational Research of Negative Emotions and Acute Endothelial Dysfunction|PUME|Columbia University|No|Recruiting|August 2013|January 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|4||Anticipated|280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01909895||62178|
NCT01934179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP-GI-049|Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy|Pilot Study Assessing the Correlation Between Telomere Length and Chemotherapy- Related Toxicity Among Early Stage and Metastatic Colorectal Patients Over the Age of 70||Fox Chase Cancer Center|No|Terminated|October 2013|||September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|Samples With DNA|whole blood|Both|70 Years|N/A|No|Non-Probability Sample|Cancer Center|March 2016|March 1, 2016|August 29, 2013|No|Yes|Low Accrual Rate|No||https://clinicaltrials.gov/show/NCT01934179||60317|
NCT01934426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303058RINC|Identification of Admission High Risk Elderly|Identification of Admission High Risk Elderly From Multiple Cohorts: a Pilot Study||National Taiwan University Hospital|No|Completed|April 2013|April 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|760|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study populations include as below; A.Retrospective cohort group B.Perspective cohort        group|April 2014|April 22, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01934426||60298|
NCT01934439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009262|AMES Treatment of the Proximal Arm in Chronic Stroke|AMES Rehabilitation of the Proximal Arm in Severely Impaired Stroke Patients|AMES|Oregon Health and Science University|Yes|Recruiting|August 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||February 2015|February 23, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934439||60297|
NCT01930331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHI|Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO|Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania||Ifakara Health Institute|Yes|Not yet recruiting|September 2013|February 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|60 Years|No|||August 2013|August 23, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01930331||60613|
NCT01939990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0720|Safety Study of Nebivolol for COPD Patients|Nebivolol in Chronic Obstructive Pulmonary Disease||University of Chicago|No|Withdrawn|January 2012|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|0|||Both|40 Years|75 Years|No|||January 2016|January 11, 2016|January 22, 2013|Yes|Yes|Funding was discontinued.|No||https://clinicaltrials.gov/show/NCT01939990||59874|
NCT01920139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07100450|Ultrasound Guided Core Biopsy vs Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy|Ultrasound Guided Core Biopsy vs Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients Suspected of Having Breast Cancer.||University of Pittsburgh|No|Completed|December 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|105|||Female|N/A|N/A|No|||August 2013|August 6, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01920139||61394|
NCT01920152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0142|Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)|A Randomized Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip||University of Colorado, Denver|Yes|Enrolling by invitation|August 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|72 Years|No|||January 2016|January 15, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920152||61393|
NCT01920165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRF NR-0166-1|Smoking Ban and Paediatric Hospital Admissions for Respiratory Tract Infections in England|Smoke-free Legislation in England and Hospital Admissions for Respiratory Tract Infections Among Children||University of Edinburgh|No|Completed|January 2001|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1660652|||Both|N/A|14 Years|Accepts Healthy Volunteers|Probability Sample|The population at risk for each time point is the number of children living in England        aged 0-14 years|August 2013|August 9, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01920165||61392|
NCT01913496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eBalance|Development of Web Application and Evaluation Its Impact on Healthy Lifestyle|Development of Internet Web Application and Evaluation of Its Impact as a Tool in Promoting Healthy Lifestyle Indicators in Adults||Hebrew University of Jerusalem|Yes|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 12, 2016|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913496||61903|
NCT01913795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266134|Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma|Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma||Children's Hospital Boston|No|Completed|May 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|29|||Both|4 Years|15 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|May 21, 2013||No||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01913795||61880|
NCT01913808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEV-POST/ESP10|Comparing Intravenous and Oral Iron in Postoperative Anemia|Efficacy of Intravenous Ferric Carboxymaltose in the Improvement of Anemia in Patients With Postoperative Knee Prosthesis||Parc de Salut Mar|No|Completed|January 2011|January 2013|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913808||61879|
NCT01914380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16623|Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration|PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea®) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration|PERSEUS|Bayer|No|Active, not recruiting|July 2013|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|988|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with wAMD treated with Eylea. Participants        will be recruited from ophthalmological clinics and practices throughout Germany.        The decision upon treatment is made at the discretion of the attending physician,        according to his/her medical practice.        The medication is prescribed at regular visits to the investigator's office. Commercially        available product will be used to treat the patients.|February 2016|February 9, 2016|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01914380||61836|
NCT01914731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001355|Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum|Fecal Microbiota Transplant (FMT) for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum||Massachusetts General Hospital|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|7 Years|90 Years|No|||October 2014|October 22, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914731||61809|
NCT01914991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS-UMA-02-13|Combined Static and Dynamic Orthotic Treatment of the PIP Joint|Treatment of the PIP Joint Flexion Contracture: Combined Static and Dynamic Orthotic Intervention Compared With Traditional Combine Therapy. A Randomized Controlled Trial|StaDinOrt|University of Malaga|Yes|Completed|June 2011|January 2013|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01914991||61789|
NCT01931306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.193|Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)|An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)||Boehringer Ingelheim||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 20, 2013||||No||https://clinicaltrials.gov/show/NCT01931306||60538|
NCT01931618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERAF-BALANCE-2|Testing the Efficacy of an Online Alcohol Intervention in a Workplace Setting|Digital Therapy: Evaluation of the Fully Automated Alcohol Intervention "Balance".||University of Oslo|No|Completed|April 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 26, 2013|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931618||60514|
NCT01931865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205010328|IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation|IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation||Yale University|No|Terminated|September 2012|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|August 26, 2013||No|lost the recruiting source- no recruitment for the past 18months, PI moving|No|August 31, 2015|https://clinicaltrials.gov/show/NCT01931865||60495|Open study, small number of patients
NCT01932099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 011|TranScatheter Aortic Valve RepLacement System US Feasibility Trial|The Direct Flow Medical TranScatheter Aortic Valve RepLacement System US Feasibility Trial|SALUS|Direct Flow Medical, Inc.|No|Active, not recruiting|August 2013|December 2018|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||November 2013|June 10, 2014|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932099||60477|
NCT01932112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPLE|Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)|Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)|APPLE|Seoul St. Mary's Hospital|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01932112||60476|
NCT01932424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12AR04|Blood Propofol Concentrations in Children During Spinal Surgery|Comparison of Measured Versus Predicted Blood Propofol Concentrations During Total Intravenous Anaesthesia in Children Undergoing Spinal Surgery||Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|1||Actual|20|||Both|5 Years|18 Years|No|||August 2013|August 29, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01932424||60452|
NCT01932437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH106|Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers|A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers||Elusys Therapeutics|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|September 30, 2014|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932437||60451|
NCT01932697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1273|Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer|Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer||Mayo Clinic|Yes|Recruiting|September 2013|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932697||60431|
NCT01932970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120359|Assess Impact on Calcium Levels When Hemodialysis Subjects With SHPT Switch From Cinacalcet HCl to AMG 416|A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416||Amgen|No|Completed|August 2013|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932970||60410|
NCT01933607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1513-CL-VL-01 SOU UK|TOPS™ System Post Marketing Study To Evaluate The Safety And Effectiveness Of TOPS™ System|A Study To Evaluate The Safety And Effectiveness Of TOPS™ System In The Lumbar Spine||Premia Spine|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|85 Years|No|||October 2015|October 19, 2015|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01933607||60361|
NCT01933919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-970|A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder|A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder||AbbVie|No|Active, not recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|6 Years|18 Years|No|||January 2016|January 22, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933919||60337|
NCT01933880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016078|A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants|An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)||Xian-Janssen Pharmaceutical Ltd.|No|Completed|December 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|August 28, 2013||No||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01933880||60340|
NCT01933893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139/13|Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients|||Assaf-Harofeh Medical Center|No|Not yet recruiting|October 2013|||May 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Women diagnosed with repeated implantation failure (RIF) who are undergoing IVF treatment.|August 2013|August 29, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933893|1 Year|60339|
NCT01934166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15084A|Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects|An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects||H. Lundbeck A/S|No|Completed|July 2013|||August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01934166||60318|
NCT01934452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA6180080|Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients|Prospective Study To Analyse The Characteristics Of Patients Achieving Complete Remission With Sunitinib In mRCC And Identify Potential Predictive Factor Of Complete Remission vs Patients Not In Complete Remission Treated With Sunitinib|APERCU|Pfizer|Yes|Recruiting|May 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|whole blood and serum|Both|18 Years|99 Years|No|Probability Sample|complete remission in mRCC patients treated with sunitinib versus non complete remission        in mRCC patients treated with sunitinib|March 2016|March 10, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01934452||60296|
NCT01940003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1147-1141|Effects of an Aquatic Physical Exercise Program on Glycaemic Control and Perinatal Outcomes of Gestational Diabetes: Study Protocol for a Randomized Controlled Trial|Effects of an Aquatic Physical Exercise Program on Glycemic Control and Perinatal Outcomes of Gestational Diabetes - a Randomized Clinical Trial||Professor Fernando Figueira Integral Medicine Institute|Yes|Recruiting|September 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|35 Years|No|||February 2015|February 24, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01940003||59873|
NCT01913210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetaBPG|Effect of Ginseng on Blood Pressure|Effect of Ginseng on Blood Pressure: A Systematic Review and Meta-Analysis of Controlled Trials||St. Michael's Hospital, Toronto|No|Completed|April 2013|January 2016|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Hypertensive Healthy|March 2016|March 2, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913210||61925|
NCT01913483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-BIV-12-03|ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial|ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial|ENDOMAX|The Medicines Company|Yes|Active, not recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3900|||Both|18 Years|N/A|No|||July 2014|November 19, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913483||61904|
NCT01914133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01316|Acarbose and Older Adults With Postprandial Hypotension|Acarbose and Older Adults With Postprandial Hypotension|PPH|University of British Columbia|Yes|Recruiting|January 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|65 Years|N/A|No|||August 2015|August 14, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914133||61855|
NCT01914393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050302|Pediatric Open-Label Extension Study|A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects||Sunovion|Yes|Recruiting|September 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|295|||Both|6 Years|17 Years|No|||January 2016|January 12, 2016|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914393||61835|
NCT01914406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010 030|High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients.|High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients With Impaired Chronotropic Response: A Randomized Controlled Crossover Trial.||Bispebjerg Hospital|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||January 2015|January 26, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01914406||61834|
NCT01914744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 13-03|Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL|Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study||Fudan University|No|Recruiting|February 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|82|||Both|18 Years|80 Years|No|||July 2013|July 31, 2013|March 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01914744||61808|
NCT01914757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00018|Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist|A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)||AstraZeneca|Yes|Active, not recruiting|August 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1296|||Both|12 Years|75 Years|No|||February 2016|February 11, 2016|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914757||61807|
NCT01915004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bladder Training Video|The Effectiveness of a Bladder Training Video for Management of Lower Urinary Tract Symptoms.|Bladder Training Video Versus Individual Urotherapy for Children With Non-neurogenic Lower Urinary Tract Dysfunction.||McMaster University|No|Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|5 Years|10 Years|No|||March 2016|March 21, 2016|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01915004||61788|
NCT01931631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM GWU DM Study-2|Plant-Based Dietary Intervention in Type 2 Diabetes-2|A Practice-Based, Nutrition Intervention in Type 2 Diabetes|WCCR-DIAB2|Physicians Committee for Responsible Medicine|Yes|Suspended|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 26, 2013||No|Erroneously duplicated study|No||https://clinicaltrials.gov/show/NCT01931631||60513|
NCT01931878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010332|Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.|Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.||Yale University|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 26, 2013||No||No|September 4, 2015|https://clinicaltrials.gov/show/NCT01931878||60494|Relatively small number of participants. crossover not parallel design
NCT01932125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28446|An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer|An Indian Multicentric Open Label Prospective Post Marketing Surveillance Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice||Hoffmann-La Roche||Not yet recruiting|February 2017|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or        primary peritoneal cancer initiated on therapy with Avastin|March 2016|March 1, 2016|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932125||60475|
NCT01932138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EJF22802|Trial to Improve Access to PMTCT Services and Reduce HIV Transmission From Mother to Child|Evaluation of Interventions to Achieve Universal Access to PMTCT Services and Reduce Mother-to-Child Transmission of HIV in Dar es Salaam, Tanzania|FS|Harvard School of Public Health|Yes|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|190530|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01932138||60474|
NCT01932450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZKIPLA-ADPKD-001|Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control|A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease|RAFALE|Shanghai Changzheng Hospital|Yes|Recruiting|August 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|60 Years|No|||September 2014|September 23, 2014|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01932450||60450|
NCT01932710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1158|A Feasibility Study of Prophylactic White Blood Cell Transfusions|A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2013|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 3, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932710||60430|
NCT01932983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-01499|Clinical Application of "Train of Four" Testing in the Intraoperative Monitoring Setting|Clinical Application of Train of Four Testing in the Intraoperative Monitoring Setting||New York University School of Medicine|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|150|||Both|18 Years|85 Years|No|Probability Sample|Subjects undergoing instrumented orthopedic surgical procedure which requires the use of        neurophysiologic intraoperative monitoring modalities.|October 2015|October 26, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01932983|1 Day|60409|
NCT01932996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307M39761|Enhancing Smoking Cessation in the Homeless Population|Enhancing Smoking Cessation in the Homeless Population||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|654|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932996||60408|
NCT01933009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79/13|The Effect of GnRH Administration During Luteal Support in Frozen-thawed Transfer Cycles|||Assaf-Harofeh Medical Center||Recruiting|August 2013|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Women undergoing frozen-thawed IVF cycles|August 2013|August 28, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933009|1 Year|60407|
NCT01933906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_CML 1|Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response|Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Recruiting|August 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933906||60338|
NCT01939171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP- Nefro 001|Thymoglobulin in Cadaver Donor|Conditioning of the Cadaver Donor by Thymoglobulin Administered to Reduce the Pro-inflammatory State After Brain Death.||Instituto de Investigación Hospital Universitario La Paz|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|80 Years|No|||September 2013|September 5, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01939171||59937|
NCT01939184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-05710|Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia|A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)||Warner Chilcott|No|Completed|August 2013|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|796|||Male|45 Years|N/A|No|||June 2015|June 1, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939184||59936|
NCT01934465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.11|Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment|Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.||Hellenic Oncology Research Group|No|Completed|February 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Clinics for cancer prevention|October 2014|October 23, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934465||60295|
NCT01934478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCH20130823-2|Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer|Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy||Qingdao Central Hospital|No|Recruiting|August 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|80 Years|No|Probability Sample|study population is among advanced Chinese breast cancer patient.|October 2015|October 11, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01934478||60294|
NCT01930305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXKJGG2012|Effects of Heating Transfusion on Brain Function|Effects of Heating Transfusion on Brain Function of Surgical Patients||General Hospital of Ningxia Medical University|Yes|Completed|June 2012|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Probability Sample|adult paitents scheduled for major surgery.|July 2014|July 10, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01930305||60615|
NCT01934491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0266|Cognitive Training for Depression II|A Novel Cognitive Training Intervention for Major Depressive Disorder||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|August 2013|August 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|55 Years|No|||December 2015|December 24, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934491||60293|
NCT01940016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-05005|Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women|A Feasibility Study on the Effects of Tailored Communication and Health Coach Support on Physical Activity in Overweight Postmenopausal Women: BePHIT|BePHIT|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2007|||November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01940016||59872|
NCT01940029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105079RC|Pharmacokinetic Study in Neurosurgical ICU Patients —Using Vancomycin as an Example|Pharmacokinetic Study in Neurosurgical ICU Patients —Using Vancomycin as an Example||National Taiwan University Hospital|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples Without DNA|Urine, Cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Neurosurgical ICU patients|September 2013|September 6, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01940029||59871|
NCT01913834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MP002|Nasally and sc Administered Teriparatide in Healthy Volunteers|A Single-centre, Open-label, Five-way Crossover Study in Healthy Female Participants to Assess the Pharmacokinetics of Nasally Administered Formulations of Teriparatide Compared to a Subcutaneous Injection.|NINTTO|Nottingham University Hospitals NHS Trust|No|Not yet recruiting|September 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|7|||Female|55 Years|90 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01913834||61878|
NCT01914146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01375|Insulin Therapy and Falls Due to Orthostatic Hypotension|Insulin Therapy and Falls Due to Orthostatic Hypotension (Pilot Study)||University of British Columbia|No|Active, not recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|65 Years|N/A|No|||August 2015|August 14, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914146||61854|
NCT01914419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000a|Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage|Administration of Oxytocin Via Intramuscular Injection and Intravenous Bolus or Intravenous Infusion in the Third Stage of Labor for Prevention of Postpartum Hemorrhage||Gynuity Health Projects|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|4983|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914419||61833|
NCT01914445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-46-13|Chromoendoscopy of the Colon After Oral Administration of Indigo Carmine|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|August 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914445||61831|
NCT01915017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082793-03|Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia|Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia|Mcog|The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|178|||Both|18 Years|60 Years|No|||July 2013|August 1, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01915017||61787|
NCT01915238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130179|Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study|Age-Related Eye Disease Study 2 (AREDS2) Ancillary Spectral Domain Optical Coherence Tomography (A2A_SDOCT) Extension Study||National Institutes of Health Clinical Center (CC)||Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|52|||Both|50 Years|85 Years|No|||June 2014|August 27, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915238||61770|
NCT01931644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN-BB-01|Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)|A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives||Sanguine Biosciences|No|Recruiting|July 2013|December 2040|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20000|Samples With DNA|Whole blood, serum, plasma, PBMC, RNA, DNA, saliva, stool, hair, skin, CSF, synovial fuid,      tumor tissue, urine|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|Diagnosed with a health condition|March 2016|March 16, 2016|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01931644||60512|
NCT01932164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2013-04|Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients|Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients||Hospital Sirio-Libanes|Yes|Active, not recruiting|May 2013|March 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|7 Years|12 Years|No|||August 2013|March 18, 2015|August 27, 2013||No||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01932164||60472|
NCT01932151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIN-TER-2010-01|Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis|Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome Associated With Sepsis||Hospital Clinic of Barcelona|No|Completed|December 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|85 Years|No|||September 2013|September 4, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01932151||60473|
NCT01932463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD002|ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Tremor||InSightec|No|Completed|May 2011|July 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|80 Years|No|||August 2013|August 29, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01932463||60449|
NCT01933035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0134|Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.|Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.||Beth Israel Medical Center|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|Samples Without DNA|Study subjects will have the following collected: Lavender tri-potassium EDTA tubes filled      according to the manufacturer's specifications [approximately 4ML of venous blood], labeled,      and promptly dispatched to the laboratory.The sample will be gently inverted several times      prior to analysis on the ADVIA 120 taking care not to overly agitate the sample. Moreover,      the specimen shall be inspected for clot formation prior to being assayed. The full blood      count shall be obtained and in the configuration sub-menu the extended platelet parameter      option shall be selected and thus actuated. A print out will be generated including the MPC,      MPM, platelet component distribution width, platelet mass distribution width, and large      platelet count in addition to the standard platelet count and mean platelet volume [MPV].|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population would consist of adult female and male subjects of all ethnic        persuasions in good general health apart from thrombocytopenia, bone marrow aplasia,        myelodysplasia, or active malignancy requiring therapy. Vulnerable strata of the hospital        population will not be recruited into the study.|October 2015|October 13, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933035|12 Months|60405|
NCT01933022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGD-EC-005|A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease|An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer|EFFECT|Astellas Pharma Inc|No|Terminated|August 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Male|18 Years|N/A|No|||November 2015|November 4, 2015|August 28, 2013||No|Termination due to high current screen rate failure and unreliable PSA mRNA assay.|No||https://clinicaltrials.gov/show/NCT01933022||60406|
NCT01933308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTION|Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study|Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study|OPTION|Hopital du Sacre-Coeur de Montreal|Yes|Recruiting|March 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|40 Years|N/A|No|||February 2014|February 28, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01933308||60384|
NCT01939197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-004|A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection|A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)|TURQUOISE-I|AbbVie|Yes|Active, not recruiting|August 2013|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|320|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939197||59935|
NCT01934192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113445|Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study|NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study||GlaxoSmithKline|Yes|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|85 Years|No|||February 2016|March 3, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934192||60316|
NCT01930318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTP-IR-EEN-1|Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery|Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery||Jinling Hospital, China|Yes|Recruiting|August 2013|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|164|||Both|18 Years|70 Years|No|||November 2014|November 7, 2014|August 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930318||60614|
NCT01913509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC102-2314-B-182-003|A Study of Post-Stroke Pain and Fatigue: Clinical Evaluation and Treatment Effect|A Study of Post-Stroke Pain and Fatigue: Clinical Evaluation and Treatment Effect||Chang Gung University|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||February 2016|February 16, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913509||61902|
NCT01913847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-SIL-301|Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension|Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure||Hanmi Pharmaceutical Company Limited|Yes|Recruiting|September 2013|May 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|20 Years|N/A|No|||March 2016|March 14, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913847||61877|
NCT01913860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE/2011/10|Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle)|Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle): Protocol for a Randomised Complex Intervention|SIMPle|National University of Ireland, Galway, Ireland|Yes|Completed|September 2013|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2577|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01913860||61876|
NCT01914159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-037.0156|Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study||RIP|University Hospital, Bonn|Yes|Active, not recruiting|February 2013|||February 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||November 2015|November 30, 2015|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914159||61853|
NCT01914432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH16410-301|Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia|A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia||Yuhan Corporation|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|210|||Both|19 Years|N/A|No|||July 2014|July 7, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914432||61832|
NCT01914770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114246|Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76|Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76||GlaxoSmithKline|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1016|||Both|18 Years|N/A|No|Probability Sample|The primary population is the subpopulation of patients from the pooled modified        Intent-to-Treat population from BLISS-52 and BLISS-76 who have renal, neurological,        haematological, or cardiovascular/respiratory organ domain involvement (as defined by a        BILAG domain score of A, B or C in at least one of the domains) at baseline and 1 of the        following:          -  are anti-double-stranded deoxyribonucleic acid (anti-dsDNA) positive (= 30 IU/mL) at             baseline, OR          -  have low C3 and/or C4 complement relative to the normal range at baseline.|September 2013|September 12, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01914770||61806|
NCT01915030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WM002-wp3|Protect - The Impact of a High Protein Diet on Preservation of Muscle Mass|Protect The Impact of a High Protein Diet on the Preservation of Muscle Mass During Caloric Restriction in Middle Age and Elderly People||Wageningen University|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01915030||61786|
NCT01915251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130181|Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women|Microbiomic and Immunologic Profiling of Women With Antibiotic Induced Vaginal Candidiasis||National Institutes of Health Clinical Center (CC)||Recruiting|July 2013|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|May 2, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915251||61769|
NCT01915602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16728|Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)|A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)||Bayer|No|Active, not recruiting|September 2013|May 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915602||61742|
NCT01915615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL117006-01A1|HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy|HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy|HCMR|University of Virginia|Yes|Recruiting|April 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2750|Samples With DNA|Blood samples for genetic analysis and biomarkers will be obtained and retained.|Both|18 Years|65 Years|No|Probability Sample|Hypertrophic cardiomyopathy clinics Cardiology clinics Genetic clinics Hypertrophic        Cardiomyopathy Association|March 2016|March 11, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915615|5 Years|61741|
NCT01931891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ztb- wharton jelly|Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2013|July 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|20|Samples With DNA|umbilical cord placenta|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|preeclamptic women|July 2013|August 28, 2013|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931891||60493|
NCT01932177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-716|EVESOR: a Phase 1 Trial of Everolimus and Sorafenib|EVESOR: a Phase 1 Trial of Everolimus and Sorafenib to Assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination|EVESOR|Hospices Civils de Lyon|Yes|Recruiting|April 2013|October 2015|Anticipated|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|August 27, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01932177||60471|
NCT01932190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM12456 - K120102|Artificial Kidney Initiation in Kidney Injury|Artificial Kidney Initiation in Kidney Injury, a Multicenter Randomised Trial|AKIKI|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|620|||Both|18 Years|N/A|No|||August 2013|February 23, 2016|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932190||60470|
NCT01932476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC001|Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes|Randomized Double-Masked Gluten Challenge to Evaluate Markers of Autoimmunity in Patients With Type-1 Diabetes and Celiac Disease After Oral Gluten Challenge||Joslin Diabetes Center|No|Recruiting|August 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Anticipated|52|||Both|18 Years|50 Years|No|||March 2014|March 25, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01932476||60448|
NCT01932723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|891025|Effect of Functional Lumbar Stabilization Exercises in Women With Menstrual Low Back Pain|Effect of Functional Lumbar Stabilization Exercises on Pain, Disability and Kinesiophobia in Women With Menstrual Low Back Pain|LBP|University of Social Welfare and Rehabilitation Science|Yes|Completed|January 2011|January 2012|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|19 Years|39 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01932723||60429|
NCT01933061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-MEL-001|Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma|A Randomized, Open Label, Multi-center Phase 2 Study of Nab-Paclitaxel Versus Epigenetic Modifying Therapy of CC-4386 With Nab-Paclitaxel in Subjects With Chemotherapy naïve Metastatic Melanoma||Celgene|No|Withdrawn|January 2014|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|August 28, 2013|Yes|Yes|Strategic decision not to proceed with the opening of this study. There are no concerns over    the safety or quality of the investigational products involved.|No||https://clinicaltrials.gov/show/NCT01933061||60403|
NCT01933594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5315|Evaluating the Safety and Efficacy of Single-Dose Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load|A Phase I/II Study of Single Dose Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2014|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933594||60362|
NCT01933321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS and stem cell therapy|Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)|Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|September 2012|June 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01933321||60383|
NCT01933620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130180|Study of the Human Microbiome in Clinical Center Patients|Studies of the Human Microbiome in Clinical Center Patients||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|January 2030|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|No|||June 2015|June 19, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933620||60360|
NCT01933633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FertilEX|Improved Fertility After Exercise in Overweight/Obese Women|Study of Pregnancy Rate After Exercise Training Prior to Assisted Fertilisation in Overweight/Obese Women|FertilEX|Norwegian University of Science and Technology|No|Recruiting|September 2013|January 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|50 Years|No|||November 2015|November 25, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933633||60359|
NCT01943045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0102|Phase 2 Study of NGM282 in Patients With Type 2 Diabetes|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus||NGM Biopharmaceuticals, Inc|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|70 Years|No|||November 2015|November 14, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943045||59639|
NCT01941147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELF-01|Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke|An Open Label, One Arm, Dose Escalation Study to Evaluate the Safety of Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke.||Campus Bio-Medico University|No|Recruiting|August 2013|||September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941147||59785|
NCT01939470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE0840|Oklahoma Native American Women's Osteoporosis Screening Study|Oklahoma Native American Women's Osteoporosis Screening Study||Oklahoma State University|No|Active, not recruiting|October 2007|March 2016|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|Samples Without DNA|Serum|Female|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of Native American who are eligible for health care services at Indian        Health Clinics in the Oklahoma City area|April 2015|April 20, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01939470||59914|
NCT01939730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-304|Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma|Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|August 1999|September 2013|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939730||59894|
NCT01913522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01689|Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration|Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: The Effect of Double Short vs. Standard Exposure Cryoablation Duration During Pulmonary Vein Isolation.|CIRCA-DOSE|University of British Columbia|No|Recruiting|September 2014|January 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913522||61901|
NCT01913535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP-002|Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)|RAPID KOR|Massachusetts General Hospital|Yes|Terminated|April 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|91|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913535||61900|
NCT01913873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATH201301|High-sensitivity Troponin in Cardiac Surgery|High-sensitivity Cardiac Troponin and CK-MB Concentrations in Patients Undergoing Cardiac Surgery||Onze Lieve Vrouw Hospital|No|Completed|January 2014|March 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|400|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913873||61875|
NCT01914783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-Particles EK-6142|Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects|Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects|Particles|Hannover Medical School|No|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 31, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914783||61805|
NCT01914796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441001|A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Crossover, Single Oral Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06412562 In Healthy Subjects||Pfizer|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|May 22, 2014|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01914796||61804|
NCT01915043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS_UMA-02-13|Improving Adherence Healthy Lifestyle With a Smartphone Application Based After Surgery in Cancer Patients|Improving Adherence Healthy Lifestyle With a Smartphone Application Based After Surgery in Cancer Patients|APPCOMCAN|University of Malaga|Yes|Active, not recruiting|January 2013|September 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|65 Years|No|||July 2013|December 3, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01915043||61785|
NCT01931930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS656/12|Effect of Perilla Extract on Improvement on Gastrointestinal Discomfort|Effect of Perilla Extract on Improvement of Intestinal Discomfort and Bowel Function in Healthy Volunteers With Gastrointestinal Discomfort||Amino Up Chemicals Co., Ltd.|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|47|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 29, 2013|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01931930||60490|
NCT01941108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004654|Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care|Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study|mP2P|Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|November 20, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01941108||59788|
NCT01931904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000009745|Eye Pressure Lowering Surgery|OBSERVATIONAL STUDY OF OCULAR BLOOD FLOW PRE- AND POST- TRABECULECTOMY SURGERY USING FUNCTIONAL AND STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY|IOP|Oregon Health and Science University|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|40 Years|80 Years|No|Probability Sample|This study will measure blood flow changes in 20 glaucoma patients undergoing        trabeculectomy surgery to lower IOP. Another 20 patients undergoing cataract surgery will        be selected as a control group.|April 2015|April 21, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931904||60492|
NCT01932502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BN001|Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy|Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy: Efficacy, Tolerability, Dosing Equivalence, and Retention Rate||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Active, not recruiting|February 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|70 Years|No|||January 2016|January 27, 2016|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932502||60446|
NCT01932489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBCE2139|The Jules Bordet Institute Molecular Profiling Program Feasibility Trial|THE JULES BORDET INSTITUTE PROGRAM FOR MOLECULAR PROFILING OF METASTATIC LESIONS: FEASIBILITY. PRECISION - Feasibility.|PRECISION-F|Jules Bordet Institute|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|N/A|No|||October 2014|May 19, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01932489||60447|
NCT01932736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13030623|Functional Manifestations of Pressure Changes in the Middle Ear System|Functional Manifestations of Pressure Changes in the Middle Ear System: An fMRI Study||University of Pittsburgh|No|Active, not recruiting|August 2013|April 2016|Anticipated|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01932736||60428|
NCT01933048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-070|Self-Administered Nasal Influenza Feasibility Study|Self-Administered Nasal Influenza Vaccine: Immunogenicity and Feasibility of Group Administration|SNIF|Uniformed Services University of the Health Sciences|Yes|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1100|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933048||60404|
NCT01933334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSSc-001|Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)|The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)||Genentech, Inc.|Yes|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|August 23, 2013|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01933334||60382|
NCT01942707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFORZATO55|Scarpa´s Fascia in the Formation of Seroma Pos Abdominoplasty After Bariatric Surgery|Study of Scarpa´s Fascia in the Formation of Seroma Pos Abdominoplasty After Bariatric Surgery||Federal University of São Paulo|No|Recruiting|March 2013|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Female|25 Years|58 Years|Accepts Healthy Volunteers|||March 2013|September 11, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01942707||59665|
NCT01942720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-209|Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects|Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects||Medtronic - MITG|No|Active, not recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|2 Years|75 Years|No|||March 2016|March 2, 2016|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942720||59664|
NCT01942733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15352A|Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder|Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|September 2013|||August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|September 11, 2013|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01942733||59663|
NCT01940614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODDI2013|Use of Copeptin in Diabetes Insipidus|Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study||University Hospital, Basel, Switzerland|Yes|Recruiting|January 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care center|January 2016|January 4, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940614||59826|
NCT01940874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/823|Cerebral Oxymetry at Elective Coronary and Valve Surgery.|Cerebral Oxymetry at Elective Coronary and Valve Surgery: An Observational Study Using Norepinephrine to Maintain Arterial Blood Pressure on Cardio Pulmonary Bypass.|Co-HLM|Oslo University Hospital|No|Completed|February 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|80 Years|No|Non-Probability Sample|We want to include 50 patients, both women and men, undergo elective coronary bypass        surgery or valve surgeon in CPB with moderate hypothermia.|October 2013|October 8, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940874||59806|
NCT01939483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 11-22|A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases|A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases||University of California, Irvine|Yes|Withdrawn|December 2012|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|September 6, 2013|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01939483||59913|
NCT01939743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11GS009SUR|Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate|Diclofenac Suppository As a Preemptive Analgesia in Ultrasound Guided Biopsy of Prostate: Randomized Controlled Trial||Aga Khan University|Yes|Completed|October 2011|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Male|51 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 7, 2013|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01939743||59893|
NCT01939756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTV-101-2012|Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms|Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms: a Phase I-II Study|Baobab|University of Rome Tor Vergata|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|90 Years|No|||September 2013|September 5, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01939756||59892|
NCT01913548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019|Multi-Center Study of Iron Overload: Survey Study (MCSIO)|Modulation of Iron Deposition in Sickle Cell Disease and Other Hemoglobinopathies SURVEY STUDY|MCSIO|Children's Hospital & Research Center Oakland|No|Active, not recruiting|March 2010|October 2013|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|16 Years|N/A|No|Non-Probability Sample|There is no gender predisposition for sickle cell disease, thalassemia major, or        Diamond-Blackfan anemia. Sickle cell anemia most frequently affects people of African        descent, thalassemia affects people of Mediterranian, northern African, Southeast Asia and        Indian descent. Diamond-Blackfan anemia occurs across all racial and ethnic groups.|July 2013|July 30, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913548||61899|
NCT01914458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-LP101004|Image Discovering Early Lung Cancer Project|Low-Dose Computed Tomography for Lung Cancer Screening in High Risk Asymptomatic Patients: the Taiwan Study|IDEALCAP|Cathay General Hospital|Yes|Recruiting|February 2013|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914458||61830|
NCT01914471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MD001648|A Randomized Controlled Trial of Students for Nutrition and eXercise|A Community-Academic Partnership to Address Disparities in Obesity Among Youth|SNaX|Children's Hospital Boston|No|Completed|September 2008|March 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2997|||Both|11 Years|N/A|Accepts Healthy Volunteers|||July 2013|August 1, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01914471||61829|
NCT01915290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gen100sub2|Physical Activity and Its Correlation to Maximal Oxygen Uptake in an Elderly Population|Self Reported Physical Activity vs Objectively Measured Physical Activity and Its Correlation to Maximal Oxygen Uptake in an Elderly Population: an Observational Study|Gen100sub2|Norwegian University of Science and Technology|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1237|||Both|70 Years|77 Years|No|Non-Probability Sample|Norwegian elderly population 70-77 years of age|August 2014|August 12, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01915290||61766|
NCT01915641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5303B|CPAP Improves the Walking Capacity in Patients With COPD and OSA|||Chang Gung Memorial Hospital|Yes|Recruiting|April 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||April 2013|February 3, 2015|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01915641||61739|
NCT01915901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV110|PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily|A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol® (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA™ (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily||Biogen||Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915901||61719|
NCT01941381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040754|Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?|Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?||University of Alberta|No|Recruiting|October 2013|June 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|137|||Both|6 Months|16 Years|No|Non-Probability Sample|All children, aged 6 months to 16 years, with clinically diagnosed Otitis Media in the        Pediatric Emergency Department of the University of Alberta Hospital, in whom the        clinician decides to adopt a delayed antibiotic strategy (ie a period of 48-72H        observation with antibiotics given only if symptoms are not resolving).|March 2016|March 9, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941381||59767|
NCT01941394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRCH-MSC|Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation|Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation||National Research Center for Hematology, Russia|No|Recruiting|October 2007|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|60 Years|No|||September 2013|September 12, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01941394||59766|
NCT01932203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130006|Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease|A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease|Challenge|Inha University Hospital|Yes|Recruiting|July 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|238|||Both|50 Years|85 Years|No|||September 2013|September 12, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932203||60469|
NCT01941628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RocSuc|Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine|A Double-blind, Randomized, Parallel Design Study to Compare Surgical Conditions for Fetus Delivery and Suture of the Uterus and Abdominal Wall in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine||Charles University, Czech Republic|Yes|Recruiting|February 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Female|18 Years|N/A|No|||January 2014|January 29, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01941628||59748|
NCT01941641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL021|Colon Neoadjuvant FOLFOXIRI Study|A Phase II Study of Neoadjuvant FOLFOXIRI Followed by Concurrent Capecitabine and Radiotherapy for High Risk Rectal Cancer||Chinese University of Hong Kong|No|Recruiting|October 2013|October 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941641||59747|
NCT01941654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN060|ATOM_local Ablative Therapy|A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI (ATOM)||Chinese University of Hong Kong|No|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941654||59746|
NCT01932749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143|The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation in Bipolar Depression|The Comparison of Effectiveness of Bilateral rTMS Versus Unilateral TMS in Patients With Bipolar Depression: a Study Randomized and Single Blind||University of Tehran|Yes|Completed|August 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||April 2014|April 3, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01932749||60427|
NCT01932762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-047|Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)|A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 With/Without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects With Chronic Hepatitis C Genotype 2, 4, 5 and 6 Infection||Merck Sharp & Dohme Corp.|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|98|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|August 27, 2013|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01932762||60426|
NCT01933074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817047|Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency|Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency||University of Pennsylvania|No|Completed|January 2013|June 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|137|Samples Without DNA|First morning urine specimens are collected from each subject after completing      questionnaires - one week from initial visit or at follow-up visit.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Urogynecology clinic|January 2013|December 8, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01933074||60402|
NCT01933087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO1202|Hand Hygiene Intervention Study|A Stepped Wedge Cluster Randomised Controlled Trial to Evaluate the Impact of a Multimodal Hand Hygiene Intervention at Sappasithiprasong Hospital, Ubon Ratchathani|HAND|University of Oxford|No|Not yet recruiting|October 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|58|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01933087||60401|
NCT01942408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHCH967|The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence|Pulmonary Vein Re-isolation as a Routine Strategy: a Success Rate Evaluation|PRESSURE|Liverpool Heart and Chest Hospital NHS Foundation Trust|Yes|Completed|November 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942408||59688|
NCT01942421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|639/2551(EC2)|Ocular Surface Reconstruction With Cultivated Autologus Mucosal Epithelial Transplantation|Ocular Surface Reconstruction With Cultivated Autologus Mucosal Epithelial Transplantation.||Mahidol University|Yes|Active, not recruiting|January 2008|December 2013|Anticipated|June 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01942421||59687|
NCT01940588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 - bjohnson|Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence|Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence||State University of New York - Upstate Medical University|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with failed back surgery syndrome and opioid use disorder 18 years of age and older|January 2015|January 5, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940588||59828|
NCT01940601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUGR-005|Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors|An Open Label, Randomized, Active Controlled, Dose Finding Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim at Doses of 300 µg/kg and 670 µg/kg in Pediatric Patients Diagnosed With Solid Tumors Receiving Chemotherapy||Teva Pharmaceutical Industries|Yes|Withdrawn|September 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|2 Years|17 Years|No|||January 2015|January 13, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940601||59827|
NCT01943305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EID-JE/YF-01|The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans|An Open-label Phase 2a Clinical Trial to Test the Effect of Yellow Fever Vaccination in a Background of Japanese Encephalitis Antibodies.||Singapore General Hospital|No|Active, not recruiting|October 2013|December 2015|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01943305||59619|
NCT01940887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1004|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.||Ophthotech Corporation|Yes|Recruiting|May 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|622|||Both|50 Years|N/A|No|||September 2015|September 8, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940887||59805|
NCT01941420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001761-15|Comparison of Blood and Crystalloid Cardioplegia|Comparison of Blood and Crystalloid Cardioplegia on Patients Operated With Significant Aortic Stenosis. A Prospective Randomized Study.||Oslo University Hospital|No|Completed|November 2006|September 2012|Actual|February 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patient material. Patients who are to undergo surgery for isolated severe aortic stenosis,        without other heart disease will be included prospectively after informed consent. They        will then be randomized to one of two types of cardioplegia same morning that they will be        operated.|September 2013|September 12, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01941420|4 Days|59764|
NCT01941160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13LAHL|Effect of a Lacidofil® STRONG in Healthy Adults Taking Antibiotic Treatment|A Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of a Probiotic Product, Lacidofil® STRONG, in Healthy Adults Taking Antibiotic Treatment||KGK Synergize Inc.||Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|May 12, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01941160||59784|
NCT01941433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00691|Arthritis Health Journal Proof of Concept Study|Proof of Concept Study of the Arthritis Health Journal, a Patient Passport for Rheumatoid Arthritis|AHJ|University of British Columbia|No|Active, not recruiting|September 2013|February 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941433||59763|
NCT01914172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233/13|Health Needs of Men With Kallmann Syndrome|Factors Affecting Health Promoting Behavior in Rare Disease Patients: A Mixed Methods Study of Men With Congenital Hypogonadotropic Hypogonadism (CHH)||Centre Hospitalier Universitaire Vaudois|No|Active, not recruiting|July 2013|December 2015|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|148|||Male|18 Years|70 Years|No|Non-Probability Sample|Adult men diagnosed with congenital hypogonadotropic hypogonadism/Kallmann syndrome will        be recuited internationally.|June 2015|June 23, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914172||61852|
NCT01914185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003800|Alberta Project Promoting Active Living and Healthy Eating in Schools|The Effectiveness of a Comprehensive School Health Intervention in Improving Healthy Eating and Physical Activity and Preventing Childhood Obesity|APPLE Schools|University of Alberta|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8663|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914185||61851|
NCT01914809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00633-36|Micro Array Analysis in Preeclampsia|Micro Array Analysis in Preeclampsia||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2011|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Female|18 Years|40 Years|No|||September 2014|September 1, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01914809||61803|
NCT01915303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2411|Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease|A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease||Novartis|No|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915303||61765|
NCT01915940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-002|Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension|A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension||ForSight Vision5, Inc.|No|Completed|October 2013|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915940||61716|
NCT01916200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117049|Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients|Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients: An Open-label, Randomized, add-on Study||GlaxoSmithKline|No|Withdrawn|January 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||July 2014|July 14, 2014|August 1, 2013|No|Yes|This study was Cancelled Before Active|No||https://clinicaltrials.gov/show/NCT01916200||61696|
NCT01942174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9144|VACcination In Methotrexate Treated Rheumatoid Arthritis Patients|Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis|VACIMRA|University Hospital, Montpellier|Yes|Recruiting|September 2013|March 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942174||59706|
NCT01941368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2013-CS03|The Effects of β-Hydroxy-β-methylbutyrate Free Acid and High-Intensity Interval Training|The Effects of β-Hydroxy-β-methylbutyrate Free Acid Gel and High-Intensity Interval Training on Quadriceps Muscle Architecture and Quality, Neuromuscular Economy, and Metabolic Performance in Recreationally Trained Individuals||Metabolic Technologies Inc.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01941368||59768|
NCT01941901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA1232|Calcium Electroporation for Treatment of Cutaneous Metastases|Calcium Electroporation for Treatment of Cutaneous Metastases||Herlev Hospital|Yes|Recruiting|September 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941901||59727|
NCT01942148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-09-004|A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia|A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pediatric Patients (Aged 13-17 Years) With Schizophrenia (031-09-003 Study)||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|August 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|17 Years|No|||November 2015|November 4, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942148||59708|
NCT01941888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PropTCI2012|Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study|Phase IV Study of Propofol TCI (Target Controlled Infusion)Administered by Gastroenterologists During Endoscopy in Moderate Sedation: a Randomized Double Blind Controlled Study|PropTCI/2012|Ospedale San Raffaele|Yes|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941888||59728|
NCT01942161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-09-003|A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia|A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|August 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|13 Years|17 Years|No|||November 2015|November 4, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01942161||59707|
NCT01942135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481023|Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)|Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without Pd-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy||Pfizer|Yes|Active, not recruiting|September 2013|January 2017|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|427|||Female|18 Years|N/A|No|||November 2015|November 16, 2015|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942135||59709|
NCT01943058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U-12-1|Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer|A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS)||University of Southern California|Yes|Withdrawn|March 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|44 Years|No|||September 2014|September 9, 2014|September 11, 2013|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01943058||59638|
NCT01940055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not yet recruiting|The Effect of a Novel Dual-Task Exercise Program for Balance, Mobility and Cognition in Community Dwelling Older Adults|A Phase II, Pilot-Randomized Clinical Trial to Study the Effect of a Novel Dual-Task Exercise Program for Balance, Mobility and Cognition in Community Dwelling Older Adults||University of Manitoba|No|Completed|December 2013|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|70 Years|80 Years|Accepts Healthy Volunteers|||December 2013|January 6, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01940055||59869|
NCT01940848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17063|Efficacy/Safety Study to Confirm Iberogast's Efficacy in Rome-III Patients in Irritable Bowel Syndrome|A Double-blind, Randomised, Placebo-controlled Study on the Efficacy of Iberogast® (STW5) in Patients With Irritable Bowel Syndrome||Bayer|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|177|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940848||59808|
NCT01940861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Co-TBI|Cerebral Oxymetry in Traumatic Brain Injury|Cerebral Oxymetry in Traumatic Brain Injury||Oslo University Hospital|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|60 Years|No|Non-Probability Sample|TBI|November 2014|November 21, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940861|1 Day|59807|
NCT01941173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13294|Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy|A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer||City of Hope Medical Center|Yes|Withdrawn|January 2014|||July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|September 9, 2013|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01941173||59783|
NCT01941186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010441|A Family Centered Intervention to Promote Optimal Child Development|A Family Centered Intervention to Promote Optimal Child Development at the Interface of the Health System and Community||Children's Hospital of Philadelphia|No|Active, not recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|64|||Both|N/A|36 Months|No|||January 2016|January 4, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941186||59782|
NCT01941446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-004|A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization|A Randomized, Placebo- and Positive Controlled, Three-Way, Crossover Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization in Healthy Male and Female Subjects: A Thorough QT/QTc Study||Tetraphase Pharmaceuticals, Inc.|No|Completed|March 2013|July 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941446||59762|
NCT01941212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB 017-13|Effect of Music Therapy Intervention on Pain After Gynecological Surgery|Effect of Music Therapy Intervention on Pain After Gynecological Surgery||Rambam Health Care Campus|No|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 15, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01941212||59780|
NCT01913899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4318-12|Short Term Effect of Post Surgical Treatment of Mirror Therapy of Phantom Limb Pain|Short Term Effect of Post Surgical Treatment of Mirror Therapy of Phantom Limb Pain|PPSS|Ruhr University of Bochum|No|Recruiting|April 2013|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||April 2012|July 30, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913899||61873|
NCT01914484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ACA06T|Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia|A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY||University Health Network, Toronto|Yes|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914484||61828|
NCT01915953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QD04.5.1-15|A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP|A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP||OrSense, Ltd.|No|Active, not recruiting|February 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|95 Years|No|Non-Probability Sample|Hematology pateints|July 2013|August 4, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915953||61715|
NCT01941667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008246|Transitional Telehealth Home Care: REACH|Transitional Telehealth Home Care: REACH||Children's Hospital of Philadelphia|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|N/A|5 Months|No|||March 2016|March 24, 2016|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01941667||59745|
NCT01941680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/B/04|High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant|Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leukaemia (T-cell Lymphoma/Leukaemia) Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old|ATLL-HR-01|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|October 2013|October 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Anticipated|20|||Both|18 Years|75 Years|No|Probability Sample|Populations of French Caribbean Islands and Guyana with ATLL-HR. .|November 2015|November 23, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01941680||59744|
NCT01942759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-PET-MR-01|The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer|The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC||Bagcilar Training and Research Hospital|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||6|Actual|43|||Female|N/A|N/A|No|Probability Sample|Female patients with breast cancer|June 2014|June 8, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01942759||59661|
NCT01942772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|byang421|A Powered Ankle Foot Rehabilitation Orthosis|Design of A Powered Ankle Foot Orthoses for Ankle Rehabilitation||Beijing Institute of Technology||Active, not recruiting|January 2013|||February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2013|September 11, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01942772||59660|
NCT01942785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15353A|Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy|Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy||H. Lundbeck A/S|No|Completed|October 2013|||July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|September 11, 2013|Yes|Yes||No|December 2, 2015|https://clinicaltrials.gov/show/NCT01942785||59659|
NCT01942434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1869|Fatty Acid Levels and Memory in Breastfed Children|The Influence of FADS2 rs 174575 on Breastmilk Fatty Acid Levels and the Recognition Memory Abilities of 6-month Old Breastfed Infants and Follow-up||University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2010|March 2016|Anticipated|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|202|Samples With DNA|saliva, blood|Both|3 Months|4 Months|Accepts Healthy Volunteers|Non-Probability Sample|Breastfeeding infants and their mothers|August 2015|August 17, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942434||59686|
NCT01942746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blueberries and Vision|Blueberry Effects on Dark Vision and Glare Recovery|Placebo-controlled Cross-over Studies Examining Blueberries Effects on Dark Vision and Recovery After Photo-bleaching||Atlantic Food and Horticulture Research Center|No|Completed|July 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|72|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01942746||59662|
NCT01940042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aşıcıoğlu07|the Effect of Simple Clinical Maneuver on Shoulder and Abdominal Pain a Laparascopic Gynecological Surgery:a Prospective Randomised Trial|||Istanbul Bakirkoy Maternity and Children Diseases Hospital||Not yet recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|110|||Female|15 Years|65 Years|No|||September 2013|September 10, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01940042||59870|
NCT01940315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rBV A/B-03|Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B|A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)|rBV A/B|DynPort Vaccine Company LLC, A CSC Company|Yes|Suspended|October 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6174|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|September 6, 2013|Yes|Yes|programmatic decision|No||https://clinicaltrials.gov/show/NCT01940315||59849|
NCT01940081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiomyopathy study|The Leiden Nonischemic Cardiomyopathy Study|The Leiden Nonischemic Cardiomyopathy Study||Leiden University Medical Center|No|Recruiting|October 2011|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|220|Samples With DNA|Per patient:      Blood samples (40 mL) Ventricular biopsies|Both|18 Years|80 Years|No|Probability Sample|Patients with nonischemic cardiomyopathy and controls who are admitted to the hospital|September 2013|September 7, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01940081||59867|
NCT01940341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-320-0108|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B||Gilead Sciences|Yes|Recruiting|September 2013|August 2019|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940341||59847|
NCT01940328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP13|Measurements of Doppler Signals Noninvasively From the Lung in Congestive Heart Failure|Evaluation of Lung Doppler Signals in Congestive Heart Failure(CHF)||Echosense Ltd.|No|Suspended|October 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 150 mpatients will be recruited during 18 months: 50 Acute decompensated left        heart failure;50 compensated left heart failure;50 non-CHF controls.|August 2013|July 14, 2015|September 9, 2013||No|For interim analysis|No||https://clinicaltrials.gov/show/NCT01940328|3 Days|59848|
NCT01940627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3795-00|Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity|Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity (Muscle Function, Oxidative Stress and Inflammatory Signaling)||Universidad de Granada|Yes|Completed|April 2013|September 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|100|||Male|31 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01940627||59825|
NCT01941199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA1229_DIM_I|Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 5 mg and Metformin IR 1000 mg After Oral Administration in Healthy Male Volunteers||Dong-A ST Co., Ltd.||Completed|July 2013|||November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01941199||59781|
NCT01933490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21849|Post-Gastric Bypass Hypoglycemia|Prevention of Hypoglycemia in Patients With Post-Gastric Bypass Hyperinsulinemic Hypoglycemia||University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|10|||Both|21 Years|N/A|No|||November 2015|November 16, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01933490||60370|
NCT01933776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td527|Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China|Clinical Safety Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China||Sanofi|No|Completed|August 2013|January 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|4 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|August 28, 2013|No|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01933776||60348|
NCT01914198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00338|Revisiting Parental Survey for Screening for Obstructive Sleep Apnea in Patients Undergoing Polysomnography|||Nationwide Children's Hospital|No|Enrolling by invitation|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|3 Years|18 Years|No|Non-Probability Sample|Patients who are having a sleep study at NCH.|March 2016|March 11, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914198||61850|
NCT01914211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00350|The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates|||Nationwide Children's Hospital|No|Suspended|July 2013|December 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|28 Days|No|Non-Probability Sample|Patients from the cardiothoracic surgery population at Nationwide Children's Hospital.|March 2016|March 14, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914211||61849|
NCT01915316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP001|Measurements Of Zinc Concentration On Specimens Taken During Trans-Perineal Prostate Biopsy|Measurements Of Zinc Concentration On Specimens Taken During Trans-Perineal Prostate Biopsy||ProSight|No|Completed|February 2014|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Male|45 Years|N/A|No|Non-Probability Sample|Men. Primary biopsy and at least one secondary (repeat) biopsy diagnosed negative.        Elevated PSA, >10ng/mL. Subject directed at saturated trans-perineal biopsy|October 2015|October 27, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915316||61764|
NCT01915329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSS_2012|Effects of Repetitive Electric Sensory Stimulation (RSS) as Intervention in Complex-regional-pain-syndrome Type I (CRPS)|Effects of Repetitive Electric Sensory Stimulation on Sensorimotor Performance and Pain Intensity in Complex Regional Pain Syndrome Type I||Ruhr University of Bochum|No|Recruiting|February 2012|||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2013|July 31, 2013|May 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01915329||61763|
NCT01915056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCO-13034|A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy|A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy||University of Rochester|Yes|Completed|July 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|70 Years|N/A|No|||October 2015|February 18, 2016|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01915056||61784|
NCT01915654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2013/194|Impact of RBC Transfusion Less Than 14 Days on Morbidity and Mortality in Cardiac Surgical Patients|Impact de la Transfusion de Culots Globulaires de Moins de 14 Jours Sur la Morbi-mortalité Chez Des Patients en Chirurgie Cardiaque|CGRCard|Centre Hospitalier Universitaire de Besancon|No|Terminated|January 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|459|||Both|18 Years|80 Years|No|Non-Probability Sample|The study involves patients operated in the cardiothoracic and ardio-vascular surgery        department of Besançon University Hospital between December 2008 and May 2009 (study        population) or from December 2007 to May 2008 and from December 2009 to May 2010        (reference population).|August 2013|August 2, 2013|August 2, 2013||No|Retrospective study from December 2007 to May 2010|No||https://clinicaltrials.gov/show/NCT01915654||61738|
NCT01915667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-107|Oral Bioavailability of Two Solid Formulations of GLPG0634|Bioavailability Study Comparing Two Solid Oral Formulations of GLPG0634 in Healthy Male Subjects||Galapagos NV|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01915667||61737|
NCT01920048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN45979711|Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure|REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease|REVIVED-BCIS2|King's College London|Yes|Recruiting|August 2013|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01920048||61401|
NCT01920321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195/12|Bronchoscopic Thermal Saline Ablation (BTSA) of Emphysematous Lung. A New Emphysema Therapy|Lung Volume Reduction in COPD Patients With an Inhomogeneous Severe Emphysema Located in the Upper Lobes, by Injecting Warm Saline Through the Bronchoscope Channel|BTSA|Assaf-Harofeh Medical Center|Yes|Recruiting|February 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||August 2013|August 8, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01920321||61380|
NCT01920568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114273|A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors|DCA114273: A Study Comparing Denosumab With Zoledronic Acid in Subjects of Asian Ancestry With Bone Metastases From Solid Tumors||GlaxoSmithKline|No|Active, not recruiting|August 2013|May 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|487|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920568||61361|
NCT01943071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCAH-ECOD|Effects and Costs of a Day Care Centre Program Designed for People With Dementia|Effects and Costs of a Day Care Centre Program Designed for People With Dementia - a 24 Month Controlled Study|ECOD|Norwegian Centre for Ageing and Health|Yes|Enrolling by invitation|August 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|65 Years|N/A|No|||April 2015|April 24, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943071||59637|
NCT01943084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-4108|A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects|A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects||Novo Nordisk A/S|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|March 18, 2015|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943084||59636|
NCT01943331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nosocomial infection in ICU|Epidemiological Investigation of CRBSI, VAP, CAUTI in Chinese ICU|Colonization and Infection in Critically Ill Patients: a Multicenter, Prospective, Observational Study in Intensive Care Units (ICUs) in China||Southeast University, China|Yes|Recruiting|March 2013|||March 2018|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients admitted into ICU are eligible for this study. All the infected patients were        treated by the attending physician, and the choice and adjustment of antibiotic were in        accordance with the recommendations of ATS guidelines.|April 2013|February 14, 2016|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01943331||59617|
NCT01942447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKT-FMT|Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis||TOCSIN|University Hospital Tuebingen||Not yet recruiting|October 2013|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01942447||59685|
NCT01942460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CA-IIT-001|Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients|Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis||Maisonneuve-Rosemont Hospital|No|Completed|September 2013|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01942460||59684|
NCT01943318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM_LC_Cohort|Boramae Liver Cirrhosis Cohort Study|||Seoul National University Boramae Hospital||Recruiting|January 2013|||March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|500|Samples With DNA|At enrollement, 20 ml of blood will be collected for freezing and storage of serum and      plasma, and constitution of a DNA library|Both|19 Years|N/A|No|Probability Sample|Seoul National University Boramae hospital|November 2014|November 17, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01943318|2018 Years|59618|
NCT01939496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102208|Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus||Janssen Scientific Affairs, LLC|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|75 Years|No|||April 2015|April 13, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939496||59912|
NCT01940367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385408-2|Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments|Percutaneous Tibial Nerve Stimulation vs. Transcutaneous Electrical Nerve Stimulation for Overactive Bladder: A Randomized Trial||Walter Reed National Military Medical Center|Yes|Enrolling by invitation|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Female|18 Years|N/A|No|||December 2014|December 12, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940367||59845|
NCT01940354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPW-STP-00003|Comparison of AccuCath IV Catheter and Conventional IV Catheter|A Prospective, Randomized, Controlled Comparison of First Attempt Success Between the AccuCath Intravenous System With Retractable Coiled Tip Guide Wire and Conventional Peripheral Intravenous Catheters||Vascular Pathways, Inc.|No|Recruiting|August 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||September 2013|September 7, 2013|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940354||59846|
NCT01940913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProAAD|Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.|||Probi AB||Completed|October 2013|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|1 Year|11 Years||||May 2014|May 8, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940913||59803|
NCT01932905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGDCA-02|Deep rTMS in Central Neuropathic Pain Syndromes|Deep rTMS in Central Neuropathic Pain Syndromes|DRTMS|University of Sao Paulo|Yes|Recruiting|March 2011|August 2015|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932905||60415|
NCT01940900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1003|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.||Ophthotech Corporation|Yes|Active, not recruiting|August 2013|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|622|||Both|50 Years|N/A|No|||September 2015|September 8, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940900||59804|
NCT01933828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN_NL40542.091.12|Treatment of Early Stage Lung Cancer by VATS Versus OPEN Lobectomy|thoracoSCopic Versus OPen Lobectomy for Early Stage Lung Cancer: a Randomized Prospective Trial|SCOPE|Radboud University|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|176|||Both|18 Years|N/A|No|||August 2013|November 7, 2013|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01933828||60344|
NCT01914510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENMD-2076-OCC|A Study of ENMD-2076 in Ovarian Clear Cell Cancers|Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas||University Health Network, Toronto|Yes|Recruiting|September 2013|January 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||July 2015|July 9, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01914510||61826|
NCT01914822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275-13-RMB|The Effect Methylphenidate Hydrochloride on Pain and Auditory Sensitivity in Healthy Subjects|The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects||Rambam Health Care Campus|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 9, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914822||61802|
NCT01919502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6004|Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment|Feasibility and Acceptability of Using a Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment||Gynuity Health Projects|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|51|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01919502||61443|
NCT01919814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 13022|A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza|A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza|Pizza|Pennington Biomedical Research Center|No|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01919814||61419|
NCT01920308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-13-001|A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY)|A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY)|REALITY|C. R. Bard|No|Enrolling by invitation|August 2013|November 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|21 Years|N/A|No|Non-Probability Sample|A prospective observational study of the Bard® LifeStent® Vascular Stents in the treatment        of symptomatic de novo or restenotic lesions.|August 2013|August 8, 2013|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920308||61381|
NCT01920594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116097|Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair|A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair||GlaxoSmithKline|Yes|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920594||61359|
NCT01921179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1111-I|Rehabilitation of Executive Functioning in Veterans With PTSD and Mild TBI|Rehabilitation of Executive Functioning in Veterans With PTSD and Mild TBI||VA Office of Research and Development|No|Recruiting|July 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|75 Years|No|||October 2015|October 28, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01921179||61314|
NCT01921192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2012|Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy|||University of Catania||Recruiting|September 2012|||July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921192||61313|
NCT01943097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703053M|Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma|The Evaluation of the 6-[18F]Fluoro-levo-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma||National Taiwan University Hospital|Yes|Active, not recruiting|June 2007|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|160|||Both|N/A|30 Years|No|Probability Sample|Patients With Neuroblastoma|April 2014|April 11, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943097|3 Months|59635|
NCT01939210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-12-392|Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy|Influence of Meditation-Based Breathing Training on Target Motion Management and Distress During Radiation for Abdominal and Lung Malignancies||Albert Einstein College of Medicine of Yeshiva University||Active, not recruiting|February 2010|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939210||59934|
NCT01939223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15983|COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy|A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases|COAST|Bayer|Yes|Active, not recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939223||59933|
NCT01939236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCMlltllt1984|Traditional Chinese Medicine for Treatment of Chronic Heart Failure|Traditional Chinese Medicine for Treatment of Chronic Heart Failure: A Multicenter Randomized Double-blind Placebo-controlled Clinical Trial||Beijing University of Chinese Medicine|No|Completed|May 2010|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|45 Years|75 Years|No|||October 2013|October 8, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01939236||59932|
NCT01939509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1445|Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol|Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol|CHAB|Hospital Italiano de Buenos Aires|No|Completed|February 2012|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|80|||Both|21 Years|N/A|No|||December 2014|December 4, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01939509||59911|
NCT01939522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2013/03|Protection Against Pneumococcal Infection in Children With T1DM|An Open Label Single-arm Trial of the Immunogenicity and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine (Prevenar13®) Given to Children With Type 1 Diabetes Mellitus Who Have Not Previously Received a Primary Schedule of Immunisation With Pneumococcal Conjugate Vaccines in Infancy.|T1DM|University of Oxford|Yes|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|6 Years|17 Years|No|||November 2015|November 6, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01939522||59910|
NCT01939769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130198|Effects of Exercise on Memory in Healthy and Brain-Injured Individuals|Acute Effects of Exercise on Memory in Healthy and Brain-Injured Individuals||National Institutes of Health Clinical Center (CC)||Completed|August 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|June 2, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939769||59891|
NCT01939782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-13-WOMC|Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics|Metabolic Clock Gene Expression in Peripheral Blood Cells During Fasting and After Food Intake in the Breakfast in Type 2 Diabetic Patients|MCG-T2D|Tel Aviv University|Yes|Recruiting|February 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|26 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01939782||59890|
NCT01939795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT & CRT|Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients|Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients||University of Sao Paulo General Hospital|No|Recruiting|January 2009|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01939795||59889|
NCT01940380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130305|The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome|The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome||Fujian Institute Of Trational Chinese Medicine|Yes|Recruiting|September 2013|||December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|25|||Female|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female ages 45 to 75 had gone through natural menopause before two years|February 2014|February 23, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01940380||59844|
NCT01940640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2011-24014|Effect of Mother DHA Supplementation on Premature Newborn.|Multidisciplinary Study of the Effect of the Mother suplementación During the Lactation With High Doses of DHA on Diverse Aspects Related to the Development of the Premature Newborn in the First Year of Life.||Universidad de Granada|Yes|Completed|January 2012|November 2015|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|N/A|6 Months|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01940640||59824|
NCT01932918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001020R|Antinociceptive Modalities on Ischemia Reperfusion Injury|The Interaction of Nociceptive Stimulation and Various Antinociceptive Modalities on Ischemia Reperfusion Injury||National Taiwan University Hospital|No|Completed|January 2011|July 2015|Actual|July 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|142|Samples Without DNA|plasma|Both|18 Years|70 Years|No|Probability Sample|End stage liver disease Lung cancer|July 2015|July 21, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932918||60414|
NCT01941225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM104940-50346-S|Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients|Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01941225||59779|
NCT01933841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131282|The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery|The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery||Vanderbilt University|Yes|Not yet recruiting|September 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who receive an intraoperative neuromuscular blockade|August 2013|August 28, 2013|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01933841||60343|
NCT01915069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF 13-14|Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary|Cilostazol and Its Effects on Human Oocyte Maturation in Vivo: A Pilot Study||University of Southern California|Yes|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Female|18 Years|33 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|July 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915069||61783|
NCT01919827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM/FPI|Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis|Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells|CMM/FPI|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Recruiting|March 2013|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|30 Years|80 Years|No|||December 2015|December 7, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01919827||61418|
NCT01920061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151002|A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents|A Phase 1b Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/mTOR Inhibitor) In Combination With Other Anti-Tumor Agents||Pfizer|No|Recruiting|September 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|94|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01920061||61400|
NCT01920334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1442/11, Ethics Committee|Effects of Zolpidem CR® in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients|Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit||Associação Fundo de Incentivo à Pesquisa|No|Recruiting|July 2013|January 2014|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2013|August 8, 2013|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920334||61379|
NCT01920607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0209|Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence|Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence|MOS STIC|Nantes University Hospital|No|Recruiting|November 2013|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920607||61358|
NCT01920633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28947|A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)|A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)||Hoffmann-La Roche||Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Both|12 Years|30 Years|No|Probability Sample|People with Down syndrome|March 2016|March 1, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920633||61356|
NCT01942798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01858|Study of WiiFit to Enhance Walking in Older Adult Amputees|Evaluation of the WiiFit to Enhance Walking in Older Adults With Lower Limb Amputation|WiiNWalk|University of British Columbia|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|50 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01942798||59658|
NCT01942811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BINAT 3P30DA027|BiNational Quit Using Drugs Intervention Trial|US-Mexico Binational Quit Using Drugs Intervention Trial (QUIT)|BiN-QUIT|University of California, Los Angeles|Yes|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|134|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942811||59657|
NCT01942824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK5058_2|Adult Influenza Vaccination Text Message Reminders|Adult Influenza Vaccination Text Message Reminders||Columbia University||Completed|September 2013|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|7250|||Both|18 Years|N/A|No|||June 2014|June 22, 2014|September 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01942824||59656|
NCT01943357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26679|Improving Self Management Skills of Older Adults With Diabetes|Improving the Self Management Skills of Older Adults With Diabetes||Stanford University|No|Active, not recruiting|September 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1400|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01943357||59615|
NCT01943370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESESS-001|Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement|Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement||University of Alberta|No|Not yet recruiting|October 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Anticipated|50|||Both|17 Years|N/A|No|||September 2013|September 16, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01943370||59614|
NCT01943344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P043-00|Safety and Performance Study of Large Hole Vascular Closure Device|Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER I Study|FRONTIER-I|Vivasure Medical Limited|Yes|Active, not recruiting|July 2013|May 2015|Anticipated|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943344||59616|
NCT01939249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1204|Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent|BIOTRONIK-A Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects With up to Two de Novo Coronary Artery Lesions - IV|BIOFLOW-IV|Biotronik AG|No|Active, not recruiting|September 2013|January 2020|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|585|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939249||59931|
NCT01939535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54441|Preoperative Staging of Endometriosis With MRI|Prospective Evaluation of the Value of Magnetic Resonance Imaging as a One-stop-shop for Preoperative Stratification of Patients With Complexe Endometriosis - Imaging Deep Endometriosis Assessment Versus Laparoscopy.|IDEAL|Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Female|N/A|N/A|No|Probability Sample|Women with endometriosis in a tertiary referral centre|October 2012|June 11, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01939535||59909|
NCT01939821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIST|A Pilot Study to Evaluate Educational Programs to Improve Fecal Incontinence Care in Nursing Homes|A Pilot Study to Evaluate Feasibility of Educational Programs With Regard to Good Fecal Incontinence Care in Nursing Homes|PEI|Norwegian University of Science and Technology|Yes|Completed|September 2013|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|60|||Both|N/A|N/A|No|||February 2016|February 9, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01939821||59887|
NCT01939808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBN854-STHK|Flexor Tendon Injury Rehabilitation Regime Study|Comparison of the Effect of Splinting the Wrist in Extension Versus Neutral Positioning During Rehabilitation Following Zone I/II Flexor Tendon Repair||St Helens & Knowsley Teaching Hospitals NHS Trust|No|Recruiting|May 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|16 Years|N/A|No|||November 2015|November 24, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01939808||59888|
NCT01940068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-UP05-E1|A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates|A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates||United Pharmaceuticals|No|Completed|March 2011|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|N/A|18 Months|No|||March 2015|March 20, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01940068||59868|
NCT01932359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01961|Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study|Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study (RAVNAS)|RAVNAS|University of British Columbia|No|Completed|October 2013|November 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932359||60457|
NCT01932372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921194|Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis|Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Active, not recruiting|July 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4535|||Both|N/A|N/A|No|Probability Sample|Adult patients with moderately to severely active rheumatoid arthritis who have had an        inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment.|March 2016|March 7, 2016|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932372||60456|
NCT01932645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01947|Etiology Study of Prostatitis|Modern Genetic Methods to Test EPS Samples in Prostatitis Patients||University of British Columbia|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|Samples With DNA|Patients will have a digital rectal exam (DRE) performed and have their Expressed Prostatic      Secretions (EPS) sampled as well as the first void after the DRE (other wise called the VB3      sample). Patients will also have their maximum urinary flow rate tested by voiding into a      special machine. This will be done at the urology clinic, 6th floor Diamond Building.      These biological samples will be tested for bacterial DNA rather than the traditional      microbiological culturing techniques. Identification of these bacterial DNA will then be      assessed between the groups to determine if prostatitis patients, in fact, do have more      bacteria than normal controls.|Male|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with prostatitis (who are suffering from pelvic pain (perineal, suprapubic,        testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain        associated with ejaculation)) vs controls|December 2015|December 10, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01932645||60435|
NCT01933230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-121-CCSICH|Trial of Cooling for Patients With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH)|Trial of Cooling for Patients With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH)|CCSICH|The Cleveland Clinic|No|Terminated|June 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 23, 2013||No|Closed study due to issues we have encountered with meeting our enrollment goals of this study    at our site.|No|February 2, 2015|https://clinicaltrials.gov/show/NCT01933230||60390|
NCT01933217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HD074683-01A1|Methylphenidate for Attention Problems After Pediatric TBI|Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI)||Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2013|August 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|17 Years|No|||September 2014|September 18, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01933217||60391|
NCT01934387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205110RIC|Geriatric Health Exam Osteoporosis Screening|Increasing Osteoporosis Awareness With Fracture Risk Assessments and Management Among Geriatric Health Examination Recipients at National Taiwan University Hospital||National Taiwan University Hospital|No|Completed|March 2013|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1319|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults visitng geraitric health exam clinics.|April 2014|April 22, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01934387||60301|
NCT01919190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSE402|EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries|Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries|TRANSCEND|Pacira Pharmaceuticals, Inc|No|Terminated|August 2013|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|August 6, 2013|Yes|Yes|Due to reasons unrelated to safety. However, a primary efficacy endpoint signal was seen    during a pre-specified interim analysis.|No||https://clinicaltrials.gov/show/NCT01919190||61467|
NCT01919515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130203|Trial of a New NuSmile ZR Esthetic Primary Molar Crown|Randomized Controlled Clinical Trial of a New NuSmile ZR Esthetic Primary Molar Crown||NuSmile, Ltd.|No|Active, not recruiting|April 2013|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|7 Years|No|||October 2014|October 7, 2014|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919515||61442|
NCT01920074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APT-NIT_S-PRO-M_PEDKPK1_E|Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure|A Phase 4, Multiple-dose, Pharmacokinetic, Safety, and Exploratory Efficacy Study of Nitroglycerin Ointment 0.4% (RECTIV®) in Adolescents (Age ≥12 to <17 Years) With Moderate to Severe Pain Due to Chronic Anal Fissure||Forest Laboratories|No|Withdrawn|June 2013|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|16 Years|No|||May 2015|May 1, 2015|August 7, 2013|Yes|Yes|Study stopped due to study enrollment challenges that impacted the feasibility of conducting    the study.|No||https://clinicaltrials.gov/show/NCT01920074||61399|
NCT01920347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112823|The Neurological Pupil Index (NPi) on Intensive Care Unit (ICU) Trial|Prospective Pilot Trial to Evaluate the NeurOptics Pupillometer and Clinical Examination of the Pupillary Reflex After Cardiac Arrest|NPI-ON-ICU|Charite University, Berlin, Germany|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Survivors after cardiac arrest|February 2015|February 16, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01920347||61378|
NCT01920620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obesity Intervention NU|Inpatient Obesity Intervention With Phone Follow-up|Inpatient Obesity: Can Weight Loss Intervention During Hospitalization Lead to Sustained Weight Loss at Six Months Following Discharge?||Northwestern University|No|Completed|January 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920620||61357|
NCT01920646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV study|Effect of African Leafy Vegetables on Nutritional Status of South African School Children.|The Effect of African Leafy Vegetables on Nutritional Status (Including Iron, Zinc and Vitamin A Status) of School Children Residing in Semi-rural Farm Community in the North West Province of South Africa|ALV|North-West University, South Africa||Completed|February 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized|2||Actual|171|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920646||61355|
NCT01920906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWK-0816|Comparative Analysis of Small and Large Plaque Psoriasis|Comparative Analysis of Small and Large Plaque Psoriasis||Rockefeller University|No|Recruiting|January 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|43|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 27, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01920906||61335|
NCT01920919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000242-18|Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis||DEXSAR|St. Antonius Hospital||Recruiting|June 2013|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|60 Years|No|||November 2014|November 18, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01920919||61334|
NCT01943110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 720|Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.|A Clinical Trial to Evaluate the Performance and Safety of Two Intradermal Delivery Devices.||PATH|No|Completed|July 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|February 3, 2016|September 11, 2013|No|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01943110||59634|
NCT01943383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-2013|Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study|PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES IN INDUCED PLURIPOTENT STEM (IPS) CELLS STUDY (PEAR-IPSC) (PEAR-iPSC)|PEAR-iPSC|University of Florida|No|Enrolling by invitation|August 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01943383||59613|
NCT01939262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osteoarthritis Diet|The Impact of Dietary Restriction of Animal Protein and Fat on Osteoarthritis|The Impact of Dietary Restriction of Animal Protein and Fat on Subjective Complaints of Osteoarthritis||Essentia Health|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01939262||59930|
NCT01939548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241019|An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia|A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia||Pfizer|Yes|Terminated|October 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|65 Years|No|||January 2015|January 8, 2015|August 9, 2013|Yes|Yes|A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified    efficacy criteria. The decision was not based on any safety concerns.|No||https://clinicaltrials.gov/show/NCT01939548||59908|
NCT01939834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16930|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes||University of Virginia|No|Terminated|December 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Both|21 Years|64 Years|No|||March 2015|March 30, 2015|August 14, 2013|No|Yes|Subjects preferred the 5 night overnight system in terms of ease of use.|No||https://clinicaltrials.gov/show/NCT01939834||59886|
NCT01940094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRC 5526A|The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach|The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach|TAPIR|University of Pennsylvania|Yes|Recruiting|February 2014|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940094||59866|
NCT01932398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3016038.01|A Study on the Inter-Hemispheric Alpha Ratio in Kids With ADHD (SHARK)|Posterior Alpha Oscillations as an Index for the Attentional Bias in Children With Attentional Deficit Hyperactivity Disorder|SHARK|Radboud University|No|Completed|November 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|84 Months|95 Months|Accepts Healthy Volunteers|Non-Probability Sample|ADHD vs no ADHD|January 2015|January 19, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01932398||60454|
NCT01932658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-001836|Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment|Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment|HSCT|University of California, Los Angeles|No|Recruiting|February 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|7 Years|70 Years|No|||September 2015|September 25, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01932658||60434|
NCT01932931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130052|Vitamin D, SSRIs and the Musculoskeletal System|Depression - Can Vitamin D Alleviate Symptoms of Depression Not Cured by Antidepressants as Well as Alleviate Negative Skeletal Effects Caused by Antidepressants?||Aalborg University|No|Recruiting|October 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Female|50 Years|90 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01932931||60413|
NCT01932944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC13-126|Accuracy Characterization Study|Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System Compared to Venous and Capillary Glucose|ACS|Abbott Diabetes Care|No|Completed|August 2013|March 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with type 1 or type 2 diabetes requiring multiple daily insulin injections (MDI)        or continuous subcutaneous insulin infusion (CSII). No more than 10 subjects (5 per site)        will have HbA1c > 8.5%, and no more than 10 subjects (5 per site) will have HbA1c < 7%        based on the subject screening.|July 2014|July 10, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01932944||60412|
NCT01933243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAANA-287112|Treatment of Anxiety and Anorexia Nervosa in Adolescents|Treatment of Anxiety and Anorexia Nervosa in Adolescents|TAANA|Nationwide Children's Hospital|No|Recruiting|August 2013|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|21 Years|No|||January 2016|January 26, 2016|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933243||60389|
NCT01933256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU1156-002|Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin|A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin||CureDM|No|Recruiting|August 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|32|||Both|30 Years|65 Years|No|||September 2013|September 23, 2013|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933256||60388|
NCT01933503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-105|Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)|An Open Label, Randomized, Single Dose and Multiple Dose Trial to Assess the Pharmacokinetics of Obeticholic Acid (OCA)||Intercept Pharmaceuticals|Yes|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933503||60369|
NCT01933815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-287-17|Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma|Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma||Cortice Biosciences, Inc.|No|Recruiting|August 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933815||60345|
NCT01934400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303003RINC|Osteoporosis and Fall Prevention Education|Osteoporosis and Fall Prevention Education With High Risk Population Telephone Follow up Study||National Taiwan University Hospital|No|Completed|April 2013|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|127|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults who attending the fall prevention educational programme.|April 2014|April 22, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01934400||60300|
NCT01934413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006242|Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study|Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study|TPC|Mayo Clinic|No|Completed|September 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|17|||Both|N/A|N/A|No|||February 2015|February 13, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934413||60299|
NCT01919528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Axillary-US-guided-1|Ultrasound-guided Catheterization of the Axillary Vein|Real-time Ultrasound-guided Catheterization of the Axillary Vein in the Intensive Care Unit||Publiczny Samodzielny Zaklad Opieki Zdrowotnej Wojewodzkie Centrum Medyczne|No|Completed|December 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|202|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01919528||61441|
NCT01920360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65463|Evaluation Study of the Effects of Sulphurous Water in the Treatment of Knee Osteoarthritis.|Study of the Effects of Immersion Baths in Sulphurous Water in Patients With Knee Osteoarthritis: Randomized Controlled Clinical Trial.||Federal University of São Paulo|Yes|Completed|February 2011|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Both|60 Years|75 Years|No|||August 2015|August 10, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01920360||61377|
NCT01920659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METAPREDICT FP7|METAPREDICT: Developing Predictors of the Health Benefits of Exercise for Individuals|Developing Predictors of the Health Benefits of Exercise for Individuals|METAPREDICT|Loughborough University|No|Completed|April 2012|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|188|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920659||61354|
NCT01920672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00088139|Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD|Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)||Johns Hopkins University|Yes|Not yet recruiting|September 2013|||June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|54|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 8, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01920672||61353|
NCT01920932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLHR13|Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma|Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma||St. Jude Children's Research Hospital|Yes|Recruiting|August 2013|April 2025|Anticipated|August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|N/A|18 Years|No|||March 2016|March 24, 2016|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920932||61333|
NCT01921231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006930-17|Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine|Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine in Knee Arthroscopy and Inguinal Hernia Repair in Ambulatory Surgery|BUPIPRILO-07|Consorci Hospitalari de Vic|Yes|Completed|May 2007|December 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01921231||61310|
NCT01943123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vani-1|Effect of Probiotic Drink on Number of Salivary Mutans Streptococci in School Going Children|Effect of Commercially Available Probiotic Drink on Number of Salivary Mutans Streptococci in School Going Children Aged 12-14 Years in Bangalore City (India): Randomized Controlled Trial||The Oxford Dental College, Hospital and Research Center, Bangalore, India|Yes|Completed|February 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01943123||59633|
NCT01943396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNHK2013/01|Treatment of AMD With Rheohemapheresis /RHF/|Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)|TARHF|University Hospital Hradec Kralove|No|Recruiting|September 2013|March 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|N/A|85 Years|No|||May 2014|May 29, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01943396||59612|
NCT01930682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI135.326|Early Routine Catheterisation After Alteplase Fibrinolysis vs. Primary PCI in Acute ST-elevation Myocardial Infarct|EARLY Routine Catheterisation or Rescue Coronary Intervention After Alteplase Fibrinolysis vs. Primary PCI in Acute ST-elevation MYOcardial Infarction: an Open, Prospective, Randomized, Multicentre Trial|EARLY-MYO|RenJi Hospital|Yes|Not yet recruiting|August 2013|September 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|75 Years|No|||August 2013|August 25, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01930682||60586|
NCT01939275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13229|64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer|64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer||City of Hope Medical Center|Yes|Recruiting|September 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01939275||59929|
NCT01939561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-MY|Lamotrigine as Treatment of Myotonia|Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study||Rigshospitalet, Denmark|Yes|Enrolling by invitation|November 2013|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939561||59907|
NCT01931813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quantin PHRC IR 2009|METHORIVAC - Vaccinal Pharmacoepidemiologic|Pharmacoepidemiological Methodology to Evaluate the Vaccination Risk in Young Infants|METHORIVAC|Centre Hospitalier Universitaire Dijon|No|Completed||||September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|500|||Both|N/A|N/A|No|Probability Sample|Children of less than 3 years hospitalized for febrile convulsions|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931813||60499|
NCT01940107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hhacarra|Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation|Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation||University of Sao Paulo||Completed|August 2010|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Female|18 Years|75 Years|No|||September 2013|September 10, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01940107||59865|
NCT01940120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401A|EVEREST II Pivotal Study High Risk Registry (HRR)|A Study of the Evalve® Cardiovascular Valve Repair (MitraClip®) System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST II) EVEREST II High Risk Registry|HRR|Evalve|Yes|Completed|February 2007|February 2013|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940120||59864|
NCT01932671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36828.041.11|The SMART-ORACLE Study|Optimising Risk Assessment With CT-angiography or Calcium Score in Patients at High Risk for a Cardiovascular Event|SMART-ORACLE|UMC Utrecht|Yes|Enrolling by invitation|August 2012|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|The study will be performed in consecutive patients entering the SMART study who are        eligible according to the in- and exclusion criteria. SMART includes patients aged 18-79        years, who are newly referred to the University Hospital Utrecht with atherosclerotic        cardiovascular disease insufficiency will be enrolled.|August 2013|August 27, 2013|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01932671||60433|
NCT01932957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ectopic Trial|Laparascopy Versus Laparatomy in the Management of Ruptured Ectopic Pregnancy|A RANDOMISED TRIAL COMPARING LAPARASCOPY VERSUS LAPAROTOMY IN THE MANAGEMENT OF WOMEN DIAGNOSED WITH ECTOPIC PREGNANCY||University of Pretoria|Yes|Recruiting|May 2012|November 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932957||60411|
NCT01933854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012MACAPASP|Urinary Incontinence in Women From Amapa|ASSESSMENT OF URINARY INCONTINENCE IN WOMEN AT AMAPA STATE: COMPARISON BETWEEN URBAN AND RIVERSIDE POPULATIONS|iuemcp|University of Sao Paulo General Hospital|No|Active, not recruiting|February 2013|February 2014|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|380|None Retained|Urban group: women aged 20 years or over, who are not pregnant and are looking for a health      facility to perform womb cancer prevention exam in Macapa, the capital city of the Amapa      State.      Riverside Group: Women aged 20 years or over, who are not pregnant and are looking for a      health facility to perform womb cancer prevention exam on the Bailique Island.|Female|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Urban group: women aged 20 years or over, who are not pregnant and are looking for a        health facility to perform womb cancer prevention exam in Macapa, the capital city of the        Amapa State.        Riverside Group: Women aged 20 years or over, who are not pregnant and are looking for a        health facility to perform womb cancer prevention exam on the Bailique Island.|August 2013|August 28, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01933854|2 Days|60342|
NCT01933516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP13-101|GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma|Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma||Sandoz K.K.||Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||March 2015|March 6, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01933516||60368|
NCT01933529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCP-115|ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)|Effects of ARA 290, a Non-hematopoietic Erythropoietin Analogue, on Glucose Tolerance, Insulin Secretion, Insulin Sensitivity and Long-term Glucose Control in Individuals With Prediabetes and/or Drug-naive Type 2 Diabetes; a Phase II Study.||Karolinska Institutet|No|Active, not recruiting|October 2013|December 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|75 Years|No|||September 2015|September 2, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933529||60367|
NCT01930279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDB001|Effect of Partial Sleep Deprivation on Immunological System in Peripheral Blood|Effect of Sleep Deprivation on Expression of T Cell Markers in Peripheral Blood of Medical Residents||Hadassah Medical Organization||Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Medical residnets|August 2013|August 27, 2013|August 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930279||60617|
NCT01919840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ROT-2010-15|Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol|Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión|ROTEM-2010|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Terminated|February 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|April 12, 2013||No|Low recruitment after the expected time to finish the study|No||https://clinicaltrials.gov/show/NCT01919840||61417|
NCT01920373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468485|Platelet-Rich Plasma vs Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint|Platelet-Rich Plasma Versus Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint||Kaiser Permanente|Yes|Withdrawn|November 2013|||November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|August 8, 2013||No|The study was cancelled.|No||https://clinicaltrials.gov/show/NCT01920373||61376|
NCT01920386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW 0919 302 Version 1.0|Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery|A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery||Daewon Pharmaceutical Co., Ltd.||Completed||||December 2013|Actual|Phase 3|Interventional|N/A|2||||||Both|20 Years|N/A|No|||January 2014|January 13, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920386||61375|
NCT01920685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0690|Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial|Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial|CITADEL|King's College London|No|Recruiting|January 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01920685||61352|
NCT01920945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLERGAN-13-002|OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study|OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study||St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01920945||61332|
NCT01921244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP00005038|Shared Decision Making to Improve Care and Outcomes for Children With Autism|Shared Decision Making to Improve Care and Outcomes for Children With Autism||Children's Hospital Medical Center, Cincinnati|No|Completed|August 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|142|||Both|4 Years|15 Years|No|||February 2016|February 4, 2016|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01921244||61309|
NCT01943136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Papaya for impetigo|The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial|||Philippine Dermatological Society||Recruiting|August 2013|||June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|1 Year|N/A|Accepts Healthy Volunteers|||December 2013|December 18, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01943136||59632|
NCT01943149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP-001|E-MAX 2nd Gen Vit E Poly On BIOLOX Delta Ceramic Heads|E-MAX 2nd Generation Vitamin E Polyethylene On BIOLOX Delta Ceramic Heads||Renovis Surgical Technologies, Inc.|No|Active, not recruiting|January 2014|||January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will be patients of specified doctors specialized in orthopedic medicine with a        specialty in joint replacement.|October 2015|October 26, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01943149||59631|
NCT01930981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2574.00|Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life|Prospective Assessment of Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|19 Years|N/A|No|Non-Probability Sample|Patients diagnosed with hematological malignancies who are being treated with allogeneic        hematopoietic cell transplantation (HCT) at the Seattle Cancer Care Alliance.|August 2015|August 10, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01930981||60563|
NCT01931280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0827|A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring|A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring: A Pilot Trial|GooD MomS|University of North Carolina, Chapel Hill|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Female|21 Years|35 Years|No|||September 2014|August 10, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01931280||60540|
NCT01939288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH0324|Effect of Neuromuscular Calf Stimulation and Intermittent Pneumatic Compression on Lower Limb Venous Hemodynamics|||Imperial College London|Yes|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|January 9, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01939288||59928|
NCT01931579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/103/HP|Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses.|Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses. "NODIVEM" Study|NODIVEM|University Hospital, Rouen|No|Active, not recruiting|May 2012|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01931579||60517|
NCT01931826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCISAL-2012-Treatment PHS|Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery|Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure||Universidade Estadual de Ciências da Saúde de Alagoas|No|Completed|January 2003|March 2009|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|15 Years|65 Years|No|||August 2013|August 26, 2013|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01931826||60498|
NCT01932060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28015|Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.|Effects of Different Oxytocin Infusions on Blood Loss and Postpartum Hemoglobin Values in Patients Undergoing Elective Cesarean Delivery||Stanford University|No|Recruiting|August 2013|September 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01932060||60480|
NCT01933269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062214|FACBC for Head and Neck Cancers|Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.||Emory University|Yes|Recruiting|May 2015|||August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933269||60387|
NCT01933542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-RS-2013|The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery|The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery||Rigshospitalet, Denmark|Yes|Completed|August 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|85 Years|No|||September 2015|September 16, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933542||60366|
NCT01933555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 0912|Impact of Women's Empowerment Program for Abused Pregnant Women|Impact of Women's Empowerment Program for Abused Pregnant Women: A Randomized Controlled Trial||Macmillan Research Group UK|Yes|Completed|January 2013|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933555||60365|
NCT01933867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 06|Water-aided Colonoscopy in Inflammatory Bowel Disease Patients|Water-aided Colonoscopy in Patients With Inflammatory Bowel Disease - a Single-center, Single-blinded Randomized Trial||Vitkovice Hospital|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|92|||Both|18 Years|N/A|No|||June 2014|November 16, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933867||60341|
NCT01934140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116725|Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination|The Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination||GlaxoSmithKline||Active, not recruiting|April 2014|April 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|17 Years|66 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934140||60320|
NCT01934101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302|Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers|A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers||GlaxoSmithKline|Yes|Terminated|August 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 15, 2013||No|Following the emergence of an unexpected pharmacodynamic effect, the sponsor has decided to    conclude the study early without fully achieving its objective|No||https://clinicaltrials.gov/show/NCT01934101||60323|
NCT01930292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1143-103|Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies|A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)||Debiopharm International SA|No|Terminated|April 2013|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 21, 2013||No|Part B was cancelled based on business decision|No||https://clinicaltrials.gov/show/NCT01930292||60616|
NCT01920087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFP-001|Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain|Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders|AFP|Allodynic Therapeutics, LLC|No|Withdrawn|March 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|No|||March 2014|March 12, 2014|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920087||61398|
NCT01920100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E13237|Resource Use and Disease Course in Dementia (REDIC)|Resource Use and Disease Course in Dementia (REDIC)|REDIC|Sykehuset Innlandet HF|No|Active, not recruiting|April 2009|January 2018|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2800|Samples With DNA|DNA samples are collected by mouth swabs from persons recruited from nursing homes.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nursing home Memory clinics In-home care Persons without dementia (Control)|May 2015|May 18, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01920100||61397|
NCT01920399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00020|A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Subjects||AstraZeneca|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01920399||61374|
NCT01920698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.798|Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation|Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation.|MITRA-FR|Hospices Civils de Lyon|Yes|Recruiting|November 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920698||61351|
NCT01920958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-2402-401-DE|Use of Tachosil® for Lymph Sealing During Surgery|Use of Tachosil® for Lymph Sealing During Surgery. A Non-Interventional Study|SEAL|Takeda|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Stationary patients in whom a lymph node resection is planned to be performed|August 2014|August 11, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01920958||61331|
NCT01921257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP009|Paediatric Safety Study in Cat-PAD|A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects||Circassia Limited|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|16|||Both|5 Years|11 Years|No|||January 2016|January 7, 2016|July 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921257||61308|
NCT01914705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/12/VA01|Landmark vs. Ultrasound Guided SCVC in the ED|Landmark vs. Ultrasound Guided Subclavian Central Venous Catheter Placement in the Emergency Department||Maimonides Medical Center|No|Terminated|February 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||July 2015|August 7, 2015|July 31, 2013||No|Too few patients who met enrollment criteria.|No||https://clinicaltrials.gov/show/NCT01914705||61811|
NCT01930448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-108|Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1|Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1||St. Luke's-Roosevelt Hospital Center|No|Withdrawn|September 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|20 Years|60 Years|No|Non-Probability Sample|severly obese patients with type 2 diabetes undergoing gastric bypass or gastric banding|September 2015|September 9, 2015|August 20, 2013||No|PI relocated to another Institution|No||https://clinicaltrials.gov/show/NCT01930448||60604|
NCT01930669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR#13465/22Dec2011|Transplanted-like Heart in Critical Ill Patients|||Ospedale L. Sacco – Polo Universitario|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01930669||60587|
NCT01931293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212066RIND|HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome|HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome||National Taiwan University Hospital|No|Recruiting|April 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|750|||Both|20 Years|80 Years|No|||January 2016|January 28, 2016|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01931293||60539|
NCT01931254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-1003-BV|Assess a Diagnostic Tool to Distinguish Between Bacterial and Viral Infection|Prospective, Blinded Validation Study to Assess Accuracy of a Diagnostics for Distinguishing Between Bacterial and Viral Etiology in Pediatric Patients With Lower Respiratory Tract Infections and Fever Without Source|OPPORTUNITY|UMC Utrecht|No|Recruiting|October 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|830|Samples Without DNA|One blood sample and one nasal swab will be collected per patient|Both|1 Month|60 Months|No|Probability Sample|The study population will include eligible subjects aged 1 to 60 months of age from both        genders that attend the hospital or the emergency department (ED) due to a suspected LRTI,        FWS or due to a non-infectious disease. These subjects are expected to fall into one of        the following categories:          1. Patients with an acute bacterial infection          2. Patients with an acute viral infection          3. Patients with an acute mixed co-infection (bacterial and viral)          4. Patients with an undetermined disease etiology          5. Patients with a non-infectious disease (control group; n=140) We estimate that             approximately 75% of the patients will fall into categories number 1-3 (i.e.,             bacterial, viral or mixed infections).|December 2014|December 3, 2014|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931254||60542|
NCT01931592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1667|Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E|Controling Intestinal Colonization of High Risk Patients With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae (ESBL-E) - A Randomized Trial (CLEAR)|CLEAR|University of Cologne|No|Recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931592||60516|
NCT01932086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCF2_2011_RP_1|Effects of White Rice, Brown Rice, and Black Rice on Postprandial Glucose and Lipid Profiles in Healthy Korean Adults|A Randomized, Crossover Clinical Trial||Chonbuk National University Hospital|Yes|Completed|March 2011|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Male|19 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01932086||60478|
NCT01932073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.43/onco13.05|Laser Therapy for the Management of Radiation Dermatitis|Low-Level Laser Therapy for the Management of Radiation Dermatitis: A Pilot Study in Breast Cancer Patients|DERMIS|Hasselt University|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Female|N/A|N/A|No|||December 2014|December 3, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932073||60479|
NCT01932385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCH20130823|Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma|Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma||Qingdao Central Hospital|No|Recruiting|August 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01932385||60455|
NCT01933282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESA-NKT2013|MESA Treatment for NK/T Cell Lymphoma|Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma|MTN|Fourth Military Medical University|Yes|Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|60 Years|No|||December 2013|December 21, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01933282||60386|
NCT01933568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12HYB|Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.|Combined Stereotactic Radiotherapy and Conventional Fractionation in Stage II and III Non Small Cell Lung Cancer (NSCLC) With Peripheral Tumors Smaller Than 5 cm|N12HYB|The Netherlands Cancer Institute|No|Recruiting|February 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933568||60364|
NCT01934153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117157|Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects|Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects||GlaxoSmithKline|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01934153||60319|
NCT01934114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1025|NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo|NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.||Dartmouth-Hitchcock Medical Center|Yes|Terminated|August 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Female|25 Years|76 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females with locally advanced breast cancer defined as being clinically appropriate for        neoadjuvant therapy and healthy volunteers|January 2015|September 28, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01934114||60322|
NCT01934127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115415|Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A and GSK2789868A Administered in Adults 21 to 64 Years of Age||GlaxoSmithKline||Completed|August 2013|October 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|427|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||May 2015|July 9, 2015|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934127||60321|
NCT01930539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|395-13-FB|Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp|Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp||University of Nebraska|Yes|Recruiting|October 2013|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|19 Years|N/A|No|||January 2016|January 14, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01930539||60597|
NCT01920113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0621|A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil|||Yonsei University|No|Completed|October 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|90 Years|No|||January 2015|January 7, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01920113||61396|
NCT01920126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0376|The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery|||Yonsei University|Yes|Recruiting|August 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|90 Years|No|||August 2013|February 24, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01920126||61395|
NCT01920412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-AP-01|Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder|A Prospective, Non-randomized, Multicenter, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of LAmbre Left Atrial Appendage Occluder||Lifetech Scientific (Shenzhen) Co., Ltd.|Yes|Recruiting|October 2012|September 2014|Anticipated|October 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2013|October 15, 2013|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920412||61373|
NCT01920711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696D2301|Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction|PARAGON-HF|Novartis|Yes|Recruiting|July 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|4300|||Both|50 Years|N/A|No|||October 2015|October 14, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920711||61350|
NCT01914120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLQ-CN|the Quality of Life Assessment of Lung Cancer Patients in China|A Multicenter, Observational, Phase III Clinical Study: the Quality of Life Assessment of Lung Cancer Patients in China.||Sun Yat-sen University|Yes|Recruiting|November 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|75 Years|No|Non-Probability Sample|Advanced non-small cell lung cancer patients diagnosed by pathological or cytological        methods, and also have a imageological diagnosis within 6 weeks for clinical staging.        Clinical stage IIIB or IV. Chemo-naive patients: have never receive any kind of        anti-cancer chemotherapy.|August 2015|August 26, 2015|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914120||61856|
NCT01914367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/422|Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)|Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)|HPVXneutra001|University Hospital, Ghent|No|Recruiting|September 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|12|||Female|9 Years|13 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01914367||61837|
NCT01930994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475139|Kenya Sino-implant (II) PK Study|A Pharmacokinetic Study to Compare Sino-implant (II) During Four Years of Use to Jadelle During Five Years of Use by Kenyan Women||FHI 360|No|Withdrawn|September 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|0|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 18 and 44 who have received contraceptive implants from the        Marie Stopes Kenya Eastleigh clinic and MSK mobile clinics in the Nairobi area.|October 2013|October 11, 2013|August 21, 2013||No|Insufficient numbers of Sino-implant users available for study participation.|No||https://clinicaltrials.gov/show/NCT01930994||60562|
NCT01931267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112134RIC|An Coach-based Intervention Study of an Extended Discharge Planning Program on Patients With COPD|An Intervention Study of an Extended Discharge Planning and Disease Management Program on Patients With COPD||National Taiwan University Hospital|Yes|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|154|||Both|20 Years|N/A|No|||April 2014|April 11, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01931267||60541|
NCT01931852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022322|Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin|Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin|CMR-IMPACT|Wake Forest Baptist Health|Yes|Recruiting|September 2013|May 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|312|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931852||60496|
NCT01931605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/173/HP|Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.|Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.|Prost-EMBOL|University Hospital, Rouen|Yes|Terminated|May 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|50 Years|85 Years|No|||July 2015|July 29, 2015|July 4, 2013||No|Enrolling participants has halted prematurely and will not resume due to the Departure of the    principal investigator|No||https://clinicaltrials.gov/show/NCT01931605||60515|
NCT01931839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-809-105|A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis|A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1200|||Both|12 Years|N/A|No|||December 2015|December 7, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931839||60497|
NCT01932684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rhayssa dissertação|Effects Of Breath And Stacking-Spirometry Incentive in Patients With Parkinson's Disease|EFFECTS OF BREATH AND STACKING-SPIROMETRY INCENTIVE PACKAGES IN THE RIB CAGE IN PATIENTS WITH PARKINSON'S DISEASE||Universidade Federal de Pernambuco|Yes|Completed|June 2012|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|15|||Both|40 Years|80 Years|No|||December 2012|August 29, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01932684||60432|
NCT01932411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483753|Factors Affect Outcomes in Cardiovascular Surgery|Factors That Affect the Outcomes of Cardiothoracic and Vascular Surgery||University of California, Davis|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing cardiovascular surgeries|December 2014|December 3, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932411||60453|
NCT01933295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR013959|Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes|Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes||Henry Ford Health System|No|Recruiting|March 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Female|45 Years|65 Years|No|||August 2015|August 24, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01933295||60385|
NCT01933581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12742|A Study to Improve Cardiovascular Outcomes in High Risk PatieNts With Acute Coronary Syndrome|ICON1: A Study to Improve Cardiovascular Outcomes in High Risk PatieNts With Acute Coronary Syndrome|ICON1|Newcastle-upon-Tyne Hospitals NHS Trust|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples With DNA|PBMCs|Both|65 Years|N/A|No|Probability Sample|ICON 1 is a prospective cohort study of older patients presenting with ACS.|March 2016|March 22, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933581||60363|
NCT01912729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH090318 STU00056069|Technology Assisted Programs That Promote Mental Health for Teenagers|Technology Assisted Intervention for the Treatment and Prevention of Depression|ProjectTECH|Northwestern University|Yes|Not yet recruiting|April 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|80|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912729||61962|
NCT01912963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-163|Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer|A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|August 2013|January 2021|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912963||61944|
NCT01912976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUDerma-01|Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease|A Randomized, Intra-individual, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment in Asian Patients With Lower Extremity Bowen's Disease||Dong-A University|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|92 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01912976||61943|
NCT01913275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIS/2/2001|Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy|Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2006|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|80 Years|No|||July 2013|July 30, 2013|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01913275||61920|
NCT01934881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013] 19|Voltage Adjustment Only Versus Combined Parameters Adjustment in PD Patients Treated With Bilateral STN DBS|||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|September 2013|||August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||August 2015|August 14, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934881||60263|
NCT01935609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A120031B|Evaluation of a Skill-Building, Supportive, and Educational Intervention for Couples|Evaluation of a Skill-Building, Supportive, and Educational Intervention for Couples (a Research Project Within the Traumatic Brain Injury Model System Grant)||Virginia Commonwealth University|No|Recruiting|March 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01935609||60208|
NCT01936454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458241-1|Contraceptive Effectiveness of Sino-implant (II) in China|A Study to Evaluate the Contraceptive Effectiveness During the Third, Fourth and Fifth Year of Sino-implant (II) Use and the Pharmacokinetics Over Five Years of Use in Chinese Women||FHI 360|No|Completed|July 2013|January 2016|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|538|||Female|20 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study Population: Women who have received contraceptive implants from the Tongxiang, An        Yang, Lingbao, and Lushi Family Planning Service Stations.|February 2016|February 16, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936454||60143|
NCT01914718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 13-02|Dose-adjusted EPOCH-R in MYC Positive DLBCL|Dose-adjusted EPOCH-R in Patients With Diffuse Large B-cell Lymphoma: a Phase II Study||Fudan University|No|Terminated|February 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|70 Years|No|||August 2014|August 19, 2014|March 2, 2013||No|Poor accrual of eligible patients|No||https://clinicaltrials.gov/show/NCT01914718||61810|
NCT01914965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDSY001|Apathy Cure Through Bupropion in Huntington's Disease|A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease|Action-HD|Charite University, Berlin, Germany|Yes|Completed|June 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|75 Years|No|||September 2014|September 8, 2014|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914965||61791|
NCT01914978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00007167|Evaluating the Effectiveness of a Handbook for Parents of Children Newly Diagnosed With Food Allergy|Living Confidently With Food Allergy: Evaluating the Effectiveness of a Handbook for the Newly Diagnosed||Children's Hospital Boston|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914978||61790|
NCT01915186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TY-02|Use of Dehydroepiandrosterone (DHEA) in Women With Normal and Poor Ovarian Reserve Undergoing IVF|A Randomized Controlled Trial on the Effect of Dehydroepiandrosterone (DHEA) Supplementation on Ovarian Reserve Markers, Response to a Standard Low Dose FSH Stimulation and IVF Cycle Outcomes in Patients With Normal and Poor Ovarian Reserve||The University of Hong Kong|Yes|Completed|October 2010|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|40 Years|No|||December 2013|December 19, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915186||61774|
NCT01915810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0183|Move To Quit - Using Physical Activity to Facilitate Smoking Cessation Among African American Adults|Using Physical Activity to Facilitate Smoking Cessation Among African American Adults||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|45|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915810||61726|
NCT01915823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 4008|Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)|Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages >4 Years to <12 Years With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|July 2013|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|348|||Both|4 Years|11 Years|No|||June 2015|June 9, 2015|August 1, 2013|Yes|Yes||No|March 22, 2015|https://clinicaltrials.gov/show/NCT01915823||61725|
NCT01916096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-837-068-BV|Lancet Blood Volume Comparison Study|Lancet Blood Volume Comparison Study||Facet Technologies|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||6|Actual|180|||Both|18 Years|85 Years|No|Non-Probability Sample|People with diabetes from the surrounding communitu|August 2013|August 1, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916096||61704|
NCT01916707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEBet-664-1a|Weight Based Enoxaparin in Trauma Patients|Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients|WeBET|Intermountain Health Care, Inc.|Yes|Active, not recruiting|July 2013|||January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916707||61658|
NCT01912742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/888|Effect of Speed of Weight Loss on Compensatory Mechanisms Activated During Weight Reduction|Effect of Speed of Weight Loss on Compensatory Mechanisms Activated During Weight Reduction|FVS|Norwegian University of Science and Technology|No|Completed|August 2013|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912742||61961|
NCT01916941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AA021156-01A1|Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin|||University of New Mexico|Yes|Recruiting|September 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916941||61640|
NCT01913288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p000936|Effects of Mother's Voice and Heartbeat Sounds on Preterm Newborns|Exposure to Biological Maternal Sounds in Extremely Preterm Infants: Effects on Short- and Long-term Outcomes||Brigham and Women's Hospital|No|Recruiting|May 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|24 Weeks|34 Weeks|No|||July 2013|July 31, 2013|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01913288||61919|
NCT01913301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0530|A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure||BREAK-DHF-1|Cardiovascular Clinical Studies|Yes|Terminated|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|134|||Both|50 Years|N/A|No|||February 2013|July 30, 2013|February 15, 2013|Yes|Yes|Sponsor lost funding|No||https://clinicaltrials.gov/show/NCT01913301||61918|
NCT01913561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWG001|The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection|The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection Compared To Standard Gel-Electrode-Based ECG||HealthWatch Ltd.|No|Recruiting|September 2013|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||August 2015|August 18, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913561||61898|
NCT01913886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC_Isquemica|Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy|Autologous Grafting of Mesenchymal Stem Cells in Severe Refractory Ischemic Cardiomyopathy||Pontifícia Universidade Católica do Paraná|No|Recruiting|January 2010|July 2014|Anticipated|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||May 2014|May 30, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913886||61874|
NCT01936168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|839-130312|MOCA Versus RFA in the Treatment of Primary Great Saphenous Varicose Veins|Mechanochemical Endovenous Ablation (MOCA) Versus RADiofrequeNcy Ablation (RFA) in the Treatment of Primary Great Saphenous Varicose Veins: a Multicentre Randomized Trial|MARADONA|Rijnstate Hospital|No|Active, not recruiting|October 2012|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|80 Years|No|||January 2015|January 19, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936168||60165|
NCT01935375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18981|Multidisciplinary Model of Nurse Midwife|Multidisciplinary Model of Nurse Midwife Psychotherapy for Postpartum Depression||Drexel University|No|Completed|July 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Female|16 Years|45 Years|No|||August 2015|August 5, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01935375||60226|
NCT01935388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJH CCP|Common Canister Protocol for Inhaler Administration in Mechanically Ventilated Patients|Common Canister Protocol for Metered Dose Inhaler Administration in Mechanically Ventilated Patients||Barnes-Jewish Hospital|No|Enrolling by invitation|June 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01935388||60225|
NCT01935622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU HM14393|Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy|Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy|DOXY-HF|Virginia Commonwealth University|No|Terminated|July 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|August 23, 2013|Yes|Yes|End of funding|No|June 20, 2014|https://clinicaltrials.gov/show/NCT01935622||60207|(No data analysis conducted. Insufficient enrollment)
NCT01927146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HER2 and Lauren|Lauren Classifications and HER2 Status in Gastric Cancer Patients|Retrospective Study of Lauren Classifications and HER2 Status in Chinese Patients With Resectable Gastric Adenocarcinoma||Sun Yat-sen University|No|Active, not recruiting|July 2013|||December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|It is single site, retrospective study by review of medical records and tissue testing.        800 gastric adenocarcinoma patients with integrity medical record and regular survival        follow up who received gastrectomy in the Cancer Center of Sun Yat-Sen University between        January 1996 to December 2006 were retrospectively studied.|August 2013|August 21, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927146||60857|
NCT01927159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-TBVPX-114|Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers|A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults||IDRI|Yes|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01927159||60856|
NCT01937078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDC FAM 2010|Famotidine for Levodopa-induced Dyskinesia in PD|An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease||University Health Network, Toronto|No|Completed|April 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||May 2014|May 1, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01937078||60095|
NCT01937091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1948|Determining the Barriers and Motivations to Clinical Trial Participation|Determining the Barriers and Motivations to Clinical Trial Participation||University of North Carolina, Chapel Hill|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-positive adults, > 18 years, who receive care at the UNC ID clinic and who have        previously been approached for (or offered) participation in a clinical trial.|April 2014|February 10, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01937091||60094|
NCT01915212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130172|Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection|Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|65|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|July 15, 2015|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915212||61772|
NCT01915537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNOVATION|Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients|A Prospective Cohort Study to Observe the Difference of Efficacy Between Infliximab With Methotrexate and Classic DMARDs in the Severe Rheumatoid Arthritis Patients With Poor Prognosis|INNOVATION|Zhang, Xiao, M.D.|Yes|Not yet recruiting|August 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||July 2013|August 1, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915537||61747|
NCT01915550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361979|Metformin as Adjuvant to Insulin Therapy in Insulin-resistant Diabetes Mellitus With Pregnancy|The Role of Adding Metformin in Insulin-Resistant Diabetic Pregnant Women - a Randomized Controlled Trial||Ain Shams University||Completed|April 2012|February 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Female|20 Years|45 Years|No|||August 2013|August 2, 2013|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915550||61746|
NCT01915849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIK066A2201|Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus||Novartis|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|14|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|August 1, 2013|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01915849||61723|
NCT01916421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12097|The Cellularity Yield of Three Different 22-gauge Endoscopic Ultrasound Fine Needle Aspiration Needles|||Texas Tech University Health Sciences Center|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|107|||Both|18 Years|88 Years|No|||November 2014|February 16, 2015|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01916421||61679|
NCT01912781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-004|Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers|Clinical Evaluation of the Safety and Efficacy of FID 120947A Compared to a Marketed Lens Care Solution in Gas Permeable Contact Lens Wearers||Alcon Research|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|112|||Both|N/A|N/A|No|||June 2015|June 10, 2015|July 29, 2013|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01912781||61958|
NCT01912989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13CRP14570008|Motivational Interviewing in NOURISH for Parents of Overweight Children|Motivational Interviewing in NOURISH for Parents of Overweight Children|NOURISH+MI|Virginia Commonwealth University|Yes|Completed|January 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01912989||61942|
NCT01913002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-109-NRM|Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects|Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study||Lexicon Pharmaceuticals|No|Completed|July 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913002||61941|
NCT01913015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9130|Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer|An Open-Label, Phase I, Randomized Pharmacokinetic Study of Dietary Effects on Abiraterone Acetate Drug Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (DEAL)||OHSU Knight Cancer Institute|Yes|Terminated|July 2013|||June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|July 29, 2013|No|Yes|After enrollment of the first 3 subjects, an interim assessment was conducted. Comparing DBS    sampling to plasma PK levels yielded unconvincing results.|No||https://clinicaltrials.gov/show/NCT01913015||61940|
NCT01913314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14930|A Study of ^14C-LY2835219 in Healthy Participants|Disposition of [^14C]-LY2835219 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913314||61917|
NCT01913574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMI-13-01-09|Efficacy Study of Acupuncture to Treat the Upper Abdominal Pain of Cancer Patients|Pilot Study of Acupuncture to Alleviate the Upper Abdominal Pain of Cancer Patients Treated With Neurolytic Celiac Plexus Block||Daegu Catholic University Medical Center|No|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913574||61897|
NCT01935115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofSKetamine-01|Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy|A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression||University of Saskatchewan|Yes|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01935115||60246|
NCT01935128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Everolimus|Evaluation of Calcineurin-inhibitor Reduction With Conversion at 3 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction|A 24-month, Single Center, Pilot, Open Label, Controlled Trial to Evaluate the Efficacy and Safety of Calcineurin-inhibitor Reduction With Conversion at 3 Months to Reduced Dose Tacrolimus/Everolimus in Adult Renal Transplant Recipients Following Campath® Induction and Steroid Avoidance||University of Toledo Health Science Campus|No|Recruiting|July 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01935128||60245|
NCT01935908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLASH-P1|Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study|Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage|SPLASH - Pilot|Vanderbilt University|No|Not yet recruiting|January 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|36|||Both|18 Years|75 Years|No|||September 2013|September 1, 2013|April 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01935908||60185|
NCT01935648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/ANAES/02|Blood Levels of Local Anaesthetic in Knee Arthroplasty Using a Continuous Infusion Device|Blood Levels of Local Anaesthetic in Knee Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Knee Arthroplasty|BLOCKS-II|Golden Jubilee National Hospital|No|Not yet recruiting|September 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Up to 11 blood samples per patient|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing elective knee joint replacement where they will be receiving the        Caledonian technique|September 2013|September 2, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01935648||60205|
NCT01936493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003657|Biologic Predictors of Leiomyoma Treatment Outcomes|Biologic Predictors of Leiomyoma Treatment Outcomes||Mayo Clinic|No|Active, not recruiting|August 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Serum aliquots and genomic DNA samples will be collected, processed and stored in the      Biospecimen Accessioning Processing (BAP) lab at Mayo Clinic in Rochester, MN.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be enrolled at Mayo Clinic in Rochester, Minnesota. These patients will        either be enrolled in leiomyoma clinical trials or undergoing leiomyoma clinical        treatment.|November 2015|November 9, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01936493||60140|
NCT01936779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxlip-2013|Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans|Investigating Intra-hepatic Fatty Acid Partitioning and Its Regulation in Man. Studies to Understand the Role of Dietary Nutrients in Liver Fat Metabolism in Relation to Obesity in Man.||University of Oxford|No|Recruiting|September 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936779||60118|
NCT01927445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-13-0001873|Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care|Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care: Protocol for a Pragmatic, Cluster-randomized Trial||Sunnybrook Health Sciences Centre|No|Active, not recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|5000|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01927445||60834|
NCT01927432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 0908000633|Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea|Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea||Cornell University|No|Recruiting|September 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Blood serum, subcutaneous fat|Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants        are between 18-38 years with a BMI of 18.5 kg/m2 or higher. Women are screened and        enrolled following consent based on their response to our advertisements. Enrollment is        restricted to the geographical area.|January 2016|January 26, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927432||60835|
NCT01915225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130176|Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer|Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|July 2013|June 2024|Anticipated|June 2023|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|90 Years|No|||April 2015|January 12, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915225||61771|
NCT01915563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBT Spain 001|Rest After Spontaneous Breathing Trial for Prevention of Post-extubation Failure|Phase 2 Study of 60-min Rest After Successful Spontaneous Breathing Trial Before Extubation as a Tool for Reduction Post-extubation Failure.||Althaia Xarxa Assistencial Universitària de Manresa|No|Completed|September 2013|January 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|450|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915563||61745|
NCT01915836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-043|Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization||Memorial Sloan Kettering Cancer Center||Completed|March 2011|||December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|30 Years|N/A|No|||December 2014|December 10, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915836||61724|
NCT01916122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-071|Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status|Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status||Memorial Sloan Kettering Cancer Center||Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916122||61702|
NCT01916694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SC/0176|Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus|A Randomised Pilot Trial to Compare Remote Blood Glucose Monitoring With Standard Clinical Care in the Gestational Diabetic Population|TREAT-GDM|University of Oxford|Yes|Recruiting|September 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Female|18 Years|40 Years|No|||August 2013|September 13, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01916694||61659|
NCT01913054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013072201|Combined Use of Etomidate and Propofol in Painless Gastroscopy.|Combined Use of Etomidate and Propofol in Painless Gastroscopy, a Multiple Center, Double Blinded, Randomized,Controled Study.||Jiangsu Nhwa Pharmaceutical Co., Ltd.||Recruiting|August 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|2450|||Both|45 Years|75 Years|No|||July 2013|December 13, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01913054||61937|
NCT01913353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-006|A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®|A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects||Bavarian Nordic|Yes|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913353||61914|
NCT01916954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN5P|Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy|Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Pregnant Women in the Democratic Republic of Congo|ALN5P|University of Oxford|No|Completed|July 2013|||March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Female|18 Years|45 Years|No|||March 2014|March 24, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916954||61639|
NCT01916967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4117-201|An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)|A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.||Merck Sharp & Dohme Corp.|No|Completed|August 2013|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|239|||Both|12 Years|N/A|No|||August 2015|August 4, 2015|August 2, 2013|No|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01916967||61638|
NCT01912755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10834-4|Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits|Anesthetic Efficacy of 4% Articaine (Mandibular Infiltration) and 2% Lidocaine (Alveolar Nerve Block), Associated With 1:100.000 Epinephrine, in Lower Molars With Irreversible Pulpits||University of Campinas, Brazil|No|Completed|February 2010|January 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01912755||61960|
NCT01913327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010489|Antipsychotic Effects on Brain Function in Schizophrenia|Locus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia|APD|University of California, San Francisco|No|Recruiting|April 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|40 Years|No|||October 2014|October 25, 2014|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913327||61916|
NCT01913600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 126 1D|Resolute Integrity US Extended Length Sub-Study(RI-US XL)|Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm|RI-US XL|Medtronic Vascular|No|Active, not recruiting|July 2013|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913600||61895|
NCT01913587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMI-13-01-21|Efficacy Study of Acupuncture on Spinal Compression Fracture|Efficacy and Safety of Acupuncture on Spinal Compression Fracture in Patients Treated With Nerve Block||Daegu Catholic University Medical Center|No|Recruiting|March 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|50 Years|N/A|No|||February 2014|February 2, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913587||61896|
NCT01913912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/481|Event Rate and Effects of Stimulants in ADHD|Can Changing the Rate at Which Information is Presented Alter the Effects of Stimulants on ADHD Information Processing. Testing a Prediction of the State Regulation Deficit Model.|ERESA|University Ghent|No|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|25|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913912||61872|
NCT01913925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-05|Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress|Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress||United States Army Research Institute of Environmental Medicine|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913925||61871|
NCT01926652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-AC-001|Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg|An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers||Shin Poong Pharmaceutical Co. Ltd.|Yes|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01926652||60895|
NCT01926665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1070|Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)|Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL)||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2014|||June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926665||60894|
NCT01935921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00807|Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer|A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer||National Cancer Institute (NCI)|Yes|Recruiting|April 2013|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01935921||60184|
NCT01927172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iS-2013-Wz|AirSonea Wheeze Detection Study|AirSonea Wheeze Detection Study - Multipart Clinical Performance Assessment to Determine Agreement on Wheeze Detection Between AirSonea™ Versus Physician Auscultation and an Expert Panel.||iSonea||Not yet recruiting|September 2013|||August 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01927172||60855|
NCT01928030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0032|Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer|Pilot Phase I/II Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy||Stanford University||Active, not recruiting|December 2013|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|23|||Both|N/A|N/A|No|||October 2015|October 1, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928030||60790|
NCT01927705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSB-AD|Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)|Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis||Kang Stem Biotech Co., Ltd.|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|20 Years|60 Years|No|||August 2015|October 26, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927705||60814|
NCT01927718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0806|Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)|A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01927718||60813|
NCT01915576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16447|Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients|A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors.||Bayer|No|Recruiting|September 2013|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915576||61744|
NCT01915589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16553|Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)|A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)||Bayer|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915589||61743|
NCT01915862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTH-A7399-1862013|Blood Pressure Variability in Acute Ischemic Stroke|Comparison of Blood Pressure Variability Indices and Ambulatory Arterial Stiffness Index as Prognostic Indicators in the Medium Term Outcome of Acute Ischemic Stroke|PREVISE|Aristotle University Of Thessaloniki|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients admitted to Departments of Medicine of three University Hospitals        (Thessaloniki, Larissa, Ioannina) with the diagnosis of acute ischemic stroke|May 2015|May 18, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915862|3 Months|61722|
NCT01916109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-103|Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer||Memorial Sloan Kettering Cancer Center||Terminated|August 2013|||July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 2, 2013|Yes|Yes|Lack of accrual|No|January 14, 2016|https://clinicaltrials.gov/show/NCT01916109||61703|
NCT01916434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005|Farmed Fish Human Intervention Study|FIsh for a Sustainable Healthy Diet In Scottish Households Study|FISHDISH|University of Aberdeen|No|Completed|March 2013|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|51|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916434||61678|
NCT01916447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-109|A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.|A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors||Taiho Oncology, Inc.|No|Recruiting|September 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916447||61677|
NCT01913366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG043584-01A1|Senior Peer Alliance for Rural Research On Wellness|Case Management and Problem Solving Therapy for Depressed Older Adults|SPARROW|University of California, San Francisco|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913366||61913|
NCT01916980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4117-202|Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)|A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.||Merck Sharp & Dohme Corp.|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|12 Years|N/A|No|||August 2015|August 5, 2015|August 2, 2013|No|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01916980||61637|
NCT01912768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-003|Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Soft Contact Lens Wearers|Clinical Evaluation of the Safety and Efficacy of FID 120947A Compared to a Marketed Lens Care Solution||Alcon Research|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|362|||Both|N/A|N/A|No|||June 2015|June 10, 2015|July 29, 2013|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01912768||61959|
NCT01913028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5180C00003|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects|A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects||AstraZeneca|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|64|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913028||61939|
NCT01913613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01|REDUCE LAP-HF TRIAL|REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD™ System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure|REDUCE LAP-HF|Corvia Medical|Yes|Active, not recruiting|September 2013|May 2019|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|40 Years|N/A|No|||October 2015|February 19, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913613||61894|
NCT01914237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Castor-2012-04|A Multi-center Trial of Single-Branched Stent Graft System to Treat Aortic Dissection|A Multi-center Trial of Castor Single-Branched Stent Graft System for Endovascular Repair of Aortic Dissection.||Changhai Hospital|No|Recruiting|April 2013|April 2017|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|80 Years|No|||August 2013|August 1, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01914237||61847|
NCT01913938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemophagocytosis_Ulm|Hemophagocytosis in Critically Ill Adult Patients|Hemophagocytosis in Critically Ill Adult Patients With Cytopenias|HCIAP|University of Ulm|No|Recruiting|July 2013|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|whole blood, serum, white cells, bone marrow|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with leukopenia who are routinely treated with rhG-CSF|December 2015|December 2, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913938||61870|
NCT01913951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309091|Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes|A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome||Washington University School of Medicine|No|Recruiting|November 2013|December 2021|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01913951||61869|
NCT01914224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13162MFDS106|Combined Dietary Education of Low Sodium and High Potassium Consumption|Research for the Effectiveness of Combined Dietary Education of Low Sodium and High Potassium Consumption||DongGuk University|No|Recruiting|March 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914224||61848|
NCT01914497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-AFL-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||January 13, 2015|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01914497||61827|
NCT01935401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31MH097406|Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa|Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa||Drexel University|No|Completed|June 2011|||September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|47|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women (ages 18-45 years) with bulimia nervosa and age, BMI, and IQ-matched controls.|October 2014|October 6, 2014|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01935401||60224|
NCT01935414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKD-TEDS-001|Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study|A Multicentre Randomised Controlled Trial Comparing the Incidence of Asymptomatic and Symptomatic Deep Vein Thrombosis Between the gekoTM Device and Thromboembolism Deterrent Stockings in Patients Recovering From Total Hip Replacement Surgery||Firstkind Ltd|No|Recruiting|August 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01935414||60223|
NCT01935427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIV2|Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume|Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume||Flashback Technologies|Yes|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy non-pregnant volunteers with no cardiovascular disease or other health issues.|March 2015|March 4, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01935427||60222|
NCT01927185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16368|Long-versus Short-Axis Ultrasound Guidance for Subclavian Vein Cannulation|Long-versus Short-Axis Ultrasound Guidance for Subclavian Vein Cannulation||Azienda Ospedaliero-Universitaria di Parma|No|Completed|June 2013|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|190|||Both|18 Years|85 Years|No|Probability Sample|adult patients admitted to cardiac surgery intensive care who need central venous catheter        for clinical reasons|December 2015|March 17, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927185||60854|
NCT01926912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100862|A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting|HOSPItal Use of Paliperidone Palmitate - A Prospective Non-Interventional Study|HOSPIPalm|Janssen-Cilag International NV|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|371|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with schizophrenia receiving paliperidone palmitate in the hospital setting|August 2015|August 21, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926912||60875|
NCT01927731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0920|Eltrombopag in Cord Blood or Haploidentical Bone Marrow Transplantation|Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation||M.D. Anderson Cancer Center|No|Recruiting|October 2013|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927731||60812|
NCT01927744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0179|Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection|Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection||M.D. Anderson Cancer Center|Yes|Recruiting|December 2013|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927744||60811|
NCT01928316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017872|A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers|Bioequivalence Study of Home-made and Imported Mizolastine Tablets in Healthy Volunteers||Xian-Janssen Pharmaceutical Ltd.|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928316||60768|
NCT01915264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16445|GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice|Glucobay M - Evaluation of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice|GLORY|Bayer|No|Withdrawn|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Type 2 diabetes|March 2015|March 20, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01915264||61768|
NCT01915277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHN-DEX|A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics|A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics||New England Research Institutes|Yes|Recruiting|March 2014|July 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|106|||Both|N/A|180 Days|No|||July 2013|February 13, 2015|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915277||61767|
NCT01915875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070706|Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis|Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis|MUCO SOPHRO|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2012|November 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|10 Years|N/A|No|||January 2016|January 29, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01915875||61721|
NCT01916135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-182|PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative|||Memorial Sloan Kettering Cancer Center||Recruiting|July 2013|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|21 Years|90 Years|No|||March 2016|March 14, 2016|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916135||61701|
NCT01916148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009528|18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia|Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia||Children's Hospital of Philadelphia||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||February 2016|February 18, 2016|July 30, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01916148||61700|
NCT01916161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDINFOSOURCE1|The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients|The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients||National Health Service, United Kingdom|No|Completed|October 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|307|||Both|18 Years|N/A|No|Non-Probability Sample|ambulatory patients attending IBD clinics at Leeds Teaching Hospitals|March 2016|March 21, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01916161||61699|
NCT01916720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480848/010|Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of the Lp-PLA2 Inhibitor SB-480848 (40, 80mg od) on Carotid Plaque Composition in Patients With Carotid Artery Disease and Planned Carotid Endarterectomy, Stratified for Statin Use and Gender, After 14+/-4 Days Treatment||GlaxoSmithKline|No|Completed|January 2003|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|35 Years|N/A|No|||August 2013|August 22, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01916720||61657|
NCT01916993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1303|Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency||Neurocrine Biosciences|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916993||61636|
NCT01913041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDI0077|An Epidemiology Survey on the Incidence of Perioperative Hypothermia|An Epidemiology Survey on the Incidence of Perioperative Hypothermia of Patients Undergo Elective Operation With General Anaesthesia in Beijing Area||Peking Union Medical College Hospital|Yes|Completed|August 2013|January 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|869|||Both|N/A|N/A|No|Probability Sample|Patients who undergo elective surgery with general anaesthesia|July 2014|July 2, 2014|July 29, 2013||No||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01913041||61938|In this study some information can hardly be completely collected such as wound infection incidence within 30 days postoperation, so further intervention study is needed to explore the relationship between hyperthermia and the potential complication.
NCT01913340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0055603-01|Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)|Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes Study|NEATO|University of California, San Francisco|No|Active, not recruiting|September 2013|September 2016|Anticipated|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|24 Hours|No|||March 2016|March 14, 2016|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913340||61915|
NCT01914250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 Dated 01 August 2012|Pain Associated With Neonatal Frenotomy|||Rambam Health Care Campus||Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|8 Weeks|No|||December 2014|December 25, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01914250||61846|
NCT01918384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-14-1|Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy|Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)|NORTH POLE DMD|Kobe University|Yes|Active, not recruiting|August 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|21|||Male|4 Years|N/A|No|||September 2015|September 2, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01918384||61529|
NCT01914523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFHU-FBR 0039|Comparison of the Macintosh, King Vision®, Glidescope® and AirTraq® Laryngoscopes in Routine Airway Management|Comparison of the Macintosh, King Vision®, Glidescope® and AirTraq® Laryngoscopes in Routine Airway Management||Dammam University|Yes|Completed|September 2013|April 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|86|||Female|18 Years|65 Years|No|||May 2015|May 12, 2015|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01914523||61825|
NCT01914835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq, Grant 402721/2010-1|Neuropsychological Rehabilitation on Cocaine/Crack Dependents|The Impact of Neuropsychological Rehabilitation on Cocaine/Crack Dependents: a Placebo-controlled Study Using Cognitive Tests and Functional Magnetic Resonance Imaging.||University of Sao Paulo General Hospital|No|Active, not recruiting|April 2011|February 2016|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|45 Years|No|||May 2015|May 26, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914835||61801|
NCT01926418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USydney|Using Implementation Intentions to Increase Safe Sex Practices in MSM|Using Implementation Intentions to Increase Safe Sex Practices Among and Australian Sample of Men Who Have Sex With Men||University of Sydney|Yes|Not yet recruiting|November 2013|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|180|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926418||60913|
NCT01926431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fMRI Study|Effects of Intense Exercise on Neural Responses to Food.|The Effects of High Intensity Exercise on Neural Responses to Images of Food||University of Birmingham|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01926431||60912|
NCT01927484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed1391963211975|Knee Osteoarthritis AND Methotrexate Use|||Faculty of Medicine, University of Alexandria|Yes|Active, not recruiting|January 2013|September 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|60 Years|N/A|No|||August 2013|August 19, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927484||60831|
NCT01927458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2012-570-12|Transcranial Direct Current Stimulation Aided Rehabilitation of Gait in Subacute Stroke|||University of Aarhus|No|Recruiting|March 2013|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927458||60833|
NCT01927471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1108002383|Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome|Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome||Cornell University|No|Recruiting|September 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|None Retained|Blood serum, subcutaneous fat|Female|18 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women must be able to transport to Cornell University and University of Rochester.        Eligible participants are between 18-48 years with a BMI of 18.5 kg/m2 or higher. Women        are screened and enrolled following consent based on their response to our advertisements.        Enrollment is restricted to the geographical area.|January 2016|January 26, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927471||60832|
NCT01928043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443-2011|Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations|Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations||Sunnybrook Health Sciences Centre|Yes|Recruiting|September 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|19 Years|No|||November 2015|November 16, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928043||60789|
NCT01929421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-GIRBA-2075|A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.|||Gachon University Gil Medical Center||Completed|December 2009|||July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|No|||August 2013|August 21, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01929421||60683|
NCT01915914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117291|A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis|A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis||GlaxoSmithKline||Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|1 Year|18 Years|No|||October 2015|November 19, 2015|June 27, 2013|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01915914||61718|
NCT01915927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009716|Stem Cell Fistula Plug in Perianal Crohn's Disease|A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease.|MSC-AFP|Mayo Clinic|No|Recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915927||61717|
NCT01915628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-EU-02|e-BioMatrix Canada Registry|A Canadian Pre-market Registry of the BioMatrix Flex™ Drug Eluting Stents.||Biosensors Europe SA|No|Recruiting|May 2013|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|533|||Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for percutaneous coronary intervention with lesions suitable for stent        implantation will be included according to the inclusion and exclusion criteria specified        below.|September 2014|September 6, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01915628|2 Years|61740|
NCT01915888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116830|Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination|Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination||GlaxoSmithKline||Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1|||Both|N/A|5 Years|Accepts Healthy Volunteers|Probability Sample|Children less than 5 years old continuously enrolled in commercial insurance or Medicaid        from birth, and received both medical and pharmacy benefits.|November 2014|November 13, 2014|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915888||61720|
NCT01916733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-172|A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study|A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery||University of Vermont Medical Center|No|Active, not recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Both|18 Years|99 Years|No|Probability Sample|LEB and open AAA patients|February 2016|February 2, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01916733||61656|
NCT01917006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-133|A Safety and Efficacy Study of BOTOX® in Premature Ejaculation|||Allergan|Yes|Recruiting|August 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|60|||Male|18 Years|50 Years|No|||March 2016|March 2, 2016|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917006||61635|
NCT01912794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-2011/18173-3|Postural Responses to External Perturbation in Post-Stroke|Postural Responses to External Perturbation in Post-Stroke: Sensorimotor Integration and Rehabilitation||University of Sao Paulo|Yes|Not yet recruiting|August 2013|October 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|45 Years|70 Years|No|||July 2013|July 30, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912794||61957|
NCT01917812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086400|mActive: A Blinded, Randomized mHealth Activity Trial|mActive: A Blinded, Randomized mHealth Trial of Digital Activity Tracking and Smart Texting to Promote Physical Activity|mActive|Johns Hopkins University|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|48|||Both|18 Years|69 Years|No|||January 2016|January 4, 2016|August 1, 2013||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01917812||61573|Given its limited size and scope, mActive may be categorized as a pilot trial. As such, it is most appropriately interpreted as exploratory evidence to guide a definitive pivotal trial in the future.
NCT01917825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-06|A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy|An Open-Label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy||Medtronic Spinal and Biologics|Yes|Active, not recruiting|July 2013|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917825||61572|
NCT01913626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC130044-13CTIL|Assessing the Efficiency of Cognitive Group Therapy for Patient With Subjective Memory Complains Using the WebNeuro System From Brain Resource(BRC)|||Meir Medical Center||Enrolling by invitation|June 2013|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01913626||61893|
NCT01913639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-080|FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer|Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01913639||61892|
NCT01913964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/1997|Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin|||University of Catania|Yes|Completed|October 1997|October 1997|Actual|October 1997|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|45 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01913964||61868|
NCT01913977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/386|Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System|Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System.||University Hospital, Ghent|No|Recruiting|June 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01913977||61867|
NCT01918397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBTC Study 32|Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB|Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB|Opti-Q|Boston University|Yes|Recruiting|January 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 4, 2015|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918397||61528|
NCT01918644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO12210|Stereotactic Body Radiation Therapy and Capecitabine Before Surgery in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery|A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.||University of Wisconsin, Madison|Yes|Recruiting|August 2013|December 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||February 2016|February 26, 2016|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918644||61509|
NCT01918631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDF-ETV-RCT studyA|A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir|||Chinese University of Hong Kong|Yes|Recruiting|August 2013|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918631||61510|
NCT01918904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205683|A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis|A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC)|STS-CALC|Loyola University|No|Withdrawn|September 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918904||61489|
NCT01919177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01415|Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity|Effect of Inorganic Nitrates on Arterial Hemodynamics and Exercise Capacity||Philadelphia Veterans Affairs Medical Center|No|Completed|January 2013|November 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01919177||61468|
NCT01926925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS#: 01-14|Endothelial Function in Hispanic Children/Adolescents at Risk for Type 2 Diabetes|Endothelial Function in Hispanic Children/Adolescents at Risk for Type 2 Diabetes||Joslin Diabetes Center|No|Completed|May 2001|February 2012|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|38|Samples Without DNA|plasma samples|Both|10 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Hispanic children/adolescents|August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926925||60874|
NCT01927198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-201|RDEA3170 Monotherapy in Subjects With Gout|A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout||Ardea Biosciences, Inc.|No|Completed|August 2013|July 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|172|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927198||60853|
NCT01928329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1307012371|A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes|A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes||Yale University|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||July 2014|November 5, 2014|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928329||60767|
NCT01928589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13104|Partial Breast Irradiation With Concurrent Chemotherapy for Women With Breast Cancer|"Randomized Trial of Partial Breast Irradiation (PBI) and Sequential vs. Concurrent Chemotherapy in Women With ER Negative Early Stage Breast Cancer (PBI 3.0)"|PBI 3|Indiana University|Yes|Recruiting|September 2013|||September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|100 Years|No|||December 2015|December 2, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928589||60747|
NCT01927757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120125|Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab|A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent|ROCkIES|Amgen|No|Completed|May 2013|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927757||60810|
NCT01928602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092982|Computerised Therapy in Chronic Stroke|Does Inner Speech Improve Access to Overt Speech in Aphasia Following Stroke? An fMRI Study Utilising Computerised Rehabilitation Software.|CATChES|Cambridge University Hospitals NHS Foundation Trust|Yes|Not yet recruiting|November 2013|August 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2014|January 23, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928602||60746|
NCT01929148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS_myomectomy|Prophylactic Bilateral Salpingectomy and Laparoscopic Myomectomy|Is Prophylactic Bilateral Salpingectomy Added to Laparoscopic Myomectomy as New Preventive Strategy for Ovarian Cancer a Safe Procedure?||University Magna Graecia|Yes|Recruiting|August 2013|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|154|||Female|18 Years|50 Years|No|||December 2014|December 4, 2014|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929148||60704|
NCT01929434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05-13 CP III|Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis|Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis|CP|General Hospital of Chinese Armed Police Forces|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|1 Year|14 Years|No|||July 2015|July 17, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929434||60682|
NCT01916213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 12-065|The Valve of Hyaluronic Binding Selection (PICSI) in Improving IVF Outcome|||St. Luke's-Roosevelt Hospital Center|Yes|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||August 2014|October 13, 2015|August 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916213||61695|
NCT01916473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20/23-02-2010|Epidural Versus Continuous Wound Ropivacaine Infusion Analgesia|Epidural Versus Continuous Wound Ropivacaine Infusion: Effect on Acute and Chronic Pain After Myomectomy or Total Abdominal Hysterectomy. A Randomized Controlled Trial||University of Athens|No|Completed|April 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|25 Years|60 Years|No|||August 2013|August 1, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01916473||61675|
NCT01916174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4026|A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects|A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects||Novo Nordisk A/S|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01916174||61698|
NCT01916187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I212|Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma|A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children With Recurrent and/or Refractory Neuroblastoma||Canadian Cancer Trials Group|No|Withdrawn|July 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Months|18 Years|No|||February 2014|February 7, 2014|July 31, 2013||No|drug company withdrww support following a re-examination of the benefit-risk assessment for    the investigational use of imetelstat in this population|No||https://clinicaltrials.gov/show/NCT01916187||61697|
NCT01916460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E13052|Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients|||Texas Tech University Health Sciences Center|Yes|Completed|March 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|80 Years|No|||November 2014|November 13, 2014|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01916460||61676|
NCT01917019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS304|A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis|A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension|MOTION - JAPAN|Biogen||Active, not recruiting|August 2013|April 2018|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|101|||Both|18 Years|70 Years|No|||November 2015|November 19, 2015|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01917019||61634|
NCT01912807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-163|Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic?|Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic? A Non-Inferiority, Randomized Control Trial|DEXPO|University of Saskatchewan|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|3 Years|9 Years|No|||March 2016|March 22, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01912807||61956|
NCT01913067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE2100|Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC|A Phase II Evaluating Cabazitaxel in Patients With Brain Metastasis Secondary to Breast and Non-small Cell Lung Cancer|CRANIAL|Jules Bordet Institute|No|Withdrawn|September 2013|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|July 18, 2013||No|Scientific rationale is deemed obsolete. Funders lost interest in the trial.|No||https://clinicaltrials.gov/show/NCT01913067||61936|
NCT01913080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000973|The Health Log: A Randomized Clinical Trial|The Use of a Health Management Tool in a Clinic Setting to Improve Self-Efficacy in Rheumatoid Arthritis Patients: a Randomized Clinical Trial.||Brigham and Women's Hospital|No|Active, not recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913080||61935|
NCT01917838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH100407-01|Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Mobile Health Solutions for Behavioral Skill Implementation Through Homework|MHealth|NYU Silver School of Social Work|No|Recruiting|November 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|7 Years|13 Years|Accepts Healthy Volunteers|||November 2015|November 1, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01917838||61571|
NCT01913652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1202|Ph II Cabazitaxel/Ifosfamide DD Liposarcoma|Randomized Phase II Trial of Cabazitaxel or Prolonged Infusional Ifosfamide in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Suspended|October 2014|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|July 30, 2013||No|Major amendment - change in design|No||https://clinicaltrials.gov/show/NCT01913652||61891|
NCT01913990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011348-01H|Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.|A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study|ER11-02|Ottawa Hospital Research Institute|Yes|Active, not recruiting|September 2011|March 2016|Anticipated|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|323|||Female|19 Years|N/A|No|||October 2015|October 21, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01913990||61866|
NCT01914003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2002|Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)|A Multi-Center Study of the Prevalence of Known Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C-Sucrose Breath Test in Children With Chronic Diarrhea or Chronic Abdominal Pain|CSID GPS|QOL Medical, LLC|No|Recruiting|May 2013|||May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|||Both|N/A|18 Years|No|Non-Probability Sample|18 years of age or younger experiencing chronic, idiopathic diarrhea or abdominal pain for        at least 4 weeks.|June 2014|June 10, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01914003||61865|
NCT01918657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009443|Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP||Children's Hospital of Philadelphia|Yes|Withdrawn|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|21 Years|No|||September 2014|September 8, 2014|July 22, 2012|Yes|Yes|Unable to get an IND from the FDA for the walnut powder|No||https://clinicaltrials.gov/show/NCT01918657||61508|
NCT01918917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/329|Adding Intra-articular Dexmedetomidine to Levobupivacaine for Postoperative Analgesia in Arthroscopic Knee Surgery|Phase 4 Study of Intra-articular Dexmedetomidine Adding to Levobupivacaine for Postoperative Analgesia in Arthroscopic Knee Surgery||TC Erciyes University|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||August 2013|August 7, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918917||61488|
NCT01919203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj0723|the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Children|the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Pediatric Patients||Yeungnam University College of Medicine|Yes|Completed|August 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|50|||Both|3 Years|12 Years|No|||July 2015|July 14, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919203||61466|
NCT01919216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6038/6996R|Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms|Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms||New York State Psychiatric Institute||Active, not recruiting|January 2010|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|24 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919216||61465|
NCT01919229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2201|A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)|A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer|MONALEESA-1|Novartis|No|Terminated|October 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|14|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|August 2, 2013|Yes|Yes|Due to low recruitment, it was decided to terminate the study.|No|September 10, 2015|https://clinicaltrials.gov/show/NCT01919229||61464|
NCT01927497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 2012_360|Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer|Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer|BIOPEX|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|March 2013|November 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927497||60830|
NCT01928056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-09-197|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium 10 mg Tablet (Test, Torrent Pharmaceuticals Ltd., India) Versus Singulair® (Montelukast Sodium) 10 mg Tablet (Reference, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition||Torrent Pharmaceuticals Limited||Completed||||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928056||60788|
NCT01928069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-09-198|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium 10mg Tablet (Test, Torrent Pharmaceuticals Ltd., India) Versus Singulair® (Montelukast Sodium) 10 mg Tablet (Reference, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition.||Torrent Pharmaceuticals Limited||Completed||||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928069||60787|
NCT01928615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28786|A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer|LISAH: An Open-label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer|LISAH|Hoffmann-La Roche||Terminated|September 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|August 21, 2013||No|Problems with drug supply|No|July 31, 2014|https://clinicaltrials.gov/show/NCT01928615||60745|
NCT01928628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ZVCL005|Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients|A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.||LG Life Sciences|No|Completed|May 2012|||April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|449|||Both|20 Years|75 Years|No|||August 2013|August 27, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928628||60744|
NCT01928849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047194|Valproic Acid for the Prevention of Post-Amputation Pain|Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain||Duke University|Yes|Recruiting|December 2013|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|420|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|February 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928849||60727|
NCT01929161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2371 IRB|Study of Wellness Behaviors as a Function of Oxytocin vs Placebo|Affective and Genomic Mediators of Sustained Behavior Change: A Randomized, Dual-blind, Placebo-controlled Experimental Design That Will Examine Wellness Behavior as a Function of Oxytocin vs. Placebo.||University of North Carolina, Chapel Hill|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|239|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929161||60703|
NCT01926262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120121|Exercise as Treatment of Neck Pain Among Helicopter Pilots and Crew Members|Physical Exercise Against Neck and Shoulder Pain in Danish Military Helicopter Pilots and Crewmembers - A Clinical Randomized, Controlled Trail||University of Southern Denmark|Yes|Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926262||60925|
NCT01916226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200165|A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis|Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|682|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|August 1, 2013|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01916226||61694|
NCT01916499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1422|MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries|MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries||Oslo University Hospital|No|Completed|May 2012|||April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|70|||Both|10 Years|15 Years|No|Probability Sample|Patients 10-15 years old surgically corrected in the neonatal period with arterial switch        procedure for transposition of the great arteries at Rikshospitalet, OUS, Norway.|February 2016|February 16, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916499||61673|
NCT01916486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00715|Vitality: Promoting Cognitive Function in Older Adults With Chronic Stroke|Complex Mental and Social Activities to Promote Cognitive Function in Older Adults With Chronic Stroke: A Randomized Controlled Trial|Vitality|University of British Columbia|Yes|Recruiting|November 2013|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|119|||Both|55 Years|N/A|No|||October 2015|October 26, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01916486||61674|
NCT01916746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEN-CSP|Treatment of Caesarean Scar Pregnancy|Safety and Effectiveness of Transvaginal Resection of Pregnancy Tissue in the Treatment of Caesarean Scar Pregnancy|CSP|First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|January 2013|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|N/A|N/A|No|||January 2013|August 2, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01916746||61655|
NCT01916759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058919|Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda|Systems Biological Responses to Influenza Vaccination in an HIV-infected and HIV-uninfected Adult Population in Kampala, Uganda||Emory University|No|Completed|June 2013|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 22, 2014|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01916759||61654|
NCT01916772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFO7256|Natural History of Cherubism Observational Study|Natural Hisotry of Cherubism Observational Study||The Cleveland Clinic||Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|We may take blood or skin samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will see patients with cherubism|August 2013|August 2, 2013|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01916772||61653|
NCT01917552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1301|Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer|Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer||Asan Medical Center|No|Recruiting|November 2013|September 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|870|||Both|18 Years|74 Years|No|||November 2015|November 26, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917552||61593|
NCT01917565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.2011.0127|The Use of Airtraq Laryngoscope Versus Macintosh Laryngoscope and Fiberoptic Bronchoscope by Experienced Anesthesiologists|||Marmara University||Not yet recruiting|August 2013|March 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|18 Years|65 Years|No|Probability Sample|patients undergoing surgery under general anesthesia|August 2013|August 5, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917565||61592|
NCT01917591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-0070|Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study|Healing of Punch Graft Wounds With Two Biologic Exracellular Matrices; a Non-inferiority Study||Kerecis Ltd.|Yes|Completed|January 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 5, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01917591||61590|
NCT01918436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-331|RCT, Proof of Concept Study of TEAMS (Training Executive, Attention and Motor Skills) Intervention Program|TEAMS (Training Executive, Attention, and Motor Skills): - Intervention Program for Preschoolers With ADHD (Attention Deficit Hyperactivity Disorder). A Rct. Proof-of-Concept Study.|TEAMS|Holbaek Sygehus|Yes|Recruiting|October 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|3 Years|6 Years|No|||August 2013|August 6, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918436||61525|
NCT01918072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-031|Controlled Trial of Tele-Support and Education for Womens Health Care in CBOCs|Controlled Trial of Tele-Support and Education for Womens Health Care in CBOCs|WH CREATE P4|VA Office of Research and Development|No|Recruiting|March 2013|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|100|None Retained|Not applicable - none|Both|N/A|N/A|No|Non-Probability Sample|VA Women's Health primary care provider in who participates in VA SCAN-ECHO learning        sessions or uses VA gynecology electronic consults.|February 2016|February 9, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01918072||61553|
NCT01918410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEED2013|Effect of Contact Lens With Alginic Acid in Dry Eye Patients|To Evaluate Effect of Contact Lens With Alginic Acid (7 Days) in Patients With Dry Eye||Singapore National Eye Centre|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Both|21 Years|90 Years|No|||June 2014|May 18, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918410||61527|
NCT01918930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA271-01a|Tissue Procurement Substudy for Participants in Study CP-MGA271-01|A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)||MacroGenics|No|Recruiting|July 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01918930||61487|
NCT01919242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0800|Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study|||Yonsei University|Yes|Recruiting|January 2013|November 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|20 Years|90 Years|No|Non-Probability Sample|patients who underwent gastrectomy with lymph node dissection for gastric cancer in Yonsei        University Hospital, Seoul|July 2014|July 24, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919242||61463|
NCT01919541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-127-GEN|Mechanistic Prehabilitation|Understanding How Exercise and Nutrition Enhance Preoperative Functional Capacity: a Mechanistic Study||McGill University Health Center|Yes|Not yet recruiting|December 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|65 Years|N/A|No|||September 2015|September 21, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01919541||61440|
NCT01928342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012MMXX2CoA008|The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia|The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial||Zhejiang University|Yes|Recruiting|March 2012|October 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|80 Years|No|||August 2013|August 19, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01928342||60766|
NCT01929447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carmel-002|Evaluation of WP200 With the Unified Probe (WP200U)|A Prospective, Comparative Study to Evaluate the Watch-PAT200 (WP200) With the Unified Probe (WP200U) Compared to the Currently Used Configuration of WP200 With the Nonin Oximetry Module||Itamar-Medical, Israel|No|Completed|October 2013|||September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|||Both|5 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects, adults and children, with suspected sleep disorders who are referred to a sleep        study and are willing to participate in this clinical study.        Additional non selective volunteers who are willing to participate in this clinical study        and consent to undergo an overnight sleep study at their home.|September 2014|September 18, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01929447||60681|
NCT01928862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000103|Efficacy and Safety of Prepopik™ in Children for Overall Colon Cleansing in Preparation for Colonoscopy|A Randomized, Assessor-Blind, Multicenter, Dose-Ranging Study Comparing the Safety and Efficacy of Prepopik™ Versus Polyethylene Glycol Preparation (Local Standard of Care) in Children Aged 9 Years to 16 Years|Prepopik PREA|Ferring Pharmaceuticals|No|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|75|||Both|9 Years|16 Years|No|||March 2016|March 1, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928862||60726|
NCT01928875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123.04-2012-GES-0009|Comparison of Adequacy of Anesthesia Monitoring With Standard Clinical Practice During Routine General Anesthesia|Comparison of Adequacy of Anesthesia Monitoring With Standard Clinical Practice During Routine General Anesthesia||GE Healthcare|No|Recruiting|December 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||July 2015|July 6, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928875||60725|
NCT01925963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-16|Normative Datasets for Assessments Planned for Mild Traumatic Brain Injury (NORMAL)|Development of Normative Datasets for Assessments Planned for Use in Patients With Mild Traumatic Brain Injury (NORMAL)|NORMAL|Intermountain Health Care, Inc.|No|Active, not recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Serum and plasma will be collected and frozen for future analyses. Future work may examine      DNA, chronic neuro-response biomarkers, plasma- and leukocyte-based markers of TBI using a      number of modern molecular techniques to examine the expression profiles of genes, proteins,      and other macromolecules and to correlate these profiles to clinical outcomes, and      genotypes.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal, healthy, non-brain injured civilians and military participants (active or        inactive)|May 2015|May 18, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925963||60948|
NCT01925976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIETARYHABITS2012-CINCO|Individualized Dietetic Intervention-eating Habits in Obese Hispanic Children of Low Socioeconomic Status|Individualized Tailor-made Dietetic Intervention Program at Schools Enhances Eating Behaviors and Dietary Habits in Obese Hispanic Children of Low Socioeconomic Status||Instituto Tecnologico y de Estudios Superiores de Monterey|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|6 Years|12 Years|No|||August 2013|August 16, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01925976||60947|
NCT01930084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL1354|ENGAGE4HEALTH: A Combination Intervention Strategy for Linkage and Retention in Mozambique|ENGAGE4HEALTH: A Combination Strategy for Linkage and Retention in HIV Care Among Adults in Mozambique|E4H|Columbia University|No|Active, not recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|2004|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930084||60632|
NCT01920581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/10/06-W|Use of Benzodiazepines and Z Drugs in the Elderly|Assessment of Problematic Use of Benzodiazepines and Z Drugs in the Elderly in France: a Public Health Issue||Nantes University Hospital|No|Recruiting|February 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1100|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|65 years old or more volunteers,with benzodiazepines or benzodiazepines related drugs        treatment for at least three months, written consent and without exclusion criteria.|August 2013|August 9, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920581||61360|
NCT01921127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000152|Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) vs. Fluticasone/Salmeterol (FSC) Combination in Patients With COPD.||AstraZeneca||Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|3000|||Both|40 Years|N/A|No|Non-Probability Sample|Health plan members with COPD aged 40 years or older receiving one or more prescriptions        of BFC or FSC during 3/1/2009 and 3/31/2013 who are naive to ISC/LABA combinbination        therapy.|February 2016|February 2, 2016|August 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921127||61318|
NCT01916785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-006854-17|OPTIMDASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)|A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML).|OPTIMDASATINIB|Central Hospital, Versailles|Yes|Completed|May 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|December 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01916785||61652|
NCT01917032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRINK001|Effect of Home-fortification With Sprinkles in Hematologic and Nutritional Status in Preschool Children in Medellín|Effect of Home-fortification With Micronutrient Powder Sprinkles in Hematologic and Nutritional Status in Preschool Children in Medellín: a Randomized Clinical Trial.||CES University|No|Not yet recruiting|September 2013|December 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|5 Months|59 Months|Accepts Healthy Volunteers|||August 2013|August 5, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917032||61633|
NCT01917331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1207-PR-0091|Efficacy of Fixed Combination of Beclomethasone + Formoterol + Glycopyrrolate Versus Foster® in Chronic Obstructive Pulmonary Diseases|A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1863|||Both|40 Years|N/A|No|||July 2015|July 30, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917331||61610|
NCT01917578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCSMANC001|Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction|Phase III Trail of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction|BCSMANC|Shandong Cancer Hospital and Institute|Yes|Recruiting|August 2008|July 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|4|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 4, 2013|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01917578||61591|
NCT01918111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0025|Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)|||Yonsei University|No|Recruiting|September 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|20 Years|85 Years|No|||July 2014|July 24, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01918111||61550|
NCT01918137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN13MT357|The Effect of a Deep-fried Chocolate Bar or Porridge on Cerebral Blood Flow|A Randomised Trial of Effect of Deep-fried Chocolate Bar and Porridge Upon Cerebrovascular Reactivity in Healthy Adult Volunteers||NHS Greater Glasgow and Clyde|No|Not yet recruiting|August 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918137||61548|
NCT01918085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP228|Human Skin Test Model in Colostomists|Open, Prospective, Single Centre, Randomized, Controlled, Cross-over. Clinical Study Investigating the Correlation in Peel Force of Standard Hydrocolloid Adhesive and a Standard Strata Adhesive From Peristomal Skin and Pre-stripped Abdominal Skin in Colostomists||Coloplast A/S|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|45 Years|75 Years|No|||January 2014|January 28, 2014|August 6, 2013||No||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01918085||61552|
NCT01918098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN08-CN-302a|Targin for Non-cancer Pain|A Randomized, Double-blind, Double-dummy, Parallel-group, Multicenter Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Non-malignant Pain Taking Oxycodone Equivalent of ≥10 mg/Day and ≤50 mg/Day as Oxycodone/Naloxone Prolonged-release (OXN) Compared to Subjects Taking Oxycodone Prolonged-release (OXY) Tablets Alone.||Mundipharma (China) Pharmaceutical Co. Ltd|No|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918098||61551|
NCT01918423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiPO-2|Lifestyle in Pregnancy and Offspring - Comparison Between Children Born to Obese Women and Children Born to Normal Weight Women|The Effects of Lifestyle Intervention During Pregnancy in Obese Women on Offspring Adiposity and Metabolic Risk Factors- Comparison With Offspring of Normal Weight Women Not Participating in a Lifestyle Intervention Programme.|LiPO|Odense University Hospital|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|258|Samples Without DNA|We have created a biobank of bloodsamples|Both|30 Months|40 Months|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of children at the ages of 2.5 til 3 years.|August 2013|August 5, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918423||61526|
NCT01918670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FrenchAFAblationSurvey|A French Multi-centric Atrial Fibrillation Catheter Ablation Survey|A French Multi-centric Atrial Fibrillation Catheter Ablation Survey|FrenchAF|Clinique Pasteur|No|Active, not recruiting|November 2010|December 2013|Anticipated|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|||||Both|18 Years|90 Years|No|Non-Probability Sample|All patients undergoing catheter ablation in one of the registry centers|August 2013|August 6, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918670|18 Months|61507|
NCT01919255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-CAN-001|Evaluation of PICOLIGHT Plus COOLPREP, PICOLIGHT Plus CLICOLON for Bowel Preparation|Evaluation of PICOLIGHT Plus COOLPREP, PICOLIGHT Plus CLICOLON for Bowel Preparation (The Phase II Prospective Randomized Clinical Trial)||National Cancer Center, Korea|No|Completed|August 2013|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|236|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01919255||61462|
NCT01919268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 18034113.7.0000.0064|Addition of the Interferential Current to the Pilates Method in the Treatment of Chronic Nonspecific Low Back Pain|Effectiveness of the Addition of the Interferential Current to the Pilates Method in the Treatment of Patients With Chronic Nonspecific Low Back Pain: a Randomized Controlled Trial||Universidade Cidade de Sao Paulo|Yes|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|80 Years|No|||June 2015|June 15, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919268||61461|
NCT01919554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO73.13|Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents|Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis||Stallergenes|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|12 Years|17 Years|No|||January 2014|January 3, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01919554||61439|
NCT01919853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01206008951|Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response|Treatment for Breast and Colorectal Cancer Survivors With Persistent Cancer-Related Fatigue: A Randomized Controlled Trial||Indiana University|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01919853||61416|
NCT01929174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUIRB00009372|Diffuse Myocardial Fibrosis in Fontan Patients|Heart Failure and Fibrosis in Adult Congenital Heart Patients With a Single Ventricle and Prior Fontan Operation.||Oregon Health and Science University|No|Enrolling by invitation|August 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood samples|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with a single ventricle palliated with a Fontan procedure|October 2015|October 15, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929174||60702|
NCT01926795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025178|Immobilization Versus Observation in Children With Toddler's Fractures: a Prospective Randomized Controlled Trial|Immobilization Versus Observation in Children With Toddler's Fractures: a Prospective Randomized Controlled Trial||Greenville Health System|No|Completed|June 2013|February 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|1 Year|5 Years|No|||April 2015|April 6, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926795||60884|
NCT01929759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroHIV001|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen||Massachusetts General Hospital|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929759||60657|
NCT01929772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-052|German Lactat Clearance in Severe Sepsis|German Lactat Clearance in Severe Sepsis|GLASS|RWTH Aachen University|No|Completed|September 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with severe sepsis or septic shock|September 2015|September 22, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01929772||60656|
NCT01929525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MarmaraUSM|Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula|Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula: A Novel Strategy for Managing Anal Fistula||Marmara University|Yes|Recruiting|August 2013|March 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Male|18 Years|80 Years|No|Non-Probability Sample|Patients with the diagnosis of anal fistula|August 2013|August 22, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01929525||60675|
NCT01929538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175/13/03/02/2013|Covered Metal Stent for Benign Biliary Stricture Caused by Chronic Pancreatitis|Covered Self-expandable Metal Stent, 6 Versus 12 Months, for Benign Biliary Stricture Caused by Chronic Pancreatitis: a Prospective Randomized Study||Helsinki University Central Hospital|No|Recruiting|August 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01929538||60674|
NCT01921140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00004|To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours|A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|September 2013|December 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|130 Years|No|||December 2015|December 27, 2015|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921140||61317|
NCT01921439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3262|OCAST Cessation Study|Matching Brief Smoking Interventions to Stage of Change||University of Oklahoma|No|Recruiting|July 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921439||61294|
NCT01917305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFS3YRCT|Influence of Platform-switching on Bone Level Alterations: a 3 Year Randomized Clinical Trial (RCT).|Influence of Platform-switching on Bone Level Alterations: a 3 Year RCT.||University Hospital, Bonn||Completed|February 2007|||March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|30 Years|75 Years|No|||August 2013|August 6, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01917305||61612|
NCT01917318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0207|Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)|A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.||University of Colorado, Denver|Yes|Completed|July 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|89 Years|No|||September 2014|September 24, 2014|July 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917318||61611|
NCT01917851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBMHB-PRS-2|Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients|Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients.||OrSense, Ltd.|Yes|Active, not recruiting|April 2011|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|300|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|July 2013|August 6, 2013|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01917851|1 Day|61570|
NCT01917864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012259|iPad Application to Treat Prosodic Deficits in Students With Communication Disorders|Handheld Technology for Speech Development in Students With Autism Spectrum Disorders||Yale University|No|Active, not recruiting|July 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|4 Years|18 Years|No|||July 2015|July 14, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917864||61569|
NCT01917877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCH-20030801|Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab|Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis||Qingdao Central Hospital|Yes|Recruiting|August 2013|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917877||61568|
NCT01918124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070148-7|A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer|A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer|EC-0701|Fudan University|Yes|Active, not recruiting|January 2008|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|75 Years|No|||August 2013|August 6, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01918124||61549|
NCT01918462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHIL|Protective Immune Mechanisms in Alcoholic Hepatitis|Protective Immune Mechanisms in Alcoholic Hepatitis|AHIL|University of Aarhus|Yes|Recruiting|April 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Whole blood, serum, plasma, PBMC's, hepatic leukocytes|Both|18 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|Patients admitted to the Department of hepatology and gastroenterology V, Aarhus        University hospital|February 2016|February 24, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01918462||61523|
NCT01918683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 16213|TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients|A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918683||61506|
NCT01918943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-Aspen-2013|Evaluation of Aspen Spinous Process Fixation System and PLIF Technique for the Treatment of Low Back Pain|Evaluation of Aspen Spinous Process Fixation System and PLIF Technique for the Treatment of Low Back Pain in the Presence of Lumbar Instability and Degenerative Disk Disease||American British Cowdray Medical Center|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|40 Years|70 Years|No|Non-Probability Sample|Patients 40 years and older with clinical and radiological signs of low back pain and        spinal instability or degenerative disc disease requiring single level decompression and        fusion.|August 2013|August 6, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918943||61486|
NCT01918969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/408|Reference Values of Circulating Endothelial Progenitor Cells|Determination of Reference Values of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in a Blood Donnor Population|ANOPEC2|Hopital Jean Minjoz|No|Not yet recruiting|October 2013|March 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy blood donors|August 2013|August 7, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918969||61484|
NCT01919281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/886|High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome|High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome. A Randomized Controlled Trial||Norwegian University of Science and Technology|No|Completed|July 2013|April 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Female|18 Years|45 Years|No|||May 2015|September 28, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01919281||61460|
NCT01919294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16037|Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)|Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis|TEREPINS|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|75 Years|No|||January 2016|January 29, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919294||61459|
NCT01919567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012095RC|Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer.|Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor.||National Taiwan University Hospital|Yes|Recruiting|November 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|255|Samples With DNA|tissue, serum, saliva|Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Medical center|November 2013|December 8, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919567||61438|
NCT01919580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112057RIB|Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor.|Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor.||National Taiwan University Hospital|Yes|Recruiting|December 2012|July 2014|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Case Control||3|Anticipated|255|Samples With DNA|tissue, serum, saliva|Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Medical center|April 2014|April 14, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919580||61437|
NCT01919866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1075/01 PEI|Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells|Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases||University Children’s Hospital Tuebingen|Yes|Recruiting|March 2004|December 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|1 Year|25 Years|No|||October 2014|October 7, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919866||61415|
NCT01929460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration|A Prospective, Placebo-controlled Trial on the Use of Antibiotics for Pancreatic Cyst Aspiration: a Pilot Study||Kaiser Permanente|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|90 Years|No|||January 2016|January 13, 2016|August 13, 2013||No||No|October 7, 2015|https://clinicaltrials.gov/show/NCT01929460||60680|
NCT01927601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00068534|Assessment of Neurologic Injury Subsequent to Transcatheter Aortic Valve Replacement: A Feasibility Study|Assessment of Neurologic Injury Subsequent to Transcatheter Aortic Valve Replacement: A Feasibility Study|TAVR-Neuro|University of Michigan|No|Recruiting|August 2013|February 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for TAVR|December 2015|December 6, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927601||60822|
NCT01927887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-132|Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study|Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study||Massachusetts General Hospital|Yes|Suspended|July 2012|July 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|August 20, 2013|Yes|Yes|Accrual Goal Completed|No||https://clinicaltrials.gov/show/NCT01927887||60801|
NCT01928173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-OR-052-ME|Self-Help Video for Insomnia in College Students|Self-Help Video for Insomnia in College Students||University of Alabama, Tuscaloosa|No|Suspended|February 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|24 Years|No|||August 2013|August 20, 2013|July 12, 2013||No|Summer vacation|No||https://clinicaltrials.gov/show/NCT01928173||60779|
NCT01929824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001194|Nasal Nitric Oxide Levels in EoE|A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis.||Mayo Clinic|No|Recruiting|August 2013|January 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with eosinophilic esophagitis|January 2016|January 4, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01929824||60652|
NCT01930019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06101968-2|The Influence of Induction Anesthetic Agents on Serum Cortisol Concentration in Morbidly Obese Patients.|The Influence of Induction Agents of General Anesthesia (Etomidate and Thiopental) on Serum Cortisol Concentration in Morbidly Obese Patients. A Randomized Controlled Trial.||Military Institute of Medicine, Poland|No|Completed|June 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|82|||Both|18 Years|62 Years|No|||August 2013|August 27, 2013|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930019||60637|
NCT01920880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43583.091.13|Nociceptive Processing in Acute Cutaneous Nerve Entrapment Syndrome|Nociceptive Processing in Acute Cutaneous Nerve Entrapment Syndrome: a Quantitative Sensory Testing Analysis.||Radboud University|No|Completed|June 2013|September 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will consist of ACNES patients that have been treated both successfully        and refractory. The control group will consist of demographically equal healthy controls        from an existing database|November 2014|November 14, 2014|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01920880||61337|
NCT01920893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12340|An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis|A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis||Sanofi|Yes|Completed|August 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920893||61336|
NCT01921153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-14H|An Environmental Intervention to Encourage Healthy Food Choices|Encouraging Healthy Food Choices With an Environmental Intervention in Military Dining Facilities||United States Army Research Institute of Environmental Medicine|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01921153||61316|
NCT01921166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diminished Ovarian Reserve|Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study|Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study||Carolinas Healthcare System|Yes|Completed|January 2011|March 2014|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||August 2014|August 4, 2014|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921166||61315|
NCT01921452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200125_507|Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit|A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit||Merck KGaA|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|283|||Both|N/A|N/A|No|||November 2014|November 20, 2014|August 9, 2013||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01921452||61293|
NCT01921465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1ILorentzen|Outpatient Care for Multiparas After Elective Cesarean Section: an Observational Study|||Herning Hospital|No|Not yet recruiting|October 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|multiparas having a elective cesarean section at Herning hospital|August 2013|August 12, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01921465|4 Months|61292|
NCT01917617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1302|Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer|The Feasibility Study of Oral Rehydration Therapy for Short Hydration in Chemotherapy With Cisplatin Plus Gemcitabine for Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Recruiting|May 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||April 2015|May 11, 2015|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01917617||61588|
NCT01918150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HXF-CT2-20111|Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII|A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS.|EVIDENCE II|Hexacath, France|Yes|Active, not recruiting|March 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1350|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918150||61547|
NCT01918475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140/12|Analgesic Effect of Oxytocin Receptor Modulation|Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers||University Hospital Inselspital, Berne|Yes|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918475||61522|
NCT01918488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-052|Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease|Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy||University of Southern Denmark|No|Enrolling by invitation|October 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|90 Years|No|||October 2013|October 14, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01918488||61521|
NCT01918449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01499|Follow-up of Patients With Obstructive Sleep Apnea in Primary Care.|Follow-up of Patients With the Apnea-hypopnea Syndrome in Primary Care and Sleep Disorders Units. Equivalence Randomized Comparative Study on Compliance and Clinical Response.||Sociedad Española de Neumología y Cirugía Torácica|No|Completed|January 2013|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|210|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01918449||61524|
NCT01918696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.10885|Controlled Evaluation of a Computerized Anger-reduction Treatment for Suicide Prevention|Controlled Evaluation of a Computerized Anger-reduction Treatment for Suicide Prevention||Florida State University|No|Recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||September 2015|September 10, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01918696||61505|
NCT01918709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VRCL001|Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers|A Randomized, Open Label, Multiple Dose, Cross-over, Phase I Trial to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers||LG Life Sciences|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01918709||61504|
NCT01918956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB/0040|PURETHAL Birch RUSH Study|A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis||HAL Allergy|No|Completed|September 2013|April 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|N/A|No|||April 2014|April 10, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01918956||61485|
NCT01919307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0313|Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures|||Denver Health and Hospital Authority|No|Active, not recruiting|May 2012|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919307||61458|
NCT01919320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-409|SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection|SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection|C2 PAS|SynCardia Systems. Inc.|Yes|Enrolling by invitation|December 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Patients with bi-ventricular failure at risk of imminent death who are implanted with the        SynCardia temporary Total Artificial Heart (TAH-t) AND who have enrolled in the INTERMACS        Registry|July 2015|July 28, 2015|August 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919320||61457|
NCT01919593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-PE-3-053/55|Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children|The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients||Thammasat University|No|Completed|January 2012|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1269|||Both|N/A|15 Years|No|||August 2013|August 9, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919593||61436|
NCT01919879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCGI 25|Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer|A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer||UNICANCER|Yes|Active, not recruiting|October 2012|October 2017|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01919879||61414|
NCT01919892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lithium001|Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium|Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant||University of Sao Paulo|No|Completed|September 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|45 Years|No|||August 2013|August 6, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01919892||61413|
NCT01926561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-072|Predictive Factors for Hypotensive Bradycardic Events During Arthroscopic Shoulder Surgery|Predicting the Occurence of Hypotensive Bradycardic Events in the Patients Undergoing Arthroscopic Shoulder Surgery in the Sitting Position Under Interscalene Brachial Plexus Block||Daegu Catholic University Medical Center|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|68|||Both|15 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients who are scheduled to receive elective shoulder arthroscopic surgery in the        sitting position under interscalene brachial plexus block|October 2013|October 7, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01926561||60902|
NCT01928706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24021985|Quality of Life After Denture Relining|Oral Health Related Quality of Life of Edentulous Patients After Relining Mandibular Dentures With Soft and Hard Denture Liners.|OHRQoL|Fundação de Amparo à Pesquisa do Estado de São Paulo|Yes|Completed|March 2009|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01928706||60738|
NCT01926054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0121|ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis|An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis||Ohio State University|Yes|Recruiting|July 2013|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01926054||60941|
NCT01926275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZIRD-201308|NPPV Added Inspiratory Muscle Training in Severe COPD|Noninvasive Positive Pressure Ventilation Added Inspiratory Muscle Training in Severe Chronic Obstructive Pulmonary Disease||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|July 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|40 Years|75 Years|No|||August 2013|August 18, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01926275||60924|
NCT01926535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RARIS-001|Amniotic Membrane Graft In Syntomathic Bullous Keratopathy|Comparative Analysis of Human Amniotic Membrane Graft Versus Contact Lenses in Syntomathic Bullous Keratopathy|AMBUK|Universidad de Valparaiso|Yes|Completed|November 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||August 2013|August 22, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01926535||60904|
NCT01917084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10HL068270|Training in Exercise Activities and Motion for Growth|Training in Exercise Activities and Motion for Growth (A Study Conducted by the Pediatric Heart Network)|TEAM 4 Growth|New England Research Institutes|Yes|Completed|June 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|N/A|30 Days|No|||December 2013|March 17, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917084||61629|
NCT01917097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00524|Bradycardia Following Intraoperative Administration of Dexmedetomidine|||Nationwide Children's Hospital|No|Enrolling by invitation|August 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients having ENT surgery at Nationwide Children's Hospital.|October 2015|October 26, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917097||61628|
NCT01917344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00003864|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study||Children's Hospital Boston|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|55 Years|No|||June 2015|June 2, 2015|August 5, 2013||No||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01917344||61609|
NCT01917604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imc25|Open Versus Closed Surgical Exposure of Impacted Canine Teeth|Open Versus Closed Surgical Exposure of Impacted Canine Teeth-A Randomised Controlled Trial||Jamia Millia Islamia|Yes|Recruiting|January 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|13 Years|25 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917604||61589|
NCT01917890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiation Therapy And Curcumin|Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer|Radiation Therapy With or Without Curcumin Supplement in Treating Patients With Prostate Cancer||hahid Beheshti University of Medical Sciences|Yes|Completed|March 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Male|50 Years|80 Years|No|||November 2015|November 16, 2015|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01917890||61567|
NCT01918163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059-13HYMC|Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.|Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.|Pomegranate|Hillel Yaffe Medical Center|No|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|55|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||July 2013|August 6, 2013|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01918163||61546|
NCT01918176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481018|Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)|A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions||Pfizer|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|August 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01918176||61545|
NCT01918722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDZX2012074|Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy|Clinical Re-evaluation of Removing Blood Stasis Therapy of Herbal Medicine in Treating Acute Cerebral Hemorrhage Safety||Guangzhou University of Traditional Chinese Medicine|Yes|Enrolling by invitation|October 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01918722||61503|
NCT01918735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1303|A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects|A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacokinetics Study of Single Ascending and Multiple Doses of GWP42006 in Healthy Volunteers||GW Research Ltd|Yes|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01918735||61502|
NCT01918982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147/362|Circulating Endothelial Progenitor Cells and Aortic Aneurysm|Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm|ANOPEC3|Hopital Jean Minjoz|No|Not yet recruiting|October 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with aortic aneurysm|August 2013|August 7, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918982||61483|
NCT01918995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-1005|Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects|A Phase 1, Randomized, Double-blind, Dose Escalation, Parallel Group, Placebo-controlled, Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects||Astellas Pharma Inc|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|August 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01918995||61482|
NCT01919008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0006|Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder|Phase I Study of FK949E - Comparison of Pharmacokinetics Between FK949E 50 mg Tablets and FK949E 150 mg Tablets in Patients With Major Depressive Disorder||Astellas Pharma Inc|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Both|20 Years|64 Years|No|||August 2013|August 6, 2013|August 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919008||61481|
NCT01919333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-OB-3-096/56|Anti-Mullerian Hormone Changes After Laparoscopic Ovarian Cystectomy for Endometrioma Compared With the Non-ovarian Conditions|||Thammasat University||Recruiting|December 2012|||December 2013|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|56|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Reproductive women , age 18- 45 years who undergo laparoscopic ovarian cystectomy or        laparoscopic non- ovarian pelvic surgery|August 2013|August 6, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919333||61456|
NCT01919606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA402S23B703|EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy|Evaluation of the Safety and Efficacy of EXPAREL(R) (Bupivacaine Liposome Injectable Suspension) When Administered Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy||Pacira Pharmaceuticals, Inc|No|Terminated|August 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|75 Years|No|||April 2014|April 15, 2014|February 26, 2013|Yes|Yes|Lack of enrollment|No|April 15, 2014|https://clinicaltrials.gov/show/NCT01919606||61435|
NCT01919619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0947|Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)|A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Recruiting|November 2013|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919619||61434|
NCT01919905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2326|Mozzarella Cheese Vitamin D and Bioavailability|Fortification of Mozzarella Cheese With Vitamin D3: Effect of High Temperature Cooking and Bioavailability of Vitamin D3||University of Toronto|Yes|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01919905||61412|
NCT01919918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62914|Muscle Afferent Feedback Effects in Patients With Heart Failure: The Development of Central Fatigue|||University of Utah|Yes|Recruiting|September 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|144|||Both|20 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919918||61411|
NCT01927315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2871P|Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes|Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial.||University of Padova|No|Recruiting|August 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|38|||Both|18 Years|65 Years|No|||December 2014|December 25, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927315||60844|
NCT01928953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12AST11894/A-12292|Longitudinal Study of Patients With Opioid-Induced Constipation|Longitudinal Study of Patients With Opioid-Induced Constipation||AstraZeneca|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|520|||Both|18 Years|85 Years|No|Probability Sample|The target population consists of patients who have been on daily opioid therapy for ≥ 4        weeks for the treatment of chronic non-cancer or cancer pain and who have opioid-induced        constipation, as per patient history.|July 2015|July 7, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01928953||60719|
NCT01929252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/07|Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy|Phase 4 Study of Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration For Total Abdominal Hysterectomy||TC Erciyes University|No|Completed|August 2011|August 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|65 Years|No|||August 2013|August 22, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01929252||60696|
NCT01929265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL INFL09|A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma|A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma|IIL INFL09|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|January 2011|December 2014|Anticipated|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|75 Years|No|||October 2010|August 22, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929265||60695|
NCT01934855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1370|Tumor Motion Management in Radiotherapy Using 4D-MRI|Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI||Sidney Kimmel Comprehensive Cancer Center|No|Completed|October 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients with cancer being treated with radiotherapy|October 2015|October 9, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934855||60265|
NCT01935089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-0575|Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV|Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic Infection||The Wistar Institute|Yes|Active, not recruiting|November 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||January 2016|February 8, 2016|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935089||60248|
NCT01935076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817124|miRNA in Fetal Overgrowth|Placental miRNA (microRNA) Profile in Fetal Overgrowth Related to Maternal Obesity Study|MIFO|University of Pennsylvania|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|82|Samples Without DNA|A small placental sample will be obtained after delivery in addition to cord blood      collection.|Female|18 Years|45 Years|No|Probability Sample|All patients delivering in the labor and delivery unit at the Hospital of the University        of Pennsylvania.|May 2014|May 23, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01935076||60249|
NCT01935323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121101004|High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents|High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents.|HIIT-MAX|University of Alabama at Birmingham|Yes|Completed|February 2013|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Male|17 Years|22 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01935323||60230|
NCT01921205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0969|Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures|A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥4 Years to <17 Years of Age With Partial Onset Seizures||UCB Pharma|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|308|||Both|4 Years|17 Years|No|||March 2016|March 18, 2016|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921205||61312|
NCT01921218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060470|Belatacept Therapy for the Failing Renal Allograft|Belatacept Therapy for the Failing Renal Allograft|IM103-133|Emory University|Yes|Recruiting|August 2013|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921218||61311|
NCT01917110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2013/05|Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.|Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.||Coopervision, Inc.|No|Active, not recruiting|September 2013|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|8 Years|12 Years|No|||July 2015|July 27, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917110||61627|
NCT01917123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f-91-128|The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease|Phase 0 Study of The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease According to Their Smoking History||Masih Daneshvari Hospital|No|Not yet recruiting|August 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|70 Years|No|||July 2013|August 3, 2013|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01917123||61626|
NCT01917357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QVX-V-D001|A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject|A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age||Crucell Holland BV|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|42 Days|64 Days|Accepts Healthy Volunteers|||February 2014|July 12, 2014|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917357||61608|
NCT01917903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64249|Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease|Walking While Talking: The Effects of Dual Task on Gait and Cognition in Individuals With Neurological Injury or Disease.||Stony Brook University|No|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917903||61566|
NCT01915797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11049|Tumor and Development (TED)|Identification of Patients/Families With a Paediatric Tumor and One or More Developmental Abnormalities - Characterization of New Tumor Predisposition Syndromes and Study Their Molecular Basis|TED|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|||Both|N/A|18 Years|No|Non-Probability Sample|Patient having developed a cancerous pathology and presenting one or several anomalies of        the development.|November 2015|November 25, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01915797||61727|
NCT01916044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111103|Ultrasound Measure of the Thickness of the Lower Segment in Women Having a History of Caesarian|Evaluation of the Efficiency of the Ultrasound Measure of the Thickness of the Lower Segment Associated With a Rule of Decision to Reduce the Foetal and Maternal Morbidity and Mortality in the Care of the Deliveries of the Women Having a History of Caesarian: a Pragmatic Randomized Trial : Lustrial||Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2942|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916044||61708|
NCT01918748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-TRAVLE|Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients|Effect of a Training Regime Featuring the I-TRAVLE System on Arm Function and Skill Performance in Persons With Multiple Sclerosis and Chronic Stroke Patients: a Single Arm Trial||Hasselt University|Yes|Recruiting|July 2013|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01918748||61501|
NCT01919021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11GA006|Assessment of Gastro-Intestinal Function to a Mixed Meal by Non-invasive Imaging|Pilot Study: Assessment of Gastric Motor and Sensory Function to a Mixed Liquid and Solid Test Meal by Gamma Scintigraphy, Magnetic Resonance Imaging and a Nutrient Drink Test in Health and Patients With Disorders of Gastric Function||Nottingham University Hospitals NHS Trust|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|72|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01919021||61480|
NCT01916603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondecyt #1130277|Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development|Effectiveness of a Normative Intervention (Diet, Physical Activity and Breastfeeding) on Maternal Nutrition and Offspring Growth and Development: Nutrition in the First 1000 Days Key to Healthy Growth and Long-term Health.||University of Chile|Yes|Not yet recruiting|September 2013|March 2017|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2400|||Female|16 Years|40 Years|No|||July 2013|August 1, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01916603||61666|
NCT01916889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT 148/2013|4-question "RACY" Delirium Screening Tool Validation Study|Validation Study of the 4-question "RACY"Delirium Screening Tool in General Medical In-patients From a Developing Country Setting|RACY|University of Cape Town|No|Active, not recruiting|August 2013|March 2015|Anticipated|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|1093|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916889||61644|
NCT01912677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4000|Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy|Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy||Gynuity Health Projects|Yes|Recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|894|||Female|18 Years|50 Years|No|||December 2015|December 8, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912677||61966|
NCT01912690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAINING|The Influence of Different Training Regimens on Electrical Stability Following Myocardial Infarction|||Hadassah Medical Organization|No|Completed|July 2013|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|September 20, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912690||61965|
NCT01912898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009-13|Development of Non-invasive Method for Quantifying Vitamin D Levels in the Body Using Spectroscopy|||Hillel Yaffe Medical Center|Yes|Recruiting|March 2013|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|40 subjects aged 18-65 will be recruted for this research: 20 patients be recruited from        the population of patients in the endocrinology department who were diagnosed withe        osteoporosis. Also, 20 healthy subjects will be recruited.|February 2013|July 30, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01912898||61949|
NCT01912911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-521|Evaluating the Efficacy and Feasibility of a Novel Wireless ECG Recording System in Monitoring Patients After Atrial Fibrillation Ablation Procedure||iTransmit|The Cleveland Clinic|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|N/A|N/A|No|Probability Sample|Patients undergoing A-fib ablations.|August 2014|August 6, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01912911||61948|
NCT01928186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7536|FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer|Imaging Early Response of ER+, HER2- Breast Cancer to Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET||University of Washington|No|Recruiting|September 2011|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928186||60778|
NCT01928433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-007|Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis|A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.||MerLion Pharmaceuticals GmbH|Yes|Completed|December 2012|October 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|N/A|No|||April 2015|March 1, 2016|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01928433||60759|
NCT01928446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|590|Lithium for Suicidal Behavior in Mood Disorders|CSP #590 - Lithium for Suicidal Behavior in Mood Disorders|Li+|VA Office of Research and Development|Yes|Recruiting|July 2015|August 2019|Anticipated|May 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1862|||Both|N/A|N/A|No|||January 2016|January 26, 2016|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928446||60758|
NCT01938677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/211-31/1|Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study|Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study||Karolinska Institutet|No|Recruiting|April 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938677||59974|
NCT01929785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-265|BIIR Gene to Manage Heart Allograft Patients|Application of In-House Developed Nanomedicine Technology for Diagnosis and Management of Post-Transplant Heart Allograft Patients||Baylor Research Institute|Yes|Completed|December 2009|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|Samples With DNA|To create new means to detect rejection at the earliest stages, to help prevent progression      through earlier treatment, to discover new avenues targets for treatment of heart graft      rejection, and to reduce the cost of post-transplant health care|Both|18 Years|73 Years|No|Probability Sample|heart transplant patients from Baylor University Medical Center,Dallas|January 2016|January 12, 2016|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01929785||60655|
NCT01935349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1187|Evaluation of Quality of Care - Patient Empowerment Programme, HA|Evaluation of Quality of Care - Patient Empowerment Programme, HA|QoC PEP|The University of Hong Kong|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2496|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients who have been enrolled into the PEP programme will be included in the        evaluation on process of care; whereas all enrolled subjects who have been recruited for        more than 12 months in the programme will be included in the evaluation on the clinical        outcomes of care. An equal number of a random sample of eligible subjects who refused to        take part in the PEP will be used as controls for the evaluation on the clinical outcomes        of care.|January 2015|January 23, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01935349||60228|
NCT01935362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 12-025|Impact of Oranges on Cardiovascular Health|Bioavailability of Flavanones Compounds and Their Impact on Cardiovascular Health||University of Leeds|Yes|Completed|June 2013|March 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 31, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01935362||60227|
NCT01935336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2002.cc|Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers|A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers||University of Colorado, Denver|Yes|Recruiting|September 2013|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935336||60229|
NCT01917136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817786|11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension|Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI||University of Pennsylvania|Yes|Recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|August 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917136||61625|
NCT01917370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k0113011-2013ICC|VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway|VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF|icc|First Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|October 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces      individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial.      Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.|Both|16 Years|90 Years|No|Non-Probability Sample|intrahepatic cholangiocarcinoma patients underwent surgical therapy|August 2013|August 5, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917370||61607|
NCT01917630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-1221|Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet||Alvine Pharmaceuticals Inc.|Yes|Active, not recruiting|August 2013|June 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||December 2014|December 16, 2014|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917630||61587|
NCT01917643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000202|Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) and Tiotropium Bromide Among COPD Patients||AstraZeneca|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2396|||Both|40 Years|N/A|No|Non-Probability Sample|Health plan members with COPD aged 40 years or older receiving one or more prescriptions        of BFC or tiotropium bromide during 3/1/2009 and 1/31/2012 who are naive to ICS/LABA and        LAMA combination therapies.|February 2016|February 2, 2016|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01917643||61586|
NCT01915784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/41|Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD|Study Evaluating Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients||Almirall, S.A.||Completed|July 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|128|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01915784||61728|
NCT01916395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR10|Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache|Comparison of Treximet and Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache.||Westside Family Medical Center, P.C.|Yes|Completed|December 2009|July 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Male and female patients with migraine headaches.|December 2009|August 2, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916395||61681|
NCT01916057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120115|Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis|Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis|CANHPARI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|March 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916057||61707|
NCT01916356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGY-241-1 6009929|Improving Knowledge About Infertility; an Online Educational Tool|Improving Knowledge About Infertility Etiologies, Risk Factors, Treatments and Fertility Myths; an Online Educational Tool||Queen's University|No|Completed|August 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916356||61684|
NCT01916369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN09-CP-0001|Safety Trial Of CTX Cells In Patients With Lower Limb Ischaemia|A Phase I Ascending Dose Safety Study Of Intramuscular CTX0E03 In Patients With Lower Limb Ischaemia||ReNeuron Limited|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|50 Years|N/A|No|||October 2015|October 9, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916369||61683|
NCT01916616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997292|A Multidisciplinary Approach to Vocal Cord Dysfunction: A Novel Pilot Study|A Multidisciplinary Approach to Vocal Cord Dysfunction: A Novel Pilot Study||CAMC Health System|No|Recruiting|August 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|18 Years|No|||September 2013|September 13, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916616||61665|
NCT01916902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001322|Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study|Effect of Pretreatment With Ticagrelor on Residual Thrombus After Percutaneous Coronary Intervention (PCI) in Patients Presenting With Acute Coronary Syndrome in Comparison With Delayed Treatment at the Time of PCI: an Optical Coherence Tomography Study||Massachusetts General Hospital||Withdrawn|February 2014|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|0|||Both|18 Years|79 Years|No|||May 2014|May 23, 2014|August 2, 2013|Yes|Yes|Despite a large number of patients screened, very few met eligibility guidelines.|No||https://clinicaltrials.gov/show/NCT01916902||61643|
NCT01916915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/06|Usage of Tramadol With Levobupivacaine for Pain Treatment After Cesarean Section|The Effect of Addition of Tramadol to Levobupivacaine in Continuous Wound Infusion for Postoperative Pain Treatment in Cesarean Section||Ufuk University|No|Recruiting|July 2013|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|45 Years|No|||May 2015|May 27, 2015|August 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916915||61642|
NCT01912703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-297-13|The Long-term Neurodevelopmental Outcome After Intraventricular Hemorrhage (IVH)-Grades I-II in Preterm Infants at Ages 1-7 Years|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|700|||Both|1 Year|7 Years|No|Non-Probability Sample|Preterm infants born in 2007-2011 at the Hillel Yaffe Medical Center|July 2013|July 30, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912703||61964|
NCT01912924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGFK001|A Prospective Trial for the Effectiveness of the Use of Spinal Cord Stimulation (SCS) in Failed Knee Surgery|A Prospective Single Centre Open Label Trial to Assess the Effectiveness of the Use of Spinal Cord Stimulation in Subjects With Chronic Knee Pain "Failed Knee Surgery"||Coastal Orthopedics & Sports Medicine|No|Withdrawn|August 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|February 3, 2010||No|Difficult enrollment, no subjects identified to enroll|No||https://clinicaltrials.gov/show/NCT01912924||61947|
NCT01913223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.709|Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial|Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial.|NESTIS|Hospices Civils de Lyon|No|Completed|June 2012|July 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913223||61924|
NCT01913236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150204|Tailored Implementation Intervention for Managing Depressed Elderly Patients in Primary Care|A Pragmatic Cluster Randomised Trial of a Tailored Intervention for Implementing Recommendations for Managing Depressed Elderly Patients in Primary Care: Protocol|TICD|Sykehuset Innlandet HF|No|Enrolling by invitation|September 2013|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|65 Years|N/A|No|||July 2013|December 17, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913236||61923|
NCT01938391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRUTH|Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal|Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal (TRUTH Study)|TRUTH|Cardiovascular Systems Inc|No|Completed|January 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2015|June 29, 2015|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01938391||59996|
NCT01934868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309-13-HMO-CTIL|Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg|A Comparison of the Long Term Outcomes of Prolotherapy Versus Interlaminar Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg||Hadassah Medical Organization|Yes|Recruiting|November 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|90 Years|No|||March 2015|March 31, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934868||60264|
NCT01938937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANX-a|The Effect of Acute Transcranial Bright Light on Anxiety Symptoms|The Effect of Acute Transcranial Bright Light on Anxiety Symptoms||University of Oulu||Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2014|February 25, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938937||59955|
NCT01938950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12080401|Resistance and Cardiorespiratory Time-matched Exercise in Youth: A Randomized Clinical Trial (RCT:RCT)|Resistance and Cardiorespiratory Time-matched Exercise in Youth: A Randomized Clinical Trial (RCT:RCT)|RCT:RCT|University of Pittsburgh||Recruiting|October 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|168|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938950||59954|
NCT01936740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ek Nr: 1268/2012|Comparison of Two Phacoemulsification-methods: HF EasyTip 2.2mm vs. HF EasyTip 2.8mm|Comparison of Two Phacoemulsification-methods: HF EasyTip 2.2mm vs. HF EasyTip 2.8mm||Medical University of Vienna||Completed|June 2012|June 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|50|||Both|50 Years|90 Years|No|||September 2013|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936740||60121|
NCT01936753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHVN_WHO_PMTCT_MoMent|The Impact of Mentor Mothers on PMTCT Service Outcomes in Nigeria|The Impact of Mentor Mother Programmes on PMTCT Service Uptake and Retention at Primary Healthcare Facilities in Nigeria|MoMent|Institute of Human Virology, Nigeria|No|Active, not recruiting|September 2012|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|492|||Female|15 Years|N/A|No|||September 2015|September 15, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936753||60120|
NCT01935596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09 - Pr. DUPONT/LAIGLE|Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5%|Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5%|ROPI-LEVO|Centre Hospitalier Universitaire, Amiens|No|Recruiting|May 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2013|September 4, 2013|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01935596||60209|
NCT01917149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRAAS-DC|Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy|Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy||Xijing Hospital|Yes|Completed|March 2005|December 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|480|||Both|18 Years|70 Years|No|||May 2014|May 16, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917149||61624|
NCT01917383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-01-2013|A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma||Inotek Pharmaceuticals Corporation|No|Completed|August 2013|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||April 2015|April 11, 2015|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917383||61606|
NCT01917396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu 04|Influence of Preoperative Enema Application on Return of Gastrointestinal Function After Elective Cesarean Section: A Randomized Controlled Study|||Istanbul Bakirkoy Maternity and Children Diseases Hospital|Yes|Approved for marketing|August 2013|October 2014|Anticipated|December 2013|Anticipated|Phase 4|Expanded Access|N/A|||||||Female|18 Years|44 Years|Accepts Healthy Volunteers|||January 2015|February 19, 2015|August 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917396||61605|
NCT01917656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3987|Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes|Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes|LIRA-Ramadan™|Novo Nordisk A/S|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|July 29, 2013|Yes|Yes||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01917656||61585|
NCT01915511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046131|Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry|Prospective Outcomes Registry of Subjects With Idiopathic Pulmonary Fibrosis|IPF-PRO|Duke University|No|Recruiting|April 2014|June 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Whole blood for DNA collected at enrollment. Plasma and serum samples collected at      enrollment and approximate 6-month intervals throughout study follow-up.|Both|40 Years|N/A|No|Non-Probability Sample|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry        are eligible for participation in the IPF-PRO registry if the participant meets the        selection criteria.|September 2015|September 8, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915511|5 Years|61749|
NCT01915524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9202-006|Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)|An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor||CureVac AG|Yes|Active, not recruiting|April 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01915524||61748|
NCT01916408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enzy-MaGIC2013/1|The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon|The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers and Coagulation After Marathon Running|Enzy-MagIC|Technische Universität München|Yes|Completed|August 2013|August 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|May 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01916408||61680|
NCT01916642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1|A Dose-response Study of Lidocaine and Etomidate|Can Intravenous Lidocaine Decrease the Minimal Inducing Dose of Etomidate?: A Randomized Placebo-controlled Dose-response Study.||West China Hospital|No|Completed|April 2013|July 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|5||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01916642||61663|
NCT01916655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-069|Improving the Frequency and Quality of Sleep Apnea Care Management|Improving the Frequency and Quality of Sleep Apnea Care Management||VA Office of Research and Development|No|Recruiting|August 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|85 Years|No|||November 2015|November 5, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01916655||61662|
NCT01916382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SONIA 2|Suitability of Nitisinone in Alkaptonuria 2|An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.|SONIA 2|University of Liverpool|Yes|Active, not recruiting|April 2014|April 2018|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|25 Years|N/A|No|||August 2013|January 12, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916382||61682|
NCT01916629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-DRUG-PHOTOCIL-PS-001|Photocil (Topical) for the Treatment of Psoriasis Vulgaris|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Psoriasis Vulgaris||Applied Biology, Inc.|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|August 1, 2013||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01916629||61664|
NCT01912937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-1363|Pharmacokinetic Study of Drug-coated Angioplasty Balloons in the Superficial Femoral or Popliteal Arteries:|ProspectIve, SingLe-Arm, MuLti-Center, Pharmacokinetic Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon|PK|Spectranetics Corporation|Yes|Active, not recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01912937||61946|
NCT01912950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-PW01|Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair|Randomized, Controlled, Open-Label Pilot Study of a Novel IPL for Removal of Unwanted Fine Hair||Cutera Inc.|No|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|July 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01912950||61945|
NCT01913249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/581(REK)|Effect of Short Term Versus Long Term Treatment With Seton Prior to LIFT Surgery for Complex Anal Fistula|Effect of Short Term Versus Long Term Treatment With Seton Prior to LIFT Surgery for Complex Anal Fistula, a Randomized Controlled Trial.||Sykehuset Innlandet HF|No|Recruiting|September 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||September 2013|September 6, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01913249||61922|
NCT01913262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFH-DR-13|IFH Depression Registry 2013|||The Institute for Family Health||Active, not recruiting|March 2013|||March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Community health patients in behavioral health treatment|July 2013|July 31, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01913262|4 Months|61921|
NCT01938690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-758-12|Effect of Transcranial Magnetic Stimulation on Recovery of Upper Limb Among Stroke Survivors|Effect of Transcranial Magnetic Stimulation on Motor Recovery of Upper Limb Among Stroke Survivors: Pilot Study||Kessler Foundation|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938690||59973|
NCT01938716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0703|Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy|Tissue Pharmacokinetics of Intraoperative Gemcitabine in Adenocarcinoma of the Pancreas After Preoperative Chemoradiation Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2012|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938716||59972|
NCT01938963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100298-01|Chinese Older Adults-Collaboration in Health (COACH)Study|The Depression/Hypertension in Chinese Older Adults-Collaboration in Health|COACH|University of Rochester|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2400|||Both|60 Years|N/A|No|||January 2016|January 7, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938963||59953|
NCT01935856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-003|Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis|A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis||Kyowa Hakko Kirin Company, Limited|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|74 Years|No|||May 2014|May 16, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01935856||60189|
NCT01935869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-66|Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100|Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100||LEO Pharma|No|Completed|August 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|3||Actual|224|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935869||60188|
NCT01935102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CESM3077/2010|Polymorphism Interaction to Predict Bevacizumab Efficacy|Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis|BEVAGENE|University of Pisa|Yes|Completed|December 2012|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|169|Samples With DNA|whole blood|Female|18 Years|90 Years|No|Non-Probability Sample|metastatic breast cancer patients from eight Italian divisions of Medical Oncology|December 2014|December 1, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01935102||60247|
NCT01936142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-0167-YMICH|The Use of Renal Guard System in Patients Undergoing CRT Implantation|The Effect of Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During CRT Implantation||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01936142||60167|
NCT01935882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOPRIM-1|Low Dose Primaquine for Clearance of Gametocytes|A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso|LOPRIM|London School of Hygiene and Tropical Medicine|Yes|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|2 Years|15 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01935882||60187|
NCT01936155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-NMES-OED-336|Does NMES Help Relieve Lower Limb Oedema and Improve Joint Mobility and Skin Tissue Oxygenation Levels?|Does Neuromuscular Electrical Stimulation (NMES) Help Relieve Lower Limb Oedema and Improve Joint Mobility and Skin Tissue Oxygenation Levels?||National University of Ireland, Galway, Ireland|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936155||60166|
NCT01914952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2013-CS02|Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses|Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses||Metabolic Technologies Inc.|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|11|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01914952||61792|
NCT01915173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000409|Response to Supplement and Placebo in GERD|Response to Supplement and Placebo in GERD||Beth Israel Deaconess Medical Center|Yes|Completed|June 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|80 Years|No|||May 2014|May 28, 2014|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01915173||61775|
NCT01915498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-221-C-001|Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation|Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation||Celgene Corporation|No|Recruiting|August 2013|September 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|375|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915498||61750|
NCT01915771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-026|Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects|A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral CapsuleDose of 20 mg Lomitapide in Healthy Subjects||Aegerion Pharmaceuticals, Inc.|No|Completed|August 2013|December 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01915771||61729|
NCT01915199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVEL|Effects of a Comprehensive Intervention on Blood Pressure Control in a Primary Care Setting|Effects of a Comprehensive Intervention on Blood Pressure Control in a Primary Care Setting||National Institute for Health and Welfare, Finland|No|Completed|October 2000|||December 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|35 Years|74 Years|No|||January 2014|January 15, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01915199||61773|
NCT01916070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPEED01|Syncope Patient Evaluation in the Emergency Department|Syncope Patient Evaluation in the Emergency Department (SPEED)||Klinikum Nürnberg|No|Completed|July 2011|May 2012|Actual|November 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|397|||Both|18 Years|N/A|No|Probability Sample|patients presenting with (near) syncope to the emergency department|August 2013|August 2, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01916070|6 Months|61706|
NCT01916083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF165696|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2016|||||N/A|N/A|N/A||||||||||||||February 22, 2016|August 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916083||61705|
NCT01916681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817897|Foley OR MisO for the Management of Induction|Foley OR MisO for the Management of Induction (FOR MOMI) Trial|FORMOMI|University of Pennsylvania|Yes|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|493|||Female|18 Years|N/A|No|||June 2015|June 18, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01916681||61660|
NCT01916668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12/10/264|A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape|A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape, South Africa||University of Stellenbosch|No|Completed|April 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic haemodialysis patients|May 2014|May 6, 2014|February 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01916668||61661|
NCT01916928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedStarWHC-OB|The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage|The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage||Medstar Research Institute|No|Completed|May 2013|December 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Blood collection will consist of two ten milliliters samples of whole blood in the cffDNA      STRECK tube. Plasma will be retained for analysis of circulating cell free fetal DNA.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women presenting to Washington Hospital Center with fetal loss would be offered DNA        sequencing of cell free fetal DNA from maternal blood in addition to the standard workup        for fetal demise and miscarriage as deemed appropriate by the patient's care provider.        Only women with sonographic evidence of products of conception in-utero will be offered        enrollment.|January 2015|January 29, 2015|August 2, 2013||No||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01916928||61641|
NCT01912716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP INDO 2013|Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis|Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients: Searching for the Optimal Dose. A Prospective, Randomized Trial||Indiana University|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1036|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912716||61963|
NCT01908933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C13-001PLV|Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema|Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema||Aeris Therapeutics|Yes|Withdrawn|September 2013|November 2013|Actual|November 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|N/A|No|||November 2013|November 13, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01908933||62251|
NCT01909154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-LEM1|Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia|Phase I Pilot Study to Evaluate the Security of Local Administration of Autologous Stem Cells Obtained From the Bone Marrow Stroma, in Traumatic Injuries of the Spinal Cord|CME-LEM1|Puerta de Hierro University Hospital|No|Completed|March 2013|March 2015|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||November 2013|June 17, 2015|July 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01909154||62234|
NCT01908894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-101|Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration|A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration||Biodel||Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|70 Years|No|||July 2013|July 24, 2013|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908894||62254|
NCT01909115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00067067|Randomized Study of Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease|Randomized Study of Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease||Emory University|Yes|Active, not recruiting|September 2013|||November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Years|19 Years|No|||December 2015|December 31, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909115||62237|
NCT01909674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108011845|Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure (CPAP)|Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure (CPAP): A Randomized Cross-over Study||Weill Medical College of Cornell University|No|Active, not recruiting|August 2011|August 2013|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909674||62195|
NCT01909687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1313-SF|Assessment of Blood Glucose Monitoring Systems|Leistungsbewertung Von Blutzuckermesssystemen im Methodenvergleich||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|N/A|||Actual|163|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|June 26, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01909687||62194|
NCT01911039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT253|Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD|A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease||Stanford University|No|Recruiting|July 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911039||62091|
NCT01910701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHS12-014900|Extension Study of the Family Spirit Program|Extension Study of the Family Spirit Program||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Female|12 Years|20 Years|Accepts Healthy Volunteers|||July 2013|January 20, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910701||62117|
NCT01911026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05-049-001|The Impact of Nurse Education on the Quality of Inpatient Bowel Preparation for Colonoscopy|The Impact of Nurse Education on the Quality of Inpatient Bowel Preparation for Colonoscopy; Randomized Single Blinded Study||Keimyung University Dongsan Medical Center|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|205|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911026||62092|
NCT01911260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APoblacionZinc|Weekly Zinc Chelate Supplementation on Children's Growth|Effect of Weekly Zinc Chelate Supplementation on Schoolchildren's Growth: a Randomized Double-blind Controlled Trial|APZinc|Federal University of São Paulo|No|Completed|September 2000|March 2001|Actual|December 2000|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|199|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|June 27, 2013|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01911260||62074|The sample loss is a factor that hinders the adoption of results as definitive. Even if they remained similar according to biodemographic variables, we cannot guarantee the maintenance of group equality defined in randomization.
NCT01911533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/505|Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis|Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis.||University Hospital, Ghent|No|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911533||62053|
NCT01912157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2013-0009_GUGKS|Couples Coping With Multiple Chronic Medical Conditions|Couples Coping With Multimorbidity: Does Solitary Expressive Writing Foster Psycho-social Adaptation?|GUGKS|University of Zurich|No|Recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01912157||62006|
NCT01911390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 06/18/2013|Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children|Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children Involved in the Healthy Hearts Program||Poudre Valley Health System|No|Active, not recruiting|July 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01911390||62064|
NCT01911403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV08025POVC|AGIR Study: Angio-Seal in Interventional Radiology|Efficacy Superiority of Angio-Seal™ vs. Manual Compression in Interventional Radiology|AGIR|St. Jude Medical|No|Terminated|December 2010|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|April 14, 2011||No|Low enrollment rate.|No|February 26, 2015|https://clinicaltrials.gov/show/NCT01911403||62063|This study has been early terminated on 15 May 2014 due to low enrollment rate and the publication of other larger studies about closure device versus manual compression.This lead to small number of subjects analyzed.
NCT01911988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHGC 001|Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer|Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer|PICC-1|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|June 2013|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|18 Years|90 Years|No|Probability Sample|Stage II /Stage III Colorectal Patients|October 2014|October 20, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911988||62018|
NCT01912313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55484|Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)|Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)||Katholieke Universiteit Leuven|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|99999999|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912313||61994|
NCT01912339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2105-001|Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)|Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)|REZUM|NxThera Inc|Yes|Active, not recruiting|July 2013|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|197|||Male|50 Years|N/A|No|||September 2015|September 10, 2015|July 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912339||61992|
NCT01911481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI|Maternal Oral Hydration and External Cephalic Version|Maternal Oral Hydration and External Cephalic Version: a Single Blind Randomised Controlled Trial||University of Milano Bicocca|Yes|Completed|October 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|164|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911481||62057|
NCT01908101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8093|Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer|Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)||University of Washington|No|Recruiting|January 2014|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|July 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908101||62314|
NCT01908426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-309|Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib|A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib|CELESTIAL|Exelixis|Yes|Recruiting|August 2013|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|760|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908426||62289|
NCT01908959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR010356-01A2|Madres Para la Salud (Mothers for Health)|Madres Para la Salud (Mothers for Health)||Arizona State University|No|Completed|February 2010|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|177|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908959||62249|
NCT01908907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHA Gap|Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants|Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants||Sanford Health|Yes|Completed|October 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|24 Weeks|33 Weeks|Accepts Healthy Volunteers|||March 2014|March 31, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01908907||62253|
NCT01909401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301010500|Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation|Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation||Indiana University|Yes|Completed|June 2013|July 2014|Actual|July 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909401||62216|
NCT01909700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011041|Single Incision Pelvic Floor Mesh Implants|Single Incision Pelvic Floor Mesh Implants||Western Galilee Hospital-Nahariya|Yes|Completed|July 2011|February 2012|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Female|30 Years|90 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909700||62193|
NCT01909999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJP2012|Release of Osteogenic Markers in Immediately and Non-loaded Dental Implants|Release of Osteogenic Markers in Immediately and Non-loaded Dental Implants||Paulista University|No|Completed|March 2010|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01909999||62170|
NCT01910012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2012-001|PH 2 ADI-PEG 20 Acute Myeloid Leukemia|Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia||Polaris Group|No|Active, not recruiting|June 2012|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910012||62169|
NCT01911286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APNEE REA|Comparison of Two Strategies to Realize Apnea Test for the Diagnostic of Brain in Potentiel Organ Donors.||APNEE REA|Poitiers University Hospital||Recruiting|July 2013|||July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|208|||Both|18 Years|75 Years|No|Probability Sample|Potentiel organs donors in brain death.|July 2013|July 26, 2013|July 26, 2013||||No||https://clinicaltrials.gov/show/NCT01911286|1 Day|62072|
NCT01911273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8471005|A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer|A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib||Pfizer|Yes|Terminated|October 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|July 26, 2013|Yes|Yes|See termination reason in detailed description.|No|June 9, 2015|https://clinicaltrials.gov/show/NCT01911273||62073|This study was prematurely terminated due to a Sponsor decision not to pursue the clinical development of PF-03446962 as monotherapy in second-line hepatocellular carcinoma.
NCT01911559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|standing_2013|Effectiveness of Standing Frame on Constipation in Children With Cerebral Palsy|Effectiveness of Standing Frame on Constipation in Children With Cerebral Palsy: a Single Subject Study|CP|University of Modena and Reggio Emilia|No|Completed|January 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|3 Years|17 Years|No|Non-Probability Sample|In this study we included children with CP, in the manifestation of severe diplegia or        quadriplegia, who do not currently use the standing-frame. The population of interest        might be referred to the Unit for severe disability in developmental age or to one of the        neuro-psychiatric and rehabilitation Units of the area of Modena and Reggio Emilia, (5.000        km2 of surface and 1.250.000 inhabitants)|May 2015|May 26, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01911559||62051|
NCT01911572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENIGASUK|Genetic Susceptibility to Severe Streptococcal Infections|Genetic Susceptibility to Invasive Streptococcal Disease||University of Oxford|No|Recruiting|December 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Family-Based||2|Anticipated|200|Samples With DNA|Primarily we will collect saliva from which DNA will be isolated. Secondly, from a subset of      individuals, we will request follow-up blood samples from which we will extract RNA and      separate leukocytes for studies of function.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be identified through an invitation sent to the Lee Spark Necrotising        Fasciitis Foundation and by infection specialists at NHS hospitals who will invite        patients whose care they have been directly involved in. In addition, a small collection        of existing samples held at Imperial College London will be used.|June 2015|June 18, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01911572||62050|
NCT01911871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10071|Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations|Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations|SUFEMYO|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2012|March 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|110|||Both|6 Years|N/A|No|Non-Probability Sample|patients affected with thalassemia, SCD, and myelodysplasia|April 2015|April 9, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911871||62027|
NCT01912144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 10-035|Absorption of Phenolic Acids From Coffee in Humans|Bioavailability of Coffee Phenolic Acids and Cardiovascular Health in Healthy Humans.||University of Leeds|No|Active, not recruiting|September 2012|||October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01912144||62007|
NCT01912456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL830_3001|A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema|A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema||CSL Behring||Completed|January 2014|||October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|80|||Both|12 Years|N/A|No|||November 2015|November 12, 2015|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912456||61983|
NCT01912469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEIR-2|Effects of Traumeel®S Tablets on Exercise Induced Muscle Damage and Muscle Soreness|||University of Giessen|No|Completed|April 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912469||61982|
NCT01911156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stop Study|Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues|Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues|Stop|University Health Network, Toronto|Yes|Recruiting|July 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01911156||62082|
NCT01910935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-785-038|Effectiveness of Physical Activity Prescription Among Hypertensive Patients of Primary Health Care.|Effectiveness of Physical Activity Prescription Among Hypertensive Patients of Primary Health Care.||Coordinación de Investigación en Salud, Mexico|No|Completed|July 2013|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|224|||Both|35 Years|70 Years|No|||February 2014|June 4, 2014|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01910935||62099|
NCT01911169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00009197|Vitamin D to Improve Endothelial Function in SLE|Vitamin D Repletion to Improve Endothelial Function in Lupus Patients||Medical University of South Carolina|Yes|Completed|June 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|80 Years|No|||May 2015|May 17, 2015|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911169||62081|
NCT01912352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0002283|Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder|Gene-environment Interactions and Brain Functional Connectivity Associated With Norepinephrine System Genes in Attention Deficit Hyperactivity Disorder||Seoul National University|Yes|Completed|May 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|83|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|July 16, 2013||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01912352||61991|
NCT01912365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01520|Splinting Versus Casting for Type I Supracondylar Fractures|Splinting Versus Above Elbow Casting for Type I Supracondylar Fractures of the Humerus in Children: A Randomized Controlled Trial||University of British Columbia|No|Recruiting|August 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|3 Years|12 Years|No|Non-Probability Sample|Eligible participants will be recruited from the Emergency Department at BC Children's        Hospital|November 2015|November 30, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912365||61990|
NCT01911767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS402|Biogen Multiple Sclerosis Pregnancy Exposure Registry|Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry||Biogen|Yes|Recruiting|October 2013|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|Within each product cohort, approximately 310 to 375 pregnant women exposed to a        Registry-specified Biogen MS product will be enrolled in order to observe 300 prospective        pregnancy outcomes. The infants born to these women will also be part of the population        studied. Patients with prenatal testing prior to enrollment (with the exception of a first        trimester ultrasound to date the pregnancy) will not be counted towards the 300        prospective pregnancy outcomes.|November 2015|November 12, 2015|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911767|52 Weeks|62035|
NCT01912001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5397-AE|Virtual Ward for Home Dialysis|Virtual Ward for Home Dialysis - A Novel Model to Address Transitions of Care|Virtual Ward|University Health Network, Toronto|No|Recruiting|September 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01912001||62017|
NCT01912014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2007.37 (REK)|Psychosocial Wellbeing Following Stroke|Psychosocial Wellbeing Following Stroke: Developing and Testing a Psychosocial Nursing Intervention for Primary Care||University of Oslo|Yes|Completed|January 2007|December 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|25|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01912014||62016|
NCT01911494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03497|Community Level Interventions for Pre-eclampsia|The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial|CLIP|University of British Columbia|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|87500|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911494||62056|
NCT01909427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100935|An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Janssen Research & Development, LLC|Yes|Completed|June 2013|May 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|257|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909427||62214|
NCT01909726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BloorviewKR|The Art of Waiting: Evaluation of an Interactive Media Experience in a Children's Hospital Clinic Waiting Space|The Art of Waiting: Evaluation of an Interactive Media Experience in a Children's Hospital Clinic Waiting Space||Holland Bloorview Kids Rehabilitation Hospital|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|310|||Both|5 Years|19 Years|No|Probability Sample|Participants include clients, their parents/guardians, and staff associated with the        outpatient clinic at Holland Bloorview Kids Rehabilitation Hospital.|July 2014|July 30, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01909726||62191|
NCT01909739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0334|The Effects of Statin on Postoperative Renal Function in Valvular Heart Surgery: a Randomized, Placebo-controlled Study|||Yonsei University|No|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|N/A|No|||February 2014|February 4, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909739||62190|
NCT01910675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-2012-003128|PCC and Fibrinogen Compared With FFP in PPH|Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage||Helsinki University Central Hospital|No|Recruiting|July 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|No|||January 2014|January 2, 2014|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01910675||62119|
NCT01911507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#238|INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer|Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer||University of California, Davis|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911507||62055|
NCT01912105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180-20130326|Evaluation of a Closed Suction System to Remove Secretions From the Endotracheal Tube|Evaluation of a Closed Suction System to Remove Secretions From the Endotracheal Tube: a Randomized Trial||Azienda Ospedaliera San Gerardo di Monza|No|Completed|April 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01912105||62010|
NCT01911065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-19385|T Cell Responses to Varicella Zoster Virus (VZV)|T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape||Stanford University|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01911065||62089|
NCT01911078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-12-079-EU-RD|Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)|Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)||St. Jude Medical|Yes|Active, not recruiting|September 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01911078||62088|
NCT01911585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817717|Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure|Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure||University of Pennsylvania|No|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911585||62049|
NCT01911598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28909|A Study of MEHD7945A in Combination With Cisplatin and 5-FU or Paclitaxel and Carboplatin on Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck||Genentech, Inc.||Active, not recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911598||62048|
NCT01911884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110124|Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky Syndrome|Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky Syndrome|MRKH|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|October 2015|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|138|||Female|18 Years|N/A|No|||June 2015|July 2, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911884||62026|
NCT01911611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28628|A Study of RO6870868 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868||Hoffmann-La Roche||Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911611||62047|
NCT01912170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUOLI_GD|Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients|||Zhejiang University||Not yet recruiting|August 2013|||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Female|18 Years|40 Years|No|||July 2013|July 27, 2013|July 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01912170||62005|
NCT01912183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEH - 126534|Family-centred E-health in Pediatric Weight Management: A Pilot Study|Family-centred E-health in Pediatric Weight Management: A Pilot Study||McMaster University|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|17 Years|No|||April 2015|April 6, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912183||62004|
NCT01912196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-CP.002|Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)|A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy||MSI Methylation Sciences, Inc.|Yes|Completed|October 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|376|||Both|21 Years|70 Years|No|||March 2016|March 17, 2016|July 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912196||62003|
NCT01911780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348.2|Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg||Boehringer Ingelheim||Completed|July 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|132|||Both|20 Years|N/A|No|||February 2015|February 4, 2015|July 26, 2013||||No||https://clinicaltrials.gov/show/NCT01911780||62034|
NCT01912027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JST1307A2|Open Latarjet Techniques Versus Arthroscopic Latarjet Techniques on Anterior Shoulder Instability: The Comparison of Clinical and Radiographic Outcomes|||Beijing Jishuitan Hospital||Recruiting|January 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||October 2013|October 9, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01912027||62015|
NCT01912040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123Iodine MIBG|Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use|A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use||Nova Scotia Health Authority|No|Recruiting|July 2006|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|1 Month|N/A|No|Non-Probability Sample|Those patients referred for MIBG assessment.|July 2013|July 29, 2013|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01912040||62014|
NCT01908699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-314d-MR-PAH-302|Beraprost-314d Added-on to Tyvaso® (BEAT)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension|BEAT|Lung Biotechnology PBC|Yes|Recruiting|May 2013|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908699||62269|
NCT01908946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-2013-IER-RPC-TSA-008|Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Children in Pakistan|Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Among Children in Pakistan||Aga Khan University|No|Recruiting|May 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|N/A|14 Days|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01908946||62250|
NCT01908114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2432-PED-ERC-12|To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan|To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan||Aga Khan University|Yes|Recruiting|July 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60000|||Both|1 Month|5 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01908114||62313|
NCT01908452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMRK0911|Pyridoxal Kinase Activity in Tardive Dyskinesia|Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6||Beersheva Mental Health Center||Withdrawn|July 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|65 Years|No|||July 2011|July 23, 2013|July 25, 2012||No|Not funded|No||https://clinicaltrials.gov/show/NCT01908452||62287|
NCT01908465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55485|Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial|Peripheral Histamine 1 Receptor Blockade in IBS||Katholieke Universiteit Leuven|Yes|Recruiting|November 2013|March 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908465||62286|
NCT01912092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-O-H-1205|Askina Calgitrol Paste Diabetic Foot Ulcers|A NON-CONTROLLED PROSPECTIVE COHORT STUDY OF THE USE OF ASKINA® CALGITROL® PASTE + STANDARD OF CARE ON MILDLY INFECTED, NON-ISCHAEMIC DIABETIC FOOT ULCERS||BBraun Medical SAS||Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01912092||62011|
NCT01908673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 103966|Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Longitudinal Pilot Feasibility Study|Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Randomized Controlled Longitudinal Pilot Feasibility Study||Lawson Health Research Institute|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|66 Years|80 Years|No|||February 2014|February 25, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01908673||62271|
NCT01908686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106008625|Pivotal Response Treatment for Children With Autism Spectrum Disorders||PRT|Yale University|Yes|Recruiting|May 2012|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|35 Years|No|||January 2016|January 6, 2016|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01908686||62270|
NCT01910064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDT.07.SPR.27125|A Long Term Study of GK530G in Subjects With Acne Vulgaris|A Long Term Study of GK530G in Subjects With Acne Vulgaris||Galderma R&D|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|436|||Both|12 Years|N/A|No|||September 2014|September 4, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910064||62165|
NCT01910077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tacrobell_BE-1301|Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Tacrobell Capsule 1mg Versus Prograf Capsule 1mg in Healthy Subjects||Chong Kun Dang Pharmaceutical|No|Completed|August 2013|November 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01910077||62164|
NCT01910415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-809-008|Phase 1, QT/QTC Interval Study in Healthy Subjects|A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|August 8, 2014|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910415||62139|
NCT01910428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPALL 2012-09|L-asparaginase Encapsulated in Red Blood Cells for Frontline Therapy of Patients With Phi-neg ALL Older Than 18 yo|Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination With the CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia||ERYtech Pharma|Yes|Recruiting|October 2013|September 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910428||62138|
NCT01911234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF-K-006|Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs' TNF-Kinoid in Adult Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Neovacs|Yes|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|75 Years|No|||January 2015|January 13, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911234||62076|
NCT01908504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033339|Adaptive Pet Study|F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Delivery of Adaptive Radiation Therapy||Duke University|No|Enrolling by invitation|January 2012|January 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|320|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908504||62283|
NCT01911650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0908|A Pilot Study: Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy|A Pilot Study Correlating Novel Ultrasound Elastography Techniques to Standard Clinical Outcomes in the Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy||University of Wisconsin, Madison|No|Recruiting|June 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911650||62044|
NCT01911299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-choline-1|Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders|Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders||San Diego State University|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|5 Years|10 Years|No|||July 2014|July 30, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911299||62071|
NCT01911624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54881|Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia|Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study.||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2013|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|90 Years|No|||July 2013|July 25, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01911624||62046|
NCT01911637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBY-036-001|Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)|A Double-Blind, Randomized, Placebo-Controlled, Sequential, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects||Virobay Inc.|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911637||62045|
NCT01911897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD0120|Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)|CALM-FIM_EUR - Controlling and Lowering Blood Pressure With the MobiusHD - A Prospective Multicenter Safety Study|CALM-FIM_EUR|Vascular Dynamics, Inc.|Yes|Recruiting|June 2013|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|July 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911897||62025|
NCT01912508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-12-0152CTIL|Preterm Labor Prediction by Cervical Contour in Ultrasound|||Meir Medical Center||Recruiting|August 2013|||August 2014|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|200|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women 14-34w|August 2014|August 12, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912508||61979|
NCT01908322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16628|Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety|SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma|SORINT|Bayer|No|Completed|August 2013|September 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with intermediate stage hepatocellular        carcinoma (BCLC-B) treated with Nexavar according to the local summary of product        characteristics. Participants will be recruited from oncological and gastroenterological        clinics and practices throughout Germany.        In this non-interventional observational study, the decision on the duration and dosage of        treatment is solely at the discretion of the attending physician.        The medication is prescribed at regular visits to the investigator's office. Commercially        available product will be used to treat the patients.|November 2015|November 10, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908322||62297|
NCT01908335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAWIN-002-1|A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C|Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C||Beijing Kawin Technology Share-Holding Co., Ltd.|No|Completed|October 2012|July 2014|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|212|||Both|18 Years|65 Years|No|||October 2014|October 16, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908335||62296|
NCT01911247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1102|Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer|Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer||UNC Lineberger Comprehensive Cancer Center|No|Completed|May 2011|February 2013|Actual|February 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|75 Years|No|||July 2013|July 25, 2013|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911247||62075|
NCT01912066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9601_PG_IV|A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601|A Phase IV Clinical Trial to Evaluate the Preventive Effectiveness of NSAID-Associated Gastroduodenal Injury (Multi-center, Double-blind, Active-controlled, Stratified Randomized, Parallel Group)||Dong-A ST Co., Ltd.|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|520|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01912066||62012|
NCT01909414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1082|Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications|A Phase 1 Study of the Safety and Immunogenicity of DNA/MVA Immunizations With Co-Expressed GM-CSF in HIV-1 Infected Young Adults With Suppressed Viremia on HAART||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|24 Years|No|||August 2013|August 19, 2013|July 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01909414||62215|
NCT01910025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2012-002|PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy|Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy||Polaris Group|No|Active, not recruiting|July 2012|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|20 Years|N/A|No|||March 2016|March 1, 2016|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910025||62168|
NCT01909713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.04.US10245|Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.|Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.||Galderma Laboratories, L.P.|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|7 Years|11 Years|No|||December 2013|February 5, 2014|July 1, 2013||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01909713||62192|
NCT01910376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1221|Cancer in Nursing Home Residents|Cancer in Elderly Nursing Home Residents in Belgium: Prospective Cohort Study Including Translational Research to Develop Better Prognostic Tools to Help With Treatment Decisions in the Elderly||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|November 2014|||March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|825|Samples With DNA|Blood samples|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents (≥ 65 years) in a nursing home in the Armonea network in Belgium.|November 2015|November 6, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01910376|2 Years|62142|
NCT01910649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114673|A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration|A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for Intravenous Dosing as an Alternative Route of Administration||BioMarin Pharmaceutical|Yes|Active, not recruiting|March 2008|December 2016|Anticipated|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|5 Years|16 Years|No|||September 2014|October 13, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01910649||62121|
NCT01910662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117249|Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)|Characterisation of the T-cell Response in Delayed Type Hypersensitivity Reactions to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) in Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01910662||62120|
NCT01908491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pectus-pain study|Comparison of IV PCA and Wound Infusion After Repair of Pectus Excavatum|Comparison of the Effects of Opioid-Based Intravenous Patient Controlled Analgesia and Continuous Ropivacaine Infusion Through Wound Catheters After Repair of Pectus Excavatum||The Catholic University of Korea|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|N/A|N/A|No|||November 2013|November 13, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908491||62284|
NCT01908166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0099|Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions|US Elastography for Characterizing Focal Lesions in the Liver and Kidney||Stanford University||Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|19 Years|N/A|No|||November 2015|November 12, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908166||62309|
NCT01908179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRS - Mets|Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)|||Swedish Medical Center|No|Recruiting|January 2013|||July 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|80 Years|No|Probability Sample|Patients with metastatic brain tumors undergoing, or have undergone, sterotactic        radiosurgery (SRS)|July 2013|July 24, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908179|12 Months|62308|
NCT01919346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0920|Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation|Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation||Heeger, Peter, M.D.|Yes|Recruiting|August 2013|December 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919346||61455|
NCT01919359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-SUP-12|A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures|A Double-blinded, Randomized Placebo Controlled Study to Assess the Efficacy of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures||DeNova Research|No|Recruiting|July 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 7, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919359||61454|
NCT01910987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018796|Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib|A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.|OPTIMRETREAT|Janssen-Cilag International NV|Yes|Completed|April 2013|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910987||62095|
NCT01911221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_59|A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.|A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.||Novartis|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|July 26, 2013||No||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01911221||62077|
NCT01911832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WqLE-201324|Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers|Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers||West China Hospital|Yes|Recruiting|March 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 15, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911832||62030|
NCT01920178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0860/08/11|Evaluation Study for the Efficacy and Safety of PinPointe FootLaser in Treatment for Onychomycosis|A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis||Cambridge Health Alliance|No|Recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||August 2013|August 13, 2013|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920178||61391|
NCT01911923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2008 / 251|Ventilation Strategy Reduces Postoperative Atelectasis|Reduction in Postoperative Atelectasis by Continuous Positive Airway Pressure and Low Oxygen Concentration After Endotracheal Extubation.||Landstinget Västmanland|Yes|Withdrawn|August 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|75 Years|No|||August 2014|August 25, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911923||62023|
NCT01911910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReDa: 007711|Heart Attack Prevention Programme for You (HAPPY) London|Heart Attack Prevention Programme for You (HAPPY) London|HAPPYLondon|Queen Mary University of London|No|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|40 Years|74 Years|No|||October 2014|October 23, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911910||62024|
NCT01912209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-028|A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome|Baptist Employee Healthy Heart Study (BEHHS) - A Novel Web-based Approach to Reduce Cardiovascular Disease Risk in a Diverse Employee Population With Metabolic Syndrome Via Diet and Lifestyle Change|BEHHS|Baptist Health South Florida|No|Completed|August 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01912209||62002|
NCT01912521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIHNIS|Mfangano Island Healthy Networks Impact Study|Mfangano Island Healthy Networks Impact Study|MIHNIS|University of California, San Francisco|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|883|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01912521||61978|
NCT01911000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-013-003|Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis|Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial||Samsung Medical Center||Recruiting|September 2013|August 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|20 Years|N/A|No|||August 2014|August 25, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01911000||62094|
NCT01911013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSS-001|A Study of Korean Society of Spine Surgery on the Outcomes of Anterior Cervical Discectomy and Fusion|A Study of Korean Society of Spine Surgery on the Outcomes of Anterior Cervical Discectomy and Fusion||Seoul National University Hospital|No|Recruiting|September 2013|September 2019|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|19 Years|N/A|No|||August 2015|August 12, 2015|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01911013||62093|
NCT01911793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stoma Tube Study|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery||Cedars-Sinai Medical Center|No|Terminated|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||July 2014|August 6, 2015|July 26, 2013||No|Not enough staff resource to complete study.|No||https://clinicaltrials.gov/show/NCT01911793||62033|
NCT01912053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-EB-CHOL-Th|Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma|An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line.|MispheC|Center Eugene Marquis|Yes|Recruiting|September 2013|April 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01912053||62013|
NCT01908478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-ABT888-0002|A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer|A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer|VelGemRad|Cedars-Sinai Medical Center|No|Recruiting|July 2013|July 2019|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|July 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908478||62285|
NCT01910038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonnotte PHRC N 2012|Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study.||HORTOCI|Centre Hospitalier Universitaire Dijon||Recruiting|November 2013|||May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||September 2013|December 3, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910038||62167|
NCT01910051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBDM-01|Explorative Assessment of Biomarkers in Overweight and Obese Subjects|Explorative Assessment of Biomarkers Indicative of Insulin Resistance and Prediabetes in Overweight and Obese Subjects||Profil Institut für Stoffwechselforschung GmbH|No|Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples Without DNA|Blood samples|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Generally healthy or Type 2 Diabetes mellitus|February 2016|February 23, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01910051||62166|
NCT01910389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL105463|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|PITCH-HF|New England Research Institutes|Yes|Terminated|November 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|N/A|No|||January 2014|April 16, 2015|July 25, 2013||No|terminated by funding agency|No|April 16, 2015|https://clinicaltrials.gov/show/NCT01910389||62141|Early termination leading to small numbers of subjects. Outcome measure data not obtained.
NCT01910402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117172|A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)|A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women||ViiV Healthcare|No|Active, not recruiting|August 2013|April 2018|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|499|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01910402||62140|
NCT01911208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMHD006941|A Randomized Recruitment Intervention Trial|A Randomized Recruitment Intervention Trial|RECRUIT|The University of Texas Health Science Center, Houston|No|Active, not recruiting|November 2011|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|January 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01911208||62078|
NCT01918761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/ NSCLC.1.1.001|Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)|Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC): a Phase I Trial to Identify a Dose of Dacomitinib in Combination With Pemetrexed That is Safe and Tolerated as Determined by the Incidence of DLT||Central European Cooperative Oncology Group|No|Recruiting|August 2013|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01918761||61500|
NCT01918774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0943-W|Pilot Study of Cognitive Behavior Therapy Focused on Competitive Employment|Cognitive Behavioral Therapy to Enhance Competitive Work Outcomes||VA Office of Research and Development|No|Active, not recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918774||61499|
NCT01908712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-07|Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients|A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials|rhLAMAN-07|Zymenex A/S|No|Active, not recruiting|August 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||July 2013|June 10, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01908712||62268|
NCT01919645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHK2013|Effectiveness and Safety of Physical Exercises in the Improvement of the Sleep Efficiency Regarding Rheumatoid Arthritis|Effectiveness and Safety of Physical Exercises in the Improvement of the Sleep Efficiency in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial Study|SRA|Federal University of São Paulo|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Female|35 Years|65 Years|No|||March 2015|March 18, 2015|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01919645||61432|
NCT01919658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 42734|Effects of Femoral vs Saphenous Nerve Blocks on Function After ACL Repair|Effects of Femoral Versus Saphenous Nerve Blocks on Knee Extensor Strength, Pain, and Patient-Perceived Physical Function Following ACL Reconstruction||Milton S. Hershey Medical Center|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919658||61431|
NCT01919632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2555/09|MOVING - MOtiVation, INtervention and Vascular chanGe|MOVING - Einfluß Eines Lebensstilprogramms Auf Gefaeßzustand, Metabolisches Risikoprofil Und Leistungsfaehigkeit (MOVING - Influence of a Lifestyle Intervention Program on Vascular Condition, Metabolic Risk Profile and Physical Performance)|MOVING|Technische Universität München|No|Completed|October 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|330|||Both|N/A|N/A|No|||May 2015|May 11, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01919632||61433|
NCT01919931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55012|Immunological Interaction Between the Host and Candida Albicans Biofilm|Immunological and Molecular Interaction Between the Host and Candida Albicans Biofilm||Universitaire Ziekenhuizen Leuven||Recruiting|March 2013|December 2016|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|140|Samples With DNA|Samples to be retained: whole blood, Plasma and White cells.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Candida albicans infection. Patients with no Candida albicans infection.        Healthy volunteers|January 2013|August 6, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01919931||61410|
NCT01920438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10SG14|Outcome Study of Endoscopically Inserted Gastrostomy (PEG)Versus Radiologically-guided Insertion of Gastrostomy (RIG)in Children|PEG Vs RIG: Percutaneous Endoscopic Gastrostomy Versus Radiologically Inserted Gastrostomy in Children|PEG Vs RIG|Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Recruiting|December 2011|August 2017|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||August 2013|August 9, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01920438||61371|
NCT01920737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-266|A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia|A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia||Memorial Sloan Kettering Cancer Center||Recruiting|August 2013|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|60 Years|No|||January 2016|January 13, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920737||61348|
NCT01912560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2003-201|Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)|PATHWAYS I|Catabasis Pharmaceuticals|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|69 Years|No|||February 2015|February 24, 2015|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912560||61975|
NCT01912222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16018|Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction|A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction||Millennium Pharmaceuticals, Inc.|No|Completed|August 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|July 26, 2013|No|Yes||No|February 24, 2016|https://clinicaltrials.gov/show/NCT01912222||62001|
NCT01912235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/02/2010|Arginine Synthesis in Healthy Adult Humans|Arginine Synthesis in Healthy Adult Humans: Does Proline or Glutamate Provide the 5-Carbon Chain?||The Hospital for Sick Children|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912235||62000|
NCT01912534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANISH|Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM|Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM|VANISH|New England Research Institutes|Yes|Recruiting|April 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|8 Years|45 Years|No|||July 2013|October 5, 2015|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01912534||61977|
NCT01912547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000653|Thromboelastography During Surgery for Malignant Pleural Mesothelioma|Thromboelastography During Surgery for Malignant Pleural Mesothelioma||Brigham and Women's Hospital|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients undergoing surgery for malignant pleural mesothelioma|January 2015|January 28, 2015|July 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01912547||61976|
NCT01908348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32353|Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus|Pilot Study: Dose Dependent Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus||Boston University|No|Active, not recruiting|July 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|35 Years|65 Years|No|||May 2014|May 9, 2014|July 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908348||62295|
NCT01911455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001- Acamprosate in FX|Study of Acamprosate in Fragile x Syndrome|Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|5 Years|23 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|July 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911455||62059|
NCT01911468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120047-LIRA1|Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin|Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin||University Medical Centre Ljubljana|No|Completed|November 2011|April 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Female|18 Years|55 Years|No|||July 2013|July 26, 2013|July 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01911468||62058|
NCT01908127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1382|Efficacy of Film Modelling in Paediatric Dentistry|The Effect of Filmed Modelling on the Anxious and Cooperative Behaviour of 4-6 Years Old Children During Dental Treatment||Zahedan University of Medical Sciences|Yes|Completed|September 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|50|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|July 17, 2013||No||No|July 28, 2013|https://clinicaltrials.gov/show/NCT01908127||62312|providing a quiet environment and patient sampling were the most important limitations.
NCT01908140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/40464/39|Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|933|||Both|40 Years|N/A|No|||February 2016|February 8, 2016|July 23, 2013||No||No|August 6, 2015|https://clinicaltrials.gov/show/NCT01908140||62311|
NCT01908153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000093|Taste Reward Processing in Pediatric Obesity|Taste Reward Processing in Pediatric Obesity||Stanford University|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|30|||Both|4 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 4-8|January 2016|January 4, 2016|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908153||62310|
NCT01909167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13IC0475|Keeping Well:Online Cognitive Behavioral Therapy (CBT) for Pregnant Women With Depressive Symptoms|A Randomized Controlled Trial of Internet Based Cognitive Behavioural Therapy (CBT) Versus Treatment as Usual (TAU) for Pregnant Women With Symptoms of Depression|OnCBTDep|Imperial College London|No|Not yet recruiting|December 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|40 Years|No|||January 2014|March 5, 2014|July 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01909167||62233|
NCT01917916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293.8|Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study)||Boehringer Ingelheim||Completed|August 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|64|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|August 2, 2013||||No||https://clinicaltrials.gov/show/NCT01917916||61565|
NCT01917929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75|Secur-Fit Advanced Outcomes Study|A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Secur-Fit Advanced Hip Stem||Stryker Orthopaedics|No|Recruiting|August 2013|December 2025|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|326|||Both|21 Years|75 Years|No|||January 2016|January 12, 2016|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917929||61564|
NCT01910974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRESTIS 2013-A00133-42|Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System|TRESTIS: Multicentric Study With a Curative Endoscopic Treatment of Superficial Neoplasia of a Digestive Tract by Endoscopic Submucosal Dissection: Evaluation of a New Water Jet System Injecting Glycerol Mix||Hôpital Edouard Herriot|Yes|Completed|July 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|90 Years|No|||July 2012|August 25, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01910974||62096|
NCT01911806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG555S021|Effectiveness of Back Care Pillow in Addition to Physical Therapy in Chronic Non-specific Low Back Pain Treatment|||Khon Kaen University|Yes|Completed|March 2013|December 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|20 Years|69 Years|No|||August 2014|August 23, 2014|March 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01911806||62032|
NCT01911819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130213|A Comparison of Bone Formation With Three Different Bone Graft Materials Following Sinus Graft|A Histomorphometric Analysis of Bone Formation With Three Different Bone Graft Materials Following Sinus Augmentation||Loma Linda University|No|Active, not recruiting|December 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|March 9, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01911819||62031|
NCT01919047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE0001|Drug Use-Results Survey of Betanis Tablets in Japan|Drug Use-Results Survey of Betanis Tablets 25 and 50 mg||Astellas Pharma Inc|No|Completed|April 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10711|||Both|N/A|N/A|No|Non-Probability Sample|Patients who received mirabegron for the first time for the treatment of urinary urgency,        daytime frequency, and urgency incontinence associated with overactive bladder.|October 2015|October 2, 2015|August 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919047||61478|
NCT01909180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-2011-GES-0003|Clinical Evaluation for GE CT System|Clinical Evaluation for GE CT System||GE Healthcare|No|Completed|May 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 14, 2014|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01909180||62232|
NCT01919671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yl-yxb09-lcsyfa-201301|Tongxinluo Capsule in Ischemic Stroke Patients（TISS)|A Randomized, Double-blind, Placebo Controlled Evaluation, Multicenter Clinical Study of Tongxinluo Capsule in Ischemic Stroke Patients||Ministry of Science and Technology of the People´s Republic of China|Yes|Not yet recruiting|September 2013|December 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1968|||Both|35 Years|75 Years|No|||August 2013|August 7, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919671||61430|
NCT01919957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-11|Episodic Memory Before and After Surgery in Drug-resistant Partial Epilepsies|Etude de la mémoire Avant et après Chirurgie d'Une épilepsie Partielle pharmacorésistante : Bases Neurobiologiques, Applications Cliniques|MemO-Epi|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|October 2013|December 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01919957||61408|
NCT01919944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VLY-686-1101|Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P|A Randomized, Double-Blind, Placebo-Controlled, Four-Way Crossover Study on Itch Control by VLY-686 Administration in Healthy Volunteers After Intradermal Injections of Substance P||Vanda Pharmaceuticals|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919944||61409|
NCT01920191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA950 Poly ICLC|Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma|Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients||University Hospital, Geneva|Yes|Recruiting|August 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01920191||61390|
NCT01921010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3954|Benefit of Elevation of HDL-C in Women|||Cedars-Sinai Medical Center|No|Completed|June 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|N/A|No|||August 2013|August 12, 2013|August 9, 2013||||No||https://clinicaltrials.gov/show/NCT01921010||61327|
NCT01921309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120038|Trinity™ BIOLOX Delta™ CoC THR Multi-center Study|Phase 3 Randomized Controlled Study to Demonstrate Safety and Effectiveness of the BIOLOX Delta CoC THR System||Corin|Yes|Recruiting|December 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|402|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|June 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921309||61304|
NCT01911949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3688|USFIB at the Inguinal Ligament for Total Hip Arthroplasty|An Ultrasound Guided Fascia Iliaca Block Placed at the Level of the Inguinal Ligament for Analgesia After Hip Arthroplasty||McMaster University|No|Suspended|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|July 26, 2013||No|Difficulty recruiting patients. Need more funding.|No||https://clinicaltrials.gov/show/NCT01911949||62021|
NCT01911962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nova-0425|A Prospective Randomized Controlled Study of Natural Orifice Medium-low Rectal Endometriosis Resection|A Prospective Randomized Controlled Study of Natural Orifice Medium-low Rectal Endometriosis Resection||First Affiliated Hospital, Sun Yat-Sen University|No|Completed|January 2011|June 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inpatients|July 2013|July 27, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01911962||62020|
NCT01908361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-M04-022|Hybrid Approach to Unilateral vs. Bilateral Upper Limb Rehabilitation in Subacute and Chronic Stroke|Hybrid Approach to Unilateral vs. Bilateral Upper Limb Rehabilitation in Subacute and Chronic Stroke||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Withdrawn|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|80 Years|No|||August 2014|August 6, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908361||62294|
NCT01908621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMMobil-COI-01|Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.|Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|March 2013|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908621||62275|
NCT01908855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCERT-130313|Cognitive-Behavioral Therapy Enriched With Emotion Regulation Training for Multiple Somatoform Symptoms|Enriching Cognitive-Behavioral Therapy With Emotion Regulation Training in Patients With Chronic Multiple Somatoform Symptoms (ENCERT): A Randomized Controlled Trial|ENCERT|Philipps University Marburg Medical Center|Yes|Active, not recruiting|October 2013|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|69 Years|No|||August 2015|August 18, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908855||62257|
NCT01912378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAO|Triadic Interactions of Families With Autism and Oxytocin|Phase 1 Study of Intranasal Oxytocin on Parents' Behavioral and Physiological Responses to Children With Autism|TAO|University of California, San Francisco|No|Withdrawn|August 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|7 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|July 26, 2013|No|Yes|unable to launch the study due to lack of participation with Autism Clinic|No||https://clinicaltrials.gov/show/NCT01912378||61989|
NCT01917162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-033|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses (Study 2)|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses||Alcon Research|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|45 Years|No|||November 2013|November 6, 2013|August 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01917162||61623|
NCT01917409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120320|Video-stylet for Nasotracheal Intubation|Comparison of Conventional Laryngoscopy and Video-stylet to Assist Nasotracheal Intubation for Patients Undergoing Oro-Maxillo-facial Surgery||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|December 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2013|August 4, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01917409||61604|
NCT01917669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0571-F1V|A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease|A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health||University of Kentucky|No|Active, not recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|Samples Without DNA|Serum and tissue (skin biopsy)|Both|40 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|We will recruit both male and female participants. The age range for this study is 40-55        years old|December 2014|December 1, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01917669||61584|
NCT01917682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECISION CorPath Registry|Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions|A Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions|PRECISION|Corindus Inc.|No|Recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with coronary artery disease and with the clinical indication for Percutaneous        Coronary Intervention (PCI).|January 2016|January 26, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01917682|3 Days|61583|
NCT01918189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0998-R|Internet-based Behavioral Pain Management|Development of an Internet-based Behavioral Pain Management Intervention||VA Office of Research and Development|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918189||61544|
NCT01918202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241017|A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers|A Phase 1, Open-label Adaptive Design Study To Evaluate Pde10 Enzyme Occupancy As Measured By Positron Emission Tomography (Pet) Following Single Oral Dose Administration Of Pf-02545920 In Healthy Male Subjects|PET|Pfizer|Yes|Completed|March 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|9|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|August 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01918202||61543|
NCT01918501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037-13-ZIV|Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients|Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients||Ziv Hospital|No|Recruiting|August 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|December 2, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01918501||61520|
NCT01919060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NLY099|Acute Non-mechanical Lower Digestive Tract Disorders Should Distinguish Whether Colonic Lesions or Not in Critically Ill Patients|||Nanjing PLA General Hospital|Yes|Completed|January 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|69|||Both|18 Years|80 Years|No|Probability Sample|The study was approved by the ethics committee of Jinling hospital and the medical school        of nanjing university. This prospective study was performed at a surgical intensive care        unit (SICU), which contain 39 beds, of general surgical departement of Jinling hospital,        affiliated hospital of medical school of nanjing university. Written informed consents        were obtained from the patients or their next of kin. Critical patients aging from 18 to        80 years old diagnosed with acute lower gastrointestinal dysfunction were recrutied to the        study.|January 2007|August 7, 2013|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919060||61477|
NCT01919034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-ER-102-026|Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients|Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients||National Cheng-Kung University Hospital|Yes|Recruiting|April 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|blood will be sampling (15cc/time), iver tissue (10mm3)|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing liver surgery and using morphine pain control analgesia (PCA) device        will be involved.|August 2013|August 6, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01919034||61479|
NCT01920451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01584|Blood Pressure, Heart Rate Variability & Sleep in Veterans With PTSD|Is Reduced Blood Pressure a Consequence of Improved Sleep in Veterans With PTSD?||Durham VA Medical Center|No|Terminated|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|21 Years|65 Years|No|||August 2014|August 4, 2014|August 8, 2013||No|PI started new position.|No||https://clinicaltrials.gov/show/NCT01920451||61370|
NCT01920464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116296|Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians|Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians|flixovate HAS|GlaxoSmithKline||Completed|April 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|160|||Both|N/A|12 Months|No|Non-Probability Sample|retrospective database extraction|September 2014|September 11, 2014|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01920464||61369|
NCT01920750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-011|Leprosy Skin Test Antigens Phase 1|Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 1989|February 1999|Actual|February 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|July 24, 2014|July 25, 2013||||||https://clinicaltrials.gov/show/NCT01920750||61347|
NCT01921335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-198|ARRY-380 + Trastuzuamab for Breast w/ Brain Mets|Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|August 2013|November 2019|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921335||61302|
NCT01921348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0165|Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis|Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis||University of Mississippi Medical Center|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921348||61301|
NCT01942564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0151|The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study|The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study|HIPP|Ohio State University|No|Active, not recruiting|August 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Age 18 or older with symptoms of increased photosensitivity since experiencing a        head injury.        Controls: Matched to cases in age, sex and race.|October 2014|October 21, 2014|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01942564||59676|
NCT01912274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI-004|Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)||MEI Pharma, Inc.|Yes|Active, not recruiting|October 2013|March 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|65 Years|N/A|No|||March 2016|March 14, 2016|July 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01912274||61997|
NCT01912287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000048|GATE: Generalized Anxiety - A Treatment Evaluation|GATE: Generalized Anxiety - A Treatment Evaluation||Massachusetts General Hospital|Yes|Recruiting|December 2013|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|230|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912287||61996|
NCT01912573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3OD|Nasal Naloxone for Narcotic Overdose|Nasal Naloxone for Narcotic Overdose||University of Cincinnati|Yes|Not yet recruiting|September 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|12 Years|N/A|No|||July 2013|July 29, 2013|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01912573||61974|
NCT01908374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-1302|Bioavailability of EPA and DHA From Two Dietary Supplements|A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides||Arctic Nutrition AS|No|Recruiting|July 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908374||62293|
NCT01908387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-MDS-001|Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms|A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms||Celgene|Yes|Terminated|July 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|July 23, 2013|No|Yes|Due to Slow Accrual study was terminated.|No||https://clinicaltrials.gov/show/NCT01908387||62292|
NCT01908634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-076|Matrix on Fruit Constituent Bioavailability|A Pilot Study to Test the Effects of Matrix on Fruit Constituent Bioavailability and Influence on Chronic Disease Risk Factors.|FRT|Institute for Food Safety and Health, United States|No|Active, not recruiting|July 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|10|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908634||62274|
NCT01921270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064292|Dysport for the Treatment of OMD|A Pilot Dose Ranging Study of Dysport® (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia||Emory University|No|Recruiting|August 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|29|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921270||61307|
NCT01917175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1220/12277 PRECO-CI|Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire|Research Platform " Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire "|PRECO-CI|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|June 1997|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|564|Samples With DNA|Plasma and whole blood for PBMC preparation|Both|18 Years|N/A|No|Non-Probability Sample|All HIV infected individuals that will have had a contact with the Blood Bank Medical        Center since 1992.|August 2013|August 5, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917175||61622|
NCT01917955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaMriSS_CSB|Cardiac MRI in Ischemic Stroke Study|Cardiac MRI in Ischemic Stroke Study|CaMriSS|Charite University, Berlin, Germany|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|Overall, 103 patients with acute ischemic stroke detected by brain magnetic resonance        imaging will be enrolled.|November 2014|November 30, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01917955||61562|
NCT01917422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-2012-03-14(II)|Clinical Specimens Testing Program of Dengue Antigen Detection Reagents|Clinical Specimens Testing Program of Dengue Antigen Detection Reagents||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|195|Samples With DNA|no biospecimens are to be retained|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples are obtained from the Kaohsiung Medical University Chung-Ho Memorial Hospital        in Kaohsiung, Taiwan.|July 2013|August 4, 2013|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01917422||61603|
NCT01917942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 07.03|Radiotherapy With Humidification in Head And Neck Cancer|A Randomised Phase III Trial of Radiotherapy With Humidification in Head And Neck Cancer|RadioHum|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Completed|June 2008|August 2013|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|210|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917942||61563|
NCT01918514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|455904-3|The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain|The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain||State University of New York - Upstate Medical University||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2013|August 6, 2013|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918514||61519|
NCT01918787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-2985C|rTMS for Adults With Autistic Spectrum Disorder|Examine the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Symptoms of Autism Spectrum Disorder||Chang Gung Memorial Hospital|No|Recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|40 Years|No|||April 2012|August 7, 2013|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918787||61498|
NCT01919970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-FET 2013|Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety|Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety||University of South Florida|No|Active, not recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919970||61407|
NCT01919372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-MTP-2012-74|Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention|Intensificación y monitorización telemática Personalizada de la modificación Del Estilo de Vida en el Tratamiento de la Obesidad y la prevención Del Riesgo cardiometabólico|PREDIRCAM 2|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Not yet recruiting|January 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919372||61453|
NCT01920204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG41973|Midostaurin in Indolent Systemic Mastocytosis|Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.||University Medical Center Groningen|Yes|Active, not recruiting|August 2013|May 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01920204||61389|
NCT01920217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH20130610|Identification Sepsis Related Single Nucleotide Polymorphism (SNP) by Whole Exome Sequencing|Identification Sepsis Related SNP by Whole Exome Sequencing: a Prospective Observational Study||Chinese PLA General Hospital|Yes|Recruiting|January 2013|December 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|whole blood sample|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|within 24 hours after admited in ICU|August 2013|August 8, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920217|28 Days|61388|
NCT01920477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116910|Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris|OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris||GlaxoSmithKline|Yes|Recruiting|August 2013|May 2021|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|70 Years|No|||June 2015|July 23, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920477||61368|
NCT01920763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiSPACECan-001|Observational Study of Safety and Outcomes After Minimally Invasive Surgery for Intracerebral Hemorrhage|Clinical Outcomes Following Parafascicular Surgical Evaluation of Intracerebral Hemorrhage: A Pilot Study|MiSPACE|Ottawa Hospital Research Institute|No|Withdrawn|July 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Patients aged 18-80 presenting with an acute non-traumatic symptomatic supratentorial        primary ICH diagnosed by CT|August 2013|April 2, 2014|July 22, 2013||No|Lack of recruitment.|No||https://clinicaltrials.gov/show/NCT01920763||61346|
NCT01920776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMBCSDXJS-SEPTIC SHOCK|Focused Ultrasound in Septic Shock Patients|||Peking Union Medical College Hospital||Recruiting|July 2013|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||August 2013|August 9, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01920776||61345|
NCT01921023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROX006|Comparison of Performance of a Conventional Blood Gas Analyser With the Proxima System|An Open, Non-randomised, Study to Provide a Comparison of Data From a Conventional Blood Gas Analyser With Those Obtained From the CE Marked Proxima System||Sphere Medical Ltd.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated in the Intensive Care Unit, High Dependency Unit or Operating Theatre who        require an arterial line to be inserted as standard care|February 2014|November 17, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921023||61326|
NCT01917214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181210|A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival|Patterns Of Care Among Australian Cohort Of Patients With Advanced Rrc Receiving Sutent||Pfizer|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|212|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who are diagnosed with metastatic renal cell carcinoma|March 2015|March 13, 2015|July 25, 2013||No||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01917214||61619|Due to retrospective nature of this study, PFS could not be determined as restaging scans are not done on a consistent and regular basis in clinical practice. Time to treatment failure was used as a surrogate for PFS.
NCT01942902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.01.CE|A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring|A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring Using the Yellow Springs Blood Glucose Analyser for Conformité Européenne (CE) Marking Purposes in a Total of Thirty Patients Admitted to The Surgical Intensive Care Unit (SICU)||GlySure|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01942902||59650|
NCT01943162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-1-0641|Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD|Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD||San Diego Veterans Healthcare System|No|Recruiting|August 2012|September 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||May 2015|May 28, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01943162||59630|
NCT01943175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1207-117-419|Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia|Stem Cell-based Approaches to Neuronal Characteristics and Endophenotype of Schizophrenia in Genetic High Risk Subjects||Seoul National University Hospital|Yes|Recruiting|September 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples With DNA|5-10mL of adipose cells in tumescent solution      5-10mL of venous blood|Both|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|-  Subjects at genetic high risk for schizophrenia          -  Healthy control|December 2013|December 4, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01943175||59629|
NCT01939301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kline-1UM NO for PE|Nitric Oxide to Treat Pulmonary Embolism|Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism||Indiana University|Yes|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939301||59927|
NCT01917695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRHCO-01|Study on Early Stage Bulky Cervical Cancers|Randomised Phase III Clinical Trial on Concurent Chemoradiation vs. Neoadjuvant Chemoradiation and Surgery vs. Neoadjuvant Chemotherapy and Surgery in Early Stage Bulky Cervical Cancers (FIGO Stages IB2, IIA2 and IIB)||Government Royapettah Hospital|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Female|18 Years|60 Years|No|||August 2015|August 11, 2015|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01917695||61582|
NCT01917968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U8090|Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|Uphold LITE|Boston Scientific Corporation|No|Recruiting|October 2013|November 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|414|||Female|18 Years|100 Years|No|Non-Probability Sample|Women 18 years or older with anterior and/or apical pelvic organ prolapse|October 2015|October 27, 2015|July 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01917968||61561|
NCT01918813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyogo college of Medicine 749|Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening|||Hyogo College of Medicine|No|Completed|November 2009|February 2012|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|662|||Both|17 Years|N/A|No|||August 2013|August 6, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918813||61496|
NCT01918215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRG-HF-1|Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.|Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction|CMR_GUIDE|Flinders University|Yes|Recruiting|June 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1055|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01918215||61542|
NCT01918228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRRPhDPF|Effect of Reassuring Information on Danish Workers Who Experience Low Back Pain in the Following Year.|Effect of an Educational Based Intervention on Danish Workers With Low Back Pain. A Randomized Controlled Single Blinded Study.|VRRPF|Glostrup University Hospital, Copenhagen|Yes|Active, not recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01918228||61541|
NCT01918527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoCol|Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer|Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer||Vejle Hospital|Yes|Recruiting|September 2013|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918527||61518|
NCT01918800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7777-R|A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis|A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis||VA Office of Research and Development|Yes|Active, not recruiting|March 2013|September 2017|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01918800||61497|
NCT01919983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HL106586-1|Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death|Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death||Johns Hopkins University|Yes|Recruiting|March 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Blood Sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a cardiomyopathy with an LVEF ≤35% who have undergone placement of an        implantable cardioverter-defibrillator for primary prevention of sudden cardiac death|August 2013|August 7, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919983||61406|
NCT01919385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3108873,|Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia|Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting||Animas Corporation|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|June 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919385||61452|
NCT01919398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14895|A Study of LY2940680 in Japanese Participants With Advanced Cancers|A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Recruiting|August 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||December 2015|December 17, 2015|August 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919398||61451|
NCT01920789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACE|Stereotactic Precision And Conventional Radiotherapy Evaluation|A Multicenter Randomized Phase II Study of Stereotactic Hypofractionated Radiotherapy With Body Frame Versus Conventionally Fractionated Radiotherapy for Stage I Medically Inoperable Non-small Cell Lung Cancer|SPACE|Swedish Lung Cancer Study Group|No|Active, not recruiting|January 2007|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|N/A|N/A|No|||December 2014|December 8, 2014|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01920789||61344|
NCT01921036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2931/10|The Effects of Combined Exercise Training on Exercise Capacity in Cardiac Rehabilitation|Individuell Dosiertes Kraft-ausdauer-training in Ambulanten Herzgruppen - Einfluss Auf Koerperliche Belastbarkeit Von Herzpatienten.|DOPPELHERZ|Technische Universität München|Yes|Completed|February 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|70|||Both|N/A|N/A|No|||January 2015|January 22, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01921036||61325|
NCT01921049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-229|Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Major Procedures in Oral and Maxillofacial Surgery|Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Major Procedures in Oral and Maxillofacial Surgery||University of Cologne|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|all patients undergoing major procedures in oral and maxillofacial surgery during the        study period|December 2014|December 7, 2014|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01921049||61324|
NCT01921361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.ERC.0.01.00.01/27|The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia|The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia||TC Erciyes University|Yes|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|65 Years|No|||August 2013|August 12, 2013|August 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01921361||61300|
NCT01917500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartBeat_V1.0|Feasibility Study of Non-invasive and Continuous Measurement of Blood Pressure and Cardiac Output: Comparison to Non-invasive and Non-continuous Measurements|Feasibility Study of Non-invasive and Continuous Measurement of Blood Pressure and Cardiac Output: Comparison to Non-invasive and Non-continuous Measurements||Rambam Health Care Campus|No|Not yet recruiting|August 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The trial will be conducted on a group of patients in the cardiac ward at the Rambam        hospital. As long as they fall under the criteria, they will fit for the trial.|August 2013|August 5, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917500||61597|
NCT01943409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPCR ID: 13-5807|Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils|Parenteral Nutrition in Hospitalized Patients: Comparison of Two Commercially Available Lipid Emulsions||University Health Network, Toronto|No|Recruiting|July 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|350|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01943409||59611|
NCT01943214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13177|Prospective Cohort Study of the Body Constitution Among Type II Diabetes Mellitus Patients|Prospective Cohort Study of the Body Constitution Among Type II Diabetes Mellitus Patients||Taichung Veterans General Hospital|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|75 Years|No|Non-Probability Sample|1000 type II diabetes mellitus patients recruited from the Endocrinology & Metabolism out        patient clinic of Taichung Veterans General Hospital.|September 2013|September 16, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01943214|2 Years|59626|
NCT01939314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX 360 HA -Schaffer|Sphenopalatine Nerve Block for Headache Tx360|A Prospective, Randomized, Double-Blind Study Comparing the Efficacy of Sphenopalatine Nerve Block by Localized Mucosal Application of an Anesthetic vs Placebo for the Emergency Department Management||Indiana University|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|65 Years|No|||July 2015|July 6, 2015|September 3, 2013|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01939314||59926|
NCT01939327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2/IPC-2012-004|Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma|A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma.|R2|Institut Paoli-Calmettes|Yes|Recruiting|September 2013|September 2020|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01939327||59925|
NCT01939340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/051/10|Prevalence of Cachexia in Patients Undergoing Chemotherapy|Prevalence and Impact of Cachexia in Cancer Patients Undergoing Chemotherapy||Charite University, Berlin, Germany|No|Completed|April 2010|May 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|285|||Both|18 Years|85 Years|No|Probability Sample|Patients will be selected in primary care clinics.|September 2013|September 11, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939340||59924|
NCT01939600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-1322|Digestibility of Selected Resistant Starches in Humans|Digestibility of Selected Resistant Starches in Humans||St. Michael's Hospital, Toronto|No|Completed|September 2013|August 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|75 Years|No|||November 2014|November 17, 2014|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01939600||59904|
NCT01939860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Warwick.123|A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment|||University of Warwick|No|Completed|December 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||February 2014|May 29, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939860||59884|
NCT01918241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JY062013B|Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia|Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia|PEG-rhG-CSF|Hangzhou Jiuyuan Gene Engineering Co. Ltd.,|No|Recruiting|July 2013|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|70 Years|No|||November 2015|November 9, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918241||61540|
NCT01918254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28752|A Study to Evaluate RO5479599 in Combination With Pertuzumab (Perjeta) and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor (HER) 3 & HER2 Protein|PHASE IB, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF RO5479599, A GLYCOENGINEERED ANTIBODY AGAINST HER3, ADMINISTERED IN COMBINATION WITH PERTUZUMAB AND PACLITAXEL IN PATIENTS WITH METASTATIC BREAST CANCER EXPRESSING HER3 &HER2 PROTEIN||Hoffmann-La Roche||Recruiting|August 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01918254||61539|
NCT01918540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Centralizer study|Importance of Hollow or Solid Centralizer for Polished, Collarless and Tapered Stems in Total Hip Arthroplasty|Comparing Hollow and Solid Centralizer Designs When Using a Polished, Collarless, Tapered Hip Prosthesis Stem (MS30). A Prospective, Randomized, Multicenter Study Evaluated by RadioStereometric Analysis (RSA).||Region Skane|No|Completed|February 2003|November 2014|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|85 Years|No|||November 2014|November 25, 2014|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01918540||61517|
NCT01918826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-06|Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs|Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs||Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||July 2012|August 7, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01918826||61495|
NCT01919073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31413|Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers|Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers||Baylor College of Medicine|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|2 Years|5 Years|No|||March 2015|March 25, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919073||61476|
NCT01919411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-053H|Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial|Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial||Massachusetts Eye and Ear Infirmary|No|Recruiting|February 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919411||61450|
NCT01919684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L6972-01|Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus|Double-blind, Placebo-controlled, Randomized, Ascending Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus||Ligand Pharmaceuticals|No|Completed|November 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2014|September 22, 2014|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919684||61429|
NCT01920230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21000021201|The Effectiveness of Mindfulness Practices in the Recovery of Burnout|The Effectiveness of Mindfulness Practices in the Recovery of Burnout|Muupu|University of Jyvaskyla|No|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01920230||61387|
NCT01921062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDRF|Motor Imagery in Rehabilitation After a Distal Radius Fracture|Kinesthetic Motor Imagery Training During Immobilization to Improve Wrist Functional Outcome After a Distal Radius Fracture in Women of 45-75 Years of Age|MIDRF|University Medical Center Groningen|No|Recruiting|July 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Female|45 Years|75 Years|No|||December 2015|December 1, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921062||61323|
NCT01921075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/08|Physiologic Plasticity of Intramyocardial Lipid Storage|Patterns and Plasticity of Orthotopic and Ectopic Fat Deposition and Associations With Insulin Sensitivity: A Magnetic-resonance-imaging and -Spectroscopy Study in Lean and Obese Individuals: Methodological Part||University Hospital Inselspital, Berne|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|males between the age of 18 and 30 years with either a BMI of 18-24|August 2013|August 8, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01921075||61322|
NCT01921374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMDK|Mother-caregivers of Children With Duchenne Muscular Dystrophy|Profile of Mother-caregivers of Children With Duchenne Muscular Dystrophy|DMDK|Federal University of São Paulo|Yes|Completed|August 2013|July 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|5||Actual|60|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921374||61299|
NCT01917227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-1452B|Evaluation of Group Health Teaching With Video in Diabetic Patients|Evaluation of Group Health Teaching With Video in Diabetic Patients|EGVD|Chang Gung Memorial Hospital|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|80|||Both|20 Years|80 Years|No|||June 2014|June 6, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01917227||61618|
NCT01918046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIOX-1|MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery|MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery||Barnes-Jewish Hospital|No|Recruiting|July 2013|September 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Only for analysis of biomarker|Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery at BJH|August 2013|August 6, 2013|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01918046||61555|
NCT01939353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-1020-SR-ADHD-201|An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder|An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder||Euthymics BioScience, Inc.|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|41|||Male|18 Years|55 Years|No|||September 2015|October 12, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939353||59923|
NCT01939106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0512-13-A740|One Piece Drainable Pouch in Subjects With an Ileostomy|A Single Center Study to Assess the Safety and Performance of a One Piece Drainable Pouch in Subjects With an Ileostomy||ConvaTec Inc.|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01939106||59942|
NCT01939366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF6005/08|Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves|Efficacy, Safety and Tolerability of Multiple Doses of Oral Cebranopadol in Subjects With Moderate to Severe Chronic Pain Due to Diabetic Peripheral Neuropathy.||Grünenthal GmbH|No|Completed|September 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|699|||Both|18 Years|80 Years|No|||January 2015|January 30, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939366||59922|
NCT01939613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-20100180|Colloid Improves Organs Function in Resuscitation of Extensive Burn Patients|Colloid Improves Organ Function by Reducing the Elevation of Intra-abdominal Pressure in Resuscitation of Critical Burn Patients||Tang-Du Hospital|Yes|Completed|July 2010|July 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|47|||Both|19 Years|60 Years|No|Probability Sample|This study was performed in the Department of Burn Intensive Care of the Tangdu Hospital,        an academic hospital of the Fourth Military Medical University of Xi'an. populaitons were        extensive burns who admitted to our hospital within 4 h since burn injury.|September 2013|September 5, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01939613|2 Days|59903|
NCT01939626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL-SCM-2013|Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging|Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.||Vitrolife|No|Recruiting|August 2013|November 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Anticipated|150|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939626||59902|
NCT01939873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KayseriERH|The Effect Of Kristeller Maneuver On Maternal And Neonatal Outcome|A Prospective, Randomized, Controlled Trial||Kayseri Education and Research Hospital|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|285|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01939873||59883|
NCT01940185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3545|A Post-Approval Study of the LINX® Reflux Management System|A Post-Approval Study of the LINX® Reflux Management System||Torax Medical Incorporated|No|Active, not recruiting|June 2012|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|21 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Gastroesophageal Reflux Disease (GERD) as defined by abnormal pH        testing, and who continue to have chronic GERD symptoms despite maximum medical therapy        for the treatment of reflux|August 2015|August 25, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940185||59859|
NCT01939639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT_PS_2013|The Influence of Oxytocin on the Processing of Social Contact|||University Hospital, Bonn|No|Completed|March 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01939639||59901|
NCT01918280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.576|Fertility Preservation in Cases of Klinefelter Syndrome.|Fertility Preservation in Cases of Spermatogenesis Failure : Prospective Study for Klinefelter Syndrome With Non-mosaic Karyotype (47, XXY, Homogeneous)|FERTIPRESERVE|Hospices Civils de Lyon|Yes|Recruiting|September 2010|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Male|15 Years|55 Years|No|||January 2016|January 20, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01918280||61537|
NCT01918553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2012/31|Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors|Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors|ECLAIR|University Hospital, Bordeaux|No|Recruiting|July 2013|September 2017|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 13, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01918553||61516|
NCT01919736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOC|Loaded and Unloaded Magnetic Resonance (MR) Imaging of Meniscus-Cartilage-Trabecular Bone in Osteoarthritis|Loaded and Unloaded Magnetic Resonance (MR) Imaging of Meniscus-Cartilage-Trabecular Bone in Osteoarthritis||University of California, San Francisco|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|35 Years|80 Years|No|||May 2015|May 26, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01919736||61425|
NCT01919086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-064|Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma|Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Recruiting|August 2013|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919086||61475|
NCT01919424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIREB 11-004|Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer|Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer||McMaster University|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01919424||61449|
NCT01919437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.118-2|Comparison of Methamphetamine-Dependent and Healthy Volunteers Using a Web-Enabled Cognitive Neuropsychological Evaluation System|Comparison of Methamphetamine-Dependent and Healthy Volunteers Using a Web-Enabled Cognitive Neuropsychological Evaluation System|5I|California Pacific Medical Center Research Institute|Yes|Active, not recruiting|April 2012|October 2013|Anticipated|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01919437||61448|
NCT01919697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-01|Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)|An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation (CIC)||Synergy Pharmaceuticals Inc.|No|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|81 Years|No|||December 2015|December 10, 2015|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919697||61428|
NCT01919710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9314-rHSA/GCSF|Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia|Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients||Tianjin SinoBiotech Ltd.|Yes|Completed|October 2012|August 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01919710||61427|
NCT01920490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDOR|Blame Rebalance fMRI Feedback Proof-of-concept|Rebalancing Blame Using fMRI Neurofeedback: a Double-blind Controlled Clinical Proof-of-concept Trial in Remitted Major Depressive Disorder|GUIMRINFB1|D'Or Institute for Research and Education|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01920490||61367|
NCT01920503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOLANGIO01|International Registry on Cholangiocarcinoma Treatment|International Registry on Cholangiocarcinoma Treatment|CHOLANGIO|International Group of Endovascular Oncology|Yes|Recruiting|July 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|primary care clinic|April 2015|April 16, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01920503|12 Months|61366|
NCT01920802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6525|Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo|Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo||New York State Psychiatric Institute|No|Completed|November 2012|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920802||61343|
NCT01921400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0958|The Pathogenesis of Hepatitis C Virus Vertical Transmission|The Pathogenesis of Hepatitis C Virus Vertical Transmission||University of North Carolina, Chapel Hill|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Our planned protocol will be to secure whole placental organs after delivery for study      patients. Tissue preparation will include a combination of segments preserved in nucleic      acid preservative (TriZol or equivalent) and flash freeze of sections to preserve cellular      anatomy.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with HCV infection who present to our collaborating institution in Egypt,        and at UNC|April 2015|April 2, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01921400||61297|
NCT01917240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2013-02|Sequential vs. Monophasic Media Impact Trial (SuMMIT)|Evaluation of the Impact of Monophasic vs. Sequential Media on the Reproductive Potential of Embryos Undergoing in Vitro Fertilization (IVF)|SuMMIT|Reproductive Medicine Associates of New Jersey|No|Active, not recruiting|July 2013|August 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|42 Years|No|||March 2015|March 25, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01917240||61617|
NCT01917253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|351/007A/2013|Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation.|Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation. A Randomized Controlled Clinical Trial to Test the Complications.|Long&short|ASL TO2 Torino|Yes|Recruiting|September 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917253||61616|
NCT01917513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-EYE 15505|Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy|Prospective Randomized Trial to Compare the Clinical Efficiency (Adenoma Detection Rate) of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy||Smart Medical Systems Ltd.|No|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917513||61596|
NCT01918059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0276|Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive|Prospective, Randomized, Controlled Trial of Tissue Adhesive (Octyl-2-Cyanoacrylate) vs. Traditional Suture in Traumatic Lid Laceration Repair||The University of Texas Health Science Center, Houston|No|Terminated|August 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|July 30, 2013||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01918059||61554|
NCT01939119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VascOcclusion/Drinking2013|Body-fluid Balance and Drinking Habits in Patients With Retinal Vascular Occlusion|Examination of the Body-fluid Balance in Patients With Retinal Vascular Occlusion Before and During Hemodilution and the Influence of Drinking Habits on the Degree of Body Hydration||Technische Universität Dresden|No|Recruiting|January 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients with retinal vascular occlusion|September 2013|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939119||59941|
NCT01939379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR#5130183|Adductor Canal Nerve Block Following Total Knee Arthroplasty|Adductor Canal Nerve Block Following Total Knee Arthroplasty: A Randomized, Prospective Study Comparing High vs. Low Volume Bolus of 0.33% Ropivacaine||Loma Linda University|No|Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|99 Years|No|||September 2015|September 28, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939379||59921|
NCT01939392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1003|Rapid Renal Sympathetic Denervation for Resistant Hypertension II|Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II|RAPID II|Medtronic Endovascular|Yes|Withdrawn|September 2013|September 2018|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||August 2015|August 14, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939392||59920|
NCT01939652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCTUZLA|Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair|Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair||University Clinical Center Tuzla|Yes|Completed|February 2009|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 5, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01939652||59900|
NCT01939925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLSRCT1|Communicating Evidence From Systematic Reviews to the Public|Communicating Evidence From Systematic Reviews to the Public: A Randomised Controlled Trial|PLSRCT|Norwegian Knowledge Centre for the Health Services|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|193|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01939925||59879|
NCT01919099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130177|Study of the Complications Associated With Certain Stem Cell Transplants|Natural History Study of the Complications Associated With Allogeneic Hematopoietic Stem Cell Transplantations||National Institutes of Health Clinical Center (CC)||Suspended|July 2013|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|N/A|||Actual|76|||Both|2 Years|N/A|No|||May 2015|November 21, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919099||61474|
NCT01919450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-058|Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation|Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation||Cardiovascular Imaging Technologies|No|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|60|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919450||61447|
NCT01919723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0077|Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion|Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention||University of Alabama at Birmingham|No|Active, not recruiting|February 2014|September 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||February 2016|February 25, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01919723||61426|
NCT01919463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINOCOLO2013|Intubation Techniques on Colonoscopy Quality (SINOCOLO2013)|Intubation Techniques on Colonoscopy Quality: A Single Center Randomized Control Clinical Trial|SINOCOLO2013|Changhai Hospital|No|Recruiting|March 2015|February 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919463||61446|
NCT01919749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO-BCA-002|A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer|A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer|SO2|Translational Drug Development|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01919749||61424|
NCT01919996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661206|PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients|Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/Tonsillitis||Pfizer|No|Terminated|December 2013|November 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|12 Years|17 Years|No|||February 2016|February 23, 2016|August 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919996||61405|
NCT01919762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00191|Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)|Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)-Part I (Prospective Collection and Freezing of Whole Blood Specimens)|DIREBT|T2 Biosystems|No|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|156|Samples With DNA|Whole blood specimens, in addition to bacterial isoaltes|Both|18 Years|95 Years|No|Non-Probability Sample|Patients with blood culture results are eligible to participate|September 2015|September 25, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919762||61423|
NCT01920243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N110002 -2|Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI)|Applying Health Mechanics to Enhance Bowel and Bladder Health for Persons With SCI||University of Michigan|Yes|Enrolling by invitation|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01920243||61386|
NCT01920516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI01|Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment|Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable|ILI|International Group of Endovascular Oncology|Yes|Recruiting|July 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|April 2015|April 16, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01920516||61365|
NCT01920815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HL115032-01A1--BAV|Bicuspid Valve Aortopathy Feasibility Study|Bicuspid Valve Aortopathy: Feasibility of a Comparative Effectiveness Study||Oregon Health and Science University|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|90 Years|No|Probability Sample|Patients with a bicuspid aortic valve.|February 2015|February 23, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920815|24 Months|61342|
NCT01920828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OregonHSU-8833|Gait Analysis in MPS IVA|Gait Analysis in Patients With MPS IVA Treated With Enzyme Replacement Therapy||Oregon Health and Science University|Yes|Recruiting|August 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|1 Year|N/A|No|Non-Probability Sample|Patients with a diagnosis of MPS IVA|August 2013|August 9, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920828||61341|
NCT01921088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF1_137023_A|Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Regulation of Psychophysiological Functions|Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Regulation of Psychophysiological Functions||University Hospital, Basel, Switzerland|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01921088||61321|
NCT01921387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2728.00|Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies|A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies||Fred Hutchinson Cancer Research Center|No|Recruiting|October 2013|||September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01921387||61298|
NCT01917266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690|Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide|Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide||St. Jude Medical|Yes|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients indicated for a Cardiac Resynchronization Therapy (CRT) device|September 2015|September 10, 2015|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01917266||61615|
NCT01917279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28898|Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC|A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer|CAMELLIA|Chinese Academy of Medical Sciences|No|Recruiting|October 2013|September 2018|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|928|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01917279||61614|
NCT01917526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066/2556 (EC3)|The Performance of Two Oxygen Delivery Devices Used After General Anesthesia.|The Performance Comparison of Two Oxygen Delivery Devices [Nasal Cannula and Mask] Used After General Anesthesia.||Mahidol University|No|Completed|April 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|70 Years|No|||June 2015|June 25, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01917526||61595|
NCT01917786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00171|Effect of Dexmedetomidine on QT Interval in Pediatric Patients Under General Anesthesia|||Nationwide Children's Hospital|No|Completed|July 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients receiving dexmedetomidine as part of their surgical anesthesia.|January 2016|January 7, 2016|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01917786||61575|
NCT01917799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDA and LMWH|Aspirin, Heparin and Miscarriage|Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage||University of Khartoum|No|Recruiting|January 2009|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|15 Years|48 Years|No|||August 2013|August 6, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01917799||61574|
NCT01909635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9230 B|Assessment of Thoughts and Feelings Occurring During and After a Meal|Assessment of Thoughts and Feelings Occurring During and After a Meal||University of Tennessee|No|Not yet recruiting|July 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|36|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909635||62198|
NCT01909648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55709|HbA2 Leuven and Its Impact on HbA1c Results|HbA2 Leuven and Its Impact on HbA1c Results|HbA2 Leuven|Universitaire Ziekenhuizen Leuven|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|N/A|N/A|No|||July 2015|July 6, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909648||62197|
NCT01943266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580-C|Determination of Protein Requirement in Elderly Male Subjects 65-75 Yrs Old.|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Male Subjects 65-75 Yrs Old.||The Hospital for Sick Children|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Male|65 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01943266||59622|
NCT01939067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009882|Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP|Pulmonary Mechanics in Preterm Infants Treated With Heated Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure.||Children's Hospital of Philadelphia|No|Withdrawn|March 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||September 2015|September 14, 2015|August 30, 2013||No|Application for regulatory approval withdrawn|No||https://clinicaltrials.gov/show/NCT01939067||59945|
NCT01939080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/B/01|Variation of Aortic Compliance Related to Exercise Training With or Without Supervised Sessions|Exercise Training in Patients With Cardiovascular Risk: Predictability of Aortic Compliance Normalization|ACT|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|April 2013|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|308|||Both|50 Years|69 Years|No|||September 2013|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939080||59944|
NCT01939093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRCT-53069|Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis|Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis|MAP|Chulalongkorn University|Yes|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|September 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939093||59943|
NCT01939665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42888.029.13|PANFIRE - Pilot-study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma|PANFIRE - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma - a Phase I Clinical Trial|PANFIRE|VU University Medical Center|Yes|Recruiting|September 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939665||59899|
NCT01939678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12|Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease|Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease||University Hospital Orebro|No|Recruiting|September 2013|||October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Bloodsamples and Aortic valve samples|Both|N/A|65 Years|No|Probability Sample|Patients with aortic valve calcification that will be treated with an aortic valve        replacement|September 2013|December 2, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01939678||59898|
NCT01939938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012713|Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With Positive Airway Pressure Treatment|Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With Positive Airway Pressure Treatment|Mask MRI|Weill Medical College of Cornell University|No|Recruiting|June 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01939938||59878|
NCT01918865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 404173-CS2|Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes|A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea||Ionis Pharmaceuticals, Inc.|No|Completed|August 2013|February 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||September 2014|February 27, 2015|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01918865||61492|
NCT01919112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000067/1|Fostering Eating After Stroke With Transcranial Direct Current Stimulation|Non-invasive Brain Stimulation for Swallowing Recovery After a Dysphagic Stroke|FEASt|Beth Israel Deaconess Medical Center|Yes|Recruiting|September 2013|May 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 14, 2014|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01919112||61473|
NCT01919476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHO17-ABC|Postprandial Response to Almond Consumption in Overweight Hispanic Pregnant Women|Postprandial Response to Almond Consumption in Overweight Hispanic Pregnant Women||Children's Hospital & Research Center Oakland|No|Recruiting|September 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01919476||61445|
NCT01919775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tohoku-ACoA amnesia MRI|Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution Magnetic Resonance (MR) Imaging Findings|Basal Forebrain Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution 3-dimensional (3D) Magnetic Resonance (MR) Imaging Findings||Tohoku University|No|Completed|December 2007|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|14|||Both|N/A|N/A|No|Probability Sample|Patients with amnesia following surgical treatment of the ACoA aneurysm.|August 2013|August 7, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919775|6 Years|61422|
NCT01920009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0064|Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines|Feasibility and Potential Impact of Community Pharmacy Care Including Motivational Interviews on Adherence to Secondary Prevention Medication in Patients With Coronary Heart Diseases|Pharmacycare|University College, London|No|Completed|September 2013|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01920009||61404|
NCT01919788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK journal nr.: M-2013-113-13|Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose|Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose||University of Aarhus|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|9|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01919788||61421|
NCT01920256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMichigan|Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care|Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care||University of Michigan|Yes|Recruiting|August 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01920256||61385|
NCT01920529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|livia1971|Aerobic Exercise in Children With Moderate and Severe Asthma|Effectiveness of a Physical Training Program on Inflammatory Response, Functional Capacity and Quality Life in Children With Moderate and Severe Asthma.|AECA|Instituto Materno Infantil Prof. Fernando Figueira|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|8 Years|19 Years|No|||August 2013|August 8, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920529||61364|
NCT01920841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-058|A Blinded Comparison Trial of Two Topical Creams to Reduce Thigh Girth and to Smooth Thigh Skin in Women|A Blinded Comparison Trial of Two Topical Creams to Reduce Thigh Girth and to Smooth Thigh Skin in Women.|ThighCream|Pennington Biomedical Research Center|No|Withdrawn|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 8, 2013||No|Study Design changed and will be resubmitted as a new study|No||https://clinicaltrials.gov/show/NCT01920841||61340|
NCT01921101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|685|Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)|Intensive Nutrition in ARDS: A Clinical Trail (INTACT)|INTACT|University of Illinois at Chicago|Yes|Terminated|July 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|90 Years|No|||August 2014|August 1, 2014|July 3, 2013||No|greater mortality in intervention group|No|April 15, 2014|https://clinicaltrials.gov/show/NCT01921101||61320|
NCT01921413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT Evaluation|Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)|Clinical Validation of Fyodor Urine Malaria Test (UMT)||Fyodor Biotechnologies Inc|Yes|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1893|Samples Without DNA|Urine|Both|2 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study population will comprise of individuals 2 years or older of both genders with fever        (axillary temperature ≥37.5°C) (Group 1), apparently "healthy" individuals (Control, Group        2), and patients positive for Rheumatoid factor (Group 3), will be recruited will be        recruited at primary healthcare facilities across four local government areas in Lagos        State, southwest Nigeria - Ikorodu, Surulere, Shomolu and Ibeju-Lekki. The sampling for        Schistosomiasis will be carried out in Imalodo and Abuletutu communities in Abeokuta-North        Local Government Area of Ogun State, also in southwest Nigeria.|April 2014|April 21, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01921413||61296|
NCT01917292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130718emp|Impact of Periodontal Intervention on Vascular Dysfunction|Periodontal Intervention Improves Vascular Function Among Chinese Prehypertensive Adults With Periodontitis||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|December 2012|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|123|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01917292||61613|
NCT01917539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120140|Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome|Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome||University of Miami|No|Withdrawn|June 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|July 19, 2013|Yes|Yes|Trouble enrolling patients|No||https://clinicaltrials.gov/show/NCT01917539||61594|
NCT01909661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRD - 2013 - JUNGLO|Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas|Tolerancia a 2 fórmulas de Leche Infantil Altamente Hidrolizadas en Base a proteínas de Arroz y a caseína en niños Con Alergia a Las proteínas de Leche de Vaca|JUNGLO|Lactalis|Yes|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|N/A|9 Months|No|||July 2013|April 16, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01909661||62196|
NCT01939431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913129|Genetic and Other Aspects of Podoconiosis|Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches||National Institutes of Health Clinical Center (CC)||Not yet recruiting|August 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|150|||Both|18 Years|70 Years|No|||February 2016|March 9, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01939431||59917|
NCT01939405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001480|Children's Use of the Built Environment for Physical Activity|Use of the Built Environment to Promote Physical Activity in Children.|CUBES|Massachusetts General Hospital|No|Completed|October 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|10 Years|16 Years|No|||September 2015|September 22, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939405||59919|
NCT01939132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02131985|Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis|Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA)||Fiechtner, Justus J., M.D., P.C.|No|Recruiting|July 2013|November 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2013|September 9, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01939132||59940|
NCT01939691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEND|Topical Treatment of Uveitic Macular Edema|Difluprednate Versus Nepafenac Plus Prednisolone Acetate for the Treatment of Cystoid Macular Edema Associated With Uveitis||University of California, San Francisco|Yes|Not yet recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|7 Years|N/A|No|||December 2015|December 1, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939691||59897|
NCT01940523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12166|Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical|Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical||Hospital for Special Surgery, New York|Yes|Recruiting|May 2013|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940523||59833|
NCT01918878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHO123-HMO-CTIL|Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.|A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).||Hadassah Medical Organization|No|Active, not recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|50 Years|N/A|No|||September 2015|January 12, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01918878||61491|
NCT01919125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-008|Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)|A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function||Merck Sharp & Dohme Corp.|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|August 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919125||61472|
NCT01919138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305085RINC|Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units|Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units of National Taiwan University Hospital: Retrospective Review||National Taiwan University Hospital|No|Completed|July 2013|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|762|||Both|20 Years|N/A|No|Probability Sample|Paitent with Severe Spesis in Surgical Intensive Care Units of National Taiwan University        Hospital|June 2014|June 22, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01919138||61471|
NCT01920035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT 04-200|Study of Endorectal Cooling During RARP to Minimize Trauma and Promote Earlier Return to Continence|A Randomized, Controlled Study of the Use of Localized Endorectal Cooling Using the UroCool System During Robotic-Assisted Radical Prostatectomy (RARP) to Minimize Trauma and to Provide Earlier Return to Continence|UroCool|Philips Healthcare|Yes|Active, not recruiting|May 2013|December 2014|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Male|18 Years|N/A|No|||November 2014|November 3, 2014|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920035||61402|
NCT01910857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO16801|Improving Hypertension Control|||Medical College of Wisconsin|No|Completed|January 2012|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|19 Years|N/A|No|||August 2015|August 24, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01910857||62105|
NCT01910870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|META1 - CJP4.1|Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes|||Centre Jean Perrin|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01910870||62104|
NCT01920022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QW2013|Quickstart of Nexplanon® at Medical Abortion|Early Versus Delayed Insertion of Nexplanon® at Medical Abortion - a Randomized Controlled Equivalence Trial.||Karolinska Institutet|Yes|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|551|||Female|18 Years|50 Years|No|||February 2016|February 24, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01920022||61403|
NCT01920269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTV-72-1993|Intravesical Adjuvant Electromotive Mitomycin-C|Intravesical Adjuvant Electromotive Mitomycin-C in Patients With pTa-pT1 and G1-G2 Non-muscle Invasive Bladder Cancer: a Randomized Controlled Trial|EMDA/MMC|University of Rome Tor Vergata|Yes|Completed|January 1994|June 2013|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|331|||Both|18 Years|90 Years|No|||August 2013|August 8, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01920269||61384|
NCT01920854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-9|A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.|A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Intravenously Administered SFP in Healthy Volunteers||Rockwell Medical Technologies, Inc.|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|June 28, 2013|Yes|Yes||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01920854||61339|
NCT01920867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMS-2013-0019.|Stem Cell Ophthalmology Treatment Study|Bone Marrow Derived Stem Cell Ophthalmology Treatment Study|SCOTS|Retina Associates of South Florida|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01920867||61338|
NCT01921114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-BF400|The PROOF Study: The PICC Related Obstruction Of Flow Study|A Randomized Prospective Multicenter Evaluation to Investigate the Incidence of Catheter Related Venous Thrombosis in Patients Undergoing Intravenous Therapy With the BioFlo™ Peripherally Inserted Central Catheter (PICC) or Bard® Dual-Lumen PowerPICC SOLO2®|PROOF|Angiodynamics, Inc.|No|Terminated|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|August 8, 2013||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01921114||61319|
NCT01908400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BMMR/2013//01|Safety and Efficacy of BMMNCin Patients With Mental Retardation|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Patients With Mental Retardation. It is Self Funded (Patients' Own Funding) Clinical Trial||Chaitanya Hospital, Pune|Yes|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|5 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01908400||62291|
NCT01921426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-001|A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck|A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.||Galera Therapeutics, Inc.|No|Active, not recruiting|August 2013|July 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01921426||61295|
NCT01908881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-079|An Intervention for Enhancing Early Attachment in Primary Health Care|Impact of a Group Intervention for Promoting Maternal Sensitivity in Primary Health Care Dyads at Psychosocial Risk. A Randomized Clinical Trial.||Pontificia Universidad Catolica de Chile|No|Completed|April 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|181|||Female|N/A|N/A|No|||November 2015|November 3, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01908881||62255|
NCT01909128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210/12|Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms|||Federico II University|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|405|||Both|12 Months|48 Months|No|||March 2015|March 18, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909128||62236|
NCT01909102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12032013|The ACTonHEART Study: Design of a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy for Cardiac Patients|The ACTonHEART Study: a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy in Cardiac Patients|ACTonHEART|Istituto Auxologico Italiano|No|Not yet recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||September 2013|September 23, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909102||62238|
NCT01909375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120353|American Joint Replacement Registry|American Joint Replacement Registry|AJRR|American Joint Replacement Registry|No|Enrolling by invitation|August 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We expect to receive data on up to 90% of all total joint arthroplasties conducted in the        United States annually.|June 2015|June 30, 2015|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01909375|5 Years|62218|
NCT01909986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4053POE004|A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053|An Open Label, Single-dose Study to Evaluate the Pharmacokinetics, Metabolism and Excretion Balance of [14C]-ONO-4053 in Healthy Adult Male Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|October 2013|||February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||July 2013|April 14, 2014|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01909986||62171|
NCT01939704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11628|Community to Clinic Linkage Program at SFGH|Community to Clinic Linkage Program at SFGH|CCLiP@SFGH|University of California, San Francisco|No|Active, not recruiting|October 2013|May 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|2250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01939704||59896|
NCT01939418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-13-670|Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer|A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negative Breast Cancer Proceeding to an Open Label Randomized Phase II Trial Comparing Gemcitabine/Cisplatin With or Without RAD001.||National Cancer Center, Korea|No|Active, not recruiting|August 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Female|20 Years|N/A|No|||March 2016|March 21, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01939418||59918|
NCT01939951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010|Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.|A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma.||California Allergy and Asthma Medical Group, Inc.|No|Not yet recruiting|January 2014|August 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 7, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01939951||59877|
NCT01940250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02EI|Magnesium Sulphate for Severe Hand, Foot and Mouth Disease in Vietnam|A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children.||Oxford University Clinical Research Unit, Vietnam|Yes|Recruiting|April 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|6 Months|15 Years|No|||November 2014|November 26, 2014|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940250||59854|
NCT01940770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5551C00001|Specific Clinical Experience Investigation for Long-term Use of Bydureon|Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN||AstraZeneca|No|Recruiting|October 2013|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|N/A|N/A|No|Non-Probability Sample|The patients with type 2 diabetes mellitus who will be given Bydureon for the first time        and who inadequately respond to sulfonylurea, biuguanides, and/or thiazolidines        (monotherapy or combination use) in addition to diet and exercise.|March 2016|March 11, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01940770||59814|
NCT01911546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AUS200T|Role of Everolimus in Highly Sensitized Patients|A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients||Cedars-Sinai Medical Center|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|March 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01911546||62052|
NCT01919489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068128|Liraglutide Hospital Discharge Trial|A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge||Emory University|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|July 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01919489||61444|
NCT01919801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-FIR-096|Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults||Shire|Yes|Completed|December 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||August 2015|September 14, 2015|July 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01919801||61420|
NCT01910883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-006|Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects|Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects||MerLion Pharmaceuticals GmbH|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01910883||62103|
NCT01920282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nebstiff|Nebivolol, Lifestyle Modification and Arterial Stiffness|Effect of Nebivolol and Lifestyle Modification on Large Artery Stiffness in Middle-Aged and Older Hypertensive Adults||Virginia Polytechnic Institute and State University|Yes|Completed|January 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|40 Years|75 Years|No|||February 2016|February 2, 2016|July 18, 2013||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01920282||61383|
NCT01920295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3196568|Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation as First-line Therapy||C-frost|Yuksek Ihtisas Hospital|Yes|Completed|January 2011|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||August 2013|August 7, 2013|May 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01920295||61382|
NCT01920542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCIRB2013-163|Dexmedetomidine on Pediatric Heart Operation|Renal Effects of Dexmedetomidine During Pediatric Cardiac Surgery: a Randomized Placebo-controlled Study||Gachon University Gil Medical Center|Yes|Recruiting|September 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|1 Year|6 Years|No|||August 2015|August 30, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920542||61363|
NCT01920555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP-003|Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)|Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)||Massachusetts General Hospital|Yes|Recruiting|December 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01920555||61362|
NCT01911728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0007|Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates|A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of MDV3100 (ASP9785) on the Pharmacokinetics of Substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in Patients With Castration-resistant Prostate Cancer||Astellas Pharma Inc|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||June 2015|June 5, 2015|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911728||62038|
NCT01912300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1033|Nutritional Adaptations to Physical or Sedentary Activities in Youth|Nutritional Adaptation to Contemporary Sedentary Behaviors and Physical Exercise in Youth: Effect of Weight Status||Université Blaise Pascal, Clermont-Ferrand|No|Withdrawn|July 2013|July 2014|Anticipated|July 2013|Actual|N/A|Interventional|N/A|2||Actual|0|||Male|12 Years|15 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01912300||61995|
NCT01912586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanFang2013035|Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer|A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer||Nanfang Hospital of Southern Medical University|No|Completed|May 2013|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Male|18 Years|70 Years|No|||February 2014|June 17, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01912586||61973|
NCT01908660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEG-HEP-2007|Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions|Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.||Valme University Hospital|No|Completed|January 2007|October 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|18 Years|N/A|No|Probability Sample|Patients seen at the infectious disease unit of a terciary care center|November 2015|November 10, 2015|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01908660|1 Year|62272|
NCT01908647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0180|Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI|Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI||Van Boven, Robert W., M.D.|No|Recruiting|April 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|45 Years|No|||April 2014|April 24, 2014|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01908647||62273|
NCT01909141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fem2013|Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS|Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome||Cairo University||Completed|August 2013|April 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|40 Years|No|||September 2015|September 30, 2015|July 15, 2013||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01909141||62235|
NCT01909388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAPROST|Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy|Phase II Study of Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion Real Time High Dose Rate (HDR) Brachytherapy in Patients With Intermediate and High Risk Prostate Cancer|BRAPROST|Hospital de Cruces|Yes|Recruiting|June 2013|July 2016|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||July 2013|July 23, 2013|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01909388||62217|
NCT01910350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-256|Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening|Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening|KinKeeper|Michigan State University|Yes|Completed|July 2010|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|516|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01910350||62144|
NCT01910363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1A2BONT|Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke|Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3|A2NTX|University of Tokushima|No|Active, not recruiting|July 2013|||January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|79 Years|No|||January 2014|January 9, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01910363||62143|
NCT01939964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012|Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles|A Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Rena ™ Activation Mist on Facial Skin Wrinkles.||California Allergy and Asthma Medical Group, Inc.|No|Not yet recruiting|November 2013|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 7, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01939964||59876|
NCT01939977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-SPAI-11-24|Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.|Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.|PARIDOINAL2013|Fundación Senefro|No|Active, not recruiting|January 2014|December 2015|Anticipated|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|August 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01939977||59875|
NCT01940263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGU-02|Purified Anthocyanin and Nonalcoholic Fatty Liver Disease|Effects of Purified Anthocyanin on Oxidative and Inflammatory Markers in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial||Shaoguan University|Yes|Completed|June 2013|June 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|65 Years|No|||July 2014|July 31, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01940263||59853|
NCT01940536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13083|The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures|The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures: A Prospective, Double-Blind, Randomized Controlled Trial||Hospital for Special Surgery, New York|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01940536||59832|
NCT01940549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-TH-334-CTIL|Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder|Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|No|||September 2013|September 8, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01940549||59831|
NCT01911858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-1204|Askina Calgitrol Paste Burns|Non-controlled Prospective Cohort Study of the Use of Askina® Calgitrol® Paste on III Degree Burns in Adults||BBraun Medical SAS|No|Withdrawn|April 2013|||December 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01911858||62028|
NCT01910272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD #120980|Brain Radiation Exposure and Attenuation During Invasive Cardiology Procedures|Brain Radiation Exposure and Attenuation During Invasive Cardiology Procedures.|BRAIN|University of California, San Diego|No|Completed|January 2013|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We plan to enroll up to 12 invasive cardiologists routinely performing cardiac        catheterization procedures at the UCSD Medical Center, La Jolla campus. We plan to monitor        radiation exposure in at least 50 cases for each operator.|July 2013|July 26, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01910272||62150|
NCT01910558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-043|The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion|The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion|FAT ABSORBER|Pennington Biomedical Research Center|Yes|Terminated|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|July 22, 2013||No|Cancelled by Sponsor|No||https://clinicaltrials.gov/show/NCT01910558||62128|
NCT01910844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJP 4.2 - META2|Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes||META2|Centre Jean Perrin|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01910844||62106|
NCT01911741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0010|A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects|A Phase I, Single-center, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and Tablet Formulations of Enzalutamide Following a Single 160 mg Dose Under Fasted Conditions in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|55|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01911741||62037|
NCT01911754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811202|Japanese Pediatric H5N1 Vaccine Study|An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years||Nanotherapeutics, Inc.|Yes|Completed|August 2013|April 2014|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||May 2014|October 7, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01911754||62036|
NCT01911377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Botox 2013|Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS|The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis||University of Manitoba|No|Terminated|October 2013|August 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|No|||October 2015|October 1, 2015|July 25, 2013|Yes|Yes|12 SCI volunteers completed the study. As the data analysis was negative, the decision was    made not to proceed with MS recruitment.|No||https://clinicaltrials.gov/show/NCT01911377||62065|
NCT01911975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFN-Lacosamide|Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy|Efficacy, Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy: a Randomized, Double-blind, Placebo Controlled, Crossover Trial||Academisch Ziekenhuis Maastricht|Yes|Recruiting|September 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|80 Years|No|||January 2016|January 3, 2016|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01911975||62019|
NCT01912599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2514|Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma|Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma||University of North Carolina, Chapel Hill|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01912599||61972|
NCT01912326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B01- 408|Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation|Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation|PAFOS|St. Jude Medical|No|Completed|July 2002|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|249|||Both|19 Years|N/A|No|||December 2014|December 17, 2014|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01912326||61993|
NCT01908413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-427-101|Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma|A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered in Subjects With Advanced and Refractory Solid Tumors or Lymphoma||Curis, Inc.|No|Recruiting|July 2013|February 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01908413||62290|
NCT01908439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-9|A Simple Method to Determine the Reflex Latency During WBV|A Simple Method to Determine the Reflex Latency During Whole Body Vibration||Bagcilar Training and Research Hospital|No|Completed|August 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 2, 2013|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01908439||62288|
NCT01908920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRVOST|Osteopathic Manipulative Treatment Effects on High Frequency Parameters in Healthy Subjects|||European Institute for Evidence Based Osteopathic Medicine|Yes|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 8, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01908920||62252|
NCT01958138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1995-Ane-ERC-11|Isoflurane Versus Propofol for Removal of LMA in Children|Isoflurane Versus Small Dose Propofol With Isoflurane for Removal of Laryngeal Mask Airway in Anesthetized Children||Aga Khan University|Yes|Enrolling by invitation|April 2012|December 2013|Anticipated|November 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01958138||58479|
NCT01958437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1381-P|Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation|Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation||VA Office of Research and Development|No|Recruiting|October 2013|October 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|88 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01958437||58456|
NCT01958151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-306-12|Pre-procedural Anxiety and Sedation.|Does Pre-procedural Anxiety Affect the Consumption of Sedatives During Colonoscopy?||Ankara University|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|75 healthy patients undergoing elective colonoscopies as a screening test.|October 2013|October 8, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01958151|1 Day|58478|
NCT01958476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032889-01A1|Improving Outcomes in Neonatal Abstinence Syndrome|Improving Outcomes in Neonatal Abstinence Syndrome||Tufts Medical Center|Yes|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|N/A|N/A|No|||February 2016|February 23, 2016|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958476||58453|
NCT01948349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAOF 49743|Impact of Bracket Design and Oral Hygiene Maintenance on Halitosis in the Orthodontic Patient|Impact of Bracket Design and Oral Hygiene Maintenance on Halitosis in the Orthodontic Patient||University of Connecticut Health Center|Yes|Active, not recruiting|October 2012|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|40|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948349||59231|
NCT01948362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVG001N|Sulforadex in Healthy Volunteers SAD|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects||Evgen Pharma|Yes|Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01948362||59230|
NCT01947764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH099747-01|Patient-Centered Disclosure Intervention for HIV-Infected Children|Patient-Centered Disclosure Intervention for HIV-Infected Children|HADITHI|Indiana University|No|Recruiting|August 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Both|10 Years|15 Years|No|||March 2015|March 19, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947764||59276|
NCT01947777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-11|Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145|A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects|DDI|Infinity Pharmaceuticals, Inc.|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947777||59275|
NCT01948050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038-08|Pilot Study of Transcranial Stimulation (tDCS)to Relieve Neuropathic Pain in Cancer Patients|Pilot Study on Safety and Efficacy of the Non-invasive Transcranial Stimulation (tDCS) to Relieve Neuropathic Pain in Cancer Patients||Beth Israel Medical Center|No|Completed|January 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|No|||June 2014|June 13, 2014|August 20, 2013|No|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01948050||59254|
NCT01948336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-200|The Effects of Dexmedetomidine on Early Stage Renal Functions in Pediatric Patients|Phase 4 THE EFFECTS OF DEXMEDETOMIDINE ON EARLY STAGE RENAL FUNCTIONS IN PEDIATRIC PATIENTS UNDERGOING CARDIAC ANGIOGRAPHY USING NON- IONIC CONTRAST MEDIA: A DOUBLE- BLIND, RANDOMIZED CLINICAL TRIAL||TC Erciyes University|No|Completed|April 2012|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|72 Months|No|||September 2013|September 18, 2013|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01948336||59232|
NCT01957462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP239|Investigation of Two Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy and Colostomy|Investigation of Two Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy and Colostomy||Coloplast A/S|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|31|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|August 6, 2013||No||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01957462||58531|
NCT01958021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2301|Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)|A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease|MONALEESA-2|Novartis|Yes|Active, not recruiting|December 2013|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|667|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958021||58488|
NCT01957969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.05.8004|French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence|French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence||Medtronic International Trading Sarl|No|Recruiting|September 2013|January 2019|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|286|||Both|18 Years|N/A|No|Non-Probability Sample|French subjects affected by fecal incontinence, indicated to sacral neuromodulation        therapy.|December 2015|December 11, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957969|15 Months|58492|
NCT01957982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-070|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2013|||||N/A|N/A|N/A||||||||||||||June 18, 2014|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957982||58491|
NCT01960127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LZPTMH2.0|Effects of Aerobic Training on Exercise Capacity in Patients With Advanced Cirrhosis 2|Effects of Aerobic Training on Exercise Capacity in Patients With Advanced Cirrhosis 2||University of Alberta|No|Recruiting|October 2013|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||October 2013|October 9, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960127||58326|
NCT01960140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14606|A Study of Baricitinib and Simvastatin in Healthy Participants|Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01960140||58325|
NCT01960413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01FD004117|Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia|Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)||Vanderbilt University|Yes|Recruiting|November 2013|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|63|||Both|16 Years|70 Years|No|||July 2015|July 8, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960413||58304|
NCT01957111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-50802|Metabolomics of Insomnia-Related Hyperarousal|Metabolomics of Insomnia-Related Hyperarousal||University of Pennsylvania|No|Recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with primary insomnia (n=15) and matched good sleepers (n=15)|September 2013|June 10, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01957111||58558|
NCT01956825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC13023-13CTIL|The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver|THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease||Meir Medical Center|Yes|Not yet recruiting|January 2014|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2013|October 7, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01956825||58580|
NCT01957033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-569|Responses of People With Neck Pain Being Treated With Varying Doses of Manual Therapy: A Pilot Study|Clinical and Biological Responses of People With Neck Pain Being Treated With Varying Doses of Manual Therapy: A Pilot Study||McMaster University|No|Active, not recruiting|October 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|9||Actual|10|||Both|21 Years|N/A|No|||January 2016|January 27, 2016|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01957033||58564|
NCT01957358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR2013|Resolving Grief After Spinal Cord Injury|Resolving Grief and Moving On After Spinal Cord Injury||University of Manitoba|No|Recruiting|October 2013|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|8|||Both|N/A|N/A|No|||January 2016|January 14, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01957358||58539|
NCT01957605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5673|Mean Systemic Pressure Measurement During Prone Position Surgery|Study of Hemodynamic Variations During Prone Position Surgery: Measurement of Mean Systemic Pressure and Venous Return Resistance||University Hospital, Strasbourg, France|No|Recruiting|December 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patient scheduled for neurosurgery in the prone position|September 2015|September 29, 2015|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01957605||58520|
NCT01957618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110057RC|The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy|The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy|CTEAM|National Taiwan University Hospital|Yes|Enrolling by invitation|October 2011|December 2021|Anticipated|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|20 Years|N/A|No|Non-Probability Sample|from hospitals|October 2013|October 1, 2013|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01957618||58519|
NCT01958177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC/BMCA/2013//01|Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia|Clinical Study to Evaluate the Safety and Efficacy of Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Cerebellar Ataxia .It is Self Funded (Patients' Own Funding) Clinical Trial||Chaitanya Hospital, Pune|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01958177||58476|
NCT01958489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14625|A Study of Evacetrapib in Japanese and Non-Japanese Participants|Effect of Evacetrapib on the Pharmacokinetics of Pravastatin in Healthy Japanese and Non-Japanese Subjects||Eli Lilly and Company|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01958489||58452|
NCT01958775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-07-0394|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like||University Health Network, Toronto|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958775||58430|
NCT01948661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL 02|Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma|Randomized Window of Opportunity Trial of Anthocyanin Extract and Phospholipid Curcumin in Subjects With Colorectal Adenoma|MIRACOL|Ente Ospedaliero Ospedali Galliera|Yes|Recruiting|March 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 3, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948661||59207|
NCT01948921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalinTCGH-hsieh-2013-3|Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.|Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.||Dalin Tzu Chi General Hospital|Yes|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|110|||Both|20 Years|80 Years|No|||September 2013|September 19, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948921||59187|
NCT01948622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mulungu-401-2011|Anxiety Control by Erythrina Mulungu|Anxiety Control by Using Erythrina Mulungu in Mandibular Third Molars Extraction||Universidade Federal de Sergipe|No|Completed|January 2012|November 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01948622||59210|
NCT01948635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_45|Impact of Tracheal Cuff Shape on Microaspiration in Intensive Care Units|Impact of Tracheal Cuff Shape on Microaspiration in Intensive Care Units|BestCuff|University Hospital, Lille|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01948635||59209|
NCT01948908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL7510|Volumes of Administration for Intranasal Midazolam|Optimal Volumes of Administration for Intranasal Midazolam in Children||Columbia University|Yes|Completed|June 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|1 Year|7 Years|No|||September 2015|September 17, 2015|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01948908||59188|
NCT01949285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETI201309|Transcutaneous Electrical Spinal Cord Stimulation for Lower Limbs|A Theranostic Tool to Assess and Enable Spared Spinal Motor Function After SCI||NeuroEnabling Technologies, Inc.|No|Active, not recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949285||59159|
NCT01958294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM-2011-01|The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)|The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)|LOTUS|Silk Road Medical|Yes|Completed|August 2011|August 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|N/A|No|||November 2015|November 16, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958294||58467|
NCT01950104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVISEV-005VINCI|Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases|Comparative Study Between Day 3 Embryo Biopsy and Blastocyst Biopsy in Preimplantation Genetic Screening Cases|VINCI|IVI Sevilla|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Female|18 Years|49 Years|No|||August 2015|August 24, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950104||59096|
NCT01958307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEL-1309--2500-S|Healthy Living in Pregnancy|Healthy Living in Pregnancy|GeLiS|Technische Universität München|No|Recruiting|September 2013|September 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2500|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958307||58466|
NCT01960426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1208|Evaluation of Health Costs and Resource Utilization|A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.|Test-No Test|University of Western Ontario, Canada|No|Terminated|April 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01960426||58303|
NCT01960439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1302|Responsiveness of Endoscopic Evaluation in UC|Responsiveness of Endoscopic Evaluation of Ulcerative Colitis Using a Central Reader Based Image Management System||University of Western Ontario, Canada|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|194|||Both|18 Years|75 Years|No|Non-Probability Sample|The study population contained a broad spectrum of endoscopic and clinical activity. At        entry patients had active disease defined by the presence of a modified UCDAI score        between 4 and 10.|December 2015|December 1, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01960439||58302|
NCT01956604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000815-26|The Oslo Study of Clonidine in Elderly Patients With Delirium||LUCID|Oslo University Hospital|Yes|Recruiting|April 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||October 2015|October 21, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01956604||58597|
NCT01957085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Undiagnosed HCV|Undiagnosed Hepatitis C Infection in an Urban Hospital|Incidence of Undiagnosed Hepatitis C Infection in an Urban Hospital||Temple University|No|Completed|June 2014|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|366|Samples Without DNA|All leftover sera and plasma will be banked at -70 degrees Celsius in a secure laboratory      for potential future research activities|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients admitted to Temple University Hospital on the study dates|February 2016|February 26, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01957085||58560|
NCT01957046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT4501|A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).|A Single-arm, Open-label, Multicentre, Non-randomised, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy for the Reversal of Opioid-induced Constipation in Subjects Suffering From Malignant or Non-malignant Pain That Requires Around-the-clock Opioid Therapy||Mundipharma Research GmbH & Co KG|No|Completed|October 2013|February 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01957046||58563|
NCT01957059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO053-CLIN-01|A Phase I/II Study of PRO053 in Subjects With Duchenne Muscular Dystrophy (DMD)|A Phase I/II, Open-label, Dose Escalating With 48 Week Treatment Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of PRO053 in Subjects With Duchenne Muscular Dystrophy.||BioMarin Pharmaceutical|Yes|Active, not recruiting|June 2013|November 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Male|5 Years|18 Years|No|||June 2015|June 3, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01957059||58562|
NCT01957371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01735|Mindful Yoga Therapy for Veterans With PTSD and Pain|Mindful Yoga Therapy as an Adjunctive Treatment for Veterans With PTSD and Pain||VA Connecticut Healthcare System|No|Withdrawn|September 2013|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|45 Years|No|||December 2014|December 8, 2014|September 29, 2013||No|Recruitment difficulty|No||https://clinicaltrials.gov/show/NCT01957371||58538|
NCT01957904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-015|ArterX Safety and Efficacy Study for Cardiac Indications|Prospective, Multi-Center, Open-Label, Post-Market ArterX® Safety and Efficacy Study Protocol for Cardiac Indications||Tenaxis Medical, Inc.|No|Completed|June 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01957904||58497|
NCT01957865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH100940-01|Real-Time Antiretroviral Therapy Adherence Intervention in Uganda|Development of a Real-Time Antiretroviral Therapy Adherence Intervention in Uganda||Massachusetts General Hospital|Yes|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|63|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01957865||58500|
NCT01957878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC10VAC02|Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL|A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL|RHEIA-VAC|Genticel|Yes|Active, not recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Female|25 Years|50 Years|No|||November 2014|November 20, 2014|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957878||58499|
NCT01958502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910359|Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold|||Emdadi Kamyab Hospital|Yes|Recruiting|July 2013|November 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01958502||58451|
NCT01959347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN-26P01|Combined Treatment for Mixed Incontinence|Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence (ESTEEM)|ESTEEM|NICHD Pelvic Floor Disorders Network|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|472|||Female|21 Years|N/A|No|||November 2015|November 30, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959347||58386|
NCT01959906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRM<1mm|Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.|Prognostic Value of a Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.||University Hospital, Gasthuisberg|No|Active, not recruiting|July 2013|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|923|||Both|18 Years|95 Years|No|Non-Probability Sample|923 consecutive pT3 patients operated between january 1990 and june 2013|October 2013|October 9, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959906||58343|
NCT01959919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831081|Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO|Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo||Pfizer|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Male|18 Years|65 Years|No|Non-Probability Sample|Approximately 200 patients with Hemophilia A (all severity levels) will be enrolled in        approximately 20 centers in Italy.|March 2016|March 24, 2016|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959919||58342|
NCT01948947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1359-P|Improving Functions in MTBI Patients With Headache by rTMS|Improving Functions in MTBI Patients With Headache by rTMS||VA Office of Research and Development|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|50 Years|No|||January 2016|January 21, 2016|September 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948947||59185|
NCT01948960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201301|Influence of Exceptional Patient Characteristics on Everolimus Exposure|Influence of Exceptional Patient Characteristics on Everolimus Exposure|INPRES|Radboud University|No|Recruiting|August 2013|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|75|||Female|18 Years|N/A|No|||May 2015|May 8, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01948960||59184|
NCT01948934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA/GH|Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds|Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Recruiting|June 2012|June 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2014|March 11, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948934||59186|
NCT01949298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IE-10-305-3|Immediate vs Delayed Loading of Two Implants Supporting a Mandibular Over Denture|Immediate vs Delayed Loading of Two Implants Supporting a Locator Retained Mandibular Overdenture - A Randomized Controlled Study||University of Connecticut Health Center|No|Completed|July 2010|November 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949298||59158|
NCT01949506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00020337|(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas|Pilot Study Evaluating Stereotactic Body Radiation Therapy (SBRT) and Adaptive Radiation Therapy (ART) for Pulmonary Metastases From Soft Tissue Sarcomas||Medical College of Wisconsin|Yes|Recruiting|September 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01949506||59142|
NCT01950364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25005|A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma|A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin||Millennium Pharmaceuticals, Inc.|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|September 23, 2013|No|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01950364||59076|
NCT01956851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE/REF/IR/KPT/03/13|Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus|Hospital Based Pilot Study: Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus||Ganga Care Hospital, Nagpur|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|55|||Both|25 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients entering medical and diabetes out patient clinics|October 2015|October 24, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956851||58578|
NCT01957917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01MH094246|Comparing Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania|Comparing Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania||University of California, Berkeley|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|785|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957917||58496|
NCT01957930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-2012|Intensive Insulin Treatment and Ischemic Foot Ulcer|Intensified Insulin Treatment and Skin Microcirculation; Its Relation to Ischemic Foot Ulcer in Patients With Type 1 Diabetes Mellitus: A Long-term Follow-up Study||Karolinska Institutet|No|Completed|January 1984|June 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|From the original from the Stockholm Diabetes Interventional Study (SDIS) 96 patients were        asked to take part in this follow up study.|November 2015|November 16, 2015|October 4, 2013|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01957930||58495|
NCT01957397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP230|Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy|Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy||Coloplast A/S|No|Completed|October 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|October 1, 2013||No||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01957397||58536|
NCT01957384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP221|Investigation of the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care|An Open-labelled, Randomized, Controlled, Comparative, Single Country (Denmark), Explorative, Cross-over Study Investigating the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care 1-piece Open Ostomy Appliances in 25 Subjects With Ileostomy||Coloplast A/S|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|25|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|February 22, 2013||No||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01957384||58537|
NCT01957631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJB88AK|Comparing Steroid Injections and Platelet Rich Plasma Injections in the Treatment of Plantar Fasciitis|Steroid Injections vs. Platelet Rich Plasma Injections in Patients With Plantar Fasciitis: A Comparison of Clinical and Ultrasound Findings||King Hamad University Hospital, Bahrain|Yes|Recruiting|June 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|October 7, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957631||58518|
NCT01957644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.33|Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML|An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Not Candidates for Haematopoetic Stem Cell Transplant||Boehringer Ingelheim||Recruiting|November 2013|November 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|88|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 1, 2013||||No||https://clinicaltrials.gov/show/NCT01957644||58517|
NCT01958788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-69066-620|Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder|Challenging Uncertainty: Behavioural Experiments in the Treatment of Generalized Anxiety Disorder||Concordia University|Yes|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 7, 2013||No||No|December 19, 2015|https://clinicaltrials.gov/show/NCT01958788||58429|Small sample size due to clinical case replication series design. This reduced statistical power and types of statistical analyses that could be conducted. Participants were homogeneous in ethnicity and language, which may limit generalizability.
NCT01957891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP2552|Hypoxia at Multiple Wavelengths of Light|Effect of Induced Hypoxia at Multiple Wavelengths||Nonin Medical, Inc|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|March 2014|March 6, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01957891||58498|
NCT01958164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.323|Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion|A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device||Boehringer Ingelheim||Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||April 2015|April 16, 2015|October 1, 2013||||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01958164||58477|The study was stopped prematurely due to slow recruitment of patients.
NCT01959607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-PK-02-JP|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Gum||Philip Morris Products S.A.|No|Completed|July 2013|April 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|65|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|October 8, 2013||No||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01959607||58366|
NCT01959620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063758|Optimal Dose of Early Intervention to Prevent PTSD|Optimal Dose of Early Intervention to Prevent PTSD||Emory University|Yes|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01959620||58365|
NCT01959633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEMUPLINT|Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation|Phase I-II Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation|VEMUPLINT|Fondazione Melanoma Onlus|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01959633||58364|
NCT01960504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1209|First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)|BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II|BIOSOLVE-II|Biotronik AG|Yes|Active, not recruiting|October 2013|February 2018|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|121|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01960504||58297|
NCT01956669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116731|Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors|A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors||Novartis|No|Recruiting|October 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|154|||Both|1 Year|18 Years|No|||March 2016|March 11, 2016|August 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01956669||58592|
NCT01949311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1225|Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis|An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials||Regeneron Pharmaceuticals|No|Enrolling by invitation|October 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949311||59157|
NCT01949519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101681|Docetaxel and Lycopene in Metastatic Prostate Cancer|A Phase I Study of Docetaxel Plus Synthetic Lycopene in Metastatic Prostate Cancer Patients With Biochemical or Clinical Relapse||Medical University of South Carolina|Yes|Active, not recruiting|November 2013|||June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||July 2015|October 1, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949519||59141|
NCT01949753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4398|Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder|Influence of Pregnenolone on Distress and Autonomic Parameters During Cognitive-behavioral Exposure Therapy in Patients With Obsessive-compulsive Disorder|P-EX|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|September 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949753||59123|
NCT01949766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12070385.2|Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease|Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease||University of Pittsburgh||No longer available||||||N/A|Expanded Access|N/A|||||||Both|6 Months|N/A||||September 2013|September 20, 2013|September 20, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01949766||59122|
NCT01957189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200254|This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples|An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers||GlaxoSmithKline|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957189||58552|
NCT01950624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913201|DS-Connect {TM}: The Down Syndrome Registry|DS-Connect [TM]: The Down Syndrome Registry||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|N/A|||Anticipated|100000|||Both|N/A|N/A|No|||June 2015|June 12, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950624||59056|
NCT01950637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAPP2|GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus|GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|4000|||Both|N/A|N/A|No|Probability Sample|Insulin treated patients with type 2 diabetes, and HCPs involved in the treatment,        management of diabetes and care of patients with type 2 diabetes.|January 2014|January 15, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950637||59055|
NCT01950910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-Neurology-WBC Tissue Bank|Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)|Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).|WBC|Carolinas Healthcare System|Yes|Recruiting|June 2007|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|blood samples (serum and protein/RNA/DNA from blood cells) and CSF|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ALS patients in the Charlotte, NC, area.|July 2014|July 2, 2014|March 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950910||59034|
NCT01951170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28703|An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis|An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)||Hoffmann-La Roche||Completed|November 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951170||59014|
NCT01956370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCZ/A/1628 Comparative study|Comparing the PrePex™ Device to Surgical MC for Rapid Scale Up of MC in Resource Limited Setting|Phase II - Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult Male Circumcision Programs in Zimbabwe (Comparative Study)||Ministry of Health and Child Welfare, Zimbabwe|Yes|Completed|November 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 6, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01956370||58615|
NCT01956617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1328-3|The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided "Shamrock" Lumbar Plexus Block|The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided "Shamrock" Lumbar Plexus Block||Oslo University Hospital|No|Completed|October 2013|||May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Anticipated|30|||Both|18 Years|70 Years|No|||June 2014|June 19, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01956617||58596|
NCT01956630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-DC/CIK-Leukemia|Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT|Clinical Study of Genetically Modified Dendritic Cells Combining to Cytokine-Induced Killer Cells for Patients With Relapse Acute Leukemia After Allo-HSCT||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|8 Years|61 Years|No|||February 2016|February 18, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01956630||58595|
NCT01927042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59093005|Effectiveness of the ECHOs Approach for Patients With Eating Disorders and Their Carers|Effectiveness of the Expert Carers Helping Others (ECHOs) Approach for Patients With Eating Disorders and Their Carers|ECHO|Nova Scotia Health Authority|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|17 Years|N/A|No|||December 2015|December 7, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927042||60865|
NCT01927328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12GA029|Iron Replacement in Oesophagogastric Neoplasia|An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma|IRON|Nottingham University Hospitals NHS Trust|No|Recruiting|August 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01927328||60843|
NCT01927341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2116|Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors|A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer||Array BioPharma||Completed|November 2013|||October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|August 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927341||60842|
NCT01958229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910027M|Efficacy Study of Telbivudine in Chronic Hepatitis B Patients|A Multicenter Open-label, Observational Study of Telbivudine Treatment Outcome in Patients With Chronic B Virus Infection||National Taiwan University Hospital|Yes|Completed|December 2009|April 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|Samples With DNA|10 c.c whole blood|Both|18 Years|65 Years|No|Probability Sample|Chronic hepatitis B patients without cirrhosis|October 2013|October 8, 2013|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01958229||58472|
NCT01957657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.32|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial||Boehringer Ingelheim||Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|October 1, 2013||||No||https://clinicaltrials.gov/show/NCT01957657||58516|
NCT01958203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122012-11|Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.|Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.|VTE|Ministry of Health, United Arab Emirates||Completed|January 2013|September 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|386|||Both|18 Years|N/A|No|Non-Probability Sample|The targe sample is paients in critical care wards and orthopaedic surgery patients. All        patients will be screened at discharge. Those who fulfill the inclusion/exclusion criteria        will go on to have a thromboembolism risk assessment using the CapriniRisk Assessment        Model. Those who have a score > 1 will be included for assessment of their VTE prophylaxis        (from medical records). Approximately 60 patients are admitted into critical care units        and 40 general and orthopaedic surgical patients are admitted to the surgical wards per        month, giving a total sample of around 400 patients.|October 2013|October 8, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01958203||58474|
NCT01958216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0008|in Vivo TICE (TransIntestinal Cholesterol Excretion)|In Vivo TICE (TransIntestinal Cholesterol Excretion) Measurement in Bile Duct Diverted Patients|in vivoTICE|Nantes University Hospital|Yes|Recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|N/A|No|||September 2013|October 8, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01958216||58473|
NCT01958814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO11-PD / BANNISTER|Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.|Controlled Randomized Double-blind Study Comparing Salbutamol and Placebo Via Aerosol in Chronic Obstructive Respiratory Insufficiency in Exacerbartion Treated With Noninvasive Ventilation|BANNISTER|University Hospital, Tours|No|Recruiting|February 2012|August 2015|Anticipated|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958814||58427|
NCT01958190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOL-III-1|Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus|A Multicenter Randomized in Primary Livertransplantation Comparing Longterm Renal Function in Recipients Treated With Tacrolimus Alone and Recipients Treated With a Combination Tacrolimus and Sirolimus||Foundation for Liver Research|No|Recruiting|January 2011|June 2020|Anticipated|December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958190||58475|
NCT01959360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100889|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term ..........|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term .........||Norwegian University of Science and Technology|No|Active, not recruiting|August 2011|June 2015|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|25 Years|70 Years|No|||May 2015|May 12, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959360||58385|
NCT01929278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114729|W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers|A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers||GlaxoSmithKline|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929278||60694|
NCT01929291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115374|Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea|Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea||GlaxoSmithKline||Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|673|||Both|11 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pre-adolescents, adolescents and adults who receive Boostrix as a part of routine practice        at a private clinic or hospital.|October 2015|October 29, 2015|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929291||60693|
NCT01956682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Bari|Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying|Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying||University of Bari|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|N/A|5 Months|Accepts Healthy Volunteers|||March 2015|March 31, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01956682||58591|
NCT01957202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200286|A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)|A Randomised, Double-blind, Placebo-controlled, 3 Way, Incomplete Block Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Once Daily Single and Repeat Doses of Intranasal Fluticasone Furoate/Levocabastine Fixed Dose Combination (FDC) Relative to Levocabastine and Fluticasone Furoate Alone on the Onset and Magnitude of Symptoms of Rhinitis in an Allergen Challenge Chamber||GlaxoSmithKline|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|65 Years|No|||October 2014|January 26, 2015|October 4, 2013||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01957202||58551|
NCT01957449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-103|Propranolol in Severely Burned Children|Safety and Efficacy of Propranolol in Severely Burned Children||The University of Texas Medical Branch, Galveston|Yes|Recruiting|December 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|18 Years|No|||February 2016|March 9, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957449||58532|
NCT01951521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46051.041.13|RECTAL BOOST Study|RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation BOOST in Locally Advanced Rectal Cancer|RECTAL BOOST|UMC Utrecht|Yes|Recruiting|September 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01951521||58988|
NCT01926574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1241-1|Evaluation of Return to Work Rehabilitation|Evaluation of Inpatient-return- To-work, Multicomponent, Rehabilitation Programs for Persons Temporary Out of Work With Musculoskeletal-, Unspecific-, and/or Common Mental Health Disorders; Randomized Controlled Trial||Norwegian University of Science and Technology|No|Active, not recruiting|January 2013|December 2020|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|300|||Both|18 Years|60 Years|No|||August 2015|August 20, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926574||60901|
NCT01957670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM001|Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients|Pilot, Open-label, Single-Arm Study Designed to Clinically Evaluate Various Lacrima Medical Device Prototypes in Adult Patients With Dry Eye Syndrome||Lacrima Medical LTD|No|Withdrawn|February 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|No|||March 2016|March 6, 2016|September 30, 2013||No|Sponsor decision due to change the clinical indication to Chronic Insomnia|No||https://clinicaltrials.gov/show/NCT01957670||58515|
NCT01926808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Longitudinal Vitamin D|Vitamin D Serum Concentrations & Supplementation in Children With Cerebral Palsy|Vitamin D Serum Concentrations and Vitamin D Supplementation in Children and Young Adults With Cerebral Palsy||Akron Children's Hospital|No|Completed|June 2013|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|115|||Both|N/A|50 Years|No|Non-Probability Sample|Severely cognitively impaired, non-mobile children and young adults who are residents at        long-term care facility|January 2016|January 28, 2016|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926808||60883|
NCT01927627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12812|Enzalutamide in Patients With High-risk Prostate Cancer|A Phase 2 Study of Enzalutamide in Patients With High-risk Prostate Cancer Who Have Undergone Local Definitive Therapy With Radical Prostatectomy||Case Comprehensive Cancer Center|Yes|Active, not recruiting|November 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||February 2016|February 4, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927627||60820|
NCT01927913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-204|Treatment of Iron Overload Requiring Chelation Therapy|A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade® (Deferasirox) for Treatment of Chronic Transfusional Iron Overload||Shire|Yes|Withdrawn|July 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|August 20, 2013|Yes|Yes|This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|No||https://clinicaltrials.gov/show/NCT01927913||60799|
NCT01927926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/5/2008|The Effects of Consuming Whey Protein Polydextrose Snacks on Appetite and Energy Intake|The Effects of Consuming Between- Meal, High Protein Polydextrose Containing Snack Bars on Subjective Satiety, Energy Intake and Metabolic Responses.||University of Nottingham|No|Completed|May 2008|October 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01927926||60798|
NCT01927614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA_CAV|Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy|Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy||Nova Scotia Health Authority|No|Recruiting|September 2014|September 2023|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Transplant Patients|August 2013|February 2, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01927614||60821|
NCT01927900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO1-2013|The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers|THE EFFECTS OF HUMAN-MILK-OLIGOSACCHARIDES ON THE FAECAL MICROBIOTA AND ON GASTROINTESTINAL SYMPTOMS IN HEALTHY VOLUNTEERS A PARALLEL, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED DOSE FINDING STUDY|HMO-VOL|Glycom A/S|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|10||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01927900||60800|
NCT01928459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398X2102|Phase 1b Trial of BGJ398/BYL719 in Solid Tumors|A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors||Novartis|No|Recruiting|October 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928459||60757|
NCT01959087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111112|Single Port Colic Laparoscopic Surgery|Single Port Colic Laparoscopic Surgery - THE TRUE TRIAL|TRUE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959087||58406|
NCT01959334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG105|Evaluate the Immunogenicity of a Novel Glucagon Formulation|A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes||Locemia Solutions ULC|No|Completed|September 2013|January 2015|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|75|||Both|18 Years|70 Years|No|||July 2015|July 7, 2015|October 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959334||58387|
NCT01928966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWU-1PS|Effect of Pumpkin Seeds on the Dietary Fatty Acid Intake and Blood Pressure in Women|Effect of Pumpkin Seeds on the Dietary Fatty Acid Intake and Blood Pressure in Women|PSS1|Texas Woman's University|Yes|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|May 11, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928966||60718|
NCT01929850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10409|Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women|Bariatric Surgery Plus Weight Watchers vs. Weight Watchers in Underserved Minorities: Randomized Controlled Cross-over Trial||University of California, San Francisco|No|Withdrawn||||October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|August 15, 2013||No|Scientific/feasibility approval required prior to IRB review|No||https://clinicaltrials.gov/show/NCT01929850||60650|
NCT01929863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200185|Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin|A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin||GlaxoSmithKline|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|30 Years|64 Years|No|||April 2014|April 24, 2014|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929863||60649|
NCT01956409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201056MIB|Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis|Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy||National Taiwan University Hospital|No|Active, not recruiting|September 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|20 Years|75 Years|No|||February 2016|February 3, 2016|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01956409||58612|
NCT01956422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE#382/2013|Continuous Positive Airway Pressure (CPAP) for Preventing Respiratory Failure After Laparoscopic Radical Prostatectomy|||Ospedale L. Sacco – Polo Universitario|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|70 Years|No|||July 2014|July 10, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956422||58611|
NCT01957215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202177|Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief|A Clinical Study to Assess the Efficacy of Pain Relief of Topical Indomethacin Patch Over Placebo in Ankle Sprain Patients||GlaxoSmithKline|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|65 Years|No|||April 2015|May 21, 2015|October 4, 2013||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01957215||58550|
NCT01956890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102011MB|18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging of the Breast|Integrative Diagnosis of 18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: a Pilot Study||National Taiwan University Hospital|No|Recruiting|June 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|20 Years|80 Years|No|||October 2013|October 13, 2013|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01956890||58575|
NCT01956903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/EICH2010|Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.|Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell|CSM/EICH2010|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||September 2013|September 30, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956903||58574|
NCT01957722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1220|NOVOCART®3D for Treatment of Articular Cartilage of the Knee|A Phase 3, Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART 3D Compared ot Microfracture in the Treatment of Articular Cartilage Defects|N3D|Aesculap Biologics, LLC|Yes|Recruiting|January 2014|August 2021|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|233|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|September 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957722||58511|
NCT01957735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-31510IV-04|BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors|A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors||Berg, LLC|No|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957735||58510|
NCT01927055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOH401|A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy|A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy||Chelsea Therapeutics|No|Terminated|November 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|August 16, 2013|Yes|Yes|Due to potential competition with a post-marketing study requested by FDA|No|November 2, 2015|https://clinicaltrials.gov/show/NCT01927055||60864|The study was prematurely terminated; the limited sample size precludes meaningful conclusions on the efficacy or safety of droxidopa in this study.
NCT01927068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1005|Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions|ILLUMENATE GLOBAL: Prospective, Single-Arm, Global Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery and/or Popliteal Lesions With a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon||Spectranetics Corporation|Yes|Active, not recruiting|July 2013|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|371|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01927068||60863|
NCT01927081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044446|Self-management Interventions for Advanced Breast Cancer|Self-management Interventions for Pain in Advanced Breast Cancer||Duke University|No|Recruiting|September 2014|March 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|21 Years|N/A|No|||January 2016|January 19, 2016|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927081||60862|
NCT01927354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112085RID|Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.|Observational Study on the Investigation of the Molecular Mechanism and Clinical Significance of the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.||National Taiwan University Hospital|Yes|Recruiting|December 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|tissue|Both|20 Years|80 Years|No|Probability Sample|Medical center|September 2013|September 13, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01927354||60841|
NCT01927367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-AF-2013|Integrated Management Program Advancing Community Treatment of Atrial Fibrillation|Integrated Management Program Advancing Community Treatment of Atrial Fibrillation|IMPACT-AF|Nova Scotia Health Authority|No|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927367||60840|
NCT01927939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207002MIB|18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.|The Effectiveness of 18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.||National Taiwan University Hospital|No|Recruiting|October 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|90 Years|No|Probability Sample|Histological proven breast cancer, with known metastatic bone lesion(s)|April 2014|April 13, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927939||60797|
NCT01928225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QHPV-RTC|Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL|A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women.||University of Witwatersrand, South Africa|Yes|Enrolling by invitation|September 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928225||60775|
NCT01928212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYF20130820|Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis|Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis||Wenzhou Medical University||Completed|August 2013|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|PD patients and healthy subjects were included and underwent OCT examinations|July 2014|July 16, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928212||60776|
NCT01928472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V131_01|Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years|Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years||Novartis|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|402|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|August 21, 2013|No|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01928472||60756|
NCT01958515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13158|Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation|Evaluation of Immunologic Responses in HPV-Associated Oropharyngeal Carcinoma Patients Receiving Chemoradiation Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|||March 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|100 Years|No|Non-Probability Sample|10 subjects with HPV-associated OPSCC (Oropharyngeal Squamous Cell Carcinoma) and 10        subjects with non-HPV associated HNSCC (Head and Neck Squamous Cell Carcinoma)|January 2016|January 14, 2016|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958515||58450|
NCT01958801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-033|Clinical Efficacy of Supraclavicular Block for Arthroscopic Shoulder Surgery|Comparison Between Ultrasound-guided Supraclavicular and Interscalene Brachial Plexus Blocks in the Patients Undergoing Arthroscopic Shoulder Surgery||Daegu Catholic University Medical Center|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|104|||Both|15 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 6, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958801||58428|
NCT01928979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16677|Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy|Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy|CLOT-AF|Bayer|No|Completed|May 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|160|||Both|18 Years|N/A|No|Probability Sample|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had        a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012.|December 2014|December 21, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01928979||60717|
NCT01928992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2011-003B|Pilot 3D Mammography Reader Study to Assess Breast Cancer Detection in 3D Versus 2D Digital Mammography|A Multi-reader, Multi-case, Controlled Clinical Trial to Evaluate the Fuji Film 3D Digital Mammography System Used in Conjunction With 2D Digital Mammography in the Detection of Breast Cancer / A Pilot Study|3DM|Fujifilm Medical Systems USA, Inc.|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with screening and diagnostic 3D or 2D mammography|August 2013|August 22, 2013|March 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928992||60716|
NCT01959100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120110|Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|ALLOZITHRO|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|February 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|460|||Both|16 Years|N/A|No|||August 2015|November 30, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959100||58405|
NCT01929564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR01/2012|Broccoli and Vascular Health Study|Broccoli and Vascular Health Study|BASH|Institute of Food Research|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|95|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 28, 2014|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01929564||60672|
NCT01929577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK09|A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects|A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Between Two ASP015K Tablet Formulations and the Food Effect on a New Tablet Formulation in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 13, 2013|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929577||60671|
NCT01956695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2012-05|Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma|Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)|REVRI|Institut Curie|Yes|Recruiting|September 2014|May 2018|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2013|September 5, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01956695||58590|
NCT01956929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004966|<Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.|Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.||Mayo Clinic|No|Active, not recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01956929||58572|
NCT01949038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391009|Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy|Comparison Between Sublingual and Oral Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy||Isfahan University of Medical Sciences|No|Completed|September 2011|January 2013|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|220|||Both|18 Years|65 Years|No|||October 2013|October 16, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01949038||59178|
NCT01949051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200285|A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis|A Randomized, Double-blind, Placebo Controlled, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of Levocabastine When Administered Once Daily or Twice Daily on the Symptoms of Rhinitis in an Allergen Challenge Chamber||GlaxoSmithKline|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|65 Years|No|||September 2014|September 18, 2014|September 19, 2013|Yes|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01949051||59177|
NCT01956916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF001|Probiotics in Cystic Fibrosis|Effects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled Trial||Federico II University|Yes|Completed|October 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|2 Years|18 Years|No|||September 2015|September 22, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01956916||58573|
NCT01949571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INPRF-01-MIR|Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.|Phase II Clinical Studies on Anti-addictive Therapeutic Effects of Mirtazapine in Human Subjects Addicted to Cocaine.|MADC|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|Yes|Completed|January 2007|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|64|||Both|14 Years|40 Years|No|||September 2013|September 20, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949571||59137|
NCT01949818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnslblzlzx2011-4|Treatment of Diffuse Large B Cell Lymphoma|A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma||Zhengzhou University|Yes|Recruiting|September 2012|September 2018|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|14 Years|70 Years|No|||December 2015|December 28, 2015|September 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949818||59118|
NCT01951196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGH-1-2013|Nocturnal Blood Pressure - Central and Peripheral 24-h Blood Pressure in Chronic Kidney Disease.|Nocturnal Blood Pressure in Chronic Kidney Disease, Obstructive Sleep Apnea and Healthy Subjects - Central and Peripheral 24-h Blood Pressure.|NOSA|Regional Hospital Holstebro|No|Active, not recruiting|October 2013|October 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|225|Samples Without DNA|Whole blood, serum, urine|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: Patients with chronic kidney disease, CKD stage III-IV. The patients is followed        for their kidney disease at Holstebro Regional Hospital, Denmark, Medical clinic, and the        are chosen to participate in the study because of this relation.        Group 2: Healthy subjects. They arerecruited through postings on public and private        companies as well as advertising in local medier.|October 2014|October 8, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951196||59012|
NCT01951209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX 000981-01|Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis|Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection||Philadelphia VA Medical Center|No|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951209||59011|
NCT01927380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE#371/2013|Autonomic Nervous System Modulation During Laparoscopic Prostatectomy|||Ospedale L. Sacco – Polo Universitario|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Human males undergoing elective laparoscopic prostatectomy|November 2014|November 3, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927380||60839|
NCT01927640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro19549|Dexmedetomidine for Reversal of Cocaine's Effects on the Heart|Phase 2B Study of Dexmedetomidine for the Reversal of Cocaine's Effects on Myocardial Perfusion||Cedars-Sinai Medical Center|No|Active, not recruiting|May 2013|August 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927640||60819|
NCT01927952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 43245|A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes|A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes||Milton S. Hershey Medical Center|No|Withdrawn|September 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|August 19, 2013||No|Study withdrawn from IRB approval process by PI|No||https://clinicaltrials.gov/show/NCT01927952||60796|
NCT01927965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minnelide™ 001|Study of Minnelide™ in Patients With Advanced GI Tumors|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.||Minneamrita Therapeutics LLC|No|Recruiting|August 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01927965||60795|
NCT01928238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/27|Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.|Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.|NAVA-VNI|University Hospital, Bordeaux|No|Completed|August 2012|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|N/A|No|||January 2015|June 24, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928238||60774|
NCT01928251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTW2013|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2013|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2013: A Prospective Study and a Randomized Controlled Trial||The University of Hong Kong|Yes|Completed|June 2013|June 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1143|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 26, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01928251||60773|
NCT01928485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6812|Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer|Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance||Case Comprehensive Cancer Center|Yes|Active, not recruiting|August 2013|August 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|45 Years|85 Years|No|||February 2016|February 11, 2016|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928485||60755|
NCT01928758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43804UG-P2|Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders|Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders||Milton S. Hershey Medical Center|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|280|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928758||60734|
NCT01928199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306111|Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant|A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant||Washington University School of Medicine|Yes|Recruiting|September 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928199||60777|
NCT01928732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|591|Comparative Effectiveness Research in Veterans With PTSD|CSP #591 - CERV-PTSD: Comparative Effectiveness Research in Veterans With PTSD|CERV-PTSD|VA Office of Research and Development|Yes|Recruiting|October 2014|July 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01928732||60736|
NCT01929590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|end-407-11-11-1|Low-volume Polyethylene Glycol Bowel Preparation for Colonoscopy|Efficacy and Tolerability of Low-volume Polyethylene Glycol (2 L) vs. Single- (4 L) vs. Split-dose (2L + 2L) of Polyethylene Glycol Bowel Preparation for Colonoscopy: a Randomized Clinical Trial.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|180|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01929590||60670|
NCT01929603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00008|Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours|A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|December 2013|December 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|99 Years|No|||January 2016|January 19, 2016|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929603||60669|
NCT01928719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43804UG-P1|Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status|Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status||Milton S. Hershey Medical Center|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928719||60737|
NCT01930110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-06|Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes|An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930110||60630|
NCT01949064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioGC1UHeidelberg|Use of Electromyography With Bio-Feedback for the Treatment of Craniomandibular Disorders|Anwendung Von Elektromyographie Mit Gleichzeitigem Bio-Feedback Zur Behandlung Von Craniomandibulären Dysfunktionen Und/Oder Bruxismus.||Heidelberg University|Yes|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|70 Years|No|||December 2014|December 2, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01949064||59176|
NCT01949584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS103-PRO-00002|Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring|Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring|SNORE|inSleep Technologies, LLC|Yes|Completed|August 2013|December 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949584||59136|
NCT01957475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP240|Investigation of Two Newly Developed 2-piece Convex Baseplates in Subjects With Ileostomy|Investigation of Two Newly Developed 2-piece Convex Baseplates in Subjects With Ileostomy||Coloplast A/S|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|August 6, 2013||No||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01957475||58530|
NCT01950923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99612|Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer|Sildenafil Prior to Robotic Partial Nephrectomy to Improve Postoperative Renal Function: A Randomized, Placebo-Controlled Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01950923||59033|
NCT01951547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMRG344/11HTM|The Periodontal Disease and Diabetes Mellitus Interrelationship Among Adult Malaysians|The Effect of Non-surgical Periodontal Therapy on Host Response and Microbiological Profile of Type 2 Diabetics With Periodontal Disease.||University of Malaya|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|70 Years|No|||September 2013|September 23, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01951547||58986|
NCT01927393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13270|Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer|Integration of Palliative Care Planning in Pancreatic and Ovarian Cancers||City of Hope Medical Center|Yes|Withdrawn|December 2014|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|21 Years|N/A|No|||December 2014|December 18, 2014|August 20, 2013||No|Study was not funded|No||https://clinicaltrials.gov/show/NCT01927393||60838|
NCT01927653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3628B|Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment|Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment||Chang Gung Memorial Hospital|Yes|Recruiting|January 2011|||July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|108|||Both|55 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patient will be recruited from the movement disorder clinics in ChangGung memorial        hospital LinKou. The healthy control will be recruited from the local community in northem        Taiwan.|August 2013|August 20, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927653||60818|
NCT01927666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE/0483|The Conversion of ENcapsulated GlucorAphanin, Gut Microbiota Phylogeny and gEnotype Study (ENGAGE)|A Human Intervention Trial Investigating the Conversion of Encapsulated Glucoraphanin to Isothiocyanates; and the Potential Link Between the Extent of the Conversion to an Individual's Gut Microbiota Phylogeny and Genotype.|ENGAGE|Institute of Food Research|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927666||60817|
NCT01928264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/13|Physical Activity in Insurance Medicine: Effects on Patients With Psychiatric Disorders|Physical Activity in Insurance Medicine: Effects on Psycho(-Physio-)Logical Functions, Capacity / Participation Skills, and the Ability to Work in Psychiatric Disorders|PhysActIV|University Hospital, Basel, Switzerland|No|Terminated|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|55 Years|No|||October 2015|October 14, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01928264||60772|
NCT01928511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK4031-398|Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy|SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL)|SWAP|National University Health System, Singapore|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|255|||Both|21 Years|70 Years|No|||March 2016|March 23, 2016|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928511||60753|
NCT01958905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|824338|Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children|Efficacy and Bio-availability of Artemether-Lumefantrine Fixed Combination in Severely Malnourished Children Compared to Non-severely Malnourished Children|MAL-NUT|Epicentre|Yes|Completed|November 2013|May 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|399|||Both|6 Months|5 Years|No|||December 2015|December 17, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958905||58420|
NCT01928498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.093 (2014-5032)|Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis|Evaluation of Drug Eluting Balloon for the Prevention of Hemodialysis Access Restenosis: A Prospective Randomized Trial (DEB Study)|DEB|Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|October 2013|March 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||July 2013|August 21, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928498||60754|
NCT01928771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00017|Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma||AstraZeneca|No|Active, not recruiting|September 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1134|||Both|12 Years|75 Years|No|||March 2016|March 16, 2016|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928771||60733|
NCT01928784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW-LBP-01|Radial Extracorporeal Shock Wave Therapy on Chronic Low Back Pain: a Prospective Controlled Study|Radial Extracorporeal Shock Wave Therapy on Chronic Low Back Pain: a Prospective Controlled Study||Beijing Jishuitan Hospital|Yes|Recruiting|June 2013|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|60 Years|No|||August 2013|August 22, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928784||60732|
NCT01928745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcidBasics001|Experimental Determination of Atot en Ka in the Critically Ill|Experimental Determination of Atot en Ka in the Critically Ill||VU University Medical Center|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples With DNA|24 mL of blood will be drawn|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Intensive Care unit of the VU University medical center|May 2014|May 19, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01928745||60735|
NCT01929005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-1440|Comprehensive Care Physician: Integrated Inpatient and Outpatient Care for Patients at High Risk of Hospitalization|Integrated Inpatient/Outpatient Care for Patients at High Risk of Hospitalization|CCP|University of Chicago|No|Recruiting|November 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01929005||60715|
NCT01929343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034925|Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving|Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving|LIDO|University of Texas Southwestern Medical Center|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|25 Years|60 Years|No|||September 2014|May 29, 2015|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929343||60689|
NCT01929304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818394b|DIVAs Perception: Difficult IV Access - Assessment of Patient Understanding|Assessment of Patient Understanding and Preference of Rescue Venous Access When Shown a Narrated Video Vignette Versus Traditional Paper Information Sheet|DIVAs 2|University of Pennsylvania|Yes|Enrolling by invitation|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|21 Years|N/A|No|Non-Probability Sample|Eligible for enrollment would be any hemodynamically stable adult 18 years of age or older        who is a HUP Emergency Department patient, able to provide informed consent, without        history of difficult intravenous access, and able to speak, read, hear, and speak English        fluently.|July 2013|August 27, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929304||60692|
NCT01929317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116991|A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.|A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.||GlaxoSmithKline|No|Completed|August 2013|June 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|20 Years|N/A|No|||January 2016|February 18, 2016|August 22, 2013||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01929317||60691|
NCT01929889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIL0522DUS03T|Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia|An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance||Northwestern University|No|Terminated|April 2012|October 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|55 Years|No|||June 2015|July 6, 2015|August 19, 2013|No|Yes|Low recruitment|No|May 19, 2015|https://clinicaltrials.gov/show/NCT01929889||60647|The most common reason for early termination was disagreement between the subjects’ self-reported diagnosis and the diagnosis obtained by the research psychiatrist.
NCT01950130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-1124|Prophylactic IABP in High-risk Patients Undergoing CABG|Prophylactic Preoperative Inatraaortic Balloon Pump (IABP) in High-risk Patients Undergoing Coronary Artery Bypass Surgery (CABG)||University of Giessen|Yes|Not yet recruiting|June 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01950130||59094|
NCT01956435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-151|Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study|Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study||Seton Healthcare Family|No|Active, not recruiting|March 2014|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956435||58610|
NCT01956448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110037|SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®|Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity® Coronary Stents in Non-selected Patients With Ischemic Heart Disease The SORT OUT VI Study*|SO VI|Aarhus University Hospital Skejby|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2800|||Both|N/A|N/A|No|||October 2013|October 6, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01956448||58609|
NCT01949350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6790|Hypohydration and Cardiorespiratory Function|Clinical Observational Study of the Effect of Hypohydration Upon Cardiorespiratory Function||Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949350||59154|
NCT01949363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0025|The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study|The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|September 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949363||59153|
NCT01951235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXL008-008|A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes|A Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Mellitus.||Poxel SA|No|Completed|January 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|315|||Both|18 Years|75 Years|No|||July 2015|July 24, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951235||59009|
NCT01951807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130909|Psychological Interventions for Gynecologic Cancer|Psychological Interventions for Gynecologic Cancer||Rutgers, The State University of New Jersey|Yes|Recruiting|June 2010|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|401|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01951807||58966|
NCT01927679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6031|Vitamin E Prevention of Visible Light Pigmentation|Effect of Vitamin E in the Prevention of Visible Light Induced Pigmentation||Innovaderm Research Inc.|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 3, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927679||60816|
NCT01927978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207067MIC|Using "PET Response Criteria in Solid Tumors (PERCIST)" in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer|Using "PET Response Criteria in Solid Tumors (PERCIST)" in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer||National Taiwan University Hospital|No|Recruiting|October 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|90 Years|No|Probability Sample|Histological proved esophageal cancer|April 2014|April 13, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927978||60794|
NCT01958606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT in chronic stroke|High Intensity Interval Training in Chronic Stroke|High Intensity Interval Training in Chronic Stroke|HIT|University of Cincinnati|Yes|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|35 Years|90 Years|No|||April 2015|April 29, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958606||58443|
NCT01958892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/311/D|To Compare Outcomes After Transurethral Enucleation of Prostate Versus Transurethral Resection of Prostate|||Singapore General Hospital||Completed||||October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Male|N/A|N/A||Probability Sample|Amles who underwent transurethral prostate surgeryr between 2006 and 2010|October 2013|October 8, 2013|October 5, 2013||||No||https://clinicaltrials.gov/show/NCT01958892||58421|
NCT01959165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5172C00001|MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients|||AstraZeneca|No|Active, not recruiting|November 2013|March 2018|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959165||58400|
NCT01959178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|825E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2013|||||N/A|N/A|N/A||||||||||||||October 8, 2013|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959178||58399|
NCT01928797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-p-001314|Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.|To Determine if the Cardiac Output Monitoring During Cesarean Delivery Under Spinal Anesthesia Will Change Our Clinical Practice of Using Vasopressors||Brigham and Women's Hospital|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|40 Years|No|||January 2015|January 26, 2015|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01928797||60731|
NCT01929044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.848|Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain|A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain||Boehringer Ingelheim||Completed|August 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|70 Years|No|||January 2016|February 10, 2016|August 22, 2013||||No|February 10, 2016|https://clinicaltrials.gov/show/NCT01929044||60712|
NCT01929057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121230|Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris|Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris||University of California, San Diego|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|34|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|June 2014|June 19, 2014|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01929057||60711|
NCT01929070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROMA-103P|A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007|A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007 in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|Yes|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01929070||60710|
NCT01929330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117342|Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers|An Evaluation of the Bioequivalence of Five 0.1 mg GI198745/Dutasteride Soft Gelatin Capsules Compared to One 0.5 mg GI198745/Dutasteride Gelatin Capsules in Healthy Male Volunteers||GlaxoSmithKline|Yes|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929330||60690|
NCT01929018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0179|Collaborative-care Rehabilitation After Dysvascular Amputation|Collaborative-care Rehabilitation to Improve Functional Outcomes After Dysvascular Amputation||University of Colorado, Denver|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01929018||60714|
NCT01929629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4930C00001|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914|A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to Assess the Effect of Food in Healthy Adult Volunteers||AstraZeneca|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929629||60667|
NCT01929642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM00037881|Rapalogues for Autism Phenotype in TSC: A Feasibility Study|Rapalogues for Autism Phenotype in TSC: A Feasibility Study|RAPT|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|2 Years|30 Years|No|||August 2015|August 31, 2015|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929642||60666|
NCT01929876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28620|A Study to Evaluate of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Subjects||Genentech, Inc.||Completed|August 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929876||60648|
NCT01929616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005655-16 EUDRACT|Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)|Regorafenib Assessment in Refractory Advanced Colorectal Cancer|RegARd-C|Jules Bordet Institute|Yes|Active, not recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|N/A|No|||May 2015|February 23, 2016|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01929616||60668|
NCT01930149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PO1HS021141-01-Project 2B|Promoting Cholesterol Screening|Reducing Disparities in Primary Prevention of Cardiovascular Disease: Promoting Cholesterol Screening||Northwestern University|Yes|Completed|December 2013|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|480|||Both|35 Years|75 Years|No|||September 2014|September 26, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930149||60627|
NCT01930162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSC835X2202|Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant|A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen||Novartis|Yes|Active, not recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|N/A|N/A|No|||March 2016|March 24, 2016|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930162||60626|
NCT01950143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR01-2013|Effect of Sulforaphane on Prostate CAncer PrEvention|A Human Dietary Intervention Study to Investigate the Effect of Sulforaphane on Prostate Cancer Interception|ESCAPE|Institute of Food Research|No|Enrolling by invitation|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|78|||Male|18 Years|80 Years|No|||January 2015|January 26, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950143||59093|
NCT01949376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR014182-01|Mild Cognitive Impairment in Breast Cancer Patients|Hippocampal Predictors of Cognitive Impairment (HippoPCI) in Breast Cancer Patients|HippoPCI|Northwestern University|No|Recruiting|June 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|120|||Female|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the following sites, all affiliated with Northwestern        University Feinberg School of Medicine (NUFSM): a) outpatient facility at Galter Pavilion        of Northwestern Medicine; b) Maggie Daley Center for Women's Cancer Care at Prentice        Women's Hospital; and c) Lynn Sage Comprehensive Breast Cancer Center at Prentice Women's        Hospital.        Participants will also be recruited a) via advertisement in local newspapers, craigslist,        Robert H. Lurie Comprehensive Cancer Center (RHLCC) Cancer Survivorship Institute website,        and at community programs that serve cancer patients, including hospitals and support        groups; and b) from community educational events sponsored by RHLCC, Women's Health        Research Institute, and Cognitive Neurology and Alzheimer's Disease Center (CNADC).|October 2015|October 29, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949376||59152|
NCT01950377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130190|Imaging and Genetic Investigation of Learning and Decision Making|Imaging and Genetic Investigation of Learning and Decision Making||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|May 2, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950377||59075|
NCT01950390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01732|Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|December 2013|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||November 2015|March 16, 2016|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950390||59074|
NCT01949831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVAprojekt|The Effect of Systematic Assessment of Functional Ability, Development of Rehabilitation Plan and Follow-up at Home for Elderly Medical Patients|The Effect of Systematic Assessment of Functional Ability, Development of Rehabilitation Plan and Follow-up at Home for Elderly Medical Patients||Aarhus University Hospital|No|Terminated|October 2013|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|52|||Both|65 Years|N/A|No|||February 2014|February 28, 2014|September 13, 2013||No|Due to inclusion problems (not recruting enough participants) recruiting participants has    halted prematurely and will not resume.|No||https://clinicaltrials.gov/show/NCT01949831||59117|
NCT01950117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR vs. polypectomy|Complete Removal of Neoplastic Large Colorectal Polyps: a Prospective Randomized Comparison of Endoscopic Mucosal Resection or Conventional Polypectomy|||Showa Inan General Hospital|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|90 Years|No|||November 2014|November 2, 2014|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950117||59095|
NCT01951560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPA-C-002|A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers or Trauma Patients|A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers or Trauma Patients||University of Michigan|Yes|Recruiting|September 2013|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951560||58985|
NCT01948570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0113|Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment|Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment|ANTI-ACNE|Derming SRL|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study will be conducted on volunteers of both genders, aged > 16 years old: 20        subjects presenting acne of mild/moderate grade not in therapy (GROUP 1) and 20 subjects        presenting acne of moderately severe/severe grade in therapy with topical or systemic        retinoids, benzoyl peroxide, clindamycin or AHA (GROUP 2).|September 2013|September 19, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01948570|2 Months|59214|
NCT01958034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-05|Bilberry as a Dietary Supplement After Myocardial Infarction (The BEAR SMART Trial)|Bilberry as a Dietary Supplement After Myocardial Infarction (The BEAR SMART Trial)|BEAR SMART|University Hospital Orebro|No|Completed|February 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01958034||58487|
NCT01958320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC4|Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus|Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial|PDA:TOLERATE|University of California, San Francisco|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|14 Days|No|||December 2015|December 1, 2015|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958320||58465|
NCT01959464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVP2013|Sexual Absorption of Vaginal Progesterone|Sexual Absorption of Vaginal Progesterone||Carolinas Healthcare System|Yes|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959464||58377|
NCT01959724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye012|Macular Detachment Associated With Intrachoroidal Cavitation|Macular Detachment Associated With Intrachoroidal Cavitation||Kyorin University|No|Completed|April 2007|September 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|10 Years|95 Years|No|||October 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959724||58357|
NCT01959737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-075|Delivery Room Skin-to-skin Study|Influence of Early SSC of Mothers and Their VLBW Infants on Maternal Sensitivity and Responsiveness, Attachment Patterns and Reactivity of HPA Axis. Molecular Characterization of SSC Influence on Stress Signaling Pathways.|deisy|University of Cologne|No|Active, not recruiting|February 2012|January 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|N/A|60 Minutes|No|||December 2015|December 4, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959737||58356|
NCT01959750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 08-220 (NAC08-069)|Psychological Intervention on Burnout in ICU Caregivers|Psychological Intervention on Burnout in ICU Caregivers: a Randomised Controlled Study||University Hospital, Geneva|No|Completed|April 2009|September 2013|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|166|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01959750||58355|
NCT01959451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MucT001-13|Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial|Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI|TROPICAL-ACS|Klinikum der Universitaet Muenchen|Yes|Recruiting|September 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2600|||Both|18 Years|80 Years|No|||March 2015|March 26, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959451||58378|
NCT01959711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN 501/ZKL/130/L|Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy|Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up||Jagiellonian University|Yes|Completed|January 2006|July 2013|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|80 Years|No|||October 2013|October 8, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01959711||58358|
NCT01929031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335.1|Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain|A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain||Boehringer Ingelheim||Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|561|||Both|18 Years|55 Years|No|||April 2014|April 2, 2014|August 22, 2013||||No||https://clinicaltrials.gov/show/NCT01929031||60713|
NCT01929356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZLMB001|Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia|The Influence of Chest Physiotherapy on Lung Function Parameters in Primary Ciliary Dyskinesia||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2013|October 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|50 Years|No|||August 2013|August 27, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929356||60688|
NCT01960309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMI-NCS|Minimal Invasive Imaging of Coronary Artery Disease in Patients With Asymptomatic Myocardial Injury After Major Non-cardiac Surgery.|Minimal Invasive Imaging of Coronary Artery Disease in Patients With Asymptomatic Myocardial Injury After Major Non-cardiac Surgery.|AMI-NCS|UMC Utrecht|Yes|Recruiting|September 2012|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|70|||Both|60 Years|N/A|No|||December 2014|December 2, 2014|July 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01960309||58312|
NCT01929902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-13-04E|Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery|Laparoscopic Aquamantys Device in General Surgery: A Prospective Observational Study to Evaluate the Efficacy and Accuracy||Carolinas Healthcare System|Yes|Completed|July 2013|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients age 18 years or older and in need of general surgery.|April 2014|April 30, 2014|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929902||60646|
NCT01956461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH No 6|Effects of Teriparatide Therapy for Japanese|||Tomidahama Hospital|No|Recruiting|September 2010|October 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|45 Years|N/A|No|Probability Sample|Osteoporotic patients who admit to our hospital|November 2015|November 3, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01956461|4 Years|58608|
NCT01949896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDD602270|Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion|Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion||Christiana Care Health Services|No|Terminated|September 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|N/A|6 Months|Accepts Healthy Volunteers|||March 2016|March 10, 2016|September 21, 2013||No|Study is being closed due to insufficient patient population for enrollment.|No||https://clinicaltrials.gov/show/NCT01949896||59112|
NCT01950403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01788|Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers|Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers||Mayo Clinic|Yes|Active, not recruiting|September 2013|||March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950403||59073|
NCT01950676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duke-NUS-TIDR/2012/0004|Feasibility of Using a Smart Phone Application for Self-titration of Insulin on Glycemic Control in Patients With T2DM|Feasibility of Using a Smart Phone Application for Self-titration of Insulin on Glycemic Control in Patients With Type 2 Diabetes||National University, Singapore|No|Completed|March 2013|December 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|66|||Both|30 Years|70 Years|No|||January 2016|January 7, 2016|September 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01950676||59052|
NCT01950689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTSp032, 11_DOG08_53|NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)|A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)|NIMRAD|Christie Hospital NHS Foundation Trust|Yes|Recruiting|May 2014|June 2020|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|470|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950689||59051|
NCT01950650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAPP1|GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus|GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus||Novo Nordisk A/S|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|1800|||Both|N/A|N/A|No|Probability Sample|Insulin treated patients with diabetes (type 1 or 2), and physicians involved in the        treatment, management of diabetes and care of patients with diabetes.|January 2014|January 15, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950650||59054|
NCT01950663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3032|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||December 4, 2014|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950663||59053|
NCT01950936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-057|Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD)|Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease|ProToCOLD|Danish Procalcitonin Study Group|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01950936||59032|
NCT01947972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKY5721|Individualized Maternal Milk Fortification for Feeding the Preterm Infants|Individualized Maternal Milk Fortification for Feeding the Preterm Infants||Aristotle University Of Thessaloniki||Recruiting|October 2013|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|80|||Both|N/A|5 Days|Accepts Healthy Volunteers|||October 2013|October 4, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01947972||59260|
NCT01948583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0513|Humectant Activity of a New Formulation of Gynomunal® Vaginalgel|Humectant Activity of a New Formulation of Gynomunal® Vaginalgel: Crossover Test Use Versus Previous Formula|GYNOMUNAL®|Derming SRL|Yes|Completed|May 2013|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01948583||59213|
NCT01949272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPERA|Optimization of PEEP for Alveolar Recruitment in ARDS|Optimization of PEEP for Alveolar Recruitment in ARDS|OPERA|Hopital of Melun|Yes|Recruiting|September 2013|May 2016|Anticipated|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All ICU patients achievinf definition of ARDS stades II and III of Berlin Classification|March 2016|March 22, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949272||59160|
NCT01958918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE23|Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD|A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)|SALT|Novartis|No|Recruiting|October 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|706|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958918||58419|
NCT01958931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FML - 204|Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer|||Fresh Medical Laboratories|Yes|Completed|September 2007|January 2011|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Probability Sample|Subjects with lung cancer symptoms and pulmonary lesions suspicious for lung cancer|October 2013|October 8, 2013|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958931||58418|
NCT01958944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT_ CP_ CF 01|Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis|Phase II Prospective, Open Labeled, Multi-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Cystic Fibrosis||Advanced Inhalation Therapies Ltd|No|Active, not recruiting|December 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|10 Years|N/A|No|||March 2015|February 3, 2016|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958944||58417|
NCT01959191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0309|Clinical Significance of Platelet Reactivity on Clopidogrel During Off-pump Coronary Artery Bypass|||Yonsei University|Yes|Completed|January 2008|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|859|None Retained|Whole blood|Both|19 Years|80 Years|No|Non-Probability Sample|Consecutive patients with indications for surgical myocardial revascularization|October 2013|October 7, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959191||58398|
NCT01959204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012O004|Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects|A Phase IV Study to Evaluate the Pharmacokinetics and Safety of Oxycodone Oral Solution in Pediatric and Adolescent Subjects||VistaPharm, Inc.|No|Recruiting|October 2013|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|N/A|17 Years|No|||November 2015|November 9, 2015|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959204||58397|
NCT01959477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1412|Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant|Personalized Monitoring of Intravenous Busulfan Dosing for Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation.||Case Comprehensive Cancer Center|Yes|Completed|March 2014|April 2015|Actual|January 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|2 Years|N/A|No|||August 2015|August 12, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959477||58376|
NCT01959763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55/2012|Prevention of the Metabolic Syndrome by New Lifestyle Intervention Methods|Prevention of the Metabolic Syndrome by a Lifestyle Intervention - an Application of the New Intervention Methods in the Primary Health Care.|PrevMetSyn|University of Oulu|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|20 Years|60 Years|No|||October 2013|October 9, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01959763||58354|
NCT01959776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye013|Asymmetrical Recovery of Cone Outer Segment Tips and Foveal Displacement After Macular Hole Surgery|Asymmetrical Recovery of Cone Outer Segment Tips and Foveal Displacement After Macular Hole Surgery||Kyorin University|No|Completed|July 2009|March 2012|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|35|||Both|10 Years|95 Years|No|||October 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959776||58353|
NCT01960036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46102-J|Body-oriented Therapy for Women in SUD Treatment|Body-oriented Therapy for Womens Substance Use Disorder Treatment||University of Washington|No|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Female|18 Years|65 Years|No|||October 2015|October 5, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960036||58333|
NCT01960322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0223|Improving Medication-taking After Liver Transplant|Intervention After MALT (I-AM): Feasibility of Improving Adherence Among Pediatric and Adult Cardiac Transplant Patients Using a Telemetric Intervention|I-AM|Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|11 Years|19 Years|No|||March 2016|March 9, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960322||58311|
NCT01960023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FC-7|Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer|A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab||NSABP Foundation Inc|No|Active, not recruiting|October 2013|December 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960023||58334|
NCT01956474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-04|CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas||Cxlusa|No|Recruiting|January 2013|June 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|8 Years|N/A|No|||August 2015|October 9, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956474||58607|
NCT01956487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116371|Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites|A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (Propafenone Hydrochloride) Manufactured at Two Different Sites||GlaxoSmithKline|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01956487||58606|
NCT01960556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-BSI and Simulation|Simulation-Based Central Venous Line Maintenance Bundle Education|Simulation-Based Pediatric Intensive Care Unit Central Venous Line Maintenance Bundle Education|CA-BSI|Children's Healthcare of Atlanta|No|Completed|December 2010|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric ICU nurses|October 2013|October 9, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960556||58293|
NCT01956955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Massive Pulmonary Embolism|Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism|||Ataturk University|No|Recruiting|January 2011|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|150|||Both|19 Years|85 Years|No|||October 2013|October 7, 2013|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956955||58570|
NCT01950429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130196|Evaluation of Sickle Cell Liver Disease|Evaluation of Sickle Cell Liver Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|N/A|||Anticipated|60|||Both|18 Years|99 Years|No|||February 2016|March 1, 2016|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950429||59071|
NCT01950156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-23-57|Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Disease Controlled Advanced Non-small Cell Lung Cancer||Shiga University|Yes|Recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|85 Years|No|||September 2013|September 24, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01950156||59092|
NCT01950416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-14|Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis|Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis||University of Patras|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||August 2015|August 19, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950416||59072|
NCT01950702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|php3|Laryngoscope Asssited Lightwand Intubation|Laryngoscope Assisted Lightwand Can Provide More Successful Intubation Than Lightwand Alone in Patients With Cervical Spine Injury : A Prospective Randomized Study||Seoul National University Hospital|Yes|Recruiting|September 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|168|||Both|20 Years|80 Years|No|||October 2014|October 22, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01950702||59050|
NCT01950949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|plaghaoc001|The Correlational Study of PPV in Various VT in Mechanically Ventilated Patients|The Correlational Study of Pulse Pressure Variation in Various Tidal Volume in Mechanically Ventilated Patients Under General Anaesthesia||Chinese PLA General Hospital|Yes|Completed|July 2012|May 2015|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|69|||Both|18 Years|60 Years|No|||September 2015|September 17, 2015|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950949||59031|
NCT01950962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lafon PHRC IR 2010|Role Of Phospholipid Transfer Proteins (Pltp) On Endotoxemia Caused By Buccal Inflammation|ROLE OF PHOSPHOLIPID TRANSFER PROTEINS (PLTP) ON ENDOTOXEMIA CAUSED BY BUCCAL INFLAMMATION|TOXIB|Centre Hospitalier Universitaire Dijon|No|Recruiting|October 2010|||April 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|240|||Both|35 Years|80 Years|No|||September 2013|September 23, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01950962||59030|
NCT01951222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002517-35|Bronchodilator Properties and Safety in Asthma|Bronchodilator Properties and Safety of a Repeated Dose of V0162 in Asthma.||Pierre Fabre Medicament|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|65 Years|No|||September 2013|September 16, 2014|September 5, 2013||||No||https://clinicaltrials.gov/show/NCT01951222||59010|
NCT01949246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001921|Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)|Analysis of Circulating Biomarkers in Predicting Response to Cardiac Resynchronization Therapy (CRT) With Biventricular Pacing in Patients With Congestive Heart Failure (BIOCRT)|BIOCRT|Massachusetts General Hospital|No|Recruiting|September 2007|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|496|Samples With DNA|Whole Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Outpatient or inpatient heart failure patients scheduled for CRT implantation|January 2015|January 29, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01949246||59162|
NCT01949259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rapid learning lung cancer|Rapid Learning for Lung Cancer|Rapid Learning in Practice: A Lung Cancer Survival Decision Support System in Routine Patient Care Data||Maastricht Radiation Oncology|No|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Lung cancer patients|October 2015|October 13, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01949259||59161|
NCT01949480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09090367|Ultrasound-Assisted Paravertebral Block v. Traditional Paravertebral Block For Pain Control|Comparison Of Ultrasound-Assisted Paravertebral Block And Traditional Paravertebral Block For Pain Control After Thoracic Surgery, A Prospective Randomized Trial||University of Pittsburgh|Yes|Recruiting|March 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2013|September 23, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949480||59144|
NCT01958957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311BDY04V05|A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.|A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6300|||Both|18 Years|80 Years|No|||May 2013|December 23, 2014|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01958957||58416|
NCT01959217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034497|Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse|Targeting Prospective Memory to Improve HIV Adherence in Adolescents at Risk for Substance Abuse||Wayne State University|Yes|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|194|||Both|16 Years|24 Years|No|||October 2013|October 8, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01959217||58396|
NCT01959230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|861|Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.|Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness||Bausch & Lomb Incorporated|No|Completed|November 2013|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959230||58395|
NCT01959503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO013-100|Progel Vascular Sealant|A Prospective, Randomized Study to Compare Progel Vascular Sealant to Gelfoam Plus as an Adjunct for the Control of Bleeding in Subjects Undergoing Thoracic Aortic Surgery||C. R. Bard|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959503||58374|
NCT01959516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A3401|Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD|Multicenter, Randomized, Blinded, Two-period Cross-over Study to Assess the Effect of Glycopyrronium (44 Micrograms QD) Versus Tiotropium (18 Micrograms QD) on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD||Novartis|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|40 Years|N/A|No|||February 2015|February 12, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959516||58373|
NCT01959789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22564/2011|In-office Bleaching With a 2-day Interval Between Sessions: Tooth Sensitivity|In-office Bleaching With a 2-day Interval Between Sessions: Tooth Sensitivity||Universidade Estadual de Ponta Grossa|No|Completed|August 2011|August 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants included in this clinical trial were at least 18 years old and had good        general and oral health. Participants were recruited by means of visual communication        through posters in the university and in stores at Umuarama city. A total of 116        participants were examined in a dental chair to check if they met the inclusion and        exclusion criteria.|October 2013|October 9, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01959789||58352|
NCT01959802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye014|Foveal Cone Outer Segment Tips Line Defect in Macular Pseudohole|Correlation Between Foveal Cone Outer Segment Tips Line Defect and Visual Acuity After Surgery for Macular Pseudohole||Kyorin University|No|Completed|April 2008|March 2012|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|10 Years|95 Years|No|||October 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959802||58351|
NCT01960049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0493-A|Novel Technique of Analgesia Following Open Liver Resection|Multicentre Evaluation of a Novel Technique of Analgesia Following Open Liver Resection: Medial Open Transversus Abdominis Plane (MOTAP) Catheters||University Health Network, Toronto|No|Recruiting|October 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01960049||58332|
NCT01960335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|whey-1001-192|Whey Protein Intake With and Without Exercise on Visceral Fat: The P+RISE Study|Whey Protein With and Without Exercise Training Enhances Total and Regional Body Composition, Insulin, Leptin, and Blood Pressure in Overweight and Obese Adults - The P+RISE Study|P+RISE|Skidmore College|No|Completed|January 2011|September 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01960335||58310|
NCT01960569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minpharm07052012|Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas|Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas||MinaPharm Pharmaceuticals|Yes|Recruiting|October 2013|April 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|60 Years|No|||October 2013|October 9, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960569||58292|
NCT01956734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D24GBM EudraCT: 2011-005935-21|Virus DNX2401 and Temozolomide in Recurrent Glioblastoma|Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent|D24GBM|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Active, not recruiting|September 2013|March 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956734||58587|
NCT01956721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9051|Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle|Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure|CALCICARD2|University Hospital, Montpellier|No|Recruiting|September 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|36|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01956721||58588|
NCT01956968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC13028-13KCTIL|Flexibility, Range of Motion and Strength Among Patients With Differing Response to the Scapular and Humeral Assistance Tests|||Meir Medical Center||Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|130 subjects referred to physical therapy due to shoulder pain.|April 2014|April 24, 2014|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01956968||58569|
NCT01956747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/164|Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies|Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies|OptiMal|VU University Medical Center|Yes|Recruiting|July 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|70 Years|N/A|No|Non-Probability Sample|Patients older than 70 years of age with advanced malignancies of colorectum, breast or        prostate, who will start with full standard anticancer treatment as decided by their        oncologist|December 2015|December 8, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956747||58586|
NCT01951261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELEMEDCOPD|Early Assisted Discharge for COPD Exacerbations With Telemonitoring.|Early Assisted Discharge With Generic Community Nursing and Pulmonary Physicians vs Telemonitoring at Home for Chronic Obstructive Pulmonary Disease Exacerbations||Puerta de Hierro University Hospital|Yes|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|116|||Both|N/A|N/A|No|||May 2015|May 16, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01951261||59007|
NCT01950715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302, JLF|Multimodal Stimulation Before and After Sacral Nerve Stimulation for Irritable Bowel Syndrome|Evaluation of the Gastro-colic Response in IBS Patients Treated With Sacral Nerve Stimulation||University of Aarhus|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|60 Years|No|||November 2014|November 10, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01950715||59049|
NCT01950975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VABRES PHRC N 2010|Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism.|Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism. National Multicentre Descriptive Study.|MOSAÏQUE|Centre Hospitalier Universitaire Dijon|No|Recruiting||||February 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|37 Weeks|N/A|No|||September 2013|September 23, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01950975||59029|
NCT01951248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGH-3-2013|Central and Peripheral 24-h Blood Pressure Before and After 3 Month of CPAP Treatment in Obstructive Sleep Apnea|Central and Peripheral 24-h Blood Pressure Measurements in Patients With Chronic Renal Failure and Obstructive Sleep Apnea Before and After Treatment With CPAP|NOSI|Regional Hospital Holstebro|No|Active, not recruiting|December 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||October 2014|October 8, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951248||59008|
NCT01948609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11221|Prospective Research of Outcomes After Salpingo-oophorectomy||PROSper|University of California, San Francisco|No|Recruiting|July 2014|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|whole blood; serum; EDTA Plasma|Female|35 Years|50 Years|No|Non-Probability Sample|Study participants will be women 35-50 years old with a confirmed diagnosis of a        deleterious BRCA 1/2 mutation recruited through UCSF.|December 2015|December 1, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01948609||59211|
NCT01948895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/2012|Desvenlafaxine Monotherapy in Dysthymia|An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia||Centre for Addiction and Mental Health|Yes|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||November 2014|November 6, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948895||59189|
NCT01950000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRS-FEN-2010-01|Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation|Efficacy and Safety of Opioid Analgesics as a Preventive Treatment of Procedural Pain Associated With Turning Among Critically Ill Patients Under Mechanical Ventilation. A Controlled Clinical Trial Comparing Placebo and Fentanyl||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|75|||Both|18 Years|85 Years|No|||September 2013|September 27, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01950000||59104|
NCT01950273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301.5|Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma|A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma||Boehringer Ingelheim||Completed|September 2013|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 23, 2013||||No||https://clinicaltrials.gov/show/NCT01950273||59083|
NCT01958970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|745-201|Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting|A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting||Pinta Biotherapeutics|No|Active, not recruiting|January 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|85 Years|No|||September 2015|September 1, 2015|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958970||58415|
NCT01959243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|862|Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.||Bausch & Lomb Incorporated|No|Completed|February 2014|June 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|507|||Both|5 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959243||58394|
NCT01959490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE14112|Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer|Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|175|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959490||58375|
NCT01959529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1250-4080|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events|DEVOTE|Novo Nordisk A/S|Yes|Active, not recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7637|||Both|50 Years|N/A|No|||January 2016|January 8, 2016|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959529||58372|
NCT01956318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thermes2010|Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency|Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency. A Randomized Clinical Trial.||Centre de Recherche Rhumatologique et Thermal|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|80 Years|No|||October 2013|October 6, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01956318||58619|
NCT01959815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00074818|Novel Screening Strategies for Scleroderma PAH|||University of Michigan|Yes|Recruiting|October 2013|||October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200||Blood samples will be drawn at rest and during exercise.|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Volunteers will be recruited from scleroderma clinics, pulmonary hypertension clinics, and        (for healthy volunteers) the Ann Arbor area.|November 2015|November 30, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959815||58350|
NCT01960062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-11NYate-01|Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial|Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial||Kaiser Permanente|No|Withdrawn|October 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|74 Years|No|||March 2014|March 18, 2014|September 24, 2013|Yes|Yes|no potential participants met the inclusion criteria|No||https://clinicaltrials.gov/show/NCT01960062||58331|
NCT01960348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-004|APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis|APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)||Alnylam Pharmaceuticals|Yes|Active, not recruiting|November 2013|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|85 Years|No|||January 2016|January 29, 2016|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960348||58309|
NCT01960361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE_001|A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant|A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol|ICE|Alpha - Bio Tec Ltd.|Yes|Recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960361||58308|
NCT01956292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-0002|Continuous Monitoring of Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage|Observational Study of Continous Monitoring of Arterial Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage|BP-MONICH|Azienda Ospedaliera Sant'Anna|No|Not yet recruiting|October 2013|June 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to hospital for intraparenchimal cerebral haemorrhage|October 2013|October 5, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01956292||58621|
NCT01956500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0173|Instaflex and Joint Pain in Community Adults|Influence of Instaflex Joint Support Supplement on Joint Pain, Stiffness, Function, and Inflammation: a Randomized, Placebo-controlled Community Trial||Appalachian State University|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956500||58605|
NCT01956279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-013-12S|Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)|Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)||VA Office of Research and Development|Yes|Recruiting|October 2013|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|40 Years|65 Years|No|||January 2016|January 7, 2016|September 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01956279||58622|
NCT01956513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etude ADC|Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer|Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein|ADC|Centre Jean Perrin|No|Withdrawn|March 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||October 2013|October 7, 2013|March 16, 2012||No|We have finally no financial support and any patients have been included.|No||https://clinicaltrials.gov/show/NCT01956513||58604|
NCT01956526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD CRL 0403|CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction|||CorAssist Cadiovascular Ltd.||Recruiting|August 2013|September 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01956526||58603|
NCT01957306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-101-001|Safety and Efficacy of Dr. Tagliaferri's Menopause Formula|A Phase 2, Open Label Clinical Trial Assessing Safety and Efficacy of Dr. Tagliaferri's Menopause Formula for Hot Flushes and Menopausal Symptoms in Postmenopausal Women||Herba Buena, Inc|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957306||58543|
NCT01957319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/1997|Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability|Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability||University of Catania|Yes|Completed|February 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|40 Years|65 Years|No|||September 2013|September 30, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01957319||58542|
NCT01951833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-01-St-Luc|Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis|Does Lung Clearance Index (LCI) Predict the Future Lung Disease Course in Patients With Cystic Fibrosis||University Hospital St Luc, Brussels|Yes|Withdrawn|January 2013|May 2017|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|6 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Cystic Fibrosis ( 6 years and older and FEV1 above 40% predicted) will be        invited to participate in this prospective non interventional study in 2 CF centers (UCL        and UZ Leuven)|November 2013|January 14, 2015|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01951833||58964|
NCT01951573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-011|Evaluation of a New Daily Disposable Multifocal Contact Lens Design|Delefilcon A Multifocal Plus Power Lens Design Evaluation||Alcon Research|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|September 24, 2013|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01951573||58984|
NCT01951820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075036|Comparison of Two Topical Anesthetics: Benzocaine Versus Pliaglis|Comparison of Efficacy of Two Topical Anesthetics: Benzocaine Versus Pliaglis for Control of Pain Associated With Dental Needle Insertion in the Palate, A Double Blind Study||University of Michigan|Yes|Recruiting|August 2013|June 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 24, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01951820||58965|
NCT01947712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26A12BPZN|Effect of Polyphenols on Peripheral Vascular Disease.|Effect of Dark Chocolate on Endothelial Function and Oxidative Stress in Patients With Peripheral Vascular Disease.||University of Roma La Sapienza|Yes|Completed|October 2010|September 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|90 Years|No|||September 2013|September 17, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947712||59280|
NCT01949493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44692.008.13|Non-surgical Treatment of Carpal Tunnel Syndrome by Means of Mechanical Traction|Study of the Effectiveness of Mechanical Traction as a Non-Surgical Treatment for Carpal Tunnel Syndrome Compared to Care as Usual: a Randomized Controlled Trial|MT-CTS|University of Tilburg|No|Active, not recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2016|January 22, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949493||59143|
NCT01949987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain and oral intake|Does Oral Intake Decreases Postoperative Pain Score in Children|The Effect of Oral Intake on Pain Score in Children Undergoing Herniorrhaphy||Ibaraki Children's Hospital|Yes|Recruiting|October 2013|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|80|||Both|18 Months|12 Years|No|||April 2015|April 23, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01949987||59105|
NCT01958983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-3041B|Music Therapy to Promote Emotion and Cognition for Dementia|The Effect of Music Therapy on Emotion and Cognition for Individuals With Mild to Moderate Dementia||Chang Gung Memorial Hospital|Yes|Recruiting|June 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|75 Years|No|||September 2013|October 6, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958983||58414|
NCT01959256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIVID|Visual Perceptual Learning for the Treatment of Visual Field Defect|Visual Perceptual Learning for the Treatment of Visual Field Defect|VIVID|Asan Medical Center|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||January 2015|January 21, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959256||58393|
NCT01956331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 08-05|Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer|Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer - A Prospective Observational Study in Elderly Patients With Non-small Cells Lung Cancer|OPERAGE|Groupe Francais De Pneumo-Cancerologie|No|Completed|March 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|302|||Both|70 Years|N/A|No|Probability Sample|Elderly patients aged 70 years and more with Non Small Cell lung Cancer.|October 2013|October 6, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01956331||58618|
NCT01956357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54475|Chronic Effects of Two Aerobic-training Models Performed in Water and on Dry Land in Patients With Type 2 Diabetes Mellitus (T2DM).|||Hospital de Clinicas de Porto Alegre||Completed|August 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|30 Years|N/A|No|||May 2014|November 4, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956357||58616|
NCT01956552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2009-05|Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)|Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting||Institut Curie|No|Terminated|November 2009|||June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|||Anticipated|250|||Female|18 Years|N/A|No|||November 2013|November 12, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01956552||58601|
NCT01957007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18R5-004|A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC|A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|September 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|90 Years|No|||September 2015|September 29, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957007||58566|
NCT01960075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18078|Established Status Epilepticus Treatment Trial|A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.|ESETT|University of Virginia|Yes|Recruiting|October 2015|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|795|||Both|2 Years|N/A|No|||October 2015|October 30, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960075||58330|
NCT01960374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00086|Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK|A Phase I, Single-centre, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Selumetinib Given Orally in Japanese and Non-Japanese Asian Healthy Male Volunteers||AstraZeneca|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|117|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960374||58307|
NCT01956305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS7309-A-U102|Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study|A Single Blind, (Subject and Investigator Blinded, Sponsor Unblinded), Two-Period, Placebo-Controlled, Randomized, Sequential, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS 7309 In Subjects With Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|48|||Both|18 Years|65 Years|No|||November 2014|November 20, 2014|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956305||58620|
NCT01957345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 068 08|Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets|Multicentre Evaluation of a New Laboratory Approach for the Diagnosis of Constitutional Functional Disorders of Platelets||University Hospital, Toulouse|No|Recruiting|February 2013|February 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|160|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01957345||58540|
NCT01956539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 680|FREnch Survey on Heart Failure|FREnch Survey on Heart Failure|FRESH|French Cardiology Society|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over 18 years with chronic heart failure, and all patients hospitalized for        acute heart failure de novo or not. The diagnosis of heart failure is the responsibility        of the cardiologist including patient.|February 2015|February 12, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956539|12 Months|58602|
NCT01956240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100/12|Effects of a Pectoralis Minor Muscle Stretching Protocol|Phase 4 Effects of a Stretching Protocol for the Pectoralis Minor Muscle on This Resting Length and on the 3D Kinematics of the Scapula During Arm Flexion in Asymptomatic Subjects and Patients With Impingement Syndrome|PMISP|Universidade Federal de Sao Carlos|No|Completed|June 2013|January 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 17, 2015|September 21, 2013||No||No|January 18, 2015|https://clinicaltrials.gov/show/NCT01956240||58625|Participants may not have maximally elongated muscle;Linear measurements such as that used to quantify muscle length cannot represent real structural changes;Only chronic pain was evaluated.
NCT01956253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2526|Single Subject Neratinib in Bladder Cancer|Single Subject Neratinib in Bladder Cancer||UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|July 2013|July 2020|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||December 2014|December 10, 2014|September 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01956253||58624|
NCT01956266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O0958-M|Emotional Prosody Treatment in Parkinson's|Treatment of Emotional Prosodic Disorders in Parkinson's Disease||VA Office of Research and Development|No|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|45 Years|85 Years|No|||October 2015|October 22, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01956266||58623|
NCT01956994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI-1154|The Effect of Whey Protein Supplementation on Vascular and Cognitive Function in Older Adults|The Effect of Whey Protein Supplementation on Cerebrovascular and Cognitive Function in Older Adults||Syracuse University|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956994||58567|
NCT01959282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102640|A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|Yes|Completed|November 2013|December 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|219|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959282||58391|
NCT01948011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-01 / BP0.52|Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules|Study of the Racecadotril Linearity After Single Administrations of 10, 30 and 60 mg of a New Racecadotril Formulation (Suspension) by Oral Route and Evaluation of the Comparative Bioavailability of This New Formulation Versus the Sachet Formulation (Granules) After a 60 mg Single Oral Administration in Healthy Male Volunteers||Bioprojet|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|53|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01948011||59257|
NCT01948024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASN-101|Bio-equivalence Study Between SAPHRIS and Asenapine|An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet|ASN|bioRASI, LLC|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|57|||Both|18 Years|80 Years|No|||February 2014|February 21, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01948024||59256|
NCT01947725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0757|Behavioral Activation for Smoking Cessation in Veterans With PTSD|Behavioral Activation for Smoking Cessation in Veterans With PTSD||University of Wisconsin, Madison|Yes|Recruiting|January 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947725||59279|
NCT01947985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16646|Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)|A Proposed Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in the Netherlands.||Bayer|No|Recruiting|February 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20000|||Both|2 Years|N/A|No|Non-Probability Sample|All patients aged 2 years and above who have been registered in the PHARMO database for at        least 1 year before the index date.|February 2016|February 29, 2016|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01947985||59259|
NCT01947998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16647|Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)|A Proposed Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in the United Kingdom.||Bayer|No|Recruiting|December 2011|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20000|||Both|2 Years|89 Years|No|Non-Probability Sample|All male and female patient aged 2 to 89 years who have been enrolled in the database        (GePaRD) for at least 1 year.|March 2016|March 10, 2016|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01947998||59258|
NCT01948297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1347-101|Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations|A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes||Debiopharm International SA|No|Recruiting|August 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948297||59235|
NCT01956396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCZ/A/1628 Safety Study|Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult MC Programs in Zimbabwe|Phase I of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe|ZW-01|Ministry of Health and Child Welfare, Zimbabwe|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|53|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 6, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01956396||58613|
NCT01949727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038838|Examining Vascular Outcomes in COPD Inpatients (AIM 1) Examining Early Rehabilitation on Discharged COPD Patients (AIM 2)|COPD Hospitalization:Examining Pulmonary and Cardiovascular Outcomes in Chronic Obstructive Pulmonary Disease Inpatients (AIM 1). COPD Rehabilitation:Examining the Impact of Early Pulmonary Rehabilitation on Discharged COPD Patients (AIM 2)||University of Alberta|No|Recruiting|October 2013|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood|Both|50 Years|N/A|No|Non-Probability Sample|The study population includes all English-speaking patients who are admitted to a        Pulmonary ward with a diagnosis of Acute Exacerbation of COPD after presenting to ED.|November 2015|November 30, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949727||59125|
NCT01949740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0552|Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer|Patient Preferences in Head and Neck Cancer Treatment Decisions - a Pilot Study of the Durability of Patient Priorities||University of Chicago|No|Terminated|June 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be identified through the Hematology/Oncology and ENT clinics a at their        first visit for newly diagnosed Head/ Neck Cancer|September 2015|September 1, 2015|September 20, 2013||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT01949740||59124|
NCT01959269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16665|Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy|RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy|RECORA|Bayer|No|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Female and male patients ≥ 18 years of age with a diagnosis of metastatic colorectal        carcinoma (mCRC) will be enrolled in the sites during the enrollment period. All treatment        decisions prior inclusion of a patient as well as during the observation must be made by        the investigator based on his regular medical practice. Patients must give written        informed consent prior to documentation.|March 2016|March 1, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959269||58392|
NCT01959828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-3001-CVS-301|Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery|Examination of Safety and Effectiveness of IK-3001 (Nitric Oxide for Inhalation) in Japanese Subjects With Pulmonary Hypertension Associated With Cardiac Surgery - Multi-Center, Open-Label, Clinical Study||INO Therapeutics|No|Completed|September 2013|July 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|80 Years|No|||April 2015|April 16, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959828||58349|
NCT01960088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2889|Adolescent Vaccination in Pharmacies|Building Evidence to Expand Adolescent Vaccination in Pharmacies|AVIP|University of North Carolina, Chapel Hill|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1704|None Retained|N=1200 anticipated in national study N=100 anticipated in pharmacy demonstration project|Both|11 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|National survey: Parents of adolescents ages 11-18. Pharmacy sample: Parents of adolescent        boys and girls, ages 11-18 whose families reside in the Chapel Hill area, and their        adolescents.|February 2016|February 25, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960088||58329|
NCT01956591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIsraelitaAE|Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis|Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis||Hospital Israelita Albert Einstein|No|Completed|September 2007|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|1100|||Both|5 Years|N/A|No|Non-Probability Sample|Out-patients on two tertiary hospitals (Hospital Israelita Albert Einstein and Hospital        das Clínicas - HCFMUSP) who seeked medical attention because of hyperhidrosis.|September 2013|October 7, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01956591||58598|
NCT01956838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44428.068.13/METC 13-2-025|The Effect of Bitter, Umami and Sweet Tastants on Food Intake|The Effect of Bitter, Umami and Sweet Tastants on Food Intake||Maastricht University Medical Center|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01956838||58579|
NCT01957020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806017R|Stereotactic Directional Vacuum-Assisted Breast Biopsy|The Diagnostic Accuracy of Stereotactic Directional Vacuum-Assisted Breast Biopsy||National Taiwan University Hospital||Completed|June 2008|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|130|||Female|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|asymptomatic women with mammographic screening, and with suspicious findings on        mammography.|October 2013|October 13, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01957020||58565|
NCT01957332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT MBC|IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer|Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging IMPACT: IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer|IMPACT-MBC|University Medical Center Groningen|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01957332||58541|
NCT01957566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 2012-0259|The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children|The Utility of Amplified Pretracheal Stethoscope in Detecting Ventilatory Abnormalities During Propofol Sedation of Non Intubated Children: a Validation Study||University of Wisconsin, Madison|No|Recruiting|January 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Anticipated|105|||Both|2 Years|18 Years|No|||May 2015|May 29, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01957566||58523|
NCT01957592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4068|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka|DiabCare Asia|Novo Nordisk A/S|No|Withdrawn|October 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|People having been treated for at least a year are eligible for the study. The selection        of the patients will be done randomly by the individual physician involved in the study.|October 2014|October 1, 2014|October 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957592||58521|
NCT01957579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2850C00001|A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies|A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies||AstraZeneca|Yes|Completed|May 2011|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|20 Years|130 Years|No|||November 2015|November 4, 2015|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01957579||58522|
NCT01958125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-003|A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.|A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache.||ElectroCore LLC|No|Completed|August 2013|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||February 2015|February 4, 2016|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958125||58480|
NCT01956760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2011-015|Effects of Acupuncture and Intradermal Acupuncture on Insomnia|A Randomized Controlled Clinical Trial to Evaluate Effectiveness of Acupuncture on Insomnia||Kyunghee University|Yes|Enrolling by invitation|September 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||January 2014|January 9, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01956760||58585|
NCT01958450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1061|Comparison of the Efficacy of Fractional Er:YAG Laser for Acne Scar|Comparitive Study of Efficacy and Safety Between Fractional Er:YAG Laser and Bipolar Radiofrequency Treatment for Acne Scar||Seoul National University Hospital|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958450||58455|
NCT01959022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-16907.5|A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD|A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD||San Francisco Veterans Administration Medical Center|No|Recruiting|October 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|69 Years|No|||December 2014|December 19, 2014|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01959022||58411|
NCT01958463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-ZH-500-CTIL|Transplantation of Fecal Microbiota for Clostridium Difficile Infection|Transplantation of Fecal Microbiota for Clostridium Difficile Infection||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958463||58454|
NCT01951872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00051415|Treatment for Caffeine Dependence|Treatment for Caffeine Dependence||Johns Hopkins University|No|Recruiting|September 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01951872||58961|
NCT01948310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045794|Effects of Ranolazine and Exercise on Daily Physical Activity Trial|Effects of Ranolazine and Exercise on Daily Physical Activity Trial|EREDA|Duke University|Yes|Recruiting|December 2013|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||August 2015|September 18, 2015|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948310||59234|
NCT01948323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTAF1402013|Pregnancy-Related Obesity Prevention Through Education & Communication Technology in AFRICA:The PROTECT-AFRICA STUDY|Pregnancy-Related Obesity Prevention Through Education & Communication Technology in AFRICA:The PROTECT-AFRICA STUDY|PROTECT-AFRI|University of Cape Town|Yes|Recruiting|September 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948323||59233|
NCT01948596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNCHRO-Open|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO): Open Trial|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) : Open Trial||Tokyo Medical University|Yes|Completed|October 2013|May 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|20 Years|N/A|No|||May 2015|May 26, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01948596||59212|
NCT01948037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingJH|Effectiveness Study of Hydrotherapy Against Pain and Other Symptoms in Diabetes-induced LEAD|Hydrotherapy for the Treatment of Symptomatic Lower Extremity Arterial Disease in Diabetes Type 2 Patients:A Randomized Controlled Trial||Nanjing Jinling Hospital|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|48 Years|85 Years|No|||August 2013|September 18, 2013|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948037||59255|
NCT01948882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16973|Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women|A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception||Bayer|Yes|Active, not recruiting|September 2013|December 2024|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|617|||Female|21 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948882||59190|
NCT01957436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0160/1105|A Phase III of ADT +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.|A Prospective Randomised Phase III Study of Androgen Deprivation Therapy With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.|PEACE1|UNICANCER|Yes|Recruiting|October 2013|October 2023|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|916|||Male|18 Years|N/A|No|||September 2015|September 21, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01957436||58533|
NCT01956656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|z59p5gy7|Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis|Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis: A 4 Day Double Blind Clinico-Microbiological Trial.||Sri Hasanamba Dental College and Hospital|Yes|Active, not recruiting|September 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956656||58593|
NCT01956344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1MH101163-01|Neural Mechanisms of CBT Response in Hoarding Disorder|Neural Mechanisms of CBT Response in Hoarding Disorder||Hartford Hospital|Yes|Recruiting|July 2013|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01956344||58617|
NCT01956565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 16453|Feasibility of Inspiratory Muscle Training in People With COPD Who Decline Pulmonary Rehabilitation|Feasibility of Inspiratory Muscle Training in People With Chronic Obstructive Pulmonary Disease (COPD) Who Decline Pulmonary Rehabilitation||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|35 Years|N/A|No|||November 2015|November 18, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956565||58600|
NCT01956578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REST|REVEAL for Respiration Detection|REVEAL for Respiration Detection||Medtronic BRC|No|Enrolling by invitation|September 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2013|October 7, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01956578||58599|
NCT01957072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17327|Pilot Study of Behavioural Intervention for Nutrition in Cystic Fibrosis|Pilot Study of Behavioural Intervention for Nutrition in Cystic Fibrosis|PIN-CF|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|17|||Both|16 Years|N/A|No|||March 2015|March 10, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957072||58561|
NCT01957098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 11 324909|The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man|The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man|M192|University of Copenhagen|No|Completed|October 2006|May 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|14|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01957098||58559|
NCT01956773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043372|Family Health History in Diverse Care Settings|Family Health History in Diverse Care Settings||Duke University|No|Recruiting|April 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|7000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956773||58584|
NCT01956786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ausa-Amlodipine B|Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine|Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotension-Converting Enzyme Inhibitor Intolerance||Shenzhen Ausa Pharmed Co.,Ltd|Yes|Recruiting|September 2013|February 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|540|||Both|18 Years|75 Years|No|||July 2013|September 30, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956786||58583|
NCT01956799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISM-BIOFER12|Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy|Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy|BIOFER12|Fondazione Italiana Sindromi Mielodisplastiche Onlus|No|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Peripheral blood and bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia undergoing        chelation therapy with deferasirox or deferoxamine|February 2016|February 2, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956799||58582|
NCT01956812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-107-04|Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer|An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)|PANCRIT®-1|Immunomedics, Inc.|Yes|Terminated|January 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 26, 2013|Yes|Yes|The DSMB conducted an interim analysis on overall survival, which showed that the treatment    arm did not demonstrate a sufficient improvement in OS vs. placebo.|No||https://clinicaltrials.gov/show/NCT01956812||58581|
NCT01960296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1067|Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?|Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01960296||58313|
NCT01948479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PatonRCT02|Insole Optimisation for Ulcer Prevention: a Feasibility Trial|Prevention of Foot Ulcer Recurrence in People With Diabetes Using an In-shoe Pressure Measurement Technology: A Randomised Control Trial Feasibility Study||University of Plymouth|No|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|30 Years|N/A|No|||September 2013|September 25, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948479||59221|
NCT01948739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS081854|Brain Machine Interface Control of an Robotic Exoskeleton in Training Upper Extremity Functions in Stroke|NRI:BMI Control of a Therapeutic Exoskeleton||The University of Texas Health Science Center, Houston|No|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01948739||59201|
NCT01948752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uwaterloo|Clinical Trial of Menu Labeling|||University of Waterloo|No|Completed|November 2010|||June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|661|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 18, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01948752||59200|
NCT01931215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOTAP|Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial|Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial|MOTAP|University Hospital, Geneva|No|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01931215||60545|
NCT01931475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13494|A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China|Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China||Eli Lilly and Company|No|Completed|December 2012|June 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|407|||Both|40 Years|N/A|No|||June 2015|June 26, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931475||60525|
NCT01931488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-ES-0341-CTIL|124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.|The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.||Tel-Aviv Sourasky Medical Center|No|Recruiting|August 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 28, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01931488||60524|
NCT01931501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-117|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable Tablets 5mg Under Fasted Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium Chewable Tablets 5mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Singulair® (Montelukast Sodium) Chewable Tablets 5mg [Reference Formulation, Merck & Co., Inc. USA] in Healthy Human Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited||Completed||||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01931501||60523|
NCT01931761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00077|Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers|A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers||AstraZeneca|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931761||60503|
NCT01931774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etik Kurul Karar No:36/14|Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris|Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris||Bezmialem Vakif University|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acne patients referred to the dermatology outpatient clinic of our university and healthy        controls matched with the patient group for age, gender and years of education. Controls        will be taken from the general population|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931774||60502|
NCT01932632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03169|Medication Minimization for Long-term Care Residents|The Effect of Medication Minimization on Mortality and Hospitalization in Long-Term Care Residents: The WiseMed RCT|WiseMed|University of British Columbia|Yes|Suspended|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|July 24, 2013||No|unable to recruit and in process of redesigning the trial|No||https://clinicaltrials.gov/show/NCT01932632||60436|
NCT01932879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS44|Blackberry Polyphenol Intake and Fuel Management|||USDA Beltsville Human Nutrition Research Center|No|Completed|July 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Male|25 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932879||60417|
NCT01937949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002880|Complex Aortic Aneurysm Repair With Fenestrated Stent Grafts|Clinical Outcomes and Quality of Life Measures in Patients Treated for Complex Abdominal Aortic Aneurysms With Fenestrated Stent Grafts.||Mayo Clinic|Yes|Recruiting|August 2013|December 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937949||60029|
NCT01937975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-050|The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)|An Open-Label Study to Investigate the Pharmacokinetics of MK-5172 and MK-8742 in Subjects With Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|February 3, 2016|September 4, 2013|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01937975||60028|
NCT01938222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-I-H-1203|Short Stitch Monomax®|A Prospective, Controlled Monocentric Study Evaluating the 6:1 Suture Technique Using Suture Material Monomax® for Abdominal Wall Closure After Primary Abdominal Incision|Short-Stitch|Diakonie-Klinikum Schwäbisch Hall gGmbH|No|Recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|351|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients|August 2015|August 3, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01938222||60009|
NCT01938235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB001-001|Exenatide for Myocardial Protection During Reperfusion Study|Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial|EMPRES|University Health Network, Toronto|Yes|Recruiting|February 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01938235||60008|
NCT01938495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001504|Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)|Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)|DPS in ALS|Barrow Neurological Institute|Yes|Suspended|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|21 Years|N/A|No|||September 2015|September 17, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01938495||59988|
NCT01938508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200611|Minocycline Bioequivalence Study|Bioequivalence Study Between Two Medications for the Oral Administration of 100 mg of Minocycline in Oral Solids in Healthy Volunteers.||GlaxoSmithKline|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938508||59987|
NCT01958255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMHPO912|Community Based Tobacco Cessation Programme Mumbai|Community Based Tobacco Cessation Programme|CBTCP|Tata Memorial Hospital|Yes|Active, not recruiting|May 2012|December 2013|Anticipated|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|333|||Female|N/A|N/A|No|||October 2013|October 8, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01958255||58470|
NCT01958541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22427|A Brief Behavioral Sleep Intervention for Depression Among Military Veterans|A Brief Behavioral Sleep Intervention for Depression Among Military Veterans||Stanford University|Yes|Recruiting|March 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958541||58448|
NCT01958554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 0917|Impact of an Integrated Intervention on Mental Health in Survivors of Intimate Partner Violence|Randomised Controlled Trial of an Integrated Intervention on Mental Health in Survivors of Intimate Partner Violence||Macmillan Research Group UK|Yes|Completed|October 2013|June 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 27, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958554||58447|
NCT01958567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC 125|Optical Coherence Tomography in the Diagnosis of Scleritis and Episcleritis|Optical Coherence Tomography in the Diagnosis of Scleritis and Episcleritis||The Eye Center and The Eye Foundation for Research in Ophthalmology|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958567||58446|
NCT01958840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31MH098512-01A1|Evaluating Behavioral Activation Efficacy in Depressed Spanish-Speaking Latinos|||University of Maryland|Yes|Completed|August 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958840||58425|
NCT01958853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-201E|Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study|An Open Label Extension Trial for Patients With Fibromyalgia Who Complete Study NPT-201 (NCT01825954) and Who Experience Inadequate Pain Reduction|PERRFECT|Cerephex Corporation|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|22 Years|65 Years|No|||September 2015|September 2, 2015|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958853||58424|
NCT01958242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7192|Effect of Blood Harvesting and Administration at End of CPB on Coagulation Profile|The Effect of Preoperative Blood Harvesting and Its Re-administration at the End of Cardio-pulmonary Bypass on the Coagulation Profile in the Pediatric Population Undergoing Open Heart Surgery.||Rabin Medical Center|No|Withdrawn|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|18 Years|No|||August 2012|November 23, 2015|April 17, 2013||No|Technical problems.|No||https://clinicaltrials.gov/show/NCT01958242||58471|
NCT01958528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 28412|A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)|A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2013|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male and Female subjects with diagnosis of MGUS or SMM by IMWG Criteria|January 2016|January 22, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958528||58449|
NCT01959373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00802-43|Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis|Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis||Assistance Publique Hopitaux De Marseille|No|Suspended|October 2013|||July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959373||58384|
NCT01959386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28759|HerSCin: An Observational Study of Herceptin (Trastuzumab) Subcutaneous in Patients With HER2-Positive Early Beast Cancer|CLINICAL PRACTICE SURVEILLANCE OF THE USE OF HERCEPTIN SUBCUTANEOUS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (HerSCin)||Hoffmann-La Roche||Active, not recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|985|||Both|18 Years|N/A|No|Probability Sample|Patients with HER2-positive early breast cancer initiated on treatment with subcutaneously        administered Herceptin|March 2016|March 1, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959386||58383|
NCT01959399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK26|Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin|A Phase 1, Open-Label, Single-Sequence Drug Interaction Study to Evaluate the Effect of Multiple-Dose ASP015K on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959399||58382|
NCT01959997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD_REDO_032|Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI|Randomized Comparison of Redo Pulmonary Vein Isolation With vs. Without Renal Denervation for Recurrent Atrial Fibrillation After Initial Pulmonary Vein Isolation||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959997||58336|
NCT01960010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIM-725|A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye|A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye||Mimetogen Pharmaceuticals USA, Inc.|Yes|Completed|October 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||May 2014|August 25, 2014|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960010||58335|
NCT01949597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX2013002|Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen|Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen||Institut Universitari Dexeus|No|Not yet recruiting|January 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|tissue|Female|18 Years|60 Years|No|Non-Probability Sample|women with symptomatic deep endometriosis|December 2014|December 18, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949597||59135|
NCT01949844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28466|Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies|Artifact-Free High-resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies||Cedars-Sinai Medical Center|No|Recruiting|May 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949844||59116|
NCT01931800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIROTH PHRC R 2004|Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae|Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae|Hyalo strepto|Centre Hospitalier Universitaire Dijon|No|Recruiting|December 2005|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|165|||Both|1 Year|N/A|No|Probability Sample|All the patients hospitalized in a service, for whom a sampling "targets" (hémoculture,        cerebrospinal fluid, bronchial brush, liquid of broncho-alveolar wash, protected tracheal        aspiration) with positive culture to Streptococcus pneumoniae.|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01931800||60500|
NCT01931514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-118|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable 5mg Tablet Under Fed Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium Chewable Tablets 5mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Singulair® (Montelukast Sodium) Chewable Tablets 5mg [Reference Formulation, Merck & Co., Inc. USA] in Healthy Human Volunteers Under Fed Conditions.||Torrent Pharmaceuticals Limited||Completed||||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01931514||60522|
NCT01931527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0509|Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status|Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation||Washington University School of Medicine|No|Completed|July 2006|November 2012|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|31|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|August 23, 2013|No|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01931527||60521|
NCT01931787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62113|CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931787||60501|
NCT01937364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIRH-13-1134|Preventing Alcohol Withdrawal With Oral Baclofen|Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial|BACLOFEN III|Essentia Health|No|Terminated|November 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|17|||Both|21 Years|N/A|No|||March 2016|March 23, 2016|September 4, 2013|Yes|Yes|The enrollment in the study was too limited for meaningful data analysis.|No||https://clinicaltrials.gov/show/NCT01937364||60073|
NCT01937624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021828|Pediatric Distal Radius US Study|Pediatric Distal Radius US Study||The Hawkins Foundation|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|51|||Both|2 Years|15 Years|No|||May 2015|May 4, 2015|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937624||60053|
NCT01937988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2246|Patient Support During Surgical Abortion|Patient Support During Surgical Abortion||University of Chicago|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937988||60027|
NCT01938001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-007|Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)|A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma|AUGMENT|Celgene|Yes|Recruiting|November 2013|December 2021|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938001||60026|
NCT01938547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-CLV-12-01|Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery (PIONEER)|Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery|PIONEER|The Medicines Company|Yes|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|17 Years|No|||August 2014|August 21, 2014|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938547||59984|
NCT01938521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0107-13-WOMC|Effects of Red Grape Cells (RGC) Powder in Type 2 Diabetics|Effects of Red Grape Cells (RGC) Powder on Glycemic and Lipid Control in Patients With Type 2 Diabetes ¬ A Double-blind, Randomized, Placebo Controlled Study|RGC-T2D|Tel Aviv University|Yes|Active, not recruiting|September 2013|November 2015|Anticipated|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|70 Years|No|||June 2015|June 2, 2015|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01938521||59986|
NCT01938534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJOU-EIRB-152692|Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use|||Ajou University School of Medicine||Recruiting|September 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|80 Years|No|||December 2013|December 31, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938534||59985|
NCT01957696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUS-PTx-01|The Norwegian Pancreas Transplantation (PTx) Study|A Prospective, Observational Study in Pancreatic Allograft Recipients: The Effect of Risk Factors, Immunosuppressive Level and the Benefits of Scheduled Biopsies - on Surgical Complications, Rejections and Graft Survival|PTx|Oslo University Hospital|No|Recruiting|September 2013|October 2020|Anticipated|October 2020|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Blood samples will be obtained at the time of Tx and later scheduled time points to:        -  Study of immune cell activation (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme           A/B, etc) and cytokines (IL-2, IL-12 etc)        -  Compare biomarkers in serum, indicative of acute rejection; RNA microarray on a series           of genes related to rejection, quantitative PCR on selected genes)      Scheduled biopsies will be taken according to our present routine protocol at 3 wks, 6 wks      and 12 mts post-Tx, as well as indication biopsies; simultaneosly from these four      transplant/organ sources:      Pancreas-Tx (P); Kidney-Tx (K); Duodenal segment of pancreas-Tx (tD; Native Duodenum      (control)      Histological and molecular evaluations will involve:        -  Rejection histology scores        -  Immunoshistochemistry on immunologic markers (CD25, FOXP3, CD4, CD3, CD8, CD45RO,           perforin, granzyme A/B, etc)        -  DNA/RNA analyses on immunologic markers: PCR, RNA microarray|Both|18 Years|65 Years|No|Non-Probability Sample|This study will be conducted at our single, national centre for organ transplantation in        Oslo.        All consecutive Pancreas-Tx recipients during 2-3 years are planned to be enrolled, with        an intented number of 60-80 patients. The study will continue until all patients have        completed a minimum of 60 months of follow-up or have discontinued participation in the        study.|October 2013|October 9, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957696|5 Years|58513|
NCT01957995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-13-2|Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors|An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors||University of Southern California|Yes|Active, not recruiting|November 2013|November 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|64 Years|No|||May 2015|May 4, 2015|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957995||58490|
NCT01958008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.5|BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis|Randomized, Placebo-controlled, Double-blind Within Dose Groups, Multiple Rising-dose Study to Evaluate Safety, Tolerability, and PK of Oral BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With COPD Associated With Chronic Bronchitis||Boehringer Ingelheim||Completed|September 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|84|||Both|40 Years|80 Years|No|||August 2014|August 6, 2014|October 1, 2013||||No||https://clinicaltrials.gov/show/NCT01958008||58489|
NCT01958268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ_02_08_2013|Dysphagia Handicap Index: A Structured Translation From English to German|Dysphagia Handicap Index: A Structured Translation From English to German of a Quality of Life Questionnaire Relating to Swallowing||University of Zurich|No|Completed|August 2013|September 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|130|||Both|18 Years|99 Years|No|Probability Sample|Patients suffering from dysphagia|December 2015|January 4, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01958268||58469|
NCT01958281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0154|Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency|A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency||Gilead Sciences|No|Recruiting|October 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958281||58468|
NCT01959126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02063|Health Enhancement And Resilience Training|The Effect of a Stress Reduction Program Using Mindfulness Techniques on Markers of Cellular Stress and Aging|HEART|University of California, San Francisco|No|Enrolling by invitation|May 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01959126||58403|
NCT01959412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2210|Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Five Different Doses of Inhaled Indacaterol (QAB149) Delivered Via the Single Dose Dry Powder Inhaler (SDDPI) in Patients With Persistent Asthma|QAB149|Novartis|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|91|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|October 8, 2013|No|Yes||No|March 16, 2015|https://clinicaltrials.gov/show/NCT01959412||58381|
NCT01959425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAT-149|Oral Anticoagulation Therapy Pilot Study|Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)|OAT|Biosense Webster, Inc.|Yes|Recruiting|August 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|90 Years|No|||January 2016|January 12, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959425||58380|
NCT01959672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441-13|Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir in Patients With Locally Advanced Pancreatic Cancer||University of Nebraska|Yes|Recruiting|September 2013|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|19 Years|N/A|No|||May 2015|May 27, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959672||58361|
NCT01959685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-109|A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal|A Dose Escalating Study To Determine the Tolerability and Pharmacokinetics of a Single Dose of Androxal in Healthy Volunteers||Repros Therapeutics Inc.|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|October 8, 2013|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01959685||58360|
NCT01948154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG3C1241|The Relationship of Speech Function and Quality of Life in Children With Cerebral Palsy: A Longitudinal Study|The Relationship of Speech Function and Quality of Life in Children With Cerebral Palsy: A Longitudinal Study||Chang Gung Memorial Hospital|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will have children with CP (n=60~80) and normal (n=50) from 2-12 years old under        consent of their family.|February 2012|February 12, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01948154|3 Years|59246|
NCT01948466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-U-0983|Nutritional PSA's on Fruit and Vegetable Consumption|Using Media to Improve Fruit and Vegetable Consumption in Elementary School Lunch Programs|PSA|University of Florida|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|750|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948466||59222|
NCT01949610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016981|A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants|Absorption, Metabolism, and Excretion of 14C-JNJ26489112 After a Single Oral Dose in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949610||59134|
NCT01949857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qiangmingsun123456!|The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines|Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine|HAV|Chinese Academy of Medical Sciences|Yes|Active, not recruiting|September 2013|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|6000|||Both|18 Months|65 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01949857||59115|
NCT01949870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00075|AZD6244 (Selumetinib, ARRY142886) J-BTC Phase 1 Study|A Phase I, Open-Label, Multi-center Study to Assess the Safety and Tolerability of AZD6244 (Selumetinib, ARRY142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)||AstraZeneca|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|N/A|No|||November 2014|November 7, 2014|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949870||59114|
NCT01949883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610-01|A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma|A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma||Constellation Pharmaceuticals|No|Recruiting|September 2013|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949883||59113|
NCT01936506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0645|Cognitive Training for Depression|Cognitive Training for Depression||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|55 Years|No|||September 2013|September 3, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936506||60139|
NCT01936818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100-0008|Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen|||ORA, Inc.|No|Completed|August 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Probability Sample|subjects at least 18 years of age of either sex and any race|October 2015|October 21, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936818||60115|
NCT01932047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-004|Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment|Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment - Establishment of Personalized Cell Library||Samsung Medical Center|No|Enrolling by invitation|April 2010|April 2015|Anticipated|August 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1523|Samples With DNA|-  The problem with the existing pre-clinical testing technology             1. Efficacy evaluation using existing cell lines             2. Existing preclinical animal models (The tumors produced by the cancer cells                subcutaneously injected into immunodeficient mice)        -  The solution plan             1. The development of patient-specific personalized cell library             2. The development of stereotactic(orthotopic) personalized animal models with the                patient-derived cell lines derived from patients|Both|N/A|N/A|No|Probability Sample|The subject diagnosed with cancer(GBM, Colon Cancer, Ovarian Cancer, Lung Cancer, Breast        Cancer, Brain metastases, Bone Metastatic Cancer, Lymphoma, Gastric Cancer, Pancreatic        Cancer, Gall bladder Cancer, Prostate Cancer, Kidney Cancer, Bladder cancer, Osteosarcoma,        Soft tissue sarcoma, Head and neck cancer),and other Brain tumor|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932047|10 Years|60481|
NCT01932346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201016RIC|Using Near Infra-red Spectroscopy to Measure Tissue Perfusion in Patients Receiving Coronary Artery Bypass Graft Surgery|Using Non-invasive Near Infra-red Spectroscopy to Measure the Regional Tissue Perfusion in Patients Receiving Off-pump Coronary Artery Bypass Graft Surgery||National Taiwan University Hospital|No|Recruiting|August 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|20 Years|75 Years|No|Probability Sample|Patients scheduled for elective coronary artery bypass surgery and age ≧20 years old, ≦75        years old|February 2014|February 21, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01932346||60458|
NCT01937637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-276|Improving Management of Breathlessness in Patients With Lung Cancer|Improving Management of Breathlessness in Patients With Lung Cancer||Massachusetts General Hospital|Yes|Completed|July 2013|November 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01937637||60052|
NCT01938248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTESiA|Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation|Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation|ARTESiA|Population Health Research Institute|Yes|Recruiting|May 2015|July 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4000|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938248||60007|
NCT01938261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-2013|The Preterm Infants' Paracetamol Study|The Preterm Infants' Paracetamol Study|PreParaS|University of Oulu|Yes|Completed|August 2013|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|N/A|24 Hours|No|||May 2015|May 27, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01938261||60006|
NCT01938560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116490|REMS Retigabine Study|REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention With POTIGA™||GlaxoSmithKline|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200 physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed        retigabine at least once in the last 12 months, and 200 pharmacists who have dispensed an        anti-epileptic drug (AED) at least once in the last 3 months.|September 2014|September 29, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938560||59983|
NCT01938820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10002004-2|Optimized Treatment and Regression of HBV-induced Early Cirrhosis|Optimized Treatment and Regression of HBV-induced Early Cirrhosis||Beijing Friendship Hospital|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938820||59964|
NCT01957709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2705.00|Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma|A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma||Fred Hutchinson Cancer Research Center|No|Recruiting|September 2013|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957709||58512|
NCT01958879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Efficacy of Arthrocentesis by Injection of Ringer With or Without Corticosteroid in Treatment of Internal Derangement|Treatment of Temporomandibular Disorder||Shiraz University of Medical Sciences|Yes|Completed|September 2012|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|80 Years|No|||October 2013|October 4, 2014|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01958879||58422|
NCT01958866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0156|Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen|||Chulalongkorn University|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958866||58423|
NCT01959139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1313|S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer|S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma||Southwest Oncology Group|Yes|Recruiting|January 2014|May 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|172|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959139||58402|
NCT01959438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eu-nr 2006-004076-13|Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma|Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma. A Phase I and Phase II Study.|SECAR|Karolinska University Hospital|Yes|Recruiting|February 2007|June 2018|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959438||58379|
NCT01959698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 240813|Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Phase I/II Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)||Roswell Park Cancer Institute|Yes|Recruiting|April 2014|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|74 Years|No|||February 2016|February 16, 2016|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959698||58359|
NCT01949090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200613|Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older||GlaxoSmithKline||Completed|September 2013|October 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|365|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949090||59174|
NCT01949389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01633|Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders|Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders||VA Connecticut Healthcare System|No|Completed|October 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|September 5, 2013||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01949389||59151|
NCT01949415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-008|An Optional Investigation of Biomarkers of Efficacy|An Optional Investigation of Biomarkers of Efficacy in TH002 Clinical Study Subjects.||Circassia Limited|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|16 Years|65 Years|No|Non-Probability Sample|The study population will consist of subjects who completed TH002 and have been dosed with        either placebo or the 12 nmol dose in the TH002 study.|May 2014|May 20, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949415||59149|
NCT01949623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRP|Biomarkers In Retinitis Pigmentosa (BIRP)|Biomarkers In Retinitis Pigmentosa (BIRP)|BIRP|Johns Hopkins University|No|Recruiting|September 2013|||September 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Anterior Chamber fluid from the eye|Both|18 Years|100 Years|No|Non-Probability Sample|Retinitis Pigmentosa patients and Controls|December 2015|December 15, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949623||59133|
NCT01949636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092468|The Chocolate Study|An fMRI Test of the Dynamic Vulnerability Model of Obesity: Risk Factor Plasticity||Oregon Research Institute|Yes|Active, not recruiting|May 2012|May 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|14 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|130 lean adolescents between 14-16 years old with BMIs between the 25th and 75th        percentile at baseline|January 2016|January 25, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01949636||59132|
NCT01937130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-02|Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF|A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure||Conatus Pharmaceuticals Inc.|Yes|Terminated|September 2013|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 4, 2013|Yes|Yes|Data needs met|No||https://clinicaltrials.gov/show/NCT01937130||60091|
NCT01937156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-0103|A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting|A Randomized, Active-control, Double-blind, Double-dummy, Parallel-group, Multi-center Study to Assess the Efficacy and Safety of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Moderately or Highly Emetogenic (ME or HE) Multi-day Chemotherapy||Solasia Pharma K.K.|No|Completed|August 2013|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|313|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01937156||60089|
NCT01936792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-135-13|Pathology in the Brain After mTBI - A Multimodal MRI Study|Pathology in the Brain After mTBI - A Multimodal MRI Study||University of Aarhus|Yes|Completed|August 2013|April 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|35 individuals with mTBI and 35 matched healthy controls (age and sex) are examined.|March 2015|April 17, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01936792|3 Months|60117|
NCT01937104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONSD-P|ONSD According to the Position During Laparoscopy|Comparison of Optic Nerve Sheath Diameter According to Position During Laparoscopy|ONSD|Chosun University Hospital|Yes|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Female|19 Years|65 Years|No|||October 2014|October 28, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937104||60093|
NCT01937117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBCRC 026|Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer|A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2014|July 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937117||60092|
NCT01938014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN-LDN-6710|Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children|Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children||University of Chicago|Yes|Recruiting|January 2009|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|None Retained|None collected; this is data-collection only, via a telephone-interview of children's      care-givers.|Both|N/A|18 Years|No|Non-Probability Sample|1. Children aged 1 to 84 months who have been diagnosed with MPS types I, II, III or VI          2. Children aged 1 to 84 months who have been diagnosed with some other lysosomal             disease          3. Children aged birth to 18 years who have been diagnosed with Krabbe disease, or who             have a positive screening for Krabbe disease|August 2015|August 10, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01938014||60025|
NCT01938287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1301|SENSIMED Triggerfish in Closed Eyes|A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Pattern Recorded With SENSIMED Triggerfish® in Healthy Subjects With Closed Eye||Sensimed AG|No|Completed|July 2013|February 2014|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01938287||60004|
NCT01938313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-ERAS-GC-PII|Early Recovery After Surgery (ERAS) Versus Conventional Protocol After Laparoscopic Gastrectomy|Comparison of ERAS (Early Recovery After Surgery) Protocol With Conventional Protocol After Laparoscopic Gastrectomy: A Prospective Randomized Controlled Trial (Phase II Study))|ERAS|Seoul National University Bundang Hospital|Yes|Recruiting|August 2012|April 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||September 2013|September 4, 2013|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01938313||60002|
NCT01938573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8027|Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer|A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer||University of Washington|No|Recruiting|December 2013|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938573||59982|
NCT01938833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13C.387|Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer|A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer||Thomas Jefferson University|Yes|Recruiting|April 2014|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938833||59963|
NCT01950897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-Neurology-MD muscle tissue|Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies|||Carolinas Healthcare System|No|Recruiting|September 2005|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|250|Samples With DNA|skeletal muscle tissue|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to the Carolinas Medical Center (CMC) Department of Neurology who meet        study criteria.|July 2014|July 2, 2014|March 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950897||59035|
NCT01958580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-03-096|Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery|A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958580||58445|
NCT01958593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-4|Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD|A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|12|||Both|21 Years|N/A|No|||September 2015|September 17, 2015|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958593||58444|
NCT01951456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL117345-01A1|Resistance Training as an Aid to Smoking Cessation Treatment|Resistance Training as an Aid to Smoking Cessation Treatment||Teachers College, Columbia University|No|Recruiting|November 2013|March 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01951456||58992|
NCT01951469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC brain metastasis 01|Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer|Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation||Sun Yat-sen University|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01951469||58991|
NCT01951482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC brain metastasis 02|Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer|Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type||Sun Yat-sen University|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01951482||58990|
NCT01959152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0513|Evaluation of Hearing Preservation in Adults With Partial Low-Frequency Hearing Implanted With the HiFocus™ Mid-Scala Electrode|Evaluation of Hearing Preservation in Adults With Partial Low-Frequency Hearing Implanted With the HiFocus™ Mid-Scala Electrode||Advanced Bionics|No|Terminated|October 2013|November 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|May 20, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959152||58401|
NCT01951976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17592|Yoga for Aromatase Inhibitor-associated Joint Pain|Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|September 2013|August 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01951976||58953|
NCT01947868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OTW-ATC-2013/1|Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor|A Prospective, Non-interventional Evaluation of Symptoms Improvement of First-Line Therapy of EGFR Tyrosine Kinase Inhibitor in Advanced NSCLC Patients With Positive EGFR Mutation - the SMILE Study||AstraZeneca|No|Completed|November 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|346|None Retained|no biospecimen collected|Both|20 Years|150 Years|No|Non-Probability Sample|advanced NSCLC patients who will be treated as first line treatment with EGFR-TKI|November 2015|November 9, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947868||59268|
NCT01949402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUS-EVLW1|A New Way of Looking at Your Lungs|Thoracic Ultrasonography in the Assessment of Extravascular Lung Water & Respiratory Failure||University of Oxford|No|Not yet recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be screened from normal clinical care in the outpatient haemodialysis        unit and specialist respiratory clinics (COPD and ILD) at the Churchill Hospital, Oxford.        Age-matched volunteers will also be sought for the control arm of the study.|June 2014|June 3, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949402|1 Day|59150|
NCT01949909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P27A_1_13|Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib|Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial|P27A|Centre Hospitalier Universitaire Vaudois|Yes|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01949909||59111|
NCT01949922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-027|Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter|Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter - a Pilot Study.||Herlev Hospital|No|Recruiting|April 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|90 Years|No|||February 2016|February 18, 2016|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01949922||59110|
NCT01950169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NutristudienSHFG|Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture|Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture||Karolinska Institutet|Yes|Completed|December 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|79|||Both|60 Years|N/A|No|||September 2014|September 10, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950169||59091|
NCT01937169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-TH-0416-CTIL|Targeting Dopamine Therapy in RLS|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||December 2013|December 17, 2013|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937169||60088|
NCT01937143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126007|A Hospital-based Postnatal Parent Education Intervention About Infant Immunizations|Immunizing Infants Against Pain: a Hospital-based Postnatal Parent Education Intervention About Infant Immunizations|IIAP|University of Toronto|No|Recruiting|October 2013|September 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|3420|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01937143||60090|
NCT01937377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.171|GLORIA-AF Registry Program (Phase II/III)|GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)||Boehringer Ingelheim||Recruiting|September 2013|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients with non-valvular AF|March 2016|March 21, 2016|September 4, 2013||||No||https://clinicaltrials.gov/show/NCT01937377||60072|
NCT01937650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-059|Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in Uganda|A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago||Makerere University|Yes|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|N/A|No|||September 2013|September 4, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937650||60051|
NCT01938027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-TAME|The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision|A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision||National Cancer Center, Korea|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|80 Years|No|||March 2015|March 25, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938027||60024|
NCT01938274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24HS018622|Leisure Expectations About Physical Activity Study|Establishing Appropriate Activity Expectations After Total Joint Replacement|LEAP|West Virginia University|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|45 Years|N/A|No|||December 2015|December 22, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01938274||60005|
NCT01938586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYDO-2013|Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures|Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures on the Back - a Prospective, Randomized, Split-scar Study||Henry Ford Health System||Not yet recruiting||||January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient dermatology clinic|September 2013|September 5, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938586||59981|
NCT01938599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-AM001-001|Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis||AmDerma|No|Active, not recruiting|September 2013|July 2014|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938599||59980|
NCT01938859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI01B04-BD|Algorithm Guided Treatment Strategies for Bipolar Depression|Algorithm Guided Treatment Strategies for Bipolar Depression|AGTs-BD|Shanghai Mental Health Center|No|Recruiting|June 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|65 Years|No|||September 2013|September 9, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938859||59961|
NCT01951768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG protocol|Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection|A Randomized, Controlled Study to Investigate the Efficacy and Safety of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection||University Hospital, Geneva|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01951768||58969|
NCT01951183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29013|A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin|A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-DAILY RO6811135 IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN||Hoffmann-La Roche||Withdrawn|December 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|September 23, 2013|Yes|Yes|Cancelled due to Sponsor's decision|No||https://clinicaltrials.gov/show/NCT01951183||59013|
NCT01947647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-018-13S|Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders|Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders|TBT-RCT|VA Office of Research and Development|No|Recruiting|November 2014|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01947647||59285|
NCT01951157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-B-004-13|A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients|A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients||PharmaMar|No|Active, not recruiting|October 2013|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951157||59015|
NCT01947881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2013-05|Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)|Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)|CHARTRES|Association for Innovation and Biomedical Research on Light and Image|No|Active, not recruiting|January 2014|February 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|40 Years|N/A|No|Non-Probability Sample|Diabetic Type 2 patients with clinically significant Diabetic Macular Edema with        therapeutic indication for treatment with intravitreal injections of anti-VEGF Lucentis.|October 2015|October 7, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947881||59267|
NCT01951729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861E|The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion|The Effects of GIP and/or Xenin-25, With and Without Atropine, on Insulin Secretion in Humans With Pre-diabetes||Washington University School of Medicine|No|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951729||58972|
NCT01951742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1401-LCL-204|Dose Finding Study In Subjects With Crow's Feet|Dose Finding Study of Botulinum Neurotoxin Type A In Subjects With Crow's Feet (Lateral Canthal Lines)||Anterios Inc.|No|Completed|September 2013|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|145|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|September 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951742||58971|
NCT01948492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580-D|Determination of Protein Requirement in Elderly Male Subjects >75 Yrs Old|||The Hospital for Sick Children|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|76 Years|90 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01948492||59220|
NCT01948765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR022013|Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.|Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery:a Randomised Controlled Trial||Universitaire Ziekenhuizen Leuven|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01948765||59199|
NCT01949077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2124|Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.||University of North Carolina, Chapel Hill|No|Active, not recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|Samples Without DNA|Serum and tissue collected through the UNC Liver Center serum and tissue bank.|Both|18 Years|N/A|No|Non-Probability Sample|Male and female adult patients: Aged 18 and older with chronic HCV treated with triple        therapy (including Boceprevir).|June 2015|June 10, 2015|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949077||59175|
NCT01949129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL SCTped FORUM 2012|Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia|Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia||St. Anna Kinderkrebsforschung|Yes|Recruiting|April 2013|April 2023|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|6 Months|18 Years|No|||February 2016|February 15, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01949129||59171|
NCT01950442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.118|Balloon Dilation to Permit Complete Endoscopic Ultrasound Staging in Esophageal Cancer|Balloon Dilation of Malignant Strictures to Permit Complete Endoscopic Ultrasound Staging in Esophageal Cancer|CT0046|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|October 2013|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950442||59070|
NCT01950455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV5-01|Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes||Navidea Biopharmaceuticals|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|275|||Both|40 Years|N/A|No|||September 2014|September 23, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950455||59069|
NCT01950728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14571013.1.0000.5512|Effects of Different Electrical Currents on Pressure Pain Threshold and Sensory Comfort.|Investigation of the Effects of Transcutaneous Electrical Nerve Stimulation, Aussie Current and Interferential Current on Pressure Pain Threshold and Sensory Comfort in Healthy Humans.||Paulista University|No|Not yet recruiting|October 2013|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950728||59048|
NCT01950988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZWETYENGA PHRC IR 2011|Effectiveness of a Novel Concept for a Manual Toothbrush Broscyl®|Effectiveness and Satisfaction-adaptability of a Novel Concept for a Manual Toothbrush Broscyl®: Randomised Clinical Trial in Children, Adults and Elderly People|BROSCYL|Centre Hospitalier Universitaire Dijon|No|Recruiting|July 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|3||Anticipated|234|||Both|8 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 25, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01950988||59028|
NCT01937182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002253-30|The Efficacy of Citalopram Treatment in Acute Stroke|The Efficacy of Citalopram Treatment in Acute Stroke|TALOS|University of Aarhus|No|Recruiting|September 2013|July 2021|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01937182||60087|
NCT01937390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.517|Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)|Post-Marketing Observational Study of the Impact of Adherence to Treatment With Once-Daily Administered Long-Acting Bronchodilators (LABAs / LAMAs) on Patients Health Related Quality of Life in COPD Patients||Boehringer Ingelheim||Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|||Both|40 Years|N/A|No|Non-Probability Sample|Caucasians|January 2016|January 13, 2016|September 4, 2013||||No||https://clinicaltrials.gov/show/NCT01937390||60071|
NCT01937663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1203|A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation|||Kissei Pharmaceutical Co., Ltd.||Completed||||January 2014|Actual|Phase 2|Interventional|N/A|4||||||Both|20 Years|N/A||||November 2014|November 11, 2014|August 27, 2013||||No||https://clinicaltrials.gov/show/NCT01937663||60050|
NCT01937689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLTN-Ib|Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer|A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|January 2013|||September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||September 2014|February 14, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01937689||60048|
NCT01937702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIP|A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection Pain|A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection Pain||Profil Institut für Stoffwechselforschung GmbH|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|80|||Both|18 Years|74 Years|No|||December 2014|December 29, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01937702||60047|
NCT01938040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001793|Effect IV Ibuprofen and Inflammatory Responses|Randomized, Double Blind, Pilot Study on the Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia: Correlation With Clinical Outcomes||Rutgers, The State University of New Jersey|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|89 Years|No|||April 2015|April 20, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01938040||60023|
NCT01938300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg-ROTEM-colorectal ca|Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery|||Seoul National University Bundang Hospital||Completed|June 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|20 Years|90 Years|No|||November 2013|November 17, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01938300||60003|
NCT01938339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETMR-Prostate|Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer|Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer||Seoul National University Hospital|Yes|Recruiting|May 2012|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|N/A|N/A|No|||December 2013|December 3, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01938339||60000|
NCT01938612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00002|A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|September 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|176|||Both|20 Years|130 Years|No|||March 2016|March 16, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938612||59979|
NCT01938872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo010|Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia|||Ospedale San Donato|No|Recruiting|September 2013|||September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|patients undergoing below-the-knee angioplasty with paclitaxel eluting balloon for        critical limb ischemia|September 2013|September 5, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938872|12 Months|59960|
NCT01951534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131025|Decisional Aid Intervention for Women Considering Breast Reconstruction|Decisional Aid Intervention for Women Considering Breast Reconstruction|BRDA|Rutgers, The State University of New Jersey|Yes|Active, not recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01951534||58987|
NCT01947660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5492|Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery|Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery|ACOSM|University Hospital, Strasbourg, France|No|Not yet recruiting|October 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947660||59284|
NCT01951508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 36/13|Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study|Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study||University Hospital, Basel, Switzerland|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951508||58989|
NCT01951755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27805|Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)|An Observational Study for Safety and Efficacy of Erlotinib Beyond 1st Line in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer||University of Athens|Yes|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced (inoperable stage IIIB or stage IV) NSCLC who had failed in        platinum based chemotherapy|December 2014|December 5, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01951755|24 Months|58970|
NCT01948193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L33|Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth||Sanofi|No|Completed|February 2014|June 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|177|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 18, 2013||No||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01948193||59243|
NCT01948206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC001|Study of Paced QRS Duration as a Marker of Sudden Cardiac Death|Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators||Pocono Medical Center|No|Recruiting|October 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects followed in the ICD clinic at Pocono Medical Center.|November 2015|November 1, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01948206||59242|
NCT01948167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH077178|Bending Adolescent Depression Trajectories Through Personalized Prevention|Bending Adolescent Depression Trajectories Through Personalized Prevention||Rutgers University|Yes|Recruiting|September 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|12 Years|17 Years|No|||May 2015|May 4, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948167||59245|
NCT01948180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-2013-01|Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma|A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)|CITADEL|Cell Medica Ltd|Yes|Recruiting|September 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948180||59244|
NCT01948778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDoX_CH012|The Effects of a Polyethyleneimine-coated Membrane (oXiris™) for Hemofiltration Versus Polymyxin B- Immobilized Fibre Column (Toraymyxin™) for Hemoperfusion on Endotoxin Activity and Inflammatory Conditions in Septic Shock- A Randomized Controlled Pilot Study (ENDoX-study)|The Effects of a Polyethyleneimine-coated Membrane (oXiris™) for Hemofiltration Versus Polymyxin B- Immobilized Fibre Column (Toraymyxin™) for Hemoperfusion on Endotoxin Activity and Inflammatory Conditions in Septic Shock- A Randomized Controlled Pilot Study||University of Zurich||Recruiting|August 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01948778||59198|
NCT01949103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104|TD-1607 MAD Study in Healthy Subjects|A Randomized, Double−Blind, Placebo−Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD−1607, a Glycopeptide−Cephalosporin Heterodimer Antibiotic, in Healthy Subjects||Theravance Biopharma Antibiotics, Inc.|No|Completed|October 2013|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949103||59173|
NCT01949116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5314|Evaluating Safety and Effectiveness of Low-Dose Methotrexate at Reducing Inflammation in HIV-Infected Adults Taking Antiretroviral Medications|Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|December 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|N/A|No|||March 2016|March 22, 2016|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949116||59172|
NCT01949649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH097720|Dissonance Eating Disorder Prevention: Clinician Led, Peer Led vs Web Delivered|Dissonance Eating Disorder Prevention: Clinician Led, Peer Led vs Web Delivered (Formerly: Effectiveness Trial of Peer-Led Dissonance Eating Disorder Prevention Groups)||Oregon Research Institute|No|Active, not recruiting|April 2013|March 2018|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|680|||Female|17 Years|22 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01949649||59131|
NCT01951001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-MATCH|Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome|Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome||Gyeongsang National University Hospital|Yes|Recruiting|July 2013|October 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|20 Years|75 Years|No|||April 2014|April 30, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951001||59027|
NCT01951859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC-DERM-0213-DFU|Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot|A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.||Calvary Hospital, Bronx, NY|No|Recruiting|August 2013|February 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 22, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01951859||58962|
NCT01951274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCP 101|VPD-737 for Treatment of Chronic Pruritus|A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus||Tigercat Pharma, Inc.|No|Completed|October 2013|April 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|257|||Both|18 Years|65 Years|No|||June 2013|May 20, 2015|July 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951274||59006|
NCT01951586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120249|Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer|A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer||Amgen|No|Active, not recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|100 Years|No|||January 2016|January 29, 2016|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951586||58983|
NCT01937195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPW-STP-00002|AccuCath™ Intravenous Catheter System Compared to Conventional Peripheral Intravenous Catheters|A Prospective, Randomized, Controlled, Multicenter Comparison Between the AccuCath™ Intravenous Catheter System With Retractable Coiled Tip Guidewire and Conventional Peripheral Intravenous Catheters||Vascular Pathways, Inc.|No|Recruiting|April 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|89 Years|No|||September 2013|September 3, 2013|April 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937195||60086|
NCT01937442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-2001-CP-001|Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Thalidomide Following Multiple Oral Dosing in Subjects With Multiple Myeloma||Celgene|No|Recruiting|November 2013|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01937442||60067|
NCT01937403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003653|Sport Cord Test Following ACL Reconstruction|The Use of the Sport Cord Test as a Measure of Physical Performance Following Anterior Cruciate Ligament Reconstruction||The Hawkins Foundation|Yes|Recruiting|October 2009|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|10 Years|50 Years|No|Non-Probability Sample|Patients receiving physical therapy/rehabilitation for an ACL surgery and are returning to        participation in sports.|May 2015|May 4, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937403||60070|
NCT01937676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K3-akuten|LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting|LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting||Karolinska Institutet|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1250|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients admitted to emergency department during study period.|June 2014|June 26, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937676||60049|
NCT01937715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151007|A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer|An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer||Pfizer|No|Terminated|February 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 27, 2013|Yes|Yes|B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the    portfolio and is not due to any safety concerns or regulatory interaction|No||https://clinicaltrials.gov/show/NCT01937715||60046|
NCT01938326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-SIDG-GS-PII|Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG)|Prospective Randomized Controlled Study of Acute Inflammatory Reaction and Morbidity After Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) and Totally Laparoscopic Distal Gastrectomy (TLDG) for Early Gastric Cancer.||Seoul National University Bundang Hospital|Yes|Recruiting|July 2012|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||September 2013|September 4, 2013|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01938326||60001|
NCT01934816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2Myo2013|Incretin and KATP Channels|Effects of KATP Channel Blockers on GLP-1 and Its Analogues' Mediated Microvascular Function||Royal Devon and Exeter NHS Foundation Trust|Yes|Recruiting|June 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01934816||60268|
NCT01935284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Analyze ABS|Evaluation of Blood Gas Syringes|Post-Market Study Evaluating Analyzer Readings of Multiple Arterial Blood Gas Syringes|Analyze ABS|Smiths Medical, ASD, Inc.|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|August 2013|August 30, 2013|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01935284||60233|
NCT01935778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1303|Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV|A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resection||Asan Medical Center|No|Recruiting|September 2013|September 2022|Anticipated|September 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|286|||Both|20 Years|75 Years|No|||November 2015|November 26, 2015|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935778||60195|
NCT01951794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1225|Validation of a Community Survey Methodology for Measuring PMTCT Program Impact|CIDRZ 1225 - Validation of a Community Survey Methodology for Measuring PMTCT Program Impact||University of North Carolina, Chapel Hill|No|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1680|Samples Without DNA|We will collect Dried Blood Specimens (DBS) from both mother and infant and link them using      pre-printed bar codes. For a mother who refuses real-time testing, but agrees to collection      of this maternal DBS specimen, she will be provided a card with a unique study-generated      identification number that can be used pick-up results at the community's designated health      facility. For those who agreed to on-site HIV testing, we will retain the DBS specimens for      quality assurance purposes. As part of the informed consent process, participants will also      be asked whether leftover specimens may be used for future use, pending local and      international ethical approvals for specified substudies.|Both|N/A|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected women and their HIV-exposed infants / children|December 2015|December 7, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01951794||58967|
NCT01947686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Survivorship and Outcomes of Robotically Assisted Patellofemoral UKA|Survivorship and Outcomes of Robotically Assisted Patellofemoral UKA||St. Helena Hospital Coon Joint Replacement Institute|No|Enrolling by invitation|February 2013|February 2023|Anticipated|February 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who underwent a primary robotically guided UKA and received an isolated        patellofemoral implant.|November 2015|November 17, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947686||59282|
NCT01951781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9117|Neutrophil CD64 for Early Diagnosis of Nosocomial Infection in Preterm Newborns|Rapid Quantitative Neutrophil CD64 Measurement for Early Diagnosis of Nosocomial Infection in Preterm Newborns|NEOCD64|University Hospital, Montpellier|Yes|Recruiting|June 2013|November 2015|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|153|||Both|N/A|5 Months|No|||September 2013|January 8, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01951781||58968|
NCT01947894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281313|A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients|Swegho- A Prospective Non Interventional Study Protocol With Primary Data Collection -Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Ghd Patients In Sweden||Pfizer|No|Recruiting|November 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Patients wiht Growth Hormone Deficiency|March 2016|March 10, 2016|June 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947894||59266|
NCT01947907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-001_CT-004|Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)|A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)||Ascendis Pharma A/S|Yes|Completed|July 2013|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|55|||Both|3 Years|12 Years|No|||March 2016|March 9, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01947907||59265|
NCT01948219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-01-PEC-1|ENTegral Clinical Trial|An Evaluation of the ENTegral Artificial Larynx (AL) in Patients Indicated for Total Laryngectomy||ProTiP Medical|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01948219||59241|
NCT01948505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00061838|Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit|||University of Utah||Recruiting|August 2013|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||December 2014|December 5, 2014|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948505||59219|
NCT01948518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-993|Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease|The Effect of Sildenafil on Diffusion Capacity Measurements in Patients With Pulmonary Hypertension and Parenchymal Lung Disease||The Cleveland Clinic|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||July 2014|September 24, 2014|September 18, 2013|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01948518||59218|
NCT01948531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermIng E2912|Clinical Trial on a Topical "Antiage" Face Gel|Clinical and Instrumental Evaluation of a Topical "Antiage" Formulation for the Face|E2912|Derming SRL|Yes|Completed|December 2012|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01948531||59217|
NCT01948791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BCN05|16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients|16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT)|INSTINCT|Novartis|No|Recruiting|August 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|186|||Both|50 Years|85 Years|No|||June 2015|June 2, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948791||59197|
NCT01948804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ytu-123|The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.|The Comparison of Effect of Four Different Treatment Protocols: Antagonist/Letrozole Protocol, Microdose Flare-up Protocol, Antagonist/Clomiphene Protocol, Antagonist on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization; a Prospective Randomized-controlled Study.||Yeditepe University Hospital|Yes|Not yet recruiting|January 2014|||March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01948804||59196|
NCT01950182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-002|Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer|A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype|SYSUCC-002|Sun Yat-sen University|Yes|Recruiting|September 2013|June 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|392|||Female|18 Years|75 Years|No|||February 2015|February 12, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01950182||59090|
NCT01947738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBY-891-001|Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)|A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects||Virobay Inc.|Yes|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947738||59278|
NCT01951300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/2013|68Ga-Citrate PET of Healthy Volunteers|68Ga-Citrate Positron Emission Tomography (PET) of Healthy Volunteers|SITRAT|Turku University Hospital|No|Completed|September 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 3, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01951300||59004|
NCT01947751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNSConceicao|Catheter Early Withdrawal or Maintenance in Sepsis or Septic Shock|Comparison Between Catheter Early Withdrawal or Maintenance in Sepsis or Septic Shock With Undefined Origin||Hospital Nossa Senhora da Conceicao|No|Recruiting|March 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|95 Years|No|||September 2013|September 19, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947751||59277|
NCT01937455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI A003/CHOP HVDDT 001|A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.|Safety and Immunogenicity Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.||International AIDS Vaccine Initiative|Yes|Recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937455||60066|
NCT01937416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12276102D|Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia|Safety and Efficacy Investigation of Patients With Diabetic Lower Limb Ischemia by Transplantation of Autologous Bone Marrow Mononuclear Cells||Hebei Medical University|Yes|Recruiting|January 2012|December 2014|Anticipated|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years|No|||December 2013|December 3, 2013|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937416||60069|
NCT01937429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.713|Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy|GRAND BLEU Study: Does the Colonoscopy With Instillation of Blue Water (Indigo Carmin® Dilute) Enable an Improved Rate of Adenoma Detection for Colonoscopy With Insufflation of Air?|GRAND BLEU|Hospices Civils de Lyon|Yes|Recruiting|January 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937429||60068|
NCT01938053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K12HD051953 Reed|Improving Sexually Transmitted Infection (STI) Results Notification and Partner Services|Improving Sexually Transmitted Infection (STI) Results Notification and Partner Services||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|April 2011|December 2013|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|609|||Both|14 Years|21 Years|No|||September 2013|September 5, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938053||60022|
NCT01937780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2274|Anal Cancer Radiotherapy Study|Anal Cancer Radiotherapy - Prospective Study of Treatment Outcome, Patient-Reported Outcomes, Utility of Imaging and Biomarkers, and Cancer Survivorship|ANCARAD|Oslo University Hospital|No|Recruiting|August 2013|||September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Tissue and blood specimens|Both|18 Years|N/A|No|Probability Sample|Patients with anal cancer to be treated with radiotherapy or chemoradiotherapy|September 2013|September 4, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01937780||60042|
NCT01938066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0028|Procellera and Negative Pressure Therapy for Acute Wounds|Clinical Outcomes for Patients With Acute Surgical Wounds Treated With Procellera and Negative Pressure Therapy Versus Standard of Care, Negative Pressure Therapy Only||Ohio State University|Yes|Active, not recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|69 Years|No|||September 2014|September 28, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938066||60021|
NCT01935297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/14/12|Exercise Training After Transcatheter Aortic Valve Implantation|Safety, Applicability and Outcome of Regular Exercise Training After Transcatheter Aortic Valve Implantation|SPORT:TAVI|Technische Universität München|No|Completed|June 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||January 2015|January 22, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01935297||60232|
NCT01947699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPMC_GLY_GDM|Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide|||University of Pittsburgh|No|Withdrawn|September 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|50 Years|No|||January 2016|January 26, 2016|September 17, 2013|Yes|Yes|PI decided to withdrawal study before recruitment started|No||https://clinicaltrials.gov/show/NCT01947699||59281|
NCT01947933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15039|A Safety Study of LY3074828|A Phase I, Randomized, Placebo-Controlled Study of LY3074828, an Anti-IL-23 Humanized Antibody||Eli Lilly and Company|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947933||59263|
NCT01947920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102458|A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Multiple Ascending Doses of Tramadol Hydrochloride in Healthy Male and Female Subjects||Janssen Scientific Affairs, LLC|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|August 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947920||59264|
NCT01947673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066932|Mechanisms of Intradialytic Hypertension|Sympathetic Regulation in Intradialytic Hypertension|MID-H|Emory University|No|Recruiting|September 2013|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947673||59283|
NCT01948544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01053013A|Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease|A Study to Evaluate Improvement in the Quality of Life and Outcomes of Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)||StratiHealth|Yes|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|65 Years|85 Years|No|Probability Sample|COPD Patients prescreened and selected by their primary care physician or pulmonologist|November 2015|November 24, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948544||59216|
NCT01948232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000035483|Pilot Study of Perindopril in Childhood Cancer Survivors|A Phase II Open Label Pilot Study of the Angiotensin-converting Enzyme Inhibitor, Perindopril, in Pediatric Cancer Survivors With Evidence of Early Cardiac Remodelling or Dysfunction.||The Hospital for Sick Children|Yes|Withdrawn|September 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|20 Years|No|||October 2015|October 2, 2015|September 18, 2013|Yes|Yes|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01948232||59240|
NCT01949142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201302|OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO-201 Given as a Single Intratympanic Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement||Otonomy, Inc.|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|6 Months|12 Years|No|||August 2015|August 17, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949142||59170|
NCT01949155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201303|OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO-201 Given as a Single Intratympanic Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement||Otonomy, Inc.|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|6 Months|12 Years|No|||August 2015|August 17, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949155||59169|
NCT01949428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH003|House Dust Mite Observational Study|A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis|May 2014|May 14, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949428||59148|
NCT01950741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1304-013-014|Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy|An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy|VAULT|Pusan National University Hospital|No|Active, not recruiting|September 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|N/A|N/A|No|||December 2014|December 17, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950741||59047|
NCT01951313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308013929|Effects of Egg Consumption on Carotenoid Absorption From Co-consumed, Non-Egg Food|EffectEffects of Egg Consumption on Carotenoid Absorption From Co-consumed, Non-Egg Food||Purdue University|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|1||Actual|17|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01951313||59003|
NCT01951612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-53|Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors|Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors||Baycrest||Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01951612||58981|
NCT01937221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047227|Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease|Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease||Duke University|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal controls and patients with mild, mild to moderate cognitive impairment|August 2015|August 6, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937221||60084|
NCT01937728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-970119|Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)|A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|March 2010|December 2015|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|750|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01937728||60045|
NCT01937754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neo-4085|Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults|Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension||Neogenis Laboratories||Active, not recruiting|January 2013|||September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937754||60044|
NCT01938079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM0950|Ketamine and Extracorporeal Membrane Oxygenation (ECMO)|The Use of Ketamine in Patients Receiving Extracorporeal Membrane Oxygenation||Columbia University|Yes|Completed|September 2013|August 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||August 2015|August 2, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938079||60020|
NCT01938352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR8020FLZ2002|Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge|Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model||Crucell Holland BV|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|September 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938352||59999|
NCT01938898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/23|The NICOLA Recruitment Trial (NICOLA-RT)|The NICOLA Recruitment Trial (NICOLA-RT): the Effect of Invitation Letters on Overall Recruitment in a Longitudinal Cohort Study in People Over Age of 50.|NICOLA-RT|Queen's University, Belfast|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Anticipated|13000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938898||59958|
NCT01935063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT-02|Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia|A Comparison of Cognitive-behavioral Couple Therapy and Lidocaine in the Treatment of Provoked Vestibulodynia: A Randomized Clinical Trial|CBCT-RCT|Université de Montréal|No|Recruiting|November 2013|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|45 Years|No|||December 2015|December 3, 2015|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935063||60250|
NCT01947946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00016|Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma||AstraZeneca|No|Terminated|November 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|75 Years|No|||October 2015|November 23, 2015|September 11, 2013|Yes|Yes|Study terminated due to sponsor decision|No|July 21, 2015|https://clinicaltrials.gov/show/NCT01947946||59262|
NCT01947959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16159|Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)|A Proposed Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in Germany||Bayer|No|Recruiting|December 2011|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20000|||Both|2 Years|N/A|No|Non-Probability Sample|All patients aged 2 years and above who have been enrolled in German        Pharmacoepidemiological Research Database (GePaRD) for at least one year.|February 2016|February 29, 2016|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01947959||59261|
NCT01948557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT063009|Vertical Transmission Study|A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women|VTS|University of KwaZulu|Yes|Completed|October 2001|October 2006|Actual|September 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|3465|||Female|16 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 18, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948557||59215|
NCT01948245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-127|Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.|A Double Blinded, Randomized, Controlled Investigation of Taurolidine-citrate/Heparin Catheter Lock Solution Versus Heparin in Patients on Home Parenteral Nutrition With Previously Proven High Risk of Catheter Related Blood Stream Infections.||Rigshospitalet, Denmark|No|Active, not recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|42|||Both|18 Years|80 Years|No|||June 2014|June 19, 2014|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948245||59239|
NCT01949168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-6 study|A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV|Phase 2a Study of Boceprevir for the Treatment of Genotype 6 Hepatitis C|HCV-6|St Vincent's Hospital Melbourne|No|Not yet recruiting|September 2013|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||September 2013|September 19, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01949168||59168|
NCT01948817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2420|Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses|A Prospective Single Arm Study to Assess the Efficacy and Safety of Deferasirox 20 mg/kg BID in Transfusion Dependent Thalassemia Patients Inadequately Responding to Current Treatment With Doses > 35mg/kg QD (Once a Day).||Novartis|No|Withdrawn|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|N/A|No|||January 2014|January 15, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948817||59195|
NCT01949662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0345|Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer|A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit||M.D. Anderson Cancer Center|Yes|Recruiting|January 2014|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949662||59130|
NCT01949935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBHC-MIR004|Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting|MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting|MIR-CABG|Horizon Health Network|Yes|Completed|March 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|974|||Both|19 Years|N/A|No|||September 2013|September 20, 2013|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01949935||59109|
NCT01950481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2110|Effect of Hepatic Impairment on LDK378 Pharmacokinetics|A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function||Novartis|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950481||59067|
NCT01951599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00005|To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.|A Phase I, Open-label, Single-center, Sequential Design Study in Healthy Volunteers to Determine the Relative Bioavailability of Different Oral Formulations of AZD9291 and the Effect of Food||AstraZeneca|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951599||58982|
NCT01951846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.1|To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours|An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|November 2002|||November 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|September 17, 2013||||||https://clinicaltrials.gov/show/NCT01951846||58963|
NCT01951885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6Z13|Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention|Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease||Case Comprehensive Cancer Center|Yes|Recruiting|May 2014|July 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|70 Years|No|||December 2015|December 4, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951885||58960|
NCT01947790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze051|Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease|Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|75 Years|No|||August 2015|August 17, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01947790||59274|
NCT01948063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000267|Ubiquinol (Reduced COQ10) for Patients With Sepsis|Ubiquinol (Reduced COQ10) for Patients With Sepsis||Beth Israel Deaconess Medical Center|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|38|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948063||59253|
NCT01937481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA NIFA 2010-85215-20648|The Colorado LEAP Study: A Socioecological Approach to Obesity Prevention in Early Childhood|A Longitudinal Study to Assess if the Effectiveness of a Preschool Nutrition and Physical Activity Program is Sustained in Elementary School||Colorado State University|No|Active, not recruiting|September 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|230|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01937481||60064|
NCT01937468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-281|Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase I Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease||Dana-Farber Cancer Institute|Yes|Recruiting|November 2013|July 2018|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937468||60065|
NCT01937767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS7056-010|Remimazolam Phase II Cardiac Anesthesia Study|A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU||Paion UK Ltd.|No|Completed|August 2013|||February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937767||60043|
NCT01934829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1163|Urea Cream Treatment Sorafenib-Associated HSFR in HCC|Randomized Controlled Phase II Study of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma||Chinese Anti-Cancer Association|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|871|||Both|N/A|N/A|No|||August 2013|August 30, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934829||60267|
NCT01934842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-P005|A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System||Seventh Sense Biosystems|No|Withdrawn|September 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|November 24, 2014|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934842||60266|
NCT01931709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7587|FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer|Quantitative Dynamic PET and MRI and Breast Cancer Therapy||University of Washington|No|Active, not recruiting|October 2011|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|65|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931709||60507|
NCT01931696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYSNXD-CC-ZDYJ039|Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma|Clinical Assessment of Acupuncture for the Treatment of Asthma: A Randomized, Multicenter, Double-blind, Parallel-group Controlled Trial||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|July 2013|July 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|65 Years|No|||August 2013|November 3, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931696||60508|
NCT01931943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLSLTN-102|A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer|A Phase Ib Study to Evaluate the Tolerability and Pharmacokinetics of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer||Qilu Pharmaceutical Co., Ltd.||Recruiting|April 2013|||December 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|65 Years|No|||August 2013|August 27, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01931943||60489|
NCT01948258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0481|Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study|Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study||SPD Development Company Limited|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|395|Samples Without DNA|Urine samples collected and retained|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Women wishing to become pregnant|September 2013|March 5, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948258||59238|
NCT01948271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSOPSO13|Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis|An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis||Tufts Medical Center|No|Terminated|July 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|September 18, 2013|No|Yes|lack of efficacy|No||https://clinicaltrials.gov/show/NCT01948271||59237|
NCT01948284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalinTzuChi-Hsieh-2013-2|Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy|A Randomized, Controlled Trial Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy||Dalin Tzu Chi General Hospital|Yes|Recruiting|August 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|74|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01948284||59236|
NCT01948856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0022X ST 3 02|CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study|||Pierre Fabre Medicament||Active, not recruiting|September 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|3 Years|4 Years|No|||April 2015|April 20, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948856||59192|
NCT01949181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/37|Blood, Hair and Lung Concentrations of Metals and Metalloids in Patients With Lung Cancer or Chronic Obstructive Pulmonary Disease|Relationship Between Blood, Hair and Lung Metals/Metalloids Concentration (Cadmium, Iron, Copper, Nickel, Chrome, Arsenic, Vanadium, Beryllium, and Zinc) and Lung Cancer or Chronic Obstructive Pulmonary Disease.|Métaux/Poumons|Hopital Foch||Recruiting|August 2011|||April 2014|Anticipated|N/A|Interventional|Primary Purpose: Basic Science|||||||Both|18 Years|75 Years|No|||September 2013|September 19, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949181||59167|
NCT01948830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2411|Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD|A 12-month, Phase IIIb, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular AMD|TREND|Novartis|No|Completed|December 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|649|||Both|50 Years|N/A|No|||January 2016|January 29, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948830||59194|
NCT01948843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-004|Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer|Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor||Polaris Group|No|Active, not recruiting|April 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948843||59193|
NCT01949194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCROC-06|Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers|A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy||Jewish General Hospital|No|Recruiting|September 2013|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01949194||59166|
NCT01949454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF1707/UND|Fluorometholone as Ancillary Therapy for TT Surgery|Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study||University of Pennsylvania|Yes|Recruiting|November 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|156|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949454||59146|
NCT01949675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC02|A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines|Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines||Sanofi|No|Completed|March 2014|August 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|336|||Both|1 Year|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949675||59129|
NCT01949441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH004|ToleroMune House Dust Mite (HDM) Tolerability Study|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Tolerability of ToleroMune House Dust Mite in Subjects With Controlled Asthma and House Dust Mite-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||June 2014|June 10, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949441||59147|
NCT01950195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1382|SRS (Stereotactic Radiosurgery) Plus Ipilimumab|A Pilot Study of Stereotactic Radiosurgery Combined With Ipilimumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine||Sidney Kimmel Comprehensive Cancer Center|Yes|Suspended|September 2013|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 5, 2015|June 21, 2013|Yes|Yes|Recruitment on hold pending amendment|No||https://clinicaltrials.gov/show/NCT01950195||59089|
NCT01950468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV5-02|A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes||Navidea Biopharmaceuticals|No|Not yet recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|275|||Both|40 Years|N/A|No|||September 2014|September 23, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950468||59068|
NCT01951287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303013430|Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults|Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes|S37|Purdue University|No|Completed|August 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|54|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01951287||59005|
NCT01950780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL7102|Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata|An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata||Columbia University|No|Completed|August 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950780||59044|
NCT01951027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-G3_HV_1|Phase I Study GX-G3 in Healthy Subjects|A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects|GX-G3|Genexine, Inc.|No|Completed|September 2013|December 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|4||Actual|53|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01951027||59025|
NCT01948076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-002845|Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination|Use of a Pocket-sized Ultrasound Device as an Aid to the Physical Examination for Internal Medicine Residents||Brigham and Women's Hospital|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|September 16, 2013||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01948076||59252|
NCT01948375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-0|A Crossover Study on the Blinding Effect of a New Pragmatic Placebo Needle|Effect of Blinding With a New Pragmatic Placebo Needle: a Crossover Study||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|60|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|September 8, 2013|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT01948375||59229|
NCT01948648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:075|Effects of Colesevelam|Effects of Colesevelam as an Adjunct Therapy for Sitosterolemia||University of Manitoba|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|15|||Both|12 Years|N/A|No|||November 2015|December 1, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948648||59208|
NCT01937793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211062RIB|Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy|Swallowing Exercises for Patients With Nasopharyngeal Cancer After Radiation Therapy||National Taiwan University Hospital|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|70 Years|No|||April 2014|April 16, 2014|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937793||60041|
NCT01938924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/YH/0480|Surgical Revascularisation and Nerve Stimulation Trial|A Randomised Control Trial to Establish if Use of the gekoTM (Trademark) Post Infra-inguinal Surgical Vein Revascularisation Increases Flow Through the Graft|SRANS|University of Hull|Yes|Withdrawn|September 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|September 5, 2013||No|No funding|No||https://clinicaltrials.gov/show/NCT01938924||59956|
NCT01931436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QE-2458-2|Pharmacokinetics Study of Qing'E Pill|A Single-site, Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics of the Main Components of Qing'E Pill (a Chinese Medicine Formula) Into the Blood in Chinese Menopausal Women||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|August 2013|||September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Female|40 Years|60 Years|No|||August 2013|August 26, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01931436||60528|
NCT01932268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colchicine_RFP 2011_1|A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin|||Seoul National University Hospital|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|19 Years|80 Years|No|||August 2013|August 26, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01932268||60464|
NCT01932281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00121|SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes|SierraSil as an Ergogenic Aid to Performance in Athletes||University of British Columbia|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932281||60463|
NCT01931969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLM vs USG for RIJVC|Central Landmark vs USG for IJV Catheterization|Comparison of Internal Jugular Vein Catheterization Entry Points Determined by Ultrasonography Versus the Central Landmark Guided Method||Ankara University|Yes|Active, not recruiting|December 2012|October 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients undergoing cardiovascular surgery who needed to have internal jugular vein        catheterization|August 2013|August 29, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01931969||60487|
NCT01931982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eudraCT: 2012-005013-38|Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.|Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2|EGOFIP|Bispebjerg Hospital|Yes|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|25 Years|75 Years|No|||June 2014|June 24, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01931982||60486|
NCT01948869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16960|Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis|An Investigator-blinded, Randomized, Monocentre, 3-arm, Pilot Trial to Compare the Efficacy and Safety of Two Topical Medical Devices in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With Untreated Skin|Phoenix II|Bayer|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|60 Years|No|||August 2014|August 6, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01948869||59191|
NCT01949220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WINGS|Willebrand International Non-interventional Global Surveillance|International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease.||Laboratoire français de Fractionnement et de Biotechnologies|No|Recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Any patient, whatever their age, with inherited von Willebrand disease|March 2016|March 7, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01949220||59164|
NCT01949233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023612-14|The Oxford Marfan Trial|A Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance Imaging||University of Oxford|No|Recruiting|October 2013|December 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|56|||Both|13 Years|N/A|No|||June 2015|June 8, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01949233||59163|
NCT01949207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT20133|RCT - Does Treating Incompetent Perforators Reduce Recurrence?|Randomised Controlled Study to Determine Whether Treating Incompetent Perforating Veins at the Time of Endothermal Varicose Vein Surgery for Truncal Reflux Reduces Recurrence After Varicose Vein Treatments.||The Whiteley Clinic|Yes|Not yet recruiting|July 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01949207||59165|
NCT01950208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beiromat_01|The Munich Knee Questionnaire - Development and Validation|The Munich Knee Questionnaire (MKQ) - Development and Validation of a New Patient-reported Outcome Measurement Tool in Knee Surgery|MKQ|Technische Universität München|No|Completed|August 2012|April 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|||Both|18 Years|N/A|No|Probability Sample|all patients with knee pain|September 2013|September 20, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01950208||59088|
NCT01949948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2011/2435|Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke|Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke|NOR-TEST|Haukeland University Hospital|Yes|Recruiting|September 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|954|||Both|18 Years|N/A|No|||October 2015|October 25, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01949948||59108|
NCT01951014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1308004041|Text for Prenatal Health Study|Text for Prenatal Health Study||Cornell University|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|30|||Both|13 Years|N/A|No|||November 2014|November 13, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01951014||59026|
NCT01951625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15371|Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)|A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)||Bayer|Yes|Completed|November 2013|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|456|||Both|18 Years|N/A|No|||July 2015|August 28, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951625||58980|
NCT01951638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15829|Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)|A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)||Bayer|Yes|Completed|November 2013|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|477|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951638||58979|
NCT01948388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA2013-01|The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients|Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging||Gaylis, Norman B., M.D.|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01948388||59228|
NCT01948401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB28850|A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma|A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA||Hoffmann-La Roche||Completed|July 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Masking: Open Label|3||Actual|54|||Both|12 Years|75 Years|No|||March 2016|March 1, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01948401||59227|
NCT01948674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00080023|Cognitive Stimulation in Adolescents|Cognitive Training in Adolescents During Treatment for Substance Use Disorders||Johns Hopkins University|No|Active, not recruiting|October 2013|February 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|14 Years|21 Years|No|||September 2015|September 10, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01948674||59206|
NCT01960244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045568|Study of Awareness and Detection of Familial Hypercholesterolemia|CAscade SCreening for Awareness and Detection of Familial Hypercholesterolemia|CASCADE-FH|The Familial Hypercholesterolemia Foundation|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed Familial hypercholesterolemia (FH).|December 2014|December 18, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01960244|3 Years|58317|
NCT01938625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102639|A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation|Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation||Janssen R&D Ireland|No|Completed|December 2013|July 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938625||59978|
NCT01938638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16519|Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies||Bayer|No|Recruiting|September 2013|March 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|21 Years|N/A|No|||March 2016|March 15, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938638||59977|
NCT01938911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215/10|The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension|The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension||University Hospital Inselspital, Berne|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|160|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938911||59957|
NCT01930864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetIri|Metformin Plus Irinotecan for Refractory Colorectal Cancer|Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer||Barretos Cancer Hospital|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930864||60572|
NCT01931137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1953-3973|A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects|A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects||Novo Nordisk A/S|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|January 3, 2014|August 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931137||60551|
NCT01931995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p001784|Investigation of Brain Network Dynamics in Depression|Investigation of Cortico-limbic Networks and Their Dynamics in Major Depressive Disorder||Brigham and Women's Hospital|No|Recruiting|February 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01931995||60485|
NCT01932593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIAMMS-II|Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis|Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (SIAMMS-II)|SIAMMS-II|North Bristol NHS Trust|No|Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|25 Years|80 Years|No|||April 2014|April 16, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01932593||60439|
NCT01932567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|physioEIT|Electrical Impedance Tomography (EIT) and Physiotherapy|Effect of Physiotherapy Evaluated by Electrical Impedance Tomography||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|August 2013|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01932567||60441|
NCT01932580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-TA-01 / McG 1319|Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma|Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma||McGill University|No|Completed|August 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 25, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01932580||60440|
NCT01949701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-23-56|Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 (URLC10) in Patients With Disease Controlled Advanced Non-small Cell Lung Cancer||Shiga University|Yes|Recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|85 Years|No|||September 2013|September 20, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949701||59127|
NCT01949688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-22-15|Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 or HLA-A*02 in Patients With Advanced Solid Tumors That Are Refractory to Standard Therapy||Shiga University|Yes|Recruiting|June 2010|March 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|20 Years|85 Years|No|||September 2013|September 20, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949688||59128|
NCT01950754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANCKOUNDIA PHRC IR 2007|Study of the Effect of a Cognitive Task on Static Balance in Depressive Elderly Subjects According to the Double Task Principle|Study of the Effect of a Cognitive Task on Static Balance in Depressive Elderly Subjects According to the Double Task Principle|DOUBLE TACHE|Centre Hospitalier Universitaire Dijon|No|Recruiting||||October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 24, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950754||59046|
NCT01950767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC84621|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||November 28, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950767||59045|
NCT01951040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYTO-2011-BRSTF|Effect of Synthetic Oxytocin Administered During Labor on Breastfeedings|Effect of Oxytocin Administered During Labor on the Onset and Duration of Breastfeeding: A Retrospective Cohort Study.||Hospital Materno-Infantil de Málaga|No|Completed|February 2011|September 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|346|||Both|N/A|N/A|No|Probability Sample|Study population consisted of children born in our center (Hospital Materno-Infantil in        Malaga) during 2006. Our hospital is a tertiary center of the Spanish national health        system where were born 7465 children, representing 41.2% of all babies born in our        province, from 7246 deliveries during that year|September 2013|September 23, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01951040||59024|
NCT01950494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiteBacFINAL|FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults|A One Month, Randomized, Two-center, Parallel-group, Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of FiteBac Hand Sanitizer TID vs Emollient Therapy in the Management of Hand Dermatitis in Adults|FiteBac|National Jewish Health|No|Completed|September 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||February 2015|February 3, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950494||59066|
NCT01950507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130197|Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease|Evaluation of Serum Concentrations of Budesonide in Patients Treated for Gastrointestinal Graft-Versus-Host Disease and the Potential Interaction With Fluconazole or Voriconazole||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|13 Years|N/A|No|||June 2015|June 25, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950507||59065|
NCT01950520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130200|Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate|The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|134|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|September 2, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950520||59064|
NCT01951326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHB-104-01|Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease|A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease|MAPUS|RedHill Biopharma Limited|Yes|Recruiting|September 2013|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|75 Years|No|||October 2015|March 10, 2016|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951326||59002|
NCT01947803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100855|A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia|Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study||Xian-Janssen Pharmaceutical Ltd.|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|353|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947803||59273|
NCT01959945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC08|Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)|Evaluation of the Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Quadrivalent Recombinant Influenza Vaccine,Seasonal Formulation) Administered Intramuscularly to Healthy Children and Adolescents Age 6-17 Years||Protein Sciences Corporation|Yes|Completed|November 2013|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|219|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959945||58340|
NCT01960231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0464-JI-CTIL|The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family|||Sheba Medical Center|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|12 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|MODY-2 family|May 2014|May 26, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01960231||58318|
NCT01960491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.4678|FIH Study With CBSO|Prospective Single Center Pilot Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device With Biodegradable Framework in Patients With Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO)||Carag AG|No|Recruiting|May 2014|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960491||58298|
NCT01960517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUCS/2013/ACS01|Feasibility Assessment of ACS Catheter|A Feasibility Assessment of a New Urinary Catheter: The Alternative Catheter System ACS)|ACS1|Alternative Urological Catheter Systems Ltd.|No|Withdrawn|January 2014|May 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|January 22, 2015|October 7, 2013||No|Sponsor decision not to proceed with study|No||https://clinicaltrials.gov/show/NCT01960517||58296|
NCT01938378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-213|Octaplas Pediatric Plasma Exchange Trial|An Open-label, Multicenter, Post-Marketing Requirement Study to Investigate the Safety and Tolerability of Octaplas™ in the Management of Pediatric Patients Who Require Therapeutic Plasma Exchange|Octaplas|Octapharma|Yes|Recruiting|April 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|4 Years|20 Years|No|||August 2015|August 27, 2015|September 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938378||59997|
NCT01938651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1277|Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer|Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Female|18 Years|N/A|No|||October 2015|October 22, 2015|September 4, 2013|Yes|Yes|funding ceased|No||https://clinicaltrials.gov/show/NCT01938651||59976|
NCT01938664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32241|A Pilot Study of Candesartan as a Treatment for Cocaine Dependence|Pilot Study of Candesartan: An Angiotensin Receptor Blocker as a Treatment for Cocaine Dependence||Baylor College of Medicine|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|64 Years|No|||January 2016|January 25, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938664||59975|
NCT01931722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Exercise and Branched Chain Amino Acids (BCAA)Requirements in Older Men|Can Branched Chained Amino Acid Supplementation Combined With Strength-Training Minimize Sarcopenia in Older Men?||University of Western Ontario, Canada|Yes|Suspended|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|55 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|August 26, 2013||No|not able to find enough participants for this study|No||https://clinicaltrials.gov/show/NCT01931722||60506|
NCT01932294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medamacs|Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support|Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support|Medamacs|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|April 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|80 Years|No|Non-Probability Sample|Participants will be screened for this study if they are between 18 and 80 years old with        low ejection fraction history and hospitalization for heart failure within the past year.        All subjects who have been admitted to the heart failure service will be screened and        recruited for study participation, either as an inpatient or during their first outpatient        follow-up appointment by the investigator and research staff caring for patients in the        advanced heart failure program of the enrolling center.|October 2015|October 12, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01932294|2 Years|60462|
NCT01932307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01151|Cervical Spine Health of Surgeons|Cervical Spine Health of Surgeons||University of British Columbia|No|Withdrawn|December 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932307||60461|
NCT01932606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004077|Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction|Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction||Mayo Clinic|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|August 27, 2013|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT01932606||60438|
NCT01932814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REAMICHOC|Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?|Retrospective Analysis of Aminoglycoside-associated Acute Renal Injury in Septic Critically Ill Patients|REAMICHOC|Université Victor Segalen Bordeaux 2|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|317|||Both|18 Years|N/A|No|Probability Sample|critically ill septic patients|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932814||60422|
NCT01949467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FERHEP|Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.|Prospective, Comparative (5 Groups), Non-randomized, Multicenter, Physiopathological Study, Evaluating Pharmacokinetic Characteristics of Serum Hepcidin Level in Response to Iron Oral Intake in Order to Evaluate Their Interest to Discriminate Patients With Dysmetabolic Hepatosiderosis or Ferroportin Disease.||Rennes University Hospital|No|Recruiting|February 2014|June 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949467||59145|
NCT01949714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0005|Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue|Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue||University of Aarhus|Yes|Recruiting|August 2013|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|15|Samples With DNA|Blood and adipose tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with adrenal tumors|November 2015|November 30, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949714||59126|
NCT01949974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PAI-2011-36|Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients|Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients: A Randomized Multicenter Clinical Trial|PAI|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Withdrawn|June 2013|June 2016|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||August 2013|May 27, 2014|September 17, 2013||No|Dificulties in the recruitment of patients.|No||https://clinicaltrials.gov/show/NCT01949974||59106|
NCT01950247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT13032|Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and to Compare Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting|A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting||Luitpold Pharmaceuticals|No|Recruiting|August 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950247||59085|
NCT01950260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002570|Early Levothyroxine Post Radioactive Iodine|Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease||Mayo Clinic|No|Recruiting|September 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 12, 2015|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950260||59084|
NCT01949961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2011/2448|The Norwegian Sonothrombolysis in Acute Stroke Study|Randomised Trial of Contrast-enhanced Sonothrombolysis in Acute Ischaemic Stroke|NOR-SASS|Haukeland University Hospital|Yes|Terminated|September 2012|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 21, 2013||No|Lack of funding for researchers|No||https://clinicaltrials.gov/show/NCT01949961||59107|
NCT01950533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMULITE 2000|The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy|The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy|IMMULITE 2000|National Jewish Health|No|Recruiting|September 2013|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|3 Years|21 Years|No|Non-Probability Sample|Study population will be primarily obtained from the pediatric clinic at National Jewish        Health from those suspected of egg, milk and/or peanut food allergy.|September 2013|September 23, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950533||59063|
NCT01950221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002413|Pomegranate Extract and Memory|12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract||University of California, Los Angeles|No|Completed|October 2011|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|212|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01950221||59087|
NCT01950234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTH-20712|ACTH in Progressive Forms of MS|Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950234||59086|
NCT01951651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26030|Effect of Exenatide on Liver and Heart Fat and Inflammation|Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus||Baylor College of Medicine|No|Completed|April 2010|March 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|70 Years|No|||September 2013|September 24, 2013|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951651||58978|
NCT01951339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2015|Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes|Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes||University of Colorado, Denver|No|Recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|28|||Both|22 Years|70 Years|No|||November 2015|December 3, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951339||59001|
NCT01951898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU-012012|Effects of Montelukast on Airway Regulatory T Cells in Asthma|Effects of Montelukast on Airway Foxp3+ and CTLA4+CD25highCD4+ T Cells in Asthmatics||Kurume University||Recruiting|June 2012|May 2015|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|20 Years|50 Years|No|||September 2013|September 24, 2013|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01951898||58959|
NCT01948089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ext-Prim-12|Exploring the Long-term Effects of Cognitive Exercise on Cognition After Stroke|||Nova Scotia Health Authority|No|Terminated|September 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2013|September 17, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01948089||59251|
NCT01960257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHF TB 001|Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis|A Pilot Clinical Trial Characterizing Use of Ingestion Sensor Enabled Rifamate in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis||mHealth UCSD|No|Recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960257||58316|
NCT01960270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/003/HP|Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients|Secondary Bilateral or Controlateral Sacral Nerve Stimulation in Overactive Bladder Patients With Unilateral Stimulation Failure - Multicenter Study|NEUROBIL|University Hospital, Rouen|No|Recruiting|October 2013|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||January 2016|January 22, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01960270||58315|
NCT01930877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32510|Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery|The Effect of Perioperative Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery: A Randomized, Double - Blinded, Placebo Controlled Study||Baylor College of Medicine|No|Withdrawn|August 2013|||April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|August 26, 2013||No|Withdrawn by PI|No||https://clinicaltrials.gov/show/NCT01930877||60571|
NCT01930357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRV06|Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years||Sanofi|No|Completed|September 2013|June 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|342|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930357||60611|
NCT01930565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1209-069-427|Effectiveness and Safety of New Botanical Component-LFCO- Compared With Existing TTO in Clinical Study|Comparison of Clinical and Histological Effects Between Lactobacillus Fermented Chamaecypris Obtusa and Tea Tree Oil for the Treatment of Mild to Moderate Acne: an 8-week Double Blind, Randomized Controlled, Split-face Study||Seoul National University Hospital|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01930565||60595|
NCT01930851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-139-13|Complications After Bariatric Surgery Based, a Questionnaire Survey|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on a Questionnaire Survey||University of Aarhus|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1429|||Both|18 Years|70 Years|No|Non-Probability Sample|Gatric bypass operated patients in the Central Denmark Region|August 2013|December 3, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01930851||60573|
NCT01932008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-100110-F|Evaluation of the Bone Mineral Density and Muscle Mass in Patients Post Coronary Artery Bypass Graft Surgery With Chronic Kidney Disease|||Far Eastern Memorial Hospital|Yes|Completed|May 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|60|||Male|40 Years|75 Years|No|Probability Sample|All patients who underwent CABG at the Department of Cardiovascular Center at Far-Eastern        Memorial Hospital since January 2000 were selected for recruitment to this study.Thirty        male patients after CABG with CKD and 30 matched controls were recruited (ages between        40-75 years old).|April 2012|August 29, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932008||60484|
NCT01932320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016765|A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813|An Open Label Study to Investigate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932320||60460|
NCT01932619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08178|The Influence of Storage Container and Defrost Process on Components in Breast Milk|The Influence of Storage Container and Defrost Process on Components in Breast Milk||Taichung Veterans General Hospital|No|Completed|January 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|60|Samples Without DNA|breast milk|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy mothers lactating breast milk during first year of their babies|August 2013|August 27, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01932619||60437|
NCT01932853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QM-RR-02|Association Between Dose Dialysis by Kt and Mortality|Evaluation of the Association of Dialysis Dose Obtained by Kt and Mortality in Hemodialysis Patients||NephroCare Spain|No|Active, not recruiting|October 2013|December 2015|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Study subjects:        Patients> 18 years in hemodialysis treatment at any FMC center of Spain that meet the        inclusion criteria.        Data will be collected according to clinical practice and patients will be categorized        according to their dose of Kt, along the two years of the study. Will seek the association        of dialysis dose with mortality and hospitalization|October 2015|October 1, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932853||60419|
NCT01932827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFMnet-02|Attidutes and Understanding of Oat Fibre Claims on Food Labels|||University of Toronto||Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1002|||Both|20 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|A subsection of the Canadian Consumer Monitor Panel - a national representative online        consumer panel comprised of 30,000 Canadians|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932827||60421|
NCT01932840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFMnet-01|Attitudes and Understanding of Plant Sterol Claims on Food Labels|||University of Toronto|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1017|||Both|20 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|A subsection of the Canadian Consumer Monitor Panel - a national representative online        consumer panel comprised of 30,000 Canadians|August 2013|August 27, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932840||60420|
NCT01932866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEA Trial|Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence|Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence (IDEA Trial)|IDEA|Wilford Hall Medical Center|No|Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|223|||Both|30 Years|75 Years|No|||August 2013|August 27, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01932866||60418|
NCT01950286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVALL-02|Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.|Four Years Experience With Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. Population-based Data.||University Hospital Orebro|No|Completed|October 2002|||February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with T-ALL diagnosis reported to the Swedish Adult Acute Leukemia Registry        between October 2002 and September 2006|September 2013|September 21, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01950286|20 Years|59082|
NCT01950559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0097|Evaluation of Potential Allergenicity of New Soybean Varieties|Evaluation of Potential Allergenicity of New Soybean Varieties|Monsanto|University of Colorado, Denver|No|Recruiting|September 2013|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Subjects may opt to have extra blood drawn. Ths sample will be de-identified and sent to the      sponsor, Monsanto, for future study that is yet to be determined.|Both|6 Months|40 Years|No|Non-Probability Sample|Study population will primarily be obtained through patients at National Jewish Health|February 2016|February 22, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950559||59061|
NCT01950806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10998|The Effect of Pecans on Biomarkers of Risk for Cardiovascular Disease and Diabetes|The Effect of Pecans on Biomarkers of Risk for Cardiovascular Disease and Diabetes: A Controlled Feeding Trial in Overweight/Obese Adults With Central Adiposity||Tufts University||Recruiting|January 2014|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|25|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950806||59042|
NCT01950819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2433|Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)|A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation|TRANSFORM|Novartis|No|Recruiting|December 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2040|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01950819||59041|
NCT01950546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOP01|Nanosilver Fluoride to Prevent Dental Biofilms Growth|Nanosilver Fluoride: a Microbiological and Clinical Trial|NSFCT|University of Pernambuco|Yes|Completed|September 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01950546||59062|
NCT01950793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11-001A|A Comparison Between Sonoguided Injection Corticosteroid and Hyaluronic Acid Injection in Treatment of Trigger Finger|Steroid Versus Hyaluronic Acid Ultrasound-guided Injection for Trigger Finger: A Comparative Study of Outcomes||Taipei Veterans General Hospital, Taiwan|Yes|Completed|November 2012|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|65 Years|No|||November 2014|November 2, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01950793||59043|
NCT01951664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 1282|Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors|Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors||Vanderbilt-Ingram Cancer Center|No|Recruiting|August 2013|January 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951664||58977|
NCT01947816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-190|Special Investigation in Patients With Ulcerative Colitis|Special Investigation in Patients With Ulcerative Colitis||AbbVie||Recruiting|August 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|99 Years|No|Non-Probability Sample|Patients for the first time receiving Humira for the treatment of Ulcerative Colitis|January 2016|January 27, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947816||59272|
NCT01959113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 131244.1|Validation of the Short-term Antimicrobial Action of Transplanted Bacteria|Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis||University of California, San Diego|No|Not yet recruiting|January 2015|November 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959113||58404|
NCT01959646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300529|The Effect of AGE on the Immune System|The Effect of Aged Garlic Extract Supplementation on the Immune System|EAGESIS II|University of Florida|No|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|91|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959646||58363|
NCT01960530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infacort 002|An Investigational Study of Hydrocortisone|A Single Centre, Open Label, Partially Randomised, Single Dose, Crossover Study to Build a Model of Hydrocortisone Metabolism and Evaluate the Pharmacokinetics, Oral Bioavailability and Relationship to Metabolic Parameters of Hydrocortisone and Infacort® in Healthy Adult Male Volunteers.||Diurnal Limited|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|14|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01960530||58295|
NCT01931163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008952|NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer|Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy|NECTAR|The Methodist Hospital System|No|Recruiting|July 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931163||60549|
NCT01931176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 286|Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults|A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2013|May 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01931176||60548|
NCT01931150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-012|Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT|A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT||Memorial Sloan Kettering Cancer Center||Completed|August 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931150||60550|
NCT01931449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDR-2014-01|Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy|Evaluation of a Modified Procedure of Digestive Tract Reconstruction Following Pancreatoduodenectomy: A Multicenter Randomized Controlled Study||Southwest Hospital, China|Yes|Not yet recruiting|January 2014|July 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||August 2013|August 26, 2013|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931449||60527|
NCT01932021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01613-40|Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting|Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting|Angiolipo|University Hospital, Caen|Yes|Recruiting|April 2013|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01932021||60483|
NCT01932333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017164|A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients|A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932333||60459|
NCT01933204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01|Acupuncture for Relieving Perimenopausal Symptoms|Acupuncture for Relieving Perimenopausal Symptoms: a Randomised Controlled Trial||Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|September 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|55 Years|No|||August 2013|September 2, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01933204||60392|
NCT01933191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221014|Exercise Treatment of Dental Anxiety|A Randomised Placebo Controlled Cross-over Trial on Exercise Treatment of Dental Anxiety||Charite University, Berlin, Germany|No|Completed|August 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||February 2015|February 6, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01933191||60393|
NCT01950013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303010805|At-home Auditory Training Clinical Trial|At-home Auditory Training Clinical Trial|Training|Indiana University|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|55 Years|79 Years|No|||November 2015|November 4, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01950013||59103|
NCT01950026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125.608|Temperature Skin Check After Cryotherapy Application|Temperature Skin Check in Different Ethnic Groups After Cryotherapy Application||Paulista University|No|Completed|January 2013|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2013|September 21, 2013|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01950026||59102|
NCT01950039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001265|Metabolic Effects of Betaine Supplementation|Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation||Joslin Diabetes Center|No|Recruiting|January 2014|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|21 Years|65 Years|No|||August 2015|August 6, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950039||59101|
NCT01950299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU HM20000024|Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)|Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3|VCU-ART3|Virginia Commonwealth University|Yes|Recruiting|July 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|21 Years|99 Years|No|||November 2015|November 9, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950299||59081|
NCT01950832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gökhan Açmaz|Eye Evaluation in Patients With PCOS|Evaluation of the Macula, Retinal Nerve Fiber Layer and Choroid Thickness in Women With Polycystic Ovary Syndrome By Using Spectral-domain Optical Coherence Tomography.||Kayseri Education and Research Hospital|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Female|16 Years|43 Years|Accepts Healthy Volunteers|Probability Sample|Participants:        Patients who were diagnosed with PCOS according to 2003 Rotterdam Criteria, had no        physical disease but PCOS, did not receive any treatment for 6 months prior to the study        for PCOS or co-morbidities and had at least primary school degre will enroll into the        study. The second group consisted of 60 healthy volunteer participants in reproductive        age.|September 2013|September 19, 2013|September 17, 2013||||No||https://clinicaltrials.gov/show/NCT01950832|1 Month|59040|
NCT01951066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMEO-001|Diabetic Macular Edema Treated With Ozurdex (DMEO)|Diabetic Macular Edema Treated With Ozurdex (DMEO)|DMEO|Johns Hopkins University|No|Active, not recruiting|October 2013|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|100 Years|No|||December 2015|December 15, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951066||59022|
NCT01951053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100064|A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients|A Blinded, Placebo- and Comparator-Controlled Three-way Crossover Study to Investigate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of JNJ-40411813 in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01951053||59023|
NCT01951352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 111295|Effects of Surfactants on the Innate Immune System|Effects of Surfactants on the Innate Immune System||University of California, San Diego|No|Active, not recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951352||59000|
NCT01951365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUNS-spine-01|Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma|Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History||Seoul National University Hospital|No|Completed|June 1998|August 2013|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|56|None Retained|The investigators analyzed MR images only|Both|20 Years|N/A|No|Probability Sample|All patients diagnosed of spinal IDEM schwannoma in 2 institutes|September 2013|September 23, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01951365||58999|
NCT01958827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-687|A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease|A Multicenter Open-label Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease||AbbVie|No|Completed|September 2013|October 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|15 Years|99 Years|No|||October 2015|October 8, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958827||58426|
NCT01959659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN28222|A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness|||Hoffmann-La Roche||Completed|May 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1431|||Both|18 Years|N/A|No|Probability Sample|Patients with persistent symptoms of schizophrenia despite receiving adequately dosed        antipsychotic treatment and who have not had an acute exacerbation in the last 3 months|March 2016|March 1, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01959659||58362|
NCT01959958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEESC|Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease|Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease||St. Jude Children's Research Hospital|No|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|6 Years|17 Years|No|Non-Probability Sample|Pediatric patients with sickle cell disease and their parents/guardians|September 2015|September 29, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959958||58339|
NCT01960543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-INTRA-2013|Effects of Bupivacaine and Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients|Comparison of the Effects of Bupivacaine or Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients Who Underwent Hip Fracture Repair||Corporacion Parc Tauli|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|70 Years|N/A|No|||February 2015|February 3, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01960543||58294|
NCT01931189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI071A1|Pharmacokinetics Study of NI-071|A Clinical Pharmacokinetics Study of NI-071||Nichi-Iko Pharmaceutical Co.,Ltd.|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|96|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01931189||60547|
NCT01931202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6836|Mechanisms of Antidepressant Non-Response in Late-Life Depression|Mechanisms of Antidepressant Non-Response in Late-Life Depression||New York State Psychiatric Institute|No|Recruiting|August 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|60 Years|90 Years|No|||December 2015|December 1, 2015|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931202||60546|
NCT01931462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1080|Microwave Coagulation in Partial Nephrectomy Protocol|A Single Arm Phase 1 Study of Microwave Coagulation Using 2450-MHz Antennae and CO2 Cooling in Partial Nephrectomy for T1 Renal Tumors||University of Wisconsin, Madison|Yes|Recruiting|August 2014|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01931462||60526|
NCT01931735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0924-R|Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears|Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears||VA Office of Research and Development|Yes|Recruiting|October 2013|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|45 Years|70 Years|No|||December 2015|December 8, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01931735||60505|
NCT01931748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCNT3|A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome|Study of Non-inferiority UNCNT Versus MELSMON in Female With Menopausal Syndrome: Randomized Confirmatory Clinical Trial|UNCNT|Unimed Pharmaceuticals|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Female|40 Years|N/A|No|||May 2014|May 7, 2014|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01931748||60504|
NCT01932034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACUSC-Van-01|Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software|Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Multiple-Model Bayesian Adaptive Control||Children's Hospital Los Angeles|No|Recruiting|September 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|N/A|N/A|No|||January 2015|January 26, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01932034||60482|
NCT01932892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130075|Quantifying Prosthetic Socket Interface Movement|Quantifying Prosthetic Socket Interface Movement||University of South Florida|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample|June 2014|June 19, 2014|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01932892||60416|
NCT01938196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1202|A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation|||Kissei Pharmaceutical Co., Ltd.||Completed||||January 2014|Actual|Phase 2|Interventional|N/A|5||||||Both|20 Years|N/A||||November 2014|November 11, 2014|August 27, 2013||||No||https://clinicaltrials.gov/show/NCT01938196||60011|
NCT01938209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|karas 003|A Comparison of Seated Thoracic Manipulation and Targeted Supine Thoracic Manipulation on Cervical Flexion Motion and Pain|A Randomized Control Trial of the Immediate Effects of Seated Thoracic Manipulation and Targeted Supine Thoracic Manipulation on Cervical Spine Flexion Range of Motion and Pain||Chatham University|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|60 Years|No|||September 2013|September 9, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01938209||60010|
NCT01933477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acct#5-30539|Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|MCH-ART|University of Cape Town|No|Recruiting|March 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|480|||Female|18 Years|N/A|No|||December 2014|December 10, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01933477||60371|
NCT01957150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102972|Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).||GlaxoSmithKline|No|Active, not recruiting|January 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|40 Years|N/A|No|||October 2015|February 4, 2016|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957150||58555|
NCT01957163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200109|Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 1||GlaxoSmithKline|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|619|||Both|40 Years|N/A|No|||August 2014|November 20, 2014|October 4, 2013|Yes|Yes||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01957163||58554|
NCT01957176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200170|A Rollover Study to Provide Continued Treatment With Eltrombopag|Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag||Novartis|No|Recruiting|October 2013|December 2023|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|1 Year|N/A|No|||March 2016|March 11, 2016|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957176||58553|
NCT01957423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 1099.0.146.000-11|Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.|Immune Response Regulation and Nutritional Status of Crohn's Disease Patients Under Anti-TNF-alpha and Azathioprine Therapy.||University of Campinas, Brazil|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|N/A|N/A|No|||September 2013|September 30, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01957423||58534|
NCT01957683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 13-003|Canadian eCLIPs™ Safety and Feasibility Study Protocol|A Multi-center Pilot Study Evaluating the Safety and Feasibility of the eCLIPs™ Family of Products for the Treatment of Unruptured Bifurcation Intracranial Aneurysms|CESIS|Evasc Medical Systems Corp.|Yes|Not yet recruiting||||December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||January 2014|January 21, 2014|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957683||58514|
NCT01957943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTX_SMOF_PRE_Eg|Omega 3 Lipid Emulsions and Liver Transplantation|Impact of Pre-treatment of Living-donor Liver Transplant Recipients With Omega 3 Enriched Lipid Emulsions on Graft and Patient Outcome. A Prospective, Randomized, Multi-central Trial.|OTLT|Mansoura University|No|Recruiting|May 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|114|||Both|20 Years|60 Years|No|||October 2015|October 6, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957943||58494|
NCT01957956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1272|Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed Glioblastoma||Mayo Clinic|Yes|Suspended|November 2013|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|November 16, 2015|October 4, 2013|No|Yes|Per study design|No||https://clinicaltrials.gov/show/NCT01957956||58493|
NCT01951079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC130077-12CTIL|Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy|The Safety and Outcome of Intra-amniotic DIGOXIN Injection for Feticide Prior to Second Trimester Abortion||Meir Medical Center|Yes|Not yet recruiting|November 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|September 23, 2013|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951079||59021|
NCT01951378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-119|Comparison of Nebulizers in ED in Pediatric Asthma Patients|Comparison of a Breath Enhanced High Density Jet Nebulizer With a Standard Jet Nebulizer for the Treatment of Children With a Moderate to Severe Asthma Exacerbation in the Emergency Department||Seton Healthcare Family|No|Active, not recruiting|September 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|242|||Both|3 Years|17 Years|No|||November 2015|November 17, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01951378||58998|
NCT01951391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 111296|Effect of Surfactants on the Skin Microbiome|Effect of Surfactants on the Skin Microbiome||University of California, San Diego|No|Active, not recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01951391||58997|
NCT01959971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY13670|Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol|A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol||Sanofi|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959971||58338|
NCT01959984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD018|Study on the Comparison Between"Standard Noodles" and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus.|Study on the Comparison Between"Standard Noodles" and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus.||Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|January 2013|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|240|||Both|16 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01959984||58337|
NCT01960283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN09-AM/MUCIS|Methotrexate in the Treatment of Chronic Idiopathic Urticaria|Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria|MUCIS|University Hospital, Tours|Yes|Recruiting|November 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01960283||58314|
NCT01936896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15342|Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction|Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction|VCU-Alpha1RT|Virginia Commonwealth University|No|Completed|December 2013|July 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|99 Years|No|||January 2016|January 15, 2016|August 30, 2013|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01936896||60109|
NCT01936909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RED-HART (HM15339)|Interleukin-1 Blockade in Recently Decompensated Heart Failure|Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study|RED-HART|Virginia Commonwealth University|Yes|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|130 Years|No|||December 2015|December 9, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936909||60108|
NCT01937208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-130825|Comparable Study of Different Radiation Dose in Esophageal Carcinoma|A Prospective, Randomised Phase 3 Study of High-dose Versus Standard-dose Radiation of Inoperable Esophageal Carcinoma Treated With Concurrent Chemoradiation||Zhejiang Cancer Hospital|Yes|Recruiting|August 2013|July 2017|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||September 2013|September 3, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01937208||60085|
NCT01947556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPD_INSJ_3|Insulin by Jet-injection for Hyperglycemia in Diabetes|The Effect of Rapid-acting Insulin Injected by Needle-free Jet-injection in the Management of Hyperglycemia in Patients With Diabetes||University Medical Center Nijmegen|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||November 2014|November 25, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01947556||59292|
NCT01943643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM - CARD - 001|Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention|The Influence of Coronary Bifurcation Lesion Plaque Characteristics Assessed by Multislice CT Angiography On Side Branch Compromise After Provisional Stenting||Clinical Hospital Center Zemun|No|Recruiting|September 2013|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 5, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943643||59593|
NCT01943812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skive-2013-BA|Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation|Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation||Regionshospitalet Viborg, Skive|No|Recruiting|December 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|722|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943812||59580|
NCT01943825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD56|Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine|Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine||Sanofi|No|Recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943825||59579|
NCT01945164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 10-08|XL999 Administered Intravenously to a Subject With Advanced Malignancies|Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900||The University of Texas Health Science Center at San Antonio|Yes|No longer available|April 2010|June 2012|Actual|June 2012|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2014|October 17, 2014|December 7, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01945164||59476|
NCT01945411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0440|Assessment of Facial Measurements, the Length of Mouth Corner-mandible Angle and Incisors-mandible Angle, for Determining the Proper Sizes of Oropharyngeal Airway|||Yonsei University|No|Completed|September 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|20 Years|80 Years|No|||July 2015|July 30, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01945411||59457|
NCT01945424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIV08|Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry|Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol||Sanofi|No|Recruiting|August 2013|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)|September 2015|September 25, 2015|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945424|15 Months|59456|
NCT01945723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-ZH-553-CTIL|Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers|Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers||Tel-Aviv Sourasky Medical Center|No|Recruiting|September 2013|October 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|Samples Without DNA|Tissue, liquid and stool samples from Gastrointestinal tract.|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 healthy volunteers|September 2013|September 17, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945723||59433|
NCT01952535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMM0101|A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Study of Administrating Single Ascending Dose of HMS5552 in Healthy Adult Volunteers||Hua Medicine Limited|Yes|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|September 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01952535||58910|
NCT01953029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0541-12-RMB|Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease|Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease||Rambam Health Care Campus|Yes|Not yet recruiting|December 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with myocardial infarction|September 2013|September 25, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01953029||58872|
NCT01953042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279-2013|Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders|A Randomized Trial Testing the Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders||Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|September 2013|February 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|N/A|No|||November 2014|November 17, 2014|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953042||58871|
NCT01938794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1497|A New Approach to Measuring Energy Expenditure in Humans|Improvements to the Doubly Labeled Water Technique to Measure Total Daily Energy Expenditure||University of Colorado, Denver|No|Recruiting|September 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults (>18 yrs)|January 2016|January 4, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938794||59966|
NCT01938807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 12-09213|Audio Health Engagement Analysis in Diabetes: The AHEAD Study|Audio Health Engagement Analysis in Diabetes: The AHEAD Study||University of California, San Francisco|No|Active, not recruiting|October 2013|||June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|12 Years|No|||October 2014|October 24, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938807||59965|
NCT01939054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-BC-001|Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients|A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|70 Years|No|||June 2015|June 3, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01939054||59946|
NCT01934972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0926-01 Breitborde DCS|A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder|A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder|DCS|University of Arizona|Yes|Active, not recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01934972||60256|
NCT01935219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP-119580|Improving Performance in Drivers With Mild Cognitive Impairment|Improving Performance in Drivers With Mild Cognitive Impairment: An RCT of Cognitive Training||Baycrest|No|Recruiting|August 2013|August 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|128|||Both|55 Years|N/A|No|||March 2016|March 9, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01935219||60238|
NCT01935479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK159 I-4|A Phase I Study of AK159 in Healthy Postmenopausal Women|||Asahi Kasei Pharma Corporation||Recruiting|August 2013|||February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|11||Anticipated|170|||Female|45 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 2, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01935479||60218|
NCT01935700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-04-03(I)|Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma|Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|August 2013|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|90 Years|No|||February 2016|February 25, 2016|August 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01935700||60201|
NCT01935713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZ Study|Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure|Novel Methods to Reduce Children's Secondhand Smoke Exposure I|EZI|University of Oklahoma|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|89|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01935713||60200|
NCT01936597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/182/HP|Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage|Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage During Training in Non-hospital Cardiac Cases.|TeleMacc|University Hospital, Rouen|No|Completed|September 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936597||60132|
NCT01936610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|educational|the Effect of Instructional Method on Decision Making|||Mashhad University of Medical Sciences|Yes|Completed|June 2010|July 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|67|||Female|20 Years|28 Years|Accepts Healthy Volunteers|||May 2010|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936610||60131|
NCT01936623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA026003-B|Computerized Brief Intervention vs. Delayed Computerized Brief Intervention|||Friends Research Institute, Inc.|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936623||60130|
NCT01936922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303013747|Testing Whether Brief Use of a Virtual Reality Device Improves Gait|Testing Whether Brief Use of a Wearable Virtual Reality Device Improves Gait, Balance, and Confidence After Falls||Weill Medical College of Cornell University|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|60 Years|N/A|No|||December 2015|December 7, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936922||60107|
NCT01955421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E100VG250|Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc|A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.|NSCLC EGFR TKI|Sun Yat-sen University|Yes|Recruiting|July 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955421||58688|
NCT01955434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1381|SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma||Mayo Clinic|Yes|Recruiting|November 2013|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||November 2015|December 3, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955434||58687|
NCT01955447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1335|Post-prandial Glucose in Healthy Subjects|Effect of Different Levels of Plant-based Ingredients on Post-prandial Glucose in Healthy Subjects||Unilever R&D|No|Completed|November 2013|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|84|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|January 20, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955447||58686|
NCT01943864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117134|A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers|A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers||GlaxoSmithKline|No|Active, not recruiting|September 2013|March 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|20 Years|80 Years|No|||February 2016|February 4, 2016|September 12, 2013||No||No|March 2, 2015|https://clinicaltrials.gov/show/NCT01943864||59576|
NCT01943877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971987|Propolis In The Treatment Of Periodontitis|Propolis In The Treatment Of Chronic Periodontitis - A Clinicomicrobiologic Study|PROPOLIS|Rajarajeswari Dental College & Hospital|Yes|Active, not recruiting|December 2012|October 2013|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01943877||59575|
NCT01956162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-ORTHO-0913|Evaluation of a New Device "Orthèse Diabète" in the Healing of Foot Ulcers in Diabetic Patients|Evaluation of a New Customized Removable Device With Rocker Sole for Plantar Off-Loading "Orthèse Diabète" in the Healing of Foot Ulcers in Diabetic Patients|ORTHODIAB|Proteor Group|Yes|Recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01956162||58631|
NCT01952223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0160/1202|A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse|A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse|PEACE2|UNICANCER|Yes|Recruiting|September 2013|September 2026|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1048|||Male|18 Years|75 Years|No|||December 2015|December 4, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952223||58934|
NCT01952236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA172205-01|Web and Mobile Smoking Cessation|Web and Mobile Smoking Cessation Interventions|MobileQuit|Oregon Research Institute|No|Recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2260|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952236||58933|
NCT01952522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110702|Effects of a Walking Intervention With Additional Weights on the Unaffected Leg in People After Stroke|Comparison of Two Rehabilitation Programs to Improve Walking in Community-dwelling People After Stroke|ANANTA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|May 4, 2015|May 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01952522||58911|
NCT01947595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZD-2012|Individualized Lifestyle Intervention in Subjects With Prediabetes|Prediabetes Lifestyle Intervention Study|PLIS|University Hospital Tuebingen||Recruiting|March 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1000|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01947595||59289|
NCT01947608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2402|Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC|An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity||Novartis||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 17, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01947608||59288|
NCT01952769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antiPD1brainad2- HMO-CTIL|Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma|A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma||Hadassah Medical Organization|No|Recruiting|February 2014|April 2019|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|21 Years|No|||October 2015|November 3, 2015|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01952769||58892|
NCT01934699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004|Intraprocedural Determination of Myocardial Vitality Using 2 Different Imaging Methods|Intraprocedural Determination of Myocardial Vitality Using Speckle Tracking Echocardiography Compared to Two-time MRI Diagnostics||RWTH Aachen University|No|Active, not recruiting|June 2011|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|130|||Both|18 Years|90 Years|No|||September 2015|September 22, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934699||60277|
NCT01934985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL050663|Dynamic Cardiac SPECT Imaging|Dynamic Cardiac SPECT Imaging|SPECT|University of California, San Francisco|No|Recruiting|March 2012|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|||Both|21 Years|N/A|No|Non-Probability Sample|University of California, San Francisco (UCSF) Cardiology Clinics|June 2015|June 4, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01934985||60255|
NCT01934998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1335|Parkinsonism in Spinocerebellar Ataxia Type 6|Characterization of the Parkinsonism and Other Non-ataxia Spectrum and Striatal Dopaminergic Degeneration in Spinocerebellar Ataxia Type 6||University of Chicago|No|Completed|July 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|SCA6 patients and healthy controls.|April 2015|April 27, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01934998||60254|
NCT01935232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bind01|Bindex Ultrasonometer for Osteoporosis Diagnostics|Validation of Bindex Bone Ultrasonometer for Osteoporosis Diagnostics||Bone Index Finland Ltd|No|Enrolling by invitation|August 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|640|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|American-Caucasian female (n=500) American-Caucasian men (n=140)|January 2016|January 25, 2016|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01935232|1 Day|60237|
NCT01935492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOG 2010-02 Stop&Go study|8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer|8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.|Stop&Go|Borstkanker Onderzoek Groep|Yes|Recruiting|November 2010|October 2019|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01935492||60217|
NCT01935505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGPLAGH301YaoHe|Study on the Model of Smoking Cessation Intervention and Service Ability Improvement|Study on the Model of Smoking Cessation Intervention and Service Ability Improvement in General Hospital||Chinese PLA General Hospital|Yes|Enrolling by invitation|October 2008|December 2018|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|2000|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|hospital-based population|September 2013|September 4, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01935505||60216|
NCT01935739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30_2013RC_IN318|Discordant HER2/Neu Status of Breast Cancer.|Discordant HER2/Neu Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.||National Cancer Institute, Thailand|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|105|Samples With DNA|Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes|Female|25 Years|70 Years|No|Non-Probability Sample|Breast Cancer Patients Stage I,II and III.|September 2013|September 14, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01935739|1 Year|60198|
NCT01935726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 4134|Pulmonary Fibrosis Contact Registry|Pulmonary Fibrosis Contact Registry||National Jewish Health|Yes|Recruiting|August 2013|January 2040|Anticipated|January 2040|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue        disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma,        dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary        supporter/caregiver of a patient with pulmonary fibrosis|August 2013|November 17, 2014|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01935726|20 Years|60199|
NCT01936038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Upper Airway Toning - 001|Upper Airway Toning for Improve the Compliance of CPAP|Effectiveness of Upper Airway Toning as Adjuvant Treatment in the Former Period of Adaptation of the Continuous Positive Airway Pressure||Fisiolistic|Yes|Recruiting|June 2013|February 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||September 2013|September 1, 2013|August 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01936038||60175|
NCT01936051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1109-086-378|Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients|Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients||Seoul National University Hospital|No|Recruiting|February 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|12|Samples With DNA|blood sample|Male|20 Years|35 Years|No|Non-Probability Sample|OCD patients|September 2013|September 2, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01936051||60174|
NCT01936285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.ACS|Colchicine in ST-elevation Myocardial Infarction|Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size||G.Gennimatas General Hospital|Yes|Recruiting|July 2013|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|80 Years|No|||April 2015|April 22, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936285||60156|
NCT01936636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELIEF|Observational Registry Study of Quality of Life When Treating BTcP With Abstral|Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets|RELIEF|Galena Biopharma, Inc.|No|Completed|October 2013|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|164|||Both|18 Years|N/A|No|Probability Sample|This observational Registry study is designed to collect self-reported TIRF REMS Access        program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of        treatment with Abstral® through the use of Quality of Life and pain measurement tools        administered via questionnaire.|November 2015|November 3, 2015|September 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936636|4 Weeks|60129|
NCT01936935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-1222|Clinical Trial to Assess the Effects of Dairy on Insulin Sensitivity and β-Cell Function|A Randomized, Controlled, Crossover Trial to Assess the Effects of Dairy Intake on Insulin Sensitivity and β-Cell Function in Men and Women at Risk for Diabetes Who Are Habitual Consumers of High Sugar Beverages||Provident Clinical Research|No|Active, not recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936935||60106|
NCT01937234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFHSR-13-7-2013|Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women|Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug||Ain Shams University|Yes|Recruiting|July 2013|September 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Female|18 Years|35 Years|No|||January 2014|January 7, 2014|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01937234||60083|
NCT01955707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101SK201|Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke|ACTION|Biogen|Yes|Completed|January 2014|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|85 Years|No|||April 2015|August 27, 2015|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955707||58666|
NCT01955694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16815|Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone|A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone|ARTS-HF Japan|Bayer|Yes|Completed|November 2013|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|72|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955694||58667|
NCT01956175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-580|Electrical Pharyngeal Stimulation for Dysphagia Therapy in Tracheostomized Stroke Patients|A Single-centre, Double Blind, Randomised Controlled Clinical Trial to Evaluate the Effect of Electrical Pharyngeal Stimulation as a Treatment for Stroke-related Dysphagia in Tracheostomized Stroke Patients||University Hospital Muenster|Yes|Completed|June 2013|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||February 2015|February 19, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01956175||58630|
NCT01956188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omega 3 and Lupus USP|Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus|||University of Sao Paulo|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|20 Years|45 Years|No|||October 2013|October 1, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01956188||58629|
NCT01952249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-005|A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian|SIERRA: A PhaSe 1b/2 Study of DemcIzumab Plus PaclitaxEl in Subjects With Platinum Resistant OvaRian, PrimAry Peritoneal or Fallopian Tube Cancer|SIERRA|OncoMed Pharmaceuticals, Inc.|No|Recruiting|August 2013|October 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Female|21 Years|90 Years|No|||August 2015|August 27, 2015|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952249||58932|
NCT01952262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR/39/05/13|Ultrasound of the Diaphragm in ICU Patients|Ultrasound Evaluation of Diaphragmatic Dysfunction in Critically Ill Patients. An Observational Study.||Università Vita-Salute San Raffaele||Recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|99 Years|No|Non-Probability Sample|Adult critically ill patients|March 2016|March 9, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01952262||58931|
NCT01943929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIEP 1392-11|Correlation Between Headaches and Septum and Nasal Mucosa Contact|Correlation Between Headaches and Septum and Nasal Mucosa Contact||Hospital Israelita Albert Einstein|No|Recruiting|November 2012|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients older than 18 years whom underwent sinuses or facial tomography.|September 2013|September 12, 2013|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01943929||59571|
NCT01943942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117015|Bioequivalence Study of Montelukast 10 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing Montelukast 10 mg (Product of GlaxoSmithKline México, S.A. de C.V. vs. Singulair, Merck Sharp & Dohme de México, S.A. de C.V.)in Fasting Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|September 12, 2013|November 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01943942||59570|
NCT01934712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3918|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|64 Years|No|||October 2014|October 15, 2014|August 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934712||60276|
NCT01934725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SECRETO|Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome|Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO)|SECRETO|SECRETO Study Consortium|Yes|Recruiting|November 2013|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|4000|Samples With DNA|Patients at baseline:      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300      µL cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube      #2, full blood for DNA extraction.      Patients at 3-month visit (fasting): 4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300      µL cryovials; 1 x 5 mL PPACK sodium citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8      mL serum tube, aliquoted in 5 x 300 µL cryovials; 1 x 9 mL EDTA tube, aliquoted in 10 x 300      µL cryovials.      Control subjects:      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300      µL cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube      #2, full blood for DNA extraction.|Both|18 Years|49 Years|Accepts Healthy Volunteers|Probability Sample|1. Patients aged 18 to 49 hospitalized due to first-ever imaging-positive ischemic             stroke of undetermined etiology;          2. Age-, gender- and race-ethnicity-matched stroke-free control subjects|December 2015|December 4, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934725||60275|
NCT01934738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5261002|A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)|A Phase 1, Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-06273340 in Healthy Subjects||Pfizer|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|March 9, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934738||60274|
NCT01935011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0566|DBS Frequency on Swallowing Function in Parkinson's Disease|Effects of the Stimulation Frequency of STN DBS on Swallowing Function in Patients With Parkinson's Disease||University of Chicago|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|45 Years|N/A|No|Non-Probability Sample|Eight PD patients with STN DBS and freezing of gait responsive to stimulation frequency        changes will be enrolled.|April 2015|April 27, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01935011||60253|
NCT01935518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH-2013121|A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Peking University Third Hospital|No|Recruiting|September 2013|May 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||September 2013|September 5, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935518||60215|
NCT01935752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110301|Pathophysiological Mechanisms of Fibromuscular Dysplasia|Pathophysiological Mechanisms of Fibromuscular Dysplasia|MeDyA|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|March 31, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01935752||60197|
NCT01935765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111009|Sleep Apnea in Type 1 Diabetes|Sleep Apnea in Type 1 Diabetes : Prevalence, Role of Glycemic Control and Autonomic Neuropathy|DIASOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|145|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01935765||60196|
NCT01936064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASUTH/09/2012|The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients|A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients.||Lagos State University|Yes|Recruiting|August 2014|August 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 16, 2014|May 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01936064||60173|
NCT01936298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLO01|Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke|Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke||Habilita, Ospedale di Sarnico|Yes|Completed|September 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|45 Years|80 Years|No|||October 2013|October 25, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936298||60155|
NCT01936311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHF-3848|Study of Screening Self-management Goals on Short Term Behavior Change|Study of Screening for Patients Self-selected Health Goal and Treatment Modality Prior to Primary Care Visit and the Effect on Short-term Behavior Change||Denver Health and Hospital Authority|No|Completed|June 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|167|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936311||60154|
NCT01938365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD020|Genetics of Type 1 Diabetes in Chinese Adolescents and Youth|A Prospective Cohort Study of Clinical Characteristics and Genetic Susceptibility of Type 1 Diabetes in Chinese Adolescents and Youth||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Whole blood,fasting serum and stool|Both|14 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|In phase 1:500 patients under diabetic conditions and sex,age-matched NGR(Normal glucose        regulation) (2:1) will be enrolled ,all aged from 14-30.        In phase 2:200 patients newly diagnosed diabetes (less than 6 month before enrollment        )will be genotyped and followed up for 3 years|November 2013|November 11, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938365||59998|
NCT01938105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJPMF-2013-428-2081|Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer|Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study||People's Hospital of Guangxi|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||September 2013|September 24, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938105||60018|
NCT01934504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN051AI|Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)|Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)|AAV|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|December 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|35|Samples With DNA|-  peripheral blood mononuclear cells (PBMCs)        -  whole blood RNA        -  serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Non-tolerant: Patients who have persistently active disease. Tolerant: Those patients who        have become ANCA negative, having been ANCA positive at the time of their acute        presentation but have been in prolonged disease- free remission off all immunotherapy for        at least two years. Healthy controls: Individuals with similar age distribution to        participants in the Non-tolerant and Tolerant cohorts.|June 2015|June 4, 2015|August 29, 2013||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01934504||60292|
NCT01946542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047311|Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure|Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure||Duke University|No|Terminated|February 2014|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|2|||Both|55 Years|90 Years|No|||November 2015|November 10, 2015|September 17, 2013|Yes|Yes|Low enrollment|No|September 28, 2015|https://clinicaltrials.gov/show/NCT01946542||59370|The study was terminated due to low enrollment.
NCT01955915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#00009475|Blood Vessel Patterns in Small Choroidal Tumors|Characterization of Small Choroidal Tumors Using Functional Optical Coherence Tomography||Oregon Health and Science University|No|Active, not recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|This study will measure blood vessel pattern/flow changes in 15 patients with small        posterior choroidal tumors.|April 2015|April 21, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955915||58650|
NCT01947075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fever Study|Etiologies of Fever Among Adults in Dar es Salaam|Etiologies of Acute Febrile Illness Among Adults Attending an Outpatient Department in Dar es Salaam||Swiss Tropical & Public Health Institute|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|538|Samples With DNA|Whole blood Serum Sputa Urine|Both|18 Years|N/A|No|Probability Sample|Every consecutive adult with temperature ≥38°C attending the outpatient department of        Mwananyamala Hospital will be screened for inclusion. Additional inclusion criteria are        fever of ≤1 week duration and first consultation for the present problem. Exclusion        criteria are refusal of HIV screening, main complaint is injury or trauma, antibiotic        treatment during the previous week (apart from cotrimoxazole prophylaxis), delivery within        the previous 6 weeks and hospitalization during the last month. Medical history will be        taken (including exposure to IAP) and clinical examination will be done in a standardized        way.|August 2014|August 20, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01947075|30 Days|59329|
NCT01947335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02358512.7.0000.0068|IVUS Guidance to Reduce Contrast in Coronary Angioplasty|Minimizing cOntrast utiliZAtion With IVUS Guidance in coRonary angioplasTy: The MOZART Study|MOZART|InCor Heart Institute|No|Recruiting|November 2012|May 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|January 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01947335||59309|
NCT01943669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0048 (UK NRES)|Exoskeletons for Spinal Cord Injury: A Feasibility Study|An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalk™ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury.||Buckinghamshire Healthcare NHS Trust|No|Recruiting|June 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|55 Years|No|||September 2013|September 16, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01943669||59591|
NCT01943955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14167|Home-based Computer Gaming in Vestibular Rehabilitation|Home-based Computer Gaming in Vestibular Rehabilitation: Effects on Gaze and Balance Impairment||University of Manitoba|No|Completed|May 2011|June 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|70 Years|No|||September 2013|September 12, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01943955||59569|
NCT01934751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIDGES|Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction|Randomized Controlled Trial on the Effectiveness of Immediate Versus Delayed Access to Hospital-based Addiction Services|H-SOAP|Women's College Hospital|No|Recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934751||60273|
NCT01935245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40546.060.12|Platelet Function in Minimal Extracorporeal Circulation in CABG|Platelet Function in Minimal Extracorporeal Circulation Versus Conventional Extracorporeal Circulation in Coronary Artery Bypass Grafting|ECCTEG|Catharina Ziekenhuis Eindhoven|No|Completed|April 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01935245||60236|
NCT01935258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/365|Psychosomatic Therapy, Feasibility and Cost Analysis|Psychosomatic Therapy, Feasibility and Cost Analysis, a Pilot Randomised Trial|PsySom|Radboud University|Yes|Completed|April 2013|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01935258||60235|
NCT01935271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391351|Nutritional Supplementation and Muscle Health: A Pilot Study on Immune Function|Nutritional Supplementation and Muscle Health: A Pilot Study on Immune Function||Central Arkansas Veterans Healthcare System|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|February 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935271||60234|
NCT01935531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diclo-TuMet_01|Effects of Topical Diclofenac on Tumor Metabolism|Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients||University Hospital Regensburg|Yes|Active, not recruiting|June 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|38|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01935531||60214|
NCT01937494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/13-03-34/4235|Bronchial Hyperreactivity During Histamine Passive Exposure|Are Technicians Showing Bronchial Hyperreactivity Able to Safely Perform Bronchial Provocation Tests?||Centre Hospitalier Universitaire Saint Pierre|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01937494||60063|
NCT01937507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-20|Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer|Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer||Western Regional Medical Center|No|Terminated|December 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|June 24, 2013|Yes|Yes|PI Decision|No||https://clinicaltrials.gov/show/NCT01937507||60062|
NCT01937806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_BVCL011|Phase 3 Study of Besifovir|A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks||IlDong Pharmaceutical Co Ltd|No|Recruiting|October 2013|January 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|188|||Both|20 Years|N/A|No|||March 2014|March 12, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937806||60040|
NCT01936974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-27|(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma|Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma|PGA|Western Regional Medical Center|No|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||January 2015|January 19, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936974||60103|
NCT01938092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208827|Vaginal Diazepam for the Treatment of Female Pelvic Pain|Intravaginal Diazepam for the Treatment of Pelvic Pain Among Women With Pelvic Floor Hypertonic Disorder: a Double Blind, Randomized, Placebo Controlled Trial||University of Missouri-Columbia|No|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938092||60019|
NCT01937819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-BP01|Patients Judging Bowel Preparation by Using SMARTPHONE Application|Patients Judging Dose Adjustment of Bowel Preparation Solution for Bowel Preparation by Using SMARTPHONE Application: A Pilot Study|BPBUSA|Inje University|No|Not yet recruiting|September 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937819||60039|
NCT01937832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTQ04104-3-CTF|A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Not yet recruiting|October 2013|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|73 Years|No|||September 2013|September 4, 2013|September 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01937832||60038|
NCT01930344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SURN0004|Investigating Three-Dimensional Versus Two-Dimensional Imaging in Laparoscopic Cholecystectomies|Does Three-Dimensional Laparoscopy Provide Significant Advantages for Patients and Surgeons? A Randomised Controlled Trial Investigating Operating Time and Surgical Errors With 3D vs 2D Visual Systems in Laparoscopic Cholecystectomies.||Royal Surrey County Hospital|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|114|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930344||60612|
NCT01946308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMC 2011-1456|Sleep Organization in Premature Infants With Feeding Difficulties|Sleep Organization in Premature Infants With Feeding Difficulties||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|26 Weeks|36 Weeks|No|||September 2013|September 18, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946308||59388|
NCT01946828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-AM-0280-CTIL|Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)|Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)|TP 7601-CL|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01946828||59348|
NCT01947088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-087|Effect of Music Therapy on Cognitive Recovery|I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery||Seton Healthcare Family|No|Withdrawn|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|6 Years|16 Years|No|||January 2015|January 7, 2015|August 27, 2013||No|Principal Investigator left facility|No||https://clinicaltrials.gov/show/NCT01947088||59328|
NCT01947101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30591|Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children|A Phase I Study of Fecal Microbiota Transplantation (FMT) in Immunomodulator Dependent Pediatric Ulcerative Colitis (UC)|FMT|Baylor College of Medicine|Yes|Active, not recruiting|February 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|September 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947101||59327|
NCT01946815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORTE|Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease|Phase 3 Study of Effect of ATorvastatin on Fractional Flow Reserve in Coronary Artery Disease|FORTE|Keimyung University Dongsan Medical Center|No|Recruiting|September 2013|September 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|119|||Both|19 Years|N/A|No|||December 2015|December 7, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946815||59349|
NCT01947621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterTAK Registry|International Takotsubo Registry (InterTAK Registry)|International Multicenter Registry on Takotsubo Cardiomyopathy|InterTAK|University of Zurich||Recruiting|January 2011|December 2020|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with manifest Takotsubo cardiomyopathy|May 2014|May 20, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01947621||59287|
NCT01947634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepFabry|Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.|Cross-sectional Study on the Incidence of Sleepiness and Sleep-disordered Breathing in Patients With Fabry Disease||University of Zurich|Yes|Completed|September 2013|February 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|18 Years|N/A|No|||February 2015|March 2, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947634||59286|
NCT01943422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-107|Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma|Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma|12-107|University of Pittsburgh|Yes|Recruiting|September 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|63|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01943422||59610|
NCT01944007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTST-5|Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers|Open-label Phase 1 Multiple Dose Escalation Trial to Assess the Safety, Tolerability, and Efficacy of Capsules Containing Cross-linked Polyelectrolyte (CLP) Given to Normal Healthy Volunteers||Sorbent Therapeutics|No|Completed|December 2007|||March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944007||59565|
NCT01943682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPX-MA-1201|Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma|A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|September 2013|September 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Months|30 Years|No|||July 2015|July 29, 2015|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943682||59590|
NCT01938846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1325.1|BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors|An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours||Boehringer Ingelheim||Recruiting|September 2013|September 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|93|||Both|18 Years|99 Years|No|||March 2016|March 7, 2016|September 5, 2013||||No||https://clinicaltrials.gov/show/NCT01938846||59962|
NCT01934764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-13-ziv|Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases|||Ziv Hospital||Not yet recruiting|September 2013|||September 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|People with autoimmune disease|August 2013|September 3, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934764||60272|
NCT01935024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5749-AE|Benefits of Exercise in Alzheimer's Disease|Assessing the Benefits of an Outpatient Aerobic Activity Program in Patients With Alzheimer's Disease||University Health Network, Toronto|Yes|Recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|95 Years|No|||November 2015|November 30, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01935024||60252|
NCT01934803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AA021989|Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort|Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort|ZINC|Boston Medical Center|Yes|Active, not recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||July 2015|July 8, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934803||60269|
NCT01935050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013002798|Guided Self-Help for Depression in Parkinson's Disease|A Guided Cognitive-Behavioral Self-Help Treatment for Depression in Parkinson's Disease||Rutgers, The State University of New Jersey|No|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|85 Years|No|||January 2016|January 20, 2016|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01935050||60251|
NCT01936649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-122-015|Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.|A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)||GE Healthcare|No|Completed|February 2014|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|63|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|September 3, 2013|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01936649||60128|
NCT01936948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS-23578|Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.|Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.||White River Junction VAMC|Yes|Recruiting|April 2013|December 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1020|||Both|18 Years|89 Years|No|||December 2015|December 9, 2015|September 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01936948||60105|
NCT01936961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-03|Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors|A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)|I-CREST|Western Regional Medical Center|No|Withdrawn|June 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 3, 2013|Yes|Yes|No patients enrolled|No||https://clinicaltrials.gov/show/NCT01936961||60104|
NCT01937247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.RK.02|Redesigned Process in the Operating Room|Redesigned Process in the Operating Room: Monitoring and Evaluating Success of Reducing Non Operative Time||American University of Beirut Medical Center|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01937247||60082|
NCT01936662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011002885|Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy|Endotracheal Intubation vs. Laryngeal Mask Airway for Esophagogastroduodenoscopy in Children||Indiana University|Yes|Completed|August 2011|February 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|84|||Both|3 Years|17 Years|No|||June 2013|September 5, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936662||60127|
NCT01936987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-002-2013-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||December 17, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936987||60102|
NCT01937000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-153-2013-07|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||December 17, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937000||60101|
NCT01937260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110184|Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects|An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis||Amgen|No|Completed|September 2013|December 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|75 Years|No|||January 2015|January 28, 2015|July 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937260||60081|
NCT01933646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_23OB|Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China|Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China: Incidence, Case Fatality Rate and Serotype Distribution||Novartis|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|N/A|90 Days|No|Non-Probability Sample|Infants (up to and including 90 days of age) born in or treated in a study hospital|January 2015|January 6, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933646||60358|
NCT01937520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012002417|Acupuncture for Reduction of Inflammation|Acupuncture for Reduction of Inflammation in Thyroid and Parathyroid Surgery: Randomized, Prospective Double Blind Pilot Clinical Trial||Rutgers, The State University of New Jersey|No|Completed|July 2013|April 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||April 2015|June 17, 2015|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01937520||60061|
NCT01934205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116666|To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944|An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666)||GlaxoSmithKline|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934205||60315|
NCT01934218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gel/1133|Gel-One Treatment in Knee Osteoarthritis|A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of Gel-One® for the Treatment of Osteoarthritis of the Knee With Open-Label Safety Extension||Seikagaku Corporation|No|Active, not recruiting|August 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|40 Years|80 Years|No|||April 2015|April 1, 2015|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934218||60314|
NCT01930578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011897|Bioimpedance Spectroscopy in Humans During Acute Fluid Volume Expansion With Different Crystalloid Solutions|Bioimpedance Spectroscopy in Humans During Acute Fluid Volume Expansion With Different Crystalloid Solutions||The Hospital for Sick Children|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01930578||60594|
NCT01955473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200637-001|Japanese Phase 1 Trial of Sym004 in Solid Tumors|A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors||Merck KGaA|No|Active, not recruiting|October 2013|February 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955473||58684|
NCT01946841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRD - 2013 - ALENPHED|Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life|Effets de la Nutrition entérale spécifique RealDiet®Renal (NES) Chez Des Patients Insuffisants rénaux hémodialysés dénutris : efficacité, tolérance, qualité de Vie.|AL-EN-PHED|Lactalis|Yes|Withdrawn|August 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|April 16, 2015|August 6, 2013||No|No Patient recruitment|No||https://clinicaltrials.gov/show/NCT01946841||59347|
NCT01946568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-106|A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.|A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections||Durata Therapeutics Inc., an affiliate of Allergan plc|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|3 Months|11 Years|No|||June 2015|June 22, 2015|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946568||59368|
NCT01946854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1050|Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonea|A Randomized Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonea||M.D. Anderson Cancer Center|Yes|Recruiting|July 2013|||July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946854||59346|
NCT01946867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBTXR3-102|NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|PhI Study of NBTXR3 With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx||Nanobiotix|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|65 Years|N/A|No|||February 2015|February 19, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01946867||59345|
NCT01947348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3-912-OA-801|Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis|Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis||Institute of Regenerative and Cellular Medicine|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||September 2014|September 2, 2014|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01947348||59308|
NCT01947361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_153R_IP10|Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)|Heterogeneity in Association of Heart Rate and Initial Presentation of Cardiovascular Diseases Using Linked Electronic Health Records||University College, London|Yes|Active, not recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1961286|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1,96 million patients registered in Clinical Practice Research Datalink (CPRD) practices|September 2013|September 17, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947361||59307|
NCT01943695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-178|Supervised Aerobic Training During or After Adjuvant Therapy for Operable Breast Cancer|Optimal Timing Trial: Randomized Trial of Supervised Aerobic Training During or After Adjuvant Therapy for Operable Breast Cancer||Memorial Sloan Kettering Cancer Center|No|Recruiting|January 2013|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|160|||Female|21 Years|N/A|No|||October 2015|October 6, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01943695||59589|
NCT01944020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO2006|Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk|Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk||Columbia University|Yes|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944020||59564|
NCT01944280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00843|Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients|Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients||MetroHealth Medical Center|No|Completed|September 2013|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|90 Years|No|||October 2015|October 2, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944280||59544|
NCT01934777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBG-DHA, VIT E, CHOLINE|Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis|Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis||Bambino Gesù Hospital and Research Institute|Yes|Completed|October 2013|July 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|4 Years|16 Years|No|||January 2016|January 13, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934777||60271|
NCT01936324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM01B-ACN01|A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel|A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris||Dermira, Inc.|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936324||60153|
NCT01936337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLX105-003-002-001|Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients|A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris||Delenex Therapeutics AG|No|Completed|August 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||August 2014|August 11, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01936337||60152|
NCT01935804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEOR-01-08|Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes|Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes|Pioglitazone|King Abdulaziz University|Yes|Completed|January 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Female|50 Years|65 Years|No|||June 2014|June 16, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01935804||60193|
NCT01936090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1286|Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase I/II Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|August 2013|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||November 2015|February 10, 2016|September 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936090||60171|
NCT01936350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05378712.0.0000.0045|Sildenafil Impact on Ventricular Function in Patients With Heart Failure|Sildenafil Impact on Ventricular Function in Patients With Heart Failure: Randomized Clinical Trial||Hospital Ana Nery|Yes|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|September 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936350||60151|
NCT01936363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066_012|Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer|Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer||EMD Serono|Yes|Active, not recruiting|September 2013|May 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936363||60150|
NCT01933347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1304|Third-line Treatment of Gefitinib in NSCLC Patients|Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective and Multi-center Study||Guangdong Association of Clinical Trials|Yes|Recruiting|November 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933347||60381|
NCT01933360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W500M|Misoprostol for Cervical Priming Prior to Vacuum Aspiration|Sublingual Versus Vaginal Misoprostol for Cervical Dilatation 1 or 3 Hours Prior to Surgical Abortion||Karolinska Institutet|Yes|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|184|||Female|18 Years|40 Years|No|||August 2014|August 13, 2014|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01933360||60380|
NCT01933945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16560|Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib|OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib.|OPTIMIS|Bayer|No|Recruiting|June 2013|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1670|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients with a diagnosis of hepatocellular carcinoma (HCC) will be        enrolled in the participating study countries and sites during the enrollment period. All        treatment decisions prior inclusion of a patient as well as during the observation must be        made by the investigator based on his regular medical practice. Patients must give written        informed consent prior to documentation.        During the course of the study, patients will be assigned to one of the following cohorts        of special interest:          1. Patients with early start of sorafenib treatment          2. Patients without early start of sorafenib treatment.|March 2016|March 16, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933945||60335|
NCT01933932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00079|Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC|A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)|SELECT-1|AstraZeneca|Yes|Active, not recruiting|September 2013|March 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|130 Years|No|||January 2016|January 26, 2016|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933932||60336|
NCT01934517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCP2013udem|Validity of Digital Models Obtained With iTero® and Lava Digital® in Comparison With Plaster Models.|Validity, Reliability and Reproducibility of Digital Models Obtained With iTero® (AlignTech) and Lava Digital® (3M) in Comparison With Plaster Models.||Université de Montréal|No|Completed|August 2013|June 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|12 Years|30 Years|No|Non-Probability Sample|Patients requiring an orthodontic treatment from the Orthodontics clinic of the University        of Montreal|January 2016|January 17, 2016|August 29, 2013||No||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01934517||60291|
NCT01955486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040671-1|Gas Supply, Demand and Middle Ear Gas Balance -- Preliminary Protocol|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 1||University of Pittsburgh|No|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|50 Years|No|||February 2016|February 15, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955486||58683|
NCT01946555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio RER|Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain|Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain|RER|Mario Negri Institute for Pharmacological Research|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|99 Years|No|Non-Probability Sample|This study involves a longitudinal evaluation of BTCP in cancer patients with pain,        through a follow-up of 4 weeks, which will examine in a dynamic clinical aspects        (variation over time of the number and duration of episodes, painful intensity, changes in        ATC and rescue therapy).|December 2015|December 15, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01946555||59369|
NCT01946581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH SAT 2013|Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery|Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses Cataracts Surgery||MDbackline, LLC|No|Recruiting|May 2013|||May 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients that have had Cataract Surgery.|September 2013|September 16, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946581||59367|
NCT01946347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G981|Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects|Effect of Hyperinsulinemia and Postprandial Metabolic Changes on Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects|EndoPat|Institute for Clinical and Experimental Medicine|Yes|Completed|September 2013|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01946347||59385|
NCT01946594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048541|Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV|Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children||Duke University|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||January 2016|January 19, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946594||59366|
NCT01946880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALE06|Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)|An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)|ALE06|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946880||59344|
NCT01947114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTF.08.11.05/31128|Remifentanil Use in Pediatric Rigid Bronchoscopy|Remifentanil-based Total Intravenous Anesthesia for Pediatric Rigid Bronchoscopy: Comparison of Propofol and Ketamine As Adjuvant||Bezmialem Vakif University|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|1 Month|12 Years|No|||September 2013|September 17, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01947114||59326|
NCT01943708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-SA-10-07|Novel Auto-continuous Positive Airway Pressure (CPAP) Validation|A Study to Validate a Novel Auto Continuous Positive Airway Pressure Therapy||Fisher and Paykel Healthcare|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|July 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01943708||59588|
NCT01944527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00941-44|Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection|Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents|ANRSCO23CUPILT|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|October 2013|June 2017|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|699|Samples With DNA|Serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Liver transplant patients with recurrent hepatitis C virus infection treated with        direct-acting antiviral agents and followed up in centers of transplantation of the        university hospitals.|February 2016|February 1, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944527||59525|
NCT01944514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL-10824: ICD-IRS|Implantable Cardioverter Defibrillators - Improving Risk Stratification|Improving Risk Stratification of Patients for Implantable Cardioverter Defibrillators Through Electrophysiological Tests, Cardiac Magnetic Resonance Imaging, Autonomic Function Tests, RNA Analysis and Plasma Biomarkers.|ICD-IRS|University Hospitals, Leicester|Yes|Completed|January 2010|||November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|92|Samples Without DNA|Fresh frozen plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ischaemic cardiomyopathy cohort: patients with a history of myocardial infarction        attending for ICD implantation / Ventricular tachycardia stimulation test.        Non-Ischaemic cohort: patients without a history of myocardial infarction attending for        ICD implantation / Ventricular tachycardia stimulation test.        Control group: Patients with normal hearts and no conditions / family history that        increases risk of sudden cardiac death attending for an electrophysiological study.|September 2013|September 19, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944514||59526|
NCT01944826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTAC|The TAKO-TSUBO And Cancer Registry|A Prospective, Multicenter, Observational Registry to Evaluate the Prevalence and Incidence of Cancer and Long-term Prognosis in Patients With Tako-Tsubo (Stress-induced) Cardiomyopathy.|TTAC|Deutsches Herzzentrum Muenchen|No|Recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Laboratory parameters and biomarkers:        -  Faecal occult blood test        -  Complete blood count including erythrocyte sedimentation rate        -  Serum protein electrophoresis        -  Prostate-specific antigen (PSA) testing in men|Both|18 Years|N/A|No|Probability Sample|Data will be collected on approximately 800 subjects with TTC.|September 2013|September 13, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944826|5 Years|59502|
NCT01938885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lene Osterballe|Hepatic Pseudoaneurysms After Trauma|Hepatic Pseudoaneurysms After Conservatively Managed Liver Injuries||Rigshospitalet, Denmark|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|238|||Both|3 Years|77 Years|No|Probability Sample|All patients conservatively managed and radiologically followed-up after liver injury,        admitted Trauma Centre at the University hospital of Copenhagen, Rigshospitalet from        January 2000 to December 2010.|September 2013|September 17, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938885||59959|
NCT01934790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16506|Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases|A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks||Bayer|Yes|Active, not recruiting|December 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|August 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934790||60270|
NCT01932515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH120870|Diagnostic Instruments for Autism in Deaf Children Study|Diagnostic Instruments for Autism in Deaf Children Study|DIADS|Leeds and York Partnership NHS Foundation Trust|Yes|Active, not recruiting|November 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|325|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932515||60445|
NCT01932775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinDiab-04|Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards|An Open, Single-centre, Non-controlled Study of Efficacy, Safety and Usability of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards||Medical University of Graz|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932775||60425|
NCT01933100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCF2_2012_RP|Comparison of Brown Rice Based-meal or Polished Rice Based-meal or Wheat Based-meal on Functional Constipation in Young Korean Women|Comparison of Brown Rice Based-meal or Polished Rice Based-meal or Wheat Based-meal on Functional Constipation in Young Korean Women: A Opened, Clinical Trial||Chonbuk National University Hospital|Yes|Completed|July 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|39|||Female|19 Years|30 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933100||60400|
NCT01933659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304065RIND|Anti-H. Pylori Effect of Deep See Water|Anti-bacterial Effects of Ingesting Deep Sea Water in Subjects With H. Pylori Infection||National Taiwan University Hospital|No|Completed|September 2013|February 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|N/A|No|||May 2014|May 12, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933659||60357|
NCT01934231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117150|Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis|A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 Combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis||GlaxoSmithKline|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|3 Months|15 Years|No|||November 2013|May 29, 2014|August 29, 2013||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01934231||60313|
NCT01934244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0112003|Post Approval NovaSure Essure Labeling Study|Evaluation of the Safety of NovaSure in the Presence of Essure Following the Essure Confirmation Test (ECT) Post-Approval Study|PANEL|Hologic, Inc.|No|Enrolling by invitation|November 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|318|||Female|18 Years|N/A|No|Non-Probability Sample|Premenopausal women 18 years of age or older who have abnormal uterine bleeding and are        candidates for a NovaSure Endometrial Ablation that have already had an Essure Permanent        Birth Control system procedure and an Essure Confirmation Test that has confirmed both        bilateral tubal occlusion and the satisfactory location of the Essure micro-inserts.|March 2016|March 8, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934244||60312|
NCT01930890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211LE202|BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis|A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis||Biogen|Yes|Terminated|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|19 Years|76 Years|No|||October 2015|November 12, 2015|August 26, 2013|Yes|Yes|Results from pre-specified criteria in study NCT01499355 did not demonstrate sufficient    efficacy to warrant continuation of the study|No||https://clinicaltrials.gov/show/NCT01930890||60570|
NCT01946334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00507-38|Does Body Position Influence Pressure Recording by High-resolution Manometry ?|Does Body Position Influence Pressure Recording by High-resolution Manometry ?||Assistance Publique Hopitaux De Marseille|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01946334||59386|
NCT01947387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Integra 11-2011|Retrospective Study Evaluating Outcomes for Integra® Skin Sheet Products in Lower Extremity Complex Wounds|A Retrospective, Multi-Center Study Evaluating the Outcomes for Integra® Skin Sheet Bilayer or Single Layer Products Used in Complex Lower Extremity Soft Tissue Reconstruction||Integra LifeSciences Corporation|No|Completed|August 2013|February 2015|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Retrospective||9|Actual|320|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who received Integra, free flap, local tissue flap, or negative pressure        wound therapy over a 5-year period. The patient must be a minimum of 1 year from the index        procedure, any follow-up occurring during the year is eligible for inclusion.|March 2015|March 2, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947387||59305|
NCT01947374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-05-INR|Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures|Matrix-encapsulated Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures for Articular Cartilage Regeneration. Randomised Clinical Trial.||Instituto Nacional de Rehabilitacion|Yes|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|50 Years|No|||March 2015|March 24, 2015|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01947374||59306|
NCT01943435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12120422|Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)|A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis||University of Pittsburgh|No|Active, not recruiting|October 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|60 Years|N/A|No|||November 2015|November 23, 2015|September 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01943435||59609|
NCT01943721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ForSight VISION5 Study 504|A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension|A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension||ForSight Vision5, Inc.|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01943721||59587|
NCT01943734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPHULW298/09|The Influence of Health Information in Stretch Break Program Participant's Lifestyle|The Influence of Health Information in Stretch Break Program Participant's Lifestyle: a Quantitative and Qualitative Study||Federal University of Paraíba|Yes|Completed|March 2010|May 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|14|||Both|28 Years|63 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01943734||59586|
NCT01944852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL_2011_DIDo|Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.|Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental Peritoneal Dialysis Therapy: the DIDo Study|DIDo|Université Catholique de Louvain|No|Recruiting|March 2013|January 2019|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|60 Years|N/A|No|||December 2015|December 23, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01944852||59500|
NCT01944839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1002|A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.||Ophthotech Corporation|Yes|Recruiting|August 2013|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|622|||Both|50 Years|N/A|No|||September 2015|September 8, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944839||59501|
NCT01945086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102538|A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis||Janssen Pharmaceutical K.K.|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|79|||Both|20 Years|65 Years|No|||February 2016|February 11, 2016|September 13, 2013|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01945086||59482|
NCT01935791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0688|Investigating Brown Adipose Tissue Activation in Humans|Investigating Brown Adipose Tissue Activation in Humans||Imperial College London|No|Active, not recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 21, 2016|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01935791||60194|
NCT01936077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010036|Severe LH Suppressed Patients After Administration of a GnRH Antagonist|To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist|OPTOMALH|Assuta Hospital Systems|No|Completed|June 2010|August 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|39 Years|No|||September 2013|September 2, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01936077||60172|
NCT01935544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0153|Effectiveness of Two Techniques in Injection Site Spotting for Botulinum Toxin Injections: Echography or Electro Stimulation.|Effectiveness of Two Techniques in Injection Site Spotting for Botulinum Toxin Injections: Echography or Electro Stimulation.||University Hospital, Clermont-Ferrand||Recruiting|September 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01935544||60213|
NCT01935557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COHERE|Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation|Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation|COHERE|Seoul St. Mary's Hospital|No|Completed|December 2012|December 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|296|||Both|N/A|N/A|No|||March 2016|March 14, 2016|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935557||60212|
NCT01932788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20570|Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation|Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation||Medical University of South Carolina|Yes|Recruiting|January 2013|April 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|450|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2014|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01932788||60424|
NCT01933113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS 5583|Deep Brain Stimulation Effects on Weight Change and Metabolic Rate|Effects of Deep Brain Stimulation of the Lateral Hypothalamic Area on Weight Change and Metabolic Rate||Allegheny Singer Research Institute|Yes|Completed|January 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2015|August 3, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933113||60399|
NCT01933373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/595-32|A Prospective Study Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia|A Prospective Randomized Trial Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia. Comparing Toupet Versus DOR.||Karolinska University Hospital|No|Completed|May 2007|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||August 2013|August 30, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01933373||60379|
NCT01934543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-PUFA|Effects of Polyunsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin-resistant Men|Differential Effects of Saturated and Polyunsaturated Fatty Acids on Chylomicron Secretion and Expression of Key Genes and Proteins That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With Insulin-resistance|PUFA|Laval University|No|Active, not recruiting|January 2014|May 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|60 Years|No|||March 2016|March 7, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934543||60289|
NCT01934556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28724|A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema|A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3 mg Ranibizumab Given Monthly Compared to a TReat and EXtend Protocol in Patients With Diabetic Macular Edema|TREX-DME|Palmetto Retina Center, LLC|No|Active, not recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|100 Years|No|||October 2015|October 29, 2015|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934556||60288|
NCT01930370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014657|Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal|Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal: A Pilot Study||The Hospital for Sick Children|No|Completed|March 2010|December 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|18 Years|No|||May 2015|May 27, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930370||60610|
NCT01930591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104|Ticagrelor for PCI Post Thrombolysis|The Safety and Efficacy of Ticagrelor for Coronary Stenting Post Thrombolysis (SETFAST) Trial.|SETFAST|St. Michael's Hospital, Toronto|Yes|Recruiting|May 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01930591||60593|
NCT01930903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202|PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon|Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon|PaneLux PTCA|Biotronik France|No|Active, not recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||February 2014|April 29, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01930903||60569|
NCT01930916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00586-37|Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients|Accuracy of a Portable International Normalized Ratio Monitor in a Population Aged 75 Years Old and Over|AGINR|University Hospital, Caen|Yes|Recruiting|October 2012|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|75 Years|N/A|No|||April 2014|April 8, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01930916||60568|
NCT01946061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0452|A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer|||Yonsei University|Yes|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|19 Years|75 Years|No|||September 2013|September 16, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946061||59407|
NCT01946074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-006|Study of ABT-165 in Subjects With Advanced Solid Tumors|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors||AbbVie|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946074||59406|
NCT01947127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|793/2012|Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department|Can Venous Lactate Predict the Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients Without Hemodynamic Shock in Emergency Department?||Chulalongkorn University|Yes|Completed|March 2013|January 2015|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|458|Samples Without DNA|Venous blood lactate obtained by standard venipuncture together with other essential blood      works before giving antibiotics or intravenous fluid, if required. Lactate level is measured      by Epoc® point-of-care blood analyzer (Epocal Inc., Ottawa, ON, Canada) within 5 minutes      after obtaining the venous sample without any preservative.|Both|18 Years|65 Years|No|Non-Probability Sample|Emergency department patients of King Chulalongkorn Memorial Hospital (a 1500-bed,        tertiary-care, university-affiliated urban hospital)|April 2015|June 2, 2015|September 10, 2013||No||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01947127|1 Month|59325|1. This was an observational study that did not evaluate the aggressiveness of the treatment strategies. 2. The study was done in a single, urban, university hospital. 3. The staging of co-morbidity (e.g. cancers) was not well-categorized.
NCT01947140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ5656|Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies|Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma|PDX+Romi|Columbia University|Yes|Recruiting|September 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|93|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01947140||59324|
NCT01947153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.21|Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.|Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto® (Two Fixed Dose Combination Tablets of Linagliptin 2.5 mg and Metformin 500 mg) Compared With the Free Combination of Linagliptin 5 mg and Metformin 1000 mg Tablets Under Fasting Conditions.||Boehringer Ingelheim||Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|September 18, 2013||||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01947153||59323|
NCT01944033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|β2-agonist|β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation|||University of Monastir|No|Recruiting|July 2013|July 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|85 Years|No|||September 2013|September 12, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01944033||59563|
NCT01944046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063950|Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors|Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors|SOARS-B|Duke University|Yes|Recruiting|August 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|17 Years|No|||September 2015|September 25, 2015|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944046||59562|
NCT01943448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303121RINC|Macular Hemorrhage in Myopic Eyes|Macular Hemorrhage in Myopic Eyes||National Taiwan University Hospital|No|Recruiting|August 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|80 Years|No|Non-Probability Sample|1. Myopia more than -6D          2. Macular hemorrhage inside arcade          3. Patients who are willing to visit our clinic and receive examination regularly for at             least 1 year|April 2014|April 13, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943448|2 Years|59608|
NCT01943461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 100070-002|Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)|A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer||Merck KGaA|No|Active, not recruiting|September 2013|May 2017|Anticipated|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|20 Years|N/A|No|||March 2016|March 24, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01943461||59607|
NCT01945125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP97/10|Effects of THW and rhTSH in Glomerular Filtration Rate During RIT|Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyroid Stimulating Hormone in Glomerular Filtration Rate During Radioiodine Therapy||University of Sao Paulo General Hospital|No|Completed|October 2011|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|December 9, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01945125||59479|
NCT01944878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCS-1|The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient|Retrospective Observational Study of Impact of Portal Hypertension for the Peptic Ulcer in Liver Cirrhosis and Chronic Hepatitis||Chuncheon Sacred Heart Hospital|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|455|||Both|18 Years|N/A|No|Non-Probability Sample|Investigators will analyze the medical records of hepatic vein pressure gradient (HVPG)        and esophagogastroduodenoscopy (EGD) cases who had LC or chronic hepatitis in single        tertiary hospital of Korea.|July 2014|July 22, 2014|September 6, 2013||No||No|January 23, 2014|https://clinicaltrials.gov/show/NCT01944878||59498|
NCT01945099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 1307012334|Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy|Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy||Yale University|No|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|12 Years|40 Years|No|||September 2013|September 13, 2013|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945099||59481|
NCT01931956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401B|Real World Expanded Multicenter Study of the MitraClip® System (REALISM)|A Continued Access Registry of the Evalve® MitraClip® System: EVEREST II Real World Expanded Multicenter Study of the MitraClip System (REALISM)|REALISM|Evalve||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2015|August 12, 2015|August 27, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01931956||60488|
NCT01932216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-RCTSS-001|Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy|||Intuitive Surgical|No|Recruiting|September 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932216||60468|
NCT01932229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9547-JB-CTIL|An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib|An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib||Sheba Medical Center|No|Recruiting|February 2013|||January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||August 2013|August 29, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01932229||60467|
NCT01932242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH109|Safety, Tolerability and PK of Repeat Administration of IV ETI-204|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers||Elusys Therapeutics|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|September 30, 2014|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932242||60466|
NCT01933672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621019|Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes|A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|33|||Both|18 Years|70 Years|No|||April 2014|April 1, 2014|August 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01933672||60356|
NCT01933685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 328|Study of Immune Responses Induced by a HIV Vaccine|Randomized, Double Blind Evaluation of Sequential Administration of gp120 B/E (AIDSVAX B/E) (GSID) With 1-Year Boosting in HIV-uninfected Thai Adults||U.S. Army Medical Research and Materiel Command|No|Recruiting|July 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933685||60355|
NCT01933958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16732|Regorafenib Post-marketing Surveillance in Japan|Drug Use Investigation of Regorafenib/ STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy||Bayer|No|Recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|135|||Both|N/A|N/A|No|Probability Sample|Patients who are treated with Regorafenib/STIVARGA and meet the product label|March 2016|March 18, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933958||60334|
NCT01934257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3332-5|The Evaluation of Infant Formulas Fed to Infants With Common Feeding Problems|The Evaluation of Infant Formulas Fed to Infants With Common Feeding Problems||Mead Johnson Nutrition|No|Completed|June 1994|June 1996|Actual|June 1996|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|296|||Both|N/A|12 Weeks|No|||August 2013|August 29, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01934257||60311|
NCT01934530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-Anderson-10|A Randomized Control Trial Testing Connective Tissue Grafts vs. Allograft on Dental Implants|Implant Associated Soft Tissue Defects in the Anterior Maxilla: A Randomized Control Trial Between Subepithelial Connective Tissue Graft and Acellular Dermal Matrix Allograft||University of Michigan|No|Completed|August 2009|July 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 3, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934530||60290|
NCT01934582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-309|A Pharmacokinetic Substudy of the TDE-PH-304 Protocol|A Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15 SR (Treprostinil Diethanolamine) in the TDE-PH-304 Protocol||United Therapeutics|No|Active, not recruiting|August 2013|||August 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|12 Years|75 Years|No|||February 2014|February 10, 2014|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934582||60286|
NCT01930383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306057RIND|Circulating Tumor Cells for Hepatocellular Carcinoma|Circulating Tumor Cells (CTCs) as Biomarkers of Prognosis and Predictors of Efficacy of Drug Therapy for Patients With Hepatocellular Carcinoma|CTCs for HCC|National Taiwan University Hospital|No|Recruiting|October 2013|||August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|The blood samples will be separated to blood cells and plasma. Blood cells will be used for      isolation and enumeration of CTCs. Plasma will be used to extract DNA to measure molecular      aberration (gene mutations related to hepatocarcinogenesis or response of HCC cells to      molecular targeted therapy).|Both|20 Years|N/A|No|Non-Probability Sample|Hepatocellular carcinoma|November 2013|November 13, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01930383||60609|
NCT01930604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTXHH11|Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis|Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis, a Randomized, Double Blind, Placebo Controlled Study||Hidrosis Clinic, Stockholm, Sweden|Yes|Recruiting|September 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|274|||Both|16 Years|N/A|No|||March 2015|March 20, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01930604||60592|
NCT01930942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0905001040531|Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma|Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma||Chinese Academy of Medical Sciences|No|Recruiting|January 2006|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01930942||60566|
NCT01943474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDVP-001/VPW-STP-00004|RIVS (AccuCath Device) Versus (Conventional) PIV Catheter|A Prospective, Non-Blinded, Randomized Controlled, Study Designed to Evaluate User Preferences Associated With the Rapid Intravascular Start (RIVS/AccuCath) System Versus Conventional Catheters for Peripheral Intravenous (PIV) Access||Vascular Pathways, Inc.|No|Recruiting|April 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|89 Years|No|||September 2013|September 11, 2013|April 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943474||59606|
NCT01943747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPRESS|International Multicentre Prevalence Study on Sepsis|Surviving Sepsis Campaign. International Multicentre Prevalence Study on Sepsis.|IMPRESS|European Society of Intensive Care Medicine|No|Completed|November 2013|January 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|patients presenting with either severe sepsis or septic shock|August 2014|August 19, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943747||59585|
NCT01943760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187177|Tamadol Wound Infiltration in Children Under Inguinal Hernioplasty|Evaluation of the Analgesic Effect of Tramadol Wound Infiltration in Children Under Inguinal Hernioplasty. A Double-blind, Randomized Study.||Federal University of São Paulo|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|3 Years|12 Years|No|||September 2013|September 16, 2013|September 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943760||59584|
NCT01944059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM-2013-001|Theramine® in the Prevention of Migraine Headache|The Role of Theramine® in the Prevention of Migraine Headache: A Pilot Study||Targeted Medical Pharma|Yes|Terminated|November 2013|October 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|31|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|September 12, 2013|No|Yes|Funding Discontinued|No||https://clinicaltrials.gov/show/NCT01944059||59561|
NCT01944072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA-FCM-MSAR-001|Pulmonary Rehabilitation in COPD: Effects of Two Aerobic Exercise Intensity in Patient-centered Outcomes|Pulmonary Rehabilitation in COPD: Effects of Two Aerobic Exercise Intensity in Patient-centered Outcomes - a Randomized Controlled Trial||Universidade Nova de Lisboa|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01944072||59560|
NCT01944293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6785|Ketamine for Suicidality in Bipolar Depression|Ketamine vs. Midazolam in Bipolar Depression||New York State Psychiatric Institute|Yes|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|September 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944293||59543|
NCT01945151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03559712.6.0000.0077|Analysis of the Electrical Muscle Activity and Resistance to Movement in Spastic Hemiparetic Patients.|Analysis of the Electrical Muscle Activity and Resistance to Movement After Pplication Neuromuscular Electrical Stimulation (EENM) in Patients With Hemiparesis Spastic.|EENM|Universidade do Vale do Paraíba|No|Recruiting|June 2013|November 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|45 Years|75 Years|No|||September 2013|September 13, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01945151||59477|
NCT01945372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-TH-0295-13-CTIL|Neurofeedback Treatment of Affective Instability in Premenstrual Dysphoric Disorder(PMDD)|Self-modulation of Prefrontal Alpha Asymmetry:Novel Neurofeedback Treatment of Affective Instability in Premenstrual Dysphoric Disorder(PMDD)||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|October 2013|August 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|50 Years|No|||September 2013|March 26, 2014|September 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945372||59460|
NCT01932255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/883|CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap|CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap||St. Olavs Hospital|No|Withdrawn|October 2013|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The planned study is a retrospective review of medical charts in consecutive patients        undergoing surgery for neurovascular conflict by microvascular decompression surgery.        Patients will be identified from the operating protocols at the respective hospitals.|May 2015|May 12, 2015|August 27, 2013||No|inadequate data|No||https://clinicaltrials.gov/show/NCT01932255||60465|
NCT01932528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-104-NRM|An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males|A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects|LX1606-104|Lexicon Pharmaceuticals|No|Completed|August 2013|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01932528||60444|
NCT01932541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001524|Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old|Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old With Bipolar I, Bipolar II and Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Suspended|January 2017|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|17 Years|No|||February 2016|February 12, 2016|August 20, 2013|No|Yes|On hold due to competing departmental studies|No||https://clinicaltrials.gov/show/NCT01932541||60443|
NCT01932554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU 23331|Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis|Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis||St. Louis University|Yes|Withdrawn|November 2013|March 2015|Actual|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|25 Years|No|||March 2015|March 24, 2015|August 19, 2013|Yes|Yes|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01932554||60442|
NCT01933698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMOXIPED-01|Bioequivalence of Two Commercial Amoxicillin Suspensions|Bioequivalence Study of Two Commercial Amoxicillin Suspension Formulations in Healthy Human Volunteers||University of Campinas, Brazil|Yes|Completed|February 2005|July 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|19 Years|46 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01933698||60354|
NCT01933971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-PK-06-175|Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®|Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®||Bio-ker S.r.l.|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|102|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933971||60333|
NCT01934270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc094-13CTIL|Growth Hormone Secretion Following the Anaerobic Exercise|Growth Hormone Secretion Following the Anaerobic Exercise||Meir Medical Center|No|Recruiting|May 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01934270||60310|
NCT01930422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 392 02|Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption|Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.|TABELEC|University Hospital, Toulouse|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||February 2014|February 21, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01930422||60606|
NCT01930396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7822377|Use of Tinzaparin for Anticoagulation in Hemodialysis|Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)|HEMO-TIN|St. Joseph's Healthcare Hamilton|Yes|Not yet recruiting|September 2013|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01930396||60608|
NCT01930409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01810|Back to the Future: Bridging the Hospital to Home Continuum After Hip Fracture|A Feasibility Study Investigating Telephone Supported Discharge From Acute Care to the Community After Hip Fracture|B2F|University of British Columbia|Yes|Completed|November 2013|January 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|N/A|No|||May 2015|May 27, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01930409||60607|
NCT01930617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2050|Irrigation of Chronic Subdural Hematomas - is More Better?|Irrigation of Chronic Subdural Hematomas - is More Better? A Population Based Study Between Different Treatment Policies||St. Olavs Hospital|No|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Anticipated|1258|||Both|18 Years|N/A|No|Non-Probability Sample|The patients have been selected to the given therapy solely on the basis of geography. All        patients treated with evacuation of primary chronic subdural hematoma(CSDH) from 2005        through 2010 at St.Olav University Hospital and UNN, and primary CSDH from 2006 through        2010 at Karolinska University Hospital (not 2005 due to practical reasons since major        changes occurred in electronic surgery protocols 2005).|February 2016|February 15, 2016|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01930617||60591|
NCT01930929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-153-13|Prevalence of Complications After Bariatric Surgery - an Epidemiologic Survey|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on an Epidemiologic Survey||University of Aarhus|No|Recruiting|November 2013|July 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|5000|||Both|18 Years|70 Years|No|Non-Probability Sample|All patients WHO have had bariatric surgery in the Central and North Denmark Region        2006-2011|August 2013|December 3, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01930929||60567|
NCT01931540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T55/2012b|Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity|Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity|DORIAN|Turku University Hospital|No|Completed|June 2012|June 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|48|||Female|N/A|N/A|No|||March 2016|March 21, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01931540||60520|
NCT01931553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoundingUCSF|A Pragmatic Cluster Randomized Controlled Trial to Standardize Attending Morning Rounds in Medicine|Back to Bedside: A Pragmatic Cluster Randomized Controlled Trial to Standardize Attending Morning Rounds in Medicine||University of California, San Francisco|Yes|Completed|September 2013|December 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1200|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01931553||60519|
NCT01936181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB2-G31-RA|A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy||Samsung Bioepis Co., Ltd.|Yes|Completed|August 2013|September 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|584|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936181||60164|
NCT01947413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0012A3|New Protocols in the Treatment of Upper Limb Dysfunctions of Patients With Stroke.|New Protocols in the Treatment of Upper Limb Dysfunctions of Patients With Stroke: An Evidence of Clinical and Kinematic Studies.||Chang Gung Memorial Hospital|Yes|Recruiting|December 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947413||59303|
NCT01943487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-078|A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet|A Phase 1, Open-label, One-sequence Study to Assess the Effect of Verapamil on the Steady State Pharmacokinetics of Solifenacin and Tamsulosin Administered as a Combination Tablet EC905 in Healthy Male Subjects.||Astellas Pharma Inc|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943487||59605|
NCT01944553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9180|Robotic-assisted Pedicule Screw Placement|A Prospective Study on the Feasibility of Pedicle Screw Placement in the Lumbar Level With a New Robotic-assisted System|ARASS|University Hospital, Montpellier|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||February 2014|February 26, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944553||59523|
NCT01944566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/681|Microbial Community Transplantation on the Armpit.|Microbial Community Transplantation on the Armpit in Order to Reduce the Malodour Generation on Armpit.||University Ghent|No|Enrolling by invitation|October 2013|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944566||59522|
NCT01944540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|optESDs2013AMC|Brief Title : Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm|Comparison of Coventional Endoscopic Submucosal Dissection and Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm||Asan Medical Center|No|Recruiting|August 2013|||March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944540||59524|
NCT01944904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XOS2 053113|Investigation of the Ability of a Supplement to Increase Good Bacteria in the Human Intestine and Blood Sugar Levels|Study of the Effect of Prebiotic Xylooligosaccharide (XOS) on Microbita and Blood Glucose|XOS2|University of California, Los Angeles|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01944904||59496|
NCT01945138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTPIAT2013|Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation|Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|64 Years|No|||December 2015|December 9, 2015|August 19, 2013|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT01945138||59478|
NCT01932801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45134|Harm Reduction With Pharmacotherapy (HaRP)|Harm Reduction With Pharmacotherapy for Homeless Adults With Alcohol Dependence|HaRP|University of Washington|Yes|Recruiting|August 2013|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|21 Years|65 Years|No|||November 2015|November 30, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01932801||60423|
NCT01933126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151/12|Intrauterine Injection of HCG and Implantation Rate|The Effect of HCG Injection to the Uterine Cavity on Pregnancy Rate in Women Undergoing IVF Treatment||Assaf-Harofeh Medical Center|No|Recruiting|August 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|No|||February 2014|February 18, 2014|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933126||60398|
NCT01933139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHyst|Informed Consent for Hysterectomy: Effectiveness of Audio-visual Presentations on Patient Comprehension|Informed Consent for Hysterectomy: Effectiveness of Audio-visual Presentations on Patient Comprehension||Brooke Army Medical Center|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01933139||60397|
NCT01933386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN008|Evaluation of Benefit for Treatment of Single Sided Deafness (SSD) Between Two Bone Conduction Prosthetic Devices; Osseointegrated Implant Versus Maxilla Anchored Removable Oral Appliance ("SoundBite")|Evaluation of Benefit for Treatment of Single Sided Deafness (SSD) Between Two Bone Conduction Prosthetic Devices; Osseointegrated Implant Versus Maxilla Anchored Removable Oral Appliance ("SoundBite")||Sonitus Medical Inc|No|Not yet recruiting|September 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|80 Years|No|||October 2013|October 25, 2013|August 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01933386||60378|
NCT01933711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD2002|Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma|Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial||University Hospital Heidelberg|No|Active, not recruiting|July 2002|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01933711||60353|
NCT01933984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-CCH-IRP-017|Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients|Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients||Changhua Christian Hospital|Yes|Recruiting|August 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933984||60332|
NCT01933997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL009|A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered as Repeated Doses to Healthy Volunteers||Alcobra Ltd.|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|January 13, 2014|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01933997||60331|
NCT01934283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc-0188-12|Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation|Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation||Meir Medical Center|No|Not yet recruiting|October 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|February 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01934283||60309|
NCT01934296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activa PC+S|Chronic Effects of DBS in Parkinson's Disease and Dystonia|Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia|Activa PC+S|University of California, San Francisco|Yes|Recruiting|November 2013|||December 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|22 Years|75 Years|No|||May 2015|May 22, 2015|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934296||60308|
NCT01934569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291023|Drug-Drug Interaction Study With PF-05089771|Evaluation Of The Effect Of PF-05089771 On The Metabolism Of Multiple Cytochrome P450 And OATP1B1 Transporter Substrates||Pfizer|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934569||60287|
NCT01930968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00039493|Definity for Ultrasound of Intraocular Tumors|Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors||Emory University|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01930968||60564|
NCT01930630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESI-2013|ESI With EUS to Differentiate T3 and T4 ESCC|Extraesophageal Saline Injection Combined With EUS to Differentiate Between T3 and T4 Stage Esophageal Squamous Cell Carcinoma — A PhaseⅠTrial|ESI|Sun Yat-sen University|Yes|Not yet recruiting|October 2013|October 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|65 Years|No|||August 2013|August 22, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01930630||60590|
NCT01930955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AURI|Non-antibiotic Prescribing for Acute Upper Respiratory Tract Infection|Non-antibiotic Prescribing for Acute Upper Respiratory Tract Infection：a Randomized-control Trial||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|August 2011|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|1 Year|3 Years|No|||August 2013|February 10, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930955||60565|
NCT01931228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/21|Mechanical Insufflation-Exsufflation in Preventing Post Extubation Respiratory Failure in Patient With Critical Care Neuromyopathy|Contribution of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure Post Extubation in Patient With Critical Care Neuromyopathy|NEUROMIE|University Hospital, Bordeaux|No|Recruiting|May 2012|May 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01931228||60544|
NCT01936194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6018|The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis|The Effects of Polyunsaturated Fatty Acids on Allergic/Atopic Dermatitis||Mead Johnson Nutrition|No|Terminated|April 2015|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|240|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2013|April 6, 2015|August 27, 2013||No|Investigators don't want to conduct this study as time is limited.|No||https://clinicaltrials.gov/show/NCT01936194||60163|
NCT01944085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|percpinremoval|Percutaneous Pin Removal in Children - is Analgesia Necessary?|Percutaneous Pin Removal in the Outpatient Clinic - do Children Require Analgesia? A Randomized Controlled Trial||KK Women's and Children's Hospital|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|240|||Both|5 Years|12 Years|No|||September 2013|September 12, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944085||59559|
NCT01943526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYS-IRL-11-4|Ireland Natalizumab (TYSABRI) Observational Program|Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)|iTOP|Biogen|No|Active, not recruiting|November 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|191|||Both|N/A|N/A|No|Non-Probability Sample|Patients with RRMS who are being treated with natalizumab and patients who meet the        criteria defined in the indication statement for prescription in Ireland. Existing        patients will be enrolled retrospectively.|February 2016|February 19, 2016|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943526||59602|
NCT01943539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akili-001|Cognitive ADHD Videogame Exploratory Study|A Study to Assess the Feasibility of EVO Gameplay to Engage Children With Attention Deficit Hyperactivity Disorder (ADHD) and to Evaluate Cognitive Interference in Children Ages 8 to 12 Years Old With ADHD Compared to Neuro-typical Children|CAVES|Akili Interactive Labs, Inc.|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||August 2014|May 12, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01943539||59601|
NCT01944306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009569|Obesity and Oral Contraceptive Failure|Prenatal Growth Programs Oral Contraceptive Metabolism and Effectiveness||Oregon Health and Science University|No|Terminated|August 2013|December 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|40|Samples With DNA|Blood, Plasma, and Urine will be collected for the analaysis of drug levels and genotyping      of various genes that could explain pharmacokinetics of oral contraceptives.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Reproductive-aged, ovulatory women seeking to initiate contraception with combined oral        contraceptives will be recruited from the female population of the Portland, OR area.        Subjects must have access to their birth weight record. Enrollment will be confined to        women who have not used a hormonal contraceptive method for 30 days or more prior to        enrollment.|April 2015|April 15, 2015|September 10, 2013||No|Due to lack of funds, the study has been terminated upon recruiting less than desired number    of subjects|No||https://clinicaltrials.gov/show/NCT01944306||59542|
NCT01943786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAMING|RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab|Prospective, Non-Interventional Study of K-ras Status Switch in K-ras Native Patients With Metastatic Colorectal Tumors Treated With FOLFIRI-Cetuximab as First-line Treatment|BEAMING|Grupo Hospital de Madrid|No|Active, not recruiting|April 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Tissue and whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cáncer and wild-type KRAS treated with        Folfiri-Cetuximab as first-line treatment.|March 2015|March 13, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01943786||59582|
NCT01944098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002417|Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients|Systemic Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients: A Randomized, Placebo-Controlled Pilot Study||University of South Florida|Yes|Recruiting|August 2013|||July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944098||59558|
NCT01944319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75505-01|Meropenem Dosage Strategy Based on PPK Model|Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients||Peking University Third Hospital|Yes|Completed|July 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|60 Years|95 Years|No|||January 2016|January 28, 2016|July 2, 2013||No||No|October 18, 2015|https://clinicaltrials.gov/show/NCT01944319||59541|
NCT01944579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS40|Blackberry Flavonoid Absorption and Effects on Intestinal Bacteria|||USDA Beltsville Human Nutrition Research Center|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|46|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944579||59521|
NCT01944865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGF|Interval Training and Performance in Mountain Bikers|Effect of Intermittent Versus Interval Training on Mountain Bike Cross-country Performance: a Parallel-group Randomized Trial||Universidade Gama Filho|No|Completed|October 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|16|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 13, 2013|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01944865||59499|
NCT01945112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28548|Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)|Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)||Stanford University|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945112||59480|
NCT01945931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SafeDeliveryApp|Evaluation of a Smartphone Application to Reduce Adverse Pregnancy Outcomes in Ethiopia|Evaluation of a Smartphone Application to Reduce Adverse Pregnancy Outcomes in Ethiopia: A Cluster-randomised Controlled Trial||University of Copenhagen|Yes|Completed|September 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3601|||Female|10 Years|45 Years|No|||October 2015|October 6, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01945931||59417|
NCT01945398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120489|IMT in Ventilatory Muscle Metaboreflex in COPD|Effect of Inspiratory Muscle Training in the Ventilatory Muscle Metaboreflex in Chronic Obstructive Pulmonary Disease Patients.||Federal University of Rio Grande do Sul|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945398||59458|
NCT01933152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16378|Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration|Review Study: A Retrospective Noninterventional Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration|REVIEW|Bayer|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|137|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must have been diagnosed to suffer from wet AMD and must have started anti-VEGF        treatment with ranibizumab between January 1, 2009, and December 31, 2009|September 2014|September 30, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01933152||60396|
NCT01933399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16527|Comparison of Extensible and Inextensible Lumbosacral Orthoses for Lower Back Pain|Comparison of Inextensible and Extensible Lumbosacral Orthoses for the Management of Episodes of Lower Back Pain|LSO LBP|Medical University of South Carolina|No|Completed|September 2007|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|June 24, 2013||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01933399||60377|
NCT01933412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLVMC1.2013|Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients|Efficacy and Safety of Sci B Vac vs. Engerix in Dialysis Patients||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|March 2012|||August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933412||60376|
NCT01934010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-12-03|AM-101 in the Treatment of Post-Acute Tinnitus 1|AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study|AMPACT1|Auris Medical, Inc.|No|Recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|18 Years|76 Years|No|||March 2016|March 23, 2016|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934010||60330|
NCT01934309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-OAA-TO-11-00060|Do Clinical Decision-support Reminders for Medical Providers Improve the Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya?|Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya?|TBTech|Indiana University|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|16 Years|N/A|No|||August 2015|August 21, 2015|August 29, 2013||||No||https://clinicaltrials.gov/show/NCT01934309||60307|
NCT01934595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3440|Optimal Protein Supplementation for Critically Ill Patients|Optimal Protein Supplementation for Critically Ill Patients||University of Oklahoma|Yes|Recruiting|September 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934595||60285|
NCT01934608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM-001|The Effect of Synching Prescription Refills on Adherence|A Randomized Controlled Trial to Test a Synchronized Prescription Refill Program to Improve Medication Adherence||University of Pennsylvania|No|Completed|September 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|691|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934608||60284|
NCT01930643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MMHIS070|Electric Muscle Stimulation for Patients With Chronic Respiratory Failure|Effect of Electric Muscle Stimulation on Patients With Chronic Respiratory Failure||Mackay Memorial Hospital|No|Recruiting|August 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|90 Years|No|||April 2015|April 10, 2015|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01930643||60589|
NCT01935661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111-12-EMC|A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.|A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients in EMEK MEDICAL CENTER Compare to Healthy Controls.||HaEmek Medical Center, Israel|No|Enrolling by invitation|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|6 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 Thalasssemia major and intermedia patients. 60 healthy controls.|September 2015|September 16, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01935661||60204|
NCT01931241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRO-001-12-101|Safety Study of Bile Acid to Treat Hypercholesteremia|Phase I Randomized Placebo Controlled Double Blind SAD and MAD Study of Oral AHRO-001 to Assess Safety, Tolerability &PK in Volunteers w/Mild/Moderate Hypercholesteremia||AtheroNova Inc.|No|Active, not recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|110|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01931241||60543|
NCT01931566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-4833/TOMM40_301|Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 Low-dose Tablets) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects|TOMMORROW|Takeda|Yes|Active, not recruiting|August 2013|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3500|||Both|65 Years|83 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|August 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01931566||60518|
NCT01935934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00890|Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer|A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer||National Cancer Institute (NCI)|No|Recruiting|April 2013|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935934||60183|
NCT01936519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 38115|Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.|A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.||Milton S. Hershey Medical Center|Yes|Recruiting|August 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|70 Years|No|||February 2016|February 24, 2016|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936519||60138|
NCT01936805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2173862|ROsuvastatin LOading and Clinical Outcomes Trial||ROLOCO|Yuksek Ihtisas Hospital|Yes|Completed|January 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||September 2013|September 2, 2013|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01936805||60116|
NCT01947439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BATTLE IN MULTI|Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI|Phase 4, Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI||Keimyung University Dongsan Medical Center|No|Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|932|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947439||59301|
NCT01944111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2315-1|Plicated Laparoscopic Adjustable Gastric Banding Study|Prospective Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding||Tenet Healthcare Corporation|No|Enrolling by invitation|September 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944111||59557|
NCT01944332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712009553|Gamete Treatment to Correct Fertilization Failure|Gamete Treatment to Correct Fertilization Failure||Weill Medical College of Cornell University|No|Recruiting|September 2007|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|60 Years|No|||June 2015|June 10, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01944332||59540|
NCT01944605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15326|Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest|Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest|TICA|Virginia Commonwealth University|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood plasma Blood serum Whole blood Stool Expired Gas|Both|18 Years|N/A|No|Probability Sample|All adult patients resuscitated from Cardiac Arrest successfully and undergoing        therapeutic hypothermia will be evaluated for potential inclusion|January 2016|January 8, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944605||59519|
NCT01944592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGET001|Teaching Associates Randomised to Evaluate the Effectiveness of Gynaecological Pelvic Examination Versus Traditional Teaching Using Manikins|Gynaecology Teaching Associates Versus Teaching on Manikins: a Randomised Controlled Trial|TARGET|Birmingham Women's NHS Foundation Trust|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|492|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944592||59520|
NCT01946490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Waiting Times|Time Trends in Waiting Times of NSCLC Patients.|Time Trends in Diagnostic Delay and Waiting Times of Four Patient Cohorts, Diagnosed With Non-small Cell Lung Cancer, Treated With High Dose Radiotherapy.||Maastricht Radiation Oncology|No|Withdrawn|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Four cohorts of NSCLC patients will be analyzed. Patients were all treated with        radiotherapy with or without chemotherapy. To investigate the time trends, cohorts        referred for radiotherapy treatment in 2001, 2004, 2006 and 2010 will be analyzed.|September 2015|September 29, 2015|September 3, 2013||No|Not subsidized, will not start in the near future|No||https://clinicaltrials.gov/show/NCT01946490||59374|
NCT01946217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-S006|Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials|Improving Participation in AMC Clinical Trials (IMPACTS)||AIDS Malignancy Consortium|No|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected persons with a diagnosis of anal dysplasia or cancer who are offered informed        consent on an AMC interventional clinical trial.|October 2015|October 1, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946217||59395|
NCT01933165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1028/43/2013|Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness|Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness||Singapore National Eye Centre|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||June 2014|June 9, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933165||60395|
NCT01933178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1029/44/2013|Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis|Inter and Intra Examiner Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis||Singapore National Eye Centre|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933178||60394|
NCT01933425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMBDK2013|Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade|Optimizing Surgical Conditions: Intraabdominal Distance During Gynecologic Laparoscopic Surgery With and Without Muscle Relaxation (The Measurement Study)||Herlev Hospital|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|N/A|No|||March 2015|March 27, 2015|August 28, 2013||No||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01933425||60375|
NCT01933438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00751|Sup-ER Protocol RCT|Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol.||University of British Columbia|No|Terminated|June 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|6 Weeks|8 Weeks|No|||July 2015|July 24, 2015|August 28, 2013||No|The study ended early after encountering logistics challenges and difficulties with site    recruitment.|No||https://clinicaltrials.gov/show/NCT01933438||60374|
NCT01934621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13070029|Adapting Daily Activity Performance Through Strategy Training|Closing the Gap: Early Intervention for Cognitive Disability After Stroke|ADAPTS|University of Pittsburgh|Yes|Recruiting|November 2013|||August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934621||60283|
NCT01934634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12104|Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer|Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer||US Oncology Research|No|Active, not recruiting|March 2014|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934634||60282|
NCT01934647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8892-003|Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)|A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension||Merck Sharp & Dohme Corp.|No|Terminated|November 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|August 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01934647||60281|
NCT01930435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 13202|Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients|A Phase II Study Monitoring Quality of Life and Correlative Biomarkers of Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy Utilizing a Personalized Sterile Humidification Device||University of California, San Francisco|Yes|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930435||60605|
NCT01930656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208029RIC|Mobile Device to Help FRAX® Screening|The Effectiveness of Using Mobile Device and the World Health Organization Fracture Risk Assessment Tool (FRAX®) to Assist Osteoporosis Assessment and Management||National Taiwan University Hospital|No|Completed|March 2013|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|225|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults visitng geraitric health exam clinics, orthopedic clinic, and endocrinology clinic|April 2014|April 22, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01930656||60588|
NCT01935960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01655|Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers|A Randomized, Double-Blind, Phase I Dose-Escalation Study of the Novel Retinoid 9cUAB30||National Cancer Institute (NCI)|Yes|Recruiting|September 2015|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|September 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01935960||60181|
NCT01935973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01659|Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Randomized Phase II Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973||National Cancer Institute (NCI)|No|Active, not recruiting|September 2013|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935973||60180|
NCT01935947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00949|Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|May 2013|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||November 2015|January 11, 2016|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935947||60182|
NCT01936207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-GLOSSARI|Intensive Care - GLObal Study on Severe Acute Respiratory Infection|A Multi-centre, International 14-day Inception Cohort Study of Severe Acute Respiratory Infections on the Intensive Care Unit||European Society of Intensive Care Medicine|No|Completed|November 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|patients with ICU-SARI|December 2014|December 10, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936207||60162|
NCT01936831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5312|High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)|The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive Tuberculosis||AIDS Clinical Trials Group|Yes|Recruiting|July 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936831||60114|
NCT01936844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU HM15347|Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)|Interleukin-1 Blockade in Acute Decompensated Heart Failure||Virginia Commonwealth University|Yes|Completed|February 2014|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|99 Years|No|||February 2016|February 19, 2016|September 3, 2013|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT01936844||60113|
NCT01943799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-330-0101|Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B||Gilead Sciences|Yes|Completed|September 2013|March 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|178|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943799||59581|
NCT01947283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-12-11-4187|Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation|Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation|PCORI|Cambridge Health Alliance|No|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|546|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947283||59313|
NCT01944397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER-12-03-PROG-18|A CALIBER Study: Risk Factors for Stroke, Heart Failure, and Myocardial Infarction in Atrial Fibrillation|Risk Factors for the Development of Stroke, Heart Failure, and Myocardial Infarction in Patients Diagnosed With Atrial Fibrillation: a CALIBER Study||University College, London|Yes|Active, not recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|125000|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 30 years and over, registered with a CPRD practice that is up-to-standard, and        having a minimum of one year of validated follow-up data. The index date is 1st January        1998 with follow-up ending on 26th March 2010, which corresponds to the administrative        censoring date of the CPRD component of the CALIBER dataset.|September 2013|September 12, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944397||59535|
NCT01944670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLP-00015-00RAA|Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow|Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow ("IJS-E")||Skeletal Dynamics, LLC|Yes|Active, not recruiting|August 2013|||August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 19, 2014|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944670||59514|
NCT01944891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151152|Diet and Nutritional Status of Adolescent Girls in Zambézia, Mozambique|Estudo do Estado Nutricional e da Dieta em Raparigas Adolescentes na Zambézia|ZANE|Helsinki University|No|Completed|January 2010|||June 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|551|Samples With DNA|Blood, urine, buccal cells|Female|15 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Adolescent girls living in Quelimane city, Maganja da Costa district and Morrumbala        district.|September 2013|September 13, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01944891||59497|
NCT01946724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perspective|In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program|A Single Center, Observational Study to Evaluate Procedural, In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program|Perspective|Piedmont Healthcare|No|Recruiting|August 2013|||August 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects experiencing clinical symptoms considered suggestive of ischemic heart disease or        having evidence of myocardial ischemia who have had or are scheduled to have percutaneous        chronic total occlusion (CTO) revasulcarization by Percutaneous Coronary Intervention        (PCI)|April 2014|April 14, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946724||59356|
NCT01933451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211078RIB|Outcome Study of Restrictive vs. Liberal Intraoperative Fluid Management Guided by PPV in Esophagectomy|Postoperative Lung Function, Kidney Function, Inflammatory Response and Short-term Outcome After Esophagectomy and Reconstruction: Intraoperative Fluid Management Controlled With Lower and Higher Pulse Pressure Variation|PPV|National Taiwan University Hospital|Yes|Terminated|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|7|||Both|20 Years|70 Years|No|||March 2013|August 28, 2013|March 19, 2013||No|The grant for this study was not allowed.|No||https://clinicaltrials.gov/show/NCT01933451||60373|
NCT01933464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130199|An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema|An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema||University of California, San Diego|No|Recruiting|August 2013|||February 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|80 Years|No|||August 2013|August 28, 2013|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01933464||60372|
NCT01933724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRC 5526B TAPIR|The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach|The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach|TAPIR|University of South Florida|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01933724||60352|
NCT01934946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-1020430|Rehabilitation Care for Hip Fracture|Effectiveness of Post Acute Rehabilitation Care for Hip Fracture||Taipei City Hospital|Yes|Recruiting|September 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|60 Years|80 Years|No|||September 2013|September 4, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01934946||60258|
NCT01935167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW1029M|To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy|A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy||Dong Wha Pharmaceutical Co. Ltd.|No|Completed|October 2013|February 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|158|||Both|30 Years|N/A|No|||February 2015|February 11, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01935167||60242|
NCT01935440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032217|A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives||P&T|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01935440||60221|
NCT01935986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-12-032|The Effect of a Probiotic on Protection Against Upper Respiratory Tract Infections in Children|The Effect of a Probiotic on Protection Against Upper Respiratory Tract Infections in Children||Probi AB||Terminated|August 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|131|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||January 2015|November 30, 2015|August 28, 2013||No|Due to bankruptcy of the CRO company|No||https://clinicaltrials.gov/show/NCT01935986||60179|
NCT01935999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0512-13-A741|One Piece Closed Pouch in Subjects With a Colostomy|A Single Center Study to Assess the Safety and Performance of a One Piece Closed Pouch in Subjects With a Colostomy||ConvaTec Inc.|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01935999||60178|
NCT01936012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE.258/EQL/2012|Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition|Bioequivalence Study of 10 mg Lisinopril Tablets (Lisinopril 10 mg) Produced by PT Dexa Medica in Comparison With The Innovator Tablets (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, Under License From Astra Zeneca UK Ltd.)||Dexa Medica Group|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 1, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01936012||60177|
NCT01936220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant 28-1241-2|Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial|Relapse Prevention in First Episode of Schizophrenia and Related Psychotic Disorders: a 5 Year Randomized Controlled Trial||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Enrolling by invitation|September 1997|February 2016|Anticipated|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|15 Years|28 Years|No|||September 2013|September 5, 2013|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01936220||60161|
NCT01936532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0447|Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)|Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years|IFM2013-06|Nantes University Hospital|No|Active, not recruiting|October 2014|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|66 Years|No|||October 2015|October 6, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936532||60137|
NCT01936545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003116M|Anesthetic Methods and Liver Transplantation|The Impact of Different Anesthetic Methods on Ischemia Reperfusion Injury Following Liver Transplantation||National Taiwan University Hospital|No|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|144|||Both|18 Years|75 Years|No|||July 2015|July 22, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01936545||60136|
NCT01936857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA037441_VNE|Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)|Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO)||Oregon Health and Science University|Yes|Recruiting|July 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936857||60112|
NCT01936870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221096|Drug Use Investigation for Toviaz|Drug Use Investigation For Toviaz||Pfizer|No|Active, not recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Probability Sample|Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096.|February 2016|February 19, 2016|September 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01936870||60111|
NCT01943578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-58-0015-30-1059|Value of Physical Capacity Tests in Lung Cancer|Prospective Observational Cohort Study of the Value of the Six Minute Walk Test and Handgrip Strength in Lung Cancer Patients Undergoing Chemotherapy||Rigshospitalet, Denmark|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Non Small Cell Lung Cancer Stage Small Cell Lung Cancer|November 2014|November 4, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01943578||59598|
NCT01943591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.092|DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial|DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial|DELTA|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|October 2013|September 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|564|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943591||59597|
NCT01945736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044082|Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal|Pharmacokinetics of Multiple Dose Methadone in Children|MTH01|Duke University|Yes|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|26|Samples With DNA|The Study team is interested in learning more about how genetic differences in proteins      known as cytochrome P450 enzymes effect the breakdown of methadone. The study team will      gather leftover blood collected from the infant or child while the infant/child was in this      study and send it to a laboratory to test for genetics. There will be no extra blood draws      for this part of the study.      The samples for genetic testing will be given a code number and will not be labeled with the      infant or child's name or initials, or any other information that could identify the infant      or child. Any remaining blood will be destroyed after the genetic laboratory testing is      complete.|Both|91 Days|18 Years|No|Non-Probability Sample|Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2        to 6 years, and ages 6 to 18 years. There will be approximately 8 to 12 participants        enrolled in each group. Additionally, at least 6 overweight or obese participants between        ages 2-18 years will be included in this study.|March 2015|March 4, 2015|September 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945736||59432|
NCT01945957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2622|Brain Imaging of Intranasal Oxytocin Treatment in Autism|Brain Imaging and Eye-tracking in Response to Intranasal Oxytocin Treatment in Children and Adolescents With Autism||University of North Carolina, Chapel Hill|No|Recruiting|September 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|28|||Both|6 Years|18 Years|No|||January 2016|January 13, 2016|February 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945957||59415|
NCT01945216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-011|Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"|Nesina Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"||Takeda|No|Active, not recruiting|July 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3317|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who have been examined at a medical institution|August 2015|August 24, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945216||59472|
NCT01944683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGF2-CV-1007|A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure|Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure||Acorda Therapeutics|No|Active, not recruiting|September 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|September 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944683||59513|
NCT01944956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baskent|Swallowing Sound in Preterm Infant Evaluation of Feeding Maturation|Swallow Maturation in Preterm and Term Infants||Baskent University|Yes|Completed|June 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|94|||Both|26 Weeks|40 Weeks|Accepts Healthy Volunteers|Probability Sample|Preterm infants (< 37 gestational weeks) and term infants (>=37 gestational weeks)|March 2011|September 15, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01944956||59492|
NCT01953016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130199|Participation in a Research Registry for Immune Disorders|NIH Participation to USIDNET Registry||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|N/A|||Anticipated|600|||Both|N/A|N/A|No|||April 2015|May 14, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953016||58873|
NCT01947257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00730-45|Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?|Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|September 2013|January 2015|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01947257||59315|
NCT01933737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFRAN|Kinesio Taping Effect on Postural Balance in Elderly|Kinesio Taping Effect on Postural Balance in Elderly||University of Franca|No|Terminated|January 2012|January 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|August 21, 2013||No|The collected data was finished|No||https://clinicaltrials.gov/show/NCT01933737||60351|
NCT01933750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-001|Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients|A Prospective, Multicenter, Controlled Clinical Study of the PresVIEW Scleral Implant for the Improvement of Near Visual Acuity in Presbyopic Patients||Refocus Ocular Europe, B.V.|Yes|Active, not recruiting|February 2013|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01933750||60350|
NCT01933763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1193-HV-1219|An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193|||Regeneron Pharmaceuticals|No|Completed|August 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|August 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01933763||60349|
NCT01934322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNS 30023B_135762/1|Case Management for Frequent Users of the Emergency Department|Case Management for Frequent Users of the Emergency Department: A Randomized Controlled Trial||University of Lausanne|No|Completed|June 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|250|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01934322||60306|
NCT01934959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tongji|A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis|A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis||Tongji Hospital|Yes|Completed|January 2008|||January 2010|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|1 Month|13 Years|No|||August 2013|August 29, 2013|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934959||60257|
NCT01935193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAR160|Aspirin Resistance Reversibility in Diabetic Patients|Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients|ARRDM|Azienda Ospedaliera San Giovanni Battista|Yes|Recruiting|November 2011|||August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01935193||60240|
NCT01935180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS-22424|Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)|Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)|CAP|White River Junction VAMC|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1000|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935180||60241|
NCT01935453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrienGene-01|A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer|A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus||OrienGene Biotechnology Ltd.|No|Recruiting|May 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||August 2013|August 30, 2013|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01935453||60220|
NCT01935674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOS|Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels|Rosuvastatin Versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults|SOS|Hospital Clinic of Barcelona|Yes|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||September 2013|October 7, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01935674||60203|
NCT01936025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/0648-DXM2|A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|A Phase IIa, Dose-finding, Double-blind, Placebo-controlled, Double-dummy, Randomized, Eightfold Cross-over Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|DXM2|Profil Institut für Stoffwechselforschung GmbH|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|34|||Male|45 Years|70 Years|No|||November 2015|November 3, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01936025||60176|
NCT01936233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC-ASPIRIN|Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery|||Fudan University|Yes|Recruiting|August 2013|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|75 Years|No|||August 2013|September 5, 2013|September 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936233||60160|
NCT01936558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210078RIC|The Origin of Phantom Limb Sensation and Phantom Limb Pain in Amputees|The Origin of Phantom Limb Sensation and Phantom Limb Pain in Amputees||National Taiwan University Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|20|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Amputees / healthy subjects|January 2014|January 14, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01936558|6 Months|60135|
NCT01936571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blood Biomarkers|Usefulness of Blood Biomarkers for Overall Survival in NSCLC|Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy.||Maastricht Radiation Oncology|No|Completed|September 2013|March 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|N/A|N/A|No|Non-Probability Sample|Non-small cell lung cancer patients|April 2014|April 10, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936571||60134|
NCT01936883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02139|Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy|IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST|BrachyQOL|British Columbia Cancer Agency|Yes|Recruiting|January 2014|October 2020|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|45 Years|80 Years|No|||August 2015|August 21, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936883||60110|
NCT01946763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH06|Does Pre-operative Patients' Education Facilitates Emergence of Anesthesia Following Bariatric Surgery?|Does Pre-operative Patients' Education Facilitates Emergence of Anesthesia Following Bariatric Surgery?||Procare Riaya Hospital|No|Recruiting|June 2013|May 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|55 Years|No|||September 2013|September 19, 2013|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01946763||59353|
NCT01947036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SRA01|T and B Cell Responses in Autoimmune Diseases|T and B Cell Responses Across Autoimmune Diseases|SRA01|National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|68|Samples With DNA|Whole blood|Both|8 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who are healthy or have a confirmed or suspected diagnosis of type 1 diabetes        (T1D, T1DM), multiple sclerosis (MS), psoriasis (Ps), Crohn's disease (CD), or rheumatoid        arthritis (RA) will be invited to donate a blood sample. No follow-ups are planned.|February 2016|February 21, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01947036||59332|
NCT01944163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|impact-001|The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain|The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain - a Cluster Randomized Trial|IMPACT|Maasstad Hospital|Yes|Active, not recruiting|September 2014|November 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|850|||Both|18 Years|45 Years|No|||November 2015|November 23, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01944163||59553|
NCT01944176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si323/2013|The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients|The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokines in COPD Patients||Mahidol University|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|35 Years|80 Years|No|||March 2016|March 15, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01944176||59552|
NCT01944124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15828|Exercise and Technology to Reduce Risk in a Rural Population With Metabolic Syndrome|A Lifestyle Intervention Supported by Mobile Health Technologies to Improve the Cardiometabolic Risk Profile of Individuals at Risk for Cardiovascular Disease and Type 2 Diabetes.||Lawson Health Research Institute|No|Completed|November 2009|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Actual|149|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944124||59556|
NCT01944618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-209|forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)|forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM|forREAL|AstraZeneca|No|Terminated|October 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with Type 2 Diabetes whom the Healthcare professional (HCP) would consider as        suitable candidates for Forxiga treatment will be invited to participate in the program        during routine clinical assessment|December 2015|December 14, 2015|September 13, 2013||No|Participants required: 5000    Participant Data obtained to 06Oct2015:    Baseline: 447 6 month follow-up: 253 Program terminated: recruitment target not met.|No||https://clinicaltrials.gov/show/NCT01944618||59518|
NCT01944631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1326.1|Iota-Carrageenan Nasal Spray in Common Cold|Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold||Boehringer Ingelheim||Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|64 Years|No|||March 2015|April 2, 2015|September 13, 2013||||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01944631||59517|
NCT01952756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKUH-10103043/BR-100-134|Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD||National Cheng-Kung University Hospital|No|Completed|January 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|20 Years|N/A|No|||July 2014|July 16, 2014|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01952756||58893|
NCT01953276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022288|Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain|Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain (ASAP CATH) Study|ASAP Cath|Wake Forest Baptist Health|No|Active, not recruiting|January 2013|July 2016|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|382|Samples With DNA|Whole blood samples are obtained from patients and processed so that the plasma is extracted      and frozen for future research.|Both|21 Years|N/A|No|Non-Probability Sample|Patients presenting to the Wake Forest Baptist Health Emergency Department with symptoms        concerning for Acute Coronary Syndrome (ACS) are eligible for enrollment.|June 2015|June 1, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953276||58853|
NCT01938781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10002004-1|Optimized Treatment and Regression of HBV-induced Liver Fibrosis|Optimized Treatment and Regression of HBV-induced Liver Fibrosis||Beijing Friendship Hospital|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938781||59967|
NCT01939041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5194A3|Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation in Patients With Subacute Stroke|Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation on Motor Control/Performance, Daily Functions, and Physiological Responses in Patients With Subacute Stroke||Chang Gung Memorial Hospital|No|Recruiting|August 2013|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|20 Years|75 Years|No|||December 2015|December 28, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01939041||59947|
NCT01935206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-174|Effect of High Dose Naloxone on Secondary Hyperalgesia|Effect of a High-dose Naloxone Infusion on Secondary Hyperalgesia After a First-degree Burn||Rigshospitalet, Denmark|Yes|Completed|June 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01935206||60239|
NCT01935466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBEPIO|Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"|Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus"PROBE-PIO"Study|PROBE-PIO|Postgraduate Institute of Medical Education and Research|No|Recruiting|July 2013|July 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|6107|||Male|50 Years|N/A|No|Non-Probability Sample|The study group will comprise of male type 2 diabetes subjects having used pioglitazone        for one year or more. The control group will include male type 2 diabetes subjects on        medications other than pioglitazone adjusted for age, household income, anti-diabetic        drugs, HbA1c,smoking, renal function and other bladder disorders.|October 2014|October 27, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01935466||60219|
NCT01935687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101006|Clinical Evaluation of Instrumented Wheel as Biomedical Device Quantifying the Displacement Efficiency|Clinical Evaluation of Instrumented Wheel of Wheelchair as Biomedical Device Quantifying the Displacement Efficiency|FRM|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2012|July 2015|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01935687||60202|
NCT01936272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00002785|Neurocognitive Outcomes and Changes in Brain and CSF Volume After Treatment of PIH in Ugandan Infants by Shunting vs ETV/CPC|Neurocognitive Outcomes and Changes in Brain and Cerebral Spinal Fluid (CSF) Volume After Treatment of Post-Infectious Hydrocephalus (PIH) in Ugandan Infants by Shunting Versus ETV/CPC||Children's Hospital Boston|Yes|Recruiting|April 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|180 Days|No|||September 2013|September 3, 2013|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936272||60157|
NCT01936246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMCProtein|Protein Supplementation in Infants With Brain Injury|Protein Supplementation in Infants With Brain Injury||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|August 2012|January 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|N/A|3 Weeks|No|||September 2013|August 22, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936246||60159|
NCT01936259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CA.GE1.12|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||December 11, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936259||60158|
NCT01936584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/381|Validation of Quality of Life Assessment After Laparoscopic TAPP and TEP Surgery of Inguinal Hernias Using EuraHS of Life Score and Carolinas Comfort Scale™|Validation of Quality of Life Assessment After Laparoscopic TAPP and TEP Surgery of Inguinal Hernias Using EuraHS of Life Score and Carolinas Comfort Scale™|LIQUOR|University Hospital, Ghent|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|101|||Both|18 Years|N/A|No|Probability Sample|patients undergoing laparoscopic unilateral inguinal hernia repair|September 2015|September 17, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01936584||60133|
NCT01939015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|Three Dimensional Versus Standard Miniplate In Fixation Of Mandibular Angle Fracture- A Prospective Randomized Controlled Clinical Trial|3D Vs Standard Miniplate in Fixation of the MAFs|RCTs|Cairo University|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|17 Years|45 Years||||December 2013|December 27, 2013|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01939015||59949|
NCT01935154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vx-001-201|Efficacy Study of Vx001 Vaccine in NSCLC Patients|Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC||Vaxon Biotech|No|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01935154||60243|
NCT01926158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS 20109714|Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women|Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women: a Randomized, Double-blind, Placebo-controlled Study|ProliaHip|Turku University Hospital|No|Recruiting|December 2013|August 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|68|||Female|65 Years|85 Years|No|||January 2014|January 7, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926158||60933|
NCT01926444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIC13-01|A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy||gicare Pharma Inc.|Yes|Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|308|||Both|40 Years|70 Years|No|||March 2014|March 19, 2014|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926444||60911|
NCT01957553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP243|Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click 2-piece|Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click in 130 Subjects With an Ileostomy.||Coloplast A/S|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|October 1, 2013||No||No|August 18, 2014|https://clinicaltrials.gov/show/NCT01957553||58524|
NCT01958099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN381904|Teaching Injury Prevention|Behavior Change by Families in a Pediatric Emergency Department After Receiving Injury Prevention Information From a Safety Specialist Compared to a Computerized Kiosk||Children's Hospital Medical Center, Cincinnati|No|Completed|August 2010|September 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|359|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 7, 2013|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958099||58482|
NCT01958112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-334|GSK1120212+GSK2141795 for Cervical Cancer|A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer||Dana-Farber Cancer Institute|Yes|Suspended|October 2013|March 2020|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|October 4, 2013|Yes|Yes|Drug supply|No||https://clinicaltrials.gov/show/NCT01958112||58481|
NCT01960101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-58|Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication|Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Psychotropic Drugs and Comparison of Its Efficiency With the Use of Aequasyal (Oxidized Glycerol Triester)Spray.|LactoXeros|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Withdrawn|October 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960101||58328|
NCT01960114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERPAI2001|Study of Long-Acting Acetaminophen in Postoperative Dental Pain|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Study of Extended-Release (ER) Acetaminophen in Postoperative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|17 Years|45 Years|No|||June 2015|June 11, 2015|October 8, 2013|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01960114||58327|
NCT01959867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-BR-001|SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy|Clinical Study Comparing Two-Stage Breast Reconstruction Following Mastectomy With and Without the Use of SurgiMend® PRS Fetal Bovine Collagen Matrix in Patients With Pre-Mastectomy Radiation Therapy||Integra LifeSciences Corporation|No|Not yet recruiting|January 2016|September 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||May 2015|May 26, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959867||58346|
NCT01959880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110390SS-0313-2|CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)|CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants in Subjects Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision||Mentor Worldwide, LLC|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1892|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959880||58345|
NCT01960387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 13-066|Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine|UPCI 13-066|University of Pittsburgh|Yes|Terminated|October 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 7, 2013|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT01960387||58306|
NCT01960400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-116|Investigation of the Efficacy of tDCS in the Treatment of Complex Regional Pain Syndrome (CRPS) Type 1|Investigation of the Efficacy of Transcranial Direct Current Stimulation (tDCS) Added to the Graded Motor Imagery (GMI) in the Treatment of Complex Regional Pain Syndrome (CRPS) Type 1||Université de Sherbrooke|Yes|Active, not recruiting|April 2013|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01960400||58305|
NCT01937065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_153R_IP4|Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study||IP4|University College, London|Yes|Active, not recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1937360|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1,93 million patients registered in Clinical Practice Research Datalink (CPRD) practices|September 2013|September 3, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01937065||60096|
NCT01936467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00079301|Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions|Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided||Johns Hopkins University|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|121|||Both|18 Years|90 Years|No|||January 2015|January 22, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936467||60142|
NCT01937312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-020|Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue|Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue||Alcon Research|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|September 4, 2013|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01937312||60077|
NCT01937936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23NR013475|Heart Failure Caregiver Study|Stress and Health in Family Caregivers of Persons With Heart Failure||University of California, Los Angeles|No|Active, not recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|21 Years|N/A|No|||January 2015|January 7, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937936||60030|
NCT01937598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-0569-DZBL-2012|Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin|Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin||Diabeteszentrum Bad Lauterberg im Harz|No|Recruiting|August 2013|February 2015|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|16|||Both|25 Years|75 Years|No|||September 2013|September 4, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01937598||60055|
NCT01938157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2327|Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study|Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study||University of North Carolina, Chapel Hill|No|Active, not recruiting|August 2013|||January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Female|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01938157||60014|
NCT01938443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114746|A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors|A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors||GlaxoSmithKline|No|Recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938443||59992|
NCT01938456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117132|Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer|An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer||GlaxoSmithKline|No|Withdrawn|October 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||July 2014|July 24, 2014|September 5, 2013||No|This study was Cancelled Before Active|No||https://clinicaltrials.gov/show/NCT01938456||59991|
NCT01938742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0032|H7N9 Mix and Match With MF59 in Healthy Adults|A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without MF59 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|700|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||September 2014|March 26, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938742||59970|
NCT01934933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013]2-93|Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis|An Open Clinical Trial to Assess Efficacy for Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis||Sun Yat-sen University|Yes|Recruiting|August 2013|August 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|65 Years|No|||January 2016|January 22, 2016|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01934933||60259|
NCT01930175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736X2203|Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris|A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris||Novartis|Yes|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|32|||Both|20 Years|70 Years|No|||March 2016|March 3, 2016|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930175||60625|
NCT01930188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3626|Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)|SUSTAIN™ 2|Novo Nordisk A/S|No|Completed|December 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1230|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930188||60624|
NCT01930201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00842|Caudal Epidural Block for Postoperative Analgesia in Adolescents Following Major Hip Surgery.|||Nationwide Children's Hospital|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|32|||Both|N/A|N/A|No|Non-Probability Sample|Patients who had major orthopedic hip surgery.|October 2014|October 28, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01930201||60623|
NCT01926678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062853|Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors|Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer||Emory University|Yes|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Female|18 Years|65 Years|No|||January 2016|January 13, 2016|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926678||60893|
NCT01926691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TABASCO|Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)|Predictors for Poststroke Outcomes: the Tel Aviv Brain Acute Stroke Cohort (TABASCO) Study|TABASCO|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|April 2008|||April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|534|Samples With DNA|whole blood, serum, white cells, saliva|Both|50 Years|N/A|No|Non-Probability Sample|Patients admitted to the Department of Emergency Medicine at the Tel-Aviv Sourasky Medical        Center (TASMC) within three-days of their first-ever acute ischemic stroke or transient        ischemic attack (TIA) symptoms onset.|August 2013|August 20, 2013|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01926691|10 Years|60892|
NCT01958762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2013_843_0010|Screening for Cancers in the Oral CAvity|Screening for Cancers in the Oral CAvity Targeting Tobacco Users in Somme, France|IDECAB|Centre Hospitalier Universitaire, Amiens|No|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958762||58431|
NCT01959542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-343|Early Changes In Multiparametric MRI In Prostate Cancer|Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|December 2013|September 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959542||58371|
NCT01959555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAEM-4076|Project to Update the Study of Congenital Haemophilia in Spain|Project to Update the Study of Congenital Haemophilia in Spain|PUCHS|Novo Nordisk A/S|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1157|||Male|N/A|N/A|No|Non-Probability Sample|Patients in active follow-up in HTCs (Haemophilia Treatment Centres) will be included in        this study. A patient is considered as active if a visit to the HTC is performed in the        period of January 2013 to December 2013.|November 2015|November 27, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959555||58370|
NCT01959841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-J01|Phase III Study of ASP2151 in Herpes Zoster Patients|Phase III Study of ASP2151 in Herpes Zoster Patients― A Double-blind, Valaciclovir-controlled Study||Maruho Co., Ltd.||Completed|August 2013|||July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|750|||Both|20 Years|79 Years|No|||March 2016|March 15, 2016|September 26, 2013||||No||https://clinicaltrials.gov/show/NCT01959841||58348|
NCT01959295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-J11|Phase III Study of ASP2151 in Herpes Simplex Patients|Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ―||Maruho Co., Ltd.||Completed|August 2013|||April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|453|||Both|20 Years|79 Years|No|||March 2016|March 15, 2016|September 26, 2013||||No||https://clinicaltrials.gov/show/NCT01959295||58390|
NCT01960452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2013-0019|A High Density EEG Comparison of Sleep Patterns in Insomnia|A High Density EEG Comparison of Sleep, Sleep Initiation, and Arousal Patterns in Insomnia Patients and Normal Controls||University of Wisconsin, Madison|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the community and from patients presenting at the        Wisconsin Sleep and UW-Psychiatry clinics for insomnia.|March 2015|September 30, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01960452||58301|
NCT01959854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XNTME2013|Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye|Evaluation of Xanthan Gum Eye Drops in Patients With Dry Eye||SIFI SpA|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|N/A|No|||October 2014|October 15, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959854||58347|
NCT01960153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001412|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)|PITCH-ER|Massachusetts General Hospital|Yes|Withdrawn|October 2013|May 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|21 Years|N/A|No|||June 2014|June 27, 2014|October 8, 2013|Yes|Yes|Award was ended by NIH for parent study|No||https://clinicaltrials.gov/show/NCT01960153||58324|
NCT01936480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A059013|Genetics of QT Response to Moxifloxacin|Genetics of QT Response to Moxifloxacin|MOXIGEN|Massachusetts General Hospital|No|Enrolling by invitation|October 2013|||September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 18, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936480||60141|
NCT01937338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2550C00004|Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge|A Double Blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood After Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)||AstraZeneca|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937338||60075|
NCT01936766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL 1302|Optimal Fluid Management in Adult Severe Malaria|Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy|DRIPICCO|University of Oxford|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|16 Years|65 Years|No|Probability Sample|Patients with severe malaria or severe sepsis admitted to the secondary or tertiary care        center|August 2014|August 15, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01936766|14 Days|60119|
NCT01928277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1230(REK)|Weaning From Mechanical Ventilation: Spontaneous Breathing Trial and the Assessment of Work of Breathing|Weaning From Mechanical Ventilation: Spontaneous Breathing Trial and the Assessment of Work of Breathing||University of Tromso|No|Completed|September 2012|December 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|ICU-patients weaning from mechanical ventilation|December 2014|December 11, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01928277||60771|
NCT01938183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTZ085-2006|Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis|Full-mouth Periodontal Debridement With or Without Adjunctive Metronidazole Gel in Smoking Patients With Chronic Periodontitis||University of Campinas, Brazil|Yes|Completed|November 2006|December 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|21 Years|70 Years|No|||September 2013|September 4, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01938183||60012|
NCT01937923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|455690|A Pre-Cellular Therapy Observational Study in Early Huntington's Disease|A Pre-Cellular Therapy Observational Study in Early Huntington's Disease|PRE-CELL|University of California, Davis|No|Active, not recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Safety labs: Complete blood count, comprehensive metabolic panel, international normalized      ration, partial thromboplastic time, thyroid stimulating hormone, urinalysis, HIV screen.      Biomarkers: Brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid (CSF) and      Plasma, BDNF related and Huntington's Disease (HD) specific gene transcription markers in      CSF and blood, Small molecule markers of HD in CSF and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be primarily recruited from the Huntington's disease clinic in the        University of California, Davis (UC Davis) department of neurology. We also plan to        recruit participants from among northern California regional support groups, from letters        to neurologists and psychiatrists who are treating patients with HD, from listing our        study on clinical trials.gov, and at regional and national HD meeting presentations, and        via print and video recordings on our website.|January 2016|January 29, 2016|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01937923||60031|
NCT01938170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2769|Home Administration of FluMist by Parents/Caregivers|A Pilot Study to Assess the Acceptability, Tolerability, and Feasibility of Home Intranasal Administration of FluMist® by a Trained Primary Caregiver to Healthy Family Members 2 Through 17 Years of Age||University of North Carolina, Chapel Hill|No|Active, not recruiting|September 2014|September 2015|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938170||60013|
NCT01938469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-117|Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery|Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery||St. Luke's-Roosevelt Hospital Center|No|Completed|September 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|33|||Both|21 Years|60 Years|No|||September 2015|September 9, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01938469||59990|
NCT01938755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|odu52|Hyperbaric Levobupivacaine for Spinal Anaesthesia|||T.C. ORDU ÜNİVERSİTESİ||Completed|June 2013|||January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|65 Years|No|||January 2014|April 18, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938755||59969|
NCT01929915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203094RIC|Analgesia and Pancreatic Cancer Surgery|Perioperative Epidural Analgesia for Short-term and Long-term Outcomes of Pancreatic Cancer Surgery- Randomised Trial||National Taiwan University Hospital|Yes|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|85 Years|No|||July 2015|July 14, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01929915||60645|
NCT01926171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IV-49|Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases|A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|June 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926171||60932|
NCT01926184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033854|RCT of an Integrative Intervention for Non-Treatment-Seeking Meth Users|Randomized Controlled Trial of an Integrative Intervention for Non-Treatment-Seeking Meth Users|ARTEMIS|University of California, San Francisco|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Male|18 Years|N/A|No|||March 2016|March 12, 2016|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926184||60931|
NCT01926938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS#: 03-30|Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes|||Joslin Diabetes Center|Yes|Completed|May 2003|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|44|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Young Latino adults with and without family history of type 2 diabetes|August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926938||60873|
NCT01959074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-URO-2012-04|The Effect of Naftopidil for the Double-J Stent Discomfort|The Effect of Naftopidil for the Double-J Stent Discomfort: Multicenter, Randomized, Double-blind, Placebo Controlled Study||Seoul National University Hospital|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|N/A|No|||December 2015|December 8, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01959074||58407|
NCT01959035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14724B|Aripiprazole Once-monthly in Patients With Schizophrenia|Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|60 Years|No|||May 2015|May 8, 2015|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01959035||58410|
NCT01959581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD076092-01A1|Movement Enhancing Device for Children|An Innovative Device for Intervention in Infants With Nervous System Injury||University of Delaware|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Month|6 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959581||58368|
NCT01957124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5377|Treatment of the Hypertensive Leg Ulcers by PRF Application|Treatment of the Hypertensive Leg Ulcers by PRF Application||University Hospital, Strasbourg, France|No|Not yet recruiting|October 2013|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01957124||58557|
NCT01957137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1670|InterStim® Sacral Nerve Modulation Cycling Study|InterStim® Sacral Nerve Modulation Cycling Study||MedtronicNeuro|No|Completed|September 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|30|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01957137||58556|
NCT01960166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2254|Active vs Passive Distraction on Procedural Pain in the Pediatric Emergency Department|Impact of Active vs Passive Distraction on Procedural Pain/Distress in the Pediatric Emergency||University of Chicago|No|Recruiting|June 2013|June 2016|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960166||58323|
NCT01937351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0555|Evaluation of the Pantheris Optical Coherence Tomography Imaging Atherectomy System for Use in the Peripheral Vasculature|Evaluation of the Pantheris Optical Coherence Tomography Imaging Atherectomy System for Use in the Peripheral Vasculature|VISION|Avinger, Inc.|Yes|Completed|July 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937351||60074|
NCT01937611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121A021007|Intramuscular Dexmedetomidine as Premedication|Comparison of Dexmedetomidine and Midazolam as Intramuscular Premedication for Suspension Laryngoscopy||Guangzhou First Municipal People’s Hospital|Yes|Recruiting|March 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||September 2013|September 7, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01937611||60054|
NCT01928810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201015|Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia|The Influence of Physical Activity (Prior to In-vivo Exposure) on the Effect of Cognitive Behavioural Therapy in Patients With Panic Disorder and Agoraphobia||Charite University, Berlin, Germany|No|Completed|March 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|65 Years|No|||February 2015|February 6, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01928810||60730|
NCT01938482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117226|Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029|A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects||GlaxoSmithKline|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938482||59989|
NCT01938768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZARI-NK-2013-02|Effects of an Early Prehospital Administration of Tranexamic Acid on Hyperfibrinolysis in Multiple Trauma|||University of Göttingen|No|Completed|November 2013|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|110|Samples Without DNA|blood samples|Both|18 Years|90 Years|No|Non-Probability Sample|Patients will be recruited by emergency physicians on the scene by taking a blood sample        for thrombelastometry.|November 2015|November 30, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938768||59968|
NCT01939028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9813|Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery|Sentinel Lymph Node Mapping for Endometrial Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|July 2013|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|N/A|N/A|No|||January 2016|January 14, 2016|July 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939028||59948|
NCT01930214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-0002-P|Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)|Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)|MACE|Cardiovascular Systems Inc|No|Active, not recruiting|September 2013|February 2019|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|18 years or older who are scheduled for percutaneous coronary revascularization involving        stent.|December 2015|December 21, 2015|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01930214||60622|
NCT01930227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2013-08-1|Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients|Effect of Transcutaneous Electrical Acupoint Stimulation(TEAS) on the Incidence of Hypotension After Spinal Anesthesia in Patients Undergoing Cesarean Section: a Prospective, Randomized Controlled Trial|THSAP|Xijing Hospital|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Female|18 Years|65 Years|No|||December 2014|December 7, 2014|August 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01930227||60621|
NCT01926704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT - 210613|MTF Image Modifications|A Pilotstudy Investigating the Impact of Image Modifications on Subjective Image Quality||Medical University of Vienna||Completed|October 2013|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy, male and female subjects 18-35 years non-smokers|February 2014|February 18, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926704||60891|
NCT01927211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF Csection Study|Prospective Study on Cesarean Wound Outcomes|A Prospective Randomized Study Assessing Post Operative Wound Infections Along With Cosmetic Outcomes Using Silver Plated Dressings Compared to Conventional Dressings on Cesarean Section Incisions||Argentum Medical LLC|No|Recruiting|July 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|660|||Female|18 Years|N/A|No|||December 2015|December 28, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927211||60852|
NCT01960192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnslblzlzx2011-6|Treatment of Primary CNS Lymphoma|The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.|FVD|Zhengzhou University|No|Recruiting|June 2012|June 2020|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|14 Years|60 Years|No|||July 2015|July 19, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01960192||58321|
NCT01958736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|369/13|Ballistic Strength Training in Stroke: A Pilot Study|Ballistic Strength Training in Stroke: A Phase II Randomized, Controlled, Assessor Blinded Pilot Study||Bayside Health|No|Recruiting|February 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958736||58433|
NCT01958749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA/Fat Graft Myringoplasty|Fat Graft Myringoplasty With and Without Platelet Rich Plasma (PRP) for Treating Smaller Tympanic Membrane Perforations|Efficacy of Fat Graft Myringoplasty Versus Fat Plus Platelet Rich Plasma (PRP) Myringoplasty in Closing Smaller Tympanic Membrane Perforations in an Outpatient Setting: a Randomized Study||Nova Scotia Health Authority||Not yet recruiting||||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|19 Years|N/A|No|||September 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958749||58432|
NCT01959308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIM Study|Adherence to Immunosuppressive Therapy Liver Transplant Recipients|Adherence to Immunosuppressive Therapy in Adult and Adolescent Liver Transplant Recipients: A Questionnaire Survey|AIM|National University Hospital, Singapore|Yes|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients (males or females age 18 years and above) who are on active follow up at        liver transplant clinic at National University Hospital, Singapore.|October 2013|October 8, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959308||58389|
NCT01959594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441002|A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers|Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects||Pfizer|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959594||58367|
NCT01959893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101-13-TLV|Computerized Cognitive Testing in Patients Suffering From Fibromyalgia|Computerized Cognitive Testing in Patients Suffering From Fibromyalgia||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|60 Years|No|Probability Sample|50 Fibromyalgia patients will be recruited at the specialized fibromyalgia clinic which is        part of the rheumatology institute of the Tel Aviv Sourasky Medical center. All patients        will be asked to give written informed consent and the study will be submitted for        approval of the institutional Helsinki committee.        The proposed number of participants (50) was chosen in order to assure sufficient        statistical power of the study, based on a multi-component regression analysis as        described under statistical methods.|October 2013|October 9, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01959893||58344|
NCT01960179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY13476|Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes|An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes||Sanofi|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|361|||Both|20 Years|N/A|No|||April 2015|April 8, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960179||58322|
NCT01926327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Bone-011|The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee|The Effects of Intraarticular Injection of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee (in a Clinical Trial Phase III)||Royan Institute|Yes|Completed|January 2013|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||September 2012|April 24, 2014|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926327||60920|
NCT01957410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102607|A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder|An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder||Janssen Research & Development, LLC|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|64 Years|No|||January 2016|January 7, 2016|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957410||58535|
NCT01927692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043906|Therapeutic Plasma Exchange in MG|Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange|TPE|Duke University|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Potentially eligible subjects with MG that will receive TPE as part of their clinical care        will be identified from clinic encounters, emergency department visits, and        hospitalizations.|June 2015|July 15, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927692||60815|
NCT01927991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Titus2|Internet-based Self-help for Tinnitus: The Role of Support|Internet-based Self-help for Tinnitus: The Role of Support||Philipps University Marburg Medical Center|No|Completed|September 2012|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01927991||60793|
NCT01928004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDGPA_02|Mandibular Implants in Elderly Patients|Implant-supported Mandibular Overdentures in Very Old Adults - a Randomized Controlled Trial||University Hospital, Geneva|No|Active, not recruiting|September 2007|April 2014|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|75 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01928004||60792|
NCT01928823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221013|Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia|Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder|Exposure-DCS|Charite University, Berlin, Germany|Yes|Completed|November 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|75 Years|No|||May 2014|May 16, 2014|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928823||60729|
NCT01929122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1038|Beans/Bran Enriching Nutritional Eating For Intestinal Health Trial|BENEFIT: Beans/Bran Enriching Nutritional Eating For Intestinal Health Trial|BENEFIT|Colorado State University|No|Active, not recruiting|August 2010|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929122||60706|
NCT01929083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12GRNT12060187|Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening|Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes||Indiana University|Yes|Completed|April 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|August 22, 2013|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT01929083||60709|
NCT01929369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross Pilot|Pilot Study of IVUS Imaging During Endovascular Interventions of Failing Hemodialysis Access Grafts|Pilot Study of IVUS Imaging During Endovascular Interventions of Failing Hemodialysis Access Grafts||Volcano Corporation|No|Completed|August 2013|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|ESRD PATIENTS WITH THROMBOSED AV GRAFTS|February 2015|February 19, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929369||60687|
NCT01929655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16430|Japanese BAY88-8223 Monotherapy Phase II Study|A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases||Bayer|No|Active, not recruiting|September 2013|May 2017|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Male|20 Years|N/A|No|||February 2016|February 9, 2016|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929655||60665|
NCT01929668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-036-002|Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC Patients|Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Patients With Inactive Ulcerative Colitis; Randomized, Single Blind, Multicenter Study|2SCANI|Keimyung University Dongsan Medical Center|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|114|||Both|18 Years|80 Years|No|||December 2014|December 25, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929668||60664|
NCT01926457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-GDM-RCT|Treating Prediabetes in the First Trimester|Treating Prediabetes in the First Trimester: A Randomized Controlled Trial||University of California, San Diego|Yes|Recruiting|July 2013|April 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01926457||60910|
NCT01926951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM13-001|Renal Denervation Using Externally Focused Therapeutic Ultrasound|A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound With External Targeting and Tracking on Patients With Refractory Hypertension||Kona Medical Inc.|Yes|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926951||60872|
NCT01928082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0062|The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass|The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass||University of Chicago|Yes|Enrolling by invitation|August 2013|||August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|40 Years|69 Years|No|||August 2013|August 20, 2013|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928082||60786|
NCT01959932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-REXC-03-EU|Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in Confinement|A Single Center, Open-label, Randomized, Controlled Study Demonstrating Reduction in Exposure to Smoke Constituents in Healthy Smokers Switching to THS 2.2 or Smoking Abstinence, Compared to Conventional Cigarettes for 5 Days in Confinement||Philip Morris Products S.A.|No|Completed|June 2013|June 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|169|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959932||58341|
NCT01959048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0676-12|Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis|Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis||Hadassah Medical Organization|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 5, 2015|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01959048||58409|
NCT01959061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCTTQ-01|Efficacy and Safety Study of Raltitrexed to Treat Advanced Colorectal Cancer|Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer|TACE|Nanjing Chia-tai Tianqing Pharmaceutical|Yes|Active, not recruiting|September 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|320|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01959061||58408|
NCT01956643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShamLT|Effect of Sham Feeding on Postoperative Ileus After Elective Liver Transplantation|Effect of Sham Feeding on Postoperative Ileus After Elective Liver Transplantation||Seoul National University Hospital|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956643||58594|
NCT01956864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro0000075|Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer|A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis||Johns Hopkins University|No|Suspended|September 2013|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Anticipated|24|||Both|18 Years|75 Years|No|||August 2014|August 11, 2014|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01956864||58577|
NCT01956877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45176.068.13|Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers|Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers||Maastricht University Medical Center||Recruiting|November 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|15 healthy volunteers, age > years|August 2014|August 4, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01956877||58576|
NCT01926821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIZO2013|Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy|The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer||Asan Medical Center|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|75 Years|No|||February 2014|February 6, 2014|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926821||60882|
NCT01928303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212013319|Predicting Oxycodone Dose From Oral Fluid Drug Levels|Predicting Oxycodone Dose From Oral Fluid Drug Levels For Chronic Pain Management Patients|AFTSLabs|Weill Medical College of Cornell University|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|55|Samples Without DNA|Once received into the laboratory at AFTS labs, oral fluid, blood and urine specimens will      be aliquoted for analysis, and any remaining sample will be transferred to long term storage      at -20 - 0°C.|Both|18 Years|72 Years|No|Non-Probability Sample|Subjects will be generally healthy males and females who are undergoing treatment for        chronic pain.|September 2014|September 12, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01928303||60769|
NCT01928017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1881|Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia|Monitoring of Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia||University of Bergen|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|13|Samples Without DNA|Plasma specimens are kept frozen.|Both|16 Years|N/A|No|Non-Probability Sample|Hospital inpatients admitted to the Department of Medicine, Section for Haematology at        Haukeland University Hospital will be invited to join the study if they meet the inclusion        criteria.|December 2014|December 2, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01928017||60791|
NCT01928290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309035|Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer|Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors|FOLFIRINOX|Washington University School of Medicine|No|Recruiting|November 2013|March 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928290||60770|
NCT01929408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2368.00|Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients|Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study||Fred Hutchinson Cancer Research Center|No|Recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|The study population will include non-M3 AML and high-risk MDS patients considered for        induction chemotherapy at FHCRC and the Seattle Cancer Care Alliance Network and other        Core institutions (Stanford School of Medicine, Cleveland Clinic, Northwestern University,        Massachusetts General Hospital, and University of Utah) in addition to an unidentified        number of affiliate sites. We anticipate enrollment of a total sample of 1000 patients.|February 2016|February 3, 2016|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01929408||60684|
NCT01928524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFE 12.17|Chemotherapy for Patients With Cancer of the Stomach|Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Esophagus or Gastric|DOS|Odense University Hospital|No|Recruiting|September 2013|August 2016|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||January 2015|January 20, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928524||60752|
NCT01928537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-24|Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine|Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine||Onconova Therapeutics, Inc.|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928537||60751|
NCT01929096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-23-01|Compound Edaravone Injection for Acute Ischemic Stroke|Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|August 2013|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|400|||Both|35 Years|75 Years|No|||July 2015|July 1, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929096||60708|
NCT01929109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14578|A Study of LY2409021 in Participants With Different Levels of Kidney Function|Pharmacokinetics of LY2409021 Following Administration to Subjects With Varying Degrees of Renal Function||Eli Lilly and Company|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929109||60707|
NCT01929382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTRL Clin 2013-001|Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers|A Randomized, Double-Blind, Crossover Study to Determine the Effect of Actimmune® Dose Titration on the Severity and Incidence of Interferon Gamma-1b-Related Flu-Like Symptoms and the Pattern of Dropouts in Healthy Volunteers|FLS|Vidara Therapeutics Research Ltd|No|Active, not recruiting|July 2013|December 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929382||60686|
NCT01929681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002380|Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression|Low Field Magnetic Stimulation in Mood Disorders: Three Daily Visits|LFMS|Mclean Hospital|No|Recruiting|July 2013|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|21 Years|65 Years|No|||September 2015|September 3, 2015|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929681||60663|
NCT01929928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-12-03B|Evaluation of Efficacy and Accuracy of a Cordless Ultrasonic Dissection System|Sonicision Cordless Ultrasonic Dissection System in General Surgery: A Prospective Post-market Observational Study to Evaluate the Efficacy and Accuracy of a Cordless Ultrasonic Dissection System|SCUD|Carolinas Healthcare System|Yes|Completed|January 2013|May 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the division of Hepatobiliary Surgery at Carolinas Medical Center in        Charlotte, NC.|February 2016|February 11, 2016|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929928||60644|
NCT01929941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 47986-103|An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies||Incyte Corporation|No|Terminated|September 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|August 22, 2013|Yes|Yes|Business decision.|No||https://clinicaltrials.gov/show/NCT01929941||60643|
NCT01929954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PER-005-GT|Safety Study of Gintuit™ in Subjects Requiring Socket Grafting|Phase 1/2, Randomized, Controlled Assessment of the Safety Of Gintuit™ Versus Bio-Gide® in Subjects Requiring Socket Grafting||Organogenesis|No|Terminated|July 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|August 13, 2013|No|Yes|Changes in corporate business environment|No||https://clinicaltrials.gov/show/NCT01929954||60642|
NCT01926717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYGDWK-02|A Comparative Clinical Research on Single Roux-en-Y and Traditional Roux-en-Y of Pancreaticojejunostomy-choledochojejunostomy For Treatment of Obstruction of Pancreatic Duct and Bile Duct|||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|December 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|30 Years|70 Years|No|Non-Probability Sample|Patients with pancreatic cancer|March 2016|March 6, 2016|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926717||60890|
NCT01928095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 13-0623-F1V|RNA Cloning and Visualization in Human Atherosclerosis|RNA Cloning and Visualization in Human Atherosclerosis||University of Kentucky|No|Active, not recruiting|October 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|discarded artherosclerotic tissue obtained during carotid endarterectomy|Both|18 Years|N/A|No|Probability Sample|Male and Female patients undergoing carotid endarterectomy|October 2013|October 21, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928095||60785|
NCT01928888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11201|Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes|A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute Heartburn Episodes.||Bayer|No|Completed|May 2003|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|559|||Both|18 Years|65 Years|No|||December 2014|December 23, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928888||60724|
NCT01929551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGPMJP2013-CINCO|Glycemic Index of Mango and Pear in Different Solid Products and Drinks|Comparison of the Glycemic Index of a Drink Made of Natural Concentrated Mango Puree With Natural Concentrated Pear Juice With That of Other Five Products Based on Mango and Pear in Different Solid Products and Drinks||Instituto Tecnologico y de Estudios Superiores de Monterey|No|Completed|August 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|7||Actual|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929551||60673|
NCT01959321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-HCV|An Observational Study of Hepatitis C Virus in Pregnancy||HCV|The George Washington University Biostatistics Center|No|Recruiting|October 2012|April 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1800|Samples With DNA|maternal serum maternal plasma infant serum infant plasma|Female|N/A|N/A|No|Non-Probability Sample|Women with singleton pregnancies presenting for prenatal care prior to 23 weeks, 6 days        gestation at Maternal-Fetal Medicine Units (MFMU) Network hospital sites.|October 2015|October 19, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01959321||58388|
NCT01926067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2305 A (REK)|Monitoring of Cardiac Function With 3-axis Accelerometers|Monitoring of Cardiac Function With 3-axis Accelerometers During Weaning of Cardiopulmonary by Pass After Heart Surgery||Oslo University Hospital|Yes|Completed|June 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|20 Years|N/A|No|Probability Sample|Patients with significant aortic stenosis scheduled for surgical AVR|February 2015|February 27, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01926067||60940|
NCT01926340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPS FU study|Early Medication Discontinuation and Long-term Clinical Outcome in FEP|The Impact of Early Medication Discontinuation on Long-term Clinical Outcome in First Episode Psychosis|FEP|The University of Hong Kong|Yes|Recruiting|July 2013|||March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|178|||Both|18 Years|65 Years|No|Non-Probability Sample|Psychiatric outpatient clinics in Hong Kong|December 2014|December 29, 2014|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01926340||60919|
NCT01926834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201/01/006284|The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels|The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels||Guangzhou University of Traditional Chinese Medicine|Yes|Not yet recruiting|August 2013|March 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926834||60881|
NCT01928563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_DIP_I|Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine|A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine in Healthy Male Subjects||Dong-A ST Co., Ltd.|No|Not yet recruiting|September 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928563||60749|
NCT01928576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1353|Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.|A Randomized Phase II Study of Epigenetic Priming With Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumab in Subjects With Recurrent Metastatic Non-Small Cell Lung Cancer.|NA_00084192|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|100 Years|No|||October 2015|October 13, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928576||60748|
NCT01928550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009572|Diabetes PRP and OCT|Pilot Study OCT of Retinal Blood Flow in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation|PRP|Oregon Health and Science University|No|Active, not recruiting|August 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|||Both|18 Years|N/A|No|Probability Sample|Individuals 18 years of age and older presenting to the Retina Service within the        Department of Ophthalmology at the Casey Eye Institute of Oregon Health & Science        University with signs and symptoms of PDR will be considered and evaluated for enrollment        into this study. This pilot study has a planned enrollment target sample size of 28        subjects needing PRP. However, up to 40 subjects will be recruited as it is possible that        after subjects sign the consent form they may not meet all eligibility criteria.|April 2015|April 21, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928550||60750|
NCT01929135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORFO-13IDL1-18270|Short-term Effect of 2% Atorvastatin Dentifrice in Periodontal Status.|Short-term Effect of 2% Atorvastatin Dentifrice as an Adjunct to Periodontal Therapy: A Randomized Double-blind Clinical Trial.||Universidad Los Andes, Chile|Yes|Completed|May 2013|June 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|35 Years|N/A|No|||July 2014|July 25, 2014|August 18, 2013||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01929135||60705|
NCT01929395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0928|A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery|A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|September 2009|November 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|136|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01929395||60685|
NCT01929694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9B2|The Effect of Consuming a guaraná and Vitamin/Mineral Complex Pre-exercise on Affect, Exertion, Metabolism and Cognition|The Effect of Consuming a Guaraná and Vitamin and Mineral Complex Before a Morning Exercise Session on Affect, Exertion and Substrate Metabolism During Exercise and Cognitive Performance During the Post-exercise Recovery Period||Northumbria University|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01929694||60662|
NCT01929967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00007001|Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data|Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data||Children's Hospital Boston|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|12 Years|No|Non-Probability Sample|Patients with a diagnosis of heterotaxy syndrome from inpatient and outpatient Cardiology        settings at Boston Children's Hospital|June 2014|June 26, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01929967||60641|
NCT01925911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-10|Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam|A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of IPI-145 on Single-Dose Pharmacokinetics of Midazolam (a CYP3A Substrate) in Healthy Subjects|DDI|Infinity Pharmaceuticals, Inc.|No|Completed|August 2013|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925911||60952|
NCT01926197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0015|Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer|A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer||Stanford University|Yes|Recruiting|August 2013|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01926197||60930|
NCT01926470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0310|The Incidence of the Intravascular Injection During S1 Transforaminal Epidural Steroid Injection in Two Approaches: Anteroposterior Versus Oblique|||Yonsei University|Yes|Completed|July 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|201|||Both|20 Years|80 Years|No|||July 2014|July 24, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926470||60909|
NCT01928355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0051-13-ziv|Cognitive Dysfunction in People Who Are Obese But Metabolically Healthy|||Ziv Hospital||Not yet recruiting|September 2013|||August 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|People with greater body mass index|August 2013|August 29, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928355||60765|
NCT01928368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110235|A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.|A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma||Amgen|No|Recruiting|August 2013|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928368||60764|
NCT01927770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130171|A Study of Consent Forms for Whole Exome and Whole Genome Sequencing|Randomized Trial of Consent Interventions for NIH Whole Exome and Whole Genome Sequencing Studies||National Institutes of Health Clinical Center (CC)||Recruiting|July 2013|March 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927770||60809|
NCT01927783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130183|Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention|Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention||National Institutes of Health Clinical Center (CC)||Recruiting|July 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|19 Years|85 Years|Accepts Healthy Volunteers|||May 2015|June 4, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927783||60808|
NCT01929187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207030MSA|A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis|A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis||National Taiwan University Hospital|No|Recruiting|February 2013|July 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|20 Years|65 Years|No|||July 2013|August 22, 2013|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929187||60701|
NCT01956383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCZ/A/1628 Nurses Study|Safety and Efficacy of the PrePex Device Circumcision When Performed by Nurses|Phase III of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe (Nurses Study)||Ministry of Health and Child Welfare, Zimbabwe|Yes|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|603|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 6, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01956383||58614|
NCT01926353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLMC13-100|Polyacrylate Polyalcohol Copolymer for Vesicoureteral Reflux|Tissue Bulking Agent -Polyacrylate Polyalcohol Copolymer for Endoscopic Correction of Vesicoureteral Reflux in Children: A Comparative Study||St. Luke's Medical Center, Philippines|Yes|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|25|||Both|1 Year|5 Years|No|Non-Probability Sample|children diagnosed with primary VUR grade 2-4 from 2006-2012 treated by a single urologist        with different treatment modalities- conservative continuous antibiotic prophylaxis,        endoscopic correction with PPC and open ureteral re-implantation with Cohen technique.|April 2015|April 5, 2015|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926353||60918|
NCT01960465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-022-13S|Race And CPAP Effectiveness|Targeted Treatment of Obstructive Sleep Apnea to Reduce Cardiovascular Disparity|RACE|VA Office of Research and Development|Yes|Recruiting|January 2015|September 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|30 Years|65 Years|No|||December 2015|December 3, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960465||58300|
NCT01960478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5476|Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke|Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke||University Hospital, Strasbourg, France|No|Not yet recruiting|October 2013|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01960478||58299|
NCT01929720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09096|Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors|Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors|FOCUS|Ohio State University Comprehensive Cancer Center|Yes|Suspended|August 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|March 13, 2013||No|Funding|No||https://clinicaltrials.gov/show/NCT01929720||60660|
NCT01928836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAALC-001-LCBP|Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China|Multicenter Study for Risk Stratification of Patients Presenting With Symptoms Related to Lung Cancer Using the Lung Cancer Biomarker Panel (LCBP) in China|LCBP|Chinese Alliance Against Lung Cancer|No|Completed|October 2012|January 2015|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|764|Samples Without DNA|10mL blood sample of the patient will be tested for cancer biomarkers, biochemical detection      and cardiovascular disease biomarkers, etc.|Both|40 Years|75 Years|No|Non-Probability Sample|Totally 1,200 cases will be collected in the hospitals, with 600 cases in control group,        which are not suspected as lung cancer from chest CT, and other 600 in suspected group.|May 2015|May 24, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01928836|1 Year|60728|
NCT01926249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/47|A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders|A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders|MEMENTO|University Hospital, Bordeaux|No|Active, not recruiting|April 2011|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2300|Samples With DNA|-  Blood sampling        -  Lumbar puncture (samples without DNA)|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients from French Research Memory Centers with at least a light cognitive deficit        defined as performing worse than one standard deviation to the mean in one or more        cognitive domains or an isolated cognitive complaint regardless of its duration while        being 60 years and older.|March 2016|March 10, 2016|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926249||60926|
NCT01925924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14372|RMGI v Composite for Orthodontic Bonding|Resin-modified Glass Ionomer or Composite for Orthodontic Bonding? - a Multi-centre, Randomised, Single Blinded Clinical Trial||Sheffield Teaching Hospitals NHS Foundation Trust|No|Active, not recruiting|February 2009|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|11 Years|N/A|No|||July 2015|December 2, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01925924||60951|
NCT01925937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392219|Atorvastatin/CoenzymeQ10 in Congestive Heart Failure|||Isfahan University of Medical Sciences||Recruiting|June 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||August 2013|August 16, 2013|August 8, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01925937||60950|
NCT01929707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14935|A Study of LY3050258 in Healthy Volunteers|A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258||Eli Lilly and Company|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929707||60661|
NCT01926236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTSp048|Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers|A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.|ABC06|Christie Hospital NHS Foundation Trust|Yes|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926236||60927|
NCT01929980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012:1089|Bortezomib to Treat Significant Complication of HSCT|Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation|Bortezomib|Children's Hospital Medical Center, Cincinnati|Yes|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|4 Months|29 Years|No|||May 2014|May 30, 2014|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01929980||60640|
NCT01926210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-2013-01-05S|Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders|The Comparison of Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders: a Prospective Randomized Study.|POR|Sun Yat-sen University|Yes|Not yet recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|20 Years|45 Years|No|||August 2013|August 20, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01926210||60929|
NCT01926223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TuftsU|Massachusetts Healthy Families Evaluation-2||MHFE2|Tufts University||Completed|February 2008|||December 2011|Actual|N/A|Interventional|N/A|2||||||Female|16 Years|20 Years||||August 2013|August 16, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01926223||60928|
NCT01927237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000222|The Pulmonary Vascular Consequences of Divergent Strategies for Low Tidal Volume Ventilation: Hypercapnia or High Respiratory Rate?|The Pulmonary Vascular Consequences of Divergent Strategies for Low Tidal Volume Ventilation: Hypercapnia or High Respiratory Rate?||Beth Israel Deaconess Medical Center|No|Withdrawn|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927237||60850|
NCT01927510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01674608|TEAM: A Trial of Early Activity and Mobility in ICU|Pilot Randomised Controlled Trial of Early Mobilisation in Critically Ill Patients to Improve Functional Recovery and Quality of Life.|TEAM-RCT|Australian and New Zealand Intensive Care Research Centre|Yes|Completed|August 2013|February 2015|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927510||60829|
NCT01928654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lasercomparison|Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema|Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema||Luigi Sacco University Hospital|No|Recruiting|July 2013|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928654||60742|
NCT01928641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSSO|Certainty Of Stroke Symptom Onset Study|Observational Study on the Certainty of Stroke Symptom Onset|COSSO|Asan Medical Center|Yes|Not yet recruiting|August 2013|August 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Probability Sample|Ischemic stroke patients admitted to Acute Stroke Unit at Asan Medical Center Patients        older than 20 years old Symptom onset within 24 hours|August 2013|August 26, 2013|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01928641||60743|
NCT01926301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83743712|Cerebrovascular Autoregulation in Sepsis, Influence of Renal Replacement Therapy|Cerebrovascular Autoregulation in Patients With Severe Sepsis and Septic Shock, Influence of Renal Replacement Therapy|SepsAR2|Johannes Gutenberg University Mainz|No|Recruiting|August 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|47|Samples Without DNA|Serum and whole blood|Both|18 Years|N/A|No|Probability Sample|Patients with severe sepsis or septic shock at the intensive care unit of an university        general hospital|August 2013|August 17, 2013|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926301||60922|
NCT01926314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-06|The Effect of Postpartum Pelvic Floor Rehabilitation in Prevention and Treatment of Pelvic Floor Dysfunction|The Effect of Postpartum Pelvic Floor Rehabilitation in Prevention and Treatment of Pelvic Floor Dysfunction- a Multiple Centers Cooperation Research.||Peking Union Medical College Hospital|No|Recruiting|August 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01926314||60921|
NCT01930097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-05|Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Compare the Efficacy of Closed-loop Operation Combined With Meal-and-carbohydrate-announcement Closed-loop Operation Combined With Meal-announcement, and Conventional Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930097||60631|
NCT01960205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXL-201308|Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity|Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity||Shandong Provincial Hospital|Yes|Recruiting|August 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|70 Years|No|||September 2014|September 23, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960205||58320|
NCT01960218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512|Gas Exchange for Predicting Hospital Heart Failure Readmissions|Gas Exchange for Predicting Hospital Heart Failure Readmissions Clinical Evaluation Study||Shape Medical Systems, Inc.|No|Recruiting|October 2013|January 2015|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Subjects will be consecutively recruited from the population of subjects admitted to the        hospital with acute decompensated heart failure.|April 2014|April 3, 2014|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01960218||58319|
NCT01926847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16787|Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator|Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)|DIGIT|Bayer|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|23|||Both|18 Years|70 Years|No|||June 2014|June 13, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926847||60880|
NCT01926860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV13 adults + Hep A|PCV13 + Hepatitis A Vaccine for Adults|Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time|PCV13+HepA|Helsinki University Central Hospital|Yes|Not yet recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926860||60879|
NCT01926587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-08|Oral Rigosertib in Combination With Azacitidine|A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia||Onconova Therapeutics, Inc.|No|Active, not recruiting|August 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926587||60900|
NCT01927094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBAGE|Effects of Probiotics and/or Prebiotics on the Duration of Diarrhea and Hospitalization in Children|The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial|PROBAGE|Eskisehir Osmangazi University|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1280|||Both|3 Months|60 Months|No|||February 2015|February 12, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01927094||60861|
NCT01927107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prob-esity|Effects of Probiotics in Obese Children|EFFECTS OF PROBIOTICS MIXTURE TO STANDARD DIET THERAPY IN OBESE CHILDREN|Prob-esity|Eskisehir Osmangazi University|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|5 Years|17 Years|No|||August 2013|August 19, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927107||60860|
NCT01929733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0192-13|Long Term Results of 450 Percutaneous Closures of PDA in a Single Center|Long Term Results of 450 Percutaneous Closures of PDA in a Single Center||Rambam Health Care Campus|No|Completed|January 1998|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|450|||Both|N/A|N/A|No|Non-Probability Sample|All the patients that underwent percutaneous closure of PDA between January 1998 and        august 2013 in the department of pediatric cardiology and congenital heart diseases in        Rambam health care campus|August 2013|August 21, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01929733||60659|
NCT01929746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205HV102|Daclizumab Japanese PK Study|A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers||Biogen||Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929746||60658|
NCT01929993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522/12|A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins|Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins||Oswaldo Cruz Foundation|No|Completed|January 2008|February 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Female|N/A|N/A|No|||June 2015|June 30, 2015|June 10, 2012||No||No|May 24, 2015|https://clinicaltrials.gov/show/NCT01929993||60639|
NCT01926990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAL0026|Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma|Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma||Stanford University||Recruiting|August 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with metastatic renal cell carcinoma prescribed a systemic targeted therapy        medication|May 2015|May 15, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926990||60869|
NCT01926509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8892-005|Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)|A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension||Merck Sharp & Dohme Corp.|No|Completed|November 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926509||60906|
NCT01926743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0414|Identification of Complete Lymph Node Removal by Application of Near Infrared Fluorescence Imaging in Laparoscopic and Robotic Gastrectomy|||Yonsei University|No|Recruiting|August 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|80 Years|No|||July 2014|July 13, 2014|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01926743||60888|
NCT01926483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTOG-1202|Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection|A Prospective, Phase II Trial of a Trimodality Regimen for Stage III (N2) Non-small-cell Lung Cancer Using Concurrent Chemoradiotherapy as Induction Treatment Followed by Subsequent Resection|ZTOG-1202|Zhejiang Cancer Hospital|Yes|Recruiting|March 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|65 Years|No|||July 2012|August 16, 2013|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01926483||60908|
NCT01926496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-63|Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%|A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial||LEO Pharma|No|Recruiting|September 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926496||60907|
NCT01926730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24-DK078228-FACES|Food and Crohn's Exacerbation Study (FACES)|Food and Crohn's Exacerbation Study (FACES)|FACES|University of Pennsylvania|No|Active, not recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|612|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01926730||60889|
NCT01926964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 26/10|Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer|Impact of Recurrence Score® on Recommendations for Adjuvant Treatment in Patients With ER-positive Breast Cancer||Swiss Group for Clinical Cancer Research|No|Completed|September 2013|February 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|229|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer        R0 resection.|September 2015|September 28, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926964|3 Weeks|60871|
NCT01927224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16004|Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients|Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry||Bayer|No|Completed|November 2013|September 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|45 Years|No|||September 2015|October 14, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927224||60851|
NCT01927809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42585.078.12|Genetic Mosaicism in Hirschsprung's Disease|Genetics of Hirschsprung's Disease - Can Genetic Mosaicism Due to Early Somatic Mutations, Explain Disease Development?||Erasmus Medical Center|No|Recruiting|April 2013|August 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Blood samples, skin tissue, colon tissue|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be selected in the two participating hospitals. The Erasmus MC - Sophia        Children's hospital and the UMC St. Radboud.|November 2015|November 30, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01927809||60807|
NCT01927822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102096-F|Factors Influencing the Abortion Interval of Second-trimester Termination of Pregnancy Using Misoprostol|||Far Eastern Memorial Hospital|Yes|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|101|||Female|13 Years|50 Years|No|Non-Probability Sample|This is a single-center, retrospective chart review study. All female patients who were        admitted for medical termination of second-trimester pregnancy from January 2008 to May        2013, at the Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital were        recruited.|July 2015|July 4, 2015|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01927822||60806|
NCT01928940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116885|Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)|A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part).||GlaxoSmithKline|No|Active, not recruiting|August 2013|March 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||December 2015|February 4, 2016|July 3, 2013||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01928940||60720|
NCT01928901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saccharin test|Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)|Randomized, Placebo-controlled, Double-blind, Cross-over Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)||Bionorica SE|No|Completed|August 2013|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|56|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01928901||60723|
NCT01926093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Policlinico-08|Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients|||Policlinico Hospital|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|ARDS patients fulfilling the Berlin definition criteria|August 2013|January 8, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01926093||60938|
NCT01926106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|twins|Nasal Intermittent Positive-Pressure Ventilation for Twin Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive-Pressure Ventilation vs Nasal Continuous Positive Airway Pressure for Twin Infants With Respiratory Distress Syndrome|twins|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|64|||Both|N/A|6 Hours|No|||August 2013|February 10, 2015|August 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926106||60937|
NCT01926366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3521C00001|AZD6423 SAD/MAD Study in Healthy Volunteers|A Randomized, Double-Blind, Third-Party-Unblinded, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD6423 in Healthy Volunteers|AZD6423|AstraZeneca|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|175|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 3, 2014|August 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926366||60917|
NCT01929837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T69/2013|Tinnitus rTMS 2013|Treatment of Tinnitus With Transcranial Magnetic Stimulation||Turku University Hospital|No|Active, not recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01929837||60651|
NCT01926873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28865|A Screening Study To Assess The Cognition Status in Healthy Volunteers|MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION||Hoffmann-La Roche||Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|Samples With DNA|Blood Samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|March 2016|March 1, 2016|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926873||60878|
NCT01926600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24 hour pH|Sublingual Administration of PPI|Sublingual Administration is More Fast Than Oral or IV Administration in PPI Dosing With Respect to Intragastric pH and Therapeutic Effectiveness: a Prospective, Randomized, Controlled Trial||The Catholic University of Korea|No|Recruiting|August 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|20 Years|75 Years|No|Probability Sample|3 groups, each group with 20 subject with peptic ulcer ages between 20 to 75|August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926600||60899|
NCT01927120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17578|In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis|In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|March 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927120||60859|
NCT01927133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCD2013-01|LIVER FIBROSIS PREVALENCE IN FRANCE||FIBROFRANCE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 1997|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Serum, liver biopsy|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population with chronic liver disease followed in tertiary centers|August 2013|August 21, 2013|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01927133||60858|
NCT01927406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26654|The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.|The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.||Stanford University|No|Not yet recruiting|August 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927406||60837|
NCT01927419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-069|Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma|Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|CheckMate 069|Bristol-Myers Squibb|No|Active, not recruiting|August 2013|May 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||November 2015|January 8, 2016|August 20, 2013|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01927419||60836|
NCT01926522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Habilita-RAR-02|Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients|Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic||Habilita, Ospedale di Sarnico|Yes|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|85 Years|No|||March 2014|March 21, 2014|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01926522||60905|
NCT01930006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-106|Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State|Phase 1 Single Dose 2-Way Crossover Comparative Bioavailability Study Of Two Oral Formulations Of MGCD265 In Healthy Male And Female Subjects - Fasting State||Mirati Therapeutics Inc.|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01930006||60638|
NCT01925950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-GVHD-08|Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD||Soligenix|No|Terminated|December 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|August 16, 2013|Yes|Yes|The study was stopped due to patient enrollment challenges.|No||https://clinicaltrials.gov/show/NCT01925950||60949|
NCT01928121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not yet applicable|Effectiveness of an Interdisciplinary, Nurse-coordinated Atrial Fibrillation Expert Program for Primary Care Patients|Effectiveness of an Interdisciplinary, Nurse-coordinated Atrial Fibrillation Expert Program for Primary Care Patients - A Clustered Randomized Controlled Trial||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|450|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928121||60783|
NCT01928134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitK2|The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis|The Efficacy of Vitamin K2 on Human Osteoporosis, Blood-vessel Calcification and Sclerosis||Changhua Christian Hospital|No|Completed|April 2011|February 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928134||60782|
NCT01927276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056339|Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive|Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive||University of Maryland|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|90|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927276||60847|
NCT01926977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28895|Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration|Evaluation of Post Injection Inflammation and Pain After Ranibizumab vs Aflibercept Intravitreal Injections||Sierra Eye Associates|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 19, 2013|Yes|Yes||No|December 29, 2015|https://clinicaltrials.gov/show/NCT01926977||60870|Small sample size. Non-randomized choice of medications.
NCT01927250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOA-003|Influence of Multi-dimensional Wellness Program on Quality of Life|Influence of Multi-dimensional Wellness Program (Diet, Art and Biofield Therapy) on Quality of Life in Japanese Population|MDWP|MOA Health Science Foundation|No|Completed|February 2007|March 2008|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12166|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01927250||60849|
NCT01927263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI071F1(EFC13464)|A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis|A Phase 3 Clinical Study of NI-071 in Patients With Rheumatoid Arthritis ―A Double-blind, Active Drug-controlled Study and Long-term Study―||Nichi-Iko Pharmaceutical Co.,Ltd.|No|Active, not recruiting|July 2013|||March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|20 Years|75 Years|No|||August 2013|September 26, 2014|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01927263||60848|
NCT01927523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBS IRB13-0691|Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports|Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports Through a Large-Scale Randomized Control Trial in Chicago||University of Chicago|Yes|Enrolling by invitation|August 2013|June 2018|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2147|||Male|N/A|N/A|No|||August 2013|August 19, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01927523||60828|
NCT01927536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0387|Evaluating Color Perception Under LED Red/Green and Green Dominant Light|Evaluating Color Perception Under LED Red/Green and Green Dominant Light||University of Colorado, Denver|No|Recruiting|July 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|66 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal color vision status|March 2016|March 9, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01927536||60827|
NCT01928381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3031C00001|Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability|A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability||AstraZeneca|No|Completed|November 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|46|||Both|18 Years|75 Years|No|||June 2015|June 22, 2015|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928381||60763|
NCT01929499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIKCC|Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer|Efficacy of Adjuvant Immunotherapy With Cytokine-induced Killer Cells in Patients With Stage II/III Colon Cancer|CIKCC|Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Not yet recruiting|September 2013|August 2019|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|80 Years|No|||August 2013|August 27, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01929499||60677|
NCT01929512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MERO-103|Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/20 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 20 mg in Healthy Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 29, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01929512||60676|
NCT01929811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1301|NeoMET Study in Neoadjuvant Treatment of Breast Cancer|Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial|NeoMET|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|October 2013|September 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|70 Years|No|||December 2015|December 29, 2015|August 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01929811||60653|
NCT01930123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031687|Impact of Fructose on Metabolism, Energy Homeostasis and MR Biomarkers in NAFLD|||Duke University|No|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|85|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01930123||60629|
NCT01930136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRESO 2|Effects of Caloric Restriction in Obesity and Type 2 Diabetes|LONG-TERM EFFECTS OF CALORIC RESTRICTION ON METABOLIC, RENAL AND RETINAL HEALTH IN SUBJECTS AFFECTED BY OBESITY AND TYPE 2 DIABETES|CRESO2|Mario Negri Institute for Pharmacological Research|No|Recruiting|May 2013|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|40 Years|N/A|No|||March 2016|March 15, 2016|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01930136||60628|
NCT01926119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25894|TMS for CRPS - Pilot Study|||Stanford University||Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|August 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926119||60936|
NCT01926379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3163|ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)|A Combination Intervention Package for Isoniazid Preventive Therapy in Ethiopia|ENRICH|Columbia University|No|Active, not recruiting|July 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01926379||60916|
NCT01926080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108060|Impact of a Neonatal-Bereavement-Support DVD on Grief|End-of-Life Care in the NICU: Does Bereavement Support Make a Difference?||Washington University School of Medicine|Yes|Completed|January 2008|||February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|107|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 16, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926080||60939|
NCT01926886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28794|A Study of Subcutaneous At Home Administration of Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer|A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer.||Hoffmann-La Roche||Active, not recruiting|November 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926886||60877|
NCT01926899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209009655|A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients|A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients||Indiana University|Yes|Recruiting|August 2013|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|1 Year|21 Years|No|||November 2015|November 24, 2015|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926899||60876|
NCT01957761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck MISP 50366|Molecular Epidemiology of Clostridium Difficile Infections in Children|Molecular Epidemiologic Survey and Risk Factor Assessment of Clostridium Difficile Infections in Children: A Focus on Recurrent and Community-associated Infections||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|132|||Both|1 Year|18 Years|No|Probability Sample|Children with Clostridium Difficile infection|October 2013|January 26, 2016|November 19, 2012||No||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01957761||58508|
NCT01957488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP242|Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece|Investigating the Safety and Performance of Two New 1-piece Ostomy Products in 180 Subjects With Ileostomy||Coloplast A/S|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|181|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|August 6, 2013||No||No|September 11, 2014|https://clinicaltrials.gov/show/NCT01957488||58529|
NCT01957748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 594|CCTG 594: Engagement and Retention in Care for HIV+|CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group||California Collaborative Treatment Group|No|Active, not recruiting|October 2013|July 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01957748||58509|
NCT01925989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14872|A Study of How LY2605541 and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics|Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01925989||60946|
NCT01926002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8351-003|A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)|A Multicenter Randomized Clinical Trial to Study the Effects of Single Doses of MK-8351 on the Early Asthmatic Response to a Lung Allergen Challenge||Merck Sharp & Dohme Corp.|No|Withdrawn|September 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||July 2015|July 15, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01926002||60945|
NCT01926756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH-Myers/Parent001|Does Straight Catheterization in Short Gynecologic Procedures Cause Bacteriuria?|Intraoperative One-Time Catheterization in Short Gynecologic Procedures and Its Potential Effect on Symptomatic and Asymptomatic Bacteriuria||Abington Memorial Hospital||Recruiting|July 2013|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926756||60887|
NCT01928667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44127.068.13|Case-Control Study to Identify Risk Factors for Microscopic Colitis|Risk Factors for Microscopic Colitis: A Dutch Case-Control Study||Maastricht University Medical Center|Yes|Enrolling by invitation|July 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|900|Samples With DNA|saliva samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The case group will be selected by a retropective search in the pathology registry.        Subjects have to be diagnosed between January 1, 2000 and December 31, 2012; have to be        older than 18 years of age and have to be living in the province of Limburg, the        Netherlands.        Healthy controls are selected via the municipal personal records databases in the same        region.|January 2016|January 18, 2016|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01928667||60741|
NCT01928680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LQ0001|Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer|Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients||Chinese Academy of Medical Sciences|Yes|Active, not recruiting|November 2012|March 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|70 Years|No|||February 2015|February 4, 2015|May 1, 2013||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01928680||60740|
NCT01928914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114582|Tafenoquine Thorough QTc Study in Healthy Subjects|A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Healthy Subjects||GlaxoSmithKline|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Actual|260|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01928914||60722|
NCT01928927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5317|Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)|Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy|TRAFIC|AIDS Clinical Trials Group|Yes|Active, not recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928927||60721|
NCT01927549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CULPRIT-SHOCK1.2|Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock|Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock|CULPRIT-SHOCK|University of Luebeck|Yes|Recruiting|April 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|706|||Both|18 Years|90 Years|No|||December 2015|December 1, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01927549||60826|
NCT01927835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 101|Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Regimens Comprising DNA-HIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX B/E in Healthy, HIV-Uninfected US and South African Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|264|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01927835||60805|
NCT01928108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2453|Fluid Intake Application to Reduce Kidney Stone Risks|Do Different Methods of Educating Patients Regarding Fluid Intake Reduce Kidney Stone Risks?||University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|October 8, 2015|August 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928108||60784|
NCT01928160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THN 1303|Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib|A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or Gefitinib||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|June 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|July 9, 2015|August 19, 2013|Yes|Yes|study not accruing|No||https://clinicaltrials.gov/show/NCT01928160||60780|
NCT01930045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-295|A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)|A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen||Merck Sharp & Dohme Corp.|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|August 23, 2013|No|Yes||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01930045||60635|
NCT01930058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8876-003|Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients||Merck Sharp & Dohme Corp.|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|August 23, 2013|No|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01930058||60634|
NCT01930071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP 114|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2013|||||N/A|N/A|N/A||||||||||||||July 22, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01930071||60633|
NCT01926028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDV3A-003|Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis|Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis||NovaDigm Therapeutics, Inc.|Yes|Active, not recruiting|July 2013|May 2016|Anticipated|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|188|||Female|18 Years|50 Years|No|||May 2015|May 27, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926028||60943|
NCT01926041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303041RINB|The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers|The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers||National Taiwan University Hospital|Yes|Recruiting|August 2013|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|446|||Both|30 Years|75 Years|No|||January 2016|January 26, 2016|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01926041||60942|
NCT01926132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2012-0154|High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study|||Yonsei University|No|Recruiting|August 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926132||60935|
NCT01926405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.681|Amylase and Hypersomnia|Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia.|Amylase|Hospices Civils de Lyon|Yes|Recruiting|January 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01926405||60914|
NCT01926613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH077210|Thinking Skills for Work in Severe Mental Illness|Cognitive Rehabilitation and Supported Employment for Severe Mental Illness|TSW|Dartmouth-Hitchcock Medical Center|No|Completed|April 2006|October 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926613||60898|
NCT01957774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01456|THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA|Double-blind, Placebo-controlled, Escalating Single-dose, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of THR-18 in Subjects With Acute Ischemic Stroke and Treated With tPA||D-Pharm Ltd.|No|Completed|October 2013|||November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||December 2013|February 3, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957774||58507|
NCT01957787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC13-LNG079|Study of Cryoablation for Metastatic Lung Tumors|Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation|SOLSTICE|Galil Medical|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01957787||58506|
NCT01958333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-300613|Muscular and Metabolic Adaptations to Exercise to Benefit High-Risk Workforce|The Effects of Medium-Term Exercise Program on Health-Related Physical Fitness and Biochemical Outcomes in High-Risk Employees||Center for Health, Exercise and Sport Sciences, Serbia|No|Enrolling by invitation|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01958333||58464|
NCT01958346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008289|New Maneuver to Facilitate Fiberoptic Intubation for Difficult Airway|New Maneuver to Facilitate Fiberoptic Intubation for Difficult Airway: A Prospective, Randomized Study||University of South Florida|No|Active, not recruiting|June 2012|November 2013|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|78|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01958346||58463|
NCT01958619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_13_004|Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers|Open Label Pharmacokinetic Study of OZ439 and Piperaquine Following Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in the Fasted State in Healthy Volunteers||Medicines for Malaria Venture|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|October 7, 2013|No|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01958619||58442|
NCT01958632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/2012BO2|Muscle-in-vein Conduits for Digital Nerve Reconstruction|Evaluation of Sensory Recovery After Reconstruction of Digital Nerves of the Hand Using Muscle-in-vein Conduits in Comparison to Nerve Suture or Nerve Transplantation||BG Trauma Center Tuebingen|No|Completed|February 2012|||June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|77|||Both|10 Years|75 Years|No|Non-Probability Sample|primary care clinic|October 2013|October 5, 2013|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01958632||58441|
NCT01926769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-GIRBA-2675|A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer|||Gachon University Gil Medical Center||Recruiting|February 2012|||January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926769||60886|
NCT01927003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTS1308112|Direct and Reversed Dorsal Digito-metacarpal Flaps: A Review of 24 Cases|||The Second Hospital of Tangshan||Completed|April 2009|September 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|24|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||April 2010|August 19, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927003||60868|
NCT01927289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lamproxvsdistal|DBRCT on the Effect of Grip Strength in Brachial Plexus vs Distal Forearm Nerve Blocks|A Double-blind Randomized Controlled Trial Between Ultrasound-guided Brachial Plexus and Distal Peripheral Nerve Blocks for Hand Surgery||University of New Mexico|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927289||60846|
NCT01927562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10000|Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes|Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes||Fractyl Laboratories, Inc.|No|Recruiting|August 2013|February 2019|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|28 Years|75 Years|No|||January 2016|January 3, 2016|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927562||60825|
NCT01929200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV50|Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation|Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|August 2013|August 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2015|May 21, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01929200||60700|
NCT01929473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-P001|Seroepidemiological Study of Pertussis and Other Infectious Diseases|Seroepidemiological Study of Pertussis and Other Infectious Diseases||Gifu Prefecture Medical Association|No|Recruiting|September 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|Samples Without DNA|Serum|Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Students of junior high school, high school or college|September 2013|September 30, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01929473||60679|
NCT01929486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW0761-IIT-01|Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.|Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.||Aichi Medical University||Active, not recruiting|February 2013|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|58|||Both|20 Years|N/A|No|||February 2016|February 16, 2016|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01929486||60678|
NCT01929798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP301|Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin|Randomized Crossover Feasibility Study of Artificial Pancreas Device (AP) Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) With and Without Basal and Insulin-to-Carbohydrate Bolus Initialization|DP3|William Sansum Diabetes Center|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|21 Years|65 Years|No|||October 2015|October 20, 2015|August 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929798||60654|
NCT01930032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000174|Pathogenic Mechanisms in C Diff Infection and Colitis|Pathogenic Mechanisms in Clostridium Difficile Infection and Colitis||Beth Israel Deaconess Medical Center|No|Enrolling by invitation|August 2013|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Colonic biopsy samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected from patients undergoing a routine screening colonoscopy at Beth        Israel Deaconess Medical Center|January 2016|January 15, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01930032||60636|
NCT01926548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_IMM_101|to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers|Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers||CJ HealthCare Corporation||Completed|February 2012|June 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01926548||60903|
NCT01927302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50|Neurobiology of Language Recovery in Aphasia: Natural History and Treatment-Induced Recovery|The Center for the Neurobiology of Language Recovery (CNLR)||Northwestern University|No|Recruiting|April 2013|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|35 Years|80 Years|No|||December 2015|December 7, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01927302||60845|
NCT01928693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eye02|A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.|A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers.|Eye02|Cornea Consultants Of Nashville|No|Terminated|July 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|90 Years|No|||August 2015|August 11, 2015|August 20, 2013|Yes|Yes|study terminated due to slow accrual|No|August 11, 2015|https://clinicaltrials.gov/show/NCT01928693||60739|The study was terminated due to slow enrollment.
NCT01937858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08/107/A|The Correlation Between HbA1c and Mean Blood Glucose in Patients With Diabetes and Renal Failure|The Correlation Between HbA1c and Mean Blood Glucose in Patients With Diabetes and Renal Failure||King Abdullah International Medical Research Center|No|Recruiting|July 2012|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|90 Years|No|Non-Probability Sample|Our target population is patients with diabetes and impaired renal function. This study        will include 80 adult patients with type1 or type 2 diabetes; 20 with normal serum        creatinine, 40 with renal failure in the predialysis stage (20 with stage 3 and 4 CKD [GFR        0f 20-40] and 20 with stage 5 CKD not yet on hemodialysis [GFR <20]), and 20 on        hemodialysis. All patients should be comfortable and committed to doing self-glucose        monitoring.|April 2015|April 5, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937858||60036|
NCT01927029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS149|Preterm Delivery Prevention in Twins With Progesterone|Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal.||Universidad del Desarrollo|No|Active, not recruiting|August 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|213|||Female|14 Years|45 Years|No|||August 2013|August 20, 2013|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927029||60866|
NCT01956708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC-13-5507-BO|Transfer of Cardioprotection During RIPC|||University Hospital, Essen|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|332|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01956708||58589|
NCT01956942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041310|Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma|Phase IV Study of Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma|MLT versus SLT|George Washington University|No|Recruiting|August 2013|August 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|November 6, 2013|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956942||58571|
NCT01957228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00960-45|Causative Diagnosis on Prosthetic Joint Infections: Establishment of a Comprehensive Diagnostic Strategy|Causative Diagnosis on Prosthetic Joint Infections: Establishment of a Comprehensive Diagnostic Strategy||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2013|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|480|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957228||58549|
NCT01926392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15603|Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns|A Prospective Randomized Trial Comparing Silver Sulfadiazine Cream to a Water-Soluble Poly-Antimicrobial Gel in Partial Thickness Burn Wounds||University of Virginia|Yes|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||August 2013|August 20, 2013|August 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926392||60915|
NCT01926626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044174|Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers|Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers|RIMA|Duke University|Yes|Completed|September 2013|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Female|18 Years|65 Years|No|||July 2015|July 1, 2015|August 19, 2013|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01926626||60897|
NCT01958359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1437-31/4|Screening and Brief Intervention Via IVR for Problematic Use of Alcohol: A Randomized Controlled Trial|Screening and Brief Intervention Via IVR for Problematic Use of Alcohol: A Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|260|||Both|18 Years|N/A|No|||November 2014|November 2, 2014|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958359||58462|
NCT01958645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5050C00001|To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.|A Phase I, Single-blind, Randomised, Placebo-controlled, Single Centre Study to Investigate the Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses in Healthy Male Subjects||AstraZeneca|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|157|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|October 7, 2013||No||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01958645||58440|Limitations: few subjects, high variability of coagulation variables
NCT01958658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01765|AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer|A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 (MK-1775) in Combination With Cisplatin and Radiation in Cervical Cancer (10041848, 10008224, 10008328)||National Cancer Institute (NCI)|Yes|Recruiting|September 2013|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|57|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01958658||58439|
NCT01927575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2012-001|Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury|Pilot Study Comparing Diagnostic Imagining Versus FujiFilm's Digital Radiographic AcSellerate CsI System With Tomosynthesis|TOMO|Fujifilm Medical Systems USA, Inc.|No|Terminated|September 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|1|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|August 20, 2013|Yes|Yes|Sponsor decision to close trial|No||https://clinicaltrials.gov/show/NCT01927575||60824|
NCT01927848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127|Improving Gait in Persons With Knee Related Mobility Limitations by Rosenoids® Food Supplement: a Randomized Double-blind Placebo-controlled Trial|||Frederiksberg University Hospital|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|N/A|No|||January 2015|January 14, 2015|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01927848||60804|
NCT01927861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-4020|Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome|A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome||Novo Nordisk A/S|No|Active, not recruiting|August 2013|July 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|3 Years|11 Years|No|||May 2015|May 28, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01927861||60803|
NCT01935817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unict11/1997|Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV|||University of Catania||Completed|June 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|65 Years|No|||September 2013|September 4, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935817||60192|
NCT01936103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-20120404|Effects of Intensive Statin Treatment on Left Ventricular Function|Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention.||Shenyang Northern Hospital|No|Recruiting|April 2012|July 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2013|September 2, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01936103||60170|
NCT01926015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-060|Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)|Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants||Merck Sharp & Dohme Corp.|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|192|||Both|6 Weeks|11 Weeks|Accepts Healthy Volunteers|||March 2015|March 27, 2015|August 16, 2013|Yes|Yes||No|March 27, 2015|https://clinicaltrials.gov/show/NCT01926015||60944|
NCT01936376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kidney Safety - Cisplatin|A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers|A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers||Foundation for the National Institutes of Health|No|Recruiting|September 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|urine and blood|Both|18 Years|N/A|No|Probability Sample|cancer patients|July 2014|January 23, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936376||60149|
NCT01926288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTQ805-4|Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B|Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Active, not recruiting|October 2008|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|65 Years|No|||August 2013|August 19, 2013|August 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01926288||60923|
NCT01927016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_01|Outcomes After Esophageal Cancer Surgery|Factors Linked to Outcomes After Esophageal Cancer Surgery: a Multicenter National Study|FREGAT I|University Hospital, Lille|Yes|Completed|July 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2944|||Both|18 Years|90 Years|No|Probability Sample|Patients operated on for a cancer of the esophagus , a Siewert I or II cancer of the        oesophago-gastric junction|March 2015|March 31, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01927016||60867|
NCT01927874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bl.Pud|Subarachnoid or Infiltration for Hemorrhoidectomy|Comparative Study of the Analgesic Effect of Subarachnoid or Infiltration for Hemorrhoidectomy||Federal University of São Paulo|No|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||February 2016|February 2, 2016|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01927874||60802|
NCT01928147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-383-101|A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients|A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients||Presidio Pharmaceuticals, Inc.|No|Completed|August 2013|November 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01928147||60781|
NCT01929213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_PAH_DI|Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration|A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Williams Design to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration in Healthy Volunteers||Dong-A ST Co., Ltd.|No|Active, not recruiting|August 2013|February 2014|Anticipated|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01929213||60699|
NCT01929226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH104|A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers|Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers|AH104|Elusys Therapeutics|No|Completed|July 2013|April 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|August 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929226||60698|
NCT01929239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-05-1-0408|Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning|Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning||Roger Williams Medical Center|Yes|Active, not recruiting|March 2006|July 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|80 Years|No|||August 2013|October 14, 2014|August 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01929239||60697|
NCT01937884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0374|Supplemental Parenteral Nutrition in Pediatric Respiratory Failure|Supplemental Parenteral Nutrition in Pediatric Respiratory Failure|SuPPeR|University of Arizona|No|Recruiting|August 2013|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|1 Month|16 Years|No|||December 2014|December 2, 2014|September 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937884||60034|
NCT01938131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346/2012|Study of Effectiveness of rMV (Repeated Muscle Vibration) in Knee Osteoarthritis|Effectiveness of Treatment With rMV (Repeated Muscle Vibration) in Patients Affected by Knee Osteoarthritis: a Prospective Randomized Clinical Trial||Catholic University of the Sacred Heart|No|Completed|August 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938131||60016|
NCT01938118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0510|Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers|Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers||University of North Carolina, Chapel Hill|No|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|468|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01938118||60017|
NCT01957514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8132|Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin|Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Patients With Triple-Negative Breast Cancer|ITOMIC|University of Washington|Yes|Recruiting|October 2013|||November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Tissue, blood, buccal mucosa, saliva, urine|Female|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic triple negative breast cancer treated at Fred Hutchinson Cancer        Research Center/University of Washington Cancer Consortium|March 2016|March 21, 2016|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957514||58527|
NCT01957800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43474EP|Weight Loss and Healthy Diet Through Mobile Phone-enabled Social Interactions|Enhancing the Sustainability of Weight Loss and Healthy Diet Through Mobile Phone-enabled Social Interactions||Milton S. Hershey Medical Center|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|21 Years|65 Years|No|||August 2015|August 31, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957800||58505|
NCT01926639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2007.1112 Lymvac-1|Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma|Radiotherapy Combined With Intratumoral Injections of Dendritic Cells and Rituximab - a Phase II Cancer Vaccine Trial for Patients With Untreated and Relapsed Indolent Non-Hodgkin`s Lymphoma|Lymvac-1|Oslo University Hospital|Yes|Completed|October 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01926639||60896|
NCT01958047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0054|A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability|A Phase 1 Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Dose of ASP3652 in Caucasian, Japanese, Black/African and Chinese Healthy Male and Female Subjects||Astellas Pharma Inc|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|64|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01958047||58486|
NCT01958060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312.1|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)||Boehringer Ingelheim||Terminated|October 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|October 1, 2013||||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01958060||58485|Due to a drug-related Serious Adverse event in the first subject of 100 mg BI 1034020 single iv dose group, the trial was prematurely terminated. No further iv dosing was performed and no planned sc dosing scheme was performed in this trial.
NCT01958372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-021|Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer|Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients||Barbara Ann Karmanos Cancer Institute||Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01958372||58461|
NCT01958385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G130163|The USGI Medical ESSENTIAL Study for Weight Loss|A RANDOMIZED, SUBJECT AND EVALUATOR-BLINDED, PARALLEL-GROUP, MULTICENTER CLINICAL TRIAL USING AN ENDOSCOPIC SUTURING DEVICE (G-CATH EZ™ SUTURE ANCHOR DELIVERY CATHETER) FOR PRIMARY WEIGHT LOSS||USGI Medical|No|Active, not recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|377|||Both|22 Years|60 Years|No|||June 2014|June 9, 2014|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958385||58460|
NCT01958671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-003|A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)|A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958671||58438|
NCT01958684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16954|Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion|A Non-interventional Study to Observe the Bleeding Pattern of LNG-IUS Inserted Immediately After Surgical Abortion Compared With Copper IUD|POST|Bayer|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|512|||Female|18 Years|N/A|No|Non-Probability Sample|All subjects should go through the surgical abortion should meet both inclusion and        exclusion criteria. And they are willing to sign an informed consent. And all recruitment        should be conducted after the decision of treatment.|October 2015|October 15, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958684||58437|
NCT01935310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMQ003|Photoaging Treatment With Imiquimod|Clinical and Histological Analysis of Photoaging Treatment With Imiquimod Cream 5%||CES University|Yes|Completed|July 2010|August 2013|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|17|||Both|40 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 30, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01935310||60231|
NCT01928394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-032|A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2013|December 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928394||60762|
NCT01936116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-016|Optimal Balloon Catheter Placement During Sonohysterography|Pain Perception and Side Effects During Sonohysterography With Balloon Catheters: a Randomized Comparative Study of Cervical With Uterine Catheter Placement||Royan Institute|Yes|Completed|May 2012|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|45 Years|No|||February 2012|May 4, 2014|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01936116||60169|
NCT01936389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12286|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma|ROCK|Glaucoma Associates of New York||Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|50 Years|85 Years|No|||April 2015|April 23, 2015|August 28, 2013|No|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT01936389||60148|
NCT01936402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD5565|Instruction to Compress Chest Approximately 6-7cm for Healthcare Provider in Hospital|Novel Instruction to Perform Chest Compression Approximately 6-7cm for Healthcare Provider Improves Chest Compression Depth During Cardiopulmonary Resuscitation in Hospital.||Hanyang University|No|Completed|February 2013|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 3, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01936402||60147|
NCT01926782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1308|Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia||Regeneron Pharmaceuticals|Yes|Completed|October 2013|May 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|803|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01926782||60885|
NCT01927588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR29T|Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients|An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.||Fundação Pró Rim|Yes|Not yet recruiting|August 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||August 2013|August 20, 2013|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01927588||60823|
NCT01928407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 040-DATA|Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts|A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL.|DATA|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Yes|Recruiting|March 2011|February 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01928407||60761|
NCT01928420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00470419|A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease|A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease||James J. Peters Veterans Affairs Medical Center|Yes|Recruiting|August 2010|December 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|95 Years|No|||August 2013|August 20, 2013|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01928420||60760|
NCT01937546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-310|The Effect of Primary Delivery of the Anterior Compared With the Posterior Shoulder on Perineal Trauma: a Randomized Controlled Trial|The Effect of Primary Delivery of the Anterior Compared With the Posterior Shoulder on Perineal Trauma: a Randomized Controlled Trial||Holbaek Sygehus|Yes|Completed|January 2013|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|650|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 23, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937546||60059|
NCT01937845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS#: 06-26|Evaluating the Health Outcomes of the Joslin Why WAIT? Program|Evaluating the Health Outcomes of the Joslin Why WAIT? Program (Weight Achievement & Intensive Treatment Program)||Joslin Diabetes Center|No|Active, not recruiting|August 2006|December 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|110|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Type 2 diabetes enrolled in the Why WAIT? Program|February 2016|February 22, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937845||60037|
NCT01938729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-148|Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma|Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|September 2013|||September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938729||59971|
NCT01938976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96/2012|Efficacy of School-Based, Peer-Led Asthma and Smoking Prevention Program on CO1 Levels and Smoking Behavior Among Early Adolescents in Jordan|Efficacy of School-Based, Peer-Led Asthma and Smoking Prevention Program on CO1 Levels, Nicotine Dependence, and Smoking Behavior Among Early Adolescents in Jordan|TAJPlus|University of Technology, Sydney|Yes|Completed|October 2012|May 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|815|||Male|11 Years|14 Years|No|||September 2013|September 5, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01938976||59952|
NCT01938404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-214|Octaplas Adult TTP Trial|Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events||Octapharma|No|Not yet recruiting|December 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Adult patients undergoing Plasma exchange for Thrombotic Thrombocytopenic Purpura|November 2014|June 5, 2015|September 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01938404||59995|
NCT01938417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tobramycin cast|Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute|||University of Lausanne Hospitals|No|Completed|October 2006|||March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Probability Sample|All adult patients treated with Osteoset® T in our orthopedic surgery department|September 2013|September 10, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01938417||59994|
NCT01957527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-15|Offset of Ticagrelor's Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry (EndoPAT Assay)|Offset of Ticagrelor's Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry (EndoPAT Assay)||University of Patras|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Probability Sample|Patients with coronary artery disease under ticagrelor maintenance dose, who are about to        discontinue ticagrelor, due to completion of 12 months dual antiplatelet therapy.|August 2015|August 19, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957527||58526|
NCT01957241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110606IRC|PLA for HCC and Esophageal ca Serum|Serum Biomarker Study for the Prognosis of Patients With Hepatocellular Carcinoma and Esophageal Cancer Undergoing Radiotherapy Using Multiplex Proximity Ligation Assay||National Taiwan University Hospital|No|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|164|Samples With DNA|We have collected the serum samples of patients before, during, and after RT with consent of      two completed clinical trials and one active trial.|Both|20 Years|90 Years|No|Non-Probability Sample|We collected the pre-treatment and post-treatment serum samples of patients with        hepatocellular carcinoma undergoing definitive radiotherapy and patients with esophageal        cancer undergoing neoadjuvant chemoradiotherapy.|April 2014|April 15, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01957241||58548|
NCT01957501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ridge II|Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel|Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel||University of Utah|No|Active, not recruiting|July 2013|||July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|75|||Both|13 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who respond to recruitment flyers displayed within the community.|November 2015|November 11, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01957501||58528|
NCT01958073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130403|Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women||VESPR|University of California, San Diego|Yes|Recruiting|October 2013|April 2015|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|138|||Female|18 Years|N/A|No|||October 2013|October 4, 2013|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01958073||58484|
NCT01958398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1126-31/1|Brief Alcohol Interventions With Mobile Phone Applications for University Students: A Randomized Controlled Trial|Brief Alcohol Interventions With Mobile Phone Applications for University Students: A Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|4408|||Both|15 Years|N/A|No|||August 2015|August 31, 2015|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958398||58459|
NCT01958697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-BMI|Age and Gender Corrected Body Mass Index|Age and Gender Corrected Body Mass Index: When Preoperative Weight Loss and Underweight Are Becomming Clinically Significant in Esophagectomy for Cancer.||University Hospital, Gasthuisberg|No|Active, not recruiting|July 2013|June 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|650|||Both|18 Years|95 Years|No|Non-Probability Sample|Esophageal cancer patients recieving an esophagectomy|October 2013|October 7, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958697||58436|
NCT01958710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPERLEU|Outcome After Treatment of Pulmonary Aspergilloma|Outcome After Surgical Treatment or Bronchial Embolisation in Aspergilloma of the Lung: a Single Center Experience.||University Hospital, Gasthuisberg|No|Active, not recruiting|October 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|||Both|1 Year|89 Years|No|Non-Probability Sample|All patients in the database with following interventions will be screened for invasive        aspergilloma in the final resection specimen:        Aspergilloma Fungal disease Lung bleeding Destroyed lung Empyema of the lung|October 2013|October 7, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958710||58435|
NCT01935583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A120031A|Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation|Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)||Virginia Commonwealth University|No|Active, not recruiting|January 2013|September 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01935583||60210|
NCT01935570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0162|Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg.|Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg.|BioChronoMag|University Hospital, Clermont-Ferrand||Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01935570||60211|
NCT01936441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MsFLASH-04|MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance|Menopausal Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) 04: A Pilot Trial of Telephone-Based Cognitive-Behavioral Therapy for Midlife Women With Menopause-related Sleep Disturbance|MsFLASH-04|Fred Hutchinson Cancer Research Center|Yes|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936441||60144|
NCT01936415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2009-077|The Importance of Different Implant Surfaces of the Tibial Component for Migration and Adaptive Bone Remodeling in Uncemented Total Knee Arthroplasty (Vanguard Versus Regenerex)|The Importance of Different Implant Surfaces of the Tibial Component for Migration and Adaptive Bone Remodeling in Uncemented Total Knee Arthroplasty (Vanguard Versus Regenerex)||Hillerod Hospital, Denmark|No|Completed|May 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||September 2013|September 3, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01936415||60146|
NCT01936428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.743|Prospective Study of the Perception of Palliative Care by Relatives of Patients Treated in Oncology|Prospective Study of the Perception of Palliative Care by Relatives of Patients Treated in Oncology||Hospices Civils de Lyon|Yes|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01936428||60145|
NCT01936675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001727|Myocardial Infarction Genes (MI-GENES) Study|Myocardial Infarction Genes (MI-GENES) Study - Using Genomic Data to Refine Risk Assessment for Heart Attack|MI-GENES|Mayo Clinic|No|Active, not recruiting|July 2013|January 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936675||60126|
NCT01936688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3222-012|A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)|A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-012)||Merck Sharp & Dohme Corp.|Yes|Withdrawn|September 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01936688||60125|
NCT01937013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-13-270|Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia|Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia|IEMO|Lawson Health Research Institute|No|Recruiting|September 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937013||60100|
NCT01937273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013 1973|The Nutritional Status of Chemo-radiotherapy Patients|Prospective Analysis of the Nutritional Status of Chemo-radiotherapy Patients|PANSOCRP|Charles Darwin University|No|Recruiting|June 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (18 years or over) who are being treated with curative intent chemo-radiotherapy at        the Alan Walker Cancer Care Centre during the data collection period|September 2013|September 4, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01937273|8 Weeks|60080|
NCT01937533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0198 CCR3938|Apparent Diffusion Coefficient as a Prognostic Biomarker in Cervical Cancer|Diffusion-weighted MRI at 3T Using an Endovaginal Coil: Evaluating the Prognostic Value of the Apparent Diffusion Coefficient Distribution in Stage 1 Cervical Tumours||Institute of Cancer Research, United Kingdom|No|Recruiting|September 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|80 Years|No|Probability Sample|Primary Care Clinic|February 2016|February 3, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01937533||60060|
NCT01937559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021253|Topical Tranexamic Acid (TXA) in Joint Arthroplasty|Topical Application of Tranexamic Acid in Joint Arthroplasty||The Hawkins Foundation|Yes|Recruiting|April 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937559||60058|
NCT01937871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14393|A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction||Eli Lilly and Company|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|855|||Male|45 Years|N/A|No|||January 2016|January 26, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937871||60035|
NCT01934894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 200|Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases|Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases||SCRI Development Innovations, LLC|No|Active, not recruiting|November 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01934894||60262|
NCT01934907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1307/212-009|Transfusion Reaction by Washed Red Blood Cell (RBC)|||Seoul National University Bundang Hospital|No|Recruiting|August 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|223|||Both|20 Years|80 Years|No|||July 2015|July 29, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01934907||60261|
NCT01938989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01311|Effect of Blue Light Filtration on Visual Performance|Effect of Blue Light Filtration on Visual Performance||Alcon Research|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|158|||Both|21 Years|N/A|No|||January 2015|January 14, 2015|September 3, 2013||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01938989||59951|
NCT01935635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZX10002002-002|A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB|A Clinical Trial on Hepatitis B Vaccine Activated-DCs Combined With Peg-interferon or Nucleotide Analogs in Chronic Hepatitis B||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|450|||Both|18 Years|65 Years|No|||October 2015|October 17, 2015|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935635||60206|
NCT01957254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211040RIB|Investigate the Activity of Endotoxin in Severe Sepsis|Investigate the Activity of Endotoxin in Patients With Severe Sepsis and Septic Shock||National Taiwan University Hospital|No|Terminated|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|2|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with severe sepsis and septic shock|December 2014|December 1, 2014|July 4, 2013||No|The quality of Limulus Amebocyte Lysate (LAL) test was poor.|No||https://clinicaltrials.gov/show/NCT01957254||58547|
NCT01957267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00009729|Functional and Structural Imaging for Glaucoma|Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma|FSOCT|Oregon Health and Science University|Yes|Recruiting|September 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll both males and females and include all ethnic and racial groups        through clinical practices in the centers. The study will enroll subjects in the older        adult age range commonly affected by glaucoma - 40 years or older. The study will exclude        people with life-threatening or debilitating illness that would make 5-year participation        unlikely or cooperation with tests difficult. For similar reasons those older than 79        years are excluded. The study also excludes those with any disease that might confound the        diagnosis of glaucoma. Otherwise people with any health status are eligible for        enrollment. Three groups of participants are recruited in the study: normal (N), glaucoma        suspects & preperimetric glaucoma (GSPPG) and perimetric glaucoma (PG).|April 2015|April 21, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01957267||58546|
NCT01957280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31287-A-U105|Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)|Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors||Daiichi Sankyo Inc.|Yes|Completed|June 2013|April 2014|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|June 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01957280||58545|
NCT01957293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013DR2134|Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects|Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects|Salmon-Basel|University of Basel|Yes|Completed|October 2013|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|December 15, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01957293||58544|
NCT01957813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10285|Evaluation of a Peer Education Program to Promote Family Planning Among Female Sex Workers in Kenya|Development and Evaluation of an Intervention to Increase Family Planning Use Among Female Sex Workers in Kenya||FHI 360|No|Completed|June 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|719|||Female|16 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01957813||58504|
NCT01957826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBHGM-ECNC017-2010|Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy|Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy.||Hospital General Universitario Gregorio Marañon||Recruiting|March 2013|March 2016|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||October 2013|October 7, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01957826||58503|
NCT01958086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120287|Brain Implant for Neural Control of a Computer|Feasibility Study for Use of a Brain Implant for Neural Control of a Computer||California Institute of Technology|Yes|Active, not recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|2|||Both|22 Years|65 Years|No|||July 2015|July 27, 2015|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01958086||58483|
NCT01958723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300232|Problem Specific Templates for Electronic Hospital Documentation|Problem Specific Templates for Electronic Hospital Documentation||University of Florida|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Physicians of the Hospital Medicine Service|April 2015|April 10, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958723||58434|
NCT01958996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OROCIEP|Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma|||Poitiers University Hospital||Recruiting|January 2009|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|65 Years|80 Years|No|||October 2013|October 8, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958996||58413|
NCT01959009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-167|High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Blood Oxygenation and Stability of Oxygenation|Does High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths Improve Oxygenation Compared to High Frequency Oscillatory Ventilation Without Sigh Breaths in Neonates?||Rigshospitalet, Denmark|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|24 Weeks|44 Weeks|No|||October 2015|October 28, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01959009||58412|
NCT01935843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-009|Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors|Clinical Study of Chimeric HER-2 Antigen Receptor-modified T Cells in Chemotherapy Refractory HER-2 Advanced Solid Tumors|CART-HER-2|Chinese PLA General Hospital|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935843||60190|
NCT01935830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307040|LAAM-HAART PET Imaging|Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging||Washington University School of Medicine|Yes|Completed|August 2013|September 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01935830||60191|
NCT01937585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMHB-DOD|Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men|Evaluation of a Culturally Targeted, Personalized Mail-Home Brochure Directed to Partners of At-Risk Men to Facilitate Prostate Cancer Risk Assessment||Fox Chase Cancer Center|Yes|Completed|August 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|231|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 7, 2013|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937585||60056|
NCT01936714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 2007/2012|Comparison of Two Phacoemulsification-methods: Low Fluidic EasyTip 2.2mm vs. High Fluidic EasyTip 2.2mm|Comparison of Two Phacoemulsification-methods: Low Fluidic EasyTip 2.2mm vs. High Fluidic EasyTip 2.2mm||Medical University of Vienna||Completed|February 2013|September 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|50|||Both|50 Years|90 Years|No|||April 2015|April 9, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936714||60123|
NCT01936727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr:1053/2011|Comparison of Two Phacoemulsification-methods: EasyTip 2.2mm vs. Infusion Assisted EasyTip 2.2mm|Comparison of Two Phacoemulsification-methods: EasyTip 2.2mm vs. Infusion Assisted EasyTip 2.2mm||Medical University of Vienna||Completed|December 2011|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|50|||Both|50 Years|90 Years|No|||September 2013|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936727||60122|
NCT01936701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 112/2011|Comparison of the Effect of Hydrophobic Acrylic and Silicone 3-piece IOLs on Posterior Capsule Opacification|Comparison of the Effect of Hydrophobic Acrylic and Silicone 3-piece IOLs on Posterior Capsule Opacification||Medical University of Vienna||Completed|March 2011|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|50|||Both|40 Years|90 Years|No|||September 2013|September 5, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01936701||60124|
NCT01937026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14604|A Study of Baricitinib and Probenecid in Healthy Participants|A Study to Investigate the Potential Impact of Organic Anion Transporter 3 Inhibition by Probenecid on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|September 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01937026||60099|
NCT01937039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0888|Johns Hopkins Breast Cancer Program Longitudinal Repository|Johns Hopkins Breast Cancer Program Longitudinal Repository||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|April 2009|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|Blood for example: whole blood, serum, plasma), urine, and tissue samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any man or woman being seen at Johns Hopkins for breast cancer treatment, or for any        screening or diagnostic breast procedures (for example: mammograms or biopsies), may join.        Individuals without a history of breast cancer, known as "healthy" or "normal" volunteers        (meaning they do not have breast cancer) may also join.|October 2015|October 9, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01937039||60098|
NCT01937286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepatocellular carcinaoma|Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits|Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits||Ain Shams University|No|Completed|January 2002|April 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|590|||Both|18 Years|62 Years|No|Non-Probability Sample|Egyptien Patient with HCC who underwent LDLT|September 2013|September 4, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937286||60079|
NCT01938430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0123|Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant||Gilead Sciences|Yes|Completed|September 2013|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|339|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938430||59993|
NCT01934920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elman-01|Identifying Patients With Unrecognized Treatable Diabetic Macular Edema|Identifying Patients With Unrecognized Treatable Diabetic Macular Edema||Elman Retina Group|No|Not yet recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients identified through medical records or admitted into Franklin Square Hospital with        a history of diabetes|August 2015|August 4, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01934920||60260|
NCT01935141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-101526|Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli|Efficacy Of Low(30 Ml) Versus Full Dose (100 Ml)Contrast CT Pulmonary Angiography Performed On 64 Multi-Detector CT In Detecting Emboli||VA Greater Los Angeles Healthcare System|Yes|Not yet recruiting|December 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01935141||60244|
NCT01935895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Exercise and Blood Pressure Reactivity|Combined Exercise Circuit Session Acutely Attenuates Stress-Induced Blood Pressure Reactivity in Healthy Adults||Universidade Federal do vale do São Francisco|Yes|Completed|September 2010|April 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|24 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample.|September 2013|September 1, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01935895||60186|
NCT01926145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DenHeart|DenHeart - Self-reported Health and Quality of Life at Hospital Discharge From a Heart Centre in Denmark|DenHeart - Self-reported Health and Quality of Life at Hospital Discharge From a Heart Centre in Denmark|DenHeart|Rigshospitalet, Denmark|Yes|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16712|||Both|18 Years|N/A|No|Non-Probability Sample|All patients discharged or transferred from one of the heart centres are potential        participants in the study. The diagnostic groups include ischemic heart disease, heart        failure, arrhythmia, heart valve disease, endocarditis, congenital heart disease and heart        transplantation.|June 2015|June 9, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01926145||60934|
NCT01956981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-221|Controlled Hypotension During Functional Endoscopic Sinus Surgery|Comparison Between Magnesium Sulfate and Dexmedetomidine in Controlled Hypotension During Functional Endoscopic Sinus Surgery: A Double-blind, Randomized Clinical Trial||TC Erciyes University|No|Completed|January 2012|July 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|No|||October 2013|October 7, 2013|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01956981||58568|
NCT01957852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13019|FloSeal in CRS and HIPEC|Can FloSeal Reduce the Risk of Intra-abdominal Bleeding After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Performed for the Treatment of Peritoneal Carcinomatosis ?||Maisonneuve-Rosemont Hospital|No|Completed|January 2008|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|86|||Both|18 Years|N/A|No|Probability Sample|Patients with peritoneal carcinomatosis (PC) of any cause followed at Hôpital        Maisonneuve-Rosemont and undergoing Cytoreductive and HIPEC surgery|February 2015|February 24, 2015|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01957852||58501|
NCT01957540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-16|Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease|Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease||University of Patras|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|19|||Both|18 Years|74 Years|No|||August 2015|August 19, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01957540||58525|
NCT01957839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu-08|Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients|||Istanbul Bakirkoy Maternity and Children Diseases Hospital|No|Completed|March 2010|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01957839||58502|
NCT01958411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET(NAFLD, EAT)|Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)|||Korea University|Yes|Completed|December 2008|||March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|340|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants who underwent a medical health check in the health promotion center        in Korea Guro University|October 2013|October 7, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01958411||58458|
NCT01958424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-16092013-CTIL|In Vitro Fertilization Outcomes in Metabolic Syndrome|The Influence of Metabolic Syndrome on in Vitro Fertilization Treatment Outcome||Meir Medical Center|No|Not yet recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|whole blood|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women undergoing ivf treatment in "Meir" medical center in "Kfar-Saba, Israel|October 2013|October 9, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01958424||58457|
NCT01959568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#8, 04/09/2013|Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery.|Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety||The S.N. Fyodorov Eye Microsurgery State Institution|Yes|Recruiting|March 2010|June 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01959568||58369|
NCT01937052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1189|Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database|Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|February 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood (for example: serum, plasma, and whole blood) and saliva samples|Both|18 Years|N/A|No|Non-Probability Sample|Men and women being prescribed hormone therapies including Tamoxifen, Raloxifene (Evista),        Anastrozole (Arimidex), Letrozole (Femara), or Exemestane (Aromasin), by their oncologist        for either prevention of breast cancer or treatment of breast cancer may join.|October 2015|October 9, 2015|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01937052||60097|
NCT01936129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R624/45/2008|Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure|Investigating the Neuroprotective Effect of Cop-1 in Acute Primary Angle Closure||Singapore Eye Research Institute|Yes|Recruiting|September 2010|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|196|||Both|21 Years|N/A|No|||September 2013|September 4, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01936129||60168|
NCT01937325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPET in CF|Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX-770 (Ivacaftor)|Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX-770 (Ivacaftor)|CPET in CF|The Alfred|No|Not yet recruiting|October 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|16 Years|70 Years|No|||September 2013|September 6, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01937325||60076|
NCT01937910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01952|Neuroplastic Change in Myelin of the Brain|Structural and Functional Correlates of Neuroplastic Change Associated With Stroke|Myelin|University of British Columbia|No|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|88|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01937910||60032|
NCT01937299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-019|Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®|Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost||Alcon Research|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 4, 2013|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01937299||60078|
NCT01937572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013735|Visionaire: A Prospective Study|Visionaire Versus Conventional Knee Arthroplasty: A Prospective Study||The Hawkins Foundation|Yes|Recruiting|November 2011|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|168|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|August 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01937572||60057|
NCT01937897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0441|Unilateral Massage as a Potential Treatment for Depression|Unilateral Massage as a Potential Treatment for Depression||University of Arizona|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01937897||60033|
NCT01938144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3971002|Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America|Three-day Clinical Evaluation Of The Efficacy And Safety Of Two Ibuprofen Combination Products For The Symptomatic Treatment Of The Common Cold And Flu: A Multicenter Study||Pfizer|No|Withdrawn|April 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01938144||60015|
NCT01939002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105MS303|Characterize Flu-like Symptoms in RRMS Patients Transitioning From IFN-B Therapies to Peginterferon Beta-1a|An Open- Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017|ALLOW|Biogen|No|Completed|November 2013|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01939002||59950|
NCT01976962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-13-03|Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer|Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer||CancerCare Manitoba|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01976962||57037|
NCT01968213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-338-014|A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)|ARIEL3|Clovis Oncology, Inc.|Yes|Recruiting|January 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968213||57707|
NCT01968486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fidelio|Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia|Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results||Second University of Naples|Yes|Completed|June 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|50 Years|No|||October 2013|October 25, 2013|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01968486||57686|
NCT01968746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602039|The AVERT Sepsis Investigation|The AVERT Sepsis Investigation: Assessment of Variability in Early Resuscitation and Treatment of Sepsis|AVERT|Christiana Care Health Services|No|Completed|August 2012|April 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted through the ED for suspected infection as primary reason for admission.|April 2015|April 14, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968746||57666|
NCT01968980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481021|A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia|A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia|SPIRE-FH|Pfizer|Yes|Active, not recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968980||57648|
NCT01969240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001359|Shared Decision Making in the Emergency Department: Chest Pain Choice Trial|Shared Decision Making in the Emergency Department: The Chest Pain Choice Trial|CPC|Mayo Clinic|Yes|Completed|October 2013|December 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|911|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969240||57628|
NCT01965210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU-IL-S1|The Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function|The Combined Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function After Short-Term Consumption||Swedish University of Agricultural Sciences|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965210||57938|
NCT01965483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/2013|Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen|Weekly Hypofractionated Radiotherapy in Breast Cancer: a Phase 2 Clinical Trial||Instituto do Cancer do Ceara|No|Recruiting|November 2013|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|50 Years|N/A|No|||November 2013|November 7, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01965483||57917|
NCT01965496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-I-05|A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 14 Weeks Injection of Polyethylene Glycol Loxenatide||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|March 2012|April 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|20 Years|70 Years|No|||October 2013|October 15, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01965496||57916|
NCT01965743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-8070|Pilot of Social Network Intrauterine Contraceptive (IUC) Intervention|The Woman-to-Woman Dissemination Project: Harnessing the Power of Social Networks to Increase IUC Use||University of California, San Francisco|Yes|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|53|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965743||57897|
NCT01965756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn-AHAF_A2012116|Effect of Insulin Sensitizer Metformin on AD Biomarkers|A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD||University of Pennsylvania|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|80 Years|No|||August 2012|October 16, 2013|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965756||57896|
NCT01965704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aim 2_RO1-HD-070795-01A1|Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women|AIM 2- Prevention of Neonatal Abstinence Syndrome|AIM2NAS|Stanford University|Yes|Recruiting|December 2013|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|N/A|45 Years|No|||June 2014|June 26, 2014|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01965704||57900|
NCT01965717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVEH KCS|Multicentre Trial Of Serum Levels Of MMP-9 As A Biomarker Of Endoleak||BIOLEAK|University of Belgrade|No|Recruiting|July 2012|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Venous blood will be drawn via an antecubital vein puncture and collected in Heparin      buffered vacutainer for plasma. Exactly 30 min after collection, blood will be centrifuged      (15 min, 1000 g, 4C) and multiple aliquots will be stored at exactly 1 h after collection at      < - 20 C.|Both|N/A|N/A|No|Probability Sample|Patients treated with implantation of endovascular stent graft due to abdominal aortic        aneurysm|February 2015|February 24, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965717||57899|
NCT01965730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816724|Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery|The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography|EACA|University of Pennsylvania|No|Recruiting|January 2013|September 2014|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965730||57898|
NCT01974869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a-TNF|Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response|The Effect of Anti-Tumor Necrosis Factor Agents on Surgical Stress Response in Inflammatory Bowel Disease Patients Undergoing Abdominal Surgery||El-Hussuna, Alaa, M.D.|Yes|Recruiting|March 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|34|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|Patients with Crohn disease, ulcerative colitis and indeterminate colitis undergoing        elective abdominal surgery (laparoscopic or open)|January 2016|January 19, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01974869|30 Days|57197|
NCT01975428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scripps WFH Study|Scripps Wired for Health Study|Scripps Wired for Health Study||Scripps Translational Science Institute|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|161|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|October 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01975428||57155|
NCT01975701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398X2201|A Phase 2 Study of BGJ398 in Patients With Recurrent GBM|A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma||Novartis|No|Recruiting|December 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975701||57134|
NCT01975961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH16410-102|PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin|A Randomized, Open-label, Single-dose, 2-way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Telmisartan and Rosuvastatin and YH16410 in Healthy Volunteers||Yuhan Corporation|No|Completed|July 2013|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|185|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01975961||57114|
NCT01976195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Thalidomide|High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP|An Open-label, Randomized Multicenter Investigation of High-dose Dexamethasone Combining Thalidomide Versus High-dose Dexamethasone Mono-therapy for Management of Newly-diagnosed Immune Thrombocytopenia||Shandong University|Yes|Recruiting|October 2013|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||October 2013|October 29, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01976195||57096|
NCT01976468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOPE-ITSCC metastases|Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"|Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"||University of Zurich|No|Active, not recruiting|November 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|organ transplant recipients|June 2015|June 11, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976468||57075|
NCT01976169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042013-042|Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)|Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|90 Years|No|||October 2015|November 9, 2015|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976169||57098|
NCT01976182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGL|Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia|Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia||Rennes University Hospital|No|Recruiting|September 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976182||57097|
NCT01976702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA021521|Multi-Level HIV Prevention for Pregnant Drug Abusers|Multi-Level HIV Prevention for Pregnant Drug Abusers|PDA|National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Female|18 Years|N/A|No|||October 2013|October 30, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976702||57057|
NCT01976715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140009|Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy|Characterization and Management of Patients With HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|October 2013|August 2022|Anticipated|August 2022|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|14 Years|N/A|No|||July 2015|August 28, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976715||57056|
NCT01976728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000070|LutrePulse Hypogonadotropic Hypogonadism|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism||Ferring Pharmaceuticals|No|Recruiting|February 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Female|18 Years|40 Years|No|||October 2015|October 8, 2015|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976728||57055|
NCT01976754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstzhejiangU|Safety Study of Dexmedetomidine in Septic Patients|The Effective Dose of Dexmedetomidine for Moderate Sedation of Adult Intubated Septic Patients in the ICU.||First Affiliated Hospital of Zhejiang University|Yes|Recruiting|September 2013|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|65 Years|No|||October 2013|October 30, 2013|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976754||57053|
NCT01976975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001352|Brain Mechanisms of Human Motivation|Multi Level Analysis of Positive Valence Systems Across Mood Disorders||Mclean Hospital|No|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|192|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|We are studying a population with depressive and/or manic or hypomanic symptoms, as well        as healthy controls.|February 2016|February 22, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01976975||57036|
NCT01968473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMES_PD_Comfort|Comfort and Tolerance of Surface Neuro Muscular Electrical Stimulation in Parkinson's Disease.|An Evaluation of Comfort and Tolerance of Surface Neuro Muscular Electrical Stimulation (NMES), When Applied to Parkinson's Disease Patients for Both Sensory and Motor Activation.||National University of Ireland, Galway, Ireland|Yes|Recruiting|September 2013|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|10|||Both|40 Years|85 Years|No|||October 2013|October 19, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01968473||57687|
NCT01965249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1308|Effect of Stitch Technique on the Occurrence of Incisional Hernia After Abdominal Wall Closure|Short Stitch Versus Long Stitch Suture Technique Using Monomax® for Abdominal Wall Closure After Primary Median Laparotomy. A Randomized, Controlled, Double-blinded, Multicenter, International Trial|ESTOIH|Aesculap AG|No|Recruiting|February 2014|December 2020|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|468|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01965249||57935|
NCT01965262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV13-545|A Clinical Assessment of the Hemacopolymer Daily Disposable Limbal Ring Soft Contact Lens|A Clinical Assessment of the Hemacopolymer Daily Disposable Limbal Ring Soft Contact Lens||Coopervision, Inc.|No|Completed|April 2014|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01965262||57934|
NCT01968993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02|Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine|A Prospective, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using nanOss Bioactive and Autograft Bone.||Pioneer Surgical Technology, Inc.|No|Completed|January 2010|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968993||57647|
NCT01969253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1210181-2|A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection|A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection (ALND)||National Cancer Center, Korea|Yes|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Female|20 Years|N/A|No|Probability Sample|This prospective study is observational study that focused on incidence of lymphedema in        breast cancer patients. Annually six hundred patients have received treatment of breast        cancer from the breast cancer center at National Cancer Center in Korea. Among of them,        two hundred patients have received surgical treatment with axillary dissection. About four        hundred patients were recruited consecutively for enrollment from May 2012 to December        2013.|October 2015|October 13, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01969253||57627|
NCT01965223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 13.01|A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)|Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial|SAFRON II|Trans-Tasman Radiation Oncology Group (TROG)|No|Recruiting|December 2014|February 2021|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01965223||57937|
NCT01965769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-216|Effects Of Not Measuring Gastric Residual Content On Feeding Tolerance In Premature Infants iNFANTS|Effects Of Not Measuring Gastric Residuals Prior To Enteral Bolus Feeding On Gastrointestinal Function And Feeding Tolerance In Very Low Birth Weight Infants||University of Florida|No|Completed|March 2011|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|N/A|3 Days|No|||October 2013|October 15, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965769||57895|
NCT01965782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15097|A Study of [14C]-LY3023703 in Healthy Participants|Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Terminated|October 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 16, 2013|No|Yes|Due to safety results from another trial of LY3023703. No participants in this study received    study drug.|No||https://clinicaltrials.gov/show/NCT01965782||57894|
NCT01965795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001426|Whole Coffee Fruit Concentrate Pilot Study 1|Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study|WCFC|University of California, Los Angeles|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|40 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965795||57893|
NCT01966042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell 0314/05|Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina|Phase II Study of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina in Patients With Normal or Slightly Reduced Left Ventricular Function.|ReACT|CellPraxis Bioengenharia Ltda.|Yes|Completed|July 2005|December 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|N/A|No|||May 2014|May 5, 2014|October 14, 2013||No||No|December 27, 2013|https://clinicaltrials.gov/show/NCT01966042||57874|Due to ethical aspects and the inability to justify the use of a surgical intramyocardial placebo in this population, this was non-randomized, open study.
NCT01966029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-502|BMN 110 Phase 3B in Australian Patients|A Multicenter Open-Label, Phase 3B Study to Evaluate the Efficacy and Safety of BMN 110 in Australian Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|MOR-AUS|BioMarin Pharmaceutical|Yes|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||August 2014|January 27, 2015|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966029||57875|
NCT01966315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1307/212-010|The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit|The Comparison of Dexmedetomidine and Midazolam for the Sleep of Mechanical Ventilated Intensive Care Unit Patients||Seoul National University Hospital|Yes|Recruiting|October 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Critical patients who take a sedative drugs (dexmedetomidine or midazolam).|December 2015|February 10, 2016|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01966315||57853|
NCT01975142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2013-03|Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.|Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.||Institut Curie|Yes|Recruiting|October 2013|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|480|||Female|18 Years|75 Years|No|||January 2016|January 21, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01975142||57177|
NCT01975155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|852/12|Dietary Assessment and Mycotoxin Exposure in Celiac Disease|Dietary Assessment and Mycotoxin Exposure in Celiac Subjects||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Recruiting|June 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult subjects with or without celiac disease|August 2015|August 26, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975155||57176|
NCT01975974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307701|Technique for Successful Ultrasound-guided Peripheral Vascular Access|Technique for Successful Ultrasound-guided Peripheral Vascular Access||University of Iowa|No|Completed|July 2013|November 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01975974||57113|
NCT01976208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAB007|Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma|A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma|AA007|Shanghai Zhangjiang Biotechnology Limited Company|No|Completed|December 2010|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|630|||Both|15 Years|65 Years|No|||December 2015|December 20, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01976208||57095|
NCT01976494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0035|The Efficacy and Safety of Accufuser Omnibus® (Elastomeric Infusion Pump); Comparative Clinical Trial|||Yonsei University|Yes|Completed|October 2013|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|86|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01976494||57073|
NCT01976793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRU-ATC-2013/1|Retrospective Observational Study DIANA Study|Retrospective Observational Study to Estimate the Duration of Initial Antidepressant Treatment in Patients With Recurrent Depressive Disorder Who Demonstrated a Suboptimal Response to Therapy: DIANA Study|DIANA|AstraZeneca|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|450|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD        (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013.        Initially treated with antidepressant monotherapy, using a flexible dosage regimen if        required, for at least 2 weeks|November 2014|November 12, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01976793||57050|
NCT01976481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sunbed study|Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27|Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27||University of Zurich|Yes|Completed|November 2013|August 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|56|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976481||57074|
NCT01976429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040671-2|Gas Supply, Demand and Middle Ear Gas Balance -- Fly/Dive Simulation|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 2||University of Pittsburgh|No|Recruiting|October 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|210|||Both|10 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01976429||57078|
NCT01976741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16443|Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor|An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors||Bayer|No|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976741||57054|
NCT01976767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0721/66|Longitudinal Assessment of Adults With Severe Asthma|Protocol for the European Multi-Centre Study Understanding Severe Asthma Longitudinal Assessment of Adults With Severe Asthma||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|April 2011|April 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|725|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Severe asthma cohorts: uncontrolled asthma symptoms or frequent severe exacerbations          -  Mild-moderate asthma cohorts: controlled or partially controlled asthma symptoms          -  Healthy controls: non-asthmatic healthy individuals free of significant disease|January 2015|January 13, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976767||57052|
NCT01977001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3542|Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department|Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department||Minneapolis Medical Research Foundation|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients presenting to the emergency department at an urban county hospital.|October 2014|October 23, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977001||57034|
NCT01968239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200543910|Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT|A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|RabOCT|University of Leipzig|Yes|Recruiting|October 2013|December 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968239||57705|
NCT01965535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0121|Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks With Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|Yes|Completed|October 2013|November 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|October 16, 2013|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT01965535||57913|There were no limitations affecting the analysis or results.
NCT01968772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001413|Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia|Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia - A Pilot Study||Mayo Clinic|No|Completed|October 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Female|40 Years|70 Years|No|||December 2014|December 23, 2014|April 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01968772||57664|
NCT01969006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILIOINGUINAL01|Ilioinguinal Block in Laparoscopic Inguinal Hernia Repair|Effect of Ilioinguinal Blockage on Postoperative Pain After Laparoscopic Inguinal Herna Repair||Randers Regional Hospital|No|Withdrawn|January 2014|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Male|18 Years|N/A|No|||October 2013|December 16, 2014|October 21, 2013||No|Another study has been planned, so we did not initiate this one.|No||https://clinicaltrials.gov/show/NCT01969006||57646|
NCT01969266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102577|A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food|Open-Label, 2-Period, Sequential Design, Exploratory Pharmacokinetic Study In Healthy Subjects to Assess the Pharmacokinetics and Safety of a Supra-Therapeutic Dose of Ibrutinib Capsule and Solution Formulations Administered With Food||Janssen Research & Development, LLC|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|August 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01969266||57626|
NCT01965236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8985|Influence of Sodium Intake on Left Ventricular-arterial Coupling|Influence of Sodium Intake on Left Ventricular-arterial Coupling in Hypertension: Biomechanical Assessment and Modelisation of Left Ventricular Function With Arterial Pressure||University Hospital, Montpellier|No|Recruiting|May 2013|June 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01965236||57936|
NCT01965509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-I-06|A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|May 2012|October 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|20 Years|70 Years|No|||October 2013|October 15, 2013|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01965509||57915|
NCT01966341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-108|Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease|A Randomized Controlled Trial Comparing a Collaborative Cognitive Behavioral Therapy / Hypnotherapy Program to Standard Medical Management in the Treatment of Pediatric Functional Gastrointestinal Disease|CAPP|Seton Healthcare Family|No|Recruiting|April 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|18 Years|No|||May 2014|May 14, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01966341||57851|
NCT01966900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X001|The Safety and Immunogenicity of a Potential HIV Vaccine|A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers||Imperial College London|No|Completed|October 2013|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|February 16, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01966900||57808|
NCT01966640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/170/HP|Basophil Activation Test (BAT) Sensitivity in Child Food Allergy|Basophil Activation Test (BAT) Sensitivity in Child Food Allergy|TAB-TPO|University Hospital, Rouen|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|6 Months|18 Years|No|||July 2015|July 29, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966640||57828|
NCT01966328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMA-001|A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment|A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment||Ophthalmic Consultants of Boston|No|Active, not recruiting|October 2013|||October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|October 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01966328||57852|
NCT01966887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081252|AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure|Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure|AGENT-HF|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|December 2013|January 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01966887||57809|
NCT01975714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-GLC-2013-06|Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study|Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Month Cross-over, Investigator Led, European Multicentre Trial (SPORT)|SPORT|Association for Innovation and Biomedical Research on Light and Image|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|40 Years|84 Years|No|||October 2015|October 28, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975714||57133|
NCT01975987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.182|Characteristics to Predict Successful Intubation With the Bonfils Fiberscope|Identification of Morphological Characteristics to Predict Successful Intubation With the Bonfils Fiberscope||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|400|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01975987||57112|
NCT01976221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2013/1762|Priority Setting and Waiting Time Decision in the Referral Process, How and by Whom?|Priority Setting and Waiting Time Decision in the Referral Process, How and by Whom? A Prospective Cluster Randomized Controlled Trial on the Effects of an Education Program in Priority Setting and Waiting Time Decision in Referrals|Priority|University of Bergen|No|Not yet recruiting|January 2014|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Anticipated|40|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01976221||57094|
NCT01976234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04121985|Stored RBC Transfusion and Immonomodulation|Infective Complication After Surgery and Transfusion of Allogenic RBC Fresh or Stored||Università degli Studi di Ferrara|Yes|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|181|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976234||57093|
NCT01976507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121204|Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism|Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter||Vanderbilt University|No|Active, not recruiting|October 2013|October 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|101|||Both|18 Years|85 Years|No|||December 2015|December 11, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976507||57072|
NCT01976806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-023|The Effects of DHA on Periodontitis|The Effects of Docosahexaenoic Acid on Periodontitis in Adults: A Pilot Randomized Controlled Trial|DAP|Beth Israel Deaconess Medical Center|No|Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2013|February 23, 2014|October 30, 2013||No||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01976806||57049|
NCT01977040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0025|Optimal Management of Vasa Previa Study - A Retrospective Study|Optimal Management of Vasa Previa: Screening, Diagnosis and Management - A Retrospective Study.|VasaPrevia|Mednax Center for Research, Education and Quality|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|72|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women at participating site who have been identified as having a vasa previa between        January 1, 2000 and December 31, 2012.|November 2015|March 11, 2016|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01977040||57031|
NCT01976442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC RSRB00035034|Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia|Impact of Washed Transfusions in Adult Patients With Acute Myeloid or Lymphoid Leukemia||University of Rochester|No|Active, not recruiting|March 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|98|||Both|N/A|50 Years|No|Non-Probability Sample|The study population is comprised of 98 men and women who were both diagnosed and treated        for Acute Myeloid Leukemia or Acute Lymphoid Leukemia at Strong Memorial Hospital, a        tertiary medical center located in Rochester, NY, USA. All of these patients received        washed red cell and platelet transfusions as part of the hospital's standard protocol for        patients with acute leukemia.|December 2015|December 21, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01976442||57077|
NCT01976455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC505|The Breathe Light Study|The Breathe Light Study: Validation of Carbon Stable Isotope Ratio in Breath as an Indicator of Energy Balance and Substrate Utilization||USDA Grand Forks Human Nutrition Research Center|No|Recruiting|July 2013|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover||2|Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Men & Women age 18 to 65 years with a BMI of 25- 40 kg/m2.|November 2015|November 23, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01976455||57076|
NCT01977027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03117|Strategies for Recovery of Dexterity Post Stroke|Strategies for Recovery of Dexterity Post Stroke||New York University School of Medicine|Yes|Recruiting|August 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01977027||57032|
NCT01969279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH No 6-2|Radiographic Influences of Bisphosphonate Treatment on Femur|Radiographic Influences of Long-term Bisphosphonate Treatment on Femur||Tomidahama Hospital|No|Recruiting|October 2000|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|100 Years|No|Probability Sample|Oateoporosis patients using bisphosphonate more than four years.|November 2015|November 3, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01969279||57625|
NCT01965288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-42|Clinical Performance of Biofinity Toric Versus Air Optix for Astigmatism|A Single-Center Study Comparing the Clinical Performance of Biofinity Toric Versus Air Optix for Astigmatism Over 1 Month of Daily Wear.||Coopervision, Inc.|No|Completed|September 2013|May 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|40 Years|No|||November 2014|November 6, 2014|October 11, 2013|Yes|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT01965288||57932|
NCT01965548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miltstudie1|Treatment of Splenic Trauma: a Retrospective Cohort Study|Treatment of Splenic Trauma: a Retrospective Cohort Study||University Hospital of North Norway|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|109|||Both|N/A|N/A|No|Non-Probability Sample|All patients with a traumatic splenic injury admitted at University Hospital North Norway        Tromsø|December 2015|January 8, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965548||57912|
NCT01965522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-D|Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer|Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer|MELO-D|Juravinski Cancer Center|Yes|Recruiting|October 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965522||57914|
NCT01965808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15239|A Study of LY2157299 in Healthy Participants|Effect of Food on the Pharmacokinetics of LY2157299 Monohydrate in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|October 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01965808||57892|
NCT01965821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_41|Impact of Mallinckrodt Electronic Device on Continuous Control of Tracheal Cuff Pressure|Impact of Mallinckrodt Electronic Device on Continuous Control of Tracheal Cuff Pressure|RCPBALSTAT|University Hospital, Lille|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965821||57891|
NCT01966055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-119|Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents|A Phase 1, Open-label, Multi-center Study to Determine the PK and Safety of Solithromycin as Add-on Therapy in Adolescents With Suspected or Confirmed Bacterial Infection||Cempra Inc|Yes|Completed|December 2013|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|12 Years|17 Years|No|||September 2015|September 25, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01966055||57873|
NCT01966068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010285|Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3|Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3||Children's Hospital of Philadelphia|No|Active, not recruiting|October 2013|December 2016|Anticipated|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|294|||Both|6 Years|12 Years|No|||March 2016|March 9, 2016|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966068||57872|
NCT01966913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100135|Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors|Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification|TAXIFIII|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2012|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966913||57807|
NCT01967199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-01|Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis|Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis|RESTORE|Asan Medical Center|Yes|Recruiting|April 2013|June 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|20 Years|N/A|No|||February 2016|February 28, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967199||57785|
NCT01967173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 006|Best African American Response to Asthma Drugs|Best African American Response to Asthma Drugs|BARD|Milton S. Hershey Medical Center|Yes|Recruiting|February 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|544|||Both|5 Years|N/A|No|||April 2015|April 22, 2015|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967173||57787|
NCT01975727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-213 (NAC 11-076)|Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting|Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting - a Randomised, Placebo-controlled, Dose-finding Study|DexPonv|University Hospital, Geneva|Yes|Recruiting|August 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|560|||Both|18 Years|80 Years|No|||October 2013|November 4, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01975727||57132|
NCT01976247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU84032|A Pilot Study Testing a Noninvasive Cryolipolysis Device Versus a High Intensity Focused Ultrasound Device for Fat Reduction|Pilot Study Comparing the Effectiveness of a Noninvasive Cryolipolysis Device vs. a High Intensity Focused Ultrasound Device for Fat Reduction: A Randomized Control Trial||Northwestern University|Yes|Active, not recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|15|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01976247||57092|
NCT01976520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 13H05|Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)|NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia||XEME Biopharma Inc.|Yes|Active, not recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976520||57071|
NCT01976819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD788_TW|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||November 5, 2013|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976819||57048|
NCT01977066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPPORT|Exercise Intervention Study for Pancreatic Cancer Patients|SUPPORT - Study Supervised Progressive Resistance Training for Pancreatic Cancer Patients: a Randomized Controlled Intervention Trial|SUPPORT|German Cancer Research Center|Yes|Recruiting|November 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|201|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977066||57029|
NCT01977326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U19MH095699-02|Task Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South Africa|The Effectiveness and Cost-effectiveness of a Task Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South Africa|AFFIRM-SA|University of Cape Town|Yes|Active, not recruiting|October 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Female|18 Years|45 Years|No|||December 2015|December 1, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977326||57009|
NCT01977053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/04|Impact of a Telephonic Monitoring During Inter-treatment Intervals on Emotional State, Quality of Life and Toxicities, on Neo Adjuvant or Adjuvant Chemotherapy-treated Patients|Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy|EMOTION|Centre Antoine Lacassagne|No|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|280|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01977053||57030|
NCT01976780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR1935|In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy|In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya||Global Emerging Infections Surveillance and Response System|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|6 Months|65 Years|No|||March 2015|March 9, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01976780||57051|
NCT01977599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7114/P21R|Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening?|A Randomised Controlled Trial Investigating the Efficacy and Effectiveness of Text Message Reminders to Improve Uptake of Breast Screening by Prevalent Women Living in the London Borough of Hillingdon||Imperial College Healthcare NHS Trust||Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|2454|||Female|47 Years|53 Years|Accepts Healthy Volunteers|||October 2013|January 26, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01977599||56988|
NCT01965301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-03/BP1.5375|First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375|Double-blind, Placebo Controlled, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 After Single Oral Administrations Ranging From 0.5 mg to 100 mg in Healthy Male Subjects (Part 1) Followed by the Assessment of the Effect of 3 Single Different BP1.5375 Oral Doses on Polysomnography in Comparison to 50 mg Diphenhydramine and Placebo in Healthy Male Subjects (Part 2).||Bioprojet|Yes|Terminated|October 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01965301||57931|
NCT01965314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haystack USgABPB sim-training|A Trial to Determine the Effect of Simulation Based Training on Initial Performance of Ultrasound Guided Axillary Brachial Plexus Blockade in a Clinical Setting|Randomised Control Trial to Determine the Effect of Simulation Based Training on Initial Performance of Ultrasound Guided Axillary Brachial Plexus Blockade in a Clinical Setting||Cork University Hospital|No|Terminated|July 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|October 11, 2013||No|1. The simulator lacked the fidelity required to meet training needs of the novices, 2.    Recruitment of novice anesthetists more difficult than anticipated|No||https://clinicaltrials.gov/show/NCT01965314||57930|
NCT01965561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13-016|Performance of Junctional Tourniquets in Normal Human Volunteers|Performance of Junctional Tourniquets in Normal Human Volunteers||United States Army Institute of Surgical Research|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 15, 2013|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01965561||57911|Rest = 5 minutes. SJT is belt with discs that inflate. JETT is belt with pads that screw down. AAT is an bladder within a belt. CRC is a vice.
NCT01965860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/783|Transferability and Cost-effectiveness of a Proficiency-based Stepwise Endovascular Curricular Training Program (PROSPECT)|The Study of Transferability and Cost-effectiveness of a Proficiency-based Stepwise Endovascular Curricular Training Program (PROSPECT) in Surgical Trainees|PROSPECT|University Ghent|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965860||57888|
NCT01965834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110069|Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma|Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma||University of Miami|Yes|Active, not recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965834||57890|
NCT01966081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonithon hors AOI 2008|AGARIC Case Control Study|Consumption of Fatty Acids, Metabolism of Adipose Tissue and Risk of Colorectal Cancer: AGARIC Case Control Study|AGARIC|Centre Hospitalier Universitaire Dijon|No|Recruiting||||November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|576|||Both|45 Years|N/A||||October 2013|October 16, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01966081||57871|
NCT01966354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/00679|Comparison of Three Techniques for Ultrasound-guided Internal Jugular Cannulation|Comparison of Three Techniques for Ultrasound-guided Internal Jugular Cannulation: Long Axis, In-plane Needle v. Short Axis, Out-of-plane Needle v. Oblique Axis, In-plane Needle|OISO-1|Fundacion Miguel Servet|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|220|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966354||57850|
NCT01966653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-014|Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women|Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection|AIDA-WP2|University Hospital, Geneva|Yes|Recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01966653||57827|
NCT01966666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI287-AD-001|A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease||University of California, San Francisco|Yes|Recruiting|November 2013|March 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|33|||Both|50 Years|82 Years|No|||January 2016|January 26, 2016|October 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01966666||57826|
NCT01966679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS-NIH-DA-12-241|Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial|Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial|FAST-AS|University of California, Los Angeles|Yes|Completed|October 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966679||57825|
NCT01966692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400464|Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution|Evaluation of the Sensitivity of Pharmacokinetics to Differences in the Aerodynamic Particle Size Distribution of Three Different Formulations of Fluticasone Propionate Dry Powder Inhalers||University of Florida|No|Not yet recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|4||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01966692||57824|
NCT01966926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIA21417|Self-Weighing Instruction Feasibility Study|Self-Weighing Instruction Feasibility Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|October 16, 2013||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01966926||57806|Small sample size; Absence of instructions that would mimic a weight loss program.
NCT01966939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106049RC|Influences of Types of Skull Surgery on Temporomandibular Joint Performance|Influences of Types of Skull Surgery on Temporomandibular Joint Performance||National Taiwan University Hospital|No|Recruiting|June 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|subjects received craniotomy or craniectomy and age, gender and teeth condtion matched        control subjects.|October 2013|October 17, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966939||57805|
NCT01975740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diaphragm Manual Technique|Manual Diaphragm Release Technique Effects On Tidal Volume in Elderly|Manual Diaphragm Release Technique Effects On Tidal Volume And Upper Rib Cage Contribution During Quiet Breathing In Elderly: A Randomized Controlled Trial||Universidade Federal de Pernambuco|Yes|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|60 Years|68 Years|Accepts Healthy Volunteers|||October 2013|November 4, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975740||57131|
NCT01976000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-009|Influence of CT 3D on the Learning Curve of Laparoscopic Colorectal Resection|The Impact of Preoperative Knowledge of the Colonic Vascular Anatomy on the Learning Curve for Laparoscopic Colorectal Resection||University of Roma La Sapienza|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|80 Years|No|Probability Sample|We included only patients in which standard laparoscopic right or left hemicolectomy was        planned and who needed a CT scan but had not received a scan prior to their first office        visit.|February 2014|March 13, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976000||57111|
NCT01977079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD061-13|Procalcitonin and Threatened Premature Delivery|Procalcitonin and Threatened Premature Delivery|MAPPRO|Centre Hospitalier Departemental Vendee|No|Recruiting|December 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977079||57028|
NCT01977339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0060|Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty|A Randomized, Double-Blinded, Control Trial to Evaluate the Efficacy of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Unilateral Total Knee Arthroplasty||St. Luke's-Roosevelt Hospital Center|No|Withdrawn|May 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|November 19, 2015|October 30, 2013|Yes|Yes|New departmental administration, loss of key study faculty|No||https://clinicaltrials.gov/show/NCT01977339||57008|
NCT01977625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814735|LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women|Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women||University of Pennsylvania|No|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977625||56986|
NCT01977300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-70188|Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode|Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode||University of British Columbia|Yes|Completed|January 2003|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|159|||Both|17 Years|N/A|No|||October 2013|November 19, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01977300||57011|
NCT01977612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304058|Randomized Clinical Trial of Skin Closure With Staples Versus Suture|Randomized Controlled Phase IIB Trial Evaluating Wound Complication Rate After Skin Closure With Staples Versus Subcuticular Suture in Patients With BMI >=30||Washington University School of Medicine|Yes|Recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Female|18 Years|85 Years|No|||September 2015|September 24, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01977612||56987|
NCT01965327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010121|Interferon Gamma-1b in Friedreich Ataxia (FRDA)|Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA)||Children's Hospital of Philadelphia|Yes|Completed|August 2013|October 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|17 Years|No|||April 2015|April 29, 2015|August 27, 2013|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01965327||57929|This study was performed in a small population of children with Friedreich ataxia (n=12) and without a placebo arm.
NCT01966419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCR002-HE209|Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)|Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study|STOP-HE|Ocera Therapeutics|Yes|Recruiting|November 2013|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|75 Years|No|||February 2016|February 8, 2016|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966419||57845|
NCT01970852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0264|Addressing Hospital Patient Information Needs Using Information Technology|Addressing Hospital Patient Information Needs Using a Personal Health Record Portal||Columbia University|No|Recruiting|March 2014|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|426|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01970852||57505|
NCT01970865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7461001|A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations|Phase 1/2 Study Of PF 06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations||Pfizer|No|Recruiting|January 2014|February 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|295|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970865||57504|
NCT01965847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMNDrawz1|Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy|Evening Dosing of Antihypertensive Medications in Chronic Kidney Disease Patients - A Pilot Study||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|100|||Both|19 Years|80 Years|No|||May 2015|May 14, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965847||57889|
NCT01966094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065880|Observational Study of HIV-associated Neurocognitive Disorder|Observational Study of HIV-associated Neurocognitive Disorder|HAND2|Emory University|Yes|Recruiting|October 2013|June 2018|Anticipated|October 2017|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|46|Samples Without DNA|Blood (plasma) samples and cerebrospinal fluid (CSF)|Both|18 Years|59 Years|No|Probability Sample|Subjects will be identified through referrals from HIV medical providers in the Atlanta        metropolitan area. Potential subjects will be recruited from the Grady Infectious Diseases        clinic as well as other clinics in the metropolitan Atlanta area, which include the Fulton        and Dekalb county health departments, the Emory Infectious Diseases clinic, as well as        private HIV medical practices in the area.|January 2016|January 19, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01966094||57870|
NCT01966367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL0156|CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease|CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease||Columbia University|Yes|Recruiting|March 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|30 Years|No|||March 2016|March 10, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966367||57849|
NCT01966380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leia|Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia|An Open Randomised, Prospective, Crossover, Proof of Concept (Design Validation) Clinical Investigation to Caompare the Performance and Safety of Wound Dressing(Leia) Compared to and Hydroactive Surgical Dressing on Low to Highly Exuding Wounds||Molnlycke Health Care AB|No|Terminated|September 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 9, 2013||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01966380||57848|
NCT01966406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111062RIC 2013|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy? A Prospective Randomized Multicenter Trial||National Taiwan University Hospital|Yes|Recruiting|September 2013|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|20 Years|N/A|No|||October 2013|October 21, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01966406||57846|
NCT01966952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130444-01H|Evaluation of Safety Mechanisms of Renal Radioablation(RSRA)for Uncontrolled Hypertension|Centre of Excellence for Treatment of Resistant Hypertension: Establishment and Critical Evaluation of Efficacy, Mechanisms and Safety of Renal Sympathetic Radioablation.|RSRA|Ottawa Hospital Research Institute|Yes|Terminated|September 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Probability Sample|All patients will be recruited from the Hypetension Units at The Ottawa Hospital and the        University of Ottawa Heart Institute. Only patients with uncontrolled hypertension will be        eligable.|February 2015|February 8, 2015|October 16, 2013||No|Simplicity HTN 3 trial did meet safety endpoint, but did not meet efficacy endpoint and    withdrew support for their catheter in 2014.|No||https://clinicaltrials.gov/show/NCT01966952||57804|
NCT01967225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16099|Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections|A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia)||Bayer|No|Recruiting|November 2013|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967225||57783|
NCT01976260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU84041|A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars|A Pilot, Split-Face Randomized, Evaluator Blinded Study on the Effectiveness of a Bipolar Fractional Radiofrequency System Versus 1550-nm Fractional Photothermolysis for the Treatment of Acne Scars.||Northwestern University|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01976260||57091|
NCT01976533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-3013-144/1/|Eisenmenger Syndrome in the Nordic Countries|Eisenmenger Syndrome in the Nordic Countries: Advanced Treatment and Mortality 1977-2012||Rigshospitalet, Denmark|Yes|Active, not recruiting|October 2012|October 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|714|||Both|N/A|100 Years|No|Probability Sample|Nordic patients with Eisnemnger syndrome|December 2015|December 23, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976533||57070|
NCT01946516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1204|S1204, Viral Screening in Newly Diagnosed Cancer Patients|A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients||Southwest Oncology Group|Yes|Recruiting|August 2013|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3061|Samples With DNA|Specimen submission is optional.|Both|18 Years|N/A|No|Non-Probability Sample|Community and academic oncology clinics|January 2016|January 26, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946516||59372|
NCT01976832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-ZH96|Music-with-Movement Intervention for People With Early Dementia and Their Families|Music-with-Movement Intervention for People With Early Dementia and Their Families||The Hong Kong Polytechnic University|Yes|Active, not recruiting|July 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|65 Years|N/A|No|||February 2016|February 26, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01976832||57047|
NCT01947049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6 IDSEP130014-01-01|Influenza Diagnosis, Treatment and Surveillance With Xpert Flu|Influenza Diagnosis, Treatment and Surveillance With Xpert Flu||Johns Hopkins University|No|Enrolling by invitation|July 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2200|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947049||59331|
NCT01947296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 12019|Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents|Evaluation of the Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents|CHIMORAL|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2013|June 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|284|||Both|18 Years|N/A|No|Probability Sample|Patients with oral antineoplastic agent introduction in the region of Ile-de-France|February 2016|February 15, 2016|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01947296||59312|
NCT01947309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-RV-CN-001|Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)|A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China||Celgene|No|Recruiting|November 2013|June 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Chinese Patients with Multiple Myeloma Treated with Revlimid (Lenalidomide) in a        Postmarketing setting|August 2015|August 31, 2015|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947309||59311|
NCT01977638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXD101-0901|Phase 1 Trial of CXD101 in Patients With Advanced Cancer|Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B||Oxford University Hospitals NHS Trust|No|Recruiting|November 2013|April 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01977638||56985|
NCT01977651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0403|A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide|A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure|UPWARD|Astellas Pharma Inc|Yes|Active, not recruiting|September 2013|October 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|424|||Male|N/A|N/A|No|||January 2016|January 28, 2016|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01977651||56984|
NCT01977313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087/13|Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women|Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women|CAG-Libido|University Hospital Inselspital, Berne|No|Completed|September 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|45|Samples With DNA|Whole blood, serum|Female|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|A community sample of 45 healthy heterosexual women, aged 45-65.|September 2015|September 24, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977313||57010|
NCT01973946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17472|Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up|Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief||University of Utah|Yes|Completed|September 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|358|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01973946||57268|
NCT01966133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-125-009|TACE as an Adjuvant Therapy After Hepatectomy for HCC|Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma||Fudan University|Yes|Enrolling by invitation|August 2011|January 2017|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01966133||57867|
NCT01967238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWA-0804|An Open Label Study of IgG Fc Glycan Composition in Human Immunity|An Open Label Study of IgG Fc Glycan Composition in Human Immunity||Rockefeller University|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967238||57782|
NCT01965873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062-0000000-0211|Enteral Nutrition in Acute Pancreatitis|Enteral Nutrition for Treatment of Acute Pancreatitis - a Prospective, Randomized Clinical Trial||University Hospital Rijeka|No|Completed|May 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965873||57887|
NCT01966107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6560C00002|Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.|Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)|ASCENT COPD|AstraZeneca|Yes|Recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4000|||Both|40 Years|130 Years|No|||March 2016|March 18, 2016|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966107||57869|
NCT01966120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA-AK-CT007|Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis With Photodynamic Therapy|A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED® Lamp||Biofrontera Bioscience GmbH|No|Completed|September 2013|April 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966120||57868|
NCT01966393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-07|Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Glucose Levels During 60 Hours in Free-living Conditions in Patients With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966393||57847|
NCT01966705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterBib|Cognitive Behavior Therapy for Health Anxiety: A Comparison of Three Forms of Self-help|Self-help Based Cognitive Behavior Therapy for Health Anxiety Delivered Via the Internet or in Book Form - the Effect of Administration Strategy and Therapist Contact: a Randomized Controlled Trial||Karolinska Institutet|Yes|Completed|October 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966705||57823|
NCT01975766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309759|Ketogenic Diet Phase 1 for Head & Neck Cancer|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer||University of Iowa|Yes|Recruiting|January 2014|November 2018|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975766||57129|
NCT01975779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14917A|Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects|Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects||H. Lundbeck A/S|No|Completed|July 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|42|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975779||57128|
NCT01976273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU84150|A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma|A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial||Northwestern University|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01976273||57090|
NCT01946282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP120229 (IRB# 082012-86)|Evidence-Based Colorectal Cancer Screening for the Uninsured|Evidence-Based Colorectal Cancer Screening for the Uninsured||University of Texas Southwestern Medical Center|No|Enrolling by invitation|September 2013|August 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|10000|||Both|50 Years|64 Years|No|||December 2015|December 29, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01946282||59390|
NCT01947062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetroCyclo1|Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma|Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma||Swami Rama Cancer Hospital and Research Institute|No|Not yet recruiting|October 2013|October 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2013|September 17, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01947062||59330|
NCT01947322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070505|Haploidentical NK-cell Infusion in Acute Myeloid Leukemia|Haploidentical NK-cell Infusion in Bad Prognosis AML Patients: Evaluation of Feasibility and Antitumoral Effect|NK|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2011|September 2015|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01947322||59310|
NCT01946776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201-071|Cardiac Arrhythmias in Epilepsy: the CARELINK-study|Cardiac Arrhythmias in Refractory Epilepsy: Identifying Prevalence and LINKage Between Seizures and Arrhythmias|CARELINK|Stichting Epilepsie Instellingen Nederland|No|Active, not recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|60 Years|No|||February 2015|February 10, 2015|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01946776||59352|
NCT01977677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRN0023|Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma|A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM||Stanford University|Yes|Recruiting|July 2014|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|75 Years|No|||June 2015|June 30, 2015|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01977677||56982|
NCT01977690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLABRA|Clavicle Splint for Pain Reduction After Posterior Cervicothoracic Surgery|||Stanford University|No|Completed|October 2013|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|95 Years|No|||September 2014|September 29, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977690||56981|
NCT01947569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV-0100-100|Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy|Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients||DiaVacs, Inc.|Yes|Not yet recruiting|October 2013|||November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|12 Years|35 Years|No|||October 2013|October 22, 2013|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01947569||59291|
NCT01943890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2125|High Volumes of Hypertonic Saline and Chest Physiotherapy in CF Patients|Establishment and Implementation of Nebulised High Volumes of Hypertonic Saline in Cystic Fibrosis Patients||Haukeland University Hospital|No|Completed|February 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||September 2013|September 16, 2013|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01943890||59574|
NCT01977898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00043549|Incidence of Headache Following an Unintentional Dural Puncture|Incidence of Post-Dural Puncture Headache Following Unintentional Dural Puncture: A Randomized Trial of Intrathecal Morphine Versus Saline||Northwestern University|No|Recruiting|November 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 9, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977898||56965|
NCT01977911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL RD & ID no. 12/0331|Clinical Trial of Stem Cell Based Tissue Engineered Laryngeal Implants|Phase I/IIa Clinical Trial of Stem Cell Based Tissue Engineered Partial Laryngeal Implants in 10 Adult Patients With End-stage Laryngeal Stenosis With 24 Months Follow-up.|RegenVOX|University College, London|Yes|Recruiting|August 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|November 25, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977911||56964|
NCT01973959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/2011|Information Transfer During Postoperative Handovers in the Post-anaesthesia Care Unit|Quality of Postoperative Patient Handover in the Post-anaesthesia Care Unit: A Prospective Analysis||University of Witten/Herdecke|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|790|||Both|18 Years|N/A|No|Probability Sample|Adult patients who undergo surgery (general surgery, neurosurgery, ophthalmic surgery,        orthopaedics, plastic surgery, trauma surgery, thoracic surgery).|October 2013|October 25, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01973959||57267|
NCT01974271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28980|An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)|IMPACT OF COMORBITIES ON HEMOGLOBIN STABILITY IN CHONIC KIDNEY DISEASE PATIENTS ON DIALYSIS TREATED WITH C.E.R.A||Hoffmann-La Roche||Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|661|||Both|18 Years|N/A|No|Probability Sample|Chronic kidney disease patients on hemodialysis or hemodiafiltration for at least 3        months, previously treated with an erythropoietin stimulating agent (ESA) and for whom        treatment with Mircera is indicated|March 2016|March 1, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974271||57243|
NCT01966965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPX2013|Efficacy and Safety Study for PIOLIN® Shampoo|Phase 3 Efficacy and Safety Study for PIOLIN® Shampoo to Treat Pediculosis|ESPX|Phytopharm Consulting Brazil|No|Not yet recruiting|July 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|2 Years|60 Years|No|||October 2013|October 22, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966965||57803|
NCT01967524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0061|Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain|Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain|MYOTOX|Nantes University Hospital|Yes|Active, not recruiting|September 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2015|February 19, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967524||57760|
NCT01970878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003008-00|Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)|A 28-Week, Multi-Center, Randomized, Double Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control||Pearl Therapeutics, Inc.|Yes|Completed|November 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|893|||Both|40 Years|80 Years|No|||July 2015|July 7, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970878||57503|
NCT01971125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G 107|Left Ventricular DYsfunction in DiAbetes|Left Ventricular DYsfunction in DiAbetes|DYDA|Heart Care Foundation|No|Completed|July 2006|November 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|970|Samples Without DNA|whole blood|Both|45 Years|N/A|No|Non-Probability Sample|Patients with diabetes mellitus type 2 without known or documented heart disease history        and recognize its predictive clinical, biohumoral and with non-invasive techniques        parameters.|October 2013|February 3, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971125||57485|
NCT01971138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121020-V02|Review of Surgical Site Infection Registration Routine at Surgery Departments in Sweden and Validation of One of the Used Routines|||Halmstad County Hospital|No|Completed|March 2013|||April 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Surgical clinics in Sweden.|October 2013|October 23, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01971138||57484|
NCT01971151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exp_SSB_LBP|Exposure Therapy and Safety-seeking Behavior in Chronic Low Back Pain|An Investigation Into the Effectiveness of Treatment of Chronic Low Back Pain||Maastricht University Medical Center|No|Active, not recruiting|February 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|65 Years|No|||October 2013|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971151||57483|
NCT01971385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001028|Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis|A Clinical Trial to Test the Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis|Squarex|Massachusetts General Hospital|No|Completed|October 2013|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971385||57465|
NCT01975493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0095|Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study|Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study|NAPPA|St George's, University of London|No|Recruiting|November 2013|||February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||6|Anticipated|600|Samples With DNA|Plasma samples and dried blood spots to be retained for retrospective analysis.|Both|N/A|15 Years|No|Non-Probability Sample|Children (aged under 16 years) and infants (including both full-term and premature        neonates), admitted to hospital and routinely prescribed one (or more) of the study        penicillins according to local hospital policy.|July 2015|December 14, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975493||57150|
NCT01968317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134119a4500|Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma|Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma||Fudan University|Yes|Recruiting|October 2013|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|45 Years|No|||November 2015|November 11, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01968317||57699|
NCT01968590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoD A-17236|Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)|A Phase II Trial on the Effect of Low-Dose Versus High-Dose Vitamin D Supplementation on Bone Mass in Adults With Neurofibromatosis Type 1 (NF1)|VitDBoneNF1|University of Utah|No|Not yet recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|320|||Both|25 Years|40 Years|No|||October 2013|October 19, 2013|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968590||57678|
NCT01946802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1303-013-470|Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims|Trial of Device for Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims||Seoul National University Hospital|No|Recruiting|December 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01946802||59350|
NCT01976871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH - 2013P000968|Switching From Oral Dopamine Agonists to Rotigotine|A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome|SWITCH|Massachusetts General Hospital|No|Active, not recruiting|August 2014|||December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976871||57044|
NCT01977105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009905|Healthy Growth Abbreviated Pilot Study|Abbreviated Pilot Trial of a Peer-Based Social Media Intervention to Promote Healthy Growth During Infancy||Children's Hospital of Philadelphia|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Female|18 Years|N/A|No|||February 2014|February 4, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977105||57026|
NCT01947582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS Bracing|The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)|The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)||University of Texas Southwestern Medical Center|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|60 Years|No|||February 2016|February 4, 2016|September 17, 2013||No||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01947582||59290|
NCT01977963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112083RID|Genetic Study of Antithyroid Drugs Associated Agranulocytosis|Genetic Study of Antithyroid Drugs Associated Agranulocytosis||National Taiwan University Hospital|No|Recruiting|April 2012|||January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|85 Years|No|Non-Probability Sample|Agranulocytosis caused by anti-thyroid drugs|October 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977963||56960|
NCT01943656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0049 (UK NRES)|Eyegaze Systems for Spinal Cord Injury: A Feasibility Study|A Longitudinal Clinical Feasibility Study to Evaluate the Psychological and Functional Effects of Using the Tobii™ Eyegaze System by Inpatients With Tetraplegia||Buckinghamshire Healthcare NHS Trust|No|Not yet recruiting|August 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|16 Years|N/A|No|||September 2013|September 12, 2013|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01943656||59592|
NCT01943916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIONEER-01|The PIONEER-01 Pivotal Study of the Imagio Breast Imaging System|A Pivotal Study of Imaging With Opto-acoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound: A New Evaluation Tool for Radiologists||Seno Medical Instruments Inc.|No|Completed|July 2013|November 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2105|||Female|18 Years|N/A|No|Non-Probability Sample|A total of 2,000 female subjects who have a recently identified lesion for which further        diagnostic work-up is necessary.|January 2016|January 20, 2016|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943916||59572|
NCT01944202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001779CR1|Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms|Reducing Outpatient Inappropriate Transthoracic Echocardiograms With An Educational Intervention: A Randomized Control Trial||Massachusetts General Hospital|Yes|Completed|August 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|112|||Both|N/A|N/A|No|||September 2013|September 12, 2013|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01944202||59550|
NCT01977924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00763-42|Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea|Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea: a Randomized Controlled Trial|PolySAS|University Hospital, Angers|No|Not yet recruiting|November 2013|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2013|November 12, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977924||56963|
NCT01943903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-903-003|The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)|Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts|PLATFORM|HeartFlow, Inc.|Yes|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|584|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects referred with intermediate likelihood of obstructive CAD with an Updated        Diamond-Forrester (UDF) risk score 20-80% with symptomatic, suspected CAD|March 2016|March 21, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01943903||59573|
NCT01944189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 567|Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics|Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children||Makerere University|No|Recruiting|September 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|6 Months|5 Years|No|||May 2014|May 27, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01944189||59551|
NCT01967251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MX030|Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction|A Randomized, Triple Blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Dose Response of Udenafil for 12 Weeks in Mexican Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction||Takeda|No|Withdrawn|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Male|45 Years|N/A|No|||March 2016|March 3, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967251||57781|
NCT01967537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130193|Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors|Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|August 2013|September 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|295|||Both|10 Years|99 Years|No|||February 2016|March 8, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967537||57759|
NCT01967511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1118|Defining the Basis of Fibromuscular Dysplasia (FMD)|Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study|DEFINE|Icahn School of Medicine at Mount Sinai|No|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|400|Samples With DNA|Fibroblasts and other cell lines generated under this protocol and all blood-derived      specimens (plasma, serum, DNA) will be kept indefinitely in a secure clinical database or      bio-repository (as appropriate).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Will enroll up to 200 FMD patients and controls at the Mount Sinai Hospital. Healthy        controls will also be recruited to this study.|January 2016|January 26, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967511||57761|
NCT01967758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-012A|Phase I Study of Safety and Immunogenicity of ADU-623|Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas||Providence Health & Services|No|Recruiting|October 2013|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967758||57742|
NCT01967771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901|Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Randomized, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901)||ViiV Healthcare|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967771||57741|
NCT01968070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15181|A Study of LY3127760 in Healthy Participants|A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|124|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968070||57718|
NCT01968603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2013-315|Weight Gain in Surgically Treated Adult-onset Craniopharyngioma|Weight Gain in Surgically Treated Adult-onset Craniopharyngioma||Huashan Hospital|No|Completed|July 2013|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|120|||Both|18 Years|81 Years|No|Non-Probability Sample|adult-onset patients with craniopharyngioma undertaking primary surgery in the        investigators' institution|October 2013|October 20, 2013|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01968603||57677|
NCT01968863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202224|Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues|Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues||University of Arkansas|No|Terminated|November 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with known or suspected dysplasia or cancer scheduled to undergo either        endoscopic or surgical resection will be approached for participation.|July 2015|July 8, 2015|October 15, 2013||No|Investigator Non Compliance|No||https://clinicaltrials.gov/show/NCT01968863||57657|
NCT01968876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202266|Is a Smartphone Application Effective as an Oral Medication Adherence Aid|Is a Smartphone Application Effective as an Oral Medication Adherence Aid||University of Arkansas|No|Recruiting|October 2013|||October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|228|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01968876||57656|
NCT01976559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1964|Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol|Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol||LifeBridge Health|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976559||57068|
NCT01977118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1180/M.CH|Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis|Phase 2/3 Study of Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|April 2013|||December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||November 2014|November 8, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01977118||57025|
NCT01977131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010B031600019|Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis|Phase 1 Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis||Guangzhou Municipal Twelfth People's Hospital|Yes|Completed|June 2010|September 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|No|||November 2013|November 20, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977131||57024|
NCT01977391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWS(mortality, DM)|Association Between Mortality and Diabetes in Elderly Koreans: the South-West Seoul (SWS) Study|||Korea University|Yes|Completed|August 1999|December 2011|Actual|December 2002|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2263|||Both|60 Years|92 Years|Accepts Healthy Volunteers|Probability Sample|Study subjects in South-West Seoul (SWS) study, a prospective observational cohort study        of an elderly Korean population residing in Seoul, the metropolitan capital city of Korea.|November 2013|November 6, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977391|10 Years|57004|
NCT01977404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NV-0484-CTIL|Nutritional Evaluation of Patients With Congestive Heart Failure|Nutritional Evaluation of Patients With Congestive Heart Failure||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|November 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|90 Years|No|Non-Probability Sample|Patients with congestive heart failure between the ages 40 to 90 years.|October 2013|October 30, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977404||57003|
NCT01977378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVS20130806|A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder|A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|October 2013|||September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||October 2013|October 30, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977378||57005|
NCT01973751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81170022|Asthma Biomarkers for Predicting Response to Therapy|Novel Asthma Biomarkers to Predict the Response to Inhaled Corticosteroid||Tongji Hospital|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973751||57283|
NCT01977950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2719007|Nutritional Risk and Nutritional Care Practices in the Hospitalized Elderly|Nutritional Status and Care of Elderly People|NUTRIELD|Oslo and Akershus University College of Applied Sciences|Yes|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|508|||Both|70 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients were recruited from a large University hospital in Norway. The university        hospital covers about 10% of the Norwegian population, providing healthcare services for        approximately half a million people living in urban and rural municipalities. The patient        population is thus heterogenic with respect to ethnicity and socioeconomic factors. All        somatic wards having nursing students in acute care clinical studies in autumn 2011 were        included in the study. The study sample comprised 14 of 16 medical and surgical somatic        wards. Additionally, one rehabilitation ward, one specialized short time unit, one        emergency medicine ward, and one cardio-monitoring ward were included.        Eligible patients were selected by the nursing students in cooperation with the ward        nursing staff.|January 2015|January 12, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977950||56961|
NCT01974284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1312013168|Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma|Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma||Yale University|No|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974284||57242|
NCT01944215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004749|Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue|Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue||Mayo Clinic|No|Completed|September 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|154|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|January 12, 2016|September 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944215||59549|
NCT01944228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoSIRS Study|Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study|Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study|NoSIRS|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944228||59548|
NCT01974505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JejuNationalUniversityHospital|Learning Curve of Optiscope by Anesthesia Providers|Learning Curve of Optiscope by Anesthesia Providers||Jeju National University School of Medicine||Not yet recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|140|||Both|20 Years|60 Years|No|||October 2013|October 28, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974505||57225|
NCT01944436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBD-312-2006|A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease|Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT||Sunnybrook Health Sciences Centre|No|Recruiting|September 2006|February 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|Samples With DNA|Functional and tag SNPs in the following genes will be assessed:      acetylcholinesterase (ACHE); butyrylcholinesterase (BCHE); M1 muscarinic receptor (CHRM1);      alpha7-nicotinic receptor (CHRNA7); Apolipoprotein E (ApoE); Cytochrome P450 2D6 (protein:      CYP2D6 /gene: CYP2D6); CYP3A4; all genes related to blood pressure disregulation, white      matter changes found on neuroimaging, and genes related to Lewy Body Spectrum disorders in      general.|Both|50 Years|N/A|No|Non-Probability Sample|Ontario, Canada.|November 2015|November 19, 2015|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944436||59532|
NCT01967264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-MX031|Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults|A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety Profile and Pharmacokinetic Parameters of Udenafil 150 mg in Healthy Mexican Subjects.||Takeda|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|83|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967264||57780|
NCT01967550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194-P-308|Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)|A 4-week, Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Assess the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel for the Relief of Signs and Symptoms in Patients With Knee Osteoarthritis||Novartis|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|50 Years|N/A|No|||June 2015|June 2, 2015|October 18, 2013||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01967550||57758|
NCT01967784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GQM09|Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan|Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan||Sanofi|No|Completed|October 2013|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|October 18, 2013||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01967784||57740|
NCT01967797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES 0014622|Implementation and Validation of the "5As Framework of Obesity Management" in Primary Care. "5AsT"|Implementation and Validation of the "5As Framework of Obesity Management" in Primary Care. "5AsT"|5AsT|University of Alberta|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967797||57739|
NCT01968083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1114|Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|51|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||October 2015|October 12, 2015|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968083||57717|
NCT01968096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-1780C|The Reversal of Neuromuscular Adaptation in Human With Spinal Cord Injury II|||Chang Gung University|Yes|Recruiting|August 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|52|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 18, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01968096||57716|
NCT01968330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014850|Postpartum Weight Loss and Sleep Amongst Obese Women|Postpartum Weight Loss in Obese Women Using a Sleep Intervention in a Group Prenatal Care Setting||University of South Florida|Yes|Recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01968330||57698|
NCT01968616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY-RV-R|Ranibizumab Treatment for Retinal Vein Occlusion|Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment||Kyoto University, Graduate School of Medicine|No|Recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01968616||57676|
NCT01968629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-386|24hr Imaging Of HCC After EOVIST|Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)||Massachusetts General Hospital|Yes|Withdrawn|December 2013|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 20, 2013|Yes|Yes|No eligible subject enrolled|No||https://clinicaltrials.gov/show/NCT01968629||57675|
NCT01968889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9163|ICU Acquired Neuromyopathy and Diaphragm Function|Diaphragm Function in Patients Acquired Weakness and Neuromyopathy in ICU: Impact on Weaning and Outcome (DIAPH-WEAK ICU)||University Hospital, Montpellier|Yes|Completed|May 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|patients acquired weakness and neuromyopathy in ICU|December 2014|December 2, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01968889||57655|
NCT01976884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeutrophilPD-L1|Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis|||Changhai Hospital|Yes|Completed|June 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|71|Samples Without DNA|Peripheral blood sample was collected for detection of neutrophil PD-L1, monocyte HLA-DR and      lymphocyte PD-1.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted in ICU at Changhai Hospital|October 2013|October 30, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976884||57043|
NCT01977144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA1-13-290|Screening of Low Responders for Aneuploidy to Improve Reproductive Efficiency|Screening of Low Responders for Aneuploidy to Improve Reproductive Efficiency|Solaire|Reproductive Medicine Associates of New Jersey|No|Recruiting|September 2013|January 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|400|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977144||57023|
NCT01977417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209707|Inflammation Inhibition in Prediabetic Humans|Inflammation Inhibition for Microvascular and Autonomic Dysfunction in Obese Prediabetic Humans|INCITE|University of Iowa|Yes|Recruiting|November 2012|||November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||October 2013|November 5, 2013|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977417||57002|
NCT01977430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEF-DIU-2013-CSPT|Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function|Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre|RRF|Corporacion Parc Tauli|Yes|Recruiting|November 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|90 Years|No|||March 2014|November 30, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977430||57001|
NCT01977703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131336|Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).|Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).||Vanderbilt University|No|Recruiting|October 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977703||56980|
NCT01977716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-785-069|Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients|The Role of Peritonitis in the Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients||Coordinación de Investigación en Salud, Mexico|Yes|Not yet recruiting|December 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|All patients starting PD as the first dialysis treatment will be considered. Recruitment        will take place over a six-months period in hospitals belonging to the Instituto Mexicano        de Seguro Social. Inclusion criteria include: adult patients with signed informed consent        given; there should not be selection for age, gender, primary cause of renal disease.        Patients will not be included if they were previously in hemodialysis or received renal        transplant. Patients will also be excluded if they are on immunosuppressive therapy, have        diagnosis of cancer, or are seropositive for HIV or hepatitis.|October 2013|November 21, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977716||56979|
NCT01973764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073/13|Intraventricular Drain Insertion: Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System|Intraventricular Drain Insertion:Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System. A Prospective Randomised Clinical Trial Study.|In-Vent|University Hospital Inselspital, Berne|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973764||57282|
NCT01973777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130928 IUB|A Pilot Study of Early Expulsion Rates of the IUB™ SCu380A|A Pilot Study of Early Expulsion Rates of the IUB™ SCu380A Spherical Copper Intrauterine Contraceptive Device.|IUB|Wiebe, Ellen, M.D.|No|Active, not recruiting|December 2013|January 2019|Anticipated|September 2015|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|October 26, 2013||No||No|December 31, 2015|https://clinicaltrials.gov/show/NCT01973777||57281|
NCT01973998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21474|Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization|Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization||Temple University|No|Recruiting|November 2013|April 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|80 Years|No|||November 2015|November 4, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01973998||57264|
NCT01974011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPNB vs. Modified DPNB|DPNB vs. Modified DPNB With Ventromedial Infiltration (DPNB According to Dalens' Technique)|Comparison of Dorsal Penile Nerve Block (DPNB According to Dalens' Technique) to Dorsale Penile Nerve Block With Ventromedial Infiltration||Charite University, Berlin, Germany|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|1 Year|17 Years|No|||November 2015|November 5, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974011||57263|
NCT01974518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9187-PG-2012|Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus|A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS||Postgraduate Institute of Medical Education and Research|No|Active, not recruiting|November 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974518||57224|
NCT01966978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072013-030|The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study|The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study|SIMPLE|University of Texas Southwestern Medical Center|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966978||57802|
NCT01967277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC650|A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy|A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy||Capillus, LLC|Yes|Completed|March 2014|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 18, 2013||No||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01967277||57779|
NCT01967810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG1005-CLN-03|ANG1005 in Patients With Recurrent High-Grade Glioma|A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma||Angiochem Inc|Yes|Active, not recruiting|October 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|83|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967810||57738|
NCT01967823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130214|T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer|Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|70 Years|No|||October 2015|November 7, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967823||57737|
NCT01968109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA224-020|Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors|A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2013|May 2018|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968109||57715|
NCT01968343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaPPesq 0013/08|Trichotillomania: Group Cognitive-Behavioral Therapy|Group Treatment for Trichotillomania: Cognitive-Behavioral Therapy Versus Supportive Therapy||University of Sao Paulo||Completed|January 2008|||December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2013|August 18, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01968343||57697|
NCT01968356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-012759|In-vivo Efficacy Study of Patient Preoperative Preps|Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions||3M||Terminated|October 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|419|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|October 21, 2013|Yes|Yes|Study discontinued due to data quality issues.|No||https://clinicaltrials.gov/show/NCT01968356||57696|
NCT01968902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPASTICITY-001|Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients|A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis||Multiple Sclerosis Center of Northeastern New York|No|Recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968902||57654|
NCT01965132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOBIO_1|Registry of Korean Patients With Rheumatic Disease Using Biologics|Prospective Cohort Study of Korean Patients With Rheumatic Disease Using Biologic Agents|KOBIO|Seoul National University Hospital|Yes|Recruiting|March 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3137|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of the following disease who will initiate, restart or switch to a biologic agent          1. Rheumatoid arthritis (RA)          2. Ankylosing spondylitis (AS)          3. Psoriatic arthritis (PsA)|June 2015|June 25, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01965132|5 Years|57943|
NCT01976897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/EVFN-01|Effect of the Physiological Angular Position of the Resting Knee on Pressure at the Heel/Surface Interface|Effect of the Physiological Angular Position of the Resting Knee on Pressure at the Heel/Surface Interface|FlessCare|Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|65|||Both|50 Years|N/A|No|Probability Sample|The study population consists of consecutive patients admitted in the functional        rehabilitation unit of the Nîmes University Hospital.|March 2015|March 25, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976897||57042|
NCT01977157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-189|Alcohol Detection Via Bioimpedance Mesurements|Alcohol Detection Via Bioimpedance Mesurements|AlkBIS|RWTH Aachen University|No|Completed|July 2012|October 2013|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male subjects|October 2013|October 30, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977157||57022|
NCT01977170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hib 0110|Safety of Hib Vaccine (Bio Farma)|Phase 1 Study of Hib Vaccine (Bio Farma)||PT Bio Farma|Yes|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|November 5, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01977170||57021|
NCT01977443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/ADE002|Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)|Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study||Adenovir Pharma AB|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977443||57000|
NCT01977729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308012517|Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline|Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline||Yale University|No|Terminated|October 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|8 Years|16 Years|No|||February 2016|February 1, 2016|October 30, 2013|Yes|Yes|funding|No||https://clinicaltrials.gov/show/NCT01977729||56978|
NCT01977742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191.2011-15/12/11|Rest-exercise Transition Training to Improve Cardiac Vagal Tone|A Sudden Rest-exercise Transition Training to Improve Cardiac Vagal Tone||Clínica de Medicina do Exercício|No|Completed|May 2011|October 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977742||56977|
NCT01974583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-2030130|Wound-healing Improvement by Resurfacing Split-Thickness Skin Donor Sites With Thin Split-thickness Grafting|Wound-healing Improvement by Resurfacing Split-Thickness Skin Donor Sites With Thin Split-thickness Grafting||Tang-Du Hospital|Yes|Completed|January 2002|March 2013|Actual|December 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|192|||Both|5 Years|56 Years|No|Probability Sample|The study cohort included 192 participants, who were randomly selected from patients who        continuously received an STSG from January 2002 to December 2010 in Department of Burn and        Plastic Surgery, Tangdu Hospital, Fourth Military Medical University.|October 2013|October 27, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01974583|1 Year|57219|
NCT01974024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSNUH 2013-1|Randomize Controlled Phase 3, Cross-over Trial of Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation|||Chung-Ang University|No|Not yet recruiting|December 2013|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974024||57262|
NCT01974037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATIETY-2|Capsaicin on Salty Gustatory Cortices|Effects of Capsaicin on Salty Gustatory Cortices in Human||Third Military Medical University|Yes|Completed|May 2013|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|8||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|October 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01974037||57261|
NCT01973985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLMAN2013|Using Ultrasound to Predict the Results of Draining Pleural Effusions|Correlation of Pleural Manometry With Real-time Thoracic Ultrasound, Symptomatic Benefit and Clinical Outcome in Patients With Pleural Effusion: a Pilot Study||University of Oxford|No|Not yet recruiting|June 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (> or = 18 years old) undergoing large-volume diagnostic and/or therapeutic pleural        aspiration or drainage for a symptomatic pleural effusion. (Large-volume aspiration or        drainage will be defined as an expectation by the clinician responsible for assessing the        patient that more than 500mL of pleural fluid is to be drained on this particular        occasion).|June 2014|June 3, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973985|3 Months|57265|
NCT01974310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-FDP-non-FDP|Postoperative Positioning After Surgery for Macular Holes|A Randomized Clinical Trial of Face-down Protocol Versus Non-face-down Protocol After Surgery for Macular Holes.||Glostrup University Hospital, Copenhagen|No|Completed|October 2013|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|40 Years|N/A|No|||February 2016|February 10, 2016|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974310||57240|
NCT01974297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVOCADO|Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid|Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.|AVOCADO|Yonsei University|No|Recruiting|July 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Both|20 Years|N/A|No|||October 2013|October 31, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974297||57241|
NCT01966991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0013|Prenatal Screening for Down Syndrome With DNAFirst|DNAFirst: Primary Screening for Down Syndrome by Maternal Plasma DNA|DNAFirst|Women and Infants Hospital of Rhode Island|No|Completed|June 2014|December 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Female|18 Years|N/A|No|Non-Probability Sample|Women with a singleton pregnancy at 10 weeks or later who agree to be contacted by        telephone to provide consent and participate in a structured survey to assess        comprehension and satisfaction with their experience.|December 2015|December 21, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966991||57801|
NCT01967004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFID-IBT-3600|Enhancing Upper Limb Prostheses With Radio Frequency Identification|Validation of a Control Method for Upper Limb Myoelectric Prostheses Using Radio Frequency Identification (RFID)|RFIDIBT|Infinite Biomedical Technologies||Active, not recruiting|August 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|March 4, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01967004||57800|
NCT01968369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRPM_Tomato_and_endothelium|Effects of Tomato Sauce on Endothelial Dysfunction Induced by a High Fat Meal in Healthy Subjects|Effects of Tomato Sauce on Endothelial Dysfunction Induced by a High Fat Meal in Healthy Subjects|VRPM|Universita di Verona|No|Active, not recruiting|October 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16|||Male|18 Years|38 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01968369||57695|
NCT01968382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 124-E|Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis|A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis|TREAT|Virginia Commonwealth University|Yes|Recruiting|December 2014|January 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968382||57694|
NCT01968395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2013_PK_CASPO70_LIVERFAILURE|Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure|Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure||Erasme University Hospital|Yes|Recruiting|September 2013|August 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01968395||57693|
NCT01967836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-059|Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients|Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients||Wheaton Franciscan Healthcare|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01967836||57736|
NCT01968668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16816|Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy||Bayer|Yes|Completed|October 2013|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|96|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968668||57672|
NCT01968122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTH-CRS|Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China|Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China-a Prospective Multicenter Registry Study||Beijing Tiantan Hospital|No|Recruiting|September 2013|January 2016|Anticipated|February 2015|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Symptomatic ischemic cerebrovascular disease caused by Intracranial atherosclerotic        atherosclerosis.Patients with ≥70% stenosis of angiopathic area symptomatic ICAD caused by        hypoperfusion combined with poor collateral flow.|January 2015|January 23, 2015|October 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968122|1 Year|57714|
NCT01968642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001779 AME3|Education and Feedback Intervention to Reduce Inappropriate Transthoracic Echocardiograms|Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms Ordered by Attending Physicians||Massachusetts General Hospital|Yes|Recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|N/A|N/A|No|||February 2014|February 10, 2014|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01968642||57674|
NCT01968655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-1-301a|Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies|Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies||Baxalta US Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2013|June 26, 2015|October 21, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01968655||57673|
NCT01965145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-78989-002|Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)|A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis|EYEGUARD™-B|Servier|Yes|Terminated|November 2012|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01965145||57942|
NCT01976910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68,876|Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"|A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|DM-CHOC-PEN|DEKK-TEC, Inc.|Yes|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976910||57041|
NCT01973790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z338-01|Phase III, Long-term, Open-label Safety Study of Z-338|A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia||Zeria Pharmaceutical|No|Active, not recruiting|March 2014|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|207|||Both|18 Years|N/A|No|||July 2015|March 23, 2016|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01973790||57280|
NCT01974050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM4906|PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging|PregText: Assessing the Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging||Columbia University||Completed|November 2013|December 2015|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|166|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974050||57260|
NCT01974063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012965|Alternate Nicotine Delivery Systems and Airway Epithelial Biology|Alternate Nicotine Delivery Systems and Airway Epithelial Biology||Weill Medical College of Cornell University|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|125|Samples With DNA|Analysis performed will be completed per the "Airway" (IRB#1204012331) protocol.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|December 2015|December 9, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01974063||57259|
NCT01974349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00069|To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers|A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years||AstraZeneca|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|39|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01974349||57237|
NCT01974596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics|Use of Probiotics in Oral Health of Patients With Dental Implants|THE EFFECT OF ORALLY ADMINISTERED PROBIOTIC LACTOBACILLUS REUTERI-CONTAINING TABLETS IN PERI-IMPLANT MUCOSITIS: A RANDOMIZED CLINICAL TRIAL||University of Valencia|Yes|Completed|January 2008|July 2010|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|34|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 27, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01974596||57218|
NCT01974817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI170883|Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease|Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis.||Michigan State University|No|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|N/A|No|||November 2013|November 4, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974817||57201|
NCT01974323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-007|Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris|||Allergan|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2241|||Both|12 Years|N/A|No|||September 2015|September 30, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974323||57239|
NCT01974336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDCA-PNAC-SBS|The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients|The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome||Jinling Hospital, China|Yes|Recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|70 Years|No|||January 2015|March 19, 2015|October 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974336||57238|
NCT01974557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-072|The Effect of Age on the Hemodynamic Response During Rest and Exercise in Healthy Humans|The Effect of Age on the Hemodynamic Response During Rest and Exercise in Healthy Humans|HemReX|Rigshospitalet, Denmark|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01974557||57221|
NCT01967017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078756|Study of Local Anesthesia as a Method to Decrease IUD Insertion Related Pain|Paracervical Block With Lidocaine as a Modality to Decrease IUD Insertion Related Pain||Johns Hopkins University|No|Not yet recruiting|December 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|December 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967017||57799|
NCT01967563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130212|Study of the Effect of a Very-Low-Carbohydrate Diet on Energy Expenditure|Effect of a Eucaloric Ketogenic Diet on Energy Expenditure: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|September 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|5|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01967563||57757|
NCT01967576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140001|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|100 Years|No|||July 2015|October 22, 2015|October 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967576||57756|
NCT01967589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9926-3950|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|82|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967589||57755|
NCT01967862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13365|Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer|F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer||City of Hope Medical Center|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967862||57734|
NCT01968681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-066|Treatment of Nevus Flammeus With Alexandrite Laser|Treatment of Nevus Flammeus With Alexandrite Laser||Bispebjerg Hospital|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|10 Years|N/A|No|||February 2015|February 22, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968681||57671|
NCT01968915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCL161A1102|Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors|A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors||Novartis||Completed|November 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968915||57653|
NCT01968408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/125/2012|Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children|Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial||Medical University of Warsaw|Yes|Completed|September 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|184|||Both|1 Month|48 Months|No|||June 2015|June 17, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01968408||57692|
NCT01968694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002903|Effects of Intravenous Lidocaine on Endometriosis Pain|Effects of Intravenous Lidocaine on Endometriosis Pain||Brigham and Women's Hospital|No|Recruiting|December 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|50 Years|No|||October 2015|October 15, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968694||57670|
NCT01969188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12174|A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement|A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement||Hospital for Special Surgery, New York|No|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a confirmed diagnosis of spondloarthritis with axial involvement and no        biologic treatment in most recent three months (see inclusion criteria).|March 2015|March 17, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01969188||57632|
NCT01969201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13EU/FSH01|FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)|Randomised Clinical Trial Comparing Highly Purified FSH Formulation (Fostimon®) and Recombinant FSH (Gonal-F®) in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles.|FAST|IBSA Institut Biochimique SA|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|720|||Female|18 Years|38 Years|No|||February 2016|February 23, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01969201||57631|
NCT01977755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-031|Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Zealand Pharma|Yes|Completed|November 2013|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|591|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977755||56976|
NCT01977768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imm03|TB Immunotherapy Trial With Heat-killed M. Vaccae|Phase III and Dose Ranging Trial of Heat-killed M. Vaccae (V7)|imm03|Lisichansk Regional Tuberculosis Dispensary|No|Active, not recruiting|March 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|80 Years|No|||April 2015|April 16, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977768||56975|
NCT01973803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL 0030|Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC) for Osteoarthritis of the First Metacarpal Joint|||Articulinx|No|Enrolling by invitation|September 2013|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|40 Years|75 Years|No|Non-Probability Sample|Men and women with early stage carpometacarpal-1 (CMC-1 joint osteoarthritis who may seek        treatment at physician hand clinics and community general practitioner clinics.|October 2013|October 27, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973803||57279|
NCT01974076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC13276|Transcranial Direct Current Stimulation (tDCS) as an Adjunct to Cognitive Behaviour Therapy (CBT)|A Study of Transcranial Direct Current Stimulation (tDCS) as an Adjunct to Cognitive Behavioural Therapy (CBT) for Depression||The University of New South Wales|Yes|Recruiting|May 2014|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01974076||57258|
NCT01974089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-2|Dysphagia and Pneumonia|Dysphagia in Patients With Community Acquired Pneumonia||Vendsyssel Hospital|No|Recruiting|October 2013|April 2015|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974089||57257|
NCT01974362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-06|Monolithic Zirconia Full-Mouth Implant Supported Rehabilitation Behavior|Cad/Cam Monolithic Zirconia Behavior in Full-Mouth Implant Rehabilitation - Case-control Study||Instituto de Implantologia|No|Not yet recruiting|January 2014|January 2015|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from a dental office that did a full-mouth (bimaxillary - maxilla and mandible)        implant-supported rehabilitation and made the final rehabilitation of both jaws in either        monolithic zirconia or in feldspathic-zirconia|October 2013|October 26, 2013|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974362||57236|
NCT01975909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000233|Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia|Transcranial Magnetic Stimulation (TMS) in Spino-Cerebellar Ataxia|TMS|Beth Israel Deaconess Medical Center|No|Active, not recruiting|September 2013|October 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 12, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975909||57118|
NCT01974830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-10-04|AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry|AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry|AL1TER|Coram Clinical Trials|No|Recruiting|October 2013|October 2025|Anticipated|October 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with Alpha-1 anti-trypsin deficiency (any phenotype) on        augmentation therapy|November 2015|November 5, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01974830|5 Years|57200|
NCT01976143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-102-12|A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety|A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors||Nektar Therapeutics|No|Recruiting|February 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976143||57100|
NCT01974570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13TBHM|Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects|A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension||KGK Synergize Inc.|No|Completed|November 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|144|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974570||57220|
NCT01974804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-094|Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis|Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis||Memorial Sloan Kettering Cancer Center||Recruiting|October 2013|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The protocol investigators on the study will identify potential research participants from        those patients who are scheduled for MRI examination as part of their routine clinical        care.|January 2016|January 15, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974804||57202|
NCT01975051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-12057|A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)|A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|60 Years|No|||November 2012|November 3, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975051||57184|
NCT01968135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1702|Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study|Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study||University of Colorado, Denver|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968135||57713|
NCT01968148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|357/13/03/12/2012 § 205|Mechanisms of Ultra-acute Hyperglycemia After Successful Resuscitation From Out-of-hospital Cardiac Arrest|||Helsinki University Central Hospital|No|Recruiting|November 2013|||October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Successfully resuscitated patients treated by physician staffed mobile intensive care unit        in Helsinki area.|March 2015|March 17, 2015|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01968148||57712|
NCT01967602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103056RB|Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support|Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support|ARDS|National Taiwan University Hospital|No|Recruiting|October 2011|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Plasma, Cell, BALF, Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are admitted to National Taiwan University Hospital for acute respiratory        distress syndrome needing ECMO placement.|October 2013|October 22, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967602||57754|
NCT01967875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOG1301|A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer|A Prospective, Multi-Center, Randomized Control Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer||China Medical University, China|No|Recruiting|July 2013|May 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|65 Years|No|||October 2013|October 18, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01967875||57733|
NCT01967888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0112|Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation|A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation||Dompé Farmaceutici S.p.A|Yes|Recruiting|February 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967888||57732|
NCT01968161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS - Switch Asenapine|Investigator Initiated Study - Asenapine Early Psychosis|An Open-label Switch Study to Asenapine in the Early Stage of Psychosis||Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec|No|Not yet recruiting|October 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968161||57711|
NCT01968421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bronchiectasis-Gao001|Prevention of OM-85 on Bronchiectasis Exacerbation|To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients||Chinese Academy of Medical Sciences|No|Recruiting|March 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|244|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01968421||57691|
NCT01968707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-012760|In-vivo Efficacy Study of Patient Pre-operative Preps|Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions||3M||Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|510|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968707||57669|
NCT01968941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-LUSTRE|Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients|A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy|LUSTRE|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|February 2014|April 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968941||57651|
NCT01968928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308044RIN|The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma|The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma||National Taiwan University Hospital|No|Not yet recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|25|None Retained|Tissue samples of tumors as well as normal-appearing mucosa collected in the tissue bank are      to be used to examine the cellular and molecular events involved. Comparisons will be made      to differentiate cellular changes between tumors and the normal counterparts.|Both|20 Years|80 Years|No|Non-Probability Sample|patients with age between 20-80 years old and had taken Radical Cystectomy or nephrectomy        between 2008-2012 were chosen as study population.|October 2013|October 24, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01968928|1 Day|57652|
NCT01965171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIALS|Transfusional Iron Overload Among Leukemia Survivors|Transfusional Iron Overload Among Leukemia Survivors||St. Jude Children's Research Hospital|No|Recruiting|October 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|61|||Both|5 Years|N/A|No|Non-Probability Sample|Participants will have been treated at SJCRH for acute lymphoblastic leukemia (ALL) or        acute myeloid leukemia (AML) and would have received ≥50 ml/kg of packed red blood cells        during their treatment.|November 2015|November 16, 2015|October 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01965171||57940|
NCT01965431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.40|Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.|Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxifloxacin as Positive Control||Boehringer Ingelheim||Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|October 16, 2013||||No||https://clinicaltrials.gov/show/NCT01965431||57921|
NCT01977781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-067H|Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease|Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease||Massachusetts Eye and Ear Infirmary|No|Recruiting|December 2013|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01977781||56974|
NCT01977794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200006-524|Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension|A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg||Merck KGaA|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977794||56973|
NCT01977807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303|A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK|||Technolas Perfect Vision GmbH|No|Recruiting|August 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||May 2015|May 19, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977807||56972|
NCT01974843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZC-160|Caudal Block With Tramadol and Levobupivacaine or Bupivacaine|The Assessment of Bupivacaine-tramadol and Levobupivacaine-tramadol Combinations for Preemptive Caudal Anaesthesia in Children: a Randomized, Double-blind, Prospective Study||Duzce University|No|Completed|January 2011|January 2013|Actual|October 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|68|||Both|2 Years|7 Years|No|Probability Sample|ASA status I children aged 2 to 7 years who were scheduled for elective inguinal        herniorrhaphy or orchidopexy were enrolled.|February 2014|February 6, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01974843|1 Day|57199|
NCT01975103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPM-001|Endpoint Management Software for Photothermal Stimulation of Macular Diseases|Phase 2 Study of Endpoint Management Software for Photothermal Stimulation of Macular Diseases|EPM|Federal University of Rio Grande do Sul|No|Recruiting|March 2013|||November 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A||||December 2013|December 1, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975103||57180|
NCT01975389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481038|The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects|Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects|SPIRE-2|Pfizer|Yes|Active, not recruiting|October 2013|March 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|11000|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975389||57158|
NCT01975623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.262|Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy|Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing Using the HARMONIC ACE + Shears (HS) for VATS Lobectomy||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||May 2015|November 24, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975623||57140|
NCT01975935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00079381|Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients|Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics||University of Michigan|Yes|Recruiting|January 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975935||57116|
NCT01976416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012139|Novel Use Of Hydroxyurea in an African Region With Malaria|Novel Use Of Hydroxyurea in an African Region With Malaria|NOHARM|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|September 2014|December 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Months|47 Months|No|||May 2015|May 29, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976416||57079|
NCT01975077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-013-00CH3|Phase Ib Study of Fruquintinib in Patients With Metastatic Colorectal Carcinoma|A Randomized, Open-label Phase Ib Trial of Fruquintinib "4mg Once Daily Continuous"Versus "5mg Once Daily 3wks on/1wk Off" in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy||Hutchison Medipharma Limited|Yes|Completed|December 2012|October 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|70 Years|No|||November 2014|December 9, 2014|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975077||57182|
NCT01975350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303119MINB|Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia|Prospective Observation of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Tracheobronchitis/Pneumonia or Lower Respiratory Tract Colonization by Multidrug Resistant Gram-negative Bacteria||National Taiwan University Hospital|Yes|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|20 Years|N/A|No|Probability Sample|Patients in medical intensive care unit with ventilator use|October 2013|October 28, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01975350||57161|
NCT01975363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13034|Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer|Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Female|19 Years|N/A|No|||October 2015|October 24, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975363||57160|
NCT01967329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007868|CANHelp Working Group Treatment Trials|Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials||University of Alberta|No|Enrolling by invitation|November 2008|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|500|||Both|16 Years|N/A|No|||January 2015|January 8, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01967329||57775|
NCT01968460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2B001/001|Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease|A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease||Pharma Two B Ltd.|Yes|Active, not recruiting|December 2013|August 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|35 Years|75 Years|No|||February 2015|April 30, 2015|October 15, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01968460||57688|
NCT01968174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oculoplasticmeir001|Astigmatic Changes Secondary to Eyelid Surgeries|Astigmatic Corneal Changes Secondary to Eyelid Surgery||Meir Medical Center|Yes|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing eyelid surgery.|August 2014|August 11, 2014|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01968174|3 Months|57710|
NCT01968187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000114|Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome|||Ferring Pharmaceuticals|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|38|||Both|10 Years|18 Years|No|||July 2015|July 6, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968187||57709|
NCT01968720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2003-202|Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia|A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia||Catabasis Pharmaceuticals|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|74 Years|No|||July 2015|July 27, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968720||57668|
NCT01968954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481019|Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|SPIRE-HR|Pfizer|Yes|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968954||57650|
NCT01969227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001690|The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures|The Effects of Subanesthetic Ketamine on Respiratory Stimulation and Transpulmonary Pressures in Mechanically Ventilated Critically Ill Patients||Massachusetts General Hospital|No|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01969227||57629|
NCT01965457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdeQ|Assessment of Adenoidal Obstruction in Children : Clinical Signs Versus Flexible Nasal Endoscopy and Roentgenographic Findings|Assessment of Adenoidal Obstruction in Children : Clinical Signs Versus Flexible Nasal Endoscopy and Roentgenographic Findings||Carmel Medical Center|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|2 Years|18 Years|No|Probability Sample|Pediatric patients aged 2-18 with suspected adenoid hypertrophy|December 2015|December 20, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965457||57919|
NCT01969214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/015213|Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea|Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea||InQpharm Group|No|Recruiting|October 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01969214||57630|
NCT01965444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEM200-001|A Test of the Investigational SEM Scanner|An Investigational, Non-significant Risk Study to Collect Data Needed to Analyze Readings Given by the SEM Scanner Point of Care 200 Series (SEM POC 200) and Its Ability to Detect Sub Epidermal Moisture.||Bruin Biometrics, LLC|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Intensive Care Units|October 2013|December 23, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965444||57920|
NCT01974375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYC-LT-01|Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients|Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients|KOPIN|Asan Medical Center|Yes|Recruiting|August 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|172|||Both|20 Years|N/A|No|||October 2013|October 27, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01974375||57235|
NCT01975116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-041|p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors|A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors||Pediatric Brain Tumor Consortium|Yes|Active, not recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|3 Years|21 Years|No|||October 2015|October 19, 2015|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975116||57179|
NCT01975402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005607|Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population|Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population|R01-Aim2|Preventice|No|Active, not recruiting|November 2013|November 2015|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|N/A|No|Probability Sample|Individuals >50 years with Congestive Heart Failure|September 2014|October 19, 2015|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975402||57157|
NCT01975636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-005|An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects|An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects||Eisai Inc.|No|Completed|June 2013|March 2014|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|January 6, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975636||57139|
NCT01975649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTC|Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder|Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder||Federal University of Minas Gerais|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|50 Years|65 Years|No|||April 2015|April 2, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975649||57138|
NCT01975922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090904|Working on Rapid Language Development in Toddlers|An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders|WORLD|Vanderbilt University|No|Active, not recruiting|September 2009|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|24 Months|42 Months|Accepts Healthy Volunteers|||December 2014|December 8, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975922||57117|
NCT01975948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2014-150|Evaluation of a Mental Health Physician Support Program in Nova Scotia|Evaluation of a Mental Health Physician Support Program in Nova Scotia: Impact on Patient Outcomes and Stigmatization||Nova Scotia Health Authority|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|285|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01975948||57115|
NCT01976156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA180030|The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity|The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity|CIDO OEA|Yale University|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|168|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01976156||57099|
NCT01975090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI 036|The SENTRY Clinical Study|A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cava Filter|SENTRY|Novate Medical|Yes|Active, not recruiting|September 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|129|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975090||57181|
NCT01975376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481022|The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects|Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.|SPIRE-1|Pfizer|Yes|Recruiting|October 2013|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|17000|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975376||57159|
NCT01975597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.053|Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer|Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer||University of Michigan Cancer Center|Yes|Recruiting|August 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|21 Years|N/A|No|||November 2015|November 6, 2015|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975597||57142|
NCT01968200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S701/412|Prevention of Anthracycline-induced Cardiotoxicity|ICOS-ONE - Prevention of Anthracycline-induced Cardiotoxicity: a Multicentre Randomized Trial Comparing Two Therapeutic Strategies.|ICOS-ONE|European Institute of Oncology|No|Active, not recruiting|December 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01968200||57708|
NCT01968759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSWER|Sevelamer in Proteinuric CKD|A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment|ANSWER|Mario Negri Institute for Pharmacological Research|No|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01968759||57665|
NCT01968434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-13-00|Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.|Randomized, Single Blind, Multicenter Study to Evaluate the Efficacy and Tolerability of Syr. Grintuss Pediatric and Syr. Mucolit in Cough Due to Upper Respiratory Tract Infection in Children|URTI|Clalit Health Services|No|Completed|December 2013|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|2 Years|5 Years|No|||October 2015|October 5, 2015|October 17, 2013||No||No|May 14, 2015|https://clinicaltrials.gov/show/NCT01968434||57690|
NCT01968447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45461.058.13|Effect of Deep Neuromuscular Block and Variations in Arterial PCO2 on the Surgical Rating Scale (SRS), Following Reversal With Sugammadex|Effect of Deep Neuromuscular Block and Variations in Arterial PCO2 on the Surgical Rating Scale (SRS), Extubation Conditions and Postoperative Conditions Following Reversal With Sugammadex|BLISSS 2|Leiden University Medical Center|Yes|Completed|February 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01968447||57689|
NCT01968733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-301|Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia|SOLITAIRE-IV|Cempra Inc|Yes|Completed|November 2013|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|863|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968733||57667|
NCT01968967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481020|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events|A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|SPIRE-LDL|Pfizer|Yes|Recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1932|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968967||57649|
NCT01965470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6475|Botswana Combination Prevention Project|Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana|BCPP|Centers for Disease Control and Prevention|Yes|Enrolling by invitation|October 2013|||October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|16 Years|64 Years|No|||February 2015|October 9, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965470||57918|
NCT01965184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102012121C|Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents|Using CBT to Examine Circuitry of Frustrative Non-reward in Aggressive Children|RDoC-CBT|Yale University|Yes|Recruiting|October 2013|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|8 Years|16 Years|No|||July 2014|July 7, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01965184||57939|
NCT01974856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-00172|A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay|A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies, Inc. Breast Cancer Intrinsic Subtype Test||NanoString Technologies, Inc.|No|Completed|October 2013|June 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|Samples With DNA|FFPE samples from breast tumor tissue|Female|N/A|N/A|No|Probability Sample|Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women        who meet the entry criteria.|September 2015|September 14, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974856||57198|
NCT01975129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYPEP003|A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin|A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women With Vaginal Atrophy||PeP-Tonic Medical AB|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975129||57178|
NCT01975415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 - 6251|Digital Medicine in Meditation|Digital Medicine in Meditation|DigMed2|Scripps Translational Science Institute|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this study will be a subset of 40 individuals from a total of ~200 who        self-selected to participate in a week-long "Seduction of Spirit" retreat at The Chopra        Center in the La Costa Resort in Carlsbad, CA. The 40 anticipated participants will be        made up of 2 cohorts: experienced meditators and novice meditators.|March 2014|March 12, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01975415||57156|
NCT01975688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP10115|A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis|An Open-label Clinical Trial to Compare the Pharmacokinetics of up to 4 Single Oromucosal Doses of 4 Sprays of Sativex® in Patients With Treatment Induced Mild, Moderate and Severe Oral Mucositis (Grade 1 - 3 RTOG Oral Mucositis) With Their Pharmacokinetic Profile Pre-treatment (When Mucositis-free)||GW Pharmaceuticals Ltd.|No|Terminated|January 2014|November 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|October 29, 2013||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01975688||57135|
NCT01975662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIDI-MRSA-001|Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia|A Multi-centre Open Label Randomized Controlled Phase IIB Trial Comparing Vancomycin Versus Daptomycin for the Treatment of MRSA Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations||Singapore General Hospital|Yes|Recruiting|January 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||February 2014|February 2, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975662||57137|
NCT01975675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0113|Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection|A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|No|Completed|October 2013|August 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|341|||Both|20 Years|N/A|No|||June 2015|June 4, 2015|October 29, 2013|Yes|Yes||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01975675||57136|
NCT01969305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0841|Youth Drug Abuse Prevention in Kazakhstan|A Computerized Family-Based Youth HIV and Drug Abuse Prevention in Kazakhstan||University of Chicago|No|Active, not recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|248|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|July 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01969305||57623|
NCT01969318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2086-202|Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|March 2012|November 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Both|20 Years|70 Years|No|||October 2013|October 21, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969318||57622|
NCT01954511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1139-4055|Manual Therapy and Exercises Applied to Cervical Spine in Patients With Temporomandibular Disorders|Effects of Manual Therapy and Exercises Applied to Cervical Spine in Patients With Temporomandibular Disorders: Pilot Study||Universidade Federal de Sao Carlos|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01954511||58758|
NCT01954524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00057016|A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis|A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis||University of Maryland|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954524||58757|
NCT01955304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-013-00CH2|Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects|A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects||Hutchison Medipharma Limited|Yes|Completed|June 2012|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|September 28, 2013|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01955304||58697|
NCT01955317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13023|Waterless Hand Cleansing With Chlorhexidine During the Perinatal Period|Waterless Hand Cleansing With Chlorhexidine During the Perinatal Period||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|November 16, 2015|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01955317||58696|
NCT01955863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OORP-2011|Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations|Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations - Open Label Randomized Pilot Study|ORP-SAC|Barretos Cancer Hospital|No|Completed|March 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Male|40 Years|75 Years|No|||January 2016|January 13, 2016|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01955863||58654|
NCT01956084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCI2|Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma|ADMINISTRATION OF LMP-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH RELAPSED EBV-POSITIVE LYMPHOMA|ALCI2|Children's Research Institute|Yes|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|N/A|No|||August 2015|August 26, 2015|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956084||58637|
NCT01952119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-11AKuo-01|Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System|Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care Delivery System||Kaiser Permanente||Completed|October 2011|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|182|||Both|18 Years|75 Years|No|||September 2013|September 24, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952119||58942|
NCT01952132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS824-SCZ-001|Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects|Phase 2 Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects||Omeros Corporation|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|No|||August 2014|August 13, 2014|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952132||58941|
NCT01952145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3952|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)|DUAL™ V|Novo Nordisk A/S|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|557|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952145||58940|
NCT01952418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013p001462|Effect of Video Monitor Size on Adenoma Detection Rate|Effect of Video Monitor Size on Adenoma Detection Rate||Massachusetts General Hospital|No|Recruiting|October 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|25 Years|80 Years|No|||September 2014|September 16, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01952418||58919|
NCT01952431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulmOne-1.0|Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)|Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)||PulmOne Advanced Medical Devices, Ltd.|Yes|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|November 9, 2014|June 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952431||58918|
NCT01953211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hormone free interval|Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity|LH, FHS, Estradiol and Progesterone Activity During the 7-Day Hormone-Free Interval of Various Combined Oral Contraceptive Regimens||University of Southern California|Yes|Completed||||December 1998|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|18 Years|35 Years||Probability Sample|Healthy, reproductive age women 18 to 35 years old, who were seeking contraception from        the general gynecology clinics of the LAC and USC Medical Center were recruited. The        research team identified potential candidates who were taking one of 6 possible monophasic        COC formulations. Informed consent was obtained from participants by the research staff.        To be eligible for participation, women reported regular menstrual cycles prior to COCs,        and had taken at least 3 cycles of the same monophasic COC prior to enrollment.|September 2013|September 25, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01953211||58858|
NCT01953224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0285|STEP AND GO: A Study of Technology-based Exercise Promotion|STEP AND GO: A Study of Technology-based Exercise Promotion and Gaming Outcomes||The University of Texas Medical Branch, Galveston|No|Recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01953224||58857|
NCT01966302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Compassionate use BPS-314d-MR|Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)|Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH).||Los Angeles Biomedical Research Institute|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|75 Years|No|||May 2015|May 27, 2015|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966302||57854|
NCT01966588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00513|Adverse Events and Genomics in Schizophrenia|Genomic Biomarkers of Adverse Events Arising From Antipsychotic Drug Therapy|AEGIS|University of British Columbia|No|Recruiting|June 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|We will be collecting and retaining whole blood samples for genomic testing.|Both|N/A|N/A|No|Non-Probability Sample|Individuals taking antipsychotic medications (in- or outpatients)|November 2015|November 30, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01966588|3 Months|57832|
NCT01966601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP027.2002|A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure|BLAST-AHF|Trevena Inc.|Yes|Recruiting|December 2013|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|620|||Both|21 Years|85 Years|No|||September 2015|September 9, 2015|September 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966601||57831|
NCT01966614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302-3-01|Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH|Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of a Single Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (The PLUS 1 Trial)|PLUS-1|Sophiris Bio Corp|Yes|Active, not recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Male|50 Years|N/A|No|||September 2014|September 2, 2014|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966614||57830|
NCT01967667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056458|Biological Evaluation of Dietary Supplement Liposomal Glutathione|Biological Evaluation of Dietary Supplement Liposomal Glutathione||University of Maryland|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|25|||Both|18 Years|60 Years|No|||March 2015|March 4, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967667||57749|
NCT01967680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130025|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation. The NONSEDA-trial. An Investigator-initiated, Randomised, Clinical, Parallel-group, Multinational, Superiority Trial|NONSEDA|Odense University Hospital|Yes|Recruiting|January 2014|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967680||57748|
NCT01967693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ_04_04_2012|Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy|Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy||University of Zurich|No|Completed|March 2008|August 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|42|||Both|18 Years|90 Years|No|Probability Sample|Former patients with laryngeal contact granuloma who were treated in this hospital.|October 2013|October 17, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967693||57747|
NCT01967446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814338|Predictors of Post Operative Morbidity in Older Women With Pelvic Organ Prolapse|Predictors of Post Operative Morbidity in Older Women With Pelvic Organ Prolapse||University of Pennsylvania|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|132|||Female|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women will be recruited from 3 sites in the University of Pennsylvania Health System: 1)        the Division of Urogynecology (OB/GYN) at Hospital of University of Pennsylvania (HUP) 2)        the Division of Urogynecology (OB/GYN) at Pennsylvania Hospital (PAH) and 3) Division of        Urology (Surgery) at Pennsylvania Hospital (PAH). Approximately 60 women age 60 or over        undergo surgery for POP at HUP and 45 each in Urogynecology and Urology at PAH each year.        This yields an eligible population of more than 150 women during the 1.25-year proposed        recruitment period. We anticipate that interest in the study will be high because the        study is investigating post-operative recovery and no invasive testing is planned.|August 2012|December 8, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01967446||57766|
NCT01967992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11813|Examining the Effects of Diet on Health With an Online Program|Examining the Effects of Diet on Health With an Online Program||University of California, San Francisco|No|Completed|October 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|100 Years|No|||October 2015|October 12, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967992||57724|
NCT01968265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 426115-CS2|Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes|A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin||Ionis Pharmaceuticals, Inc.|No|Completed|October 2013|May 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||May 2015|May 11, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01968265||57703|
NCT01969045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-103|Effect of the EnkFiberoptic Atomizer Set on Usage of Anaesthetics During the Bronchoscopy|Effect of the EnkFiberoptic Atomizer Set on Usage of Anaesthetics During the Bronchoscopy|EnkAtomizer|RWTH Aachen University|No|Completed|February 2014|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|85 Years|No|||February 2016|February 17, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969045||57643|
NCT01969058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5325|Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery|A Prospective Randomized Controlled Study to Evaluate the Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery on Suppressive Antiretroviral Therapy (ART)||AIDS Clinical Trials Group|Yes|Recruiting|July 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Both|18 Years|80 Years|No|||January 2016|January 22, 2016|August 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969058||57642|
NCT01969331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGL/02/09|Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori|An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori||University Hospital Rijeka|No|Completed|December 2008|December 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|804|||Both|16 Years|N/A|No|||October 2013|October 21, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01969331||57621|
NCT01955031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 424 03|Effectiveness and Cost-effectiveness of a Telemonitoring Program for Diabetic People at Home|Effectiveness and Cost-effectiveness Analysis of a Telemonitoring Program on Lifestyle for People With Type 2 Diabetes at Home. Study Based on a Health Network in Diabetology.|EDUC@DOM|University Hospital, Toulouse|Yes|Recruiting|November 2013|September 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|282|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01955031||58718|
NCT01955044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJN 8662|PUFA Supplementation in Premature Infants|Early DHA Supplementation in Extremely Low Birth Weight Infants||NorthShore University HealthSystem Research Institute|Yes|Active, not recruiting|September 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||February 2015|February 9, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955044||58717|
NCT01955655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSCPSQ|Recurrent Crying Spells in Cerebral Palsy|Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study|RCSCPSQ|Sathbhavana Brain Clinic|Yes|Completed|December 2005|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|N/A|12 Years|No|||October 2013|October 6, 2013|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01955655||58670|
NCT01955876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16626|Fosrenol Post-marketing Surveillance in Japan|Drug Use Investigation of Fosrenol for Hyperphosphatemia With Chronic Kidney Disease Not on Dialysis||Bayer|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Chronic renal failure patients who have not been treated with dialysis and will be treated        with Fosrenol for hyperphosphatemia|February 2016|February 24, 2016|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01955876||58653|
NCT01952171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913207|The Genetic Basis of Congenital Heart Disease in Africa|The International Genetic Basis of Congenital Heart Disease Study||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|March 9, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952171||58938|
NCT01952184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/777|Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage.|Oocyte Survival After Vitrification in an Open or Closed Commercial Device: Study on Sibling Donor Oocytes.||Universitair Ziekenhuis Brussel|No|Completed|September 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952184||58937|
NCT01952470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342/13|Preliminary Study of Dornase Alpha to Treat Chest Infections Post Lung Transplant.|Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.||The Alfred|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01952470||58915|
NCT01952704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-687-11|Aerobic Exercise to Improve Memory in TBI|A Randomized Controlled Trial of Aerobic Exercise to Improve Memory in TBI||Kessler Foundation|Yes|Not yet recruiting|October 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|No|||September 2013|September 30, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952704||58897|
NCT01952717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-006|PMA Required Pivotal Multi-reader Multi-case Reader Study|A Multi-Reader Multi-Case Clinical Trial To Evaluate Diagnostic Accuracy of 3D Koning Breast CT Compared to 2D Diagnostic Mammography||Koning Corporation|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|236|||Female|35 Years|N/A|No|Probability Sample|This study will involve 18 readers reading and scoring the conventional 2D diagnostic        mammograms and the 3D KBCT images of 236 cases.|March 2015|March 10, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952717||58896|
NCT01952730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-436|GVAX for Colorectal Cancer|A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor||Massachusetts General Hospital|Yes|Recruiting|July 2013|July 2025|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|April 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952730||58895|
NCT01953263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00025341|Muscle Fiber Fragment Treatment for Urinary Incontinence|A Phase 1 Study of Human Muscle Fiber Fragment (MFF) Treatment for Urinary Incontinence||Wake Forest School of Medicine|Yes|Not yet recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|75 Years|No|||September 2013|September 25, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953263||58854|
NCT01953510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/19|Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam|Evaluation of Different Infant Vaccination Schedules Incorporating Pneumococcal Vaccination||Menzies School of Health Research|No|Recruiting|September 2013|December 2016|Anticipated|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|1400|||Both|60 Days|74 Days|Accepts Healthy Volunteers|||February 2016|February 2, 2016|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953510||58835|
NCT01966627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104008388|Genetics of Fatty Liver Disease in Children|Genetics of Fatty Liver Disease in Childhood Obesity.||Yale University|No|Recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Serum|Both|7 Years|18 Years|No|Non-Probability Sample|The majority of the research subjects will be recruited from the Yale Pediatric Obesity        Clinic and the Endocrine Clinic.|March 2015|March 16, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01966627||57829|
NCT01966874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation|Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation||Gynuity Health Projects|Yes|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women at the study clinics who want medical abortion and meet eligibility        criteria.|October 2013|October 17, 2013|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966874||57810|
NCT01967147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-027|Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects|Evaluation of Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects With Lipid Deficiency||Alcon Research|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 18, 2013||No||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01967147||57789|
NCT01968278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39/12 Asaf|Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients|||Assaf-Harofeh Medical Center||Recruiting|January 2013|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|30 Years|No|||October 2013|October 20, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01968278||57702|
NCT01968005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-7EAT-1009|Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of Etoreat®(Etodolac-Lidocaine Topical Patch) in the Treatment of Acute Low Back Pain||MEDRx USA, Inc.|No|Completed|November 2013|||May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|232|||Both|14 Years|N/A|No|||December 2013|May 6, 2014|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968005||57723|
NCT01968525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199987|The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients|The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients||Fudan University|Yes|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|45|||Female|18 Years|45 Years|No|||October 2013|October 18, 2013|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01968525||57683|
NCT01968551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0119|Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults|A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults||Gilead Sciences|Yes|Active, not recruiting|September 2013|April 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968551||57681|
NCT01969097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MotorCtx-Stroke-tDCS|Efficacy Basics of Bihemispheric Motorcortex Stimulation After Stroke|Efficacy Basics of Bihemispheric Motorcortex Stimulation After Stroke||Charite University, Berlin, Germany|No|Completed|May 2012|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01969097||57639|
NCT01968798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3U01AG029824-02S1|ASPREE Cancer Endpoints Study|ASPREE Cancer Endpoints Study|ACES|Minneapolis Medical Research Foundation|Yes|Enrolling by invitation|September 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|14500|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968798||57662|
NCT01968811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avance A01|Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen|A Multi-Centre, Post CE Mark, Open Clinical Investigation to Evaluate an Abdominal NPWT (Negative Pressure Wound Therapy) System (Avance® Pump and Avance® Foam Abdominal Dressing Kit) in Subjects With Open Abdominal Wounds||Molnlycke Health Care AB|No|Completed|November 2013|||March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01968811||57661|
NCT01969071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No: 2013.2/1|The Effects of Levosimendan During Mitral Valve Surgery|The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery.||Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|Yes|Completed|July 2009|September 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|30 Years|80 Years|No|||September 2013|October 23, 2013|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01969071||57641|
NCT01969084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000057|The Effect of Linagliptin on Mitochondrial and Endothelial Function|||Beth Israel Deaconess Medical Center|No|Recruiting|October 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|70 Years|No|||November 2015|November 12, 2015|August 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01969084||57640|
NCT01965886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALGUSKNEE|Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: a Randomized Clinical Trial|Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: Prospective and Randomized Clinical Trial|ValgusKnee|University of Sao Paulo General Hospital|No|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|N/A|N/A|No|||October 2013|January 5, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965886||57886|
NCT01955642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208094|Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke|Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke : Role of Platelet alpha2-adrenergic Receptors|AAPIX|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|91|Samples With DNA|Blood DNA|Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as        usual indications|December 2015|December 30, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955642||58671|
NCT01956123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000071|Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2|A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme|ESTHER-2|Ferring Pharmaceuticals|No|Active, not recruiting|October 2013|December 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|513|||Female|18 Years|40 Years|No|||October 2015|October 23, 2015|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956123||58634|
NCT01952509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28747|A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis|Multinational, Multicenter, Non Interventional Study, in Patients With Rheumatoid Arthritis (RA) Treated With Tocilizumab.||Hoffmann-La Roche||Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|169|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis initiating treatment with        RoActemra/Actemra in accordance with the local label|March 2016|March 1, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01952509||58912|
NCT01952743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009062|Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation|Concomitant Renal Denervation Therapy in Hypertensive Patients Undergoing Atrial Fibrillation Ablation - A Feasibility Study||Mayo Clinic|No|Terminated|September 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|September 23, 2013|No|Yes|Lack of efficacy with renal denervation in multicenter trials|No||https://clinicaltrials.gov/show/NCT01952743||58894|
NCT01952483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.SK1.04|Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients|Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients||American University of Beirut Medical Center|No|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|86|Samples Without DNA|We will focus on proliferation and cytokine production to myelin basic protein (MBP) and      myelin oligodendrocyte glycoprotein (MOG) peptides and on the percentage of Th1 (IFN gamma      producing cells) and Th17 (IL-17 producing cells) during in vitro polarization assays|Both|18 Years|N/A|No|Non-Probability Sample|Group 1: low vitamin D (less than 25 ng/ml) Group 2: normal vitamin D level (greater than        35 ng/ ml)|September 2013|September 25, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01952483|3 Months|58914|
NCT01953003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 311 B0|Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Multicenter, Randomised, Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously||Pierre Fabre Medicament|No|Recruiting|September 2013|December 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|334|||Female|21 Years|80 Years|No|||September 2013|September 25, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01953003||58874|
NCT01950325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130189|VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...|VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected Adults||National Institutes of Health Clinical Center (CC)||Completed|August 2013|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|70 Years|No|||August 2015|August 22, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950325||59079|
NCT01953523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSN111|Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions|Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.||Cell Surgical Network Inc.|Yes|Recruiting|March 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01953523||58834|
NCT01953536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-004|Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)|A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects With Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection||Endocyte|No|Withdrawn|April 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953536||58833|
NCT01967186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIK01|Intraportal or Intramuscular Site for Islets in Simultaneous Islet and Kidney Transplantation|Open Multi-Center Randomized Study to Compare Safety and Efficacy of Islet Transplantation Using The Intraportal or Intramuscular Site in Simultaneous Islet and Kidney Transplantation||The Nordic Network For Clinical Islet Transplantation|Yes|Active, not recruiting|April 2007|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01967186||57786|
NCT01967459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44804.101.13|Effects Vitamin D Suppletion on Postprandial Leukocyte Activation|Effects of High and Low Dose Vitamin D Suppletion on Postprandial Leukocyte Activation, Oxidative Stress and Vascular Function in Healthy Overweight and Obese Females|DOSFEM|Sint Franciscus Gasthuis|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967459||57765|
NCT01968018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013510|A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain|A Study of Safety and Efficacy of Ultracet in Patients With Chronic Cancer Pain||Janssen-Cilag Ltd.,Thailand|No|Completed|July 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01968018||57722|
NCT01968031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-014|A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease|A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease|KW-6002|Kyowa Hakko Kirin Pharma, Inc.|No|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|609|||Both|30 Years|N/A|No|||November 2015|November 13, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968031||57721|
NCT01968291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206011|Use of Teach Back to Improve Comprehension of Discharge Instructions for Emergency Patients With Limited Health Literacy|The Impact of Teach-back on Comprehension of Discharge Instructions Among Emergency Patients With Limited Health Literacy: A Randomized, Controlled Study||Washington University School of Medicine|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|254|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01968291||57701|
NCT01968538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-096|Prostate Metabolomic Study|A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy||Georgetown University|No|Enrolling by invitation|January 2009|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Specimen:For future Research Optional Destruction if requested identifiable Urine yes no yes      no Sputum yes no yes no Blood yes no yes no|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200 prostate cancer patients vs. 200 healthy men|August 2015|August 27, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01968538||57682|
NCT01969110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPIPD|Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy||Chiba University|Yes|Recruiting|January 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2013|October 24, 2013|October 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969110||57638|
NCT01968824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02386|Brachial Plexus Block in Post-Op Pain Control After Distal Upper Extremity Fracture: A Prospective Randomized Study|Efficacy of Brachial Plexus Block in Post-Operative Pain Control After Distal Upper Extremity Fracture: A Prospective Randomized Study||New York University School of Medicine|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968824||57660|
NCT01965340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 195/13|Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission|||University of Lausanne Hospitals|Yes|Recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01965340||57928|
NCT01965353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-262|A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma|A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma|PanRVD|Dana-Farber Cancer Institute|Yes|Recruiting|October 2013|August 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965353||57927|
NCT01965574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.783|Preload Dependence During Prone Position In ARDS Patients|Evaluation of Performance Diagnosis of Hemodynamic Parameters of Preload Dependence in ARDS Patients During Prone Position|PRD-ARDS-PP|Hospices Civils de Lyon|No|Recruiting|October 2013|||October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965574||57910|
NCT01966718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATC 005|Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.|Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action||Arthritis Treatment Center, Maryland|No|Recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||July 2015|July 31, 2015|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966718||57822|
NCT01955356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306-C-119-CV/IVI Valencia|Embryo Implantation After Induced Endometrial Injury|Evaluation of Induced Endometrial Injury in the Subsequent IVF Cycle.||Instituto Valenciano de Infertilidad, IVI VALENCIA|Yes|Recruiting|October 2013|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|19 Years|44 Years|No|||October 2013|March 23, 2015|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01955356||58693|
NCT01955369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.253.09|Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate|Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate||Klinikum Ludwigshafen|Yes|Active, not recruiting|October 2009|September 2015|Anticipated|September 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|residents of the state of Rhineland-Palatinate, Germany (4 million inhabitants)|April 2015|April 21, 2015|September 28, 2013||No||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01955369|3 Years|58692|
NCT01952210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205017RIC|Effectiveness of a Nutritional Consultation and Exercise Program in Esophageal Cancer Patient|The Effectiveness of a Nutritional Consultation and Exercise Program in Esophageal Cancer Patient Receiving Neoadjuvant Chemoradiation.||National Taiwan University Hospital|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|56|||Both|20 Years|90 Years|No|||April 2014|April 22, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952210||58935|
NCT01949324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTMT-02|A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel|A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)||Neurotech Pharmaceuticals|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|68|||Both|21 Years|80 Years|No|||August 2015|August 27, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949324||59156|
NCT01949532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ001|Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease|An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease||Onyx Pharmaceuticals|No|Active, not recruiting|October 2013|October 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|September 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949532||59140|
NCT01952496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15994|Load Experienced While Using a Stander in Children With Cerebral Palsy|Load Experienced While Using a Stander in Children With Cerebral Palsy||Gillette Children's Specialty Healthcare|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|17 Years|No|||February 2016|February 15, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01952496||58913|
NCT01950312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052180|The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease|An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease||XOMA (US) LLC|Yes|Completed|August 2013|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950312||59080|
NCT01950338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 52/2012|Deep Dry Needling for the Management of Post-stroke Spasticity|CHANGES IN SPASTICITY, WIDESPREAD PRESSURE PAIN SENSITIVITY, AND BAROPODOMETRY AFTER DRY NEEDLING IN STROKE PATIENTS||Universidad Rey Juan Carlos|Yes|Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||October 2013|October 28, 2013|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950338||59078|
NCT01950351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1003|Hypofractionated Proton Beam Therapy for Localized Prostate Cancer|Phase II Trial of Hypofractionated Proton Beam Therapy in Men With Localized Prostate Adenocarcinoma||M.D. Anderson Cancer Center|No|Recruiting|October 2013|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Male|18 Years|N/A|No|||October 2015|October 19, 2015|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950351||59077|
NCT01967706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHM-PK-05-JP|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Gum.||Philip Morris Products S.A.|No|Completed|August 2013|May 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|73|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|October 18, 2013||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01967706||57746|
NCT01967719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHM-PK-06-US|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)|A Single-center, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Menthol Following Single Use in Smokers Compared to Menthol Conventional Cigarettes and Nicotine Nasal Spray||Philip Morris Products S.A.|No|Completed|October 2013|May 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|62|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967719||57745|
NCT01968057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14605|A Study of Baricitinib and Ciclosporin in Healthy Participants|A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968057||57719|
NCT01968304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/18|Prospective Evaluation of Iron Status in Cancer Patients Beginning Chemotherapy|Prospective Evaluation of Iron Status in Cancer Patients Beginning Chemotherapy|CANFER|Centre Antoine Lacassagne|Yes|Recruiting|September 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|480|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968304||57700|
NCT01968564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6398|Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular Function|Clinical Translation of Curcumin Therapy to Treat Arterial Aging||University of Colorado, Boulder|Yes|Active, not recruiting|June 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|118|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|October 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968564||57680|
NCT01968577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBAM-120758|Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention|Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention|CLEAR-PCI|University of Sao Paulo|No|Recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|528|||Both|18 Years|N/A|No|||October 2013|October 19, 2013|October 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968577||57679|
NCT01968837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1545-12|The Kilimanjaro Cervical Screening Project|The Kilimanjaro Cervical Screening Project|KCCP|Queen's University|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|300|||Female|25 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01968837||57659|
NCT01977937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009681|Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin|Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction||Oregon Health and Science University|Yes|Recruiting|November 2013|||November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|10 Years|19 Years|No|||April 2015|April 20, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977937||56962|
NCT01969344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0048|Study of COPD Subgroups and Biomarkers|Subpopulations and Intermediate Markers in COPD Study|SPIROMICS|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|November 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|3200|Samples With DNA|Whole blood, serum, plasma, urine, lung biopsies, lung bronchial wash and lavage fluid, oral      rinse and tongue scrapping, and sputum|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Never-smokers, current and former smokers without COPD, and current and former smokers        with COPD with access to one of the study clinical centers.|December 2015|December 3, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01969344||57620|
NCT01969357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-SP-201|A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|June 2011|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|200|||Both|20 Years|70 Years|No|||October 2013|October 21, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969357||57619|
NCT01966432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043463_1|Screening, Brief Intervention, and Referral to Treatment in Primary Care|Screening, Brief Intervention, and Referral to Treatment in Primary Care (SBIRT-PC): An add-on Project to "Duke University Southeastern Diabetes Initiative"|SBIRT-PC|Duke University|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|May 28, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966432||57844|
NCT01966731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-4221|Realizing Effectiveness Across Continents With Hydroxyurea (REACH)|Realizing Effectiveness Across Continents With Hydroxyurea (REACH): A Phase I/II Pilot Study Of Hydroxyurea For Children With Sickle Cell Anemia|REACH|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2014|January 2020|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|1 Year|10 Years|No|||February 2016|February 25, 2016|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966731||57821|
NCT01955889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-SAR-635|Mobile Health Technology to Promote Physical Activity in Persons With Parkinson Disease|Mobile Health Technology to Promote Physical Activity in Persons With Parkinson Disease||Boston University|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|100 Years|No|||October 2015|October 5, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955889||58652|
NCT01948973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-170-13, JLF|Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome|A Randomised, Controlled Crossover Study of Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome||University of Aarhus|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||November 2014|November 10, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01948973||59183|
NCT01948986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-009|Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)|A Phase 1, Non-Randomized, Open-Label, Single Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|September 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948986||59182|
NCT01949337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031201|Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer|Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer||Alliance for Clinical Trials in Oncology|Yes|Recruiting|January 2014|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1224|||Male|18 Years|N/A|No|||September 2015|September 18, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01949337||59155|
NCT01949545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ002|Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment|An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment||Onyx Pharmaceuticals|No|Completed|October 2013|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|47|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949545||59139|
NCT01949558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIV 2011-0193|Randomized Controlled Trial of Lifestyle Intervention Postpartum in Primary Health Care|From Efficacy to Effectiveness: Randomized Controlled Trial of Lifestyle Intervention Postpartum Among Overweight and Obese Women Within Primary Health Care in the Vastra Gotaland Region|LIV|Göteborg University|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Female|N/A|N/A|No|||January 2016|January 7, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949558||59138|
NCT01950052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH12-109|Pre-operative Diet: Effect of Wound Healing After Bariatric Surgery|Randomised Controlled Trial to Study the Effects of Preoperative Very Low Calorie Diet on Wound Healing in Morbidly Obese Patients Undergoing Bariatric Surgery||King's College Hospital NHS Trust|No|Recruiting|November 2012|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||September 2013|September 24, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01950052||59100|
NCT01950078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gene and Pain|The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population|The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population||Huazhong University of Science and Technology|Yes|Completed|August 2013|December 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1533|Samples With DNA|Heparin anti-coagulated blood (5 ml) was collected from the periphery venous of subjects and      all blood samples were stored at -80℃. Genomic DNA was extracted from the blood samples      using a guanidinium isothiocyanate method.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|anticipative 500 healthy volunteers and 1000 surgical patients|February 2015|February 12, 2015|September 23, 2013||No||No|January 30, 2015|https://clinicaltrials.gov/show/NCT01950078||59098|
NCT01967472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-ACT-01|Adherence to Antimalarial Drugs in Sierra Leone|Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone||London School of Hygiene and Tropical Medicine|No|Recruiting|September 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|792|||Both|6 Months|59 Months|No|||October 2013|October 18, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967472||57764|
NCT01967485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-002161|Text Messaging Adherence to Stimulant Medication|Text Messaging Adherence to Stimulant Medication||Massachusetts General Hospital|No|Active, not recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|35|||Both|6 Years|17 Years|No|||March 2016|March 18, 2016|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967485||57763|
NCT01977092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034973-01A1|Reducing Offenders' HIV Risk: MI Enhanced Case Management With Drug-Free Housing|Reducing Offenders' HIV Risk: MI Enhanced Case Management With Drug-Free Housing||Public Health Institute, California|Yes|Enrolling by invitation|January 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 15, 2014|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01977092||57027|
NCT01977352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0064|Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery|Comparison of Cumulative Opioid Consumption After Interscalene Brachial Plexus Block With Liposomal Bupivacaine (Exparel; 88 mg in 20 cc) Versus Bupivacaine 0.25% for Arthroscopic Shoulder Surgery||St. Luke's-Roosevelt Hospital Center|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|17 Years|N/A|Accepts Healthy Volunteers|||February 2015|June 2, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977352||57007|
NCT01977365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSSOOO1|Effectiveness of Child Centered Counseling on Child Nutrition Status|Effectiveness of Child Centered Counseling on Child Nutrition Status. A Cluster Randomized Trial in Rural Burkina Faso.|LUCOMAI|Institut de Recherche en Sciences de la Sante, Burkina Faso|Yes|Completed|February 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2341|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2013|November 5, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977365||57006|
NCT01977664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|In Vitro Maturation Induction of Oocytes From a Woman With Syndrome of Repeated Oocyte Maturation Failure in Vitro|The Factors Primarily Intrinsic to the Oocyte Are Responsible to the Oocyte Maturation Defective: a Case Report.||The Second Affiliated Hospital of Kunming Medical University|Yes|Completed|March 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1|||Female|32 Years|32 Years|No|Non-Probability Sample|a patient with repeated oocyte maturation failure in IVF cycles|October 2013|November 6, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01977664||56983|
NCT01965899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reveal LINQ Usability Study|Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System|Reveal LINQ Usability Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|September 2013|December 2015|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|151|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965899||57885|
NCT01965912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700773-002|Kuvan®'s Effect on the Cognition of Children With Phenylketonuria|A Phase 4 Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children With Phenylketonuria Treated With Sapropterin Dihydrochloride (Kuvan®) for 7 Years|KOGNITO|Merck KGaA||Recruiting|October 2013|December 2022|Anticipated|November 2022|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|4 Years|5 Years|No|||August 2015|August 11, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965912||57884|
NCT01973972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-053|Jump Starting Shared Medical Appointments for Diabetes With Weight Management|Jump Starting Shared Medical Appointments for Diabetes With Weight Management||VA Office of Research and Development|Yes|Enrolling by invitation|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|308|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01973972||57266|
NCT01966445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117158|Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors|A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors||GlaxoSmithKline|No|Recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|155|||Both|18 Years|N/A|No|||October 2015|November 12, 2015|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01966445||57843|
NCT01948427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-014|Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)|Long-Term Registry of Patients With Urea Cycle Disorders (UCDs)|THRIVE|Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Recruiting|September 2013|September 2026|Anticipated|September 2026|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a confirmed or suspected diagnosis of UCD|February 2016|February 1, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01948427|10 Years|59225|
NCT01956136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141106|Efficacy and Neural Basis of Music-based Neurological Rehabilitation for Traumatic Brain Injury|Efficacy and Neural Basis of Music-based Neurological Rehabilitation for Traumatic Brain Injury|MUBI|Helsinki University|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|60 Years|No|||August 2015|August 18, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01956136||58633|
NCT01956149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CabaGast|Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer|Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach||Krankenhaus Nordwest|Yes|Active, not recruiting|September 2013|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01956149||58632|
NCT01952197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-PCEH-2013|Passive Leg Raise (PLR) During Cardiopulmonary Resuscitation (CPR)|Passive Leg Raise (PLR) During Cardiopulmonary Resuscitation (CPR): a Randomised Study of Survival in Out-of-hospital Cardiac Arrest (OHCA)|EP-PCEH|University Rovira i Virgili|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|3130|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01952197||58936|
NCT01948999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20100085|Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study|Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study||University of Aarhus|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01948999||59181|
NCT01949012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dental capnog|Capnography Monitoring During Intravenous Conscious Sedation Sedation With Midazolam for Oral Surgery|A Randomised Control Trial to Determine Whether Intervention Based on a Microstream Capnography-based Ventilation Monitoring System Will Decrease Hypoxaemaia During Intravenous Sedation With Midazolam.||University College Cork|Yes|Recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|210|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01949012||59180|
NCT01953328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120122|Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia|AMG145|Amgen|Yes|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|409|||Both|20 Years|85 Years|No|||November 2015|November 19, 2015|September 26, 2013|Yes|Yes||No|September 23, 2015|https://clinicaltrials.gov/show/NCT01953328||58849|
NCT01953588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011106|Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery|Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study||Alliance for Clinical Trials in Oncology|Yes|Recruiting|December 2013|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2820|||Female|18 Years|N/A|No|||September 2015|September 9, 2015|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953588||58829|
NCT01953900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32335 VEGAS|iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS|Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas (VEGAS)||Baylor College of Medicine|Yes|Recruiting|April 2014|April 2033|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|N/A|N/A|No|||December 2015|December 29, 2015|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953900||58805|
NCT01953913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.66|Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation|An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)||Boehringer Ingelheim||Recruiting|September 2013|July 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 25, 2013||||No||https://clinicaltrials.gov/show/NCT01953913||58804|
NCT01949779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4023|TransForm™ Occlusion Balloon Catheter Registry|||Stryker Neurovascular|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|80 Years|No|Non-Probability Sample|primary care/hospitals|October 2014|January 13, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01949779|1 Day|59121|
NCT01950065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0806|Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles|||MyoScience, Inc||Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01950065||59099|
NCT01950091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Back Pain II Study|Internet App to Self-Manage Occasional Low Back Pain|Randomized Controlled Trial of Internet App to Self-Manage Occasional Low Back Pain|BackPain2|Oregon Center for Applied Science, Inc.|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|606|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01950091||59097|
NCT01954381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002883-26|Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis|Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis||Assistance Publique Hopitaux De Marseille|No|Completed|October 2011|July 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|July 21, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01954381||58768|
NCT01954394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13463|Open Label Study of Long Term Safety Evaluation of Alirocumab|Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia|ODYSSEY OLE|Sanofi|Yes|Active, not recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954394||58767|
NCT01967212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210059RIC|Swallowing Training Combined With Game-based Biofeedback in Post-stroke Dysphagia|Swallowing Training Combined With Game-based Biofeedback in Post-stroke Dysphagia||National Taiwan University Hospital|Yes|Active, not recruiting|December 2012|||December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||October 2013|October 17, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01967212||57784|
NCT01967745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01091981|Laparoscopic Versus Open Appendectomy|Laparoscopic vs. Open Surgical Procedure in Management of Acute Appendicitis||Varazdin General Hospital|No|Completed|January 2007|September 2013|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|100|||Both|16 Years|90 Years|No|Probability Sample|Adult patients with clinical, laboratory, and radiologic signs of acute appendicitis|October 2014|October 22, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01967745||57743|
NCT01968044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL015|A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)|A Multicenter,Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase IIIb Study to Evaluate the Safety and Efficacy After 12 Weeks Administration of Gemigliptin and Placebo in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment With an Additional 40 Weeks, Double-blind,Active-controlled, Double-dummy,Long-term Extension Study|GUARD|LG Life Sciences||Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|19 Years|75 Years|No|||March 2016|March 21, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01968044||57720|
NCT01969370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1865|NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing|NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing|NCGENES|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|645|||Both|N/A|N/A|No|||March 2016|March 17, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01969370||57618|
NCT01965366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068205|Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD|A Pilot Study of the Effects of Dexamethasone Administration on Virtual Reality Exposure Therapy for PTSD|Dex|Emory University|No|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|65 Years|No|||January 2016|January 6, 2016|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965366||57926|
NCT01965587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novasure2013|RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia|RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia. A Pilot Study||Walsall Healthcare NHS Trust|No|Not yet recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 17, 2013|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965587||57909|
NCT01966159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2279|EVOLVE China Clinical Trial|EVOLVE China: A Prospective, Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)|EVOLVE China|Boston Scientific Corporation|No|Active, not recruiting|October 2013|December 2019|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|412|||Both|18 Years|75 Years|No|||April 2015|January 21, 2016|October 17, 2013||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01966159||57865|
NCT01966146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-067|Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI|Quantitative Analysis of Catheter-based Interventional Therapies for Treating Valve Insufficiency by Using 3D Echocardiography.|3D_TTE_TAVI|RWTH Aachen University|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966146||57866|
NCT01966458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW004-A|A Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)|A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure||HeartWare, Inc.|Yes|Active, not recruiting|October 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|465|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966458||57842|
NCT01966744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART|Self-Management Assistance for Recommended Treatment (SMART) Portal|Self-Management Assistance for Recommended Treatment (SMART) Portal|SMART|Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|July 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|||Both|11 Years|18 Years|No|Non-Probability Sample|Patients, caregivers, clinicians, and nurses will be recruited from the IBD clinic at        Cincinnati Children's Hospital Medical Center.|August 2015|August 3, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01966744||57820|
NCT01948440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44DA026232-02|ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery|ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery||Inflexxion, Inc.|Yes|Completed|July 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|39|||Both|N/A|N/A|No|||September 2013|September 20, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01948440||59224|
NCT01948453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|513|Effect of Garlic Tablet Some Indicators Related to Atherosclerosis|Effect of Garlic Tablet on Carotid Intima Media Thickness and Flow-mediated Dilation in Patients Undergoing Angioplasty||Shahid Beheshti University|Yes|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|56|||Both|25 Years|75 Years|No|||September 2013|May 27, 2015|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01948453||59223|
NCT01948687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-ELASTO|Real Time Elastography in Liver Fibrosis|The Role of Real Time Elastography in the Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis|RT-ELASTO|University of Medicine and Pharmacy Craiova|Yes|Recruiting|August 2013|November 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The patients included in the study will be healthy voluntaries, patients with chronic        hepatitis B or C and patients with liver cirrhosis. ARFI and Hitachi elastography will be        performed for each patient and the results will be compared with final diagnosis. The        final diagnosis (the stage) will be established based on Transient elastography and or        liver biopsy.|September 2013|September 18, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01948687||59205|
NCT01948700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AA017878-05|Assessing the Fit of Motivational Interviewing by Cultures With Adolescents|AMICA: Assessing the Fit of Motivational Interviewing by Cultures With Adolescents|AMICA|University of New Mexico|Yes|Completed|October 2009|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|506|||Both|13 Years|18 Years|No|||December 2015|December 11, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01948700||59204|
NCT01949025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALARM1|Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.|Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.|ALARM|Universiteit Antwerpen|Yes|Active, not recruiting|October 2013|January 2017|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70000|||Both|17 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01949025||59179|
NCT01954134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-485|P53 in Differentiated Thyroid Cancer|P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?||Cumhuriyet University|Yes|Completed|December 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|199|Samples Without DNA|Serum|Both|16 Years|80 Years|No|Probability Sample|A total of 171 patients with an age range of 16-80 yrs (mean: 47.7±13.5 yrs) and a total        of 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs) were included        in this study.|September 2013|September 26, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01954134||58787|
NCT01954147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC/GLP-1|Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus|Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus||Diabetes Care Center of Nanjing Military Command|Yes|Active, not recruiting|October 2013|October 2015|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|35 Years|65 Years|No|||February 2014|February 19, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01954147||58786|
NCT01954420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0733|A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer|A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer||University of Wisconsin, Madison|No|Recruiting|December 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954420||58765|
NCT01954667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anthropometric Measures &GERD|Anthropometric Measures and Severity of Gastroesophageal Reflux Disease|||Ain Shams University|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This prospective, case-controlled study included 60 Egyptian patients who attended Ain        Shams University Hospitals and Theodor Bilharz Research Institute; Cairo, Egypt|September 2013|September 29, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01954667|6 Weeks|58746|
NCT01949792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7777-4086|A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors|An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors||Novo Nordisk A/S|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|N/A|No|||November 2014|November 13, 2014|September 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01949792||59120|
NCT01949805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROUD-PV|Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera|A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera|PROUD-PV|AOP Orphan Pharmaceuticals AG|Yes|Active, not recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01949805||59119|
NCT01955174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.779|Botulinum Toxin Injection in Hypercontractile Esophagus|Endoscopic Injection of Botulinum Toxin in Patients With Hypercontractile Esophageal Motility Disorders: a Prospective, Randomized, Double-blind, Controlled Study|TIBOH|Hospices Civils de Lyon|Yes|Recruiting|August 2013|April 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955174||58707|
NCT01954407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818764|Young Adults' Responses to Anti-smoking Messages|Young Adults' Anti-smoking Message Ratings and Ideas About Smoking Survey||University of Pennsylvania|No|Not yet recruiting|September 2013|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|2200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954407||58766|
NCT01967498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-MH-0170-13-CTIL|Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study|Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study|COME|Tel-Aviv Sourasky Medical Center||Not yet recruiting|November 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967498||57762|
NCT01967732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-PK-01-EU|Nicotine Pharmacokinetic Profile and Safety of The Tobacco Heating System 2.2 (THS 2.2)|A Single-centre, Open-label, Randomized, Controlled, Crossover Study Investigating Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Nasal Spray||Philip Morris Products S.A.|No|Completed|November 2013|July 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|62|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967732||57744|
NCT01976845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025204|Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Propofol or Midazolam Versus Placebo for Preoperative Medication in Patients Undergoing Elective Orthopedic Surgery||Cedars-Sinai Medical Center|No|Completed|November 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|139|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|October 30, 2013||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01976845||57046|
NCT01976858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-I-03|A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 8 Weeks Injection of Polyethylene Glycol Loxenatide||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|June 2011|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|20 Years|65 Years|No|||October 2013|October 30, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976858||57045|
NCT01965379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fornasari01|Effect of Restriction of Foods Containing Phosphorus Additives|Effect of Restriction of Foods Containing Phosphorus Additives on the Phosphatemia of Patients With End-stage Renal Disease.||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Completed|January 2012|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01965379||57925|
NCT01965600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5211007|A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model|A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose, 2 Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of Pf 06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects|POM|Pfizer|No|Terminated|March 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01965600||57908|
NCT01965613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-PT025|RA-18C3 Therapy for Subjects With Pyoderma Gangrenosum|A Phase II Open Label Study of RA-18C3 in Subjects With Pyoderma Gangrenosum||XBiotech, Inc.|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965613||57907|
NCT01965925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1573|Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil|Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965925||57883|
NCT01966172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smerte1|Multimodal Analgesic Treatment Versus Traditional Morphine Analgesia After Cardiac Surgery|Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial||Rigshospitalet, Denmark|No|Completed|March 2007|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01966172||57864|
NCT01966484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK003|Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy|||Dr. Horst Schmidt Klinik GmbH|No|Completed|October 2013|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966484||57840|
NCT01966471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO28407|A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer|A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER||Hoffmann-La Roche||Active, not recruiting|January 2014|May 2023|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1846|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966471||57841|
NCT01966497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11020|Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia|Observational Study of Patients Older Than 60 Years and With Acute Myeloblastic Leukemia Who Are Administered Standard Chemotherapy Based on Idarubicine-cytarabine|ALFA1200|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|November 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|60 Years|N/A|No|Non-Probability Sample|hospital admissions from the participating centres|April 2015|April 20, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966497||57839|
NCT01966757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00376|Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities|Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities||Nationwide Children's Hospital|No|Recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patient with a known diagnosis of Neuronal Ceroid Lipofuscinosis by biopsy or genetic        testing|October 2013|October 17, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01966757||57819|
NCT01953341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130102|Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines.||Amgen|No|Completed|October 2013|November 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953341||58848|
NCT01948713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SimoneM|Effect of Pelvic Floor and Hip Muscle Strengthening in the Treatment of Stress Urinary Incontinence|Effect of Pelvic Floor and Hip Muscle Strengthening in the Treatment of Stress Urinary Incontinence: Randomized Blind Clinical Trial||University of Sao Paulo General Hospital|No|Active, not recruiting|January 2013|November 2014|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|30 Years|70 Years|No|||September 2013|October 7, 2014|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01948713||59203|
NCT01953926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA-NER-5201|An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification|An Open-label, Multicenter, Multinational, Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors With Activating HER2, HER3 or EGFR Mutations or With EGFR Gene Amplification.||Puma Biotechnology, Inc.|No|Recruiting|September 2013|December 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|292|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953926||58803|
NCT01954160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047050|Study of Renal Denervation in Patients With Heart Failure|Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure|PRESERVE|Duke University|Yes|Terminated|December 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|80 Years|No|||December 2015|December 30, 2015|September 24, 2013|Yes|Yes|DSMB decision based upon noted lack of efficacy in manufacturers pivotal trials.|No|December 30, 2015|https://clinicaltrials.gov/show/NCT01954160||58785|Data Safety Monitoring Board (DSMB) terminated trial based upon noted lack of efficacy in manufacturers pivotal trials. Endpoint data not collected or analyzed.
NCT01954173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059097|Adjuvant Radiation for High Risk Bladder Cancer|Phase II Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer||Emory University|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954173||58784|
NCT01954680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0195-07 COGFLEX|Retrain Your Brain in Children/Adolescents With Bipolar Disorder: A Pilot Study|COGFLEX: Pilot Translational Intervention of Pediatric Bipolar Disorder|COGFLEX|Bradley Hospital|Yes|Recruiting|August 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|17 Years|No|||January 2016|January 11, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01954680||58745|
NCT01954121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01364|Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures|An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures||UCB Pharma|No|Completed|September 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|436|||Both|16 Years|N/A|No|||February 2016|February 16, 2016|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954121||58788|
NCT01955538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTF4|The Effect of BAT Versus Mixed Physical Activity as add-on Treatment for Traumatised Refugees.|Treatment of Traumatised Refugees: the Effect of Basic Body Awareness Therapy Versus Mixed Physical Activity as add-on Treatment. A Randomised Controlled Trial.|PTF4|Mental Health Services in the Capital Region, Denmark|Yes|Enrolling by invitation|September 2013|November 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|310|||Both|18 Years|N/A|No|||February 2015|September 21, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01955538||58679|
NCT01955551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDBP_Research_Grant_2013|Motivational Interviewing to Increase Parent Engagement in Preventive Parenting Programming|A Randomized Controlled Trial Evaluating the Use of Motivational Interviewing to Increase Engagement by Low-income Parents in Preventive Parenting-skills Programming||University of Michigan|Yes|Completed|September 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|112|||Both|2 Years|N/A|No|||December 2015|December 1, 2015|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01955551||58678|
NCT01955148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10Q01|fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth|Prospective Phase III Evaluation Of Fetal Fibronectin In A High Risk Asymptomatic Population For The Prediction Of Spontaneous Preterm Birth||Hologic, Inc.|No|Recruiting|October 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|1210|Samples Without DNA|cervicovaginal fluid|Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Only subjects who are at high risk for preterm birth and meet the inclusion criteria will        be included in this study. Subjects may be recruited from each clinical site's routine or        referral population. Pregnant women who meet the study eligibility criteria will be        screened for possible inclusion in the study.|August 2015|August 24, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955148||58709|
NCT01976546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-CS-13|Intubation With McGrath Video Laryngoscope and Boedeker Intubation Foreceps in a Population of Patients With Predictors of Difficult Airway|Intubation With McGrath Video Laryngoscope and Boedeker Intubation Foreceps in a Population of Patients With Predictors of Difficult Airway, an Observational Pilot Study||Rigshospitalet, Denmark|Yes|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with one or more predictors of difficult airway|October 2014|October 24, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976546||57069|
NCT01969123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-024|Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication||FORUM Pharmaceuticals Inc||Suspended|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|790|||Both|55 Years|85 Years|No|||September 2015|September 14, 2015|October 21, 2013|Yes|Yes|Study has been suspended due to clinical hold.|No||https://clinicaltrials.gov/show/NCT01969123||57637|
NCT01969136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-025|Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication||FORUM Pharmaceuticals Inc||Suspended|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|790|||Both|55 Years|85 Years|No|||September 2015|September 14, 2015|October 21, 2013|Yes|Yes|Study has been suspended due to clinical hold.|No||https://clinicaltrials.gov/show/NCT01969136||57636|
NCT01969383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06708912.8.0000.5503.|Comparative Analysis Between Electrical Muscle Activity In Water And Soil|COMPARATIVE ANALYSIS BETWEEN THE ELECTRICAL ACTIVITY WITH AND WITHOUT MUSCULAR STRENGTH IN WATER AND SOIL||Universidade do Vale do Paraíba|No|Recruiting|April 2013|October 2013|Anticipated|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01969383||57617|
NCT01965392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCPD-2010|Efficiency of an Educational Program for Informal Caregivers of Hospitalized, Dependent Patients: Cluster Randomised Trial|||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Yes|Completed|March 2009|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 15, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01965392||57924|
NCT01965626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Oseltamivir|A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level|A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level||Shandong University|Yes|Recruiting|October 2013|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|240|||Both|20 Years|70 Years|No|||May 2014|May 26, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965626||57906|
NCT01965938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121408|RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope|RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: A Comparison of the Ease of Use During Intubation on Difficult Airways||Vanderbilt University|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|41|||Both|18 Years|N/A|No|||October 2013|December 10, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965938||57882|
NCT01967030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-04EGund-03-H|SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy|SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy|SWIFT|Kaiser Permanente|No|Active, not recruiting|May 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1035|Samples With DNA|We collected fasting and 2-hour plasma specimens during each Oral Glucose Tolerance Test      (OGTT). The EDTA treated plasma specimens and buffy coats are stored in cryovials at -70      degrees Centrigrade in low temperature freezers.|Female|20 Years|45 Years|No|Non-Probability Sample|SWIFT participants were recruited from 13 Kaiser Permanente Northern California (KPNC)        medical facilities throughout the region. Participating field sites for data collection        were located within the three primary areas including:        North area: Sacramento, South Sacramento, and Roseville Medical Centers, and Rancho        Cordova, Elk Grove, Point West, and Folsom Medical Offices; East area: Division of        Research (DOR) Research Clinic (Oakland), Hayward Medical Center and Fremont Medical        Offices and Richmond Medical Center; South area: Santa Clara, and San Jose Medical        Centers. The prospective cohort enrolled women who received prenatal care and delivered a        singleton, live born infant of 35 weeks gestation or longer at a Kaiser Permanente        hospital between July 2008 and October 2011.|July 2015|July 6, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01967030||57798|
NCT01967290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-NEU/102075/2008_SWORD|Stroke Wearable Operative Rehabilitation Device Impact Trial|Phase II Study of the Impact of the SWORD Device on Rehabilitation Tasks Performance in the Early Post Stroke Period|SWORD-IT|Centro Hospitalar de Entre o Douro e Vouga|No|Completed|May 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967290||57778|
NCT01967849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11190|Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children|Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children||Yale University|No|Recruiting|September 1999|September 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2000|||Both|7 Years|21 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01967849||57735|
NCT01953354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AUC02|Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis|A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|November 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|September 24, 2013|Yes|Yes|Manufacturer's business decision to d/c TSO production -unrelated to any safety concern.|No||https://clinicaltrials.gov/show/NCT01953354||58847|
NCT01953614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-0010|Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography|Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography||Life University||Recruiting|June 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|30|||Both|10 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01953614||58827|
NCT01948726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO 2013-04|Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer|Multicenter Phase-II-Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer||University of Schleswig-Holstein|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01948726||59202|
NCT01953939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMU/JS0122|Outcome Measures for Lower Limb Amputees - A Repeatability Study|PhD Research Project: Clinimetric Properties of Outcome Measures of Physical Function Used With Lower Limb Amputees, Study 2||Queen Margaret University|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01953939||58802|
NCT01954706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00056384|Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients|Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients|BCS2|Baltimore VA Medical Center|Yes|Terminated|November 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5|||Female|40 Years|80 Years|No|||November 2015|November 25, 2015|September 27, 2013||No|The study was stopped due to recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01954706||58743|
NCT01954901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20120029H|Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers|Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers: a Double-blind, Randomized,Controlled Clinical Trial.||David Grant U.S. Air Force Medical Center|Yes|Terminated|October 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 27, 2013|Yes|Yes|Failure to enroll subjects due to change in referral policy.|No||https://clinicaltrials.gov/show/NCT01954901||58728|
NCT01955564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-3509A/001/I/2011|A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.|A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.||Newron|Yes|Completed|June 2013|February 2015|Actual|September 2014|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|54|None Retained|PK specimens will be drawn to determine the maximum tolerated dose of NW-3509a in heathly      male volunteers|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Male Vounteers|February 2015|February 3, 2015|August 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01955564||58677|
NCT01955785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1346|Respiratory Treatment of Patients With Moderate and Severe Traumatic Brain Injury|Respiratory Treatment of Patients With Moderate and Severe Traumatic Brain Injury: A Randomised Comparison of Pressure Controlled Ventilation and Pressure Regulated Volume Controlled Ventilation||Norwegian University of Science and Technology|No|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|16 Years|N/A|No|||October 2015|October 27, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955785||58660|
NCT01955161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14861A|Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil|STARSHINE|H. Lundbeck A/S|Yes|Recruiting|October 2013|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|930|||Both|50 Years|N/A|No|||December 2015|December 10, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955161||58708|
NCT01968850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT 021|Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial|Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial|BATARI|St. Michael's Hospital, Toronto|Yes|Recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01968850||57658|
NCT01969396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-012|Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology|Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology||Cook||Terminated|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|2|||Female|18 Years|N/A|No|||December 2014|December 22, 2014|October 17, 2013||No|Enrollment considerations and current status of the clinical study|No||https://clinicaltrials.gov/show/NCT01969396||57616|
NCT01965119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2013-06-039|Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma|Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma|JAK2|Samsung Medical Center|Yes|Recruiting|November 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|80 Years|No|||June 2014|June 15, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01965119||57944|
NCT01966185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-FSP-088|Establishing Learning Curves in Virtual Simulation Training of Mastoidectomy|Establishing Learning Curves in Virtual Simulation Training of Mastoidectomy||Rigshospitalet, Denmark|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966185||57863|
NCT01966510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110145|Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies|A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies.|LYMPHCORD|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2013|December 2017|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966510||57838|
NCT01966770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-44|Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses|Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses||Coopervision, Inc.|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|20|||Both|18 Years|40 Years|No|||February 2015|February 25, 2015|October 15, 2013|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01966770||57818|
NCT01966523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R21AG042325|A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia|A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia||Hebrew Rehabilitation Center, Boston|Yes|Active, not recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|21 Years|N/A|No|||September 2015|September 15, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966523||57837|
NCT01966783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUS-2/UCA|Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis|Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis||Dr. Falk Pharma GmbH|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01966783||57817|
NCT01967043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORAX-01-13-US|A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies|A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies||Kinex Pharmaceuticals Inc|Yes|Active, not recruiting|October 2013|May 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967043||57797|
NCT01967303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3186|Restless Legs Syndrome in Stroke Patients|Restless Legs Syndrome in Stroke Patients||Rambam Health Care Campus|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|447|||Both|18 Years|N/A|No|Probability Sample|Patients hospitalized with stroke or transient ischemic attack.|October 2013|October 17, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01967303||57777|
NCT01967316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERVE|Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users|A PILOT STUDY OF THE SAFETY AND EFFECTIVENESS OF THE LIVE ZOSTER VACCINE IN ANTI-TNF USERS|VERVE|University of Alabama at Birmingham|Yes|Recruiting|May 2014|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|50 Years|N/A|No|||August 2015|August 30, 2015|July 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967316||57776|
NCT01953640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1351|Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy|PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)|PROMOTE|Mayo Clinic|Yes|Active, not recruiting|May 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|N/A|No|Non-Probability Sample|Males age > 18 years with adenocarcinoma of the prostate|May 2015|January 14, 2016|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953640||58825|
NCT01953653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 112|Feasibility of Using a Structured Daily Diary|Feasibility of Using a Structured Daily Diary to Assess Mood, Stressful Events, Support, Substance Use, and Sexual Behavior in HIV-Positive Young Men Who Have Sex With Men||Westat|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|67|||Male|16 Years|24 Years|No|||March 2016|March 1, 2016|January 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01953653||58824|
NCT01953601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8931-019|Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)|A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)|APECS|Merck Sharp & Dohme Corp.|Yes|Recruiting|November 2013|March 2021|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1500|||Both|50 Years|85 Years|No|||February 2016|February 25, 2016|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953601||58828|
NCT01954719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-14-06|Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial|Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|November 2012|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|N/A|N/A|No|||September 2013|October 4, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01954719||58742|
NCT01954433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUA-OrthopaedicsOE-CIP-v2.0|Costs and Consequences of Three Common Orthopedic Procedures on the Upper Extremity|Costs and Consequences of Three Common Orthopedic Procedures on the Upper Extremity - Health Economic Investigation (Cost-effectiveness and Cost-utility Analyses) With Before and After Surgery Comparison||Schulthess Klinik|Yes|Recruiting|November 2013|November 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||6|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|-  Patients with shoulder arthritis and/or rotator cuff tear arthropathy indicated for             total shoulder prosthesis (TSA)          -  Patients with rotator cuff tear indicated for arthroscopic rotator cuff             reconstruction (RCR)          -  Trapeziometacarpal osteoarthritis (TMC OA) patients indicated for resection             interposition suspension arthroplasty|November 2015|November 17, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01954433||58764|
NCT01954693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON803-10|A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis|TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous Sclerosis|TRON|Cardiff University|Yes|Recruiting|June 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|16 Years|60 Years|No|||August 2015|August 21, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01954693||58744|
NCT01954914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-MOBIL1-056|Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers|Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers|MOBIL1|Technische Universität Dresden|No|Recruiting|December 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01954914||58727|
NCT01955187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARMEN 01-2013|Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy|European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)|STARMEN|Hospital Universitario 12 de Octubre|Yes|Recruiting|January 2014|April 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01955187||58706|
NCT01955798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX2013001|Direct Trocar Entry Versus Veress Needle Entry in Laparoscopic Gynecological Surgery|Direct Trocar Entry Versus Veress Needle Entry in Laparoscopic Gynecological Surgery , a Randomized Study||Institut Universitari Dexeus|No|Suspended|January 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|80 Years|No|||April 2015|April 13, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01955798||58659|
NCT01955525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS ID: 134080|Long-term Follow-up of Health Related Quality of Life in Patients With Acute Coronary Syndrome|Long-term Follow-up of Health Related Quality of Life in Patients Hospitalised With Acute Coronary Syndrome: Evaluation of the Methods and Management of Acute Coronary Events (EMMACE)-3X|EMMACE-3X|University of Leeds|Yes|Not yet recruiting|November 2013|November 2023|Anticipated|November 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been hospitalised with an ACS during the period of 2011 to 2013 and took        part in EMMACE3 study(REC number 10/H1313/74)|September 2013|October 4, 2013|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01955525|10 Years|58680|
NCT01969149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API/2009/10|Exenatide for Stress Hyperglycemia|Intravenous Exenatide (Byetta®) Versus Insulin for Perioperative Glycemic Control in Cardiac Surgery: the Open-labeled Randomized Phase II/III ExStress Study|ExSTRESS|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|January 2015|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|544|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01969149||57635|
NCT01965951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-1004-13|Remediation of Spatial Neglect Trial|RESPONSE: Remediation of Spatial Neglect Trial|RESPONSE|Posit Science Corporation|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965951||57881|
NCT01965652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1326V9235|Long Term Safety of Naldemedine|A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy||Shionogi Inc.|Yes|Active, not recruiting|August 2013|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965652||57904|
NCT01965964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ_05_07_2011|Translation of the Sydney Swallow Questionnaire and Validation of the German Version|Sydney Swallow Questionnaire: Translation of a Questionnaire Relating to the Function of Swallowing and Validation of the German Version||University of Zurich|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients suffering from Dysphagia for at least half a year|December 2015|December 14, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01965964||57880|
NCT01966198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31082013|Estimation of Autonomic Nervous System Modulation by Pulse Plethysmographic Analysis|||Ospedale L. Sacco – Polo Universitario|No|Completed|October 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|25 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01966198||57862|
NCT01966211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-006|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||February 2, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966211||57861|
NCT01966536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neofol2013|CD133 Transplantation to Generate Oocytes in Poor Ovarian Reserve|CD133+ Autologue Transplantation to Promote Ovarian Follicles Development in Women With Poor Ovarian Reserve.||Hospital Universitario La Fe|No|Withdrawn|November 2013|June 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|October 17, 2013|Yes|Yes|Due to fundamental changes in procedures design no patients have been enrolled|No||https://clinicaltrials.gov/show/NCT01966536||57836|
NCT01966796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102013-E|Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia|Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia||Far Eastern Memorial Hospital|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|530|||Both|18 Years|N/A|No|Probability Sample|Patients who were admitted to the Far Eastern Memorial Hospital, an 800-bed tertiary care        hospital in northern Taiwan, from January 2005 to December 2010 were screened by discharge        diagnoses.The patients whose primary discharge diagnosis was pneumonia (International        Classification of Diseases codes 482, 485, and 486) were selected.|October 2013|October 17, 2013|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01966796||57816|
NCT01967056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001783|Predictors of Respiratory Failure Following Extubation in the SICU|Predictors of Respiratory Failure Following Extubation in Teh Surgical Intensive Care Unit (SICU)||Massachusetts General Hospital|No|Recruiting|June 2013|October 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|The population of patients used for this study will be those admitted to the Surgical        Intensive Care Unit|October 2013|October 17, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01967056||57796|
NCT01953692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-013|A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)|A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies||Merck Sharp & Dohme Corp.|No|Recruiting|November 2013|June 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|156|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953692||58821|
NCT01954199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFCSPA|The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain|The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain||Federal University of Health Science of Porto Alegre|Yes|Recruiting|March 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01954199||58782|
NCT01953627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00757-36|Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study|Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||July 2014|July 23, 2014|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01953627||58826|
NCT01953952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1221|Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer|Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer||Radiation Therapy Oncology Group||Withdrawn|December 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 26, 2013|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01953952||58801|
NCT01954732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1213|Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery|A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|January 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|September 27, 2013|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01954732||58741|
NCT01954940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 12/17E|Whole Body Vibration Therapy in Boys With Duchenne Muscular Dystrophy|THE EFFECT OF WHOLE BODY VIBRATION THERAPY UPON MUSCLE STRENGTH & FUNCTION IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY||Children's Hospital of Eastern Ontario|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Male|8 Years|14 Years|No|||March 2016|March 3, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01954940||58725|
NCT01954927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMVOC|Pain Management in Children and Young Adults With Sickle Cell Disease|Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease||St. Jude Children's Research Hospital|No|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|1 Year|20 Years|No|||February 2016|February 16, 2016|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954927||58726|
NCT01955200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response|Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study|OPTIMAL|The First Affiliated Hospital with Nanjing Medical University|No|Recruiting|October 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1350|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|September 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01955200||58705|
NCT01956019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10_RADIO_96|MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study|Feasibility Study to Compare Early Response Assessment and Planning Volumes With Contrast-enhanced Computed Tomography (CT), MRI Including Diffusion Weighted MRI (DWI) and Dynamic-contrast Enhanced (DCE) MRI in Patients With Limb Sarcoma Undergoing Pre-operative Radiotherapy||Christie Hospital NHS Foundation Trust|No|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01956019||58642|
NCT01955993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1809|Fentanyl Metabolism in Obese Adolescents|The Pharmacokinetics of Intravenous Fentanyl in Adolescent Patients With Higher BMI Percentiles.||Children's Research Institute|No|Completed|September 2011|September 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|whole blood|Both|12 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Single, hospital based surgical center|September 2013|September 30, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01955993||58644|
NCT01969162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195263-008|Tear Collection in Adult Volunteers|||Allergan|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|Tears|Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Adult volunteers without ocular disease.|November 2014|November 17, 2014|October 21, 2013||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01969162||57634|
NCT01969175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPT 2013-059|Effect of a Low-glycemic-load and Milk-free Diet on Acne Severity|||Hospital Parc Taulí, Sabadell|Yes|Recruiting|October 2013|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|20 Years|No|||November 2013|November 8, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969175||57633|
NCT01965665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046972|Advancing the Standard of Care for Pin Site Care|Advancing the Standard of Care for Pin Site Care: Prospective Single Center Study Using Medihoney HCS||Duke University|No|Completed|October 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|95 Years|No|||August 2015|August 17, 2015|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965665||57903|
NCT01965678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESoQoLiO-1|Epidemiological Study of Quality of Life in Osteopathy||ESoQoLiO|European Institute for Evidence Based Osteopathic Medicine|Yes|Completed|September 2010|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|1000|||Both|18 Years|80 Years|No|||October 2013|October 17, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965678||57902|
NCT01965977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC2013-04-124|Bortezomib Maintenance in High Risk DLBCL|Open-label, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients With High Risk Diffuse Large B Cell Lymphoma|Borma|Samsung Medical Center|Yes|Recruiting|July 2013|December 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|53|||Both|20 Years|N/A|No|||October 2013|October 16, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965977||57879|
NCT01966224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHIB-2013|A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects|A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated CryJ2-DNA-LAMP Vaccinated Subjects and the Safety of a Booster Vaccination||Immunomic Therapeutics, Inc.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|63 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966224||57860|
NCT01967342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-021-ME|Literacy-Adapted Psychosocial Treatments for Chronic Pain --- "Learning About Mastering/My Pain"|Reducing Disparities With Literacy-Adapted Psychosocial Treatments for Chronic Pain: A Comparative Trial|LAMP|University of Alabama, Tuscaloosa|Yes|Active, not recruiting|May 2013|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|299|||Both|19 Years|N/A|No|||January 2016|January 11, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01967342||57774|
NCT01967615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2BiTO13|P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI|P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry|P2BiTO|G. d'Annunzio University|No|Enrolling by invitation|January 2015|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3150|||Both|18 Years|80 Years|No|Probability Sample|All patients aged 18-80 undergoing PCI of a CTO or bifurcating lesion (all Medina types,        side branch ≥2 mm) with "biologically active stents" (DES or BVS) between January 2012 and        december 2014 at participating centers will be deemed eligible to enter the registry.|January 2015|January 12, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967615||57753|
NCT01967901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37319/S-RAD13-07|Impact of Multidisciplinary Self-care Management of Diabetic Nephropathy on Quality of Life, Self-care Behavior, Glycemic Control, and Renal Function.|Impact of a Multidisciplinary Self-care Management Program on Quality of Life, Self-care Behavior, Adherence to the Anti-hypertensive Treatment, Glycemic Control, and Renal Function in Adults Living With Diabetic Kidney Disease||University of Applied Sciences of Western Switzerland|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|40|||Both|18 Years|95 Years|No|||December 2014|December 13, 2014|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967901||57731|
NCT01967914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046443|PVI for Prediction of Spinal Induced Hypotension|Can Plethysmography Variability Index (PVI) Predict Spinal Induced Hypotension in Women Undergoing Cesarean Delivery?||Duke University|Yes|Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Female|18 Years|50 Years|No|Non-Probability Sample|Women undergoing cesarean delivery under spinal anesthesia|June 2015|June 15, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967914||57730|
NCT01954186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EtlikWHTH|When and How to Administer Oxytocin for Active Management of Third Stage of Labour|When and How to Administer Oxytocin for Active Management of Third Stage of Labour||Etlik Zubeyde Hanim Womens' Health and Teaching Hospital|No|Completed|January 2010|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|600|||Female|N/A|N/A|No|||September 2013|September 26, 2013|September 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01954186||58783|
NCT01954758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304-C-107-CS|The ERA as a Diagnostic Guide for Personalised Embryo Transfer|Clinical Study, International, Multicentre, Prospective, Randomised, Interventional, and Controlled, Comparing Fresh Embryo Transfer (FET) Versus Elective Delayed Embryo Transfer (EDET), and Personalised Embryo Transfer (pET) Guided by the ERA (Endometrial Receptivity Array) Test as a Diagnostic Tool in Patients Treated by IVF/ICSI (in Vitro Fertilisation; Intra-cytoplasmic Sperm Injection)||Igenomix|Yes|Recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|5||Anticipated|2442|||Female|18 Years|37 Years|No|||October 2015|October 16, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954758||58739|
NCT01954953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-02|Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe|European Research Projects on Rare Diseases Driven by Young Investigators|EURUSH|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|Yes|Recruiting|September 2013|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|6 Months|70 Years|No|Non-Probability Sample|USH1, USH2 and USH3 as defined by the Usher syndrome consortium|September 2013|February 3, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01954953||58724|
NCT01954966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811940|Progesterone and Brain Imaging Study|Impact of Progesterone Administration on Cortical Amino Acid Neurotransmitters & Smoking Behavior||University of Pennsylvania|Yes|Recruiting|November 2010|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|June 30, 2014|November 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954966||58723|
NCT01955226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Giuliano913|CHG Dressings in Children With Central Lines|Unit Based Comparison of Non- Versus Chlorhexidine-Impregnated Central Line Dressings||Yale University|Yes|Recruiting|February 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|314|||Both|2 Months|18 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955226||58703|
NCT01955239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2011-04|Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy|Prevention of Radiation-induced Parotid Gland Dysfunction by Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy(SCS-IMRT)|SCS-IMRT|University Medical Center Groningen|Yes|Recruiting|September 2013|||September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||September 2013|October 4, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955239||58702|
NCT01955213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/169|Methylnaltrexone for Opioid Induced Constipation|Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone|RILAX|VU University Medical Center|No|Recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|195|Samples Without DNA|From patients who also give informed consent for the second part of the study 50 ml of      heparinized blood will be drawn before the first administration of methylnaltrexone (day 0),      after 24 hours (day 1), at day 14 and approximately day 42 for immuno- and angiogenic      measurements (see flow chart below).      From this blood sample the size, phenotype and function of various leukocyte subsets, serum      cytokine levels, VEGF levels, thrombocyte levels and circulating endothelial cell levels      will be determined by means of fluorescence-activated cell sorting (FACS) or enzyme-linked      immunosorbent assay (ELISA).|Both|18 Years|N/A|No|Probability Sample|Patients receiving palliative care who are being treated with opioids for symptoms of pain        or dyspnea, suffering from constipation, that is not relieved by first line oral        laxatives.|December 2015|December 8, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01955213||58704|
NCT01956032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-000|Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources|Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources||AbbVie|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|99 Years|No|Probability Sample|Participants with advanced Parkinson's disease admitted to movement disorder specialty        clinics|January 2016|January 25, 2016|September 30, 2013||No||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01956032||58641|
NCT01956058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01667-36|Brachytherapy for Recurrent Prostate Cancer|Recurrent Prostate Cancer After Irradiation Treated With Brachytherapy Remedial: Phase 2 Study|CAPRICUR|Centre Georges Francois Leclerc|Yes|Recruiting|September 2013|September 2020|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|19 Years|N/A|No|||June 2015|June 23, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01956058||58639|
NCT01956006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-MIL-2|Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure|Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure||The Alfred|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||January 2016|January 6, 2016|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01956006||58643|
NCT01965639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043463|Southeastern Diabetes Initiative Clinical Intervention|A Clinical Intervention to Serve High-Risk Patients in the Southeastern Diabetes Initiative and Durham Diabetes Coalition|SEDI|Duke University|No|Active, not recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|600|||Both|18 Years|N/A|No|||April 2015|May 28, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965639||57905|
NCT01965405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034537-01A1|Smoking Cessation for People Living With HIV/AIDS|Behavioral Smoking Cessation Treatment for People Living With HIV/AIDS||Wayne State University|Yes|Recruiting|August 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|400|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01965405||57923|
NCT01966237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2507|Milrinone Pharmacokinetics and Acute Kidney Injury|USE OF ACUTE KIDNEY INJURY BIOMARKERS TO PREDICT IMPAIRED MILRINONE PHARMACOKINETICS IN CHILDREN FOLLOWING CARDIAC SURGERY|MIL-PK|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|74|||Both|N/A|1 Year|No|Non-Probability Sample|All patients less than or equal to 1 year who present for cardiac surgery at Cincinnati        Children's Hospital Medical Center who meet the eligibility criteria.|February 2015|February 2, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01966237||57859|
NCT01966250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013012|Electroacupuncture as a Complement to Usual Care for Patients With Non-acute Pain After Back Surgery|Electroacupuncture as a Complement to Usual Care for Patients With Non-acute Pain After Back Surgery: a Study Protocol for a Pilot Randomized Controlled Trial||Korean Medicine Hospital of Pusan National University||Completed|October 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|70 Years|No|||March 2015|March 30, 2015|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966250||57858|
NCT01966549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102318|A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Placebo Controlled Double-Blind, Multi-Center, Phase II Study to Assess the Efficacy and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease||Janssen Research & Development, LLC|Yes|Completed|November 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Both|40 Years|75 Years|No|||January 2016|January 5, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966549||57835|
NCT01966809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00023580|Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas|A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults||Medical College of Wisconsin|Yes|Active, not recruiting|June 2015|June 2021|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966809||57815|
NCT01967069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206|A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis|||Promius Pharma, LLC|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967069||57795|
NCT01967082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0369|APPSPIRE: Expanding the Reach of an Innovative Tobacco Control Program for Youth|APPSPIRE: Expanding the Reach of an Innovative Tobacco Control Program for Youth||M.D. Anderson Cancer Center|No|Recruiting|October 2013|||October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|38|||Both|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Smoking and non-smoking student at the University of Houston.|November 2015|November 24, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01967082||57794|
NCT01967355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-15|Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis|Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis||University Hospital Freiburg|No|Recruiting|April 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01967355||57773|
NCT01967368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12339|Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults|Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults||The University of Hong Kong|No|Recruiting|October 2013|June 2015|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 17, 2013|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967368||57772|
NCT01967628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 06-0003|Human Lung Responses to Respiratory Pathogens|Human Lung Responses to Respiratory Pathogens||University of Iowa|Yes|Completed|June 2007|October 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|105|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967628||57752|
NCT01967927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138725|Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy|Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy||University of Arkansas|Yes|Active, not recruiting|December 2013|July 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967927||57729|
NCT01953965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMREF-PH Imaging|Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.|11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension||Brigham and Women's Hospital|Yes|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|72 Years|No|||October 2015|October 8, 2015|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953965||58800|
NCT01954459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012208|Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?|Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?||Yale University|No|Recruiting|September 2013|September 2015|Anticipated|March 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|8 Years|44 Years|No|||September 2013|September 26, 2013|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954459||58762|
NCT01954446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK011|A Novel Non-interfering Arterial Blood Pressure Monitoring Device|A Novel Non-interfering Arterial Blood Pressure Monitoring Device||Sense A/S|No|Withdrawn|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 26, 2013|May 29, 2013||No|The investigational devices need alterations before validation|No||https://clinicaltrials.gov/show/NCT01954446||58763|
NCT01955265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sports2013HK|Promoting Adolescent Development Through Sports in Hong Kong|Promoting Adolescent Development Through Sports in Hong Kong: A Randomised Controlled Trial||The University of Hong Kong|No|Completed|September 2013|February 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|719|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955265||58700|
NCT01955291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/09 vers. 2.0|Reinforced Feedback in Virtual Environment|The Role of Virtual Therapy by Means of Reinforced Feedback in Virtual Environment on Upper Limb Function in Post-stroke Patients.|RFVE|IRCCS San Camillo, Venezia, Italy|Yes|Recruiting|January 2008|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955291||58698|
NCT01955252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YESA-13|Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea|Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea|YESA-13|Lihir Medical Centre|No|Active, not recruiting|March 2013|||May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|2 Months|N/A|No|||August 2015|August 31, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955252||58701|
NCT01955577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130033|Vitamin D Supplement for Patients With Tibial Fracture|Vitamin D Supplement for Patients With Tibial Fracture Treated With an External Ring Fixator. A Prospective Randomized Double-blind Study.||Northern Orthopaedic Division, Denmark|No|Not yet recruiting|April 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|90 Years|No|||April 2015|April 9, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955577||58676|
NCT01952093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112106RIB|Effects of Early Intervention for Preterm Children at School Age|Effects of Early Intervention for Preterm Children at School Age||National Taiwan University Hospital|No|Recruiting|May 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|240|||Both|7 Years|7 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01952093||58944|
NCT01952106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305092RIND|Effects of Distraction on Pain and Distress During Venepuncture in Children|Effects of Distraction on Pain and Distress During Venepuncture in Children||National Taiwan University Hospital|Yes|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Both|5 Years|7 Years|No|||December 2014|December 4, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01952106||58943|
NCT01952067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.1996|Comparison of Two Cementing Techniques of the Femoral Component in a Hip Prosthesis|Comparison of Two Cementing Techniques of the Femoral Component in a Hip Prosthesis. A Randomized Single-blind Trial||Norwegian University of Science and Technology|Yes|Recruiting|March 2013|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|75 Years|No|||October 2015|October 21, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01952067||58946|
NCT01965158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314V9231|Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy||Shionogi Inc.|Yes|Completed|August 2013|||January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965158||57941|
NCT01965418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10005002|A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial|||Beijing 302 Hospital|Yes|Recruiting|September 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|65 Years|No|||August 2015|August 14, 2015|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965418||57922|
NCT01966562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT002899231|PAHA Study: Psychological Active and Healthy Ageing|Psychological Well Being, Proactive Attitude and Happiness Effects of Whole-body Vibration vs. Multi-component Training in Aged Women: a Randomized Controlled-trial Study Protocol|PAHA|University of Bergamo|No|Completed|November 2011|July 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|69|||Female|55 Years|75 Years|No|||September 2013|October 16, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01966562||57834|
NCT01966822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTEODOLU|Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density|MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY||Fundacio Lluita Contra la SIDA|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|65 Years|No|||November 2015|November 27, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01966822||57814|
NCT01967095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-278|Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer|A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967095||57793|
NCT01967108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0346-13-RMB CTIL|Post Extubation Chest Physiotherapy in ICU|The Effect of Post Extubation Chest Physiotherapy on Respiratory Complications and Weaning Failure in Critically Ill Patients||Rambam Health Care Campus|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||February 2014|May 6, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967108||57792|
NCT01967641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6269R|Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse|Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse|PAIN|New York State Psychiatric Institute|Yes|Completed|November 2005|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||October 2013|October 18, 2013|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967641||57751|
NCT01967407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-UKMD-URO-001|IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.|Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).|IRENE|University of Magdeburg|Yes|Recruiting|October 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01967407||57769|
NCT01967940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0117|Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults|A Phase 3, Two Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults||Gilead Sciences|Yes|Active, not recruiting|August 2013|October 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967940||57728|
NCT01967953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVLP_2011|Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation|Ex-Vivo Lung Perfusion to Improve Donor Lung Function and Increase the Number of Organs Available for Transplantation|EVLP_MI|Policlinico Hospital|Yes|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|7|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01967953||57727|
NCT01968226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5 IND|TRACER RGD-K5 Carotid Plaque Imaging Study|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|TRACER|The Cleveland Clinic|No|Recruiting|November 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01968226||57706|
NCT01954472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-188|Enhanced Multicenter Dietary Portfolio Study|The Effect of an Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk in High Risk Individuals.|EDP8|St. Michael's Hospital, Toronto|No|Withdrawn||||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||January 2014|January 16, 2015|September 23, 2013||No|This study was combined with another CIHR funded study (NCT02078635). Both studies involve the    same dietary portfolio and the same study population.|No||https://clinicaltrials.gov/show/NCT01954472||58761|
NCT01954485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laser-Lok® abutment|Adhesion of Connective Tissue Around Laser-treated Abutments for Dental Implants - Clinical Trial in Humans|Histological Differences in the Adhesion of Connective Tissue Around Laser-treated Abutments and Standard Abutments for Dental Implants - Clinical Trial in Humans||University of Barcelona|No|Recruiting|January 2013|September 2014|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 26, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01954485||58760|
NCT01955018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0166|Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions|Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions||University Hospital, Clermont-Ferrand||Completed|September 2012|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|90|||Both|18 Years|90 Years|No|||September 2013|October 4, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01955018||58719|
NCT01955278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCSP10070PPHP|Role of Prosthetic Mesh in Preventing Parastomal Hernias|Prospective Randomized Study of the Role of Prosthetic Mesh in Preventing Parastomal Hernias in Patients With Definitive End Colostomy|RPMPPH|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|March 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|85 Years|No|||September 2015|September 16, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01955278||58699|
NCT01956071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-050|Workers' Acceptability of a Prototype Integrated and Interactive Pedal Desk|Workers' Acceptability of a Prototype Integrated and Interactive Pedal Desk|WAPD|Pennington Biomedical Research Center|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|44||No biospecimens will be retained|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Full-time employees at Pennington Biomedical Research Center|January 2016|January 15, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956071||58638|
NCT01955811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiT2012|Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion|Bicentric Clinical Trial With in Vitro Experiments to Assess the Effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia|FiT2012|Medical University Innsbruck|No|Completed|December 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|130|||Both|18 Years|85 Years|No|||March 2016|March 22, 2016|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01955811||58658|
NCT01952691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEK 10/58-48|Initial Effects of Kinesiotaping in Non Surgical Treatment of Hallux Valgus|Initial Effects of Kinesiotaping in Conservative Treatment of Hallux Valgus||Hacettepe University|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|55 Years|No|||April 2015|February 18, 2016|September 19, 2013||No||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01952691||58898|
NCT01952080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-C13-003|A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome|A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support||Shire|Yes|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|1 Year|17 Years|No|||July 2015|November 10, 2015|September 23, 2013|Yes|Yes||No|August 12, 2015|https://clinicaltrials.gov/show/NCT01952080||58945|
NCT01965691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00220|Protein Requirements in Children With Phenylketonuria (PKU)|Application of Stable Isotopes to Determine Protein Requirements in Children With Phenylketonuria (PKU)||University of British Columbia|Yes|Recruiting|October 2013|June 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|6|||Both|5 Years|18 Years|No|||November 2015|November 3, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965691||57901|
NCT01965990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23bis|VLCD by Enteral Route for Weight Loss|A 2-week Course of Enteral Treatment With a Very Low-calorie Protein-based Formula for the Management of Severe Obesity|NEP|San Giuseppe Moscati Hospital|Yes|Completed|April 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|364|||Both|18 Years|70 Years|No|Non-Probability Sample|Consecutive severly obese patients attending the Clinical Nutrition Unit of our        institution for a weight loss program|October 2013|October 18, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01965990||57878|
NCT01966575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02187|Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate|Effect of Progestin-Induced Endometrial Shedding on Ovulation Induction Cycles With Clomiphene Citrate: A Randomized Study||University of British Columbia|No|Withdrawn|October 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|38 Years|No|||November 2014|November 4, 2014|September 17, 2013||No|Recent findings suggest that letrozole may be a superior Clomiphene Citrate.|No||https://clinicaltrials.gov/show/NCT01966575||57833|
NCT01967121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 13-849F|Compex Use With Delayed Onset Muscle Soreness: A Comparison to Other Methods|Compex Use With Delayed Onset Muscle Soreness: A Comparison to Other Methods||Michigan State University|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|October 16, 2013|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01967121||57791|
NCT01967381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033394|Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse|Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse||University of Kentucky|Yes|Recruiting|October 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967381||57771|
NCT01967394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15NR013563-01A1|Social Media, Teen Moms and PPD|Social Media, Teen Moms, and Postpartum Depression||University of Louisville|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|287|||Female|13 Years|21 Years|No|||December 2015|December 25, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01967394||57770|
NCT01967420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NW/0385|Cognitive Remediation for First Episode of Psychosis Patients|Using Computerised Training to Improve Cognition and Functioning in the First Episode of Psychosis||University of Manchester||Recruiting|August 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|35 Years|No|||June 2015|June 9, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01967420||57768|
NCT01967654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00413|Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam|||New York University School of Medicine|No|Withdrawn|January 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01967654||57750|
NCT01967966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28755|A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers|A PHASE 1 STUDY TO INVESTIGATE THE ABSOLUTE BIOAVAILABILITY OF GDC-0032 AND THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-GDC-0032 IN HEALTHY MALE SUBJECTS||Genentech, Inc.||Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967966||57726|
NCT01954212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA 2012/09|Stroke Oral healthCare pLan Evaluation|A Multi-centred, Stepped Wedge, Cluster Randomised Controlled Trial to Compare the Clinical and Cost Effectiveness of a Complex Oral Health Care Intervention and Standard Oral Health Care in Stroke Care Settings: a Phase II Pilot Trial.|SOCLE II|Glasgow Caledonian University|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|N/A|N/A|No|||September 2015|September 7, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01954212||58781|
NCT01954225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314|Role of Udumbara Sutra in the Management of Fistula in Ano a Rare Case Study|Role of Udumbara Sutra in the Management of Fistula in Ano a Rare Case Study|Bhagandara|Government Ayurved College and Hospital|No|Completed|February 2006|September 2006|Actual|April 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|5 Years|N/A|No|||September 2013|September 26, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01954225||58780|
NCT01954745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-221|A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy|A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy||Massachusetts General Hospital|Yes|Active, not recruiting|September 2013|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954745||58740|
NCT01955005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-178|Use of the My HealtheVet for Health Information Sharing|Pilot of My HealtheVet Training to Improve Co-Managed Care for Veterans||VA Office of Research and Development|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|August 20, 2013||No||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01955005||58720|
NCT01955616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-007|A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy|MOVE-PD|Rhythm Pharmaceuticals, Inc.|No|Terminated|September 2013|September 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955616||58673|
NCT01955629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLIBC06561|Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient|A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient|AMOR|Sanofi|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955629||58672|
NCT01952158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130195|Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel|Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel||National Institutes of Health Clinical Center (CC)||Completed|September 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 24, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952158||58939|
NCT01952444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH110|Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers|An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers||Elusys Therapeutics||Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|September 30, 2014|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952444||58917|
NCT01952457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-121003|The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions||ZILVERPASS|Flanders Medical Research Program||Recruiting|August 2014|November 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01952457||58916|
NCT01955590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD-NTNU-1|A Randomized Controlled Trial of Metacognitive Therapy and EMDR for Posttraumatic Stress Disorder|A Randomized Controlled Trial of Metacognitive Therapy and Eye Movement Desensitization and Reprocessing for Posttraumatic Stress Disorder||Norwegian University of Science and Technology|No|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||February 2016|February 4, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955590||58675|
NCT01955824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bron/Lig/Tr-1|A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy|"A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY"||Postgraduate Institute of Medical Education and Research|Yes|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|500|||Both|12 Years|80 Years|No|||December 2014|December 26, 2014|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01955824||58657|
NCT01955837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10040090|Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia|Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies|TERRA|Taiho Pharmaceutical Co., Ltd.||Active, not recruiting|September 2013|June 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01955837||58656|
NCT01952977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT_1|Effect of Medium Chain Triglyceride Consumption on Appetite||MCT|St. Luke's-Roosevelt Hospital Center|No|Completed|June 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|17|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 27, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952977||58876|
NCT01952990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-07|Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects|A Single-Center, Study Evaluating The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of Kovacaine Mist To Healthy Pediatric Subjects||St. Renatus, LLC|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952990||58875|
NCT01952405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC102-2314-B-195-002-My3|Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder|Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder: a Controlled Trial in Taiwan||Mackay Memorial Hospital|Yes|Recruiting|September 2013|July 2018|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|No|||April 2015|April 6, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01952405||58920|
NCT01966003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120265|Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer|A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer||Amgen|Yes|Completed|October 2013|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|642|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|October 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966003||57877|
NCT01966263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497|Fast Track Total Knee Arthroplasty: Local Infiltration Analgesia vs Femoral Nerve Block|Fast-track Rehabilitation Protocol for Total Knee Arthroplasty: A Randomized Controlled Trial Comparing Local Infiltration Analgesia With Femoral Nerve Block||Sint Maartenskliniek|No|Active, not recruiting|November 2013|November 2015|Anticipated|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|80 Years|No|||February 2015|February 25, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01966263||57857|
NCT01967160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101363|Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid|A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway||Amgen||Active, not recruiting|January 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3600|||Both|18 Years|N/A|No|Probability Sample|Cancer patients treated with antiresorptive therapies|November 2013|November 25, 2013|October 18, 2013||Yes||No||https://clinicaltrials.gov/show/NCT01967160||57788|
NCT01967433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAASIPCO|Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids|Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids||University of Oklahoma|Yes|Recruiting|December 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|64 Years|No|||December 2014|December 2, 2014|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967433||57767|
NCT01967134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-032-456|Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis|Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection||Aeras|Yes|Completed|November 2011|June 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01967134||57790|
NCT01968252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107-14-EP|Speckle-tracking Tricuspid Annular Plane Systolic Excursion|Validation of Speckle-tracking Echocardiography Measurements of Tricuspid Annular Plane Systolic Excursion During Transesophageal Echocardiography||University of Nebraska|No|Completed|May 2014|November 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|112|||Both|19 Years|90 Years|No|Non-Probability Sample|All subjects will be scheduled to undergo a surgical procedure requiring general        anesthesia and either due to subject factors or procedure factors, the use of        intraoperative transesophageal echocardiographic monitoring will occur. These subjects        will then have both transesophageal and transthoracic echocardiographic measurements of        one variable of right ventricular function to validate the results from the        transesophageal window.|November 2015|November 30, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01968252||57704|
NCT01968499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Pharmacogenetic and Pharmacokinetic Study of Clopidogrel|Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study|PPSC|The First Affiliated Hospital with Nanjing Medical University|No|Recruiting|March 2011|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|DNA samples of all recuited patients are collected and stored for future analysis.|Both|18 Years|80 Years|No|Probability Sample|All patients who receive stent implantation and aged >18 years and ≦80 years old.|February 2016|February 12, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01968499|1 Year|57685|
NCT01968785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Denervation|Renal Denervation in Patients With Uncontrolled Blood Pressure|RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION||Medstar Research Institute|No|Recruiting|August 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|No|||August 2014|August 8, 2014|October 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01968785||57663|
NCT01969019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD015|A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy|A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy||Ruijin Hospital|Yes|Recruiting|January 2010|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||October 2013|October 21, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969019||57645|
NCT01954771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z131100004013044|SMBG Protocols Predicting Glucose Levels in Senior Diabetics With CAD|A Prospective, Randomized, Controlled Study on Self-monitoring of Blood Glucose (SMBG) Protocols in Predicting Glucose Levels in Senior Patients With Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)||Beijing Anzhen Hospital|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Both|65 Years|N/A|No|||February 2015|April 1, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01954771||58738|
NCT01954979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-358|A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)|A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)||Dana-Farber Cancer Institute|Yes|Recruiting|October 2013|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954979||58722|
NCT01954992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-GF-301|Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer|A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine||Eleison Pharmaceuticals LLC.|Yes|Recruiting|September 2013|December 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954992||58721|
NCT01954784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1A13|Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma|A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma||Case Comprehensive Cancer Center|Yes|Recruiting|October 2013|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|50 Years|No|||March 2016|March 8, 2016|September 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01954784||58737|
NCT01956097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX106|Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function|Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments||Ewha Womans University|Yes|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|September 26, 2013||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01956097||58636|
NCT01956110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000004|Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme|ESTHER-1|Ferring Pharmaceuticals|No|Active, not recruiting|October 2013|December 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1328|||Female|18 Years|40 Years|No|||October 2015|October 23, 2015|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01956110||58635|
NCT01955603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8210-3927|A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis|A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|75 Years|No|||October 2014|October 14, 2014|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01955603||58674|
NCT01955850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UvA-2013-KP-3125|Online or Face-to-face Treatment for Insomnia?|Online or Face-to-face Treatment for Insomnia? A Wait-list Controlled Trial||VU University of Amsterdam||Completed|October 2013|December 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01955850||58655|
NCT01956045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0164|Critically Ill Patient's Capacity|Critically Ill Patient's Capacity|Capacity|University Hospital, Clermont-Ferrand||Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|215|||Both|18 Years|N/A|No|Non-Probability Sample|critically-ill patients|July 2014|July 3, 2014|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01956045||58640|
NCT01953237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH094555|MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications|MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications||University of Maryland|No|Active, not recruiting|September 2013|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|64 Years|No|||November 2015|November 30, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953237||58856|
NCT01953250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-54351|Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection|To Assess the Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection||Universitaire Ziekenhuizen Leuven|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|143|||Female|N/A|N/A|No|Non-Probability Sample|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the        indication of deep infiltrating endometriosis|April 2012|September 25, 2013|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01953250||58855|
NCT01952951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-13-687|Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer|A Randomized Phase II Trial of Preoperative Chemoradiation (Preop CRT) Followed by CapOx (Capecitabine Plus Oxaliplatin) Versus Preop CRT Alone for Locally Advanced Rectal Cancer (LARC)||National Cancer Center, Korea|Yes|Recruiting|June 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|N/A|No|||April 2015|April 14, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01952951||58878|
NCT01952964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-10-0196/ER-3|The Effects of Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients|The Effectiveness of a Physical Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients|JUCspray|The Queen Elizabeth Hospital|Yes|Recruiting|March 2011|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|78|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952964||58877|
NCT01966016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRZ0046-12CTIL|Efficacy and Safety of Multisite Cardiac Resynchronization Therapy|Efficacy and Safety of Multisite Cardiac Resynchronization Therapy - a Prospective Single Center Study in Selected Patient Population||Barzilai Medical Center|No|Recruiting|January 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|90 Years|No|||October 2013|October 16, 2013|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01966016||57876|
NCT01966276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPAX-002-01|The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome|Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula||K-PAX Pharmaceuticals, Inc.|No|Active, not recruiting|November 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|59 Years|No|||September 2014|September 22, 2014|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966276||57856|
NCT01966289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13138|SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)|A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|December 2013|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01966289||57855|
NCT01966835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR sleep|Effect of Moderate to High Intensity Aerobic Interval Training on Polysomnographic Measured Sleep in Patients With Rheumatoid Arthritis|Effect of Moderate to High Intensity Aerobic Interval Training on Polysomnographic Measured Sleep in Patients With Rheumatoid Arthritis. A Randomized Controlled Trial|JR|Glostrup University Hospital, Copenhagen|Yes|Recruiting|May 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|44|||Both|18 Years|70 Years|No|||July 2014|July 17, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01966835||57813|
NCT01966848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-086|Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties. A Trial Evaluating Early Component Migration by RSA and Patient Reported Outcome.|Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties. A Randomized Controlled Trial Evaluating Early Component Migration by RSA and Patient Reported Outcome.||Hvidovre University Hospital|No|Active, not recruiting|November 2013|November 2024|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|100 Years|No|||November 2015|November 3, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01966848||57812|
NCT01966861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDOR-03-2013|Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)|Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)|WEANLUS-BR|D'Or Institute for Research and Education|Yes|Enrolling by invitation|March 2016|May 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01966861||57811|
NCT01967979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28977|A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects|A Single-Center, Open-Label, One-Sequence, 2-Period, Within-Subject Study in 2 Cohorts to Investigate the Effect of Multiple Doses of Itraconazole (Cohort 1) and Fluoxetine (Cohort 2) on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects||Hoffmann-La Roche||Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01967979||57725|
NCT01968512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285.841|Neurobiological Aspects of the Attention Deficit Hyperactivity Disorder|Neurobiological Aspects of the Attention Deficit Hyperactivity Disorder: Contribution of the Transcranial Direct Current Stimulation in Control Inhibitory.|NAADHD|Federal University of Bahia|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||April 2014|April 30, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01968512||57684|
NCT01969032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATN-2ICR|Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer|Phase 2 Study of Two Consequent Chemotherapy Regimens as Induction Preoperative Therapy for Patients With Locally Advanced Triple Negative Breast Cancer||Russian Academy of Medical Sciences|No|Completed|August 2011|September 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|75 Years|No|||November 2014|November 4, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969032||57644|
NCT01969292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Col001|Colometer - A Real Time Quality Improvement Feedback System for Screening Colonoscopy|Colometer - A Real Time Quality Improvement Feedback System for Screening Colonoscopy||University of Calgary|No|Terminated|September 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|79|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|September 26, 2013||No|Stage 1 Complete; Stage 2 and 3 not pursued|No||https://clinicaltrials.gov/show/NCT01969292||57624|
NCT01965275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDP-ADNSCLC|High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs|An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs||Anhui Medical University|Yes|Recruiting|October 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||June 2015|June 27, 2015|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965275||57933|
NCT01955070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMP for Informed Consent|Use of a Multimedia Presentation for Informed Consent|Use of a Multimedia Presentation to Enhance the Informed Consent for Ketamine Sedation in a Pediatric Emergency Department||Nationwide Children's Hospital|No|Completed|May 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|184|||Both|1 Year|18 Years|No|||September 2013|September 27, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01955070||58715|
NCT01963052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS15E-13-1|ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer||Astellas Pharma Inc|No|Recruiting|August 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01963052||58102|
NCT01963065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0332|NICU-HEALTH (Hospital Exposures and Long-Term Health)|Chemical Exposures and Infant Outcomes in the Neonatal Intensive Care Unit||Icahn School of Medicine at Mount Sinai|No|Recruiting|March 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Samples with DNA - samples retained, with potential for extraction of DNA from at least one      fo the types of samples retained (e.g., frozen tissue, whole blood)|Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|All neonates admitted to the Mount Sinai NICU who are classified as VLBW will be eligible        for enrollment.|February 2016|February 10, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01963065||58101|
NCT01963351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27816|Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC|Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer||University of Athens|Yes|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically or cytologically documented advanced metastatic (patients who        are not candidates for radiotherapy, i.e. supraclavicular lymph node metastases or Stage        IIIb with malignant pleural or pericardial effusion or Stage IV) or recurrent non-squamous        non-small cell lung cancer.|December 2014|December 5, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01963351|24 Months|58079|
NCT01963364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11072013SCSMRI|Pilot Study of the Effect of Fructans on Fermentation in the Colon & Transit|A Pilot Study Using Magnetic Resonance Imaging to Measure the Effect of Dietary Supplementation With Fructans on Whole Gut Transit Time, Colonic Gas Volume, and Volume Change in Response to a Fructan Challenge|PERFECT|University of Nottingham|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01963364||58078|
NCT01992276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102576|Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection||Crucell Holland BV|Yes|Withdrawn|December 2013|February 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|November 11, 2013|Yes|Yes|Due to preliminary efficacy results from an influenza challenge trial|No||https://clinicaltrials.gov/show/NCT01992276||55863|
NCT01963871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13763|The Effect of Yoga in Chronic Low Back Pain|The Effect of Yoga in Chronic Low Back Pain||University of Kansas Medical Center|No|Completed|August 2013|||May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|65 Years|No|||May 2014|May 22, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963871||58039|
NCT01963637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.721|Gastric Volumetry by Gastric Tomodensitometry With Gas|Evolution of Gastric Volume Measured by Gastric Tomodensitometry With Gas After Gastric Bypass Surgery or Sleeve Gastrectomy. Research for a Correlation With Weight Evolution : Pilot Study.|VOLUSCAN|Hospices Civils de Lyon|No|Completed|September 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Both|18 Years|60 Years|No|||November 2015|November 18, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963637||58057|
NCT01963884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-04|Relate Tooth Alveolar Extraction Socket Anatomy to Alveolar Remodeling Rate|Study of Tooth Alveolar Extraction Socket Anatomy and Its Relation to Alveolar Post-extraction Changes||Instituto de Implantologia|No|Not yet recruiting|January 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients that require at least on tooth extraction of the upper anterior jaw (maxilla)        canine, central incisor and lateral incisor.|October 2013|October 12, 2013|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963884||58038|
NCT01964794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135288|Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling|Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling||University of Arkansas||Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Blood specimens to identify coumadin genetic and metabolic biomarkers.|Male|60 Years|69 Years|No|Non-Probability Sample|Originally, for this pilot study, we chose a sample population size of 150 with a focus on        veterans from the Korean War. Towards the end of recruitment the protocol was revised to        remove the focus on veterans from just the Korean War.|January 2016|January 6, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01964794||57969|
NCT01961882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-12-001|A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|60 Years|N/A|No|||February 2016|February 22, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961882||58192|
NCT01962168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009|Evolution® Biliary Stent System Clinical Study|Palliation of Biliary Neoplasms With the Cook Evolution® Biliary Stent System||Cook||Completed|December 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|Candidates for biliary stent placement based on institutional guidelines and product IFU.|April 2015|April 7, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962168||58170|
NCT01952678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-001-011|Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)|A Retrospective Clinical Study to Compare the Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)||GE Healthcare|No|Active, not recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|232|||Both|18 Years|N/A|No|Non-Probability Sample|Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor        (ET).|September 2015|September 18, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01952678||58899|
NCT01952925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-D-9699|Combined Afib Ablation and RA Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension|Combined Atrial Fibrillation Ablation and Renal Artery Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension||Oregon Health and Science University||Not yet recruiting|January 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952925||58880|
NCT01953471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/09|Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)|Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen by the Assessment of the Relationship Between the Symptom Scores and Global Rating of Change Questionnaires on the Quality of Life and Well-being.||Hopital Foch||Completed|April 2011|||September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|6 Years|65 Years|No|Non-Probability Sample|Patients with allergic rhinitis due to grass pollen|September 2013|September 26, 2013|September 6, 2013||||No||https://clinicaltrials.gov/show/NCT01953471||58838|
NCT01953783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16016|Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB|A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|March 2014|March 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953783||58814|
NCT01953796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kufa university|Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome|Study of Stair-step Clomiphene Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome (PCOS) Compared to Traditional Protocol.|PCOSCCTvUSS|Kufa University|Yes|Completed|May 2010|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|21 Years|34 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953796||58813|
NCT01954043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200072|A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors|An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors||GlaxoSmithKline|No|Recruiting|December 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01954043||58794|
NCT01953770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-MB 2008|Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008|Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents|ALL-MB 2008|Federal Research Institute of Pediatric Hematology, Oncology and Immunology|Yes|Active, not recruiting|February 2008|June 2018|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|3000|||Both|1 Year|18 Years|No|||March 2015|March 10, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953770||58815|
NCT01954836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIT08/2013|Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial|Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial|FIT|Charite University, Berlin, Germany|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|35 Years|70 Years|No|||August 2015|August 19, 2015|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01954836||58733|
NCT01954810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC24|Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children|Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV||Khon Kaen University|No|Not yet recruiting|October 2013|May 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|88|||Both|72 Months|80 Months|Accepts Healthy Volunteers|||October 2013|October 6, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954810||58735|
NCT01954537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307M38681|Comparing Risk of Heat Illness Based on Peak Core Temps During Preseason Football Camp Across 3 Different Age Levels|"Using Peak Core Temperature in Hot Preseason American Football Practice to Compare and Contrast Risk of Heat Illness at High School, College, and Professional Levels."||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|22|||Male|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be volunteers from the Minnesota Vikings Professional football team, Bethel        University Division III football team, and Roseville High School football team.|September 2013|September 26, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01954537||58756|
NCT01955668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5330C00001|AZD6738 First Time in Patient Multiple Ascending Dose Study|A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Relapsed/Refractory B Cell Malignancies With Expansion to Patients With Prospectively Identified 11q-deleted or ATM-deficient, Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)||AstraZeneca|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955668||58669|
NCT01994057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX09506001-004 (2)|A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment|Retrospective Study Based on Somatic Mutations and Genetic Polymorphisms Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.||Sun Yat-sen University|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|1. FFPE samples of tissue needle biopsy were used for EGFR mutation detection.        2. EDTA-whole blood was centrifuged at 4000rpm*10min,plasma was separated within four           hours for somatic mutation detection.The remaining samples were used for germline           mutation detection. All the blood samples were frozen in -80℃ until analysis.|Both|18 Years|85 Years|No|Non-Probability Sample|locally advanced or metastatic NSCLC (non-small cell lung cancer) patients; administrated        with gefitinib,erlotinib .|November 2013|November 20, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01994057||55726|
NCT01995162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1028|A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities in Free-living Conditions (eMouve2)|A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities in Free-living Conditions (eMouve 2)||Institut National de la Recherche Agronomique|Yes|Completed|April 2013|October 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995162||55642|
NCT01992783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umsu.rec.1392.75|Resistant Starch, Antioxidant Status and Insulin Resistance|The Effect of Resistant Starch Supplementation on Antioxidant Status and Insulin Resistance in Overweight and Obese Adults||Urmia University of Medical Sciences|Yes|Completed|August 2013|||November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|21|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01992783||55824|
NCT01963091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009981|Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals|Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals||Medical University of South Carolina|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|33|||Both|18 Years|65 Years|No|||December 2013|December 18, 2013|July 13, 2011|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT01963091||58099|
NCT01993004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0220060134|Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells|Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells||Rutgers, The State University of New Jersey|No|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|24|Samples With DNA|peripheral blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control human subjects and patients with RRMS will be enrolled in New Brunswick, NJ|May 2015|May 5, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993004||55807|
NCT01964521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxT Ag 05|TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended|An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended|MxT Ag 05|Molnlycke Health Care AB|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2014|September 7, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01964521||57990|
NCT01964534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFUGEM D12-2|Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer|Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer|AFUGEM|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Active, not recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964534||57989|
NCT01960790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-152|Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)|Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)||AbbVie||Recruiting|July 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|99 Years|No|Non-Probability Sample|All patients who receive Humira® (Adalimumab) for the treatment of Intestinal Behcet's        disease|January 2016|January 27, 2016|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01960790||58275|
NCT01960803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI-001|Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)|Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT) As A Single, Full Dose Partial Breast Irradiation For Early Stage, Node Negative, Invasive Breast Cancer||Advocate Health Care||Recruiting|May 2013|July 2023|Anticipated|July 2022|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|60 Years|95 Years|No|||October 2013|October 9, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01960803||58274|
NCT01960816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP026|InFlux System for Nasal Breathing Improvement|Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing||Aerin Medical|No|Active, not recruiting|September 2013|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|50 Years|No|||December 2015|December 28, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960816||58273|
NCT01962545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C740|Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study|Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study|OAC-ALONE|Kyoto University, Graduate School of Medicine|Yes|Recruiting|October 2013|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|20 Years|N/A|No|||August 2015|August 31, 2015|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01962545||58141|
NCT01953198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226/12|High Altitude Medical Research Expedition Himlung 2013 - a Study of Human Adaption to Hypoxia|High Altitude Medical Research Expedition Himlung 2013 - an Observational Cohort Study of Human Adaption to Hypobaric Hypoxia|HiReach 2013|University Hospital Inselspital, Berne|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|serum urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and trained volunteers with basic mountaineering experience|September 2013|September 25, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953198||58859|
NCT01953809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112163|A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women|A Phase 1, Randomized, Single Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women of Childbearing Age Who Are of Non-Childbearing Potential Due to Surgical Sterilization or IUD Placement (PDF112163)||GlaxoSmithKline|No|Withdrawn|August 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|0|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|September 26, 2013|Yes|Yes|Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not    seen that changed the risk: benefit profile and led to a termination|No||https://clinicaltrials.gov/show/NCT01953809||58812|
NCT01953822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116239|Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom|An Observational Cohort Study to Assess the Risk of Autoimmune Diseases in Adolescent and Young Adult Women Aged 9 to 25 Years Exposed to Cervarix® in the United Kingdom||GlaxoSmithKline||Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1053|||Both|9 Years|25 Years|No|Non-Probability Sample|Female population is composed of female subjects vaccinated with Cervarix® between the        ages of 9 to 25 years and unexposed female subjects identified from historical data. Male        population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.|April 2015|April 2, 2015|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953822||58811|
NCT01954303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHHD-BM-001|HsTnT in Stable Coronary Artery Disease|Elevated High-sensitivity Cardiac Troponin T Levels in Patients With Stable Coronary Artery Disease||University Hospital Heidelberg|No|Completed|October 2013|April 2015|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|965|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We plan to conduct a single-centre pilot study in a cohort with clinically stable patients        (n=910) of our outpatient clinic who presented 12 months after introduction of the        high-sensitivity troponin T assay (june 2009) for routine workup. No patients will be        excluded.        All patients with stable CAD with or without cardiovascular comorbidities will be selected        and classified as "troponin positive" or "troponin negative" according to initially        documented hs-cTnT value.|May 2015|May 9, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954303||58774|
NCT01954030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044274|Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure|A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure||Duke University|No|Terminated|October 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 26, 2013|Yes|Yes|Study terminated early due to funding reasons prior to completing Phase 1|No||https://clinicaltrials.gov/show/NCT01954030||58795|
NCT01955096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-172|Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer: a Randomized Controlled Trial|Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric|FTSlapAG|First Hospital of Jilin University|Yes|Completed|September 2010|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|61|||Both|N/A|75 Years|No|||October 2013|October 8, 2013|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955096||58713|
NCT01955109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLFUS-VIPES|Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children|Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut|OLFUS-VIPES|DBV Technologies|Yes|Active, not recruiting|September 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|171|||Both|7 Years|56 Years|No|||September 2015|September 11, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955109||58712|
NCT01955057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5579|Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology|Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology||University Hospital, Strasbourg, France|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited in the pneumology ward of Strasbourg University Hospital,        precisely in hospitalization units involved in cancer care (Units 1404,1403,1202,2099)|March 2016|March 10, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01955057||58716|
NCT01955902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271201300015C|Using mHealth to Aid Opioid Addicts|Using mHealth to Aid Opioid Medication Adherence Focus Groups||Care Team Solutions|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|21 Years|N/A|No|Probability Sample|Community Sample|November 2013|November 8, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01955902||58651|
NCT01962480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOSE-GAP-1|The Effect of Laparoscopically Closing the Hernia Defect in Laparoscopic Ventral Hernia Repair on Postoperative Pain|The Clinical Effects of Intracorporally Closure of the Hernia Defect in Laparoscopic Umbilical or Epigastric Hernia Repair|CLOSE-GAP|Hvidovre University Hospital|Yes|Enrolling by invitation|November 2013|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01962480||58146|
NCT01962493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202182|An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining|A Study to Evaluate the Effect of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Digluconate Tooth Staining||GlaxoSmithKline|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|160|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|October 10, 2013||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01962493||58145|
NCT01962506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPACS13|Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of NSTE-ACS|Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study|COPACS|G. d'Annunzio University||Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Emergency Department.|October 2013|October 10, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962506||58144|
NCT01962519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K/ZDS/002306|Early Oral Feeding After Total Gastrectomy for Cancer|A Randomized Clinical Trial of Early Oral Feeding as a Component of Accelerated Recovery Protocol After Total Gastrectomy for Cancer||Jagiellonian University|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|112|||Both|18 Years|80 Years|No|||October 2013|October 10, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962519||58143|
NCT01994876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP229|Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy|Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy||Coloplast A/S|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|October 1, 2013||No||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01994876||55664|
NCT01993264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33343|Fetal Cardiac Strain Imaging Research|Standardization Of A Novel Method To Assess Fetal Cardiac Function: Myocardial Deformation Analysis||Baylor College of Medicine|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|64 Years|No|Non-Probability Sample|Patients at the obstetrics clinic at Texas Children's Hospital Pavilion for Women at the        time of their second trimester screening ultrasound will be asked to volunteer to take        part in the study.|November 2013|November 20, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01993264||55787|
NCT01963377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B076201215478|Toward the Development of a Bronchoscope With a Dedicated O2 Channel ?|Evaluation of Feasibility of Dedicated Extra O2-channel in a Bronchoscope.||Centre Hospitalier Universitaire Saint Pierre|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 11, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01963377||58077|
NCT01963897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/513|Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of Life.|Duchenne Muscular Dystrophy in Norway. Genotype/Phenotype in Patients Younger Than 18 Years, With a Main Focus on Growth, Puberty, Bone Health and Quality of Life.||Oslo University Hospital|No|Recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|whole blood, serum|Male|N/A|18 Years|No|Probability Sample|All patients with Duchenne muscular dystrophy under 18 years in Norway|October 2014|October 31, 2014|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963897|3 Years|58037|
NCT01963390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000184|Metabolomics During Testosterone Therapy|Testosterone Therapy and Its Effects on Metabolic Function||Men's Health Boston|No|Recruiting|July 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum samples obtained for metabolomics|Male|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Testosterone deficient men who intend to undergo testosterone therapy at an outpatient        men's health clinic.|April 2015|April 8, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963390||58076|
NCT01965041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The AVA Study|Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy|Use Of Intravitreal Aflibercept Injections In The Treatment Of Adult-Onset Vitelliform Detachments Associated With Pattern Dystrophy|AVA|Manhattan Eye, Ear & Throat Hospital|Yes|Withdrawn|October 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|90 Years|No|||December 2014|December 30, 2014|October 11, 2013|Yes|Yes|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT01965041||57950|
NCT01965054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1542|The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy|The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy||Icahn School of Medicine at Mount Sinai|No|Withdrawn|December 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||October 2013|October 15, 2013|October 11, 2013|No|Yes|Logistics unresolved at the IRB at Elmhurst Hospital|No||https://clinicaltrials.gov/show/NCT01965054||57949|
NCT01961596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Balgrist 2013-0359|The Influence of a "Cooling Ice Spray " Application on the Time to Stability After a Forward Jump?|Does Have a Short-term "Cooling Ice Spray" Application at the Lateral Ankle an Influence on the Time to Stability After a Forward Jump?||Balgrist University Hospital|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961596||58214|
NCT01964235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2203|Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma|A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment||Novartis|Yes|Suspended|March 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|69|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964235||58012|
NCT01953484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VECLA-ECMO|Changes in Spontaneous Ventilation in Response to Changes in Extracorporeal Carbon Dioxide Removal|Changes in Spontaneous Ventilation in Response to Changes in Extracorporeal Carbon Dioxide Removal||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Recruiting|July 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01953484||58837|
NCT01953497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC001KR|Phase 1 Study of URC102 in Healthy Subjects|A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics||JW Pharmaceutical|No|Active, not recruiting|June 2013|June 2014|Anticipated|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01953497||58836|
NCT01954056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0052|Hydrocortisone for Term Hypotension|Hydrocortisone Treatment of Cardiovascular Insufficiency in Term and Late Preterm Infants: A Randomized Controlled Trial||NICHD Neonatal Research Network|Yes|Active, not recruiting|July 2014|July 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|646|||Both|34 Weeks|N/A|No|||October 2015|October 5, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954056||58793|
NCT01954329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43627.041.13|Markers in the Diagnosis of TIA|Markers in the Diagnosis of TIA|MIND-TIA|UMC Utrecht|Yes|Recruiting|September 2013|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|350|Samples With DNA|Serum, RNA and DNA material.|Both|18 Years|N/A|No|Non-Probability Sample|350 patients suspected of TIA by the GP|June 2015|June 12, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954329||58772|
NCT01954316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFI-400945-CL-001|A Study of CFI-400945 Fumarate in Patients With Advanced Cancer|An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer||University Health Network, Toronto|Yes|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954316||58773|
NCT01954550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG043392-01A1|Effects of Aerobic Exercise for Treating Alzheimer's Disease|Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume Effects|FIT-AD|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|66 Years|N/A|No|||November 2015|November 30, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01954550||58755|
NCT01954563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB035|Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity|A Phase I Trial Evaluating Mucosal Administration of a Candidate TB Vaccine, MVA85A, as a Way to Induce Potent Local Cellular Immune Responses and Avoid Anti-vector Immunity||University of Oxford|Yes|Completed|October 2013|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|37|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954563||58754|
NCT01954576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306042|NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of the NovoTTF-100A System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme||Washington University School of Medicine|No|Recruiting|October 2013|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|22 Years|N/A|No|||November 2015|November 4, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954576||58753|
NCT01954823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0065-CTIL|Use of an Electronic Diary by People With Multiple Sclerosis|Randomized Controlled Trial for the Evaluation of the Use of an Electronic Diary by People With Multiple Sclerosis||Carmel Medical Center|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 2, 2015|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01954823||58734|
NCT01948414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.784|Cognitive Processes Study in Obese Women With and Without Eating Disorders|Cognitive Processes Study in Obese Women With and Without Eating Disorders : Research of Electro-physiological Similarity With Addiction|P300|Hospices Civils de Lyon|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|90|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 21, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01948414||59226|
NCT01993706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140019|Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults|VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|29|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|November 19, 2015|November 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01993706||55753|
NCT01993719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140022|Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Phase II Study for Metastatic Melanoma Using High Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes Plus IL-2 With the Administration of Pembrolizumab in the Retreatment Arm||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|September 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||July 2015|February 23, 2016|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993719||55752|
NCT01991509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBR-101-011|Safety and Bioavailability of IV and SC LBR-101|A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously||Teva Pharmaceutical Industries|No|Completed|October 2013|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|6||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991509||55922|
NCT01991522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-197c|A Randomized Control Trial of a Simulation-based Curriculum to Enhance Skills in Colonoscopy|A Comprehensive Simulation-based Curriculum as a Means to Enhance Technical and Non-technical Skills in Colonoscopy: a Randomized Control Trial||St. Michael's Hospital, Toronto|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991522||55921|
NCT01992016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1908.cc|A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine|A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine||University of Colorado, Denver|Yes|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Male|19 Years|N/A|No|||December 2015|December 3, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992016||55883|
NCT01992029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/13|Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis|Etude de l'Expression Des Micro-RNA Comme Biomarqueur Diagnostic et Pronostic Dans la Sclérose Latérale Amyotrophique|MIRSLA|University Hospital, Bordeaux|No|Recruiting|June 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|Whole blood Cerebrospinal fluid muscle|Both|45 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from ALS, neuropathy, myopathy or control subjects having a shoulder        surgery during which they will have a muscle (deltoid) biopsy|January 2015|January 8, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01992029||55882|
NCT01962857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBLS1020|Effect of 4 Weeks of Shuttle Run Training on Insulin Sensitivity in Sedentary Men|Effect of 4 Weeks of Shuttle Run Training on Insulin Sensitivity in Sedentary Men||University of Glasgow|No|Recruiting|October 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962857||58117|
NCT01962870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB26034|The Role of Vasopressin in the Social Deficits of Autism|Randomized Placebo-controlled Trial of Vasopressin Treatment for Social Deficits in Children With Autism||Stanford University|Yes|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|12 Years|No|||December 2015|December 2, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962870||58116|
NCT01963156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008813|Synchronization to Improve Non-Adherence to Cardiovascular Medications|Synchronization to Improve Non-Adherence to Cardiovascular Medications (SyNCMed)|SyNCMed|Brigham and Women's Hospital||Terminated|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3675|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963156||58094|
NCT01964170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3550-CL-0010|A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer|ASP3550 Phase III Study - An Open-Label, Active-Controlled, Parallel-Arm Study, Comparing ASP3550 With Goserelin Acetate in Patients With Prostate Cancer -||Astellas Pharma Inc|No|Active, not recruiting|August 2013|November 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Male|20 Years|N/A|No|||June 2015|June 26, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964170||58017|
NCT01963676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2995|Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia|Clinical Trial to Assess Transcranial Current Stimulation as a Treatment for Medication Refractory Auditory Hallucinations in Schizophrenia||University of North Carolina, Chapel Hill|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 13, 2013|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01963676||58054|
NCT01963949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC|Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events|Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events||University of Texas Southwestern Medical Center|No|Withdrawn|October 2013|||November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|To collect tumor tissue from patients with liver masses suspicious for primary liver cancer.|Both|18 Years|90 Years|No|Non-Probability Sample|500 patients with a liver mass suspicious for HCC|May 2014|May 15, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963949|5 Years|58033|
NCT01964248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.011 (GAEL)|Local Anesthesia Before Arterial Puncture for Blood Gas Analysis|Evaluation of Local Anesthesia Before Arterial Puncture for Blood Gas Analysis Randomized, Control Placebo Study|GAEL|University Hospital, Brest|Yes|Completed|December 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01964248||58011|
NCT01964261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00492|Providing Closed Loop Cortical Control of Extracorporeal Devices to Patients With Quadriplegia|A Feasibility Study of the Ability of the Neural Prosthetic System 2 to Provide Direct Closed Loop Cortical Control of Extracorporeal Devices Through the Use of Intracortical Microstimulation in Patients With Quadriplegia||California Institute of Technology|Yes|Recruiting|November 2013|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|2|||Both|22 Years|65 Years|No|||July 2015|July 27, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964261||58010|
NCT01953835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117171|A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184|A Two-part Healthy Volunteer Study to Investigate Both the Interaction of GSK2586184 With Rosuvastatin and Simvastatin and to Compare the Pharmacokinetics of Two Different Formulations of GSK2586184||GlaxoSmithKline|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953835||58810|
NCT01954069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6005|Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service|Simplifying Menstrual Regulation (MR): Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service Provision in Pakistan||Gynuity Health Projects|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|280|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954069||58792|
NCT01954342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 13020|Determinants of Gestational Weight Gain in Obese Pregnant Women|MomEE: Determinants of Gestational Weight Gain in Obese Pregnant Women|MomEE|Pennington Biomedical Research Center|No|Recruiting|December 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Placenta, Cord Blood, fasting Urine, fasting Maternal plasma and serum (during pregnancy and      postpartum).|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 obese, pregnant women|March 2016|March 21, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954342||58771|
NCT01954355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 65/12|LDE225 and Paclitaxel in Solid Tumors|LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|September 2013|June 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01954355||58770|
NCT01954589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-074-101|Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206|Double-blind, Placebo- and Active-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206 in Healthy Male Subjects||Actelion|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|7||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01954589||58752|
NCT01951911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/539|Effectiveness of Ketamine in Malignant Neuropathic Pain Relief|Low-dose Ketamine as Adjuvant Treatment to Morphine in Neuropathic Cancer Pain|KETA-1|Haukeland University Hospital|Yes|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||June 2015|June 9, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01951911||58958|
NCT01951924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10E-0901|LIME Study (LFB IVIg MMN Efficacy Study)|A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy|LIME|Laboratoire français de Fractionnement et de Biotechnologies|No|Active, not recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|No|||December 2015|January 11, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01951924||58957|
NCT01955083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hyli38|Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients|Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients||Chang Gung Memorial Hospital|Yes|Completed|August 2010|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|60 Years|No|||October 2013|July 28, 2014|July 29, 2010|Yes|Yes||No|October 6, 2013|https://clinicaltrials.gov/show/NCT01955083||58714|The major limitations to this study were unbalanced randomization in Total-Imax despite insignificant differences in other baseline parameters between the two groups and the small sample size of the study limited the subgroup analysis.
NCT01955382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913209|Evaluation of Oral Activated Charcoal on the Ability of an Antimalarial Drug to Kill Parasites in Malian Children With Mild Malaria|Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria||National Institutes of Health Clinical Center (CC)||Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|2 Years|10 Years|No|||July 2015|August 26, 2015|September 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955382||58691|
NCT01948128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120362-2OH|Effects of Vitamin D in Patients With Breast Cancer|A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Vitamin D in Patients With Breast Cancer. The ICARUS Trial|OTT 12-06|Ottawa Hospital Research Institute|Yes|Completed|October 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|83|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01948128||59248|
NCT01994603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1590|Expansion to Interdisciplinary HIV Prevention in Women|Preventing FAS/ARND in Russian Children/Expansion to Interdisciplinary HIV Prevention in Women||University of Oklahoma|Yes|Completed|December 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|41|||Female|18 Years|44 Years|No|||January 2016|January 13, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01994603||55685|
NCT01991730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJRetina-ML28942|Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients|Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients||NJ Retina|No|Recruiting|October 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|65 Years|90 Years|No|Probability Sample|Private practice patients referred to retinal specialist for treatment of Neovascular        Age-Related Macular Degeneration|April 2015|April 20, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01991730||55905|
NCT01962779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S#12-03068|Sleep, Aging and Risk for Alzheimer's Disease|Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study|SARA|New York University School of Medicine|Yes|Recruiting|July 2013|July 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|45|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01962779||58123|
NCT01963078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH099619-01|Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin|Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin||Medical University of South Carolina|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|38|||Both|18 Years|50 Years|No|||February 2016|February 5, 2016|October 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963078||58100|
NCT01963182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001275-21|Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer|Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer|IriGen|Centre Jean Perrin|No|Recruiting|October 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||October 2013|May 7, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963182||58092|
NCT01963442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-12-202.0496 - PTC|Short Duration Treatment of Non-severe Community Acquired Pneumonia|A Non-Inferiority, Multicentered, Controlled, Randomized, Double Blinded Study Investigating the Antibiotic Treatment Duration (3-day Versus 8-day) for Subjects Admitted to Emergency Services With Acute Non-severe Community Acquired Pneumonia (CAP)||Central Hospital, Versailles|Yes|Recruiting|November 2013|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963442||58072|
NCT01963169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041186|Dissemination of a Theory-Based Bone Health Program in Online|Dissemination of a Theory-Based Bone Health Program in Online Communities||University of Maryland|No|Active, not recruiting|June 2011|May 2014|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|866|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 12, 2013|April 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01963169||58093|
NCT01963468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00081066|Maximizing Language Development in Children With Hearing Loss|Pre-Implantation Communication Treatment for Children With Hearing Loss||Northwestern University|No|Active, not recruiting|October 2013|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963468||58070|
NCT01963455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Kidney-001|Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency|The Effect Evaluation of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Urinary Incontinency||Royan Institute|Yes|Completed|January 2013|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|40 Years|65 Years|No|||January 2013|May 5, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963455||58071|
NCT01963689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|469376|Aromatherapy for Anxiety and Self-esteem: Clinical Trial|Aromatherapy for Anxiety and Self-esteem: Clinical Trial||University of Sao Paulo|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|34|||Both|34 Years|53 Years|Accepts Healthy Volunteers|||October 2013|October 13, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963689||58053|
NCT01963702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDZL-TXELOX|A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC|Phase II Trial of Exploring the Predictive Factors of Docetaxol Plus Capecitabine(TX) Regimen and Oxaliplatin Plus Capecitabine (XELOX) Regimen in the First Line Treatment of Patients With Metastatic Gastric Cancer (MGC)||Fudan University|No|Recruiting|August 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||October 2013|October 12, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01963702||58052|
NCT01950572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130202|Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma|Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|July 2034|Anticipated|July 2033|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|2 Years|N/A|No|||May 2015|July 17, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950572||59060|
NCT01950585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130203|Hydroxyurea in Pulmonary Arterial Hypertension|Hydroxyurea in Pulmonary Arterial Hypertension||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2013|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01950585||59059|
NCT01953848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-053|A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)|An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Volunteers Over 45 Years of Age||Astellas Pharma Inc|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953848||58809|
NCT01951092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lifespan Dev Grant Rana-2012|mHealth Intervention Supporting HIV Treatment Adherence and Retention|mHealth Intervention Supporting HIV Treatment Adherence and Retention||The Miriam Hospital|Yes|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01951092||59020|
NCT01951105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00081444|Effect of L-dopa In Subacute Back Pain Population|Corticostriatal Plasticity in the Transition to Chronic Pain: Effect of L-dopa||Northwestern University|Yes|Recruiting|February 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951105||59019|
NCT01951404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CV07|Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study|Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study|Altered|University of Dundee|Yes|Active, not recruiting|September 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951404||58996|
NCT01954849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-001|Assessment of a Probiotic to Treat Gingivitis in Pediatric Patients|Assessment of Therapeutic Potential of a Novel Dental Probiotic in Pediatric Patients Affected by Gingivitis||Lawson Health Research Institute|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|11 Years|18 Years|No|||August 2015|August 17, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954849||58732|
NCT01955395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-266|Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma|Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma||Massachusetts General Hospital|Yes|Recruiting|October 2013|September 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955395||58690|
NCT01955408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNERGO-OAB|Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment|Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment for Bladder Cancer|OABSYNERGO|Meir Medical Center|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|335|||Both|18 Years|N/A|No|Non-Probability Sample|Bladder cancer patients after Synergo treatment completion and no evidence of disease at        cystoscopic evaluation|March 2016|March 15, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01955408|12 Weeks|58689|
NCT01955681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OTW-XXX-2013/1|A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.|A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy - SEQUENCE Study|SEQUENCE|AstraZeneca|No|Completed|December 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|150 Years|No|Non-Probability Sample|Patients with locally advanced or metastatic Epidermal Growth Factor Receptor mutated        Non-small-cell Lung Cancer who Previously Treated with Epidermal Growth Factor Receptor        Tyrosine Kinase Inhibitor as First-line therapy and chemotherapy as second-line Therapy -        SEQUENCE study|November 2015|November 3, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955681||58668|
NCT01961661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF pilot|Probiotics on Intestinal Inflammation in Cystic Fibrosis|Effect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot Study||Federico II University|No|Completed|September 2009|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|22|||Both|2 Years|18 Years|No|||October 2013|October 11, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961661||58209|
NCT01995422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00934-37|Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up|Effects of Physical Activity Program on the Emotional and Cognitive Dynamics in Major Depressive Disorder Patients|2DPAP|Laboratory Motricité, Interactions, Performance|Yes|Completed|December 2011|June 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|16|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01995422||55622|
NCT01995435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL-321-REF|Refraction Determination Analysis|||Lee, Steven, M.D.||Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01995435||55621|
NCT01962233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12276102D-Neurologic Disorder|Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy|Safety and Efficacy Investigation of Patients With Hypoxic Ischemic Encephalopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells||Hebei Medical University|Yes|Recruiting|September 2013|December 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||September 2013|October 10, 2013|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962233||58165|
NCT01962597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-468|Trial of Hemodialysis Based Exercise for Strength Improvement Study|Comparison of Aerobic Exercise, Strength Training, or Its Combination in Hemodialysis Patients: a Randomized Controlled Trial|THESIS|St. Joseph's Healthcare Hamilton|No|Not yet recruiting|October 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962597||58137|
NCT01963481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00761|Exemestane and Cyclophosphamide for Metastatic Breast Cancer|Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer||New York University School of Medicine|Yes|Active, not recruiting|September 2013|September 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963481||58069|
NCT01963715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0501|A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors|A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors||ImmunoGen, Inc.|No|Terminated|October 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01963715||58051|
NCT01963728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inova NODAT-001|Comparison of Insulin Therapy in Treating Post-Transplant Diabetes|Comparison of Insulin Isophane (NPH) With Insulin Glargine in New Onset Diabetes After Transplant (NODAT)||Inova Health Care Services|No|Terminated|May 2014|March 2015|Actual|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 10, 2013|Yes|Yes|Difficult to enroll. The blood sugar status of the two enrolled subjects was not evaluable due    to multiple hospital admissions.|No||https://clinicaltrials.gov/show/NCT01963728||58050|
NCT01950598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FvF 08.275|Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers|Boston Keratoprosthesis Type 1 Surgery: Use of Frozen Versus Fresh Corneal Donor Carriers||Centre hospitalier de l'Université de Montréal (CHUM)|No|Enrolling by invitation|September 2013|January 2020|Anticipated|November 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||September 2013|September 22, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01950598||59058|
NCT01950845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.770|Automated Versus Manual Fluid Management for High Risk Abdominal Surgical Patient. A Prospective, Randomized Trial|Per Operative Fluid Optimisation Comparison of an Automated Closed-Loop System Versus Current Practice in High Risk Abdominal Surgical Patient. A Prospective, Randomized Clinical Trial.|CL vs CP|Hospices Civils de Lyon|Yes|Recruiting|February 2014|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01950845||59039|
NCT01950858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91/12*1|Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee|Safety and Efficacy of Hyper Baric Oxygen Therapy (HBOT) in Patients Presenting With Spontaneous Osteonecrosis of the Knee||Assaf-Harofeh Medical Center|No|Recruiting|May 2012|August 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Months|85 Years|No|||September 2013|September 19, 2013|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01950858||59038|
NCT01951118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6655|Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly|Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly||New York State Psychiatric Institute|Yes|Recruiting|October 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|170|||Both|55 Years|95 Years|No|||October 2015|October 5, 2015|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951118||59018|
NCT01951131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1000-0068|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||June 23, 2014|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951131||59017|
NCT01951417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SRE.04.US10268|Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris|Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris||Galderma Laboratories, L.P.|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|81|||Both|9 Years|N/A|No|||February 2016|February 17, 2016|September 23, 2013|Yes|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01951417||58995|Open label study with small sample sizeShort study duration
NCT01951716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861 D|Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy|Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy||Washington University School of Medicine|No|Active, not recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951716||58973|
NCT01956201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146MHL13011|Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin|Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study.||Chong Kun Dang Pharmaceutical|No|Recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|476|||Both|19 Years|N/A|No|||February 2015|February 2, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01956201||58628|
NCT01951677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV002|Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine|Phase 1 Randomized, Controlled, Double-blind Study to Compare the Safety and Effectiveness of Hepatitis B Vaccines in Individuals With Renal Impairment, Diabetes Mellitus or Age Greater Than 40 Years||Vaxine Pty Ltd|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|12||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01951677||58976|
NCT01951690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-201|Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer|Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer||Verastem, Inc.|No|Active, not recruiting|September 2013|February 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951690||58975|
NCT01951703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5509|Senofilcon A Investigational Manufacturing Process|Clinical Investigation of Senofilcon A Manufactured Using an Alternate Hydration Process||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|136|||Both|18 Years|70 Years|No|||July 2015|July 6, 2015|September 23, 2013|Yes|Yes||No|July 6, 2015|https://clinicaltrials.gov/show/NCT01951703||58974|
NCT01947829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-O-H-1205|Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)|Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)|IVP|B.Braun Avitum AG|No|Not yet recruiting|October 2013|||July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on chronic hemodialysis.|September 2013|September 20, 2013|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01947829||59271|
NCT01948102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-Neurology_ALS_TDI_PEG|Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples|Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples||Carolinas Healthcare System|Yes|Recruiting|July 2008|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|skin and adipose tissue|Both|19 Years|N/A|No|Non-Probability Sample|Patients at the Carolinas Neuromuscular/ALS-MDA Center and patients at Carolinas Medical        Center.|July 2014|July 2, 2014|March 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01948102||59250|
NCT01948115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0254|Evaluation of the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV)|Prospective Randomized Controlled Trial to Evaluate the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV) in Singleton Pregnancy in Breech Presentation at Term|MEOREV|Nantes University Hospital|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||November 2015|December 17, 2015|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01948115||59249|
NCT01961674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00785|Studying the Effect of Capsinoids on Brown Fat Using Infrared Thermal Imaging.|Infrared Thermal Imaging for Assessing the Effect of Capsinoids on Brown Adipose Tissue Activity.||Clinical Nutrition Research Centre, Singapore|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Male|21 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961674||58208|
NCT01961947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7374-CL-0102|Study of ASP7374, Cell-culture-derived Influenza Vaccine|Phase 3 Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults ≥20 and <65 Years of Age－||Astellas Pharma Inc|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|900|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961947||58187|
NCT01962259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIWE-1|Active Commuting To Improve Well-being and Health in Everyday Life|Active Commuting To Improve Well-being and Health in Everyday Life|GO-ACTIWE|University of Copenhagen|Yes|Active, not recruiting|October 2013|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|175|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01962259||58163|
NCT01962272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2009-135|The Effect of Nutritional Counseling for Cancer Patients|Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients||University of Copenhagen|No|Completed|January 2010|September 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|61|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962272||58162|
NCT01962610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1414|Improving Pain Management for Older Adults in the Emergency Department (ED)|Improving Management of Acute Pain for Older Adults in the ED Setting||Icahn School of Medicine at Mount Sinai|No|Completed|June 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|4693|||Both|20 Years|N/A|No|||November 2015|November 4, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962610||58136|
NCT01962883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEOVtPCS|Effects of Osteopathic Treatment on Vestibular Disturbed Active Post Concussed Individual|The Effects of Osteopathic Treatment on Balance and Dizziness of the Vestibular Disturbed Active Post Concussed Individual.|PCS|Collège d'Études Ostéopathiques|No|Completed|August 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|45 Years|No|||February 2015|February 2, 2015|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01962883||58115|
NCT01962896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW-GCT-001|A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors|A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2014|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|12 Months|50 Years|No|||September 2015|September 21, 2015|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962896||58114|
NCT01963195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEI-ADNSCLC|Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy|An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy||Anhui Medical University|Yes|Not yet recruiting|October 2013|October 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||October 2013|October 15, 2013|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963195||58091|
NCT01963494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110014|Days in Motion: A Planning Intervention Study With Couples to Enhance Daily Physical Activity|Days in Motion: A Planning Intervention Study With Couples to Enhance Daily Physical Activity (DiM)|DiM|Freie Universität Berlin|No|Completed|March 2013|January 2016|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|346|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01963494||58068|
NCT01963741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTD4NAPT201218|Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis|Leukotriene D4 Nasal Provocation Test: Rationale, Methodology, Diagnostic Value and Its Impact on Airway Inflammation in Allergic Rhinitis With or Without Asthma||Guangzhou Institute of Respiratory Disease|No|Completed|November 2012|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01963741||58049|
NCT01950611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8225 27/02/13|Proteasome Inhibition in Acute Promyelocytic Leukemia|Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia|PIAPL|Christian Medical College, Vellore, India|Yes|Recruiting|May 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|75 Years|No|||September 2013|September 24, 2013|September 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01950611||59057|
NCT01950871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2P01127|Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning|Diagnostic Performance of Prostate HistoScanningTM (PHS) in Men at Risk of Prostate Cancer Scheduled for an Initial Prostate Biopsy|PHSTT-01|Advanced Medical Diagnostics s.a.|No|Terminated|October 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Male|18 Years|N/A|No|||January 2015|January 2, 2015|September 19, 2013||No|Sponsor is bankrupt|No||https://clinicaltrials.gov/show/NCT01950871||59037|
NCT01951144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431001|A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects||Pfizer|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01951144||59016|
NCT01951430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS0413|Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients|Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors.||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|March 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult myelodysplastic syndrome patients|February 2016|February 22, 2016|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01951430||58994|
NCT01951443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRAB|Korean Red Ginseng Rg3 Extract on Arterial Stiffness and Blood Pressure|Acute Effect of Rg3-enriched Korean Red Ginseng (Steamed Panax Ginseng C.A. Meyer) Standardized Extract on Arterial Stiffness and Aortic and Brachial Blood Pressure in Healthy Individuals|KRAB|St. Michael's Hospital, Toronto|No|Completed|August 2013|||February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|April 25, 2014|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01951443||58993|
NCT01956214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: 12309|Functional Electrical Stimulation (FES) Exercise Training in Hemodialysis Patients|Efficacy of Functional Electrical Stimulation Exercise Training in Hemodialysis Patients||University of Illinois at Urbana-Champaign|No|Terminated|December 2012|November 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|9|||Both|31 Years|85 Years|No|||August 2014|August 25, 2015|April 17, 2013||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01956214||58627|
NCT01952288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1195-I|Simvastatin for mTBI|Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI||VA Office of Research and Development|Yes|Recruiting|September 2013|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|21 Years|50 Years|No|||March 2016|March 4, 2016|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01952288||58929|
NCT01951963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-158|Sub-dissociative Ketamine for the Management of Acute Pediatric Pain|Sub-dissociative Ketamine for the Management of Acute Pediatric Pain||HealthPartners Institute|No|Recruiting|December 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|17 Years|No|||August 2014|August 7, 2014|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01951963||58954|
NCT01951937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINS-547|Herring and Mackerel Intervention and Learning Abilities|Herring and Mackerel Intervention and Learning Abilities in German Youths|FINS|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01951937||58956|
NCT01951950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00083793|Nicardipine vs Esmolol Craniotomy Emergence|Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy||Northwestern University|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|September 24, 2013|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT01951950||58955|
NCT01947842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCOP-001|Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females|Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females: a Randomized-controlled Trial.||Belmont University|No|Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01947842||59270|
NCT01961986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02125|Rotator Cuff Sparing Total Arthroplasty|Rotator Cuff Sparing Total Arthroplasty - A Prospective, Randomized Clinical Trial||New York University School of Medicine|No|Recruiting|July 2010|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|No|||October 2015|October 5, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961986||58184|
NCT01962298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 13/5/60|Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex|Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial|SUDIA|University Hospital, Antwerp|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962298||58160|
NCT01961960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7374-CL-0105|A Study to Evaluate Intramuscular ASP7374|Phase 3 Study of ASP7374 －Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age－||Astellas Pharma Inc|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|61 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961960||58186|
NCT01962246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alien-Craft|Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction|Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer|A-C|Hebei Medical University|No|Recruiting|February 2012|December 2018|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|75 Years|No|||October 2013|October 10, 2013|July 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01962246||58164|
NCT01962285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INERTIA|Neuronal Inertia in Propofol Anesthesia|Neuronal Inertia´s Effect on Pharmacological Behavior Representation of Propofol|INERTIA|Universidad del Desarrollo|No|Completed|August 2013|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 11, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962285||58161|
NCT01962909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16678|Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer|A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma||University of Virginia|Yes|Terminated|November 2013|January 2016|Actual|January 2016|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 19, 2013|Yes|Yes|From preliminary imaging data, the study was stopped due to futility.|No||https://clinicaltrials.gov/show/NCT01962909||58113|
NCT01963208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0603|Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension|A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment||Marinus Pharmaceuticals|No|Active, not recruiting|October 2013|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963208||58090|
NCT01963221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentralHNF|Relationship Between Thoracic Aortic Structure Assessed B PET/CT Scan and Arterial Stiffness in Elderly Patients|RELATIONSHIP BETWEEN THORACIC AORTIC STRUCTURE ASSESSED BY PET/CT SCAN AND ARTERIAL STIFFNESS IN ELDERLY PATIENTS: FICTEP STUDY|FICTEP|Central Hospital, Nancy, France|Yes|Completed|January 2010|September 2013|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 13, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01963221||58089|
NCT01963507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE RT|Effects of a Resistance Training Period on Blood Pressure of Hypertensive Elderlies: Influence of the Polymorphism of the Angiotensin Converting Enzyme|Effects of a Resistance Training Period on Blood Pressure of Hypertensive Elderlies: Influence of the Polymorphism of the Angiotensin Converting Enzyme||Federal University of São Paulo|Yes|Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|60 Years|85 Years|No|||October 2013|October 11, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01963507||58067|
NCT01964027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIEG|The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer|The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer|SIEG|Anhui Medical University|Yes|Not yet recruiting|October 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||October 2013|October 14, 2013|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964027||58028|
NCT01954654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-58-0010|Effectiveness of Accelerated Intervention With Compression Sleeve in Mild and Moderate Breast Cancer-related Lymphedema|Effectiveness of Accelerated Intervention With Custom-made Compression Sleeve in Women With Mild and Moderate Arm Lymphedema Secondary to Breast Cancer Treatment||Aarhus University Hospital||Recruiting|October 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|95 Years|No|||October 2013|October 6, 2013|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01954654||58747|
NCT01950884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LISTEN|Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis|A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis||University of Palermo|Yes|Enrolling by invitation|October 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01950884||59036|
NCT01955720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1321.2|Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran|Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers||Boehringer Ingelheim||Completed|September 2013|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|46|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|September 30, 2013||||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01955720||58665|
NCT01955733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301.4|Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis|Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial||Boehringer Ingelheim||Active, not recruiting|September 2013|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|82 Years|No|||January 2016|January 18, 2016|September 30, 2013||||No||https://clinicaltrials.gov/show/NCT01955733||58664|
NCT01955928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UvA-2013-KP-3152|Internet-delivered CBT for Insomnia: Role of Sleep-related Cognitions|Internet-delivered CBT for Insomnia: Role of Sleep-related Cognitions||VU University of Amsterdam||Completed|October 2013|December 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01955928||58649|
NCT01952301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13562-007|Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation|A Randomized, Controlled Clinical Trial to Evaluate a Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation||Perio Health Professionals, PLLC|No|Completed|November 2010|January 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|70 Years|No|||May 2014|May 24, 2014|September 24, 2013||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01952301||58928|
NCT01952275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-DER-AAN-019|Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases|Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses|NEUTROGENE|University of Zurich|No|Recruiting|January 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|600|Samples With DNA|Saliva or Blood Serum Histology FFPE|Both|N/A|N/A|No|Probability Sample|Patients with a history of Neutrophil-Mediated Inflammatory Dermatoses (NMID) of any        subtype|June 2014|June 11, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01952275||58930|
NCT01952548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-312-1.01US|Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers|||Kowa Research Institute, Inc.||Completed|May 2013|||December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|14||||||Both|18 Years|45 Years||||December 2013|December 30, 2013|September 19, 2013||Yes||||https://clinicaltrials.gov/show/NCT01952548||58909|
NCT01947855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.35|Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|74 Years|No|||December 2014|December 16, 2014|September 18, 2013||||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01947855||59269|
NCT01952561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 034|Expanded Use PK of Dapivirine Vaginal Ring|An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods||International Partnership for Microbicides, Inc.|No|Not yet recruiting|November 2013|May 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|September 17, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01952561||58908|
NCT01948141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 225512|Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens|FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2014|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01948141||59247|
NCT01961999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANCCH01|Early Versus Late Renal Replacement Therapy After Cardiac Surgery|"Early" and "Late" Timing Indication for Starting Renal Replacement Therapy in Acute Renal Failure After Cardiac Surgery: a Prospective, Controlled, Interventional, Single-center Trial||Ospedali Riuniti Ancona|No|Completed|July 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1800|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01961999||58183|
NCT01962324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARAPLY-1|Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer|Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV|PARAPLY-1|Umeå University|No|Recruiting|March 2015|November 2022|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Male|18 Years|80 Years|No|||November 2015|November 30, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962324||58158|
NCT01961973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShettyKimRF 001|A Study to Compare Two Techniques for Articular Cartilage Repair: Cultured Chondrocytes Vs. Cultured BMAC|Trial to Compare the Efficacy of Two Surgical Techniques for Articular Cartilage Repair in the Knee: The Use of Cultured Chondrocytes Vs. the Use of Cultured Bone Marrow Aspirate Cells.|Cultured|Shetty-Kim Research Foundation|Yes|Not yet recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2013|October 10, 2013|October 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01961973||58185|
NCT01962662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101080RB|Intervention Study of EMG Biofeedback Assisted Force Control to Treat Stroke Movement Disorder|Effects of Force Level Control Training Using EMG Biofeedback on Transcranial Magnetic Stimulation-Induced Excitability to Anterial Tibialis and Motor Functions After Stroke||National Taiwan University Hospital|Yes|Recruiting|January 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|90 Years|No|||October 2013|October 10, 2013|January 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01962662||58132|
NCT01962623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00083893|Interpersonal Psychotherapy for Youth With Severe Mood Dysregulation|Interpersonal Psychotherapy for Youth With Severe Mood Dysregulation- Randomized Trial||Johns Hopkins University|Yes|Recruiting|August 2013|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|12 Years|17 Years|No|||March 2015|March 30, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962623||58135|
NCT01962636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OC013|Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases|Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases||Masonic Cancer Center, University of Minnesota|No|Not yet recruiting|June 2016|October 2023|Anticipated|October 2023|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962636||58134|
NCT01962649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-314|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||October 10, 2013|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962649||58133|
NCT01963234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0937|Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)|Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)|Seva|University of Wisconsin, Madison|Yes|Recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of federally qualified health centers with drug use disorders.|February 2016|February 10, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01963234||58088|
NCT01963520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHDCSS-01|Prosthetic Hip Infections: Prospective Study|Prospective Study of Patients Treated for Prosthetic Hip Infection and Followed for at Least 2 Years|PHIPS|Groupe Hospitalier Diaconesses Croix Saint-Simon|No|Completed|November 2002|March 2012|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|347|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hip arthroplasty infection who underwent surgery and received antibiotic        therapy in a specialized French orthopaedic center for bone and joint infection.|October 2013|October 11, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01963520||58066|
NCT01963754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-03|Compare Subperiosteal and Loco-Regional Anesthesia in Posterior Mandible Dental Implant Installation|Compare Articaine 1:100.000, 4% Epinephrine, Subperiosteal With Loco-regional Anesthesia for Placing Dental Implants in Posterior Mandible - Double-Blinded Randomized Clinical Trial||Instituto de Implantologia|No|Not yet recruiting|January 2014|January 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 12, 2013|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963754||58048|
NCT01964040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-38-2013|Perineural Dexmedetomidine and Femoral Nerve Block|Perineural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.||Cairo University|Yes|Active, not recruiting|August 2013|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|45|||Both|18 Years|45 Years|No|||October 2013|October 14, 2013|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964040||58027|
NCT01964352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.25|Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)|A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2013|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|813|||Both|40 Years|N/A|No|||October 2015|October 23, 2015|October 14, 2013||||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01964352||58003|
NCT01955512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMMED1063|Effect of Clopidogrel on Allergen Challenge in Asthma|Effect of Clopidogrel on Allergen Challenge in Asthma||University of Southampton|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|50 Years|No|||September 2013|September 27, 2013|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955512||58681|
NCT01954888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13054|Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain|Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain||Maisonneuve-Rosemont Hospital|Yes|Recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954888||58729|
NCT01955499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01810|Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma||National Cancer Institute (NCI)||Recruiting|September 2013|||December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|September 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01955499||58682|
NCT01955941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#00009501|Vascular Response to Brachytherapy Using Functional OCT|Characterization of Vascular Response to Brachytherapy Using Functional Optical Coherence Tomography||Oregon Health and Science University|No|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|||Both|18 Years|N/A|No|Probability Sample|This study will measure blood flow changes in 28 patients with uveal melanoma requiring        radiation therapy.|April 2015|April 21, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955941||58648|
NCT01956227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSS-IL-006|Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior|Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior|FARMS-2|University of Illinois at Urbana-Champaign|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|37|||Both|50 Years|75 Years|No|||November 2014|November 23, 2014|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01956227||58626|
NCT01952587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP 53 X LIBRIS|X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study|Frequency and Functional Impact of the c.32A>T Genetic Polymorphism of TLR7 in Women Infected With HIV-1 : the ANRS EP53 Study|X LIBRIS|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01952587||58906|
NCT01952574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120178|A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention||Amgen|No|Active, not recruiting|August 2013|March 2020|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|483|||Both|18 Years|60 Years|No|||April 2015|April 30, 2015|August 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952574||58907|
NCT01952782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001543|Neuropeptides in Human Reproduction|Neuropeptides in Human Reproduction||Massachusetts General Hospital|Yes|Recruiting|January 2014|||August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|128|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952782||58891|
NCT01953068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13043|Executive Reaction Time Test in Assessment of Cognitive Dysfunction After Aortic Valve Procedures|Executive Reaction Time Test in Assessment of Cognitive Dysfunction After Aortic Valve Procedures||Tampere University Hospital|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|60 Years|85 Years|No|Probability Sample|Elective aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI)        patients at Tampere University Hospital Heart Center|September 2015|September 3, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953068||58869|
NCT01961726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-003|Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure|A Phase I/II Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Retrograde Delivery to Cohorts of Adults With Ischemic Heart Failure|RETRO-HF|Juventas Therapeutics, Inc.|Yes|Active, not recruiting|October 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961726||58204|
NCT01962311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN11-CA-METABALS|Evaluation of Metabolomic Analysis in Early Diagnosis of ALS|Evaluation of Metabolomic Analysis in Early Diagnosis of ALS|METABALS|University Hospital, Tours|Yes|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|30 Years|80 Years|No|||May 2014|March 23, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01962311||58159|
NCT01962363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-743 PM|EPI-743 in Friedreich's Ataxia Point Mutations|A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations||University of South Florida|No|Active, not recruiting|October 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962363||58155|
NCT01962376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YZHANG0001|Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis|Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis||Hebei Medical University|No|Recruiting|February 2013|April 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2013|October 10, 2013|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01962376||58154|
NCT01962922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 3004|Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.|Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.||Veloxis Pharmaceuticals|No|Completed|November 2013|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962922||58112|
NCT01962935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5200C00002|Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069|A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days||AstraZeneca|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01962935||58111|
NCT01963533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207006RIC|The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis|The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis||National Taiwan University Hospital|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|peripheral blood|Both|20 Years|N/A|No|Non-Probability Sample|Patients who are newly diagnosed as lung cancer and prepared for scheduled chemotherapy in        National Taiwan University Hospital will be enrolled for screening. The diagnosis is based        on pathology via surgical specimen, or biopsy; or cytology via lung, lymph node aspiration        or effusion study.|October 2013|October 16, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01963533||58065|
NCT01963767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001021|Nutraceutical Effects on Long-Term Memory|Phase II Study of a Nutraceutical on the Cognitive Performance of Older Adults.||University of South Florida|No|Completed|May 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|139|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||April 2014|June 2, 2014|October 9, 2013|Yes|Yes||No|May 2, 2014|https://clinicaltrials.gov/show/NCT01963767||58047|
NCT01964053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228-13-EP|Self-management Adherence in Heart Failure Patients|Promoting Self-management Through Adherence Among Heart Failure Patients|PATCH|University of Nebraska|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964053||58026|
NCT01955954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAHS 1-001-13|Using the Canary Breathing System for Panic Disorder Patients|Investigation of the Canary Breathing System for Treating the Symptoms of Panic Disorder||Palo Alto Health Sciences, Inc.|No|Recruiting|September 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|60 Years|No|||May 2014|May 21, 2014|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955954||58647|
NCT01955746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG3C1151|PST Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan|Parent-sibling Tracing (PST) Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan for Novel HLA and Non-HLA Candidate Risk Alleles Detection|PATT|Chang Gung Memorial Hospital|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|The family of more than one member with T1D|September 2013|June 10, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955746||58663|
NCT01955759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0115/09 - (2013)|Atrial Fibrillation and By-pass Surgery|Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery||Heart Center BH Tuzla||Not yet recruiting|December 2013|February 2015|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|260|||Both|N/A|N/A|No|||December 2013|December 15, 2013|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01955759||58662|
NCT01952314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-URO-2012-03|Medical Expulsive Therapy for Ureter Stone Using Naftopidil|Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study||Seoul National University Hospital|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|N/A|No|||December 2015|December 8, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952314||58927|
NCT01952327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-AAR-008|Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.|Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.|ADEPT|Sequana Medical AG|No|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952327||58926|
NCT01952600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110920130510|Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)|Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)|EPOCH-RRT|Arbor Research Collaborative for Health|No|Completed|June 2013|December 2015|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|181|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients residing in the United States with advanced chronic kidney disease or on        dialysis.|March 2016|March 21, 2016|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01952600||58905|
NCT01952808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003408|Healthy Immigrant Families: Working Together To Move More and To Eat Well|Healthy Immigrant Families: Working Together To Move More and To Eat Well||Mayo Clinic|No|Active, not recruiting|September 2013|October 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|151|||Both|11 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952808||58889|
NCT01952821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004891|Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck|The Validity and Reliability of the Six-Minute Walk Test, Ten-Meter Walk Test, 30 Second Chair Stand, Linear Analog Scale of Function, and the Modified Brief Fatigue Inventory in Patients With Cancer of the Head and Neck||Mayo Clinic|No|Completed|September 2013|January 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|85 Years|No|Non-Probability Sample|Community-dwelling patients with a new or recurrent diagnosis of head and neck cancer.|May 2015|May 21, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01952821||58888|
NCT01952795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-DHE-2011-42|Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle|Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|January 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|35 Years|No|||February 2014|May 6, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01952795||58890|
NCT01953081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0082|A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance|A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance||Theravance Biopharma R & D, Inc.|No|Completed|January 2014|October 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|85 Years|No|||December 2014|December 15, 2014|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953081||58868|
NCT01962389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Winsor - 001|First in Human Study of Winsor Laser Catheter: A Prospective Registry to Evaluate The Safety and Performance of the Winsor Laser Catheter in the Treatment of In-Stent Restenosis|First in Human Study of Winsor Laser Catheter||Spectranetics Corporation|No|Withdrawn|January 2014|||April 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|No|||December 2014|December 4, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01962389||58153|
NCT01962337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPA008-001|Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects|A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis||Five Prime Therapeutics, Inc.|No|Recruiting|October 2013|March 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|89|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962337||58157|
NCT01962948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN-064|Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Fox Chase Cancer Center|Yes|Active, not recruiting|October 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962948||58110|
NCT01962675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110344|Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury|Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury|SLT|University of Miami|No|Terminated|July 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|September 30, 2013||No|PI left study institution, declined to continue study at new institution|No|November 13, 2015|https://clinicaltrials.gov/show/NCT01962675||58131|
NCT01963546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WQie|Effects of Different Types of Anesthesia on Stress Response in Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus|Effects of Different Types of Anesthesia on Stress Response in Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus and the Effect of Dexmedetomidine on the Stress Response in Patients With Diabetic Undergoing Gastric-bypass Surgery||Guangzhou General Hospital of Guangzhou Military Command|Yes|Recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|60 Years|No|||January 2014|September 17, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01963546||58064|
NCT01963780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-LUN-012013|International EXPAND Lung Pivotal Trial|International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Lung For Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for Transplantation (EXPAND Trial)|EXPANDLung|TransMedics|No|Recruiting|November 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963780||58046|
NCT01963793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0066-1019|Topical Aprepitant in Prurigo Patients|Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo|iTAPP|LEO Pharma|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||February 2014|October 6, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01963793||58045|
NCT01963806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-smart|ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder|Guided and Unguided CBT for Social Anxiety Disorder and/or Panic Disorder Via the Internet and a Smartphone Application||Stockholm University|No|Completed|September 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963806||58044|
NCT01955967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Effect of Intravenous Lidocaine on Trigeminal Neuralgia|||Pain Relief & Palliative Care Center, Athens, Greece||Completed|April 2006|||September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||September 2013|October 7, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955967||58646|
NCT01955980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12082.102|Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis|A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes® Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis||Pari Pharma GmbH|No|Recruiting|April 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01955980||58645|
NCT01951989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0167|Intra-monocyte Imiglucerase Kinetics in Gaucher Disease|Study of Intra-monocytic Imiglucerase Kinetic and Its Correlation With Clinical and Biological Gaucher Disease|CIMI|University Hospital, Clermont-Ferrand||Recruiting|November 2012|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Years|N/A|No|||September 2013|September 24, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01951989||58952|
NCT01952002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0166.0.000.399-11|Clinical Safety for the Inspiratory Muscle Training|CLINICAL SAFETY FOR THE INSPIRATORY MUSCLE TRAINING IN CARDIOPULMONARY REHABILITATION PROGRAM||Clínica de Medicina do Exercício|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients regularly attending a supervised exercise program|September 2013|September 24, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01952002|1 Day|58951|
NCT01952340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF2013|The Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals|A Phase II/III, Randomized, Double-Blinded, Controlled Clinical Trial to Investigate the Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals||St. Boniface General Hospital Research Centre|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||November 2015|November 23, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952340||58925|
NCT01953120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000270|Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)|Mechanisms of Belatacept (Nulojix) Effect on Alloimmunity and Antiviral Response After Kidney Transplantation - (BMS Study# IM 103-309)||University of California, Los Angeles|No|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953120||58865|
NCT01953133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH086346|Couples in Context: An RCT of a Couples-based HIV Prevention Intervention|Randomized Controlled Trial of a Couples-based Intervention to Increase Testing for HIV Among Heterosexual Couples in Vulindlela, KwaZulu-Natal, South Africa||University of California, San Francisco|Yes|Active, not recruiting|April 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 21, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01953133||58864|
NCT01952834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00019610|Effect of Probiotic Supplementation on Endothelial Function|Effect of Probiotic Supplementation on Endothelial Function in Men With Coronary Artery Disease||Medical College of Wisconsin|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|40 Years|75 Years|No|||December 2015|December 15, 2015|September 24, 2013||No||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01952834||58887|
NCT01953094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNEOCC 1|Overlooked Population at Risk for AIN.|The Overlooked Population at Risk for AIN: Women With High-grade Lower Genital Tract Dysplasia or Cervical Cancer.||Sunnybrook Health Sciences Centre|No|Recruiting|October 2014|December 2018|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|40 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 22, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953094||58867|
NCT01953367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12012.102|Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects|Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects||Pari Pharma GmbH|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01953367||58846|
NCT01953380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISICA-13|Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy|Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy|ISICA-13|Region Skane|No|Recruiting|October 2013|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01953380||58845|
NCT01962012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-03|Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners|Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners||OrthoAccel Technologies Inc.|No|Recruiting|October 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962012||58182|
NCT01962350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150.067/12|Treatment of Bipolar Depression With H1-Coil Deep Brain rTMS: Clinical-Cognitive and Safety Evaluation|Evaluation Clinical, Cognitive and Safety in the Treatment of Bipolar Depression With H1-Coil Deep Transcranial Magnetic Stimulation|rTMSH1Coil|University of Sao Paulo|Yes|Recruiting|February 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962350||58156|
NCT01962402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALB-1259|Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study|Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study||Southern California Institute for Research and Education|Yes|Recruiting|January 2014|||July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||January 2014|January 29, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962402||58152|
NCT01962415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC for HSCT in NMD|Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT|A Phase II Study of Reduced Intensity Conditioning in Patients ≤35 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation Transplantation|RIC HSCT NMD|University of Pittsburgh|Yes|Recruiting|December 2013|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|2 Months|35 Years|No|||December 2015|December 1, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962415||58151|
NCT01962701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CopOCT|Fetal Copeptin After Oxytocin Challenge Test|Fetal Copeptin After Oxytocin Challenge Test|CopOCT|University of Zurich|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|140|Samples Without DNA|EDTA plasma of arterial umbilical cord blood|Female|18 Years|50 Years|No|Probability Sample|Primary care hospital, healthy pregnant women presenting for delivery at term|December 2014|December 19, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962701||58129|
NCT01963247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-22|An Investigator Initiated Study to Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion|Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth Athletes||ElMindA Ltd|No|Completed|October 2013|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|145|||Male|11 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|150 male athletes enrolled in Minnesota Youth Hockey Programs, aged 11-15 years.|April 2015|April 8, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963247||58087|
NCT01963260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8723-001|Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)|A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura||Merck Sharp & Dohme Corp.|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|52|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|October 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01963260||58086|
NCT01963286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-12-092-GE-HV|Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators|Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators|ReduceIT|St. Jude Medical|Yes|Active, not recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|730|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963286||58084|
NCT01963559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.661|Cutaneous Microcirculation and Diabetic Foot|Cutaneous Microcirculation and Diabetic Foot|M2P2|Hospices Civils de Lyon|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963559||58063|
NCT01963572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212092RINC|A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer|A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer||National Taiwan University Hospital||Recruiting|August 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|20 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 13, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01963572||58062|
NCT01964443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100972|Clinical Assessment and Psychosocial Impact of Psoriasis|EPidemiological Study In Patients With Recently DiagnosEd PSOriasis: Clinical Assessment and Psychosocial Impact of This Disease|EPIDEPSO|Janssen Pharmaceutica N.V., Belgium|No|Completed|September 2013|November 2015|Actual|November 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|719|||Both|18 Years|N/A|No|Probability Sample|Men and women, 18 years of age and older, who have had the onset of the first symptoms of        plaque psoriasis less than 10 years before study entry, are naïve or experienced to        topical treatment, and are eligible for phototherapy or systemic treatment|December 2015|December 14, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01964443||57996|
NCT01964729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120343|rTMS Effects in the Neuromodulation and Pain Threshold of Chronic Myofascial Pain Patients|Effect of Transcranial Magnetic Stimulation in the Cortical, Subcortical Neuromodulation and in Pain Threshold of Chronic Myofascial Pain Patients||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|August 2013|May 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Female|19 Years|65 Years|No|||October 2013|October 17, 2013|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964729||57974|
NCT01955772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0165|Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation.||NEPHA|University Hospital, Clermont-Ferrand||Recruiting|November 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|55 Years|No|||February 2015|February 5, 2015|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01955772||58661|
NCT01952353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-200602|Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion|Efficacy of Preoperative Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Prospective Non-Randomized Comparative Study||Sun Yat-sen University|Yes|Completed|February 2006|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|80 Years|No|||September 2013|September 24, 2013|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01952353||58924|
NCT01952015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A1302|Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)|A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability up to 52 Weeks in Japanese Subjects With Generalized Pustular Psoriasis||Novartis||Active, not recruiting|August 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952015||58950|
NCT01952847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0308|Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis|Randomized, Double Blinded Placebo-Controlled Study of Glutamine in Patients With Oral Mucositis on an mTOR Inhibitor-based Regimen or Esophagitis on a Regimen Receiving Radiation to the Esophagus||M.D. Anderson Cancer Center|Yes|Recruiting|July 2014|||July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Anticipated|180|||Both|17 Years|N/A|No|||January 2016|January 14, 2016|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952847||58886|
NCT01952873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287332|Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation|Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation on the Results of Stent Deployment|INFLATION/DE|Central Arkansas Veterans Healthcare System|No|Not yet recruiting|December 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||July 2014|July 11, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01952873||58884|
NCT01953419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEM001|Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy|Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: a Prospective Phase II Study||Sun Yat-sen University|Yes|Completed|September 2010|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|80 Years|No|||June 2014|June 23, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01953419||58842|
NCT01953406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUNG M_FM|The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma|Phase II Study Evaluating the Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma Who Had Progressive Disease With Sorafenib||Seoul National University Hospital|No|Withdrawn|November 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|September 21, 2013||No|No participants were enrolled. Therefore, we stop this study, prematurely.|No||https://clinicaltrials.gov/show/NCT01953406||58843|
NCT01953107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNEOCC2|Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.|A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.||Sunnybrook Health Sciences Centre|No|Recruiting|November 2013|November 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|200|||Male|18 Years|N/A|No|||May 2015|May 22, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953107||58866|
NCT01953393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH TAL|The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans|The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans||Rigshospitalet, Denmark|No|Completed|April 2006|October 2006|Actual|May 2006|Actual|N/A|Interventional|Primary Purpose: Basic Science|||||||Male|20 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01953393||58844|
NCT01953666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12053|Evaluation of the Efficiency of Word Prediction Software to Text Input Speed for Tetraplegia|Phase 1 Evaluation of the Influence of Settings of Word Prediction Software (Phase 1)and the Efficiency of Rehabilitation Programm (Phase 2)to Text Input Speed for People With Spinal Cord Injury|Smartwrite|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|September 2013|October 2017|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|People with spinal cord injury : tetraplegia|October 2015|February 12, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01953666||58823|
NCT01953679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN013|Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days|A Phase IIb Randomized, Double Blind, Comparative Study to Assess the Efficacy, Safety, Tolerability and Inhibition of Ovulation of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days|CCN013|Health Decisions|Yes|Completed|March 2014|November 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|180|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|August 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953679||58822|
NCT01961739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL H1-5|Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids|Double Blinded Randomized Clinical Trial of the Efficacy of Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids|H1-5|University Hospital Dubrava|Yes|Recruiting|October 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961739||58203|
NCT01961752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0147|The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial|||Yonsei University|No|Completed|July 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|111|||Both|20 Years|80 Years|No|||October 2013|October 10, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961752||58202|
NCT01962688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0324|Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment|A Randomized Study of Pocket Ultrasound Derived IVC Diameter for Guided Management of Heart Failure||Icahn School of Medicine at Mount Sinai|No|Recruiting|August 2013|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|438|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962688||58130|
NCT01962974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102117|A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)|A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)|REGAIN|Janssen Biotech, Inc.|No|Terminated|October 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|76 Years|No|||January 2016|January 21, 2016|October 11, 2013|No|Yes|Cancelled due to low enrollment|No||https://clinicaltrials.gov/show/NCT01962974||58108|
NCT01963299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRARD-BERTRAND 2013|Clonidine - Ropivacaine in Peribulbar Anesthesia|Prospective Randomised Double-blind Study to Compare Ropivacaine 10mg/mL Alone Versus Ropivacaine 10mg/mL Associated With Clonidine 1µg/kg for Peribulbar Anesthesia in Posterior Eye Surgery|CRAPO|Centre Hospitalier Universitaire Dijon|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963299||58083|
NCT01962961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU SRI 1306011647|N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults|A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy||Indiana University|Yes|Completed|October 2013|October 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|50 Years|N/A|No|||December 2015|January 11, 2016|October 11, 2013||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01962961||58109|
NCT01963273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5082|Video Assisted Ablation of Pilonidal Sinus|Video Assisted Ablation of Pilonidal Sinus. Evaluation of Safety and Efficacy of a New Minimally Invasive Technique||Federico II University||Active, not recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|15 Years|90 Years|No|||October 2013|October 15, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963273||58085|
NCT01963819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miacol-2013-1H|Therapeutic Endometrial Biopsy|||University of Aarhus|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|40 Years|No|||December 2014|December 2, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963819||58043|
NCT01963832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130410007|RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke|RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke||University of Alabama at Birmingham|Yes|Withdrawn|November 2016|November 2021|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Male|40 Years|N/A|No|||December 2014|January 9, 2015|October 11, 2013|No|Yes|not funded|No||https://clinicaltrials.gov/show/NCT01963832||58042|
NCT01964092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPS-NAV|Effect Evaluation of Individual Placement and Support (IPS)|Effect Evaluation of Individual Placement and Support (IPS)||Uni Research|Yes|Active, not recruiting|May 2013|September 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|67 Years|No|||June 2015|June 25, 2015|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01964092||58023|
NCT01964105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210065|3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery|3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery: Does 3D Improve Patient Reported Outcomes in Primary Breast Augmentation?||Washington University School of Medicine|No|Recruiting|November 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01964105||58022|
NCT01964118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303081|Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?|Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?|IF|Washington University School of Medicine|No|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01964118||58021|
NCT01952028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMDIR-003|LAMA2-related Muscular Dystrophy Brain Study|A LAMA2-related Muscular Dystrophy Study: Brain Magnetic Resonance Imaging (MRI)and Brain Electrophysiology Evaluation||Cure CMD|No|Withdrawn|November 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|LAMA2-MD|October 2015|October 5, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01952028||58949|
NCT01952366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODE-2013|Prognosis of Depression in the Elderly (PRODE). A Multicentre, Longitudinal Study of Elderly Depressed Patients.|Prognosis of Depression in the Elderly (PRODE)|PRODE|Sykehuset Innlandet HF|No|Active, not recruiting|December 2009|April 2016|Anticipated|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|338|Samples With DNA|Apolipoprotein E polymorphism|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Elderly (>60 years) depressed patients referred to treatment at specialist helth care        service in Norway.|February 2012|November 21, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952366||58923|
NCT01952626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2013-03-032-001|Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron|Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron||Kyungpook National University|Yes|Completed|April 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|19 Years|70 Years|No|||April 2015|April 7, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01952626||58903|
NCT01952613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kessler-RP-R03-1|Effect of FES Interventions on Gait Dynamics in Stroke Population|Identification of Responders to the FES Interventions in Stroke Population||Kessler Foundation|Yes|Recruiting|April 2013|April 2015|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|75 Years|No|Non-Probability Sample|Ten subjects between the ages of 18 and 75 with hemiplegia and drop foot secondary to        chronic stroke will be recruited for this study.|September 2013|September 24, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952613||58904|
NCT01953146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS_time-lapse|The Influence of Polycystic Ovairan Syndrome on Embryonic Developmental Timing|Timing of Development in Embryos Derived From Women With Polycystic Ovairan Syndrome and Controls|PCOS|University of Aarhus|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|240|||Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|A consecutive cohort of 249 infertile women attending In vitro fertilization (IVF) or        Intra-cytoplasmic sperm injection (ICSI) treatment at the Fertility Clinic, Arhus        University Hospital from February 2011 to May 2013.|September 2013|September 25, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01953146||58863|
NCT01953744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FlucoLBrBaMa|High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus|Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis||Hospital Universitário Professor Edgard Santos|Yes|Terminated|February 2014|November 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|September 25, 2013||No|Low cure rate in the study (fluconazole) group|No||https://clinicaltrials.gov/show/NCT01953744||58817|
NCT01953718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2008]20|A Retrospective Study of the Effects of Different Parameters on Motor Symptoms of PD in Bilateral STN Stimulation|A Retrospective Study of the Effects of Different Parameters on Motor Symptoms of PD in Bilateral STN Stimulation||First Affiliated Hospital, Sun Yat-Sen University||Completed|July 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|27|||Both|40 Years|75 Years|No|Non-Probability Sample|PD patients who received bilateral STN DBS in the First Affiliated Hospital of Sun Yat-sen        University|October 2013|October 9, 2013|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953718||58819|
NCT01953731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481017|A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)|A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers||Pfizer|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953731||58818|
NCT01953705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG043398|n-3 PUFA for Vascular Cognitive Aging|Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline||Oregon Health and Science University|Yes|Recruiting|May 2014|March 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|80 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 5, 2014|September 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953705||58820|
NCT01954498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130929|Effect of Walnuts on Sperm Parameters and Male Fertility|Effect of Walnuts on Sperm Parameters and Male Fertility||University of California, Los Angeles|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Male|21 Years|N/A|No|||December 2015|December 5, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01954498||58759|
NCT01962064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00681-40|Social Cognition in Ageing and in Frontotemporal Lobar Degeneration|Social Cognition in Ageing and in Frontotemporal Lobar Degeneration (Frontotemporal Dementia and Semantic Dementia): a Cognitive and Neuroimaging Study|COSIMAGE|University Hospital, Caen|Yes|Recruiting|June 2013|November 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|80|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01962064||58178|
NCT01962077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nathalie- HMO-CTIL|Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.|Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth||Hadassah Medical Organization|Yes|Active, not recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01962077||58177|
NCT01962038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAI0002AGG|A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment|A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment||Palo Alto Veterans Institute for Research|No|Recruiting|May 2013|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|90 Years|No|||July 2015|July 10, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01962038||58180|
NCT01962051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL07123|AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational||ACP LA|St. Jude Medical|Yes|Withdrawn|October 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with nonvalvular atrial fibrillation (NVAF)|January 2014|January 17, 2014|October 10, 2013||No|St. Jude Medical business decision|No||https://clinicaltrials.gov/show/NCT01962051||58179|
NCT01963000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP01ED|Standardized Emergency Care for Community Acquired Pneumonia (CAP)|Reduction of Mortality in Community-Acquired Pneumonia After Implementing Standardized Care Bundles in the Emergency Department||Klinikum Nürnberg|No|Completed|January 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2819|||Both|18 Years|N/A|No|Probability Sample|Emergency department patients|October 2013|October 15, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963000||58106|
NCT01963585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200-11|Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children|Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children||Rambam Health Care Campus||Completed|July 2011|October 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|131|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects (age range 6 to 18 years) referred for Methacholine Challenge Test (MCT)|October 2013|October 13, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963585||58061|
NCT01963598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1033-SRC-1239|Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia||Regeneron Pharmaceuticals|No|Completed|November 2013|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|253|||Both|70 Years|N/A|No|||March 2015|March 31, 2015|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963598||58060|
NCT01963845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sitagliptin-NAFLD|Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease|Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease||University of California, San Diego||Not yet recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|October 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01963845||58041|
NCT01964768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG40.08|Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing|Determination of Sensitivity and Specificity of Three Solutions of Allergen Extract (5 Grasses, Birch Pollens and Dermatophagoides Pteronyssinus Mites) for Diagnosis by Skin Prick Testing||Stallergenes|No|Completed|December 2010|February 2012|Actual|June 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|||Actual|324|||Both|5 Years|60 Years|No|||October 2013|October 14, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964768||57971|
NCT01952041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH103148-01|A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia|A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01952041||58948|
NCT01952054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0007|Denosumab for Breast Cancer With Bone Mets|Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|September 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952054||58947|
NCT01952652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA12/268|Naproxen Codeine in Arthroscopic Surgery|Comparison of Post-operative Analgesic Effects of Naproxen Sodium and Naproxen Sodium-codeine Phosphate Administered Preemptively for Arthroscopic Meniscus Surgery||Baskent University|Yes|Completed|January 2013|July 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|60 Years|No|||September 2013|September 26, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01952652||58901|
NCT01952639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-3-045|Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans|Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans||Maastricht University Medical Center|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|60|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01952639||58902|
NCT01952860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0496|Hatha Yoga in Lung Cancer Couples|A Feasibility Study of Hatha Yoga in Couples Coping With Lung Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2013|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952860||58885|
NCT01953432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-014-12F|Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse|Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse||VA Office of Research and Development|Yes|Recruiting|April 2014|October 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01953432||58841|
NCT01953172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NBU-1034|Health Status and Quality of Life in the Elderly|Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly||Unilever R&D|No|Terminated|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||February 2015|March 10, 2015|September 13, 2013||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01953172||58861|
NCT01953445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311126|Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer|Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer||Washington University School of Medicine|No|Withdrawn|August 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2014|December 5, 2014|September 19, 2013|Yes|Yes|The study sponsor found the trial to be not viable.|No||https://clinicaltrials.gov/show/NCT01953445||58840|
NCT01953991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18134|OHQoL With Removable Partial Dentures; a Pilot Study|A Pilot Study Investigating Oral Health Related Quality of Life Improvements in Removable Partial Denture Treatments for the Replacement of Missing Teeth||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953991||58798|
NCT01953978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-RS-2012|The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery|The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen as Adjuvant, Postoperative Pain After Herniated Disc Surgery||Rigshospitalet, Denmark|Yes|Completed|December 2012|September 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|85 Years|No|||October 2015|October 26, 2015|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953978||58799|
NCT01954264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200187|Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa|Epidemiology Study of Malariometric Determinants in Selected Post-Approval Programme Study Sites in Sub-Saharan Western Africa||GlaxoSmithKline||Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1680|||Both|6 Months|9 Years|Accepts Healthy Volunteers|||May 2014|June 26, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01954264||58777|
NCT01962441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0153|SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection|A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.||Gilead Sciences|No|Active, not recruiting|September 2013|June 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|601|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 10, 2013|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01962441||58149|There were no limitations affecting the analysis or results.
NCT01962454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200030|A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers|A Pilot Study in Healthy Male Volunteers to Evaluate a Skeletal-Muscle Microbiopsy Technique for Suitability of Use With Dynamic Proteomic Measurement||GlaxoSmithKline|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|20|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||April 2015|July 9, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962454||58148|
NCT01962428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0214|Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI|Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention||General Hospital of Chinese Armed Police Forces|Yes|Completed|June 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|80 Years|No|||September 2015|December 17, 2015|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962428||58150|
NCT01962714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-006-13S|Loving-Kindness Meditation for PTSD|A Trial of Loving-Kindness Meditation and Cognitive Processing Therapy for PTSD||VA Office of Research and Development|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962714||58128|
NCT01962727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112034RIB|Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification Test|Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification Test||National Taiwan University Hospital|Yes|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|50 Years|No|Non-Probability Sample|Sixty subjects (36 males and 14 females, age: 22.5 ± 2.6) were recruited.Potential        participants from outpatient clinic in a University hospital and local internet media were        evaluated and recruited. They read and signed the informed consent approved by the        Hospital institutional review boards.|October 2013|October 10, 2013|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01962727||58127|
NCT01962987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71204901|A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Actavis) to Solaraze ® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis||Actavis Inc.|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|585|||Both|18 Years|75 Years|No|||October 2013|October 11, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962987||58107|
NCT01963611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200575-001|Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)|A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis||EMD Serono|Yes|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|255|||Both|18 Years|60 Years|No|||July 2015|July 24, 2015|October 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963611||58059|
NCT01963858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Relaxation|Effect of Functional Relaxation on Patients Undergoing Colonoscopy|Effect of Functional Relaxation on Patients Undergoing Colonoscopy: A Prospective Randomized Controlled Trial||The Catholic University of Korea|Yes|Not yet recruiting|November 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|80 Years|No|||October 2013|October 12, 2013|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963858||58040|
NCT01963312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSECUR-11|Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.|A Randomised Clinical Trial to Compare Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate Compared Versus the Transurethral Resection of the Prostate to Treat the Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.||Fundacion Miguel Servet||Recruiting|March 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|60 Years|N/A|No|||November 2015|November 12, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963312||58082|
NCT01964469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000940|Consumer Access to Personal Health Information for Asthma Self-Management|Consumer Access to Personal Health Information for Asthma Self-Management Phase 2 (Pilot Implementation)|ASMA|Lawson Health Research Institute|No|Active, not recruiting|February 2013|March 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01964469||57994|
NCT01964482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-115|In-hospital and Post-discharge Training of Older Medical Patients|In-hospital and Post-discharge Training of Older Medical Patients||Copenhagen University Hospital, Hvidovre|Yes|Recruiting|October 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|65 Years|N/A|No|||September 2015|September 28, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964482||57993|
NCT01964781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004964-23|The Effect of Topical Administration of Common Drugs on Postoperative Bleeding and Pain|The Effect of Topical Administration of Tranexamic Acid, Adrenaline and Bupivacain on Postoperative Bleeding and Pain in Patients Undergoing Breast Surgery. A Four-armed Placebo-controlled Double Blinded Randomized Study||St. Olavs Hospital|Yes|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|30|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964781||57970|
NCT01952379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mel-Infla1|Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators|Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators||Universidad Autonoma de San Luis Potosí|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|20|Samples With DNA|3 mm Skin punch biopsies|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women affected with malar melasma.|November 2014|November 22, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01952379||58922|
NCT01952665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-41|A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear|A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear||Coopervision, Inc.|No|Completed|October 2013|March 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|40 Years|No|||August 2015|August 20, 2015|September 18, 2013|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01952665||58900|
NCT01952938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-I-H-1112|Outcome EnduRo Versus LINK SL Rotating Hinge Knee|||Orthopaedische Klinik Koenig-Ludwig-Haus|Yes|Recruiting|July 2012|||July 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients need hinged knee prosthesis|September 2013|September 27, 2013|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01952938|1 Year|58879|
NCT01953159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0775|Assessment of Paclitaxel-Induced Neuropathy|Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy||University of Chicago|No|Recruiting|August 2013|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|40|Samples With DNA|Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated with paclitaxel|January 2016|January 6, 2016|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953159||58862|
NCT01954017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP206-002|STP206 for the Prevention of NEC|A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates||Sigma Tau Pharmaceuticals, Inc.|Yes|Recruiting|December 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|4 Days|No|||November 2015|November 16, 2015|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01954017||58796|
NCT01953757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM DN-2|A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)|A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)||Physicians Committee for Responsible Medicine|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|65 Years|No|||April 2015|April 24, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953757||58816|
NCT01954238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC2107_102|A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers|A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Sequential Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GCC-4401C in Healthy Males||Green Cross Corporation|Yes|Completed|August 2013|May 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|46|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01954238||58779|
NCT01954251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117036|Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older||GlaxoSmithKline||Completed|October 2013|March 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|829|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|February 8, 2016|September 19, 2013|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01954251||58778|
NCT01954797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAPTISe|Biomarkers and Perfusion - Training-Induced Changes After Stroke|Biomarkers and Perfusion - Training-Induced Changes After Stroke (BAPTISe): Protocol of an Observational Study Accompanying a Randomized Controlled Trial|BAPTISe|Charite University, Berlin, Germany|Yes|Recruiting|October 2013|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Patients will receive blood draws (whole blood) for blood biomarker analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Patients recruited for this study are collected at the rehabilitation hospital and are        participating in the PHYS-STROKE trial.|January 2016|January 20, 2016|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01954797||58736|
NCT01962467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200284|A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine|A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine With Levocabastine and Fluticasone Furoate Alone||GlaxoSmithKline|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962467||58147|
NCT01962740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-043|Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)|Serial Evaluation of Drug-Eluting Stents Using OCT|STRUT-OCT|North Texas Veterans Healthcare System||Recruiting|September 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|48|||Both|18 Years|89 Years|No|||October 2013|October 10, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962740||58126|
NCT01963013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUTI-001|Non-returning Catheter Valve for Reducing CAUTI|A Pilot Study of Non-returning Catheter Valve for Reducing Catheter-associated Urinary Tract Infection in Critically-ill Patients||Khon Kaen University|Yes|Completed|June 2012|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963013||58105|
NCT01963026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44697.068.13|Linking Brain to Behaviour Research in SCI|Plasticity, Motor Learning and Functional Recovery Induced by Client-centred Task-oriented Training of the Upper Extremity in Tetraplegia||Adelante, Centre of Expertise in Rehabilitation and Audiology|No|Completed|November 2013|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||December 2015|December 28, 2015|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01963026||58104|
NCT01963039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZTilburg2|A Trial of Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures (Vertos V)|A Randomised Sham Controlled Trial of Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures|VERTOSV|Elisabeth-TweeSteden Ziekenhuis|Yes|Completed|May 2013|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|180|||Both|50 Years|95 Years|No|||February 2016|February 9, 2016|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01963039||58103|
NCT01963325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1vsNab-P20130819|S-1 in Combination With Abraxane in Treating Cholangiocarcinoma|Phase II Study of Abraxane Plus S-1 as Second-line Treatment for Cholangiocarcinoma||Sun Yat-sen University|Yes|Recruiting|August 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01963325||58081|
NCT01963338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cev2012-vaxid|A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination|A Randomized Controlled Study to Assess the Acceptability and Usability of New Delivery Device for Intradermal Vaccination in Healthy Volunteers||Universiteit Antwerpen|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|102|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01963338||58080|
NCT01963624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elasto-Doppler Ultrasonography|Combined Elastography and Color Doppler Ultrasonography for Breast Screening With Ultrasound|Multicenter Prospective Study to Evaluate the Value of Combined Elastography and Color Doppler Ultrasonography for Breast Screening With Ultrasound||Seoul National University Hospital|Yes|Active, not recruiting|November 2013|October 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1241|||Female|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population will consist of asymptomatic women who visit the hospital for breast screening.        The sites are located in 4 cities of South Korea.|November 2015|November 20, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963624||58058|
NCT01964131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961TC00004|BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects|An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects||AstraZeneca|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964131||58020|
NCT01964144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0405|An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer|||Yonsei University|Yes|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|90 Years|No|||November 2014|November 26, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01964144||58019|
NCT01964157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0237|An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement|||Yonsei University|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|20 Years|N/A|No|||June 2014|June 2, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01964157||58018|
NCT01964495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Duijkers|Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)|Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)|REDUCE|Medical Center Alkmaar|Yes|Recruiting|December 2013|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|468|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01964495||57992|
NCT01964508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM0003-HMO-CTIL|microRNA in Thyroid Cancer|The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.||Hadassah Medical Organization|No|Recruiting|September 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|FNA samples, CDNA, RNA|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients undergoing FNA|October 2013|October 14, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964508|1 Year|57991|
NCT01961050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA016234_IRB 2758|Preventing FAS/ARND in Russian Children|Preventing FAS/ARND in Russian Children||University of Oklahoma|Yes|Completed|September 2007|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|767|||Female|18 Years|44 Years|No|||February 2016|February 18, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961050||58256|
NCT01952392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-BRI-2012/1|Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome|Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome|AReMIS|AstraZeneca||Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3750|||Both|18 Years|130 Years|No|Probability Sample|Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to        participate and able to respond to an interview in French and/or providing the details of        an alternative replier (proxy) if necessary.|February 2016|February 12, 2016|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01952392||58921|
NCT01953185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|taciano01|MANUAL DIAPHRAGM RELEASE TECHNIQUE INCREASES TIDAL VOLUME IN ELDERLY|MANUAL DIAPHRAGM RELEASE TECHNIQUE INCREASES TIDAL VOLUME AND UPPER RIB CAGE CONTRIBUTION DURING QUIET BREATHING IN ELDERLY: A RANDOMIZED CONTROLLED TRIAL||Universidade Federal de Pernambuco|Yes|Completed|January 2011|December 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|60 Years|68 Years|Accepts Healthy Volunteers|||December 2012|September 27, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953185||58860|
NCT01953458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS CO22 HEPATHER|Therapeutic Option for Hepatitis B and C: a French Cohort|Therapeutic Option for Hepatitis B and C: a French Cohort|HEPATHER|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|August 2012|August 2022|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25000|Samples With DNA|whole blood, serum, plasma and urine|Both|18 Years|N/A|No|Non-Probability Sample|HBV-positive patients and/or HCV-positive patients|June 2014|September 5, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01953458||58839|
NCT01952886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041233|Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients|Phase II Randomized Cross-over Study to Evaluate Patient Satisfaction, Efficacy and Compliance of Granisetron Patch vs. Ondansetron in Malignant Glioma Patients Receiving Standard Radiotherapy (RT) and Concomitant Temozolomide (TMZ)||Duke University|Yes|Withdrawn||||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|September 25, 2013|Yes|Yes|Lack of approval and funding from company|No||https://clinicaltrials.gov/show/NCT01952886||58883|
NCT01952899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82315-97-12025|The ICU DElirium in Clinical PracTice Implementation Evaluation Study Screening and Treatment|Improvement of Care for ICU Patients With Delirium by Early Screening and Treatment|iDECePTIvE|Erasmus Medical Center|No|Recruiting|April 2012|April 2016|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ICU patients and professionals|September 2013|September 30, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952899|4 Weeks|58882|
NCT01952912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKEP-OP|Plasmakinetic Enucleation of the Prostate and Open Prostatectomy to Treat Large Prostates|Comparison of Plasmakinetic Enucleation of the Prostate With Open Prostatectomy for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate||Fuzhou General Hospital|Yes|Completed|January 2004|June 2013|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Male|50 Years|70 Years|No|||December 2003|September 27, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01952912||58881|
NCT01954290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136-2013|Study of Stroke Related Edema Treatments|Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke||University of Florida|No|Withdrawn|September 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|September 26, 2013|Yes|Yes|Investigator is leaving the institution.|No||https://clinicaltrials.gov/show/NCT01954290||58775|
NCT01954277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-259|Immune-Pineal Axis Function in Chronic Tension-Type Headache|Immune-Pineal Axis Function in Chronic Tension-Type Headache: Noradrenergic Modulation and the Effect of Electroacupuncture||Hospital de Clinicas de Porto Alegre|Yes|Completed|October 2010|November 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|60 Years|No|||September 2013|November 15, 2013|September 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954277||58776|
NCT01954004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCEDE-1000|Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients||Myriad Genetic Laboratories, Inc.|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1270|||Male|18 Years|N/A|No|Non-Probability Sample|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer|May 2015|May 29, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954004|4 Months|58797|
NCT01955330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kiaii-LTFUP-Hybrid-2013|Long Term Follow-up Hybrid Revascularization|Long Term Follow-up of Robotic Hybrid Surgical Revascularization With CT Angiography||Lawson Health Research Institute|No|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have previously had Hybrid robotic coronary artery revascularization        performed approximately 5-7 years ago at the London Health Sciences Centre, University        Hospital by Dr. Kiaii.|September 2013|September 27, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955330||58695|
NCT01955343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRLC-1109|Immune Response in Lung Cancer|Immune Response in Lung Cancer|IRLC|Lithuanian University of Health Sciences|No|Recruiting|March 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Blood serum and lung biopsy|Both|18 Years|80 Years|No|Non-Probability Sample|Lithuanian residents who are investigated ant treated in Hospital of Lithuanian University        of Health Sciences Kaunas Clinics Department of Pulmonology and Immunology and Department        of Heart, thoracic and vascular surgery|August 2014|August 6, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01955343||58694|
NCT01975610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-292-RA-001|Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis|A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis||Celgene|No|Active, not recruiting|October 2013|March 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Female|18 Years|80 Years|No|||February 2016|February 16, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975610||57141|
NCT01975896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21H119665|Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens|Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens||University of Massachusetts, Worcester|Yes|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|53|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975896||57119|
NCT01977521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS_UMC|Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations|Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations A Sham-controlled Trial|tDCS|UMC Utrecht|Yes|Recruiting|April 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977521||56994|
NCT01977833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0145-13-WOMC|Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes|Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes|GLP-1inT2D|Tel Aviv University|No|Recruiting|October 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|70 Years|No|||October 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977833||56970|
NCT01973842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agonist triggering dose|Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients|Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH.|ATD|Aristotle University Of Thessaloniki|Yes|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|20 Years|40 Years|No|||February 2016|February 11, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973842||57276|
NCT01974115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConceptClinic-1|Extracorporeal Shock Wave Treatment for Cellulite|Clinical Effects of the Radial Extracorporeal Shock Wave Therapy (rESWT) Using the EMS Swiss Dolorclast and the Power+ Handpiece for Local Treatment of Cellulite||Concept-Clinic|No|Completed|December 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|20 Years|59 Years|No|||October 2013|October 28, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974115||57255|
NCT01974128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-AMI-001|Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation by a Catheter Delivery System and/or Intravenously In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction|Acute MI|Ageless Regenerative Institute|No|Not yet recruiting|October 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2014|March 19, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974128||57254|
NCT01974141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-006|A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris|||Allergan|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2156|||Both|12 Years|N/A|No|||September 2015|September 30, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974141||57253|
NCT01974635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00009635|Proprioception Testing in Persons With Sensorimotor Impairment|Proprioception Testing in Persons With Sensorimotor Impairment||Oregon Health and Science University|Yes|Recruiting|October 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974635||57215|
NCT01974622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICG- guided PDT Study|ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study|Indocyanine Green Angiography-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities.|ICGguidedPDT|Manhattan Eye, Ear & Throat Hospital|No|Recruiting|April 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 28, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974622||57216|
NCT01944241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFC2|Cervical Surgery and the Fertility Effect (c-SAFE)|Cervical Surgery and the Fertility Effect|c-SAFE|Merrion Fertility Clinic|No|Enrolling by invitation|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1500|||Female|25 Years|40 Years|No|Non-Probability Sample|This study will be a retrospective cohort study in women of reproductive age, who attended        the colposcopy services in the National Maternity Hospital from the years 2001 to 2007.        The cases will include women who have had cervical surgery, either LLETZ or cone biopsy        and the controls will be women who have attended colposcopy but who have not had surgery.        The cases will be identified by using the Mediscan database in the colposcopy clinic to        identify those women who have had a LLETZ procedure and those who have had a cone biopsy        will be identified by accessing pathology records for cone biopsies for the specified        years. The controls will be selected by using Mediscan again, identifying women who have        attended colposcopy but who have not had cervical surgery|September 2013|September 12, 2013|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01944241||59547|
NCT01953562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC#33186|Positioning and the Spontaneous Breathing Test in Neonates|Evaluation of the Influence of Positioning and Time Duration on the Spontaneous Breathing Test in Neonates||Christiana Care Health Services|No|Withdrawn|October 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|6 Months|No|Non-Probability Sample|Intubated infants who qualify for the routine spontaneous breathing test.|June 2014|June 16, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01953562||58831|
NCT01953575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005778|Mucosal Impedance and Eosinophilic Esophagitis|Mucosal Impedance in Eosinophilic Esophagitis and the Effect of Treatment|EoE|Mayo Clinic|No|Recruiting|September 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|90 Years|No|||January 2016|January 8, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01953575||58830|
NCT01945034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491009|5% Topical Ibuprofen (IBU) for Ankle Sprain|Placebo-controlled, Double-blind Evaluation Of The Efficacy And Safety Of Ibuprofen 5% Topical Gel For The Treatment Of Ankle Sprain||Pfizer|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|305|||Both|12 Years|N/A|No|||March 2015|March 26, 2015|June 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945034||59486|
NCT01945047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB2012023|Action of Ketamine in Treatment-Resistant Depression|Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action||University of Ottawa|Yes|Recruiting|May 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|65 Years|No|||May 2014|May 6, 2014|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01945047||59485|
NCT01945580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U9920|Xenform Postmarket Surveillance Study|A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|Xenform|Boston Scientific Corporation|No|Recruiting|February 2014|November 2018|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|454|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with pelvic organ prolapse at or beyond the hymen who will be treated surgically.|June 2015|June 18, 2015|September 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945580|36 Months|59444|
NCT01945827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-000036-PRO|Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms|||Codman & Shurtleff|No|Withdrawn|January 2014|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Subjects who have been diagnosed with a ≥ 6 mm intracranial aneurysm.|July 2014|July 2, 2014|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945827|12 Months|59425|
NCT01946087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0283|Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery|||Yonsei University|No|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|90 Years|No|||March 2016|March 18, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01946087||59405|
NCT01945268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT IVVE 2015|Influenza Vaccine To Prevent Adverse Vascular Events|A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events|RCT-IVVE|McMaster University|No|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3500|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945268||59468|
NCT01947166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047214|Pancreatic Resection, Malnutrition and Readmission|Pancreatic Resection, Malnutrition, and Readmission: Assessment and Prevention||Duke University|Yes|Recruiting|December 2013|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|August 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01947166||59322|
NCT01945814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSTAT|Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)|Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)||Children's Research Institute|Yes|Recruiting|February 2014|March 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|N/A|45 Years|No|||August 2015|August 26, 2015|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945814||59426|
NCT01977222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00006063|Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training|Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training||Children's Hospital Boston|No|Active, not recruiting|December 2013|March 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01977222||57017|
NCT01977248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00460|Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12|Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12|SMART|Nationwide Children's Hospital|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|2 Years|12 Years|No|||February 2015|February 3, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01977248||57015|
NCT01977274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-BIO-IPC 2013-010|Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010|Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010|GC-BIO|Institut Paoli-Calmettes|No|Recruiting|December 2013|December 2028|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Female|18 Years|N/A|No|||December 2013|December 31, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977274||57013|
NCT01977534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-304|To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels|A Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb BVS|ABSORB UK|Abbott Vascular|Yes|Active, not recruiting|January 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1005|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from the general interventional cardiology population|December 2015|December 3, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01977534|3 Years|56993|
NCT01977846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFBCRI-PROGSTAR-01/02|A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies|Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease|ProgSTAR|Foundation Fighting Blindness Clinical Research Institute|No|Active, not recruiting|August 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Both|6 Years|N/A|No|Non-Probability Sample|The study population shall consist of up to 250 Stargardt disease patients (minimum of 150        patients) recruited at up to 14 clinical centers across the US and Europe. Must be at        least 6 years old, able to cooperate in performing the examinations and be willing to        attend regular 6 month follow-up visits for up to 24 months. Must present with atrophic        lesions secondary to STGD and previously genotyped (at least 2 confirmed pathogenic        mutations in the ABCA4 gene). If only 1 ABCA4 allele contains a pathogenic mutation, then        the patient needs typical phenotype, i.e. at least one eye must have flecks at the level        of the retinal pigment epithelium typical for STGD. Best-corrected visual acuity (BCVA)        must be 20 ETDRS letters (20/400 Snellen equivalent) or better.|October 2015|October 5, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977846||56969|
NCT01973855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX10004301-003|Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms|Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research||Guangzhou 8th People's Hospital|Yes|Recruiting|January 2012|December 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|October 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973855||57275|
NCT01973868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16547|Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination|A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment||Bayer|No|Recruiting|November 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973868||57274|
NCT01974427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140002|Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions|Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions||National Institutes of Health Clinical Center (CC)||Recruiting|October 2013|April 2023|Anticipated|April 2023|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|December 24, 2015|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974427||57231|
NCT01974648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBHGMECNC002-2011|Propofol for Supreme LMA Insertion With and Without Remifentanil|ED 50 of Propofol for Supreme LMA Insertion With and Without Remifentanil. A Randomized Trial|SC50|Hospital General Universitario Gregorio Marañon|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|59|||Both|N/A|N/A|No|||October 2013|October 25, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01974648||57214|
NCT01974908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSTT-FF-1|Fibrillatory Factor in Ventricular Tachycardia|Using Fibrillatory Factor to Predict the Source of Ventricular Tachycardia in Man||Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|July 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01974908||57194|
NCT01975168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-LAAC-OB-001|The Effect Evaluation of Laser Acupuncture in Obesity|The Effect Evaluation of Laser Acupuncture in Obesity||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|September 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|75 Years|No|||November 2013|November 5, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975168||57175|
NCT01974882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004593|Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy|Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy|Ice|Emory University|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|55|||Both|18 Years|89 Years|No|||October 2013|October 28, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01974882||57196|
NCT01944254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/409|The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients|Comparison of the Precision of Cardiac Output-measures at Random to Respiration, Synchronised With Expiration and Instructed Slow Exhalation, Obtained by Pulmonal Artery Catheter Thermodilution Technique With Cold Injection|TEMP2|Norwegian University of Science and Technology|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|90 Years|No|||December 2013|November 28, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01944254||59546|
NCT01944735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-4430-CF-001|Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days||Celtaxsys, Inc.|Yes|Completed|September 2013|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|55 Years|No|||March 2015|March 4, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01944735||59509|
NCT01944748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA031910|Family Mediation Program For At-Risk Youth|Family Mediation Program For At-Risk Youth||RAND|Yes|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|12 Years|19 Years|No|||June 2014|June 6, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01944748||59508|
NCT01944449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCCBI 057-2011-165|Effects of Whey Protein in Type 2 Diabetics|Effect of Chronic Administration of Whey Protein on HbA1c and Postprandial Glycemia in Type 2 Diabetic Individuals|WHEY-T2D|Tel Aviv University|Yes|Active, not recruiting|September 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|70 Years|No|||January 2016|January 21, 2016|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01944449||59531|
NCT01944462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP ID 50926|Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center|Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center for Adults Aged 65 Years or Older or Those With Defined Risk Factors for Invasive Pneumococcal Disease|PPVP|Thomas Jefferson University|No|Active, not recruiting|January 2014|March 2016|Anticipated|November 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944462||59530|
NCT01944475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-186-13|Follow-up of Girls With Premature Thelarche and Precocious Puberty|Follow-up of Girls With Premature Thelarche and Precocious Puberty: a Clinical and Paraclinical Study of Girls With Thelarche and Healthy Controls||University of Aarhus|Yes|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|50|Samples With DNA|GnRH test, p-estrogen, p-testosterone , p-SHBG, p- androstenedione, p-dihydroandrostendion,      p-inhibin B, p-thyroid parameters, ultrasound examination of the genitalia interna and a      blood sample for studies of polymorphism in the estrogen receptor gene and aromatase enzyme      gene.|Female|N/A|8 Years|No|Non-Probability Sample|0-6 year old girls diagnosed with premature thelarche or precocious puberty from 1998 to        today at the Children's Section A, AUH, Skejby. Girls who are 8 years old or under at        baseline (1st of september) will be contacted and asked to participate in a clinical and        paraclinical re-examination.|September 2013|September 12, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01944475|1 Day|59529|
NCT01945593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261302|Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A|A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients With Severe Hemophilia A||Baxalta US Inc.|No|Recruiting|October 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Male|N/A|75 Years|No|||October 2015|October 6, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945593||59443|
NCT01945606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16718|Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker|A Single Blind, Placebo Controlled Pilot Study to Explore the Safety and Tolerability of a Single Oral Dose of 30 mg BAY1067197 in Patients With Chronic Heart Failure on the Background of Preexisting Beta-blocker Therapy||Bayer|No|Completed|November 2013|March 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||June 2015|June 12, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945606||59442|
NCT01946373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAT-02|T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma|A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma||Karolinska University Hospital|Yes|Recruiting|October 2013|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|74 Years|No|||March 2016|March 18, 2016|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946373||59383|
NCT01946386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-69|A Vasoconstriction Study With LEO 90100|||LEO Pharma|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01946386||59382|
NCT01945567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-039|Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor|Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor||The University of Western Australia|No|Recruiting|August 2012|February 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01945567||59445|
NCT01946893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009841|Mindfulness Meditation for Cognition and Mood|Mindfulness Meditation for Cognition and Mood: A Pilot Study Evaluating Feasibility and Collecting Preliminary Data||Oregon Health and Science University|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|21|||Both|65 Years|90 Years|No|||July 2015|July 9, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946893||59343|
NCT01976988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVT|Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery|PROSPECTIVE STUDY ON PREOPERATIVE VERSUS POSTOPERATIVE VENOUS THROMBOPROPHYLAXIS IN PATIENTS UNDERGOING MAJOR COLORECTAL SURGERY||Cedars-Sinai Medical Center|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|410|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01976988||57035|
NCT01977235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDICC|Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer|An Open, Randomized, Parallel Control, Multiple-center Phase II Trial of Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer|TDICC|Third Military Medical University|Yes|Recruiting|September 2013|September 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|75 Years|No|||October 2013|October 30, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01977235||57016|
NCT01977547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302030|Age of Blood in Children in Pediatric Intensive Care Units|Age of Blood in Children in Pediatric Intensive Care Units|ABC PICU|Washington University School of Medicine|Yes|Recruiting|January 2014|August 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1538|||Both|N/A|15 Years|No|||November 2015|November 23, 2015|August 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977547||56992|
NCT01977560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302095|Diet and Exercise Intervention in Type 2 Diabetes|Diet and Exercise Intervention in Type 2 Diabetes|LID|Washington University School of Medicine|Yes|Recruiting|October 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|25 Years|68 Years|No|||March 2016|March 1, 2016|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01977560||56991|
NCT01977859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 472930|BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects|BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects||Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Active, not recruiting|November 2013|June 2018|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|5||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977859||56968|
NCT01973881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00077505|Quantitative MRI for Myelofibrosis|Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment||University of Michigan|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|99 Years|No|||December 2015|December 2, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973881||57273|
NCT01974154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013966|COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function|COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function||Weill Medical College of Cornell University|No|Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|226|Samples With DNA|Lung epithelial lining fluid (ELF) obtained by bronchoalveolar lavage (BAL)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|December 2015|December 9, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974154||57252|
NCT01974167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/9/9 Ver1.0|Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol||e-GLORIA|e-GLORIA trial Protocol Review Committee|No|Recruiting|December 2013|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|85 Years|No|||May 2014|August 5, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974167||57251|
NCT01974661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-102|Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma|A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma||Immunicum AB|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01974661||57213|
NCT01974895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806|Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) in Children 6 to 35 Months of Age||GlaxoSmithKline||Completed|October 2013|July 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|316|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2015|April 9, 2015|October 23, 2013|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01974895||57195|
NCT01975181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|372910-6|Cardiovascular Prevention Program Registry|Cardiovascular Prevention Program Registry||Walter Reed National Military Medical Center|Yes|Recruiting|September 2013|October 2020|Anticipated|October 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult Military Health-Care Beneficiaries|November 2015|November 10, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975181|3 Years|57174|
NCT01975441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU 3 vs 2 LF ELIM PNG|Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa|Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa||University Hospital Case Medical Center|Yes|Recruiting|October 2013|June 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975441||57154|
NCT01944267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10893|Procedures for Improving the Mucosa Around Implants|Apically Positioned Flap, Free Gingival Graft and Apically Positioned Flap With Collagen Matrix Around Dental Implants||Tufts University School of Dental Medicine|No|Active, not recruiting|October 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944267||59545|
NCT01944761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000019124|The Neuro-protective Effects of Exercise in Children With Brain Tumors|The Neuro-protective Effects of Exercise in Children With Brain Tumors||The Hospital for Sick Children|No|Completed|July 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|7 Years|18 Years|No|||November 2015|November 16, 2015|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01944761||59507|
NCT01944787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-05-SP-50|Hydration and Rate of Cesarean Delivery Among Nulliparous|Intrapartum Hydration and Rate of Cesarean Delivery Among Nulliparous at > 37 Weeks: A Multicenter Randomized||Chauhan, Suneet P., M.D.|No|Not yet recruiting|September 2013|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|670|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01944787||59505|
NCT01946100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007569|Treatment of Multifocal Lung Adenocarcinoma|A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing||Mayo Clinic|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946100||59404|
NCT01946646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211048MPC|Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer|A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)|SR-GS|National Taiwan University Hospital|No|Recruiting|October 2013|||June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|79 Years|No|||October 2013|October 22, 2013|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01946646||59362|
NCT01946360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-MBT-01|Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).|||Institute of Liver and Biliary Sciences, India|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|70 Years|No|||September 2015|September 26, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01946360||59384|
NCT01946906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1037|The Rifaximin Study in CVID|Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial||Oslo University Hospital|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|74 Years|No|||November 2014|April 23, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946906||59342|
NCT01946919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-Pharmacy-002|Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study|Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study|PACER|Peking University Third Hospital|Yes|Recruiting|October 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18000|||Both|N/A|N/A|No|Non-Probability Sample|Inpatient using the cinepazide in the department of neurology in 61 hospitals in China.|November 2013|November 30, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946919|14 Days|59341|
NCT01943500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T30-0001|Collection of Blood Specimens for Circulating Tumor Cell Analysis|Collection of Blood Specimens for Circulating Tumor Cell Analysis||Viatar LLC|No|Active, not recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Confirmed patients with stage II-IV breast, prostate, or colorectal cancer, (Or) subjects        with no prior history of cancer.|June 2015|June 15, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01943500||59604|
NCT01947400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200279|Effect of AIDET on Physician-Patient Communication|Does Use of the AIDET (Acknowledge, Introduce, Duration, Explanation, Thank) Method for Physician-patient Communication Improve Patient Satisfaction in a Real World Setting as Measured by Modified HCAHPS (Hospital Consumer Assessment of Health Plans Survey) Scores?|AIDET|University of Florida|No|Terminated|December 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Physicians: Physicians of the Hospital Medicine Service|April 2015|April 10, 2015|September 17, 2013||No|The data that was critical to the study was not able to be obtained.|No||https://clinicaltrials.gov/show/NCT01947400||59304|
NCT01977014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMS/PAH/LP/001|NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up|NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up||NordicInfu Care AB|Yes|Recruiting|October 2013|||September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|Patients in Scandinavia who received a LenusPro pump|December 2013|December 9, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01977014|3 Years|57033|
NCT01977261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-HTO|High Tibial Osteotomy for Osteoarthritis of the Knee|High Tibial Osteotomy for Osteoarthritis of the Knee: a Randomised Controlled Trial|HTO|Erasmus Medical Center|Yes|Completed|January 2001|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||October 2013|October 30, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01977261||57014|
NCT01977573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113747|A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)|A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.||GlaxoSmithKline|Yes|Completed|October 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|99 Years|No|||October 2015|November 19, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977573||56990|
NCT01977586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM0754|Functional Imaging in the Assessment of mRCC Response to Sunitinib|Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment||Imperial College Healthcare NHS Trust|No|Withdrawn|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|November 20, 2015|September 30, 2013||No|Difficulty in recruiting suitable patients at centre|No||https://clinicaltrials.gov/show/NCT01977586||56989|
NCT01973894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|724|Midazolam Whole Body Physiologically Based Pharmacokinetic Model|Whole Body Physiologically Based Pharmacokinetic (PBPK) Model to Estimate Cerebral and Systemic Midazolam Concentrations in ICU Patients Under Sedation.|MidPBPK|Università degli Studi dell'Insubria|Yes|Recruiting|January 2013|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|serum and urine|Both|18 Years|N/A|No|Probability Sample|Critically ill patients in Intensive Care Unit, mechanically ventilated, sedated with        midazolam, intravenous continued perfusion.|October 2013|October 25, 2013|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01973894||57272|
NCT01974193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFL01|Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer|Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer: a Pilot Study||Ewha Womans University Mokdong Hospital|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Female|20 Years|80 Years|No|||February 2015|February 10, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974193||57249|
NCT01974180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013972|Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function|Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function||Weill Medical College of Cornell University|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|Samples With DNA|Airway epithelial samples collected under IRB protocol #1204012331 will be used.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|May 2015|December 9, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974180||57250|
NCT01974440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102786|A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)||Janssen Research & Development, LLC|Yes|Active, not recruiting|January 2014|August 2021|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974440||57230|
NCT01974921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-TER-2013-70|Study of Physiopathological Mechanisms and Results of Treatment With Bronchial Thermoplasty in Severe Asthma|Study of Physiopathological Mechanisms and Results of Treatment With Bronchial Thermoplasty in Severe Asthma||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|November 19, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01974921||57193|
NCT01975467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-001|Post Treatment Comparison Intramedullary Nail vs. Nonoperative Treatment|CLAVICLE FRACTURE OUTCOMES: 1-3 YEAR FOLLOW UP OF DISPLACED MIDSHAFT FRACTURES TREATED WITH INTRAMEDULARY NAIL vs. NONOPERATIVE TREATMENT||Sonoma Orthopedic Products, Inc.|No|Terminated|October 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population is open to anyone over the age of 18 that meet the study eligibility        criteria.|April 2015|April 12, 2015|October 23, 2013|No|Yes|Low Enrollment|No||https://clinicaltrials.gov/show/NCT01975467||57152|
NCT01975454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-mCRC|Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer|A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer||Shanghai University of Traditional Chinese Medicine|No|Recruiting|April 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|70 Years|No|||October 2015|November 23, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975454||57153|
NCT01944813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050880|Advance Care Planning: A Way to Improve End-of-life Care Life Care|Advance Care Planning: A Way to Improve End-of-life Care||University of Aarhus|Yes|Recruiting|November 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|360|||Both|18 Years|N/A|No|||September 2013|December 19, 2014|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01944813||59503|
NCT01944488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-631-12|LH Response to GnRH Test in Prepubescent Girls Under 6 Years|LH Response to GnRH Test in Prepubescent Girls Under 6 Years||University of Aarhus|Yes|Not yet recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|7 Months|6 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01944488||59528|
NCT01945307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/11|Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases|Sourcing Human Blood Products to Support the Development of New Vaccines Against Infectious Diseases|C2|University of Oxford|No|Recruiting|October 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Serum only, no DNA or other blood components are stored.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers, who are willing and able to give informed consent for        participation in the study.|November 2015|November 6, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945307||59465|
NCT01946399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ozurdex RVO 2013|Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF|Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications||Retina Research Institute, LLC|No|Terminated|September 2013|December 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|September 16, 2013|Yes|Yes|enrollment not met|No||https://clinicaltrials.gov/show/NCT01946399||59381|
NCT01947192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPGO0017|Chlorhexidine as Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions|Chlorhexidine as Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions and Failure-prognostic Variables: A Randomized Controlled Trial||Federal University of Pelotas||Completed|November 2011|||November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01947192||59320|
NCT01946633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNF-NaviCam-001|Remote-controlled Capsule Endoscopy: a Feasibility Study|Remote-controlled Capsule Endoscopy: a Feasibility Study||Nanfang Hospital of Southern Medical University|Yes|Recruiting|October 2013|||September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|75 Years|No|||October 2013|October 28, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946633||59363|
NCT01943513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211HV103|A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers||Biogen|No|Completed|October 2013|May 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943513||59603|
NCT01947179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03969|Cognitive Anxiety Sensitivity Treatment for Suicide|Development and Evaluation of a Brief, Suicide Prevention Intervention Reducing Anxiety Sensitivity|CAST|Florida State University|No|Completed|September 2011|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01947179||59321|
NCT01977287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FESvsAFO2013|Walking With FES or AFO in People With MS With Foot Drop|A Pilot Study to Assess the Effects of Using FES or AFO as an Assistive Mobility for Period of 12 Weeks for People With Multiple Sclerosis With Foot Drop||Queen Margaret University|No|Recruiting|June 2011|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|75 Years|No|Non-Probability Sample|People with Multiple Sclerosis who have been prescribed either FES or an AFO to treat foot        drop by their physiotherapist.|April 2015|April 22, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977287||57012|
NCT01974206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-CL-2001|A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor||Astellas Pharma Inc|Yes|Active, not recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974206||57248|
NCT01974219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306013986|HIV-related Accelerated Aging of the Airway Epithelium|HIV-related Accelerated Aging of the Airway Epithelium||Weill Medical College of Cornell University|No|Recruiting|April 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|330|Samples With DNA|Blood, Urine, Cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|April 2015|April 20, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974219||57247|
NCT01974453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pertini3|RAdiation Dose In percutANeuos Coronary Procedures Through Transradial Approach (RADIANT Observational Study)|RAdiation Dose In percutANeuos Coronary Procedures Through Transradial Approach (RADIANT Observational Study)|RADIANT|Ospedale Sandro Pertini, Roma||Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Medical operators that performe diagnostic and interventional coronary procedures|January 2016|January 27, 2016|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974453|1 Day|57229|
NCT01974674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030415|Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes|Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes|GRIIF|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2013|January 2022|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|55 Years|No|||September 2015|September 24, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974674||57212|
NCT01974687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682-001|Single and Multiple Dose Study of MK-3682 (IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)|A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects||Merck Sharp & Dohme Corp.|No|Completed|October 2013|September 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|178|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974687||57211|
NCT01974700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCBS-0001|Seizure Prophylaxis in Aneurysm Repair|Seizure Prophylaxis in Aneurysm Repair||Indiana University||Terminated|July 2013|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 28, 2013|No|Yes|Lack of enrollment - since the start of the study in 2013, only 17 subjects have consented. Of    those, only 8 completed the study.|No|March 7, 2016|https://clinicaltrials.gov/show/NCT01974700||57210|
NCT01975194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0481540|Rosuvastatin in African Americans With Cerebrovascular Disease|Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease|RIAA|Wayne State University|No|Terminated|January 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|30 Years|N/A|No|||November 2013|November 1, 2013|October 28, 2013|No|Yes|loss of research personnel|No||https://clinicaltrials.gov/show/NCT01975194||57173|
NCT01975207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH-SCN-01|Comparison Study of Family Practice Interventions for Depression in Adults|||AHS Cancer Control Alberta|No|Active, not recruiting|November 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|4500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975207||57172|
NCT01976013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUV-Coagu|Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring|Prediction of Major Bleeding in Extremely Low Birth Weight Infants (<1000g) by Sequential Coagulation Monitoring||Medical University of Vienna|No|Recruiting|October 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|126|||Both|N/A|7 Days|No|||September 2015|September 22, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976013||57110|
NCT01943968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-075-13|Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|60 Years|No|||September 2013|September 12, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943968||59568|
NCT01943981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC13OISI0099|Exercise Performance in Patients With Atrial Fibrillation|Exercise Performance in Patients With Atrial Fibrillation: Usefulness of Cardiopulmonary Exercise Test|AF-CPX|Incheon St.Mary's Hospital|No|Not yet recruiting|September 2013|||February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|30 Years|80 Years|No|Non-Probability Sample|Patients with atrial fibrillation and preserved left ventricular systolic function|September 2013|September 12, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943981|2 Years|59567|
NCT01943994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00016166|Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study|Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study||Johns Hopkins University|No|Recruiting|September 2008|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943994||59566|
NCT01945320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112008RIC|The Effects Nutrition Status and Body Composition on HD Patients' Outcome|The Effects Nutrition Status and Body Composition on HD Patients' Outcome||National Taiwan University Hospital|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|plasma|Both|20 Years|90 Years|No|Probability Sample|HD patients|April 2014|April 11, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01945320||59464|
NCT01945060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15215 & 17256|Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator|Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator||University of Virginia|No|Recruiting|September 2013|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|12 Years|17 Years|No|||October 2014|October 30, 2014|September 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945060||59484|
NCT01945840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/K02115X/1|Gut Hormones and Roux en Y Gastric Bypass|Do Gut Hormones Mediate the Beneficial Effects of Roux-en-Y Bypass?||Imperial College London|Yes|Not yet recruiting|October 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|136|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945840||59424|
NCT01946932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTMcogsub|Cognitive Impairment Following Cardiac Arrest and Target Temperature Management|Cognitive Impairment Following Cardiac Arrest and Target Temperature Management||Region Skane|Yes|Completed|June 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|287|||Both|18 Years|N/A|No|||August 2013|December 4, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946932||59340|
NCT01946438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC52|Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines, 2013-2014 Formulations||Sanofi|No|Completed|September 2013|July 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 16, 2013|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT01946438||59378|
NCT01947426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3565-00|Effect of Mother DHA Supplementation on Term Newborn.|Effect of Maternal Supplementation With DHA During Pregnancy and Lactation on the Development of the Term Newborn||Universidad de Granada|Yes|Completed|April 2008|April 2011|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|N/A|40 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01947426||59302|
NCT01946945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reprogenetics-3.109|Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis|Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Whole Chromosome Analysis by Next Generation Sequencing, and Replacement of a Single Euploid Embryo||Reprogenetics|Yes|Recruiting|September 2013|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|240|||Female|18 Years|42 Years|No|||September 2014|September 8, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01946945||59339|
NCT01943773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1590|Functional Prehabilitation and Major Elective Surgery|Functional Prehabilitation and Major Elective Surgery||University of Colorado, Denver|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|50 Years|89 Years|No|||July 2015|July 15, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01943773||59583|
NCT01977885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013106780|Exercise-Induced Epigenetic Modifications in Obese Aging Women||DIVAS2|University of Georgia|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|50 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01977885||56966|
NCT01977872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR062317|JointADventure: A Worksite Activity-Diet Intervention for Chronic Knee Pain|JointADventure: A Worksite Activity-Diet Intervention for Chronic Knee Pain||Northwestern University|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977872||56967|
NCT01973907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-295|Pilot Study for the SQUEEZE Trial|Pilot Study for the SQUEEZE Trial: a Trial to Determine Whether Septic Shock Reversal is Quicker in Pediatric Patients Randomized to an Early Goal Directed Fluid-sparing Strategy vs. Usual Care (SQUEEZE)|SQUEEZE|McMaster Children's Hospital|No|Recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|17 Years|No|||October 2013|January 6, 2014|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01973907||57271|
NCT01974232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310014390|A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag Froom 2009-2013|A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag Froom 2009-2013||Weill Medical College of Cornell University|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|33|||Both|19 Months|21 Years|No|Probability Sample|Patients eligible for this study included both males and females ≤ 21 years old (actual        range 19 months - 19 years) with persistent/chronic ITP lasting >6 months and were        diagnosed according to the clinical practice guidelines from the American Society of        Hematology.|October 2013|October 25, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974232||57246|
NCT01974466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJpancreatitis01|Fluid Resuscitation Goal in Early Stage of Severe Acute Pancreatitis|Fluid Resuscitation Goal in Early Stage of Severe Acute Pancreatitis||Ruijin Hospital|Yes|Recruiting|August 2013|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2013|November 18, 2013|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974466||57228|
NCT01974934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pristiq-2013|Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression|A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression||Hotel-Dieu Grace Healthcare|No|Recruiting|December 2013|||April 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|80 Years|No|||March 2015|March 18, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01974934||57192|
NCT01975220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.13|Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets|Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|October 29, 2013||||No||https://clinicaltrials.gov/show/NCT01975220||57171|
NCT01975233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12001|WEB French Observatory of the WEB Aneurysm Embolization System|WEB French Observatory||Sequent Medical, Inc|No|Active, not recruiting|November 2012|July 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|The decision to use a WEB device to treat the patients has been made before and        independently of the decision to include the patient in the French Observatory|February 2016|February 24, 2016|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975233||57170|
NCT01975753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/004/HP|First Evaluation of Morphine Hydrochloride by Nebulisation in Healthy Volunteers|First Evaluation of Morphine Hydrochloride by Nebulisation Compared to Intravenous Route in Healthy Volunteers: Preliminary Study Dose|AEROMORPH1|University Hospital, Rouen|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975753||57130|
NCT01945970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF-BEV-1134|Effect of Black Tea on Vascular Function|Randomized Double Blind Placebo Controlled Crossover Study to Assess the Effect of Black Tea on Flow-Mediated Dilation in Healthy, Non-tea Drinking Males|Heraclitus|Unilever R&D|No|Completed|September 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|September 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01945970||59414|
NCT01946269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRICS-02|Goal-Directed Therapy in Cancer Surgery|Goal-directed Resuscitation in High-risk Patients Undergoing Major Cancer Surgery: a Controlled and Randomized Study|GRICS II|University of Sao Paulo|Yes|Recruiting|September 2013|May 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|80 Years|No|||September 2013|September 18, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946269||59391|
NCT01944501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFSNCC2013|Neuromodulation Techniques in the Treatment of Chronic Tinnitus With Hearing Loss|Neuromodulation Techniques in the Treatment of Chronic Tinnitus With Hearing Loss||University of Brasilia|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|45 Years|70 Years|No|||September 2013|September 12, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01944501||59527|
NCT01944800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE 00113|Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome|Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5|ISAR-REACT 5|Deutsches Herzzentrum Muenchen|Yes|Recruiting|September 2013|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4000|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944800||59504|
NCT01945645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ready to Act|Ready to Act - Health Education in People With Hyperglycaemia|Ready to Act. A Health Education Programme for People With Screen-detected Hyperglycaemia||University of Aarhus|No|Completed|September 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|509|||Both|40 Years|69 Years|Accepts Healthy Volunteers|||September 2013|September 14, 2013|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01945645||59439|
NCT01945619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31634, EAP CHALLAH|Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)|Expanded Access Protocol: Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After HSCT|EAP CHALLAH|Baylor College of Medicine||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2016|January 19, 2016|September 16, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01945619||59441|
NCT01945632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|root planing tophography|Effect of Root Planing on Surface Topography.|||Universidad de Granada|Yes|Completed|January 2011|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01945632||59440|
NCT01946113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4209|Mineral-Homeostasis in Continuous Renal Replacement Therapy|Phosphate, Magnesium and Calcium-Homeostasis in Patients With Acute Renal Failure and Continuous Renal Replacement Therapy||Heinrich-Heine University, Duesseldorf|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|intensive care unit patients with acute renal failure undergoing renal replacement therapy|August 2015|August 19, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01946113||59403|
NCT01946126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-CM-13-592|A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache|||Allergan|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|459|||Both|18 Years|65 Years|No|Probability Sample|Patients with a diagnosis of chronic migraine or other diagnosis of migraine or headache.|February 2016|February 15, 2016|September 17, 2013||No||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01946126||59402|
NCT01946685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOL-11-80|A Randomized Clinical Trial of Mifepristone in PTSD|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone||James J. Peters Veterans Affairs Medical Center|Yes|Recruiting|November 2012|June 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Male|18 Years|89 Years|No|||March 2015|March 30, 2015|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946685||59359|
NCT01946698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo|Endometriosis, Food Consumption and Fertility|A Study on the Differences in Inflammatory Markers Between Women With Endometriosis and Women Without in Relation to Fertility and Food Consumption.||University of Aarhus|No|Recruiting|June 2013|September 2030|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood samples for inflammatory markers, hormones and genetic testing. Follicular fluid for      inflammatory markers. Cells from the uterus for testing of different additives and what      characterize cells from women with endometriosis compared to controls.|Female|18 Years|41 Years|No|Non-Probability Sample|Women attending an infertility Clinic, some with endometriosis compared to women without        endometriosis|September 2013|September 19, 2013|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01946698|4 Months|59358|
NCT01946672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110903|Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer|Individualisation du Drainage Lymphatique Des Membres inférieurs Lors du Curage Pelvien Pour Cancer gynécologique|SENTIJAMBE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2013|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Female|18 Years|N/A|No|||November 2015|November 13, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946672||59360|
NCT01947452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-1112|The Effects of Summer Employment on Disadvantaged Youth: Experimental Evidence|The Effects of Summer Employment on Disadvantaged Youth: Experimental Evidence||University of Chicago|No|Active, not recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1634|||Both|14 Years|21 Years|No|||December 2014|December 5, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01947452||59300|
NCT01947465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS_2013_01|Immunogenicity and Safety of Vaccinations in Immunocompromised Persons|A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls||University of Zurich|No|Completed|October 2013|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|645|Samples Without DNA|Sera from participants will be kept in a biobank for further measurements of antibody      responses after vaccination.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The cohort will be selected from patients with rheumatic diseases under treatment at 6        rheumatology outpatient clinics in Switzerland (University of Basel, University of Bern,        University of Geneva, University of Zurich, Cantonal Hospital Aarau, Cantonal Hospital St.        Gallen)|February 2016|February 24, 2016|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01947465||59299|
NCT01947205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kayseri ERH|Pain and Suction Curettage|||Kayseri Education and Research Hospital|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|111|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 16, 2013||||No||https://clinicaltrials.gov/show/NCT01947205||59319|
NCT01943552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2514|Ipratropium Bromide in Peri-Operative COPD|Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial.||Boehringer Ingelheim||Completed|October 2013|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|192|||Both|50 Years|75 Years|No|||September 2015|September 23, 2015|September 12, 2013||||No||https://clinicaltrials.gov/show/NCT01943552||59600|
NCT01974245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq473838/2011-7|Supplementation With Cholecalciferol in Dialysis Patients|Impact of Treatment With Cholecalciferol on Immunological Markers in Patients With Hypovitaminosis D on Dialysis||Federal University of São Paulo|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|80 Years|No|||December 2014|December 16, 2014|October 8, 2013||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01974245||57245|
NCT01974258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29026|Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients|A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES||Hoffmann-La Roche||Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974258||57244|
NCT01973920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-ICP-P2 -01|Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study|A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study||Oshadi Drug Administration||Recruiting|December 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|21 Years|N/A|No|||April 2015|April 21, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01973920||57270|
NCT01973933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPI02|Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR|A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Pyrimethamine and Metformin IR After Oral Administration in Healthy Male Volunteers||Seoul National University Hospital|No|Completed|June 2013|||August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 27, 2013|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01973933||57269|
NCT01974713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042010|Inflammatory Markers and Adverse Outcomes in Chronic Kidney Disease|CAN-AIM to PREVENT: CANadian Study, Assessing Inflammatory Markers to PRedict EVents in Nephrology sTudy|AIMtoPREVENT|Institute of Kidney Lifescience Technologies|No|Active, not recruiting|April 2010|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2530|Samples With DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients in chronic kidney disease clinic setting|November 2015|February 22, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974713|3 Years|57209|
NCT01974947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 10033|Metabolic Syndrome and Male Infertility|Relationship Between Sperm Parameters and Metabolic Syndrome in a Infertile Couple Partner Man|Metasperme|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|Samples With DNA|Blood and sperm samples will be collected from all patients BLOOD :Whole blood was collected      on dry, heparin or EDTA tubes. After several soft turnings, tubes were centrifuged at 1900g      for 10min.Then plasma, serum, buffy coat or red blood cells were taken in microtubes and      frozen at -80°C.      SPERM: After liquefaction, total sperm was centrifuged at 600g for 10min. Seminal plasma was      collected directly on microtubes and stored at -80°C. After trypsinisation, spermatozoa were      fixed in Carnoy solution and stored at -20°C.      DNA was separated from buffy coat using DNA extract kit|Male|18 Years|45 Years|No|Non-Probability Sample|Man consulting for primary or secondary infertility, with or without earlier notion of        paternity|December 2015|December 15, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974947||57191|
NCT01975480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2382578|Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities|||START Clinic for Mood and Anxiety Disorders||Recruiting|January 2013|||June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975480||57151|
NCT01945502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-434-13|Nasopharyngeal Packing and Rhinologic Surgery.|The Effectiveness of Three Different Nasopharyngeal Packing on the Prevention of Postoperative Nausea- Vomiting and Postoperative Throat Pain in Rhinologic Surgery.||Ankara University|No|Recruiting|September 2013|||December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|60 Years|No|Probability Sample|Adult patients (18-60 years) scheduled for routine nasal and/or paranasal sinus surgeries        in Ankara Univerity Faculty of Medicine, ETN operating rooms were recruited into this        study.|September 2013|September 16, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945502||59450|
NCT01945749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.04|Exercise and Steroid in Knee Osteoarthritis|Combined Intra Articular Corticosteroid and Physiotherapeutic Exercise in Patients With Osteoarthritis of the Knee: A Random-ised Clinical Trial||Frederiksberg University Hospital|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|N/A|No|||May 2014|May 5, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945749||59431|
NCT01946529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESFT13|Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors|Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors||St. Jude Children's Research Hospital|Yes|Active, not recruiting|November 2013|July 2026|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|25 Years|No|||December 2015|December 1, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946529||59371|
NCT01946789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITN06-ALT-803|A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer||Altor Bioscience Corporation|Yes|Recruiting|April 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946789||59351|
NCT01945073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000|Improving Disease Knowledge in Adolescents With Sickle Cell Disease|An Educational Intervention to Improve Disease Knowledge Among Adolescents With Sickle Cell Disease|KNOW-IT|The University of The West Indies|No|Completed|August 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|150|||Both|13 Years|19 Years|No|||November 2015|November 30, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01945073||59483|
NCT01945879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO-004/1|Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer|Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.||CONKO-Studiengruppe|Yes|Completed|January 2003|April 2004|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01945879||59421|
NCT01946412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-770-109|Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation|A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation||Vertex Pharmaceuticals Incorporated|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|2 Years|N/A|No|||March 2016|March 4, 2016|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946412||59380|
NCT01945853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00080565|Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)|Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)||Johns Hopkins University|No|Withdrawn|July 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945853||59423|
NCT01945866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol U|Phase II Combination Steroid and Anti-VEGF for Persistent DME|Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy||Diabetic Retinopathy Clinical Research Network|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945866||59422|
NCT01946659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-193|Promoting Adherence to Sleep Apnea Treatment Among Blacks With Metabolic Syndrome|Promoting Adherence to Sleep Apnea Treatment Through Health Education Among Blacks With Metabolic Syndrome|MetSO|New York University School of Medicine|No|Completed|September 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|344|||Both|18 Years|85 Years|No|||September 2015|September 9, 2015|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01946659||59361|
NCT01946139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-084|Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV|Screening HIV-Infected Women for Anal Cancer Precursors||AIDS Malignancy Consortium|No|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|300|||Female|18 Years|N/A|No|||September 2015|December 17, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946139||59401|
NCT01946152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0018|Pomalidomide and Dexamethasone With Growth Factor Support|A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|March 2014|||March 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946152||59400|
NCT01946165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0332|Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide|A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence||M.D. Anderson Cancer Center|Yes|Active, not recruiting|October 2013|||October 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|69|||Male|18 Years|N/A|No|||September 2015|September 18, 2015|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946165||59399|
NCT01946984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Specialized Arab Hospital|Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis|Intramuscular Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial, In Post ERCP Pancreatitis.||Specialized Arab Hospital|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|182|||Both|16 Years|90 Years|No|||September 2013|September 19, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01946984||59336|
NCT01946958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-13683|Triple P With Pediatric Residents|Randomized Control Study of the Impact of Primary Care Triple P on Pediatric Residents and Their Patients||Seattle Children's Hospital|No|Completed|July 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|155|||Both|18 Months|12 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01946958||59338|
NCT01943565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001850|Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study|Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study||Brigham and Women's Hospital|No|Not yet recruiting|October 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943565||59599|
NCT01947478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10102118DOC|MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery|Randomized Trial of MDT-2113 Drug-Eluting Balloon (DEB) vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery|MDT-2113 SFA|Medtronic Endovascular|Yes|Active, not recruiting|September 2013|December 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|85 Years|No|||January 2016|January 25, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947478||59298|
NCT01974492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHTS_KBKim_Saphenous|Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting|A Comparison of Histologic and Immunohistochemical Characteristics Between the Upper and Lower Leg Saphenous Veins Used for Coronary Artery Bypass Grafting|COSAVEGUL-1|Seoul National University Hospital|Yes|Active, not recruiting|October 2013|September 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|75 Years|No|||November 2014|November 18, 2014|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974492||57226|
NCT01974479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCARCD19|Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia||National University Health System, Singapore|No|Recruiting|January 2014|December 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|80 Years|No|||May 2015|May 11, 2015|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01974479||57227|
NCT01974973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-02|Stem Cell Therapy in Autism Spectrum Disorders|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Autism Spectrum Disorders||Neurogen Brain and Spine Institute|Yes|Recruiting|August 2009|October 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|6 Months|40 Years|No|||September 2014|September 13, 2014|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01974973||57190|
NCT01975246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348.1|Add-on to Micamlo BP Trial|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg||Boehringer Ingelheim||Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|309|||Both|20 Years|N/A|No|||July 2014|July 23, 2014|October 29, 2013||||No||https://clinicaltrials.gov/show/NCT01975246||57169|
NCT01945515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robot-tDCS-2013|Robotic-assisted Gait Training Combined With Transcranial Direct Current Stimulation to Maximize Gait Recovery After Stroke|Robotic-assisted Gait Training Combined With Transcranial Direct Current Stimulation to Maximize Gait Recovery After Stroke: A Double-blind, Randomized, Controlled Trial||Seoul National University Hospital||Recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945515||59449|
NCT01945983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si507/2013|Early Use of Norepinephrine in Septic Shock Resuscitation|The Comparison Between Early Norepinephrine Use and Standard Treatment During Severe Sepsis and Septic Shock Resuscitation.|CENSER|Mahidol University|Yes|Recruiting|September 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945983||59413|
NCT01946295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005513-40|Famotidine in Schizophrenia|Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia||Helsinki University|No|Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01946295||59389|
NCT01976286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU84250|A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma|A Pilot Study Comparing the Efficacy of Glycolic Acid Peels vs. Salicylic Acid Peels for the Treatment of Melasma: A Randomized Control Trial||Northwestern University|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01976286||57089|
NCT01976572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E17|Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects|A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects||Mitsubishi Tanabe Pharma Corporation|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|October 30, 2013||No||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01976572||57067|
NCT01945333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6721|Personalized and Scalable Cognitive Remediation Approaches|Personalized and Scalable Cognitive Remediation Approaches||New York State Psychiatric Institute|No|Recruiting|September 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|65 Years|No|||October 2015|December 15, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945333||59463|
NCT01945346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167700-002CL|An Exploratory Study of PRX167700 in Patients With Knee Osteoarthritis|A Double-Blind, Randomised, Exploratory Study to Investigate the Safety, Efficacy and Pharmacokinetics of PRX167700 in Subjects With Knee Osteoarthritis.||Proximagen Limited|No|Completed|September 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|45 Years|75 Years|No|||August 2015|August 25, 2015|September 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945346||59462|
NCT01946425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC51|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine (2013-2014 Formulation)||Sanofi|No|Completed|September 2013|July 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 16, 2013|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT01946425||59379|
NCT01946178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 1006|Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids|Clinical Study of a Focused Ultrasound Device for Treating Uterine Fibroids and Menorrhagia||Mirabilis Medica, Inc.|No|Completed|January 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|55 Years|No|||February 2016|February 24, 2016|September 16, 2013||No||No|February 24, 2016|https://clinicaltrials.gov/show/NCT01946178||59398|
NCT01946477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-014|Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.|A Phase 2, Multicenter, Single-Arm, Open-Label Study of Pomalidomide In Combination With Low-Dose Dexamethasone In Subjects With Relapsed Or Refractory Multiple Myeloma Following Lenalidomide-Based Therapy In the Second-Line Setting|POM MM 014|Celgene|No|Recruiting|May 2014|June 2021|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946477||59375|
NCT01946451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SilesianMU|Gene Expression in Patients With Epiretinal Membranes|Gene Expression and Their Correlations in Patients With Idiopathic and Secondary Epiretinal Membranes in Proliferative Diabetic Retinopathy||Medical University of Silesia|No|Active, not recruiting|June 2012|December 2013|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|55 Years|N/A|No|Non-Probability Sample|Study population description:        The blood and ERM samples were obtained from patients treated in the Department of        Ophthalmology, University Hospital No. 5, Medical University of Silesia, Katowice, Poland.        All subjects underwent a complete ophthalmic examination: best corrected visual acuity        (BCVA), tonometry, slit lamp examination of anterior and posterior segment, optical        coherence tomography (OCT) of the central retina.|September 2013|September 18, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946451||59377|
NCT01946464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001161|Novel Technique for Face Mask Ventilation|Novel Technique for Face Mask Ventilation||Rutgers, The State University of New Jersey|No|Terminated|September 2012|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|30|||Both|18 Years|85 Years|No|Probability Sample|pts coming to Same Day Surgery who require anesthesia|January 2016|January 7, 2016|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01946464||59376|
NCT01947270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50789|Multidisciplinary Program "Optimization of Drug Prescription" : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients|OPMED STUDY: Multidisciplinary Program "Optimization of Drug Prescription" : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients|OPMED|Hospices Civils de Lyon|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1596|||Both|75 Years|N/A|No|Non-Probability Sample|Hospitalized elderly patients from 75 years old.|July 2015|July 16, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01947270||59314|
NCT01943617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10002004-3|Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis|Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis||Beijing Friendship Hospital|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943617||59595|
NCT01943851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116183|A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies|A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies||GlaxoSmithKline|No|Recruiting|May 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|March 3, 2016|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943851||59577|
NCT01947218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00553-42|EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE|EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE||Assistance Publique Hopitaux De Marseille||Recruiting|July 2014|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|70|||Both|18 Years|80 Years|No|||August 2015|August 20, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01947218||59318|
NCT01947231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2436/2013|GPR vs Manual PT for Chronic Neck Pain|Randomized Controlled Trial of Global Postural Re-education vs. Standard Manual Physical Therapy for Non-specific Chronic Neck Pain With Cross-over||University of Bologna|No|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||September 2013|December 3, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01947231||59317|
NCT01947244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D89MC23146|Doula Home Visiting Randomized Trial|Illinois Maternal, Infant, and Early Childhood Home Visiting (MIECHV): Doula Randomized Controlled Trial||University of Chicago|No|Enrolling by invitation|November 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Female|14 Years|24 Years|No|||December 2014|December 4, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01947244||59316|
NCT01947491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205|A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis|||Promius Pharma, LLC|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|394|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01947491||59297|
NCT01945476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0444|Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer|||Yonsei University|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|82|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 5, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01945476||59452|
NCT01944410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Use of PRP in Treatment of Mandibular Traumatic Bone Cyst|Efficacy of Platelet-rich Plasma in Treatment of Mandibular Traumatic Bone Cyst|TBC|Shiraz University of Medical Sciences|Yes|Completed|January 2013|April 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|15 Years|65 Years|No|||October 2014|October 5, 2014|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01944410||59534|
NCT01944423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA034658|Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine|Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine|DCS/PSRT|University of Texas at Austin|No|Recruiting|October 2013|||October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01944423||59533|
NCT01974726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040671-3|Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 3||University of Pittsburgh|No|Recruiting|October 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|460|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01974726||57208|
NCT01974739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR 44878|Hydrochloorthiazide and Hypernatriaemie|Hypernatraemia and Diuretics in Intensive Care Patients||Medical Centre Leeuwarden|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974739||57207|
NCT01974752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1344C00001|Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)|A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)|SUMIT|AstraZeneca|No|Active, not recruiting|April 2014|June 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|130 Years|No|||January 2016|January 20, 2016|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974752||57206|
NCT01944969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14767B|Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder|Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Terminated|October 2013|||May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|September 13, 2013|Yes|Yes|The study was terminated because the lead-in study (14571A) in elderly was terminated; see    Detailed Description.|No|August 17, 2015|https://clinicaltrials.gov/show/NCT01944969||59491|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.
NCT01945229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/9 B|Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)|Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)|TAMBOURINE|Karolinska Institutet|No|Recruiting|February 2014|December 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|423|||Both|N/A|N/A|No|Non-Probability Sample|We will screen all patients residing in the extended region around Stockholm, Sweden who        have been referred and admitted to the Radiumhemmet clinic for investigation (and usually        treatment) with radioiodine. As of February 2016, we will also include patients referred        for treatment with antithyroid drugs at the endocrinology clinics of 1) Sahlgrenska        University Hospital, Gothemburg Sweden, 2) Karolinska University Hospital, Stockholm,        Sweden, 3) Danderyds Hospital, Stockholm, Sweden|January 2016|January 19, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945229||59471|
NCT01945762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00104|Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer|European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer|Caprelsa104|AstraZeneca|No|Recruiting|February 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic        Medullary Thyroid Cancer (MTC)|March 2016|March 14, 2016|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01945762||59430|
NCT01976585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1347|In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy|A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|December 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976585||57066|
NCT01945359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-001-TEC|Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design|A Pilot Study to Assess Disease State Stability, Efficacy, and Tolerability in a Natalizumab to Dimethyl Fumarate Crossover Design|IIT6|Rocky Mountain MS Research Group, LLC|No|Completed|September 2013|June 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Serum Samples|Both|18 Years|N/A|No|Non-Probability Sample|30 participants with relapsing remitting multiple sclerosis crossing over from natalizumab        to dimethyl fumarate (DMF) therapy|October 2015|October 14, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945359||59461|
NCT01945658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 0071-13|The Impact of In-Vitro Fertilization (IVF) ON Vitamin D|Evaluate the Influence of Different Levels of Vitamin D on IVF -ICSI Cycles. We Will Evaluate as Well the Influence of Increased Estradiol Level in IVF-ICSI Cycles on Peripheral Vitamin D.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|November 2013|May 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|blood for vitamin-D|Female|20 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergo IVF treatments|August 2013|September 15, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945658||59438|
NCT01945892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/ISS/OPH/RET/011|Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome|Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome||Ludwig-Maximilians - University of Munich|No|Completed|November 2011|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|90 Years|No|Probability Sample|Patients older than 18 years.|September 2013|September 18, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945892||59420|
NCT01945177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/796/E|RCT: WLE vs. NBI in Upper Gastrointestinal Endoscopy|A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in Subjects Undergoing Upper Gastrointestinal Endoscopy||Changi General Hospital|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|600|||Both|50 Years|N/A|No|||September 2013|August 24, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01945177||59475|
NCT01945190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-079|Acupuncture for Inflammatory Pain and Central Sensitization - A Pilot Study|Acupuncture for Inflammatory Pain and Central Sensitization - A Pilot Study||University of Vermont|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01945190||59474|
NCT01946711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12082.101|Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi|A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients||Pari Pharma GmbH|No|Recruiting|April 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01946711||59357|
NCT01946971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Konect-LASP|Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)|Lansoprazole in Preterm Infants With Gastroesophageal Reflux||Seoul National University Hospital|Yes|Completed|September 2013|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|6 Months|No|||November 2014|November 17, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01946971||59337|
NCT01943630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS101-IL#002|Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts|A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts.||BioMAS Ltd|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01943630||59594|
NCT01944371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10948|Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study|Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study||University of California, San Francisco|Yes|Completed|August 2013|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01944371||59537|
NCT01944384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912097M|Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart|Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart||National Taiwan University Hospital|No|Completed|August 2010|December 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01944384||59536|
NCT01944657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHS IRB [354612-3]|Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study|Supplemental TMS vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study||Sheppard Pratt Health System|No|Withdrawn|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|September 6, 2013|Yes|Yes|unable to enroll subjects|No||https://clinicaltrials.gov/show/NCT01944657||59515|
NCT01945489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-OAB-113|OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder||COMFORT|Allergan|No|Active, not recruiting|October 2013|February 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|September 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945489||59451|
NCT01944709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG269/06|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma||Cantonal Hospital of St. Gallen|No|Terminated|August 2006|December 2010|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|September 13, 2013||No|Progressive Disease|No||https://clinicaltrials.gov/show/NCT01944709||59511|
NCT01974986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-US-1307|Rehydration Following Exercise-Induced Dehydration|Rehydration Following Exercise-Induced Dehydration: Beverage Formula Effects in Team Sport Athletes||University of Illinois at Chicago|No|Active, not recruiting|July 2013|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974986||57189|
NCT01944696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0406|Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?|Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?||The University of Texas Health Science Center, Houston|Yes|Recruiting|March 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|N/A|24 Hours|No|||June 2015|June 30, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944696||59512|
NCT01975506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16898|Occupational Therapy in the Context of Head Start|An Examination of Occupational Therapy in the Context of Head Start||Texas Woman's University|No|Not yet recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01975506||57149|
NCT01975792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817255|Fetal Thymus Involution as a Predictor of Adverse Neonatal Outcomes|Fetal Thymus Involution as a Predictor of Adverse Neonatal Outcome in Women at High Risk for Preterm Delivery|TIPS|University of Pennsylvania|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant patients with singleton pregnancies admitted to labor and delivery at the        Hospital of the University of Pennsylvania between 28-36 weeks gestation for the        management of spontaneous preterm labor (defined as uterine contractions and documented        cervical change) and/or preterm premature rupture of membranes.|December 2015|December 18, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01975792||57127|
NCT01976039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-FMUSP 211-11|Rhinopharyngeal Retrograde Clearance is Effective to Adequate Upper Airways Function in Adults|The Effectiveness of Rhinopharyngeal Retrograde Clearance on the Upper Airways Symptomatology and Function in Adults||University of Sao Paulo|Yes|Completed|July 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|November 4, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976039||57108|
NCT01976026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.114|DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment|Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment|DIVERT|Centre hospitalier de l'Université de Montréal (CHUM)|No|Active, not recruiting|November 2013|||January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976026||57109|
NCT01976299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-6364|AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN|AVERT™ Clinical Trial|AVERT™|Osprey Medical, Inc|No|Completed|December 2013|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|578|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976299||57088|
NCT01976598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALG-ANA1001|Sub-Sensory Intraspinal Neurostimulation Therapy|Sub-Sensory Intraspinal Neurostimulation Therapy In the Treatment of Neuropathic Back and/or Leg Pain||Algos Clinical Development|No|Terminated|October 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|22 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the        treatment of chronic back and/or leg pain|January 2015|January 15, 2015|October 30, 2013||No|Protocol proved too cumbersome. Consequently, only one one patient enrolled, and completed.|No||https://clinicaltrials.gov/show/NCT01976598||57065|
NCT01976611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-139|Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea|||Allergan|No|Completed|June 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|402|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.|April 2015|April 7, 2015|October 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976611||57064|
NCT01945385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0185|Impact of Video Intervention on Postabortal Uptake of Long Acting Reversible Contraception (LARC)||LARC IUD|University of Chicago|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|193|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01945385||59459|
NCT01945697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207019|Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Validation of DNA Methylation Biomarkers for Oral Cancer Detection||National Taiwan University Hospital|Yes|Recruiting|December 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|Cells from oral mouthwash|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients come to the Department of Dentistry of National Taiwan University Hospital for        oral health care or treatment.|April 2014|April 14, 2014|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945697||59435|
NCT01945671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 0070-13|The Influence of Obesity on Oocyte, Cumulus and Granulosa Functioning|The Influence of Obesity on Oocyte Functioning and Fertilization, Cumulus and Granulosa Functioning and Metabolic Factors.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|November 2013|May 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|1. triglycerides, free fatty acid, cholesterol (HDl, LDL), insulin, glucose, lactate, IGF-1,      Leptin E2, Progessterone, IL-1, Il-6 and TNF-2. α.blood free fluid from the leading follicle      will be collected in a container for further evaluation of metabolic markers including      triglycerides, free fatty acid, cholesterol (HDl, LDL), insulin, glucose, lactate, IGF-1,      Leptin E2, Progessterone, IL-1, Il-6 and TNF-α , ROS.      3. Cumulus cells 4. Oocytes diameter 5. GV oocytes, M1 and M2 that fail to fertilize 6.      GDF-9, BMP-15, BMP-6, TNF-α, SMAD family will be analyzed by western blott as marker for      oocytes quality.|Female|20 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergo IVF treatments|August 2013|September 17, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945671||59437|
NCT01945684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWP450002|A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity|||Daewoong Pharmaceutical Co. LTD.|No|Completed|September 2013|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945684||59436|
NCT01945905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES02013|Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia|Cost-effectiveness of Two Forms of Delivery of Directly Observed Treatment in a Demonstration Area of the DOTS Strategy in Colombia|DOTS|Fundación FES|Yes|Completed|December 2009|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|264|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01945905||59419|
NCT01945944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-13-11|Nebulized Hypertonic Saline for Mechanically Ventilated Children|Nebulized Hypertonic Saline for Mechanically Ventilated Children||University Hospital Case Medical Center|Yes|Completed|October 2013|May 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|18 Years|No|||December 2014|December 8, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01945944||59416|
NCT01946230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306005RINC|The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma|The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma|p62/SQSTM1|National Taiwan University Hospital|No|Not yet recruiting|June 2014|||August 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Doctor of Dental Surgery|April 2014|April 25, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946230|6 Years|59394|
NCT01946243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-QP01|The Feasibility of Florbetapir Quantitation|The Feasibility and Reliability of Utilizing Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Qualitative Interpretation of Amyvid Brain Scans||Avid Radiopharmaceuticals|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|96|||Both|N/A|N/A|No|||June 2015|June 1, 2015|September 17, 2013|No|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01946243||59393|No conclusions can be drawn regarding the relative performance of software packages (different readers) or on impact of additional qualitative practice on quantitative interpretation results (Vis Q always after Qualitative).
NCT01944150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K121201|Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis|Interest of the Association of Two Complementary Techniques, Hypnosis and Transcutaneous Electrical Nerve Stimulation in the Treatment of Chronic Non-cancer Pain, Nociceptive and / or Neuropathic Pain: Randomized Trial|HYPTENS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Both|18 Years|80 Years|No|||June 2015|June 17, 2015|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01944150||59554|
NCT01944930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-077|Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases|||Lahey Clinic||Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944930||59494|
NCT01944943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISMOLY|Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia|Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia|VISMOLY|The Lymphoma Academic Research Organisation|Yes|Terminated|February 2013|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|February 22, 2013||No|lack of efficacy|No||https://clinicaltrials.gov/show/NCT01944943||59493|
NCT01945203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105097RC|The Relationship Between Aortic Pulse Wave, Aortic Calcification and Peripheral Artery Occlusion Disease in Peritoneal Dialysis Patients|The Relationship Between Aortic Pulse Wave, Aortic Calcification and Peripheral Artery Occlusion Disease in Peritoneal Dialysis Patients||National Taiwan University Hospital|Yes|Completed|December 2011|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|174|Samples Without DNA|Plasma, 8ml/patient|Both|20 Years|90 Years|No|Probability Sample|PD patients|September 2013|September 15, 2013|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01945203||59473|
NCT01944722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDS-USHPV|Clinical Evaluation of the HPV Assay on the BD Viper LT System With Cervical Specimens|Clinical Evaluation of the HPV Assay on the BD Viper LT System With Cervical Specimens.||Becton, Dickinson and Company|No|Active, not recruiting|August 2013|February 2016|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|47000|||Female|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|September 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944722||59510|
NCT01974765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-119|Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies|A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies||Memorial Sloan Kettering Cancer Center||Recruiting|November 2013|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01974765||57205|
NCT01975012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1111|Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age|A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naive HIV-1 Infected Children, < 12 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn|September 2014|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|11 Years|No|||August 2015|August 31, 2015|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975012||57187|
NCT01975272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-2-018|The Use of Iron Therapy for Patients With Anemia After Surgery|The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial|VITAPOP|Maastricht University Medical Center|Yes|Not yet recruiting|November 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 28, 2013|September 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975272||57167|
NCT01975259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004|Investigating the Incretin Effect in Cystic Fibrosis|Investigating the Incretin Effect in Cystic Fibrosis|IECF|Liverpool Heart and Chest Hospital NHS Foundation Trust|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Blood|Both|17 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The CF Cohort will be recruited from the population of Patients attending Adult CF Service        at Liverpool Heart & Chest Hospital, Liverpool, United Kingdom        The control group will be invited to participate from the general public. We will        advertise our study through the Liverpool Heart & Chest Hospital and also via GP surgeries        (Primary care clinics) in both electronic & paper forms.|September 2015|September 1, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01975259||57168|
NCT01975519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105SAR101|A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma|A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma||Tracon Pharmaceuticals Inc.|No|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|12 Years|N/A|No|||March 2016|March 16, 2016|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01975519||57148|
NCT01975805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTP-09-00380|Chlorhexidine Gluconate Versus Povidone Iodine at Cesarean Delivery: a Randomized Controlled Trial|To Determine the Difference in Positive Bacterial Cultures in Cesarean Sections With 2% Chlorhexidine- Gluconate, 70% Isopropyl Alcohol (Chloraprep) vs. Povidone-iodine 10% (Betadine) Preoperative Surgical Scrub||University of Southern California|Yes|Completed|January 2010|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01975805||57126|
NCT01976052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSABiomarker|Evaluation of Potential Biomarkers for Obstructive Sleep Apnea and the Effect of Positive Pressure Treatment|||Karolinska University Hospital|No|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|Samples With DNA|Whole blood, serum, plasma|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|OSA patients will be recruited from an outpatient sleep clinic|March 2016|March 2, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01976052||57107|
NCT01976325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010462-01H|Evaluating the Ottawa Malaria Decision Aid|Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care|OMDA|Ottawa Hospital Research Institute|No|Recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01976325||57086|
NCT01976312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002E2302|Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)|A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia]|Camellia|Novartis|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01976312||57087|
NCT01976338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002E2303|Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)|A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]|Blossom|Novartis|No|Active, not recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01976338||57085|
NCT01976624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-087|Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea|||Allergan|Yes|Completed|August 2009|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|756|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Ganfort® for open-angle glaucoma or ocular hypertension in clinical        practice.|August 2015|August 28, 2015|October 30, 2013|No|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01976624||57063|
NCT01976637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNr 772/2009|Compression Treatment of Superficial Vein Thrombosis|Compression Treatment of Superficial Vein Thrombosis||Medical University of Vienna|Yes|Completed|December 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976637||57062|
NCT01977456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS044283-13|Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)|Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)|CLEAR-FDR|University of Cincinnati|Yes|Completed|September 2013|April 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|85 Years|No|||October 2015|December 16, 2015|October 18, 2013|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01977456||56999|Small sample size and open design. Did not include endovascular therapy patients.
NCT01945710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-112|An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors|An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors||Eisai Inc.|No|Recruiting|December 2012|May 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945710||59434|
NCT01946997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-11-05-03|Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography|Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography||Johns Hopkins University|No|Completed|July 2006|December 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal, non-diabetic patients|September 2013|September 19, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946997||59335|
NCT01945918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0645|Comparing Strategies for Translating Self-management Support Into Primary Care|Comparing Strategies for Translating Self-management Support Into Primary Care||University of Colorado, Denver|Yes|Enrolling by invitation|October 2013|September 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1080|||Both|21 Years|89 Years|No|||November 2015|November 10, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01945918||59418|
NCT01946191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS021162|Computer-Based Weight Maintenance in Primary Care|Maintaining Activity and Nutrition Through Technology-Assisted Innovation in Primary Care|MAINTAIN-PC|University of Pittsburgh|No|Active, not recruiting|October 2013|September 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|196|||Both|18 Years|75 Years|No|||September 2015|September 10, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946191||59397|
NCT01946204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102931|A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer|SPARTAN|Aragon Pharmaceuticals, Inc.|Yes|Recruiting|October 2013|August 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1200|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946204||59396|
NCT01946503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-13-00053|Infant & Toddler Short Gut Feeding Outcomes Study|Infant & Toddler Short Gut Feeding Outcomes Study||Children's Hospital Los Angeles|No|Recruiting|April 2013|||April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|3 Months|6 Years|No|Non-Probability Sample|Patients seen in home-TPN clinic and subjects who meet the inclusion criteria will be        invited to participate.|February 2015|February 2, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01946503||59373|
NCT01946737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/P/050|High Definition CT Coronary Angiography Accuracy Trial|Diagnostic Performance of 64 Slice High Definition Computed Tomographic Coronary Angiography in Patients With High Risk of Significant Coronary Artery Disease.||Plymouth Hospitals NHS Trust|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|302|||Both|40 Years|N/A|No|||September 2013|September 16, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01946737||59355|
NCT01946750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB : 2012-A00224-39|Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections|Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections|SERODIFF|Central Hospital, Versailles|Yes|Recruiting|December 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01946750||59354|
NCT01947023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01748|Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery|A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer||National Cancer Institute (NCI)|Yes|Suspended|August 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 16, 2013|No|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01947023||59333|
NCT01954862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG. 2013/3403|Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy|Comparison of Methods for Luminal Distention for on Demand Sedation Colonoscopy: Air Insufflation, Carbon Dioxide and Water-aided Colonoscopy. A Randomized Controlled Trial.||Presidio Ospedaliero Santa Barbara|No|Completed|October 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|624|||Both|18 Years|85 Years|No|||July 2014|July 30, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01954862||58731|
NCT01946256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC/2013/09/06|Treatment of Antenatal Chlamydia Infection|Erythromycin Versus Amoxicillin for Treatment of Antenatal Chlamydia Trachomatis Infection: A Randomized Controlled Trial||Obafemi Awolowo University Teaching Hospital|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Female|N/A|N/A|No|||March 2014|March 26, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946256||59392|
NCT01974999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-17|A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study|A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study (CTOT-17)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|243|||Both|N/A|N/A|No|Non-Probability Sample|The study population was selected based on their previous participation in the parent        study (CTOT-01). A total of 280 subjects were enrolled and transplanted in the Clinical        Trials in Organ Transplantation|January 2015|January 22, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974999||57188|
NCT01974531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Louwen/Oddo-Preterm birth|Psychological Distress & Stress in Parents With Preterm infants-a Prospective Study|Psychological Distress & Stress in Parents With Preterm infants-a Prospective Study on Risk and Protective Psychobiological Aspects||Johann Wolfgang Goethe University Hospitals|No|Recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|180|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women either with risk of with no risk of preterm birth from the obstetric ward        or from the antenatal class of the obstetric department and their partners|September 2015|September 4, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974531|2 Years|57223|
NCT01974778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|345-13|A Role for Brown Adipose Tissue in Postprandial Thermogenesis?|A Role for Brown Adipose Tissue in Postprandial Thermogenesis?||Bayside Health|No|Terminated|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|4|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 23, 2013||No|Participant numbers too low. Could not ingest required fat.|No||https://clinicaltrials.gov/show/NCT01974778||57204|
NCT01975285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032547|Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery|Prospective Randomized Double Blind Study to Evaluate the Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery.||Cedars-Sinai Medical Center|No|Terminated|August 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|90 Years|No|||September 2015|September 3, 2015|October 29, 2013||No|On initial statistical analysis, we have not found statistical significance.|No||https://clinicaltrials.gov/show/NCT01975285||57166|
NCT01975025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/13|Hemodialysis Frequency and the Calcification Propensity of Serum|Hemodialysis Frequency and the Calcification Propensity of Serum|Intensified HD|University Hospital Inselspital, Berne|No|Not yet recruiting|January 2014|January 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01975025||57186|
NCT01975311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17284|Effect of Lower Back Treatment in People With Patellofemoral Pain Syndrome.|Effect of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity, Pain Intensity, and Functional Activity in People With Patellofemoral Pain Syndrome.||Texas Woman's University|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|50 Years|No|||November 2014|January 9, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975311||57164|
NCT01975532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-MRI-DTI-on-DBS|Evaluation of Diffusion MRI as a Tool in Planning Deep Brain Stimulation (DBS)|Evaluation of MRI Based Fiber Tracking as a Tool in Deep Brain Stimulation for Movement Disorders||University of Aarhus|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|N/A|N/A|No|Non-Probability Sample|Patients screened and deemed eligible for treatment with Deep Brain Stimulation|December 2015|December 4, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01975532||57147|
NCT01975545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCIC-001|Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21|Efficacy of the Addition of Silver Nanoparticles to a Fluor Varnish in the Remineralization of Temporary Teeth in Patients With Trisomy 21. Randomized Clinical Trial.||Universidad Autonoma de San Luis Potosí|No|Active, not recruiting|September 2012|May 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|1 Year|6 Years|No|||March 2014|March 5, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01975545||57146|
NCT01975818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16208|Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934|A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan|DIALOGUE4|Bayer|Yes|Completed|October 2013|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|201|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975818||57125|
NCT01975831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2013-003|A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab|A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors||Ludwig Institute for Cancer Research|No|Recruiting|December 2013|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975831||57124|
NCT01976065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130467H|Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots|Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|September 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|6 Years|20 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976065||57106|
NCT01976351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907036R|Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus|Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus and Evaluation of Its Invasiveness in Patients With Gastroesophageal Reflux Disease||National Taiwan University Hospital|No|Terminated|September 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|Samples With DNA|A standardized endoscopic biopsy protocol was performed at sites with ESEM which usually      appeared as a reddish discoloration in an otherwise relatively whitish esophageal mucosa.      Two pieces of specimen were taken; one for histological confirmation and another one      (preserved as frozen tissue) for DNA analysis or immuno-histochemical staining. Biopsy from      gastric cardia was also taken for histological confirmation.|Both|20 Years|80 Years|No|Probability Sample|Patients were eligible for the study if they were scheduled for endoscopic examination at        the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or        without a previous history of dysplasia. Exclusion criteria included patients who are        younger than 20 years of age or patients with esophageal or cardiac varices or pregnant        women.|October 2013|October 29, 2013|October 23, 2013||No|Insufficient research manpower|No||https://clinicaltrials.gov/show/NCT01976351||57084|
NCT01976364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921092|Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis|A Long Term, Open-label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis|OPAL BALANCE|Pfizer|Yes|Recruiting|February 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|650|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976364||57083|
NCT01977469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EditalUniversal2011|Randomized Controlled Study to Investigate the Impact of Different Intensities Training on ADL and BODE Index in COPD|IMPACT OF AEROBIC AND HIGH AND LOW STRENGTH TRAINING ON DAILY LIFE ACTIVITIES AND BODE INDEX IN COPD PATIENTS||Universidade Federal de Sao Carlos|No|Recruiting|March 2013|December 2016|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||March 2013|December 10, 2013|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01977469||56998|
NCT01977482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113633|Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia|A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin||GlaxoSmithKline|Yes|Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|216|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01977482||56997|
NCT01947010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJK001|Pneumococcal Vaccination of Crohn Patients|Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease|PneuVAC|Statens Serum Institut|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|151|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01947010||59334|
NCT01947504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3525|Early Intervention Following Mild TBI|Acute and Brief Intervention Following Mild Traumatic Brain Injury: A Randomized Controlled Clinical Trial||McGill University Health Center|No|Recruiting|January 2016|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947504||59296|
NCT01943604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28698|The Effects of Breakfast on Neuropsychological Functioning|The Effects of Breakfast on Neuropsychological Functioning in Children Ages 8-10 From Low to Middle Income Families||Baylor College of Medicine|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|195|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01943604||59596|
NCT01944917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS2013|Effects of Pulsed Electromagnetic Field on Autonomic Function in Patients With Chronic Musculoskeletal Pain|Pilot Study to Investigate Autonomic Function in Patients With Chronic Musculoskeletal Pain.||Aerotel Ltd|No|Recruiting|August 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|35 Years|75 Years|No|Probability Sample|Patients suffering from musculoskeletal pain visiting weekly the Department for        Complementary Medicine at Sheba Medical Center will be recruited to this study.|September 2013|September 15, 2013|August 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01944917|1 Day|59495|
NCT01945437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg_TKA|Magnesium and TKA Pain|||Seoul National University Bundang Hospital||Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2013|September 13, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945437||59455|
NCT01954368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-10|Intranasal Sufentanil Pain-management at Entrance of Emergency Department : Influence on Pain-relief Delay|Acute Severe Traumatic Pain in the ED : Can we Improve Time to Pain-relief With a Single Dose of Intranasal Sufentanil Given at Triage ? A Randomized Double-blinded Placebo Controlled Study (InSPEED Study)|InSPEED|Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||September 2015|September 29, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01954368||58769|
NCT01947530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5056-B|Study Using Combined Virtual 4-D Electromagnetic (EM) Tip-Tracked Devices & EBUS in Diagnosis of Lung Nodules|Pilot Study Using Combined Virtual 4-D EM Tip-Tracked Devices and Endobronchial Ultrasound (EBUS)in the Diagnosis of Peripheral Pulmonary Nodules||University Health Network, Toronto||Recruiting|September 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01947530||59294|
NCT01947543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol no: 2012-11|Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study|Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study||University Hospital Orebro|No|Not yet recruiting|February 2015|||May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|Whole blood|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with ventricular tachycardia of unknown origin and treated with an ICD|September 2013|December 2, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01947543||59293|
NCT01954602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 13028 TNT study|Use of Touch and no Touch Guide-wire Techniques for Deep Biliary Cannulation: the TNT Study|A Multicenter Randomized Trial Comparing the Use of Touch and no Touch Guide-wire Techniques for Deep Biliary Cannulation: the TNT Study|TNT|Azienda Usl di Bologna|No|Recruiting|October 2013|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01954602||58751|
NCT01954615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-075-101|Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects|A Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Oral Dose and Food Interaction Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects||Actelion|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01954615||58750|
NCT01954628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQX-1125-202|Efficacy and Safety of AQX-1125 in Unstable COPD|The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway|FLAGSHIP|Aquinox Pharmaceuticals, Inc.|No|Active, not recruiting|October 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|40 Years|N/A|No|||August 2014|February 4, 2015|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01954628||58749|
NCT01954875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-Neurology-ALS stool sample|Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases|Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases||Carolinas Healthcare System|No|Recruiting|December 2009|||December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|blood, feces|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients at Carolinas Medical Center with and without neurodegenerative disease|September 2013|September 27, 2013|March 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01954875||58730|
NCT01955122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSDPR100|Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study|Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study||EndoAid|Yes|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|126|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01955122||58711|
NCT01974544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-141|Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines|Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines|PRODIGIES|Pontificia Universidad Catolica de Chile|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||October 2013|October 27, 2013|May 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01974544||57222|
NCT01975038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00086547|Adaption of the Skin Sun Sensitivity Scale|Adaption of the Skin Sun Sensitivity Scale for People With All Pigment Varieties||Northwestern University|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|292|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of approximately 200 Northwestern University students, employees        (faculty and staff), patients attending the dermatology clinic, and attendees of        Northwestern University dermatology-related events will be selected for measurement of the        melanin index with the Mexameter MX18.        The characteristics of the sample will be monitored to assure that each category of skin        type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample        will have equal representation from 4 ethnic groups within each skin type category:        African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify        as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.|July 2014|July 30, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975038||57185|
NCT01975298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAQ-MS-306|A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).|LIBRETTO|Teva Pharmaceutical Industries|Yes|Withdrawn|January 2014|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||March 2014|March 3, 2014|October 28, 2013|No|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT01975298||57165|
NCT01975324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dalfampridine 13-265|A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Ampyra|Neuro-Ophthalmologic Associates, PC|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|N/A|No|||October 2015|January 22, 2016|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01975324||57163|
NCT01975558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181/11|Radiation Metabolic Signature|The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study||University Hospital Inselspital, Berne|No|Enrolling by invitation|August 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Female|50 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 28, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01975558||57145|
NCT01975844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-12-197|The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability|The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability||Baystate Medical Center|Yes|Terminated|July 2013|||March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|August 13, 2013||No|Study has been terminated due to lack of financial support|No||https://clinicaltrials.gov/show/NCT01975844||57123|
NCT01976923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1338-P|Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy|Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group||King Khaled Eye Specialist Hospital||Active, not recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|374|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01976923||57040|
NCT01977183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRC/2013/1285|Effects of MSPrebiotic on Gut Health in the Elderly|Effects of MSPrebiotic on Gut Health in the Elderly||St. Boniface General Hospital Research Centre|Yes|Active, not recruiting|September 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 17, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01977183||57020|
NCT01977495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818810|Take Charge of Your Diabetes|Testing Enrollment Methods on Participation in Behavioral Economic Interventions for Diabetes Care: A Randomized Controlled Pilot Study||University of Pennsylvania|No|Completed|December 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|136|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01977495||56996|
NCT01973829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007998|The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)||Mayo Clinic|No|Recruiting|November 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15000|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01973829||57277|
NCT01947517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Punctal plugs|The Retention Rate Between Brand A and Brand B Punctal Plugs|The Retention Rate Between Superflex Punctal Plugs, and Parasol Punctal Occluders||Queen's University|No|Recruiting|September 2013|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|Patients will be recruited from cornea and general ophthalmology specialist practices at        Hotel Dieu Hospital, Queens University|September 2013|September 26, 2013|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01947517||59295|
NCT01943838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12863|A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245408 Polymorph E Administered Once Daily to Subjects With Solid Tumors or Lymphoma||Sanofi|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01943838||59578|
NCT01944137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-258|Improving Care After Chemotherapy|Improving Care After Chemotherapy|IMPACT|Massachusetts General Hospital|No|Active, not recruiting|September 2013|||November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|April 8, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944137||59555|
NCT01945450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0186-HMO-CTIL|Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial|Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth||Hadassah Medical Organization|Yes|Not yet recruiting|January 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|15 Years|50 Years|No|||August 2013|November 26, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945450||59454|
NCT01945463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0378-13|The Effect of Breast Augmentation on the Quality of Echocardiography Test|||Hadassah Medical Organization|No|Not yet recruiting|October 2013|||October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Female|18 Years|75 Years|No|Non-Probability Sample|Women undergoing breast augmentation|September 2013|September 15, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01945463||59453|
NCT01953887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-072|A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin|An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®)||Astellas Pharma Inc|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953887||58806|
NCT01954095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPRU Progestin|The Impact of Vaginal and IM Progestins on the Cervix|Determining the Pharmacodynamic Impact of Vaginal and IM Progestins on the Cervix||University of Pittsburgh|Yes|Completed|August 2013|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|89|Samples With DNA|Blood for DNA extraction, hormone, and metabolomic analyses      Cervicovaginal fluid for proteome, cytokines, and matrix metalloproteins (MMPs)|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study consists of 4 groups of women who are between 16 0/7 - 23 6/7 weeks gestation.        The allocation of a subject to a group is based on two objective assessments (history of        preterm birth and cervical length) and the joint clinical decision of the woman and her        physician regarding treatment options.        Study participants who have no prior preterm births and a normal cervical length will be        assigned to Group 1. If the participant has no prior preterm births and a short cervical        length, she will be assigned to Group 2 regardless of treatment or no treatment. Group        assignment for women with a prior preterm birth and normal cervical length is based on        17-OHPC use. Participants who elect to use 17-OHPC will be assigned to Group 3 and those        who choose not to receive any treatment will be assigned to Group 4.|December 2015|December 1, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954095||58790|
NCT01954108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTENA-INT-2013-03|Hyaluronan in the Treatment of Painful Achilles Tendinopathy.|Hyaluronan in the Treatment of Painful Achilles Tendinopathy.||TRB Chemedica AG|No|Completed|December 2013|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01954108||58789|
NCT01954641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1474|Accountability for Cancer Care Through Undoing Racism and Equity|Accountability for Cancer Care Through Undoing Racism and Equity|ACCURE|University of North Carolina, Chapel Hill|No|Recruiting|April 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01954641||58748|
NCT01945775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|673-301|A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)|A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease|EMBRACA|Medivation, Inc.|No|Recruiting|October 2013|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|429|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945775||59429|
NCT01945788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301|Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo|Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo||Bio Sidus SA|No|Active, not recruiting|June 2013|November 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|50 Years|81 Years|No|||September 2013|January 21, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01945788||59428|
NCT01955135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 /145|Anesthesia for Retinopathy of Prematurity|DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia||TC Erciyes University|No|Completed|September 2010|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|32 Weeks|40 Weeks|No|||September 2013|September 27, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01955135||58710|
NCT01955460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0758|Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII|Lymphodepletion Plus Adoptive Cell Transfer With TGF-Beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||October 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|12 Years|N/A|No|||February 2016|February 25, 2016|September 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01955460||58685|
NCT01974791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00007276|GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain|GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain|GET Living|Children's Hospital Boston|Yes|Recruiting|October 2013|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|8 Years|18 Years|No|||January 2016|January 26, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01974791||57203|
NCT01975337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2112|Evaluate the Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Diasease on Hemodialysis Compared to Healthy Subjects.|An Open-label Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Alisporivir (DEB025) in Subjects With End Stage Renal Disease on Hemodialysis Compared to Matched Healthy Subjects||Novartis|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|16|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975337||57162|
NCT01975571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G110089|Hybrid Cochlear Implants in Severe to Profound Adults, Children, and Adolescents|Iowa Cochlear Implant Clinical Research Center Hybrid Cochlear Implants in Severe to Profound Adults, Children, and Adolescents||University of Iowa|No|Enrolling by invitation|July 2011|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|5 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01975571||57144|
NCT01975857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061854|Mind-Body Rehabilitative Program for Veterans With mTBI (Mild Traumatic Brain Injury)|Evaluating a Novel Sleep-focused Mind-body Rehabilitative Program for Veterans With mTBI and Other "Polytrauma" Symptoms: An Randomized Controlled Trial (RCT) Study||University of Utah|No|Recruiting|October 2013|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01975857||57122|
NCT01976078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-11-00334|Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents|Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents||Children's Hospital Los Angeles|No|Recruiting|September 2012|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|18 Years|No|||January 2015|January 26, 2015|September 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01976078||57105|
NCT01976091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01AR060911|Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA|Phase I/IIa Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA||Nationwide Children's Hospital|Yes|Enrolling by invitation|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|8|||Both|7 Years|N/A|No|||February 2015|February 26, 2015|July 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976091||57104|
NCT01976377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307074RIND|Mucin Glycosylating Enzymes in Head and Neck Cancers|Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.||National Taiwan University Hospital|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|250|||Both|20 Years|90 Years|No|Non-Probability Sample|Head and neck cancer patients receiving operation in National Taiwan University Hospital|October 2015|October 28, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976377||57082|
NCT01976650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-029|Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea|||Allergan|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|724|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or        non-infectious uveitis affecting the posterior segment of the eye treated with (OZURDEX®)        in clinical practice.|December 2015|December 8, 2015|October 30, 2013|No|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01976650||57061|
NCT01976663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S17L-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||December 22, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976663||57060|
NCT01976936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD9004|Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2|A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.|NeuSTART2|Columbia University|Yes|Active, not recruiting|February 2009|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|164|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976936||57039|
NCT01977196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penta 0111|The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)|Phase 1 of DTP/Hepatitis B 10ug Hib Vaccine||PT Bio Farma|Yes|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|6 Weeks|11 Weeks|Accepts Healthy Volunteers|||October 2013|November 5, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01977196||57019|
NCT01977820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700773-004|Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria|SIGNAL|Merck KGaA||Terminated|February 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|29 Years|No|||January 2016|January 14, 2016|October 31, 2013||No|Recruitment challenges|No|September 21, 2015|https://clinicaltrials.gov/show/NCT01977820||56971|The study was prematurely discontinued by the Sponsor due to severe enrolment difficulties as a consequence of the limited availability of treatment naïve patients with a diagnosis of phenyl ketonuria.
NCT01974102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012264|Family Based Mindfulness Intervention|Preventing Childhood Obesity Through a Family-Based Mindfulness Intervention||Yale University|Yes|Active, not recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01974102||57256|
NCT01953549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHYS-Stroke|Physical Fitness Training in Subacute Stroke (PHYS-Stroke)|Physical Fitness Training in Subacute Stroke (PHYS-Stroke)||Charite University, Berlin, Germany|Yes|Recruiting|October 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|215|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01953549||58832|
NCT01954082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0053|Inositol to Reduce Retinopathy of Prematurity|INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants|INS-3|NICHD Neonatal Research Network|Yes|Active, not recruiting|April 2014|April 2019|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1760|||Both|N/A|72 Hours|No|||February 2016|February 17, 2016|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01954082||58791|
NCT01953874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-12-12-01|Cardiovascular Improvements With MV ASV Therapy in Heart Failure|Cardiovascular Improvements With Minute Ventilation-targeted ASV Therapy in Heart Failure (CAT-HF)|CAT-HF|ResMed|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|126|||Both|21 Years|N/A|No|||January 2016|January 4, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01953874||58807|
NCT01945242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-012|Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"|Nesina Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"||Takeda|No|Completed|March 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1382|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who have been examined at a medical institution|August 2014|August 7, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945242||59470|
NCT01945541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2059/2012|Body Composition Monitoring(BCM) for Determination of the Fluid Status in Patients Undergoing General Anesthesia|Body Composition Monitoring for Determination of the Fluid Status in Patients Undergoing General Anesthesia|BCM|Medical University of Vienna|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|80 Years|No|||March 2016|March 21, 2016|August 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01945541||59447|
NCT01946009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-7412|A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients|A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients|CIDAN12|Fundacion SEIMC-GESIDA|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01946009||59411|
NCT01946022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0120|Evaluation of Granulosa Cells Function After IVF Protocols|In Vitro Evaluation of Luteinized Granulosa Cells After Being Submitted to in Vitro Fertilization Protocols With Gonadotropin-Releasing Hormone (GnRH) Agonist and GnRH Antagonist||Hospital de Clinicas de Porto Alegre||Recruiting|September 2013|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01946022||59410|
NCT01945996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00382|Harnessing mHealth and Social Support to Improve Diabetes Related Health Behavior for Inner-city Patients|Trial to Examine Text-based mHealth for Emergency Department Patients With Diabetes With Family And Friend Network Supporter|TExTMEDFANS|University of Southern California|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|118|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01945996||59412|
NCT01975064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN/CKF-11115|Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia|A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer|CAN|Uppsala University|Yes|Recruiting|November 2013|December 2022|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|8000|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975064||57183|
NCT01975870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55635|A stAPP to a Healthier Lifestyle|A stAPP to a Healthier Lifestyle: a Randomized Controlled Trial||Universitaire Ziekenhuizen Leuven|Yes|Completed|September 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|19 Years|59 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01975870||57121|
NCT01975883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYRACH001|Glycemic Instability After Spine Surgery|Glycemic Instability of Non-diabetic Patients After Spine Surgery: a Prospective Observational Cohort Study|GLYRACH|Beaujon Hospital|No|Completed|July 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|91|||Both|18 Years|N/A|No|Probability Sample|Sequential patients scheduled for spine surgery in our center, including degenerative,        deformative, tumoral and traumatologic indications are eligible to participate.|October 2013|October 29, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01975883||57120|
NCT01976104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-311|Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure|A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure||Eisai Inc.|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||November 2015|December 17, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976104||57103|
NCT01976390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0229|Comparing Everolimus and Sirolimus in Renal Transplant Recipients|A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress® (Everolimus) Versus Rapamune® (Sirolimus) in Combination With Low Dose Neoral® (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin® (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.||Ohio State University|No|Active, not recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2015|June 12, 2015|October 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01976390||57081|
NCT01976676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1157|Folic Acid vs 5-methyltetrahydrofolate (5MTHF) in Recurrent Abortion|Comparison of the Effect of Folic Acid and 5-methyltetrahydrofolate (5MTHF) on Serum Folate and Homocysteine Levels, and Abortion Rates in Women Suffering From Recurrent Abortion||National Nutrition and Food Technology Institute|Yes|Completed|April 2011|September 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|50 Years|No|||June 2015|June 14, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976676||57059|
NCT01977508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-001|The Vascutek Rapidax™ II Post Market Surveillance Registry|The Vascutek Rapidax™ II Post Market Surveillance Registry||Vascutek Ltd.|No|Active, not recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|At least 10 patients who have been implanted with a Rapidax II Vascular Access Graft for        haemodialysis applications in patients with End Stage Renal Disease (ESRD), who are        undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic        graft.|May 2015|May 18, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01977508|1 Year|56995|
NCT01973816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/001/HP|MEdical Versus SUrgical Treatments of Rectal Endometriosis|Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery|MESURE|University Hospital, Rouen|No|Recruiting|November 2014|November 2019|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Female|35 Years|50 Years|No|||January 2016|January 22, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973816||57278|
NCT01974401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89462|Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood Dyscrasia|Effect of Using Supragingival Irrigators Containing Chlorhexidine on Oral Health in Patients With Blood Dyscrasia||Mashhad University of Medical Sciences|Yes|Completed|January 2010|June 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|12 Years|60 Years|No|||October 2013|October 26, 2013|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974401||57233|
NCT01953289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-54473|Importance of Peritoneal Free Fluid Cultures in Acute Appendicitis|Importance of Peritoneal Free Fluid Cultures in Both Perforated and Non-perforated Appendicitis|IFFSA|Universitaire Ziekenhuizen Leuven|No|Withdrawn|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|6 Years|90 Years|No|Non-Probability Sample|Patients with perforated or non-perforated appendicitis|July 2015|July 3, 2015|February 19, 2013||No|Sub investigator is working no longer in the hospital. No participants were enrolled.|No||https://clinicaltrials.gov/show/NCT01953289||58852|
NCT01953302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24011983|Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair|Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair - a Pilot Study on 55 Patients||Varazdin General Hospital|No|Recruiting|May 2010|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|April 24, 2014|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01953302||58851|
NCT01944345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001, Ver3|Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device|VariLift Lumbar and Cervical Patient Registry||Wenzel Spine|No|Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|69|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing spinal fusion using VariLift lumbar or cervical devices must be        screened by the investigating surgeon for eligibility into the registry using the primary        diagnosis parameters and the inclusion/exclusion criteria. In addition physicians must        follow the associated VariLift Instructions for Use.|October 2015|October 5, 2015|September 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01944345|1 Year|59539|
NCT01944358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH rec 201003111R|Comparisons of Serologic Response of Early Syphilis|Comparisons of Treatment Response to Standard Treatment With Penicillin Between HIV-infected and HIV-uninfected Patients With Syphilis||National Taiwan University Hospital|Yes|Completed|January 2007|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1128|||Both|20 Years|N/A|No|Non-Probability Sample|persons aged ≧20 year-old, who had documented syphilis infection (RPR titer≧ 1:4 and TPPA        ≧1:320)|September 2013|September 12, 2013|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01944358||59538|
NCT01944644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012777|Low Field Magnetic Stimulation for Treatment Resistant Depression|The Effect of Low Field Magnetic Stimulation on Resting State Networks in Major Depressive Disorder||Weill Medical College of Cornell University||Recruiting|August 2013|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2013|September 12, 2013|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01944644||59516|
NCT01944982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNJ-NKAES-2012|Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma|Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.|HNJ-NKAES-2012|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Yes|Recruiting|July 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|21 Years|No|||February 2016|February 23, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944982||59490|
NCT01945255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112007RIC|The Relationship Between Aortic Pulse Wave and Peripheral Artery Occlusion Disease in Hemodialysis Patients|The Relationship Between Aortic Pulse Wave and Peripheral Artery Occlusion Disease in Hemodialysis Patients||National Taiwan University Hospital|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|plasma|Both|20 Years|N/A|No|Probability Sample|HD patients|April 2014|April 11, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01945255||59469|
NCT01945008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITER 01|Observational Study in HCV Chronic Infection|Prospective Multicentric Observational Study in HCV Chronic Infected Patients.||Istituto Superiore di Sanità|No|Recruiting|April 2014|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Patient characteristics: :          -  any clinical and histopathologic stage of HCV infection          -  infected by any HCV genotypes          -  Untreated at the time of the enrolment (previously treated subjects are eligible)          -  With/without HBV co-infection          -  With/without HIV co-infection (in any clinical stage of HIV infection, with or             without antiretroviral treatment)|March 2015|March 24, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01945008||59488|
NCT01945021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OO 12-01|Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC|Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus||OxOnc Development LP||Active, not recruiting|September 2013|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01945021||59487|
NCT01945528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000478-32|Platelet Rich Plasma (PRP) in Chronic Epicondylitis|Pilot Randomized Controlled Trial to Evaluate Safety and Efficacy of Percutaneous Needle Tenotomy With Platelet Rich Plasma (Leukocyte Depleted)in Epicondylitis|B-PRPtendon|Basque Health Service|No|Recruiting|April 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Years|75 Years|No|||July 2015|July 21, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945528||59448|
NCT01945554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 13/061|The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration|The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration|InfStu|Cantonal Hospital of St. Gallen|Yes|Active, not recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||May 2015|May 3, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01945554||59446|
NCT01946321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMU/JS0121|Outcome Measures for Lower Limb Amputees - A Rehabilitation Study|PhD Research Project: Clinimetric Properties of Outcome Measures of Physical Function Used With Lower Limb Amputees, Study 1||Queen Margaret University|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946321||59387|
NCT01975584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055151|Neuroendocrine and Immune Response to Stress in Schizophrenia|Neuroendocrine and Immune Response to Stress in Schizophrenia|TSST|University of Maryland|No|Recruiting|September 2013|September 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01975584||57143|
NCT01976117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ENO-2009-21|E-nose Utility in the Diagnosis of Bacterial Infection in COPD|E-nose Utility in the Diagnosis of Bacterial Infection in Chronic Obstructive Pulmonary Disease (COPD)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|August 4, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976117||57102|
NCT01976130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-MUC-2009-20|Mechanisms of Lung Defense and Their Relationship With Airway Infection in Chronic Obstructive Pulmonary Disease (COPD)|Mechanisms of Lung Defense and Their Relationship With Airway Infection in Chronic Obstructive Pulmonary Disease (COPD)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|June 2012|June 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2009|October 29, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01976130||57101|
NCT01976403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2010|Intervention Study to Enhance Patients' Pain Management After Cardiac Surgery|AA Randomized Controlled Trial to Evaluate the Effect of an Intervention to Enhance Patients' Pain Management After Discharge From Cardiac Surgery||Oslo and Akershus University College of Applied Sciences|No|Completed|January 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|416|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01976403||57080|
NCT01976689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIBU009158|New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation|New- Onset Diabetes and Glucose Regulation Are Significant Determinants of Left Ventricular Hypertrophy in Renal Transplant Recipients||Baskent University|No|Completed|March 2012|September 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|159|||Both|18 Years|80 Years|No|Probability Sample|Between years 2007-2010, 63 patients were diagnosed as NODAT in our transplantation center        from the total 267 patients who underwent renal transplantation. Among these, 159 kidney        transplant recipients were selected.|November 2013|November 6, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01976689||57058|
NCT01976949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57065|Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress|Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress||Loma Linda University|No|Completed|July 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|347|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01976949||57038|
NCT01977209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTCA|Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression|A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression|GTCA|Third Military Medical University|Yes|Recruiting|September 2013|September 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|75 Years|No|||October 2013|October 30, 2013|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01977209||57018|
NCT01974388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morbid Obesity|Impact of Extent of Antral Resection on Outcomes of Sleeve Gastrectomy|Impact of Extent of Antral Resection on Surgical Outcomes of Sleeve Gastrectomy for Morbid Obesity (A Prospective Randomized Study)|LSG|Mansoura University|Yes|Completed|January 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|60 Years|No|||January 2008|November 20, 2015|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974388||57234|
NCT01974414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900166|Cedar Honey in Oral Lichen Planus|Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial||Mashhad University of Medical Sciences|Yes|Completed|September 2011|December 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||October 2013|October 26, 2013|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01974414||57232|
NCT01974609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Narcotic vs. Non-narcotic Pain|Narcotic vs. Non-narcotic Pain Study Protocol|A Randomized, Controlled Trial Comparing Combination Therapy of Ibuprofen + Acetaminophen Versus Hydrocodone + Acetaminophen for the Treatment of Pain After Carpal Tunnel Surgery||Horizon Health Network|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|90 Years|No|||December 2015|December 6, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01974609||57217|
NCT01953055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALOB-SATURN2013|SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)|Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)|SATURN|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|November 2013|September 2019|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 9, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01953055||58870|
NCT01953315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00023616|Muscle Progenitor Cell Therapy for Urinary Incontinence|A Phase 1 Pilot Safety and Feasibility Study of Muscle Progenitor Cell (MPC) Therapy for Urinary Incontinence||Wake Forest School of Medicine|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|75 Years|No|||March 2014|March 31, 2014|August 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01953315||58850|
NCT01953861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-054|A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet|An Open-label, Single Dose, Randomized, Three-way Cross-over Study to Evaluate the Effect of Food on the Pharmacokinetics of Solifenacin and Tamsulosin Administered as Combination Tablet EC905 in Young, Healthy Male Subjects||Astellas Pharma Inc|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|September 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01953861||58808|
NCT01944995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01524-39|Work of Breathing in Nasal CPAP Versus High Flow Nasal Prong in Infants With Severe Acute Bronchiolitis|Work of Breathing in Nasal CPAP Versus High Flow Nasal Prong in Infants With Severe Acute Bronchiolitis||Assistance Publique Hopitaux De Marseille|No|Recruiting|September 2013|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|18|||Both|N/A|3 Months|No|||August 2014|August 27, 2014|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01944995||59489|
NCT01944774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-5|Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride|A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP)||TaiGen Biotechnology Co., Ltd.|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|207|||Both|18 Years|75 Years|No|||February 2015|February 1, 2015|August 26, 2013|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01944774||59506|
NCT01945281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-064|Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)|A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age||Merck Sharp & Dohme Corp.|Yes|Recruiting|January 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|3 Months|No|||March 2016|March 18, 2016|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01945281||59467|
NCT01945294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3034-107|Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)|A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy With MK-3034 (SCH 503034)/Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects With Chronic HCV Genotype 1 in Asia||Merck Sharp & Dohme Corp.|No|Completed|October 2013|November 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01945294||59466|
NCT01945801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG-13-0272|Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea|The Effect of Sodium-Restricted Diet and Diuretic in the Severe Sleep Apnea: a Randomized Controlled Trial - DESALT Study|DESALT|Hospital de Clinicas de Porto Alegre|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01945801||59427|
NCT01946607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0605/60|Antidepressants, Emotions and Personality|Antidepressants, Emotions and Personality: Comparing the Neuropsychological Effects of the Antidepressant Citalopram in Healthy Volunteers With High and Low Neuroticism||Medical Research Council Cognition and Brain Sciences Unit|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01946607||59365|
NCT01946620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3509|A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD|A Randomised, Double-blind, Double Dummy, Parallel Group Study Comparing Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 250/10 µg (2 Puffs BID) and Flutiform® 125/5 µg (2 Puffs BID) Versus Formoterol Fumarate Dihydrate (Atimos®) 12 µg (1 Puff BID) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).||Mundipharma Research Limited|No|Active, not recruiting|October 2013|May 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1530|||Both|40 Years|N/A|No|||September 2015|September 25, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01946620||59364|
NCT01946035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012RC14|Alpha-Blockers in Allergic Rhinitis (MAN 01)|A Proof of Concept Study in Allergic Rhinitis, to Evaluate the Differential Effects Between Single and Chronic Dosing of Doxazosin on Nasal Airway Calibre|MAN01|University of Dundee|No|Completed|September 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|70 Years|No|||December 2015|December 11, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01946035||59409|
NCT01946048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12276102D-Cardiac Disease|Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy|Safety and Efficacy Investigation of Patients With Ischemic Cardiomyopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells||Hebei Medical University|Yes|Not yet recruiting|October 2013|December 2014|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|80 Years|No|||October 2013|October 5, 2013|September 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01946048||59408|
NCT01982487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 243013|Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission|A Phase I/IIb Study of Recombinant ALVAC(2)-NY-ESO-1 (M)/TRICOM in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||Roswell Park Cancer Institute|Yes|Withdrawn|December 2013|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Female|18 Years|N/A|No|||December 2013|December 17, 2013|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982487||56614|
NCT01982760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10-21|DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty|A Prospective Randomized Trial for the Use of DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty.||University Hospital Case Medical Center|Yes|Not yet recruiting|December 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||November 2013|November 14, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982760||56593|
NCT01982994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41440|Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients|Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients||Milton S. Hershey Medical Center|Yes|Recruiting|October 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01982994||56575|
NCT01983306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP333201-01|Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)|A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients With Non-malignant Chronic Pain Receiving Opioid Therapy|OIC|Synergy Pharmaceuticals Inc.|No|Active, not recruiting|November 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|75 Years|No|||September 2014|September 25, 2014|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983306||56551|
NCT01983501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-380-004|A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer|A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)||Oncothyreon Inc.|Yes|Active, not recruiting|February 2014|May 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01983501||56536|
NCT01983826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13GRNT16490002|Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease|Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease||University of Iowa|No|Recruiting|November 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01983826||56511|
NCT01984086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200921|Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.|An Open-label, Randomised, Cross-over, Two Cohort, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the Delivery of Salbutamol and to Compare the Pharmacokinetic Profile With the MDI and Diskus Presentations.||GlaxoSmithKline|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984086||56491|
NCT01984645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK1805|Primary-care-provider Identification And Notification|Identifying Primary Care Providers and Notifying Them Upon Admission of Their Patients to New York-Presbyterian Hospital|PIANO|Columbia University|No|Completed|September 2012|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7023|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01984645||56448|
NCT01985009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M118|Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.|Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference.||Echosens|No|Recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985009||56420|
NCT01984658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-004|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients||CytoVac A/S|No|Terminated|October 2013|September 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 31, 2013||No|recruitment difficulties as a new treatment for this indication available|No||https://clinicaltrials.gov/show/NCT01984658||56447|
NCT01984671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047952|Mobile Pain Coping Skills Training for Stem Cell Transplant Patients|Home-Based Tablet Computer Pain Coping Skills Following Stem Cell Transplant||Duke University||Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|21 Years|N/A|No|||January 2016|January 19, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01984671||56446|
NCT01989507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034628-01A1|Very Low-Nicotine Cigarettes in Smokers With SUD|Very Low-Nicotine Cigarettes in Smokers With SUD: Smoking, Substance Use Effects|VLNC|Brown University|No|Recruiting|February 2014|May 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989507||56075|
NCT01990027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-2013-0330|Swiss Kidney Stone Cohort (SKSC)|Swiss Kidney Stone Cohort (SKSC)|SKSC|The Swiss National Centre of Competence in Research Kidney Control of Homeostasis|Yes|Recruiting|April 2014|April 2024|Anticipated|April 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Whole blood; serum; urine|Both|18 Years|N/A|No|Probability Sample|Patients with a kidney stone episode|October 2015|October 6, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01990027|10 Years|56035|
NCT01990040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-R13-002|A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome|A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome||Shire|No|Recruiting|June 2014|December 2029|Anticipated|December 2028|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|1310|||Both|N/A|N/A|No|Non-Probability Sample|This registry is to enroll both male and female patients, of any age, with a diagnosis of        SBS.|March 2016|March 17, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01990040|10 Years|56034|
NCT01994538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-13S|Seven vs. 14 Days Treatment for Male Urinary Tract Infection|Seven vs. 14 Days Treatment for Male Urinary Tract Infection||VA Office of Research and Development|Yes|Recruiting|April 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|319|||Male|18 Years|N/A|No|||March 2016|March 9, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994538||55689|
NCT01994811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U24MD006938-04|Eastern Caribbean Health Outcomes Research Network (ECHORN)|Eastern Caribbean Health Outcomes Research Network (ECHORN)|ECHORN|Yale University|No|Recruiting|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5500|Samples With DNA|Blood and Saliva samples|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We plan to enroll and follow a community-based sample of 1% of the total population of the        4 ECHORN sites combined (total n = 5,500). We seek to populate the cohort to roughly        approximate the populations of the participating sites and deliberately oversample from        Barbados and the U.S.Virgin Islands(USVI) to maximize sample heterogeneity along        race/ethnicity/culture. Puerto Rico residents will comprise 40% of the cohort (n=2200        total), Trinidad and Tobago residents at 30% (n=1650 total), Barbados residents at 20% (n        =1100) and the USVI at 10% (n=550).|January 2015|January 21, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994811||55669|
NCT01995097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044933|BABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit|SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit||Duke University|No|Recruiting|March 2014|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|522|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995097||55647|
NCT01995110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRICHIP-1-transcriptome|Postprandial Blood Cell Transcriptome of Normal Weight and Obese Subjects to 3 Caloric Doses of a High-fat Meal|Identification of Nutritional Health Biomarkers for Metabolic Flexibility in Blood - a Randomized, Postprandial, Caloric Dose-response Strategy||Agroscope Liebefeld-Posieux Research Station ALP|Yes|Completed|March 2011|November 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995110||55646|
NCT01995084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40274.018.12|In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study|In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study|HYPE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995084||55648|
NCT01991431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1149-9900|ROUTE Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve|Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve|ROUTE|Institut für Pharmakologie und Präventive Medizin|No|Active, not recruiting|February 2013|March 2016|Anticipated|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|303|||Both|18 Years|N/A|No|Non-Probability Sample|All Patients undergoing transaortic transcatheter valve implantation with commercially        available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System        in participating sites|March 2015|March 31, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01991431|30 Days|55927|
NCT01991444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1149-9951|CGA-TAVI Registry to Evaluate the Predictive Value of a CGA in Predicting TAVI Outcomes|Registry Study to Evaluate the Predictive Value of a Comprehensive Geriatric Assessment With Regard to the Outcome of a Transcatheter Aortic Valve Implantation.|CGA-TAVI|Institut für Pharmakologie und Präventive Medizin|No|Active, not recruiting|February 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|72|||Both|80 Years|N/A|No|Non-Probability Sample|All patients undergoing transcatheter valve implantation with commercially available        Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.        Routine data about the invervention (transcatheter valve Implantation) will be collected.        In addition, data describing the geriatric status of the patient, including a patient        questionnaire evaluating his/her Quality of life will be collected.|January 2016|January 26, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991444|12 Months|55926|
NCT01991691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TabPRO I|Tablet-based Patient Reported Outcome|Pilot Study for Tablet-based Questionnaire of Patient-reported Outcomes From Patients Undergoing Chemotherapy (TabPRO I)||University Hospital, Bonn|No|Recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|57|||Female|18 Years|N/A|No|||December 2014|December 2, 2014|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991691||55908|
NCT01991678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-102-13|A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)|An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment||Nektar Therapeutics|No|Recruiting|November 2013|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991678||55909|
NCT01983319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2013-268-13|tDCS Combined With Constraint Induced Movement Therapy and Role of GABA Activity in Stroke Recovery|Transcranial Direct Current Stimulation Combined With Constraint Induced Movement Therapy and Role of GABA Activity in Stroke Recovery||University of Aarhus|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01983319||56550|
NCT01983514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2727|Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults|Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic Resonance Imaging Changes, Cognitive Response, Heart Rate Variability, Plasma Pharmacokinetics and Saliva Concentration After Single-dose Oxytocin 8 or 24 International Units (IU) Intranasally or 1 IU as Slow Intravenous Infusion||OptiNose AS|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|19|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01983514||56535|
NCT01983033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/708|Training Protocol 'Drop it'. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission|Drop it. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission|Drop It|University Hospital, Ghent|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983033||56572|
NCT01983800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 13-5845|AnaConDa Long Term Sedation Study|Use of Volatile Anesthetics for Long-Term Sedation In Critically Ill Patients|VALTS|University Health Network, Toronto|No|Recruiting|July 2013|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01983800||56513|
NCT01983813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL116311-01A1|Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care|Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care|ICARE|University of Iowa|Yes|Enrolling by invitation|March 2014|August 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|50 Years|N/A|No|||June 2015|June 2, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01983813||56512|
NCT01984073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOFAT|Effects of Niacin On Fatty Acid Trapping|Effect of Niacin On Fatty Acid Trapping|NOFAT|University of Pennsylvania|No|Recruiting|December 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|20|||Both|22 Years|75 Years|No|||November 2013|November 7, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984073||56492|
NCT01988649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00086297|Oxytocin and Pain Sensitivity and Threshold|The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study||Northwestern University|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988649||56141|
NCT01989156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHM-REXA-08-US|Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting|A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 91 Days||Philip Morris Products S.A.|No|Completed|December 2013|May 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|160|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989156||56102|
NCT01989169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-117|Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects|A Phase 1, Randomized, Open Label, Crossover Study to Evaluate the Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects||Shire||Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|November 14, 2013|No|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01989169||56101|
NCT01989520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3551C00002|Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069|An Open-label, Single Centre Relative Bioavailability Study With an Adaptive Design Comparing up to 5 Solid Oral AZD5069 Formulations After Single Dose Administration to Healthy Volunteers||AstraZeneca|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01989520||56074|
NCT01989819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10 023|Primary Sjögren Syndrome||NeuroSenSS|University Hospital, Limoges|No|Recruiting|September 2012|June 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sjögren's syndrome|October 2011|December 2, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01989819|12 Months|56051|
NCT01994837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-212|A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)|A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)||AbbVie|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|99 Years|No|||December 2015|December 18, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994837||55667|
NCT01994850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17413|A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas|A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2013|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994850||55666|
NCT01994824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreemptiveATG|Preemptive Therapy of GVHD|Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin||University of Calgary|No|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994824||55668|
NCT01995123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-002-12F|Behavioral Activation for Smoking Cessation in PTSD|Behavioral Activation for Smoking Cessation in Veterans With PTSD||VA Office of Research and Development|Yes|Recruiting|September 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995123||55645|
NCT01995357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP244|The Influence of Baseplate Adhesive on the Degree of Leakage|The Influence of Base Plate Adhesive Type, Shape and Application on Degree of Leak-age - a Randomized Controlled Trial in Subjects With Ileostomy and Colostomy||Coloplast A/S|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|22|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|November 21, 2013||No||No|January 19, 2015|https://clinicaltrials.gov/show/NCT01995357||55627|
NCT01995370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-TADD-1300-1|Cilostazol Stroke Prevention Study for Antiplatelet Combination|Cilostazol Stroke Prevention Study for Antiplatelet Combination|CSPS・com|Japan Cardiovascular Research Foundation|Yes|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4000|||Both|20 Years|85 Years|No|||December 2013|December 3, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01995370||55626|
NCT01991457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1285|Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia|Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen|FluTBI|University of Alabama at Birmingham|Yes|Recruiting|September 2013|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|65 Years|No|||December 2015|December 17, 2015|September 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01991457||55925|
NCT01992003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00524F|Butterfly Sensor With Rev K Version|Assessing the Accuracy of the Butterfly Sensor With RevK Version for Non-Invasive Hemoglobin Monitoring||University of California, San Francisco|Yes|Terminated|January 2014|December 2014|Actual|December 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing spine surgery|April 2015|April 8, 2015|November 18, 2013||No|Interim analysis indicated accuracy unchanged from previous versions|No||https://clinicaltrials.gov/show/NCT01992003||55884|
NCT01991704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nidd_peking|Incubation of Alcohol Craving During Abstinence|The Neural Mechanisms of the Incubation of Cue-induced Craving in Alcohol Dependence||National Institute on Drug Dependence, China|Yes|Completed|October 2011|October 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|99|None Retained|The blood samples of all participants were collected at each point of withdrawal.|Male|18 Years|60 Years|No|Probability Sample|alcohol dependence|November 2013|November 18, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01991704||55907|
NCT01991964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-FS-0563-13-CTIL|The Yield of Laryngeal Ultrasound in the Diagnosis of Laryngomalacia|The Yield of Laryngeal Ultrasound in the Diagnosis of Laryngomalacia||Tel-Aviv Sourasky Medical Center||Not yet recruiting|December 2013|||January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|N/A|12 Months|No|||November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991964||55887|
NCT01992211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCWP1202_102|Evaluating of Pharmacokinetic Profile of BCWP_C001 and Co-administration of Rosuvastatin and Metformin|Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of BCWP_C001 Formulation Compared to Coadministration of Rosuvastatin and Metformin SR Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C001 After Single Oral Administration to Healthy Male Subjects||BC World Pharm Co. Ltd.|Yes|Not yet recruiting|May 2016|February 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992211||55868|
NCT01983046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44507.068|Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism|The Effects of Rectal Administration of SCFA on Human Substrate and Energy Metabolism||Maastricht University Medical Center|Yes|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01983046||56571|
NCT01983540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L28|Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination|Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination With Investigational (DTaP-IPV-Hep B-PRP~T) or Infanrix Hexa™ Vaccines in Latin America||Sanofi|No|Completed|October 2013|December 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|558|||Both|42 Months|54 Months|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983540||56533|
NCT01983332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17075|Impact of MOHO on Therapists Working With Clients in Cancer Population|Impact of the Introduction of Model of Human Occupation (MOHO) on Clinical Reasoning in Therapists Working With Clients in the Cancer Population|MDACC-MOHO|Texas Woman's University|No|Active, not recruiting|November 2013|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|25 Years|65 Years|No|Non-Probability Sample|Participants will be outpatient-focused therapists working within the MD Anderson Cancer        Center. Participants must have worked in this setting for at least 90 days before the        study begins and will self-select to participate in the study. Recruitment of therapists        at the MDACC will involve an introduction of the study by an onsite collaborator. The        onsite collaborator will gather the names of individuals interested in participating in        the study. Then, an onsite collaborator and PI will work together to determine if the        therapists meet the inclusion criteria for the study. Once the therapists are determined        to meet inclusion criteria, an invitation for participation will be extended by an onsite        collaborator.|January 2015|January 29, 2015|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01983332||56549|
NCT01983527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADAC|Corticosteroids and / or Arthrographic Distention in the Treatment of Adhesive Capsulitis|A Prospective Randomized 3-arm Trial Comparing Intra-articular Corticosteroid Injection vs Arthrographic Distention vs Arthrographic Distention Plus Intra-articular Corticosteroid Injection in the Treatment of Adhesive Capsulitis|CADAC|Imelda Hospital, Bonheiden|Yes|Not yet recruiting|December 2013|November 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983527||56534|
NCT01988662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A-MAX-IL-01|UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD|A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients|UNRAVEL|Novartis|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|195|||Both|50 Years|N/A|No|||January 2016|January 26, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988662||56140|
NCT01988909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080705|WR 279,396 for the Treatment of Cutaneous Leishmaniasis|An Open-Label Study to Examine the Safety and Efficacy, of WR 279,396 (Paromomycin + Gentamicin Topical Cream) for the Treatment of Cutaneous Leishmaniasis in France|PAGELEC|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|80 Years|No|||November 2015|November 25, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988909||56121|
NCT01984333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWMRF-133|Online Response Inhibition Training for Trichotillomania|Developing Online Response Inhibition Training for Individuals With Trichotillomania|OTTM|University of Wisconsin, Milwaukee|No|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|8 Years|17 Years|No|||November 2015|November 30, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01984333||56472|
NCT01984346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-1200|CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)|Convergence Of Epicardial And Endocardial Radiofrequency (RF) Ablation For The Treatment Of Symptomatic Persistent AF|CONVERGE|nContact Surgical Inc.|Yes|Recruiting|December 2013|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|153|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984346||56471|
NCT01984359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22313|HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer|A Pilot, Single-Center Study Of Quantitative HPV Serum Or Plasma DNA As A Prognostic Marker In P16+/HPV+ Squamous Carcinomas Of The Oropharynx And Unknown Primary Head And Neck Cancers||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2013|||May 2017|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984359||56470|
NCT01989182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1226SVS|The Spiration Valve System for the Treatment of Severe Emphysema|The Spiration Valve System for the Treatment of Severe Emphysema|SVS|Spiration, Inc.|No|Recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|75 Years|No|||December 2013|December 9, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01989182||56100|
NCT01982292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2209|Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure|Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure|RELAX-REPEAT|Novartis|Yes|Completed|May 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|321|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982292||56628|
NCT01982578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-GEN-2013-01|Genistein as a Possible Treatment for Alzheimer's Disease.|Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.|GENISTEÍNA_2|Fundación para la Investigación del Hospital Clínico de Valencia|Yes|Recruiting|November 2013|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982578||56607|
NCT01995149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I+CS;CEICA-B80|Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.|Effect of Weight Loss on Lipids Concentration and Cholesterol Metabolism in Overweight and Obese Subjects With Primary Hypercholesterolemia.||Instituto Aragones de Ciencias de la Salud|No|Completed|June 2010|||September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995149||55643|
NCT01995136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-047|Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma|Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma||Alcon Research|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|November 21, 2013|No|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01995136||55644|
NCT01991470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP249|CEP249 Pediatric Accuracy Study|A Performance Evaluation of the Enlite™ and Enlite 3 Glucose Sensor to Support Use in Children||Medtronic Diabetes|No|Active, not recruiting|March 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|260|None Retained|Blood|Both|2 Years|18 Years|No|Probability Sample|Children from 2-18 years of age|March 2016|March 15, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991470||55924|
NCT01995383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP28586|A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers|A Single Oral Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Subjects Including a Single Intravenous Microdose of RO6836191||Hoffmann-La Roche||Recruiting|November 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|96|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|November 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995383||55625|
NCT01983566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.44|Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects|Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of Deleobuvir Following Single Oral Administration in Healthy Caucasian and Japanese Subjects (an Open-label, Randomised, Four-way Crossover Study)||Boehringer Ingelheim||Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|November 5, 2013||||No||https://clinicaltrials.gov/show/NCT01983566||56531|
NCT01983579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1304|TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection|A Single-center, Open Label, Prospective Study Assessing the IOP (Intraocular Pressure) Patterns Using SENSIMED Triggerfish® in Association With Anti-VEGF Injection||Sensimed AG|No|Terminated|October 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|4|||Both|50 Years|99 Years|No|||November 2015|November 16, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01983579||56530|
NCT01992263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1304003801|Vitamin D Supplementation and TB|A Trial of Vitamin D Supplementation Among Tuberculosis Patients in South India||Cornell University|Yes|Not yet recruiting|September 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Anticipated|200|||Both|18 Years|60 Years|No|||July 2015|July 28, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01992263||55864|
NCT01991977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1374|18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy|Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas||Mayo Clinic|Yes|Recruiting|December 2013|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991977||55886|
NCT01991990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29049|A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers|A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects||Hoffmann-La Roche||Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 18, 2013|No|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01991990||55885|
NCT01982773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-W81XWH-10-2-0178|Virtual Hope Box - Effectiveness of a Smartphone App for Coping With Suicidal Ideation|Effectiveness of a Virtual Hope Box Smartphone App in Enhancing Veterans' Coping With Suicidal Ideation: A Randomized Clinical Trial.|VHB-RCT|National Center for Telehealth and Technology|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982773||56592|
NCT01982786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR15|Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer|Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer||Canadian Cancer Trials Group|No|Active, not recruiting|November 2013|October 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|57|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982786||56591|
NCT01983553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD57|Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study|Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine||Sanofi|Yes|Active, not recruiting|November 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3997|||Both|7 Years|16 Years|No|Non-Probability Sample|Participants in study CYD23 (NCT00842530) that are hospitalized with dengue cases.|January 2016|January 15, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983553||56532|
NCT01983839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOXI-274-13|PK Analysis of Moxifloxacin in the Treatment of CAP|Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in the Empiric Treatment of Community-Acquired Pneumonia||University of Aarhus|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|18|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Patients with community-acquired pneumonia, treated with moxifloxacin, admitted to the        Department of Infectious diseases, Aarhus University Hospital, Denmark|March 2015|March 25, 2015|July 10, 2013||No||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01983839||56510|
NCT01984099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 2009-044|RCT on the Efficacy of Methotrexate for the Prevention of GTD|The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole||University of the Philippines|Yes|Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|99|||Female|35 Years|N/A|No|||November 2013|November 7, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984099||56490|
NCT01988675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003.083|MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier|MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier||University of Michigan Cancer Center|Yes|Recruiting|July 2004|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988675||56139|
NCT01988883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131371|Modafinil and Cognitive Function in POTS|Modafinil and Cognitive Function in Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|47|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988883||56123|
NCT01988896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28363|Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase 1b Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors||Hoffmann-La Roche||Recruiting|December 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|151|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988896||56122|
NCT01989195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24224|Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease|Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease||Stanford University|Yes|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|70 Years|No|||November 2013|November 14, 2013|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989195||56099|
NCT01982591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP-BR-059|Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy|Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy||Fox Chase Cancer Center|Yes|Completed|January 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Cancer Center|May 2015|May 1, 2015|October 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982591||56606|
NCT01982604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-179|Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers|A Phase 1, Open-label, Randomized, Crossover Clinical Trial to Evaluate PK/PD of 30 U TI Inhalation Powders Prepared With Insulin From Two Different Suppliers||Mannkind Corporation|No|Completed|November 2013|August 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 1, 2014|November 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982604||56605|
NCT01982877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1AG045176-01|The Four Supports Study: Family Support Intervention in Intensive Care Units|A Trial to Improve Surrogate Decision-Making for Critically Ill Older Adults||University of Pittsburgh|Yes|Recruiting|January 2014|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|21 Years|N/A|No|||February 2016|February 18, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982877||56584|
NCT01983943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001080|Olive Oil and Cardiovascular Health|Effects of Hydroxytyrosol on Vascular Health||Mayo Clinic|No|Withdrawn|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 7, 2013|No|Yes|No participants were enrolled|No||https://clinicaltrials.gov/show/NCT01983943||56502|
NCT01986634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-13-12|Laser Spot Treatment of Perioral Rhytids|Efficacy of Spot Treatment of Perioral Rhytids Compared to Full Field Laser Resurfacing||University Hospital Case Medical Center|No|Not yet recruiting|September 2013|December 2015|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2013|November 11, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986634||56295|
NCT01982838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00031086|Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients|A Randomized Trial of the Impact of Three Labor Analgesia Techniques on Labor Duration in Spontaneously Laboring Nulliparous Parturients||Northwestern University|No|Terminated|July 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|129|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|November 6, 2013||No|Low qualified candidate enrollment|No||https://clinicaltrials.gov/show/NCT01982838||56587|
NCT01991717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13A06|Victus Versus Conventional|An Open-label Investigator-masked Study Comparing Femtosecond Laser Assisted With Conventional Phacoemulsification Cataract Surgery||Augenabteilung Allgemeines Krankenhaus Linz||Recruiting|December 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991717||55906|
NCT01983592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194318|An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy|An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy||The Canadian College of Naturopathic Medicine|No|Completed|December 2013|September 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983592||56529|
NCT01983852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PELICAN_2012_2015|Paediatric End of Life Care Needs in Switzerland|Paediatric End of Life Care Needs in Switzerland|PELICAN|University of Basel|No|Completed|June 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|18 Years|No|Probability Sample|Children between 0-18 years of age dying due to a chronic condition|July 2015|July 13, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01983852||56509|
NCT01992523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOJITO Study|Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )|Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )||Careggi Hospital|Yes|Completed|November 2013|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|November 19, 2013||No||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01992523||55844|
NCT01983345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00385-40|Prenatal Surgical Repair of Fetal Myelomeningocele|Prenatal Surgical Repair of Fetal Myelomeningocele|PRIUM|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||January 2015|January 15, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983345||56548|
NCT01987791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-PLT-100|Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B Cirrhosis|Comparison of Prednisone and Cyclosporine in the Treatment of Thrombocytopenia in Patients With Cirrhosis Associated With Hepatitis B in China: a Collaborative, Open-label, Real World Observational Study||Peking University People's Hospital|Yes|Enrolling by invitation|January 2005|||November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|15|Samples With DNA|whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|Consecutive patients were enrolled from 15 centers in China from January 1, 2005 to        September 31, 2013.|November 2013|November 13, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987791||56206|
NCT01988116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130725013|Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease|Vitamin D Replacement in Chronic Kidney Disease and Its Effects on Iron Homeostasis, Serum Hepcidin, and Hemojuvelin Levels.||University of Alabama at Birmingham|Yes|Completed|October 2013|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|19 Years|N/A|No|||August 2015|August 21, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988116||56182|
NCT01988363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005836|Greater Occipital Nerve Injection Study|Ultrasound-guided Greater Occipital Nerve Injection at Novel Proximal Location: A Clinical Series|GON|Mayo Clinic|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988363||56163|
NCT01985867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013|Lcr35 for Children With Functional Constipation|Effectiveness of Lactobacillus Casei Rhamnosus Lcr35 in the Management of Children With Functional Constipation: a Randomized, Double-blind, Placebo- Controlled Trial.||Medical University of Warsaw|No|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|N/A|5 Years|No|||December 2015|December 29, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01985867||56354|
NCT01988922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307034|CYP2B6 Polymorphisms in Ketamine|Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance||Washington University School of Medicine|No|Recruiting|November 2013|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988922||56120|
NCT01986439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101982|The Contraceptive Choice Project|The Contraceptive Choice Project||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9256|Samples Without DNA|vaginal swab specimens for chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis.      Blood specimens for HIV and syphilis.|Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of reproductive age who reside in the St. Louis metropolitan region.|April 2015|April 13, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01986439||56310|
NCT01983644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDIRECT|RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study|RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study: a Prospective Randomised Control Trial(REDIRECT)|REDIRECT|Jinling Hospital, China|Yes|Recruiting|September 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||July 2015|December 28, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983644||56525|
NCT01994564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356715-1 Dyschromatopsia|Prevalence of Dyschromatopsia in Glaucoma Patients|Prevalence of Dyschromatopsia in Glaucoma Patients||Massachusetts Eye and Ear Infirmary|No|Withdrawn|November 2012|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of open-angle glaucoma of the Glaucoma Department at        Massachusetts Eye & Ear Infirmary, Boston, MA 02114, US|July 2012|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994564||55688|
NCT01983098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-CRC-DNAc|Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment|||Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2013|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples were collected from patients treated for colorectal cancer. Blood samples were      collected in EDTA tubes every two weeks before each cycles of chemotherapy. Blood samples      were processed within 2 hour after collection and were centrifuged to separate the plasma      from the peripheral-blood cells.|Both|18 Years|N/A|No|Probability Sample|Patients > 18 ans treated in our center (European Georges Pompidou Hospital) by        chemotherapy for metastatic colorectal cancer|October 2013|November 5, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01983098|1 Year|56567|
NCT01983111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP13-KR-401|Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)|A Multicenter, Phase IV, Interventional Study to Compare the Efficacy and Safety of NORSPAN to Tramadol/Acetaminophen in Patients With Prolonged Postoperative Pain After Spinal Surgery (PASSION)||Mundipharma Korea Ltd|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01983111||56566|
NCT01995396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTV-398121|Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in Rectal Cancer: a Randomized Study|Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in Rectal Cancer: a Randomized Study|HAPIrect|Landstinget Västmanland|Yes|Recruiting|February 2014|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995396||55624|
NCT01995409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG13/10649|Mothers Learning About Second-hand Smoke - MLASS Study|Mothers Learning About Second-hand Smoke - MLASS Study||The Leeds Teaching Hospitals NHS Trust||Recruiting|September 2013|||September 2014|Anticipated|N/A|Interventional|Primary Purpose: Prevention|||||||Both|17 Years|40 Years||||September 2014|September 23, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995409||55623|
NCT01991483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15268|A Study of LY2928057 in Hemodialysis Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients||Eli Lilly and Company|No|Completed|December 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991483||55923|
NCT01983891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS011|Improving Nutritional Outcomes Among Food Insecure Twin Cities Residents|||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 8, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983891||56506|
NCT01991756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTURA-ELE-1|Safety and Performance of Altura Endograft in Abdominal Aortic Aneurysm (AAA) Endovascular Repair|ELEVATE International: Kissing Endografts for Peripheral AAA Exclusion|ELEVATE|Altura Medical Inc.|No|Enrolling by invitation|April 2014|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease with suitable        aneurysm morphology for endovascular repair.|January 2015|January 13, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991756||55903|
NCT01992042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN-STOPCa_001|Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer|Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer||University Health Network, Toronto|Yes|Recruiting|February 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|75 Years|No|||December 2015|December 21, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01992042||55881|
NCT01983865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11 Grabi Pilot|Monocenter 6-period Study in Patients With Seasonal Allergic Rhinitis to Birch Pollen to Establish a Challenge Model With Natural Birch Pollen in an Environmental Challenge Chamber (ECC)|||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|November 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983865||56508|
NCT01983878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15045|A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer|A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients||Eli Lilly and Company|No|Active, not recruiting|December 2013|March 2017|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|N/A|No|||January 2016|January 25, 2016|November 7, 2013|No|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01983878||56507|
NCT01984112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0232/11|Proximal Humerus Fractures: Randomized Study Between Locking Nails and Locking Plates for Neer 2 and 3 Parts|Proximal Humerus Fractures: Randomized Study Between Intramedullary Locking Nails and Locking Plates for Neer 2 and 3 Parts Displaced Fractures||University of Sao Paulo|No|Completed|May 2011|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|50 Years|85 Years|No|||October 2015|October 2, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01984112||56489|
NCT01983358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-NC-P1-13|The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.|JPI-289|Jeil Pharmaceutical Co., Ltd.|Yes|Completed|November 2013|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01983358||56547|
NCT01987804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYPEP002|Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women|A Double-blind, Placebo Controlled Single Centre Trial to Evaluate the Dose-relationship of the Effects of Vaginally Administered Oxytocin on the Vaginal Mucosal Membrane in Postmenopausal Women With Vaginal Atrophy|OXYPEP002|PeP-Tonic Medical AB|No|Completed|January 2012|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Female|40 Years|N/A|No|||November 2013|November 20, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987804||56205|
NCT01988129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000697|Fire Fighter Fatigue Management Program: Operation Healthy Sleep|Fire Fighter Fatigue Management Program: Operation Healthy Sleep||Brigham and Women's Hospital|No|Completed|March 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1189|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 1, 2015|July 27, 2010||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01988129||56181|
NCT01988142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-0973B|The Effect of Continuous Passive Motion Training on Neuromuscular Adaptation|||Chang Gung University|Yes|Completed|August 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|N/A|No|||November 2013|November 19, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988142||56180|
NCT01988376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100140-E|Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer|||Far Eastern Memorial Hospital||Completed|March 2012|||December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Female|20 Years|N/A|No|||November 2013|March 30, 2014|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01988376||56162|
NCT01986140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H: 33692 SCALP|Scalp Cooling to Prevent Chemo-induced Hair Loss|Scalp Cooling for Alopecia Prevention (SCALP)|SCALP|Baylor Breast Care Center|Yes|Recruiting|December 2013|December 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|235|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986140||56333|
NCT01988935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01DA035930|Integrated PTSD and Smoking Treatment|Integrated PTSD and Smoking Treatment||University of Texas at Austin|Yes|Recruiting|October 2013|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988935||56119|
NCT01982305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acta No. 277 Aug 6, 2012|Pilot Study of a Nerve Block Simulator for the Training in Axillary Blocks|Simulator Versus Cadaver Training to Perform Ultrasound-guided Axillary Nerve Bocks||Fundación Universitaria de Ciencias de la Salud|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 12, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982305||56627|
NCT01982318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitro-US-1001|A Prospective Randomized, Double-Blind, Placebo-Controlled Trial Comparing VitroGro® ECM to Placebo in Patients With Venous Leg Ulcers|A Prospective, Multi-Center, Randomized, Double Blind, Placebo-Controlled Trial Comparing Vitrogro® ECM To Placebo As An Adjunct To Standard Care In Patients With Venous Leg Ulcers||Tissue Therapies Ltd.||Not yet recruiting|January 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982318||56626|
NCT01994863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP224|Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy|An Open-labeled, Randomised, Controlled, Comparative, Cross-over Study Investigating the Safety and Performance of a New 1-piece Ostomy Product Compared to Standard Care 1-piece in Subjects With Ileostomy||Coloplast A/S|No|Terminated|September 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|February 26, 2013||No|Problems with product performance|No|February 19, 2015|https://clinicaltrials.gov/show/NCT01994863||55665|Early termination leading to small number of subjects analyzed
NCT01982565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDX 110|Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers|A Clinical Pilot Study of an Oxides of Nitrogen Generating Gel Dressing System to Stimulate Healing in Diabetic Foot Ulcers|ProNOx1|Edixomed Ltd|Yes|Completed|June 2013|December 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01982565||56608|
NCT01982851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00031120|Effects of Analgesic Techniques on Duration of Labor for Induction Patients|A Randomized Trial of the Impact of Three Labor Analgesia Techniques on Labor Duration in Nulliparous Labor Inductions||Northwestern University|No|Terminated|July 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|134|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|November 6, 2013||No|low qualified candidate enrollment|No||https://clinicaltrials.gov/show/NCT01982851||56586|
NCT01995175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200150|A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From Birth up to 2 Years of Age|A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus (RSV) Associated, Suspected Lower Respiratory Tract Infections (LRTIs) in Newborns, From Birth up to 2 Years of Age||GlaxoSmithKline||Active, not recruiting|December 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2400|||Both|N/A|5 Days|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01995175||55641|
NCT01983085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDX 120|Nitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds|ProNOx 2 - A Clinical Study of Superficial Partial Thickness Wound Treatment With an Oxides of Nitrogen Generating Gel Dressing|ProNOx2|Edixomed Ltd|Yes|Active, not recruiting|September 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|1 Year|N/A|No|||January 2016|January 19, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01983085||56568|
NCT01983371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 14-096|Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer|Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer||University of Vermont|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983371||56546|
NCT01992055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:389|Outcomes Following Neuropsychological Intervention in Acquired Brain Injury Outpatients With Executive Dysfunction|Functional Outcomes Following Neuropsychological Intervention in Acquired Brain Injury Outpatients With Executive Dysfunction||University of Manitoba|No|Enrolling by invitation|December 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01992055||55880|
NCT01984138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVIVE|REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy|H- 30956 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy|REVIVE|Baylor Breast Care Center|No|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984138||56487|
NCT01984125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP000312|Testing the Use of Prompts to Increase Adolescent Immunization Rates|Adolescent Vaccination in the Medical Home|AIMHi|University of California, Los Angeles|No|Completed|April 2011|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7040|||Both|11 Years|18 Years|No|||December 2015|December 16, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984125||56488|
NCT01984411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCColumbia|Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization|Comparison of Vascular ACcess for Radial and Femoral Completion of Diagnostic Cardiac Catheterization Performed at the Clinic Patients Northern General de Barranquilla in 2013. Controlled Clinical Trial of Non-inferiority|COMPACT|Centro Cardiológico del Caribe, Columbia|No|Completed|January 2013|August 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|90 Years|No|||November 2013|November 14, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01984411||56466|
NCT01987817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC001|Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT|Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy|ARC001|Aimmune Therapeutics, Inc.|Yes|Completed|January 2014|August 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|4 Years|26 Years|No|||August 2015|August 31, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987817||56204|
NCT01987830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-322|Bevacizumab w / Temozolomide PET & Vascular MRI For GBM|A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI||Massachusetts General Hospital|Yes|Recruiting|November 2013|September 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|17|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987830||56203|
NCT01988155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-928|Eccentric Exercise Versus Eccentric Exercise and Astym for Insertional Achilles Tendinopathy|Eccentric Exercise Versus Eccentric Exercise and Astym® in the Management of Insertional Achilles Tendinopathy: A Randomized Controlled Trial||Indiana University Health Ball Memorial Hospital Rehabiliation Services|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01988155||56179|
NCT01988389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/22|Effect of Apples on cardioVascular Risk And Gut Health|Effect of Apples Consumption on Blood Lipid Levels,Vascular Function and Gut Health in Moderate Hypercholesterolemic Subjects|AVAG|University of Reading|Yes|Completed|September 2013|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|23 Years|69 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01988389||56161|
NCT01982630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8521-003|Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)|A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|November 2013|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|November 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982630||56603|
NCT01986127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAI|Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients|A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01986127||56334|
NCT01986426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-315-03|Dose Escalation Study of LTX-315 in Patients With Transdermally Accessible Tumours|A Phase I, Open-label, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 in Patients With Transdermally Accessible Tumours||Lytix Biopharma AS|No|Recruiting|November 2013|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01986426||56311|
NCT01983163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9968480606|Dietary Therapy in Children With Refractory Epilepsy|Efficacy of Modified Atkins Diet Versus Ketogenic Diet in Children With Refractory Epilepsy Aged 1 Year to 18 Years: a Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Completed|April 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|1 Year|18 Years|No|||December 2015|December 31, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01983163||56562|
NCT01983176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307054RIND|Retrospective Clinical Outcome of Parotid Tumor Surgery|Retrospective Clinical Outcome of Parotid Tumor Surgery||National Taiwan University Hospital|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|767|||Both|10 Years|84 Years|No|Non-Probability Sample|All patients who underwent parotid surgery by a single operator in National Taiwan        University Hospital from January 2004 to December 2012 were assessed for histopathological        results and postoperative complications.|November 2013|November 25, 2013|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01983176||56561|
NCT01983423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoBx- IVF|Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Multicenter Study|Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Randomized, Multicenter Study|EndoBx-IVF|Pacific Centre for Reproductive Medicine|Yes|Recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|332|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01983423||56542|
NCT01983657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120401|Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.|Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.|PAP|Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|January 2012|October 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|17 Years|80 Years|No|||November 2013|November 14, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983657||56524|
NCT01986400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000038163|Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT|Virtual Peer-to-Peer Support Mentoring for Adolescents With Juvenile Idiopathic Arthritis: A Feasibility Pilot Randomized Controlled Trial||The Hospital for Sick Children|No|Recruiting|July 2013|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|12 Years|18 Years|No|||December 2014|December 29, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986400||56313|
NCT01994889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461028|Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy|A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)|ATTR-ACT|Pfizer|Yes|Active, not recruiting|December 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|441|||Both|18 Years|90 Years|No|||February 2016|February 3, 2016|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994889||55663|
NCT01995201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28709|A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis|A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis||Hoffmann-La Roche||Active, not recruiting|September 2013|March 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|401|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995201||55639|
NCT01991223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRBD_DEX_PHPKHC|Dexmedetomidine for Catheter-related Bladder Discomfort|Efficacy of Dexmedetomidine for the Therapy of Catheter-related Bladder Discomfort|CRBDEX|Seoul National University Hospital|Yes|Recruiting|November 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|114|||Both|19 Years|80 Years|No|||March 2014|March 18, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991223||55943|
NCT01983384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANESDEPTH|Anesthesia Depth And Postoperative Delirium Trial 2|THE EFFECTS OF LIGHT vs DEEP ANESTHESIA ON POSTOPERATIVE COGNITIVE OUTCOMES|ADAPT2|University of California, San Francisco|Yes|Recruiting|August 2015|December 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|202|||Both|64 Years|N/A|No|||January 2016|January 13, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01983384||56545|
NCT01983605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-001 V3.0_120709|Left Atrial Appendage Exclusion Study|Left Atrial Appendage Exclusion Study II|PLACE II|SentreHEART, Inc.|No|Active, not recruiting|December 2009|December 2013|Anticipated|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983605||56528|
NCT01992341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101151|AMG 386 Drug-Drug Interaction Study With Paclitaxel|An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors||Amgen|Yes|Completed|July 2012|September 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992341||55858|
NCT01992354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2013-GES-0012|Development of an Integrated PET/MR System, Accessories and Components|Development of an Integrated PET/MR System, Accessories and Components||GE Healthcare|No|Terminated|November 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|November 6, 2013|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01992354||55857|
NCT01992289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-002e|Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002|Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002|ECP-002e|Edimer Pharmaceuticals|No|Recruiting|March 2014|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Male|6 Months|1 Year|No|Non-Probability Sample|This is an open-label extension study without additional study drug administration on as        many as 10 XLHED-affected males previously having received EDI200 in the ECP-002 trial.        XLHED-affected male infants who completed the ECP-002 trial will be followed with yearly        visits starting at age 1 year.|May 2015|May 7, 2015|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01992289||55862|
NCT01992302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-BBP|Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients|Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients||Hospital Clinic of Barcelona||Completed|June 2004|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|289|||Both|18 Years|80 Years|No|Probability Sample|Bipolar I and II disorder patients|November 2013|November 18, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01992302||55861|
NCT01984424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120332|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3|A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects||Amgen|Yes|Active, not recruiting|December 2013|November 2017|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|511|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01984424||56465|
NCT01987414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309M42881|Forearm Rotation Orthosis for Stroke|Efficacy of a Forearm Rotation Orthosis for Persons With a Hemiparetic Arm||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|August 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01987414||56235|
NCT01987427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-A001-402|A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults|A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults||Eisai Inc.|No|Completed|October 2013|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|238|||Both|18 Years|60 Years|No|||December 2014|January 22, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987427||56234|
NCT01987440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk16|Effect of Lubricating Gel for Pain Relief During Speculum Examination in Gynecologic Oncology Patients|||Erzincan Military Hospital||Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|N/A|N/A|No|||June 2014|June 12, 2014|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987440||56233|
NCT01985412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17666|Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection|Genome Transplant Dynamics: Non-Invasive Sequencing-Based Diagnosis of Rejection|GTD|Stanford University|No|Enrolling by invitation|March 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|430|Samples With DNA|A single whole blood specimen from both the donor and recipient of the organ prior to      transplant. Additionally, blood samples are taken post-transplant at specified timepoints      and spun down into a plasma, buffycoat layer. The plasma and buffycoat are retained while      the rest is discarded.|Both|N/A|N/A|No|Non-Probability Sample|Stanford and Lucille Packard adult and pediatric, lung or heart transplant recipients and        Kaiser adult heart transplant recipients.|June 2015|June 3, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01985412||56389|
NCT01988168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03009|Closure of Skin in ChorioAmnionitis Research Pilot Study|Closure of Skin in ChorioAmnionitis Research Pilot Study|CSCAR|University of British Columbia|No|Recruiting|February 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|No|||July 2015|July 16, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988168||56178|
NCT01988402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20070235H|Does Allopurinol Prolong a Treated, Acute Gout Flare?|Does Allopurinol Prolong a Treated, Acute Gout Flare?||Wilford Hall Medical Center|No|Completed|December 2007|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||December 2014|December 20, 2014|November 6, 2013|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01988402||56160|
NCT01982903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s55992|Prospective Study of Urinary Markers of Fibrosis in Kidney Transplants|Prospective Study of Urinary Connective Tissue Growth Factor and Related Pro-fibrotic Mediators as Potential Early Biomarkers of Progressive Renal Allograft Fibrosis in de Novo Kidney Recipients||Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|whole blood, serum, urine, renal allograft tissue|Both|18 Years|80 Years|No|Probability Sample|Adult recipients of a primary or secondary cadaveric or living donor single renal        allograft at the University Hospitals Leuven.|September 2015|September 27, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01982903|24 Months|56582|
NCT01986452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StrOSA2013|Telemonitoring of CPAP Therapy in Apoplexy Patients With OSA|CPAP Therapie Mit Telemonitoring Bei Obstruktiver Schlafapnoe Und Apoplexie||Institut für Pneumologie Hagen Ambrock eV|No|Recruiting|December 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986452||56309|
NCT01986465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387278|Effectiveness of Steroid Injection in Treating Patients With Lateral Epicondylitis|Comparing the Effectiveness of Steroid Injection Versus Placebo and Immobilization Versus no Immobilization in Treating Patients With Lateral Epicondylitis||Isfahan University of Medical Sciences|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|65 Years|No|||November 2013|November 11, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986465||56308|
NCT01983436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP/12/ADV/DLMOF|Impact of Manual Lymphatic Drainage on Postoperative Edema of the Face and the Neck After Orthognathic Surgery|Impact of Manual Lymphatic Drainage on Postoperative Edema of the Face and the Neck After Orthognathic Surgery.Open-label Multicenter Randomized Controlled Trial|DLMOF|University Hospital, Tours|No|Recruiting|November 2013|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|14 Years|50 Years|No|||January 2016|January 5, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01983436||56541|
NCT01983670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0951B|The Investigation of the Pre-movement Facilitation of Agonist-antagonist Muscles and the Effect of the Feedforward Rehabilitation in Individuals With Hypermetria|||Chang Gung University|Yes|Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 7, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983670||56523|
NCT01994616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/292|Prospective Evaluation of the Use of Intralesional Cryotherapy for Treatment of Keloid and Hypertrophic Scars|Intralesional Cryotherapy for Treatment of Keloid Scars: a Prospective Evaluation||VU University Medical Center|No|Completed|January 2009|June 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|10 Years|N/A|No|Non-Probability Sample|A mixed patient population with all Fitzpatrick skin types|November 2013|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994616||55684|
NCT01994629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_67|Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers|A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers||Novartis|No|Completed|November 2013|October 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|202|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||October 2015|October 2, 2015|November 11, 2013|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01994629||55683|
NCT01994902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP232|Investigation of Newly Developed Ostomy Products in Subjects With Ileostomy|Investigation of Newly Developed 1-and 2-piece Convex Ostomy Products in Subjects With Ileostomy.||Coloplast A/S|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|October 18, 2013||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01994902||55662|
NCT01995188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29006|A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer||Genentech, Inc.||Recruiting|December 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995188||55640|
NCT01991574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6320|Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion.|Study of the Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus.||Medical Research Council|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991574||55917|
NCT01995448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11020 SEPTIFLUX 2|Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis|Prognostic Interest of Leucocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry During the Acute Phase of Sepsis|SEPTIFLUX2|University Hospital, Limoges|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|Samples With DNA|Residue of blood further to NFS.|Both|18 Years|N/A|No|Probability Sample|Patient with two criteria of systemic inflammatory response syndrome and a progressive        infection which is clinically or microbiologically documented|August 2015|February 23, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01995448||55620|
NCT01991535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-VEN-2013-23|Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern|Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Not yet recruiting||||December 2016|Anticipated|N/A|Interventional|Masking: Single Blind (Subject)|||Anticipated|10|||Both|18 Years|90 Years|No|||October 2015|October 29, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991535||55920|
NCT01991548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP284|User Evaluation of the MiniMed 640G Insulin Pump|A User Evaluation of the MiniMed® 640G Insulin Pump and Guardian® Link Transmitter||Medtronic Diabetes|No|Not yet recruiting|November 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|7 Years|N/A|No|Non-Probability Sample|Patients within the research center diabetes population who currently use insulin pump for        their diabetes therapy.|November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991548||55919|
NCT01991743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00050371|A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version|A Randomized Controlled Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version||Northwestern University|No|Recruiting|May 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|226|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991743||55904|
NCT01993316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|neurofeedbackTMS1|Neurofeedback Using TMS as an Assessment Tool|Validating of Neurofeedback Practice by Utilizing TMS as an Assessment Tool||Beersheva Mental Health Center|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|22 Years|28 Years|Accepts Healthy Volunteers|||November 2013|November 22, 2013|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01993316||55783|
NCT01992315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST Adipose ECM|Investigation of A-ECM for the Correction of Soft Tissue Defects|Investigation of Decellularized Adipose Derived-ECM for the Correction of Acquired Soft Tissue Deformities of the Body and Face||Aegeria Soft Tissue LLC|Yes|Not yet recruiting|March 2014|August 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01992315||55860|
NCT01992328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-CT4-12-405|IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency|IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency|IVIG|Ajou University School of Medicine|Yes|Active, not recruiting|December 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|75 Years|No|||June 2015|June 21, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992328||55859|
NCT01992588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3890|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|64 Years|No|||October 2014|October 15, 2014|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01992588||55839|
NCT01987453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1118|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study|An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study||Gilead Sciences|No|Completed|November 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987453||56232|
NCT01986153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/475|Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients|Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients||Radboud University|No|Completed|December 2013|November 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Long-term parenteral nutrition dependent patients:Patients who visit the outpatient clinic        of the Department of Gastroenterology and Hepatology at the Radboud University Medical        Nijmegen Center.        Healthy controls: volunteers who are residents in the Netherlands.|November 2013|November 11, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986153|1 Day|56332|
NCT01985672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/181|Vitamin D Deficiency and Pregnancy Rates in Women Undergoing Frozen Embryo Transfer|Vitamin D Deficiency and Pregnancy Rates in Women Undergoing Frozen Embryo Transfer. A Prospective Cohort Study||Universitair Ziekenhuis Brussel|No|Completed|August 2013|July 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|280|||Female|18 Years|39 Years|No|Probability Sample|Infertile women undergoing a frozen ET with 1 or 2 Day 5 (blastocyst stage) embryo|August 2015|August 5, 2015|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01985672||56369|
NCT01985880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0616|The Efficacy of Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome|Experimental Study of Biomarker in Patient With Interstitial Cystitis/Painful Bladder||Asan Medical Center|Yes|Recruiting|November 2013|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|bladder biopsy, urine, blood|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients >20 years old with interstitial cystitis control|December 2015|December 29, 2015|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01985880|6 Months|56353|
NCT01982916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGR_P3|Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean|A 4 Week Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of AGR Tablet in the Treatment of Perennial Allergic Rhinitis in Korean : a Phase III Clinical Trial Bridging Study||Ahn-Gook Pharmaceuticals Co.,Ltd|No|Recruiting|December 2013|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|12 Years|N/A|No|||February 2014|February 18, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01982916||56581|
NCT01982890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telomeres and TREC|Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time|Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals||Université de Sherbrooke|No|Enrolling by invitation|January 2005|April 2020|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Genomic DNA extracted from peripheral blood|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal human controls apparied for gender and for groups of age with patients of the EUPA        cohort (with inflammatory arthritis of between 1 and 12 months duration presenting for        clinical care at the Rheumatology Division of the Centre hospitalier universitaire de        Sherbrooke.)|December 2014|December 2, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982890|5 Years|56583|
NCT01983683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-061A302|Clinical Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea|AC-061A302, A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD).||Actelion|Yes|Recruiting|November 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983683||56522|
NCT01983969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0186|Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma|Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2013|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|15 Years|65 Years|No|||June 2015|June 16, 2015|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983969||56500|
NCT01983982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00077174|Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms|Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms in Early Stage Breast Cancer||University of Michigan|No|Active, not recruiting|November 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|N/A|No|Non-Probability Sample|Women initiating adjuvant chemotherapy to treat stage I-III breast cancer.|November 2015|November 30, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983982||56499|
NCT01994642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71205503|Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes|A Randomized, Double-Blind, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Acute Bacterial Otitis Media in Children With Patent Tympanostomy Tubes||Par Pharmaceutical, Inc.|No|Terminated|November 2013|March 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|203|||Both|6 Months|12 Years|No|||June 2015|June 1, 2015|November 20, 2013|Yes|Yes|FDA's draft guidance (revised March 2015) provided two options for determining bioequivalence:    1) in-vitro or 2) in-vivo studies|No||https://clinicaltrials.gov/show/NCT01994642||55682|
NCT01994655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEK-8357-wp|Chinese Health Ivvestigation Of Nurse Aging|||Peking University First Hospital|No|Active, not recruiting|August 2008|September 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Anticipated|2000|||Female|40 Years|55 Years|No|||November 2013|November 20, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994655||55681|
NCT01994668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3541001|Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects|A Phase 1, Randomized Single-blind (Subject-blind), Placebo Controlled Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects||Pfizer|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|8|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994668||55680|
NCT01991262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0112-CTIL|A Nationwide Epidemiological, Educational Support Program for Improving Treatment Adherence in Patients With HBV|A Nationwide Epidemiological, Non-Interventional Study Evaluating an Educational Support Program for Improving Treatment Adherence in Patients With Hepatitis B Viral Infection|Help-B|Carmel Medical Center|Yes|Not yet recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|252|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult newly diagnosed with chronic hepatitis B patients, eligible to begin treatment with        first line therapy.|March 2015|March 22, 2015|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991262||55940|
NCT01992081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDD001D2101|Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.|A 6-month Multicenter Randomized Trial to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD|PROactive|Novartis|No|Withdrawn|May 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|N/A|No|||May 2014|May 14, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992081||55878|
NCT01991236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059584|Video-Based Education for Dermatology Patients on Systemic Corticosteroids|The Efficiency and Effectiveness of Video-Based Education for Dermatology Patients Qualifying for Chronic Treatment With Systemic Corticosteroids||Emory University|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01991236||55942|
NCT01991561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-H5VLP-005|Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.|Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.||Medicago|Yes|Completed|June 2013|November 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|390|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991561||55918|
NCT01991769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1801|Negative Postprandial Effect on Endothelium After a Not-healthy Meal in Type 2 Diabetes as Affected by Training|Negative Postprandial Effect on Endothelium After a Not-healthy Meal in Type 2 Diabetes as Affected by Training||Norwegian University of Science and Technology|No|Completed|February 2012|November 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|40 Years|65 Years|No|||August 2014|August 21, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01991769||55902|
NCT01993602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0150/11|Lung Expansion Technics on Chest Wall Mechanics and Preventing Pulmonary Complication After Abdominal Surgery|COMPARISON OF LUNG EXPANSION TECHNICS ON THORACOABDOMINAL MECHANICS AND THEIR INFLUENCE ON THE INCIDENCE OF PULMONARY COMPLICATIONS AFTER ABDOMINAL SURGERY: A RANDOMIZED AND CONTROLLED CLINICAL TRIAL||University of Sao Paulo General Hospital|No|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|171|||Both|18 Years|N/A|No|||November 2013|March 7, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01993602||55761|
NCT01992601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH16410-101|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer|YH16410 DDI|Yuhan Corporation|No|Completed|November 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|48|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 22, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01992601||55838|
NCT01985685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000240|The Effect of Thiamine vs. Placebo on VO2 in Critical Illness|The Effect of Thiamine vs. Placebo on VO2 in Critical Illness|TVO2 RCT|Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985685||56368|
NCT01987466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0575|Plasma Neutrophil Gelatinase-associated Lipocalin (NGAL) as Early Biomarker for Renal Dysfunction and Good Neurologic Outcome in Out of Hospital Cardiac Arrest Patients|||Yonsei University|No|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|73|||Both|19 Years|N/A|No|Non-Probability Sample|Patients over 19 years of age admitted to our hospital after succesful resuscitation from        out of hospital cardiac arrest. Mental state of the patient is less than 8 in GCS scale        and the patient should be undergoing therapeutic hypothermia.Exclusion criteria is age        younger than 19 years, terminal illness or do-not resuscitation status, pre-existing coma,        abnormal mental status with defined intracranial lesion (ex. cerebral hemorrhage, cerebral        infarction, etc), unstable vital sign and previous end-stage renal disease.|November 2013|November 12, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987466||56231|
NCT01986166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29030|A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS|A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS||Genentech, Inc.||Recruiting|November 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986166||56331|
NCT01986179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14647|Comparing Remote Interpreter Modalities in the Pediatric Emergency Department|Impact of Remote Interpreter Modality on Comprehension, Communication Quality, and Consistency of Interpreter Use in the Pediatric Emergency Department||Seattle Children's Hospital|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|208|||Both|N/A|18 Years|No|||May 2015|May 18, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986179||56330|
NCT01986478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-001|OCT Reference Database|Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Reference Database Study||Topcon Medical Systems, Inc.|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|389|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that are Normal|March 2014|March 25, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986478||56307|
NCT01982331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-H2N2-01|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine||PATH|Yes|Completed|October 2013|March 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|May 23, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982331||56625|
NCT01982617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2006|Motivational Interviewing Compared to Psychoeducation for Smoking Precontemplators With SMI|A Randomized, Controlled Trial of Motivational Interviewing Compared to Psychoeducation for Smoking Precontemplators With Severe Mental Illness||Massachusetts General Hospital|No|Completed|January 2003|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|61|||Both|18 Years|65 Years|No|||November 2013|November 12, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982617||56604|
NCT01983228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-030|A Proactive Walking Trial to Reduce Pain in Black Veterans|A Proactive Walking Trial to Reduce Pain in Black Veterans||VA Office of Research and Development|No|Not yet recruiting|July 2016|June 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|90 Years|No|||December 2015|December 21, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983228||56557|
NCT01983189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5594|Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism|Repetetive Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behavior in Subjects With Autism Spectrum Disorders.||New York State Psychiatric Institute|Yes|Terminated|November 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|No|||November 2013|November 6, 2013|March 14, 2012||No|Principal investigator (Dr. Sporn) left the sponsoring institution.|No||https://clinicaltrials.gov/show/NCT01983189||56560|
NCT01983995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00078882|Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients|Prospective Pilot Study Evaluating the Inter-relationships Between Sleep Disturbance, Fatigue, Pain, and Daytime Activity in Breast Cancer Patients Starting Aromatase Inhibitor Therapy||University of Michigan|No|Recruiting|November 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|50 Years|N/A|No|Non-Probability Sample|University of Michigan Cancer Center|November 2015|November 30, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983995||56498|
NCT01984229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28990|A Study of the Effects of Posaconazole on RO5424802 Pharmacokinetics in Healthy Volunteers|An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects||Hoffmann-La Roche||Completed|December 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984229||56480|
NCT01995214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20130602|Sevoflurane and Propofol Anesthesia on Postoperative Delirium|Comparison of Sevoflurane and Propofol Anesthesia on Postoperative Delirium in Geriatric Patients||Huazhong University of Science and Technology|Yes|Recruiting|June 2013|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|60 Years|N/A|No|||November 2013|November 21, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01995214||55638|
NCT01991249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00251-44|Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia|Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2014|January 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|18 Years|No|||April 2015|April 8, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991249||55941|
NCT01991808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 26812|Suitability of DCE-MRI for Detection of Vascular Changes After VBT|A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|20|||Female|18 Years|N/A|No|||June 2015|June 15, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01991808||55899|
NCT01992627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-2013-01|Clinical Trial for High Intensity Laser Therapy (HILT) for Elbow Epicondylosis|A Prospective Randomized Clinical Trial of High Intensity Laser Therapy for Elbow Epicondylosis|HILT|CM Chungmu Hospital|Yes|Recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|65 Years|No|||November 2013|November 19, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992627||55836|
NCT01991782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120725|The Impact of Telemedicine on Orthopaedic Trauma Patients With Closed Fractures|The Impact of Telemedicine on Orthopaedic Trauma Patients With Closed Fractures||Vanderbilt University|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01991782||55901|
NCT01992367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN003-001|Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003|A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects||Aslan Pharmaceuticals|Yes|Completed|August 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|61|||Male|21 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 1, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01992367||55856|
NCT01992068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1309|Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function|Prospective Pilot Study of High-resolution Manometry to Assess Radiation-induced Changes in Esophageal Function in Patients With Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Enrolling by invitation|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|99 Years|No|Non-Probability Sample|Lung cancer patients age 18 or above who have a histologically confirmed lung cancer        diagnosis and are scheduled to undergo conventionally fractionated radiation treatment.|January 2016|January 17, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01992068||55879|
NCT01994200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ-2013-10963|Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients|Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial|ITCA-ThyCa|Jewish General Hospital|No|Withdrawn|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994200||55715|
NCT01994213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN- Ⅱ- GEPNET|A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor|A Randomized, Single-arm, Open-label, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|October 2011|November 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|75 Years|No|||November 2013|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994213||55714|
NCT01993589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|{kayseriERH}|Effect of Paracetamol, Dexketoprofen Trometamol, Lidocaine Spray, Pethidine and Diclofenac Sodium Application for Pain Relief During Fractional Curettage|||Kayseri Education and Research Hospital|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|144|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01993589||55762|
NCT01985698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLOAPR|A Trial of Robotic-assisted Versus Laparoscopic Versus Open Abdominoperineal Resection for Treating Low Rectal Cancer|A Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Versus Open Abdominoperineal Resection for the Curative Treatment of Low Rectal Cancer|RLOAPR|Fudan University|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||November 2013|November 9, 2013|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01985698||56367|
NCT01985100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLukesMO # 2013.021|The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke|Hyperbaric Oxygen in the Reduction of Post Stroke Ischemic Penumbra|HBO|St. Luke's Hospital, Chesterfield, Missouri|No|Withdrawn|November 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|80 Years|No|||September 2014|September 3, 2014|November 7, 2013||No|Unable to recruit any patients that fulfilled the narrow enrollment requirements|No||https://clinicaltrials.gov/show/NCT01985100||56413|
NCT01982344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mini-exchange-room|A Study Comparing the Impact of Mini-exchange-room and Usual Care on Physical Activity and Quality of Life in Peritoneal Dialysis Patients|||Peking University First Hospital|No|Recruiting|October 2013|January 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2|||Both|18 Years|80 Years|No|||February 2014|October 28, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01982344||56624|
NCT01982643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0054|Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder|CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder|ADAPT|University of California, Los Angeles|Yes|Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982643||56602|
NCT01982656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003346|Massage Technique for Pain, Anxiety and Delirium in SAH Patients|Effects of Massage Technique for Pain, Anxiety, and Delirium Management in ICU Patients With Subarachnoid Hemorrhage||Mayo Clinic|No|Recruiting|December 2013|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01982656||56601|
NCT01983241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTi1201|Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)|A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency|SPARTA|Grifols Therapeutics Inc.|No|Recruiting|November 2013|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|339|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983241||56556|
NCT01983462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307779|Vascular Dysfunction in Human Obesity Hypertension|Vascular Dysfunction in Human Obesity Hypertension: Integrative Role of Sympathetic and Renin-Angiotensin Systems|VANISH|University of Iowa|Yes|Recruiting|October 2013|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01983462||56539|
NCT01983202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25624548|Obstetric Outcomes in Women With PCOS|Size at Birth in Newborn Children and Obstetric Outcomes in Women With PCOS||Odense University Hospital|No|Completed|January 2003|September 2013|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1248|||Female|N/A|N/A|No|Probability Sample|208 women diagnosed with PCOS at Department of Endocrinology and Metabolism and giving        birth at Odense University Hospital during 2003-2011. Women with PCOS are matched 1:5 to a        date-of-childbirth matched control group of 1040 pregnant women giving birth at Odense        UNivesity Hospital.|November 2013|November 6, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01983202||56559|
NCT01983215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0045|Effects of Prevena Therapy on Obese and or Diabetic Patients With Surgical Groin Sites|EFFECTS OF PREVENA THERAPY ON REDUCTION OF GROIN SURGICAL SITE INFECTIONS IN OBESE PATIENTS UNDERGOING VASCULAR SURGERY||Ohio State University|No|Enrolling by invitation|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|276|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983215||56558|
NCT01984008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-BKL-2013|A Prospective, Randomized Controlled Clinical Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy|||Universal Integrated Corp.||Active, not recruiting|October 2013|July 2015|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2013|May 31, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01984008||56497|
NCT01984242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29074|A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma [IMmotion150]|A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma||Hoffmann-La Roche||Active, not recruiting|January 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|305|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984242||56479|
NCT01984255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102013-007|A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients|A Two-Arm, Single Center Pase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01984255||56478|
NCT01991587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-Q12VLP-004|Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults|Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent Virus-like-particle (VLP) Influenza Vaccine in Adults||Medicago|Yes|Completed|October 2013|September 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991587||55916|
NCT01991795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D513BC00001|A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus|A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)|THEMIS|AstraZeneca|Yes|Recruiting|February 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|19000|||Both|50 Years|130 Years|No|||March 2016|March 7, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991795||55900|
NCT01992380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A03|A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects|Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.||Avid Radiopharmaceuticals|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 6, 2014|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01992380||55855|
NCT01992614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7611001|A Single Dose Study Of PF-06678552 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects||Pfizer|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992614||55837|
NCT01992835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5507|Resolution of Allergic Inflammation|Resolution of Allergic Inflammation: Identification and Kinetics of Specific Lipid Mediators During Nasal Allergen Challenge||University Hospital, Strasbourg, France|No|Not yet recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|18 Years|55 Years|No|||November 2013|November 22, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01992835||55820|
NCT01993056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saarland University 10/2011|The Influence of 11+ on Injury Incidence and FMS-Score in Veteran Soccer Players|||Saarland University||Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|265|||Male|32 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 22, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993056||55803|
NCT01993862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40009529/B|Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant|Safety and Cost Effectiveness of Same Day Discharge After Implantable Cardioverter-Defibrillator Implant Versus Next Day Discharge|SDD for ICD|St. Jude Medical|No|Active, not recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|266|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993862||55741|
NCT01993875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMP-0211-301|Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation|A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation||Sucampo Pharma Americas, LLC|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993875||55740|
NCT01986192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAIS-1.1-12-12|Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study|An Efficacy and Safety Study of Ribaroxaban for the Prevention of Deep Vein Thrombosis Recurrence in Patients With Acute Iliofemoral Venous Thrombosis Initially Treated With Thrombolysis|PRAIS|Seoul National University Hospital|No|Recruiting|November 2013|November 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|75 Years|No|||November 2014|November 18, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986192||56329|
NCT01985893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNGO/01 THOR|Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer|Randomised, Open-label Phase II Study to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Trastuzumab-resistant HER2-overexpressing Metastatic Breast Cancer|THOR|Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.|No|Withdrawn|September 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|64 Years|No|||January 2016|January 13, 2016|November 10, 2013||No|Due to missing patient recruitment, the financial support was stopped.|No||https://clinicaltrials.gov/show/NCT01985893||56352|
NCT01986491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016264|A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants|An Open-Label, Single Dose, Relative Bioavailability Study of Solid Formulations in Fed and Fasted Conditions Followed by a Repeated Dose Study of a Selected Solid Formulation of JNJ-39393406 in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|November 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986491||56306|
NCT01982357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2013-9505|Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies|Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies||University of California, Irvine|No|Recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|N/A|1 Month|Accepts Healthy Volunteers|Probability Sample|Study population will be selected from University of California Irvine Medical Center at        Neonate Intensive Care Unit|February 2016|February 5, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01982357||56623|
NCT01982383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021236|Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy|A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy||George Washington University|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|30 Years|60 Years|No|||October 2013|November 12, 2013|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982383||56622|
NCT01982669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATIETY-1|Spicy Diet on Salty Taste and Salt Intake|Effects of Spicy Diet on Salty Taste and Salt Intake||Third Military Medical University|Yes|Completed|February 2013|December 2013|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|606|Samples With DNA|Blood, Urine|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents from four cities(Shenyang, Jinan, Chengdu and Chongqing) in China|January 2016|January 7, 2016|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01982669||56600|
NCT01983267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cannabis-related cog impair|Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.|Cannabis-related Cognitive Impairment: Prospective Evaluation of Possible Influences in Cancer Patients During Active Oncology Treatment||Rambam Health Care Campus|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|120 Years|No|||November 2015|November 19, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01983267||56554|
NCT01983722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-5518|Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome|Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome||Children's Hospital Medical Center, Cincinnati||Available||||||N/A|Expanded Access|N/A|||||||Both|6 Months|N/A||||July 2015|September 25, 2015|November 7, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01983722||56519|
NCT01983735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HT13015|Efficacy and Safety of TELMINUVO to Stage 2 Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension||Chong Kun Dang Pharmaceutical|Yes|Not yet recruiting|January 2014|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983735||56518|
NCT01983449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSP0149|Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease|Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization|DANCE|Mercator MedSystems, Inc.|No|Active, not recruiting|November 2013|December 2017|Anticipated|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|285|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01983449||56540|
NCT01983696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHC-2013-02|The Effect of Low Oxygen Tension on the Early Development of Human Embryo in IVF/ICSI|The Effect of Low Oxygen Tension on the Early Development of Human Embryo in IVF/ICSI||Shanxi Provincial Maternity and Children's Hospital|Yes|Recruiting|November 2013|October 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|N/A|N/A|No|||November 2013|November 25, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983696||56521|
NCT01984034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCMGIAI1|Trial to Assess the Effectiveness of Educational Outreach in Prescription Guidelines|An Open Cluster-randomized, 18 Month Trial to Compare the Effectiveness of Educational Outreach Visits With Usual Guideline Dissemination to Improve Family Physician Prescribing|TEP|Universidade Nova de Lisboa|No|Active, not recruiting|November 2013|December 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984034||56495|
NCT01984047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200784|Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002|A Phase 1, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (Anti-CCL20 Monoclonal Antibody) in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|49|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984047||56494|
NCT01984268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13146|ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate|Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|November 2013|October 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984268||56477|
NCT01984281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13804413.3.1001.5133|Effects of a Pedometer-based Unsupervised Exercise Program Upon Lifestyle Physical Activity of Asthmatic Adults|Effects of a Pedometer-based Unsupervised Exercise Program Upon Lifestyle Physical Activity of Asthmatic Adults||Federal University of Juiz de Fora|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|37|||Both|18 Years|65 Years|No|||December 2015|December 5, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984281||56476|
NCT01984970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121126001|McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation|Evaluation McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation||Huazhong University of Science and Technology|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|43|||Both|18 Years|65 Years|No|Probability Sample|adult patients scheduled for thoracic surgery requiring double-lumen tube insertion for        one-lung ventilation|July 2014|July 10, 2014|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984970|3 Days|56423|
NCT01992107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V130_03|Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old|A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Trivalent Subunit Influenza Virus Vaccines in Subjects Ages ≥4 Years to < 18 Years||Novartis|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|2333|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 7, 2013|Yes|Yes||No|March 16, 2015|https://clinicaltrials.gov/show/NCT01992107||55876|
NCT01992640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2013|Recovery After Laparoscopic Surgery|Recovery After Laparoscopic Surgery||Herlev Hospital|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients scheduled for laparoscopic surgery at Herlev Hospital and expected        discharge on the same day as surgery.|June 2014|June 18, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01992640||55835|
NCT01993069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 2013-020286|Yoga Training for Returning Veterans With Headache|Yoga Training for Returning Veterans With Headache||University of California, Los Angeles|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01993069||55802|
NCT01993082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00HL109247-03|Fitness, Cellular Aging, and Caregiver Stress Study|The Effects of Exercise and Life Stress on Telomere Maintenance and Cardiovascular Disease Risk|FAST|University of California, San Francisco|No|Active, not recruiting|January 2014|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|70|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01993082||55801|
NCT01992848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP-Calcification|MAP-Calcification: MicroRNAs as Potential Biomarkers for Coronary Artery Calcification|A Case-control Study of MicroRNAs a Potential Biomarkers for Coronary Artery Calcification (CAC) - An Additional Substudy to Determine the Relationship Between CAC and Bone Mineral Density and Markers of Bone Metabolism||University of Surrey|Yes|Recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|No|||May 2014|May 20, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01992848||55819|
NCT01993329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-009|A Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma|A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma||Afferent Pharmaceuticals, Inc.|No|Completed|December 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|65 Years|No|||December 2013|June 12, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01993329||55782|
NCT01993888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-13-005|The EVARREST™ Fibrin Sealant Patch Liver Study|A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery||Ethicon, Inc.|Yes|Completed|October 2013|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993888||55739|
NCT01993615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213011|A Physical Therapy Program Versus Surgery for Femoroacetabular Impingement: Randomized Clinical Trial|A Supervised Physical Therapy Program vs. Arthroscopic Surgery for Femoroacetabular Impingement: A Randomized Clinical Trial||Madigan Army Medical Center|Yes|Active, not recruiting|March 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01993615||55760|
NCT01993927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340-012|Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"|Basen Tablets 0.2 / Basen Oral Disintegrant（OD） Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"||Takeda|No|Completed|November 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|742|||Both|N/A|N/A|No|Non-Probability Sample|Patients with impaired glucose tolerance|July 2014|July 23, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993927||55736|
NCT01994460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-1310-026-523|Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis|Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial||Seoul National University Hospital|Yes|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|429|||Both|20 Years|80 Years|No|||December 2014|December 27, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01994460||55695|
NCT01986205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024845|Hyperbaric Oxygen for Civilian Post-concussive Syndrome|A Double-blind Randomized Trial of Hyperbaric Oxygen Versus Sham in Civilian Post-concussive Syndrome|HYBOBI2|Intermountain Health Care, Inc.|No|Not yet recruiting|October 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|No|||August 2015|August 24, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986205||56328|
NCT01986218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA002-001|Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors|Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors||Bristol-Myers Squibb|No|Active, not recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986218||56327|
NCT01985906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOUS-AP0807|Safety and Efficacy of Multiple Overlapping Uncovered Stents for Pararenal Aortic Aneurysm Repair|Evaluation of the Safety and Efficacy of Multiple Overlapping Uncovered Stents for Endovascular Pararenal Aortic Aneurysm Repair|SEMPER|Changhai Hospital|Yes|Recruiting|May 2014|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|No|||May 2014|May 5, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01985906||56351|
NCT01982396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PENTA 13|Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children|Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection|PENTA 13|PENTA Foundation|No|Completed|January 2003|March 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|2 Years|13 Years|No|||November 2013|November 5, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01982396||56621|
NCT01982409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02038508|Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children|A Study of Immune Persistence After Inoculated With One-dose Freeze-dried Live Attenuated Varicella Vaccine in Children Aged 1-6 Years||Changchun Changsheng Life Science and Technology Co., Ltd.|Yes|Active, not recruiting|June 2013|December 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|350|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01982409||56620|
NCT01982682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.352|Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor||Thomas Jefferson University|Yes|Recruiting|October 2013|November 2020|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982682||56599|
NCT01982929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001906|An Evaluation of Post Caesarean-Section Pain Control Regimens: Non-Opioid Oral Regimen With and Without Transversus Abdominis Plane Block|An Evaluation of Post Caesarean-Section Pain Control Regimens: Non-Opioid Oral Regimen With and Without Transversus Abdominis Plane Block||Massachusetts General Hospital||Not yet recruiting|November 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|240|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982929||56580|
NCT01983709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1348|Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer|A Phase 1 Study of Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer|MSC|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983709||56520|
NCT01983748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DERMA-ER-DC 08|Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma|A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA||University Hospital Erlangen|Yes|Recruiting|June 2014|June 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01983748||56517|
NCT01984606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.22|Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes|A Phase IIIb Randomised, Double-blind, Active-controlled, Parallel Group, Efficacy and Safety Study of Once Daily Oral Administration of Empagliflozin 25 mg Compared to Sitagliptin 100 mg During 52 Weeks in Type 2 Diabetes Mellitus Patients Who Are Treatment-naïve or on Treatment With Metformin With Insufficient Glycaemic Control||Boehringer Ingelheim||Withdrawn|January 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|November 8, 2013||||No||https://clinicaltrials.gov/show/NCT01984606||56451|
NCT01984619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0834|Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles|A Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles Utilizing the Iovera With Blunt Tip Cannula Smart Tip||MyoScience, Inc||Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects, male or female, age 18 - 65 with forehead wrinkles deemed significant        per protocol inclusion criteria.|March 2015|March 23, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01984619||56450|
NCT01984983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-VEEV-001|Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers|A Phase I, Randomized, Observer-blind, Placebo Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered Intramuscularly or Intradermally by Electroporation to Healthy Adults||Ichor Medical Systems Incorporated|No|Completed|December 2013|May 2015|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|42|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|September 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01984983||56422|
NCT01993381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINV_CUKorea|Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting|Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting(CINV)||The Catholic University of Korea|No|Recruiting|November 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood sampling|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin,        Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy|March 2016|March 1, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01993381||55778|
NCT01992861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8118|MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer|MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix||University of Washington|No|Recruiting|February 2014|||September 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|237|||Female|18 Years|N/A|No|||November 2015|November 3, 2015|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01992861||55818|
NCT01992874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200066-013|Relative Bioavailability of Pimasertib in Cancer Patients|A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients||EMD Serono|No|Completed|November 2013|February 2015|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|80 Years|No|||April 2015|April 17, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992874||55817|
NCT01993095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL-0009|FlexToBa for People With Multiple Sclerosis|Improving Functional Performance in Persons With MS Via Physical Activity DVD Intervention||University of Illinois at Urbana-Champaign|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|N/A|No|||March 2015|March 16, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01993095||55800|
NCT01993342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joan03|Determination of Adipocytokine in Synovial Fluid of Osteoarthritis Patients|Determination of Adipocytokine in Synovial Fluid of Osteoarthritis Patients With Joint Pain and Effusion||Hospital Parc Taulí, Sabadell|No|Recruiting|October 2013|March 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|35|Samples Without DNA|Synovial fluid|Both|50 Years|81 Years|No|Probability Sample|Patient with knee osteoarthritis and synovial effusion who attende to a Rheumatologist        unit for this problem. We made the visit and anonimously we kept the results of        examination and ultrasonography in our database and we freezed synovial fluid. Now we will        determine the adipocytokines and classic inflammatory parameters in this synovial fluid|November 2013|November 19, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01993342||55781|
NCT01993355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBP-PT_ATR_274-2012|Chronic Low Back Pain: A Multidisciplinary Approach|A Multidisciplinary Approach to Treat and Rehabilitate Patients With Chronic Low Back Pain|CLBP-HUVH|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|March 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|66|||Both|30 Years|80 Years|No|||June 2015|June 15, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01993355||55780|
NCT01993901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBR041575|The Influence of CSRT-led Telephone Follow-up on ESAS Scores in Patients Who Have Been Treated With Lung SBRT|The Influence of Clinical Specialist Radiation Therapist (CSRT)-Led Telephone Follow-up on Edmonton Symptom Assessment Scale (ESAS) Scores in Patients Who Have Been Treated With Lung Stereotactic Body Radiation Therapy (SBRT)||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|August 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993901||55738|
NCT01993914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2011-2104|Prevalence of MTHFR Polymorphisms in Venous Disease|Prevalence of MTHFR Polymorphisms in Venous Disease With or Without Concomitant Thrombosis|MTHFR|Health Diagnostic Laboratory, Inc.|No|Completed|February 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|90|Samples With DNA|Whole blood and serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Elite Laser Vein Center, representative of the ethnic population of Los        Angeles, CA, estimated as 40% Non Hispanic White, 40% Hispanic, 10% African American, 10%        Asian.|November 2014|November 14, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993914||55737|
NCT01994772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2012-A00405-38|Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm|Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm at Rescue Arrival: The HYPERION Study|HYPERION|Centre Hospitalier Departemental Vendee|Yes|Recruiting|January 2014|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|584|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01994772||55672|
NCT01994226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/11|Colchicine Or Naproxen Treatment for ACute gouT|Multi-centre, Open-label, Active-comparator, Pragmatic Clinical Trial of Low-dose Colchicine Versus Naproxen in Patients With Acute Gout.|CONTACT|Keele University|Yes|Recruiting|January 2014|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994226||55713|
NCT01986244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001600|Total Ankle Replacement for Ankle Arthritis|Total Ankle Replacement for Ankle Arthritis|TAR1600|Duke University|No|Enrolling by invitation|June 2007|June 2026|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who will benefit from a total ankle replacement.|November 2015|November 11, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986244||56325|
NCT01986517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feedback-01|Feedback and Psychotherapeutic Competencies|Impact of Feedback on the Devolpment of Psychotherapeutic Competencies: a Randomized Controlled Trial||Goethe University|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986517||56304|
NCT01986504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044645|The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study|The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study||Johns Hopkins University|No|Active, not recruiting|June 2011|June 2016|Anticipated|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|100 Years|No|Probability Sample|Hematopoietic stem cell (bone marrow) and solid organ transplant patients|February 2016|February 23, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986504|5 Years|56305|
NCT01982422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6749|Developmental Origins of Attention Deficit Hyperactivity Disorder|Developmental Origins of Attention Deficit Hyperactivity Disorder||Oregon Health and Science University|No|Recruiting|August 2012|August 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982422||56619|
NCT01982695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00149|Cardiomyopathy in DMD: Lisinopril vs. Losartan|Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy||Nationwide Children's Hospital|No|Completed|March 2009|September 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|N/A|N/A|No|||November 2013|November 5, 2013|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982695||56598|
NCT01982942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN102 SPRINT - MS|Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis|A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis||MediciNova|Yes|Active, not recruiting|November 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|21 Years|65 Years|No|||May 2015|May 12, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982942||56579|
NCT01982955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200095-006|MSC2156119J With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib||Merck KGaA|Yes|Recruiting|December 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|169|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982955||56578|
NCT01983475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113536|Denosumab Administration After Spinal Cord Injury|The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|Yes|Recruiting|January 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983475||56538|
NCT01983488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGS10201|Clinical Outcome in Uveitis|Clinical Outcome and Causes of Visual Loss in Uveitis||Moorfields Eye Hospital NHS Foundation Trust|No|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patient data will be gathered from the uveitis clinic at Moorfields Eye Hospital.|September 2015|September 29, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01983488||56537|
NCT01983761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-101-001|Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation|A Phase I/IIa, Open-label, Non-randomized, Study of ASC-101 in Patients With Hematologic Malignancies or Myelodysplastic Syndrome (MDS) Who Are Candidates for Dual-cord Umbilical Cord Blood Transplantation (UCBT)||Targazyme, Inc.|No|Active, not recruiting|November 2013|||March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|1 Year|80 Years|No|||November 2013|November 14, 2013|November 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983761||56516|
NCT01983774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC5640|Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations|Effect of Proton Pump Inhibitors on CF Exacerbations||Columbia University|Yes|Terminated|February 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|November 6, 2013|Yes|Yes|Closed by sponsor of the study; PI has left the institution and Columbia is now the sponsor of    the record|No||https://clinicaltrials.gov/show/NCT01983774||56515|
NCT01984021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483712|Evaluation of the Immediate Effect of Acupuncture on the Upper Trapezius Muscle in Patients With Nonspecific Neck Pain.|Evaluation of the Immediate Effect of Acupuncture on Pain, Cervical Range of Motion and Electromyographic Activity of the Upper Trapezius Muscle in Patients With Nonspecific Neck Pain: Randomized, Single-blinded, Sham-controlled Study.||University of Nove de Julho|Yes|Completed|December 2013|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|40 Years|No|||May 2015|May 29, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984021||56496|
NCT01985295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09RTP|Combined Modality Treatment of Sarcomas of the Extremities|Phase I Clinical Study of a Combined Modality Treatment of Sarcomas of the Extremities With Radiotherapy (RT) and Dose-escalation of Pazopanib|PASART-1|The Netherlands Cancer Institute|No|Completed|June 2010|November 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01985295||56398|
NCT01985308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRT-001|A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism|A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder||Newport Brain Research Laboratory|Yes|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|4 Years|12 Years|No|||April 2014|April 15, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985308||56397|
NCT01985581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES 13-001|Efficacy of Intuniv Extended Release as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD|A Single-Center, Randomized, Double Blind, Placebo-Controlled, Crossover Evaluation of the Effect of INTUNIV Extended Release as Adjunctive Treatment With Stimulant on Executive Function and Quality of Life at Home and School in Children With ADHD||JPM van Stralen Medicine Professional|Yes|Recruiting|October 2013|August 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|12 Years|No|||November 2013|November 10, 2013|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01985581||56376|
NCT01994499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/009/HP|Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion|Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion|VIDMED|University Hospital, Rouen|No|Recruiting|January 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01994499||55692|
NCT01994785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-13-792|Use of Capnography in EGD and Colonoscopy With Moderate Sedation.|Does the Use of Capnography in Routine EGD and Colonoscopy Targeting Moderate Sedation With a Benzodiazepine and Opioid Improve Safety?||The Cleveland Clinic|Yes|Recruiting|November 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|4||Anticipated|372|||Both|18 Years|N/A|No|||December 2013|August 12, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01994785||55671|
NCT01993628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5565|Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))|Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)||University Hospital, Strasbourg, France||Recruiting|October 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|45 Years|N/A|No|||November 2013|November 18, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01993628||55759|
NCT01993940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315V9232|Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy||Shionogi Inc.|Yes|Active, not recruiting|November 2013|||May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993940||55735|
NCT01993368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PP-07|Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis|Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis|PAG|Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01993368||55779|
NCT01994486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20132125|Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1|Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1|STEADFAST|University of Florida|Yes|Completed|December 2013|September 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|November 12, 2013|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01994486||55693|
NCT01991912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEDL|Irrigation Endoscopic Decompressive Laminotomy|Irrigation Endoscopic Decompressive Laminotomy. A New Endoscopic Unilateral Approach for Bilateral Lumbar Decompression: A Blinded Non-randomized Controlled Trial.||Cairo University|No|Completed|June 2009|November 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991912||55891|
NCT01991925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZL-INT-01|Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis|Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|January 2014|||March 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|Phase 1: RAND-modified Delphi Method: experts in the field of hereditary haemochromatosis        Phase 2: Patients with hereditary haemochromatosis|November 2013|November 18, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991925||55890|
NCT01995045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00053514|Postoperative Pain Control Following Vitreoretinal Surgery|The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery||Emory University|Yes|Completed|July 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|89 Years|No|||December 2015|December 28, 2015|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01995045||55651|
NCT01986543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12292 RIFAVIRENZ|Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection|Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection|RIFAVIRENZ|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986543||56302|
NCT01986530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAS-1-MANTZ|Circulating Levels of Irisin in Healthy Young Subjects|Circulating Irisin in Healthy Young Men and Women and Correlation With Lean Body Mass, Fat Mass and Adipocytokines. Circadian and Seasonal Variation and the Effect of Food Intake and Exercise|IRISSAS|424 General Military Hospital|Yes|Completed|November 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|122|Samples Without DNA|Serum|Both|18 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be healthy volunteers of both sexes recruited from the Greek Military        Medical School personnel, Thessaloniki, Greece.|January 2015|January 20, 2015|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01986530||56303|
NCT01982435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACT Study|Safety and Efficacy of Ranibizumab for Diabetic Macular Edema|Safety and Efficacy of Intravitreal Ranibizumab for Diabetic Macular Edema Previously Treated With Intravitreal Bevacizumab: A Randomized Dual Arm Comparative Dosing Trial|REACT|The Cleveland Clinic|Yes|Active, not recruiting|December 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982435||56618|
NCT01982708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-744FM|A Prospective Study of a Haptic Device Evaluation of the Acute Abdomen|A Prospective Study of a Haptic Device Evaluation of the Acute Abdomen||Michigan State University|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency department and inpatient referrals for general surgery evaluation for acute        abdominal presentation|June 2014|June 11, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982708||56597|
NCT01982721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roee_HMO-CTIL|Evaluation of an Acceleration-Based Prosthetic Knee Locking Mechanism for Reducing the Risk of Falling in Transfemoral Amputees|||Hadassah Medical Organization||Not yet recruiting|November 2014|||October 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982721||56596|
NCT01982968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049804|Treatment of IPF With Laparoscopic Anti-Reflux Surgery|Weighing Risks and Benefits of Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis|WRAP-IPF|University of California, San Francisco|Yes|Recruiting|December 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|N/A|N/A|No|||December 2015|December 1, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982968||56577|
NCT01983254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043171|Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers|Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers||Duke University|Yes|Active, not recruiting|October 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01983254||56555|
NCT01984060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AG043319-01A1|Feasibility of an Exercise Intervention|Feasibility of an Exercise Intervention In HIV+ Older Adults|MESH|University of Rochester|No|Active, not recruiting|December 2013|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|45 Years|80 Years|No|||April 2015|April 20, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01984060||56493|
NCT01984294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0133|Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection|A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|No|Completed|October 2013|July 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|November 8, 2013|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01984294||56475|
NCT01984307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CV-1302|A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis|A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis|HELICON|AstraZeneca|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100000|||Both|N/A|N/A|No|Probability Sample|Patient with acute coronary syndrome with a history of MI 1-3 years ago.|May 2014|May 12, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01984307||56474|
NCT01984996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0069|Freedom Inguinal Hernia Repair System Study|Freedom Inguinal Hernia Repair System Study||Insightra Medical, Inc.|No|Active, not recruiting|December 2013|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01984996||56421|
NCT01985321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-H-211|Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores|A Multicenter, Placebo-Controlled, Randomized, Double-Blind Study of the Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Episodic Treatment of Recurrent Herpes Labialis||Topical Remedy||Completed|November 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|469|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|November 8, 2013|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01985321||56396|
NCT01985035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMR-PRO|Influence of Obstrutive Sleep Apnea on Metabolism and Weight Loss in Obese Individuals|Influence of Obstrutive Sleep Apnea on Metabolism and Weight Loss in Obese Individuals||Federal University of São Paulo|No|Recruiting|October 2013|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|90|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985035||56418|
NCT01985594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-2013-407|Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial|STUDY ON EFFICACY OF UTROGESTAN AS TOCOLYSIS FOR PRETERM LABOR|UTROGESTAN|National University of Malaysia|Yes|Not yet recruiting|November 2013|October 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|32|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 10, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985594||56375|
NCT01994265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP/UFMG 2013|Cognitive Impairment Related to Atrial Fibrillation Prevention Trial|Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin|GIRAF|University of Sao Paulo|Yes|Recruiting|October 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|70 Years|N/A|No|||November 2015|November 30, 2015|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01994265||55710|
NCT01995058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-210|Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer|A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer||Exelixis|No|Terminated|December 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|54|||Male|18 Years|N/A|No|||February 2015|February 19, 2015|November 14, 2013|Yes|Yes|Study stopped after results of cabozantinib Phase 3 CRPC study XL184-307.|No||https://clinicaltrials.gov/show/NCT01995058||55650|
NCT01995071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-595|A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)|A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|89|||Both|18 Years|70 Years|No|||June 2015|June 25, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995071||55649|
NCT01995318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAcar - 1|Effectiveness of Kinesiotaping in the Treatment of Acute Ankle Sprains|Effectiveness of Kinesiotaping in the Treatment of Acute Ankle Sprains|KINACAS|Etimesgut Military Hospital|No|Completed|July 2013|November 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||November 2013|March 2, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995318||55630|
NCT01995331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL20102601|Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia|Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia||Chinese Academy of Medical Sciences|Yes|Active, not recruiting|March 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|18 Years|No|||November 2013|November 21, 2013|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995331||55629|
NCT01994239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0160/1204|Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy|A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy|GETUG-AFU22|UNICANCER|Yes|Recruiting|December 2012|June 2025|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|No|||November 2013|November 20, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01994239||55712|
NCT01991665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST-2013-50|R. I. S. POS. T. A|Randomised Italian Sonography for Occiput POSition Trial Ante Vacuum|RISPOSTA|University of Bologna|Yes|Recruiting|January 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991665||55910|
NCT01995344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_DOG14_12|TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment|A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy With Tumour Infiltrating Lymphocytes (TIL) and Assessment of High Versus Low Dose Interleukin-2|METILDA|Christie Hospital NHS Foundation Trust|Yes|Not yet recruiting|October 2013|December 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995344||55628|
NCT01991418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR002|Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)|Early Warning Study of Plasma Thioredoxin Reductase Activity in Non-small Cell Lung Cancers Received Surgery||Hunan Province Tumor Hospital|No|Completed|May 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|165|Samples With DNA|3-4 ml whole blood was obtained and then centrifuged and stored at -20℃.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with resectable non-small lung cancer and received surgery in        Affiliated Cancer Hospital of xiangya School of Medicine Central South University,        HunanPTH|February 2016|February 14, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01991418||55928|
NCT01992185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-DRUG-PHOTOCIL-VT-001|Photocil (Topical) for the Treatment of Vitiligo|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo||Applied Biology, Inc.|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|November 19, 2013||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01992185||55870|
NCT01982461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMB102ROS10-01|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.|A Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Roty F.C. Tablets 10mg Versus Crestor 10mg F.C. Tablets in Patients With Hypercholesterolemia||Pin Siang Medical Biotechnology Co., Ltd.|No|Recruiting|November 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|85 Years|No|||November 2013|November 6, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982461||56616|
NCT01982474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00409|Safety of Lymph Node Injection for Allergen Immunotherapy|Phase I Study of Allergen-Specific Intralymphatic Immunotherapy in the United States||Nationwide Children's Hospital|Yes|Active, not recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|15 Years|24 Years|No|||February 2016|February 5, 2016|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982474||56615|
NCT01982448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-383|Cisplatin vs Paclitaxel for Triple Neg|A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker||Dana-Farber Cancer Institute|Yes|Recruiting|February 2014|June 2021|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982448||56617|
NCT01982734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051113-HS2|Improved Oral Bioavailability of Curcumin Incorporated Into Micelles|Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain||University of Hohenheim|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 5, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01982734||56595|
NCT01982747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGN1703-C04|A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703|A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers||Mologen AG|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|November 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982747||56594|
NCT01982981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINYS 917|Instrument Design and Validation to Asses the Perception of Wellbeing Associated to Plain Water.|Instrument Design and Validation to Evaluate the Perception of Well-being Associated to Plain Water Consumption Among Mexican Adults Residing in the City of "Cuernavaca".||Mexican National Institute of Public Health|Yes|Completed|March 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|142|||Both|21 Years|59 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01982981||56576|
NCT01983280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013 6058 09081008|The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients|The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients: A Prospective Cross Over Trial|Sleep5|Shriners Hospitals for Children|Yes|Completed|October 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|5 Years|21 Years|No|||November 2013|November 20, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01983280||56553|
NCT01983293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60037834|CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients|CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). A Prospective, Randomized, Postmarket, Pilot Study.|ENHANCE CRT|St. Jude Medical|No|Enrolling by invitation|November 2013|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2015|February 2, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01983293||56552|
NCT01983787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-275-13|Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis|Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis||University of Aarhus|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Whole blood|Both|18 Years|50 Years|No|Probability Sample|Patients with Cystic Fibrosis, suffering from acute pulmonary exacerbations.|November 2015|November 6, 2015|July 11, 2013||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01983787||56514|
NCT01984320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92013|Cabergoline and Coasting to Prevent OHSS|Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial|OHSS|Cairo University|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|300|||Female|20 Years|35 Years|No|||December 2015|December 15, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01984320||56473|
NCT01984632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO04|Barbed Suture in Single-port Laparoscopic Myomectomy|Single-port Laparoscopic Myomectomy Using Barbed Suture Versus Multi-port One: a Multi-center Randomized Controlled Trial||CHA University|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|55 Years|No|||July 2015|July 30, 2015|November 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984632||56449|
NCT01985282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.33.NRC|Feasibility Clinical Study of NLA Tool|Evaluate the Feasibility of the NLA Tool, a Combined Assessment of Nutritional and Physical Functional Status, to Provide Personalized Advice for the Independence and Mobility of Elderly.||Nestlé|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|250|||Both|65 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Free-living or institutionalized elderly (65-90years)|November 2013|November 8, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01985282||56399|
NCT01985022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064779|Changing Developmental Trajectories Through Early Treatment|Autism Center of Excellence: Project 3 - Changing Developmental Trajectories Through Early Treatment||Emory University|Yes|Recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|9 Months|24 Months|No|||January 2016|January 7, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985022||56419|
NCT01989494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001171|Study of the Physical Activity in Anesthesiologists|Evaluation of the Physical Activity Associated With Clinical Work in Anesthesia Residents and Attendings||Brigham and Women's Hospital|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective observational and retrospective survey study of the physical        activity of the anesthesiologists, which would require subjects to wear pedometer in five        consecutive days at work as well as recall their physical activity in the past seven-day        week.|February 2015|February 19, 2015|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01989494||56076|
NCT01985334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A3401|Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen|A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen||Novartis|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|4470|||Both|40 Years|N/A|No|||February 2016|February 9, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985334||56395|
NCT01994278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-038A|Comparison of Soft Toothbrush and Brushless Cleaner in Their Ability to Remove Plaque From Teeth|Comparison of Soft Toothbrush and Brushless Cleaner in Their Ability to Remove Plaque From Teeth||Peri-Swab, LLC|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|November 19, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01994278||55709|
NCT01994525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-22|Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites|Phase 1 Trial With Challenge to Assess the Safety and Biomarkers of Protection in Malaria-naïve Adults of Immunization Via Mosquito Bite With Radiation-Attenuated Plasmodium Falciparum Sporozoites (IMRAS)|IMRAS|U.S. Army Medical Research and Materiel Command|No|Recruiting|December 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994525||55690|
NCT01994512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS 01|Swedish Spinal Stenosis Study|Swedish Spinal Stenosis Study. An RCT Comparing Decompression With Fusion to Decompression Only in Lumbar Spinal Stenosis With or Without Degenerative Olisthesis.|SSSS|Uppsala University|No|Completed|October 2006|June 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|50 Years|80 Years|No|||December 2015|December 16, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994512||55691|
NCT01994798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T122E2|Rapid Exchange Devices Observational Registry.|Prospective, Non-randomized, Multicentre, Observational Registry to Assess Clinically Relevant Benefit of Performing the Whole PTA Procedure Using the Rapid Exchange (RX) Devices.|RXRegistry|Terumo Europe N.V.|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|525|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with one lesion located in Superficial Femoral Artery(SFA) or popliteal artery        planned to be treated as per hospital practice with plain old balloon angioplasty and        nitinol stent using monorail (rapid exchange) delivery system.|September 2015|September 10, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994798|30 Days|55670|
NCT01991405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI Working Memory Training.|Memory Aid - Working Memory Training in Patients With Mild Cognitive Impairment.|Memory Aid - Computer Based Working Memory Training in Elderly With Mild Cognitive Impairment (MCI). A Randomized, Controlled Trial.|MCI|Sorlandet Hospital HF|No|Recruiting|August 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|90|||Both|55 Years|N/A|No|||May 2014|May 22, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991405||55929|
NCT01971164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ951-U-12-004|Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease|Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease||Akros Pharma Inc.|No|Completed|May 2013|July 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|75 Years|No|||July 2014|July 11, 2014|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971164||57482|
NCT01971177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304|Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure|A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure||Technolas Perfect Vision GmbH|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|40 Years|N/A|No|||March 2014|March 13, 2014|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971177||57481|
NCT01962584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/13|CMR in Patients With Myocarditis|Value of CMR Including T1 Mapping in Patients With Acute Myocarditis||University Hospital, Bonn|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with suspected acute myocarditis and otherwise unremarkable cardiac history        exclusion of CAD in invasive coronary angiography|December 2015|December 9, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01962584||58138|
NCT01973036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0379|FOLCROM Trial: Foley Catheter in Rupture of Membranes|Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)|FOLCROM|Geisinger Clinic|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|March 9, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01973036||57338|
NCT01972451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCTU065|Feasibility of Reduction in Right Sided Bowel Cancer Through Contrast Enhanced Colonoscopy|A Feasibility Randomised Controlled Trial (RCT) of Contrast Enhanced vs Non-enhanced Colonscopy in Index Bowel Cancer Screening to Reduce Bowel Cancer Mortality|CONSCOP|Cardiff University|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1320|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01972451||57383|
NCT01972139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTN-4|Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4|Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4|HTN-4|Medtronic Vascular|Yes|Active, not recruiting|October 2013|February 2017|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||October 2015|October 15, 2015|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972139||57407|
NCT01972152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSGP-201|Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia|A RANDOMIZED, PHASE 2, DOUBLE-BLIND, 3-WAY CROSSOVER STUDY WITH G-PEN™ (GLUCAGON INJECTION) TO EVALUATE SAFETY, TOLERABILITY AND COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS TO LILLY GLUCAGON™ (GLUCAGON FOR INJECTION [rDNA ORIGIN]) IN HEALTHY VOLUNTEERS||Xeris Pharmaceuticals|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 18, 2013|Yes|Yes||No|November 20, 2015|https://clinicaltrials.gov/show/NCT01972152||57406|
NCT01973023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1687472|Stroke's Gait Pattern Modifications of Induced by Repeated BTI|Improvement of Chronic Stroke Patients Gait Pattern Following Repetitive Multifocal Botulinum Toxin Injection Sessions in Paretic Lower Limb: an Observational Study.||Centre d'Investigation Clinique et Technologique 805|No|Completed|July 2013|January 2014|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|STROKE PATIENTS|March 2014|March 1, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01973023||57339|
NCT01973231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3867|Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes|LIRA-LIXI™|Novo Nordisk A/S|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|404|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|October 23, 2013|Yes|Yes||No|November 18, 2015|https://clinicaltrials.gov/show/NCT01973231||57323|
NCT01972126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Magnitude|MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction|MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction|MAGNITUDE|Medtronic Bakken Research Center|No|Terminated|September 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with acute MI and LVEF between 36% and 50%, and QRS Fragmentation assessed by MFI        within 3 to 10 days post-MI|January 2016|January 11, 2016|October 24, 2013||No|Manufacturer of the MFI QRS Fragmentation Systems used in the study, has filed for insolvency|No||https://clinicaltrials.gov/show/NCT01972126||57408|
NCT01970371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-007|A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)|A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)|CARE|Achaogen, Inc.|Yes|Recruiting|September 2014|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|85 Years|No|||November 2015|November 10, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970371||57542|
NCT01970098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1301|A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||March 2015|Anticipated|Phase 3|Interventional|N/A|2||||||Both|20 Years|N/A||||October 2013|October 22, 2013|October 22, 2013||||No||https://clinicaltrials.gov/show/NCT01970098||57563|
NCT01970111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1302|An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||September 2015|Anticipated|Phase 3|Interventional|N/A|1||||||Both|20 Years|N/A||||October 2013|October 22, 2013|October 22, 2013||||No||https://clinicaltrials.gov/show/NCT01970111||57562|
NCT01990066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046121|Home Based Exercise Program for Elderly Cancer Patients|Single Institution Randomized Controlled Study of a Home Based Exercise Program to Reduce Functional Decline, Cancer Related Fatigue (CRF and Improve Quality of Life for the Elderly Gynecologic Oncology Patient)||Duke University|Yes|Terminated|March 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|8|||Female|65 Years|N/A|No|||November 2014|December 23, 2014|November 15, 2013||No|Difficulty recruiting adequate enrollment|No||https://clinicaltrials.gov/show/NCT01990066||56032|
NCT01990053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013B0307|Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression|Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression||Ohio State University|No|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01990053||56033|
NCT01990898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1271|Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action|Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action|CIC|The Cleveland Clinic|Yes|Completed|November 2013|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||October 2014|January 27, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01990898||55968|
NCT01991171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE14385813.1.0000.5512|Effectiveness of the Kinesio Taping® in Muscle Activation|Effectiveness of the Kinesio Taping® in Activation of Quadriceps Muscle and Reflex Inhibition of Hamstrings Muscle: Randomized Controlled Trial|EKTAQRIH|Paulista University|No|Completed|May 2013|November 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|48|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991171||55947|
NCT01986933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM003JG|A Phase 2 Study of CIM331 for Atopic Dermatitis Patients|A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY||Chugai Pharmaceutical|Yes|Active, not recruiting|November 2013|June 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|264|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986933||56272|
NCT01991184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29089|A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.|AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA||Genentech, Inc.||Active, not recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991184||55946|
NCT01991197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPIDM-2012-01|Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.|Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.|DIP|University College Dublin|Yes|Active, not recruiting|April 2014|July 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01991197||55945|
NCT01987206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11 C2T|Feasibility Study of PID Versus MPC and HMS|Feasibility Study of Using a PID (Proportional-Integral-Derivative) Controller Versus an MPC (Model Predictive Control) Controller Algorithm and Health Monitoring System (HMS)||William Sansum Diabetes Center||Active, not recruiting|July 2014|||January 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|November 17, 2014|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01987206||56251|
NCT01986946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041252|Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions|A Comparison of Epidural Analgesia With Standard Care Following Lumbar Spinal Fusion: A Prospective Randomized Study||Duke University|No|Terminated|October 2013|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|January 3, 2013|Yes|Yes|Lack of recruitment.|No||https://clinicaltrials.gov/show/NCT01986946||56271|
NCT01984788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4161-203|Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE|A Phase 2a Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Safety and Efficacy of BCX4161 as a Prophylactic Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema|OPuS-1|BioCryst Pharmaceuticals|Yes|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|65 Years|No|||August 2014|August 14, 2014|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984788||56437|
NCT01984801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117225|Study to Investigate the Irritation Potential of GSK1940029 Gel|A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients||GlaxoSmithKline|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01984801||56436|
NCT01984814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-04|Stem Cell Therapy for Amyotrophic Lateral Sclerosis|The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on the Survival Duration in Amyotrophic Lateral Sclerosis - A Retrospective Control Study||Neurogen Brain and Spine Institute|Yes|Completed|December 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|26 Years|76 Years|No|||November 2013|November 14, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984814||56435|
NCT01970917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-190313|Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects|Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects||Medical University of Vienna|Yes|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01970917||57500|
NCT01971190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFECT_001|Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy|Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy||Asan Medical Center|No|Completed|October 2013|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|60 Years|No|||June 2015|June 24, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01971190||57480|
NCT01971398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTO1 2005-999-01|Development of Education Materials for Prevention of FAS in Russia|Development of Education Materials for Prevention of Fetal Alcohol Syndrome (FAS) in Russia||University of Oklahoma|No|Completed|April 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|422|||Female|18 Years|44 Years|No|||October 2013|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971398||57464|
NCT01971619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0424|Association of Vitamin D, Parathyroid Hormone and Fibroblast Growth Factor-23 With Infarction-related Arrhythmia in Patients With Acute Myocardial Infarction|||Yonsei University|No|Recruiting|August 2013|August 2015|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|510|Samples With DNA|plasma blood sample (5ml)|Both|20 Years|90 Years|No|Probability Sample|patients with acute myocardial infarction|October 2013|October 28, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971619||57447|
NCT01973283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6470|Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults|Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults||New York State Psychiatric Institute|No|Recruiting|September 2011|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|60 Years|95 Years|No|||October 2013|June 5, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973283||57319|
NCT01973257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612091R|Perfusion and Diffusion Mechanism of Intervertebral Disc-Significance With Age, Degeneration, Posture and Stress Loading.|Perfusion and Diffusion Mechanism of Intervertebral Disc-Significance With Age, Degeneration, Posture and Stress Loading.||National Taiwan University Hospital||Completed|August 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|50|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01973257||57321|
NCT01973270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH102063-01|Community-Based Cognitive Training in Early Schizophrenia|Community-Based Cognitive Training in Early Schizophrenia|COTES|University of California, San Francisco|Yes|Recruiting|December 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|125|||Both|18 Years|35 Years|No|||May 2015|May 14, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01973270||57320|
NCT01972685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044455|Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)|Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)||Duke University|No|Recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01972685||57365|
NCT01972672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QU1305ICR|The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma|An Open-label,Single-arm Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma||Beijing Shenogen Biomedical Co., Ltd|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||January 2015|January 27, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01972672||57366|
NCT01970384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-140|Transcranial Direct Current Stimulation for Dysphagia Therapy in Acute Stroke Patients|Transcranial Direct Current Stimulation for Dysphagia Therapy in Acute Stroke Patients||University Hospital Muenster|Yes|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||October 2015|October 12, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970384||57541|
NCT01970397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-JUV13001|JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines|A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel Versus Belotero Balance® for Perioral Lines||Allergan|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|35 Years|N/A|No|||August 2015|August 5, 2015|October 23, 2013|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01970397||57540|
NCT01970670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0031|Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer|Contrast-Enhanced Digital Mammography (CEDM) vs Contrast-Enhanced Breast MRI (CE-MRI) in Patients With Known Breast Cancer||Stanford University|No|Recruiting|April 2015|||April 2017|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|70 Years|No|Non-Probability Sample|Adult women, ages18-70 years old, of any race and ethnicity, with a recent diagnosis of        breast cancer (histologically confirmed invasive and/or in situ carcinoma of the        breast)who have not undergone surgery, are not planned to undergo neoadjuvant        chemotherapy; and have a CE-MRI within 1 month(31 days) of enrollment.|April 2015|April 20, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970670||57519|
NCT01982864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12008 DIAMS|Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.|Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.|DIAMS|University Hospital, Limoges|No|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01982864||56585|
NCT01990339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|467-531|Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms|Takepron Specified Drug-use Survey "Gastroesophageal Reflux Disease With Dyspepsia Symptoms"|LEGEND|Takeda|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14965|||Both|N/A|N/A|No|Non-Probability Sample|Gastroesophageal reflux disease with dyspepsia symptoms|November 2014|November 4, 2014|November 15, 2013||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01990339||56011|There were no control groups in this single-arm study. The observed subjective symptom improvement rates and frequency of adverse drug reactions may be used in an exploratory manner to understand drug use but cannot be treated as verified results.
NCT01990326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XAF5 B1|Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat||Topokine Therapeutics, Inc.|No|Suspended|November 2013|||June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||July 2014|February 26, 2016|November 1, 2013|Yes|Yes|Feasibility cohorts competed. Efficacy cohort not initiated for business reasons|No||https://clinicaltrials.gov/show/NCT01990326||56012|
NCT01990638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701193|Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery|Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery||National Taiwan University Hospital|No|Completed|November 2004|May 2005|Actual|April 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|51|Samples Without DNA|fasting glucose|Both|20 Years|70 Years|No|Non-Probability Sample|patients after coronary artery bypass surgery|November 2013|November 15, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990638||55988|
NCT01990911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDPAF1|Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study|Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study|RDPAF|Pace Clinic|Yes|Recruiting|March 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|55 Years|N/A|No|||April 2015|April 28, 2015|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01990911||55967|
NCT01991210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28609|A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer|A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER||Genentech, Inc.||Active, not recruiting|February 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991210||55944|
NCT01986673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-6006-001-01|Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults|||Strategic Science & Technologies, LLC||Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986673||56292|
NCT01986959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Periodontal dressing 1246|Periodontal Dressing After Surgical Crown Lengthening|Periodontal Dressing After Surgical Crown Lengthening: A Randomized Clinical Trial||Franciscan University Center|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 12, 2013|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01986959||56270|
NCT01985425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COP-AF Pilot|Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study|Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study.|COP-AF Pilot|McMaster University|No|Completed|April 2014|September 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01985425||56388|
NCT01970293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA021732-01A1|AA Linkage for Alcohol Abusing Women Leaving Jail|AA Linkage for Alcohol Abusing Women Leaving Jail||Butler Hospital|Yes|Recruiting|October 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01970293||57548|
NCT01970930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0481|Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients|Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53||Icahn School of Medicine at Mount Sinai|No|Recruiting|August 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|CD34+ cells isolated from the peripheral blood Splenic CD34+ cells|Both|N/A|N/A|No|Non-Probability Sample|Patients who have polycythemia vera or essential thrombocythemia|January 2016|February 1, 2016|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01970930||57499|
NCT01971203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0807|Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat|Double-blind, Randomized, Active Controlled Study of the Efficacy and Safety of Extended-release Quetiapine Fumarate (Seroquel XR) as Adjunctive Medication Therapy to Cognitive Behavioral Therapy in the Treat,Ent of Patients With Comorbid Major Depression and Generalized Anxiety Disorder||Icahn School of Medicine at Mount Sinai|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||October 2013|October 23, 2013|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971203||57479|
NCT01971424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011491|Assessment of Physical Performance After Oral Supplementation of Magnesium in a Sample of Old Women in Good Health||Magnesium|University of Padova|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Female|65 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971424||57462|
NCT01971671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.14.NRC|Evaluation of the Nutrients Composition of Breast Milk of Chinese Lactating Mothers and Their Nutrition Intake|Evaluation of the Nutrients Composition of Breast Milk of Chinese Lactating Mothers and Nutrition Intake of Chinese Pregnant and Lactating Mothers, Infants and Young Children|MING|Nestlé|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|560|Samples Without DNA|breask milk sample.|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy Chinese lactating mother 0-270 days after delivery (inclusive) will be enrolled.|October 2013|October 23, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01971671||57443|
NCT01971411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT.D.DEF.1|Vitamin D Deficiency in Elderly African American Women in Central Texas|Vitamin D Deficiency in Elderly African American Women in Central Texas||McLennan County Medical Education and Research Foundation|Yes|Completed|March 2006|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||60|||Female|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African American females aged 70 years or older and non-institutionalized|October 2013|October 23, 2013|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971411||57463|
NCT01973062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4413|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma|Phase II Study of Radioimmunotherapy With Zevalin (Ibritumomab Tiuxetan) Therapy for Patients With Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)||Case Comprehensive Cancer Center|Yes|Terminated|March 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|October 25, 2013|Yes|Yes|Funding Unavailable|No||https://clinicaltrials.gov/show/NCT01973062||57336|
NCT01973517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27423-001|High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases|7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases||Stanford University|No|Suspended|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Population will be composed of patients with the diagnosis of relapsing remitting multiple        sclerosis (MS) who are followed at the Stanford Neurosciences Clinic.|July 2015|July 1, 2015|October 16, 2013|Yes|Yes|Logistical factors affecting recruitment|No||https://clinicaltrials.gov/show/NCT01973517||57301|
NCT01969487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU_00074621|Effect of Preoperative Simulator Warmup on Intraoperative Robotic Surgical Skills|Effect of Preoperative Warmup on a Simulator by Trainee Surgeons on Intraoperative Robotic Surgical Skill and Postoperative Patient Outcomes||Johns Hopkins University|No|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01969487||57609|
NCT01973504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-207|Phase 2c Dose Comparison Study of MP4OX in Trauma|A Multi-center, Multinational, Randomized, Double-blind, Controlled, Dose Comparison Study to Evaluate Safety and Efficacy of MP4OX Plus Standard Treatment, in Severely Injured Trauma Subjects With Lactic Acidosis Due to Hemorrhagic Shock||Sangart|Yes|Withdrawn|December 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|August 20, 2013||No|Sangart ceased operations|No||https://clinicaltrials.gov/show/NCT01973504||57302|
NCT01969461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA022891-01|Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth|Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth||Wayne State University|Yes|Not yet recruiting|July 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|16 Years|24 Years|No|||October 2013|October 21, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969461||57611|
NCT01969474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.01|Effectiveness of Cannabis in the Treatment of Tinnitus Patients|Phase 1 Study to Study the Efficacy and Safety of Cannabis in the Treatment of Tinnitus||Wolfson Medical Center|No|Suspended|December 2013|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|N/A|No|||December 2015|December 19, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01969474||57610|
NCT01973244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4042|A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency|A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|December 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|6 Years|13 Years|No|||March 2015|March 25, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973244||57322|
NCT01969435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312115|Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma|A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation||Washington University School of Medicine|No|Active, not recruiting|March 2014|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|October 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969435||57613|
NCT01970683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2013-132|Probiotics and Recovery From Surgery|Effect of Perioperative Probiotics on Clinical Outcomes of Patients Undergoing Major Abdominal Operation in Community Settings.|PROGRESS|Catholic Health Initiatives|No|Recruiting|August 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|172|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970683||57518|
NCT01983150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19275|A Randomized Controlled Trial to Test the Effect of a Smartphone Quit Smoking Intervention on Young Adult Smokers|Effect of a Smartphone Intervention on Quitting Smoking in a Young Adult Population of Smokers: A Randomized Controlled Trial||University of Waterloo|Yes|Completed|January 2014|November 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1601|||Both|19 Years|29 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983150||56563|
NCT01983410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-217|A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma|A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|November 2013|||November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|Samples With DNA|Blood specimens tumor tissue samples will be requested|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|BRCA mutation carriers with PDAC will be identified by the PIs, co-investigators and by        the research staff at all participating sites.|November 2015|November 24, 2015|November 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01983410|3 Years|56543|
NCT01983124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004172-18|Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib|A Phase II Single-arm Study for the Treatment After Recurrence of Advanced Melanoma Patients Harboring the V600BRAF Mutation and Pretreated With Vemurafenib, With the Association of Vemurafenib Plus Fotemustine.|BeyPro1|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|February 2013|September 2015|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983124||56565|
NCT01983137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN9510|A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain.|The Efficacy, With Regard to Pain Relief, of Targinact® Treatment for Patients With Severe Pain Compared to Previous Analgesic Treatment; a Non-interventional Study.||Mundipharma CVA|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1338|||Both|18 Years|N/A|No|Non-Probability Sample|GPs and specialists|November 2013|November 6, 2013|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01983137||56564|
NCT01990651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15847|Study of Use of CTC in NSCLC|The Use of Circulating Tumor Cells in Non-Small Cell Lung Cancer: Novel Isolation Methods and Clinical Applications||University of Virginia|Yes|Recruiting|September 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|November 2013|November 15, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990651||55987|
NCT01990924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7.5 vs 15 Cine|Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention|Low Rate Fluoroscopy at Reducing Operator and Patient Radiation Dose During Transradial Coronary Diagnostic Angiography and Interventions||Laval University|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|385|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01990924||55966|
NCT01990937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-031|Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD)|Effectiveness of Oral Midazolam for Sedation in Patients Undergoing Upper Gastrointestinal Endoscopy||Phramongkutklao College of Medicine and Hospital|No|Recruiting|October 2013|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|70 Years|No|||October 2014|October 27, 2014|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01990937||55965|
NCT01986686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB1956|Recurrence Following CT-guided Drainage of 1st Episode Hinchey II Diverticulitis|Diverticulitis: A Randomized Controlled Trial||Stony Brook University|Yes|Recruiting|October 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients with successfully treated first episode diverticulitis and intraabdominal        abscess|May 2015|May 26, 2015|August 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01986686||56291|
NCT01984437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP020|Registry of the Magellan Robotic System|The Robotic Vascular and Endovascular Registry (ROVER)|ROVER|Hansen Medical|No|Recruiting|November 2013|||November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects must be diagnosed with vascular disease in the peripheral vasculature, meet all        inclusion and no exclusion criteria, and be willing to comply with all protocol testing        and follow-up.|September 2015|September 10, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984437|14 Days|56464|
NCT01970592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O0844-R|Power Training Post-stroke|Skeletal Muscle Plasticity As An Indicator of Functional Performance Post-Stroke||VA Office of Research and Development|No|Recruiting|October 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970592||57525|
NCT01972178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 4016 13202|Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia||Pronova BioPharma|Yes|Terminated|November 2013|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|79 Years|No|||October 2015|October 7, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972178||57404|
NCT01972191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0049|Comparison of Three Corneal Horizontal Marking Techniques Using iTrace™|||Yonsei University|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|156|||Both|50 Years|86 Years|Accepts Healthy Volunteers|Probability Sample|Who visited professor Tae Im Kim's clinic, department of ophthalmology, Severance        hospital.|October 2013|October 23, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01972191||57403|
NCT01972464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA035924|Progesterone for Postpartum Smokers|Progesterone for Postpartum Smokers: Feasibility, Breastfeeding and Infant Safety||Yale University|Yes|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972464||57382|
NCT01971931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioBone01|Prospective Evaluation of Biomarkers Variability in Knee Prosthetic Surgery|Prospective Evaluation of Biomarkers Variability in Knee Prosthetic Surgery||University of Milan|No|Active, not recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Serum, tibial bone biopsy.|Both|40 Years|80 Years|No|Non-Probability Sample|Patients undergoing TKR surgery.|February 2016|February 16, 2016|July 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01971931||57423|
NCT01973309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18R5-002|A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer|A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|September 2013|September 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Female|18 Years|90 Years|No|||June 2015|September 8, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973309||57317|
NCT01973296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200390|Implementing an Emergency Department to Home Care Transition Intervention|Implementing an Emergency Department to Home Care Transition Intervention||University of Florida|Yes|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|62|||Both|60 Years|N/A|No|||January 2015|January 22, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01973296||57318|
NCT01973530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHJRC_HK_TKR_Study_2014|Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR)|Comparison of the Analgesic Efficacy of Continuous Femoral Nerve Block and Adductor Canal Block With Steroid Adjuvant in Patients Undergoing Total Knee Arthroplasty||Queen Elizabeth Hospital, Hong Kong|Yes|Not yet recruiting|October 2014|June 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||September 2014|September 8, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973530||57300|
NCT01969812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evie 2013|Tolerability and Satisfaction With Evie|Patient Satisfaction and Tolerability With the Evie® Slow-Release Insemination Device: Pilot Study||Carolinas Healthcare System|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969812||57584|
NCT01969825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Massage2013|The Role of Massage in Increasing Total Motile Sperm Count of IUI|The Role of Massage in Increasing Total Motile Sperm Count of Intrauterine Insemination||Carolinas Healthcare System|No|Completed|December 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969825||57583|
NCT01969786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10EY02280|Village Integrated Eye Workers Trial|Village Integrated Eye Workers Trial|VIEW|University of California, San Francisco|Yes|Recruiting|February 2014|August 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|216000|||Both|N/A|N/A|No|||December 2015|December 9, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969786||57586|
NCT01969799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-01-102|Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia|A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)|IASIS|Cardeas Pharma|Yes|Active, not recruiting|December 2013|April 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969799||57585|
NCT01971502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of BI 1060469 in Healthy Male Volunteers (Single-blind, Placebo-controlled, Randomised, Partly Fixed-sequence, Parallel Group Design) and Effect of Food on the Bioavailability of BI 1060469 (Open-label, Randomised, Two-way Cross-over)||Boehringer Ingelheim||Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|October 24, 2014|October 8, 2013||||No||https://clinicaltrials.gov/show/NCT01971502||57456|
NCT01971515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR100018-001|First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies|A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies||EMD Serono||Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971515||57455|
NCT01983631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-1184B|The Effect of Whole Body Vibration Training on Neuromuscular Property in Individuals With Ataxia|||Chang Gung University|Yes|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|17|||Both|20 Years|N/A|No|||November 2013|November 13, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983631||56526|
NCT01983397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ansai-01|Effects of Two Physical Exercise Protocols on Cognition and Physical Performances in Elderly Over 80 Years|Effects of Two Physical Exercise Protocols on Cognition and Physical Performances in Oldest Old: a Randomized Controlled Trial||Universidade Federal de Sao Carlos|Yes|Completed|August 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|80 Years|95 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01983397||56544|
NCT01983618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.226|Impact of Interscalene Nerve Block on Cerebral Perfusion During Surgery in the Beachchair Position|Impact of Interscalene Nerve Block on Cerebral Perfusion During Surgery in the Beachchair Position Under General Anesthesia||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|February 2014|September 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983618||56527|
NCT01983904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20948|DBS for Treatment Resistant Depression|Therapeutic Brain Stimulation for Refractory Depression|CRIO-DBS|University of Calgary|No|Recruiting|August 2013|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|20 Years|60 Years|No|||November 2015|November 30, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01983904||56505|
NCT01984151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050016|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2017|||||N/A|N/A|N/A||||||||||||||January 25, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984151||56486|
NCT01985113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR001|Correlation Research of Thioredoxin Reductase in Lung Cancer|Correlation Study of Blood and Tissue Thioredoxin Reductase Activity in Early Stage On-small Cell Lung Cancers|TRCRLC|Hunan Province Tumor Hospital|No|Completed|May 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|165|Samples With DNA|tumor tissue and lung benign mass are obtained in surgery, and blood serum before surgery      and 3-5 days after surgery, blood should be taken and centrifuged then stored at -20 degree,      tumor tissue and lung benign mass should be stored at -180 degree within 5 mins during      surgery.|Both|18 Years|80 Years|No|Probability Sample|Patients with early staged NSCLC and lung benign lesion Patients show resectable lung mass        in CT scan, suspected lung cancer and receive surgery in Affiliated Cancer Hospital of        Xiangya School of Medicine Central South University|February 2016|February 14, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985113||56412|
NCT01970605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1310|Silver Graft All Comers Registry|Silver Graft All Comers Registry is to Assess the Long Term Clinical Benefit of Silver Graft in an Unselected Patient Population||B. Braun Melsungen AG|Yes|Recruiting|October 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Patients with PAOD Fontaine classification > IIa Patients in need of aneurysm repair        Patients in need of revisions, i.e. graft infections|February 2016|February 26, 2016|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970605||57524|
NCT01972477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1449-0111|DLBS1449 in Diabetic Patients With Low HDL|The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo||Dexa Medica Group|Yes|Not yet recruiting|July 2016|January 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|21 Years|70 Years|No|||February 2016|February 10, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972477||57381|
NCT01972724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-9999-301-KR|Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy|A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)|ADD|Takeda|No|Active, not recruiting|January 2014|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|114|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972724||57362|
NCT01972737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13S.462|Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer|A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients||Thomas Jefferson University|Yes|Active, not recruiting|October 2013|December 2018|Anticipated|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|October 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01972737||57361|
NCT01972750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258ADE02T|Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma|The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma|TKI258|University Hospital, Bonn|Yes|Recruiting|October 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972750||57360|
NCT01972698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCUS-Toronto01|Focused Cardiac and Lung Ultrasound in Anesthesia/Critical Care - The Role of Self-directed Simulation-assisted Training Compared to a Traditional Supervised Approach|Focused Cardiac and Lung Ultrasound in Anesthesia/Critical Care - The Role of Self-directed Simulation-assisted Training Compared to a Traditional Supervised Approach||St. Michael's Hospital, Toronto|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972698||57364|
NCT01972711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP361-104|Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics|A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.||Sunovion|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972711||57363|
NCT01973543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-1101|AADC Gene Therapy for Parkinson's Disease|An Open-label Safety and Efficacy Study of AAV2-hAADC Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa|AADC|Voyager Therapeutics|Yes|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|40 Years|70 Years|No|||December 2015|December 28, 2015|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973543||57299|
NCT01973556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20095191|Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project|Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project||University of California, San Diego|No|Completed|July 2010|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|75|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973556||57298|
NCT01969864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60MD00265DT3|University Student Intervention to Increase Organ Donation|College and University Student Intervention to Increase Consent for Organ Donation||Case Western Reserve University|No|Recruiting|October 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Anticipated|1200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969864||57580|
NCT01969877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2012-001879-37|A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.|A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.|ARTSCANIII|Lund University Hospital|No|Recruiting|November 2013|||November 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|618|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01969877||57579|
NCT01969500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH100195-01|Development of a Mobile System for Self-management of Schizophrenia (SOS)|Development of a Mobile System for Self-management of Schizophrenia (SOS)||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01969500||57608|
NCT01969838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-352-0101|Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis|A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|Simplify 1|Gilead Sciences|Yes|Recruiting|January 2014|April 2021|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969838||57582|
NCT01970059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWDLEH2012|A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension|Efficacy and Safety Comparison of Extended-Release Carvedilol Sulfate and Sustained-release Metoprolol Succinate in Patients With Hypertension||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|October 2013|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|302|||Both|18 Years|70 Years|No|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970059||57565|
NCT01970358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-240|A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma|A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma||Dana-Farber Cancer Institute|Yes|Recruiting|January 2014|September 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970358||57543|
NCT01984190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version date: 9 -8 -10|Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty|ActiveCare+S.F.T® Outcomes Registry (ACOR)|ACOR|Medical Compression Systems|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|411|||Both|18 Years|N/A|No|Probability Sample|The registry will include all Adult patients scheduled for elective unilateral total hip        arthroplasty (THA) or total knee arthroplasty (TKA), or unicondylar knee arthroplasty        (UKA), where the orthopaedic surgeon is using the ActiveCare+S.F.T® mobile compression        device as a monotherapy for venous thromboembolism prevention.|November 2013|September 3, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984190|3 Months|56483|
NCT01983917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001117|Mobile Application to Enhance Diabetic Care|Clinical Trial of Mobile Application to Enhance Diabetic Health Care||University of California, Los Angeles|No|Recruiting|September 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|14 Years|75 Years|No|||November 2013|November 7, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01983917||56504|
NCT01983930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000821|Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment|Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment||University of California, Los Angeles|Yes|Recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Both|55 Years|90 Years|No|||December 2014|December 5, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01983930||56503|
NCT01984177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/2012|Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence|Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence: A [11C]-(+)-PHNO PET Investigation||Centre for Addiction and Mental Health|No|Suspended|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|whole blood|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|CD subjects are recruited from the local community using flyers and internet        advertisements, and through referral from local clinical programs. CD subjects are        recruited from the community using flyers and internet advertisements.|September 2015|September 4, 2015|October 9, 2013||No|awaiting protocol revision approval|No||https://clinicaltrials.gov/show/NCT01984177||56484|
NCT01984164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070087|CAndesartan vs LIsinopril Effects on the BRain|CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)|CALIBREX|Emory University|Yes|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|55 Years|N/A|No|||January 2016|January 23, 2016|October 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984164||56485|
NCT01984450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKRF 002|A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC|A Study to Compare Two Articular Cartilage Repair Techniques in the Knee Joint: Autologous Collagen Induced Chondrogenesis (ACIC) Vs. Mesenchymal Cell Induced Chondrogenesis (MCIC).||Shetty-Kim Research Foundation|Yes|Not yet recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2013|November 13, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01984450||56463|
NCT01984827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPL-01-12|Effect of Glucose on QTc Interval in Type 1 Diabetes|A Crossover Study to Evaluate the Effect of Glucose on Cardiac Repolarisation Using a Glucose Clamp and a Single 400 mg Dose of Moxifloxacin as a Positive Control in Male and Female Patients With Type I Diabetes||Richmond Pharmacology Limited|No|Not yet recruiting|March 2014|August 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|20 Years|64 Years|No|||November 2013|November 14, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984827||56434|
NCT01985438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKMCHRC-IRB-13-15|A Trial Comparing Two Modalities of Prophylactic Nutritional Support During Treatment for Head and Neck Cancer|Prophylactic Nutritional Support During Treatment for Head and Neck Cancer: A Single-Center, Open-label, Prospective, Randomized, Controlled Trial Comparing Feeding With Percutaneous Endoscopic Gastrostomy Tubes and Nasogastric Tubes|PRONUS|Shaukat Khanum Memorial Cancer Hospital & Research Centre|No|Recruiting|November 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01985438||56387|
NCT01971684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00008709|ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP|ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia|ICON1|Children's Hospital Boston|Yes|Recruiting|August 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|1 Year|18 Years|No|Non-Probability Sample|Pediatric refractory ITP patients starting on a new second line therapy|August 2015|August 25, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01971684||57442|
NCT01972230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17713|Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery|||Regina Elena Cancer Institute|Yes|Recruiting|January 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|75 Years|No|||November 2014|November 5, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972230||57400|
NCT01972243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI316|Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model|Identification of Patients at Low Risk of Recurrent Venous Thromboembolism After Stopping Anticoagulant Treatment: A Prospective Multicenter Cohort Study (Validation of the Vienna Prediction Model)||Medical University of Vienna||Recruiting|September 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|first unprovoked deep vein thrombosis or pulmonary embolism|October 2013|October 29, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972243||57399|
NCT01972490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCMCC|Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer|Study of Avastin in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer|ACCMCC|Fudan University|Yes|Recruiting|June 2011|March 2016|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||December 2014|December 9, 2014|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972490||57380|
NCT01972763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28904|Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.||RESCUE|Northern California Retina Vitreous Associates||Recruiting|October 2013|||September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|October 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01972763||57359|
NCT01973049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-113|UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis|A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis||Bristol-Myers Squibb|No|Completed|December 2013|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|202|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973049||57337|
NCT01969513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R13/029-1|Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo|Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Posterior Canal Benign Paroxysmal Positional Vertigo||Jordi Gol i Gurina Foundation|Yes|Recruiting|January 2013|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01969513||57607|
NCT01970163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-001|DermACELL in Subjects With Chronic Wounds of the Lower Extremities|A Multicenter, Randomized, Controlled, Open Label Trial of DermACELL in Subjects With Chronic Wounds of the Lower Extremities||LifeNet Health|No|Active, not recruiting|October 2013|March 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|202|||Both|21 Years|80 Years|No|||March 2016|March 1, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970163||57558|
NCT01970423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPGRADE|Sleep Apnea and CRT Upgrading|Central Sleep Apnea and New-onset Cardiac Resynchronization in Patients With Conventional Pacemaker or ICD Therapy: a Multicenter, Randomized Clinical Trial||Medical University Innsbruck|No|Recruiting|January 2014|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|85 Years|No|||March 2016|March 18, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970423||57538|
NCT01970696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|International OTST Registry|International Ovarian & Testicular Stromal Tumor Registry|International Ovarian & Testicular Stromal Tumor Registry|OTST|Children's Hospitals and Clinics of Minnesota|No|Recruiting|December 2011|||December 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||3|Anticipated|100|Samples With DNA|1) whole blood for DNA extraction and lymphoblastoid cell line generation, 2) stained and      unstained slides and snap frozen tumor tissue (if available), and 3) paraffin blocks.|Both|N/A|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospectively or retrospectively diagnosed patients with ovarian or testicular stromal        tumors or ovarian small cell carcinoma|October 2015|October 16, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970696|10 Years|57517|
NCT01970124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1303|A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||September 2015|Anticipated|Phase 3|Interventional|N/A|1||||||Both|20 Years|N/A||||October 2013|October 22, 2013|October 22, 2013||||No||https://clinicaltrials.gov/show/NCT01970124||57561|
NCT01970137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1304|A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||March 2015|Anticipated|Phase 3|Interventional|N/A|1||||||Both|20 Years|N/A||||October 2013|October 22, 2013|October 22, 2013||||No||https://clinicaltrials.gov/show/NCT01970137||57560|
NCT01970150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104382|The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease|To Investigate the Effect of Application of Repeated Trans-cranial Magnetic Stimulation (rTMS) Applied on the Left Prefrontal Cortex on Electroencephalography Signal Recorded From Brain Regions Involved in Cognitive Function in Patients With Alzheimer's Disease (AD)||Lawson Health Research Institute|No|Terminated|February 2014|December 2015|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|55 Years|85 Years|No|||April 2015|April 30, 2015|October 22, 2013||No|1. New data from a published trial requires substantial change in study protocol      2. no funding available to carry the study further|No||https://clinicaltrials.gov/show/NCT01970150||57559|
NCT01969851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0966|A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.|A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENERALIZED SEIZURES.||UCB Pharma|No|Recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Month|18 Years|No|||March 2016|March 4, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969851||57581|
NCT01970072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMZL-PIa|A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers|A Placebo- and Midazolam-Controlled, Phase Ia, Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam Tosylate||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|October 2013|||October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Anticipated|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970072||57564|
NCT01983956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102/13|A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial)|A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial)|SENS|University Hospital Inselspital, Berne|Yes|Recruiting|December 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01983956||56501|
NCT01984476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-13-042|Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury|Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 subjects with SCI, 20 age-matched non-SCI controls and 20 older non-SCI controls will        be recruited from out-patient clinics at Kessler Institute for Rehabilitation. This        includes subjects who have completed various protocols in the Cardiovascular autonomic        testing laboratory or patients referred by their physicians following routine physical        examinations. Physicians will be informed of the inclusion and exclusion criteria for this        study and will be able to provide us with the assurance that the patient is an appropriate        candidate for the study and that he/she was willing to speak with the study coordinators.|August 2015|August 31, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984476||56461|
NCT01984489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR117887-201|Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SHR117887 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|June 2012|August 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|20 Years|70 Years|No|||November 2013|November 18, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984489||56460|
NCT01984853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS: ED-CARDS ACS Registry|Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative|Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative|ED~Cards|Henry Ford Health System|Yes|Completed|May 2013|April 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|575|Samples Without DNA|Approximately 6-8.5 ml of blood will be collected in each of two anticoagulant tube types:      SST and K2EDTA plasma.      The first blood collection in the ED is designated as t0 ED ECG time (+ 60 minutes).      Additional blood draws of approximately 6-8.5 mL/tube type will occur at t1 = 30 (+/- 10      minutes) after t0, t2=1 (+/-15 minutes) hour after t0, t4 = 3 (+/- 15 minutes) hours after      t0 (if the patient is still in the ED/hospital).|Both|18 Years|N/A|No|Probability Sample|Candidates for enrollment will be individuals presenting with signs and/or symptoms of        Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).|July 2015|July 30, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01984853|18 Months|56432|
NCT01984463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.203|Impact of Epidural Morphine on Shoulder Pain Following Thoracotomy.|Impact of Epidural Morphine on the Incidence and Severity of Shoulder Pain Following Thoracotomy.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Terminated|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|75 Years|No|||May 2014|May 9, 2014|November 4, 2013||No|Increased incidence of respiratory depression in the morphine group|No||https://clinicaltrials.gov/show/NCT01984463||56462|
NCT01984840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN-TN-001|Telemedicine for Patients Suffering From COPD (Danish Telecare North Trial)|Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish "TeleCare North" Pragmatic Cluster-randomized Trial.|TCN|Aalborg University|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1033|||Both|N/A|N/A|No|||April 2015|April 23, 2015|June 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01984840||56433|
NCT01985126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102651|An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD|An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985126||56411|
NCT01985919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01709|Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples|Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985919||56350|
NCT01972204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-2013-01|Intensive Instruction on the Use of Aricept|A Study About the Impact of Intensive Instruction on the Use of Aricept and the Reasons for Discontinuation in Patients With Alzheimer's Disease||Mirai Iryo Research Center, Inc.||Recruiting|September 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||October 2013|October 24, 2013|October 24, 2013||||No||https://clinicaltrials.gov/show/NCT01972204||57402|
NCT01972217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081DC00008|Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel||AstraZeneca|No|Active, not recruiting|April 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|158|||Male|18 Years|130 Years|No|||November 2015|November 16, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972217||57401|
NCT01972503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Octree Study|Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer|A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.||Fudan University|Yes|Recruiting|June 2008|September 2015|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01972503||57379|
NCT01972789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AAU15|Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment.|A Phase IV, Randomised, Controlled, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)|FLUID|Novartis|Yes|Active, not recruiting|October 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|347|||Both|50 Years|N/A|No|||February 2016|February 3, 2016|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972789||57357|
NCT01972802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006077R|International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study|International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study|InterCHANGE|National Taiwan University Hospital|No|Recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|900|Samples With DNA|BLOOD 20ML, Fresh (biopsy)samples, Oral scrape|Both|18 Years|80 Years|No|Probability Sample|NTUH HEAD AND NECK PATIENT AND CONTROLS|October 2013|October 29, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972802||57356|
NCT01972776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBM076X2203|A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.|A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD||Novartis|Yes|Terminated|November 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|48|||Both|35 Years|75 Years|No|||February 2016|February 24, 2016|October 24, 2013|Yes|Yes|Part 1 was completed. Part 2 was terminated for safety reasons.|No|January 22, 2016|https://clinicaltrials.gov/show/NCT01972776||57358|Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.
NCT01973075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22547|Genetic Etiology in Premature Ovarian Insufficiency|Genetic Etiology in Premature Ovarian Insufficiency|POI|Sisli Etfal Training & Research Hospital|No|Recruiting|November 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|4ml whole blood sample|Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|patients who are admitted to obstetrics and gynecology department|May 2015|May 18, 2015|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01973075|6 Months|57335|
NCT01970436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64042|Personalized Prenatal Care for Low-Risk Pregnancies Using Telemedicine|Personalized Prenatal Care for Low-Risk Pregnancies Using Remote Patient Monitoring||University of Utah|No|Active, not recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200|||Female|20 Years|39 Years|No|||January 2016|January 28, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970436||57537|
NCT01970449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 099|Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults|A Phase 1 Randomized, Double-blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of DNA Prime and NYVAC Boost With 3 Different HIV-1 Envelope Inserts (Nat-B Env, CON-S Env, and Mosaic Env) in Healthy, HIV-1-uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970449||57536|
NCT01970709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-101|Diagnosing Adverse Drug Reactions Registry|DART Registry: Diagnosing Adverse Drug Reactions Registry|DART|Renaissance RX|No|Active, not recruiting|November 2013|||November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|250000|Samples With DNA|Buccal swab|Both|18 Years|N/A|No|Non-Probability Sample|Male and female subjects over the age of 18, taking three or more medications, two of        which are metabolized by the CYP450 pathway.|March 2015|March 18, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970709|60 Days|57516|
NCT01971034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 96/2010|Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.|A Prospective Study to Evaluate the Combination of Metformin With Paclitaxel in the Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.||Instituto do Cancer do Estado de São Paulo||Completed|June 2011|||June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|September 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01971034||57492|
NCT01970410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWITCH-001|Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide|Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?||Multiple Sclerosis Center of Northeastern New York|Yes|Recruiting|October 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|21 Years|60 Years|No|||September 2015|September 21, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970410||57539|
NCT01984567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40392.068.12 / METC 12-3-047|Vitamin E or Lipoic Acid on Serum Oxyphytosterol Concentrations|The Effects of Consumption of Vitamin E or Lipoic Acid on Serum Oxyphytosterol Concentrations in Subjects With Impaired Glucose Tolerance or Type II Diabetes||Maastricht University Medical Center|No|Active, not recruiting|April 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|75 Years|No|||November 2013|November 8, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984567||56454|
NCT01984502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062013-052|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer|A Phase I CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|November 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984502||56459|
NCT01984515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 13-204|Increasing Engagement in Evidence-Based PTSD Therapy for Primary Care Veterans|Increasing Engagement in Evidence-Based PTSD Therapy for Primary Care Veterans||VA Office of Research and Development|No|Completed|January 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 7, 2013||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT01984515||56458|
NCT01984528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301-PR-PRI-198|To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.|Biological Standardization of Alternaria Alternata Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).||Laboratorios Leti, S.L.|No|Completed|February 2014|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|59 Years|No|||May 2013|January 2, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984528||56457|
NCT01984866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOMHGUGM032012|CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.|Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.||Hospital General Universitario Gregorio Marañon||Recruiting|July 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|tissue samples from breast tumors|Female|18 Years|75 Years|No|Non-Probability Sample|Female patients with breast tumors sensitive to neoadjuvancy|August 2015|August 19, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01984866||56431|
NCT01984879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0592|Vaccination Status, Knowledge and Attitude in Korean Patients With IBD|Vaccination Status, Knowledge About Vaccination and Attitude to Vaccination in Korean Patients With Inflammatory Bowel Diseases||Asan Medical Center|Yes|Recruiting|November 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with inflammatory bowel diseases who are visiting Asan Medical Center and who        give consent to the survey|December 2013|December 3, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01984879||56430|
NCT01985139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-33|Pleasure for Food and Endocannabinoids in Obesity|A New Method for the Characterisation of Pleasure for Food in Obesity and Relationships With the Endocannabinoid System|PLOBEC|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985139||56410|
NCT01985451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI002|Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）|Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL||Shandong Cancer Hospital and Institute|Yes|Active, not recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|75 Years|No|||November 2013|November 8, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985451||56386|
NCT01985464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-UCMSCRA-001|Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis|Feasibility Study of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UC-MSC) in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis||Translational Biosciences|Yes|Recruiting|October 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985464||56385|
NCT01985711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBCCFPWDAD|Web-Based Collaborative Care for Patients With Diabetes and Depression|Effects of a Web-Based Collaborative Care Management System (WBCCMS) on Psychosocial Outcomes and Biochemical Outcomes Among Patients With Diabetes and Depression|WBCC|Beijing Anzhen Hospital|No|Not yet recruiting|May 2014|April 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|70 Years|No|||November 2013|November 14, 2013|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01985711||56366|
NCT01985932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07812|Functional MRI Use in Prostate Radiation Treatment Planning|A Prospective Study Evaluating Non-Endorectal Coil Functional MRI Identification of Intraprostatic Tumor During Radiation Treatment Planning||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|July 2012|||April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|15|||Male|18 Years|N/A|No|||December 2015|December 14, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985932||56349|
NCT01971957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560-12|Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers|Sjogren-Larsson Syndrome: A Longitudinal Study of Natural History, Clinical Variation and Evaluation of Biochemical Markers|SLS|University of Nebraska|Yes|Recruiting|April 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood, urine, skin|Both|N/A|N/A|No|Non-Probability Sample|The study population will come from cohorts of Sjögren-Larsson syndrome patients currently        followed at STAIR sites, from the RDCRN contact registry, and from the pool of new        patients who directly contact STAIR sites or are referred to STAIR centers by their        physicians.|October 2013|October 29, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01971957|5 Years|57421|
NCT01973322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST172.02|Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study|Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study|ABSIDE|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01973322||57316|
NCT01973335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOL-DIURESIS-CHF|Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure|Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure|DIURESIS-CHF|Hasselt University|Yes|Recruiting|November 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973335||57315|
NCT01973569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG162-D-J301|AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment|A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)|DESIRABLE|Daiichi Sankyo Inc.|No|Active, not recruiting|October 2013|March 2018|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|667|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973569||57297|
NCT01970462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0328|Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery|Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery||Ohio State University|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970462||57535|
NCT01969890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G112|STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial|Phase III Study on STem cElls Mobilization in Acute Myocardial Infarction|STEM-AMI|Heart Care Foundation|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1530|||Both|18 Years|75 Years|No|||March 2015|March 26, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969890||57578|
NCT01970176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004644|Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)|Define in Preclinical Systolic Dysfunction (PSD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition|Aim2|Mayo Clinic|Yes|Recruiting|November 2013|May 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|45|||Both|21 Years|90 Years|No|||December 2015|December 17, 2015|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970176||57557|
NCT01970189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBR-017 (TRA114972)|The International ITP Registry|A Multi-centre, Prospective Disease Registry for Adults Diagnosed With Primary Immune Thrombocytopenia (ITP) in International Countries||South Eastern Sydney Local Health District|No|Recruiting|January 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adults recently-diagnosed with primary ITP will be prospectively enrolled into the        registry. In cases where prospective data collection is not possible from initial        diagnosis, eg if sites see mainly referred patients, those patients with pre-existing ITP        of no longer than 6 months duration since diagnosis will be allowed into the registry,        provided they are still prospectively being followed up or under ongoing review /        treatment at the participating institution.|November 2015|November 25, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01970189|24 Months|57556|
NCT01971060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLocmyo|a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.|A Case Study to Evaluate Adhesion Risk in Fertility Patients' Post Laparoscopic Myomectomy Utilizing Vloc Suture.|VLocmyo|The Advanced Gynecologic Surgery Institute|Yes|Withdrawn|August 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|September 24, 2013|No|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01971060||57490|
NCT01971320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/002/HP|Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia|Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia|TENSDEG|University Hospital, Rouen|No|Recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|85 Years|No|||January 2016|January 22, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971320||57470|
NCT01971294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 12-291|Lower Urinary Tract Symptoms in Systemic Sclerosis|Lower Urinary Tract Symptoms in Patients Suffering From Systemic Sclerosis: a Multi-centric Longitudinal Study||University Hospital, Geneva|No|Enrolling by invitation|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|480|||Both|18 Years|N/A|No|Non-Probability Sample|Systemic sclerosis suffering patients in Brescia (I), Geneva (CH), Padova (I) and Paris        (F)|October 2013|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971294||57472|
NCT01971307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44597.068.13/ METC 13-3-034|Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan.|Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan.|SGE-PsyScan|Maastricht University Medical Center|Yes|Completed|December 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|336|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01971307||57471|
NCT01971528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-3167A3|Central and Peripheral Fatigue in Individuals With Parkinson's Disease - Evaluation and Training|||Chang Gung University|Yes|Recruiting|February 2012|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01971528||57454|
NCT01984580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R-11-3038L|Effect of Zinc on Barrett's Metaplasia|Effect of Zinc on Barrett's Metaplasia||Main Line Health|Yes|Recruiting|April 2011|December 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2013|November 8, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984580||56453|
NCT01984918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC Study|Predictors of Colonoscopy Non-attendance and the Efficacy of a Short Message Service (SMS) Reminder to Reduce Non-attendance Rate|Predictors of Colonoscopy Non-attendance and the Efficacy of a Short Message Service (SMS) Reminder to Reduce Non-attendance Rate: A Prospective Randomized Controlled Trial (NAC Study)||Chinese University of Hong Kong|No|Recruiting|November 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|2706|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01984918||56427|
NCT01984554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT13033|Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia|Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia||Luitpold Pharmaceuticals|No|Completed|September 2013|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|551|||Both|18 Years|N/A|No|Probability Sample|Subjects presenting for IDA treatment|March 2015|March 18, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984554||56455|
NCT01985152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-AZTP1a|A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers|A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|September 2013|||December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|62|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985152||56409|
NCT01985165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRARXB00434|A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis|A Multicenter，Open-label Phase Ⅳ Trial of Imrecoxib in Treatment of Knee Osteoarthritis||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|May 2013|||November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2400|||Both|18 Years|75 Years|No|||November 2013|November 7, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01985165||56408|
NCT01985477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0624|Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Terminated|December 2013|||September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985477||56384|
NCT01985490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-163|Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane|||Samsung Medical Center|No|Recruiting|November 2013|May 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|20 Years|N/A|No|||November 2013|November 25, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01985490||56383|
NCT01985724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.17|Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer|A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in Women With HER-2 Negative, Axillary Lymph Node Positive Breast Cancer||Hellenic Oncology Research Group||Completed|October 2007|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|650|||Female|18 Years|N/A|No|||May 2014|May 13, 2014|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01985724||56365|
NCT01985945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08113|Yoga for Breast Cancer|A Randomized Study of the Effect of Yoga in Patients With Breast Cancer Receiving Radiation Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|March 2013|||July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985945||56348|
NCT01986231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006947|Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver|The Effect of Repeated Doses of Subcutaneous Glucagon on Hepatic Glycogen Stores in Persons With Type 1 Diabetes||Legacy Health System|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|November 5, 2013||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT01986231||56326|
NCT01972256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0023|A Study Comparing Fusion Rates of Two Lumbar Fusion Procedures|Prospective Multicenter Clinical Evaluation of Fusion||Baxano Surgical, Inc.|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Subject candidates are those who had required fusion at L4-L5-S1 where these were the only        lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or        degenerative disc disease (DDD).|June 2014|June 3, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972256||57398|
NCT01973582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012127RB|Hepatitis B Seroepidemiology Among Young Adults|A Retrospective Cohort Study of Hepatitis B Seroepidemiology Among Young Adults||National Taiwan University Hospital|Yes|Recruiting|July 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples Without DNA|Serum, blood cells|Both|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adults 20 to 30 years old.|October 2013|October 25, 2013|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01973582||57296|
NCT01969526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01503|Effectiveness of a Multifactorial Intervention on Frailty|Effectiveness of a Multifactorial Intervention to Modify Frailty Parameters in Elderly Population||Jordi Gol i Gurina Foundation|No|Recruiting|January 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Both|65 Years|N/A|No|||August 2013|October 21, 2013|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01969526||57606|
NCT01969539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.65|Ventilator Adapters for Combivent Respimat|Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.||Boehringer Ingelheim||Terminated|October 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|40 Years|N/A|No|||January 2016|January 19, 2016|October 14, 2013||||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01969539||57605|The study was closed early based on the results of an interim pharmacokinetic analysis, prior to enrollment of any patient in cohort 2, therefore only the Trudell adapter was assessed (in cohort 1)
NCT01970475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120262|Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis|RA|Amgen|Yes|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|526|||Both|18 Years|80 Years|No|||May 2015|May 14, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970475||57534|
NCT01970735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-01|Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2|Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|75 Years|No|||October 2013|December 10, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970735||57514|
NCT01970722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12316|Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer|Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin||City of Hope Medical Center|Yes|Recruiting|May 2014|||December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970722||57515|
NCT01971840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/02400|Effectiveness of a Physical Activity Intervention on Preventing Obesity During the Adiposity Rebound Period.|Effectiveness of an Intervention of Physical Activity Promotion in Schoolchildren on Preventing Obesity During the Adiposity Rebound Period: a Cross-over Randomized Cluster Trial.|MOVI-KIDS|University of Castilla-La Mancha|Yes|Enrolling by invitation|September 2013|June 2015|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||October 2013|December 22, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01971840||57430|
NCT01971047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00067662|Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery|The Safety and Efficacy of Correcting Preoperative Hyperglycemia in Ambulatory Surgical Patients With Diabetes: A Randomized Controlled Clinical Trial||Emory University|No|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 20, 2015|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971047||57491|
NCT01971346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 652|The Immunological Basis for Treatment Resistance to Anti-TNF Treatments|The Immunological Basis for Treatment Resistance to Anti-TNF Treatments||University of Michigan|No|Recruiting|March 2014|December 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971346||57468|
NCT01971333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309024RIND|Dynamic Preload Parameters During Liver Transplantation|The Validity of Dynamic Preload Parameters During Liver Transplantation||National Taiwan University Hospital|No|Recruiting|October 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|6 Months|75 Years|No|Non-Probability Sample|End stage liver disease patients scheduled for liver transplantation in National Taiwan        University Hospital|October 2013|October 29, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971333||57469|
NCT01971541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-112|Groups for Regaining Our Wellbeing (GROW)|A Non-inferiority Trial of MBSR and CPT for PTSD|GROW|VA Office of Research and Development|No|Withdrawn|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971541||57453|
NCT01984593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Region Skane|Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension|Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension - A Randomized Controlled Multicenter Trial in Primary Care|YHIP2|Region Skane|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|30 Years|80 Years|No|||November 2014|November 4, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984593||56452|
NCT01984203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoCTExPRIMARY|Rotator Cuff Tendinopathy Exercise Trial|Progressive Heavy Strength Training Compared to General Low-load Exercises in Patients With Rotator Cuff Tendinopathy: a Randomized Controlled Trial|RoCTEx|University of Southern Denmark|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01984203||56482|
NCT01984216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRUGIA-CHN|Billroth II Versus Roux-en-Y for the Gastrojejunostomy in the Pancreatoduodenectomy|Billroth II Versus Roux-en-Y for the Gastrojejunostomy Reconstruction in the Pancreatoduodenectomy: a Randomized Controlled Study||Fundacion Miguel Servet|No|Recruiting|November 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984216||56481|
NCT01984541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6058-PR-PRI-200|To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.|Biological Standardization of Artemisia Vulgaris Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).||Laboratorios Leti, S.L.|No|Completed|March 2014|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|60 Years|No|||May 2013|January 2, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01984541||56456|
NCT01985204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-24|Iodine Supplementation in Obesity|Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency||Swiss Federal Institute of Technology|No|Completed|November 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|162|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985204||56405|
NCT01984892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1687|Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)|Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC): A Phase II Clinical Study|Hiltonol|Icahn School of Medicine at Mount Sinai|Yes|Terminated|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|14 Years|N/A|No|||October 2014|February 16, 2016|November 5, 2013|Yes|Yes|PI discretion|No||https://clinicaltrials.gov/show/NCT01984892||56429|
NCT01985178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders|Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders||McMaster University|No|Recruiting|October 2013|||August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|18 Years|No|||April 2015|April 14, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01985178||56407|
NCT01985191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD13388|A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients|A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer||Sanofi|No|Completed|November 2013|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985191||56406|
NCT01985503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAT-Follow-Up|Longitudinal Follow-up of Brown Adipose Tissue Function and Structure|Brown Adipose Tissue: Longitudinal Follow-up of Brown Adipose Tissue Structure and Associations With Obesity and Cardiovascular Risk Factors in Healthy Participants of Baseline PET Studies (BAT-Follow-Up)|BATFollowUp|Turku University Hospital|No|Active, not recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|95|Samples With DNA|Blood samples, fecal samples, adipose tissue biopsies and skeletal muscle biopsies.|Both|22 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Study subjects are healthy 22-55-year-old Caucasians. Population contains both lean and        obese subjects.|November 2015|November 7, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985503|5 Years|56382|
NCT01985737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33004|Catheter Biofilm Microbiome in Infected Neonatal Catheters.|BIOFILM MICROBIOME AND MICROBIAL DNA LOAD IN NEONATAL CATHETER-ASSOCIATED BLOODSTREAM INFECTIONS||Baylor College of Medicine|No|Active, not recruiting|November 2013|December 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|144|Samples With DNA|We will collect approximately 10 drops of blood from the infant for our research study. We      will take the blood directly from the PICC tube when it is being removed. We will also take      a skin swab from around the area where the PICC tube was placed.|Both|N/A|3 Weeks|No|Non-Probability Sample|All neonates admitted to Texas Children's Hospital (TCH) NICU with indwelling catheters        will be recruited at the time of line insertion.|December 2015|December 17, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985737||56364|
NCT01986257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 2013/1321-31/3|ERGT for Women Engaging in NSSI - an Effectiveness Study|Emotion Regulation Group Therapy (ERGT) for Women Engaging in Non-suicidal Self-Injury (NSSI) - an Effectiveness Study||Karolinska Institutet|No|Completed|September 2013|March 2015|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Female|18 Years|65 Years|No|||January 2016|January 3, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01986257||56324|
NCT01986270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A160-104|Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo|A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine||Pfizer|Yes|Completed|December 1996|January 1998|Actual|January 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1141|||Both|18 Years|65 Years|No|||November 2013|November 11, 2013|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986270||56323|
NCT01973088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Southwest Hospital,TMMU|Screening and Identification of Human Urate Transporter hURAT1 MicroRNA|||Southwest Hospital, China||Active, not recruiting|November 2013|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|65 Years|No|Probability Sample|Experiment are divided into uric acid stones group (A), non-uric acid stones group (B),        control group (C), A, C recruited 30 patients each group, B group recruited 20 patients.|September 2013|December 8, 2013|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01973088||57334|
NCT01969552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIFHT-161013|Interrelations Between FT3, FT4 and Pituitary TSH|Interrelations Between FT3, FT4 and Pituitary TSH and Implications For Thyroid Hormone Treatment (IIFHT-Study)|IIFHT|Klinikum Lüdenscheid|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1912|||Both|18 Years|N/A|No|Probability Sample|Adult subjects presenting for thyroid testing or treatment to the Department of Nuclear        Medicine, Klinikum Luedenscheid, Luedenscheid, Germany.|September 2014|September 1, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01969552||57604|
NCT01969565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060113|Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma|An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma||Emory University|Yes|Terminated|August 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 4, 2013|Yes|Yes|Logistical reasons|No|October 6, 2015|https://clinicaltrials.gov/show/NCT01969565||57603|One patient consented but withdrew prior to beginning treatment.
NCT01970202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-GL-0241-CTIL|Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity|Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01970202||57555|
NCT01971073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARILAN-13-0116-MV-CTIL|Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia|Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia||Bar-Ilan University, Israel|No|Recruiting|January 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01971073||57489|
NCT01970748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V101C-016；V102C-094|Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices|Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices|P-HCC|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|August 2009|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|No|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970748||57513|
NCT01971853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1753|Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry|Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry?|Analgesia|University of Colorado, Denver|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971853||57429|
NCT01971866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1215-DS02|Camera Based System to Monitor Patient Movement During Radiation Treatment|Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System|DS02|University of Florida|Yes|Terminated|October 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are undergoing proton radiation therapy at UFPTI|January 2016|January 26, 2016|October 17, 2013|No|Yes|Slow enrollment, feasibility issues|No||https://clinicaltrials.gov/show/NCT01971866||57428|
NCT01971554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8666-003|Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients||Merck Sharp & Dohme Corp.|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|October 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971554||57452|
NCT01972061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13020474|Foot Neuromodulation for Overactive Bladder (OAB)|Foot Neuromodulation for Overactive Bladder (OAB)|FootStim|University of Pittsburgh|No|Enrolling by invitation|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972061||57413|
NCT01971827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/00761|Effectiveness of a Physical Activity Intervention to Prevent Obesity and Improve Academic Performance|Effectiveness of Physical Activity Intervention to Prevent Obesity and Improve Academic Performance in Children With and Without Attention Deficit Hyperactivity Disorder (ADHD) Risk|MOVI-KIDS|University of Castilla-La Mancha|Yes|Enrolling by invitation|September 2013|June 2015|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||October 2013|December 22, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01971827||57431|
NCT01972334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093-12|Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection|A Randomized, Placebo-controlled Pilot Trial to Administer Fecal Microbial Therapy (Stool Transplant) or Placebo in Children Ages 8 to 18 With Recurrent C. Difficile Infection||MemorialCare Health System|No|Recruiting|October 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|1 Year|21 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972334||57392|
NCT01972048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS063|Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening|Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|149|||Female|40 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972048||57414|
NCT01972594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCU_ALARG_AJ_002|Pedometer Based Intervention After Total Hip Replacement-A Pilot Study|A 12 Week Pedometer Based Walking Intervention to Enhance Physical Activity Performance Following Total Hip Replacement-A Pilot Study||Glasgow Caledonian University|Yes|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|20|||Both|60 Years|80 Years|No|||March 2015|March 12, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01972594||57372|
NCT01985256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-13-01|Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor|A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC||Tocagen Inc.|Yes|Active, not recruiting|October 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01985256||56401|
NCT01985269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-623-A-00-08-00003|Modified Directly Observed Antiretroviral Therapy|Modified Directly Observed Antiretroviral Therapy (M-DART): An Intensive, Nurse-directed, Home-centered, Treatment Strategy to Reduce Mortality and Loss to Follow-up in High-risk HIV-infected Patients Initiating Antiretroviral Therapy|M-DART|Moi University|Yes|Active, not recruiting|August 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|511|||Both|14 Years|N/A|No|||November 2013|November 8, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01985269||56400|
NCT01984905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00209-36|Study of Prognostic Factors in Aortic Dissection Type B|Exploratory Study of Prognostic Factors in Aortic Dissection Type B: Role of Imaging (18F-FDG PET-Scan and Angioscan) and Biomarkers|TEDAC|University Hospital, Caen|No|Recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from chronic type B aortic dissection (since more than 1 month and less        than 5 years)and medically treated.|November 2013|November 8, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01984905||56428|
NCT01985217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07020|Prevalence of Digestive Carriage of Integrons|Prevalence of Digestive Carriage of Integrons to Resistance in Two Populations in Limousin|APIHA|University Hospital, Limoges|No|Completed|August 2009|December 2013||April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|492|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people working in the hospital kitchen|November 2013|November 8, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985217||56404|
NCT01985230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950002|ReActiv8 for Chronic Low Back Pain|Investigation of the ReActiv8 Implantable Stimulation System for Chronic Low Back Pain|ReActiv8-A|Mainstay Medical|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985230||56403|
NCT01985516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/13|Female Urethral Catheterization - Instillation of the Lubricating Gel Into the Urethra or Pouring it on the Catheter's Tip?|Pain Level During Female Urethral Catheterization - Should we Instill the Lubrication Gel Into the Urethra or Just Lubricate the Catheter's Tip? a Prospective Randomized Study||Assaf-Harofeh Medical Center|No|Recruiting|October 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|96|||Female|18 Years|N/A|No|||November 2013|November 10, 2013|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01985516||56381|
NCT01985750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-KP001|Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception|Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception||University of Oxford|No|Recruiting|November 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01985750||56363|
NCT01985958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14213|A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas|A Pilot Study to Evaluate Radiotherapy-Induced Ant-Tumor Immunity in Metastatic Carcinoma of the Pancreas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985958||56347|
NCT01985971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15910|F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer|F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|March 2011|||March 2014|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985971||56346|
NCT01986556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-129|Lesinurad Tablet Relative Bioavailability|A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Lesinurad Tablets Manufactured at Two Different Sites||Ardea Biosciences, Inc.|No|Completed|November 2013|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986556||56301|
NCT01973348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307011930|Comparison of AmblyzTM Glasses and Patching for Amblyopia|Comparison of AmblyzTM Glasses and Patching for Amblyopia||Indiana University|Yes|Recruiting|November 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|116|||Both|3 Years|8 Years|No|||February 2016|February 22, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973348||57314|
NCT01970215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-03|TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of TA-8995 in Patients With Mild Dyslipidaemia, Alone and In Combination With Statin Therapy|TULIP|Xention Ltd|Yes|Completed|August 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|364|||Both|18 Years|75 Years|No|||August 2014|August 20, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01970215||57554|
NCT01972113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611523 (Pro00000912)|Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)|Vitamin K and Glucose Metabolism in Children at Risk for Diabetes||Georgia Regents University|Yes|Recruiting|September 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972113||57409|
NCT01971567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024763|High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia|High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia: A Randomized, Placebo-Controlled Clinical Trial||Wake Forest School of Medicine|No|Not yet recruiting|October 2013|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971567||57451|
NCT01972360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITNEC B5|Non-isotope Based Imaging Modalities vs Technetium-99m Single-Photon Emission Computed Tomography(99mTcSPECT)|Non-isotope Based Imaging Modalities vs 99mTcSPECT to Detect Myocardial Ischemia in Patients at High Risk for Ischemic Cardiovascular Events|MITNECB5|Montreal Heart Institute|No|Recruiting|October 2012|April 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|450|||Both|18 Years|87 Years|No|Non-Probability Sample|450 patients accross Canada. Patients will be identified after a clinically indicated        SPECT for evaluation of myocardial ischemia.The investigator will assign the patient in        one of the three groups based on his medical assessment and availability of equipment at        the center.|March 2016|March 18, 2016|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01972360||57390|
NCT01972321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|﻿﻿OPP1002407|ICCM of Common Childhood Diseases: Mozambique and Uganda|Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda|inSCALE|Malaria Consortium|Yes|Completed|April 2013|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|2289|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01972321||57393|
NCT01972074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001826|Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder|Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder||Massachusetts General Hospital|Yes|Recruiting|November 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972074||57412|
NCT01972347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200332|Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma|An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma||Melanoma Institute Australia|Yes|Recruiting|October 2014|August 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01972347||57391|
NCT01972620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-01/515|RCT: Multi-modal Analgesia for Laparoscopic Cholecystectomy|Prospective Randomized Controlled Trial (PRCT) Comparing Standard Analgesia With Multi-modal Targeted Operative and Port-Site Local Anesthesia for Post-Operative Pain Management in Elective Laparoscopic Cholecystectomy (LapChole)|LapChole|Klinicki Centar Vojvodine|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01972620||57370|
NCT01972607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081511|The Effect of Aerobic Exercise Training for Migraine Prevention.|The Effect of Aerobic Exercise Training for Migraine Prevention.||Federal University of São Paulo|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01972607||57371|
NCT01972932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUM 2014-5056|Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea|Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients||Bio-K Plus International Inc.|No|Terminated|November 2013|November 2016|Anticipated|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|90 Years|No|||June 2014|January 14, 2016|October 25, 2013||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01972932||57346|
NCT01985802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048871|Pacing in First-degree AV-block|Optimal Pacing in Patients With First-degree AV-block||Duke University|No|Recruiting|December 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||January 2016|January 25, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985802||56359|
NCT01984931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-2013-02|Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study||CM Chungmu Hospital|Yes|Recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|45|||Both|N/A|70 Years|No|||November 2013|November 8, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01984931||56426|
NCT01984944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081103|Characterisation of Circadian Rhythm in Autistic Spectrum Disorder|Characterisation of Circadian Rhythm in Autistic Spectrum Disorder : a Clinical, Biochemical and Genetic Study||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|42|||Both|6 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 6, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01984944||56425|
NCT01985243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S065653|Building Capacity for Sustainable Livelihoods and Health|Building Capacity for Sustainable Livelihoods and Health Through Public-private Linkages in Agriculture and Health Systems||McGill University|No|Active, not recruiting|November 2013|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|3000|||Both|N/A|15 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01985243||56402|
NCT01985529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000175|A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD|A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD||University of California, Los Angeles|No|Completed|December 2008|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|N/A|N/A|No|||November 2013|November 8, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01985529||56380|
NCT01985763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1697|Genistein in Treatment of Metastatic Colorectal Cancer|Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985763||56362|
NCT01985984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02-8/02-extern-6820|Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Patients|Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Using Multi-parameter Modelling: Disease Control, Toxicity and Quality of Life|OutcomeH&N|Maastricht Radiation Oncology|Yes|Recruiting|July 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Characteristics of the population:          -  Patients with Head and Neck Cancer, treated with curative intent          -  Any tumor site          -  Stage I-IV, M0          -  Treated with radiotherapy alone or in combination with systemic therapy          -  Definitive radiotherapy or postoperative radiotherapy|September 2015|September 23, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985984|5 Years|56345|
NCT01986283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501016|Abuse Potential Study of PF-00345439|A Randomized, Double-blind, Triple-dummy, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Pf-00345439 (Oxycodone Extended Release Capsules) Compared To Immediate-release Oxycodone And Placebo When Administered Orally Whole And/or Chewed To Non-dependent, Recreational Opioid Users Under Fasted Conditions||Pfizer|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|67|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986283||56322|
NCT01986296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD001|ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Medication Refractory Obsessive Compulsive Disorder|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound Treatment of Medication-Refractory OCD||InSightec|Yes|Recruiting|January 2013|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986296||56321|
NCT01986309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG 08-12|Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery|Use of Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery, With or Without Adenoids|LETSVN|Pontificia Universidad Catolica de Chile|Yes|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|2 Years|12 Years|No|||September 2015|September 22, 2015|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01986309||56320|
NCT01986569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES13001|Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer|A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer||Asan Medical Center|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|94|||Both|19 Years|N/A|No|||December 2015|December 30, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01986569||56300|
NCT01973595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300475|Almonds: Digestive Health and Immune Function of Adults and Children|Almonds: Digestive Health and Immune Function of Adults and Children||University of Florida|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01973595||57295|
NCT01969929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKK-13-247|Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy|Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy|20Gvs23G|University of Cologne|Yes|Active, not recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01969929||57575|
NCT01969903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00716|Study of Use of Dexmedetomidine for Regional Anesthesia|Effect of Dexmedetomidine Added to Lidocaine for Infra- and Supraclavicular Brachial Plexus Block||New York University School of Medicine|Yes|Withdrawn|November 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|70 Years|No|||March 2016|March 1, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969903||57577|
NCT01969916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15237B-AM005|Stress CT Perfusion in Patients With Chest Pain|Comprehensive Evaluation of Patients With Chest Pain Using Cardiac Computed Tomography: Value of Adding Regadenoson Stress Perfusion Imaging to Noninvasive Coronary Angiography||University of Chicago|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969916||57576|
NCT01970774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048123|Medication Therapy Management With Pharmacogenetic Testing|Assessing Feasibility and Utility of Enhancing Medication Therapy Management With Pharmacist-Delivered Pharmacogenetic Testing||Duke University|Yes|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|April 17, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970774||57511|
NCT01963117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2013-06-040|Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Gastrointestinal Tract Cancer Liver Metastasis|Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Unresectable Chemoresistant Multiple Liver Metastasis From Gastrointestinal Tract Cancer: Prospective Phase II Trial||Samsung Medical Center|No|Terminated|October 2013|April 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|N/A|No|||August 2014|May 18, 2015|September 25, 2013||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT01963117||58097|
NCT01972633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boltzmann-001|Endoluminale Obliteration Der Stammvene Mit Dem 1470nm Laser Versus VNUS Closure Fast|Endovenous Treatment of the Saphenous Vein With Biolitec 1470nm Laser Versus Vnus Closure Fast||Ludwig Boltzmann Institute for Operative Laparoscopy|No|Recruiting|June 2010|April 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01972633||57369|
NCT01972087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44640-EJ|Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest|Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest|STAT911|University of Washington|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|212|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01972087||57411|
NCT01972945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAST|Vaginoscopy Against Standard Treatment (VAST): a Randomised Controlled Trial|Vaginoscopy Against Standard Treatment (VAST): a Randomised Controlled Trial|VAST|Birmingham Women's NHS Foundation Trust|No|Recruiting|March 2014|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1600|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01972945||57345|
NCT01972919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17687|MR Guided Dose Escalated RT + Concurrent Chemotherapy in Unresectable Pancreatic Cancer|MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-metastatic Pancreatic Cancer||Medical College of Wisconsin|Yes|Recruiting|March 2016|December 2023|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972919||57347|
NCT01973166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-TPS04|Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal|Randomized, Split-tattoo Study Comparing Safety and Efficacy of Picosecond and Nanosecond Q-switched Nd:YAG Lasers for Tattoo Removal||Cutera Inc.|No|Completed|September 2013|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973166||57328|
NCT01964586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/167|Comparison of Preincisional Infiltrated Dexmedetomidine and Lidocaine Plus Adrenaline for Nasal Sephoplasty Surgery.|Phase 4 Study of Comparison of Preincisional Infiltrated Dexmedetomidine and Lidocaine Plus Adrenaline for Surgical Conditions and Postoperative Analgesic Consumption in Nasal Sephoplasty Surgery.||TC Erciyes University|No|Completed|March 2013|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|60 Years|No|||October 2013|October 15, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964586||57985|
NCT01985815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s50927|Refining the Target for Deep Brain Stimulation (DBS) in Severe, Treatment Refractory Obsessive Compulsive Disorder (OCD)|||Universitaire Ziekenhuizen Leuven|No|Completed|March 2008|||February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|65 Years|No|||June 2013|November 8, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01985815||56358|
NCT01984957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110401|Differential Study of Muscle Transcriptome|Differential Study of Muscle Transcriptome in Patients With Neuromuscular Disease and Control Subjects|TRANE|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|18 Years|75 Years|No|||June 2014|March 20, 2015|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01984957||56424|
NCT01985555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-504-00CH1|Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors|A Phase I, Open-label, Multicenter Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Volitinib in Patients With Advanced Solid Tumors|HMPL-504|Hutchison Medipharma Limited|Yes|Recruiting|May 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01985555||56378|
NCT01985789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPY2013/14|Anti-histamines and Methacholine Challenges.|The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients||University of Saskatchewan|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01985789||56360|
NCT01985542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The effects of immunotherapy|The Effects of Immunotherapy in the Nose|The Molecular Biological Effects of Immunotherapy in the Nose|Birch11|Helsinki University Central Hospital|No|Completed|May 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|12 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985542||56379|
NCT01985776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L5-4293(B))|Effects of Exercise Intervention on Patients With Low Back Pain Due to Spondylolytic Spondylolisthesis.|Effects of Exercise Intervention on Patients With Low Back Pain Due to Spondylolytic Spondylolisthesis.|ExerciseLBP|University of Primorska|No|Active, not recruiting|June 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|20 Years|60 Years|No|||June 2014|June 5, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01985776||56361|
NCT01985997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-VA-MEDI3250-1115|Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age|Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age||MedImmune LLC|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|95000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults 2 to 49 years of age vaccinated with Q/LAIV, TIV or no vaccine at        Kaiser Permenente Northern California sites.|November 2014|November 3, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01985997||56344|
NCT01986010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V160-001|Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults||Merck Sharp & Dohme Corp.|No|Active, not recruiting|November 2013|March 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|17||Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|November 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986010||56343|
NCT01983007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14343|Effect of Physical Exercise on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Effect of Physical Exercise on Endothelial Function in Patients With Type 2 Diabetes Mellitus||Universidade Federal do Ceara|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|31|||Both|40 Years|65 Years|No|||March 2014|March 20, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983007||56574|
NCT01983020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 073-10|Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery|Randomized Double Blind Comparison of Peri-Operative Standard Analgesia With Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery||Beth Israel Medical Center|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01983020||56573|
NCT01970228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T125/2012|Imaging of Joint Replacement Complications by PET/CT|Prospective Intra-individual Comparison of 18F-FDG and 68Ga-citrate PET/CT in Symptomatic Total Hip Arthroplasty Patients|Propeli|Turku University Hospital|No|Recruiting|October 2012|||December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|September 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970228||57553|
NCT01970488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120263|Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (Humira®) in Adults With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis||Amgen|Yes|Completed|October 2013|March 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970488||57533|
NCT01970761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120246|Autologous Fat Graft Alleviate Scar Pain|Alleviation of Neuropathic Scar Pain With Autologous Fat Graft||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|February 2008|April 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|36|||Both|19 Years|75 Years|No|Non-Probability Sample|patients received autologous fat grafting in scar areas|December 2012|October 23, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970761||57512|
NCT01971086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40.56|Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary|Treatment With Rhinospray Plus of Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary||Boehringer Ingelheim||Completed|October 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|6 Years|N/A|No|Non-Probability Sample|adults and children at and above 6 years old|March 2015|March 13, 2015|October 14, 2013||||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01971086||57488|
NCT01963130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN73824458|Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study|Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study||Bezmialem Vakif University|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|97|||Both|18 Years|80 Years|No|Probability Sample|type 2 Diabetes Mellitus (DM)|October 2013|October 11, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963130||58096|
NCT01963143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMX07|Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases|A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases|GMX07|Bio Products Laboratory|Yes|Recruiting|February 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|2 Years|55 Years|No|||January 2016|January 11, 2016|September 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01963143||58095|
NCT01971359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF-13-004|Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study|Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study|MISPACE|OSF Healthcare System|Yes|Recruiting|September 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients that present with an ICH at OSF St. Francis Medical Center|April 2014|April 25, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971359||57467|
NCT01971580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-300-D076|The Effects of Ambrisentan on Exercise Capacity in Fontan Patients|The Effects of Ambrisentan on Exercise Capacity in Fontan Patients||Washington University School of Medicine|Yes|Completed|August 2012|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|50 Years|No|||June 2015|June 1, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971580||57450|
NCT01963663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92/d/130/499|Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients|Comparison of Metformin and Pioglitazone Effects on Serum YKL-40 Concentrations in Patients With Newly Diagnosed Type 2 Diabetes||Tehran University of Medical Sciences|No|Completed|November 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|84|||Both|35 Years|N/A|No|||October 2013|October 15, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963663||58055|
NCT01972958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200908042R|Effects of Community Health Programs by Nurses for Older Adults|Effects of Community Health Programs by Nurses for Older Adults||National Taiwan University Hospital|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|220|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 24, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01972958||57344|
NCT01973452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-163|Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery|A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery||Memorial Sloan Kettering Cancer Center||Recruiting|October 2013|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973452||57306|
NCT01972386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5898-CE|EBUS/Spectrum Analysis|Spectrum Image Analysis of Lymph Nodes During Endobronchial Ultrasound-Guided (EBUS) Transbronchial Needle Aspiration (TBNA) in Patients With Lung Cancer||University Health Network, Toronto|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lung cancer or suspected lung cancer who undergo EBUS TBNA for lymph node        staging.|September 2015|September 14, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972386||57388|
NCT01972399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00077816|Laser Therapy Treatment of Peri-implantitis.|Influence of Laser Therapy Upon Surgical Treatment of Peri-implantitis Lesions.||University of Michigan|No|Withdrawn|January 2016|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|October 7, 2013|Yes|Yes|Withdrawn from IRB at PI's request|No||https://clinicaltrials.gov/show/NCT01972399||57387|
NCT01972412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EERP - 146.171|Telephone Use for Care of Persons With Diabetes Mellitus.|Telephone Support for Self-monitoring of Persons With Diabetes Mellitus Using the Chronic Care Model|TCDM|University of Sao Paulo|Yes|Recruiting|April 2013|March 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|296|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 31, 2013|March 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01972412||57386|
NCT01985607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP08-ALLAR|Efficacy of a New Thickened Extensively Hydrolyzed Formula|Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Cow's Milk Hypersensitivity|ALLAR|United Pharmaceuticals|No|Completed|February 2011|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|6 Months|No|||March 2015|March 20, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01985607||56374|
NCT01985620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-YS-0503-13-CTIL|The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.|The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate and Morbidity in Infants Born Premature.||Tel-Aviv Sourasky Medical Center|No|Recruiting|November 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|6 Months|2 Years|Accepts Healthy Volunteers|||November 2013|June 25, 2014|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01985620||56373|
NCT01985568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1550|Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program|Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program||University of Colorado, Denver|No|Recruiting|November 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01985568||56377|
NCT01986049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBNet # 367320|Transversus Abdominis Plane (TAP) Block for Post Caesarian Pain|Phase 3 Study Comparing Transversus Abdominis Plane Block After Caesarian Section Usin Bupivacaine 0.5% vs. Bupivacaine 0.25% vs. Placebo (Normal Saline).|TAP Block|New York Methodist Hospital|Yes|Recruiting|February 2013|||February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|50 Years|No|||November 2013|November 14, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01986049||56340|
NCT01986322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penta 0211|Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine|Phase 2 Study of Immunogenicity and Safety of DPT/HB/Hib (Bio Farma) Vaccine Compared to DTP/HB (Bio Farma) Vaccine Given Simultaneously With Hib (Registered) Vaccine in Indonesian Infants||PT Bio Farma|Yes|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|6 Weeks|11 Weeks|Accepts Healthy Volunteers|||November 2013|November 11, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01986322||56319|
NCT01986582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoAL001|NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis|Stage 2, Double-blind, Randomized, Parallel Groups, One Centre Study in Patients With Allergic Rhinitis Treated With Nasal Oxymetazoline in Combination With Nasal Hydroxyl-propyl-methyl Cellulose (HPMC) or Placebo|NOPAR|Association Asthma, Bulgaria|Yes|Completed|October 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||September 2015|September 21, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01986582||56299|
NCT01982500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/12.01|Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer|A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice.||Hellenic Oncology Research Group|No|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Clinics for cancer prevention|October 2015|October 7, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01982500||56613|
NCT01983059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLVTS-SASL-35|Swiss Liver Venous Thrombosis Study|A Multicenter Prospective Observational Cohort Study|SLVTS-SASL-35|University Hospital Inselspital, Berne|No|Recruiting|March 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|blood, serum, plasma, stool and urine samples|Both|18 Years|N/A|No|Non-Probability Sample|Population of adolescent, adults and elderly|July 2015|July 13, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01983059||56570|
NCT01970501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-CLIN-303|Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure|GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure|GENETIC-AF|ARCA Biopharma, Inc.|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|120 Years|No|||March 2016|March 1, 2016|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970501||57532|
NCT01970514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-01|Safety Study of ARO Spinal System as an Adjunct to Lumbar Decompression|Temporary Axial Rotation Stabilization for Lumbar Disc Prolapse Surgery With the ARO® Spinal System: A Non-randomized Prospective Analysis of Clinical Efficacy, Safety and Cost Effectiveness||ARO Medical|No|Active, not recruiting|April 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||January 2015|January 13, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970514||57531|
NCT01970787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-250|A Trial of Radiofrequency Ablation for Anal Intraepithelial Neopplasia Using the HALO Ablation System|A Trial of Radiofrequency Ablation for Anal Intraepithelial Neopplasia Using the HALO Ablation System|AIN|Medtronic - MITG|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|75 Years|No|||July 2015|July 16, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970787||57510|
NCT01970800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/01/VA03|The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature|The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature||Maimonides Medical Center|Yes|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|5 Years|11 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970800||57509|
NCT01971879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2012-07|Protection of Arteritic Patients by Remote Preconditioning|Protection of Arteritic Patients by Remote Preconditioning|PARADIS|University Hospital, Angers|No|Recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01971879||57427|
NCT01972100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UFRN 401/09|Use of Low-level Laser Therapy (808nm) to Muscle Fatigue Resistance|Use of Low-level Laser Therapy (808nm) to Muscle Fatigue Resistance: a Randomized Double-blind Crossover Trial||Universidade Federal de Sao Carlos||Completed|April 2013|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Male|18 Years|28 Years|No|||October 2013|October 29, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01972100||57410|
NCT01971632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3401|A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain|||Mundipharma Research GmbH & Co KG||Completed|January 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|463|||Both|18 Years|N/A|No|||October 2013|February 21, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01971632||57446|
NCT01971645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00610|Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy|Dexamethasone as an Adjuvant to Ropivacaine for Femoral Nerve Blocks in Children Undergoing Knee Arthroscopy||Nationwide Children's Hospital|Yes|Recruiting|July 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|10 Years|19 Years|No|||January 2016|January 20, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971645||57445|
NCT01963416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOR-0001|Effects of Fruit Consumption on Risk Factors of Chronic Disease|A Randomized Controlled, Crossover in Design, Double Blind Clinical Trial Investigating the Effects of Whole Versus Processed Fruit Consumption on Risk Factors for Chronic Disease and Performance Indicators.||University of Reading|Yes|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|34|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963416||58074|
NCT01963429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS 13-695|Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC|A Randomized Phase III Study of the Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation in Patients With Recurrent/Residual Small Hepatocellular Carcinoma (APROH Study)||National Cancer Center, Korea|No|Recruiting|October 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2015|March 22, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01963429||58073|
NCT01972373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43407.042.13|Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer|Visualization of a VEGF-targeted Optical Fluorescent Imaging Tracer in Rectal Cancer During Flexible NIR Fluorescence Endoscopy|RAPIDO-TRACT|University Medical Center Groningen|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01972373||57389|
NCT01963923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-RSG-2011|Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Patients Awaiting Lung Resection|Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Exercise Tolerance and Quality of Life in Patients Awaiting Lung Resection by Video-assisted Thoracic Surgery||Universidade da Coruña|No|Recruiting|October 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||October 2013|December 19, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963923||58035|
NCT01963936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLMA in neonatal resuscitation|Supreme-LMA for Neonatal Resuscitation: a Prospective, Randomized Single-center Study|NEWBORN VENTILATION IN THE DELIVERY ROOM: CAN IT BE IMPROVED WITH A LARYNGEAL MASK AIRWAY? A Prospective, Randomized Single-center Study||University of Padova|Yes|Recruiting|July 2012|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|N/A|5 Minutes|No|||October 2013|October 15, 2013|October 11, 2013||||No||https://clinicaltrials.gov/show/NCT01963936||58034|
NCT01964222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309076|Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation|A Mixed Methods Study to Reduce Disparities in Cancer Clinical Trials by Adapting a Health Literacy Intervention for Informed Consent and Comparing it to Usual Care in a Randomized Experiment||Washington University School of Medicine|Yes|Completed|May 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|201|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 7, 2013||No||No|September 25, 2015|https://clinicaltrials.gov/show/NCT01964222||58013|
NCT01964573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0885|Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects|A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects||UCB Pharma|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2014|October 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964573||57986|
NCT01973010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0302.1|Massage Therapy for Chronic Low Back Pain|Phase 1 Study of Massage Therapy for Chronic Low Back Pain||Chengdu University of Traditional Chinese Medicine|Yes|Completed|June 2013|August 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|55 Years|No|||September 2014|September 7, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01973010||57340|
NCT01990300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136-011|Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus|Long-term Use of Alogliptin/Pioglitazone Combination Tablets in Patients With Type 2 Diabetes Mellitus||Takeda|No|Completed|November 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3281|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who have been examined at a medical institution|April 2015|April 15, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990300||56014|
NCT01990313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25916|Neural Signatures of Parkinson's Disease|Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation.|BrainRadio|Stanford University|Yes|Enrolling by invitation|October 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990313||56013|
NCT01986062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR11.001|Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting|A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom||Arbor Pharmaceuticals, Inc.|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|6 Years|12 Years|No|||June 2014|June 11, 2014|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986062||56339|
NCT01986023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D43TW008660|Improving Medication Adherence Through SMS (Short Messaging Service) in Adult Stroke Patients: a Randomised Controlled Behaviour Intervention Trial|A Randomized Controlled SMS Intervention For Improving Medication Adherence in Adult Stroke Patients||Aga Khan University|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01986023||56342|
NCT01986036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32AN4|The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake|The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake||Northumbria University|No|Active, not recruiting|November 2013|May 2014|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986036||56341|
NCT01986335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penta 0312|Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial|Phase 3 of Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial||PT Bio Farma|Yes|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|600|||Both|6 Weeks|11 Weeks|Accepts Healthy Volunteers|||October 2013|November 11, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01986335||56318|
NCT01986595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306008RINB|A Pilot Study on ALK Gene Mutations in Neuroblastoma|A Pilot Study on ALK Gene Mutations in Neuroblastoma||National Taiwan University Hospital|No|Recruiting|August 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Biopsy tumor tissue(mail tumor or bone marrow) or Blood|Both|N/A|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Neuroblastoma (NB) originates from the sympathetic nervous system and is one of the most        common cancers in infants and children. In our hospital, nearly 70% of patients are        diagnosed with stage 4, metastatic disease with a poor prognosis, despite the use of        multimodal therapy including chemotherapy, surgery, autologous stem cell transplantation,        radiation therapy, and differentiation therapy.|November 2013|November 11, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01986595|5 Years|56298|
NCT01982526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-84|Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients|Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients||Kanuni Sultan Suleyman Training and Research Hospital|No|Recruiting|May 2012|May 2014|Anticipated|May 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|We are collecting serum samples of pre and post operative endometroma patients and measuring      anti müllerian hormone levels.|Female|17 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females who are administring gynecology clinic suffering from symptomatic benign ovarian        cysts.|May 2012|November 12, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982526|2 Years|56611|
NCT01982513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-09|Influence of the Method of Alleviation of Aorto-Caval Compression on the Trans-Hepatic Ultrasound-Assessed Inferior Vena Cava Diameter In Pregnant Patients|Influence of the Method of Alleviation of Aorto-Caval Compression on the Trans-Hepatic Ultrasound-Assessed Inferior Vena Cava Diameter In Pregnant Patients: An Observational Study of the Left Lateral Tilt and of the Left Uterine Displacement||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-laboring, term prengnant women with singleton pregnancies who are admitted at Mount        Sinai Hospital for induction of labor, elective cesarean section or for observation for        any medical reason.|June 2014|June 3, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982513||56612|
NCT01983072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.08.INF|Symbiotic & Colonization|Effect of Starter Formula With Symbiotic on Microbiota Balance||Nestlé|No|Completed|April 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|141|||Both|N/A|4 Months|Accepts Healthy Volunteers|||November 2013|November 12, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01983072||56569|
NCT01971372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3411|Post-Operative Pain Management With NSAIDS|Comparing Methods of NSAID Delivery for Postoperative Pain||University of Oklahoma|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited and consented through an IRB-approved process. Women and        minorities are included in the research protocol. We will not exclude potential subjects        from participating in this or any study solely on the basis of ethnic origin or        socioeconomic status. There are no children involved in this study.|December 2014|December 2, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971372||57466|
NCT01971593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI170964|The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease|Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease||Washington University School of Medicine|Yes|Terminated|August 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|October 23, 2013|Yes|Yes|Investigator left institution|No||https://clinicaltrials.gov/show/NCT01971593||57449|
NCT01962805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPV-101|Comparison of Two Formulations of Proellex for Vaginal Administration|A Double-Blind, Crossover Study in Healthy Volunteers to Compare Two Formulations of Proellex for Vaginal Administration||Repros Therapeutics Inc.|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|8|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962805||58121|
NCT01962818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1936M|High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance.|High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths in Neonates Compared With Standard High Frequency Oscillatory Ventilation - Effects on Lung Volume Monitored by Electric Tomography Impedance||Rigshospitalet, Denmark|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|24 Weeks|44 Weeks|No|||October 2015|October 28, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962818||58120|
NCT01971658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0284|Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)|A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA."|IFM2013-04|Nantes University Hospital|No|Completed|October 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|358|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01971658||57444|
NCT01971606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0253|Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study|||Yonsei University|Yes|Completed|October 2007|March 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|234|||Both|19 Years|90 Years|No|||October 2013|October 31, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971606||57448|
NCT01972646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16936e|Predictors of Failure of Empiric Outpatient Antibiotic Therapy in Emergency Department Patients With Uncomplicated Cellulitis.|Predictors of Failure of Empiric Outpatient Antibiotic Therapy in Emergency Department Patients With Uncomplicated Cellulitis.||Lawson Health Research Institute|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft        tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer,        or rash) were screened for eligibility by ED staff or trained research assistants and        invited to participate in this study once an emergency physician confirmed a cellulitis        infection.|October 2013|October 24, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01972646||57368|
NCT01972971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105109RC|To Establish a Novel Prototype of Clinical Pharmacy Services by Warfarin Consultation in a Pharmacist Clinic|To Establish a Novel Prototype of Clinical Pharmacy Services by Warfarin Consultation in a Pharmacist Clinic||National Taiwan University Hospital|No|Recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|300|||Both|20 Years|N/A|No|||October 2013|October 24, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01972971||57343|
NCT01972984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011712-01H|Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients|The NEO (NEOADJUVANT ENDOCRINE OUTCOMES) TRIAL: Neoadjuvant Endocrine Therapy for Primary Breast Cancer: Investigation of Clinical and Translational Outcomes|NEO ER 11-05|Ottawa Hospital Research Institute|Yes|Completed|October 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01972984||57342|
NCT01969448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302004|Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction|A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction|NASSM|Washington University School of Medicine|Yes|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01969448||57612|
NCT01986075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6850|A Sequenced Behavioral and Medication Intervention for Cocaine Dependence|A Sequenced Behavioral and Medication Intervention for Cocaine Dependence||New York State Psychiatric Institute|Yes|Recruiting|January 2014|October 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|155|||Both|18 Years|60 Years|No|||October 2015|October 26, 2015|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986075||56338|
NCT01986348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-004|A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas|A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas|KING|Karyopharm Therapeutics, Inc|No|Recruiting|March 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986348||56317|
NCT01986361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-STR-01|Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method|A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method||Reckitt Benckiser LLC|No|Recruiting|October 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986361||56316|
NCT01986608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0036|Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects|A Single Center Open-label, Randomized, Single-dose, 3-way Crossover Study to Compare the Safety, Tolerability, and Pharmacokinetics of Lacosamide Administered as Oral Tablet or Intravenous Infusion in Healthy Japanese Subjects||UCB Pharma|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|26|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986608||56297|
NCT01982539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0072|Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute|An Open-Label Study of the Safety and Efficacy of Zipsor® (Diclofenac Potassium) Liquid Filled Capsules in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute Pain||Depomed|No|Completed|November 2013|September 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|17 Years|No|||September 2014|April 30, 2015|November 1, 2013|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01982539||56610|
NCT01982799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22245|Local Anesthesia and Analgesics in Endodontic Pain|Local Anesthesia and Analgesics in Post-Operative Endodontic Pain|LAAEP|University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|February 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01982799||56590|
NCT01987219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00004|The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia|The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia||New York University School of Medicine|Yes|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|12 Years|80 Years|No|||January 2015|January 26, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01987219||56250|
NCT01962194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE403-HMO-CTIL|Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus|Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus||Hadassah Medical Organization|No|Not yet recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|75 Years|No|||June 2013|October 10, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01962194||58168|
NCT01962207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200171|To Evaluate the Antibody Persistence 6, 7, 8, 9 and 10 Years After Administration of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Meningitec or Mencevax ACWY as Well as Safety and Immunogenicity of a Booster Dose of MenACWY-TT Vaccine 10 Years Post Primary Vaccination|The Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Meningitec or Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Administered 10 Years Post-primary Vaccination||GlaxoSmithKline||Recruiting|October 2013|June 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|204|||Both|6 Years|21 Years|Accepts Healthy Volunteers|||November 2015|February 4, 2016|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962207||58167|
NCT01962558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-T-02|Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus|A Blinded Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus vs. VNS With Unpaired Tones||MicroTransponder Inc.|Yes|Active, not recruiting|February 2014|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|22 Years|65 Years|No|||September 2015|September 21, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962558||58140|
NCT01962571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000053|Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial|Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial|TONE|University Eye Hospital, Freiburg|Yes|Recruiting|November 2014|December 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|No|||March 2016|March 18, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01962571||58139|
NCT01962831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-13-51|Randomized Controlled Trial: Induction of Labour of Obese Women With Dinoprostone or Single Balloon Catheter|Randomized Controlled Trial: Single Balloon Catheter Versus Dinoprostone Vaginal Insert for Induction of Labour of Women With a BMI Equal to or Greater Than 30||Regina Qu'Appelle Health Region|Yes|Recruiting|October 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01962831||58119|
NCT01962844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC 0305|Coconut Oil in Cardiovascular Disease|The Effect of Extra Virgin Coconut Oil Treatment Nutritional Associated With Data Anthropometric and Lipid Profile in Patients With Chronic Heart Disease|HCCO|Universidade Federal do Rio de Janeiro|Yes|Active, not recruiting|January 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|20 Years|85 Years|No|||October 2013|October 10, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962844||58118|
NCT01972165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0072|Comparison of Subjective Outcomes and Changes of Ultrasonographic Morphology of Median Nerves of Mini-open and Endoscopic Carpal Tunnel Release in Patients With Idiopathic Carpal Tunnel Syndrome|||Yonsei University|No|Completed|November 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|27 Years|82 Years|No|||October 2013|October 23, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01972165||57405|
NCT01971918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/006/HP|Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics|Comparative Analysis of Two Therapeutic Strategies: "Early Switch" Versus "Therapeutic Intensification" in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion.|STRADA|University Hospital, Rouen|No|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|80 Years|No|||July 2015|July 29, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01971918||57424|
NCT01971892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9015|Non Invasive Ventilation in Abdominal Postoperative Period|Non Invasive Ventilation After Abdominal Surgery in Postoperative Acute Respiratory Failure: a Multicenter Randomized Controlled Trial.|NIVAS|University Hospital, Montpellier|Yes|Active, not recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01971892||57426|
NCT01971905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-366|Perfusion Scanning's for Kidney Tumors|Perfusion Scanning's for Kidney Tumors||University Hospital Roskilde|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|35 Years|75 Years|No|Probability Sample|the cohort will be selected from department of urology, Roskilde Hospital|November 2015|November 15, 2015|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01971905||57425|
NCT01972425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH6293|Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship|A Randomised Controlled Trial of Biomarker-based Exclusion of VAP to Improve Antibiotic Stewardship|VAPRapid-2|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|October 2013|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972425||57385|
NCT01972438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130206|A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients|A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients||National Institutes of Health Clinical Center (CC)||Suspended|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||May 2015|January 12, 2016|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01972438||57384|
NCT01970033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-SP2086-301|Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|December 2012|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|80 Years|No|||October 2013|October 22, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01970033||57567|
NCT01970046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-SP2086-302|A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|April 2013|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|80 Years|No|||October 2013|October 22, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01970046||57566|
NCT01989806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-1|Robotic-assisted Locomotor Training on Mobility and Cardiopulmonary Function in Patients Suffering From Spinal Cord Injury|Investigation on the Effect of Robotic-assisted Body Weight Supported Treadmill Training on Walking and Cardiopulmonary Recovery in Patients Suffering From Incomplete Spinal Cord Injury||Kowloon Hospital, Hong Kong|No|Recruiting|December 2013|May 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2014|August 10, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01989806||56052|
NCT01990625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN First Look Ultrasound|A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings|Global Network First Look: A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings||NICHD Global Network for Women's and Children's Health|Yes|Recruiting|April 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|16000|||Female|12 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990625||55989|
NCT01986374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCG 2013|Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF|Intrauterine Injection of Human Chorionic Gonadotropin to Enhance Embryo Implantation||Servy Massey Fertility Insititute|No|Recruiting|June 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|21 Years|47 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986374||56315|
NCT01986387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000036188|Virtual Peer-to-Peer (VP2P) Support Mentoring for Chronic Pain: A Pilot RCT|Virtual Peer-to-Peer (VP2P) Support Mentoring for Adolescents With Chronic Pain: A Feasibility Pilot Randomized Controlled Trial||The Hospital for Sick Children|No|Recruiting|July 2013|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|12 Years|18 Years|No|||December 2014|December 29, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986387||56314|
NCT01986621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antiplatelet therapy after PCI|Myocardial Injury or Type 4 Infarction Following Elective Coronary Artery Stenting|Identifying Patients at Higher Risk for Periprocedural Myocardial Injury or Infarction Who Might Benefit From More Potent Antiplatelet Therapy Following Elective PCI||University Hospital Heidelberg||Completed|April 2014|July 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|530|||Both|18 Years|N/A|No|Probability Sample|Patients with stable or unknown CAD undergoing elective coronary intervention without        receiving additional examination, such as biopsy, Ablation or any other procedure that        could lead to myocardial injury resulting in elevation of the cardiac Troponin.|January 2016|January 8, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986621||56296|
NCT01991158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-030-01|GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma|An Open, Single-center, Phase II Clinical Trial for Treatment of Untreated Extranodal NK/T Cell Lymphoma With High Dose of Methotrexate in Combination With Gemcitabine, Pegaspargase and Dexamethasone (GAD-M Regimen)||Sun Yat-sen University|Yes|Recruiting|November 2013|November 2020|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2013|November 17, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991158||55948|
NCT01982552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPEAL|An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life|An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life||LEO Pharma|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending a hospital outpatient clinic or the private practice of a        board-certified dermatologist, dermatology-certified nurse practitioner or physician        assistant trained in dermatology|July 2015|July 20, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982552||56609|
NCT01986920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-201|Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis||Aclaris Therapeutics, Inc.|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986920||56273|
NCT01982812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7R01NS074409-02|A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM|A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria||University of Rochester|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|24 Months|83 Months|No|||June 2015|June 19, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01982812||56589|
NCT01982825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059657|Innovative Web-Based Intervention for Smoking Cessation Among College Students|Innovative Web-Based Intervention for Smoking Cessation Among College Students||Emory University|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01982825||56588|
NCT01987193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1214 - DS01|Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)|Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy||University of Florida|No|Enrolling by invitation|July 2012|June 2019|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Patients treated at radiation oncology clinic|October 2015|October 13, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01987193||56252|
NCT01987232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ004|Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer|Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer||Onyx Pharmaceuticals|No|Recruiting|September 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987232||56249|
NCT01962220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL5557|Mother Infant Retention for Health: MIR4Health|Mother Infant Retention for Health: Evaluation of a Multicomponent Strategy to Link and Retain Newly Identified HIV-infected Pregnant Women and Their Infants Throughout the Antenatal and Post-partum Period|MIR4HEALTH|Columbia University|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|680|||Female|16 Years|N/A|No|||December 2015|December 19, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962220||58166|
NCT01980602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/YH/0210|Effect of Exercise on Patients With Claudication Undergoing Surgery|A Randomised Controlled Trial to Analyse the Histological, Physiological and Haemorrheological Adaptations to Supervised Exercise Training in Claudicants||University of Hull|No|Recruiting|March 2011|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|45 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 4, 2013|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980602||56757|
NCT01981681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5391002|A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects|A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects||Pfizer|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981681||56675|
NCT01981980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1362|Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation|Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation||Universidade Federal do Triangulo Mineiro|No|Completed|October 2009|October 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Female|27 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01981980||56652|
NCT01981993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/048|Validation of a Urinary Biomarker as Diagnostic Tool for AKI in Sepsis|Value of a Urinary Biomarker Set Obtained by a Proteomics Approach to Predict Acute Kidney Injury and Prognosis in Sepsis Patients: a Prospective Cohort Study||University Hospital, Ghent|No|Active, not recruiting|June 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples Without DNA|urine samples for proteomic analysis|Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients admitted to a tertiary care intensive care unit (ICU) with sepsis|December 2014|December 4, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01981993||56651|
NCT01982240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-00|12-Week Study of Plecanatide for CIC (The CIC3 Study)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)||Synergy Pharmaceuticals Inc.|No|Active, not recruiting|November 2013|April 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1350|||Both|18 Years|80 Years|No|||February 2015|February 17, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01982240||56632|
NCT01982227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208138|Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.|Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2013|December 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|70 Years|No|Non-Probability Sample|Patient with progressive colorectal cancer in intra-abdominal surgery requiring resection        +/- Chemotherapy Hyperthermic Intraperitoneal|January 2015|January 29, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982227||56633|
NCT01978184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI# 13-074|Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine|Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine||University of Pittsburgh|Yes|Recruiting|November 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978184||56943|
NCT01978171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201302|Prediction of Everolimus-induced Interstitial Lung Disease|Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity|PREVENT|Radboud University|No|Recruiting|May 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|whole blood, serum, skin biopsies, broncho-alveolar lavage fluid|Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose        disease is refractory to non steroidal aromatase inhibitors, and are eligible for        treatment with exemestane and everolimus.|May 2015|May 8, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978171||56944|
NCT01978444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ-20131101|Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer|Prospective Randomized Controlled Trial of Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）vs. Laparoscopic D2 Lymphadenectomy for Advanced Gastric Cancer||Huazhong University of Science and Technology|Yes|Active, not recruiting|October 2013|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|167|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978444||56923|
NCT01978977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.17|Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer|Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy Plus Bevacizumab in Women With HER2-Negative Metastatic Breast Cancer. An Observational Study.||Hellenic Oncology Research Group|No|Completed|July 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|Clinics for cancer prevention|October 2015|October 6, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01978977||56882|
NCT01979276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306014005|Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma|A Phase I/II Study of Pomalidomide (CC-4047®), Dexamethasone and Romidepsin in Patients With Relapsed or Refractory Multiple Myeloma (Romi Poma)|Romi Poma|Weill Medical College of Cornell University||Recruiting|November 2013|November 2020|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979276||56859|
NCT01970345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1206|A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder|A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|5 Years|12 Years|No|||March 2016|March 14, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970345||57544|
NCT01970982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-REXC-04-JP|Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting|A Controlled, 3-arm Parallel Group Study to Demonstrate Reduction in Exposure to Smoke Constituents in Healthy Smokers Switching to THS 2.2 or to Smoking Abstinence, Compared to Conventional Cigarettes for 5 Days in Confinement||Philip Morris Products S.A.|No|Completed|July 2013|July 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|166|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01970982||57496|
NCT01971450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16777|Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension|Prospective Multicentre Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension|IVENT|Bayer|No|Recruiting|December 2013|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients ≥ 18 years old with PH, treated with Ventavis and for which the        inclusion and exclusion criteria are fulfilled, are eligible for enrolment into the study.|March 2016|March 11, 2016|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01971450||57460|
NCT01971697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046624|Socio-Economic Survey in Uganda|Short Term Socio-economic Impact Due to Blunt Orthopedics Trauma on the Victims in Uganda||Duke University|No|Completed|September 2013|March 2015|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Urgent care patients. Patients coming to the ER with a orthopaedic injury.|May 2015|October 15, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01971697||57441|
NCT01971463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818577|Bolus of Saline in Stroke|Optical Measurement of Cerebral Blood Flow Response After Ischemic Stroke|BOSS|University of Pennsylvania|No|Recruiting|October 2013|||October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|110 Years|No|||December 2015|December 23, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971463||57459|
NCT01971736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R079h/55|Efficacy of Long Pulsed 1064nm Laser for Facial Skin Tightening|Randomized-controlled Split-face Treatment of Facial Rhytids and Laxity in Asians Using Long-pulse 1064nm Laser||Phramongkutklao College of Medicine and Hospital|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|22|||Both|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults with visble signs of aging|October 2013|October 23, 2013|March 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01971736||57438|
NCT01980316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLH3|Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting|Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting||Jinling Hospital, China|Yes|Completed|April 2010|July 2013|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|80 Years|No|||October 2015|October 21, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980316||56779|
NCT01981161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235207|Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis|Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques|BEST-MS|University Hospital, Toulouse|Yes|Recruiting|November 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Observational|Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|urine and blood|Both|18 Years|55 Years|No|Non-Probability Sample|Multiple sclerosis|December 2015|December 22, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981161||56714|
NCT01981408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15283|A Study of LY2801653 in Healthy Participants|Disposition of [^14C]-LY2801653 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981408||56695|
NCT01982253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_203|Fasiglifam 25 mg BID vs 50 mg QD|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Control in Subjects With Type 2 Diabetes||Takeda|No|Terminated|November 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|November 5, 2013|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT01982253||56631|
NCT01978210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moisture Pager Intervention|Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism|Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism||University of Rochester|No|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|3 Years|6 Years|No|||January 2016|January 22, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01978210||56941|
NCT02009358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCY2009|Mental Health Promotion Interventions Among Migrant Workers in China|Mental Health Promotion Interventions for Reducing Self-reported Depression and Improving Rates of Early Detection of Depression Among Migrant Workers in China, a Cluster Randomised Controlled Trial||Peking University|Yes|Completed|March 2010|November 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|913|||Both|18 Years|60 Years|No|||December 2013|February 22, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02009358||54554|
NCT01978197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 2013-0003|Evaluation of Cessation Preferences of Menthol Smokers|Evaluation of Cessation Preferences of Menthol Smokers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978197||56942|
NCT01978457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104008404|Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction|Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction||Yale University||Active, not recruiting|October 2012|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|50 Years|No|||December 2015|December 28, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978457||56922|
NCT01978769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|effortdiscounting.ctil|The Effect of Physical Effort in the Decision Making Process of Preadolescents With ADHD|The Effect of Physical Effort in the Decision Making Process of Preadolescents With ADHD||Shaare Zedek Medical Center|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|11 Years|13 Years|No|Non-Probability Sample|residents of jerusalem|July 2013|September 6, 2015|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01978769||56898|
NCT01979289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH095830|Computerized Cognitive Remediation for Geriatric Depression|Computerized Cognitive Remediation for Geriatric Depression||Weill Medical College of Cornell University|Yes|Recruiting|August 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|89 Years|No|||November 2013|November 1, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979289||56858|
NCT02010242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSN000200|Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria||Genkyotex Innovation SAS|Yes|Completed|October 2013|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||March 2015|March 27, 2015|June 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010242||54487|
NCT01970657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-033|Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247|An Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247 in Subjects Who Participated in Study 802-247-09-032(EU)||Healthpoint|Yes|Active, not recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970657||57520|
NCT01970631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000916|The Study of Physical Activity Rewards After Knee Surgery||SPARKS|Brigham and Women's Hospital|Yes|Recruiting|November 2013|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|200|||Both|40 Years|N/A|No|||December 2015|December 16, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970631||57522|
NCT01970644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:129|Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases|Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases||CancerCare Manitoba|Yes|Terminated|April 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple (>= 4) brain metastases undergoing radiosurgery at the Winnipeg        Centre for Gamma Knife Surgery.|December 2015|December 4, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970644||57521|
NCT01971255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130215|Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People|Evaluation of Anti-Hemagglutinin Antibodies as a Correlate of Protection in an H1N1 Influenza Healthy Human Challenge Model||National Institutes of Health Clinical Center (CC)||Completed|September 2013|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|74|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|October 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971255||57475|
NCT01971242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003363-64|Trial of Exenatide for Parkinson's Disease|A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease|EXENATIDE-PD|University College, London|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|75 Years|No|||March 2015|March 16, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971242||57476|
NCT01971762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-STA-2011-01|Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology|Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|April 2011|January 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|14 Years|N/A|No|Non-Probability Sample|All patients diagnosed bacteremia by S. aureus attended in participating centers will be        included|November 2013|December 4, 2014|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01971762||57436|
NCT01972269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-06|Determination of the Effective Volume of 0.125% Bupivacaine-fentanyl 5mcg/mL in Labour Epidurals|Determination of the Effective Volume of the 0.125% Bupivacaine-fentanyl 5mcg/mL Mixture Used for Epidural Analgesia in Labor||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|14||Actual|80|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972269||57397|
NCT01971970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-42736.078.13|Biomarkers of Anti-TNF Treatment in IBD|Biomarkers Predicting the Effect of Anti-TNF Treatment in Pediatric and Adult Inflammatory Bowel Disease||Erasmus Medical Center|No|Recruiting|October 2013|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|whole blood, gastrointestinal tract biopsies,buccal epithelium|Both|6 Years|N/A|No|Probability Sample|Pediatric and adult IBD patients from the Department of Pediatric Gastroenterology of        Erasmus MC-Sophia Children's Hospital and from the Department of Gastroenterology of        Erasmus MC respectively.|September 2015|September 4, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01971970||57420|
NCT01980875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0118|Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Active, not recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980875||56736|
NCT01981395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311094|Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers|A Double Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Anti-hyperalgesic Efficacy of a Single Dose of Fenobam on Heat/Capsaicin Induced Cutaneous Hyperalgesia in Adult Healthy Volunteers.||Washington University School of Medicine|Yes|Active, not recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981395||56696|
NCT01981707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003058-25|F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer|F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide|PRECHOL|University Hospital, Grenoble|No|Terminated|December 2013|March 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|August 1, 2013||No|enrollment default|No||https://clinicaltrials.gov/show/NCT01981707||56673|
NCT02009059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scs-2013|Accuracy of Non-invasive Temperature Measurement in Deep Hypothermia|Accuracy of Non-invasive Temperature Measurement in Deep Hypothermia; a Prospective Cohort Study||Oslo University Hospital|No|Enrolling by invitation|November 2013|March 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients undergoing elective thoracic surgery in deep hypothermia|January 2015|October 28, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02009059||54577|
NCT02009449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM0010-001|A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors||ARMO BioSciences|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|24||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009449||54547|
NCT02009371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2011-4023-03|A Clinical Study of Light Therapy on Depressive Episodes of Bipolar Disorder|||Peking University||Completed|January 2013|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||June 2015|October 19, 2015|May 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009371||54553|
NCT01978470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-076014-01|External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy|External Trigeminal Nerve Stimulation for Epilepsy|eTNS for DRE|NeuroSigma, Inc.|Yes|Recruiting|June 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|65 Years|No|||November 2013|November 1, 2013|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978470||56921|
NCT01978483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6030|Effect of RANKL Inhibition on UV-induced Immunosuppression|Effect of RANKL Inhibition on UV-induced Immunosuppression||Innovaderm Research Inc.|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 23, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978483||56920|
NCT01978782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF12.04|Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).|Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).|RECITAL|Radboud University|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01978782||56897|
NCT01978990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406-13- HMO-CTIL|Assessment of a Health Informatics System on Insulin-treated Diabetic Patients|||Hadassah Medical Organization|No|Not yet recruiting|January 2017|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Type 1 or 2 diabetics diagnosed at least 12 months prior to study enrollment|January 2016|January 4, 2016|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01978990||56881|
NCT01979003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202459|A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion|A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion||University of Arkansas|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01979003||56880|
NCT02010541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECH-EDU-KIDS-T1D-2013|The Influence of Technology, Education and Psychological Support on Metabolic Control in Children With T1D|The Influence of Diabetes Related Technology, Education and Psychological Support on Metabolic Control in Young Children With Type 1 Diabetes||University Medical Centre Ljubljana|No|Active, not recruiting|December 2013|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|7 Years|No|Non-Probability Sample|All children that have diabetes in Slovenia are controlled at the Dept. of Pediatric        Endocrinology, Diabetes & Metabolism, University Children's Hospital, UMCL and the        population will be taken from here|February 2014|February 12, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010541||54464|
NCT02010814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO|Characterization of a Prospective Cohort of Women With PCOS|Metabolic and Endocrinological Characterization of a Prospective Cohort of Women With PCOS||Odense University Hospital|No|Recruiting|January 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|Blood and urine samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with PCOS, diagnosed by the Rotterdam criteria which include at least two of the        following:          -  irregular mestrual cycle          -  polycystic ovaries          -  biochemical/clinical hyperandrogenemia|July 2014|July 31, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02010814|1 Day|54443|
NCT02011087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99813A|Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy|Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Small Cell Lung Cancer||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|February 2014|||February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011087||54422|
NCT01971021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN Linkoping 2013/56-31|Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.|Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.||Linkoeping University|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients with cancer and the need for central venous access|September 2015|September 21, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01971021|12 Months|57493|
NCT01971268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-02|Compare the Success Rate of T3 Dental Implant (Biomet 3I) With or Without Platform-switch Concept|Marginal Bone Behavior of Dental Implants to Different Rehabilitation Protocols||Instituto de Implantologia|No|Not yet recruiting|January 2014|January 2015|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population from a private office who seek care to replace missing teeth, must have        economical status to do implant supported rehabilitations|October 2013|October 23, 2013|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01971268||57474|
NCT01970995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHM-REXA-07-JP|Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting|A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 90 Days||Philip Morris Products S.A.|No|Completed|August 2013|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|160|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01970995||57495|
NCT01971008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABOHP|Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)|Abdominal Binders for the Treatment of Orthostatic Hypotension in Parkinson's Disease: an Investigator-initiated Randomized, Placebo-controlled, Cross-over Study|ABOHP|Medical University Innsbruck|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|14|||Both|40 Years|90 Years|No|||August 2014|August 12, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01971008||57494|
NCT01971489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 240413|Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors||Roswell Park Cancer Institute|No|Withdrawn|September 2015|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971489||57457|
NCT01971476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.27|Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known|Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known||Boehringer Ingelheim||Active, not recruiting|October 2013|February 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|2 Years|17 Years|No|||February 2016|February 22, 2016|October 10, 2013||||No||https://clinicaltrials.gov/show/NCT01971476||57458|
NCT01971749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSG-TCI-2012-01|Register of Treatment of Unprotected Left Main Coronary Artery Stenosis in Andalucía|Multicenter, Prospective, Observational Study of of Treatment of Unprotected Left Main Coronary Artery Stenosis in Andalucía|RETRATO|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|May 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|315|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients with unprotected left main coronary artery stenosis in Andalucia who        can follow a year monitoring in participating centers|August 2015|August 4, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01971749|2 Years|57437|
NCT01972828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.440|Early Haemodynamic Optimization Using Preload Dependence During Septic Shock = EHOSS-1|Effect of Haemodynamic Optimization Using Preload Dependence Indexes and Pulmonary Thermodilution on Cardiovascular Failure Duration During Septic Shock: a Randomized Study|EHOSS-1|Hospices Civils de Lyon|No|Completed|July 2007|||August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01972828||57354|
NCT01972516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-375|Tivozanib As Maintenance Therapy In GYN|A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Dana-Farber Cancer Institute|Yes|Terminated|November 2013|January 2016|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|October 24, 2013|Yes|Yes|due to slow accrual|No||https://clinicaltrials.gov/show/NCT01972516||57378|
NCT01972815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205060RIB|Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs|Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs||National Taiwan University Hospital|No|Recruiting|October 2012|||October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|suspect NPC patients|October 2013|October 29, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972815||57355|
NCT01981174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU84470|A Pilot Study of Needle Size and Pain Perception With Botulinum Toxin A Injections|The Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin A Injections||Northwestern University|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|20|||Female|25 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981174||56713|
NCT01981187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818AUS03|LGX818 for Patients With BRAFV600 Mutated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors|SIGNATURE|Array BioPharma|No|Completed|January 2014|||September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981187||56712|
NCT01982006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/23|Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery|Impact Médico-Economique de la Chirurgie de la cATaracte au Laser Femtoseconde|FEMCAT|University Hospital, Bordeaux|No|Recruiting|October 2013|April 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1050|||Both|22 Years|N/A|No|||January 2015|January 12, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01982006||56650|
NCT02009462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTCTC-01-001|Artefill for the Treatment of HIV-associated Facial Lipoatrophy|Artefill for the Treatment of HIV-associated Facial Lipoatrophy||AIDS Research and Treatment Center of the Treasure Coast|Yes|Enrolling by invitation|December 2013|January 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009462||54546|
NCT02009748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITDZIRR|Vitamin D Supplementation in Cirrhotic Patients|Vitamin D Supplementation in Cirrhotic Patients: A Randomized, Multi-center, Double-blind, Placebo Controlled Trial to Evaluate Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels in Cirrhotic Patients||Medical University of Graz|No|Completed|December 2013|June 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||June 2015|June 3, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009748||54525|
NCT02010073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUNG-SAFE|Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE|A Multicentre, Prospective, Observational, 4-week Inception Cohort Study Being Carried Out by the Acute Respiratory Failure Section of ESICM|LUNG-SAFE|European Society of Intensive Care Medicine|No|Completed|February 2014|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14000|||Both|16 Years|N/A|No|Probability Sample|Our aim is to obtain a sample of at least 1000 ARDS patients within the cohort of patients        receiving assisted ventilation.|December 2014|December 10, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02010073||54500|
NCT02009644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-0008-12|Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms|A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms||Bolton Medical|Yes|Recruiting|November 2013|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|85 Years|No|||August 2015|August 21, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009644||54532|
NCT02010021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13236|Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.|Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|18 Years|N/A|No|||November 2013|October 15, 2015|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010021||54504|
NCT02010034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112010-159|Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury||Children's Medical Center Dallas|Yes|Enrolling by invitation|August 2013|December 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|2 Months|10 Years|No|||February 2015|February 4, 2015|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010034||54503|
NCT02010255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0124|Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant||Gilead Sciences|Yes|Completed|January 2014|August 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|334|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010255||54486|
NCT02010528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIS-PSY-PAR-T1D-2013|Diabetes Distress, Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With T1D|Diabetes Distress,Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With Type 1 Diabetes||University Medical Centre Ljubljana|No|Completed|December 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All children that have diabetes in Slovenia are controlled at the Dept. of Pediatric        Endocrinology, Diabetes & Metabolism, University Children's Hospital, UMCL and the        population will be taken from here|February 2014|February 12, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010528||54465|
NCT02012400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016||Effects of Regular Exercise on Adult Asthma|Effects of Regular Exercise on Physical Fitness, Asthma Control and Quality of Life of Adult Asthmatics||University of Oulu|No|Recruiting|August 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|16 Years|65 Years|No|||December 2013|December 9, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02012400||54322|
NCT02012673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOIL-study|A Safety and Feasibility Study of Re-treating Patients With Severe Emphysema With the RePneu LVRC System.|The Safety and Feasibility of Re-treating Patients With Severe Emphysema With the RePneu LVRC System: a Pilot Study.|RECOIL|University Medical Center Groningen|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||October 2015|October 2, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02012673||54301|
NCT02008812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108029RD|Ad Sensor-based Real-time Diagnosis of Adenovirus|Ad Sensor-based Real-time Diagnosis of Adenovirus||National Taiwan University Hospital||Recruiting|August 2011|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 12, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008812||54596|
NCT02009098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002068-29|RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section|Antibiotic Prophylaxis and Intervention for Postpartum Infections Following Caesarean Section|APIPICS|Odense University Hospital|Yes|Withdrawn|October 2014|June 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||October 2014|April 20, 2015|May 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02009098||54574|
NCT01972009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0812|Wave Intensity Analysis in the Pulmonary Artery|Systematic Assessment of Pulmonary Artery Haemodynamics Using Wave Intensity Analysis||Imperial College London|Yes|Not yet recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with normal pulmonary pressures will be recruited from patients who are on the        waiting list awaiting routine cardiac catheterisation at Hammersmith Hospital for the        investigation of shortness of breath and chest pain.        Patients with pulmonary hypertension will be recruited from the National Pulmonary        Hypertension Service, Hammersmith Hospital, who are awaiting right and left heart        catheterisation studies as part of their routine diagnostic work up.|October 2013|October 31, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972009||57417|
NCT01972022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSFORM 1207/2013|TRANSFORM OCT TRiple Assessment of Neointima Stent FOrmation to Reabsorbable polyMer With Optical Coherence Tomography|A Prospective Optical Coherence Tomography (OCT) Study on Coronary Vessel Wall Response to Stent Eluting Everolimus From a Biodegradable Polymer (EES SYNERGY™) Compared With Stent Eluting Zotarolimus From a Durable Polymer (ZES, RESOLUTE Integrity™).|TRANSFORM|A.O. Ospedale Papa Giovanni XXIII|Yes|Active, not recruiting|November 2013|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2015|July 2, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972022||57416|
NCT01971281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-20|Safety Feasibility and Effect of TTFields Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma|A Phase II Study of TTFields Concomitant With Gemcitabine and TTFields Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma|PANOVA|NovoCure Ltd.|No|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971281||57473|
NCT01971996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-FSP|Measuring the Effect of External Pressure on the Regional Cerebral Oxygen Saturation Monitored by Near-infrared Spectroscopy(NIRS) Technology|Measuring the Cerebral Oxygen Saturation With NIRS Sensor Placed on the Forehead of Patients in the Prone Position. How Does the External Pressure Affect the Measurement.||Glostrup University Hospital, Copenhagen|Yes|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing lumbar spine surgury, and are placed in the prone position|July 2014|July 1, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01971996||57418|
NCT01971983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osteo-ufcspa|Effect of Two Osteopathic Techniques on Thickness of Paravertebral Muscles of the Lumbar Spine|Effect of Two Osteopathic Techniques on Thickness of Paravertebral Muscles of the Lumbar Spine: Randomized Controlled Trial||Federal University of Health Science of Porto Alegre|No|Active, not recruiting|February 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|March 15, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01971983||57419|
NCT01973114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M 05 - 2013|Latanoprost for the Treatment of Menière's Disease|A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease||Synphora AB||Active, not recruiting|October 2013|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01973114||57332|
NCT01973361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130152-01H|Efficacy Study of Ultrasound-Assisted Debridement to Influence Wound Healing|A Randomized Controlled Trial to Investigate if Application of Low Frequency Ultrasound-assisted Debridement May Improve Healing and Infection Outcomes for the Person With Vasculopathy and Recalcitrant Wounds of the Lower Extremity|UltraHeal|Ottawa Hospital Research Institute|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973361||57313|
NCT01973101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 217/2012|Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.|Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.|CIRCE|Instituto do Cancer do Estado de São Paulo||Recruiting|June 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|70 Years|No|||July 2014|July 14, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01973101||57333|
NCT01980901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0010|Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System|A Post-Market Approved (PMA) Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System||TriVascular, Inc.|Yes|Active, not recruiting|October 2013|October 2018|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|N/A|No|Probability Sample|320 subjects enrolled with an estimated 192 evaluable subjects at the fifth year from the        following cohorts:          -  Available data from the 161 pivotal cohort subjects          -  All Continued Access subjects;          -  All subjects from the HDE PAS (reference H100008); and          -  A minimum of 59 subjects from de novo enrollment.|April 2015|November 23, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980901||56734|
NCT01981200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210977|Feasibility of Strength Training in Patients Hospitalized Due to COPD|Feasibility of Progressive Knee Extension Strength Training Using Ankle Weight Cuffs in Patients Hospitalized With COPD in Acute Exacerbation||Frederikssunds Hospital, Denmark|Yes|Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||February 2014|February 9, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01981200||56711|
NCT01981421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0193|Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis|||Yonsei University|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|19 Years|80 Years|No|Probability Sample|Patients who have chronic liver disease and who are planned to receive anti-viral        treatment.|November 2013|November 4, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981421||56694|
NCT01981720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-102-F03|Extension Study of PRX-102 for 24 Months|A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients||Protalix|No|Enrolling by invitation|December 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981720||56672|
NCT02013258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5208|Oxytocin Trial in Prader-Willi Syndrome|Oxytocin Trial in Prader-Willi Syndrome||University of Florida|Yes|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|5 Years|11 Years|No|||September 2015|September 17, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013258||54257|
NCT02009761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293.7|Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).|Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.||Boehringer Ingelheim||Active, not recruiting|December 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 9, 2013||||No||https://clinicaltrials.gov/show/NCT02009761||54524|
NCT02009072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pterygium Surgery|Comparison Between Sutureless and Glue Free Versus Sutured Limbal Conjunctival Autograft in Primary Pterygium Surgery|Comparison Between Sutureless and Glue Free Versus Sutured Limbal Conjunctival Autograft in Primary Pterygium Surgery||Minia University|Yes|Completed|April 2010|November 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|24 Years|74 Years|No|||January 2014|January 5, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02009072||54576|
NCT02009384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-MEL-11-01|Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox|A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox||James Graham Brown Cancer Center|Yes|Terminated|January 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|March 2, 2016|December 9, 2013|Yes|Yes|low enrollment r/t requirement of prior treatment with denileukin diftitox|No||https://clinicaltrials.gov/show/NCT02009384||54552|
NCT02009397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-MEL-11-02 (Ipi2)|A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients|A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients||James Graham Brown Cancer Center|Yes|Recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009397||54551|
NCT02009410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-954|A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2|A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2||Abbott|No|Withdrawn|November 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|N/A|No|||June 2014|June 19, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02009410||54550|
NCT02009670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inulin and SCFA production|Inulin,SCFA Production and Metabolic Response|SCFA Production and Their Metabolic Effects After Inulin Ingestion||Maastricht University Medical Center|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|15|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2014|November 24, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009670||54531|
NCT02009683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-2-033.3|Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy|Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy|MULTI-AF|Maastricht University Medical Center|Yes|Recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples With DNA|Blood biomarkers and SNPs|Both|18 Years|N/A|No|Non-Probability Sample|Patients with persistent atrial fibrillation scheduled for direct current cardioversion.|April 2015|April 15, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009683||54530|
NCT02010827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-012|Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion|Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion|EGP_Glucagon|University Hospital, Gentofte, Copenhagen|Yes|Completed|November 2013|August 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples With DNA|hole blood, serum, white cells, urine|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 2 diabetes Healthy control subjects|November 2015|November 30, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02010827||54442|
NCT02011607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812903|Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia|Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia|SEDLine|University of Pennsylvania|No|Recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|90 Years|No|Probability Sample|patints undergoing advanced endoscopic procedures|December 2013|December 12, 2013|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02011607||54383|
NCT02011620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D001|Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus|Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus.||Tameside Hospital NHS Foundation Trust|Yes|Not yet recruiting|February 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|75 Years|No|||December 2013|December 13, 2013|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011620||54382|
NCT02012959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-276|Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia|A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|November 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|18 Years|No|||October 2015|October 29, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012959||54280|
NCT01971801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAMC11|Vitamin D Supplementation in Older Adults With Urinary Incontinence|Vitamin D Supplementation in Older Adults With Urinary Incontinence||University of Alabama at Birmingham|Yes|Completed|January 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Female|50 Years|N/A|No|||March 2016|March 23, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01971801||57433|
NCT01972555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMILE|Cardiac Function After Minimally Invasive Aortic Valve Implantation|Single-center Randomized Controlled Trial of Cardiac Function After Minimally Invasive Aortic Valve Implantation (CMILE)|CMILE|Karolinska University Hospital|No|Recruiting|October 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01972555||57375|
NCT01972529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-310|Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure|A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure||Eisai Inc.|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972529||57377|
NCT01972841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-101|This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder|SYNERGY|Astellas Pharma Inc|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|6991|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972841||57353|
NCT01973608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 062235-005|MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma|A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab||EMD Serono||Terminated|January 2014|August 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 25, 2013|Yes|Yes|The study is terminated prematurely as the sponsor decided to discontinue program of NHS-IL2    (MSB0010445).|No||https://clinicaltrials.gov/show/NCT01973608||57294|
NCT01973621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zel-002_2012 back acne|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2012|||||N/A|N/A|N/A||||||||||||||December 17, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973621||57293|
NCT01973374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817181|Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy|Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy|Sugar Text|University of Pennsylvania|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|30|||Female|18 Years|50 Years|No|||February 2015|February 19, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01973374||57312|
NCT01981434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-132|Technology Based Obesity Prevention Project (TeBOPP)|Technology Based Obesity Prevention Project (TeBOPP)||Maricopa Integrated Health System|No|Recruiting|August 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981434||56693|
NCT02012634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPYS-01|Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer|A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer|MACRO|Xijing Hospital|No|Recruiting|January 2013|December 2018|Anticipated|December 2015|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|340|Samples With DNA|10 ml blood sample is taken before randomization|Both|18 Years|70 Years|No|Probability Sample|Breast cancer patients of vascular endocrine surgery department in Xijing Hospital|November 2014|November 11, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02012634||54304|
NCT01981733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THRIVE-1|Improving Lower Limb Blood Flow in Healthy Adult Volunteers|A Study to Determine the Effects of a Novel Method for Improving Lower Limb Blood Flow in Healthy Adult Volunteers|THRIVE-1|Queen Mary University of London|No|Completed|March 2005|||April 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981733||56671|
NCT02012920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-VT-464-CL-001|A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer||Innocrin Pharmaceutical|No|Recruiting|December 2011|August 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|141|||Male|18 Years|N/A|No|||October 2015|October 7, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012920||54283|
NCT02012426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDS-2013-SLW|The Effect of a Multi-component Weight Management Program on Appetite, Food Preference and Body Weight|The Effect of a Multi-component Weight Management Program on Appetite, Food Preference and Body Weight|SWSS|University of Leeds|No|Active, not recruiting|January 2014|May 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012426||54320|
NCT02009085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH 2012|Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.|Pilot Study to Asses the Identification of Melanoma in Skin Lesions.||Orlucent, Inc|Yes|Active, not recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|126|||Both|18 Years|N/A|No|Probability Sample|Patients above 18 years scheduled for a skin biopsy.|December 2013|December 6, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02009085||54575|
NCT02010268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111104|Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates|Evaluation of a Clinico-biological Predictive Score of Enterocolitis and Enteropathy of the Preterm Neonates. Usefulness of the Rapid Assay of the Faecal Calprotectin.|CALPROPREMA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|122|||Both|N/A|33 Months|No|||January 2016|January 16, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02010268||54485|
NCT02010554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC 0138-02|Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS|Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS|MIMS|University of Missouri, Kansas City|No|Completed|December 2013|September 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010554||54463|
NCT02010567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1315|Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer|Phase Ib/II Study of Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Locally Advanced Rectal Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|December 2013|December 2022|Anticipated|December 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010567||54462|
NCT02011373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.804|Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study|Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study|PRO-COLLE|Hospices Civils de Lyon|No|Recruiting|November 2013|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|N/A|No|||November 2014|November 21, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02011373||54400|
NCT02012153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-Tx tolerance|Mesenchymal Stromal Cells in Kidney Transplant Recipients|AUTOLOGOUS MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS||Mario Negri Institute for Pharmacological Research|No|Recruiting|December 2013|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02012153||54341|
NCT02012387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUN-OMAL-UCOL|Efficacy Study of Omalizumab in Cholinergic Urticaria|Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial|CUN-OMAL-UCOL|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Active, not recruiting|January 2014|June 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|14 Years|N/A|No|||March 2016|March 1, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02012387||54323|
NCT02009111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7U49CE001246-06|Dyadic, Skills-Based Primary Prevention for Partner Violence in Perinatal Parents|||New York University|No|Completed|March 2008|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|706|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 6, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02009111||54573|
NCT02009423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB12004|Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence|A Prospective, Multicenter, Randomised, Double-blinded, Placebo-controlled, Two-parallel Groups, Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary Gastrointestinal Stromal Tumor (GIST) After Complete Surgery and With High Risk of Recurrence||AB Science|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|November 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009423||54549|
NCT01971814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF|Early Serum Infliximab Levels in Severe Ulcerative Colitis.|Early Serum Infliximab Levels in Severe Ulcerative Colitis|EaSiFx|University of California, San Francisco|Yes|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971814||57432|
NCT01972035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307M37702|ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation|ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|N/A|N/A|No|||December 2015|December 1, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01972035||57415|
NCT01971775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENERGY_FRM001480|Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer|Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer: Conventional Monopolar Electrosurgery vs. Ultrasonically Activated Shear(UAS)||Seoul National University Hospital||Completed|August 2011|||May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|20 Years|75 Years|No|||October 2013|October 23, 2013|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01971775||57435|
NCT01971788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATRIXOCT2013|The MATRIX OCT Substudy|||S.M. Misericordia Hospital||Recruiting|June 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|N/A|No|||October 2013|October 23, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01971788||57434|
NCT01972282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90875647|Registry on WATCHMAN Outcomes in Real-Life Utilization|Registry on WATCHMAN Outcomes in Real-Life Utilization|EWOLUTION|Boston Scientific Corporation|No|Active, not recruiting|October 2013|November 2017|Anticipated|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1021|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation|January 2016|January 11, 2016|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972282|2 Years|57396|
NCT01972542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-ENDO4|The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk|The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes||Seoul National University Bundang Hospital|Yes|Completed|June 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|80|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01972542||57376|
NCT01972854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL-005|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus||Avedro, Inc.|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|206|||Both|12 Years|N/A|No|||December 2015|December 23, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972854||57352|
NCT01973634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/655|Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery.|Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery|SeqB vs SIB|University Hospital, Ghent|No|Recruiting|December 2012|March 2021|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|170|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01973634||57292|
NCT01969578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1206|Androgen Deprivation Therapy in Advanced Salivary Gland Cancer|A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01969578||57602|
NCT02012894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGEOB/76|Laparoscopic Sleeve Gastrectomy and Gastroesophageal Acid Reflux|Physiopathologic Evaluation of Esophageal Function After Laparoscopic Sleeve Gastrectomy||University of Turin, Italy|No|Completed|June 2009|September 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|65|||Both|18 Years|60 Years|No|Probability Sample|Consecutive morbidly obese patients selected for LSG|December 2013|December 10, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02012894||54284|
NCT02011399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I0001|Brain Computer Interfaces (Mu Rhythm Learning)|EEG-based Brain Computer Interface and Mu Rhythm for Computer Access||University of Michigan|No|Terminated|February 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|December 2013|December 9, 2013|April 15, 2011||No|Training procedure was not effective.|No||https://clinicaltrials.gov/show/NCT02011399||54398|
NCT02009150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960-CSP-ISR_HighRiskMC_ILS1|Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.|Evaluation of REAL IMAGING'S 3D Functional Metabolic Imaging and Risk Assessment ("3D MIRA") System in Women at High Risk for Breast Cancer||Real Imaging Ltd.||Recruiting|April 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who are determined to have high risk of breast cancer and who are screened        biannually by existing screening modalities (mammography, ultrasound or MRI)|January 2015|January 27, 2015|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02009150||54570|
NCT02013271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0017-01|Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries|A Prospective, Multicenter, Single-Arm Trial With the Lutonix Drug Coated Balloon for Treatment of Long Lesions in Femoropopliteal Arteries||C. R. Bard|Yes|Active, not recruiting|December 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013271||54256|
NCT02010047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRTALK|Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients|A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.|PCRTALK|British Columbia Cancer Agency|No|Enrolling by invitation|December 2013|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|144|||Both|19 Years|N/A|No|||July 2014|July 30, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02010047||54502|
NCT01980472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIDO1201|A Phase II Study of Chemotherapy Regimen Plus Bevacizumab in Elderly Non-small Cell Lung Cancer (NSCLC) Patients Selected by Geriatric Assessment|Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel||Grupo de Investigación y Divulgación Oncológica||Active, not recruiting|August 2013|||June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|70 Years|85 Years|No|||August 2015|August 26, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01980472||56767|
NCT01980485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37326EP|The Get Quit - Stay Quit Study|The Get Quit-Stay Quit Study: a Randomized Trial of Health Risk Feedback and Relapse Prevention for Treatment-seeking Smokers|GQSQ|Milton S. Hershey Medical Center|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980485||56766|
NCT01980498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOLT-2013-02|PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy|Multicenter Randomized Open Trial to Evaluate Efficacy of Fentanyl Pectin Nasal Spray vs Physician Choice-Usual Care in Reducing Predictable Breakthrough Pain at Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy|PERFECT FAST|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.||Withdrawn|September 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||June 2014|October 6, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01980498||56765|
NCT02011100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarnoDMCVD|Effect of Carnosine on Diabetes and Cardiovascular Risk Factors|Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors|Carnorisk|Slovak Academy of Sciences|No|Active, not recruiting|December 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|25 Years|50 Years|No|||December 2014|December 2, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02011100||54421|
NCT02011113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-011|Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 2, Multicenter, Single-arm, Open-label Study in Japan to Evaluate the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma||Celgene|No|Completed|December 2013|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|N/A|No|||October 2015|October 9, 2015|December 10, 2013|Yes|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT02011113||54420|
NCT02011880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYSNXD-CC-ZDYJ043|Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer|Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer||Shanghai University of Traditional Chinese Medicine||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Female|20 Years|70 Years||||September 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011880||54362|
NCT02011893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-07|SUNBURST (Success Using Neuromodulation With BURST) Study|Success Using Neuromodulation With BURST (SUNBURST™) Study|SUNBURST|St. Jude Medical|No|Active, not recruiting|December 2013|July 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|173|||Both|22 Years|N/A|No|||March 2016|March 2, 2016|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011893||54361|
NCT02012686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131127|The Effect of Transcutaneous Electrical Nerve Stimulation on Posterior Neck Pain After Thyroidectomy|The Effect of Transcutaneous Electrical Nerve Stimulation for Reduction of Posterior Neck Pain After Thyroidectomy||Yonsei University|Yes|Completed|November 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|60 Years|No|||May 2014|May 12, 2014|December 4, 2013||No||No|February 28, 2014|https://clinicaltrials.gov/show/NCT02012686||54300|
NCT01981538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914006|Web-based Patient Reported Outcome Measurement Information System (PROMIS ) to Explore Burden and Stress in Cancer Caregivers (BaSiC2)|Web-Based Patient Reported Outcome Measurement Information System to Explore Burden, and Stress in Cancer Caregivers (BaSiC2)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|172|||Both|18 Years|N/A|No|||August 2015|January 23, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01981538||56686|
NCT01972906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0302|Moxibustion for Primary Dysmenorrhea|Traditional Chinese Moxibustion for Primary Dysmenorrhea||Chengdu University of Traditional Chinese Medicine|Yes|Completed|February 2012|June 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Female|13 Years|35 Years|No|||November 2014|November 25, 2014|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972906||57348|
NCT01972295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90879496|Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry|Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry|WASP|Boston Scientific Corporation|No|Recruiting|October 2013|January 2018|Anticipated|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation|September 2015|December 7, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01972295|2 Years|57395|
NCT01972308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HL116285-01|A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults|A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults|HAP2|University of Pennsylvania|Yes|Active, not recruiting|November 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|312|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01972308||57394|
NCT01972867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-NK310|Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients|A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low Risk Patient Population||Angiodynamics, Inc.|No|Withdrawn|November 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|50 Years|70 Years|No|||February 2016|February 10, 2016|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972867||57351|
NCT01973127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISPA-IZ/MB22|Transcranial Magnetic Stimulation in the Treatment of Addiction|Repetitive Transcranial Magnetic Stimulation (rTMS) in Alcohol Dependent Patients: a Mechanistic Study.|MAGENTA|IrisZorg|No|Not yet recruiting|May 2014|December 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|23 Years|65 Years|No|||October 2013|October 25, 2013|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01973127||57331|
NCT01973387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102604|A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma|A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Janssen Research & Development, LLC|Yes|Active, not recruiting|October 2013|February 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973387||57311|
NCT01969942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0176|A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma|A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma|ASCT|University of Louisville|No|Recruiting|April 2013|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|30 Years|No|||August 2015|November 30, 2015|October 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01969942||57574|
NCT01969591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-171|Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery|Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery|FTS|First Hospital of Jilin University|Yes|Completed|January 2011|September 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|70|||Both|N/A|75 Years|No|||October 2013|October 21, 2013|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969591||57601|
NCT01969604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-Sedentary Behaviour|Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis|Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis. A Randomized Controlled Trial.||Glostrup University Hospital, Copenhagen|Yes|Active, not recruiting|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969604||57600|
NCT02012933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jacobus compassionate program|3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)|3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia||Oregon Health and Science University||Available||||||N/A|Expanded Access|N/A|||||||Both|2 Years|N/A||||April 2015|April 20, 2015|December 11, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT02012933||54282|
NCT02012946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|levodobu|Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery|||Azienda Policlinico Umberto I||Not yet recruiting|December 2013|||December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|85 Years|No|||December 2013|December 11, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012946||54281|
NCT02012179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP130275|SODIUM-HF: Study of Dietary Intervention Under 100 MMOL in Heart Failure|The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure|SODIUM-HF|University of Alberta|Yes|Recruiting|January 2014|December 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012179||54339|
NCT02013011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1306/206-004|Effects of Recruitment Maneuver in Patients Undergoing Robotic Assisted Radical Prostatectomy|||Seoul National University Hospital||Recruiting|November 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|80 Years|No|||July 2014|July 16, 2014|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013011||54276|
NCT02013284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007084|Is Our Microbiome a Predictor of Cardiac Risk|Is Our Microbiome a Predictor of Cardiac Risk?||Mayo Clinic|No|Recruiting|November 2013|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood (50 cc) and stool samples will be collected on consenting participants. Participants      will have the option of allowing us to store samples for future research|Both|18 Years|N/A|No|Non-Probability Sample|Consenting participants who are undergoing coronary angiography.|September 2015|September 21, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013284||54255|
NCT01979393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62113-55115|IRCI Gynae Sarcomas, High Grade Uterine Sarcoma|A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|February 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979393||56850|
NCT01979757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentPure|Outcomes After Centrifugation Versus PureGraft for Fatgrafting to the Breast|Outcomes After Centrifugation Versus PureGraft for Fatgrafting to the Breast After Breast-conserving Therapy||Bulovka Hospital|No|Completed|April 2011|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|N/A|N/A|No|||November 2013|November 7, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979757||56822|
NCT01980030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110204|Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell|Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell|AGRAH003|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2013|November 2016|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980030||56801|
NCT01980004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3010|Potassium Citrate Supplementation vs. Dietary Counseling|Does Potassium Citrate Supplementation Reduce Stone Recurrence in Calcium Phosphate Stone Formers With Risk Factors?||University of North Carolina, Chapel Hill|No|Withdrawn|November 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|October 7, 2015|November 1, 2013||No|closure due to failure to recruit any patients that met study criteria|No||https://clinicaltrials.gov/show/NCT01980004||56803|
NCT01980017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130177-01H|Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs|A Prospective Cluster-Randomized Trial to Implement the Ottawa Model for Smoking Cessation in Diabetes Education Programs.|OMSC in DEP|Ottawa Heart Institute Research Corporation|No|Recruiting|July 2013|May 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|890|||Both|18 Years|80 Years|No|||November 2015|November 6, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01980017||56802|
NCT01980758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14809|Pilot Study of Laparoscopic Gastric Plication in Adolescents With Severe Obesity|Pilot Study of Laparoscopic Gastric Plication in Adolescents With Severe Obesity||Virginia Commonwealth University|Yes|Recruiting|May 2013|October 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|14 Years|19 Years|No|||December 2015|December 10, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01980758||56745|
NCT01980771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P20MD006875, subproject 5174|Barbershop Talk: HIV Prevention for African American Heterosexual Men|Barbershop Talk: HIV Prevention for African American Heterosexual Men||State University of New York - Downstate Medical Center|No|Recruiting|November 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|875|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01980771||56744|
NCT01981057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUV-Numeta|Clinical Experience With Numeta|Clinical Experience With Numeta- Impact on Intake of Nutrients and Costs|Numeta|Medical University of Vienna|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|N/A||2|Actual|50|||Both|N/A|3 Months|No|Non-Probability Sample|preterm infants|May 2014|May 10, 2014|November 5, 2013||No||No|May 10, 2014|https://clinicaltrials.gov/show/NCT01981057|6 Days|56722|
NCT01981291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-ORT-03|Duration of Sciatic Nerve Block After Injection of Local Anesthetic In or Around the Nerve|Duration of Subgluteal Sciatic Nerve Block After Intra- or Perineural Injection of Mepivacaine: a Randomized, Controlled Trial||University of Parma|No|Completed|October 2012|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981291||56704|
NCT01981070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095/2013|Parent Supports Intervention Project|Parent Supports Intervention Project for Parents of Adults With Developmental Disabilities||Centre for Addiction and Mental Health|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01981070||56721|
NCT01973439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PENTA15|PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months|PENTA15: Plasma Pharmacokinetic Study of Once Versus Twice Daily Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV-1 Infection Aged 3 Months to <36 Months|PENTA15|PENTA Foundation|No|Completed|July 2006|June 2009|Actual|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|3 Months|36 Months|No|||February 2014|February 3, 2014|October 25, 2013||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01973439||57307|
NCT01973153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHNCT-012|The Added Value of Telephone Follow Up and Home Visits in Helping Children to Grow Up Healthy|The Added Value of Telephone Follow Up and Home Visits in Helping Children to Grow Up Healthy||Connecticut Children's Medical Center|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|81|||Both|N/A|50 Months|Accepts Healthy Volunteers|||January 2014|January 30, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973153||57329|
NCT01972568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700461-023|Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus|A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)|ADDRESS II|EMD Serono||Active, not recruiting|December 2013|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01972568||57374|
NCT01972581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBAPL-201309-191|Neurocognitive Visual Reaction Training|Neurocognitive Visual Reaction Training||High Point University|No|Completed|October 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01972581||57373|
NCT01972880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-7001|A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets|ASP1941 Pharmacokinetic Study - Verification of Bioequivalence Between ASP1941 New Tablets and ASP1941 Conventional Tablets -||Astellas Pharma Inc|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01972880||57350|
NCT01972893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYD1/1001|A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, a Selective Glucagon-like Peptide (GLP) 1 Agonist, Following Subcutaneous Administration in Healthy Volunteers.|ZYD1|Cadila Healthcare Limited|Yes|Completed|February 2011|June 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01972893||57349|
NCT01973140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00071984|Effects of Tolvaptan in Healthy Adults|Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults||Northwestern University|Yes|Recruiting|November 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|September 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973140||57330|
NCT01973400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENUS-7327|Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus|A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus|VENUS|University of Science Malaysia|Yes|Active, not recruiting|June 2011|December 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|20 Years|N/A|No|||August 2015|August 10, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01973400||57310|
NCT01973413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-Stanford|Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study|Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study||University of Virginia|Yes|Completed|July 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|10 Years|35 Years|No|||April 2015|April 3, 2015|October 24, 2013|No|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01973413||57309|
NCT01970813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRF-2011-0021389|Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease|Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease||Kyunghee University Medical Center|Yes|Completed|October 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Both|N/A|N/A|No|||September 2015|September 6, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01970813||57508|
NCT01970241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRF-13-3658|Inpatient Diabetes on Corticosteroids|Inpatient Diabetes on Corticosteroids||Minneapolis Medical Research Foundation|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|79 Years|No|||March 2016|March 21, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01970241||57552|
NCT02011139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-ESRD|Cognitive-behavioral (CBT) in ESRD Patients With Depression|Effectiveness of Cognitive-behavioral Group Therapy for Enhancing Mental Health and Quality of Life in Maintenance Hemodialysis Patients||Seoul National University Boramae Hospital|Yes|Completed|October 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|15|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02011139||54418|
NCT02011152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199812|Spinal Anesthesia Magnesium Infusion|The Effect of Intravenous Magnesium Sulfate Infusion on Sensory Spinal Block and Postoperative Pain Score in Abdominal Hysterectomy||Karadeniz Technical University|No|Completed|December 1998|December 1999|Actual|December 1999|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|18 and 65 female patients undergoing abdominal hysterectomy|December 2013|December 12, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011152|3 Months|54417|
NCT02008838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450|Effects of Synbiotic Supplementation in Metabolic Syndrome|||National Nutrition and Food Technology Institute||Completed|April 2012|||November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008838||54594|
NCT02008851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL011|A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes|A Phase 1, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease||Tengion|Yes|Terminated|December 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Both|30 Years|70 Years|No|||December 2014|December 10, 2014|December 6, 2013|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02008851||54593|
NCT01979744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0052|Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial|||Yonsei University|Yes|Recruiting|November 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1116|||Both|19 Years|85 Years|No|||November 2014|November 27, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01979744||56823|
NCT01980524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPOTESIS|The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes|HYPOglycemia Linked to Cardiac sTEatoSIS? - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes (HYPOTESIS)|HYPOTESIS|Medical University of Vienna|Yes|Active, not recruiting|October 2013|||November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01980524||56763|
NCT01981109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-1|A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer|A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer|PREDICT|Dendreon|No|Recruiting|January 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood, serum|Male|18 Years|N/A|No|Non-Probability Sample|Men with Castration-Resistant Prostate Cancerand no known M1 disease who are at least 18        years of age at the time of screening are eligible.|February 2016|February 29, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01981109||56718|
NCT01980537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stereotaxis and CTO|Stereotaxis and Chronic Total Occlusion|||Medical University of Vienna||Completed|April 2008|||April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980537||56762|
NCT01980797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000260|International Bicuspid Aortic Valve Consortium (BAVCon)|International Bicuspid Aortic Valve Consortium (BAVCon)|BAVCon|Brigham and Women's Hospital|No|Recruiting|November 2013|November 2033|Anticipated|November 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|We are collecting DNA from either saliva or blood.|Both|8 Years|90 Years|No|Probability Sample|Patients with and without bicuspid aortic valves disease|February 2015|February 2, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01980797|10 Years|56742|
NCT01980251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delirium and cEEG|Delirium, Electroencephalographic Alterations and Cortical Spreading Depression (CSD) in Critical Illness|Delirium, Electroencephalographic Alterations and Cortical Spreading Depression in Critical Illness||Glostrup University Hospital, Copenhagen|Yes|Recruiting|October 2013|February 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples With DNA|Blood, cerebrospinalfluid, urine|Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients with and without acute cerebral trauma|November 2013|November 4, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980251|1 Year|56784|
NCT01981083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217B500602013026|Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients|Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients||Centro Medico Lic Adolfo Lopez Mate|Yes|Not yet recruiting|November 2013|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2013|November 5, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01981083||56720|
NCT01980511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroVISION v3.0|Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN|Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN|NeuroVISION|McMaster University|Yes|Recruiting|March 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|65 Years|N/A|No|Non-Probability Sample|Patients undergoing elective non-cardiac surgery, ≥ 65 years old and an anticipated        hospital stay of at least 3 days after elective noncardiac surgery that occurs under        general or neuraxial anesthesia.|February 2016|February 1, 2016|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01980511||56764|
NCT01980784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPZ12036|Posttraumatic Changes in Energy Expenditure and Body Composition in Patients With Acute Spinal Cord Injury|Posttraumatic Changes in Energy Expenditure and Body Composition in Patients With Acute Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|whole blood|Both|18 Years|70 Years|No|Non-Probability Sample|Patients of a spinal cord injury rehabilitation centre|February 2014|February 7, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01980784||56743|
NCT01978340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-CLC-2013_Prot_1|Eval EarlySense Bet Lowenstein Sleeplab|Evaluation of EarlySense - a Contact-less Heart and Respiration Rate Monitor in Hospitalized Patients||EarlySense Ltd.|No|Withdrawn|November 2013|April 2014|Anticipated|February 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|0|None Retained|no Biospeciments will be taken.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Different patient population will be monitored including obese, morbidly obese, patients        with or without apnea, patients with or without arrhythmia as well as healthy population        who arrive to sleep lab for general evaluation will be monitored|December 2015|December 14, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01978340|1 Day|56931|
NCT01969630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo011|Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions|||Ospedale San Donato|No|Recruiting|October 2013|||October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969630||57598|
NCT01973426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-CS-0026|Evaluating Human-Machine Interfaces in a Robotic Thumb Orthosis|Development and Evaluation of a Human-Machine Interface for Grasp Assistance Using a Robotic Thumb Orthosis in Children With Hemiplegic Cerebral Palsy and Hemiplegic Stroke|IOTA|Wyss Institute at Harvard University|No|Active, not recruiting|October 2013|December 2015|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|7 Years|16 Years|No|Non-Probability Sample|Children with hemiplegic cerebral palsy or hemiplegic stroke.|September 2015|September 9, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01973426||57308|
NCT01973647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR013937-01A1|A Behavioral Therapy for Insomnia Co-existing With COPD|Efficacy and Mechanisms of a Behavioral Therapy for Insomnia Co-existing With COPD||University of Illinois at Chicago|Yes|Recruiting|June 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|45 Years|N/A|No|||December 2015|December 1, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01973647||57291|
NCT01973660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1114|PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer|PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer|PAMELA|SOLTI Breast Cancer Research Group|Yes|Active, not recruiting|October 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973660||57290|
NCT01969617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15660A|Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge|Interventional, Randomized, Double-blind, Cross-over, Placebo-controlled Study to Investigate the Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge||H. Lundbeck A/S|No|Completed|November 2013|||October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Male|20 Years|65 Years|No|||November 2014|November 10, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969617||57599|
NCT01970826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-05|Compare Sterilized Clean vs Sterilized Aseptic Dental Implant Surgery|Sterilized Aseptic Versus Sterilized Clean Field for Dental Implant Placement - Randomized Clinical Control Trial for Non-inferiority Comparison||Instituto de Implantologia|No|Not yet recruiting|January 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01970826||57507|
NCT01970839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048542|Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study|Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study||Duke University||Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01970839||57506|
NCT01971099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTM1|Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder|Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder||Federal University of Minas Gerais|No|Completed|May 2013|September 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|45 Years|No|||January 2016|January 13, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971099||57487|
NCT01971112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378 DGIP-I|Nutritional Intervention and Respiratory Infections in Older Subjects|Effect of Supplementation With Multivitamins and Minerals on the Incidence of Respiratory Infections in Older People in Ecuador: a Randomised Controlled Trial.||Corporacion Ecuatoriana de Biotecnologia|Yes|Recruiting|October 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01971112||57486|
NCT02011919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU / TU / FA|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|HIFU|Theraclion|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011919||54359|
NCT01979107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61110-2095|Early Detection of and Intervention Towards Chronic Diseases Among Individuals Without Formal Education|Early Detection of and Intervention Towards Chronic Diseases Among Individuals Without Formal Education||University of Southern Denmark|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979107||56872|
NCT01979380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD101-101|Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Single Oral Dose, Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects||Kwang Dong Pharmaceutical co., ltd.|No|Completed|December 2013|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979380||56851|
NCT01979770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-IRB2012/109.1611|Early Life Nutritional Exposures and Long-term Health and Cognitive Outcomes|Association of Early Life Nutritional Related Exposures and Long-term Health and Cognitive Development Outcomes in Adolescents in Northeast, Thailand||Mahidol University|No|Active, not recruiting|January 2013|October 2015|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|529|Samples With DNA|DNA from blood specimens|Both|13 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents who participated in an intervention trial of iron and zinc supplementation and        a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast        of Thailand.|November 2013|November 2, 2013|July 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979770||56821|
NCT01981122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-2|A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer|A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer||Dendreon|Yes|Active, not recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|52|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981122||56717|
NCT01980849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCAN-20131105|Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer|Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin|LCAN|Fourth Military Medical University|Yes|Recruiting|November 2013|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|272|||Both|18 Years|75 Years|No|||November 2013|November 20, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01980849||56738|
NCT01981577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42613.068.13|Subthalamic Nucleus Connectivity in Parkinson's Disease With Ultra-high Field Magnetic Resonance Imaging|Ultra-high Field Imaging of the Cortico-striato-subthalamic Functional and Structural Connectivity to Improve Deep Brain Stimulation Surgery in Parkinson's Disease Patients||Maastricht University Medical Center||Recruiting|April 2014|||October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Parkinson's patients scheduled for deep brain stimulation surgery at Maastricht             University Medical Center          -  Healthy volunteers from a community sample|March 2016|March 21, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01981577||56683|
NCT01981837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTRSC-002|Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis|A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis||Alnylam Pharmaceuticals|No|Completed|December 2013|January 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981837||56663|
NCT01978028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vifor-HF|Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose|Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose||University of Zurich||Recruiting|October 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978028||56955|
NCT01978041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOPBioq004|Fluoride Bioavailability After Ingestion of Water or Foods Prepared With Fluoridated Water|Fluoride Bioavailability in Plasma and Saliva After Ingestion of Water or Foods Prepared With Fluoridated Water||University of Campinas, Brazil|No|Completed|January 2013|December 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978041||56954|
NCT01973673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6050|Healthy Bones Study|Healthy Bones Study: An Intervention to Improve Healthy Bone Behaviours in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)||University Health Network, Toronto|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01973673||57289|
NCT01973686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIWE-2|GO-ACTIWE Energy Metabolism|Active Commuting To Improve Well-being and Health in Everyday Life (ACTIWE)||University of Copenhagen|Yes|Active, not recruiting|October 2013|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|125|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01973686||57288|
NCT01973699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2012-61|Visualization in Shoulder Arthroscopy With and Without Epinephrine|Surgeon Determined Visualization in Shoulder Arthroscopy: A Randomized, Blinded, Controlled Trial Comparing Irrigation Fluid With and Without Epinephrine||St. Luke's Hospital, Pennsylvania|Yes|Completed|November 2012|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|100 Years|No|||December 2015|December 31, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973699||57287|
NCT01969643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGNLVA-001|A Safety Study of SGN-LIV1A in Breast Cancer Patients|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer||Seattle Genetics, Inc.|No|Recruiting|September 2013|August 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|October 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01969643||57597|
NCT01969656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2MD-3H-1B/C|Safety Study of an Oral Vitamin D Analog in Postmenopausal Women|A Phase 1B, Double-Blind, Placebo-Controlled, Calcitriol Active-Controlled, Daily-Dose, Escalating-Dose, Safety and Tolerance Study of 2MD Soft Gel Capsules in Normal Healthy Postmenopausal Women||Deltanoid Pharmaceuticals||Completed||||June 2004|Actual|Phase 1|Interventional|N/A|7||||||Female|45 Years|80 Years||||October 2013|October 24, 2013|October 22, 2013||Yes||||https://clinicaltrials.gov/show/NCT01969656||57596|
NCT01969669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-364|A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199|A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199||AbbVie|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969669||57595|
NCT01969955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-031|Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer|A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy||Chinese Academy of Medical Sciences|Yes|Recruiting|September 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969955||57573|
NCT01970254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0961|Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy|Widespread Versus Selective Screening for Hepatitis B Infection Prior to Chemotherapy||M.D. Anderson Cancer Center|No|Recruiting|June 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3441|||Both|18 Years|N/A|No|Non-Probability Sample|Adult cancer patients scheduled to receive chemotherapy in the Ambulatory Treatment Center        (ATC) at The University of Texas (UT) MD Anderson Cancer Center.|January 2016|January 7, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970254||57551|
NCT01970527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9031|Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma|RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma||University of Washington|No|Recruiting|March 2014|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970527||57530|
NCT01961622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP@home04|Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions|An Open-label, Multi-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of 12 Week Day and Night Automated Closed-loop Glucose Control Under Free Living Conditions Compared to Conventional Insulin Pump Therapy Combined With Continuous Glucose Monitoring in Adults With Type 1 Diabetes With Sub-optimal Glucose Control|AP@home04|University of Cambridge|Yes|Completed|April 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01961622||58212|
NCT01961908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPE-202EXT|Open-Label Extension Study to ZPE-202|A Phase 2, Multi-Center, Open-Label Extension Study to Evaluate the Safety and Efficacy of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis||Repros Therapeutics Inc.|Yes|Withdrawn|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|47 Years|No|||February 2014|February 6, 2014|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961908||58190|
NCT01961921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-003|The Study of an Investigational Drug, ALN-TTR02 (Patisiran), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)|A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02||Alnylam Pharmaceuticals|No|Active, not recruiting|October 2013|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|85 Years|No|||February 2016|February 4, 2016|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961921||58189|
NCT02012712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHR-001|Personal Health Records and Elder Medication Use Quality|Personal Health Records and Elder Medication Use Quality||University of Iowa|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1163|||Both|65 Years|95 Years|No|||December 2013|December 10, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02012712||54298|
NCT02012998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HXV02C|Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA|An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA||Sanofi Pasteur MSD|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|751|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012998||54277|
NCT01979133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082013-042|Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders|A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders||University of Texas Southwestern Medical Center|No|Recruiting|October 2013|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2015|January 8, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979133||56870|
NCT01979406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-PA-100-001|A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines|A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)||PaxVax, Inc.|Yes|Active, not recruiting|October 2013|February 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|October 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01979406||56849|
NCT01981096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR063412|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens|FIT Teens|Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|12 Years|18 Years|No|||August 2015|August 3, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01981096||56719|
NCT01981135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11-0772|Interaction Effects of Temperature and Ozone|Interaction Effects of Temperature and Ozone|TROPICOZ|Environmental Protection Agency (EPA)|No|Completed|September 2011|January 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01981135||56716|
NCT01981317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOCDF2013|Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder||SC-CBT|University of South Florida||Recruiting|October 2013|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|17 Years|No|||June 2015|June 22, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981317||56702|
NCT01981330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1650 and 2014-51432|Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring|Pilot Study of Patients With Severe Hoarseness and Vocal Fold Scarring Treated With Mesenchymal Stem Cells With and Without Hyaluronan Gel||Karolinska University Hospital|No|Recruiting|January 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 8, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981330||56701|
NCT01981590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPs-breathing|Mapping for Acute Transvenous Phrenic Nerve Stimulation Study|Mapping for Acute Transvenous Phrenic Nerve Stimulation Study (MAPS Study)|MAPs|Medtronic BRC|No|Recruiting|August 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01981590||56682|
NCT01981603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00660|Transplant Navigator Dissemination|||MetroHealth Medical Center|No|Recruiting||||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1200|||Both|18 Years|70 Years|No|||October 2015|October 2, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01981603||56681|
NCT01981850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRM-151G-101|A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis|A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)||Promedior, Inc.|Yes|Recruiting|October 2013|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981850||56662|
NCT01982123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8180|SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy|Pulmonary Functional Imaging for Radiation Treatment Planning||University of Washington|No|Recruiting|January 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|19 Years|N/A|No|||October 2015|October 1, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982123||56641|
NCT01982110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17004|A Mindfulness Based Application for Smoking Cessation|A Mindfulness Based Application for Smoking Cessation|MBSC|University of Virginia|Yes|Recruiting|September 2013|October 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01982110||56642|
NCT01978067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEN-PCSD|Quality of Life and Sexual Function of Vaginal Operation in The Treatment Of Previous Cesarean Scar Defect|Safety ,Validity and Quality of (Sexual)Life of Vaginal Operation in The Treatment Of Previous Cesarean Scar Defect|PCSD|First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Female|N/A|N/A|No|Non-Probability Sample|60 patients diagnosed PCSD scheduled for vaginal operation in The First Affiliated        Hospital between December 2013 and December 2015|February 2014|February 26, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978067||56952|
NCT01964820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CHR 13-12256|Online Positive Emotion Skills Intervention for Symptoms of Depression|Online Positive Emotion Skills Intervention for Symptoms of Depression - Pilot Feasibility Trial|MARIGOLD|University of California, San Francisco|No|Recruiting|July 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964820||57967|
NCT01964833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375.454|PDT and Periodontal Treatment in DMT2 Patients|Combination of Photodynamic Therapy and Periodontal Treatment in Patients With Type 2 Diabetes Mellitus: Randomized, Double-blind Clinical Trial|PDTDMT2|University of Nove de Julho|No|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964833||57966|
NCT01965080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSGO-EC-0302|Exemestane in Advanced and Recurrent Endometrial Carcinoma|Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma||Nordic Society for Gynaecologic Oncology|No|Completed|March 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||October 2013|October 15, 2013|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01965080||57947|
NCT01965093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IQ208|Growth and Intelligence Outcome in Children Who Developed Perioperative Desaturation|Possible Effect of Peri-operative Desaturation on Growth and Intelligence Outcome in Children Undergone General Anesthesia at a Tertiary Care Hospital in Southern Thailand||Prince of Songkla University|Yes|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|104|||Both|N/A|5 Years|No|Non-Probability Sample|children aged 0-5 years who receive general anesthesia at Songklanajarind Hospital between        2008-2011|October 2013|October 15, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01965093|1 Year|57946|
NCT01969968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-API-01|Lipophilic Organic Polluants and Morbid Obesity|Lipophilic Organic Polluants and Morbid Obesity: Kinetic of the Release and Impact on the Metabolic Syndrome Before and After Bariatric Surgery|POLOB|Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2013|November 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|250|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969968||57572|
NCT01970267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01836|Clear Vision Study|Randomized Trial of Laser Ablation for Highly Symptomatic Floaters||University of British Columbia|No|Recruiting|October 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||June 2014|June 20, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970267||57550|
NCT01970540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-003-10|Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors||PharmaMar|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970540||57529|
NCT01970553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-004-10|Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Gemcitabine in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors||PharmaMar|No|Completed|May 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|75 Years|No|||October 2013|March 31, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970553||57528|
NCT01970566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-001-12F|Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity|Effect of Intense-Exercise/Moderate-Calorie vs Topiramate-Phentermine on Obesity||VA Office of Research and Development|Yes|Withdrawn|November 2013|November 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|70 Years|No|||January 2014|January 14, 2014|August 28, 2013||No|The project was not announced to the field and it was not funded.|No||https://clinicaltrials.gov/show/NCT01970566||57527|
NCT01970579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1214|Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter|Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter|ConSeQuent|B. Braun Melsungen AG|Yes|Active, not recruiting|October 2013|April 2017|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970579||57526|
NCT01961934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIC-AC-003|C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression|Carbon-11-Sodium Acetate Positron Emission Tomography/Computed Tomography (PET/CT) Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression||Phoenix Molecular Imaging|No|Recruiting|May 2014|May 2018|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|70 Years|No|||March 2015|March 6, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961934||58188|
NCT01980550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hongqiang-2010|Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy|Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy||National Institute on Drug Dependence, China|No|Completed|March 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|1||Actual|250|||Both|20 Years|70 Years|No|||November 2013|November 10, 2013|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980550||56761|
NCT01980810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-037-nab|First Line Chemotherapy for Advanced Cancer|Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma|GC-A-003|Chinese Academy of Medical Sciences|No|Recruiting|September 2013|February 2016|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980810||56741|
NCT01980823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM2306|Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer|Pre-Surgical "Window of Opportunity" Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer||Columbia University|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|21 Years|N/A|No|||February 2016|February 3, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980823||56740|
NCT01981369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104572|Effect of Intravenous Dexmedetomidine on Analgesic Duration of Infraclavicular Block|Effect of Intravenous Dexmedetomidine on the Analgesic Duration of Infraclavicular Block With Ropivacaine for Upper Limb Surgery: a Prospective, Randomized, Double Blind Study||Lawson Health Research Institute|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|80 Years|No|||February 2016|February 4, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981369||56698|
NCT01981343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12AGHS|A Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.|A Randomized, Double Blind, Placebo Controlled Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.||KGK Synergize Inc.|No|Active, not recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||April 2015|December 23, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981343||56700|
NCT01981616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13013|Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab||Millennium Pharmaceuticals, Inc.|No|Completed|September 2011|July 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|127|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|October 30, 2013|No|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01981616||56680|
NCT01981629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3496|The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock|The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock||Minneapolis Medical Research Foundation|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department at an urban county hospital.|October 2014|October 23, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01981629||56679|
NCT01981863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrinolysis|Fibrinolysis Before Cardiopulmonary Bypass?|Fibrinolysis Before Cardiopulmonary Bypass?||Stanford University|No|Recruiting|September 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01981863||56661|
NCT01981876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P172/06/2010|Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital|Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital|STEP|Tenwek Hospital|Yes|Completed|October 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|305|Samples With DNA|Blood and Urine specimens|Both|20 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult Asymptomatic subjects residing within a 50 kilometer radius of Tenwek Hospital|February 2015|February 26, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01981876||56660|
NCT01982136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9859|Functional Outcome of Urethral Reconstructive Surgery|Prospective Long-term Single Center Cohort Study Assessing Functional Outcome of Urethral Reconstructive Surgery||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|August 2009|||February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|115|||Male|18 Years|N/A|No|Non-Probability Sample|All patients who underwent urethral reconstruction in our center from 2009 to this date|November 2015|December 10, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01982136|4 Years|56640|
NCT01978106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0041|Comparisons of the Astigmatic Power of Toric Intraocular Lens Using Three Toric Calculators: AcrySof, TECNIS, and iTrace Toric Calculator|||Yonsei University|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|100|||Both|33 Years|87 Years|Accepts Healthy Volunteers|Probability Sample|Subjects who planned to undergo cataract removal by phacoemulsification between January        2013 to April 2013 at the Department of Ophthalmology, Yonsei University College of        Medicine, Seoul, South Korea were included in this study.|November 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978106||56949|
NCT01978119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115645|A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma|A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents With Asthma||GlaxoSmithKline|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|12 Years|80 Years|No|||December 2015|February 4, 2016|October 31, 2013||No||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01978119||56948|
NCT01978080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AG034708-03|Continuous Tremor Assessment During Daily Activities|ETSense: Adaptive Portable Essential Tremor Monitor - Symptomatic Impact Study||Great Lakes NeuroTechnologies Inc.||Completed|October 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|39|||Both|N/A|N/A|No|||December 2014|December 9, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978080||56951|
NCT01978093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112931|Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Hib-MenCY-TT Vaccine 792014 Compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) Vaccine in Healthy Infants and Toddlers||GlaxoSmithKline||Active, not recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||February 2016|March 17, 2016|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978093||56950|
NCT01973712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPDF|Periprosthetic Distal Femur Fracture|Treatment of Periprosthetic Distal Femur Fractures: A Randomized Controlled Trial of Locking Plate Osteosynthesis Versus Retrograde Nailing||St. Michael's Hospital, Toronto|No|Recruiting|May 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973712||57286|
NCT01969682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-366|A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199|A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199||AbbVie|No|Withdrawn|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|October 22, 2013|Yes|Yes|This study will be conducted in healthy volunteer subjects.|No||https://clinicaltrials.gov/show/NCT01969682||57594|
NCT01960855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-550|A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy||AbbVie|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|276|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960855||58270|
NCT01961076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0161|Overnight Feeding Study in Glycogen Storage Disease Type 1|New Approaches for Over-night Feeding in Glycogen Storage Disease Type 1 (GSD 1)||University of Zurich||Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961076||58254|
NCT01961089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIOS-13/01|Galilei Lens Professional|GALILEI Lens Professional vs. Predicate Devices: a Comparison Study||Ziemer Ophthalmic Systems AG|Yes|Recruiting|October 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 10, 2013|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01961089||58253|
NCT01961336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-9|Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF|The Effect of Transdermal Testosterone Pretreatment in Poor Responders Undergoing Ovarian Stimulation for In-vitro Fertilization (IVF)||Aristotle University Of Thessaloniki|No|Completed|October 2013|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|25 Years|N/A|No|||February 2016|February 11, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961336||58234|
NCT01961349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0092C00002|Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy|A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy|Kagami_SDS|AstraZeneca|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|279|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|October 10, 2013||No||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01961349||58233|
NCT01969708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCORE2|Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)|Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.|SCORE2|The EMMES Corporation|Yes|Active, not recruiting|September 2014|March 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|362|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969708||57592|
NCT01969721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.11|Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients|Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2013|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|229|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|October 22, 2013||||No|January 14, 2016|https://clinicaltrials.gov/show/NCT01969721||57591|
NCT01970891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMES_PD_S_FOG|Electrical Stimulation for the Relief of Freezing of Gait (FOG) in Parkinson's Patients|Electrical Stimulation for the Relief of Freezing of Gait (FOG)||National University of Ireland, Galway, Ireland|Yes|Recruiting|October 2013|November 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|15|||Both|40 Years|85 Years|No|||October 2013|October 22, 2013|October 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01970891||57502|
NCT01970904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2222|Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients|A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients||Novartis|Yes|Active, not recruiting|October 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01970904||57501|
NCT01978834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bind02|Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer|Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer||Bone Index Finland Ltd|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|560|||Female|50 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female (American-Caucasian)|January 2015|January 28, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01978834|1 Day|56893|
NCT01979094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0104|Spinal Arthrodesis and Spinal Arthroplasty Database Study|General Spinal Arthrodesis and Spinal Arthroplasty Database||Ohio State University|No|Recruiting|May 2013|May 2022|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|Spinal arthrodesis and/or spinal arthroplasty can be performed through either anterior,        posterior, or lateral approaches for a variety of traumatic, degenerative, or deformity        conditions.|August 2015|August 13, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01979094||56873|
NCT01980563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/367|Optimizing Ovarian Stimulation for IVF and ICSI|Optimizing Ovarian Stimulation for IVF and ICSI||University Hospital, Ghent|No|Completed|January 2011|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Female|18 Years|45 Years|No|||November 2013|November 4, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980563||56760|
NCT01980576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110053|Qualitative Pain Measurement at Patients With Degenerative Low Back Pain|Qualitative Pain Measurement and Sensitization at Patients With Degenerative Low Back Pain With Indication for Lumbar Intervertebral Disc||Northern Orthopaedic Division, Denmark|No|Terminated|December 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|80 Years|No|Probability Sample|Primary care clinic.|April 2015|April 9, 2015|October 28, 2013||No|Lack of patients with the right criteria for inclusion|No||https://clinicaltrials.gov/show/NCT01980576||56759|
NCT01980589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003|A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects|A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects|CHAMPION 2|Onyx Pharmaceuticals|No|Active, not recruiting|August 2013|April 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980589||56758|
NCT01980836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-OE-245-CTIL|Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine|The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 4, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980836||56739|
NCT01981356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-132|Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis|Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis|ACT-IP|VA Office of Research and Development|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981356||56699|
NCT01981642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW_EK-243/2011|Noninvasive Diagnostics in Left Ventricular Assist Device Patients|Nicht-invasive Diagnostik in Patienten Mit Herzunterstützungssystemen||Medical University of Vienna|No|Recruiting|December 2011|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|70 Years|No|||March 2016|March 18, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01981642||56678|
NCT01981889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02183|Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease|Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease||University of British Columbia|No|Enrolling by invitation|October 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|19 Years|N/A|No|||January 2016|January 13, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01981889||56659|
NCT01982149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013973|Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer|Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer||Weill Medical College of Cornell University|No|Active, not recruiting|September 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood, urine and cells obtained for this study may be retained for future research with      given consent.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|April 2015|April 20, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01982149||56639|
NCT01978392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMRIS 11-08|MANAGE AT WORK: Addressing the Challenge of Chronic Physical Health Conditions in the Workplace|MANAGE AT WORK: Evaluation of a Group-based Self-management Program to Address Workplace Discomfort and Fatigue Associated With Chronic Physical Health Conditions||Liberty Mutual Research Institute for Safety|No|Recruiting|November 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978392||56927|
NCT01978379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44750-B|The Nociception Level During General Anesthesia|The Nociception Level During Anesthesia in Patients Undergoing Video-assisted Thoracoscopic Surgery||University of Washington|Yes|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing elective Video-Assisted Thoracoscopic Surgery at University of        Washington Medical Center|August 2014|August 12, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978379||56928|
NCT01978652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105HV104|Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.|A Two-Arm, Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) in Japanese and Caucasian Adult Healthy Subjects||Biogen||Completed|December 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978652||56907|
NCT01973179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-ReKo-2013|Re-irradiation of Recurrent Head and Neck Cancer|Observational Study to Re-irradiation for Recurrent Head and Neck Cancer|ReKo|Technische Universität Dresden|No|Recruiting|July 2015|August 2023|Anticipated|August 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a recurrent or secondary head and neck carcinoma|January 2016|January 6, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973179||57327|
NCT01973465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF-13-003|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis||OSF Healthcare System|No|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 25, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01973465||57305|
NCT01972997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1220|SENSIMED Triggerfish Sensor Sizes|A Single-center, Randomized, Double-blinded, Prospective Study to Assess the Changes in the 24-hour IOP (Intraocular Pressure) Pattern in Relation to SENSIMED Triggerfish® Sensor Sizes in Healthy Subjects||Sensimed AG||Completed|July 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01972997||57341|
NCT01973491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200166-001|ATX-MS-1467 in Multiple Sclerosis|An Open-label, One-arm, Baseline-controlled Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis||Merck KGaA|Yes|Active, not recruiting|February 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01973491||57303|
NCT01969695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-835|An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma|An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma||AbbVie|No|Active, not recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01969695||57593|
NCT01969981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHERLOCK 3CG|A Study to Assess Placement and Confirmation of Peripheral Inserted Central Catheters Tip Position Using a New Electrocardiographic Method|An Observational, Prospective, Single-center Study of Placement and Confirmation of Peripheral Inserted Central Catheters Tip Position Using a New Electrocardiographic Method|SHERLOCK 3CG|Centre Leon Berard|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|571|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be included as well as they are ambulatory or hospitalized in Centre Leon        Berard.|September 2014|September 11, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969981||57571|
NCT01970280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0146-13-MMC|Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.|||Meir Hospital, Kfar Saba, Israel||Recruiting|September 2013|January 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|26|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970280||57549|
NCT01970306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-178|Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material|A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material||Memorial Sloan Kettering Cancer Center||Recruiting|October 2013|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970306||57547|
NCT01970319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14606|Mechanisms and Reversibility of Heart Failure Associated With Diabetes||MRHD|University of Leeds|Yes|Recruiting|October 2013|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|125|Samples Without DNA|Frozen serum|Both|18 Years|N/A|No|Non-Probability Sample|Primary care patients with type 2 diabetes|October 2013|October 25, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970319||57546|
NCT01969994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8215022|Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans|A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin Following Oral Intake||The Institutes for Pharmaceutical Discovery, LLC|Yes|Completed|December 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969994||57570|
NCT01978587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ951-U-13-005|Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease|A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease||Akros Pharma Inc.|No|Completed|October 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|75 Years|No|||March 2014|March 15, 2014|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978587||56912|
NCT01978860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-C200-02 Rev 01|A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter|A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter in (CTO) Coronary Lesions||Nitiloop Ltd.|No|Completed|November 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|25 Years|80 Years|No|||October 2015|October 6, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978860||56891|
NCT01979120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISROTH20033|Validation of the "ApneaScan" Algorithm for the Detection of Sleep Disordered Breathing in Chronic Heart Failure|Validation of the "ApneaScan" Algorithm for the Detection of Sleep Disordered Breathing in Patients With Stable Symptomatic Chronic Heart Failure|VASA|Medical University of Vienna|Yes|Recruiting|December 2012|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stable symptomatic chronic heart failure and implanted ICD/CRT-D of the        "INCEPTA" series|August 2013|November 3, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979120||56871|
NCT01981148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/12|Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope|Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope|FLIO Group|University Hospital Inselspital, Berne|Yes|Enrolling by invitation|February 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of patients and healthy subjects attending the        department of ophthalmology at the University of Bern|January 2016|January 4, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981148||56715|
NCT01981655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLACE1|0.5M Na Lactate Solution in Acute Heart Failure (AHF)|A Phase 2, Randomised, Single-Blind, Placebo-controlled Study of Half Molar Sodium Lactate Solution in the Treatment of Subjects With Acute Heart Failure|SOLACE1|Nepean Blue Mountains Local Health District|Yes|Completed|December 2009|August 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||November 2013|November 9, 2013|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01981655||56677|
NCT01981668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZ-L-06233|The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation|The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation||Nova Scotia Cancer Centre|No|Withdrawn||||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||March 2014|March 18, 2014|October 29, 2013|Yes|Yes|no Canadian centre interested in conducting study in a reasonable timeframe|No||https://clinicaltrials.gov/show/NCT01981668||56676|
NCT01981902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-20129075|Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees|Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees||University of California, Irvine|No|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Study population are the volunteers who are training for a marathon individually or under        the guidance of the Leukemia Society Team in Training, the American Heart Association, or        similar groups. These organizations run programs that include providing group-training        situations for individuals interested in preparing for a marathon while participating in        fund raising efforts.|February 2016|February 5, 2016|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01981902||56658|
NCT01981915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIC2013|Optimum Insufflation Capacity in NMD|Optimum Insufflation Capacity and Peak Cough Flow Augmentation in Patients With Neuromuscular Disease||Universität Duisburg-Essen|No|Completed|January 2011|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|6 Years|N/A|No|||November 2013|November 5, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01981915||56657|
NCT01982162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0801/65|Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze|Protocol for the European Multi-Centre Study Understanding Severe Asthma Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|April 2011|April 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|300|||Both|1 Year|17 Years|No|Non-Probability Sample|-  Severe school aged asthma cohort: persistent symptoms or frequent severe             exacerbations or persistent airflow limitation          -  Mild-moderate school aged asthma cohort: controlled or partially controlled asthma             symtomps          -  Severe pre school wheeze cohort: persistent symptoms or frequent severe exacerbations          -  Mild-moderate pre school wheeze cohort: controlled symptoms or partially controlled|June 2015|June 22, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982162||56638|
NCT01982175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAB004|Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia|A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia|CLL004|Shanghai Zhangjiang Biotechnology Limited Company|No|Recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||November 2013|November 5, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01982175||56637|
NCT01982188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-09-001|Single Incision Suburethral Sling at Time of Robotic Sacrocolpopexy|Single Incision Suburethral Sling at Time of Robotic Sacrocolpopexy||Atlantic Health System|Yes|Enrolling by invitation|September 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Female|N/A|N/A|No|Probability Sample|Our study population included all women undergoing single incision sling placement at the        time of robotic sacrocolpopexy|November 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01982188||56636|
NCT01978132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45381.091.13|Primary Hyperaldosteronism and Ischemia-reperfusion Injury|Primary Hyperaldosteronism and Endothelial Ischemia-reperfusion Injury|PHA-FMD|Radboud University|Yes|Enrolling by invitation|November 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978132||56947|
NCT01978704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/13|Glycaemic Load and Pre-meal Insulin Doses in Type 1 Diabetes Patients|Use of the Glycemic Load for the Adjustment of the Dose of Preprandial Insulin in Patients With Type 1 Diabetes Mellitus in Insulin Pump Therapy|GLUT|Federico II University|No|Completed|February 2013|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years||||November 2013|November 1, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978704||56903|
NCT01978717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO.2011-197|General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer|||Fudan University|Yes|Completed|September 2011|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|51 Years|65 Years|No|||November 2013|November 1, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978717||56902|
NCT01978665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004503-13|The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and Inflammatory Response During and After Exercise|The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and the Inflammaroty Response During and After Exercis.|COPDprednisone|Bispebjerg Hospital|Yes|Not yet recruiting|April 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|14|||Male|40 Years|75 Years|No|||November 2013|November 6, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978665||56906|
NCT01978678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aperitif|Does Asthma Phenotype Have Impact on Disease Control|Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyper Responsiveness Ensure Stable Disease Faster|Aperitif|Bispebjerg Hospital|Yes|Recruiting|November 2012|||January 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|15 Years|N/A|No|Probability Sample|Newly referred asthma patients|November 2013|November 6, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978678|9 Months|56905|
NCT01972659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU 2012 KAEK 144|Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients|Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients||Kocaeli University|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|60 Years|No|||January 2014|January 10, 2014|October 11, 2013|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01972659||57367|
NCT01969409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL119960|Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis|Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)|ART-IPF|University of Alabama at Birmingham|Yes|Recruiting|January 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|50 Years|85 Years|No|||November 2015|November 6, 2015|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01969409||57615|
NCT01973192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL116211-01|Viral Pathogenesis of Early Cystic Fibrosis Lung Disease|Viral Pathogenesis of Early Cystic Fibrosis Lung Disease|Early CF|Indiana University|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Blood Urea, Bronchopulmonary Lavage samples, Nasal swabs and Oral swabs, Stool samples|Both|2 Months|4 Months|No|Non-Probability Sample|Infants, less than 4 months of age who have been diagnosed with Cystic Fibrosis|November 2015|November 13, 2015|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01973192||57326|
NCT01973478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC08_8902|Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression|Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression|STHYM|Rennes University Hospital|Yes|Recruiting|May 2014|February 2020|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01973478||57304|
NCT01973725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-29|Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy|PhaseⅡ Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy||Sun Yat-sen University|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973725||57285|
NCT01973738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH 05|Comparison Between Raloxifene and Bazedoxifene|Comparison of the Clinical Efficacy and Safety Between Raloxifene and Bazedoxifene in Postmenopausal Women.||Tomidahama Hospital|No|Recruiting|January 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Female|45 Years|100 Years|No|Probability Sample|Osteoporosis patients using SERM more for five years.|November 2015|November 3, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01973738||57284|
NCT01971437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBC|Cystoscopy and Cystodistension; Therapeutic and Aetiological Aspect in Overactive Bladder|A Randomised Study of Cystoscopy and Cystodistension Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome.||Medway NHS Foundation Trust|Yes|Completed|October 2013|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|N/A|No|||March 2016|March 20, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01971437||57461|
NCT01978847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0153|Retrospective Review of Anterior and Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries|Proposal for Retrospective Review of Anterior&Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries Performed at OSU.||Ohio State University|No|Recruiting|May 2013|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Spinal arthrodesis can be performed through either anterior, posterior, or lateral        approaches for a variety of traumatic, degenerative, or deformity conditions.|August 2015|August 13, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01978847||56892|
NCT01980290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100966|Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C|Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts|INTEGRATE|Janssen Pharmaceutica N.V., Belgium|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Men or women who have HCV infection genotype 1, a quantifiable serum HCV RNA,        documentation of the degree of liver fibrosis assessed by liver biopsy or non-invasive        test (eg, fibrotest, fibroscan), physician decision to start triple therapy with        telaprevir and PegIFN alfa/RBV, have never been treated with antiviral treatment (naïve)        or who have relapsed after IFN or PegIFN plus RBV (relapsers), have a history of injecting        drugs, and are currently under stable substitution therapy (eg, methadone, buprenorphine)        and/or followed in an addiction center will be eligible to enter this study.|March 2016|March 7, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980290||56781|
NCT01980303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101101|A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers|An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Subjects||Janssen Research & Development, LLC|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|29|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|November 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01980303||56780|
NCT01980862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-83|Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes|||Fujirebio Diagnostics, Inc.|Yes|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|45 matched door serum and plasma. Samples set collected form individual Heart Failure        patients for galecin-3 measurements|August 2014|August 4, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01980862|1 Day|56737|
NCT01981954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-074|A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)|A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity||Astellas Pharma Inc|Yes|Completed|September 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|6 Months|4 Years|No|||January 2016|January 26, 2016|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981954||56654|
NCT01982214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908095|Effects of Whole Body Vibration (WBV) on Musculoskeletal System of Aged Women|Effects of Whole Body Vibration (WBV) on Musculoskeletal System of Aged Women|VIBROS|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|April 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|225|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982214||56634|
NCT01981928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7962-CL-0001|A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans|A Phase 1, Randomized, Subject- and Investigator-blinded, Sponsor-unblinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of ASP7962, Including a Food-effect Evaluation in Healthy Subjects||Astellas Pharma Inc|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01981928||56656|
NCT01981941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0103|Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment|Post-marketing Clinical Study of Gabapentin Enacarbil ―Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment―||Astellas Pharma Inc|No|Completed|May 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|80 Years|No|||July 2015|July 13, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01981941||56655|
NCT01982201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-130|Antacid Interaction Study|A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|November 2013|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01982201||56635|
NCT01978145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115646|A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|November 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|665|||Both|40 Years|80 Years|No|||December 2015|January 21, 2016|October 31, 2013||No||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01978145||56946|
NCT01978405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Wze088|Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes|Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes||Wuhan General Hospital of Guangzhou Military Command|Yes|Recruiting|November 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|75 Years|No|||October 2013|November 6, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978405||56926|
NCT01978691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2782|The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass|The Effect of Separate or Combined Supplementation of Probiotic (Bifidobacterium Lactis B420) and Polydextrose on Body Fat Mass|MetSProb|Danisco|No|Completed|November 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|225|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978691||56904|
NCT01978951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#07-004|Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand|Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand (ESCORT Study)|ESCORT|Bhumirajanagarindra Kidney Institute, Thailand|Yes|Completed|July 2011|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|443|||Both|18 Years|70 Years|No|||March 2014|March 29, 2014|December 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01978951||56884|
NCT01978938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-010|Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections||Tetraphase Pharmaceuticals, Inc.||Active, not recruiting|December 2013|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|840|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978938||56885|
NCT01973205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|863-P-303|Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine|A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine||Novartis|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|900|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|October 25, 2013|No|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01973205||57325|
NCT01973218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_42|Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.|A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea||Novartis|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|264|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 25, 2013|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01973218||57324|
NCT01970020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100989|A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.|An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 in Healthy Subjects Following a Single Oral Dose Administration of 14C-JNJ-38518168||Janssen Research & Development, LLC|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01970020||57568|
NCT01969422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0340|Online Question-answering and Conventional Consultation With a Dermatologist|Online Question-answering and Conventional Consultation With a Dermatologist||University of Zurich|Yes|Completed|November 2013|September 2014|Actual|September 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|1 Year|N/A|No|Non-Probability Sample|persons with a question on skin disease|December 2014|December 2, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01969422||57614|
NCT01970332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-10|Mechanisms That Produce the Leg Dysfunction of Claudication (Leg Pain and Limping During Walking) and Treatment Strategies for the Care of Patients With Claudication|Mitochondrial Dysfunction, Oxidative Damage and Inflammation in Claudication||University of Nebraska|No|Recruiting|September 2010|August 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|200|||Both|N/A|N/A|No|||October 2013|October 22, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01970332||57545|
NCT01969734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFH2|Endobronchial Valves in Moderate COPD|Response to Endobronchial Valves in Moderate Obstructive Airways Disease and Exercise Limitation - The REMODEL Trial|REMODEL|Sherwood Forest Hospitals NHS Foundation Trust|No|Recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01969734||57590|
NCT01969747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.78|Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days|A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2)||Boehringer Ingelheim||Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|October 22, 2013||||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01969747||57589|
NCT01970007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-010|VIVO Clinical Study|Evaluation of the Zilver® Vena™ Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction||Cook||Recruiting|October 2013|October 2019|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|243|||Both|18 Years|N/A|No|||December 2015|March 18, 2016|October 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01970007||57569|
NCT01979796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCARIS|Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.|Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning: Design of a Randomized Trial. Smoking Cessation And Reduction In Schizophrenia (The SCARIS Study)|SCARIS|Universita degli Studi di Catania|Yes|Not yet recruiting|September 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|153|||Both|18 Years|65 Years|No|||November 2013|November 2, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01979796||56819|
NCT01980264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903064D|Harmonics-based in Vivo Optical Virtual Biopsy|Harmonics-based in Vivo Optical Virtual Biopsy||National Taiwan University Hospital|Yes|Recruiting|January 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01980264||56783|
NCT01980277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAKTIC - IPC 2012-008|Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer|A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008|TAKTIC|Institut Paoli-Calmettes|Yes|Recruiting|January 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980277||56782|
NCT01981382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR013932-01|Characterizing the Role of Pain Sensitivity in Acute to Persistent Low Back Pain|Characterizing Pain Sensitivity in Persistent Nonspecific Low Back Pain||Virginia Commonwealth University|Yes|Active, not recruiting|October 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|whole blood|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Men and women between the ages of 18-50 years of age who are diagnosed with an acute        nonspecific LBP episode defined as pain anywhere in the region of the low back bound        superiorly by T12 and inferiorly by the buttock crease, which has been present for >24        hours but <4 weeks duration and was preceded by at least 1 pain-free month.|February 2016|February 19, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981382||56697|
NCT01981694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601001|A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Crossover, Single Oral Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Healthy Subjects||Pfizer|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981694||56674|
NCT01981967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC17|Post-licensure Safety Study of IMOJEV® in Thailand|Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand||Sanofi|Yes|Active, not recruiting|November 2013|June 2016|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10000|||Both|9 Months|4 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981967||56653|
NCT01978158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX2|Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α|Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α. A Pilot Proof of Principle Study||Radboud University|Yes|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978158||56945|
NCT01978418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAISTY-1|Inhaled Salbutamol in Elective Caesarean Section|Inhaled Salbutamol in Elective Caesarean Section|SAISTY|Helsinki University Central Hospital|Yes|Recruiting|November 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|62|||Both|N/A|1 Hour|Accepts Healthy Volunteers|||December 2014|December 5, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978418||56925|
NCT01978431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001006250|Impulsivity and Stimulant Administration|Impulsivity and Stimulant Administration||Yale University||Active, not recruiting|November 2012|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978431||56924|
NCT01978730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW001|The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule|Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia：A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension||Shineway Pharmaceutical Co.,Ltd|Yes|Active, not recruiting|December 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|372|||Both|40 Years|N/A|No|||May 2014|May 7, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978730||56901|
NCT01978743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroHIV002|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen||Massachusetts General Hospital|No|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|October 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01978743||56900|
NCT01978756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-25-15/08|Outpatient Clinic for Late Outcome for Breast Carcinoma in MAASTRO Clinic.|Outpatient Clinic to Evaluate Late Outcome in Patients Curatively Treated for Breast Carcinoma in MAASTRO Clinic.||Maastricht Radiation Oncology|No|Enrolling by invitation|March 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|As part of the study a blood sample or saliva will be obtained, if the patient has given      written informed consent to participate in the Biobank. The purpose to determine, by means      of DNA and protein analysis, the relationship between DNA and protein profiles and a number      of endpoints, which are important for the patient such as overall survival and side effects.      For detailed information: ClinicalTrials.gov Identifier: NCT01084785|Female|18 Years|N/A|No|Non-Probability Sample|Participants are all patients who have been treated for breast cancer with curative intent        in MAASTRO clinic in 2002-2003. They will be retrieved from the appointment -IT system.        For all these patients will be checked whether they are alive using the MBA (municipal        base administration).|September 2013|October 31, 2013|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01978756||56899|
NCT01978964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-10-002|Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors|Maintenance Therapy With ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients Who Have Previously Received ONT-10||Oncothyreon Inc.|Yes|Completed|November 2012|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978964||56883|
NCT01979250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSAEKtrial1|Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology|Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology||Aarhus University Hospital|No|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||January 2015|January 13, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01979250||56861|
NCT01969760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0614|Pilot-Testing a Family-Based Intervention to Improve Child Outcomes and Increase Family Activity|Pilot-Testing a Family-Based Intervention to Improve Child Outcomes and Increase Family Activity|HFDC|Georgetown University|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|18|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969760||57588|
NCT01969773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL009|Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment|Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial||Buddhist Tzu Chi General Hospital|No|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|85 Years|No|||October 2013|October 22, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01969773||57587|
NCT01970969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6159|THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring|This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.|GIRAFFE|Scripps Translational Science Institute|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|None Retained|A blood sample (in a 4 ml EDTA tube) for genotyping and a serum sample (in two 10ml red top      tubes) will be obtained from each patient.|Both|18 Years|N/A|No|Non-Probability Sample|Patients defined, as high risk for atrial fibrillation will be persons with:          1. No prior history of atrial fibrillation and/or atrial flutter (AFIB/AF) - with             symptoms of high clinical suspicion for AFIB/AF prompting referral for ambulatory             cardiac rhythm monitoring to evaluate for potential AFIB/AF, and          2. Any of the following features: ischemic stroke with no defined etiology (In prior 6             months) [3, 4, 6, 7], hypertension [33], increased body mass index (BMI >30kg/m2)             [33], heart failure [33], clinically significant murmur [33], prolonged PR interval             on resting ECG (>200msec) [33], chronic kidney disease [34], hypertrophic             cardiomyopathy [35], congenital heart disease [36], chronic obstructive pulmonary             disease [37, 38], sleep apnea [39-41], thyroid disease [42, 43], family history of             atrial fibrillation [44], diabetes [45] or excess alcohol consumption (Male > 14             drinks/week, Female >7 drinks/week)[46].|October 2015|October 14, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01970969||57497|
NCT01970618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST001|Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients|A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1162 in Healthy Subjects and Subjects With Chronic Obstructive Pulmonary Disease.||Respivert Ltd|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01970618||57523|
NCT01971229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-168-BMA|Gastric Emptying and Insulin Response to Test Drink|Assessment of Insulin Response Following Ingestion of a Carbohydrate/Whey Protein Drink. A Cross-over Randomized Double Blind Study.||McGill University Health Center|Yes|Active, not recruiting|December 2013|July 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971229||57477|
NCT01970943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT007530-01|Molecular and Functional PET-fMRI Measures of Analgesia in Migraine|Molecular and Functional PET-fMRI Measures of Analgesia in Migraine||Massachusetts General Hospital|No|Active, not recruiting|March 2013|||April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|28|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01970943||57498|
NCT01971216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NT05|Mother-infant Signalling During Breastfeeding|Mother-infant Signalling During Breastfeeding: A Randomised Trial Investigating the Effects of a Relaxation Intervention in Breastfeeding Mothers on Breast Milk Production, Breast Milk Cortisol and Infant Behaviour and Growth.|MOMS|University College, London|No|Recruiting|December 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01971216||57478|
NCT01971710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF-003|The ACCLAIM Project|Advancing Community Level Action for Improving MCH/PMTCT|ACCLAIM|Elizabeth Glaser Pediatric AIDS Foundation|No|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|187335|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01971710||57440|
NCT01971944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1985|The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure|The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure||University of North Carolina, Chapel Hill|No|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|57|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who are admitted to the General Cardiology and Heart Failure Services at the        University of North Carolina Hospitals with acute decompensated heart failure, and who are        deemed by the health care team to require pulmonary artery catheter placement and        inotropic therapy with either dobutamine or milrinone by continuous infusion.|February 2016|March 7, 2016|October 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01971944||57422|
NCT01971723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC#: 2013.10364|Multi-ingredient Supplement for Strength and Power|The Impact of T+ Supplementation on Anabolic Hormone Profile and Performance in Power Athletes||Florida State University|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 27, 2013||No||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01971723||57439|Unable to standardize individual ingredients in T+ supplement. Volume of lifts not tested was not analyzed for statistical significance. Neuromuscular adaptations were not tested. Length of study may have affected body composition measures.
NCT01980082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProphylacticABxHN|Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery|Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery||Rabin Medical Center|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|120 Years|No|||October 2015|October 27, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980082||56797|
NCT01980056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013915|Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy|A Phase 1/2, Open-label, Dose Escalation Clinical Study of the Safety and Clinical Activity of Vosaroxin in Patients With Intermediate 2 or High-risk Myelodysplastic Syndrome (MDS) After Failure of Hypomethylating Agent-based Therapy||Weill Medical College of Cornell University|No|Recruiting|October 2013|May 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980056||56799|
NCT01994473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP361-106|Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|A 2-Part Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose and Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|SEP-363856|Sunovion|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|55 Years|No|||February 2015|February 6, 2015|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01994473||55694|
NCT01995019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Artralgia1|Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone|PhaseIV Study of Intra-articular Methylprednisolone in TMJ Arthralgia||Uppsala University|Yes|Enrolling by invitation|December 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995019||55653|
NCT01995032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD02|L-citrulline and Metformin in Duchenne's Muscular Dystrophy|"A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy"||University Hospital, Basel, Switzerland|No|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|7 Years|10 Years|No|||November 2015|November 23, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995032||55652|
NCT01995292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atomizer1.0|Comparison of Two Different Types of "Spray as You go" Technique for Awake Fiberoptic Intubation|Comparative Clinical Trial of Conventional and Modified "Spray as You go" Technique With the "Enk Fiberoptic Atomizer Set" for Awake Fiberoptic Intubation (Atomizer Study)||Johannes Gutenberg University Mainz|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01995292||55632|
NCT01991366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Integrilin Stemi|Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?|Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?||Medstar Research Institute|No|Active, not recruiting|October 2013|||October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|800|||Both|N/A|N/A|No|Probability Sample|Patients who underwent primary Percutaneous Coronary Intervention at Washington Hospital        Center since September 2000 and received eptifibatide pre-or during PCI or have received        no eptifibatide.|August 2014|August 8, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991366||55932|
NCT01991379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-162|MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)||Memorial Sloan Kettering Cancer Center||Recruiting|November 2013|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991379||55931|
NCT01991639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-039|Healthy Life for Frail Malnourished Seniors Performed Together With Trained Lay Buddies|Nutrition Intervention and Physical Training in Malnourished, Frail, Community-dwelling, Elderly Subjects Carried Out by Trained Lay "Buddies"||Medical University of Vienna|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01991639||55912|
NCT01991860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10015|US Phase III Study of APD421 in PONV|Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting||Acacia Pharma Ltd|Yes|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|364|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991860||55895|
NCT01992913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1157-R|Building Employment Skills Through Therapy for Veterans|Integrated Cognitive Behavior Therapy to Improve Work Outcomes in Schizophrenia|BEST Vet|VA Office of Research and Development|No|Recruiting|June 2015|September 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01992913||55814|
NCT01993407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-743-12|Training Executive Functions to Facilitate Recovery Following Traumatic Brain Injury|Training Executive Functions to Facilitate Recovery Following Traumatic Brain Injury||Kessler Foundation|Yes|Completed|June 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01993407||55776|
NCT01992887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0251|Pre-ART Retention in Care in Tanzania|Retention and Engagement in Care of Patients Prior to ART Initiation in the Kagera Region of Tanzania|PARC|Columbia University|No|Active, not recruiting|March 2012|February 2016|Anticipated|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|948|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited at four HIV CTCs in the Kagera region of northwestern        Tanzania. The 8,000 patients enrolled in HIV care at these clinics represent 30% of HIV        patients ever enrolled in ICAP-supported clinics across Kagera Region. Patients will be        eligible for selection for either in-depth interviews or focus group discussions if they        have made at least one prior visit to the clinic.|December 2014|January 26, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01992887|24 Months|55816|
NCT01992900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST3073-ST3074-DM-12-002|A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria|A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria||sigma-tau i.f.r. S.p.A.|Yes|Completed|November 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|6 Months|12 Months|No|||July 2015|July 8, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992900||55815|
NCT01994252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN00208414|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation|RAFT-PermAF|Ottawa Heart Institute Research Corporation|Yes|Recruiting|August 2013|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|950|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01994252||55711|
NCT01962792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1119-CA|Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma||Pharmacyclics|Yes|Recruiting|December 2013|September 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962792||58122|
NCT01965106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK208|Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)|Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)||Quark Pharmaceuticals|No|Completed|December 2013|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|46|||Both|40 Years|N/A|No|||October 2015|October 14, 2015|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01965106||57945|
NCT01960868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00760-45|Early Rehabilitation Program is Feasible and Safe in ICU in Liver Transplanted Patients|Early Rehabilitation Program is Feasible and Safe in ICU in Liver Transplanted Patients||Assistance Publique Hopitaux De Marseille|Yes|Active, not recruiting|October 2013|April 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960868||58269|
NCT01960582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMAS 2011-907|Evaluation of Housing Adaptations and Mobility Devices|Housing Adaptations and Mobility Devices - Evaluation of a New Practice Strategy|FORMASEvid|Lund University|No|Recruiting|April 2013|December 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|340|||Both|20 Years|N/A|No|||March 2015|March 31, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01960582||58291|
NCT01961895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Altermatt 09-148|Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture|Evaluation of the Effect of Perioperative Continuous Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture.||Pontificia Universidad Catolica de Chile|Yes|Completed|May 2010|||May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|N/A|N/A|No|||October 2013|October 11, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961895||58191|
NCT01992991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS-RHN|Transcranial Stimulation for Upper Limb Training of Individuals With Sequelae From Intracranial Hemorrhage|Transcranial Direct Current Stimulation for Upper Limb Training of Individuals With Sequelae From Intracranial Hemorrhage|tDCS-ICH|University of Aarhus|No|Active, not recruiting|December 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||February 2014|February 17, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992991||55808|
NCT01994343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0044UG|Pain in Women With Chronic Pelvic Pain|Musculoskeletal Disturbances in Women With Chronic Pelvic Pain||Universidad de Granada|Yes|Recruiting|November 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult women with more than eighteen years with non-menstrual or noncyclic pelvic pain with        duration of at least 6 months, sufficiently intense to interfere with habitual activities.|December 2014|December 9, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994343||55704|
NCT01961648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:132|Respiratory Drive on Obstructive Apnea|Effect of Increasing Respiratory Drive on Severity of Obstructive Apnea||University of Manitoba|Yes|Terminated|August 2013|June 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|21 Years|70 Years|No|||September 2013|June 26, 2015|September 6, 2013||No|Investigators were not able to continue recruiting and enrolling.|No||https://clinicaltrials.gov/show/NCT01961648||58210|
NCT01995305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumc001|Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents|Exome Sequencing of Fanconi Anemia Children and the Their Parents||Chinese Academy of Medical Sciences||Available||||||N/A|Expanded Access|N/A|||||||Both|1 Month|18 Years||||November 2013|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995305||55631|
NCT01994759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-150-FJ|Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof.|Optimal Treatment of Plantar Fasciitis: A Randomized Clinical Trial Using Physical Training, Glucocorticoid Injections or a Combination Thereof.||Bispebjerg Hospital|No|Active, not recruiting|September 2013|January 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|20 Years|65 Years|No|||March 2016|March 20, 2016|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01994759||55673|
NCT01991886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013PR01|Using Nasal High Flow From Birth in Premature Infants - a Pilot Study|A Pilot Study to Determine the Feasibility of the Use of Nasal High Flow From Birth in Premature Infants Born at Less Than or Equal to 30 Week Gestational Age.||Ashford and St. Peter's Hospitals NHS Trust|No|Not yet recruiting|January 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|24 Weeks|30 Weeks|No|||December 2013|December 6, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01991886||55893|
NCT01991899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN/002/2013|Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.|Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Recruiting|February 2015|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1560|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||April 2015|April 13, 2015|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991899||55892|
NCT01992172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-DRUG-PHOTOCIL-AD-001|Photocil (Topical) for the Treatment of Atopic Dermatitis|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Atopic Dermatitis||Applied Biology, Inc.|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|November 19, 2013||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01992172||55871|
NCT01992432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13278|Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)|A Pilot Study of Structural and Functional Brain Magnetic Resonance Imaging Findings of Chemotherapy Toxicity in Older Women With Breast Cancer|Brain fMRI-BC|City of Hope Medical Center|Yes|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Female|65 Years|N/A|No|Non-Probability Sample|Using a prospective longitudinal study design, 25 patients will be recruited for this        study from the outpatient medical oncology practice at City of Hope Medical Center.|January 2016|January 28, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01992432||55851|
NCT01993420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM02-ADM02|A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Atopic Dermatitis||Dermira, Inc.|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|No|||April 2014|April 14, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01993420||55775|
NCT01993641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI-005|Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA|A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone|MEI-005|MEI Pharma, Inc.|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||June 2015|March 14, 2016|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993641||55758|
NCT01993953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boppet|BodyPump and Personal Training - Changes in Muscle Strength and Body Composition|BodyPump and Personal Training - Changes in Muscle Strength and Body Composition||Norwegian School of Sport Sciences|No|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|144|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01993953||55734|
NCT01993966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308047RIN|EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells|Mechanism of (-)-Epigallocatechin -3-gallate (EGCG) to Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells||National Taiwan University Hospital|No|Not yet recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|25|||Both|20 Years|80 Years|No|Non-Probability Sample|patients with age between 20-80 years old and had taken Radical Cystectomy or nephrectomy        between 2008-2012 were chosen as study population|November 2013|November 19, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01993966|1 Day|55733|
NCT01963403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD IRB Protocol Number 478388|Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive|Relief of Bleeding on the Implant: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With a Combined Oral Contraceptive: A Placebo-Controlled Randomized Trial|ROBI|University of California, Davis|No|Terminated|December 2013|September 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Female|14 Years|N/A|No|||December 2015|December 2, 2015|October 10, 2013||No|Futility of recruitment|No||https://clinicaltrials.gov/show/NCT01963403||58075|
NCT01964625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32186|Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)|Assessment of Positron Emission Tomography - Computed Tomography (PET-CT) Scanning as a Potential Biomarker to Assess Disease Activity in Chronic Graft Versus Host Disease (GvHD): A Pilot Study||University of Rochester|Yes|Terminated|November 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|December 1, 2010||No|Terminated due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT01964625||57982|
NCT01964846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2013-023|Effect of Antioxidant Intake on Cardiovascular Risk|The Effect of Resveratrol and Curcumin on Postprandial Inflammation in Men and Postmenopausal Women||Laval University|No|Completed|October 2013|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964846||57965|
NCT01960595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120357|Post-operative Pain Management In Patients Undergoing Hullax Valgus Surgery|Comparison of the Efficacy and Cost Analysis of Regional Anesthesia and Intravenous Fentanyl for Postoperative Pain Management in Patients Undergoing Hullax Valgus Surgery||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Active, not recruiting|August 2013|May 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2013|October 9, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01960595||58290|
NCT01960608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24UNainCKD|The Analysis of Correlation About the 24hours Urine Sodium and the Blood Pressure in Patient With CKD|||Inje University||Not yet recruiting|June 2015|||November 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|400|||Both|18 Years|80 Years|No|Non-Probability Sample|chronic kidney disase|March 2015|March 24, 2015|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01960608||58289|
NCT01960621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0406/102|Effect of Cyclodextrin on Sensory Nerve Activity: A Novel Anti-tussive Therapy|The Effect of Cyclodextrin on Sensory Nerve Activity and the Cough Relex in Man: A Novel Anti−Tussive Therapy||Imperial College London||Terminated|August 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|May 8, 2008||No|Study has not been able to start due to difficulty in obtaining an intravenous formulation of    cyclodextrin (intravenous 2HPBCD) suitable for man|No||https://clinicaltrials.gov/show/NCT01960621||58288|
NCT01961362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 4134a|Supplemental Oxygen in Pulmonary Fibrosis|Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis||National Jewish Health|Yes|Recruiting|October 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue        disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma,        dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary        supporter/caregiver of a patient with pulmonary fibrosis|April 2015|April 14, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961362||58232|
NCT01961635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-01|Healing of Bone/Soft Tissue to Different Abutment Biomaterials and the Impact on Marginal Bone Loss|Healing Response if Peri-implant Tissues to Different Abutment Materials - Double-blinded Randomized Clinical Trial||Instituto de Implantologia|No|Recruiting|January 2016|January 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 21, 2016|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01961635||58211|
NCT01961375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16199|MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study|MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study.|MIDAS|Bayer|No|Recruiting|October 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|18 Years|49 Years|No|Probability Sample|The study subjects will be enrolled from multiple sites like women's hospitals, tertiary        care institutes, Family planning clinics and gynaecological consulting centres.|March 2016|March 7, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961375||58231|
NCT01992445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20133770|Suicidal Thought and Biological Markers|Suicidal Thought and Biological Markers: A Prospective Multicenter Study Validating Verbal, Non-verbal and Genetic Methods to Assess Suicidal Intent|STM|Children's Hospital Medical Center, Cincinnati|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|375|Samples With DNA|Buccal swabs|Both|13 Years|N/A|No|Non-Probability Sample|Emergency Department and inpatients|September 2015|September 25, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01992445||55850|
NCT01992458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|913203|Primary Prevention ICD French Registry|Observatoire Multicentrique Français Des Porteurs de Défibrillateur Automatique Implantable en Prévention Primaire (Cardiopathie Ischémique ou Cardiomyopathie Dilatée)|DAI-PP|Clinique Pasteur|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|5576|||Both|N/A|N/A|No|Non-Probability Sample|All patients from 12 medical centers implanted with an implantable cardioverter        defibrillator (ICD) in the setting of primary prevention since Jan. 1, 1997, in France|November 2013|November 19, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992458||55849|
NCT01991392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111062RIC|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?||National Taiwan University Hospital|Yes|Recruiting|November 2012|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|20 Years|N/A|No|||November 2013|November 24, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991392||55930|
NCT01991652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CollabWilmsAfrica|Collaborative Wilms Tumour Africa Project|Collaborative Wilms Tumour Africa Project||VU University Medical Center|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|N/A|18 Years|No|||December 2014|December 9, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01991652||55911|
NCT01992926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130784|Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid Trial|Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid Trial||Vanderbilt University|Yes|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|109|||Both|18 Years|80 Years|No|||January 2015|January 21, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01992926||55813|
NCT01992939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulsOx-002|The Effect of Heat on Blood and Oxygen Flow Readings Part 2|The Effect of Heat on Blood and Oxygen Flow Readings Part 2||VA Pittsburgh Healthcare System|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01992939||55812|
NCT01993121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0514|Exercise and Type 2 Diabetes: Gender and Endothelial Function|Exercise and Type 2 Diabetes: Gender and Endothelial Function||University of Colorado, Denver|No|Completed|September 2002|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01993121||55798|
NCT01993134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATB-001|Efficacy Assessment of Two Antibiotic Prophylaxis Regimens in Oral and Maxillofacial Trauma Surgery|Efficacy Assessment of Two Antibiotic Prophylaxis Regimens in Oral and Maxillofacial Trauma Surgery.|EAPRTS|Universidade Federal do Rio Grande do Norte|Yes|Recruiting|December 2011|December 2014|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|75|||Both|15 Years|75 Years|No|||November 2013|November 18, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01993134||55797|
NCT01993459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14091991|The Effects of Midazolam on the Quality of Postoperative Recovery|A Randomized Controlled Trial on the Effects of Midazolam on the Quality of Postoperative Recovery in Patients|WOLII|Erasmus Medical Center|No|Completed|February 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993459||55772|
NCT01994005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5327714500|Randomized Controlled Trial of Adjunctive Social Media for More Effective Contraceptive Counseling|Randomized Controlled Trial of Adjunctive Social Media for More Effective Contraceptive Counseling||New York Presbyterian Hospital|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|144|||Female|18 Years|45 Years|No|||November 2013|November 19, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01994005||55730|
NCT01993654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-028|In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions|In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions||Massachusetts Eye and Ear Infirmary|No|Terminated|September 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|17|||Both|18 Years|N/A|No|Probability Sample|Male or female patients over the age of 18 and belonging to one of the following groups        will be recruited for this study.        Group 1: Nevus Group 2: Racial melanosis Group 3: Primary Acquired Melanosis Group 4:        Malignant Melanoma of the Conjunctiva Group 5: Normal Subjects with no pigmented lesions        Normal subjects will be recruited from patients normally seen during clinic for cataract        evaluations. Groups 1-4 will be identified by the investigators at MEEI and other 2 sites        as potential study subjects during regular clinic visits.|May 2012|January 11, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01993654||55757|
NCT01993979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2011/10031|A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)|A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer|POUT|Institute of Cancer Research, United Kingdom|Yes|Recruiting|May 2012|May 2022|Anticipated|May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|345|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993979||55732|
NCT01993992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310021RIND|Parental Anxiety and Its Relationship With Pediatric Patients' Post-operative Responses|Parental Anxiety and Its Relationship With Pediatric Patients' Post-operative Responses||National Taiwan University Hospital|No|Active, not recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Age younger than 16-year-old who required surgery|July 2015|July 7, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01993992||55731|
NCT01964599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215-2011|Potato Fiber and Gastrointestinal Function: Phase 3|Potato Fiber and Gastrointestinal Function: Phase 3 (Grant #94521)||University of Florida|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964599||57984|
NCT01964638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-01613|Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.|Comparative Analysis of Software-based MRI-Ultrasound Image Fusion Against Cognitive Targeting of Multi-Parametric MRI Findings With Prostate Biopsy||New York University School of Medicine|Yes|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|126|||Male|40 Years|75 Years|No|||October 2013|October 14, 2013|October 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964638||57981|
NCT01964859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068684|Feasibility Study for Fibroblast Autologous Skin Grafts|Feasibility Study for Fibroblast Autologous Skin Grafts: Biopsy of Skin Fibroblasts, Expansion in Cell Therapy Core, Topical Injection of Fibroblasts, and Subsequent Removal of Graft for Laboratory Studies.||Johns Hopkins University|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964859||57964|
NCT01960634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-1304|Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma|Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma|BRAFV600|Grupo Español Multidisciplinar de Melanoma|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|58|Samples With DNA|Serum and Plasma|Both|N/A|N/A|No|Probability Sample|Patients with histologically confirmed melanoma and BRAF V600 mutation|April 2015|May 4, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960634||58287|
NCT01960920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3439/10/028|Effects of Air Pollution Exposure Reduction by Filter Mask on Heart Failure|Effects of Air Pollution Exposure Reduction by Filter Mask on Heart Failure: a Prospective Randomized Double-blind Controlled Trial||InCor Heart Institute|No|Completed|February 2013|January 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960920||58265|
NCT01960894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol_NIPVA Study_v1_050613|Non-invasive Pressure-Volume Analysis (NIPVA): Extending Comprehensive Left Ventricular Pump Function Assessment to More Patients and Settings|Non-invasive Pressure-Volume Analysis (NIPVA): Extending Comprehensive Left Ventricular Pump Function Assessment to More Patients and Settings|NIPVA|Imperial College London|No|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending cardiology out-patient clinics|September 2013|October 10, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960894||58267|
NCT01961128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-291|RPFNA Assessment of Exercise Effect in Breast Cancer|Pilot Feasibility Study of the Use of Random Periareolar Fine Needle Aspiration Exercise Induced Changes in Breast Tissue||Dana-Farber Cancer Institute|No|Completed|October 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|January 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01961128||58250|
NCT01961388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16667|Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy|Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy|STARCH AM|Bayer|No|Withdrawn|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Drug-naïve sub-optimally controlled (by diet and physical exercise) type 2 diabetic        patients (Female and male patients who are at least 18 years of age) selected from        secondary or tertiary referral centers, private hospitals / clinic with good inflow of        patients with diabetes|March 2015|March 20, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961388||58230|
NCT01991938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-5584-101|Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma|A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma||Verastem, Inc.|No|Recruiting|November 2013|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01991938||55889|
NCT01991951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMCEP01|Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation|Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients||Korea University Anam Hospital||Recruiting|July 2013|July 2017|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Both|20 Years|N/A|No|||November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991951||55888|
NCT01992198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP BUNDLE-ANTIBIOTICS|Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis|Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis||Ruijin Hospital|No|Recruiting|July 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2013|November 18, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01992198||55869|
NCT01992679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSS-IL-011|Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis|Body Weight Supported Treadmill Training in Advanced Multiple Sclerosis||University of Illinois at Urbana-Champaign|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992679||55832|
NCT01992692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkinson-remifentanil|Remifentanil Requirement in Patients Receiving Surgical Treatment of Parkinson's Disease|||Changhai Hospital|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator        placement, as well as non-Parkinsonian patients undergoing intracranial surgery|June 2013|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992692||55831|
NCT01993160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-FCH-PET/MR|18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer|18F-FCH-PET/MR in Staging of High-Risk Prostate Cancer: A Multiparametric Approach||University Health Network, Toronto|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|18 Years|99 Years|No|||March 2016|March 8, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01993160||55795|
NCT01993173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td528|Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.|Immunogenicity and Safety of Sanofi Pasteur's Tdap Combined Vaccine (ADACEL) as a Booster Dose, Versus Local DT Vaccine in Healthy Children or Versus Local Td Vaccine in Healthy Adolescents and Adults in China||Sanofi|No|Completed|November 2013|April 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1440|||Both|4 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993173||55794|
NCT01993147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-MED-HUM00074465|Functional Differences in Effortful Control|Functional Differences in Effortful Control|FDEC|University of Michigan|No|Active, not recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|180|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993147||55796|
NCT01993667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00050402|Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing|Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing||University of Utah|Yes|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993667||55756|
NCT01994291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261009|A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema|A Phase 2, Randomized, Double-masked, Placebo-controlled, Parallel Group, Multi-center Study To Compare The Efficacy And Safety Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema||Pfizer|No|Terminated|November 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994291||55708|
NCT01964612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205106RIC|Illness Crisis Adapting in Early or Middle Phase of Patient With Chronic Disease: Study of Meta-cognition Model|Illness Crisis Adapting in Early or Middle Phase of Patient With Chronic Disease: Study of Meta-cognition Model||National Taiwan University Hospital||Recruiting|July 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|460|||Both|20 Years|N/A|No|Non-Probability Sample|adults with obvious chronic diseases of hypertension or diabetes, or both diseases        diagnosed by doctors in Taiwan.|October 2013|October 14, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01964612||57983|
NCT01964898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23HL107391|Post Acute Coronary Event Smoking Study|Integrated Smoking Cessation and Mood Management for Cardiac Patients|PACES|The Miriam Hospital|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|75 Years|No|||March 2016|March 10, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964898||57961|
NCT01964872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102784|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants|A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects||Janssen Cilag N.V./S.A.|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964872||57963|
NCT01964885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/012213|Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections|Clinical Trial to Explore Benefit and Tolerability of IQP-AS-105 (Xaludicin®) in Subjects With Increased Susceptibility to Upper Respiratory Tract Infections||InQpharm Group|No|Terminated|October 2013|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 15, 2013||No|No significant results during interim analysis|No||https://clinicaltrials.gov/show/NCT01964885||57962|
NCT01960933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANAMI-3-PRIMULTI|Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization|Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization (DANAMI-3-PRIMULTI) A Randomised Comparison of the Clinical Outcome After Complete Revascularisation Versus Treatment of the Infarct-related Artery Only During Primary Percutaneous Coronary Intervention|PRIMULTI|Rigshospitalet, Denmark|Yes|Active, not recruiting|May 2011|February 2019|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960933||58264|
NCT01960907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHROMEDB|Clinical Trials for Elderly Patients With Multiple Disease|Clinical Trials for Elderly Patients With Multiple Disease|CHROMED|Restech Srl|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|65 Years|N/A|No|||November 2014|November 6, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960907||58266|
NCT01961141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP17|Evaluation of Lung Doppler Signals in Patients Presenting to EMD|Evaluation of Lung Doppler Signals in Patients With Acute Cardiovascular or Pulmonary Conditions Presenting to the Emergency Medicine Department by a Modified Ultrasound Doppler TCD Device.||Echosense Ltd.|No|Withdrawn|November 2014|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the EMD with acute cardiovascular and/or pulmonary conditions,        including- but not restricted to- pneumonia, pulmonary embolism, CHF exacerbation, COPD        exacerbation, shock, etc.|May 2013|August 12, 2015|October 6, 2013||No|review the study concept|No||https://clinicaltrials.gov/show/NCT01961141||58249|
NCT01961154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5801124|Stepping Down of Asthma Medication in Controlled Asthma|Stepping Down of Asthma Medication in Controlled Asthma||Kuopio University Hospital|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961154||58248|
NCT01961167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gore PI 13-05|Evaluation of the GORE® PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries|Feasibility Evaluation of the GORE® PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries|PI13-05|W.L.Gore & Associates|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01961167||58247|
NCT01961700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122541|In-hospital Physiotherapy for Patients Undergoing Thoracic Surgery - a Randomized Controlled Trial|||University Hospital Orebro||Recruiting||||December 2016|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||April 2014|April 9, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961700||58206|
NCT01992224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP bundle -- MV|Effect of Early Mechanical Ventilation to Severe Acute Pancreatitis|Effect of Early Mechanical Ventilation to Severe Acute Pancreatitis||Ruijin Hospital|No|Recruiting|July 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|80 Years|No|||November 2013|November 18, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01992224||55867|
NCT01992484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLANTIS-ACS|Platelet Function in Patients With an Acute Coronary Syndrome|Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome|ATLANTIS-ACS|Medical University of Vienna|Yes|Recruiting|August 2012|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients presenting with an acute coronary syndrome|November 2013|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992484||55847|
NCT01992497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.14.INF|Cesarean Section Study|Effect,Tolerance and Safety of a Supplementation With a Probiotic in Healthy Newborn Term Infants Born by Cesarean Section Over a 12 Months Period Study||Nestlé|No|Recruiting|December 2013|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|740|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||July 2015|October 14, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992497||55846|
NCT01992510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH2013|The Effect of Postural Changes on Intraocular Pressure in Silicone Oil-filled Eyes|||Kyungpook National University||Completed|January 2012|||January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|||Both|33 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|silicone tamponade patients|December 2013|December 19, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992510||55845|
NCT01992471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-215|Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing|Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2013|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|Samples With DNA|blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients will also be eligible if they are referred to the MSKCC Clinical Genetics Service        from outside providers after receiving negative full sequence BRCA1/2 results from those        outside providers.|January 2016|January 11, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992471||55848|
NCT01992952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAKTION|Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer|A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor|FAKTION|Wales Cancer Trials Unit|Yes|Recruiting|May 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||June 2014|June 10, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01992952||55811|
NCT01993472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCRC-013|Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer|Andrographolides With or Without Capecitabine for Elderly Patients With Locally Advanced or Recurrent or Metastasis Inoperable Colorectal Cancer: a Randomized, Open-label Trial.|AGCRC-013|The First Affiliated Hospital with Nanjing Medical University|Yes|Not yet recruiting|November 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|65 Years|N/A|No|||November 2013|November 20, 2013|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993472||55771|
NCT01993485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP TAVI|The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function|The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function||Heinrich-Heine University, Duesseldorf|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|patients with aortic valve stenosis screened for TAVI|June 2014|June 3, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01993485||55770|
NCT01993433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM02-PSO02|A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Plaque Psoriasis||Dermira, Inc.|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||April 2014|April 14, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01993433||55774|
NCT01993446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM02-ROS02|A Safety and Efficacy Study of DRM02 in Subjects With Rosacea|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Rosacea||Dermira, Inc.|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||April 2014|April 14, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01993446||55773|
NCT01993680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2011-0358|Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment|A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson`s Disease||University of Zurich|Yes|Active, not recruiting|June 2012|January 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|50 Years|80 Years|No|||September 2015|September 29, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01993680||55755|
NCT01994031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJLYSK-LPS-2013-01|Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments|Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments||Nanjing Luye Sike Pharmaceutical Co.,Ltd.|Yes|Recruiting|August 2014|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Both|18 Years|75 Years|No|||August 2014|August 26, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01994031||55728|
NCT01994018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF-13-002|Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake|Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake||OSF Healthcare System|No|Recruiting|November 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MS Group: Relapsing-remitting MS (RR-MS) patients according to the McDonald criteria who        are treated with a FDA approved immuno-modulatory drugs.        Control Group: Healthy individuals not on vitamin D supplementation.|November 2013|November 19, 2013|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01994018||55729|
NCT01994304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC--P2|Assessment and Evaluation of the Safe Childbirth Checklist --Phase II|Assessment and Evaluation of the Safe Childbirth Checklist --Phase II Rajasthan, India||Public Health Foundation of India|No|Active, not recruiting|June 2012|February 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200000|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01994304||55707|
NCT01964274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CESARO|Relevance of the Peripheral Cholinesterase-activity on Neurocognitive Dysfunctions in Surgical Patients|Relevance of the Peripheral Cholinesterase-activity on Neurocognitive Dysfunctions in Surgical Patients|CESARO|Charite University, Berlin, Germany||Recruiting|October 2013|December 2019|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|Adult, elective surgery patients of both gender|January 2016|January 25, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964274||58009|
NCT01960647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eur-003|FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease|Phase III FREERIDE STUDY Freeway Randomized Angioplasty Study||Eurocor GmbH|No|Recruiting|May 2011|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01960647||58286|
NCT01960660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0216|A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products|A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products||Nordic Pharma, USA|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960660||58285|
NCT01961180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24638418|The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS|The Effect of Cipralex in Polycystic Ovary Syndrome||Odense University Hospital|Yes|Recruiting|June 2013|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||December 2014|December 9, 2014|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961180||58246|
NCT01961401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1021|Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Gestational Diabetes Mellitus|Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Pregnant Women With and Without Gestational Diabetes Mellitus|GDMakutt|Norwegian University of Science and Technology|No|Recruiting|January 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961401||58229|
NCT01961414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-1319|Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910|Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910)|RANGE|Palmetto Retina Center, LLC|No|Active, not recruiting|October 2013|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||October 2015|October 29, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961414||58228|
NCT01961687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE-011|A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.|A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.||C. R. Bard||Active, not recruiting|September 2013|||March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961687||58207|
NCT01961713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-207|Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy|Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy||Massachusetts General Hospital|Yes|Recruiting|April 2010|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood samples|Male|18 Years|N/A|No|Non-Probability Sample|Men with prostate cancer that will be undergoing prostatectomy at Massachusetts General        Hospital|May 2015|May 22, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01961713||58205|
NCT01992237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charité-MEEP-01|Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients|Pilot Study of Measuring Energy Expenditure in ECMO Patients Under Consideration of Type of Ventilation and to Approximate Cardiac Output|MEEP|Charite University, Berlin, Germany|Yes|Recruiting|October 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Whole blood will be obtained for metabolomic analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with ALI|February 2015|February 5, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01992237||55866|
NCT01992250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0011|Cryoablation of Small Breast Tumors in Early Stage Breast Cancer|Freezing Alone Instead of Resection Of Small Breast Tumors: A Study of Cryoablation in the Management of Early Stage Breast Cancer|FROST|Sanarus Technologies, LLC|No|Recruiting|November 2013|June 2022|Anticipated|December 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|50 Years|N/A|No|||June 2015|June 3, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992250||55865|
NCT01992718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00076620|What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography|What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography||University of Michigan|Yes|Recruiting|November 2013|November 2019|Anticipated|November 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01992718||55829|
NCT01992705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055716|Borderline Pancreas Study: FOLFIRINOX +SBRT|Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study|GCC 1324|University of Maryland|Yes|Recruiting|March 2014|December 2020|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992705||55830|
NCT01993186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX007G-CL201|Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome||Ultragenyx Pharmaceutical Inc|Yes|Recruiting|January 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|100 Years|No|||February 2016|February 9, 2016|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993186||55793|
NCT01993199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deep biopsy111|Deep Biopsy Via Endoscopic Submucosal Dissection in Upper GI Subepithelial Tumors|Prospective Study: Deep Biopsy Via Endoscopic Submucosal Dissection in Upper GI Subepithelial Tumors||Hanyang University Seoul Hospital|No|Active, not recruiting|May 2010|December 2015|Anticipated|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|No|||November 2013|November 19, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01993199||55792|
NCT01993212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-304|A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%|||Repros Therapeutics Inc.|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Male|18 Years|60 Years|No|||September 2014|September 29, 2014|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993212||55791|
NCT01993693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-02|Wearable Therapeutic Ultrasound Study for Knee Osteoarthritis|Wearable Therapeutic Ultrasound Study||ZetrOZ, Inc.|No|Terminated|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|35 Years|80 Years|No|||June 2014|November 17, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993693||55754|
NCT01994044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKSWAD SpinalSC|Randomized WAD Study|Treating Selected Chronic WAD Patients: Cervical Fusion or Multidimensional Rehabilitation. A Randomized Study||Spinal Surgery Clinic, Strängnäs|Yes|Completed|July 1999|October 2013|Actual|October 2005|Actual|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|60 Years||||November 2013|November 22, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01994044||55727|
NCT01994330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVA|Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery|Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery||Pontificia Universidad Catolica de Chile|No|Completed|June 2009|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|N/A|N/A|No|||November 2013|November 19, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01994330||55705|
NCT01994317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF7-6|Use of an Algorithm to Determine IV Sedation Dosing During First-trimester Surgical Abortion|Use of an Algorithm to Determine IV Sedation Dosing During First-trimester Surgical Abortion||Planned Parenthood League of Massachusetts|Yes|Completed|November 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|196|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01994317||55706|
NCT01963962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50483|Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception|A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception|COLIEC|University of Utah|Yes|Completed|July 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|188|Samples Without DNA|Urine to test for progesterone and/or pregnandiol|Female|18 Years|35 Years|No|Non-Probability Sample|Women presenting for emergency contraception to family planning clinics in Salt Lake City,        UT|February 2016|February 18, 2016|October 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01963962||58032|
NCT01963988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05-127|Comparison of the Efficacy Between Transurethral Coagulation and Transurthral Resection of Ulcer in Bladder Pain Syndrome Patients|Pilot Study for Comparison of the Efficacy Between Transurethral Coagulation and Transurthral Resection of Ulcer in Bladder Pain Syndrome Patients||Samsung Medical Center|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|90 Years|No|Probability Sample|Patients will be enrolled diagnosed with bladder pain syndrome by ESSIC proposal.|May 2014|February 12, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01963988||58031|
NCT01964287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA2012/25|First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.|Phase I-II Trial of Gemcitabine Plus Nab-paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.|GABRINOX|Institut du Cancer de Montpellier - Val d'Aurelle|No|Recruiting|August 2013|March 2016|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||March 2015|March 2, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01964287||58008|
NCT01964651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102575|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Subjects||Janssen Research & Development, LLC||Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964651||57980|
NCT01964911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0252|To Assess Analgesia Provided by Continuous Sciatic Nerve Block in Patients With Hypertensive Leg Ulcer|Monocentric Prospective Study, in Order to Assess Analgesia Provided by Continuous Sciatic Nerve Block, in Patients With Hypertensive Leg Ulcer.|ANGIOCATH|Nantes University Hospital|Yes|Recruiting|February 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964911||57960|
NCT01960972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01HL114180|Launching a Salt Substitute to Reduce Blood Pressure at the Population Level in Peru|Launching a Salt Substitute to Reduce Blood Pressure at the Population Level - Peru||Universidad Peruana Cayetano Heredia|No|Active, not recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960972||58262|
NCT01961193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7517|A Comparison Between Bandage Contact Lens, Punctal Plugs and Standard Measures in Preventing Corneal Injuries|A Comparison Between Bandage Contact Lens, Punctal Plugs and Standard Measures in Preventing Corneal Injuries Related to Exposure in Patients Admitted to the General Intensive Care Unit.|COMLENPLSTAN|Rabin Medical Center|Yes|Not yet recruiting|May 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|105|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01961193||58245|
NCT01961427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013‐12|Dose and Response of Dietary Nitrate in Healthy and Active Men|Dose and Response of Dietary and Inorganic Nitrate in Healthy and Active Men||Swiss Paraplegic Centre Nottwil|No|Active, not recruiting|September 2013|July 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|21|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961427||58227|
NCT01961440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zssywzb02|Prognosis Scoring System for Acute-on-Chronic Liver Failure|||Third Affiliated Hospital, Sun Yat-Sen University||Not yet recruiting|October 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|60 Years|No|Probability Sample|The population from large hospitals will be selected.|September 2013|October 9, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961440||58226|
NCT01961453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01442|Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function|Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension|ISMN|Philadelphia Veterans Affairs Medical Center|No|Recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|89 Years|No|||October 2014|September 21, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961453||58225|
NCT01992744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815839|BDNF Pregnancy Study|Peripheral Serum BDNF Levels and Poor Birth Outcomes|BDNF|University of Pennsylvania|No|Completed|May 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples With DNA|- Brain-Derived Neurotrophic Factor|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women from the greater Philadelphia and surrounding areas who are ages 18 to 39 and        between 8 to 12 weeks pregnant will be considered for enrollment into this study. All        subjects must be physically healthy without a serious, major medical illness as well as be        carrying a healthy fetus. Subject will be enrolled through OB/GYN waiting room recruiting,        fliers, advertisements and social media outlets.|October 2013|May 29, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01992744||55827|
NCT01992978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHB2013-005|Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis|The Influence of Radiofrequency-assisted Hepatectomy on the Perioperative Outcomes and the Long-term Prognosis of HCC With Cirrhosis：A Prospective Randomized Controlled Trial||Southwest Hospital, China|Yes|Recruiting|November 2013|December 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||November 2015|November 22, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992978||55809|
NCT01993225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-305|A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%|||Repros Therapeutics Inc.|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Male|18 Years|60 Years|No|||September 2014|September 29, 2014|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993225||55790|
NCT01992731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUI versus IVF/ICSI|IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial.|IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial||Universitair Ziekenhuis Brussel|Yes|Recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Female|38 Years|42 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992731||55828|
NCT01992965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM-ky0521|Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients|Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients||West China Hospital|Yes|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|65 Years|No|||May 2014|May 6, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01992965||55810|
NCT01993238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-140-LP-H|Evaluation of Procedural Analgesia for Liposonix Treatment|An Evaluation of Procedural Analgesia for Out-Patient Liposonix Treatment||Valeant Pharmaceuticals|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|November 11, 2013|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01993238||55789|
NCT01993498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 0140/1103 CANTO|Breast Cancer Toxicity|A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer|CANTO|UNICANCER|No|Recruiting|February 2012|March 2026|Anticipated|March 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20000|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01993498||55769|
NCT01985633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adi_MSC_PRP_OA_2013|Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee|Autologous Bone Marrow Derived Mesenchymal Stem Cells Enhanced With Platelet Rich Plasma Versus Platelet Rich Plasma In Osteoarthritis Knee:A Comparative Study|MSCPRPOAK|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|75 Years|No|||November 2013|November 15, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985633||56372|
NCT01986101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1002001|A Phase III Study of SM-13496 in Patients With Bipolar I Depression.|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.||Sumitomo Dainippon Pharma Co., Ltd.|No|Recruiting|November 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|501|||Both|18 Years|74 Years|No|||June 2015|June 30, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01986101||56336|
NCT01986114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1002002|A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.|A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.||Sumitomo Dainippon Pharma Co., Ltd.|No|Recruiting|November 2013|September 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|405|||Both|18 Years|74 Years|No|||June 2015|June 30, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01986114||56335|
NCT01994577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMI-3|Optimum Troponin Cutoffs for ACS in the ED|Determining the Optimum Treatment Cutoffs for Cardiac Troponin Assays in Patients Presenting to the Emergency Department With Suspected Cardiac Ischemia|ROMI-3|McMaster University|No|Active, not recruiting|May 2013|November 2015|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|In accordance with the Third Universal Definition of MI and recommendations by both Canadian      and international expert groups, we will collect and measure blood for cTnI and hs-cTn      measurements at ED presentation and 3 hours later for patients who currently would only      undergo a single cTn measurement and 6 hours later if serial cTn measurements are required.      This does not preclude cTn measurements for clinical purposes at any additional times of      choosing by the EP.|Both|18 Years|N/A|No|Probability Sample|Adult residents presenting to any of three EDs in Hamilton, Ontario|September 2015|September 25, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994577||55687|
NCT01994590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0086|Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|A Phase II Study of Dovitinib (TKI258) Combined With Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer Evaluating Markers of FGF and AR Signaling in Bone Marrow and Plasma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2014|||May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||August 2015|August 20, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994590||55686|
NCT01964001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF13197|The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer|||Taichung Veterans General Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|20 Years|80 Years|No|||February 2014|February 17, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964001||58030|
NCT01964300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-039|Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery|Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma||Pediatric Brain Tumor Consortium|Yes|Recruiting|September 2013|||January 2100|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Months|25 Years|No|||April 2015|April 27, 2015|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964300||58007|
NCT01964313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI11B06|Acute Coronary Syndrome Genetic Study|Comprehensive Intervention and Outcome Research Programs for Acute Coronary Syndrome||Peking University First Hospital|No|Recruiting|July 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|4ml of vein blood are to be retained for genetic analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients from 75 hospitals in China.|October 2013|October 14, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964313||58006|
NCT01964924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01895|Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer|A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer||National Cancer Institute (NCI)|Yes|Suspended|October 2013|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|October 15, 2013|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01964924||57959|
NCT01960673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306042RIND|The Influence of Head and Neck Position About Oropharyngeal Leak Pressure and Sealing Between the Laryngeal Mask and Vocal Cord Using Different Types of Supraglottic Airway Device|The Influence of Head and Neck Position About Oropharyngeal Leak Pressure and Sealing Between the Laryngeal Mask and Vocal Cord Using Different Types of Supraglottic Airway Device||National Taiwan University Hospital|No|Completed|September 2013|December 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|120|||Both|20 Years|80 Years|No|||November 2015|November 11, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01960673||58284|
NCT01960686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX757.M202|RSV F Dose-Ranging Study in Women|A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age||Novavax|Yes|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|720|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960686||58283|
NCT01960985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tamine Capato 01|Balance Training in Parkinson's Disease Using Cues|Efficiency of Motor Training Program Associated With Extrenal Cues on the Balance of Patients With Parkinson's Disease.||University of Sao Paulo General Hospital|Yes|Completed|August 2006|August 2012|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||October 2013|June 29, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01960985||58261|
NCT01960946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P0023402|Galectin-3 Blockade in Patients With High Blood Pressure|Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension||Massachusetts General Hospital|Yes|Recruiting|October 2013|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|21 Years|70 Years|No|||March 2016|March 7, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960946||58263|
NCT01961206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRRSH-ESBL01|Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis|Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase (ESBL)Producing Escherichia Coli or Klebsiella Pneumoniae in China: Prevalence, Risk Factors and Prognosis||Sir Run Run Shaw Hospital|No|Completed|October 2013|September 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|960|Samples With DNA|bacterial strains|Both|18 Years|95 Years|No|Non-Probability Sample|All adult patients visited any of the 28 particitant hospitals during the study period        were screened. Patients with community-onset bacteremia caused by E.coli or K. pneumoniae        and without a recent hospitalization in any hospital will be included|November 2015|November 19, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01961206||58244|
NCT01962025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130148|Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis|Vanguard Multi-Centre Feasibility Trial to Determine if Buttonhole Versus Step Ladder Cannulation for High Dose Hemodialysis is Associated With Reduced Overall Cost||Ottawa Hospital Research Institute|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|49|||Both|18 Years|90 Years|No|||May 2015|May 21, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01962025||58181|
NCT01984372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4061|Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®|A Multi-centre, Open Label, Observational, Non-interventional, Post Marketing Surveillance to Evaluate Safety and Effectiveness During Long-term Treatment With Tresiba® (Insulin Degludec) in Patients With Diabetes Mellitus Requiring Insulin Therapy Under Normal Clinical Practice Conditions||Novo Nordisk A/S|No|Enrolling by invitation|November 2013|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus requiring insulin therapy not previously treated with        Tresiba®, including newly-diagnosed patients whom the physician has judged as appropriate        to start treatment with Tresiba®.|November 2015|November 11, 2015|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01984372||56469|
NCT01984684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-3341-303|Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections||Melinta Therapeutics, Inc.|No|Completed|May 2014|January 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|850|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984684||56445|
NCT01984697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-010|A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)|A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|December 2013|June 2017|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|1500|||Both|9 Years|26 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984697||56444|
NCT01984710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066843|DBS for TRD Medtronic Activa PC+S|Deep Brain Stimulation for Treatment Resistant Depression: Exploration of Local Field Potentials (LFP) With the Medtronic Activa Primary Cell + Sensing (PC+S) "Brain Radio" System||Emory University|Yes|Recruiting|September 2013|September 2023|Anticipated|September 2023|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|September 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984710||56443|
NCT01985048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2013-3102|Cardiometabolic Risk in Cardiac Rehab|Cardiometabolic Risk in the Setting of Cardiac Rehabilitation||Health Diagnostic Laboratory, Inc.|No|Active, not recruiting|October 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole Blood and Serum|Both|18 Years|N/A|No|Non-Probability Sample|Representative of the ethnic population of the areas served by the respective study sites.|February 2015|February 12, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01985048||56417|
NCT01985347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/13/TQEHLMH/14|The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study|The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study|SAD|The Queen Elizabeth Hospital|Yes|Not yet recruiting|November 2013|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|75 Years|No|||November 2013|November 8, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01985347||56394|
NCT01985646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|A Trial on Conservative Treatment for Infants' Hirschsprung Disease|A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Normal and Short-segment Hirschsprung Disease for Infants||Tongji Hospital|Yes|Completed|October 2009|||November 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|N/A|3 Months|No|||November 2013|November 10, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985646||56371|
NCT01985854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIVA DES conversion|Conversion From Total Intravenous Anesthesia Technique to Desflurane Anesthesia for Long Duration Neurosurgery|Conversion From Total Intravenous Anesthesia Technique to Desflurane Anesthesia for Long Duration Neurosurgery: A Pilot Study for Assessment of Recovery Parameters||Tokyo Women's Medical University|No|Not yet recruiting|January 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||November 2013|November 9, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01985854||56355|
NCT01993732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126204|Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function|Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function||Medical College of Wisconsin|No|Active, not recruiting|October 2003|December 2041|Anticipated|December 2041|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Female|3 Years|N/A|No|||October 2015|October 21, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01993732||55751|
NCT01993745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804046R|The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)|The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)||National Taiwan University Hospital|Yes|Completed|May 2008|December 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|106|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|adult age>18 years old|November 2013|November 20, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01993745||55750|
NCT01985828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5307|CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer|Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer||Advocate Health Care|No|Recruiting|March 2014|December 2024|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|N/A|No|||October 2015|October 11, 2015|April 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01985828||56357|
NCT01985841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.15|Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer|Phase II, Open-label Non-randomized Trial to Investigate the Efficacy of Bevacizumab in Combination With Dose Dense Sequential Chemotherapy in the Neo-adjuvant Setting for HER2 Negative Breast Cancer Patients||Hellenic Oncology Research Group|No|Terminated|October 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|September 13, 2013||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT01985841||56356|
NCT01986088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A160-318|Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study|A Multicentre, Double Blind, Double Dummy, Parallel Group, Placebo Controlled, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels Oral Sumatriptan Given for the Acute Treatment of Migraine(With and Without Aura).||Pfizer|Yes|Completed|November 1996|January 1998|Actual|January 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1008|||Both|18 Years|76 Years|No|||November 2013|November 11, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986088||56337|
NCT01986647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13090264|On the Move: Optimizing Participation in Group Exercise|On the Move: Optimizing Participation in Group Exercise to Prevent Walking Difficulty in At-Risk Older Adults|OTM-PCORI|University of Pittsburgh|Yes|Active, not recruiting|December 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986647||56294|
NCT01964014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-CT4-11-391|Once-a-day Immunosuppression(CISECON_a_day)|Clinical Investigation for Safety and Efficacy, Patient Reported Outcomes of the Conversion to ONce-a-day Immunosuppression After Kidney Transplantation|CISECON|Ajou University School of Medicine|Yes|Active, not recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|20 Years|65 Years|No|||June 2015|June 28, 2015|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01964014||58029|
NCT01964326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581189|Actual Use Trial of Atorvastatin Calcium 10 mg|A Multicenter, Actual Use Trial In A Simulated Over-the-counter Environment Of Atorvastatin Calcium 10 Mg||Pfizer|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1311|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 14, 2013|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01964326||58005|
NCT01964339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1240-OHSPREV-MS|Obesity Hypoventilation Syndrome Prevalence Study|Obesity Hypoventilation Syndrome Prevalence Study||Philips Respironics|No|Recruiting|October 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|21 Years|N/A|No|Non-Probability Sample|People with a BMI greater than or equal to 30kg/m2 scheduled for a routine polysomnograpy        (PSG) test. Participants will be recruited from pulmonology clinics or referred to the        sleep lab via hospital admissions.|October 2013|October 14, 2013|October 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964339||58004|
NCT01964677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0424 CCR3772|MR-HIFU for Bone Metastases|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study||Institute of Cancer Research, United Kingdom|Yes|Recruiting|January 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964677||57978|
NCT01964950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-013|Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea|Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea||Takeda|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1101|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who have been examined at a medical institution|January 2015|January 23, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964950||57957|
NCT01960699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK_Nr_1740/2013|Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation|Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation||Medical University of Vienna|No|Enrolling by invitation|October 2013|December 2018|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Plasma samples stored at -80°C|Both|18 Years|N/A|No|Probability Sample|Resuscitated patients|April 2015|April 16, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01960699|3 Years|58282|
NCT01960725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049081|An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)|An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months)||Duke University|No|Active, not recruiting|February 2014|June 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|83 Days|Accepts Healthy Volunteers|||January 2016|January 7, 2016|October 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01960725||58280|
NCT01961219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-775|Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis|Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis: A Comparison.||University of Missouri, Kansas City|No|Recruiting|November 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01961219||58243|
NCT01961466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAUVET-GELINIER 2009|Diabetes and Psychological Profile|Prospective Study on the Influence of Psychosocial Variables (Stress, Type A Behaviour Pattern, Quality of Life of the Diabetic) on Glycemic Balance in Patients With Type 1 and 2 Diabetes.|DPP|Centre Hospitalier Universitaire Dijon|No|Recruiting||||December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Type 1 or 2 Diabetes|October 2013|October 10, 2013|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961466||58224|
NCT01961479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|praemensis_2013|Treatment of Premenstrual Syndrome - Internet-based Self-help|Development and Evaluation of an Internet-based Cognitive Behaviour Therapy for Women With Premenstrual Syndrome (PMS)|praemensis|Philipps University Marburg Medical Center|No|Recruiting|July 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|45 Years|No|||April 2015|April 27, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961479||58223|
NCT01961765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-363|Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).||Massachusetts General Hospital|Yes|Recruiting|November 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961765||58201|
NCT01961778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001776|Comparison of Radiofrequency Ablation and Cryotherapy for the Treatment of Barrett's Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma|Prospective Randomized Trial Comparing Radiofrequency Ablation (Barrx™) and Cryotherapy (TruFreeze™) for the Treatment of Barrett's Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma||Massachusetts General Hospital|No|Recruiting|November 2013|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||September 2014|September 16, 2014|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961778||58200|
NCT01984385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HipVISION Pilot - 2013|Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study|Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study||Population Health Research Institute|No|Completed|December 2013|October 2015|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hip fracture|October 2015|October 5, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01984385|30 Days|56468|
NCT01984398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-110|Comparison of Two Formulations of Androxal|A DOUBLE-BLIND CROSSOVER STUDY IN HEALTHY VOLUNTEERS TO COMPARE TWO FORMULATIONS OF ANDROXAL||Repros Therapeutics Inc.|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984398||56467|
NCT01984723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-019|EVP-6124 Renal Impairment Study|A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Renal Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Renal Impairment Compared to Subjects With Normal Renal Function||FORUM Pharmaceuticals Inc|No|Completed|June 2013|||February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984723||56442|
NCT01984736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-020|EVP-6124 Hepatic Impairment Study|A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function||FORUM Pharmaceuticals Inc|No|Completed|June 2013|||December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01984736||56441|
NCT01984749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078|Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy|A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia|FREED|Freed Study Group||Active, not recruiting|November 2013|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|65 Years|N/A|No|||December 2015|December 9, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01984749||56440|
NCT01985061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-IPC2011-003|Evaluation of 3 Different Doses of IV Busulfan|Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies|AAA|Institut Paoli-Calmettes|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|177|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985061||56416|
NCT01985360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 - Bangalore|ISCHEMIA-Chronic Kidney Disease Trial|International Study of Comparative Health Effectiveness With Medical and Invasive Approaches—Chronic Kidney Disease Trial|ISCHEMIA-CKD|New York University School of Medicine|Yes|Recruiting|January 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985360||56393|
NCT01985373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD2012.02|Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml|Pharmacokinetics and Safety of the Intravenous Human Immunoglobulin Product Nanogam 100 mg/ml|Nanogam|Sanquin|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985373||56392|
NCT01985386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-05-2|Iron Absorption From GDS Capsules II|Iron Absorption Mechanism From a Slow Release Iron Capsule Using the Gastric Delivery System (Ferrous Sulfate)||Swiss Federal Institute of Technology|No|Completed|November 2013|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01985386||56391|
NCT01993524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-DM/SBK-prOVag2-01/08|Supplementation of Standard Antibiotic Therapy With Oral Probiotics for Bacterial Vaginosis|Efficacy and Safety Assessment of prOVag Dietary Supplement in Recurrent Bacterial Vaginitis. Multi-centre, Randomized, Double-blind, Placebo-controlled Clinical Study.||IBSS Biomed S.A.|No|Completed|March 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|594|||Female|18 Years|50 Years|No|||November 2013|November 20, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01993524||55767|
NCT01993758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1310/221-007|Efficacy of Lower Tourniquet Pressure During Total Knee Arthroplasty|The Efficacy of Using Lower Tourniquet Pressure During Total Knee Arthroplasty: Comparison With Conventional Tourniquet Pressure Group||Seoul National University Hospital|Yes|Recruiting|November 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|40 Years|90 Years|No|||May 2014|May 20, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993758||55749|
NCT01993771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOLOBIS|Monitoring of Anaesthesic Depth in the Cerebral Cortex Using Bispectral Bilateral System.|Monitoring of Anaesthetic Depth at Different Locations in the Cerebral Cortex Using Bispectral Bilateral System||Parc de Salut Mar|No|Completed|September 2013|October 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with alopecia scheduled for general anaesthesia.|July 2014|October 19, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01993771||55748|
NCT01986413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVAPSleep 2013|Intelligent Volume Assured Pressure Support to Improve Sleep Quality and Respiratory Events in Patients With Non Invasive Ventilation|German: Einfluss Von Gesichertem Atemminutenvolumen Auf Schlafqualität Und Häufigkeit Respiratorischer Ereignisse Bei Patienten Mit Nicht Invasiver Beatmung (NIV)||Institut für Pneumologie Hagen Ambrock eV|No|Completed|July 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|40 Years|75 Years|No|||March 2015|March 23, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986413||56312|
NCT01986660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST0225-US-011-001|Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults|||Strategic Science & Technologies, LLC||Completed|October 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|October 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986660||56293|
NCT01964365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1330001|Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Rosuvastatin and Fenofibric Acid in Healthy Adult Subjects||Daewoong Pharmaceutical Co. LTD.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||October 2013|February 12, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964365||58002|
NCT01964664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8912|Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments|Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments|MSPi|Oregon Health and Science University|No|Active, not recruiting|January 2013|August 2025|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|10|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01964664||57979|
NCT01964690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL2013|Lactate Use as Triage Tool in Sepsis : Veinous, Capillary or Arterial?|Lactate and Sepsis : What Dosage Use as Triage Tool in Emergency Department for Patients With Suspected Infection.||Hopital Saint Roch|Yes|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected infection in emergency department (admission time)|January 2014|April 26, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964690||57977|
NCT01964937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 102|Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNAHIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964937||57958|
NCT01964703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED13024|Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes|Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study||Korea University Anam Hospital|Yes|Completed|April 2013|||October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|19 Years|N/A|No|||October 2013|October 14, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964703||57976|
NCT01964716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4671001|13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.|A Phase 3, Randomized, Open-label Trial To Evaluate The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials Given With Routine Pediatric Vaccinations In Healthy Infants||Pfizer|Yes|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|42 Days|70 Days|Accepts Healthy Volunteers|||February 2015|February 27, 2015|September 9, 2013|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01964716||57975|
NCT01964963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-015|Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus|Nesina Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus||Takeda|No|Active, not recruiting|August 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19192|||Both|N/A|N/A|No|Non-Probability Sample|Patients with mild type 2 diabetes mellitus who have been examined at a medical        institution|July 2014|July 29, 2014|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964963||57956|
NCT01960712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/1142-31/3|The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.|The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.||Karolinska University Hospital|No|Enrolling by invitation|November 2008|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||March 2016|March 10, 2016|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960712||58281|
NCT01961258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016-13-MMC|"SEVERE ASTHMA" in the COMMUNITY|"SEVERE ASTHMA" in the COMMUNITY: How Severe it Really is and to What Extent Its Management Has Been Exhausted||Meir Medical Center|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|250|||Both|20 Years|70 Years|No|Non-Probability Sample|The study will include all patients at the age interval of 20-70 years with bronchial        asthma treated by CMS, Sharon-Shomron district.        A. Screening of the computerized database of CMS to detect all patients at the age        interval of 20-70 years with a computerized title-diagnosis of bronchial asthma during the        period of January 1st -December 31, 2011, and January 1st -December 31, 2012. To detect        from this database the asthmatic patients that are considered to have "severe asthma"        according to the level of medication that is prescribed to them.        B. Patients having co-morbidities and/or potential triggers (computerized title-diagnosis)        that may interfere with asthma management (WHO group two: potentially "difficult to treat        severe asthma"). Severe asthmatics without these co-morbidities /triggers will be        considered as having WHO group three "treatment resistant severe asthma".        C. Patients with "severe asthma" that underwent evaluation for anti IgE-therapy.|October 2013|April 12, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01961258|30 Days|58240|
NCT01961232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB090650|Trans-pulmonary Biomarkers in Pulmonary Hypertension|Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy||Vanderbilt University|No|Active, not recruiting|August 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Pulmonary Vascular Clinic|December 2015|December 8, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01961232||58242|
NCT01961492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15881|Fecal Microbiota Transplantation in Patients With Ulcerative Colitis|Single Fecal Microbiota Transplantation Via Colonoscope as an Adjunct Therapy in the Treatment of Ulcerative Colitis||Turku University Hospital|No|Recruiting|October 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|75 Years|No|||December 2014|December 2, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961492||58222|
NCT01961505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z111107058811104|External Therapy With Compound Tripterygium Gel for Decreasing Disease Activity in Patients With Rheumatoid Arthritis|A 8-Week, Double Blind, Randomized Study to Determine the Effects of External Therapy With Compound Tripterygium Gel, in Subjects With Active Rheumatoid Arthritis.||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Enrolling by invitation|October 2011|March 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|65 Years|No|||October 2013|October 9, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01961505||58221|
NCT01962090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10000350|Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain in Dentistry Students|A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain in Dentistry Students: a Randomized Controlled Trial.||A.T. Still University of Health Sciences|No|Recruiting|October 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|22 Years|45 Years|No|||September 2013|February 19, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01962090||58176|
NCT01962103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PST-001|To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors|A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.||Celgene Corporation|No|Recruiting|December 2013|February 2020|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|134|||Both|6 Months|21 Years|No|||March 2016|March 24, 2016|September 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01962103||58175|
NCT01961843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-209|Abiraterone Acetate for Castrate Resistant Prostate Cancer|Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer||Massachusetts General Hospital|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||May 2015|May 22, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961843||58195|
NCT01984762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|684-11|Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.|Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. Randomised Controlled Trial|CONTROL|Göteborg University|No|Recruiting|September 2012|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|60 Years|No|||January 2016|January 7, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01984762||56439|
NCT01984775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117191|A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects|An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects||GlaxoSmithKline|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01984775||56438|
NCT01985074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-AHS-MBS-1|A Case Management Study Targeted to Reduce Health Care Utilization for Frequent Emergency Department Visitors|A Case Management Study Targeted to Reduce Health Care Utilization for Frequent Emergency Department Visitors||Health Navigator|No|Active, not recruiting|July 2010|December 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15000|||Both|18 Years|N/A|No|||September 2015|September 13, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985074||56415|
NCT01985087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-NEU-13 GB70|A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70|A Phase I/ II Study of Hypofractionated Radiotherapy With Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old With Newly Diagnosed Glioblastoma||James Graham Brown Cancer Center|Yes|Recruiting|September 2014|May 2019|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|70 Years|N/A|No|||January 2016|February 29, 2016|October 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01985087||56414|
NCT01985399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAC Neuro Study|Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")|Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")||Stanford University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|50 Years|N/A|No|Probability Sample|50 individuals on an EFV-containing regimen and 50 individuals on a protease-inhibitor        (PI)-containing regimen|May 2015|May 26, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01985399||56390|
NCT01985659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pN+VATS|Nodal Upstaging in VATS Anatomical Resections for NSCLC|Cohort Analysis of Nodal Upstaging in the Era of Increase of VATS Anatomical Resections for NSCLC||University Hospital, Gasthuisberg|No|Active, not recruiting|November 2013|June 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|By including all patients, open or VATS, and comparing cohorts instead of the surgical        technique used, the selection bias is absent. We compare three cohorts. In the first        (20007-2009) almost all patients where operated through a thoracotomy. In a second cohort,        (2010-2011) the experience with vats was early. In the third period (2012-2013), a        standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy        was used.|November 2013|November 10, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01985659||56370|
NCT01993537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120585|The Role of Vitamin D in the Pathophysiology of Chronic Failure|The Role of Vitamin D in the Pathophysiology of Chronic Failure: Insight in to Mechanisms of Action and Implications for Vitamin D Supplementation||Ottawa Heart Institute Research Corporation|Yes|Completed|January 2013|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|91|||Both|18 Years|90 Years|No|||March 2016|March 2, 2016|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01993537||55766|
NCT01993550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K07CA168883-01A1|Telephone Support Program for Lung Cancer Patients and Their Family Caregivers|Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers||Indiana University|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|262|||Both|18 Years|100 Years|No|||March 2016|March 9, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01993550||55765|
NCT01994395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSTU00085161|Development of Walk Assist Device to Improve Community Ambulation|Randomized Control Trial Comparing Walking Task Specific Training With Stride Management Assist (SMA) Device vs.Functional Task Specific Training on Functional Walking Ability in Outpatient Stroke Rehabilitation||Rehabilitation Institute of Chicago|Yes|Active, not recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|85 Years|No|||January 2016|January 7, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01994395||55700|
NCT01994681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004108|Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air|Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air||Rauscher, Gregory E., M.D. PA||Recruiting|October 2013|||October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with pancreatic cancer, biopsy confirmed, before treatment, ages above 18. vs.        Healthy subjects without pancreatic cancer.|December 2013|December 4, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994681||55679|
NCT01994070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00408|Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation|A Randomized Crossover Trial to Evaluate Electrical Versus Chemical Cardioversion in Patients With Acute Atrial Fibrillation||University of British Columbia|No|Completed|November 2013|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|19 Years|85 Years|No|||June 2015|June 10, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01994070||55725|
NCT01994083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX-0101|A Study of Multiple Oral Doses of IX-01 in Healthy Men|A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects||Ixchelsis Limited|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994083||55724|
NCT01994356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUC Disclosure|Physician Self Disclosure of IUC Use|Pilot Study of Physician Self-disclosure of Personal Intrauterine Contraceptive Use Versus Usual Counseling||University of Michigan|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|44 Years|No|||November 2013|November 19, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994356||55703|
NCT01964378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF6005/07|CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer|Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer.|CORAL|Grünenthal GmbH|Yes|Terminated|November 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|October 7, 2013||No|low accrual that made the study no longer feasible/ decision not related to safety and    efficacy|No||https://clinicaltrials.gov/show/NCT01964378||58001|
NCT01964391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28851|A Study of Patient Satisfaction and Safety With Subcutaneously Administered Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer|AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE IIIB STUDY WITH SUBCUTANEOUS ADMINISTRATION OF TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER TO EVALUATE PATIENT SATISFACTION||Hoffmann-La Roche||Recruiting|February 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964391||58000|
NCT01964404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034699-01A1|Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?|Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|July 2014|April 2020|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|240|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964404||57999|
NCT01964417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-0488|The Comparative Study Between Bowel Preparation Method|The Comparative Study Between Bowel Preparation Method: 4L-split Dose of PEG Solution, Low-volume PEG Plus Ascorbic Acid Focusing on the Bowel Cleansing Efficacy, Patients' Affinity to Preparation Solution and Mucosal Injury|CSBPM|Inje University|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|319|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01964417||57998|
NCT01964430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-003|Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)|A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma|apact|Celgene|Yes|Recruiting|March 2014|October 2020|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964430||57997|
NCT01965002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0095|Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors|A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities||Stanford University|No|Recruiting|May 2014|February 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|N/A|No|||November 2015|November 18, 2015|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01965002||57953|
NCT01961011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206073|Bilateral vs Unilateral CTR|Simultaneous Bilateral Versus Unilateral Carpal Tunnel Release: A Prospective Comparison of Early Pain and Limitations in Activities of Daily Living||Washington University School of Medicine|Yes|Enrolling by invitation|June 2012|March 2014|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients presenting to a tertiary care orthopedic practice with bilateral carpal tunnel        syndrome|October 2013|October 9, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961011||58259|
NCT01961245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL-NIV2|Effects of Nocturnal Non-invasive Ventilation on Energy Expenditure in Patients With Severe Chronic Obstructive Pulmonary Disease|||Klinikum Berchtesgadener Land der Schön-Kliniken||Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|85|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01961245||58241|
NCT01961518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGC001|Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome|Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome Type A and Maroteaux-Lamy Syndrome||Greenwood Genetic Center|No|Completed|October 2013|May 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|17|Samples With DNA|Consent will be requested for specimen storage (DNA and urine) to allow use of the specimens      for future research related or unrelated to the participant's condition.|Both|N/A|18 Years|No|Non-Probability Sample|We plan to recruit 75 patients who will meet chart review criteria, selected from a        population of 250-300 patients in the Shriners Hospitals for Children--Greenville (SHC)        database. In addition, any patients evaluated at a monthly Genetics clinic held at SHC who        meet eligibility criteria will be offered enrollment in the study in person (with a goal        of 15). Participants of any ethnicity and both genders will be represented in this study.        Since participants will be selected from the SHC patient database, as well as Greenwood        Genetic Center clinics held at SHC in Greenville, SC, study participant's geographic        location will be concentrated in the Southeastern region of the United States.|August 2015|August 10, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961518||58220|
NCT01962116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUENOT DB 2012|Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU|Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU = Multicentre, Controlled, Randomised Superiority Trial|VERROUREA|Centre Hospitalier Universitaire Dijon|No|Recruiting|June 2013|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|386|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01962116||58174|
NCT01992796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM97AJNN|Angiotensin II Antagonist in Severe Sepsis|Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients|SartSep|University of Salerno|Yes|Not yet recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||November 2013|November 19, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01992796||55823|
NCT01993017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK9253|Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes|Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes|CODIACSQoL|Columbia University|Yes|Recruiting|November 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|1500|||Both|21 Years|95 Years|No|||October 2015|October 22, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993017||55806|
NCT01993277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Evaluating Neuromodulation Technologies in Early Recovery|A Comparator Trial Evaluating Three Neuromodulation Technologies' Effectiveness in Early Recovery From Substance Abuse Disorders as Compared to Relaxation Therapy||Behavioral Health of the Palm Beaches|Yes|Not yet recruiting|December 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|November 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993277||55786|
NCT01994122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/101(REK)|Mental Health and Resilience in Emerging Adulthood|Mental Health and Resilience in Emerging Adulthood||University of Tromso|No|Recruiting|August 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 18-25 years old who have dropped out of school and who are currently unemployed|August 2015|August 10, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01994122||55721|
NCT01994135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 12-037|Effects of Carbohydrase-inhibiting Polyphenols on Glycaemic Response in Vivo|Effects of Carbohydrase-inhibiting Polyphenols on Glycaemic Response in Vivo||University of Leeds|Yes|Completed|August 2014|September 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|December 3, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994135||55720|
NCT01994707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCN-2012/07/B/NZ5/02549|Remote Ischemic Preconditioning of Human Myocardium|Remote Ischemic Preconditioning of Human Myocardium||Medical University of Silesia|No|Recruiting|August 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2016|March 13, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994707||55677|
NCT01994941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-402|Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome|Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome||The University of Hong Kong|Yes|Completed|August 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01994941||55659|
NCT01994096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41676.042.12|Optimal Dosage of Caspofungin in Critically Ill Patients|Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis||University Medical Center Groningen||Completed|November 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994096||55723|
NCT01994109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-SIAL-301|Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects|MYSTICOL|US WorldMeds LLC|No|Active, not recruiting|November 2013|December 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994109||55722|
NCT01994369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818065|Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer||University of Pennsylvania|Yes|Recruiting|May 2014|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994369||55702|
NCT01994382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-601|Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma|A Phase I Open-Label, Multi-Dose, Dose Escalation Study Of PRT062070 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Or B-Cell Non Hodgkin Lymphoma (NHL)||Portola Pharmaceuticals|No|Recruiting|August 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994382||55701|
NCT01964066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/2007/12/24|Study of Effectiveness of Thoracic Epidural Analgesia for the Prevention of Acute Pancreatitis After ERCP Procedures|Effectiveness of Thoracic Epidural Analgesia for the Prevention of Post-ERCP Pancreatitis||Volgograd State Medical University|Yes|Completed|January 2008|September 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|491|||Both|15 Years|92 Years|No|||October 2013|October 13, 2013|September 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964066||58025|
NCT01964079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPASS-BPV|Comparision of Blood Pressure Variability Between Amlodipine and Losartan|The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension||Wonju Severance Christian Hospital|Yes|Recruiting|April 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|20 Years|79 Years|No|||December 2014|December 11, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964079||58024|
NCT01960738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN009-12|Common Recreational Diving Practices: A Randomized Control Trial Using Pre-Dive Checklist|A Group Randomized Trial to Evaluate the Efficacy of Using Pre-dive Checklist to Prevent the Incidence of Recreational Scuba Diving Mishaps|Checklists|Divers Alert Network||Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 9, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960738||58279|
NCT01964755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090166|Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma|Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for Relapsed Epstein Barr Virus Associated Lymphoma||University of Miami|Yes|Suspended|April 2011|||April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 14, 2013|Yes|Yes|Temporarily closed to accrual due to pending amendment|No||https://clinicaltrials.gov/show/NCT01964755||57972|
NCT01961284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SS/0106|Zygomatic Versus Conventional Dental Implants in Augmented Maxillae|Zygomatic Versus Conventional Dental Implants in Augmented Maxillae: a Pragmatic Multicentre Randomised Clinical Trial.||NHS Lothian||Not yet recruiting|October 2013|||December 2030|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 10, 2013|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01961284||58238|
NCT01960998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1059-R|Perioperative Post-Prostatectomy Incontinence Home Telehealth Program|Perioperative Post-Prostatectomy Incontinence Home Telehealth Program|ProsTel|VA Office of Research and Development|No|Recruiting|August 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Male|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01960998||58260|
NCT01961531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291|BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)|BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)||Brown University|Yes|Recruiting|July 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|50 Years|N/A|No|||January 2016|January 11, 2016|October 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961531||58219|
NCT01961791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0798|Lymph Node Staging System With a Novel Concept for Gastric Cancer: a Hybrid Type of Topographic and Numeric Ones|||Yonsei University|No|Completed|January 2000|September 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6025|||Both|18 Years|N/A|No|Non-Probability Sample|patients who underwent gastrectomy with lymph node dissection for gastric cancer in Yonsei        University Hospital, Seoul|October 2013|October 9, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961791||58199|
NCT01961804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2012-02|PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma|Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment|PREVACT|University Hospital, Angers||Recruiting|March 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961804||58198|
NCT01962753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN10-VC/ ASAP|Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)|Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)|ASAP|University Hospital, Tours|Yes|Recruiting|May 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|55 Years|N/A|No|||October 2013|February 13, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962753||58125|
NCT01962766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-13-OP-DegluLang|Myofunctionnal Therapy on Nasal Breathing and Orthodontic Corrections Stability|Myofunctionnal Therapy on Nasal Breathing and Orthodontic Corrections Stability||Université de Montréal|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01962766||58124|
NCT01992562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIALT01|Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy|A Phase 4, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial of a Single Shot of Intrathecal Ziconotide for the Treatment of Chronic, Medically Refractory Pain From Painful Peripheral Neuropathy or Myelopathy||Ohio State University|No|Active, not recruiting|October 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992562||55841|
NCT01992575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00010138|OCT in Retinal Vein Occlusions|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vein Occlusions||Oregon Health and Science University||Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Probability Sample|This study will measure blood vessel pattern/flow changes in up to 35 patients with        retinal vein occlusions.|April 2015|April 21, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992575||55840|
NCT01993290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-PB|USG Brachial Plexus Block for Upper Extremity Surgery|Ultrasound-guided Brachial Plexus Block With the Single-penetration Multiple-injection-technique for Upper Extremity Surgery||Bispebjerg Hospital|Yes|Completed|April 2013|June 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01993290||55785|
NCT01993563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI_RCT_STROKE|Graded Motor Imagery for Patients Within a Year After Stroke.|The Effect of a Graded Motor Imagery Approach for Stroke Patients Within a Year After Stroke|GMI|IRCCS San Camillo, Venezia, Italy|Yes|Recruiting|February 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|80 Years|No|||March 2015|March 27, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01993563||55764|
NCT01993784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC-N-301|Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.|Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas||Peking University|Yes|Recruiting|August 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|75 Years|No|||November 2013|November 20, 2013|August 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01993784||55747|
NCT01994408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030558|Default BP Medication Intensification|Automatic Medication Increase Protocol in the Treatment of Elevated Blood Pressure||Cedars-Sinai Medical Center|No|Recruiting|November 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||February 2015|February 2, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01994408||55699|
NCT01991301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9997-AN-CTIL|Carfilzomib for the Prevention of Graft Versus Host Disease|The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease||Sheba Medical Center|No|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991301||55937|
NCT01991314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023797-39|Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate|Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue||Queen Mary University of London|No|Completed|December 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|13 Years|80 Years|No|||November 2015|November 30, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991314||55936|
NCT01994694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|riskperception.ctil|Risk Perception in Adults With Attention Deficit and Hyperactivity Disorder (ADHD)|Risk Perception in Adults With Attention Deficit and Hyperactivity Disorder (ADHD)||Shaare Zedek Medical Center|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|18 Years|50 Years|No|Non-Probability Sample|Adults with ADHD|July 2015|November 17, 2015|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01994694||55678|
NCT01994915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0045UG|Effects of Occupational Therapy in COPD|Effects on Functionality of Occupational Therapy Added to Physiotherapy in Severe COPD Patients|COPD|Universidad de Granada|Yes|Recruiting|December 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994915||55661|
NCT01994928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-4429|Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.|Prospective Randomised Study on Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High Flow Nasal Cannula Oxygen.||Universitätsklinikum Hamburg-Eppendorf||Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994928||55660|
NCT01991275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMRoboProstDMHong|Intrathecal Morphine in Robot-assisted Prostatectomy|The Efficacy of Intrathecal Morphine in Patients Undergoing Robot-assisted Prostatectomy|RoboITMProst|Seoul National University Hospital|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|80 Years|No|||July 2015|July 1, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991275||55939|
NCT01964742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00505-40|Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients|Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients||Assistance Publique Hopitaux De Marseille|No|Completed|October 2013|August 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|68|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964742||57973|
NCT01964976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-014|Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides|Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides||Takeda|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1096|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who have been examined at a medical institution|January 2015|January 23, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01964976||57955|
NCT01964989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V118_05|Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.|A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.||Novartis|Yes|Active, not recruiting|November 2013|May 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|13620|||Both|6 Months|72 Months|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964989||57954|
NCT01960764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 131244.2|Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival|Phase 1 Study of Whether Host Preconditioning Modifies Short-term Transplant Survival||University of California, San Diego|No|Not yet recruiting|August 2015|May 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|September 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01960764||58277|
NCT01961037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 R49 CE002109-DLJ|Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches|Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches||West Virginia University|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|236|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01961037||58257|
NCT01960751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-01|Long Term Neurocognitive Effects of Low-dose Radiation in the Brain: Study of 150 Patients in the French Hemangioma Cohort|Etude Des séquelles Neurocognitives à Long Terme Des Faibles Doses de Radiation Chez 150 Patients traités Par radiothérapie Dans l'Enfance Pour un hémangiome cutané à l'Institut Gustave Roussy (IGR) Entre 1941 et 1973|CogRad|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|October 2013|March 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 8, 2013|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01960751||58278|
NCT01961557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130210|Evaluating a New Knee-Ankle-Foot Brace to Improve Crouch Gait in People With Cerebral Palsy|Evaluating an Extension Assist Knee Ankle Foot Orthosis to Improve Crouch Gait in Cerebral Palsy||National Institutes of Health Clinical Center (CC)||Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|5 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 5, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961557||58217|
NCT01961570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL 0031|Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC)for Osteoarthritis of the First CarpoMetacarpal Joint|Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC) for Osteoarthritis of the First CarpoMetacarpal Joint: A New Study of the ICMC in a Clinical Setting||Articulinx|No|Enrolling by invitation|October 2013|July 2016|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|40 Years|75 Years|No|Probability Sample|Men and women with early stage carpometacarpal-1 (CMC-1)joint osteoarthrititis.|October 2013|October 18, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961570||58216|
NCT01961271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP12-AP-401|Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain|Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia||Mundipharma Pte Ltd.|No|Completed|June 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|80 Years|No|||January 2015|January 13, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01961271||58239|
NCT01961544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKI-CT-1301|Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer|Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer|ESKIMO|Eisai Inc.||Active, not recruiting|June 2013|January 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Female|20 Years|N/A|No|||January 2016|January 27, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961544||58218|
NCT01961817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1386/2013|Airway Management Via the Retromolar Route Access|Airway Management Via the Retromolar Route Access - a Clinical Study||Medical University of Vienna|No|Completed|July 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01961817||58197|
NCT01961830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1100-CL-102|Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers|An Open-label, Single Dose Study to Assess Intrapulmonary Pharmacokinetics of ME1100 Inhalation Solution Administered to Healthy Volunteers||Meiji Seika Pharma Co., Ltd.|No|Completed|September 2013|||December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01961830||58196|
NCT01993511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHJNBJ-FX10|Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass|Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass||Hvidovre University Hospital|Yes|Recruiting|June 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|24|Samples Without DNA|Serum and plasma.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Morbid obese patients who are already enrolled for Roux-en-y gastric bypass surgery will        be invited to participate (investigators do not assign patients to the surgery). 8 with        type 2 diabetes, 8 with impaired glucose tolerance and 8 with normal glucose tolerance.        Glucose tolerance will be assessed with an oral glucose tolerance test (OGTT) prior to        surgery and prior to the other tests. Plasma glucose 120 minutes after OGTT will define        glucose tolerance. Normal: < 7,8 mM. Impaired: 7,8 - 11,1 mM. Diabetic: >11,1 mM.        Subjects are recruited from the outpatient clinic of endocrinology and gastrosurgical        clinic at Hvidovre University Hospital.|November 2013|November 20, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01993511||55768|
NCT01993030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XY-201301|Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds|Randomized, Active-controlled, Single-blind, Parallel Two-group Trial of HQ® Matrix Medical Wound Dressing and Sidaiyi® Wound Dressing for the Treatment of Donor Site Wounds||Zhejiang Xingyue Biotechnology Co., Ltd.|Yes|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|60 Years|No|||June 2015|June 2, 2015|November 14, 2013||No||No|May 7, 2015|https://clinicaltrials.gov/show/NCT01993030||55805|
NCT01993303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVIT-01-2012|Direct Comparison of 2D Cardiac PET With 3D Cardiac PET|Direct Comparison of 2D Cardiac PET With 3D Cardiac PET Using a 3D Monte-Carlo Scatter COrrection Algorithm||Cardiovascular Imaging Technologies|No|Completed|January 2004|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male.|November 2013|November 20, 2013|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01993303||55784|
NCT01993576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000100-41|ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.|Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.|EC2075|Jules Bordet Institute|Yes|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|65 Years|No|||July 2014|October 14, 2014|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01993576||55763|
NCT01993797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMSGH|Lung Ultrasound in Diagnosis and Management of Bronchiolitis Bronchiolitis|Lung Ultrasound: a Useful Tool in Diagnosis and Management of Bronchiolitis?||S. Giacomo Hospital|Yes|Active, not recruiting|January 2010|||December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|80|||Both|N/A|1 Year|No|Non-Probability Sample|children presented with signs suggestive of bronchiolitis|December 2013|December 12, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01993797||55746|
NCT01993810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1308|Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer|Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC||Radiation Therapy Oncology Group|Yes|Recruiting|February 2014|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01993810||55745|
NCT01993823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G238OTIII/11IA01|Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis|A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis||Salvat||Completed|May 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01993823||55744|
NCT01994148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGI-201302016|Application of Laparoscopy in Gastrointestinal Injury|Study of Laparoscopy in Gastrointestinal Injury||West China Hospital|No|Not yet recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|60 Years|No|||November 2013|November 20, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01994148||55719|
NCT01995240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40501.018.12|Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study|Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study|REMP|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995240||55636|
NCT01991834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPFabiola|Antibiotic Prophylaxis in Gynecologic Laparoscopy|Antibiotic Prophylaxis in Gynecologic Laparoscopy||Universidade do Vale do Sapucai|No|Completed|September 2013|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|114|||Female|18 Years|65 Years|No|||April 2015|April 24, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991834||55897|
NCT01994954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP00009772|A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants|||Children's Hospital Boston|Yes|Enrolling by invitation|November 2013|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|146|||Both|N/A|37 Weeks|No|||March 2015|March 26, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994954||55658|
NCT01995227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-019-HCC-VAX|An Individualized Anti-Cancer Vaccine Study in Patients With HCC|An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)||Immunovative Therapies, Ltd.|Yes|Withdrawn|December 2013|July 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 18, 2013||No|Study site change|No||https://clinicaltrials.gov/show/NCT01995227||55637|
NCT01991288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-0786-GI|Analgesic Efficacy of Saphenous Nerve Block in Total Knee Replacement|Does Saphenous Nerve Block Improve Analgesia After Total Knee Replacement When Used in Combination With Local Infiltration Analgesia? A Prospective Randomised Double Blinded Trial.||Cork University Hospital|Yes|Completed|November 2012|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||November 2013|November 21, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991288||55938|
NCT01991821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10014|European Phase III Study of APD421 in PONV|Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting||Acacia Pharma Ltd|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|368|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01991821||55898|
NCT01964456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13-P001|"Self-consciousness and the Inter-subjective Body"|"Narcisse & Echo : Self-consciousness and the Inter-subjective Body"|Narcisse|Centre Hospitalier St Anne|Yes|Completed|November 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01964456||57995|
NCT01961024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0006|Postprandial VLDL-TG Metabolism|Postprandial VLDL-TG Metabolism||University of Aarhus|Yes|Active, not recruiting|January 2014|January 2018|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20|Samples With DNA|specimen of muscle specimen of adipose tissue|Male|30 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males with diabetes from the department´s out-patient clinic. Control group of healthy        volunteers|November 2015|November 30, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01961024||58258|
NCT01960777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONLAP|Chronic Pain After Inguinal Hernia Repair, the ONSTEP Technique Versus the Laparoscopic Approach|Chronic Pain After Inguinal Hernia Repair, ONSTEP vs. Laparoscopic Approach, A Randomised Observer Blinded Multicenter Study|ONLAP|Herlev Hospital|No|Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Male|18 Years|90 Years|No|||February 2016|February 22, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960777||58276|
NCT01963910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01551|Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream|Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream|LipTRP|University of British Columbia|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01963910||58036|
NCT01961297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1156|Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response|Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961297||58237|
NCT01961583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0382|[18F]Fluciclatide PET Imaging of Pazopanib Response|Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study||Asan Medical Center|No|Terminated|September 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|20 Years|N/A|No|||February 2016|February 27, 2016|October 7, 2013||No|Termination of [18F]Fluciclatide production|No||https://clinicaltrials.gov/show/NCT01961583||58215|
NCT01961856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-17|Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.|Platelet Reactivity After Ticagrelor Loading Dose Versus Clopidogrel Loading Dose and Reloading With Ticagrelor, in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention (PCI).||University of Patras|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961856||58194|
NCT01962129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thauvin PHRC N 2010|Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene|Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene|OFD1|Centre Hospitalier Universitaire Dijon|No|Recruiting|June 2011|||June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|133|||Both|N/A|N/A|No|Probability Sample|Orofaciodigital Syndromes type I, type VII or other orofaciodigital syndromes|October 2013|October 10, 2013|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01962129||58173|
NCT01992809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0681/09CAPPESQ|Omega 3 Supplementation in Fatty Liver|Polyunsaturated Fatty Acid (Pufa) Omega 3 in the Reduction of the Inflammatory Component of the Nonalcoholic Steatohepatitis (Nash):Randomized Placebo Controlled Study|OMEGA 3 NASH|University of Sao Paulo General Hospital|Yes|Completed|September 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01992809||55822|
NCT01993043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39946-I|Laser and Bevacizumab Treatment for Retinopathy of Prematurity|Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity||Baylor College of Medicine|No|Recruiting|October 2010|October 2017|Anticipated|October 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|||Both|30 Weeks|40 Weeks|No|Probability Sample|Premature infants|November 2013|November 20, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01993043|3 Years|55804|
NCT01994421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGeneva|Effects of Kinesiotape on Quadriceps and Hamstring Muscle Strength|Effects of Kinesiotape on Quadriceps and Hamstring Muscle Strength||University Hospital, Geneva||Completed|September 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 17, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01994421||55698|
NCT01994434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSWang9804|Ulnar Nerve Deep Branch Compression by a Ganglion|||The Second Hospital of Tangshan|Yes|Completed|March 2000|November 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2012|November 19, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01994434||55697|
NCT01994720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5134C00001|[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]|A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.|SOCRATES|AstraZeneca|Yes|Active, not recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|13600|||Both|40 Years|130 Years|No|||December 2015|December 18, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994720||55676|
NCT01994967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT074|Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.|Study Phase III to Evaluate the Noninferiority of Heavy Levobupivacaine 50% Enantiomeric Excess (Levobupivacaine S75:R25) Compared to Racemic Heavy Bupivacaine (Bupivacaine S50:R50) in Spinal Anesthesia for Lower Limb Orthopedic Procedures||Cristália Produtos Químicos Farmacêuticos Ltda.|Yes|Not yet recruiting|January 2016|August 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01994967||55657|
NCT01994980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0205|Duration of Antibiotic Treatment for Early VAP (DATE) Trial|A Randomized Clinical Trial of 4 vs. 8 Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit|DATE|Denver Health and Hospital Authority|Yes|Recruiting|December 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01994980||55656|
NCT01991327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-106|Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males|AN OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE DRUG-DRUG INTERACTIONS OF ANDROXAL WITH CYTOCHROME P450 ISOENZYMES IN HEALTHY MALE SUBJECTS||Repros Therapeutics Inc.|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991327||55935|
NCT01991340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21975|H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer|H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.||Hoffmann-La Roche||Completed|November 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|657|||Both|18 Years|N/A|No|Probability Sample|Patients with HER2-positive breast cancer eligible for treatment with Herceptin|November 2013|November 18, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991340||55934|
NCT01991613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1422|Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants|Early Liquid Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|26 Weeks|33 Weeks|No|||September 2015|September 21, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01991613||55914|
NCT01992146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP_SM01_2013|Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.|Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair. A Randomized, Placebo-controlled, Double-blind Crossover Study||Rigshospitalet, Denmark|Yes|Recruiting|November 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Male|18 Years|65 Years|No|||November 2015|November 23, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01992146||55873|
NCT01991600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6129|A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.|A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.||Medical Research Council|No|Completed|May 2006|May 2010|Actual|May 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|71|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991600||55915|
NCT01992094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V130_01|Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older|A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age||Novartis|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2680|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 7, 2013|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01992094||55877|
NCT01992393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-17|Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)|Targeted Self-Management for Epilepsy and Serious Mental Illness||Case Western Reserve University|No|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01992393||55854|
NCT01965015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VW-SP-1|The V-Wave Shunt: FIM Safety and Feasibility Study|The V-Wave Shunt For 'Left Atrial Decompression' In Patients With Advanced Chronic Heart Failure: FIM Safety and Feasibility Study|VW-SP-1|V-Wave Ltd|No|Recruiting|March 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|85 Years|No|||September 2014|June 1, 2015|October 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01965015||57952|
NCT01963104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R33DC011769-02|Community-Based Kiosks for Hearing Screening and Education|Community-Based Kiosks for Hearing Screening and Education||Portland VA Medical Center|No|Enrolling by invitation|September 2013|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|8||Anticipated|2400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|April 10, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01963104||58098|
NCT01964547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS1137|A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients|A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis||GW Pharmaceuticals Ltd.|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|October 15, 2013||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01964547||57988|
NCT01964560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0034|Long-term Extension Study to Investigate Lacosamide as an Add-on Therapy in Children With Partial Onset Seizures|A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures||UCB Pharma|No|Enrolling by invitation|March 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|1 Month|17 Years|No|||March 2016|March 18, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01964560||57987|
NCT01964807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0052956|Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products|Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products||University of California, San Francisco|No|Recruiting|November 2013|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01964807||57968|
NCT01961063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13282|Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma|Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs||City of Hope Medical Center|Yes|Recruiting|June 2014|June 2031|Anticipated|June 2031|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|September 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01961063||58255|
NCT01961869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13052|Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers|Phytochemical Release Rate From Black Raspberry Confections Alters Gene Expression and Chemical Profiles Relevant to Inhibition of Oral Carcinogenesis||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|July 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961869||58193|
NCT01962142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B076201214059|Assessment of Activity Limitation in Asthma Patients|Subjective and Objective Assessment of Activity Limitation in Asthma Patients||Centre Hospitalier Universitaire Saint Pierre||Recruiting|September 2012|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Exacerbated asthma patients coming to the outpatient clinic of pulmonology.|August 2015|August 7, 2015|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01962142||58172|
NCT01962155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10002005|Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters|Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus|HBV|Peking University First Hospital|Yes|Recruiting|August 2013|December 2015|Anticipated|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|liver biopsy samples and blood samples|Both|18 Years|65 Years|No|Probability Sample|patients infected with hepatitis B virus for at least 6 months|November 2015|November 4, 2015|October 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01962155|2 Weeks|58171|
NCT01992822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01508-37|Pain Sensitivity of Subjects With Fibromyalgia Before and After Repetitive Transcranial Magnetic Stimulation Treatment|Experimental Pain Sensitivity of Subjects With Fibromyalgia Before and After rTMS Treatment in Relation to the Clinical Improvement||Centre Hospitalier Esquirol|No|Recruiting|November 2013|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|72|||Both|18 Years|65 Years|No|||July 2015|July 31, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01992822||55821|
NCT01994161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XW125-S003|Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis(CRTICAS)|Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial||Xuanwu Hospital, Beijing|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|840|||Both|30 Years|80 Years|No|Non-Probability Sample|This trial is an prospective, government-funded registration study that will observe the        safety and effectiveness of intracranial stenting for preventing stroke during a mean        follow-up of 3 years in patients with symptomatic stenosis of a major intracranial artery        (MCA, carotid, vertebral, basilar). This trial was launched by Xuanwu Hospital, Capital        University of Medical Science, with 20 collaborators participating. Enrollment will begin        in 2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is        scheduled to complete in 2015.|October 2013|November 20, 2013|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994161|12 Months|55718|
NCT01994733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)|Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET): Intensive vs Liberalized Phosphate Control in Hemodialysis Recipients|TARGET|St. Michael's Hospital, Toronto|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01994733||55675|
NCT01994993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048773|Antibiotic Safety (SCAMP)|Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial)|SCAMP|Duke University|Yes|Recruiting|December 2013|September 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|284|||Both|N/A|120 Days|No|||October 2015|October 28, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994993||55655|
NCT01995006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 264/13|Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects|Effect of Metamizole on Renal Function in Salt-depleted Healthy Subjects Single-center, Randomized, Open, Controlled Parallel-group Study to Investigate the Effects of Oral Metamizole or Naproxen on Renal Function in Healthy Male Salt-depleted Subjects||University Hospital, Basel, Switzerland|Yes|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995006||55654|
NCT01995253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU979|A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities|A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities||Institut National de la Recherche Agronomique|Yes|Completed|September 2012|October 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995253||55635|
NCT01991847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-PROTECT|Tertiary Prevention by Exercise in Colon Cancer Therapy|Feasibility Study of the PROTECT-trial (The Potential and Role Of Tertiary Prevention by Exercise in Colon Cancer Therapy)|F-PROTECT|Technische Universität München|Yes|Recruiting|November 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|40 Years|80 Years|No|||November 2014|December 1, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991847||55896|
NCT01992419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bspp2013|Evaluation of Out-of-Hospital Cardiac Arrest Recognition by Non-physicians Dispatchers in a French Emergency Dispatch Call Center|Evaluation of Cardiac Arrest Recognition by Non-physicians Dispatchers in the Paris Fire Brigade Emergency Call Dispatch Center|OCAR|Fire Brigade Of Paris Emergency Medicine Dept|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|300|||Both|15 Years|N/A|No|Probability Sample|residents of Paris urban and suburban area|December 2013|December 6, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01992419|1 Year|55852|
NCT01992666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.769|GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus|GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus|GENIAL|Hospices Civils de Lyon|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|280|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01992666||55833|
NCT01992120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA01419|Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome|Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome||New York University School of Medicine|No|Terminated|November 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 30, 2013||No|Key Personnel left institution|No||https://clinicaltrials.gov/show/NCT01992120||55875|
NCT01992133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-10-679-6202|Effects of Vitamin D Supplementation on Glucose Metabolism in Women With Former Gestational Diabetes Mellitus|The Effects of Vitamin D Supplementation on Blood Glucose and Markers of Metabolic Syndrome in Women With Vitamin D Deficiency and Previous Gestational Diabetes Mellitus||Penang Medical College|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Female|N/A|N/A|No|||November 2013|November 18, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992133||55874|
NCT01992653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29044|A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma|A PHASE Ib/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB OR OBINUTUZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA||Genentech, Inc.||Recruiting|November 2013|May 2020|Anticipated|May 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|60 Years|80 Years|No|||September 2015|September 1, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992653||55834|
NCT01965028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-tRNS01|Daily Bi-temporal Transcranial Random Noise Stimulation in Tinnitus|Effectiveness of Daily Bi-temporal Transcranial Random Noise Stimulation in Patients With Chronic Tinnitus|tRNS-tin|University of Regensburg||Completed|October 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||March 2016|March 4, 2016|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01965028||57951|
NCT01963650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-MLD-092|Natural History Study of Children With Metachromatic Leukodystrophy|Natural History Study of Children With Metachromatic Leukodystrophy||Shire|No|Active, not recruiting|December 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Sample for genotype testing is collected and any remaining sample is retained for follow up      or repeat testing. The sample is not retained for unspecified additional testing.|Both|N/A|12 Years|No|Non-Probability Sample|This study will enroll up to 30 male or female children (<12 years of age) with a        confirmed MLD diagnosis.|March 2016|March 3, 2016|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01963650||58056|
NCT01965067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK8616-099|Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex|A Randomized, Parallel-group, Safety-assessor-blinded Phase IV Study to Estimate the Influence of Mild Hypothermia on Reversal of Rocuronium-induced Neuromuscular Block With Sugammadex||MSD Korea Ltd.|Yes|Completed|October 2013|April 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|65 Years|No|||July 2014|July 25, 2014|October 9, 2013||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01965067||57948|
NCT01960829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CCN28T|Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study|A Single-armed, Open-labeled and Single-centered Phase II Trial of Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study||Beijing Cancer Hospital|No|Recruiting|September 2013|||May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||April 2015|April 30, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01960829||58272|
NCT01960842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-921|A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications|An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication||AbbVie|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|30 Years|N/A|No|||May 2015|May 21, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960842||58271|
NCT01961609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AGB01|Secukinumab in TNF-IR Psoriasis Patients.|Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults|SIGNATURE|Novartis|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01961609||58213|
NCT01992757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818918|Thromboelastography-derived Functional Fibrinogen Levels|Comparison of Thromboelastography-derived Functional Fibrinogen Levels During and After Cardiopulmonary Bypass|TEG FF|University of Pennsylvania|No|Recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The population for this study will be elective cardiac surgical patients who will be        undergoing elective primary cardiac surgery.|November 2013|November 19, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01992757||55826|
NCT01992770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/448|A Stepped-care Model of Tailored Behavioural Medicine Pain Intervention in Primary Care|STEP-UP - A Randomised Controlled Trial for the Study of a Stepped-care Model Including a Tailored Behavioural Medicine Pain Intervention in Primary Care|STEP-UP|Uppsala University|No|Not yet recruiting|September 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|364|||Both|18 Years|65 Years|No|||September 2013|November 19, 2013|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01992770||55825|
NCT01993836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045180|Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care|Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care|MADCO-PC|Duke University|No|Recruiting|November 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|140|||Both|60 Years|N/A|No|||January 2016|January 7, 2016|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993836||55743|
NCT01993849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028506|Use of NAC in Fingernail Biting|A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia||Medical University of South Carolina||Completed|October 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|30 Years|No|||March 2016|March 7, 2016|September 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993849||55742|
NCT01994447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHF-001|The Train Study: Parental Understanding of Informed Consent|"Traditional Research Nurses Versus an Innovative Undergraduate Research Assistant Program: Parental Understanding of Informed Consent " (the TRAIN Study)|TRAIN|University of Calgary|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|110|||Both|N/A|14 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994447||55696|
NCT01995266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-036|Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual|A Phase 3, Open-Label Study With Daclatasvir And Asunaprevir (DUAL) for Subjects With Genotype 1b Chronic Hepatitis C (HCV) Infection Who Are Intolerant or Ineligible to Interferon Alfa Therapies With or Without Ribavirin||Bristol-Myers Squibb|No|Completed|February 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|159|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995266||55634|
NCT01995279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCS_EA|Ear Acupuncture Reducing Pain and Improving Balance|The Effects of a Single Session of Ear Acupuncture in Pain Sensation and Body Balance|EARPIB|Universidade Cruzeiro do Sul|No|Recruiting|November 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|50 Years|No|||November 2013|November 25, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995279||55633|
NCT01991353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-122|Platelet Rich Plasma Study With Meniscal Repair|Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.||Simon Fraser Orthopaedic Fund|No|Not yet recruiting|July 2015|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|60 Years|No|||May 2015|May 19, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991353||55933|
NCT01991626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fe-LNS|Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods|Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From Lipid Nutrient Supplements Added to Complementary Foods||Swiss Federal Institute of Technology|No|Completed|September 2013|August 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|10||Actual|47|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991626||55913|
NCT01991873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-KRK-0212|Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer|Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer|PanaMa|AIO-Studien-gGmbH|Yes|Recruiting|April 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01991873||55894|
NCT01992159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101291|Study With AMG 785 to Treat Japanese Women With Postmenopausal Osteoporosis|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Japanese Women With Postmenopausal Osteoporosis||Amgen|No|Completed|October 2012|January 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|252|||Female|55 Years|85 Years|No|||September 2015|September 11, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992159||55872|
NCT01993394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10co706|Effect of Hyperoxia and Hypergravity on Lung Ventilation and Perfusion|Influence of Hyperoxia and Hypergravity on Pulmonary Ventilation and Perfusion||Direction Centrale du Service de Santé des Armées|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01993394||55777|
NCT01992406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSRECTAL|Feasibility, Safety and Outcome of Transrectal Hybrid-NOTES Anterior Resection|Feasibility, Safety and Outcome of Transrectal Hybrid-NOTES Anterior Resection||Cantonal Hosptal, Baselland|No|Recruiting|November 2013|||November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with benign indication for left sided colectomy|July 2015|July 15, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01992406|6 Months|55853|
NCT01993108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00047129|Control of Cognition|Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study|NMAS|University of Michigan|No|Recruiting|October 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|160|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01993108||55799|
NCT01962181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE0379-HMO-STILL|Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment|Identifying Characteristic Signature of Brain Activity of Electroencephalogram Records in Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment||Hadassah Medical Organization|No|Not yet recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|October 10, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01962181||58169|
NCT01962532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102388|A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma||Janssen Research & Development, LLC|No|Recruiting|August 2013|November 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|47|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|July 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01962532||58142|
NCT01964183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-111|Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine|Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine -||Astellas Pharma Inc|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964183||58016|
NCT01964196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0303|ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-|ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-||Astellas Pharma Inc|No|Completed|August 2013|December 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|107|||Both|20 Years|74 Years|No|||January 2016|January 4, 2016|October 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01964196||58015|
NCT01964209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83064|Initial Validation of the Vanderbilt ADHD Measure for Adolescent Patients in the ICISS Project|Initial Validation of the Vanderbilt Attention Deficit Hyperactive Disoder (ADHD) Measure for Adolescent Patients in the Integrated Clinical Information Sharing System (ICISS) Project||Children's Hospital Boston|Yes|Recruiting|May 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Boston Children's Hospital patients which will be recruited from the following divisions:        Adolescent/Young Adult Practice, Developmental Medicine Center and Department of        Psychiatry.|February 2015|February 13, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01964209||58014|
NCT01960881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-096|Evaluation of Diet and Exercise in Prostate Cancer Patients|Canadian Real Life Evaluation of Exercise and Diet in Patients Treated With Lupron® for the Management of Prostate Cancer:(CRONOS II)|CRONOS II|AbbVie|No|Recruiting|September 2013|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|860|||Male|18 Years|99 Years|No|Non-Probability Sample|Patients will be enrolled from the offices of University or community        urologists/radio-oncologists across Canada treating patients with PCa|January 2016|January 13, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01960881||58268|
NCT01961102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-Gyn1|OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer|Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer||Krankenhaus Barmherzige Schwestern Linz|Yes|Recruiting|May 2013|September 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Female|45 Years|N/A|No|Non-Probability Sample|Postmenopausal women|January 2014|June 13, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961102||58252|
NCT01961115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITN-04|Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma|A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma||Fred Hutchinson Cancer Research Center||Recruiting|September 2013|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961115||58251|
NCT01961310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOIt/2012/JPL-02|Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis|Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis|MICROPOLY|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 50 adult subjects will be included: 25 with newly diagnosed RA (<12 months)        based on the American College of Rheumatology criteria, and 25 healthy volunteers without        RA.|March 2016|March 18, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01961310||58236|
NCT01961323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0493|Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart|Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01961323||58235|
NCT01992536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_03E1|Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03|Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03||Novartis|No|Completed|December 2013|April 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Actual|194|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992536||55843|
NCT01992549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-15|Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII|Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII||Octapharma|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|N/A|N/A|No|||October 2015|October 23, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01992549||55842|
NCT01993251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-732|Does Melatonin Restore Sleep Architecture in Autistic Children|Does Melatonin Restore Sleep Architecture in Autistic Children?|SOMELIA|Hospices Civils de Lyon|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|3 Years|12 Years|No|||March 2016|March 15, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01993251||55788|
NCT01994174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|583-13-FB|Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics|Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics||University of Nebraska|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|19 Years|N/A|No|Probability Sample|Patients with established diagnosis of retinal vascular diseases (diabetic macular edema,        neovascular macular degeneration, presumed ocular histoplasmosis syndrome, high myopia)        who require intravitreal injection of anti-VEGF drugs such as bevacizumab, ranibizumab or        aflibercept and are likely to need three monthly doses.|February 2014|February 14, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01994174|3 Months|55717|
NCT01994187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XW125-S004|Revascularization of Extracranial Carotid Artery Stenosis|the Clinic Registration Study of Carotid Stenosis Revascularization|RECAS|Xuanwu Hospital, Beijing|Yes|Recruiting|July 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2100|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|one group:1050 cases of endarterectomy; the other group:1050 cases of carotid artery        stent; totally:2100 cases of ravascularization for carotid stenosis|September 2013|November 20, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01994187|12 Months|55716|
NCT01994746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INGluc001|Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults|Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes||T1D Exchange Clinic Network Coordinating Center|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|64 Years|No|||April 2015|April 14, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01994746||55674|
NCT02001649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/092/HP|Genetic Variants Associated With Adolescent Suicide Attempts|Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.|VGTSA|University Hospital, Rouen|No|Recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|300|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02001649||55146|
NCT02002975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-016|Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"|Actos Tablets Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"||Takeda|No|Completed|October 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18197|||Both|20 Years|74 Years|No|Non-Probability Sample|Type 2 diabetes mellitus|December 2013|December 1, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02002975||55044|
NCT02003300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177/03|An Improved Method for the Measurement of Oxygen and Anaesthetic Agent Uptake in Patients Using the Foldes-Biro Equation|The Modified Foldes-Biro Equation Used in Patients Under General Anaesthesia for the Measurement of Oxygen and Anaesthetic Agent Uptake||Bayside Health|No|Completed|April 2005|November 2006|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|18 Years|18 Years|No|||December 2004|December 5, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003300||55019|
NCT02003313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012L02647|Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine|Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine in More Than 2 Years Old Children and Adults||Beijing Minhai Biotechnology Co., Ltd|No|Completed|November 2013|July 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1260|||Both|2 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 19, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02003313||55018|
NCT02008214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTX-HCV/HIV|Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients|Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860||Centro Universitario de Ciencias de la Salud, Mexico|No|Not yet recruiting|December 2013|March 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2013|December 6, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02008214||54642|
NCT02008513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF006A|Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006|A Randomized, Controlled, Parallel Group, Double-blind, Multi-centre, Phase IIb Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in the AFFITOPE® AD02 Phase II Study AFF006.||Affiris AG|Yes|Terminated|June 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|50 Years|85 Years|No|||June 2015|June 23, 2015|October 30, 2013||No|Study AFF006A was early terminated by the sponsor based on the results of study AFF006.|No||https://clinicaltrials.gov/show/NCT02008513||54619|
NCT02008500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014|Comparison Of Clinical Efficacy Of A Herbal And A Non-Herbal Mouthwash On Dentinal Hypersensitivity|COMPARISON OF CLINICAL EFFICACY OF A HERBAL AND A NON HERBAL MOUTHWASH ON DENTINAL HYPERSENSITIVITY: A TRIPLE MASKED RANDOMIZED CONTROLLED CLINICAL TRIAL||Government Dental College and Research Institute, Bangalore|Yes|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02008500||54620|
NCT01999933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJFL-201309-CCPOSTOP|Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer|Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer||Fourth Military Medical University|Yes|Recruiting|November 2013|November 2018|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Female|18 Years|70 Years|No|||November 2013|December 2, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999933||55278|
NCT02000193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSFASL0042|Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer|Maintenance Hormone Therapy With Fulvestrant After First-Line Chemotherapy for Postmenopausal Hormone-receptor-positive (HR) Positive Advanced Breast Cancer: A Multicenter, Prospective Phase II Study|FANCY|Sun Yat-sen University|Yes|Recruiting|November 2013|November 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Female|N/A|N/A|No|||September 2014|September 29, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02000193||55258|
NCT02000206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC13ctl|Comparison of Propofol/Alfentanil With Propofol/Ketamine|Safety and Efficacy of Sedation for Flexible Fiberoptic Bronchoscopy: Comparison of Propofol/Alfentanil With Propofol/Ketamine|KET-001|Rabin Medical Center|Yes|Not yet recruiting|February 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||November 2013|November 26, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02000206||55257|
NCT02000219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC5-OL-01|Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis|A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis||OxThera|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|N/A|N/A|No|||May 2015|May 18, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000219||55256|
NCT02000232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01FD004257-01|Impact of Unapproved Drug Initiative on Colchicine Use|Impact of Unapproved Drug Initiative on Colchicine Use||Stanford University|No|Recruiting|January 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All adults diagnosed with gout. Patient's from Stanford hospital and clinics and VA Palo        Alto Heath care system are eligible|November 2013|November 26, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02000232|2 Years|55255|
NCT02000505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-333|Comparison of the Quality of CPR by Lay Rescuers With and Without Feedback Devices|Comparison of the Quality of CPR by Lay Rescuers With and Without Telephone Instructions by a Simulated Rescue Coordination Center|frequenz|University Hospital of Cologne|No|Recruiting|November 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 2, 2015|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02000505||55234|
NCT02000778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818533|EC17 for Intraoperative Imaging in Occult Ovarian Cancer|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma||University of Pennsylvania|Yes|Recruiting|November 2013|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000778||55213|
NCT02000791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|laryngeal mask|Does Laryngoscopic Tecnique Facilitate cLMA Insertion?|Does Laryngoscopic Tecnique Facilitate cLMA Insertion?|cLMA|Diskapi Yildirim Beyazit Education and Research Hospital|No|Not yet recruiting|December 2013|May 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|180|||Both|18 Years|65 Years|No|||November 2013|December 3, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02000791||55212|
NCT02010489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:388|The Impact of a Pre-Operative Exercise Program on Fitness Outcomes Following Bariatric Surgery|The Impact of a Pre-Operative Exercise Program on Fitness Outcomes Following Bariatric Surgery||University of Manitoba|No|Active, not recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010489||54468|
NCT02010502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J2013:089|Beet Root Supplement Trial|Effects of Two Forms of Beetroot Juice Supplementation on Exercise Performance in Cyclists||University of Manitoba|Yes|Active, not recruiting|August 2013|May 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|December 7, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010502||54467|
NCT02001909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16675|Effect of Neomycin on the Pharmacokinetics of Regorafenib|Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects||Bayer|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02001909||55126|
NCT02002169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 12-0404-AE|Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres Pilot Study|Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres (HIPPO SAT) Pilot Study|HIPPO-SAT|University Health Network, Toronto|No|Recruiting|December 2012|November 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002169||55106|
NCT02002741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBUACA CTIL|Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants|Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial||Rambam Health Care Campus|No|Not yet recruiting|August 2014|February 2017|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|2 Months|No|||July 2014|July 23, 2014|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02002741||55062|
NCT02002754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cough2009|The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma|Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment.||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|June 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||December 2013|December 5, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002754||55061|
NCT02003391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-038|Global DuoTrav® Study|Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker||Alcon Research|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003391||55012|
NCT02003001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_VA|Botulinum Toxin Injection to Prevent Ventricular Arrhythmias|Endomyocardial Botulinum Toxin Injection Can Prevent Ventricular Arrhythmias: Pilot Study||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|June 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2015|September 24, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003001||55042|
NCT02002715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cough001|Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients|Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|January 2012|February 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||December 2013|December 2, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002715||55064|
NCT02001376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007040R|A Health Promotion Project for Workers at National Taiwan University Hospital|A Health Promotion Project for Workers at National Taiwan University Hospital||National Taiwan University Hospital|Yes|Recruiting|April 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2013|December 3, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02001376||55167|
NCT02001389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6308-002|Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308|A Phase 1, Open-Label, Multiple Ascending Dose, [18F]MNI-659 PET-Imaging Study to Evaluate PDE10A Occupancy After Dosing With EVP-6308 in Healthy Subjects||FORUM Pharmaceuticals Inc||Completed|October 2013|||June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001389||55166|
NCT02002390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2013-054-02|Efficacy and Safety of FTY720 for Acute Stroke|Efficacy and Safety of FTY720 for the Treatment of Acute Stroke||Tianjin Medical University General Hospital|Yes|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|87|||Both|18 Years|80 Years|No|||September 2014|September 16, 2014|November 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002390||55089|
NCT02007408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KERH|Comparison of Lidocaine Spray and Paracervical Block Application for Pain Relief During First-trimester Surgical Abortion: a Randomized, Double-blind, Placebo-controlled Trial|||Kayseri Education and Research Hospital|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|108|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02007408||54704|
NCT02007642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTQCT01-2013|Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.|Performance Assessment of High Throughput Sequencing for the Detection of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.|PATHOQUEST1|Pathoquest|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|DNA sample by patient|Both|1 Year|N/A|No|Non-Probability Sample|Immunocompromised patients hospitalized for a suspected infectious disease|October 2013|April 20, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02007642||54686|
NCT02007915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009396|The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head|The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head||The Hospital for Sick Children||Completed|July 2009|June 2013|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|18 Years|No|||December 2013|December 5, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02007915||54665|
NCT02008526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA035092|Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM|Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM||Friends Research Institute, Inc.|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|285|||Male|18 Years|65 Years|No|||May 2014|May 27, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02008526||54618|
NCT02008786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFER-SCAD|Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD|The Effects of Statin and Angiotensin-converting Enzyme Inhibitor on Coronary Flow Reserve, indEx of Microcirculatory Resistance, and Symptoms in Patients With Spontaneous Coronary Artery Dissection (SAFER-SCAD) Study|SAFER-SCAD|Cardiology Research UBC|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|N/A|N/A|No|||July 2014|March 24, 2015|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008786||54598|
NCT02008799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA2013|Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia|Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia||Man Clinic for Andrology, Male Infertility and Sexual Dysfunction|No|Recruiting|January 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Male|N/A|N/A|No|||April 2015|April 7, 2015|December 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02008799||54597|
NCT02008773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310496490|A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia|A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia|VISTA|Indiana University|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|40 Years|No|||December 2015|December 16, 2015|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008773||54599|
NCT02000245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAF|Effects of Sympathy and Touch on Anxiety of Patients Undergoing Fiberoptic Bronchoscopy|Effects of Sympathy and Touch on Anxiety of Patients Undergoing Fiberoptic Bronchoscopy||Seoul National University Hospital|Yes|Recruiting|October 2013|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|267|||Both|19 Years|N/A|No|||November 2013|November 26, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02000245||55254|
NCT02000258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02071|Effect of Tunnel Placements on Clinical and MRI Findings Two Years After ACL Reconstruction With DB Technique|Effect of Tunnel Placements on Clinical and MRI Findings Two Years After Anterior Cruciate Ligament Reconstruction With Double-Bundle Technique||Tampere University Hospital|Yes|Completed|March 2003|August 2013|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02000258||55253|
NCT02000518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-514/2011|Emergency Radiotherapy in Metastatic Spinal Cord Compression of Patients With Non-small Cell Lung Cancer|Phase 1 Study of Neurological Outcome After Emergency Radiotherapy in Metastatic Spinal Cord Compression|CK-INF|Heidelberg University|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|80 Years|No|Non-Probability Sample|histologically confirmed non-small cell lung cancer and bone metastases of the thoracic or        lumbar segments of the vertebral column|December 2013|December 3, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000518|6 Weeks|55233|
NCT02000804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117326|Darapladib China PK|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.||GlaxoSmithKline|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02000804||55211|
NCT02001701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRVA - 2013 - RELEASE|Intravitreal Gas for Vitreomacular Adhesion|Intravitreal Injection of Expansile Sulfa Hexafluoride Gas for Symptomatic Vitreomacular Adhesion|RELEASE|Northern California Retina Vitreous Associates|No|Withdrawn|November 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|November 24, 2013||No|No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT02001701||55142|
NCT02002182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1411|ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer|Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma||Baylor College of Medicine|Yes|Recruiting|December 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002182||55105|
NCT02002442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10951|Dental Implants and Mouth Rinse|Comparison of the Effect of the Preoperative Use of Chlorhexidine, Essential Oil, and Cetylpyridinium Chloride Mouthwashes on Bacterial Contamination During Dental Implant Placement: A Randomized Controlled Clinical Trial||Tufts University School of Dental Medicine|No|Recruiting|November 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002442||55085|
NCT02003404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5642-O|Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin|Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin||Hollister Incorporated|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|17|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ostomates with a normal peristomal skin and normal ipsilateral abdominal skin|September 2015|September 22, 2015|November 20, 2013||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT02003404||55011|Small sample size may not be generalizable to the population.
NCT01999764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET IDA 02|Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation|Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation||QLT Inc.|No|Completed|November 2013|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|43|||Both|60 Years|N/A|No|||June 2015|June 16, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999764||55291|
NCT02002728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECD0613|Comparison of Early Caries Detection in Children Utilizing an Electrical Conductance Device and the Gold Standard of Visual-tactile Technique.|||Ortek Therapeutics, Inc.|Yes|Completed|November 2006|April 2009|Actual|April 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|6 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 6 - 9 years.|December 2013|December 6, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02002728|14 Months|55063|
NCT02002143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02812|GMVs in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People|Group Medical Visits (GMVs) in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People|GAP|University of British Columbia|Yes|Recruiting|January 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002143||55108|
NCT02002156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG-2013/04|A Study of the Interaction Between BCG And MenC Immunisation: BAM|A Pilot Study of the Impact of BCG Administration on the Immunogenicity of Serogroup C Meningococcal Conjugate Vaccine in Healthy Infants|BAM|University of Oxford|No|Active, not recruiting|June 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|28|||Both|N/A|7 Days|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02002156||55107|
NCT02001883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807/2013/D-2|Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients|Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE|ADHERENCE|University of Roma La Sapienza|No|Recruiting|November 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||December 2013|December 4, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02001883||55128|
NCT02002663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-13- YR FIRST STEP CWI-PP|Continuous Local Anesthetic and Steroid Infusion in Abdominal Surgery|Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial|GR-CWI|IRCCS Policlinico S. Matteo|Yes|Recruiting|August 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||February 2015|February 8, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02002663||55068|
NCT02002676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013KLY-022|Prevalence and Outcome of Hypermetabolism in Initial Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study|Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study||Nanjing University School of Medicine|Yes|Recruiting|December 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|62|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who admitted ICU with hypermatebolic status, which the results of indirect        calorimetry show that the actual rest energy expenditure values are remarkably higher than        the predicted ones.|June 2014|June 12, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02002676||55067|
NCT02007928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-12|Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic|Assessment of Incidence of Adverse Events in a Naive Pediatric Population Treated With an (Typical and Atypical) Antipsychotic Drug Over 12 Months Follow-up||Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|April 2013|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|200|||Both|6 Years|17 Years|No|||February 2016|February 9, 2016|April 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02007928||54664|
NCT02007941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19RI113017|Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects|An Open-label, Non-randomized, Parallel-group Design Clinical Trial for Comparative Evaluation of Pharmacokinetics After CKD-501 Between Patients With Renal Impairment and Control Subjects With Normal Renal Function||Chong Kun Dang Pharmaceutical|No|Recruiting|March 2014|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|38|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2013|July 30, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02007941||54663|
NCT02008227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28915|A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK"|A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH DOCETAXEL IN PATIENTS WITH NON&#8722;SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM CONTAINING CHEMOTHERAPY [OAK]||Hoffmann-La Roche||Active, not recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1225|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008227||54641|
NCT02004184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/645|Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy|Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study|IDA|Norwegian University of Science and Technology|Yes|Recruiting|December 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|765|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02004184||54951|
NCT02004470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-37405|Lavage and Suction of the Right Upper Quadrant to Reduce Post Laparoscopic Shoulder Pain|Lavage and Suction of the Right Upper Quadrant to Reduce Post Laparoscopic Shoulder Pain: A Randomized Controlled Trial||University of Tennessee|No|Not yet recruiting|January 2014|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02004470||54929|
NCT02004457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH098694-02|Engaging HIV Patients in Primary Care by Promoting Acceptance|Engaging HIV Patients in Primary Care by Promoting Acceptance|HIV Engage|Butler Hospital|No|Active, not recruiting|March 2013|January 2017|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004457||54930|
NCT02004717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8895-A-J101|Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors|Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Recruiting|October 2013|May 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|N/A|No|||January 2016|January 29, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02004717||54910|
NCT02004444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000249 RG 452 3-A-1|JC Virus Reactivation in Multiple Sclerosis|JC Virus Reactivation in Multiple Sclerosis|JCV in MS|Beth Israel Deaconess Medical Center|No|Completed|October 2010|January 2016|Actual|January 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|50|Samples With DNA|Blood, Urine, and Cerebrospinal Fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients selected mostly from the neurology clinic at Beth Israel Deaconess Medical Center|January 2016|January 28, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02004444|1 Day|54931|
NCT02004704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13632|A Long-Term Study of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency|A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency||Sanofi|Yes|Recruiting|December 2013|August 2021|Anticipated|August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004704||54911|
NCT02004977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111S06384|Improving High School Breakfast Environments|Improving High School Breakfast Environments|breakFAST!|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|February 2013|February 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02004977||54890|
NCT02001935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81302846|Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline|Association Between CytochromeP4501A2(CYP1A2) and CytochromeP4502E1(CYP2E1) Gene Polymorphisms and Metabolism of Theophylline in a Chinese Population||Zhujiang Hospital|Yes|Completed|September 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|102|||Both|18 Years|75 Years|No|||July 2014|August 19, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02001935||55124|
NCT02001948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02-09|Intrathecal Morphine for Inguinal Hernia Repair.|The Comparison of Two Different Doses of Morphine Added to Spinal Bupivacaine for Inguinal Hernia Repair.||Ankara University|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||November 2013|November 29, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001948||55123|
NCT02002195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATURE01|Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer|Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer|MATURE|International Group of Endovascular Oncology|No|Recruiting|November 2013|May 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|47|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients with recurrent or metastatic gastric cancer|April 2015|April 16, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002195||55104|
NCT02003066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0638|Effect of Goal-directed Fluid Therapy Using Stroke Volume Variation in Patients Undergoing Free Flap Reconstruction After Head and Neck Cancer Resection|||Yonsei University|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|20 Years|80 Years|No|||November 2015|November 27, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02003066||55037|
NCT02003378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP|Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer|Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer|RAP|Albany Medical College|No|Recruiting|September 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003378||55013|
NCT02003040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP-9000011|Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions|Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions||Mespere Lifesciences Inc.|No|Enrolling by invitation|September 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of        acute decompensated heart failure.|September 2015|September 25, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003040||55039|
NCT02006498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE13T0.01|Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)|A Randomised, Double-blind, Placebo-controlled, Phase II, Single-centre Study to Assess the Safety and Efficacy of Silymarin 700 mg Capsules TID for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)||University of Malaya|No|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006498||54773|
NCT02006511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00057511|Incisional Negative Pressure Dressing on Clean Closed Groin Incisions|Incisional Negative Pressure Dressing on Clean Closed Groin Incisions in High Risk Patients||University of Maryland|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02006511||54772|
NCT02002403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMILS-RX09-001|Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema|A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema||St. Michael's Hospital, Toronto||Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|N/A|No|||November 2013|December 5, 2013|November 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002403||55088|
NCT02007096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0960|Does a Transabdominal Plane Block Decrease Patient Pain After Ventral Hernia Repair?|Transabdominal Plane (TAP) Blocks in Ventral Hernia Repair||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02007096||54727|
NCT02007395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/2013|Prospective Study on Polypectomy Complications: SPoC.|||Valduce Hospital||Completed|June 2013|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5170|||Both|18 Years|80 Years|No|Non-Probability Sample|Population undergoing endoscopic polypectomy|December 2013|December 5, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007395||54705|
NCT02008240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydrosalpinx2|Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET|Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET.A Randomized Controlled Trial||Aljazeera Hospital|Yes|Completed|August 2011|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|37 Years|No|||February 2015|February 16, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008240||54640|
NCT02008539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC_apceth_101/1|Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|TREAT-ME 1|Apceth GmbH & Co. KG|Yes|Recruiting|October 2013|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02008539||54617|
NCT02008552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDIAGENE|Study of the Effect of the Benfluorex|Research for Genetic Factors Involved in the Individual Susceptibility to Develop a Valvulopathy During a Medicinal Exposure in the Benfluorex.|MEDIAGENE|University Hospital, Brest|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02008552||54616|
NCT02004197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asif-HP-001|Quadruple and Phytomedicine-based Therapies in H. Pylori Infection|Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial||Shifa Ul Mulk Memorial Hospital|Yes|Completed|January 2010|January 2013|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004197||54950|
NCT02004210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACE_TARE|A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma|A Randomized, Multi-center, Open Label, Phase 3 Trial Comparing Conventional TACE and Transarterial Radioembolization in Patients With Unilobar Advanced Hepatocellular Carcinoma||Seoul National University Hospital|No|Recruiting|April 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|20 Years|80 Years|No|||November 2014|November 26, 2014|October 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02004210||54949|
NCT02004743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258-2012|Early Prevention of Post Traumatic Stress Disorder|Program Development in Guideline Development, Early Recognition and Specialized Treatment of Post Traumatic Stress Disorder (PTSD) at Sunnybrook Health Sciences Center, Canada's Largest Trauma Center||Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2013|March 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|14 Years|N/A|No|||August 2014|August 20, 2014|February 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02004743||54908|
NCT02004730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-Disappears|Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears|Italian Diffuse/Multivessel Disease ABSORB Prospective Registry Under the Auspices of Società Italiana di Cardiologia Invasive-GISE (IT-DISAPPEARS)||Istituto Clinico Sant'Ambrogio|Yes|Recruiting|December 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02004730||54909|
NCT02004990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310M44463|Dental Office Prevention Strategies for Children|Dental Office Prevention Strategies for Children: 10% Povidone Iodine (PI) Cleansing Prior to Fluoride Varnish (FV) Application||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02004990||54889|
NCT02005315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18R5-003|A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|September 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|34|||Both|18 Years|90 Years|No|||August 2015|August 31, 2015|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005315||54864|
NCT02005614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012291|A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection|A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection||Yale University|Yes|Recruiting|November 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005614||54841|
NCT02001727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20110054-97/262|HEP-FYN 12-Years Follow-up|Long-term Effect of Screening and Eradication of Helicobacter Pylori in the General Population - HEP-FYN 12-years Follow-up||Odense University Hospital|Yes|Active, not recruiting|March 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|52 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02001727||55140|
NCT02002767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-281-1056|Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment|A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment||Gilead Sciences|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02002767||55060|
NCT02003053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022663|A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU|A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU||Wake Forest School of Medicine||Completed|April 2013|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|10|||Both|18 Years|90 Years|No|||December 2015|December 21, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02003053||55038|
NCT02003677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3891|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|November 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02003677||54990|
NCT02008864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Senna in Uremic Pruritus|Evaluating the Effect of Senna in Uremic Pruritus|Phase II Study of the Effect of Senna Alexandrina Mill. on Uremic Pruritus and Serum IL-2, INF-δ and TNF-α Levels of Hemodialysed Patients||Shiraz University of Medical Sciences|Yes|Completed|August 2011|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02008864||54592|
NCT02003937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF297836|Aerobic Training in Patients With Spinal Muscular Atrophy Type III|Aerobic Training Improves Oxidative Capacity, But Not Function in Spinal Muscular Atrophy III||Rigshospitalet, Denmark|Yes|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02003937||54970|
NCT02003651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0064|Echinacea and Acute Respiratory Illness|Efficacy of Ingesting Gaia Herb's Quick Defense Product in Reducing Acute Respiratory Illness Symptomatology in Women: a 12-Week, Double Blind, Placebo-Controlled Randomized Trial||Appalachian State University|No|Completed|November 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003651||54992|
NCT02003664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819017|A Study of Baclofen ER|A Randomized Placebo-controlled Study of Baclofen ER on Brain and Behavioral Outcomes in Cocaine Dependence|CURE|University of Pennsylvania|Yes|Not yet recruiting|January 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||November 2013|December 2, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003664||54991|
NCT02007109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H32424|Use of Baxter Animated Retching Faces (BARF) Scale to Measure Nausea in Children Who Speak Spanish|Use of Baxter Animated Retching Faces (BARF) Scale to Measure Nausea in Children Who Speak Spanish||Baylor College of Medicine|No|Recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|7 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Spanish Speaking patients undergoing surgery|February 2016|February 1, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007109||54726|
NCT02006810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0168|Development of Endothelial Biomarkers|Development of Endothelial Biomarkers for Use in Cohort Studies. Comparison With Reference Biomarkers.|NUTREND|University Hospital, Clermont-Ferrand||Recruiting|July 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|60|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02006810||54749|
NCT02006823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035949|Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C|Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C||Duke University|No|Completed|March 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|African-American or Caucasian patients with Type 1 Chronic Hepatitis C|December 2014|December 11, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02006823||54748|
NCT02007668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:16832013.9.0000.5512|Is Kinesio Taping More Effective Than Medical Adhesive Tape in Patients With Chronic Non-specific Low Back Pain?|Is Kinesio Taping More Effective Than Medical Adhesive Tape in Patients With Chronic Non-specific Low Back Pain? A Randomized Controlled Trial||Paulista University|No|Completed|August 2013|November 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||December 2013|December 5, 2013|November 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02007668||54684|
NCT02007954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1306|Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma|Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma (DEBDOX)|DEBDOX|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2014|||February 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007954||54662|
NCT02008253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ-1-14 - ARVO|Intrastromal Corneal Ring for Ectasia After Refractive Surgery (Anel)|Intrastromal Corneal Ring Segment Implantation for Ectasia After Refractive Surgery||Instituto de Olhos de Goiania|Yes|Completed|April 2010|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|29|||Both|19 Years|48 Years|No|Probability Sample|Patients residents in Brazil with ectasia after refractive surgery|December 2013|December 6, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02008253||54639|
NCT02008266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25384|Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis|Case Study of the Treatment of Early Rheumatoid Arthritis in Algerian Patients in Both the Private and Public Healthcare Sectors.||Hoffmann-La Roche||Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|532|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Rheumatoid Arthritis that has been progressing for > 3 months and < 2 years.|December 2013|December 6, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02008266||54638|
NCT02008279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102823|A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants|A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CNTO3157 Following an Escalating Single SC Dose to Healthy Japanese and Caucasian Subjects or a Single Intravenous Dose to Healthy Caucasian Subjects||Janssen Research & Development, LLC|No|Completed|December 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|December 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02008279||54637|
NCT02008565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN- 18PO1|Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)|Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe): a Randomized Placebo Controlled Trial|CAPABLe|NICHD Pelvic Floor Disorders Network|Yes|Active, not recruiting|February 2014|September 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|294|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008565||54615|
NCT02004769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28670|Phase II Study of Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer|Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer||Sun Yat-sen University|Yes|Recruiting|November 2013|August 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|75 Years|No|||December 2013|December 3, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004769||54906|
NCT02005029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15105|Erythromycin in Parkinson's Disease|Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics||Virginia Commonwealth University|Yes|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02005029||54886|
NCT02005003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF8vsPlaceboJC2013|Cognitive and Metabolic Effects of a Probiotic Supplement|Placebo-controlled Randomized Trial of Cognitive and Metabolic Effects of a Probiotic Supplement||Uppsala University|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02005003||54888|
NCT02005016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O0832-R|Dosage and Predictors of Naming Treatment Response in Aphasia|Dosage and Predictors of Naming Treatment Response in Aphasia||VA Office of Research and Development|No|Recruiting|October 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||March 2016|March 9, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02005016||54887|
NCT02005328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC0161 BS 0 01|Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia|Study of the Effect and Safety of Three New Oral Sprays and a Reference Marketed Oral Spray in the Relief of Drug-induced Xerostomia Associated With Hyposialia.||Pierre Fabre Medicament||Completed|December 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005328||54863|
NCT02005341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02b|NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine|A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive||Pioneer Surgical Technology, Inc.|No|Withdrawn|October 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|N/A|No|||April 2015|April 27, 2015|December 3, 2013|Yes|Yes|A change in research priorities after a merger|No||https://clinicaltrials.gov/show/NCT02005341||54862|
NCT02002208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/017/13|Effect of OC000459 on Moderate to Severe Atopic Dermatitis|A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study||Atopix Therapeutics, Ltd.|No|Active, not recruiting|October 2013|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|48 Years|No|||July 2015|July 27, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02002208||55103|
NCT02002455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T70/2013|Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI|Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma|Flucipro|Turku University Hospital|No|Active, not recruiting|December 2013|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Male|50 Years|85 Years|No|||November 2015|November 3, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002455||55084|
NCT02002468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cervix cancer screening|Follow-up of Abnormal and Inadequate Smear-test Results|Follow-up of Abnormal and Inadequate Test Results in the Danish Cervical Cancer Screening Program.||University of Aarhus|No|Active, not recruiting|October 2012|October 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|125000|||Female|23 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002468||55083|
NCT02003417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1218|Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy|A Multicenter Study to Evaluate Cardiovascular Risk Factors and Receipt of Primary and Preventive Care in Prostate Cancer Patients Who Receive Definitive Radiation Therapy and Androgen Deprivation Therapy.||UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|June 2012|December 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|101|||Male|18 Years|N/A|No|Non-Probability Sample|Histologically-confirmed, non-metastatic prostate cancer patients who visit radiation        oncology clinics at participating institutions: The University of North Carolina at Chapel        Hill Cancer Hospital, Rex Cancer Center at the Raleigh and Wakefield locations, Marion J.        Shepard Cancer Center, Coastal Carolina Radiation Oncology, The University of Virginia,        High Point Regional UNC Health Care, and MedStar Georgetown University. Patients with        planned radiation treatment and androgen deprivation therapy with curative intent (in        definitive or post-prostatectomy settings) are eligible.|December 2014|December 29, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02003417||55010|
NCT02009163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-346|Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder||Shire|No|Completed|January 2014|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|55 Years|No|||August 2014|April 27, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009163||54569|
NCT02009800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICI-VPH-1|ICI-VPH: Impact of HPV Immunisation Schedules Against HPV|ICI-VPH: Impact Des Calendriers d'Immunisation Contre Les HPV|ICI-VPH|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Enrolling by invitation|November 2013|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4000|||Female|14 Years|16 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009800||54521|
NCT02009176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHZSG003|Laparoscope Anatomical and Aon-anatomical Hepatectomy|The Prospective, Randomized Case-control(RCT) Research of Laparoscope Anatomical and Aon-anatomical Hepatectomy Treat HCC||Southwest Hospital, China|Yes|Recruiting|March 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|70 Years|No|||December 2013|December 8, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009176||54568|
NCT02000024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109006877|Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes|Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes||Indiana University|No|Active, not recruiting|December 2011|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|225|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000024||55271|
NCT02007434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-13-36|Patient Experience Study of Deoxycholic Acid Injection|A Single Center, Double-blind, Parallel-group, Two Factor Patient-Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|84|||Both|18 Years|65 Years|No|||July 2015|July 6, 2015|October 30, 2013|Yes|Yes||No|June 12, 2015|https://clinicaltrials.gov/show/NCT02007434||54702|
NCT02007421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPANC|Study of the Prevention of Anal Cancer|The Natural History of Anal Human Papillomavirus Infection and Anal Cellular Abnormalities in Homosexual Men|SPANC|Kirby Institute|No|Recruiting|September 2010|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Male|35 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 18, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02007421||54703|
NCT02007655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-286|Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation|Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation||Bristol-Myers Squibb|No|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5500|||Both|18 Years|N/A|No|Non-Probability Sample|University hospitals, general hospitals, and clinics that have relevant departments, such        as cardiology, cerebrovascular medicine, neurology, internal medicine, neurosurgery, etc,        where the surveillance drug is mainly prescribed|January 2016|January 14, 2016|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02007655||54685|
NCT02007967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00070087|Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation|Can Non-Contrast Magnetic Resonance Angiography Accurately Define Arterial Access and Aortic Root Anatomy in Patients Referred for Transcatheter Aortic Valve Implantation?||University of Michigan|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Study population will include patients undergoing clinically indicated computed tomography        angiography for evaluation for possible transcatheter aortic valve implantation.|December 2013|December 6, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02007967||54661|
NCT02007980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02715|Indwelling Stent Discoloration Project|Examining the Underlying Factors That Cause Ureteral Stent Discoloration in Japanese and Canadian Ureteral Stents||University of British Columbia|No|Recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patient with indwelling ureteral stent due to urologic indication.|December 2015|December 17, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02007980||54660|
NCT02008578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-I-0031|Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)|Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|December 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02008578||54614|
NCT02004223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-NSCCRO-P001|Early Investigation of High Precision Radiotherapy Prior to Commencing Standard Radiotherapy for Prostate Cancer|Phase I Dose Escalation Study of Stereotactic BOOST for Prostate cancER|BOOSTER|Royal North Shore Hospital|Yes|Recruiting|January 2014|December 2023|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|35 Years|85 Years|No|||July 2015|July 12, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02004223||54948|
NCT02002013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-CCT300413|The Fluid Translation of Research Into Practice Study|The Fluid Translation of Research Into Practice Study (Fluid-TRIPS): An International Cross-Sectional Survey of Fluid Resuscitation Practice|Fluid-TRIPS|The George Institute for Global Health, Australia|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2000|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients present in the ICU on the study day|March 2015|March 9, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002013||55118|
NCT02004483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-091|Analysis of Myocardial Layer Specific Systolic and Diastolic Function During and After PCI|Comprehensive Analysis of Myocardial Layer Specific Systolic and Diastolic Function in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention|PCI-Strain|RWTH Aachen University|No|Completed|August 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|90 Years|No|||September 2015|September 22, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02004483||54928|
NCT02004496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PatAPP1, Version 1.3|Randomized Controlled Single-blind Trial to Evaluate the Mobile Tracking of Symptoms in Ambulatory Breast Cancer Patients||PatAPP1|University of Zurich|Yes|Terminated|December 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|139|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|November 25, 2013||No|Termination due to relevant update of the operation system. Adaption of the application was    not foreseen in the intervention study.|No||https://clinicaltrials.gov/show/NCT02004496||54927|
NCT02004756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000016650|Mechanisms of Dysfunction and the Influence of Exercise on Cardiac and Musculoskeletal Function|Mechanisms of Dysfunction and the Influence of Exercise on Cardiac and Musculoskeletal Function in Children After the Fontan Procedure||The Hospital for Sick Children|No|Terminated|January 2010|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|August 25, 2013||No|Feasibility issues|No||https://clinicaltrials.gov/show/NCT02004756||54907|
NCT02005354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/P/168|Does Trans-Cutaneous Electrical Nerve Stimulation (TENS) Alleviate The Pain Experienced During Bone Marrow Sampling?|Does Trans-Cutaneous Electrical Nerve Stimulation (TENS) Alleviate The Pain Experienced During Bone Marrow Sampling in Addition to Standard Techniques?A Randomised, Double-Blinded, Controlled Trial|TENS|Plymouth Hospitals NHS Trust|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005354||54861|
NCT02005640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCT-TAVI 1|Transcatheter Heart Valve (THV) Sizing and Leakage After Transcatheter Aortic Valve Implantation (TAVI) Before and After Establishing Routine Preprocedure Multi Slice Computerized Tomography (MSCT) Aortic Assessment. A Retrospective Registry Study|Transcatheter Heart Valve (THV) Sizing and Leakage After Transcatheter Aortic Valve Implantation (TAVI) Before and After Establishing Routine Preprocedure Multi Slice Computerized Tomography (MSCT) Aortic Assessment. A Retrospective Registry Study||Aarhus University Hospital Skejby|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|150|||Both|N/A|N/A|No|Probability Sample|Primary analysis will be done in patients with a successful THV implantation and        availability of high quality echocardiographic assessment and in the post routing MSCT        group on the availability of a high quality MSCT scan.|March 2015|March 18, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005640||54839|
NCT02005367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001|A Novel Person-Centered Treatment Component for Substance Use Treatment|Outcome of a Novel Person-Centered Treatment Component for Substance Use Treatment||Hampton VA Medical Center|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|643|||Both|18 Years|85 Years|No|||December 2013|December 4, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02005367||54860|
NCT02002780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020209|Recognizing and Treating Psychosocial Stress Among Children With Complex Heart Problems|Recognizing and Treating Psychosocial Stress Among Children With Complex Heart Problems||The Hospital for Sick Children|No|Withdrawn|January 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|12 Years|No|||December 2013|December 2, 2013|December 2, 2013||No|Study not started, investigator left the institution|No||https://clinicaltrials.gov/show/NCT02002780||55059|
NCT02003079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFSinus-001|Evaluating the Impact of Chronic Rhinosinusitis on the Health-Related Quality of Life Among Adults With Cystic Fibrosis|||St. Paul's Hospital, Canada||Completed|September 2013|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|113|||Both|19 Years|N/A|No|Non-Probability Sample|Adult individuals over the age of 19 years with a definitive diagnosis of Cystic Fibrosis.|November 2014|November 19, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02003079||55036|
NCT02003092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-5902-P1-01|RX-5902 Treatment of Subjects With Solid Tumors|A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors||Rexahn Pharmaceuticals, Inc.|Yes|Recruiting|August 2013|September 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003092||55035|
NCT02003690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH100056|Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder|Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder|DBT|University of Pittsburgh|Yes|Recruiting|February 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|18 Years|No|||January 2016|January 6, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003690||54989|
NCT02009527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR|Arginase Inhibition in Ischemia-reperfusion Injury|Effect of Arginase Inhibition on Endothelial Function Induced by Ischemia-reperfusion in Patients With Coronary Artery Disease||Karolinska Institutet|No|Completed|January 2012|September 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Male|N/A|80 Years|No|||April 2015|April 17, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009527||54541|
NCT02009813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAH121212a|Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.|Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.|HOTAIR2|University of Adelaide|No|Completed|March 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009813||54520|
NCT02010099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP110 01|A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-H® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3|||Peritech Pharma Ltd.|No|Completed|November 2013|June 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|70 Years|No|||June 2014|June 1, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010099||54498|
NCT02009826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRI13/37/348|Psychosis-Associated Neuroinflammation in Schizophrenia|Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects|PANS|Universiteit Antwerpen|No|Recruiting|November 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Plasma samples|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young schizophrenia patients admitted to psychiatric hospital for acute relapse or        first-episode of psychosis|December 2014|December 11, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009826||54519|
NCT01999777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USL261-301|Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU|A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)||Upsher-Smith Laboratories|Yes|Completed|November 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|12 Years|N/A|No|||September 2015|September 10, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999777||55290|
NCT02007447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 10922213.7.0000.0068|Oxytocin in Adolescents With Autism Spectrum Disorders|Oxytocin in Adolescents With Autism Spectrum Disorders|OXYASD|University of Sao Paulo General Hospital|No|Active, not recruiting|November 2013|November 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|12 Years|18 Years|No|||November 2013|December 5, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007447||54701|
NCT02007681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEFMH // Parecer 14/2013|What is in Fact the Contribution of Reducing Time Spent in Sedentary Behaviors on Daily Energy Expenditure? A Doubly Labeled Water Study|The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults||Technical University of Lisbon|Yes|Completed|September 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02007681||54683|
NCT02007993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|halitose01|Photodynamic Therapy in Adolescents Halitosis|Photodynamic Therapy as Novel Treatment for Halitosis in Adolescents: Crontolled Clinical Trial||University of Nove de Julho|Yes|Recruiting|November 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|130|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||December 2013|July 31, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02007993||54659|
NCT02008292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210010989|Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors|Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors|nic_physo|Yale University|No|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02008292||54636|
NCT02004236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Autism and tRNS|Transcranial Random Noise Stimulation (tRNS) Over Fronto-temporal Cortex Improves Verbal Fluency and Empathy in Autism Children|Transcranial Random Noise Noninvasive Brain Stimulation Applied to the Fronto-temporal Cortex Improves Verbal Fluency and Emphaty in Children With Autistic Spectrum Disorder|tRNS25112013|Spanish Foundation for Neurometrics Development|Yes|Completed|January 2014|September 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|5 Years|12 Years|No|||November 2015|November 21, 2015|November 25, 2013||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT02004236||54947|
NCT02004249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-IVD-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2013|||||N/A|N/A|N/A||||||||||||||December 3, 2013|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004249||54946|
NCT02004262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADU-CL-04|Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting|A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma|ECLIPSE|Aduro Biotech, Inc.||Active, not recruiting|January 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004262||54945|
NCT02004522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-07|A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)|A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)||Infinity Pharmaceuticals, Inc.|Yes|Active, not recruiting|November 2013|June 2021|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004522||54925|
NCT02004509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILENT|SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial||SILENT|InCor Heart Institute|Yes|Not yet recruiting|February 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2054|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02004509||54926|
NCT02005055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PlastChirVUmc 01|High Dose Rate Brachytherapy for Treatment of Keloids|Prospective Evaluation of the Use of High-dose-rate Brachytherapy for the Treatment of Recalcitrant Keloids||VU University Medical Center|No|Completed|January 2003|December 2010|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|43|||Both|10 Years|N/A|No|Probability Sample|All patients with recalcitrant keloids meeting inclusion criteria|December 2013|December 3, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02005055||54884|
NCT02005406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wei JET|Testing the Efficacy and Safety of the WEI Nasal Jet|Efficacy and Safety of the WEI Nasal Jet|WNJ|Fudan University|Yes|Completed|June 2012|April 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|49|Samples Without DNA|•Patients receiving various types of surgeries under sedation, especially for procedures of      colonoscopy, upper gastrointestinal endoscopy, endoscopic retrograde      cholangiopancreatography (ERCP) cystoscopy and other brief surgeries you are interested in      the study.|Both|22 Years|58 Years|Accepts Healthy Volunteers|Probability Sample|Suggested patient inclusion criteria:        Patients receiving various types of surgeries under sedation, especially for procedures of        colonoscopy, upper gastrointestinal endoscopy, endoscopic retrograde        cholangiopancreatography (ERCP) cystoscopy and other brief surgeries you are interested in        the study.|December 2013|December 6, 2013|July 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005406|1 Year|54857|
NCT02005666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRL/CT/09/11-12|To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel|A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® Gel (of Stiefel Laboratories, USA) Versus Placebo (Vehicle Gel) in the Ratio of 2:2:1 Respectively, in Patients With Acne Vulgaris||Cadila Healthcare Limited|Yes|Recruiting|November 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|850|||Both|12 Years|40 Years|No|||November 2015|November 24, 2015|November 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005666||54837|
NCT02005042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI-BENI-Heron|Physical Activity and Daily Experiences Study|Developing a Real-time, Ecologically Sensitive Physical Activity Intervention Using Smartphones and Bluetooth-enabled Pedometers: Feasibility and Initial Efficacy||Penn State University|No|Active, not recruiting|November 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|May 2, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02005042||54885|
NCT02005380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GJU001|Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation|Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation||German-Jordanian University|No|Completed|November 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|20|||Both|60 Years|N/A|No|Non-Probability Sample|Darat Samir Shamma, a senior residential care facility and|December 2013|December 6, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02005380||54859|
NCT02005393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-13-003|Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)|A Concurrence Study of Diagnostic Visualization Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)|FICE|Fujifilm Medical Systems USA, Inc.|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 4, 2013|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005393||54858|
NCT02003118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKT-001|A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain|||Akron Molecules AG||Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|40 Years|75 Years|No|||October 2014|October 21, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003118||55033|
NCT02003430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132824|Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers|Functional Assessment and Radiation Adherence/Toxicity in Older and Younger Patients With Non-Ovarian Gynecological Cancers||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|Samples With DNA|Whole blood|Female|18 Years|N/A|No|Non-Probability Sample|Patients age 18 years of age or above with a diagnosis of cervical, vaginal, vulvar, or        endometrial cancer with either pelvic radiotherapy or chemoradiotherapy planned as part of        standard treatment with curative intent at the Department of Radiation Oncology at UNC        Chapel Hill.|January 2016|January 17, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02003430||55009|
NCT02013024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53410|The Effect of Vitrification Versus Slow Freezing on Day 3: a Randomised Controlled Trial.|||Katholieke Universiteit Leuven|No|Completed|September 2011|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|417|||Female|18 Years|40 Years|No|||February 2015|February 4, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013024||54275|
NCT02013037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR 205237|The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation|The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]|DUET|Cedars-Sinai Medical Center|No|Enrolling by invitation|November 2012|March 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013037||54274|
NCT02010385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Le Roux 12 June 12|Investigation of the Effects of Obesity Surgery on Appetitive Behaviour|Investigation of the Effects of Obesity Surgery on Appetitive Behaviour - Impact of Gut Hormones||University College Dublin|Yes|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010385||54476|
NCT02010112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-MPBA-0813|Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori|Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Congruent Biopsy Results||Exalenz Bioscience LTD.|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|193|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010112||54497|
NCT02009475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACT_HF_KIN|The Effect of Two Exercise Training Protocols on Physiological and Biochemical Parameters in Congestive Heart Failure|||Sheba Medical Center|No|Recruiting|February 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|N/A|N/A|No|||November 2014|November 17, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02009475||54545|
NCT02007707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRDRP 22RT-0089|A Family-Based Approach To Reduce Smoking in Vietnamese Men|A Family-Based Approach To Reduce Smoking in Vietnamese Men|Tobacco LHW|University of California, San Francisco|Yes|Recruiting|April 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02007707||54681|
NCT02007720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2302|Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF|A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients|RELAX-AHF-ASIA|Novartis|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1520|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007720||54680|
NCT02007694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-KP-2464|Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants|Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants||VU University of Amsterdam||Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|75 Years|No|||July 2015|July 6, 2015|March 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02007694||54682|
NCT02008305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC/DM_MPN_2012-4|Comparison of Two Protocols of Optimization of X Ray Radiations in Pediatric Interventional Neuroradiology|Comparison of Two Protocols of Optimization of X Ray Radiations in Pediatric Interventional Neuroradiology|MINIRAD|Fondation Ophtalmologique Adolphe de Rothschild|No|Terminated|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|N/A|14 Years|No|||March 2015|March 24, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02008305||54635|
NCT02008591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001927|Comparison of Epidural Labor Pain Relief Techniques on Maternal and Fetal Outcomes|Comparison of Epidural Labor Pain Relief Techniques on Maternal and Fetal Outcomes||Brigham and Women's Hospital|Yes|Recruiting|December 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|50 Years|No|||August 2014|August 3, 2014|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008591||54613|
NCT02004288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0083|The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa|The Role of Lactobacillus Reuteri in Nutritional Recovery and Treatment of Constipation in Children and Adolescents With Anorexia Nervosa - Randomised, Double Blind, Placebo Controlled Study||BioGaia AB|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|8 Years|18 Years|No|||September 2015|September 16, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02004288||54943|
NCT02001532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-349-13|Arterial Stiffness and Complication Risk in Type 2 Diabetes|Arterial Stiffness and Complication Risk in Type 2 Diabetes||University of Aarhus|No|Recruiting|May 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200||Whole blood Serum/plasma Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 patients with type 2 diabetes (cases) were enrolled from the outpatient clinic of the        Department of Endocrinology, Aarhus University Hospital between 2008-11.        100 sex and age-matched healthy controls were recruited in the same time period through        the local press.|November 2013|June 11, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02001532||55155|
NCT02001779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR-C-STENT-MBO-83272121|IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction|Study of Stent Insertion Combined With or Without Brachytherapy in Patients With Inoperable Malignant Biliary Obstruction Caused by Cholangiocarcinoma|IRCSMBO|Zhongda Hospital|Yes|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|90 Years|No|||November 2013|December 4, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001779||55136|
NCT02001792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PatPo2012|Patient Positioning During Colonoscopy: Effects on Safety and Diagnostic Outcome||PACSO|Technische Universität München|No|Completed|April 2012|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|412|||Both|18 Years|90 Years|No|||November 2014|November 13, 2014|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT02001792||55135|
NCT02005068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEF-IT-17|Ceftaroline in the Treatment of Bone and Joint Infections|Ceftaroline in the Treatment of Bone and Joint Infections||Orlando Health, Inc.|No|Withdrawn|April 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|November 21, 2013|Yes|Yes|Failed to enroll any patients despite study modifications|No||https://clinicaltrials.gov/show/NCT02005068||54883|
NCT02002507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6432-BE|Jugular Venous Flow Neurosurgical Patients|Effect of Different Surgical Positions on the Cerebral Venous Drainage: an Ultrasound Study on Neurosurgical Patients||University Health Network, Toronto|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Neurosurgical patients in either park bench or prone position for their surgery|February 2015|February 2, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002507||55080|
NCT02005679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0008|Mini-Mental State (MMS-LS) and Sign Language|Transposition of the Mini-Mental State in Sign Language|MMS-LS|Lille Catholic University|No|Recruiting|June 2011|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|185|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02005679||54836|
NCT02006004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA LMA 2013|Epidemiologic Registry PETHEMA LMA 2013|Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2013)||PETHEMA Foundation|No|Completed|January 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with acute myeloid leukemia|October 2015|October 13, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02006004||54811|
NCT02006017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-480|Do Clinicians Want Recommendations?|Do Clinicians Want Recommendations? A Randomized Trial Comparing Evidence Summaries With and Without Evidence Based Recommendations||McMaster University|No|Recruiting|September 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|198|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 4, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02006017||54810|
NCT02012192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GANNET53|GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer|A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Medical University Innsbruck|Yes|Recruiting|June 2014|October 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Female|18 Years|N/A|No|||July 2015|July 9, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02012192||54338|
NCT02012439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCT v CT for MS Pain|Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain|The Efficacy and Mechanisms of Cognitive Therapy Compared to Mindfulness-Based Cognitive Therapy in Multiple Sclerosis (MS) Pain||University of Washington|No|Active, not recruiting|October 2013|June 2015|Anticipated|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02012439||54319|
NCT02012452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-018-13S|Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD|Tobacco Treatment as Augmentation to Cognitive Processing Therapy for PTSD||VA Office of Research and Development|Yes|Terminated|December 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 26, 2013||No|PI moving outside VA- grant not transferable|No||https://clinicaltrials.gov/show/NCT02012452||54318|
NCT02009189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tauro-1|Taurolidine Lock in Long Term Parenteral Nutrition|The Value of Taurolidine Lock in Long Term Parenteral Nutrition||Stanley Dudrick's Memorial Hospital|No|Completed|November 2012|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009189||54567|
NCT02009488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103062|Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus||Janssen Research & Development, LLC|No|Recruiting|September 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|56|||Both|25 Years|70 Years|No|||March 2016|March 11, 2016|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009488||54544|
NCT02009501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC/09/05/ULTA|V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds|A Prospective, Open, Comparative, Randomized Single-center Study to Evaluate the Effect of V.A.C. VeraFlo™ Therapy With .125% Dakins vs V.A.C. Ulta™ Therapy on Biofilm Removal/Disruption/Elimination in Chronically Infected Wounds||St. Luke's-Roosevelt Hospital Center|No|Completed|November 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2015|June 17, 2015|November 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009501||54543|
NCT02010138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-083|Extent of ILM Removal and Its Impact on Outcomes of MH Surgery|Extent of Internal Limiting Membrane Removal and Its Impact on Outcomes of Macular Hole Surgery||Samsung Medical Center|No|Completed|July 2013|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|20 Years|N/A|No|||January 2016|January 5, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010138||54495|
NCT02010684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADE-IT Study 1P20MD00148-03|Mood and Diabetes Empowerment & Improvement Training|University of California, Los Angeles (UCLA)/Drew Project EXPORT: Mood and Diabetes Empowerment & Improvement Training (MADE IT)|MADE-IT|University of California, Los Angeles|No|Completed|April 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|August 1, 2013||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT02010684||54453|
NCT02010333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-003|A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation|||Hatchtech Pty Ltd||Completed|April 2013|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|6 Months|2 Years|No|||September 2015|September 9, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010333||54480|
NCT02010346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/2003|The Effect of Timing on Orthodontic Treatment|The Effect of Timing on Orthodontic Treatment - Studied by Randomized Clinical Settings||University of Oulu|No|Active, not recruiting|January 2005|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|18 Years|No|||December 2015|December 9, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010346||54479|
NCT02007733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470125|DeHydration: Assessing Kids Accurately|Assessment of Severe Dehydration in Children With Diarrhea in Bangladesh|DHAKA|Rhode Island Hospital|Yes|Active, not recruiting|February 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1700|||Both|N/A|60 Months|No|||June 2014|May 4, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02007733||54679|
NCT02008019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHONRAD|A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas|A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas|CHONRAD|Centre Leon Berard|Yes|Recruiting|March 2014|August 2019|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|57|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008019||54657|
NCT02008006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BENEFIT|BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)|A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma|BENEFIT|Centre Leon Berard|No|Recruiting|March 2014|January 2020|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||February 2015|June 8, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008006||54658|
NCT02008604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUTSTROKE|Influence of Stroke on the Composition of Intestinal Microbiota|Influence of Stroke on the Composition of Intestinal Microbiota (GUTSTROKE)|GUTSTROKE|Charite University, Berlin, Germany|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|26|Samples With DNA|Stool samples, Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|patients at the rescue center, the Stroke Unit and the neurological intensive care unit of        the Charité University hospital|January 2016|January 20, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02008604||54612|
NCT02004275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A061202|Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma|A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy||Alliance for Clinical Trials in Oncology|Yes|Recruiting|February 2014|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004275||54944|
NCT02001545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CBG-XXX-2013/1|REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients|REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients|RE-ACT|AstraZeneca|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|814|||Both|18 Years|N/A|No|Probability Sample|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment        elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial        infarction) within 24 hours of symptom onset.|November 2014|November 13, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02001545||55154|
NCT02001558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIC-UABWC-001|Pressure Ulcer Healing With Microcyn|A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects||University of Alabama at Birmingham|No|Recruiting|March 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02001558||55153|
NCT02002052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO-FLAIR|Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial|Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial|FLAIR|Lawson Health Research Institute|Yes|Recruiting|May 2014|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002052||55115|
NCT02002273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Airleak-2013-1|Effect of Regulated Pleural Pressure on Air Leak and Fluid Drainage Following Pulmonary Resections: A Multicenter Randomized Trial|The Effect of Regulated Pleural Pressure on The Duration of Air Leak and Fluid Drainage Following Pulmonary Anatomic Resections: A Multicenter Randomized Trial||Ospedali Riuniti Ancona||Not yet recruiting|February 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|90 Years|No|||December 2013|December 4, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002273||55098|
NCT02002247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSTAIN CSX|SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).|SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Pilot Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients|SUSTAINCSX|Clinical Evaluation Research Unit at Kingston General Hospital|Yes|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002247||55100|
NCT02002260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD074751|Stopping Heavy Periods Project|Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses|SHiPP|Women and Infants Hospital of Rhode Island|Yes|Recruiting|February 2013|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|59|||Female|18 Years|51 Years|No|||November 2015|November 24, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02002260||55099|
NCT02002520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13-354|Epigenetic Influences on Post-Surgical Acute and Chronic Pain|An Exploratory Study of the Epigenetic Influences on Post-Surgical Acute and Chronic Pain||The University of Hong Kong|No|Recruiting|January 2014|November 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|RNA and DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects at Prince Philip Dental Hospital and Queen Mary Hospital|January 2014|January 21, 2014|November 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02002520||55079|
NCT02002806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011003552|Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control|A Randomized Controlled Trial of Intraoperative Chemical Splanchnicectomy for Patients With Resected Pancreatobiliary Malignancies||Indiana University|Yes|Active, not recruiting|January 2012|December 2024|Anticipated|December 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||February 2016|February 6, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002806||55057|
NCT02002819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV-AD|Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability|Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability|LEV-AD|University of California, San Francisco|No|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|45 Years|80 Years|No|||December 2015|December 2, 2015|October 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002819||55056|
NCT02003131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-MTFOA-001|Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis|Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis||Translational Biosciences|Yes|Active, not recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003131||55032|
NCT02008877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC023|SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)|A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors||Sarcoma Alliance for Research through Collaboration|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|16 Years|N/A|No|||March 2016|March 17, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008877||54591|
NCT02008890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A3301|Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis||Novartis|No|Active, not recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|237|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008890||54590|
NCT02009202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS60-12/567|Preparation Prior to Colonoscopy in Children|Preparation Prior to Colonoscopy in Children||Skane University Hospital|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|10 Years|18 Years|No|||May 2015|May 18, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02009202||54566|
NCT02008903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0223|Esophageal String Test in Eosinophilic Esophagitis|Phase 2 Study of Esophageal String Test in Diagnosing Eosinophilic Esophagitis||University of Colorado, Denver|No|Recruiting|January 2009|||May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|440|||Both|7 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any pediatric or adult patient undergoing a clinically indicated endoscopy with biopsy at        a participating site may be recruited. (initial cohort)|December 2015|December 7, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008903||54589|
NCT02009215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRAA6910|School-Based Treatment With ACT to Reduce Transmission|'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial|START-IPT|London School of Hygiene and Tropical Medicine|Yes|Completed|February 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10746|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02009215||54565|
NCT02009514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02058M|Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients|Glucose Control During Glucose Containing And Glucose Free Hemodialysate Evaluated By Continuous Glucose Monitoring In Type 2 Diabetic Patients||Tampere University Hospital|No|Completed|October 2002|March 2004|Actual|February 2004|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009514||54542|
NCT02010398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot.1160/L|Effects of the Cross-Training in Patients With Multiple Sclerosis|Neurophysiological, Dynamometric, Functional and Clinical Assessment of the Cross-Training Effect in Patients With Multiple Sclerosis|CTSM|Università degli Studi di Sassari|Yes|Recruiting|July 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010398||54475|
NCT02000674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/CHU/05|Succinylcholine vs Rocuronium for Prehospital Emergency Intubation|Succinylcholine vs Rocuronium for Prehospital Emergency Intubation : a Randomized Trial|CURASMUR|Centre Hospitalier Universitaire de la Réunion|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1300|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02000674||55221|
NCT02008032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1861|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Breast Augmentation|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Breast Augmentation||University of North Carolina, Chapel Hill|No|Recruiting|December 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|December 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02008032||54656|
NCT02008318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15242|A Study of LY2157299 in Participants With Myelodysplastic Syndromes|Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes||Eli Lilly and Company|Yes|Active, not recruiting|March 2014|May 2019|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008318||54634|
NCT02001233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-EV71-3003|A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine|An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine||Sinovac Biotech Co., Ltd|No|Completed|March 2013|October 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10077|Samples With DNA|Serum samples will be taken from 1200 subjects in the immunogenicity subgroup 26 months      after the first vaccination.      Throat and anal swab samples will be taken from the cases with Hand, Foot and mouth disease      for the detection of PCR assays and the isolation of EV71.|Both|6 Months|35 Months|Accepts Healthy Volunteers|Probability Sample|Healthy Chinese infants aged 6 to 35 months old|May 2015|May 20, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001233||55178|
NCT02001246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00067796|Two Anger Management Programs for Teens.|An Exploratory Study of Two Intervention Programs for Anger Management for Teens.||University of Utah|No|Active, not recruiting|January 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|13 Years|17 Years|No|||August 2014|April 27, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001246||55177|
NCT02001805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marathon Cohorte|Marathon Runners Compared to Sedentary Matched Control Subjects|Fitness, Glucosemetabolism, Cognitive Function, Bodycomposition and Muscular Function in Active Runners and Matched Controls||Rigshospitalet, Denmark|Yes|Recruiting|December 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|Whole blood, plasma, muscle tissue|Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Runners with high amount of training|November 2013|November 28, 2013|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT02001805||55134|
NCT02002078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinicalTrials.gov|Caustic Esophageal Burns in Children and High Doses of Methylprednisolone|High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children||Sisli Etfal Training & Research Hospital|No|Completed|February 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Actual|83|||Both|12 Months|17 Years|No|||November 2013|November 28, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02002078||55113|
NCT02002286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TwHF Pilot|Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses|Pilot Study: Safety and Efficacy Study of Tripterygium Wilfordii Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses||Peking Union Medical College|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||November 2013|November 29, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02002286||55097|
NCT02002026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1150-4666|Uterine Artery Ligation to Decrease Blood Loss With Central Placenta Previa|Uterine Artery Ligation to Minimize Blood Loss in Patients With Central Placenta Previa||Minia Maternity University Hospital|Yes|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02002026||55117|
NCT02002039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erythropoietin 01|Neuroprotective Role of Erythropoietin in Perinatal Asphyxia|Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial||Sheri Kashmir Institute of Medical Sciences|Yes|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|6 Hours|No|||November 2015|November 16, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02002039||55116|
NCT02002845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Non-Tumor based TORS procedure|A Retrospective Multicenter Investigation of the Use of the da Vinci® Surgical System in Non-Tumor Based TORS Procedures|A Retrospective Multicenter Investigation of the Use of the da Vinci® Surgical System in Non-Tumor Based TORS Procedures||Intuitive Surgical|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|285|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have undergone benign non-tumor TORS procedures using the da Vinci Surgical        System|December 2015|December 8, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002845||55054|
NCT02002533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC12048|Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy|Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial||University of Rochester|Yes|Active, not recruiting|February 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Female|21 Years|N/A|No|||February 2016|February 19, 2016|November 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002533||55078|
NCT02002832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1070004|A Clinical Trial of Lurasidone in Treatment of Schizophrenia|A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone||Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|No|Recruiting|December 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|380|Samples With DNA|blood,urine|Both|18 Years|65 Years|No|Probability Sample|the patient with schizophrenia|April 2014|May 14, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002832|7 Days|55055|
NCT02003144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-NMO-302|An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients|A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)||Alexion Pharmaceuticals|Yes|Enrolling by invitation|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003144||55031|
NCT02003157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 A00081-40|Efficacy of Hypnosis During Embryo Transfer Procedure on Clinical Pregnancy Rate for Patients Undergoing Assisted Reproductive Technology IVF or ICSI||HYPNOART|University Hospital, Angers||Completed|June 2011|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Female|18 Years|41 Years|No|||October 2011|January 14, 2016|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02003157||55030|
NCT02013063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM RAD0030|Single Pulmonary Nodule Investigation|Accuracy and Cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography in the Characterisation of Solitary Pulmonary Nodules|SPUtNIk|University Hospital Southampton NHS Foundation Trust.|Yes|Recruiting|August 2012|October 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|375|||Both|18 Years|N/A|No|Probability Sample|Hospital Chest Clinics PET referal centres|November 2014|November 21, 2014|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013063||54272|
NCT02008929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC_ MG4101|to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)|A Single Center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) in Hepatocellular Carcinoma After Curative Resection|MG4101|Samsung Medical Center|Yes|Completed|August 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|69 Years|No|||November 2015|November 30, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008929||54587|
NCT02009839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG-SIG/05016|Web-Based CBT Protocol for Treatment of Selective Mutism|Effectiveness of a Web-Based CBT Protocol for Treatment of Selective Mutism in Singapore||National Healthcare Group, Singapore|No|Completed|July 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|38|||Both|6 Years|12 Years|No|||May 2014|May 19, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009839||54518|
NCT02009852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309076RIN|The Role of microRNA-29b in the Oral Squamous Cell Carcinoma|The Role of microRNA-29b in the Oral Squamous Cell Carcinoma|microRNA-29b|National Taiwan University Hospital|Yes|Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|100|Samples With DNA|tissue, serum, saliva|Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Medical center|December 2013|December 9, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009852|3 Years|54517|
NCT02010125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFstudy|Feasibility Trial Using Imaging and Biochemical Technologies to Measure Knee Cartilage Composition in Acute ACL Injury|A Multi-Center Feasibility Trial Establishing Imaging and Biochemical Technologies as Measures of Knee Cartilage Composition Following Acute ACL Injury||University of California, San Francisco|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Urine, Whole Blood, Synovial Fluid|Both|13 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women with acute ACL injury (within 28 days)|January 2015|January 13, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010125||54496|
NCT02011243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/OM-01|Internal Rotation Deficit of the Glenohumeral Joint in Advanced-level Handball Players|Evaluation of the Internal Rotation Deficit of the Glenohumeral Joint in Advanced-level Handball Players Occurring Over One Training Season|GIRDH|Centre Hospitalier Universitaire de Nīmes|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|86|||Both|N/A|N/A|No|Non-Probability Sample|The study population is composed of all members of the professional and pre-professional        handball clubs in the city of Nîmes, France (the USAM and HBCN clubs). Younger players who        are members of the training centers associated with these same clubs will also be        included.|March 2015|March 25, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02011243||54410|
NCT02011256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130027|Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack|Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack - A Prospective Study|NOTICE|University of Southern Denmark|Yes|Active, not recruiting|September 2013|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02011256||54409|
NCT02011490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8616-105|Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 13, 2015|December 10, 2013|No|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT02011490||54391|
NCT02000687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080127|Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss|Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss||University of Miami|No|Recruiting|December 2008|July 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|75 Years|No|Non-Probability Sample|Ages 18-75 years old that received at least one IT. Participants will be obtained from the        pool of islet transplant recipients transplanted at the Diabetes Research Institute at the        University of Miami, Miller School of Medicine.|December 2015|December 16, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000687||55220|
NCT02000648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/13|Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand|Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand||Chulalongkorn University|No|Recruiting|January 2012|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with chronic rhinitis or chronic urticaria|September 2015|September 3, 2015|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02000648|2 Years|55223|
NCT02000661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02709|Routine Versus Selective Use of FFR to Guide PCI|A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI)|FFR-SELECT|Cardiology Research UBC|No|Terminated|January 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 27, 2013||No|Stopped early by DSMB due to slow enrollment - obtained data to be analyzed|No||https://clinicaltrials.gov/show/NCT02000661||55222|
NCT02008331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guida56|Effect of the Synbiotic Probinul-Neutro® on Gastrointestinal Symptoms and Plasma p-Cresol Level in Chronic Renal Failure|EFFECT OF SHORT-TERM TREATMENT WITH THE SYNBIOTIC PROBINUL-NEUTRO® ON GASTROINTESTINAL SYMPTOMS AND CIRCULATING PLASMA p-CRESOL LEVEL IN PATIENTS WITH CHRONIC RENAL FAILURE: A RANDOMIZED DOUBLE BLIND PILOT STUDY.||Federico II University|Yes|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||December 2013|December 6, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02008331||54633|
NCT02001571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016948|A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function|A Phase 1 Single Dose Open-Label Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function||Cougar Biotechnology, Inc.|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|40 Years|80 Years|No|||November 2013|November 28, 2013|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001571||55152|
NCT02001818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML11|Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia|Phase II Study of Nilotinib Plus Pegylated Interferon Alfa-2b as First-line Therapy in Chronic Phase Chronic Myelogenous Leukaemia Aiming to Maximize Complete Molecular Response and Major Molecular Response.|PInNACLe|Australasian Leukaemia and Lymphoma Group|Yes|Recruiting|April 2014|December 2021|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2013|May 18, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02001818||55133|
NCT02002065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HA-4013 version 2.0|The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children|The Phase IV, Open-labelled, Follow-up Study to Evaluate the Five-year Immune Persistence of One Injection of Inactivated or Attenuated Alive Hepatitis A Vaccine in Healthy Chinese Children||Sinovac Biotech Co., Ltd|No|Completed|October 2008|June 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|Samples Without DNA|Serum samples were taken from subjects.|Both|18 Months|35 Months|Accepts Healthy Volunteers|Probability Sample|Healthy Chinese children aged 18 to 35 months old|May 2015|May 28, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002065||55114|
NCT02002299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCtopfront1|Does Surface Tell us About the Invasive Front in Colorectal Cancer|Prospective Study of Colorectal Cancer Comparing the Surface With the Invasive Front|CRC1|Roskilde County Hospital|No|Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Surgical resection specimens of colorectal cancers|Both|N/A|N/A|No|Non-Probability Sample|All patients from Roskilde Hopsital with colorectal cancer who is having surgical        resection of the tumor|July 2013|November 29, 2013|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002299|14 Days|55096|
NCT02002572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU AMIENS - PI11 - Dr DAKPE|Quantification, Analysis and Simulation of Facial Mimics Movements||SIMOVI|Centre Hospitalier Universitaire, Amiens|No|Recruiting|June 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002572||55075|
NCT02002546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 13-069|Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction|Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction||Chattanooga-Hamilton County Hospital Authority|No|Active, not recruiting|January 2014|September 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients presenting to the Emergency Department with chest pain or similar symptoms,        and risk factors for ACS.|September 2015|September 3, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002546||55077|
NCT02002858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA03474101|Smoking Cessation for Depression and Anxiety Treatment|Integrated Smoking Cessation Treatment for Emotional Dysregulation|SDAT|University of Houston|Yes|Recruiting|October 2014|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2015|January 5, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002858||55053|
NCT02003170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #136272|Etiology and Early Diagnosis of Neurodevelopmental Disorders|Etiology and Early Diagnosis of Neurodevelopmental Disorders||University of Arkansas|No|Recruiting|May 2012|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood, urine, cerebrospinal fluid, muscle, and skin samples may be retained.|Both|N/A|99 Years|No|Non-Probability Sample|Children who present to various Arkansas Children's Hospital Outpatient clinics for        standard care related to neurodevelopmental disorders.|February 2016|February 2, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02003170||55029|
NCT02003456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00080193|Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging|Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging||University of Michigan|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02003456||55007|
NCT02009228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-004IA|Single-port LC Might be Preferable for Managing Ovarian Dermoid Cyst.|Single-Port Compared With Conventional Laparoscopic Cystectomy for Ovarian Dermoid Cysts||Taipei Veterans General Hospital, Taiwan|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 8, 2013|December 8, 2013||||No||https://clinicaltrials.gov/show/NCT02009228||54564|
NCT02009865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5880C00001|Epanova® for Lowering Very High Triglycerides II (EVOLVE II)|A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)|EVOLVEII|AstraZeneca|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|760|||Both|N/A|N/A|No|||December 2015|December 11, 2015|December 9, 2013|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT02009865||54516|
NCT02009878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-12-203|A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)|A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009878||54515|
NCT02009891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100OFC|Use of Predictive Model to Assist Patients Having an Embryo Transfer After IVF|The Application of a Validated Patient and Clinic Specific Predictive Model to Reduce the Incidence of Multiple Births Resulting From Fresh In Vitro Fertilization Cycles||Ottawa Fertility Centre|No|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|276|||Female|18 Years|38 Years|No|Probability Sample|Women under age 38 undergoing 1st or 2nd IVF treatment who havae not had previous IVF        pregancy nor cancelled IVF cycle for poor response.|June 2015|June 29, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009891||54514|
NCT02011269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNDO 201-201|TSO for Plaque Psoriasis|A Randomized, Blinded, Placebo-controlled Multicenter Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis||Coronado Biosciences, Inc.|No|Withdrawn|March 2014|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||May 2015|May 5, 2015|December 10, 2013|Yes|Yes|Study not conducted|No||https://clinicaltrials.gov/show/NCT02011269||54408|
NCT02010957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS8-341|Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia|￼Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia|FAMIAN|Wuerzburg University Hospital|Yes|Not yet recruiting|June 2014|June 2020|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|220|||Both|30 Years|N/A|No|||December 2013|December 10, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02010957||54432|
NCT02010970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00004|A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate|A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers|AZD3293DDI|AstraZeneca|No|Completed|December 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|December 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02010970||54431|
NCT02001012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-13-18375|P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine|Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial)|CAN KNOW|Menzies School of Health Research|No|Recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|1 Year|N/A|No|||November 2013|January 11, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001012||55195|
NCT02000986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14062|Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors|Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor||Virginia Commonwealth University|Yes|Withdrawn|August 2012|July 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|11 Years|17 Years|No|||November 2015|November 19, 2015|November 26, 2013||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT02000986||55197|
NCT02001259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orthoTU05|Efficacy of Epidural Steroid for Controlling Pain After Primary TKA|Efficacy of Epidural Steroid in Controlling Postoperative Pain After Primary Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial||Thammasat University|Yes|Recruiting|June 2013|July 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||November 2013|November 27, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001259||55176|
NCT02000960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03330|Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome|A Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome|Glut1C7|University of British Columbia|Yes|Recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|1 Year|18 Years|No|||November 2015|November 30, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000960||55199|
NCT02000973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131012|Effects of Epidural Local Anesthetics on Propofol Induction|Effects of Thoracic Epidural Anesthesia With Different Local Anesthetics on Propofol Induction||First Hospital of China Medical University|Yes|Completed|November 2013|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|45 Years|65 Years|No|||April 2014|April 20, 2014|November 22, 2013||No||No|March 6, 2014|https://clinicaltrials.gov/show/NCT02000973||55198|
NCT02001584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-917-001|A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults|||Gedeon Richter Plc.||Completed||May 2014|Actual|May 2014|Actual|Phase 1|Interventional|N/A|2||||||Both|18 Years|45 Years||||July 2014|July 4, 2014|November 15, 2013||||No||https://clinicaltrials.gov/show/NCT02001584||55151|
NCT02002091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAlgiers FM 401/desm/07|Prevalence of Morbidity in Newly Diagnosed type2 Diabetes in Adults|Prevalence of Micro and Macroangiopathy in Newly Diagnosed type2 Diabetic Adults in Suburban Area of Algiers||University of Algiers|Yes|Completed|January 2009|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|327|Samples Without DNA|Blood. Urines. Tissue (kidney) for few patients.|Both|40 Years|70 Years|No|Probability Sample|Population of type 2 diabetes patients that diabetes is diagnosed recently, in one of the        health structures, in the east suburban area of Algiers. In the first step they are        recruited by primary care physicians, on the basis of glycemia >= 1.26 g/l (capillary or        venous); then they are automatically directed to the main investigator, in hospital        consultation, to confirm by two blood samples, the hyperglycemia; and (second step) screen        for differential diagnosis (secondary diabetes)before the definitive recruitment.Patients        are systematically,consecutively recruited. They are followed up during 1 year, they are        seen every 3months at least.|March 2015|March 18, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002091||55112|
NCT02002104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201009047R|Endothelialized ePTFE Graft by Nanobiotechnology|Endothelialized ePTFE Graft by Nanobiotechnology||National Taiwan University Hospital|Yes|Completed|September 2010|June 2011|Actual|September 2010|Actual|N/A|Observational|N/A||2|Actual|6|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Native arteriovenous fistulas are not available in up to 40 percent of patients with renal        dialysis. Therefore, the replacement of autologous blood vessels by artificial grafts is        urgently needed. Expanded polytetrafluoroethylene( ePTFE) grafts are the most clinically        used artificial blood vessels.|November 2013|November 29, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02002104||55111|
NCT02002312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO2009/322|Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer|Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer||Radboud University|Yes|Completed|August 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002312||55095|
NCT02002117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103039RB|Genotyping of Non-small Cell Lung Cancer|Genotyping of Non-small Cell Lung Cancer Cells - A Study of Taiwan Lung Cancer Clinical Trial Consortium (TALCC)||National Taiwan University Hospital|No|Recruiting|January 2012|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|tissue and plasma|Both|18 Years|N/A|No|Probability Sample|We plan to collect 300 EGFR mutation positive samples (approximately 200 de novo, 100        after treatment), 200 EGFR wild type adenocarcinoma patients and 100 other NSCLC patients        in 3 years.|July 2014|July 28, 2014|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02002117||55110|
NCT02002585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1|Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease|Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study)|KPS|Charles University, Czech Republic|No|Recruiting|November 2013|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2013|December 1, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02002585||55074|
NCT02002559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.077|Narrow Band Imaging (NBI) Against Lugol for Squamous Esophageal Cancer|Endoscopic Surveillance Comparing Narrow Band Imaging (NBI) Against Lugol Chromoendoscopy for Detection of Synchronous Superficial Squamous Esophageal Neoplasia Among High Risk Patients||Chinese University of Hong Kong|No|Completed|April 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|180|||Both|18 Years|80 Years|No|Non-Probability Sample|1. Patients with Head and Neck Cancer          2. Patients with esophageal cancer treated by chemoradiotherapy and in remission for 2             years          3. Patients with esophageal cancer treated by endoscopic resection|December 2013|December 5, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002559||55076|
NCT02003196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0228|Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)|Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)|IBIS-VIRUS|Nantes University Hospital||Recruiting|February 2014|||February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|75 Years|No|Probability Sample|-  Acute brain injury (trauma, subarachnoid haemorrhage, stroke, infection) with Glasgow             Coma Scale <= 12          -  Age between 18 and 75 years|March 2016|March 22, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003196||55027|
NCT02003183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001077|Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy|FDDNP-PET Imaging in Persons at Risk for Chronic Traumatic Encephalopathy|TBI and CTE|University of California, Los Angeles|Yes|Active, not recruiting|March 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|30 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003183||55028|
NCT02003469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00028634|Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II|Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II|PROTECTII|University of Michigan|Yes|Completed|April 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|67|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003469||55006|
NCT02010151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUEMS201309|Can Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation Improve Survival of out-of Hospital Cardiac Arrest?|Population Based Intervention Trial of Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation||Seoul National University Hospital|Yes|Not yet recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3776|||Both|15 Years|N/A|No|||August 2015|August 4, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010151||54494|
NCT02010164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoQ10follicle|CoQ10 Treatment to Improve Fertility in Elderly Patients|THE EFFECT OF COQ10 SUPPLEMENTATION ON FOLLICULAR CELLS' BIOLOGY/PROPERTIES IN ELDERLY IVF PATIENTS||Hadassah Medical Organization||Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|45 Years|No|||August 2015|August 26, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02010164||54493|
NCT02009540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL02/2013|Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity|Efficacy of Peri-trigonal Onabotulinumtoxin Injections in the Treatment of Refractory Idiopathic Detrusor Overactivity (IDO): A Single-blind, Randomised Controlled Trial Comparing Peri-trigonal Injections vs Injection of the Bladder Body.||University Hospital of Limerick|No|Not yet recruiting|December 2013|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|November 29, 2013||||No||https://clinicaltrials.gov/show/NCT02009540||54540|
NCT02009553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/13|Pre-procedural Information Sheet Reduces Anxiety of Patients Before Urodynamic Studies|Pre-procedural Information Sheet Reduces Anxiety of Patients Before Urodynamic Studies||Assaf-Harofeh Medical Center|No|Recruiting|December 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|104|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who will be designated to have multichannel Uridynamic study in our center.|December 2013|December 9, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02009553||54539|
NCT02009566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00063233|Healthy Volunteer Visibility Study of Micromachined Tags for the Detection of Surgical Sponges|Healthy Volunteer Visibility Study of Micromachined Tags for the Detection of Surgical Sponges||University of Michigan|No|Withdrawn|July 2013|August 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|November 11, 2013||No|Initial PI Dr. Marentis left the University of Michigan hospital|No||https://clinicaltrials.gov/show/NCT02009566||54538|
NCT02010710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/38/01|Use of Decision Support in the Management of Labour|A Multicentre Randomised Controlled Trial of an Intelligent System to Support Decision Making in the Management of Labour Using the Cardiotocogram|INFANT|University College, London|Yes|Active, not recruiting|January 2010|May 2014|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|46000|||Female|16 Years|N/A|No|||December 2013|December 13, 2013|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02010710||54451|
NCT02010723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060508|Surgery Versus Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis|Comparison of Surgery Versus Foam Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis||Medical University of Vienna|Yes|Completed|June 2006|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||December 2013|December 12, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02010723||54450|
NCT02011282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM-TRIAL|Electro-Neuro-Muscular Stimulation in ICU|Electro-Neuro-Muscular Stimulation in Hospitalized Intensive Care Patients||University of Thessaly|Yes|Completed|October 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|85 Years|No|||August 2014|March 27, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02011282||54407|
NCT02011295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047251|Bone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions|Bone Marrow Aspirate Concentrate Supplementation to Microfracture in the Treatment of Osteochondral Lesions of the Talus|BMAC|Duke University|No|Recruiting|December 2013|August 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|95 Years|No|||February 2016|February 9, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011295||54406|
NCT02011503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFVLU003|Use of dHACM in the Treatment of Venous Leg Ulcers|A Randomized Controlled Clinical Trial Evaluating The Application Of Dehydrated Human Amnion/ Chorion Membrane (dHACM) Plus Standard Of Care Vs. Standard Of Care Alone In The Treatment Of Venous Leg Ulcers||MiMedx Group, Inc.|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02011503||54390|
NCT02011802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5568|Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision|Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision|SORKYSA|University Hospital, Strasbourg, France|No|Recruiting|December 2013|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011802||54368|
NCT02000713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00069508|Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)|Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)||University of Michigan|Yes|Recruiting|October 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02000713||55218|
NCT02000726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00073082|Neuroimaging Predictors of Antidepressant Treatment Outcome|||University of Michigan|No|Withdrawn|July 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|0|||Both|18 Years|55 Years|No|||December 2014|December 1, 2014|October 24, 2013|Yes|Yes|Lack of funding to complete the trial phase of the study.|No||https://clinicaltrials.gov/show/NCT02000726||55217|
NCT02000999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cytology 2013|Diagnosis of Bile Duct Strictures|The Diagnostic Yield of Malignancy Comparing Cytology, FISH and Molecular Analysis of Cell Free Cytology Brush Supernatant in Patients With Biliary Strictures Undergoing Endoscopic Retrograde Cholangiography (ERC): A Prospective Study||Washington University School of Medicine|No|Recruiting|November 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|Patients over the age of 18 undergoing ERCP for the diagnosis and treatment of bile duct        stricture|June 2015|June 1, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02000999||55196|
NCT02001272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-772|EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer|EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer|EWOC-1|Hospices Civils de Lyon|Yes|Recruiting|November 2013|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Female|70 Years|N/A|No|||January 2016|January 20, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001272||55175|
NCT02001285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJKim2|Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation|Comparison of the Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Ordinary Tracheal and Double-lumen Endobronchial Intubation During Propofol-remifentanil Total Intravenous Anesthesia||Jeju National University School of Medicine||Recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|60 Years|No|||November 2013|November 27, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02001285||55174|
NCT02001831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMF-3000|Multi-ingredient Nutrition Supplement in Older Adults|Effect of a Nutrition Supplement Containing Fish Oil, Whey Protein, Vitamin D, and Resveratrol, on Muscular and Cognitive Function in Older Adults||University College Dublin|No|Not yet recruiting|January 2014|January 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 28, 2013|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02001831||55132|
NCT02002325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCVC-STROKE-001|THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)|THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)|THAWS|National Cerebral and Cardiovascular Center|Yes|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002325||55094|
NCT02002351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ParacelsusHCBS 22/13|Prospective Study on Rehabilitation Patients With Pulmonary Hypertension and Other Pulmonary Diseases|||Paracelsus Harz Clinic Bad Suderode.|No|Active, not recruiting|December 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All rehabilitation patients with pulmonary diseases in the Paracelsus-Harz-Clinic Bad        Suderode will be included, starting December 2013,ending Novermber 2014.|January 2015|January 27, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002351|12 Months|55092|
NCT02002338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pterygium surgery|Different Surgical Techniques for Pterygium Surgery|Epidemiological Profile and Comparison Between Different Surgical Techniques for Pterygium Surgery||Instituto de Olhos de Goiania|Yes|Completed|February 2013|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|38|||Both|40 Years|85 Years|No|Non-Probability Sample|Individuals who were underwent pterygium surgery|November 2013|November 30, 2013|November 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02002338||55093|
NCT02002598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ2359|Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma|Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma||Columbia University|Yes|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002598||55073|
NCT02002611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19DDI13016|Drug-drug Interaction Study(Lobeglitazone, Warfarin)|Open Label, Randomized, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Lobeglitazone and Warfarin in Healthy Subjects||Chong Kun Dang Pharmaceutical|No|Completed|December 2013|May 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02002611||55072|
NCT02002871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EczemaCT01|Blue Light for Treating Eczema|Monocenter, Randomized, Intraindividual, Open Label, Exploratory Study Comparing 4 Weeks of Treatment With 453nm Blue Light With no Treatment in Patients With Eczema||Light and Health Venture|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||June 2015|June 24, 2015|December 2, 2013||No||No|March 16, 2015|https://clinicaltrials.gov/show/NCT02002871||55052|
NCT02002884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3072_1|Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy|Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy|XARA|Merz Pharmaceuticals GmbH|Yes|Recruiting|February 2014|April 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|344|||Both|2 Years|17 Years|No|||March 2016|March 22, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002884||55051|
NCT02003209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02228|Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer|A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2014|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|312|||Female|18 Years|N/A|No|||February 2016|March 24, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003209||55026|
NCT02003222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02229|Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia|A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults||National Cancer Institute (NCI)|Yes|Recruiting|December 2013|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|30 Years|70 Years|No|||December 2015|March 24, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003222||55025|
NCT02003482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060212|Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer|Prospective Observational Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer||University of Miami|No|Recruiting|March 2006|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with pathologic stage I-IV cancers of the head and neck (site of tumor origin        nasopharynx, parotid, oral cavity, oropharynx, larynx, or hypopharynx,) either following        gross total resection and requiring postoperative XRT for high-risk features or undergoing        definitive concurrent chemo-radiation.|February 2016|February 15, 2016|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02003482||55005|
NCT02003495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013L01041|Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine|Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China||Beijing Minhai Biotechnology Co., Ltd|No|Completed|October 2013|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|2195|||Both|2 Months|6 Years|Accepts Healthy Volunteers|||September 2015|September 19, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003495||55004|
NCT02003781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0581|Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center - HIgh Risk Cohort) CMERC-HI|||Yonsei University|No|Recruiting|October 2013|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|serum, whole blood, urine, DNA|Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|high risk cardiovascular disease patients and their relatives|December 2013|December 2, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003781||54982|
NCT02010736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UFRN 76519/2012|Loading Gait in Spatic Cerebral Palsy|Immediate Effects of a Single Treadmill Gait Training Session With Additional Loading on Kinematic Gait Parameters in Children With Spastic Cerebral Palsy|SCP|Universidade Federal do Rio Grande do Norte|No|Completed|September 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|5 Years|13 Years|No|||December 2013|December 13, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02010736||54449|
NCT02010983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55021|Achalasia and Dysplasia|Screening for Dysplasia in Longstanding Idiopathic Achalasia: a Prospective Study||Katholieke Universiteit Leuven|No|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02010983||54430|
NCT02010411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-038|Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis|Effects of Prolastin Aerosol Therapy on Bacterial Density in the Airways of Patients With Cystic Fibrosis||Université de Sherbrooke|No|Terminated|June 2004|October 2005|Actual|October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|14 Years|N/A|No|||December 2013|December 11, 2013|December 9, 2013||No|Technical problems with measure of CFU's. Outcomes published: PMID:16986483|No||https://clinicaltrials.gov/show/NCT02010411||54474|
NCT02011009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PP-02|Evaluation of Therapeutic Management in ESBL-infected Patients or Carriers by Providing and Sharing a Free Tool - the "ESBL toolKIT"and Interventional Study of a Prospective Cohort of HIV+ Patients Searching for Possible Sexual Transmission Factors in ESBL Carriers|Evaluation of Therapeutic Management in ESBL-infected Patients or Carriers by Providing and Sharing a Free Tool - the "ESBL toolKIT" and Interventional Study of a Prospective Cohort of HIV+ Patients Searching for Possible Sexual Transmission Factors in ESBL (Extended-spectrum ß-lacatamase-producing Bacteria) Carriers|Calires|Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2013|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02011009||54428|
NCT02011022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chzj-HDMTX-20131205|Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies|Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Significant Impact Factors and Establishment of a Clinically Relevant Model|HDMTX|The Children's Hospital of Zhejiang University School of Medicine|No|Completed|May 2009|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|291|||Both|N/A|18 Years|No|||December 2013|December 10, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02011022||54427|
NCT02011061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-108|Validation of Coronary Calcium Subtraction to Improve Diagnostic Accuracy of Coronary CT Angiography|Prospective International Study of Coronary Substraction Using 320 Row-detector CT|C-Sub320|Rigshospitalet, Denmark|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|55 Years|N/A|No|Probability Sample|Patients (N=200) referred for in hospital invasive coronary evaluation|October 2015|October 11, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02011061||54424|
NCT02011516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818755|Baclofen Effects on Marijuana Dependence|A Randomized Placebo-controlled Study of Baclofen on Brain and Behavioral Outcomes in Marijuana Dependence||University of Pennsylvania|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011516||54389|
NCT02011815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BreastCA_circa_mech|Exploring Biological Linkage Between Circadian Disruption and Cancer Progression|A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression||Seoul National University Hospital|Yes|Recruiting|November 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|236|Samples With DNA|Whole blood, serum Saliva Urine|Female|18 Years|70 Years|No|Non-Probability Sample|University (Tertiary) hospital, oncology clinic|November 2015|November 27, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011815||54367|
NCT02001051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140021|Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism|Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|99 Years|No|||July 2015|December 10, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001051||55192|
NCT02001311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|Effect of Chlorhexidine Gel on Bacterial Count During Fixed Orthodontic Treatment|Effect of Chlorhexidine Gel on Bacterial Count and Orthodontic Brackets During Fixed Orthodontic Treatment; In-vivo & In-vitro Study||King Abdulaziz University|Yes|Not yet recruiting|January 2014|June 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02001311||55172|
NCT02001324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0062|HMB- Data Collection Methods|Patient-based Outcomes for Heavy Menstrual Bleeding: Comparisons of Treatments and Methods of Data Collection||Women and Infants Hospital of Rhode Island|No|Terminated|March 2013|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|42|||Female|18 Years|51 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 27, 2013||No|this pilot project is no longer funded|No||https://clinicaltrials.gov/show/NCT02001324||55171|
NCT02001298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJKim3|Remifentanil and Nitroprusside for Controlled Hypotension|The Comparison of the Cardiovascular Effects of Remifentanil and Nitroprusside for Controlled Hypotension||Jeju National University School of Medicine||Completed|June 2012|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|20 Years|60 Years|No|||November 2013|December 3, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02001298||55173|
NCT02001597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02267|Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy|Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy|TRUS-RP|University of British Columbia|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Male|N/A|N/A|No|Non-Probability Sample|Men who undergo robot-assisted radical prostatectomy.|December 2013|December 4, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001597||55150|
NCT02001610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300549|Acidophilus Pearls Fecal Recovery Study|Clinical Trial of the Viability of LAB and Bifidobacteria From Acidophilus Pearls in Human Stool Samples||University of Florida|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02001610||55149|
NCT02001844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIA - FOs intervention|Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA|Single Blinded RCT to Investigate the Clinical Effectiveness of Pre-formed Semi-rigid Foot Orthoses (FOs) on Pain, Quality of Life and Dynamic of Gait With Children Diagnosed With Juvenile Idiopathic Arthritis (JIA).||University of Newcastle, Australia|No|Completed|May 2009|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|18 Years|No|||December 2013|December 3, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02001844||55131|
NCT02001857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/472|Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.|Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.||University Hospital, Ghent|No|Recruiting|September 2013|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2014|December 4, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02001857||55130|
NCT02002364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Journal nr. H-3-2012-001|Comparison of a Single Use (Ambu aScope) and a Reusable Flexible Optical Scope for Intubation Through a Supraglottic Airway Device (Aura-i)|A Comparison Between Flexible Single Use Endoscopes (Ambu aScopes) and Reusable Flexible Endoscopes Used as a Standard of Car When Intubation the Trachea Via an Aura-I Supraglottic Airway Device||Rigshospitalet, Denmark||Recruiting|November 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02002364||55091|
NCT02002377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections|The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Routine Ranibizumab Injections|SHIFT-2|St. Michael's Hospital, Toronto|No|Recruiting|April 2014|October 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|51 Years|N/A|No|||February 2016|February 12, 2016|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002377||55090|
NCT02002624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCP SC 2837|Patient-Specific Versus Conventional Instrumentation in TKA|RCT Multicenter Comparison of Patient-Specific Versus Conventional Instrumentation in Primary TKA|Visio|Cochin Hospital|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|85 Years|No|||December 2013|December 5, 2013|December 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02002624||55071|
NCT02002637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COT1-13-01|Feasibility of the Latella Implant System for Medial Osteoarthritis (OA)|Evaluation of the Latella Implant System for Lateralization of the Iliotibial Band to Offload the Medial Condyle for Pain Relief in Patients With Medial Osteoarthritis - A Safety Study||Cotera, Inc.||Active, not recruiting|November 2013|September 2018|Anticipated|September 2015|Actual|N/A|Interventional|N/A|1||||||Both|30 Years|65 Years|No|||January 2016|January 19, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002637||55070|
NCT02002897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCU-24684|Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma|Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study||Cairo University|Yes|Recruiting|April 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||September 2014|September 9, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02002897||55050|
NCT02002910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-DEFINE|Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect|Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect||Associations for Establishment of Evidence in Interventions|Yes|Active, not recruiting|October 2013|||November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|N/A|No|Non-Probability Sample|Patient who is adaptable to CAG and/or coronary revascularization|December 2013|January 3, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02002910||55049|
NCT02002923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_AF+PVI|Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|June 2013|December 2015|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002923||55048|
NCT02003248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0051|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's Disease|||Yonsei University|Yes|Recruiting|November 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|80 Years|No|||December 2013|December 1, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02003248||55023|
NCT02003508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP50939|Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination|Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination|Impress|The Alfred|No|Recruiting|January 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Penile sampling for HPV DNA|Male|17 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males aged 17-19 recruited from sexual health clinics and community sources|February 2016|February 23, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003508||55003|
NCT02003794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIS 001|Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)|Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)|IVIS|Chulalongkorn University|Yes|Terminated|May 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||August 2015|August 2, 2015|December 3, 2013||No|More progressive stroke in one arm|No||https://clinicaltrials.gov/show/NCT02003794||54981|
NCT02010437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVCA Trial|RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI|A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency.|EVCA|University of Hull|Yes|Withdrawn|January 2014|April 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 9, 2013|Yes|Yes|Study design has been substantially revised and a new registration will be made in the future.|No||https://clinicaltrials.gov/show/NCT02010437||54472|
NCT02010450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-017|Re-enforcing Safe Sleep Practices for Caregivers With Tangible Incentives|Re-enforcing Safe Sleep Practices for Caregivers With Tangible Incentives: Pilot Testing of the MSSC Physician Safe Sleep Taskforce Caregiver Incentive Toolkit||University of Kansas Medical Center|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010450||54471|
NCT02010996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSF20131201|Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass|Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass - a Randomized Control Clinical Trial||Changhai Hospital|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|72|||Both|10 Years|80 Years|No|||September 2014|September 30, 2014|December 3, 2013||No||No|September 30, 2014|https://clinicaltrials.gov/show/NCT02010996||54429|
NCT02011035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:133|Evaluating the Clinical Efficacy and Safety of Colflex|Evaluating the Clinical Efficacy and Safety of Colfelx||University of Manitoba|Yes|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents in town|March 2015|March 25, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02011035||54426|
NCT02011048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-097|Giant Ventral Incisional Hernia: Abdominal Wall Function, Respiratory Performance and Quality of Life|Giant Ventral Incisional Hernia: Characteristics of Abdominal Muscle-matrix, and Effect of Hernia Repair on Abdominal Wall Function, Respiratory Performance and Quality of Life|GIVINA|Bispebjerg Hospital|No|Active, not recruiting|November 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|Samples With DNA|Skeletal muscle biopsy, connective tissue biopsy, whole blood serum|Both|18 Months|N/A|No|Non-Probability Sample|Patients referred to the outpatient clinic at Digestive Disease Center, Bispebjerg        Hospital.|January 2016|January 12, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011048||54425|
NCT02002689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225XUS20|LDE225 for Patients With PTCH1 or SMO Mutated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors|SIGNATURE|Novartis|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|December 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02002689||55066|
NCT02002702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A1201|Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients||Novartis|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|20 Years|N/A|No|||September 2015|September 11, 2015|December 1, 2013|Yes|Yes||No|August 3, 2015|https://clinicaltrials.gov/show/NCT02002702||55065|
NCT02011529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44422-G|TEAMcare for Diabetes in Mental Health Centers|A Team Approach to Improve the Quality of Diabetes Care for Patients With Schizophrenia||University of Washington|No|Completed|November 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|70 Years|No|||October 2015|October 1, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02011529||54388|
NCT02011308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/13/03/02/08|KTP (Potassium-titanyl-phosphate) Laser Versus TUR-P (Transurethral Resection of Prostate)|The Effect of KTP Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia (BPH), a Prospective Randomized Study||Helsinki University|No|Recruiting|January 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|40 Years|90 Years|No|||December 2013|December 10, 2013|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011308||54405|
NCT02001064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Care4Today-13|Care4Today v2.0 Application for Improving Adherence to HIV Medications|Pilot Study of Care4Today v.2.0 Application for Improving Adherence to HIV Medications||University of California, San Diego|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|65|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001064||55191|
NCT02001025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Absorb/Xience 01|Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study|||Medical University of Vienna|No|Recruiting|November 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Patients with coronary artery disease|November 2013|November 27, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001025||55194|
NCT02001038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC 6608|Survey of Current Management of Orthopaedic Complications in CMT Patients|Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients||University College London Hospitals|No|Completed|February 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|16|||Both|N/A|N/A|No|Non-Probability Sample|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients        attending centres participating in INC.|January 2015|January 29, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001038||55193|
NCT02001337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006868|Examination of the Pancreas in New-onset Diabetes|Examination of the Pancreas in New-onset Diabetes (EXPAND Study)|EXPAND|Mayo Clinic|No|Recruiting|May 2013|August 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|60ml of whole blood. 5ml urine sample for pregancy testing (if necessary). Stool and saliva      samples may be collected.|Both|50 Years|85 Years|No|Probability Sample|Suspected or definite new-onset diabetes|January 2016|January 12, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001337||55170|
NCT02001350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIB-USG.GDA.PL|Carotid Ultrasound Study|Carotid Ultrasound Study||Noblewell|No|Completed|November 2013|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|23|||Both|18 Years|75 Years|No|Probability Sample|30 patients with longstanding or resistant hypertension|March 2015|March 27, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001350||55169|
NCT02001870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 553 01|Comparison of the Efficiency of Intra-uterine Insemination and in Vitro Fertilization in Women Over 37 Years|Comparison of the Efficiency of Intra-uterine Insemination and in Vitro Fertilization in Women Over 37 Years|AMPAGE|University Hospital, Toulouse|No|Recruiting|May 2014|September 2019|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Female|37 Years|42 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001870||55129|
NCT02002130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GABA-GAD|The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes|The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.|GABA|University of Alabama at Birmingham|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|4 Years|18 Years|No|||September 2015|October 12, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02002130||55109|
NCT02003846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 2013-02-10|Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants|Comparing the Effects of Bubble Nasal CPAP Versus Ventilator Nasal CPAP in Preterm Infants||Maimonides Medical Center|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|18|||Both|N/A|3 Months|No|Probability Sample|Premature infants admitted to the Neonatal Intensive Care Unit (NICU) at Maimonides        Medical Center.|June 2015|June 27, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02003846||54977|
NCT02004080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602714|CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe|CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe|CREACTIVE|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|No|Recruiting|October 2013|September 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|TBI patients admitted to ICU for specific care|March 2015|March 18, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004080|12 Months|54959|
NCT02004093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17931|A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer|A Randomized, Open-label Study of the Effect of Omnitarg in Combination With Carboplatin-based Chemotherapy Versus Carboplatin-based Therapy Alone on Treatment Response in Patients With Platinum-sensitive Recurrent Ovarian Cancer||Hoffmann-La Roche||Completed|December 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Female|18 Years|N/A|No|||November 2014|November 25, 2014|December 3, 2013||No||No|July 31, 2014|https://clinicaltrials.gov/show/NCT02004093||54958|
NCT02004106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28920|A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors|AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS||Hoffmann-La Roche||Recruiting|December 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004106||54957|
NCT01999920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6856|Vilazodone for Separation Anxiety Disorder|Vilazodone for Separation Anxiety Disorder||New York State Psychiatric Institute|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||October 2015|October 13, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999920||55279|
NCT02002936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012004|Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study|Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Extension Study||SymBio Pharmaceuticals||Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||December 2013|December 11, 2013|December 1, 2013||||No||https://clinicaltrials.gov/show/NCT02002936||55047|
NCT02003235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-TMSC-1|Assessment of Device for Treatment of Amblyopia|||Visior Technologies Ltd.|No|Recruiting|October 2013|||October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|8 Years|No|||December 2013|March 26, 2014|December 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02003235||55024|
NCT02003261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAKENHI 25705018|Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)|An Assessor-blinded, Randomized, 20-week, Parallel-group, Superiority Study to Compare the Efficacy of Transdiagnostic Cognitive Behavioral Therapy Versus Waiting-list in Depressive and Anxiety Symptoms of Depressive and Anxiety Disorders||National Center of Neurology and Psychiatry, Japan|No|Recruiting|November 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|20 Years|65 Years|No|||April 2015|April 27, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003261||55022|
NCT02003274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verona Artificial Pancreas|Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas|Meal Glucose Regulation in Type 1 Diabetes on Insulin Pump Therapy: Towards a Better Understanding of the Glucose-Insulin System.||Azienda Ospedaliera Universitaria Integrata Verona|No|Recruiting|October 2013|October 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|December 3, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003274||55021|
NCT02003521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426195-4|Impact of Lung Flute Therapy on Asthma|Impact of Lung Flute Therapy on Asthma||Medical Acoustics LLC|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|Samples With DNA|Sputum|Both|12 Years|N/A|No|Non-Probability Sample|We are seeking patients diagnosed with asthma. All subjects will have already been        screened as a consequence of their being established asthma patients at the clinical        sites. Patients will be identified and screened by their attending physician who will        notify the investigators. The investigators are responsible for recruiting identified        subjects.|October 2014|October 27, 2014|November 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003521||55002|
NCT02003534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-BRI-1002|A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension||APOTUS|Allergan|No|Completed|July 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|376|||Both|N/A|N/A|No|||June 2014|June 24, 2014|December 2, 2013|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT02003534||55001|
NCT02003807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0326|Incidence and Predictive Factor of Irritable Bowel Syndrome After Acute Diverticulitis in Korea|||Yonsei University|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|102|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who had admitted Severance hospital, Seoul, South Korea.|December 2013|December 2, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003807||54980|
NCT02003820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pedidentalautism|Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder|Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism||Yale University|No|Active, not recruiting|July 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|5 Years|14 Years|No|||January 2015|January 23, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003820||54979|
NCT02010190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASCC|Vascular Assessment in Adult Survivors of Childhood Cancer|Vascular Assessment in Adult Survivors of Childhood Cancer||St. Jude Children's Research Hospital|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|404|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|202 potential cancer survivor participants will be recruited from the St. Jude Children's        Research Hospital (SJCRH) SJLIFE Cohort Study and stratified by survival time (10-14,        15-19, 20-24, 25-29, and ≥ 30 years).        202 potentially eligible comparison group participants will be recruited from the parent,        sibling, relative or friend population who accompany patients to SJCRH. Control        participants will not be a first-degree relative of a survivor participant. Potential        comparison group members will be matched to potentially eligible participants by gender        and age group.|October 2015|October 16, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010190||54491|
NCT02010749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9052A1-3001 PHL|Protein Concentration in Infant Formula: A Follow-up Study of Growth at 2 Years of Age|Protein Concentration in Infant Formula: A Follow-up Study of Growth at 2 Years of Age||Nestlé|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|267|Samples Without DNA|stool|Both|2 Years|3 Years|No|Probability Sample|Children 2 years of age who were enrolled in the Wyeth Nutrition study|December 2013|December 9, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02010749||54448|
NCT02010463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK085605-04|Neuroimaging Study of Factors Related to Exercise|Neuroimaging Studies of Reward, Impulsivity, and Adherence to an Exercise Program||University of Kansas Medical Center|No|Active, not recruiting|October 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010463||54470|
NCT02011321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-CLEVIDIPINE-PV|Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)|Clevidipine for Vasospasm After Subarachnoid Hemorrhage|CLEVAS|Henry Ford Health System|No|Not yet recruiting|March 2014|September 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2013|December 10, 2013|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011321||54404|
NCT02011334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28700|A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.|A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA||Hoffmann-La Roche||Active, not recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02011334||54403|
NCT02002988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_PAF01|Botulinum Toxin Injection Prevent Paroxysmal Atrial Fibrillation|Endomyocardial Botulinum Toxin Injection Can Prevent Drug-Resistant Paroxysmal Atrial Fibrillation: Pilot Study||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002988||55043|
NCT02001415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z131107002213127|Efficacy Study of Different Lens Treatments on Chinese Adolescent Myopia|Randomized Controlled Trial of Different Lens Treatments on Chinese Adolescent Myopia|DLTCAM|Peking University People's Hospital|Yes|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|10 Years|15 Years|No|||September 2015|October 19, 2015|November 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02001415||55164|
NCT02001662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-ME-13|Adductor Canal Block and Arthroscopic Knee Surgery, High Pain Responders|The Analgesic Efficacy of the Adductor Canal Blockade in High Pain Responders After Arthroscopic Knee Surgery - a Randomized Clinical Trial||Glostrup University Hospital, Copenhagen|Yes|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||December 2013|December 5, 2013|April 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001662||55145|
NCT02001363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-099-01|Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury|Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction||Chinese PLA General Hospital|Yes|Recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001363||55168|
NCT02001623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN701|HuMax®-TF-ADC Safety Study in Patients With Solid Tumors|First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor||Genmab|Yes|Recruiting|November 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001623||55148|
NCT02001636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DONM-UHOH-386|Effect of Protein Supplementation After Bariatric Surgery|Impact of Protein Supplementation After Bariatric Surgery - a Randomized, Controlled, Double Blind Pilot Study|EPEAB|University of Hohenheim||Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|35|||Both|18 Years|65 Years|No|||November 2013|November 27, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02001636||55147|
NCT02002650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131106-7|Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|A Prospective, Randomized, Controlled Trial of Pre-operational Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in Average-risk Patients.|Indomethacin|Fourth Military Medical University|Yes|Completed|December 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2600|||Both|18 Years|90 Years|No|||February 2016|February 2, 2016|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02002650||55069|
NCT02002962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_AFL|Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter|Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter to Prevent Post-procedural Atrial Fibrillation||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2013|January 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02002962||55045|
NCT02003287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-282|Comparing FEES to VFSS in Diagnosing Laryngeal Penetration and Aspiration in Infants in the NICU|Determining the Efficacy of Using FEES Compared to VFSS to Diagnose Laryngeal Penetration and Aspiration in Infants in the Neonatal Intensive Care Unit (NICU)||Baylor Research Institute|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|25|||Both|37 Weeks|N/A|No|||March 2015|March 5, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003287||55020|
NCT02003573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.30|Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)|An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia||Boehringer Ingelheim||Active, not recruiting|January 2014|February 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|127|||Both|65 Years|N/A|No|||March 2016|March 7, 2016|December 3, 2013||||No||https://clinicaltrials.gov/show/NCT02003573||54998|
NCT02003586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1462|Effect of a Plant-based Ingredient on Generalized Hormonal Responses|Effect of a Plant-based Ingredient on Generalized Hormonal Responses||Unilever R&D|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2014|April 8, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02003586||54997|
NCT02003859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCH-001|Predictive Value of pCLE Findings in Pediatric IBD|Predictive Value of pCLE Findings in Pediatric IBD||Scientific Center of Children's Health RAMS|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|None Retained|Optical biopsy|Both|10 Years|21 Years|No|Probability Sample|Pediatric patients with IBD from all over Russia, treated from IBD in our Center|November 2014|November 18, 2014|November 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02003859||54976|
NCT02004119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4577-002|Phase 2 Study of KHK4577|Randomized Double-blind Placebo-controlled Study of KHK4577 in Patients With Atopic Dermatitis||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|20 Years|64 Years|No|||March 2016|March 15, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004119||54956|
NCT02004132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15281|A Study of Axiron® in Healthy Participants|A Phase 1, Single-Dose Study to Evaluate Testosterone on Clothing After Axiron® Use in Healthy Male Subjects||Eli Lilly and Company|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|December 3, 2013|No|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT02004132||54955|
NCT02002949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2314193|Conventional Hemodialysis Vs Short Daily Hemodialysis for Patients Coming From Peritoneal Dialysis (HAPD/CAPD)|Cost-Utility of Conventional Hemodialysis (CHD) Vs Short Daily Hemodialysis (SDHD) for Patients Coming From Peritoneal Dialysis (HAPD/CAPD): A Randomized Controlled Trial|CHDvsSDHD|Azienda Ospedaliero-Universitaria Consorziale|Yes|Recruiting|February 2014|December 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02002949||55046|
NCT02003547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA0076-M-101|A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects|A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects||Amakem, NV|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|21|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003547||55000|
NCT02003560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIO-APERT_01|Accelerated Partial Breast Irradiation With 3D-CRT and IMRT|Accelerated Partial Breast Irradiation After Breast Conserving Surgery for Low-risk Invasive Breast Cancer: 3D Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) - Prospective Phase II Study|APERT|National Institute of Oncology, Hungary|No|Active, not recruiting|December 2006|March 2024|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|40 Years|N/A|No|||August 2014|August 12, 2014|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003560||54999|
NCT02003833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLLA SkinQ|Poly-L-lactic Acid for Skin Quality|Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality||Sadick Research Group|No|Completed|September 2013|September 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003833||54978|
NCT02010203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS410-101|A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT|A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)||Heat Biologics|Yes|Active, not recruiting|December 2013|May 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010203||54490|
NCT02010216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML23037|A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)|Non-Randomized Phase IV Trial on Efficacy and Safety of Actemra in the Treatment of Adult Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|December 4, 2013|No|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT02010216||54489|
NCT02010476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3971|Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men|Cerebrospinal Fluid Changes in Insulin-Resistant Men|ADDM|University of Eastern Finland|No|Active, not recruiting|November 2013|December 2015|Anticipated|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|58|Samples With DNA|whole blood, serum, plasma, white cells, urine, cerebrospinal fluid|Male|55 Years|70 Years|No|Non-Probability Sample|the research data sources of METSIM study (METabolic Syndrome In Men; professor Markku        Laakso) performed in the Department of Internal Medicine, University of Eastern Finland|December 2015|December 14, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010476|1 Day|54469|
NCT02010762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.45391.018.13|The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease|The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial|DETECT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|136|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02010762||54447|
NCT02010775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-130|Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy|||Allergan|Yes|Recruiting|January 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|50 Years|No|||January 2016|January 11, 2016|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010775||54446|
NCT02010788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-134|Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea|||Allergan|No|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with urinary incontinence due to NDO or OAB.|January 2016|January 8, 2016|December 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02010788||54445|
NCT02002416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-met in gastric cancer|Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma|Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma: the Comparison Between the Primary and Metastatic Lesions, Early Stage and Advanced Stage||Sun Yat-sen University|No|Active, not recruiting|January 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|200|Samples Without DNA|Paraffin-embedded tumor tissue|Both|18 Years|70 Years|No|Non-Probability Sample|We retrospectively collect the metastatic gastric cancer patients who received a surgical        resection of both primary diseases and metastatic lesions during January 2006 and December        2012. c-MET protein expression and amplification are assessed in paraffin-embedded tissues        of the primary and metastatic diseases obtained from 100 patients by immunohistochemistry        (IHC) and Fluorescence in situ hybridization (FISH). In order to compare c-Met expression        and amplification between early and advanced stage, we will match 100 early stage (stage I        and stage II) patients. MET IHC will employ the Dako MET IHC assay and supplied assay        protocol and pathology scoring guideline.|November 2013|November 29, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02002416||55087|
NCT02002429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086597|Medial Branch Blocks vs. Intra-articular Injections: Randomized, Controlled Study|||Johns Hopkins University|No|Recruiting|December 2013|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02002429||55086|
NCT01987778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131105/Styrka|Health Effects of Resistance Training on Postmenopausal Women|Health Effects of Resistance Training on Postmenopausal Women||Ostergotland County Council, Sweden|No|Recruiting|November 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|45 Years|N/A|No|||February 2014|February 5, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987778||56207|
NCT01979640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_bloodtightseal|Adequate Additional Bronchial Cuff Volume to Achieve Blood-tight Seal After Air-tight Seal in Double Lumen Tube|||Seoul National University Hospital|Yes|Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|132|||Both|20 Years|85 Years|No|||November 2013|November 3, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979640||56831|
NCT01979653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0615|A Comparision of Midazolam-dexmedetomidine With Dexmedetomidine Alone for Hemodynamic Stability and Quality of Sedation in Elderly Patients Under Spinal Anesthesia|||Severance Hospital|No|Recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|65 Years|N/A|No|||November 2013|November 3, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979653||56830|
NCT01979900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTao|Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis|Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in High Risk Groups of Tuberculosis Infection||Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|Yes|Active, not recruiting|October 2013|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|10000|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||August 2014|May 18, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979900||56811|
NCT01980173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/VL-04|Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care|Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care|Bakri|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|66|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01980173||56790|
NCT01980420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001|Prospective Study of the Impact of Sleeve Gastrectomy on Gastro-esophageal Junction Function|Prospective Study of the Impact of Sleeve Gastrectomy on Gastro-esophageal Junction Function|FFSI|IHU Strasbourg|No|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01980420||56771|
NCT01980693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SonicBone Medical|Ultrasound Evaluation of Bone Age in Healthy Children|Cohort Study to Investigate the Relationship Between Ultrasound Apparatus Results (SonicBone's BAUS) and Skeletal Maturity Status (Bone Age) Among Healthy Children and Adolescence||Clalit Health Services|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||April 2013|March 5, 2015|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980693||56750|
NCT01980706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1743|Efficacy and Safety of High Dose Baclofen for Alcohol Dependence|Efficacy and Safety of High Dose Baclofen for Alcohol Dependence||University of North Carolina, Chapel Hill|Yes|Recruiting|November 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||February 2016|February 19, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980706||56749|
NCT01980953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28619|A Study of the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects||Genentech, Inc.||Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980953||56730|
NCT01980966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV28985|A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model||Genentech, Inc.||Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|101|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01980966||56729|
NCT01981226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007055R|Sonoelastographic Changes After Low Energy Extracorporeal Shock Wave Therapy (ESWT) in Plantar Fasciitis|Sonoelastographic Changes After Low Energy Extracorporeal Shock Wave Therapy (ESWT) in Plantar Fasciitis||National Taiwan University Hospital||Recruiting|September 2010|||September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981226||56709|
NCT02005302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJFH-EC/2013-076|Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition|Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients||Beijing Friendship Hospital|Yes|Enrolling by invitation|January 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|80 Years|No|||December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005302||54865|
NCT02005601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-016|Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?|Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?||Hospital for Special Surgery, New York||Completed|November 2013|August 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|25 Years|75 Years|No|||July 2015|January 29, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005601||54842|
NCT02005926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCP07|The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes|Phase II Trail of Removing Sonographic Abnormal Lymph Node in Sentinel Lymph Node Biopsy of Breast Cancer Patient||Peking University|No|Completed|May 2010|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|N/A|N/A|No|||June 2014|June 16, 2014|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005926||54817|
NCT02006524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-85|Screening for Silent Atrial Fibrillation During Influenza Vaccination|Screening for Silent Atrial Fibrillation During Influenza Vaccination||UMC Utrecht|Yes|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|February 18, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006524||54771|
NCT02006862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-OLZ-EL-40|eVAluatIon of OLanzapine TreatmEnT|Olanzapine in Standard Clinical Practice. 6-month Efficacy and Safety Monitoring|VIOLET|Elpen Pharmaceutical Co. Inc.|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|468|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with schizophrenia or bipolar disorders|August 2014|March 13, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02006862||54745|
NCT02007460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-P1|The Influence of High Impact Exercise on Musculoskeletal Health in Older Men|The Influence of High Impact Exercise on Musculoskeletal Health in Older Men|Hiphop|Loughborough University|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02007460||54700|
NCT01986894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-CP-010|A Phase 1 QT Study in Healthy Male Subjects|A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects|QT/QTc|Celgene|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|72|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986894||56275|
NCT01986907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AIT02|Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye|A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With BCVA Below 2/10 and/or Second Affected Eye|TWEYES|Novartis|No|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1044|||Both|50 Years|N/A|No|||March 2016|March 9, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01986907||56274|
NCT01978496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A160-102|Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine|A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine||Pfizer|Yes|Completed|July 1996|December 1997|Actual|December 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1334|||Both|18 Years|78 Years|No|||November 2013|November 11, 2013|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978496||56919|
NCT01987180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICU2Home Feasability|Using Smartphones in the Neonatal Intensive Care Unit|NICU-2-HOME: Using HIT to Support Parents of NICU Graduates Transitioning Home||Northwestern University|No|Completed|January 2013|June 2015|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|No|Probability Sample|Parents of Very Low Birth Weight infants preparing for transition to home|October 2015|October 5, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01987180||56253|
NCT01979029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Left Colic Artery|Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery|Affection on Anastomotic Blood Flow and the Lymph Nodes Dissection Between Division at the Root of the Inferior Mesenteric Artery and Preserving the Left Colic Artery in Rectum Cancer Surgery|POTLCAORCS|First Hospital of Jilin University|No|Recruiting|February 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||October 2014|October 12, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979029||56878|
NCT01979679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6481|A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone|A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone||University of California, Irvine|Yes|Completed|December 2008|||October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|60 Years|No|||November 2013|November 1, 2013|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979679||56828|
NCT01979692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0526-ST-CTIL|Feasibility of Confocal Laser Microscopy (CLM)in the Computed Tomography-guided Needle Biopsy of Pulmonary and Mediastinal Lesions|Feasibility of Confocal Laser Microscopy CLM in the Computed Tomography-guided Needle Biopsy of Pulmonary and Mediastinal Lesions||Sheba Medical Center|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|80 Years|No|||May 2014|May 12, 2014|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01979692||56827|
NCT01979705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 07/2013|Detect Novel Pathogens and Characterize Emerging Infections|A Prospective Study to Detect Novel Pathogens and Characterize Emerging Infections|NP|Singapore General Hospital|No|Recruiting|July 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|1. Blood        2. Throat Swab        3. Nasal Swab        4. ETT Swab (if patient is intubated)        5. Urine        6. Stool|Both|N/A|N/A|No|Non-Probability Sample|This is a prospective study with inclusion criteria as specified below:        Inclusion criteria:        Any person admitted to Singapore General Hospital or seen as an outpatient in the        Specialist Outpatient Clinic who has:        1. clinical history and/or clinical syndromes compatible with a suspected        novel/re-emerging infective etiological agent.|November 2013|November 3, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01979705||56826|
NCT01979666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9707-AL-CTIL|Nitrate Patch Use as Treatment of Knee AVN|the Effect of a Nitrate Patch on the Healing Process of AVN of the Knee||Sheba Medical Center|No|Not yet recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2014|January 21, 2014|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979666||56829|
NCT01979926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-N02RS1|Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis|Double-blind, A Multicenter, Randomized, Placebo-controlled, Parallel, Phase 2 Study to Comparative Evaluate the Efficacy of N02RS1 600mg/Day, 12,00mg/Day in Korean Patients With Acute and Chronic Bronchitis||PharmaKing|Yes|Completed|November 2013|March 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|20 Years|75 Years|No|||May 2014|May 29, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01979926||56809|
NCT01979913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-260213|An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More|An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More||Ordination Dr. Hommer|Yes|Completed|October 2013|September 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979913||56810|
NCT01980186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTC-002|Transcranial Ultrasonography Using Linear 2D Imaging of the Brain|Transcranial Ultrasonography Using Linear 2D Imaging of the Brain and Surrounding Tissues||Brain Treatment Center|Yes|Enrolling by invitation|November 2013|||November 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|100|||Both|6 Months|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with autism of any age and their neurotypical otherwise healthy siblings of        any included age (6 months to 21 years).|November 2013|November 8, 2013|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980186||56789|
NCT01980199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXI VL 001|Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan|Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan||Drugs for Neglected Diseases|No|Terminated|November 2013|September 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|15 Years|60 Years|No|||July 2014|October 29, 2015|November 4, 2013||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01980199||56788|
NCT01980433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121105|Inhibitory rTMS in Dystonic Wilson Patients|Study of Writing Improvement in Patients With Wilson Disease and Dystonia After One Session of Inhibitory Repetitive Transcranial Magnetic Stimulation|WILSTIM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||May 2015|June 1, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980433||56770|
NCT01980719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038766|Molecular Determinants of Persistent Cancer Related Fatigue|Molecular Determinants of Persistent Cancer Related Fatigue|MDOF|University of Michigan|No|Completed|July 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female breast cancer survivors|November 2013|March 25, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01980719||56748|
NCT01980979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remodulin in ACHD|Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension|Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension||University of California, Los Angeles|No|Terminated|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|September 24, 2013||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01980979||56728|
NCT01981239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chhwang4|Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration|Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration;Prospective, Positive-controlled, Single-blind, Single Cohort Clinical Study of Efficacy||Ulsan University Hospital|Yes|Withdrawn|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|N/A|N/A|No|||December 2014|December 1, 2014|November 4, 2013||No|no participation over the long period|No||https://clinicaltrials.gov/show/NCT01981239||56708|
NCT01981252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-137|Peri-orbital and Peri-oral Wrinkle Reduction Trial|Evaluation of the Safety and Efficacy of the Ulthera® System for Wrinkle Reduction in the Peri-orbital and Peri-oral Regions||Ulthera, Inc|Yes|Terminated|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|November 4, 2013|Yes|Yes|Lack of efficacy.|No||https://clinicaltrials.gov/show/NCT01981252||56707|
NCT02005939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-01Expl|Effect of Biophenol-rich Pomegranate Extract Intake on Blood Pressure, Hormones, Body Composition and Quality of Life in Healthy Volunteers.|Effect of Pomegranate Extract Intake on Anthropometric, Metabolic and Hormonal Parameters in Human Volunteers: a Double Blinded, Placebo Controlled, Randomised, Exploratory 4 Week Trial.|POM-01Expl|Queen Margaret University|Yes|Completed|April 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005939||54816|
NCT02006238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03052|A Comparison of Farabloc Fabric With Placebo on Alleviation Hot Flash in Menopausal Women|A Comparison of Farabloc Fabric With Placebo on Alleviation Hot Flash in Menopausal Women|Flash|University of British Columbia|No|Recruiting|February 2014|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|45 Years|60 Years|No|||June 2014|June 19, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006238||54793|
NCT02006875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-wf-eva-04|rTMS Study to Improve Functional Performance for Patients With Stroke|The Potential Benefit of 1-Hz rTMS to Improve Gross Motor Function After Stroke: A Randomized Controlled Trial.||Taipei Medical University WanFang Hospital|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006875||54744|
NCT02006888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-04|The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery|||ICON Bioscience Inc||Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|394|||Both|40 Years|N/A|No|||March 2015|March 23, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006888||54743|
NCT02007473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1974/MCP|A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma|A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma||Maco Productions S.A.S.|No|Completed|July 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients requiring plasma transfusion|September 2015|September 8, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02007473||54699|
NCT01978509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003983|The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies|The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies||Mayo Clinic|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01978509||56918|
NCT01978795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD056610|Interactive Training in Sports Concussion Prevention and Management|The Effectiveness of a Web-Based Resource in Improving Post-Concussion Management in High Schools||Oregon Center for Applied Science, Inc.|No|Completed|August 2011|February 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|November 6, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01978795||56896|
NCT01979016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1307|Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|No|Completed|December 2013|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979016||56879|
NCT01979042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0150-CTIL|Urinary Markers for Unilateral Kidney Obstruction|Can Modern Urinary Markers be Used as Markers for Acute Kidney Failure Due to Stone Obstruction||Carmel Medical Center|No|Recruiting|October 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|urine|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|100 men and women - 80 presented in the ER with a unilateral ureteral stone and 20        presented for ambulatory surgery not related to urinary stones or bladder outlet        obstruction|July 2015|July 9, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01979042||56877|
NCT01980238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cannula ileostomy|Defunctioning Cannula Ileostomy After Lower Anterior Resection of Rectal Cancer|Defunctioning Cannula Ileostomy After Lower Anterior Resection of Rectal Cancer.||First Affiliated Hospital of Zhejiang University|No|Active, not recruiting|January 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||November 2013|November 16, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01980238||56785|
NCT01979939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-102|UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects|A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C||Bristol-Myers Squibb|No|Completed|December 2013|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979939||56808|
NCT01979952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.187|Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)|A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months||Boehringer Ingelheim||Recruiting|November 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|November 4, 2013||||No||https://clinicaltrials.gov/show/NCT01979952||56807|
NCT01980212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRSTILC|Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer|Serum Thioredoxin Reductase Activity Research in First-line Chemotherapy Advanced Non-small Cell Lung Cancer||Hunan Province Tumor Hospital|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|3-4 ml whole blood was obtained and then centrifuged and stored at -20 ℃|Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with non-small lung cancer and receiving platinum based first-line        chemotherapy in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya        School of Medicine Central South University/Hunan Province Tumor Hospital|February 2016|February 14, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980212||56787|
NCT01980446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091118|Cognitive Auditory Evoked Potential After Cardiac Arrest: Interest of Mismatch negativiTY|Cognitive Auditory Evoked Potential After Cardiac Arrest: Interest of Mismatch negativiTY: The CAPACITY Study|CAPACITY|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|142|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980446||56769|
NCT01980732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET0017|68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors|68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors||Stanford University|Yes|Available|November 2013|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 4, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT01980732||56747|
NCT01980992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0197|Oral Immunotherapy for Wheat Allergy|Oral Immunotherapy for Wheat Allergy|Wheat OIT|Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|October 2013|April 2017|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|4 Years|30 Years|No|||March 2016|March 16, 2016|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01980992||56727|
NCT01981005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28989|A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802|A PHASE 1, SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE AND PHARMACOKINETICS OF AN INTRAVENOUS TRACER OF [14-C]-RO5424802 IN HEALTHY MALE SUBJECTS||Hoffmann-La Roche||Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981005||56726|
NCT01981018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPP_0174|MAPP: Imagery-focused Therapy for Bipolar Disorder|Mood Action Psychology Programme (MAPP): a Case Series Investigation of Brief Imagery-focused Cognitive Therapy (imCT) for Bipolar Disorder.|MAPP|Medical Research Council Cognition and Brain Sciences Unit|No|Completed|November 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981018||56725|
NCT01981265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109024RC|Genome-wide Study for Disease Susceptibility Gene(s) in Patients With Hand Osteoarthritis|Genome-wide Study for Disease Susceptibility Gene(s) in Patients With Hand Osteoarthritis||National Taiwan University Hospital||Recruiting|February 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|1. Participating patients must be at least 45 years of age.          2. All Patients must have radiographic hand OA.          3. All Patients must be of Han Chinese ethnic background.          4. Enrolled participants must give voluntary written consents to participate in this             study.|November 2013|November 5, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981265||56706|
NCT01981486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3441008|A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults|A Phase I, Placebo Controlled, Randomized, Subject-And Investigator-Blind, Sponsor-Open, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers||Pfizer|No|Withdrawn|June 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981486||56689|
NCT01981499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3441009|A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults|A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects||Pfizer|No|Terminated|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|31|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|November 5, 2013|No|Yes|The trial was prematurely terminated on 01April2014 due to safety concerns.|No||https://clinicaltrials.gov/show/NCT01981499||56688|
NCT02005952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/078/992|Effectiveness of Two Methods for Quality Control in Primary Care Spirometry|Effectiveness of Two Methods for Quality Control in Primary Care Spirometry||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|February 2010|June 2012|Actual|March 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3000|||Both|15 Years|N/A|No|Non-Probability Sample|Patients requiring spirometry performing a diagnostic or tracking control for respiratory        disease|May 2009|December 4, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02005952|1 Day|54815|
NCT02006251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 13-940|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2013|||||N/A|N/A|N/A||||||||||||||July 9, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006251||54792|
NCT02006264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-329|Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring|Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring|TDF IVR-001|Albert Einstein College of Medicine of Yeshiva University||Completed|November 2013|||December 2014|Actual|Phase 1|Interventional|Allocation: Randomized|2|||30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006264||54791|
NCT02006576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503-13-ET|Prostaglandin Inhibition for Emphysema|Proof-of-concept Study to Demonstrate Inhibition of Prostaglandin E (PGE) Production and Associated Biological Effects in the Lower Respiratory Tract by Ibuprofen.|PIE|University of Nebraska|Yes|Recruiting|January 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|46 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 13, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006576||54767|
NCT02006589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200956|Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions|An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006589||54766|
NCT02006225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-MB-0693-12-CTIL|Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.|GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.|GCSF|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2014|February 2020|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|30 Years|No|||April 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006225||54794|
NCT02006550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100200|Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples|Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples||University of Miami||Recruiting|June 2010|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|These are samples derived from discarded tissue obtained through the routine surgical        resection of tumors|December 2015|December 7, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006550||54769|
NCT02007174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-002-2011|Bevacizumab Injection for Recurrent Pterygium|Triple Subconjunctival Bevacizumab Injection for Early Recurrent Pterygium. One Year Follow-up||Instituto de Oftalmología Fundación Conde de Valenciana|Yes|Completed|March 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||December 2013|December 5, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02007174||54721|
NCT02007187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ZX09304-07V1.2|Danhong Injection in the Treatment of Unstable Angina Pectoris|A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris||China Academy of Chinese Medical Sciences|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|35 Years|75 Years|No|||March 2016|March 17, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007187||54720|
NCT02007746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120222|Liver Fibrosis in Sickle Cell Disease|Assessment of Liver Fibrosis in Patients With Sickle Cell Disease||University of Miami|No|Recruiting|July 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|10 Years|65 Years|No|Non-Probability Sample|30 subjects with sickle cell disease and iron overload. 30 control subjects without        history of chronic transfusions (less than 4 transfusions in lifetime) and without        evidence of liver pathology.|December 2015|December 18, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007746||54678|
NCT01978522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUB-1112-QT|The NICOLA Questionnaire Trial (NICOLA-QT)|The NICOLA Questionnaire Trial (NICOLA-QT): Effect of Timing and Mode of Delivery on Completion and Completeness of a Self-assessment Questionnaire in a Longitudinal Study in People Over Age of 50.||Queen's University, Belfast|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Anticipated|8500|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978522||56917|
NCT01978808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307045RINC|Efficiency Study of the EUS-FNA Needles With and Without a Side Port in Pancreatic Masses|A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUS-FNA Needles With and Without a Side Port in Pancreatic Masses||National Taiwan University Hospital|No|Recruiting|October 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|90 Years|No|Probability Sample|patients referred for EUS-FNA of pancreatic masses|November 2013|November 11, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01978808||56895|
NCT01979978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:205|Healthy Buddies Manitoba|Healthy Buddies Manitoba: A Cluster Randomized Controlled Effectiveness Trial of Peer Mentoring for Healthy Eights in Children.||University of Manitoba|No|Completed|September 2009|May 2013|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|647|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||October 2013|November 1, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979978||56805|
NCT01979991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038447|Model-Based Image Reconstruction for X-Ray CT in Lung Imaging|Model-Based Image Reconstruction for X-Ray CT in Lung Imaging||University of Michigan|Yes|Completed|August 2010|December 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|184|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979991||56804|
NCT01988701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12208|Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease|Lymphocyte Profiles and Activation Status in the Development of Chronic Graft-versus-Host Disease||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|February 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|0|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients who have received an autologous stem cell transplant and stem cell transplant at        The Ohio State University.|February 2015|February 26, 2015|November 14, 2013||No|Decision made by the PI to withdraw study|No||https://clinicaltrials.gov/show/NCT01988701||56137|
NCT01979965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0173|Effect of Ranolazine on Valvular Disease in Patients With Pacemakers|Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy|REIN-MR|University Cardiology|Yes|Enrolling by invitation|November 2013|September 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01979965||56806|
NCT01980225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VanLanduyt2013|Implantation Rate of Vitrified-warmed Collapsed Blastocysts|Randomized Controlled Trial Comparing the Implantation Rate of Vitrified-warmed Blastocysts With and Without Artificial Shrinkage Before Vitrification||Centre for Reproductive Medicine, Belgium|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|270|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01980225||56786|
NCT01980459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#071317|Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis|Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis|MagInGlu|George Washington University|No|Recruiting|October 2013|December 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|20 Years|70 Years|No|||August 2015|August 18, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01980459||56768|
NCT01980745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0697/07|CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS|DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS||University of Sao Paulo General Hospital|No|Active, not recruiting|February 2002|November 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|70 Years|No|||September 2013|November 4, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01980745||56746|
NCT01981031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT005|A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes|Phase 1 Study to Assess the Efficacy and Safety of BioChaperone® Combo and Humalog® Mix 25 in Subjects With Type 1 Diabetes||Adocia|No|Completed|November 2013|August 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|64 Years|No|||September 2014|September 1, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01981031||56724|
NCT01981044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURE-007|A SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair|||Allergan||Active, not recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||December 2015|December 18, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981044||56723|
NCT01981278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100458|A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 250-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 250-mg Tablet Under Fasted Conditions in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981278||56705|
NCT01981525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140005|A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome|A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|99 Years|No|||June 2015|February 6, 2016|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01981525||56687|
NCT01981798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Praev123|Effect of an Outpatient Intervention Program in Patients With Chronic Back or Neck Pain|The Long-term Effect of an Outpatient Intervention Program With a Behavioral Therapy Approach in Patients With Chronic Back or Neck Pain With a Focus on Psychosocial Aspects|CPS|Orthopedic Hospital Vienna Speising|Yes|Completed|March 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|55 Years|No|||November 2013|November 5, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01981798||56666|
NCT02006277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081041|A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation|A Phase 1, Open-label, Crossover Taste And Pharmacokinetic Study In Healthy Adult Volunteers To Evaluate The Palatability And Estimate The Bioavailability Of Three Prototype Formulations Of Crizotinib||Pfizer|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006277||54790|
NCT02006290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441003|Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease|A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease||Pfizer|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|30 Years|75 Years|No|||September 2015|September 30, 2015|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006290||54789|
NCT02006602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011|Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions|An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 16mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 16mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006602||54765|
NCT02006563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100809|Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors|Evaluation of Metabolic Tumor Volumes in Radiation of Primary Brain Tumors||University of Miami|Yes|Recruiting|January 2011|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|It is estimated that approximately 39% of the patients with primary brain tumors, seen in        the Department of Radiation Oncology, Sylvester Cancer Center are women. Further, it is        estimated that 58% of patients are White, 6% are African American, 36% are Hispanic and 0%        are other based upon standard NIH definitions.|September 2015|September 10, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006563||54768|
NCT02007200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03618|Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery|A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2009|||September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|19 Years|79 Years|No|||June 2015|September 28, 2015|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007200||54719|
NCT01979055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00076471|Achieving Better Control for Older Adults With Asthma|Use of a Self-regulation Intervention to Improve Control and Outcomes in Older Adults With Asthma||University of Michigan|Yes|Recruiting|November 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|368|||Both|55 Years|N/A|No|||December 2015|December 7, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979055||56876|
NCT01979068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET_MONW|Vascular Inflammation Stratified by Body Size Phenotype|||Korea University|Yes|Completed|March 2008|||March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|250|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers who underwent a medical health check in the health promotion center in        Korea University Guro Hospital|November 2013|November 3, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979068||56875|
NCT01979354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552/2556(EC3)|0.15 mg Spinal Morphine vs. no Treatment for Morphine Requirement After VATs.|The Comparison of 0.15 Milligram Spinal Morphine vs.no Treatment for Morphine Requirement After Video-assisted Thoracoscopic Surgery. A Pilot Randomized Control Study||Mahidol University|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01979354||56853|
NCT01979718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chhwang3|The Post-operative Analgesia of the Virtual Reality Using a Mirror Therapy After Total Knee Arthroplasty|The Post-operative Analgesia of the Virtual Reality Using a Mirror Therapy After Total Knee Arthroplasty: Prospective, Single-blind, Parallel Group, Randomized, Single Cohort Clinical Trial of Efficacy||Ulsan University Hospital|Yes|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|N/A|No|||December 2015|December 1, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979718||56825|
NCT01988415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-114-SARA|New Treatment Algorithm to Reduce Spherical Aberration After LASIK Correction for Myopia|A Prospective Study to Evaluate the Feasibility of a New Treatment Algorithm for Wavefront-Guided Lasik Correction of Myopic Refractive Errors||Abbott Medical Optics|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 14, 2013|No|Yes||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01988415||56159|
NCT01988688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS Tinnitus|Pilot Study of Deep Brain Stimulation (DBS) in Area LC for Chronic Tinnitus|Pilot Study of Deep Brain Stimulation (DBS)in Area LC for Chronic Tinnitus||University of California, San Francisco|Yes|Recruiting|January 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|22 Years|75 Years|No|||December 2015|December 2, 2015|November 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988688||56138|
NCT01988948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-42|Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise|Impact de la Vaccination Sur la Distribution Des génotypes de Papillomavirus (HPV) et Suivi de la Dynamique Intra-individuelle de l'Infection et Des Co-infections Dans Une Population d'étudiantes âgées de 18 à 20 Ans|DyPAVIR|Institut Pasteur|No|Enrolling by invitation|October 2013|December 2020|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5000|||Both|18 Years|20 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988948||56118|
NCT01989208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG1002-001|Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients|A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients||Sulfagenix Australia Pty Ltd.|No|Active, not recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|14|||Both|35 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01989208||56098|
NCT01989533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140011|Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers|Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|October 2013|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|440|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2015|July 16, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01989533||56073|
NCT01989546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140015|Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations|Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|120 Years|No|||July 2015|March 2, 2016|November 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989546||56072|
NCT01989832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10007|Pharmaco-economical Study in Kidney Transplantation|Pharmaco-economical Study in Kidney Transplantation|EPHEGREN|University Hospital, Limoges|No|Recruiting|February 2013|December 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|renal transplant patients|February 2013|November 15, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01989832||56050|
NCT01990105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCS-2013-1|Treatment of Atrial Fibrillation in Finland|Treatment of Atrial Fibrillation in Finland - the FinFib 2 Study|FinFib2|Finnish Cardiac Society|No|Completed|November 2013|April 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1013|||Both|18 Years|N/A|No|Non-Probability Sample|The study data will be obtained in the form of a cross-section sampling over two weeks.        All patients with ECG-diagnosed AF who attend emergency clinics for examination or        treatment of arrhythmia or other cardiac diseases during the study period will be        included. The estimated number of patients is about 1000.|March 2015|March 6, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990105||56029|
NCT01990079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048990|Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD|Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD|QUIT4EVER|Duke University|No|Completed|December 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||September 2015|September 15, 2015|November 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01990079||56031|
NCT01990092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-003|The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Nutritional Benefits of Metanx® in Subjects With Diabetic Peripheral Neuropathy|MEDIAN|Pamlab, Inc.|No|Active, not recruiting|November 2013|March 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|238|||Both|25 Years|80 Years|No|||January 2016|January 15, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990092||56030|
NCT01990352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300000710|Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy|A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin||University of Arizona|Yes|Recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990352||56010|
NCT01990365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH No 6-3|The Influence of Vertebral Mobility on Low Back Pain in Patients With Acute Osteoporotic Vertebral Fractures|The Influence of Vertebral Mobility on Low Back Pain in Patients With Acute Osteoporotic Vertebral Fractures||Tomidahama Hospital|No|Recruiting|January 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|45 Years|100 Years|No|Probability Sample|Osteoporotic patients with acute vertbral fracture|November 2015|November 3, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990365||56009|
NCT01990378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-10-066|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA) in Healthy Human Volunteers Under Fasting Condition.||Torrent Pharmaceuticals Limited||Completed||||September 2010|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|November 15, 2013||||No||https://clinicaltrials.gov/show/NCT01990378||56008|
NCT02005627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13IC0847|Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study|Randomised Placebo-controlled Study of Grass Pollen Allergen Immunotherapy Tablet (AIT) for Seasonal Rhinitis: Time Course of Nasal, Cutaneous and Immunological Outcomes|Pollen+|Imperial College London|No|Active, not recruiting|December 2013|March 2017|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 27, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005627||54840|
NCT02005978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRO-INC-TME|Brain-gut Interaction in Irradiated Patients With Acromegaly|Incretin Effect and Gastrointestinally Mediated Glucose Disposal in Cranially Irradiated Patients With Acromegaly||Rigshospitalet, Denmark|No|Active, not recruiting|April 2013|June 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|Samples Without DNA|Blood samples|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acromegaly treated with radiation therapy or surgery|October 2014|October 26, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02005978||54813|
NCT02005991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2081015|A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377|A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects||Pfizer|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|4|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 15, 2014|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005991||54812|
NCT02006901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/643|Comparative Effectiveness of Microdecompression and Laminectomy for Central Lumbar Spinal Stenosis|Comparative Effectiveness of Microdecompression and Laminectomy for Central Lumbar Spinal Stenosis - An Observational Study||St. Olavs Hospital|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|721|||Both|18 Years|N/A|No|Non-Probability Sample|patients who had operation in ≤2 lumbar levels with either open decompressive laminectomy,        bilateral microdecompression or unilateral microdecompression for bilateral decompression        in Norway in the time period between October 2006 and December 2011|April 2015|April 7, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02006901||54742|
NCT02006615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-011A|The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory|The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory in Stroke, Parkinson, and Elderly Patients||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|80 Years|No|||December 2013|December 5, 2013|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006615||54764|
NCT02007486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRDF 2013|Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study|Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study||McGill University|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|32|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory, male and female heart failure patients (n=24) will be recruited from the Heart        Failure and Heart Transplant Centre of the Royal Victoria Hospital, McGill University        Health Centre. Healthy, sedentary, non-smoking, asymptomatic, control subjects (n=8) will        be recruited through advertisement in the Montréal and surrounding area|August 2015|August 24, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02007486||54698|
NCT01999803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0029-003|A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS|A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution||Newron Sweden AB|Yes|Terminated|September 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|November 22, 2013||No|Issues with development and supply of infusion system for delivery of IMP. Lack of favorable    benefit risk ratio in sNN0029-003 study (review of interim data).|No||https://clinicaltrials.gov/show/NCT01999803||55288|
NCT02000336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KG1204|Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis|Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial|CORRA|Ruhr University of Bochum|Yes|Recruiting|January 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02000336||55247|
NCT02000349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reprogenetics-3.117|Comparison of Frozen-thawed Embryo Transfers and Fresh Embryo Transfers With Whole Chromosome Analysis Using Next Generation Sequencing|||Reprogenetics|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|186|||Female|18 Years|42 Years|No|||November 2015|November 16, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02000349||55246|
NCT01979367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTSC030113|Study Neurological Ischemia Lower Extremity Pain and Swelling|To Evaluate the Efficacy Treatment of Lower Extremity Pathologies Derived From Neurological Ischemia Disorders|DTSC|American Association of Sensory Electrodiagnostic Medicine|Yes|Enrolling by invitation|March 2012|March 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|25 Years|90 Years|No|||May 2015|January 6, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979367||56852|
NCT01979731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18170313500000064|Effects Job Rotation in the Prevention of Work Related Musculoskeletal Disorders|Effects Job Rotation in the Prevention of Work Related Musculoskeletal Disorders: Cluster Randomized Trial|Jobrotation|Universidade Cidade de Sao Paulo|Yes|Completed|September 2013|February 2016|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|116|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01979731||56824|
NCT01989247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-1010-46/1|How to Cope With Anxiety and Depression. A Randomized Controlled Trial.|Self-management of Depression and Anxiety. A Randomized Controlled Trial.||University of Aarhus|No|Completed|June 2013|January 2016|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|853|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989247||56095|
NCT01989260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0055|Post-operative Ovarian Adhesion Study in Women With Endometriosis|Effectiveness of Anti-adhesive Gel in Preventing Post Operative Ovarian Adhesions in Women With Pelvic Endometriosis: A Double Blind Randomized Controlled Trial||University College London Hospitals|Yes|Not yet recruiting|December 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|50|||Female|19 Years|55 Years|No|||November 2013|November 14, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989260||56094|
NCT01989221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21086|Sancuso® for Gastroparesis: An Open Label Study.|Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study.||Temple University|Yes|Recruiting|November 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989221||56097|
NCT01989234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP10811C006|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation|||SK Life Science|Yes|Completed|October 2013|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|334|||Both|18 Years|65 Years|No|||December 2014|December 3, 2014|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989234||56096|
NCT01988961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102851|A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|No|Completed|December 2013|January 2016|Actual|February 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988961||56117|
NCT01989559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02097|Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery|A Pilot Study to Assess the Immunologic Response to Booster Vaccination With a Modified gp100 Melanoma Peptide (209-2M) Vaccine in Previously Vaccinated HLA-A2.1+ Patients With Melanoma||National Cancer Institute (NCI)||Completed|October 2002|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|N/A|N/A|No|||November 2013|January 23, 2015|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01989559||56071|
NCT01989845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVTE13-01|Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer|Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers||Seoul National University Hospital|No|Recruiting|October 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|127|||Both|20 Years|N/A|No|||February 2016|February 5, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01989845||56049|
NCT01989858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021052-25|ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)|ITACA-S2(Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach:Comparison of the Efficacy of a Peri-operative Versus a Post-operative Chemotherapy Treatment in Patients With Operable Gastric Cancer and Assessment of the Benefit of a Post-operative Chemo-radiotherapy.|ITACA-S2|Mario Negri Institute for Pharmacological Research|Yes|Terminated|November 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1180|||Both|18 Years|N/A|No|||July 2010|January 28, 2015|June 16, 2011||No|lack of clinical cases|No||https://clinicaltrials.gov/show/NCT01989858||56048|
NCT01990391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008.0.197.185-11|Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities|Effect of Brazil Nut Consumption in the Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities in Hypertensive and Dyslipidemic Subjects||Universidade Federal do Rio de Janeiro|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 20, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01990391||56007|
NCT01990417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPS-1310|Evaluation of Passive Stretching in the Hamstrings Flexibility|Evaluation of Passive Stretching in the Hamstrings Flexibility of Who Practice Exercises|EPSHF|Fortaleza University|Yes|Completed|December 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Actual|1|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01990417||56005|
NCT01990404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 066 08|Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain|Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain: a Randomized Double-blind Study|MEOPA-PA|University Hospital, Toulouse|No|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|114|||Both|65 Years|N/A|No|||August 2015|August 25, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01990404||56006|
NCT01990690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aouoh|Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial|Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial|ao&uoh|Woman's Health University Hospital, Egypt|Yes|Completed|January 2014|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990690||55984|
NCT01990976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208050|Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.|Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.|FSHD3|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|Muscles|Both|18 Years|N/A|No|Non-Probability Sample|Patient with facioscapulohumeral dystrophy and who have participated to the FSHD1 and        FSHD2 studies|July 2015|July 27, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01990976||55962|
NCT02005965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2943|Low Rectal Cancer Study (MERCURY II)|The Low Rectal Cancer Study.|MERCURY II|Royal Marsden NHS Foundation Trust|Yes|Active, not recruiting|September 2007|March 2020|Anticipated|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|542|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with biopsy proven adenocarcinoma within 6cm of the anal verge confirmed on MRI.|March 2016|March 11, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02005965||54814|
NCT02003950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-037|Pre- and Post-restriction Chocolate Candy Consumption|Effect of Three-Week Chocolate Candy Restriction on Pre- and Post-restriction Chocolate Candy Consumption in Healthy Adults||Purdue University|No|Completed|March 2013|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02003950||54969|
NCT02006914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002499|Novel Therapy for Glucose Intolerance in HIV Disease|Novel Therapy for Glucose Intolerance in HIV Disease||Stony Brook University|Yes|Completed|June 2005|April 2012|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|47|Samples With DNA|Fat and muscle biopsy samples|Both|18 Years|N/A|No|Probability Sample|Anyone with a positive diagnosis of HIV disease.|December 2013|December 5, 2013|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT02006914||54741|
NCT02006927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-420|A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function|A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Neural Regeneration and Erectile Function||William Beaumont Hospitals|Yes|Enrolling by invitation|July 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|40 Years|80 Years|No|||March 2016|March 3, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006927||54740|
NCT02006628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWAP1241|A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder|A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder||GW Research Ltd|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006628||54763|
NCT02007213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140023|Development of a Proxy Motor Outcome Measure in Young Children With Neuromuscular Disease|Development of a Proxy Motor Outcome Measure in Young Children With Neuromuscular Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007213||54718|
NCT02000050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST 154.01|Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)|Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma|COLORE|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||December 2015|December 31, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000050||55269|
NCT02000076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleepy Brain Study Wave 1|The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old|The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old||Karolinska Institutet|No|Completed|November 2012|May 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|98|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02000076||55267|
NCT02000362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSB-CD|Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)|An Open-labelled, Single Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease||Kang Stem Biotech Co., Ltd.|Yes|Recruiting|August 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|70 Years|No|||August 2014|October 20, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02000362||55245|
NCT01987843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E06|Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|September 2013|November 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|142|||Both|18 Years|65 Years|No|||December 2014|December 16, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987843||56202|
NCT01988181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVM-RXOS|Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study|Blood Volume Monitoring Guided Ultrafiltration Biofeedback on Reduction of Intra-dialytic Hypotensive Episodes in Hemodialysis: A Randomized Cross Over Study||University of Calgary|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01988181||56177|
NCT01989624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD064-13|PAncreatic Adenocarcinoma in Hospital|PAncreatic Adenocarcinoma in Hospital|APACH|Centre Hospitalier Departemental Vendee|No|Active, not recruiting|October 2013|December 2020|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1204|||Both|18 Years|N/A|No|Non-Probability Sample|patient in hepatogastroenterology in general hospital|December 2015|January 6, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01989624||56066|
NCT01989611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrEP Brasil|Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.|Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.|PrEPBrasil|Oswaldo Cruz Foundation|No|Active, not recruiting|June 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01989611||56067|
NCT01989884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-GBM-6272|An Efficacy Study Of Ortataxel In Recurrent Glioblastoma|Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma|Ortataxel|Mario Negri Institute for Pharmacological Research|No|Suspended|November 2013|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||November 2014|February 9, 2016|October 23, 2013||No|the number of patients for the interim analysis was reached|No||https://clinicaltrials.gov/show/NCT01989884||56046|
NCT01989572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02101|Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma|A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma||National Cancer Institute (NCI)|Yes|Completed|December 1999|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|815|||Both|18 Years|N/A|No|||May 2015|July 30, 2015|November 18, 2013|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01989572||56070|
NCT01989585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02103|Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors||National Cancer Institute (NCI)|No|Suspended|October 2013|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 18, 2013|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01989585||56069|
NCT01989598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02148|Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)|No|Suspended|October 2013|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|November 18, 2013|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT01989598||56068|
NCT01989871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9574-IM-CTIL|Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm Infants|Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm||Sheba Medical Center|No|Not yet recruiting|December 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|25 Weeks|32 Weeks|No|||November 2013|November 14, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01989871||56047|
NCT01990118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.041|Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients|A Randomized, Multi-center, Open Label Trial to Establish the Therapeutic Equivalence Between Neoral® and Gengraf® in Stable Renal Allograft Recipients [Gengraf Conversion Study]||Penang Hospital, Malaysia|Yes|Completed|November 2004|May 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|70 Years|No|||November 2013|November 15, 2013|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990118||56028|
NCT01990430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|behaviourchanges|Behavioural Changes in Breast Cancer Patients|Integrative Exercise and Life Style Intervention Increase Leisure Time Activity in Breast Cancer Patients.|BHVBC|Universidad Politecnica de Madrid|Yes|Recruiting|January 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||January 2014|January 12, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01990430||56004|
NCT01990703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62844|BLIS - Breastfeeding Levonorgestrel IUD Study|Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Levonorgestrel IUD to Assess Breast Feeding Outcomes (BLIS - Breastfeeding Levonorgestrel IUD Study)|BLIS|University of Utah|Yes|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|317|||Female|18 Years|40 Years|No|||February 2016|February 18, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990703||55983|
NCT01990989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012042|Clopidogrel Pharmacogenetic Score System|Clopidogrel Pharmacogenetic Score System Established for Chinese Patients|CPASS|Chinese PLA General Hospital|Yes|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|DNA extracted from peripheral whole blood|Both|18 Years|85 Years|No|Probability Sample|consecutive patients treated with maintenance dose of clopidogrel|November 2013|November 18, 2013|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990989||55961|
NCT01986725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOMAN-PRO II program|The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence|The Impact of the Self-management Intervention "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence: A Mixed-Methods Project|WOMAN-PROII|St.Gallen University of Applied Sciences|Yes|Completed|September 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|45|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01986725||56288|
NCT02005653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM0603-CEC-VCRC|Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection|Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration||Indian Council of Medical Research|Yes|Completed|February 2009|August 2013|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|146|||Both|18 Years|65 Years|No|||December 2013|December 6, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005653||54838|
NCT01999790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocoloretracao|Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy|Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy||University of Sao Paulo|No|Recruiting|March 2012|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||November 2013|November 25, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01999790||55289|
NCT02000063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1105|Australian Trial in Acute Hepatitis C Recall Study|Long-term Outcomes Following Treatment of Recently Acquired Hepatitis C Virus Infection.|ATAHC Recall|Kirby Institute|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Stored serum and peripheral blood mononuclear cells.|Both|16 Years|N/A|No|Non-Probability Sample|An anticipated 60 participants will be recruited from 3 study sites: St Vincent's        Hospital, Sydney; The Alfred Hospital, Melbourne; Royal Adelaide Hospital, Adelaide.|September 2014|September 29, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02000063||55268|
NCT02000375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST174.08|A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)|A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)|ARTT|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Terminated|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|November 21, 2013||No|Due to slow recruitment and recent new published data|No||https://clinicaltrials.gov/show/NCT02000375||55244|
NCT02000388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012-2011-SPRIX|Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain|Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain||Citrus Valley Medical Research, Inc.|No|Enrolling by invitation|February 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Male|25 Years|64 Years|No|||November 2013|December 3, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000388||55243|
NCT01988428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42001.029.13|Prehospital Antibiotics Against Sepsis Trial|A Prospective Randomized Controlled Trial to Investigate the Effects of Training Emergency Medical Services (EMS) Personnel in Recognizing and Initiating Treatment in the Prehospital Setting Together With Early Administration of Antibiotics for Patients Suspected of (Severe) Sepsis and Septic Shock|PHANTASi|VU University Medical Center|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2200|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01988428||56158|
NCT01988714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1MH068725|Cognitive Remediation of Schizophrenia in a Community Mental Health Setting|Cognitive Remediation of Schizophrenia in a Community Mental Health Setting|SECT|University of California, San Francisco|Yes|Recruiting|September 2009|June 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||May 2015|May 14, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988714||56136|
NCT01988727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-036|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2014|||||N/A|N/A|N/A||||||||||||||June 10, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988727||56135|
NCT01988974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007768|Feasibility Testing of the Alert for Atrial Fibrillation Program|Feasibility Testing of the Alert for Atrial Fibrillation Program||Mayo Clinic|Yes|Recruiting|November 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988974||56116|
NCT01990495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0915-R|Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients|Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients|PERFECT|VA Office of Research and Development|No|Recruiting|November 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|60 Years|80 Years|No|||December 2015|December 9, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01990495||55999|
NCT01990742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-641|Improving Palliative Care Through Teamwork|Improving Palliative and End-of-Life Care in Nursing Homes|IMPACTT|University of Rochester|No|Active, not recruiting|April 2013|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01990742||55980|
NCT01989897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0217|Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests|Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests||Ohio State University|Yes|Recruiting|March 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|30|||Both|18 Years|60 Years|No|||November 2013|November 15, 2013|June 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989897||56045|
NCT01990131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF02397|Computerized Anxiety Treatment for Suicide|Suicide Risk Prevention Among Patients With Anxiety Psychopathology|CATS|Florida State University|No|Recruiting|October 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||August 2015|September 10, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990131||56027|
NCT01990443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/1107|Absolute Bioavailability of Reslizumab in Healthy Subjects|A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects||Teva Pharmaceutical Industries|No|Completed|June 2013|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990443||56003|
NCT01990456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLVE ARDS_01|Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study|Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study|SOLVE ARDS|University of Toronto|No|Recruiting|September 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|16 Years|N/A|No|||November 2014|November 5, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01990456||56002|
NCT01990469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL010|Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin|||LG Life Sciences|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|19 Years|N/A|No|||September 2015|September 9, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990469||56001|
NCT01990716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 393 02|Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases|Quantitative Analysis of Lipid Mediators in Colonic Biopsies From Patients With Inflammatory Bowel Diseases and From Control Patients.|MICILIP|University Hospital, Toulouse|No|Active, not recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990716||55982|
NCT01991002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diet003|14/21 Diet-walking in the Park|Prospective Interventional Study of the Impact of 3-step Diet With Complimentary Exercise Program||Assuta Hospital Systems|No|Active, not recruiting|July 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 24, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01991002||55960|
NCT01991015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU_STU00077507|Goals of Care Discussions for Hospitalized Patients With Advanced Cancer|Gender Differences in Inpatient Goals of Care Discussions in Patients With Advanced Cancer||Northwestern University|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be hospitalized at Northwestern Memorial Hospital and be having a goals of        care discussion with their physician. In addition, eligible patients must be greater than        the age of 18 years, speak English fluently, be able to physically and cognitively        complete the informed consent process, and have metastatic cancer that has progressed        despite treatment.|February 2015|February 6, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991015||55959|
NCT01986751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130625002|Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery|Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery||University of Alabama at Birmingham|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||July 2015|August 21, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986751||56286|
NCT01987024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00780-45|Advantage of Detection of phIGFBP-1 to Reduce Hospitalization Time for Stable Patients With a Risk of Preterm Labour.|Advantage of Detection of phIGFBP-1 to Reduce Hospitalization Time for Stable Patients With a Risk of Preterm Labour.||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2013|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|420|||Female|18 Years|N/A|No|||July 2014|July 23, 2014|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01987024||56265|
NCT02006641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14862A|Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|STARBEAM|H. Lundbeck A/S|Yes|Recruiting|February 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|840|||Both|50 Years|N/A|No|||December 2015|December 10, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006641||54762|
NCT02003443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N015749|Acupressure for Knee Pain in Older Adults|Acupressure for the Treatment of Pain in Older Adults With Symptomatic Knee Osteoarthritis|AKP|University of Michigan|No|Completed|August 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|65 Years|N/A|No|||May 2015|May 27, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003443||55008|
NCT02003716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDA-001-2012|DeFRA Questionnaire as an Anamnestic Form|Use of the DeFRA Questionnaire as a "Primary Anamnestic Form" Through a Large Scale Screening of the Population||Valmontone Hospital|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|767|||Female|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|general population, never screened before for osteoporosis and never subject to treatment|November 2014|November 11, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02003716||54987|
NCT02003963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-046|Social Exergaming for Healthy Weight in Adolescent Girls|Klub Kinect: Social Exergaming for Healthy Weight in Adolescent Girls|Klub Kinect|Pennington Biomedical Research Center|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02003963||54968|
NCT02000700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103045|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus|Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin||Janssen Research & Development, LLC||Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|10 Years|17 Years|No|||March 2016|March 11, 2016|November 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02000700||55219|
NCT01988441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102066-F|The Influence of Autophagy on Fatty Liver|The Influence of Autophagy on Nonalcoholic Fatty Liver Disease||Far Eastern Memorial Hospital|Yes|Recruiting|September 2013|April 2017|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|serum, WBC DNA|Both|6 Years|18 Years|No|Probability Sample|Obese Taiwanese children and adolescents|September 2015|October 12, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988441|1 Month|56157|
NCT01988740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/87|Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin|Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin|IMA|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|November 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|180|||Female|N/A|N/A|No|Non-Probability Sample|first trimester pregnancy with absence of fetal cardiac activity|November 2013|November 14, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988740||56134|
NCT01988987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12318|Evaluating for Type-2 Diabetes in the Very Early Postpartum Period|Evaluating for Type-2 Diabetes in the Very Early Post-Partum Period||Winthrop University Hospital|No|Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Women hospitalized for delivery at a teaching hospital.|December 2015|December 11, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988987||56115|
NCT01990508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001130|Randomized Trial of Financial Incentives to Reduce Sugar-sweetened Beverage Purchases by Low-income, Latino Families|Randomized Trial of Financial Incentives to Reduce Sugar-sweetened Beverage Purchases by Low-income, Latino Families||Massachusetts General Hospital|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990508||55998|
NCT01990755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brambilla trial|Neurobiology of Eating Disorders Treatments|Lack of Efficacy of Psychological and Pharmacological Treatments of Eating Disorders: Neurobiological Background|NEDT|University of Turin, Italy|No|Completed|May 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Female|15 Years|35 Years|No|||November 2013|November 15, 2013|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01990755||55979|
NCT01990144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_R-BENDA FRAIL|Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL|Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma: a Phase II Multicenter Study of the Fondazione Italiana Linfomi (FIL)||Fondazione Italiana Linfomi ONLUS|Yes|Recruiting|November 2011|February 2016|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 15, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990144||56026|
NCT01990482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk15|Influence of Coffee Intake on Postoperative Bowel Function After Comprehensive Staging Surgery for Gynecological Malignancies: A Randomized Controlled Trial.|||Erzincan Military Hospital||Recruiting|November 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|118|||Female|N/A|N/A|No|||November 2013|November 17, 2013|November 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01990482||56000|
NCT01990729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTRA-PMS-LBP/2012|Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain|Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Non-specific Chronic Low Back Pain of Lumbosacral Localization in Ambulatory Care||Unipharm, Inc.|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10000|||Both|40 Years|65 Years|No|Non-Probability Sample|Patients with chronic low back pain in ambulatory care|November 2013|November 15, 2013|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01990729||55981|
NCT01986764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817642|E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy|Predictors of Healthy Mood and Memory After Oophorectomy|E2 LDX|University of Pennsylvania|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Female|30 Years|48 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01986764||56285|
NCT01987037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00644-41|Neuropsychomotor Functions in Children With Autism Spectrum Disorder|Neuropsychomotor Functions in Children With Autism Spectrum Disorder||Centre Hospitalier Esquirol|No|Recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|4 Years|11 Years|No|Non-Probability Sample|children attended in the Centre Hospitalier Esquirol and the CRA (Autism Reference Center)        in Limousin, France, for suspiscion of autism|July 2015|July 31, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987037||56264|
NCT01987310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0694-ZBE-CTIL|Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment|Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment||Sheba Medical Center|No|Not yet recruiting|December 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01987310||56243|
NCT02003703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45/2012|Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .|Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV : A Randomised Trial|CORE-HIV|Universidad de Valparaiso|No|Recruiting|May 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003703||54988|
NCT02003729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29539|SIESTA: Home Sleep Study With ApneaDx™ for the Diagnosis of Obstructive Sleep Apnea|SIESTA: Home Sleep Study With ApneaDx™ for the Diagnosis of Obstructive Sleep Apnea: A Pragmatic Randomized Controlled Trial||University of Toronto|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003729||54986|
NCT02003976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-SOG-13-020|A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone|A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone||Western University, Canada|Yes|Recruiting|September 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|25 Years|55 Years|No|||July 2015|July 27, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003976||54967|
NCT01999816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-06-00064|Pressure Ulcer Prevention Study in SCI|Lifestyle Redesign for Pressure Ulcer Prevention in Spinal Cord Injury|PUPS|University of Southern California|Yes|Active, not recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|170|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999816||55287|
NCT02000089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00087754|The Cancer of the Pancreas Screening-5 CAPS5)Study|The Cancer of the Pancreas Screening-5 CAPS5)Study|CAPS5|Johns Hopkins University|Yes|Recruiting|January 2014|December 2023|Anticipated|October 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|2500|Samples With DNA|approximately 40 ml of blood approximately 5-20 ml pancreas juice approximately 10 ml saliva      (optional) pancreas cyst fluid (if available)|Both|18 Years|N/A|No|Probability Sample|Individuals at elevated risk for developing pancreas cancer|February 2016|February 22, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000089||55266|
NCT02000102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28279|Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab|||Stanford University||Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or        ranibizumab|November 2014|November 17, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000102||55265|
NCT01988753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30472|Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases|Utility of Shearwave Elastography (SWE) and Non-Invasive Serum Biomarkers to Detect Fibrosis in Pediatric Patients With Liver Diseases||Baylor College of Medicine|No|Recruiting|October 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|1. Shearwave elastography is a non-invasive procedure to measurement liver tissue           elasticity. Images will be obtained in the right lobe of the liver through intercostal           spaces with the subject lying supine with right arm abduction. A total of 10           measurements will be obtained across the liver to obtain a more comprehensive           evaluation.        2. Biomarker Analysis      A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the      purposes of the serum biomarker study. If subjects return for an additional liver biopsy in      the future or a standard of care visit they may be asked to provide an additional sample for      biomarker analysis. Blood will be processed, aliquoted and stored by pathology.      B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken      during the liver biopsy to be stained for additional biomarker analysis.|Both|N/A|17 Years|No|Non-Probability Sample|Children will be recruited from the >2500 inpatient/outpatient referrals made to the Texas        Children's Liver Center per year. We will test the utility of putative serum markers of        fibrosis and fibrogenesis, obtained from patients for diagnosis and prediction of the        likelihood of progression to fibrosis.|December 2015|December 15, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988753||56133|
NCT01989000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45913.018.13|The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome|The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome|MIPA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|November 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|95|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01989000||56114|
NCT01989013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST001|Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated Therapy|Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated Therapy||Zia, Al Raza|No|Recruiting|February 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989013||56113|
NCT01989273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI-NCH-10-016|Detection and Management of Non‐Compressible Hemorrhage by Vena Cava Ultrasonography|Detection and Management of Non‐Compressible Hemorrhage by Vena Cava Ultrasonography||University of California, San Diego|No|Recruiting|August 2012|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted as Major Trauma Victims via Emergency Medical Services to Level 1 Trauma        Centers|February 2016|February 4, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989273||56093|
NCT01989286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0043UG|Postural Assessment in Plagiocephaly|Postural Assessment in Children With Non-synostotic Plagiocephaly||Universidad de Granada|Yes|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children who were diagnosed by plagiocephaly and a control group.|December 2014|December 9, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989286||56092|
NCT01990781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387/070/071|Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness.|Combined Effect of Intravenous Lidocaine and Dexamethasone on Postoperative Sore Throat, Cough and Hoarseness. A Randomized Controlled Trial||B.P. Koirala Institute of Health Sciences|No|Completed|April 2013|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|180|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|November 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990781||55977|
NCT01990768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47114-A|Prehospital Tranexamic Acid Use for Traumatic Brain Injury|Prehospital Tranexamic Acid Use for Traumatic Brain Injury|TXA|University of Washington|Yes|Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1002|||Both|15 Years|N/A|No|||June 2015|June 28, 2015|October 30, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01990768||55978|
NCT01991054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGA1C vs D|The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency|A Prospective, Double Blind, Randomized, Phase 4, Clinical Trial of The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency|VDD|HaEmek Medical Center, Israel|No|Recruiting|December 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991054||55956|
NCT01991028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-180-12|A Study to Investigate Lung Deposition of Radiolabelled OligoG|An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients||Bio-Images Research Ltd|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991028||55958|
NCT01986777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817628|LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy|LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy|LDX|University of Pennsylvania|No|Recruiting|July 2013|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01986777||56284|
NCT01987050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-8256|Intranasal Oxytocin in Schizophrenia Patients|A Double-Blind, Placebo Controlled Comparison of Two Fixed Doses of Oxytocin and Placebo Administered Intranasally in Schizophrenia Patients||University of California, Irvine|Yes|Recruiting|March 2012|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|71|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987050||56263|
NCT01987323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R967/76/2012|Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertension|Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertensive Patients||Singapore Eye Research Institute|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|80 Years|No|||November 2013|November 18, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01987323||56242|
NCT01987596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-062|Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer|Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|August 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|1 Year|25 Years|No|||January 2016|January 25, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987596||56221|
NCT01987609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 131026|Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques|Evaluation of the Effect of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques||University of California, San Diego|No|Not yet recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||February 2015|February 18, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987609||56220|
NCT01987921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric AWARE Study|Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes|Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology|AWARE|Children's Hospital Medical Center, Cincinnati|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5296|Samples Without DNA|Urine samples will be collected from participating centers (pending local IRB approval)|Both|3 Months|25 Years|No|Non-Probability Sample|All medical and surgical patients admitted to the pediatric intensive care unit|February 2015|February 2, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987921|28 Days|56196|
NCT01987934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDER-1301-AR|Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma|Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma|OSCC|Academy of Interdisciplinary Dental Education and Research|Yes|Enrolling by invitation|June 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Oral mucosal biopsy specimens of study participants will be collected.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population comprises of subjects reporting to dental departments of tertiary care        hospitals of Lahore district in Pakistan.|November 2013|November 13, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01987934|2 Weeks|56195|
NCT02003742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX1207-IT-CL 0414|Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH|Efficacy and Safety of a Single Transrectal Ultrasound(TRUS)-Guided Intraprostatic Injection of NX-1207 in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Phase III European Study||Recordati Industria Chimica e Farmaceutica S.p.A.|No|Recruiting|September 2013|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|340|||Male|45 Years|N/A|No|||December 2013|December 2, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003742||54985|
NCT02003755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3614B|The Effects of Continuous Passive Motion on Hypertonia of Soleus in Individuals With Cerebral Palsy|||Chang Gung University|Yes|Completed|April 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|16 Years|50 Years|No|||December 2013|December 3, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02003755||54984|
NCT02003989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM_CLL_2012-7|Revealing Increased Axonal Loss in Treated HIV Patients|Revealing Increased Axonal Loss in Treated HIV Patients||Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|May 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|HIV patients infected for at least 10 years with undetectable viral load, selected among        infectious disease outpatients (consecutive exhaustive recruitment)        non HIV patients matched for age and gender|October 2015|October 27, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02003989||54966|
NCT01999842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201072|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age||GlaxoSmithKline||Completed|November 2013|January 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|424|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|July 23, 2015|November 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999842||55285|
NCT01999829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-23|Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo|Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2013|March 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||August 2015|November 16, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999829||55286|
NCT02000115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203|Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial|Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial|PORTICO IDE|St. Jude Medical|Yes|Recruiting|May 2014|June 2022|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1206|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000115||55264|
NCT02000401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703-2012-SPRIX|Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain|To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain||Citrus Valley Medical Research, Inc.|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|64 Years|No|||November 2013|December 3, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000401||55242|
NCT02000414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005699-33|Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection|Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Patients With Peritoneal Dialysis and Peritoneal Infection|DAPTODP|University Hospital, Caen|Yes|Recruiting|September 2013|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02000414||55241|
NCT02000427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120216|Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia|A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)||Amgen|Yes|Active, not recruiting|December 2013|February 2017|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000427||55240|
NCT01989637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE STR|Effect of Strawberries on Cardiovascular Disease Risk|Effects of a Freeze Dried Strawberry Powder on Postprandial Vascular Function and Blood Markers of Cardiovascular Risk||Penn State University|No|Completed|July 2013|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|34|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01989637||56065|
NCT01989650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Break|The Effect of Taking Break During Colonoscopy Session on Adenoma Detection, a Prospective, Randomized Control Study|The Effect of Taking Break During Colonoscopy Session on Adenoma Detection, a Prospective, Randomized Control Study||Chinese University of Hong Kong|No|Completed|February 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1379|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01989650||56064|
NCT01989910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-MISP-39299|Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients|An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection||Taipei Veterans General Hospital, Taiwan|No|Completed|September 2013|||December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|20 Years|60 Years|No|||November 2013|January 5, 2016|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01989910||56044|
NCT01990157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB08_RA01|Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis|Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis in Which Methotrexate (MTX) Treatment is Not Effective||Theramab LLC|No|Recruiting|November 2013|July 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|65 Years|No|||December 2013|December 10, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01990157||56025|
NCT01990170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013080VS|Longterm Outcomes of Venous Ulcers After Foam Sclerotherapy|Long-term Healing and Recurrence of Chronic Venous Ulcerations Following Ultrasound-guided Foam Sclerotherapy||Heart of England NHS Trust|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Probability Sample|Patients at Heart of England NHS Foundation Trust who took part in a previous study        investigating Chronic Venous Ulcers.|August 2015|August 18, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01990170||56024|
NCT01987115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTF-1|Comparison of Fascial Manipulation With Traditional Physiotherapy for the Treatment of Trigger Fingers|Comparison of Fascial Manipulation With Traditional Physiotherapy for the Treatment of Trigger Fingers.||Clalit Health Services|Yes|Recruiting|November 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2013|February 4, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987115||56258|
NCT01991067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT_2011-002928-41|Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients|Characterization of Humoral and Cellular Immunity for Tick-borne Encephalitis (TBE) Vaccination in Allogeneic Blood and Marrow Graft Recipients: a Pilot Study||Medical University of Vienna|Yes|Recruiting|July 2014|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01991067||55955|
NCT01991080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biofeedback|The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy|Examining the Relationship Between Relaxation Combined With Biofeedback or Wheat Germ Juice to the Immune Indices and Quality of Life Measures in Patients With Colorectal Cancer Who Receive Prophylactic Chemotherapy After Surgery||Rambam Health Care Campus|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|100 Years|No|||November 2015|November 19, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01991080||55954|
NCT01991041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-E044-401|European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)|European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS).||Eisai Inc.||Active, not recruiting|June 2008|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|225|||Both|4 Years|N/A|No|Non-Probability Sample|Participation in this study will be offered to any patient of four years or older, who has        a known diagnosis of LGS, who requires a change in anti-epileptic therapy. This will        include patients who are started on rufinamide, as an adjuvant therapy.|November 2013|November 18, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991041||55957|
NCT01986790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS020309|Effective Communication to Improve Decision Making About Health Care Plans|Effective Communication to Improve Decision Making About Health Care Plans||Washington University School of Medicine|Yes|Completed|April 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|420|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01986790||56283|
NCT01987063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI12012|National Prospective and Comparative Study on the Mode of Delivery of Twins|National Prospective and Comparative Study on the Mode of Delivery of Twins|JUMODA|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|February 2014|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9000|||Female|N/A|N/A|No|Non-Probability Sample|cohort of pregnant woman with twins or triplets or quadruples|June 2015|June 23, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01987063||56262|
NCT01987336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-022|A Prospective Analysis of Biofilm in Urinary Catheters Study|A Prospective Anaylsis of Biofilm in Urinary Catheters Study||Southwest Regional Wound Care Center|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|A 30cc urine sample would also be collected, along with the used catheter. The molecular      evaluation will be looking specifically at the biofilm accumulated on the catheter surface.      The technologies to be used are proteomics, metabolomics and metagenomics.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who require a standard foley catheter.|December 2015|December 10, 2015|March 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01987336||56241|
NCT01987622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acustenosis|Acupuncture for Lumbar Spinal Stenosis|Acupuncture for Lumbar Spinal Stenosis: a Parallel, Randomized Controlled Pilot Study With Usual Care Comparison||Korean Medicine Hospital of Pusan National University|Yes|Completed|November 2013|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||February 2015|February 5, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987622||56219|
NCT01987635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/900|Assessment of Sustained Systolic-to-diastolic Flexibility of the Mitral Valve Annulus With the Sorin MEMO 3D Mitral Anuloplasty Ring|Assessment of Sustained Systolic-to-diastolic Flexibility of the Mitral Valve Annulus With the Sorin MEMO 3D Mitral Anuloplasty Ring|MEMO 3D|University Hospital, Ghent|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987635||56218|
NCT01987947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29107|A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria|||Genentech, Inc.||Completed|December 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|November 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01987947||56194|
NCT01987960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14865A|Brexpiprazole as an Additional Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)||H. Lundbeck A/S|No|Terminated|December 2013|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|417|||Both|18 Years|65 Years|No|||November 2015|November 6, 2015|November 13, 2013|Yes|Yes|The study was terminated due to challenges with patient eligibility; the decision to terminate    was not based on any safety concerns|No||https://clinicaltrials.gov/show/NCT01987960||56193|
NCT01987973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-182|Allograft Reconstruction of Massive Rotator Cuff Tears vs Partial Repair Alone|Arthroscopic Repair of Chronic Two-tendon Rotator Cuff Tears by Human Dermal Allograft||Nova Scotia Health Authority|No|Not yet recruiting|February 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01987973||56192|
NCT01988285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1122|Risk Factors and Biomarkers for Diagnosis and Treatment of EoE|Risk Factors and Biomarkers for Diagnosis and Treatment of EoE||University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2011|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|Esophageal, gastric, and duodenal biopsies. Blood samples.|Both|18 Years|N/A|No|Non-Probability Sample|The source of the study population will be patients aged 18-80 presenting at the        gastrointestinal (Gl) Endoscopy Clinic at UNC-Chapel Hill for elective upper endoscopy        with a primary or secondary indication of dysphagia and/or reflux symptoms. Any patient        undergoing endoscopy with dysphagia and/or reflux symptoms is eligible to participate in        the study.|February 2016|February 16, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01988285||56169|
NCT02003768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0626|The Effect of Pnemoperitoneum on Intracranial Pressure and Cerebral Oxygenation During Laparoscopic Surgery According to Anesthesia Agents: Propofol Based Total Intravenous Anesthesia vs Desflurane Anesthesia|||Yonsei University|Yes|Withdrawn|October 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|20 Years|80 Years|No|||July 2014|July 13, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003768||54983|
NCT01999855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5517|Frequency of Dysphonia in Asthmatic Patients|Evaluation of the Frequency of Dysphonia by Subjective and Objective Methods in Asthmatic Patients||University Hospital, Strasbourg, France|No|Not yet recruiting||||April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|December 3, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999855||55284|
NCT01999868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN059AI|Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris|Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)|PAUSE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2014|February 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999868||55283|
NCT02000128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PD-BIA|Fluid Management Guided by Bioimpedance Analysis in Peritoneal Dialysis(PD) Patients.|A Prospective, Randomized Controlled Study of Bioimpedance Analysis(BIA) Guided Fluid Management in Peritoneal Dialysis Patients.||Sun Yat-sen University|Yes|Recruiting|November 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000128||55263|
NCT02000440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117283|A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)|Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)||GlaxoSmithKline|No|Active, not recruiting|July 2014|September 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000440||55239|
NCT02000453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200208|Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.|An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.||GlaxoSmithKline|No|Terminated|December 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|November 27, 2013||No|GSK has elected to terminate development principally as a result of the statin drug-drug    interaction (DDI) study.|No||https://clinicaltrials.gov/show/NCT02000453||55238|
NCT02000739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13214|Genetically-informed Therapies for Patients With Metastatic Cancer|Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer|GENIUS|Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|January 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000739||55216|
NCT01989663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13080462|A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04|A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04|FAME 04|CONRAD||Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|78|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01989663||56063|
NCT01989676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3271002|A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)|A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast Cancer||Pfizer|Yes|Active, not recruiting|February 2014|February 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|690|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989676||56062|
NCT01989923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2506|Smoking Cessation in Women With Gynecological Conditions|Immediate Smoking Cessation for Patients at Risk for Cervical Dysplasia, Cervical Cancer and Lower Genital Tract Dysplasia and Cancer - A Feasibility Study Comparing Nicotine Replacement Therapy With the Electronic Nicotine Delivery System.||University of Oklahoma|No|Active, not recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01989923||56043|
NCT01990183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-2011.5.1-287932|CareToy - A Modular Smart System for Infants' Rehabilitation at Home Based on Mechatronic Toys|CareToy - A Modular Smart System for Infants' Rehabilitation at Home Based on Mechatronic Toys|CareToy|IRCCS Fondazione Stella Maris|Yes|Completed|July 2013|December 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|3 Months|9 Months|Accepts Healthy Volunteers|||February 2016|February 11, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01990183||56023|
NCT01987388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS42|Metabolic Flexibility as a Biomarker of Adaptation to Diet and Exercise Challenges|||USDA Beltsville Human Nutrition Research Center|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|16|||Both|22 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987388||56237|
NCT01987076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110108|Comparison Between Corticosteroid and Topical Steroids in the DRESS|DRESS - Setting of Corticosteroid Treatment.|DRESSCODE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01987076||56261|
NCT01987349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-17219|T-cell And General Immune Response to Seasonal Influenza Vaccine(SLVP018)|Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus Research Project 2: T-cell and General Immune Responses to Influenza; Research Project 3: Single-cell Phospho-protein Signaling Analysis of the Response to Influenza Vaccination; Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire||Stanford University|No|Active, not recruiting|July 2009|March 2015|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|550|||Both|1 Year|N/A|Accepts Healthy Volunteers|||November 2013|November 12, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01987349||56240|
NCT01987648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-058|Feasibility and Safety of Early Extubation After Elective Brain Surgery|Feasibility and Safety of Early Extubation After Elective Craniotomy - a Prospective Observational Single Center Study||University Hospital Inselspital, Berne|No|Recruiting|November 2011|September 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|All patients who 18 years or older,who get an elective craniotomy (no biopsy, no awake        surgery, no re-operation) and who are treated at the Department of Neurosurgery|February 2016|February 15, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987648||56217|
NCT01987661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Airtrap2013|The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD|German: Einfluss Von Airtrapping Auf Atmung Und Schlaf Bei Nichtinvasiver Beatmung (NIV) Von COPD Patienten||Institut für Pneumologie Hagen Ambrock eV|No|Active, not recruiting|October 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987661||56216|
NCT01987986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-831|A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy|A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy||Endo Pharmaceuticals|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Female|18 Years|45 Years|No|||March 2015|March 17, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987986||56191|
NCT01987999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN9892131|Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor|Phase II Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate(ATP)Inhibitor.||Optimal Health Research|Yes|Completed|February 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|40 Years|75 Years|No|||December 2015|December 21, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01987999||56190|
NCT01988012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28698|A Study of the Efficacy and Safety of RoActemra/Actemra in Patients With Rheumatoid Arthritis.|An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.||Hoffmann-La Roche||Completed|January 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988012||56189|
NCT01988025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPS-JAK-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2013|||||N/A|N/A|N/A||||||||||||||January 26, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988025||56188|
NCT01988298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Complejoh 02|Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia|Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery.||Complejo Hospitalario Dr. Arnulfo Arias Madrid|Yes|Completed|October 2013|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|114|||Female|15 Years|44 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01988298||56168|
NCT01988558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-001-IL|A Phase I/II to Assess Safety, Tolerability and Efficacy of DL-lactic Acid Syrup in Children With Recurrent Tonsillitis|A Phase I/II, Randomized, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of DL-lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis.||Yali Pharmaceuticals||Recruiting|December 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|16 Years|No|||June 2015|June 10, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01988558||56148|
NCT01988571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98213|Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)|Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)||Wake Forest NCORP Research Base|Yes|Recruiting|February 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Female|30 Years|80 Years|No|||September 2014|September 5, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01988571||56147|
NCT02004002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSP-201303080|Protein Intake & Insulin Action|Dietary Protein Intake, Insulin Sensitivity and β-cell Function||Washington University School of Medicine|Yes|Recruiting|December 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02004002||54965|
NCT01999881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13034|Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients|Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients||University of Wisconsin, Madison||Completed|December 2013|February 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999881||55282|
NCT02000141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/8/4.5(3778)|The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study|The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study - a Prospective Observational Cohort Study|ACER/AMN|Western Sydney Local Health District|Yes|Recruiting|January 2014|January 2034|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients referred to a study centre for colonic WF-EMR of a known sessile colonic polyp or        laterally spreading tumour (LST) ≥20mm in size.|December 2015|December 15, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000141||55262|
NCT02000466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201086|FluLaval® Quadrivalent Pregnancy Registry|FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception||GlaxoSmithKline||Withdrawn|November 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|12 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women, residing in the US, exposed to FluLaval Quadrivalent and who are        volunteering to take part in the Pregnancy Registry before the outcome of the pregnancy is        known.|October 2014|October 23, 2014|November 27, 2013|No|Yes|GSK has merged all individual pregnancy registries, which are terminated, for its seasonal    influenza vaccines into one combined registry, EPI-FLU-039 VS US PR.|No||https://clinicaltrials.gov/show/NCT02000466||55237|
NCT02000752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 36/2010|Influence of Acupuncture in the Placental Expulsion Time|Influence of Acupuncture in the Placental Expulsion Time||Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|120|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|November 20, 2013||No||No|July 4, 2015|https://clinicaltrials.gov/show/NCT02000752||55215|
NCT01989936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601006|Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan|A Multicenter, Double - Blind, Randomized, Placebo - Controlled Parallel Group Study of the Efficacy and Safety of Oral Eletriptan (40 and 80mg) Given for the Treatment of Acute Migraine in Subjects Discontinued From Oral Sumatriptan||Pfizer|Yes|Completed|January 1999|September 2000|Actual|September 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|446|||Both|18 Years|68 Years|No|||November 2013|November 20, 2013|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989936||56042|
NCT01989949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-006|Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women|Phase 1, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous TP-434 in Healthy Men and Women|BAL|Tetraphase Pharmaceuticals, Inc.|No|Completed|November 2012|April 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989949||56041|
NCT01990196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMT13001|Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer|Randomized, Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer||Jonsson Comprehensive Cancer Center|Yes|Recruiting|September 2014|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990196||56022|
NCT01990521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-2013|Prostate Screening Study Using MRI in BRCA Carriers|Screening Male BRCA Mutation Carriers: Effectiveness of Multispectral 3T Magnetic Resonance Imaging||Toronto Sunnybrook Regional Cancer Centre|No|Recruiting|January 2014|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|50 Years|N/A|No|||January 2016|January 11, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990521||55997|
NCT01990534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25007|A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma|A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|March 2014|December 2019|Anticipated|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990534||55996|
NCT01987401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|595|Service and Health During the Iraq and Afghanistan Era|CSP #595 - Respiratory Health and Deployment to Iraq and Afghanistan Pilot|CSP #595 Pilot|VA Office of Research and Development|No|Active, not recruiting|October 2014|August 2018|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2760|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Veterans who served during the Iraq and Afghanistan Era, without regard to actual        deployment, identified from the Department of Defense (DoD) Defense Manpower Data Center        (DMDC) master personnel roster of all persons serving during the time period of interest.|January 2016|January 21, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987401||56236|
NCT01987739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-057-116|Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users|A Single Center, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Six-way Crossover Single-dose Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Central Nervous System (CNS) Depressant Drug Users||Midnight Pharma, LLC|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|6||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987739||56210|
NCT01986803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRI-003|ABSORB STEMI: the TROFI II Study|Comparison of the ABSORBTM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction||ECRI bv|Yes|Active, not recruiting|December 2013|September 2017|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||January 2015|November 23, 2015|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01986803||56282|
NCT01986816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROI-LGBP|Return on Investment on Lap Gastric Bypass Regarding Quality of Life|Lap Gastric Bypass and Its Impact on Wheightloss, QoL and Economic Cost|ROI-LGBP|Lund University|Yes|Not yet recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|60 Years|No|Probability Sample|Populutaion af morbid obese patients with BMI of 35 or more eligible for bariatric surgery|November 2013|November 12, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986816||56281|
NCT01986829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309108|Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy|Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy||Washington University School of Medicine|No|Recruiting|February 2014|August 2022|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986829||56280|
NCT01987089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-017-13S|The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse|The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse||VA Office of Research and Development|No|Recruiting|August 2014|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|21 Years|65 Years|No|||October 2015|October 9, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987089||56260|
NCT01987362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-010-001|A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously|A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies.||Tensha Therapeutics|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|November 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01987362||56239|
NCT01987674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2013/239-31PMB|Pre-meal Protein Drink Improve Glycemic Regulation|Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes|PMB/T2D|Lund University|No|Enrolling by invitation|January 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||February 2015|February 17, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987674||56215|
NCT01987687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32W7|Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.|Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.||Northumbria University|No|Suspended|November 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|November 13, 2013||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01987687||56214|
NCT01988038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013979|Repository Study of Autosomal Dominant Polycystic Kidney Disease|Repository Study of Autosomal Dominant Polycystic Kidney Disease|Repository|The Rogosin Institute|No|Recruiting|November 2013|November 2053|Anticipated|November 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood sample for genotyping of specific PKD1 and PKD2 mutations. Buccal and/or semen sample      (optional and only if needed)|Both|18 Years|N/A|No|Non-Probability Sample|All patients enrolled in this study will have the diagnosis of autosomal dominant        polycystic kidney disease (ADPKD). The diagnostic criteria for at-risk individuals (i.e.,        with a first degree family member with ADPKD) includes the presence of at least two        (unilateral or bilateral) renal cysts, and two cysts in each kidney are considered        sufficient for diagnosis in aged 15 to 29 years and in 30 to 59 years, respectively. In        families of unknown genotype, the presence of one or more (unilateral or bilateral) renal        cysts is sufficient for establishing the diagnosis in individuals aged 15 to 29 years, two        or more cysts in each kidney is sufficient for individuals aged 30-49 years.|February 2016|February 8, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988038|20 Years|56187|
NCT01988311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00047665|Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators||Johns Hopkins University||Completed|May 2013|May 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988311||56167|
NCT01988584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0876|Safety and Effectiveness of Banked Cord Blood or Bone Morrow Stem Cells in Children With Cerebral Palsy (CP).|Autologous Cell Therapies for Cerebral Palsy-Chronic (ACT for CP)|ACT for CP|The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2013|May 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|2 Years|10 Years|No|||February 2016|February 29, 2016|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988584||56146|
NCT01988597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1047/62/2013|Dry Eye Symptoms and Quality of Life|Dry Eye Symptoms and Quality of Life||Singapore National Eye Centre|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be recruited from Dry Eye Clinic at Singapore National Eye        Center.|June 2014|June 9, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988597||56145|
NCT02004015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM_WTR_2012-9|Assessment Study of the Effect of NMBA on Bowel Peristalsis|Effect of an Induction Dose of Non Depolarizing Neuro Muscular Blocking Agents (NMBA) on Ultrasound Bowel Peristalsis.|CURARES|Fondation Ophtalmologique Adolphe de Rothschild|No|Terminated|November 2013|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||March 2015|December 11, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004015||54964|
NCT02004028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-203|Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.|An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.||Verastem, Inc.|Yes|Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02004028||54963|
NCT01999894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-67|Open-label Study of Safety and Tolerability of Memantine in Children With Autism|An Open-label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism||Forest Laboratories|No|Completed|November 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|6 Years|18 Years|No|||January 2014|January 31, 2014|November 26, 2013|No|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01999894||55281|
NCT02000154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001|Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study|Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome - Extension Study||SymBio Pharmaceuticals||Recruiting|October 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||November 2013|December 2, 2013|November 26, 2013||||No||https://clinicaltrials.gov/show/NCT02000154||55261|
NCT02000167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 136271|Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment|Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment||University of Arkansas|Yes|Completed|May 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|51|||Both|1 Year|21 Years|No|Non-Probability Sample|Patients will be identified through the registry for this specific aim. PMS patients in        the registry will be offered to be entered the study.|June 2015|June 22, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02000167||55260|
NCT02000180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-060|Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training|Do Progressive Levels of Simulation Fidelity Enhance Colonoscopic Skill Acquisition and Transfer in Novice Endoscopic Trainees?||St. Michael's Hospital, Toronto|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02000180||55259|
NCT02000479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.11/cardio11.01|Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure|Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure||Hasselt University|No|Completed|April 2011|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|N/A|N/A|No|||December 2013|December 8, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02000479||55236|
NCT02000765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115774|A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects|An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)||GlaxoSmithKline|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02000765||55214|
NCT02001077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|627-2007|Sleep and Pain Interventions in Fibromyalgia|Sleep and Pain Interventions in Fibromyalgia: Hyperalgesia and Central Sensitization|SPIN|University of Florida|No|Completed|February 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|113|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001077||55190|
NCT02001090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK nr 2013/1758|Vascular Function on the First Day After Cardiac Surgery|Vascular Function on the First Day After Cardiac Surgery||Norwegian University of Science and Technology|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|30 Years|N/A|No|Probability Sample|Patients undergoing coronary artery bypass surgery.|September 2015|September 28, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001090||55189|
NCT02001402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83573214|Chinese Health Investigation of Nurse Aging|||Peking University First Hospital|Yes|Enrolling by invitation|August 2008|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|2|||Female|40 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|About 2000 nurese aged 40-55 living in peking will be investigated.We will measure the        symptoms of perimenopausal syndrome by kupperman index、HRQOL（health -related quality of        life) to evaluate the severity of menopausal syndrome and quality of life.We choose nurses        whose KMI is above 15 and divided them into intervention group and control group.In        intervention group,we give them health education and exercise intervention.|November 2013|November 27, 2013|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001402||55165|
NCT01990547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20318-17|Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder|The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder|ViRTICo-BP|Walter Reed National Military Medical Center|Yes|Completed||August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Combat OIF/OEF Veterans|February 2016|February 9, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01990547||55995|
NCT01990794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103|90‐Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers|A 90-Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers||Cardno ChemRisk|Yes|Completed|June 2012|July 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples With DNA|whole blood, serum and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers from work site and off work site|October 2014|October 3, 2014|November 12, 2013||No||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01990794||55976|The primary limitation of our study was its small sample size. We believe the study was sufficiently robust because we evaluated effects on hematologic and thyroid variables, both of which have been identified as sensitive markers of cobalt exposure.
NCT01991093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-IIS|Multiple Electrode Aggregometry & Clopidogrel Resistance|The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.||Elpen Pharmaceutical Co. Inc.|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|280|||Both|18 Years|85 Years|No|Non-Probability Sample|type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD)patients who will be        detected for clopidogrel resistance|March 2015|March 13, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01991093||55953|
NCT01988103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-011|Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis|A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis||Celgene|Yes|Completed|July 2013|December 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|254|||Both|20 Years|N/A|No|||January 2016|January 26, 2016|May 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988103||56183|
NCT01979302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082425|Effectiveness of a Depression Care Management Initiative in Home Healthcare|Effectiveness of a Depression Care Management Initiative in Home Healthcare||Weill Medical College of Cornell University|No|Active, not recruiting|January 2009|||December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|310|||Both|65 Years|N/A|No|||July 2014|July 9, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01979302||56857|
NCT01987375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0049|Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures|Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures||Stanford University|Yes|Recruiting|November 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|19 Years|N/A|No|||November 2015|November 23, 2015|October 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987375||56238|
NCT01987713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309023|Chronic Conditions in Childhood Obesity Subject: An Mixed Methods Research Approach|Chronic Conditions in Childhood Obesity Subject: An Mixed Methods Research Approach||National Taiwan University Hospital|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|200|||Both|7 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 27, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987713||56212|
NCT01987700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTF 01-13|Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias|A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique||Musculoskeletal Transplant Foundation|No|Recruiting|July 2013|October 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987700||56213|
NCT01988064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sbcvrc-106-1014|Face to Face vs. Group Training Methods on Pulse Rate Taking in Patients With Cardiovascular Diseases.|Comparison of the Short-term Efficacy of Two Training Methods (Face to Face vs. Group Training) on Pulse Rate Taking in Patients With Cardiovascular Diseases, a Randomized Trial.||hahid Beheshti University of Medical Sciences|No|Recruiting|October 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|75 Years|No|||November 2013|November 13, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01988064||56186|
NCT01988324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.2708|AR and ER Imaging in Metastatic Breast Cancer|Androgen Receptor and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients||University Medical Center Groningen||Completed|August 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01988324||56166|
NCT01988610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26482|Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals|Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals||Stanford University|Yes|Recruiting|October 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988610||56144|
NCT01988831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG-MEL-BB|Efficacy of Propranolol Treatment to Prevent Melanoma Progression|Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial||University Hospital, Geneva|No|Suspended|June 2016|March 2022|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 13, 2013||No|We must delay the study for some financial reasons|No||https://clinicaltrials.gov/show/NCT01988831||56127|
NCT01989091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-CL-0001|Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC|Multi-Center, Prospective, Randomized, Open-Label, Sponsor-Blinded, Active-Control (Heparin) Clinical Investigation to Evaluate the Safety and Effectiveness of B-Lock™ as an Antimicrobial Catheter Lock Solution in Dialysis Patients With a Central Venous Catheter||Great Lakes Pharmaceuticals Inc.|Yes|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|85 Years|No|||November 2013|November 14, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01989091||56107|
NCT01989429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-EU04|Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients|A Randomized, Double-blind, Parallel Group Phase III Multi-center Trial to Compare Twice Daily Topical Application of M518101, Daivonex® and Vehicle in Patients With Plaque Psoriasis III||Maruho Europe Limited|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|788|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989429||56081|
NCT02004041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VLY-686-2101|Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis||Vanda Pharmaceuticals|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||January 2015|June 1, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02004041||54962|
NCT02004054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC_CLL_2012-8|Interest of Dynamic Measures of the Pupil in Optic Neuritis|Interest of Dynamic Measures of the Pupil in Optic Neuritis|PCT-NORB|Fondation Ophtalmologique Adolphe de Rothschild|No|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients with unilateral optic neuritis or with multiple sclerosis and an optic neuritis        in the previous 5 years|December 2013|December 5, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02004054||54961|
NCT01999907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD0001|Vitamin D to Reduce Colds and Asthma Attacks in Young Children|Vitamin D vs. Placebo in the Prevention of Viral-induced Exacerbations in Preschoolers With Asthma: a Pilot RCT|DIVA-pilot|St. Justine's Hospital|Yes|Completed|November 2013|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|1 Year|5 Years|No|||January 2015|January 8, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999907||55280|
NCT02000492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-038|Frequent Ballgames Training for 9-11 Year Old Schoolchildren|Intense School Based Physical Activity - Physiological, Cognitive and Sociological Aspects||University of Copenhagen|No|Recruiting|September 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|9 Years|11 Years|No|||November 2013|November 26, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000492||55235|
NCT02001896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTHLC001|Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation|A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation||Xinjiang Medical University|No|Not yet recruiting|December 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2013|November 28, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02001896||55127|
NCT02005900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSP/DHA/2010|Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.|Double-blind, Placebo-controlled, Randomized 48 Weeks of Duration Study. The Effect of the Administration of Docosahexaenoic Acid on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in Patients With HIV Infection Under High Activity Antiretroviral Treatment||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|June 2011|October 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||October 2013|December 4, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02005900||54819|
NCT02006212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARB 23th November 2013|Impact of Cerebral Monitoring on Neurologic Outcome in Cardiac Surgery|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|January 2014|August 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1500|||Both|18 Years|99 Years|No|||January 2016|January 27, 2016|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006212||54795|
NCT02006849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024943|ACTH Treatment of APOL1- Associated Nephropathy|ACTH Treatment of APOL1- Associated Nephropathy||Wake Forest School of Medicine|No|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||December 2014|December 9, 2014|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006849||54746|
NCT01990560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1061|Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism|Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990560||55994|
NCT01990807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCALL2012|Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia|Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine||Chinese Academy of Medical Sciences|Yes|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|18 Years|No|||November 2013|November 20, 2013|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01990807||55975|
NCT01991106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1313|Effects of Exercise Intensity in Obese Children and Adolescents|A Multi-centre Randomized Controlled Trial Examining the Effects of High Intensity Interval Training on Cardio-metabolic Outcomes in Obese Children and Adolescents||Norwegian University of Science and Technology|No|Recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|100|||Both|7 Years|16 Years|No|||December 2015|December 3, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01991106||55952|
NCT01986842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-3-050|Habitual Protein Intake and Muscle Protein Synthesis|The Impact of Habitual Dietary Protein Intake on the Anabolic Response in Elderly Men|Pro-Hab|Maastricht University Medical Center|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|24|||Male|55 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01986842||56279|
NCT01987102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-MTX-003|Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.|An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients||Isofol Medical AB|Yes|Recruiting|December 2013|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|12 Years|40 Years|No|||February 2016|February 23, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01987102||56259|
NCT01979315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK-1|Cross Correlation of Pain Hypersensitivity and Clinical Features and Electromyography in Low Back Pain Patients|Cross Correlation of Pain Hypersensitivity and Clinical and EMG Parameters||University of Belgrade|No|Recruiting|December 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients with subacute LBP from tertiary rehabilitation clinic|February 2016|February 3, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979315|5 Days|56856|
NCT01979328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THRIVE-III|Geko™ Plaster Cast Study, Deep Vein Thrombosis (DVT) Prophylaxis|The Efficacy of a Neuromuscular Stimulation Device (Geko™) in Promoting Blood Flow in a Plaster Cast as a Way of Offering Mechanical DVT Prophylaxis|THRIVE-III|University Hospital Southampton NHS Foundation Trust.|No|Completed|March 2012|||May 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|November 4, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01979328||56855|
NCT01987726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12067|Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors|Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|September 2013|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987726||56211|
NCT01987752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-040|Safety and Efficacy of Combigan® Ophthalmic Solution in Korea|||Allergan|No|Completed|January 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|732|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan® Ophthalmic        Solution in Clinical practice.|February 2014|February 25, 2014|November 13, 2013|No|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01987752||56209|
NCT01988077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipilimumab TIL|Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients|Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients||Sheba Medical Center|No|Recruiting|October 2013|October 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||November 2013|November 13, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01988077||56185|
NCT01988337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPIC36|Lesion Progression After Icon Treatment in Young Adults|Double Blind Randomized Controlled Clinical Trial of Lesion Progression After Treatment With Icon vs. Placebo in Caries Lesions in Young Adults Over 36 Months||DMG Dental Material Gesellschaft mbH|No|Recruiting|January 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|150|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988337||56165|
NCT01988623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-25229|Pivotal Response Treatment for Individuals With Intellectual Disabilities|Pivotal Response Treatment for Individuals With Intellectual Disabilities||Stanford University|No|Recruiting|December 2012|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|2 Years|17 Years|No|||December 2015|December 2, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988623||56143|
NCT01988844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0042UG|Upper Limbs Assessment in Children With Cerebral Palsy|Manual Dexterity and Upper Limbs Functionality Assessment in School Children With Cerebral Palsy||Universidad de Granada|Yes|Recruiting|November 2013|July 2016|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|6 Years|10 Years|No|Non-Probability Sample|School children with cerebral palsy.|December 2014|December 9, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988844||56126|
NCT01988857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115739|Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children|Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix™) in Healthy Vietnamese Children||GlaxoSmithKline||Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|302|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988857||56125|
NCT01989104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC13019|Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)|Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)||Pennington Biomedical Research Center|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Observational|Time Perspective: Cross-Sectional||3|Anticipated|150|||Both|6 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|September 2015|September 2, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989104||56106|
NCT01989117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR102013|Effectiveness of Osteopathy in the Preoperative Treatment of Postoperative Pain in Patients Undergoing Total Knee Replacement|Prospective Non-randomized Comparative Study Evaluating the Effectiveness of Osteopathy in the Preoperative Treatment of Postoperative Pain in Patients Undergoing Total Knee Replacement in Osteoarthritis Indication||Hospital Ambroise Paré Paris||Recruiting|November 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|54|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for primary total knee arthroplasty (TKA) for osteoarthritis.|November 2015|November 30, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989117||56105|
NCT01989455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA42-0113|A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers|A Single Center, Phase I, Double-blind, Placebo-controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Deferiprone Administered by Intravenous Infusion to Healthy Male and Female Volunteers||ApoPharma|Yes|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 15, 2013||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01989455||56079|
NCT01989468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2318|24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis||Novartis|No|Active, not recruiting|April 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|414|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989468||56078|
NCT02004067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 17821013.0.0000.5505|Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease|Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease||Federal University of São Paulo|No|Active, not recruiting|January 2013|February 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004067||54960|
NCT02001675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01265-38|Comparison of Both Metabolic and Functional Effects Induced by Two Neuromuscular Electrical Stimulation Protocols: A Comprehensive Approach Using Magnetic Resonance Imaging and Spectroscopy|Comparison of Both Metabolic and Functional Effects Induced by Two Neuromuscular Electrical Stimulation Protocols: A Comprehensive Approach Using Magnetic Resonance Imaging and Spectroscopy||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|December 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|December 4, 2013|December 21, 2012||No||No||https://clinicaltrials.gov/show/NCT02001675||55144|
NCT02001688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada-AAT (inhaled)-006|Phase II, Safety and ELF Study of "Kamada-API for Inhalation"|Phase II, Double-blind, Placebo-controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects||Kamada, Ltd.||Recruiting|April 2014|||February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|65 Years|No|||February 2015|February 8, 2015|November 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001688||55143|
NCT02005913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309068RINC|A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence|A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence||National Taiwan University Hospital|No|Not yet recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|20 Years|N/A|No|Probability Sample|diagnosed colorectal cancer patient|December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005913||54818|
NCT02006199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306-076-498|Effect of Mindfulness Based Treatment for Obsessive-compulsive Disorder|Effect of Mindfulness Based Treatment for Obsessive-compulsive Disorder||Seoul National University Hospital||Recruiting|October 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|17 Years|55 Years|No|||December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006199||54796|
NCT02006537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117023|A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects|A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study Will Also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294||GlaxoSmithKline|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 14, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006537||54770|
NCT02007122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEFTAROLINE_RRT|Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy|Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy||Medical University of Vienna|Yes|Recruiting|December 2013|August 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007122||54725|
NCT02007135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_SBrumagne_pneumvibrators|Comparison of Pneumatic and Electromagnetic Muscle Vibrators to Stimulate Muscle Proprioceptors|Comparison of fMRI Compatible Pneumatic and Electromagnetic Muscle Vibrators to Stimulate Muscle Proprioceptors||Katholieke Universiteit Leuven|Yes|Completed|November 2013|October 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Young Flemish Volunteers|October 2015|October 14, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007135||54724|
NCT01990820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH09-177|Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty|A Randomized Trial of the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinusplasty||NorthShore University HealthSystem Research Institute|No|Recruiting|March 2009|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|2 Years|12 Years|No|||February 2015|February 11, 2015|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01990820||55974|
NCT01991119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-03-085-001|Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation|Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion||Samsung Medical Center|No|Completed|May 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||November 2013|November 17, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01991119||55951|
NCT01986855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-001|A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|468|||Both|25 Years|N/A|No|||March 2016|March 15, 2016|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986855||56278|
NCT01987128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC04-13|Popliteal Sciatic Nerve Block: Intraneural or Extraneural?|Blocco Del Nervo Sciatico al Poplite, Intraneurale o Extraneurale? Confronto Prospettico, Randomizzato in Cieco Tra la modalità di Iniezione di Anestetico Locale Per il Blocco Eco Guidato Del Nervo Sciatico al Poplite Nella Chirurgia Dell'Alluce Valgo||ASST Gaetano Pini-CTO|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987128||56257|
NCT01987141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205512|Gestational Weight Gain and the Electronic Medical Record|WATE Study - Gestational Weight Gain and the Electronic Medical Record|WATE|Loyola University|No|Recruiting|October 2013|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 11, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01987141||56256|
NCT01979341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaIVF-RCT-dual trigger|The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes|Dual Trigger With Gonadotropin-releasing Hormone Agonist (GnRHa) and Human Chorionic Gonadotropin (hCG) to Optimize ICSI Reproductive Outcomes||Antalya IVF|No|Recruiting|October 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|800|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979341||56854|
NCT01987765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198027-A|Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea|||Allergan|No|Completed|January 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|847|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in        clinical practice.|March 2014|March 26, 2014|November 13, 2013|No|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01987765||56208|
NCT01979627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuxhtransulnar|Safety and Feasibility of Transulnar Artery Approach for Coronary Angiography or Angioplasty|Safety and Feasibility of Transulnar Artery Approach for Coronary Angiography or Angioplasty||The Second Hospital of Hebei Medical University||Recruiting|October 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||January 2015|January 8, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01979627||56832|
NCT01988090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33261|High Dose Vitamin D vs Standard Dose Vitamin D Study|A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors||Baylor Breast Care Center|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988090||56184|
NCT01988350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064360|Pancreatic Insufficiency Secondary to Tobacco Exposure|Pancreatic Insufficiency Secondary to Tobacco Exposure||Emory University|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|202|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Smokers and non-smoking controls without a h/o pancreatic disease.|November 2013|November 13, 2013|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01988350||56164|
NCT01988636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914010|Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults|Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults||National Institutes of Health Clinical Center (CC)||Completed|October 2013|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|450|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01988636||56142|
NCT01988870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17091|IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer|A Pilot, Single Arm, Study of the Safety and Feasibility of Single-Fraction Intraoperative Radiation Treatment (IORT) With CT-On-Rails-Guided HDR Brachytherapy for the Treatment of Early-Stage Breast Cancer||University of Virginia|Yes|Completed|December 2013|November 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|50 Years|N/A|No|||March 2016|March 1, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988870||56124|
NCT01989130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071346|Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED|Evaluation of the Cepheid Xpert CT/NG For Management of STI in the ED: Immediate V. Delayed Test Results||George Washington University|No|Recruiting|October 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|December 15, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01989130||56104|
NCT01989143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7541001|Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.|A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects||Pfizer|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|92|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01989143||56103|
NCT01989481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI10B02-OS|Predicting the Outcome of Total Knee Arthroplasty and Spinal Surgeon|Prospective Study of Risk Factors and Outcomes Following Total Knee Arthroplasty and Spinal Surgeon||Beijing Jishuitan Hospital|No|Recruiting|November 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood samples collected from Peripheral Venous Blood； Tissues collected from the operation|Both|18 Years|65 Years|No|Non-Probability Sample|Inpatients; Patients have been diagnosed with osteoarthritis or disc degeneration disease.|March 2015|March 23, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01989481||56077|
NCT01989793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078435|A Study of Muscle Strength Maintenance in Older Adults|A Study of Muscle Strength Maintenance in Older Adults||Johns Hopkins University|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989793||56053|
NCT02001428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT099875_Malaria in Early Life|Malaria in Early Life Study|Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial||Gadjah Mada University|Yes|Recruiting|May 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|756|||Both|N/A|1 Year|No|||February 2016|February 17, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02001428||55163|
NCT02001441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000781|UCLA Fitness and Memory Study|Physical Activity Levels and Hippocampal Sub-region Structure in MCI|AIM|University of California, Los Angeles|No|Terminated|August 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Whole blood|Both|60 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Southern California Residents with memory complaints aged 60-89.|December 2015|December 2, 2015|November 27, 2013||No|Fitness Tracking Device No Longer Available|No||https://clinicaltrials.gov/show/NCT02001441||55162|
NCT02001103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112171MID|Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia|Memantine add-on for Improving Cognitive Impairments and Negative Symptoms in Patients With Schizophrenia||National Taiwan University Hospital|No|Recruiting|January 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|45 Years|No|||July 2015|July 14, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001103||55188|
NCT02005588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ferrot2013|Treatment of Iron Deficiency Anemia With Pregnancy|Comparison Between Aminoacid Chelated Iron and Iron Salt in Treatment of Iron Deficiency Anemia With Pregnancy||Cairo University|No|Completed|December 2013|July 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Female|20 Years|40 Years|No|||July 2015|July 27, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02005588||54843|
NCT02006836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tongji201201|Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients|Glycemic Index & Glycemic Responses to Majia Pomelos||Huazhong University of Science and Technology|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|59|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|May 25, 2014|December 5, 2013|Yes|Yes||No|December 21, 2013|https://clinicaltrials.gov/show/NCT02006836||54747|
NCT02007148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICADO01|MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer|MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study|MICADO|International Group of Endovascular Oncology|No|Recruiting|November 2013|May 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02007148||54723|
NCT02007161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2013-004636-29|Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers|Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers|DDD13DICLO|Katholieke Universiteit Leuven|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007161||54722|
NCT01991132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1059/74/2013|Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands|Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands||Singapore National Eye Centre|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||June 2014|May 18, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01991132||55950|
NCT01986881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-004|Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|November 2013|June 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|3900|||Both|40 Years|N/A|No|||January 2016|January 7, 2016|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986881||56276|
NCT01986868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27850|Identification of Adverse Plaque Characteristics by Coronary MR Angiography|Identification of Adverse Plaque Characteristics by Coronary Magnetic Resonance Angiography||Cedars-Sinai Medical Center|No|Recruiting|April 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01986868||56277|
NCT01987154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6020|Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula|Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula||Mead Johnson Nutrition|No|Recruiting|February 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|N/A|N/A|No|||November 2015|November 16, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01987154||56255|
NCT01987167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-330|Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis|Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis|ACHTAR|Neuro-Ophthalmologic Associates, PC|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01987167||56254|
NCT02026778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0691|Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy|||Yonsei University|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|168|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02026778||53221|
NCT02026999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17393|Sugammadex Versus Neostigmine Use in Patients Undergoing Septoplasty Operations|Phase IV Study of the Use of Sugammadex Versus Neostigmine in Septoplasty Operations||Ankara University|No|Completed|January 2012|February 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|65 Years|No|Non-Probability Sample|patients undergoing septoplasty operation|January 2014|January 1, 2014|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02026999|1 Day|53204|
NCT01997749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-1-2013-012|Effects of a Ketogenic Diet on Acute Stroke|The Effect of a Ketogenic Diet on Blood Glucose, Function and Disease Progress in Acute Stroke Patients||University of Copenhagen|No|Completed|May 2013|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01997749||55444|
NCT01998503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0703|Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis|Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation Versus Autologous Stem Cell Transplantation Alone in the Treatment of AL Amyloidosis||Nanjing University School of Medicine|Yes|Completed|December 2007|August 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||November 2013|November 25, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01998503||55387|
NCT01998516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI 366|Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder|Emotional Intelligence in Schizophrenia and Bipolar I Disorder: a Comparison Between Patients, Their Siblings, and Healthy Controls||Medical University Innsbruck|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||5|Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Psychiatric out- and inpatient setting|March 2016|March 21, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01998516||55386|
NCT01998828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-354-0101|Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia|A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia||Gilead Sciences|No|Terminated|February 2014|May 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998828||55362|
NCT01998776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISO-SB|Evaluate Misoprostol for the Healing of Small Bowel Ulcers in Low-dose Aspirin Users Complicated by Small Bowel Bleeding|A Double-blind, Randomized, Placebo Controlled Trial of Misoprostol for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding (MISO-SB Study)||Chinese University of Hong Kong|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|82|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998776||55366|
NCT01998789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL1602|Everolimus Post Orthotopic Liver Transplant|A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients||Columbia University|No|Recruiting|October 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998789||55365|
NCT01998802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-3|Phase 3 Study of EBI-005 in Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease|EBI-005|Eleven Biotherapeutics|Yes|Completed|January 2014|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|670|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998802||55364|
NCT01995955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00986-37|Evaluation of Coronary Microvascular Dysfunction (EVACORY)|The Proposed Study is to Validate a New Non-invasive Imaging Technique for Evaluation of Cardiac Microciculation in Coronary Artery Disease With a Comparison With Validated Technique Invasive, Which is Measure of Index of Myocardial Resistance|EVACORY|University Hospital, Grenoble|Yes|Recruiting|June 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|March 22, 2016|November 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01995955||55581|
NCT01999283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSUPT2013A|Effect of Group Pilates and Yoga Exercise Classes for Chronic Cervical Pain|Effect of Group Pilates and Yoga Exercise Classes on Function, Range of Motion, Endurance, Postural Position, Medication Use and Balance in Adults With Chronic Cervical Pain|Pilates/Yoga|Wayne State University|No|Completed|July 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01999283||55328|
NCT01999556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-HEM-SPEC-001|LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia|LCI-HEM-SPEC-001: Tissue Collection for Familial Acute Myelogenous Leukemia Genetic Analysis||Carolinas Healthcare System|Yes|Recruiting|November 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients must have a diagnosis of acute myelogenous leukemia. Family members of patients        with acute myelogenous leukemia may be enrolled.|January 2016|January 28, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999556||55307|
NCT01995578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-192|Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse|A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|1 Year|75 Years|No|||September 2015|September 21, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995578||55610|
NCT01981473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801364|Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab|Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)|ANTIBODY-RA|Pfizer|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 4|Observational|Time Perspective: Cross-Sectional||3|Actual|605|||Both|18 Years|N/A|No|Non-Probability Sample|Population will be selected from patients seen in a rheumatology clinical setting who        currently treated with etanercept, adalimumab or infliximab for rheumatoid arthritis|December 2015|December 8, 2015|November 5, 2013|No|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT01981473||56690|
NCT01981772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0437|Efficacy of Buffered Lidocaine in Patients With Facial Swelling|Anesthetic Efficacy of 4% Buffered Lidocaine in Emergency Patients With Facial Swelling.||Ohio State University|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01981772||56668|
NCT01977976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TY03|RCT on the Effect of Endometrial Injury on Ongoing Pregnancy Rate in Subfertile Women Undergoing IVF|A Randomized Controlled Trial on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing in Vitro Fertilization Treatment||The University of Hong Kong|Yes|Completed|April 2011|April 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977976||56959|
NCT01978548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103012|A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease|A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma||Janssen Research & Development, LLC|Yes|Completed|December 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|50 Years|90 Years|No|||June 2015|June 24, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978548||56915|
NCT01979081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Labarge 2013-02|Detecting and Addressing Preclinical Disability|Detecting and Addressing Preclinical Disability||McMaster University|Yes|Active, not recruiting|January 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|44 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care center|September 2015|September 22, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01979081||56874|
NCT02029365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0449|Transversal, Controlled and Not Randomized Study, Laying on the Desire of Children and Eating Disorders in a Population of Infertile Women|Single-center Study, Transversal, Controlled and Not Randomized, Laying on the Desire of Children and Eating Disorders in a Population of Infertile Women|TCA2|Nantes University Hospital|No|Terminated|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|71|||Female|18 Years|N/A|No|||March 2015|March 9, 2015|January 6, 2014||No|recruitment difficulties|No||https://clinicaltrials.gov/show/NCT02029365||53022|
NCT01997463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200000709|Supervised Asthma Medication in Schools (SAMS)|The Cost Effectiveness of School-Based Supervised Asthma Therapy|SAMS|University of Arizona|Yes|Active, not recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|5 Years|12 Years|No|||December 2015|December 1, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997463||55466|
NCT01997476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105005314/1010-26|EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease|Evaluation of Combined Endoscopic Ultrasound Ductal Evaluation Before & After Secretin Stimulation in One EUS Session for the Diagnosis of Exocrine Pancreas Disease||Indiana University|Yes|Recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01997476||55465|
NCT01997489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry-Eyes-13|Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.|Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients||Rigshospitalet, Denmark|No|Completed|September 2001|October 2014|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|15 Years|N/A|No|||October 2014|October 26, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01997489||55464|
NCT01997229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-MG-301|Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)||Alexion Pharmaceuticals|No|Active, not recruiting|December 2013|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||September 2015|September 13, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997229||55484|
NCT01997502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494171|Accuracy of SpHb Monitoring|Prospective Observational Study Characterizing Noninvasive Hemoglobin (SpHb) Measured With Pulse Co-Oximetry Technology in a Variety of Surgical Cases||University of California, Davis||Completed|August 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective surgery.|June 2015|June 30, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01997502||55463|
NCT01998308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|October6U-0001|Comparison Between Four Types of Single Dose Hyaluronic Acid Injection in Patients With Knee Osteoarthritis|Intra-articular Hyaluronic Acid Knee Injection: Randomized Control Trial.||October 6 University|Yes|Recruiting|December 2012|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Anticipated|200|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|patient with knee osteoarthiritis|September 2015|September 28, 2015|November 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998308|24 Months|55402|
NCT01997996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU 10/038|ProViS (Prolift+M and Vita Sexualis) Study|ProViS (Prolift+M TM and Vita Sexualis) Study|ProViS|Cantonal Hospital of St. Gallen|Yes|Completed|May 2011|October 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Female|18 Years|N/A|No|Non-Probability Sample|Patients visiting specialist in hospitals and specialized doctor's offices scheduled to        undergo Prolapse surgery.|November 2013|November 25, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01997996||55425|
NCT01999608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/180|Vitamin D Deficiency and Ovarian Reserve Among Infertile Patients|Vitamin D Deficiency and Ovarian Reserve Among Infertile Patients. A Cross-sectional Analysis||Universitair Ziekenhuis Brussel|No|Recruiting|August 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|43 Years|No|Non-Probability Sample|Infertile women 18-43 years old undergoing IVF/ICSI|November 2013|November 25, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01999608||55303|
NCT01998542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-010-HNC|Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck|Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.|HNC|Immunovative Therapies, Ltd.|Yes|Active, not recruiting|December 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|70 Years|No|||December 2015|December 7, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01998542||55384|
NCT01998815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 310-13|Role and Mechanisms of Obesity Surgery - Physical Activity and Other Predictors of Hospital Stay, Recovery and Complications After Obesity Surgery|Role and Mechanisms of Obesity Surgery - Physical Activity and Other Predictors of Hospital Stay, Recovery and Complications After Obesity Surgery|RAMOSPHYSSURG|Göteborg University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|65 Years|No|Non-Probability Sample|All obese patients undergoing laparoscopic Roux-en-Y gastric bypass surgery at Sahlgrenska        University Hospital in Gothenburg and Kärnssjukhuset in Skövde, Sweden.|January 2016|January 7, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998815||55363|
NCT01999036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0046|Save Hearts in Arizona Registry and Education (SHARE) Project||SHARE|University of Arizona||Recruiting|November 2004|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Probability Sample|Out-of-hospital cardiac arrest patients on which resuscitation was attempted by Emergency        Medical Services in the state of Arizona|May 2015|May 28, 2015|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01999036||55346|
NCT01995968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC12 08|Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.|Antenatal Detection of Fetal Growth Restriction : Determinants and Consequences for Stillbirths Rate.|REPERE|University Hospital, Grenoble|No|Active, not recruiting|November 2013|December 2015|Anticipated|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|480|||Both|24 Weeks|42 Weeks|No|Probability Sample|SGA births to mothers residents in 3 French districts (Isère, Savoie and Haute-Savoie)|December 2014|July 31, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01995968|1 Week|55580|
NCT01995617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-004-001|Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of GEN-004, a Streptococcus Pneumoniae Protein Subunit Vaccine, in Adult Subjects||Genocea Biosciences, Inc.|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 10, 2015|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995617||55607|
NCT01995630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOLvsAIOL|Optical Quality After Implantation of a Spherical or Aspherical Intraocular Lens in Hypermetropic Patients|Optical Quality After Implantation of a Spherical or Aspherical Intraocular Lens in Hypermetropic Patients: A Randomized Clinical Trial||Medical University of Graz|No|Recruiting|November 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|220|||Both|40 Years|80 Years|No|||April 2015|April 7, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995630||55606|
NCT01995643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-114|Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.|Effect of Grape Seed Extract on Modulation of Oxidative Stress/ Inflammation/ Insulin Sensitivity Induced by High Fat-carbohydrate Meal in Healthy Human Subjects|GSE2|Institute for Food Safety and Health, United States|No|Active, not recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995643||55605|
NCT01995929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_2013_003|Functional Endoscopy in Neurogenic Dysphagia|Transnasal Endoscopic Evaluation of Swallowing: Functional Esophagoscopy Using an Ultrathin Video Endoscope in Neurogenic Dysphagia||University Hospital Muenster|No|Recruiting|September 2012|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The focus of our observational study are patients with suspected neurogenic dysphagia.|November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01995929||55583|
NCT01996202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045042|A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma|A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma||Duke University|Yes|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01996202||55562|
NCT01981785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-CFCT-04|Investigation of Immune Disorders and Deficiencies|Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies||O & O Alpan LLC|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with abnormal immune responses or potential PID or immune disorders (allergies,        autoimmune diseases) will be enrolled as the study group and patients with no prior immune        abnormalities will be enrolled as the control group.|May 2015|May 6, 2015|May 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01981785||56667|
NCT01982045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44095.041.13|RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion|A Randomized Controlled Trial of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion|AxA|UMC Utrecht|No|Enrolling by invitation|October 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01982045||56647|
NCT01978288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308055098|Microbial Influence on Airway Function and Inflammation|Microbial Influence on Airway Function and Inflammation||Indiana University|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Nasal swabs, blood, stool specimens will be retained|Both|N/A|72 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Infants whose mother has asthma|November 2015|November 5, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978288||56935|
NCT01987245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013S-512|Plethysmographic Waveform for Monitoring the Quality of Cardiopulmonary Resuscitation|The Application Research of Plethysmographic Waveform in Quality Control Feedback System During Cardiopulmonary Resuscitation|PWMQC|Peking Union Medical College Hospital|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|617|||Both|18 Years|75 Years|No|Non-Probability Sample|emergency room sample of multi-centers|April 2015|April 27, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01987245||56248|
NCT01987479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28702|The Safety and Efficacy of RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rheumatoid Arthritis Patients.|Multi-center, Open-label Single Arm Phase IIIb Study on Safety and Efficacy of Subcutaneous (SC) Tocilizumab in Monotherapy or in Combination With Methotrexate (MTX) or Other Non-biologic Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients With an Inadequate Response to Non-biologic DMARDs||Hoffmann-La Roche||Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01987479||56230|
NCT01987492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB28182|A Study of Lebrikizumab in Patients With Severe Asthma Who Depend on Oral Corticosteroids (OCS)|A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Oral Corticosteroid-Sparing Effect of Lebrikizumab in Patients With Severe Corticosteroid Dependent Asthma||Hoffmann-La Roche||Recruiting|February 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|225|||Both|12 Years|75 Years|No|||March 2016|March 1, 2016|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987492||56229|
NCT02030106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818914|Motherhood and Microbiome|Revealing the Role of the Cervico-vaginal Microbiome in Spontaneous Preterm Birth|M&M|University of Pennsylvania|No|Recruiting|October 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1470|Samples With DNA|Women will self-collect samples of their cervicovaginal fluid using large cotton swabs.      Subjects who have had a previous preterm birth will also have cervical cells collected in      the same manner that cells are collected for a routine pap smear.|Female|13 Years|50 Years|No|Non-Probability Sample|Pregnant women will be recruited from three locations: Penn ObGyn Associates, Helen O.        Dickens Clinic, and Maternal Fetal Medicine at 2000 Courtyard. Potential subjects will be        identified from clinical schedules and will be pre-screened in EPIC for eligibility. They        may be approached during a clinical visit, or the research team may call them prior to or        after a scheduled visit to introduce the study. Women can be enrolled anytime between the        confirmation of pregnancy and 20 weeks/0 days gestation. For convenience, research visits        can be conducted at the time of a scheduled clinical visit, or at a separate time.|April 2015|April 6, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02030106||52965|
NCT01998035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM3752|Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies|Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Replapsed and Refractory Lymphoid Malignancies||Columbia University|Yes|Recruiting|November 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998035||55422|
NCT01998048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINNISH|Operative Treatment of Traumatic Anteroinferior Shoulder Instability in Young Male Patients|Operative Treatment of Traumatic Anteroinferior Shoulder Instability in Young Male Patients. The Outcome of Arthroscopic Bankart vs. Open Latarjet Stabilization Surgery, a Randomized Controlled Trial.||Turku University Hospital|Yes|Recruiting|November 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Male|16 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 24, 2015|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01998048||55421|
NCT01998841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN28352|A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease (AD), Including a Placebo-Treated Noncarrier Cohort|A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Nonrandomized, Placebo-Treated Noncarriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease||Genentech, Inc.||Recruiting|December 2013|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|30 Years|60 Years|No|||March 2016|March 1, 2016|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998841||55361|
NCT01999062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5181-CE|Automated Breast Radiation Therapy Using an MR-Guided Process|Automated Breast Radiation Therapy Using an MR-Guided Process||University Health Network, Toronto|Yes|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01999062||55344|
NCT01998009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-5985|Study of In-home Tests for Colorectal Cancer|Performance Characteristics of Immunochemical and Guaiac FOBT|SIT|Centers for Disease Control and Prevention|No|Completed|May 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1382|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998009||55424|
NCT01998022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00207-38|Hypertension of Our Patients: Knowledge, Control, Comorbidity|Hypertension of Our Patients: Knowledge, Control, Comorbidity|H3C|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|383|||Both|18 Years|N/A|No|Non-Probability Sample|Treated hypertensive population|October 2014|October 2, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01998022||55423|
NCT01999361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071058|Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss|Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss||University of Miami|No|Recruiting|January 2009|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|18|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999361||55322|
NCT01998555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306066RINC|Web-based Psychological Intervention to Coronary Artery Heart Disease Patients|Development and Evaluation of a Web-based Group Cognitive-behavioral Therapy Program for Coronary Artery Heart Disease Patients||National Taiwan University Hospital|No|Active, not recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|30 Years|70 Years|No|||August 2014|August 11, 2014|October 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01998555||55383|
NCT01999322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3931|A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes|A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes|onset® 4|Novo Nordisk A/S|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999322||55325|
NCT01999335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPZ007|A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple Myeloma|Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects||Onyx Pharmaceuticals|Yes|Active, not recruiting|November 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999335||55324|
NCT01995656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15197|A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|44|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|November 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995656||55604|
NCT01995669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0261|Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma|A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995669||55603|
NCT01996228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0002|Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy|Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy||Tianhe Stem Cell Biotechnologies Inc.||Recruiting|November 2013|||October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|14 Years|No|||March 2014|March 18, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996228||55560|
NCT01996241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/2013|Evaluation of an Intervention for Adolescent Girls in Karnataka|Evaluation of an Intervention Supporting Adolescent Girls From Marginalized Communities to Complete Secondary Schooling|Samata|Karnataka Health Promotion Trust|No|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1530|||Female|13 Years|15 Years|No|||March 2015|March 30, 2015|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01996241||55559|
NCT01982058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131023|Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer|Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer||Rutgers, The State University of New Jersey|Yes|Recruiting|August 2011|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|372|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01982058||56646|
NCT01977989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02478-FB|Vancomycin in Spine Surgery|Randomized Control Trial of Vancomycin Powder Following Posterior Instrumented Spinal Surgery for Trauma||University of Tennessee|Yes|Enrolling by invitation|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01977989||56958|
NCT01986972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAntoniazzi|Supragingival Plaque Removal With and Without Dentifrice|Supragingival Plaque Removal With and Without Dentifrice: A Randomized Controlled Trial||Franciscan University Center|Yes|Completed|July 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|17 Years|28 Years|No|||November 2013|November 12, 2013|March 9, 2013||No||No||https://clinicaltrials.gov/show/NCT01986972||56269|
NCT01987505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28943|MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma.|OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA.||Hoffmann-La Roche||Active, not recruiting|November 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|November 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01987505||56228|
NCT01987856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aCGH vs blastocyst morphology|Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle|Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a Frozen Embryo Transfer (FET) Cycle; Array Comparative Genome Hybridization (aCGH) Euploid Screened Versus Morphology Selected Blastocyst.||Antalya IVF|No|Withdrawn|January 2014|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2014|February 22, 2014|November 13, 2013||No|loss of funding|No||https://clinicaltrials.gov/show/NCT01987856||56201|
NCT01988194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11353|Pragmatic Research eXamining Inpatient Symptoms|Pragmatic Randomized Controlled Trial of Adjunct Acupuncture vs Usual Care Among Hospitalized Patients|PRAXIS|University of California, San Francisco|Yes|Active, not recruiting|November 2013|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01988194||56176|
NCT01997216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-036|Multifocal Lens Design Evaluation|Multifocal Lens Design Evaluation (US)||Alcon Research|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|42|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|November 19, 2013|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01997216||55485|
NCT01996995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46084.075.13|Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications|Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications|LASER-1|Medical Research Foundation, The Netherlands|No|Active, not recruiting|March 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996995||55502|
NCT01997008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CHR 13-11990|Optimizing Resilience and Coping in HIV Via Internet Delivery|Optimizing Resilience and Coping in HIV Via Internet Delivery|ORCHID|University of California, San Francisco|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|22|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997008||55501|
NCT01998594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00027968|Use of FlexHD as Post Trapeziectomy Spacer|Use of FlexHD as a Post-Trapeziectomy Spacer in Patients Treated for Thumb Basal Joint Arthritis|MTF|Cedars Sinai Medical Care Foundation|No|Recruiting|August 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 27, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01998594||55380|
NCT01998854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL03537|Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation|Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation||Gynesonics|No|Terminated|February 2013|January 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Female|28 Years|N/A|No|Non-Probability Sample|Patients of specified clinical sites with complaint of symptomatic uterine fibroids.|March 2015|March 9, 2015|November 25, 2013|No|Yes|Investigational device changes|No||https://clinicaltrials.gov/show/NCT01998854||55360|
NCT01998568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-451-02-1|The Intraocular Pressure Measured by Different Tonometers in Corneal Edema|The Variation of the Intraocular Pressure Measured by Different Tonometers in Patients With Clinical Corneal Edema||Prince of Songkla University|Yes|Recruiting|November 2013|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a clinical central corneal edema after clear cornea phacoemulsification        and intraocular lens implantation|June 2015|June 11, 2015|November 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01998568||55382|
NCT01998581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLBELLA-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2013|||||N/A|N/A|N/A||||||||||||||August 26, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998581||55381|
NCT01996293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00079810|Pregnant Women Taking Lamictal for Bipolar Disorder|Pharmacokinetics of Lamotrigine in Pregnant and Postpartum Women With Bipolar Disorder|PK-LAPB|Northwestern University|No|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Blood serum specimen will be obtained to measure lamotrigine and estradiol levels. Standard      of care labs will be obtained on every participant that is eligible and signs informed      consent. Participants will not have more than 50 ml of blood drawn every 8 weeks.      Participants will also have the option to have blood drawn for DNA banking.      Participants in the study that elect to receive analgesia for pain related to labor and have      a spinal-epidural at Northwestern University will have CSF stored and banked for future      analysis.|Female|18 Years|45 Years|No|Non-Probability Sample|Participants will be recruited broadly from Northwestern clinical services including        Internal Medicine, OB/GYN, Family Medicine, and Psychiatry, registries, and from the local        Chicagoland community. Patients that sign consent, complete the evaluation and meet        criteria for Bipolar Disorder, any subtype, will be enrolled into the study.|January 2016|January 8, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01996293||55555|
NCT01996306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXEPT|A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC|A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer|AXEPT|Epidemiological and Clinical Research Information Network|Yes|Active, not recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|650|||Both|20 Years|N/A|No|||February 2016|February 2, 2016|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996306||55554|
NCT01999049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50813|Observational Study of the Argus® II Retinal Prosthesis System|Observational Study of the Argus® II Retinal Prosthesis System||University Health Network, Toronto|No|Recruiting|April 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|25 Years|N/A|No|Non-Probability Sample|Patients with severe to profound outer retinal degeneration|April 2015|April 23, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999049||55345|
NCT01995708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009|CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|November 2013|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995708||55600|
NCT01996826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-113H|A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival||Massachusetts Eye and Ear Infirmary|Yes|Recruiting|April 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|October 1, 2015|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996826||55515|
NCT01996839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|842|Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|December 2013|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|514|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996839||55514|
NCT01996852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE14812|Improving Erectile Function and Quality of Life After Prostate Cancer Treatment|Improving Erectile Function and Quality of Life After Prostate Cancer Treatment||Case Comprehensive Cancer Center|Yes|Suspended|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|144|||Male|21 Years|N/A|No|||February 2016|February 15, 2016|November 22, 2013||No|Administrative hold|No||https://clinicaltrials.gov/show/NCT01996852||55513|
NCT01996254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0123-CSP-000|Electrical Stimulation for the Treatment of Post-Amputation Pain Using the Smartpatch System|A Randomized, Double-Blinded, Controlled, Parallel Group, Multicenter Pilot Study of the Smartpatch Peripheral Nerve Stimulation (PNS) System for the Treatment of Post-Amputation Pain||NDI Medical, LLC|No|Recruiting|October 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996254||55558|
NCT01996267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13TRT|Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2|Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study|TRAIN-2|The Netherlands Cancer Institute|Yes|Active, not recruiting|December 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01996267||55557|
NCT01996553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743024-6|The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention|The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention||Jesse Brown VA Medical Center|Yes|Recruiting|April 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects consist of patients who present to the cardiac catheterization laboratory for        an angiogram or percutaneous intervention for the first time.|February 2016|February 22, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996553||55535|
NCT01990950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005|Fenestrated AAA Endovascular Graft Post-Approval Study|Evaluation of the Long-term Safety and Performance of the Zenith® Fenestrated AAA Endovascular Graft Post-Approval Study||Cook||Active, not recruiting|March 2014|April 2024|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2015|March 7, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990950||55964|
NCT01990963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346|Brain Densitometric Assessment With Axial Computerized Tomography After Severe Brain Trauma.|Brain Densitometric Assessment With Axial Computerized Tomography After Severe Brain Trauma.||Università degli Studi dell'Insubria|Yes|Recruiting|January 2010|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Male and female, any ethnic group with severe brain trauma|November 2013|November 16, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01990963||55963|
NCT01986699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144467|Laparascopic Assisted Colonoscopic Polypectomy|Randomized Controlled Trial-Laparoscopic Assisted Colonoscopic Polypectomy||Stony Brook University|No|Completed|March 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|34|||Both|18 Years|90 Years|No|Probability Sample|GI clinic|May 2015|May 8, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01986699||56290|
NCT01987518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peps Data Base|French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis|French Digestive Polyposis Cohorte||Hôpital Edouard Herriot|No|Recruiting|January 2011|August 2017|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|350|Samples With DNA|Genetic Diagnostic|Both|12 Years|90 Years|No|Probability Sample|Digestive Polyposis Cohort|March 2015|March 17, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987518||56227|
NCT01987531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816482|Temporary Biventricular Pacing|Hemodynamic Effect of Temporary Biventricular Pacing After Mitral and/or Tricuspid Valve Surgery in Patients With Preoperative Biventricular Dysfunction|BIPACE|University of Pennsylvania|No|Recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|84 Years|No|||October 2013|November 12, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987531||56226|
NCT01988207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-135|Treating Laryngeal Hyperfunction With Flow Phonation|||University of Central Arkansas|Yes|Not yet recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||November 2013|November 13, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01988207||56175|
NCT01988220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHai012013|The Effects of Lower Extremity Sensory Retraining Treatment in Individuals With Post-stroke Sensory Impairment|The Effects of Lower Extremity Sensory Retraining Treatment in Individuals With Post-stroke Sensory Impairment||University of Haifa|No|Recruiting|December 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01988220||56174|
NCT01996774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0013|Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance|Immunologic Profile of Children and Teenagers With Severe Allergy to Peanuts and Nuts After Induction of Tolerance: a Pilot Project|TOY|Lille Catholic University||Completed|February 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|70|Samples Without DNA|Blood, serum, saliva|Both|1 Year|17 Years|Accepts Healthy Volunteers|Probability Sample|Children with allergy to peanuts and nuts hospitalized for initial diagnosis or for        treatment in the Allergology Center of GHICL.|August 2014|August 18, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996774||55519|
NCT01997515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00081191|Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study|Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study||Northwestern University|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|82|||Both|18 Years|64 Years|No|||October 2015|October 5, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997515||55462|
NCT01997528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr. 1191/2013|Gas Transfer on ILA-Activve|Efficiency of Gas Exchange Using a Miniaturized Pump Driven Veno-venous Extracorporeal Gas Exchange Device (ILA-Activve)||Medical University of Vienna|No|Recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|89 Years|No|||November 2013|November 22, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01997528||55461|
NCT01997762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:151|Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?|Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?||University of Manitoba|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|112|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|May 9, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01997762||55443|
NCT01998607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110102|Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw|Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw||Amgen|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|420|||Both|N/A|N/A|No|Probability Sample|Oncology specialists treating adult patients with bone metastases from solid tumours|June 2015|June 15, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998607||55379|
NCT01995721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50934|4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children|Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children||National Institute of Child Health, Hungary|No|Not yet recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|17 Years|No|||November 2013|November 20, 2013|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995721||55599|
NCT01995734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230CUS33|An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly|An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy (ACCESS)|ACCESS|Novartis||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||December 2015|December 26, 2015|November 20, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT01995734||55598|
NCT01999348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/039|A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting|||Allergan|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1553|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open-angle glaucoma or ocular hypertension|October 2015|November 3, 2015|November 26, 2013||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01999348||55323|
NCT01999595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-4765B|The Antalgic Effect of Pulse Frequency and Pad Size of TENS on Blunt Pressure Pain|The Effect of Pulse Frequency and Pad Size of Transcutaneous Electrical Nerve Stimulation (TENS) on Experimental Blunt Pressure Pain in Healthy Participants|TENS|Chang Gung University|No|Enrolling by invitation|November 2013|May 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|180|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||November 2013|December 2, 2013|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999595||55304|
NCT01996319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ADE03|Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.|MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|MOVE|Novartis||Not yet recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|N/A|No|||January 2014|January 27, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01996319||55553|
NCT01996332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17915|A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option||Hoffmann-La Roche||Completed|April 2004|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1805|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|November 22, 2013|No|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01996332||55552|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01995682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.34.NRC|Feasibility Clinical Study of NLA Tool-US|Evaluate the Feasibility of the NLA Tool, a Combined Assessment of Nutritional and Physical Functional Status, to Provide Personalized Advice for the Independence and Mobility of Elderly|NLA|Nestlé|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|154|None Retained|No biospecimens are to be collected or retained.|Both|65 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Independently living men and women at 65-90 years old who are able to walk with or without        walking aid|August 2014|August 6, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995682||55602|
NCT01995695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 13-001|Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|October 2013|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|March 15, 2016|November 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995695||55601|
NCT02027857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131211-8|Comparison of the Application in Traumatic Brain Edema Between EIT and Non-invasive ICP Monitoring|Comparison of the Application in Traumatic Brain Edema Between Electrical Impedance Tomography and Non-invasive Intracranial Pressure Monitoring|EIT|Xijing Hospital|Yes|Not yet recruiting|January 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|16 Years|65 Years|No|||January 2014|January 2, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02027857||53138|
NCT01996280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-10-100|A Randomized Clinical Trial of Culturally Tailored MI|A Randomized Clinical Trial of Culturally Tailored Motivational Interviewing|CTMI|Northeastern University|No|Recruiting|December 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01996280||55556|
NCT01990664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5464|Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses|A Multi-Center Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-Fit Into Spherical or Toric Senofilcon A Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|November 15, 2013|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01990664||55986|
NCT01990677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECSelsior|Eplerenone for the Treatment of Central Serous Chorioretinopathy|Eplerenone for the Treatment of Central Serous Chorioretinopathy||Wills Eye|No|Active, not recruiting|October 2013|May 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|108|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990677||55985|
NCT01986985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2013-GES-0014|Comparison of 18F FDG PET/CT TO PET MRI|Comparison of 18F FDG PET/CT TO PET MRI|PET/MR US|GE Healthcare|No|Completed|January 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|November 6, 2013|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01986985||56268|
NCT01987258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-141|The Acute Effect of Interval-walking|The Acute Effect of Interval-walking|acute IWS|Rigshospitalet, Denmark|No|Completed|June 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|30 Years|80 Years|No|||February 2014|February 26, 2014|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01987258||56247|
NCT01987271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0.381.0.172.099-11|Effects Of Noninvasive Ventilation On Functional Capacity Of Patients With Cystic Fibrosis|Effects Of Noninvasive Ventilation During The Treadmill Walking Test On Cardiorespiratory System, Walk Distance, And Thoracoabdominal Kinematics Of Patients With Cystic Fibrosis: Clinical Randomized Controlled Trial.||Universidade Federal de Pernambuco|Yes|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|7 Years|16 Years|No|||November 2013|November 12, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01987271||56246|
NCT01987869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-88|Hiperemezis and Serotonin Elevated Serum Serotonin Levels in Hyperemesis|Relationship Between Elevated Serum Serotonin Levels in Symptomatic Patients With Hyperemezis||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|October 2013|March 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|90|||Female|15 Years|50 Years|No|Probability Sample|pregnant women between six and fourteen weeks|November 2013|November 18, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987869||56200|
NCT01987882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313575|Cerebral Palsy Hip Outcomes Project - International Multi-centre Study|Outcomes of Hip Interventions for Children With Cerebral Palsy - An International Multi-centre Prospective Comparative Cohort Study||Holland Bloorview Kids Rehabilitation Hospital|No|Recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|||Both|2 Years|18 Years|No|Non-Probability Sample|Children with severe, non-ambulant cerebral palsy (GMFCS level IV and V) and their parent        / primary caregiver will be enrolled in the study.|January 2016|January 19, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987882|2 Years|56199|
NCT01988454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2011-2103|Characterization of Dyslipidemia in Adolescent Obesity|Characterization of Dyslipidemia in Adolescent Obesity||Health Diagnostic Laboratory, Inc.|No|Completed|September 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|50|Samples With DNA|Whole Blood and serum|Both|13 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Enrollment will be representative of the ethnic population of Charlotte, NC, estimated as        50% Caucasian, 35% African American, 10% Hispanic, and 5 % other.|February 2015|February 12, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988454||56156|
NCT01988467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6322/6.3.13|The Protective Role of the Nose During Acute Exposure to Passive Smoking.|The Protective Role of the Nose During Acute Exposure to Passive Smoking.||Hellenic Anticancer Society|Yes|Completed|August 2011|July 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01988467||56155|
NCT01988480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.514|Guided Surgery Versus Sinus Graft|Clinical Assessment of Innovative Procedure Using Image-guided Surgery to Avoid Sinus Lift|SINIMAGE|Hospices Civils de Lyon|No|Active, not recruiting|March 2009|September 2018|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01988480||56154|
NCT01997242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMN-18/2013|The Surgery After Stenting (SAS) Registry|A Multicenter Registry of Consecutive Patients Undergoing Cardiac and Noncardiac Surgery or Operative Endoscopic/Endovascular Procedures After Implantation of a Coronary Stent|SAS registry|Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|June 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic        procedures|September 2013|April 24, 2014|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01997242|1 Month|55483|
NCT01997255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33251|Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)|An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome||Baylor College of Medicine|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|18 Years|No|||December 2015|December 15, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997255||55482|
NCT01997775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-BR-102-039|Metformin in Stage IV Lung Adenocarcinoma|A Phase II Trial to Examine the Effect of Metformin on Plasma IL-6 Level in Patients With Advanced Non-Small Cell Lung Cancer||National Cheng-Kung University Hospital|No|Recruiting|August 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|48|||Both|20 Years|80 Years|No|||November 2013|November 24, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01997775||55442|
NCT01997788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMPKidney|The Intrathecal Morphine for Nephrectomy|The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy|EMPON|Seoul National University Hospital|Yes|Completed|August 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|80 Years|No|||July 2015|July 1, 2015|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01997788||55441|
NCT01998061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangU|Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression|Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)||Zhejiang University|No|Recruiting|December 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||December 2013|December 19, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01998061||55420|
NCT01998074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP2010-Paradice|Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy|Evaluation of the Efficacy of a New Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy|Paradice|United Pharmaceuticals|No|Completed||||November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|N/A|6 Months|No|||November 2013|November 27, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01998074||55419|
NCT01998321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|October6U-0002|PSI for Bilateral Simultaneous TKA in Sever Varus|Bilateral Simultaneous Total Knee Arthroplasty in Patients With Severe Articular Deformities||October 6 University|Yes|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|30 Years|80 Years|No|||November 2013|November 23, 2013|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01998321||55401|
NCT01999647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-ORT-04|Efficacy of Ultrasound-Guided Local Anesthetic Injection Into or Around the Sciatic Nerve for Lower Limb Anesthesia|Intraneural Injection of Ropivacaine for Subgluteal Sciatic Nerve Block Leads to Faster Onset and Higher Success Rates: a Randomized, Controlled Trial||University of Parma|No|Completed|December 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999647||55300|
NCT01999660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Space-CS-01|Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™|Prospective National Post-marketing Surveillance for the Investigation of the Efficacy and Safety of SpaceOAR™ to Maintain Space Between the Rectum and Prostate During Radiation Therapy||CS Diagnostics GmbH|No|Recruiting|November 2013|January 2019|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Male|18 Years|N/A|No|Non-Probability Sample|prostate cancer patients treated by radiotherapy and prophetically by SpaceOAR™|November 2013|February 24, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999660||55299|
NCT01995747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109045RC|The Effect of Anti-CεmX on IgE Production|The Effect of Humanized Anti-CεmX Antibody (h4B12) on IgE Production in the PBMC Isolated From Atopic Dermatitis Patients|h4B12PBMC|National Taiwan University Hospital|No|Completed|February 2012|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|patients of atopic dermatisis|November 2013|November 26, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995747||55597|
NCT01999075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/26E|Stacking Exercises Aid the Decline in FVC and Sick Time|Stacking Exercises Attenuate the Decline in Forced Vital Capacity and Sick Time (STEADFAST)|STEADFAST|Children's Hospital of Eastern Ontario|Yes|Recruiting|March 2013|December 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|6 Years|16 Years|No|||February 2016|February 23, 2016|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01999075||55343|
NCT01999621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-16|Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure|Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure|CBP-DO|University Hospital, Grenoble|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|140|||Both|18 Years|N/A|No|Non-Probability Sample|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or        directly in ICU will be included|November 2013|November 25, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01999621||55302|
NCT01999634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0024|Monitoring by Microdialysis of Postoperative Complications After Proctectomy|Evaluation of Microdialysis to Monitor Postoperative Outcomes After Proctectomy|MTM-COLON-II|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|November 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999634||55301|
NCT01997086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTED-MED|Percutaneous Transforaminal Endoscopic Discectomy vs Microendoscopic Discectomy for Treatment of Lumbar Disc Herniation|Percutaneous Transforaminal Endoscopic Discectomy (PTED) Versus Microendoscopic Discectomy (MED) for the Treatment of Lumbar Disc Herniation: A Prospective Randomized Controlled Study||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|October 2013|August 2023|Anticipated|August 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|345|||Both|18 Years|65 Years|No|||December 2014|December 9, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01997086||55495|
NCT01997307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/2013|The LADIES Acute Coronary Syndromes Study|Age at Menopause and Severity of Coronary Artery Disease Among Postmenopausal Women With Acute Coronary Syndromes|Ladies ACS|Arcispedale Santa Maria Nuova-IRCCS|Yes|Completed|April 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|675|||Both|55 Years|N/A|No|Non-Probability Sample|Consecutive patients older than 55 years with an acute coronary syndromes, undergoing        coronary angiography are eligible for the study, irrespective of subsequent        revascularization. Eligible are women and men with a 2:1 enrolment ratio.|December 2015|December 21, 2015|September 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01997307||55478|
NCT01997320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-068|Effect of Strength Training and Protein Supplementation on Muscles in the Very-old|Effect of Strength Training and Protein Supplementation on the Muscle Function in Very Old Nursinghome Residents|83+|Bispebjerg Hospital|Yes|Completed|November 2013|October 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|83 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01997320||55477|
NCT01986712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck MISP 50422|An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron|An Observational Pilot Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon Alfa Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma||St. Luke's Hospital and Health Network, Pennsylvania|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with surgically resected melanoma receiving adjuvant therapy with HDI or PEG IFN        thherapy|January 2016|January 21, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01986712||56289|
NCT01987284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2271|SER100 in Isolated Systolic Hypertension|A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.||Serodus ASA|No|Completed|November 2013|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|50 Years|80 Years|No|||August 2014|September 26, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01987284||56245|
NCT01987544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telebike2013|Effects of Ergometer Training With Telemonitoring in Patients With Chronic Obstructive Pulmonary Disease (COPD) After Exacerbation|German: Effekte Eines Telemonitorisch überwachten Ergometertrainings Bei Patienten Mit Einer COPD Nach Exazerbation: Eine Prospektiv Randomisierte Studie|COPD|Institut für Pneumologie Hagen Ambrock eV|No|Completed|September 2012|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01987544||56225|
NCT01987557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDRC|Amplitude and Rate of Intrinsic Feedback During Treadmill Training for Parkinson's Disease|The Therapeutic Contributions of Somatosensory Feedback During Exercise in Parkinson's Disease; A Randomized, Controlled Trial.||Wilfrid Laurier University|No|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|40 Years|79 Years|No|||June 2015|June 12, 2015|October 9, 2013||No||No|February 18, 2015|https://clinicaltrials.gov/show/NCT01987557||56224|
NCT01988233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR013151|BAILA: Being Active, Increasing Latinos Healthy Aging|BAILA: Being Active, Increasing Latinos Healthy Aging|BAILA|University of Illinois at Chicago|Yes|Active, not recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|333|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01988233||56173|
NCT01988246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMISE Trial|Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery|Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery|PROMISE|The Cleveland Clinic|Yes|Recruiting|December 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01988246||56172|
NCT01989299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-HF Registry|Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction|Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction (VIP-HF)|VIP-HF|University Medical Center Groningen|Yes|Recruiting|October 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with heart failure with preserved ejection fraction (HFpEF)|July 2015|July 27, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989299|2 Years|56091|
NCT01997554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.672|Validation of a New TSH Test|Validation of a New TSH Test for Early Screening of Hypothyroidism||Hospices Civils de Lyon|No|Completed|March 2012|||August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|1654|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 11, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01997554||55459|
NCT01998087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2181-198-03-04-13-0027|Proactive Breastfeeding Support in First Time Mothers|The Effect of Written Information and Support Phone Calls for First Time Mothers on Breastfeeding Rates: A Randomized Controlled Trial||University of Split|No|Recruiting|June 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|500|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01998087||55418|
NCT01998334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP BUNDLE-CRRT|Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis|Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis||Ruijin Hospital|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||November 2013|November 23, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01998334||55400|
NCT01999673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1202|Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer|SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer|SUNRISE|Peregrine Pharmaceuticals|Yes|Active, not recruiting|December 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|582|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999673||55298|
NCT01996605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00025901|Efficacy of Spinal Oxytocin in Healthy Volunteers|Efficacy of Intrathecal Oxytocin in Human Volunteers||Wake Forest School of Medicine|Yes|Recruiting|June 2014|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|36|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996605||55531|
NCT01995981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-ONCO-201303|Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS|Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS|PREDICT|Radboud University|No|Recruiting|December 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced soft tissue sarcoma who have an indication for pazopanib treatment.|June 2015|June 23, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995981||55579|
NCT01995994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1203-106-404|Continuous Glucose Monitoring System in Intensive Care Unit|Continuous Glucose Monitoring System in Intensive Care Unit - Preliminary Study Evaluating Accuracy||Seoul National University Hospital|No|Completed|June 2012|February 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Probability Sample|Patients planned to stay in intensive care units longer than 72 hours|November 2013|May 19, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995994||55578|
NCT01996865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-008|Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.|A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma|MAGNIFY|Celgene|Yes|Recruiting|April 2014|March 2023|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996865||55512|
NCT01996878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH060105|Genetic Polymorphism and Parkinson's Disease in Taiwanese|Association Analysis of Single Nucleotide Polymorphisms and the Incidence of Parkinson's Disease in a Hospital-based Case-control Study in Taiwan||Changhua Christian Hospital||Completed|February 2006|October 2013|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|334|Samples With DNA|Collect 10 mL peripheric blood for DNA extraction|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Taiwanese|November 2013|November 22, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996878||55511|
NCT02027428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-NSCL-003|Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer|A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)|aboundsqm|Celgene|Yes|Recruiting|February 2014|December 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027428||53171|
NCT01996579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1569-13|Prevention of Nosocomial Infections in Critically Ill Patients With Lactoferrin: The PREVAIL Study|A Phase 2 Randomized Controlled Trial to Determine the Efficacy of Lactoferrin for the Prevention of Nosocomial Infections.|PREVAIL|Queen's University|No|Recruiting|November 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|100 Years|No|||February 2016|February 17, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01996579||55533|
NCT02028130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CI004B, 12/LO/0809|Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation: A Safety and Feasibility Study|The Safety and Feasibility of Concomitant Left Atrial Appendage Electrical Isolation and Occlusion in the Treatment of Persistent Atrial Fibrillation|LEIO-AF|Royal Brompton & Harefield NHS Foundation Trust|No|Enrolling by invitation|July 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||June 2014|June 2, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028130||53117|
NCT02028403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5326|Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy|Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|8|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028403||53096|
NCT01997333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX011-04|Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer|A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)|METRIC|Celldex Therapeutics|Yes|Recruiting|November 2013|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997333||55476|
NCT01997840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-MM-102|ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma|A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dex in Patients With Relapsed-and-Refractory Multiple Myeloma||Acetylon Pharmaceuticals Incorporated|No|Recruiting|November 2013|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997840||55437|
NCT01986738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.055|A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer|A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|January 2012|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|39|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01986738||56287|
NCT01986998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oral-CORTEM|Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse|Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.||Germans Trias i Pujol Hospital|No|Recruiting|October 2013|March 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|59 Years|No|||December 2015|December 4, 2015|January 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01986998||56267|
NCT01987011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1109_P3|Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers|Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers||Green Cross Corporation|No|Completed|August 2013|March 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|420|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01987011||56266|
NCT01987570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMU_2011|Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.|Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.||Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|August 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|20 Years|40 Years|No|||July 2015|July 22, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01987570||56223|
NCT01987895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-061A301|Clinical Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea|AC-061A301, A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)||Actelion|Yes|Recruiting|November 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987895||56198|
NCT01988493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200095-004|Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma|A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function||Merck KGaA||Recruiting|January 2014|May 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|167|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988493||56153|
NCT01988766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-1889|Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement|Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement||University of Chicago|No|Completed|October 2012|August 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1424|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who had a PICC line placed at the University of Chicago by the procedure service        between September 1, 2010 and December 31, 2011|November 2014|November 20, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988766||56132|
NCT01989026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVK-2013-1303771|A Randomized Trial of Providing BCG Vaccination Immediately|Reducing Mortality at the Neonatal Intensive Care Unit in Guinea-Bissau: A Randomized Trial of Providing BCG Vaccination Immediately||Bandim Health Project|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|1064|||Both|N/A|30 Days|No|||October 2013|July 14, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01989026||56112|
NCT01989312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-99-12|The Simultaneous Use of Supraclavicular and Distal Blocks|Can we Gain an Advantage by Combining Distal Median, Radial and Ulnar Nerve Blocks With Supraclavicular Block? A Randomized Controlled Study||Ankara University|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|75|||Both|18 Years|80 Years|No|||November 2013|November 20, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01989312||56090|
NCT01989325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-216|A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma|||Array BioPharma|No|Active, not recruiting|November 2013|||February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989325||56089|
NCT01997801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_KEThyRobot|Ketamine in Robot-assisted Thyroidectomy|The Efficacy of Intraoperative Ketamine in Patients Undergoing Robot-assisted Thyroidectomy|KEThyRobot|Seoul National University Hospital|Yes|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Both|19 Years|80 Years|No|||November 2013|November 24, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01997801||55440|
NCT01998620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XMX-HBV-001|Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis|Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis||Zhejiang Hisun Pharmaceutical Co. Ltd.|No|Recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01998620||55378|
NCT01999088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-2889|Health Benefits of Functional Meat (With n-3 Fatty Acids and Rosemary Extract) on Low Risk for Cardiovascular Disease People|Randomized, Double-blind, Cross-over Placebo-controlled Study to Assess the Functional Meat Products With n-3 and Rosemary Extract Fluid in Biochemical Markers of Cardiovascular Disease Related Risk in Subjects at Low Risk for Cardiovascular Disease||Instituto de Investigación Hospital Universitario La Paz|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 25, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01999088||55342|
NCT01999374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130034|Long Term Follow up of Recipients of Functional Islet Allografts|Long Term Follow up of Recipients of Functional Islet Allografts||University of Miami|No|Recruiting|March 2013|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Subject with Type 1 diabetes mellitos status post islet transplantation|December 2015|December 16, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999374||55321|
NCT01996033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-064-GE-HT|EnligHTN German Observational Study|EnligHTN German Observational Study||St. Jude Medical|No|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population enrolled in this investigation will consist of males and females        with uncontrolled hypertension who meet all inclusion criteria, and none of the exclusion        criteria.|January 2016|January 7, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996033||55575|
NCT02027194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD thesis|Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis|Effects of Chinese Herbal Medicine for Treatment of Allergic Rhinitis: A Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Completed|June 2012|October 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|298|||Both|18 Years|30 Years|No|||March 2015|March 12, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027194||53189|
NCT01996007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2013/05|Understanding Pneumococcal Carriage and Disease|Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months Following Introduction of PCV13.||University of Oxford|Yes|Completed|March 2014|||August 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|1200|Samples Without DNA|Bacteria grown from nasopharyngeal swabs Serum|Both|13 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|One thousand healthy children aged 13-48 months, of which at least 600 will be aged 21-48        months, who have received 3 doses of PCV13 will be recruited along with a subset (200) of        their parents/legal guardians|November 2015|November 6, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996007||55577|
NCT01996020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1208-018-421|Measurement of Cerebral Flow Using Transfontanellar Doppler in Infants Under Cardiopulmonary Bypass|Intraoperative Trans-fontanel Cerebral Ultrasonography in Infants During Pediatric Cardiac Surgery Under Cardiopulmonary Bypass||Seoul National University Hospital|Yes|Completed|September 2012|August 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Both|N/A|1 Year|No|Probability Sample|pediatric patients with congenital heart disease scheduled to recieve cardiac surgery        under CPB|May 2015|May 19, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996020||55576|
NCT02027870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREDIT-III-131113|EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)|A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II With Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery . (CREDIT-III Trial)|CREDIT-III|JW Medical Systems Ltd|Yes|Recruiting|January 2014|June 2019|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|621|None Retained|According to the CREATE (Multi - Center Registry of Excel Biodegradable Polymer Drug Eluting      Stent) registration results show that ExcelTM drug-eluting stents implanted an average of 12      months, target lesion (TLF) the failure rate of 6.7%.Will this study expected target lesion      group stent failure rate estimate of 6.7%, the target is 9.5%;Test hypothesis: bilateral      0.05% 0.05%, master degree, clinical follow-up requirements is more than 95%, this research      need at least 829 patients, remove the CREDIT II randomized controlled study can provide the      number of cases of test group 208 examples, this study still need to be included in the 621      patients.|Both|18 Years|75 Years|No|Probability Sample|the Patients With de Novo Coronary Artery Lesions|January 2014|January 2, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027870|5 Years|53137|
NCT01996592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 22468|Persistent Pain After CS Delivery|Novel Approach Using Pre-surgery Psychosocial State and Pain Trajectory Methods to Identify Patient Characteristics and Predict Patients at Risk for Persistent Pain After Cesarean Delivery||Wake Forest School of Medicine|Yes|Completed|May 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|575|||Female|18 Years|55 Years|No|Probability Sample|those subjects who are scheduled to have an elective cesarean section (CS) and able to        complete a preoperative psychosocial/depressive questionnaire and who agree to be        contacted on a daily basis for 60 days postoperatively|February 2016|February 4, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996592||55532|
NCT02028143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE|ICE: Intracardiac Ultrasound Within the Left Atrium During Radiofrequency Ablation of Nonvalvular Atrial Fibrillation|ICE: Intracardiac Ultrasound Within the Left Atrium During Radiofrequency Ablation of Nonvalvular Atrial Fibrillation|ICE|Wellmont CVA Heart Institute|No|Recruiting|November 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2014|January 6, 2014|December 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028143||53116|
NCT02028754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-CMC-1101|A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms||RLOTUS|Allergan|No|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|60 Years|80 Years|No|||March 2014|March 19, 2014|January 6, 2014|Yes|Yes||No|March 19, 2014|https://clinicaltrials.gov/show/NCT02028754||53069|
NCT02028416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBD2571975|Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia|Protocol for Comparison of Two Different Regimens of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia|ATG|National Institute of Blood Disease Center, Pakistan|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|65 Years|No|||November 2014|November 6, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02028416||53095|
NCT02028689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-128|Metformin and Furosemide Drug-Drug Interaction Study|A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate Potential Pharmacokinetic Interaction Between Lesinurad and Metformin and Between Lesinurad and Furosemide in Health Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|October 2013|January 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02028689||53074|
NCT02028702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mntl-1877|Alternative Treatments for Menopausal Women|Alternative Treatments for Menopausal Women: The Efficacy of a Novel Red Clover Treatment on Menopausal Women.||Aarhus University Hospital|Yes|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT02028702||53073|
NCT01987297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL2012|Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL|Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study||Shanghai Jiao Tong University School of Medicine|No|Recruiting|October 2012|October 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|680|||Both|18 Years|65 Years|No|||November 2014|November 26, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01987297||56244|
NCT01987908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aes-103-003|Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease|A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Two Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease||Baxalta US Inc.|No|Terminated|October 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|60 Years|No|||August 2015|August 7, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01987908||56197|
NCT01988259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISDCS|Head-neck Coordination Analysis After Minimally Invasive Surgery in the Dorsal Cervical Spine|Comparison of Open vs Minimally Invasive Dorsal Approaches for Foraminotomy and Laminoplasty in the Cervical Spine Through Performance of Head-neck-coordination Analysis|MISDCS|Schoen Klinik Hamburg Eilbek|No|Recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988259||56171|
NCT01988506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130101|Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases|Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach|TRANSREG|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01988506||56152|
NCT01988779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45566|Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations|Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations||University of Rochester|No|Recruiting|October 2013|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988779||56131|
NCT01989039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hsu2013-TMU-JIRB201307021|IR, Inflammatory and Cardiovascular Markers in PCOS Among Obese and Non-obese Women|||Taipei Medical University WanFang Hospital|No|Recruiting|August 2013|July 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Female|13 Years|48 Years|No|Non-Probability Sample|Women had been fulfilled with whole anthropometric measurements, clinic and biochemical        survey about insulin resistance, cardiovascular and inflammatory markers.|November 2013|November 19, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01989039||56111|
NCT01989689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00039574|Etanercept and Vascular Function in Psoriasis|Etanercept and Vascular Function in Psoriasis|EVIP|Emory University|Yes|Completed|August 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|70 Years|No|||December 2014|December 12, 2014|November 13, 2012||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01989689||56061|
NCT01998867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2013-1003|Fasting Predictors of OGTT and MMTT Response|Identification of Fasting Biomarkers That Predict Responses to the Oral Glucose Tolerance Test (OGTT) and Mixed Meal Tolerance Test (MMTT)||Health Diagnostic Laboratory, Inc.|No|Active, not recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood and serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Representative of the ethnic population of Richmond, VA|February 2015|February 12, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998867||55359|
NCT01999101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS-Px-104-II-01|Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients|A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients||Phenex Pharmaceuticals AG|No|Terminated|October 2013|January 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||November 2014|October 26, 2015|November 19, 2013||No|Discontinued development.|No||https://clinicaltrials.gov/show/NCT01999101||55341|
NCT01999114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1025|The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (Mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers|A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects||Purdue Pharma LP|Yes|Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|328|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999114||55340|
NCT01999686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS3233-1013|PCOS Treatment Using DLBS3233, Metformin, and Combination of Both|Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility|POSITIF|Dexa Medica Group|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|186|||Female|18 Years|40 Years|No|||November 2015|November 25, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999686||55297|
NCT01999387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41/13|Follow up of Patients After Oral Immunotherapy for Cow's Milk, Eggs and Peanuts||OIT followup|Assaf-Harofeh Medical Center|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples Without DNA|Blood tests|Both|4 Years|40 Years|No|Non-Probability Sample|Patients > 4 years old with IgE mediated allergy to cow;s milk, eggs or peanuts who        completed an OIT program >6 months ago|June 2013|December 2, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999387||55320|
NCT02026947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3418363|Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.|Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.|AttenPsyc|Niuvanniemi Hospital|No|Withdrawn|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|15 Years|30 Years|No|||April 2014|April 9, 2014|December 27, 2013||No|We did not commence the trial because there were no patients who could fulfill the inclusion    criteria.|No||https://clinicaltrials.gov/show/NCT02026947||53208|
NCT02027207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-12090|Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh|An Individually Randomized, Placebo-controlled Trial to Measure the Protection Conferred by a Single Dose Regimen of Bivalent, Killed, Whole Cell Oral Cholera Vaccine (Shanchol™) in Dhaka, Bangladesh|SCVB|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|204438|||Both|1 Year|N/A|Accepts Healthy Volunteers|||June 2015|July 26, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02027207||53188|
NCT02027636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0465/08/10|Comparative Effectiveness Research for Eliminating Disparities|UPR-CHA Research Center of Excellence- Supplement|CERED|Cambridge Health Alliance|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|257|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02027636||53155|
NCT02027649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K14 in bladder cancer|Detection of K14 in Bladder Cancer With a Non Invasive Technique|K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.||Corporacion Parc Tauli||Not yet recruiting|January 2014|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Urine|Both|18 Years|N/A|No|Probability Sample|Hospital patients.|January 2014|January 3, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027649|2 Years|53154|
NCT02027623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205051|Spinal Control During Functional Activities to Improve Low Back Pain Outcomes|Spinal Control During Functional Activities to Improve Low Back Pain Outcomes|LBP|Washington University School of Medicine|Yes|Recruiting|December 2013|March 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|60 Years|No|||January 2016|January 7, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027623||53156|
NCT02028767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.24|Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets|Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study)||Boehringer Ingelheim||Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|January 6, 2014||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT02028767||53068|
NCT02028780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1321.5|Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects|Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).||Boehringer Ingelheim||Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|80|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 6, 2014||||No|November 13, 2015|https://clinicaltrials.gov/show/NCT02028780||53067|
NCT02028793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHTCPHARM2|Work Pressure for Pharmacist With Home Pharmaceutical Care|Factors Related to Work Pressure and Turnover Intention for Pharmacists With Home Pharmaceutical Care||Taichung Veterans General Hospital|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community pharmacists who attend the protocol (offered by National Health Insurance        Administration,, Taiwan). the protocol is designed to provide home pharmaceutical care        (PC) to the patients with heavy health expenditure. This group of community pharmacists        needs to operate their pharmacy while offering PC with small amount of payment. This study        investigates the work load, pressure, and intention of leaving the protocol.|August 2014|August 27, 2014|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02028793||53066|
NCT02028429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepatology PGIMER 2012|Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.|To Study The Proof of Concept in The Improvement of Cognition and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy by Means of a Pharmacological Intervention With Sildenafil (A Phosphodiesterase-5 Inhibitor).||Postgraduate Institute of Medical Education and Research|Yes|Active, not recruiting|July 2012|January 2014|Anticipated|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|70 Years|No|||January 2014|January 3, 2014|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02028429||53094|
NCT02028715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.08.22.F2|Efficacy of IV Acetaminophen for Pain Management|Efficacy of IV Acetaminophen for Pain Management Following Major Gynecologic Surgery: Effect on Opioid Rescue, Return of Bowel Function, Cost and Length of Hospital Stay.||Aultman Health Foundation|No|Recruiting|January 2014|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|85 Years|No|||January 2014|January 6, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028715||53072|
NCT01987583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients|The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients in Jeddah, 2013, A Randomised Controlled Trial||King Abdulaziz University|Yes|Completed|November 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|65 Years|No|||May 2014|May 13, 2014|November 13, 2013||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01987583||56222|
NCT01988519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNHK 13|Drains in Pancreatic Surgery|Does the Type of Drain Influence the Postoperative Pancreatic Fistula Rate After Pancreatic Resection?|DRAPA|University Hospital Hradec Kralove|No|Recruiting|October 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||January 2015|January 1, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988519||56151|
NCT01989052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047969|Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma|A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma||Duke University|No|Suspended|May 2014|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|138|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|October 21, 2013|Yes|Yes|Study is temporarily suspended for funding reasons.|No||https://clinicaltrials.gov/show/NCT01989052||56110|
NCT01989338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUT09/37-26|Effects of Hallux Valgus Deformity on Rear Foot Position, Pain, Function, and Quality of Life in Women|Effects of Hallux Valgus Deformity on Rear Foot Position, Pain, Function, and Quality of Life in Women||Hacettepe University|No|Completed|March 2012|February 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Effects of hallux valgus deformity in women|September 2013|November 14, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01989338||56088|
NCT01990209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 203|Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)|A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)||SCRI Development Innovations, LLC|No|Recruiting|February 2014|June 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990209||56021|
NCT01998880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21004 (Stage 1b)|CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities||Hoffmann-La Roche||Active, not recruiting|December 2009|July 2020|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|787|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|November 25, 2013|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01998880||55358|To date only an abbreviated CSR has been produced for Stage 1b.
NCT02026479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201307|Sudden Hearing Loss Multi-center Clinical Trial|Glucocorticoid Postauricular Injection Treatment for Sudden Hearing Loss: a Multi-center, Opened, Randomized, Controlled Clinical Trial||Peking University People's Hospital||Not yet recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|60 Years|No|||December 2013|December 31, 2013|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02026479||53244|
NCT01995760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310037RINA|The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?|The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?||National Taiwan University Hospital|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|123|||Both|20 Years|N/A|No|Non-Probability Sample|Inpatients of National Taiwan University Hospital. During the period of 2001/1/1 to        2013/12/31, age above or equal to 20 year-old adult with positive methicillin-resistant        Staphylococcus aureus blood culture who receiving vancomycin therapy with therapeutic        monitoring.|September 2014|September 2, 2014|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01995760||55596|
NCT02026960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047147|RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)|RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)||Duke University|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02026960||53207|
NCT02027467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV/121108/SA/HSC|Study to Assess the Effect of StemAlive® Supplement on the Levels of Stem Cells in Human Volunteers|Assessment of the Effect of StemAlive® Herbal Supplement on the Levels of Circulating Hematopoietic Stem Cells in Human Volunteers|Hematoalive|Vedic Lifesciences Pvt. Ltd.|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|23|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 3, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02027467||53168|
NCT02027896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP ATTACK Trial v4.0|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|HIP ATTACK|McMaster University|Yes|Recruiting|March 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|45 Years|N/A|No|||March 2016|March 15, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027896||53135|
NCT02027441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK4101|Enhanced Prevention in Couples: Feasibility Study #2|Enhanced HIV Prevention in Serodiscordant Couples in Lesotho: Feasibility Study #2|EPIC|Columbia University|No|Completed|September 2012|September 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|191|None Retained|HIV rapid tests will also be conducted using whole blood ﬁnger-stick.Blood will be collected      speciﬁcally for this study. Specimens will not be stored. All rapid HIV test kits will be      labeled using a unique participant identiﬁcation number. Participant names will not be      included on the label.|Both|18 Years|N/A|No|Non-Probability Sample|Pregnant and postpartum women already tested for HIV attending participating antenatal        clinics. Men and women already tested for HIV receiving care and treatment at        participating TB clinics. This study will recruit women attending ANC and men and women        attending TB clinics. All men and women recruited for the study will have already been        tested for HIV and received their test results. These facilities were selected as entry        points for the study as these clinics are locations where large numbers of individuals are        offered HIV testing and become engaged in HIV prevention and/or care and treatment        services.|March 2015|March 23, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02027441||53170|
NCT02027454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117009|Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction|A Study to Evaluate the Effect of GSK1265744 150mg Administered Orally Every 12h x 3 Doses on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin||ViiV Healthcare|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02027454||53169|
NCT02027662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-OSV-02-D|Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules|Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules|OsvaRenNEW|Fresenius Medical Care Deutschland GmbH|No|Completed|January 2014|June 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02027662||53153|
NCT02027883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF Induction|Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD)|Comparison of Ventricular Fibrillation Induction Techniques During Medtronic Implantable Cardioverter Defibrillator Implant|VF|Wellmont CVA Heart Institute|No|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 31, 2013|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT02027883||53136|
NCT02026570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01234|Enhancement of Residual Limb Proprioception and Rehabilitation Training Methods With a Vibrotactile Device.|Enhancement of Residual Limb Proprioception and Rehabilitation Training Methods With a Vibrotactile Device.||Southern California Institute for Research and Education|No|Active, not recruiting|June 2013|December 2015|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|6|||Both|18 Years|70 Years|No|||July 2015|July 14, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02026570||53237|
NCT02026791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0723|The Comparison of the Clinical Efficacy Between I-gel and LMA-Supreme, the Two Most Recently Developed Supraglottic Airway Devices, in Elderly Patients|||Yonsei University|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|114|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02026791||53220|
NCT02029040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 012013-040|Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis|A Randomized Trial of Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in The Emergency Department||University of Texas Southwestern Medical Center|No|Recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Months|12 Months|No|||January 2014|January 7, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02029040||53047|
NCT02028728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1307|BIOFLOW III Satellite-Italy|Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent Within Daily Clinical Practice III-Italy||Biotronik Italia S.p.A.|No|Active, not recruiting|February 2014|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)|September 2015|September 8, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02028728|18 Months|53071|
NCT01988272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01EB001994|Imaging Based Dosimetry for Individualized Internal Emitter Therapy|Imaging Based Dosimetry for Individualized Internal Emitter Therapy||University of Michigan|Yes|Active, not recruiting|June 2011|January 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01988272||56170|
NCT01988792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02741-FB|Human Milk Fortification in Very Low Birth Neonates|Human Milk Fortification and Feeding Intolerance in Very Low Birth Weight Neonates||University of Tennessee|Yes|Completed|November 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|7 Days|No|||July 2015|July 28, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01988792||56130|
NCT01989351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC03-13|Predisposition to Persistent Pain After Orthopaedic Surgery: Genetic Aspects|LA PREDISPOSIZIONE AL DOLORE PERSISTENTE POST OPERATORIO IN AMBITO ORTOPEDICO: ASPETTI GENETICI||ASST Gaetano Pini-CTO|No|Recruiting|March 2013|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|Samples Without DNA|Blood plasma|Both|18 Years|N/A|No|Probability Sample|Patients undergoing total knee arthoplasty.|March 2014|March 4, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01989351||56087|
NCT01989702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProMeta|Effect of a Probiotic-based Product on Blood Pressure|The Effect of a Probiotic-based Product on Blood Pressure and Other Known Risk Factors Linked to Cardiovascular Diseases.||Probi AB||Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|142|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01989702||56060|
NCT01989715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00634-41|Body Posture Assessment Considering Jaws Position Before and After Orthognathic Surgery on Adult Patient.|Body Posture Assessment Considering Jaws Position Before and After Orthognathic Surgery on Adult Patient.||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2013|May 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|27|||Both|18 Years|60 Years|No|||July 2014|July 23, 2014|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01989715||56059|
NCT01989962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPID-439-13-E4E|E4E-Health Professional Education for Improving Care for Canadian Aboriginal Populations|Phase 2: Evaluation of Education for Equity (E4E)--Exploring How Health Professional Education Can Reduce Disparities in Chronic Disease Care and Improve Outcomes for Indigenous Populations|E4E|Queen's University|No|Active, not recruiting|February 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|860|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01989962||56040|
NCT01990222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000124|Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot|Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot||University of California, Los Angeles|No|Recruiting|January 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|5 Years|12 Years|No|Non-Probability Sample|Parents taking their children to Augustus Hawkins Mental Health Center for treatment of        ADHD who were prescribed stimulant medication for the first time. The attending physicians        will work at the clinic.|December 2014|December 3, 2014|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01990222||56020|
NCT01999400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA-SOL-1120920|Correlation of Mesalamine Pharmacokinetics With Local Availability|Correlation of Mesalamine Pharmacokinetics With Local Availability||University of Michigan||Active, not recruiting|April 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999400||55319|
NCT02026492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-208/13|Exercise Challenge in a Cold Chamber|Exercise-induced Bronchoconstriction in a Cold Chamber Compared to Methacholine Challenge||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|79|||Both|6 Years|45 Years|No|||March 2015|March 16, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02026492||53243|
NCT02026713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WD-131213|Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors|"Impact of Cigarette Smoking on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With P2Y12 Inhibitors" - Trial COPTER -|COPTER|University of Roma La Sapienza|No|Recruiting|July 2014|July 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|90 Years|No|||June 2015|June 7, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02026713||53226|
NCT02027220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBCD-001|Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma|Phase Ⅱ Study of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma||Second Affiliated Hospital of Soochow University|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||January 2014|January 2, 2014|December 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02027220||53187|
NCT02027909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIPS|A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction|A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction.|CRIPS|Wellmont CVA Heart Institute|No|Recruiting|November 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|60 Years|95 Years|No|||January 2014|January 2, 2014|December 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027909||53134|
NCT02028156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA06|Feeding Intolerance in Formula-Fed Infants|Evaluation of Feeding Intolerance in Formula-Fed Infants: A Non-Randomized, Single-Group, Multi-Center Study||Abbott Nutrition|No|Terminated|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|N/A|60 Days|Accepts Healthy Volunteers|||November 2014|November 5, 2014|December 6, 2013||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT02028156||53115|
NCT02028442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoAd1-1001|Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients|A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer|EVOLVE|PsiOxus Therapeutics Ltd|Yes|Recruiting|September 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|161|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02028442||53093|
NCT02028455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAT-02|A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia||Seattle Children's Hospital|Yes|Recruiting|January 2014|January 2032|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|1 Year|26 Years|No|||December 2015|December 30, 2015|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028455||53092|
NCT02028741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPS2011|The Immediate Effects of Thoracic Transverse Mobilization in Patients With Primary Complaint of Mechanical Neck Pain: A Pilot Study|||University of Puget Sound|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02028741||53070|
NCT02027038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063/11/07032011|Pelvic Belt Effects on Osseous Anatomy, Muscule Activation and Ground Reaction Forces|||University of Leipzig|No|Completed|August 2011|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 1, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02027038||53201|
NCT02029053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67709|Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness|VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness||ViroPan, Inc.|Yes|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Female|35 Years|N/A|No|||December 2015|December 14, 2015|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02029053||53046|
NCT02029066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTAKC|Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis|An Open-label, Single Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis||G&E Herbal Biotechnology Co., LTD|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|20 Years|N/A|No|||August 2015|August 10, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02029066||53045|
NCT02029300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15520|A Comparison of Nasal Versus Oral Fiberoptic Intubation in Children|A Randomized Comparison of Nasal Versus Oral Fiberoptic Intubation in Children Less Than Two Years of Age||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|2 Years|Accepts Healthy Volunteers|||May 2014|May 24, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02029300||53027|
NCT01988532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAEM-4073|Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia|Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia||Novo Nordisk A/S|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|381|||Male|18 Years|N/A|No|Non-Probability Sample|Consecutive adult PWH in the United States of America (USA) willing to consent to        participation who have any history of joint bleeding or joint pain presenting for a        comprehensive care visit during which joint range of motion will be assessed.|December 2014|December 2, 2014|October 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01988532||56150|
NCT01988545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.GLP-1|GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow|GLP-1's Influence on Intestinal Blood Flow||University Hospital Koge|No|Recruiting|November 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|8|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988545||56149|
NCT01989364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100251|Repetitive Functional Imaging in Locally Advanced Cervical Cancer|Multicenter Validation of Repetitive Functional Imaging in Locally Advanced Cervical Cancer|IMAP|Aarhus University Hospital|Yes|Recruiting|January 2011|January 2018|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced cervical cancer eligible for chemo-radiotherapy|November 2013|November 15, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01989364|1 Day|56086|
NCT01989377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR2_CSP_0020_RA|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2013|||||N/A|N/A|N/A||||||||||||||November 14, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989377||56085|
NCT01989403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2011-03|Alternative and Integrative Therapy for Lumbar Disk Herniation|The Long-term Course of Patients Undergoing Alternative and Integrative Therapy for Lumbar Disk Herniation: A Prospective Observational Study||Jaseng Hospital of Korean Medicine|Yes|Completed|February 2006|March 2013|Actual|August 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|60 Years|No|Non-Probability Sample|integrative hospital that offers both Western and traditional Korean medical services|November 2013|November 14, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01989403|5 Years|56083|
NCT01989416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|567-2556-EC4|Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients|Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients||Mahidol University|Yes|Completed|December 2013|April 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|481|||Both|18 Years|95 Years|No|||November 2015|November 30, 2015|October 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01989416||56082|
NCT01989728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sickness absence 1|Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence|Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence|PRW|Region MidtJylland Denmark|No|Completed|November 2004|December 2010|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1121|||Male|18 Years|65 Years|No|||November 2013|November 14, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01989728||56058|
NCT01989741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00399-34|Effect of Sleep Restriction on Decision Making and Inflammation|Effect of Sleep Restriction on Decision Making and Inflammation||Institut de Recherche Biomedicale des Armees|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|January 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01989741||56057|
NCT01989975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR06|CareLink Connect - Technical Evaluation Study|A Multi-center, Non-randomized Study in Subjects With Diabetes Mellitus Treated With Sensor-Augmented Pump Therapy to Evaluate the Performance and Safety of CareLink Connect Transferring Pump Data to Web Connected Devices Via CareLink||Medtronic|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|12 Years|65 Years|No|Non-Probability Sample|Clinic patients|November 2013|November 15, 2013|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01989975||56039|
NCT01990573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302099|Methadone in Pediatric Anesthesiology II|Methadone in Pediatric Anesthesia II|MEPA II|Washington University School of Medicine|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|11 Years|18 Years|No|||January 2016|January 11, 2016|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01990573||55993|
NCT02030288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-334|Relational Agent for Alcohol Screening and Treatment|Relational Agent to Improve Alcohol Screening and Treatment in Primary Care: RCT|RAAST|VA Office of Research and Development|No|Recruiting|February 2015|March 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02030288||52951|
NCT02026505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010254|Evaluation of Cardiotoxic Effects of Bortezomib|Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma||Oregon Health and Science University|Yes|Not yet recruiting|March 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Whole blood and serum for batch analysis. Once the assays have been completed, the samples      will be discarded.|Both|18 Years|70 Years|No|Non-Probability Sample|Adult patients (>18 years and <70 years) with multiple myeloma|December 2013|December 31, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02026505||53242|
NCT02026739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSHTA2013001|The Optimal Intraoperative Supplemental Oxygen Administration During Minimally Invasive Esophagectomy|The Impact of Different Intraoperative Supplemental Oxygen Administration on the Pulmonary Function Following Minimally Invasive Esophagectomy: A Prospective Randomized Controlled Clinical Trial||Fudan University|No|Recruiting|September 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2013|December 31, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026739||53224|
NCT02026726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11158|Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?|Oral Steroid Dose Pack Used As A Predictor For The Effectiveness Of Epidural Steroid Injections||Dartmouth-Hitchcock Medical Center|No|Recruiting|November 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that had magnetic resonance imaging (MRI) documented lumbar herniated discs with        unilateral radicular symptoms that correlated to their physical exam and MRI findings.|December 2013|December 31, 2013|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026726||53225|
NCT02027298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-Yao-2012001|Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study|Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study||The Cleveland Clinic|No|Withdrawn|November 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|November 18, 2013|Yes|Yes|No Enrollment|No||https://clinicaltrials.gov/show/NCT02027298||53181|
NCT02027675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERIIT project|Meal-Exercise Challenge and Physical Activity Reduction Impact on Immunity and Inflammation|Meal-Exercise Challenge and Physical Activity Reduction Impact on Immunity and Inflammation|MERIIT|Universidade do Porto|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|April 28, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02027675||53152|
NCT02027688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819247|Feeding Progression in Preterm Infants|Feeding Progression in Preterm Infants||University of Pennsylvania|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|N/A|120 Days|No|||December 2015|December 1, 2015|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02027688||53151|
NCT02028169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-518|To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis|To Observe the Impacts of Anti-TNF's Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis|PsA|AbbVie|No|Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|90 Years|No|Probability Sample|Patients from both genders will be included to this non-interventional epidemiological        study from selected university or state hospital or Ministry of Health of Turkey training        and research hospitals in Turkey.|January 2016|January 27, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028169||53114|
NCT02028182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 1PL 201|Clinical Evaluation of Lyral® Dose Response Study|Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study||Allerderm|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028182||53113|
NCT02028468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811419|Anterolateral Watson Jones Approach Versus Transgluteal Approach for Uncemented Hemi- Arthroplasty in Displaced Femoral Neck Fracture|||Sorlandet Hospital HF||Recruiting|February 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|70 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028468||53091|
NCT02028481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012815b1|Air Tamponade in Macular Holes < 400 μm|Air Tamponade in Macular Holes < 400 μm||Helse Stavanger HF|No|Active, not recruiting|December 2013|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|N/A|N/A|No|||November 2015|November 16, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028481||53090|
NCT01999257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3281|Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.|Assessing the Outcomes of Web-based Pre-test Educational Module for Carrier Genetic Screening in Individuals of Ashkenazi Jewish Descent||McGill University Health Center|No|Active, not recruiting|July 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999257||55330|
NCT01999270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303069|Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors|Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study||Washington University School of Medicine|No|Recruiting|April 2013|April 2019|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|21 Years|No|||March 2016|March 17, 2016|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999270||55329|
NCT02027272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0269|Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):|Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.|PRESIDEX|University of Mississippi Medical Center|No|Terminated|February 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|45 Years|No|||January 2014|January 2, 2014|January 15, 2013||No|Difficulty recruiting, only one participant in 18 months, rarity of event|No||https://clinicaltrials.gov/show/NCT02027272||53183|
NCT02029313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-M01RS1|Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma|A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects||PharmaKing|Yes|Completed|November 2013|March 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02029313||53026|
NCT02027935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1055|Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4|Phase II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Recruiting|January 2015|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027935||53132|
NCT01988805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0346|Gene Polymorphism Study of Normal Individual Inflammasome Genes|Immunological Characterization of Blood and Inflammasome Gene Segment Polymorphism Analysis of Normal Healthy Individuals||Ohio State University||Withdrawn|February 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal volunteers.|October 2014|October 16, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01988805||56129|
NCT01989065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050555|Healthy Lifestyles Program for You (HLP4U): Augmenting Childhood Obesity Treatment.|Healthy Lifestyles Program for You (HLP4U): Augmenting Childhood Obesity Treatment Through Provider-to-parent Text Messaging.|HLP4U|Duke University|Yes|Completed|September 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|5 Years|12 Years|No|||December 2015|December 1, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01989065||56109|
NCT01989078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056125|Losartan for Sickle Cell Kidney Disease|Losartan Treatment for Sickle Cell Chronic Kidney Disease|SCD-Losartan|Emory University|Yes|Active, not recruiting|December 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|De-identified blood and urine samples will be stored for future testing. Testing and storage      of DNA samples is an optional part of the consent, and may be excluded if desired.|Both|10 Years|N/A|No|Non-Probability Sample|sickle cell disease|November 2015|November 16, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01989078||56108|
NCT01989390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR2_CSP_0022_RA|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||November 14, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989390||56084|
NCT01989988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSIRB2013003|DMBSS-A Randomized Trial of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM|A Randomized Trial Study of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM|DMBSS|Min-Sheng General Hospital|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|67 Years|No|||November 2013|November 15, 2013|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01989988||56038|
NCT01990235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10847|Improving Advance Care Planning by Preparing Diverse Seniors for Decision Making|Improving Advance Care Planning by Preparing Diverse Seniors for Decision Making|PREPARE|University of California, San Francisco|Yes|Recruiting|January 2013|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|55 Years|N/A|No|||June 2015|June 2, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01990235||56019|
NCT01990833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120101|Molecular Characteristics of the Persistent Intestinal Fistulae After Glue Application|||Jinling Hospital, China|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|22|Samples Without DNA|Plasmas and fistula tissues|Both|18 Years|65 Years|No|Non-Probability Sample|Low-output enterocutaneous fistulas receiving glue application|November 2013|November 21, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01990833||55973|
NCT01990846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT02-1002|Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects||Autoimmune Technologies, LLC|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|68|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01990846||55972|
NCT01990859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-396|Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients|Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma||Bristol-Myers Squibb|No|Completed|December 2013|February 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|N/A|No|||February 2016|February 12, 2016|November 18, 2013|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01990859||55971|
NCT02030301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSV2-101|Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults||Vical|Yes|Active, not recruiting|December 2013|February 2016|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|165|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030301||52950|
NCT02027233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-47|Clinical Trial to Assess the Influenza Vaccination for Seasonal 2013-2016|Efficiency in Population of Influenza Vaccination for Seasonal 2013-2016 for Flu Prevention of the Hospitalized Adults|FLUVAC EV-03|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02027233||53186|
NCT02026973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007623|Impact of Endogenous E2 on SSI and GH Rebound|Impact of Endogenous Estrogen on Somatostatin Inhibition and Growth Hormone Rebound in Older Women||Mayo Clinic|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|62|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|December 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02026973||53206|
NCT02027012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S6007|Treatment of Resistant Hypertension by Renal Denervation in China|Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter in China|REDUCE-HTN-CN|Boston Scientific Corporation|No|Not yet recruiting|January 2014|September 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||January 2014|January 2, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02027012||53203|
NCT02027246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-05|Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury|Autologous Bone Marrow Mononuclear Cell Therapy for Spinal Cord Injury||Neurogen Brain and Spine Institute|Yes|Completed|December 2008|February 2013|Actual|August 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|8 Months|63 Years|No|||January 2014|March 10, 2014|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02027246||53185|
NCT02028494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLACOM Cap 7/7|Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer|Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer|CAP7/7|Latin American & Caribbean Society of Medical Oncology|Yes|Recruiting|August 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|N/A|No|||June 2015|June 19, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028494||53089|
NCT02028507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2013-02|Phase III Study of Palbociclib (PD-0332991) in Combination With Exemestane Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors|Phase III Study of Palbociclib (PD-0332991) in Combination With Exemestane Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors (PEARL).|PEARL|Spanish Breast Cancer Research Group|Yes|Recruiting|March 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|348|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02028507||53088|
NCT02028806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-321|mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer|Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China||Sun Yat-sen University|Yes|Recruiting|February 2013|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||May 2015|May 22, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02028806||53065|
NCT02029586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB12066_201|Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis||KT&G Life Sciences Corp||Terminated|January 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|20 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|January 6, 2014||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT02029586||53005|
NCT01999023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF13223|Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in CKD Patients|The Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in Patients With Chronic Kidney Disease||Taichung Veterans General Hospital|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|85 Years|No|||November 2013|November 25, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01999023||55347|
NCT02027948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-264|A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer|A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|65 Years|N/A|No|||September 2015|September 28, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027948||53131|
NCT01988818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Köln_2013-02|Prospective, Randomized Study of 2 Different Wound Dressings|A Mono-centre, Post CE-mark, Prospective-randomized Clinical Trial to Evaluate the Performance of a Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip or Knee Arthroplasty or Primary Spine Surgery in Comparison to a Standard Wound Dressing (Cosmopor E®Steril, Fa. Hartmann)|Close|University of Cologne|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01988818||56128|
NCT01989754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102647|A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus|A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus|CANVAS-R|Janssen Research & Development, LLC|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5826|||Both|30 Years|N/A|No|||February 2016|February 26, 2016|October 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01989754||56056|
NCT01990248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28492|An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)|ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf®)||Hoffmann-La Roche||Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients with unresectable or metastatic melanoma treated with vemurafenib|August 2015|August 17, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990248||56018|
NCT01990261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28496|A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment.|THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN.||Hoffmann-La Roche||Terminated|May 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|Adult patients diagnosed with locally advanced, metastatic or recurrent non-small cell        lung carcinoma with wild-type EGFR.|March 2016|March 1, 2016|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01990261||56017|
NCT01990586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-10-067|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA) in Healthy Human Volunteers Under Fed Condition.||Torrent Pharmaceuticals Limited||Completed||||September 2010|Actual|Phase 1|Interventional|N/A|||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|November 15, 2013||||No||https://clinicaltrials.gov/show/NCT01990586||55992|
NCT01990599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1221/2012|Airway Management for Trigeminal Thermal Coagulation|Airway Management in Patients Undergoing Thermal Ganglion Gasseri Coagulation, a New Method - Preliminary Results||Medical University of Vienna|No|Completed|July 2012|||June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|N/A|N/A|No|||November 2013|November 15, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990599||55991|
NCT01991145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBnEPOinCP|Allogeneic UCB Therapy With EPO in Children With CP|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy Combined With Erythropoietin in Children With Cerebral Palsy: a Double-blind, Randomized, Placebo-controlled Clinical Trial||Bundang CHA Hospital|No|Recruiting|November 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|10 Months|6 Years|No|||November 2013|November 17, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01991145||55949|
NCT02026245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dataglove-02|A Comparison of Two Electronic Gloves in the Measurement of Joint Movement in Patients With Rheumatoid Arthritis|A Comparison of Two Electronic Goniometric Gloves in the Measurement of Joint Movement in Patients With Rheumatoid Arthritis||University of Ulster|No|Not yet recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|12|||Both|18 Years|80 Years|No|||October 2014|October 3, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02026245||53261|
NCT02028832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM1|Pediatric Integrative Medicine Trial Pilot|Pilot Study of Pediatric Integrative Medicine in Pediatric Oncology, General Pediatrics and Pediatric Cardiology|PIM|University of Alberta|Yes|Active, not recruiting|February 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|16 Years|No|||May 2015|May 26, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02028832||53063|
NCT02027480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM2314|Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study|Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: Establishment of a Prospective Cohort, iMACS Study|iMACS|Columbia University|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|685|Samples With DNA|Blood and urine samples will be collected from study participants at 4 different points      during their 12 months of participation. 15 mL of blood and 10 mL of urine will collected      via venipuncture at baseline, 2 months, 6 months, and 12 months. Specimens will be retained      for 10 years.|Both|18 Years|N/A|No|Non-Probability Sample|Cohort participants will be consenting HIV-infected men and women initiating ART at four        to eight study sites.|December 2015|December 22, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027480||53167|
NCT02027922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinical effectiveness of FV|Clinical Effectiveness of Various Professionally Applied Fluoride Prophylaxes in Groups at High Risk|Randomized Clinical Trial Comparing the Clinical Effectiveness of Various Professionally Applied Fluoride Prophylaxes in Deciduous Teeth in Groups at High Risk||Medical University of Warsaw|No|Recruiting|November 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|3 Years|5 Years|No|||March 2015|July 11, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02027922||53133|
NCT02027714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0372|Enhanced HIV Prevention in Couples: Feasibility Study #1|Enhanced HIV Prevention in Discordant Couples in Lesotho: Feasibility Study #1|EPIC|Columbia University|No|Completed|April 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|230|||Both|18 Years|50 Years|No|Non-Probability Sample|Pregnant and postpartum women within 6 months of delivery and men will be enrolled.        This feasibility study is targeting women seeking care in ANCs as these clinics are where        large numbers of women learn their HIV status and become engaged in HIV prevention and/or        care and treatment services. It is through these women that men from the community will be        recruited for participation in the study.|March 2015|March 23, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02027714||53149|
NCT02027727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infiximab Dosing|Individualized Infiximab Dosing-Proof of Concept Study|Individualized Infiximab Dosing-Proof of Concept Study||Cedars-Sinai Medical Center|No|Recruiting|November 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|56|||Both|6 Years|23 Years|No|Probability Sample|Males and females patients age 6 to 23|October 2014|October 3, 2014|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027727||53148|
NCT02029079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/962|The Effect of Food and Beverage Based Nutritional Supplements in Recipients of Home Care Services at Risk of Malnutrition|The Effect of Food and Beverage Based Nutritional Supplements in Recipients of Home Care Services at Risk of Malnutrition||Haukeland University Hospital|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02029079||53044|
NCT02029326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-074|Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab|||Samsung Medical Center|No|Recruiting|February 2010|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|colorectal cancer patients who are treated with cetuximab|January 2014|January 5, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02029326||53025|
NCT02026284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-828|Factors Affecting Anesthesia Preferences of Gravid Women|Factors Affecting Anesthesia Preferences of Gravid Women Who Are to Deliver by Caesarean Section||Ankara University|No|Completed|February 2010|February 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|750|||Female|20 Years|44 Years|No|Probability Sample|A questionnaire consisting of 20 questions were applied to gravid women applying for        delivery by elective caesarean operation, at Ankara University Faculty of Medicine        Hospital for Gynaecology and Obstetrics between February 2010 and February 2011|December 2013|December 31, 2013|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02026284||53258|
NCT01999296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thunderbeat in Laparoscopy|Prospective Evaluation of the Use of Thunderbeat Vessel Sealing Device in Laparoscopic Surgery|||Cantonal Hosptal, Baselland|No|Active, not recruiting|October 2013|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an indication for laparoscopic visceral or gynecologic surgery.|July 2015|July 15, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01999296|30 Days|55327|
NCT01999309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43806|Simvastatin Addition for Patients With Recent-onset Schizophrenia|Simvastatin Addition for Patients With Recent-onset Schizophrenia||UMC Utrecht|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|50 Years|No|||December 2015|December 23, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01999309||55326|
NCT01999569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2013|The Role of Estrogen in Luteinizing Hormone Surge and Ovulation|The Role of Estrogen in Luteinizing Hormone Surge and Ovulation||Carolinas Healthcare System|No|Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|10|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999569||55306|
NCT02027493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLI-YAGCC-CUPH-HCV-PEG-PED|Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV|Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection||National Liver Institute, Egypt|Yes|Completed|February 2009|August 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|3 Years|19 Years|No|||January 2014|January 3, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02027493||53166|
NCT02027701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro20_3004|Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003||CSL Behring|Yes|Enrolling by invitation|July 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027701||53150|
NCT02028533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12534|Cocaine Opioid Oxytocin Option - Limited|Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A 2-week Pilot Study|COOOL|University of California, San Francisco|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028533||53086|
NCT01989442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Map-NIV Trial|Nasal Mask and Prong Use in Non-invasive Ventilation for Newborns|Efficacy and Safety of Nasal Mask and Prong Use in Non-invasive Ventilation for Newborns|NIV|Ankara University|Yes|Recruiting|November 2013|January 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||January 2015|January 14, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01989442||56080|
NCT01989767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sickness absence 2|Application of Psychiatric Knowledge in the Rehabilitation Process in Return to Work.|Application of Psychiatric Knowledge in the Rehabilitation Process in Return to Work.|PKRW|Region MidtJylland Denmark|Yes|Completed|November 2011|October 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|317|||Both|N/A|N/A|No|||November 2013|November 20, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01989767||56055|
NCT01989780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBCRG-M04|Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer|Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-|BOOSTER|Japan Breast Cancer Research Group|Yes|Active, not recruiting|November 2013|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|20 Years|75 Years|No|||February 2016|February 15, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01989780||56054|
NCT01990001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Besider|Randomized Trial of Provider‐Assisted Versus Patient‐Initiated Enrollment in the Bedsider.Org Online Contraceptive Reminder Tool|Randomized Trial of Provider‐Assisted Versus Patient‐Initiated Enrollment in the Bedsider.Org Online Contraceptive Reminder Tool||Medical University of South Carolina|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|118|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||November 2013|September 22, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01990001||56037|
NCT01990612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-ARRIVE|A Randomized Trial of Induction Versus Expectant Management|Induction in Nulliparous Women at 39 Weeks to Prevent Adverse Outcomes: A Randomized Controlled Trial|ARRIVE|The George Washington University Biostatistics Center|Yes|Recruiting|March 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Female|N/A|N/A|No|||October 2015|October 19, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01990612||55990|
NCT01990872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-IC-1111-10005|Inter-relationship Between Vitamin D Requirements and Calcium Intake in Older Adults|Randomized Controlled Trial to Explore the Inter-relationship Between Vitamin D Requirements and Calcium Intake|VitD-Ca|University College Cork|Yes|Completed|October 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|125|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01990872||55970|
NCT01990885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-7010.01|Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.|A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Systemic Exposure of Single Escalating Administrations and Repeated Administration of BL-7010 in Well-Controlled Celiac Patients||BioLineRx, Ltd.||Completed|December 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01990885||55969|
NCT01978223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116494|Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis|Case-control Study to Evaluate the Vaccine Effectiveness of RotarixTM Against Rotavirus Severe Gastroenteritis Among Hospitalised Children Aged 12 Weeks to < 5 Years, in Venezuela||GlaxoSmithKline||Withdrawn|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Stool sample|Both|12 Weeks|5 Years|No|Non-Probability Sample|Children aged 12 weeks to < 5 years, hospitalised for SGE in the study hospitals.|March 2015|March 6, 2015|October 31, 2013||No|As vaccine coverage rates have drastically improved in Venezuela, the study lost its objective    to show positive impact of the vaccine to stimulate higher usage|No||https://clinicaltrials.gov/show/NCT01978223||56940|
NCT02026986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131231|Sleep Deprivation Reduces Tear Secretion and Impairs the Tear Film|||Hallym University Medical Center|No|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|20|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02026986||53205|
NCT02029612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0495|An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS (Project Legacy)|An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS||M.D. Anderson Cancer Center|No|Withdrawn|April 2014|||April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 27, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02029612||53003|
NCT02029625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-1205-01|Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe|A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers|NVP-1205|Navipharm Corporation|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|41|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02029625||53002|
NCT02029872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ 15167|Stop Community MRSA Colonization Among Patients|Stop Community MRSA Colonization Among Patients (SUSTAIN)|SUSTAIN|Johns Hopkins University|Yes|Active, not recruiting|January 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|6 Months|N/A|No|||August 2015|August 31, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02029872||52983|
NCT02027259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12CRP9840018|Behavioral Activation Therapy for Both Depression and Diabetes Vs. Diabetes Alone Delivered Via Group Visits|Behavioral Activation Therapy for Both Depression and Diabetes Vs. Diabetes Alone Delivered Via Group Visits|BA-MEDIC|Providence VA Medical Center|No|Recruiting|January 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02027259||53184|
NCT01998282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6457|Evaluation of a Project to Distribute Water Filters and Cook Stoves in Western Rwanda--Phase 1B|Assessing the Impact of Water Filters and Improved Cook Stoves on Drinking Water and Quality and Indoor Air Pollution: A Matched Cohort Study in Rwanda||London School of Hygiene and Tropical Medicine|No|Enrolling by invitation|October 2013|July 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4000|||Both|N/A|N/A|No|Probability Sample|Lower income (ubudehe groups 1 and 2) householders from 18 villages (9 intervention and        matched controls) in 11 designated Districts in Rwanda: Rutsiro, Karongi, Ngororero,        Nyamasheke, Nyabihu Districts of Western Province (excluding part of the district to the        north of the Ruhengeri road); Rubuvu District (excluding part of the district to the north        of the Ruhengeri road); Nyaruguru, Nyamagabe, Muhanga, and Ruhango Districts in Southern        Province; Gakenke District in Northern Province.|March 2015|March 10, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01998282||55404|
NCT01998529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0657|Hyperthermic Thoracic Perfusion (HITEC) for Children, Adolescents and Adults With Sarcomas|A Phase I Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy||M.D. Anderson Cancer Center|No|Recruiting|August 2014|||August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Years|21 Years|No|||October 2015|October 30, 2015|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01998529||55385|
NCT02029846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052707|Glycemia in Diabetic Elders Trial|Glycemia in Diabetic Elders Trial||Johns Hopkins University|No|Enrolling by invitation|April 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|No|||January 2014|January 7, 2014|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029846||52985|
NCT02030080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819371|Way to Be Active IV (Framing vs Incentives)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing vs Incentives||University of Pennsylvania|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|288|||Both|18 Years|100 Years|No|||January 2016|January 21, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02030080||52967|
NCT02026804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y21000505|Prevalence ， Associated Factors and Influences of Prenatal Mental Disorders|||Zhejiang Provincial Natural Science Foundation of China||Recruiting|January 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|plasma, serum, white cells, placenta tissue|Female|18 Years|60 Years|No|Probability Sample|Pregnant women who had perinatal health care in a Women's & Children's Health Hospital of        zhejiang province, China|January 2015|January 20, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026804||53219|
NCT02027025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_11_03|Study of SPARC1103 in Subject With Spasticity|||Sun Pharma Advanced Research Company Limited|No|Recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027025||53202|
NCT01999582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-REN-002|A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis|A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoeisis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept||Celgene Corporation|No|Active, not recruiting|November 2013|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999582||55305|
NCT02028221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300000596|Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk|Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk||University of Arizona|Yes|Recruiting|March 2014|December 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|30 Years|54 Years|No|||June 2015|June 1, 2015|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028221||53110|
NCT02028520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing|Use of Indocyanine Green (ICG) Fluorescence as a Noninvasive Means to Assess Burn Wound Severity and Healing||Texas Tech University Health Sciences Center|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|89 Years|No|||May 2015|May 11, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028520||53087|
NCT02029092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1302|BIOFLOW III Satellite-ELADIS|BIOTRONIK- Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice III- ELADIS||C.E.M. Biotronik, S.A.|No|Active, not recruiting|February 2014|July 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)|September 2015|September 7, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02029092|12 Months|53043|
NCT01990014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/08-I|Craniectomy Protocol|Multicenter Clinical Study Evaluating the Functional Prognosis and Quality of Life at Least 2 Years in Patients Treated With Decompressive Craniectomy for Malignant Sylvian Ischemic Stroke||Nantes University Hospital|No|Completed|June 2011|July 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|No|Probability Sample|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having        received treatment by decompressive craniectomy.|November 2013|November 15, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01990014||56036|
NCT01990274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XACT.2011.10800.003|The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa|The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)|XACT|University of Cape Town|Yes|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|875|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01990274||56016|
NCT01990287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-12|SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) Study|SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation)Study for the Treatment of Chronic Low Back and Leg Pain|SENSE|St. Jude Medical|No|Suspended|November 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|22 Years|N/A|No|||February 2016|February 25, 2016|November 15, 2013|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01990287||56015|
NCT01982019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/129/HP|Influence of Bariatric Surgery on Serum Levels of 26RFa|Determination of Serum Levels of the Orexigenic Neuropeptide 26RFa in Obese Female Patients With or Without Diabetes. Influence of Bariatric Surgery|RFa-Ba-S|University Hospital, Rouen|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Female|30 Years|60 Years|No|||July 2015|July 29, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01982019||56649|
NCT01982266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP052|A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the Hip|A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the Hip||Biomimedica, Inc|Yes|Recruiting|November 2013|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01982266||56630|
NCT01982279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HabEat WP31 Follow up|Longitudinal Measurement of Caloric Compensation and Eating in the Absence of Hunger in French Preschool Children|One Year Change in Caloric Compensation and Eating in the Absence of Hunger in French Preschool Children||Centre des Sciences du Goût et de l'Alimentation|Yes|Completed|February 2011|June 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|236|||Both|2 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population was composed of 236 children at inclusion. Among them, 98 participated in        the three time of measurements of caloric compensation or eating in the absence of hunger.|November 2013|November 12, 2013|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01982279||56629|
NCT01978236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116521|Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites|An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain||GlaxoSmithKline|No|Recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|January 21, 2016|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978236||56939|
NCT01978249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0277|A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis|||Yonsei University|No|Recruiting|June 2013|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|20 Years|90 Years|No|||November 2013|November 19, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978249||56938|
NCT02026544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-0001|Effect of Low Frequency Ultrasound on Kidney Function|Evaluation of the Effect of Low Frequency Therapeutic Ultrasound (LOTUS) on Kidney Function in Chronic Kidney Disease||Sonogenix|No|Recruiting|December 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2013|December 31, 2013|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026544||53239|
NCT02026557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/392|Lethality Among Children With Congenital Heart Disease in Norway|Lethality Among Children With Congenital Heart Disease in Norway||Sorlandet Hospital HF|No|Completed|January 1990|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|15000|||Both|N/A|N/A|No|Non-Probability Sample|Oslo University hopsital´s registry of patients with congenital heart disease|December 2013|December 31, 2013|July 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02026557||53238|
NCT02026765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5AT-6M|Clinical Outcomes About Heparin Surface Modified Aspheric Lens|Clinical Outcomes About Heparin Surface Modified Aspheric Lens||Wenzhou Medical University|Yes|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02026765||53222|
NCT02026310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yml2013|Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment|Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin||Chongqing Medical University|Yes|Completed|January 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|70 Years|No|||January 2016|January 26, 2016|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02026310||53256|
NCT02027974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1-M-239|Post-Market Study of the ICONACY Hip System|ICONACY Hip Clinical Data Acquisition (13-1-M-239)||Iconacy Orthopedic Implants, LLC.|Yes|Withdrawn|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|N/A|No|||May 2014|May 12, 2014|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027974||53129|
NCT01997723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0222|Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea|Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea||University of Illinois at Chicago|Yes|Completed|August 2011|April 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 22, 2013|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01997723||55446|This trial did not compare different portable devices for diagnostic accuracy compared to polysomnography (gold standard).
NCT01997736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toray America 2013-001|Pilot Study Evaluating the Toray Satake Balloon Thermal Ablation System for Treatment of Paroxysmal Atrial Fibrillation|A Pilot Study Evaluating the Safety and Effectiveness of the Toray Satake Balloon Thermal Ablation System for the Treatment of Paroxysmal Atrial Fibrillation||Toray Industries (America), Inc.|Yes|Recruiting|November 2013|||September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|November 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997736||55445|
NCT02028195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tryg 7-11-0500|Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme|The CORE-trial: a Pragmatic Randomized Controlled Trial in Primary Care Investigating Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme Offered Population-wide to 30-49 Years||University of Aarhus|Yes|Recruiting|May 2013|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|11000|||Both|30 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02028195||53112|
NCT02028208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP12 2PM2 201|Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study|Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study||Allerderm|No|Recruiting|November 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|60|||Both|15 Years|N/A|No|||January 2014|September 22, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028208||53111|
NCT01998295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0.2011|Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine|Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Among Children With Uncomplicated P. Falciparum Malaria Five Years After Wide Scale Use of the Drug in Tanzania|PCT|Muhimbili University of Health and Allied Sciences|No|Completed|May 2012|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|6 Months|120 Months|No|||March 2014|March 15, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01998295||55403|
NCT01999010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-2013|Mental Health Telemetry for Self-Management in Major Depression|Mental Health Telemetry for Self-Management in Major Depression|MHTV|Sunnybrook Health Sciences Centre|No|Active, not recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|113|||Both|14 Years|N/A|No|||November 2015|November 5, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01999010||55348|
NCT01995942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3873|Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial|Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer|MARVEL|Royal Marsden NHS Foundation Trust|No|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|Histopathology samples taken after rectal tumour removal surgery will be analysed using      micrarray techniques. The pathological tissue microarrays (TMAs) will be generated using the      Alphelys Tissue Arrayer Minicore®3 system. Markers that will be evaluated will be initially      directed at epithelial to mesenchymal (EMT) transition pathways, as our preliminary studies      suggest that this phylogenetically conserved molecular program has important roles in tumour      dissemination and resistance to conventional chemotherapy.|Both|18 Years|N/A|No|Non-Probability Sample|Patients aged over 18 years of age presenting with adenocarcinoma of the rectum. This will        be diagnosed on colonoscopy and/or biopsy and MRI, and treatment strategy will include        pre-operative CRT followed by surgery.|July 2013|November 26, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995942||55582|
NCT01999530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224/2012|The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study|Exploring the Effects of Prazosin on Basal Dopamine in Healthy Humans: A [11C]-(+)-PHNO PET Pilot Study||Centre for Addiction and Mental Health|Yes|Active, not recruiting|November 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999530||55309|
NCT01999543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1373|Post-prandial Glucose in Healthy Indian Subjects|Effect of Plant-based Ingredient in Different Food Formats on Post-prandial Glucose in Healthy Indian Subjects||Unilever R&D|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|120|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 21, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999543||55308|
NCT01995552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0 , 03 Aug 2014|IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)|IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)|INSPIRE-ELR|Medtronic Bakken Research Center|No|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995552||55612|
NCT01995565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS_002|Regional Cerebral Hemodynamics Related to Global Hemodynamics|Impact of Systemic Hemodynamic Changes on Cerebral Perfusion and Oxygenation||Johannes Gutenberg University Mainz|No|Recruiting|July 2011|||July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|64|||Both|18 Years|80 Years|No|Non-Probability Sample|critically ill patients mechanically ventilated patients|July 2011|November 25, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995565||55611|
NCT01981447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00570-FB|IV Lacosamide: The Safety of Intravenous Lacosamide|IV Lacosamide: The Safety of Intravenous Lacosamide||Le Bonheur Children's Hospital|Yes|Completed|April 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|4 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|May 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981447||56692|
NCT01981460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-002692|PhotoDynamic Therapy for Line Infection Prevention (PLIP): Pilot Study on Healthy Volunteers.|PhotoDynamic Therapy for Line Infection Prevention (PLIP): Pilot Study on Normal Volunteers||Massachusetts General Hospital|No|Completed|May 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981460||56691|
NCT01981746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-PJ-13|Adductor Canal Block and Effect of 10 Versus 30 ml Ropivacaine on Muscle Strength: a Randomized Study in Healthy Volunteers|Adductor Canal Block and Effect of 10 Versus 30 ml Ropivacaine on Muscle Strength: a Randomized Study in Healthy Volunteers||Rigshospitalet, Denmark|Yes|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01981746||56670|
NCT01981759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02991|D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions|D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions||New York University School of Medicine|Yes|Recruiting|February 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|68 Years|No|||September 2015|September 22, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01981759||56669|
NCT01982032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43116.041.13|Edwards SAPIEN Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation (the ELECT Trial)||ELECT|UMC Utrecht|Yes|Recruiting|November 2013|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01982032||56648|
NCT01978262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 292|Immune and Hormone Response to Influenza Vaccine|A Pilot Study of the Immune Response to Influenza Vaccination and Effect on Reproductive Hormones||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|October 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|October 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978262||56937|
NCT01978275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC02-13|Stimulating Catheter for Lumbar Plexus|Are Stimulating Catheters More Efficacy for Lumbar Plexus Block Compared With Traditional Non-stimulating Ones? A Randomized, Prospective, Blinded, up and Down Study.||ASST Gaetano Pini-CTO|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|N/A|No|||December 2013|February 14, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978275||56936|
NCT01978535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009963|Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)|A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)||Mayo Clinic|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|21 Years|No|||January 2016|January 13, 2016|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01978535||56916|
NCT01978821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-01|Stem Cell Therapy for Cerebral Palsy|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy||Neurogen Brain and Spine Institute|Yes|Completed|August 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|17 Months|22 Years|No|||October 2013|October 31, 2013|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978821||56894|
NCT02028546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Srinakharinwirot fund|The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study|The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study||Srinakharinwirot University||Completed|January 2013|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|45 Years|No|||January 2014|January 5, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02028546||53085|
NCT02029352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47392.068.13|Topical Green Tea Ointment in Treatment of Superficial Skin Cancer|Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial.||Maastricht University Medical Center|No|Recruiting|November 2014|August 2015|Anticipated|March 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029352||53023|
NCT02026596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TampereUH|SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage|Observational Study on Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage||Tampere University Hospital|Yes|Recruiting|March 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100||-  Blood samples        -  Cerebrospinal fluid samples        -  Microdialysate samples (from the extracellular fluid of the brain)        -  Tissue samples|Both|18 Years|N/A|No|Probability Sample|Patients suffering from aneurysmal subarachnoid haemorrhage|January 2014|January 1, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02026596|6 Months|53235|
NCT02026830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURK-DAY|The Microbiologic Profile of Diabetic Foot Infections in Turkey - TURK-DAY|The Microbiologic Profile of Diabetic Foot Infections in Turkey (TURK-DAY): Prospective Multicenter Cohort Study|TURK-DAY|Gulhane Military Medical Academy|No|Completed|January 2014|July 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|447|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with DM presenting with a diabetic foot infection will be enrolled in the current        trial to determine the causative microorganisms and their antibiotic sensitivity patterns        in diabetic patients with a foot infection in Turkey.|March 2015|March 10, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026830||53217|
NCT02012023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Controllable tube ileostomy|Use of One Kind of Controllable Tube Ileostomy in the Low Rectal Cancer|Use of One Kind of Controllable Tube Ileostomy to Protect Anastomotic Leakage in the Low Rectal Cancer.|CTI|First Affiliated Hospital of Zhejiang University|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||December 2013|December 16, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02012023||54351|
NCT02011750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12020320|Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia|Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii||University of Pittsburgh|Yes|Enrolling by invitation|March 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|No|||May 2015|February 26, 2016|June 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02011750||54372|
NCT02012010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102124-F|Comparison of Infusion Methods for Hysteroscopic Procedures|Comparison of Manual Syringe Infusion Method and Conventional Pump Infusion Method for Hysteroscopic Procedures: a Randomized Controlled Trial.||Far Eastern Memorial Hospital|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Female|20 Years|99 Years|No|||February 2016|February 22, 2016|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02012010||54352|
NCT02011425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-105-CERES-D|The Effects of Oral Appliance Therapy on Masseter Muscle Activity in Obstructive Sleep Apnea|The Effects of Mandibular Advancement Appliance Therapy on Masseter Muscle Activity During Sleep in Obstructive Sleep Apnea Patients: a Study in Clinical Practice||Université de Montréal|No|Recruiting|February 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|25|||Both|30 Years|65 Years|No|||October 2014|October 1, 2014|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011425||54396|
NCT02011711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0235|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives||Ohio State University|No|Recruiting|November 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Female|15 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Women seeking to initiate use of an oral contraceptive, depot-medroxyprogesterone acetate,        or Mirena.|February 2016|February 23, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011711||54375|
NCT02012517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0447-13-SMC|Antibiotic Prophylaxis in Prosthetic Breast Reconstructions|Antibiotic Prophylaxis in Prosthetic Breast Reconstructions||Sheba Medical Center|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|N/A|No|||December 2013|December 13, 2013|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012517||54313|
NCT02009306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PecEp1|Nasal Fentanyl and Buccal Midazolam for Dying Patients|Can Nasal Fentanyl and Buccal Midazolam Give Better Symptom Control for Dying Patients When Compared With Standard Subcutaneous Medication? Pilot Randomised Controlled Trial and Qualitative Interview Study.||Gloucestershire Hospitals NHS Foundation Trust|Yes|Not yet recruiting|April 2014|July 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009306||54558|
NCT02009917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01683|Non- Essential Amino Acid Requirements and Metabolism in Humans|Application of Indicator Amino Acid Oxidation Technique to Determine Non-essential Amino Acids/Nitrogen Requirements in Adult Humans||University of British Columbia|Yes|Completed|October 2013|April 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Breath and urine samples|Male|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Physiologically Healthy Adult males, 20-40 years of age|May 2015|May 29, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009917||54512|
NCT02009956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-1004|EXCELLA Post-Approval Study|POST MARKETING STUDY OF THE ELIXIR DESyne® NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne® BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS||Elixir Medical Corporation|No|Active, not recruiting|February 2014|June 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009956||54509|
NCT02010177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0686-IB-CTIL|Clinical Outcome of Patients With Low-gradient Severe Aortic Stenosis|Clinical Outcome of Patients With Low Ejection Fraction or Low-gradient Severe Aortic Stenosis||Sheba Medical Center|No|Recruiting|December 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|95 Years|No|Probability Sample|Subjects with severe symptomatic aortic stenosis defined as aortic valve area of less than        1 cm2 or index area of 0.6 cm2/m2 by echocardiography, together with low-gradient (mean        gradient across the aortic valve <40 mmHg) who are referred for treatment of AS will be        recruited. A total of up to 100 consecutive subjects of both genders will be enrolled at        the Sheba Medical Center. The study procedures, clinical management and follow up will be        done at the Sheba Medical Center.|May 2015|May 31, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010177|1 Year|54492|
NCT02009930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20130024H|Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service|Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service||David Grant U.S. Air Force Medical Center|Yes|Terminated|October 2013|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|37|||Both|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Active duty military enlisted members with 10 or more years of service|January 2016|January 19, 2016|December 9, 2013||No|Failure to recruit enough subjects|No||https://clinicaltrials.gov/show/NCT02009930||54511|
NCT02009943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 13-3151|A Randomized Pilot Study of Ferric Carboxymaltose as Compared to Iron Sucrose for the Treatment of Functional Iron Deficiency Associated With Surgical Critical Illness|A Randomized Pilot Study of Ferric Carboxymaltose as Compared to Iron Sucrose for the Treatment of Functional Iron Deficiency Associated With Surgical Critical Illness||Denver Health and Hospital Authority|No|Not yet recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009943||54510|
NCT01979263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012686R001-IRB|Attention Bias Modification Treatment for Anxious Youth||ABMT|Weill Medical College of Cornell University|No|Recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|7 Years|17 Years|No|||December 2015|December 10, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01979263||56860|
NCT01979588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|What's Going Around|How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice|How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice|WGA|NorthShore University HealthSystem|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|206703|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 3, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01979588||56835|
NCT02010801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010036D|Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors|Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors||National Taiwan University Hospital|Yes|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02010801||54444|
NCT02011074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08-043|Perioperative Changes of Heart Rate Variability Related to Anxiety and Depressiveness in Patients Undergoing General Anesthesia|Perioperative Changes of Heart Rate Variability Related to Anxiety and Depressiveness in Psychologically Normal Patients Undergoing General Anesthesia||Samsung Medical Center|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Male|30 Years|80 Years|No|Non-Probability Sample|Hepatocellular carinoma patients undegoing Hepatectomy with general anesthesia|November 2014|November 17, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02011074||54423|
NCT02011347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/26|Ketamine and Closed-Loop Anesthesia System|Influence of Ketamine on a Closed-Loop Anesthesia System|LoopKeta|Hopital Foch|No|Recruiting|July 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||June 2015|June 17, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02011347||54402|
NCT02011568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013106-01|Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients|Therapeutic Hypothermia Following Out-of-Hospital Cardiac Arrest - A Randomized Trial Comparing Mild and Moderate Therapeutic Hypothermia (CAPITAL CHILL)|CAPITALCHILL|Ottawa Heart Institute Research Corporation|Yes|Recruiting|August 2013|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02011568||54386|
NCT02008825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN2013-62|Evaluation of the ViSiGiTM Calibration System|Evaluation of the ViSiGiTM Calibration System for Effectiveness With Sleeve Visual Delineation at Various Suction Levels.|ViSiGi|St. Luke's Hospital and Health Network, Pennsylvania|Yes|Not yet recruiting|January 2014|May 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008825||54595|
NCT02010060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SDG17140091|Aerobic Training and Non-Exercise Physical Activity|The Intervention Composed of Aerobic Training and Non-Exercise Physical Activity (I-CAN)|I-CAN|East Carolina University|No|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|40 Years|65 Years|No|||January 2016|January 20, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02010060||54501|
NCT02010593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-024/IPM031|Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women|Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population||International Partnership for Microbicides, Inc.||Completed|December 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|96|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||September 2015|February 16, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010593||54460|
NCT02011659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PONV-NHIS-GYN-001|Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy|A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy|PONV|National Health Insurance Service Ilsan Hospital|Yes|Recruiting|November 2013|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|128|||Female|18 Years|70 Years|No|||December 2013|December 12, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011659||54379|
NCT02010645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0590|Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)|Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2014|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02010645||54456|
NCT02010658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018749|Effect of Cognitive Aid on Adherence to Perioperative Guidelines|Effect of Cognitive Aid on Adherence to Perioperative Guidelines||Medical University of South Carolina|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Crossover Assignment|2||Actual|111|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02010658||54455|
NCT02010359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK095913-01A1|Fish Oils and Adipose Inflammation Reduction||FAIR|University of Pennsylvania|Yes|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010359||54478|
NCT02010905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44943.018.13|Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System|Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System|Redefine|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|December 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2015|December 21, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02010905||54436|
NCT02010918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-ART-03(01/08)|Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis|A Phase III, Multicenter, Randomized, Parallel, Open Label and Comparative Study to Evaluate the Efficacy of 500 mg Glucosamine Sulfate (GS) / 400 mg Chondroitin Sulfate (CS)Capsules and 1500 mg GS / 1200 mg CS Sachet Compared With Cosamin DS® Capsule in Treatment of Knee Osteoarthritis..||Ache Laboratorios Farmaceuticos S.A.|Yes|Completed|February 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|922|||Both|40 Years|N/A|No|||December 2013|December 10, 2013|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02010918||54435|
NCT02011763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAF87|Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents|Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) Administered 6 Months Apart in Healthy Toddlers, Children and Adolescents Aged 12 Months to 15 Years in China||Sanofi|No|Completed|December 2013|August 2015|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Both|12 Months|15 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011763||54371|
NCT02011776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FML-001|A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome|A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome||Santen Pharmaceutical(China) Co.,LTD|No|Completed|March 2013|November 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|35|||Both|18 Years|70 Years|No|Probability Sample|the people who suffered from the dry eye disease coused by the Sjögren syndrome|July 2014|July 7, 2014|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011776|8 Weeks|54370|
NCT02012803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evo-rad-akilles-2|Achilles Tendon Rupture, Conservative vs. Operative Treatment: Prospective Randomized Controlled Trial|Conservative vs. Operative Treatment of Achilles Tendon Rupture, Prospective Randomized Controlled Trial||University of Oulu|No|Active, not recruiting|April 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02012803||54291|
NCT02013128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTX-IB-104|Ublituximab + Ibrutinib in Select B-cell Malignancies|A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies||TG Therapeutics, Inc.|Yes|Enrolling by invitation|December 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 8, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013128||54267|
NCT02011737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC2013-08-066|Naftopidil 75mg for Improving Clearance of Urinary Stones|The Effectiveness and Safety of Naftopidil 75mg for Improving Clearance of Ureteral and Renal Stones After Shockwave Lithotripsy: Prospective Randomized Controlled Study||Samsung Medical Center|No|Not yet recruiting|February 2014|April 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|15 Years|80 Years|No|||December 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011737||54373|
NCT02012257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2952|Success Rate of Anterior Middle Superior Alveolar (AMSA) Nerve Block in Three Different Sites of Injection|||hahid Beheshti University of Medical Sciences|Yes|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02012257||54333|
NCT02008981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM platelet function|Effect of Herbal Products on Platelet Function and Clotting|A Randomized, Double Blind, Placebo-controlled Crossover Study on the Effect of Commonly Used Herbal Products on Platelet Function and Coagulation Profile of Healthy Volunteers||Singapore General Hospital|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008981||54583|
NCT02009618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.1.2013 / 1|The Effects of Rifaximin Therapy in Irritable Bowel Syndrome|The Effects of Rifaximin Therapy in Patients Pre-Diagnosed With Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo Controlled Study||Bezmialem Vakif University|No|Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|50 Years|No|||December 2013|December 11, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02009618||54534|
NCT02009969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01685|Serial Comparisons of Abdominal and Neurological MRI Scans|Serial Comparisons of Abdominal and Neurological MRI Scans of Patients With Refractory Psychosis Disorders|SCANMRI|University of British Columbia|No|Recruiting|September 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|12 Years|N/A|No|Non-Probability Sample|Participants who have recently been seen at the BC (British Columbia) Psychosis Program at        the University of British Columbia hospital.|December 2015|December 10, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009969||54508|
NCT02009982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062061|Cardioneuroablation for Neurocardiogenic Syncope|Cardioneuroablation for Neurocardiogenic Syncope|Ablate-NCS|Emory University|Yes|Active, not recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009982||54507|
NCT02010229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11061|Clinical Situations at High Risk of Placenta Accreta / Percreta|Clinical Situations at High Risk of Placenta Accreta / Percreta: Impact of Diagnostic Methods and Management on Maternal Morbidity.|Paccreta|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2013|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|630|||Female|18 Years|N/A|No|Non-Probability Sample|Women delivering in maternity units of 8 French regions.|January 2016|January 29, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02010229||54488|
NCT01979601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGT209X2101|Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia on Stable Doses of Statin Medications||Novartis||Completed|December 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|74|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979601||56834|
NCT01979614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2203|Study of the Vascular Effects of Serelaxin|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease||Novartis|No|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979614||56833|
NCT02011581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-09110|Diurnal Variability in the Regulation of Beta-cell Function and Insulin Sensitivity in Overweight People|Diurnal Variability in the Regulation of Beta-cell Function and Insulin Sensitivity in Overweight People|24Hr|Washington University School of Medicine|Yes|Completed|October 2011|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|16|Samples Without DNA|Blood samples, adipose tissue samples and muscle samples|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of female subjects of all races and ethnic groups.        Participants will be recruited by reviewing our database of research subjects containing        thousands of research study volunteers and by St. Louis metro area postings.|April 2015|April 28, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02011581||54385|
NCT02011594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1407|Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma|Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma||Zhejiang University|No|Withdrawn|January 2014|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||February 2015|February 11, 2015|December 7, 2013||No|There was no participants enrolled in this clinical trial.|No||https://clinicaltrials.gov/show/NCT02011594||54384|
NCT02011867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-13/315|A New Cochlear Implant Electrode For Inner Ear Malformations|A New Cochlear Implant Electrode With A "Cork" Type Stopper For Inner Ear Malformations||Hacettepe University|No|Completed|May 2013|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||December 2013|December 9, 2013|November 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02011867||54363|
NCT02012114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-605|A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications|A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications|Crystobs|Hospices Civils de Lyon|Yes|Recruiting|December 2011|May 2015|Anticipated|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|4 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT02012114||54344|
NCT02009436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-382|Inhaled Azacitidine in Patients With Advanced Non-small Cell Lung Cancer|Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2014|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009436||54548|
NCT02011672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46103.081.13|Effect of Milk Ingredients on Glucose Regulation and Inflammation|Effect of Milk Ingredients on Glucose Regulation and Inflammation in Overweight Subjects||NIZO Food Research|No|Completed|November 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011672||54378|
NCT02010372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01IP000502|Optimizing Application And Support Of Immunization Information Systems (OASIS)|Optimizing the Practical Application of Immunization Information System Use in Primary Care Practices|OASIS|University of Rochester|No|Completed|December 2013|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|31|||Both|N/A|N/A|No|||February 2016|February 23, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010372||54477|
NCT02010671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD IRB Protocol Number 477211|Survey of Women's Choice of Delivery Before Consulting With Her Obstetrician|Understanding a Woman's Choice of Mode of Delivery Before Initial Consult With Her Obstetrician After Having One Prior Cesarean Section||University of California, Davis|No|Completed|September 2013|July 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|8|||Female|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from the new obstetrics patients in the University of        California, Davis Department of Obstetrics and Gynecology department clinics.|December 2015|December 2, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02010671||54454|
NCT02012283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGSPICE-12-001119|Influence of Spices on Mixed Vegetable Intake Including Brassica Vegetables|||University of California, Los Angeles|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|20|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012283||54331|
NCT02012296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0979|Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer|A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)||University of Chicago|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Male|N/A|N/A|No|||January 2016|January 6, 2016|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012296||54330|
NCT02012543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agar jelly|Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients|||Showa Inan General Hospital|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02012543||54311|
NCT02012530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKRF 003|PRP vs HA Intra-articular Knee Injections for Cartilage Defects|A Cohort Comparison Study Comparing Platelet Rich Plasma vs Hyaluronic Acid Intra-articular Knee Injections for Early Cartilage Defects in the Knee||Shetty-Kim Research Foundation|Yes|Not yet recruiting|January 2014|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2013|December 10, 2013|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012530||54312|
NCT02013154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEK-Dkk1-P102|A Study of DKN-01 in Combination With Paclitaxel|A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination With Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients With Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients With Relapsed or Refractory Esophageal Squamous Cell Cancer||Leap Therapeutics, Inc.|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|92|||Both|30 Years|N/A|No|||March 2016|March 11, 2016|December 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02013154||54265|
NCT02013167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00103311|Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL|A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)||Amgen|Yes|Active, not recruiting|December 2013|August 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013167||54264|
NCT02012270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175008|Aneurysma Hernia Study - Incidence of Incisional Hernias After Abdominal Aortic Aneurysm Repair|Prospective Case-control Study on the Incidence of Incisional Hernias at 12 Months After Closure of Midline Laparotomies in Patients Treated for Abdominal Aortic Aneurysm|АНЕУРИЗМА|University of Belgrade|No|Recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|N/A|N/A|No|Probability Sample|Patient operated due to Abdominal Aortic Aneurysm with open repair through laparotomy.|February 2015|February 26, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012270||54332|
NCT02009319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO - 004|Endobronchial Ultrasound Elastography: the Utility of Strain Ratio for Lymph Node Staging in Lung Cancer Patients|Endobronchial Ultrasound Elastography: the Utility of Strain Ratio for Lymph Node Staging in Lung Cancer Patients||The University Clinic of Pulmonary and Allergic Diseases Golnik|Yes|Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|Samples With DNA|EBUS TBNA lymph node specimen - a part of routine diagnostic procedure|Both|18 Years|N/A|No|Probability Sample|Consecutive patients at least 18 years old, referred to bronchoscopy with suspicion for        lung cancer according to chest CT-scan|September 2015|September 8, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02009319||54557|
NCT02009332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC001|Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer|A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer||Aadi, LLC|Yes|Recruiting|April 2014|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009332||54556|
NCT02009345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH Canada|Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada|Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada|FHCanada|McGill University Health Center|No|Recruiting|November 2013|November 2020|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|6000|Samples With DNA|Plasma and Buffy coat for DNA extraction DNA stock samples|Both|N/A|N/A|No|Non-Probability Sample|Patients from primary care clinics|June 2014|June 20, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02009345|15 Years|54555|
NCT02009631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-020|A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors|A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors||AbbVie|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009631||54533|
NCT02009592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18245212-108-99/164|Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients|The Efficacy of Antibiotic Rifaximin on the Lipopolysaccharides (LPS) and Related Cytokine Levels in Non Alcoholic Fatty Liver Disease Patients||Bezmialem Vakif University|No|Completed|June 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|70 Years|No|||May 2014|May 15, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02009592||54536|
NCT02009605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP 1401|Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer|An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer||Zhejiang University|Yes|Not yet recruiting|March 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009605||54535|
NCT02009995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026315|The Diabetes Aerobic and Resistance Bands Exercise (DARE-Bands) Trial|The Diabetes Aerobic and Resistance Bands Exercise Trial (The DARE-Bands Trial)|DARE-Bands|University of Calgary|No|Not yet recruiting|January 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|555|||Both|35 Years|75 Years|No|||December 2013|December 9, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009995||54506|
NCT02001454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-13|Quality of Pain Management at the Ziv Medical Center|Quality of Pain Management at the Ziv Medical Center||Ziv Hospital|Yes|Recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|400|||Both|25 Years|65 Years|No|Probability Sample|The population includes patients in pain.|November 2013|November 27, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001454||55161|
NCT02001714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-204|Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms|Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms|Gladiolus|William Beaumont Hospitals|Yes|Active, not recruiting|September 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|465|||Female|55 Years|N/A|No|||January 2016|January 5, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02001714||55141|
NCT02001922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD Integrated Care Valais|Soins intégrés BPCO (Broncho-pneumopathie Chronique Obstructive) en Valais - Mieux Vivre Avec ma BPCO (COPD Integrated Care Program Valais - Living Well With COPD)|COPD Integrated Care Program Valais - Living Well With COPD, a Pilot Study Assessing Feasibility, Acceptability and Effectiveness in the Canton of Valais, Switzerland||Centre Hospitalier du Centre du Valais|No|Recruiting|March 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|35 Years|N/A|No|||November 2013|November 29, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02001922||55125|
NCT02010515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMG-181211|An Arrhythmia Risk Predictor Trial|Clinical-Electrophysiological Risk Marker Trial Goettingen||University Medical Center Goettingen|No|Completed|January 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|282|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ischemic or dilated cardiomyopathy and "standard indications" for ICD        treatment. "Stamdard indications" are approved and strictly follow current guidelines, the        decision on ICD implantation is based on left-ventricular ejection fraction or the history        of malignant arrhythmia. i.e. secondary prevention of sudden cardiac death). Implantation        procedure is performed at University Medical Center Goettingen.|December 2013|December 9, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010515||54466|
NCT02011386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANGO|Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis|Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis|MANGO|Hvidovre University Hospital|Yes|Not yet recruiting|December 2013|July 2021|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with axial spondyloarthritis with moderate to high disease activity (BASDAI >= 40        mm), who are going to start treatment with tumor-necrosis-factor-alpha inhibitor.|December 2013|December 10, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02011386||54399|
NCT02011633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MERO-105|Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 500/10 mg and Coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg in Healthy Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011633||54381|
NCT02012413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/50167-6|Effect of Pulsed Signal Therapy in Patella Chondromalacia|Effect of Pulsed Signal Therapy in Patella Chondromalacia. Randomized Prospective Trial.||University of Sao Paulo General Hospital|No|Recruiting|November 2012|July 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02012413||54321|
NCT02012972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32549|Non‐Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population|Non‐Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population|RapIT-NCD|Boston University|No|Active, not recruiting|January 2014|May 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|35 Years|N/A|No|Non-Probability Sample|The study population will be non-pregnant adults who initiated antiretroviral therapy        (ART) for HIV at least 12 months prior to study enrollment and are at least 35 years old.        The age restriction will allow the study to focus on older patients who are at greater        risk of NCDs. Pregnant women will be excluded because they face a different set of NCD        risks directly related to pregnancy; women less than 6 months post-partum are also        excluded to allow for the remaining effects of pregnancy.|July 2015|July 20, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012972||54279|
NCT01978561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-04|Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)|Pregnancy, Delivery, And Neonatal Outcomes In Subjects With Ongoing Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)|Thrive-IVF F/U|Nora Therapeutics, Inc.|Yes|Completed|October 2013|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|40|||Female|21 Years|39 Years|No|||September 2015|September 10, 2015|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978561||56914|
NCT01978574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSS-PP1854|Intellectual Enrichment to Build Cognitive Reserve in MS|A Randomized Controlled Trial of Intellectual Enrichment to Build Cognitive Reserve in Multiple Sclerosis||Kessler Foundation|Yes|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|25 Years|65 Years|No|||October 2013|November 6, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978574||56913|
NCT01978015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP424/2010|Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG|Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma||University of Campinas, Brazil|Yes|Completed|October 2011|January 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|69|||Both|18 Years|95 Years|No|||October 2013|October 31, 2013|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978015||56956|
NCT02010944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-103|A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels|An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects||Astellas Pharma Inc|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|December 10, 2013|October 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02010944||54433|
NCT02011217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU-IL-S2|The Effects of Rye Crisp Bread on Appetite and Metabolic Function|The Effects of Rye Crisp Bread on Subjective Appetite and Metabolic Function After Short-term Consumption|S2RBAM|Swedish University of Agricultural Sciences|No|Completed|August 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02011217||54412|
NCT02012556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH9507-CTR-1015|Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients|A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients||Theratechnologies|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||December 2013|December 10, 2013|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02012556||54310|
NCT02013180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zinc/PSA|Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection|Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection||Bagcilar Training and Research Hospital||Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|480|Samples Without DNA|serum, prostatic tissue|Male|N/A|N/A|No|Non-Probability Sample|patient with LUTS(lower urinary tract symptomps) and elevated serum PSA levels/suspicious        rectal examination who undergone transrectal ultrasonography guided prostate biopsy|December 2013|February 3, 2014|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02013180||54263|
NCT02013193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTQ001-RangerSFA|Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries|Prospective, Randomized, Multicentre Clinical Study of the Hemoteq Ranger™ Paclitaxel-Coated PTA Balloon Catheter (Ranger DCB) in Comparison to Uncoated PTA Balloons in Femoropopliteal Lesions|RANGER-SFA|Hemoteq AG|Yes|Active, not recruiting|January 2014|November 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013193||54262|
NCT02013141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101|An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years|An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years||Theravance Biopharma Antibiotics, Inc.|No|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|32|||Both|1 Year|17 Years|No|||October 2015|October 7, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013141||54266|
NCT02008994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH SSKT001|Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer|A Phase II Pilot Study Utilizing Genomic and Proteomic Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer||Sanford Health|Yes|Terminated|September 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|October 30, 2013||No|Resignation of Principal Investigator|No||https://clinicaltrials.gov/show/NCT02008994||54582|
NCT02009020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.531.11 (8073)|Evaluation of a Non-invasive Device to Measure Blood Pressure and Difference in Pulse Pressure (dPP) Intraoperatively|||Johannes Gutenberg University Mainz||Completed|July 2012|||April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|26|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective abdominal or urological surgery|December 2013|December 7, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02009020||54580|
NCT02009033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-063|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery. A Randomised Clinical Study||Rigshospitalet, Denmark|Yes|Completed|September 2011|December 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT02009033||54579|
NCT02013232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI201206|Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia|Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study||Beijing HuiLongGuan Hospital|Yes|Recruiting|February 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|45 Years|No|||December 2013|December 11, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02013232||54259|
NCT02013245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTBVAC-01|Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.|Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers|MTBVAC|Biofabri, S.L|Yes|Active, not recruiting|January 2013|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 18 to 45 years, ELISPOT Tb and HIV negative|December 2013|December 11, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02013245||54258|
NCT02009046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04704-01-01|Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students|Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students|SEI|Public Health Institute, California|No|Active, not recruiting|September 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|2379|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02009046||54578|
NCT02000830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-205|Follow up Study of Patients Having Participated in Clinical Trial 64,185-204|A 48-52 Month Blinded-Outcomes Follow up Study of Patients Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-204|JASMINE_205|InfaCare Pharmaceuticals Corporation|Yes|Enrolling by invitation|August 2013|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|N/A|52 Months|No|Probability Sample|patients who received a single dose of trial medication in clinical trial 64,185-204.|February 2016|February 9, 2016|June 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000830||55209|
NCT02010008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 7124|Screening Mammography and Latinas: A Multilevel Intervention|Understanding and Preventing Breast Cancer Disparities in Latinas: Screening Mammography and Latinas: A Multilevel Intervention||Fred Hutchinson Cancer Research Center|No|Completed|May 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|540|||Female|40 Years|74 Years|No|||July 2015|July 1, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010008||54505|
NCT02001480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-039|Surrogate Markers for Sudden Cardiac Death in Patients With Diabetes Mellitus and End Stage Renal Disease|||RWTH Aachen University|No|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02001480||55159|
NCT02011360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049226|Prader-Willi Syndrome Macronutrient Study|Evidence-Based Approach to Dietary Management of Prader-Willi Syndrome (PWS)||Duke University||Recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|13|||Both|5 Years|17 Years|No|||March 2016|March 11, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011360||54401|
NCT02012166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0893-002|A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, 3-Period, 4 Treatment Incomplete Crossover Study to Assess the Effects of Single Oral Doses of L-001241689 on Glucagon-Induced Glycemic Excursion in Healthy Male Subjects Following Intravenous Administration of Glucagon, Sandostatine® and Insulin||Merck Sharp & Dohme Corp.|No|Completed|July 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02012166||54340|
NCT02012985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC5-DB-01|Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria|A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria||OxThera|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|2 Years|N/A|No|||October 2015|October 14, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012985||54278|
NCT02009124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-03|Stem Cell Therapy in Spinal Cord Injury|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Spinal Cord Injury||Neurogen Brain and Spine Institute|Yes|Recruiting|August 2012|August 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|12 Months|65 Years|No|||December 2013|December 6, 2013|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009124||54572|
NCT01979783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMGUS|Correlation Between Electromyography and Thickness Change of the Trunk Muscles in Subjects With Low Back Pain|||University of Belgrade||Not yet recruiting|November 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|tertiary care clinic|November 2013|November 7, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01979783|1 Day|56820|
NCT01978314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST mGFR -002|FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.|A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) Test™ in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods||FAST BioMedical|Yes|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978314||56933|
NCT01978327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200592|GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers|Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers||GlaxoSmithKline||Terminated|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|June 5, 2014|October 31, 2013||No|Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to    investigate higher doses of GSK2647544 in the following two cohorts|No||https://clinicaltrials.gov/show/NCT01978327||56932|
NCT02010697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UO1 CA154280 IRB #130764|Nonsmokers Helping Smokers Quit|Mail Campaigns That Target Smokers or Nonsmokers Who Live With Smokers|Project BEST|University of California, San Diego|No|Active, not recruiting|December 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3090|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02010697||54452|
NCT02011230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13022|Measuring Pain and Hydration After Tonsillectomy|Pain Control as a Function of Hydration Status in the Post Tonsillectomy Patient.||TriHealth Inc.|Yes|Terminated|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|4 Years|N/A|Accepts Healthy Volunteers|||April 2015|August 10, 2015|December 3, 2013|Yes|Yes|IRB closed study: irregularities in documentation of informed consent, HIPAA|No||https://clinicaltrials.gov/show/NCT02011230||54411|
NCT02012049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016576|Bioequivalence Test for Risperdal 2mg of Janssen Korea|Bioequivalence Test for Risperdal OD Tab. 2mg of Janssen Korea||Janssen Korea, Ltd., Korea|No|Completed|August 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012049||54349|
NCT02012062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-IMRT-N|Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).|||Fudan University|Yes|Recruiting|July 2012|June 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|70 Years|No|||December 2013|December 10, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02012062||54348|
NCT02012075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWDLHF2012|A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure|Efficacy and Safety Comparison of Extended-Release Carvedilol Sulfate and Sustained-release Metoprolol Succinate in Patients With Heart Failure||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|December 2013|||February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012075||54347|
NCT02012842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060173|Metabolic Syndrome and Periodontitis|The Effect of Periodontal Treatment on Quality of Life in Patients With Metabolic Syndrome||Federal University of Rio Grande do Sul|Yes|Recruiting|May 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|158|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02012842||54288|
NCT02012855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000041|Effect of Different Types of Carbohydrates Consumed After Exercise on Blood Fat Levels|Effect of Exercise and Glycemic Index of Carbohydrate Feeding on Postprandial Lipid Metabolism||University of Saskatchewan|No|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02012855||54287|
NCT02009007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-09-058|Vasopressors for Cerebral Oxygenation|Effect of Phenylephrine or Dopamine Infusion on Cerebral Oxygen Saturation in Thoracic Surgery Patients||Samsung Medical Center|Yes|Recruiting|December 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|90 Years|No|||December 2013|December 6, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02009007||54581|
NCT02012868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120004jln|The Prevalence of Obstructive Sleep Apnoea in Patients Prior to and One Year After Bariatric Surgery|The Prevalence of Obstructive Sleep Apnoea in Patients Prior to and One Year After Bariatric Surgery||University of Southern Denmark|No|Enrolling by invitation|March 2012|August 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|63|||Both|18 Years|65 Years|No|Probability Sample|patients attending bariatric surgery|November 2013|December 10, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02012868||54286|
NCT02012881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130104|LCoMotion. Learning, Cognition and Motion. Effect of a Four Month School-based Cluster-randomized Intervention||LCoMotion|University of Southern Denmark|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|870|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012881||54285|
NCT02000544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECC MODULAR|Clinical Evaluation of a Modular Extracorporeal Circulation Circuit|Clinical Evaluation Study of a Novel Modular Extracorporeal Circulation Circuit in Open Heart Surgery|MECC MODULAR|AHEPA University Hospital|No|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||December 2013|December 3, 2013|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02000544||55231|
NCT02000817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116505|Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients|A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients||GlaxoSmithKline|No|Recruiting|March 2014|January 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|40|||Both|16 Years|27 Years|No|||July 2015|October 29, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02000817||55210|
NCT02001142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA 7-13-TS-35|Effect of Exercise on Metabolic Health|Effect of Exercise on Novel Insulin Signaling Events in Human Muscle||University of Michigan|No|Recruiting|November 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001142||55185|
NCT02000843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03261|Tympanoplasty Using Conchal Cavum Approach and Conchal Pericondrium|Tympanoplasty -- Conchal Cavum Approach||University of British Columbia|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|N/A|N/A|No|||October 2014|October 2, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02000843||55208|
NCT02001116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHOCCT-001|Improving the Quality of Paediatric Hospital Care in the Kyrgyz Republic|Improving the Quality of Paediatric Hospital Care in the Kyrgyz Republic: Evaluation of the Impact of the Intervention||WHO Collaborating Centre for Maternal and Child Health, Trieste|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|4626|||Both|2 Months|59 Months|No|||August 2015|August 24, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001116||55187|
NCT02001129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEF 14-040|Improving Follow-Up Adherence in a Primary Eye Care Setting|Improving Follow-Up Adherence in a Primary Eye Care Setting: A Prospective, Randomized Controlled Trial||Wills Eye|No|Active, not recruiting|August 2013|August 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1000|||Both|18 Years|N/A|No|||November 2013|December 3, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02001129||55186|
NCT02009696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120226 (Phase B)|ProMRI Study of the Entovis Pacemaker System (Phase B)|||Biotronik, Inc.|Yes|Completed|December 2013|January 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|221|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigators' general patient        population according to the inclusion and exclusion criteria.|October 2015|October 29, 2015|December 9, 2013|Yes|Yes||No|June 17, 2015|https://clinicaltrials.gov/show/NCT02009696||54529|
NCT02009709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-0001|Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2|Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 in Eyes With Keratoconus or Ectasia||Mack Eye Center|No|Recruiting|October 2013|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009709||54528|
NCT02009722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008490|Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose|Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose||Mayo Clinic|Yes|Completed|January 2014|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||May 2015|May 20, 2015|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02009722||54527|
NCT02010281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120126|Analgesic Effects of rTMS in Peripheral Neuropathic Pain|Long-term Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Motor or Prefrontal Cortex in Peripheral Neuropathic Pain: a Multicenter Randomized Placebo Controlled Trial|TRANSNEP|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|230|||Both|18 Years|75 Years|No|||August 2015|August 24, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02010281||54484|
NCT02010840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|748113|The Effect of a Father Inclusive Psychoeducation Program on Postnatal Depression|The Effect of a Father Inclusive Psychoeducation Program on Postnatal Depression: a Randomized Controlled Trial||The University of Hong Kong|Yes|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1152|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02010840||54441|
NCT02012699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMC 253-13|Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.|Integrated Cancer Repository for Cancer Research|iCaRe2|University of Nebraska|No|Recruiting|November 2013|December 2099|Anticipated|December 2099|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9999|Samples With DNA|Questionnaire: Patients fill out questionnaires at baseline, and potentially follow up      questionnaires at 6 months and annually.      Blood: obtain 30 ml of blood at enrollment and an additional 30ml may be obtained biannually      or at recurrence.      Urine: obtain 1/4 cup of urine at enrollment date. Additional 1/4 cup of urine may be      collected at follow up visits.      Tissue procurement and banking of excess biological materials. This includes but not limited      to tumor tissue and/or metastatic cancer tissue and/or paraffin embedded tissue collected      and saved from biopsy and/or surgery done in the past or future, from registry participants.      If subjects have tissue outside of UNMC, subjects will sign a release of information so      tissue slides can be obtained.|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults (male and female, age 19 and older) who have diagnosis of cancer and adults        considered to be an "at risk individual for cancer", such as but not limited to a tumor,        mass, nodules, family history of cancer, or suspicious clinical findings.|December 2014|December 12, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02012699|80 Years|54299|
NCT02009137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1307-210-002|Efficacy and Safety Study of EVERA to Augment Small Breast|A Randomized-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Breast Augmentation With EVERA(Korean External Soft Tissue Expansion System) as Compared to AESTES (American External Soft Tissue Expansion||Seoul National University Hospital|Yes|Completed|December 2013|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Female|24 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02009137||54571|
NCT01979159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1356-P|A Novel Treatment for Aphasia and Apraxia of Speech : Measurement of Outcomes|A Novel Treatment for Aphasia and Apraxia of Speech: Measurement of Outcomes|AA: MoO|VA Office of Research and Development|No|Recruiting|October 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|21 Years|75 Years|No|||December 2015|December 9, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01979159||56868|
NCT01980043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209013050|Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse|Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse With Abdominal Fixation Under Sedation and Local Anesthesia||Weill Medical College of Cornell University|No|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|75 Years|100 Years|No|||December 2015|December 4, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01980043||56800|
NCT02011477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEULS-PI-001/2013|Hypoalgesic Effects Neural Mobilization Techniques|Comparison of Hypoalgesic Effects of Neural Stretching Versus Neural Gliding: a Randomized Clinical Trial|NM|Universidad Rey Juan Carlos|No|Completed|March 2013|November 2013|Actual|October 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02011477||54392|
NCT02011789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL45|Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans|A Pilot Study To Determine The Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Human Subjects||USDA, Western Human Nutrition Research Center|No|Completed|April 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|10|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02011789||54369|
NCT02012569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THO-IM_01-CT|Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting|A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft|EHTIC|Thrombotargets Europe S.L|Yes|Completed|November 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||November 2015|February 23, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02012569||54309|
NCT02012088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEL-R-COMP-2013|Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb|Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Yes|Active, not recruiting|October 2013|August 2021|Anticipated|February 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|60 Years|N/A|No|||February 2016|February 17, 2016|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02012088||54346|
NCT02012816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1310|The Use of Peer Referral Incentives to Increase Demand for Voluntary Medical Male Circumcision in Zambia|The Use of Peer Referral Incentives to Increase Demand for Voluntary Medical Male Circumcision in Zambia: an Impact Evaluation||University of North Carolina, Chapel Hill|No|Active, not recruiting|June 2014|February 2016|Anticipated|February 2015|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|21259|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02012816||54290|
NCT02012829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/19NI|Influence of a Brief Intervention on CRC Screening|Brief Intervention to Improve Colorectal Cancer Screening|Hem-FMG|University Paris 7 - Denis Diderot|No|Completed|December 2011|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|45|||Both|N/A|N/A|No|||December 2013|December 10, 2013|March 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02012829||54289|
NCT02013206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO18660|A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy|An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers||Hoffmann-La Roche|No|Completed|September 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|December 11, 2013|No|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT02013206||54261|Treatment was ongoing for 3 patients at the time of the Clinical Study Report (CSR) cut-off. In the addendum to the CSR, there were no findings for these 3 patients that deviated from those observed in the original report.
NCT02013219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29158|A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer|A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|April 2014|February 2019|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|53|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013219||54260|
NCT02000271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12132-12-089|Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery?|Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery? A Randomized Controlled Trial||TriHealth Inc.||Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02000271||55252|
NCT02000531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29028|Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population|Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial||Hoffmann-La Roche|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 27, 2013|No|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02000531||55232|
NCT02000557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDER-1302-AE|Photographic Analysis of Soft Tissue Facial Profile in Patients With Class II Malocclusion|Photographic Analysis Of Soft Tissue Facial Profile In Patients With Class II Malocclusion|STFP|Academy of Interdisciplinary Dental Education and Research|Yes|Completed|October 2012|August 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|||Both|12 Years|30 Years|No|Non-Probability Sample|Study population comprises of subjects reporting to Dental department of Shaikh Zayed        Medical Complex, Lahore and Department of Orthodontics at University College of Medicine        and Dentistry, Lahore.|December 2013|December 4, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02000557|1 Month|55230|
NCT02000856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEET-PAH|BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension|BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension|BEET-PAH|Uppsala University|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02000856||55207|
NCT02000869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0016|Impact of Arterial Stiffness and Central Aortic Blood Pressure on Kidney Transplant Outcomes.|Impact of Pre- and Post-transplant Arterial Stiffness and Central Aortic Blood Pressure on Post-kidney Transplant Cardiovascular and Allograft Outcomes.||Louisiana State University Health Sciences Center Shreveport|No|Not yet recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Probability Sample|Wait-listed kidney transplant candidates who have been on the waiting list for at least 2        years|November 2013|November 27, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02000869||55206|
NCT02001467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-FSP 10|The Effects of Simulation-based Ultrasound Training on Continuity of Care in Managing Pre-mature Onset of Labor|||Rigshospitalet, Denmark|No|Completed|November 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02001467||55160|
NCT02010580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3555|Effects of Ospemifene on Pelvic Vascularity and Blood Flow|The Effects of Vaginal Ospemifene on Pelvic Organ Vascularity and Blood Flow in Postmenopausal Women|Osphena|University of Oklahoma|No|Withdrawn|January 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|N/A|No|Probability Sample|We estimate that we will need a total of 30 patients recruited to this study. Eligible        subjects will be postmenopausal women who have undergone menopause and have had a        hysterectomy.|December 2014|December 2, 2014|December 9, 2013||No|Never received necessary funding.|No||https://clinicaltrials.gov/show/NCT02010580||54461|
NCT02011126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1321|Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors||Children's Oncology Group||Withdrawn|June 2014|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|30 Years|No|||June 2014|June 3, 2014|December 10, 2013|Yes|Yes|IND no longer available.|No||https://clinicaltrials.gov/show/NCT02011126||54419|
NCT02011646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0765|Healthy Body Study|Testing a Healthy Weight Intervention in Adolescents||Icahn School of Medicine at Mount Sinai|No|Terminated|November 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|12 Years|24 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|December 10, 2013||No|The PI changed institutions|No||https://clinicaltrials.gov/show/NCT02011646||54380|
NCT01978002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00054279|Sensory Sensitivity and Urinary Symptoms in the Female Population|||University of Michigan|No|Recruiting|November 2011|||September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group 1 will be women with a clinical diagnosis of IC/BPS or OAB, at least 18 years of        age, who have had urodynamic testing performed within the preceding 6 months. All of these        subjects will complete the questionnaires, mechanical sensitivity testing, and auditory        sensitivity testing        Group 2 will be women recruited from the community sample, at least 18 years of age. All        of these subjects will complete the questionnaires, mechanical sensitivity testing, and        auditory sensitivity testing. Half of the subjects (n=30) will also undergo urodynamic        testing to measure bladder sensitivity.|December 2014|December 1, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01978002||56957|
NCT01978301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117287|Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars|A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials||GlaxoSmithKline|No|Terminated|April 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|9|||Both|18 Years|55 Years|No|||June 2015|June 25, 2015|October 31, 2013||No|Temporary hold on recruitment during staff changes at the site|No||https://clinicaltrials.gov/show/NCT01978301||56934|
NCT01979458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001115|Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon|Pilot Study to Evaluate Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon||Massachusetts General Hospital|No|Completed|November 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||September 2014|September 16, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979458||56845|
NCT01979471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pro00041644|The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH|The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH|RxEACH|University of Alberta||Recruiting|January 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|704|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979471||56844|
NCT01979432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11014|The Cognitive and Cardiovascular Health in the Elderly Study|The Cognitive and Cardiovascular Health in the Elderly Study|COACHES|University Hospital, Limoges|Yes|Recruiting|December 2013|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|386|||Both|70 Years|N/A|No|||March 2015|March 8, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979432||56847|
NCT01979445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-CAN-13-02|Cangrelor to Clopidogrel or Prasugrel Transition Study|A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.||The Medicines Company|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|15|||Both|18 Years|75 Years|No|||October 2013|March 26, 2014|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979445||56846|
NCT02012036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-58150-002|Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice|Prospective Non-Interventional Study To Optimize Photodynamic TUR-B In Clinical Practice|OPTIC-III|Ipsen|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Bladder cancer patients|November 2014|November 3, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02012036||54350|
NCT02012582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS203/II/1/03|Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury|An Exploratory Phase 2 a Study to Assess Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of VAS203 in Patients With Moderate and Severe Traumatic Brain Injury|NOSTRA|Vasopharm GmbH|Yes|Completed|November 2009|September 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|December 10, 2013||No||No|December 29, 2015|https://clinicaltrials.gov/show/NCT02012582||54308|
NCT02012595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01|[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease|[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease||University of Aarhus|Yes|Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's patients with moderate symptoms (diagnosis > 4 years earlier, bilateral        disease). Will be recruited through department of neurology Aarhus University Hospital,        Denmark.        Healthy controls recruited through local media.|May 2015|May 31, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02012595||54307|
NCT02012322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AG026338-01|UCSD Q10 and Aging Study|Coenzyme Q10 and Aging: A Planning Grant||University of California, San Diego|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|44|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012322||54328|
NCT02012335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0196|Ketamine Use in Electroconvulsive Therapy|Ketamine Use in Electroconvulsive Therapy: Clinical, Cognitives and Neurotrophic Outcomes||Hospital de Clinicas de Porto Alegre|No|Withdrawn|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|November 18, 2013||No|Methodologicals and logistics issues.|No||https://clinicaltrials.gov/show/NCT02012335||54327|
NCT02012608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202253|Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy|Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast||University of Arkansas|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02012608||54306|
NCT02012621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2104|Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy|Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy.|2104|University of Colorado, Denver|No|Recruiting|December 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole Blood|Both|18 Years|89 Years|No|Non-Probability Sample|HIV-infected individuals who are taking tenofovir.|November 2015|November 30, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02012621||54305|
NCT02000284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137162|Mitochondrial Dysfunction in Autism Spectrum Disorder|Defining Subgroups of Mitochondrial Disease and Dysfunction in Autism Spectrum Disorder|Mito|University of Arkansas|No|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|400|Samples With DNA|Biochemical Measures        1. Mitochondrial Energetics        2. Redox Metabolism        3. ATP Measurement        4. Mitochondrial Copy Number        5. Clinical Laboratory Testing        6. Urine Testing        7. Stool Testing        8. Teeth Collection        9. Saliva Collection|Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit several groups of children for this study: 50 children with ASD who have        MD (ASD/MD); 50 children with ASD who do not have MD (ASD/NoMD); 50 no ASD/MD; 50 no        ASD/no MD but DD; 50 TD controls; and a general population of 150 children with ASD.|February 2016|February 2, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02000284||55251|
NCT02001493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIME-01|Metabolomic Profiling in Renal Cell Carcinoma|Observational Prospective Study to Analyze a Metabolomic Profile and to Explore it as Prognostic Factor in Patients With Renal Cell Carcinoma (mRCC)||Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|January 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|None Retained|urine and blood|Both|18 Years|N/A|No|Non-Probability Sample|volunteer patients with renal cell carcinoma|June 2015|June 22, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02001493||55158|
NCT02001740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-246-12|An RCT in Treatment of Adhesive Capsulitis Arthrographic Joint Distention With Local Anesthetic Alone|Treatment of Adhesive Capsulitis: A Randomized Placebo-Controlled Trial Comparing Arthrographic Joint Distention With Steroid and Local Anesthetic Versus Arthrographic Joint Distention With Local Anesthetic Alone||Queen's University||Completed|December 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|19 Years|70 Years|No|||November 2015|November 21, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02001740||55139|
NCT02001155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEH - 10-989E|Comparing the Effect of the Water Drinking Test on Intraocular Pressure|Comparing the Effect of the Water Drinking Test on Intraocular Pressure in Patients With Prior Trabeculectomy or Tube Shunt Surgeries||Wills Eye|No|Completed|July 2013|July 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|21 Years|90 Years|No|Non-Probability Sample|All participants will have open angle glaucoma and have undergone either tube shunt        surgery or trabeculectomy. All participants will be matched for range of recent        intraocular pressure (average over the prior three visits of <12 mm Hg, 12 to <18 mm Hg,        or >18 mm Hg), as well as number of medications (none, 1-2, 3 or more).|December 2015|December 8, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02001155||55184|
NCT01981811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316-13-211|Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder|A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Withdrawn|March 2014|December 2014|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|October 22, 2013|Yes|Yes|The trial was terminated because it was determined that the usability of the MIND1 System in    the intended population was necessary before conducting this trial.|No||https://clinicaltrials.gov/show/NCT01981811||56665|
NCT02011906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95983|The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients|||Tehran University of Medical Sciences|Yes|Enrolling by invitation|October 2013|August 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|20|||Male|45 Years|65 Years|No|||December 2013|December 10, 2013|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011906||54360|
NCT01982071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-MA-MYC-IC-2012|A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia|A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)||Astellas Pharma Inc|No|Terminated|September 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|November 6, 2013|No|Yes|Due to administrative reasons|No||https://clinicaltrials.gov/show/NCT01982071||56645|
NCT01981824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11110000|Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study|Femur Length to Mid-thigh Circumference Ratio in Prediction of IUGR|IUGR|Ain Shams Maternity Hospital|Yes|Recruiting|October 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population This study will be conducted at the department of Obstetrics and        Gynecology recruiting pregnant women selected from the attendees of antenatal clinic,        emergency department and from inpatient wards of Ain Shams University Maternity Hospital        from the period of October 2013 to October 2014.        This study will include 100 pregnant women these cases will divided into 2 groups:          1. Normal growth Fetuses Group: will include 50 pregnant females all in third trimester.          2. IUGR fetuses Group: will include 50 pregnant females all in third trimester.|October 2013|November 6, 2013|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01981824||56664|
NCT01982097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16933|Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma|Multicenter, Prospective, Non-interventional Study "Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma"|SANE|Bayer|No|Active, not recruiting|January 2014|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients ≥ 18 years old with untreated metastatic RCC for whom treatment        with Nexavar is planned with subsequent cytoreductive nephrectomy and resumption of        Nexavar in case of clinical feasibility|February 2016|February 28, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01982097||56643|
NCT01979835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130717|GyneFix-Viz*: A Study of Serosal-Anchor (SA) Distance|GYNEFIX-VIZ*: A STUDY OF SEROSAL-ANCHOR (SA) DISTANCE IN WOMEN IMMEDIATELY AND 6-8 WEEKS FOLLOWING INSERTION|GF|Wiebe, Ellen, M.D.|No|Active, not recruiting|February 2013|June 2015|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01979835||56816|
NCT01979809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD067314-01A1|Encouraging Young Adults to Make Effective Nutrition Choices|Encouraging Young Adults to Make Effective Nutrition Choices: MENU GenY Study|MENU GenY|Henry Ford Health System|Yes|Active, not recruiting|February 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|1624|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979809||56818|
NCT01979822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-1|LenusPro Safety (LPS) Study in Patients With PH|LPS (Lenus Pro Safety) - Study in Pulmonary Hypertension (PH)||University Medicine Greifswald|Yes|Recruiting|February 2013|September 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Probability Sample|Patients from pulmonary centers|September 2013|November 3, 2013|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01979822||56817|
NCT01980069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0451|A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery|||Yonsei University|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|90 Years|No|||April 2015|April 22, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01980069||56798|
NCT02012309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2405|Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses|Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses||University of Colorado, Denver|Yes|Recruiting|August 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012309||54329|
NCT02011841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifaximin_SBP|Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients|Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study||Seoul National University Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|56|||Both|18 Years|80 Years|No|||November 2014|November 26, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011841||54365|
NCT02003599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPMarina|Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy|Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy||Universidade do Vale do Sapucai|No|Completed|May 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Female|30 Years|70 Years|No|||May 2015|May 26, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003599||54996|
NCT02003612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120310|Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia|An Analysis of Historical Data on Hematological Remission and Survival Among Adult Patients With Relapsed / Refractory B-Precursor Acute Lymphoblastic Leukemia||Amgen|No|Completed|October 2013|April 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2373|||Both|15 Years|N/A|No|Non-Probability Sample|Adults with relapsed / refractory B-precursor acute lymphoblastic leukemia identified in        study group databases from multiple sites in EU and US|May 2014|May 22, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003612||54995|
NCT02003625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-195|Meloxicam vs Placebo for Mobilization|Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial||Massachusetts General Hospital|Yes|Not yet recruiting|October 2013|March 2021|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2013|December 2, 2013|October 10, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT02003625||54994|
NCT02003872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0670-13-SMC|The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss|The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss||Sheba Medical Center|Yes|Terminated|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||December 2015|December 21, 2015|December 2, 2013||No|Stopeed due to lack of recruitment|No||https://clinicaltrials.gov/show/NCT02003872||54975|
NCT02004145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001234|Trial of a Positive Psychology Intervention in Major Depressive Disorder|Trial of a Positive Psychology Intervention to Reduce Suicide Risk in Patients With Major Depression|HOPE|Massachusetts General Hospital|No|Enrolling by invitation|October 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004145||54954|
NCT02004158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001961|Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome|Study of a Positive Psychology Program to Improve Healthy Behaviors After an Acute Coronary Syndrome: Proof of Concept Study|PEACE II|Massachusetts General Hospital|No|Completed|November 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004158||54953|
NCT01999946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03724|Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry|Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry|XOR|New York University School of Medicine|Yes|Recruiting|June 2014|May 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|255|||Both|18 Years|99 Years|No|||October 2015|October 26, 2015|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999946||55277|
NCT01999959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3061750|Effect of Pertubation on Pregnancy Rates Before Intrauterine Insemination Treatment|||Gazi University||Completed|January 2010|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Female|18 Years|44 Years|No|||November 2013|November 26, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999959||55276|
NCT02001168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XinjiangMU|Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB|Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin: a Randomized, PhaseⅢ and Open Clinical Study of Non-small Cell Lung Cancer in PhaseⅠB||Xinjiang Medical University|Yes|Active, not recruiting|October 2013|October 2022|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|392|||Both|18 Years|70 Years|No|||November 2013|November 26, 2013|November 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02001168||55183|
NCT02001506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0116|Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer|A Randomized Phase III Trial of Neoadjuvant Chemotherapy With 3 Cycles of FEC Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Adriamycin Plus Cyclophosphamide Followed by 4 Cycles of Docetaxel in Node-positive Breast Cancer|Neo-shorter|Asan Medical Center|Yes|Recruiting|November 2012|November 2020|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Female|20 Years|N/A|No|||December 2013|January 17, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02001506||55157|
NCT02001753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wze20130100|Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes|Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|December 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|88|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|November 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02001753||55138|
NCT02001987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28693|A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy|A Multicenter Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Tocilizumab in Tocilizumab-Naive Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARD and/or Biologic Therapy||Hoffmann-La Roche||Active, not recruiting|February 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|November 29, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02001987||55120|
NCT02001961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12CC23|Pathophysiology of Dilated Cardiomyopathy|Using Novel Blood and Imaging Biomarkers to Better Understand the Pathophysiology of Paediatric Dilated Cardiomyopathy||Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Not yet recruiting|January 2014|||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|Samples Without DNA|Blood plasma (>400 UL) will be collected in heparinised tubes plasma will be extracted and      the cell fraction discarded. Plasma will be stored at 80°C prior to transport on dry ice,      via protected courier.|Both|N/A|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Heart Failure Patients (MRI Clinically indicated)          2. Heart Failure Patients (Voluntarily recruited from clinic)               1. 8-16 years of age               2. Non-GA only          3. Control subjects (Clinically indicated brain MRI with contrast)|November 2013|November 29, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02001961||55122|
NCT02001974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0111|Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)|Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)||Dompé Farmaceutici S.p.A|Yes|Completed|January 2012|June 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Female|18 Years|65 Years|No|||June 2015|June 30, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02001974||55121|
NCT01981304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807/2013/D|Effects of a rapamycIn-eluting carboNized Stent With a Completely biodEgradable polymeR Coating|Effects of a rapamycIn-eluting carboNized Stent With a Completely biodEgradable polymeR Coating on inflammaTory Biomarkers and Endothelial Damage|INERT|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Probability Sample|Coronary artery disease|November 2013|November 8, 2013|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01981304||56703|
NCT01981551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140007|Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis|Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|120 Years|No|||July 2015|October 6, 2015|October 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01981551||56685|
NCT01982084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG2013/06|Group B Streptococcus: Attitudes to Immunisation in Pregnancy|Attitudes to Immunisation Against Group B Streptococcus During Pregnancy in England and Scotland||University of Oxford|No|Completed|January 2014|||March 2014|Actual|N/A|Observational|N/A||1|Actual|758|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 18 years and over of any gestation receiving antenatal care in the        Oxford area (part one and two) or within Imperial college and St Georges's NHS trusts in        London and Edinburgh Royal infirmary (part two).        Maternity healthcare professionals (midwives and doctors)working in the above areas.        Parents who have had a child with Group B streptococcal disease (part one only).|November 2015|November 6, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT01982084||56644|
NCT01981564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINR.NR013486|Asthma Express: Bridging the Emergency to Primary Care in Underserved Children|Study of an Asthma Express Intervention to Bridge Emergency to Primary Care for High Risk Children With Asthma||Johns Hopkins University|Yes|Recruiting|April 2013|February 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|264|||Both|3 Years|12 Years|No|||March 2015|September 16, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01981564||56684|
NCT01979146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7846-00|Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System|Telephone Linked Care for Cancer Symptom Management||University of Utah|Yes|Completed|April 2001|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|250|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01979146||56869|
NCT01979419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI12C0713|Korea Alzheimer's Disease Neuroimaging Initiative|Korea Alzheimer's Disease Neuroimaging Initiative|K-ADNI|Korean Alzheimers' Disease Neuroimaing Intitiative|Yes|Active, not recruiting|November 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|500|Samples With DNA|Blood, Serum, CSF|Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Community Sample|May 2015|May 6, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01979419|36 Months|56848|
NCT01980329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078492|Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites|Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites||Johns Hopkins University|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980329||56778|
NCT01980095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHB-105-01|ERADICATE Hp - Treating Helicobacter Pylori With RHB-105|A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients|ERADICATE Hp|RedHill Biopharma Limited|No|Active, not recruiting|November 2013|||June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980095||56796|
NCT02011828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00032685|Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol|Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol||University of Utah|Yes|Completed|May 2009|||January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT02011828||54366|
NCT02003339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-JE-CHC-Pron|Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium|Pilot Prospective Study on Interest of Functional MRI in Early Assessment of Radioembolization Efficiency in Patients Suffering From Hepatocellular Carcinoma|ICY|Center Eugene Marquis|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02003339||55016|
NCT01999738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1456-01|Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors|A Phase I Study of Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors||Endocyte|No|Recruiting|October 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999738||55293|
NCT01999985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17176|Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)|Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999985||55274|
NCT02003885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160063|Effect of Desflurane on Cardiac Function During Cardiac Surgery: Tissue Doppler Imaging of Mitral Valve Annular Velocity|Effect of Desflurane on Left Ventricular Function in Remifentanil-based Anesthesia for Cardiac Surgery: Tissue Doppler Imaging of Mitral Valve Annular Velocity||Konkuk University Medical Center|Yes|Recruiting|January 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02003885||54974|
NCT02004171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6863 P50DA009236-20|Electronic Cigarettes or Nicotine Inhaler for Smoking Cessation|Electronic Nicotine Delivery Devices (ENDDs) or Nicotine Inhaler for Smoking Cessation||New York State Psychiatric Institute|Yes|Terminated|December 2013|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 25, 2013||No|Changed requirements for studying e-cigarettes.|No||https://clinicaltrials.gov/show/NCT02004171||54952|
NCT01999972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061068|A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors|A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (AG-013736) In Combination With Crizotinib (PF-02341066) In Patients With Advanced Solid Tumors||Pfizer|No|Recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999972||55275|
NCT02000882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11025|Capecitabine + BKM120 TNBC BC Brain Met|Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Triple Negative Breast Cancer (TNBC) Patients With Brain Metastases||US Oncology Research|Yes|Recruiting|May 2014|January 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||November 2015|November 7, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000882||55205|
NCT02001181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921214|Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)|A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis||Pfizer|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|60 Years|No|||September 2015|September 16, 2015|November 27, 2013||No||No|September 16, 2015|https://clinicaltrials.gov/show/NCT02001181||55182|
NCT02002234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIDO 2002|Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|HeMMI|University of the Philippines||Terminated|January 2002|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|65 Years|No|||February 2014|February 16, 2014|November 7, 2013||No|Recruitment for the study was terminated due to slow recruitment|No||https://clinicaltrials.gov/show/NCT02002234||55101|
NCT02002494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6244-BE|Jugular Venous Flow Healthy Volunteers|Effect of Different Surgical Positions on the Cerebral Venous Drainage: an Ultrasound Study on Healthy Volunteers||University Health Network, Toronto|Yes|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|July 2015|July 20, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002494||55081|
NCT02002221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1405|Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients|A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus||Novartis||Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|20 Years|74 Years|No|||January 2016|February 2, 2016|November 29, 2013||No||No|February 2, 2016|https://clinicaltrials.gov/show/NCT02002221||55102|
NCT02002481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-289|Comparison of the Quality of CPR by Professional Helpers (Emergency Physicians / Paramedics) During Flights|Vergleich Der Qualität Der Kardiopulmonalen Reanimation Durch Professioneller Helfer (Notärzte / Rettungsassistenten) während Lufttransporten|flights|University Hospital of Cologne|No|Recruiting|December 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 2, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002481||55082|
NCT01978600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-037|Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension|Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy||Alcon Research|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|October 30, 2013|Yes|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT01978600||56911|
NCT01978873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0030-78-10|Efficacy Study Evaluating Chemotherapy in Prostate Cancer|Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease|SensiCab|Örebro University, Sweden||Recruiting|November 2012|November 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||November 2013|November 1, 2013|February 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01978873||56890|
NCT01978613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9927-4022|Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects||Novo Nordisk A/S|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|100|||Male|18 Years|64 Years|No|||June 2014|June 27, 2014|November 1, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978613||56910|
NCT01978886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gundtoft-01|Prevalence of Unknown and Known Diabetes in Patients With Frozen Shoulder|Prevalence of Unknown and Known Diabetes in Patients With Frozen Shoulder||Sygehus Lillebaelt|Yes|Completed|December 2013|February 2016|Actual|February 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|220|Samples Without DNA|whole blood for patients not diagnosed with diabetes.|Both|25 Years|75 Years|No|Probability Sample|All newly referred patients to one of the involved hospitals who is diagnosed with frozen        shoulder.|February 2016|February 10, 2016|October 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01978886|2 Years|56889|
NCT01979172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASIK/IOL|Comparison of Intraocular Lens Power Calculation Methods After Corneal Laser Refractive Surgery in Axial and Refractive Ammertropia|Comparison of Intraocular Lens Power Calculation Methods After Corneal Laser Refractive Surgery in Axial and Refractive Ammertropia||The National Eye Hospital, Cairo, Egypt|Yes|Recruiting|November 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patient undergoing laser refractive surgery|November 2013|November 3, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979172||56867|
NCT01980342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00087585|Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz|||Johns Hopkins University|No|Not yet recruiting|July 2014|||June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980342||56777|
NCT01980628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1121-CA|Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma|A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma||Pharmacyclics|No|Active, not recruiting|December 2013|December 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980628||56755|
NCT01980615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010001-00|Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers|A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort® Inhalation Aerosol in Healthy Volunteers||Pearl Therapeutics, Inc.|Yes|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|84|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980615||56756|
NCT02011542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-1-0593|Probiotic (VSL#3) for Gulf War Illness|Probiotics (VSL#3) for Gulf War Illness||University of Utah|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Years|75 Years|No|||February 2016|February 9, 2016|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011542||54387|
NCT02003638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812962|Assessment Of Vascular Health After Niacin Therapy (AVANT)|A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY FLUORODEOXYGLUCOSE-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES|AVANT|University of Pennsylvania|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|9|||Both|45 Years|N/A|No|||June 2014|June 24, 2014|November 18, 2013|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT02003638||54993|
NCT02003898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP266/Z25/D|Post Approval Study of the Threshold Suspend Feature With the Medtronic MiniMed® 530G Insulin Pump|Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System||Medtronic Diabetes|No|Recruiting|November 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|None Retained|Whole blood will be drawn for lab testing. No specimens will be retained|Both|16 Years|N/A|No|Non-Probability Sample|Subjects will be selected from patient populations of 50 investigational centers across        the United States. Investigators are specialists in the treatment of diabetes|March 2016|March 18, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003898||54973|
NCT02000011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01038-37|Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study|Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study|epigac|Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2013|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|380|||Both|70 Years|N/A|No|||August 2015|August 6, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000011||55272|
NCT01999998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD12/10519|FDG PET-CT for Lymphoma Radiotherapy Planning Version 1.3|A Pilot Study to Optimise the Use of FDG PET-CT and Deformable Image Co-registration for Lymphoma Radiotherapy Planning||The Leeds Teaching Hospitals NHS Trust||Recruiting|August 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01999998||55273|
NCT02000297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1309/220-005|Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy|Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy||Seoul National University Hospital|Yes|Recruiting|October 2013|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||October 2014|October 13, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02000297||55250|
NCT02000570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.813|Dynamic Preload Indicators in Sitting Position|Abilities of Dynamic Preload Dependence Indicators to Predict Fluid Responsiveness During Neurosurgery in Sitting Position||Hospices Civils de Lyon|No|Recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2013|December 3, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02000570||55229|
NCT02000583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13376|Alzheimer's Prevention Through Exercise|Effect of Aerobic Exercise on Pathophysiology of PreClinical Alzheimer's Disease|APEx|University of Kansas Medical Center|Yes|Recruiting|November 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|65 Years|N/A|No|||October 2015|October 29, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000583||55228|
NCT02000895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100986|Early Detection of Progressive Kidney Disease in Preterm Infants|Early Detection of Progressive Kidney Disease in Preterm Infants||University of Miami|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples Without DNA|Urine Cord Blood|Both|N/A|1 Week|No|Probability Sample|Preterm infants from 24 to 37 weeks' gestation enrolled at birth to be studied for kidney        size and function. Term infants >37 weeks' gestation who are stable without complications        to serve as controls.|April 2015|April 9, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02000895|5 Years|55204|
NCT02000908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS085|Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy|Prospective, Randomized, Double Blind Study of Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|January 2014|December 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|70|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000908||55203|
NCT02002000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-802|Chronic Pain and Vitamin D|Chronic Pain and Vitamin D: a Randomized Pilot Study in General Practice|DOVID|Hospices Civils de Lyon|No|Not yet recruiting|December 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|No|||December 2013|December 9, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02002000||55119|
NCT02011165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2013/781|An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery||Helse Stavanger HF|No|Completed|October 2013|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|43|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing pars plana vitrectomy for macular hole formation, or conditions as        epiretinal menbrane or vitreomacular traction where a macular hole formation is likely.|December 2014|December 16, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02011165||54416|
NCT02011412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024710|Intermountain Risk Score and Trauma|The Intermountain Risk Score's Association With Mortality Prediction in Trauma Patients||Intermountain Health Care, Inc.|No|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who suffer from a traumatic injury and present to the Emergency Department as        a Trauma Activation|February 2016|February 22, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02011412||54397|
NCT02011685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54NS081765-5162|Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors|Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors||New York University School of Medicine|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011685||54377|
NCT02002793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP bundle-abdominal drainage|Effects of Early Stage Mini-invasive Abdominal Drainage on Complications and Prognosis of SAP|Effects of Early Stage Mini-invasive Abdominal Drainage on Complications and Prognosis of SAP||Ruijin Hospital|Yes|Recruiting|August 2013|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2013|December 1, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02002793||55058|
NCT02003105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS1301.|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||September 11, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003105||55034|
NCT01978054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111105|Disseminating Public Health Evidence to Support State Health Department Prevention of Cancer and Other Chronic Diseases|Disseminating Evidence-Based Interventions to Control Cancer||Washington University School of Medicine|No|Active, not recruiting|September 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|960|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01978054||56953|
NCT01978353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 08223513.3.0000.0068|Memory Training in Patients With Amnestic Mild Cognitive Impairment|Episodic Memory Training for Face Name Association in Patients With Amnestic Mild Cognitive Impairment: Cognitive Measures and Functional Resonance Magnetic Imaging Outcomes||University of Sao Paulo General Hospital|Yes|Completed|November 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|N/A|No|||October 2015|October 23, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01978353||56930|
NCT01978899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-336|Healthy Living After Cancer: Weight Management Pilot Study|Healthy Living After Cancer: Weight Management Pilot Study||Dana-Farber Cancer Institute|Yes|Recruiting|November 2013|September 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|October 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01978899||56888|
NCT01979185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-114|Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects|A Phase 1, Randomized, Open-label, Cross-over Study to Evaluate the Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Simvastatin in Healthy Adult Subjects||Shire||Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|November 1, 2013|No|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01979185||56866|
NCT01979497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451808|Adhesive Strips in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Adhesive Strips in Dermatologic Surgery: Is Cosmetic Appearance Improved?||University of California, Davis|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979497||56842|
NCT01979510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663B-164|Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)|A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain||Merck Sharp & Dohme Corp.|Yes|Withdrawn|November 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 24, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979510||56841|
NCT01980355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-133|TXA Study in Major Oncologic Surgery|The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery|TXA|Spectrum Health Hospitals|Yes|Recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980355||56776|
NCT01980888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0123|Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Active, not recruiting|February 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980888||56735|
NCT02003326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13AOI07|Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)|Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)|AMIS|Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02003326||55017|
NCT01999751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12274|Study to Monitor Patients With Pacemakers or ICDs Who Undergo MRI Scans|SMDC CRM-MRI Prospective Case Series||Essentia Health|No|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Any person followed at St. Mary's Medical Center, Duluth, MN, with a permanent pacemaker        or implantable cardioverter-defibrillator implanted for at least 6 weeks, referred for a        medically-required MRI scan by a physician or provider not participating in the trial. If        patients elect not to participate, they may still receive an MRI and will sign the        clinical consent. If they elect not to have an MRI, they will be referred back to the        ordering provider to discuss other options.|September 2015|September 19, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999751|1 Year|55292|
NCT02000921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS012|Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors|Models for Tobacco Productive Evaluation: Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000921||55202|
NCT02000310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-CFCT-07|Molecular and Cellular Mechanisms of Lysosomal Storage Diseases|Investigation of Molecular and Cellular Mechanisms of Lysosomal Storage Diseases||O & O Alpan LLC|No|Recruiting|November 2013|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients or suspected carriers of a lysosomal storage disorders.|May 2015|May 19, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02000310||55249|
NCT02000596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00054959; 1303GCC|1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.|1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma||University of Maryland|Yes|Terminated|January 2014|January 2025|Anticipated|January 2024|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Female|60 Years|N/A|No|||March 2016|March 1, 2016|November 21, 2013|Yes|Yes|funding withdrawn by sponsor|No||https://clinicaltrials.gov/show/NCT02000596||55227|
NCT02000609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-01535BC1-02|A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients|Phase II, Partial Blind, Randomized, Placebo Controlled, 5-way Cross-over Study to Evaluate the Pharmacodynamics of BDP(Beclomethasone Diproprionate)/B17MP (Beclomethasone-17-Monoproprionate) and FORMOTEROL FUMARATE (FF) Across Two Different Dose Levels of CHF 1535 NEXThaler DPI (Dry Powder Inhaler) and CHF 1535 pMDI (Pressurized Metered-dose Inhaler)in Adult COPD (Chronic Obstructive Pumonary Disease) Patients|NEXThaler|Chiesi Farmaceutici S.p.A.|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|49|||Both|40 Years|75 Years|No|||November 2014|November 3, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02000609||55226|
NCT02001766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-070|ATP Release and Sympathetic Nerve Activity in Patients With Type II Diabetes|ATP Release and Sympathetic Nerve Activity in Patients With Type II Diabetes||Rigshospitalet, Denmark|Yes|Recruiting|February 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|45|||Both|40 Years|65 Years|No|||June 2015|June 15, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02001766||55137|
NCT02010866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00009003|Reaching Out to Distressed Medical Residents, Fellows and Faculty|Reaching Out to Distressed Medical Residents, Fellows, and Faculty Through the OHSU Resident and Faculty Wellness Program Interactive Screening Program (ISP)||Oregon Health and Science University|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02010866||54439|
NCT02010879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDAPFA-100 TRIAL|The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants|The Impact of Platelet Count, Platelet Mass Index and Platelet Function Evaluated by Platelet Function Analyzer (PFA-100) on Spontaneous Ductal Closure in Preterm Infants|PFA100|Ankara University|No|Recruiting|December 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|7 Days|Accepts Healthy Volunteers|Probability Sample|preterm infants with gestational age below 30 weeks and birth weght lower than 1500 g|December 2013|December 19, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02010879||54438|
NCT02012725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5KL2TR000116-03|Molecular MRI of the Fibrotic Heart|Molecular MRI of the Fibrotic Heart||University of Kentucky|No|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Participants taking part in this study will be:          -  Referred from the University of Kentucky Gill Heart Institute (planned enrollment for             this group is 100 patients)          -  Referred from another study on chronic kidney disease (planned enrollment for this             group is 100 patients and 50 healthy volunteers)|December 2015|December 7, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02012725||54297|
NCT02011932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJYAH-2011-045|Prospective Observational Study of Disease Progression in Chronic Hepatitis C|Observational Study of Disease Progression and Risk Factors in Chronic Hepatitis C Caused by Plasma Donation||Beijing YouAn Hospital|Yes|Active, not recruiting|July 2010|July 2030|Anticipated|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|133|Samples With DNA|whole blood, serum, plasma,liver biopsies specimens,|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The plasma donors were primarily chosen from healthy farmers and agricultural workers        living in a remote small city in the Northwest China.|December 2013|December 13, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02011932||54358|
NCT02011945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-373|A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia|A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)||Bristol-Myers Squibb|No|Recruiting|February 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|November 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02011945||54357|
NCT01978366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-DMD-02|Open Label Extension Study of HT-100 in Patients With DMD|An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01||Akashi Therapeutics|Yes|Suspended|October 2013|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Male|6 Years|20 Years|No|||February 2016|February 3, 2016|October 31, 2013|Yes|Yes|All dosing suspended temporarily|No||https://clinicaltrials.gov/show/NCT01978366||56929|
NCT01978626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307042RINC|Enhancing Performance of Cognitive Behavioral Therapy for Insomnia With an Integrative Mobile Platform|Enhancing Performance of Cognitive Behavioral Therapy for Insomnia With an Integrative Mobile Platform||National Taiwan University Hospital|No|Recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|N/A|No|||May 2015|May 7, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978626||56909|
NCT01979198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-030BC|Thoracolumbar Burst Fracture Treated With Pedicle Screws: Radiographic Outcomes|Thoracolumbar Burst Fracture Treated With Pedicle Screws: Radiographic Analysis of Discs and Vertebral Body Height at Fractured and Adjacent Levels||Taipei Veterans General Hospital, Taiwan|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Both|N/A|60 Years|No|Probability Sample|Patients suffered from burst fracture of the thoracolumbar and lumbar spine|October 2013|October 31, 2013|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT01979198|10 Years|56865|
NCT01979484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-103|Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations|A Phase 1, Open-Label, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers||Presidio Pharmaceuticals, Inc.|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|October 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01979484||56843|
NCT01980108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-07|Quantitative Ultrasound Assessment of Gastric Volume in Pregnant Women at Term|Quantitative Ultrasound Assessment of Gastric Volume in Pregnant Women at Term||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|6||Anticipated|90|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980108||56795|
NCT01980654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1125-CA|Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma|A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma||Pharmacyclics|No|Active, not recruiting|December 2013|April 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01980654||56753|
NCT01980667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-008-13|Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors||PharmaMar|No|Recruiting|February 2014|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01980667||56752|
NCT01980641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS-15-2013|Clinical Effect Size of an Educational Intervention in the Home and Compliance on People Who Suffer From Stroke|Clinical Effect Size of an Educational Intervention in the Home and Compliance With a Smartphone-based Reminder on People Who Suffer From Stroke: a Protocol Study.||University of Malaga|Yes|Completed|September 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|85 Years|No|||February 2015|February 9, 2016|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01980641||56754|
NCT02003014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-017|Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"|Actos Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"||Takeda|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|899|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes mellitus|December 2013|December 1, 2013|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02003014||55041|
NCT02003027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_VT Storm|Botulinum Toxin Injection to Prevent VT Storm|Endomyocardial Botulinum Toxin Injection Can Decrease the Number of Episodes of VT Storm: Pilot Study||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|June 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02003027||55040|
NCT02000622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0819C00003|Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|OlympiAD|AstraZeneca|No|Active, not recruiting|March 2014|December 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02000622||55225|
NCT02000934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C34001|A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies|An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies||Millennium Pharmaceuticals, Inc.|No|Recruiting|December 2013|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02000934||55201|
NCT02000947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00006|A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer|A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer|D4190C00006|MedImmune LLC|No|Recruiting|October 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|418|||Both|18 Years|99 Years|No|||February 2016|February 19, 2016|November 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02000947||55200|
NCT02001194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819101|Way to Be Active I (Teams)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Team Incentives||University of Pennsylvania|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|304|||Both|18 Years|N/A|No|||November 2013|October 1, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001194||55181|
NCT02001519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNBC AC-CDDP|Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy|A Phase ll Trial of Impact of Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer Not Achieving Clinical CR After 4 Cycles of Neoadjuvant Adriamycin Plus Cyclophosphamide|PACER|Asan Medical Center|No|Completed|March 2012|July 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Female|20 Years|N/A|No|||November 2013|November 29, 2014|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02001519||55156|
NCT02010606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33203|Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma|Phase I Trial of Vaccination With Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line for Patients With Newly Diagnosed or Recurrent Glioblastoma||Cedars-Sinai Medical Center|Yes|Recruiting|December 2013|||October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02010606||54459|
NCT02011958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV/VL 0511|Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.|A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.||Drugs for Neglected Diseases|Yes|Active, not recruiting|July 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02011958||54356|
NCT02012465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306071|Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients|Validation of Insulin Protocol for Prevention and Management of Hyperglycemia in Oncology Patients With Diabetes Receiving High Dose Glucocorticoid Therapy||Washington University School of Medicine|Yes|Enrolling by invitation|September 2013|||August 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02012465||54317|
NCT02012205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH044|Wet Cupping in Non-specific Low Back Pain|Safety and Efficacy of Wet Cupping on Persistent Non-specific Low Back Pain: A Randomized, Controlled, Open-label, Parallel-group||National Center for Complementary and Alternative Medicine, Saudi Arabia|Yes|Completed|April 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02012205||54337|
NCT02012218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-001|Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy|A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|December 4, 2013|Yes|Yes||No|September 4, 2015|https://clinicaltrials.gov/show/NCT02012218||54336|
NCT02012738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-2012-AdG 323977 Memo TV|Treatment of Trauma and Violence in the Townships of South Africa|MemoTV: Epigenetic, Neural and Cognitive Memories of Traumatic Stress and Violence in Former Offenders of the Townships of South Africa||University of Konstanz|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|45|||Male|10 Years|40 Years|No|||January 2016|February 2, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02012738||54296|
NCT02013050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDR-OM-01|A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer|A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck||Soligenix|No|Active, not recruiting|December 2013|August 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013050||54273|
NCT01978639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS 2013-022|Injections of FloGraft Therapy, Autologous Stem Cells, or Platelet Rich Plasma for the Treatment of Degenerative Joint Pain|Outcomes of Single Injections of FloGraft Therapy, Autologous Stem Cells, or Platelet Rich Plasma for the Treatment of Pain in the Lumbar Facet Joints, Sacroiliac Joints, Upper Extremity Joints, and Lower Extremity Joints||Arizona Pain Specialists|No|Not yet recruiting|January 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adults age 18 or older|December 2013|December 10, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978639||56908|
NCT01978912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTP-001-CL-101|A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation|Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation||Teijin America, Inc.|Yes|Recruiting|February 2013|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|30 Years|70 Years|No|||September 2015|September 17, 2015|October 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01978912||56887|
NCT01979523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02091|Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma|A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma||National Cancer Institute (NCI)|No|Suspended|October 2013|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 4, 2013|Yes|Yes|Scheduled interim monitoring|No||https://clinicaltrials.gov/show/NCT01979523||56840|
NCT01979536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02167|Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma|A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)||National Cancer Institute (NCI)|Yes|Recruiting|November 2013|||September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|21 Years|No|||December 2015|March 24, 2016|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979536||56839|
NCT01979549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEDUGESSH|Adverse Events During Upper Gastrointestinal Endoscopy|Adverse Events During Upper Gastrointestinal Endoscopy With and Without Sedation: a Multiple Center Report From Shanghai|AEDUGESSH|RenJi Hospital|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who will undergo the upper gastrointestinal endoscopy|December 2013|January 20, 2014|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979549||56838|
NCT01980121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-08|Gastric Sonography in the Fasted Term Pregnant Patient for Elective Cesarean Delivery|Gastric Sonography in the Fasted Term Pregnant Patient for Elective Cesarean Delivery: a Prospective Descriptive Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|103|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Term pregnant patients who have scheduled elective cesearean sections.|June 2014|June 18, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980121||56794|
NCT01980927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24116|Changes in Intracranial Compliance in Migraine Subjects Following a National Upper Cervical Chiropractic Association Atlas Correction|Changes in Intracranial Compliance in Migraine Subjects Following a National Upper Cervical Chiropractic Association (NUCCA)Atlas Correction Intervention - a Pilot Study||University of Calgary|No|Completed|November 2011|November 2014|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||December 2014|December 10, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980927||56732|
NCT01980940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-168|The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)|A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients||Merck Sharp & Dohme Corp.|No|Completed|December 2013|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|70|||Both|40 Years|N/A|No|||January 2016|February 3, 2016|November 5, 2013|No|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01980940||56731|
NCT01980914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02734|Hypoglycemia (Low Blood Sugar) and the Heart|Impact of Hypoglycemia on Cardiac Function in Elderly Patients With Diabetes||University of British Columbia|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|70 Years|N/A|No|Non-Probability Sample|These patients will be enrolled from the elderly diabetes clinic at Vancouver General        Hospital.|August 2015|August 14, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01980914||56733|
NCT02003352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBC11013|Study of PTSD in Military Veterans Who Have Suffered Traumatic Brain Injuries|Evaluation of the Effectiveness of a Novel Brain and Vestibular Rehabilitation Treatment Modality in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries|PTSD-TBI|Carrick Institute for Graduate Studies|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|60 Years|No|||January 2015|January 20, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02003352||55015|
NCT02003365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2013-005|Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee|An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee||Flexion Therapeutics, Inc.|No|Completed|November 2013|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|40 Years|N/A|No|||August 2015|August 10, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003365||55014|
NCT02000635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/B/16|Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique|Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique|Ciné LEPTO|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|December 2014|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of leptospirosis confirmed|February 2016|February 29, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02000635||55224|
NCT02010307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|davidp-HMO-CTIL|Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis|||Hadassah Medical Organization|No|Not yet recruiting|January 2014|October 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010307||54482|
NCT02010320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMAL-13|Computer Guided Doing of Tacrolimus in Renal Transplantation|Prospective Testing of Pharmacokinetic Population Models for Dosing of Transplanted Patients|OPTIMAL|University of Oslo School of Pharmacy|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010320||54481|
NCT02001207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1304-072-482|Salivary Cortisol in Intensive Care Unit|Association of Salivary Cortisol Levels and Outcome of Critically Ill Patients in the Intensive Care Unit||Seoul National University Hospital|Yes|Recruiting|July 2013|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the intensive care unit in Seoul National University Hospital|December 2013|November 18, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02001207||55180|
NCT02001220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151113|Screening Frequency Trial to Identify Weaning Candidates|LibeRation From MEchanicaL VEntilAtion and ScrEening Frequency Trial: The RELEASE Trial|RELEASE|St. Michael's Hospital, Toronto|No|Active, not recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|50|||Both|16 Years|N/A|No|||March 2016|March 9, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02001220||55179|
NCT02011698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hernia-01|Absorbable Sutures , Non Absorbable Sutures or Biologic Fibrin Glue for Protesic Mesh Fixing in Lichtenstein Technique for Primitive Groin Hernia Repair: a Randomized Prospective Multicentric Trial|Absorbable Sutures , Non Absorbable Sutures or Biologic Fibrin Glue for Protesic Mesh Fixing in Lichtenstein Technique for Primitive Groin Hernia Repair: a Randomized Prospective Multicentric Trial||Ospedale di Circolo - Fondazione Macchi|No|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|900|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011698||54376|
NCT02011724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-VLU-003-AG|A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®|An Open Label, Multi Center, Post Marketing Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®||Organogenesis|No|Active, not recruiting|November 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011724||54374|
NCT02012231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX120-01|Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.|A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors||Plexxikon|No|Terminated|February 2014|August 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012231||54335|
NCT02012244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0044|Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer|||Severance Hospital|No|Completed|January 2014|December 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|80 Years|No|||January 2016|January 10, 2016|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02012244||54334|
NCT02012491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818434|Comparative Effectiveness of Pregnancy Failure Management Regimens|Comparative Effectiveness of Pregnancy Failure Management Regimens|PreFaiR|University of Pennsylvania|No|Recruiting|January 2014|January 2019|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|No|||September 2015|October 9, 2015|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012491||54315|
NCT02012478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817790|Using a Motivational Interviewing (MI) Informed Text Messaging Program to Lower Blood Sugar in Diabetic Patients.|The Impact of a Motivational Interviewing (MI) Informed Text Messaging (SMS) Program Tailored to Level of Patient Activation on Glycemic Control in a Population of Poorly Controlled Diabetic Patients.|MI-SMS|University of Pennsylvania|No|Recruiting|December 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|90 Years|No|||December 2013|December 10, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012478||54316|
NCT02012751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1206|Nevus Doctor Clinical Decision Support|Nevus Doctor Clinical Decision Support Program for Pigmented Skin Lesions and Melanoma||University Hospital of North Norway|No|Recruiting|October 2014|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02012751||54295|
NCT02013076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ|Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth|Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth|DOORWAY|St. Justine's Hospital|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1011|Samples With DNA|Saliva for cotinine and for DNA and nasopharyngeal samples for viral analysis.|Both|1 Year|17 Years|No|Probability Sample|Children aged 1 to 17 years with moderate to severe asthma with Pediatric Respiratory        Assessment Measure (PRAM) ≥4.|July 2014|July 18, 2014|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013076||54271|
NCT01978925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPaRAR 01|Pharmaceutical Care in Emergency Department|Effectiveness Pharmaceutical Care at Discharge in the Emergency Department: a Randomized Controlled Trial|AMPaRAR|Hospital Moinhos de Vento|Yes|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01978925||56886|
NCT01979211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHN-12-001|Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck|Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck||University of Cincinnati|Yes|Recruiting|October 2013|October 2021|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979211||56864|
NCT01980134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORDIS Study 010044-002|The MORDIS Study Clinical Investigational Plan|Multicenter, Open, Prospective Study on Modified Resect and DIScard Strategy of Small Colonic Lesions Using WavSTAT4 Optical Biopsy System: The MORDIS Study Clinical Investigational Plan|MORDIS|SpectraScience|No|Recruiting|December 2013|November 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1200|Samples With DNA|Samples will be sent for pathological examination and potentially used for other research      purposes.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|~1200 patients ≥ 18 years of age at the time of enrollment showing presence of diminutive        colorectal polyps.|April 2014|April 22, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01980134||56793|
NCT02012101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009CB522111|Non-invasive Mechanical Ventilation as a Rescue Therapy to Relieve Dyspnea in Patients With Stable Severe COPD|The Efficacy of Non-invasive Mechanical Ventilation as a Rescue Therapy for Relieving Dyspnea in Patients With Stable Severe COPD||Guangzhou Institute of Respiratory Disease|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|30 Years|80 Years|No|||June 2014|June 23, 2014|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02012101||54345|
NCT01981213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIH-2011-17|Attempted Suicide With Acetaminophen Among 8-18 Year-old Children / Adolescents in Denmark|Attempted Suicide With Acetaminophen Among 8-18 Year-old Children / Adolescents||Hillerod Hospital, Denmark|No|Recruiting|January 2005|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|500|Samples Without DNA|The initial and maximum levels of the biochemical parameters will be registered from the      electronic biochemistry files of each patient: GLU, basic phosphatase (BP), INR, ALT, and      AST.|Both|8 Years|18 Years|No|Non-Probability Sample|Pediatric Department, children/adolescents who have tried to commit suicide with        acetaminophen (8-18 years-old)|November 2013|November 5, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01981213|5 Days|56710|
NCT02003911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-05-187|Azithromycin for Children Hospitalized With Asthma|A Double-Blind, Randomized, Placebo-Controlled Trial of Azithromycin in Children Hospitalized With Acute Asthma Exacerbations||Montefiore Medical Center|Yes|Recruiting|October 2013|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|214|||Both|4 Years|12 Years|No|||September 2015|September 21, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02003911||54972|
NCT02003924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-14|Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer|A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer|PROSPER|Medivation, Inc.|No|Recruiting|December 2013|December 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1560|||Male|18 Years|N/A|No|||December 2015|February 18, 2016|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02003924||54971|
NCT02010086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12000556|Schema, Emotion and Behavior-Based Therapy for School Children|Cognitive Behavioral Therapy for Core Autism Symptoms in School-Age Children|SEBASTIEN JR|University of California, Los Angeles|No|Active, not recruiting|December 2011|November 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|6 Years|10 Years|No|||January 2016|January 26, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010086||54499|
NCT02010619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDD RCT|Internet Delivered CBT for Body Dysmorphic Disorder|Internet Delivered Cognitive Behavior Therapy for Body Dysmorphic Disorder - a Randomized Controlled Trial||Karolinska Institutet||Active, not recruiting|November 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02010619||54458|
NCT02010632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDPK-CLO-2013|Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products|Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products in Thai Healthy Volunteers||Khon Kaen University|Yes|Completed|August 2013|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|December 3, 2013|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT02010632||54457|
NCT02010294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120136|Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections|Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections|StreptoPedia|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|serum|Both|1 Month|15 Years|No|Probability Sample|Children hospitalized for invasive or non invasive GAS infection|February 2016|February 24, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02010294||54483|
NCT02011971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044949|Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy|Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy||Emory University|No|Suspended|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|December 4, 2013|Yes|Yes|Currently on hold pending interim analysis and donor funding of 2nd half of the project as    originally agreed.|No||https://clinicaltrials.gov/show/NCT02011971||54355|
NCT02012777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100334|Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease|Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study||University of Miami|Yes|Recruiting|June 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|7 Years|17 Years|No|||February 2016|February 12, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012777||54293|
NCT02013089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU04|A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study|A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers|GITIC|Sun Yat-sen University|No|Recruiting|December 2013|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|50|||Both|18 Years|70 Years|No|||December 2013|December 23, 2013|December 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02013089||54270|
NCT02008942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-ASA-006|Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients|Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)|RITE|PLx Pharma|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|57|||Both|21 Years|79 Years|No|||February 2016|February 9, 2016|December 6, 2013|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT02008942||54586|
NCT02012764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR06/7674|The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?|The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?|CCP|University of Leeds|Yes|Recruiting|January 2007|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|DNA sample currently retained as part of a sub-study for a departmental tissue bank.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are attending GP Practices in the Yorkshire and surrounding regions.|July 2015|July 28, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02012764||54294|
NCT02008916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2314|16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients|A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis|MEASURE 3|Novartis|Yes|Active, not recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008916||54588|
NCT02009254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Potato study 2: mashed potato|The Effect of Mashed Potato Composition on Food Intake, Satiety and Blood Glucose|||University of Toronto|No|Completed||||January 2007|Actual|N/A|Interventional|Primary Purpose: Prevention|3||||||Male|18 Years|35 Years||||December 2013|December 8, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009254||54562|
NCT01979562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130074|Knowledge of Predicting Increased Risk for an Overuse Injury in Runners|Knowledge of Predicting Increased Risk for an Overuse Injury in Runners Related to the Mutual Length of Femur and Tibia and the Running Style||Northern Orthopaedic Division, Denmark|No|Recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 male runners from athletic associations in Northern Jutland.|May 2015|May 28, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979562|1 Year|56837|
NCT01979575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|495567|Trendelenburg Study|An Observational Study on the Effects of Steep Trendelenburg Position and Pneumoperitoneum on Hemodynamic Changes Observed With Non-invasive Cardiac Monitors||University of California, Davis|No|Recruiting|October 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective surgery.|June 2015|June 30, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979575||56836|
NCT01979848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-8932|MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon|MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon||University of California, Irvine|Yes|Recruiting|June 2013|September 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Male|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteers (n=2) to test the MR Temperature Mapping calibration        AND        Men who will be undergoing robotic assisted radical prostatectomy will undergo the thermal        MRI scans|December 2014|December 1, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01979848||56815|
NCT01979861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-3000|Safety & Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding|A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the AEGEA Vapor System for the Treatment of Excessive Uterine Bleeding||Aegea Medical, Inc.|No|Active, not recruiting|February 2014|May 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Female|30 Years|50 Years|No|||May 2015|May 2, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979861||56814|
NCT01980368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007483|Tai Chi on Colorectal Cancer Survivors With Fatigue|Pilot Study of Effects of Tai Chi Easy on Colorectal Cancer Survivors Experiencing Fatigue||Mayo Clinic|No|Recruiting|October 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01980368||56775|
NCT01980381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTK/120995|Treatment of Depression and/or Anxiety - the Tree Theme Method® (TTM) as an Intervention|Treatment of Depression and/or Anxiety - a Randomized Clinical Trial of the Tree Theme Method® (TTM) as an Intervention||Kronoberg County Council|No|Recruiting|January 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01980381||56774|
NCT02012374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1065|Overcoming Learned Non-Use in Chronic Aphasia|Overcoming Learned Non-Use in Chronic Aphasia: Behavioral, fMRI and QoL Outcomes||University of Massachusetts, Amherst|Yes|Active, not recruiting|March 2012|January 2017|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02012374||54324|
NCT02012348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 121622|Analysis of the Effect of Antimicrobial Soap on Bacterial Survival|Analysis of the Effect of Antimicrobial Soap on Bacterial Survival||University of California, San Diego|No|Active, not recruiting|December 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02012348||54326|
NCT02012361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400033|Inspired Helium for Ischemic Protection During Knee Replacement Surgery|Inspired Helium for Ischemic Protection During Knee Replacement Surgery||University of Florida|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012361||54325|
NCT02000323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJpancreatitis02|Early Enteral Nutrition in Severe Acute Pancreatitis|Early Enteral Nutrition in Severe Acute Pancreatitis||Ruijin Hospital|Yes|Recruiting|August 2012|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2013|November 26, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02000323||55248|
NCT02010931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120148|Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients|A Retrospective Analysis of Hematological Relapse Free Survival and Overall Survival in Adult Patients With Philadelphia-Negative B-Precursor Acute Lymphoblastic Leukemia in Complete Hematological Remission With Minimal Residual Disease||Amgen|No|Completed|September 2013|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|310|||Both|15 Years|N/A|No|Non-Probability Sample|adult acute lymphoblastic leukemia|July 2014|July 9, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02010931||54434|
NCT02011178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1530-31|Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine|Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine; a Prospectivee, Randomized, Multicenter Study|PROMISE|Karolinska Institutet|Yes|Recruiting|March 2014|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011178||54415|
NCT02011438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH095959-01A1|Coping With Adolescent Peer Victimization and Reducing Anxious/Depressed Symptoms|Coping With Adolescent Peer Victimization and Reducing Anxious/Depressed Symptoms||University of Miami|Yes|Completed|June 2012|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|13 Years|18 Years|No|||December 2015|December 16, 2015|June 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02011438||54395|
NCT02010892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01633|Effective Treatments for Thoracic Aortic Aneurysms (ETTAA Study): A Prospective Cohort Study|Effective Treatments for Thoracic Aortic Aneurysms (ETTAA Study): A Prospective Cohort Study|ETTAA|Papworth Hospital NHS Foundation Trust|Yes|Recruiting|February 2014|July 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being referred to a specialist centre for diagnosis and treatment of their        aneurysm|October 2015|October 19, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02010892||54437|
NCT02011984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|recam2013_eucatech|Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system|Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system in Peripheral Superficial Femoral Arteries|RECAM|Eucatech AG|No|Recruiting|December 2013|February 2017|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|95 Years|No|Non-Probability Sample|patients with de novo stenotic lesions in the superficial femoral artery|February 2015|February 10, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02011984|2 Years|54354|
NCT02012790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3284|Nutrition for Migraine Prevention|Clinical & Metabolic Effects of Altering n-3 & n-6 Fatty Acids in Migraine (RCT)||University of North Carolina, Chapel Hill|Yes|Recruiting|July 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|153|||Both|18 Years|99 Years|No|||October 2015|October 7, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02012790||54292|
NCT02013102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DREAM-201|A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome|A Randomized, Controlled, Multi-center Collaborative Phase Ⅳ Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome|DREAM|Cttq|Yes|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02013102||54269|
NCT02013115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|curosurf/Budesonide for NRDS|Curosurf/Budesonide for Infants With Respiratory Distress Syndrome|Curosurf/Budesonide for Infants With Respiratory Distress Syndrome|Budesonide|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|January 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|12 Hours|No|||December 2013|February 10, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013115||54268|
NCT02008955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580 E|Lysine Requirements of Elderly Female Subjects 65-75 Years Old.|||The Hospital for Sick Children|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|13|||Female|65 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008955||54585|
NCT02009241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22729413.6.0000.0068|Pulmonary Rehabilitation in Lymphangioleiomyomatosis|Evaluation of the Impact of a Pulmonary Rehabilitation Program on Exercise Capacity in Patients With Lymphangioleiomyomatosis||University of Sao Paulo General Hospital|Yes|Completed|November 2013|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|N/A|N/A|No|||December 2015|December 9, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02009241||54563|
NCT02009579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGOG-cx1/ENGOT-cx1|ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer|BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."||Belgian Gynaecological Oncology Group|Yes|Recruiting|March 2014|July 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||July 2015|July 22, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02009579||54537|
NCT01979874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11778|The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II|The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation II|OMEGA-PAD II|University of California, San Francisco|No|Recruiting|February 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|50 Years|N/A|No|||June 2015|June 29, 2015|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01979874||56813|
NCT01980147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFW-2013|Skills for Wellness|Skills for Wellness: Cognitive-behavioural Skills Training for Psychotic-like Experiences, Basic Symptoms, Affective Lability and Anxiety in Youth|SWELL|Nova Scotia Health Authority|No|Not yet recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|9 Years|21 Years|No|||November 2013|November 4, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01980147||56792|
NCT01980407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPCH1301|Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer|A Safety and Efficacy Study of S-1, Oxaliplatin, and Leucovorin (SOL) in Patients With Advanced Gastric Cancer||Jilin Provincial Tumor Hospital|No|Recruiting|November 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||November 2013|March 4, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01980407||56772|
NCT01980680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agonist5|The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients|The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients|GnRHa trigger|Regionshospitalet Viborg, Skive|No|Recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|40 Years|No|||November 2015|November 4, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01980680||56751|
NCT02009735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203067RIC|Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus|Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus||National Taiwan University Hospital|No|Recruiting|June 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 12, 2013|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT02009735||54526|
NCT02012647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-2013|Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease|Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease||University of Florida|Yes|Recruiting|August 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02012647||54303|
NCT02012660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-051213|Relationship Between Heat Wave and Hyponatremia|Relationship Between Heat Wave and Moderate to Severe Hyponatremia in the Emergency Departement of Primary and Tertiary Care Teaching Hospital.||University Hospital, Geneva|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|28734|||Both|16 Years|N/A|No|Non-Probability Sample|Adults admitted to the emergency departement of a primary and tertiary care teaching        hospital|April 2015|April 28, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02012660||54302|
NCT02000037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00800-45|Interest in the Medium Term of an Infrared Reflexotherapy on Overweight or Class I Obese People|Interest in the Medium Term of an Infrared Reflexotherapy on Overweight or Class I Obese People|REFLEX-IR|Institut Pasteur de Lille|No|Recruiting|October 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|87|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02000037||55270|
NCT02011451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4818-A-1|Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis|Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis||Louisiana State University Health Sciences Center in New Orleans|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 2, 2015|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02011451||54394|
NCT02011191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH DK 36823-28|Biotin Deficiency and Restless Legs Syndrome|Biotin Deficiency and Restless Legs Syndrome: Evidence for a Causal Relationship From Randomized, Double-Blind, Placebo-Controlled Trial||Saint Patrick Hospital|Yes|Completed|December 2006|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|N/A|N/A|No|||December 2013|December 12, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02011191||54414|
NCT02011204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001505|Study of Electrical Impedance Myography (EIM) in ALS|Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance||Skulpt, Inc.|No|Active, not recruiting|November 2013|March 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People with ALS People diagnosed with early ALS (possible, probable, probable- laboratory        supported or definite ALS according to El Escorial criteria)        Other Neurological Diseases People with a diagnosis of a disease that mimics ALS        Healthy Controls Healthy Volunteers that do not have ALS or another neurological disease        that mimics ALS.|March 2016|March 7, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02011204||54413|
NCT02011997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAH-GZU-001|Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion|Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion|cVATS|The First Affiliated Hospital of Guangzhou Medical University|Yes|Not yet recruiting|December 2013|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|79 Years|No|||December 2013|December 13, 2013|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02011997||54353|
NCT02012504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012-127|Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients|Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Who Meet Comorbidity of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)||Shanghai Zhongshan Hospital|Yes|Recruiting|June 2013|December 2014|Anticipated|January 2014|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|65 Years|No|Probability Sample|Chinese patients who meet DSM-5 criteria for the combidity of MDD and GAD|December 2013|December 10, 2013|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02012504||54314|
NCT02009293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44729.078.13|The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis|Observational Study of the Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis|Cough-IPF|Erasmus Medical Center|Yes|Recruiting|December 2013|October 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|40 Years|85 Years|No|Probability Sample|Patients with IPF about to start on Pirfenidone according to regular practice in the        participating University Hospitals|March 2016|March 20, 2016|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02009293||54559|
NCT02009904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01421|Simple Breath Test to Examine Phenylalanine Metabolism|Use of a Simple Breath Test to Examine Phenylalanine Metabolism in Children With Phenylketonuria (PKU)||University of British Columbia|Yes|Enrolling by invitation|January 2013|June 2016|Anticipated|March 2015|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Breath samples from both groups (children with PKU and healthy controls)|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with PKU will be enrolled from the Biochemical Diseases clinic at the British        Columbia Children's Hospital.        Healthy controls will be enrolled from the community and will undergo screening for age        and gender match.|May 2015|May 29, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009904||54513|
NCT02008968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allo2013|Effect of Allopurinol Treatment on Insulin Resistance|||Istanbul Medeniyet University|No|Recruiting|December 2013|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|130|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008968||54584|
NCT02009267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00702|Nuss Procedure: Clinical Options in Pediatric Pain Management?|||Nationwide Children's Hospital|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|32|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing the Nuss procedure to correct pectus excavatum at Nationwide        Children's Hospital.|March 2016|March 7, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02009267||54561|
NCT02009280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0648|A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial|||Yonsei University|No|Recruiting|November 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|20 Years|N/A|No|||December 2013|December 8, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02009280||54560|
NCT02010424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/819|Evaluation of Group Culture in WOW Dishes of Human Embryos in Order to Optimize the Single Embryo Transfer (SET) Strategy.|Multicentric Clinical Trial to Improve Blastocyst Utilisation Rate (in Relation to 2 PN Embryos) by Group Culture of Human Embryos in WOW Dishes.|WOW|University Hospital, Ghent|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|40 Years|No|||December 2014|December 4, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02010424||54473|
NCT01979224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-001|Efficacy of Educational Intervention for Parents of Children With Asthma|Efficacy of Educational Intervention for Parents of Children With Asthma in 4-11 Years and Their Impact on the Control Children as Measured by ACT. Randomized Controlled Clinical||Universidad Autonoma de San Luis Potosí|Yes|Completed|February 2012|October 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|4 Years|11 Years|No|||October 2013|October 31, 2013|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01979224||56863|
NCT01979237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307037RINC|Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial|Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial||National Taiwan University Hospital||Not yet recruiting|November 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|90 Years|No|||October 2013|November 3, 2013|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT01979237||56862|
NCT01979887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195263-007|Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction|||Allergan|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|75|Samples With DNA|Tears|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants characterized as with or without Meibomian Gland Dysfunction.|August 2014|August 14, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01979887||56812|
NCT01980160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMT-Nometex|Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy|Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy||Christiana Care Health Services||Withdrawn|November 2013|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|100 Years|No|||September 2015|September 30, 2015|October 14, 2013|Yes|Yes|Did not receive IRB approval from our institution therefore the study was closed.|No||https://clinicaltrials.gov/show/NCT01980160||56791|
NCT01980394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liestal-2012-OES|Esophageal Stump Washout|Esophageal Stump Washout Reduces Free Intraluminal Tumor Cells During Resection of Carcinomas of the Esophagus and Cardia||Kantonsspital Liestal|No|Completed|May 2004|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|95 Years|No|||February 2016|February 24, 2016|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01980394||56773|
NCT02011854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PW2013A-41|Acupuncture for Post-stroke Shoulder-hand Syndrome|Acupuncture and Traditional Chinese Medicine Combined With Rehabilitation Therapy for Post-stroke Shoulder-hand Syndrome in Community Hospital: a Multicenter，Randomized，Controlled Trial||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|80 Years|No|||December 2013|December 12, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011854||54364|
NCT02012127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-54-52030-266|Description of the Association of Signs and Symptoms Present at Acromegaly Diagnosis|Description of the Associations of Sign-and-symptom at Acromegaly Diagnosis.|ACRO-POLIS|Ipsen|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|648|||Both|18 Years|N/A|No|Probability Sample|Acromegalic patients|July 2014|July 28, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02012127||54343|
NCT02012140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZSC01|Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI|||LifeBridge Health|No|Not yet recruiting|January 2014|||January 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|November 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02012140||54342|
NCT02010853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 201 02|Transient Global Amnesia (TGA). Exploratory Study of the Default Mode Network During the Acute Phase|Transient Global Amnesia (TGA) Exploratory Study of the Default Mode Network in Resting State Functional MRI (fMRI) During the Acute Phase|ICTUS|University Hospital, Toulouse|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|44|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02010853||54440|
NCT02009774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOPTION|Accuracy of the Optical Diagnosis of Small Colonic Polyps Using the Nice Classification||ADOPTION|Technische Universität München|No|Completed|January 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|380|Samples Without DNA|Colon polyps|Both|18 Years|90 Years|No|Probability Sample|Patients will be recruited at the three participating study centers (Munich, Frankfurt,        Berlin). Two of the three centers are tertiary referral-centres whereas the last one is a        major regional hospital. All patients undergo colonoscopy for medical indications.|August 2015|November 5, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02009774||54523|
NCT02009787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-098-01|Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia|Effect of Vitamin D and Statins on Plasma Lipid Profiles in Chinese Patients With Hypercholesterolemia||Chinese PLA General Hospital|Yes|Recruiting|December 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||December 2013|December 9, 2013|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02009787||54522|
NCT02011464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-02|Evaluation Exparel Delivered in Knee Replacement|Evaluation of the Efficacy of Exparel Delivered Into the Posterior Capsule During Knee Replacement||Maimonides Medical Center|Yes|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||October 2015|October 29, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02011464||54393|
NCT02024243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0431|Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing|Tissue Oxygenation and miR-210 Role In Wound Healing|miR210|Ohio State University|No|Recruiting|October 2014|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|wound tissue biopsies|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|non-diabetic or controlled diabetic, chronic (open >4 weeks) Venous leg ulcers|March 2016|March 16, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02024243||53415|
NCT02024477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-305|Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes|Effect of Saxagliptin on Endothelial Progenitor Cells as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients||George Washington University|No|Recruiting|November 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||March 2015|March 10, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024477||53397|
NCT02025738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGNET2014|Perioperative Management of Patients With Cardiac Implantable Electronic Devices|Perioperative MAnaGement of patieNts With Cardiac Implantable Electronic Devices: Randomized Controlled Pilot Trial (MAGNET Trial)|MAGNET|Rambam Health Care Campus||Not yet recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025738||53300|
NCT02024711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYE-C-7.00|EYEFILL® C. -US Viscoelastic Clinical Investigation|EYEFILL® C.-US Viscoelastic Clinical Investigational Protocol- For Institutional Review Boards / Ethical Review Committees and Clinical Investigators||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2013|||December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|284|||Both|22 Years|N/A|No|||June 2015|June 1, 2015|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024711||53379|
NCT02022293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013018|Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis|Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis: A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|December 2013|January 2024|Anticipated|December 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|324|||Both|40 Years|65 Years|No|||March 2016|March 11, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02022293||53564|
NCT02025166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB343-13|Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion|Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion||Rambam Health Care Campus|No|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025166||53344|
NCT02025478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2412|Human Breastmilk in Children Receiving a Bone Marrow Transplant|A Pilot Study of Enteral Donor Human Milk in Young Children Receiving Bone Marrow Transplantation|MILK|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|May 2013|March 2016|Anticipated|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|N/A|5 Years|No|||January 2016|January 26, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02025478||53320|
NCT02025725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-IN-003|Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis|Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis||Evoke Pharma|No|Recruiting|April 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|75 Years|No|||December 2015|December 28, 2015|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025725||53301|
NCT02025972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBCP|Allogeneic Umbilical Cord Blood Therapy in Children With CP|Changes in Cytokines and Functional Outcomes of Allogeneic Cord Blood Therapy in Children With Cerebral Palsy||Bundang CHA Hospital|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|15 Years|No|||July 2014|July 18, 2014|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02025972||53282|
NCT02023086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ-2012-10918|Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients|Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Relation With Visual Field Loss in Fabry Patients||Université de Montréal|No|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients known as Fabry patients, already followed at Universite de Montréal eye clinic.        COntrol will come from the normal clinical population seen at the same site.|June 2015|June 2, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02023086|2 Years|53504|
NCT02023099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-004|Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)|GIFT I|AbbVie|Yes|Completed|December 2013|October 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|363|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|December 23, 2013||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT02023099||53503|
NCT02023957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e2013 - 291|A Pilot With Interactive Computer-assisted Screening for Mental Health in Primary Care|Interactive Computer-assisted Screening for Mental Health in Primary Care|iCAS|York University|No|Active, not recruiting|November 2013|April 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 23, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02023957||53437|
NCT02018913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46089.068.13|Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study|||Maastricht University Medical Center||Not yet recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To obtain variation in macrovascular pathology and cognitive outcome measures, patients        with AD, VaD, mixed AD and VaD, mild cognitive impairment (due to AD), vascular cognitive        impairment and subjective cognitive impairment will be included. The total number of        patients is 120, approximately 20 patients per disorder category as mentioned above. The        patients will be recruited from the memory clinic of the Maastricht University Medical        Center. Also a group of 20 age-matched healthy controls will be included. The total number        of participants is thus 140.|December 2013|December 17, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02018913||53824|
NCT02027181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 10-071 FreeO2-Hypox|Automatic Administration of Oxygen During Respiratory Distress|Automation of the Oxygen's Administration in Spontaneous Ventilation (FreeO2) During the Hypoxemic Acute Respiratory Distress|FreeO2-Hypox|University Hospital, Brest|Yes|Completed|August 2011|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02027181||53190|
NCT02019420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1986-002|TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia|A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia||Cubist Pharmaceuticals LLC|Yes|Recruiting|January 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|726|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019420||53785|
NCT02019433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1212|Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®|Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®||Aesculap AG|No|Terminated|July 2012|December 2016|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|specialist clinical centre|January 2015|January 13, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02019433||53784|
NCT02027610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13068|Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants|Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants||USDA, Western Human Nutrition Research Center|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|258|Samples With DNA|Infant specimens containing DNA isolated from periferal blood mononuclear cells (PBMC) will      be retained for future analyses. Maternal specimens containing DNA from cheek swabs will be      retained for future analyses.|Both|12 Months|24 Months|No|Non-Probability Sample|The present study will recruit infants who completed NCT01583972 when they are from 12 to        24 months of age. Mothers of these infants will also be recruited for collection of DNA        from a cheek swab.|November 2015|November 17, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02027610||53157|
NCT02024269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-AMD-001|Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Injected Intravitreal in Dry Macular Degeneration||Bioheart, Inc.||Withdrawn|December 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|90 Years|No|||September 2015|September 15, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02024269||53413|
NCT02024737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17337|SILO2 (Signal Intensity Lung washOut)|A Pilot Study to Establish the Sensitivity of MR Imaging Markers to Changes in Regional Lung Function and Gas Washout in Patients With Mild-moderate COPD|SILO2|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|40 Years|N/A|No|Non-Probability Sample|Patients will be recruited from COPD clinics in Sheffield, the surrounding area and the        nurse-led clinics running alongside them, by open advertisement, after pulmonary        rehabilitation, and via invitation by their local GP. The target is to recruit 6 subjects        within 4 months.|September 2015|September 28, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024737||53377|
NCT02023671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-EMD-2013|IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE|||Azienda Ospedaliera San Giovanni Battista|No|Active, not recruiting|December 2013|||December 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Actual|70|||Both|18 Years|N/A|No|Probability Sample|Patients with multiple myeloma|December 2013|December 24, 2013|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02023671||53459|
NCT02025179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1195|12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)|12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI||Northwestern University|Yes|Active, not recruiting|January 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|N/A|No|||October 2015|October 7, 2015|December 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025179||53343|
NCT02025491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLLipoBA001|Liposomal Amphotericin in Disseminated Leishmaniasis|Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis||Hospital Universitário Professor Edgard Santos|No|Completed|April 2011|August 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|14 Years|80 Years|No|||December 2013|December 30, 2013|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02025491||53319|
NCT02025985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-005|Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer|A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast Cancer|SIGN|Karyopharm Therapeutics, Inc|Yes|Active, not recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|106|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025985||53281|
NCT02024724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00083918|Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain|Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial.||Northwestern University|No|Recruiting|November 2013|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 1, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024724||53378|
NCT02022306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094|TD-6450 SAD and MAD in Healthy Subjects|A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Completed|February 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022306||53563|
NCT02022566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-08|The Effect of Structured Information and Individually Adapted Exercise on Levels of Physical Activity Measured by Accelerometer in Patients With Knee or Hip Osteoarthritis|The Effect of Structured Information and Individually Adapted Exercise on Levels of Physical Activity Measured by Accelerometer in Patients With Knee or Hip Osteoarthritis - an Observational Study With Control Group.||Lund University||Recruiting|April 2009|September 2014|Anticipated|April 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients are coming on referral to Supported self management of osteoartrithis program        from doctors and physical therapists from primary care clinics and specialist clinics.|December 2013|December 27, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02022566|12 Months|53544|
NCT02022852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HarbinMU-BCui-001|Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer|Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial||Harbin Medical University|No|Recruiting|July 2013|January 2018|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02022852||53522|
NCT02023112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-153|Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection|An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II)|GIFT II|AbbVie|Yes|Completed|January 2014|September 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|75 Years|No|||October 2015|October 10, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023112||53502|
NCT02023125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28991|A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of RO5424802 in Healthy Volunteers.|AN OPEN-LABEL, TWO GROUP STUDY TO INVESTIGATE THE EFFECT OF FOOD (GROUP 1) AND ESOMEPRAZOLE (GROUP 2) ON THE SINGLE ORAL DOSE PHARMACOKINETICS OF RO5424802 IN HEALTHY SUBJECTS||Hoffmann-La Roche||Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023125||53501|
NCT02023476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM|Neurologic Examination of Wide and Narrow Tourniquets|Nerve Function in Healthy Human Volunteers With Two Different Tourniquets|HEM|Medical University of Vienna|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023476||53474|
NCT02023463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.461|Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer|Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer||Thomas Jefferson University|Yes|Recruiting|April 2014|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||August 2015|August 11, 2015|December 23, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023463||53475|
NCT02018926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-014|Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS|A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)||Mirati Therapeutics Inc.|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018926||53823|
NCT02019186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRI-VITCE|Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes|Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes||Nationwide Children's Hospital|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|8 Years|15 Years|No|||February 2015|February 2, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019186||53803|
NCT02019446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03369|Laser Treatment for Onychomycosis in Diabetes|Evaluating the Effectiveness of Laser Treatment for Onychomycosis of the Hallux in Patients With Diabetes: A Randomized Controlled Trial||BCDiabetes.Ca||Not yet recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||July 2015|July 27, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02019446||53783|
NCT02019459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U54DA031659-03|Very Low Nicotine Cigarettes in Smokers With Schizophrenia|Very Low Nicotine Cigarettes in Smokers With Schizophrenia||Brown University|Yes|Recruiting|November 2014|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|70 Years|No|||September 2015|September 25, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019459||53782|
NCT02019706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140028|Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome|Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|90 Years|No|||October 2015|January 22, 2016|December 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019706||53763|
NCT02024971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073-011|Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus|Metact® Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for Type 2 Diabetes Mellitus||Takeda|No|Completed|July 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1103|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes mellitus|December 2013|December 29, 2013|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02024971||53359|
NCT02025192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-380-005|A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer|A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer||Oncothyreon Inc.|Yes|Active, not recruiting|December 2013|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025192||53342|
NCT02024958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICALIC|New Indirect Calorimetry Device for Energy Expenditure Measurement|Development and Validation of a New Indirect Calorimetry Device for Energy Expenditure Measurement in ICU Patients: The ICALIC International Multicentric Study|ICALIC|University Hospital, Geneva|No|Not yet recruiting|May 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|182|||Both|18 Years|N/A|No|Non-Probability Sample|All adult ICU patients with spontaneous breathing, or on invasive or non-invasive        mechanical ventilation admitted into the intesive care unit|December 2013|December 28, 2013|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02024958||53360|
NCT02025504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoWrap-002|Carolina-ColoWrap® in Colonoscopy Performance and Outcomes Study|Efficacy of ColoWrap® Abdominal Binder in Improving Performance and Tolerance of Colonoscopy: a Randomized, Sham-Controlled, Blinded Clinical Trial|C3PO|ColoWrap, LLC|Yes|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|350|||Both|40 Years|80 Years|No|||March 2015|March 31, 2015|December 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025504||53318|
NCT02025751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-IN-004|Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis|Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis||Evoke Pharma|No|Recruiting|April 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|75 Years|No|||December 2015|December 28, 2015|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025751||53299|
NCT02025998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBUD|Development of Ibudilast for Alcohol Use Disorder|Development of Ibudilast as a Novel Treatment for Alcohol Dependence||University of California, Los Angeles|Yes|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|65 Years|No|||February 2016|February 19, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025998||53280|
NCT02021981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2013-1094|Improving Health Outcomes: Blood Pressure|Improving Health Outcomes: Blood Pressure Program in Practice Sites Located in the Chicago Metropolitan Area and in Maryland|IHO:BP|American Medical Association|No|Active, not recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||10|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This quality improvement project will be conducted in 10 ambulatory practice sites that        are distinguished by their medical specialty and practice size. There are 9 diverse sites        that specialize in family medicine and internal medicine. One site is a cardiology        practice. Practices range in size from a mid-size medical group to a single-physician        practice. The total number of physicians participating in this project is between 40 and        50. The sites are located in various neighborhoods in the Chicago and Baltimore        metropolitan areas and in rural Maryland. The patient populations of the sites are        representative of the United States population.|January 2015|January 26, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02021981||53588|
NCT02021994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Andon Health 9|BPM Cuff： 15-24cm, 20-34cm, 30-44cm, 40-48cm, 22-42cm|||Andon Health Co., Ltd||Completed|June 2013|||September 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|85|||Both|20 Years|83 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community|December 2013|December 20, 2013|September 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021994||53587|
NCT02022046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-4131C|Methylation Biosignature in Childhood Chronic Kidney Disease|Methylation Biosignature in Childhood Chronic Kidney Disease: the Link Among Asymmetric Dimethylarginine, Homocysteine, and Cardiovascular Disease|childhoodCKD|Chang Gung Memorial Hospital|Yes|Recruiting|April 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged <18 years visit pediatric nephrology clinic during study period|August 2015|August 3, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02022046||53583|
NCT02022579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN 6702|DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer|A MULTI-CENTER STUDY EVALUATING THE UTILITY OF DIFFUSION WEIGHTED IMAGING FOR DETECTION AND DIAGNOSIS OF BREAST CANCER||American College of Radiology Imaging Network|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||February 2014|February 21, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02022579||53543|
NCT02022865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-12-0412|Correlation Between Inflammatory Markers in Gingival Crevicular Fluid, Serum and Amniotic Fluids in Periodontal Pregnant Women|Correlation Between Inflammatory Markers in Gingival Crevicular Fluid, Serum and Amniotic Fluids in Periodontal Pregnant Women||Hadassah Medical Organization|No|Not yet recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|gingival crevicular fluid, serum, aminiotic fluid|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy pregnant women, undergoing elective amniocentesis|December 2013|December 23, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02022865||53521|
NCT02023164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETTAU-02|Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.|||JDP Therapeutics, Inc.||Completed|July 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023164||53498|
NCT02023177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhA01|Phase Angle and Mortality in Patients With Cirrhosis|Phase Angle as a Nutritional Marker Related to Prognosis Inpatients With Cirrhosis: A Cutt-off Value for Mexican Population||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|January 2008|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|||Both|18 Years|65 Years|No|Non-Probability Sample|Population will be selected from the Liver Clinic at the Department of Gastroenterology in        a tertiary care center in Mexico|November 2014|November 14, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023177||53497|
NCT02023710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-MM-131101|Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma|A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma||Beijing Cancer Hospital|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|70 Years|No|||February 2016|February 27, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02023710||53456|
NCT02019212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130446-01H|Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-Tetrofosmin|Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-tetrofosmin||Ottawa Heart Institute Research Corporation|No|Active, not recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical patients who have undergone myocardial perfusion imaging.|February 2016|February 23, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02019212||53801|
NCT02019199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032595|Magnetic Resonance Imaging (MRI) in Motion|Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.||Duke University|No|Completed|November 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|21 Years|N/A|No|Non-Probability Sample|Adults males or females with primary or secondary cancer tumors of the lung, liver or        pancreas|December 2015|December 8, 2015|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019199||53802|
NCT02019979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METRO 090-13|Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)|Metformin With a Carbohydrate Restricted Diet In Combination With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - METRO Study|METRO|Beth Israel Medical Center|No|Recruiting|December 2013|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|February 23, 2016|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019979||53742|
NCT02019992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU-ICU-2013-01|Investigation of Plasma Mitochondrial DNA Level in Septic Patients|Plasma Levels of Mitochondrial DNA in Patients Presenting to ICU With Sepsis||Central South University|Yes|Recruiting|September 2013|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20|Samples With DNA|plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Sepsis and severe septic patients enrolled in 2014 will be collected.|December 2013|December 18, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02019992||53741|
NCT02020291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2562|Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer|Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer||WntResearch AB|Yes|Completed|June 2013|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02020291||53718|
NCT02020304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 23933|Combined Spinal-Epidural Temperature and Duration of Action|Effect of Temperature of Combined Spinal Epidural Dosing on Duration||Wake Forest School of Medicine|Yes|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|60|||Female|18 Years|55 Years|No|||June 2014|June 2, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02020304||53717|
NCT02024763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APkit|Educational Program and Schoolchildren's Energy Expenditure|Effect of an Educational Program on Schoolchildren's Energy Expenditure During Physical Education Classes||Federal University of São Paulo|No|Completed|September 1999|November 2000|Actual|November 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|352|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024763||53375|
NCT02025205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0014|Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study|A Multicentre, Prospective, Randomized, Controlled, One-way Crossover Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous Emphysema|IMPACT|Pulmonx, Inc.|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|40 Years|N/A|No|||September 2015|January 12, 2016|December 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02025205||53341|
NCT02025218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRENE study - NVALT 16|Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients|Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)|IRENE|VU University Medical Center|Yes|Terminated|January 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025218||53340|
NCT02025517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UFRN 03063812.0.0000.5537|Gait Training With Cognitive Tasks in Parkinson's Disease|Immediate Effects of Treadmill Gait Training Combined With Cognitive Tasks in Individuals With Parkinson's Disease: Randomized Controlled Trial||Universidade Federal do Rio Grande do Norte|Yes|Completed|August 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|45 Years|70 Years|No|||November 2012|December 27, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02025517||53317|
NCT02025764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHCA_IRB_2013-56|The Clinical Feature of Ulcer Base Over Time After Prophylactic Argon Plasma Coagulation in Colonic EMR|The Clinical Feature of the Exposed Vessels in Ulcer Base Over Time After Prophylactic Argon Plasma Coagulation in Colonic Endoscopic Mucosal Resection||Soonchunhyang University Hospital|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Between August 2013 and May 2014, patients who were enrolled underwent prophylactic APC        for non-bleeding visible vessels after colonic endoscopic mucosal resection.|June 2014|June 20, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02025764|1 Month|53298|
NCT02025777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-210|Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease|Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease|UC|Medtronic - MITG|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 31, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025777||53297|
NCT02022007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP13-013|Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis|Metabolic and Endocrine Effects of Combination of Metformin and DPP4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study|BMS-AZPCOS|Woman's|Yes|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Female|18 Years|42 Years|No|||February 2016|February 23, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022007||53586|
NCT02022020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.162|Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa|An Observational Study Assessing the Management of Gastrointestinal and Urogenital Bleeding Events in Patients With Atrial Fibrillation Treated With Dabigatran Etexilate||Boehringer Ingelheim||Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|204|||Both|18 Years|N/A|No|Non-Probability Sample|AF patients with bleeding event using Dabigatran etexilate|October 2015|October 27, 2015|November 25, 2013||||No||https://clinicaltrials.gov/show/NCT02022020||53585|
NCT02022072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00218-37|Evaluation of Vital Capacity|Measurement of Assisted Vital Capacity to Appreciate the Level of Recruitment in Neuromuscular Diseases|CVassist|Centre d'Investigation Clinique et Technologique 805|No|Terminated|May 2013|April 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|November 5, 2013||No|With 50 patients, the measure of assist vital capacity has been validated|No||https://clinicaltrials.gov/show/NCT02022072||53581|
NCT02022085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAS5477|Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)|Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)||Cochlear Bone Anchored Solutions|No|Recruiting|June 2014|March 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|December 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022085||53580|
NCT02022319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWE-var 112013|The Observer Variation of Shear Wave Elastography|Intra- and Inter-observer Variation of Thyroid Shear Wave Elastography - a Variability Study||University of Aarhus|Yes|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02022319||53562|
NCT02022345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301136|Safety and Efficacy of PCI at California Hospitals Without Onsite Cardiac Surgery|PCI California Audit Monitored Pilot With Offsite Surgery|PCI-CAMPOS|University of California, Davis|Yes|Recruiting|August 2010|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3773|||Both|N/A|N/A|No|||December 2014|December 3, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02022345||53561|
NCT02022592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoveMi|Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care|Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care||Charite University, Berlin, Germany|No|Recruiting|June 2014|March 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02022592||53542|
NCT02023190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT01|Changes in Body Composition and Nutritional Status in Patients Undergoing Liver Transplantation|Changes in Body Composition and Nutritional Status Assessed by Bioelectrical Impedance Vector Analysis in Cirrhotic Patients Undergoing Liver Transplantation||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients will be selected from the transplant enrollment list at the Department of        Gastroenterology in a tertiary care center in Mexico|September 2015|September 29, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023190||53496|
NCT02023203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-PTFE|Efficacy of Macroporous Polytetrafluoroethylene Mesh in Laparoscopic Hernia Repair|Prospective Randomized Clinical Trial Comparing Microporous Polypropylene Mesh and Flexible Macroporous Polytetrafluoroethylene Mesh in Totally Extraperitoneal Laparoscopic Inguinal Hernia Repair|PTFE|Hospitales Universitarios Virgen del Rocío|No|Completed|January 2011|August 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Male|20 Years|80 Years|No|||December 2013|December 23, 2013|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023203||53495|
NCT02022878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP-0021-106/1416/13|Computed Tomography Angiography Prediction Score for Percutaneous Revascularization of Chronic Total Occlusions|Development of Computed Tomography Angiography Prediction Score for Percutaneous Revascularization of Chronic Total Occlusions: Multicenter CT-RECTOR Registry|CT-RECTOR|Kerckhoff Heart Center|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|229|||Both|18 Years|N/A|No|Probability Sample|The study population consists of patients at multiple international centers undergoing        preprocedural coronary CTA before attempted PCI of CTO between 2007 and 2013.|July 2014|July 30, 2014|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02022878||53520|
NCT02023138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT Canada 87776|Evaluation of the Acceptability, Feasibility and Effectiveness of Two Methods of Involvement of Patients With Cognitive Disability in Clinical Guidelines Development: a Randomized Crossover Pilot Trial|Evaluation of the Acceptability, Feasibility and Effectiveness of Two Methods of Involvement of Patients With Cognitive Disability in Clinical Guidelines Development: a Randomized Crossover Pilot Trial||Laval University|No|Not yet recruiting|January 2014|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023138||53500|
NCT02023151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00081287|Predicting the Clinical Response to Omalizumab With Anti-IgE Ab Response or Syk Expression in Basophils|Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils||Johns Hopkins University|Yes|Recruiting|February 2013|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023151||53499|
NCT02023489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1128/2013|Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations|Myocardial Lipid and Glycogen Metabolism & Cardiac Function in Patients With Impaired Glucose Tolerance or Type 2 Diabetes Mellitus and Calcium Sensing Receptor Mutations - A Cross Sectional Magnetic Resonance Spectroscopy and Imaging Study|RISC_7T|Medical University of Vienna|Yes|Recruiting|July 2013|July 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|90|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023489||53473|
NCT02020005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS014|Evaluation of Cessation Preferences of Menthol Smokers|Evaluation of Cessation Preferences of Menthol Smokers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02020005||53740|
NCT02020018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001832|Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection|Negative Pressure Wound Therapy for Prevention of Wound Infection After Heart Surgery||Mayo Clinic|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|950|||Both|18 Years|100 Years|No|||March 2016|March 15, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020018||53739|
NCT02019719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116099|Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease|A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease||GlaxoSmithKline|Yes|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|97|||Both|20 Years|N/A|No|||October 2014|October 16, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02019719||53762|
NCT02019732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117233|Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States|Burden of Mild Outcomes Due to Influenza in the United States, July 2000 Through April 2009 and October 2010 to May 2011||GlaxoSmithKline||Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|All records related to physician office visits of subjects less than 65 years of age and        65 years of age and older in the United States with an outcome of interest in the relevant        Marketscan database.|December 2013|January 2, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02019732||53761|
NCT02020681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4-CURAF|Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions|Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions: A Mono-centre, Split-mouth, Double-blinded, Placebo Controlled, Randomised, Post Marketing Clinical Study||Credentis AG|No|Completed|September 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|14 Years|65 Years|No|||January 2016|January 26, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020681||53688|
NCT02020980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52120-181|RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke|A Prospective, Observational Study to Assess Pain Relief After 4 Botulinum Toxin Type A (BoNT-A) Injection Cycles in Patients With Post-stroke Lower Limb Spasticity|RELIEF|Ipsen|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|184|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with post-stroke lower limb spasticity in Rehabilitation and Neurology        Units of hospitals.|February 2016|February 5, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020980||53665|
NCT02024997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2012-07-YANG-MRIRESP|Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study|Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study||Cedars-Sinai Medical Center|No|Completed|January 2013|||September 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02024997||53357|
NCT02024984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPFPCCPCOS|Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial|Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial||Ain Shams Maternity Hospital|Yes|Recruiting|November 2013|July 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Female|20 Years|40 Years|No|||March 2014|March 10, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02024984||53358|
NCT02025530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN2156|The Midlands and North of England Stillbirth Study|The Midlands and North of England Stillbirth Study - A Case-Control Study of Modifiable Factors in Late Stillbirth|MiNESS|University of Manchester|No|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|871|Samples Without DNA|Hair|Female|16 Years|50 Years|No|Probability Sample|The sample will be recruited from maternity units in the Midlands and the North of        England.|November 2015|November 30, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02025530||53316|
NCT02025790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-POEM-01|POEM Versus Pneumatic Dilatation in Achalasia Cardia|A Prospective Trial Comparing POEM to Pneumatic Dilatation for Treatment of Achalasia Cardia||Asian Institute of Gastroenterology, India|No|Recruiting|December 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||December 2013|December 31, 2013|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02025790||53296|
NCT02025803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-114-101|A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025803||53295|
NCT02026024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-3596B|Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients|Clinical and Genetic Variations Study of Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients|IBCT2|Chang Gung Memorial Hospital|No|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|Samples With DNA|DNA for sequencing|Both|20 Years|80 Years|No|Probability Sample|Poorly Controlled Type 2 Diabetic Patients|January 2016|January 31, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026024||53278|
NCT02026037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI 21-2716-3128|Reducing PTSD in Hospitalized Burn Patients|A Brief Intervention to Reduce PTSD in Acutely Burned Hospital Patients||University of Southern California|No|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026037||53277|
NCT02026011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX-AA|Naltrexone for Individuals of East Asian Descent|Optimizing Naltrexone for Individuals of East Asian Descent||University of California, Los Angeles|Yes|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|65 Years|No|||February 2016|February 19, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026011||53279|
NCT02022033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295|BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 295:Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial||Brown University|Yes|Recruiting|February 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022033||53584|
NCT02022059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-12|Prospective Monocentric Study on the Efficacy of Lidocain Spray for Patient Comfort During Nasogastric Tube Insertion in Enteral Nutrition|Prospective Monocentric Study on the Efficacy of Lidocain Spray for Patient Comfort During Nasogastric Tube Insertion in Enteral Nutrition: the Xylonut Trial|Xylonut|Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2013|May 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||December 2013|December 26, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02022059||53582|
NCT02022371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0244|Prostate Cancer Genomic Heterogeneity||PROGENY|University College London Hospitals||Recruiting|September 2013|||June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Male|18 Years|N/A|No|||December 2013|December 20, 2013|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02022371||53559|
NCT02022358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/085|Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?|A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma||University College, London|Yes|Terminated|July 2007|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|5 Years|50 Years|No|||June 2015|June 3, 2015|November 26, 2013||No|Recruitment almost complete, has been slow and challenging|No||https://clinicaltrials.gov/show/NCT02022358||53560|
NCT02022605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131208-4|Effect of Continuously Coached Practice Using EMS on ERCP Performance of Trainees|Effect of Continuously Coached Practice Using EMS on ERCP Performance of Trainees: a Prospectively Randomized, Controlled Study|ERCP|Fourth Military Medical University|Yes|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|400|||Both|18 Years|90 Years|No|||December 2015|December 14, 2015|December 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02022605||53541|
NCT02022618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(BIO/SA05/13)|Target Organ Damage and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects|Target Organ Damage and Blood Pressure, Retinal Vessels, Oxidative Stress and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects (LOD-Hypertension)|LOD-HTA|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|October 2013|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|486|Samples With DNA|Human biospecimens used will be collected, stored, used, shared, and disposed of in      accordance with the informed consent signed by the subject, or under a waiver of informed      consent granted by an independent ethical review body, in accordance to Spanish Law (Ley      Orgánica de Protección de Datos de Carácter Personal (15/1999 del 13 de Diciembre, LOPD), y      en las condiciones que marca la Ley 14/2007 de investigación biomédica) of Protection of      Human Subjects.|Both|20 Years|80 Years|No|Non-Probability Sample|Population: 486 hypertensive patients (20-80 years) will be assessed with all tests        recommended in 2013 European guidelines of hypertension|September 2014|September 4, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02022618||53540|
NCT02023788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-006-F/U-5y|Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study|Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study||Medipost Co Ltd.|No|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|9|||Both|45 Months|63 Months|No|Non-Probability Sample|Infants who were enrolled in the 2-year follow-up study (NCT01632475) of phase 1 clinical        trial for the safety and efficacy evaluations of PNEUMOSTEM® treatment in premature        infants with bronchopulmonary dysplasia|January 2016|January 6, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023788||53450|
NCT02023801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0004|A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System||Minerva Surgical, Inc.|Yes|Completed|August 2011|May 2015|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|25 Years|50 Years|No|||October 2015|October 6, 2015|December 24, 2013|Yes|Yes||No|August 26, 2015|https://clinicaltrials.gov/show/NCT02023801||53449|
NCT02023515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R56HL116517-01A1|Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome|Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome||University of Kentucky|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|55 Years|No|||July 2014|July 28, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023515||53471|
NCT02019238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818358|Second Study to Assess Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Long Standing Persistent Atrial Fibrillation|Second Randomization Study to Assess Efficacy of Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Long Standing Persistent Atrial Fibrillation: RASTA XT Study|RASTA XT|University of Pennsylvania|Yes|Terminated|August 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|February 3, 2015|October 30, 2013|Yes|Yes|PI discretion|No||https://clinicaltrials.gov/show/NCT02019238||53799|
NCT02019498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RelaxLWS-13|Effectiveness of App-based Relaxation for Patients With Chronic Low Back Pain (Relaxback)|A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Low Back Pain|Relaxback|Charite University, Berlin, Germany|No|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019498||53779|
NCT02020317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZMI-KEK-ZH-Nr. 2013|Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions|Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions||University of Zurich|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3341|||Both|N/A|N/A|No|||June 2015|June 5, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020317||53716|
NCT02020031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004988|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|VIDACARE|Mayo Clinic|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020031||53738|
NCT02020044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/108/12|Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|Prospective Clinical Study on Postoperative Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)||Charite University, Berlin, Germany|Yes|Recruiting|September 2012|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02020044||53737|
NCT02020694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|752/11|Vitamin D Supplementation for the Prevention of Cardiovascular Risk|The Role of Vitamin D Supplementation in the Prevention of Cardiovascular Risk Factors||Catholic University of the Sacred Heart||Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020694||53687|
NCT02021552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44109-A|Genetic Polymorphisms & The Risk for Sepsis After Trauma|Genetic Polymorphisms & The Risk for Sepsis After Trauma||University of Washington|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|White blood cells extracted from discarded blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Prospective cohort in which patients with severe injury, defined by combined anatomic        injuries sufficient to require admission to the intensive care unit for treatment (blood        transfusions, mechanical support of respiration) and intensive monitoring that is expected        to be required for more than 24 hours, will be enrolled|December 2013|December 19, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02021552||53621|
NCT02024789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27832|A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)||Hoffmann-La Roche||Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|173|||Both|12 Years|30 Years|No|||March 2016|March 1, 2016|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024789||53373|
NCT02025231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH ReRT 2011|Image Guided Reirradiation of High-grade Glioma|Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study||Rigshospitalet, Denmark|No|Active, not recruiting|December 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02025231||53339|
NCT02025244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 05|EUS-FNA Versus KHB in Diagnostics of Upper Gastrointestinal Submucosal Tumors|Endosonography-Guided Fine-Needle-Aspiration (EUS-FNA) Versus Key Hole Biopsy (KHB) in Diagnostics of Upper Gastrointestinal Submucosal Tumors - a Randomized Trial||Vitkovice Hospital|Yes|Recruiting|November 2010|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|52|||Both|18 Years|95 Years|No|||November 2015|November 23, 2015|October 14, 2012||No||No||https://clinicaltrials.gov/show/NCT02025244||53338|
NCT02025543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1174|Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content|Confounder-Corrected Quantitative Magnetic Resonance Imaging (MRI) Biomarker of Hepatic Iron Content||University of Wisconsin, Madison|No|Recruiting|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|10 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known or suspected iron overload|November 2015|November 24, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025543||53315|
NCT02025556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBR-101-022|A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine||Teva Pharmaceutical Industries|No|Completed|January 2014|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|319|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025556||53314|
NCT02025816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-002|RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections||NSTI|Texas Tech University Health Sciences Center|No|Active, not recruiting|December 2013|January 2017|Anticipated|January 2015|Actual|N/A|Observational|N/A||1|Anticipated|25|Samples With DNA|Tissue biopsies for RNAseq analysis of microbial gene expression|Both|18 Years|N/A|No|Non-Probability Sample|Twenty to twenty five patients with necrotizing soft tissue infections (NSTI) admitted to        the University Medical Center, Lubbock, TX|October 2015|October 2, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02025816||53294|
NCT02026050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/639|Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus|Phase 4 Study of Comparison of Postoperative Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus Blockade for Arthroscopic Shoulder Surgery||TC Erciyes University|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026050||53276|
NCT02026063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-302-CS|Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms|A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)|TELEPATH|Lexicon Pharmaceuticals|Yes|Recruiting|December 2013|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026063||53275|
NCT02022098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1143-201|Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial|A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.||Debiopharm International SA|Yes|Recruiting|October 2013|January 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|75 Years|No|||March 2016|March 24, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02022098||53579|
NCT02022631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIF_aim1RCT1|New Alternative Formats vs Standard of SoF Tables. Non-inferiority Randomized Controlled Trial|Comparison Between Standard and New Alternative Formats of the Summary-of-Findings Tables in Cochrane Review Users. A Non-inferiority Randomized Controlled Trial||McMaster University|No|Enrolling by invitation|December 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 21, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02022631||53539|
NCT02022644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nano CED|Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma|A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium In Patients With Recurrent High Grade Glioma||University of California, San Francisco|Yes|Enrolling by invitation|February 2014|January 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022644||53538|
NCT02022891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC_MOE_2012-6|Systematic Psychological and Medical Care for Children With SCD|The Impact of Systematic Psychological and Medical Care for Treatment of Pediatric Patients With SCD: : A Luxury or a Necessity?|Drépano|Fondation Ophtalmologique Adolphe de Rothschild|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|160|||Both|N/A|18 Years|No|Non-Probability Sample|children with sickle cell disease|August 2014|August 5, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02022891||53519|
NCT02020135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMA ADC 2301EXT|An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)|An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)||Progenics Pharmaceuticals, Inc.|No|Completed|October 2013|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||March 2015|March 10, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020135||53730|
NCT02023528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00063655|Dialysis Registry in Utah|Dialysis Registry in Utah||University of Utah|No|Recruiting|January 2008|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|New patients starting on dialysis at the University of Utah care dialysis program.|December 2013|December 23, 2013|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023528||53470|
NCT02023541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310084|Proton Beam Therapy to Treat Esophageal Cancer|A Phase I Study of Proton Beam Therapy in the Treatment of Esophageal Cancer||Washington University School of Medicine|No|Terminated|January 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|December 23, 2013|No|Yes|Lack of insurance coverage for proton beam treatment|No||https://clinicaltrials.gov/show/NCT02023541||53469|
NCT02020707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1371|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery|Targeted Complex Therapy for Advanced Melanoma: Nab-paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)||Mayo Clinic|Yes|Recruiting|March 2014|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|February 23, 2016|December 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02020707||53686|
NCT02019758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4047|Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis|Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis||University of North Carolina, Chapel Hill|Yes|Recruiting|October 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|16 Years|80 Years|No|||February 2016|February 16, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019758||53759|
NCT02021292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055E201|Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|MERIT-1|Actelion|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021292||53641|
NCT02021019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527/13|Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease|Renal Denervation to Improve Outcomes in Patients With End-stage Renal||Baker IDI Heart and Diabetes Institute|No|Active, not recruiting|January 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02021019||53662|
NCT02021032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-04-401-01|Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)|Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)||Medifocus, Inc.|No|Recruiting|February 2006|August 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Male|18 Years|N/A|No|||September 2015|September 23, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021032||53661|
NCT02024802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLP-001-PC|Compounded Pain Creams and Patient Perception|Clinical Trial: Transdermal Compounded Pain Creams and Patient Pain Perception||Marwood LowCost Pharmacy|No|Withdrawn|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|85 Years|No|Non-Probability Sample|community sampling of patients with a diagnosis of neurologic or nociceptive pain whom        will be beginning a new regimine of custom compounded pain cream as a pain management        therapy.|July 2014|July 3, 2014|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02024802||53372|
NCT02025010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-449|Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.|Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.||Dana-Farber Cancer Institute|Yes|Recruiting|December 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025010||53356|
NCT02025270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT010066099|MSCs For Treatment of Azoospermic Patients|Using of Bone Marrow Derived Mesenchymal Stem Cells For Treatment of Azoospermic Patients||Al-Azhar University|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Male|20 Years|50 Years|No|||April 2015|April 7, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025270||53336|
NCT02025569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKCollins-SCS|The Effect of Strain-counterstrain on Ankle Instability|The Effectiveness of Strain Counterstrain in the Treatment of Patients With Chronic Ankle Instability: a Randomized Clinical Trial||Long Island University|No|Terminated|January 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|December 24, 2013||No|Data collection was terminated due to unavailability of additional participants.|No||https://clinicaltrials.gov/show/NCT02025569||53313|
NCT02025829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01CH2013|IL-17 Neutrophils in CF Lung Inflammation|The Role of IL-17 Neutrophils in CF Lung Inflammation||University Hospital Case Medical Center|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|12|Samples With DNA|peripheral white cells, serum, sputum white cells, sputum supernatants|Both|18 Years|50 Years|No|Non-Probability Sample|Patients seen in the cystic fibrosis outpatient clinic (Clinically Stable Cohort) and        inpatient unit (Exacerbation/IV Antibiotics Cohort) of Cystic Fibrosis Center in        Cleveland, OH (Rainbow Babies and Children's Hospital/University Hospitals Case Medical        Center)|May 2015|May 28, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02025829||53293|
NCT02026076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manual Unloading|Manual Unloading of the Lumbar Spine: Can it Predict Responders to Mechanical Traction?|Manual Unloading of the Lumbar Spine: Can it Predict Response to Mechanical Traction? A Study or Reliability and Criterion Referenced Predictive Validity||University of Connecticut Health Center|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|75 Years|No|||November 2013|December 30, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02026076||53274|
NCT02022670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL107105|Sodium Nitrite to Treat Arterial Aging|Clinical Translation of Nitrite Therapy to Treat Arterial Aging in Humans||University of Colorado, Boulder|Yes|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|December 13, 2013|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT02022670||53536|
NCT02022384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMO-GLIO 01|Immunophenotyping From Blood of Patients With Malignant Gliomas|Immunophenotyping From Blood From Patients With Glioblastoma and Anaplastic Astrocytoma Before and During Chemoradiation as Well as During Adjuvant Chemotherapy||University of Erlangen-Nürnberg Medical School|No|Recruiting|December 2013|December 2021|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|whole blood, serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|patients with primary diagnosed glioblastoma multiforme or anaplastic astrocytoma|October 2015|October 23, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02022384||53558|
NCT02022657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0427|Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots|PrEP Adherence Monitoring Using Dried Blood Spots|DOT-DBS|University of Colorado, Denver|Yes|Recruiting|April 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022657||53537|
NCT02022904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037349|Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology|Development of a Novel Method to Detect Prostate Cancer Circulating Tumor Cells (CTCs) Based on Epithelial-mesenchymal Transition Biology||Duke University|No|Withdrawn|May 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Male|18 Years|N/A|No|||July 2015|July 28, 2015|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022904||53518|
NCT02021370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15141|15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of 5 Fixed Doses of BAY85-3934 Administered Orally in the Correction of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease Not Currently Treated With Erythropoiesis-stimulating Agent in Europe and Asia Pacific|DIALOGUE 1|Bayer|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|123|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021370||53635|
NCT02024074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064317|Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients|Performance of Tc99m Sestamibi Molecular Breast Imaging (Tc-MBI) Versus Magnetic Resonance Imaging in the Diagnosis of Breast Carcinoma: A Pilot Study||Emory University|Yes|Terminated|November 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Female|18 Years|N/A|No|||February 2015|February 5, 2015|December 23, 2013|Yes|Yes|Study terminated by the Sponsor due to slow enrollment|No||https://clinicaltrials.gov/show/NCT02024074||53428|
NCT02024087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A041-05|Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma||Acceleron Pharma, Inc.|No|Recruiting|June 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024087||53427|
NCT02020330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOCRU1301|Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day|An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar|AL3vs5|University of Oxford|No|Active, not recruiting|January 2014|December 2015|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|6 Years|N/A|No|||June 2015|June 30, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02020330||53715|
NCT02020343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208668|Insulin Resistance in the Control of Intestinal Lipid Metabolism|Insulin Resistance in the Control of Intestinal Lipid Metabolism||University of Missouri-Columbia|No|Recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|24|Samples With DNA|DNA will be collected for future determination of genotypes that impact taste senstivity|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, insulin resistant and type 2 diabetic subjects.|December 2015|December 4, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02020343||53714|
NCT02021006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT trial|Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract|Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract|PREDICT|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|December 2013|June 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|436|||Both|1 Month|4 Months|No|||January 2014|January 14, 2014|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02021006||53663|
NCT02020356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 385 02|Music Therapy in Alzheimer's Disease|Impact of Music Therapy on Prescription of Neuroleptics in Alzheimer's Disease ou Related Symptoms Associated With Disruptive Behaviours.|PRE-MUSICAL|University Hospital, Toulouse|No|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|35|||Both|65 Years|100 Years|No|||September 2015|September 29, 2015|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02020356||53713|
NCT02021045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706/2013|Cerebral Microembolism During Hemodialysis|Quantity, Quality and Laterality of Cerebral Microembolism During Veno-Venous Hemodialysis.||Medical University of Vienna|No|Completed|September 2013|March 2016|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|The study population incloses patients who are in renal failure needing renal replacement        therapy under intensive care conditions.|March 2016|March 3, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021045||53660|
NCT02025036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstHenanUST|Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer|Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer|CRTCOESC|The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|630|||Both|45 Years|75 Years|No|||January 2016|March 10, 2016|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02025036||53354|
NCT02025023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42336-D|Chalazia Treatment Study|Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study|CTS|University of Washington|No|Recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||December 2013|December 29, 2013|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025023||53355|
NCT02025257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|462-13|Effects of Exercise in Patients With Coronary Artery Disease Aged 80 Years or Older|Effects of Exercise in Patients With Coronary Artery Disease Aged 80 Years or Older - a Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|Yes|Recruiting|December 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|80 Years|N/A|No|||March 2016|March 13, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02025257||53337|
NCT02025582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003848|Kinesio Taping Effectiveness on Idiopathic Toe Walking|The Effectiveness and Efficacy of Kinesio Taping Method on Muscle Elasticity in Children Who Toe Walk||Mayo Clinic|No|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|10 Years|No|||September 2015|September 3, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02025582||53312|
NCT02025842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma|Long-term Nucleoside/Nucleotide Treatment of Hepatitis B Virus HBeAg-negative Genotype D Patients and Risk of Hepatocellular Carcinoma:Evidence From the CLEO Cohort Study|HBV/HCC|Azienda Ospedaliera San Camillo Forlanini|Yes|Completed|January 2000|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Actual|306|||Both|18 Years|75 Years|No|Non-Probability Sample|From January 2000 to December 2013, 745 HBV-infected patients were included in the        database. Of these, 438 were excluded: 226 did not fulfil the diagnosis of CHB, 75 had        HBeAg-positive CHB, 20 had received NUC for <18 months, 26 had HCC diagnosed before or        within the first 18 months of therapy, and 61 presented a different HBV genotype. Thirty        patients had decompensated cirrhosis. A total of 306 HBeAg-negative genotype D patients        were selected and included in this study.|December 2013|December 31, 2013|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02025842|62 Months|53292|
NCT02026089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1380|Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine|Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine||University of Colorado, Denver|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026089||53273|
NCT02022397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183/09|Automated Assessment of Difficult Airway With Facial Recognition Techniques|Automatic Assessment of Difficult Ventilation and Intubation From Automatic Face Analysis and Artificial Intelligence|PeScho|University of Lausanne Hospitals|No|Recruiting|March 2012|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patient undergoing general anesthesia necessitating endotracheal intubation|August 2015|August 6, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02022397|1 Day|53557|
NCT02022410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV 144/13|CAS and Length of Hospital Stay After TKA|Cumulated Ambulation Score and Length of Hospital Stay After TKA||University of Lausanne Hospitals|No|Completed|September 2013|June 2015|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|18 Years|N/A|No|Non-Probability Sample|TKA patients just after surgery|June 2015|June 1, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02022410|1 Year|53556|
NCT02019056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG|Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis|A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis||PharmaKing|Yes|Completed|November 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|70 Years|No|||April 2015|April 27, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02019056||53813|
NCT02022917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGOG11-003|Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer|A Phase II Trial of Postoperative Chemotherapy Plus Adjuvant and Maintenance Bevacizumab After Neoadjuvant Chemotherapy Followed by Interval Surgery in Patients With Extensive Stage IIIC or IV Ovarian, Tubal, and Peritoneal Cancer||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|February 2014|May 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Female|20 Years|75 Years|No|||December 2013|December 23, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02022917||53517|
NCT02023554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81302846-1|Drug Interaction Study of Azithromycin and Theophylline|A Pharmacokinetic Drug Interaction Study to Evaluate the Effect of Azithromycin on the Steady-State Plasma Levels of Theophylline in a Chinese Population||Zhujiang Hospital|Yes|Completed|December 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|75 Years|No|||August 2014|August 18, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023554||53468|
NCT02021110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLD 11-01|Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease|An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease|CURSOR|Radboud University|Yes|Recruiting|December 2013|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||November 2014|November 5, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02021110||53655|
NCT02020421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORTHSTAR|NOn-invasive Repeated THerapeutic STimulation for Aphasia Recovery|NOn-invasive Repeated THerapeutic STimulation for Aphasia Recovery|NORTHSTAR|Thiel, Alexander, M.D.|Yes|Recruiting|December 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|50 Years|85 Years|No|||May 2015|May 11, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02020421||53708|
NCT02020434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 504|The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency|A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|January 2014|October 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|March 10, 2015|December 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02020434||53707|
NCT02020447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROIVCARM-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2013|||||N/A|N/A|N/A||||||||||||||December 18, 2013|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020447||53706|
NCT02020109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11-05/06-extern-6295|Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia|Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia (CLL)||Maastricht Radiation Oncology|Yes|Recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic lymphatic leukaemia (CLL).|January 2016|February 9, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020109||53732|
NCT02020369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-FVIIa-006-13|A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX|A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX||rEVO Biologics|Yes|Completed|April 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|12 Years|75 Years|No|||September 2015|September 3, 2015|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02020369||53712|
NCT02019511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-0703|Safety Study of High-dose Methylprednisolone in Fast-track Total Knee Arthroplasty|Safety Aspects of High-Dose Methylprednisolone in Fast-track Total Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Active, not recruiting|October 2013|October 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|6000|||Both|18 Years|N/A|No|Probability Sample|Consecutive unselcted patients with unilateral elective total fast-track knee arthroplasty        in a standardized perioperative set-up and with completed prospective registration of        preoperative chartacteristics and co-morbidity|November 2015|November 26, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019511||53778|
NCT02019784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH14-183_RIFSYS_V4.0|Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy|A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy|RIFSYS|King's College Hospital NHS Trust|No|Recruiting|January 2015|April 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|75 Years|No|||December 2013|February 10, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019784||53757|
NCT02020083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI121204|Placental Transfer of Tenofovir|Study of Placental Transfer of Tenofovir and Its Factors of Variability Using the Human Placental Perfusion Model|TDF-PTP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2013|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Tissue samples will be collected. The expression levels of several efflux transporters      (ABCC2/MRP2, ABCC4/MRP4, ABCC10/MRP7) and an uptake transporter (hOAT3) will be determined      to explain the variability of placental transfer.|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women (at term >37 to 41 weeks of gestational age) without complications during        pregnancy|November 2015|November 19, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02020083||53734|
NCT02021591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM0057|Effectiveness Study of Interactive Web Application for Problem Solving in Diabetes Management|Randomized Clinical Trial of Health Information Technology for Problem Solving in Diabetes Management||Columbia University|Yes|Recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|65 Years|No|||February 2015|February 26, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02021591||53618|
NCT02025855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smoot_8503|Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit|Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit||Henry Ford Health System|No|Enrolling by invitation|January 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025855||53291|
NCT02021851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125|Prevention of Nausea and Vomiting in Patients After Surgery|THE EFFECT OF THE COMBINATION OF DEXAMETHASONE WITH ONDANSETRON VERSUS DEXAMETHASONE WITH APREPITANT TO PREVENT POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC SURGERY||Yeditepe University Hospital|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|60 Years|No|||December 2013|December 19, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02021851||53598|
NCT02025283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-402-13|Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy|The Comparison of the Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy: A Retrospective Review|RFNaTDD|Ankara University|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|73|||Both|35 Years|60 Years|No|Probability Sample|120 patients with lumbar radiculopathy undergoing nucleoplasty and targetted disc        decompression in Algology Department of a University Hospital between 2010 and 2012 were        retrospectively evaluated and complete data of only 73 patients were reached and they were        included to the study|December 2013|December 30, 2013|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025283||53335|
NCT02018562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086689|Evaluation of a Tracheostomy Tube That Enables Communication|Prospective Evaluation of a Tracheostomy Tube That Enables Communication in Ventilator Dependent Patients - A Pilot Study|BLUSA|Johns Hopkins University|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|100 Years|No|||January 2016|January 27, 2016|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018562||53851|
NCT02018549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD_01535BC1_01|An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI|An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler Dry Powder Inhaler (DPI) Device|PIF3|Chiesi Farmaceutici S.p.A.|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|72|||Both|40 Years|N/A|No|||July 2014|July 29, 2014|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02018549||53852|
NCT02018796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011|Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan|Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Kazakhstan: A Study of 600 µg Sublingual Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation||Gynuity Health Projects|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|290|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women seeking an abortion at participating study sites|August 2015|August 11, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02018796||53833|
NCT02019615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/201/B|tDCS in MCS: Repeated Stimulations|Repeated tDCS in Chronic Minimally Conscious State Patients : a Sham-controlled Randomized Double Blind Study|tDCS in MCS|University Hospital of Liege|Yes|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|75 Years|No|||October 2014|October 23, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019615||53770|
NCT02020460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036722|Clinical Evaluation of Direct Dorsal Column Stimulation|A Clinical Evaluation of Direct Dorsal Column Stimulation for the Management of Chronic, Medically Refractory Neuropathic Pain|DDCS|Duke University|No|Terminated|June 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|6|||Both|18 Years|75 Years|No|||August 2015|August 13, 2015|December 11, 2013|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT02020460||53705|
NCT02019303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00068472|Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer|Ultrasound Guided Core Needle Biopsy Versus Fine Needle Aspiration of Morphologically Abnormal Axillary Lymph Node in Patients With New Diagnosis or Suspected Diagnosis of Invasive Breast Carcinoma||University of Utah|Yes|Recruiting|February 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02019303||53794|
NCT02019576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-053|Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib|A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy||Sunnybrook Health Sciences Centre|No|Recruiting|May 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02019576||53773|
NCT02019589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXP13-01|A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea|A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhea|SPRY|TherapeuticsMD|No|Terminated|December 2013|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|6|||Female|18 Years|40 Years|No|||November 2014|November 19, 2014|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019589||53772|
NCT02019823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMSBP|Effectiveness of SMS-text Message Support for Patients With Hypertension to Improve Blood Pressure|SMS-text Adherence Support (StAR*) Study, a Randomized Three-arm Open Parallel Group Trial to Evaluate the Effects of a Structured Programme of Hypertension Treatment Adherence Support Delivered Remotely Through SMS-text Messages on Blood Pressure at 12 Months as Compared With Usual Care.|*StAR|University of Oxford|No|Completed|June 2012|August 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|1372|||Both|20 Years|N/A|No|||November 2014|November 10, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019823||53754|
NCT02021123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 13.06|Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)|Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery.|ADOPT|Radboud University|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02021123||53654|
NCT02021617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-14|Infusion Flow Rates and Blood Sampling|A Study Comparing Infusion Flow Rates Using the Proximal Humerus and Proximal Tibia Intraosseous Vascular Access Insertion Sites and Comparing Intraosseous and Venous Blood for Laboratory Specimen Sampling||Vidacare Corporation|No|Enrolling by invitation|November 2013|December 2013|Anticipated|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 19, 2013|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02021617||53616|
NCT02019810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003276-13|Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury||DEBITC|University Hospital, Grenoble|No|Recruiting|October 2014|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||August 2015|August 14, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019810||53755|
NCT02020122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0472-13-RMB.CTIL|Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles|||Rambam Health Care Campus|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02020122||53731|
NCT02020382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120903|Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases|Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Disease|MicroMICI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|300|||Both|5 Years|N/A|No|||November 2015|December 8, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02020382||53711|
NCT02020395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI peptides obese adolescents|Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents|Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents||University Hospital, Basel, Switzerland|No|Completed|June 2009|October 2013|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020395||53710|
NCT02020759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1557/2013|Neurological Monitoring During Extracorporeal Membrane Oxygenation|Multimodal Neurological Monitoring in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO) - a Prospective Observational Pilot Study.||Medical University of Vienna|No|Recruiting|December 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing ECMO therapy unter intensive care conditions|October 2015|October 5, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020759||53682|
NCT02020772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1232|Coordinating Teams in Primary Health Care.|Coordination Between General Practitioners and Physical Therapists in Primary Health Care for Musculoskeletal Pain: Effect on Sick Leave and Referral to Specialist Care.||Norwegian University of Science and Technology|No|Recruiting|December 2013|December 2021|Anticipated|August 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Anticipated|880|||Both|21 Years|58 Years|No|||November 2015|November 25, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020772||53681|
NCT02020720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1373|18F-DOPA-PET in Planning Surgery in Patients With Gliomas|Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas||Mayo Clinic|No|Recruiting|January 2014|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|7 Years|N/A|No|||January 2016|January 20, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020720||53685|
NCT02020733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20.12.13/160|Evaluation of Pain During Hysterosalpingography With The Use Of Balloon Catheter Versus Metal Cannula|||Etlik Zubeyde Hanim Womens' Health and Teaching Hospital||Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|194|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||December 2013|December 24, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020733||53684|
NCT02020746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW 2013-07-10|Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds|A Multicenter, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx||MediWound Ltd||Active, not recruiting|August 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020746||53683|
NCT02026856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Se-AOX 109/2011|Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis|Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis|Se-AOX|Pavol Jozef Safarik University|Yes|Completed|December 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|4|||Both|20 Years|80 Years|No|Probability Sample|Critically ill patients with APACHE II score between 19 and 24 points after admision with        sepsis, severe sepsis or septic shock during hospitalization as defined by the        International Sepsis Definitions Conference|December 2013|December 31, 2013|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026856||53215|
NCT02018588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580T|Tryptophan Requirement of Healthy School Age Children|Tryptophan Requirement of Healthy School Age Children Determined by the Indicator Amino Acid Oxidation Method||The Hospital for Sick Children|No|Suspended|December 2013|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|7|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||December 2014|May 29, 2015|December 17, 2013||No|Actively trying to recruit personnel to complete the study|No||https://clinicaltrials.gov/show/NCT02018588||53849|
NCT02017977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRB13069-GEL|Geographic Influences on Emergency Laparotomy Outcomes|Geographic Influences on Emergency Laparotomy Outcomes||University of Edinburgh|No|Completed|January 2001|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||9|Anticipated|40000|||Both|18 Years|N/A|No|Probability Sample|All Scottish adult residents undergoing emergency laparotomy during the study period|December 2013|December 16, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02017977||53896|
NCT02026102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3152|A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)|A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)||University of Colorado, Denver|No|Active, not recruiting|September 2014|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02026102||53272|
NCT02018289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0010|Effect of Triclosan-coated Suture on Superficial SSI|||Hospital General Universitario Elche||Completed|October 2007|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|N/A|N/A|No|||December 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018289||53872|
NCT02019628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090384|Enhanced Natural Killer Cell Activity and RBAC|Enhancement of Natural Killer Cell Activity in Healthy Adults by Rice Bran Arabinoxylan Compound, a Novel Oligosaccharide||University of Miami|No|Completed|November 2009|November 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 23, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019628||53769|
NCT02022111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064913|INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study|INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study|INDEPENDENT|Emory University|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|465|||Both|35 Years|N/A|No|||December 2015|December 15, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02022111||53578|
NCT02022423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG045136-01|Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease|Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease|PAD|University of Michigan|No|Recruiting|September 2014|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|200|||Both|40 Years|N/A|No|||October 2015|October 6, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02022423||53555|
NCT02019069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM0036|CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent||Stanford University||Recruiting|February 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|60 Years|N/A|No|||March 2016|March 8, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019069||53812|
NCT02019316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|BioSteel Supplementation and Performance|The Effect of BioSteel Sports Drink Supplementation on Muscular Fatigue, Cognitive Function, and Recovery Following Sprint Interval Exercise||University of Western Ontario, Canada|No|Not yet recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02019316||53793|
NCT02019602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0017|A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta|A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol)|CRIB|UCB Pharma|No|Recruiting|January 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019602||53771|
NCT02020473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0858|Informed Consents for Withholding/Withdrawing Life Support in Intensive Care Units|||Yonsei University|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|348|||Both|N/A|92 Years|No|Non-Probability Sample|patients who died from January 2012 to December 2012 in the surgical or medical Intensive        Care Unit (ICU)|December 2013|December 18, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020473||53704|
NCT02020486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-K082-047|A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects|A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects||Eisai Inc.|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2014|February 27, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02020486||53703|
NCT02020811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBALEV-1|Safety and Efficacy of Immages System in Patients Recieving IV Therapy|A Study to Assess the Functionality of Pro-IV's IMMAGES Infusion System in Patients Hospitalized in Bait Balev, Receiving Intravenous Therapy|IV|PRo-IV|No|Recruiting|November 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2013|December 19, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020811||53678|
NCT02021097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-ZQ-03RCT|Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception|A Multicenter, Randomized, Open-labe, Controlled Study to Evaluate the Efficacy and Safety of the Combined Levonorgestrel(LNG) 100mcg and Ethinyl Estradiol(EE) 20mcg for Oral Contraception||Regenex Pharmaceutical, China|No|Recruiting|February 2012|February 2016|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1008|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02021097||53656|
NCT02017795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02666|Asthma Self-management Via Application of Telehealth|Managing Asthma With Tele-health Technology: A Feasibility Study|asthma|University of British Columbia|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|19 Years|85 Years|No|||April 2015|April 15, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02017795||53910|
NCT02021929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819185|Sorafenib for Hepatopulmonary Syndrome|Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial|SHPS|University of Pennsylvania|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||March 2016|March 8, 2016|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021929||53592|
NCT02021942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230CIC01T|Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size|Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size||University of Regensburg||Active, not recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021942||53591|
NCT02021383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207S16661|Lose 2 Win A Novel Method to Motivate Weight Loss Maintenance Among College Students|"Lose 2 Win" Contests: A Novel Method to Motivate Weight Loss Maintenance Among College Students|L2W|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|144|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021383||53634|
NCT02021396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 02|Benefit of Prophylactic Embolization of the Splenic Salvage|Benefit of Prophylactic Embolization of the Splenic Salvage in Trauma Patients at High Risk of Splenectomy.|Splash|University Hospital, Grenoble|Yes|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|74 Years|No|||June 2014|June 23, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02021396||53633|
NCT02030119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819149|Way to Be Active III (Framing Incentives)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing Incentives||University of Pennsylvania|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|281|||Both|18 Years|100 Years|No|||January 2016|January 21, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02030119||52964|
NCT02030132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819370|Way to Be Active V (Framing vs. Forgiveness)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing vs. Forgiveness||University of Pennsylvania|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|288|||Both|18 Years|100 Years|No|||January 2016|January 21, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02030132||52963|
NCT02020408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090661|Monoamine Contributions to Neurocircuitry in Eating Disorders|Monoamine Contributions to Neurocircuitry in Eating Disorders||University of California, San Diego|Yes|Recruiting|May 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020408||53709|
NCT02026609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#135318|Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)||University of Arkansas|Yes|Terminated|May 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples With DNA|Serum, plasma, and PBMCs|Both|18 Years|75 Years|No|Probability Sample|Consecutive patients will be recruited from the Gastroenterology / Hepatology Clinics at        UAMS and other participating centers. Those fulfilling inclusion/exclusion criteria will        be invited to participate.|January 2015|January 27, 2015|December 26, 2013||No|Lack of patient accrual|No||https://clinicaltrials.gov/show/NCT02026609||53234|
NCT02021058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.10.INF|Study in Unsettled Infants Experiencing Feeding Intolerance|Effect of an Experimental Infant Formula in Unsettled Infants Experiencing Feeding Intolerance||Nestlé|No|Active, not recruiting|December 2013|September 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|N/A|90 Days|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021058||53659|
NCT02021071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCY612-130031|Virtual Path Planning for Image-guided Needle Interventions|Evaluation of Adding Virtual Path Planning to the Philips FD20 XperGuide to Reduce Radiation Dose During Image-guided Needle Interventional Procedures.||Philips Healthcare|No|Enrolling by invitation|December 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Probability Sample|Patients of all ages. Patient weight is limited to the specification of the patient table.|February 2015|February 6, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02021071||53658|
NCT02018822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|765-552|Evaluate the Effectiveness of an Experimental Urethane Dimethacrylate Resin Based Dental Composite Material|Clinical Evaluation of an Experimental Urethane Dimethacrylate Resin Based Composite||University of Rochester|No|Active, not recruiting|June 2013|October 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018822||53831|
NCT02019082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|د 50/259|Electrical Stimulation and Expression of VEGF and NO in Diabetic Foot Ulcer|The Effect of Low-intensity Direct Current on the Expression of Vascular Endothelial Growth Factor and Nitric Oxide in Diabetic Foot Ulcers||Tarbiat Modarres University|Yes|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 23, 2013|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02019082||53811|
NCT02018302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 082013-016|Post Study Continuation of C7 for G1D|Post Study Continuation of C7 for G1D||University of Texas Southwestern Medical Center|No|Available|January 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|1 Month|28 Years|No|||December 2013|December 26, 2013|December 11, 2013|No|Yes||||https://clinicaltrials.gov/show/NCT02018302||53871|
NCT02019329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29188|A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone|A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE.||Hoffmann-La Roche||Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|60 Years|No|||February 2016|February 1, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019329||53792|
NCT02019095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309-27-11-2013|Clinical and Biological Markers in Acute Respiratory Failure|Clinical and Biological Markers in Ventilator-associated Pneumonia and the Acute Respiratory Distress Syndrome||University of Athens|Yes|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|Bronchoalveolar Lavage Fluid|Both|18 Years|75 Years|No|Non-Probability Sample|Intensive care unit patients with acute respiratory failure due to ventilator-associated        pneumonia or the acute respiratory distress syndrome.|February 2015|February 1, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02019095||53810|
NCT02018809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819129-A|Social Forces to Improve Statin Adherence (Study A)|Using Social Support To Improve Medication Adherence In Statin Users With Diabetes||University of Pennsylvania|No|Completed|January 2014|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|N/A|No|||December 2014|June 9, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018809||53832|
NCT02019836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10000|Comparison of Maternal and Neonatal Vitamin D Levels in Term Neonates With and Without Early Onset Sepsis|||Kanuni Sultan Suleyman Training and Research Hospital|Yes|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|N/A|72 Hours|Accepts Healthy Volunteers|Probability Sample|Infants admitted to neonatal care unit with the diagnosis of high probable sepsis will        constitute the sepsis group, whereas infants admitted to outpatient clinic without        findings of sepsis will constitute the control group|December 2013|December 26, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019836|1 Year|53753|
NCT02019888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1268-R|Comprehensive Wide Bandwidth Test Battery of Auditory Function in Veterans|Comprehensive Wide Bandwidth Test Battery of Auditory Function in Veterans|CWTBAFV|VA Office of Research and Development|No|Enrolling by invitation|December 2014|January 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|640|||Both|20 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited for this study who have had a hearing evaluation from the VA        Audiology Service at the Portland VA Medical Center and the H. Quillen VA Medical Center.|November 2015|November 18, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019888||53749|
NCT02020148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00082402|Can Oxytocin Level Predict Postpartum Depression?|Can Prenatal Plasma Oxytocin Concentration Predict Likelihood of Postpartum Depression? An Opportunity for Early Intervention and Prevention in a Vulnerable Population||Northwestern University|No|Active, not recruiting|December 2013|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|A 3 milliliter (about half a teaspoon) blood sample will be obtained to measure oxytocin      level.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy Pregnant Women|July 2015|July 29, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020148||53729|
NCT02020161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA LPA2012|Clinical Guidelines for APL Treatment|||PETHEMA Foundation|No|Recruiting|June 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||September 2015|September 16, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02020161||53728|
NCT02020174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Preeclampsia Registry|The Preeclampsia Registry|TPR|Preeclampsia Foundation|Yes|Recruiting|July 2013|May 2023|Anticipated|May 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||1|Anticipated|20000|None Retained|Biospecimens are not currently being collected, however, participants are asked for their      permission to be contacted about providing a biospecimen in the future. It is not certain      yet what type of biospecimen may be collected.|Female|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who self-report a medical diagnosis of preeclampsia or related hypertensive        disorders of pregnancy (HDP), their family members, and women who have never had a        diagnosis of preeclampsia (controls) will be invited to participate in this registry. Data        will be collected on family members (including children) as reported by the participating        individual. Minors who have been affected by preeclampsia, such as teens, will be allowed        to participate with consent provided by a parent or guardian as well as assent given by        the minor. The registry and informed consent may be completed by an authorized        representative on behalf of a woman with a history of preeclampsia if she is physically or        mentally disabled or is deceased.|October 2015|October 22, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02020174|20 Years|53727|
NCT02020499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9B-52030-265|Predictive Factors Study|Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.|TAPAS|Ipsen|No|Terminated|August 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects in hospitals and private practices, suffering from acromegaly who are        scheduled to receive ATG or already on treatment with ATG for a maximum of 3 months.|September 2015|September 29, 2015|December 19, 2013||No|Poor enrolment|No||https://clinicaltrials.gov/show/NCT02020499||53702|
NCT02020824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRLSTRESS|Virtual Reality and Concept of Control in the Treatment of Acrophobia|Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test|CTRLSTRESS|Qualissima|No|Recruiting|April 2014|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020824||53677|
NCT02017821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/639|The Effect of Aerobic Endurance Training in Patients With Drug Addiction|The Effect of Aerobic Endurance Training in Patients With Drug Addiction||Norwegian University of Science and Technology|No|Completed|August 2012|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|No|||August 2014|August 12, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017821||53908|
NCT02025959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1766|Sleep for Inpatients: Empowering Staff to Act|Sleep for Inpatients: Empowering Staff to Act|SIESTA|University of Chicago|No|Recruiting|August 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02025959||53283|
NCT02021409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15261|Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934|A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific|DIALOGUE 2|Bayer|Yes|Completed|January 2014|November 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|126|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021409||53632|
NCT02029924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT006|A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes||Adocia|No|Completed|December 2013|August 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|64 Years|No|||September 2014|September 1, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02029924||52979|
NCT02026323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSAir|The Effect of Acupuncture on Insulin Sensitivity Polycystic Ovary Syndrome|Effect of Acupuncture on Insulin Sensitivity in Women With Polycystic Ovary Syndrome and Insulin Resistance: Study Protocol of a Prospective Observational Study||The First Affiliated Hospital of Guangzhou Medical University|Yes|Enrolling by invitation|January 2014|May 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|49 Years|No|||September 2014|September 5, 2014|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026323||53255|
NCT02026336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/122/1161|E-nose and Inflammatory Asthma Phenotypes|Inflammatory Asthma Phenotypes Discrimination by an Electronic Nose Breath Analyzer||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|52|||Both|18 Years|80 Years|No|||December 2013|December 31, 2013|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02026336||53254|
NCT02026349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T705US316|Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316)||MDVI, LLC|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|860|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026349||53253|
NCT02026843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH2013-1|Analysis of Angiogenic Factor Levels in Eyes With Diabetic Retinopathy|Analysis of Angiogenic Protein and Anti-angiogenic Levels in Eyes With Diabetic Retinopathy.||Kyungpook National University|Yes|Recruiting|April 2012|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|certain protein levels in aqueus humor|Both|20 Years|80 Years|No|Non-Probability Sample|A total of 100 patients will be included. 50 patients with diabetic retinopathy scheduled        for intravitreal bevacizumab injection or phacoemulsification and 50 control patients        scheduled for pars plana vitrectomy for nondiabetic retinal disease or        phacoemulsification.|March 2015|March 30, 2015|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02026843||53216|
NCT02018328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc137511|The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection|The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection|CurHP|Rabin Medical Center|No|Not yet recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 13, 2014|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018328||53869|
NCT02018601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProsMaMa 13.1|Intercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block for no Reconstructive Breast Surgery|Intercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block, Ultrasound Guided Blocks for no Reconstructive Breast Surgery. Randomized Trial||Complexo Hospitalario Universitario de A Coruña|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|75 Years|No|||January 2016|January 29, 2016|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018601||53848|
NCT02018835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01093-40|Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study.|Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study.||Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2012|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT02018835||53830|
NCT02019901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GotNet 2014 SU|GotNet Study, The Gothenburg Nurse-led Tight Control Study|A Randomized, Controlled Study Evaluating the Efficacy of Person-centered, Tight Control Nurse-led Clinic of Patients With Established Rheumatoid Arthritis and Moderate to High Disease Activity Compared to Patients Receiving Regular Care||Vastra Gotaland Region|No|Active, not recruiting|January 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019901||53748|
NCT02019342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102154|Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)|Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study|MAP-ALIVE|Washington University School of Medicine|No|Withdrawn|June 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing surgery at Barnes-Jewish Hospital or the University of Michigan|February 2015|February 12, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT02019342||53791|
NCT02019355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303070|Actinic Keratosis Study|The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions|AK|Washington University School of Medicine|Yes|Recruiting|October 2013|||November 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|50 Years|N/A|No|||December 2013|December 17, 2013|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019355||53790|
NCT02019849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1213|Post Market Clinical Follow-Up of Plasmafit® Cup|||Aesculap AG|No|Active, not recruiting|January 2012|June 2023|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Specialist Clinical Centre|January 2016|January 14, 2016|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02019849||53752|
NCT02019862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1314|TRJ Post Market Clinical Follow Up|TRJ PMCF Köln: 2-years Results||Aesculap AG|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|specialist clinical centre|April 2015|April 15, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02019862||53751|
NCT02019875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47115-D|CYP3A4 Induction and Mineral Homeostasis|Hormonal Regulation of CYP3A||University of Washington|No|Recruiting|June 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019875||53750|
NCT02020863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES03|Closed-Loop Fluid Administration System Using Hemodynamic Monitors|Closed-Loop Fluid Administration System Using Hemodynamic Monitors||University of California, Irvine|Yes|Completed|November 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020863||53674|
NCT02020187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2-2013-066|Aerobic Training in Patients With Congenital Myopathies|Aerobic Training in Patients With Congenital Myopathies||Rigshospitalet, Denmark|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|75 Years|No|||May 2015|May 11, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02020187||53726|
NCT02020512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-BIM-1102|A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension||LOTUSDI|Allergan|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|N/A|N/A|No|||June 2014|June 24, 2014|December 19, 2013|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT02020512||53701|
NCT02020525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSF-CYTOK|Blood Transfusions and Immune Response|The Impact of Lowering Transfusion Trigger on Patient Immune Response During Major Abdominal Surgery||Aretaieion University Hospital|Yes|Completed|December 2004|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|58|||Both|18 Years|80 Years|No|||August 2014|August 16, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02020525||53700|
NCT02020837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202676|A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema|A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema||University of Arkansas|Yes|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|70 Years|No|||January 2016|January 4, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020837||53676|
NCT02020850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03144|Young Toe-Brachial Index Assessment|Determining the Normal Toe-Brachial Index in Young Adults|TBI|University of British Columbia|No|Recruiting|February 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the classes of Faculty of Medicine in the University        of British Columbia|July 2014|July 2, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020850||53675|
NCT02026232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110258|Metabolic Effects of Hydroxychloroquine|Metabolic Effects of Hydroxychloroquine|MetaHcQ|Washington University School of Medicine|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02026232||53262|
NCT02022267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK10-218-1210|Gait Analysis in Ponseti Clubfoot|Results of Gait Analysis Including Oxford Foot Model in Children With Clubfoot Treated With the Ponseti Method||Orthopedic Hospital Vienna Speising|No|Completed|October 2011|September 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|51|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a minimum age of three years from a prospective, consecutive database of        patients with clubfoot treated with the Ponseti method beginning in 2002|December 2013|December 20, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02022267||53566|
NCT02030171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49RC08_0014|Effect of Three Therapeutics Strategies on Patients With a Chronic Back Pain (PLURICLEF).|Effect of Three Therapeutic Strategies on the Restriction of the Participation of Patients With a Chronic Back Pain : Multidisciplinary is it the Key Component ?|PLURICLEF|University Hospital, Angers|No|Active, not recruiting|April 2009|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|55 Years|No|||January 2014|January 6, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02030171||52960|
NCT02026362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYZ Cell Therapy Co..|Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).|Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens|HCC DC CTL|SYZ Cell Therapy Co..|No|Active, not recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|70 Years|No|||November 2015|November 18, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02026362||53252|
NCT02030145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOA Grant #06-04-545|Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease|Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease||A.T. Still University of Health Sciences|No|Withdrawn|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2011|January 7, 2014|July 22, 2011||No|PI relocated|No||https://clinicaltrials.gov/show/NCT02030145||52962|
NCT02026635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.296|Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)|Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in Heart Failure Patients (CONFIRM-HF)|CONFIRM-HF|Thomas Jefferson University|No|Withdrawn|September 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|hospital inpatients|February 2015|February 4, 2015|December 16, 2013||No|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT02026635||53232|
NCT02026622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 2012 - TD / EMPHILINE|Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion|Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion|EMPHILINE|University Hospital, Tours|No|Completed|February 2013|August 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|76|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02026622||53233|
NCT02018848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU-ATP-OCD-2013|Internet-delivered Attention Training for Obsessive-Compulsive Disorder|Internet-delivered Attention Training for Obsessive-Compulsive Disorder||Humboldt-Universität zu Berlin||Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||November 2014|November 11, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02018848||53829|
NCT02018861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 50465-101|A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies|A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies||Incyte Corporation|No|Recruiting|March 2015|January 2019|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|312|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018861||53828|
NCT02019147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM0113UCC|BiHiVE2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.|BiHiVE 2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.|BiHiVE2|University College Cork|Yes|Active, not recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|500|Samples With DNA|Umbilical cord blood|Both|N/A|1 Hour|Accepts Healthy Volunteers|Non-Probability Sample|Term Neonates born in hospital|November 2015|November 16, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02019147||53806|
NCT02019108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02688|Gait Modification Treatment for Knee Osteoarthritis|Effects of Toe-out Gait Modification on Clinical and Biomechanical Measures in People With Knee Osteoarthritis||University of British Columbia|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|No|||December 2015|December 2, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02019108||53809|
NCT02019121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|521455|Dexmedetomidine and Renal Transplants|Dexmedetomidine and Renal Transplants||University of California, Davis|No|Active, not recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Renal transplant patients|December 2014|December 3, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02019121||53808|
NCT02019368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-843|Antioxidant Effect of Aged Garlic Extract|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Antioxidant Effect of Aged Garlic Extract in Heavy Smokers||Hiroshima University|No|Completed|November 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019368||53789|
NCT02019654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140032|An Investigation of the Biological and Neuronal Mechanisms of Post Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury|An Investigation of the Biological and Neuronal Mechanisms of Post-Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 19, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02019654||53767|
NCT02019394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14915A|Absolute Bioavailability of Lu AE58054 in Healthy Subjects|Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects||H. Lundbeck A/S|No|Completed|December 2013|||February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019394||53787|
NCT02020200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0021-12-SHA|The Effect of Methylphenidate on Cognitive Abilities of Adults With Bipolar Disorder|A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With Attention Deficit Hyperactivity Disorder (ADHD).||Shalvata Mental Health Center||Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|21 Years|50 Years|No|||December 2013|December 23, 2013|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02020200||53725|
NCT02019641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140027|The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease|The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|July 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|80 Years|No|||August 2015|November 25, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02019641||53768|
NCT02020564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-755-12|Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment|Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment: A Randomized Clinical Trial||Kessler Foundation|No|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|59 Years|No|||November 2014|November 21, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020564||53697|
NCT02020577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.122|Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours|A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours||Boehringer Ingelheim||Active, not recruiting|December 2013|May 2016|Anticipated|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 19, 2013||||No|January 14, 2016|https://clinicaltrials.gov/show/NCT02020577||53696|The data presented is based on a cut-off date of 18Nov15
NCT02021136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00613-42|Efficacy and Safety of Rebel Reliever Brace in Internal Femoral and Tibial Knee Osteoarthritis|Efficacy and Safety of Rebel Reliever Brace in Internal Femoral and Tibial Knee Osteoarthritis. Phase 3, Multicenters, Randomised and Controlled Study With 2 Parallel Groups.|ROTOR|Thuasne|Yes|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02021136||53653|
NCT02021149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0614|Enhancing Psychotherapy for Mood Disorders With Whole Body Hyperthermia|||University of Arizona|No|Terminated|July 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|November 26, 2013||No|Investigator transferred to the University of Wisconsin - Madison|No||https://clinicaltrials.gov/show/NCT02021149||53652|
NCT02021422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-018|A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy|A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients||Baylor Research Institute|Yes|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021422||53631|
NCT02021435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BAI05B04|Tibet Salt Reduction Study|Using Salt Substitute to Reduce Population Blood Pressure in Tibet: Tibet Salt Reduction Study||Beijing Jishuitan Hospital|Yes|Not yet recruiting|April 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4500|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 8, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021435||53630|
NCT02021656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0131|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|No|Active, not recruiting|December 2013|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|20 Years|N/A|No|||October 2015|October 26, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021656||53613|
NCT02021903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120008|Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies|Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies: the Model of an Oral Glucose Load|HYPOSOMNPARK|University Hospital, Toulouse|No|Recruiting|May 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|24|||Both|35 Years|85 Years|No|||March 2016|March 11, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021903||53594|
NCT02021916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397.05|Louisville Cooperative Tissue Biorepository|Louisville Cooperative Tissue Biorepository of the James Graham Brown Cancer Center Tissue Collection Consent|LCTB|University of Louisville|Yes|Recruiting|July 2005|||January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|Collection of normal or abnormal tissue at the time of surgery from consented subjects.      Collection of blood and urine the day of consent or day of surgery.|Both|7 Years|N/A|No|Probability Sample|Patients undergoing surgery for removal of normal or abnormal tissues that are removed        from the human body as part of standard medical and surgical practice at the University of        Louisville Hospital, Norton Hospital downtown, Jewish Hospital downtown and Kosair        Children's Hospital.|December 2013|December 20, 2013|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021916||53593|
NCT02030184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1401|Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas|Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan||New Mexico Cancer Care Alliance|Yes|Withdrawn|April 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|January 6, 2014|Yes|Yes|PI has left the study institution.|No||https://clinicaltrials.gov/show/NCT02030184||52959|
NCT02026388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005413|Rare Kidney Stone Consortium Biobank|Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network||Mayo Clinic|Yes|Recruiting|May 2013|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|400|Samples With DNA|Urine, blood and tissue samples|Both|N/A|N/A|No|Non-Probability Sample|Individuals with a confirmed Diagnosis of Primary Hyperoxaluria, Dent Disease, APRT        deficiency or Cystinuria. Family members of individuals with these four diseases.|November 2015|November 30, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026388||53251|
NCT02026401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0103|Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis||NGM Biopharmaceuticals, Inc|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|75 Years|No|||December 2014|December 31, 2014|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026401||53250|
NCT02026648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102159-E|Outcome of Women With Cervical Cancer|||Far Eastern Memorial Hospital||Recruiting|January 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|20 Years|99 Years|No|Non-Probability Sample|the cases with cervical cancer|February 2016|February 22, 2016|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02026648||53231|
NCT02026869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vaginal Metformin- Ahmed Nasr|Vaginal Administration of Metformin in PCOS Patients.|Impact of Vaginal Administration of Metformin in Women With PCOS.|VMPCO|Assiut University|No|Active, not recruiting|January 2013|February 2014|Anticipated|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|35 Years|No|||January 2014|January 2, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026869||53214|
NCT02018887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15259|A Study of LY2969822 in Healthy Participants|A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|106|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018887||53826|
NCT02019381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13005|Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.|The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.||Winthrop University Hospital|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|132|||Female|50 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019381||53788|
NCT02019407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0639|Prospective Randomized Study on Clinical Effectiveness of Carvo-Tricuspid Isthmus Block in Patients With Paroxysmal Atrial Fibrillation|||Yonsei University|No|Recruiting|December 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||July 2014|July 13, 2014|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02019407||53786|
NCT02019667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140033|Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency|Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|22|||Both|8 Years|N/A|No|||October 2015|December 17, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019667||53766|
NCT02019914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H130095|Effects of CPAP Therapy on PTSD Symptoms|Effects of Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea on PTSD Symptoms||Veterans Medical Research Foundation|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|Veterans with confirmed diagnoses of PTSD and OSA who are willing to try CPAP therapy.|December 2015|December 10, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019914||53747|
NCT02020538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382/13|Limiting IV Chloride to Reduce AKI After Cardiac Surgery|Does Varying the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?|LICRA|Bayside Health|No|Recruiting|February 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020538||53699|
NCT02020551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kerhGA|Lidocaine 10% Spray Reduces Pain During Intrauterine Device Insertion|||Kayseri Education and Research Hospital|No|Completed|May 2013|||August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|223|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2013|December 24, 2013|December 11, 2013||||No||https://clinicaltrials.gov/show/NCT02020551||53698|
NCT02020889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115921|A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis|A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy||GlaxoSmithKline|Yes|Active, not recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020889||53672|
NCT02020902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200638|Contac Bien Z Adverse Effect Survey|Contac Bien Z Adverse Effect Survey||GlaxoSmithKline|No|Recruiting|March 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Both|15 Years|65 Years|No|Probability Sample|Participants who purchase the marketed cetrizine hydrochloride formulation from pharmacy        stores in Japan.|March 2015|March 12, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020902||53671|
NCT02020915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sphincterotomy MSOE|Ultrasound Guided Lateral Sphincterotomy: Long Term Results|Ultrasound Guided Lateral Sphincterotomy: Long Term Results||Hvidovre University Hospital|No|Recruiting|October 2007|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|28|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing lateral sphincterotomy for chronic anal fissure|March 2015|March 19, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020915||53670|
NCT02020876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU001|Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations|GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?|DECIDE|GenomeDx Biosciences Corp|No|Completed|August 2012|December 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|21|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is an exploratory study utilizing archived tumor specimens and demographic and        pathologic characteristics derived from the patient's medical charts. The study        participants are the urologists who review the selected case files.|December 2013|December 19, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02020876||53673|
NCT02021162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gilenya-thalamus|Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis|Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.|GLT|University at Buffalo|No|Active, not recruiting|November 2013|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples With DNA|Whole blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 relapsing MS patients naïve to Gilenya who fulfill the inclusion and exclusion criteria        used for screening and start Gilenya, on a clinical basis will be enrolled in the study.        In addition, 20 healthy controls will be included as a reference population. The plan is        to recruit the 50 subjects (30 relapsing MS and 20 healthy controls) at a single center.|February 2016|February 11, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021162||53651|
NCT02021448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5059|Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -|Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -||University Hospital, Strasbourg, France|No|Recruiting|December 2013|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|350|||Both|18 Years|65 Years|No|||December 2013|December 19, 2013|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02021448||53629|
NCT02021669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309002|Omega-3 for Depression and Other Cardiac Risk Factors - 2|Omega-3 for Depression and Other Cardiac Risk Factors-2|Omega-3(2)|Washington University School of Medicine|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|75 Years|No|||March 2016|March 3, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021669||53612|
NCT02021682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|In Vivo metabolism of ABeta|CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease|CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.||Washington University School of Medicine|Yes|Enrolling by invitation|December 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples Without DNA|Plasma and cerebro spinal fluid|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults from the Alzheimer's Disease Research Center and Memory and Aging Project at        Washington University.|June 2015|June 23, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021682||53611|
NCT02023411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABAR-1072013|Efficacy of Teriparatide in Diabetic Inactive Charcot's Neuroarthropathy of Foot.|To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus.||Postgraduate Institute of Medical Education and Research|Yes|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||December 2013|December 23, 2013|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023411||53479|
NCT02023424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9855-BBZ-CTIL|An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome|An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate (Copaxone ®) on Girls Woth Rett Syndrome||Sheba Medical Center|Yes|Recruiting|January 2014|February 2015|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|6 Years|15 Years|No|||February 2014|February 3, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023424||53478|
NCT02017834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCENT005|Does the Harmonic Scalpel Reduce Blood Loss and OR Time in Major Head and Neck Cancer Surgery Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma?|Does the Harmonic Scalpel Reduce Operating Time and Blood Loss in Patients Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma? A Prospective, Randomized Trial.|HS2|University of Calgary|No|Completed|February 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||December 2013|December 1, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT02017834||53907|
NCT02018081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 150 02|Pharmacokinetics of Levofloxacin in Intensive Care Unit|Population Pharmacokinetics of Levofloxacin in Intensive Care Patients With Severe Community-acquired Pneumonia.|LEVO-PHARM|University Hospital, Toulouse|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02018081||53888|
NCT02026427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06101968-1|Urinary Retention in Orthopedic Patients|The Incidence of Urinary Retention in Orthopedic Patients Under Spinal Anesthesia|UriRet|Military Institute of Medicine, Poland|No|Completed|August 2010|August 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|40 Years|No|Probability Sample|Patients scheduled for orthopedic surgery under spinal anesthesia.|August 2014|August 6, 2014|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026427||53248|
NCT02026414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131230|Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)|Effects of PrimaVie and Exercise Training on Human Skeletal Muscle Adaptation||Natreon, Inc.|No|Active, not recruiting|January 2014|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02026414||53249|
NCT02026895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5616|Virulence of Staphylococcus Lugdunensis in Severe Infections|Virulence of Staphylococcus Lugdunensis in Severe Infections|VISLISI|University Hospital, Strasbourg, France|Yes|Completed|December 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|82|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02026895||53212|
NCT02026882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-11|Supreme LMA Use in Urgent Caesarean Section|Supreme Laryngeal Mask Use in Urgent Caesarean Section||QuanZhou Women and Children's Hospital|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Female|18 Years|50 Years|No|||December 2013|December 31, 2013|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026882||53213|
NCT02027155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR09.001|Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09|A Phase I, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects||Arbor Pharmaceuticals, Inc.|Yes|Terminated|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|March 14, 2016|December 29, 2013|No|Yes|Study stopping criteria was met|No||https://clinicaltrials.gov/show/NCT02027155||53192|
NCT02023385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTL-9000 LLLT|BTL-9000 Low Level Laser Therapy for the Waist Circumferential Reduction|Evaluation of the BTL-9000 Low Level Laser Therapy for the Waist Circumferential Reduction||BTL Industries Ltd.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|September 17, 2014|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023385||53481|
NCT02019160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chuch14|Effectiveness of Dental Caries Arrest Treatment in Primary Teeth Using AgNO3 Followed by NaF Varnish|Effectiveness of Biannual Application of Silver Nitrate Solution Followed by Sodium Fluoride Varnish in Arresting Early Childhood Caries in Preschool Children: a 30-month, Randomised, Double-blind, Non-inferiority Trial||The University of Hong Kong|No|Recruiting|September 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2360|||Both|3 Years|5 Years|No|||December 2015|December 1, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02019160||53805|
NCT02019173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:403|Rehabilitation Boot Camp: Intensive Balance and Mobility Therapy for People With Acquired Brain Injury|Rehabilitation Boot Camp: an Innovative, Four-Week Program to Deliver Intensive Balance and Mobility Therapy to People With Acquired Brain Injury (ABI)||University of Manitoba|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|No|||December 2013|March 19, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02019173||53804|
NCT02023918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI178028|Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes|Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes|PEGIR|University of California, San Francisco|No|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|December 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023918||53440|
NCT02019927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-232|Electric Stimulation of the Eye to Improve Vision After Trauma|Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma|TES|Wills Eye|Yes|Recruiting|July 2013|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019927||53746|
NCT02020226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-414|A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors|A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors||Threshold Pharmaceuticals|No|Recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020226||53723|
NCT02020213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF13263|Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection.|Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment|Posaconazole|Taichung Veterans General Hospital|No|Withdrawn|December 2013|||December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|65 Years|No|||December 2013|December 11, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02020213||53724|
NCT02024932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBVS857X2202|Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy|A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)||Novartis|Yes|Recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|38|||Male|18 Years|N/A|No|||March 2016|March 20, 2016|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024932||53362|
NCT02021175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60MD006923|Korean Youth Smoking Cessation Study|Adaptation and Development of a Web and Cell Phone Quit Smoking Treatment for Korean Youth||University of California, Los Angeles|Yes|Not yet recruiting|June 2016|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|14 Years|19 Years|No|||December 2015|December 1, 2015|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02021175||53650|
NCT02021461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-212|Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours|Double-blind Study in Paediatric Epileptic Subjects Aged From 5 to Less Than 8 Years to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours||Bial - Portela C S.A.|No|Completed|December 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|38|||Both|5 Years|8 Years|No|||February 2014|February 24, 2014|December 20, 2013||No||No|January 9, 2014|https://clinicaltrials.gov/show/NCT02021461||53628|
NCT02021695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00023 [JIRB]|DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes|DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes||Weill Medical College of Cornell University|Yes|Recruiting|September 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood|Both|30 Years|N/A|No|Non-Probability Sample|Subjects will be recruited for the study at Hamad Medical Corporation. Most of the        subjects will belong to the outpatients clinics. However, the subjects with bad Diabetes        control might be recruited from the inpatient clinic as well.|December 2015|December 18, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021695||53610|
NCT02023437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304_3M|Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery|A Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery||Technolas Perfect Vision GmbH|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|40 Years|N/A|No|||May 2014|May 22, 2014|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023437||53477|
NCT02023450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPI-PAH-0|Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension|||The Third Xiangya Hospital of Central South University|Yes|Recruiting|December 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||September 2014|September 4, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023450||53476|
NCT02026219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUH-IRB-13-2256|Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction|Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)||Inha University Hospital|Yes|Completed|October 2013|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|80 Years|No|||September 2015|September 30, 2015|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02026219||53263|
NCT02022280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23848|Effect of Proton Pump Inhibitors on Endothelial Function|Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.|PPI|Stanford University||Recruiting|March 2013|||May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022280||53565|
NCT02026687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Speed|Recovery and Analgesia After Surgery for Gynecological Cancer|Will Intrathecal Analgesia Contribute to a Faster Recovery Compared With Epidural Analgesia After Open Surgery for Gynecological Cancer. An Open Controlled Randomized Study.|Speed|University Hospital, Linkoeping|Yes|Recruiting|March 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||December 2015|December 1, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02026687||53228|
NCT02026661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102160-E|Effectiveness of Intracytoplasmic Sperm Injection and Laser Assisted Hatching on in Vitro Fertilization Outcomes of Patients With Different Causes of Infertility|||Far Eastern Memorial Hospital||Completed|January 2014|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|375|||Female|20 Years|N/A|No|Non-Probability Sample|the patients with different causes of infertility|July 2015|July 4, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02026661||53230|
NCT02026674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLO-ISR-01|Reliability of Home Uroflowmetery Using a Disposable Digital Device|Reliability of Home Uroflowmetery Using a Disposable Digital Device in Comparison to Standard Clinical Uroflowmetry in Men With LUTS||Flometrica Ltd.|No|Recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|65 Years|No|||January 2014|January 13, 2014|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02026674||53229|
NCT02027168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSH-2012-001|Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women|Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women||Clear Passage Therapies, Inc|No|Terminated|February 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Female|18 Years|50 Years|No|Non-Probability Sample|Women with elevated FSH levels that undergo the CPA treatment|January 2015|January 22, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027168||53191|
NCT02027376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2012-12|Study With LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients|A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients "EDALINE"|EDALINE|Spanish Breast Cancer Research Group|No|Active, not recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02027376||53175|
NCT02023398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTL-9000 HFT|BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction|Evaluation of the Effectiveness of the BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction||BTL Industries Ltd.|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023398||53480|
NCT02023658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44167-EG|Systems Analysis and Improvement to Optimize pMTCT|Systems Analysis and Improvement to Optimize pMTCT: A Cluster Randomized Trial||University of Washington|No|Not yet recruiting|January 2014|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|12|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 23, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02023658||53460|
NCT02023931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-079|Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa|Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa|BSE|University of Pittsburgh|Yes|Completed|March 2014|January 2015|Actual|April 2014|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|January 14, 2016|December 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023931||53439|
NCT02024230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWRAPS|Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation||REWRAPS|Fujita Health University||Recruiting|May 2014|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|20 Years|N/A|No|||March 2015|March 17, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02024230||53416|
NCT02024464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-10-002|Compare the Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Having Cataract Surgery (Hydrus III)|A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery|Hydrus III|Ivantis, Inc.|No|Recruiting|August 2011|January 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||December 2013|December 27, 2013|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02024464||53398|
NCT02020590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLOB-DU1|Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures|A Pilot Phase 1/2a, Multicentre, Open Proof-of-concept Study on the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Non-infected Delayed-Union Fractures||Bone Therapeutics S.A|Yes|Recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|70 Years|No|||December 2013|December 19, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020590||53695|
NCT02024945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-9999-401-BE|Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome|Evaluation of Health-Related Quality of Life in Patients With Overactive Bladder Syndrome (OAB) Treated With Propiverine, and Its Efficacy and Tolerance in Daily Practice in Belgian General Practitioners and Urologists||Takeda|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|437|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with OAB symptoms, who the treating physician decided to treat with propiverine,        were to be included by General Practitioners (GP) and urologists in private practice in        Belgium.|December 2013|December 28, 2013|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02024945||53361|
NCT02025153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/512/D|Comprehensive Pain Programme to Determine Mechanism of Transition of Acute to Chronic Postsurgical Pain|Comprehensive Pain Programme to Determine Mechanism of Transition of Acute to Chronic Postsurgical Pain- Functional Brain Imaging, Quantitative Sensory Testing, Psychological and Genetic Screening: Prospective Cohort Study|TAHP|KK Women's and Children's Hospital|Yes|Recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|444|||Female|21 Years|70 Years|No|||September 2015|September 3, 2015|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02025153||53345|
NCT02025452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS 13-749|Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis|Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial||Hamilton Health Sciences Corporation|No|Completed|March 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|3 Months|60 Months|No|||March 2016|March 1, 2016|December 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025452||53322|
NCT02025465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997386|Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control|Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control||CAMC Health System|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02025465||53321|
NCT02025712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M004/EXE-EVE|Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer|A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer||Organisation for Oncology and Translational Research|Yes|Not yet recruiting||||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||December 2013|December 29, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02025712||53302|
NCT02025699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-1004-TT|Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis|Observational Multi-center, Prospective Study to Characterize Novel pathogen-and Host-related Factors in Hospitalized Patients and Patients on the Emergency Department Presenting With Lower Respiratory Tract Infections and/or Sepsis.|TailoredT|MeMed Diagnostics Ltd.|Yes|Active, not recruiting|February 2014|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1200|Samples Without DNA|Blood samples Nasopharyngeal samples|Both|1 Month|120 Years|Accepts Healthy Volunteers|Probability Sample|Eligible subjects aged one month of age and older from both genders that attend the        hospital or the ED due to a suspected respiratory infections and/or sepsis (onset of        symptoms ≤8 days prior to recruitment) or due to a non-infectious disease. These subjects        are expected to fall into one of the following categories:          1. Patients with an acute bacterial infection          2. Patients with an acute viral infection          3. Patients with an acute mixed co-infection (bacterial and viral)          4. Patients with a fungal infection          5. Patients with an undetermined disease etiology          6. Patients with a non-infectious disease (control group) Patients from subgroups 1-6             will also be classified based on the presence or absence of sepsis or severe sepsis.|March 2016|March 6, 2016|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02025699||53303|
NCT02022540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-01-101|Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD|A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)||PanOptica, Inc.|Yes|Active, not recruiting|February 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|50|||Both|50 Years|N/A|No|||March 2016|March 24, 2016|December 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022540||53546|
NCT02026921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSGO-OC-0303|A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer|A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer||Nordic Society for Gynaecologic Oncology|No|Completed|June 2004|December 2008|Actual|March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Female|18 Years|N/A|No|||December 2013|December 31, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02026921||53210|
NCT02026934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-024|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2013|||||N/A|N/A|N/A||||||||||||||October 16, 2015|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026934||53209|
NCT02026908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 00081296|Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)|Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)||Northwestern University|Yes|Recruiting|January 2014|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|45 Years|N/A|No|||January 2016|January 6, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026908||53211|
NCT02027415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2013003273|The Effect of Juice Types on the Responses to Air Pollution|Effects of Oral Nitrate Supplementation on Vascular and Pulmonary Oxidative Stress Markers Following Traffic Pollution Exposure||Rutgers, The State University of New Jersey|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02027415||53172|
NCT02027402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seoul -S2|Effects of Drainage in Laparoscopic Cholecystectomy|To Drain or Not to Drain in Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder ; a Multicenter Randomized Controlled Trial||Seoul St. Mary's Hospital|Yes|Completed|November 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|198|||Both|N/A|N/A|No|||November 2014|November 30, 2014|December 30, 2013||No||No|November 23, 2014|https://clinicaltrials.gov/show/NCT02027402||53173|
NCT01997931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/04|The Impact of Bispectral Index Monitoring on Sedation Administration in Mechanically Ventilated Patients|The Impact of Bispectral Index Monitoring on Sedation Administration in Mechanically Ventilated Patients||Bayside Health|No|Completed|September 2004|July 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT01997931||55430|
NCT01996917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM2053|Use of Prineo in Breast Reduction Surgery|Use of Prineo™ for Wound Closure in Breast Reduction Surgery|Prineo|Columbia University|No|Recruiting|August 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|65 Years|No|||September 2015|September 15, 2015|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996917||55508|
NCT01997125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reanimation in Tetraplegia|Reanimation in Tetraplegia|Reanimation in Tetraplegia||Ohio State University|No|Recruiting|November 2013|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|21 Years|89 Years|No|||February 2016|February 19, 2016|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01997125||55492|
NCT01998451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYGDWK-03|The Discovery of the Double Sphincter in Gallbladder|The Discovery of the Double Sphincter in Gallbladder||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 6, 2016|November 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01998451||55391|
NCT01998464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00010137|Optical Coherence Tomography (OCT) in Retinal Vasculitis|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vasculitis||Oregon Health and Science University||Recruiting|January 2014|||January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Probability Sample|This study will measure blood vessel pattern/flow changes in up to 35 patients with        retinal vasculitis.|April 2015|April 21, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01998464||55390|
NCT01998958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102968|A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression|A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)|SYNAPSE|Janssen Research & Development, LLC|No|Completed|January 2014|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|108|||Both|20 Years|64 Years|No|||October 2015|October 29, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998958||55352|
NCT01999192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|986_TREAT 2b|Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis|A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)|986|Biotest|Yes|Terminated|October 2013|July 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|321|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|November 17, 2013|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01999192||55335|
NCT01999205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175|Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland|Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland (MTB)|MTB|UKK Institute|No|Completed|November 2013|May 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|396|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01999205||55334|
NCT01999491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0466|A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma|A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|November 2013|||November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999491||55312|
NCT01995487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioNIR-001|Study of BioNIR Drug Eluting Stent System in Coronary Stenosis|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial|BIONICS|Medinol Ltd.|Yes|Active, not recruiting|January 2014|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1906|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995487||55617|
NCT01999504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BNH-1268|Gut Hormone Response After Paleolithic-type Meals|Gut Hormone Response After Two Paleolithic-type Meals Compared to a Modern-type Meal Composed According to WHO Guidelines|FooA2|Unilever R&D|No|Completed|October 2013|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|24|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01999504||55311|
NCT01995877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00034464|Evaluation of the Influence of Body Position on the Inferior Vena Cava (IVC) Diameter|Evaluation of the Influence of Body Position on the Inferior Vena Cava (IVC) Diameter||University of Michigan|Yes|Recruiting|October 2010|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are receiving an IVC(inferior vena cava) filter as part of their standard        therapy.|November 2013|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995877||55587|
NCT02022826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-501|Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis|Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis||Medtronic - MITG|No|Active, not recruiting|January 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|172|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|December 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022826||53524|
NCT02022839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/125|Role of Lung Ultrasound in Predicting Weaning Outcomes|B-lines at Lung Ultrasound Predicts Weaning Failure From Mechanical Ventilation||Hospital Moinhos de Vento|No|Completed|December 2010|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanical ventilation patients in a mixed intensive care unit|December 2013|December 22, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT02022839|2 Days|53523|
NCT02024334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900527|Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis|Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis|JIA|Mashhad University of Medical Sciences|Yes|Recruiting|June 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|2 Years|19 Years|No|||December 2013|December 25, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02024334||53408|
NCT02024516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT2013091614680N1|The Effect of Concentrated Pomegranate Juice Consumption on Lipid Profile and Inflammatory Factors in Patients With Type 2 Diabetes|||Ahvaz Jundishapur University of Medical Sciences||Recruiting|January 2013|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|25 Years|60 Years||||December 2013|December 30, 2013|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02024516||53394|
NCT02024529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-004-A|Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee|A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of a Single Intra-articular Injection of AmpionTM (<5 Kilodalton Ultrafiltrate of 5% Human Serum Albumin) in Adults With Pain Due to Osteoarthritis (OA) of the Knee||Ampio Pharmaceuticals. Inc.|Yes|Completed|December 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|538|||Both|35 Years|85 Years|No|||February 2016|March 2, 2016|December 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024529||53393|
NCT02024750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00016300|Tailored Diabetes Self-Management Resources|Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources||University of Wisconsin, Madison|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|8 Years|16 Years|No|||October 2015|October 9, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024750||53376|
NCT02004691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI12712|Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|ASCEND|Sanofi|Yes|Recruiting|December 2015|August 2022|Anticipated|August 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004691||54912|
NCT02004964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20053135|Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation|Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation||University of Miami|No|Recruiting|April 2009|December 2019|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with type 1 DM|December 2015|December 16, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02004964||54891|
NCT02005289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13031|Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL|A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2013|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005289||54866|
NCT01996371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0171|Radiographic and Clinical Outcomes Following Unilateral or Bilateral Posterior Fixation in MI-TLIF|Radiographic and Clinical Outcomes Following Unilateral or Bilateral Posterior Fixation in Minimally Invasive Transforaminal Lumbar Interbody Fusions||Ohio State University|No|Recruiting|January 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01996371||55549|
NCT01997671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-342|Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention|Effectiveness of an Intervention to Improve the Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention: Randomized Clinical Trial||Jordi Gol i Gurina Foundation|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60000|||Both|35 Years|74 Years|No|||November 2013|November 28, 2013|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01997671||55450|
NCT01997398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12BN123|DBS Under General Anesthesia: Comparison To The Standard Technique|DBS Under General Anesthesia Without Neurophysiology: Initial Experience and Comparison To The Standard Technique||St. Joseph's Hospital and Medical Center, Phoenix|No|Completed|November 2012|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected by CPT codes corresponding to bilateral DBS electrode placement        placed under general anesthesia with Leksell sterotactic navigation, portable CT and        without the use of microelectrode recordings (MER).|December 2015|December 2, 2015|November 18, 2013|No|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01997398||55471|
NCT01997684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISR-ENDO-2013-001|Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction|Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study||Nanfang Hospital of Southern Medical University|Yes|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01997684||55449|
NCT01998191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STDA3106|Avoidable Mortality Case Note Review Trial|A Randomized Controlled Trial to Assess the Best Method for Evaluating Avoidable Mortality in Hospitals Using Retrospective Record Review.||Imperial College London|Yes|Not yet recruiting|February 2014|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|200|||Both|18 Years|N/A|No|||June 2013|November 25, 2013|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT01998191||55411|
NCT01998438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011GWH1|Prospective Trial of Tranexamic Acid in Cardiac Surgery|A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|955|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|November 12, 2013||No||No|January 29, 2016|https://clinicaltrials.gov/show/NCT01998438||55392|
NCT01998204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkinson-propofol|Requirement of Propofol for Induction of Unconsciousness in Patients With Parkinson's Disease|||Changhai Hospital|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Our study recruits patients with Parkinson's disease undergoing deep brain stimulator        implantation and pulse generator placement under general anesthesia and non-Parkinsonian        patients without Parkinson's disease undergoing intracranial surgery under general        anesthesia|November 2013|November 23, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998204||55410|
NCT01998763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCX2-EW-R-10-VDII|Vitamin D Intervention Trial in Healthy Chinese, Phase II|Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study||Chinese Academy of Sciences|Yes|Completed|November 2013|December 2015|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|448|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998763||55367|
NCT01998737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bind03|Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX|Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX||Bone Index Finland Ltd|No|Enrolling by invitation|November 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1100|||Female|50 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 1100 postmenopausal women (age 50 -79 years) will participate the study. The        subjects will be divided into two groups: healthy (100 women) and under osteoporosis        suspicion (1000 women). The groups will be matched by BMI.        Women for the under osteoporosis suspicion group will be invited from those who have got a        referral for DXA examination from their doctor.|January 2016|January 25, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998737|1 Day|55369|
NCT01999218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-002|Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)|A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1230|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999218||55333|
NCT01999478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA128641|Novel Biophotonics Methodology for Colon Cancer Screening|Novel Biophotonics Methodology for Colon Cancer Screening|BRP|Boston Medical Center|No|Recruiting|February 2008|February 2015|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be obtained in the gastroenterology clinics.|November 2013|July 31, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999478||55313|
NCT01999231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTao-EC|Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10||Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|No|Completed|September 2013|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|November 4, 2013||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01999231||55332|If the operator don't have standard measurement of transverse diameter and the vertical diameter of induration or redness ,we get unreliable data .The participant lost any follow-up will lead to small numbers of subjects analyzed.
NCT01995539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP274|Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India|Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India||Medtronic Diabetes|No|Completed|December 2012|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|70 Years|No|||March 2015|March 8, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01995539||55613|
NCT02024282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54664|Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care|Validation of a Vital Signs and Symptoms Decision Tree and the Effect of a Point-of- Care CRP Test, Oxygen Saturation, a Brief Intervention and a Parent Leaflet on Diagnosing, Antibiotic Prescribing Rate and Parental Satisfaction in Acutely Ill Children in Primary Care."|ERNIE2|Katholieke Universiteit Leuven|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|8962|||Both|1 Month|16 Years|No|||February 2015|February 16, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02024282||53412|
NCT02023736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFI-001|Assessing Psychotherapy Outcome With Feedback|Assessing Psychotherapy Outcome in Treatment as Usual Versus Treatment as Usual With the STIC Feedback System||The Family Institute at Northwestern University|No|Recruiting|December 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|12 Years|N/A|No|||February 2016|February 5, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02023736||53454|
NCT02023996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-165|PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer|Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023996||53434|
NCT02024009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_063|Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2|A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer|SCALOP-2|University of Oxford|Yes|Recruiting|March 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|289|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02024009||53433|
NCT02024022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL GASTRO 4|A Multicenter Single-blind Comparison Between Standard and Individualized Approach in Bowel Preparation Before Colonoscopy|A Comparison of Bowel Prep Quality and Patient Satisfaction in Outpatients Undergoing Colonoscopy Preparation With Either a Standard Bowel Preparation or an Individualized Approach Using Sodium Picosulphatge/Magnesium Citrate or 4L Polyethylene Glycol Preparation Regimens||Clinical Hospital Colentina|No|Completed|February 2014|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|185|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02024022||53432|
NCT02024542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228969|Genetic and Biochemical Characteristics of Human Adipose Tissue|Evaluation of White Adipose Tissue (WAT) in Morbid Obesity||University of California, Davis|No|Recruiting|February 2011|||February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|500|||Both|18 Years|65 Years|No|||December 2013|December 25, 2013|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02024542||53392|
NCT02024308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHXY-AML01|AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy|A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia||Changhai Hospital|Yes|Recruiting|November 2010|December 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|65 Years|No|||December 2013|December 27, 2013|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02024308||53410|
NCT02024503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013CB733803|A Longitudinal Study of Multimodal Resonance Imaging in Stroke Patients|A Longitudinal Study of Multimodal Resonance Imaging in Stroke Patients||Zhongda Hospital|No|Recruiting|September 2013|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|Extraction of DNA from the blood of patients.|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospitalized patients with stroke and the some healthy volunteers recruited from community|December 2013|December 30, 2013|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02024503||53395|
NCT01996631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hsu2013-TMU-JIRB 201301040|The Impact of EDCs Relative Markers and Reproductive Hormone in Taiwanese Women|Serum Markers of OS, Inflammation, and EDCs and Impact on the Menstrual Cycle and Reproductive Hormone in Taiwanese Women||Taipei Medical University WanFang Hospital|No|Active, not recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|20 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|Patients who are reproductive aged and come visit our OPD clinic, except postmenopausal        and before menarche.|November 2013|November 26, 2013|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996631||55529|
NCT01996644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212062|A Double Blind Clinical Trial of DCS for Food Anxiety|A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa||Washington University School of Medicine|Yes|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|14 Years|65 Years|No|||December 2014|December 9, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01996644||55528|
NCT01997957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_06366|A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC|A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma|SOON|Beijing Cancer Hospital|No|Recruiting|October 2013|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||November 2013|November 25, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01997957||55428|
NCT01997944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921302|Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients|Phase Ib Study of Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Chronic Hepatitis B Patients||Beijing Bio-Fortune Ltd.|No|Completed|November 2013|November 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||November 2014|November 14, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997944||55429|
NCT01998217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rem-ESWL-Pancreas|Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone|||Changhai Hospital|Yes|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998217||55409|
NCT01998477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P15|A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications|A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications||Novartis|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|430|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998477||55389|
NCT01998490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1144|Animal-assisted or Robot-assisted Interventions in Health Promotion for Elderly With Dementia|Animal-assisted or Robot-assisted Interventions in Health Promotion for Elderly With Dementia: Impact on Factors Related to the Risk of Falls, on Evidence Based Practice and on the Relatives' Burden||Norwegian University of Life Sciences|No|Completed|January 2013|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|88|||Both|65 Years|N/A|No|||September 2014|September 26, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998490||55388|
NCT02005081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter|Baxter: Actifuse SHAPE vs DBX in ACC|A Prospective Study Using Actifuse SHAPE Versus Autograft With Demineralized Bone Matrix to Achieve Bone Fusion in Anterior Cervical Corpectomy (ACC)||Wayne State University|Yes|Recruiting|October 2013|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2013|December 3, 2013|November 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005081||54882|
NCT01998750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00009351|Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.|Genetics of Early Childhood Obesity|GECO|Children's Hospital Boston|No|Recruiting|February 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Saliva or blood|Both|3 Years|18 Years|No|Probability Sample|This study will enroll children > 3 years of age with BMI > 99th percentile for age noted        at an age < 6 years.|May 2014|May 5, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998750||55368|
NCT01999517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConanTrial|Contrast Nephropathy and Nitrates|Contrast Nephropathy and Nitrates|CoNaN|Mt. Sinai Medical Center, Miami|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01999517||55310|
NCT02006056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ondissolve|Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting|Prospective Study of Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting - a Phase II Study||Sunnybrook Health Sciences Centre|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|November 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006056||54807|
NCT02006303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100-SDR|Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients|Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study||Royal Victoria Hospital, Canada|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Male|40 Years|95 Years|No|||November 2014|November 3, 2014|November 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006303||54788|
NCT02006316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUH|Beneficial Effects of Microsurgical Varicocelectomy on Semen Parameters for Causes Other Than Infertility|Beneficial Effects of Microsurgical Varicocelectomy on Semen Parameters in Patients Who Underwent Surgery for Causes Other Than Infertility||Seoul National University Hospital|Yes|Completed|January 2000|March 2010|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|121|||Male|20 Years|45 Years|No|Probability Sample|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other        than infertility such as testicular pain, discomfort or scrotal mass|May 2014|May 13, 2014|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006316||54787|
NCT02023983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KN-11-2013|Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction|Official Title Verification of the Safety of Early Discharge (Within 72 Hours) in Low Risk Patients After Acute ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Open Randomized Study.||Municipal Hospital Ostrava|No|Recruiting|November 2013|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|18 Years|75 Years|No|||March 2016|March 20, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02023983||53435|
NCT02024321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPN-tumor|Study on Blood Glucose Variations in Tumor Patients Before and After Total Parenteral Nutrition|Phase 1: Select Tumor Patients to be Observed Phase 2: Observe the Blood Glucose Values During TPN Phase 3: Sort Data|TPN|Chinese Academy of Medical Sciences|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|86|||Both|N/A|N/A|No|Probability Sample|Tumor patients using TPN in abdominal surgery department in Cancer Hospital.|December 2013|December 27, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02024321||53409|
NCT02024373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDH2013|Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma|Multi-Center, Randomized, Placebo-Controlled, Double Blind Study of the Atorvastatin: Effect on Patients With Chronic Subdural Hematoma||Oriental Neurosurgery Evidence-Based-Study Team|No|Active, not recruiting|December 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|90 Years|No|||February 2016|February 29, 2016|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02024373||53405|
NCT02024776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/00425|Effectiveness of Prehabilitation Program for High-risk Patients Underwent Abdominal Surgery|The Effectiveness of Tailored Physical Training Intervention (Prehabilitation) in High-risk Patients Underwent Major Abdominal Surgery on Postoperative Complications: Randomized Controlled Trial||Hospital Clinic of Barcelona|No|Recruiting|February 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024776||53374|
NCT02024555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL117074|Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis|Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial||Vanderbilt University|Yes|Recruiting|March 2014|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|December 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024555||53391|
NCT01996345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0028|Vaginal Pessary Versus Expectant Management for Placenta Previa|Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa||Mednax Center for Research, Education and Quality|Yes|Not yet recruiting|April 2016|May 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|54 Years|No|||March 2016|March 11, 2016|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01996345||55551|
NCT01996358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK004|Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy|Comparing Intubating Conditions Using Succinylcholine or Rocuronium/Sugammadex for Rigid Bronchoscopy: a Randomized Study||Dr. Horst Schmidt Klinik GmbH||Not yet recruiting|August 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996358||55550|
NCT01996618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20043-7|Study to Reduce Symptoms of Premature Beats With Ranolazine|Reduction of Symptomatic Ventricular Premature Beats With Ranolazine|RSVP|Walter Reed National Military Medical Center|Yes|Recruiting|January 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2013|April 30, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996618||55530|
NCT01996059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012017|Functional Jejunal Interposition Improve Nutritional Status After Total Gastrectomy|A Multi-center Pilot Randomized Controlled Trial Examining the Differences of Nutritional Status of Patients Undergoing Functional Jejunal Interposition Or Roux-en-Y After Total Gastrectomy for Gastric Cancer|FJINS|Sun Yat-sen University|No|Recruiting|July 2012|June 2022|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||November 2013|November 21, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01996059||55573|
NCT01996930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK 4249|Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites|A Prospective, Randomised Controlled Trial to Determine the Safety and Efficacy of Steroid Impregnated Tape Compared to Standard Therapy With Silver Nitrate in the Treatment of Over-granulating Peritoneal Dialysis Catheter Exit Sites|STOP|University Hospital Birmingham NHS Foundation Trust|No|Recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996930||55507|
NCT01997151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT10236132|Promoting Health During Pregnancy: A Multiple Behavior Computer Tailored Intervention|Promoting Health During Pregnancy: A Multiple Behavior Computer Tailored Intervention||Pro-Change Behavior Systems|No|Completed|December 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|374|||Female|18 Years|N/A|No|||November 2013|November 22, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997151||55490|
NCT01997385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAAPD_01_112013|The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients|The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients||Fresenius Medical Care Korea|No|Completed|June 2012|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1075|||Both|20 Years|75 Years|No|||January 2016|January 21, 2016|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01997385||55472|
NCT01997437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.G34.31.0065|Laryngo-Tracheal Tissue-Engineered Clinical Transplantation|Clinical Trial Evaluation of Stem-cell Based Bioartificial Airway Transplantation for Patients With Benign and Malignant Laryngo-tracheal Diseases||Kuban State Medical University|Yes|Active, not recruiting|December 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||January 2016|January 25, 2016|November 5, 2013||No||No|January 3, 2014|https://clinicaltrials.gov/show/NCT01997437||55468|
NCT01998230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenanCH|Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer|Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer: a Randomized Clinical Trial||Henan Cancer Hospital|Yes|Completed|February 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|80 Years|No|||October 2015|October 14, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01998230||55408|
NCT01997970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-338-31|NEAT - Prevention and Treatment of Overweight and Obesity.|Non-exercise Activity Thermogenesis (NEAT) - Prevention and Treatment of Overweight and Obesity|InphactUm|Umeå University|No|Active, not recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|67 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|November 2, 2013||No||No||https://clinicaltrials.gov/show/NCT01997970||55427|
NCT02005094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308008RINA|The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease|The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease||National Taiwan University Hospital|No|Recruiting|November 2013|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1. Age ≥ 20 years          2. MAC/MAB lung disease: Diagnosis is based on the guidelines made by American Thoracic             Society (Table 1)[1]. In brief, there should be pulmonary symptoms, comparable             findings in chest image and appropriate exclusion other possible causes as well as             meeting the microbiology criteria.          3. MAC/MAB pulmonary colonizers: Those without fulfilling the diagnostic criteria but             having at least one set of positive sputum for MAC/MAB are defined.          4. Healthy controls: patient without documented MAC/MAB lung disease and pulmonary             colonization|June 2014|June 27, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02005094||54881|
NCT01998997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104385|A Family Intervention for Delirium Prevention|A Family Intervention to Decrease Delirium: a Pilot Study||Lawson Health Research Institute|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|79|||Both|70 Years|N/A|No|||December 2015|December 23, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998997||55349|
NCT01998971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103015|A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma|An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma||Janssen Research & Development, LLC|Yes|Recruiting|February 2014|October 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|190|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01998971||55351|
NCT02006043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28941|Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)|A Phase II, Open, Single Arm Trial to Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Line Treatment in Advanced or Recurrent NSCLC With EGFR Wild Type and Without C-met Expression||Sun Yat-sen University|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02006043||54808|
NCT02005731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSWT-004-EU|Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile Dysfunction|A Prospective Multicenter Pilot Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction|LISW|Initia|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Male|20 Years|80 Years|No|Non-Probability Sample|Sexual Medicine clinic|June 2014|June 10, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005731||54832|
NCT02005744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19HI13018|A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function|A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function||Chong Kun Dang Pharmaceutical|Yes|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|24|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||May 2014|April 29, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005744||54831|
NCT02006368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10|Assessment of Whole Blood Cold Stored Platelets|Assessment of Whole Blood Cold Stored Platelets|Brrr|Puget Sound Blood Center|No|Active, not recruiting|October 2013|||October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006368||54783|
NCT02006381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3288|Oxytocin Levels in Typically Developing Boys|Ontogenic Measurement of Plasma Oxytocin in Typically Developing Boys Using Extracted and Unextracted EIA Methods||University of North Carolina, Chapel Hill|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|60|||Male|3 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|This population will be a community sample representative of the community of the area.|September 2015|September 18, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02006381||54782|
NCT02006329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0089-13-ziv|Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture|||Ziv Hospital||Not yet recruiting|January 2014|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|November 27, 2013||||No||https://clinicaltrials.gov/show/NCT02006329||54786|
NCT02006342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0535|Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis|Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis: A Pilot Study|GT-COG|The University of Texas Health Science Center, Houston|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02006342||54785|
NCT02006355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5560|Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay|Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay|GLASGOW|University Hospital, Strasbourg, France|No|Recruiting|April 2014|August 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02006355||54784|
NCT02023502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1788/2013|Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study|Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study||Medical University of Vienna|No|Recruiting|November 2013|||April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the urogynaecology and general gynecology outpatient        clinic of the Department of Obstetrics and Gynaecology at the Medical University of Vienna|December 2013|December 23, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023502||53472|
NCT02023723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20130042H|Evaluation of Monster Energy® Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers|Evaluation of Monster Energy® Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers||David Grant U.S. Air Force Medical Center|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 24, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023723||53455|
NCT02025049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01501|DP-b99 in the Treatment of Acute High-risk Pancreatitis|Pilot Trial of Intravenous DP-b99 in the Treatment of First-ever Episode of Non-obstructive Acute High-risk Pancreatitis||D-Pharm Ltd.|No|Terminated|December 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2013|June 22, 2015|December 25, 2013||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT02025049||53353|
NCT02024347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSSM-RCT|A New Screening Strategy for Varices|A Randomized Controlled Trial of a New Screening Strategy for Varices Based on Liver and Spleen Stiffness Measurement (LSSM) in Cirrhotic Patients|LSSM-RCT|Chinese University of Hong Kong|No|Recruiting|July 2013|December 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|548|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will be recruited from the medical clinics of Prince of Wales Hospital and Alice        Ho Miu Ling Nethersole Hospital. Patients with known chronic liver diseases, radiological        evidence of liver cirrhosis and compensated liver function will be invited.|January 2016|January 26, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02024347||53407|
NCT02024360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ 1P01HS021138-01-03|Community Outreach - Obesity Prevention Trial (CO-OPT)|Center for Research in Implementation Science and Prevention (CRISP) - Community Outreach - Obesity Prevention Trial (CO-OPT)|CO-OPT|Denver Health and Hospital Authority|No|Active, not recruiting|March 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|December 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02024360||53406|
NCT02024568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105/13|Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia|Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia||Assaf-Harofeh Medical Center||Not yet recruiting|December 2013|May 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Female|18 Years|N/A|No|||December 2013|December 26, 2013|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024568||53390|
NCT01995799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/R/CAR/04|IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN|ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide|IRNMAN|University of Edinburgh|No|Recruiting|June 2013|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|80|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01995799||55593|
NCT01995812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ola Hou i ka Hula|Ola Hou i ka Hula: Hula and Hypertension|Ola Hou i ka Hula: A Pilot Study to Investigate Hula and Hypertension Control|Ola Hou|University of Hawaii||Completed|March 2012|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01995812||55592|
NCT01997697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9110|Reduction of Emotional Eating After a Behavior Change Program in Obesity|Predictive Factors of the Reduction of Emotional Eating After a Behavior Change Program Among Individuals With Obesity of Class II and Class III.||University Hospital, Montpellier|No|Recruiting|November 2013|December 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|138|||Both|18 Years|65 Years|No|||December 2013|April 4, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997697||55448|
NCT01997190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MpeTK01|Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion|A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion|MpeTK01|Advantagene, Inc.|Yes|Active, not recruiting|October 2013|October 2020|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01997190||55487|
NCT01997710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-083/2013b|Minimal Invasive Rehabilitation of Tooth Loss in the Posterior Segment (MIZE-S)|Clinical Performance of Two Different Designs of All-ceramic Resin-bonded Fixed Dental Prostheses in the Posterior Segment - a Randomized Controlled Pilot Study.|MIZE-S|University Hospital Heidelberg|Yes|Active, not recruiting|October 2013|December 2026|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01997710||55447|
NCT02004782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/7/4.5(3702)|Barretts oEsophageal Resection With Steroid Therapy Trial|Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.|BERST|Western Sydney Local Health District|Yes|Recruiting|June 2014|June 2020|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|126|||Both|18 Years|90 Years|No|||January 2015|January 13, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02004782||54905|
NCT02004795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-06-016A|BNCT and IG-IMRT for Recurrent Head and Neck Cancer|A Phase I/II Trial of Boron Neutron Capture Therapy (BNCT) Combined With Image-guided Intensity Modulated Radiotherapy (IG-IMRT) for Locally Recurrent Head and Neck Cancer||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|November 2013|November 2018|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|19 Years|79 Years|No|||November 2013|December 3, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02004795||54904|
NCT02004808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tasmc-12-RE-0247-CTIL|Neutrophil Extracellular Traps and Sickle Cell Disease|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|10CC of peripheral venous blood will be collected from each patient at several time points:      at diagnosis ,during pain crisis , at Hydroxyurea treatment.|Both|1 Month|18 Years|No|Probability Sample|Infants and children who suffer from sickle cell disease and/or Infants and children with        sickle cell disease treated with hydroxyurea at the pediatric hemato-oncology department|July 2012|December 3, 2013|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02004808||54903|
NCT02004821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.17.NIHS|Clinical Trial in Constitutional Thinness|Génomique de la résistance à la Prise de Poids Dans la Maigreur Constitutionnelle||Nestlé|No|Recruiting|December 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02004821||54902|
NCT02004834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260320131980|The Synergistic Effect of Local Anesthetics on Hemodynamic Changes During the Application of Paravertebral Block|The Synergistic Effect of Local Anesthetics on Hemodynamic Changes During the Application of Paravertebral Block||University Hospital Dubrava|No|Active, not recruiting|August 2013|October 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|80|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|March 15, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02004834||54901|
NCT02005419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET1310128-2|Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection|A Phase II, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of the Combination of Gemcitabine and Metformin in Treating Patients With Pancreatic Cancer After Curative Resection||Fudan University|Yes|Recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02005419||54856|
NCT02005692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-002|A Pilot Study to Assess the DynaSense System|A Pilot Study to Assess the DynaSense System||Leaf Healthcare, Inc.|No|Completed|December 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|1||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 10, 2014|November 27, 2013|Yes|Yes||No|July 19, 2014|https://clinicaltrials.gov/show/NCT02005692||54835|
NCT01998984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0105-1020|Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis||LEO Pharma|Yes|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|223|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01998984||55350|
NCT01999244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209313|Impact of Self-Monitoring Technology and Interventionist Contact on Weight Loss|Impact of Self-Monitoring Technology and Interventionist Contact on Weight Loss||The Miriam Hospital|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999244||55331|
NCT02006069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-006-ID-HF|MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing|MOre REsponse on Cardiac Resynchronization Therapy (CRT) With MultiPoint Pacing (MPP)|MORE-CRT MPP|St. Jude Medical|No|Recruiting|December 2013|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1898|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02006069||54806|
NCT02007005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB01|Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer|Dose-Escalation-Study With abnobaVISCUM® Fraxini 2 (AVF2) as Intravesical Instillation in Patients With Superficial Bladder Cancer According to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice) - Guidelines: a Phase Ib/IIa Study||Abnoba Gmbh|No|Completed|January 2004|September 2013|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|80 Years|No|||May 2015|May 5, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007005||54734|
NCT02023749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12161MFDS118|Effects of Nut Consumption on Metabolic Syndrome|Effects of Nut Consumption on Metabolic Syndrome in Korean Adults - A Randomized Controlled Dietary Intervention Trial||Ministry of Food and Drug Safety, Korea||Completed|April 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 23, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023749||53453|
NCT02024035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-ORL|Protocole Advanced RadioTherapy ORL|Health Economic Evaluation of Tomotherapy and Dynamic Arctherapy in ENT Epidermoid Carcinoma|ART-ORL|Centre Leon Berard|Yes|Completed|November 2009|November 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with Cavum Epidermoïd or undifferentiated carcinoma; or oropharynx epidermoïd        carcinoma; or oral cavity epidermoïd carcinoma|December 2013|December 23, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT02024035||53431|
NCT02024581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR003-01|A Dose Range-Finding Phase 2 Trial of a Botanical Drug for the Treatment of Molluscum Contagiosum in Pediatric Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized Safety and Efficacy Trial of a Botanical Drug Product, East Indian Sandalwood Oil (EISO), at One Dose Level for the Treatment of Molluscum Contagiosum in Pediatric Subjects||ViroXis Corporation|No|Not yet recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|17 Years|No|||July 2015|July 16, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024581||53389|
NCT02024815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM81310|Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.|Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma.||Lithuanian University of Health Sciences|Yes|Enrolling by invitation|September 2011|June 2015|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2013|December 28, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02024815||53371|
NCT01996683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iron chelation in thalassemia|Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)|A Randomized Prospective Comparative Study of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)||Ain Shams University|Yes|Not yet recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|18 Years|No|||January 2015|January 13, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996683||55525|
NCT01997359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1960|Multi-level Determinants of Starting ART Late: Aim 3|Multi-level Determinants of Starting ART Late in Sub-Saharan Africa (LSTART Study): A Case-control Study to Identify Individual-level Risk Factors for Late ART Initiation in Ethiopia|LSTART|Columbia University|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1214|||Both|18 Years|N/A|No|Non-Probability Sample|The prospective cohort will include all patients initiating ART at one of the six study        sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4        count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals        initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be        excluded from the case-control analysis in order to ensure meaningful distinction between        the two groups. We will enroll 720 patients for the case control study nested in the        prospective cohort, which will include 360 cases and 360 controls, who will be frequency        matched by sex, month of ART initiation, and clinic.|December 2014|December 15, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01997359|12 Months|55474|
NCT01997372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xzhu|Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia|Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia||Chinese Academy of Medical Sciences|Yes|Recruiting|December 2010|November 2015|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|18 Years|No|||December 2013|December 2, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01997372||55473|
NCT01997658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13 - 0294|Preoperative Glucocorticoid Use in Major Hepatectomy|Preoperative Glucocorticoid Use in Major Hepatectomy - A Randomized Controlled Trial||University of Calgary|No|Recruiting|October 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01997658||55451|
NCT02008357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15275|Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss|Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)|A4|Eli Lilly and Company|Yes|Recruiting|February 2014|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1150|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008357||54631|
NCT01998243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fis PI070682|Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity|Usefulness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity To Decrease Bariatric Surgery Morbidity||Hospital Severo Ochoa|Yes|Recruiting|January 2009|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998243||55407|
NCT01998256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not yet available|Clinical Benefit of Rigourous AV Delay Optimization in Patients With a Dual Chamber Pacemaker|A Prospective, Patient Blinded, Cross-over Study of the Effect on Clinical Outcomes of AV Optimization in All Comer Ambulatory Patients With a Dual Chamber Pacemaker - The Role of Atrial Function and Interatrial Conduction Delay|CBRAVO|Jessa Hospital|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998256||55406|
NCT01998269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3049|A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)|A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes.|MeDS|University of North Carolina, Chapel Hill|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult, primary care patients with diabetes and hypertension|November 2014|April 1, 2015|November 15, 2013||No||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01998269||55405|
NCT02004535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC009010.1|Clinical Study of Cochlear Implants in Adults With Asymmetrical Hearing Loss|Clinical Study of Cochlear Implants in Adults With Asymmetrical Hearing Loss||Washington University School of Medicine|No|Recruiting|April 2006|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004535||54924|
NCT02004548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-89-1|Phase I Clinical Study of Metatinib Tromethamine Tablet|A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|May 2013|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|74 Years|No|||November 2015|December 28, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004548||54923|
NCT02004561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109009034|Outcomes Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy and Gastric Bypass Surgeries in Obese Adolescents|Outcomes Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy, and Gastric Bypass Surgeries in Obese Adolescents||Yale University|No|Active, not recruiting|January 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|26|||Both|14 Years|19 Years|No|Non-Probability Sample|The research subjects will be recruited from the Yale Pediatric Obesity Clinic and the        Endocrine Clinic.|June 2014|June 16, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02004561|24 Months|54922|
NCT02005146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESG-HEP-2013-01|Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs|Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide        analogues|April 2015|April 30, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02005146||54877|
NCT02005159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-ANT-2011-01|Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae|Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST and Pharmacokinetic/Pharmacodynamic) in Prognosis of Bacteremia by Enterobacteriaceae|BACTERIEMIA|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|March 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1064|Samples With DNA|Whole blood|Both|17 Years|N/A|No|Non-Probability Sample|Patients with bacteremia by Enterobacteriaceae attended in participants Hospitals during        the study period|August 2015|August 4, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02005159||54876|
NCT02005107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSteffenVLX|Venlafaxine PK Following Bariatric Surgery|A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery|VLX|North Dakota State University|No|Active, not recruiting|December 2013|December 2015|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005107||54880|
NCT02005120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangUniv|Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC|Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC)||Zhejiang University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||December 2013|December 19, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02005120||54879|
NCT02005133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AGB16|A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics|A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics||Novartis|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|Male and female subjects diagnosed with visual impairment due to wet AMD who are        undergoing routine assessment in UK opthalmology clinics.|January 2016|January 12, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005133||54878|
NCT02005705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 1307012373|Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.|Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.||Yale University|No|Recruiting|December 2013|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|242|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005705||54834|
NCT02006030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-003|Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma|Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma|TACE|Polaris Group|No|Recruiting|June 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006030||54809|
NCT02006693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-001|Evaluation of the XEN Implant in Moderate POAG Subjects|Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects||AqueSys, Inc.|Yes|Active, not recruiting|January 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02006693||54758|
NCT02006706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20388|A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy|An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure||Hoffmann-La Roche||Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||October 2014|October 31, 2014|December 5, 2013|No|Yes||No|October 31, 2014|https://clinicaltrials.gov/show/NCT02006706||54757|
NCT02007018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPTUNE|Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections|Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections|NEPTUNE|Lawson Health Research Institute|Yes|Recruiting|January 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007018||54733|
NCT02023762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MitraClip under sedation|Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System|Safety and Feasibility of Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System||Heinrich-Heine University, Duesseldorf|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with severe mitral regurgitation characterized by trans-thoracic and        trans-esophageal echocardiography undergoing PMVR using the MitraClip® system|December 2013|December 24, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02023762||53452|
NCT02023775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melody™ France|Non Interventional Study on Pulmonary Valve Replacement by Thranscatheter Pulmonary Valve Melody™|Non Interventional Study on Pulmonary Valve Replacement by Thranscatheter Pulmonary Valve Melody™|Melody™ France|Medtronic Bakken Research Center|No|Recruiting|March 2013|March 2020|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|all patients receiving a valve implantation, without exception (exhaustive population)|December 2013|December 23, 2013|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02023775|5 Years|53451|
NCT02024048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECTP-EDI|Evaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography|Evaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography||Gaia Hospital|No|Active, not recruiting|December 2013|July 2014|Anticipated|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|12|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women in the third trimester of pregnancy|January 2014|January 27, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02024048|6 Months|53430|
NCT02024061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/DES/113591/2009|Treatment of Pediatric Obesity (TOP) - A Multidisciplinary Approach Involving Adolescents and Their Peers|Tratamento da Obesidade Pedi ́Atrica (TOP) - Uma Abordagem Multidisciplinar Envolvendo Pais e Pares|TOP|Grupo Lusófona|No|Active, not recruiting|September 2012|October 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|99|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 26, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02024061||53429|
NCT02017743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREBECA|Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism|Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism - An Observational Study|TREBECA|Trio Grup Clinical Research|No|Recruiting|December 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients to enroll will be cancer patients diagnosed for VTE and who are able to receive        outpatient LMWH treatment.|December 2013|December 16, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02017743||53914|
NCT02017756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tsinghua-985|Chinese Atherosclerosis Risk Evaluation- Phase II|A Phase II Study of Chinese Atherosclerosis Risk Evaluation: Investigation of Carotid Atherosclerotic Disease in Patients With Ischemic Cerebrovascular Events|CARE-II|Tsinghua University|Yes|Recruiting|January 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|85 Years|No|Probability Sample|In this study, we plan to recruit patients with recent TIA of ischemic stroke (within 2        weeks) and carotid atherosclerotic plaque determined by ultrasound. The patients will be        recruited from more than 10 hospitals in different areas of China.|December 2013|December 16, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02017756||53913|
NCT02025296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-healthcare system|Ubiquitous Healthcare Service With Multifactorial Intervention in Diabetes Care|Ubiquitous Healthcare Service With Multifactorial Intervention in Diabetes Care: a Randomized Controlled Trial||Seoul National University Bundang Hospital|No|Completed|December 2013|October 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|60 Years|N/A|No|||October 2014|October 11, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02025296||53334|
NCT02025595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2013ObesiBrain001|Obesity and Brain: Genes and Environment|The Role of Central Reward and Satiety Centers in the Etiology of Obesity: Genetic and Environmental Influences||VU University Medical Center|No|Recruiting|December 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|90|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the Netherlands Twin Registry (NTR). All subjects are        voluntary participants and have received surveys on lifestyle and health every 2 years. In        addition, genome wide data are available in a large number of these individuals.|December 2013|December 27, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02025595||53311|
NCT02025608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSI.13.01|Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome|Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS|AUTOREST|Ospedale Regionale di Lugano|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025608||53310|
NCT01997164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R910-3-OD-1403|Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)|An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME||Regeneron Pharmaceuticals|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01997164||55489|
NCT01997411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INGluc002|Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes|Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes||T1D Exchange Clinic Network Coordinating Center|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|4 Years|16 Years|No|||April 2015|April 14, 2015|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997411||55470|
NCT01997424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-007|ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS|ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS||Johann Wolfgang Goethe University Hospitals|No|Recruiting|May 2013|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|340|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT01997424||55469|
NCT02008630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1144-1|Animal-assisted Interventions in Health Promotion for Elderly With Dementia|Animal-assisted Interventions in Health Promotion for Elderly With Dementia; Impact on Factors Related to Risk of Falls||Norwegian University of Life Sciences|No|Completed|January 2013|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|122|||Both|65 Years|N/A|No|||September 2014|September 26, 2014|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008630||54610|
NCT02008617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00085894|Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction|Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction||Northwestern University|No|Active, not recruiting|December 2013|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|106|||Both|18 Years|70 Years|No|||October 2015|October 1, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008617||54611|
NCT02004301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM1202A|A Study to Investigate Delayed-release Tablets|A Pilot Pharmacoscintigraphic Clinical Study to Investigate the Behaviour of Delayed-release Tablets Consisting of a Diclofenac Potassium Core Coated With Barrier Granules, in Healthy Volunteers||Bio-Images Research Ltd|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02004301||54942|
NCT02004847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsoriasisCT02|Blue Light for Treating Psoriasis Vulgaris|Monocenter, Randomized, Double Blinded, Intraindividual, Exploratory Study of Effectiveness and Safety of 3 Months Treatment With 2 Peak Intensities of 453nm Blue Light for the Treatment of Mild Plaque Type Psoriasis Vulgaris||Light and Health Venture|No|Completed|September 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|November 19, 2013||No||No|August 12, 2015|https://clinicaltrials.gov/show/NCT02004847||54900|
NCT02004860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/104/HP|Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis|Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face|Disease|University Hospital, Rouen|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004860||54899|
NCT02005783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1302|Study of Danggui Buxue Decoction in Preventing Neutropenia|Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer：A Prospective, Randomized Trial|DIPE|Shanghai Jiao Tong University School of Medicine|Yes|Completed|October 2013|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|70 Years|No|||May 2015|December 29, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005783||54828|
NCT02005445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1351-P|Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation|Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation||VA Office of Research and Development|No|Recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005445||54854|
NCT02005757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32RA13007|Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)|Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug|AMOLED|Chong Kun Dang Pharmaceutical|Yes|Recruiting|November 2013|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||June 2015|June 24, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005757||54830|
NCT02005432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRALA|PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy|Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy.||University of Sao Paulo|No|Active, not recruiting|February 2012|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005432||54855|
NCT02005718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090129|Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD|Impact of Cholecalciferol on Endothelial Fucntion and Blood Biomarkers in Patients With Chronic Kidney Disease||St George's, University of London|No|Completed|June 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|80 Years|No|||December 2013|December 3, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005718||54833|
NCT02006732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.26|Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)|A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2013|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|809|||Both|40 Years|N/A|No|||December 2015|December 10, 2015|October 14, 2013||||No|October 23, 2015|https://clinicaltrials.gov/show/NCT02006732||54755|
NCT02007304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112068MIB|Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Vascular Function|Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Preventing Arterial Stiffening Effects Induced by Acute and Chronic Eccentric Exercise||National Taiwan University Hospital|No|Recruiting|November 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02007304||54711|
NCT02007317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-BCC-P2-01|Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study|A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study||Oshadi Drug Administration|No|Recruiting|November 2013|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||April 2015|April 21, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02007317||54710|
NCT02024386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049150|Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude|The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure||Duke University|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024386||53404|
NCT02024594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88311|Comparison of Effect of Nitrous Oxide-Oxygen Conscious Sedation and Cognitive-behavioral Therapy on Children's Anxiety in Dentistry|||Mashhad University of Medical Sciences|No|Completed|October 2009|||July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|45|||Both|36 Months|78 Months|Accepts Healthy Volunteers|||December 2013|December 27, 2013|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024594||53388|
NCT02024607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-246|A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer|A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer||Boston Biomedical, Inc|No|Recruiting|January 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|168|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024607||53387|
NCT02024828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR005182|Testing Four Feeding Approaches to Oral Feeding in Preterm Infants|Feeding Readiness in Preterm Infants|PRO|Children's Hospital Medical Center, Cincinnati|Yes|Completed|July 2006|April 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|109|||Both|N/A|32 Weeks|No|||May 2011|December 26, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02024828||53370|
NCT02017769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-100|MRI in Diagnosing and Monitoring CIDP|Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.||University of Aarhus|No|Enrolling by invitation|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated with subcutaneous immunoglobulin for CIDP are invited to participate.        They will be recruited from the outpatient clinic at Department of Neurology in Aarhus,        Odense and at Rigshospitalet (Copenhagen)        Healthy controls will be recruited by public announcement|August 2015|December 2, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02017769||53912|
NCT02021604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-060|Fluorodopa F 18 in Congenital Hyperinsulinism|The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism||Cook Children's Health Care System|Yes|Recruiting|December 2013|June 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|18 Years|No|||July 2015|July 27, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021604||53617|
NCT02021838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZD-CX-0001|Evaluation of the Office on Violence Against Women's Domestic Violence Homicide Prevention Demonstrative Initiative|Evaluation of the Domestic Violence Homicide Prevention Initiative||Yale University|No|Enrolling by invitation|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|4|||Both|N/A|N/A|No|Non-Probability Sample|The study will include all domestic violence offenders and victims within the four        demonstration communities.|July 2014|April 8, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02021838||53599|
NCT01996709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01337|Effectiveness of a Marketed One-Step Peroxide Lens Care Solution in Symptomatic Contact Lens Wearers|Effectiveness of a Marketed One-Step Peroxide Lens Care Solution in Symptomatic Contact Lens Wearers||Alcon Research|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|142|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 18, 2013|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01996709||55523|
NCT01996969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regorafenib biomarker|Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer|Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer: A Prospective Explorative Study||Seoul National University Hospital|Yes|Active, not recruiting|October 2013|August 2015|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|117|||Both|20 Years|N/A|No|||June 2015|June 29, 2015|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01996969||55504|
NCT01997177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|motion capture in colonoscopy|Assessment of Competence in Colonoscopy Using Motion Capture|Assessment of Competence in Colonoscopy Using Motion Capture||Rigshospitalet, Denmark|Yes|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|N/A||2|Actual|21|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Doctors in gastroenterology|November 2013|November 22, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997177||55488|
NCT02004327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW1029M-I-3|The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer|Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer||Dong Wha Pharmaceutical Co. Ltd.|No|Completed|December 2013|June 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|6|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02004327||54940|
NCT02004314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 246|Chloroquine as a Modulator of T Cell Immune Activation|Chloroquine as a Modulator of T Cell Immune Activation to Improve CD4 Recovery in HIV-infected Participants Receiving Antiretroviral Therapy: A Proof-of-concept Study||CIHR Canadian HIV Trials Network|Yes|Completed|October 2009|March 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||December 2013|December 3, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02004314||54941|
NCT02004574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPLK 2013-01|Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris|Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris|TRIANGLE|Samsung Medical Center|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|201|||Both|19 Years|N/A|No|||June 2014|June 3, 2014|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02004574||54921|
NCT02004587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL014|Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers|A Single-center, Open-label Trial, Investigating the Pharmacokinetics, Pharmacodynamics and the Safety Profile After a Single Oral Dose of Gemigliptin (Investigational Product) in Healthy Subjects and Subjects With Mild or Moderate Hepatic Impairment and After Multiple Oral Dose in Healthy Subjects||LG Life Sciences|No|Completed|September 2013|July 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|28|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02004587||54920|
NCT02005458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1309CSF|Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy|Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.||Xiamen Amoytop Biotech Co., Ltd.|No|Recruiting|December 2013|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|70 Years|No|||August 2015|August 28, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005458||54853|
NCT02005796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siniset perunat|Bioavailability of Anthocyanins of Blue Potatoes as Compared With Bilberries|Bioavailability of Anthocyanins of Blue Potatoes as Compared With Bilberries||University of Turku|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005796||54827|
NCT02005809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2nd look EGD|Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm|Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm|SLEGD|Kosin University Gospel Hospital|Yes|Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|268|||Both|20 Years|90 Years|No|||December 2013|December 4, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02005809||54826|
NCT02006082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS-IDPVO2011/50|Readmissions to Hospital Among Patients With COPD After Telemedicine Video Consultation - a Pilot Project|Readmissions to Hospital and Patient Satisfaction Among Patients With Chronic Obstructive Pulmonary Disease After Telemedicine Video Consultation - a Pilot Project||Helse Stavanger HF|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|99|||Both|40 Years|88 Years|No|Probability Sample|All COPD patients living in the southern part of Rogaland county in Western Norway, who        were monitored at home by TVC following discharge after emergency hospitalization for COPD        exacerbation at Stavanger University Hospital, or at Dalane Medical Center (DMC) in        Egersund, or who had tele-monitoring at home under outpatient treatment for acute COPD        deterioration during a pilot project period (16th April 2010 - 31st December 2011)|December 2013|December 4, 2013|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02006082||54805|
NCT02005770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0408|Anesthesia and Circulating Tumor Cells in Breast Cancer|Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.||University of Zurich|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|231|||Female|18 Years|85 Years|No|||December 2015|December 14, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005770||54829|
NCT02007031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24300771KYTEM|Cardiovascular Responses to Cold in Hypertension|Cardiovascular Responses to Cold Exposure in Hypertension|ColdHTN|University of Oulu|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|91|||Male|55 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study participants were included according to a population based recruitment where a        random sample of 1000 men (55-65 years old) living in Oulu, Finland was drawn from the        Finnish Population Register. They were screened by telephone interviews for eligibility        for the study. Eligible attendees measured their blood pressure home for a week according        to the recommendations of the European Society of Hypertension and were classified either        to hypertensive (systolic blood pressure ≥135 and/or diastolic blood pressure ≥85 mmHg) or        normotensive (blood pressure <135/85mmHg). For the study we aimed at a 2:1 ratio of        hypertensive and normotensive. The final study group consisted of 56 hypertensive and 35        normotensive middle-aged men.|December 2013|December 10, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007031||54732|
NCT02007590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.LO.1124|Aerosure and Six Minute Walk Distance in Severe COPD|Does High-frequency Airflow Oscillation, Delivered Using Aerosure, Increase Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease?|ACCORD|Actegy Ltd.|Yes|Recruiting|February 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|40 Years|N/A|No|||January 2016|January 18, 2016|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02007590||54690|
NCT02007603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPISUL/AMOXICLAV-HD_V1.4|Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients|Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients||Medical University of Vienna|Yes|Active, not recruiting|August 2013|December 2015|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02007603||54689|
NCT02020785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082089|Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23|Randomized Cross-over Study Examining the Effects of Phosphorus Additives on Urinary Albumin Excretion and Fibroblast Growth Factor-23|SODA-POP|Geisinger Clinic|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020785||53680|
NCT02020798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1328|Glycemic Response Testing|||PepsiCo Global R&D||Completed|December 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020798||53679|
NCT02021084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0173-13-RMB CTIL|The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.|||Rambam Health Care Campus|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|5 Years|18 Years|No|||December 2013|December 26, 2013|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02021084||53657|
NCT02018341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44817|The Homeogenomic Trial|A Randomized Double-blind Placebo Controlled Homeopathic Pathogenetic Trial (HPT) on Healthy Volunteers Proving XX in the Potency of 30C, "The Homeogenomic Trial"||University of Washington|No|Withdrawn|June 2013|February 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 20, 2013|June 20, 2013||No|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT02018341||53868|
NCT02021331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041254|The Effect of Immediate Implant Placement and Provisionalization in the Esthetic Zone|The Effect of Immediate Implant Placement and Provisionalization in The Esthetic Zone: A Randomized Clinical Trial|3i|University of Michigan|No|Suspended|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|December 13, 2013|Yes|Yes|Waiting for additional funding|No||https://clinicaltrials.gov/show/NCT02021331||53638|
NCT02021344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMH 1RC1MH089757-01|Mental Health First Aid for College Students|Mental Health First Aid for College Students: A Multi-campus Randomized Control Trial of a Community Health Intervention||University of Michigan|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|2543|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02021344||53637|
NCT02021357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-2205-AR|Proprioceptive Treatment for Temporomandibular Dysfunction|The Influence of Proprioceptive Treatment for the Intensity of Pain, Muscle Activity, Level of Severity and Mandible Mobility in Individuals With Temporomandibular Dysfunction: Clinical Trial, Randomized, Controlled, Double-Blind||University of Nove de Julho|Yes|Recruiting|January 2014|December 2014|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|40 Years|No|||December 2013|February 4, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021357||53636|
NCT02018315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 122010-186|Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)|Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)||University of Texas Southwestern Medical Center|No|Active, not recruiting|January 2012|March 2014|Anticipated|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|1 Month|20 Years|Accepts Healthy Volunteers|||December 2013|December 26, 2013|December 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018315||53870|
NCT02018575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580 amendment|Metabolic Availability of Lysine From White Maize|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From White Maize Protein, in Young Adult Men||The Hospital for Sick Children|No|Active, not recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|7|||Male|20 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018575||53850|
NCT01997450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-VA-MEDI3250-1116|A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|ICICLE|MedImmune LLC|No|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|8760|Samples With DNA|A nasal swab specimen will be collected and tested for influenza and other viral pathogens.|Both|2 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 2 to 17 years of age who are seeking care in an outpatient setting for febrile        acute respiratory illness.|February 2016|February 24, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT01997450||55467|
NCT01997983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01803295|Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients|Pilot Study Evaluating Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in Interstitial Cystitis Patients||UroGen Pharma Ltd.|Yes|Completed|November 2013|August 2015|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||August 2015|August 30, 2015|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01997983||55426|
NCT02004873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micra|Micra Transcatheter Pacing Study|Micra Transcatheter Pacing Study||Medtronic Cardiac Rhythm Disease Management|Yes|Active, not recruiting|November 2013|September 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|780|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02004873||54898|
NCT02005172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506493-2|Validation of an iPhone-based Event Recorder for Arrhythmia Detection|Validation of an iPhone-based Event Recorder for Arrhythmia Detection||University at Buffalo|No|Recruiting|November 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005172||54875|
NCT02005471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28667|A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB||Hoffmann-La Roche||Recruiting|March 2014|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02005471||54852|
NCT02005484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17263|A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression|An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy||Hoffmann-La Roche||Terminated|January 2004|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||July 2014|July 23, 2014|December 4, 2013|No|Yes|Study terminated due to slow patient recruitment.|No|June 9, 2014|https://clinicaltrials.gov/show/NCT02005484||54851|Due to slow patient recruitment, the study was prematurely terminated.
NCT02006108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94027|Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance|Non-invasive MR Imaging Diagnosis of Transplant Rejection||Stanford University|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|8 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006108||54803|
NCT02006121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-37527-13-0124|Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease|Multicenter,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment|TOLEDO|Britannia Pharmaceuticals Ltd.|No|Recruiting|December 2013|July 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|30 Years|N/A|No|||December 2013|May 12, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02006121||54802|
NCT02006095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NS081416-01|Neuroimaging Correlates of Memory Decline Following Carotid Interventions|||Stanford University|Yes|Recruiting|November 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing carotid intervention|February 2015|February 20, 2015|October 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02006095||54804|
NCT02006394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #110549|Novel Dietary Interventions for Treating Insulin Resistance|||University of California, San Diego|No|Completed|January 2012|November 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|41|||Both|21 Years|55 Years|No|||December 2013|December 10, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006394||54781|
NCT02007330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0692|The Effect of Systemic Lidocaine Infusion to Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children|||Yonsei University|Yes|Completed|November 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|66|||Both|1 Year|6 Years|No|||June 2015|June 5, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007330||54709|
NCT02007343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAND-ABC|Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals|The Attributable Burden and Costs of Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria in Dutch Hospitals|GRAND-ABC|UMC Utrecht|No|Recruiting|June 2013|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|4160|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to hospitals|December 2015|December 3, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02007343||54708|
NCT02007616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI2010-21609-C02-01|Cognitive Aging and Training With Video-games|Compensation Factors of Cognitive Ageing: Using Computer Technology to Reduce Cognitive Decline in Ageing||Universidad Nacional de Educación a Distancia|Yes|Completed|January 2011|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|57 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02007616||54688|
NCT02021864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hypocalcemia of pregnancy|Vitamin D Treatment and Hypocalcemic Pregnant Women|Effect of Treatment of Vitamin D Deficiency During Pregnancy on Hypocalcemia||Sina Hospital, Iran|Yes|Recruiting|January 2014|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 19, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021864||53597|
NCT02021877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU funded project nr 270259|Evidence Based Diagnostics and Treatment Planning Solution for Traumatic Brain Injuries|Evidence Based Diagnostics and Treatment Planning Solution for Traumatic Brain Injuries - the TBIcare Project||Turku University Hospital|No|Completed|February 2011|July 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|396|Samples With DNA|Serum and plasma samples for proteomic, metabolomic and genetic analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients, age ≥ 18 years, with clinically diagnosed mild, moderate or severe brain        trauma will be asked to participate in the study. If such possible subjects are either        unconscious, sedated or confused to the extent, that no personal decisions can be drawn,        her next of kin will be asked for the permission to include the subject in question to the        study. Control group subjects will be patients with acute orthopaedic injuries without any        signs of eventual concomitant brain trauma of any degree. The source populations will        consist of citizens from the local catchment areas of the participating centres.|May 2015|May 22, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021877||53596|
NCT02018627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002549|Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon|Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon||Massachusetts General Hospital|Yes|Active, not recruiting|April 2014|December 2015|Anticipated|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|80 Years|No|||September 2015|September 10, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018627||53846|
NCT02017990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2012/1419|Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival|The Levels of Marine n-3 Polyunsaturated Fatty Acids in Plasma Phospholipids as a Prognostic Marker of Mortality and Graft Loss Endpoints in Renal Transplant Recipients.||Oslo University Hospital|No|Completed|October 1999|June 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2002|Samples Without DNA|Plasma phospholipids.|Both|16 Years|N/A|No|Probability Sample|Renal transplant recipients|February 2014|February 28, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017990||53895|
NCT02018003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201309|The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research|The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Stage Cervical Cancer||Peking University|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Female|18 Years|N/A|No|Probability Sample|The women with early stage cervical cancer, who underwent operation in Peking University        School of Oncology.|November 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018003||53894|
NCT02007785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:400|Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease|Determining the Applicability of the Cognitive Orientation to Daily Occupational Performance (CO-OP) as a Meta-Cognitive Rehabilitation Strategy for Individuals With Parkinson's Disease-Related Cognitive Impairment||University of Manitoba||Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|N/A|No|||October 2015|October 15, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02007785||54675|
NCT02007759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH NMES for Dysphagia|Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates|Randomized Treatment of Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates||Sanford Health|Yes|Recruiting|November 2013|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|36 Weeks|42 Weeks|No|||December 2013|December 5, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02007759||54677|
NCT02007772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIBICO|Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients|Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients|TIBICO|University of Leipzig|No|Recruiting|November 2009|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02007772||54676|
NCT02008045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23NS0-63371|MR Imaging of Perinatal Brain Injury|Advanced MR Imaging of Perinatal Brain Injury: Correlation With Neurocognitive Outcome||University of Pittsburgh|No|Recruiting|April 2009|||March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|N/A|6 Months|No|||January 2016|January 25, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02008045||54655|
NCT02008344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T705US317|Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza||MDVI, LLC|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1161|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|December 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008344||54632|
NCT02004600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-11|Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB|Bicentric, Open and Pilot Study Evaluating the Efficiency and the Tolerance of the Photodynamic Therapy in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary Dystrophic Epidermolysis Bullosa||Centre Hospitalier Universitaire de Nice|No|Withdrawn|December 2013|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|November 26, 2013||No|health statement of pre-screenined patients were too bad for being enrolled in the study|No||https://clinicaltrials.gov/show/NCT02004600||54919|
NCT02004613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1379|Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery|Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery|DexCardiac|The Cleveland Clinic|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|965|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02004613||54918|
NCT02004886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0893-005|A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)|A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|August 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|74|||Both|21 Years|65 Years|No|||March 2015|March 31, 2015|December 3, 2013|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT02004886||54897|
NCT02005185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anes255HippocampalDysfcn|Human Subject Study on the Cognitive Effects of Anesthesia on Children Anesthetized Prior to 5 Years Old|Is Pediatric Anesthesia Associated With Long-term Hippocampal Dysfunction?||University of California, San Francisco|No|Recruiting|November 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|300|||Both|6 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children currently 6-11 years old who have been anesthetized between ages 0-2 or between        ages 4-7 and a matched group of children that did not undergo anesthesia.|December 2015|December 2, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005185||54874|
NCT02005198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4123|Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)|Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)||Novo Nordisk A/S|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|23 Years|79 Years|No|Non-Probability Sample|Adult patients with a diagnosis of growth hormone deficiency (GHD), naïve to treatment        currently and for at least 6 months prior, who are beginning a new prescription treatment        for their GHD. Patients will be selected by sites as per inclusion and exclusion criteria|January 2016|January 6, 2016|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005198||54873|
NCT02005822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-MM-2|Congenital Cytomegalovirus: Efficacy of Antiviral Treatment|The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group|CONCERT 2|Leiden University Medical Center|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|12 Weeks|No|||June 2015|June 17, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005822||54825|
NCT02006147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC399.1|Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)|A Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability||Taiwan Liposome Company||Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|N/A|No|||June 2015|June 2, 2015|November 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006147||54800|
NCT02006446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/005/HP|Relationship Between Sperm Head Vacuoles and Sperm DNA Alterations in Infertile Men|Are Sperm Head Vacuoles Associated With Sperm Nuclear Alterations?|VATES|University Hospital, Rouen|No|Recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|spermatozoa|Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|infertile men attending the assisted reproduction units in Rouen and Lille|January 2016|January 22, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02006446|1 Day|54777|
NCT02006420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00074229|Scleroderma ARFI Imaging of the Skin|Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases|ARFI|University of Michigan|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006420||54779|
NCT02006433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120429|Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation|Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation||University of Miami|Yes|Recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|22 Years|60 Years|No|||February 2016|February 17, 2016|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006433||54778|
NCT02006407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.117|A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors|A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors||University of Michigan Cancer Center|Yes|Active, not recruiting|June 2013|||August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|6 Years|21 Years|No|||March 2016|March 8, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006407||54780|
NCT02006719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-871|Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder|AC|Endo Pharmaceuticals|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006719||54756|
NCT02007356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 205/13|A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®|A Phase I/II Single-center Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®|CCS|University Hospital, Basel, Switzerland|Yes|Recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02007356||54707|
NCT02007629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16719|Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor|An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Phosphodiesterase-5 Inhibitors (PDE-5i)|RESPITE|Bayer|No|Active, not recruiting|February 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|December 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02007629||54687|
NCT02021630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0360|The Collateral Impact of Bariatric Surgery on Families|The Collateral Impact of Bariatric Surgery on Families|Collateral|Geisinger Clinic|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|150|Samples Without DNA|urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled in the bariatric surgery program at Geisinger Medical Center's Center        for Nutrition and Weight Management along with their spouse/partner and/or child(ren) ages        5-16.|July 2015|July 16, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021630||53615|
NCT02017782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XDOZ-1201|Controlled Human Exposure to Indoor Air, Dust and Ozone|Controlled Human Exposure to Indoor Air, Dust and Ozone|XDOZ|University of Aarhus|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||April 2013|December 16, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02017782||53911|
NCT02018367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO #12-0289|Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Neoplasia|Accuracy, Yield and Clinical Impact of a Low-Cost High Resolution Microendoscope in the Early Diagnosis of Esophageal Neoplasia||Anandasabapathy, Sharmila, M.D.|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018367||53866|
NCT02018016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRB13069-VA|The Hospital Volume Relationship in Appendicectomy Outcomes|The Hospital Volume Relationship in Appendicectomy Outcomes||University of Edinburgh|No|Completed|January 2001|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||3|Anticipated|40000|None Retained|Please note with regard to enrollment: that although this study period has ended and data is      being collated, the actual number of subjects is not known at this point since data has yet      to be received. We requested data on all subjects meeting our criteria within the time frame      mentioned.|Both|N/A|N/A|No|Probability Sample|All Scottish residents undergoing appendicectomy during the study period.|December 2013|December 16, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02018016||53893|
NCT02007798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-1st-001|Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia|Randomized, Parallelled and Double-blinded Trial of Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia||China Medical University, China|Yes|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|35 Years|65 Years|No|||January 2014|January 11, 2014|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02007798||54674|
NCT02008071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK-123|Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight|Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight|STEP|University of Tennessee|Yes|Completed|March 2013|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|57|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2013|July 21, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02008071||54653|
NCT02008058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1231|Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|December 2013|December 2023|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|N/A|No|Non-Probability Sample|Oncology clinic|January 2016|January 17, 2016|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008058||54654|
NCT02008370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-18|Exparel in Minimally Invasive Cardiac Surgery|The Use of Exparel for Extended Pain Control in Minimally Invasive Cardiac Surgery||Maimonides Medical Center|No|Recruiting|November 2013|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008370||54630|
NCT02004899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104456|Trial of Onset of Epidural Pain Relief With Low Dose Bupivacaine and Different Doses of Fentanyl in Laboring Women|Onset of Labor Epidural Analgesia With Low Dose Bupivacaine and Different Doses of Fentanyl: a Randomized Double Blinded Clinical Trial.||Lawson Health Research Institute|No|Not yet recruiting|December 2013|June 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 6, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004899||54896|
NCT02004912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38/2012|Evaluation of an MNCH Mentoring Intervention in Karnataka|Monitoring and Evaluation of an MNCH Mentoring Intervention in Two Districts of Karnataka||Karnataka Health Promotion Trust|No|Completed|September 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|295|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02004912||54895|
NCT02005211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00003|A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Healthy Japanese Male and Non-Fertile Female Volunteers Including Elderly||AstraZeneca|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|114|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2015|October 13, 2015|December 4, 2013|No|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT02005211||54872|
NCT02005224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMUC-NIH-LCHF-P1-2012|Effect of Low-carbohydrate/High-fat Diet on Glucose Tolerance and Lipid Profile in Lean, Healthy Women|Effect of Low-carbohydrate/High-fat Diet on Glucose Tolerance and Lipid Profile in Lean, Healthy Women|LCHF|Atlantis Medical University College|Yes|Completed|August 2012|March 2013|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005224||54871|
NCT02005497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45447-EJ|Increasing Implementation of Evidence-based Interventions at Low-wage Worksites|Increasing Implementation of Evidence-based Interventions at Low-wage Worksites||University of Washington|No|Active, not recruiting|December 2013|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|75|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005497||54850|
NCT02005835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUREMalawi|Promoting Uptake and Retention of Option B+ in Malawi|Improving Uptake and Retention in PMTCT Services Through Novel Approaches in Family Supported Care and in Community Peer Outreach Support in Malawi|PURE|Lighthouse Trust|No|Recruiting|November 2013|August 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|1050|||Both|16 Years|N/A|No|||December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02005835||54824|
NCT02006134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00894|Pediatric Vasculitis Initiative|Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes|PedVas|University of British Columbia|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1600|Samples With DNA|Serum, plasma, biopsy tissue, urine, DNA|Both|N/A|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children or adolescents diagnosed with vasculitis at any of the participating PedVas study        centres|July 2015|July 16, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02006134|2 Years|54801|
NCT02006160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU3270511E|Effects of Dalfampridine on Cognition in Multiple Sclerosis|Effects of Dalfampridine on Cognition in Multiple Sclerosis||State University of New York at Buffalo|No|Recruiting|December 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||January 2016|January 6, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006160||54799|
NCT02006758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-064-EU-HT|Observational Study of the EnligHTN Renal Denervation System in Patients With Uncontrolled Hypertension|EnligHTN European Observational Study||St. Jude Medical|No|Recruiting|November 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with uncontrolled hypertension|January 2016|January 20, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006758||54753|
NCT02007044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0703|Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)|Randomized Study of Ibrutinib Versus Ibrutinib Plus Rituximab (i Versus iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|Yes|Recruiting|December 2013|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|208|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007044||54731|
NCT02006745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 052|An Open Label Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Treatment of Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection|An Open Label, Randomised, Pilot Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Response Guided Treatment of Acute Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection|CHAT|St Stephens Aids Trust|No|Completed|January 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006745||54754|
NCT02007369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWRP2013|Relapse Prevention Through Social Networking Groups|Effectiveness of Using Social Networking Service to Prevent Smoking Relapse Among Self-reported Quitters: A Pilot Randomized Control Trial||The University of Hong Kong|Yes|Completed|January 2014|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02007369||54706|
NCT01999426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05AR17|Safety and Efficacy of Emergency On-call Respiratory Physiotherapy Services in the Paediatric Intensive Care Unit|Safety and Efficacy of Emergency On-call Respiratory Physiotherapy Services in the Paediatric Intensive Care Unit||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Completed|July 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|93|||Both|N/A|16 Years|No|||November 2013|November 26, 2013|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01999426||55317|
NCT01999699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-22|A Study of the Immune Response to Heplisav in Healthy Older Adults|A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.||Dynavax Technologies Corporation|No|Completed|November 2013|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||August 2015|February 26, 2016|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999699||55296|
NCT02021643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0115|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection|A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection||Gilead Sciences|No|Active, not recruiting|December 2013|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|687|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021643||53614|
NCT02021890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALLANDO|Efficacy Study of Standard Ballroom and Latin Dance Program in Type 2 Diabetes and Obesity|A Standard Ballroom and Latin Dance Program to Improve Fitness and Adherence to Physical Activity in Individuals With Type 2 Diabetes and Obesity|BALLANDO|University of Bologna|No|Completed|September 2011|March 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|40 Years|70 Years|No|||December 2013|December 20, 2013|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021890||53595|
NCT02018354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 104524|Standard ACL Reconstruction vs ACL + Lateral Extra-Articular Tenodesis Study|Multicenter Randomized Clinical Trial Comparing Anterior Cruciate Ligament Reconstruction With and Without Lateral Extra-articular Tenodesis in Individuals Who Are At High Risk of Graft Failure.|STAbiLiTY|University of Western Ontario, Canada|No|Recruiting|January 2014|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|14 Years|25 Years|No|||November 2013|December 10, 2014|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02018354||53867|
NCT02018666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N° 2011-001|Study Comparing Two Ventilation Modes NAVA (Neurally Adjusted Ventilatory Assist) Mode and Spontaneous Breathing With Inspiratory Pressure Support (IPS) Mode in Consecutive Patients Hospitalized for Acute Respiratory Failure Requiring Mechanical Ventilation With Endotracheal Tube.|ZEPHYR: Multicenter, Prospective, Randomized, Open-label Study in Consecutive Patients Hospitalized for Acute Respiratory Failure Requiring Mechanical Ventilation With Endotracheal Tube. This Study Compared Two Ventilation Modes: NAVA Mode and Spontaneous Breathing With Inspiratory Pressure Support (the Latter is Considered as the Reference Ventilation Mode).||Clinact||Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02018666||53843|
NCT02018614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0172|International Validation Study Of The Algoplus Scale In Five Languages|INTERNATIONAL VALIDATION STUDY OF THE ALGOPLUS SCALE IN FIVE LANGUAGES|ALGOPLUS LE|University Hospital, Clermont-Ferrand||Recruiting|January 2014|January 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|250|||Both|65 Years|N/A|No|Non-Probability Sample|elderly patients|July 2014|July 4, 2014|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02018614||53847|
NCT02008669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0022|Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis|Evaluation of the Nutritional Status of Patients With Multiple Sclerosis and Relationship With Fatigue|NUTRISEP|Lille Catholic University|No|Recruiting|November 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|360|Samples Without DNA|Biological analysis in serum: magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with MS defined according to the revised diagnostic criteria of Mac Donald, with        ages between 18 to 65 years with an Expended disability status scale (EDSS) between 0 and        7 and followed in the services of neurology or physical medicine and rehabilitation.|February 2016|February 5, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02008669||54607|
NCT02008084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNAI-MNA-03|A Pilot Study to Evaluate the Lipid Effects of TRIA-662|A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)||Cortria Corporation|No|Completed|December 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008084||54652|
NCT02008383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049983|Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer|Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer|CaboMAb|Duke University|Yes|Recruiting|January 2014|||January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02008383||54629|
NCT02008643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AOI-07|Health Related Quality of Life in Children With Food Allergy: Comparison to Controls and Other Chronic Diseases|Health Related Quality of Life in Children With Food Allergy: Comparison to Healthy Children and Children With Other Chronic Diseases||Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2014|April 2016|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|1137|||Both|8 Years|18 Years|No|||March 2016|March 18, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02008643||54609|
NCT02008656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-213|Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management|A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management||Memorial Sloan Kettering Cancer Center||Recruiting|November 2013|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008656||54608|
NCT02004639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No.101127-F|Trismus Prevention, Diagnosis and Management: Radiotherapy Planning, Early Detection, and Physical Therapy Intervention|Taiwan: Institutional Review Board||Far Eastern Memorial Hospital||Active, not recruiting|March 2013|||March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|60|||Both|N/A|N/A|No|||December 2013|December 4, 2013|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02004639||54916|
NCT02005562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19912|OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.|A Randomized Study Comparing the Incidence of Acute Clinical or Subclinical Rejection With Two Dosing Regimens of CellCept in de Novo Renal Transplant Recipients Receiving Induction, Cyclosporine and Brief Steroid Therapy||Hoffmann-La Roche||Completed|May 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|December 4, 2013|No|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT02005562||54845|
NCT02004925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070675|Accuracy of Ultrasonography for the Diagnosis of Pneumoperitoneum in the Emergency Department|Accuracy of Ultrasonography for the Diagnosis of Pneumoperitoneum in the Emergency Department||Azienda Ospedaliero-Universitaria Careggi|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients more than 18 years presenting to emergency departments with acute abdominal pain        and clinical suspected pneumoperitoneum|April 2015|April 22, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02004925||54894|
NCT02005510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44731-K|Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women|Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women||University of Washington|No|Enrolling by invitation|March 2014|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|17600|||Female|30 Years|64 Years|No|||December 2015|December 3, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005510||54849|
NCT02005523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.1.1.H2|Study of RNS60 on Pain and Function After Hip Labral Repair|Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Hip Labral Repair or Reconstruction Surgery||Revalesio Corporation||Withdrawn||||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||February 2015|February 4, 2015|December 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02005523||54848|
NCT02005848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada-AAT(IV)-011|Phase II-III Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes|Phase II-III Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes||Kamada, Ltd.|Yes|Recruiting|April 2014|July 2017|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|192|||Both|8 Years|25 Years|No|||February 2015|February 8, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02005848||54823|
NCT01997879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR13324-CS101|Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers|An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers||Aerie Pharmaceuticals|No|Completed|November 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 25, 2013|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01997879||55434|
NCT02006771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461813|Cultural Meal and Postprandial Oxidative Stress|A Randomized Crossover Trial to Compare the Changes of Postprandial Oxidative Stress After Consumption of Meals From Different Cultures in Healthy Chinese Adults||Chinese University of Hong Kong|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|33|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02006771||54752|
NCT02007057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR112013|Effectiveness of Suprascapular Nerve Block in Arthroscopic Shoulder Surgery|Prospective Randomized Comparative Study of the Effectiveness of Suprascapular Nerve Block in Arthroscopic Shoulder Surgery||Hospital Ambroise Paré Paris|Yes|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02007057||54730|
NCT01999153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/119/HP|Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site|Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site|ROPI|University Hospital, Rouen|No|Recruiting|December 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01999153||55338|
NCT01999413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMYLY|Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients|Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics|FAMYLY|French Innovative Leukemia Organisation|Yes|Recruiting|November 2013|December 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|61 Years|No|||March 2016|March 15, 2016|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01999413||55318|
NCT01998724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000220|Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial|Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial|LEAP|Beth Israel Deaconess Medical Center|Yes|Recruiting|August 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|90|||Both|40 Years|N/A|No|||November 2015|November 13, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998724||55370|
NCT02018068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9202|Postoperative Patient-controlled Perineural Analgesia After Orthopedic Surgery by "Remote Control" Versus "Bedside Care"|Postoperative Patient-controlled Perineural Analgesia After Orthopedic Surgery: A Medico-economic Comparative Evaluation of Patient Management by Remote Control Versus Bedside Care|MICREL|University Hospital, Montpellier|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02018068||53889|
NCT02022813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 371-13|Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses|Impact of Supplemental Parenteral Nutrition (SPN) on Energy Balance, and Infection Rate in Intensive Care Patients: Underlying Metabolic, Inflammatory and Immune Mechanisms.|SPN2|Centre Hospitalier Universitaire Vaudois|No|Recruiting|April 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|16 Years|90 Years|No|||February 2016|February 18, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02022813||53525|
NCT02018874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000671-33|A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine|A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer|INPAKT|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02018874||53827|
NCT02019134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Relaxneck-13|Effectiveness of App-based Relaxation for Patients With Chronic Neck Pain|A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Neck Pain|Relaxneck|Charite University, Berlin, Germany|No|Recruiting|April 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019134||53807|
NCT02008682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4075|The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes|The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)||Novo Nordisk A/S|No|Completed|December 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|79 Years|No|||January 2016|January 11, 2016|December 5, 2013|Yes|Yes||No|November 18, 2015|https://clinicaltrials.gov/show/NCT02008682||54606|
NCT02004340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81273829|Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy|Transcutaneous Auricular Vagus Nerve Stimulation as a Complementary Treatment for Pediatric Epilepsy||China Academy of Chinese Medical Sciences|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02004340||54939|
NCT02004626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT071|Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.|Study Phase III, Randomized, Double-blind, Multicenter, National, to Evaluate the Non-inferiority in Efficacy of Investigational Product Regarding the Comparator Product, in Debridement of Devitalized Tissue in Uninfected Pressure Ulcers.||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Withdrawn|January 2015|September 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||July 2015|July 15, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02004626||54917|
NCT02005861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008310|"One-step" Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions|"One-step" Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions|BMDC|Istituto Ortopedico Rizzoli|Yes|Recruiting|April 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|15 Years|50 Years|No|||March 2015|March 27, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02005861||54822|
NCT02005536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV46 (EFC13614)|Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan|Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan||Sanofi|No|Completed|December 2013|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|December 3, 2013||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT02005536||54847|
NCT02005549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19869|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer|A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients||Hoffmann-La Roche||Completed|February 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|70 Years|No|||May 2014|June 30, 2014|December 4, 2013|No|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT02005549||54846|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01998139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305013944|Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis|Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis||Weill Medical College of Cornell University|Yes|Recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|450|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|Subjects will be eligible for enrollment at the time of clinician decision to admit to the        Medical Intensive Care Unit (MICU) for presumed sepsis.|December 2015|December 18, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01998139||55414|
NCT02006459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-123|Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal|Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal|Px-GIGD|University Hospital, Gentofte, Copenhagen|No|Completed|September 2013|October 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|plasma, serum and buffycoat|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients operated at/or cared for at the endocrinology out-patient-clinic, Rigshospitalet,        University of Copenhagen, Copenhagen Denmark|November 2015|November 30, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02006459||54776|
NCT02006472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV7820-CNS-20002|A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease|A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease||Teva Pharmaceutical Industries|Yes|Active, not recruiting|February 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|409|||Both|21 Years|N/A|No|||March 2016|March 2, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006472||54775|
NCT02006485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTX-TGR-103|Ublituximab in Combination With TGR-1202 +/- Ibrutinib in Patients With B-cell Malignancies|A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib, in Patients With B-cell Malignancies.||TG Therapeutics, Inc.|Yes|Recruiting|December 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02006485||54774|
NCT02006784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISA 2013 TASK II|Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)|Pilot Study in Children With Systemic Lupus Erythematosus (SLE) to Assess Flares and to Measure Traditional and Novel Blood Biomarkers and Antibody Titers Following Receipt of Inactivated Influenza Vaccine (IIV)||Vanderbilt University|No|Recruiting|September 2013|December 2015|Anticipated|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serum Blood|Both|8 Years|18 Years|No|Non-Probability Sample|This study will recruit and enroll thirty pediatric patients, 8-18 years of age,with a        diagnosis of mild to moderate (SLEDAI < 6) Systemic Lupus Erythematosus, who are seen for        routine clinic visits in the rheumatology clinics at Texas Scottish Rite Hospital and        Children's Medical Center, Dallas, TX during the 2013-2014 influenza seasons. Treatment        Arms 1 and 2 will be comprised of patients with similar demographics in terms of race,        ethnicity, and gender.|March 2015|March 3, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006784||54751|
NCT02006797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS12-XP/REPHVIM|Communication Between Hospital and Community Pharmacists: Impact on Drug Management at Discharge|Impact of Drug Reconciliation at Discharge and Pharmaceutical Communication Between Hospital and Community Pharmacists on Drug Related Problems: Study Protocol for a Cluster Randomized Cross-over Trial|REPHVIM|University Hospital, Tours|No|Recruiting|January 2014|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|1176|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006797||54750|
NCT02007070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-025|Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)|An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.|No|Active, not recruiting|February 2014|September 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02007070||54729|
NCT01998412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-01-12-001|Iluvien Registry Safety Study|An Open Label, Registry Study of the Safety of Iluvien® 190 Micrograms Intravitreal Implant in Applicator|IRISS|Alimera Sciences|No|Recruiting|December 2013|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|Patients with vision impairment associated with chronic diabetic macular oedema considered        insufficiently responsive to available therapies that were selected to be treated with an        intravitreal implant of ILUVIEN.|August 2015|August 19, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01998412|5 Years|55394|
NCT01998711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156/04|Impact of a Memory Group for Older Adults Reporting Memory Difficulties|Memory Group Intervention for Mild Cognitive Impairment: Impact of a Memory Group for Older Adults Reporting Memory Difficulties.||Bayside Health|No|Completed|October 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|62|||Both|N/A|N/A|No|||September 2005|November 25, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT01998711||55371|
NCT01999179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO21429|Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis|Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis||Medical College of Wisconsin|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|56|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999179||55336|
NCT02018029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0173|Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers|Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers|PREFAC-CRT|University Hospital, Clermont-Ferrand||Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patient eligible to cardiac resynchronisation therapy|December 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018029||53892|
NCT02018042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK2167|An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata|An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata||Columbia University|Yes|Active, not recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018042||53891|
NCT02018055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TALOS-AMI|Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI|A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI||The Catholic University of Korea|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3288|||Both|18 Years|N/A|No|Probability Sample|In this study, 3,288 patients with AMI who underwent PCI with DES and took dual        antiplatelet therapy as aspirin and ticagrelor during 1 month from index PCI will be        randomized to aspirin and ticagrelor versus aspirin and clopidogrel during 11 months.|May 2015|May 26, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018055||53890|
NCT02018380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2986-06-0038|Effects of Shock Absorbing Insoles on Knee Pain and Walking in Persons With Knee Osteoarthritis|Immediate Effects of Shock Absorbing Insoles on Knee Pain, Functional Mobility, and Lower Extremity Biomechanical Characteristics in Persons With Knee Osteoarthritis||Winston Salem State University|No|Completed|August 2006|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|N/A|No|||December 2013|December 16, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT02018380||53865|
NCT02023684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2013.CTIL|Routine Irrigation With Ropivacaine vs. Lidocaine vs. Saline of Surgical Bed in Sleeve Gastrectomy|Routine Irrigation With Ropivacaine vs. Lidocaine vs. Saline of Surgical Bed in Sleeve Gastrectomy||The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|60 Years|No|||November 2013|December 27, 2013|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02023684||53458|
NCT02018640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001144 Phase 2|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2|MAW Phase 2|Mayo Clinic|Yes|Completed|December 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Alaska Native women and their confidants|January 2016|January 12, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018640||53845|
NCT02018653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0452|CASAD for Severe Diarrhea in the Emergency Department|A Double-Blinded Placebo-Controlled Pilot Trial of Calcium Alumina-Silicate (CASAD) in the Treatment of Severe Diarrhea (Grade 3 or 4) in Cancer Patients Presenting for Emergency Care||M.D. Anderson Cancer Center|No|Terminated|December 2013|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|December 17, 2013|No|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT02018653||53844|
NCT02004353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL 5277|Observation of Benefits for Patients Implanted With a Hearing Implant of the Company Cochlear|Cochlear-Implanted Recipient Observational Study|IROS|Cochlear|No|Recruiting|July 2011|July 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|10 Years|N/A|No|Non-Probability Sample|Primary care routine clinical patients, with permanent hearing loss seeking implant        treatment for hearing rehabilitation. Adolescent and Adult patients have limited or no        benefit from conventional acoustic hearing aids.|October 2015|October 15, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004353|2 Years|54938|
NCT02004366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066548|Linagliptin Inpatient Trial|Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes||Emory University|Yes|Recruiting|January 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|280|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02004366||54937|
NCT01997099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Work Smart Study|A Workflow and Satisfaction Study Evaluating the Implementation of a New "Smart" Ambulatory Infusion System|A Workflow and Satisfaction Study Evaluating the Implementation of a New "Smart" Ambulatory Infusion System: Work Smart Study|Work Smart|Smiths Medical, ASD, Inc.|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Home healthcare organizations that utilize ambulatory infusion pumps for their patients        will be approached for participation in the study|November 2015|November 4, 2015|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997099||55494|
NCT02005237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERCONN|Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity|Randomized Controlled Trial Investigating the Effects of a Standardized Aerobic Exercise Intervention on Cognitive Function and Brain Connectivity in Relapsing-remitting Multiple Sclerosis|AERCONN|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|December 2013|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|October 19, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005237||54870|
NCT02005250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thyroid Xtreme|Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism|Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism||Odense University Hospital|No|Recruiting|February 2012|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||10|Anticipated|300|Samples Without DNA|blood, urine|Female|18 Years|85 Years|No|Probability Sample|Women with untreated hyper- or hypothyroidism|April 2015|April 24, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005250||54869|
NCT02006173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCT-TAE|Safety and Efficacy Study of Lidocaine Mixed Hyaluronate on Nasolabial Folds Correction|Safety and Efficacy Study of Hya-Dermis Mixed With Lidocaine Injection for the Improvement of Nasolabial Folds||SciVision Biotech Inc.|No|Not yet recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006173||54798|
NCT02006186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL113810|Pilot and Feasibility Bicycle Train Study|Pilot Study on Bicycle Trains to Improve Children's Physical Activity||Seattle Children's Hospital|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006186||54797|
NCT01998386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWHPA|Tooth Whitening With Hydrogenperoxide in Adolescents|Tooth Whitening With Hydrogenperoxide in Adolescents - Controlled Clinical Trial||University of Nove de Julho|Yes|Recruiting|November 2013|September 2017|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|64|||Both|12 Years|20 Years|No|||September 2013|November 23, 2013|September 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01998386||55396|
NCT01998399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131908|Ticagrelor in Severe Community Acquired Pneumonia|Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia|TCAP|Vanderbilt University|Yes|Terminated|August 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|50 Years|N/A|No|||February 2016|February 12, 2016|November 15, 2013|Yes|Yes|poor enrollment, unable to meet recruitment goals|No|January 8, 2016|https://clinicaltrials.gov/show/NCT01998399||55395|
NCT01998685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550|Prothrombotic Factors and Anaesthesia in Prostate Cancer|Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy||Regina Elena Cancer Institute|No|Completed|June 2013|November 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01998685||55373|
NCT01998698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192/19-11-2013|Monovision vs Multifocal Lens Insertion in Cataract Patients|Monovision Correction Versus Multifocal Lens Insertion Following Emulsification Cataract Surgery||Democritus University of Thrace|Yes|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|75 Years|No|||November 2013|November 29, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998698||55372|
NCT02007083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2034|The NORDSTEN Studies/ The Spinal Stenosis Study|Comparison of Different Surgical Treatments for Lumbar Spinal Stenosis. A Randomized Controlled Trial Comparing the Clinical and Radiological Results Using "Spinous Process Osteotomy", "Bilateral Laminotomy" and "Unilateral Laminotomy With Crossover"|NORDSTEN/SST|Haukeland University Hospital|Yes|Recruiting|November 2013|December 2025|Anticipated|October 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|465|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02007083||54728|
NCT01998945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306014003|Back on My Feet: Emotional Recovery From Fall Injury|Back on My Feet: Emotional Recovery From Fall Injury||Weill Medical College of Cornell University|Yes|Active, not recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|60 Years|N/A|No|||December 2015|December 7, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01998945||55353|
NCT01995474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00012314|Simple Technique to Improve Diagnostic Yield in EUS-FNA|Eliminating the Residual Negative Pressure in the EUS-FNA Needle Before Withdrawal Enhances the FNA Cytology Yield||Medical College of Wisconsin|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01995474||55618|
NCT02017808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-OCT|Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months|A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months|GAO|University at Buffalo|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with relapsing remitting multiple sclerosis Healthy controls without known        neurological problems.|December 2014|December 1, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02017808||53909|
NCT02022527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEU2013|Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis|Cost Effectiveness Analysis for Combination Of Aspirin And Warfarin Versus Warfarin Alone In Egyptian Patients With Heart Valve Prosthesis|HVP|Pharmacoeconomic Unit, Egypt|Yes|Recruiting|June 2013|||July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|300|||Both|15 Years|50 Years|No|||December 2013|December 26, 2013|December 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022527||53547|
NCT02023073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-9977-YR-CTIL|Determination of Physical Parameters Relevant to Ophthalmic Lasers|Study of Physical Parameters Related to Laser Radiation and Its Interaction With Different Parts of the Human Eye||Sheba Medical Center|No|Not yet recruiting|December 2015|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|November 2015|November 22, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023073|1 Day|53505|
NCT02018900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3-016|The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function and Immune Modulation|The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function|CRIB|Maastricht University Medical Center||Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02018900||53825|
NCT02008409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028255|Evaluation of Safety and Efficacy of the EndoLift Liver Retractor|Evaluation of Safety and Efficacy of the EndoLift Liver Retractor: a Pilot Study of a New Internal Laparoscopic Liver Retraction Device||Duke University|No|Withdrawn|November 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 22, 2013|No|Yes|The study was terminated. Six subjects were consented & all were withdrawn before any study    activities took place.|No||https://clinicaltrials.gov/show/NCT02008409||54627|
NCT02008422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XinjiangMU (006)|Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer|A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer||Xinjiang Medical University|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||August 2013|December 6, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02008422||54626|
NCT02008695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD071958|Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo|Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo||Johns Hopkins University|Yes|Active, not recruiting|August 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|984|||Both|10 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008695||54605|
NCT02004938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 13.0345|Internal Jugular Ultrasound Measures During Respiration in Children|Characteristics of the Internal Jugular Vein by Ultrasonography During Respiration in Children||University of Louisville|No|Completed|January 2014|June 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|pediatric emergency department|June 2015|June 30, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02004938||54893|
NCT02005263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0230|Hysteroscopic Assessment of Fallopian Tubal Patency|Hysteroscopic Assessment of Fallopian Tubal Patency||University of Mississippi Medical Center|No|Recruiting|December 2013|April 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Female|18 Years|50 Years|No|||March 2016|March 15, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005263||54868|
NCT02005874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-RD-01|A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition|A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition||Inflamax Research Incorporated|No|Completed|November 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|Samples With DNA|Samples with DNA (Tears) - samples retained, with no intention for extraction of DNA but      rather protein and cytokine analysis will be conducted from the tear collection|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 16 healthy adult volunteers (male or female), aged 18 and older, of which        50% must have signs and symptoms of mild-moderate dry eye syndrome.|December 2013|December 6, 2013|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02005874||54821|
NCT01997346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1192|Multi-level Determinants of Starting ART Late: Aim 2|Multi-level Determinants of Late ART Initiation in Sub-Saharan Africa (LSTART Study): A Cross-sectional Qualitative Situation Analysis at 4 HIV Care and Treatment Clinics in Ethiopia|LSTART|Columbia University|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|136|||Both|18 Years|N/A|No|Non-Probability Sample|We will conduct key informant interviews with 4 clinic personnel (16 across the 4 sites)        to learn about actual practices and provider perspectives in the HIV clinic or ancillary        clinics such as VCT. The 4 clinic personnel in each site will include: the        physician-in-charge of the HIV clinic, a nurse working in the HIV clinic, one peer        educator from the HIV clinic, and a nurse or community counselor from the VCT clinic.|December 2014|December 15, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01997346||55475|
NCT01997632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/914|Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults|Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults|IPV-004|University Hospital, Ghent|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997632||55453|
NCT01997892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120126|TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta|TRANSFORM - Observational Cohort Study of Aranesp Use in EU Haemodialysis Patients Switched From Mircera|TRANSFORM|Amgen|No|Completed|August 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1027|||Both|18 Years|N/A|No|Non-Probability Sample|CKD dialysed patients from EU centers treated with PEG epoetin beta for a minimum of        14weeks prior to switching to darbepoetin alfa.|June 2014|June 3, 2014|December 18, 2012||No||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01997892||55433|
NCT01997905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2011-2|Stroke Feasibility Study|Feasibility Clinical Investigation of a Minimally Invasive Surgically Deployed AtriCure AtriClip Left Atrial Appendage Exclusion System for Stroke Prophylaxis in Patients With Non-Valvular Atrial Fibrillation and in Whom Long Term Oral Anticoagulation Therapy is Medically Contraindicated||AtriCure, Inc.||Completed|January 2014|August 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997905||55432|
NCT01998919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO18633|A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.|A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).||Hoffmann-La Roche||Completed|August 2006|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|November 25, 2013|No|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01998919||55355|
NCT01998152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013230|Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)|The Effect of Individualized NUTritional Counselling on Muscle Mass and Treatment Outcome in Patients With Metastatic COLOrectal Cancer Undergoing Chemotherapy: the COLONUT Study|COLONUT|VU University Medical Center|Yes|Recruiting|November 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01998152||55413|
NCT01999465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedSAU-NMES|NMES Efficacy on Patients With NBPP|Neuromuscular Electrical Stimulation (NMES) Efficacy on Patients With Neonatal Brachial Plexus Palsy (NBPP)||University of Michigan|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Months|6 Months|No|||July 2015|July 27, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01999465||55314|
NCT01995851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCIRN PD05 ON07|Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools|Randomized Evaluation of Live Attenuated vs.Trivalent Inactivated Influenza Vaccines in Schools (RELATIVES)Pilot Study|RELATIVES|Dalhousie University|Yes|Completed|October 2013|April 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|902|||Both|3 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children from junior kindergarten to Grade 8, from 10 elementary schools will participate        in this study.|May 2015|May 25, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01995851||55589|
NCT01995513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-10|Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients|A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer|PLATO|Medivation, Inc.|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|509|||Male|18 Years|N/A|No|||February 2016|February 16, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995513||55615|
NCT02018094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIT Trial|The Amputation Surgical Site Infection Trial (ASSIT)|A Randomised Control Trial to Determine Whether a 5 Day Course of Antibiotics is More Clinically and Cost Effective Than a 24 Hour Prophylactic Course for the Prevention of Surgical Site Infection Following Lower Limb Amputation|ASSIT|University of Hull|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|164|||Both|18 Years|N/A|No|||December 2014|December 14, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02018094||53887|
NCT02024490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10001|The Effect of Maternal and Neonatal Vitamin D Levels on Respiratory Distress Syndrome in Preterm Infants|||Kanuni Sultan Suleyman Training and Research Hospital|Yes|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|N/A|3 Days|No|Probability Sample|Premature infants admitted to neonatal intesive care unit with the diagnosis of        respiratory distress syndrome (RDS) will constitute the RDS group, whereas preterm infants        without RDS will constitute the non-RDS group|January 2014|January 6, 2014|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024490||53396|
NCT02023047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 112|An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing|An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing||RDD Pharma Ltd|No|Terminated|March 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||January 2015|November 15, 2015|December 11, 2013||No|Met primary endpoint|No||https://clinicaltrials.gov/show/NCT02023047||53507|
NCT02023060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0685-IB-CTIL|Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation|||Sheba Medical Center|No|Recruiting|November 2013|||November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Subjects with severe aortic or mitral valve dysfunction (stenosis or regurgitation)        selected for transcatheter aortic or mitral valve replacement|May 2015|May 31, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02023060|1 Year|53506|
NCT02004379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-TEL-2013-01|Register of Telaprevir and Boceprevir in Routine Clinical Practice|||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|1553|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic hepatitis C, genotype 1, who are elegible to be treated with        telaprevir or boceprevir|July 2015|July 14, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02004379|12 Months|54936|
NCT02004392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-026|Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025|A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication||FORUM Pharmaceuticals Inc|Yes|Suspended|June 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|55 Years|85 Years|No|||September 2015|September 14, 2015|November 27, 2013|Yes|Yes|Study has been suspended due to clinical hold.|No||https://clinicaltrials.gov/show/NCT02004392||54935|
NCT02004652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGS-2013-PRU|Prucalopride for Postoperative Ileus in Patients Undergoing Gastrointestinal Surgery|A Randomized, Controlled, Double-blind Efficacy and Tolerability Study Of Prucalopride For The Treatment Of Postoperative Ileus In Patients Undergoing Gastrointestinal Surgery||Jinling Hospital, China|Yes|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||August 2015|August 29, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004652||54915|
NCT02005276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819103|Way to Be Active 2 (Lotteries)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Lottery Incentives||University of Pennsylvania|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|209|||Both|18 Years|N/A|No|||November 2013|March 10, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02005276||54867|
NCT01996891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006708|Asthma (and Dietary) Inflammation Reduction|Effects of an Anti-Inflammatory Diet on Pulmonary Function in Pediatric Asthma|AIR|Children's Hospital Boston|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|41|||Both|10 Years|21 Years|No|||July 2015|July 27, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996891||55510|
NCT01996904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-2013-03|Prospective Randomized Comparative Study of Outcome of Subscapularis Tear|A Prospective Randomized Comparative Study of 191 Subscapularis Tear: Clinical and Radiologic Outcome - Arthroscopic Repair vs Debridement||CM Chungmu Hospital|Yes|Completed|March 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|191|||Both|44 Years|83 Years|No|||January 2014|January 24, 2014|November 22, 2013||No||No|December 6, 2013|https://clinicaltrials.gov/show/NCT01996904||55509|Limitation of this study was the low retention of patients during follow-up period. Our cases only yielded 75% retention of patients after twenty-four-months follow-up and this might act as a bias in our study.
NCT02005887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 41-13|TRial on the Endocrine Activity of Neoadjuvant Degarelix|A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer|TREND|International Breast Cancer Study Group|Yes|Recruiting|February 2014|September 2021|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02005887||54820|
NCT01997112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATHBP_2013|PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study|PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study|PATH-BP|University of Edinburgh|Yes|Recruiting|January 2014|August 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 23, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997112||55493|
NCT01997606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/398|House Dust Mite Allergen Reduction in Bedding: Purotex Impregnated Covers of Bekaert Textiles|Cross-over Study of the Impact of Purotex Covers on the Concentration of House Dust Mite Allergen in Bedding and the Quality of Life in Patients With Allergic Rhinitis to House Dust Mite.|Purotex covers|University Hospital, Ghent|No|Enrolling by invitation|November 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997606||55455|
NCT01997619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30245705|Biological Mesh Repair of Complex Hernias in High Risk Patients|Biological Mesh Repair of Complex Ventral Hernias in High Risk Patients||Rigshospitalet, Denmark|Yes|Completed|November 2011|November 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|||Both|18 Years|85 Years|No|Non-Probability Sample|16 consecutive patients with biological mesh repair|November 2013|November 24, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT01997619||55454|
NCT01997866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300300|Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure|Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure||University of Florida|No|Suspended|January 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|700|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|November 1, 2013||No|Re-evaluate inclusion/exclusion criteria|No||https://clinicaltrials.gov/show/NCT01997866||55435|
NCT01997645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FN HK CP 2013|Surgical Treatment of High Perianal Fistulas|Ligation of Intersphincteric Fistula Tract (LIFT) Versus Rectal Advanced Mucosal Flap (RAF) in Surgical Treatment of High Perianal Fistulas|LIFTRAF|University Hospital Hradec Kralove|Yes|Recruiting|November 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997645||55452|
NCT01997918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTS 2. Haplo HSCT|Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT|Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Relapse After a First Allogeneic HSCT: a Retrospective Cohort Study by the German Cooperative Transplant Study Group||University Hospital Tuebingen|No|Enrolling by invitation|October 2013|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving salvage secondary haploidentical allogeneic HSCT after failure of        primary allogeneic HSCT|December 2014|December 3, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01997918||55431|
NCT01998165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102524|A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised|An Open-Label Study to Evaluate the Efficacy and Safety of JNJ-268229 in Pediatric Subjects General Anesthetised||Janssen Pharmaceutical K.K.|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|1 Year|15 Years|No|||November 2015|November 13, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01998165||55412|
NCT01998425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB100-2929B-FibLC-CGMH|Circulating Fibrocytes in Non-small Cell Lung Cancer.|||Chang Gung Memorial Hospital|No|Recruiting|November 2013|July 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with histologically or cytologically confirmed non-small cell lung cancer (NSCLC)        will be enrolled and evaluated from 2013 to 2016. Disease in all cases was staged with        computed tomography (CT) of the chest, breast (if resectable) and positron emission        tomography (PET, if resectable) within 3 months before enrollment.|October 2013|July 29, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT01998425||55393|
NCT01995500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioNIR-002|Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study|NIREUS|Medinol Ltd.|Yes|Active, not recruiting|January 2014|||October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995500||55616|
NCT01995526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14682|A Study of Insulin Peglispro in Healthy Male Japanese Participants|A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of Insulin Peglispro (LY2605541) in Healthy Male Japanese Subjects||Eli Lilly and Company|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|November 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01995526||55614|
NCT02022254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3817|Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects|An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects||Novo Nordisk A/S|No|Completed|December 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 1, 2014|December 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022254||53567|
NCT02022553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNKOR2013|Procedure RACHEL in Complex Treatment of Rectal Cancer|Complex Treatment of Rectal Cancer|RACHEL|Voronezh N.N. Burdenko State Medical Academy|Yes|Active, not recruiting|February 2006|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|75 Years|No|||December 2013|December 27, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02022553||53545|
NCT02023697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16507|Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone|A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone||Bayer|Yes|Active, not recruiting|March 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|370|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|December 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023697||53457|
NCT02023970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0241|TRANSLINK: Defining the Role of Xeno-directed and Immune Events (SVD) in Patients Receiving Animal-derived Bioprosthetic Heart Valves|TRANSLINK: A Prospective, Multi-center, Multi-national, Non Randomized, Open, Study to Defining the Role of Xeno-directed and Immune Events (SVD) in Patients Receiving Animal-derived Bioprosthetic Heart Valves.|TRANSLINK|Nantes University Hospital|No|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1460|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02023970||53436|
NCT02024295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XMX-AH-001|Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis|Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis||Zhejiang Hisun Pharmaceutical Co. Ltd.|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|90 Years|No|||May 2014|May 28, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02024295||53411|
NCT02023944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1389-P|Maintaining Cognitive Health in Aging Veterans|Maintaining Cognitive Health in Aging Veterans||VA Office of Research and Development|No|Recruiting|November 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|164|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02023944||53438|
NCT02024256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG33|Cold Magnesium Sulfate Solution for Perineal Swelling Following Vaginal Delivery|Comparison Between Treatment With Gauze Soaked With Cold Magnesium Sulfate Solution Against Gauze Soaked With Cold Water for Treatment of Perineal Swelling Following Vaginal Delivery - A Double Blind Placebo Controlled Trial|MgSo4|HaEmek Medical Center, Israel|Yes|Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|206|||Female|18 Years|N/A|No|||February 2016|February 21, 2016|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02024256||53414|
NCT02004405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUES01|Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises|The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises||Federal University of Espirito Santo|Yes|Completed|July 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|65 Years|No|||December 2013|December 6, 2013|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02004405||54934|
NCT02004418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-Amanie-02|A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland|A Prospective Single-Arm Phase I/II Study Using 11C-Choline PET Scans for Dose Escalated Hypofractionated Image Guided Inversely Planned Intensity Modulated External Beam Radiotherapy With Boost to PET Defined Dominant Intraprostatic Lesions and as a Predictive Factor for Biochemical Disease-Free Survival in Patients With Localized Prostate Cancer||AHS Cancer Control Alberta|Yes|Recruiting|March 2014|December 2022|Anticipated|December 2022|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Male|18 Years|N/A|No|||December 2015|December 31, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02004418||54933|
NCT02004665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo012|Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study|Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study by the DELIRIUM-CORDIS Investigators.||Ospedale San Donato|No|Recruiting|December 2013|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|70 Years|N/A|No|Probability Sample|patients with acute coronary syndrome and delirium|December 2013|December 4, 2013|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02004665|12 Months|54914|
NCT02004678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1150-A-U101|Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus|Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|September 2013|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||December 2013|December 4, 2013|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02004678||54913|
NCT02004951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0290|BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions|BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions|BATTLE|Nantes University Hospital|No|Recruiting|March 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|186|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02004951||54892|
NCT02005575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032069|The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade|The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade||Cedars-Sinai Medical Center||Active, not recruiting|October 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2015|February 2, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02005575||54844|
NCT01996657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-002|D-dimer and Oral Anticoagulation Therapy in Patients With Mechanical Valve Replacement|D-dimer Levels Determined the Intensity of Oral Anticoagulation in Patients With Mechanical Valve Replacement|3D-intensity|Wuhan Asia Heart Hospital|Yes|Completed|November 2013|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|800|Samples Without DNA|Plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffered mechanical valves replacement because of valves dysfunction; and oral        anticoagulation therapy with warfarin|December 2015|February 29, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01996657||55527|
NCT02017288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914018|Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan|Natural History Of Oral Cancer Precursor Lesions: A Prospective Cohort Study||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|N/A|||Anticipated|4000|||Both|21 Years|100 Years|No|||February 2016|March 1, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02017288||53949|
NCT02016781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1102|Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)|A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)||Medical College of Wisconsin|Yes|Recruiting|December 2013|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|50 Years|75 Years|No|||March 2016|March 4, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016781||53988|
NCT02017054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0827-IB-CTIL|Feasibility and Outcomes of Repetitive Radial Approach|Feasibility and Outcomes of Repetitive Radial Approach||Sheba Medical Center|No|Recruiting|January 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with previous history of trans radial cardiac cath who are planned for additional        trans radial cardiac cath|June 2015|June 2, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02017054|1 Month|53967|
NCT02013791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-024|Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease|||Allergan|Yes|Recruiting|April 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013791||54217|
NCT02013804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-514-01|A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies||MedImmune LLC|No|Active, not recruiting|December 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013804||54216|
NCT02013817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18434|CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy|CHAIROS - Effect of Early Brief Intensification by Chemoimmunotherapy With FCR Followed by FR and Rituximab Maintenance on Clinical Response in Chemo-naïve Patients With B-CLL||Hoffmann-La Roche||Completed|October 2005|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|December 3, 2013|No|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT02013817||54215|
NCT02014103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-223-SOL-00102|Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients|Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients||University of Cincinnati|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014103||54193|
NCT02014116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13873|A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body|A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014116||54192|
NCT02014129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15154|A Study of LY2835219 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY2835219 in Japanese Patients With Advanced Cancer||Eli Lilly and Company|No|Active, not recruiting|December 2013|December 2015|Anticipated|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|N/A|No|||July 2015|July 15, 2015|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014129||54191|
NCT02013778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22213|Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC|Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2013|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|49|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013778||54218|
NCT02014376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-003|Study of Effectiveness and Safety of SD-101 in Subjects With Epidermolysis Bullosa|A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa||Scioderm, Inc.|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|6 Months|N/A|No|||June 2014|June 26, 2014|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014376||54172|
NCT02014623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514/13|Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis|Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis||Bayside Health|No|Not yet recruiting|February 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|65 Years|No|||January 2014|January 16, 2014|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014623||54153|
NCT02014636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200249|Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)|A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma||Novartis|Yes|Recruiting|December 2013|May 2021|Anticipated|May 2021|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014636||54152|
NCT02014948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 13527313.3.0000.5503|Vibratory Therapy for Patients With Chronic Low Back Pain|Implementation of a Physiotherapy Intervention for Patients With Chronic Low Back Pain||Laboratório de Engenharia de Reabilitação Sensorio Motora|Yes|Recruiting|June 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02014948||54128|
NCT02014675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67 (TA108)|SD01 Registry (SD01 ICD Lead)|SD01 Registry (SD01 ICD Lead)|SD01 Registry|Biotronik SE & Co. KG|No|Active, not recruiting|March 2014|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|280|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard ICD/CRT-D (cardiac resynchronization therapy plus defibrillator)        indication|October 2015|October 7, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02014675|5 Years|54149|
NCT01995864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1845|Critical Time Intervention-Task Shifting: Randomized Controlled Trial|A Pilot Multi-center Randomized Controlled Trial of Critical Time Intervention - Task Shifting (CTI-TS) Versus Usual Care for People With Psychotic Disorders|CTI-TS RCT|Columbia University|Yes|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|110|||Both|21 Years|65 Years|No|||July 2015|July 29, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01995864||55588|
NCT02006940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRCC FMBA|The Study Of Probe-Based Confocal Laser Endomicroscopy Of Distal Airways In Diagnostics Of Lung Diseases|Comparative Study Of The Methods Of Probe-Based Confocal Laser Endomicroscopy Of Distal Airways, High Resolution Computed Tomography And Morphology In Diagnostics Of Lung Diseases|pCLE|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia|No|Recruiting|September 2011|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02006940||54739|
NCT02007252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885X2201|ACZ885 for the Treatment of Abdominal Aortic Aneurysm|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of Subcutaneous ACZ885 for the Treatment of Abdominal Aortic Aneurysm|AAA|Novartis|No|Terminated|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|57|||Both|45 Years|N/A|No|||January 2016|January 12, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007252||54715|
NCT02007512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-12|Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal||Medivation, Inc.|No|Active, not recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007512||54696|
NCT02007525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|321872|Yoga to Improve Physical Function and Maximal Walking Distance Among Patients With Peripheral Arterial Disease|Yoga to Improve Physical Function and Maximal Walking Distance Among Patients With Peripheral Arterial Disease: A Pilot Study||University of Michigan||Terminated|February 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|7|||Both|41 Years|N/A|No|||December 2015|December 11, 2015|November 22, 2013||No|Insufficient enrollment; non-interest by target sample|No||https://clinicaltrials.gov/show/NCT02007525||54695|
NCT02015767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-407-RD|Patient Registry of Roflumilast In Real Life|Patient Registry of Roflumilast In Real Life||Takeda|No|Active, not recruiting|February 2013|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1950|||Both|18 Years|N/A|No|Non-Probability Sample|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing        authorization.        The registry sites will comprise hospitals, and office-based physicians. The investigators        will be mainly pulmonologists, or as per the standard practice of the specific country.|January 2016|January 15, 2016|December 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015767||54066|
NCT02015780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_311|Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasiglifam (TAK-875) Compared to Placebo as Add-on to Preexisting Antihyperglycemic Therapy Over 16 Weeks With 36-week Extension in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or Stage 5 on Dialysis||Takeda|No|Withdrawn|December 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|December 13, 2013|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT02015780||54065|
NCT02016807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMI-008|ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial|Treatment and Prevention of Oral and Alimentary Mucositis Using Polymerized Cross-Linked High Potency Sucralfate as a Single Agent Therapy||Ashley Downs Bioscience|Yes|Active, not recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|180|||Both|18 Years|95 Years|No|Non-Probability Sample|Cancer-treatment patients who have developed or at risk of developing mucositis of the        oropharyngeal cavity, esophagus, stomach, small and large intestine.|December 2013|December 16, 2013|December 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02016807||53986|
NCT02016820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM9955|Effect of Acid Suppression Medication on Pediatric Microbiome|Effect of Proton Pump Inhibitors on the Colonic Microbiome in Children||Columbia University|Yes|Recruiting|November 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|N/A|4 Years|No|||February 2015|February 2, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016820||53985|
NCT02017067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-101020-E|The Effect of Exercise Training in the Community-dwelling Adults With Chronic Disorders|The Effect of Exercise Training in the Community-dwelling Adults With Chronic Disorders||Far Eastern Memorial Hospital|Yes|Completed|April 2012|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|58|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02017067||53966|
NCT02013505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203774|A Validated Educational Video Intervention Improves the Quality of Bowel Preparation for Colonoscopy|||University of Missouri-Columbia|No|Active, not recruiting|February 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|298|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013505||54239|
NCT02017574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0970-M|Motor Learning in Stroke|Facilitating Implicit Learning to Improve Neurorehabilitation in Stroke||VA Office of Research and Development|No|Active, not recruiting|October 2013|September 2016|Anticipated|September 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|45 Years|80 Years|No|||October 2015|October 28, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017574||53927|
NCT02013518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1943|Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia|Cognitive Behavioural Therapy for Persons With Mild Cognitive Impairment or Dementia in the Early Stages||Oslo University Hospital|No|Enrolling by invitation|September 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2013|December 11, 2013|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013518||54238|
NCT02013830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18469|A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer|A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy||Hoffmann-La Roche||Completed|May 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|December 3, 2013|No|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT02013830||54214|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT02013843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCOCmunicipalities|Treatment of Overweight and Obese Children -Using the "Holbaek-Method" in a Municipality Based Treatment Program.|Treatment of Overweight and Obese Children - the "Holbaek-Method" in a Municipality Based Treatment Program.||Holbaek Sygehus|Yes|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|800|||Both|3 Years|18 Years|No|||December 2013|December 16, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02013843||54213|
NCT02014389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA -13 -0640-YR-CTIL|Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer|Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinal Dystrophy Patients||Sheba Medical Center|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two Groups: 1. Control, 2. Patients - Glaucoma patients with early damage (nasal step) of        Humphrey visual field (HVF), Glaucoma patients with advanced damage of HVF (arcuate ,        tubular vision) and retinal dystrophy patientsl|November 2015|November 22, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014389||54171|
NCT02014649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA51-350-203|Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza|Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B|FROSTY|Biota Scientific Management Pty Ltd|Yes|Terminated|November 2013|May 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|5 Years|17 Years|No|||October 2015|October 6, 2015|November 24, 2013|Yes|Yes|Study was terminated as per BARDA decision to terminate contract.|No||https://clinicaltrials.gov/show/NCT02014649||54151|
NCT02014662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200794|A Methodology Study to Assess Muscle Damage After Eccentric Exercise|A Pilot Study to Measure Force Recovery and Protein Synthetic Rates After Unilateral Eccentric Exercise in Healthy Males Volunteers Unaccustomed to Eccentric Exercise||GlaxoSmithKline|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014662||54150|
NCT02014688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2013-3 NORM-us|Optical Coherence Tomography (OCT) Normative Data Collection Study|Multi-center Study for Normal Database of Optic Nerve Head, Retinal Nerve Fiber Layer, and Macula Parameters With the Heidelberg Spectralis OCT, Study 3|S-2013-3|Heidelberg Engineering GmbH|Yes|Completed|December 2013|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|166|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Recruitment will be from persons who respond to recruitment initiatives at the individual        centers or have signed a release saying that they are willing to be approached for        participation in research.        At least 87 subjects (enrollment target: 135 subjects) will be selected from qualifying        normal volunteers. Age range will be from ≥18 to 90 years. The age of the subjects will be        defined by their month of birth versus the month of giving consent to participate in this        study. A subject who is 40 years and 11 months old will be counted as being in the age        group "31 to 40 years". Each site will attempt to recruit subjects in about equal numbers        in each age group. The distribution in the age groups should be fairly equal among        subjects in each ethnic group alone.|August 2015|August 19, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02014688||54148|
NCT01996150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/URMC- 2013|Bleach Bath Treatment of Adults With Atopic Dermatitis|Assessing the Impact of Bleach Baths on Itch, Cutaneous Inflammation, Microbial Flora and Skin Barrier Function in Adult Atopic Dermatitis Subjects||University of Rochester|No|Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01996150||55566|
NCT01996436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVT_201310 (HSC-MS-13-0586)|The Intra-arterial Vasospasm Trial|The Intra-arterial Vasospasm Trial- A Multi-center Randomized Study|IVT|The University of Texas Health Science Center, Houston|Yes|Recruiting|April 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|330|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01996436||55544|
NCT02006966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0693|The Impact of Intraoperative Systemic Lidocaine Infusion on Chronic Postoperative Pain After Video-assisted Thoracic Surgery (VATS)|||Yonsei University|Yes|Recruiting|December 2013|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|168|||Both|20 Years|65 Years|No|||December 2013|December 4, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006966||54737|
NCT02007239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010459|Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)|Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis||Children's Hospital of Philadelphia|Yes|Recruiting|December 2013|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Months|25 Years|No|||October 2015|October 26, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02007239||54716|
NCT02007538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR01|Thin Prep Versus Traditional Cytological Procedure for Lung Cancer|Assessment of Adequacy and Characteristics Molecular of the Sample Obtained by Fine-needle Aspiration (FNA) Cytology Lung, Mounted With Thin Prep Compared to the Conventional Smear, in the Diagnosis of Lung Cancer.||Università degli Studi di Ferrara|No|Recruiting|May 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|84 Years|No|Probability Sample|Patients with suspected lung cancer|December 2013|December 5, 2013|May 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02007538||54694|
NCT02015234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F203|12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients|A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia|BESTFIT-OLE|Tonix Pharmaceuticals, Inc.|No|Completed|December 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|18 Years|65 Years|No|||October 2015|October 23, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015234||54107|
NCT02015494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX2012Q-01|Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention|Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years||VaxInnate Corporation|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|316|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015494||54087|
NCT02016274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG7001|Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer|Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as First Line Treatment for Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial||Peking University|Yes|Recruiting|December 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02016274||54027|
NCT02016794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR_ACIS|A Focused Registry on Anterior Cervical Interbody Spacer ACIS|A Focused Registry on Anterior Cervical Interbody Spacer Procedures in Patients With Cervical Spine Degeneration|ACIS|AO Clinical Investigation and Documentation|No|Active, not recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|21 Years|N/A|No|Probability Sample|Patients undergoing surgery for degenerative cervical condition that requires anterior        decompression and fusion in a single or multiple levels|February 2016|February 10, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016794|6 Months|53987|
NCT02016547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005493-66|Thrombectomy Under Reopro Versus Alteplase to Treat Stoke|Thrombectomy Under Reopro Versus Alteplase and Neurologic Deficit Outcome Trial|TURANDOT|SOS Attaque Cérébrale|Yes|Terminated|September 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016547||54006|
NCT02016560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A05|Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects|An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease||Avid Radiopharmaceuticals|No|Active, not recruiting|December 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|383|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016560||54005|
NCT02017080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440/VI-3|Fetal Thyroid Ultrasound And Fetal Thyroid Hormones|Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus||University of Belgrade|No|Recruiting|January 2014|January 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Female|20 Years|45 Years|No|Probability Sample|Groups are selected from State tertiary referral centre for Gynecology and Obstetrics|January 2015|January 5, 2015|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02017080||53965|
NCT02017301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-800-12-13-1|Vector Analysis of Body Composition in Cirrhotic Patients With Infections|Impact of Acute Infections in Cirrhotic Patients on Body Composition Determined by Bioelectrical Impedance and Vector Analysis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Active, not recruiting|November 2009|February 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Population will be selected from the Liver Clinic at the Department of Gastroenterology at        at tertiary care center in Mexico|September 2015|September 29, 2015|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02017301||53948|
NCT02017587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-001|Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection|Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection||Vaccine and Gene Therapy Institute, Florida|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|plasma/serum PBMC|Both|18 Years|N/A|No|Non-Probability Sample|Patients volunteers|February 2015|February 25, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017587||53926|
NCT02013531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-002|Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms|Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2013|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013531||54237|
NCT02013856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR05/2013|The Effects of Apple Derived Flavanols on Cardiovascular Disease Risk (FLAVASCULAR Study)|The Effects of Apple Derived Flavanols on Cardiovascular Disease Risk|FLAVASCULAR|Institute of Food Research|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|39|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02013856||54212|
NCT02013869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|Low Flow Anaesthesia|Low Flow Anaesthesia; Cost-effectiveness of the Flow-I Anaesthesia Machine, a Comparison to Established Anaesthesia Delivery Unit|LF|Karolinska Institutet|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|November 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013869||54211|
NCT02014142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU M1|Comparison of Latanoprost PPDS With Timolol Maleate GFS in Subjects With Ocular Hypertension or Open-Angle Glaucoma|A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma||Mati Therapeutics Inc.||Recruiting|December 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014142||54190|
NCT02014155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNISC_001|Inspiratory Muscle Training and Respiratory Electromyographic Activity in COPD|Effects of Inspiratory Muscle Training on Respiratory Electromyographic Activity in Patients With COPD Participants and Non-participants of a Pulmonary Rehabilitation Program||University of Santa Cruz do Sul|No|Recruiting|August 2013|December 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|45|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|November 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02014155||54189|
NCT02014402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1202 (IG1202-A, -B, -C, -D)|Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Open Surgeries|A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries||Grifols Biologicals Inc.|No|Completed|December 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|181|||Both|N/A|N/A|No|||November 2015|November 13, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014402||54170|
NCT02044432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST_02|Treatment of Patients With Chronic Osteoarthritis With Ginger Kidney Compress - a Randomized, Controlled Trial|Treatment of Patients With Chronic Osteoarthritis (Gonarthrosis) With Ginger Kidney Compress - a Randomized, Controlled Trial|OST_02|ARCIM Institute Academic Research in Complementary and Integrative Medicine||Enrolling by invitation|January 2014|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|32|||Both|30 Years|N/A|No|||January 2014|January 22, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02044432||51867|
NCT02044666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004|Cook Micronized Small Intestinal Submucosa (SIS) for Critical Limb Ischemia|Pilot Safety Study of Micronized Small Intestinal Submucosa (SIS) for Critical Limb Ischemia||Cook||Active, not recruiting|February 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|January 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044666||51849|
NCT02006654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14863A|Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor|Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor|STARBRIGHT|H. Lundbeck A/S|Yes|Recruiting|March 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|720|||Both|50 Years|N/A|No|||December 2015|December 10, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02006654||54761|
NCT02007265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306-2011|Post-stroke Triage "DOC": Simple Screening for Depression, Obstructive Sleep Apnea and Cognitive Impairment|Post-stroke Triage "DOC": Simple Screening for Depression, Obstructive Sleep Apnea and Cognitive Impairment||Sunnybrook Health Sciences Centre|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1504|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics.|November 2015|November 23, 2015|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02007265||54714|
NCT02008396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAA-1|MDMA-assisted Therapy for Social Anxiety in Autistic Adults|Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|February 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008396||54628|
NCT02016027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|carica 2013|Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter|Pharmacological Effect of Carica Folia Mother Tincture in Healthy Individual's Blood Parameter.|CF2013|Fr Muller Homoeopathic Medical College|Yes|Enrolling by invitation|September 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2013|December 14, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02016027||54046|
NCT02016521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00-M108-13A|Cooling Fabrics and Exercise Performance in Endurance Athletes|"Keep Cool": a Randomized Trial on the Effect of Wearing a Garment Made of Cooling Fabrics on Thermoregulatory, Cardiorespiratory, and Perceptual Responses to Exercise in Endurance-trained Athletes||McGill University|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016521||54008|
NCT02016534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130111|Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors|A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors||Amgen|No|Active, not recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016534||54007|
NCT02046070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16020|Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma|An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|March 2014|July 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|148|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046070||51741|
NCT02046304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-532|PP-Gemcitabine & External Beam Radiation-Sarcomas|A Phase I Study of Preoperative Concomitant Gemcitabine and External-Beam Radiation Therapy and Surgical Resection for Patients With Extremity and Trunk Soft Tissue Sarcomas||M.D. Anderson Cancer Center|No|Completed|December 2001|||March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|No|||March 2015|March 25, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046304||51723|
NCT02046551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305012021|Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers|||Yale University|Yes|Suspended|April 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|No|||March 2016|March 23, 2016|January 23, 2014|Yes|Yes|funding lost|No||https://clinicaltrials.gov/show/NCT02046551||51704|
NCT02046564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-12-005|Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|February 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|64 Years|No|||February 2016|February 22, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046564||51703|
NCT02046824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell Saver-001|Cell Savers and Blood Quality|The Rheologic Properties and Oxygen Transport Capacity of Red Blood Cells Processed by 3 Different Types of Cell Saving, and Its Effects on Microcirculatory Blood Flow and Tissue Oxygenation in Vivo||University Medical Center Groningen|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|4||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02046824||51683|
NCT02017314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830458909|VAS Correlation With BMI|Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial||Istanbul University|Yes|Recruiting|November 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|60 Years|No|||December 2013|December 16, 2013|December 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017314||53947|
NCT02017327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2345-PIV-02/13|Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose|Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance||Laboratoires Thea|No|Recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|396|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02017327||53946|
NCT02047357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROS-PILL-001|Participatory Intervention to Reduce Maternal Depression and Under Five Child Morbidity|Participatory Intervention to Reduce Maternal Depression and Under Five Child Morbidity- A Cluster-Randomized Controlled Trial|ROSHNI|Pakistan Institute of Learning and Living|Yes|Recruiting|December 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|44 Years|No|||August 2015|August 15, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02047357||51642|
NCT02047370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0046UG|Manual Therapy in Patients With Asthma|Effects of Manual Therapy in Patients With Asthma||Universidad de Granada|Yes|Suspended|January 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|No|||December 2015|December 3, 2015|January 22, 2014||No|The sample size was not completed|No||https://clinicaltrials.gov/show/NCT02047370||51641|
NCT02047656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFF269X2105|To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension|A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects||Novartis|No|Terminated|August 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047656||51619|
NCT02047669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA09|Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians|Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|67 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047669||51618|
NCT02043717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitaminD-HMO-CTIL|The Effect of Vitamin D on Lung Function in Patients With Cystic Fibrosis|The Effect of Vitamin D on Lung Function in Patients With Cystic Fibrosis||Hadassah Medical Organization|Yes|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|plasma|Both|4 Years|N/A|No|Non-Probability Sample|CF patients (both children and adults) from The Center for Chronic Diseases in Hadassah        Medical Organization.|January 2014|January 21, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02043717|1 Year|51922|
NCT02014168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU006|Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine|A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and the Viroflu® Seasonal Influenza Vaccine||University of Oxford|No|Terminated|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 29, 2014|November 8, 2013||No|Futility|No||https://clinicaltrials.gov/show/NCT02014168||54188|
NCT02014415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1F-SLU-7113|Alpha-1 Antitrypsin Deficiency Adult Liver Study|Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study||St. Louis University|No|Recruiting|December 2013|August 2021|Anticipated|August 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Samples of liver tissue, serum, plasma, and blood for genetic testing (Induced Pluripotent      Stem Cells (iPS cells), microRNA and DNA) will be collected from each subject at defined      time points.|Both|18 Years|N/A|No|Non-Probability Sample|Pi-ZZ AAT deficient adults with either no previous history of liver disease or Pi-ZZ        adults with mild-moderate liver disease. Biologic family members who are also Pi-ZZ and ≥        18 years of age, will be offered enrollment into the study. The purpose of including        family members is to determine if the natural history of the liver disease is consistent        in a given family.|September 2015|September 22, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014415|5 Years|54169|
NCT02044692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1111_OS|The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients|The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients||Green Cross Corporation|No|Recruiting|January 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|34|||Both|N/A|N/A|No|Non-Probability Sample|Hunter Syndrome(Mucopolysaccharidosis II) Patients|June 2014|June 19, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02044692||51847|
NCT02044705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07-4508 A|Impact of Active and Healthy Families|Impact of Active and Healthy Families (Familias Activas y Saludables): A Family-Based Group Medical Appointment Model for Childhood Obesity in Federally Qualified Health Centers|AHF|University of California, Berkeley|No|Completed|September 2012|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044705||51846|
NCT02006667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17600|A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer|An Open-label Pilot Study Evaluating the Effect of a Combination Regimen of Herceptin, Cisplatin, and Gemcitabine on Time to Disease Progression in Patients With Metastatic Urothelial Cancer||Hoffmann-La Roche||Completed|January 2001|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|December 5, 2013|No|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT02006667||54760|
NCT02006953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00046483|Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement|Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement||University of Michigan|No|Recruiting|August 2011|October 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|113|||Both|N/A|17 Years|No|||December 2014|December 3, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006953||54738|
NCT02008097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45374-EA|Clinical Benefits of B-Flow Ultrasound|Evaluation of Clinical Benefits of B-Flow With the LOGIQ E9 Ultrasound System||University of Washington|No|Enrolling by invitation|October 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|260|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|October 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008097||54651|
NCT02008110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC10-108|Carbohydrate Antigen 125-guided Therapy in Heart Failure|A Randomized Controlled Trial of Carbohydrate Antigen 125-guided Therapy Among Patients Recently Discharged for Acute Heart Failure: Effect on 1-year Mortality or Readmission for Acute Heart Failure (CHANCE-HF).|CHANCE-HF|Fundación para la Investigación del Hospital Clínico de Valencia|Yes|Completed|December 2011|May 2015|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008110||54650|
NCT02008123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|434350-2|Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant|Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant||Dent Neuroscience Research Center|No|Enrolling by invitation|August 2013|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|90 Years|No|||February 2015|February 10, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008123||54649|
NCT02016040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#12-030|Focal Therapy Using HIFU for Localised Prostate Cancer|Focal Therapy Using High Intensity Focused Ultrasound (ABLATHERM®) for Localised Prostate Cancer||Jewish General Hospital|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|50 Years|N/A|No|||December 2013|December 13, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02016040||54045|
NCT02016053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-AKI-02|Incidence and Spectrum of Acute Kidney Injury in Cirrhotics and Assessment of New Biomarkers as Early Predictors of Acute Kidney Injury|||Institute of Liver and Biliary Sciences, India|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|450|||Both|18 Years|70 Years|No|Probability Sample|500 patients with normal renal function. 200 patients with abnormal renal function        fulfilling AKI (Acute Kidney Injury) criteria will be prospectively studied.|November 2014|August 11, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02016053||54044|
NCT02016287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG7002|Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer|Sequential Paclitaxel Chemotherapy and Radiotherapy as First Line Treatment for Elderly Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial||Peking University|Yes|Recruiting|December 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|69 Years|N/A|No|||December 2013|December 13, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02016287||54026|
NCT02016300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oss-mfx-2013|Effects of Unloader Bracing in Clinical Outcome and Cartilage Physiology Following Microfracture of Chondral Defects|Effects of Unloader Bracing in Clinical Outcome and Articular Cartilage Physiology Following Microfracture of Isolated Chondral Defects|Mfxbracing|Stanford University|Yes|Active, not recruiting|January 2013|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|15 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02016300||54025|
NCT02046577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-116|Study of Vitamin D for the Prevention of Acute Respiratory Infections in Children|A Randomized, Double-blind, Controlled Trial of Vitamin D for the Prevention of Acute Respiratory Infections in Children Aged 18 to 36 Months in Santiago, Coyhaique and Punta Arenas, Chile||Pontificia Universidad Catolica de Chile|No|Recruiting|February 2014|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|276|||Both|18 Months|36 Months|Accepts Healthy Volunteers|||April 2015|April 28, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046577||51702|
NCT02046837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN ADT Ex 01|An Exercise Trial and Economic Analysis in Men With Prostate Cancer|A Pilot RCT and Economic Analysis of Three Exercise Delivery Methods in Men With Prostate Cancer on ADT|ADT Ex RCT|University Health Network, Toronto|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|100|||Male|N/A|N/A|No|||March 2016|March 4, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02046837||51682|
NCT02046850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00085|To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers|A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years||AstraZeneca|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046850||51681|
NCT02047097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS401|Dimethyl Fumarate (DMF) Observational Study|A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)|ESTEEM|Biogen|No|Recruiting|November 2013|October 2022|Anticipated|October 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing routine clinical care for Multiple Sclerosis.|July 2015|July 31, 2015|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047097|5 Years|51662|
NCT02047110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.8|BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)|A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.||Boehringer Ingelheim||Active, not recruiting|January 2014|July 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|159|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|January 24, 2014||||No||https://clinicaltrials.gov/show/NCT02047110||51661|
NCT02047682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA10|Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load|Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load|IRMA10|National Research Centre for the Working Environment, Denmark|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Female|18 Years|67 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047682||51617|
NCT02047695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100126|Women With Migraine With Aura Neuroimaging Study|Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins|WOMAN|Odense University Hospital|No|Active, not recruiting|February 2011|||April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|330|||Female|30 Years|60 Years|No|Non-Probability Sample|Selected from a population-based twin registry|January 2014|October 13, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047695||51616|
NCT02043730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002973-23|Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.|A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial|GAP|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Recruiting|January 2014|January 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02043730||51921|
NCT02043951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0015-01|Use and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity|A Prospective, Multicenter, Single Arm, Post-Market, Real-World Global Registry Assessing the Clinical Use and Safety of the LUTONIX Drug Coated Balloon Catheter in Arteries of the Lower Extremity (LUTONIX® Lower Extremity Global (LEG) Registry)|LEG|C. R. Bard|No|Active, not recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Real-world patients requiring drug coated balloon treatment.|September 2015|September 29, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02043951|2 Years|51904|
NCT02043938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS-EEG|Improving Information Extraction From EEG on Cerebral Anesthetic Drug Effects|'Study of the Cerebral Effects of Sevoflurane, Propofol and Remifentanil as Measured by the Spontaneous Electro-encephalogram'||Masimo Corporation|No|Recruiting|January 2014|July 2017|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02043938||51905|
NCT02044172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA96/20/99|Prostate Testing for Cancer and Treatment|The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer|ProtecT|University of Oxford|Yes|Active, not recruiting|June 2001|December 2020|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100000|||Male|50 Years|69 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044172||51887|
NCT02006680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303M29681|Markers of Pubertal Suppression During Therapy for Precocious Puberty|Markers of Adequate Pubertal Suppression During Supprelin LA Therapy for Central Precocious Puberty||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|None Retained|Serum will be collected at four different time points.|Female|3 Years|9 Years|No|Non-Probability Sample|Females diagnosed with central precocious puberty or rapidly progressive puberty based        upon age at start of puberty, physical examination, serum hormone levels and bone age        X-Ray will be recruited. This will be a convenience sample of children scheduled to        receive Supprelin LA insert placement. The subjects will be recruited from two pediatric        endocrinology clinic systems.|September 2014|September 3, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02006680||54759|
NCT02006979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03090|Acute Exercise Cardioprotection From Doxorubicin|The Effects of Exercise Before Doxorubicin Chemotherapy on Cardiac Function||University of British Columbia|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006979||54736|
NCT02006992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJ57|Growth of Infants Fed Hydrolysate Formulas|Growth of Infants Fed Hydrolysate Formulas||Abbott Nutrition|No|Completed|March 2000|November 2000|Actual|November 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|195|||Both|N/A|9 Days|Accepts Healthy Volunteers|||December 2013|December 11, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02006992||54735|
NCT02007837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-ERC: 05/05/2012|Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial|Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) - a Randomised, Placebo-controlled, Double-blind Clinical Trial|4P|UMC Utrecht|Yes|Not yet recruiting|October 2015|February 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Female|18 Years|50 Years|No|||May 2015|May 3, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02007837||54671|
NCT02008708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD006075|Microfinance Intervention to Improve Health of Trauma Survivors in DRC|Microfinance Intervention to Improve Health of Trauma Survivors in DRC||Johns Hopkins University|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|878|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02008708||54604|
NCT02015819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13401|Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas||City of Hope Medical Center|Yes|Recruiting|October 2014|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|December 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015819||54062|
NCT02016066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102897|A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 Following Single Intravenous Administration||Janssen Pharmaceutical K.K.|No|Not yet recruiting|December 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|December 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02016066||54043|
NCT02046057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140020|Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer|Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer|ENCASe|Loma Linda University|No|Enrolling by invitation|February 2014|||February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited through the Loma Linda University Cancer Center. Subjects will        be females with breast cancer undergoing sentinel lymph node dissection between 18 and 100        years of age.|March 2015|March 31, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046057|2 Years|51742|
NCT02046317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0035|Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles|Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles|TUFFEN|The University of Texas Health Science Center, Houston|No|Enrolling by invitation|May 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02046317||51722|
NCT02046330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0004|Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression|Deep Brain Stimulation (DBS) Therapy for Treatment Resistant||The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|22 Years|65 Years|No|||December 2015|December 19, 2015|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046330||51721|
NCT02046343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL111718|Promotora-Led Physical Activity Intervention Trial for Latinas in Texas|ENLACE: A Promotora-Led Physical Activity Intervention Trial for Latinas in Texas||The University of Texas Health Science Center at San Antonio|No|Recruiting|August 2012|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|704|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046343||51720|
NCT02046590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B406201318623|RCT of Efficacy and Safety of Sedation Compared to General Anesthesia for ERCP|A Randomized Controlled Trial (RCT) of Efficacy and Safety of Sedation Compared to General Anesthesia for Endoscopic Retrograde Cholangio-pancreatography||Erasme University Hospital|No|Recruiting|February 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02046590||51701|
NCT02046863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43NS081902-01|Pilot Study for Automated Deep Brain Stimulation Programming|DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping - Phase I||Great Lakes NeuroTechnologies Inc.||Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02046863||51680|
NCT02046876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMA-1301|Swimming Adapted, Therapeutic Exercise and Health Education in the Treatment of Chronic Neck Pain|||University of Malaga|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|175|||Both|18 Years|65 Years|No|||January 2014|January 24, 2014|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02046876||51679|
NCT02046889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMBDS2012|A Bicycle Training Intervention|The Effects of a Bicycle Training Intervention on Health, Physical Activity, Sleep & Community Participation in Youth With Down Syndrome & Autism Spectrum Disorders||University of Michigan|No|Completed|June 2010|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|155|||Both|9 Years|18 Years|No|||January 2014|January 24, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02046889||51678|
NCT02047383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0047UG|Hospital Stay and Respiratory Infection|Repercussion of Hospital Stay in Patients With Respiratory Infection||Universidad de Granada|Yes|Recruiting|January 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|N/A|No|Non-Probability Sample|Hospitalized patients with an acute respiratory infection|December 2015|December 3, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047383||51640|
NCT02047396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009187|Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study|Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study||Mayo Clinic|No|Recruiting|January 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|420|Samples Without DNA|Plasma, serum, and WBCs|Both|18 Years|N/A|No|Non-Probability Sample|Subjects in the 7 County area who are admitted to the Mayo Clinic Hospitals in Rochester,        Minnesota who have their first myocardial infarction and are willing to have blood drawn        and return for an echocardiogram in 3 months.|February 2016|February 1, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02047396||51639|
NCT02047422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0808|A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)|||Yonsei University|Yes|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|80 Years|No|||January 2014|January 26, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047422||51637|
NCT02043496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH099040-01A1|Integrative Cognitive-Affective Therapy for Binge Eating Disorder|Integrative Cognitive-Affective Therapy for Binge Eating Disorder||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02043496||51939|
NCT02043743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT0221012014|Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure|Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure||El-Rayadh Fertility Centre|Yes|Recruiting|January 2014|January 2015|Anticipated|April 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|40 Years|No|||January 2014|January 21, 2014|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043743||51920|
NCT02044185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-SGC-Lymphoma-LAB-01|Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation|Observational Study for Clinical Implications of HMGB1 (High-mobility Group Protein B1) in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation|CHIP-SCT|Seoul St. Mary's Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|blood plasma biopsy tissue samples of colon|Both|18 Years|75 Years|No|Probability Sample|1. patients with bone marrow transplantation of patients with acute leukemia, lymphoma             in patients group          2. normal populations in Health Promotion Center in control group|April 2015|April 21, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044185||51886|
NCT02044445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-10|Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?|||Aristotle University Of Thessaloniki||Completed|November 2009|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Female|20 Years|43 Years|No|||May 2014|May 26, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02044445||51866|
NCT02007278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ACO01|Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride|Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin|GLOBE|Novartis|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007278||54713|
NCT02007551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RelAte-12122|Evaluating the RelAte Mealtime Program as an Intervention to Treat Social Isolation and Improve Cooking Behaviour Among Older Adults Living Alone|RelAte: An Investigator-blinded, Randomised, 8-week, Parallel-group, Controlled Stepped Wedge Design Study to Evaluate the Effectiveness of a Complex Nutritional, Cooking and Social Intervention Against a Control Group in the Improvement of Dietary Self-efficacy and Energy Intake Among Older Adults Living Alone.|RelAte|University of Dublin, Trinity College|No|Completed|May 2013|May 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|100|||Both|55 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02007551||54693|
NCT02007811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKER-BLZ-PH1|Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination|Prospective, Open-label, Multicentre Clinical Trial, Phase I/IIa, to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates CD3+-Depleted, CD19+-Enriched, Cryopreserved (Single Administration After Day 120 Following Allogeneic Stem Cell Transplantation (SCT), Donor-identical) in 4 Groups With Escalating Doses for Immune Response Enhancement, Measured as Response to a Antedated Single Vaccination|B-cell therapy|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02007811||54673|
NCT02008136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01769|New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain|New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain||VA Connecticut Healthcare System|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||July 2015|July 13, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008136||54648|
NCT02008721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMESA|Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach|Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)|PROMESA|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02008721||54603|
NCT02008734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002967-24|Randomized Phase II Study to Assess PD 0332991 in Breast Cancer|Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in Early Breast Cancer Patients|POP|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02008734||54602|
NCT02045745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/FAP/2012|CLINICAL TRIAL PHASE I / II, PROSPECTIVE, OPEN, NONRANDOMIZED, FOR TREATMENT OF POSTOPERATIVE AIR LEAK AFTER LUNG RESECTION IN HIGH RISK PATIENTS THROUGH THE ADMINISTRATION OF MESENCHYMAL AUTOLOGOUS CELLS.|CLINICAL TRIAL PHASE I / II, PROSPECTIVE, OPEN, NONRANDOMIZED, FOR TREATMENT OF POSTOPERATIVE AIR LEAK AFTER LUNG RESECTION IN HIGH RISK PATIENTS THROUGH THE ADMINISTRATION OF MESENCHYMAL AUTOLOGOUS CELLS.|CSM/FAP/2012|Red de Terapia Celular|No|Recruiting|December 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2014|January 22, 2014|January 22, 2014||||No||https://clinicaltrials.gov/show/NCT02045745||51766|
NCT02045758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-P002|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick||Seventh Sense Biosystems|No|Not yet recruiting|December 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 2, 2014|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045758||51765|
NCT02045771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAVE Pilot Trial|A Pilot Study to Assess the Effectiveness of BehaviouRal ActiVation Group Program in Patients With dEpression: BRAVE|A Pragmatic Randomized Trial to Investigate the Effectiveness of BehaviouRal ActiVation Group Therapy in Reducing dEpressive Symptoms and Improving Quality of Life in Patients With Depression: BRAVE Pilot Study|BRAVE|St. Joseph's Healthcare Hamilton|No|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045771||51764|
NCT02046356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWH-66|Early Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation|Early Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation: a Multi-center Prospective Case-control Study||Southwest Hospital, China|Yes|Active, not recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|86|||Both|18 Years|70 Years|No|Non-Probability Sample|In-patients from three affiliated hospital of the Third Military Medical University|October 2015|October 26, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046356|2 Years|51719|
NCT02046369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050326|Lurasidone Pediatric Bipolar Study|A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression|Illuminate|Sunovion|Yes|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|10 Years|17 Years|No|||February 2016|February 4, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046369||51718|
NCT02046603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28641|A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent|||Hoffmann-La Roche||Active, not recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046603||51700|
NCT02046616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28691|A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs|Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-arm, Open-label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will be Measured by Ultrasound||Hoffmann-La Roche||Recruiting|May 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046616||51699|
NCT02046902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-6448|Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection|Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection|DECIDE-PCI|University of Missouri, Kansas City|Yes|Enrolling by invitation|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Adults with and without coronary artery disease|March 2016|March 4, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046902||51677|
NCT02047136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALC-001|Dietary Treatment for Chronic Urticaria|Can Low Histamine Diet Reduce Symptoms of Patients With Idiopathic Urticaria?|DTCU|Hong Kong Sanatorium & Hospital|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047136||51659|
NCT02047123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elena García-García 2|Nutritional Intervention With Yogurt and Flaxseed in Women With Profiles Lipi|Nutritional Intervention With Yogurt and Flaxseed in Women With Profiles Lipidic to the Limit: A Randomized Controlled Trial|flaxseed|Universidad Miguel Hernandez de Elche|Yes|Completed|November 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|89|||Female|25 Years|75 Years|No|||July 2014|July 19, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047123||51660|
NCT02047409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDT-13001-PD|Prognostic Value of Sympathetic Modulation in Patients With Heart Failure|Prognostic Value of Oscillatory Pattern of Sympathetic Nerve Activity Muscle in Patients With Heart Failure||University of Sao Paulo General Hospital|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|30 Years|65 Years|No|Probability Sample|The sample consisted of patients with heart failure in clinical follow up at the Heart        Institute (InCor), University of São Paulo, School of Medicine.|September 2015|September 18, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047409|12 Months|51638|
NCT02043509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13113|MiQuit Trial: Tailored Text Messages for Pregnant Women|Evaluation of a Tailored Text Message Intervention for Pregnant Smokers (MiQuit): a Pilot Trial|MiQuit|University of Nottingham|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|407|||Female|16 Years|N/A|No|||February 2016|February 17, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02043509||51938|
NCT02043756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cspcmitlip|Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection|Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Completed|August 2011|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||January 2014|January 21, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043756||51919|
NCT02043964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0021|Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion|Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears)|POLAR|Lille Catholic University|No|Recruiting|October 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|242|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02043964||51903|
NCT02044198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC054|A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria|A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria||University of Oxford|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044198||51885|
NCT02007291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172 / 2010|Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment|Good Rate of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease After Three Months of Treatment|NINDS-AIREN|Federal University of Minas Gerais|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|97|Samples With DNA|A blood sample was drawn from the patients on the first consultation for use in DNA      extraction and Apolipoprotein E (APOE) genotyping. For the patients who were taking      donepezil, after three, six and twelve months of treatment another blood sample were also      drawn, separated in plasma and kept into the freezer at - 70 Celsius degree for further      analysis of serum level of donepezil.|Both|59 Years|93 Years|Accepts Healthy Volunteers|Non-Probability Sample|A longitudinal, naturalist study, conducted at the Geriatric Outpatient Clinic of the        Hospital das Clínicas at the Federal University of Minas Gerais (UFMG), in Belo Horizonte        (MG), Brazil.        The sample comprised patients evaluated from June, 2009 until October, 2011.|December 2013|December 9, 2013|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02007291||54712|
NCT02007564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR011112|Legacy Intervention Family Enactment (LIFE)|Legacy Intervention Family Enactment|LIFE|University of Alabama, Tuscaloosa|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|164|||Both|55 Years|N/A|No|||July 2014|July 13, 2014|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02007564||54692|
NCT02007824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2013-020|Clinical Trial to Evaluate Ultrasonic Surgical Device in Chronic Pressure Ulcer|Clinical Trial to Evaluate Efficacy and Safety of Ultrasonic Surgical Device (ULSC-12D)in Chronic Pressure Ulcer||Seoul National University Hospital|No|Completed|August 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|N/A|No|||April 2014|April 4, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02007824||54672|
NCT02008435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-123242|Increasing the Effectiveness of the Diabetes Prevention Program|Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial||McGill University|No|Active, not recruiting|April 2013|March 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|154|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008435||54625|
NCT02004431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/P/159|Peri-operative Psychology and Post-operative Pain Study|A Case-control Study of Peri-operative Psychological State and Acute and Chronic Post-operative Pain|4P|Plymouth Hospitals NHS Trust|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of all patients following elective orthopaedic surgery with        a planned inpatient stay of at least 24 hours|September 2014|November 4, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02004431||54932|
NCT02045238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263/13 - University Hospital|Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis|Study of the Effect of Inhaled 3% Hypertonic Saline Compared With Normal Saline (0,9%) for the Treatment of Acute Viral Bronchiolitis in a Short Stay Ward||University of Sao Paulo|No|Terminated|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|12 Months|No|||January 2015|January 5, 2015|January 22, 2014||No|Technical difficulties (reduced staff plus university strike)|No|January 5, 2015|https://clinicaltrials.gov/show/NCT02045238||51805|
NCT02045485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901215|P Wave and QT Dispersion in Psoriasis|Increased Risk of Atrial and Ventricular Arrhythmia in Long-lasting Psoriasis||Yuzuncu Yıl University|No|Completed|January 2006|||June 2006|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|145|||Both|18 Years|72 Years|Accepts Healthy Volunteers|Probability Sample|Diagnosis of psoriasis was confirmed by dermatological examination and/or punch biopsy.|January 2014|January 22, 2014|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02045485|6 Months|51786|
NCT02046096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-018|Cook IVC Filter Study|Cook IVC Filter Study|CIVC|Cook||Recruiting|January 2014|January 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|470|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046096||51739|
NCT02046382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13068|RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief|Randomized Control Trial of IV Acetaminophen for Post Cesarean Delivery Pain Relief||TriHealth Inc.|No|Recruiting|January 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|116|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046382||51717|
NCT02046629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM12788|A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers|An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects||Sanofi|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046629||51698|
NCT02046915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003678-29|Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide|Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE in RelapSed Myeloma Plus rEsponse Adapted Cyclophosphamide as a Tailored InnoVativE Strategy|PESPECTIVE|University Hospital Tuebingen|Yes|Recruiting|April 2014|||April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046915||51676|
NCT02047149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA 180-338|Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia|Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia||University of Massachusetts, Worcester|Yes|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047149||51658|
NCT02047448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPF|Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model|Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model||Wilkes University|No|Recruiting|January 2014|August 2015|Anticipated|February 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047448||51635|
NCT02047461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1101-MCD-201|Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP|A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)||Alexion Pharma GmbH|Yes|Active, not recruiting|April 2014|June 2018|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||February 2016|February 17, 2016|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047461||51634|
NCT02047435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Storm-P-2014|Integrating Lonely Elderly Patients in Workshops in a Cartoon Museum: An Efficacy Study|Integrating Lonely Elderly Patients in Workshops in a Cartoon Museum: An Efficacy Study||Research Unit Of General Practice, Copenhagen|No|Recruiting|February 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|May 22, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047435||51636|
NCT02043990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCHIDINI2013|Adjusted Ventilatory Assist (NAVA-NIV) in Infants: Short-term Physiological Study|Patient Ventilator Interaction During Non-invasive Ventilation Delivered With Neurally Adjusted Ventilatory Assist (NAVA-NIV) in Infants||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Recruiting|March 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|1 Month|2 Years|No|||January 2014|January 21, 2014|April 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02043990||51901|
NCT02044224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRE-01|Effects of Dexmedetomidine During IRE Procedures for Solid Tumours|Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours||Uppsala University Hospital|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||October 2015|October 19, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02044224||51883|
NCT02044237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTM|Online Treatment of Trichotillomania|Decoupling as Internet Based Intervention: an Randomized Controlled Study to Treat Trichotillomania||University of Zurich|No|Active, not recruiting|August 2011|December 2014|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|65 Years|No|||January 2014|January 22, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044237||51882|
NCT02043977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL053|Efficacy and Safety Study of Propofol Infusion for Refractory Chronic Primary Insomnia|An Open Label, Pilot Study Utilizing an IV Infusion of Propofol in Male and Female Volunteers With Refractory Chronic Primary Insomnia||Life Extension Foundation Inc.|No|Active, not recruiting|June 2013|||November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02043977||51902|
NCT02044211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL114016|Blended Collaborative Care for Heart Failure and Co-Morbid Depression|Blended Collaborative Care for Heart Failure and Co-Morbid Depression||University of Pittsburgh|Yes|Recruiting|February 2014|December 2018|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|750|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044211||51884|
NCT02007577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19254|Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?|Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?||Stanford University|No|Completed|July 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|41|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|March 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02007577||54691|
NCT02007850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1308/214-010|Effect of Mode of Femoral Nerve Analgesia on Quadriceps Muscle Strength|Effect of Continuous Femoral Analgesia on Quadriceps Muscle Strength-0.2% Ropivacaine Continuous Infusion Versus Patient Controlled Femoral Analgesia||Seoul National University Hospital|No|Recruiting|February 2014|July 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|80 Years|No|||July 2014|July 29, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02007850||54670|
NCT02008149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1410-P|FES Rowing for Skeletal Health After SCI|Using Musculoskeletal Models to Assess FES Rowing for Skeletal Health After SCI|FES-R|VA Office of Research and Development|No|Recruiting|November 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02008149||54647|
NCT02008461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_SVT|Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias|||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|June 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008461||54623|
NCT02008474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211699-14|SHARE Study 4: Financial Incentives for Weight Loss|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies: Study 4||The Miriam Hospital|No|Active, not recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|70 Years|No|||July 2015|July 22, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008474||54622|
NCT02008747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK 002|Atrial Fibrillation and Neuropathic Pain After Thoracotomy and Continuous Application of Magnesium Sulphate.|Effects of Prophylactic Administration of Magnesium Sulfate on the Incidence of Atrial Fibrillation and Chronic Neuropathic Pain After Thoracotomy for Lung Resection.||Dr. Horst Schmidt Klinik GmbH|No|Completed|January 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||December 2013|December 7, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02008747||54601|
NCT01999725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP788-001|Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788|A Randomized, Double-Blind, Placebo-Controlled, Ascending One-Day (Single and Divided Dose) Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers||Enanta Pharmaceuticals|Yes|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01999725||55294|
NCT02045784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-21|Establishing the Iodine Requirement in Infancy|Establishing the Iodine Requirement in Infancy: a Double-blind Dose-response, Cross-over Balance Study||Swiss Federal Institute of Technology|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|60|||Both|5 Weeks|14 Weeks|Accepts Healthy Volunteers|||November 2015|November 27, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045784||51763|
NCT02045797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116704|Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections|A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections||GlaxoSmithKline|Yes|Completed|March 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|126|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045797||51762|
NCT02046083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0177|Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers|Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers|PITA 3|University Hospital, Clermont-Ferrand||Recruiting|July 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|18 Years|No|||January 2014|January 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046083||51740|
NCT02045810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH2013-2|Surgical Pleth Index- Relevance in Small Children|Surgical Pleth Index - Relevance in Small Children. A Randomised Double Blinded Study|SPIinChildren|Tampere University Hospital|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|30|||Both|N/A|2 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045810||51761|
NCT02047162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6469|Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan|Randomized, Double-blind, Placebo-controlled Trial of the Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients in Pakistan||Centers for Disease Control and Prevention|Yes|Completed|May 2014|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|400|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047162||51657|
NCT02047175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147DDI13019|CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)|A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047175||51656|
NCT02047474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012255|Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer|Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer||Yale University||Recruiting|September 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047474||51633|
NCT02043535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140012|CO2 as a Stress Agent for Perfusion Imaging|Effects of Controlled Hypercapnic Stimulation on Myocardial Blood Flow Measured With Positron Emission Tomography|CO2 STRESS|Ottawa Heart Institute Research Corporation|No|Active, not recruiting|March 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02043535||51936|
NCT02043561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56275|The Effect of Inhibitory Control Processes Induced by Rectal Distension on Impulse Control Measured by Stroop Task Performance and Intertemporal Discounting.|||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|March 2014|||March 2015|Anticipated|N/A|Interventional|N/A|1||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|January 17, 2014||||No||https://clinicaltrials.gov/show/NCT02043561||51934|
NCT02044250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOST-EXAM Trial|Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)|Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation||Seoul National University Hospital|Yes|Not yet recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5500|||Both|20 Years|N/A|No|||January 2014|January 22, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044250||51881|
NCT02043522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130692|123I-mIBG SPECT Imaging|Optimization of Cardiac Iodine-123 Meta-iodobenzylguanidine (123I-mIBG) SPECT Imaging||Ottawa Heart Institute Research Corporation|No|Completed|December 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02043522||51937|
NCT02044783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3021|Identifying and Treating Physical Function Impairment in Elders|Identifying and Treating Physical Function Impairment in Elders||University of Colorado, Denver||Enrolling by invitation|January 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|65 Years|85 Years|No|||January 2016|January 5, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044783||51840|
NCT02045043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRADE|Genetic Risk Assessment of Defibrillator Events|Genetic Risk Assessment of Defibrillator Events: A Prospective Multicenter Observational Study|GRADE|University of Iowa|Yes|Completed|March 2002|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1807|Samples With DNA|Blood was obtained for DNA (all subjects) and serum (subgroup of subjects)|Both|18 Years|N/A|No|Non-Probability Sample|Subjects 18 years of age and over with a cardiomyopathy, an ejection fraction less than or        equal to 30%, and an implantable cardioverter defibrillator|January 2014|January 22, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045043||51820|
NCT02044484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-2468|HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission|HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission|APTcare|Centers for Disease Control and Prevention|No|Recruiting|January 2014|October 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2794|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044484||51863|
NCT02044770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG 13-001|ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy|Initial Clinical Experience With the ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy||Ethicon Endo-Surgery|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|29|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult participants (age ≥ 18 and < 80 years of age, on the day of the procedure),        scheduled to undergo a planned colectomy, anticipated to be performed laparoscopically|September 2014|April 28, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044770||51841|
NCT02007863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080774|Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia|Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation||University of Miami|Yes|Completed|August 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|21 Years|No|||November 2015|November 20, 2015|December 3, 2013|No|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT02007863||54669|THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.
NCT02008162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREPTV-108.7|Bronchoreversibility and Radiologic Morphology of Emphysema|Response to Bronchodilation With Tiotropium Plus Salbutamol Correlates With Radiologic Morphology of the Lung in COPD of the Emphysematous Phenotype||University of Rome Tor Vergata|No|Recruiting|November 2009|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|75 Years|No|Non-Probability Sample|Patients with severe heterogeneous emphysema selected as potential candidtes for lung        volume reduction surgery|December 2013|December 6, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008162||54646|
NCT02008175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED_CXL|Conventional Collagen Crosslinking in Young Keratoconus|Evaluation of Conventional Collagen Crosslinking in Young Keratoconus.|PED-CXL|Vasan Eye Care Hospital|No|Completed|January 2012|November 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|3 Years|18 Years|No|||December 2013|December 12, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02008175||54645|
NCT02008760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-327|QOL, ADL and Pain Before and After Intervention With N3 From Krill With D3.|Survey of Chronic Pain Patients' Self-rated Quality of Life, ADL Function and Pain Before and After Intervention With Omega 3 Fatty Acids From Krill With Vitamin D3||Hospitalet Valdemar|Yes|Enrolling by invitation|February 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02008760||54600|
NCT01997138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anakinrapain1|Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy|Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy -a Double Blind, Placebo Controlled Study Using Microdialysis Technique||Oslo University Hospital|No|Active, not recruiting|March 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2013|April 24, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997138||55491|
NCT02045511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00088278|The Baltimore HEARS Pilot Study|The Baltimore HEARS Pilot Study: Hearing Health Care Equality Through Accessible Research & Solutions|HEARS|Johns Hopkins University|Yes|Active, not recruiting|February 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045511||51784|
NCT02045524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETTAU-01P (CTN-P1-571)|A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers|||JDP Therapeutics, Inc.||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 23, 2014|January 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045524||51783|
NCT02045823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maestro2000AP|OCT Agreement and Precision Study|Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Agreement and Precision Study||Topcon Medical Systems, Inc.|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that are Normal, or shows signs of Glaucoma, or Retinal Ocular Pathology.|July 2014|July 28, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045823||51760|
NCT02045836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116889|Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older||GlaxoSmithKline||Active, not recruiting|March 2014|June 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|865|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 21, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045836||51759|
NCT02047188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12YZ036|Observation of Microvessels and Invasion in Early Colorectal Lesions by NBI|Observation of Microvessels and Invasion in Early Colorectal Lesions by Narrow Band Imaging:Combination With Microvessel Count and MMP-7 Expression||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2010|December 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|418|Samples Without DNA|Samples after biopsy or resection are to be retained.|Both|18 Years|90 Years|No|Non-Probability Sample|patients with early colorectal lesions|January 2014|January 25, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02047188||51655|
NCT02047487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-110-02|After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study|Docetaxel (T), Cisplatin (P) After Induction Chemotherapy With and Without Cisplatin (P) Concurrent Radiotherapy (X) Plus Bevacizumab (B) Phase II Clinical Study||Chinese PLA General Hospital|Yes|Recruiting|May 2013|August 2018|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with pathological diagnosis of head and neck squamous cell carcinoma|January 2014|January 26, 2014|January 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047487|5 Years|51632|
NCT02043548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039599|Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis|Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis|TIM|University of Pittsburgh|Yes|Recruiting|October 2014|January 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|July 17, 2015|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043548||51935|
NCT02045134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuromed-GR-2008-1146478|Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery|Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery|Polyphemus|Neuromed IRCCS|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045134||51813|
NCT02043769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1736|Pediatric Enhanced Surveillance Study|Enhanced Surveillance and 2 Year Outcomes of Children Enrolled on Antiretroviral Therapy (ART) in Public Health Facilities in the Eastern Cape Province, South Africa|PESS|Columbia University|No|Completed|April 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|396|Samples Without DNA|Small amounts of additional blood will be drawn at the same time as routine blood draws and      presents minimal risk to subjects (5cc of additional whole blood may be drawn from infants 1      month to 12 months of age or less than 10 kg in weight; 5 to 10 cc of additional blood may      be drawn from children older than 12 months of age or >10 kg in weight); these risks usually      include bruising at the site of the venipuncture, transient pain and a negligible chance for      infection. No more than three attempts to obtain the blood specimens will be allowed per      patient per blood collection visit. If collection of a blood sample/s fails this may be      attempted at the next scheduled visit.|Both|1 Month|12 Years|No|Non-Probability Sample|Human immunodeficiency virus (HIV)-infected children accessing HIV care and treatment        services in the Eastern Cape of South Africa are the population of interest for the        overall study.          -  Records review: All children with a record of care at the study facilities in the             Wellness or antiretroviral (ART) clinic will form the study population.          -  Prospective cohort: ART-naïve children receiving care at participating sites who have             reached eligibility for ART and consent to participate will form the study             population. The sample for the study will be a subset of all children enrolled and             receiving care at these public health care facilities.|December 2015|December 4, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02043769||51918|
NCT02044003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A|Safety & Feasibility Study of Tack-It Device for Vessel Dissection Repair|Safety & Feasibility Study of the Innovasc Tack Intravascular Staple System (Tack) for Securing Vascular Flaps Resulting From Balloon Angioplasty in the Infrainguinal Artery(Ies)||Intact Vascular|Yes|Completed|December 2009|December 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|85 Years|No|||January 2014|January 21, 2014|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044003||51900|
NCT02044016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-FSP|The Achilles Tendon Length Measure (ATLM) - Development and Validation|The Achilles Tendon Length Measure (ATLM) - Development and Validation||Hvidovre University Hospital|No|Completed|April 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with an acute achilles tendon rupture, between week 8 and 16 after injury. The        patients are participating in a rehabilitation exercise group led by a physiotherapist 2        times a week for one hour at the time. Therefore, the patients in this study will be        recruited from this program, and if they accept, they will be followed through the        program, during the 2 examinations.|August 2015|August 1, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02044016||51899|
NCT02044497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00006691|Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients|Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients||Children's Hospital Boston|Yes|Recruiting|May 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|68|||Both|N/A|6 Years|No|||July 2015|July 27, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044497||51862|
NCT02044510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG193|Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients|A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients||Lawson Health Research Institute|No|Enrolling by invitation|July 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044510||51861|
NCT02044796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2734.00|Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2014|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044796||51839|
NCT02044809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0278|Cannabidiol: a Novel Intervention for Cannabis Use Problems?|A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence.||University College, London|Yes|Recruiting|March 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|168|||Both|16 Years|60 Years|No|||December 2015|December 4, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044809||51838|
NCT02045056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG042419|Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease|Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease||University of Kentucky|Yes|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|72|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 15, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045056||51819|
NCT02045303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004597|Healing Rate of Leg Wounds Treated With Contact and Noncontact Ultrasound: The VIP Ultrasound Protocol|Healing Rate of Chronic and Sub-Acute Lower Extremity Ulcers Treated With Contact Ultrasound Followed by MIST Therapy: The VIP Ultrasound Protocol||Texas Health Resources|No|Enrolling by invitation|February 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045303||51800|
NCT02045576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSA|RCT: Oral Appliance Therapy and Sleep Position Trainer in Patients With Position Dependant Obstructive Sleep Apnea|Positional Therapy With the Sleep Position Trainer Versus Oral Appliance Therapy in Patients With Position Dependent Obstructive Sleep Apnea; A Randomised Controlled Trial|POSA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|June 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 1, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02045576||51779|
NCT02007876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062864|Mobility and Activity Training (MAT) to Optimize Outcomes for Older Adult Abdominal Surgery Patients|Mobility and Activity Training (MAT) to Optimize Outcomes for Older Adult Abdominal Surgery Patients|MAT|University of Michigan|Yes|Withdrawn|June 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|60 Years|N/A|No|||January 2016|February 1, 2016|October 31, 2013||No|Difficulty enrolling|No||https://clinicaltrials.gov/show/NCT02007876||54668|
NCT02007889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShahidBU|L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis|The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis||Shahid Beheshti University||Recruiting|November 2013|October 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|78|||Both|1 Month|10 Years|No|||December 2013|December 5, 2013|September 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02007889||54667|
NCT02008448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_AFPers|Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation|||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|June 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008448||54624|
NCT02008201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-status|Vitamin D Status and Supplementation in Athletes|Vitamin D Status and Supplementation in Elite Athletes|D-status|Wageningen University|No|Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|153|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2014|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02008201||54643|
NCT01996046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817940|FDG PET/CT in Breast Cancer Bone Mets|18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer||University of Pennsylvania|Yes|Recruiting|September 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Female|18 Years|N/A|No|Non-Probability Sample|Adult patients with a history of ER+ breast cancer with documented bone metastases from        breast cancer. Patients must be planning to start new hormone therapy for their breast        cancer.|December 2015|December 3, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01996046||55574|
NCT02045849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117349|Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects|A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction With Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects||GlaxoSmithKline|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|November 13, 2014|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045849||51758|
NCT02045862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-102|A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder|SYNERGY II|Astellas Pharma Inc|No|Active, not recruiting|March 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2084|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045862||51757|
NCT02046109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalDent-2014-01|Study of the Success and Survival of Dental Composite Restorations Being Repaired Instead of Being Replaced|Replacement Versus Repair of Composite Restorations, a Randomized Controlled Trial|RVR|Dalhousie University|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046109||51738|
NCT02046993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX-13-026(60-09)|Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care|Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care||Kwong Wah Hospital|Yes|Recruiting|January 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|30 Years|N/A|No|||January 2014|January 27, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02046993||51670|
NCT02047006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-Nephrology-ADV|Dose-finding of Rivaroxaban in Hemodialysis|Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients||AZ Sint-Jan AV|Yes|Completed|September 2013|October 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047006||51669|
NCT02044315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNY-168|Prevention of Inappropriate ICD Shocks||RISSY-ICD|Yuksek Ihtisas Hospital|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|201|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044315||51876|
NCT02044328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV57|Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA (N0-1) Adenocarcinoma With EGFR Mutation|Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA (N0-1) Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|January 2014|July 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||March 2015|March 12, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044328||51875|
NCT02043574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0944-W|Nutrition and Aerobic Exercise in Chronic Stroke|Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke||VA Office of Research and Development|Yes|Recruiting|November 2014|December 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||March 2016|March 1, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02043574||51933|
NCT02043587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130934|Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma|A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma||University of California, San Diego|Yes|Recruiting|January 2014|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|60 Years|No|||January 2016|January 11, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043587||51932|
NCT02043782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP241|Investigation of a New 1-piece Convex Ostomy Product|Investigation of a New 1-piece Convex Ostomy Product in Subjects With Ileostomy and Colostomy||Coloplast A/S|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|38|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|January 16, 2014||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT02043782||51917|
NCT02043795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/539/C|Drug Impregnated Bioabsorbable Stent in Asian Population Extremity Arterial Revascularization (DISAPEAR Study)|Drug Impregnated Bioabsorbable Stent in Asian Population Extremity Arterial Revascularization (DISAPEAR Study)|DISAPEAR|Changi General Hospital|No|Recruiting|December 2013|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|21 Years|N/A|No|||February 2016|February 16, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02043795||51916|
NCT02045329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 13-1513|Impact of Mupirocin Decolonization on the Nasal Microbiome|Impact of Mupirocin Decolonization on the Nasal Microbiome||VA Eastern Colorado Health Care System|No|Terminated|October 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|Samples With DNA|Nasal swabs|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus        aureus|January 2014|June 19, 2015|January 22, 2014||No|Logistically unable to recruit subjects prior to initiation of mupirocin treatment|No||https://clinicaltrials.gov/show/NCT02045329||51798|
NCT02045342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104111|The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance|The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance||University of Western Ontario, Canada|Yes|Not yet recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045342||51797|
NCT02044263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1836|Cognitive Behavior Therapy for Insomnia Delivered by a Therapist or on the Internet|Cognitive Behavior Therapy for Insomnia Delivered by a Therapist or on the Internet: a Randomized Controlled Noninferiority Trial||St. Olavs Hospital|No|Recruiting|July 2014|August 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044263||51880|
NCT02044276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM22-ONC-305|A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia|A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta®, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia|AVOID|Teva Pharmaceutical Industries|No|Recruiting|March 2014|November 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|85 Years|No|||March 2016|March 2, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044276||51879|
NCT02047526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-XXX-2012/1|A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India|A Non-interventional, Prospective Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India||AstraZeneca|Yes|Withdrawn|November 2013|||July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|All patients with Dyspnea and/or signs of systemic congestion|January 2014|January 27, 2014|February 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02047526||51629|
NCT02043600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5560-BO|Randomized-controlled Trial of Yoga for Ulcerative Colitis|Randomized-controlled Trial of Yoga for Ulcerative Colitis||Universität Duisburg-Essen|No|Completed|February 2014|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043600||51931|
NCT02044536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCS-2|Current Practice Pattern and Effect of Training in Upper Endoscopic Biopsy|Retrospective Study of Current Practice Pattern and Effect of Training in Upper Endoscopic Biopsy||Chuncheon Sacred Heart Hospital|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1208|||Both|N/A|N/A|No|Non-Probability Sample|From May to July 2013, all the biopsy specimens from diagnostic esophagogastroduodenoscopy        will be collected and analyzed in a single teaching hospital of Korea.|January 2014|January 22, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044536||51859|
NCT02045316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-221281|The Expression of Aquaporin 3, 8 and 9 in Placenta in Normal and Preeclamptic Pregnancies: Perinatal and Neonatal Outcomes.|The Expression of Aquaporin 3, 8 and 9 in Placenta, Umbilical Cord and Fetal Membranes in Normal Pregnancies and Pregnancies Complicated by Preeclampsia: Perinatal and Neonatal Outcomes.||Trakya University|Yes|Not yet recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|210|||Female|17 Years|45 Years|No|Probability Sample|105 pregnant women with preeclampsia and 105 women with normal pregnancy, who applied to        Trakya University Faculty of Medicine's.|January 2014|January 22, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02045316||51799|
NCT02045589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-VCNA-002|A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer|A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane® in Advanced Pancreatic Cancer||VCN Biosciences, S.L.|No|Recruiting|January 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045589||51778|
NCT02007902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/CHU/02|Plasma Protein Levels and Very Preterm Birth|Early Plasma Protein Levels and Neonatal Hemodynamics: a Prospective Evaluation in Very Preterm Infants|ProHémie|Centre Hospitalier Universitaire de la Réunion|No|Completed|January 2014|June 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|N/A|1 Hour|Accepts Healthy Volunteers|Non-Probability Sample|Very preterm infants with birth at less than 32 weeks of gestational age|July 2015|July 28, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02007902||54666|
NCT02008188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Italy - Phase 4|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (Italy)|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes||University of Virginia|No|Active, not recruiting|December 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|21 Years|64 Years|No|||April 2015|April 2, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008188||54644|
NCT02008487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR014310|Wound Powder for Pressure Ulcers at End-of-life|Novel Wound Powder RGN107 to Reduce Wound Odor, Pain and Exudate at End-of-life|RGN107|Medical University of South Carolina|Yes|Recruiting|April 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|21 Years|N/A|No|||December 2013|April 7, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02008487||54621|
NCT01995786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19.11|Clinical Outcomes and Costs Analyses in Use of Goal Directed Therapy|||Regina Elena Cancer Institute|No|Recruiting|January 2012|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995786||55594|
NCT01999439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00080065|EoE(Eosinophilic Esophagitis)|Quantitative MRI Evaluation of Esophageal Remodeling/Response to Treatment in Children and Adolescents With Eosinophilic Esophagitis Presenting With Dysphagia||University of Michigan|Yes|Active, not recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|8 Years|18 Years|No|||December 2015|December 7, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01999439||55316|
NCT01996384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 9664|Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study|Provoked, Localized Vulvodynia Treatment With Acupuncture and lidocaine-a Feasibility Pilot Study||Oregon College of Oriental Medicine|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||November 2015|November 7, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01996384||55548|
NCT01996397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/140|Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy|Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy|CCI impact|Oslo University Hospital|No|Recruiting|May 2013|September 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01996397||55547|
NCT02046642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KafkasUniversity1|Effect of Maternal Rest and Resting Positions on Amniotic Fluid|Effect of Maternal Rest and Resting Positions on Amniotic Fluid: A Randomized Prospective Study||Kafkas University|No|Completed|March 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|69|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 24, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046642||51697|
NCT02046928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6-005|Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia||Ångstrom Pharmaceuticals|No|Recruiting|February 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046928||51675|
NCT02045407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12500913400000068|Computed Tomography Angiography to Brain Death Assessment|Computed Tomography Angiography to Brain Death Assessment||University of Sao Paulo|Yes|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Individuals of any genre or age.|December 2015|December 1, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045407||51792|
NCT02045654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-086|Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome|Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients||Samsung Medical Center|No|Recruiting|January 2014|March 2015|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1|||Both|18 Years|N/A|No|Probability Sample|Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or        secondary) based on the World Health Organization (WHO) classifications|January 2014|January 23, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02045654||51773|
NCT02044575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeptiClock|Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study|Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study||Charite University, Berlin, Germany|No|Recruiting|April 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients with septic shock|December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02044575||51856|
NCT02044523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.062|Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound|Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis|ELF|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|108|Samples Without DNA|Liver biopsy specimens.|Both|18 Years|N/A|No|Non-Probability Sample|The target population is adults with any of the three main causes of liver fibrosis: HBV,        HCV or NASH. For the purpose of this study, we will recruit patients seen at the        hepatology clinic of St-Luc Hospital, a tertiary care center.|January 2016|January 28, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02044523||51860|
NCT02043808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.183|The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis||Boehringer Ingelheim||Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|25586|||Both|18 Years|N/A|No|Non-Probability Sample|NVAF|July 2015|July 1, 2015|January 10, 2014||||No|May 22, 2015|https://clinicaltrials.gov/show/NCT02043808||51915|
NCT02044822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0133|Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion|A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion|Havasu|Gilead Sciences|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044822||51837|
NCT02045914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA1-191|Calcium Ionophore Solution Can Increase Fertilization Rate in Patients During Intracytoplasmic Sperm Injection(ICSI) Who Have Poor Ovarian Reserve?|Effect of Calcium Ionophore Solution on Fertilization Rate During ICSI Cycles of Poor Ovarian Reserve Patients||Baskent University|Yes|Recruiting|January 2014|August 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|162|||Female|23 Years|39 Years|No|||January 2014|January 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02045914||51753|
NCT02046174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-MB-203|Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer|A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma||The Rogosin Institute|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046174||51733|
NCT02046694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1357|A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL|A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|N/A|30 Years|No|||March 2015|March 31, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046694||51693|
NCT02044042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver005|Vertical Transmission of Hepatitis C Virus|Mother-To-Child Transmission (MTCT) of Hepatitis C Virus and Spontaneous Viral Clearance in Infected Children: a Retrospective Study.||Hopital Lariboisière|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|9 Months|15 Years|No|Non-Probability Sample|HCV chronically infected pregnant women with a positive HCV RNA who gave birth in the        Maternity Department, Lariboisiere Hospital, Paris, France|September 2015|September 30, 2015|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02044042||51897|
NCT02045082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002-1399, 2012-1649|The Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis|Comparison Between the Sensibility of the Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Terminated|October 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|146|||Both|18 Years|N/A|No|||January 2016|February 25, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045082||51817|
NCT02045095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33001|A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|February 2014|February 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|119|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02045095||51816|
NCT02044835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lishen58173|The Evaluation Studies of Curative Effect of Fu-zheng-qu-zhuo Oral Liquid in Treatment of Ischemic Nephropathy|||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|January 2013|||September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2014|January 22, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044835||51836|
NCT02045628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0212-27034|The Impact of an Investment Based Intervention on Weight-loss and Beliefs About Food in Patients Post Bariatric Surgery|The Impact of an Investment Based Intervention on Weight-loss and Beliefs About Food in Patients Post Bariatric Surgery.||University of Surrey|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|212|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02045628||51775|
NCT01999712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058588|Right Ventricular Failure After Implantation of Left Ventricular Assist Devices|Right Ventricular Failure After Implantation of Left Ventricular Assist Devices||Emory University|No|Recruiting|July 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Serum and plasma will be stored for biomarkers analysis|Both|18 Years|75 Years|No|Non-Probability Sample|Patients eligible for LVAD implantation seen at Emory University Hospital|December 2015|December 16, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999712||55295|
NCT01995773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280278|Glucose Metabolism and Quality of Life in Healthy Women|Glucose Metabolism, Adrenal Function, Cortisol Metabolism, Body Composition Physical Activity, and Quality of Life in Healthy Women|Healthy women|Odense University Hospital|No|Completed|December 2011|June 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|Samples Without DNA|blood and urine samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 healthy women with regular menstrual cycle, normal hair growth, and body mass index        between 18 and 35 kg/m2|November 2013|November 26, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995773||55595|
NCT01999166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00211-4|Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis|Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis: Contribution of Genetic in the Diagnosis and Early Management of Patients.|Exorhum|University Hospital, Caen||Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|5|||Both|18 Years|N/A|No|Non-Probability Sample|Family With Early Onset Osteoarthritis|January 2015|January 9, 2015|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01999166||55337|
NCT01996085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIM-0000000148|Non-invasive Haemodynamic Assessment in Hypertension|The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension|FINE-PATH|Military Institute of Medicine, Poland|No|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01996085||55571|
NCT01996670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|huohuiyi20131121|Early NCPAP Before Surfactant Treatment in Very Preterm Infants With RDS|||Xiangya Hospital of Central South University|Yes|Completed|January 2007|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|683|||Both|N/A|2 Hours|No|Non-Probability Sample|inborn infants at 26-32 weeks gestation with RDS, whom received NCPAP as the initial        treatment, followed by surfactant treatment within 24 h after birth|January 2007|November 21, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996670||55526|
NCT02046655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-11|Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI|Corifollitropin Alfa Compared to Daily Rec FSH in Poor Responders Undergoing ICSI Using a GnRH Antagonist Protocol||Aristotle University Of Thessaloniki||Completed|January 2011|||March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|45 Years|No|||May 2014|May 13, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02046655||51696|
NCT02046668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/WS/0232|The Effect of Spironolactone on Pain in Older People With Osteoarthritis|A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis|SPIR-OA|University of Dundee|Yes|Recruiting|November 2013|May 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|70 Years|N/A|No|||January 2014|January 28, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02046668||51695|
NCT02046941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1532-I|Brain Biomarkers of Response to Treatment for Apraxia of Speech|Brain Biomarkers of Response to Treatment for Apraxia of Speech|SPT|VA Office of Research and Development|No|Recruiting|March 2014|March 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|44|||Both|40 Years|70 Years|No|||March 2016|March 8, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02046941||51674|
NCT02044068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver003|Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women|Prevention of Hepatitis B Virus Mother-to-Child Transmission (MTCT) From HIV-HBV Co-infected Pregnant Women by Use of Nucleosides/Nucleotides Analogues With Dual Activity During Pregnancy.||Hopital Lariboisière|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|35|||Both|9 Months|15 Years|No|Non-Probability Sample|All children born in the Maternity Department, Lariboisiere Hospital, Paris, France, from        HIV-HBV co-infected women|September 2015|September 30, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02044068||51895|
NCT02044081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3J13-201-01|Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel and/or Mouth Rinse Doses to Healthy Adult Subjects||C3 Jian, Inc.|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|February 12, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044081||51894|
NCT02047500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200592-006|Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer|An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma||EMD Serono||Recruiting|January 2014|July 2017|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047500||51631|
NCT02017262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH093557|Group Self-Management of Depression and Medical Illness|Group Self-Management for Persons With Depression and Medical Illness||University of Southern California|No|Recruiting|September 2013|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||December 2013|December 15, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02017262||53951|
NCT02045069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESIDEN|Efficacy and Safety of Ivermectin Against Dengue Infection|A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection||Mahidol University|Yes|Recruiting|February 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|15 Years|N/A|No|||October 2015|October 29, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045069||51818|
NCT02046967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ErasmusMC|Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins|Comparative Randomized Clinical Trial of Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins|LAST|Erasmus Medical Center|Yes|Completed|November 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046967||51672|
NCT02047227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200061-005|Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)|A Phase III, Randomized, Controlled, Single-blind, Multicentre, Parallel Arm Trial to Assess the Efficacy and Safety of Pergoveris® (Follitropin Alfa and Lutropin Alfa) and GONAL-f® (Follitropin Alfa) for Multifollicular Development as Part of an Assisted Reproductive Technology Treatment Cycle in Poor Ovarian Responders, as Defined by the European Society of Human Reproduction and Embryology Criteria|ESPART|Merck KGaA||Completed|January 2014|August 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|939|||Female|18 Years|41 Years|No|||September 2015|September 9, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047227||51652|
NCT02047240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FILT01|Renal Function Determination in Patients With Liver Cirrhosis|Renal Function Determination With Creatinine and Cystatin C Dependent Formulas Compared to Gold Standard DTPA-TC-99 (Diethylene-triamine-pentaacetate- Technetium-99) in Mexican Cirrhotic Patients||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Active, not recruiting|April 2013|January 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients will be selected from the Liver Clinic from the Gastroenterology Department        at a tertiary care center in Mexico|September 2015|September 29, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02047240||51651|
NCT02047513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-PAK-0313|Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer|Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group|NEONAX|AIO-Studien-gGmbH|Yes|Recruiting|April 2015|February 2022|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02047513||51630|
NCT02014337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1073-500|Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors|Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.||Corcept Therapeutics|No|Recruiting|January 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|October 1, 2015|December 4, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014337||54175|
NCT02045355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2004-WP4|Effects of Fish or Meat Consumption in Elderly|Effects of Fish or Meat Consumption on Sarcopenia and Mobility in Elderly After Hip Fracture||University of Bergen|No|Terminated|February 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14|||Both|65 Years|N/A|No|||December 2015|December 11, 2015|January 17, 2014||No|Not enough patients to recruite.|No||https://clinicaltrials.gov/show/NCT02045355||51796|
NCT02045368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0655|Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R|STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R||University of Illinois at Chicago|Yes|Recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045368||51795|
NCT02045615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56066|Removal Wichita Fusion Nail After Knee Arthrodesis|||Universitaire Ziekenhuizen Leuven||Enrolling by invitation|October 2013|||July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|4|||Both|20 Years|80 Years|No|Non-Probability Sample|All patients who had to have their Wichita Fusion Nail extracted|October 2013|January 23, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045615||51776|
NCT02046187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-13BN069|Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma|Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar(R) Chemotherapy Followed by Adjuvant Temodar(R) Chemotherapy.||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|October 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02046187||51732|
NCT01998932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0574|Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb|Clinical Study to Identify Biological Markers to Predict Wound Healing in Patients With Chronic Venous Ulceration of the Lower Limb|MOJITO|Imperial College London|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|Samples With DNA|Human serum Human urine Human venous ulcer fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic venous ulceration in London and Cambridge|June 2015|June 29, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT01998932||55354|
NCT01995825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048923|Lamotrigine Bioequivalence|Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients||University of Maryland|Yes|Completed|May 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|34|||Both|18 Years|65 Years|No|||March 2015|March 12, 2015|January 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01995825||55591|
NCT01996072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818060|EC17 for Intraoperative Imaging for Parathyroidectomy|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.||University of Pennsylvania|Yes|Recruiting|November 2013|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996072||55572|
NCT01996943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08579|The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study|Investigating the Effects of Ethanol on Atrial Fibrillation Susceptibility and Pathogenesis|HOLIDAY|University of California, San Francisco|Yes|Recruiting|September 2012|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|21 Years|81 Years|No|||January 2015|January 15, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT01996943||55506|
NCT01996956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1303-114-478|Prediction of Fluid Responsiveness by NICOM (Non-invasive Cardiac Output Monitoring) in Children With Congenital Heart Disease After Cardiac Surgery|||Seoul National University Hospital|Yes|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|30|||Both|N/A|5 Years|No|||November 2013|November 21, 2013|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT01996956||55505|
NCT02046954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/249/13|EVENT - Evaluation of the Influence of hTEE|Retrospective Matched Pair Analyses for Evaluating the Influence of Hemodynamically Focussed Transesophageal Echocardiography (hTEE) on Postoperative Outcome in Cardiosurgery Patients|EVENT|Charite University, Berlin, Germany|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|36|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery followed by postoperative observation on an ICU of the        anaesthesiology department of the Charité hospital|January 2014|January 25, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02046954||51673|
NCT02045381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.113|Optimization of MRI for Radiation Therapy|Optimization of MRI for Radiation Therapy||University of Michigan Cancer Center|Yes|Recruiting|February 2013|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|140|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045381||51794|
NCT02045394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAEMOPTYSIS76|Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study|Multicenter, Prospective, Observational Study on Epidemiology and Diagnosis of Haemoptysis||University of Milan|No|Completed|June 2013|||October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|610|||Both|18 Years|N/A|No|Probability Sample|Inpatients and outpatients with haemoptysis requiring a diagnosis referred for medical        consultation to italian university and clinical hospitals.|December 2015|December 2, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02045394|18 Months|51793|
NCT02047201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHNCTE-1309|Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC|Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma.||Lithuanian University of Health Sciences|Yes|Completed|June 2013|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047201||51654|
NCT02047214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-287-18|Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy|Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen||Cortice Biosciences, Inc.|No|Terminated|January 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 24, 2014|Yes|Yes|Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date|No||https://clinicaltrials.gov/show/NCT02047214||51653|
NCT02044029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE29037|Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.|A SINGLE CENTER, LONGITUDINAL, NON-DRUG STUDY TO ASSESS THE ABILITY OF MUSCLE IMAGING AND OF MOTOR FUNCTION MEASURE (MFM) TO DETECT CHANGES IN DISEASE PROGRESSION IN AMBULANT SPINAL MUSCULAR ATROPHY (SMA) PATIENTS AS COMPARED TO AGE-MATCHED HEALTHY CONTROLS||Hoffmann-La Roche||Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|Samples With DNA|Whole blood samples taken at screening and at week 24 from patients with spinal muscular      atrophy (SMA).|Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ambulant patients with spinal muscular atrophy (SMA) and age- and gender-matched healthy        volunteers.|March 2016|March 1, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02044029||51898|
NCT02016495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg-ALA|Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions|||AGUNCO Obstetrics and Gynecology Centre||Completed||||February 2013|Actual|Phase 4|Interventional|N/A|2||||||Female|23 Years|41 Years||||October 2013|December 16, 2013|December 16, 2013||||No||https://clinicaltrials.gov/show/NCT02016495||54010|
NCT02045602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-VCNA-001|Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors||VCN Biosciences, S.L.|No|Recruiting|January 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045602||51777|
NCT02013466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sip.1.C/B|Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement|Amino Acid Bioavailability in Healthy Elderly After Bolus Intake of a High Whey-protein, Leucine-rich, Low-caloric Oral Nutritional Supplement|ArenA|Nutricia Research|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02013466||54242|
NCT02043821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140116|Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker|Maintenance Chemotherapy for Metastatic Colorectal Carcinoma||Beijing Chao Yang Hospital|Yes|Not yet recruiting||||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||January 2014|January 23, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043821||51914|
NCT02044289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202351|MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression|MR Imaging Biomarkers of Disease Response to ECT in Depression||University of Arkansas|Yes|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|100 Years|No|Non-Probability Sample|No more than 20 patients will be enrolled for this study in order to obtain completion of        the study by at least 10 participants. All inpatients with depression, 18 and older, who        are referred for ECT treatment and consent for ECT treatments after a standard pre-ECT        work-up will be considered potential participants for the study. The investigative team        will discuss potential study participation with the primary treatment team.|February 2016|February 2, 2016|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044289||51878|
NCT02013479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-CATALYST|Selenium Supplementation in Autoimmune Thyroiditis|The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial|CATALYST|Odense University Hospital|Yes|Recruiting|June 2014|September 2027|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|472|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02013479||54241|
NCT02013752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-HBG-13|The Effect of the Modified Perineal Protection Device During Delivery|Randomized Controlled Trial (RCT) of Primiparous Women Using the Modified Perineal Protection Device||Helsingborgs Hospital|No|Recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|45 Years|No|||March 2015|March 18, 2015|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02013752||54220|
NCT02045927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-519|BIS-Guided Sedation Monitoring|BIS-Guided Sedation Monitoring: A Prospective Randomized Study||Englewood Hospital and Medical Center|No|Terminated|January 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 22, 2014||No|study staff change|No||https://clinicaltrials.gov/show/NCT02045927||51752|
NCT01999452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwePaD|The Swedish Study on Paleolithic Diet for Type 2 Diabetes|The Swedish Study on Paleolithic Diet for Type 2 Diabetes|SwePaD|Lund University Hospital|No|Recruiting|October 2015|December 2022|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01999452||55315|
NCT01995461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAR10112|Bilateral Transforaminal Epidural Steroid Injections for Degenerative Lumbar Spinal Stenosis|Effectiveness of Bilateral Transforaminal Epidural Steroid Injections in Degenerative Lumbar Spinal Stenosis Patients With Neurogenic Claudication: A Prospective Outcome Study||Marshfield Clinic Research Foundation|No|Terminated|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Both|40 Years|90 Years|No|||October 2015|October 22, 2015|November 18, 2013||No|biostatistician determined 20 subjects would be adequate to perform statistics|No|September 22, 2015|https://clinicaltrials.gov/show/NCT01995461||55619|
NCT01996098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1002|Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation|A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation|ICTAN|Sun Yat-sen University|Yes|Recruiting|January 2014|January 2021|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|477|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996098||55570|
NCT01996111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIPF003|Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis|A Prospective, Randomized, Controlled, Blinded, Comparative Study of Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis|dHACM|MiMedx Group, Inc.|No|Terminated|September 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|October 10, 2013||No|Change in Regulatory Status|No||https://clinicaltrials.gov/show/NCT01996111||55569|
NCT01996124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|902 CEC|Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients|Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients in Stable Conditions. Pilot Study||University of Milan|Yes|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|50 Years|85 Years|No|||November 2014|November 11, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996124||55568|
NCT01996137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHGDSRB_D_2013/01042|VASSTII: An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill System for Hemiparetic Gait Rehabilitation After Stroke|An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill System for Hemiparetic Gait Rehabilitation After Stroke|VASSTII|Tan Tock Seng Hospital|Yes|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|21 Years|80 Years|No|||May 2015|May 14, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996137||55567|
NCT01996423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-185|Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis|Impact of Vitamin D Supplementation on Clinical Severity and Immunologic Tolerance of Pediatric Atopic Dermatitis|VIDATOPIC|Pontificia Universidad Catolica de Chile|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|2 Years|17 Years|No|||February 2015|February 28, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT01996423||55545|
NCT02045108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-520|Cognitive Retraining and Brain Stimulation for Alcohol Use|Modifying Alcohol Approach Motivations With tDCS and Cognitive Retraining||The Mind Research Network|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|93|||Both|21 Years|30 Years|No|||March 2016|March 14, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045108||51815|
NCT02045121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRG/0042/2013|Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management|A Multicentre Randomised Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis in Patients With a Malignant Pleural Effusion||National University Hospital, Singapore||Recruiting|January 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|19 Years|N/A|No|||January 2014|January 22, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02045121||51814|
NCT02046720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008181|The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation|The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2010|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|70|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02046720||51691|
NCT02015988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-284|Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome|Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome||Dnipropetrovsk State Medical Academy|No|Recruiting|January 2014|September 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|May 4, 2015|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02015988||54049|
NCT02016222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0006|Tear Analysis in the Diagnosis of Multiple Sclerosis|Tear Analysis in the Diagnosis of Primary Progressive Forms of Multiple Sclerosis|LARMES|Lille Catholic University|No|Active, not recruiting|April 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|November 9, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02016222||54031|
NCT02016235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004774|Role Of Phosphorus And FGF 23 In Patients With Dent Disease|Role Of Phosphorus And FGF 23 In Patients With Dent Disease||Mayo Clinic|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016235||54030|
NCT02016508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT 4619792013|Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration|Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)||Al-Azhar University||Recruiting|March 2013|June 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|50 Years|N/A|No|||December 2013|December 20, 2013|May 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016508||54009|
NCT02017522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00079881|Non-Invasive Characterization in Cardiac Sarcoidosis|Non-Invasive Characterization in Cardiac Sarcoidosis||University of Michigan|No|Recruiting|December 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017522||53931|
NCT02017041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN271201300015C-1|Using mHealth to Aid Opioid Medication Adherence Pilot Study|Using mHealth to Aid Opioid Medication Adherence Pilot Study||Care Team Solutions|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|21 Years|N/A|No|Probability Sample|community sample|February 2015|February 2, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017041||53968|
NCT02013726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI_Sc-02|MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue|Pilot Study: Dedicated Dual Head Molecular Breast Imaging Compared to Breast Tomosynthesis for Evaluation of Patients With Type 3 or 4 Mammographic Breast Density||Gamma Medica, Inc.|No|Withdrawn|April 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|25 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 22, 2014|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013726||54222|
NCT02013739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.78/cardio11.13|Description of Insulin Resistance in Patients With Chronic Heart Failure|Description of Insulin Resistance and Explanatory Variables in Patients With Chronic Heart Failure||Hasselt University|No|Completed|May 2011|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Both|N/A|N/A|No|Non-Probability Sample|patients with chronic heart failure|December 2013|December 11, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02013739||54221|
NCT02014038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21271|Ultrarunners Longitudinal TRAcking Study (ULTRA)|Ultrarunners Longitudinal TRAcking Study (ULTRA)||Stanford University|No|Enrolling by invitation|May 2011|December 2031|Anticipated|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2452|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult healthy volunteers who have completed at least one ULTRA marathon (50K distance or        greater) prior to enrollment in the study.|December 2013|December 11, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02014038|20 Years|54198|
NCT02014077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/2013|VATS ( Video-Assisted Thoracoscopy) Compared to Reinsertion of a Thoracostomy Tube for Persistent Haemothorax|VATS( Video-Assisted Thoracoscopy ) Compared to Reinsertion of a Thoracostomy Tube for Persistent Haemothorax A Single Center Prospective Randomized Study||University of Cape Town|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02014077||54195|
NCT02014090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177/07|Acute Hemodynamic and Biological Effects of ECP and Exercise|Acute Cardiovascular Effects of External Counterpulsation (ECP) in Comparison With Physical Exercise in Healthy Individuals||University Hospital Inselspital, Berne|Yes|Completed|March 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT02014090||54194|
NCT02014584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200209|Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia|A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia||GlaxoSmithKline|No|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|50 Years|No|||January 2016|February 4, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014584||54156|
NCT02014597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30109|Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma|Use of a Novel, Objective Optokinetic Contrast Device to Determine Scotopic Range Visual Function and Discriminate Between Patients With and Without Glaucoma|HOCD|Baylor College of Medicine|No|Recruiting|May 2015|July 2021|Anticipated|July 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|November 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014597||54155|
NCT02046434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2808|Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain|Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain||University of Colorado, Denver|Yes|Active, not recruiting|January 2014|||February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046434||51713|
NCT02046707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASILLAS Fondation Av 2008|Evaluation of the Effects of Eccentric Muscle Training Versus Conventional Concentric Training in Chronic Heart Failure|Evaluation of the Effects of Eccentric Muscle Training Versus Conventional Concentric Training in Chronic Heart Failure||Centre Hospitalier Universitaire Dijon||Recruiting||||July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|45 Years|85 Years||||April 2011|January 24, 2014|January 20, 2014||||No||https://clinicaltrials.gov/show/NCT02046707||51692|
NCT02014064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01019707|Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls|A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine||University of California, Los Angeles|Yes|Completed|August 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014064||54196|
NCT01995838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-G000-201|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia||Eisai Inc.|No|Completed|November 2013|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|616|||Both|18 Years|80 Years|No|||March 2015|June 25, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01995838||55590|
NCT01996696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-Usmani-01|Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate|Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate|PREMIUM|AHS Cancer Control Alberta|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Male|18 Years|N/A|No|||January 2016|January 27, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996696||55524|
NCT01996982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-148|Study of a New Clinical Device for Reducing Body Core Temperature|Study of a New Clinical Device for Reducing Body Core Temperature||Seton Healthcare Family|No|Terminated|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|November 4, 2013||No|The Prinicipal Investigator left the organization and decided to close the trial|No||https://clinicaltrials.gov/show/NCT01996982||55503|
NCT01997203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-VD2013|Long Term Vitamin D Therapy in HCV Treated Patients|Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment|VD-HCV|Ain Shams University|Yes|Terminated|April 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|55 Years|No|||November 2013|November 27, 2013|November 19, 2013|No|Yes|complete patients samples required|No||https://clinicaltrials.gov/show/NCT01997203||55486|
NCT02045940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200181|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses|A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects||GlaxoSmithKline|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|99|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045940||51751|
NCT02045953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201092|A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer|A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate From FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol From SERETIDE™ 250/25 HFA pMDI When Given With the VENTOLIN Mini-Spacer Compared to the Aerochamber Plus Spacer in Healthy Subjects||GlaxoSmithKline|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02045953||51750|
NCT02047565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-A-U158|A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation|A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation||Daiichi Sankyo Inc.|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|5||Actual|110|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|December 2, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02047565||51626|
NCT02043626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1HD070740|Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.|School Wellness Policy: RCT to Implement & Evaluate Impact on Childhood Obesity|H&A|Yale University|No|Recruiting|August 2011|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1100|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043626||51929|
NCT02016001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|draeezamalik|Effective Fluoride Concentration In Toothpaste For Dental Caries Prevention|Identification of Effective Fluoride Concentration In Toothpaste For Dental Caries Prevention; A Randomized Controlled Trial|DMFT|Dow University of Health Sciences|Yes|Recruiting|April 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|380|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02016001||54048|
NCT02016248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-12|Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer|Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost||MemorialCare Health System|No|Recruiting|June 2012|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|167|||Male|18 Years|N/A|No|||September 2015|September 22, 2015|December 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016248||54029|
NCT02016261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-996|Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine|Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine||Moscow Research Institute of Psychiatry|No|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016261||54028|
NCT02017561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.00240|Metformin in the Diastolic Dysfunction of Metabolic Syndrome|Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial|MET-DIME|Universidade do Porto|Yes|Recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|40 Years|64 Years|No|||November 2015|November 30, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017561||53928|
NCT02016768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201304|Decompressive Cervical Surgery and Hypertension|Decompressive Cervical Surgery for Antihypertensive Effect in Patients With Cervical Spondylosis and Hypertension-A Cohort Study||Peking University First Hospital|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|84 Years|No|Non-Probability Sample|Patients at our Spine Center suffering signs and symptoms of cervical myelopathy and with        evidence of radiographic cervical cord compression with hypertension.|June 2014|June 30, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016768||53989|
NCT02017548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn 819325|Default Options in Advance Directives|Default Options in Advance Directives||University of Pennsylvania|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|270|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017548||53929|
NCT02017275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANDA-Ⅲ|Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice|A Prospective, Multicenter, RAndomized, CoNtrolled, Study Comparing the Safety and Efficacy Between BuMA eG Based BioDegradable Polymer Stent and EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "ReAl-World" Practice (PANDA-III)|PANDA-III|Sino Medical Sciences Technology Inc.|Yes|Completed|November 2013|||September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2348|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017275||53950|
NCT02013492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 13023|Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery|A Pilot Study of Beta-Blockers in Patients With Advanced Cancer||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|January 2014|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013492||54240|
NCT02017535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206M15365|An Adaptive Treatment Strategy for Adolescent Depression-Continuation|A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression|PTAD GIA|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|June 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|45|||Both|12 Years|17 Years|No|||March 2016|March 15, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017535||53930|
NCT02013765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17599|A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer|An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression||Hoffmann-La Roche||Terminated|January 2001|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|December 3, 2013|No|Yes|Trial was terminated prematurely because of recruitment difficulties.|No|July 24, 2014|https://clinicaltrials.gov/show/NCT02013765||54219|
NCT02014051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012002|Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)|Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome||SymBio Pharmaceuticals||Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A||||December 2013|December 11, 2013|December 1, 2013||||No||https://clinicaltrials.gov/show/NCT02014051||54197|
NCT02014350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI2013|Outcomes Following Delta Xtend Reverse Shoulder System|||Rothman Institute Orthopaedics||Enrolling by invitation||||March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A||Probability Sample|patients who were implanted with the DePuy Delta Xtend Reverse Total Shoulder Arthoplasty        between 2008-2012|December 2013|December 17, 2013|December 12, 2013||||No||https://clinicaltrials.gov/show/NCT02014350||54174|
NCT02014935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 1542193200005503|Immediate Effect of Laser on Spasticity|Immediate Effect of Low Intensity Laser on the Spastic Muscle Fatigued.||Laboratório de Engenharia de Reabilitação Sensorio Motora|Yes|Recruiting|July 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|80 Years|No|||December 2013|December 18, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02014935||54129|
NCT01996410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-13-00465|The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients|The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients||OhioHealth||Active, not recruiting|November 2013|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|66|||Female|18 Years|N/A|No|||March 2015|March 9, 2015|November 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996410||55546|
NCT01996735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43379.091.13|Ticagrelor and Adenosine|The Effect of Ticagrelor on the Adenosine System||Radboud University|No|Completed|April 2013|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2013|January 9, 2014|April 26, 2013||No||No||https://clinicaltrials.gov/show/NCT01996735||55522|
NCT01996748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF277OTIII/11ES01|Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema|A Multicenter, Randomized, Parallel, Double-blind, Clinical Trial Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in Patients With Otic Eczema||Salvat|No|Completed|February 2012|March 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|12 Years|N/A|No|||November 2013|November 21, 2013|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT01996748||55521|
NCT02007226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAU-11-075|Coronary Artery Calcification Score and Risk Factors for Coronary Artery Disease in Persons With Spinal Cord Injury|Coronary Artery Calcification (CAC) Score and Risk Factors for Coronary Artery Disease in Persons With Spinal Cord Injury(SCI)|CAC|James J. Peters Veterans Affairs Medical Center|No|Recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Serum and Plasma|Both|35 Years|75 Years|No|Probability Sample|Subjects will be recruited from hospital clinics, through advertisements, and referral        from primary care physicians|October 2015|October 21, 2015|December 14, 2012||No||No||https://clinicaltrials.gov/show/NCT02007226||54717|
NCT02007499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00021202|Pre-arrival Instructions Effect on Bystander Cardiopulmonary Resuscitation (CPR).|The Effect of Pre-arrival Instructions on the Rate of Bystander Cardiopulmonary Resuscitation (CPR) for Patients in "Out of Hospital Cardiac Arrest (OHCA)".||Medical College of Wisconsin|No|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|4000|||Both|21 Years|N/A|No|Non-Probability Sample|The population of this study will be all patients with OHCA (absence of a detectable        pulse, unresponsiveness, and apnea) occurring in the select communities, from January 1,        2009, to December 31, 2013 (five years).|December 2013|December 5, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02007499||54697|
NCT02047266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICSREVS|Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting|Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting (MICS CABG) Versus Off Pump (OPCABG) and on Pump Coronary Artery Bypass Grafting (ONCABG) in Patients With Multi-vessel Coronary Disease||Vitebsk Regional Clinical Hospital|Yes|Recruiting|January 2014|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||December 2015|December 19, 2015|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02047266||51649|
NCT02043847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0201|Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)|BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma|BMT-03|University of Illinois at Chicago|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043847||51912|
NCT02016014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/00618|Effectiveness of the Use of a Mobile Tool in Improving Lifestyles|Effectiveness of the Use of a Mobile Tool Added to a Standard Intervention in Improving Lifestyles in Adults||Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|January 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1200|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02016014||54047|
NCT02020603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUB2013|Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding|Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps in Comparison With Argon Plasma Coagulation for Acute Peptic Ulcer Bleeding||Kyunghee University Medical Center|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02020603||53694|
NCT02020616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14515|A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Terminated|December 2013|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|21 Years|N/A|No|||May 2015|May 8, 2015|December 13, 2013|Yes|Yes|Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT02020616||53693|
NCT02020629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16|Study on Lixisenatide and Counterregulation to Hypoglycemia|Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes||Lund University|No|Completed|December 2013|August 2015|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02020629||53692|
NCT02020928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3547-13|Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation?|Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial.|lasertherapy|Instituto Materno Infantil Prof. Fernando Figueira|No|Enrolling by invitation|January 2015|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|60 Years|No|||September 2013|December 19, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020928||53669|
NCT02021201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-062|The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia|The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia, a Comparative Study||University of Copenhagen|Yes|Terminated|July 2008|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|1|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|September 19, 2011||No|No suitable patients could be recruited in the available time period|No||https://clinicaltrials.gov/show/NCT02021201||53648|
NCT02028975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERGES 2009|Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.|Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.||Centre Hospitalier Universitaire Dijon||Recruiting||||July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Both|18 Years|N/A||||July 2012|January 6, 2014|December 18, 2013||||No||https://clinicaltrials.gov/show/NCT02028975||53052|
NCT02028988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-444|Enzalutamide + External Beam Rt For Prostate|Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study||Dana-Farber Cancer Institute|Yes|Recruiting|January 2014|June 2021|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Male|18 Years|N/A|No|||October 2015|October 14, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028988||53051|
NCT02029248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD10/06-R|National Study on the Quality of Life of Patients With Anorectal Malformation|National Study on the Quality of Life of Patients With Anorectal Malformation (MARQOL)|MARQOL|Nantes University Hospital|No|Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Anticipated|2000|||Both|6 Years|30 Years|No|Non-Probability Sample|Patients initially treated in a french pediatric surgery service for anorectal        malformation|July 2015|July 20, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02029248||53031|
NCT02021708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00055 [JIRB]|Effect of Shisha Smoking on the Biology of the Airway Epithelium in Qatar|Effect of Shisha Smoking on the Biology of the Airway Epithelium in Qatar||Weill Medical College of Cornell University|Yes|Not yet recruiting|February 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|Blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited in the pulmonary and smoking cessation clinics of HMC.|December 2013|December 19, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021708||53609|
NCT02029989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090M72212|Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness|Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications?||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|121|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|September 30, 2013||No||No|April 15, 2014|https://clinicaltrials.gov/show/NCT02029989||52974|Limitations include: 1) Short time duration to achieve metabolic outcome goals, 2) Smaller than anticipated sample size, 3) High number of subjects lost to follow up after 12-months.
NCT02017860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C1X01B|Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.|An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment||Novartis|No|Active, not recruiting|January 2014|January 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||October 2015|October 12, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017860||53905|
NCT02018120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-Dis-004|Platelet Rich Fibrin in the Treatment of Multiple Gingival Recessions|Comparison of Platelet Rich Fibrin and Connective Tissue Graft in Treatment of Multiple Gingival Recessions||Ege University|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018120||53885|
NCT02018393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-1405|Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors|Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients||Hospital Universitario La Paz||Not yet recruiting|January 2014|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with severe haemophilia A and inhibitors treated with FEIBA® (on demand or        prophylaxis) for the control of bleedings.|December 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018393||53864|
NCT02026466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPEN CTO V1.2|Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion|Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)|OPEN-CTO|Saint Luke's Health System|No|Active, not recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|18 or older with CAD and at least one chronic total occluded vessel.|July 2015|July 24, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02026466|5 Years|53245|
NCT01996215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046073|Brain Connectivity in Age-Related Macular Degeneration|Cognitive Changes and Brain Connectivity in Age-Related Macular Degeneration||Duke University|No|Recruiting|April 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include 240 participants: 120 subjects with AMD plus 120 age, gender, and        education-matched adults without AMD. All participants will receive baseline and 2 year        neurocognitive tests and a subset will provide structural and "resting stage"functional        magnetic resonance images (MRIs) at each time point.|August 2015|August 3, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996215||55561|
NCT01996514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodAdsKids_21595|Food Advertisements, Satiety and Food Intake in Children|Effect of Food Advertisements on Satiety and Meal-Time Food Intake in 9-14 y Old Boys and Girls||University of Toronto|No|Completed|November 2010|||August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|59|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996514||55538|
NCT01995916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1867|Wellness Intervention for Menstrual Mood Disorders|Intervention for Menstrual Mood Disorders & Early Life Abuse: BioPsych Mechanisms|WIMM|University of North Carolina, Chapel Hill|Yes|Recruiting|August 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|55 Years|No|||December 2015|December 2, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT01995916||55584|
NCT01996787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-540|Clinical Study of Visibility Tinted Clariti Contact Lens|The Clinical Performance of the Clariti Contact Lens (Including Handling Tint) for Daily Wear||Sauflon Pharmaceuticals Ltd|No|Completed|June 2013|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|38|||Both|19 Years|56 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996787||55518|
NCT01997268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-13-009|The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)|A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)||Sancilio and Company, Inc.|No|Not yet recruiting|April 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|November 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997268||55481|
NCT01997541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kang528|Insertion Depth Comparison of Tracheal Tubes|||Kyung Hee University Hospital at Gangdong||Completed|June 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|76|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|American Society of Anesthesiologists physical status I, II patients scheduled for        elective surgery with general anesthesia|November 2013|November 27, 2013|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT01997541||55460|
NCT02027844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUNG999ANXIETY|Cartoon Distraction and Parental Presence on Anxiety in Pediatric Anesthesia|Cartoon Distraction and Parental Presence During Induction of Anesthesia on Preoperative Anxiety and Postoperative Behavior Change in Children Undergoing General Anesthesia||Yeungnam University College of Medicine|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|117|||Both|1 Year|7 Years|No|||October 2015|October 4, 2015|December 30, 2013|No|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT02027844||53139|Parental anxiety was assessed using a self-reporting rating scale. we did't measure the baseline temperament of children using a validated behavioral assessment tool and were unable to calculate the ‘use of parents’ item of the mYPAS.
NCT02027831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-ICG-IV|NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG|Near-infrared Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After Intravenous Injection of Indocyanine Green (a Feasibility Study)||Jules Bordet Institute|No|Recruiting|December 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027831||53140|
NCT02028091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1242/2012|Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements|Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements||Medical University of Vienna|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|50 patients over 18 years with diagnosed type II diabetes mellitus are included into the        diabetes group.        50 healthy patients with no known or diagnosed diabetes mellitus or damage of the vessels        are included into the non diabetes group.|January 2014|January 4, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028091||53120|
NCT02028104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-06|Stem Cell Therapy in Traumatic Brain Injury|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Traumatic Brain Injury||Neurogen Brain and Spine Institute|Yes|Recruiting|March 2010|June 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Months|65 Years|No|||January 2014|January 3, 2014|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028104||53119|
NCT02028390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV13CL-0008 Revision 02|Overlaying a Visual Wound Trace Onto Its Thermal Image in a Wound Clinic|Scout Overlay-Trace-On-Thermal Feature in a Wound Clinic Setting: A Prospective Study||Wound Vision|No|Terminated|December 2013|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|18 Years|N/A|No|||May 2014|June 12, 2014|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028390||53097|
NCT02020941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0414|Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy|A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy||Indiana University|Yes|Recruiting|September 2013|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020941||53668|
NCT02021214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131297|Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety|Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety: a Placebo-controlled fMRI Study in Healthy Male Subjects||University of California, San Diego|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02021214||53647|
NCT02021188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093095|Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography|The Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography Study|VISION|University of Cambridge|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Carotid artery plaques|Both|40 Years|N/A|No|Non-Probability Sample|The study will recruit participants with recent transient ischaemic attack or stroke due        to carotid artery disease, from which they have made a good functional recovery. A        proportion of these patients will undergo carotid endarterectmy as part of clinical        management. We will also recruit participants with asymptomatic carotid atheroma, and        those with stable coronary artery disease or recent acute coronary syndrome.|May 2015|May 27, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02021188||53649|
NCT02021474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-201|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis|Phase II Study to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis||BioHealthonomics Inc.|No|Not yet recruiting|September 2015|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021474||53627|
NCT02021487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5515|Prokinecitine in Acute Myocardial Infarction|Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction|Prok-Idm|University Hospital, Strasbourg, France|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute St elevation myocardial infarction of less than 6 hours|December 2013|December 19, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021487||53626|
NCT02021721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00058 [JIRB]|Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility|Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility||Weill Medical College of Cornell University|Yes|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with be recruited from HMC infertility clinic.|December 2015|December 22, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021721||53608|
NCT02029755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309028|Transversus Abdominis Plane Block Versus Local Anesthetic Infiltration for Pain Control in the Abdominal Surgery|Ultrasound-guided-transversus Abdominis Plane(TAP) Block Versus Local Anesthetic(LA) Infiltration—the Effectiveness of Post-operative Pain Control in the Abdominal Surgery|TAP|Taipei Medical University Hospital|Yes|Completed|December 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|108|||Both|20 Years|65 Years|No|||May 2015|May 24, 2015|January 5, 2014|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT02029755||52992|
NCT02018705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4519|Retrospective Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM)|Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM) for Treatment of Achalasia, a Retrospective Multicenter Study|POEM 3|Universitätsklinikum Hamburg-Eppendorf|No|Terminated|August 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Achalasia patients who have been treated with either POEM or LHM|July 2014|May 21, 2015|December 17, 2013||No|data income too low|No||https://clinicaltrials.gov/show/NCT02018705||53840|
NCT02018406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0468|Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury|||Yonsei University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||July 2014|July 13, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02018406||53863|
NCT02018679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUDerma-02|Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma|Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up||Dong-A University|No|Completed|March 2011|September 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|38 Years|78 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02018679||53842|
NCT01996540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST100.08|The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.|The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.||Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|August 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01996540||55536|
NCT01996527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC NEU 1268|3T MRI Biomarkers of Glioma Treatment Response|Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|May 2012|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|November 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996527||55537|
NCT01997034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBBERUP 3|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Cross-sectional Study|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Cross-sectional Study||University of Copenhagen|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|80|Samples With DNA|Whole blood, muscle and fat tissue.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Former participants of Ubberup Folk High School will be included in this study. Ubberup        Folk High School is a privately hold externate that teaches lifestyle intervention courses        with focus on weight loss. A stay at Ubberup has a duration of 10-14 weeks and is        primarily self-financed. The study population will consist of men and women of two        different age Groups (18-35 and 35-65yr). We will recruit participants who succeeded in        maintaining the weight loss and participants who regained in weight.|January 2016|January 29, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997034||55499|
NCT01997567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip-Scope-Block|Are Preemptive Femoral and Lateral Femoral Cutaneous Nerve Blocks Given Immediately Prior to Hip Arthroscopy Effective for Acute Postoperative Pain Management?|Are Preemptive Femoral and Lateral Femoral Cutaneous Nerve Blocks Given Immediately Prior to Hip Arthroscopy Effective for Acute Postoperative Pain Management?||Rush University Medical Center|No|Terminated|July 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|June 13, 2013||No|Study Surgeon indicates that study subject recruitment is too difficult and he forsees that    will not improve, and therefore requested we terminate the study.|No||https://clinicaltrials.gov/show/NCT01997567||55458|
NCT02028117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoAd1-2001|Phase I / II Study Of Enadenotucirev Intraperitoneally in Ovarian Cancer Patients|A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.|OCTAVE|PsiOxus Therapeutics Ltd|Yes|Recruiting|January 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||October 2015|October 23, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028117||53118|
NCT02028364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB-BCTL:20120306|Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women|Pet Imaging as a Biomarker of Everolimus Added Value in Hormone Refractory postmenopausaL Women|PEARL|Jules Bordet Institute|No|Recruiting|January 2014|August 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Female|18 Years|N/A|No|||December 2015|February 23, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02028364||53099|
NCT02028377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212004|Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma|Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients With Pancreatic Adenocarcinoma||Washington University School of Medicine|Yes|Enrolling by invitation|January 2013|January 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02028377||53098|
NCT02020239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bham_CPW_PhysActIntervention|The Effect of Physical Activity Intervention Flexibility on the Time Course of Changes in Body Composition and Metabolism|The Effect of Physical Activity Intervention Flexibility on the Time Course of Changes in Body Composition and Metabolism||University of Birmingham|No|Active, not recruiting|December 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020239||53722|
NCT02017626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-489 DK|FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.|FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.||Rigshospitalet, Denmark|Yes|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02017626||53923|
NCT02017639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT12684|Sarilumab Effect on the Pharmacokinetics of Simvastatin|A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis||Sanofi|Yes|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|14|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017639||53922|
NCT02017873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nº 2013/41 FOUCH|Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients|"Evaluation of the Effectiveness and Longevity Post Whitening Carbamide Peroxide 10% in Smokers and Nonsmokers. Double-blind Multicenter Clinical Trial. "|BLESMOK|University of Chile|Yes|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02017873||53904|
NCT02021500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-CA046C|A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.|MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046||Celgene Corporation|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients previously enrolled in study CA046|March 2016|March 24, 2016|December 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02021500||53625|
NCT02018419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-014-TACT-MBC|Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients|In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of AllostimTM in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine|MBC|Immunovative Therapies, Ltd.|Yes|Withdrawn|March 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|70 Years|No|||April 2015|April 1, 2015|December 17, 2013|No|Yes|changing indication from breast cancer to metastatic colorectal cancer|No||https://clinicaltrials.gov/show/NCT02018419||53862|
NCT02018731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD01|L-citrulline and Metformin in Becker's Muscular Dystrophy|Pilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular Dystrophy||University Hospital, Basel, Switzerland|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018731||53838|
NCT02017847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN100Study5|Intensity of Physical Activity Measured by Activity Monitors in Elderly Persons|Assessment of Intensity Cut Off Points for Physical Activity Measured by Activity Monitors in Elderly Persons|GEN100|Norwegian University of Science and Technology|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|150|||Both|70 Years|76 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons in the age of 70-76 living in Trondheim, Norway|July 2015|July 24, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017847||53906|
NCT02020057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSXL|Comparison of Highly Cross-Linked and Conventional Polyethylene in Total Knee Arthroplasty|Comparison of Highly Cross-Linked and Conventional Polyethylene in Posterior Cruciate-Substituting Total Knee Arthroplasty in the Same Patients||Ewha Womans University|Yes|Completed|February 2006|September 2013|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|20 Years|N/A|No|||December 2013|December 18, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02020057||53736|
NCT02020070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-134|Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy|A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|53|||Male|18 Years|N/A|No|||March 2016|March 10, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020070||53735|
NCT02018939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORIPENEM IN CVVH, MARS AND HD|Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.|Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.||Medical University of Vienna|Yes|Completed|March 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02018939||53822|
NCT01996813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC-205159|Compression Stocking Use in Shoulder Arthroscopy in Beach Chair|The Effect of Compression Stockings on Cerebral Desaturation Events in Obese Patients Undergoing Shoulder Arthroscopy in the Beach Chair Position: an Observational Study||Loyola University|Yes|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|90 Years|No|Non-Probability Sample|Any patient evaluated at our outpatient orthopaedic clinic at a major academic institution        who has a BMI > 30 who will undergo shoulder arthroscopy in the beach chair position will        be invited to participate in the study, provided they do not have any exclusion criteria        listed below.|May 2014|May 29, 2014|November 22, 2013||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01996813||55516|
NCT01996800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCU-AUT-01|Study of Chiropractic and Neuromuscular Reeducation as a Treatment for Autism Symptoms|The Effects of Spinal Manipulative Therapy and Neuromuscular Reeducation on the Presentation of Autistic Symptoms in Children||Southern California University of Health Sciences|Yes|Recruiting|August 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|5 Years|15 Years|No|||November 2013|November 21, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01996800||55517|
NCT01997281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1307-133-508|The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones|The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones||Seoul National University Hospital|Yes|Active, not recruiting|December 2013|July 2014|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|20 Years|65 Years|No|||June 2014|June 30, 2014|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997281||55480|
NCT01998100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS10-106|Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)|||University of Texas at Austin|Yes|Completed|September 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01998100||55417|
NCT01998347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMECS 01|Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer|Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer: an Open-label, Randomised Phase 3 Trial.||Shantou University Medical College|Yes|Withdrawn|November 2013|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|November 17, 2013||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01998347||55399|
NCT02019680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140034|Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels|Effects of Dietary Blackcurrant Extract and PCSO-524 (PernaCanaliculus Supercritical Oil) on Endothelial Function and Biomarkers of Vascular Health||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|122|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||September 2015|November 21, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02019680||53765|
NCT02019693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140037|A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer|A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|100 Years|No|||September 2015|October 6, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019693||53764|
NCT02019940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308012549|A Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)|Structural and Spectroscopy Pharmaco-Imaging Paradigm to Investigate the Effect of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)||Yale University|No|Recruiting|January 2014|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019940||53745|
NCT02019953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0057|Effects of Health Promoting Programs on Cardiovascular Disease Risk|Effects of Health-Promoting Programs on CVD Risk: JHS||University of Mississippi Medical Center|Yes|Active, not recruiting|July 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|375|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02019953||53744|
NCT02020642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRS-SASinTx|Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)|Prospective Interventional Study Investigating the Effect of Renal Transplantation on Obstructive Sleep Apnea and Its Correlation to Nocturnal Rostral Fluid Shift, in End Stage Renal Disease Patients|SASinTx|Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020642||53691|
NCT02017899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03_01TP|A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.|A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults.||Novartis|Yes|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017899||53902|
NCT02018172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000122|Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device||ZOMAXEPT|Ferring Pharmaceuticals|No|Terminated|July 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a growth hormone deficiency or Turner's syndrome.|May 2015|May 11, 2015|December 17, 2013||No|Terminated due to lack of recruitment and difficulty in the selection of sites|No||https://clinicaltrials.gov/show/NCT02018172||53881|
NCT02018432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roflumilast_compliance|Strategy to Improve Adherence of Roflumilast|Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast||Asan Medical Center|Yes|Not yet recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||December 2013|December 17, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02018432||53861|
NCT02018445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC3-US-2012-2|Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion||Integra LifeSciences Corporation|No|Recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018445||53860|
NCT02018484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01337-38|Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.|Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.|PSI-PUC|Rennes University Hospital|No|Recruiting|December 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02018484||53857|
NCT02018497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEMD001|Essential Hypotension and Adaptability Registry|Essential Arterial Hypotension and Adaptability Registry|EssentialHAR|CES University|No|Recruiting|January 1995|December 2020|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Probability Sample|Consecutive patients that visits a cardiologist's office in Medellin, Colombia. The        population consists of patients of any age and gender, which are classified according to        their blood pressure in: normotensive, hypertensive and hypotensive, they are also        classified according to their adaptability in hypo, normo and hyper.|February 2016|February 8, 2016|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02018497|15 Years|53856|
NCT02018692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-9579-YR-CTIL|The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa|The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa||Sheba Medical Center|No|Not yet recruiting|December 2015|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|18 Years|No|||November 2015|November 22, 2015|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018692||53841|
NCT02018952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0393|Ultrasonography Assessment of Septic Arthritis on Native Joint|Ultrasonography Assessment of Septic Arthritis on Native Joint: a Descriptive, Exploratory, Prospective, Multicentric Trial|SEPT'ECHO|Nantes University Hospital|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02018952||53821|
NCT02021968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 287|Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults|A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2013|December 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02021968||53589|
NCT02019524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0139|Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients|Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients|J65|San Antonio Military Medical Center|Yes|Active, not recruiting|September 2013|August 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019524||53777|
NCT02019537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-13-01|Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome|||Seoul National University Hospital||Recruiting|January 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019537||53776|
NCT02019472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103111|A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis|SIRROUND-H|Janssen Research & Development, LLC|Yes|Active, not recruiting|April 2014|August 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|559|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019472||53781|
NCT02019485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100457|A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 100-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 100-mg Tablet Under Fasted Conditions in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019485||53780|
NCT02019745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2246|Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers|Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers||University of North Carolina, Chapel Hill|No|Recruiting|June 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood, urine, nasal lavage fluid, nasal epithelial cells|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Nonsmokers          2. Cigarette smokers          3. Primarily e-cigarette smokers          4. Primarily hookah smokers          5. Primarily Little Cigar smokers|October 2015|October 6, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019745||53760|
NCT01997060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBBERUP2|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Longitudinal Study|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Longitudinal Study||University of Copenhagen|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997060||55497|
NCT01997073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|489455|One Lung Ventilation|Effect of One-Lung Ventilation on Respiratory Gas Heat Content||University of California, Davis|No|Recruiting|August 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for elective surgery.|June 2015|June 30, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT01997073||55496|
NCT01997047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00783|Diagnosing Pneumonia Under Low-resource Conditions|Improving the Diagnosis of Pediatric Pneumonia at Hospital and Village Levels: A Multi-centre Indian Study||University of British Columbia|No|Completed|October 2012|October 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|502|||Both|N/A|5 Years|No|Non-Probability Sample|This study is intended to clinically relevant. All tachypneic children below 5 yrs age are        eligible for enrollment. There are no exclusion criteria. Sampling will be by convenience.|December 2014|December 2, 2014|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01997047||55498|
NCT01997814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKDC12|Role of Herbal Immunomodulators in the Treatment of Chronic Periodontitis|EFFECT OF SRP WITH ADJUNCTIVE THERAPY OF HERBAL IMMUNOMODULATORS ON THE SERUM C REACTIVE PROTEIN (CRP) LEVELS & CLINICAL PARAMETERS IN CHRONIC PERIODONTITIS PATIENTS - A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, CLINICAL TRIAL.|Septilin|Tatyasaheb Kore Dental College||Completed|March 2012|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997814||55439|
NCT01998633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1204|Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)|Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI) (BMT CTN #1204)|RICHI|Medical College of Wisconsin|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|4 Months|45 Years|No|||February 2016|February 5, 2016|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT01998633||55377|
NCT02019966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0704|A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy|||Yonsei University|No|Not yet recruiting|August 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|Chronic hepatitis B patients who had "difficult-to-treat" antiviral resistance owing to        prior treatment failures|July 2014|July 13, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019966||53743|
NCT02020252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1233|Effect of Multi-Media Enrollment|A Pilot Investigation to Examine the Effect of a Multi-Media, Computer Based Tool (Talking Touchscreen) on Enrollment in Adult Oncology-Specific Clinical Trials at an Academic Medical Center||University of Chicago|No|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at the University of Chicago Medical Center|January 2016|January 6, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02020252||53721|
NCT02020265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-13|fMRI Based EEG Neurofeedback as a Method of Enhancing Emotional Resilience Among Soldiers|Longitudinal Study of the Effect of Neurofeedback Training on Soldiers Emotional Regulation Ability and Mental Resilience to Stress.||Tel-Aviv Sourasky Medical Center|No|Recruiting|February 2013|February 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02020265||53720|
NCT02020278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-11-294|An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)||Otsuka Pharmaceutical Development & Commercialization, Inc.||Not yet recruiting|December 2014|||April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|N/A|18 Years|No|||October 2014|October 24, 2014|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020278||53719|
NCT02021227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9231|Early Chair Sitting Exercise in Mechanically Ventilated Critically Ill Patients.|Effects of Chair Sitting Exercise Intervention on Weaning From Mechanical Ventilation and Mortality of Critically Ill Patients With Acute Respiratory Failure: a Randomised Controlled Trial.|RehabVent|University Hospital, Montpellier|No|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|90 Years|No|||November 2013|December 19, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021227||53646|
NCT02021240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13-525|Ketamine in Post-operative Dental Pain and Recovery|Effects of Ketamine in Post-operative Pain and Recovery Outcomes in Bilateral Third Molar Surgery Under General Anaesthesia||The University of Hong Kong|No|Not yet recruiting|December 2013|April 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02021240||53645|
NCT02021734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00065 [JIRB]|Genetics of Mendelian Diseases in Qatar|Genetics of Mendelian Diseases in Qatar||Weill Medical College of Cornell University|Yes|Recruiting|January 2012|December 2020|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|physicians and by thorough review of the literature to establish that the disease is        indeed Mendelian and with unknown gene.|December 2015|December 18, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021734||53607|
NCT02017652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORE-SIGHT|Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg|Validation of FORE-SIGHT Cerebral & Tissue Oximeter to Measure Cerebral & Somatic Tissue Oxygen Saturation Measurements at Different Body Locations on Neonates ≤ 5 kg|FORE-SIGHT|Sharp HealthCare|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|N/A|7 Days|No|Non-Probability Sample|Neonatal subjects (32 to 36 and 6/7 weeks), with umbilical venous catheterization will be        enrolled from the NICU. Demographic information of the subject will be recorded, including        race, gender, weight, gestational age (GA), study age, and diagnosis.|May 2015|May 18, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02017652||53921|
NCT02017886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-158|Salivary IgA and Cytokines Response to Dietary Supplementation of Lactobacillus Reuteri|Salivary IgA and Cytokines Response to Dietary Supplementation of Lactobacillus Reuteri||University of Copenhagen|No|Active, not recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02017886||53903|
NCT02018523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32774|Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer|A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy||Baylor College of Medicine|Yes|Recruiting|June 2014|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018523||53854|
NCT02018770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18032013.4.0000.5511|Effect of Phototherapy in Individuals With Temporomandibular Disorder.|Effect of Phototherapy on Pain, Muscles Activity and Joint Mobility in Individuals With Temporomandibular Disorder: A Randomized, Placebo-Controlled and Double-Blind Clinical Trial.||University of Nove de Julho|Yes|Recruiting|January 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|40 Years|No|||January 2014|March 10, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018770||53835|
NCT02019225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817911|A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration|Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial|TiME|University of Pennsylvania|Yes|Recruiting|December 2013|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6432|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02019225||53800|
NCT02019290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29245|A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE BITOPERTIN ON SINGLE DOSE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY VOLUNTEERS||Hoffmann-La Roche||Withdrawn|February 2014|March 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019290||53795|
NCT02018965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN006|Niacin on Immune Activation : a Proof-of-concept Study|Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study||McGill University Health Center|No|Active, not recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018965||53820|
NCT01996566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-036|Fatty Acid Taste Thresholds: Caproic, Lauric, Oleic, Linoleic, Linolenic|Fatty Acid Taste Thresholds: Caproic, Lauric, Oleic, Linoleic, Linolenic||Purdue University|No|Completed|January 2013|August 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Saliva will be collected to obtain DNA for analysis of genes for fatty acid receptors and      their potential correlation with sensitivity.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals between 18 and 60 years of age from any ethnic background who are in good        health and are available for the next three months will be eligible.|October 2015|October 14, 2015|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT01996566||55534|
NCT01997827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-083/2013a|Minimal Invasive Rehabilitation of Tooth Loss in the Anterior Segment|Clinical Performance of Porcelain-fused-to-metal and All-ceramic Resin-bonded Fixed Dental Prostheses in the Anterior Segment - a Randomized Controlled Pilot Study.|MIZE-F|University Hospital Heidelberg|Yes|Withdrawn|October 2013|October 2025|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 18, 2013||No|Lack of Participants|No||https://clinicaltrials.gov/show/NCT01997827||55438|
NCT01997294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20130115|Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction|Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study（The STRAIT Study）||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01997294||55479|
NCT01997580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A121987|Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder|Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder||Seoul National University Bundang Hospital|Yes|Recruiting|July 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 22, 2013|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01997580||55457|
NCT01998360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicirc 002|Rapid, Minimally-invasive Voluntary Adult Male Circumcision|Rapid, Minimally-invasive Voluntary Adult Male Circumcision: a Quasi-experimental Study||Simunye Primary Health Care|No|Completed|October 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Male|18 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 11, 2013||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT01998360||55398|
NCT01999140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICD Registry|Implantable Cardioverter Defibrillator (ICD Registry)|Implantable Cardioverter Defibrillator (ICD Registry)||American College of Cardiology|Yes|Recruiting|June 2005|||October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1750|||Both|N/A|N/A|No|Non-Probability Sample|All facilities performing ICD implants|March 2015|March 26, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01999140|1 Day|55339|
NCT02020655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46877.068.13|Measurement of Cytokines (IL-1α) After Shear- Force Application at the Skin|Measurement of Cytokines (IL-1α) After Shear- Force Application at the Skin||Maastricht University Medical Center|No|Completed|November 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 healthy volunteers|December 2014|December 1, 2014|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02020655||53690|
NCT02020668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 1210|Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient|Phase II Study of Physiotherapy in Rheumatoid Arthritis: Randomized Single Blind Wait-list Controlled Trial||Macmillan Research Group UK|Yes|Not yet recruiting|May 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|65 Years|No|||May 2014|May 6, 2014|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02020668||53689|
NCT02020954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Becker-Heart-Study|Prospective Becker-Heart-Study|Prospective Cohort Study of Patients With Mutations in the Dystrophin Gene (X Linked Dilated Cardiomyopathy and Becker Muscular Dystrophy)|Becker-HS|Institut de Myologie, France|Yes|Recruiting|January 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood, serum|Male|18 Years|70 Years|No|Probability Sample|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated        cardiomyopathy|March 2015|March 23, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020954||53667|
NCT02020967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52030-280|Programme of Acromegaly Screening in Patients With Associated Somatic Disorders|Programme of Acromegaly Screening in Patients With Associated Somatic Disorders, Who Are Observed at the Moscow Board of Health Endocrinology Dispensary and Endocrinology Hospital at First Moscow State Medical University for the Purpose of Early Identification of the Disease.|ACROSCREEN|Ipsen|No|Completed|November 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|367|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with somatic disorders associated with acromegaly, who are observed at the Moscow        Board of Health Endocrinology dispensary and Endocrinology Hospital at First Moscow State        Medical University|November 2015|November 30, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02020967||53666|
NCT02017665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/374/E|Singapore Neurologic Infections Program|Singapore Neurologic Infections Program|SNIP|Singapore General Hospital|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood, cerebrospinal fluid, throat/nasopharyngeal swabs, urine and rectal swabs or stool      samples wil be stored for maximum 10 years.All samples will be de-identified and coded|Both|21 Years|100 Years|No|Non-Probability Sample|Any patient admitted to the hospital and who meets clinical case definition will be        recruited in the study.|November 2015|November 18, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02017665|6 Months|53920|
NCT02017678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-044|Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin|A Single-arm, Open-label, Phase 2 Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by 5 Weekly Intravenous (IV) Infusions in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin||Mount Sinai Hospital, Canada|Yes|Withdrawn|January 2014|June 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||September 2014|September 15, 2014|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02017678||53919|
NCT02018471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOV-2012 ANXIETY|Psychological Counselling in Diagnostic Screening|Management of Anxiety Related to Diagnostic Screenings: an Exploratory Pilot Study||Istituto Oncologico Veneto IRCCS|No|Completed|April 2012|May 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|43|||Both|25 Years|65 Years|No|||December 2013|December 20, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018471||53858|
NCT02018718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9097|Development and Validation Phase of Diffusion Tensor Imaging and Arterial Spin Labelling at 3 Tesla Using a Long-term Effort Model Applicable to Skeletal Muscle Characterization.|||University Hospital, Montpellier|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||December 2013|January 8, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018718||53839|
NCT02018536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102928|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.|A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK2336805 (Part 1), Followed by an Open-label, Randomized, 4-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Co-administration of TMC435 and GSK2336805 at Steady-state (Part 2), in Healthy Japanese Subjects||Janssen R&D Ireland|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|48|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018536||53853|
NCT02018133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMK-001|Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients|||University of Illinois at Chicago|No|Completed|December 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018133||53884|
NCT02018146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0570|Efficacy of Nasopharyngeal Ventilation With Endotracheal Tube for Otolaryngologic and Oral Maxillofacial Surgery|Efficacy of Nasopharyngeal Ventilation With Endotracheal Tube for Otolaryngologic and Oral Maxillofacial Surgery|MASK|University of Louisville|No|Recruiting|August 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02018146||53883|
NCT02018159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000102|An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos|||Ferring Pharmaceuticals|No|Recruiting|January 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Female|21 Years|45 Years|No|Non-Probability Sample|Women seeking fertility treatment|October 2015|October 27, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018159||53882|
NCT02018458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-154|Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer|Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer||Baylor Research Institute|Yes|Recruiting|May 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|80 Years|No|||January 2016|January 12, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018458||53859|
NCT02029638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN054ST|BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance|Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|January 2014|January 2021|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029638||53001|
NCT02029651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC-2013-04-035|Effects of Novel Game Rehabilitation System on Upper Extremity Function of Patients With Stroke|Effects of Novel Game Rehabilitation System (E-glove System) on Upper Extremity Function of Patients With Stroke :Randomized Controlled Trial||National Rehabilitation Center, Seoul, Korea|No|Active, not recruiting|January 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|59|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02029651||53000|
NCT01997593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130801|Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected|Evaluate the Analgesic Effect of Intraperitoneal Infiltration of Ropivacaine in Children Undergoing Laparoscopic Surgery||Tongji Hospital|No|Completed|November 2013|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|70|||Both|6 Months|5 Years|No|||March 2015|March 25, 2015|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT01997593||55456|
NCT01998373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7971|Group Training and Quality of Life and Reduction of Pain in Rheumatoid Arthritis Patients|The Effect of Group Training on the Quality of Life and Reduction of Pain in Rheumatoid Arthritis Patients||Tehran University of Medical Sciences|Yes|Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|34 Years|60 Years|No|||November 2013|November 23, 2013|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT01998373||55397|
NCT01998646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4058-CL-1001|A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacoknetics of ASP4058 Following Single Oral Doses in Healthy Subjects||Astellas Pharma Inc|No|Completed|August 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|130|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01998646||55376|
NCT01998113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ADO-2013-153|Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review|Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Retrospective||6|Actual|2509|||Female|N/A|N/A|No|Probability Sample|pregnant women with gestational diabetes mellitus requiring drug treatment|November 2013|March 23, 2015|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT01998113||55416|
NCT01998906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO16432|A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer|A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer||Hoffmann-La Roche||Completed|May 2002|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|330|||Female|18 Years|N/A|No|||October 2014|October 24, 2014|November 25, 2013|No|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT01998906||55356|
NCT02029768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-029|Gender Disparity in Burn Injury Survival|Gender Disparity in Burn Injury Survival||Texas Tech University Health Sciences Center|No|Recruiting|December 2013|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Serum samples to be used for cytokine measurements|Both|18 Years|65 Years|No|Non-Probability Sample|Study population will be derived from adult patients admitted to the University Medical        Center with greater than 15% total body surface area burns|October 2015|October 2, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02029768|6 Weeks|52991|
NCT02030015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syner_G_Regimen|Synergistic Enteral Regimen for Treatment of the Gangliosidoses|Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)|Syner-G|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|204 Months|No|||March 2016|March 4, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030015||52972|
NCT02021253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/130/HP|Influence of Probiotics Administration Before Liver Resection in Liver Disease|Circulating Endotoxemia After Liver Resection for Hepatocellular Carcinoma in Liver Disease - Influence of Preoperative Administration of Probiotics|LIPROCES|University Hospital, Rouen|No|Recruiting|April 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02021253||53644|
NCT02021266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-14070-120611-Exp Access|Single Patient Expanded Access Protocol: Metabolic Boost|Single Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders|14070 Boost|University of Louisville||No longer available||||||N/A|Expanded Access|N/A|||||||Female|N/A|N/A||||January 2016|January 21, 2016|December 19, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT02021266||53643|
NCT02021279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL2012-001|ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study|Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders||ACell Inc.|Yes|Recruiting|June 2014|||January 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021279||53642|
NCT02021513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EO3SLE|Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus|Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus||University of Texas Southwestern Medical Center|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|64 Years|No|||December 2013|December 19, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02021513||53624|
NCT02021526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCG1D2014|Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)|Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency||University of Texas Southwestern Medical Center|No|Not yet recruiting|December 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|30 Months|55 Years|No|||December 2013|December 26, 2013|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021526||53623|
NCT02017691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-295|Cerebral Oxygenation to Guide Supplemental Oxygen|Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition After Birth (COSGOD) - a Prospective Two-centre Randomized Controlled Pilot Feasibility Study|COSGOD|Medical University of Graz|No|Completed|December 2013|April 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|15 Minutes|No|||April 2015|April 16, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02017691||53918|
NCT02017704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1360|Chemoradiation or Brachytherapy for Rectal Cancer|Chemoradiation OR Brachytherapy for RECTal Cancer|CORRECT|Sidney Kimmel Comprehensive Cancer Center||Recruiting|October 2013|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|100 Years|No|||March 2016|March 8, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017704||53917|
NCT02017912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT-001-US|Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS|A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS|NurOwn|Brainstorm-Cell Therapeutics|Yes|Active, not recruiting|May 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||July 2015|January 13, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017912||53901|
NCT02018185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:144|Study of Magnetic Brain Stimulation in Treatment of Obsessive Compulsive Disorder|The Efficacy of Deep Repetitive Transcranial Magnetic Stimulation in Treatment of Obsessive Compulsive Disorder, a Double Blind Randomized Clinical Trial|rTMS|University of Manitoba|Yes|Recruiting|January 2014|May 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||September 2015|September 18, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02018185||53880|
NCT02018198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0830|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2014|||||N/A|N/A|N/A||||||||||||||February 16, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018198||53879|
NCT02028845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE2-13-175|Loop-tipped Guidewire in Selective Biliary Cannulation|Loop-tipped Guidewire in Selective Biliary Cannulation: a Prospective, Randomized, Controlled Trial||Ajou University School of Medicine|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|90 Years|No|||January 2016|January 4, 2016|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02028845||53062|
NCT02028858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13A-1339|Cannabis and Parkinson's Disease Tremor: A Natural History Study|Cannabis and Parkinson's Disease Tremor: A Natural History Study||Bastyr University|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinics; Washington State Parkinson's Disease Registry|January 2016|January 13, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02028858||53061|
NCT02018978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH095869|Comprehensive Triaged HIV Prevention in Tanzania|Phase II RCT of Comprehensive Triaged HIV Prevention: Tanzania||Medical University of South Carolina|No|Active, not recruiting|October 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|739|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|April 6, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018978||53819|
NCT02019771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STD-MSM-HIV|Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men|Prevalence of Gonorrhea and Chlamydia Infections in Multiple Anatomical Sites in HIV-infected Men Who Have Sex With Men at an HIV Clinic in Omaha, Nebraska||University of Nebraska|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|150|||Male|19 Years|N/A|No|Non-Probability Sample|This cross-sectional study will be conducted at the Specialty Care Center of the        University of Nebraska Medical Center, in Omaha, Nebraska. Adult men who have a history of        sex with men who visit the clinic for their appointments will be eligible to participate        in the study|December 2014|December 2, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019771||53758|
NCT02018991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW-0001|Late Acquired Malaposition and Different Polymers|Incidence and Predictors for Late Acquired Stent Malaposition of Drug-Eluting-Stents With Second-Generation Permanent and Biodegradable Polymer-Coatings - a Prospective, Randomized Comparison Using Optical Coherence Tomography||Medical University of Vienna|No|Completed|October 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|N/A|No|||December 2013|December 26, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018991||53818|
NCT02029404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-001|Approach to Continuous Sciatic Nerve Block for Orthopedic Procedures in Day Surgery With Two Different Techniques|Approach to Continuous Sciatic Nerve Block for Orthopedic Procedures in Day Surgery With Two Different Techniques||Ospedale di Circolo - Fondazione Macchi|Yes|Completed|December 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||October 2014|April 7, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029404||53019|
NCT02019251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047929|Lung Transplant Subjects Using 19F MRI|Evaluation of Regional Lung Function in Lung Transplant Recipients Using 19F Magnetic Resonance Imaging of Inert Perfluorinated Gases Mixed With Oxygen|DIAL1001005|Duke University|Yes|Completed|December 2013|August 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019251||53798|
NCT02019264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-G000-401|A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors|CAMELLIA-TIMI|Eisai Inc.|Yes|Recruiting|January 2014|June 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12000|||Both|40 Years|N/A|No|||November 2015|November 5, 2015|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02019264||53797|
NCT01997853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKDC13|Omega-3 Fatty Acids in Chronic Periodontitis.|Effect of Scaling & Root Planing (SRP) Combined With Therapy Of Omega-3 Fatty Acid on Clinical Parameters and Serum Levels of C-Reactive Protein (CRP) in Chronic Periodontitis - A Randomised Control Trial.|omega3|Tatyasaheb Kore Dental College|Yes|Completed|July 2012|November 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 24, 2013|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01997853||55436|
NCT01998126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI66705|Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer|Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts||University of Utah|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|62|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|July 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT01998126||55415|
NCT02029261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50GM021700P4_1|Observational Study of Insulin Resistance and Muscle Wasting After Burn Injury|Project 4: Molecular Mechanisms in Burn-induced Insulin Resistance in Humans||National Institute of General Medical Sciences (NIGMS)|No|Recruiting|April 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|Samples Without DNA|whole blood, plasma, isolated leukocytes, skeletal muscle, fat, skin|Both|18 Years|N/A|No|Non-Probability Sample|Massachusetts General Hospital (MGH) burn patients from the emergency department,        intensive care unit, burn unit, or other MGH inpatient unit|April 2015|April 6, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02029261||53030|
NCT01998659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS-Px-102-I-01|Single Ascending Oral Dose Phase I Study With Px-102|A Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of Px-102 to Healthy Subjects||Phenex Pharmaceuticals AG|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 3, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998659||55375|
NCT01998672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS-Px-102-I-02|Multiple Ascending Oral Dose Phase I Study With Px-102|A Double-blind, Randomised, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Multiple Oral Doses of Px-102 to Healthy Subjects||Phenex Pharmaceuticals AG|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT01998672||55374|
NCT01998893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M39004|A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma|Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)||Hoffmann-La Roche||Completed|January 1997|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2014|November 17, 2014|November 25, 2013|No|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01998893||55357|
NCT02029781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apple study 2013|The Laparoscopic Appendicitis Score; a Multicenter Validation Study|APPLE Study (APPendicitis and Laparoscopic Evaluation) Study; Multicenter Prospective Validation of the Laparoscopic APPendicitis (LAPP) Score|APPLE|University Medical Center Groningen|Yes|Recruiting|September 2013|||September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|778|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029781||52990|
NCT02029794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02627|ASPIRE Pilot: Comparing Self-collected HPV Testing With Visual Inspection With Acetic Acid Screening for Cervical Cancer|ASPIRE Pilot: Determining Optimal Cervical Cancer Screening in a Low-resource Setting: A Randomized Controlled Trial Comparing Self-collected HPV Testing With Visual Inspection With Acetic Acid (VIA) Screening in Kampala, Uganda|ASPIRE|University of British Columbia|No|Active, not recruiting|March 2014|June 2015|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|500|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02029794||52989|
NCT02030028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13080577|ACTH Gel Therapy in Rheumatoid Arthritis|Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis||University of Pittsburgh|No|Recruiting|November 2014|October 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|100 Years|No|||January 2016|January 14, 2016|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030028||52971|
NCT02020993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-proBNP Trial|Urine NT-ProBNP in Neonatal Respiratory Distress|The Prognostic Value of Urine NT-ProBNP in Neonatal Respiratory Distress|NT-proBNP|Ankara University|No|Recruiting|December 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Urine NT-proBNP|Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Newborns with first postnatal 2 days with or without respiratory distress|January 2014|January 3, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02020993||53664|
NCT02021539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/VL-01|The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery|The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery|ElastoMAP|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|204|||Female|18 Years|N/A|No|Probability Sample|The study population consists of pregnant women presenting between the 24th and 34th week        of pregnancy, with uterine contractions associated with cervical changes objectified by        ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both        single or multiple pregnancies can be included).|February 2016|February 19, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021539||53622|
NCT02017717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-143|A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment|A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma|CheckMate 143|Bristol-Myers Squibb|Yes|Recruiting|January 2014|January 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|440|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017717||53916|
NCT02018250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMB4-09-1001 S-12-08|Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)|A Phase 1 Double-Blind, Placebo-Controlled, Single-Center Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intramuscular Administration of a New Oxime, MMB4 DMS Enhanced Formulation (EF)|MMB4(DMS)|U.S. Army Medical Research and Materiel Command|Yes|Suspended|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|7||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|December 27, 2012|No|Yes|FDA clinical hold|No||https://clinicaltrials.gov/show/NCT02018250||53875|
NCT02017925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13044|Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation|Pulmonary Rehabilitation in Locally Advanced Non-Small Cell Lung Cancer||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|October 2013|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017925||53900|
NCT02018211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-Sport-001|Neuromuscular Electrical Stimulation Via the Peroneal Nerve Reduces Muscle Soreness Following Intermittent Exercise|Neuromuscular Electrical Stimulation Via the Peroneal Nerve Reduces Muscle Soreness Following Intermittent Exercise||Firstkind Ltd|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Male|20 Years|22 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018211||53878|
NCT02018510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA-0835|A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117|A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers||Rockefeller University|Yes|Completed|January 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|15||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018510||53855|
NCT02028572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLC-STR-FN|Structure Function Correlation in Primary Open Angle Glaucoma|A Cross Sectional Study of Correlation Between Retinal Nerve Fibre Thickness Measured by Optical Coherence Tomography and Humphrey Visual Fields in Early and Moderate Open Angle Glaucoma|STR_FN|Vasan Eye Care Hospital|No|Completed|February 2013|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|130|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects presenting to the glaucoma clinic of a tertiary eye care hospital an diagnosed to        have primary open angle glaucoma|December 2014|December 28, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02028572||53083|
NCT02018744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVAS-Global|Multicenter, Observational Registry to Assess Outcomes With the Nellix® System for Abdominal Aortic Aneurysm Repair|Multicenter, Observational, Post-Market, Real World Registry to Assess Outcomes of Patients Treated With the Nellix® System for Endovascular Abdominal Aortic Aneurysm Repair|EVAS-Global|Endologix|Yes|Active, not recruiting|October 2013|September 2019|Anticipated|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Up to 300 patients diagnosed with AAA who are considered candidates for Endovascular        Repair, who meet the study eligibility criteria and sign the Informed consent may be        subsequently enrolled in the study|October 2014|October 6, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02018744|5 Years|53837|
NCT02018757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012AA022701|Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC|Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma|SEATH|First Hospital of China Medical University|Yes|Not yet recruiting|January 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||May 2014|May 25, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02018757||53836|
NCT02019004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU83962|A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles|Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial||Northwestern University|Yes|Active, not recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02019004||53817|
NCT02019277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28784|A Study of Perjeta (Pertuzumab) and Herceptin (Trastuzumab) Treatment in Combination With a Taxane in Patients With Advanced HER2-positive Breast Cancer|An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|December 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02019277||53796|
NCT02029677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00001280|Appetite Suppression / Hormone Study Control Group|Putative Hormonal Mechanisms of Appetite Suppression Following LAGB: A Pilot Study||Oregon Weight Loss Surgery, LLC|No|Enrolling by invitation|September 2008|September 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Each time these hormone assays are performed, aliquots of plasma will be frozen at -80C:        -  Total immunoreactive ghrelin - Plasma will be assayed in duplicate for immunoreactive           ghrelin concentration using a commercial radioimmunoassay (RIA)        -  Lipids - Plasma total cholesterol, TG, HDL-C, and LDL-C will be measured        -  Glucose and insulin - Plasma glucose concentrations will be measured in triplicate           using the glucose oxidase method. Plasma insulin will be measured in duplicate using a           modification of a double antibody radioimmunoassay        -  Adiponectin and other gut hormones - Adiponectin, PYY3,36 and GLP-1 will be measured           using a commercial RIA. Pancreatic polypeptide (PP) will be measured using a commercial           RIA|Both|18 Years|69 Years|No|Non-Probability Sample|Patients with morbid obesity or severe obesity with comorbidities who meet the National        Institutes of Health criteria for bariatric surgery and required by insurance to        participate in a medically supervised weight loss program prior to authorization for        surgery will be offered enrollment into the study. The 10 subjects enrolled will be men        and women ages 18 to 69 years with a BMI of greater than or equal to 35 kg/m2 and less        than 60 kg/m2. Patients must be fit to undergo major abdominal surgery and be reasonably        expected to complete the six-month study protocol prior to authorization for surgery.|January 2014|January 6, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02029677||52998|
NCT02019797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Desflurane|Desflurane-induced Myocardial Protection|Desflurane-induced Myocardial Protection in Aortic Valve Surgery: A Pilot Study||Keio University|Yes|Not yet recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|90 Years|No|||December 2013|December 18, 2013|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019797||53756|
NCT02020096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20131001|Ultrasound Plus Nerve Stimulator Versus Nerve Stimulator Guided Lumbar Plexus Block|A Randomized Comparison of Ultrasound Plus Nerve Stimulator Guided Lumbar Plexus Block to Conventional Nerve Stimulator Guided Technique Using Winnie Approach||Huazhong University of Science and Technology|Yes|Recruiting|November 2013|April 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||December 2013|December 23, 2013|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02020096||53733|
NCT02029001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET12-081|Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment|A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors|MOST|Centre Leon Berard|Yes|Recruiting|February 2014|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029001||53050|
NCT02029274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312X2206|Safety and Efficacy of BAF312 in Dermatomyositis|A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.||Novartis|No|Terminated|November 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|70 Years|No|||January 2016|January 24, 2016|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029274||53029|
NCT02029287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL2013022|Hospital-Community-Family-Care Management Platform for Chronic Heart Failure|Remote Prevention and Treatment Based on Community Under the Guidance of Regional Central Hospital for Patients With Chronic Heart Failure|HCF-CMP-CHF|Northern Jiangsu Province People's Hospital|Yes|Recruiting|December 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|1000 subjects with chronic, moderate heart failure (NYHA functional class II-III) with        reduced ejection fraction (≤45%) will be enrolled (500 randomly allocated to receive and        500 to receive placebo in addition to standard therapy). Determination of study        eligibility will be established by the Investigator on the basis of the inclusion and        exclusion criteria.|August 2015|August 22, 2015|December 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029287|12 Months|53028|
NCT02029508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCC_BPPV_Kr|The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo|The Effectiveness Comparison of Three Different Methods for the Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Prospective, Double Blinded, Randomized, Multicenter Clinical Trial|BPPV|Asan Medical Center|No|Completed|October 2012|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029508||53011|
NCT02029807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2334|Comparison of Physiological Variables During Blood Donation|Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume During Blood Donation||University of Colorado, Denver|No|Active, not recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers donating blood|December 2015|December 3, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029807||52988|
NCT02030041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simvavitd|Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy|Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|50 Years|No|||October 2014|October 27, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02030041||52970|
NCT02021305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230283|The Role of TLR-4 Polymorphisms in Children With Urinary Track Infections|The Role of TLR-4 Asp299Gly and Thr399Ile Polymorphisms in Children With Urinary Tack Infections|TLR-4|Aristotle University Of Thessaloniki|No|Recruiting|February 2013|February 2017|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|Whole Blood|Both|6 Months|14 Years|Accepts Healthy Volunteers|Probability Sample|Patients an controls are selected from the Emergency Department and Outpatient Clinics of        the 4th Department of Pediatrics , Aristotle University of Thessaloniki, Papageorgiou        Hospital, Thessaloniki, Greece|December 2013|December 20, 2013|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021305||53640|
NCT02021747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00403 [JIRB]|Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis|Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis||Weill Medical College of Cornell University|Yes|Recruiting|January 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|180|Samples With DNA|Blood Biological material from the lungs|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment will be from the referral base of the responsible investigator and other        physicians, and review of admissions and hospital database. Patients, who may qualify for        this study, will be identified by chart review, physician referral, and recruited by study        investigators. The source of potential subjects will be the population of potential        subjects with TB (smokers or non smokers), and with both TB and COPD, as defined before.        Accrual will be random with no bias as to gender or racial/ethnic group.|December 2015|December 18, 2015|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02021747||53606|
NCT02021760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOND|Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction|Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction in Stockholm (RECOND)|RECOND|Karolinska Institutet|Yes|Completed|May 2013|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021760||53605|
NCT02021773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBR-101-021|Assessment of LBR-101 In Chronic Migraine|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine||Teva Pharmaceutical Industries||Completed|January 2014|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|277|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021773||53604|
NCT02018263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212011268|Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans|||Yale University||Active, not recruiting|October 2013|||April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|50 Years|No|||December 2015|December 28, 2015|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02018263||53874|
NCT02018276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0719|Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery|||Yonsei University|Yes|Completed|December 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|135|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02018276||53873|
NCT02017938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5141B|Establishing the Central and Peripheral Fatigue Indexes and VR Based Anti-fatigue Training Paradigm for Individuals With Parkinson Disease|||Chang Gung University|Yes|Recruiting|August 2013|July 2016|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|90|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02017938||53899|
NCT02018224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|evo-rad-akilles3|Achilles Tendon Rupture, Comparison Two Different Operative Techniques. Prospective Randomized Controlled Trial. 14 Years Follow-up.|Achilles Tendon Rupture, Comparison Two Different Operative Techniques. Prospective Randomized Controlled Trial. 14 Years Follow-up.||University of Oulu|No|Completed|October 1998|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||September 2014|September 15, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02018224||53877|
NCT02018237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12111|High Fructose Corn Syrup|The Effect of High Fructose Corn Syrup Feeding in Nonalcoholic Fatty Liver Disease|Fructose|Washington University School of Medicine|Yes|Recruiting|March 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02018237||53876|
NCT02028585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12162-mfds-118|Effects of Low Fat Milk Consumption on Metabolic Syndrome|Effects of Low-fat Milk Consumption on Metabolic and Atherogenic Biomarkers in Korean Adults With Metabolic Syndrome: a Randomized Controlled Trial||Ministry of Food and Drug Safety, Korea||Completed|April 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|58|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02028585||53082|
NCT02019017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTACH2012|Botox Injection in Treatment of Cluster Headache|Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues||Norwegian University of Science and Technology|Yes|Completed|October 2013|August 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||October 2015|October 23, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02019017||53816|
NCT02019030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130322|Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode|Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study||Olympus Corporation of the Americas|No|Recruiting|December 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Male|18 Years|N/A|No|Non-Probability Sample|Symptomatic BPH patients seen at Urology clinic at Loma Linda University Medical Center        and VA Greater Los Angeles Healthcare System|October 2015|October 14, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02019030||53815|
NCT02019043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 130440|Evaluation of Enhanced Syphilis Screening Among HIV-positive Men|Enhanced Syphilis Screening Among HIV-positive Men (ESSAHM): Evaluation of a Clinic-based Intervention||St. Michael's Hospital, Toronto|No|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|3131|||Male|16 Years|N/A|No|||January 2016|January 14, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02019043||53814|
NCT02019550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200136-573|Rebif® Rebidose® Versus Rebiject II® Ease-of-Use|A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week||EMD Serono|No|Recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02019550||53775|
NCT02019563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000019443|MTA/FS Pulpotomy for Vital Primary Incisors: A Randomized Controlled Trial|Mineral Trioxide Aggregate/Ferric Sulfate Pulpotomy for Vital Primary Incisors: A Randomized Controlled Trial|MTA/FS|The Hospital for Sick Children|No|Completed|September 2010|September 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||February 2016|February 5, 2016|December 18, 2013||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT02019563||53774|Limitations of the study design included no blinding of personnel providing treatment or raters assessing clinical and radiographic outcomes.
NCT02029014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAA v1.1|Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin|Evaluation of Safety and Efficacy of the New Generation of Left Appendage Closure With the LAmbre Device in AF Patients Not Suitable for Use of Warfarin||Lifetech Scientific (Shenzhen) Co., Ltd.|No|Recruiting|March 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|154|||Both|18 Years|80 Years|No|||March 2014|March 16, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029014||53049|
NCT02029534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16729|Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)|Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation||Creighton University|Yes|Recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|19 Years|N/A|No|||November 2015|November 27, 2015|August 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029534||53009|
NCT02029521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMP/clin.stud/2010/1.|Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients|Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure||Brigham Young University|No|Completed|March 2011|July 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Months|10 Years|No|||January 2016|January 16, 2016|December 30, 2013||No||No|June 20, 2014|https://clinicaltrials.gov/show/NCT02029521||53010|This trial was limited to one site. The number was relatively small. Since PFT's were not done on children under the age of 5, there is even smaller number of participants contributing PFT data.
NCT02029547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-JPT01|Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians|Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans||Avid Radiopharmaceuticals|No|Withdrawn|October 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|N/A|No|||October 2014|October 22, 2014|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02029547||53008|
NCT02026518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459|Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome|||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2014|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|100|||Female|18 Years|75 Years|No|||November 2014|November 17, 2014|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02026518||53241|
NCT02026752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVQPS-US12-001|Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay|Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay||Gen-Probe, Incorporated|No|Active, not recruiting|January 2014|October 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|468|Samples With DNA|plasma|Both|15 Years|N/A|No|Non-Probability Sample|HIV-infected male and female subjects ≥15 years of age who are attending participating US        medical facilities will be eligible to enroll. Participating sites may include academic        institutions with clinical divisions, infectious disease clinics, and other medical        facilities such as sexually transmitted infection, HIV, and public health facilities|July 2015|July 24, 2015|December 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02026752||53223|
NCT02021318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0610|FG-4592 in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa|A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|Dolomites|Astellas Pharma Inc|Yes|Recruiting|February 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|570|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021318||53639|
NCT02021565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7873-R|Evaluating the CG ASSIST Program for Caregiving Dyads|Evaluating the CG ASSIST Program for Caregiving Dyads|CG ASSIST|VA Office of Research and Development|No|Active, not recruiting|December 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|180|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02021565||53620|
NCT02021786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-2012-09062883|A web-and Mobile Phone-based Intervention in 4-year-olds: a Population-based Randomized Controlled Trial|A Web- and Mobile Phone-based Intervention to Prevent Obesity in 4-year-olds (MINISTOP): a Population-based Randomized Controlled Trial||Karolinska Institutet|Yes|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|315|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021786||53603|
NCT02021799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102400|The Effect of Under-nutrition on the Human Microbiota|The Effect of Nutrition on the Microbiome in Pregnant Women and the Use of Micronutrient Supplemented Probiotic Yogurt to Improve Outcomes||Western University, Canada|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|77|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02021799||53602|
NCT02021812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSB 11-02|Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms||W.L.Gore & Associates|Yes|Recruiting|December 2013|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02021812||53601|
NCT02028247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD CBT for ASD|Psychotherapy for Anxiety in Children With Autism Spectrum Disorder|2/3 Treatment of Anxiety in Autism Spectrum Disorder|TAASD|University of South Florida|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|201|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02028247||53108|
NCT02028559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45658-K|Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones|Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones||University of Washington|No|Enrolling by invitation|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||May 2015|May 31, 2015|January 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028559||53084|
NCT02028936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARDOU FUI 2013|Study of the Impact of the Regular Consumption of Polyphenol-rich Grape Juice on the Biological Parameters of Oxidative Stress and on Endothelial Function in Healthy Subjects|Study of the Impact of the Regular Consumption of Polyphenol-rich Grape Juice on the Biological Parameters of Oxidative Stress and on Endothelial Function in Healthy Subjects: a Prospective Randomised Double-blind Study|Fijus Raisol|Centre Hospitalier Universitaire Dijon||Completed|October 2013|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|100|||Both|18 Years|50 Years||||October 2013|December 3, 2014|December 18, 2013||||No||https://clinicaltrials.gov/show/NCT02028936||53055|
NCT02018783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dessensibilizantes|Single Application of Desensitizing Pastes as Dentin Sensitivity Treatment|Clinical Evaluation of the Effectiveness of Immediate Relief Obtained With Desensitizing Creams - A Controlled, Randomized, Triple Masked, Split-Mouth Clinical Trial||Federal University of São Paulo||Completed|April 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|138|||Both|22 Years|48 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02018783||53834|
NCT02029391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304048RINB|Kinesio Taping in Subjects With Myofascial Pain Syndrome: a Randomized Controlled Trial|Kinesio Taping on Short Term Changes in Subjects With Myofascial Pain Syndrome: a Randomized Controlled Trial||National Taiwan University Hospital|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|60 Years|No|||January 2014|January 7, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029391||53020|
NCT02029131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpoMed Low Back|Exercise and Low Back Pain|Effects of a Home-based Exercise Program on Low Back Pain in Employees||Hannover Medical School|No|Completed|January 2014|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|226|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02029131||53040|
NCT02029417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 245213|Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age||Roswell Park Cancer Institute|Yes|Terminated|July 2014|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|65 Years|N/A|No|||January 2016|January 11, 2016|January 6, 2014|Yes|Yes|Major revisions needed in study|No||https://clinicaltrials.gov/show/NCT02029417||53018|
NCT02029430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P2-KS-01|A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma|An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma||CytRx|No|Active, not recruiting|January 2014|June 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029430||53017|
NCT02029443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-001|ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia|A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia||Acerta Pharma BV|No|Recruiting|January 2014|||January 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|286|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02029443||53016|
NCT02029885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM14-001|Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension|Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension|WAVE_IV|Kona Medical Inc.|Yes|Recruiting|August 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|90 Years|No|||January 2016|January 6, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029885||52982|
NCT02029898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/175/HP|Remifentanil for General Anesthesia in the Context of Immaturity|Adaptation to Neonatal Life After an Anesthetic Protocol Using Remifentanil for General Anesthesia for Caesarean Section in a Context of Prematurity - REAGI Protocol|REAGI|University Hospital, Rouen|No|Recruiting|February 2014|June 2018|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029898||52981|
NCT02029027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00235-38|Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal Reeducation|Evaluation de l'intérêt de l'électrostimulation Intra-vaginale à Domicile Par Rapport à Une Prise en Charge Habituelle Dans la Prise en Charge de Patientes Incontinentes Ayant bénéficié d'Une rééducation périnéale||Effik|Yes|Active, not recruiting|August 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Female|18 Years|N/A|No|||January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029027||53048|
NCT02030054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060114|Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)|Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors|gRANADa|University of Roma La Sapienza|No|Not yet recruiting|January 2015|September 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||December 2014|December 3, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030054||52969|
NCT02026258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IE-12-047-2|Efficiency of Piezotome-Corticision Assisted Orthodontics|Efficiency of Piezotome-Corticision Assisted Orthodontics in Alleviating Mandibular Anterior Crowding - A Randomized Controlled Clinical Trial||University of Connecticut Health Center|Yes|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 10, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02026258||53260|
NCT02030067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-3117-P1-01|Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies|A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies||Rexahn Pharmaceuticals, Inc.|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030067||52968|
NCT02026271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI001-102|A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma|A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma||Ziopharm|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|December 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02026271||53259|
NCT02026531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14070|Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease|Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|November 2010|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT02026531||53240|
NCT02021825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITONMO|Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders|Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders||Xuanwu Hospital, Beijing|Yes|Recruiting|March 2009|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|55 Years|No|||December 2013|December 19, 2013|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02021825||53600|
NCT02021578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8482529|A Family Depression Prevention Program|Family Cognitive Behavioral Prevention of Depression in Youth and Parents|FDP|Vanderbilt University|Yes|Recruiting|December 2014|December 2021|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|9 Years|15 Years|No|||December 2015|December 7, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02021578||53619|
NCT02017951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRB13069-GA|Geographic Influences on Appendicectomy Outcomes|Geographic Influences on Appendicectomy Outcomes||University of Edinburgh|No|Completed|January 2001|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||9|Anticipated|40000|||Both|N/A|N/A|No|Probability Sample|All Scottish residents undergoing appendicectomy during the study period.|December 2013|December 16, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02017951||53898|
NCT02017964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS1221|Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma|A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age||Children's Oncology Group|Yes|Recruiting|December 2013|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|47 Months|No|||December 2015|December 2, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017964||53897|
NCT02027519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM6800|Enhanced HIV Prevention in Couples: Feasibility Study #3|Enhanced HIV Prevention in Serodiscordant Couples Study #3: Feasibility of Home-based Partner Self Testing for HIV|EPIC|Columbia University|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|53|None Retained|HIV rapid tests will be conducted using self-collected oral mucosa transudate. These tests      use oral ﬂuid and do not require blood drawing. Oral swab samples will not be stored.      Following the completion of the self-testing, study staff will conduct conﬁrmatory standard      HIV testing.      Following self-testing procedures, conﬁrmatory rapid testing will be conducted using whole      blood ﬁnger-stick. Blood samples from confirmatory tests will not be stored. If there is a      discrepancy between the two tests, the individual will be counseled and referred for re-test      in 4-6 weeks.|Both|18 Years|N/A|No|Non-Probability Sample|Pregnant and postpartum women already tested for HIV and known to be HIV-infected        attending participating antenatal clinics. Men and women already tested for HIV and known        to be HIV infected receiving care and treatment at participating TB and/or ART clinics.|September 2014|September 29, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027519||53164|
NCT02027740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|almond.2013|Almond Intervention in Type 2 Diabetes Mellitus|Effect of Almond Supplementation on Glycemic and Cardiovascular Risk Factors in Asian Indians in North India With Type 2 Diabetes Mellitus: A 24-week Prospective Cohort Study||Diabetes Foundation, India|Yes|Completed|January 2009|February 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|25 Years|65 Years|No|||January 2014|January 3, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027740||53147|
NCT02027753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTUL06638|Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy|Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine)|TED|Sanofi|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|20 Years|N/A|No|||August 2015|August 26, 2015|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02027753||53146|
NCT02027987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130814-7|Traumatic Neuroprotection and Epilepsy Prevention of Valproate Acid|Clinical Study on the Neuroprotection and Epilepsy Prevention of Valproate Acid Administered After Severe Traumatic Brain Injury|VPA|Xijing Hospital|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|16 Years|65 Years|No|||November 2013|January 2, 2014|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02027987||53128|
NCT02028949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUIU APJ 2012|Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study|LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study||Centre Hospitalier Universitaire Dijon||Recruiting||||November 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A||||August 2012|January 6, 2014|December 18, 2013||||No||https://clinicaltrials.gov/show/NCT02028949||53054|
NCT02029118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0302.2|Acupoint Application in Patients With Stable Angina Pectoris (AASAP)|Effect of Acupoint Application With Herbal Medicine in Patients With Stable Angina Pectoris: Randomized, Controlled,Double Blind Clinical Study|AASAP|Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|October 2012|August 2015|Anticipated|May 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|35 Years|85 Years|No|||September 2014|September 7, 2014|November 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029118||53041|
NCT02029378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12NE462|Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study|Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study|ICA-GBS|NHS Greater Glasgow and Clyde|Yes|Recruiting|September 2014|March 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029378||53021|
NCT02029144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-390|Observational Study of Dydrogesterone in Cycle Regularization|Dydrogesterone in Cycle Regularization in Abnormal Uterine Bleeding - Ovulation Dysfunction (AUB-O) Patients: A Prospective, Observational Study||Fudan University|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|114|||Female|16 Years|N/A|No|Probability Sample|Chinese women who is suffering from irregular menstrual cycle for at least 3 months and        has been diagnosed as AUB-O|February 2015|February 9, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029144||53039|
NCT02029157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-009|A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)|A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy|JET-HCC|Kyowa Hakko Kirin Company, Limited|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|N/A|No|||February 2016|February 22, 2016|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02029157||53038|
NCT02029690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-006|Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin|Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)|TRAP|Polaris Group|No|Recruiting|April 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029690||52997|
NCT02029716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1305|RTA 408 Lotion in Healthy Volunteers|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 Lotion in Healthy Volunteers||Reata Pharmaceuticals, Inc.|Yes|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|109|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029716||52995|
NCT02029664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC-2013-04-037|Gait Control of Stroke Patients Using Visual Feedback|||National Rehabilitation Center, Seoul, Korea|No|Recruiting|January 2014|||October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 27, 2015|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02029664||52999|
NCT02029911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0003|A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System||Minerva Surgical, Inc.|Yes|Completed|June 2011|June 2015|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|25 Years|50 Years|No|||October 2015|October 6, 2015|January 6, 2014|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT02029911||52980|
NCT02029820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/05339|RenalGuard System for Prevention of Contrast Induced Nephropathy|RenalGuard System for Prevention of Contrast Induced Nephropathy - A Randomized Trial|REPRECIN|Hospital Sao Lucas da PUCRS|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029820||52987|
NCT02029833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:137|Canola Oil Multi-Centre Intervention Trial II|Effects of Oleic Acid Enriched and Regular Canola Oil on Body Composition and Lipid Metabolism in Participants With Metabolic Syndrome|COMIT2|University of Manitoba|No|Recruiting|March 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|140|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02029833||52986|
NCT02027285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00088MI01|Nutrition, Health and Quality of Life: Development of New Formulations of Traditional Products of the "Made in Italy" Diet Optimized for Consumers With an Age Over 50 Years (MIAO 50)|Nutritional Trial With Fortified Milk in 65+ Years Old Subjects|MIAO50|University of Bologna|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|63 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02027285||53182|
NCT02028234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010114|"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-|"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors"|dOPPLER|University of Roma La Sapienza|No|Not yet recruiting|February 2014|April 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||January 2014|January 6, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02028234||53109|
NCT02017730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-106|To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers|An Open-Label Study To Evaluate The Safety and Tolerability Of A Novel LPA1 Receptor Positron Emission Tomography (PET) Ligand [11C]BMT-136088 And To Assess Receptor Occupancy In Human Lung Following Oral Administration Of BMS-986020 In Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02017730||53915|
NCT02027766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129|Stretching and Pain Sensitivity|Local and Systemic Changes in Pain Sensitivity After 4 Weeks of Calf Muscle-tendon Stretching: A Randomised Trial||Frederiksberg University Hospital||Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027766||53145|
NCT02027779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GreenGene™ F_E_P3|Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A|An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A||Green Cross Corporation|No|Recruiting|January 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||January 2014|January 3, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027779||53144|
NCT02028000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17928|Postoperative Pain and Skin Closure Methods After Cesarean Section|Post-Operative Pain and Skin Closure Methods After Cesarean Section|Skin|Wake Forest School of Medicine|No|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|150|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|October 9, 2012||No||No||https://clinicaltrials.gov/show/NCT02028000||53127|
NCT02028013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Management of Sexual Dysfunction With Bioresonance Technique|Management of Male Sexual Dysfunction With Bioresonance Technique, a New Egyptian Device||Man Clinic for Andrology, Male Infertility and Sexual Dysfunction|Yes|Recruiting|January 2013|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Male|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients complaining from erectile dysfunction|April 2015|April 7, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028013||53126|
NCT02028273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032012-021|Hippocampal Neurogenesis in Human Subjects|Hippocampal Neurogenesis in Human Subjects (Pilot Study)|NG|University of Texas Southwestern Medical Center|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from residential sober living and outpatient facilities.        Patients will also be recruited through flyers placed locally. Healthy controls will be        recruited from the Greater Dallas community.|January 2014|May 29, 2015|January 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02028273||53106|
NCT02029222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCOCO|Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.|In Silico Clinical Trial on Re-irradiation Lung Cancer, Comparing Photon, Proton and 12C-ion Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients.||Maastricht Radiation Oncology|No|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|25 patients with SCLC|January 2016|March 21, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02029222||53033|
NCT02028871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120700|Intranasal Insulin for Weight Management During Smoking Cessation|||University of New Mexico|Yes|Recruiting|July 2014|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028871||53060|
NCT02028884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-307JG|Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD|A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)||Chugai Pharmaceutical|Yes|Recruiting|February 2014|June 2020|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|12 Years|74 Years|No|||December 2015|December 8, 2015|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02028884||53059|
NCT02029170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUKSHHOS|Early Weightbearing Versus Non-weightbearing After Operative Treatment of an Ankle Fracture|Early Weightbearing Versus Non-weightbearing After Operative Treatment of an Ankle Fracture: A Randomized Multicenter Non-inferiority Trial||Hallym University Medical Center|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029170||53037|
NCT02029729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1303|RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER|An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors|DISCOVER|Reata Pharmaceuticals, Inc.|Yes|Completed|December 2013|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029729||52994|
NCT02029937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0396|High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia|High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: A Randomized, Multicenter Trial of Accuracy, Yield, and Clinical Impact||Anandasabapathy, Sharmila, M.D.|Yes|Recruiting|January 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029937||52978|
NCT02030158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/MR001|Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock|Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International, Multicentre, Randomised, Controlled Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock||Australian and New Zealand Intensive Care Research Centre||Not yet recruiting|January 2015|June 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|4210|||Both|18 Years|N/A|No|Non-Probability Sample|Severe sepsis and septic shock|January 2014|January 7, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02030158||52961|
NCT02028819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0003|Compassionate Use of Ibalizumab for the Treatment of HIV Infection|Compassionate Use of Ibalizumab for the Treatment of HIV Infection||University of Colorado, Denver||Available|January 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 3|Expanded Access|N/A|||||||Both|18 Years|89 Years|No|||December 2015|December 10, 2015|January 3, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02028819||53064|
NCT02029560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWP-SDS-405|Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System|Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia|CV|JW Pharmaceutical|No|Recruiting|October 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Male|50 Years|N/A|No|Probability Sample|The number of study subjects was calculated based on safety end-point which was variable        change in SBP measurement before and after the administration of Silodosin. In previous        studies, the standard deviation in before and after administration of Silodosin was 12.81.        Therefore, this study assumed the standard deviation in before and after administration to        be 12.81.        When the significance level was 0.05, the confidence interval was 1.41 and standard        deviation of SBP measurement before and after the administration of Silodocsin was 12.81,        the standard sample size will be 318 people and target number of study subject will be 400        as the expected drop rate is 20%.|November 2013|January 6, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02029560|3 Months|53007|
NCT02029573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFMC-CNS-01|Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma|Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma|ART|King Fahad Medical City|Yes|Recruiting|January 2014|January 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02029573||53006|
NCT02026583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB no : 2013-07-088|A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients|A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients||Samsung Medical Center||Active, not recruiting|December 2013|February 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026583||53236|
NCT02027961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI4736-1161|Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone|A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone||MedImmune LLC|No|Active, not recruiting|December 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027961||53130|
NCT02027103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-111-60037|Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients|Comparative Effects of Metformin and Pioglitazone on Fetuin-A and Osteoprotegerin Concentrations in Patients With Newly Diagnosed Diabetes: A Randomized Clinical Trial||Tehran University of Medical Sciences|No|Completed|January 2012|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|102|||Both|35 Years|N/A|No|||January 2014|January 2, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027103||53196|
NCT02027116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGX-6150-01|Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection|Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection|VGX-6150-01|GeneOne Life Science, Inc.|No|Active, not recruiting|January 2014|March 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|19 Years|65 Years|No|||December 2015|December 23, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02027116||53195|
NCT02027077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross2013|Evaluating a Small Change Approach to Preventing Long Term Weight Gain in Overweight and Obese Adults|A Randomized Controlled Trial Evaluating a Small Change Approach to Preventing Long Term Weight Gain in Overweight and Obese Adults||Queen's University|No|Active, not recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|344|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027077||53198|
NCT02027090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV17|High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease|High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|75 Years|No|||May 2015|May 21, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02027090||53197|
NCT02027311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOMI-1|Etomidate vs. Midazolam for Sedation During ERCP|Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP)||Cheju Halla General Hospital|Yes|Completed|April 2013|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|20 Years|90 Years|No|||June 2015|June 9, 2015|April 16, 2013||No||No|May 3, 2014|https://clinicaltrials.gov/show/NCT02027311||53180|To standardize proper sedation level we used Ramsay Sedation Scale but this scale could be calculated subjectively.Double blindness was not applied strictly because of quite different pharmacodynamics of two experimental drugs.
NCT02027792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5581 KoGon|Cabbage Leaf Wraps in Osteoarthritis of the Knee|Randomised Controlled Trial on the Efficacy of Cabbage Leaf Wraps in Symptomatic Primary Osteoarthritis of the Knee|KoGon|Universität Duisburg-Essen|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027792||53143|
NCT02028026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VII-IT-10|The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives|The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives||Massachusetts General Hospital|No|Recruiting|April 2013|April 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Female|18 Years|50 Years|No|||January 2014|January 3, 2014|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028026||53125|
NCT02028299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060922|Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography|Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography||George Washington University|No|Completed|April 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Both|18 Years|N/A|No|||April 2013|January 3, 2014|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028299||53104|
NCT02028312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI.HER-002|A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®|||Holprovision|No|Withdrawn|January 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|80 Years|No|||March 2015|March 17, 2015|January 3, 2014|Yes|Yes|Per Sponsor|No||https://clinicaltrials.gov/show/NCT02028312||53103|
NCT02028624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASt|Lifestyle Interventions Based on the Mediterranean Diet for Patients With Rheumatoid Arthritis|Lifestyle Interventions Based on the Mediterranean Diet for Patients With Rheumatoid Arthritis: a Randomized Controlled Trial||Harokopio University|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|48|||Both|18 Years|N/A|No|||January 2014|January 4, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02028624||53079|
NCT02028260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002105|Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill|Modafinil vs. Placebo for Hypoactive Delirium in the Critically Ill: A Randomized, Controlled Trial||Brigham and Women's Hospital|Yes|Recruiting|January 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||July 2014|July 16, 2014|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028260||53107|
NCT02028897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-13-0040|Comparison of Alternative Embryo Culture Systems|Comparison of Alternative Embryo Culture Systems||Fertility Center of Las Vegas|No|Withdrawn||||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02028897||53058|
NCT02028910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110105|Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter|Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter|Ondangapi|Assistance Publique - Hôpitaux de Paris|No|Terminated|January 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|6 Months|15 Years|No|||October 2012|December 3, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02028910||53057|
NCT02028923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2013-01|Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds|Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds|EMGEL|Institut Curie|No|Recruiting|April 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02028923||53056|
NCT02029456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538.38792-903/6190|Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism|Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial||Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital|No|Recruiting|June 2011|August 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02029456||53015|
NCT02029703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-GENZYME-2012|Optimization of Synvisc-One for Knee OA|Investigating the Efficacy of Synvisc-One® (Hylan G-F 20) as Adjunctive Therapy for Patients With Knee Osteoarthritis (OA) Requiring Physical Therapy||The Cleveland Clinic|No|Recruiting|August 2012|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|275|||Both|21 Years|N/A|No|||January 2014|January 6, 2014|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029703||52996|
NCT02029950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02426|Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS||National Cancer Institute (NCI)|Yes|Recruiting|December 2013|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02029950||52977|
NCT02029339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81000153|Continuous Topical Instillation for Open Abdomen in the Septic Patients With Complicated Intra-abdominal Infections|Continuous Topical Triple-tube Instillation and Suction for for Open Abdomen in the Septic Patients With Complicated Intra-abdominal Infections|Triple-tube|Southeast University, China|Yes|Completed|January 2007|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||January 2014|July 31, 2014|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02029339||53024|
NCT02029599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China.JLMXFYQ2008-01|The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis|A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis||Maoxiang Group Jilin Pharmaceutical Co., Ltd.|Yes|Completed|March 2014|||August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02029599||53004|
NCT02027064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2013](38)|Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT|||Peking University People's Hospital||Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|65 Years|No|||April 2015|April 27, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027064||53199|
NCT02029105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-280-1|Serum Biomarkers in Diagnosis of Mesothelioma|PREDICTING MALIGNANT MESOTHELIOMA BY ANALYZING HYALURONAN, OSTEOPONTIN, C-ERC/MESOTHELIN, N-ERC/MESOTHELIN AND SYNDECAN-1 SERUM LEVELS||Eskisehir Osmangazi University|Yes|Completed|January 2004|October 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|230|Samples Without DNA|Serum samples of the patients|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with pleural diseases; mesothelioma, metastatic malignant pleural diseases,        benign pleural diseases and benign asbestos pleurisy.|January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029105||53042|
NCT02027129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-30-10-2013|Physiological Study of Low-frequency HFO/HFO-TGI and High-frequency HFO|Comparison of Cardio-respiratory Variables Between Low-frequency High Frequency Oscillation With/Without Tracheal Gas Insufflation and High-frequency High-frequency Oscillation in Severe ARDS.||University of Athens|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|18 Years|75 Years|No|||January 2016|January 2, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027129||53194|
NCT02027324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002037|Prevention of Surgical Site Infection After Cesarean Delivery|Chlorhexidine-Alcohol Vs. Povidone-Iodine for Prevention of Surgical Site Infection After Cesarean Delivery: A Randomized Trial|CAPISSI|Brigham and Women's Hospital|Yes|Withdrawn|June 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|45 Years|No|||January 2016|January 11, 2016|January 2, 2014||No|Another study with similar methods was recently published|No||https://clinicaltrials.gov/show/NCT02027324||53179|
NCT02027532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-060|Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin|Prevention of Infection in Surgical Treatment of Closed Fractures: A Comparative Study of Cefazolin Versus Vancomycin||University of Tennessee|No|Enrolling by invitation|October 2009|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|85 Years|No|||March 2015|July 6, 2015|January 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02027532||53163|
NCT02027805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEN/TG-001|Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD|A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease.||Xenikos|Yes|Recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027805||53142|
NCT02028039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0204|IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)|Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With IPI-145||M.D. Anderson Cancer Center|No|Withdrawn|December 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|16 Years|N/A|No|||January 2014|January 3, 2014|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028039||53124|
NCT02028052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036432|Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE)|Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE) by Cytopathologist|ROSE|Duke University|No|Terminated|April 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|18 Years|N/A|No|||January 2015|February 2, 2016|December 20, 2013||No|similar study data published|No||https://clinicaltrials.gov/show/NCT02028052||53123|
NCT02028286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-002|A 21 Day Pharmacokinetics Study in Papulopustular Rosacea|A Phase 1, Open Label, Multiple Center Study to Evaluate the Pharmacokinetics of Once-Daily CLS001 Topical Gel Under Maximal Use Conditions Administered for 21 Days in Subjects With Papulopustular Rosacea||Cutanea Life Sciences, Inc.|No|Completed|January 2014|||March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 11, 2014|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028286||53105|
NCT02028650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL13-307PLAH-AHS|Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation|HLA-mismatched Peripheral Hematopoietic Stem Cells Infusion in the Treatment of Leukemia Patients Relapse After HLA- Matched Allogeneic Stem Cell Transplantation: A Randomized Clinical Trial||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Active, not recruiting|February 2005|October 2014|Anticipated|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|20|Samples With DNA|the blood and bone marrow samples before and after transplantation and DSI|Both|9 Years|67 Years|No|Probability Sample|Eligible patients were between 9 and 67 years of age with de novo diagnosed or        treated-related Acute leukemia relapsed after HLA-matched hematological stem cell        transplantation from Feb 2005 to Feb 2013.|January 2014|January 4, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02028650||53077|
NCT02028598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-PED-DDI-1|Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males|A Randomized, Open-labeled, 6-sequence, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Co-administration of Clomipramine HCl (Condencia Tab.) 15mg and Sildenafil Citrate (Viagra Tab.) 100mg on the Safety and Pharmacokinetic/Pharmacodynamic Properties of Clomipramine and Sildenafil Compared to the Effects After Single Oral Administration in Healthy Male Volunteers||CTC Bio, Inc.|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Male|19 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028598||53081|
NCT02028611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPark|Comparison of Gray-scale Inverted Rib Series With Conventional Ones in Rib Fracture Detection by Emergency Physicians and Medical Students|||Hanyang University||Completed|June 2013|||July 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|55|||Both|N/A|N/A|No|Non-Probability Sample|Emergency medicine residents|January 2014|January 4, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02028611||53080|
NCT02029742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ7350|Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT|Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT|HABIT|Columbia University|Yes|Completed|September 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|10 Years|18 Years|No|||January 2016|January 26, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029742||52993|
NCT02029183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2694-01|Screening and Treatment of SAHS in Patients With Acute Ischemic Stroke|Screening and Treatment of in Sleep Apnea Hypopnea Syndrome（SAHS)Patients With Acute Ischemic Stroke|SAHS|Peking University|Yes|Recruiting|December 2013|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|35 Years|70 Years|No|||January 2014|January 6, 2014|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02029183||53036|
NCT02029196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITG EVP G1 S2|A Study to Evaluate the Safety Profile of an e-Vapour Product|A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product||Imperial Tobacco Group PLC|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|420|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|August 25, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02029196||53035|
NCT02030236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAERvest-001|CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.|CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.||Bodychillz Ltd|No|Not yet recruiting|March 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030236||52955|
NCT02030249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/535 - SUB-STUDY|Sub-Study of the PREVIEW Study Australia|Sub-Study of the PREVIEW Study Australia: Effects of Weight Loss on Appetite, Bone Mass and Muscle Strength||University of Sydney|No|Active, not recruiting|January 2014|May 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|292|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02030249||52954|
NCT02029963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:178|Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?|The Efficacy of Repetitive Transcranial Magnetic Stimulation in Relapse Prevention of Major Depressive Disorder||University of Manitoba|Yes|Enrolling by invitation|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|85 Years|No|||October 2015|October 28, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029963||52976|
NCT02029976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00029947|School Nurse-directed Secondary Obesity Prevention for Elementary School Children|School Nurse-directed Secondary Obesity Prevention for Elementary School Children||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|April 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|8 Years|12 Years|No|||December 2015|December 2, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029976||52975|
NCT02030197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00572|Impact of CRISP on Self-Efficacy, Loneliness, and Depression|Effects of an Educational Socialization Program Designed to Improve Self-Efficacy and Subsequent Effects on Decreasing Loneliness and Depression Among People With Multiple Sclerosis|CRISP|New York University School of Medicine|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030197||52958|
NCT02030210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4ACS\2013\1|CP4ACS - Delphi Study to Determine Appropriateness of STEMI Quality Indicators in Belgium|Quality of Care for STEMI - Patients. a Research to Determine Appropriateness of STEMI Quality Indicators in Belgium, a RAND/UCLA Modified Delphi Study||European Pathway Association|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We aim to engage 20 cardiologists and 20 cardio nurses, all experienced in the care for        STEMI patients|January 2014|January 7, 2014|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02030210||52957|
NCT02029859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/070/HP|Sleep Apnea, Obesity and Pregnancy|Sleep Apnea, Obesity and Pregnancy|GOS|University Hospital, Rouen|No|Completed|April 2011|March 2015|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|205|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029859||52984|
NCT02030093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|077/13|Telephone-Based Continuing Care for Alcohol Dependence|Evaluation Study of the Effectiveness of a High- Versus Low-frequency Telephone-based and Sort Message-based (Sms) Continuing Care Provided to Patients Who Have Achieved a 12 Week In-patient Treatment for Alcohol Dependence||University of Bern|No|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|320|||Both|N/A|N/A|No|Non-Probability Sample|Patients of the clinic Südhang (Bern) and the Forel clinic (Zürich), both specialized        clinics for the treatment of alcohol dependency|February 2016|February 3, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02030093||52966|
NCT02026297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tranexamic Acid TEG|Tranexamic Acid and Thromboelastography During Cesarean Delivery|The Influence of Prophylactic Tranexamic Acid on Thromboelastography During Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial|TA TEG|Brigham and Women's Hospital|Yes|Recruiting|July 2014|January 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|200|||Female|18 Years|50 Years|No|||January 2015|January 16, 2015|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02026297||53257|
NCT02027506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dvavl2185|Diagnostic Value of Electrocardiographic St-t Wave Changes in Patients With Chronic Stable Angina|DIAGNOSTIC VALUE OF ELECTROCARDIOGRAPHIC ST-T WAVE CHANGES IN LEAD aVL IN PATIENTS WITH CHRONIC STABLE ANGINA|ECG|Alexandria University|No|Not yet recruiting|February 2014|January 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|This study will be a prospective observational study conducted on 150 patients admitted at        the Alexandria university hospitals or referred from secondary hospitals with documented        CAD as proved by non invasive tests (ECG, echocardiography, treadmill exercise, myocardial        perfusion imaging or multi-slice CT coronary angiography) requiring invasive coronary        angiography.|January 2014|January 3, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02027506||53165|
NCT01996761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-09-084-001|Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke|Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke|E-COMPASS|Samsung Medical Center||Recruiting|January 2011|||November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|80 Years|No|||November 2013|November 26, 2013|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT01996761||55520|
NCT02027142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleep and endometriosis.|Sleep Quality, Daytime Sleepiness and Insomnia in Patients With Endometriosis: a Case-control Study.|Symptomatic Endometriosis of the Posterior Cul-de-sac is Associated With Impaired Sleep Quality, Excessive Daytime Sleepiness and Insomnia: a Case-control Study.||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|290|||Female|18 Years|50 Years|No|Non-Probability Sample|In this study were recruited women referred to two academic centres for the diagnosis and        treatment of endometriosis (cases) and women referred to our Institutions because of        routine gynaecologic consultations (controls).|October 2015|October 25, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027142||53193|
NCT02027350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008074|New Methods to Diagnose Constrictive Pericarditis|Pressure-Volume Analysis of Constrictive Pericarditis||Mayo Clinic|No|Active, not recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02027350||53177|
NCT02027337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01200707998|Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants|The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants||Tyumen State Medical Academy|Yes|Recruiting|December 2013|October 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Anticipated|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|November 20, 2014|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02027337||53178|
NCT02027545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-411|Promoting Veteran-Centered Colorectal Cancer Screening|Promoting Veteran-Centered Colorectal Cancer Screening|PROM-IS|VA Office of Research and Development|No|Enrolling by invitation|October 2015|May 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|440|||Both|70 Years|75 Years|No|||February 2016|February 17, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02027545||53162|
NCT02028065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8616-101|A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|382|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|January 3, 2014|No|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT02028065||53122|
NCT02028078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILOT_EGP|Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia|An Open, Non-randomized, Single-center Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemic Clamp in Type 1 Diabetes Mellitus Subjects|PILOT_EGP|Medical University of Graz|Yes|Enrolling by invitation|January 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|64 Years|No|||March 2016|March 1, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028078||53121|
NCT02028325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCBS-0003|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Fluorescein|Indiana University|Yes|Terminated|December 2013|October 2016|Anticipated|October 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 18, 2013||No|Lack of enrollment. No new subjects had been enrolled for nearly a year.|No||https://clinicaltrials.gov/show/NCT02028325||53102|
NCT02029482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058-109|Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects|Single-center, Double-blind, Placebo-controlled, Randomized, Parallel-group, Up-titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Increasing Doses of ACT-128800 in Healthy Male and Female Subjects||Actelion|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02029482||53013|
NCT02028637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43/2009|Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.|Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|July 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Both|18 Years|80 Years|No|||January 2014|January 4, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02028637||53078|
NCT02029495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090406|Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1|AMVISION-1|Amgen|Yes|Terminated|March 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|478|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|January 6, 2014|Yes|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT02029495||53012|
NCT02029209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-03-II 1.2-2|To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer|||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|110|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02029209||53034|
NCT02030002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2013|Evaluation of a "Flash-free" Adhesive Resin for Orthodontic Bracket Bonding|Use of a "Flash-free" Adhesive Resin for Orthodontic Bracket Bonding: a Clinical Study of Bonding Time, Bond Survival, and Adhesive Remnant Cleanup||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|45|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02030002||52973|
NCT02026453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2TR000122-00032874|Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy|Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy||Cedars-Sinai Medical Center|No|Active, not recruiting|January 2014|May 2015|Anticipated|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|283|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026453||53246|
NCT02030223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM-2345-1786|Transversus Abdominis Plane Block and Inguinal Hernia Repair|The Analgesic Efficacy of the Ultrasound Guided Transversus Abdominis Plane Block After Inguinal Hernia Repair With a Mesh.||Aretaieion University Hospital|Yes|Recruiting|January 2014|June 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||January 2015|January 14, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030223||52956|
NCT02026440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200008|Evaluation of An Oral Fluid Collection Device|Collection and Testing of Human Oral Fluid Samples/VioOne OF Sample Collection Device||Avioq, Inc.|No|Recruiting|December 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and adult population|December 2013|December 31, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02026440||53247|
NCT01995890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVPEI|Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes|Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study||Dr T V Patel Eye Institute|Yes|Completed|December 2012|April 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|327|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 22, 2013|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT01995890||55586|
NCT01995903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00061126|Developing a Discrimination Model to Diagnose ALS|Developing a Discrimination Model to Diagnose ALS Using Advanced MRI Techniques||University of Michigan|Yes|Recruiting|April 2012|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT01995903||55585|
NCT02026817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MERO-104|Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg in Healthy Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|December 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02026817||53218|
NCT02027051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-15|Etude génétique Des Arméniens|Etude génétique Des Arméniens||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2014|January 2017|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|Saliva samples|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Descends of individuals originating from Armenia.|January 2014|January 24, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027051||53200|
NCT01996449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL113738|The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension|The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension||University of Texas Southwestern Medical Center|Yes|Recruiting|July 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01996449||55543|
NCT01996462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-109|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet Containing Escitalopram (20mg) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® Tablet (20mg) [Reference Formulation, Forest Laboratories, USA] in Healthy Human Volunteers Under Fasting Condition||Torrent Pharmaceuticals Limited||Completed||||May 2008|Actual|Phase 1|Interventional|N/A|1||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 21, 2013||||No||https://clinicaltrials.gov/show/NCT01996462||55542|
NCT01996475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-110|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed Condition|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet 20mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® (Escitalopram Oxalate Tablet 20mg) [Reference Formulation, Forest Laboratories Inc, USA] in Healthy Human Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||May 2008|Actual|Phase 1|Interventional|N/A|1||||||Male|18 Years|45 Years||||November 2013|November 26, 2013|November 21, 2013||||No||https://clinicaltrials.gov/show/NCT01996475||55541|
NCT01996488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-134|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Olanzapine Orally Disintegrating 5mg Tablets (Test Formulation; Torrent Pharmaceuticals Ltd., India) Versus Zyprexa® Zydis® 5 mg Tablets (Reference Formulation; Eli Lilly and Company, USA) in Healthy Human Volunteers Under Fasting Condition.||Torrent Pharmaceuticals Limited||Completed||||January 2009|Actual|Phase 1|Interventional|N/A|1||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 21, 2013||||No||https://clinicaltrials.gov/show/NCT01996488||55540|
NCT01996501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-135|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Olanzapine Orally Disintegrating 5mg Tablets (Test Formulation; Torrent Pharmaceuticals Ltd., India) Versus Zyprexa® Zydis® 5 mg Tablets (Reference Formulation; Eli Lilly and Company, USA) in Healthy Human Volunteers Under Fed Condition||Torrent Pharmaceuticals Limited||Completed||||January 2009|Actual|Phase 1|Interventional|N/A|1||||||Male|18 Years|45 Years||||November 2013|November 26, 2013|November 21, 2013||||No||https://clinicaltrials.gov/show/NCT01996501||55539|
NCT02027389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008045|Impact of Rapid Detection of MRSA|Clinical and Economic Impact of a Rapid Test for Detection of Methicillin-resistant Staphylococcus Aureus (MRSA) From Sterile Sites (the Alere&#8482; PBP2a)||Mayo Clinic|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|240|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus        cultures between Sept 15, 2012 - Dec 31, 2012 (control) and Sept 15, 2013 - Dec 31, 2013        (intervention)|April 2015|September 24, 2015|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02027389||53174|
NCT02027584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-CHOLIN|Observational Study of Choline, Its Metabolites, and Phospholipids in Preterm Infants|Supply of Term and Preterm Neonates With Choline, Lipids and Vitamines|NEO-CHOLIN|University Hospital Tuebingen|No|Completed|November 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|414|||Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|term and preterm neonates, parturients, non-pregnant females|December 2013|January 2, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02027584||53159|
NCT02027363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maintenance study|Maintenance Treatment With Capecitabine in Colorectal Cancer Patients|Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study||Sun Yat-sen University|Yes|Active, not recruiting|January 2010|June 2014|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|245|||Both|18 Years|75 Years|No|||January 2014|January 2, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02027363||53176|
NCT02027558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-353|Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans|Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans||VA Office of Research and Development|No|Enrolling by invitation|January 2014|March 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|N/A|No|||November 2015|November 20, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02027558||53161|
NCT02028338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-023/IPM 030|Phase 2a Study of Dapivirine Ring in Adolescent Females|Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females||International Partnership for Microbicides, Inc.|No|Enrolling by invitation|March 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|96|||Female|15 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02028338||53101|
NCT02028351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVS 001|Vision Measured by the Vimetrics CVA Compared With Chart Testing Under Similar Luminance and Contrast Conditions|Comparison of Vision Measured by the Vimetrics Central Vision Analyzer With That Measured by logMAR Acuity Chart Testing Under Similar Conditions of Luminance and Contrast||Sinclair Technologies, LLC|Yes|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Eye Clinic|January 2014|January 3, 2014|December 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02028351||53100|
NCT02028663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_201|Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis||CJ HealthCare Corporation|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|206|||Both|20 Years|70 Years|No|||August 2014|August 6, 2014|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02028663||53076|
NCT02029235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 00076|Post-operative Analgesia in Elective, Soft-tissue Hand Surgery|Post-operative Analgesia in Elective, Soft-tissue Hand Surgery: A Randomized, Double Blind Comparison of Acetaminophen/Ibuprofen Versus Acetaminophen/Hydrocodone||Milton S. Hershey Medical Center|No|Enrolling by invitation|February 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|90 Years|No|||February 2016|February 1, 2016|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02029235||53032|
NCT02028962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renuntlafumat|Computer Tailored Program for Smoking Cessation Among Romanian Adults|Development, Implementation and Evaluation of a Computer Tailored Program for Smoking Cessation Among Romanian Adults||Iuliu Hatieganu University of Medicine and Pharmacy|Yes|Recruiting|October 2013|November 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|640|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02028962||53053|
NCT02021955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-130|Integrating Care After Exacerbation of COPD|Integrating Care After Exacerbation of COPD (InCasE)|InCasE|VA Office of Research and Development|Yes|Enrolling by invitation|February 2015|October 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|259|||Both|N/A|N/A|No|||January 2016|January 22, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02021955||53590|
NCT02029469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP- HRA-001|Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study|Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study||Ascension Orthopedics, Inc.|No|Terminated|October 2007|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|75 Years|No|||August 2014|August 15, 2014|April 25, 2012|Yes|Yes|Study was terminated due to PI leaving the institution|No||https://clinicaltrials.gov/show/NCT02029469||53014|
NCT02018107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-464|PET/CT-Assessment of Liver Tumor Ablation|PET/CT-Guided Liver Tumor Ablation: Intraprocedural Assessment of Results Using Ammonia Perfusion PET||Dana-Farber Cancer Institute|Yes|Recruiting|January 2014|December 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02018107||53886|
NCT02030262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-10-1231|Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping|Study of the Impact of Air Versus SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|December 2013|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030262||52953|
NCT02030275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1301|A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults|A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults||RXi Pharmaceuticals, Corp.|Yes|Active, not recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02030275||52952|
NCT02026700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bariederm-HMO-CTIL|Bariederm Cream in Chronic Contact Dermatitis|Bariederm Cream in Chronic Contact Dermatitis||Hadassah Medical Organization|No|Not yet recruiting|February 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02026700||53227|
NCT01995591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2068|Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer|Prospective Open-label Study Using ex Vivo Injection of ICG to Detect SLN in Patients With Colon Cancer|2068|Jules Bordet Institute|No|Completed|January 2013|February 2015|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with colon cancer who will have colectomy|June 2015|January 11, 2016|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT01995591||55609|
NCT01995604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFLR001|Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face|A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face||MiMedx Group, Inc.|Yes|Withdrawn|September 2013|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01995604||55608|
NCT01996163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-FS-0561-13-CTIL|The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITU|The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITU||Tel-Aviv Sourasky Medical Center||Not yet recruiting|December 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|40|||Both|N/A|1 Year|No|Probability Sample|All infants 0-1 year old, admitted to PICU after craniosynostosis repair or untethering of        cord.|November 2013|November 26, 2013|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996163||55565|
NCT01996176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61110-2071|Take a Stand! - an Intervention to Reduce Occupational Sitting Time|Take a Stand ! - a Cluster Randomized Controlled Intervention Study at Four Office-based Workplaces Aiming to Reduce Occupational Sitting Time||University of Southern Denmark|Yes|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|337|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01996176||55564|
NCT01996189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPFF-11-1-YYW|Arterial Puncture Using Insulin Syringe is Less Painful Than Standard Syringe|Arterial Puncture Using Insulin Syringe is Less Painful Than Standard Syringe, a Randomized Crossover Study||National University Hospital, Singapore|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT01996189||55563|
NCT01997021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2594|Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults|Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults|B-WELL|University of Colorado, Denver|No|Recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|25|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT01997021||55500|
NCT02027597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35095-EB|Improving Oral Health With Serious Games|Improving Oral Health With Serious Games|AOTSM|University of Washington|No|Completed|October 2008|August 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|161|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027597||53158|
NCT02027571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Number: 12-01970-FB|Pathobiology and Reversibility of Prediabetes in a Biracial Cohort|Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)|PROP-ABC|University of Tennessee|Yes|Enrolling by invitation|October 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027571||53160|
NCT02027818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-TUM-ICG-IV|Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy|Study of the (Intravenously Injected) Indocyanine Green Distribution in the Margins of Breast Cancer After Tumorectomy||Jules Bordet Institute|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||December 2013|October 14, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02027818||53141|
NCT02028676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0300400|Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa|A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa|ARROW|Medical Research Council|Yes|Completed|March 2007|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|1206|||Both|3 Months|17 Years|No|||June 2014|June 4, 2014|December 31, 2013|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT02028676||53075|
NCT02037750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DA032634|Foster Teens' Risk During Transition|Foster Teens' Risk During Transition: Preventing Drug Use, HIV, & School Problems|LINKS|Oregon Social Learning Center|No|Recruiting|December 2012|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037750||52379|
NCT02038049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736X2202|A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis|A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis||Novartis|Yes|Terminated|December 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|55 Years|No|||December 2015|December 7, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038049||52356|
NCT02038374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00401-44|Clinico-biological Correlation of Severe Asthma in Children|Clinico-biological Correlation of Severe Asthma in Children||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|November 2013|April 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|N/A|18 Years|No|||August 2014|August 29, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02038374||52331|
NCT02038621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2ndSichuan|The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer|Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer|GZH-001|The Second People's Hospital of Sichuan||Not yet recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038621||52312|
NCT02038634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO20646|Ultrasound-guided Injection for DeQuervain's|Ultrasound-guided Injection for DeQuervain's||Medical College of Wisconsin|Yes|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038634||52311|
NCT02038868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4901-CL-0201|A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia|Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia||Astellas Pharma Inc|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|320|||Male|40 Years|74 Years|No|||December 2014|December 4, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038868||52293|
NCT02039128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS743/13 // AKBM109H|KOmparison Study KOmparison Study|A Double-blind, Randomized, Placebo-controlled Study to Assess Changes in the Omega-3 Index in Erythrocytes After Twelve Weeks of Daily Intake of SuperbaTM Krill Oil or Fish Oil||Aker Biomarine Antarctic AS|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|240|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02039128||52273|
NCT02043223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13060|Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit|Stopping Postpartum Vitamin A Supplementation: Are we Missing Concealed Benefit?||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|128|||Female|18 Years|32 Years|Accepts Healthy Volunteers|||June 2015|July 26, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043223||51960|
NCT02034851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISPV_Pediatria_Dexcar|Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection|Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR|DEXCAR-0212|Institut Investigacio Sanitaria Pere Virgili|Yes|Recruiting|April 2013|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|180|||Both|2 Months|14 Years|No|Probability Sample|Those children between 2 months and 14 years with a provable acute pyelonephritis that        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.|April 2014|November 24, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034851|6 Months|52601|
NCT02039934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT and insulin sensitivity|Effect of High-intensity Low-volume Training on Insulin Sensitivity in Type 2 Diabetes|Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects|HIT|German Diabetes Center|No|Recruiting|July 2013|August 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT02039934||52211|
NCT02040506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGN523-01|A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML|A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia||Igenica Biotherapeutics, Inc.|No|Completed|February 2014|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040506||52167|
NCT02041364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker fatigue ABC001|Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer|Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer: Evaluation of Plasma and Lymphocyte Expression.||Faculdade de Medicina do ABC|No|Recruiting|November 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|||Female|18 Years|80 Years|No|Non-Probability Sample|Patients with stage I, II and III breast cancer undergoing adjuvant systemic chemotherapy        based on the use of anthracyclines will be screened before the start of their treatment.|January 2014|January 18, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02041364||52101|
NCT02041052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1262-31/3|The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection.|Phase Two Randomized Study of The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection.||Karolinska University Hospital|No|Terminated|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|N/A|N/A|No|||August 2015|August 31, 2015|December 10, 2013||No|Terminated due to insufficient inclusion rate.|No||https://clinicaltrials.gov/show/NCT02041052||52125|
NCT02043652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6371|Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil|Efficacy of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil||Centers for Disease Control and Prevention|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|5 Years|70 Years|Accepts Healthy Volunteers|||January 2014|February 4, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043652||51927|
NCT02043873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUCH2012/10|Can Repair Increase the Useful Life of Composite Resins?|Can Repair Increase the Useful Life of Composite Resins? Clinical Trial: Triple-blind Controlled - 10 Year Follow-up|REPCOMP|University of Chile|Yes|Completed|August 2003|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A cohort of 28 patients aged 18 to 80 years (mean 26.5 years) of both females (58%) and        males (42%) with 50 composite restorations were recruited at the Operative Dentistry        Clinic at the Dental School of the University of Chile|January 2014|January 22, 2014|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043873||51910|
NCT02044107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeSSIAM_01|The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala|Measuring the Effectiveness of Co-packaging to Improve Provider and Caregiver Behavior in the Treatment of Diarrhea With Zinc & ORS and Pneumonia With Zinc & Antibiotics for Children Under 5 Yrs From San Marcos, Guatemala|Zinc10|Center for Studies of Sensory Impairment, Aging and Metabolism|No|Not yet recruiting|February 2014|June 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|320|||Both|2 Months|59 Months|Accepts Healthy Volunteers|||January 2014|January 23, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044107||51892|
NCT02044120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESP1/SARC025|ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma|||Sarcoma Alliance for Research through Collaboration||Recruiting|May 2014|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|N/A|No|||July 2015|July 13, 2015|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044120||51891|
NCT02044133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD026-12|Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)|Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)||Centre Hospitalier Departemental Vendee|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|January 26, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044133||51890|
NCT02036944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMRC-1909-1|Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting|Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting||Providence Medical Research Center|No|Terminated|March 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|13|Samples Without DNA|The serum remaining from 10 mL of blood will be aliquoted and frozen at -70 degrees. If      future funding allows, these samples will be tested for autoimmune and malabsorption      markers.|Both|18 Years|N/A|No|Probability Sample|Patients from Providence Internal Medicine Clinic, Providence Internal Medicine Residency        Services and Providence Family Medicine Residency Services|April 2015|April 27, 2015|January 13, 2014||No|Study stopped due to severe lack of enrollment and no compelling data to continue.|No||https://clinicaltrials.gov/show/NCT02036944||52441|
NCT02036931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH20.13|A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System||G7 Early Eval|Biomet, Inc.|No|Active, not recruiting|October 2013|April 2025|Anticipated|April 2025|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|315|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2016|January 6, 2016|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036931||52442|
NCT02037165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.3|Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers|Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study)||Boehringer Ingelheim||Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|5||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|January 14, 2014||||No||https://clinicaltrials.gov/show/NCT02037165||52424|
NCT02037477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CPH-010|Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of TAK-438|Phase 3 Open-Label Crossover Pharamacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects||Takeda|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037477||52400|
NCT02038075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-1-0569|Brief Cognitive Behavioral Therapy for Military Populations|Brief Cognitive Behavioral Therapy for Military Populations||University of Utah|No|Active, not recruiting|January 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038075||52354|
NCT02042339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-265ex11/12|Hyperbaric Oxygenation in Diabetic Ulcer|Hyperbaric Oxygenation (HBO) in Chronic Diabetic Leg Ulcer.||Medical University of Graz|No|Not yet recruiting|July 2014|October 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||January 2014|January 20, 2014|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042339||52028|
NCT02042586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROUILLOUD AOI 2007|Evaluation of Locomotor Activity Before and After Total Hip Replacement in Patients With Hip Osteoarthritis.|Evaluation of Locomotor Activity Before and After Total Hip Replacement in Patients With Hip Osteoarthritis. Use of Ganglion and Neural Network Techniques to Identify Objective Criteria for the Success of Arthroplasty||Centre Hospitalier Universitaire Dijon||Recruiting||||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|25 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|hip osteoarthritis indication for total hip replacement|March 2011|January 20, 2014|January 17, 2014||||No||https://clinicaltrials.gov/show/NCT02042586||52009|
NCT02042599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0175|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury|SEVOKID|University Hospital, Clermont-Ferrand||Not yet recruiting|January 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02042599||52008|
NCT02042872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5481-03-0013|Zoledronic Acid Administration in Acute Spinal Cord Injury|The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|No|Completed|May 2006|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|49 Years|No|||May 2015|May 5, 2015|January 21, 2014||No||No|March 12, 2014|https://clinicaltrials.gov/show/NCT02042872||51987|The clinical trial was not randomized, it had a relatively small sample size, and 5 participants received high-dose corticosteroids in an attempt to preserve neurologic function upon that could have had a profound adverse effect on the skeleton.
NCT02042885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314-12-401|A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer|A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment||Otsuka Novel Products GmbH|Yes|Terminated|January 2014|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|79|||Both|18 Years|N/A|No|||July 2014|October 19, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042885||51986|
NCT02039375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00087038|Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke|Optimal Post Tpa-Iv Monitoring in Ischemic STroke|OPTIMIST|Johns Hopkins University|Yes|Recruiting|March 2014|August 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039375||52254|
NCT02043470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101357|Retinal Oxygen Function After Radiation Therapy|Changes in Regional Retinal Oxygen Extraction and Function After Radiation Therapy||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a history of radiation therapy for a tumor in the vicinity of the        retina(s) at the Department of Radiation Oncology, UNC-CH.|August 2015|August 26, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02043470||51941|
NCT02039635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGC-S-02|Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer|A Study of Korean Red Ginseng for Evaluation of Improvement of Cancer-related Fatigue in Patients With Colorectal Cancer With Chemotherapy: A Randomized, Double-blind, Placebo-Controlled, Parallel, Multicenter Trial|KRG|Korea Ginseng Corporation|Yes|Active, not recruiting|December 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|438|||Both|20 Years|N/A|No|||March 2016|March 3, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02039635||52234|
NCT02040207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-12-04|AM-101 in the Treatment of Post-Acute Tinnitus 2|AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) - an Open-Label Extension to the TACTT3 Study|AMPACT2|Auris Medical, Inc.|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|76 Years|No|||March 2016|March 23, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02040207||52190|
NCT02040779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDB-AS-304|A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|December 2013|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|274|||Both|12 Years|N/A|No|||May 2015|May 21, 2015|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040779||52146|
NCT02041026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P446/08/2013|Investigating the Effects of Probiotic Yoghurt on Reducing the Levels of Aflatoxin B1 Toxin Among the School Children in Eastern Kenya|Investigating the Effects of Probiotic Yoghurt on Reducing the Levels of Aflatoxin B1 Toxin Among the School Children in Eastern Kenya||Technical University of Kenya|Yes|Not yet recruiting|February 2014|May 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|60|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041026||52127|
NCT02041065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2:4|Waterjet Versus Ultrasound Dissection During Hepatic Transection|Waterjet Versus Ultrasound Dissection During Hepatic Transection||Karolinska University Hospital|No|Completed|February 2011|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02041065||52124|
NCT02044393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.10|Interaction of BI 691751 With Itraconazole|Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)||Boehringer Ingelheim||Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|January 22, 2014||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT02044393||51870|
NCT02044614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCR-BXT-2013-01|Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis|Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis||Davita Clinical Research|Yes|Not yet recruiting|May 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02044614||51853|
NCT02036294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-7118|Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease|An Integrative Multilevel Study for Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease|BREATHE|Johns Hopkins University|Yes|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|N/A|No|||August 2015|August 31, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036294||52491|
NCT02040974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1978|Allergen Immunotherapy in Allergic Patients|Long Term Follow up in Patients Using Immunotherapy: Efficacy and Impact on Quality of Life||Istanbul University|No|Recruiting|January 2007|September 2014|Anticipated|January 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|18 Years|70 Years|No|Probability Sample|Allergic rhinitis patients sensitized to at least one common aero-allergen who completed a        three or five year period of allergen immunotherapy in our outpatient clinic between        2002-2013 were enrolled in the study and patients with allergic rhinitis who received only        medical treatment were chosen as the control group. Patients were separated in two groups        according to sensitization patterns including pollens or house dust mites. All patients        were evaluated before immunotherapy, in the first and the fifth years of treatment and two        years after the treatment.|January 2014|January 17, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040974|7 Years|52131|
NCT02041273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481036|Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions|A Phase 1, Open-label 6 Sequence 3 Period Crossover Study of Palbociclib (PD- 0332991) in Healthy Volunteers to Estimate the Relative Bioavailability of Palbociclib Formulations||Pfizer|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02041273||52108|
NCT02037178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/JLLD-01|Screening for Arteriopathy in General Medicine: a Preliminary Feasibility Study|Screening for Arteriopathy in General Medicine: a Preliminary Feasibility Study|DAG|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|October 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|50 Years|N/A|No|Non-Probability Sample|The study populations consists of men and women consulting with general practitioners and        who are at high risk for cardio vascular disease a defined by the French Society of        Vascular Medecin.|November 2015|November 9, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037178||52423|
NCT02037490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010702|Grow2Gether Pilot Study|Grow2Gether: Pilot Trial of a Peer-Based Social Media Intervention to Promote Healthy Growth During Infancy||Children's Hospital of Philadelphia|No|Active, not recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|172|||Female|18 Years|N/A|No|||October 2015|October 19, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037490||52399|
NCT02037763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain-OMICS PRT|A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain|A Prospective Controlled Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain||IRCCS Policlinico S. Matteo|Yes|Not yet recruiting|December 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Whole blood samples will be collected at recruitment in all enrolled patients. Blood samples      will be collected also at the 3 months and 6 months follow up visits in patients who will      develop CLBP after the episode of acute LBP.|Both|18 Years|N/A|No|Non-Probability Sample|Each clinical centre will identify patients with an episode of acute LBP, with or without        irradiation, referred from primary care physicians, orthopaedic specialists or directly        selected in the emergency room (accessing hospital for acute low back pain).        The enrolment will be competitive among the participating clinical centres.|March 2015|March 31, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037763||52378|
NCT02037776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tj43-p2-t1|The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia|Double-blind Trial With Rikkunshito Versus Placebo on Efficacy and Safety in Patients With Functional Dyspepsia: Multi-center Study (DREAM Study)||Osaka City University|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|20 Years|N/A|No|||April 2015|April 23, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02037776||52377|
NCT02042105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1303|A Prospective Epidemiologic Study of ALK-Positive NSCLC in China|A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China|C-TALK|Guangdong Association of Clinical Trials|Yes|Recruiting|November 2013|July 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|unselected Chinese patients with non-small-cell lung cancer|January 2014|January 19, 2014|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02042105||52046|
NCT02042612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0176|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients|CISEVOB|University Hospital, Clermont-Ferrand||Recruiting|October 2013|August 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02042612||52007|
NCT02042898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICSIII|Transfusion Requirements in Cardiac Surgery III|An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Patients Undergoing Cardiac Surgery|TRICS-III|St. Michael's Hospital, Toronto|Yes|Recruiting|January 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|3592|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042898||51985|
NCT02042911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012003|Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia|A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma||SymBio Pharmaceuticals||Recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years||||January 2014|January 20, 2014|December 17, 2013||||No||https://clinicaltrials.gov/show/NCT02042911||51984|
NCT02043236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6823|Strategies to Improve Bone Health in Men on ADT|A Phase II RCT of Strategies to Improve Bone Health in Men on ADT||University Health Network, Toronto|No|Active, not recruiting|November 2013|November 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|100|||Male|50 Years|N/A|No|||July 2015|July 28, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043236||51959|
NCT02043483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCM-|Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome|Obstructive Sleep Apnoea and Associated Metabolic/Cardiovascular Disorders: Understanding Mechanisms Towards Early Diagnosis and Prognosis||Universidade Nova de Lisboa|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Male|25 Years|60 Years|No|Probability Sample|Obstructive Sleep Apnoea Syndrome Males 25-60 years|February 2015|February 16, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02043483||51940|
NCT02039388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1766/2013|Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma|Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma|LUSTIC|Medical University of Vienna|No|Recruiting|November 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039388||52253|
NCT02039401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMALS-001 / B|Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis|A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis||ViroMed Co., Ltd. dba VM BioPharma|Yes|Active, not recruiting|February 2014|April 2017|Anticipated|September 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|21 Years|75 Years|No|||February 2016|February 9, 2016|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039401||52252|
NCT02039947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117277|Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain|BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain||GlaxoSmithKline|Yes|Recruiting|February 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|October 15, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039947||52210|
NCT02040519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44879.068.13|Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation|Time of Onset and Time of Offset of Sacral Neuromodulation Effect - "Wash in - Wash Out"||Maastricht University Medical Center|No|Recruiting|January 2014|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||May 2015|May 7, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02040519||52166|
NCT02041039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK089070|REWARD SYSTEM RESPONSES TO FOOD AROMAS|||Indiana University|Yes|Recruiting|October 2010|||October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects to be drawn from the Indianapolis and greater metropolitan area|March 2015|March 13, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041039||52126|
NCT02041390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120920-5|Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases|Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases: a Prospectively Randomized, Controlled Study||Fourth Military Medical University|Yes|Completed|September 2012|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|80 Years|90 Years|No|||January 2014|January 18, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02041390||52099|
NCT02044159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRIPES-Pilot|Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study|Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study (STRIPES)|STRIPES|Children's Hospital of Eastern Ontario|Yes|Recruiting|July 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|17 Years|No|||January 2016|January 26, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044159||51888|
NCT02044406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344.1|Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design)||Boehringer Ingelheim||Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|65|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|January 22, 2014||||No||https://clinicaltrials.gov/show/NCT02044406||51869|
NCT02044419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-032|A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled|A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana ("Sprinkled Contents") to a Single Oral Capsule Dose of 20 mg Lomitapide ("Intact Capsule") in Healthy Subjects||Aegerion Pharmaceuticals, Inc.|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|November 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02044419||51868|
NCT02036619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEDIP-N study|The Belgian Diabetes in Pregnancy Study: BEDIP-N Study|Prospective and Multi-centric Study on Diabetes During Pregnancy in Belgium|BEDIP-N|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|April 2014|April 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2563|Samples With DNA|For women at risk for an heritable form of diabetes, genetic testing for MODY will be      performed.|Female|18 Years|45 Years|No|Non-Probability Sample|Pregnant women without known diabetes attending a first prenatal visit in obsetrical        centers, both in university and in non-university hospitals|December 2013|May 28, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02036619||52466|
NCT02041533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-026|An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)|An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer||Bristol-Myers Squibb|Yes|Active, not recruiting|March 2014|January 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|535|||Both|18 Years|N/A|No|||August 2015|March 11, 2016|January 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041533||52088|
NCT02041559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0753|The Effect of Different Doses of Remifentanil on Kidney Function During Robot Assisted Prostatectomy - A Retrospective Study|||Yonsei University|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1500|||Male|20 Years|85 Years|No|Probability Sample|male patients undergoing robot assisted prostatectomy|January 2014|January 17, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02041559||52086|
NCT02041234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bariatric Surgery RCT|Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment|Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment||Khoo Teck Puat Hospital|No|Recruiting|February 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|65 Years|No|||September 2015|September 2, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02041234||52111|
NCT02041247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPROTECT1|Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection|Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study||InnaVirVax|Yes|Active, not recruiting|January 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|90|||Both|18 Years|60 Years|No|||August 2015|August 24, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02041247||52110|
NCT02041520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2011-785-058|Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients|Effect of Omega 3 Fatty Acids on Oxidative Stress in Seropositive HIV Patients||Coordinación de Investigación en Salud, Mexico|No|Completed|January 2013|June 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|70|||Both|20 Years|60 Years|No|||July 2015|July 28, 2015|January 17, 2014|Yes|Yes||No|February 6, 2015|https://clinicaltrials.gov/show/NCT02041520||52089|
NCT02041780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120128|Non Invasive Assessment of Liver Fibrosis in Children: Comparison of ShearWave Elastography, Fibrotest and Liver Biopsy|Non Invasive Assessment of Liver Fibrosis in Children: Evaluation of Diagnostic Performances of ShearWave Elastography (SWE) and Fibrotest®/ Fibromax® by Comparison With Fibrosis Score on Liver Biopsy|SHEARWAVE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|N/A|18 Years|No|||December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041780||52069|
NCT02041793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMR-PP 5/10|Laparoscopic Cystogastrostomy Versus Endoscopic Cystogastrostomy|A Prospective Randomized Controlled Trial Comparing Laparoscopic Versus Endoscopic Drainage for Pseudocyst of the Pancreas||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|August 2011|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|80 Years|No|||January 2014|January 18, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02041793||52068|
NCT02042352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSkive|PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting|||Regionshospitalet Viborg, Skive||Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|195|Samples With DNA|Vaginal flora swabs|Female|18 Years|42 Years|Accepts Healthy Volunteers|Probability Sample|IVF patients|January 2016|January 1, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02042352||52027|
NCT02042365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0178|Prospective Multicentre Study Assessing the Feasibility of Enhanced Recovery After Sleeve Gastrectomy for Obesity|Prospective Multicentre Study Assessing the Feasibility of Enhanced Recovery After Sleeve Gastrectomy for Obesity|SLEEVERAS|University Hospital, Clermont-Ferrand||Not yet recruiting|February 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|150|||Both|18 Years|65 Years|No|Probability Sample|obese patients undergoing a sleeve gastrectomy|February 2014|February 7, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042365||52026|
NCT02042924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS100|Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies|Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Suspended|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 21, 2014|Yes|Yes|Updating protocol and consents|No||https://clinicaltrials.gov/show/NCT02042924||51983|
NCT02043249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 0042-13|Cord Milking and Activity Of The Immune System In Preterm Infants|Cord Milking and Activity Of The Immune System In Preterm Infants||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|200|||Both|24 Weeks|37 Weeks|Accepts Healthy Volunteers|||November 2013|January 19, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02043249||51958|
NCT02043262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/295|The Effectiveness of Reablement in Home Dwelling Older Adults. A Randomized Controlled Trial|Evaluating Reablement for Home-dwelling Elderly in a Norwegian Municipality||Bergen University College|No|Active, not recruiting|May 2012|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||May 2015|November 17, 2015|November 20, 2012||No||No||https://clinicaltrials.gov/show/NCT02043262||51957|
NCT02039167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVGU-014-Kar|Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease|WATCH Bleeding Episodes After Left Atrial Appendage Occlusion Versus Usual Care in Patients With Atrial FIBrillatIon and Severe to eNd-stage Chronic Kidney Disease (WatchAFIB in CKD)|WatchAFIB|University of Magdeburg|Yes|Recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|80 Years|No|||December 2014|December 2, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039167||52270|
NCT02039960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201235|PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011|PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011||GlaxoSmithKline|No|Active, not recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|A DAWN case is any ED visit involving recent drug use. DAWN cases are identified through        the review of ED medical records in participating hospitals. DAWN captures both ED visits        that are directly caused by drugs and those in which drugs are a contributing factor but        not the direct cause of the ED visit. These criteria encompass all types of drug-related        events, including accidental ingestion and adverse reaction, as well as drug misuse or        abuse.        DAWN collects data on all types of drugs—illegal drugs, prescription and over-the-counter        medications, dietary supplements, and both pharmaceutical and nonpharmaceutical inhalants.        DAWN notes whether alcohol is involved in addition to drug(s) for patients of all ages.        Because alcohol is considered an illicit drug for minors, alcohol abuse without the        involvement of other drugs is considered a drug-related ED visit for patients under the        age of 21. DAWN does not report current medications that are deemed to be unrelated to the        ED visit.|March 2015|March 9, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02039960||52209|
NCT02040220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16641|Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)|Special Drug Use Investigation of EYLEA for CRVO|JPMS-CRVO|Bayer|No|Active, not recruiting|January 2014|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients with a diagnosis of CRVO will be enrolled after the decision for        treatment with EYLEA has been made by the investigator. Those patients prescribed EYLEA        previously will not be included in this study. Physicians should consult the full        prescribing information for EYLEA before enrolling patients and familiarize themselves        with the safety information in the product package label. Eligible patients who receive        EYLEA will be enrolled and documented in the eCRF.|March 2016|March 17, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02040220||52189|
NCT02040233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16782|Multiple Dose Study in Heart Failure of BAY 1067197|A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study.|PARSiFAL|Bayer|No|Completed|January 2014|April 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02040233||52188|
NCT02040792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0117|A 28-Day Parallel Group Study of TD-4208 in COPD|A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease||Theravance Biopharma R & D, Inc.|No|Completed|May 2014|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|355|||Both|40 Years|N/A|No|||December 2014|December 1, 2014|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040792||52145|
NCT02040545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20092198|Salivary Diagnostic Testing|Venopuncture-Free IVF: Can "Patient-friendly" Salivary Hormone Measurements Replace Serum Monitoring of IVF Patients?||Boston IVF|No|Enrolling by invitation|December 2009|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing In Vitro Fertilization (IVF) at a participating infertility center|February 2016|February 3, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02040545||52164|
NCT02040805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-6000|Comparison of Treatment for Hoarding Disorder|Comparison of Peer Facilitated Support Group and Cognitive Behavioral Therapy for Hoarding Disorder||University of California, San Francisco|Yes|Recruiting|February 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040805||52144|
NCT02041403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE ICH-158/12|RENAL RESISTIVE INDEX POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?|MAY RENAL RESISTIVE INDEX BE AN EARLY PREDICTIVE TOOL OF POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?||Istituto Clinico Humanitas|No|Completed|June 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|18 Years|N/A|No|Non-Probability Sample|Patients submitted to major high risk surgery|January 2014|January 21, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02041403||52098|
NCT02041416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13103|Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers|Delivering the Geriatric Assessment Tool to Older Adults With Cancer Using Computer Survey Methodologies: Testing Feasibility, Reliability, and Validity of Research Electronic Data Capture (REDCap) and Support Screen (Touchscreen) Technologies||City of Hope Medical Center|Yes|Active, not recruiting|June 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|65 Years|N/A|No|Non-Probability Sample|Using a prospective longitudinal study design, 100 patients will be recruited for this        study from the outpatient medical oncology and hematology practice at City of Hope Medical        Center.|September 2015|September 24, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02041416||52097|
NCT02036957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-01|MARY D&Apos;UOL REPAIR BALM IN THE PREVENTION OF SKIN TOXICITY BY CAPECITABINE|EFFECTIVENESS OF OF MARY D&Apos;UOL REPAIR BALM TO PREVENT THE SKIN TOXICITY IN PATIENTS WITH CAPECITABINE. RANDOMIZED CLINICAL TRIAL|B-DUOL|Basque Health Service|No|Recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|N/A|N/A|No|||October 2015|October 20, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02036957||52440|
NCT02037191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/121/HP|The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade|RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)|MP3|University Hospital, Rouen|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2015|October 21, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037191||52422|
NCT02040480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201039|Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib|A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040480||52169|
NCT02040714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPSG 001|Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease|Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease|IPSG1|Texas Scottish Rite Hospital for Children|No|Recruiting|August 2012|September 2023|Anticipated|September 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|600|||Both|6 Years|16 Years|No|Non-Probability Sample|Participants with a recent diagnosis of Perthes disease that are being followed by a        participating orthopedic surgeon. Participants are invited to participate during a visit        to their treating hospital.|May 2015|May 12, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02040714||52151|
NCT02041572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05/MM/PROMISE 0001|Attentional Bias Retraining in Veterans|Attentional Bias Retraining in Veterans|ABR|VA Pacific Islands Health Care System|No|Active, not recruiting|May 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|89 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041572||52085|
NCT02041845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2163|Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer|A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer||Norwegian University of Science and Technology|No|Recruiting|January 2014|December 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02041845||52064|
NCT02041546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB0607|Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome|Zekai Tahir Burak Maternity Teaching Hospital||Zekai Tahir Burak Women's Health Research and Education Hospital||Recruiting|September 2013|||September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|7 Days|No|||January 2014|January 17, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041546||52087|
NCT02041806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS/2013/81|Assessing Peripheral Nerve Block Scoring Systems for Intra-Operative and Post-Operative Analgesia|The Effectiveness of Peripheral Nerve Block Scoring Systems in Predicting the Success of a Block for Intra-Operative and Post-Operative Analgesia||The Adelaide and Meath Hospital|No|Recruiting|July 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing orthopaedic or vascular surgery who would receive a peripheral nerve        block as part of their care.|January 2014|January 18, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041806||52067|
NCT02042118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMAvsFMV|Randomized Clinical Trial Assessing Laryngeal Mask Airway Versus Face-mask Ventilation in Neonatal Resuscitation|Randomized Clinical Trial Assessing Laryngeal Mask Airway (LMA) Versus Face-mask Ventilation (FMV) in Neonatal Resuscitation at Mulago Hospital, Uganda|LMAvsFMV|Centre For International Health|No|Active, not recruiting|April 2014|December 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|1 Hour|No|||March 2016|March 4, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02042118||52045|
NCT02042131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01481|Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations|Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations|BISSR|University of Utah|No|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042131||52044|
NCT02042625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1443|Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study|Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study||The Cleveland Clinic|No|Recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|90 Years|No|||August 2015|August 7, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02042625||52006|
NCT02039180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00005|Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects|A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects|BA|AstraZeneca|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|1|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039180||52269|
NCT02039414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306109|Effects of Obesity and Physical Inactivity on Pregnancy Outcomes|Effects of Physical Activity on Maternal Lipid Metabolism, Oxidative Stress, and Neonatal Outcomes in Obese Pregnancy||Washington University School of Medicine|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples Without DNA|The investigators are collecting maternal blood at 7 different time points (all in one      day/visit) during the 3rd trimester of thier pregnancy. The investigators are also      collecting cord blood when the babies are born. All of these samples are stored at -80 with      patient identification numbers.|Female|18 Years|44 Years|No|Non-Probability Sample|All women who seek pre-natal care at the Women's Health Clinic at Barnes Jewish        Hospital/Washington University will be screened for inclusion BMI by history at the        clinic. Subjects will be recruited late in their 2nd trimester at the women's health        clinic after asking about their exercise habits. All patients who meet criterion with        on-going pregnancies will be approached for enrollment in the study. This study will        compare 2 groups of pregnant women between 30 and 35 weeks gestation. The first group will        inactive obese women and the other will be active obese women. We will recruit 15 subjects        per group (N=30). Groups will be race-matched.|January 2014|January 27, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039414||52251|
NCT02040246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81070651|Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China|Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China||RenJi Hospital|Yes|Completed|February 2009|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|40 Years|65 Years|No|||January 2014|January 16, 2014|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02040246||52187|
NCT02040532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002196|Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms in Peri- and Postmenopausal Women|Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms in Peri- and Postmenopausal Women With Vasomotor Symptoms||Massachusetts General Hospital|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|40 Years|65 Years|No|||February 2016|February 8, 2016|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040532||52165|
NCT02040558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV10100386|Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors|A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors||Mallinckrodt|No|Recruiting|July 2013|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040558||52163|
NCT02040818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT 131309|Treatment of Hemodialysis Catheter-Related Bacteremia|RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia||University of California, San Diego|Yes|Withdrawn|November 2013|||January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label|2||Actual|0|||Both|18 Years|100 Years|No|||October 2015|October 6, 2015|January 16, 2014||No|no enrollment|No||https://clinicaltrials.gov/show/NCT02040818||52143|
NCT02041078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/563-31/2|Intra Versus Extrahepatic Division of Right Hepatic Vein During Rightsided Hemihepatectomy|Randomized Phase 2 Study of Intra Versus Extrahepatic Division of Right Hepatic Vein During Rightsided Hemihepatectomy||Karolinska University Hospital|No|Enrolling by invitation|May 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|90 Years|No|||March 2016|March 10, 2016|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02041078||52123|
NCT02041091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15193|A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus|Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus||Eli Lilly and Company|No|Completed|January 2014|November 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041091||52122|
NCT02036645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4750C00001|SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease|A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.||AstraZeneca|No|Recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|121|||Both|55 Years|85 Years|No|||March 2016|March 4, 2016|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036645||52464|
NCT02037516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC|Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?|Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?||Coastal Anesthesiology Consultants|No|Completed|January 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|N/A|N/A|No|||February 2016|February 4, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037516||52397|
NCT02037529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-303|A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer|||Academic and Community Cancer Research United|Yes|Recruiting|March 2014|October 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|910|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02037529||52396|
NCT02037802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS2014-1|Caudal Epidural Catheterization in Pediatric Renal Transplant: Effect on Hemodynamics and Pain After Surgery|Caudal Extradural Catheterization in Pediatric Renal Transplant: Effect on Perioperative Hemodynamics and Pain Scoring.||Cairo University|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|3 Years|12 Years|No|||October 2014|October 2, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037802||52375|
NCT02037815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY-2013-002-003|Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy|Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy||Capital Medical University||Completed|January 2014|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|35|||Both|18 Years|65 Years|No|||July 2014|July 29, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037815||52374|
NCT02040987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00008|AZD3293 Thorough QT Study in Healthy Male Volunteers|A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects|AZD3293TQT|AstraZeneca|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040987||52130|
NCT02041260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 28313|A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting|A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041260||52109|
NCT02041819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1405|Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus|A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus||Zhejiang University|No|Withdrawn|February 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|January 10, 2014||No|No recruitment|No||https://clinicaltrials.gov/show/NCT02041819||52066|
NCT02042144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16821|Safety and Effectiveness of Regorafenib|Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings|CORRELATE|Bayer|No|Recruiting|April 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with mCRC who have been previously treated with, or are not considered        candidates for, other locally approved standard treatment(s) and for whom the decision has        been made per investigator's routine treatment practice to prescribe regorafenib.|March 2016|March 1, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042144||52043|
NCT02042378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-338-023|A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation|A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation||Clovis Oncology, Inc.|Yes|Active, not recruiting|April 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042378||52025|
NCT02043288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-6004-005|Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer|A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Orient Europharma Co., Ltd.|No|Recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|20 Years|75 Years|No|||August 2015|August 30, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02043288||51955|
NCT02039206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJD MEIR dTMS|The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease|The Influence of Deep Repetitive Transcranial Magnetic Stimulation (TMS) on Cerebellar Signs in Patients With Spinocerebellar Ataxia Type 3 (SCA3 - Machado Joseph Disease)||Brainsway|Yes|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|80 Years|No|||September 2014|September 15, 2014|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039206||52267|
NCT02039687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCP-112|Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis|A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis||Araim Pharmaceuticals, Inc.|Yes|Completed|January 2014|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|70 Years|No|||February 2015|January 4, 2016|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039687||52230|
NCT02039648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRW 300262502|The Influence of Rumex Acetosa L on the Intraoral Colonization With Porphyromonas Gingivalis|Proanthocyanidin- Enriched Extract From Rumex Acetosa L. as a Prophylactic Agent Against Intraoral Colonization With Porphyromonas Gingivalis|RPG-I|Heinrich-Heine University, Duesseldorf|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039648||52233|
NCT02039661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gookhan|Effect of Lidocaine Spray for Pain Relief During Endometrial Biopsy: a Randomized, Double-blind, Placebo-controlled Clinical Trial|||Kayseri Education and Research Hospital|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|55 Years|No|||January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039661||52232|
NCT02039986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010465|Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)|Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis||Children's Hospital of Philadelphia|No|Recruiting|January 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|6 Years|N/A|No|Non-Probability Sample|Patients with a confirmed diagnosis of cystic fibrosis.|February 2016|February 10, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039986||52207|
NCT02040259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4025|Trevo® Retriever Registry Post Market Surveillance|Stryker Neurovascular Trevo® Retriever Registry||Stryker Neurovascular|No|Recruiting|November 2013|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Acute ischemic stroke patients who may be referred for mechanical thrombectomy is used to        removed thrombus in the neurovasculature|January 2016|January 20, 2016|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040259|90 Days|52186|
NCT02040844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP007 A|Phase III Cat-PAD Follow-on Study|An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment||Circassia Limited|No|Enrolling by invitation|February 2014|||May 2019|Anticipated|Phase 3|Observational|Time Perspective: Prospective||3|Anticipated|1182|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have previously completed clinical study CP007 [NCT01620762]|March 2016|March 22, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040844||52141|
NCT02041429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-494|Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca|Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|February 2014|January 2021|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041429||52096|
NCT02041104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLINOTEST/618-001|Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism|Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism in a Population With Metabolic Syndrome||Mlinotest Zivilska Industrija d.d.|No|Enrolling by invitation|February 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|65 Years|No|||October 2015|October 7, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041104||52121|
NCT02037204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT|IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.|Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.|IMPACT|UMC Utrecht|Yes|Active, not recruiting|March 2013|August 2015|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|45 Years|No|||July 2014|July 17, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037204||52421|
NCT02037542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072013|A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer|A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer||Baptist Health South Florida|No|Recruiting|September 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02037542||52395|
NCT02038166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100930005|Nasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis|Chloride Secretagogues for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (NPD Protocol)||University of Alabama at Birmingham|Yes|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|19 Years|N/A|No|Non-Probability Sample|Patients presenting to UAB for evaluation of CRS|March 2016|March 2, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02038166||52347|
NCT02038426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00759-36|Ultrasonography Assessment of Peripheral Entheses in Axial Spondyloarthritis and in Healthy Subjects, Athletes or Not|Ultrasonography Assessment of Peripheral Entheses in Axial Spondyloarthritis and in Healthy Subjects, Athletes or Not.||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|November 2013|January 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02038426||52327|
NCT02041286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2013-001-01|Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System|User Performance of the Karajishi Contour Blood Glucose Monitoring System||Ascensia Diabetes Care|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|136|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 17, 2014|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT02041286||52107|
NCT02041299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA38-0411|Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias|The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias|FIRST|ApoPharma|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|2 Years|N/A|No|||February 2016|February 9, 2016|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041299||52106|
NCT02042157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-22588|Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting|Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting||Stanford University|No|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042157||52042|
NCT02042170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-SHCL010|Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients|A Phase II, Multi-center, Randomized, Comparative, Parallel, Open, Dose Finding Study to Assess the Efficacy and Safety After 26 Week-treatment of Eutropin Plus (SR-hGH) Compared to Eutropin Inj. in Pre-pubertal Children With Idiopathic Short Stature||LG Life Sciences|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|4 Years|14 Years|No|||September 2015|March 23, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042170||52041|
NCT02042430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02483|Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|December 2013|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|19 Years|N/A|No|||March 2016|March 9, 2016|January 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042430||52021|
NCT02042391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPTLDSG-IIT-PTLD-2|Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy|Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial|PTLD-2|Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH|Yes|Recruiting|December 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|January 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042391||52024|
NCT02042638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27122013|The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism|||Gulhane School of Medicine|Yes|Completed|January 2011|August 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Male|16 Years|45 Years|No|Probability Sample|Patients with Idiopathic Hypogonadotropic Hypogonadism|December 2013|January 22, 2014|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02042638|6 Months|52005|
NCT02042651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-178|A Sham Controlled Study of the Effects of Ultrasonic Shockwaves as a Treatment for Chronic Pelvic Pain|Low Intensity Extracorporeal Shockwave Therapy Against Chronic Pelvic Pain: a Randomized and Sham Controled Study|CPPESWT|Herlev Hospital|Yes|Withdrawn|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||March 2015|March 23, 2015|January 10, 2014||No|study stopped because of insuficient number of comparable patients available.|No||https://clinicaltrials.gov/show/NCT02042651||52004|
NCT02042937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009283|Enhancing Gluteus Maximus Recruitment|Enhancing Gluteus Maximus Recruitment: a Randomized Controlled Pilot Trial||Mayo Clinic|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02042937||51982|
NCT02042950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0259|A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|July 2014|||July 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042950||51981|
NCT02042963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNOW-KT|KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)|KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation : A 9-year Longitudinal Cohort Study of the Kidney Transplantation (KNOW-KT)|KNOW-KT|Seoul National University Hospital|Yes|Enrolling by invitation|March 2012|||February 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|DNA, serum, urine, RNA (blood and urine)|Both|N/A|N/A|No|Non-Probability Sample|Kidney transplant recipients and their donors (donors for baseline data)|January 2014|January 20, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042963|9 Years|51980|
NCT02043275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#E2013:015|Effect of Resistance Training on Jump Landing Mechanics in Young Female Athletes|Effect of a Resistance Training Program on the Jump Landing Biomechanics of Young Female Athletes||University of Manitoba|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043275||51956|
NCT02039193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ00P1_136973 / 1|Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial.|Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial.||University of Zurich|Yes|Completed|August 2012|August 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02039193||52268|
NCT02039219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT 002|Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)|A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)|TREAT|Indiana University|Yes|Recruiting|November 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||May 2015|May 13, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039219||52266|
NCT02039232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBOFIX P CLD PPS1|Safety and Efficacy of the CarboFix Pedicle Screw System|CarboFix Pedicle Screw System||CarboFix Orthopedics Ltd.||Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02039232||52265|
NCT02039427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUH-3368-sore throat|The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery|The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery||Yeungnam University College of Medicine|Yes|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|192|||Female|20 Years|60 Years|No|||December 2015|December 28, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039427||52250|
NCT02039674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-021|A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)|A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma||Merck Sharp & Dohme Corp.|No|Recruiting|February 2014|June 2019|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|308|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039674||52231|
NCT02039973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH100338-01|Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women.|Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women.||Harvard Medical School|Yes|Enrolling by invitation|January 2014|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|720|||Female|18 Years|49 Years|No|||June 2015|June 26, 2015|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02039973||52208|
NCT02040272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARS2|MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma|A Study to Determine if it is Feasible to Recruit Into a Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma|MARS2|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|May 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||June 2015|June 22, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02040272||52185|
NCT02040571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1151-3297|The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes|The Impact of the Overnight Closed Loop System on Glycemia, Subsequent Day-time Metabolic Control, Insulin Delivery, Counter Regulatory Hormones, Sleep Quality, Cognition and Satisfaction With Treatment, Compared to Open Loop System (Sensor Augmented Pump Therapy) in Both the Clinical Trial Centre and in the Home Setting in Type 1 Diabetes||St Vincent's Hospital Melbourne|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|14 Years|N/A|No|||May 2015|May 18, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02040571||52162|
NCT02041663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 10106|Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis|Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis|SAMIRA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2012|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|6 Months|18 Years|No|||December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041663||52078|
NCT02041988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1846/08.04.10|Preemptive Analgesia With Morphine Sulphate in Major Urological Surgery|Influence of Premedication With Oral Morphine Sulphate on Analgesic Consumption in Patient Undergoing Major Urological Surgery. Comparison Between Two Different Doses||University of Roma La Sapienza|Yes|Recruiting|February 2013|July 2014|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Case Control||2|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients selected for major urological surgery|January 2014|January 17, 2014|July 1, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041988||52054|
NCT02041962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS021425-01A1|Implementing Health Plan-Level Care Management for Solo & Small Practices|Implementing Health Plan-Level Care Management for Solo & Small Practices||University of Michigan|No|Active, not recruiting|July 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|280|||Both|21 Years|99 Years|No|||December 2015|December 4, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02041962||52056|
NCT02041975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5117800|Effects of Prebiotic-based Snacks on the Gut Microbiota and Perceived 'Satisfaction'|Investigating the Effects of Prebiotic-based Snacks on Perceived Feelings of 'Satisfaction' and on the Balance of Bacteria in the Human Gut (NutriSAT)|NutriSAT|University of Reading|No|Recruiting|October 2013|October 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|22 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02041975||52055|
NCT02037243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11024|Disgust and Shame Based Safe Water and Handwashing Promotion|Testing the Use of Disgust and Shame Messages in Safe Water and Handwashing Promotion in Urban Dhaka||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|August 2011|June 2014|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|420|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|June 11, 2015|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT02037243||52418|
NCT02037256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-134|Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant|A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|July 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||March 2015|March 25, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037256||52417|
NCT02037828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201303|Exhaled Breathing Condensate (EBC) Features and Lung Function Decline in Chinese Adults|The Screening and Confirmation of Protein Markers Which Can Predict the Decline of Lung Function of Chinese Adults in EBC (Exhaled Breathing Condensate )||Peking University First Hospital|Yes|Not yet recruiting|January 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2400|Samples With DNA|EBC,Blood|Both|50 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The study will be a community based, multicenter prospective cohort designed, which        including a total of 24OO study subjects, it will focus on two different communities,        which are Shi Cha Hai community, De Sheng Community in Beijing|January 2014|January 14, 2014|December 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02037828||52373|
NCT02037841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11/10E|The Impact of Implementing a Nursing-driven Clinical Pathway for Inpatient Management of Children With Asthma|The Impact of Implementing a Nursing-driven Clinical Pathway for Inpatient Management of Children Admitted to a Tertiary Care Centre With a Diagnosis of Asthma: A Randomized Controlled Trial|NAP|Children's Hospital of Eastern Ontario|Yes|Completed|March 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|2 Years|17 Years|No|||January 2014|January 29, 2016|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02037841||52372|
NCT02038439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRN86465|Multifaceted Online Interventions to Increase Clinicians Searching of Current Best Evidence to Answer Clinical Questions|Multifaceted Online Interventions to Increase the Quantity and Quality of Searching for Current Best Evidence to Answer Clinical Questions|MPFS|McMaster University|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|8||Actual|908|||Both|N/A|N/A|No|||April 2015|April 7, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038439||52326|
NCT02041585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCPROMIS|Discharge Functional Status and Rehospitalization in the Elderly|The Contribution of Low Physical Function, Emotional Function and Social Support to Rehospitalization Risk Among Older Adults|DC PROMIS|Northwestern University|Yes|Active, not recruiting|October 2012|April 2014|Anticipated|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|65 Years|N/A|No|Non-Probability Sample|General medical service inpatient hospitalist service population, aged greater than or        equal to 65|January 2014|January 17, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041585|30 Days|52084|
NCT02041832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILR-Afib-study|Detection of Subclinical Atrial Fibrillation in High Risk Patients Using Implantable Loop Recorder|Detection of Subclinical Atrial Fibrillation in High Risk Patients (> 65 Years, Hypertension, Diabetes Mellitus) Using Implantable Loop Recorder||Odense University Hospital|No|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|65 Years|90 Years|No|||January 2014|January 18, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02041832||52065|
NCT02042443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02485|Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery|Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer||National Cancer Institute (NCI)|No|Active, not recruiting|February 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|89|||Both|N/A|N/A|No|||January 2016|March 24, 2016|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042443||52020|
NCT02042404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EarLens CRP00004|The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study|The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study||EarLens Corporation|Yes|Completed|March 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|January 20, 2014|No|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT02042404||52023|
NCT02042976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCT-KOL-2014|Mindfulness-based Cognitive Therapy for Chronic Obstructive Pulmonary Disease|A Randomised Controlled Trial of Mindfulness-based Cognitive Therapy (MBCT) for Patients With Chronic Obstructive Pulmonary Disease (COPD)||University of Aarhus|No|Recruiting|February 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2014|June 3, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042976||51979|
NCT02042989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0511|MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies|A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies||M.D. Anderson Cancer Center|No|Recruiting|June 2014|||June 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042989||51978|
NCT02043301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481024|Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia||Pfizer|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02043301||51954|
NCT02043015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054863|Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)|Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study||Emory University|No|Active, not recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02043015||51976|
NCT02043314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.ISZ18-08BE.02|A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers|New Strategy for Treating Latent Tuberculosis Infection in Brazil: A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers||Oswaldo Cruz Foundation|Yes|Completed|October 2008|March 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02043314||51953|
NCT02039453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0351|Safety and Efficacy of Fentanyl Versus Pethidine During Propofol-based Sedated Colonoscopy: Prospective Randomized Study|||Yonsei University|No|Recruiting|September 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02039453||52248|
NCT02039466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAng UH|The Effect of Pressure-controlled Ventilation on the Respiratory Complication in Patients Undergoing Laparoscopic Colectomy Compared With Volume-controlled Ventilation|||Chung-Ang University Hospital||Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|20 Years|90 Years|No|||July 2014|July 10, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039466||52247|
NCT02039440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311_FU2013|6-year Antibody Check After Third Vaccination Against Japanese Encephalitis|Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection||Medical University of Vienna|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039440||52249|
NCT02039713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-01|DESyne in Routine Clinical Practice|Evaluation of Effectiveness and Safety of DESyne in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRIS DESYNE|Asan Medical Center|Yes|Recruiting|July 2014|June 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|patients with DeSyne stent|November 2015|November 10, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039713||52228|
NCT02039700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-131|Bioavailability of Lesinurad and Intravenous [14C]Lesinurad|A Phase 1, Open-Label Study to Assess the Absolute Bioavailability of a Single Oral Dose of Lesinurad With Respect to an Intravenous Micro Tracer Dose of [14C]Lesinurad in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Completed|January 2014|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039700||52229|
NCT02040285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-Prep 1|Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)|Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC). Comparison vs Laxative Free CTC.||Azienda Policlinico Umberto I||Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|85 Years|No|||January 2014|January 17, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02040285||52184|
NCT02040298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReBUILD|Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis|A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis|ReBUILD|University of California, San Francisco|No|Active, not recruiting|January 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||May 2015|May 19, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02040298||52183|
NCT02040584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001HES01|A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.|A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study.|REDUCE|Novartis|Yes|Active, not recruiting|December 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02040584||52161|
NCT02040597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-10|A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.|Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.|TRIPLE10|Chiesi Farmaceutici S.p.A.|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02040597||52160|
NCT02040831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 291|Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|September 2014|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|51|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040831||52142|
NCT02042248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3613|A Phase I/II Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004|IGHID 1309 - A Phase I/II Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection||University of North Carolina, Chapel Hill|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042248||52035|
NCT02042508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASILLAS PARI 2011|Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.|Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.||Centre Hospitalier Universitaire Dijon||Recruiting||||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|45 Years||||January 2013|January 20, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042508||52015|
NCT02037568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2639|Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress|Improved Behavioral Outcome in Allogeneic Hematopoietic Stem Cell Transplant Patients by Reducing Caregiver Distress: Behavioral and Physiological Evidence||University of Colorado, Denver|Yes|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037568||52393|
NCT02038179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130408004|UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure|UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure||University of Alabama at Birmingham|Yes|Recruiting|July 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038179||52346|
NCT02038725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1224|MIDNOR-TIA - a Study of 600 Patients With Transient Ischemic Attack|MIDNOR-TIA - a Prospective Cohort Study of 600 TIA Patients in Central Norway|MIDNOR-TIA|Norwegian University of Science and Technology|No|Completed|October 2012|July 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|584|Samples Without DNA|Blood samples|Both|18 Years|90 Years|No|Non-Probability Sample|Patients referred to a hospital in Central Norway with a recent probable or possible        transient ischemic attack|October 2015|October 26, 2015|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02038725||52304|
NCT02042183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG/0211PFC-1131|Efficacy and Safety of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation||Sucampo Pharma Americas, LLC|Yes|Recruiting|December 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|570|||Both|6 Years|17 Years|No|||February 2016|February 29, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042183||52040|
NCT02042417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRatio_CoaguChek|Comparison of POC-test-equipment With the Laboratory|Comparison of POC-test-equipment With the Standard Method (Laboratory) at ICU-patients||Medical University of Vienna||Not yet recruiting|February 2014|||December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|N/A|No|||January 2014|January 20, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042417||52022|
NCT02042196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0537 SHAPE2|Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women|Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency|SHAPE2|University of Colorado, Denver|No|Recruiting|December 2013|||December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|100|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042196||52039|
NCT02042456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124.03-2013-GES-0003|Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts|Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts||GE Healthcare|No|Terminated|April 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected from the patients arriving at the clinic for yearly breast        cancer screening exams|October 2015|October 16, 2015|January 20, 2014|Yes|Yes|Change in study staff at the site, change in Sponsor direction|No||https://clinicaltrials.gov/show/NCT02042456||52019|
NCT02043028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kneeling Posture|Kneeling Posture With a Kneeling Stool During Cardiopulmonary Resuscitation in Hospital|Kneeling Posture With a Kneeling Stool During Cardiopulmonary Resuscitation in Hospital||Hanyang University|Yes|Completed|August 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043028||51975|
NCT02043041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00042405|Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study|Explaining the Differences in HIV Prevalence and Incidence Between Black and White Men Who Have Sex With Men in Atlanta||Emory University|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|45|Samples With DNA|Dried blood spots will be collected and inspected for quality. Once quality is determined,      samples will be destroyed. No identifying information will be associated with the sample.|Male|18 Years|N/A|No|Non-Probability Sample|Participants will be enrolled or previously enrolled in the InvolveMENt Study through        Emory University. They will be assesed for study interest either at the end of their        scheduled appointment with InvolveMENt, or will be contacted if consent to contact them        for future studies was previously obtained through InvolveMENt.|June 2015|June 24, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043041||51974|
NCT02043327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PassFailstudy|Simulation Based Training in Colonoscopy|Simulation-based Training for Colonoscopy: Establishing Criteria for Competency||Rigshospitalet, Denmark|Yes|Completed|November 2012|November 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|25|||Both|28 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experienced: 10 consultants of gastroenterology with experience in Colonoscopy (>350        procedures) Novices: 15 fellows of gastroenterology with limited experience in Colonoscopy        (<2 procedures)|January 2014|January 21, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02043327||51952|
NCT02039778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0151|Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma|STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial|STRONG|Beth Israel Medical Center|No|Recruiting|December 2013|June 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Both|18 Years|70 Years|No|||August 2015|September 21, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039778||52223|
NCT02039752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-15|Asan Multivessel Registry|Asan Medical Center Registry for Multivessel|ASAN MV|Asan Medical Center|No|Recruiting|March 2014|June 2025|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|25000|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with multivessel disease from 1995 to 2015 in Asan Medical Center|November 2015|November 16, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02039752||52225|
NCT02039765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|863/13-100-0007|Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.|A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects.||Bausch & Lomb Incorporated|No|Active, not recruiting|February 2014|April 2014|Anticipated|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039765||52224|
NCT02039726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC220-007|(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive|A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation||Daiichi Sankyo Inc.|Yes|Recruiting|April 2014|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|326|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039726||52227|
NCT02039739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-02|Orsiro™ Drug Eluting Stent in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Orsiro™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRIS ORSIRO|Asan Medical Center|Yes|Recruiting|July 2014|June 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|patients with Orsiro™ Drug Eluting Stent|November 2015|November 9, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039739||52226|
NCT02039999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACADMED240913|An Investigation Into the Mechanism of Inhalation Cough Challenge|An Investigation Into the Mechanism of Inhalation Cough Challenge||Hull and East Yorkshire Hospitals NHS Trust|Yes|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|16 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02039999||52206|
NCT02040610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 1401|Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer|A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer||Provision Center for Proton Therapy|Yes|Recruiting|January 2014|December 2025|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|235|||Male|18 Years|N/A|No|||October 2014|October 27, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040610||52159|
NCT02040623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-932348-004|Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)|A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease|DROPS-2|Rigel Pharmaceuticals|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|85 Years|No|||July 2015|July 17, 2015|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040623||52158|
NCT02040857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-559|A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer|A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2014|June 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040857||52140|
NCT02041117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX09303-005-001|Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging|Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging in Two Years|REALM|Ministry of Science and Technology of the People´s Republic of China|No|Not yet recruiting|January 2014|July 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|75 Years|No|||January 2014|January 17, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02041117||52120|
NCT02042261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-TDM|The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study|The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study||Linkoeping University|No|Completed|January 2012|March 2016|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed patients with culture verified tuberculosis|March 2016|March 1, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042261|6 Months|52034|
NCT02042521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021 / 2013|A Dietary Supplement for Early Cigarette Withdrawal|A Dietary Supplement for Early Cigarette Withdrawal|CIGAR|Centre for Addiction and Mental Health|No|Active, not recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02042521||52014|
NCT02037854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1324|PEP-1324: Glycemic Response Testing|||PepsiCo Global R&D||Recruiting|January 2014|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037854||52371|
NCT02037867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13GA006|Nottingham Community Liver Biomarkers Cohort|The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers||University of Nottingham|No|Recruiting|May 2013|May 2033|Anticipated|May 2033|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Serum, whole blood and urine samples stored a -80 degrees Celsius.|Both|18 Years|N/A|No|Non-Probability Sample|A Primary Care database search (Systmone, TPP)will be performed to identify patients        eligible for study (see inclusion criteria) in the discrete patient populations.|July 2015|July 31, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037867|20 Years|52370|
NCT02038452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|464/11|Injection Versus Splinting in Carpal Tunnel Syndrome|Randomised, Multicentre, Open Label, Parallel Group Pragmatic Clinical Trial of Local Steroid Injection Versus Night Splinting in Mild to Moderate Carpal Tunnel Syndrome (CTS)|INSTinCTS|Keele University|Yes|Recruiting|April 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|January 20, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02038452||52325|
NCT02041897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL-EUS-FNA|Clinical Evaluation of EUS-FNA on Diagnosis of Pancreatic Cystic Lesions|Clinical Evaluation of EUS-FNA on Diagnosis of Pancreatic Cystic Lesions----A Multiple Center,Prospective Study||Fourth Military Medical University|No|Recruiting|January 2014|January 2020|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|18 Years|80 Years|No|||January 2014|January 18, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02041897||52060|
NCT02042469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Awareness|Awareness and Attitude of Cancer Patients About Participation in Clinical Research (CR) in Saudi Arabia|||National Guard Health Affairs|No|Completed|April 2011|May 2013|Actual|May 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Both|18 Years|80 Years|No|Non-Probability Sample|The study is planned to take place among Oncology patients ( inpatient and outpatient).|January 2014|January 19, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02042469|2 Years|52018|
NCT02042703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050919|Imaging Lens Deposits in Exfoliation Syndrome|Imaging Lens Changes in Exfoliation Syndrome Using Anterior Segment OCT||Duke University|Yes|Terminated|February 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|4|||Both|40 Years|N/A|No|Non-Probability Sample|Participants will be recruited from Glaucoma and Comparehensive clinics at the duke Eye        Center.|October 2015|October 20, 2015|January 21, 2014||No|Unanticipated slow enrollment|No||https://clinicaltrials.gov/show/NCT02042703||52000|
NCT02042664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 -022792-57|Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics|Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics||Assistance Publique Hopitaux De Marseille|No|Completed|January 2011|June 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02042664||52003|
NCT02042677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5566-O|Assessment of a Skin Barrier|User Assessment of a One-Piece Skin Barrier||Hollister Incorporated|No|Terminated|January 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|Current users of either Dansac flat Nova or NovaLife skin barriers with drainable pouches        who have an ileostomy.|September 2015|September 22, 2015|January 14, 2014||No|Slow recruitment of participants|No||https://clinicaltrials.gov/show/NCT02042677||52002|
NCT02043002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thomas|Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)|Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)||University of Aarhus|No|Recruiting|April 2013|||April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02043002||51977|
NCT02043340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVS031102|Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green|Effect of A Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green In The Treatment Of Chronic Periodontitis||SVS Institute of Dental Sciences|Yes|Completed|October 2012|December 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|30|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02043340||51951|
NCT02039245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103255|Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination|An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects||Janssen Research & Development, LLC|Yes|Completed|January 2014|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039245||52264|
NCT02040051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 13/36|Efficacy of Sound Insulation and Music Therapy on the Comfort of Mechanically Ventilated Patients Admitted to Intensive Care Unit|Randomized Clinical Trial to Assess the Effect of Sound Insulation and Music Therapy on the Comfort of Mechanically Ventilated Patients Admitted to Intensive Care Unit||Althaia Xarxa Assistencial Universitària de Manresa|Yes|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|82|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040051||52202|
NCT02040337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-14-021|Sequencing T-cells in Type I Diabetes Mellitus|Sequencing T-cell Receptor Repertoire of Auto-Antigen Specific T-cells in Type I Diabetes Mellitus||Seton Healthcare Family|No|Active, not recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Whole blood|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Endocrinology clinic patients currently receiving treatment for Type II Diabetes|June 2015|June 2, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040337||52180|
NCT02040025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20140010H|Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus|Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus||David Grant U.S. Air Force Medical Center|No|Enrolling by invitation|April 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Department of Defense type 2 diabetic patients enrolled in the Travis AFB, CA EECP clinic.|August 2015|August 3, 2015|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040025||52204|
NCT02040038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043325|Diabetes Self-Management & Support LIVE|Diabetes Self-Management & Support LIVE (Learning in Virtual Environments)||Duke University|Yes|Recruiting|July 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|21 Years|N/A|No|||January 2016|January 11, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040038||52203|
NCT02040012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZP01-CLI-001|A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus|A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus||Alizé Pharma|No|Active, not recruiting|July 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02040012||52205|
NCT02041442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-529|Electrophysiologic Mapping of the Bladder|Pilot of Electrophysiologic Mapping of the Urinary Bladder||Englewood Hospital and Medical Center|No|Recruiting|March 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041442||52095|
NCT02041676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K 110701|Chest Physiotherapy Technique Increasing Inspiratory Flow on Weaning From Non Invasive Ventilation|Evaluating the Impact of Chest Physiotherapy Technique Increasing Inspiratory Flow on Weaning From Non Invasive Ventilation (KVNI) Pilot Study|KVNI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|24 Weeks|32 Weeks|No|||December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041676||52077|
NCT02042534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMI-2013-1013|Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation|Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation: Acute Stroke With Xarelto to Reduce Intracranial Bleeding, Recurrent Embolic Stroke, and Hospital Stay, Phase 2, Conceptual Multicenter Trial|TripleAXEL|Asan Medical Center|Yes|Recruiting|January 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|19 Years|N/A|No|||July 2015|July 3, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042534||52013|
NCT02042794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0711-25080|Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection|Randomised Controlled Trial of Pringle Manoeuvre Versus Portal Vein Clamping in Patients Undergoing Liver Resection for Colorectal Liver Metastasis - A Pilot Study||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|June 2013|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Cancer, inflammatory and immune study, oral and gastrointestinal.|February 2015|February 20, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02042794||51993|
NCT02042807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-8-II-TWN|To Evaluate the Effect of MCS® in Prostate Cancer Prevention|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention|MCS-8|Health Ever Bio-Tech Co., Ltd.||Recruiting|October 2014|October 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|702|||Male|50 Years|75 Years|No|||April 2015|April 13, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02042807||51992|
NCT02043145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-MULT-100|Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea|||Allergan|No|Completed|July 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|727|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard        of care in clinical practice.|May 2014|May 15, 2014|January 21, 2014|No|Yes||No|May 15, 2014|https://clinicaltrials.gov/show/NCT02043145||51966|
NCT02038192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041954|Pilot Study of the Living With Hope Program for Family Caregivers of Persons With Dementia Residing in Long Term Care|Living With Hope: Pilot Study of the Living With Hope Program for Family Caregivers of Persons With Dementia Residing in Long Term Care Facilities||University of Alberta|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|21|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|October 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02038192||52345|
NCT02038751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306007RINB|The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea|The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea||National Taiwan University Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||4|Anticipated|360|Samples With DNA|whole blood and serum|Both|20 Years|N/A|No|Non-Probability Sample|moderate to severe OSA from primary care clinic friends and families from recommendation        of OSA patients|January 2014|January 16, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038751||52302|
NCT02038959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-12-11-4701|Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes|Using Technology to Deliver Multi-disciplinary Care to Individuals With Parkinson Disease in Their Homes: the Connect.Parkinson Study||University of Rochester|No|Active, not recruiting|March 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|480|||Both|30 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02038959||52286|
NCT02038972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|434269|Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss|Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss||Florida Hospital|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Weeks|6 Years|No|||March 2015|March 31, 2015|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038972||52285|
NCT02038985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451140|Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis|An Evaluation of Fluorescence Imaging + ICG Dye (Firefly) for Use in the Visual Diagnosis of Endometriosis: A Prospective Study|FIREFLY|Florida Hospital|No|Active, not recruiting|June 2013|December 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|55 Years|No|||January 2016|January 22, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02038985||52284|
NCT02042209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903508|Medical Telephone Triage of Emergency Calls for Thoracic Pain|Medical Telephone Triage of Emergency Calls for Thoracic Pain: Construction of a Probability Score for Acute Coronary Syndrome.|DOREMI2|University Hospital, Toulouse|No|Completed|May 2010|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4205|||Both|N/A|N/A|No|Non-Probability Sample|Patients over 18 years, with a non-traumatic chest pain.|January 2014|January 17, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042209||52038|
NCT02042716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120601|Added Value of Supersonic Shear Imaging in the Diagnosis of White Matter Damage in Preterm Infants|Added Value of Supersonic Shear Imaging in the Diagnosis of White Matter Damage in Preterm Infants|BELUGA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|24 Weeks|40 Weeks|No|||February 2016|February 23, 2016|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02042716||51999|
NCT02043067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1226/IRB12-0416|Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV|Enhanced TB Screening to Determine the Prevalence and Incidence of TB in a Cohort of HIV Clinic Patients in Lusaka, Zambia||University of North Carolina, Chapel Hill|No|Completed|October 2011|May 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Additional samples (10 ml blood, and 20 ml urine) will be stored in the specimen repository      at the CIDRZ laboratory for future studies. For patients who agree to provide samples for      the repository and are diagnosed with TB, isolates from positive cultures (blood, urine,      and/or sputum) will also be stored in the repository.|Both|16 Years|N/A|No|Probability Sample|Four hundred new enrollees at the Kalingalinga HIV Care and Treatment Clinic who are not        currently being treated for TB.|December 2014|December 11, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043067||51972|
NCT02042690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-13|Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients|A Randomised Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia||Peking University|Yes|Active, not recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|39 Years|No|||January 2014|January 20, 2014|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02042690||52001|
NCT02039258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103259|Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food|A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of Canagliflozin (JNJ-28431754) and Metformin Extended Release in Healthy Subjects||Janssen Research & Development, LLC|Yes|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039258||52263|
NCT02039479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KG1307|Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode|Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode||Technische Universität Dresden|Yes|Not yet recruiting|January 2014|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|254|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039479||52246|
NCT02040636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD9809|Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis|Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) Compared to Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) and Hepatitis B Vaccine Given Concurrently In Adolescents 11-14 Years of Age||Sanofi|No|Completed|January 1999|May 2000|Actual|May 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|277|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040636||52157|
NCT02041143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.19.MET|Protein Intake on Muscle Protein Synthesis Overnight|Effects of Protein Intake on Muscle Protein Synthesis and Whole Body Protein Balance During an Overnight Fast: an Exploratory Study||Nestlé|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|17|||Male|55 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041143||52118|
NCT02040311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI/TOP-INT-35|Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects|A Multicenter Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Subjects Following Participation in an Intensive, Non-pharmacologic Weight Loss Program|TOBES|University of Copenhagen|No|Terminated|August 2000|June 2002|Actual|June 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|701|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|January 7, 2014||No|Study was terminated early as sponsor wanted to develop an improved formulation.|No||https://clinicaltrials.gov/show/NCT02040311||52182|
NCT02040324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA UKE|Laryngeal Mask Airway in Lower Abdominal Surgery|Comparison of Lung Function in Patients After Lower Abdominal Surgery Exceeding 2hrs Under the Use of Laryngeal Mask vs. Endotracheal Tube for Airway Management||Universitätsklinikum Hamburg-Eppendorf|No|Completed|November 2009|March 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Male|18 Years|N/A|No|||January 2014|January 16, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02040324||52181|
NCT02041689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASELEARN|A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment|A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment||St. Jude Children's Research Hospital|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|||Both|7 Years|11 Years|No|Non-Probability Sample|Participants will be patients at St. Jude Children's Research Hospital.|January 2016|January 19, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041689||52076|
NCT02042001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-IT-264-1331|Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects|A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue Efavirenz (EFV)-Based Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects|SWEAR|Azienda Ospedaliera San Gerardo di Monza|Yes|Not yet recruiting|April 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042001||52053|
NCT02038842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002456-14|Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers|Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection|VRI01|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|92|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02038842||52295|
NCT02034838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-979|Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study|Microboosting of Atazanavir 300 mg With 50 mg Versus 100 mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study||Ottawa Hospital Research Institute|No|Completed|January 2014|September 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034838||52602|
NCT02039076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-018|A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects|||Eisai Inc.|No|Completed|December 2013|September 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2014|December 16, 2014|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039076||52277|
NCT02039089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-003|A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects|A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects||Eisai Inc.|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039089||52276|
NCT02038738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68Ga-DOTATATE|68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors|68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors||Ochsner Health System|No|Not yet recruiting|March 2014|||March 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038738||52303|
NCT02038764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4351003|A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes|A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Adults With Type 1 Diabetes||Pfizer|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038764||52301|
NCT02038777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371005|A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies|A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy Or Low-Dose ARA C In Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome||Pfizer|No|Recruiting|March 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038777||52300|
NCT02038998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBIR002|Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients|Unicentric, Phase II, Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients||Fundacion Rioja Salud|No|Recruiting|January 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|87|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02038998||52283|
NCT02042482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC01-35-12|The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome|The Effect of the Nutritional Supplements: Ultra Q10 and L-carnitine on the Clinical Course of Myelodysplastic Syndrome||Kaplan Medical Center|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||January 2014|January 19, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02042482||52017|
NCT02043080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1402|Optimizing Clinical Outcomes in HIV-Infected Adults & Children|CIDRZ 1201 - Optimizing Clinical Outcomes in HIV-Infected Adults & Children Using Xpert MTB/RIF in Zambia||University of North Carolina, Chapel Hill|No|Recruiting|August 2012|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2816|||Both|N/A|N/A|No|||June 2015|June 1, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043080||51971|
NCT02043093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1MH091452|Effectiveness Trial of Youth Suicide Prevention Delivered by Teen Peer Leaders|Effectiveness Trial of Suicide Prevention Delivered by Teen Peer Leaders||University of Rochester|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|14000|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02043093||51970|
NCT02043366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWang001|Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients|Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery||Tianjin Medical University General Hospital|Yes|Completed|February 2014|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|180|||Both|20 Years|60 Years|No|||December 2015|December 8, 2015|January 15, 2014|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT02043366||51949|
NCT02043054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0398 / 201200242278|Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)|Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial|LYDIA|University of Leicester|Yes|Recruiting|January 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|50 Years|No|||May 2015|June 4, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02043054||51973|
NCT02043353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-RT-03-5510-CTIL|The Natural History and Outcome of Sleep Disordered Breathing in Children|The Natural History and Outcome of Sleep Disordered Breathing in Children||Tel-Aviv Sourasky Medical Center||Recruiting|August 2010|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|2856|||Both|N/A|30 Years|No|Non-Probability Sample|Healthy children 0-18 years old that underwent PSG evaluation at the Pediatric Sleep        Center at Dana Children's hospital between 2005-2010|January 2014|January 21, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02043353||51950|
NCT02039492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENERVHTA|Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension.|Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension||Parc de Salut Mar|No|Completed|September 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039492||52245|
NCT02039505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002/CCT-101|Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis|Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Ulcerative Colitis||Takeda|No|Active, not recruiting|March 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|278|||Both|15 Years|80 Years|No|||January 2016|January 26, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039505||52244|
NCT02039791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-CC-072|Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer|Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer||Biotech Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|January 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02039791||52222|
NCT02040870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2109|LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib|A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Study Type: Interventional||Novartis|No|Active, not recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02040870||52139|
NCT02040883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSPC-SED20130516|Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia|Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia|TAAS|Guangzhou Psychiatric Hospital|No|Not yet recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2014|January 17, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02040883||52138|
NCT02041156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011:369|Effects of Different Exercise Training Programs in CKD 4-5|Long-term Effects of Basic Aerobic Training Combined With Either Resistance - or Balance Training in CKD Patients - a Comparative Study|RENEXC|Region Skane|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|October 14, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02041156||52117|
NCT02041130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB: 2013/00457|Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)|Renal Sympathectomy in Heart Failure (the RESPECT-HF Study) - a Study of Renal Denervation for Heart Failure With Preserved Ejection Fraction|RESPECT-HF|National University Hospital, Singapore|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02041130||52119|
NCT02042027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB70983|Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions|Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions||University of Utah|Yes|Recruiting|July 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042027||52051|
NCT02042274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fish Oil and Health Study|Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health|Omega-3 Fatty Acids and Genes Interact to Influence Cardiometabolic Health.|FOHS|University of Guelph|Yes|Active, not recruiting|October 2012|December 2014|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042274||52033|
NCT02035384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3553|Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A|A Multi-centre Non-interventional Study of Safety and Efficacy of Turoctocog Alfa (rFVIII) During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (FVIII =<2%)|guardian™ 5|Novo Nordisk A/S|No|Enrolling by invitation|June 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Male|N/A|N/A|No|Probability Sample|Previously FVIII treated (more than 150 exposure days) patients with severe and moderately        severe haemophilia A with FVIII below or equal to 2%.|March 2016|March 18, 2016|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02035384||52560|
NCT02035085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086592|19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction|This is a First-in-man, Phase I Study Utilizing 19F Magnetic Resonance Imaging (MRI) to Track Autologous, Adipose Derived Stem Cells.|CS-1000|Johns Hopkins University|No|Not yet recruiting|June 2016|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035085||52583|
NCT02035358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0106|Immunotherapy Study for Metastatic Renal Cell Cancer|A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer||NewLink Genetics Corporation||Recruiting|May 2015|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035358||52562|
NCT02038478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012013-015|Allograft for Sickle Cell Disease and Thalassemia|Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|45 Years|No|||October 2015|October 9, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038478||52323|
NCT02039011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012RC15|Ultra-long Acting Bronchodilator Therapy in Asthmatics|Proof of Concept Study to Evaluate Single and Chronic Dosing Effects of Ultra-long Acting Bronchodilator Therapy on Mannitol Challenge in Asthmatic Patients Taking Inhaled Corticosteroids|MAN02|University of Dundee|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|16 Years|N/A|No|||November 2015|November 13, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039011||52282|
NCT02042742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBELTEII|Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers|Effects of Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers Related With Cardiovascular Disease: a Crossover Study in Healthy Middle-aged Volunteers|PROBELTEII|Instituto de Investigación Hospital Universitario La Paz|No|Completed|April 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|76|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02042742||51997|
NCT02039804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trochanter Bursitis|Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study.|Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study.||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|March 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02039804||52221|
NCT02039817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-05|PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers|An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers||Conatus Pharmaceuticals Inc.|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|January 15, 2014|Yes|Yes||No|September 20, 2015|https://clinicaltrials.gov/show/NCT02039817||52220|
NCT02040064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003015-21|Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients|Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients|GEFTREM|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|January 2014|January 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02040064||52201|
NCT02040077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opioid Overdose|Evaluation of a Computerized Opioid Overdose Prevention Program|Development and Validation of a Computerized Opioid Overdose Intervention.||Johns Hopkins University|Yes|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02040077||52200|
NCT02039271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130342|Effects of Music Listening on Pain and Patient Satisfaction Within First 48 Hours After Knee Replacment Surgery|Effects of Music Listening on Pain and Patient Satisfaction Within First 48 Hours of Knee Replacement Surgery||Loma Linda University|No|Completed|February 2014|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|50 Years|70 Years|No|||August 2014|August 28, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039271||52262|
NCT02040350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1151-9883|Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?|Study Effect of WHO Recommended Dose of Pralidoxime in the Treatment of Organophosphorus Poisoning||Sheri Kashmir Institute of Medical Sciences|Yes|Completed|April 2012|November 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|14 Years|60 Years|No|||January 2014|January 16, 2014|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040350||52179|
NCT02040649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130025b|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on PTSD|Substudy of the NONSEDA-trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Posttraumatic Stress Disorder||Odense University Hospital|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02040649||52156|
NCT02040662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2014|Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy|Comparison of Continuous Epidural and Continuous Paravertebral Blockade in Postoperative Analgesia After Videothoracoscopic Lung Lobectomy||Pulmonary Hospital Zakopane|No|Completed|January 2013|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||April 2015|April 28, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02040662||52155|
NCT02040896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047697|Who Contributes to the Ordering of CT Scans in Emergency Department Patients?|Who Contributes to the Ordering of Computed Tomography in Emergency Department Patients? A Prospective Survey Study||Duke University|No|Completed|January 2014|||January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patients from age 0 to <17 years, and patients age 18 years and older with traumatic and        non-traumatic presentations, who visit Adult and Pediatric EDs and receive a CT scan        during their ED visit|November 2014|October 12, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02040896||52137|
NCT02041169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC13-9907-CLASH|Lower Extremity Peripheral Arterial Disease and Exercise Ischemia|Lower Extremity Peripheral Arterial Disease and Exercise Ischemia: Walking Capacity Variability, Pain Evolution and Pathophysiological Responses. The CLASH Study.|CLASH|Rennes University Hospital|No|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02041169||52116|
NCT02041455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-261|Immune-Pineal Axis Function in Fibromyalgia|Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|June 2010|March 2014|Anticipated|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Female|18 Years|65 Years|No|||January 2014|January 17, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041455||52094|
NCT02038296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAE001|Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma|||Guangdong General Hospital||Completed|January 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|75 Years|No|||January 2014|January 16, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038296||52337|
NCT02038309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRACS|Persistent Platelet Reactivity in Acute Coronary Syndrome|Persistent Platelet Reactivity in Acute Coronary Syndrome||Hopital Lariboisière|No|Recruiting|January 2013|December 2015|Anticipated|November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Acute coronary syndrome|January 2014|January 15, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02038309|1 Year|52336|
NCT02038569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1017|Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis|Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis||LEO Pharma|No|Recruiting|January 2014|June 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|17 Years|No|||May 2015|May 26, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038569||52316|
NCT02038582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44549-A|Strategies to Increase HIV Testing, Linkages to Care, and Male Circumcision in Africa|An Evaluation of Strategies to Increase Testing and Linkages of HIV Positive Individuals to Care and HIV Negative Men to Male Circumcision in Sub-Saharan Africa||University of Washington|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|11||Actual|2075|||Both|16 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02038582||52315|
NCT02035670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHust-P1312|A Two-step Method Apparently Improved the Physicians' Level of Diagnosis Decision-making for Adult Patients With FUO|A Multicenter Prospective，Randomized and Controlled Pilot Study on the Diagnostic Strategy of So-called Two-step Method in Patients With FUO||Tongji Hospital|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|65 Years|No|Probability Sample|patients meeting the definition of Classical FUO :          1. Fever with axillary temperature ≥38°C at least twice over a ≥3-week period.          2. Unknown cause after three outpatient visits or during one week of hospitalization.|June 2015|August 22, 2015|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035670|24 Weeks|52539|
NCT02035683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETRA|PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy|Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|PETRA|National Cancer Institute, Naples|No|Recruiting|October 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02035683||52538|
NCT02038491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090016600|RICALOR Italian Registry for Complications During Regional Anesthesia|RICALOR - Registro Italiano Complicanze Anestesia LOco Regionale - Italian Registry for Complications During Regional Anesthesia|RICALOR|IRCCS Policlinico S. Matteo|Yes|Completed|May 2009|March 2013|Actual|May 2009|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63692|||Both|N/A|N/A|No|Probability Sample|All patients undergoing surgery with regional anesthesia during study period will be        considered for complications` incidence calculation .|January 2014|January 16, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02038491|6 Months|52322|
NCT02038504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTIS-EN-1|Investigating the Role of EN in NTIS Among Fistula Patients|a Prospective Study to Investigate the Role of Enteral Nutrition in Nonthyroidal Illness Syndrome Among Fistula Patients|EN;NTIS|Jinling Hospital, China|Yes|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|Department of general surgery in Jinling hospital|June 2014|June 27, 2014|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038504||52321|
NCT02034786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cryo 394.191|Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid|Phase I Study of a Filler Agent Composed of Mesenchymal Stem Cells Obtained From Autologous Adipose Tissue Associated With Hyaluronic Acid|LipAge|Cryopraxis Criobiologia Ltda.|No|Not yet recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034786||52606|
NCT02035007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2, 17.04.09 / EK1649|Transpulmonary Thermodilution Measurements in Patients With Heart Diseases|Transpulmonary Thermodilution Measurements in Patients With Heart Diseases||University of Zurich|Yes|Completed|July 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT02035007||52589|
NCT02039518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WXH-gemcitabine-SCLC|Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients|Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy||Fudan University|Yes|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02039518||52243|
NCT02039531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 05/2011|Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis|THE APPLICATION OF PLASMA RICH IN GROWTH FACTORS FOR KNEE OSTEOARTHRITIS IMPROVES THE QUALITY OF LIFE AND FUNCTIONAL CAPACITY COMPARED WITH CONVENCIONAL TREATMENT WITH VISCOSUPLEMENTATION||Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias|No|Completed|August 2011|January 2015|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|55 Years|84 Years|No|||May 2015|May 4, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02039531||52242|
NCT02039544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131205|A Study of Xuebi Formula for Diabetic Peripheral Neuropathy(Qi-deficiency and Blood-stasis)|A Randomized, Parallel-controlled, Clinical Study to Evaluate the Efficacy of Xuebi Prescription Compared With Placebo in the Treatment of Diabetic Peripheral Neuropathy(Qi Deficiency and Blood Stasis)|XB|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|January 2014|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|70 Years|No|||January 2014|January 15, 2014|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02039544||52241|
NCT02039830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC01:GROUP|Group Versus Individual Physiotherapy for Urinary Incontinence in Aging Women|Group Physiotherapy Compared to Individual Physiotherapy to Treat Urinary Incontinence in Aging Women: A Randomized Control Trial|GROUP|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|No|Recruiting|July 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|364|||Female|60 Years|N/A|No|||January 2014|January 16, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02039830||52219|
NCT02039843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDPTSD|Can Service Dogs Improve Activity and Quality of Life in Veterans With PTSD?|Can Service Dogs Improve Activity and Quality of Life in Veterans With PTSD?|SDPTSD|VA Office of Research and Development|Yes|Recruiting|December 2014|October 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02039843||52218|
NCT02040090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAMRAB-003|Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects|A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects|KAMRAB-003|Kamada, Ltd.|No|Active, not recruiting|April 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|118|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|November 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02040090||52199|
NCT02040363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9224|Muscle Training Induced Angiogenesis in COPD|Impact of Different Training Modalities on Skeletal Muscle Angiogenic Response in COPD Patients - COPDµvasc Study|COPDµvasc|University Hospital, Montpellier|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|24|||Both|40 Years|78 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02040363||52178|
NCT02040376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039383|Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma|Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma||The Hospital for Sick Children|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|21 Years|No|||June 2015|June 1, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02040376||52177|
NCT02037139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R33DC011510-03|Hearing Health Care Service Access and Use|Primary Care Intervention Promoting Hearing Health Care Service Access and Use||University of California, San Francisco|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|204|||Both|60 Years|N/A|No|||September 2015|September 15, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037139||52426|
NCT02037438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-12-11-4137|Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study|Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)|SMART DOCS|Stanford University|Yes|Active, not recruiting|January 2014|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1836|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037438||52403|
NCT02037724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UG-0001-IDA|Fermented Iron-rich Supplement in Reducing Anemia|Fermented Iron-rich Supplement in Reducing Anemia|FISRA|University of Ghana|No|Not yet recruiting|March 2014|October 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|120|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037724||52381|
NCT02041468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CROC-05|Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients|A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients||Jewish General Hospital|No|Recruiting|January 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|The study will collect plasma, platelet-depleted plasma, tumor tissue (biopsy of a      metastatic site that has acquired resistant to treatment) and primary archived tissue.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) found        positive for ALK mutation from participating hospitals in Quebec.|October 2015|October 28, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02041468||52093|
NCT02042014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQTI571AJP01|Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan|An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment||Novartis|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042014||52052|
NCT02038322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER-000025|The Stork OTC: Collection, Placement & Delivery|The Stork™ Conception System (OTC) Clinical Trial: Semen Collection, Placement and Delivery||Rinovum Women's Health, Inc.|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|53|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|October 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038322||52335|
NCT02038595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK090764|The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue|The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue||Yale University|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02038595||52314|
NCT02039102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75764|Contraceptive Use and Respiratory Conditions Among Scottish Women|Use of Hormonal Contraceptives in Relation to Asthma and Wheezing Disorders in Scottish Women: a Population-based Cross-sectional Survey||University of Edinburgh|No|Active, not recruiting|December 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|||||Female|16 Years|45 Years||Probability Sample|Non-pregnant women aged 16-45 years|January 2014|January 22, 2014|January 15, 2014||||No||https://clinicaltrials.gov/show/NCT02039102||52275|
NCT02035098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFPS-2006-6-341684|Improving Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial|The Effectiveness of the Quality Program Pac-IficO to Improve Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial||Arcispedale Santa Maria Nuova-IRCCS|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|504|||Both|18 Years|N/A|No|||November 2013|January 13, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02035098||52582|
NCT02035111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-TSJN-JN-Ⅳ|A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.|To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study.||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Recruiting|March 2014|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|65 Years|No|||December 2013|May 5, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035111||52581|
NCT02035124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 79|Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel|Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort||SCRI Development Innovations, LLC|No|Withdrawn|April 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||February 2016|February 10, 2016|January 10, 2014|Yes|Yes|Study withdrawn due to slow accrual. No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT02035124||52580|
NCT02035397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1597|Intragastric Injections of Botox for the Treatment of Obesity|Treatment of Morbid Obesity by Intragastric Injections of Botulinum Toxin A. A Randomized, Double-blind, Placebo Controlled, Phase II-trial||Norwegian University of Science and Technology|No|Recruiting|February 2014|December 2022|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2015|October 21, 2015|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035397||52559|
NCT02035410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISINFECTION I|Decrease Implantation Site INFECTION (DISINFECTION I): a Randomized Controlled Trial|Phase 1 Study of Prevention of Cardiac Device Implantation Site Infection||Seoul St. Mary's Hospital|Yes|Recruiting|December 2013|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|2|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035410||52558|
NCT02039037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|josicomachio|Efficacy of Acupuncture and Electroacupuncture in Patients With Chronic Nonspecific Low Back Pain: Randomized Clinical Trial|Efficacy of Acupuncture and Electroacupuncture in Patients With Chronic Nonspecific Low Back Pain: Randomized Clinical Trial||University of Sao Paulo General Hospital|Yes|Recruiting|January 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|20 Years|60 Years|No|||April 2015|April 2, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02039037||52280|
NCT02034799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-13-002|Phase IV Bioseal Study in Brain Tumor Surgery|A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery||Ethicon, Inc.|No|Completed|November 2013|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|75 Years|No|||March 2015|April 8, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034799||52605|
NCT02035020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFT/1|A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients|A Phase IIa Clinical Trial to Test the Safety and Efficacy of Interferon Gamma Treatment in Elevating Frataxin Levels in Friedreich's Ataxia (FRDA) Patients||Azienda Policlinico Umberto I|No|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|45 Years|No|||January 2014|January 13, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035020||52588|
NCT02035033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0003-CTIL|The Relationship Between Ca Intake , Blood Level of Ca, PTH, TSH, Vitamin D, and Urine Ca, P and Cardiac Calcium Scoring|The Relationship Between Calcium and Cardiac Calcium Scoring|TSHPTHCA|Carmel Medical Center|Yes|Not yet recruiting|January 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||3|Anticipated|500|||Both|50 Years|80 Years|No|Probability Sample|participants how recent or planned cardiac CT in the Carmel hospital.|January 2014|January 10, 2014|November 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02035033|1 Day|52587|
NCT02035293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP|Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|PEP|University Hospital, Brest|Yes|Recruiting|January 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|750|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02035293||52567|
NCT02039297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007918|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)|AWARE|Mayo Clinic|Yes|Recruiting|March 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12000|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039297||52260|
NCT02039557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P# 04.01.020/030|Long Term Follow Up Protocol for NiCord Patients|Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells||Gamida Cell ltd|No|Recruiting|March 2014|||March 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|2 Years|60 Years|No|Non-Probability Sample|NiCord transplanted patients|February 2016|February 15, 2016|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039557||52240|
NCT02040103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12-045|Pneumatic Compression for Preventing Venous Thromboembolism|Prophylaxis of Thromboembolism in Critically Ill Patients Using Combined Intermittent Pneumatic Compression(IPC) and Pharmacologic Prophylaxis Versus Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial|PREVENT|King Abdullah International Medical Research Center|No|Recruiting|July 2014|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|14 Years|N/A|No|||June 2015|June 14, 2015|November 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040103||52198|
NCT02040389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92/13|Visual Guidelines and Tutoring in Pediatric Urological Surgery|Visual Guidelines and Tutoring in Pediatric Urological Surgery||Shaare Zedek Medical Center|No|Recruiting|March 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Months|18 Years|No|||November 2013|November 19, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02040389||52176|
NCT02040402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-024|Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7|Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants||The University of Hong Kong|Yes|Completed|February 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|6 Weeks|9 Weeks|Accepts Healthy Volunteers|||January 2014|January 16, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02040402||52175|
NCT02040675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCH01|Use of NAVA-catheter Positioning Screen to Identify Different Cardiac Arrhythmias|Use of NAVA-catheter Positioning Screen to Identify Different Cardiac Arrhythmias||ProMedica Health System|No|Recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|The population will be a convenience sample of adults with various arrhythmias who are        scheduled to undergo an electrophysiology study and-or ablation (EPSA) under general        anesthesia (GETA) at The Toledo Hospital.|April 2015|April 30, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02040675||52154|
NCT02036879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072013-079|Gender Disparity and Hormones in Cystic Fibrosis|Gender Disparity and Hormones in Cystic Fibrosis||University of Texas Southwestern Medical Center|No|Recruiting|December 2013|||December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02036879||52446|
NCT02037152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMT-CP-1|Smartphone-based Mindfulness Training for Chronic Pain|Smartphone-based Mindfulness Training for Chronic Pain: A Randomized Controlled Trial||University of California, San Francisco|No|Withdrawn|January 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|January 13, 2014||No|Problems with the software intervention, PI finished training and left UCSF.|No||https://clinicaltrials.gov/show/NCT02037152||52425|
NCT02037451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-3809A3|The Effects of Auditory Cueing on Rhythmic Movement and Cortical Excitability in Patients With Parkinson's Disease|||Chang Gung University|Yes|Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|20 Years|N/A|No|||January 2014|January 14, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037451||52402|
NCT02037464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264-2013|CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer|CAPSAICIN Trial: A Prospective Study of Capsaicin in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance or Radical Prostatectomy|CAPSAICIN|Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|January 2014|January 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Male|19 Years|N/A|No|||January 2014|January 14, 2014|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037464||52401|
NCT02037737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-409|Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting|Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study|ReACTION|Bristol-Myers Squibb|No|Not yet recruiting|September 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|220|||Both|18 Years|N/A|No|Non-Probability Sample|RA patients with inadequate response to one or more conventional DMARDs including        Methotrexate and treated with Abatacept IV according to routine clinical practice in        France|February 2016|February 3, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02037737||52380|
NCT02038010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 13B06|BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx|A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy||Northwestern University|Yes|Active, not recruiting|February 2014|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038010||52359|
NCT02039115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461672|Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy|Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial.||Florida Hospital|Yes|Recruiting|March 2014|December 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|126|||Both|18 Years|89 Years|No|||November 2015|November 24, 2015|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039115||52274|
NCT02039622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECAME-2010-01|Cardiovascular Toxicity Induced by Antitumoral Drugs: Risk Assessment and Early Diagnosis. CARDIOTOX Registry|Cardiovascular Toxicity Induced by Antitumoral Drugs: Risk Assessment and Early Diagnosis. CARDIOTOX Registry||Instituto de Investigación Hospital Universitario La Paz|Yes|Recruiting|July 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|3400|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|A case is defined as a patient on treatment (started or programmed, regardless of previous        treatments or prior radiotherapy) with the following target antineoplastic agents:          -  Alkylating agents          -  Antimicrotubule agents          -  Vinca alkaloids          -  Monoclonal Antibodies          -  Antimetabolites          -  Anthracyclines          -  Angiogenesis inhibitors          -  Interleukins          -  Small molecule tyrosine kinase inhibitors          -  Other antineoplastic agents|January 2014|January 15, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02039622|2 Years|52235|
NCT02039921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-7913|Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients|Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of Antiretroviral Treatment Regimen in HIV-positive Patients Between January 2011 and July 2012 in Spanish Hospitals|SWITCHART|Fundacion SEIMC-GESIDA|No|Completed|October 2013|December 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|250|||Both|18 Years|N/A|No|Non-Probability Sample|HIV patients that have changed antirretroviral régimen between Jan 2011 and Jul 2012|January 2014|January 16, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039921||52212|
NCT02040753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBBERUP1|The Effect of Repeated Lifestyle Intervention on Weight Loss Maintenance|The Effect of Repeated Lifestyle Intervention on Weight Loss Maintenance||University of Copenhagen|Yes|Completed|February 2014|January 2016|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Former participants of Ubberup Folk High School.|January 2016|January 29, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02040753||52148|
NCT02034812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU001.B|Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists|GenomeDx Decipher Test for Metastatic Disease Prognosis in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Radiation Oncologist' Treatment Recommendations?|DECIDE3|GenomeDx Biosciences Corp|No|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians:        Radiation oncologists targeted for recruitment into the study must meet the following        criteria:          -  Practicing, board-certified radiation oncologists.          -  Perform consultations on at least 80 patients with prostate cancer annually.        Patients:        Patients diagnosed with localized prostate cancer that received radical prostatectomy as        the first line treatment.        De-identified patient cases were selected from an independent clinical validation study of        patients with adverse pathology features treated between 2000 and 2006. (Karnes et al.,        2013)|September 2014|February 26, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034812||52604|
NCT02035046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120111|Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter|Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter|HEPHYGI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02035046||52586|
NCT02035306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M120677|Usefulness of Non-invasive Pulse Co-oximetry Haemaglobin Measurements in Critically Ill Black Patients|Usefulness of Non-invasive Pulse Co-oximetry Haemaglobin Measurements in Critically Ill Black Patients||Chris Hani Baragwanath Academic Hospital|No|Not yet recruiting|February 2014|||February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|1 Month|N/A|No|||January 2014|January 13, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02035306||52566|
NCT02039856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-026|Implementation of VA Womens Health Patient Aligned Care Teams WH-PACTs|Implementation of VA Womens Health Patient Aligned Care Teams WH-PACTs|WH PACT|VA Office of Research and Development|No|Enrolling by invitation|May 2014|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|420|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02039856||52217|
NCT02035644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD021|Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)|||Shanghai Jiao Tong University School of Medicine||Not yet recruiting|February 2014|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|360|||Both|20 Years|70 Years|No|||January 2014|January 12, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035644||52541|
NCT02035956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB_0004-01|IVAC MUTANOME Phase I Clinical Trial|First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma||Biontech RNA Pharmaceuticals GmbH|Yes|Active, not recruiting|December 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035956||52517|
NCT02036268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202007926|Education for Care of Ostomy Site|A Prospective, Single-Center Study to Assess the Impact of Pre- and Post-Surgical Ostomy Care Education on Patient Outcomes and Quality of Life||Indiana University|Yes|Recruiting|May 2012|May 2024|Anticipated|May 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|75|||Both|18 Years|90 Years|No|||December 2014|December 1, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036268||52493|
NCT02036281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102013-010|A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain|A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036281||52492|
NCT02036593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATCH-PATH|Community Approaches to Cardiovascular Health: Pathways to Heart Health|Community Approaches to Cardiovascular Health: Pathways to Heart Health (CATCH-PATH)|CATCH-PATH|University of Michigan|Yes|Completed|July 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|695|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 14, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02036593||52468|
NCT02036892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001|Electronically Connected Health Coaching in Type 2 Diabetes|Electronically Connected Health Coaching in Improving Type 2 Diabetes Self Management - Phase III Trial||York University|No|Recruiting|February 2012|June 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|75 Years|No|||January 2014|January 13, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02036892||52445|
NCT02036905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181-13|Cervical and Upper Thoracic Mobilization and Manipulation for Mechanical Neck Pain|Comparing the Early Use of Cervical/Upper Thoracic Mobilization and Manipulation for Individuals With Mechanical Neck Pain.||Youngstown State University|No|Completed|July 2013|August 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02036905||52444|
NCT02038062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar7|Tissue Oxygenation of the Tibial Anterior Muscle After Clamping of the Femoral Artery|Influence of Sevoflurane Preconditioning on Tissue Oxygenation of the Tibial Anterior Muscle Measured by Near-infrared Spectroscopy After Clamping of the Femoral Artery for Vascular Surgery|NIRSFEM|University of Schleswig-Holstein|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038062||52355|
NCT02038335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13080550|HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC|HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC|Zim CHIC|University of Pittsburgh|Yes|Active, not recruiting|February 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|451|Samples With DNA|whole blood, plasma archive, vaginal swabs, serum, cervicovaginal lavage fluid|Female|18 Years|34 Years|No|Non-Probability Sample|Healthy women, age 18-34 years, who are HIV negative and non-pregnant.|February 2016|February 8, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02038335||52334|
NCT02038348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003294-10|Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study|Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02038348||52333|
NCT02038361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00263-42|Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array|Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2014|January 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|18 Years|No|||April 2015|April 8, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02038361||52332|
NCT02038608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.722|Compensatory Mechanisms in Parkinson Disease (PD)|Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET|CompensationPD|Hospices Civils de Lyon|No|Completed|December 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|49|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02038608||52313|
NCT02038023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intravaneous Iron in Pregnancy|Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women|Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron.||Auerbach Hematology Oncology Associates P C|No|Completed|July 2013|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|45 Years|No|||January 2016|January 4, 2016|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038023||52358|
NCT02038036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424B2401|Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.|Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)|RESPONSE 2|Novartis|No|Active, not recruiting|March 2014|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038036||52357|
NCT02038855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0910/06/12|International Latino Research Partnership|International Latino Research Partnership|ILRP|Cambridge Health Alliance|No|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|70 Years|No|||February 2015|June 2, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038855||52294|
NCT02039362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver002|Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy|Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL||Hopital Lariboisière|No|Recruiting|November 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039362||52255|
NCT02040181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311047RINC|Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese|Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese||National Taiwan University Hospital|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|700|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients or inpatients of National Taiwan University Hospital who had 24 hour urine        creatinine collections during 2010/1/1 to 2012/12/31.|July 2014|July 28, 2014|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02040181||52192|
NCT02040194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-12-02|AM-101 in the Treatment of Acute Tinnitus 3|Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3|TACTT3|Auris Medical, Inc.|No|Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|630|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02040194||52191|
NCT02040766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDB-AS-302|A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma||Teva Pharmaceutical Industries|No|Active, not recruiting|December 2013|March 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|628|||Both|4 Years|11 Years|No|||March 2016|March 1, 2016|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040766||52147|
NCT02041351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON13-004|Biweekly Docetaxel in Patients With Metastatic Breast Cancer.|Docetaxel in Patients With Metastatic Breast Cancer Who Have Been Heavily Pretreated, Including Prior Treatment With Paclitaxel or Docetaxel.||Centro Universitario contra el Cáncer|Yes|Completed|November 2013|December 2015|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|21 Years|85 Years|No|||January 2016|January 26, 2016|January 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041351||52102|
NCT02043639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-40 ClinicCompanion.|ClinicCompanion. Compared to the Use of a Goniometer|A Study of Effectiveness of clinicCompanion. Compared to the Use of a Goniometer for Range of Motion Measurement.||Aurora Health Care|Yes|Recruiting|August 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|New or established clinic patients from Aurora St. Luke's Medical Center. The subjects        will be recruited from the principal investigator's medical practice. Any patient may be        included in the study, regardless of his/her diagnosis and must be 18 years of age and        older.|June 2015|June 23, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02043639||51928|
NCT02043860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0202|Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma|BMT-02: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Multiple Myeloma Following Initial Induction Therapy|BMT-02|University of Illinois at Chicago|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043860||51911|
NCT02044094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-13-0002|Multiple Dose Study of Blockade of Opioid Effects of Injections of Buprenorphine in Participants With Opioid Disorder|A Multiple-Dose Study of Blockade of Subjective Opioid Effects, Plasma Levels, and Safety of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Subjects With Opioid Use Disorder||Indivior Inc.|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|55 Years|No|||August 2015|August 7, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044094||51893|
NCT02036606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5582|Racing and Crowded Thoughts in Mood Disorders|Psychopathological and Cognitive Mechanisms of Racing and Crowded Thoughts in Mood Disorders||University Hospital, Strasbourg, France|No|Not yet recruiting|April 2014|April 2020|Anticipated|April 2019|Anticipated|N/A|Observational|N/A||2|Anticipated|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|January 2014|January 13, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02036606||52467|
NCT02036918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047231|Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer|Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer||Duke University|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036918||52443|
NCT02015884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50794|Antisocial Behavior on Healthcare Professionals in an Emergency Unit.|Impact of a Program to Prevent the Risk of Antisocial Behavior and Attacks of Patients or Attendant on Healthcare Workers in an Ophthalmic Emergency Unit.|PREVURGO|Hospices Civils de Lyon|No|Completed|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|58465|||Both|N/A|N/A|No|Non-Probability Sample|All patients admitted to the ophthalmologic emergency unit will be included in the study.|October 2015|October 22, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02015884||54057|
NCT02015585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPGO0014|Evaluation of Influence of Two Treatment Protocols on Mandibular Movements and Condyle-fossa Relation|Evaluation of Mandibular Movements and Condyle-fossa Relation From Two Treatment Protocols. A Randomized Clinical Trial.||Federal University of Pelotas|No|Active, not recruiting|August 2013|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015585||54080|
NCT02016105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP17-301|Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira|A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|ADACCESS|Sandoz|Yes|Active, not recruiting|December 2013|April 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|448|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016105||54040|
NCT02017431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01831/2013|Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction|Strengthening the Case for Ongoing Reduction of Exposure to Traffic-Related Air Pollution|DE3|University of British Columbia|No|Recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|18|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017431||53938|
NCT02017444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_13-022|Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.|Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.|IIH:DT|University of Birmingham|Yes|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|55 Years|No|||December 2015|December 1, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017444||53937|
NCT02016352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 045 08|Cerebrospinal Fluid Proteome in Hydrocephalus|Cerebrospinal Fluid Proteome in Hydrocephalus|PROLIPHYC|University Hospital, Toulouse|No|Active, not recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02016352||54021|
NCT02016885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM04-HH01|A Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis|A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis||Dermira, Inc.|No|Completed|November 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|198|||Both|18 Years|N/A|No|||October 2015|November 17, 2015|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016885||53980|
NCT02017418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10531|The Effects of a Zeaxanthin Intervention on Visuomotor Function|The Effects of a Zeaxanthin Intervention on Visuomotor Function||University of Georgia|No|Completed|February 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|102|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017418||53939|
NCT02013596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2013-08-2|Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum|Effect of Transcutaneous Electrical Acupoint Stimulation(TEAS) on the Hepatic and Renal Function Impaired by Pneumoperitoneum: a Prospective, Randomized Controlled Trial|TRIP|Fourth Military Medical University|Yes|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|60 Years|No|||January 2016|January 13, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02013596||54232|
NCT02014272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3801003|A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers|An Open Label, Single Dose, 2-Way Cross-Over Randomized Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 (Contains 150 Mg Rifampicin And 75 Mg Isoniazid Per Tablet) To An Equivalent Dose Of Single Drug Reference Preparations Of Rifampicin And Isoniazid Following Oral Administration In Healthy Adults Under Fasting Conditions||Pfizer|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|December 12, 2013||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT02014272||54180|
NCT02014493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHB-2013|Changes in Respiratory Effort in Preterm Infants|Respiratory Effort in Preterm Infants in the Transition From Continuous Positive Airway Pressure (CPAP) to High Flow Nasal Cannulae (HFNC)||St. Olavs Hospital|No|Active, not recruiting|January 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|28 Weeks|34 Weeks|No|||May 2015|May 12, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02014493||54163|
NCT02041611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1389|Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas|Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|January 2014|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||October 2014|November 5, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02041611||52082|
NCT02041624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-PES-05-WO|International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis|An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.|ALTO|Stallergenes|Yes|Recruiting|May 2014|June 2020|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1500|||Both|5 Years|N/A|No|Non-Probability Sample|Patients with allergic rhino-conjunctivitis are visiting their allergist during        grass-pollen season when symptoms are strong. In accordance with the terms of the        Marketing Authorization, ORALAIR® treatment has to be set-up "at the right moment" about 4        months before the next grass-pollen season.|May 2015|May 20, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02041624|5 Years|52081|
NCT02014441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120324|Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec|A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma||Amgen|No|Active, not recruiting|April 2014|August 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|100 Years|No|||February 2016|February 3, 2016|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014441||54167|
NCT02014181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815533|Flaxseed Modulates Inflammation and Oxidative Stress in CF|Flaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy Controls||University of Pennsylvania|No|Completed|July 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2012|January 6, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02014181||54187|
NCT02014428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-123|Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis|||AGUNCO Obstetrics and Gynecology Centre||Completed||||April 2013|Actual|Phase 4|Interventional|N/A|2||||||Female|45 Years|65 Years||||December 2013|December 12, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02014428||54168|
NCT02014727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-18 AMA-DiCo|Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults|Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial|AMA1-DiCo|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|January 2014|July 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|66|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2015|February 1, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014727||54145|
NCT02015312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAME-AL|A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)|A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)|TAME-AL|University Hospital Heidelberg|Yes|Recruiting|April 2013|September 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02015312||54101|
NCT02015325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC-BAIF/001|Evaluate the Effect of Planet Water Foundation's Clean Water, Sanitation and Hygiene Intervention|Assessing the Health Impact of Safe Water, Sanitation, and Hygiene Education in the Developing World||University of Nebraska|Yes|Recruiting|June 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|828|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015325||54100|
NCT02015299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43473.042.13|Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes|Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes|RELEASE|University Medical Center Groningen|No|Active, not recruiting|March 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|70 Years|No|||October 2015|October 28, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015299||54102|
NCT02015897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130091|Effect of Physical Therapy on Breast Cancer Related Lymphedema|Effect of Physical Therapy on Breast Cancer Related Lymphedema; A Multicenter, Randomized, Single-blind, Equivalence Trial||Hospital of South West Denmark|Yes|Recruiting|January 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|90 Years|No|||April 2015|April 9, 2015|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015897||54056|
NCT02016118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAISC-RUTI|Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections|INTRAVESICAL ADMINISTRATION OF COMBINED HYALURONIC ACID (HA) AND CHONDROITIN SULPHATE (CS) vs. STANDARD OF CARE FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTIs)|RAISC-RUTI|Study Group for Urogenital Diseases, Italy|No|Recruiting|January 2014|December 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Female|18 Years|75 Years|No|Probability Sample|The study will consider women with recurrent urinary tract infections who started their        treatments at the Urology Departments at the enrolling centres.|February 2014|February 11, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02016118||54039|
NCT02016378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655655|EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents|EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents||University of Michigan|No|Recruiting|January 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|14 Years|65 Years|No|||January 2016|January 24, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02016378||54019|
NCT02016937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|leylakutlucan|Mother Lactation in The Postpartum Period|Effects of Different Anesthesia Protocols on Mother Lactation in The Postpartum Period|lactation|Duzce University|No|Completed|January 2011|February 2012|Actual|January 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|84|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|84 patients were included. 63 of them were undergoing elective caesarian section and 21        patients had normal vaginal delivery in the Clinic of Gynecology and Obstetrics. All        patients were between 18-40 years old and with the risk of ASA II.|December 2013|December 16, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02016937|1 Year|53976|
NCT02016950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHT Pacemaker analysis|Long-term Pacemaker Arrhythmia Analysis|East Sussex Long-term Pacemaker Arrhythmia Analysis||Eastbourne General Hospital|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2551|||Both|18 Years|N/A|No|Non-Probability Sample|Those with permanent pacemakers|February 2015|February 10, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02016950||53975|
NCT02016638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/Med/Sleep_Preg|Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes|Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2013|May 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02016638||53999|
NCT02017145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH Chloraprep reapplication|Study on the Reapplication of Chloraprep After Lower Extremity Surgery and Prior to Dressing Application|Role of Post-operative Re-application of Chloraprep® Following Lower Extremity Surgeries on Surgical Site Bacterial Colonization.||Sanford Health|No|Recruiting|February 2014|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017145||53960|
NCT02017158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00158|Virtual Sprouts: Web-based Gardening Games to Teach Nutrition and Combat Obesity|Virtual Sprouts: Web-based Gardening Games to Teach Nutrition and Combat Obesity||University of Southern California|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||December 2013|December 15, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02017158||53959|
NCT02017171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK101108|A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes|PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D||Joslin Diabetes Center|Yes|Active, not recruiting|February 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|490|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017171||53958|
NCT02013375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0849|SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD|SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease|SCD-Haplo|University of Illinois at Chicago|Yes|Recruiting|November 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|16 Years|60 Years|No|||June 2015|June 17, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013375||54248|
NCT02013947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESF 2/308/2010|Effects of Moderate Altitude Training on Metabolic Parameters in Voluntary Study Participants With Metabolic Syndrome|Randomized Controlled Trial to Analyze the Effects of Moderate Altitude Training on Metabolic Parameters in Voluntary Study Participants With Metabolic Syndrome.||Pure Mountain Solda|Yes|Enrolling by invitation|November 2013|December 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 26, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02013947||54205|
NCT02013960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099-13-RMB CTIL|Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy|Comparison Between Sublingual Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy||Rambam Health Care Campus|No|Enrolling by invitation|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02013960||54204|
NCT02013622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-006|Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia|Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2013|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|35 Years|No|||January 2015|January 13, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013622||54230|
NCT02013973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH Sahlgrenska|Predictive Value of AMH in IVF; a Prospective RCT|Predictive Value of AMH (AMH=Anti Müllerian Hormone ) in IVF (IVF=In Vitro Fertilization ); a Prospective Randomized Controlled Trial|AMH|Sahlgrenska University Hospital, Sweden|No|Recruiting|March 2013|January 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|40 Years|No|||November 2014|November 20, 2014|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02013973||54203|
NCT02014285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00022113|Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery|Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery|MUSCULAR|Wake Forest School of Medicine|Yes|Recruiting|November 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Muscle tissue and serum/plasm|Both|18 Years|N/A|No|Non-Probability Sample|Study participants will consist of 30 patients with Acute Respiratory Failure admitted to        the Intensive Care Units of Wake Forest Baptist Health.|December 2015|December 21, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02014285||54179|
NCT02041377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2013-002-01|Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System|User Performance of the Karajishi Contour TS Blood Glucose Monitoring System||Ascensia Diabetes Care|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|134|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 17, 2014|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT02041377||52100|
NCT02041637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM11030|Unknown Cause of Acute Liver Failure|Unknown Cause of Acute Liver Failure: Determination of Early Mortality Predictive Factors|HASIPRO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Acute liver failure without cause identified at admission|December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041637||52080|
NCT02041910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT0550330|Testicular Injection of Autologous Stem Cells for Treatment of Patients With Azoospermia|Testicular Injection of Autologous Human Bone Marrow Derived Stem Cells for Treatment of Patients With Azoospermia||El-Rayadh Fertility Centre|Yes|Recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|25 Years|60 Years|No|||January 2014|January 18, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02041910||52059|
NCT02014220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Potato study 3: cultivar chips|The Food Intake, Satiety and Blood Glucose After Ingestion of Potato Chips Produced From Three Potato Cultivars|||University of Toronto||Completed||||December 2008|Actual|N/A|Interventional|Primary Purpose: Prevention|5||||||Male|18 Years|35 Years|No|||December 2013|December 11, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02014220||54184|
NCT02014233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTTW-N3-1|Short Term Omega-3 Supplementation on Performance|The Effect of Short Term Omega-3 Supplementation on Exercise Performance and Neuromuscular Function.||University of Toronto|No|Active, not recruiting|June 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02014233||54183|
NCT02014740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120811|Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes|Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes||University of Miami|No|Recruiting|March 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014740||54144|
NCT02015000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306012RINC|Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation|Surgical Result of Primary/Recurrent Pterygium by Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation||National Taiwan University Hospital|No|Recruiting|November 2013|November 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||December 2013|December 12, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02015000||54124|
NCT02015013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140020|Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models|Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|March 15, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015013||54123|
NCT02015026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140029|Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma|Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|67|||Both|12 Years|100 Years|Accepts Healthy Volunteers|||August 2015|March 16, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015026||54122|
NCT02015039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140030|Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp|Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|100 Years|No|||October 2015|November 3, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015039||54121|
NCT02015572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GoBack-001|Retention in Physically Demanding Jobs With Low Back Pain: A Randomised Controlled Trial (GoBack)|Retention in Physically Demanding Jobs With Low Back Pain: A Randomised Controlled Trial (GoBack)|GoBack|Frederiksberg University Hospital|Yes|Active, not recruiting|January 2016|December 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02015572||54081|
NCT02015910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-RC50959|Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers|Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers||Georgetown University|Yes|Terminated|January 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||May 2015|May 1, 2015|December 13, 2013|No|Yes|Terminated by the sponsor due to slow enrollment|No||https://clinicaltrials.gov/show/NCT02015910||54055|
NCT02017184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0737-BA-CTIL|Non-invasive Sensor for Core Temperature Measurement|Non-invasive Sensor for Core Temperature Measurement|Drager|Sheba Medical Center|No|Not yet recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017184||53957|
NCT02016963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1021-C1069|An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection|An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects||Human Genome Sciences Inc.|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2014|May 22, 2014|December 16, 2013|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT02016963||53974|
NCT02016976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094-13-HYMC|Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016976||53973|
NCT02016898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048136|The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device|The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device||Duke University|No|Recruiting|March 2014|June 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016898||53979|
NCT02013362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-JP1|Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma||Mundipharma K.K.|Yes|Active, not recruiting|December 2013|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|20 Years|N/A|No|||August 2015|August 31, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02013362||54249|
NCT02013609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-003|Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment|Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2013|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|35 Years|No|||November 2014|November 6, 2014|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013609||54231|
NCT02013388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N91115-1H-01|MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects|SNO2|Nivalis Therapeutics, Inc.|Yes|Completed|February 2014|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|December 9, 2013|Yes|Yes||No|March 5, 2015|https://clinicaltrials.gov/show/NCT02013388||54247|
NCT02013401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013173|Transmission of Mother-Infant Stress Communication|Transmission of Discrimination-Related Stress Reactivity and Reduction From Mother to Infant|MIBLS|University of Massachusetts, Boston|No|Recruiting|October 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|56|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Community sample of women (ages 18-40) with infants ages 4-9 months|December 2013|December 16, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013401||54246|
NCT02013635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/087/HP|Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations|Study of Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Correlation With Clinical and Radiological Evolution|PHRC-TVC|University Hospital, Rouen|No|Recruiting|July 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|plasma, serum and whole blood|Both|16 Years|N/A|No|Probability Sample|Patients over 16 years old hospitalized with an acute cerebral venous thrombosis|July 2015|July 29, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT02013635||54229|
NCT02013986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X01PA131001|Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children|Phase 1 Study of Circadian Rhythm of Salivary Cortisol in Health Children ;Phase 2 Study of Circadian Rhythm of Salivary Cortisol of Children Undergoing Surgery Using Etomidate or Not Using Etomidate.||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|September 2013|August 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02013986||54202|
NCT02013999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1306/208-005|The Development of Upper Extremity Rehabilitation Program Using Virtual Reality for the Stroke Patients|||Seoul National University Bundang Hospital||Recruiting|October 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 28, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02013999||54201|
NCT02014298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3-2009-149|Non Ablative Fractional Laser Treatment of Burn Scars|LONG-TERM AND CONTINUED IMPROVEMENT OF MATURE BURN SCARS IN RESPONSE TO NONABLATIVE FRACTIONAL LASER - A RANDOMIZED CONTROLLED TRIAL WITH HISTOLOGICAL EVALUATION||Bispebjerg Hospital|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||December 2013|December 12, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014298||54178|
NCT02041650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0186|Paradigm Shift in the Treatment of Patients With ACS|Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome||Harbin Medical University||Not yet recruiting|March 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|80 Years|No|||January 2014|January 17, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041650||52079|
NCT02041923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0139|Feeding and Transition to Home for Preterms at Social Risk|Feeding and Transition to Home for Preterms at Social Risk|H-HOPE|University of Illinois at Chicago|Yes|Completed|January 2007|June 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|N/A|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041923||52058|
NCT02041936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00052144|Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System|Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study||University of Maryland|Yes|Recruiting|April 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041936||52057|
NCT02014467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114165|Denosumab China Phase III Study|A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture||GlaxoSmithKline||Completed|January 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|487|||Female|60 Years|90 Years|No|||October 2015|October 22, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014467||54165|
NCT02014454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DROP-PROP|Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature|Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP)|DROP-PROP|Azienda Ospedaliero, Universitaria Meyer|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|1 Month|4 Months|No|||July 2015|July 6, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02014454||54166|
NCT02014753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECHANISM-AMI|Multicenter Randomized Comparison of Early Vascular Responses Between Everolimus-eluting Cobalt-chromium Stent and Identically Designed Bare-Metal Stent in Patients With Acute Myocardial Infarction|Multicenter Randomized Comparison of Early Vascular Responses Between Everolimus-eluting Cobalt-CHromium Stent ANd Identically DeSigned Bare-Metal Stent in Patients With Acute Myocardial Infarction: MECHANISM-AMI|MECHANISM-AMI|Iwate Medical University|No|Not yet recruiting|January 2014|December 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|20 Years|N/A|No|||December 2013|December 18, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014753||54143|
NCT02014766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inter1|Supraclavicular Versus Interscalene Block|A Randomized Comparison of Ultrasound-guided Supraclavicular and Interscalene Block After Shoulder Surgery||Cheju Halla General Hospital|No|Recruiting|November 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||December 2013|December 12, 2013|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014766||54142|
NCT02015351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brazilian VKH Study Group|Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study|Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study||University of Sao Paulo|No|Active, not recruiting|September 2012|June 2014|Anticipated|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|10 Years|70 Years|No|||December 2013|December 12, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02015351||54098|
NCT02015338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311M45303|Comparing the Location of the Motor Cortex in Children Using Two Methods|Comparing the Location of the Motor Cortex in Children Using Two Methods: EEG and TMS||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2014|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Children with congenital hemiparesis and typically developing children|March 2016|March 1, 2016|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02015338||54099|
NCT02016911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4082|Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment|Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function||Novo Nordisk A/S|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2015|February 4, 2015|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02016911||53978|
NCT02016924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-216-0128|Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects|A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects||Gilead Sciences|Yes|Active, not recruiting|January 2014|December 2024|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|100|||Both|3 Months|17 Years|No|||February 2016|February 11, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016924||53977|
NCT02016677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-02|An Observational Study Exploring the Esthetic Outcomes of Breast Reduction Surgery and /or Mastopexy|An Observational Study Exploring the Esthetic Outcomes of Breast Reduction Surgery and /or Mastopexy||Orbix Medical Ltd.|Yes|Terminated|December 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Female|30 Years|55 Years|No|Non-Probability Sample|Female Patients, 30 years of age or older referred for elective breast reduction surgery        and /or mastopxy|October 2015|December 22, 2015|December 10, 2013||No|Slow enrollment rate. Low scientific value|No||https://clinicaltrials.gov/show/NCT02016677||53996|
NCT02013414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045065|Fusion Targeted Biopsy of the Prostate|Molecular Image-directed, 3D Ultrasound-guided Biopsy of the Prostate||Emory University|Yes|Recruiting|September 2013|December 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Male|18 Years|99 Years|No|||October 2015|October 14, 2015|November 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013414||54245|
NCT02013674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120660|The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)|A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.|Trident|University of Miami|Yes|Recruiting|November 2013|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|90 Years|No|||October 2015|October 2, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013674||54226|
NCT02013687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FhCMB Pfs25-001|Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults|A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults||Fraunhofer, Center for Molecular Biotechnology|Yes|Active, not recruiting|November 2013|July 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|November 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02013687||54225|
NCT02017197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT 01 GW|Therapeutic Equivalence Between Branded and Generic Warfarin Tablets in Brazil|Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial||Federal University of São Paulo|No|Recruiting|May 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02017197||53956|
NCT02017457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-TC-10|Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.|Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.||University Hospital of Mont-Godinne|No|Recruiting|December 2013|December 2022|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017457||53936|
NCT02017470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB:2013/00088|A Culture-Centered Approach to Promoting Women's Heart Health in Singapore|A Culture-Centered Approach to Promoting Women's Heart Health in Singapore|WHH|National University Hospital, Singapore|No|Active, not recruiting|September 2013|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Female|21 Years|N/A|No|||November 2014|November 20, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02017470||53935|
NCT02014545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121004005 (UAB 1208)|Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer|Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Suspended|November 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||June 2015|August 10, 2015|December 12, 2013|Yes|Yes|PI left the University of Alabama at Birmingham and study will not be resumed by another    institutional PI.|No||https://clinicaltrials.gov/show/NCT02014545||54159|
NCT02014558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0101|Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia||Astellas Pharma Inc|No|Active, not recruiting|October 2013|June 2019|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014558||54158|
NCT02013648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 21-13|Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)|Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)||University of Ulm|Yes|Recruiting|July 2014|July 2022|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|277|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013648||54228|
NCT02013661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-ASA-10|Clinical Evaluation of Sutures in Periodontal Surgery|Clinical Evaluation of Four Types of Suture in Periodontal Surgery||Universitat Internacional de Catalunya|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 0|Observational|Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients treated at the CUO (dental clinic at the Universitat Internacional de Catalunya)        that are prescribed for periodontal resective surgery|December 2013|December 16, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02013661||54227|
NCT02015156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3271006|A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)|Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 2-Arm, Safety Study Of PF-05280014 And Trastuzumab Sourced From The US Administered To Healthy Male Volunteers||Pfizer|No|Completed|January 2014|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|162|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|December 6, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015156||54113|
NCT02015169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-078|Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis|Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis||Samsung Medical Center|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02015169||54112|
NCT02015455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH2AT007766-01|Trial of Inserting Prevalence Information Into Lumbar Spine Imaging Reports|Lumbar Imaging With Reporting of Epidemiology: A Pragmatic Cluster Randomized Trial|LIRE|University of Washington|Yes|Enrolling by invitation|April 2014|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250000|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02015455||54090|
NCT02042495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-140111|Endometrial Cancer Biomarker Changes Following Exposure to Metformin|A Clinical Trial to Evaluate Endometrial Cancer Biomarker Changes Following Exposure to the Insulin Sensitizer Metformin||Jewish General Hospital|No|Not yet recruiting|March 2016|||December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|80 Years|No|||October 2015|October 6, 2015|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02042495||52016|
NCT02042729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2022-J081-006|A Phase 1 Comparative Study of E2022 Current and New Patch Formulations|A Phase 1 Comparative Study of E2022 Current and New Patch Formulations||Eisai Inc.||Completed|August 2012|December 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Male|20 Years|39 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02042729||51998|
NCT02015611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022395|Vitamin D and Muscle Function Study|Lay Title - Exploring VItamin D's Effects on NeuromusCular Endpoints Study; Grant Title - Trial of Vitamin D Supplementation and Neuromuscular Function in Older Adults|EVIDENCE|Wake Forest School of Medicine|Yes|Recruiting|December 2013|April 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015611||54078|
NCT02015624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYESHOT|EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)|EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry|EYESHOT|Heart Care Foundation|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|2597|||Both|18 Years|N/A|No|Probability Sample|Patients with a diagnosis of Acute Coronary Syndrome consecutively admitted in the Italian        Cardiac Care Unit, located in hospitals with and without cardiac cath lab and cardiac        surgery, during a period of 3 weeks|March 2014|April 8, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015624||54077|
NCT02014779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1391-31/5|Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program|Internet-Based Relapse Prevention With Therapist Support vs Face to Face Therapy at an Employee Assistance Program: A Randomized Controlled Non-inferiority Trial|FoBeMA|Karolinska Institutet|No|Terminated|January 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 12, 2013||No|Only 1 participant recruited to study. Qs addressed in other ongoing studies.|No||https://clinicaltrials.gov/show/NCT02014779||54141|
NCT02014792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNS9195677|Heart Rate Variability & Fatty Acid Status: Haemodialysis Patients|Heart Rate Variability and Omega-3 Fatty Acid Status in Haemodialysis Patients: an Observational Pilot Study||King's College London|No|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|80|Samples Without DNA|Blood Plasma Washed and isolated red blood cells|Both|40 Years|80 Years|No|Non-Probability Sample|Patients attending King's College Hospital and Guy's and St Thomas' Hospitals who have        recently commenced haemodialysis treatment.|September 2015|September 1, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014792||54140|
NCT02015065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130208|Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors|Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2013|August 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|3 Years|99 Years|No|||March 2016|March 18, 2016|December 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015065||54120|
NCT02015078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914014|Black Family Eating Behaviors Study|Black Family Eating Behaviors Study||National Institutes of Health Clinical Center (CC)||Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|N/A|||Anticipated|350|||Both|18 Years|N/A|No|||June 2015|February 4, 2016|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02015078||54119|
NCT02016391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-01|Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours|Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours||Uppsala University Hospital|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||December 2014|December 16, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016391||54018|
NCT02015598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD201319|Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome|Comparison of Oral Intake of Antioxidant Carbocysteine and Nasal Continuous Positive Airway Pressure (CPAP) for Treating in Moderate and Severe Obstructive Sleep Apnoea Syndrome Patients : a Randomized Clinical Trial||Guangzhou Institute of Respiratory Disease|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|65 Years|No|||January 2015|January 6, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02015598||54079|
NCT02016417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHGX20131212|Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma|Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma||Cancer Hospital of Guangxi Medical University|Yes|Not yet recruiting|May 2014|December 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||December 2013|April 15, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016417||54016|
NCT02016690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-296|Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis|Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis||AbbVie||Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|328|||Both|1 Year|24 Years|No|Non-Probability Sample|Single-arm, Multi-center, Prospective Cohort|March 2016|March 16, 2016|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02016690||53995|
NCT02017223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-NCMHD|Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth|Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth|KNOWME|University of Southern California|Yes|Completed|October 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 15, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02017223||53954|
NCT02017496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08450d|Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment|Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment|NeoBCT|Oslo University Hospital|No|Recruiting|October 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Sampling of primary tumor DNA and RNA is not included as a study specific procedure, but if      the patient is included in a different ongoing protocol with tumor sampling, there is      approval/allowance for using tumor tissue for the purpose of the current study      (characteristics of the primary tumor that may predict residual tumor pattern and BCT      success)|Female|18 Years|N/A|No|Probability Sample|Patients referred to neoadjuvant treatment at the University Hospitals in Norway who are        candidates for neoadjuvant treatment.|December 2013|December 16, 2013|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02017496||53933|
NCT02017210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOS (SVH 13/143)|Insulin-sensitive Obesity: Lessons From Follow up and Weight Loss Interventions|Insulin-sensitive Obesity: Prospective and Interventional Studies|ISOS|Garvan Institute of Medical Research||Recruiting|November 2013|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|118|||Both|26 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02017210||53955|
NCT02017483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211008RIB|Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD|Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD||National Taiwan University Hospital|Yes|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|200|||Both|8 Years|16 Years|No|Non-Probability Sample|We will recruit 100 children and adolescent with ADHD and 100 typical controls.|December 2013|December 16, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02017483||53934|
NCT02014025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHZSG004|Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC|Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC With a Tumor Size of 5-10cm:a Prospective Case-control Study||Southwest Hospital, China|Yes|Completed|March 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|70 Years|No|||August 2015|August 8, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02014025||54199|
NCT02014883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-37|Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS|Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS|GLUT-HEP|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|December 2013|April 2018|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|N/A|No|||January 2014|April 30, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02014883||54133|
NCT02014571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116976|Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.|A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.||GlaxoSmithKline|No|Completed|December 2013|January 2015|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|60 Years|No|||September 2015|September 14, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014571||54157|
NCT02042755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POD AY 26P FineVision|Pilot Study With a Diffractive Trifocal IOL (POD AY 26P FineVision)|Pilot Study With a Diffractive Trifocal IOL (POD AY 26P FineVision)||Physiol|No|Not yet recruiting|February 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|N/A|No|Non-Probability Sample|Cataract patients wishing high spectacle independance after the surgery|January 2014|January 20, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02042755||51996|
NCT02042768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/12|Observational Study of Glucose Metabolism and How Dialysate Glucose Affects This|An Investigation of the Effects of Different Dialysis Prescriptions on Systemic Glucose Metabolism and Mortality in Non-diabetic Peritoneal Dialysis Patients|PD-CRAFT|Keele University|No|Active, not recruiting|March 2013|June 2017|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|Samples With DNA|Blood stored in EDTA for assays including DNA on all PD-CRAFT patients. 10mls blood in EDTA      taken during PET on all patients eligible for glucose study.      30mls of spent dialysate stored in both filtered and unfiltered aliquots on all patients on      PD for more than 3 years.|Both|18 Years|N/A|No|Non-Probability Sample|All incident and prevalent non-diabetic peritoneal dialysis patients at centres        participating in PD-CRAFT in the UK. PD-CRAFT is designed to oversample patients on PD for        longer periods of time.|January 2016|January 20, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02042768||51995|
NCT02042222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32003 NDEPTH|Novel Dose Escalation to Predict Treatment With Hydroxyurea|Novel Dose Escalation to Predict Treatment With Hydroxyurea|NDEPTH|Baylor College of Medicine|Yes|Recruiting|October 2013|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Both|1 Year|16 Years|No|||August 2015|August 24, 2015|January 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02042222||52037|
NCT02042235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0027|Very Preterm Children With Language Delay and Parent Intervention|Parent-implemented Intervention for Very Preterm Children With Language Delay|EPILANG|Lille Catholic University|Yes|Recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|28 Months|32 Months|No|||May 2015|May 29, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042235||52036|
NCT02039284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5261A3|Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy|Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy||Chang Gung Memorial Hospital|Yes|Recruiting|May 2013|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|3 Years|20 Years|No|||February 2016|February 15, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02039284||52261|
NCT02015923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01CCRe-IV|Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases|Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor|CCRe-IV|Hospital Universitari de Bellvitge|Yes|Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|336|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02015923||54054|
NCT02016131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQDSA_EVAR|CQDSA in Evaluation of Prognosis After EVAR|Application of Color-coded Quantitative Digital Subtraction Angiography in Evaluation of Prognosis After Endovascular Repairment of Abdominal Aortic Aneurysm||Shanghai Zhongshan Hospital|No|Completed|January 2012|March 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|49|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who present type I endoleak after EVAR for AAA.|May 2015|May 26, 2015|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02016131||54038|
NCT02015936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17389|Physical Activity for Advanced Stage Cancer Patients|Physical Activity for Advanced Stage Cancer Patients||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|December 2013|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015936||54053|
NCT02016144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLee_optimal_length|Optimal Length of Pre-inserted ETT for Nasal Fiber Optic Intubation|Optimal Length of the Pre-inserted Endotracheal Tube for Obtaining Good View of Laryngeal Opening for Nasal Fibreoptic Intubation||Seoul National Uinversity Dental Hospital|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|20 Years|65 Years|No|Non-Probability Sample|Patients scheduled to undergo an elective oral and maxillofacial surgery requiring a nasal        intubation of ETT for general anesthesia|December 2013|December 14, 2013|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02016144||54037|
NCT02016664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKPCS|Plasma Concentration of Ketamine and Norketamine .|Plasma Concentration of Ketamine and Norketamine in Patients on Oral Ketamine for Chronic Neuropathic Pain : A Pilot Study.||Lawson Health Research Institute|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|75 Years|No|||February 2016|February 28, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016664||53997|
NCT02016430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-863|Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)|Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)|GRADY|The Cleveland Clinic|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016430||54015|
NCT02017236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-504-CH1|A Food Effect Phase I Study of the Volitinib in Healthy Subjects|A Single Center, Open-label, Randomized, Four-Sequence, Four-period Crossover Study to Investigate Food Effect on the Pharmacokinetics of Single Dose of Volitinib in Healthy Subjects|HMPL-504|Hutchison Medipharma Limited|Yes|Completed|November 2013|June 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|October 29, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02017236||53953|
NCT02023255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015760|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-39393406 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|88|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023255||53491|
NCT02017509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-107A|Immunoscore in Rectal Cancer|A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy||Providence Health & Services|No|Recruiting|September 2013|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|86|Samples With DNA|Patients who enroll in the study will all undergo proctoscopy, as part of their standard of      care evaluation of their rectal mass. Biopsies will be obtained at the time of proctoscopy      and samples will be sent to pathology for paraffin embedded blocks for diagnostic evaluation      and for subsequent research. Patients will also have tissue stored in RNA later for      subsequent microarray analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of a rectal mass suspicious for or known to be an adenocarcinoma        of the rectum.|September 2015|September 4, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02017509||53932|
NCT02013700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120946|Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)|A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis|AETHER|University of Miami|Yes|Active, not recruiting|August 2013|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|25|||Both|40 Years|90 Years|No|||July 2015|July 16, 2015|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013700||54224|
NCT02014012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2013-40|PWV for Cardiovascular Complication After Cardiac Surgery|Evaluation of Pulse Wave Velocity as a Predictive Factor for Postoperative Cardiovascular Complication After Cardiac Surgery: a Prospective Study||Seoul National University Hospital|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|40 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery|April 2015|April 10, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02014012||54200|
NCT02014311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-065|CArdiac cT in the Treatment of Acute CHest Pain 2 - Myocardial CT Perfusion|Myocardial Perfusion 320 MDCT Guided Treatment Strategy for the Clinical Management of Patient With Recent Acute-onset Chest Pain. A Randomized Controlled Trial|CATCH2|Rigshospitalet, Denmark|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Both|50 Years|N/A|No|||October 2015|October 11, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014311||54177|
NCT02024100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD_EPR_OS2013|Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)|Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure in Hypertensive Patients With Metabolic Syndrome||Handok Pharmaceuticals Co., Ltd.|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|240|||Both|20 Years|80 Years|No|Non-Probability Sample|General hospitals|October 2015|January 3, 2016|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02024100||53426|
NCT02014324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42787.018.13|Single Scope Staging of Lung Cancer With Endosonography|Complete Endosonographic Staging of Lung Cancer: a Systematic Single Scope Approach|SCORE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|215|||Both|18 Years|N/A|No|Probability Sample|Patients with potentially operable and resectable NSCLC are eligible if there is an        indication for mediastinal nodal sampling. Patients have an indication for EBUS-TBNA.|October 2014|October 17, 2014|May 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02014324|4 Weeks|54176|
NCT02024620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|529128|Mobile Apps for the Treatment of Depression|Evaluation of Mood Coach in the Treatment of Major Depressive Disorder||Central Arkansas Veterans Healthcare System|Yes|Withdrawn|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|89 Years|No|||December 2015|December 14, 2015|December 4, 2013||No|The mobile phone app upon which the study was based was not available.|No||https://clinicaltrials.gov/show/NCT02024620||53386|
NCT02042781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG545102|Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours|An Open-label, Multi-centre Phase I Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours||Progen Pharmaceuticals|No|Recruiting|January 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02042781||51994|
NCT02043106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC_SCIPS|Can Vibration Stimulation of the Foot Sole Activate Leg Muscles?|Plantar Cutaneous Stimulation Used to Elicit Muscle Activity in Individuals With Incomplete Spinal Cord Injury||Wilfrid Laurier University|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02043106||51969|
NCT02043379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13114002|Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates|||University of Alabama at Birmingham|Yes|Completed|May 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|6 Months|No|||May 2015|July 14, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043379||51948|
NCT02043392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11536|Magnamosis First-in-human Study of Feasibility and Safety|Magnetic Compression Anastomosis (Magnamosis) First-in-human Study of Feasibility and Safety|Magnamosis|University of California, San Francisco|Yes|Recruiting|May 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043392||51947|
NCT02015091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140035|Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults|VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|January 12, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015091||54118|
NCT02015377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME-HS-0700735|Food, Adolescence, Mood, and Exercise|Food, Adolescence, Mood and Exercise|FAME|University of Southern California|Yes|Completed|September 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|100|Samples With DNA|During the 8 hours stay in the Observation Laboratory, a 5-mL blood sample will be drawn by      a licensed medical staff at 12 specific time point (-5, 15, 30, 60, 90,120, 150, 180, 210,      240, 270 and 300 min after the initial meal).|Both|14 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent included in the study are Latino and African American adolescents within 14-16        years of age.|December 2013|December 12, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015377||54096|
NCT02015390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100|Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects|The Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Reconstruction Techniques for the Treatment of Large Long Bone Deficiencies||The University of Texas Medical Branch, Galveston|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|May 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015390||54095|
NCT02015403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-IH-01|To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed|TO COMPARE THE EFFICACY OF N -ACETYLCYSTEINE AND STANDARD THERAPY VERSUS STANDARD THERAPY IN THE PREVENTION OF ISCHEMIC HEPATITIS AND SURVIVAL POST UPPER GI BLEED||Institute of Liver and Biliary Sciences, India|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|75 Years|No|||March 2015|August 11, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015403||54094|
NCT02015637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-3341-304|Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea|A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea||Melinta Therapeutics, Inc.|No|Terminated|January 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|15 Years|N/A|No|||November 2014|January 23, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015637||54076|
NCT02015650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITOCET|Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck|Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck||Medical University Innsbruck|No|Recruiting|April 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||April 2015|April 29, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015650||54075|
NCT02015663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100CUS03|Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles|A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis||Novartis|No|Terminated|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|6 Years|N/A|No|||February 2015|February 4, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015663||54074|
NCT02015949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH1824|The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)|The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition||Imperial College London|Yes|Recruiting|February 2014|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|65 Years|No|||October 2015|October 27, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02015949||54052|
NCT02016157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shaurya Manjunath|Moxifloxacin in Situ Gel to Treat Periodontal Pocket.|Moxifloxacin In Situ Gel as an Adjunct in the Treatment of Periodontal Pocket: A Randomized Clinical Trial.||Sri Hasanamba Dental College and Hospital|Yes|Completed|September 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|6|||Both|25 Years|65 Years|No|||December 2013|December 18, 2013|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016157||54036|
NCT02016404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0793|The Effect of a Low Sodium-High Potassium Salt on Blood Pressure in Vietnamese Adults|The Effect of a Low Sodium-High Potassium Salt on Blood Pressure in Vietnamese Adults||Wageningen University|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02016404||54017|
NCT02016989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0169|Matrix Therapy And Bacterial Keratitis|REGENERATING AGENT (OTR4120) AND BACTERIAL KERATITIS : A RANDOMISED TRIAL|CACICOL|University Hospital, Clermont-Ferrand||Recruiting|November 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02016989||53972|
NCT02023268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2762-PIII-08/13|Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome|Phase III: Comparison of the Efficacy and Safety of T2762 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome||Laboratoires Thea|No|Completed|December 2013|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023268||53490|
NCT02023840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.2013.ERYTHRITOL.PROED|The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis|The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Periodontitis: a Split-mouth Randomized Controlled Clinical Trial||Proed|No|Recruiting|December 2013|June 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023840||53446|
NCT02023216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO-2013-NNS|Effects of Non-Nutritive Sucking on Gastroesophageal Reflux and Related Apneas in Symptomatic Preterm Infants|Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.|NNS-GER-SO|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|May 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|N/A|4 Months|No|Non-Probability Sample|Due to the exploratory nature of this study, at least 30 preterm infants admitted to the        Neonatal Intensive Care Unit of Sant'Orsola-Malpighi Universitary Hospital and fulfilling        the inclusion criteria will be enrolled.|October 2015|October 13, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023216||53494|
NCT02013427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00080585|Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial|BRAIN MECHANISMS FOR CLINICAL PLACEBO IN CHRONIC PAIN: A Double-Blind Randomized Clinical Trial of Placebo and Chronic Back Pain||Northwestern University|Yes|Completed|October 2014|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|125|||Both|18 Years|N/A|No|||February 2016|March 21, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02013427||54244|
NCT02013453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.046|A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer|A Phase II Randomized Trial Evaluating the Use of Proton Pump Inhibitors (PPIs) in Conjunction With Chemotherapy, in Patients With Recurrent Unresectable or Metastatic Cancers of the Head and Neck||University of Michigan Cancer Center|Yes|Withdrawn|December 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|December 11, 2013|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02013453||54243|
NCT02013713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 449|French Observatory of Familial Hypercholesterolemia in Cardiology|French Observatory of Familial Hypercholesterolemia in Cardiology|FH Care|French Cardiology Society|No|Recruiting|November 2014|December 2023|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The study is proposed to cardiology services hospitals. Aged 18 or more, seen in        cardiology (USIC, Hospitalization, Consultation), who agreed to participate in the        observatory, and coronary patients who have LDL-c levels|February 2015|February 12, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02013713||54223|
NCT02023814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emato_aferesi|Peripheral Blood CD34-positive Cells Enumeration as Predictor of Stem Cell Harvest|Peripheral Blood CD34+ Cells Count as Predictor of Stem Cell Harvest After Chemotherapy and G-CSF. A Single Center Experience||Ospedale Santa Croce-Carle Cuneo|No|Completed|January 2002|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|250|||Both|16 Years|75 Years|No|Non-Probability Sample|Patients who underwent mobilization|December 2013|December 24, 2013|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02023814||53448|
NCT02024412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131123|Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC|The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer||Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02024412||53402|
NCT02024399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87468|Cardiovascular Risk Factors, Body Composition, Fitness Levels And Quality Of Life In Overweight And Obese 8-17 Year Olds|Pilot Study of 10 Week Exercise and Nutrition Program for Children Who Are Overweight / Obese.||Stony Brook University|Yes|Completed|August 2004|August 2005|Actual|August 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|48|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 26, 2013|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02024399||53403|
NCT02024867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB 2456|Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage|Randomized Non-inferiority Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage||State University of New York at Buffalo|No|Completed|February 2010|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|249|||Both|3 Months|17 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|December 26, 2013||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT02024867||53367|
NCT02043158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0626|Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer|Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer||M.D. Anderson Cancer Center|No|Recruiting|January 2014|||January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Long term and short term ovarian cancer survivors at the University of Texas MD Anderson        Cancer Center in Houston, Texas|December 2015|December 28, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043158||51965|
NCT02043405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1551|Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity|Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity.||University of Colorado, Denver|Yes|Recruiting|January 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02043405||51946|
NCT02043119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130560-01H|BEST ABCs: Benefits and Effectiveness of Support Offered Through A Breastfeeding Clinic Study|BEST ABCs: Benefits and Effectiveness of Support Offered Through A Breastfeeding Clinic Study|BEST ABCs|Ottawa Hospital Research Institute|Yes|Completed|January 2014|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|472|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043119||51968|
NCT02043132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-060|Tranexamic Acid in Reverse Total Shoulder Arthroplasty|Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty|TXA|William Beaumont Hospitals|Yes|Recruiting|September 2013|January 2015|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043132||51967|
NCT02039310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00057382|Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy|||University of Michigan||Recruiting|March 2012|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|65 Years|N/A|No|Non-Probability Sample|Patients meeting eligibility criteria will be recruited from genitourinary cancer clinics        at the University of Michigan Comprehensive Cancer Center. Patients undergoing initial        consultation, active treatment, or surveillance after endoscopic or intravesical therapy        will be identified and screened. Interested patients will be counseled by Dr. Lee or her        designee, who will review the rationale and benefits of the study, the potential risks and        probability of their occurrence, and the procedures to minimize these risks. Patients who        wish to enter the study will be asked to sign a consent form that meets the requirements        of the University of Michigan IRB. A signed copy of the patient consent will be entered        into the medical record.|May 2015|May 26, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039310||52259|
NCT02015104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140036|Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG|A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|100 Years|No|||August 2015|February 19, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015104||54117|
NCT02015117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02343|Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases From KRAS-, BRAF-, NRAS- or HRAS- Mutant Malignancies||National Cancer Institute (NCI)|Yes|Suspended|January 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 16, 2013|No|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02015117||54116|
NCT02015416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC-G305-2013-001|A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer|A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer||Immune Design|Yes|Active, not recruiting|November 2013|August 2015|Anticipated|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||February 2015|February 2, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015416||54093|
NCT02015429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pea_Fractionation_mixed_meal|Effect of Yellow Pea Protein and Fibre Added to a High-carb Meal on Glycemic Response and Food Intake|||University of Toronto|Yes|Completed|December 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|15|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015429||54092|
NCT02015676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M77035|A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer|'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.'||Hoffmann-La Roche||Completed|July 2001|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|70 Years|No|||February 2015|February 26, 2015|December 3, 2013|No|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT02015676||54073|
NCT02015689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203008361|Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children|Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children||Indiana University|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|802|||Both|18 Years|N/A||||December 2013|December 18, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015689||54072|
NCT02016183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220-011|Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)|ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months)||Takeda|No|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3157|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Hypertension|December 2013|December 14, 2013|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02016183||54034|
NCT02016170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAP3|Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor|Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study|SWAP3|University of Florida|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|74 Years|No|||November 2015|November 10, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02016170||54035|
NCT02017249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1364|Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme|A Double-Blinded Randomized Placebo-Controlled Trial Exploring the Efficacy of Oral ARginine Supplementation to Improve Cellular Immune Function in Patients With Glioblastoma Multiforme|ArginineGBM|Inova Health Care Services|No|Completed|March 2014|||September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|November 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02017249||53952|
NCT02022943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR|Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies|Alzheimer's Prevention Registry|APR|Banner Health|No|Recruiting|May 2012|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|250000|||Both|18 Years|110 Years|Accepts Healthy Volunteers|Non-Probability Sample|Anyone who meets entry criteria is eligible to join the Registry. We anticipate 250,000        individuals will join.|December 2015|December 9, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02022943|16 Years|53515|
NCT02024152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETTAU-01 (CTN-P0-741)|Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg|||JDP Therapeutics, Inc.||Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 2, 2014|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02024152||53422|
NCT02023307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131586|Use of V-Loc Suture for Mid-face Lifting in Short-flap Rhytidectomy|Use of the V-Loc Suture for Mid-Face Lifting in Short-flap Rhytidectomy||Lifestyle Lift|Yes|Terminated|February 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|December 23, 2013||No|Clinic Closed|No||https://clinicaltrials.gov/show/NCT02023307||53487|
NCT02023229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enterex01|Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis|High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|January 2011|May 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023229||53493|
NCT02023242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-12-001|Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes|A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStent® for Lowering Intraocular Pressure in Primary Open Angle Glaucoma|Hydrus V|Ivantis, Inc.|No|Recruiting|October 2012|January 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|45 Years|84 Years|No|||December 2013|December 23, 2013|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023242||53492|
NCT02023567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013CB531305|The Establishment of the Objective Diagnostic Markers and Personalized Medical Intervention in Patients With Major Depressive Disorders (MDD)|||Peking University|Yes|Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|2700|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|December 23, 2013|December 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023567||53467|
NCT02024113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/081U|LC-NMR Study Biomarkers to Detect Lung Cancer|Search for Biomarkers to Detect Lung Cancer by Means of a NMR Spectroscopic Analysis of Blood Plasma||Hasselt University|No|Completed|February 2013|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|646|Samples Without DNA|Plasma is used to determine the metabolic profile by NMR spectroscopy|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population: patients with a new diagnosis of lung cancer Control population: matched        subjects with no diagnosis of cancer|February 2015|February 9, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02024113||53425|
NCT02024126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOM-TOR-2009|Dose-response Effects of Medical Exercise Therapy in Patients With Osteoarhritis of the Knee|Dose-response Effects of Medical Exercise Therapy in Patients With Osteoarhritis of the Knee - A Nordic Multicenter Clinical Trial||Karolinska Institutet|No|Recruiting|December 2013|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|85 Years|No|||December 2013|December 26, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02024126||53424|
NCT02024139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD01/13|Efficacy of Chewing Sugarless Gum for Reduction of Orthodontic Appliance Pain|Efficacy of Chewing Sugarless Gum for Reduction of Orthodontic Fixed Appliance Activation Pain||Kuwait University|Yes|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|10 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02024139||53423|
NCT02024880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKUQMHCARE002|Comparison of Two Embryo Transfer Catheters in Patients Undergoing in Vitro Fertilization and Embryo Transfer|A Randomized Single-blind Comparison of Two Embryo Transfer Catheters in Patients Undergoing in Vitro Fertilization and Embryo Transfer||The University of Hong Kong|No|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|720|||Female|N/A|42 Years|No|||December 2015|December 10, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024880||53366|
NCT02024633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV48|Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer|Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|December 2013|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||July 2015|July 14, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02024633||53385|
NCT02024854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC28-32|Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation|Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation. A Randomized Controlled Trial||Norwegian University of Science and Technology|No|Recruiting|February 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|28 Weeks|32 Weeks|No|||February 2016|February 2, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02024854||53368|
NCT02025335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1040|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients (ACE-KT)|ACE-KT|Asan Medical Center|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|199|||Both|16 Years|90 Years|No|Non-Probability Sample|Kindeny transplant recipients|September 2015|September 24, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02025335||53331|
NCT02025348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1840M00044|Explore the Performance of IntelliCap.|A Randomised, Open-label, 4-way Crossover Study in Healthy Subjects to Explore the Performance of IntelliCap® by Comparing Pharmacokinetic Profiles of a Probe Drug.||AstraZeneca|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02025348||53330|
NCT02034825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU003|Multi-site Decision Impact Study for Decipher|ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery|ASSESS-D|GenomeDx Biosciences Corp|No|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Female|N/A|N/A|No|Non-Probability Sample|Patient cases will be retrospectively selected from at least 5 sites. Participating        urologists at each site will be asked to each identify a minimum of 10 to a maximum of 50        suitable cases retrospectively|March 2015|February 26, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034825||52603|
NCT02043418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12140 -12225|Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM Project|Outcome at 5 Years of Early Treated HIV Infected Infants on Antiretroviral Multi-therapy in the PEDIACAM ANRS12140 Project in Cameroon|PEDIACAM|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|460|Samples With DNA|a biobank (plasma / serum stored at -80 ° C) will be established|Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children|July 2014|July 11, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043418||51945|
NCT02035059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB195/13|Predictability of Gestational Diabetes Mellitus in First and Second Trimester|Predictability of Gestational Diabetes Mellitus in First and Second Trimester, Using Novel Biomarkers, and the Development of New Biomarkers by Quantitative Proteomic Analysis|GDMPredict|University Hospital, Basel, Switzerland|Yes|Recruiting|February 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|Samples Without DNA|Blood Saliva|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|October 2015|October 7, 2015|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035059||52585|
NCT02035319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laser Capillary Malformation|Effect of Laser Treatment on Capillary Malformations|Effect of Laser Treatment on Capillary Malformations Using Skin Imaging and Analysis||Children's Hospital Medical Center, Cincinnati|No|Withdrawn|January 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|17 Years|No|Non-Probability Sample|The research will be conducted among up to 100 patients of the Hemangioma and Vascular        Malformation Center at Cincinnati Children's Hospital Medical Center who will undergo        laser treatment for capillary malformations.|August 2015|August 21, 2015|January 7, 2014||No|No enrollments|No||https://clinicaltrials.gov/show/NCT02035319||52565|
NCT02035332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0001|A Two-Phase Clinical Study of the Minerva AURORA Ablation System|A Two-Phase Clinical Study of the Minerva AURORA Ablation System||Minerva Surgical, Inc.|Yes|Completed|May 2011|February 2015|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|35 Years|50 Years|No|||September 2015|September 23, 2015|January 10, 2014|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT02035332||52564|
NCT02035345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-413|Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment|Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment||Massachusetts General Hospital|Yes|Recruiting|January 2014|November 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035345||52563|
NCT02015130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract2012-004883-23|Individually Tailored Treatment of Type 2 Diabetes|Individually Tailored Treatment of Type 2 Diabetes|ITT|Odense University Hospital|Yes|Recruiting|October 2013|October 2025|Anticipated|October 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2246|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02015130||54115|
NCT02015442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SucroseLiver|Effect of Sucrose on Liver Fat|Effect of Eucaloric High and Low Sucrose Diets on Liver Fat in Healthy Adult Men With Liver Fat Levels Below 5%||Imperial College London|No|Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2013|December 18, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015442||54091|
NCT02015702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReadingHMC-IRB-045-12|Educational Intervention to Increase Physician Satisfaction and Effectiveness With a New Electronic Health Record|Interventions to Increase Physician Effectiveness and Acceptance of a Electronic Health Record System||The Reading Hospital and Medical Center|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|44|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015702||54071|
NCT02015715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP29017|A Single Ascending Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Volunteers|A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS||Hoffmann-La Roche||Completed|December 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015715||54070|
NCT02015962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIPS|Comparison of Enteral Versus Intravenous Potassium Supplementation|Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial|EIPS|Aga Khan University|No|Recruiting|October 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|25 Years|No|||December 2013|December 14, 2013|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02015962||54051|
NCT02016443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIZANIDINE|Tizanidine and Pain After Herniorrhaphy|Investigation of the Effectiveness of Tizanidine on Pain After Herniorrhaphy||Diskapi Teaching and Research Hospital|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|70 Years|No|||October 2013|April 21, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016443||54014|
NCT02017002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308069DIND|Comparison of Ivor Lewis and Tri-incision Approaches for Patients With Esophageal Cancer|Comparison of Ivor Lewis and Tri-incision Approaches in Performing Minimally||National Taiwan University Hospital|No|Recruiting|March 2014|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|75 Years|No|||June 2014|June 27, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017002||53971|
NCT02022956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-025|Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age|An Open-label, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetic Properties of BELVIQ in Obese Adolescent Subjects Ages 12-17 (Inclusive)||Arena Pharmaceuticals|No|Completed|December 2013|||December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022956||53514|
NCT02023320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-842|Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Blueberry Dry Powder on Prediabetes||Hiroshima University|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023320||53486|
NCT02023580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100973-01A1|Scale-up of an Internet-Delivered Study for HIV+ Men|Scale-up of an Internet-Delivered Randomized Controlled Trial for HIV+ Men|Positive View|Public Health Solutions|Yes|Not yet recruiting|June 2014|January 2016|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Male|18 Years|N/A|No|||December 2013|December 23, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023580||53466|
NCT02024165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBM-WP-2013|Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability|Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability|FHR|OBMedical Company|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|71|||Female|18 Years|50 Years|No|Non-Probability Sample|Laboring women in Labor and Delivery Ward|April 2015|April 22, 2015|December 2, 2013||No||No|April 1, 2015|https://clinicaltrials.gov/show/NCT02024165||53421|
NCT02023827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44DA024900|Computerized Stage-Matched Intervention for Juvenile Offenders|Computerized Stage-Matched Intervention for Juvenile Offenders||Pro-Change Behavior Systems|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1000|||Both|13 Years|N/A|No|||March 2016|March 23, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023827||53447|
NCT02024646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110144|Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2|AMVISION-2|Amgen|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|484|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024646||53384|
NCT02024438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131201|Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer|The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Gastric Cancer||Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02024438||53400|
NCT02025088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC 13/14|Comparison of Treatments for Atrophic Acne Scars|Comparison of Non-ablative Fractional Erbium Laser 1340nm and Microneedling for the Treatment of Atrophic Acne Scars: a Randomized Clinical Trial.||Hospital de Clinicas de Porto Alegre|No|Recruiting|December 2013|November 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|23|||Both|N/A|N/A|No|||December 2013|December 29, 2013|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02025088||53350|
NCT02025101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-13-HYMC|Characterization of Slow Coronary Flow|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2014|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|90|||Both|20 Years|90 Years|No|Probability Sample|Patients who were hospitalized with anginal pain|December 2013|December 29, 2013|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02025101||53349|
NCT02024893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WingateShoulder1|Range of Motion, Humeral Retroversion and Rotator Cuff (RC) Muscle Strength of the Shoulder in Overhead Athletes|Range of Motion, Humeral Retroversion and RC Muscle Strength in the Shoulder of Overhead Athletes||Wingate Institute|No|Not yet recruiting|January 2014|August 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Elite athletes consisiting of the national tean roster in several overhead sports; Women's        volleyball Men's handball Women's water- polo|December 2013|December 28, 2013|December 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02024893|12 Months|53365|
NCT02035371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3888|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|6 Years|64 Years|No|||October 2014|October 15, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02035371||52561|
NCT02035982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107-2010|Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease|A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting||Sunnybrook Health Sciences Centre|No|Completed|July 2010|September 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||November 2015|November 26, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02035982||52515|
NCT02035072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST157.01|Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.|Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.||Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|November 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035072||52584|
NCT02035657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC-G100-2013-001|A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma|A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma||Immune Design|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||July 2015|July 13, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035657||52540|
NCT02035969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2012-56X-22028-01-3|Assessment of Group Peer Support to Children With HIV in Vietnam|A Randomized Controlled Trial to Assess the Effect of Group Peer Support to Children With HIV in Relation to Adherence, Virological Treatment Failure as Well as Physical Development||Karolinska Institutet|Yes|Recruiting|December 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|520|||Both|N/A|12 Years|No|||January 2014|January 13, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02035969||52516|
NCT02016196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 551 01|Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS|Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS|PRPET|University Hospital, Toulouse|Yes|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02016196||54033|
NCT02016456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH/021213|TMS Treatment for Depression in the National Health Service|An Evaluation of Transcranial Magnetic Stimulation in the National Health Service|TDEP|Institute of Mental Health Nottingham|No|Recruiting|October 2014|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016456||54013|
NCT02016469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDBP-1|Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation|A Randomized, Controlled, Single-blind Study of Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation to Patients With Inflammatory Bowel Disease||Jinling Hospital, China|Yes|Recruiting|December 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|70 Years|No|||December 2013|December 15, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016469||54012|
NCT02016742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC5-1-01|A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers|A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers||Chronos Therapeutics Ltd|No|Completed|December 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016742||53991|
NCT02016755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-CLI-0209|A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia|A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia||AnGes|No|Recruiting|November 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|90 Years|No|||February 2016|February 15, 2016|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016755||53990|
NCT02016703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-TDEOH05|Gastrointestinal Tolerance of Erythritol-containing Beverages in Young Children|Gastrointestinal Tolerance of Erythritol-containing Beverages in Young Children||Cargill|Yes|Completed|March 2006|July 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|185|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016703||53994|
NCT02016716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120156|A Randomized Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis||Amgen|No|Completed|December 2013|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|294|||Female|55 Years|90 Years|No|||September 2015|September 22, 2015|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016716||53993|
NCT02016729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120234|A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia|A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia||Amgen|No|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016729||53992|
NCT02017015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-001|Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer|A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA|PANC-001|Celgene|No|Active, not recruiting|December 2013|January 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017015||53970|
NCT02022683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0015/A|To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV|A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema|TRANSFORM|Pulmonx, Inc.|No|Recruiting|December 2013|February 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|40 Years|N/A|No|||October 2015|March 22, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02022683||53535|
NCT02023593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOLFIRI-29|FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma|Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma||Sun Yat-sen University|Yes|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02023593||53465|
NCT02023632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01593|GrOup-based Physical Activity for oLder Adults Trial|A Self-categorization Theory Approach to Fostering Physical Activity Adherence Among Older Adults: A Randomized Controlled Feasibility Trial.|GOAL|University of British Columbia|Yes|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|554|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02023632||53462|
NCT02024178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU11-00220|Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery|A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy||New York University School of Medicine|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Male|18 Years|N/A|No|||December 2013|December 26, 2013|December 26, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02024178||53420|
NCT02023606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P111|Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M.|An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers.||Supernus Pharmaceuticals, Inc.|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 23, 2013|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02023606||53464|
NCT02024425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALIBIRDII|Functional Bioactive Supplement Effect in Lost Weight Treatment|A Randomized, Double-blind Trial to Evaluate the Effect of a Functional Bioactive Supplement Associated With a Hypocaloric Equilibrated Diet to Treatment of Obese and Overweight Individuals|ALIBIRDII|Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|September 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Female|18 Years|65 Years|No|||November 2015|November 18, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024425||53401|
NCT02024191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031|The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy|The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial|GELUPO|Ankara Education and Research Hospital|No|Recruiting|December 2013|June 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|65 Years|No|||December 2013|December 30, 2013|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02024191||53419|
NCT02024906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000073|Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants|Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants||University of Kansas Medical Center|No|Withdrawn|February 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|25 Years|70 Years|No|||September 2015|September 21, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024906||53364|
NCT02025127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19966|A Randomized Controlled of Enteral Nutrition in Septic Shock|A Randomized Controlled Study of Enteral Nutrition in Septic Shock||Medical College of Wisconsin|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02025127||53347|
NCT02024659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TongRen-BJO|Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps|Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps||Beijing Tongren Hospital|Yes|Completed|September 2010|January 2014|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024659||53383|
NCT02025387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_GO_034|Physical Activity in Patients With Gynecological Surgery|||Seoul National University Hospital|No|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Female|N/A|N/A|No|||December 2013|December 27, 2013|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025387||53327|
NCT02025673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Betatrophin-Human|Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects|Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects||Qingdao University|Yes|Active, not recruiting|August 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|200|Samples Without DNA|Whole blood serum|Both|20 Years|N/A|No|Non-Probability Sample|19 healthy pregnant women and 9 pregnant women with gestational diabetes mellitus (GDM)        were enrolled in the study. 24 patients with newly diagnosed type 2 diabetes mellitus        before treatment, 35 patients with type 2 diabetes mellitus after treatment. Subjects were        recruited from patients at the Department of Clinical Endocrinology and Maternity        Department, Affiliated Hospital of Qingdao University.|December 2013|December 30, 2013|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025673||53305|
NCT02035696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P16|Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 4 Years Old|A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.||Novartis|Yes|Completed|December 2013|December 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|672|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035696||52537|
NCT02035709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCI-PCA-001|Postoperative Pain Therapy With Hydromorphone Using TCI-PCA|Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) After Elective Cardiac Surgery|TCI-PCA|University of Erlangen-Nürnberg Medical School|Yes|Completed|December 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02035709||52536|
NCT02036307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00076636|Supplementation With Omega-3: Mechanism of Action|Supplementation With Omega-3: Mechanism of Action|SOMA|Johns Hopkins University|No|Suspended|April 2013|May 2016|Anticipated|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|13|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 13, 2014||No|This study was suspended because there is no more funds to complete the study.|No||https://clinicaltrials.gov/show/NCT02036307||52490|
NCT02036320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5477|A Non-dispensing Fit Evaluation of Investigational Limbal Ring Soft Contact Lenses With Polyvinylpyrrolidone (PVP) in Asian Eyes|||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|January 10, 2014|Yes|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT02036320||52489|
NCT02025634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503526|Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy|Determining the Efficacy of Intravenous Acetaminophen as a Non-Narcotic Postoperative Pain Management Technique Following Knee Arthroscopy|IVTYLENOL|Florida Hospital|No|Completed|November 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|89 Years|No|||October 2015|October 2, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02025634||53308|
NCT02016209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1402|Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer|Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage Ⅱ B and IIIA Non-small Cell Lung Cancer Patients||Zhejiang University|No|Not yet recruiting|January 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2013|December 14, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02016209||54032|
NCT02016482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-674|A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis||AbbVie|No|Active, not recruiting|January 2014|August 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02016482||54011|
NCT02022124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88/CES-2013|Open Label Placebo in the Treatment of Low Back Pain|Open Label Placebo in the Treatment of Low Back Pain||Hospital de Egas Moniz|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02022124||53577|
NCT02017028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0824-IB-CTIL|Correlation Between Endothelial Function and Trans Radial-procedural Events|Correlation Between Endothelial Function and Trans Radial-procedural Events||Sheba Medical Center|No|Recruiting|January 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Patients planned for elective trans-radial cath|June 2015|June 2, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02017028|1 Day|53969|
NCT02022930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR1.1|Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis|A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee||Carbylan Therapeutics, Inc.|No|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|510|||Both|40 Years|85 Years|No|||July 2015|July 29, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022930||53516|
NCT02015286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-534|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East|Easypod Connect: A Regional, Multicentre, Observational Study to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment|ECOS UAE|Merck KGaA|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|7|||Both|2 Years|18 Years|No|Non-Probability Sample|Pediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the        easypod™ electromechanical device.|March 2015|March 3, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02015286||54103|
NCT02023619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK NORD 2013/758|Corneal Epithelial and Stromal Thickness Distribution in Keratoconus|Comparison of Corneal Epithelial and Stromal Thickness Distributions Between Eyes With Keratoconus and Healthy Eyes With Corneal Astigmatism >2.0 D||SynsLaser Kirurgi AS|Yes|Completed|July 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|20 eyes with diagnosed keratoconus and 20 healthy eyes with astigmatism >2.0 D|December 2013|December 23, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02023619||53463|
NCT02023853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proed.08.2013.periimplantitis|Non Surgical Treatment of Periimplantitis|The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis.||Proed|No|Recruiting|December 2013|June 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023853||53445|
NCT02023866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-MITO-001|Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease|Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease|RP103-MITO-001|Raptor Pharmaceuticals Inc.|No|Enrolling by invitation|June 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|2 Years|17 Years|No|||June 2015|January 28, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023866||53444|
NCT02024672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1557|Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth|Ultrasound Surveillance of IUDs Placed Immediately Postpartum||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from the group of women receiving prenatal care at Mount Sinai        Hospital in New York City and Elmhurst Hospital in Queens. Patients who express an        interest in an IUD for contraception after delivery will be given information about        immediate postpartum IUDs and the study.|December 2015|December 29, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024672||53382|
NCT02025140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Computer Controlled Local Anesthesia in Children|Comparison of The Computer Controlled Local Anesthesia and The Conventional Inferior Alveolar Nerve Block in Primary Molars Pulptomies|STA machine|King Abdulaziz University|Yes|Completed|September 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|91|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025140||53346|
NCT02025400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eRehab101|Internet Enhanced, Patient-Centered Orthopedic Care: A Prospective, Randomized, Controlled Pilot Trial|Phase I Study Comparing Internet Delivered Home Exercise Programs to Standard Orthopedic Care and Outpatient Physical Therapy.||Charlotte Sports Medicine Institute, PA|No|Completed|July 2012|December 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 31, 2013|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02025400||53326|
NCT02025413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032772|Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method|Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method|CTC-EMT|Duke University|No|Active, not recruiting|November 2011|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025413||53325|
NCT02025686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBO12-04-2013|Hyperbaric Oxygen Therapy Attenuates Central Sensitization Induced by a Thermal Injury in Human Volunteers (HBO)|Hyperbaric Oxygen Therapy Attenuates Central Sensitization Induced by a Thermal Injury in Human Volunteers (HBO)||Rigshospitalet, Denmark|Yes|Completed|March 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 30, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02025686||53304|
NCT02040168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/53|Reduce Pediatric Sedation to Reduce Mechanical Ventilation Complication in ICU|Evaluation of the Interest of a Nurse-implemented Sedation Protocol for the Reduction of the Duration of Mechanical Ventilation Complication Associated With Extended Sedation in Pediatric Intensive Care Unit.|PEDIASED|Nantes University Hospital|No|Recruiting|October 2010|October 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|202|||Both|N/A|18 Years|No|Non-Probability Sample|The old children from 28 days to 18 years admitted in pediatric intensive care unit of        Nantes University Hospital requiring mechanical ventilation for at least 24 hours can be        included in this study.|January 2014|January 16, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02040168||52193|
NCT02035995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GokhanAcmaz|EVALUATION OF THE MACULAR, PERIPAPILLARY NERVE FIBER LAYER AND CHOROID THICKNESS CHANGES IN THE GESTATIONAL DIABETES MELLITUS, HEALTHY PREGNANT AND WOMEN VOLUNTEERS.|EVALUATION OF THE MACULAR, PERIPAPILLARY NERVE FIBER LAYER AND CHOROID THICKNESS CHANGES IN THE GESTATIONAL DIABETES MELLITUS, HEALTHY PREGNANT AND WOMEN VOLUNTEERS.||Kayseri Education and Research Hospital|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|76|None Retained|no biospecimens are to be retained|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2014|January 11, 2014|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02035995|6 Weeks|52514|
NCT02036008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153-2013|Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial|Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial||Sunnybrook Health Sciences Centre|No|Recruiting|August 2013|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02036008||52513|
NCT02025868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12269 THILAO|Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa|Systematic "Adherence Intervention" Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study.|THILAO|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|March 2013|August 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02025868||53290|
NCT02026115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-6553|Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice|Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice||University of Illinois at Chicago|No|Enrolling by invitation|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|380|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02026115||53271|
NCT02022449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10040081|Stress Management Intervention for Mothers of Children With Cancer|Stress Management Intervention for At-Risk Mothers of Children With Cancer|CTC|University of Pittsburgh|Yes|Completed|September 2010|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02022449||53553|
NCT02022436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG042352-01|Evaluation of Predictors of Aortic Aneurysm Growth and Rupture|Aortic Wall Behavior as a Predictor of Aortic Aneurysm Growth and Rupture||University of Pittsburgh|Yes|Recruiting|May 2012|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|145|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022436||53554|
NCT02022696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140038|Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector|Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector||National Institutes of Health Clinical Center (CC)||Completed|December 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|1 Year|65 Years|No|||February 2016|March 5, 2016|December 20, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022696||53534|
NCT02022969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS 1120/2013|Detection of SpO2-oscillations of Low Ventilated Areas|Detection of SpO2-oscillations Caused by Cyclic Recruitment and Derecruitment of Low Ventilated Areas in the Lung (Atelectasis) During Mechanical Ventilation|MAS|Medical University of Vienna|Yes|Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|None Retained|Spo2 Ventilation|Both|18 Years|N/A|No|Probability Sample|40 patients in 2 groups|September 2015|September 25, 2015|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02022969||53513|
NCT02022982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-506|PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors|Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors||Dana-Farber Cancer Institute|Yes|Recruiting|January 2014|December 2020|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|139|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022982||53512|
NCT02016339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAPCOMPL-01|Intensive Versus Standard Follow up to Improve Continuous Positive Airway Pressure (CPAP) Compliance|Intensive Versus Standard Follow up to Improve Continuous Positive Airway Pressure Compliance: The Greek Experience||University of Crete|No|Completed|June 2007|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2836|||Both|18 Years|65 Years|No|||December 2013|December 20, 2013|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02016339||54022|
NCT02023879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13786|Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin||Sanofi|Yes|Active, not recruiting|December 2013|June 2017|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|233|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023879||53443|
NCT02023892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHuang002|Single Dose of Atorvastatin and Circulating Endothelial Microparticles|The Effect of Single Dose of Atorvastatin on Change of Circulating Endothelial Microparticles||Sun Yat-sen University|No|Not yet recruiting|June 2014|||August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02023892||53442|
NCT02024204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00448|Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program|Uncontrolled Lower Respiratory Symptoms in the World Trade Center Survivor Program||New York University School of Medicine||Enrolling by invitation|January 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02024204||53418|
NCT02024919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnkaraU1|Effect of Diltiazem on Coronary Artery Ectasia|Short Term Effect of Diltiazem on Myocardial Perfusion in Patients With Isolated Coronary Artery Ectasia- a Prospective Clinical Study||Ankara University||Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02024919||53363|
NCT02016573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/12|Renal Denervation for Uncontrolled Hypertension|Renal Denervation for Uncontrolled Hypertension|RDNP-2012-02|Baker IDI Heart and Diabetes Institute|No|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016573||54004|
NCT02017353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55201|Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma|Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma||University Hospital, Gasthuisberg|No|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||May 2015|May 28, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017353||53944|
NCT02025426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032812|Phenylephrine Versus Ephedrine in Pre-eclampsia|Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia||Duke University|No|Recruiting|September 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||December 2015|December 16, 2015|December 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025426||53324|
NCT02025439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD075192|Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness|Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness||Edward Hines Jr. VA Hospital|Yes|Recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|4|||Both|18 Years|64 Years|No|||August 2015|August 3, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025439||53323|
NCT02017093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHaifa|Error Enhancement of the Velocity Component|Error Enhancement of the Velocity Component in the Course of Stroke Patients' Reaching Movements - A Pilot Study||University of Haifa|No|Completed|January 2009|May 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|7|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||June 2015|December 9, 2015|June 20, 2013||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT02017093||53964|
NCT02040727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMB|Effect of Resistance Training on Musculoskeletal Endocrine Interactions|Communications of Muscle and Bone|COMB|University of Alabama at Birmingham|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|16|||Male|7 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02040727||52150|
NCT02025881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004842-14|Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma|Phase I / II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk Medulloblastoma|HR MB-5|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|September 2013|September 2022|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|5 Years|No|||February 2016|February 5, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02025881||53289|
NCT02025894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01|Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study|Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study|ONCOCIP|Institut de Cancérologie de la Loire|No|Completed|February 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2929|||Both|18 Years|N/A|No|Non-Probability Sample|cohort of consecutive patients|December 2013|February 25, 2016|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02025894||53288|
NCT02026128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00008052|Optical Coherence Tomography (OCT) in Uveitis|Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography||Oregon Health and Science University|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll both males and females and include all ethnic and racial groups        through clinical practices. The study will enroll subjects 18 years of age or older with        physician-confirmed, active uveitis. A total of thirty subjects will be recruited.|April 2015|April 21, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02026128||53270|
NCT02026141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofS 13-232|Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study|Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study||University of Saskatchewan|Yes|Recruiting|December 2013|January 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2013|January 2, 2014|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02026141||53269|
NCT02022137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-588-12/13-1|Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy|Evaluation of the Effect of a Cereal Bar With Added Agave Fructans or Lactitol or Lactose, in Patients With Minimal Hepatic Encephalopathy||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Active, not recruiting|October 2013|March 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02022137||53576|
NCT02022150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-819-12/13-1|Body Composition Analysis in Cirrhotic Treated With Paracentesis|Body Composition Analysis in Cirrhotic Patients With Ascites Treated With Paracentesis|Paracentesis|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|The cohort will be selected from the Liver Clinic, Department of Gastroenterology at a        tertiary care center in Mexico|September 2015|September 29, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02022150||53575|
NCT02022462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bridge2014|Project Bridge: Peer Health Navigator Intervention|A Randomized Controlled Trial of "The Bridge", a Peer Health Navigation Intervention|Bridge|University of Southern California|No|Active, not recruiting|April 2014|July 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02022462||53552|
NCT02022709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124119a8601|Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients|Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder||Shanghai Mental Health Center|No|Recruiting|January 2014|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02022709||53533|
NCT02023281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU4261 from WyndhurstCC|The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers|The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers||Liberty University|No|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 23, 2013|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023281||53489|
NCT02023294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTL-EG-01|Conventional Laparoscopic Sleeve Gastrectomy Versus Endograb-assisted Single-port Sleeve Gastrectomy|Prospective Randomized Clinical Trial Comparing COnventional Laparoscopic Sleeve Gastrectomy Versus Endograb-assisted Single-port Sleeve Gastrectomy|GTLEND|Hospitales Universitarios Virgen del Rocío|Yes|Completed|April 2011|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||December 2013|December 23, 2013|December 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023294||53488|
NCT02023346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-253|Prognostic Awareness and Patient-Physician Communication in Malignant Glioma|Prognostic Awareness and Patient-Physician Communication in Malignant Glioma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the inpatient Neurology service. Caregivers will be        recruited from either the inpatient Neurology service (if they are physically present at        the hospital at the time of the patient's consent to participate) or via telephone        communication (if not physically present at the time of patient consent).|September 2015|September 17, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023346||53484|
NCT02024685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE19806|Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial|Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial||Case Comprehensive Cancer Center|Yes|Terminated|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Male|N/A|N/A|No|||November 2015|November 9, 2015|December 27, 2013||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT02024685||53381|
NCT02024698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-43|Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist|Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist||Coopervision, Inc.|No|Completed|January 2014|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|40 Years|No|||February 2015|February 12, 2015|December 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024698||53380|
NCT02016313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G850-tinnitus1|The Effect of Physiotherapy on Cervicogenic Somatic Tinnitus|Evaluation of the Effect of Cervical Spine Treatment in Tinnitus Patients||Universiteit Antwerpen|No|Completed|May 2014|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02016313||54024|
NCT02016326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23474-M|I-Scan Vs High Definition White Light (Main Study)|A Randomized Controlled Trial Comparing High-definition White Light Colonoscopy to I-scan Enhanced Colonoscopy for Adenoma Detection in a Population at Increased Risk of Colorectal Cancer (Main Study)||University of Calgary|No|Recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|1500|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02016326||54023|
NCT02017366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFECTS|Design of the EFECTS Trial|Design of the EFECTS Trial, Investigating the Influence of Postoperative Enteral Feeding in Esophageal Cancer paTients on Survival|EFECTS|University Hospital, Gasthuisberg|No|Not yet recruiting|February 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|85 Years|No|||December 2013|December 19, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017366||53943|
NCT02016833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX_DCtagTM_LeadIn_001|Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity|Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients||PX Biosolutions|No|Completed|October 2013|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|15|Samples With DNA|PBMCs isolated from whole blood|Both|18 Years|70 Years|No|Non-Probability Sample|Three type of patients will be enrolled in this study:          -  Women with a confirmed diagnosis of serous or undifferentiated ovarian cancer          -  Women with a confirmed diagnosis of CIN3 or cervical cancer          -  HLA-A2 positive men or women with a confirmed diagnosis of AML of CML All these             patients will be less than 70 years of age and will show no evidence of active             progressive disease on follow up. For ovarian cancer patients, a woman with a rising             CA125 and negative imaging is acceptable.|April 2015|April 29, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02016833||53984|
NCT02013557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015015|Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes|Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes||University of South Florida|Yes|Terminated|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|57|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|December 11, 2013||No|Resources allocated elsewhere.|No||https://clinicaltrials.gov/show/NCT02013557||54235|
NCT02040493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCMH-001|Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer|Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer||Xoft, Inc.|Yes|Active, not recruiting|September 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Female|45 Years|N/A|No|||January 2015|July 17, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040493||52168|
NCT02040740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAKC|Mediators of Kidney-Bone Communication in Childhood|Pubertal Assessment of Kidney-Bone Crosstalk|PAKC|University of Alabama at Birmingham|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|26|Samples With DNA|Plasma DNA collected to obtain ancestry informative markers and single nucleotide      polymorphisms involved in mineral metabolism|Male|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy boys ages 7-11y|January 2014|January 15, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02040740||52149|
NCT02041000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-COPD-001|Adipose Derived Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease||Bioheart, Inc.||Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041000||52129|
NCT02025660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 39|Efficacy of Mw Vaccine in Treatment of Severe Sepsis|Does Immune-modulation Improve the Survival in Patients With Severe Sepsis? "A Proof of the Concept Study"|MISS|Postgraduate Institute of Medical Education and Research|No|Completed|August 2013|March 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||March 2014|March 19, 2014|December 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02025660||53306|
NCT02026154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/749/13/KB|Finding Early Predictors of Myocardial Dysfunction|Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension - Pilot Study.||Medical Universtity of Lodz|Yes|Completed|October 2012|March 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|120|Samples Without DNA|blood plasma|Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|persons (age 30-70 years old) will be included in the study, patients with stage I or II        primary hypertension according to the European Society of Hypertension|May 2014|May 5, 2014|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02026154||53268|
NCT02022163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-H7VLP-006|Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.|Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.||Medicago|Yes|Completed|December 2013|December 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02022163||53574|
NCT02022176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JETF-6996-NO|Modulation of Metabolic Rate by Inorganic Nitrate|Dietary Inorganic Nitrate: Effects on Metabolic Rate, Reactive Oxygen Species Production, Glucose Uptake and Primary Myotube Respiration.||Karolinska Institutet||Completed|March 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02022176||53573|
NCT02022475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kray-1213|Effect of Vitamin D Treatment on Fatigue|Effect of Peroral Vitamin D Versus Placebo on Self-reported Fatigue in Adults With Low 25-hydroxy-vitamin D Levels||University of Zurich|Yes|Completed|December 2013|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02022475||53551|
NCT02022722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC IRB Study #: 2013-0677|Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain|Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections||University of Cincinnati|No|Recruiting|August 2013|June 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|N/A|No|||December 2013|December 27, 2013|December 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02022722||53532|
NCT02022995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310053RIND|Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients|Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients||National Taiwan University Hospital|No|Not yet recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|180|||Both|20 Years|80 Years|No|Non-Probability Sample|Age between 20-80 years old Patient had surgery in NTUH|December 2013|December 30, 2013|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02022995||53511|
NCT02023333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-211|Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma|Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023333||53485|
NCT02023905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis- CRAD001CUS225T|Everolimus With and Without Temozolomide in Adult Low Grade Glioma|PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma||University of California, San Francisco|Yes|Recruiting|February 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|159|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023905||53441|
NCT02024217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAGCCS001|Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma|Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma|NEWEAR|Fudan University|No|Recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||December 2013|December 25, 2013|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02024217||53417|
NCT02016092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECH-13-24|Biomarker Discovery in Parkinson's Disease|Proteomics, Metabolomics, Lipidomics and Genetic Analysis for Biomarker DISCOVERY in Parkinson's Disease|DISCOVERY-PD|The Parkinson's Institute|No|Active, not recruiting|December 2013|June 2016|Anticipated|March 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|400|Samples With DNA|Blood & Urine Specimen Collection: Up to 20mL of venous blood samples will be collected for      plasma multi-omic analysis, as well as optional genetic, analyses.      Urine samples (~50ml) will be collected via sterile urine cup and transferred into      appropriate urine tube for multi-omic analysis.      All Samples may be saved for future studies, if consented.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Parkinson's patients|March 2016|March 10, 2016|December 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02016092||54041|
NCT02024451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130712R|Radial Shock Wave and Acupuncture for Myofascial Pain|Comparison of the Effect of Radial Shock Wave and Acupuncture in the Treatment of Myofascial Pain Syndrome||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|January 2014|December 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|20 Years|80 Years|No|||February 2016|February 3, 2016|December 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02024451||53399|
NCT02015546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036210|Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone|A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone||Duke University|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|October 8, 2013|Yes|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT02015546||54083|
NCT02015845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/19|Evaluation of Accuvein in Obese Patients|Evaluation of Accuvein in Obese Patients||Hopital Foch|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02015845||54060|
NCT02016079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCHP-01|Effect of Omega-3 Supplementation on Child Behavior Problems|Randomized Controlled Trial of Omega-3 on Child Behavior Problems||Joint Child Health Project, Mauritius|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|8 Years|16 Years|No|||December 2013|December 14, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016079||54042|
NCT02017106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVLTAP|Concomitant or Sequential Phlebectomy After Endovenous Laser Therapy for Varicose Veins|Randomized Clinical Trial of Concomitant or Sequential Phlebectomy After Endovenous Laser Therapy for Varicose Veins|EVLTAP|University of Hull|No|Completed|April 2006|||April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02017106||53963|
NCT02017119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-282-10/11-1|Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients|Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients: Impact on the Recurrence of Encephalopathy, Tolerance and Adherence to Treatment, Costs, and Quality of Life||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|January 2011|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||August 2014|August 18, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017119||53962|
NCT02017613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP6530-1301|Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies|A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies|PI3K|Rhizen Pharmaceuticals SA|Yes|Recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02017613||53924|
NCT02013297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBRT|Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)|Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors|SBRT|Centre Leon Berard|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Months|20 Years|No|||June 2015|June 8, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02013297||54254|
NCT02013310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-0712-201|HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)|A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing HT-0712 With Placebo in Subjects With Age-Associated Memory Impairment (AAMI)|PRIME|Dart NeuroScience, LLC|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|50 Years|80 Years|No|||December 2015|December 1, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013310||54253|
NCT02041013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909209E|Talking Card for Asthma|The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control||Children's Mercy Hospital Kansas City||Completed|November 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|64|||Both|4 Years|11 Years|No|||August 2015|August 20, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041013||52128|
NCT02041312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-1312|Serum Cholesterol and Gastric Neoplasm|Serum Cholesterol and Gastric Neoplasm: Nested Case-control Study|SCGN|Asan Medical Center|No|Not yet recruiting|February 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1178|||Both|N/A|N/A|No|||January 2014|January 17, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02041312||52105|
NCT02041325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1831|Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias|Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias||Boston VA Research Institute, Inc.|Yes|Active, not recruiting|April 2005|||January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|37|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041325||52104|
NCT02022215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1111-2|Efficacy and Safety Study of ME1111 in Patients With Onychomycosis|A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis||Meiji Seika Pharma Co., Ltd.|No|Active, not recruiting|December 2013|||October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|December 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022215||53570|
NCT02022228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dual Trigger|Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome|Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol||Nanfang Hospital of Southern Medical University|No|Recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|N/A|40 Years|No|||October 2013|December 20, 2013|December 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022228||53569|
NCT02025907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103477|A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin|A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy||Janssen Research & Development, LLC|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|75 Years|No|||November 2015|November 2, 2015|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02025907||53287|
NCT02026167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43302-K|Spinal Cord Injury Collaborative Care Study|SCI-CARE (Northwest Regional Spinal Cord Injury Site Specific Project)|SCI-Care|University of Washington|No|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02026167||53267|
NCT02022189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003738|Review of Kidney Biopsies of Dent Disease Patients|Systematic Review of Clinical Biopsies of Dent Disease Patients||Mayo Clinic|Yes|Completed|October 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Male|N/A|N/A|No|Non-Probability Sample|All patients in the Dent Registry with a previous renal biopsy|September 2015|September 19, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02022189||53572|
NCT02022202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1137|Breast Cancer Genome Guided Therapy Study (BEAUTY)|Breast Cancer Genome Guided Therapy Study (BEAUTY)|BEAUTY|Mayo Clinic|Yes|Active, not recruiting|February 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Breast cancer tissue and blood specimens|Both|18 Years|99 Years|No|Probability Sample|Primary Care Clinic|March 2015|January 7, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02022202||53571|
NCT02023008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01513|Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy|Convenient and Live Movement (CALM): Feasibility of Interactive Gentle Yoga for Women With Breast Cancer||Comprehensive Cancer Center of Wake Forest University|No|Terminated|May 2014|||February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Female|18 Years|N/A|No|||February 2015|February 3, 2015|December 23, 2013||No|Study is not feasible|No||https://clinicaltrials.gov/show/NCT02023008||53510|
NCT02022735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130225|Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease|Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease.||University of Miami|No|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||October 2015|October 27, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02022735||53531|
NCT02022748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00067|Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects|A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialyisis Patients to Subjects With Normal Renal Function||AstraZeneca|No|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|December 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022748||53530|
NCT02023645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10516|The Effects of a Carotenoid Intervention on Cognitive Function|The Effects of a Lutein + Zeaxanthin Intervention on Cognitive Function and Neural Efficiency||University of Georgia|No|Active, not recruiting|January 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02023645||53461|
NCT02014974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INORMUSINDIA|InterNational ORthopaedic MUlticenter Study in Fracture Care|INORMUS 5,000: Large Observational Study of Orthopedic Trauma Patients|INORMUS|McMaster University|Yes|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4822|||Both|18 Years|N/A|No|Non-Probability Sample|We have planned a multicenter, prospective observational study of patients sustaining        fractures and presenting to orthopaedic fracture units across hospitals in India. All        patients with an orthopaedic injury presenting participating hospitals during an 8-week        period will be approached for study enrolment.|December 2013|December 18, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT02014974||54126|
NCT02015858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/22|Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor|Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor in Patients With or Without Epidural Anesthesia|Pain Drain|Hopital Foch|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Lung surgical patients|June 2015|June 24, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02015858||54059|
NCT02016365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No:2011-005236-25|Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis|A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis|Dox/Urso|Umeå University|No|Active, not recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||August 2015|August 21, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02016365||54020|
NCT02015832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRI-002|A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI|A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating||ECRI bv|Yes|Recruiting|December 2013|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with de novo 3 vessel disease|July 2015|August 4, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015832|5 Years|54061|
NCT02016846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209-13|Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes|||Rabin Medical Center||Not yet recruiting|January 2014|||January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2013|December 22, 2013|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02016846||53983|
NCT02016859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF-2013-Rambam|Observational Prospective Study of the Predicted Value of Immature Thrombocytes Counts in Three Different Groups of Critically Ill Patients|||Rambam Health Care Campus|Yes|Not yet recruiting|January 2014|November 2014|Anticipated|May 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|blood and serum|Both|18 Years|N/A|No|Probability Sample|admmitted patients to multiple departements|December 2013|December 15, 2013|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02016859|6 Months|53982|
NCT02016872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-186|Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients|Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients||Memorial Sloan Kettering Cancer Center||Recruiting|December 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02016872||53981|
NCT02017392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013]2-85|A RCT of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for GA|A Randomized Controlled Study of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for General Anesthesia||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|December 2013|April 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017392||53941|
NCT02017405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH4001|Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults|A Randomized, Crossover Clinical Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate (SBI) in Healthy Adults||Entera Health, Inc|No|Completed|December 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02017405||53940|
NCT02017379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E13018|Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.|||Texas Tech University Health Sciences Center|Yes|Recruiting|June 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||June 2014|June 24, 2014|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02017379||53942|
NCT02013583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 062012-080|The Glucose Transporter Type I Deficiency (G1D) Registry|The Glucose Transporter Type I Deficiency (G1D) Registry||University of Texas Southwestern Medical Center|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited from the investigator's patients at the Rare Brain Disorders        Clinic and from the national and international community of patients with Glucose        Transporter Type I Deficiency|December 2013|December 26, 2013|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02013583|5 Years|54233|
NCT02041338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-026|Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer|Phase 2 Randomized Study of Different Neoadjuvant Regimens in Subtypes of Breast Cancer||Chinese Academy of Medical Sciences|No|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Female|18 Years|N/A|No|||February 2014|November 24, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041338||52103|
NCT02041858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00079765|Effect of Altered Alarm Settings on Patient Adverse Events and Alarm Signal Frequency|Effect of Altered Alarm Settings on Patient Adverse Events and Alarm Signal Frequency: A Randomized Controlled Trial Feasibility Study||Johns Hopkins University|No|Active, not recruiting|April 2013|April 2016|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||September 2015|September 1, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041858||52063|
NCT02041871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120207|Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer|Interest of Preoperative Immunonutrition in Liver Resection for Cancer|PROPILS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041871||52062|
NCT02022241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Repeated GnRHa trigger|Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome|Repeated Injection of GnRH Agonist for Triggering Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol||Nanfang Hospital of Southern Medical University|No|Recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|N/A|40 Years|No|||December 2013|December 20, 2013|December 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022241||53568|
NCT02022488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162|Sevoflurane Induced Emergence Agitation|Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia With Ketamine-midazolam Combination: A Prospective Randomized Clinical Trial||Yeditepe University Hospital|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|78|||Both|1 Year|8 Years|No|||December 2013|December 26, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02022488||53550|
NCT02022501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35-001|A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration|A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration||Santen Inc.|No|Active, not recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|55 Years|N/A|No|||January 2014|January 14, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022501||53549|
NCT02022761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA51-350-101|Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma||Biota Scientific Management Pty Ltd|No|Completed|October 2013|February 2014|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|December 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02022761||53529|
NCT02022774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-KKH-01|Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion|A Single-arm, Open, Clinical Study to Evaluate the Effects of Fimasartan on Arterial Stiffness in Patients With Hypertension|STIFFNESS|Boryung Pharmaceutical Co., Ltd|Yes|Recruiting|April 2012|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|70 Years|No|Non-Probability Sample|Multiple secondary and tertiary centers|August 2015|August 31, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02022774||53528|
NCT02022787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0064-CTIL|Value of Various Chemokines in the Detection and Follow up of RCC|Value of Various Chemokines in the Detection and Follow up of RCC||Carmel Medical Center|No|Recruiting|January 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Renal tumor tissue and patients' serum|Both|20 Years|90 Years|No|Probability Sample|Patients scheduled for partial or radical nephrectomy|March 2015|March 4, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02022787||53527|
NCT02023021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-1312129-8|Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection|A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection||Fudan University|Yes|Recruiting|January 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02023021||53509|
NCT02023034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEPAR - 04|Virtual Exercises in Patients With Parkinson's Disease.|EFFECTIVENESS OF VIRTUAL EXERCISES ON THE FUNCTIONAL EXERCISE CAPACITY, FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A RANDOMIZED CLINICAL TRIAL||Faculdade Evangelica do Parana|No|Completed|February 2013|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|80 Years|No|||December 2013|October 4, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023034||53508|
NCT02023359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JDK02|Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer|Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer||Novartis|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Female|18 Years|N/A|No|Probability Sample|Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who are        treated with everolimus and exemestane according to the approved SmPC will be included in        the study.|December 2015|December 26, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023359||53483|
NCT02014714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311-0466|Single Dose Morphine and Fentanyl Added to Intrathecal Mixture on Orthopedics Patients With Undiagnosed Obstructive Sleep Apnea|Randomized Comparison Study of Single Dose Morphine and Fentanyl Added to Intrathecal Mixture on Orthopedics Patients With Undiagnosed Obstructive Sleep Apnea||University of Malaya|Yes|Recruiting|December 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014714||54146|
NCT02015871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000006A|An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer|An Extension Long-Term Safety and Tolerability Trial of Degarelix, Following a 1-year Open-Label, Multi-Centre, Randomised, Parallel-group Trial in Which the Efficacy and Safety of Degarelix One-month Dosing Regimen Was Compared With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy|PandaExtension|Ferring Pharmaceuticals|No|Active, not recruiting|January 2014|June 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|206|||Male|18 Years|N/A|No|||October 2015|October 12, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015871||54058|
NCT02016651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120101|Positioning and Gastric Aspiration in Ventilated Premature Infants|Positioning and Gastric Aspiration in Ventilated Premature Infants||Cairo University|Yes|Completed|January 2012|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|N/A|28 Days|No|||December 2013|December 16, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016651||53998|
NCT02016586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL08|Breastfeeding Intervention Study|Breastfeeding Intervention Study||Abbott Nutrition|No|Completed|November 2013|May 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|228|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02016586||54003|
NCT02016599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33536|Physiological Effects of Vasoactive Medications in ELBW Infants|Delineating the Effects of Transitional Circulation Physiology on Extremely Low Birth Weight (ELBW) Infants||Baylor College of Medicine|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|Samples Without DNA|Blood samples will be taken to assess the lactate levels. These samples will be destroyed      once analysis is complete.|Both|N/A|1 Week|No|Non-Probability Sample|All ELBW infants are eligible for enrollment. There will not be a placebo group. Instead,        those infants who require treatment for hypotension will be coded as such and those who do        not require treatment for hypotension will be considered the control group.|December 2015|December 15, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016599||54002|
NCT02016612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Seri Surgical Scaffold Support of the Lower Pole of the Breast|Seri Surgical Scaffold (TM) Support of the Lower Pole of the Breasts in Augmentation Mastopexy or Breast Reduction Patients|Seri Support|Bengtson Center|No|Recruiting|October 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|150|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02016612||54001|
NCT02016625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.61|Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus|Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial)||Boehringer Ingelheim||Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|December 16, 2013||||No||https://clinicaltrials.gov/show/NCT02016625||54000|
NCT02017132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-02Extr|Effect of Pomegranate Extract Intake on Body Composition and Blood Pressure.|The Effect of Pomegranate Extract on Anthropometric, Physiological and Biochemical Parameters in Human Volunteers: an 8 Week Parallel, Double Blinded, Placebo Controlled, Randomised Trial.||Queen Margaret University|Yes|Active, not recruiting|April 2013|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017132||53961|
NCT02013336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC-2012-001|Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors|Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors||Merrimack Pharmaceuticals|No|Recruiting|December 2013|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Months|20 Years|No|||April 2015|April 6, 2015|December 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02013336||54251|
NCT02013349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-1203|DESolve Post-Approval Study|POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS||Elixir Medical Corporation|No|Recruiting|March 2014|August 2022|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013349||54250|
NCT02013323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/10/2013-14|Clinical and Microbiological Efficacy of Systemic Ayurvedic Immunomodulator Septilin in the Treatment of Chronic Periodontitis|Clinical and Microbiological Efficacy of Systemic Ayurvedic Immunomodulator Septilin in the Treatment of Chronic Periodontitis-- A Randomized Controlled Clinical Trial.||Government Dental College and Research Institute, Bangalore|Yes|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02013323||54252|
NCT02014259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4079|Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function|Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function||Novo Nordisk A/S|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02014259||54181|
NCT02041598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i09-0510|DREAM Project Community Health Worker Intervention|DREAM Project Community Health Worker Intervention||New York University School of Medicine|No|Active, not recruiting|July 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|240|||Both|25 Years|85 Years|No|||February 2016|February 25, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02041598||52083|
NCT02041884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/333-31|CBT Through Internet and Smartphones for Adults With ADHD - a Randomized Controlled Trial|Psychological Treatment Through Internet and Smartphones for Adults With Attention Deficit Hyperactive Disorder (ADHD) - a Randomized Controlled Trial|Ad5|Karolinska Institutet|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02041884||52061|
NCT02013882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE561247|1-1-12 Wash-in for Desflurane Low Flow Anesthesia|1-1-12 Wash-in for Desflurane Low Flow Anesthesia||Khon Kaen University|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing general anesthesia with endotracheal intubation and controlled        ventilation|February 2014|February 8, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02013882||54210|
NCT02022514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/OCC/2012|Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.|Phase IIb Clinical Trial, Unicentric, Open, Randomized and Controlled to Assess the Effectiveness of Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|November 2013|May 2017|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|80 Years|No|||June 2015|June 23, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02022514||53548|
NCT02022800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/56|Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)|Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET) in a Multidisciplinary Meeting Therapeutic Proposal When Caring for Patients Diagnosed Primary or Secondary Cerebral Tumors|IMOTEP|Centre Antoine Lacassagne|Yes|Recruiting|November 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|85|||Both|18 Years|85 Years|No|||November 2015|November 13, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02022800||53526|
NCT02014987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130035|Running Related Injury Among Novice Runners|The Initial Running Volume and Running Related Injury Among Novice Runners||Northern Orthopaedic Division, Denmark|No|Recruiting|July 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02014987||54125|
NCT02023372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2013-11-07|Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine|NuTech NuCel®: A Prospective, Efficacy Study of NuCel® in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Lumbar Spine.||NuCel, LLC|No|Recruiting|December 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||October 2015|October 5, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02023372||53482|
NCT02014701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSTEMI Optison Study|Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.|Incremental Utility of Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery and Risk Area in Patients With Non-ST Segment Elevation Myocardial Infarction.||Cedars-Sinai Medical Center|No|Recruiting|August 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|31 Years|90 Years|No|||December 2013|December 12, 2013|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014701||54147|
NCT02015559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO-US B10|Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus|Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.||Jonsson Comprehensive Cancer Center|Yes|Recruiting|October 2014|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015559||54082|
NCT02030821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050108|TXA vs. Amicar in Total Knee and Hip Arthroplasty|TXA (Tranexamic Acid) vs. Amicar (Aminocaproic Acid) in Total Knee and Hip Arthroplasty- Effectiveness, Safety, and Cost Analysis||Duke University|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030821||52910|
NCT02030834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13413|Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas|Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030834||52909|
NCT02031068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01780|Exercise for Adolescents Following Sport-Related Concussion: A Randomized Control Trial|Active Rehabilitation for Slow to Recover Adolescents Following Sport-Related Concussion: A Randomized Control Trial||University of British Columbia||Recruiting|December 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|18 Years|No|||April 2015|April 7, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02031068||52891|
NCT02031081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PruGP|Prucalopride Versus Placebo in Gastroparesis|Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial||University of Calgary|No|Recruiting|March 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|64 Years|No|||January 2016|January 15, 2016|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02031081||52890|
NCT02031341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGINTDVR001|Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals|Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals|PEAKS|VU University Medical Center|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|Blood will be collected|Both|30 Years|80 Years|No|Probability Sample|50 subjects with T2DM and 50 nondiabetic individuals|December 2015|December 8, 2015|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02031341||52870|
NCT02031601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLHX-0531|Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer|Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer|TCL-1|Qilu Hospital||Recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02031601||52850|
NCT02061930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai9|Evaluation of the Aesthetic Outcomes of the Single Crowns Supported by Tissue Level Implants|Evaluation of the Soft Tissue Stability Around Single Crowns Supported by Tissue Level Implants Placed in Non-augmented Healed Sites in the Anterior Maxilla: a Retrospective Study|PES/WES|Shanghai 9th People's Hospital|No|Not yet recruiting|February 2014|June 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Have at least one implant-supported single crown in the anterior maxilla region (13-23)        with Straumann (Institute Straumann AG, Waldenburg, Switzerland) tissue level implants        placed between December 2005 and October 2008.|February 2014|February 11, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061930||50525|
NCT02062151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture|Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies|Acupuncture Use in Infants Treated for Neonatal Abstinence Syndrome: a Pilot Study||University of South Florida|Yes|Recruiting|February 2014|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|N/A|3 Months|No|||April 2015|April 25, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02062151||50508|
NCT02062463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFS-AS-40035|Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma|A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® (160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma|ELIOT|Teva Pharmaceutical Industries|No|Completed|June 2014|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062463||50484|
NCT02063061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-13-07-011546|Low-energy Linear Extracorporal Shock Wave Therapy for Erectile Dysfunction.|Low-energy Linear Extracorporal Shock Wave Therapy for Erectile Dysfunction.|ESWTvsED|University of Southern Denmark|Yes|Active, not recruiting|February 2014|October 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Male|40 Years|N/A|No|||December 2014|December 3, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02063061||50439|
NCT02063334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitDbol|The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression|The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25-hydroxyvitamin D3 and Vitamin D Receptor Target Gene Expression (VitDbol)|VitDbol|University of Eastern Finland|No|Active, not recruiting|February 2014|June 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02063334||50418|
NCT02063347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/13|Innate Human Collateral Supply to Different Vascular Regions|Innate Human Collateral Supply to Different Vascular Regions||University Hospital Inselspital, Berne|No|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients electively referred for coronary angiography in the context of chest pain.|July 2015|July 16, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063347||50417|
NCT02014532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKDC15|Role of Leukotriene Receptor Antagonists in Treatment of Chronic Periodontitis|The Effect Of SRP With Adjunctive Systemic Therapy Of Leukotriene Receptor Antagonist-Montelukast On The Serum C Reactive Protein Levels & Clinical Parameters In Chronic Periodontitis Patients - A Randomized Controlled Trial||Tatyasaheb Kore Dental College|Yes|Completed|March 2012|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014532||54160|
NCT02014870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1N1_CS_01|Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers|A Phase I, Open-label, Ascending Dose Study to Determine the Safety and Reactogenicity of a Wild Type Seasonal A/California/ H1N1 2009 Influenza Challenge Virus in Healthy Volunteers, Following a Single Intranasal Administration||Immune Targeting Systems Ltd|Yes|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|29|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02014870||54134|
NCT02015975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2013|Clinical Outcome After Treatment of Patellar Fractures With Locking Plates|Clinical Outcome After Treatment of Patellar Fractures With Locking Plates||Diakoniekrankenhaus Friederikenstift|No|Recruiting|May 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a fracture of the patellar, which were operated with a locking plate        osteosynthesis in the Friederikenstift Hannover since May 2013.|February 2016|February 14, 2016|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02015975|2 Years|54050|
NCT02033785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L201401N1|Functional Changes of Urogenital System After Holmium Laser Prostatectomy|Prospective Cohort Study of Holmium Laser Prostatectomy For Observing Functional Changes in Benign Prostate Hyperplasia Patients||The Catholic University of Korea|Yes|Not yet recruiting|February 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|86|||Male|50 Years|80 Years|No|Probability Sample|Primary Care Clinic|January 2014|January 9, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02033785|1 Year|52683|
NCT02064062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0419|Autologous Stem Cells in Achilles Tendinopathy|Autologous Stem Cells in Achilles Tendinopathy|ASCAT|University College, London|No|Not yet recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02064062||50362|
NCT02064075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6163-1/2013/EKU|The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies|Phase 4 Prospective, Randomized, Blinded Study on the Effect of Different Hydration Strategies on Mortality and Changes in Quality of Life of Patients Suffering From Subarachnoid Haemorrhage||University of Debrecen|Yes|Completed|February 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|80 Years|No|||February 2014|February 13, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02064075||50361|
NCT02064595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortofmabc1|Open Tibia Fractures a Comparative Study Between Biplane External Fixator and Locked Intramedullary Nail|TREATMENT OF EXPOSED FRACTURES OF TIBIA: A COMPARATIVE STUDY BETWEEN BIPLANE EXTERNAL FIXATOR AND LOCKED INTRAMEDULLARY NAIL||Faculdade de Medicina do ABC|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02064595||50321|
NCT02061878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REXCEPTOR-101|A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects|A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects||ReXceptor, Inc.|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|12|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|February 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061878||50529|
NCT02063178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK097158-01|Dissemination of the Look Ahead Weight Management Treatment in the Military|Dissemination of the Look Ahead Weight Management Treatment in the Military|FITBLUE|University of Tennessee|No|Recruiting|December 2013|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063178||50430|
NCT02060981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-00008959|Evaluation of a Decision Support Tool|Primary Medication Adherence Phase 2 Evaluation of a Decision Support Tool|PRIMA|Brigham and Women's Hospital|Yes|Active, not recruiting|February 2014|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|140|||Both|25 Years|N/A|No|||February 2015|February 16, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060981||50598|
NCT02060994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0088-13-CTIL|Respiratory Morbidity Among Children Who Were Born by Elective Cesarean Section After 37-38 Weeks vs. 39 Weeks and More|Respiratory Morbidity Among Children Who Were Born by Elective Cesarean Section After 37-38 Weeks vs. 39 Weeks and More||Hillel Yaffe Medical Center|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|123|||Both|4 Years|8 Years|No|Non-Probability Sample|Children born in 2007-2009 in "Hillel Yaffe" medical center by elective Cesarean section        according to a list of IDs we have.|May 2014|May 1, 2014|February 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02060994||50597|
NCT02031094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SS/0019|Energy Expenditure and Regeneration Following Liver Resection Resection|The Effect of Liver Regeneration on Resting Energy Expenditure After Liver Resectional Surgery|EAGLE|University of Edinburgh|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|28|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing hepatic resection for benign or malignant neoplasms.|October 2014|October 15, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02031094||52889|
NCT02031354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308012508|A Pilot Study of Dietary Chloride Supplementation on Cardiorenal Function in Heart Failure|Prospective "Pre-post" Pilot Study on the Effects of Dietary Chloride Supplementation on Neurohormonal and Diuretic Function in Patients With Heart Failure||Yale University|No|Recruiting|January 2014|||January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02031354||52869|
NCT02061722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDIKI1201/PET-HD-PDE10A|[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.|[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington´s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography|PEARL-HD|CHDI Foundation, Inc.|Yes|Recruiting|January 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061722||50541|
NCT02061943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068259|Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change|Validity and Reliability of the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Quantifying Symptom Change||Emory University|No|Withdrawn|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|85 Years|No|Non-Probability Sample|People with spasmodic dysphonia are eligible for this study.|December 2015|December 3, 2015|February 11, 2014||No|Study not started|No||https://clinicaltrials.gov/show/NCT02061943||50524|
NCT02062164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384c|Weight Loss Surgery in Adolescents With Extreme Obesity|Effectiveness and Safety of Weight Loss Surgery in Adolescents With Extreme Obesity Within a Structured Pre- and Post-surgery Treatment Program, Subproject 3|YES|University of Ulm|Yes|Recruiting|November 2013|December 2025|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Samples of fasting plasma, serum, DNA, urine, visceral and subcutaneous fat will be      retained.|Both|14 Years|24 Years|No|Non-Probability Sample|Subjects will be recruited from a cohort of young adults and adolescents participating in        the "Adolescents with extreme Obesity" Study.|November 2015|November 16, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02062164||50507|
NCT02062177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propofol TCI endoscopy|Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy|Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy: a Randomized Double Blind Controlled Study|Propofol TCI|Università Vita-Salute San Raffaele|Yes|Completed|February 2014|May 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|February 3, 2014||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT02062177||50506|
NCT02062489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCT2014001|Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients|||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|May 2014|May 2023|Anticipated|May 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|688|||Female|18 Years|65 Years|No|||May 2015|May 18, 2015|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062489||50482|
NCT02063035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000266|Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery|Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery||Massachusetts General Hospital|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|47|||Both|18 Years|85 Years|No|||January 2016|January 19, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063035||50441|
NCT02063048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1606 (Fischer)|Text Messaging for Weight Loss|The Comparative Effectiveness of Clinic-Based Weight Loss Strategies||Denver Health and Hospital Authority|Yes|Completed|April 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|163|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063048||50440|
NCT02063360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-020|DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)|Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects||Bristol-Myers Squibb|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063360||50416|
NCT02063373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM/MOHE/HIR D000010-16001|Gait, Stair Climbing and Postural Stability in Knee Osteoarthritis Patients After Hyaluronic Acid Injection|||University of Malaya|No|Completed|September 2012|||October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|85|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063373||50415|
NCT02063633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102118-F|PET With Respiratory Gating Technique in Evaluation of Response and Normal Tissue Effect in Thoracic Cancer|Radiotherapeutic Tumor Response and Normal Tissue Effect in Treating Thoracic Malignancy : as Comparing With Free-breathing Non-gating Methods.||Far Eastern Memorial Hospital|Yes|Not yet recruiting|March 2014|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|80 Years|No|Non-Probability Sample|Thoracic cancer who will be scheduled further radiotherapy|February 2014|February 13, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02063633||50395|
NCT02015728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-9006|Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors|The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors|SEED|Seattle Children's Hospital|Yes|Recruiting|December 2013|June 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|1 Month|30 Years|No|||November 2015|November 17, 2015|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015728||54069|
NCT02015741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/36|Comparability of Bispectral Index and NeuroSENSE in Aged Patients|Comparability of Bispectral Index and NeuroSENSE in Aged Patients||Hopital Foch|No|Withdrawn|November 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|75 Years|N/A|No|Non-Probability Sample|Aged patients|June 2015|June 24, 2015|December 5, 2013||No|difficulty of recrutment|No||https://clinicaltrials.gov/show/NCT02015741||54068|
NCT02015754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1305|Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer|Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2014|||June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|December 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015754||54067|
NCT02025621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-LVO-01|Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass|A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass|LEVO-CTS|Tenax Therapeutics, Inc.|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|760|||Both|18 Years|N/A|No|||September 2015|February 3, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02025621||53309|
NCT02033798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L201401N2|The Effect of Daily Tamsulosin 0.2mg Administration on Renal Function in Patients With Benign Prostatic Hyperplasia|Impact of Medical Treatment for Benign Prostatic Hyperplasia on Chronic Renal Failure||The Catholic University of Korea|Yes|Not yet recruiting|February 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Male|40 Years|80 Years|No|||January 2014|January 15, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033798||52682|
NCT02033811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MitraClip® Registry|MitraClip® Registry|MitraClip® Registry - an Observational Study of Percutaneous Mitral Valve Repair Using the MitraClip® System||Heinrich-Heine University, Duesseldorf|No|Recruiting|January 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing percutaneous mitral valve repair (PMVR) with the MitraClip® system|February 2016|February 10, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033811|12 Months|52681|
NCT02064296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuAfference|Neuroimaging Approaches to Deconstructing Acupuncture for Chronic Pain|Neuroimaging Approaches to Deconstructing Acupuncture for Chronic Pain||University of Michigan|Yes|Recruiting|December 2014|July 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064296||50344|
NCT02064309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS Dnr2013/299|An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus|An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus||Uppsala University Hospital|Yes|Recruiting|February 2014|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064309||50343|
NCT02061631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCETL06445|Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|Open Label, Non Controlled, Non Randomized, Interventional Study to Evaluate the Response Rate After Induction Therapy With DocEtaxel and CIsplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of heaD and nEck|DECIDE|Sanofi|No|Completed|May 2014|October 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|64 Years|No|||October 2015|October 7, 2015|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061631||50548|
NCT02062658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6811|Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)|Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)||New York State Psychiatric Institute|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|55 Years|No|||August 2015|August 27, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062658||50469|
NCT02062671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RePKID|Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease|||Odense University Hospital|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062671||50468|
NCT02030496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37754.018.12|Volar Internal Plate Fixation vs. Plaster in Extra- Articular Distal Radial Fractures|Volar Internal Plate Fixation vs. Plaster in Extra- Articular Distal Radial Fractures|VIPER|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|December 2012|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030496||52935|
NCT02030509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT_ORL_2014_1|Quick Diagnostic Program for Head and Neck Cancer|||Corporacion Parc Tauli|No|Recruiting|February 2014|||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|All patients with symptoms of head and neck cancer|July 2015|July 31, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030509||52934|
NCT02061462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVLP_2013|EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs|Extracorporeal Lung Perfusion and Ventilation to Evaluate the Eligibility for Transplantation of Lungs Retrieved From Donors After Cardio-circulatory Death (DCD)|EVLP-DCD|Policlinico Hospital|Yes|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Both|15 Years|N/A|No|||November 2014|November 25, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061462||50561|
NCT02061475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCLDKY-13115|Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation|The Efficacy and Safety of Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation Before Surgery: a Multicenter, Randomized, Double -Blind, Placebo-controled and Parallel-group Designed Clinical Trail||RenJi Hospital|Yes|Recruiting|April 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|65 Years|No|||June 2014|August 28, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061475||50560|
NCT02061228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29012014REFRESH|REFRESH: Receptivity Enhancement by Follicular-phase Renewal After Endometrial ScratcHing|Endometrial Receptivity Enhancement Through Induced Injury and Repair During Ovarian Stimulation in an Antagonist Down-regulated Cycle|REFRESH|Universitair Ziekenhuis Brussel|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|40 Years|No|||December 2015|December 8, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061228||50579|
NCT02061436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11-099|Prospective Global Registry for the Study of Chronic Total Occlusion Intervention|Multicenter Registry of Chronic Total Occlusion Interventions|PROGRESS CTO|University of Texas Southwestern Medical Center|No|Recruiting|January 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing CTO PCI at each of the participating centers.|January 2016|January 4, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02061436|1 Year|50563|
NCT02061449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU S13-00686|Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma|A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma||New York University School of Medicine|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061449||50562|
NCT02062190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESV-110553|Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia|Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal||Federal University of Rio Grande do Sul|Yes|Completed|March 2014|May 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Male|18 Years|65 Years|No|||December 2015|December 7, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062190||50505|
NCT02062502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-063|Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)|A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II||Merck Sharp & Dohme Corp.|No|Completed|March 2014|October 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|611|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 12, 2014|Yes|Yes||No|February 2, 2016|https://clinicaltrials.gov/show/NCT02062502||50481|
NCT02062801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEASE111199|Prophylactic Ephedrine and Combined Spinal Epidurals for Labor|Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study|CEASE|Sharp HealthCare|No|Completed|January 2012|October 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|710|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 11, 2015|February 7, 2014||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT02062801||50458|
NCT02062515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV51|Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency|Safety Assessment of Icotinib in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|February 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062515||50480|
NCT02062528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 15|Hot Flashes and Omega 3|Evaluation de l'efficacité Des Acides Gras oméga 3 Hautement concentrés en EPA Sur Les bouffées de Chaleur, Chez Des Femmes en période de péri-ménopause et ménopause : étude Monocentrique, en Groupes parallèles, contrôlée, randomisée vs Placebo|BOOM3|Vivatech|No|Completed|March 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Female|35 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062528||50479|
NCT02062827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB-1317|Genetically Engineered HSV-1 Phase 1 Study|A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma|M032-HSV-1|University of Alabama at Birmingham|Yes|Recruiting|September 2014|June 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||February 2016|February 2, 2016|February 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062827||50457|
NCT02063087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004659|Shared Decision Making in Parents of Children With Head Trauma: Head CT Choice|Shared Decision Making in Parents of Children With Head Trauma: Head CT Choice|Head CT Choice|Mayo Clinic|Yes|Recruiting|April 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1004|||Both|N/A|18 Years|No|||March 2016|March 14, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063087||50437|
NCT02063386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00007|AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study|A Phase I, Single-centre, Open-label Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of a Single Oral Dose of 14C-labelled AZD1722 in Healthy Male Volunteers||Ardelyx|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Male|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063386||50414|
NCT02015468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1393A|The Value of Early Mobilization and Physiotherapy Following Wrist Fractures Treated by Volar Plating|The Value of Early Mobilization and Physiotherapy Following Wrist Fractures Treated by Volar Plating||University Hospital, Akershus|No|Active, not recruiting|January 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2015|February 6, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02015468||54089|
NCT02025322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-51163|A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS|A Pilot Study Using Randomized, Parallel Design to Compare the Efficacy of Peer Mentoring Versus Standard of Care in Promoting Medication Adherence Among Newly Diagnosed and Medication Non-adherent People Living With HIV/AIDS||Apait Health Center|No|Active, not recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02025322||53332|
NCT02063828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01213|Reducing Lung Cancer Survivors' Anxiety and Dyspnea (RELAX)|Reducing Lung Cancer Survivors' Anxiety and Dyspnea (RELAX)|RELAX|Wake Forest NCORP Research Base|Yes|Recruiting|January 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02063828||50380|
NCT02034045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC - RCT|Expanding Paramedicine in the Community|The Expanding Paramedicine in the Community (Study)|EPIC|St. Michael's Hospital, Toronto|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|695|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034045||52663|
NCT02034344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102355|A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers|Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers||Janssen Research & Development, LLC|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|77|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02034344||52640|
NCT02034591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-111|Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects|Bioavailability of Apixaban Oral Solution Administered Through a Nasogastric Tube in the Presence of Boost® Plus and Apixaban Administered as Crushed Tablet Through a Nasogastric Tube Relative to Apixaban Oral Solution in Healthy Subjects||Bristol-Myers Squibb|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034591||52621|
NCT02034604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02-043|Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia|||Samsung Medical Center|No|Recruiting|December 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|20 Years|80 Years|No|||January 2014|February 12, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034604||52620|
NCT02030522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013717|Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma|Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma||University of South Florida|No|Recruiting|November 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02030522||52933|
NCT02061488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01604-41|Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA)|Prospective, Monocentric, Crossover Randomized Trial, to Assess a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC)|PPA|Rennes University Hospital|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|70 Years|No|||July 2014|July 22, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061488||50559|
NCT02061501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5542|Evaluation of the Efficacy of Optometric Rehabilitation on Visual Cognitive Deficits in Children|Evaluation of the Efficacy of Optometric Rehabilitation on Visual Cognitive Deficits in Children||University Hospital, Strasbourg, France|No|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|5 Years|12 Years|No|||June 2014|June 20, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061501||50558|
NCT02061735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMC 2011-0443|Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities|Ontogeny and Quantitative Multimodal Skin Imaging of Infantile Hemangiomas||Children's Hospital Medical Center, Cincinnati|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|118|||Both|1 Month|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients being seen at the the Hemangioma and Vascular Malformation Center of Cincinnati        Children's Hospital Medical Center|May 2015|May 5, 2015|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061735||50540|
NCT02062203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0010|Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers|A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers||Akebia Therapeutics|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062203||50504|
NCT02062216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81/2014/D|Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis|Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis|Receptors|University of Roma La Sapienza|No|Not yet recruiting|February 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Study Population 1 Patients with ST-elevation myocardial infarction (STEMI) with        angiographic evidence of massive thrombosis in the culprit artery undergoing primary        percutaneous coronary intervention (PCI)        Study Population 2 Patients with coronary artery disease in stable conditions scheduled to        undergo elective percutaneous coronary intervention and patients with Class I indication        to elective percutaneous coronary intervention|March 2014|March 13, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02062216||50503|
NCT02062840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-121-670-10|The Brain on Whole Body Hyperthermia: A Neuroimaging Study|The Brain on Whole Body Hyperthermia: A Neuroimaging Study||University of Arizona|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02062840||50456|
NCT02063074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00789|Bone, Endocrine and Lifestyle Longitudinal Study||BELLS|University of Southern California|Yes|Recruiting|June 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Premenopausal women over the age of 18|June 2014|June 2, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063074||50438|
NCT02063659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-303-CS|Telotristat Etiprate for Carcinoid Syndrome Therapy|A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome|TELECAST|Lexicon Pharmaceuticals|Yes|Active, not recruiting|February 2014|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063659||50393|
NCT02063672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0018-01|Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis|A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis|SFA ISR|C. R. Bard|Yes|Recruiting|March 2014|December 2021|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063672||50392|
NCT02063945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0564-DG-CTIL|Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders|The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders||Sheba Medical Center|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|5 Years|18 Years|No|||February 2014|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063945||50371|
NCT02025309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-627-13|Intraoperative Methylprednisolone and Sugammadex|Does Intraoperatively Administered Methylprednisolone Prolong the Neuromuscular Blocade Reversal Effect of Sugammadex?||Ankara University|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|65 Years|No|||December 2013|December 30, 2013|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025309||53333|
NCT02033538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1403|Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus|A Phase II Trial of Neoadjuvant Chemotherapy With Nanoparticle Albumin-bound Paclitaxel and Fluorouracil Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus||Zhejiang University|No|Withdrawn|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|December 16, 2013||No|This clinical trial was closed due to slow recruitment of patients.|No||https://clinicaltrials.gov/show/NCT02033538||52702|
NCT02064127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU_2013_2|Triage of Abdominal Pain in the Emergency Department|Evaluation of Triage Criteria for Abdominal Pain in the Emergency Department||University Hospital, Geneva|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|4000|||Both|16 Years|N/A|No|Non-Probability Sample|Adults (> 16 y) admitted with abdominal pain in the Emergency Departement of a primary and        tertiary teaching urban hospital.|December 2015|December 24, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02064127||50357|
NCT02064387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117159|Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA||GlaxoSmithKline|No|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|February 18, 2016|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064387||50337|
NCT02034058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEAVE Trial|Post Market Surveillance Study of the Wingspan Stent System|WEAVE™ Trial: Wingspan StEnt System Post MArket SurVEillance Study|WEAVE|Stryker Neurovascular|No|Recruiting|December 2013|July 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|389|||Both|N/A|N/A|No|||August 2015|January 12, 2016|January 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034058||52662|
NCT02034357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110265|Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease|Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease||University of Miami|Yes|Completed|June 2011|March 2016|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|89|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02034357||52639|
NCT02034617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LinkoepingU|Evaluation of a Parent-Infant Interaction Model|Evaluation of a Parent-Infant Interaction Model in the Neonatal Intensive Care|LiMoNid|Linkoeping University|No|Recruiting|January 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|126|||Both|N/A|96 Hours|No|||March 2016|March 4, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02034617||52619|
NCT02034630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH_GRDBuFlu|Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD|Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Genetic Rare Disease||Seoul National University Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|21 Years|No|||May 2015|May 26, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034630||52618|
NCT02030535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.7|Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers|A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|53|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|January 7, 2014||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT02030535||52932|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information".
NCT02030548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS003684|Bleeding in Patients Undergoing CABG During Dual Antiplatelet Therapy|Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor||Medical University of Graz|No|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|90 Years|No|Non-Probability Sample|consecutive patients undergoing acute CABG with or without valve during dual antiplatelet        therapy|October 2015|October 2, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030548||52931|
NCT02030561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC01/21/13|NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer|Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer||National University Hospital, Singapore|Yes|Recruiting|January 2014|August 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030561||52930|
NCT02061514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLEEP_ANNIE|The Effect of Two Different General Anesthesia Regimes on Postoperative Sleep Quality|The Effect of Two Different General Anesthesia Regimes on Postoperative Sleep Quality||Aretaieion University Hospital|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061514||50557|
NCT02061748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.192|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis||Boehringer Ingelheim||Completed|October 2014|March 2016|Actual|March 2016|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|20000|||Both|18 Years|N/A|No|Non-Probability Sample|NVAF|March 2016|March 22, 2016|February 12, 2014||||No||https://clinicaltrials.gov/show/NCT02061748||50539|
NCT02061761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA224-022|Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM|A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas||Bristol-Myers Squibb|No|Recruiting|February 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061761||50538|
NCT02061969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071545|ADA Linagliptin in Long Term Care|A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents With Type 2 Diabetes||Emory University|Yes|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061969||50522|
NCT02061956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-0014|A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma|A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|647|||Both|18 Years|75 Years|No|Probability Sample|Patients with unresectable HCC received TACE.The diagnosis of HCC was confirmed by either        histology, cytology, elevated alpha-fetoprotein (AFP, >400 ng/mL), or by typical        radiological appearance.|February 2014|February 11, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02061956||50523|
NCT02062541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-02-2014|Effect of Functional Assessment and Immediate Rehabilitation of ED Admitted Elderly With Reduced Functional Performance|Effect of Functional Assessment and Immediate Rehabilitation of ED Admitted Elderly With Reduced Functional Performance||University of Southern Denmark|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|336|||Both|65 Years|N/A|No|||February 2016|February 13, 2016|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062541||50478|
NCT02062554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1|Brasilia Heart Study|Brasilia Heart Study of Outcome Markers in ST-elevation Myocardial Infarction|BHS|University of Campinas, Brazil|No|Recruiting|May 2006|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Plasma Leucocyte DNA|Both|N/A|N/A|No|Non-Probability Sample|ST-elevation Myocardial Infarction patients admitted to Hospital de Base de Distrito        Federal, Brasilia, Brazil|May 2015|May 29, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062554|10 Years|50477|
NCT02063100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-055-03|Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis|Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial||Chinese PLA General Hospital|Yes|Recruiting|February 2014|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|720|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063100||50436|
NCT02062853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384968|Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video|CQI Pilot Study Evaluating the Utility of an Educational Video in the Setting of Topical 5-fluorouracil Therapy to Treat Actinic Keratoses and Its Influence on Patient Satisfaction||University of California, Davis|No|Active, not recruiting|November 2012|November 2015|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|44|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02062853||50455|
NCT02063685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_FOLL12|Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma|A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.||Fondazione Italiana Linfomi ONLUS|No|Recruiting|July 2012|July 2019|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|602|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 13, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02063685||50391|
NCT02063997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB102-21425|Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients|A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients||CymaBay Therapeutics, Inc.|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|248|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063997||50367|
NCT02015182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000023222|Bupivacaine Pharmacokinetics Following TAP Block|Bupivacaine Pharmacokinetics in Children Following Transversus Abdominis Plane Block||The Hospital for Sick Children|No|Recruiting|September 2011|March 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood (serum)|Both|3 Months|18 Years|No|Non-Probability Sample|Children undergoing TAP block for postoperative pain control|May 2015|May 29, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02015182||54111|
NCT02015195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSP-001|Effective Treatments for Jellyfish Stings|Efficacy of Topical Agents in the Treatment of Chrysaora Chinensis Stings||Stanford University|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|97|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|December 4, 2013|No|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT02015195||54110|
NCT02063555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAR-901-MDES|Phase I Trial of DAR-901|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG||Dartmouth-Hitchcock Medical Center|No|Active, not recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063555||50401|
NCT02063568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051122|The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery|The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery||Duke University||Withdrawn|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Female|18 Years|N/A|No|||October 2015|December 14, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063568||50400|
NCT02064400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH6919|Pilot Study of Ultrasound in Rheumatoid Arthritis|A Pilot Study of Musculoskeletal Ultrasound Assessment in Patients With Rheumatoid Arthritis||Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Secondary care rheumatology outpatient clinic|June 2015|June 25, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064400||50336|
NCT02064413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17069|Essure (Model ESS310) Placement Rate Study|A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System||Bayer|No|Completed|March 2014|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|134|||Female|21 Years|44 Years|Accepts Healthy Volunteers|||November 2015|December 14, 2015|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064413||50335|
NCT02064114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4300|SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients|Supervised Obesity Reduction Trial for AF Ablation Patients|SORT-AF|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||February 2016|February 5, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064114||50358|
NCT02064361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUBACYC|High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation|High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation||University of Split|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02064361||50339|
NCT02064374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201167|Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Parallel Group, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects||ViiV Healthcare|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064374||50338|
NCT02064660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|blueicek|The Efficacy and Safety of Periocular Acupoint Stimulation on Myopia Progression in Children|An Integrative Medical Approach of Acupoint Stimulation for Children With Myopia : A Pilot Study||Korean Medicine Hospital of Pusan National University|Yes|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|7 Years|12 Years|No|||September 2015|September 2, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064660||50316|
NCT02064881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMMET_LP001|Efficacy Study of Metformin Glycinate on Postprandial Lipemia|Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients||Laboratorios Silanes S.A. de C.V.|No|Not yet recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|35 Years|65 Years|No|||February 2014|February 14, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064881||50299|
NCT02061280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332965|Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial|Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial|MICT|Nemours Children's Clinic|No|Enrolling by invitation|October 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|12 Years|17 Years|No|||April 2015|April 14, 2015|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061280||50575|
NCT02061774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-015|Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion After Administration of Preoperative Followed by Scheduled Intravenous Acetaminophen:|Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion After Administration of Preoperative Followed by Scheduled Intravenous Acetaminophen: A Prospective, Randomized, Double Blind, Placebo-controlled Trial||Texas Tech University Health Sciences Center|No|Recruiting|October 2013|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061774||50537|
NCT02061787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPETPH|the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension|the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension|CPETPH|Chinese Pulmonary Vascular Disease Research Group|No|Recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|15 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|pulmonary hypertension who may accomplish cardiopulmonary exercise testing.|October 2015|October 28, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061787|5 Years|50536|
NCT02061800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK8060|CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant|CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease||Columbia University|Yes|Recruiting|November 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|N/A|22 Years|No|||March 2015|March 26, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061800||50535|
NCT02062229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IULIANO_Rago|Oxidative Stress and Lipidomics in Male Infertility|Oxidative Stress, Vitamin E and Lipidomics in Seminal Fluid as Potential Link to Infertility||University of Roma La Sapienza|Yes|Active, not recruiting|February 2012|June 2016|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|120|Samples Without DNA|Collection of male seminal fluid|Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects referring to an infertility center|December 2015|December 10, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02062229||50502|
NCT02062242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 211.405|Electrical Stimulation and Vaginal Palpation in Pelvic Floor Muscles Awareness|Electrical Stimulation and Vaginal Palpation in the Pelvic Floor Muscles Awareness: a Randomized Controlled Trial||University of Sao Paulo|No|Recruiting|March 2013|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 11, 2014|February 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02062242||50501|
NCT02063113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0437|Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.|Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.|MYELOME-PA|Nantes University Hospital|No|Recruiting|May 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|70 Years|100 Years|No|||January 2016|January 20, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063113||50435|
NCT02063399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU-ChemPath-001|Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis|Prospective 20,000-person Nasopharyngeal Carcinoma (NPC) Screening Programme Using Plasma Epstein-Barr Virus (EBV) DNA Analysis||Chinese University of Hong Kong|No|Recruiting|July 2013|June 2023|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|Plasma samples are retended for future study to evaluate the accuracy of sequencing-based      biomarkers|Male|40 Years|62 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male Hong Kong residents of Chinese ethnicity|July 2015|July 27, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063399||50413|
NCT02064010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNC102-201|A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia||Synchroneuron Inc.|No|Completed|February 2014|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|75 Years|No|||September 2015|September 4, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064010||50366|
NCT02064023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02375|Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy|Comparison of Continuous Subcutaneous Insulin Infusion (CSII) With Multiple Daily Injections (MDI) for the Treatment of Pregestational Diabetes During Pregnancy||University of British Columbia|No|Terminated|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Female|19 Years|N/A|No|||December 2015|December 3, 2015|February 3, 2014||No|Some sites withdrew because no contract with insulin pump supplier|No||https://clinicaltrials.gov/show/NCT02064023||50365|
NCT02024841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKUGCDTC01|Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis|Feasibility Study of Intraperitoneal Docetaxel Combined With Intravenous Cisplatin and Oral TS-ONE for Gastric Cancer Patients With Peritoneal Carcinomatosis||The University of Hong Kong|Yes|Recruiting|December 2013|May 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02024841||53369|
NCT02025062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K120902|Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients|Impact of Comprehensive Geriatric Assessment on Malnutrition, Functional Status and Survival in Elderly Patients With Head and Neck Squamous Cell Carcinomas (HNSCCs): a Randomized Controlled Multicenter Clinical Trial|EGéSOR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|September 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|704|||Both|65 Years|N/A|No|||December 2013|October 16, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02025062||53352|
NCT02025075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-50706|Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.|A Prospective, Double-blind, Randomized, Crossover Design Study to Compare the Hemodynamic and Respiratory Variations During Laparoscopic Surgery in Patients With and Without Deep Neuromuscular Blockade.||Massachusetts General Hospital|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02025075||53351|
NCT02063841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210010994.Jamidar|Digestive Endoscopy Suite Radiation Controlling Protective Strategies|A Prospective Double-blind, Randomized, Sham-controlled Trial to Evaluate the Effect of a Lead Free Drape on Scatter Radiation Exposure to Endoscopy Staff During Endoscopic Retrograde Cholangiopancreatography|D-ERCP|Yale University|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2|||Both|45 Years|50 Years|No|||August 2015|August 18, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063841||50379|
NCT02063854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-401|A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets|A Phase II/III Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Oral Administration of NE-58095NF Tablets Versus Once-daily Oral Administration of NE-58095 2.5-mg Tablets for the Treatment of Involutional Osteoporosis||Takeda|Yes|Active, not recruiting|February 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|760|||Both|50 Years|N/A|No|||August 2015|August 11, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063854||50378|
NCT02064439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16416|Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)|Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism|EinsteinChoice|Bayer|Yes|Recruiting|March 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|2850|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064439||50333|
NCT02064673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042013-080|Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy|Randomized Trial of Adjuvant Curcumin After Prostatectomy||University of Texas Southwestern Medical Center|Yes|Recruiting|May 2014|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Male|18 Years|80 Years|No|||October 2015|October 9, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064673||50315|
NCT02064894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUCH|Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries|A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries||St. Justine's Hospital|Yes|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|501|||Both|6 Years|17 Years|No|||December 2015|December 8, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064894||50298|
NCT02061007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17034|Biomarker Correlates of Hypoxia in Metastatic Melanoma|Biomarker Correlates of Hypoxia in Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061007||50596|
NCT02061241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHR CSP 146533|A Comparison of Two Techniques for Choosing the Best Place to Put a Pacing Lead for Cardiac Resynchronisation Therapy|Intracardiac Haemo-dynamics and Echocardiographic Assessment to Optimise Lead Placement for CRT|IDEAL-CRT|Oxford University Hospitals NHS Trust|Yes|Completed|April 2014|October 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Due to have CRT device implants.|October 2015|October 16, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061241||50578|
NCT02061306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001965|Celiac Disease Genomic Environmental Microbiome and Metabolomic Study|Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) Study|CDGEMM|Massachusetts General Hospital|Yes|Recruiting|March 2014|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Infant stool and whole blood samples. Maternal stool and breast milk samples.|Both|N/A|6 Months|No|Non-Probability Sample|Newborns and infants younger than 6 months who are first-degree relatives of CD patients        (at least one parent or sibling affected with biopsy-proven CD) are eligible for        participation.|September 2015|September 23, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02061306||50573|
NCT02061813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-007|Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion|A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design||Hatchtech Pty Ltd|No|Completed|January 2014|May 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 30, 2014|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061813||50534|
NCT02061527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL/KUH-ADM-LFC-2014|Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment|Immediate Breast Reconstruction With or Without the Use of Acellular Dermal Matrix: A Randomized Controlled Multicenter Study||Karolinska University Hospital|Yes|Recruiting|April 2014|November 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061527||50556|
NCT02061540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-401|Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis|A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis|CAMEO|Shire|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061540||50555|
NCT02062255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 13-0041|Impact of COX2 on Sera Biomarkers From Obese Subjects|A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062255||50500|
NCT02062268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jsdd1301|The Study of KAP on Drink Driving in Jiangsu Province in China|Study of KAP and Influential Factors on Drink Driving in Public in Jiangsu Province in China|KAP|Jiangsu Province Centers for Disease Control and Prevention|No|Not yet recruiting|March 2014|August 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||5|Anticipated|3565|||Both|18 Years|70 Years|No|Probability Sample|urban and rural residents in Jiangsu province aged 18-70.|February 2014|February 12, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062268||50499|
NCT02061982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9568|Do It Yourself (DIY) Coffee Study; Test Effect of Coffee on Cognition in an at Home Setting|A Non Invasive Intervention Study Performed by Subjects Themselves at Home; Evaluation of Study Infrastructure by Measuring the Effect of Caffeine on Attention and Alertness||TNO|No|Completed|November 2013|April 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 8, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02061982||50521|
NCT02062866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407301|Evaluation of Purse-String Closure Vs Second Intention|Intradermal Purse-String Closure Vs Second Intention Healing||University of California, Davis|No|Completed|April 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02062866||50454|
NCT02063425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D505|"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"|"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"|EFLUSTIM|Centre Hospitalier St Anne|Yes|Terminated|February 2014|April 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|January 6, 2014||No|Not enough recruitment|No||https://clinicaltrials.gov/show/NCT02063425||50411|
NCT02063412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-TR116583|Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens|The Impact of Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens in the Management of Advanced Esophago-gastric Cancer in Hong Kong||Chinese University of Hong Kong|No|Active, not recruiting|August 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Adult patients who were diagnosed with AEGC and were prescribed with either XELOX-based or        FOLFOX4-based chemotherapy treatment|February 2014|February 13, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063412||50412|
NCT02064218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070002649|Emerging Biomarkers in Hypertension|Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up||University of Pavia|Yes|Recruiting|November 2007|||January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Patients with naive essential hypertension aged < 65 years without previous cardiovascular        events|November 2007|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064218||50350|
NCT02025647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-0022|An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting|An Open, Non-Randomized, Evaluation of Innerview™, an MHCDS Tool Used to Report Symptoms and Functioning Related to Common Mental Health Disorders in the Primary Care Setting||Pearson/Clinical Assessment|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|139|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Innerview will be given universally / as indicated to 150 non-randomly selected subjects        aged 18 and over seeking primary care in selected primary care study sites.|September 2015|September 21, 2015|December 22, 2013||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT02025647||53307|
NCT02025361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer detection in TRUS-Bx|Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy|Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy||Bagcilar Training and Research Hospital|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|422|||Male|N/A|N/A|No|||December 2013|December 30, 2013|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02025361||53329|
NCT02025374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|osagir1|Hyperbaric Bupivacaine and Hyperbaric Levobupivacaine in C/S|The Comparison of Hyperbaric Bupivacaine Plus Fentanyl and Hyperbaric Levobupivacaine Plus Fentanyl Administered Intrathecally in Patients Undergoing Elective Cesarean Section||Balikesir University|No|Recruiting|August 2013|March 2014|Anticipated|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||December 2013|December 31, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02025374||53328|
NCT02064140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV NMBA JNLH13|Supported Ventilation in ARDS Patients|Reducing High Respiratory Drive to Facilitate Supported Ventilation in ARDS Patients: a Pilot Study||University Medical Center Nijmegen|No|Completed|February 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064140||50356|
NCT02064686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-TAE-2011-145|Exhaled Air Temperature (TAE) As A Marker Of Airway Inflammation In Asthma|EXHALED AIR TEMPERATURE (TAE) AS A MARKER OF AIRWAY INFLAMMATION IN ASTHMA||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|April 2009|||April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064686||50314|
NCT02060747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIPOST|Optimization of Osteoporosis Management Among Patients Older Than 45 Years Old With Low Energy Fracture.||OPTIPOST|Groupe Hospitalier Paris Saint Joseph|Yes|Active, not recruiting|October 2013|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|329|||Both|45 Years|95 Years|No|||February 2016|February 9, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02060747||50616|
NCT02061020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR12144 / P111114|Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users|Pilot Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol and the Ability to Drive in Chronic or Occasional Cannabis Users|VIGICANN|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2014|March 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02061020||50595|
NCT02061254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFUI 2013 - AM / TEDECAD|Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)|Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)|TEDECAD|University Hospital, Tours|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061254||50577|
NCT02061995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREOB-OP1|Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis|Treatment of Severe Osteoporosis by Intravenous Infusion of Pre-osteoblastic Cells - An Open Pilot Study||Erasme University Hospital|Yes|Recruiting|December 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|85 Years|No|||February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061995||50520|
NCT02062294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25224|An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients|Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program||Hoffmann-La Roche||Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|14|||Both|16 Years|N/A|No|Non-Probability Sample|Liver transplant recipients at high risk of developing Cytomegalovirus disease|January 2016|January 14, 2016|February 12, 2014||No||No|January 14, 2016|https://clinicaltrials.gov/show/NCT02062294||50497|
NCT02062567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR_US_Denmark_2014|Ultrasonographic Guided Treatment of Acute Achilles Tendon Rupture. Evaluation of Two Novel Ultrasonographic Measurements|||Hvidovre University Hospital|No|Recruiting|February 2014|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|70 Years|No|Non-Probability Sample|130 patients who are treated for acute Achilles tendon rupture at Copenhagen University        Hospital Hvidovre. Patients who fulfil the inclusion criteria but do not wish to        participate are treated according the standard regimen (non-operatively without early        controlled movement of the ankle joint).|February 2016|February 17, 2016|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02062567||50476|
NCT02062879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mueller2014|Ketamine Patient-Controlled Analgesia for Acute Pain|Ketamine Patient-Controlled Analgesia for Acute Pain in Native Airway Multiple and Orthopedic Trauma Patients: A Randomized, Active Comparator, Blinded Trial||University of Cincinnati|No|Enrolling by invitation|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062879||50453|
NCT02063438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00082406|Thoracotomy Closure Technique and Postoperative Pain Study: A Randomized Controlled Trial|Thoracotomy Closure Technique and Postoperative Pain Study: A Randomized Controlled Trial||University of Michigan|Yes|Recruiting|February 2014|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|99 Years|No|||December 2015|December 2, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02063438||50410|
NCT02063698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1364|Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome|A Pilot Randomized, Placebo-Controlled Study to Test Auranofin (Ridaura®) to Control the Paclitaxel-Induced Pain Syndrome (PIAPS)||Mayo Clinic|Yes|Active, not recruiting|February 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063698||50390|
NCT02063984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA015186-DartmouthSpectrum|Behavioral Treatment of Adolescent Substance Use|Behavioral Treatment of Adolescent Marijuana Use|SMART|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|November 2013|February 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|18 Years|No|||August 2015|August 14, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063984||50368|
NCT02064543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072012-090|Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism|Measurement of Gait Using the Opal APDM and an Instrumented Gait Mat in Persons With Parkinsonism||University of Texas Southwestern Medical Center||Recruiting|July 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults between the ages of 18 and 80 years of age with a primary diagnosis of PD and        similar parkinsonian syndromes and clinical signs of FoG|May 2014|May 15, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02064543||50325|
NCT02025114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312070MIPC|Selumetinib in Combination With Gefitinib in NSCLC Patients|A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment||National Taiwan University Hospital|Yes|Recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|20 Years|N/A|No|||December 2014|December 29, 2014|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02025114||53348|
NCT02026180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-090|Micropuncture vs. Standard Common Femoral Artery Access|Randomized Comparison of Micropuncture vs. Standard Common Femoral Artery Access for Reducing Vascular Access Complications||North Texas Veterans Healthcare System|No|Terminated|December 2013|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|552|||Both|18 Years|N/A|No|||July 2014|July 12, 2014|December 31, 2013||No|low incidence of primary endpoint|No||https://clinicaltrials.gov/show/NCT02026180||53266|
NCT02063893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLB-001|Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer|Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Breast|CSC|Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2014|February 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|40|Samples Without DNA|We will keep the CSC of every patient|Female|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients who unresectable after Cryotherapy|February 2014|June 1, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063893||50375|
NCT02064426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16209|Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934|A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis in the United States and Japan|DIALOGUE5|Bayer|Yes|Active, not recruiting|March 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064426||50334|
NCT02064153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB 2013/1950|Studying the Effect of Dialysate Temperature on Toxin Removal and Hypotension|Potential of Manipulating the Dialysate Temperature for Prevention of Intra-dialytic Hypotensive Episodes in Maintenance Hemodialysis Patients||National University Hospital, Singapore|Yes|Completed|July 2013|January 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|14|||Both|21 Years|70 Years|No|||April 2015|April 1, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064153||50355|
NCT02064699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10002 QUANTIC-R+|Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.|Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.|QUANTIC-R+|University Hospital, Limoges|No|Recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|460|Samples Without DNA|Detection of the CMV in sang, the leukocytes, or plasma with or without the viral      quantification.|Both|18 Years|N/A|No|Non-Probability Sample|Renal transplant recipient Immunized against the Cytomegalovirus.|February 2014|February 14, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064699||50313|
NCT02060760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 13-3690|Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes|Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes|UTROPIA|Minneapolis Medical Research Foundation|No|Active, not recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Excess blood is biobanked as EDTA-plasma and heparin samples after being used for the      clinical cTnI assay according to IRB approval HSR # 07-2854|Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting to Hennepin County Medical Center through the emergency department        within the defined study period will be considered for inclusion.|August 2015|August 27, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02060760|180 Days|50615|
NCT02061033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHMJA2014|Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease|GLOBAL HEMOSTATIC METHODS IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE CORRELATION WITH PATIENTS' CLINICAL STATUS AND USEFULNESS FOR TREATMENT MONITORING|GHMHW|Karolinska University Hospital|No|Recruiting|March 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|180|Samples With DNA|Citrated plasma and whole blood DNA samples|Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 patients with moderate and severe hA, 30 patients with moderate and severe hB and 50        patients with VWD (primarily severe type I and type III) from hemophilia centers        Stockholm, Sweden and Belgrade, Serbia.|August 2015|August 31, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061033||50594|
NCT02061046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRD 10-II-7|To Study the Impact of CPAP on Gait Parameters in OSA Patients|Impact of the CPAP on Gait in OSA Patients|OSA_Gait|University Hospital, Geneva|No|Active, not recruiting|August 2009|May 2018|Anticipated|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|N/A|N/A|No|Non-Probability Sample|OSA patients without any prior treatment|November 2015|November 30, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061046||50593|
NCT02061267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2011-29008|Olive Oil on Nampt and Its Relation With Postprandial Inflammation and Atherosclerosis in the Setting of Metabolic Syndrome.|OLIVE OIL ON NAMPT AND ITS RELATION WITH POSTPRANDIAL INFLAMMATION AND ATHEROSCLEROSIS IN THE SETTING OF METABOLIC SYNDROME. The OLNAMS Project|OLNAMS|National Research Council, Spain|No|Active, not recruiting|January 2012|December 2014|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02061267||50576|
NCT02061553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBIMS HN4473|SMS Messaging to Reduce Depression and Anxiety Following TBI|Use of SMS Messaging to Promote Emotional Health for People With Traumatic Brain Injury: A Randomized Controlled Trial||Albert Einstein Healthcare Network|No|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061553||50554|
NCT02061826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ditan-2014-01|Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)|Establishment of Drug-induced Liver Injury Databases and Application of Circulating miRNA||Beijing Ditan Hospital|Yes|Not yet recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||1|Anticipated|800|Samples With DNA|whole blood, serum,plasma,PBMC|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|community sample and primary care clinic|February 2014|February 15, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02061826|3 Years|50533|
NCT02062008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Combined PET-MRI|Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications|Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications||University of California, San Francisco|No|Not yet recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|No|||October 2014|October 1, 2014|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062008||50519|
NCT02062281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEPI-002|Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults|A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years.||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|November 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|2225|||Both|3 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062281||50498|
NCT02062593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORBITA-1|Comparison of Coronary Angioplasty and Optimum Medical Therapy Versus Optimal Medical Therapy in the Stable Angina|Defining a Gold Standard for Ischaemia: Effects of Interventional Revascularisation Versus Optimum Medical Therapy on Exercise Capacity in Patients With Stable Coronary Artery Disease|ORBITA|Imperial College London|Yes|Recruiting|December 2013|September 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||February 2016|February 24, 2016|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062593||50474|
NCT02062580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-00-9-900-01871|Early Versus Delayed BCG Vaccination of HIV-exposed Infants|Influence of BCG Immunization on Immune Responses and Disease Progression in South African HIV Exposed and Infected Infants||University of Cape Town|No|Completed|June 2010|||April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|151|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062580||50475|
NCT02063126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAE 01-2012|Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.|A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS.|ReConnect|Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|January 2013|December 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|65 Years|No|||February 2015|February 18, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02063126||50434|
NCT02063139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT2504|Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.|A Single (Assessor)-Blind, Randomised, Three-period, Cross-over Study to Compare the Safety of Flutiform pMDI, Fluticasone pMDI, and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years With Mild Persistent Asthma by Means of Knemometry||Mundipharma Research Limited||Completed|February 2014|January 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|5 Years|12 Years|No|||January 2015|January 27, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063139||50433|
NCT02064036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRO025|Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate|Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.|CCRO025|University of California, Davis|Yes|Recruiting|March 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Male|18 Years|N/A|No|||February 2014|February 14, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02064036||50364|
NCT02063711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-941|Acute Fetal Response to Prenatal Yoga|Acute Fetal Response to Prenatal Yoga: A Single Blinded, Randomized Controlled Trial (TRY Yoga Study)|TRY|University of Missouri, Kansas City|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|46|||Female|18 Years|45 Years|No|||March 2015|March 30, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02063711||50389|
NCT02064244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3464|Inferior Vena Cava (IVC) Size in Acute Renal Failure|Does the Inferior Vena Cava Size Assessment Help in the Management of Acute Kidney Injury in Critically Ill Patients?||University of Oklahoma|No|Recruiting|February 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|33|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients presenting to the intensive care unit with a diagnosis of acute renal        failure ( Defined as 1.5 fold increase in plasma creatinine level compared to baseline)|March 2015|March 9, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02064244||50348|
NCT02064829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STI-102|Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer|An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer|TRIBECA|Sorrento Therapeutics, Inc.|No|Completed|March 2014|July 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Female|30 Years|N/A|No|||March 2016|March 23, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064829||50303|
NCT02025920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/558|Project Healthy Eating in Adults. A Study on the Health Effects of Fish Intake in Overweight Adults (FINS)|Title in Norwegian: Sunn og Frisk. En Studie av Helseeffekter av Fiskeinntak i Overvektige Voksne (FINS)||University of Bergen|No|Active, not recruiting|January 2014|June 2019|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Whole blood will be collected for DNA analysis|Both|20 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults will be invited to participate in the study. Participants should not use        prescription medications that affects lipid metabolism, glucose regulation or the immune        system|August 2015|August 11, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02025920||53286|
NCT02025933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/541|Project Healthy Eating in Children. A Study on the Health Effects of Fish Intake in Overweight Children|Title in Norwegian: Ung og Frisk. En Studie av Helseeffekter av Fiskeinntak i Overvektige Barn.||University of Bergen|No|Terminated|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|25|Samples With DNA|Whole blood for DNA analysis|Both|9 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Cildren aged 9-12 years are invited to participate in the study. The children must be        healthy and not use prescription medications that affects lipid metabolism, glucose        regulation or the immunesystem.|August 2015|August 11, 2015|December 17, 2013||No|We were unable to recruit a sufficient number of participants|No||https://clinicaltrials.gov/show/NCT02025933||53285|
NCT02026193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0439-13|IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing|||Rambam Health Care Campus|No|Completed|January 2014|April 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Female|20 Years|40 Years|No|||May 2015|May 20, 2015|December 30, 2013||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT02026193||53265|
NCT02026206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-03-2011-005|Low-level Light Therapy for Primary Dysmenorrhea|Skin Adhesive Low-level Light Therapy for Primary Dysmenorrhea: A Double-blind Randomized Controlled Trial||Pusan National University School of Medicine|Yes|Completed|October 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Female|18 Years|35 Years|No|||February 2014|February 20, 2014|December 31, 2013||No||No|January 2, 2014|https://clinicaltrials.gov/show/NCT02026206||53264|
NCT02063932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014SDU-QILU-G02|Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome|Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome||Shandong University|Yes|Recruiting|December 2013|||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|The metagenome was obtained from biopsy specimen.|Both|18 Years|80 Years|No|Non-Probability Sample|Prospective patients scheduled for pCLE examination at Qilu Hospital, Shandong University|January 2014|February 14, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02063932||50372|
NCT02064166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN-1|Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.|A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy||University of Massachusetts, Worcester|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064166||50354|
NCT02064452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021307-06A1|Evaluating an Online Parenting Support System Disseminated by Pediatric Practices|Evaluating an Online Parenting Support System Disseminated by Pediatric Practices||Oregon Research Institute|No|Recruiting|May 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|3 Years|N/A|No|||October 2015|October 15, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02064452||50332|
NCT02064712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCPAPwean|Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates|Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates||University of Texas Southwestern Medical Center|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|N/A|32 Weeks|No|||June 2015|June 30, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064712||50312|
NCT02064725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX-EC-2-2013|Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA|A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma||Kevelt AS|Yes|Recruiting|September 2014|July 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064725||50311|
NCT02060773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhongdaH|Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock|Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock||Zhongda Hospital|No|Recruiting|December 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|90 Years|No|Probability Sample|Critical patients with early septic shock admitted to ICU within 24 hours after onset|December 2012|February 8, 2014|February 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060773||50614|
NCT02061059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1-112.3|Cost-effectiveness of In-shoe Pressure Measurement for Therapeutic Shoes|Improving the Cost-effectiveness of Therapeutic Shoes for Diabetic Patients With a Previous Foot Ulcer Using an In-shoe Pressure Device||Maastricht University|No|Not yet recruiting|March 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|40|||Both|N/A|N/A|No|||February 2014|February 11, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061059||50592|
NCT02061085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBU-SW-H-02|Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment|A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes|MERIBEL|MedSIR|No|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||March 2015|March 18, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061085||50590|
NCT02062021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_01|Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease|Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease: a CALIBER Proposal Using Linked GPRD-MINAP-HES Data||University College, London|Yes|Active, not recruiting|January 2014|June 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients registered in Clinical Practice Research Datalink (CPRD) practices|April 2015|April 20, 2015|January 30, 2014||||No||https://clinicaltrials.gov/show/NCT02062021||50518|
NCT02062307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cmeric2000|Bone Mineral Markers in Hypogonadism|Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism||Gulhane School of Medicine|No|Completed|August 2012|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|92|Samples Without DNA|Serum and plasma samples|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study group was selected from the male subjects with hypogonadotropic hypogonadism who        were not previously given testosterone or human chorionic gonadotropin therapy. The        patients did not have any chronic metabolic disorders or organ dysfunction. Forty three        age and BMI matched male volunteers were enrolled as control subjects.|February 2014|February 12, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062307||50496|
NCT02062320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT13906-4/2012|Establishment and Evaluation of a Post Caesarean Acute Pain Service (PCAPS)|Establishment and Evaluation of a Post Caesarean Acute Pain Service|PCAPS|Brno University Hospital|No|Completed|October 2009|||October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|407|||Female|N/A|N/A|No|Probability Sample|We evaluated all patients undergoing delivery via Caesarean Section under anaesthesia in        the period 10/2009 - 10/2011.|February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062320||50495|
NCT02062333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/425|The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea|The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea||TC Erciyes University|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02062333||50494|
NCT02062606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-001|MESA Rail™ AIS Study - Preservation of Curve Correction|Preservation of Thoracic Kyphosis and Coronal Curve Correction as a Function of Rod Stiffness in the Surgical Treatment of Adolescent Idiopathic Scoliosis With the Use of the K2M MESA Rail™ Deformity System||K2M, Inc.|Yes|Enrolling by invitation|May 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|204|||Both|11 Years|21 Years|No|Non-Probability Sample|Two-hundred four (204) total subjects with the MESA Rail Deformity System at up to 18        clinical sites, geographically distributed worldwide.|October 2015|October 22, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02062606||50473|
NCT02062892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1583|Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients|Differentiating Sirolimus and Everolimus in Combination With Calcineurin Inhibitors in Long-term Maintenance of Kidney Transplant Patients - The Effects on Vascular Endothelial and Kidney Function. The DESIRE Study.|DESIRE|University of Colorado, Denver||Withdrawn|December 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|70 Years|No|||December 2014|December 1, 2014|February 11, 2014|Yes|Yes|Patients meeting the inclusion/ exclusion criteria did not agree to participate. It became    obvious that recruitment goals could not be met.|No||https://clinicaltrials.gov/show/NCT02062892||50452|
NCT02062905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-14-001|Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis|A Single Center, Randomized, Double-Masked, Vehicle Controlled Phase 2/3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC™)||Ocular Therapeutix, Inc.|No|Completed|March 2014|January 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062905||50451|
NCT02062918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP?UNIFESP-1726/10|Abdominal Belt Use to Treat Low Back Pain|Effectiveness of Abdominal Belt for the Chronic Low Back Pain Treatment||Federal University of São Paulo|No|Completed|January 2010|February 2013|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062918||50450|
NCT02063152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305072RINC|102 Annual Pap Smear Screening Database Maintenance Project|102 Annual Pap Smear Screening Database Maintenance Project||National Taiwan University Hospital||Recruiting|January 1995|||December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300000|||Female|20 Years|130 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women attended screening and found abnormal results, and women who were diagnosed as        cervical cancer were the main study population. Women who did not attend screening for at        least 6 years were also included.|February 2016|February 17, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063152|25 Years|50432|
NCT02063191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH13342|Activation Timing and Atrial Fibrillation|Proof-of-concept Study to Assess Ventricular Activation Timing During Atrial Fibrillation, or Bundle Branch Block and Sinus Rhythm|AF-Activate|Essentia Health|No|Terminated|January 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Single center study of patients who are followed at Essentia Health - St. Mary's Medical        Center who are referred for a clinically indicated diagnostic EP study with or without        ablation.|February 2014|November 1, 2014|February 11, 2014||No|Methods of activation timing measurements too imprecise|No||https://clinicaltrials.gov/show/NCT02063191||50429|
NCT02063204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00081|To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects|An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects||AstraZeneca|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063204||50428|
NCT02064257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2304|The Listening Project: Tuning Into Change|The Listening Project: Tuning Into Change||University of North Carolina, Chapel Hill|No|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|7 Years|14 Years|No|||February 2016|February 11, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02064257||50347|
NCT02061189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120124|Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA)|Physical Exercise and Neuromuscular Diseases: Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy|ExerASI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2014|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|10 Years|No|||March 2016|March 17, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061189||50582|
NCT02025946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-12|Observational Study of Total Ankle Arthroplasty and Tibiotalar Arthrodesis|Observational Study of Total Ankle Arthroplasty and Tibiotalar Arthrodesis||Integra LifeSciences Services|Yes|Withdrawn||January 2026|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|40 Years|75 Years|No|Non-Probability Sample|Patient with isolated symptomatic end-stage ankle arthritis who needs a tibiotalar        arthrodesis or a mobile-bearing total ankle arthroplasty, receiving CE-marked medical        devices and planned to be operated in compliance with their respective Instructions for        Use|August 2015|August 11, 2015|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02025946||53284|
NCT02013544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-238|Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause|||EndoCeutics Inc.|No|Completed|February 2014|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|558|||Female|40 Years|80 Years|No|||February 2016|February 19, 2016|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013544||54236|
NCT02014194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13674113.2.0000.0068|Attentional Bias and Attentional Bias Modification Treatment in Obsessive-compulsive Disorder|Attentional Bias and Attentional Bias Modification Treatment in Obsessive-compulsive Disorder||University of Sao Paulo|No|Recruiting|November 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02014194||54186|
NCT02064478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C47|Clinical Survey of Oticon Medical Ponto Implants and a Surgical Technique With Tissue Preservation|Clinical Survey of Oticon Medical Ponto Implants and a Surgical Technique With Tissue Preservation||Oticon Medical|No|Active, not recruiting|February 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|All patients to be included are already planned for treatment with a bone anchored hearing        aid at Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands).|January 2016|February 11, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064478||50330|
NCT02064751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_704|MultiPoint Pacing Programming Guided by Noninvasive Hemodynamics|Noninvasive Hemodynamics for MultiPoint(TM) Pacing Programming in Cardiac Resynchronization Therapy Patients||St. Jude Medical|Yes|Active, not recruiting|March 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064751||50309|
NCT02064465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200697|The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects||GlaxoSmithKline|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064465||50331|
NCT02064738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P002683|High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)|A Pilot Study of the Effectiveness of a High Omega-3/Low Omega-6 Treatment Diet for Treating Aspirin-exacerbated Respiratory Disease||Brigham and Women's Hospital|No|Recruiting|March 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|No|||July 2015|July 22, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064738||50310|
NCT02060786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plavitor|Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)|Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)||Ajou University School of Medicine|No|Completed|October 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|19 Years|74 Years|No|||February 2014|February 11, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02060786||50613|
NCT02061072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-351-D|Web-based Application for the Population Pharmacokinetic Service - Phase 1|The Development of the Web-based Application for the Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) - Phase 1|WAPPS|McMaster University|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Actual|N/A|Observational [Patient Registry]|N/A||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe or moderate Hemophilia A or B|March 2016|March 18, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02061072|1 Week|50591|
NCT02061293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00614|A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence|A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence||New York University School of Medicine|Yes|Recruiting|June 2014|January 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|25 Years|65 Years|No|||February 2016|February 8, 2016|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061293||50574|
NCT02061839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00073-42|Prevention of Melasma Relapse During Summertime|Prevention of Melasma Relapse During Summertime||Centre de Pharmacologie Clinique Applique a la Dermatologie|No|Completed|March 2013|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061839||50532|
NCT02061852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00079-38|Evaluation of the Safety of the Medical Device Simeox®|Prospective Trial for the Evaluation of Safety, Tolerability and Efficacy of the Medical Device Simeox ® Compared to Traditional Respiratory Physiotherapy Techniques for Airway Secretion Clearance|SIMETOL|Physio-Assist|No|Terminated|July 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02061852||50531|
NCT02062034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDNP-20100102|Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy|Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study||University of Guadalajara|Yes|Completed|February 2011|January 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|July 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02062034||50517|
NCT02062632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC13C1|Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy|MC13C1, A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy||Mayo Clinic|Yes|Active, not recruiting|March 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|January 7, 2016|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062632||50471|
NCT02062931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT223101547|Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure|Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure||Al-Azhar University|Yes|Recruiting|March 2012|November 2016|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|20 Years|40 Years|No|||May 2014|May 12, 2014|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062931||50449|
NCT02062619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/K022563/1|Brain Mechanisms Underlying Reading Improvement in Central Alexia|Brain Mechanisms Underlying Reading Improvement in Central Alexia||University College, London|Yes|Recruiting|March 2014|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062619||50472|
NCT02063451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWMCNI_01|Neurohormonal & Behavioral Correlates of Obesity and Weight Loss|||University of Michigan|No|Enrolling by invitation|February 2011|August 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063451||50409|
NCT02063750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UNIFESP - 1785/11|Strengthening Exercises for Fibromyalgia|Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial||Federal University of São Paulo|No|Completed|January 2011|October 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|65 Years|No|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063750||50386|
NCT02061657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIN-1111-MM|Impact of Misoprostol on Blood Loss In Myomectomy Operations|Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations||Ain Shams University|Yes|Completed|June 2013|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Female|35 Years|50 Years|No|||July 2014|August 9, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061657||50546|
NCT02017340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILVAD2012|A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease|A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease|NILVAD|St. James's Hospital, Ireland|Yes|Active, not recruiting|October 2012|December 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|50 Years|N/A|No|||May 2015|May 25, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02017340||53945|
NCT02017600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCND420/201112|A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus|A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus||Nang Kuang Pharmaceutical Co., Ltd.|No|Recruiting|August 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|20 Years|N/A|No|||December 2013|December 22, 2013|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02017600||53925|
NCT02014207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Potato study 1: processing|The Effect of Potato Fries Processing on Food Intake, Satiety and Blood Glucose|||University of Toronto||Completed||||January 2007|Actual|N/A|Interventional|Primary Purpose: Prevention|5||||||Male|18 Years|35 Years|No|||December 2013|December 11, 2013|December 7, 2013||||No||https://clinicaltrials.gov/show/NCT02014207||54185|
NCT02064764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symplicity AF|Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation|Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation|Symplicity AF|Medtronic Atrial Fibrillation Solutions|Yes|Recruiting|February 2015|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|245|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064764||50308|
NCT02060812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSNB&ANB|Axillary Nerve Block Combined With Suprascapular Nerve Block|The Effect of Sono-guided Suprascapular Nerve Block Combined With Axillary Nerve Block in Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial|SSNBANB|Chuncheon Sacred Heart Hospital|Yes|Completed|November 2012|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|20 Years|N/A|No|||February 2014|February 11, 2014|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060812||50611|
NCT02060825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00687|The Use of Optical Oximetry in Determining Gastrointestinal Complications After the Hybrid Procedure|||Nationwide Children's Hospital|No|Enrolling by invitation|November 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing surgical repair of hypoplastic left heart syndrome.|January 2016|January 11, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02060825||50610|
NCT02060799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLariboisiere|European Dyspnoea Survey in the EMergency Departments|European Dyspnoea Survey in the EMergency Departments|EuroDEM|Hopital Lariboisière|Yes|Completed|February 2014|November 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2156|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients presenting to the Emergency Department with Dyspnea as main complaint        during the study period.|December 2014|December 16, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02060799|30 Days|50612|
NCT02061098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBAS-CSIC-4|Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects|Effect of an Ellagitannin Rich Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects. A Double-blind, Cross-over, Dose-response, Randomized, Placebo-controlled Trial (The POMEcardio Study)|POMEcardio|National Research Council, Spain|Yes|Completed|February 2014|December 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061098||50589|
NCT02061319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130774-01H|Randomized Trial of Nordic Walking vs. Standard Cardiac Rehabilitation in Patients With Heart Failure|Randomized Trial of Nordic Walking vs. Standard Cardiac Rehabilitation in Patients With Heart Failure||Ottawa Heart Institute Research Corporation|No|Recruiting|March 2014|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061319||50572|
NCT02061579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31635|Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study|Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study|IMPACT|Stanford University|No|Not yet recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|300|||Both|30 Years|65 Years|No|||November 2015|November 16, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061579||50552|
NCT02061592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5553|Evaluation of Etafilcon A Daily Disposable Lenses|Clinical Evaluation of Two Etafilcon A Daily Disposable Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|February 7, 2014|Yes|Yes||No|July 6, 2015|https://clinicaltrials.gov/show/NCT02061592||50551|
NCT02061605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTW-LPN-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2016|||||N/A|N/A|N/A||||||||||||||March 5, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061605||50550|
NCT02062346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bean ICRF clinical study|Endothelin Antagonism in ANCA Vasculitis|The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis||University of Edinburgh|No|Not yet recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062346||50493|
NCT02062645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ATR04|Study of Efficacy and Safety of CVAA489 in Hypertensive Patients|A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients||Novartis|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|178|||Both|18 Years|55 Years|No|||August 2014|August 4, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062645||50470|
NCT02060890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivy Precision Trial|A Pilot Trial Testing the Feasibility of Molecular Profiling in Recurrent/Progressive Glioblastoma|A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma|TGEN|University of California, San Francisco|Yes|Active, not recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060890||50605|
NCT02060903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-001|Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation|A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation||Hatchtech Pty Ltd|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|379|||Both|6 Months|N/A|No|||August 2015|September 9, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060903||50604|
NCT02063165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0259|Healthy Oils for Women (HOW Study)|Healthy Oils for Women: Reducing Visceral Adipose Tissue in Women With Metabolic Syndrome (HOW Study)|HOW|Ohio State University|Yes|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|50 Years|69 Years|No|||October 2014|October 14, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063165||50431|
NCT02062684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-IGN3321|BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration|A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy||Anthera Pharmaceuticals|Yes|Active, not recruiting|July 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062684||50467|
NCT02063464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140056|Blood Collection From People With Ovarian Cancer|Collection of Blood From Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|250|||Female|18 Years|100 Years|No|||November 2015|December 15, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063464||50408|
NCT02063477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oligo_extract|Effect of Oligopin® on Blood Pressure.|Effect of a French Maritim Pine Bark Extract Oligopin® on Blood Pressure: Double Blind, Crossover, Placebo-controlled Nutrition Intervention Trial||Technological Centre of Nutrition and Health, Spain|Yes|Completed|November 2013|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063477||50407|
NCT02064582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082013-032|Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer|Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|May 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|90 Years|No|||October 2015|October 9, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064582||50322|
NCT02032927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-14-OA|Treatment of Chronic Pain From Osteoarthritis|A COMPARATIVE STUDY BETWEEN TWO PHARMACOLOGICAL ASSOCIATIONS OXYCODONE/NALOXONE AND CODEINE / PARACETAMOL IN TREATMENT OF MODERATE-SEVERE CHRONIC PAIN DUE TO OSTEOARTHRITIS OF KNEE AND/OR HIP||IRCCS Policlinico S. Matteo|No|Recruiting|June 2013|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|182|||Both|60 Years|N/A|No|||September 2014|September 3, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032927||52748|
NCT02033252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRC-KIM-02|Acupuncture for Rhinitis Complicated With Asthma|Acupuncture for Persistent Allergic Rhinitis Complicated With Asthma, A Randomized Controlled Pilot Trial||Korean Medicine Hospital of Pusan National University||Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02033252||52724|
NCT02013895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSA-KHSC|Accuracy and Reliability of GSA for Remnant Liver Function|Accuracy and Reliability of GSA for Remnant Liver Function in Scheduled Hepatectomized Patients|GSA|Kochi University||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||December 2013|December 11, 2013|December 9, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT02013895||54209|
NCT02013570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/556|Efficacy of Peritonsillar Dexmedetomidine Infiltration for Postadenotonsillectomy Pain|||TC Erciyes University||Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|3 Years|9 Years|No|||September 2013|December 11, 2013|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02013570||54234|
NCT02013908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATPED|Acupuncture for Pain Control in the Emergency Department|Acupuncture for Non-emergent Acute Musculoskeletal Pain and Primary Headache in an Emergency Department Setting: a Parallel, Randomized, Controlled Pilot Trial||Korean Medicine Hospital of Pusan National University|Yes|Terminated|December 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|19 Years|N/A|No|||December 2015|December 3, 2015|November 27, 2013||No|Low recruitment rate (17 patients;43% enrollment for 2 years).|No||https://clinicaltrials.gov/show/NCT02013908||54208|
NCT02064504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010|Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination|An Open Label, Randomised, Six-way Crossover, Single Dose Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination||GlaxoSmithKline|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064504||50328|
NCT02064517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.131|Treatments of the Post-traumatic Necrosed Immature Teeth (REV)|Randomized Comparative Test Multicentric, Forward-looking Single-blind, Between a Reference Technique and an Innovative Technic.||University Hospital, Brest|Yes|Recruiting|October 2014|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|126|||Both|6 Years|N/A|No|||February 2016|February 10, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064517||50327|
NCT02064777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012MAR19|Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation|Tacrolimus Disposition in Pediatric Transplantation: Influence of Age, Genetic Polymorphisms, Intestinal and Hepatic Relative Contribution on Pharmacokinetics, in Relationship With Clinical Outcomes||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|July 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|18 Years|No|||February 2014|February 14, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064777||50307|
NCT02061111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-361|NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease|NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease||Naestved Hospital|Yes|Recruiting|January 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood samples from 120 mothers and - if possible - their children´s cords will be stored for      15 years for supplementary analyses|Female|18 Years|50 Years|No|Non-Probability Sample|The study population will be selected among pregnant women in region Zealand that will        give birth by cesarean section|April 2015|April 15, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02061111||50588|
NCT02061332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807010|DC Vaccine for Patients With Ductal Carcinoma In Situ|A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS|DCIS6|University of Pennsylvania|Yes|Recruiting|July 2009|July 2019|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|54|||Female|18 Years|N/A|No|||February 2014|February 11, 2014|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061332||50571|
NCT02061566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310062RINA|Indoxyl Sulfate Induces Leukocyte-endothelial Interactions Through Up-regulation of ICAM-1 in Acute Kidney Injury|National Taiwan University Hospital Yu-Lin Branch||National Taiwan University Hospital|No|Not yet recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Serum BUN, Cre, ICAM-1|Both|20 Years|90 Years|No|Probability Sample|AKI in ICU|February 2014|February 23, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061566||50553|
NCT02062047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP/277|Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects|Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects: Clinical, Immunological and Microbiological Outcomes||University of Guarulhos|Yes|Completed|December 2007|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|30 Years|70 Years|No|||February 2014|February 11, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02062047||50516|
NCT02063724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818532|HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer|Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer|Adjuvant|Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|January 2014|||February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063724||50388|
NCT02064569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-LHON/CLIN/01|Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients|An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene||GenSight Biologics|Yes|Active, not recruiting|February 2014|February 2019|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|21|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064569||50323|
NCT02061384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46478-A|RA-2 13-cis Retinoic Acid (Isotretinoin)|A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia|RA-2|University of Washington|No|Active, not recruiting|August 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|21 Years|60 Years|No|||March 2016|March 1, 2016|February 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061384||50567|
NCT02061644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spinal-IOP|Spinal Anesthesia - Intraocular Pressure|Intraocular Pressure Changes After Spinal Anesthesia: Acute and Subacute Effects||Adiyaman University Research Hospital|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|65 Years|No|||April 2014|April 4, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061644||50547|
NCT02064283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.111|Early Assessment of Treatment Response Using Functional Diffusion Mapping|Early Assessment of Treatment Response Using Functional Diffusion Mapping||University of Michigan Cancer Center|Yes|Completed|May 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|N/A|N/A|No|||December 2014|December 8, 2014|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064283||50345|
NCT02060916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAZ320-002|Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes|Study to Evaluate the Safety and Efficacy of PAZ320 When Added to Oral Agents or Insulin in Patients With Type 2 Diabetes Mellitus|PAZ320|Boston Therapeutics|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||February 2014|February 12, 2014|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02060916||50603|
NCT02032940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-020|Non-Enhanced Magnetic Resonance Angiography With the t-SLIP Technique|Non-Enhanced Magnetic Resonance Angiography With the t-SLIP Technique|MRAtSLIP|Miami Cardiac and Vascular Institute|Yes|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|All Patients Needing Thoracic, Aortic, Renal, Iliac and/or Femoral Vasculature MRIs|March 2016|March 17, 2016|January 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02032940||52747|
NCT02013921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12040|Interest of Daily Physical Activity After Cancer Treatment|Evaluation du Niveau d'activité Physique Quotidien, Chez Des Patientes Porteuses d'un Cancer du Sein en période Post thérapeutique|APQ|University Hospital, Limoges|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a breast cancer and are completing treatment|April 2015|August 31, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02013921||54207|
NCT02013934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAB/011013|Probiotics in Prevention of Common Cold|Benefit and Tolerability of a Probiotic Product in Subjects With Increased Susceptibility to Common Cold||Probi AB|Yes|Recruiting|October 2013|||April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|312|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02013934||54206|
NCT02014246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903329|Genetic Characterization of Movement Disorders|Genetic Characterization of Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|December 2016||December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|12000|||Both|2 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014246||54182|
NCT02060864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-PEP-03|Effect of AN-PEP Enzyme on Gluten Digestion in Gluten Sensitive Individuals|Effect of the Enzyme AN-PEP on Gluten Degradation in the Stomach of Gluten-sensitive Individuals|AN-PEP-03|DSM Food Specialties|Yes|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|18|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02060864||50607|
NCT02061137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2201T|Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome|A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome.|FINGORETT|University Hospital, Basel, Switzerland|Yes|Recruiting|August 2013|July 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|6 Years|N/A|No|||March 2016|March 14, 2016|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02061137||50586|
NCT02061150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-104-13|Neonatal Sepsis Workup for High Risk Newborns - Evaluation of Need and Ways to Prevent|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2014|June 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|N/A|48 Hours|No|Probability Sample|Asymptomatic term/near term newborns to a mother with infectious risk factors such as        premature rupture of membranes, GBS-carrier etc, that underwent sepsis work up due to        their maternal risk factors,|February 2014|February 11, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061150||50585|
NCT02060838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00762|The Impact of Storage Techniques on Platelets Number and Function After Acute Normovolemic Hemodilution (ANH)|||Nationwide Children's Hospital|No|Active, not recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing open-heart surgery who will be having acute normovolemic hemodilution        (ANH) as part of their surgery.|October 2015|October 22, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02060838||50609|
NCT02060851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kunshan002|Effects of Early Short-term Intravenous Iron Supplements Combinded EPO in Preterm Infants|||Kunshan First People's Hospital Affiliated to Jiangsu University|Yes|Recruiting|February 2014|||July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|138|||Both|N/A|24 Hours|No|||January 2014|February 9, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02060851||50608|
NCT02061124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-148|Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota|Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota||University Hospital, Gentofte, Copenhagen||Completed|February 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|50|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02061124||50587|
NCT02061345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0558|PET Imaging in MCI Following ADT for PCa|A PET Imaging Study to Detect the Presence of Activated Microglia in the Brains of Prostate Cancer Patients Who Develop Mild Cognitive Impairment Following Androgen Deprivation Therapy||Imperial College London|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|12|Samples With DNA|Blood samples for determining TSPO (Ala147Thr) polymorphism, testosterone and estrogen      hormone levels|Male|50 Years|80 Years|No|Non-Probability Sample|A total of 12 prostate cancer patients on ADT with LHRHa will be recruited for the imaging        part of the study; six patients having significant cognitive impairment attributable to        LHRHa and six patients without cognitive impairment.|February 2016|February 23, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061345||50570|
NCT02062385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-024|Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants||Merck Sharp & Dohme Corp.|Yes|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|4040|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2015|June 16, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062385||50490|
NCT02063737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120428|SleepTrackTXT Feasibility and Pilot Study|The Sleep Track Text Pilot Trial in Emergency Care Clinicians|SleepTrackTXT|University of Pittsburgh|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|January 10, 2014||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT02063737||50387|
NCT02062086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6911 03|Estimation of Muscle Mass in Older Adults Using Deuterated Creatine|Estimation of Muscle Mass in Older Adults Using Deuterated Creatine|MM-DC|University Hospital, Toulouse|No|Recruiting|June 2014|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|62|||Both|65 Years|N/A|No|||February 2015|April 24, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02062086||50513|
NCT02062398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02-001|BlueWind Medical Reprieve System for the Treatment of PNP|Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain (PNP)|PNP|Rainbow Medical|No|Active, not recruiting|May 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062398||50489|
NCT02062944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00072766|SRL (Sirolimus) Withdrawal|Liver Transplant Tolerance Enhanced By Sirolimus Therapy|SRL|Northwestern University|No|Recruiting|March 2013|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02062944||50448|
NCT02062957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF81300148|Endovascular Function in Atrial Fibrillation (AF) Patients|Endovascular Function in Patients With Atrial Fibrillation|HEAF|Beijing Chao Yang Hospital|Yes|Recruiting|February 2014|||July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients with AF|February 2014|February 23, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062957||50447|
NCT02062970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01251-44|Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock|Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|230|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02062970||50446|
NCT02032420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR vs. ART|The Effects of the STAR Maneuver on UGRA Training|A Double Blinded Randomized Controlled Trial on the Effects of Four Sequential Maneuvers on Ultrasound Guided Nerve Block Performance||University of New Mexico|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|62|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02032420||52787|
NCT02032433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA CTN-0051|Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment|CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment||New York University School of Medicine|Yes|Recruiting|January 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032433||52786|
NCT02032654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44512.018.13|Duration of ANtibiotic Therapy for CEllulitis|Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis|DANCE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|August 2014|June 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032654||52769|
NCT02014480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116132|A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|207|||Both|40 Years|N/A|No|||March 2015|July 2, 2015|December 12, 2013|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT02014480||54164|
NCT02014805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCRT|Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma|A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma||Chinese Academy of Medical Sciences|Yes|Recruiting|July 2013|July 2021|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||December 2013|December 12, 2013|December 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02014805||54139|
NCT02015364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR_Denmark_2014|Non-operative Treatment of Acute Achilles Tendon Rupture: Early Controlled Mobilization Compared With Immobilization|Non-operative Treatment of Acute Achilles Tendon Rupture, Early Controlled Mobilization Compared With Immobilization: A Blinded Randomized, Controlled Trial||Hvidovre University Hospital|No|Recruiting|February 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|70 Years|No|||February 2016|February 28, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015364||54097|
NCT02061371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20749113.5.0000.5503|Virtual Therapy in Rehabilitation Spastic Hemiparesis|VIRTUAL THERAPY IN REHABILITATION SPASTIC HEMIPARESIS||Universidade do Vale do Paraíba|Yes|Recruiting|November 2013|December 2014|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|75 Years|No|||January 2014|February 10, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061371||50568|
NCT02062411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013－9－23－3|A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder|A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder||Peking University Sixth Hospital|No|Recruiting|October 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|73|||Both|18 Years|45 Years|No|||April 2015|April 28, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062411||50488|
NCT02061358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 13-0001|Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects|UV|Unither Virology|Yes|Completed|July 2014|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061358||50569|
NCT02061618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-07-250|Culturally Relevant Exercise for Diabetes (CURE-D)|Culturally Relevant Exercise for Diabetes (CURE-D)|CURE-D|Palo Alto Medical Foundation|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02061618||50549|
NCT02061865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2176-3-AMD-1303|Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD|||Regeneron Pharmaceuticals|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|N/A|No|||February 2015|February 9, 2015|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02061865||50530|
NCT02061410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS-2007791|Effects of Neuromuscular Electrical Stimulation (NMES) in Patients With Knee Osteoarthritis|Diagnosis and Treatment of Muscle Inhibition of the Extensor Muscles of the Knee in Elderly||Federal University of Rio Grande do Sul|Yes|Completed|January 2006|||November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|50 Years|80 Years|No|||February 2014|February 10, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061410||50565|
NCT02064049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1302|Surveillance and Treatment of Prisoners With Hepatitis C|A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting|SToP-C|Kirby Institute|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Male|18 Years|N/A|No|||August 2015|August 31, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02064049||50363|
NCT02064270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208434|A Study to Assess the Prevention of Postsurgical Incision Healing Complications in Patients Undergoing Primary or Revision Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA), Treated With Either Single-Use Negative Pressure Wound Therapy (NPWT) or Standard Postsurgical Dressings.|A Prospective, Randomized, Controlled Clinical Study to Assess the Prevention of Postsurgical Incision Healing Complications in Patients Undergoing Primary or Revision Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA), Treated With Either Single-Use Negative Pressure Wound Therapy (NPWT) or Standard Postsurgical Dressings.|PICO|University of Missouri-Columbia||Recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064270||50346|
NCT02064556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144HPS13012|CKD-330 Drug-Drug Interaction Study (Amlodipine)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers|CKD-330(A)|Chong Kun Dang Pharmaceutical|Yes|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064556||50324|
NCT02064803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP382/13|Gastric Partitioning Procedure for the Treatment of Unresectable and Obstructive Distal Gastric Cancer|Randomized Clinical Trial Comparing Gastric Partitioning Plus Gastro-entero Anastomosis Versus Gastro-entero Anastomosis Only in Patients With Unresectable and Obstructive Distal Gastric Cancer.||Instituto do Cancer do Estado de São Paulo|No|Recruiting|June 2013|March 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|85 Years|No|||September 2014|September 3, 2014|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064803||50305|
NCT02064816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200136-570|A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis|Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis|RELIEF|Merck KGaA||Recruiting|May 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|60 Years|No|||February 2016|February 11, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064816||50304|
NCT02031575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1647|Study on Mhealth and Reproductive Health in Teens|Study on Mhealth and Reproductive Health in Teens|SMART|Harvard University||Completed|January 2014|July 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|1419|||Both|14 Years|24 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031575||52852|
NCT02031874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090858|Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study|Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study||University of Miami|No|Completed|December 2009|December 2012|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|Samples With DNA|Frozen PBMC for future experiments as per results.|Both|6 Months|25 Years|No|Non-Probability Sample|Perinatally Infected Children|April 2014|April 23, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031874||52829|
NCT02032147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRN2009|Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)|||Fudan University||Completed|March 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients must have undergone definitive RT for histologically confirmed NPC years before.        They were required to have at least two consecutive magnetic resonance imaging (MRI) study        supporting the diagnosis of CRN with an interval of 3-4 months, with the second MRI        showing progressive disease compared with the first MRI. The necrotic mass shown on MRI        must be measured in two dimensions in order to define the response to treatment. Other        radiologic studies were also required to support the non-existence of local or regional        recurrence, distant metastasis. Patients must have undergone mental status examinations        and had progressive neurologic symptoms or signs. In addition, they were required to have        a Karnofsky performance status of at least 70 and were supposed to live more than 6        months.|January 2014|January 8, 2014|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02032147||52808|
NCT02032407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-ACZ-13-001|A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris|||Allergan|No|Completed|December 2013|September 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|January 8, 2014|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT02032407||52788|
NCT02062476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/14|Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy|EPIGENETIC EFFECTS ELICITED BY LACTOBACILLUS GG IN CHILDREN WITH COW'S MILK ALLERGY: A POSSIBLE EFFECT OF ATOPIC MARCH||Federico II University||Recruiting|July 2013|||August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Months|48 Months|No|||February 2014|February 12, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02062476||50483|
NCT02062762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI-MBSR-Pilot|Internet-based Stress Reduction Training for Students|Internet-based Stress Reduction Training for Students - a Pilot Study|IBSR-stud|Karolinska Institutet|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02062762||50461|
NCT02032667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-701723|Exercise Games and Physical Activity: Can a Home-based Exergame System Increase Physical Activity?|Exercise Games and Physical Activity: Does Multi-player Online Play Improve Adherence?||University of Victoria|No|Completed|September 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|72|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02032667||52768|
NCT02062775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH13-356|Comparison of Self-Fixating vs Non-Fixating Hernia Mesh|A Randomized Controlled Study of Self Fixating Mesh Versus Non Fixating Polyester Mesh for Laparoscopic Inguinal Hernia Repair||NorthShore University HealthSystem|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062775||50460|
NCT02063022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISG/AIEOP EW-1|Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma|Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.|EW-1|Italian Sarcoma Group|Yes|Recruiting|February 2009|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|N/A|40 Years|No|||March 2016|March 2, 2016|February 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02063022||50442|
NCT02063295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-221|An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury|Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension||Zafgen, Inc.|Yes|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||January 2015|January 9, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063295||50421|
NCT02063308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000581|Oxaloacetate Pharmacokinetics and Safety|Oxaloacetate Pharmacokinetics and Safety||University of Kansas Medical Center|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063308||50420|
NCT02014818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECHANISM-Elective|Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case|Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case : MECHANISM-Elective||Kobe University|Yes|Not yet recruiting|January 2014|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|20 Years|84 Years|No|Non-Probability Sample|primary care clinic|December 2013|December 12, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014818||54138|
NCT02014844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P2-GBM-01|Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma|An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide||CytRx|No|Active, not recruiting|March 2014|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|January 19, 2016|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014844||54136|
NCT02014857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ege University|Evaluation of GCF MMP-1, -8 and Growth Factor Levels in Smokers With Periodontal Health|Evaluation of GCF MMP-1, -8 and Growth Factor Levels in Smokers With Periodontal Health||Ege University|No|Completed|May 2012|September 2013|Actual|September 2013|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|None Retained|Gingival crevicular fluid|Both|19 Years|27 Years|Accepts Healthy Volunteers|Probability Sample|Dental faculty students|December 2013|December 12, 2013|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02014857||54135|
NCT02062099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO13-CH/ NIDeCo|PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)|PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)|NIDeCo|University Hospital, Tours|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|60 Years|80 Years|No|||February 2014|February 11, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02062099||50512|
NCT02063490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-B300201111744|Nurse-led Intervention to Improve Phosphate Binder Adherence|A Nurse-led Multifactorial Intervention to Improve Phosphate Binder Adherence: Results From a One-year Clinical Trial|MedAM|Universiteit Antwerpen|Yes|Completed|November 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|135|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063490||50406|
NCT02063503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201215600|Development of Clinical Prediction Rules for Rehabilitation in Chronic Nonspecific Low Back Pain Patients|Development of Clinical Prediction Rules for Rehabilitation in Chronic Nonspecific Low Back Pain Patients||Universiteit Antwerpen|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063503||50405|
NCT02063763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP0614|TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.|Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.|ITP0614|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|May 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|ITP adult patients having undergone splenectomy after a bridge therapy with eltrombopag or        romiplostim.|May 2015|May 26, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063763||50385|
NCT02060929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102971|A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device|An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device||Janssen Research & Development, LLC|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02060929||50602|
NCT02061670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR007|Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|65 Years|No|||January 2015|January 20, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02061670||50545|
NCT02062060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-002|P3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation|Hatchtech Study of a Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation||Hatchtech Pty Ltd|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|325|||Both|6 Months|N/A|No|||September 2015|September 9, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062060||50515|
NCT02062073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-006|Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design||Hatchtech Pty Ltd|No|Completed|January 2014|June 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|238|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062073||50514|
NCT02030795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-Dec13|Techniques for Lung Deflation With Arndt® Blocker|Lung Deflation With Arndt® Blocker During Video-Assisted Thoracoscopy: A Comparison of the Disconnection Technique With a Continuous Bronchial Suction||Dammam University|Yes|Completed|January 2014|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030795||52912|
NCT02031055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-108|Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|No|Active, not recruiting|February 2014|February 2016|Anticipated|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02031055||52892|
NCT02061176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holbaek Haemorrhoid Study|THD Versus Open Haemorrhoidectomy|Transanal Haemorrhoidal Dearterialization (THD) Versus Open Haemorrhoidectomy for the Treatment of Haemorrhoids. An Open Prospective Randomized Study.||Holbaek Sygehus|No|Recruiting|January 2014|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||February 2014|February 11, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02061176||50583|
NCT02031328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|312-2013|Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer|Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer|2STAR|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|January 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 9, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031328||52871|
NCT02031588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAFREU53|Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.|Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.|EVOTAR|Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2012|September 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|77|Samples With DNA|Stool samples will be collected on 4 separate days for patients treated with antibiotics:      T0: before treatment begins T1: at the end of treatment or discharge from the hospital T2:      3-6 months after the end of treatment T3: 10-14 months after the end of treatment For      patients receiving sequentially ceftriaxone followed by a FQ, an additional sample will be      collected at the end of ceftriaxone treatment.      In the reference group, stool samples will be collected:      T0: at inclusion in the study T1: at hospital discharge The purpose is to study the      bacterial DNA contained in the stool. No analysis will be performed on the human patient      DNA.      Changes in the gut microflora will be analysed by metagenomics deep sequencing performed by      Dushko Ehrlich (INRA, France).|Both|18 Years|N/A|No|Non-Probability Sample|-  Hospitalized patients treated with ceftriaxone and / or an oral fluoroquinolone at             Beaujon hospital, Clichy, France.          -  A reference group of hospitalized patients not receiving antibiotics, hospitalized in             the same wards as the treated patients|November 2015|December 8, 2015|January 7, 2014||No|lack of recruitement|No||https://clinicaltrials.gov/show/NCT02031588||52851|
NCT02031887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.19.INF|Effect of a Starter Formula With Synbiotics on Stool Microbiota in Infants After Normal or Caesarean Section Delivery|Effect of a Starter Formula With Synbiotics on Stool Microbiota in Infants After Normal or Caesarean Section Delivery||Nestlé|No|Terminated|October 2008|October 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|430|||Both|N/A|3 Days|Accepts Healthy Volunteers|||January 2014|January 7, 2014|January 7, 2014||No|South African Health Authorities now promote that HIV positive mothers should receive    anti-retroviral drugs and breastfeed their infants.|No||https://clinicaltrials.gov/show/NCT02031887||52828|
NCT02032160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC306B|A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines|Study to Generate Exploratory Training Data Characterising Innate/ Adaptive Immune Responses Following 1st & 3rd Intra-muscular Immunisations With Fendrix/Engerix B Vaccines in Healthy Adult Males With no Pre-existing Immunity to Hep B||University of Surrey|No|Completed|May 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02032160||52807|
NCT02062788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORS-colectomy|Evaluation of Preoperative Oral Rehydration Solution in Colectomy|Preoperative Oral Carbohydrate-rich Solution in Colorectal Cancer Patients: a Randomized Controlled Trial||Seoul National University Hospital|No|Not yet recruiting|February 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|19 Years|75 Years|No|||February 2014|February 12, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02062788||50459|
NCT02063321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUB012013|Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic|Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic||National Institute of Endocrinology and Diabetology, Slovakia|Yes|Enrolling by invitation|December 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|762|||Both|18 Years|N/A|No|Probability Sample|Adults regularly examined in National Institute of Endocrinology and Diabetology (NIED)        for their severity and complications of diabetes will undergo a screening procedure using        fundus camera to assess the back of the eye (fundus examination).|February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063321||50419|
NCT02063607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNG01|The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients|The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients||Nanogen Pharmaceutical Biotechnology Co., Ltd||Recruiting|December 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063607||50397|
NCT02063867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|367981|Active Bathing to Eliminate Infection (ABATE Infection) Trial|Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial)|ABATE|University of California, Irvine|No|Active, not recruiting|April 2014|December 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|53|||Both|12 Years|N/A|No|||March 2016|March 1, 2016|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063867||50377|
NCT02014506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCPHO-SCT1303|Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents|||Asan Medical Center||Recruiting|January 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|21 Years|No|||December 2013|December 12, 2013|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02014506||54162|
NCT02014519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116804|A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary|Seroprevalence of Bordetella Pertussis in Adults in Hungary||GlaxoSmithKline||Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1905|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014519||54161|
NCT02014831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PENILANE|Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)|A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma|PENILANE|Centre Leon Berard|Yes|Withdrawn|February 2016|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|December 5, 2013||No|Industry decline to supply study drug|No||https://clinicaltrials.gov/show/NCT02014831||54137|
NCT02015143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011(37)|A Comprehensive Assessment and Follow up Descriptive Study on Bipolar Disorder||CAFE-BD|Peking University|No|Enrolling by invitation|January 2012|December 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|970|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The cases were selected from the Sixth Hospital of Peking University and other eight        hospitals, and they must meet the diagnosis inclusion criteria of un-bipolar and bipolar        disorders. The control group of non-mood disorders will be selected from heathy population        who met the following inclusion criteria of healthy controls. Informed consent must be        obtained.|December 2013|December 12, 2013|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02015143||54114|
NCT02063217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304030|Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction|Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction||Washington University School of Medicine|Yes|Recruiting|December 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063217||50427|
NCT02063230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00082|To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects|An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment||AstraZeneca|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|34|||Both|18 Years|130 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|February 13, 2014|No|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT02063230||50426|In the moderate group, 2 patients received Selumetinib 25mg and are not included in sumaries for AUC and Cmax. Dose normalized parameters are more appropriate for comparisons between groups and are included for all subjects.
NCT02061683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-BIM-0901|A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension||LOTUS|Allergan|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|263|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|February 11, 2014|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT02061683||50544|
NCT02061904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD&BIG|Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting|Prospective Exploratory Study:Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting|BMD&BIG|Rijnstate Hospital|No|Active, not recruiting|January 2014|November 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|20|||Both|35 Years|75 Years|No|||May 2015|May 11, 2015|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02061904||50527|
NCT02061202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1565|Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease|Inhaled Mometasone to Promote Reduction in Vasoocclusive Events|IMPROVE|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|15 Years|N/A|No|||April 2015|April 8, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061202||50581|
NCT02062359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140058|T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma|Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma||National Institutes of Health Clinical Center (CC)||Completed|February 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||October 2015|February 26, 2016|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02062359||50492|
NCT02062372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335-1812-intern-6485|Spatial Analysis and Validation of Glioblastoma on 7 T MRI|Spatial Analysis and Validation of Glioblastoma on 7 T MRI||Maastricht Radiation Oncology|Yes|Recruiting|May 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062372||50491|
NCT02030808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-Dec13(2)|Remifentanil Without Muscle Relaxant for Thoracotomy|Target-Controlled Infusion of Remifentanil Without Muscle Relaxant Allows Acceptable Surgical Conditions During Thoracotomy||Dammam University|Yes|Completed|January 2014|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|70 Years|No|||September 2014|September 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030808||52911|
NCT02036216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD-J14|Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.|Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.||Peking Union Medical College Hospital|No|Recruiting|January 2014|March 2016|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Human plasma；Human blood cells without plasma; HCC tissues (frozen);|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The HCC patients who will receive the surgical treatment in Peking Union Medical College        Hospital from Jan of 2014 till the end of this study.|January 2014|January 12, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02036216||52497|
NCT02036489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-RI/2008|Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia|Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute||PETHEMA Foundation|Yes|Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|15 Years|N/A|No|||September 2015|January 16, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02036489||52476|
NCT02036502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-023|A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)|A Phase I Trial of MK-3475 (Pembrolizumab) in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma||Merck Sharp & Dohme Corp.|No|Recruiting|February 2014|August 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036502||52475|
NCT02037711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS2013|Intraperitoneal Application of Levobupivacaine During Laparoscopic Surgery in Kids.|Intraperitoneal Instillation of Levobupivacaine in Laparoscopic Pediatric Procedures||Cairo University|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|40|||Both|N/A|12 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02037711||52382|
NCT02046460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340/12|Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD|Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD|TREAT-CAD|University Hospital, Basel, Switzerland|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|169|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046460||51711|
NCT02046473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00054436|3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts|3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts||University of Michigan|Yes|Completed|July 2013|April 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046473||51710|
NCT02047617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-37815003/2012A00665-38|Study of Safety and Efficacy on Neuromyopathy of Early Standing With the Assistance of Tilt Table in Critically Patients|Study of Safety and Efficacy on Neuromyopathy of Early Standing With the Assistance of Tilt Table in Critically Patients|TILT|Centre Chirurgical Marie Lannelongue|Yes|Recruiting|August 2013|February 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|82|||Both|18 Years|80 Years|No|||August 2015|September 3, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02047617||51622|
NCT02043665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA 009|Systemic Treatment of Resistant Metastatic Disease|A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Combination With Cytotoxic Chemotherapy in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).|STORM|Viralytics||Recruiting|January 2014|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|January 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02043665||51926|
NCT02046772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPA-EC-01-2012|Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids|Assessment of the Analgesic Efficacy of Morphine Chloride in Addition to a Low Dose Solution of Spinal Anaesthetic in Hemorrhoidectomy Compared to a Standard Dose of Spinal Local Anaesthetic. Simple Blind, Randomized, With Blinded Evaluation by Third Parties Clinical Trial.||Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|64 Years|No|||August 2014|August 21, 2014|January 22, 2014||No||No|August 5, 2014|https://clinicaltrials.gov/show/NCT02046772||51687|
NCT02047279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-04-31491|Ablation and Left Atrium Reduction During Mitral Valve Surgery for Atrial Fibrillation|Left Atrium Reduction Versus no Left Atrium Reduction for Patients With Enlarged Left Atria and Persistent or Long Standing Persistent Atrial Fibrillation Undergoing Mitral Valve Surgery|ALARM-vs-AF|Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047279||51648|
NCT02047578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH_ALL_BuFluVP|Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.|Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia||Seoul National University Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|N/A|21 Years|No|||May 2015|May 26, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02047578||51625|
NCT02044679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU365|Evaluation of Spot Urine as a Biomarker of Fluid Intake in Real Life Conditions|||Danone Research|No|Recruiting||||March 2014|Anticipated|N/A|Interventional|N/A|3||Anticipated|82|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044679||51848|
NCT02045004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCD-MRI|Cohort Study to Investigate the Association Between Changes in Brain Volume and Postoperative Cognitive Dysfunction|Association Between Changes in Cerebral Gray Matter Volume and Postoperative Cognitive Dysfunction in Elderly Patients Following Sevoflurane Anesthesia (POCD-MRI)|POCD-MRI|University Hospital, Basel, Switzerland|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Whole blood|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants in Group 1 (Surgery group Sevoflurane) will be recruited as patients of        the Basel University Hospital, a tertiary medical center affilitated to the University of        Basel, Switzerland. Study participants in Group 2 (Control group) will be recruited        randomly from the local population.|November 2015|November 17, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045004||51823|
NCT02045498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|capnography feedback|Effect of Capnography Feedback During Cardiopulmonary Resuscitation (CPR ) on Patient's Outcome|Effect of Capnography Feedback During Cardiopulmonary Resuscitation on Quality Performance of Rescuers and Outcome of the Patient||Mashhad University of Medical Sciences|No|Completed|February 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|130|||Both|18 Years|80 Years|No|||January 2014|January 23, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02045498||51785|
NCT02034734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0048|A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects|A Phase I, Open-label Study to Investigate the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ASP3652 in Healthy Young Caucasian Male Subjects||Astellas Pharma Inc|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034734||52610|
NCT02034942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130025a|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function|Substudy of Non-Seda Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function. An Investigator-initiated, Randomised, Clinical, Parallel-group, Multinational, Superiority Trial||Odense University Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034942||52594|
NCT02035228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM-SB-001|Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients|Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease: A Feasibility Study||Liberate Medical||Completed|March 2013|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|7|||Both|40 Years|N/A|No|||February 2014|February 18, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035228||52572|
NCT02036866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16794|Corticospinal Excitability and Rehab in Knee Osteoarthritis|Corticospinal Excitability and Rehab in Knee Osteoarthritis||Creighton University|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036866||52447|
NCT02036515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-006|Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|405|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036515||52474|
NCT02036528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-RBM-2011-001 DFU|Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers|A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes||Royer Biomedical, Inc.|No|Terminated|January 2014|||December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036528||52473|
NCT02037113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-047|Outcomes of Femoro-popliteal Disease After Stent Deployment Under Intravascular Ultrasound Guidance|Outcomes of Femoro-popliteal Disease After Stent Deployment Under Intravascular Ultrasound Guidance (CRI14-007)|IVUS-PAD|Texas Tech University Health Sciences Center|Yes|Recruiting|January 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|25 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients who have peripheral arterial disease and underwent elective abdominal        aortograms with runoff with peripheral artery intervention in University Medical Center        hospital, Lubbock Texas, during January 2014 to December 30, 2015.|December 2015|December 11, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037113||52428|
NCT02037126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND_121000|Psilocybin-facilitated Treatment for Cocaine Use|Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study||University of Alabama at Birmingham|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||November 2015|December 5, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037126||52427|
NCT02037412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0764|Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome|||Yonsei University|Yes|Recruiting|February 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|444|||Both|20 Years|80 Years|No|||January 2014|January 14, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037412||52405|
NCT02045992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110298|Arrhythmic Effects of Hight Dose Caffeine|Effect of High-dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure - a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Recruiting|April 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|112|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02045992||51747|
NCT02046239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS13/10722|Suture vs Staples for Skin Closure After Liver Resection|A Randomised Controlled Trial to Compare Subcuticular Suture vs Staples for Skin Closure After Liver Resection.||The Leeds Teaching Hospitals NHS Trust||Recruiting|March 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046239||51728|
NCT02046252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-DA-0263360-01|Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone|Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone||University of Pennsylvania|Yes|Active, not recruiting|June 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|October 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046252||51727|
NCT02043678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15396|Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms|A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)|ERA 223|Bayer|Yes|Recruiting|March 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043678||51925|
NCT02047032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-MUI|Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence|Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Moderate and Severe Mixed Urinary Incontinence in Female: a Multicenter, Noninferiority, Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|April 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|35 Years|75 Years|No|||September 2015|September 26, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047032||51667|
NCT02047591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11017|Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery.|Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery.|TOUTETDOU|University Hospital, Limoges|No|Not yet recruiting|February 2014|September 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|232|||Both|7 Years|17 Years|No|Probability Sample|7 to 17 years old child, having benefited from a surgical operation with the settle of a        Redon's drain.|January 2014|January 28, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047591||51624|
NCT02047604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2013-0302|(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).||Valeant Pharmaceuticals International, Inc.|Yes|Recruiting|December 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|75 Years|No|||August 2014|March 12, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047604||51623|
NCT02044991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nadler 2013|Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain|The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial||Loyola University|Yes|Recruiting|January 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|21 Years|50 Years|No|||March 2016|March 1, 2016|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044991||51824|
NCT02045277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-118A-201|Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis|A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|212|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045277||51802|
NCT02045264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-FIR-101|Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers|An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers||Shire|No|Completed|February 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|January 13, 2014|No|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT02045264||51803|
NCT02045537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-7312|Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in Spain|Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in Spain|INFOHS|Fundacion SEIMC-GESIDA|No|Recruiting|June 2013|September 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|Patients HIV in followed up betwen 1 Jan 1997 and 1 Jan 2012|January 2014|January 23, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02045537||51782|
NCT02034747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-KT-13-01|A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients|A Multicenter, Randomized, Comparison, Open-label, Phase IV Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients|COSMOS|Astellas Pharma Inc|No|Completed|November 2013|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034747||52609|
NCT02034955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5318-C|Prostatectomy Adaptive Radiation Therapy (ART)|A Feasibility Study of Post-operative Adaptive Radiation Therapy for Localized Prostate Cancer||University Health Network, Toronto|No|Active, not recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||July 2015|July 6, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02034955||52593|
NCT02035241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUND-AFC-STAGE3-SPICES|Effect of Herbs and Spices on Metabolic Regulation and Appetite in Healthy Subjects|Investigation on Effect of Herbs and Spices on Glucose and Insulin Responses, Anti-inflammatory Properties, Antioxidative Capacity and Satiety in Healthy Subjects|AFC-SPICES|Lund University|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035241||52571|
NCT02035267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-13-27|Safety Study of ATX-101 in Subjects With Varying Chin Sizes|A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 or CR-SMFRS Grade 4||Kythera Biopharmaceuticals|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|93|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|January 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035267||52569|
NCT02035891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMU-2013-QLi|Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria|Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study||Chongqing Medical University|Yes|Recruiting|December 2013|June 2021|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|30 Years|70 Years|No|||September 2015|September 6, 2015|January 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02035891||52522|
NCT02045966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-021|Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects|Effect of a Fixed Dose Combination Formulation of Daclatasvir/Asunaprevir/BMS-791325 on the Pharmacokinetics of a Cocktail of CYP Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, and Midazolam) and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045966||51749|
NCT02045979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.8|Pharmacokinetics and Safety in Healthy Volunteers|Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study||Boehringer Ingelheim||Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||||||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|January 23, 2014||||No||https://clinicaltrials.gov/show/NCT02045979||51748|
NCT02045160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312090RINC|A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy|A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy||National Taiwan University Hospital||Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who are treated in the National Taiwan University Hospital|July 2014|July 31, 2014|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045160||51811|
NCT02045420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO13-204|Vascular Abnormalities in Idiopathic Parkinson's Disease|Vascular Abnormalities in Idiopathic Parkinson's Disease|IPD|University of Saskatchewan|No|Active, not recruiting|December 2013|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be comprised of patients with Idiopathic Parkinson's Disease and        Age-Matched Normal Volunteers|November 2015|November 30, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02045420||51791|
NCT02046798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0003|A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652|An Open Label Study to Evaluate the Pharmacokinetics of ASP3652 After a Single Oral Dose of 14C-labeled ASP3652 in Healthy Caucasian Male Subjects||Astellas Pharma Inc|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 24, 2014|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046798||51685|
NCT02047045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01SCC|Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled Trial|Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Multi-center Noninferiority Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|April 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|75 Years|No|||September 2015|September 25, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047045||51666|
NCT02047058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFGC-001-MCP|Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics|A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|March 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples With DNA|tumor sample|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with glioblastoma undergo operation and sufficient tumor specimens|January 2014|January 25, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02047058|2 Years|51665|
NCT02047331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA12/269|Periarticular Injection Versus Fascia Iliaca Block for Total Knee Arthroplasty|Multimodal Periarticular Injection Versus Fascia Iliaca Compartment Block for Total Knee Arthroplasty||Baskent University|Yes|Completed|February 2013|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|70 Years|No|||January 2014|January 27, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02047331||51644|
NCT02047630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-11-1242|Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension|||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|January 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02047630||51621|
NCT02043886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00510|Acarbose, Postprandial Hypotension and Type 2 Diabetes|The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes||University of British Columbia|No|Completed|June 2007|May 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|65 Years|N/A|No|||September 2015|September 16, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043886||51909|
NCT02043899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/12/002|A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma|A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma||Cancer Research UK|No|Recruiting|February 2014|||October 2018|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Both|1 Year|N/A|No|||September 2015|September 7, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043899||51908|
NCT02044146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130601|A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk|Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study|RAPID MANAGE|Ottawa Heart Institute Research Corporation|Yes|Recruiting|September 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|75 Years|No|||January 2016|January 1, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044146||51889|
NCT02044380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.48|Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations|An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)||Boehringer Ingelheim||Completed|March 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 22, 2014||||No||https://clinicaltrials.gov/show/NCT02044380||51871|
NCT02044718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.50/intens11.01|Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals|Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals||Hasselt University|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|878|||Both|16 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2014|January 22, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02044718||51845|
NCT02044731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07-4508 B|Impact of a Childhood Obesity Intervention for African American Families|Impact of a Childhood Obesity Intervention for African American Families||University of California, Berkeley|No|Completed|January 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044731||51844|
NCT02046122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043247|Adoptive Transfer of Haplo-identical DLI for AML and MDS|Safety and Efficacy of Chemotherapy Combined With Adoptive Transfer of Human Leukocyte Antigen (HLA)-Haploidentical Donor Lymphocyte Infusion (DLI) in Older Patients With Righ-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||Duke University|No|Recruiting|July 2014|July 2020|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|55 Years|N/A|No|||January 2016|January 20, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046122||51737|
NCT02045550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeHe02|Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheezy Bronchitis|Tolerance and Effect of a Prophylactical Treatment With a Cough Medicine Con-taining Ivy Leaves Dry Extract in Children With Recurrent Wheezy Bronchitis||Technische Universität Dresden|Yes|Recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|1 Year|3 Years|No|||January 2014|January 23, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02045550||51781|
NCT02034760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-070|Counteracting Age-related Loss of Skeletal Muscle Mass|Counteracting Age-related Loss of Skeletal Muscle Mass|CALM|Bispebjerg Hospital|Yes|Recruiting|January 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|205|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034760||52608|
NCT02034968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1406|Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma|Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma||Zhejiang University|No|Withdrawn|February 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|January 10, 2014||No|No recruitment|No||https://clinicaltrials.gov/show/NCT02034968||52592|
NCT02036242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJFY13007|Sole Local Anesthetic Versus Opioid Plus Local Anesthesia in Epidural Labor Analgesia|Sole Epidural Local Anesthetic Versus Opioid Plus Local Anesthetic in Epidural Labor Pain Control|OLAA|Nanjing Medical University|Yes|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|500|||Female|18 Years|45 Years|No|||February 2014|February 1, 2014|January 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036242||52495|
NCT02036541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-001|AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN 45 Glaucoma Implant in Subjects With Refractory Glaucoma||AqueSys, Inc.|No|Active, not recruiting|January 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|45 Years|N/A|No|||February 2015|February 26, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036541||52472|
NCT02036554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AKR11T|Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients|To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients|PROTECT|Seoul St. Mary's Hospital|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|234|||Both|20 Years|N/A|No|||September 2014|September 22, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02036554||52471|
NCT02036580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2212C00002|D2212C00002 J-Phase II Study|A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis||AstraZeneca||Completed|January 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|50 Years|N/A|No|||December 2015|December 9, 2015|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036580||52469|
NCT02045147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|336-13-EP|Home Based Care Transitions Tailored by Cognition and Patient Activation|Home Based Care Transitions Tailored by Cognition and Patient Activation: A Prudent Use of Transitional Care Resources||University of Nebraska|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|222|||Both|19 Years|N/A|No|||May 2015|May 27, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045147||51812|
NCT02046499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH Prevention Trial|A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section|A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section||University of Pretoria|Yes|Not yet recruiting|January 2014|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046499||51708|
NCT02046512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310102|Probiotics to Promote Intestinal Health|Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health||Washington University School of Medicine|No|Enrolling by invitation|January 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|418|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046512||51707|
NCT02046200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVM|Development of Ivermectin for Alcohol Use Disorders|Repositioning Ivermectin for the Treatment of Alcohol Use Disorders||University of California, Los Angeles|Yes|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|21 Years|65 Years|No|||February 2016|February 19, 2016|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046200||51731|
NCT02046213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-007|An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects|An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects||Eisai Inc.|No|Completed|February 2014|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046213||51730|
NCT02046226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-13-0001|Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia|A Prospective, Randomized, Single-center Pilot Study of the OxyGenesys™ Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia||Halyard Health|No|Terminated|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|21 Years|N/A|No|||November 2014|October 8, 2015|January 23, 2014||No|inability to meet enrollment goals in this subject population|No|October 8, 2015|https://clinicaltrials.gov/show/NCT02046226||51729|
NCT02047344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHNSCLC-2 001|Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC|A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy||Golden Biotechnology Corporation|Yes|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047344||51643|
NCT02047292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORDePuyD57613|Dynamic ROM Via Gait Analysis and 3D Fluoroscopy in THA With Different Head Diameters|Dynamic Range of Motion (ROM) Assessment Using Gait Analysis and Three-dimensional Fluoroscopy in Patients Treated by Total Hip Arthroplasty (THA) With Different Head Diameters|DROMDP|Istituto Ortopedico Rizzoli|No|Recruiting|January 2014|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|35 Years|55 Years|No|||January 2014|January 24, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047292||51647|
NCT02047305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300|Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia|A Single-center Trial of Endoscopic Radiofrequency Ablation of Moderate and High-grade Intra-epithelial Squamous Neoplasia and Early Flat-type Squamous Cell Carcinoma Using the HALO Ablation System||Covidien, GI Solutions|Yes|Active, not recruiting|January 2009|September 2016|Anticipated|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||January 2014|March 12, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047305||51646|
NCT02047318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-303|An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome|A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome|IMAGINE|Shire|No|Active, not recruiting|December 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|12 Months|18 Years|No|||June 2015|June 10, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047318||51645|
NCT02043704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13072|RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain|The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial||TriHealth Inc.|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|70 Years|No|||February 2016|February 29, 2016|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043704||51923|
NCT02036021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cost904|Cost of Hospitalization in Children Who Develop Perioperative Respiratory Event|Comparison of Cost of Hospitalization in Children After General Anesthesia With and Without Perioperative Respiratory Event at a Tertiary Care Hospital in Southern Thailand||Prince of Songkla University|Yes|Completed|November 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1004|||Both|N/A|14 Years|No|Non-Probability Sample|Children aged < 15 years who received general anesthesia in Songklanagarind Hospital        between November 2012 and December 2013|October 2014|October 30, 2014|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02036021||52512|
NCT02036034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eyedrapCO2|Effectiveness of Modified Ophthalmic Draping Method in Preventing Carbon Dioxide Accumulation in Patient Undergoing Eye Surgery Under Local Anesthesia|Effectiveness of Modified Ophthalmic Draping Method in Preventing Carbon Dioxide Accumulation in Patient Undergoing Eye Surgery Under Local Anesthesia||University of Malaya|Yes|Completed|October 2010|January 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|40 Years|80 Years|No|||August 2011|January 11, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT02036034||52511|
NCT02043691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400001|Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modifed Endograft in Treating Aortic Pathologies|Evaluation of All-Cause Mortality and Pulmonary Morbidity in Treating Juxtarenal, Suprarenal and Thoracoabdominal Aortic Pathologies Using the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft and Surgeon-Modified Endografts||University of Florida|No|Recruiting|June 2014|October 2023|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02043691||51924|
NCT02043912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV002|Drug Interactions With Risk of QT-prolongation in a General Hospital|Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study||Katholieke Universiteit Leuven|No|Completed|July 2013|April 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|222|||Both|18 Years|N/A|No|Probability Sample|patients who are treated with haloperidol (every tuesday we will make a selection of the        patients who received haloperidol on monday)|June 2014|June 10, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043912||51907|
NCT02043925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF/2010/02|QT-prolongation in Psychiatric Hospitals|QT-prolongation in Psychiatric Hospitals||Katholieke Universiteit Leuven|No|Completed|October 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Probability Sample|Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a        QT-prolonging drug is added to a medication profile that already contains a potential        QT-prolonging drug.|July 2015|July 27, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043925||51906|
NCT02036632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211016|Eye Patch Therapy for Central Serous Retinopathy (CSR)|Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy||Washington University School of Medicine|No|Completed|November 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036632||52465|
NCT02044757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08545|The Potentially Addictive Properties of Soda: A Feasibility Study|The Potentially Addictive Properties of Soda: A Feasibility Study||University of California, Berkeley|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044757||51842|
NCT02045017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-013|Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency|A Phase 4 Multicenter, Open-label Study With Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone to Determine the Safety and Efficacy in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis||Celgene|No|Recruiting|May 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02045017||51822|
NCT02046135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007B|Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery|Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial||Northwell Health|Yes|Recruiting|September 2013|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|21 Years|No|||September 2015|September 4, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046135||51736|
NCT02046148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_12|Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women|A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women||Novartis|Yes|Active, not recruiting|March 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|75|||Female|18 Years|40 Years|No|||November 2015|November 9, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046148||51735|
NCT02046395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258683|Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus|Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus|UFLC|Tulane University Health Sciences Center|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|80 Years|No|||May 2015|May 25, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046395||51716|
NCT02034773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-220-CP-002|3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule|A Phase 1, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of CC-220 and to Evaluate the Relative Bioavailability of a Formulated CC-220 Capsule in Healthy Subjects||Celgene|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|8||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034773||52607|
NCT02034981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1303|Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1|AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.|AcSé|UNICANCER|Yes|Recruiting|August 2013|July 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|488|||Both|1 Year|N/A|No|||February 2016|February 16, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02034981||52591|
NCT02034994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-PAPPAS2-project|Combining Primary and Secondary Prevention for Reduction of Excessive Weight Gain in School|Combining Primary and Secondary Prevention for Reduction of Excessive Weight Gain in School||Rio de Janeiro State University|Yes|Not yet recruiting|February 2014|December 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Both|9 Years|15 Years|No|||January 2014|January 10, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034994||52590|
NCT02035254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIP1401|A Multidisciplinary e-Health Program to Promote Regular Physical Activity|Evaluating a Multidisciplinary e-Health Program to Promote Regular Physical Activity Among Individuals at Increased Risk of Cardiovascular Disease.||McGill University|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|93|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035254||52570|
NCT02036255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL-001|Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase|Prevention of Tunneled Cuffed Catheter Malfunction With Prophylactic Use of a Taurolidine Locking Solution Containing Urokinase : a Multicentric Randomized Controlled Trial||Universitair Ziekenhuis Brussel|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|99 Years|No|||December 2015|December 16, 2015|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02036255||52494|
NCT02036567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28503|Evaluation of Pain Measurement Device|Longitudinal Observational Pilot Study to Assess the Capabilities of an Experimental Device to Objectively Measure Pain.||Stanford University|Yes|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women of all ethnicities will be included.|March 2015|March 31, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036567||52470|
NCT02046265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StepUpToPrevention|Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors|Step up to Prevention : A Nurse Practitioner Guided Cervical Cancer Prevention Intervention|StepUp|University of Pennsylvania|No|Active, not recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|53|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02046265||51726|
NCT02046278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-LS-0110|LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge|LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge||LifeBond Ltd.|Yes|Active, not recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||March 2015|March 18, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046278||51725|
NCT02046291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS089|Safety of Romiplostim (Nplate®) Following UCBT|Safety of Romiplostim (Nplate®) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046291||51724|
NCT02045667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mexiletine20142015|Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)|Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia.||Radboud University|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045667||51772|
NCT02035722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-110463AE|Intravitreal Injections-related Anxiety|A Visual Approach to Reducing Anxiety and Improving Knowledge Transfer for Patients Receiving Intravitreal Injections||University Health Network, Toronto|Yes|Completed|September 2011|June 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|73|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035722||52535|
NCT02047643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29205|Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol|||Stanford University|No|Recruiting|January 2014|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|25 Years|No|||January 2014|January 24, 2014|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047643||51620|
NCT02036359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203009MIB|Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca|An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation.|Oncology|National Taiwan University Hospital|No|Recruiting|May 2012|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02036359||52486|
NCT02036658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-MBSR 10521038|Emotion Regulation During RCT of CBT vs. MBSR for Social Anxiety Disorder|fMRI of Emotion Regulation During RCT of CBT vs. MBSR for Social Anxiety Disorder||Stanford University|Yes|Active, not recruiting|March 2011|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02036658||52463|
NCT02036671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP-0001|Novel Endovascular Access Trial (NEAT)|Novel Endovascular Access Trial (NEAT): A Study of the FLEX System for Percutaneous AV Fistula Creation in Hemodialysis Patients|NEAT|TVA Medical Inc.|Yes|Active, not recruiting|January 2014|November 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036671||52462|
NCT02036333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00078909|The Role of Cerebral Oximetry in Pediatric Concussion Assessment|The Role of Cerebral Oximetry in Pediatric Concussion Assessment||Johns Hopkins University|No|Not yet recruiting|January 2014|||December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|This pilot study will employ a prospective cohort study design. Children aged 10-18 years        will be recruited within the Johns Hopkins Hospital Pediatric Emergency Department (JHH        PED) to participate in this study. All children must be conversant in English.|June 2014|June 23, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036333||52488|
NCT02036346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LarissaUH|Electrolyte Profile, Nutritional Status and Ileostomy Formation.|The Effect of Ileostomy Formation on Nutritional Status and Electrolyte Profile in Rectosigmoidectomy Patients: a Prospective Randomized Trial.||Larissa University Hospital|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|130|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036346||52487|
NCT02044458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#13-46E :Foley Catheter|Foley Catheter for Induction of Labor|A Randomized Control Trial of Foley Catheter Placement for Induction of Labor: Stylette Versus no Stylette||Aurora Health Care||Completed|April 2013|December 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02044458||51865|
NCT02045290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DX Insulin Clamp Ancillary|Insulin Clamp Ancillary Study for Assessment of Insulin Resistance|Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance||T1D Exchange Clinic Network Coordinating Center|Yes|Recruiting|January 2014|April 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|12 Years|19 Years|No|||October 2014|October 22, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02045290||51801|
NCT02045563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETIT PARI 2011|Genetic Polymorphisms, Steatosis and Diabetes|Genetic Polymorphisms, Hepatic Steatosis and Lipid Anomalies in Diabetic Patients||Centre Hospitalier Universitaire Dijon||Recruiting||||October 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|587|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of type 2 diabetes over 18 subjects treated with diet alone        or with oral antidiabetic glitazones outside of patients with type 1 and of age-matched        healthy volunteers and sex.|December 2012|January 23, 2014|January 21, 2014||||No||https://clinicaltrials.gov/show/NCT02045563||51780|
NCT02046421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1000|Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer||University of Chicago|No|Active, not recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02046421||51714|
NCT02046408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034253-01|Computer-Facilitated 5A's for Smoking Cessation in Primary Care|Computer-Facilitated 5A's for Smoking Cessation in Primary Care||University of California, San Francisco|No|Completed|July 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|1100|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046408||51715|
NCT02035280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEEDS|Prospective Evaluation of Elderly Deformity Surgery|Prospective Evaluation of Elderly Deformity Surgery: A Prospective Observational, Multicenter Study||AOSpine International|Yes|Recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|60 Years|N/A|No|Probability Sample|Elderly patients undergoing elective surgery for spinal deformity|December 2015|December 23, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02035280||52568|
NCT02035592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21478-C|The Health Effects of Blueberry Anthocyanins in Metabolic Syndrome (the CIRCLES-study)|The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.|CIRCLES|University of East Anglia|No|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|144|||Both|50 Years|74 Years|No|||November 2014|November 10, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035592||52545|
NCT02035605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-AT3SC-001|A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients|A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)||Alnylam Pharmaceuticals|No|Recruiting|January 2014|April 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02035605||52544|
NCT02045433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 082013-064|Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer|A Phase II Study for Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer (LACC)||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|18 Years|N/A|No|||March 2015|March 19, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045433||51790|
NCT02045706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS 2486|The Impact of Community Health Worker Training by US Health Volunteers on the Health of Rural Ugandans|A Randomized Prospective Trial to Measure Health-Related Behavioral Changes in Local Villagers Following The Implementation of a Village Health Team Program Facilitated by The Ugandan Ministry of Health and US Health Volunteers||Omni Med|Yes|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1419|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 22, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045706||51769|
NCT02044887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS772/B/13|Physical Activity to Patients With Dementia and Their Caregivers.|Physical Activity Program for Patients With Dementia and Their Relative Caregivers. Randomized Clinical Trial in Primary Health Care. APISDEMyF|AFISDEMyF|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044887||51832|
NCT02044900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-001-SJC|Polysomnography and Heart Rate Indexes in Obstructive Sleep Apnea|Polysomnography and Heart Rate Indexes in Obstructive Sleep Apnea||Universidade Castelo Branco|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|50|||Male|18 Years|50 Years|No|Probability Sample|primary care clinic|January 2014|January 23, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044900|1 Day|51831|
NCT02046811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA175231|Reducing Skin Cancer Risk in Childhood Cancer Survivors|Reducing Skin Cancer Risk in Childhood Cancer Survivors||Harvard School of Public Health|No|Enrolling by invitation|March 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Anticipated|801|||Both|30 Years|65 Years|No|||March 2015|March 4, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02046811||51684|
NCT02046785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemodinamica|Hemodynamic Measurements at Different Inclinations of the Head|Comparison of CVP Values , ΔPP and Echocardiographic at Different Angles Headwaters Before and After Volume Challenge|HMDIH|Federal University of Uberlandia|Yes|Recruiting|April 2013|May 2014|Anticipated|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|60 Years|No|||January 2014|January 24, 2014|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02046785||51686|
NCT02046525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312022|Autologous Fecal Therapy|Restoration of the Fecal Microbiome After Antimicrobial Exposure With Autologous Fecal Flora Restoration Therapy||Washington University School of Medicine|No|Active, not recruiting|March 2014|October 2015|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046525||51706|
NCT02035436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130025c|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function|Substudy of the NONSEDA Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function||Odense University Hospital|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035436||52556|
NCT02036047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exacto|The Effectiveness of an Exclusive Cold Snare Polypectomy Snare for the Removal of Diminutive Colorectal Polyps|||Showa Inan General Hospital|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|90 Years|No|||November 2014|November 2, 2014|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02036047||52510|
NCT02036060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003811-23|Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.|Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.|ABIDO|Spanish Oncology Genito-Urinary Group|No|Recruiting|February 2014|February 2020|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|119|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02036060||52509|
NCT02036073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZZ-EPO|Effect of Erythropoietin on Preterm Brain Injury||EPO|Zhengzhou Children's Hospital, China|Yes|Completed|January 2009|December 2013|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|490|||Both|N/A|72 Days|No|||January 2014|January 13, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02036073||52508|
NCT02036684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-201327|Prehabilitation for Prostate Cancer Surgery|A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy||University of Guelph-Humber|No|Recruiting|November 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Male|40 Years|80 Years|No|||December 2014|December 10, 2014|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02036684||52461|
NCT02036970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-1302|Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT|A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension||Reata Pharmaceuticals, Inc.|Yes|Recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|208|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036970||52439|
NCT02044471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35006|The IMPULSE Study: Pilot|The IMPULSE Pilot Study-- Investigating a Novel Synergy: Applying Ischemic Conditioning to Modulate the Altered Physiology From Contemporary continUous Flow Left Ventricular Assist Devices, to Reduce Stroke and Other Adverse Effects|IMPULSE|Baylor College of Medicine|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044471||51864|
NCT02044744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-08-5557|Physical Activity Referrals to the Community|Primary Care Physical Activity Referrals to the Community|PARC|University of California, Berkeley|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044744||51843|
NCT02043834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARPF-123|Virtual Reality-based Exercise in Older Adults|Promoting Virtual Reality-based Exercise to Prevent Falls in Older Adults: Pilot Study||University of Arizona|No|Completed|November 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|65 Years|N/A|No|||July 2014|July 25, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02043834||51913|
NCT02044055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver004|Mother-to-child Hepatitis D Transmission|Hepatitis D Virus (HDV) Mother-To-Child Transmission (MTCT) From Hepatitis B Virus (HBV)-Hepatitis D Virus (HDV) Co-infected Pregnant Women: a Retrospective Study.||Hopital Lariboisière|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|9 Months|15 Years|No|Non-Probability Sample|All children born in the Maternity Department, Lariboisiere Hospital, from HBV-HDV        co-infected women|September 2015|September 30, 2015|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02044055||51896|
NCT02046681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSMariaMisericordia|Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65|Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65. The MOSE65 Study|MOSE65|Azienda Ospedaliera S. Maria della Misericordia|Yes|Completed|June 2014|March 2015|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|65 Years|N/A|No|Probability Sample|individuals age 65 years or older initiating analgesic treatment po following emergency        department visits.|June 2014|March 2, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046681|2 Weeks|51694|
NCT02044848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2227|Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus|A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)||Novartis|No|Terminated|February 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|35 Years|No|||January 2016|January 19, 2016|January 22, 2014|Yes|Yes|This study was terminated prematurely by the Sponsor for business reasons only.|No|September 9, 2015|https://clinicaltrials.gov/show/NCT02044848||51835|
NCT02035618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSCar/CEP 270/2010|Exercises Associated or Not With Manual Therapy Shoulder Impingement|||Universidade Federal de Sao Carlos|No|Completed|September 2010|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|60 Years|No|||January 2014|January 13, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035618||52543|
NCT02035904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-006331-35|Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery|||IRCCS Policlinico S. Matteo|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||January 2014|January 13, 2014|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02035904||52521|
NCT02035917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392120|Comparison of Tibial Plateau Fractures Outcomes Treated With Non-locking and Locking Plate|||Isfahan University of Medical Sciences||Recruiting||||April 2014|Anticipated|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|19 Years|60 Years|No|||January 2014|January 11, 2014|January 11, 2014||||No||https://clinicaltrials.gov/show/NCT02035917||52520|
NCT02036229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|topical ivermectin, demodex|Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis|a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis||Rabin Medical Center|No|Recruiting|February 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 10, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02036229||52496|
NCT02045719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC2013|Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors|Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors|cat´sclaw|Faculdade de Medicina do ABC|No|Recruiting|December 2013|September 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|51|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02045719||51768|
NCT02045732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4351002|A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)|A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)||Pfizer|No|Terminated|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|55 Years|No|||January 2016|January 12, 2016|January 22, 2014|No|Yes|Study B4351002 was terminated on April 8, 2015, 2 due to a corporate decision not related to    safety or tolerability issues.|No||https://clinicaltrials.gov/show/NCT02045732||51767|
NCT02045680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SURN0014|RADOX' Reduced Abdominal Distension and Oxygen Delivery|Haemodynamic Changes and Oxygen Delivery in Patients Undergoing Laparoscopic Colorectal Surgery With Deep Neuromuscular Block|RADOX|Royal Surrey County Hospital NHS Foundation Trust|Yes|Recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective laparoscopic colorectal surgery over the age of 18years|September 2014|September 4, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02045680||51771|
NCT02046005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR047782-6121|Personalized Risk Estimator for Rheumatoid Arthritis Family Study|Communication of Biomarker, Genetic, and Lifestyle Risk Factor Profiles for Rheumatoid Arthritis to First Degree Relatives|PRE-RA|Brigham and Women's Hospital|No|Active, not recruiting|January 2014|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|222|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046005||51746|
NCT02046018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCU_AHSI|Integrated Community Case Management (ICCM) Delivered by Village Health Teams in Bushenyi District in Uganda|Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?||Healthy Child Uganda|Yes|Completed|October 2009|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|5000|||Both|N/A|59 Months|Accepts Healthy Volunteers|||July 2014|July 9, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02046018||51745|
NCT02035137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2011-01|131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat|NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma|N2011-01|New Approaches to Neuroblastoma Therapy Consortium|Yes|Recruiting|July 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|2 Years|30 Years|No|||December 2015|December 11, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035137||52579|
NCT02047071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/00743|Effect of CPAP Treatment in Women With Moderate-to-severe OSA.|Effect of Continuous Positive Airways Pressure (CPAP) in Women With Moderate-to-severe Obstructive Sleep Apnea (OSA). A Multicenter, Randomized, Controlled Trial.||Sociedad Española de Neumología y Cirugía Torácica|No|Completed|February 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Female|18 Years|75 Years|No|||August 2015|August 17, 2015|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02047071||51664|
NCT02047084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Venous Leg Ulcer Head to Head|Comparison of Human Allograft to Apligraf for Venous Leg Ulcers|Proposal for a Single [Multi] Center Site Randomized, Prospective Controlled Head-to-head Clinical Trial Comparing a Bioengineered Skin Substitute to a Biologically Active Human Skin Allograft for the Treatment of Venous Leg Ulcers.||Soluble Systems, LLC|Yes|Recruiting|June 2013|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|21 Years|90 Years|No|Probability Sample|Patients with Chronic Venous Leg wounds|January 2014|January 25, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02047084|5 Months|51663|
NCT02036086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28606|Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases|A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.||Sunnybrook Health Sciences Centre|No|Recruiting|August 2015|October 2022|Anticipated|October 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02036086||52507|
NCT02036099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL129896|Driving in Mild Dementia Decision Tool|Driving in Mild Dementia Decision Tool|DMD-DT|Sunnybrook Health Sciences Centre|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02036099||52506|
NCT02035735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 203 02|Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers|Usefulness of Narrow-band Imaging to Estimate the Superficial Spread of Squamous Cell Carcinomas in Oropharynx, Hypopharynx and Larynx||University Hospital, Toulouse|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|87|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035735||52534|
NCT02035748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-056|Assessment of Patients Treated With JETREA® for Vitreomacular Traction|Assessment of Anatomical and Functional Outcomes in Patients Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)||Alcon Research|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|628|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|January 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02035748||52533|
NCT02036697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013060|Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section|Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section||University of Manitoba|No|Recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|40|||Female|18 Years|40 Years|No|||September 2013|June 23, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02036697||52460|
NCT02036710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI-20810|Location of GLP-1 Release|Location of Glucagon-Like Peptide (GLP)-1 Release||University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2011|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population consisted of morbidly obese individuals who had decided to undergo open        duodenal switch surgery|March 2014|March 26, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02036710||52459|
NCT02036983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308124192|Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair|Comparison of an Ultrasound Guided Bilateral Transversus Abdominis Plane Block With Dexamethasone and Preperitoneal Instillation of Local Anesthetic With Dexamethasone to a Standard Anesthetic Technique for Analgesic Efficacy and Patient Satisfaction Following a Total Extraperitoneal Bilateral Inguinal Hernia Repair: A Prospective Randomized Single Blinded Study||Indiana University|No|Active, not recruiting|November 2013|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02036983||52438|
NCT02037217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET001K|ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor||InSightec|Yes|Completed|February 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037217||52420|
NCT02037230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.094|Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas|Phase 1 DOSE ESCALATION TRIAL OF THE Wee1 INHIBITOR MK1775, IN COMBINATION WITH GEMCITABINE (+RADIATION) FOR PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREAS||University of Michigan Cancer Center|Yes|Recruiting|January 2014|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037230||52419|
NCT02045030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CROC-04|Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer|A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy||CR-CSSS Champlain-Charles-Le Moyne|No|Active, not recruiting|January 2014|August 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||July 2015|October 26, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045030||51821|
NCT02045875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-5816|Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence|Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence||Asthma Management Systems|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02045875||51756|
NCT02045888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVER|Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears|Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study in Patients With Documented Grade II Hamstring Tears Treated With Intramuscularly Delivered Adipose Derived Regenerative Cells - RECOVER|RECOVER|Cytori Therapeutics|Yes|Withdrawn|January 2014|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|60 Years|No|||November 2014|November 19, 2014|January 13, 2014|Yes|Yes|Withdrawn (No Participants Enrolled)|No||https://clinicaltrials.gov/show/NCT02045888||51755|
NCT02046161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310073RINA|Comparison of Colon Cleansing Quality Between the Setting of Colon Cleansing Room and the Standard Colon Preparation in a Community Base Setting -- a Prospective Randomized Controlled Trial|Comparison of Colon Cleansing Quality Between the Setting of Colon Cleansing Room and the Standard Colon Preparation in a Community Base Setting -- a Prospective Randomized Controlled Trial||National Taiwan University Hospital|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|130|||Both|50 Years|N/A|No|||July 2014|July 29, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02046161||51734|
NCT02044549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carbitocin|Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section|Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section||Cairo University|No|Completed|June 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||||||Female|18 Years|39 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044549||51858|
NCT02044562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-07-08|Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients|Study of Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients Receiving Concurrent Chemo-radiotherapy||Capital Medical University|No|Recruiting|September 2013|September 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|60 Years|No|||January 2014|January 22, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044562||51857|
NCT02044861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-PFK-01|Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies|Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies||Advanced Cancer Therapeutics|No|Recruiting|March 2014|||September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044861||51834|
NCT02044874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-035|A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation|A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation||Arena Pharmaceuticals|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|603|||Both|18 Years|65 Years|No|||May 2015|May 4, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044874||51833|
NCT02035631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICOP|Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention|Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention|PREDICOP|Institut Català d'Oncologia|No|Not yet recruiting|January 2014|January 2022|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Female|18 Years|75 Years|No|||January 2014|January 13, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035631||52542|
NCT02035930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWang|Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle|Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle||Fudan University|Yes|Completed|November 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|110|||Female|24 Years|40 Years|No|||January 2014|January 11, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035930||52519|
NCT02035943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127|Tight Glycemic Control and Insulin Administration During Parenteral Nutrition|Tight Glycemic Control and Insulin Administration During Parenteral Nutrition, in Critical Ill Patients||Policlinico Hospital|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|16 Years|N/A|No|||January 2014|January 13, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT02035943||52518|
NCT02038881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-037|Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection|Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection||Bavarian Nordic|Yes|Recruiting|April 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|45 Years|No|||October 2015|November 30, 2015|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038881||52292|
NCT02046031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-YXPU-ZS-IV3|Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.|Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|July 13, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02046031||51744|
NCT02046044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK&DU-Iva-Dig2014|Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction|Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm|DIVA-REF|Kocaeli University|No|Recruiting|January 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2014|January 23, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02046044||51743|
NCT02046538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014302|Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer|Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer||Weill Medical College of Cornell University|Yes|Not yet recruiting|February 2014|February 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046538||51705|
NCT02039154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062012-055|The Effect of Long Duration Exercise on the Diastolic Function of the Heart|The Effect of Long Duration Exercise on the Diastolic Function of the Heart|PEP|University of Texas Southwestern Medical Center|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02039154||52271|
NCT02034877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851140|13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India|A Phase 4/3, Open-label, Single-arm, Multicenter Study To Describe The Safety And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Adults 50 To 65 Years Of Age And In Children 6 To 17 Years Of Age In India||Pfizer|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1200|||Both|6 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034877||52599|
NCT02035423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRI-1390|Community Interventional Trial (CITFOMIST)|Community Interventional Trial (CITFOMIST) to Study the Efficacy and Compliance of Different Degrees of Vitamin D Fortified Milk|CITFOMIST|Tehran University of Medical Sciences|Yes|Completed|January 2011|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|6000|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02035423||52557|
NCT02034890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-7350|Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection|Is Intra - Neobladder Installations of Hyaluronic Acid, Effective in Reducing Neobladder Orthotropic Reconstruction Post-operative Urinary Tract Infections?||Rabin Medical Center|Yes|Not yet recruiting|July 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 9, 2014|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034890||52598|
NCT02036424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA 003|Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema|A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema||Maturi, Raj K., M.D., P.C.|Yes|Completed|January 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 13, 2014|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT02036424||52481|
NCT02036723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALATIR/BCD-021-3|Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration|Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration|GALATIR|Biocad||Not yet recruiting|June 2016|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|50 Years|80 Years|No|||December 2015|January 12, 2016|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036723||52458|
NCT02037009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC_JMD_2013-1|Centralised Anesthesic Monitoring in the Surgery of the Ocular Anterior Segment: Non Inferiority Study|Centralised Anesthesic Monitoring in the Surgery of the Ocular Anterior Segment: Non Inferiority Study|SACHS|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Completed|November 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|900|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037009||52436|
NCT02036372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 41467.018.12|Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus|PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II|PILGRIM|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|315|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02036372||52485|
NCT02036385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-HRA-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||January 13, 2014|March 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036385||52484|
NCT02036398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-6405|Tubeless Versus Standard Upper Pole Percutaneous Nephrolithotomy|Comparison of Complications Between Patients Undergoing Standard Percutaneous Nephrolithotomy With Nephrostomy Tube Placement and Tubeless Percutaneous Nephrolithotomy With Double J Stent Only Placement||Rabin Medical Center|No|Recruiting|January 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036398||52483|
NCT02036411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEH GynObs-5|Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B|Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B||Bagcilar Training and Research Hospital|No|Enrolling by invitation|September 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Women receiving infertility treatment|January 2014|January 13, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02036411||52482|
NCT02037269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-001|LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens|A Pilot Study to Evaluate Cerenkov Luminescence Imaging for Measuring Margin and Lymph Node Status in Breast Cancer Surgical Specimens||Lightpoint Medical Limited|No|Recruiting|June 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Female|30 Years|N/A|No|Non-Probability Sample|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving        surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection        (ALND)|March 2016|March 11, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037269||52416|
NCT02036996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-CLC-2013_Prot_4|Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined|Official Title Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined||EarlySense Ltd.|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Different patient population will be monitored including obese, morbidly obese, patients        with or without apnea, patients with or without arrhythmia as well as healthy population        who arrive to sleep lab for general evaluation will be monitored|January 2016|January 7, 2016|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036996||52437|
NCT02037555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1307|Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass|A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass||Grifols Therapeutics Inc.|No|Recruiting|March 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|404|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037555||52394|
NCT02045901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-301|A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents|A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents|PED-301|Duchesnay Inc.|No|Recruiting|February 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045901||51754|
NCT02047253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130725012 (UAB 1336)|Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment|A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors||University of Alabama at Birmingham|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|19 Years|N/A|No|||February 2016|February 23, 2016|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047253||51650|
NCT02045641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-246-13|Pleural and Pericardial Effusion Following Open Heart Surgery|The Clinical Impact of an Aggressive Approach Towards Pleural and Pericardial Effusions Following Open Heart Surgery: a Step Towards Standard Guidelines|IMAGING|Aarhus University Hospital Skejby|Yes|Completed|September 2013|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045641||51774|
NCT02044354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004243-22|Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer|A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer|CABA-DOC|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|January 2014|May 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|174|||Male|18 Years|N/A|No|||February 2016|February 5, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044354||51873|
NCT02044367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.194|Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers|Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study)||Boehringer Ingelheim||Completed|January 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|January 22, 2014||||No|April 10, 2015|https://clinicaltrials.gov/show/NCT02044367||51872|
NCT02044341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR01.006|Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media|A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years|AR01006|Arbor Pharmaceuticals, Inc.|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|2 Months|18 Years|No|||March 2015|March 19, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044341||51874|
NCT02044601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0556|Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)|Phase I/II Trial Using a Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2014|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044601||51854|
NCT02044588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWC-001|Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients|The Outcomes of Kidney Transplantation Between Recipients Receiving Graft From Donors With Positive and Negative HBsAg||Chulalongkorn University|Yes|Recruiting|January 2000|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|All kidney transplant recipients from January 1, 2000 until the present (upto year 2013)        were prospective follow-up.|January 2014|January 22, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02044588|10 Years|51855|
NCT02039141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203007572|Diabetes Prevention Program for Obese Latino Youth|Community-Based Diabetes Prevention Program for Obese Latino Youth: Every Little Step Counts|ELSC|Arizona State University|Yes|Active, not recruiting|April 2012|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02039141||52272|
NCT02034864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110142|Comparison of the Effectiveness of 2 Manual Therapies Administered by Osteopaths on Functional Outcome in Sub-acute and Chronic Low Back Pain|Comparison of the Effectiveness of 2 Manual Therapies Administered by Osteopaths on Functional Outcome in Sub-acute and Chronic Low Back Pain Less Than 1 Year Duration: a Randomised Controlled Trial|LC OSTEO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2014|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034864||52600|
NCT02035163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIP|Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi|Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi||Seoul St. Mary's Hospital|No|Recruiting|October 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|N/A|N/A|No|||November 2014|November 18, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035163||52577|
NCT02035449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McGrath MAC 1|Video Laryngoscopy in Pre-hospital Critical Care|||University of Aarhus|No|Recruiting|December 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|15 Years|N/A|No|Probability Sample|Patients in the Central Region of Denmark where the anaesthesiologists on the        participating pre-hospital critical care teams attempt prehospital endotracheal        intubation.|December 2013|January 10, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035449||52555|
NCT02035150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-022|Effect of Different Fiber Breakfasts on Appetite and Weight Change in Overweight Subjects|The Effect of Ingesting Breakfasts Varying in Fiber on Appetite and Weight Change in Overweight Subjects||New York Obesity and Nutrition Research Center|No|Completed|March 1998|December 2002|Actual|February 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02035150||52578|
NCT02036736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120702|Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring - COGNIDES|Randomized Study Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring|Cognides|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||March 2013|December 19, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036736||52457|
NCT02037022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-28314|Pivotal Response Treatment Package for Young Children With Autism|Pivotal Response Treatment Package for Young Children With Autism|PRT-P|Stanford University|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|2 Years|5 Years|No|||December 2015|December 2, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037022||52435|
NCT02037035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305011972|Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling|Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling||Yale University|No|Recruiting|July 2013|||July 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|November 19, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02037035||52434|
NCT02037308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/18G|Glu298Asp Polymorphism and Blood Pressure|The Effects of Beetroot Bread on Postprandial Blood Pressure According to Glu298Asp Polymorphism in the eNOS Gene||University of Reading|Yes|Completed|June 2010|December 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037308||52413|
NCT02037321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetaVeg2013|Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk|Effect of Substituting Vegetable Protein for Animal-Protein on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Feeding Trials to Provide Evidence-Based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|May 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Varied|May 2015|May 26, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037321||52412|
NCT02037282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140043|A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects|A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037282||52415|
NCT02037295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914045|Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans|Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|June 3, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037295||52414|
NCT02037581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KQ1002B|Integrated Care Including Assertive Community Treatment in Early Psychosis|Integrated Care in Early Psychosis (ICEP Study): a 12-month Quasi Experimental Study With Historic Control Group|ICEP|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|June 2011|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|29 Years|No|||July 2015|July 13, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037581||52392|
NCT02046980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-0001|Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo|||Keimyung University Dongsan Medical Center|No|Completed|September 2013|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|209|||Both|19 Years|80 Years|No|||February 2016|February 12, 2016|January 25, 2014||No||No|December 4, 2015|https://clinicaltrials.gov/show/NCT02046980||51671|
NCT02043613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130130|Context Effects in Exercise Therapy for Knee and/or Hip Pain|Effect of Physical Surroundings on Effects From Exercise as Treatment for Hip or Knee Pain: A Double-blind Randomized Controlled Clinical Trial|CONEX|University of Southern Denmark|No|Completed|February 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|35 Years|N/A|No|||March 2015|March 26, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043613||51930|
NCT02015481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBCO-001|Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients|Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients|HOPEMD|Bioblast Pharma Ltd.|No|Active, not recruiting|February 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|October 10, 2015|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02015481||54088|
NCT02014909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN3379-CL-001|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors|Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy||Kolltan Pharmaceuticals, Inc.|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014909||54131|
NCT02044926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-1472-0002|Intraductal Papillary Mucinous Neoplasm With Malignant Change|Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012||Asan Medical Center|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|93|||Both|20 Years|N/A|No|Probability Sample|Patents who are suspected to have pancreas IPMN by clinicians or imaging studies|December 2015|December 28, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02044926||51829|
NCT02045186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1338|Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)|Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT)||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|December 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045186||51809|
NCT02044913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0421-FSCP-Z202|Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety|Randomized-controlled Trial of Aftercare-Coordination by Phone for Patients With Depression and Anxiety Subsequent to an Inpatient Treatment.||Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|218|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044913||51830|
NCT02045173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1332|Automate Detection of Sleep Apnea by ApneascanTM|Screening for Sleep-disordered Breathing in Routine Cardiology Practice: Validation of the Apnea + Hypopnea Detection by an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy-defibrillator (CRT-D) With Impedance-based Respiration Sensor (ApneaScanTM)|AIRLESS|University Hospital, Grenoble|Yes|Recruiting|January 2014|January 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02045173||51810|
NCT02038400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00490-45|Efficacy of KNT® (KINETUBE) in Recurrent Chronic Otitis Media in Children|Evaluation of the Efficiency of KINETUBE® in the Recurrent Chronic Tubal Ear Otitis Care (Otitis Media With Effusion, Atelectatic Otitis or Retraction) in Children With an Age Range of 7-15 Years.|KINETUBE|Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|November 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|7 Years|15 Years|No|||March 2013|January 15, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02038400||52329|
NCT02038673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5878-CL-0101|An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors|An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors||Astellas Pharma Inc|No|Recruiting|November 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|N/A|No|||March 2016|March 16, 2016|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038673||52308|
NCT02038894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0100|Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies|Comparison Of Different Anesthetic Techniques In Children Undergoing Esophagogastroduodenoscopies||Children's Hospital Medical Center, Cincinnati|No|Completed|December 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|179|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||July 2015|September 25, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02038894||52291|
NCT02035774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSNB|A Novel Selective Block of the Suprascapular Nerve|A Novel Selective Block of the Suprascapular Nerve||University Hospital of North Norway|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2014|June 16, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035774||52531|
NCT02035761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS044233|PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)|Pathogenesis and Diagnosis of Multiple System Atrophy (MSA): PET Study of Neurochemical and Autonomic Disorders in MSA||University of Michigan|No|Recruiting|July 2011|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples With DNA|DNA Banking (this is optional): Subjects will have whole blood drawn sample for DNA banking      to support genetic research of human disease and human genetic factors. About two      tablespoons (approximately 20 ml) of blood will be taken from you. The blood will be shipped      to the laboratory of Dr. Philip Low, Mayo Clinic, MN. Dr. Low's laboratory will extract the      DNA. Members of the North American MSA - Study Group and their collaborators will use the      DNA to try to find out if changes in certain genes are associated with MSA. The samples will      be used for the preparation of DNA, and possibly, an immortalized cell line. The cell line,      DNA, and accompanying data will be distributed to scientists including those in research,      teaching, and industry. The samples may be kept indefinitely. The samples and accompanying      information will be used for studying of many disorders and genetic factors, not just MSA.|Both|30 Years|80 Years|No|Non-Probability Sample|Possible or Probable Multiple System Atrophy of either Parkinsonian or Cerebellar sub-type|July 2015|July 15, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035761||52532|
NCT02037334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2013-0244|Biomechanics Based Prediction of Preterm Delivery|Biomechanics Based Prediction of Preterm Delivery|Softcervix|University of Zurich|No|Recruiting|April 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women at our institutions at 20 weeks of pregnancy and postpartum|February 2015|February 4, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037334||52411|
NCT02037607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208009386|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures||Indiana University|No|Completed|September 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|1 Month|12 Years|No|Non-Probability Sample|100 children between the ages of 1 month-12 years having an elective neurosurgical        procedure and James Whitcomb Riley Hospital for Children.|August 2015|August 24, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037607||52390|
NCT02037620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB140483CVEpiStim|Recovery of Cardiovascular Function With Epidural Stimulation After Human Spinal Cord Injury|Recovery of Cardiovascular Function With Epidural Stimulation After Human Spinal Cord Injury||University of Louisville|No|Recruiting|January 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|N/A|N/A|No|||January 2016|January 8, 2016|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037620||52389|
NCT02037360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305012015|Mobile Mindfulness Training for Smoking Cessation|||University of Massachusetts, Worcester|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037360||52409|
NCT02037893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNX-CL-001|Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media|A Four-arm, Randomized, Double-blind, Active and Placebo Controlled Study to Determine the Safety and Efficacy of a Combination Antupyrine and Benzocaine Otic Solution Compared With Antipyrine Otic Solution Alone, Benzocaine Otic Solution Alone and to Placebo Otic Solution to Relieve Pain Symptoms in Children With Acute Otitis Media.||Pernix Theraputics LLC|No|Completed|November 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|112|||Both|2 Months|12 Years|No|||January 2014|November 19, 2014|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037893||52368|
NCT02037594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349555-6|Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting|Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting|SPARK|Hunter College|Yes|Recruiting|January 2014|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|445|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037594||52391|
NCT02037880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSIII-1|Natural History Studies of Mucopolysaccharidosis III|Natural History Studies of Mucopolysaccharidosis III||Nationwide Children's Hospital|Yes|Completed|February 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples With DNA|Biobanking will include:        1. Serum/Plasma        2. Cerebrospinal fluid|Both|2 Years|N/A|No|Non-Probability Sample|Individuals affected by MPS IIIA or MPS IIIB will be considered for this study.|November 2015|November 12, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02037880||52369|
NCT02047539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401013288|Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis|Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Patients With the Clinical Risk Syndrome for Psychosis||Yale University|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|19 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047539||51628|
NCT02047552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0089|Pilot Study of Goal-Directed Iron Supplementation +/- Oxandrolone for Functional Iron Deficiency of Critical Illness|A Randomized Controlled Pilot Study of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients With Functional Iron Deficiency, With and Without Oxandrolone||Denver Health and Hospital Authority|Yes|Not yet recruiting|April 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|January 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047552||51627|
NCT02044302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kwei11.13.13|A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction|A Prospective Randomized Double Blind Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction||Yale University|No|Recruiting|April 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|N/A|No|||July 2015|July 2, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044302||51877|
NCT02015208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424XCA03T|Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia|A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions||Sunnybrook Health Sciences Centre|Yes|Recruiting|April 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|65 Years|N/A|No|||April 2014|April 21, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02015208||54109|
NCT02014922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/439/13/AVR|A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)|A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products|DUNLIN|University of Waterloo|No|Completed|December 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02014922||54130|
NCT02015793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-232|Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease|A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein||AbbVie|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|70 Years|No|||February 2015|February 23, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015793||54064|
NCT02044627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-011|Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002|A Phase 1, Open-Label,Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 in Healthy Male Volunteers||Esperion Therapeutics|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02044627||51852|
NCT02044640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00480|Identifiable Factors That May Lead to Postoperative Nausea and Vomiting After Simple Laparoscopic Appendectomy|||Nationwide Children's Hospital|No|Withdrawn|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing a laparoscopic appendectomy|June 2015|June 3, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044640||51851|
NCT02045199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00111 CR 0 02|Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.|||Pierre Fabre Medicament||Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|193|||Both|18 Years|80 Years|No|||April 2015|April 24, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02045199||51808|
NCT02045212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-ON-001|Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).|A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).||Regenera Pharma Ltd|No|Recruiting|February 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02045212||51807|
NCT02045446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092013-070|Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial|Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial||University of Texas Southwestern Medical Center|Yes|Recruiting|February 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045446||51789|
NCT02045693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-108|Drug Interaction & Methadone & Buprenorphine|A Phase1, Open-Label, Drug-Drug Interaction Study Between Methadone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC + 75mg BMS-791325 and Between Buprenorphine/Naloxone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC +75mg BMS-791325||Bristol-Myers Squibb|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02045693||51770|
NCT02038907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-107|Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine|A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted With or Without Monophosphoryl Lipid A and Aluminum Hydroxide in Adults|NOR-107|Takeda|No|Completed|March 2014|September 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|14||Actual|420|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038907||52290|
NCT02034669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-VD-2012|Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment|A Phase II Study of Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Completely Acute Spinal Cord Injury.||Tri Phuoc Biotechnology., JSC|Yes|Recruiting|February 2013|March 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|19 Years|60 Years|No|||January 2014|January 10, 2014|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034669||52615|
NCT02034903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5283|Effect of Feed Warming Method on Feeding Tolerance in the Preterm Infant Born at Less Than 30 Weeks Gestation|Effect of Feed Warming Method on Feeding Tolerance in the Preterm Infant Born at Less Than 30 Weeks Gestation||Advocate Center for Pediatric Research|Yes|Recruiting|November 2013|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|86|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 13, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02034903||52597|
NCT02036125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-143|Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection|Syndrome du Tunnel Carpien - Essai Clinique randomisé évaluant l'efficacité de l'Utilisation de l'échographie Lors de l'Infiltration de corticostéroïdes|STC-EI|Université de Sherbrooke|No|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2014|December 13, 2014|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02036125||52504|
NCT02036112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELAPE1127|Conventional Versus Individual Extralvator Abdominoperineal Excision for Advanced Lower Rectal Cancer|Randomized Clinical Trial of Conventional Versus Individual Extralevator Abdominoperineal Excision for Locally Advanced Lower Rectal Cancer|ELAPE|Beijing Chao Yang Hospital|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2014|January 12, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02036112||52505|
NCT02037074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6308-003|Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics|A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen||FORUM Pharmaceuticals Inc||Completed|June 2014|||December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|60 Years|No|||January 2015|January 9, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037074||52431|
NCT02037347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901004673|Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis|Palifermin Treatment of Toxic Epidermal Necrolysis||Yale University|No|Recruiting|October 2010|||February 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037347||52410|
NCT02037633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|478-9227/25-7-2012|Analgesia for Positioning Hip Fracture Patients for Spinal Anesthesia|Fascia Iliaca Compartment Block Versus Fentanyl for Positioning Patients With Hip Fractures for Central Nervous Blockade: a Randomized Trial.||Asklepieion Voulas General Hospital|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|N/A|N/A|No|||January 2014|January 15, 2014|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02037633||52388|
NCT02037373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-215|Post-Marketing Requirement to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.|Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.||Octapharma|Yes|Recruiting|August 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Study population will include patients undergoing orthotopic liver transplantation|August 2015|August 27, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037373||52408|
NCT02037646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|926.24|Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral|Evaluating the Effectiveness of Screening Strategies Using Quantitative Versus Qualitative Fecal Immunochemical Test (FIT) to Prioritize Urgency of Colonoscopy Referral - a Randomized Controlled Trial Protocol||University of Malaya|Yes|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|700|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037646||52387|
NCT02037659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dermabond|Dermabond Treatment for Gastric Variceal Bleeding|Endoscopic Ultrasound (EUS) Gastric Variceal Bleeding Database Repository||Indiana University|No|Recruiting|December 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients treated with DermaBond for gastric varices.|November 2015|November 11, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037659|36 Months|52386|
NCT02038205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|336315|Ultrasonographic Measurements of the Median Nerve Before and After Splinting for Carpal Tunnel Syndrome|High Resolution Ultrasonographic Measurements of the Median Nerve Before and After Wrist Splinting for Carpal Tunnel Syndrome||University of California, Davis||Recruiting|January 2014|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Those with diagnosis of carpal tunnel syndrome, and healthy control subjects with no        symptoms of CTS.|December 2015|December 9, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02038205||52344|
NCT02038465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5539|Cognitive Remediation of Autobiographical Memory in Schizophrenia Using SenseCam®|REMEDIATION COGNITIVE DE LA MÉMOIRE AUTOBIOGRAPHIQUE DANS LA SCHIZOPHRENIE AU MOYEN DE SENSECAM||University Hospital, Strasbourg, France||Not yet recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|January 14, 2014|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02038465||52324|
NCT02015221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTitouch EOU|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort||Tactile Medical|No|Completed|November 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02015221||54108|
NCT02015806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-00009085|Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices|Assessing the Impact of Low-Touch Devices on Medication Adherence|REMIND|Brigham and Women's Hospital||Completed|March 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|14||Actual|53480|||Both|18 Years|64 Years|No|||January 2016|January 7, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02015806||54063|
NCT02037503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-TH-0270-CTIL|Oral Ketamine for Suicidal Ideation|Effect of Oral Ketamine Treatment on Suicidal Ideation and Drug Resistant Major Depression, a Clinical and fMRI Study||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|No|||January 2014|January 15, 2014|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037503||52398|
NCT02044939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_23/1917|Pulmonary Rehabilitation in Patients With Sarcoidosis|Pulmonary Rehabilitation in Fibrotic Pulmonary Sarcoidosis (Stage IV): Randomized Controlled Trial||University Hospital, Lille|No|Recruiting|June 2012|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044939||51828|
NCT02045459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16821|Microvascular Disease Exercise Trial|Assessment of Perfusion Reserve and Effects of Exercise in Microvascular Angina|MOVE|University of Virginia|Yes|Recruiting|May 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|165|||Both|18 Years|85 Years|No|||December 2015|December 28, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02045459||51788|
NCT02038387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|717/12|Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)|Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano||University of Roma La Sapienza||Recruiting|July 2012|||December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|40 Years|70 Years|No|||January 2014|January 14, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02038387||52330|
NCT02034916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|673-201|A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)|A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer|ABRAZO|Medivation, Inc.||Recruiting|January 2014|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034916||52596|
NCT02035176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 9747|Novel Measure of Social Deficits in Children|Oregon Animation Test for Social Reciprocity (OATS)|OATS|Oregon Health and Science University|No|Recruiting|February 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|||Both|6 Years|11 Years|Accepts Healthy Volunteers|Probability Sample|Children 6-11 years of age with autism, ADHD, or typical, with and IQ exceeding 70.|November 2014|November 21, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02035176||52576|
NCT02035475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-13-00471|Prevention of Lymphoceles After Robotic PLND|A Pilot Clinical Trial for the Prevention of Lymphoceles After Robotic Pelvic Lymph Node Dissections for Prostate Malignancies Using the da Vinci® EndoWrist® One™ Vessel Sealer|PLND|OhioHealth|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|120|||Male|18 Years|N/A|No|||July 2014|October 13, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035475||52554|
NCT02036749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1293|Ultrasound-guided Quadratus Lumborum Block for Postoperative Pain Relief After Cesarean Delivery|Ultrasound-guided Quadratus Lumborum Block for Postoperative Pain Relief After Cesarean Delivery||Oslo University Hospital|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|40|||Female|18 Years|45 Years|No|||October 2015|October 6, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036749||52456|
NCT02036762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFMUSP 1295/09|STRETCH OF RESPIRATORY MUSCLES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE|EFFECTS OF RESPIRATORY MUSCLE STRETCH ON THORACOABDOMINAL MECHANIC, FUNCTIONAL CAPACITY, PSYCHOLOGICAL AND SOCIAL ASPECTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE||University of Sao Paulo|Yes|Completed|November 2011|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|80 Years|No|||January 2014|January 13, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02036762||52455|
NCT02036437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|elkont1984|Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor|Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor: a Randomized Control Trial||Ain Shams University|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 17, 2014|January 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02036437||52480|
NCT02037087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|newborn2013|The Impact of Prenatal Short Messages (SMS) on Maternal and Newborn Health|The Impact of Prenatal Short Messages on Maternal and Newborn Health|SMS|Harvard School of Public Health|Yes|Active, not recruiting|September 2013|October 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|5200|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|September 11, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037087||52430|
NCT02037685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1KG11|Improving Adherence to Statins Among Minority Populations|Improving Adherence to Cholesterol Lowering Medications Among Minority Populations in Florida: A Randomized Trial||University of Miami|No|Completed|June 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|779|||Both|35 Years|85 Years|No|||January 2016|January 21, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037685||52384|
NCT02037945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-199|18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases|18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases||Memorial Sloan Kettering Cancer Center||Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|21 Years|N/A|No|||February 2016|February 23, 2016|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02037945||52364|
NCT02037672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAXAS|PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome|Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome||University Medical Centre Ljubljana|No|Completed|September 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|55 Years|No|||January 2014|January 21, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037672||52385|
NCT02037958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGHLMAS2010|Laryngeal Mask Airway Supreme Versus the Tracheal Tube as an Airway Device in Elective Laparoscopic Cholecystectomy|The Laryngeal Mask Airway Supreme (TM) is an Effective Alternative to Laryngoscope-guided Tracheal Intubation for Patients Undergoing Elective Laparoscopic Cholecystectomy-- A Prospective Randomized Controlled Trial||Changi General Hospital|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|76|||Both|21 Years|80 Years|No|||January 2014|January 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037958||52363|
NCT02037906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/3948/IRB|Escalating, Constant and Reduction Energy Output in SWL for Renal Stones|Comparison of Escalating, Constant and Reduction Energy Output in SWL for Renal Stones: Multi-arm Prospective Randomized Study.|SWL|Princess Al-Johara Al-Ibrahim Cancer Research Center|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|30 Years|60 Years|No|||January 2014|April 30, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02037906||52367|
NCT02038218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI-022|Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors|A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System|DM-CHOC-PEN|DEKK-TEC, Inc.|Yes|Recruiting|September 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038218||52343|
NCT02014896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCH01|Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)|Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)|BASE|Ischemia Care LLC|Yes|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|Samples Without DNA|Biospecimen will be whole blood samples.|Both|18 Years|N/A|No|Probability Sample|Subjects eligible for enrollment include:          1. Ischemic stroke within 8 hours of symptom onset.          2. Transient Ischemic Attack (TIA) within 8 hours of symptom onset.          3. Non-ischemic transient neurologic event (TNE) within 8 hours of onset.          4. Normal controls that will be non-neurologic patients who are matched with the other             ischemic stroke and TIA patients for age, race, gender and smoking plus one or more             of the following vascular risk factors: diabetes, hypertension, atrial fibrillation,             hyperlipidemia.|January 2016|January 14, 2016|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02014896||54132|
NCT02014610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 13-15|White Blood Cell Counts and Onset of Cardiovascular Diseases: a CALIBER Study|Leukocyte Counts and Initial Presentation of Cardiovascular Diseases: a CALIBER Study|CALIBER|University College, London|Yes|Active, not recruiting|January 1997|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800000|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohort study of patients in the CALIBER database who have a record of a full blood count        (complete blood count) during the study period while registered at one of 225 general        practices contributing data to CPRD (the Clinical Practice Research Datalink) and        consenting to data linkage.|December 2013|December 12, 2013|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014610||54154|
NCT02015533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102898|A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 Following Single Intravenous Administration||Janssen Pharmaceutical K.K.|No|Not yet recruiting|December 2013|April 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|December 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015533||54084|
NCT02038088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LKZ-GAHBV-01|The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication|The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication|HBV|Southwest Hospital, China|Yes|Completed|January 2014|January 2015|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples With DNA|serum|Both|18 Years|65 Years|No|Probability Sample|patients with HBV infection receive surgery under general anesthesia|January 2015|January 27, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038088|4 Days|52353|
NCT02038101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCHTTE-001|A Multi-centered Feedback and Education Intervention Designed to Reduce Inappropriate Transthoracic Echocardiograms|Feedback and Education Intervention to Reduce Inappropriate Transthoracic Echocardiograms (TTE)||Women's College Hospital|No|Recruiting|December 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|256|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 15, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038101||52352|
NCT02038647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14018|Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)|A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038647||52310|
NCT02038660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-10|Drug-Eluting Balloon Registry in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study|IRIS DEB|Asan Medical Center|Yes|Recruiting|January 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|Patients treated with balloon angioplasty|November 2015|November 10, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038660||52309|
NCT02035189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202342|Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients|Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes||University of Arkansas|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients with Multiple Myeloma at UAMS receiving Stem Cell transplantation|March 2015|March 2, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02035189||52575|
NCT02035202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100417|Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness|Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness||University of California, San Diego|Yes|Recruiting|October 2013|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|18 Years|55 Years|No|||January 2014|January 10, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02035202||52574|
NCT02035488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tobra-02|Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis|Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis||University Medical Center Groningen|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|December 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02035488||52553|
NCT02035501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SimonEdvardson1|Treatment of TNNT1-Myopathy With L-Tyrosine.|Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.||Hadassah Medical Organization||Enrolling by invitation|January 2014|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|20 Years||||January 2014|January 13, 2014|July 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035501||52552|
NCT02035787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1326|Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients|Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035787||52530|
NCT02035800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 11-0163|Bone Resorption, Osteoclastogenesis and Adalimumab|Bone Resorption, Osteoclastogenesis and Adalimumab|BROCAII|Université de Sherbrooke|Yes|Recruiting|May 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02035800||52529|
NCT02036463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINRG0513|A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy|CINRG0513: A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Withdrawn|November 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|0|||Male|3 Years|6 Years|No|||February 2015|February 13, 2015|January 6, 2014|Yes|Yes|No funding for project.|No||https://clinicaltrials.gov/show/NCT02036463||52478|
NCT02037048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6213|FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma|A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia||Case Comprehensive Cancer Center|Yes|Recruiting|January 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037048||52433|
NCT02037061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1413|Reducing Post-Op Pain After Sacrospinous Ligament Colpopexy|A Randomized Control Trial on the Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Colpopexy||The Cleveland Clinic|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037061||52432|
NCT02037386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0096|H-Side Branch Stent, A New Stent for the Treatment of True Bifurcation Lesions|||Yonsei University|Yes|Withdrawn|February 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|January 13, 2014||No|problem with balloon catheter|No||https://clinicaltrials.gov/show/NCT02037386||52407|
NCT02037971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03315312.8.0000.5505|Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.|Effectiveness of Exercise Training in Improving Sleep in Patients With Systemic Lupus Erythematosus: A Controlled Randomized Trial.|EFEXO|Federal University of São Paulo|Yes|Recruiting|February 2013|March 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|20|||Female|18 Years|69 Years|No|||May 2013|January 14, 2014|March 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02037971||52362|
NCT02038257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8082|Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP|Prospective Open Label Parallel Study Comparing Use of Carbon Dioxide Laser Versus Dermabrasion for Denuding Epithelium and Collagen Dressing Versus Vaseline Impregnated Gauze for the Melanocyte Keratinocyte Transplant Procedure|MKTP|Henry Ford Health System|No|Recruiting|January 2014|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 14, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02038257||52340|
NCT02037919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS#50302: Women's Health MISP|Nexplanon Application Post-Abortion|Immediate vs. Delayed Insertion of Nexplanon After Termination of Pregnancy Over 14-weeks Gestation (NAPA)|NAPA|University of Pittsburgh|No|Active, not recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037919||52366|
NCT02037932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00021229|Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry|Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry|GELATIN|Medical College of Wisconsin|No|Withdrawn|January 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||November 2015|November 5, 2015|January 14, 2014|Yes|Yes|Investigator left institution|No||https://clinicaltrials.gov/show/NCT02037932||52365|
NCT02038231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8753|Parenting Mindfully Study|Reducing Stress With Parenting-focused Mindfulness to Prevent Youth Substance Use|PM|George Mason University|No|Recruiting|February 2014|July 2019|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02038231||52342|
NCT02038244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135393-BO|Integrative Medicine for Chronic Pain|Integrative Medicine for Chronic Pain - Process-Outcome-Study in the Context of an Internal Medicine Ward for Integrative Medicine|POSITIVE|Universität Duisburg-Essen|No|Completed|February 2014|March 2015|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|75 Years|No|||May 2015|September 22, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02038244||52341|
NCT02014363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETS6103-003|Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)|Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors.|ETS6103-003|e-Therapeutics PLC|No|Active, not recruiting|October 2013|January 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|162|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02014363||54173|
NCT02015247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Functional capacity PAO|Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia|Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia||University of Aarhus|No|Completed|December 2013|March 2015|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2013|November 19, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02015247||54106|
NCT02015507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-770-017|An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor|An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on the Multiple-Dose Pharmacokinetics of Ivacaftor and on the Multiple-Dose Pharmacokinetics of VX-661 Administered in Combination With Ivacaftor||Vertex Pharmaceuticals Incorporated|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|December 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02015507||54086|
NCT02037789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain-OMICS RT|A Retrospective Study to Identify New "Omics" Biomarkers of Chronic/Persistent Low Back Pain|A Retrospective Study to Identify New "Omics" Biomarkers of Chronic/Persistent Low Back Pain||IRCCS Policlinico S. Matteo|Yes|Recruiting|March 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|9000|Samples With DNA|Whole blood samples will be collected from cases (patients already diagnosed with      persistent/chronic low back pain) and from controls (healthy subjects).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases will be collected at each participating centre. Every effort will be made to        accumulate a well phenotyped cohort of patients with persistent CLBP, sub-grouped into 6        categories: discogenic pain, spinal stenosis (congenital or acquired), facet joint pain,        sacroiliac joint pain, low back pain with radicular pain (not predominant radicular pain)        and widespread low back pain.        Controls (patients without chronic/persistent pain as defined above) will be retrieved        from 2 different sources:        Existing biobanks of healthy subjects which have collected information about        chronic/persistent back pain.        Subjects from the companion prospective study on acute LBP who will not have developed        CLBP.        Age (decades) and gender distribution of controls will be similar to cases.|September 2014|September 3, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02037789||52376|
NCT02038140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2011-07E|Zimmer Trabecular Metal Total Ankle|Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle||Zimmer, Inc.|No|Recruiting|March 2014|March 2027|Anticipated|March 2027|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|February 19, 2016|January 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038140||52349|
NCT02038114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340-2011|The Impact of a Patient Education Intervention for Ambulatory Oncology Patients|The Impact of a Patient Education Intervention on Knowledge, Self-efficacy, Symptom Burden, Health Related Quality of Life and Satisfaction With the Experience of Care for Oncology Ambulatory Patients Post Completion of the Edmonton Screening Assessment System||Sunnybrook Health Sciences Centre|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|96|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02038114||52351|
NCT02038127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GangwonPCI|Gangwon PCI Registry|Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province|GWPCI|Yonsei University|Yes|Recruiting|January 2013|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples Without DNA|CBC, Electrolyte, Chemistry, Cardiac biomarker, Platelet function test|Both|19 Years|N/A|No|Probability Sample|Patients who were at least 18 years of age, who have stable coronary artery disease (CAD)        or acute coronary syndrome (ACS), including myocardial infarction (MI) with or without        ST-segment elevation will be included in the study.|January 2015|January 21, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02038127|3 Years|52350|
NCT02038686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPTCOT2013/01|Treatment of Unstable 31.A2 and 31.A3 Trochanteric Fractures. Randomised Comparison of the Proximal Femoral Nail PFN-A Short and the PFN-A Long.||PFN-A|Corporacion Parc Tauli|Yes|Completed|January 2014|||January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|60 Years|N/A|No|||February 2016|February 14, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038686||52307|
NCT02035527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13141|Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2014|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035527||52550|
NCT02035813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-IV|DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).|DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).||University of Ulm|Yes|Recruiting|January 2014|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Female|18 Years|N/A|No|||January 2015|January 7, 2015|January 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02035813||52528|
NCT02035826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001902/BWH|A Randomized Trial of Patient Financial Incentives to Reduce CVD Risk|||University of Pennsylvania|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|53|||Both|18 Years|80 Years|No|||November 2013|December 8, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035826||52527|
NCT02036138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-13-HMO-CTIL|The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity.|||Hadassah Medical Organization|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|168|||Both|18 Years|70 Years|No|||January 2016|January 4, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036138||52503|
NCT02036450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-025|Atrial Fibrillation Detected by Continuous ECG Monitoring|Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals.|LOOP|Rigshospitalet, Denmark|Yes|Recruiting|January 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6000|||Both|70 Years|90 Years|No|||March 2016|March 17, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036450||52479|
NCT02036476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-490|Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma|Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Recruiting|January 2014|January 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036476||52477|
NCT02036775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.510|Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers|An Open-label, Randomised, Multiple-dose, Three-period Crossover Study in Healthy Male and Female Volunteers to Characterise Pharmacokinetics and Assess the Relative Bioavailability of Two New Oral Formulations of Ambroxol Hydrochloride as Lasolvan® Prolonged-release Hard Capsules 75 mg and Lasolvan® Effervescent Tablets 60 mg Compared to Lasolvan® Tablets 30 mg.||Boehringer Ingelheim||Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|January 13, 2014||||No|April 17, 2015|https://clinicaltrials.gov/show/NCT02036775||52454|
NCT02036788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Policlinico-11|Comparison of Two Tests in the Assessment of the Accuracy of Esophageal Pressure Variations Measurement During Mechanical Ventilation|||Policlinico Hospital|Yes|Recruiting|December 2013|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients admitted to ICU after surgery treated with mechanical ventilation|April 2015|April 27, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036788||52453|
NCT02036801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|policlinico-10|The Specific Elastance in ARDS Patients: a Pediatric Study|The Specific Elastance in ARDS Patients. Connections Between Volutrauma and Barotrauma - A Pediatric Study||Policlinico Hospital|Yes|Completed|June 2009|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|1 Year|12 Years|No|Non-Probability Sample|ARDS pediatric patients in mechanical ventilation or patients with healthy lung treated        with mechanical ventilation for clinical purposes|March 2015|March 18, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02036801||52452|
NCT02037698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0062|Role of CT Scan for the Successful Recanalization of Chronic Total Occlusion; a Randomized Comparison Between 3D CT-guided PCI vs. Conventional Treatment (CT-CTO Trial)|||Yonsei University|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|404|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02037698||52383|
NCT02038283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-973|Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening|A Study on Health-related Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening in Hong Kong||The University of Hong Kong|No|Completed|October 2009|June 2012|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|587|||Both|18 Years|N/A|No|Non-Probability Sample|All Chinese patients of 18 years old or above with a histology of confirmed colorectal        polyp or cancer for at least six months were recruited from specialist outpatient medical        and surgical colorectal clinics of Queen Mary hospital in Hong Kong.|January 2015|January 23, 2015|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02038283||52338|
NCT02038270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nexfin_002|Accuracy of Nexfin® and NIBP to Predict IBP|Evolution of the Accuracy of the Nexfin Pressure Signal Compared to Invasive and Noninvasive Arterial Blood Pressure||University Medical Center Groningen|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|110|||Both|18 Years|N/A|No|Probability Sample|120 Adult patients, that are having a routine surgical procedure.|January 2014|January 14, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02038270||52339|
NCT02038517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDOMP-1301|Cirrhosis, Effects of TRAnsplantation and Diabetes|Insulin Secretion and Sensitivity in Subjects With Liver Cirrhosis Undergoing Orthotopic Liver Transplantation (OLT): Pre- and Post-OLT Analysis|CETRA|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|June 2013|December 2026|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Serum, plasma, urines and DNA|Both|18 Years|65 Years|No|Probability Sample|Secondary care outpatients clinic|February 2016|February 29, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02038517|10 Years|52320|
NCT02038790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBP-OSZ1|Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population|A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population||Indivior Inc.|No|Active, not recruiting|November 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2013|January 15, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038790||52299|
NCT02039024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-4356A|Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET|Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET||Chang Gung Memorial Hospital|Yes|Completed|March 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039024||52281|
NCT02015260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA/2/C|A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts|A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts||University of Aberdeen|No|Completed|September 2001|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|299|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|August 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02015260||54105|
NCT02015520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM133-066|Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis|A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors||Alder Biopharmaceuticals, Inc.|No|Completed|January 2014|June 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|143|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|December 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02015520||54085|
NCT02045225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203HHP-279414-PB1ABAF146056|HIV Prevention for HIV-Negative Men Via Reduction of Social Anxiety|An HIV Prevention Intervention for HIV-negative Men Who Have Sex With Men Via Reduction of Social Anxiety and Substance Use in Sexual Situations||Ryerson University|No|Recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Male|18 Years|65 Years|No|||November 2015|November 18, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02045225||51806|
NCT02045472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIS-C001|A Study of VIS410 to Assess Safety and Pharmacokinetics|Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VIS410) to Influenza Type A Hemagglutinin||Visterra, Inc.|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02045472||51787|
NCT02038153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-08-148|Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant|A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML)||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|December 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|60 Years|75 Years|No|||March 2015|March 2, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038153||52348|
NCT02038413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCOCO Lung stage I|State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients|In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and 12C-ion Therapy for Stage I NSCLC: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients|Lung stage I|Maastricht Radiation Oncology|No|Completed|January 2014|January 2016|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of 25 NSCLC patients; stages I (cT1/cT2aN0M0). Consecutive        patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All        patients received respiratory gated CT (4DCT) scans. All were patients referred for        primary radiotherapy or chemo radiation.|January 2016|January 11, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038413||52328|
NCT02038920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002/CCT-001|Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease|Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease||Takeda|No|Recruiting|March 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|15 Years|80 Years|No|||August 2015|August 11, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02038920||52289|
NCT02034682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1085|The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy|The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy||University Hospital, Ghent|No|Completed|January 2014|April 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02034682||52614|
NCT02034695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1186|Evaluation of Quality of Care - Risk Assessment Management Programme, HA|Evaluation of Quality of Care - Risk Assessment Management Programme, HA|QoC RAMP|The University of Hong Kong|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2496|||Both|18 Years|N/A|No|Probability Sample|Patients with DM who are mostly independent in their activities of daily living and being        followed up at GOPC regularly will be recruited. All enrolled patients will undergo a        comprehensive risk assessment and screening for complications, who will then be assigned        to receive appropriate interventions and education from multi-disciplinary healthcare        professionals according to their risk level. Low risk patients will continue with the        usual GOPC follow up, medium risk patients will be given additional intervention by an        advanced practice nurse (APN), and high risk patients will be given additional        intervention by an APN and an associate consultant (AC) in family medicine (FM).|September 2014|September 1, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02034695||52613|
NCT02035540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surveillance Protocol 2013-11|European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR|European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR|ESPOIR|corlife|Yes|Recruiting|August 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients with acquired and congenital heart disease requiring heart valve replacement.|June 2015|June 18, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035540||52549|
NCT02035553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-019|A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis|A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease||ACADIA Pharmaceuticals Inc.|Yes|Recruiting|November 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|50 Years|N/A|No|||January 2016|January 18, 2016|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035553||52548|
NCT02035839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FROST I-Trial|Finding the Optimal Cooling tempeRature After Out-of-HoSpiTal Cardiac Arrest|A Multicenter Randomized Trial on the Effectiveness of Different Levels of Cooling in Comatose Survivors of Out-of-hospital Cardiac Arrest.|FROSTI|ZOLL Circulation, Inc., USA|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|150|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02035839||52526|
NCT02035852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062010-160|High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors|High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors||University of Texas Southwestern Medical Center|Yes|Recruiting|August 2009|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at the Simmons Cancer Center at UTSW|October 2015|October 9, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT02035852||52525|
NCT02035865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK sør-øst 2013/1260|Mood and Cognitive Outcome After Heart Transplantation (the MOODHEART Study)|Nevropsykiatri og Hjertetransplantasjon||Oslo University Hospital|No|Enrolling by invitation|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|Samples Without DNA|Serum and plasma|Both|N/A|N/A|No|Non-Probability Sample|Surviving participants from two former studies|April 2015|April 20, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02035865||52524|
NCT02036151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAU|Impact of Maternal Xylitol Consumption on Mutans Sterptococci|Impact of Maternal Xylitol Consumption on Mutans Sterptococci ,Plaque and Caries Levels in Children||King Abdulaziz University|Yes|Completed|February 2009|September 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|10 Months|36 Months|Accepts Healthy Volunteers|||January 2014|January 12, 2014|December 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036151||52502|
NCT02036827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0210|The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy|The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy||Yonsei University|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|108|||Both|20 Years|N/A|No|||February 2015|February 4, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02036827||52450|
NCT02036840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00822|Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients|||Nationwide Children's Hospital|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|513|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a history of allergy to penicillin who required antibiotic prophylaxis prior        to/during surgery.|April 2015|April 20, 2015|January 13, 2014||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT02036840||52449|
NCT02036814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq779/05|Program for Health Promotion to Improve Therapeutic Compliance in Hypertensive Patiente|A PROGRAM OF HEALTH EDUCATION PROMOTION BY NURSING CAN IMPROVE BLOOD PRESSURE CONTROL AND QUALITY OF LIFE IN HYPERTENSIVE PATIENTS?|PHPTCHP|University of Sao Paulo General Hospital|Yes|Completed|March 2007|February 2011|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|21|||Both|25 Years|75 Years|No|||January 2014|January 14, 2014|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02036814||52451|
NCT02037100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-RT-07-066-CTIL|Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children|Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children||Tel-Aviv Sourasky Medical Center||Recruiting|June 2007|||September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|6 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 6-20 years old|January 2014|January 14, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037100||52429|
NCT02037984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-004|A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)|A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Anticipated|340|||Both|2 Months|49 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02037984||52361|
NCT02037997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJH-Erlotinib-2013|Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC|Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study||Fudan University|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02037997||52360|
NCT02046733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP/IFCT 4-12|Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease|A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy|STIMULI|European Thoracic Oncology Platform|Yes|Recruiting|July 2014|January 2022|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||October 2015|January 22, 2016|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02046733||51690|
NCT02046746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA03|The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status|The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status and Other Outcomes||Abbott Nutrition|No|Recruiting|November 2013|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02046746||51689|
NCT02046759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthma-001|A Comparative Study of an Integrated Pharmaceutical Care Plan and a Routine Care in Bronchial Asthma|A Comparative Study of an Integrated Pharmaceutical Care Plan and a Routine Care in Bronchial Asthma||Ain Shams University|Yes|Completed|March 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|70 Years|No|||January 2014|January 24, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02046759||51688|
NCT02038543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000150|Hydroxyproline Influence on Oxalate Metabolism|Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate||Mayo Clinic|Yes|Recruiting|September 2013|January 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|15 Years|65 Years|No|||November 2015|November 30, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038543||52318|
NCT02038556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006921|Exploring the Outcomes and Financial Impact of a CBT-I Group Program Provided by Registered Nurses for Adults With Insomnia|Exploring the Outcomes and Financial Impact of a CBT-I Group Program Provided by Registered Nurses for Adults With Insomnia||Mayo Clinic|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02038556||52317|
NCT02038530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-4D|The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study|D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study|4D|McMaster University|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Male and females outpatients with a suspected Deep Vein Thrombosis|June 2015|June 2, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02038530||52319|
NCT02038803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13080201|Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution|Patient Preferences and Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS)|PETIS|Rush University Medical Center|No|Recruiting|October 2013|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|Adult (≥ 18 years) diagnosed with cystic fibrosis|January 2014|January 15, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038803||52298|
NCT02014961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 142060|Worm Study: Modifier Genes in Sudden Cardiac Death|Worm Study: Identification of Modifier Genes in a Unique Founder Population With Sudden Cardiac Death||Maastricht University Medical Center|Yes|Recruiting|April 2015|April 2025|Anticipated|April 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|223|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02014961||54127|
NCT02015273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200104-540|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Taiwan (ECOS TWN)|Easypod Connect: a Multinational, Multicentre, Observational Study to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "easypodTM" Electromechanical Device for Growth Hormone Treatment||Merck KGaA|No|Active, not recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|69|||Both|2 Years|18 Years|No|Non-Probability Sample|Pediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the        easypod™ electromechanical device.|March 2015|March 3, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02015273||54104|
NCT02038699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer|A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options||Oncoceutics, Inc.|Yes|Withdrawn||||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|December 18, 2015|January 14, 2014|Yes|Yes|Protocol not activated.|No||https://clinicaltrials.gov/show/NCT02038699||52306|
NCT02038933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-139|Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)|A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT||Bristol-Myers Squibb|No|Active, not recruiting|February 2014|July 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|March 17, 2016|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038933||52288|
NCT02034721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0098|Protein and Recovery From Exercise-induced Muscle Damage|Influence of Protein-amino Acid Supplementation on Recovery From Exercise-induced Muscle Damage in NASCAR Pit Crew Athletes||Appalachian State University|No|Completed|December 2013|December 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Male|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034721||52611|
NCT02034929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRS ID 003053|EndoCuff-assisted Versus Standard Colonoscopy for Adenoma Detection|A Randomized Controlled Study to Compare EndoCuff-assisted With Standard Colonoscopy for the Detection of Adenomas||Helios Albert-Schweitzer-Klinik Northeim||Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|500|||Both|18 Years|N/A|No|||August 2014|September 12, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02034929||52595|
NCT02035566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044150|Telehome Monitoring for Chronic Disease Management|Effectiveness of Telehome Monitoring on Quality of Life and Health Resources Utilization Among People With Chronic Disease Residing in Rural Maryland||University of Maryland|No|Completed|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|23|||Both|21 Years|N/A|No|||January 2014|January 10, 2014|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02035566||52547|
NCT02035878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POTTERHUNTER_PROBIOTICS_2013|Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression|Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression||Acadia University|No|Active, not recruiting|August 2012|April 2014|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||January 2014|January 11, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02035878||52523|
NCT02036177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOS-2000-04|Multivariate Assessment of the IUB Intrauterine Device Compared With a T380A IUD|A Prospective, Randomized, Single Blind, Two Arms Controlled Study to Confirm the Safety and Verify Performance of the IUB™ SCu300A Intrauterine Device in Comparison to TCu380 IUD Intra-uterine Contraceptive Device||Ocon Medical Ltd.|No|Active, not recruiting|May 2014|||January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|363|||Female|25 Years|42 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02036177||52500|
NCT02036164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COA-CREC 002/2013|Adjuvant Chemotherapy for Locally Advanced Cervical Cancer|Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients|ACT-LACC|Navamindradhiraj University|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|70 Years|No|||November 2015|November 18, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02036164||52501|
NCT02036853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-NEUR-001|An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome|An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)|GLUT1DS|Cook Children's Health Care System|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|35 Years|No|||January 2016|January 26, 2016|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02036853||52448|
NCT02037399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0577|Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection|||Yonsei University|Yes|Recruiting|July 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||January 2014|January 14, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02037399||52406|
NCT02037425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002AL|Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine|Exploratory Study of the Natural History, Clinical Outcomes, and Neuronal Endplate Changes in Subjects Reporting Short Duration vs. Long Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine||Cady, Roger, M.D.|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 14, 2014|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT02037425||52404|
NCT02046447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|354-2013|Neuroimaging of Dystonia|Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida|NID|University of Florida|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|60|||Both|7 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02046447||51712|
NCT02046486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIQUID study|OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)|OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study|LIQUID|University of Patras|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02046486||51709|
NCT02047019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14727|Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil|A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy||Bayer|No|Not yet recruiting|December 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|504|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047019||51668|
NCT02038816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ACA02T|Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)|A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)||Sunnybrook Health Sciences Centre|No|Not yet recruiting|March 2014|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02038816||52297|
NCT02038829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN101-201|A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD|A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|GOLDEN 6|Sunovion Respiratory Development Inc.|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|96|||Both|40 Years|65 Years|No|||August 2015|August 25, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038829||52296|
NCT02039050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013RC09|Evaluation of Long-Acting Muscarinic Antagonists in COPD|Proof of Concept Evaluation of Drug-Device Interaction With Aclidinium Bromide Via Genuair® and Tiotropium Bromide Via HandiHaler® in COPD Using Impulse Oscillometry|MAN04|University of Dundee|No|Completed|February 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|40 Years|80 Years|No|||November 2015|November 13, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039050||52279|
NCT02039063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6011-J081-101|A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease|A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease||Eisai Inc.|No|Recruiting|May 2014|March 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|20 Years|64 Years|No|||January 2016|January 19, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02039063||52278|
NCT02044653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-E2(EPO-hyFc)_P2|Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)|Phase II Clinical Trial to Explore the Optimal Fixed Starting Dose & Dosing Interval and to Evaluate the Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease and Receiving Hemodialysis (HD) / Peritoneal Dialysis (PD)||Genexine, Inc.|No|Recruiting|July 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Anticipated|250|||Both|18 Years|80 Years|No|||January 2014|February 2, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02044653||51850|
NCT02045251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.33|An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection|AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION||American University of Beirut Medical Center|Yes|Withdrawn|June 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||March 2013|January 14, 2015|July 18, 2013||No|Unavailability of clarithromycin 250 mg in the market|No||https://clinicaltrials.gov/show/NCT02045251||51804|
NCT02044952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDTW-1|Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission|Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission||Jinling Hospital, China|Yes|Recruiting|January 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||January 2014|January 22, 2014|January 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02044952||51827|
NCT02044965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHSC - AP 1|Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder|A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections||London Health Sciences Centre|No|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|36|||Both|12 Years|17 Years|No|||March 2015|March 5, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02044965||51826|
NCT02044978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tandskruv tidsserie|Initial Fixation of Bisphosphonate-coated Dental Implants|Initial Fixation of Bisphosphonate-coated Dental Implants||University Hospital, Linkoeping|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|N/A|No|||June 2015|June 8, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02044978||51825|
NCT02038712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-164|fMRI and Ghlrein in Obesity and Binge Eating Disorder|fMRI and Ghlrein in Obesity and Binge Eating Disorder||New York Obesity and Nutrition Research Center|No|Completed|June 2006|September 2013|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|93|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02038712||52305|
NCT02038946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-140|Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)|A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)||Bristol-Myers Squibb|No|Recruiting|March 2014|October 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02038946||52287|
NCT02034708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-058|Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors|Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors|REMIND|Guerbet|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|280|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034708||52612|
NCT02035215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-OM-8302|Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia|Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study||Kuhnil Pharmaceutical Co., Ltd.|No|Recruiting|January 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|80 Years|No|||March 2014|March 19, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02035215||52573|
NCT02035514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELLTRiMS|Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis|Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis||Germans Trias i Pujol Hospital|No|Active, not recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|50 Years|No|||September 2015|September 28, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02035514||52551|
NCT02035579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPR112665|Aerobic Training for Management of Post-Concussion Syndrome in Adolescents|Aerobic Training for Management of Post-Concussion Syndrome in Adolescents||Children's Hospital Medical Center, Cincinnati|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|17 Years|No|||February 2016|February 10, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02035579||52546|
NCT02036190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL110883-01A1|Ancillary T Cell Based Studies in SPIROMICS|||University of California, San Francisco|No|Recruiting|February 2012|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|Samples With DNA|PBMC|Both|40 Years|80 Years|No|Probability Sample|Former or current smokers, over 40 years of age recruited in SPIROMICS at UCSF|August 2015|August 7, 2015|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02036190||52499|
NCT02036203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOS-2000-05|A Study on the Safety and Efficacy of the SCu300A IUB Compared to the TCu380 Copper IUD|A Prospective, Randomized, Single Blind, Two Arms Controlled Study of the Safety and Efficacy of the SCu300A IUB™ Spherical Copper Intrauterine Ball in Comparison to TCu 380 IUD Intra-uterine Contraceptive Device||Ocon Medical Ltd.||Not yet recruiting|April 2014|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Female|25 Years|42 Years|Accepts Healthy Volunteers|||January 2014|January 12, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02036203||52498|
NCT02058446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHAM1301|PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension|An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension||TSH Biopharm Corporation Limited|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|80 Years|No|||February 2014|November 11, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058446||50793|
NCT02058771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10824: ULTIMATE|Utilising Lifemap to Investigate Malignant Arrhythmia Therapy|ULTIMATE: Utilising Lifemap to Investigate Malignant Arrhythmia ThErapy|ULTIMATE|University Hospitals, Leicester|No|Recruiting|October 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Fresh Frozen Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ischaemic cardiomyopathy attending for ICD implantation|June 2015|June 26, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058771||50768|
NCT02058784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI-006|Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects|A 2-Cohort Study to Evaluate the Effect of Food and the Effect of Cigarette Smoking on the Single-Dose Bioavailability of Pracinostat in Healthy Adult Subjects|HVFE|MEI Pharma, Inc.|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|June 17, 2015|February 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02058784||50767|
NCT02059018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypNOCOX-2|The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia|The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia||University of Aarhus|No|Completed|February 2014|August 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2014|August 17, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059018||50749|
NCT02059031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117020|A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects|A Two Part, Single-center, Randomized, Open-label, Crossover Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects||ViiV Healthcare|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|February 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059031||50748|
NCT02059265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00209|Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer|A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression||National Cancer Institute (NCI)|No|Recruiting|February 2014|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Female|18 Years|N/A|No|||February 2016|March 24, 2016|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059265||50730|
NCT02060630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST-CLI Trial|Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia|Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia|BEST-CLI|New England Research Institutes|Yes|Recruiting|August 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060630||50625|
NCT02060643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3687|A Cross-sectional Study Looking at the Effect of Radiotherapy on Carotid Intima-medial Thickness in Head and Neck Cancer|A Cross-sectional Study Looking at the Effect of Radiotherapy on Carotid Intima-medial Thickness in Head and Neck Cancer||Royal Marsden NHS Foundation Trust|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|N/A||Probability Sample|Adult patients with histologically confirmed cancer or benign tumours of the head and neck        area treated with hemi-neck radiotherapy to ≥ 50Gy|February 2014|February 10, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060643||50624|
NCT02056561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESUT-81|Effects on Immun System of Anesthesia|Investigation Of The Effects Of General Anesthesia On The Oxidant/Antioxidant System||Duzce University|No|Completed|January 2010|January 2011|Actual|July 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|45|Samples With DNA|Before induction and after the operation venous blood samples were taken.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|45 patients ASA I-II between 18-50 years with planned laparoscopic cholecystectomy under        general anesthetic were included in the study. Patients were divided into 3 groups on the        way to surgery; TIVA (group T n: 15), sevoflurane (group S n: 15) and desflurane (group D        n: 15).|February 2014|February 5, 2014|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056561|3 Days|50937|
NCT02060669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02-047|Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer|A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer||Samsung Medical Center|No|Recruiting|June 2010|September 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02060669||50622|
NCT02056548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSCTC-R01-HEPATO|Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy|Comparison of the Occurrence of HBV Reactivation According to the Duration of Preemptive Antiviral Therapy in Chronic Hepatitis B Virus Carriers Receiving Cancer Chemotherapy for Hematologic Diseases||Seoul St. Mary's Hospital|No|Not yet recruiting|March 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|126|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Chronic hepatitis B patients who will be newly diagnosed as malignant lymphomas and        receive standard chemotherapies at Seoul St. Mary's Hospital in Korea.|February 2014|February 4, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056548||50938|
NCT02057081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1106-R|Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI|Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI|MFG-mTBI|VA Office of Research and Development|Yes|Recruiting|October 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|91|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02057081||50897|
NCT02057094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02H|Effects of Protein Supplementation on Lean Body Mass Recovery From Extreme Military Training|Effect of Protein Supplementation on Lean Body Mass Recovery and Physiological Resilience Following Survive, Evade, Resist, Escape (SERE) School||United States Army Research Institute of Environmental Medicine|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|71|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02057094||50896|
NCT02057107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-112|Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)||University of Pittsburgh|Yes|Recruiting|May 2013|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057107||50895|
NCT02054650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-127|OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus|Osteopathic Manipulative Treatment of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus||University of North Texas Health Science Center|No|Terminated|May 2014|November 2015|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|79 Years|No|||October 2015|October 29, 2015|January 31, 2014||No|Scheduling and recruitment difficulties|No||https://clinicaltrials.gov/show/NCT02054650||51083|
NCT02057003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPAVIR-DAA|Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients|Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort.||Valme University Hospital|No|Recruiting|January 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|All patients who consecutively attend the Unit of Infectious Diseases of the Study Group        for Viral Hepatitis (HEPAVIR) of the Andalusian Society of Infectious Diseases (Sociedad        Andaluza de Enfermedades Infecciosas, SAEI), Spain, will be considered for this study.|November 2015|November 10, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02057003||50903|
NCT02057848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZBL-2014-1|Carbohydrates to Prevent Hypoglycaemia During Physical Activity in Patients With Type 1 Diabetes|A Prospective, Randomized Trial Testing Different Regimens of Carbohydrate Administration to Prevent Hypoglycaemia During a Standardized Bout of Moderate Physical Activity in Patients With Type 1 Diabetes||Diabeteszentrum Bad Lauterberg im Harz|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|37|||Both|18 Years|75 Years|No|||February 2014|February 6, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057848||50839|
NCT02057510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-040-E|Observational Study of Dental Outcomes in Head and Neck Cancer Patients|Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients|ORARAD|Carolinas Healthcare System|Yes|Recruiting|February 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|756|||Both|18 Years|N/A|No|Non-Probability Sample|Head and Neck Radiation Oncology patients|December 2015|December 2, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057510|24 Months|50864|
NCT02057523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0764|Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients|Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients||University of Illinois at Chicago|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2014|December 3, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057523||50863|
NCT02058134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-169|The CardioPAT Project: A Randomized Trial|CardioPAT Project - Reducing the Need for Allogenic Blood Transfusion After On-pump Cardiac Surgery With Intra- and Postoperative Use of a New Device: a Randomized Trial||Rigshospitalet, Denmark||Terminated|December 2013|January 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|100 Years|No|||January 2016|January 2, 2016|February 6, 2014||No|Due to other trials in the department|No||https://clinicaltrials.gov/show/NCT02058134||50817|
NCT02058433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAP|Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)|Phase 3, Randomized, Open-label Study of the Safety of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetic Follow up Versus Conventional Dosage in First-line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Tongji University|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||February 2014|February 6, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02058433||50794|
NCT02058147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12404|Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM|A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM|LixiLan-O|Sanofi|Yes|Completed|February 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1170|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058147||50816|
NCT02059044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130285|Information Systems-enabled Outreach Program for Adverse Drug Events|Information Systems-enabled Outreach Program for Adverse Drug Events|ISTOP-ADE|Ottawa Hospital Research Institute|No|Not yet recruiting|December 2015|January 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2200|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059044||50747|
NCT02059278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-2345-001|Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension||Nephron Pharmaceuticals Corporation|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059278||50729|
NCT02059525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeTPAT|Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection|Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection: an Observational Study in Belgium|SeTPAT|Institute of Tropical Medicine, Belgium|No|Active, not recruiting|July 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|serum, plasma and urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a new diagnosis of syphilis infection who receive treatment for their        syphilis at the Institute of Tropical Medicine (ITM), and a control group , consisting of        patients who are HIV infected but have no evidence of syphilis|November 2015|November 23, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059525||50710|
NCT02059538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121102|Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases|Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases|METACARDIS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|8||Anticipated|2350|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|August 28, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02059538||50709|
NCT02059824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051285|Normal Eyelid Sensation Distribution|Normal Eyelid Sensation Distribution||Duke University|Yes|Completed|March 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 16, 2015|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059824||50687|
NCT02060357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/0948|Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)|Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes|OCT-DES|Barts & The London NHS Trust|Yes|Completed|November 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|80 Years|No|||August 2015|August 6, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02060357||50646|
NCT02060656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH CCR: 3862|Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)|A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL).|LEGEND|Royal Marsden NHS Foundation Trust|Yes|Recruiting|September 2013|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02060656||50623|
NCT02060682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU100|Post-Market Registry of the ACIST CPM System and Navvus Catheter in Clinical Practice|Post-Market Registry of the ACIST Cardiovascular Pressure Measurement (CPM) System and Navvus Catheter in Clinical Practice-ADVANCE-EU|ADVANCE-EU|Acist Medical Systems|No|Active, not recruiting|February 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects 18 years of age or older, in whom FFR measurement is indicated to guide PCI        strategy and use of the ACIST CPM System and Navvus Catheter is attempted.|July 2014|July 15, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02060682|1 Day|50621|
NCT02054455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-SIBO-01|Proton Pump Inhibitors and Gastrointestinal Symptoms|Protective Effects of Probiotic Administration on SIBO Development and Bowel Symptom Onset in GERD Patients at Long-term PPI Treatment: a Randomized Controlled Cross-sectional Study||Federico II University|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|70 Years|No|||February 2014|February 3, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT02054455||51098|
NCT02056834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-BIO-T-XX-004-04|chronOS Inject in Proximal Tibial Fractures|Prospective, Multi-Center, Observational Study Evaluating the Augmentation With Calcium Phosphate Cement (chronOS Inject) for Bone Defect After Internal Fixation of Proximal Tibial Fractures||Synthes GmbH|No|Completed|March 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Probability Sample|Patients with proximal tibial fractures of type Schatzter I - VI, AO-OTA 41, AO-OTA 42        with bone defect are assessed for eligibility to enter the study. A computerized        tomography is performed if necessary to confirm the fracture type and the amount of bone        defect. Patients eligible for the study are followed over time to 12 months after surgery.        A total of 30 patients who meet the inclusion/exclusion criteria are enrolled in the        study, which is conducted at Kyungpook National University Hospital and Hanyang University        Guri Hospital in the Republic of Korea.|June 2014|June 24, 2014|January 31, 2014||No||No|April 11, 2014|https://clinicaltrials.gov/show/NCT02056834||50916|
NCT02056574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-1-006|Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms|Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms|ENACT-2|NoNO Inc.|Yes|Withdrawn|November 2015|April 2020|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|August 3, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056574||50936|
NCT02054715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC12107|Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trial Participation|Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials||University of Rochester|Yes|Recruiting|May 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|392|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054715||51078|
NCT02054728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_IMT_RHK_82/2012|Inspiratory Muscle Training During Right-heart Catheterization|Inspiratory Muscle Training During Right-heart Catheterization||Wissenschaftliches Institut Bethanien e.V|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT02054728||51077|
NCT02054741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC13059|Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer|A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults||University of Rochester|Yes|Recruiting|May 2014|December 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|700|||Both|70 Years|N/A|No|||February 2016|February 20, 2016|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02054741||51076|
NCT02055027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTES-NCPAP|Adherence to Continuous Positive Airway Pressure Among Obstructive Sleep Apnoea Patients.|Adherence to Continuous Positive Airway Pressure Among Obstructive Sleep Apnoea Patients. An Anaesthetic Algorithmic Approach to Prevent Postoperative Complications.||Astes|No|Completed|February 2008|April 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Sleep Study Center|February 2014|February 3, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055027||51054|
NCT02055300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03005|Safety, Tolerability and Pharmacokinetics Study of LY03005|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005|LY03005SAD|Luye Pharma Group Ltd.|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|88|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055300||51033|
NCT02054663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130605-01H|Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?|Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study.||Ottawa Heart Institute Research Corporation|Yes|Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 28, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02054663||51082|
NCT02057289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-4868|A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis|Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study|Micafungin|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|January 2014|February 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|6 Months|10 Years|No|||December 2015|December 3, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057289||50881|
NCT02057549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13040380|Haloperidol vs Conventional Therapy for Gastroparesis|Haloperidol vs Conventional Therapy for Gastroparesis|HATGAS|The University of Texas Health Science Center, Houston|No|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|90 Years|No|||June 2015|June 11, 2015|July 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057549||50861|
NCT02057536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC# 34006|The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.|Pilot Study for the Effect of Exercise Intervention in Breast Cancer Patients With Arthralgias Receiving Aromatase Inhibitors||Christiana Care Health Services|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|40 Years|N/A|No|||February 2015|February 3, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057536||50862|
NCT02058186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218/2555|Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination|||Srinakharinwirot University||Completed|December 2011|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|1 Year|18 Years|No|||February 2014|February 6, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058186||50813|
NCT02058173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP7-92|"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"|||Shiraz University of Medical Sciences|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|No|||October 2015|October 18, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02058173||50814|
NCT02058472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G3041_BE_I|Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers||Dong-A ST Co., Ltd.|No|Active, not recruiting|December 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058472||50791|
NCT02057822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0170|Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months|Cytokine Assay in Tears of Healthy Children and With Vernal Keratocunjonctivitis: Case Control Study and Monitoring of Cases at 6 Months||University Hospital, Clermont-Ferrand||Recruiting|November 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|||Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy children children with vernal keratoconjunctivitis|February 2014|February 6, 2014|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02057822||50841|
NCT02057835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.5|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.||Boehringer Ingelheim||Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|February 6, 2014||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT02057835||50840|
NCT02058160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12405|Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes|A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With T2DM|LixiLan-L|Sanofi|Yes|Completed|January 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|736|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058160||50815|
NCT02058797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTprocrast|Efficacy of Coherence Therapy for Procrastination|Efficacy of Coherence Therapy for Procrastination: a Randomized Controlled Trial|CTFORPRO|University of Barcelona|No|Terminated|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|19 Years|26 Years|No|||June 2015|June 1, 2015|February 6, 2014||No|The Coherence Therapy intervention could not be delivered in a reliable and valid way for a    variety of reasons.|No||https://clinicaltrials.gov/show/NCT02058797||50766|
NCT02059291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885N2301|Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers|Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers||Novartis|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|2 Years|N/A|No|||November 2014|November 24, 2014|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059291||50728|
NCT02059551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120133|Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism|Diagnostic Performances of Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism|IRM-EP2|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|August 2013|November 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1058|||Both|18 Years|99 Years|No|||October 2015|February 23, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02059551||50708|
NCT02059837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2014-1|Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery|Retrospective Study of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery||Kyungpook National University|Yes|Completed|February 2009|October 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|116|||Both|21 Years|85 Years|No|Non-Probability Sample|A total of 116 patients were included. They had pterygium excision and conjunctival        autograft surgery and followed by anterior photographs.|February 2014|February 10, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059837||50686|
NCT02060084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSD2012021|Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm|Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm||Kunshan First People's Hospital Affiliated to Jiangsu University|Yes|Recruiting|January 2014|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|N/A|24 Hours|No|||January 2014|February 9, 2014|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02060084||50667|
NCT02060344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCHS-SOL|Hispanic Community Health Study / Study of Latinos|Hispanic Community Health Study / Study of Latinos (HCHS/SOL)|HCHS/SOL|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|January 2006|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16400|Samples With DNA|Blood and DNA samples were collected.|Both|18 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|The of over 16,400 persons of Hispanic/Latino origin, specifically Cuban, Puerto Rican,        Mexican, and Central/South American, to be recruited through four Field Centers affiliated        with San Diego State University, Northwestern University in Chicago, Albert Einstein        College of Medicine in the Bronx area of New York, and the University of Miami.|January 2014|February 10, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02060344||50647|
NCT02054182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/M/83/2013:PG|Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection|Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa||University of Limpopo|No|Not yet recruiting|February 2014|January 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|1 Month|5 Years|No|||January 2014|February 2, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02054182||51119|
NCT02054468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSANNA|Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia|Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol|ROSANNA|Technische Universität München|Yes|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02054468||51097|
NCT02058875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ACA15T|Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring|Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.|COBACAM|University of Saskatchewan|No|Withdrawn|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|74 Years|No|||October 2015|October 8, 2015|January 15, 2014||No|The study funder retracted their grant funding offer before contract signed.|No||https://clinicaltrials.gov/show/NCT02058875||50760|
NCT02054754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETS2101-101|Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects|Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects||e-Therapeutics PLC|Yes|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02054754||51075|
NCT02059343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049942|Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)|Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)||Duke University|No|Completed|March 2014|November 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|18|Samples Without DNA|Blood will be collected for plasma pharmacokinetic analysis.|Both|N/A|2 Years|No|Non-Probability Sample|The study population will include children less than or equal to 2 years of age who        undergo cardiopulmonary bypass and receive dexmedetomidine per standard of care during the        bypass session.|October 2014|November 21, 2014|February 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059343||50724|
NCT02059603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2013.009|Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery|A Randomized Clinical Trial of Electroacupuncture Versus Fast-track Perioperative Program for Reducing Duration of Postoperative Ileus and Hospital Stay After Laparoscopic Colorectal Surgery||Chinese University of Hong Kong|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|80 Years|No|||February 2014|February 10, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059603||50704|
NCT02054676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-DS-9-43|Validation of the Jawbone Anatomy Classification in Endosseous Dental Implant Treatment|Validation and Clinical Assessment of Clinical and Radiological Classification of the Jawbone Anatomy in Endosseous Dental Implant Treatment||Lithuanian University of Health Sciences|No|Enrolling by invitation|February 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02054676||51081|
NCT02054988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM3110|"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"|"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"|CyCLOPS|University of Roma La Sapienza|No|Recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|240|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 7, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054988||51057|
NCT02055001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHOW|Sexual Hormones and Haemostasis: Observations for Women Health|Haemostasis Evaluation Related to Sexual Hormones: Gender Perspective|SHOW|University of Roma La Sapienza|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood, serum samples Urine|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|21 healthy women with 28-30 day regular menstrual cycle|May 2015|May 27, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02055001||51056|
NCT02057562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECADE|Impact of Diverticular Disease on the Detection of Colon Adenomas||DECADE|Technische Universität München|No|Recruiting|February 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1891|Samples Without DNA|Colon polyps and mucosa|Both|18 Years|90 Years|No|Probability Sample|Patients receiving routine colonoscopy at the both study centers are eligible for        participation.|November 2015|November 5, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057562||50860|
NCT02057575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG324-CS201|Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure|||Aerie Pharmaceuticals||Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|298|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057575||50859|
NCT02057913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2012/10036|A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)|A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis|VinCaP|Institute of Cancer Research, United Kingdom||Recruiting|March 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Male|18 Years|N/A|No|||September 2014|September 10, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057913||50834|
NCT02057861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ozlemersoy|Reversal of Neuromuscular Blockade in Diabetic Patients|The Comparison of Reversal of Neuromuscular Blockade in Diabetic and Non-Diabetic Patients||Duzce University|No|Completed|January 2013|December 2013|Actual|August 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|||Both|18 Years|65 Years|No|Probability Sample|The patients (diabetic and non-diabetic) between 18-65 years|February 2014|February 6, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057861|9 Months|50838|
NCT02058199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU-rivpd-001|Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery|A Pharmacodynamic Study of Rivaroxaban in Subjects Who Have Undergone Roux-en-Y Gastric Bypass Surgery||State University of New York - Upstate Medical University|No|Terminated|December 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 4, 2016|February 6, 2014|Yes|Yes|PI left the Institution; No replacement PI identified;|No||https://clinicaltrials.gov/show/NCT02058199||50812|
NCT02058485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duzce-2011/160|Dexmedetomidine Premedication in Hypertensive Patients|Does the Use of Dexmedetomidine for Premedication Provide Hemodynamic Stability in Hypertensive Patients?||Duzce University|No|Completed|January 2012|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|162|||Female|40 Years|60 Years|No|||February 2014|February 6, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058485||50790|
NCT02058498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004699|Increasing Activity in Liver Transplant Patients|Increasing Physical Activity in Post Liver Transplant Patients||Mayo Clinic|No|Not yet recruiting|February 2014|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|65 Years|No|||February 2014|February 6, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058498||50789|
NCT02058459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRFLOW-1|Targeted Lung Denervation for Patients With Moderate to Severe COPD|A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira™ Lung Denervation System in Patients With Moderate to Severe COPD.|AIRFLOW-1|Holaira|Yes|Recruiting|July 2014|November 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|40 Years|75 Years|No|||December 2015|December 21, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02058459||50792|
NCT02059070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050412M1F|Bupivacaine Versus Ropivacaine on Diaphragmatic Motility and Ventilatory Function|The Effect of Continuous Interscalene Brachial Plexus Block With 0.125% Bupivacaine Versus 0.2% Ropivacaine on Diaphragmatic Motility and Ventilatory Function||Anesthesiology WSU/DMC-NorthStar|Yes|Completed|June 2012|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|January 10, 2014||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT02059070||50745|
NCT02059564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-102|A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus|A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus||Hanmi Pharmaceutical Company Limited|No|Recruiting|December 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|44|||Both|18 Years|70 Years|No|||February 2014|February 7, 2014|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059564||50707|
NCT02059850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2720.00|NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma|A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|July 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059850||50685|
NCT02060097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0000697|Effects of Cocoa Flavanol on Skin Aging|Effects of 24-week Cocoa Flavanol Supplementation on Photo-aged Facial Skin||Seoul National University Hospital|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Female|40 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02060097||50666|
NCT02060110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9492-IG-CTIL|MADIT-CRT LONG-TERM INTERNATIONAL FOLLOW-UP REGISTRY - EUROPE|||Sheba Medical Center|No|Completed|May 2010|January 2014|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|447|||Both|21 Years|N/A|No|Probability Sample|The registry involves only those patients that participated in the MADIT-CRT IDE study        within Europe.|February 2014|February 9, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02060110|3 Years|50665|
NCT02060123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-555|Qigong Intervention Program for Abused Chinese Women|A Randomized, Wait-list Controlled Trial of a Qigong Intervention Program on Telomerase Activity and Psychological Stress in Abused Chinese Women||The University of Hong Kong|No|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060123||50664|
NCT02058264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-4000-CL-101|A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis|A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.||Brickell Biotech, Inc.||Completed|February 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|45 Years|No|||September 2014|September 10, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058264||50807|
NCT02058550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN0005|Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy|Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy||Stanford University||Recruiting|September 2014|September 2022|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|72|||Female|19 Years|N/A|No|||February 2016|February 3, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058550||50785|
NCT02059629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014|Eluna Family / Sentus BP Master Study|Eluna Family / Sentus BP Master Study||Biotronik SE & Co. KG|No|Active, not recruiting|February 2014|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from available pacemaker or CRT patients directly by the        treating physician at the investigational site|June 2015|June 22, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059629||50702|
NCT02059915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501015|Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions|An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study Of 40 Mg Doses Of Pf-00345439 To Evaluate The Bioequivalence Of Modified Formulation K Vs. Original Formulation X Under Intermediate-Fat Fed Conditions And To Estimate Relative Bioavailability Under Fasting Conditions In Healthy Volunteers||Pfizer|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|134|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059915||50680|
NCT02060188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-142|A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)|A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer||Bristol-Myers Squibb|No|Recruiting|March 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|December 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060188||50659|
NCT02055248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140055|Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders|Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|300|||Both|2 Years|80 Years|No|||December 2013|March 15, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055248||51037|
NCT02055261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM C08-07|Pedunculopontine Nucleus Stimulation for Gait Disorders in Parkinson's Disease|Effects of Low Frequency Deep Brain Stimulation of the Pedunculopontine Nucleus on Gait and Balance Disorders of Parkinson's Disease||Hôpital de la Salpétrière|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|70 Years|No|||February 2014|February 3, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02055261||51036|
NCT02055274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03003|Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease|A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections|03003MAD|Luye Pharma Group Ltd.|Yes|Completed|October 2013|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055274||51035|
NCT02055287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03004|Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder|An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder|LY03004SAD|Luye Pharma Group Ltd.|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055287||51034|
NCT02058212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antioxidants for endometriosis|Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI)|Does Antioxidant Supplementation to Endometriotic Women Undergoing ICSI Could Alter Reactive Oxygen Species (ROS) Levels and Affect Pregnancy Outcome|ROS|Cairo University|Yes|Completed|March 2013|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058212||50811|
NCT02057874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1343|3-Tesla MRI Response to TACE in HCC (Liver Cancer)|Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC)||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|February 2014|||June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057874||50837|
NCT02057887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-IFN-201|Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)|||Hanmi Pharmaceutical Company Limited||Recruiting|July 2013|||August 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|64|||Both|18 Years|65 Years|No|||February 2014|February 6, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02057887||50836|
NCT02058511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pupillometry and Analgesia|Infrared Pupillometry During General Anesthesia to Predict Pain|Intraoperative Use of Infrared Pupillometry During General Anesthesia to Predict Pain and Quality of Regional Anesthesia After Surgery||University of California, San Francisco|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058511||50788|
NCT02058524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0212|A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis|A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis||University of Chicago|Yes|Active, not recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|August 27, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02058524||50787|
NCT02058836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121364|Botulinum Toxin for the Management of Chronic Orchialgia|Botulinum Toxin for the Management of Chronic Orchialgia||Wake Forest Baptist Health||Recruiting|November 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|N/A|N/A|No|||December 2015|December 8, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058836||50763|
NCT02058849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-HN-23-MCC|Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck|Randomized Phase II Study of Concentrated Beet Root in Participants Being Treated for Locally Advanced Unresectable, Previously Untreated Squamous Cell Cancer of the Head and Neck||University of Kentucky|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02058849||50762|
NCT02058810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300513|Nasal High Flow at Acute Hart Failure|Does the Use of Optiflow High Flow Oxygen on Patients With Acute Cardial Decompensation (NYHA Classification Stage III-IV) Allow for Quicker Improvement of the Organ Dysfunction Than Conventional Standard-Oxygen-Insufflation-Therapy?||University Hospital Regensburg|No|Recruiting|September 2010|May 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058810||50765|
NCT02059057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0016|LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)|Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066|CROSSOVER|PneumRx, Inc.|Yes|Enrolling by invitation|January 2014|May 2021|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|36 Years|N/A|No|||October 2015|October 26, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059057||50746|
NCT02059083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0412|Biofeedback for Adolescent Cannabis Use Disorder|Biofeedback for Adolescent Cannabis Use Disorder||Denver Health and Hospital Authority|No|Withdrawn|September 2014|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|13 Years|19 Years|No|||April 2015|April 28, 2015|February 5, 2014|Yes|Yes|Funding not received; study was never started|No||https://clinicaltrials.gov/show/NCT02059083||50744|
NCT02059577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NutritionDietAutism|Nutritional and Dietary Treatment Study for Children/Adults With Autism|Nutritional and Dietary Treatment Study for Children/Adults With Autism||Arizona State University|No|Completed|November 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|30 Months|60 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059577||50706|
NCT02059863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPNPBE2610|SPRING Cluster Randomised Controlled Trial|SPRING (for the Millennium Development Goals): Sustainable Programme Incorporating Nutrition and Games (for Maximising Development, Growth and Survival)|SPRING|London School of Hygiene and Tropical Medicine|Yes|Not yet recruiting|March 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|12000|||Both|N/A|24 Months|No|||February 2014|February 10, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059863||50684|
NCT02059876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120608|Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer|A Pilot Study of Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer||Guangdong General Hospital|Yes|Recruiting|November 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||November 2013|February 11, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059876||50683|
NCT02053909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brilinta ISSBRIL0220|Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis|Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?|TARGET|Boca Raton Regional Hospital|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|90 Years|No|||July 2015|July 20, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053909||51140|
NCT02059122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC0202/0093|Sensitivity Study of Diagnostic for Early Detection of Dengue Infection|Determination of Estimated Sensitivity for Dengue NS1 ELISAs||InBios International, Inc.||Active, not recruiting|April 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|250|Samples Without DNA|serum|Both|N/A|N/A|No|Probability Sample|Human males and females of varying ages and geographical locations where dengue fever is        endemic. We will use retrospective (archived) and prospective human serum samples.        Some study sites will only use retrospective (archived) serum samples not collected        specifically for this study and not individually identifiable to the Investigators. These        samples will fall under the category of "leftover" specimens as described by FDA guidance.        These archived samples will have been collected from patients within 7 days after onset of        symptoms consistent with Dengue infection.        In addition paired prospective samples will be collected in compliance with human subject        protection. The prospective samples will be collected from patients with symptoms        consistent with Dengue infection. The first sample will be collected within the first 7        days of symptom onset; the second sample will be collected: 1) at least seven days later;        and 2) between the 10th and 21st day of symptom onset.|February 2016|February 5, 2016|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059122||50741|
NCT02059369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-13|Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation|Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation|ADLINE|Deutsches Herzzentrum Muenchen|No|Recruiting|August 2012|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2014|February 7, 2014|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02059369||50722|
NCT02059616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CCA_201|A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension|A Randomized, Double-blind, Multi-center, PhaseⅡ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension||CJ HealthCare Corporation|No|Recruiting|February 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|384|||Both|19 Years|75 Years|No|||April 2014|April 29, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059616||50703|
NCT02059928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-149|Intraosseous Pressure Monitoring in Intensive Care Unit Patients|Intraosseous Pressure Monitoring in Intensive Care Unit Patients||HealthPartners Institute|Yes|Recruiting|December 2013|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059928||50679|
NCT02060435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-101-001|Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma|The Impact of the Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B Cell Lymphoma||Samsung Medical Center|No|Completed|January 2013|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|571|Samples With DNA|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit      (Leica Microsystems, Bannockburn, IL, USA).|Both|17 Years|90 Years|No|Probability Sample|(1) pathologically confirmed de novo DLBCL, according to the World Health Organization        (WHO) classification: (ii) registered in Samsung Medical Center (SMC) Lymphoma Cohort        Study I/II (ClinicalTrials.gov Identifier: NCT00822731, NCT01877109) or identified from        Asan Medical Center (AMC) medical database: (iii) adequate amount and quality of        paraffin-embedded biopsy specimen or unstained slides for EBV-encoded RNA (EBER) in situ        hybridization.|February 2014|February 11, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060435||50640|
NCT02055014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12DIAB15|Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)|Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)||Sandwell & West Birmingham Hospitals NHS Trust|Yes|Recruiting|July 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055014||51055|
NCT02064868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A3301|Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|RELAX-AHF-EU|Novartis|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2685|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064868||50300|
NCT02060955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-005|Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan|An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan||CytoVac A/S|Yes|Terminated|February 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 10, 2014|Yes|Yes|Substantial design modifications required.|No||https://clinicaltrials.gov/show/NCT02060955||50600|
NCT02057627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD065156-01|Mother-Infant Intervention for Postpartum Depression and Associated Mother-Infant Relationship Dysfunction|Dyadic Intervention for Women at Risk for Postpartum Depression and Their Infants||Spaulding Rehabilitation Hospital|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|N/A|N/A|No|||February 2014|February 5, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057627||50856|
NCT02057926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-45-ASA-08|The Effect of Tetracycline in Degradation and Permeability of Collagen Membrane|||Universitat Internacional de Catalunya||Completed|November 2009|||November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057926||50833|
NCT02058225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84421489-1|Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development|Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development||Children's Hospital Boston|No|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|Probability Sample|The participants are recruited from two major hospitals at the bedside soon after normal        delivery.|November 2014|November 3, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058225||50810|
NCT02057939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049865|Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)|Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)|STREAM|Duke University|Yes|Active, not recruiting|April 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057939||50832|
NCT02058251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018127-002 Seq. 1|Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress|Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress||Medical University of South Carolina|Yes|Recruiting|February 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|21 Years|65 Years|No|||September 2014|June 4, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058251||50808|
NCT02058537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bethanechol|Bethanechol for Eosinophilic Esophagitis|Bethanechol for Treatment of Eosinophilic Esophagitis (EoE)||University of Iowa|Yes|Terminated|February 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|February 4, 2014|Yes|Yes|Initial PI left, study not continued|No||https://clinicaltrials.gov/show/NCT02058537||50786|
NCT02058823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-32|Intermittent Hypoxia 2: Cardiovascular and Metabolism|Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators|IH2|University Hospital, Grenoble|No|Active, not recruiting|August 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT02058823||50764|
NCT02052440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2883|Preventing Alcohol Withdrawal Syndrome With Oral Baclofen|Preventing Alcohol Withdrawal Syndrome With Oral Baclofen: A Randomized, Placebo Controlled Trial||Denver Health and Hospital Authority|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|21 Years|N/A|No|||October 2015|October 15, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052440||51252|
NCT02059304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLM PrDelivery Study|Prediction of Preterm Deliveries by Cervical Length Measurement With Embryo Transfer Catheter in ICSI Patients|Can Cervical Length Measurement With Embryo Transfer Catheter Predict Preterm Deliveries in ICSI Patients?||Acibadem University|Yes|Completed|January 2012|July 2014|Actual|April 2014|Actual|N/A|Interventional|Primary Purpose: Screening|2||||||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059304||50727|
NCT02059317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/AD-02|Evaluation of Dynamic Stability in the Low Back Pain Patient|Evaluation of Dynamic Stability in the Low Back Pain Patient|SDL|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited during consultations in the department of Physical Medicine and        Rehabilitation at the Nîmes University Hospital for lower back (lumbar) pain. The study        population will include patients with chronic low back pain (lasting for more than 6        months and not postoperative).        Healthy volunteers will be recruited at the Faculty of Medicine and the University        Hospital of Nîmes.|February 2016|February 5, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059317||50726|
NCT02053363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312010|Tranexamic Acid Dosing in Adult Spinal Deformity Surgery|Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial||Washington University School of Medicine|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053363||51182|
NCT02053649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|540053-2|Integrated Chronotherapy for Perinatal Depression|Integrated Chronotherapy for Perinatal Depression||Rhode Island Hospital|Yes|Recruiting|January 2014|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|No|||October 2015|October 26, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053649||51160|
NCT02057952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201007860|HealthyMe Online Weight Management Education/HealthyMe at Home|RCT of Video-Conference & In-Person Weight Loss Services for Adult CHC Patients|HOME|Indiana University|No|Enrolling by invitation|April 2012|April 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|40 Years|64 Years|No|||March 2015|March 23, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02057952||50831|
NCT02059356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048143|Ammonia Levels and Cognitive Impairment|Prevalence of High Ammonia Levels in Patients With Cognitive Impairment. Does Treatment Help?||Duke University|No|Terminated|January 2014|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|N/A|N/A|No|Non-Probability Sample|Residents of assisted living center or the general public|March 2015|March 13, 2015|January 6, 2014||No|Low patient recruitment|No||https://clinicaltrials.gov/show/NCT02059356||50723|
NCT02059642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL012|A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )|A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)||Alcobra Ltd.|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|55 Years|No|||March 2014|March 3, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059642||50701|
NCT02060201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-341|Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)|A Bioequivalence Study of 2.5-mg Saxagliptin/5-mg Dapagliflozin and 5-mg Saxagliptin/10-mg Dapagliflozin Fixed Dose Combination Tablets Relative to Coadministration of Their Respective Individual Components in Healthy Subjects and a Characterization of the Effect of Food on the Fixed Dose Combination Tablets||AstraZeneca|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|February 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02060201||50658|
NCT02064608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANCAP02|Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer|A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy|CaNCaP02|Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|October 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||January 2015|January 30, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064608||50320|
NCT02064621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144HPS13013|CKD-330 Drug-Drug Interaction Study (Candesartan)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers|CKD-330(C)|Chong Kun Dang Pharmaceutical|Yes|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|September 1, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064621||50319|
NCT02060396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12-01|Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action|Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action||Aragon Institute of Health Sciences|Yes|Completed|April 2013|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060396||50643|
NCT02055586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Y12|A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Anti-Angiogenic Cancer Treatment|A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Anti-Angiogenic Cancer Treatment||Case Comprehensive Cancer Center|Yes|Suspended|October 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 3, 2014|No|Yes|Drugs unavailable|No||https://clinicaltrials.gov/show/NCT02055586||51011|
NCT02058238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN105|ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity|ADDRESS - Multicenter, Partially-randomized Controlled Trial of Adult Deformity Robotic vs. Freehand Surgery to Correct Adult Spine Deformity||Mazor Robotics|No|Recruiting|October 2014|January 2027|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|2000|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients (age over 21 years) undergoing long (5 or more consecutive vertebrae) open        or minimally invasive instrumentation, correction and fusion sugery in the thoracic,        lumbar or sacral spine who have been found to have kypho/scoliotic curve, sagittal or        coronal imbalance or a combination of these.|January 2016|January 5, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058238||50809|
NCT02056132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201200137|Breath Condensate Study in Patients With Cystic Fibrosis.|Exhaled Breath Condensate for Evaluation of Lung Infections and Exacerbations in Patient With Cystic Fibrosis.||University of Florida|Yes|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples With DNA|Exhaled breath condensate.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patient with Cystic Fibrosis.|August 2015|August 20, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056132||50970|
NCT02056379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|508177|Comparison Between Budesonide and Dexamethasone Treatments for Respiratory Discomfort After Extubation on Children|Comparison Between Inhaled Budesonide and Intravenous Dexamethasone Treatments for Postextubation Stridor in Children|BUDEXA|Hospital Israelita Albert Einstein|No|Not yet recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|1 Month|19 Years|No|||February 2014|February 4, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02056379||50951|
NCT02059096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0179|Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis|Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis|STIMASEP|University Hospital, Clermont-Ferrand||Recruiting|February 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|60 Years|No|||February 2014|February 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059096||50743|
NCT02052453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDON2013|ICD-ON Registry: Periop Management of Cardiac Devices|ICD-ON Registry: Perioperative Management of Pacemakers and Implanted Cardioverter Defibrillators||Edward Hospital|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a PM or ICD undergoing procedures with anticipated electrocautery.|July 2014|August 3, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052453|3 Months|51251|
NCT02057965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43712.000.13|Mesenchymal Stromal Cell Therapy in Renal Recipients|Autologous Bone Marrow Derived Mesenchymal Stromal Cell Therapy in Combination With Everolimus to Preserve Renal Structure and Function in Renal Recipients|MSCs|Leiden University Medical Center|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057965||50830|
NCT02053064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2-SAF-301|Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy|Long-term Follow-up of Patients With Sanfilippo Type A Syndrome Who Have Previously Been Treated in the P1-SAF-301 Clinical Study Evaluating the Tolerability and Safety of the Intracerebral Administration of SAF-301.||LYSOGENE|Yes|Active, not recruiting|May 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||March 2016|March 23, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02053064||51205|
NCT02053077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinDiab-05|Risk Identification of the GlucoTab System in Routine Use|A Study to Identify Risks in Routine Use of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards||Medical University of Graz|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|non-critically ill patients with type 2 diabetes at general wards|February 2016|February 11, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02053077||51204|
NCT02053376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100|A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy|A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy||University of Pittsburgh|Yes|Recruiting|January 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 6, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053376||51181|
NCT02057666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-58102-003|Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer|A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer|TasQ003|Ipsen|Yes|Terminated|January 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Male|20 Years|N/A|No|||June 2015|June 29, 2015|February 6, 2014||No|Development of tasquinimod in prostate cancer discontinued|No||https://clinicaltrials.gov/show/NCT02057666||50853|
NCT02059135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB AT PPE 01-13|Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia|Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)|PRESERVE-1|rEVO Biologics|Yes|Recruiting|May 2014|October 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|16 Years|N/A|No|||November 2015|November 2, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059135||50740|
NCT02059382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10688|EXercise Continuation Incorporating Technology Enhancements (EXCITE) Study|EXercise Continuation Incorporating Technology Enhancements (EXCITE) Study|EXCITE|University of California, San Francisco|Yes|Completed|August 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02059382||50721|
NCT02059941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44679-J|Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines|Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP)- Guidelines Development and Testing||University of Washington|No|Recruiting|August 2013|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|780|||Both|13 Years|N/A|No|Probability Sample|In this study, there will be about 780 study subjects from 14 sites in Latin America.        Subjects will be about 390 from clinical sites previously exposed to protocols for        management of TBI, and about 390 from sites without prior exposure to protocols. Half of        the study subjects (about 390 total) will be treated in accordance with a consensus-based        protocol. Subjects will consist of patients with TBIs sufficiently severe to fulfill the        inclusion criteria. To qualify, patients must be 13 or older and have a non-penetrating        traumatic brain injury. The major criterion is severe TBI to be treated without the use of        intracranial pressure monitoring|February 2014|February 10, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059941||50678|
NCT02060227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0704|Approach to Shoulder Instability|Approach to Shoulder Instability: a Randomized, Controlled Trial||Ottawa Hospital Research Institute|Yes|Recruiting|February 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02060227||50656|
NCT02060474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT8-2014-1|Triac Trial in MCT8 Patients|Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial.||Erasmus Medical Center|Yes|Active, not recruiting|October 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|N/A|99 Years|No|||January 2016|January 25, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02060474||50637|
NCT02056431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-7250|Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy|Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy||Kaiser Permanente|No|Enrolling by invitation|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1190|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02056431||50947|
NCT02064634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSB_OS|A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule|A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug||Green Cross Corporation|Yes|Recruiting|May 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|6700|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with osteoarthritis being treated with anti-inflammatory analgesic drug at        general hospitals and clinics in South Korea|March 2016|March 15, 2016|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02064634||50318|
NCT02064647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF CCTN|Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study)|Evaluation of a Novel CGM Trend Arrow Adjustment Tool in Children & Adolescents With Type 1 Diabetes Using Insulin Pump Therapy and Continuous Glucose Monitoring (TAAT Study)|TAAT|Children's Hospital of Eastern Ontario|Yes|Completed|July 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|5 Years|18 Years|No|||January 2016|January 27, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064647||50317|
NCT02060409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-081-003|Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome|Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome||Samsung Medical Center|No|Completed|January 2012|February 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|58|Samples With DNA|Genomic DNA extracted from bone marrow aspirate|Both|17 Years|90 Years|No|Probability Sample|de novo MDS patients were included in the study who had received 1st line decitabine        treatment and had adequate genomic DNA from pretreated bone marrow samples|February 2014|February 11, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060409||50642|
NCT02060721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055E202|Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|MERIT-2|Actelion|No|Recruiting|February 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060721||50618|
NCT02055885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fvie_RePox-1|Correction of Exercise-induced Desaturation by Acute Oxygen Supply and Exercise Responses in COPD|Does Correction of Exercice-induced Desaturation by O2 Improve Systematically Exercise Tolerance in COPD Patients ?|RePox-1|5 Santé|No|Completed|February 2014|July 2015|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|255|||Both|40 Years|90 Years|No|Probability Sample|Patients with chronic obstructive pulmonary disease and exhibiting an exercise-induced        desaturation during six minute walkink test.|July 2015|July 7, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055885||50989|
NCT02052141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-301|Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema|A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema||Shire|No|Recruiting|February 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|12|||Both|6 Years|11 Years|No|||September 2015|September 11, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052141||51275|
NCT02052154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120131|Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults|Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults|SPLENEVAC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2014|September 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02052154||51274|
NCT02058277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871041|A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers|An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects||Pfizer|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|February 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02058277||50806|
NCT02057692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-301|Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome|The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease|ITCH|Shire|Yes|Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|12 Months|18 Years|No|||January 2016|January 15, 2016|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057692||50851|
NCT02058290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B6A/6B|A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)|IMPROVE-Lap|Pacira Pharmaceuticals, Inc|Yes|Terminated|December 2011|February 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|122|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|February 6, 2014|Yes|Yes|Slower than expected enrollment|No|February 19, 2014|https://clinicaltrials.gov/show/NCT02058290||50805|
NCT02058563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115231|Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)||GlaxoSmithKline||Completed|July 2014|September 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1000|||Both|7 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058563||50784|
NCT02052778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-120-101|A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities|A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed By A Phase 2 Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities||Taiho Oncology, Inc.|No|Recruiting|July 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|835|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052778||51227|
NCT02053090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AT006392|Complementary and Alternative Medicine (CAM) for Fibromyalgia|||Oregon Health and Science University|Yes|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Female|18 Years|75 Years|No|||September 2015|September 22, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053090||51203|
NCT02053103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731002|A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 In Adult Subjects With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|No|Terminated|March 2014|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|65 Years|No|||May 2014|May 16, 2014|January 30, 2014|No|Yes|On 25April2014, study was terminated before any dosing due to an AE of safety concern that    occurred in protocol B1731003 with the same drug.|No||https://clinicaltrials.gov/show/NCT02053103||51202|
NCT02058888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTU 08.808|Amplification and Selection of Antimicrobial Resistance in the Intestine|Self-controlled Cohort Study of the Amplification and Selection of Antimicrobial Resistance in the Human Intestine|ASARI|University Hospital Tuebingen||Recruiting|January 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Bacterial DNA from human stool samples.|Both|18 Years|N/A|No|Probability Sample|The study population will be selected from patients admitted to the University Hospital        Tuebingen or to the University Hospital Cologne.|December 2015|December 1, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02058888||50759|
NCT02059395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mastery of BLS|Mastery Learning Versus Time-based Education: Skill Acquisition and Retention of Basic Life Support in Laypeople|||Ottawa Hospital Research Institute||Completed|November 2013|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|49|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 2, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059395||50720|
NCT02059408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2014R34|Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons|Can a Targeted Screen-and-treat Program for Chronic Kidney Disease Improve Blood Pressure (BP) Management Among Persons at High Risk for Complications ?||University of California, San Francisco|No|Recruiting|September 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|80 Years|No|||October 2015|October 14, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02059408||50719|
NCT02059655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON 1266-14|Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)|Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial|BIMA|Cardiff University|No|Active, not recruiting|November 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|31|||Both|18 Years|75 Years|No|||April 2015|April 16, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059655||50700|
NCT02060448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31MH100761|Treatment Study for Non-Suicidal Self-Injury|Exploring Two Emotion-Focused Treatment Modules in Non-Suicidal Self-Injury|NSSI|Boston University|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02060448||50639|
NCT02060461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-744|LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser|LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser: 3 Months Follow-up of Initial US Clinical Series|FS200|The Cleveland Clinic|No|Active, not recruiting|August 2012|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02060461||50638|
NCT02060240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUIRB#10299|Physical Activity and Obesity|Physical Activity and Obesity: The Role of Nitric Oxide and Eicosanoids in Regulating Capillary Perfusion and Vascular Insulin Resistance||Oregon Health and Science University|No|Recruiting|February 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|30 Years|60 Years|No|||April 2015|April 20, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060240||50655|
NCT02060253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-168|Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer|A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|April 2014|January 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02060253||50654|
NCT02060487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481324|Effects of Oral Sildenafil on Mortality in Adults With PAH|A Multinational, Multicenter Study To Assess The Effects Of Oral Sildenafil On Mortality In Adults With Pulmonary Arterial Hypertension (Pah)|AFFILIATE|Pfizer|Yes|Recruiting|September 2014|June 2022|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|429|||Both|18 Years|74 Years|No|||March 2016|March 23, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060487||50636|
NCT02053116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731006|A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Terminated|March 2014|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|65 Years|No|||May 2014|May 16, 2014|January 30, 2014|No|Yes|On 25April2014, study was terminated before any dosing due to an AE of safety concern that    occurred in protocol B1731003 with the same drug.|No||https://clinicaltrials.gov/show/NCT02053116||51201|
NCT02053129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1217/IRB12-0417|Evaluation of PTB Screening in ANC in Lusaka, Zambia|Pilot Evaluation of Pulmonary Tuberculosis Screening in Antenatal Clinics in Lusaka, Zambia||University of North Carolina, Chapel Hill|No|Completed|November 2011|December 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5033|||Female|18 Years|N/A|No|||December 2014|December 11, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053129||51200|
NCT02056418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECDB-1|Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult|A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult|EN|Jinling Hospital, China|Yes|Active, not recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 4, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02056418||50948|
NCT02060734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSCTRIGGERINJ1402|Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated Disorder|Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated disorder-a Randomized Controlled Trial||Hamilton Health Sciences Corporation|No|Not yet recruiting|October 2015|September 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|70 Years|No|||August 2015|August 18, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02060734||50617|
NCT02056873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300850|Tourette Syndrome Deep Brain Stimulation|The Human Thalamocortical Network in Tourette Syndrome||University of Florida|Yes|Recruiting|May 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056873||50913|
NCT02056613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140057|Blood Collection From Healthy Volunteers and Patients for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products|Collection of Blood From Healthy Volunteers and Clinical Research Subjects for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|October 2028|Anticipated|October 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 24, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056613||50933|
NCT02056626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL105520|Conditioned Pharmacotherapeutic Effects in Hypertension|Conditioned Pharmacotherapeutic Effects in Hypertension||University of Rochester|Yes|Recruiting|March 2011|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|121|||Both|18 Years|80 Years|No|||September 2015|September 22, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056626||50932|
NCT02056886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-N-2012-08|Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer|Multicentric, National, Prospective, Comparative, Non Randomized Study, Assessing Medico-economic Impact of Three Strategies of Sentinel Lymph Node Analysis in Immediately Operable Breast Cancer|SAGE|Institut Cancerologie de l'Ouest|Yes|Recruiting|July 2013|January 2022|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|920|||Female|18 Years|65 Years|No|||November 2015|November 6, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056886||50912|
NCT02057120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21892213.4.0000.5511|Influence of Kinesio Taping on Muscle Activation, Muscle Strength and Performance of Young Football Athletes Jump|INFLUENCE OF KINESIO TAPING ON MUSCLE ACTIVATION, MUSCLE STRENGTH AND PERFORMANCE JUMP IN YOUNG ATHLETES. CLINICAL STUDY, RANDOMIZED, PLACEBO-CONTROLLED AND DOUBLE BLIND||University of Nove de Julho||Recruiting|January 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Male|15 Years|20 Years|No|||December 2013|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057120||50894|
NCT02057133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15252|A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread|A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer||Eli Lilly and Company|No|Active, not recruiting|March 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|102|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02057133||50893|
NCT02057146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1658-31|Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts|Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts||Karolinska University Hospital|No|Enrolling by invitation|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|95 Years|No|||October 2015|October 21, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02057146||50892|
NCT02052167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-MTX.16/HF Children|Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis|Human Factors Study for the Evaluation of the Methotrexate Prefilled Pen (50 mg/mL) for Subcutaneous Injection in Pediatric and Adolescent Patients With Juvenile Idiopathic Arthritis||medac GmbH|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|2 Years|20 Years|No|||March 2015|March 13, 2015|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052167||51273|
NCT02058316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-221|Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study|Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study||Medical University of Graz|No|Recruiting|February 2013|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|All stored or routinely obtained BAL samples from adult patients at risk for invasive        pulmonary Aspergillosis will be eligible for study inclusion. The treating clinicians will        be blinded to BAL Lateral Flow Device test results and the test will therefore have no        impact on patient management / treatment decisions. The treating clinicians will be        blinded to BAL Lateral Flow Device test results. Test results will therefore have no        impact on clinical / treatment decisions and therefore not affect the included patients.        Underlying diseases, EORTC status of IFI (both available from the clinical order        accompanying the BAL sample) and other microbiological/mycological test results will be        recorded in an electronic data base. No patient related personal data will be required.|March 2016|March 18, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02058316||50803|
NCT02057978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREDIT-II-131105|EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.|A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )|CREDIT-II|JW Medical Systems Ltd|Yes|Enrolling by invitation|November 2013|October 2019|Anticipated|October 2015|Anticipated|Phase 2|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|416|None Retained|Endpoint Classification: Safety/Efficacy Study Enrollment: 416 cases [Anticipated]|Both|18 Years|75 Years|No|Probability Sample|This study will plan for a total of 416 patients with primary, in situ coronary artery        lesions (all of the patients was selected in different blood vessels, a total of up to two        target disease Variable and each target lesion 1 stents, such as placing stents need more        than one in the operation, require the use of the same brand of stents, mix does not        recommend the same patients Other brand support, unless save extra stents.) Choose lesions        reference diameter of 2.5 mm to 2.5 mm (visual), each lesion length 32 mm or less        (visual), participants must conform to the standard can be selected.|February 2014|February 6, 2014|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02057978|5 Years|50829|
NCT02058576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116108|Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects||GlaxoSmithKline|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|77|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058576||50783|
NCT02058303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04262013|Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery|Exparel (Bupivacaine Liposome Injectable Suspension) for Distal Upper Extremity Blocks in Orthopedic Surgery||Ochsner Health System|Yes|Terminated|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|March 21, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058303||50804|
NCT02058602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117275|Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients|A Study to Characterise Lung Function, Airway Morphometry, Pharyngometry and Inhalation Profiles From Patients With Idiopathic Pulmonary Fibrosis (IPF)||GlaxoSmithKline|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|40 Years|N/A|No|||August 2015|August 6, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058602||50781|
NCT02058901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/75|Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.|A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.||VU University Medical Center|Yes|Recruiting|July 2013|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02058901||50758|
NCT02059954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-122 ex 13/14|Vaginal vs. Laparoscopic Hysterectomy|Vaginal Hysterectomy Versus Total Laparoscopic Hysterectomy for Benign Indications: A Randomized Controlled Trial||Medical University of Graz|No|Active, not recruiting|January 2014|September 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|80 Years|No|||February 2016|February 1, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059954||50677|
NCT02059434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-190792-01|Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD|A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects||AstraZeneca|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Actual|55|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059434||50717|
NCT02060214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20000453|Development of Novel Cystometrics for Overactive Bladder|Development of Novel Cystometrics for Overactive Bladder||Virginia Commonwealth University|No|Recruiting|January 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|104|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample and Urology Clinic Patients|February 2016|February 25, 2016|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02060214||50657|
NCT02059967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13-09209|Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC|A Phase I Image-Guided Adaptive Radiotherapy Study Using Active Breathing Control (ABC) and Simultaneous Integrated Boost for Patients With Inoperable Non-Small Cell Lung Cancer||Virginia Commonwealth University|Yes|Withdrawn|March 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|February 7, 2014|No|Yes|Due to no accrual.|No||https://clinicaltrials.gov/show/NCT02059967||50676|
NCT02056470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO-U-101A|Evaluate the Safety, Functionality, and the Quality of Life of Patients Who Receive the Freedom Total Knee ® System|A Prospective, Multicenter, Single Arm Adaptive-Design Study to Evaluate the Safety, Functionality, and the Quality of Life of Patients Who Receive the Freedom Total Knee ® System||Maxx Orthopedics Inc|No|Recruiting|September 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|40 Years|80 Years|No|||February 2014|February 4, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056470||50944|
NCT02060500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056015|Cardiaplication: A Novel Antireflux Operation|Cardiaplication: A Prospective Observational Trial||Emory University|No|Active, not recruiting|June 2012|July 2016|Anticipated|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|12 Months|No|||September 2015|September 29, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02060500||50635|
NCT02060513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1580|Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections|Rapid Microbiological Diagnostics for MDRO Quantitative Identification and Resistance Phenotyping to Guide Antibiotic Selection in Wounded Warriors and Veterans|RAMPED|Denver Health and Hospital Authority|No|Recruiting|August 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20000|Samples Without DNA|Isolates of intresting bacteria|Both|18 Years|N/A|No|Non-Probability Sample|Inpatients with a suspected infection.|October 2015|October 27, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02060513||50634|
NCT02053142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1208/IRB12-0390|Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women|Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women||University of North Carolina, Chapel Hill|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Female|18 Years|50 Years|No|||December 2014|December 11, 2014|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02053142||51199|
NCT02057185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMATO 0113|Occupational Status and Hematological Disease|Occupational Status and Hematological Disease: Effects and Counseling Needs|EMATO0113|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|15 Years|74 Years|No|Non-Probability Sample|Patients with a chronic hematological disease aged between 15 and 74 years old fully able        to understand Italian.|September 2015|September 29, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057185||50889|
NCT02056639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819122|Prevention of Preterm Birth With a Pessary in Twin Gestations|Prevention of Preterm Birth With a Pessary in Twin Gestations|PoPPT|University of Pennsylvania|Yes|Recruiting|February 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|164|||Female|18 Years|50 Years|No|||June 2015|June 17, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056639||50931|
NCT02056899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|423140-2|Maintenance Gabapentin to Prolong Pregnancy.|Effect of Maintenance Gabapentin Therapy on the Rate of Premature Birth in Women With Preterm Labor After Receiving Tocolysis.||University at Buffalo|Yes|Completed|June 2013|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|4|||Female|18 Years|45 Years|No|||August 2015|August 2, 2015|July 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056899||50911|
NCT02057718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-501|Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis|Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis|INDIGO|Shire|Yes|Active, not recruiting|February 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Months|18 Years|No|||October 2015|October 8, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057718||50849|
NCT02057172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-203|Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes|A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes||Hanmi Pharmaceutical Company Limited|No|Completed|January 2014|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|254|||Both|18 Years|74 Years|No|||February 2016|February 18, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057172||50890|
NCT02057406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043654|Omega 3 for Treatment of Depression in Patients With Heart Failure|Omega 3 for Comorbid Depression and Heart Failure Treatment|OCEAN|Duke University|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|21 Years|N/A|No|||February 2015|February 10, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057406||50872|
NCT02057380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7487-CL-0209|A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial|A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial||Astellas Pharma Inc|No|Active, not recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057380||50874|
NCT02057159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR902-231|A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis|A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis||Immune Response BioPharma, Inc.|Yes|Not yet recruiting|February 2017|February 2019|Anticipated|February 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|No|||February 2016|February 22, 2016|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057159||50891|
NCT02057679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2111|Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis|Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary?||Hospital Italiano de Buenos Aires|Yes|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||December 2015|December 16, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057679||50852|
NCT02058927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1204/IRB12-0400|Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia|Immune Reconstitution to Measles Virus of HIV-1-Infected Zambian Children Initiating Antiretroviral Therapy||University of North Carolina, Chapel Hill|No|Completed|May 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|203|Samples With DNA|blood samples will be stored in a repository for five years beyond the end of the study      period. Some samples may be exported to the Johns Hopkins Bloomberg School of Public Health      when assays cannot be performed in Zambia.|Both|9 Months|10 Years|No|Probability Sample|HIV-1 infected children initiating ART in public clinics within Lusaka, Zambia.|September 2014|September 17, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058927||50756|
NCT02058615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25908|Feasibility Testing and Evaluation of an Online Toolkit for Male Spouses of Women With Breast Cancer|Living With Hope: Development and Feasibility Evaluation of a Transition Toolkit for Make Partners of Women With Breast Cancer||University of Alberta|No|Completed|March 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|57|||Male|18 Years|N/A|No|||December 2015|December 22, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058615||50780|
NCT02058628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200398|Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris|A Multi-centre, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris||GlaxoSmithKline|No|Completed|February 2014|September 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|221|||Both|12 Years|45 Years|No|||October 2014|October 23, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058628||50779|
NCT02058589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116886|Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant|Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant||GlaxoSmithKline||Active, not recruiting|March 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058589||50782|
NCT02058914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fructadol|Effects of Sugar Sweetened Beverage on Metabolic Health in Male and Female Adolescents|Moderate Amounts of High Fructose- or High Glucose-sweetened Beverages do Not Differentially Alter Metabolic Health in Male and Female Adolescents|adol|University of Missouri-Columbia|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058914||50757|
NCT02059148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15175|A Study of LY2835219 in Healthy Participants|Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|November 19, 2014|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059148||50739|
NCT02059161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293-003|A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)|A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 1 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|October 2013|November 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|730|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059161||50738|
NCT02059447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tinnitus MBCT|A Comparison of the Benefits of Mindfulness Based Cognitive Therapy, Relaxation Therapy and a Waiting List Control in the Management of Distress in Chronic Tinnitus Patients|A Comparison of the Benefits of Mindfulness Based Cognitive Therapy, Relaxation Therapy and a Waiting List Control in the Management of Distress in Chronic Tinnitus Patients.||University College London Hospitals|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02059447||50716|
NCT02059460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Terli-NGAL-111|Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney|Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney|Terli-NGAL|National Liver Institute, Egypt|Yes|Recruiting|May 2013|May 2015|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|25|||Both|18 Years|65 Years|No|||February 2014|February 8, 2014|November 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02059460||50715|
NCT02059694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051289|Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery|The Application of Recombinant Human Hyaluronidase is Effective for the Use of Local Blocks for Eyelid Surgery||Duke University|No|Withdrawn||||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059694||50697|
NCT02059707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-003 V1.0_30Oct2012|LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS|LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS Suture Delivery Device||SentreHEART, Inc.|No|Enrolling by invitation|January 2014|July 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|21 Years|N/A|No|||February 2014|February 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059707||50696|
NCT02059980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21-RIT_OC-LEE|Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania|Developing Effective Response Inhibition Training for Symptom Relief in Obsessive-Compulsive and Related Disorders and Trichotillomania||University of Wisconsin, Milwaukee|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059980||50675|
NCT02060279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-42|Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity|A 6-month Family-based, Intense Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity: A Pilot Study||Nemours Children's Clinic|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|8 Years|11 Years|No|||February 2014|February 7, 2014|April 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02060279||50652|
NCT02060565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL V-0214|Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease|Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.|PVNIM|Association HGE CHU Bordeaux Sud|Yes|Recruiting|February 2014|||January 2023|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|all consecutive patients with an age over eighteen and chronic liver disease|July 2015|July 29, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02060565||50630|
NCT02056717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0863|Use of Dexamethasone in Uterine Artery Embolization|The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization||Severance Hospital|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Female|20 Years|60 Years|No|||April 2015|April 15, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056717||50925|
NCT02053974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Makpek-1|Spironolactone Against Anthracycline-induced Cardiomyopathy|Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy||TC Erciyes University|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|90 Years|No|||February 2014|February 1, 2014|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053974||51135|
NCT02053987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enhanced ESD|Enhanced Early Supported Discharge for Stroke in Camden|Evaluation of the Implementation of an Enhanced ESD Service for Stroke Survivors With Moderate to Severe Impairments and the Resulting Clinical and Cost Outcomes When Compared to Similar Patients in an Unchanged Stroke Care Pathway in a Neighbouring Borough.|EESD|Camden Clinical Commissioning Group|Yes|Completed|March 2014|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02053987||51134|
NCT02056691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ed-1|EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues|Clinical and Biological Effects of a Preoperative Exercise Programme in Colorectal Tumour and Skeletal Muscle Tissues (Exercise inDuced Changes In Colorectal Cancer Tissues)|EDICT|The Royal Bournemouth Hospital|Yes|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056691||50927|
NCT02057419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH-506070|Women's Input on Sexual Health|K24: Advancing Reproductive Health: Women's Input on Sexual Health (Project WISH)|WISH|The Miriam Hospital|Yes|Recruiting|April 2014|March 2017|Anticipated|August 2016|Anticipated|Phase 4|Observational|Time Perspective: Prospective||2|Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females who are 18-45 years old, HIV negative or unknown (self report), non-pregnant        (urine test) and not intending to get pregnant (self-report), report vaginal sex with a        man in the past month, and present with a need/desire for sexual lubrication and/or        contraception.|October 2015|October 5, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02057419||50871|
NCT02057731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300688|Study of Glycogen Storage Disease Expression in Carriers|Characterizing Expression of Glycogen Storage Disease in Heterozygous Carriers||University of Florida|No|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|120|||Both|18 Years|100 Years|No|Non-Probability Sample|Parents and other family members of patients currently undergoing treatment for GSD at the        University of Florida|January 2016|January 21, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057731||50848|
NCT02057198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043361|Impact of Oral Antibiotic Treatment on C. Difficile|Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile|C-Diff|Duke University|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Fecal specimen and perianal swab.|Both|18 Years|N/A|No|Non-Probability Sample|Non-pregant hospitalized adults with laboratory-proven C. difficile diarrhea and can        provide consent will be eligible to be enrolled in this study.|August 2015|January 19, 2016|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02057198||50888|
NCT02058004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003837|Does Cricoid Pressure Reduce the Risk of Aspiration?|Does Cricoid Pressure Reduce the Risk of Aspiration?||Mayo Clinic|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02058004||50827|
NCT02057432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-454|A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)|A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2012|January 2016|Anticipated|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Female|18 Years|75 Years|No|||February 2015|February 9, 2015|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057432||50870|
NCT02057705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-101-13|Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)|Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)|MTM|Valerion Therapeutics, LLC|No|Recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|-  5 ml sample of whole blood will be collected during the study to assess the immunity           against various AAV serotypes        -  5 ml blood sample may be obtained for peripheral blood mononuclear cells (PBMC) to           quantify X-linked myotubular myopathy gene 1 (MTM1) production        -  24-hour urine collection will be performed every 6 months in order to measure urinary           creatinine excretion        -  Slides and tissue from a previously performed muscle biopsy will be obtained for a           central review and quantification of histo- and immunohistopathological features of MTM|Both|N/A|N/A|No|Non-Probability Sample|Investigative Research Centers|January 2016|January 21, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057705||50850|
NCT02057393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247374|Infrared Lymphangiography as a Method of Sentinel Node Identification||SPY SN|Milton S. Hershey Medical Center|No|Recruiting|June 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|89|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057393||50873|
NCT02058368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114265|Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia|A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia||GlaxoSmithKline|No|Active, not recruiting|February 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Male|50 Years|N/A|No|||May 2015|May 7, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02058368||50799|
NCT02058667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-BRE-47-MCC|Reirradiation With Concurrent Paclitaxel for Breast Cancer|A Phase I Study of Twice Weekly Paclitaxel and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer||University of Kentucky|Yes|Recruiting|July 2014|March 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058667||50776|
NCT02059174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293-005|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)|A Single Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1293 and to Compare Its Pharmacologic Properties to Those of Another Basal Insulin in Subjects With Type I Diabetes||Merck Sharp & Dohme Corp.|No|Completed|February 2014|April 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||May 2015|May 22, 2015|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059174||50737|
NCT02059187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293-006|The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)|A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|536|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059187||50736|
NCT02059421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8674|Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors|Comparative-effectiveness of Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors||University of Arizona|Yes|Enrolling by invitation|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||December 2014|November 30, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059421||50718|
NCT02059668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR- HNprädBio-2013|Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)|Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)||Technische Universität Dresden|No|Recruiting|March 2014|June 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|480|Samples With DNA|if possible fresh-frozen tumor tissues, blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with the diagnosis locally advanced squamous cell carcinoma of the head and neck        area|December 2015|December 8, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059668||50699|
NCT02059681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S225/612|Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)|Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)|RECARDIO|Centro Cardiologico Monzino|No|Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||June 2015|June 29, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059681||50698|
NCT02059746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2013/RdeT|Perineal Consequences of Twin Pregnancies According to Mode of Delivery|Perineal Consequences of Twin Pregnancies According to Mode of Delivery|JUMODA-CP|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|February 2014|March 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3039|||Female|18 Years|N/A|No|Non-Probability Sample|This is an ancillary to the "JUMODA" study (please see NCT01987063). The study population        is composed of primiparous women pregnant with twins (non primiparous patients in the        study JUMODA will therefore not includable), giving birth after 34 weeks to 2 live        children.|October 2015|November 3, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059746||50693|
NCT02059772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReCaLL-2013|Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema|Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study|ReCaLL|GWT-TUD GmbH|No|Active, not recruiting|April 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02059772||50691|
NCT02059720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ3702|Haplo-SCT vs ASCT With or Without Decitabine in AML CR1|Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study||The First Affiliated Hospital of Soochow University||Recruiting|February 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059720||50695|
NCT02059733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-1273A|Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET|Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET||Chang Gung Memorial Hospital|Yes|Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|20 Years|80 Years|No|||November 2015|November 1, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059733||50694|
NCT02060526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-SAN-093|Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease|A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of rhHNS (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Early Stage Mucopolysaccharidosis Type IIIA Disease||Shire|Yes|Active, not recruiting|February 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|12 Months|48 Months|No|||March 2015|March 11, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060526||50633|
NCT02060539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-13-47|Multicenter Dispensing Study of Biofinity Lenses in Extended Range|Multicenter Dispensing Study of Biofinity Lenses in Extended Range||Coopervision, Inc.|No|Completed|October 2013|December 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|February 6, 2014|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT02060539||50632|
NCT02060578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC13_9749_DELI-DEVI|Determinants of End-of-life Place of Care for Children Suffering From Cancer.|DELI-DEVI : Determinants of End-of-life Place of Care for Children Suffering From Cancer.|DELI-DEVI|Rennes University Hospital|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02060578||50629|
NCT02060552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diagout1|Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels|Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation||Tongji Hospital|No|Completed|January 2013|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|February 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02060552||50631|
NCT02054000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Makpek-2|Intracoronary Tirofiban on No-Reflow Phenomena|Effectiveness of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||TC Erciyes University||Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|90 Years|No|||February 2014|February 1, 2014|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054000||51133|
NCT02056704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-088|Trial Comparing Angiography and Angiography With IVUS for Treatment of Hemodialysis Access Failures|A Prospective Randomized Feasibility Trial Comparing Angiography and Angiography With IVUS for Treatment of Hemodialysis Access Failures||Baylor Research Institute|Yes|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02056704||50926|
NCT02057211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS Dnr2013/195|Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study|Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study||Uppsala University Hospital||Recruiting|February 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|40 Years|No|||November 2015|November 20, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057211||50887|
NCT02057445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-561|3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma|A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Refractory /Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial||New York Medical College|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|1 Year|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057445||50869|
NCT02058329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-023|A Geriatric Home Visit Program to Reduce Post-Hip Fracture Complications|A Geriatric Home Visit Program to Reduce Post Hip Fracture Morbidity and Mortality||Northwell Health|Yes|Terminated|November 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|65 Years|N/A|No|||February 2014|February 6, 2014|October 25, 2012||No|Many patients were lost to follow-up|No||https://clinicaltrials.gov/show/NCT02058329||50802|
NCT02058342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-13-0142.54155|Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study|Family-based Exercise Intervention for Children and Adolescents With Prader-Willi Syndrome|APAH|California State University, Fullerton|No|Recruiting|May 2011|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|8 Years|15 Years|No|||February 2014|February 7, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058342||50801|
NCT02057991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-13-6|Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers|A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers||University of Southern California|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|65 Years|No|||June 2015|June 20, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057991||50828|
NCT02058381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719XIC01|A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer|A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer|B-YOND|Novartis|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||February 2016|February 28, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02058381||50798|
NCT02058394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.08|Retained Lens Fragments After Phacoemulsification|Postoperative Events in Patients With and Without Retained Nuclear Fragments in the Anterior Vitreous After Routine Phacoemulsification||Ophthalmic Consultants, Corneal and Refractive Surgery Assoicates, PC|No|Active, not recruiting|March 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited serially from eligible candidates on the basis of presentation        for cataract evaluation and subsequent cataract surgery with phacoemulsification.|February 2014|February 6, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058394||50797|
NCT02058680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O11-10678|Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients|A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients|PSA|OncBioMune, LLC|Yes|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Male|18 Years|N/A|No|||April 2015|April 21, 2015|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02058680||50775|
NCT02058940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1391|Intravenous Exenatide in Patients With Acute Brain Injury|Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury||University of North Carolina, Chapel Hill|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|February 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02058940||50755|
NCT02059200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFN-MBCL-2013-2017|Mindfulness Based Compassionate Living in Recurrent Depression|The Effectiveness of Mindfulness Based Compassionate Living in Recurrent Depression|MBCL-RD|Radboud University|No|Completed|July 2013|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02059200||50735|
NCT02059785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HA1301|Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke|Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|June 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|35 Years|75 Years|No|||February 2014|February 7, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059785||50690|
NCT02059798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L201402N1|Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy|Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy||The Catholic University of Korea|Yes|Not yet recruiting|March 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|76|||Both|25 Years|65 Years|No|Probability Sample|Patients having cervical myelopathy, aged between 25 and 65|February 2014|February 10, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059798|6 Months|50689|
NCT02060266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3789|Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects|A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|45 Years|64 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02060266||50653|
NCT02060019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_EXR_101|A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects|A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects||CJ HealthCare Corporation|No|Not yet recruiting|March 2014|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|57|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 9, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060019||50672|
NCT02060591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PAR01|Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA)|||Rothman Institute Orthopaedics||Recruiting|January 2014|||January 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||February 2014|February 11, 2014|February 10, 2014||||No||https://clinicaltrials.gov/show/NCT02060591||50628|
NCT02056496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBAS-CSIC-3|Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Urolithins in Healthy Subjects.|Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Gut Microbiota-derived Metabolites (Urolithins) in Overweight Subjects. Comparison Between Two Pomegranate Extracts|POMEkinetics|National Research Council, Spain|Yes|Completed|January 2014|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056496||50942|
NCT02056509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305100RINB|The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.|The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation||National Taiwan University Hospital|No|Recruiting|October 2013|July 2015|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|20 Years|N/A|No|Non-Probability Sample|Cardiac arrest patient received CPR in Emergency Department Age > 20 years old|April 2015|April 1, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02056509||50941|
NCT02054286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THV01-11-01|Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).|A Multi-center, Randomized, Double-blind, Placebo-controlled Phase I/II Trial to Compare the Safety, Tolerability and Immunogenicity of the Therapeutic THV01 Vaccination at 5.10E+6 TU (Transducing Unit) , 5.10E+7 TU (Transducing Unit) or 5.10E+8 TU (Transducing Unit) Doses to Placebo in HIV-1 Clade B Infected Patients Under Highly Active Antiretroviral Therapy (HAART)||Theravectys S.A.|Yes|Active, not recruiting|December 2012|March 2019|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|55 Years|No|||December 2015|December 8, 2015|February 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02054286||51111|
NCT02054299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-OCT|Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1|Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs|PG-OCT|University Medical Center Goettingen|No|Recruiting|April 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02054299||51110|
NCT02057250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC12665|To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis|A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy|SARIL-RA-EASY|Sanofi|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057250||50884|
NCT02056912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/13|Identification of a New Gene Involved in Hereditary Lipodystrophy|Identification of a New Gene Involved in Hereditary Lipodystrophy - LIPOGENE|LIPOGENE|University Hospital, Bordeaux|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02056912||50910|
NCT02056925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9167|Echocardiographic Analysis in Healthy Child.|Speckle Tracking 2D Echocardiography in Healthy Child. Comparison of Two Different Software Systems : Echopac (General Electric) and QLAB 9.0 (Philips).||University Hospital, Montpellier|Yes|Recruiting|December 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02056925||50909|
NCT02057224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|joan2014|Metabolic and Cardiovascular Effects of Renal Denervation|Metabolic and Cardiovascular Effects of Renal Denervation||Umeå University|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02057224||50886|
NCT02057458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK100783|Blood Flow and Vascular Function in Cystic Fibrosis|Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis|CF-FLOW|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|April 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057458||50868|
NCT02057744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN110|MIS ReFRESH: Robotic vs. Freehand Minimally Invasive Spinal Surgeries|Multi-center, Partially Randomized, Controlled Trial of MIS Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries||Mazor Robotics|No|Recruiting|October 2014|March 2027|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|||Both|21 Years|99 Years|No|Non-Probability Sample|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae)        thoracic, lumbar or lumbosacral percutaneous/minimally invasive spinal fixation sugery.|March 2016|March 20, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057744||50847|
NCT02058641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200934|Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)|An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|60 Years|No|||November 2014|December 4, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058641||50778|
NCT02058654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201131|A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population|A Randomised, Double-blind, Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population Using Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS) and Functional Magnetic Resonance Imaging (fMRI)||GlaxoSmithKline|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058654||50777|
NCT02058407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200186|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects|A Randomised, Double-blind (Sponsor Unblind), Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects||GlaxoSmithKline|No|Terminated|January 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|January 9, 2014||No|Drug related AEs observed upon repeat dosing that with longer treatment duration could become    worse. Required action on some biomarkers not observed.|No||https://clinicaltrials.gov/show/NCT02058407||50796|
NCT02058693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTHF-1|Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Adjunctive, Flexible-Dose Mixed Salts Amphetamine (MSA) in Adult Outpatients With Major Depressive Disorder (MDD) Responding Inadequately to Current Antidepressant Therapy (ADT)||Rush University Medical Center|No|Completed|December 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||December 2014|December 18, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058693||50774|
NCT02058706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-083|LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer|Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058706||50773|
NCT02058953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 13-052 (IMWG-01)|CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases|Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Blood From Patients With Melanoma Brain Metastases|13-052|University of Pittsburgh|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Peripheral blood; extracranial melanoma tissue; Cerebrospinal fluid; CNS tumor specimens;      adjacent "normal" CNS tissue; tissue slides/blocks from original biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with biopsy-proven melanoma who present with melanoma CNS metastases, a condition        that has been previously either biopsy-proven or there is strong suspicion based on the        radiologic imaging (brain MRI or brain CT with intravenous contrast) will be considered        for the study.|January 2016|January 8, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058953||50754|
NCT02059213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.117|A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer|A Randomized Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer||University of Michigan Cancer Center|Yes|Recruiting|June 2014|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||September 2015|September 3, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059213||50734|
NCT02059512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBK-2901-AMNKM|Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease|Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease||St. Petersburg State Pavlov Medical University||Recruiting|February 2013|February 2018|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|80 Years|No|||September 2014|July 7, 2015|February 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02059512||50711|
NCT02060032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2011-2012/B|1.2% Atorvastatin and 1.2% Simvastatin in Treatment of Chronic Periodontitis|COMPARATIVE EVALUATION OF CLINICAL EFFICACY OF SUBGINGIVALLY DELIVERED 1.2% ATORVASTATIN AND 1.2% SIMVASTATIN IN TREATMENT OF CHRONIC PERIODONTITIS: A RANDOMIZED CONTROLLED TRIAL||Government Dental College and Research Institute, Bangalore|Yes|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|30 Years|50 Years|No|||February 2014|February 9, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02060032||50671|
NCT02059993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2009-2012|The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease|The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease||Chinese Pulmonary Vascular Disease Research Group|Yes|Completed|January 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|45 Years|75 Years|No|||April 2015|April 8, 2015|February 9, 2014||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT02059993||50674|First, the sample size was relatively small. Second, this was a nondouble-blind study. Third, we did not use 24-hour ambulatory BP to monitor changes in BP and could not evaluate the nighttime BP.
NCT02060006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13060453|TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial|A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults||University of Stellenbosch|Yes|Recruiting|April 2014|April 2015||April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02060006||50673|
NCT02056795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122017|Study of Effects of Electroacupuncture on Balance in Subjects With Chronic Functional Ankle Instability|A Single Application of Electroacupuncture Improves Balance Greater Than Placebo Control in Subjects With Chronic Functional Ankle Instability||Canadian Memorial Chiropractic College|No|Completed|January 2013|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|24|||Both|18 Years|50 Years|No|||March 2014|March 18, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02056795||50919|
NCT02056522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS 001|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)||Orlucent, Inc|Yes|Recruiting|September 2014|November 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|660|||Both|21 Years|N/A|No|Probability Sample|Individual referred by a dermatologist or plastic surgeon for a skin biopsy or lesion        excision.|February 2014|October 14, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02056522||50940|
NCT02054026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP699102|Impact Evaluation of the Reducing the Risk Program|Impact Evaluation of the Reducing the Risk Program||Mathematica Policy Research, Inc.|No|Active, not recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2220|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054026||51131|
NCT02054312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH079353|Family Based Interpersonal Psychotherapy (FB-IPT) for Depressed Preadolescents|Phase II Study of Family Based Interpersonal Psychotherapy (FB-IPT) for Depressed Preadolescents||University of Pittsburgh|No|Completed|October 2010|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|7 Years|12 Years|No|||December 2015|December 28, 2015|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02054312||51109|
NCT02056977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|513.205|PEEP Levels Selected by PEEP Titration and PEEP Levels Routinely Used in Post-operative Cardiac Patients With ARDS|Comparison Between PEEP Levels Selected by Individualized PEEP Titration - Rapid Titration by EIT - and PEEP Levels Routinely Used in Post-operative Cardiac Patients With ARDS.||University of Sao Paulo General Hospital|No|Recruiting|February 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||April 2015|September 10, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056977||50905|
NCT02056938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0051|ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF|Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.|PREDICT-DGF|Nantes University Hospital|No|Recruiting|June 2014|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056938||50908|
NCT02057237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO222|A Safety and Feasibility Study of Mitotane in Prostate Cancer|A Safety and Feasibility Study of Mitotane in Prostate Cancer||University Health Network, Toronto|Yes|Completed|September 2013|October 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||November 2015|November 11, 2015|January 28, 2014||No||No|November 11, 2015|https://clinicaltrials.gov/show/NCT02057237||50885|
NCT02057471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09GS002|Intravenous Iron: Measuring Response in Anemic Surgical Patients|An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron||Nottingham University Hospitals NHS Trust|No|Completed|September 2009|March 2012|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02057471||50867|
NCT02057757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTZ-SARI|Evaluating the Safety, Effectiveness, and Tolerability of Nitazoxanide in Addition to Standard Care for the Treatment of Severe Acute Respiratory Illness in People Who Are Hospitalized|A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Nitazoxanide Versus Placebo in Addition to Standard Care for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|12 Months|N/A|No|||May 2015|May 15, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057757||50846|
NCT02058017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01/27/13|OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy|The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal Carcinoma Followed By A Biomarker Study Evaluating OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy||National University Hospital, Singapore|Yes|Terminated|November 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|January 15, 2014||No|Lactic and metabolic acidosis of OPB-51602 is not tolerable|No||https://clinicaltrials.gov/show/NCT02058017||50826|
NCT02058355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNFBrAB2013|Development and Evaluation of Effectiveness of an Internet-based Brief Intervention for Alcohol Use Among Brazilian College Students|Development and Evaluation of Effectiveness of an Internet-based Brief Intervention for Alcohol Use Among Brazilian College Students||Federal University of São Paulo||Enrolling by invitation|March 2014|October 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|6500|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058355||50800|
NCT02058719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2986|Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease|Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease.||University of Colorado, Denver|No|Recruiting|March 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|210|Samples Without DNA|Blood and bronchoscopy (BAL) samples will be collected|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive (smokers and non-smokers) and negative subjects (smokers and non-smokers)        will be recruited. HIV positive (with and without COPD) and HIV negative with COPD will        also be recruited. All subjects will be between ages 18 and 70.|December 2015|December 10, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02058719||50772|
NCT02058966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8874|Pilot Study of Entacapone for Methamphetamine Abuse|Pilot Study of the Dose Response of Entacapone on Methamphetamine Induced Interest, Mood Elevation, and Reward||Oregon Health and Science University|Yes|Recruiting|June 2014|||June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058966||50753|
NCT02059226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036087|Evaluating an Internet-based Program for Anxious Youth: a Pilot RCT|Evaluating an Internet-based Program for Anxious Youth: a Pilot RCT||University of Alberta|No|Recruiting|April 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02059226||50733|
NCT02059473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acutecufftearhannahallgren|Treatment of Small Acute Cuff Tears, a Randomized Study|Treatment of Small Acute Full-thickness tears-a Prospective Randomised Controlled Trial||University Hospital, Linkoeping|Yes|Recruiting|November 2013|November 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||February 2014|February 7, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02059473||50714|
NCT02060071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kap118711ctil|Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression and Severity|Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression, Severity, Symptoms and Left Ventricular Function Assessed by 2D Strain Echocardiography||Kaplan Medical Center|Yes|Recruiting|July 2011|June 2014|Anticipated|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|92 Years|Accepts Healthy Volunteers|||February 2014|February 9, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02060071||50668|
NCT02059811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048112|Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study|Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study||Duke University|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059811||50688|
NCT02060045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REINA|Prevention Ventilator Associated Pneumonia|Impact of 4 Sequential Measures on the Prevention of Ventilator Associated Pneumonia in Major Heart Surgery Intensive Care Unit|REINA|Hospital General Universitario Gregorio Marañon|No|Completed|November 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1534|||Both|18 Years|N/A|No|||February 2014|February 9, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02060045||50670|
NCT02060292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3251|Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease|Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease|NOVASC COPD|North Bristol NHS Trust|No|Recruiting|April 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|55|Samples Without DNA|Serum|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Stable COPD|February 2014|August 10, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02060292||50651|
NCT02056808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMT C11002|A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)|SMT C1100 - A Phase 1b, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients With Duchenne Muscular Dystrophy||Summit Therapeutics|Yes|Completed|November 2013|July 2014|Actual|May 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|5 Years|11 Years|No|||August 2014|August 26, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02056808||50918|
NCT02056821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A20030|Hemodynamic Effects on Cerebral Autoregulation in Acute Stroke|||Henry Ford Health System|No|Recruiting|February 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|90 Years|No|Probability Sample|Acute (< 12 hours) ischemic stroke patients presenting to the Emergency Department|March 2015|March 19, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056821||50917|
NCT02057042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-310|Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression|Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression||VA Office of Research and Development|No|Enrolling by invitation|June 2015|March 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|330|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02057042||50900|
NCT02054910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130822012|CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis|Randomized Single Blinded Control Trial Comparing EUS Guided Celiac Plexus Block (CPB) Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis||University of Alabama at Birmingham|No|Recruiting|October 2013|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|19 Years|N/A|No|||March 2015|March 9, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02054910||51063|
NCT02055144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERISTRAT/IST|Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy|An Exploratory Study of the Performance of Mass-Spectrometry Based Test Veristrat in Prediction of Benefit of First Line NSCLC Patients From Treatment With Standard Chemotherapy Regimens||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Recruiting|February 2011|May 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Serum samples, urine samples, circulating tumour cells from peripheral blood. Such samples      will be obtained before start of treatment (within 2 weeks), and at each patient's      evaluation and at progression|Both|18 Years|N/A|No|Non-Probability Sample|Patients affected by advanced non small cell lung cancer who are chemotherapy-naive and        candidates for first-line chemotherapy. This population includes patients with        non-squamous histology and patients with squamous histology.|November 2014|November 23, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02055144||51045|
NCT02056951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0421-FSCP-0529|Interprofessional Rehabilitation for Adults With Chronic Non-specific Low Back Pain|Interprofessional Biopsychosocial Rehabilitation to Optimize Inpatient Multidisciplinary Orthopedic Rehabilitation for Chronic Low Back Pain|PASTOR|University of Erlangen-Nürnberg|No|Completed|January 2008|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|536|||Both|18 Years|65 Years|No|||September 2015|September 8, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056951||50907|
NCT02057796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12290|Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3|Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial|STATIS|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|September 2014|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1050|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057796||50843|
NCT02058082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sperm DNA damage study|Testicular Versus Ejaculated Spermatozoa for IVF/ICSI in Men With High Sperm DNA Damage|Randomized Control Trial on the Use of Testicular Versus Ejaculated Spermatozoa for IVF/ICSI on Pregnancy Outcomes for Men With High Sperm DNA Damage||Mount Sinai Hospital, Canada|No|Completed|June 2005|December 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|N/A|No|||February 2014|February 6, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02058082||50821|
NCT02058095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006194|Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)|Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition|Aim 3|Mayo Clinic|Yes|Recruiting|March 2014|June 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|45|||Both|21 Years|90 Years|No|||January 2016|January 27, 2016|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058095||50820|
NCT02058108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2306|Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection|A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection||Novartis|Yes|Recruiting|October 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|2 Years|18 Years|No|||October 2015|October 13, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058108||50819|
NCT02057770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401080|Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML||Washington University School of Medicine|No|Recruiting|February 2014|May 2020|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057770||50845|
NCT02057783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-agir-04|Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension|Comparison of Standard Treatment by Continuous Positive Airway Pressure (CPAP) and CPAP Combined to a Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension: RAP Randomized Controlled Trial||AGIR à Dom|Yes|Recruiting|January 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057783||50844|
NCT02058030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phdkim1|The Influence of Degree of Head Elevation on Insertion Success for ProSeal Laryngeal Mask Airway Insertion|The 3 cm of Head Elevation Provides Higher Insertion Success Than do the 6 cm of it for ProSeal Laryngeal Mask Airway Insertion in Adult Patients||National Medical Center, Seoul|Yes|Completed|November 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02058030||50825|
NCT02058732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00078370|Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis|Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis||University of Michigan|Yes|Active, not recruiting|November 2013|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|17|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02058732||50771|
NCT02058745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11060487|SmartCare: Innovations in Caregiving Interventions|SmartCare: Innovations in Caregiving Interventions|SmartCare|University of Pittsburgh|No|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|420|||Both|21 Years|N/A|No|||May 2015|May 27, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02058745||50770|
NCT02058979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17266|Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery|Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery||University of Virginia|No|Active, not recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058979||50752|
NCT02059239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012875|Lymphoma Bridge Transplant Study|A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's)||Weill Medical College of Cornell University|Yes|Recruiting|February 2014|February 2019|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059239||50732|
NCT02059486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP699104|Impact Evaluation of the Teen Choice Program|Impact Evaluation of the Teen Choice Program||Mathematica Policy Research, Inc.|No|Enrolling by invitation|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02059486||50713|
NCT02059759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/WC-01|Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2|Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2|IMODALS|Centre Hospitalier Universitaire de Nīmes|Yes|Active, not recruiting|September 2015|June 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|No|||December 2015|December 22, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059759||50692|
NCT02060318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-072|Regulatory T-cells and Crohn's Disease|The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells|CrohnReg|Hvidovre University Hospital|No|Recruiting|February 2014|October 2023|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|47|Samples With DNA|Serum, plasma, peripheral blood mononuclear cells.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the gastroenterology department at Hvidovre Hospital and Køge Sygehus are        eligible for entry.        Healthy controls are recruited by advitising at Hvidovre Hospital.|March 2016|March 4, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060318||50649|
NCT02060604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSAIDs_01|Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration|A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration||Università degli Studi di Brescia||Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|N/A|No|||February 2014|February 8, 2014|February 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02060604||50627|
NCT02060058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-2013-10-03 (I)|Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy|Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy|BOLERO-CB|Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|20 Years|80 Years|No|||August 2013|February 9, 2014|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02060058||50669|
NCT02060305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305041MINB|Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis|A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis||National Taiwan University Hospital|Yes|Recruiting|February 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02060305||50650|
NCT02057068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7249-W|Improving Sleep in Veterans and Their CGs|Improving Sleep In Veterans and Their Family Caregivers|SLEEP-E Dyads|VA Office of Research and Development|No|Recruiting|November 2010|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02057068||50898|
NCT02057055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 131420|The Effect of Surfactants on the Bacterial Composition of the Layers of the Skin|The Effect of Surfactants on the Bacterial Composition of the Layers of the Skin||University of California, San Diego|No|Active, not recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4|||Male|21 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057055||50899|
NCT02054624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29-2013|Rural Lifestyle Eating and Activity Program (Rural LEAP)|Rural Lifestyle Eating and Activity Program|Rural LEAP|University of Florida|Yes|Active, not recruiting|August 2013|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|540|||Both|21 Years|75 Years|No|||February 2016|February 9, 2016|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054624||51085|
NCT02056730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCU COA no.637/2013|The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid|The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients||Chulalongkorn University|No|Recruiting|November 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2014|February 4, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02056730||50924|
NCT02056743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH_2012_RG|Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers|Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group||Chonbuk National University Hospital||Completed|September 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2013|February 4, 2014|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02056743||50923|
NCT02056756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN09|Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma|CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)||Stichting Hemato-Oncologie voor Volwassenen Nederland|Yes|Recruiting|April 2014|February 2019|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056756||50922|
NCT02057484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1213|A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant|A Long-term Follow-up of Adult Kidney and Liver Allograft Recipients Previously Enrolled Into a Tacrolimus (Advagraf) Trial. A Multicentre Non-interventional Post Authorization Study (PAS)|ADDRESS|Astellas Pharma Inc|No|Recruiting|March 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who had previously participated in the following Astellas sponsored clinical        trial also known as "feeder trials":        DIAMOND / PMR-EC1106 ADVANCE / PMR-EC-1211 ADHERE / PMR-EC-1212 Any potential new        Astellas-sponsored Advagraf trial|December 2015|December 21, 2015|February 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02057484||50866|
NCT02057497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBDM-02|An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms|An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms Related to GPCR Dependent Signalling and the FTO Gene in Healthy Volunteers and in Patients With Diabetes||Profil Institut für Stoffwechselforschung GmbH|No|Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|300|Samples With DNA|whole blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and patients with diabetes|September 2015|September 1, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057497||50865|
NCT02057809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-3767B|"Family-centered" Pediatric Rehabilitation Services in Children With Developmental Disabilities|Investigation of "Family-centered" Pediatric Rehabilitation Services Received by Children With Developmental Disabilities||Chang Gung University|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|130|||Both|2 Years|12 Years|No|Non-Probability Sample|Children with developmental disabilities (DD) aged 2-12 years. Children with DD refer to a        diverse group of severe, chronic disability that is attributed to mental and/or physical        impairments, resulting in substantial functional limitations in major life activity.|February 2015|February 8, 2015|December 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02057809||50842|
NCT02058121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/294|An ACT Group Intervention for ED-patients|Randomised Controlled Trial With Acceptance and Commitment Therapy (ACT) for Patients With Eating Disorders - a Manualised Group Therapy to Enhance Body Acceptance||Örebro County Council|No|Active, not recruiting|January 2010|May 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|50 Years|No|||December 2015|December 14, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02058121||50818|
NCT02058420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB L14-056|Tocotrienols and Bone Health of Postmenopausal Women|Effect of Tocotrienols on Bone Health: A Pilot Study||Texas Tech University Health Sciences Center|No|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|78|||Female|40 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|February 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058420||50795|
NCT02058043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00147|Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET|Study of MRI 3 Tesla Using Arterial Spin Labeling (Without Infusion) in Cognitive Atypical Disorders and Comparison to FDG-PET|ASLDEM DS|Rennes University Hospital|No|Recruiting|November 2012|||April 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with atypical cognitive disorders|February 2014|February 6, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02058043||50824|
NCT02058056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 15/12|Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC|Early Prophylactic Cranial Irradiation With Hippocampal Avoidance in Patients With Limited Disease Small-cell Lung Cancer. A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02058056||50823|
NCT02058069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIOTKA_2014|Robotic Arm Assisted Total Knee Arthroplasty|Robotic Arm Assisted Total Knee Arthroplasty||MAKO Surgical Corp.|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|21 Years|N/A|No|||February 2016|February 18, 2016|February 3, 2014|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT02058069||50822|
NCT02058758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312M4621|Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer|Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|March 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients: recruited from the group of patients that have a known cancer and        are scheduled to receive a breast MRI at the UMN Center for Clinical Imaging Research        (CCIR)|December 2014|December 1, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02058758||50769|
NCT02058992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293-101|Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty|Rozerem Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty||Takeda|No|Completed|July 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3339|||Both|N/A|N/A|No|Non-Probability Sample|Insomnia|February 2014|February 7, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02058992||50751|
NCT02059005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-1306-03482|Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions|Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions||Treatment Research Institute|Yes|Recruiting|November 2014|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02059005||50750|
NCT02059252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SML001/13|Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold|Proof of Concept Study Assessing Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold||Smart Matrix Limited|Yes|Terminated|August 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|December 11, 2013||No|Mode of application to be reconsidered by Sponsor|No||https://clinicaltrials.gov/show/NCT02059252||50731|
NCT02059499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-088|Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive|A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women||AIDS Malignancy Consortium|Yes|Recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|27 Years|N/A|No|||September 2015|February 22, 2016|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059499||50712|
NCT02060331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206058|Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study|Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study|SOPPO|Loyola University|No|Withdrawn|January 2014|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|The awake and asleep renal nocturia urine panels will require the patient to collect her      urine output into two laboratory provided basins for one twenty-four hour period. The "renal      nocturia, awake" urine panel will be obtained from urine collected from 0600-1800. The      "renal nocturia, asleep" urine panel will be obtained from urine collected from 1800-0600,      ie through the following day.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Ambulatory Urogynecology Clinic|August 2014|August 27, 2014|February 10, 2014||No|Difficult to recruit to.|No||https://clinicaltrials.gov/show/NCT02060331||50648|
NCT02060617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7|A Comparison of Two Different Methods of Physical Therapy to Treat Acute and Subacute Low Back Pain|Impairment-Based Versus Classification-Based Physical Therapy for Acute and Subacute Low Back Pain: a Randomized Controlled Trial||Hendricks Regional Health|No|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||August 2015|August 17, 2015|December 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02060617||50626|
NCT02056535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA018119|Screening and Brief Intervention in the ED Among Mexican-origin Young Adults|Screening and Brief Intervention in the ED Among Mexican-origin Young Adults||Public Health Institute, California|No|Completed|May 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|698|||Both|18 Years|30 Years|No|||June 2013|February 4, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02056535||50939|
NCT02056847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-PTV-713|to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia|Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)|SIPHON|JW Pharmaceutical|Yes|Recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|318|||Both|20 Years|70 Years|No|||February 2014|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056847||50915|
NCT02057315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH10200|Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine|A Randomized, Double-Blind, Cross-Over, Placebo-Controlled Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine||Achelios Therapeutics|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||November 2014|January 23, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057315||50879|
NCT02057588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-12-082-FR-HV|Enhanced Diagnosis of Ventricular Activation Pattern Using Intracardiac Electrograms|Enhanced Diagnosis of Ventricular Activation Pattern Using Intracardiac Electrograms||St. Jude Medical|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02057588||50858|
NCT02054637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHV106-B.05|Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy|Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy||Universitair Ziekenhuis Brussel|Yes|Not yet recruiting|April 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 31, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02054637||51084|
NCT02057029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#: 1309012695|Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer|Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer||Yale University|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|96|||Female|N/A|N/A|No|||January 2016|January 6, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02057029||50901|
NCT02057263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000040|The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults|The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults - a Randomized Placebo-controlled Pilot Study||Massachusetts General Hospital|No|Completed|April 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02057263||50883|
NCT02056990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56252|Screening of Athletes|Screening of Athletes for Prevention of Injury and Optimisation of Performance||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|March 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|16 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Athletes will be selected from a list offered by the Flemish Atlethics League. This        incorporates a group of athletes with potential to become Elite Athletes of the highest        international level|September 2015|September 16, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056990|2 Years|50904|
NCT02057276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001 - rTMS/hemiparesis|Repetitive TMS and Occupational Therapy in Children and Young Adults With Chronic Hemiparesis|Motor Control Enhancement Through Repetitive Transcranial Magnetic Stimulation Plus Rehabilitation in Hemiparetic Cerebral Palsy and Stroke||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|September 2012|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|10 Years|20 Years|No|||July 2015|July 30, 2015|June 5, 2013|Yes|Yes|Study was terminated due to low recruitment.|No|July 30, 2015|https://clinicaltrials.gov/show/NCT02057276||50882|
NCT02033317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-201|An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis|An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients||Relypsa, Inc.|No|Terminated|August 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|January 9, 2014|Yes|Yes|Study terminated due to slow enrollment|No|November 11, 2015|https://clinicaltrials.gov/show/NCT02033317||52719|The initial intent was to enroll 12-24 adult male and female participants on hemodialysis into the study. Due to significant recruitment challenges, the study was discontinued after six participants were enrolled in the study.
NCT02033330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cordiart-PKA-1|Assessment of Bioavailability of Phenolics From an Orange Peel Extract|Assessment of Bioavailability of Phenolics From an Orange Peel Extract||Maastricht University Medical Center|No|Completed|July 2013|January 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033330||52718|
NCT02033343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-NSCCRO-P002|Feasibility Study Into Adjustment of the Radiation Beam to Account for Prostate Motion During Radiotherapy.|Phase I Feasibility Study of Prostate Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator Adaptation and Radiofrequency Tracking (Calypso)|CALYPSO|Royal North Shore Hospital|Yes|Active, not recruiting|October 2013|December 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|35 Years|85 Years|No|||July 2015|July 12, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033343||52717|
NCT02034162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100933|A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants|A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects||Janssen Research & Development, LLC|Yes|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|295|||Both|1 Year|16 Years|No|||November 2015|November 2, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034162||52654|
NCT02034435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131139|Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism|Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism||Vanderbilt University|Yes|Recruiting|October 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|57|||Both|18 Years|70 Years|No|||February 2015|February 5, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034435||52633|
NCT02034448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRRTNet|CRRTNet Registry- A Prospective Observational Registry|CRRTNet Outcome Registry|CRRT|AKI Critical Care Research Foundation|No|Recruiting|November 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|89 Years|No|Non-Probability Sample|This is a prospective observational registry. A minimum sample size of 2000 patients with        the detailed information being obtained would embody the largest and most detailed        repository of adult CRRT patient information available.|January 2015|January 12, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034448||52632|
NCT02030639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-23|Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers|Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers||Onconova Therapeutics, Inc.|No|Completed|January 2014|August 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02030639||52924|
NCT02030899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP_2014|The Comparison Between the Stand-alone Cage and the Autologous Iliac Bone Graft/Anterior Plating in the Single-level Surgical Treatment of the Cervical Spine|The Comparison Between the Stand-alone Cage and the Autologous Iliac Bone Graft/Anterior Plating in the Single-level Surgical Treatment of the Cervical Spine|CAP_2014|Seoul National University Hospital|No|Recruiting|December 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|30 Years|70 Years|No|||November 2015|November 15, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02030899||52904|
NCT02030327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-236|Proteomics in Multiple Trauma to Identify Organ Failure|Analysis of Predictive Parameters by Proteomics for Early Diagnosis of Organ Dysfunction in Multiple Trauma Patients - A Pilot Study||Universitätsklinikum Köln|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|85|Samples Without DNA|serum (blood) and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|older than 18 years multiple trauma patients ISS >16|January 2016|January 25, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02030327||52948|
NCT02030912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09040|Effect of Minocycline & Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas|Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas|ANTIRESDEV|Helperby Therapeutics Ltd|No|Completed|December 2009|December 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030912||52903|
NCT02030626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS versus tDCS|Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain|Comparison of the Efficacy of Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation of the Motor Cortex in Patients With Neuropathic Pain Due to Chronic Radiculopathy||Hospital Ambroise Paré Paris|No|Completed|January 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030626||52925|
NCT02030886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1302|IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients|A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfish® in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients||Sensimed AG|No|Terminated|December 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|100 Years|No|||November 2015|November 16, 2015|December 30, 2013||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT02030886||52905|
NCT02031172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00048640|Effects of Sustained Reading on the Ocular Surface|Effects of Sustained Reading on the Ocular Surface||University of Rochester|No|Recruiting|March 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|50 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|We plan to recruit 30 subjects from 3 populations (dry eye, Sjogren's, and healthy        controls). Subjects will be recruited regardless of gender, race, or ethnicity; and        enrollment will based on specific criteria as described below.|December 2015|December 4, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02031172||52883|
NCT02055313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1|Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival|The Exceptional Patient in Cancer Care||Meir Medical Center|Yes|Active, not recruiting|May 2012|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified through the HMO registry in a region of 630,000 members with a        diagnosis of pancreatic cancer, advanced lung cancer, advanced stomach cancer and advanced        esophageal cancer that are still alive from 2001-2008.|April 2015|April 6, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02055313||51032|
NCT02040155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050297|Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy|Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy||Duke University|No|Completed|February 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|January 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040155||52194|
NCT02031640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDB-AS-301|A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|December 2013|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|532|||Both|12 Years|N/A|No|||May 2015|May 21, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031640||52847|
NCT02040142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-332|Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C|Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C||Montefiore Medical Center|Yes|Enrolling by invitation|November 2011|November 2019|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|May 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040142||52195|
NCT02040428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-13-004|The Fibrin Pad CV Phase III Study|A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery||Ethicon, Inc.|Yes|Completed|January 2014|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02040428||52173|
NCT02040441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000452-34|Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria|Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria|PRIORITY|Steno Diabetes Center|Yes|Recruiting|November 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|3500|||Both|18 Years|75 Years|No|||March 2014|January 30, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02040441||52172|
NCT02031900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-01|High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging System|||NinePoint Medical||Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and females >18 years of age undergoing esophagogastroduodenoscopy (EGD).|March 2014|March 21, 2014|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031900||52827|
NCT02032186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIPBMGF|A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy|A Randomized Clinical Trial of Oral Magnesium Supplementation In Pregnancy for the Prevention of Preterm Birth and Perinatal and Maternal Morbidity||Professor Fernando Figueira Integral Medicine Institute|Yes|Recruiting|March 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|3000|||Female|18 Years|40 Years|No|||March 2015|March 10, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02032186||52805|
NCT02032199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nbhsf36|Quality of Life Following Gastric Bypass Surgery.|A Prospective Analysis of Changes in Health-Related Quality of Life Following Roux-en-Y Gastric Bypass.||Odense University Hospital||Completed|April 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients treated with Roux -en-Y gastric bypass surgery in 2008-2010 i Region of Southern        Denmark.|January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032199||52804|
NCT02032446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2012-000582-21|Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) FOR THE TREATMENT OF SEVERE (GRADE III-IV) STEROID-RESISTANT GRAFT VERSUS HOST DISEASE (GvHD): A PHASE I/II TRIAL|PTC-UC-MSC|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|N/A|70 Years|No|||April 2015|April 20, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02032446||52785|
NCT02032979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-06|Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2|Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|January 2014|||October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|75 Years|No|||December 2013|January 9, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02032979||52744|
NCT02033005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1461|Newborn Feeding and Infant Phenotype|Newborn Feeding and Infant Phenotype||Imperial College London|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|107|Samples Without DNA|Urine Stool Breast milk|Both|N/A|4 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, full term, appropriate weight for gestational age infants recruited on the        postnatal ward at Chelsea and Westminster Hospital, London, UK.|January 2014|January 13, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033005||52743|
NCT02033616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-OVA-P00|Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas|Phase II, Double-Blind, Randomized, Single Center Trial Of Ovapuldencel-T (Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells In GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells In GM-CSF (MC) as a Component of Maintenance or Secondary Therapy in Patients With Stage III or IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma After Debulking Surgery and Adjuvant Chemotherapy||Caladrius Biosciences, Inc.|No|Not yet recruiting|July 2016|December 2022|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|99|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033616||52696|
NCT02034461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55621|Micro-Electrodes Implanted in a Human Nerve|Can an Array of Micro-electrodes Implanted in a Human Nerve Record Neural Signals and Provide Sensory Feedback Useful for Controlling a Prosthetic Device?||University of Utah|Yes|Enrolling by invitation|April 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|May 3, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02034461||52631|
NCT02031185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI-24100018|A Wearable mHealth Device to Promote Teenagers' Physical Activity|A Wearable mHealth Device to Promote Teenagers' Physical Activity: A Pilot RCT||Seattle Children's Hospital|No|Active, not recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|40|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031185||52882|
NCT02031432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF6005/09|CORAL XT - Open-label Extension Trial of the CORAL Trial|An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial.|CORAL XT|Grünenthal GmbH|No|Active, not recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02031432||52863|
NCT02031718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511572|Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone|Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone||University of California, Davis|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|13 Years|19 Years|No|||February 2015|February 26, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031718||52841|
NCT02031731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28211|The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors|A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS||Hoffmann-La Roche||Recruiting|December 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031731||52840|
NCT02031991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7391001|A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers||Pfizer|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|102|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031991||52820|
NCT02059902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-105|Continuous Lidocaine Infusion for Management of Perioperative Burn Pain|Continuous Lidocaine Infusion for Management of Perioperative Burn Pain||HealthPartners Institute|No|Completed|September 2012|February 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02059902||50681|
NCT02031653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-151|Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test|||Samsung Medical Center|No|Recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|193|||Male|40 Years|N/A|No|Non-Probability Sample|Male patients with Low Urinary Tract Symptoms over 6 months.|January 2014|February 12, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031653||52846|
NCT02040454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-532|Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2)|The Use of Intravascular Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis: A Randomized Study (PaciFIST-2)|PaciFIST-2|Englewood Hospital and Medical Center|No|Withdrawn|March 2014|October 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 16, 2014||No|required catheters not available|No||https://clinicaltrials.gov/show/NCT02040454||52171|
NCT02040467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209025|Registry for Proton Beam Radiation Therapy|Registry for Proton Beam Radiation Therapy||Washington University School of Medicine|Yes|Recruiting|December 2013|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3200|||Both|N/A|N/A|No|Non-Probability Sample|Patient receiving proton beam therapy|February 2016|February 29, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040467|10 Years|52170|
NCT02031614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phlebotomy-2014|The Immunomodulatory Effects of Phlebotomy|The Immunomodulatory Effects of Phlebotomy||Radboud University|Yes|Not yet recruiting|January 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031614||52849|
NCT02031627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4010 FlexDose|Treatment Response to Different Lymphoedema Compression Programs Using a Pneumatic Compression Device|Physiologic Response to Varying Lymphoedema Compression Programs With the Flexitouch System||Tactile Medical|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031627||52848|
NCT02032459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0320070046|Vitamin D and Pregnancy: Camden Study|Vitamin D Status in Pregnant Women||Rowan University|No|Completed|April 2007|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1141|Samples With DNA|Blood and urine collection: Fasting (>8 h) maternal blood samples were collected at entry to      care and week 28 of gestation. Blood specimens were also collected at 1-hour of the 50g      glucose challenge test. Fasting blood samples collected at each visit were immediately      refrigerated and centrifuged at 4oC. Plasma and serum were preserved from each patient (at      -70oC) until assayed. 20 ml of urine was collected at entry to care and week 28 in metal      free plastic containers and stored at -70oC.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is conducted from previously collected data (N=1141) from the Camden Study of        low income gravidae and minority gravidae (White, African-American and Hispanic) living in        the northeastern United States (New Jersey).|January 2014|January 8, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02032459||52784|
NCT02032693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130411|Everycell's Effect on DNA Damage, Inflammation, and Stress|The Effect of Dietary Supplementation on DNA Damage, Inflammation, Stress, and Related Factors Important in Somatic and Stem Cell Senescence in Healthy Adults||University of Miami|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02032693||52766|
NCT02032966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-010|Surgical Versus Nonsurgical Treatment of Fibular Fractures: A Prospective Randomized Study|Outcomes Following Surgical Versus Nonsurgical Treatment of Fibular Fractures Following Operative Fixation of Unstable Medial Malleolus Fractures: A Prospective Randomized Study||University of Tennessee|No|Enrolling by invitation|April 2011|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|July 6, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032966||52745|
NCT02033356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-PJ-13|ED95 of Lidocaine 1.0% for Filling the Adductor Canal|An Estimate of the ED95 of Lidocaine 1.0% for Filling the Adductor Canal When Placing an Adductor Canal Block in Healthy Volunteers||Rigshospitalet, Denmark|Yes|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033356||52716|
NCT02033369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6853|Imaging Dopamine Release in Depression|Ventrostriatal Dopamine Release and Reward Motivation in MDD||New York State Psychiatric Institute|Yes|Recruiting|February 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033369||52715|
NCT02033902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-402|A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years|A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years||Eisai Inc.|No|Not yet recruiting|April 2014|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|12 Years|N/A|No|Non-Probability Sample|Epilepsy patients prescribed adjunctive treatment in countries where perampanel has        received marketing approval. Multiple treating physicians will prescribe perampanel to        patients, who then will be observed for approximately 52 weeks.|March 2014|March 28, 2014|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033902||52674|
NCT02034175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SomnaPatch-001|Comparison of SomnaPatch With Polysomnography in Sleep Disordered Breathing|Comparison of the Somnarus Sleep Apnea Diagnostic Technology SomnaPatch With Polysomnography in Sleep Disordered Breathing||Somnarus Inc|No|Recruiting|January 2014|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|85 Years|No|Non-Probability Sample|Patient who have been diagnosed with sleep disordered breathing (apnea or Cheyne-Stokes        respiration)|May 2015|May 18, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034175|1 Day|52653|
NCT02031198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-AD-002|18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease|An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study "AXON CO 18700"|FUNDAMANT|Axon Neuroscience SE|Yes|Active, not recruiting|January 2014|September 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|50 Years|86 Years|No|||May 2015|May 27, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031198||52881|
NCT02031211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29290|TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial|Etanercept for the Treatment of Chronic Regional Pain Syndrome||Stanford University||Recruiting|June 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Female|10 Years|17 Years|No|||November 2014|November 18, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031211||52880|
NCT02030340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-WF|Comparison of Air Charged Catheters With Water Filled Catheters for Urodynamic Study|In Vivo Comparison of Air Charged Catheters With Water Filled Catheters for Intravesical and Intrarectal Pressures Recording During Urodynamic Study|ACWF|UMC Utrecht|Yes|Recruiting|December 2013|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled (on the basis of contemporary clinical standards and protocols) for        standard urodynamic investigation.|January 2014|January 6, 2014|March 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02030340||52947|
NCT02030353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1323|The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors|Feasibility of Using Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors: a Randomized Pilot Study||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|35|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02030353||52946|
NCT02030652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIAE-2013-001|Impact of Synchronized Nasal Intermittent Positive Pressure Ventilation Using NAVA in Preterm Infants With RDS|Impact of Synchronized Nasal Intermittent Positive Pressure Ventilation Using Non Invasive Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants With Respiratory Distress||Hospital Israelita Albert Einstein|No|Recruiting|January 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|23 Weeks|36 Weeks|No|||August 2015|August 17, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030652||52923|
NCT02030925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-3718-201|Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors|A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors||Ironwood Pharmaceuticals, Inc.|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|65 Years|No|||November 2014|August 10, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030925||52902|
NCT02030938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-SERI-13-001|SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery|SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery||Allergan|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030938||52901|
NCT02030951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 13/115|Measurement of Feeding Experience for Infants With Non-Oral Feedings|Measurement of Feeding Experience for Infants With Non-Oral Feedings||Medical College of Wisconsin|No|Terminated|January 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|N/A|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Seventy-five infants who are expected to receive a minimum of two weeks of non-oral        formula/breast milk feedings during hospitalization and their mothers.|January 2016|January 13, 2016|December 11, 2013||No|Funding completed|No||https://clinicaltrials.gov/show/NCT02030951||52900|
NCT02031445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C012013|Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension|C012013|Celsus Therapeutics PLC|No|Recruiting|July 2014|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|2 Years|17 Years|No|||October 2014|October 14, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031445||52862|
NCT02031744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28345|A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer|A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH ERLOTINIB AS SECOND- OR THIRD-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE INCURABLE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER||Hoffmann-La Roche||Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031744||52839|
NCT02032004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41750/3100|The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure.|A Double-blind, Randomized, Sham-procedure-controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP-41750) in Patients With Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology||Teva Pharmaceutical Industries|Yes|Recruiting|January 2014|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032004||52819|
NCT02032017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201318915|Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation.|Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation Compared to the Anterolateral Approach.||Universiteit Antwerpen|Yes|Recruiting|October 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|80 Years|No|||January 2014|January 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032017||52818|
NCT02039596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutritional Metabolomics AIKN|Nutritional Metabolomics: the Search for Dietary Exposure Variables|Nutritional Metabolomics: the Search for Dietary Exposure Variables||Göteborg University|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02039596||52237|
NCT02031913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV_FL|Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD|Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease||Seoul National University Boramae Hospital|No|Recruiting|January 2013|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|We intended to collect sera from registered subjects, but no biospecimens are to be retained      yet.|Both|20 Years|80 Years|No|Non-Probability Sample|Chronic hepatitis B patients who showed evidences of hepatic steatosis on ultrasonography|December 2015|December 1, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031913|20 Years|52826|
NCT02031926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP training|Evaluation of Correct PEP Use With the Time|Evaluation of the Reproductibility of the Pressure Generated by a Positive Expiratory Pressure Device||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|November 2012|January 2014|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031926||52825|
NCT02032212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITG EVP G1 S1|A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product|A Randomised, Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product, a Nicotine Inhalator and a Conventional Cigarette||Imperial Tobacco Group PLC|No|Completed|December 2013|||May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02032212||52803|
NCT02032225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-34|Generation of a Cellular Model of CADASIL From Skin Fibroblasts|Obtention d'un modèle Cellulaire de la Maladie CADASIL à Partir de Fibroblastes cutanés de Patients||Institut National de la Santé Et de la Recherche Médicale, France|No|Enrolling by invitation|February 2014|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Skin biopsies will be collected to derive fibroblasts. These will be retained and      reprogrammed to iPS cells (also to be retained). iPS cells will be differentiated in      vascular smooth muscle cells.|Both|30 Years|60 Years|No|Non-Probability Sample|patients with CADASIL managed at the reference centre for rare vascular diseases of the        central nervous system and the retina (CERVCO) (Lariboisière Hospital, Paris, France)|January 2014|January 7, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02032225||52802|
NCT02032472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOF_IDIAP|Efficiency of Monitoring and Control Program of Hypertension Through Pharmacy Offices. APOF Project|Efficiency Program Monitoring and Control of Hypertension Through Pharmacy Offices. APOF Project|APOF|Jordi Gol i Gurina Foundation|No|Completed|January 2010|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|677|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02032472||52783|
NCT02032706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|Validation of Safety and Efficacy for Night Shift Therapy|Validation of Safety and Efficacy for Night Shift Therapy||Advanced Brain Monitoring, Inc.|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|No|||June 2014|February 3, 2016|January 8, 2014|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT02032706||52765|
NCT02033629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-JAN14|Low Remifentanil Target Controlled Infusions for Cardiac Surgery|Early Extubation After Cardiac Surgery: What Is the Appropriate Target Remifentanil Effect-Site Concentration?||Dammam University|Yes|Recruiting|August 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033629||52695|
NCT02030964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2012-01|N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan|N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma|DFMO|New Approaches to Neuroblastoma Therapy Consortium|Yes|Recruiting|December 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|30 Years|No|||December 2015|December 11, 2015|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030964||52899|
NCT02030366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9994-12-SMC|Chromatic Multifocal Pupillometer for Detection and Follow-up of Acute Head Injury|A Portable Chromatic Multifocal Pupillometer for Objective Early Detection and Follow-up of Changes in Intracranial Pressure in Patients With Acute Head Injury||Sheba Medical Center|No|Not yet recruiting||||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|TBI patients addmitted to Tel Hashomer Intensive Care Unit, and halthy volunteers.|December 2013|January 6, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030366||52945|
NCT02030379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14970|Developing an Online Clinical Trial Specific Question Prompt List|Developing an Online Clinical Trial Specific Question Prompt List||Virginia Commonwealth University|Yes|Terminated|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|December 10, 2013||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT02030379||52944|
NCT02030678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STao|A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer|To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.||Liaoning Tumor Hospital & Institute|Yes|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|65 Years|No|||July 2014|August 13, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030678||52921|
NCT02031458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28754|A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"|A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER||Hoffmann-La Roche||Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|635|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031458||52861|
NCT02031757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaitPert|Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments|The Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments.||Hadassah Medical Organization|No|Not yet recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2013|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031757||52838|
NCT02032030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203088|Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys|SATISFY-SOS: Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys|SATISFY-SOS|Washington University School of Medicine|No|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|36000|||Both|18 Years|N/A|No|Non-Probability Sample|We are attempting to recruit all-comers visiting our preoperative assessment clinic, with        current daily enrollment rates approaching 60%.|December 2015|December 23, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032030|1 Year|52817|
NCT02031471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28701|TOSCARA Study: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment|An Open-label, Single Arm Study to Evaluate the Efficacy and Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-naïve Patients With Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 16, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02031471||52860|
NCT02032303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ticagrelor - Prasugrel|Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .|||Azienda Policlinico Umberto I||Not yet recruiting|February 2014|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|18 Years|75 Years|No|||January 2014|January 8, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02032303||52796|
NCT02032316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 14-32-002|Feasibility Study of the Uriprene Stent Following Uncomplicated Ureteroscopy|URIPRENE: Feasibility Study to Evaluate the Preliminary Safety and Effectiveness of the Uriprene Stent Following Uncomplicated Ureteroscopy|URIPRENE|Adva-Tec|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|19 Years|79 Years|No|||January 2015|January 13, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032316||52795|
NCT02032550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC201|Treatment Preference and Patient Centered Prostate Cancer Care|Treatment Preference and Patient Centered Prostate Cancer Care||University of Pennsylvania|Yes|Active, not recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02032550||52777|
NCT02039908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH099030|Examining Tolerance to CNS Stimulants in ADHD|Examining Tolerance to CNS Stimulants in ADHD||Florida International University|Yes|Recruiting|April 2013|March 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|6 Years|12 Years|No|||February 2016|February 3, 2016|March 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02039908||52213|
NCT02031367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTPS PRP VS Steroid|Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome|Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater||C.R.Darnall Army Medical Center|Yes|Not yet recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031367||52868|
NCT02031380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43EY023122-01A1-1|iDropper Usability in Glaucoma|Improving Ophthalmic Medication Adherence||Care Team Solutions|Yes|Withdrawn|April 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|21 Years|85 Years|No|||December 2015|December 6, 2015|January 7, 2014|No|Yes|Funding|No||https://clinicaltrials.gov/show/NCT02031380||52867|
NCT02031393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217/13|Establishing First Trimester Markers for the Identification of High Risk Twin|Establishing First Trimester Sonographic, Biochemical and Clinical Markers for the Identification of High Risk Twin in the First Trimester||Assaf-Harofeh Medical Center|No|Active, not recruiting|September 2009|July 2014|Anticipated|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Maternal serum|Female|18 Years|50 Years|No|Non-Probability Sample|pregnant women that will come to our first trimester clinic inorder to preform first        trimester screeninig|December 2013|January 30, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031393|9 Months|52866|
NCT02031666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103299|A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|120|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031666||52845|
NCT02031939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013013|Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer|Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer||Sun Yat-sen University|Yes|Recruiting|January 2014|January 2023|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|556|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02031939||52824|
NCT02032238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAVNAV-2|Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema|||OD-OS GmbH||Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032238||52801|
NCT02032251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Emb-017|Reduction of Sperm DNA Fragmentation by Oral Ginger|Reduction of Sperm DNA Fragmentation by Oral Ginger (Zingiberofficinale) Extract Treatment||Royan Institute|Yes|Completed|December 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2009|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032251||52800|
NCT02032485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000653-42|Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer|Feasibility Study of the (Intravenously Injected) Indocyanine Green (ICG) Imaging of Tumoral Implants in Patients With Peritoneal Carcinomatosis From Colorectal Cancer|OC-AP-ICG-IV|Jules Bordet Institute|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2014|October 14, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02032485||52782|
NCT02032719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-259|Improved Self Management in Uncontrolled Systolic Hypertension|Investigating Improved Self Management in Uncontrolled Systolic Hypertension||York University|No|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|25 Years|70 Years|No|||January 2014|January 9, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02032719||52764|
NCT02033018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJ - 3/2013|Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization|Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization|AflibxMyopia|Instituto de Olhos de Goiania|Yes|Recruiting|October 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02033018||52742|
NCT02033031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Sacu|Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion|Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience||Medical University of Vienna|No|Completed|August 2012|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033031||52741|
NCT02033915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107036RB|The Effectiveness of Interactive Discussion Group Intervention About Suicide Risk Identification and Assessment for Clinical Nurses|The Effectiveness of Interactive Discussion Group Intervention to Improve Nurses' Abilities of Risk Identification and Assessment on People With Suicide Attempt or Self-harm Behavior||National Taiwan University Hospital||Completed|October 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 9, 2014|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT02033915||52673|
NCT02034500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03_02TP|Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults|A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults.||Novartis|Yes|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|14||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02034500||52628|
NCT02030704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDCCTA01|CCTA-based Coronary Plaque Characterization and High-sensitive Troponin T for the Prediction of Cardiovascular Outcomes|Comprehensive 'Bio-Imaging' Using Quantitative Coronary Plaque Composition Assessment and the High-sensitive Troponin T for the Prediction of Cardiac Outcomes.||University Hospital Heidelberg|No|Recruiting|February 2008|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|90 Years|No|Probability Sample|Consecutive patients scheduled to undergo CCTA|January 2014|January 7, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030704||52919|
NCT02030392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA1143/9-1|A Randomized-controlled Study of a Cognitive-behavioral Intervention for Children With Functional Abdominal Pain|"Stop the Pain"-A Multicenter, Randomized-controlled Study of a Cognitive-behavioral Intervention for Children With Functional Abdominal Pain|Stop-FAP|University of Potsdam|Yes|Active, not recruiting|April 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|7 Years|12 Years|No|||March 2016|March 24, 2016|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02030392||52943|
NCT02030691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/10|Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress|Tolerance of Nasal High Frequency Percussive Ventilation Versus Nasal CPAP in Neonatal Respiratory Distress in Term and Preterm (> 33 Weeks of Gestation) Neonates|TONIPEP|University Hospital, Bordeaux|No|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|30 Minutes|No|||July 2015|July 22, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030691||52920|
NCT02030977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|046468|The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis||National Nutrition and Food Technology Institute||Completed|June 2012|March 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||January 2014|January 7, 2014|December 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02030977||52898|
NCT02031224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWG13/2007|Supplemented Very Low Protein Diet and the Progression of Chronic Kidney Disease|Effect of Very Low Protein Diet Supplemented With Ketoanalogues of the Essential Amino Acids on the Progression of Chronic Kidney Disease|KETOPROG|Anemia Working Group Romania|Yes|Recruiting|March 2008|August 2014|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|85 Years|No|||August 2014|August 23, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031224||52879|
NCT02031484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zio study|Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial||Bardy Diagnostics, Inc.|No|Not yet recruiting|July 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Chicago, Charlotte, and Iowa under the care of a physician for symptoms listed        in the inclusion criteria|June 2014|June 25, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031484||52859|
NCT02031770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2017|Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease|Effect of Treatment of Metabolic Acidosis on Vascular Function in Patients With Chronic Kidney Disease: A Pilot Study||University of Colorado, Denver|No|Recruiting|January 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|70 Years|No|||January 2016|January 13, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031770||52837|
NCT02031783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.09.PER|Glucose:Fructose Versus Glucose Carbohydrate Ingestion and Endurance Performance|||Nestlé||Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|74|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02031783||52836|
NCT02060149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjhx-song1|The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline|The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study|NAEDRAP|Xijing Hospital|Yes|Not yet recruiting|March 2014|April 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||February 2014|February 9, 2014|March 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02060149||50662|
NCT02060162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1220/IRB 12-2568|Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa|CIDRZ 1220 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA)||University of North Carolina, Chapel Hill|No|Recruiting|December 2012|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|900|Samples With DNA|Specimen storage is optional and participants will provide additional informed consent. The      laboratory will store leftover blood specimens for up to 5 years for hepatitis related      serologic, immunological, and virologic studies pending availability of funding. Use of      specimens for any tests outside the realm of the goals and objectives of this study will      require additional approval by the REC.|Both|18 Years|N/A|No|Non-Probability Sample|Enrollment of 1,900 consecutive patients starting ART (900 in Zambia and 1,000 in        Mozambique) is planned.|December 2015|December 9, 2015|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02060162||50661|
NCT02060175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0076|Comparison of the 3-month Strut Coverage After Coronary Stenting by Optical Coherence Tomography; Cilotax and DESyne|||Yonsei University|No|Withdrawn|February 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|February 7, 2014||No|Because of the problem with Cilotax stent permission|No||https://clinicaltrials.gov/show/NCT02060175||50660|
NCT02031107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF-146639-1|Randomized Trial of Transcranial Theta-burst Stimulation and Transcranial Direct Current Stimulation|Randomized Controlled Trial of Transcranial Theta-burst Stimulation and Transcranial Direct Current Stimulation in Subacute Stroke||University Hospital, Geneva|No|Recruiting|September 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|16 Years|N/A|No|||December 2015|December 2, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02031107||52888|
NCT02031406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2TR000122-00034358|Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence|Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence||Cedars-Sinai Medical Center||Active, not recruiting|January 2014|July 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|155|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031406||52865|
NCT02031679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00089252|Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines|A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTH2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines||Johns Hopkins University|No|Recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||January 2014|January 24, 2014|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031679||52844|
NCT02031952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rvrl2005|Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma|Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma ----A Prospective Randomized Controlled Clinical Trail||Sun Yat-sen University|Yes|Completed|December 2005|June 2013|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|No|||January 2014|January 8, 2014|January 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031952||52823|
NCT02031965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-037|Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery|A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)||Pediatric Brain Tumor Consortium||Recruiting|December 2013|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|21 Years|No|||October 2015|October 19, 2015|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031965||52822|
NCT02032498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001555-12|Evaluation of Two Techniques for the SLN Detection in BC Patients|Evaluation of Near- InfraRed Imaging of ICG in Comparison With the Lymphoscintigraphic Technique Using Intramammary and Peritumoral Injection of 99mTc-HSA-Nanocolloids for the SLN Detection in BC Patients.||Jules Bordet Institute|No|Recruiting|July 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|214|||Female|18 Years|N/A|No|||July 2014|July 23, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02032498||52781|
NCT02032511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00073557|Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|Comparison of RAM Cannula NCPAP Versus Infant Flow NCPAP||University of Michigan||Enrolling by invitation|September 2013|||April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|6 Months|No|Non-Probability Sample|infants less than or equal to 7kg with an order for nasal continuous positive pressure|January 2014|January 9, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032511||52780|
NCT02032732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-106|Utilization of Leukocyte Esterase in the Diagnosis of Pediatric Joint Infections|Utilization of Leukocyte Esterase in the Diagnosis of Pediatric Joint Infections||University of Tennessee|No|Enrolling by invitation|December 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|3 Months|18 Years|No|Probability Sample|pediatric patients at a tertiary referral center who will receive an intra-articular        aspiration|March 2015|July 6, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02032732||52763|
NCT02033044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGREHAB|Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder|Randomized Controlled Trial Comparing the Effects on Psychosocial Functioning of Cognitive Rehabilitation Versus Psychoeducation in Borderline Personality Disorder||Hospital San Carlos, Madrid|Yes|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|45 Years|No|||January 2014|January 9, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02033044||52740|
NCT02030665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12728-11|Marijuana Treatment Project 4|Individualized Assessment and Treatment for Marijuana Dependence: Treatment Mechanisms|MTP4|University of Connecticut Health Center|No|Recruiting|February 2013|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|275|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030665||52922|
NCT02030717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 151:2010/81099|Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma|Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma|ASA|Umeå University|Yes|Completed|February 2012|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030717||52918|
NCT02030730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOXSIKF01|RCT of Brief Universal Parenting Program to Prevent Child Behavioural and Emotional Difficulties in Greece|A Randomised Controlled Trial of the Efficacy of Triple P (Positive Parenting Program) Seminar Series as a Universal Parenting Intervention for the Prevention of Emotional and Behavioural Difficulties in Greek Children Aged 2 to 12.||University of Oxford|Yes|Completed|March 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|124|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|January 7, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030730||52917|
NCT02031003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3611001|Effect of Infant Formulas Containing a New Fat Blend or the New Fat Blend Plus Fiber in Healthy Term Infants|Effect of an Infant Formula With High 2-Palmitic Vegetable Oil or an Identical Formula Supplemented With Oligofructose on Stool Composition and Stool Characteristics in Healthy Term Infants in Taiwan|9055A1-2000|Nestlé|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|220|||Both|N/A|45 Days|Accepts Healthy Volunteers|||January 2014|January 7, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02031003||52896|
NCT02031263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thermoplasty-Br|Efficacy of Bronchial Thermoplasty in Korean|Efficacy of Bronchial Thermoplasty in Korean Patients With Severe Asthma||Asan Medical Center|Yes|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02031263||52876|
NCT02031276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.6|Efficacy, Safety and Pharmacokinetics of BI 655066 in Patients With Active, Moderate-to-severe Crohn's Disease.|A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naïve to, or Were Previously Treated With Anti-TNF Therapy.||Boehringer Ingelheim||Active, not recruiting|February 2014|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|December 16, 2013||||No||https://clinicaltrials.gov/show/NCT02031276||52875|
NCT02030990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2014.0032|The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements|The Use of Intraoperative Mitomycin-C During Photorefractive Keratectomy and Its Effect on Postoperative Topical Steroid Requirements||United States Naval Medical Center, San Diego|Yes|Recruiting|August 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Anticipated|300|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030990||52897|
NCT02031237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.003|MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy|MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy||University of Michigan Cancer Center|Yes|Completed|April 2005|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|52|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|November 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031237||52878|
NCT02031250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.062|Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer|Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer||University of Michigan Cancer Center|Yes|Recruiting|February 2014|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031250||52877|
NCT02031497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012EL0905SEDULC|Comparison of the Effects of a 12-Week Consumption of Two Carbonated Beverages on Insulin Sensitivity||SEDULC|Institute For European Expertise in Physiology|No|Active, not recruiting|October 2012|September 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031497||52858|
NCT02031796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004257|Cardiac Vascular Reconstruction DynaCT for TAVI Procedures|Cardiac Vascular Reconstruction (CAVAREC) DynaCT for 3D Assessment of Aortic Valve During TAVI Procedures|CAVAREC|Mayo Clinic|Yes|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031796||52835|
NCT02032056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-064|Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period|The Effect of Probiotics in Reducing Infections and Allergic Manifestations in Young Children During the Complementary Feeding Period|ProbiComp|University of Copenhagen|No|Terminated|September 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Both|9 Months|13 Months|Accepts Healthy Volunteers|||June 2014|June 18, 2014|November 20, 2013||No|Changes in study design|No||https://clinicaltrials.gov/show/NCT02032056||52815|
NCT02032069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B406201112693|Pneumoproteins Expression in the Organ Donor|Pneumoproteins Expression in the Organ Donor||University Hospital of Mont-Godinne|No|Completed|January 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|20|Samples With DNA|lung tissues and serum|Both|5 Years|70 Years|No|Non-Probability Sample|Organ donors and lung recipients|March 2016|March 13, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02032069||52814|
NCT02032082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVLP-CO|Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning|||University Hospital of Mont-Godinne||Active, not recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|40|||Both|5 Years|65 Years|No|||March 2016|March 13, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032082||52813|
NCT02060422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-2011|Mindfulness-based Psychotherapy for Drug-resistant Epilepsy|Mindfulness-based Psychotherapy and Social Support Intervention for Drug-resistant Epilepsy||Chinese University of Hong Kong|Yes|Completed|August 2011|July 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060422||50641|
NCT02056652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817797|Prevention of Preterm Birth With a Pessary in Singleton Gestations|Prevention of Preterm Birth With a Pessary in Singleton Gestations|PoPPS|University of Pennsylvania|Yes|Recruiting|February 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|242|||Female|18 Years|50 Years|No|||June 2015|June 17, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02056652||50930|
NCT02031159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THER-ZeroHeatFlux|Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Temperature Monitoring|Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Method in Comparison With Sublingual and Nasopharyngeal Temperature Measurement||University of Schleswig-Holstein|Yes|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|17 Years|N/A|No|Non-Probability Sample|Patients older than 16 years undergoing elective surgery in either gynecology or trauma        surgery with a planned surgery time > 60 min.|May 2014|May 15, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02031159||52884|
NCT02031419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-DLBCL-001|Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma|A Phase 1b, Multi-Center, Open-Label Study Of Novel Combinations Of CC-122, CC-223, CC-292, And Rituximab In Diffuse Large B Cell Lymphoma||Celgene|No|Recruiting|December 2013|August 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02031419||52864|
NCT02031705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI|Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation|Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation for Paroxysmal Atrial Fibrillation||Seoul St. Mary's Hospital|No|Recruiting|November 2012|August 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|N/A|N/A|No|||May 2015|May 23, 2015|September 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02031705||52842|
NCT02031978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-3198-B-11-0020|Feeding My Baby - A National WIC Study|Women, Infant, and Children (WIC) Infant-Toddler Feeding Practices Study - II (ITFPS-2)||USDA Food and Nutrition Service|No|Active, not recruiting|July 2013|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4435|||Both|N/A|3 Months|No|Probability Sample|The target study participant is the infant. Mothers will be recruited prenatally and        mothers/primary caregivers of infants will be recruited postnatally at 80 WIC clinic        service locations.|May 2015|May 27, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031978||52821|
NCT02032264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2013-04|Next Generation Sequencing Screening for Embryonic Ploidy Status|Evaluation of the Efficacy of Next Generation Sequencing in Predicting Embryonic Karyotype and Subsequent Pregnancy Outcomes in in Vitro Fertilization Cycles (IVF)|nexgen|Reproductive Medicine Associates of New Jersey|No|Active, not recruiting|December 2013|October 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|42 Years|No|||November 2015|November 16, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032264||52799|
NCT02033928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13135|Comprehensive Frailty Assessment|Comprehensive Frailty Assessment||Ohio State University Comprehensive Cancer Center|No|Recruiting|April 2014|August 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at The Ohio State University with a plamsa cell dyscrasia and/or any patient        receiving a blood or marrow transplant at Ohio State will be considered for this study.|October 2015|October 16, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02033928||52672|
NCT02033382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02903|Biomarkers in First Episode Schizophrenia|Biomarkers in First Episode Schizophrenia||New York University School of Medicine|Yes|Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|-  Whole Blood        -  DNA        -  Saliva        -  Serum        -  Plasma|Both|16 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be 20 patients , ages 15-40, with first episode schizophrenia or        schizophreniform disorder with onset before age 35 who are medication naive and do not        meet criteria for major depression or significant suicidal ideation or substance abuse        (except nicotine) and 20 age and gender matched healthy controls. Subjects will be        recruited by physicians in the Bellevue Hospital emergency room, outpatient clinic and on        the Bellevue psychiatric inpatient units.        Potential subjects will be identified by clinicians and asked whether they would like to        speak to a researcher. Healthy subjects will be recruited through advertising by using a        flyer. Potential subjects referred by a clinician or expressing interest in participation        will meet with study staff for an informational meeting. The study will be explained to        the individual and in the event that he or she is interested in participating will then be        given the consent form to read and review.|October 2015|October 5, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02033382||52714|
NCT02033642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HealthU R01|A Family-Based Weight Loss Intervention for Youth With Intellectual Disability|A Family-Based Weight Loss Intervention for Youth With Intellectual Disability|HealthU|University of Massachusetts, Boston|Yes|Completed|August 2012|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|15 Years|22 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02033642||52694|
NCT02034487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01328087|Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment|Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment - Retrospective Experience From a Single Tertiary Referral Centre 1990-2013||Rigshospitalet, Denmark||Completed|January 1990|October 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|451|Samples With DNA|serum and white cells|Male|13 Years|20 Years|No|Non-Probability Sample|The study population consisted of boys who were referred to be evaluated for delayed        puberty at the Department of Growth and Reproduction between January 1990 and February        2013.|January 2014|January 10, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034487||52629|
NCT02030743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19456|A Study of Visual Attention Training to Improve Balance and Mobility|A Study of Visual Attention Training to Improve Balance and Mobility||University of Waterloo|No|Completed|February 2014|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02030743||52916|
NCT02030756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vibrant-14-MS-CTIL|Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals|Assessment of the Performance, Efficacy and Safety of Vibrating Capsule Medical Device in Aiding Reliving Constipated Individuals.||Vibrant Ltd.|No|Recruiting|July 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|80 Years|No|||December 2015|December 9, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030756||52915|
NCT02031016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFLECT study|Remifentanil vs Fentanyl During Cardiac Surgery and Chronic Thoracic Pain|A Randomised Clinical Trial Evaluating the Effect of Remifentanil vs Fentanyl During Cardiac Surgery on the Incidence of Chronic Thoracic Pain|REFLECT|St. Antonius Hospital||Active, not recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|126|||Both|18 Years|85 Years|No|||February 2016|February 10, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02031016||52895|
NCT02031289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFA2012/IDCS|Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.|Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.||University of Zurich|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02031289||52874|
NCT02031510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-Nov13(2)|Dexmedetomidine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy|Dexmedetomidine as an Adjuvant to Bupivacaine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy: Multicentre Study||Dammam University|Yes|Completed|January 2014|March 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|195|||Both|18 Years|65 Years|No|||April 2015|April 3, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031510||52857|
NCT02031809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC_VATS complic|Multicentric Study VATS Major Introperative Complications|Analysis of the Most Common Major Intraoperative Complications During Video-assisted Thoracoscopic Surgery (VATS) Anatomical Resections - On Behalf of MITIG-ESTS||University Hospital, Gasthuisberg|No|Active, not recruiting|January 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2000|||Both|18 Years|90 Years|No|Probability Sample|All patients intended to undergo a vats anatomical resection|January 2014|January 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031809||52834|
NCT02032095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B211-10|The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.|The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.||Japan Blood Products Organization|No|Completed|November 2013|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032095||52812|
NCT02032355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61538|The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section|The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section||Fudan University||Recruiting|January 2014|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Female|20 Years|40 Years|No|Probability Sample|American Society of Anesthesiologists physical status I and II patients undergoing        elective cesarean delivery under combined spinal-epidural (CSE) anesthesia|January 2014|January 9, 2014|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032355||52792|
NCT02056665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-MANECE|Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome|Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome|A-MANECE|Puerta de Hierro University Hospital|No|Completed|January 2014|November 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|6 Years|30 Years|No|||October 2014|October 19, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056665||50929|
NCT02031692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2013-092|Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV|Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in Benign Paroxysmal Positional Vertigo: A Prospective Multicenter Randomized Trial||Seoul National University Bundang Hospital|Yes|Recruiting|December 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2018|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031692||52843|
NCT02032524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13769|NeoGAA Extension Study|An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease|NEO-EXT|Sanofi|Yes|Recruiting|February 2014|June 2024|Anticipated|May 2024|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|N/A|N/A|No|||March 2016|March 3, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032524||52779|
NCT02032745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-35|Genomic Signatures to Predict Treatment Response|Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer|AGO-Austria|Medical University of Graz|Yes|Recruiting|August 2011|September 2020|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|277|Samples With DNA|Breast cancer tissue|Female|18 Years|80 Years|No|Probability Sample|Breast cancer patients with advanced HER 2 negative breast cancer|February 2016|February 1, 2016|November 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02032745||52762|
NCT02033057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pi12/01018|Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.|Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.||Hospital Universitario La Fe|No|Recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2012|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033057||52739|
NCT02033395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0910-JZ-CTIL|A Correlation Between Hair Cortisol Levels and the Development of Post Traumatic Stress Disorder (PTSD)|A Correlation Between Hair Cortisol Levels and the Development of Post Traumatic Stress Disorder (PTSD)||Sheba Medical Center|No|Not yet recruiting|January 2014|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women, age 18-70, who were examined in the ER following a traumatic event.|January 2014|January 9, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033395||52713|
NCT02034474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6729|Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia|Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial||New York State Psychiatric Institute|No|Recruiting|February 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|59 Years|No|||December 2015|December 3, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034474||52630|
NCT02034240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNVK:1305 385|Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis?|Secretion of Neutrophil Gelatinase Associated Lipocalin in Septic Patients and the Development of Acute Kidney Injury||Sygehus Lillebaelt|Yes|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|N/A||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with no prior record of kidney failure|April 2015|April 19, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02034240|5 Weeks|52648|
NCT02030405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0028|Ixazomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) With Mutated Nucleophosmin-1 (NPM1+)||Stanford University||Terminated|March 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|November 25, 2013|No|Yes|Due to GCP findings from another study audit|No||https://clinicaltrials.gov/show/NCT02030405||52942|
NCT02030769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130925-4|Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer|Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer||Xijing Hospital of Digestive Diseases|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030769||52914|
NCT02031302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP6461|RESPOND Post Market Study|RESPOND: Repositionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes|RESPOND|Boston Scientific Corporation|No|Recruiting|May 2014|January 2021|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed        the Informed Consent Form (ICF) and are selected to receive a Lotus Valve will be        evaluated for enrollment in this study.|July 2015|July 20, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02031302||52873|
NCT02031536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2212|Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery|A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver||Eastern Cooperative Oncology Group|No|Recruiting|January 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031536||52855|
NCT02031549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-13-0038|Prospective Observational Correlation of Sperm Assay Results With Blastocyst Formation|Prospective Observational Correlation of Sperm Assay Results With Blastocyst Formation||Fertility Center of Las Vegas|No|Completed|January 2014|April 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Couples who undergoing IVF treatment who have surplus sperm available after oocyte        insemination.|March 2015|March 4, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031549||52854|
NCT02031523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO.2-20130301|Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis|A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|45 Years|No|||December 2013|November 18, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02031523||52856|
NCT02031822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6804|Two US-guided Techniques for Greater Occipital Nerve Blocks|Evaluation of Two Ultrasound-guided Techniques for Greater Occipital Nerve Injections of Local Anesthetic and Steroid for Treatment of Primary Headaches|GON|University Health Network, Toronto|No|Recruiting|June 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031822||52833|
NCT02032108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LID|Effects of Lifestyle Education Programs on Diabetes Control in Rwanda|Effects of Lifestyle Education Programs on Diabetes Control Among Diabetic Patients at Kigali University Teaching Hospital Rwanda|LIDI|Kigali University Teaching Hospital|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|250|||Both|21 Years|75 Years|No|||January 2014|January 8, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032108||52811|
NCT02032368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCtrial001|Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence|Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence||Guangdong General Hospital|Yes|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|57|||Both|18 Years|75 Years|No|||January 2014|January 8, 2014|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032368||52791|
NCT02056678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140011H|Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA|Use of IV Acetaminophen Intraoperatively in Obese Patients at Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Cholecystectomy||The University of Texas Health Science Center at San Antonio|No|Terminated|February 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|February 5, 2014|Yes|Yes|Investigator left institution|No||https://clinicaltrials.gov/show/NCT02056678||50928|
NCT02032277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-011|A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer|A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)||AbbVie|Yes|Recruiting|April 2014|February 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|624|||Female|18 Years|99 Years|No|||February 2016|February 7, 2016|December 13, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02032277||52798|
NCT02032758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007930|Study of Arm and Putter Movement in Golfers With Golfer's Cramp|Golfer&Apos;s Cramp: Correlation of Wrist Movements and Surface EMG With Putter Movements||Mayo Clinic|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02032758||52761|
NCT02032771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-M22-IPL&ResurFX-13-02|Impact of M22 Synergistic Sequential Treatment (SST)|Impact of M22 Synergistic Sequential Treatment (SST) Using Intense Pulsed Light and Fractional Non-ablative Photothermolysis on Skin Texture||Lumenis Ltd.|No|Active, not recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032771||52760|
NCT02033096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-203|Follow-up, Blinded-Outcomes Trial of Subjects Having Received IMP in Clinical Trial 64,185-202|A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 Trial Number: 64,185-203 Trial Phase:||InfaCare Pharmaceuticals Corporation||Completed|October 2008|June 2015|Actual|June 2015|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|42|||Both|N/A|4 Years|No|Non-Probability Sample|Subjects who have received stansaporfin in clinical trial 64,185-202|January 2016|January 6, 2016|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02033096||52736|
NCT02033070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Barrett's RFA|Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System|Single Center Patient Registry Using Radio Frequency Ablation of Barrett's Esophagus Using HALO System|HALO|Ochsner Health System|No|Not yet recruiting|November 2013|||November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|||Samples Without DNA|Serum from Biopsy|Both|N/A|N/A|No|Non-Probability Sample|Adult patients presenting with esophageal intestinal metaplasia (IM), including the        pathological subclasses of non-dysplastic IM, low-grade dysplasia (LGD) and high-grade        dysplasia (HGD)|January 2014|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033070|2 Years|52738|
NCT02033083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|laminariavsdilapan|Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation|Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation: A Randomized Controlled Trial||Planned Parenthood of New York City, Inc.|Yes|Recruiting|December 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 24, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033083||52737|
NCT02033408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCS-FMT-01|Manipulating the Microbiome in IBD by Antibiotics and FMT|Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial|FMT|Shaare Zedek Medical Center|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|28|||Both|2 Years|75 Years|No|||May 2015|May 25, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02033408||52712|
NCT02033655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050540|A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women|A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women|POWR-UP|Duke University|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|45 Years|N/A|No|||December 2015|March 7, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033655||52693|
NCT02033668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116891|Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers|A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|January 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02033668||52692|
NCT02034188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-UCMSC-001|Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis|Phase 1//2 Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis||Translational Biosciences|Yes|Active, not recruiting|January 2014|August 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||February 2016|February 4, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034188||52652|
NCT02034201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119273|Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence|||University of Arkansas||Recruiting|February 2014|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034201||52651|
NCT02034214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037044|Shaping the Health of Adolescents in Zimbabwe|Economic Opportunity for Zimbabwean Adolescent Orphans|SHAZ!|University of California, San Francisco|No|Completed|February 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|367|||Female|16 Years|19 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034214||52650|
NCT02034227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-2000-II-01|Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia|An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia||Spirogen||Terminated|April 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|60 Years|No|||November 2015|November 19, 2015|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034227||52649|
NCT02030418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-02374|The LEADLESS Pacemaker IDE Study (Leadless II)|Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker||St. Jude Medical|Yes|Enrolling by invitation|February 2014|||June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|667|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030418||52941|
NCT02030444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExtStaging-2014.1|Extensive Staging in Lung Cancer|Randomized Study Comparing Standard Staging of Lung Cancer With Extended Staging Including EBUS-TBNA and PET-MRI|ExtStaging|St. Olavs Hospital|No|Recruiting|August 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|N/A|N/A|No|||October 2015|October 26, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02030444||52939|
NCT02031315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-SD 2013|Epidemiology of Sudden Death in Cameroon|Sudden Death in Sub-Saharan Africa: Design and Protocol of The DOUALA-SD Prospective Survey|DOUALA-SD|Cameroon Resuscitation Council|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|First, the subject must be a permanent resident of one of 4 'health areas' included in the        study. Second, each district of interest must have an updated population census.|January 2014|January 9, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031315|72 Months|52872|
NCT02031562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1002090203|Geriatrics Balance and Low Back Pain Study|Geriatric Balance and Low Back Pain and Balance Assessment and Management||Logan College of Chiropractic|Yes|Completed|October 2009|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02031562||52853|
NCT02031848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11123|Brain Function Predictors And Outcome Of Weight Loss And Weight Loss Maintenance|Brain Function Predictors And Outcome Of Weight Loss And Weight Loss Maintenance||University of Kansas Medical Center|No|Completed|September 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|137|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031848||52831|
NCT02031861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-004PIV|Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension|Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension||Shanghai Shyndec Pharmaceutical Co.,Ltd.|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|No|||April 2014|February 3, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02031861||52830|
NCT02031835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIoannina612014|Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury Patients|Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury Patients||University of Ioannina|No|Recruiting|March 2012|March 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|88 Years|No|||May 2015|May 26, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02031835||52832|
NCT02032121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070584|Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors|Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors||University of Miami|No|Completed|October 2007|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|6 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032121||52810|
NCT02032381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120137|Prospective Study of Belated Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.|Prospective Study of Late Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.|RESPPEDHEM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|500|||Both|N/A|18 Years|No|||February 2016|February 24, 2016|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02032381||52790|
NCT02032615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051046|Let's be Well Red: Efficacy of Gudness Bars in Improving the Hemoglobin and Hematocrit Levels of Anemic Subjects|Let's Be Well Red (LBWR)|LBWR|Duke University|No|Completed|April 2014|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|358|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032615||52772|
NCT02032628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQA-5|DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise|DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise|GEM|University of Colorado, Boulder|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|240|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02032628||52771|
NCT02032901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-218|Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV|A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection|ALLY 3|Bristol-Myers Squibb|No|Completed|January 2014|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|January 9, 2014|Yes|Yes||No|August 12, 2015|https://clinicaltrials.gov/show/NCT02032901||52750|
NCT02056444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeACH-R Trial|Efficacy of Intravenous Versus Topical Tranexamic Acid in Primary Total Hip Arthroplasty|Tranexamic Acid Comparison in Hip Replacement (TeACH-R) Trial: Comparative Efficacy of Intravenous Versus Topical Tranexamic Acid for Reducing Blood Loss in Elective Primary Total Hip Arthroplasty.|TeACH-R|Lawson Health Research Institute|No|Completed|February 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056444||50946|
NCT02032290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ticagrelor - Clopidogrel|Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel|||Azienda Policlinico Umberto I||Not yet recruiting|February 2014|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|18 Years|75 Years|No|||January 2014|January 8, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02032290||52797|
NCT02032537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shavit.ctil|Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus|||Shaare Zedek Medical Center||Not yet recruiting|November 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02032537||52778|
NCT02033109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #558|Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use|A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptability of PC-1005 Microbicide Gel Formulation in HIV-seronegative Women||Population Council|Yes|Active, not recruiting|May 2014|June 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|35|||Female|19 Years|49 Years|Accepts Healthy Volunteers|||September 2014|April 29, 2015|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033109||52735|
NCT02033421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IE-100-2014|Beta-lactam Pharmacokinetics in Patients With Infective Endocarditis|Beta-lactam Pharmacokinetic Profiles in Patients With Infective Endocarditis||University of Aarhus|No|Recruiting|December 2013|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Patients admitted with infective endocarditis at the Department of Cardiology, Aarhus        University Hospital, Denmark, treated with beta-lactam antibiotics.|June 2015|June 17, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02033421||52711|
NCT02032810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17439|Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma|A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02032810||52757|
NCT02033122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETA1|Effect of Aerobic Training in Moderate or Severe Asthmatic Patients|Effect of Aerobic Training on Bronchial Hyperresponsiveness and Systemic Inflammation in Patients With Moderate or Severe Asthma: a Randomized Controlled Trial|ETA1|Instituto de Investigação em Imunologia|No|Recruiting|July 2012|December 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|20 Years|59 Years|No|||January 2014|January 9, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02033122||52734|
NCT02033434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECINKT-001|Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study|Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study|PRECINKT|University of Calgary|Yes|Not yet recruiting|March 2014|September 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|79 Years|No|||January 2014|January 9, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02033434||52710|
NCT02033941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0307|Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)|Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2014|November 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||November 2015|November 5, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033941||52671|
NCT02033954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0088 / 04|Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding|PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding - OCCLUDE II|OCCLUDE-II|ArtVentive Medical Group, Inc.|Yes|Recruiting|July 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects requiring permanent occlusion of the peripheral vessels for the following        conditions:          1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury          2. Hemorrhage caused by a neoplasia          3. Neoplastic process (tumor)          4. Gastrointestinal bleeding          5. Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous             malformations or an arteriovenous fistula          6. Interrupting blood supply to an organ or part of an organ for permanent             devascularization          7. Devascularization of tissues involved by a neoplastic process either pre-operatively             or as a palliative measure.          8. Transjugular Intrahepatic Portosystemic Shunt (TIPS)|June 2015|June 22, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033954|30 Days|52670|
NCT02030457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDB-AS-101|A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults|A Randomized, Open-Label, 3-Period Crossover, Single-Dose Clinical Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Beclomethasone Dipropionate (160 and 320 mcg) Delivered Via Breath-Actuated Inhaler (BAI) and Metered-Dose Inhaler (MDI) in Healthy Adult Subjects||Teva Pharmaceutical Industries|No|Completed|December 2013|June 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02030457||52938|
NCT02030470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5716|Evaluation of Photodynamic Treatment FOTOSAN® Efficacy in Periodontology|Evaluation of Photodynamic Treatment FOTOSAN® Efficacy in Periodontology||University Hospital, Strasbourg, France|No|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|36|||Both|40 Years|N/A|No|||December 2013|June 16, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02030470||52937|
NCT02041715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKM-EBOV-002|Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With An Additional Multiple-Dose Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers||Arbutus Biopharma Corporation|Yes|Terminated|January 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|January 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02041715||52074|
NCT02041728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54845|The Detection of Early Dementia With the Digital Game Memory|||Universitaire Ziekenhuizen Leuven|Yes|Completed|January 2013|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|20|||Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  healthy subjects of 75 or older          -  subjects with mild dementia of 75 or older|January 2013|January 17, 2014|June 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02041728||52073|
NCT02041741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAP-FLA|Improving Happiness in Flanders|Happiness in Flanders: A Randomized, Wait-List Controlled Study|HAP-FLA|Universitaire Ziekenhuizen Leuven|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|10863|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|May 28, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02041741||52072|
NCT02042053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU S12-03902|PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer|Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients||New York University School of Medicine|Yes|Terminated|January 2014|October 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|18 Years|N/A|No|||March 2016|March 10, 2016|January 17, 2014|No|Yes|Due to PI leaving the institution|No||https://clinicaltrials.gov/show/NCT02042053||52050|
NCT02032134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUP: G33F1100003000|Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia|Experimental Protocol for the Infusion of Platelets,Cryopreserved With Dimethyl Sulphoxide (DMSO) and Obtained From Multiple Donors Buffy Coats, in Patients With Severe Thrombocytopenia|MICE|University of Palermo|Yes|Recruiting|July 2015|September 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032134||52809|
NCT02032394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMS910212|Effect of Chlorhexidine on Bacteriuria|Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit||Mashhad University of Medical Sciences|No|Recruiting|July 2013|April 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|105|||Both|18 Years|55 Years|No|||January 2014|January 8, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032394||52789|
NCT02032641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120936|Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars|Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars||University of Miami|No|Completed|June 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032641||52770|
NCT02032914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Prevalence of Colon Cancer in Pyogenic Liver Abscess|The Prevalence of Colonic Neoplasm in Cryptogenic Pyogenic Liver Abscess||Inje University|No|Completed|January 2014|February 2016|Actual|February 2016|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|The patients diagnosed as pyogenic liver abscess, the cause of which is not found at        initial evaluation|February 2016|February 26, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032914|3 Months|52749|
NCT02033226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVS031101|Clinical, Anti-Inflammatory And Anti-Infective Properties Of Amniotic Membranes Used For Guided Tissue Regeneration|Evaluation of Clinical, Anti-Inflammatory and Anti-Infective Properties of Amniotic Membranes Used For Guided Tissue Regeneration in Contained Defects||SVS Institute of Dental Sciences|Yes|Completed|March 2012|September 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|54|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033226||52726|
NCT02033239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3887|A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|64 Years|No|||October 2014|October 15, 2014|January 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02033239||52725|
NCT02056457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR06997|An Evaluation of Selected Responsible Fatherhood and Healthy Marriage Programs: Parents and Children Together|Parents and Children Together|PACT|Mathematica Policy Research, Inc.|No|Recruiting|December 2012|November 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02056457||50945|
NCT02032784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|541923|Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding|Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding||Florida Hospital|Yes|Recruiting|March 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|124|||Both|18 Years|89 Years|No|||November 2015|November 24, 2015|January 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02032784||52759|
NCT02032797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFETA-5|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.|PROFETA-5|Universitair Ziekenhuis Brussel|No|Recruiting|November 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|39 Years|No|||January 2014|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032797||52758|
NCT02032563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-ICG-IV-NACT|Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy|Study of the (Intravenously Injected) Indocyanine Green Distribution in Tumour Bearing Breasts and in Axillary Pieces of Dissection of Patients Who Have Received Neoadjuvant Therapy for Histologically Proven Mammary Cancer||Jules Bordet Institute|No|Recruiting|December 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||July 2014|July 23, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02032563||52776|
NCT02032823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081CC00006|Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer|A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy|OlympiA|AstraZeneca|Yes|Recruiting|April 2014|February 2028|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|130 Years|No|||February 2016|February 26, 2016|January 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02032823||52756|
NCT02033447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0257|Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men|Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men|MAGNABLATE I|University College London Hospitals|Yes|Recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Male|N/A|N/A|No|||January 2014|January 9, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02033447||52709|
NCT02033707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082804|Effects of Hallucinogens and Other Drugs on Mood and Performance|Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance||Johns Hopkins University|Yes|Recruiting|April 2014|January 2020|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033707||52689|
NCT02033720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104666|Study of Survivors of Different Types of Cardiac Arrest and Their Neurological Recovery|Neurological Outcomes After Cardiac Arrest in Pulseless Electrical Activity in Comparison to Asystole. Are All Non-shockable Rhythms the Same?||Lawson Health Research Institute|No|Not yet recruiting|January 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|400|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients admitted to the intensive care unit (ICU) with a diagnosis of postcardiac        arrest between Jan 2008 and Dec 2012 will be examined.|January 2014|January 9, 2014|January 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02033720||52688|
NCT02033967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN_SVV_CVP|Vasodilator-induced Hypovolemia in Living Liver Donors|Vasodilator-induced Hypovolemia in Living Liver Donors: Central Venous Pressure-guided vs Stroke Volume Variation-guided Technique||Seoul National University Hospital|Yes|Recruiting|January 2014|||January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|20 Years|60 Years|No|||May 2015|May 27, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033967||52669|
NCT02033681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-1|Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution|Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution to Visualize Operation Field in Hand Surgery Without Tourniquet||Indonesia University|Yes|Enrolling by invitation|September 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02033681||52691|
NCT02033694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The LRP Study|The Lipid-Rich Plaque Study|The Lipid-Rich Plaque (LRP) Study|LRP|InfraReDx|Yes|Recruiting|January 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|9000|||Both|N/A|N/A|No|Non-Probability Sample|Patients presenting for coronary angiography in whom IVUS and/or NIRS evaluation is        planned or could be utilized as part of their clinically-indicated evaluation will be        screened for participation.|February 2016|February 22, 2016|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033694||52690|
NCT02034513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3995|A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes|A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)|SWITCH 1|Novo Nordisk A/S|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|503|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034513||52627|
NCT02041702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-031-AP-LV|Safety and Efficacy of St Jude Medical ( SJM ) MRI Conditional Pacing System Undergoing Cardiac MRI Scan|A Clinical Evaluation of the Safety and Efficacy of SJM MRI Conditional Pacing System in Patients Undergoing Cardiac Magnetic Resonance Imaging (Conducted Under the Protocol Title "A Clinical Evaluation of the SJM MRI Conditional Pacing System in Subjects Undergoing Cardiac Magnetic Resonance Imaging " in India)||St. Jude Medical|No|Recruiting|June 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||July 2014|July 6, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02041702||52075|
NCT02041754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/009913|Safety and Efficacy of IQP-AK-102 in Reducing Appetite|Double Blind, Randomized, Placebo-controlled, Monocentric Clinical Investigation to Evaluate Efficacy of IQP-AK-102 on Appetite Reduction in Healthy Overweight and Obese Subjects||InQpharm Group|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02041754||52071|
NCT02042066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHT-01|Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension|Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension|RHT|Medispec|No|Not yet recruiting|January 2015|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2014|January 21, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02042066||52049|
NCT02042287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026/13|Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis|Controlled, Monocentre, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV)||University Hospital Inselspital, Berne|No|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042287||52032|
NCT02042300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-11|XIENCE Xpedition/Alpine in Routine Clinical Practice|Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY|IRIS XPEDITION|Asan Medical Center|Yes|Recruiting|July 2014|June 2021|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|19 Years|N/A|No|Non-Probability Sample|patients with XIENCE Xpedition or Alpine stent|March 2016|March 14, 2016|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02042300|5 Years|52031|
NCT02042547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAURENT PARI 2010|Study Of Factors Favoring The Onset Of Novo Atrial Fibrillation In The Immediate Aftermath Of Coronary Artery Bypass Surgery|STUDY OF FACTORS FAVORING THE ONSET OF NOVO ATRIAL FIBRILLATION IN THE IMMEDIATE AFTERMATH OF CORONARY ARTERY BYPASS SURGERY||Centre Hospitalier Universitaire Dijon||Completed|September 2010|||September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|79 Years|No|Probability Sample|Coronary artery bypass graft with or without extracorporeal circulation|November 2010|January 22, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042547||52012|
NCT02042820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-149H|Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation|Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation||Massachusetts Eye and Ear Infirmary|No|Completed|January 2014|||July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without Dry Eye Disease|December 2014|October 27, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042820||51991|
NCT02042833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25557|An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)|||Hoffmann-La Roche||Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|815|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease not on dialysis (with or without previous renal        transplantation), initiating treatment with Mircera, and erythropoiesis-stimulating agent        (ESA)-naïve or not|November 2015|November 2, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02042833||51990|
NCT02043171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2014-CS01|Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2|Year-long Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D With and Without Exercise on Muscular Strength and Functionality in Older Adults.||Metabolic Technologies Inc.|Yes|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02043171||51964|
NCT02043184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA162401-01A1|Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR|Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR||Michigan State University|No|Recruiting|March 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|274|||Both|21 Years|N/A|No|||December 2015|December 28, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043184||51963|
NCT02056964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00025114|HEART Pathway Implementation|The HEART Pathway: Bridging the Gap Between Operations, Research, and Education||Wake Forest Baptist Health|No|Recruiting|November 2013|November 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|8000|||Both|21 Years|N/A|No|Probability Sample|The target population is adult patients with acute chest pain, but without obvious Acute        Coronary Syndrome (ACS) on Electrocardiogram (ECG). Therefore, adult patients (>21 years        old) with acute chest pain, for whom the provider orders troponins, and without evidence        of an ST-segment elevation myocardial infarction (STEMI) on ECG, will be included. Based        on STEMI rates at Wake Forest Baptist Medical Center (WFBMC) we expect less than 5% of        patients with acute chest pain to be excluded due to ECG criteria.|December 2015|December 8, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056964||50906|
NCT02032329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S4UD|FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device|FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device||customKYnetics|No|Recruiting|January 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|21 Years|80 Years|No|||January 2014|January 8, 2014|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02032329||52794|
NCT02032849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCYHRT-001|Air-impingement Manipulation to Clear Subglottic Secretion Compared With Drainage Tube in Prolonged Intubated Patients|Air-impingement Manipulation to Clear Subglottic Secretion Compared With Drainage Tube in Prolonged Intubated Patients, a Randomized Controlled Trial.||Beijing Chao Yang Hospital|Yes|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|90 Years|No|||August 2014|August 13, 2014|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02032849||52754|
NCT02033135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 4 2012 027|Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis|Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA)|PESETA|Rigshospitalet, Denmark|No|Recruiting|June 2012|August 2017|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033135||52733|
NCT02033148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 237913|Icotinib Hydrochloride in Treating Patients With Advanced Cancers|A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers||Roswell Park Cancer Institute|No|Withdrawn|August 2014|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|January 8, 2014|Yes|Yes|changes in study design by sponsor not acceptable for participating|No||https://clinicaltrials.gov/show/NCT02033148||52732|
NCT02033733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5511|When Cooling a Patient After Cardiac Arrest, Does Use of a Neuromuscular Blocking Agent Make Your Job Easier?|Post-arrest Therapeutic Hypothermia. Does Use of Neuromuscular Blockers Achieve Faster Cooling Time?||Lawson Health Research Institute|No|Not yet recruiting|January 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients admitted to the intensive care unit (ICU) with a diagnosis of postcardiac        arrest between Jan 2008 and Dec 2012 will be examined.|January 2014|January 9, 2014|January 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02033733||52687|
NCT02033980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxh[2013]125|Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions|Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions ----- a Multicenter Study in China||Shanghai Jiao Tong University School of Medicine|No|Not yet recruiting|January 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|90 Years|No|||January 2014|January 9, 2014|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02033980||52668|
NCT02034253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH102951|Glutamate, Brain Connectivity and Duration of Untreated Psychosis|Glutamate, Brain Connectivity and Duration of Untreated Psychosis|DUP|University of Alabama at Birmingham|No|Recruiting|January 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|134|Samples With DNA|Genes related to glutamate, n-acetyl-aspartate, dopamine, schizophrenia, and treatment      response to antipsychotic medication will be collected.|Both|17 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators expect to enroll a total of 67 male and female patients with first        episode psychosis and 67 demographic matched controls.        Among patients who participate in research at the University of Alabama at Birmingham        (UAB) the approximate gender, ethnic and race distribution is 75% male and 25% female; 1%        Hispanic and 99% Non-Hispanic; 54% White, 44% Black, and 1% Asian/Pacific Islander. The        gender distribution is consistent with that observed in clinical populations with        schizophrenia.        Persons below the age of 17 and above the age of 35 are excluded to minimize the variance        in cognitive functioning or brain connectivity that might be attributable to development        rather than diagnosis.|September 2015|September 11, 2015|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034253||52647|
NCT02034526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2013-225-13|Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome.|A Randomised Controlled Trial of Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome and Dual Chamber Pacemaker.|DANPACEII|Aarhus University Hospital|No|Recruiting|May 2014|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02034526||52626|
NCT02030431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-362-13|Dynaloc for Treatment of Femoral Neck Fractures|Dynaloc vs. Multiple Cancellous Screws for Treatment of Femoral Neck Fractures||Aarhus University Hospital|Yes|Terminated|March 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|110 Years|No|||October 2015|October 19, 2015|January 7, 2014||No|overweight of hard-ware removals in the Dynaloc group|No||https://clinicaltrials.gov/show/NCT02030431||52940|
NCT02031029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/113|Character Traits and Stress in Suspected Prostate Cancer|A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis?||Helse Stavanger HF|No|Enrolling by invitation|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Blood samples|Male|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Men referred to urological outdoor department or gastroenterological outdoor department|January 2014|January 7, 2014|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02031029|2 Years|52894|
NCT02031042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/441-31/4|Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer|Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer||Stockholm South General Hospital|No|Completed|October 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|220|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically verified breast cancer planned for neoadjuvant chemotherapy|January 2016|January 3, 2016|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02031042||52893|
NCT02041494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-NIDDK-1R21DK093006-01A1|Complex Ventral Hernia Repair Using Biologic or Synthetic Mesh|Study Comparing the Efficacy, Safety, and Cost of a Permanent, Synthetic Prosthetic Versus a Biologic Prosthetic in the One-stage Repair of Ventral Hernias in Clean and Contaminated Wounds.|CVHR|University of California, San Francisco|Yes|Recruiting|March 2014|June 2019|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|330|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|January 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041494||52091|
NCT02042573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROJAK APJ 2012|Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression|TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression|TMSFOS|Centre Hospitalier Universitaire Dijon||Recruiting|November 2013|||January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 20, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02042573||52010|
NCT02042859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRFA|Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer|Pilot Study to Assess Safety and Efficacy Of An Endoscopic Bipolar Radiofrequency Probe (EndoHPB) In the Management of Unresectable Bile Duct and Pancreatic Cancer|EndoHPB|Ochsner Health System|No|Enrolling by invitation|February 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02042859||51988|
NCT02042313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131015A|Postoperative Pain Management After Minimally Invasive Esophagectomy||MIEPVBEA|Sun Yat-sen University||Recruiting|February 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|20 Years|75 Years|No|||December 2015|December 15, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02042313||52030|
NCT02042560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LORCERIE PARI 2010|Physiopathology Study of Auto-immune Thrombopenia. Multicentre, Open, Controlled Study|Physiopathology Study of Auto-immune Thrombopenia. Multicentre, Open, Controlled Study||Centre Hospitalier Universitaire Dijon||Recruiting||||June 2014|Anticipated|N/A|Interventional|N/A|2||Anticipated|175|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|June 3, 2014|January 17, 2014||||No||https://clinicaltrials.gov/show/NCT02042560||52011|
NCT02042846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spo-01|Clinical Evaluation of the SportWelding FijiAnchor® in Hand and Hand Wrist Surgery|Prospective Clinical Evaluation of the Bioabsorbable SportWelding FijiAnchor® for Ligament Repair of the Hand and Hand Wrist||SportWelding GmbH||Active, not recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02042846||51989|
NCT02043197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-326|Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder|Post-Marketing Observational Program of Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorders (FRIENDS)|FRIENDS|Abbott|No|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Primary care clinics|February 2016|February 1, 2016|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02043197||51962|
NCT02043444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 555 01|Secretory Azoospermia and FDG (Fluoro Deoxyglucose) PET-CT|Comparison of FDG PET-CT Estimated Testis Functional Value Between Patients Having Positive Testicular Sperm Cells Extraction and Patients With a Negative Extraction, in Men With Azoospermia|AzoPredHisto|University Hospital, Toulouse|No|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|160|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02043444||51943|
NCT02056483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REBECCA|REBECCA - Research in Rehabilitation After Breast Cancer|Optimized Rehabilitation: A Randomized Study of Systematic Monitoring and Management of Breast Cancer Patients' Symptoms|REBECCA|Danish Cancer Society|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Female|18 Years|N/A|No|||August 2015|August 5, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056483||50943|
NCT02032576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPH-2008-12|Predictors of the Response and Relapse/Recurrence After ECT for Depressed Patients|||Kaohsiung Kai-Suan Psychiatric Hospital|Yes|Completed|January 2008|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|18 Years|80 Years|No|||January 2014|January 7, 2014|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02032576||52775|
NCT02032836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16483|Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)|A Multi-center, Open-label, Randomized Cross-over Study to Compare the Acute Tolerability and Pharmacokinetics of BAYQ6256 (Iloprost; Ventavis) Inhalation Using the I-Neb Nebulizer and the FOX Nebulizer in Patients With Pulmonary Arterial Hypertension||Bayer|No|Active, not recruiting|March 2014|September 2017|Anticipated|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02032836||52755|
NCT02032875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-215|Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant|A Phase 3 Evaluation of Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 1-6 Chronic Hepatitis C Infection Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant|ALLY 1|Bristol-Myers Squibb|No|Active, not recruiting|March 2014|January 2016|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 9, 2014|Yes|Yes||No|August 18, 2015|https://clinicaltrials.gov/show/NCT02032875||52752|
NCT02033161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|icbt fgid pilot 2012|Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study||Karolinska Institutet|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|13 Years|17 Years|No|||January 2014|January 9, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02033161||52731|
NCT02033174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlcoholInfl_IiSGM_2000|Effects of Alcoholic Beverages in Pro-inflammatory and Antioxidant Profile After an Oral Fat Diet|Effects of Acute and Chronic Red Wine Intake in the Expression of Pro-inflammatory and Prothrombotic Factors in Circulating Monocytes||Instituto de Investigación Sanitaria Gregorio Marañón|Yes|Completed|January 2001|July 2001|Actual|July 2001|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033174||52730|
NCT02033460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-551|Manual Therapy Versus Manual Therapy and Exercise and Education in Chronic Neck Pain|Manual Therapy vs Manual Therapy and Exercise vs Manual Therapy and Exercise and Education in Patients With Chronic Neck Pain||Universidad Rey Juan Carlos|No|Completed|January 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033460||52708|
NCT02033746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001595|Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment|A Crossover Study Using Transdermal Electroacupuncture as Adjunctive Treatment to Reduce Opiate Cravings in Post-Detox Outpatients Receiving Buprenorphine-Naloxone||Mclean Hospital|No|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|59 Years|No|||September 2015|September 3, 2015|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033746||52686|
NCT02033993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL12|Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.|A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.||Canadian Cancer Trials Group|Yes|Recruiting|February 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|199|||Both|18 Years|N/A|No|||November 2015|March 22, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033993||52667|
NCT02034006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002FIT01|A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.|A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|OLIMPIC|Novartis|No|Active, not recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034006||52666|
NCT02034279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFECIR 2|The INFECIR-2 Albumin Prevention Study|Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality|INFECIR2|EASL - CLIF Consortium|Yes|Recruiting|May 2014|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|512|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034279||52645|
NCT02034266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DM Omega-3 study|The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes|Phase 2 Study of the Effects of Omega-3 Fatty Acid Supplementation on Nerve Structure and Function in Type 1 Diabetes Mellitus - A Clinical Pilot Study||University Health Network, Toronto|No|Recruiting|January 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034266||52646|
NCT02034539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VADOplex-1|VADOplex Critical Limb Ischemia Study|Prospektive, Randomisierte Und Kontrollierte Studie Zum Einfluss Des VADOplex-Systems Auf Die Lebensqualität im Rahmen Der Behandlung Der Chronisch-kritischen Extremitätenischämie im Stadium IV Nach Fontaine||Asklepios Kliniken Hamburg GmbH|No|Recruiting|October 2013|November 2014|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034539||52625|
NCT02041208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SET-ANE-2011-01|Variability of Hemoglobin Levels After Kidney Transplantation|A Retrospective, Observational Study to Evaluate Hemoglobin Variability in Kidney Transplant Recipients With Chronic Renal Anemia.||Sociedad Española de Trasplante|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|368|||Both|18 Years|N/A|No|Probability Sample|Adult kidney transplant recipients with chronic renal anemia.|January 2014|January 17, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02041208||52113|
NCT02042326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRCN10-PR-DEVAUCHELLE|Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations|Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations||Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|September 2014|June 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|N/A|No|||July 2015|July 28, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02042326||52029|
NCT02033291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2-036|Blood-brain Barrier Quantification in Cerebral Small Vessel Disease|Blood-Brain Barrier Permeability Quantification in Cerebral Small Vessel Disease -- Reproducibility of Dynamic Contrast-enhanced MRI||Maastricht University Medical Center|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|General:          -  Age >18 years old          -  The condition of the patient must be well enough to allow participation in the study,             which is decided in consultation with the treating physician.        cSVD patients: - patients who present with a transient ischemic attack (TIA) and cSVD        related abnormalities on brain MRI. MRI abnormalities include extended white matter        lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces.        The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after        the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the        first.        Cortical stroke or primary intracerebral hemorrhage patients:        - patients who have a clear clinical presentation of either cortical stroke or primary        intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI        scans can be performed within 0-6 weeks of the vascular event and on two subsequent days.|April 2015|April 9, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033291||52721|
NCT02033551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-144|A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors|An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors||AbbVie|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033551||52701|
NCT02033564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3215|Incidence of Sore Throat With Traditional Intubation Blades or Glidescope Blade|Does the Incidence of Sore Throat Increase With the Use of a Traditional Intubation Blade or the Glidescope||Albany Medical College|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033564||52700|
NCT02033824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRAN001|Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring|A Multicenter Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane dHACM in Decompressive Craniectomy Patients to Reduce Postoperative Scarring||MiMedx Group, Inc.|No|Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02033824||52680|
NCT02033837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuma1594|Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT|Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT With 0.275-sec Gantry Rotation Speed||Kumamoto University||Recruiting|January 2013|||May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|350|||Both|20 Years|90 Years|No|Probability Sample|Consecutive patients referred for coronary CT angiography at our hospital|January 2014|January 9, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033837||52679|
NCT02043210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009151|CBT for Spanish Speakers|Computer Based Training in CBT for Spanish-speaking Substance Users||Yale University|Yes|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02043210||51961|
NCT02043457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00030088|Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance|Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance||University of Michigan|No|Recruiting|August 2009|||August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|DNA that is de-indentified is stored.|Both|18 Years|63 Years|Accepts Healthy Volunteers|Non-Probability Sample|1800 obese and 200 lean controls participating in a 2 year clinical weight loss and weight        maintenance program may opt-in to participate in a number of evaluations including        depression inventory and HRQOL questionnaires, assessing hunger and appetite, work        performance (including presenteeism and absenteeism), oral glucose tolerance testing,        mixed meal tolerance testing with metabolomics, DNA, RNA, with or without muscle and        adipose tissue biopsies, body composition by DEXA or BodPod, measurements of posture        allocation and physical activity by Sensewear Body Media, measurements of REE and V02 max        before at baseline, after 10-15% weight loss and after the 2 year clinical program.|December 2015|December 1, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02043457||51942|
NCT02039349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140042|A Novel Compound for Alcoholism Treatment|A Novel Compound for Alcoholism Treatment: A Translational Strategy||National Institutes of Health Clinical Center (CC)||Completed|January 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|65 Years|No|||September 2015|October 6, 2015|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039349||52256|
NCT02039609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutritional Metabolomics AIKN2|Nutritional Metabolomics: the Search for Dietary Exposure Variables 2|Nutritional Metabolomics: the Search for Dietary Exposure Variables 2||Göteborg University|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|200|Samples With DNA|Whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects Adults|February 2016|February 4, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02039609||52236|
NCT02056769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-PIPS|CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage|CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage|CT-PIPS|Nova Scotia Health Authority|No|Recruiting|April 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02056769||50921|
NCT02056782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-ODSH-2013-AML-1|A Pilot Study of ODSH in Acute Myeloid Leukemia|A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia|PGX-AML|Cantex Pharmaceticals|Yes|Completed|December 2013|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||February 2014|February 12, 2015|January 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02056782||50920|
NCT02057016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTIT-090114|Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease|Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease: a Single-centre Observational Pilot Study||Catholic University of the Sacred Heart|Yes|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|258|||Both|N/A|N/A|No|Non-Probability Sample|Patients with inflammatory bowel disease receiving long-term (> 2 years) scheduled        treatment with infliximab|February 2015|February 2, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057016||50902|
NCT02032888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-216|A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.|A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)||Bristol-Myers Squibb|No|Completed|February 2014|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|238|||Both|18 Years|N/A|No|||August 2015|September 24, 2015|January 9, 2014|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT02032888||52751|
NCT02033187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120502|Daily Chlorhexidine Bathing and Infection Rates in Critically-ill Patients|Phase 4 Study of the Impact of Daily Bathing With Chlorhexidine-gluconate Impregnated Bathing Cloths on Nosocomial Infections in Critically Ill Patients||Vanderbilt University|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|12000|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033187||52729|
NCT02033200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-402|Safety Study Looking at the Effects of Stendra on Vision|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects||VIVUS, Inc.|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|January 8, 2014|Yes|Yes||No|March 2, 2015|https://clinicaltrials.gov/show/NCT02033200||52728|
NCT02033473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 182 03|Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers|Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers|APELINS|University Hospital, Toulouse|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02033473||52707|
NCT02033486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000488|Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)|Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)||Massachusetts General Hospital|No|Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|375|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033486||52706|
NCT02034552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16544|A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)|A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases||Bayer|No|Active, not recruiting|December 2013|June 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034552||52624|
NCT02030483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306014004|Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma|A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (Palbociclib) in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|PD + RD|Weill Medical College of Cornell University|No|Recruiting|March 2014|January 2019|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030483||52936|
NCT02034292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-TG1C-1301|Safety Study of APD-791 With Aspirin and/or Clopidogrel|Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin|TG1C|IlDong Pharmaceutical Co Ltd|No|Not yet recruiting|January 2014|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Anticipated|88|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2013|August 28, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02034292||52644|
NCT02034305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11100704|Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy|Pilot Study of Cough Peak Flow And Airway Clearance in Pediatric Patients With Neuromuscular Disease||University of Pittsburgh|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|||Male|6 Years|21 Years|No|Non-Probability Sample|Boys 6-21 years of age with Duchenne Muscular Dystrophy|February 2016|February 24, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034305||52643|
NCT02030782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS009908|Youth Partners in Care: Depression and Quality Improvement|Youth Partners in Care: Depression & Quality Improvement|YPIC|Agency for Healthcare Research and Quality (AHRQ)|Yes|Completed|October 1999|December 2003|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|418|||Both|13 Years|21 Years|No|||December 2008|January 7, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02030782||52913|
NCT02041481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13355|MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer|A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy||City of Hope Medical Center|Yes|Active, not recruiting|June 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02041481||52092|
NCT02042079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-604|Endoscopic Full Thickness Resection With Laparoscopic Assistance|Endoscopic Full Thickness Resection With Laparoscopic Assistance, Single Center Single Arm Study|EFTR-LA|National Cancer Center, Korea|No|Recruiting|July 2012|||March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|N/A|No|||January 2014|January 19, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02042079||52048|
NCT02042092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-2013/1655|Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS|A Head-to-Head Comparison of Color Doppler Ultrasonography (CDUS) and Magnetic Resonance Angiography (MRA) in Patients With Systemic Large Vessel Vasculitis (sLVV) - A Cross Sectional Study|MUSES|Hospital of Southern Norway Trust|No|Completed|December 2013|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 21, 2016|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02042092||52047|
NCT02033850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2321706|Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II|The Rehabilitation of Attention in Patients With Mild Cognitive Impairment and Brain Subcortical Vascular Changes Using the Attention Process Training-II|RehAtt|Azienda Ospedaliero-Universitaria Careggi|Yes|Active, not recruiting|November 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02033850||52678|
NCT02033863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0080/07|Evaluation of PerformanCe of the Peripheral EOS in the Treatment of Varicocele or Pelvic Congestion SynDromE|PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM in the Treatment of Varicocele or Pelvic Congestion SynDromE - OCCLUDE I|OCCLUDE-I|ArtVentive Medical Group, Inc.|Yes|Enrolling by invitation|July 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects requiring permanent occlusion of the peripheral vessels for the following        conditions:          1. Cohort A: Varicocele arising from the spermatic vein(s) and pampiniform plexus, with             or without concomitant diagnosis of infertility or subfertility.          2. Cohort B: Pelvic varices in females for the treatment of pelvic congestion syndrome             (e.g., pelvic venous incompetence).|June 2015|June 22, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033863|30 Days|52677|
NCT02034084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLAR|A Comparison of Left and Right Radial Approach for Percutaneous Coronary Procedures|||Capital Medical University|Yes|Completed|March 2011|June 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1400|||Both|20 Years|85 Years|No|||January 2014|April 22, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034084||52660|
NCT02034097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112132|A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer|A Phase II Study to Evaluate Foretinib in Genomic Subpopulations of Subjects With Non-Small-Cell Lung Cancer (NSCLC)||GlaxoSmithKline|No|Withdrawn|April 2014|December 2016|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|November 27, 2013||No|GSK has decided to terminate the Product Development of foretinib and conclude our Development    Agreement with Exelixis|No||https://clinicaltrials.gov/show/NCT02034097||52659|
NCT02034383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS45|The Effect of Processing on the Measured Energy Value of Almonds in the Human Diet|Macronutrient Absorption From Almonds: The Effect of Processing on the Measured Energy Value of Almonds in the Human Diet||USDA Beltsville Human Nutrition Research Center|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|5||Anticipated|18|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034383||52637|
NCT02034110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117019|Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers|A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib||GlaxoSmithKline|No|Recruiting|March 2014|August 2025|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034110||52658|
NCT02034071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC025|Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome|A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension||Essentialis, Inc.|Yes|Active, not recruiting|April 2014|||February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|10 Years|22 Years|No|||January 2015|January 23, 2015|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034071||52661|
NCT02034370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36398|Effect of Interscalene Block on Obstructive Sleep Apnea in Shoulder Surgery Patients|Influence of Inter-scalene Blockade on Postoperative Episodic Desaturation in Patients at High Risk of Obstructive Sleep Apnea (OSA)||University of Michigan|Yes|Recruiting|March 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Our study population consists of patients who are receiving an interscalene nerve block as        an anesthetic for their scheduled shoulder surgery, and are at risk for OSA.|December 2014|December 4, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02034370|1 Week|52638|
NCT02034643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_Cuff|Transesophageal Echocardiography(TEE) Probe Insertion and Tracheal Cuff Pressure|Increase of Tracheal Cuff Pressure During Transesophageal Echocardiography Probe Insertion: Double-lumen Tube Versus Single-lumen Tube|TEE|Seoul National University Hospital||Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|80 Years|No|||January 2014|September 15, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034643||52617|
NCT02030574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 300|Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin|BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin||Brown University|Yes|Terminated|July 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 20, 2013|Yes|Yes|The study is being closed to accrual secondary to low accrual and an interest in opening up a    different trial.|No|October 27, 2015|https://clinicaltrials.gov/show/NCT02030574||52929|The study has been terminated secondary to low accrual and an interest in opening up a different trial; more tailored to Physician interests and patient need.
NCT02030587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2012.193-T|Laparoscopic Adrenalectomy Versus Radiofrequency Ablation|Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial|LARFA|Chinese University of Hong Kong|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||January 2014|January 7, 2014|January 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030587||52928|
NCT02030847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 21413|Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia|Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030847||52908|
NCT02057302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008ZX09202-007|A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia|A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study||China Academy of Chinese Medical Sciences|Yes|Completed|March 2010|||December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|2400|||Both|18 Years|75 Years|No|||February 2014|February 6, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02057302||50880|
NCT02033499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2047|Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes|Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-insulin Treated Diabetes||University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|30 Years|N/A|No|||July 2015|July 29, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02033499||52705|
NCT02033759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anxiety & Lymphedema|Patient Anxiety Associated With Lymphedema Surveillance Method|A Study of Patient Anxiety Associated With Lymphedema Surveillance: Comparing Volumetric Analysis and Bio-Impedance Analysis||Mercy Integrative Medicine|No|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|50|||Female|18 Years|85 Years|No|||December 2015|December 1, 2015|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02033759||52685|
NCT02034019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-13-002|Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery|||Ocular Therapeutix, Inc.|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034019||52665|
NCT02034318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090004|Fatigue and Cardiac Sympathetic Denervation in Parkinson Disease|Fatigue and Cardiac Sympathetic Denervation in Parkinson Disease|Fatigue|University of Miami|Yes|Completed|March 2009|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|65 Years|No|Probability Sample|Elderly/aged Outpatients|March 2015|March 8, 2015|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034318||52642|
NCT02034565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-029|Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects|Study of Bioavailability of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects||Bristol-Myers Squibb|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034565||52623|
NCT02034578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-091|Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects|Study of Apixaban Oral Solution Bioavailability When Administered Through a Nasogastric Tube in Healthy Subjects||Bristol-Myers Squibb|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034578||52622|
NCT02040909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20132312|Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation|Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation|NEOPROP2|Erasmus Medical Center|Yes|Recruiting|July 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|160|||Both|N/A|28 Days|No|||August 2015|August 4, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02040909||52136|
NCT02041182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA-YIA-2013|Electronic Pre-visit Questionnaire to Prompt Discussions of Youth Violence in Primary Care|Use of an Electronic Pre-visit Questionnaire and Effect on Patient-provider Discussions of Youth Violence in Primary Care||Rhode Island Hospital|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Actual|183|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||January 2014|August 19, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02041182||52115|
NCT02041195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-493-009|Phase 1b/2a Study to Evaluate Safety and Efficacy of RM-493 in Obese Patients|Staged, Phase 1b/Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of RM 493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients Using a Once or Twice Daily Sub-Cutaneous Injection Formulation||Rhythm Metabolic, Inc.|No|Completed|January 2014|December 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02041195||52114|
NCT02040922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13091|Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota|An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli|CERAMIC|University of Nottingham|No|Enrolling by invitation|January 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Stool (Faeces) Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Adults in the Nottinghamshire area with no previous history of gastrointestinal disorder        or surgical resection. Those who submit a stoo lsample from which Campylobacter spp. is        cultured will be invited to take part.|January 2015|January 21, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02040922||52135|
NCT02040935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28878|A Study of Subcutaneous Herceptin (Trastuzumab) Administered at Home By Single-Use Injection Device in Patients With Early HER2-Positive Breast Cancer (HOMERUS)|HOMERUS: A LOCAL OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER||Hoffmann-La Roche||Recruiting|February 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02040935||52134|
NCT02032953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-459-GEN|Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia|Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia||McGill University Health Center|No|Recruiting|December 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032953||52746|
NCT02033278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/MD/2013|Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.|Multicenter Phase II-III Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Recruiting|January 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|51|||Both|18 Years|70 Years|No|||June 2015|July 29, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033278||52722|
NCT02033603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/ 921/ D|Adductor Canal Versus Femoral Nerve Block for Analgesia Post Total Knee Arthroscopy|A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Femoral Nerve Block for Analgesia Post Total Knee Arthroplasty||Changi General Hospital|No|Recruiting|January 2014|December 2014|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|85 Years|No|||January 2014|December 31, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033603||52697|
NCT02033876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004908|Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin|Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment||Mayo Clinic|No|Active, not recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||December 2015|December 18, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033876||52676|
NCT02034123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200858|Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma|A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma||GlaxoSmithKline|No|Recruiting|February 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034123||52657|
NCT02034409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-006-13S|A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis|A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis|PLUS+OA|VA Office of Research and Development|Yes|Recruiting|May 2015|June 2019|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|40 Years|N/A|No|||October 2015|October 16, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02034409||52635|
NCT02034656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC10RSGI0437|Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)|Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA): A Retrospective Feasibility Study||Seoul St. Mary's Hospital|Yes|Recruiting|July 2010|November 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|Korean Adult CML or Ph positive ALL patients|January 2014|January 10, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT02034656||52616|
NCT02030600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3998|A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes|A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)|SWITCH 2|Novo Nordisk A/S|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|724|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030600||52927|
NCT02030860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23213|A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer|A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030860||52907|
NCT02031120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGeneva 13-006|Management of Drug Hypersensitivity in Children|Improved Management Based on Pathophysiology of Drug Hypersensitivity in Childhood|DHC|University Hospital, Geneva|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|whole blood, serum, white cells|Both|N/A|16 Years|Accepts Healthy Volunteers|Probability Sample|Children with suspected drug allergies in a pediatric hospital (including ambulatory        departments)|January 2014|January 8, 2014|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02031120|2 Years|52887|
NCT02031133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-207E|Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C|Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection||Santaris Pharma A/S|No|Active, not recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Plasma|Both|21 Years|70 Years|No|Non-Probability Sample|Null responder subjects with CHC genotype 1 virus infection who have participated in study        SPC3649-207.|November 2014|November 17, 2014|January 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02031133||52886|
NCT02057601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM4 (zz) 09/04/13|Postoperative Analgesia for Fractured Neck of Femur With Periarticular Infiltration of Local Anaesthetic|Postoperative Analgesia Following Surgery for Fractured Neck of Femur: a Comparison of Periarticular Infiltration of Local Anaesthetic With Systemic Postoperative Analgesics||Cork University Hospital|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|60 Years|N/A|No|||February 2014|February 5, 2014|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057601||50857|
NCT02057900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100303|Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure|Transplantation of Human Embryonic Stem Cell-derived CD15+ Isl-1+ Progenitors in Severe Heart Failure|ESCORT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|81 Years|No|||October 2015|October 5, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02057900||50835|
NCT02033772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00503|Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery|||Nationwide Children's Hospital|No|Enrolling by invitation|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|6 Months|No|Non-Probability Sample|Infants < 6 months of age undergoing thoracoscopic surgery.|March 2016|March 8, 2016|November 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02033772||52684|
NCT02039323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3940|A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants|A Feasibility Study to Assess Protection of Vaginal and Cervical Tissues From Ex-Vivo HIV-1 Challenge Following Oral Administration of Maraviroc and Tenofovir||University of North Carolina, Chapel Hill|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02039323||52258|
NCT02034032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-03-K|Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to Total Knee Arthroplasty||Regenerative Sciences, LLC|No|Active, not recruiting|January 2014|January 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||August 2015|August 13, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034032||52664|
NCT02034331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAF-12-018|IR and Microvascular Blood Flow in SCI|Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|No|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|160|||Both|20 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|January 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02034331||52641|
NCT02040116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022197|Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases|Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases||Wake Forest Baptist Health|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|80 Years|No|||August 2014|August 4, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02040116||52197|
NCT02040129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH2014-01|Reduction of Corneal Astigmatism With Toric Intraocular Lens Implantation in Congenital Cataract|Reduction of Corneal Astigmatism With Toric Intraocular Lens Implantation : Early Results in Patients With Congenital Cataract||Kyungpook National University|Yes|Completed|January 2009|November 2009|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|1 Year|13 Years|No|||January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02040129||52196|
NCT02040415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-1030_301|Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients|A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients||Daewon Pharmaceutical Co., Ltd.||Not yet recruiting||||December 2014|Anticipated|Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A|No|||January 2014|January 17, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02040415||52174|
NCT02040961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/64|Assessment of the the ETView Double-lumen Tube|Assessment of the the ETView Double-lumen Tube|ETView1|Hopital Foch|No|Terminated|September 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|84|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|January 16, 2014||No|An incident, burned tube, happened before intubation. The promoter decided to stop the study.|No||https://clinicaltrials.gov/show/NCT02040961||52132|
NCT02040688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-RT-0471-11-CTIL|Sensory Integration (Processing) Disorder Among Children With Behavioral Insomnia and Children With Feeding Disorder|Sensory Integration (Processing) Disorder Among Children With Behavioral Insomnia and Children With Feeding Disorder||Tel-Aviv Sourasky Medical Center||Recruiting|August 2011|||November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|7 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|7-36 months old children will be selected from:          -  The clinic of feeding disorders at Dana Children's Hospital.          -  The Pediatric Sleep Center at Dana Children's hospital          -  Well-care clinics in the metropolitan of Tel Aviv|January 2014|January 15, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02040688||52153|
NCT02041767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090205|Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration|Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration|ERTAPRO|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2013|June 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|80 Years|No|||January 2016|January 29, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02041767||52070|
NCT02033577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01514799|Effects of Long Biliopancreatic Limb Versus Long Alimentary Limb in Superobesity, a Randomized Study|Effects of Long Biliopancreatic Limb vs Long Alimentary Limb in Superobesity|BMI>50|Aleris Obesity|Yes|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||March 2015|March 16, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033577||52699|
NCT02033590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURE-005|Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction|||Allergan||Withdrawn||||June 2016|Anticipated|N/A|Interventional|N/A|1||Actual|0|||Female|18 Years|65 Years|No|||July 2014|October 8, 2014|January 9, 2014||||No||https://clinicaltrials.gov/show/NCT02033590||52698|
NCT02033889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-007|A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02033889||52675|
NCT02034136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH-13722|Ginsenoside Improve Metabolic Syndrome|Effects of Ginsenoside Supplementation on Insulin Resistance and Cardiometabolic Risk Factors in Men With Metabolic Syndrome: a Randomized Controlled Trial.||CHA University|Yes|Not yet recruiting|February 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|July 21, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02034136||52656|
NCT02034149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-206|The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population|The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population||China Medical University Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|411|||Both|20 Years|85 Years|No|||July 2014|July 31, 2014|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02034149||52655|
NCT02034422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1215-W|Understanding the Exercise-Hypertension Paradox|Understanding the Exercise-Hypertension Paradox: Implication for Rehabilitation||VA Office of Research and Development|Yes|Recruiting|February 2014|December 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|72|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02034422||52634|
NCT02034396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10120155|Clinical Implications of Genetic Variations of Venous Stasis Ulceration|Clinical Implications of Genetic Variations of Venous Stasis Ulceration||University of Pittsburgh|Yes|Recruiting|May 2011|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02034396||52636|
NCT02030314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15331|Chlorthalidone for the Management of Resistant Hypertension in Kidney Transplant Patients|Chlorthalidone for the Management of Resistant Hypertension in Kidney Transplant Patients||Virginia Commonwealth University|No|Recruiting|July 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2015|February 1, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02030314||52949|
NCT02030613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111102|Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis|Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis|Etaplus|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|140|||Both|4 Years|17 Years|No|||October 2015|October 8, 2015|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02030613||52926|
NCT02030873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-FSP-2|The Effect of Virtual Simulation Training in Mastoidectomy|The Effect of Virtual Simulation Training With the Visible Ear Simulator on Mastoidectomy Performance of Otorhinolaryngology Trainees||Rigshospitalet, Denmark|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02030873||52906|
NCT02031146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45122-A|Lumbar Puncture and Syphilis Outcome|Lumbar Puncture and Syphilis Outcome||University of Washington|No|Recruiting|August 2013|||June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|280|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02031146||52885|
NCT02057328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELNEB|Comparative Study of the Effects of Telmisartan and Nebivolol|Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension|TELNEB|Aristotle University Of Thessaloniki|No|Recruiting|December 2010|January 2017|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||February 2014|February 5, 2014|October 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02057328||50878|
NCT02039882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15114|Point of Care (POC) Biomarkers of Ischemia|Point of Care (POC) Biomarkers of Ischemia||Virginia Commonwealth University|No|Recruiting|April 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|peripheral blood, Plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Fifty total patients presenting for evaluation of ACS (acute coronary syndrome) in the        hospital emergency department (ED) at Virginia Commonwealth University Health Systems,        Twenty five Patents requiring percutaneous Intervention, Twenty five patients not        requiring intervention Fifty control subject from Virginia Commonwealth University Health        Systems without known cardiac disease that are age ± 5years and sex matched from|January 2014|January 16, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02039882||52215|
NCT02039895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-102135-F|Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma|Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma|HITS|Far Eastern Memorial Hospital|Yes|Active, not recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2014|August 1, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039895||52214|
NCT02039570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaemorrhoidsJan2104|The Relationship Between Haemorrhoids and Pelvic Vein Reflux|Investigating the Relationship Between Haemorrhoids, Internal Iliac Veins and Tributary Reflux||The Whiteley Clinic|Yes|Not yet recruiting|March 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|57|||Female|18 Years|80 Years|No|Non-Probability Sample|the sample will be selected from female patients presenting in primary care with        symptomatic haemorrhoids|January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039570||52239|
NCT02039869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20000591|Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)|Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)|CE_NERD|Virginia Commonwealth University|Yes|Withdrawn||||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|79 Years|No|||December 2015|December 7, 2015|December 20, 2013||No|Could not recruit patients - modifying protocol and plan resubmission to our IRB|No||https://clinicaltrials.gov/show/NCT02039869||52216|
NCT02040701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-RT-06-122-CTIL|Sleep Disordered Breathing in Children: Inflammation and Oxidative Stress|||Tel-Aviv Sourasky Medical Center||Recruiting|May 2006|||May 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|6 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|children ages 6 months-18 years who will undergo overnight sleep study at the Dana        Children's hospital, Tel Aviv Medical Center because of snoring and suspected        sleep-disordered breathing or will attend the pre-operative ENT clinic for adenoidectomy        or adenotonsillectomy|January 2014|January 15, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02040701|8 Weeks|52152|
NCT02040948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/56|Accuracy of Pulse Pressure Variation and of Pleth Variability Index to Predict the Response to a Fluid Challenge|Accuracy of Pulse Pressure Variation (Nexfin) and of Pleth Variability Index (Radical 7) to Predict the Response to a Fluid Challenge: Comparison With the Reference Method (Measurement of Stroke Volume by Esophageal Doppler)|Nexfin2|Hopital Foch|No|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02040948||52133|
NCT02041221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARC_Ltd_ CLR_13_16|Pharmacology Study of Sun Pharma Advanced Research Company Limited's S0597|Study to Access Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Compound S0597 by Oral Inhalation: A Phase I/IIa Observer and Double Blind, Placebo and Active Controlled Parallel and Crossover Study.||Sun Pharma Advanced Research Company Limited|No|Not yet recruiting|January 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02041221||52112|
NCT02032173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DFR11|Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase|A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis® (Ranibizumab 0,5mg) in Diabetic Patients With Visual Impairment Due to Macular Edema Evaluating a Spaced Out Follow-up After Intensive Loading Phase|CONSTELLATION|Novartis|No|Terminated|May 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02032173||52806|
NCT02041507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI.2013.2502|Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange for Adenoma Detection Rate in Screening Colonoscopy||Presidio Ospedaliero Santa Barbara|No|Active, not recruiting|February 2014|April 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|1224|||Both|50 Years|70 Years|No|||March 2016|March 21, 2016|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02041507||52090|
NCT02032680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-332|Comparison of E-health vs. In-person MFG|Comparison of E-Health vs. In-Person Delivered Family Psychoeducation Treatment||VA Office of Research and Development|No|Recruiting|August 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|284|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02032680||52767|
NCT02033304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7124|Factors Predicting Postoperative Cesarean Section Pain|Analysis of Factors Predicting Postoperative Pain and Wound Hyperalgesia After Cesarean Section||Rabin Medical Center|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|229|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Women after cesarean section|January 2013|May 6, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033304||52720|
NCT02078687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDU-2014-LHT|Growth, Risks of Allergy and Metabolic Syndrome in 6 Year Old Children Born Preterm Compared to Postdischarge Nutrition|Growth, Risks of Allergy and Metabolic Syndrome in 6 Year Old Children Born Preterm Compared to Nutrition in the First Four Month After Hospital Discharge||University of Southern Denmark|Yes|Enrolling by invitation|October 2010|February 2017|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|278|||Both|6 Years|8 Years|No|||May 2015|May 28, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078687||49242|
NCT02078427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061001|ADVATE Hemophilia A Outcome Database (AHEAD)|ADVATE Hemophilia A Outcome Database|AHEAD|Baxalta US Inc.|No|Recruiting|June 2011|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include male and female participants of any race and age who        have a diagnosis of hemophilia A (Factor VIII (FVIII) =5%). Participants must have been        prescribed ADVATE for the management of hemophilia A by the treating physician prior to        the decision to enroll in the study.|March 2016|March 19, 2016|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078427||49262|
NCT02081404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3155105|Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study|Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study||Midwest Biomedical Research Foundation|Yes|Recruiting|March 2011|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02081404||49033|
NCT02082314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA|Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty|Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty|RFA|Sunnybrook Health Sciences Centre|No|Recruiting|February 2014|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|The study population will be derived from patients with advanced cancers with        spinal/pelvic metastases who have been referred to interventional radiology and have        consented to receiving RFA and/or cementoplasty for their disease. Such patients will be        followed with a daily diary for 10 days after treatment. The Brief Pain Inventory will be        used to assess pain and functional interference on these days.|November 2014|November 18, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02082314||48963|
NCT02079272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00929-36|REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)|REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity): Evaluation of Radiation-induced Cardiotoxicity of Adjuvant Radiotherapy With Tomotherapy for Breast Cancer|REBECCA|Institut de Radioprotection et de Surete Nucleaire|No|Withdrawn|November 2014|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|40 Years|70 Years|No|||April 2015|April 3, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02079272||49197|
NCT02080078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Theophylline 1.0|A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline|A Phase I, Single-center, Non-randomized, Open-label Study to Determine the Lowest Effective Theophylline Dose That Decreased Erlotinib's Diarrhea at the Standard Dose of 150 mg/Day and to Determine the Highest Erlotinib Dose in Combination With Theophylline That Can be Administered to Patients||AHS Cancer Control Alberta|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02080078||49135|
NCT02081417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4484|Patient-Centered Trauma Treatment|Patient-Centered Trauma Treatment for PTSD and Substance Abuse: Is it an Effective Treatment Option?|PaCTT|University of New Mexico|No|Recruiting|October 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02081417||49032|
NCT02081430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLVPT-1301|Immediate Effects of Manipulation Versus Stretching on Upper Trapezius Pressure Pain Thresholds|The Immediate Effects of Cervicothoracic Manipulation vs. Stretching on Upper Trapezius Pressure Pain Thresholds and Cervical Spine Range of Motion||University of Nevada, Las Vegas|Yes|Completed|May 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081430||49031|
NCT02082288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Edessy ICSI Outcome Embryo Score (EIOS) Efficacy|Edessy ICSI Outcome Embryo Score (EIOS) Efficacy||Al-Azhar University|Yes|Completed|December 2010|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|243|||Female|20 Years|40 Years|No|||January 2015|January 11, 2015|March 4, 2014||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT02082288||48965|
NCT02082301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-IRB12-00581|Oral Glucose Tolerance Testing After Gestational Diabetes|Oral Glucose Tolerance Testing After Gestational Diabetes||MetroHealth Medical Center|No|Active, not recruiting|October 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Serum for measurements of insulin, markers of inflammation|Female|18 Years|N/A|No|Non-Probability Sample|Primary cohort is obtained from a pregnant population at two academic medical centers.|April 2015|April 28, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082301||48964|
NCT02078206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPT-2013/057|Early Neurocognitive Rehabilitation in Intensive Care|Early Neurocognitive Rehabilitation in Intensive Care|ENRIC|Corporacion Parc Tauli||Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078206||49279|
NCT02070315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-011|Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM|Quantitative Evaluation of Liver Disease With Liver and Kidney Elastography Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine||Baylor Research Institute|Yes|Recruiting|February 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|participants will be from Liver Consultants of Texas patient population|January 2016|January 21, 2016|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02070315||49885|
NCT02070575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-041|Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence|Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence||Memorial Sloan Kettering Cancer Center||Recruiting|February 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|Samples Without DNA|Blood sample|Male|30 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment, the        protocol investigator, or research team at Memorial Sloan Kettering Cancer Center (MSKCC).|December 2015|December 9, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070575||49865|
NCT02079961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC CRP4 Senegal|Distribution of Fortified Yoghurt in Senegal to Decrease Children's Anemia and Improve Milk Supply|Better Nutrition Through Agricultural Contracts; Better Contracts Through Nutrition Incentives: A Case Study of Utilizing a Dairy Value Chain in Northern Senegal to Reduce Anemia and Improve Milk Supply||International Food Policy Research Institute|No|Completed|January 2013|March 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|471|||Both|24 Months|59 Months|Accepts Healthy Volunteers|||March 2014|March 5, 2014|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02079961||49144|
NCT02080468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-029|Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects|A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects||Aegerion Pharmaceuticals, Inc.|No|Completed|February 2014|October 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|32|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|March 23, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080468||49105|
NCT02080741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAUVET-GELINIER APJ 2013|Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile|Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile|Diatolepsy|Centre Hospitalier Universitaire Dijon||Recruiting|September 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2014|December 3, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02080741||49084|
NCT02080442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-o11-WP|Balance Training for Chronic Obstructive Pulmonary Disease (COPD)|Balance Training for COPD in Pulmonary Rehabilitation (PR): An Effectiveness Study||West Park Healthcare Centre||Completed|May 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|19|||Both|N/A|N/A|No|Non-Probability Sample|Patients with COPD enrolled in PR|March 2014|March 4, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02080442||49107|
NCT02080455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-024|Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.|A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects||Aegerion Pharmaceuticals, Inc.|No|Completed|February 2014|October 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|March 23, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080455||49106|
NCT02081326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002633|Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes|Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes||Massachusetts General Hospital|Yes|Recruiting|June 2015|July 2023|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02081326||49039|
NCT02081547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC|IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery|IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery||Uppsala University|No|Recruiting|April 2012|September 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|250 ml NaCl is poured in the abdominal cavity 3 times during the operation and is collected      for accurence of cancer cells with Haemathoxylin&Eosin staining and immunohistochemistry.      DNA sequencing is not performed.|Both|18 Years|N/A|No|Non-Probability Sample|40 patients with rectal cancer and 10 patients without rectal cancer that are operated.|March 2014|March 5, 2014|October 11, 2012||No||No||https://clinicaltrials.gov/show/NCT02081547||49022|
NCT02081560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLPKZH11|Colistin Pharmacokinetics in Continuous Renal Replacement Therapy|Colistimethate and Colistin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy (CRRT)||University of Zurich|No|Recruiting|November 2013|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02081560||49021|
NCT02081833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6506|The Investigation of Methods to Capture Acute Respiratory and Gastrointestinal Infections of Children Aged 1 to 3 Years|The Investigation of Methods to Capture Acute Respiratory and Gastrointestinal Infections of Children Aged 1 to 3 Years. Feasibility Study for the Braunschweig Birth Cohort LöwenKIDS (Infections and the Development of the Immune System)||Helmholtz Centre for Infection Research|Yes|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|Parent-collected anterior-nasal swabs and stool samples|Both|1 Year|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|children aged one to three years visiting a child care center in Braunschweig, Germany|January 2016|January 11, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02081833||49000|
NCT02081846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2O|Hospital to Home Outcomes|Hospital to Home Outcomes (H2O): A Study to Improve the Fluidity of Transitions Between Hospital and Home||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|March 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|1600|||Both|N/A|18 Years|No|||February 2016|February 11, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081846||48999|
NCT02081859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-090|Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts|Does Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts for Transfer Improve Pregnancy Rates?|Embryoscope|The Cleveland Clinic|No|Completed|April 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|45 Years|No|||January 2016|January 29, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081859||48998|
NCT02078089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0453|Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain|A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain||Indiana University|Yes|Recruiting|February 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078089||49288|
NCT02078414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFSU1|Continued Use of Effective Contraception After Use of Emergency Contraception|||Karolinska Institutet||Completed|March 2014|||February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|7|||Female|18 Years|45 Years|No|Non-Probability Sample|Women without contraception or with a failed contraceptive method seeking emergency        contraception|November 2015|November 25, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078414||49263|
NCT02078674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-MI7A-201|A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant|A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™||Novavax|Yes|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|610|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078674||49243|
NCT02079194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-01-161|Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES|Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents|SMART-CHOICE|Samsung Medical Center|Yes|Recruiting|March 2014|February 2020|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5100|||Both|18 Years|N/A|No|||October 2014|October 19, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079194||49203|
NCT02079207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP606_PCVA_III_2013|Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine|Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naïve to Pneumococcal Vaccine||SK Chemicals Co.,Ltd.|No|Completed|December 2013|March 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|767|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079207||49202|
NCT02081963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCFB-AMK-01|Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis|A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis||Qilu Hospital||Active, not recruiting|March 2014|December 2015|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02081963||48990|
NCT02082002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.13.02|Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino|Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino||Ospedale Civico, Lugano|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with multiple sclerosis|December 2015|December 17, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082002||48987|
NCT02079831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-014|PrOtein and WEight Loss in teenageRs|Effects of Varied Macronutrient Composition on Weight Loss in Obese Adolescents|POWER|Pennington Biomedical Research Center|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079831||49154|
NCT02080572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG033947-03A1|Parkinstep: Automated PD Gait and Balance Assessment for Optimizing DBS|||Great Lakes NeuroTechnologies Inc.|No|Completed|February 2014|||December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|22|||Both|21 Years|N/A|No|Non-Probability Sample|Individuals with Parkinson's disease, gait impairment, and deep brain stimulation will be        recruited.|February 2015|February 4, 2015|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080572||49097|
NCT02080585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/027|Effectiveness of a Web-based, Computer-tailored, Pedometer-based Physical Activity Intervention for Adults: a Cluster-randomized Controlled Trial|Effectiveness of a Web-based, Computer-tailored, Pedometer-based Physical Activity Intervention for Adults: a Cluster-randomized Controlled Trial||University Ghent|No|Completed|May 2012|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|274|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080585||49096|
NCT02080598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00127-40|Cigarette and Gastric Contents|||Hôpital Edouard Herriot||Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment|2||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080598||49095|
NCT02078765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGH-2-2013|Nocturnal Blood Pressure and Hypertension - Central and Peripheral 24-h Blood Pressure.|Nocturnal Blood Pressure in Hypertension, Obstructive Sleep Apnea and Healthy Subjects - Central and Peripheral 24-h Blood Pressure|HOSA|Regional Hospital Holstebro|No|Enrolling by invitation|January 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples Without DNA|whole blood, serum, urine|Both|55 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: 75 patients with hypertension, recruited from another study in the Holstebro        Area, contacted by letter.        Group 2: healthy subjects are recruited though posters in public and private companies as        well as advertising in local media.|October 2014|October 8, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078765||49236|
NCT02079025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-UHR-002|Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer|Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer||Exact Imaging|No|Enrolling by invitation|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2000|||Male|40 Years|79 Years|No|||March 2015|September 2, 2015|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079025||49216|
NCT02071654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN2013-10/V2.0|Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation|Efficacy and Safety Evaluation of Transcatheter Pulmonary Valve Implantation for Right Ventricular Outflow Tract (RVOT) Stenosis After Congenital Heart Defect Surgical Correction Complicated With Severe Pulmonary Regurgitation||Venus MedTech (HangZhou) Inc.|Yes|Recruiting|February 2014|February 2016|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|60 Years|No|||January 2015|January 3, 2015|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02071654||49782|
NCT02070887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2013-0276|Inhibiting COMT in Parkinson's Disease|Inhibiting COMT in Parkinson's Disease A Monocenter, Observational, Rater-blinded Trial of Entacapone in Parkinson's Disease||University of Zurich|Yes|Recruiting|February 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|60 Years|75 Years|No|Probability Sample|Tertiary movement disorder clinic|September 2014|September 11, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02070887||49841|
NCT02080754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 120120|Sellick Interest in Rapid Sequence Induction|Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial|IRIS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3500|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02080754||49083|
NCT02081014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSMP-201|Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes|A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)||Xeris Pharmaceuticals|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|50 Years|No|||December 2014|December 2, 2014|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081014||49063|
NCT02081027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN001- Riluzole in Autism|Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2013|July 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|12|||Both|12 Years|26 Years|No|||March 2014|March 5, 2014|August 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081027||49062|
NCT02080988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC 13OISE0066_2|Reflexive Coughing Force in Severe Aspirators|Cross Sectional Evaluation of Coughing Force in Stroke Patients With Severe Aspiration||The Catholic University of Korea|No|Completed|October 2013|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Stroke patients with dysphagia with aspiration|November 2015|November 3, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080988||49065|
NCT02081001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSGO-201|PK/PD Study With G-Pump (Glucagon Infusion) in DM1 Patients|COMPARISON OF PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF G-PUMP™ (GLUCAGON INFUSION) VS GLUCAGEN® DELIVERED SUBCUTANEOUSLY TO SUBJECTS WITH TYPE 1 DIABETES (DM1)||Xeris Pharmaceuticals|No|Completed|March 2014|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||October 2015|October 25, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081001||49064|
NCT02081872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-101|Utility of PharmacoGenomics for Reducing Adverse Drug Effects|Utility of PharmacoGenomics for Reducing Adverse Drug Effects|UPGRADE|Companion Dx Reference Lab, LLC|No|Recruiting|April 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|279000|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female subjects over the age of 18, receiving at least one medication with        metabolism known to depend on genetic allelic variation.|September 2015|October 7, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081872|90 Days|48997|
NCT02082171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-55|Multidomain Intervention to Prevent Disability in Elders|Multidomain Intervention to Prevent Disability in Elders|MINDED|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|60 Years|N/A|No|||February 2015|February 5, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082171||48974|
NCT02082184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-CI-APO-12018|An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes|Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on HbA1c in Type 2 Diabetes|REPLACE|Abbott Diabetes Care|No|Completed|March 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|302|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082184||48973|
NCT02078102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0419|A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma|A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma||Indiana University|Yes|Recruiting|March 2014|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078102||49287|
NCT02078401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56406|Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.|Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.||Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2014|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Probability Sample|Children with neurofibromatosis type 1 with and without optic pathway glioma|July 2014|July 1, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02078401||49264|
NCT02082210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15246|A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer|A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer||Eli Lilly and Company|No|Recruiting|March 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082210||48971|
NCT02078115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRODITE-2|Assessment of Blood Pressure Control and Target Organ Damage in Patients With Chronic Kidney Disease and Hypertension -II|Observational Study of Blood Pressure Control Pattern and the Impact on the Target Organ Damages||Seoul National University Hospital|No|Recruiting|April 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|20 Years|74 Years|No|Non-Probability Sample|chronic kidney disease patients with hypertension|March 2014|March 3, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02078115|1 Year|49286|
NCT02079493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11109-Conformis|Prospective Functional Outcome Study of the Knee|Prospective Functional Outcome Study of the Knee|PFOSK|Tufts Medical Center|No|Recruiting|January 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|55 Years|N/A|No|Non-Probability Sample|Total knee arthroplasty patients|April 2014|April 2, 2014|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079493||49180|
NCT02078180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSF223201310164C|Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns|Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns||University of Michigan||Recruiting|April 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|50|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078180||49281|
NCT02082015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1308-214-002|Efficacy and Safety Study of rTMS for Upper Extremity Motor Function Recovery in Ischemic Stroke Patients|A Randomized, Double-Blind, Sham-Controlled, Multi-center Clinical Trial to Evaluate Efficacy and Safety of rTMS 『TMS』 for Upper Extremity Motor Function Recovery in Patients With Ischemic Stroke|TAMAS|Seoul National University Bundang Hospital|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|20 Years|80 Years|No|||February 2016|February 15, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082015||48986|
NCT02082028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGSTA_L_05978|Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin|Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only|SELF CARE|Sanofi|No|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|45 Years|N/A|No|||November 2015|November 26, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082028||48985|
NCT02078219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5491C00001|Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia|A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, 24-Week Phase II Study to Evaluate Efficacy and Safety of RDEA3170 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg Versus Placebo and Open-Label Allopurinol 200 mg as a Reference Arm in Japanese Patients With Gout or Asymptomatic Hyperuricemia||AstraZeneca|Yes|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|381|||Both|20 Years|70 Years|No|||March 2015|March 25, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02078219||49278|
NCT02078518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00724|Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors|||National University Hospital, Singapore|No|Recruiting|September 2013|||August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|21 Years|N/A|No|Probability Sample|Multiple Myeloma patients treated in National University Hospital.|March 2014|March 3, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02078518||49255|
NCT02078531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01005|A Prospective Pilot Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive and Brain Function of Breast Cancer Patients|||National University Hospital, Singapore|No|Not yet recruiting||||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|Whole blood.|Female|21 Years|65 Years|No|Probability Sample|Patients being treated with breast cancer at National University Hospital.|March 2014|March 3, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02078531||49254|
NCT02078778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGH-4-2013|Central and Peripheral Blood Pressure in Treatment of Obstructive Sleep Apnea.|Central and Peripheral 24-h Blood Pressure Monitoring in Patients With Hypertension and Obstructive Sleep Apnea Before and After Treatment With Continuous Positive Airway Pressure.|HOSI|Regional Hospital Holstebro|No|Recruiting|February 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|55 Years|70 Years|No|||January 2015|January 30, 2015|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078778||49235|
NCT02079298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2013-003611-21|Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants|Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics||Karolinska Institutet|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|80|||Both|23 Weeks|42 Weeks|No|||September 2015|September 1, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02079298||49195|
NCT02070614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP3A4 and sufentanil|Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption|Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption||Huazhong University of Science and Technology|Yes|Completed|December 2013|May 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|72|Samples With DNA|The blood samples were drawn before anesthesia，30 min and 45min after anesthesia      respectively，used for genotyping and plasma sufentanil concentration detection with high      performance liquid chromatography-mass spectrometry (HPLC-MS).|Both|18 Years|65 Years|No|Probability Sample|60 Chinese male and female patients receiving elective upper abdominal surgery (liver,        pancreatic, gallbladder) under general anesthesia|August 2015|August 30, 2015|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02070614||49862|
NCT02080767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10331|Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure|Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses||U.S. Army Medical Research and Materiel Command||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||October 2015|October 28, 2015|March 4, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02080767||49082|
NCT02080780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN307-DDI-001|Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects|Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects||Ventrus Biosciences, Inc|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 4, 2014|No|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT02080780||49081|
NCT02081040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC 13OISE0066_1|Coughing in Infratentorial Brain Lesion Patients|Cross Sectional Observation Study of Cough Dysfunction in Infratentorial Brain Lesion Patients, as Assessed by M-mode Sonography||The Catholic University of Korea|No|Completed|September 2013|August 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|42|||Both|18 Years|80 Years|No|Probability Sample|Dysphagia patients due to brain lesions at a university affiliated hospital|February 2015|February 22, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081040||49061|
NCT02081339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2038|Cohort Study of the Clinical Course of Macular Diseases in Japanese|Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients||Kyoto University, Graduate School of Medicine|No|Recruiting|March 2014|March 2024|Anticipated|March 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Patients who visit Department of Ophthalmology Kyoto University Hospital with macular        diseases.|September 2015|September 1, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02081339|5 Years|49038|
NCT02081573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13050427|Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study|Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study||University of Pittsburgh|No|Recruiting|January 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|65 Years|No|||March 2014|March 5, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02081573||49020|
NCT02081586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040441|mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study|mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study||University of Pittsburgh|No|Recruiting|May 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|30 Years|65 Years|No|||March 2014|March 6, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02081586||49019|
NCT02081885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chitosan-2014-1|Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture|Therapeutic Efficacy of Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture||Instituto Mexicano del Seguro Social|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|45 Years|No|||March 2014|March 5, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02081885||48996|
NCT02082197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-886|An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men|A Multicenter, Open-Label, Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men||AbbVie|No|Withdrawn|March 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|80 Years|No|||May 2014|May 29, 2014|March 6, 2014|No|Yes|Other - not a safety issue|No||https://clinicaltrials.gov/show/NCT02082197||48972|
NCT02082223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005601|Individualized Preoperative Rehabilitation Pilot|Individualized Preoperative Rehabilitation (iPREHAB) Pilot|iPREHAB|Mayo Clinic|No|Active, not recruiting|March 2014|December 2016|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082223||48970|
NCT02078713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-6874|Patient-Centered Support for Contraceptive Decision-Making|Patient-Centered Support for Contraceptive Decision-Making: A Cluster Randomized Controlled Trial of a Contraceptive Decision Support Tool||University of California, San Francisco|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|758|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02078713||49240|
NCT02078947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 602405-2|Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure|Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure- Clinical Study|OptimEx-Clin|Technische Universität München|Yes|Recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|40 Years|N/A|No|||May 2015|May 11, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02078947||49222|
NCT02078960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41443/2057|A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)|An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies||Teva Pharmaceutical Industries|Yes|Recruiting|May 2014|July 2020|Anticipated|May 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078960||49221|
NCT02080559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG2012/05 EUCLIDS|Investigating the Immune Response to 4CMenB in Infants|A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB)||University of Oxford|Yes|Active, not recruiting|July 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|160|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02080559||49098|
NCT02081989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01/13|Renal Denervation in Diabetes.|Effect of Renal Sympathetic Denervation on Glycemic Status Independent of Blood Pressure-lowering.||Monash University|No|Not yet recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02081989||48988|
NCT02082041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOUND-MSU|Measurement of Blood Perfusion in Response to Loading in Patients With Wounds|||Michigan State University|No|Active, not recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with wounds on their legs, wound clinic patients|April 2015|April 13, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082041||48984|
NCT02082054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGNA2014-001|StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study|A Phase 2, Double-Blind, Parallel-Group, Dose-Ranging Study Evaluating Safety/ Efficacy Atropine Doses With Pseudoephedrine and Chlorpheniramine in SAR Patients 12 Years of Age and Older||Magna Pharmaceuticals, Inc.|No|Active, not recruiting|March 2014|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|125|||Both|12 Years|60 Years|No|||February 2014|May 28, 2014|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082054||48983|
NCT02082327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-018|A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers With an Open-Label, Randomized, Two-Way Crossover Arm||Amicus Therapeutics|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|June 17, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082327||48962|
NCT02078232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFED N°98|Comparison of Two Needles (19G Flex Versus 22G Standard) for Pancreatic Solid Tumors Diagnosis|Randomized, Comparative Study of 19G Flex Versus 22G Standard Needles for Pancreatic Solid Tumors Diagnosis.|EASYFLEX|French Society of Digestive Endoscopy|No|Recruiting|April 2013|September 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2014|March 3, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02078232||49277|
NCT02078544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00705|Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO)|||National University Hospital, Singapore|No|Recruiting|December 2013|||August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|I. Tumour samples from patients with a diagnosis of gynaecological cancer from year 1995 to      31 July 2013 will be obtained from the pathology archives and tissue repository.      II. Blood, tumour and ascitic and pleural fluid samples will be prospectively collected.|Female|21 Years|N/A|No|Probability Sample|Patients treated with gynaecological cancers at National University Hospital.|March 2014|March 3, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02078544||49253|
NCT02078557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8892-007|A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)|A Multiple Dose Titration Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892 in Patients With Pulmonary Hypertension and Left Heart Disease||Merck Sharp & Dohme Corp.|No|Terminated|May 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|80 Years|No|||November 2015|November 2, 2015|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078557||49252|
NCT02078791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LINE-01|Discomfort and Psychosocial Difficulties in Fibromyalgia|Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain|Fibroebre|University Rovira i Virgili|Yes|Completed|July 2012|February 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Both|14 Years|N/A|No|||September 2014|September 15, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02078791||49234|
NCT02079064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesthesia 98T|Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy|Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis.||Theodor Bilharz Research Institute|No|Recruiting|January 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|55 Years|No|||January 2016|January 5, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02079064||49213|
NCT02079038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-TDDS-01|The STEPS - Totalis™ Trial|A Prospective, Multi-center, Randomized Controlled Double-Blind Trial Evaluating the VertiFlex® Totalis™ Direct Decompression System Versus a Sham Surgical Procedure in Patients With Lumbar Spinal Stenosis||VertiFlex, Incorporated|No|Active, not recruiting|May 2014|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|55 Years|N/A|No|||November 2015|November 23, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02079038||49215|
NCT02079051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00025897|Impact of Weight Loss on Physical Function|Impact of Medical Weight Loss on Physical Function in Severely Obese Older Adults|OPTIFAST|Wake Forest School of Medicine|Yes|Completed|February 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|65 Years|N/A|No|||December 2014|December 8, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02079051||49214|
NCT02070926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADM CCTA|The CRONOS-ADM Registry|Coronary CT Angiography Evaluation for Clinical Outcomes in Asymptomatic Patients With Type 2 Diabetes Mellitus||Seoul St. Mary's Hospital||Completed|January 2006|||December 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|N/A||Probability Sample|The study population consist of patients with asymptomatic type 2 diabetes mellitus at two        centers of catholic university of Korea|February 2014|February 23, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02070926|3 Years|49838|
NCT02070939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7411001|Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects|A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06260414 In Healthy Western And Japanese Male Subjects||Pfizer|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|72|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|February 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070939||49837|
NCT02081365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4100054871|Clinical Management of Anxiety and Access to Health Care|Clinical Management of Anxiety and Access to Health Care||Temple University|Yes|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02081365||49036|
NCT02081599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A15|Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes|A Phase IV Study of Teneligliptin (MP-513) in Combination With Insulin in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|N/A|No|||July 2015|July 22, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081599||49018|
NCT02081898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wt loss_20140305|Effects of Long Term Calorie Restriction on Sphingomyelin and Amino Acids|Three-year Mild Calorie Restriction Partially Protects Against Age-related Increase in Sphingomyelin and Reduces Obesity-associated Amino Acids||Yonsei University|Yes|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|120|||Both|40 Years|59 Years|No|||March 2014|March 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081898||48995|
NCT02081352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRG-H01-01|A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers|Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure™ in Patients With "Hard to Heal" Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm||TRx Wound Care Limited|No|Recruiting|August 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||November 2015|November 4, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081352||49037|
NCT02078128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105013MB|To Study the Effect of β-glucans on Wound Healing|To Study the Effect of β-glucans on Wound Healing||National Taiwan University Hospital|Yes|Completed|July 2011|February 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|20 Years|60 Years|No|||March 2014|March 3, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT02078128||49285|
NCT02078141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0002|18F-deoxyglucose (FDG) PET-CMD|Monocentric, Prospective, Uncontrolled Pilot Study of Extra Cardiomyocytary Fixation Profile in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography in Patients With Dilated Cardiomyopathy.||Nantes University Hospital|No|Recruiting|June 2014|||May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|December 18, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02078141||49284|
NCT02078440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-PEDS BA-2010|Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects|Single Dose Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets Following Administration of a Weight-Adjusted Dose in Male and Female Children and Adolescent Type 2 Diabetes Mellitus Subjects VS-PEDS BA-2010-V4||VeroScience|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|17 Years|No|||December 2015|December 22, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078440||49261|
NCT02078973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFA-1-2014|Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)|The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.|DOVA|Regional Hospital Holstebro|Yes|Active, not recruiting|February 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078973||49220|
NCT02078986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSvsHIT|Effectiveness of WB-EMS Versus HIT-Resistance Training (RT)|Comparison of the Effect of Whole-Body Electromyostimulation Versus High Intensity Resistance Exercise Training on Body Composition and Strength in Middle Aged Males|EMSvsHIT|University of Erlangen-Nürnberg Medical School|No|Terminated|February 2014|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078986||49219|
NCT02079220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-145|A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer|A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer||University of Pittsburgh|Yes|Withdrawn|March 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|March 3, 2014|Yes|Yes|Funding for the study was withdrawn, no participants were ever recruited.|No||https://clinicaltrials.gov/show/NCT02079220||49201|
NCT02079233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTST-16|Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers|Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers||Sorbent Therapeutics|No|Completed|May 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 4, 2014|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079233||49200|
NCT02081105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.818|Validation of Digital Chest-X-ray (CXR) to Assess Lung Recruitment in ARDS|Bedside Assessment of PEEP-induced Lung Recruitment by Using Digital Chest-X-ray in ARDS Patients. A Multicenter Prospective Study.|RECRUTEX|Hospices Civils de Lyon|No|Recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2014|May 6, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02081105||49056|
NCT02081456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-242|Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain|The Effects of Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain With Evidence of Neural Mechanical Sensitivity: A Randomized Clinical Trial||University of Nevada, Las Vegas|Yes|Completed|November 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081456||49029|
NCT02078011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17277|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU): A Feasibility Study|HIFU-FA-001|University of Virginia|Yes|Recruiting|April 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||December 2014|December 2, 2014|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078011||49294|
NCT02078297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6034|IL-17 Role in Variants of Psoriasis|Role of Il-17a in Difficult to Treat Variants of Psoriasis Including Palmo-plantar Psoriasis||Innovaderm Research Inc.|No|Completed|February 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|90|Samples With DNA|Skin biopsies and blood samples will be taken. Samples will be retained until final analyses      have been performed according to protocol and destroyed thereafter.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Invitation to volunteer|March 2015|March 25, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078297||49272|
NCT02077985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34DE022263-02|Sensory Adapted Dental Environment to Enhance Oral Care for Children With ASD|Sensory Adapted Dental Environment to Enhance Oral Care for Children With Autism|SADE|University of Southern California|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077985||49296|
NCT02078245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1001-32|Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.|Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer||Karolinska University Hospital|No|Recruiting|August 2010|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Bloodsamples|Both|18 Years|N/A|No|Non-Probability Sample|Familial risk for pancreatic cancer|October 2015|October 21, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02078245|15 Years|49276|
NCT02078258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Attention Bias Modification Treatment for Major Depression Disorder in Adolescents|Attention Bias Modification Treatment for Major Depression Disorder in Adolescents: A Randomized Controlled Trial||Hunan Normal University|No|Enrolling by invitation|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|11 Years|19 Years|No|||August 2014|August 19, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02078258||49275|
NCT02078271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST|Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children|Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children|FIRST|Indonesia University|No|Active, not recruiting|January 2011|May 2014|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|480|||Both|9 Months|11 Months|Accepts Healthy Volunteers|||March 2014|March 3, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02078271||49274|
NCT02078284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-04|Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets|Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding||U.S. Army Medical Research and Materiel Command|Yes|Recruiting|August 2014|May 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|28|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078284||49273|
NCT02078570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dtectDx-Breast-002|Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol|||Provista Diagnostics, Inc||Active, not recruiting|March 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|35mL or 2 1/2 tablespoons of blood will be drawn from your arm|Female|25 Years|75 Years|No|Non-Probability Sample|Primary Care Clinics|November 2015|November 3, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078570||49251|
NCT02079077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:042|Inducing Immune Quiescence to Prevent HIV Infection in Women|Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract|IIQ|University of Manitoba|Yes|Active, not recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079077||49212|
NCT02079337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMBVAL2013|Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery|Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery||Herlev Hospital|Yes|Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|14|||Female|18 Years|N/A|No|||July 2014|July 8, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02079337||49192|
NCT02032043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306100|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast||Washington University School of Medicine|No|Recruiting|February 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|16000|Samples Without DNA|Study procedures include collection of finger prick blood that will be tested for      microfilaremia and for serology testing (antigenemia and antibody testing). Investigators      will also collect skin snips (small superficial skin biopsies) to detect Onchocerca      microfilariae, and stool samples to detect parasitic worm eggs indicative of STH infections.      All assays will be performed in Ivory Coast(filarial serology tests, MF smears, stool      examinations).|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study populations are people who live in areas of Ivory Coast that are co-endemic for        lymphatic filariasis and onchocerciasis.|August 2015|August 26, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032043||52816|
NCT02081924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1807|Reproductive Hormones During Sustained Administration of Kisspeptin|Prospective Placebo-controlled Parallel Design Physiological Study of the Natural Hormone Kisspeptin|KisspeptPump|Imperial College London|Yes|Recruiting|March 2014|February 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|76|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02081924||48993|
NCT02082249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-923|An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications|An Open-Label Two-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications||AbbVie|No|Active, not recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|30 Years|99 Years|No|||January 2016|January 12, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02082249||48968|
NCT02081911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2014-005|Total Knee Arthroplasty Utilizing Adductor Canal Block: Effect on Quadriceps Sparing|Postoperative Pain Management Following Total Knee Arthroplasty Utilizing Adductor Canal Block: Effects on Pain Management and Quadriceps Sparing||Hospital for Special Surgery, New York|No|Terminated|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|80 Years|No|||January 2015|January 29, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02081911||48994|
NCT02082236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP101|Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects|Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects||AcelRx Pharmaceuticals, Inc.|No|Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02082236||48969|
NCT02078466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Functional ability in older|Assessment of Functional Ability and Follow-up at Home for Older Medical Patients|Assessment of Functional Ability and Follow-up at Home for Older Medical Patients||Aarhus University Hospital|No|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|352|||Both|65 Years|N/A|No|||January 2016|January 4, 2016|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078466||49259|
NCT02078726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13185|Glucagon and Colonoscopy|Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial||University of California, San Francisco|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02078726||49239|
NCT02078739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08383|Tele-yoga Program in COPD and Heart Failure|Tele-Yoga for Chronic Obstructive Pulmonary Disease and Heart Failure Patients: A Pilot Study|Tele-yoga|University of California, San Francisco|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|14|||Both|40 Years|85 Years|No|||January 2015|January 26, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02078739||49238|
NCT02079805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279/NRP-001|A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R|A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R||Takeda|No|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079805||49156|
NCT02079818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 7463|Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System|CLP 7463: Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System||Penumbra Inc.|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||November 2014|November 6, 2014|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079818||49155|
NCT02081664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/34974(NSD)|Feasibility of an Integrated Medical Care Program for Patients With Continuing Health Complaints After Amalgam Removal|Development and Feasibility Assessment of an Integrated Medical Care Rehabilitation Program for Patients With Continuing Health Complaints After Amalgam Removal - The IMCR Trial|IMCR|University of Tromso|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|70 Years|No|||June 2015|June 9, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081664||49013|
NCT02081677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5146|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2014|||||N/A|N/A|N/A||||||||||||||May 6, 2015|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081677||49012|
NCT02081690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-310|A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain|A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™|ORCHESTRA|Actelion|No|Terminated|March 2014|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|March 5, 2014|No|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT02081690||49011|
NCT02078323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNZ-IT-01|Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients|Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients||Georgia Regents University|Yes|Recruiting|February 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|45|||Both|18 Years|64 Years|No|||September 2014|September 16, 2014|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078323||49270|
NCT02082067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC05-14|Total Knee Prosthesis With Continuous Block of Adductor Canal and Outcome|Total Knee Arthroplasty & Outcome: A Prospective Randomized Comparison Between Adductor Canal Block and Femoral Nerve Block||ASST Gaetano Pini-CTO|No|Recruiting|March 2014|March 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|112|||Both|18 Years|N/A|No|||March 2014|June 10, 2014|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082067||48982|
NCT02078310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-200|Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia|A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.||Intra-Cellular Therapies, Inc.||Completed|February 2014|November 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 25, 2014|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078310||49271|
NCT02077998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#237|Oxaliplatin in Treating Patients With Metastatic Breast Cancer|A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy||University of California, Davis|Yes|Completed|May 2015|December 2015|Actual|May 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02077998||49295|
NCT02079662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0112|The Role of Lifestyle Factors in Breast Cancer-Related Outcomes|The Role of Lifestyle Factors in Breast Cancer-Related Outcomes||M.D. Anderson Cancer Center|No|Recruiting|June 2013|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079662||49167|
NCT02078804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2058- 31/3|Colonoscopy and FIT as Colorectal Cancer Screening Test in the Average Risk Population|SCREESCO - Screening of Swedish Colons||Uppsala University Hospital|Yes|Enrolling by invitation|March 2014|December 2034|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|200000|||Both|59 Years|62 Years|No|||June 2015|June 3, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02078804||49233|
NCT02078817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22225|Ketamine in Adolescents With Treatment-Resistant Depression|Open-Label Intravenous Subanesthetic Ketamine for Adolescents With Treatment-Resistant Depression||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|September 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|18 Years|No|||October 2015|October 12, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02078817||49232|
NCT02032342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth-Nov13(1)|Selective Lobar Blockade and Bronchial Blockers|Selective Lobar Blockade: A Randomized Trial of Three Bronchial Blockers||Dammam University|Yes|Recruiting|January 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02032342||52793|
NCT02081937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN301-XYK-CAR001|CART-19 Immunotherapy in Mantle Cell Lymphoma|Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma||Chinese PLA General Hospital|Yes|Recruiting|March 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|50 Years|80 Years|No|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02081937||48992|
NCT02081950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA/13/1|A Single-Dose Study to Examine the Within Subject Variability of Clexane® in Healthy Adult Subjects Under Fasting Conditions|A Single-Dose Study to Examine the Within Subject Variability of Clexane® (80 mg) s.c. in Healthy Adult Subjects Under Fasting Conditions||Chemi S.p.A.|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02081950||48991|
NCT02071420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306711|Efficacy of a Combined Ergonomic Health Promotion Intervention on Employee Health|Efficacy of a Combined Ergonomic Health Promotion Intervention on Employee Health||University of Iowa|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071420||49800|
NCT02078154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-Dimer DVT|Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis|Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis||Diagnostica Stago|Yes|Terminated|April 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Plasma samples|Both|N/A|80 Years|No|Probability Sample|Patients with proximal DVT diagnosed by imaging technique and with a low and moderate        Wells score|June 2015|June 2, 2015|February 26, 2014||No|Decision to start a new study on DVT with another protocol|No||https://clinicaltrials.gov/show/NCT02078154||49283|
NCT02078453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDEC-01|Impact of the Radiographic Examination on Diagnosis and Treatment Decision of Caries Lesions in Primary Teeth|CARies DEtection in Children - Impact of the Radiographic Examination on Diagnosis and Treatment Decision of Caries Lesions in Primary Teeth|CARDEC-1|University of Sao Paulo|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|250|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02078453||49260|
NCT02069743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-080|Pain Management in Cancer Patients Using a Mobile Application|Pain Management in Cancer Patients Using a Mobile Application|ePAL|Massachusetts General Hospital|No|Recruiting|February 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069743||49928|
NCT02070276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERU-1401|Predict Fluid Responsiveness in Spinal Anesthesia|Can Non Invasive Methods for Fluid Responsive Assessment Optimize Preventive Volemic Repletion in Order to Prevent Significant Hypotension After Spinal Anesthesia? A Randomized Trial|CERU-1401|Ente Ospedaliero Cantonale, Bellinzona|Yes|Recruiting|May 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|510|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02070276||49888|
NCT02079506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR208-I-01|Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin|An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers||Alvogen Korea|No|Completed|February 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079506||49179|
NCT02079519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18704|A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma|Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma||Hoffmann-La Roche||Terminated|May 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|75 Years|No|||June 2014|June 6, 2014|March 4, 2014|No|Yes|The study was discontinued prematurely by the sponsor due to a lack of recruitment.|No|June 6, 2014|https://clinicaltrials.gov/show/NCT02079519||49178|
NCT02080299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135355-BO|Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation|Protection of Heart, Brain and Kidney by Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation - a Randomized, Single-blind Study||University Hospital, Essen|Yes|Active, not recruiting|September 2013|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02080299||49118|
NCT02081729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0107|Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)|Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)||Asan Medical Center|No|Recruiting|March 2014|February 2015|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|181|||Both|16 Years|N/A|No|Non-Probability Sample|Kindeny transplant recipients|March 2014|March 5, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081729||49008|
NCT02081183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18989|A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis|A Study to Evaluate the Efficacy of CellCept, Administered in a Sequential Treatment Scheme, in Delaying Progressive Renal Damage in Patients With Lupus Nephritis||Hoffmann-La Roche||Terminated|March 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|March 5, 2014|No|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT02081183||49050|Data were not analyzed because the study was terminated early.
NCT02081196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA13-005|Colder Flank Study|Non-Invasive Reduction of Subcutaneous Fat Layer With an Alternative Treatment Parameter||Zeltiq Aesthetics|No|Active, not recruiting|February 2014|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|October 14, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081196||49049|
NCT02081742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCV-003|Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)|COMPARATIVE STUDY OF THE EFFICACY OF TWO NON-INVASIVE IMAGING TECHNIQUES IN POPULATION SCREENING FOR COLORECTAL CANCER (CRC): COLON CAPSULE AND VIRTUAL COLONOSCOPY|VICOCA|Hospital Clinic of Barcelona|Yes|Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|374|||Both|50 Years|69 Years|No|Probability Sample|The population we are concerned with in this study is the healthy population—men and women        50-69 years of age with no significant history. Therefore, the screening method we offer        must be the least invasive and the most comfortable method possible so that good        compliance is achieved. This means techniques that are painless and essentially harmless        in comparison with conventional colonoscopy. If we were to observe higher concordance        between these techniques and conventional colonoscopy in terms of detecting lesions, we        would use the latter strictly for therapeutic reasons in this population, thereby        significantly reducing the complications associated with it|August 2015|August 25, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02081742|6 Months|49007|
NCT02081755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-307|Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer|A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria||Baylor Research Institute|Yes|Recruiting|March 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081755||49006|
NCT02078583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEKING SEDATION|The Effect of Analgesia Based Sedation Protocol on Brain Function of Critical Care Patients|||Peking University People's Hospital||Not yet recruiting|July 2014|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|85 Years|No|||July 2014|July 15, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078583||49250|
NCT02078830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB-2013-024|Prospective Randomised Study for Use of CHG Dressing at Entry Site of EVD's to Reduce EVD-associated Infections|EXTERNAL VENTRICULAR DRAIN ASSOCIATED INFECTIONS STUDY (EVDAI-STUDY) - A Prospective Randomised Microbiological Study for Use of 3M™ Tegaderm™ Chlorhexidinegluconate Dressing at Entry Site of EVD's to Reduce EVD-associated Infections|EVDAI|University Hospital, Basel, Switzerland|Yes|Recruiting|October 2013|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|90 Years|No|||September 2015|September 28, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02078830||49231|
NCT02079090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00273|Ketofol Versus Fentofol for Procedural Sedation in the Pediatric Emergency Department|Ketofol Versus Fentofol for Procedural Sedation of Children 3 to 17 Years Old: a Double-Blind Randomized Controlled Trial||University of British Columbia|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|3 Years|17 Years|No|||November 2015|November 30, 2015|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02079090||49211|
NCT02079363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypmet|DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer|Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma."||Aalborg Universitetshospital|Yes|Recruiting|August 2013|January 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|330|Samples With DNA|Cell free methylated DNA in EDTA plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pancreatic adenocarcinoma, who were referred to Aalborg University Hospital        between 2008 and 2012. Blodsamples are stored in a biobank.        Patients with chronic pancreatitis, who are hospitalized or have an outpatient visit at        Aalborg University Hospital.        Patients with acute pancreatitis, who are hospitalized at Aalborg University Hospital.        Patients who are referred to Aalborg University Hospital for suspected upper GI cancer.        Subsequent examinations invalidate the cancer diagnosis.|July 2014|July 29, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079363||49190|
NCT02079376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CP TAN2012-60|The DIAMOND® for the Treatment of Type 2 Diabetes|The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study||Metacure|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02079376||49189|
NCT02079623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCaNanoK|Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer|Implementation of Electroporation - NanoKnife as Treatment for Advanced Pancreatic Cancer.|NanoKnife|Aalborg Universitetshospital|Yes|Enrolling by invitation|November 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079623||49170|
NCT02032589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|698-11 GE|Testing the Efficacy of Self-Generation Treatment Protocol|Exploring the Effects of a Memory Intervention on Memory and Everyday Life Activities With Persons With MS||Kessler Foundation|No|Not yet recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2014|January 9, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02032589||52774|
NCT02032862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920157|Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating|Multicentric, Randomized, Double Blind Study for Assessment of Efficacy and Tolerability of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating||Bioforce AG|No|Terminated|December 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Female|50 Years|65 Years|No|||July 2015|July 20, 2015|January 8, 2014||No|Insufficient recruitment rate|No||https://clinicaltrials.gov/show/NCT02032862||52753|
NCT02071160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01012012|Melatonin for Neuroprotection Following Perinatal Asphyxia|Melatonin for Neuroprotection Following Perinatal Asphyxia||Tanta University|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|N/A|6 Hours|Accepts Healthy Volunteers|||February 2014|February 23, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02071160||49820|
NCT02072265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309057RINC|Using a Thermal Imaging System to Evaluate the Wound of Port-A and the Relationship Between Thermal Images and Infection|Utilization of a Medical Dual-spectrum Infrared Thermal Imaging System to Evaluate the Wound Healing of Permanently Implantable Venous Port (Port-A) and to Investigate the Relationship Between the Thermal Images and Subcutaneous/Bloodstream Infection||National Taiwan University Hospital|No|Not yet recruiting|March 2014|||November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|20 Years|75 Years|No|Non-Probability Sample|Patients receiving Port-A implantation and removal|February 2014|February 24, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02072265||49736|
NCT02072278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15835A|Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects|Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects||H. Lundbeck A/S|No|Completed|February 2014|||November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|August 31, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072278||49735|
NCT02072590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11187|Improved Diagnostics of Celiac Disease in Children|Improved Diagnostics of Celiac Disease in Children||Tampere University Hospital|Yes|Recruiting|August 2011|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood, serum, intestinal mucosal biopsies|Both|N/A|17 Years|No|Non-Probability Sample|Hospital clinic; secondary and tertiary centers|November 2015|November 4, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02072590||49711|
NCT02070029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12053|Acupuncture for Sexual Dysfunction|Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort||TriHealth Inc.|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|55 Years|No|||February 2014|October 15, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02070029||49906|
NCT02078479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS with malignancy pain|rTMS as a Treatment of Neuropathic Pain Secondary to Malignancy|Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain Secondary to Malignancy.||Assiut University|No|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years||||February 2014|March 1, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078479||49258|
NCT02079246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14861B|Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease|STAR Extension|H. Lundbeck A/S|Yes|Enrolling by invitation|April 2014|||October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1770|||Both|50 Years|N/A|No|||December 2015|December 10, 2015|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079246||49199|
NCT02080065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-080|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Liver Transplantation|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Liver Transplantation||Samsung Medical Center|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|573|||Both|20 Years|70 Years|No|Non-Probability Sample|patients who underwent living donor liver transplantation between 2010 and 2013|August 2015|August 27, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080065||49136|
NCT02080832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM15378|Brain Function and Structure in Cocaine Dependence|Brain Function and Structure in Cocaine Dependence||Virginia Commonwealth University|Yes|Completed|February 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|50 Years|No|||February 2016|February 19, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080832||49077|
NCT02081482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-05|Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation|Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation|MET-ONS|Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|March 2014|August 2016|Anticipated|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081482||49027|
NCT02082080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adjazayery|Prevention and Control of Obesity in Primary School Children in Tehran|||Tehran University of Medical Sciences|Yes|Active, not recruiting|December 2012|||June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|9 Years|14 Years|No|||March 2014|March 5, 2014|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02082080||48981|
NCT02082093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eNephro|Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure|Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure|eNephro|Pharmagest Interactive|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02082093||48980|
NCT02078596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4592R|DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF DEPAKOTE_ (DIVALPROEX SODIUM) IN CHILDREN WITH TEMPER OUTBURSTS AND SEVERE MOOD SWINGS|DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF DEPAKOTE_ (DIVALPROEX SODIUM) IN CHILDREN WITH TEMPER OUTBURSTS AND SEVERE MOOD SWINGS||New York State Psychiatric Institute|No|Completed|March 1997|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|7 Years|11 Years|No|||March 2014|March 3, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02078596||49249|
NCT02078609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGH447X2102|A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome||Novartis|No|Recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078609||49248|
NCT02078622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140101S|Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients With COPD|A Prospective Randomized Controlled Trial to Evaluate the Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients Diagnosed With COPD|RTQOL|StratiHealth|Yes|Enrolling by invitation|March 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|55 Years|80 Years|No|Probability Sample|Patients who are diagnosed with COPD|November 2015|November 24, 2015|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078622|24 Weeks|49247|
NCT02078843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092/11|Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors|Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors|GaIN|University Hospital Inselspital, Berne|No|Recruiting|March 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|133|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02078843||49230|
NCT02079389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110135|The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum|The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum: A Prospective Randomized Trial||Odense University Hospital|Yes|Completed|May 2013|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|280|||Both|18 Years|N/A|No|||May 2013|May 4, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079389||49188|
NCT02079649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-069|Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis|A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model||Alcon Research|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|224|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|March 4, 2014|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT02079649||49168|
NCT02079103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UiB-228792|Virtual Reality Training for Upper Extremity After Stroke|Virtual Reality Based Training - a Motivating and Effective Way of Regaining Arm Motor Function After Stroke? The VIRTUES Trial: A Multi-center RCT|VIRTUES|University of Bergen|No|Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02079103||49210|
NCT02079116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Process HCRP: 14080/2011|Ingestion of Lipids and Changes in Cerebral Blood Flow of People With Obesity|Acute Ingestion of Lipids and Alteration of Cerebral Perfusion in Obese Patients.||University of Sao Paulo|No|Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02079116||49209|
NCT02079935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/344|Treatment of Eating Disorders by Physical Activity and Nutrition Counseling|Treatment of Eating Disorders - a Randomised, Controlled, Prospective Study|FAKT|Norwegian School of Sport Sciences|Yes|Recruiting|March 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|40 Years|No|||March 2016|March 17, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02079935||49146|
NCT02080182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC1165|Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.|Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis.||hahid Beheshti University of Medical Sciences|Yes|Recruiting|January 2014|||October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|1 Year|16 Years|No|||March 2014|March 4, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02080182||49127|
NCT02080416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13174|Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors|A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|July 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080416||49109|
NCT02032602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v5EGIU|Dry Needling on Myofascial Trigger Points in Older Adults With Nonspecific Shoulder Pain|Efficacy of Dry Needling on Myofascial Trigger Points in Adults Over 65 Years Old With Non-specific Shoulder Pain: Single Blind Randomized Controlled Clinical Trial||University of Alcala|Yes|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|65 Years|N/A|No|||August 2014|August 15, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02032602||52773|
NCT02071953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|765-550|Comparative Study of Experimental Dental Adhesive With and Without Phosphoric Acid Pretreatment|Clinical Evaluation of an Experimental Universal Adhesive Used With and Without Phosphoric Acid Pretreatment in Posterior Composite Resin Restorations||Dentsply International|No|Completed|April 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071953||49759|
NCT02073045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1113|Intensive Education in Increasing Understanding of Lymphedema in Patients With Breast Cancer Undergoing Surgery|Effect of Intensive Education on Breast Cancer Patient's Understanding of Lymphedema||Case Comprehensive Cancer Center|No|Terminated|August 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|17|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|February 25, 2014||No|research cancelled|No||https://clinicaltrials.gov/show/NCT02073045||49676|
NCT02070536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0182|Predictive Values of Plasma Soluble RAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients|Predictive Values of Plasma Soluble RAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients|PrediRAGE|University Hospital, Clermont-Ferrand||Recruiting|February 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Population at high risk for ARDS development|February 2014|February 24, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070536||49868|
NCT02078167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMOLIPID|Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study|Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study||Comitato Etico di Area Vasta Sud Est|Yes|Completed|January 2009|December 2013|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|60|||Both|18 Years|60 Years||||March 2014|March 4, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078167||49282|
NCT02079259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aquadex|CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure|CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure - A Pilot Study to Optimize Individualized Volume Depletion|Aquadex|Heinrich-Heine University, Duesseldorf|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic heart failure listed for LVAD|March 2015|March 13, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02079259||49198|
NCT02081144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005437-3|Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study|Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study||Yale University|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081144||49053|
NCT02081157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1050|Use of GalaFlex in Ptotic Breast|Use of GalaFlex in Ptotic Breast||Galatea, Corp|No|Enrolling by invitation|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|21 Years|N/A|No|||June 2014|March 9, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081157||49052|
NCT02081443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIT|In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients|In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor Mediated Signaling in Ticagrelor Treated Patients||University of Florida|Yes|Completed|April 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|80 Years|No|||October 2015|November 10, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081443||49030|
NCT02081768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yttrium2014|90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors|Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90yttrium Colloid for Treatment of Cystic Lesions of the Pituitary and Surrounding Areas (Sellar/Parasellar Region)||Nova Scotia Health Authority|No|Recruiting|June 2014|June 2025|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|17 Years|N/A|No|||January 2016|January 26, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081768||49005|
NCT02078024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU-10-205|Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana|Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana.||University Hospital Case Medical Center|Yes|Not yet recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|375|||Both|18 Years|60 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02078024||49293|
NCT02078635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-260|Magnetic Resonance Imaging-Portfolio Diet Study #7|The Canada-wide Human Nutrition Trialists' Network|MRIPD#7|St. Michael's Hospital, Toronto|No|Withdrawn||||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|N/A|No|||January 2015|January 16, 2015|February 18, 2014||No|The study was amalgamated with another study to include exercise as another intervention.|No||https://clinicaltrials.gov/show/NCT02078635||49246|
NCT02078648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-701-0114|Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme|A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)||Stemline Therapeutics, Inc.|Yes|Recruiting|May 2014|April 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078648||49245|
NCT02078856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3384-001|Double-blind, Randomised Study of A3384 in BAM/BAD|A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)||Albireo|No|Recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|80 Years|No|||August 2014|August 4, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078856||49229|
NCT02078869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO-wave|Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial|Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial||Toronto Centre for Advanced Reproductive Technology|Yes|Not yet recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|43 Years|No|||March 2014|March 4, 2014|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078869||49228|
NCT02079415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OJS2817|Infants of Diabetic Mothers: A Cohort Study|Study of Outcome of Infants of Diabetic Mothers in a Tertiary Hospital Set up||Security Forces Hospital|Yes|Completed|January 2011|October 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|601|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All Infants of diabetic mothers born at security Forces Hospital, Riyadh|May 2015|May 22, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02079415||49186|
NCT02079701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-00-2-0013|Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits|Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease||Naval Health Research Center|No|Completed|October 2000|June 2007|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|152723|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 5, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079701||49164|
NCT02079129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #013-185|Paravalvular Leak for Transcatheter Valve Replacement|A Novel Imaging Approach to Assess Paravalvular Leak for Transcatheter Valve Replacement|PVL-TAVR|Baylor Research Institute|Yes|Recruiting|January 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study cohort will consist of 50 patients who have undergone Edwards Sapien TAVR who        meet the following eligibility criteria and have provided written informed consent.|January 2016|January 13, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079129||49208|
NCT02079714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AR064066-01|Streamlining Trauma Research Evaluation With Advanced Measurement|Streamlining Trauma Research Evaluation With Advanced Measurement: STREAM Study|STREAM|Major Extremity Trauma Research Consortium|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|80 Years|No|Probability Sample|Orthopaedic trauma patients who are currently enrolled in the PAIN, FIXIT, OUTLET, OXYGEN,        or TAOS METRC studies. These studies look at outcomes following injuries to the foot,        ankle, tibia etc.|December 2015|December 1, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02079714||49163|
NCT02079402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-ITA-005|Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care|Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial|CLASSIC|Scandinavian Critical Care Trials Group|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02079402||49187|
NCT02079675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKI3246_IBS_II_2012|Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome|Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome||SK Chemicals Co.,Ltd.|No|Completed|January 2013|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|279|||Both|20 Years|75 Years|No|||May 2015|May 29, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079675||49166|
NCT02079688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB011/02/2013|Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema|A Phase IIa, Single-centre, Randomised, Vehicle Controlled, Double-blind Trial for Assessment of Efficacy, Safety and Tolerability of the Topical Formulation SB011 Containing a Human GATA-3 Specific DNAzyme and of Systemic Absorption of hgd40 Following Application to Lesional Skin in Patients With Atopic Eczema||Sterna Biologicals GmbH & Co. KG|Yes|Recruiting|February 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|60 Years|No|||March 2014|May 19, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079688||49165|
NCT02079948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182013|Inflammation Control For Elders: ICE Study|Role of Methotrexate in Improving Physical Function in Older Adults With Elevated Levels of Inflammation|ICE|University of Florida|Yes|Withdrawn|February 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|0|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|March 4, 2014|No|Yes|Potential participants had concerns about taking the study drug (methotrexate).|No||https://clinicaltrials.gov/show/NCT02079948||49145|
NCT02033213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JORTK3|Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial|Intraoperative Volume Restriction in Esophageal Carcinoma Surgery: an Exploratory Randomized Clinical Trial||Klinički Bolnički Centar Zagreb|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|January 7, 2014||No||No|January 19, 2014|https://clinicaltrials.gov/show/NCT02033213||52727|Small number of participants due to small overall number of patients with esophageal cancer treated in our hospital.
NCT02072811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALG-AML2012|Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia|Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells|PALG-AML2012|Polish Adult Leukemia Group|Yes|Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|400|||Both|18 Years|60 Years|No|||February 2014|February 25, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072811||49694|
NCT02073305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRS-SASinHD_003|Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients|Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients|SASinHD_003|Centre Hospitalier Universitaire Vaudois|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients with end stage renal disease on renal replacement therapy|January 2016|January 26, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073305|3 Years|49656|
NCT02073539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-010-001|The Manikin Study of Chest Compression With One Accelerometer Feedback Device|The Method of Proper Chest Compression Depth With Conventional and One Accelerometer Feedback Device During CPR in Hospital||Hanyang University Seoul Hospital|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073539||49638|
NCT02069496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114128|Drug Use Investigation for Arepanrix® (H1N1)|Drug Use Investigation for Arepanrix® (H1N1)||GlaxoSmithKline|No|Completed|February 2010|October 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3405|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Japanese subjects who receive Arepanrix® intramuscular injection for the first time|August 2012|February 20, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069496||49947|
NCT02078999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ventilator-adquired Pneumonia|Biomarkers in Patients Undergoing Mechanical Ventilation|Observational Study in Patients Admitted in the Intensive Care Unit.Tracheal Bacterial Load Surveillance in Patients Undergoing Mechanical Ventilation - Assessment of Biomarkers in the Distinction Between Colonization and Infection|VAP|Corporacion Parc Tauli|No|Recruiting|September 2008|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|400|Samples Without DNA|Bronchoalveolar lavage,biochemical lab,exhaled air.|Both|18 Years|N/A|No|Probability Sample|Patients admitted in the ICU|March 2014|March 4, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02078999||49218|
NCT02080858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVDAT-1.0|Triple vs. Dual Therapy|The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate||Medical University of Vienna|Yes|Completed|May 2014|February 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080858||49075|
NCT02080871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BES 10-07|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||February 17, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080871||49074|
NCT02080624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSW2011|Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome|Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.|RSW|Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|January 2011|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|23|||Both|16 Years|65 Years|No|||October 2013|March 4, 2014|April 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02080624||49093|
NCT02080884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29201|An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia|A MULTICENTER NON-INTERVENTIONAL STUDY EVALUATING THE BENEFIT OF THE COMBINATION OF MABTHERA (RITUXIMAB) WITH STANDARD CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN HUNGARY||Hoffmann-La Roche||Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with untreated chronic lymphocytic leukemia (CLL)|March 2016|March 1, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080884||49073|
NCT02080897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044852|Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease|Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire||Duke University|Yes|Recruiting|March 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with soft tissue sarcoma with metastatic lung disease|August 2015|August 5, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080897||49072|
NCT02081170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-066|The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes|||Samsung Medical Center||Recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|20 Years|N/A|No|||March 2014|March 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081170||49051|
NCT02082106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-2014-MET-SKI|Metabolic and Physiological Stress During Skiing.|Metabolic and Physiological Stress During Alpine Skiing, Cross-country Skiing and Indoor Training in Untrained and Trained Persons.||Paracelsus Medical University|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|Samples With DNA|Blood serum, blood plasma, blood cells|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twenty healthy subjects (male=10/female=10) aged 30+ will be recruited.|April 2015|April 28, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02082106||48979|
NCT02082119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138|Hypofractionated IMRT With Temozolomide for HGG|Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)||Istituto Clinico Humanitas|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|70 Years|No|||January 2014|March 5, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02082119||48978|
NCT02078349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPT330-A1|Phase I Study of KPT330 in Asian Patients|An Investigator Sponsored Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients With Advanced or Metastatic Solid Tumor Malignancies||National University Hospital, Singapore|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|21 Years|N/A|No|||September 2015|September 7, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02078349||49268|
NCT02078362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK002|ADCC Against Gastric Cancer Cells|Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells||National University Hospital, Singapore|No|Recruiting|September 2013|May 2018|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Peripheral blood|Both|21 Years|80 Years|No|Probability Sample|Gastric cancer patients treated at National University Hospital.|June 2015|June 11, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02078362||49267|
NCT02078895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-9702|Randomization of Botox for Stent Pain and Irritative Voiding Symptoms|Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms||University of California, Irvine|No|Recruiting|February 2014|||February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 3, 2014|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078895||49226|
NCT02078882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-457|Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis|Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid|PBC|University of California, Davis|Yes|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078882||49227|
NCT02079142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH095748-01|Implementation of Evidence-based Treatments for On-campus Eating Disorders|Implementation of Evidence-based Treatments for On-campus Eating Disorders||Washington University School of Medicine|Yes|Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|165|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079142||49207|
NCT02079740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00461|Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors|An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors||National Cancer Institute (NCI)|No|Suspended|March 2014|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 4, 2014|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02079740||49161|
NCT02079987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400005|An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use|An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use||University of Florida|Yes|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1324|||Both|60 Years|N/A|No|||December 2015|December 2, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079987||49142|
NCT02080000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROC001|R-wave Optimisation in Cardiac Resynchronisation Therapy Study|Use of the R-wave to Optimise VV Delay in Heart Failure Patients Treated With Cardiac Resynchronisation Therapy||The Royal Bournemouth Hospital|Yes|Recruiting|February 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080000||49141|
NCT02079974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4169720110|Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis|Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis||Toronto Centre for Advanced Reproductive Technology|No|Withdrawn|July 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|38 Years|No|||March 2014|November 5, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079974||49143|
NCT02080208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OptSCM|Which Place for High Flow Oxygen in ICU ?|Which Place for High Flow Oxygen in Intensive Care Unit ?||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|90 Years|No|||January 2016|January 29, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02080208||49125|
NCT02080221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 292|BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial||Brown University|Yes|Recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080221||49124|
NCT02033512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPQ202316|TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS|NANOSTRUCTURED TRANSDERMAL HORMONE REPLACEMENT THERAPY RELIEVING MENOPAUSAL SYMPTOMS: A CONFOCAL RAMAN SPECTROSCOPY STUDY|THRT|University Potiguar|Yes|Completed|January 2003|April 2008|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Female|51 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|December 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02033512||52704|
NCT02079883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-018|Ocriplasmin Research to Better Inform Treatment (ORBIT)|Ocriplasmin Research to Better Inform Treatment (ORBIT)|ORBIT|ThromboGenics|No|Recruiting|May 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|None Retained|No biospecimens collected|Both|18 Years|N/A|No|Probability Sample|This study will assess clinical outcomes and safety in patients treated with JETREA®        administered in a real-world setting for the treatment of symptomatic VMA|July 2015|September 23, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079883|12 Months|49150|
NCT02082262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229666-005|AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis|||Allergan|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|10 Years|N/A|No|||February 2016|February 11, 2016|March 6, 2014|Yes|Yes||No|September 8, 2015|https://clinicaltrials.gov/show/NCT02082262||48967|
NCT02079857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02325|Symptom Management for Irritable Bowel Syndrome|Symptom Management for Irritable Bowel Syndrome||New York University School of Medicine||Recruiting|November 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|183|||Both|18 Years|70 Years|No|||July 2015|July 2, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02079857||49152|
NCT02079870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3685|Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo|A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo||Novo Nordisk A/S|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 14, 2015|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079870||49151|
NCT02080104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-01.14-02-02|Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery|Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial|oxytocin|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Female|18 Years|45 Years|No|||March 2014|March 4, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02080104||49133|
NCT02080338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20092E07|0.018 or 0.022 Bracket Slot System More Effective in Orthodontic Treatment?|Is the 0.018-inch or the 0.022-inch Bracket Slot System More Effective in Orthodontic Treatment? A Randomized Clinical Trial.|Bracket slot|University of Dundee|Yes|Recruiting|January 2010|December 2016|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|12 Years|N/A|No|||March 2014|March 4, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02080338||49115|
NCT02081222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-096|The Predictability of Intraoperative Rotational Thromboelastometry on Postoperative Bleeding and Transfusion Requirements|The Predictability of Intraoperative Rotational Thromboelastometry on Postoperative Bleeding and Transfusion Requirements||Samsung Medical Center|No|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|119|||Both|N/A|10 Years|No|Non-Probability Sample|pediatric patients who underwent surgery for congential heart disease with cardiopulmonary        bypass|November 2015|November 10, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081222||49047|
NCT02081469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-174-0207|Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy|Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy||Chang Gung Memorial Hospital|Yes|Recruiting|March 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|70 Years|No|||March 2014|March 8, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081469||49028|
NCT02078336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55859|Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability|Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability|OptiSeDent|Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|February 28, 2014|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078336||49269|
NCT02078050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00638-37|Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures|Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures||Centre d'Investigation Clinique et Technologique 805|Yes|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02078050||49291|
NCT02078661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-PG-EF001|Safety and Efficacy of PG101 for Dry Eye Syndrome|A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome|PG101|Rhodes Pharmaceuticals, L.P.|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078661||49244|
NCT02079428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI11B10|China National Heart Failure Registry|The National Registry Study of Hospitalized Heart Failure Patients in China|CN-HF|Shanghai Institute of Cardiovascular Diseases|Yes|Recruiting|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|The study planed to consecutively enroll 10 000 heart failure patients fulfilling the        inclusion criteria. Each center will register all patients with heart failure involved in        the discharge or death diagnosis in consecutive 6 months.|March 2014|March 4, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02079428|3 Years|49185|
NCT02079727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12EU/Ct06|Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA|A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis||IBSA Institut Biochimique SA|No|Active, not recruiting|June 2014|April 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|50 Years|N/A|No|||February 2016|February 23, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02079727||49162|
NCT02079753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCs|Single Portable Pulse-dose-conserving Device vs. Combined Use of Stationary and Portable.|Oxygenation Using a Single Portable Pulse-dose-conserving Device Compared to Combined Use of Stationary and Portable Oxygen Delivery Devices.||Hospital Son Espases|Yes|Completed|June 2011|March 2014|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|80 Years|No|||March 2014|March 5, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02079753||49160|
NCT02080013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JVS-D-14-00218|Endovenous Radiofrequency Versus Laser Ablation for the Treatment of Great Saphenous Vein Reflux|Prospective, Randomized Study of Endovenous Segmental Radiofrequency Versus 1320 nm Laser Ablation for the Treatment of Great Saphenous Vein Reflux (RVLAb Study)||Ain Shams University|Yes|Completed|December 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|60 Years|No|||March 2014|April 2, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080013||49140|
NCT02080026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMGF1|Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis|Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis|BMGF1|Radboud University|Yes|Completed|June 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080026||49139|
NCT02080234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELOX1|Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL|Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) With Concurrent Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma:a Phase II Study||Sun Yat-sen University|No|Recruiting|March 2014|March 2017|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|69 Years|No|||November 2014|November 17, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02080234||49123|
NCT02080481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1299|Needle Guidance in Ultrasound Guided Nerve Blocks|Effect of InfinitiPlusTM Needle Guidance in Ultrasound Guided Regional Anesthesia||The Cleveland Clinic|No|Active, not recruiting|March 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|85 Years|No|||October 2015|October 9, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080481||49104|
NCT02043431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR-01|Electronic Medical Records and Genomics|Genetic and Electronic Medical Records to Predict Outcomes in Heart Failure Patients||University of Sao Paulo General Hospital|No|Active, not recruiting|August 2012|December 2016|Anticipated|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|Samples With DNA|Whole blood, urine. Exhaled acethone|Both|18 Years|80 Years|No|Non-Probability Sample|The elegible individuals are patients of a tertiary cardiology hospital|December 2015|December 15, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02043431|2 Years|51944|
NCT02079545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103367|Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants|A Phase 1, Randomized, Open-label, Parallel-design Study to Assess Absolute Bioavailability and Single-dose Pharmacokinetics Following Subcutaneous Administration of Sirukumab Delivered By A Pre-filled Syringe Fitted With UltraSafe Passive™ Delivery System or an Autoinjector in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|144|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079545||49176|
NCT02079558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRHRC-021|Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section|Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section||hahid Beheshti University of Medical Sciences|Yes|Completed|September 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|220|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 4, 2014|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079558||49175|
NCT02079571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301076RINB|Investigation of Pulse Waves, Channel Entries, and Food Attributes in Healthy Subjects With Different Constitutions|Investigation of Pulse Waves and Channel Entries Produced in Healthy Subjects With Different Constitutions and Their Changes After Treated With Foods of Different Food Attributes||National Taiwan University Hospital|No|Recruiting|May 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|240|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|June 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02079571||49174|
NCT02080351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0485|A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident|A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident: A Randomised Controlled Study in an Emergency Department|SCARTA|University of Oxford|Yes|Completed|March 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080351||49114|
NCT02080364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP488-301|Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease|Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine|STEADFAST|vTv Therapeutics|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|50 Years|N/A|No|||January 2016|January 15, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080364||49113|
NCT02080637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050118|Ambrisentan in Single Ventricle|Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients||Duke University|No|Recruiting|July 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|24 Months|120 Months|No|||October 2015|October 26, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080637||49092|
NCT02080910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2012.185-T|A Psychoeducational Intervention for Stroke Family Caregivers|The Effects of a Psychoeducational Intervention on Stroke Family Caregiver Outcomes and the Use of Health and Social Services Among Stroke Survivors: A Randomized Controlled Trial||Chinese University of Hong Kong|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|128|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080910||49071|
NCT02081209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA14-001|Outer Thigh Study With Varied Treatment Parameters|Non-Invasive Fat Layer Reduction in the Lateral Thighs With a Cryolipolysis System Using Varied Treatment Parameters||Zeltiq Aesthetics|No|Active, not recruiting|February 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081209||49048|
NCT02080650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052149|Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)|Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)||Duke University|No|Recruiting|March 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|8||Anticipated|85|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02080650||49091|
NCT02080923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-VA-CX-0001|A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration|A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration|PLR|Boston University|Yes|Not yet recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|16 Years|18 Years|No|||March 2014|March 5, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080923||49070|
NCT02081235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-101|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury in Pediatric Patients Who Undergoing Surgery for Congenital Heart Disease|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury in Pediatric Patients Who Undergoing Surgery for Congenital Heart Disease||Samsung Medical Center|No|Recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|10 Years|No|Non-Probability Sample|patients who underwent surgery for congenital heart disease between 2009 and 2013 in        Samsung Medical Center|November 2015|November 13, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081235||49046|
NCT02078375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115687|The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis|The PRESS RA Study: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis|PRESSRA|Johns Hopkins University|No|Recruiting|February 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|50|||Both|60 Years|95 Years|No|||December 2015|December 22, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078375||49266|
NCT02078388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01090|Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients|||National University Hospital, Singapore|No|Recruiting|November 2013|||October 2015|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood|Female|21 Years|N/A|No|Probability Sample|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant        chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had        a pre-doxorubicin echocardiography done at NUHS will be enrolled.|March 2014|March 3, 2014|December 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02078388||49265|
NCT02078921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/077/11|The Effects of Inorganic Nitrate on Cardiac Muscle in Angina|The Effects of Inorganic Nitrate on Cardiac Muscle: Physiology, Pharmacology and Therapeutic Potential in Patients Suffering From Angina||University of Aberdeen|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02078921||49224|
NCT02078934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoscopic Gastric Plication|Endoscopic Gastric Plication for Weight Loss in Morbidly Obese Patients Prior to Incisional Hernia Repair|Endoscopic Gastric Plication for Weight Loss in Morbidly Obese Patients Prior to Incisional Hernia||University of California, San Francisco|No|Recruiting|April 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078934||49223|
NCT02079155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12811|Robotic Athermal Nerve-Sparing Radical Prostatectomy|Prospective Single-Center Randomized Study of Robotic Athermal Nerve-Sparing Radical Prostatectomy: Laparoendoscopic Single-Site Versus Standard Approach||Case Comprehensive Cancer Center|Yes|Withdrawn|June 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Male|35 Years|72 Years|No|||January 2016|January 20, 2016|March 3, 2014|No|Yes|Research Cancelled|No||https://clinicaltrials.gov/show/NCT02079155||49206|
NCT02079168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1401|A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults|A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults||RXi Pharmaceuticals, Corp.|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079168||49205|
NCT02079441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0613-BW-CTIL|Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy|Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy||Sheba Medical Center|No|Not yet recruiting|March 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Blood tests|Both|N/A|3 Months|No|Probability Sample|This is a multicenter prospective controlled trial. The study population includes infants        born to mothers with IBD, divided into two groups: Study group- infants of IBD patients        treated with anti-TNF during pregnancy. Control group- infants of IBD patients treated        with non-anti TNF medications during pregnancy.|March 2014|March 4, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02079441||49184|
NCT02080039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012‐13|Electrical Stimulation of Denervated Muscles After Spinal Cord Injury|Clinical Pilot Study of the Effect of Electrical Stimulation of Denervated Muscles After Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Terminated|September 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||November 2014|November 19, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02080039||49138|
NCT02080260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-GI-PAN-REG-001|A Study of Regorafenib in Advanced Pancreatic Cancer Patients|A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas||Carolinas Healthcare System|Yes|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080260||49121|
NCT02080520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDF-01|Nattokinase Atherothrombotic Prevention Study|Nattokinase Atherothrombotic Prevention Study|NAPS|University of Southern California|Yes|Recruiting|April 2014|September 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|55 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080520||49101|
NCT02080247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPMREB-2012-051-CT-PGH|Treatment of Incontinence Associated Dermatitis in Older Children and Adults|A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults||University of the Philippines|Yes|Completed|December 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|12 Years|N/A|No|||April 2014|April 10, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080247||49122|
NCT02080494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-036|Tranexamic Acid in Orthopaedic Trauma Surgery|Tranexamic Acid in Orthopaedic Trauma Surgery||University of Tennessee|No|Enrolling by invitation|May 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|July 6, 2015|January 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080494||49103|
NCT02080507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068138|rTMS in Treatment Resistant Depression|rTMS in Treatment Resistant Depression|rTMSECT|Emory University|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080507||49102|
NCT02039336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45985.031.13|Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies|Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Colorectal, Non-small Cell Lung and Pancreatic Cancer|M13DAP|The Netherlands Cancer Institute|No|Recruiting|January 2014|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02039336||52257|
NCT02039583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRF NR-0166-1.2|Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England|Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England: a Quasi-experimental Study||University of Edinburgh|No|Completed|January 1995|January 2014|Actual|December 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community||1|Actual|10291118|||Both|N/A|1 Year|Accepts Healthy Volunteers|Probability Sample|All singleton births in England. See 'statistical analysis' for specification of base        population for each outcome.|January 2014|January 16, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02039583||52238|
NCT02079584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fwa00003543|Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant|Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant||Indiana University|No|Active, not recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|350|Samples With DNA|A blood sample will be obtained at the initial outpatient visit within 30 days (+/- 14 days)      post diagnosis and/or start of treatment and at the 180 day (+/- 14 days) follow up post      treatment visit and at each annual visit for up to 5 years.|Both|N/A|N/A|No|Non-Probability Sample|Heterogeneous group of patients pulled primarily from an emergency department population,        diagnosed with low-risk VTE.|March 2016|March 9, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079584|5 Years|49173|
NCT02079597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINJ1-001|The Role of Ninjurin-1 During Systemic Inflammation|Prospective Study to Analyze Ninjurin-1 and Its Soluble Part During Systemic Inflammation|Ninj1|Johann Wolfgang Goethe University Hospitals|No|Completed|February 2014|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|Samples With DNA|whole blood, plasma, RNA and cDNA extracted from whole blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|SIRS patients: Intensive care unit|September 2014|September 1, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079597||49172|
NCT02080117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-089|Adequate Definition of Delayed Graft Function in Living and Deceased Donor Kidney Transplantation|Adequate Definition of Delayed Graft Function in Living and Deceased Donor Kidney Transplantation||Samsung Medical Center|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|patients who underwent living or deceased donor kidney transplantation between 2008 and        2013|November 2015|November 10, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080117||49132|
NCT02080130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPS-03|Efficacy of Two Probiotic Preparations in Children With Acute Diarrhoea|Efficacy of Two Probiotic Preparations in Children With Acute Viral Diarrhoea, Randomised Controlled Trial||Sinaloa Pediatric Hospital|No|Recruiting|February 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|1 Month|5 Years|No|||December 2015|December 7, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080130||49131|
NCT02080143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014003|A Comparative Study to Evaluate Two Air-Activated Adhesive Backed Heat Patches|A Randomized, Open-Label, Comparative Study To Evaluate the Adhesion and Temperature Properties of Two Air-Activated, Adhesive Backed Heat Patches in Healthy Volunteers||Chattem, Inc.|Yes|Terminated|March 2014|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|January 26, 2016|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080143||49130|
NCT02080377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRACES|A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS|A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS|GRACES|University of Edinburgh|No|Active, not recruiting|July 2014|April 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Female|16 Years|50 Years|No|||December 2015|December 3, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080377||49112|
NCT02080663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC Van Nuffel De Smet|Long-term Outcome of Proximal Row Carpectomy. Influence of the Shape of the Capitate|Long-term Outcome of Proximal Row Carpectomy. Influence of the Shape of the Capitate||University Hospital Pellenberg|No|Enrolling by invitation|March 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|All patients who underwent a Proximal row carpectomy in our institution more than 10 year        ago will be contacted for review|March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080663||49090|
NCT02081248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1205|Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN 1205)|Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN #1205)||Medical College of Wisconsin|Yes|Recruiting|December 2013|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|198|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02081248||49045|
NCT02081495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103500|A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer|A Pivotal Bioequivalence Study of DOXIL®/CAELYX® Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer||Janssen Research & Development, LLC|No|Active, not recruiting|August 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02081495||49026|
NCT02078908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR-1-2013|The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study|The Effect of Sodium Nitrite on Renal Variables, Brachial and Central Blood Pressure in Healthy Humans. A Randomized, Cross Over, Placebo Controlled Dose-response Study||Regional Hospital Holstebro|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02078908||49225|
NCT02079779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONS-Gilliaux-02|Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Acute Stroke Patients|Study of the Effectiveness of an Interactive Robot for the Rehabilitation of the Upper Limb in Acute Stroke Patients by Evaluating the 3 Fields of the ICF: a Prospective, Randomized, Controlled, Simple Blind Study||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||July 2015|July 27, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079779||49158|
NCT02079181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-12-3|18F-FMAU PET/CT in Imaging Patients With Advanced Cancers|18F-FMAU for Imaging in Cancer Patients||University of Southern California|Yes|Suspended|January 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|19 Years|N/A|No|||October 2015|October 24, 2015|March 3, 2014|Yes|Yes|Pending production of human use 18F-FMAU|No||https://clinicaltrials.gov/show/NCT02079181||49204|
NCT02079454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|invos0001|Post-operative Cardiac Outcome of Non-cardiac Surgery Predicted by INVOS|Valeur Predictive de l'INVOS Sur l'Outcome Cardiaque en Post-opératoire. (French Title)||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|Samples Without DNA|blood samples for troponin I measurement|Both|18 Years|N/A|No|Non-Probability Sample|patient with high cardiac comorbidities undergoing a general anesthesia for a surgery of        over two hours with bleding potential.|March 2014|March 4, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02079454||49183|
NCT02079766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A07|18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy|18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy||Avid Radiopharmaceuticals|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079766||49159|
NCT02080806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC 13OISE0066_3|Pilot Study of Efficacy of Mechanical Insufflation Exsufflation in Stroke|Effects of Mechanical Insufflation-exsufflation in Stroke Patients With Dysphagia - Pilot Study||The Catholic University of Korea|Yes|Completed|October 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|85 Years|No|||December 2014|December 23, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080806||49079|
NCT02081079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1119|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection|A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection||Gilead Sciences|No|Completed|March 2014|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 5, 2014|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT02081079||49058|There were no limitations affecting the analysis or results.
NCT02080793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEJEUNE-CORMIER INCA 2012|STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS|STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS|CALIPSO|Centre Hospitalier Universitaire Dijon||Recruiting|May 2013|||May 2017|Anticipated|N/A|Interventional|N/A|2||Anticipated|680|||Both|50 Years|70 Years|No|||February 2014|March 5, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02080793||49080|
NCT02081053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-13-03|Evaluating Clinical Outcomes of Targeted Radiofrequency Ablation and Kyphoplasty (Also Known as Vertebral Augmentation) to Treat Painful Metastatic Vertebral Body Tumors|A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)|EU-STAR|DFINE Inc.|No|Recruiting|January 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02081053||49060|
NCT02081066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-20|Identification of CETP as a Marker of Atherosclerosis|Relationship Between Endogenous CETP Activity and Atherosclerosis Distribution in Patients With High Cardiovascular Risk|CETP-ATHERO|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|September 2014|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1800|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02081066||49059|
NCT02079311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD13-001|Evaluation of Core Body Temperature When Using Forced Air Warming or an Active Blanket to Prevent Perioperative Hypothermia|Evaluation of Perioperative Core Body Temperature When Using Forced Air Warming or BARRIER® EasyWarm to Prevent Inadvertent Perioperative Hypothermia: An Open-label, Randomized Non-inferiority Comparison||Molnlycke Health Care AB|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|55|||Both|18 Years|N/A|No|||June 2014|October 14, 2015|February 18, 2014||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT02079311||49194|
NCT02079324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-051_HNC_1|Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer|A Single Center, Open-Label, Accelerated Titration, Dose-Escalating, Phase Ι Study to Evaluate the Safety and Tolerability of IT Injection GX-051, Stem Cell Based Gene Therapeutics in Patients With Very Advanced Head and Neck Cancer|GX-051|Genexine, Inc.|No|Active, not recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|19 Years|N/A|No|||March 2014|April 29, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02079324||49193|
NCT02079610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-013-00|Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases|Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases||Laureate Institute for Brain Research, Inc.||Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|No|||August 2015|March 1, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079610||49171|
NCT02079896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXH94C301|Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients|Safety, PK/PD, and Efficacy of NOX-H94 in Dialysis Patients With ESA-hyporesponsive Anemia: A Randomized, Double Blind, Placebo Controlled Parallel Group Study With a Single Blind Cross-over Group||NOXXON Pharma AG|No|Completed|May 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|85 Years|No|||November 2015|November 23, 2015|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079896||49149|
NCT02080156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-881206|Impact of Continuous Positive Airway Pressure (CPAP) Therapy on Outcomes in Patients Undergoing Coronary Revascularization|Impact of Continuous Positive Airway Pressure Therapy on Outcomes in Patients Undergoing Coronary Revascularization||Beijing Anzhen Hospital|Yes|Recruiting|January 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02080156||49129|
NCT02080390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300763|Strain Imaging in Breast Cancer Patients Receiving Trastuzumab|Strain Imaging in Breast Cancer Patients Receiving Trastuzumab||University of Florida|No|Recruiting|September 2014|June 2019|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Women or men recieveing Trastuzumab (Herceptin) for HER2 positive breast cancer.|December 2015|December 14, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02080390||49111|
NCT02080676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0001-CTIL|Effects of Marihuana Use on Optic Nerve Parameters and Ocular Blood Flow|Effects of Marihuana Use on Optic Nerve Parameters and Ocular Blood Flow||Carmel Medical Center|No|Recruiting|March 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Adult patients over the age of 18, with no ocular pathology that are being treated in the        neurology or pain clinics with medical cannabis for different indications.|October 2015|October 13, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080676||49089|
NCT02080936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVIE_M2W|Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD|Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD|M2W|5 Santé|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|138|||Both|N/A|N/A|No|Non-Probability Sample|COPD patients from "Clinique du Souffle La vallonie" and "Clinique du Souffle La Solane"|March 2014|March 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080936||49069|
NCT02081508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-800-13|Consolidation & Interference in Multiple Sclerosis|Consolidation & Interference in Multiple Sclerosis||Kessler Foundation|No|Recruiting|March 2014|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081508||49025|
NCT02081781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-P103002|The Factors That Affected the Outcome of Treatment of Congenital Nasolacrimal Duct Obstruction|Case Control Study of the Factors That Affected the Outcome of Treatment of Congenital Nasolacrimal Duct Obstruction||Cathay General Hospital|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|800|||Both|N/A|5 Years|No|Non-Probability Sample|primary care clinic|March 2014|March 5, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081781||49004|
NCT02081794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE18Z13|Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients|Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients: A Pilot Study||Case Comprehensive Cancer Center|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|91|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081794||49003|
NCT02078700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE148/2012|Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.|Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.||Arcispedale Santa Maria Nuova-IRCCS|No|Completed|July 2013|December 2014|Actual|April 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||January 2015|July 30, 2015|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02078700||49241|
NCT02082275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009513|OB Nest; Redefining Continuity of Care for Expectant Mothers|Implementation and Evaluation of the OB Nest Project at the Point of Care: Redefining Continuity of Care for Expectant Mothers.||Mayo Clinic|No|Completed|February 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082275||48966|
NCT02080273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2012-10-CT-BKK-YPZ|Six Month Plaque and Gingivitis Study Using Colgate Total Toothpaste|The Clinical Investigation of Colgate Total Toothpaste as Compared to Parodontax Toothpaste and Colgate Cavity Protection Toothpaste in Controlling Established Plaque and Gingivitis. (A Six Month Study)||Colgate Palmolive|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080273||49120|
NCT02080533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penn-SON|Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension|Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension||University of Pennsylvania|Yes|Recruiting|February 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|21 Years|N/A|No|||January 2014|December 18, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02080533||49100|
NCT02080546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019452|Vaginal Cuff Dehiscence and Thermal Injury During TLH|Vaginal Cuff Dehiscence and Thermal Injury at the Time of Total Laparoscopic Hysterectomy: A Review of the Duke Experience and Randomized Controlled Trial||Duke University||Completed|December 2009|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|N/A|No|||November 2014|September 24, 2015|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080546||49099|
NCT02080819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM 20000079|Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse|Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse||Virginia Commonwealth University|Yes|Recruiting|February 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080819||49078|
NCT02081378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABL001X2101|A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)|A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL||Novartis|No|Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081378||49035|
NCT02081612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0001|Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy|Comparison of Weight Loss Among Early Stage Breast Cancer Patients Post Chemotherapy: Nutrition Education in Combination With Weight Loss Acupuncture Vs. Nutrition Education Alone||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2014|June 2020|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081612||49017|
NCT02079350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11739|Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation|||Turkiye Yuksek Ihtisas Education and Research Hospital|No|Completed|January 2011|December 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Both|18 Years|65 Years|No|Probability Sample|patients undergoing living donor liver transplantation|March 2014|March 1, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02079350|1 Month|49191|
NCT02079636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15266|A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)|A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC||Eli Lilly and Company|No|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079636||49169|
NCT02080169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAqiluICU|Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients|Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients||Qilu Hospital|No|Recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02080169||49128|
NCT02079909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T817MAUS202|Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)|A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease||Toyama Chemical Co., Ltd.|Yes|Active, not recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|55 Years|85 Years|No|||March 2015|December 24, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02079909||49148|
NCT02080689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU 004|Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery|PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]|PRO-IMPACT|GenomeDx Biosciences Corp|No|Active, not recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|286|||Male|N/A|N/A|No|||August 2015|February 26, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02080689||49088|
NCT02080949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRT|Phase I Dose Escalation in Patients With 1-3 Unresectable Brain Metastases|Study Phase I Dose Escalation With Hypofractionated Stereotactic Radiotherapy in Patients With 1-3 Unresectable Brain Metastases||Barretos Cancer Hospital|Yes|Withdrawn|January 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|March 1, 2014||No|Low rate of recruitment.|No||https://clinicaltrials.gov/show/NCT02080949||49068|
NCT02081261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-116|Predicting Acute Kidney Injury After Coronary Artery Bypass Graft|Predicting Acute Kidney Injury After Coronary Artery Bypass Graft : a Simplified Clinical Risk Scoring Model||Samsung Medical Center|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1300|||Both|20 Years|N/A|No|Non-Probability Sample|patients who underwent coronary artery bypass surgery during between 2010 and 2013 in        Samsung Medical Center|August 2015|August 27, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081261||49044|
NCT02082132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM0659|MODY in Young-onset Diabetes in Different Ethnicities|A Cross-sectional Study of Young-onset Diabetes in Two UK Ethnic Groups.|MYDIABETES|Imperial College London|No|Recruiting|October 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|916|Samples With DNA|We will be collecting blood and urine samples for routine diabetes tests as well as more      specialist tests that will help define what type of diabetes is present. We'll also collect      DNA to look for MODY (maturity onset diabetes of the young), the genetic cause of diabetes,      in some people.|Both|6 Months|N/A|No|Probability Sample|People in the UK diagnosed with any type of diabetes before the age of 30 years from        either white European or South Asian origin.|February 2016|February 23, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02082132||48977|
NCT02078037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1407|Systemic Normothermia in Intracerebral Hemorrhage (ICH)|Systemic Normothermia in Intracerebral Hemorrhage (ICH)|SNICH|The Cleveland Clinic|No|Active, not recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||February 2015|May 6, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078037||49292|
NCT02079467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miller-01|Unrestricted Rehabilitation Following Primary THA|Unrestricted Rehabilitation Following Primary Total Hip Arthroplasty: Implications for Patient Satisfaction and Functional Performance||Sunnybrook Health Sciences Centre|No|Recruiting|December 2013|November 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|50 Years|N/A|No|||March 2014|March 4, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02079467||49182|
NCT02079480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM142-003|Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects|Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects||Bristol-Myers Squibb|No|Active, not recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|9||Anticipated|130|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02079480||49181|
NCT02078492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-19|A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management|A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department"||Maimonides Medical Center|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 2, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078492||49257|
NCT02078505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSGut|Gut Microbiome in Patients With Polycystic Ovary Syndrome|The Effect of Diet on the Microbiome of Women With Polycystic Ovary Syndrome||Meir Medical Center|Yes|Not yet recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02078505||49256|
NCT02080286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/sc/0556|Transcranial Stimulation (tDCS) and Prism Adaptation in Spatial Neglect Rehabilitation|Boosting the Therapeutic Benefits of Prism Adaptation by Combining it With tDCS||University of Oxford|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080286||49119|
NCT02080312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120004|Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent|Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent||University of California, San Diego|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 3, 2014|No|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT02080312||49117|
NCT02081118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-204|Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes|A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin||Hanmi Pharmaceutical Company Limited|No|Completed|February 2014|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|209|||Both|18 Years|74 Years|No|||February 2016|February 18, 2016|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081118||49055|
NCT02081131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLOT|Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT)|A Prospective Randomized Controlled Trial Comparing Laparoscopic Versus Open Pancreatoduodenectomy for Malignant Periampullary and Pancreatic Head Lesions|PLOT|GEM Hospital & Research Center|Yes|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|30 Years|70 Years|No|||September 2015|September 14, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02081131||49054|
NCT02081092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-7051|Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT|Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT|PAP|Children's Hospital Medical Center, Cincinnati|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|8 Years|75 Years|No|Probability Sample|Patients with Pulmonary Alveolar Proteinosis|January 2016|January 26, 2016|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02081092||49057|
NCT02081391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503/65|An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants|An Evaluation of the Efficacy and Safety of Tapentadol Oral Solution in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Subjects Aged From Birth to Less Than 18 Years Old||Grünenthal GmbH|Yes|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|18 Years|No|||December 2015|December 21, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02081391||49034|
NCT02081625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCNP/DMT01|Exploratory Study of NS-065/NCNP-01 in DMD|Exploratory Study of NS-065/NCNP-01 in Duchenne Muscular Dystrophy||National Center of Neurology and Psychiatry, Japan|No|Active, not recruiting|June 2013|March 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|5 Years|18 Years|No|||November 2014|November 13, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081625||49016|
NCT02081638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140039|Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study|Elite Controller and ART-Treated HIV+ Statin Versus ASA Treatment Intervention Study||National Institutes of Health Clinical Center (CC)||Recruiting|December 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|February 13, 2016|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081638||49015|
NCT02081651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272/13|Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy|Parmigiano-Reggiano Cheese as a Possible Strategy of Immunonutrition Able to Stimulate the Acquisition of Oral Tolerance in Childre With Cow's Milk Allergy||Federico II University||Not yet recruiting|March 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|3 Years|10 Years|No|||March 2014|March 5, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02081651||49014|
NCT02079922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7611002|A Multiple Dose Study Of PF-06678552 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Administration Of Multiple Escalating Oral Doses In Healthy Adult Subjects||Pfizer|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079922||49147|
NCT02080702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1209|An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract|An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract.|PROMEGAT|Aesculap AG|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|630|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients|November 2015|November 25, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02080702||49087|
NCT02080715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMT and vigilance|Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance|A Randomized, Double-blind, Placebo-controlled Examination of the Effects of Tolcapone (TASMAR) on Vigilance in Healthy Volunteers After Sleep Deprivation||University of Zurich|Yes|Completed|June 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Male|20 Years|30 Years|No|||September 2014|September 11, 2014|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02080715||49086|
NCT02080403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI/016P|The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis|Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis.||Dexcel Pharma Technologies Ltd.|No|Recruiting|July 2014|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02080403||49110|
NCT02081274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-146|Influence of Tidal Volume During Mechanical Ventilation on Postoperative Clinical Outcome in Pediatric Patients Undergoing Congenital Heart Surgery|Influence of Tidal Volume During Mechanical Ventilation on Postoperative Clinical Outcome in Pediatric Patients Undergoing Congenital Heart Surgery||Samsung Medical Center|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|10 Years|No|Non-Probability Sample|pediatric patients who underwent surgery for congenital heart disease with cardiopulmonary        bypass|November 2015|November 10, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081274||49043|
NCT02081521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA511|Evaluation of a Multiple Behaviour Programme for Diarrhoea Management|Evaluation of a Multiple Behaviour Programme to Prevent and Manage Diarrhoea Among Children Under-five in Lusaka, Zambia||London School of Hygiene and Tropical Medicine|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|640|||Both|1 Month|59 Months|No|||March 2016|March 10, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081521||49024|
NCT02081807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.207|Sequential Expansion of Comparative Effectiveness of Anticoagulants|Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study||Boehringer Ingelheim||Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|120000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age and older with non-valvular AF initiating oral anticoagulation        therapy|March 2016|March 8, 2016|March 6, 2014||||No||https://clinicaltrials.gov/show/NCT02081807||49002|
NCT02081534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5613C00001|Dose Finding Study to Treat High Phosphate Levels in the Blood.|A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)||Ardelyx|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|597|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081534||49023|
NCT02081820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKD-NCH-2014-001|Admission HbA1C in Aneurysmal Subarachnoid Hemorrhage|Observational Study on the Prognostic Relevance of Admission Glycated Hemoglobin (HbA1C) in Patients With Aneurysmal Subarachnoid Hemorrhage||Heinrich-Heine University, Duesseldorf|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with confirmed aneurysmal subarachnoid hemorrhage admitted within 72 hours to        our department aged over 18 years.|March 2015|March 17, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02081820|6 Months|49001|
NCT02082145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1844|Electrical Stimulation in Diabetic Peripheral Neuropathy|Electrical Stimulation in Diabetic Peripheral Neuropathy|NERVES|Imperial College London|Yes|Enrolling by invitation|July 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|August 5, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02082145||48976|
NCT02079792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeadPositionMAD2014|The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device|The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device: A Randomized, Single-blind, Parallel Trial Comparing the Lying-Head-Back Versus the Head-Down-to-Floor Positions|Head Position|St. Paul's Hospital, Canada|No|Recruiting|June 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|19 Years|N/A|No|||November 2014|November 19, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079792||49157|
NCT02079012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML10148|Effects of a Walking Program in People With Mental Disorders|Short- and Long-term Effects of a Walking Program ("Join the Walk?") on Physical Activity, Physical Fitness and Subjective Well-Being With Members of a Sports Federation for People With Mental Disorders (Psylos).||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02079012||49217|
NCT02080052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1163|Robot-Assisted MRI-Guided Prostate Biopsy|||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2012|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Male|35 Years|75 Years|No|||March 2014|March 4, 2014|February 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080052||49137|
NCT02078752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7521001|A Study Of PF-06647263 In Patients With Advanced Solid Tumors|A First-In-Human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647263 In Adult Patients With Advanced Solid Tumors||Pfizer|No|Recruiting|April 2014|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|109|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02078752||49237|
NCT02079532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19070|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor|An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent||Hoffmann-La Roche||Completed|November 2006|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|March 4, 2014||No||No|June 17, 2014|https://clinicaltrials.gov/show/NCT02079532||49177|
NCT02080845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026868|Effects of a Cocoa Shot on the Human Brain 2|Effects of a Cocoa Shot on the Human Brain 2||Wake Forest School of Medicine|No|Completed|March 2014|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080845||49076|
NCT02081703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADYX-003|Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery|A Phase 2 Study to Evaluate the Safety & Efficacy of Two Dose/Volume Levels of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty||Adynxx, Inc.|Yes|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|40 Years|80 Years|No|||July 2015|July 14, 2015|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081703||49010|
NCT02081716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0103|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)||Asan Medical Center|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|88|||Both|16 Years|99 Years|No|Non-Probability Sample|bone marrow transplant recipients|November 2015|November 17, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081716||49009|
NCT02081976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/Saibliss 2120|Periodontal Therapy in a Primary Prevention of Cardiovascular Disease|A Randomized, Controlled Trial to Study Effects of Periodontal Therapy in Primary Prevention of Cardiovascular Disease.||Macmillan Research Group UK|Yes|Completed|April 2013|January 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|60 Years|No|||March 2014|March 6, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02081976||48989|
NCT02078193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-302|Efficacy of Belatacept in Reducing DSA|An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients||East Carolina University|No|Recruiting|November 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02078193||49280|
NCT02070523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangzhouJP|Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:|Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells||Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.|Yes|Recruiting|December 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|60 Years|No|||February 2014|July 6, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070523||49869|
NCT02080429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIHRI-PD|Passive Descent in Obese Nulliparous Gravidae|Can Passive Descent Increase the Spontaneous Vaginal Delivery Rate in Obese Women?||Women and Infants Hospital of Rhode Island|Yes|Not yet recruiting||||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Female|N/A|N/A||||March 2014|March 5, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02080429||49108|
NCT02080195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13134|Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)|A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||July 2015|July 1, 2015|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02080195||49126|
NCT02080962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399/2010|Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer|Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer: Study Phase II Clinical Trial||Barretos Cancer Hospital|Yes|Terminated|January 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|February 3, 2014||No|Low rate of recruitment.|No||https://clinicaltrials.gov/show/NCT02080962||49067|
NCT02080728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jazayeri-Steinmetz AOI 2012|Transversus Abdominis Plane Block During Kidney Transplant Surgery|Transversus Abdominis Plane Block During Kidney Transplant Surgery: Prospective Controlled Randomized Double-blind Trial Comparing Ropivacaine 0.2% With Placebo.||Centre Hospitalier Universitaire Dijon||Recruiting||||September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|50|||Both|18 Years|N/A||||April 2013|March 5, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02080728||49085|
NCT02081313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-56|Natural History and Biological Study of Netherton Syndrome|Syndrome de Netherton : Aspects Cliniques, Physiopathologiques et Identification de Cibles thérapeutiques|NSnatbio|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|April 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02081313||49040|
NCT02080975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071344|Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals|Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals|IN-CONTACT|Emory University|Yes|Completed|March 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02080975||49066|
NCT02081287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBDAT-2013-MJM|Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?|Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?||San Diego Veterans Healthcare System|No|Recruiting|May 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081287||49042|
NCT02081300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPCN 1021-13-001|Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism|Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men|SOAR|Lipocine Inc.|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|315|||Male|18 Years|80 Years|No|||July 2015|July 10, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02081300||49041|
NCT02082158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300693|Assessment of Novel Respiratory Protective Devices in Healthcare|Assessment of Novel Respiratory Protective Devices in Healthcare||National Center for Occupational Health and Infection Control|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|383|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02082158||48975|
NCT02078063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIUC13 version II|Analgesia for Insertion of Intrauterine Contraception|Mepivacaine for Pain Relief at Insertion of Intrauterine Contraception||Karolinska Institutet|No|Recruiting|November 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02078063||49290|
NCT02078076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-04|IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère|IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère||Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|June 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Both|8 Years|N/A|No|||February 2016|February 23, 2016|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02078076||49289|
NCT02052050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI2013-MP-18|Core Stability Program in Colorectal Cancer Survivors|Effectiveness of Core Stability Exercises on Abdominal Deep Muscles in Colorectal Cancer Survivors||Universidad de Granada|No|Completed|September 2012|April 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|75 Years|No|||January 2014|June 1, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02052050||51282|
NCT02052323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR2017|Harmonized AS/MQ Efficacy Study - Thailand|Study to Determine the Efficacy of Artesunate-mefloquine Combination Therapy for the Treatment of Uncomplicated P. Falciparum Malaria in Thailand||Armed Forces Research Institute of Medical Sciences, Thailand|No|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|5 Years|65 Years|No|||January 2016|January 22, 2016|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02052323||51261|
NCT02052674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300634|Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems|Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems||University of Florida|No|Withdrawn|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|January 30, 2014|Yes|Yes|Unable to enroll any patients in the study due to other on-going studies.|No||https://clinicaltrials.gov/show/NCT02052674||51234|
NCT02052687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFX453X2101|A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453|A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453, After Multiple Topical Applications in Healthy Volunteers.||Novartis|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02052687||51233|
NCT02052934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0023|Safety of Sublingual dmLT for ETEC|A Phase 1 Dose Escalating Study of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Sublingual or Oral Immunization to Determine Safety and Immunogenicity of a Multi-dose Regimen in Adult Humans||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|March 17, 2016|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052934||51215|
NCT02053298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S - 54854|Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients|Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|December 2, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053298||51187|
NCT02053311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/13|Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents|Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Treatment With a Taxane: A Multicentre Randomized Double-blind Placebo-controlled Phase III Trial||Swiss Group for Clinical Cancer Research|No|Suspended|June 2014|December 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|218|||Male|18 Years|N/A|No|||September 2014|September 2, 2014|January 29, 2014||No|The decision follows the results of 2 phase 3 clinical trials in metastatic, castration    resistant prostate cancer (mCRPC).|No||https://clinicaltrials.gov/show/NCT02053311||51186|
NCT02053610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21004 (Stage 2)|CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.||Hoffmann-La Roche||Active, not recruiting|December 2009|July 2020|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|787|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|November 25, 2013|Yes|Yes||No|August 15, 2014|https://clinicaltrials.gov/show/NCT02053610||51163|
NCT02053818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022428-58|Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.|Fast-track in Cardiac Surgery. Remifentanyl & Sufentanil Anaesthesia for CABG+/-AVR Evaluated by Recovery, Cognitive Dysfunction, Haemodynamics (PAC/TTE) and Cardiac Biochemical Markers (CKMB, TNT, Pro-BNP)|PRECON2|Aarhus University Hospital|No|Completed|August 2011|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|60 Years|80 Years|No|||August 2015|August 11, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02053818||51147|
NCT02053831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1040|GalaFlex Mesh in Facelift|GalaFlex Mesh in Facelift||Galatea, Corp|Yes|Completed|November 2011|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Both|21 Years|N/A|No|Non-Probability Sample|Primary Care Clinics|March 2015|March 9, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053831||51146|
NCT02054117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300797|Association Between Haptoglobin Genotype and Brain Swelling|Association Between Haptoglobin Genotype and the Development of Perihematomal Edema After Spontaneous Intracerebral Hemorrhage||University of Florida|No|Terminated|March 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|85 Years|No|Non-Probability Sample|Participants will be recruited from within the hospital setting.|March 2015|March 4, 2015|February 3, 2014||No|Principal Investigator is leaving institution.|No||https://clinicaltrials.gov/show/NCT02054117||51124|
NCT02054390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEmetsend|Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction|Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome||Ankara University||Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|459|||Both|18 Years|80 Years|No|Probability Sample|Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:          1. high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated             blood glucose)          2. abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)          3. high blood pressure (>130/>85 mmHg or drug treatment for hypertension)          4. hypertriglyceridemia (serum triglycerides ≥150 mg/dl)          5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in             women).|June 2014|June 19, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054390||51103|
NCT02063906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02-045|Prognostic Relevance of Biological Subtype in Breast Cancer|Prognostic Relevance of Biological Subtype Overrides That of TNM Staging in Breast Cancer: Discordance Between Stage and Biology||Samsung Medical Center|No|Recruiting|February 2014|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|202|||Female|18 Years|N/A|No|Non-Probability Sample|Patients who received curative surgery for stage I-III breast cancer between January 2004        and September 2008 and had available immunohistochemistry profiles.|February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063906||50374|
NCT02063919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014SDU-QILU-G01|Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome|Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome||Shandong University|Yes|Completed|November 2013|June 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|45|Samples With DNA|The mucosal metagenome was obtained from biopsy specimen.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with indications for colonoscopy in Qilu Hospital outpatient and inpatient        department are the study population of this study.|June 2015|June 27, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02063919||50373|
NCT02054598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0537|Improving Colon Cancer Screening for Diverse Populations|The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations||University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2014|December 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|300|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054598||51087|
NCT02055157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111-202|A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia|A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia|ACH|BioMarin Pharmaceutical|Yes|Enrolling by invitation|January 2014|January 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|5 Years|14 Years|No|||February 2016|February 5, 2016|April 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055157||51044|
NCT02054858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preconditioning-ReDUCE-F|Preconditioning Against Renal Damage Under Contrast Examination|Preconditioning Against Renal Damage Under Contrast Examination: a Single Centre, Randomized, Sham -Controlled Clinical Feasibility Trial|Re-DUCE-F|Mid Western Regional Hospital, Ireland|Yes|Recruiting|January 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054858||51067|
NCT02056002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-IHS-1306-02505|Peer-Driven Intervention for Sleep Apnea|Peer-Driven Intervention as an Alternate Model of Care Delivery and Coordination for Sleep Apnea|PCORI|University of Arizona|Yes|Enrolling by invitation|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|257|||Both|18 Years|85 Years|No|||October 2014|November 30, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056002||50980|
NCT02056015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C35001|A Phase I Study of MLN6907 in Patients With Metastatic Colorectal|A Phase 1, First-in-Human, Single-Dose, Open-Label, Positron Emission Tomography (PET) Imaging Study of [68Ga]MLN6907 in Patients With Metastatic Colorectal Carcinoma.||Millennium Pharmaceuticals, Inc.|No|Recruiting|June 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02056015||50979|
NCT02056262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/LH|Pathogenic Species and Genotypes of Bacterial Diversity in Relation to the Severity of Dental Caries|Prevalence and Identification of Pathogenic Species and Genotypes of Bacterial Diversity in Relation to the Severity of Dental Caries|Caries Species|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|56|Samples With DNA|Plaque and saliva samples; DNA analysis is aimed at describing microbial communities.|Both|3 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers aged 3 to 45 who come in to the hospital for a dental consultation.        Patients are recruted according to age in order to form two groups: 1/2 of participants        will be between 3 and 16 years of age; the other half of participants will be between 17        and 45 years of age.|March 2016|March 18, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056262||50960|
NCT02056028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BileLeakLiverSurgery|Bile Leak After Liver Surgery|Validation of Our Policy of Long-term Drains Maintenance After Hepatic Resection: Results of a Prospective Cohort Analysis||University of Milan|No|Completed|January 2004|February 2014|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|475|||Both|18 Years|90 Years|No|Probability Sample|The records of 475 consecutive patients who were submitted to hepatectomy between        2004-2012 were reviewed.|February 2014|February 4, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056028|90 Days|50978|
NCT02056041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SafeSurgeryHCC|Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma|Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma: Validation on 336 Consecutive Hepatectomies.||University of Milan||Completed|January 2004|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|336|||Both|18 Years|90 Years|No|Probability Sample|The records of 336 consecutive patients who were submitted to hepatectomy between        2004-2012 were reviewed.|June 2014|June 17, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056041||50977|
NCT02056275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA01|A Study of an Oral Nutrition Supplement (ONS) in Children.|A Study of an Oral Nutrition Supplement (ONS) in Children.||Abbott Nutrition|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|256|||Both|24 Months|72 Months|No|||October 2014|March 5, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056275||50959|
NCT02052063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/132/HP|Does the Stapled Transanal Rectal Resection (STARR Procedure) Has an Effect on Anal Compliance ?|Does the Stapled Transanal Rectal Resection (STARR Procedure) Has an Effect on Anal Compliance ?|Compli-STARR|University Hospital, Rouen|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|28|||Female|18 Years|65 Years|No|||September 2015|September 28, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02052063||51281|
NCT02052336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_103|Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between CJ-12420 and Clarithromycin in Healthy Male Subjects||CJ HealthCare Corporation|No|Active, not recruiting|October 2013|January 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02052336||51260|
NCT02052349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-108|Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects|A Phase I, Open-Label Study to Investigate the Regional Bioavailability of ABT-333 When Delivered to Different Sites Within the Gastrointestinal Tract in Healthy Subjects||AbbVie|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052349||51259|
NCT02052713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116897|Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects||GlaxoSmithKline|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|78|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052713||51232|
NCT02052726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5091002|A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.|A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years||Pfizer|Yes|Completed|January 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|184|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|December 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02052726||51231|
NCT02052960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXMab52201|CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer|Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus Chemotherapy in Comparison to Cetuximab Plus Chemotherapy for the Treatment of Patients With Stage III/IV Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|RESGEX|Glycotope GmbH|Yes|Recruiting|January 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||June 2014|November 13, 2014|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052960||51213|
NCT02053272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWDM1302|A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes|A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes||GW Research Ltd|No|Recruiting|February 2014|July 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053272||51189|
NCT02053324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AvOX/ST2210-CR-12-001|AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer|A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Liver Metastases From Colorectal Cancer||sigma-tau i.f.r. S.p.A.|Yes|Recruiting|September 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||July 2015|July 8, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02053324||51185|
NCT02053870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-BEB/101943/2008|Lung Sounds as Indicators of Severity and Recovery of Lung Disease|Adventitious Lung Sounds as Indicators of Severity and Recovery of Lung Pathology and Sputum Location||Aveiro University|No|Completed|September 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|98|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053870||51143|
NCT02053883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-210-201|Cethrin in Acute Cervical Spinal Cord Injury|A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury||BioAxone BioSciences, Inc.||Withdrawn|July 2015|||May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|62 Years|No|||November 2014|November 25, 2014|January 31, 2014|Yes|Yes|Compound recently partnered with another company for continued development.|No||https://clinicaltrials.gov/show/NCT02053883||51142|
NCT02053844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P30AG012810-20|Analyzing the Impact of the Now iKnow Health Care Price Transparency Tool|Analyzing the Impact of the Now iKnow Health Care Price Transparency Tool||Harvard Pilgrim Health Care|No|Recruiting|August 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|90000|||Both|N/A|N/A|No|||March 2015|March 17, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053844||51145|
NCT02054429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSULIN|Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke|||University at Buffalo||Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||January 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054429||51100|
NCT02054403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47347.068.13/METC 13-2-060|Angle Closure (Glaucoma) in Caucasians|Structural and Functional Parameters in Caucasian Patients With Angle Closure on SS-OCT||Maastricht University Medical Center|No|Not yet recruiting|April 2014|October 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|This study will consist of Caucasian patients, aged 40-80 years. Patients will be        recruited at the University Eye Clinic Maastricht, the Netherlands. All study participants        are derived from the study 'Caucasian patients with angle closure on SS-OCT', METC        13-4-108.|February 2014|February 3, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02054403||51102|
NCT02063646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2012-242|Effect of a Polyphenol-rich Food Supplement on Cognitive Function in Healthy Aging Adults|Effect of a Polyphenol-rich Food Supplement on Cognitive Function in Healthy Aging Adults: Randomized, Placebo-controlled, Double-blind Clinical Trial|Neurophenol|Neurophenols Consortium|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|204|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||October 2014|May 25, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063646||50394|
NCT02055443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13070234|Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain|Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain|MID-EPIC|University of Pittsburgh|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|18 years or older|December 2014|December 1, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02055443||51022|
NCT02054871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWRH09644|RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty|Randomised Controlled Trial to Evaluate the Reno-protective Benefits of Remote Ischaemic Preconditioning in Patients Undergoing Infrainguinal Peripheral Angioplasty||Mid Western Regional Hospital, Ireland|Yes|Recruiting|September 2013|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054871||51066|
NCT02054884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F16IL2TAXO-03/12|F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma|Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma||Philogen S.p.A.|No|Recruiting|October 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||October 2014|October 20, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054884||51065|
NCT02055456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-H-RTC-0002|Nandrolone Decanoate in the Treatment of Telomeropathies|Male Hormones for Telomere Related Diseases||University of Sao Paulo|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|N/A|No|||December 2015|December 1, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055456||51021|
NCT02055742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBI-01-CTNG|Detection of Chlamydia (CT) and Gonorrhea (NG)|Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays||Meridian Bioscience, Inc.|No|Active, not recruiting|March 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Leftover urine samples|Both|14 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|Symptomatic and asymptomatic subjects at least 14 years of age|September 2014|September 25, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055742||50999|
NCT02056054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302011561|De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation|De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation||Yale University|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|180|||Both|3 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohorts will be obtained from clinical settings and include pediatric and adult subjects.        See eligibility criteria for detailed descriptions of the population.|January 2016|January 6, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02056054||50976|
NCT02056288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27386|A Comparison of UGSB and GA to IV Narcotics and GA for Post-Op Pain in Children With Supracondylar Fractures.|A Randomized Comparison of Ultrasound Guided Supraclavicular Block(UGSB) and General Anesthesia (GA) to IV Narcotics and General Anesthesia for Postoperative Pain Relief in Children With Supracondylar Fractures.||Baylor College of Medicine|Yes|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056288||50958|
NCT02056301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H31096|A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excuvatum Repair|A Comparison Trial Between Patient Controlled Intravenous Analgesia (PCA) and Epidural Analgesia for Pectus Excavatum Repair||Baylor College of Medicine|Yes|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056301||50957|
NCT02052076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2/13|Influence of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles an Appetite in Healthy Women|Influence of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles an Appetite in Healthy Women||University of Nottingham|No|Completed|January 2013|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052076||51280|
NCT02052362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-229|Bioavailability of ABT-450 and ABT-267 With Ritonavir|A Phase I, Open-Label, Single Centre Study Designed to Determine the Absolute Bioavailability of ABT-450 (150 mg) and ABT-267 (25 mg) When Administered as an Oral Co-Formulated Product With Ritonavir (100 mg), ABT 450/r/ABT 267, to Healthy Adult Subjects||AbbVie|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052362||51258|
NCT02052375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408-CL-0201|A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate||Astellas Pharma Inc|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|24|||Both|18 Years|75 Years|No|||February 2014|February 5, 2014|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052375||51257|
NCT02053012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00003|Investigating Reaction Time Among Children Who Snore|||Nationwide Children's Hospital|No|Enrolling by invitation|January 2014|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|6 Years|18 Years|No|Non-Probability Sample|Children who snore and are coming to Nationwide Children's for a sleep study or        adenotonsillectomy.|March 2016|March 11, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053012||51209|
NCT02053025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1332|Appetite Regulation and Mycoprotein|Appetite Regulation and Mycoprotein|mycoprotein|Imperial College London|Yes|Completed|March 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|August 26, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02053025||51208|
NCT02052973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10726612.8.0000.5149|Efficacy of Propolis Varnish Against Oral Biofilm|Efficacy of Brazilian Green Propolis Varnish Against Streptococcus Mutans in Saliva: a Phase II Study.||Federal University of Minas Gerais|No|Completed|September 2014|July 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02052973||51212|
NCT02053623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPI-219939|Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor|Evaluation of a Novel Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor Against Invasive Intra-Arterial Pressure Monitoring - A Pilot Study||Health Parametrics Inc.|No|Active, not recruiting|December 2013|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|We will recruit a minimum of 20 qualified adult patients who come to the catheterization        lab at the University of Ottawa Heart Institute for an angiography. The patients will have        at least one of the following chronic conditions: atrial fibrillation, obesity,        atherosclerosis, and heart failure.|January 2014|March 17, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053623||51162|
NCT02053636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-80881-001|A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer|An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer|FINESSE|Servier|Yes|Recruiting|December 2013|April 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|123|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02053636||51161|
NCT02053896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISU302-003|A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease|A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase||ISU Abxis Co., Ltd.||Completed|May 2011|February 2012|Actual|February 2012|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|8 Years|29 Years|No|Probability Sample|Patient diagnosed with type-1 Gaucher disease|February 2014|February 3, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02053896||51141|
NCT02053857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUFA-RUTF Pilot|Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition|A Randomized, Double-blind Pilot Study of Polyunsaturated Fatty Acid-optimized Ready-to-use Therapeutic Food, Compared to Standard RUTF, in the Therapy of Severe Acute Malnutrition||Washington University School of Medicine|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|6 Months|59 Months|No|||September 2014|September 26, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053857||51144|
NCT02054130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-MEDI9929-1146|Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma|A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma||MedImmune LLC|Yes|Active, not recruiting|December 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|552|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|December 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054130||51123|
NCT02054442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHN01|A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck|A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society|COMMENCE|Radboud University|Yes|Suspended|February 2014|February 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054442||51099|
NCT02054416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVB012013|External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality|External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality in Underserved Philadelphia Patient Population: A Randomized Controlled Study|ArtAssist|Temple University|Yes|Recruiting|October 2013|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|No|||September 2015|September 11, 2015|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054416||51101|
NCT02064179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3167|Assessment of the Efficacy of the First Aspirin Dose in Children Undergoing Surgery for Congenital Heart Disease (CHD) Who Require Post-operative Antiplatelet Therapy|Assessment of Efficacy of the First Aspirin Dose in Children Undergoing Surgery for Congenital Heart Disease (CHD) Who Require Post-operative Antiplatelet Therapy; Evaluated by Thromboelastograph (TEG) Analysis and TEG-platelet Mapping||University of Colorado, Denver|No|Active, not recruiting|April 2014|||June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|Samples Without DNA|Whole blood samples for immediate processing via thromboelastograph (TEG) and TEG-platelet      mapping (TEG-PM)|Both|N/A|18 Years|No|Non-Probability Sample|The study population includes children aged 0-18 with congenital heart disease (CHD) in        the immediate post- operative period who receive heparin infusion prior to initiation of        long-term antiplatelet therapy. The current study population includes patients who have        undergone one of these surgeries requiring aspirin therapy. The following are the surgical        procedures included in this study:          1. Arterio-venous shunts: classic and modified Blalock-Taussig (BT) shunts, and central             shunts.          2. Veno-venous shunts: partial cavo-pulmonary connections (Glenn anastomosis), total             cavo-pulmonary shunts (Fontan), and right ventricle to pulmonary artery conduits.          3. Patients requiring coronary artery re-implantation: arterial switch operation for             transposition of the great arteries and repair of anomalous left coronary artery             arising from the pulmonary artery.          4. Pulmonary valve replacement.|June 2015|June 25, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064179||50353|
NCT02054923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-QUALY|The Effect of Routine Video-recording on Colonoscopy Quality Indicators.|The Effect of Routine Video-recording on Colonoscopy Quality Indicators: a Cluster Randomized Trial.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|5200|||Both|N/A|N/A|No|||August 2015|August 3, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054923||51062|
NCT02055716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVG002N|Sulforadex in Healthy Human Males MAD|A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects Following Daily Dosing for 7 Days||Evgen Pharma|Yes|Completed|January 2014|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02055716||51001|
NCT02055729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/CDR-01|Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study|Changes in Cutaneous, Digestive and Urinary Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study|EscaFlor|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|Bedsore superficial (swabbing) and deep (punch biopsies) samples are retained; stool and      urine samples are retained. DNA extraction is aimed at describing microbial communities.|Both|18 Years|N/A|No|Probability Sample|The study population consists of patients hospitalized in the Propara neurological        rehabilitation (Montpellier, France) having at least one stage 3 or 4 bedsore in the        pelvic region.|November 2015|November 5, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055729||51000|
NCT02055469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009393|Achalasia: Mechanisms Underlying Treatment Failure|Achalasia; Mechanisms Underlying Persistent Symptoms After Treatment||Barts & The London NHS Trust|No|Not yet recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with achalasia (or suspected achalasia) either before or after treatment referred        from secondary care to the GI physiology unit of the Royal London Hospital|February 2014|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055469||51020|
NCT02055482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15653|Long-term Pre-dialysis Extension in Europe and Asia Pacific|A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Darbepoetin Alfa Comparator in the Long Term Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease in Europe and Asia Pacific|DIALOGUE 3|Bayer|Yes|Active, not recruiting|June 2014|October 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055482||51019|
NCT02055755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13309-1|WEMR With Clinical Decision Support for Diabetic Foot Ulcers|Wound Research Database With Clinical Decision Support for Patients With Diabetic Foot Ulcers||Winthrop University Hospital|No|Recruiting|April 2013|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|N/A|No|Non-Probability Sample|Male or female patients at Winthrop University Hospital diagnosed with a Diabetic Foot        Ulcer.|December 2015|December 7, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055755||50998|
NCT02055781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERSIST-2 (PAC326)|Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia|A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis|PAC326|CTI BioPharma|Yes|Active, not recruiting|December 2013|August 2019|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055781||50997|
NCT02056067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0906005263|Hormones and Physical Exercise (HOPE) Study|Hormones and Physical Exercise (HOPE) Study||Yale University|Yes|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Female|18 Years|75 Years|No|||March 2014|March 27, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056067||50975|
NCT02056314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126/2013|Developing and Evaluating Effectiveness of a Reinstatement Tutorial|Developing and Evaluating Effectiveness of a Reinstatement Tutorial||Centre for Addiction and Mental Health|No|Recruiting|February 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|19 Years|N/A|No|||October 2015|October 14, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056314||50956|
NCT02052089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-2014-04|Comparative Study for the Optimal Treatment Method of Lateral Epicondylosis|Prospective Randomized Clinical and Radiologic Study for the Treatment of Lateral Epicondylosis; Comparison Among PRP (Platelet-Rich Plasma) , Prolotherapy, Physiotherapy and ESWT (Extracorporeal Shockwave Therapy)||CM Chungmu Hospital|Yes|Completed|March 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|231|||Both|35 Years|80 Years|No|||January 2014|January 29, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02052089||51279|
NCT02052388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIX-BRI-204|Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections|A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)||Cellceutix Corporation|Yes|Completed|February 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|215|||Both|18 Years|85 Years|No|||August 2014|May 19, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052388||51256|
NCT02052986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCT-01|An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels||CARE|New York Hospital Queens||Not yet recruiting||||January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|December 16, 2013||||No||https://clinicaltrials.gov/show/NCT02052986||51211|
NCT02052999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRPV1-ROSACEA_IIT|Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients|An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea||Amorepacific Corporation|Yes|Completed|February 2013|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|20 Years|65 Years|No|||January 2014|January 31, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02052999||51210|
NCT02053337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE047ALF|A RCT to Compare Performance of Two Foam Dressings on Patient Well-being Related Endpoints.|A Randomised Cross-over Clinical Evaluation to Compare Performance of ALLEVYN◊ Life and Mepilex™ Border Dressings on Patient Well-being Related Endpoints.||Smith & Nephew Medical Ltd|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02053337||51184|
NCT02053350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17576|Efficacy Study of Alanyl-glutamine Supplementation for the Treatment of C. Difficile Infection|Alanyl-glutamine Supplementation of Standard Treatment of C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial||University of Virginia|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053350||51183|
NCT02063776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NU02|Haemodiafiltration vs Conventional Haemodialysis in Children|The Effects of Haemodiafiltration (HDF) vs Conventional Haemodialysis (HD) on Growth and Cardiovascular Markers in Children - 3H (HDF, Hearts and Height) Study|3H|Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Recruiting|February 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|serum only|Both|1 Year|18 Years|No|Non-Probability Sample|-  HDF patients will be compared with age-matched HD patients in a 1:1 study design.          -  Children will be recruited from paediatric dialysis units within the UK and also             centres in Europe, through the 4C-study.|December 2015|December 30, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063776||50384|
NCT02063789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC5107A_P3|An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia|Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP).||Green Cross Corporation|No|Recruiting|June 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|19 Years|N/A|No|||March 2015|March 18, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063789||50383|
NCT02054143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17637-1/2012/EKU|The Effect of Sevoflurane on Cerebral CO2 Sensitivity and Systemic Arteries|The Effect of Sevoflurane on Cerebral Vasoreactivity Ans Systemic Arteries||University of Debrecen|Yes|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|60 Years|No|||February 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054143||51122|
NCT02064335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9981|Effects of Physical Activity Coaching on Health and Behaviour Parameters in Diabetic Persons|Short and Long Term Effects of Physical Activity Coaching on Physical Activity, Physical Fitness, Subjective Well Being and Health in Diabetic Persons||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||February 2014|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064335||50341|
NCT02054689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-091|Fractionated Stereotactic Radiosurgery for Large Brain Metastases|PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES||University of Pittsburgh|Yes|Recruiting|July 2013|December 2020|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054689||51080|
NCT02054702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-008|Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia|Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|February 2014|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|February 2, 2014|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT02054702||51079|
NCT02064491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAP|Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC|Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC||Finnish Lung Cancer Group|Yes|Recruiting|February 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064491||50329|
NCT02054936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062541|Evaluation of Wound Drainage After Knee or Hip Arthroplasty|Evaluation of Wound Drainage Following Rivaroxaban (Xarelto) or Warfarin (Coumadin) for Post op Venous Thromboembolism (VTE) Prophylaxis, After Knee or Hip Arthroplasty a Randomized Study.||University of Michigan|No|Withdrawn|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 23, 2014|Yes|Yes|Change in standard of care, no possibility of recruitment|No||https://clinicaltrials.gov/show/NCT02054936||51061|
NCT02055170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLC001|Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer|Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer||CancerCare Manitoba|No|Recruiting|June 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Male|18 Years|N/A|No|||August 2015|August 5, 2015|February 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055170||51043|
NCT02055183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-010|BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin|Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin.||Cangene Corporation|No|Enrolling by invitation|October 2014|April 2018|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Any patient of any age [age category: pediatric—newborn infants (0 to 27 days), infants        and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to        <17-years); adult (17-64-years); and geriatric (≥65-years)] with a confirmed or suspected        exposure to botulinum toxin who were treated with BAT® deployed from the national or state        stockpiles.|March 2015|March 6, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02055183|6 Months|51042|
NCT02055495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40286|Arthroereisis Versus Lateral Column Lengthening in the Treatment of Planovalgus Feet|Prospective Comparison of Subtalar Arthroereisis To Lateral Column Lengthening for Painful Flatfeet||University of Utah|No|Completed|March 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|7 Years|17 Years|No|Non-Probability Sample|Patient ages ranged from 7 to 17 (mean 12.8y) at the time of surgery. Inclusion criteria        were patients with planovalgus deformity, painful symptoms refractory to conservative        treatment for at least 6 months, and independent ambulation without the use of assistive        devices.        A longitudinally study of two patient cohorts: 1) children with planovalgus foot deformity        treated with arthroereisis (subtalar implant) and 2) children with planovalgus foot        deformity treated by calcaneal (lateral column) lengthening.|August 2014|August 7, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055495||51018|
NCT02055794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00079230|Promoting Optimal Healing After Laceration Repair Study|Promoting Optimal Healing After Laceration Repair Study - PALS Study|PALS|University of Michigan|No|Enrolling by invitation|February 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055794||50996|
NCT02056080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-DBL-2012-01|Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib|Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib|TRASTYVERE|MedSIR|No|Recruiting|January 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|111|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with HER2 positive metastatic breast cancer who progressed to antiHER2 therapy        with trastuzumab and / or lapatinib for the metastasic disease and that between January        2005 and December 2011, began treatment with the combination of trastuzumab and lapatinib        (TL).|February 2014|March 28, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02056080||50974|
NCT02056327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN268201300056C|Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea|Phase One Study Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea||Dartmouth-Hitchcock Medical Center|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|2|||Both|21 Years|65 Years|No|Non-Probability Sample|Adults diagnosed with obstructive sleep apnea who are currently being treated with an oral        appliance or who wish to transition to an oral appliance|March 2014|March 25, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056327||50955|
NCT02052102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast-26159|Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart|A Cohort Study Assessing Cardiac Function With MRI in Left-Sided Breast Cancer Patients Treated With Deep Inspiration Breath Hold (DIBH) Technique to Improve Cardiac Sparing During Adjuvant Radiotherapy||AHS Cancer Control Alberta|Yes|Recruiting|October 2014|March 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|63|||Female|18 Years|70 Years|No|||September 2015|September 21, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02052102||51278|
NCT02052401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA13I20184|Domiciliary Intervention by Occupational Therapy to Prevent Elderly Rehospitalization|Domiciliary Intervention by Occupational Therapy After Hospital Discharge, to Prevent Rehospitalization in Elderly: Randomized Clinical Trial||Comisión Nacional de Investigación Científica y Tecnológica|Yes|Completed|February 2014|February 2016|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|60 Years|N/A|No|||February 2016|February 1, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052401||51255|
NCT02052414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 2012-01|Study of Gralise to Treat Fibromyalgia Patients|Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.|Gralise|The Center for Clinical Research, Winston-Salem, NC|Yes|Completed|July 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 2, 2013||No||No|July 28, 2015|https://clinicaltrials.gov/show/NCT02052414||51254|small sample size, geographical bias, relatively short duration of treatment, open label, single arm study without a control group.
NCT02052739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-SSE-201|Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus|An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus|SRSE|Sage Therapeutics|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|2 Years|N/A|No|||August 2015|August 11, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052739||51230|
NCT02052752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201244|A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions|A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use||GlaxoSmithKline|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|12 Years|45 Years|No|||May 2015|May 14, 2015|January 30, 2014|No|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT02052752||51229|
NCT02052765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-022-FR-HV|AnalyST & Brugada Syndrome - Feasibility Study|AnalyST & Brugada Syndrome - Feasibility Study||St. Jude Medical|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|January 30, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT02052765||51228|
NCT02053038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM1797|Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation|Prospective, Multi-center, Double Blind, Randomised Study to Test the Safety of Deferral of Stenting in Physiological Non-significant Lesions in a Clinical Population of Intermediate Stenoses Using iFR and FFR|DEFINE-FLAIR|Imperial College London|No|Recruiting|January 2014|||November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|2500|||Both|18 Years|90 Years|No|||November 2013|June 3, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02053038||51207|
NCT02053051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM0091|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)|Clinical Assessment of an Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)|ABC4D|Imperial College London|Yes|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|176|||Both|18 Years|N/A|No|||May 2013|May 27, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02053051||51206|
NCT02063516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wang001|Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal|Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal — A Perspective, Randomized，Blind Study|Guardian|Tianjin Medical University General Hospital|Yes|Completed|June 2013|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|80|||Both|18 Years|65 Years|No|||December 2014|January 10, 2015|January 13, 2014|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT02063516||50404|We only use size-4 devices in adult patients with neuromuscular blockade, we presumed that same results would be obtained in patients who have not received neuromuscular blockade. lastly our data was not blinded causing potential source of bias.
NCT02063802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI/11/311/04/108|Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children|Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients||Laboratorios Silanes S.A. de C.V.|No|Recruiting|August 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|8 Years|18 Years|No|||February 2014|February 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063802||50382|
NCT02063815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-A-040609-0167|A Trial of Caries Prevention Effect of Fissure Sealants|A Randomized Controlled Trial of Caries Prevention Effect of a Glass Ionomer Sealant Versus a Resin Sealant||Marmara University|No|Completed|June 2009|February 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|40|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063815||50381|
NCT02054156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMIZE-IP-12|OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis|OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial|OPTIMIZE|Seattle Children's Hospital|Yes|Recruiting|June 2014|April 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|274|||Both|6 Months|18 Years|No|||September 2015|September 25, 2015|February 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054156||51121|
NCT02054169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mCAM-ED|Feasibility of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)|Pilot Study on the Feasibility of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)||University Hospital, Basel, Switzerland|No|Completed|August 2013|||August 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|340|||Both|65 Years|N/A|No|Probability Sample|The samples consisted of consecutive ED patients.|February 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054169||51120|
NCT02064348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3652|A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects|A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration||Novo Nordisk A/S|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064348||50340|
NCT02063958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX5422-CLN-009|Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors|A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.||Esanex Inc.|No|Recruiting|February 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063958||50370|
NCT02063971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3513 / SC13-235|Tolerance and Efficacy Evaluation of 3 Face Creams|Tolerance and Efficacy Evaluation of Three Face Creams in Subjects Undergoing to Injection Procedure With Hyaluronic Acid (Intradermal Implant)|FILLER|Derming SRL|Yes|Active, not recruiting|December 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|45|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02063971||50369|
NCT02064192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 602299|Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe|Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe|EU-CERT-ICD|University Medical Center Goettingen|Yes|Recruiting|May 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2500|Samples With DNA|Whole blood sample for genetic analysis|Both|18 Years|N/A|No|Probability Sample|Patients who are eligible for primary prophylactic ICD implantation and potentially        eligible for study participation will be identified based on echocardiographic and/or 12        lead ECG results. For ICD Group patients, screening will be shortly before scheduled ICD        implantation. For Control Group patients, the time span between primary diagnosis of        eligibility for primary ICD implantation and the date of the primary diagnosis of        cardiomyopathy must be recorded in the eCRF, together with how and when the decision not        to prescribe a defibrillator was reached. Control group will be recruited from patients        with ischemic or dilated cardiomyopathies and LVEF ≤ 35%. Patients scheduled for ICD        implantation (ICD Group) undergo screening and baseline assessments prior to ICD        implantation. Patients for the Control Group will undergo baseline assessments as soon as        possible after screening. Baseline assessments are identical for the ICD Group and the        Control Group.|December 2015|December 9, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064192||50352|
NCT02054949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00325|Treatment Resistant Epilepsy and N-Acetyl Cysteine|Pilot Study of N-acetyl Cysteine for Refractory Generalized Epilepsy in Children With Autism|TRE-NAC|Nationwide Children's Hospital|Yes|Withdrawn|April 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Years|21 Years|No|||October 2015|October 7, 2015|February 3, 2014|Yes|Yes|no eligible subjects located|No||https://clinicaltrials.gov/show/NCT02054949||51060|
NCT02055196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13455|Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas||City of Hope Medical Center|Yes|Withdrawn||||May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|64 Years|No|||May 2014|May 30, 2014|January 30, 2014|No|Yes|New study written|No||https://clinicaltrials.gov/show/NCT02055196||51041|
NCT02055508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSITIVE-III-S-326/2013|POSITIVE - Study (Part III) Heidelberg|Physical Exercise Program in Lung Cancer Patients With Non-operable Disease Undergoing Palliative Treatment|POSITIVE|German Cancer Research Center|Yes|Recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02055508||51017|
NCT02055521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.815|Search Tolerance Signature in Vascularised Composite Allograft|Search Tolerance Signature in Vascularised Composite Allograft|BIOCTA|Hospices Civils de Lyon|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02055521||51016|
NCT02055807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.293|Role of Lung Ultrasound Imaging in the Comparison of Two Mechanical Ventilation Strategies During Laparotomy|Role of Lung Ultrasound Imaging in the Comparison of Two Mechanical Ventilation Strategies During Laparotomy.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055807||50995|
NCT02056093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOREP|Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist|Breathing Pattern Variability, Respiratory Discomfort and Work of Breathing in Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist|PAVANAVA|Pierre and Marie Curie University|No|Recruiting|September 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02056093||50973|
NCT02056340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000026|Statin Therapy in Acute Influenza|Statin Therapy in Acute Influenza||Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02056340||50954|
NCT02052427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATHENA II|Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)|Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II|ATHENA II|Cytori Therapeutics|Yes|Active, not recruiting|January 2014|May 2019|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|20 Years|80 Years|No|||October 2015|October 21, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052427||51253|
NCT02062437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301-T-CERAM-R|Clinical and Radiological Results of Total Hip Arthroplasty Using a Ceramic Friction Pair|Multicentric Observational Study Evaluating Clinical and Radiological Results of a Total Hip Arthroplasty Using a Ceramic Friction Pair|CERAM|Tornier, Inc.|No|Completed|September 2013|January 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|132|||Both|18 Years|N/A|No|Probability Sample|Cohort of European patients with a primary total hip replacement using a ceramic friction        pair including Meije Duo® stem associated with a Dynacup® cup.|February 2014|February 12, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062437||50486|
NCT02062450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204-T-DOUBLEMOB-RM|Observational Study Evaluating Outcomes of Hip Arthroplasty Using Tornier Dual Mobility Acetabular Cup|Multicentre, Observational Study Evaluating the Clinical and Radiological Outcomes of Hip Arthroplasty Using the Dual Mobility Cup||Tornier, Inc.|No|Completed|May 2013|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|379|||Both|18 Years|N/A|No|Probability Sample|The global cohort: All the patients who received a Tornier Dual Mobility acetabular cup        between October 2010 and October 2011 and who we were able to be contacted by phone.        "Primary replacement" group: All the patients who received a Tornier Dual Mobility        acetabular cup between October 2010 and October 2011 for primary hip replacement and who        were seen for their follow-up visit at 2 years post-procedure.        "Revision" group: All patients who received a Tornier Dual Mobility acetabular cup between        October 2010 and October 2011 for revision surgery and who were seen for their follow-up        visit at 2 years post-procedure.        All the performance criteria were analysed for the patients in the "Primary replacement"        and "Revision" groups|February 2014|February 12, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062450||50485|
NCT02063243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/293|Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars|Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars||VU University Medical Center|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|10 Years|N/A|No|||February 2014|February 13, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02063243||50425|
NCT02063529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU05|FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer|A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver|FOCULM|Sun Yat-sen University|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|65 Years|No|||November 2014|November 1, 2014|February 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02063529||50403|
NCT02063542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHandPOCD|Acetylcholine and Postoperative Cognitive Change in Aged Patients|Cerebrospinal Fluid Acetylcholine and Postoperative Cognitive Change in Aged Patients||RenJi Hospital|Yes|Recruiting|April 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Cerebral spinal fluid|Both|60 Years|N/A|No|Non-Probability Sample|Aged patients undergoing lower lower limbs osteopathic surgery.|February 2014|May 27, 2014|February 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02063542||50402|
NCT02052180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVM-3-27|Early Post-Operative Pain Control Following Wrist Operations|Bupivicaine Extended-Release Liposome Injection Versus Marcaine for Early Post-Operative Pain Control Following Wrist Operations||University of Tennessee|No|Enrolling by invitation|May 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02052180||51272|
NCT02064088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9206|Transversus Abdominis Plane Block in Pediatrics: Volume or Concentration ?|Volume or Concentration for the Transverse Abdominal Plane Block in Children Aged 1-5 Years: Analgesic Effects and Safety|TAP Bloc|University Hospital, Montpellier|No|Recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|70|||Both|1 Year|5 Years|No|||February 2014|February 13, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02064088||50360|
NCT02064322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 007-001|SAIF: Sacroiliac Fusion Study|SAIF: Sacroiliac Fusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System|SAIF|Zyga Technology, Inc.|No|Recruiting|February 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the Investigator's standard patient population diagnosed        with SIJ pain and representing candidates' for SIJ fusion.|April 2015|April 6, 2015|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064322||50342|
NCT02052791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS12|An Open-label Safety and Tolerability Study of IONIS SMNRx in Patients With Spinal Muscular Atrophy Who Previously Participated in IONIS SMNRx-CS2 or IONIS SMNRx-CS10|An Open-label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in 396443-CS2 or 396443-CS10||Ionis Pharmaceuticals, Inc.|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|N/A|N/A|No|||December 2015|December 31, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052791||51226|
NCT02064231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP222|A Clinical Investigation Examining the Performance and Handling of New 2-piece Ostomy Products in 28 People With an Ileostomy.|||Coloplast A/S|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|February 13, 2014||No||No|February 25, 2014|https://clinicaltrials.gov/show/NCT02064231||50349|
NCT02064530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/37|Postoperative Analgesic Effects of Dexmedetomidine for Transversus Abdominis Plane Block|Postoperative Analgesic Effects of Dexmedetomidine Added to Bupivacaine for Transversus Abdominis Plane Block for Lower Abdominal Surgery|TAP|TC Erciyes University|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||September 2015|September 11, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064530||50326|
NCT02064205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JZ PDX Satiety|Appetite Suppression Trial With Polydextrose|A Double Blind, Placebo Controlled, Randomized, Cross-over Study to Assess the Effects of Polydextrose on Appetite Suppression and Its Mechanisms of Action in Healthy Women With a Normal Weight and Overweight Female Participants.||TNO|No|Completed|May 2014|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064205||50351|
NCT02054962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0172|Persistent Pain Among Elderly Experiencing Motor Vehicle Collision|Persistent Pain and Associated Functional Decline Among Elderly Experiencing Motor Vehicle Collision|Elderly CRASH|University of North Carolina, Chapel Hill|No|Recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Saliva samples collected for participants 1-150. Saliva, whole blood DNA and RNA collected      for participants 151-250|Both|65 Years|N/A|No|Non-Probability Sample|Elderly experiencing motor vehicle collision|September 2015|September 14, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054962||51059|
NCT02055209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140048|Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)|GENE-FORECASTSM: Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|N/A|||Anticipated|3341|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|March 24, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055209||51040|
NCT02055534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVSMATT01 - amyloid nutr|Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis|Nutritional Counseling in Systemic Immunoglobulin Light-chain (AL) Amyloidosis: a Prospective Randomized, Controlled Trial.||IRCCS Policlinico S. Matteo|Yes|Completed|July 2007|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055534||51015|
NCT02055547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8521-002|A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)|A Single and Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8521 in Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|19||Actual|61|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055547||51014|
NCT02055820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27878|A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma|A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chop) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL||Hoffmann-La Roche||Recruiting|June 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055820||50994|
NCT02055833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120001310|Intensive Nutritional Counseling in Head-neck Cancer Patients Undergoing Radiotherapy|Intensive Nutritional Counseling in Head-neck Cancer Patients Undergoing Radiotherapy: a Randomized, Controlled Trial||IRCCS Policlinico S. Matteo|Yes|Recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055833||50993|
NCT02056353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGIC-Insulin 2.1.1|Multicentre LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness (LOGIC-2)|LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-2 Multicentre Randomized Controlled Trial|LOGIC-2|Katholieke Universiteit Leuven|Yes|Completed|February 2014|August 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1550|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056353||50953|
NCT02062112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-13-MED-60|Improving Tolerability of Bowel Preparation Laxative for Colonoscopy|Comparison of Patterns of Laxative Ingestion to Improve Bowel Preparation for Colonoscopy: A Pilot Randomized Trial||Howard University||Recruiting|February 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02062112||50511|
NCT02052115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1311|Behavioral Weight Loss and Exercise After Treatment (BEAT)|Behavioral Weight Loss and Exercise After Treatment (BEAT): Predictors of Weight Loss Success in Overweight Breast Cancer Survivors|BEAT|University of Vermont|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|21 Years|69 Years|No|||December 2014|December 2, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052115||51277|
NCT02052128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR18-CT-101|Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers|Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers||Arno Therapeutics|Yes|Recruiting|January 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Female|18 Years|N/A|No|||June 2015|June 22, 2015|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052128||51276|
NCT02062710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-IRB-13-10-170|Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo|Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo||Montefiore Medical Center|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|22|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|January 31, 2014|Yes|Yes||No|September 16, 2014|https://clinicaltrials.gov/show/NCT02062710||50465|
NCT02062723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOLT-2009-002|Observational Study to Assess the Efficacy and Tolerability of Eptadone®, in Heroin Addicted Patients in a MMT|Prospective Observational Study to Assess the Efficacy and Tolerability of Eptadone®, in Heroin Addicted Patients Undergoing a Methadone Maintenance Treatment|METHODE|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.|No|Completed|September 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|515|||Both|18 Years|N/A|No|Probability Sample|Male and female patients with heroin addiction, over 18 years of age.|February 2014|February 13, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02062723||50464|
NCT02055599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13308-1|WEMR With Clinical Decision Support for All Wounds|Wound Research Database With Clinical Decision Support for Patients With All Wounds||Winthrop University Hospital|No|Recruiting|April 2013|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|N/A|No|Non-Probability Sample|Male or female patients at Winthrop University Hospital with any chronic wound (defined as        a break in the integument).|December 2015|December 7, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055599||51010|
NCT02062983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herceptin|Early Predictor of Herceptin Cardiotoxicity|||National Guard Health Affairs|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|80 Years|No|Non-Probability Sample|Pilot study trying to identify early predictor for developing cardiotoxicity in such        patients.|February 2014|February 12, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02062983||50445|
NCT02062996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00016|Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption|The Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery and From the Nasal Mucosa During Operative Dentistry||Nationwide Children's Hospital|No|Withdrawn|June 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|2 Years|12 Years|No|||August 2015|August 6, 2015|February 12, 2014|Yes|Yes|Could not receive FDA approval for IND|No||https://clinicaltrials.gov/show/NCT02062996||50444|
NCT02063009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00003-40|Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery|Measurement of Cardiac Index by Transpulmonary Thermodilution Using an Implanted Central Venous Access Port: a Prospective Study in Patients Scheduled for Oncologic High-risk Surgery|ThermoD-PAC|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|patients scheduled for oncologic high-risk surgery|February 2014|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063009||50443|
NCT02056392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00071|To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers|A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years||AstraZeneca|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|October 7, 2015|February 5, 2014|No|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT02056392||50950|
NCT02052193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZDO 2012_PHOTOTOX|Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study|Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study||University Hospital Tuebingen|No|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02052193||51271|
NCT02052206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BalgristUH_CARD_03|Accuracy Evaluation of Shoulder Replacement Surgery|Accuracy Evaluation of Shoulder Replacement Surgery With Computer-assisted 3D Planning||Balgrist University Hospital|No|Recruiting|March 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 20, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052206||51270|
NCT02064101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2281|Validation of Triggered EMG Values for Pedicle Screws Using a Powered Screwdriver|Validation of Triggered EMG Values for Pedicle Screws Using a Powered Screwdriver||University of Colorado, Denver|No|Enrolling by invitation|February 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|8 Years|21 Years|No|Non-Probability Sample|Patients between the ages of 8-21 years of age with a diagnosis of adolescent idiopathic        scoliosis (AIS) who will be receiving a spinal fusion.|January 2015|May 19, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064101||50359|
NCT02052804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHFMRITG200801018|Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics|Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics|Alberta HEART|University of Alberta|No|Recruiting|April 2009|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Alberta, Canada with heart failure or at risk for developing heart failure|April 2015|April 21, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02052804||51225|
NCT02053701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210M23141|High-field Brain Magnetic Resonance Spectroscopy|Technical Developments for High-field Brain Magnetic Resonance Spectroscopy||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy subjects|May 2015|May 26, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053701||51156|
NCT02060877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGA-2013|Distress and Quality of Life During the Diagnostic Phase of a Suspected Serious Lung Disease|How Burdensome is the Diagnostic Phase ? Distress and Quality of Life in Patients Suspected of Having a (Serious) Lung Disease|DIADISS|Universiteit Antwerpen||Recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|108|||Both|18 Years|N/A|No|Probability Sample|patients with abnormal imaging suggestive of lung cancer consulting a pulmonologist|December 2015|December 1, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02060877||50606|
NCT02064790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00069871|Comparison of Gabapentin and Pregabalin for Radicular Pain|Comparison of Gabapentin and Pregabalin for Cervical and Lumbar Radicular Pain||Emory University|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Adult participants of both genders and all ethnicities will be invited to participate in        this study as they present to Emory Orthopaedics and Spine Clinic and are diagnosed with        and treated for cervical or lumbar radicular pain.|March 2016|March 8, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064790||50306|
NCT02054975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00504|Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial|Prospective Open Pilot of Low vs. Higher Dose Vitamin D in D-deficient Asthmatic Children: Does Diet Predict Immune Function and Asthma Symptom Response to Vitamin D Supplementation?|D-Asthma|Nationwide Children's Hospital|Yes|Active, not recruiting|January 2014|January 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|8 Years|17 Years|No|||October 2015|October 7, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054975||51058|
NCT02055222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140049|Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease|Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|N/A|||Anticipated|223|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|December 15, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055222||51039|
NCT02055859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-Rt acouneu|Cyberknife Radiosurgery for Patients With Neurinomas|Cyberknife Radiosurgery for Patients With Neurinomas|ACOUNEU|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Recruiting|April 2011|November 2021|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055859||50991|
NCT02056106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH098996|Comparative Trial of Antidepressant Treatment Models in HIV Care in Uganda|Task Shifting Model of Depression Treatment to Unleash HIV Public Health Benefits|INDEPTH-Uganda|RAND|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1252|||Both|18 Years|65 Years|No|||October 2015|October 2, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056106||50972|
NCT02062125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2012001886|Calcinosis in a Single-Center Scleroderma Population|A Prospective, Observational Study of Calcinosis in a Single-Center Population With Scleroderma-Spectrum Disorders|SSc-calcinosis|Rutgers, The State University of New Jersey|No|Recruiting|October 2012|December 2030|Anticipated|October 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|85 Years|No|Probability Sample|Adult scleroderma subjects with and without calcinosis will be enrolled|September 2015|September 28, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02062125|10 Years|50510|
NCT02061696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI-001|ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System|A Randomized Controlled Trial to Assess Safety and Efficacy of AXERA (Device Name) 2 Access System Compared to Manual Compression|ARISTOCRAT|Borgess Research Institute|No|Terminated|January 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|52|||Both|18 Years|85 Years|No|||December 2015|December 16, 2015|January 30, 2014|Yes|Yes|Device was modified and no longer available to investigator|No||https://clinicaltrials.gov/show/NCT02061696||50543|
NCT02062424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol no.:H-1-2013-110|Diet and Prevention of Ischemic Heart Disease: a Translational Approach|Diet and Prevention of Ischemic Heart Disease: a Translational Approach|DIPI|Technical University of Denmark|Yes|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|222|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02062424||50487|
NCT02062138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAB|Effectiveness of Passive and Active ROM Exercises Following TKA|Effectiveness of New Interventional Approaches to Improve Physical Function Following Total Knee Arthroplasty||University of Rostock|No|Recruiting|January 2014|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|50 Years|80 Years|No|||December 2014|December 2, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02062138||50509|
NCT02055612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ASK01 EPI|Mobile Clinic - a Cross-sectional Epidemiological Survey|Mobile Clinic- a Cross-sectional Epidemiological Survey to Investigate the Prevalence of Wet Aged-related Macular Degeneration (wAMD) in Elderly Population in Slovak Republic||Novartis Slovakia, s.r.o.|No|Completed|March 2013|July 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3278|||Both|55 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults from general population across Slovak Republic over 55 years of age, predominantly        with home base far than 35 km from nearest retina center|February 2014|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055612||51009|
NCT02055625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1241-31/1|Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease|Treatment of Oral Mucosa in Patients With Graft-versus-host Disease Following Injection of Mesenchymal Stem Cells - Human Pilot Study||Karolinska Institutet|No|Recruiting|January 2014|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055625||51008|
NCT02062736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M.E.T.O.D.O.|Observational Study to Assess the Adequacy of Methadone Dosage, in Heroin Addicted Patients in a MMT.|Studio Osservazionale Per Valutare l'Adeguatezza Del Dosaggio Del Metadone, Nelle Terapie di Mantenimento, in Rapporto Agli Obbiettivi di Outcome, in Pazienti Tossicodipendenti da Eroina. (METODO)|METODO|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.|No|Active, not recruiting|February 2010|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Probability Sample|patients addicted to heroin and who have undertaken a methadone maintenance treatment,        observed in involved centres.|January 2014|February 12, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02062736||50463|
NCT02062749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0438|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Colon Cancer|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) In Pediatric and Adolescent Colon Cancer||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|9 Years|21 Years|No|||January 2016|January 14, 2016|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02062749||50462|
NCT02056145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/36/241|Ultrasound Guided Lateral Femoral Cutaneous Block (LFCNB) And Femoral Nerve Block (FNB) For Postoperative Pain Control After Hip Surgery|||University Hospital, Antwerp|No|Active, not recruiting|October 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|80 Years|No|||July 2014|July 1, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056145||50969|
NCT02056158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307014135|HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium|HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium||Weill Medical College of Cornell University|No|Recruiting|December 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Anticipated|480|Samples With DNA|Blood samples and biopsies from the lower respiratory tract.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|December 2015|December 9, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056158||50968|
NCT02056405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2104|Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery|Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery|ILEUS|Hospital Italiano de Buenos Aires|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|85 Years|No|||December 2015|December 16, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02056405||50949|
NCT02052817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toad_Brace_07-13-11|Randomized, Prospective Evaluation of the Toad Brace in Plantar Ulcer Off-loading and Healing|Randomized, Prospective Evaluation of the Toad Brace in Plantar Ulcer Off-loading and Healing||Toad Medical Corporation|Yes|Recruiting|December 2013|||May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02052817||51224|
NCT02053155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6/11/2013|Peri Operative Smoking Cessation Program|Development and Implementation of a Peri Operative Smoking Cessation Program With Computer Based Patient Education.||University Health Network, Toronto|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|345|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053155||51198|
NCT02052466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1244|Prediction of Development of Scapular Notching Following Reverse Total Shoulder Arthroplasty|Prediction of Development of Scapular Notching Based on Glenosphere Positioning, Scapular Morphology, and Simulated Impingement-free Motion Using Three-dimensional Computed Tomography Analysis||The Cleveland Clinic|No|Not yet recruiting|January 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Patients who had a reverse Total Shoulder Arthroplasty at the Cleveland Clinic from 2004        to 2011 and who had a high quality preoperative CT scan.|January 2014|January 30, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02052466||51250|
NCT02053714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3211|Improving Diabetes Outcomes for Persons With Severe Mental Illness|Improving Diabetes Outcomes for Persons With Severe Mental Illness||University of North Carolina, Chapel Hill|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|25|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02053714||51155|
NCT02053454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-005|A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers||Alnylam Pharmaceuticals|No|Completed|January 2014|June 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02053454||51175|
NCT02061397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The SOS Trial|Safety of Simvastatin in LAM and TSC|The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)|SOS|University of Pennsylvania|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061397||50566|
NCT02061163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00080030|Contrast-Enhanced Ultrasound in Human Crohn's Disease|Evaluation of Contrast-Enhanced Ultrasound in Human Crohn's Disease||University of Michigan|Yes|Withdrawn|February 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|10 Years|N/A|No|||June 2015|June 12, 2015|February 6, 2014|Yes|Yes|PI leaving UM at the end of the month|No||https://clinicaltrials.gov/show/NCT02061163||50584|
NCT02055235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140054|Study of Pain Processing in Experienced Yoga Practitioners|Pain Processing and Pain Control in Experienced Yoga Practitioners||National Institutes of Health Clinical Center (CC)||Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|47|||Both|30 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055235||51038|
NCT02055560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBI-5FU-005|Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients|Retrospective Data Comparison of Toxicity and Efficacy in Colorectal Cancer (CRC) Patients Managed With and Without 5-FU Exposure Optimization Testing|5-FU RECORD|Saladax Biomedical, Inc.|No|Enrolling by invitation|January 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients treated with 5-FU containing therapy regimens by US based        oncologists in community and academic setting. Sites which ordered >20 Myriad OnDose tests        in 2012 will be approached for participation in the study.|December 2015|December 2, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055560||51013|
NCT02055846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPPR / IPC 2012-002|Analysis of the Mechanisms of Actions of Heat Shock Protein (Hsp27) Responsible of the Androgen-independent Evolution in Prostate Cancer|Analysis of the Mechanisms of Actions of Hsp27 Responsible of the Androgen-independent Evolution in Prostate Cancer||Institut Paoli-Calmettes|No|Terminated|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Male|18 Years|N/A|No|||December 2012|June 24, 2015|October 26, 2012||No|Insufficient biological material for analysis|No||https://clinicaltrials.gov/show/NCT02055846||50992|
NCT02056119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13070203|RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit|Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit||Rush University Medical Center|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|120|||Both|1 Year|N/A|No|||December 2014|December 26, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02056119||50971|
NCT02056366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA_IIT01|The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy|The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study|CANON|The Catholic University of Korea|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|80 Years|No|||February 2014|February 4, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056366||50952|
NCT02061709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR006|Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber|A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|280|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02061709||50542|
NCT02054767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Anesthetic Efficacy in Irreversible Pulpitis|Anesthetic Efficacy of Articaine, Lidocaine and Mepivacaine in Patients With Irreversible Pulpitis of Mandibular Molar||University of Sao Paulo|No|Completed|August 2010|July 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|January 31, 2014|September 3, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054767||51074|
NCT02061917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSD-0702|Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus|Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus - A Multi-center Evaluation of Health-related Quality of Life Assessments and Biomarkers of Exposure and Harm|QoL|R.J. Reynolds Tobacco Company|No|Completed|February 2007|November 2009|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|163|||Both|28 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02061917||50526|
NCT02055326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT003669-02S1|Yoga for Men Attempting Smoking Cessation|Complementary Treatments for Smoking Cessation||The Miriam Hospital|No|Completed|September 2009|July 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|38|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|February 4, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055326||51031|
NCT02056184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG/1096|Targeted Ultrasound in Rheumatoid Arthritis|Targeted Ultrasound in Rheumatoid Arthritis|TURA|University of Leeds|Yes|Recruiting|December 2013|||January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02056184||50966|
NCT02055898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFFE2012|SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)|Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate|SAFFE|Imperial College London|Yes|Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|10|||Both|25 Years|65 Years|No|||November 2013|August 26, 2015|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02055898||50988|
NCT02056171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014323|Efficacy of Quetiapine for Pediatric Delirium|Efficacy of Quetiapine for Pediatric Delirium||Weill Medical College of Cornell University|Yes|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|22 Years|No|||December 2015|December 7, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056171||50967|
NCT02052518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD073966-02|Early Childhood Obesity Prevention Program|Early Childhood Obesity Prevention Program: Building Better Families and Communities|ECHO|Connecticut Children's Medical Center|Yes|Recruiting|June 2013|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|1 Month|No|||January 2014|January 30, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02052518||51246|
NCT02052531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1_PII-01|Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus|A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus||Amorepacific Corporation|Yes|Completed|January 2013|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Both|20 Years|65 Years|No|||September 2015|September 11, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02052531||51245|
NCT02052830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP699101|Impact Evaluation of the Wise Guys Program|Impact Evaluation of the Wise Guys Program||Mathematica Policy Research, Inc.|No|Enrolling by invitation|August 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Male|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052830||51223|
NCT02052843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP699103|Impact Evaluation of the Steps to Success Program|Impact Evaluation of the Steps to Success Program||Mathematica Policy Research, Inc.|No|Enrolling by invitation|May 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Female|14 Years|21 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052843||51222|
NCT02052479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297013|Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)|Differences in Insulin Secretion and Insulin Sensitivity/Resistance in African-American and Caucasian Adolescent Females With Polycystic Ovary Syndrome||Nationwide Children's Hospital||Recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Primary Purpose: Diagnostic|2||Anticipated|30|||Female|12 Years|18 Years|No|||February 2015|February 2, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02052479||51249|
NCT02052492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-001|Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors|A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF EF-022 (MODIFIED VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES||Efranat Ltd.||Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|46|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052492||51248|
NCT02052505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS01|Reducing Inappropriate Prescribing for Psychiatric Patients Using Nurse-led Medication Reviews|Reducing Inappropriate Prescribing for Psychiatric Patients Using Nurse-led Medication Reviews - an Interventional Study||Aalborg University|No|Completed|October 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02052505||51247|
NCT02053727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101329|Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background|Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.|RA|University of California, Los Angeles|No|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053727||51154|
NCT02062697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1148/2011|Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.|Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study|LUDOC|Medical University of Vienna|No|Recruiting|February 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02062697||50466|
NCT02055573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIH 13-0080|The Early ABCs Study|Can we Promote Early Literacy and Prevent Shaken Baby Syndrome in the Well Child Nursery?.A Randomized Controlled Study, The Early ABC Study.|EarlyABCs|Women and Infants Hospital of Rhode Island|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02055573||51012|
NCT02055872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-13343|Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial|A Single-centre, Randomized, Double-blinded, Placebo-controlled Pilot Study to Determine the Feasibility of a Full-scale Clinical Trial to Compare the Effect of Furosemide With or Without 25% Albumin in the Diuresis of Edema in Volume-overloaded ICU Patients in the Post-resuscitation Phase of Illness.|FADE|Hamilton Health Sciences Corporation|No|Recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055872||50990|
NCT02061215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|742-13-EP|Study of CMV in Kidney Transplant Recipients|Effects of Age on Immune Risk Profile in CMV Seropositive Kidney Transplant Recipients After Release From CMV Prophylaxis||University of Nebraska|Yes|Withdrawn|April 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recipients of renal transplants at the University of Nebraska Medical Center|December 2015|December 1, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02061215||50580|
NCT02061423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818561|HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy|Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy|Neoadjuvant|Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|January 2014|||February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02061423||50564|
NCT02054780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD070720|Randomized Controlled Trial of Ways to Improve OVC HIV Prevention and Well-being|Randomized Controlled Trial of Ways to Improve OVC HIV Prevention and Well-being||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|February 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|13 Years|17 Years|No|||January 2016|January 12, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02054780||51073|
NCT02055040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-443|Detection of Cardiac Fibrosis in Patients With Lymphoma|Non-invasive Detection of Cardiac Fibrosis After Administration of Doxorubicin-Based Chemotherapy in Patients With Lymphoma Using Cardiac Magnetic Resonance: A Pilot Study||Dana-Farber Cancer Institute|No|Recruiting|March 2012|||March 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|77|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055040||51053|
NCT02055339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MountSinaiH|Pilot Study Comparing Different Modes of Non-invasive Ventilation for the Oral Feeding of Preterm Infants|Comparison of Nasal Continuous Positive Airway Pressure With Low Flow Oxygen Versus Heated, Humidified High Flow Nasal Cannula for Oral Feeding of the Premature Infant (CHOMP Trial): A Pilot Study|CHOMP|Mount Sinai Hospital, Canada|No|Recruiting|February 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|32 Weeks|34 Weeks|No|||April 2015|April 8, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055339||51030|
NCT02055352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BAR01|Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD|24-week Study to Evaluate Efficacy and Safety of the Combination Budesonide / Indacaterol vs Fluticasone / Salmeterol in Patients With COPD|COMBINE|Novartis|No|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|40 Years|N/A|No|||May 2014|May 21, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055352||51029|
NCT02056197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL002|Influence of an Exercise for Trunk Stabilization Performed in Stable and Unstable Surfaces for Chronic Low Back Pain.|Influence of an Exercise Program for Trunk Stabilization Performed in Stable and Unstable Surfaces for Chronic Low Back Pain: Single-blind, Randomized Controlled Clinical Trial.||University of Nove de Julho|Yes|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|80 Years|No|||January 2014|February 4, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02056197||50965|
NCT02055911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retinal Ganglion Cell_DME|Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema|Retinal Ganglion Cell Function After Repeated Intravitreous Ranibizumab in Diabetic Macular Edema||Federal University of São Paulo|Yes|Not yet recruiting|March 2014|July 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055911||50987|
NCT02052219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-IGN3331|BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy||Anthera Pharmaceuticals|Yes|Withdrawn|October 2014|October 2021|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052219||51269|
NCT02052232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL19|Study of Protein Metabolism in Healthy Older Subjects|Study of Acute Muscle Protein Metabolism in Healthy Older Subjects||Abbott Nutrition|No|Recruiting|January 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|28|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|December 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02052232||51268|
NCT02052544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICT-01|Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device|Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device||DSM Nutritional Products, Inc.|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|123|||Both|N/A|N/A|No|Non-Probability Sample|Subjects undergoing UFH anticoagulation therapy will are needed for this study. Typically,        such patients are undergoing cardiovascular surgery, are being treated for thromboembolic        events, or are receiving heparin intravenously for thrombosis prophylaxis due to its more        advantageous pharmacokinetic profile in some situations.|May 2015|May 4, 2015|January 17, 2014|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT02052544||51244|
NCT02053194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 201303MOP-299872-KTR|A Randomized Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly|Developing Pharmacist-led Research to Educate and Sensitive Community Residents to the Inappropriate Prescription Burden in the Elderly|D-PRESCRIBE|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Yes|Enrolling by invitation|March 2014|September 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|65 Years|N/A|No|||January 2016|January 26, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053194||51195|
NCT02053441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14082012|Modulation of Muscle Protein Synthesis With Diet and Exercise in Old Aged Women|The Efficacy of Leucine Enriched-EAA Supplements vs. Whey Protein in the Modulation of Muscle Protein Synthesis, Albumin Synthesis and Leg/ Muscle Blood Flow in Older Women||University of Nottingham|No|Recruiting|January 2013|September 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|48|Samples With DNA|Blood samples for Glucose and RNA analysis Muscle biopsies for protein synthesis|Female|60 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy females aged 60-70|December 2015|December 8, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02053441||51176|
NCT02054013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU 13.030|Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia|Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia: A Prospective Randomized Trial||Cantonal Hospital of St. Gallen|No|Recruiting|February 2014|February 2021|Anticipated|February 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|40 Years|N/A|No|||January 2016|January 31, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054013||51132|
NCT02033525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-MEN-01|Mesenchymal Stromal Cells for Degenerative Meniscus Injury|A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury||Banc de Sang i Teixits|No|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|60 Years|No|||November 2015|December 10, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02033525||52703|
NCT02061891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-039|Very Early veRsus Deferred Invasive Evaluation Using Computerized Tomography in Patients With Acute Coronary Syndromes|Entire Danish Initiative To ImrpOve Revascularization Strategies (EDITORS) - A Randomised Evaluation of Clinical Outcome After Acute or Deferred Invasive Intervention Integrated With MDCT Imaging in Patients With Acute Coronary Syndromes|VERDICT-EDI|Rigshospitalet, Denmark|Yes|Recruiting|November 2010|November 2020|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02061891||50528|
NCT02060968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-03|IRIS-PREMIER REGISTRY|Evaluation of Effectiveness and Safety of Promus PREMIER in Routine Clinical Practice; A Multicenter, Phase-IV, Prospective Observational Study|IRIS-PREMIER|Asan Medical Center|Yes|Recruiting|June 2014|June 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Non-Probability Sample|patients with Promus PREMIER stent|November 2015|November 9, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02060968||50599|
NCT02060942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-127123|Mean Systemic Filling Pressure and Heart Performance Predicting Fluid Responsiveness|Mean Systemic Filling Pressure and Heart Performance as Predictors of Successful Fluid Responsiveness in Patients With Coronary Artery Bypass Grafting, Aortic Valve Replacement and Sepsis||Catharina Ziekenhuis Eindhoven|No|Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Coronary artery bypass grafting, aortic valve replacement and septic shock patients|February 2014|February 11, 2014|August 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02060942||50601|
NCT02054195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jm1|Training Model on Insertion Techniques for Postplacental Intra Uterine Device|Study of Special Guided Training Model on Insertion Techniques for Postplacental Intra Uterine Device to Prevent Expulsion|PTKP|Showa University|No|Completed|August 2012|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|230|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 1, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02054195||51118|
NCT02054208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-010|Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease|A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease||Medipost Co Ltd.|No|Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|50 Years|85 Years|No|||January 2016|January 6, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02054208||51117|
NCT02054481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.2|BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab|A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)||Boehringer Ingelheim||Completed|February 2014|July 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|166|||Both|18 Years|75 Years|No|||August 2015|August 12, 2015|February 3, 2014||||No||https://clinicaltrials.gov/show/NCT02054481||51096|
NCT02054494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038/13|T1 Mapping in HIV Patients With High and Low CD4+ Cell Counts|Myocardial T1-mapping and T1-derived Extracellular Volume Fraction (ECV) in HIV-infection Patients With Chronic High and Low CD4+ Counts and in a Healthy Control Group||University Hospital, Bonn|No|Recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV patients are recruted from the HIV outpatients clinic of our hospital.|December 2015|December 9, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054494||51095|
NCT02055079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V5.1/20.1.2013|Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease|Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study|RAP|Medical University of Vienna|No|Recruiting|April 2014|December 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055079||51050|
NCT02055053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID 2013-031|Effects of Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair|A Randomized, Double-blinded, Placebo-controlled Trial of the Effects of Infusing Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair||Lahey Clinic|No|Recruiting|August 2013|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02055053||51052|
NCT02055066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARGX-111-1301|A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.|A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.||arGEN-X BVBA|Yes|Recruiting|January 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|35|||Both|18 Years|N/A|No|||January 2015|January 25, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055066||51051|
NCT02055924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBLOS|Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas|A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas|BIBLOS|The Lymphoma Academic Research Organisation|No|Recruiting|May 2014|November 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|70 Years|No|||March 2016|March 14, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055924||50986|
NCT02051998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL 658/4-1|Directional Spread in Geographic Atrophy|Analysis of the Directional Spread of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD)|DSGA|University Hospital, Bonn|Yes|Active, not recruiting|June 2013|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|Whole blood|Both|55 Years|N/A|No|Non-Probability Sample|Patients suitable for the study will be recruited at the University of Bonn, Department of        Ophthalmology|December 2015|December 7, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02051998||51286|
NCT02051959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0733-IS-CTIL|Long-term Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Phantom Limb Pain (PLP)|Long-Term Treatment of Patients Experiencing Phantom Limb Pain With Transcranial Direct Current Stimulation (tDCS)||Sheba Medical Center|No|Suspended|May 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|January 28, 2014||No|Signing a contract with the company owning the equipment|No||https://clinicaltrials.gov/show/NCT02051959||51289|
NCT02051972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP005|The LEADLESS Observational Study|Nanostim Study for a Leadless Cardiac Pacemaker System||St. Jude Medical|Yes|Recruiting|December 2013|March 2022|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are at least 18 years old and who are indicated for a VVI(R) pacemaker|October 2015|October 6, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051972||51288|
NCT02052245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.39.NRC|Pre/Term Milk Profiling|Longitudinal Composition of Human Milk for Term and Preterm Infants||Nestlé|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mothers who will breast feed their baby|September 2014|September 12, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02052245||51267|
NCT02052557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2013-09|The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery|The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery||Des Moines University|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02052557||51243|
NCT02052856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03439|Anterior Cruciate Ligament (ACL) Tunnel Widening Comparing All-inside and Interference Screw Fixation Technique|Interference Screw Fixation Versus All-Inside Suspensory Fixation Method Comparing Radiographic Tunnel Widening in Anatomic Single Bundle Anterior Cruciate Ligament (ACL) Reconstruction.||University of British Columbia|No|Completed|December 2012|May 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|16 Years|N/A|No|Non-Probability Sample|All anterior cruciate ligament (ACL) surgeries performed at the Joint Preservation Centre        of BC from November/2012 to present|September 2014|September 25, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02052856||51221|
NCT02053480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00010515|Pyruvate Kinase Deficiency Natural History Study|Pyruvate Kinase Deficiency (PKD) Natural History Study|PKD NHS|Children's Hospital Boston|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Pyruvate Kinase Deficiency of all ages|August 2015|August 30, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02053480|2 Years|51173|
NCT02053493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050042|Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction|Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction|NEAT|Duke University|Yes|Completed|April 2014|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|50 Years|N/A|No|||April 2015|April 22, 2015|January 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053493||51172|
NCT02053168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE-015|A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair|A Prospective, Multicenter All Comers Study of a Novel Resorbable Mesh (Phasix Mesh) for Ventral or Incisional Hernia Repair||C. R. Bard|No|Active, not recruiting|February 2014|June 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053168||51197|
NCT02053181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-061-103|Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection|A Phase 1, Open-label, Single Oral Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Cadazolid in Patients With Severe Clostridium Difficile Infection (CDI)||Actelion|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|80 Years|No|||January 2014|January 31, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053181||51196|
NCT02033265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000940|Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity|Perineural Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity on Block Performance Time, Failure Rate and Incidence of Acute Complications||Lawson Health Research Institute|No|Recruiting|August 2013|December 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled        to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic        modality at SJHC|March 2016|March 1, 2016|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02033265||52723|
NCT02053389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F021723 - 060077|Testing Decision Aids About Early Stage Prostate Cancer|Promoting Shared Decision Making in Prostate Cancer Through Decision Aids||University of Michigan|Yes|Completed|November 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|564|||Male|18 Years|N/A|No|||May 2015|May 28, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02053389||51180|
NCT02064842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103540|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants|A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With a Pharmacokinetic Enhancer (Part 1) Followed by an Open-label, Randomized, 3-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Coadministration of TMC435, TMC647055 and a Pharmacokinetic Enhancer, at Steady-state (Part 2) in Healthy Japanese Subjects.||Janssen R&D Ireland|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064842||50302|
NCT02064855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-003|Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers With K2M EVEREST® Spinal System|The Fusion Rate With K2M VESUVIUS® Demineralized Fibers Used With K2M EVEREST® Spinal System Compared to Autologous Bone Graft With Posterior Stabilization||K2M, Inc.|Yes|Enrolling by invitation|August 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|204|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be identified from the surgeon's practice.|August 2015|August 7, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02064855||50301|
NCT02053922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCMCS|The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)|The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section||Ain Shams University|Yes|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|270|||Female|18 Years|45 Years|No|||February 2014|February 5, 2014|March 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053922||51139|
NCT02054221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOCM - 95|Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.|Compare Results of Mitral Valve Replacement or Repair in the Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy With Severe Mitral Insufficiency.||Meshalkin Research Institute of Pathology of Circulation|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|75 Years|No|||July 2015|July 1, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02054221||51116|
NCT02054507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU.10.11|Prematurity Related Risks of Cognitive Impairment at School Age|Prematurity Related Risks of Cognitive Impairment at School Age With Regards to Social, Family and Care Environment|NEORIS|Maternite Regionale Universitaire|No|Completed|April 2013|March 2015|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02054507||51094|
NCT02055638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN009|Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder|An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)|AVN009|Azevan Pharmaceuticals|No|Recruiting|May 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|21 Years|55 Years|No|||July 2015|July 22, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055638||51007|
NCT02055937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA2012/37|Immediate Implant Breast Reconstruction|Immediate Implant Breast Reconstruction for Patients With Mastectomy Ans Post opérative Chest Wall Radiotherapy|ISIS|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Female|18 Years|N/A|No|||March 2015|March 2, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02055937||50985|
NCT02052271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-24|Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation|Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Transcranienne Par Courant Direct (tDCS) du Cortex Cerebelleux|ELECTRE2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Not yet recruiting|February 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Anticipated|30|||Both|18 Years|65 Years|No|||January 2014|January 30, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02052271||51265|
NCT02051985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC 877|Early-start Exercise Training in Subacute Heart Failure|Early-start Exercise Training After Acute Hemodynamic Decompensation in Patients With Chronic Heart Failure. A Multicenter, Randomized, Controlled Trial on Feasibility and Impact on Functional Capacity, Symptoms and Neurohumoral Activation.|RE-START|Fondazione Salvatore Maugeri|Yes|Recruiting|October 2013|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2014|January 29, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051985||51287|
NCT02052869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lazarus 003|Spirometric Detection of Esophageal Intubation|Spirometric Detection of Esophageal Intubation||University Medical Center Groningen|No|Not yet recruiting|January 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02052869||51220|
NCT02052882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-132|Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia|A Randomized Open Label Phase II Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia||Memorial Sloan Kettering Cancer Center||Recruiting|January 2014|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052882||51219|
NCT02053207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01907|Feasibility Study of Preoperative Cognitive Training in Cardiac Surgical Patients|The Cog-Train Feasibility Study: a Single-arm Trial Investigating the Feasibility of a Preoperative Cognitive Training Intervention (Cog-Train) in Cardiac Surgical Patients|Cog-Train|Papworth Hospital NHS Foundation Trust|No|Not yet recruiting|April 2016|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|60 Years|N/A|No|||January 2016|January 25, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02053207||51194|
NCT02053220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoAd1-1002|Mechanism of Action Trial of ColoAd1|A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour|MOA|PsiOxus Therapeutics Ltd|No|Active, not recruiting|June 2013|December 2015|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053220||51193|
NCT02053506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10-H|Nutrition Interventions to Support the Immune System in Response to Stress|Nutrition Support for Immune Recovery||United States Army Research Institute of Environmental Medicine|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02053506||51171|
NCT02053467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130674-01H|Building Capacity for Specialized Services Through eConsultation|Building Capacity for Specialized Services Through eConsultation|eConsult|Bruyere Research Institute|Yes|Enrolling by invitation|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|N/A|N/A|No|||January 2014|January 31, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053467||51174|
NCT02053740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH 2012-1|Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial|||Tri-Service General Hospital||Completed|January 2013|||August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|59|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053740||51153|
NCT02053753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120186|A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product|A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product||Amgen|No|Completed|February 2014|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|146|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053753||51152|
NCT02053402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/M/82/2013:PG|Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital|Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa||University of Limpopo|No|Not yet recruiting|March 2014|April 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|12 Years|No|||January 2014|January 30, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02053402||51179|
NCT02053662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12158|Biomarker Identification for Bladder Cancer Patients|Biomarker Identification for Bladder Cancer Patients||Ohio State University Comprehensive Cancer Center|No|Recruiting|January 2014|||November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|179|Samples With DNA|bladder cancer tissue samples, blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected muscle-invasive bladder cancer and appropriate control population|September 2015|September 4, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053662||51159|
NCT02053935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-286|Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects|Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|December 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02053935||51138|
NCT02053948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSICT1126|Pursestring Wound Closure vs "Gunsight" Skin Incision and Closure Technique to Reverse Stoma|Randomized Clinical Trial of Stoma Reversal Comparing Pursestring Wound Closure vs "Gunsight" Skin Incision and Closure Technique to Eliminate the Risk of Wound Infection|GSICT1126|Beijing Chao Yang Hospital|No|Recruiting|November 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||February 2014|February 3, 2014|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02053948||51137|
NCT02054520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0304|Immunotherapy Study for Patients With Stage IV Melanoma|A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients||NewLink Genetics Corporation||Recruiting|June 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054520||51093|
NCT02054793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Itraconazole/Orteronel|Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)|Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)||Johns Hopkins University|Yes|Withdrawn|June 2014|July 2016|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||July 2014|July 22, 2014|January 30, 2014|No|Yes|This study was never able to open due to lack of funding from the pharmaceutical company.|No||https://clinicaltrials.gov/show/NCT02054793||51072|
NCT02054806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-028|Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)|Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Active, not recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|440|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02054806||51071|
NCT02055365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRO-0828|Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers|Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers||Rockefeller University|No|Active, not recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02055365||51028|
NCT02055378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-IRB-032-XD|the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control|the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|73|||Both|6 Years|12 Years|No|||December 2012|February 3, 2014|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02055378||51027|
NCT02055651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17312|Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil|Descriptive Observational Study of Cardiovascular Health Risk Factors in Workers of Bayer S.A. Company in São Paulo||Bayer|No|Active, not recruiting|August 2013|February 2016|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|361|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bayer's employees (São Paulo, Brazil)|January 2016|January 5, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02055651||51006|
NCT02056210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZBL-2996P/13|Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects|Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects||University of Padova|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056210||50964|
NCT02052284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071319|The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants|The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants||George Washington University|No|Recruiting|January 2014|April 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|24 Hours|No|||March 2015|March 10, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02052284||51264|
NCT02052258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120283|Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence|Oxytocin in Opiate Dependence: A Double-blind, Within-subjects, Placebo-controlled Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence||MacDonald, Kai, M.D.||Recruiting|January 2013|||December 2015|Anticipated|Phase 1|Interventional|N/A|1||||||Male|18 Years|N/A||||September 2014|September 11, 2014|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052258||51266|
NCT02052895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVD2001|Utility of Presepsin in Distinguishing Between Sepsis and SIRS|Utility of Presepsin in Distinguishing Between Sepsis and SIRS (Systemic Inflammatory Response Syndrome): an Exploratory, Prospective Observational Study in Critically Ill Patients||Mochida Pharmaceutical Company, Ltd.|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|226|Samples Without DNA|Blood plasma Blood serum|Both|21 Years|N/A|No|Non-Probability Sample|Subjects with presentation to ICU with critical illness compatible with either sepsis or        systemic inflammatory response syndrome (SIRS).|September 2015|September 23, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052895||51218|
NCT02052908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00046|Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome|A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer||National Cancer Institute (NCI)|Yes|Recruiting|January 2014|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|85|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02052908||51217|
NCT02053233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-03-2013-011|Robot-assisted Training for Stroke Recovery|Clinical Trial of Robot-assisted Training for Motor and Gait Recovery in Patients With Stroke||Pusan National University School of Medicine|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|85 Years|No|||January 2014|January 31, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02053233||51192|
NCT02053766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0600|Anesthesia in Patients With Mitochondrial Disease|Anesthesia in Patients With Mitochondrial Disease||The University of Texas Health Science Center, Houston|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|60|||Both|N/A|17 Years|No|||February 2014|February 7, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053766||51151|
NCT02054611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READS1|The Educational ARDS Diagnosis Study|Randomized Educational ARDS Diagnosis Study (READS)|READS|University of Toronto|No|Completed|February 2014|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054611||51086|
NCT02054897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3623|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes|SUSTAIN™1|Novo Nordisk A/S|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|388|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054897||51064|
NCT02063256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS93-2013|7 NUTS Study. Diet Modification and Male Fertility.|7 NUTS Study . A Randomized Dietary Intervention Trial on the Influence of Diet on Human Sperm Quality in Subfertile Men.||Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Recruiting|May 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|21 Years|N/A|No|||May 2014|May 25, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02063256||50424|
NCT02063269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DKR15T|Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles|Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)||Seoul National University Hospital|Yes|Active, not recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|55 Years|80 Years|No|||May 2015|May 12, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02063269||50423|
NCT02063282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShaareZMC|The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers|The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers||Shaare Zedek Medical Center|Yes|Not yet recruiting|February 2014|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|744|||Both|65 Years|N/A|No|Non-Probability Sample|Newly admitted patients in the Emergency Department and Internal wards, .|February 2014|February 13, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02063282|2 Weeks|50422|
NCT02053415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Krill oil pilot-2014|Krill Oil as Supplementation to Healthy Young Adults.|Study of the Effect of Krill Oil Supplement on Omega-3 Fatty Acid Index and Tolerance||University of Bergen|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|35|||Both|18 Years|36 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053415||51178|
NCT02053428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0298B|Comparison of Percutaneous Image-guided Gastrostomies|Comparison of Percutaneous Image-guided Gastrostomies: A Single Centre Pilot Study||University Health Network, Toronto|No|Completed|June 2013|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2014|November 14, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02053428||51177|
NCT02053675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasopress FAPESP 2010/50096-6|Hemodynamic Effects of Vasopressin in Early Septic Shock Stage|Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage||Federal University of São Paulo|No|Completed|May 2008|||April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||May 2010|January 31, 2014|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02053675||51158|
NCT02054234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVISE France|ADenoVirus Initiative Study in Epidemiology in France|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis||NicOx|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|357|||Both|1 Year|N/A|No|Non-Probability Sample|Any female and male patients from one year of age with signs and symptoms of acute        conjunctivitis either seen during ophthalmology consultations or who are in the emergency        room or hospitalized, can be enrolled in the study|February 2015|February 9, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02054234||51115|
NCT02054819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 2011-01|Treating NSCLC Minimal Stage IV With Curative Intent|A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent||Leo W. Jenkins Cancer Center|Yes|Recruiting|June 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02054819||51070|
NCT02055092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229002|Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family|A Nordic Multicentre Observational Study of Persons With Young Onset Dementia and Their Families - Factors Influencing Quality of Life, Theirs Specific Needs and the Use of Healthcare Resources||Norwegian Centre for Ageing and Health|No|Active, not recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|Samples With DNA|Bio samples are collected for analysis and storage in a bio bank as part of the routines for      the National Registry of Dementia:        -  Blood plasma and serum for the later analysis of inflammation markers.        -  Whole blood for analysis of apolipoprotein E4-genotype.        -  Cerebrospinal fluid for dementia markers (tau-protein, amyloid).        -  Saliva cortisol.|Both|N/A|69 Years|No|Non-Probability Sample|YOD participants are community residing persons recruited from memory clinics in Norway        and Nordic countries (Iceland, Sweden and Denmark).|October 2015|October 6, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02055092||51049|
NCT02055391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32DK083910|A Weight Loss Trial for Emotional Eating|A Randomized Controlled Trial of a Novel Weight Loss Intervention for Obesity||Temple University|No|Completed|September 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|21 Years|65 Years|No|||February 2014|February 4, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT02055391||51026|
NCT02055404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-045|On-Eye Evaluation of Contact Lens Rotation Marks|||Alcon Research|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 4, 2014|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT02055404||51025|
NCT02055664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIREK 2013|The Tap Block Technique Via the Anterior Approach in Elective Surgery of the Spine|THE TAP BLOCK TECHNIQUE VIA THE ANTERIOR APPROACH IN ELECTIVE SURGERY OF THE SPINE: Prospective, Randomised, Double Blind Trial, Comparing TAP BLOCK With Continuous Infiltration of Ropivacaine Versus Placebo|TAPBloc Rachis|Centre Hospitalier Universitaire Dijon||Recruiting||||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|80|||Both|18 Years|N/A||||December 2013|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055664||51005|
NCT02055677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VegMed2013|Personality Profiles, Values and Empathy: Differences Between Ovo/Lacto-vegetarians and Vegans|Personality Profiles, Values and Empathy: Differences Between Ovo/Lacto-vegetarians and Vegans|VegMed 2013|Charite University, Berlin, Germany|Yes|Completed|January 2014|July 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10000|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|5000-10000 vegetarian volunteers|July 2014|July 17, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02055677||51004|
NCT02055950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICTION|Pulsed Perfusion for Marginal Kidneys|A PROSPECTIVE STUDY TO COMPARE EARLY GRAFT FUNCTION OF RECIPIENTS OF SINGLE OR DUAL KIDNEY ORGANS STORED IN ICE COLD SOLUTION OR PULSED PERFUSION|PREDICTION|Mario Negri Institute for Pharmacological Research|No|Recruiting|July 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Serum, urine.|Both|50 Years|N/A|No|Non-Probability Sample|Patients who are eligible to receive a single or dual transplant from older/marginal        deceased donors identified according to the Nord Italia Transplant criteria who consent to        receive perfused with a pulsatile machine.|October 2015|October 9, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02055950||50984|
NCT02055963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0510|Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer|Minocycline for Reduction of Symptom Burden After Surgery in Patients With Head and Neck Malignancy: A Randomized Study||M.D. Anderson Cancer Center|Yes|Recruiting|May 2014|||May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055963||50983|
NCT02052011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312013144|Ranolazine and Microvascular Angina by PET in the Emergency Department|Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED)|RAMP-ED|Yale University|Yes|Recruiting|April 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|N/A|No|||April 2015|April 15, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052011||51285|
NCT02053246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501144|Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure|Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure||University of Florida|No|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02053246||51191|
NCT02052570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047417|School Reintegration After Pediatric Hematopoietic Stem Cell Transplant|School Reintegration After Pediatric Hematopoietic Stem Cell Transplant: Experiences of Children, Parents, Teachers and Providers||Duke University|Yes|Withdrawn|January 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|0|||Both|10 Years|16 Years|No|Non-Probability Sample|Children transplanted in the PBMT (Pediatric Bone Marrow Transplant) program at DUMC (Duke        University Medical Center) in the past 5 years for allogeneic HSCT to include diagnoses        for malignancy, immunodeficiency, bone marrow failure and inherited metabolic disease.        They must have previously attended school prior to transplant.|February 2015|February 2, 2015|January 27, 2014||No|Unable to meet all criteria as outlined for participants|No||https://clinicaltrials.gov/show/NCT02052570||51242|
NCT02053779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27111969|GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT|The Impact of a Single Dose of GnRH Agonist (Triptorelin 0,1 mg) at the Time of Implantation on the Reproductive Outcome in IVF Cycles Triggered by a GnRH Agonist Followed by a Small Bolus of HCG the Day of Oocyte Retrieval|GTMLPSGI|Centre Hospitalier Universitaire Ibn Rochd|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|328|||Female|18 Years|40 Years|No|||January 2016|January 29, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053779||51150|
NCT02053532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00313|Functional Brain Imaging in PTSD|Functional Brain Imaging in PTSD||New York University School of Medicine|Yes|Completed|May 2013|February 2016|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are between the age range of 18 to 65, are medically healthy and currently not        taking any medications to treat any medical illness, and either have no history of        post-traumatic stress disorder (PTSD) or have been diagnosed with PTSD.|March 2016|March 2, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02053532||51169|
NCT02053545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0813 Haplo|Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion|Haplo-identical Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Post-Transplant In-Vivo T-cell Depletion||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||January 2014|January 30, 2014|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02053545||51168|
NCT02054039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186.780|Incentive Spirometry and Breath Stacking|Comparison Between Incentive Spirometry and Breath Stacking After Cardiac Surgery||Federal University of São Paulo|Yes|Recruiting|February 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|118|||Both|18 Years|80 Years|No|||February 2014|February 23, 2014|February 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02054039||51130|
NCT02054065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-06-225|Effect of CAUTI Prevention Alert - A Randomized Control Trial|Effect of CAUTI Prevention Alert - A Randomized Control Trial||Montefiore Medical Center|Yes|Not yet recruiting|February 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10830|||Both|21 Years|N/A|No|||January 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054065||51128|
NCT02054351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-IMAB-002-01|Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)|A First-in-human Dose Escalation and Dose Finding Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)|OVAR|Ganymed Pharmaceuticals AG|Yes|Active, not recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||February 2014|April 15, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02054351||51106|
NCT02063581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29066|A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects||Genentech, Inc.||Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063581||50399|
NCT02063594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARV2013-CP-001|Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers|Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers||Marval Pharma Ltd.|No|Terminated|March 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02063594||50398|
NCT02054247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clinics-2013-0627|Continuous And Pulsed Ultrasound Treatments On Carpal Tunnel Syndrome|The Placebo-Controlled Continuous And Pulsed Ultrasound Treatments on Carpal Tunnel Syndrome : A Randomised Trial||Eskisehir Osmangazi University|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|46|||Female|N/A|N/A|No|||February 2014|February 3, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02054247||51114|
NCT02054260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHBC_IRB_2013-40|Surgicel® (Fibrillar) in Non-variceal UGI Bleeding|||Soonchunhyang University Hospital||Recruiting||||December 2015|Anticipated|N/A|Interventional|N/A|1||||||Both|20 Years|75 Years||||November 2014|November 18, 2014|February 3, 2014||||No||https://clinicaltrials.gov/show/NCT02054260||51113|
NCT02053688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL001|Evaluation Study on Corneal Lens for Vision Correction|Evaluation Study on Corneal Lens for Vision Correction||FORSIGHT Vision3|Yes|Completed|February 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|February 2, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053688||51157|
NCT02053961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dTMS-Tinnitus- wolfson|Deep TMS of the Left Auditory Cortex Using the HMCIPCC Coil, in the Treatment of Patients With Tinnitus.|The Efficacy of dTMS Among Patient Who Suffer From Tinnitus||Brainsway|Yes|Not yet recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|70 Years|No|||September 2014|September 15, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02053961||51136|
NCT02054832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-337-PED|Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch|A Comparison of Quality of Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard and Modified Uncooked Cornstarch||McGill University Health Center|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|2 Years|50 Years|No|Non-Probability Sample|Patients with Glycogen Storage Disease taking uncooked cornstarch to prevent hypoglycemia        followed at the Montreal Children's Hospital and St-Luc Hospital.|September 2015|September 23, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054832||51069|
NCT02055105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHNX-biosep-12159|Modulation of Molecular Fingerprinting in Pediatric Sepsis|Modulation of Molecular Fingerprinting in Pediatric Sepsis||Phoenix Children's Hospital|No|Recruiting|March 2014|August 2015|Anticipated|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|1 Year|18 Years|No|||June 2015|June 29, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02055105||51048|
NCT02055690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_DOG01_119|PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer|A Phase Ib and Randomised Phase II Trial of Pazopanib With or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer|PAZOFOS|Christie Hospital NHS Foundation Trust|Yes|Recruiting|September 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02055690||51003|
NCT02055976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481036|Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects|A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Naïve.||Pfizer|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|20 Years|N/A|No|||December 2015|December 21, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055976||50982|
NCT02056223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARIDA 01/2013|Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.|Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.|PARIDA|University of Padua|Yes|Not yet recruiting|September 2015|June 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|72 Hours|No|||May 2015|May 27, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056223||50963|
NCT02052024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-206-1010|Myobloc Atrophy Study|Myobloc Atrophy Study|MAS|Georgetown University|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052024||51284|
NCT02052635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00065|Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.|A Phase IV, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin|NSTE-ACS|AstraZeneca|No|Terminated|September 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052635||51237|
NCT02052583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-02|Cardiac ARrest : Brain OXymetry Depending on HYpothermia Depth|Evaluation de l'oxymétrie cérébrale à Deux Niveaux d'Hypothermie thérapeutique après arrêt Cardiaque Extra-hospitalier|CARBOXHYD|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2014|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02052583||51241|
NCT02052596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116887|Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older||GlaxoSmithKline||Active, not recruiting|February 2014|July 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|903|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|February 4, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052596||51240|
NCT02053259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU-SNHP01|A Walking Intervention Through Text Messaging|Walking Intervention Through Texting Study: A Factorial Trial|WalkIT|Arizona State University|No|Active, not recruiting|February 2014|January 2018|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02053259||51190|
NCT02053571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO19417|Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure|Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure||Medical College of Wisconsin|No|Enrolling by invitation|April 2014|December 2018|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|99 Years|No|||September 2015|September 22, 2015|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053571||51166|
NCT02053584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0002|Dario™ Blood Glucose Monitoring System - User Performance Evaluation|Dario™ Blood Glucose Monitoring System - User Performance Evaluation||LabStyle Innovations Ltd.|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|161|||Both|N/A|N/A|No|||January 2014|January 31, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053584||51165|
NCT02054052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZTO1401|Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer|Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer||Guangzhou Medical University|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054052||51129|
NCT02054078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSL002|Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion|Efficacy and Safety of Intrapleural Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion, A Randomized, Multicenter Study||Tang-Du Hospital|Yes|Recruiting|January 2012|||March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|183|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02054078||51127|
NCT02054325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 4127.2012|Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins|A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs.||UPECLIN HC FM Botucatu Unesp|No|Recruiting|September 2012|August 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|69 Years|No|||February 2014|February 3, 2014|February 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02054325||51108|
NCT02054338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 303 B0|A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer|Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy|VICTORIA|Pierre Fabre Medicament|Yes|Completed|June 2006|April 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1004|||Female|18 Years|75 Years|No|||January 2014|February 3, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054338||51107|
NCT02063880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41540-D|Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)|Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections|PUSH|University of Washington|Yes|Completed|March 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Both|N/A|12 Years|No|||November 2015|November 30, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT02063880||50376|
NCT02054273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVISE Germany|ADenoVirus Initiative Study in Epidemiology in Germany|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis||NicOx|No|Recruiting|October 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|1 Year|N/A|No|Non-Probability Sample|Any female and male patients from one year of age with signs and symptoms of acute        conjunctivitis either seen during ophthalmology consultations or who are in the emergency        room or hospitalized, can be enrolled in the study|January 2014|February 9, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02054273||51112|
NCT02054533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0899|Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease|Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I|PUCCINI|Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|patients with IBD undergoing intra-abdominal surgery|December 2015|December 22, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02054533||51092|
NCT02054546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514/13|TIMP-2 and IGFBP7 for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury|Novel Biomarkers (TIMP-2 and IGFBP7) of Tubular Renal Cell Damage for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - A Feasibility Study||University Hospital, Basel, Switzerland|Yes|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|adults with planned cardiac surgery and cardiopulmonary bypass|February 2015|February 26, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02054546||51091|
NCT02054559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_NHL02|R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL|Randomized Phase III Trial Comparing R-CHOP Alone and R-CHOP Plus Radiotherapy for Localized CD20+ Diffuse Large B-cell Lymphoma (DLBCL)|ASPIRE|Asan Medical Center|Yes|Withdrawn||January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|January 29, 2014||No|No consensus among trial centers regarding protocol|No||https://clinicaltrials.gov/show/NCT02054559||51090|
NCT02055118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-094|Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment|A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment|AIM-IT|Shire|Yes|Recruiting|February 2014|September 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|N/A|18 Years|No|||January 2016|January 8, 2016|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055118||51047|
NCT02055417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH092208-03|Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention|Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention||University of Maryland|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|60 Years|No|||December 2015|December 11, 2015|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02055417||51024|
NCT02055703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-003|A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil|||Eisai Inc.|No|Completed|January 2014|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|195|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02055703||51002|
NCT02055989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 1978|A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx|A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx||Royal Marsden NHS Foundation Trust|No|Completed|January 2002|||December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A||||February 2014|February 4, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02055989||50981|
NCT02056236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEF-14-18|TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation|TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation|TELSTAR|University of Twente|Yes|Recruiting|April 2014|September 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056236||50962|
NCT02056249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103008163|Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand|Evaluation of the Effect of Hypoglycemia on the Noradrenergic System With PET and a Highly Selective Norepinephrine Transporter Ligand||Yale University|No|Completed|June 2011|August 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|9|Samples With DNA|whole blood|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potentially eligible subjects (healthy controls) will be recruited through flyers and the        Yale web site for this pilot project.|October 2014|October 1, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02056249||50961|
NCT02052921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP172/11|Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy|Open Randomized Study of Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy||Instituto do Cancer do Estado de São Paulo|No|Recruiting|November 2011|February 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||September 2014|September 3, 2014|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052921||51216|
NCT02052648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2102|Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors|A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors||NewLink Genetics Corporation|Yes|Recruiting|March 2014|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|144|||Both|16 Years|N/A|No|||March 2016|March 14, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052648||51236|
NCT02052661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106793|This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa|Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy||GlaxoSmithKline||Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|301|||Both|12 Years|13 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|January 30, 2014|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT02052661||51235|
NCT02052947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.795|Co-LEsions in Alzheimer Disease and Related Disorders|Co-LEsions in Alzheimer Disease and Related Disorders|CLEM|Hospices Civils de Lyon|No|Not yet recruiting|January 2014|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|214|||Both|70 Years|N/A|No|||January 2014|January 31, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02052947||51214|
NCT02053519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012GA03|Can Vitamin D Supplementation Improve Hepatitis C Cure Rates|Can Vitamin D Supplementation Improve Hepatitis C Cure Rates : A Pilot Multicentre Randomised Controlled Clinical Trial|ViaDUCT|University of Dundee|Yes|Recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02053519||51170|
NCT02053285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12051502-IRB01|Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer|Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer||Rush University Medical Center|No|Recruiting|January 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stage III lung cancer treated with chemoradiotherapy or chemoradiotherapy        followed by surgery|August 2014|August 29, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02053285||51188|
NCT02053558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00086849|Tranversus Abdominis Plane (TAP) Block vs. Systemic Lidocaine: Effects on Recovery After Outpatient Gynecological Laparoscopy|Tranversus Abdominis Plane (TAP) Block vs. Systemic Lidocaine to Improve Quality of Recovery After Outpatient Laparoscopic Surgery: A Non-inferiority, Randomized, Double Blinded, Placebo Controlled Trial|TAP|Northwestern University|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|101|||Female|18 Years|65 Years|No|||August 2015|August 11, 2015|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053558||51167|
NCT02053597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE2142|TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen|A Phase II TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen Composed of Doxorubicin and Paclitaxel|TRIUMPH|Jules Bordet Institute|No|Withdrawn|October 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|No|||September 2015|September 16, 2015|January 27, 2014||No|due to evolving scientific knowledge in the field that would make the questions being    addressed in the trial less relevant|No||https://clinicaltrials.gov/show/NCT02053597||51164|
NCT02053792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL654_3003|A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B|A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B||CSL Behring||Recruiting|February 2014|||March 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Male|N/A|70 Years|No|||March 2016|March 8, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02053792||51149|
NCT02053805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0582_13_RMC|Prostate Cancer Screening Among Men With High Risk Genetic Predisposition|Personalized Prostate Cancer Screening Among Men With High Risk Genetic Predisposition- a Prospective Cohort Study||Rabin Medical Center|Yes|Recruiting|February 2014|||June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Male|40 Years|70 Years|No|||March 2016|March 17, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02053805||51148|
NCT02054091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-136|Feeding Bovine Colostrum to Preterm Infants|Bovine Colostrum as Nutrition for Preterm Infants in the First Days of Life: A Pilot Feasibility Study|PreColos|Rigshospitalet, Denmark|Yes|Recruiting|February 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|1 Day|No|||October 2015|October 5, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02054091||51126|
NCT02054104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140053|Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum|Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum||National Institutes of Health Clinical Center (CC)||Suspended|January 2014|November 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|99 Years|No|||September 2015|November 21, 2015|February 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02054104||51125|
NCT02054364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH101281|Feasibility of Combining Family and Cognitive Therapy to Prevent Chronic Anorexia|||Stanford University|Yes|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|11 Years|19 Years|No|||November 2015|November 17, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02054364||51105|
NCT02054377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6463|Cystic Fibrosis- Children and Adults Tai Chi Study|Cystic Fibrosis- Children and Adults Tai Chi Study: Can Tai Chi Improve Quality of Life for People With Cystic Fibrosis and Their Carers? Second Phase Study|CFCATS2|London South Bank University|Yes|Active, not recruiting|June 2014|July 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|6 Years|100 Years|No|||March 2016|March 17, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02054377||51104|
NCT02063620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gokceakman|The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA|The Effect of Different Anesthetic Agents Management on Electrocardiographic Changes of Patients Who Were Operated Under Regional Intravenous Anesthesia||Duzce University|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02063620||50396|
NCT02054585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0078-CTIL|IV NaCl (Sodium Chloride) 0.9% Vs (Versus) IV NaCl 0.9% + 5% Dextrose in Pediatric ER for Dehydration|Intravenous Fluids With or Without Dextrose as Treatment for Dehydration in Children. What's the Formula That Will Bring to a Faster Improvement? A Prospective Randomized Double Blinded Study.||Carmel Medical Center|No|Recruiting|July 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02054585||51088|
NCT02054572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130147|An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [14C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis|An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [14C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis||Amgen|No|Completed|February 2014|August 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|80 Years|No|||September 2014|September 29, 2014|February 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02054572||51089|
NCT02054845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWO/13-05E|BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's Disease|BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's diseasE.|BEWARE|VU University Medical Center|Yes|Enrolling by invitation|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|No|||February 2014|February 3, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02054845||51068|
NCT02055131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|913|Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis|a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis||Tunis University|Yes|Recruiting|November 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Both|N/A|N/A|No|||February 2014|February 3, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02055131||51046|
NCT02055430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61177|Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage|Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage in Children With Obstructive Anuria and Acute Renal Failure Due to Ureteral Calculi: a Prospective, Randomized Study||Cairo University|Yes|Completed|March 2010|September 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|N/A|12 Years|No|||March 2014|March 19, 2014|February 3, 2014||No||No|February 4, 2014|https://clinicaltrials.gov/show/NCT02055430||51023|
NCT02052037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05|Egg Ingestion in Adults With Type 2 Diabetes|Egg Ingestion in Adults With Type 2 Diabetes: Effects on Glycemic Control, Anthropometry, Diet Quality and Cardiometabolic Status A Randomized, Controlled, Crossover Trial||Griffin Hospital|No|Active, not recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|35 Years|N/A|No|||July 2015|July 15, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02052037||51283|
NCT02052297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116235|A Validation and Dosimetry Study of GSK2634673F PET Ligand|Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)||GlaxoSmithKline|No|Recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|16|||Both|45 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02052297||51263|
NCT02052310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-063|Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients|Phase 3, Multicenter, Randomized, Open-Label,Active-Controlled Study of the Efficacy and Safety of FG-4592 (Roxadustat) in the Treatment of Anemia in Incident-Dialysis Patients|Himalayas|FibroGen|Yes|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|January 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02052310||51262|
NCT02052609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-005|A Phase 3 Clinical Study of KHK 4827|An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma||Kyowa Hakko Kirin Company, Limited|No|Active, not recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02052609||51239|
NCT02052622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16045|Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|Long-term, Follow-up Study of Subjects Who Completed Phase 3 Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|201|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02052622||51238|
NCT02076282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46711.041.13|MRI Optimization Study in Stage III NSCLC|MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients||UMC Utrecht|Yes|Recruiting|March 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  10 healthy volunteers          -  20 patients with pathologically proven stage III NSCLC with lymph node metastases             (i.e. excluding T4N0) referred to the department of Radiation Oncology.|February 2015|February 1, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076282||49427|
NCT02076542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH022014_1|Diabetes and Sports: Evaluation of a Diabetes Education Module|A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic "Diabetes and Sports" in a Randomized Controlled Trial|PRIMO_Sports|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076542||49407|
NCT02076815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOP18007|Anagrelide Retard in Essential Thrombocythemia|A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)|TEAM-ET|AOP Orphan Pharmaceuticals AG|Yes|Completed|February 2014|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02076815||49386|
NCT02077361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028599|An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia|An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1)||University of Alberta|Yes|Active, not recruiting|April 2015|December 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|18 Years|N/A|No|||July 2015|July 10, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02077361||49344|
NCT02077400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0115-09-EMC|Prophylactic Antibiotic in Treatment of Fingertip Amputation|The Use of Prophylactic Antibiotic in Treatment of Fingertip Amputation: A Randomized Prospective Trial||HaEmek Medical Center, Israel||Completed|January 2006|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 9, 2015|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077400||49341|
NCT02077127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dongli|Monocyte Chemoattractant Protein-1 2518A/G Polymorphism|Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes|MCP-1|Harbin Medical University|No|Completed|September 2011|April 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1043|Samples With DNA|Blood had been stored in -80℃.|Both|41 Years|68 Years|No|Non-Probability Sample|residents of a certain province|March 2014|March 3, 2014|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02077127||49362|
NCT02077413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USAMRMC W81XH-11-1-0454|Muscle Injury Prevention & Rehabilitation in Military Personnel|Muscle Injury Prevention & Rehabilitation in Military Personnel||University of Florida|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|41|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077413||49340|
NCT02077946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4161|A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden|A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden||Novo Nordisk A/S|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1059|||Both|18 Years|N/A|No|Non-Probability Sample|Data will be analyzed for patients with type 2 diabetes treated with liraglutide or        sitagliptin from January 2010 to December 2013, with a treatment length of 180 days.|September 2014|September 25, 2014|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02077946||49299|
NCT02073838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin=005|Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML|A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)||Jewish General Hospital|No|Recruiting|May 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073838||49615|
NCT02048631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20130085|Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients|Retrospective Analysis Of Sensory Recovery Of Donor Size And Related Quality Life In Oral Cancer Patients Receiving Free Flap Reconstruction||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|July 2013|June 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Oral Cancer Patients Receiving Free Flap Reconstruction|July 2013|January 28, 2014|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02048631||51544|
NCT02048644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acadmed18013|Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|March 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|85 Years|No|||June 2015|June 22, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048644||51543|
NCT02048657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMHK-IRB-96023|The Effectiveness of Foley Airway Stylet Tool on Proseal LMA Insertion|The Efficiency of ProSeal Laryngeal Mask Airway Insertion: Compared the Techniques of Foley Airway Stylet Tool With Introducer-Tool||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|March 2008|June 2013|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2008|January 27, 2014|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02048657||51542|
NCT02074319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVERY-001|RCT of Methotrexate Added to Treatment As Usual in Schizophrenia|A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia|RECOVERY|Pakistan Institute of Learning and Living|No|Completed|December 2013|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|35 Years|No|||September 2015|September 19, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074319||49578|
NCT02074332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001052-12046|Study on Obesity Intervention With Physical Exercise Among Students in Changping District, Beijing|Development and Application of Appropriate Technology for Obesity Prevention and Control -- Study on Personalized Aerobic and Appropriate Exercise Technology||Peking University||Completed|September 2012|February 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|921|||Both|7 Years|15 Years|No|||April 2015|April 28, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074332||49577|
NCT02074644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAE-01-2013|Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia|Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers||Hospital St. Louis, Lisbon, Portugal|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Male|45 Years|N/A|No|||August 2015|August 20, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074644||49553|
NCT02074683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13080186|Fat Grafting for Pedal Fat Pad Atrophy in Diabetics|Fat Grafting for Pedal Fat Pad Atrophy in Diabetics||University of Pittsburgh|Yes|Recruiting|November 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074683||49550|
NCT02075437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043556|Feeling and Body Investigators|Feelings and Body Investigators (FBI): Interoceptive Exposure for Child Abdominal Pain|FBI|Duke University||Recruiting|March 2014|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|126|||Both|60 Months|107 Months|No|||January 2016|January 19, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075437||49492|
NCT02075957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00827-36|Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer|Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer|SITRR|University Hospital, Angers|No|Recruiting|October 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|192|Samples With DNA|-  Three blood samples are going to be conserved : one during the week before the           operation, one four to eight weeks next to the operation and the last one, at the           relapse.        -  Biopsie of non small cell lung cancer will be conserved too.|Both|18 Years|N/A|No|Probability Sample|Patients with non small cell lung cancer|February 2014|February 27, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02075957||49452|
NCT02076230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200592-007|A Phase 1 TH-302 Mass Balance Trial|A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors||Merck KGaA|Yes|Active, not recruiting|February 2014|December 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|70 Years|No|||August 2015|August 21, 2015|February 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02076230||49431|
NCT02076243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1697|Treatment With Nab-paclitaxel in Cutaneous SCC|Phase II Trial of Nab-Paclitaxel as First Line Cytotoxic Chemotherapy in Patients With Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma||Icahn School of Medicine at Mount Sinai|No|Terminated|March 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 26, 2014|Yes|Yes|Closed by sponsor|No||https://clinicaltrials.gov/show/NCT02076243||49430|
NCT02075931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2568|Collaborative-care Intervention to Promote Physical Activity After Total Knee Arthroplasty|Collaborative-care Intervention to Promote Physical Activity After Total Knee Arthroplasty||University of Colorado, Denver|No|Recruiting|February 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|75 Years|No|||October 2015|October 2, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075931||49454|
NCT02075944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130171|Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults|Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults Aged 15-21 Years||University of Southern Denmark|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|130|||Both|15 Years|21 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075944||49453|
NCT02075983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2049|Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes|A Phase I Clinical Trial to Assess the Safety and Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via the Intramuscular, Intradermal and Transcutaneous Routes in Healthy Male and Female Volunteers|CUT*HIVAC001|Imperial College London|Yes|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|February 27, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075983||49450|
NCT02076295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00083054|Cholinergic Nicotinic Receptors and Cognition in PD|[18F]Flubatine: a Novel Biomarker of Cholinergic a4ß2 Nicotinic Receptors and Cognition in Parkinson's Disease|CHONI|University of Michigan|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Saliva samples to collect DNA|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Primary care clinic          -  Community sample|November 2015|November 30, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076295||49426|
NCT02076555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH022014_3|Diabetes and Social Issues: Evaluation of a Diabetes Education Module|A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic "Diabetes and Social Issues" in a Randomized Controlled Trial|PRIMO_Social|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076555||49406|
NCT02077101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/35|Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital|Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital : Multicentric Interventional Study Qualitative and Quantitative|RAVVIH|Hopital Foch|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|220|||Both|18 Years|75 Years|No|||January 2015|January 16, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02077101||49364|
NCT02077114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM1304|Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma|Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)||Herlev Hospital|Yes|Completed|February 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||September 2014|September 25, 2014|February 20, 2014||||No||https://clinicaltrials.gov/show/NCT02077114||49363|
NCT02077374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-06|A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases|NAFLD|Conatus Pharmaceuticals Inc.|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077374||49343|
NCT02077140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-01|A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy|A Phase II, Dose-escalating, Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetic Profile of MDT-10013 Versus Standard of Care in the Treatment of Acute Postoperative Pain Following Bunionectomy||Medtronic Spinal and Biologics|Yes|Active, not recruiting|February 2014|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077140||49361|
NCT02068651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11120861|A Community-based Advance Care Planning Programme for Patients With Advanced Disease|A Community-based Advance Care Planning Programme to Improve End-of-life Care in Patients With Advanced Disease: A Mixed-method Approach||Food and Health Bureau, Hong Kong|Yes|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02068651||50012|
NCT02068911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01629-36|Concordance Between ETCO2, PTCO2 and PaCO2 in the Home-ventilated Neuromuscular Patient|Validation of the Measure of ETCO2, Compared to PTCO2 and PaCO2 in the Home-ventilated Neuromuscular Patient|Capnovivo|Centre d'Investigation Clinique et Technologique 805|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|The patients will be recruited among the neuromuscular patients treated at the University        Hospital Raymond Pointcaré, Garches (France), during a routine follow-up hospitalization        for their home-ventilation.|February 2016|February 25, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02068911||49992|
NCT02076009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103663|A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma|Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma||Janssen Research & Development, LLC|Yes|Active, not recruiting|May 2014|September 2020|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|571|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076009||49448|
NCT02076022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050147|Amp 30: Autologous Fat Grafting, Amputation Sites Pain: Randomized|Adipose Stromal Cell Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites: A Single Center Site, Prospective, Randomized, Pilot Outcomes Trial|Amp 30|University of Pittsburgh|Yes|Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076022||49447|
NCT02076035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain-Omics Periduroscopy|Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.|A Prospective Study to Analyze, in a Population Undergoing to a Periduroscopy Approach, the Correlation Between Outcome of Procedure and Histological-biochemical Neuroinflammation and Genetic Factors||University of Parma|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|3 whole blood samples will be collected: before epiduroscopy, immediately after it and after      a month for genetic analyses and cytokine dosage. An epidural bioptic sample will be      performed according to usual clinical practice|Both|18 Years|75 Years|No|Non-Probability Sample|We will enroll a well phenotyped cohort of patients with chronic low back pain,        sub-grouped into categories: spinal stenosis (congenital or acquired) and failed back        surgery syndrome.|February 2014|December 30, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076035||49446|
NCT02065375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1307|RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery|A Multicenter, Randomized, Dose-Ranging, Double-Masked, Placebo-Controlled Phase 2 Study Evaluating the Safety and Efficacy of RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery||Reata Pharmaceuticals, Inc.|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065375||50261|
NCT02048943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 242513|Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer|A Phase Ib Study of Dovitinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors and Pancreatic Cancer||Roswell Park Cancer Institute|No|Withdrawn|March 2015|||November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 27, 2014|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02048943||51521|
NCT02074345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-816/OCT-002|Phase III Study of Intramuscular TAK-816 in Healthy Infants|A Phase III, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants||Takeda|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||June 2015|June 15, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074345||49576|
NCT02074358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-156|A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects|A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects||Bristol-Myers Squibb|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|February 26, 2014|No|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT02074358||49575|
NCT02074670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL003|fMRI In Spinal Cord Injury Patient After Rehabilitation|FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI) OF THE SENSORIMOTOR CORTEX IN SPINAL CORD INJURY PATIENT AFTER INTENSIVE REHABILITATION INCLUDING ROBOTIC DEVICES||University of Nove de Julho|No|Completed|February 2007|||February 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|15 Years|65 Years|No|||February 2014|February 25, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02074670||49551|
NCT02074371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-002-SJC|Postoperative Respiratory Depression After Cardiac Surgery|Perioperative Parameters to Predict Postoperative Respiratory Depression After Cardiac Surgery|CABG PRD|Universidade Castelo Branco|No|Completed|January 2012|November 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|N/A|No|Probability Sample|Patients with coronary artery disease submitted to elective CABG with CPB.|January 2016|January 12, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074371||49574|
NCT02066441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120195|Vitamin D's Effect on Physical Performance in the Elderly|The Effect of Vitamin D on Serum Vitamin D Levels, Bone Formation, Resorption, and Mineral Density, Inflammation, Flexibility, and Balance in the Elderly||University of Miami|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|101|||Both|55 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066441||50180|
NCT02066454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 1320|Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs|Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study|MYELAXAT|University Hospital, Grenoble|Yes|Recruiting|April 2014|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066454||50179|
NCT02074930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPrep|Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure|Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure||University of Zurich|Yes|Completed|February 2014|||April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02074930||49531|
NCT02074943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03126|Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia|Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia: A Double-Blind, Randomized, Placebo Controlled Trial||Vancouver General Hospital|Yes|Recruiting|April 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074943||49530|
NCT02075216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT1502231|Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy|Transurethral Autologous Myoblast Injection for Treatment of Urinary Incontinence in Children With Bladder Exstrophy||Al-Azhar University|Yes|Recruiting|December 2013|December 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|2 Years|10 Years|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075216||49509|
NCT02075749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393009|Comparing Triamcinolone Acetonide Mucoadhesive Films With Licorice Mucoadhesive Films|Comparison of Triamcinolone Acetonide Mucoadhesive Film With Liquorice Mucoadhesive Film On Radiotherapy-Induced Oral Mucositis: A Randomized Double-Blinded Clinical Trial||Isfahan University of Medical Sciences|Yes|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075749||49468|
NCT02076256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC102-2314-B-006-013-MY3|The Influence of Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With Chronic Kidney Disease: A Longitudinal Study|The Influence of Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With Chronic Kidney Disease: A Longitudinal Study||National Cheng Kung University|No|Recruiting|August 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 9, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02076256||49429|
NCT02076269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117178|Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison|Characterisation Of Very Severe Chronic Obstructive Pulmonary Disease Patients For Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry||GlaxoSmithKline|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|40 Years|N/A|No|||March 2014|March 6, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02076269||49428|
NCT02067546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-RY-244-CTIL|Innovative Toilet Seat Test for Patients With Symptoms of Constipation and/or Emptying Disorders|Innovative Toilet Seat Test for Patients With Symptoms of Constipation and/or Emptying Disorders|constipation|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2014|February 18, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067546||50097|
NCT02067819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012905|Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome|Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome||Weill Medical College of Cornell University||Recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|7 Years|25 Years|No|||December 2014|December 9, 2014|February 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02067819||50076|
NCT02068105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-209|A Study of ALKS 5461 in Healthy Volunteers|A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects||Alkermes, Inc.|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|104|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02068105||50054|
NCT02068404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK/PD_Nifedipine|Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour|Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Patients Hospitalized for Acute Threatened Preterm Labour||Centre Hospitalier Universitaire Vaudois|No|Recruiting|April 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068404||50031|
NCT02076828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HacettepeU|Comparison of Ferrous Sulfate, Polymaltose Complex and Iron-zinc in Iron Deficiency Anemia|Comparison of Ferrous Sulfate, Polymaltose Complex and Iron-zinc in Iron Deficiency Anemia||Hacettepe University|No|Completed|January 2008|December 2011|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|6 Months|180 Months|No|||February 2014|February 28, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076828||49385|
NCT02065128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005|The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome|The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome||St. Michael's Hospital, Toronto|No|Not yet recruiting|August 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ILS Patients|December 2015|December 23, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02065128||50280|
NCT02065388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-IRB01-100070|Pharmacogenetic Dosing of Warfarin|||Academia Sinica, Taiwan|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|20 Years|N/A|No|||February 2014|February 16, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02065388||50260|
NCT02065401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-112|Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)|A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose||Shire||Withdrawn|February 2014|March 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|February 10, 2014|No|Yes|This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|No||https://clinicaltrials.gov/show/NCT02065401||50259|
NCT02076347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0307|Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin|Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin||Ohio State University|No|Completed|February 2014|October 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|489|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076347||49422|
NCT02076360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013617|RCT: Impact of Preop Video on Patient Preparedness for Surgery|Impact of Preoperative Patient Education Video on Patient Preparedness After Sacrocolpopexy: A Single Blind Randomized Controlled Trial||University of South Florida|Yes|Recruiting|August 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|N/A|No|||June 2015|June 10, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02076360||49421|
NCT02065960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-699|Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer|Feasibility Study of the Role of Stereotactic Body Radiotherapy for the Treatment of Early Stage Breast Cancer|ARTEMIS|Juravinski Cancer Center|Yes|Recruiting|February 2014|June 2020|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|70 Years|N/A|No|||March 2015|March 30, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065960||50216|
NCT02048696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1509|Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction|Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction: The EXercise Interval Training - V Study|EXIT-V|Montreal Heart Institute|Yes|Recruiting|February 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02048696||51539|
NCT02048956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0049UG|Hydrotherapy Intervention in Elderly With Knee Osteoarthritis|8-weeks Hydrotherapy Intervention in Patients With Knee Osteoarthritis.||Universidad de Granada|Yes|Recruiting|January 2014|November 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||December 2014|December 9, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048956||51520|
NCT02074124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-067|CT Perfusion Changes in GI Cancer During Adenosine Vasodilation Test|Abdominal Tissue Perfusion Changes in Esophageal and Gastric Cancer During Adenosine Vasodilation Measured With Computed Tomography (CT) Perfusion||University of Copenhagen|No|Completed|October 2012|December 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with biopsy proven tumors in esophagus or stomach|February 2014|February 26, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02074124||49593|
NCT02074137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZL06499|Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer|Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen||Sanofi|No|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02074137||49592|
NCT02074384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04356-14-A|Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)|Understanding Patient and Provider Glucose Reporting Preferences in Type 1 Diabetes: Cloud Based Ambulatory Glucose Profile (AGP)||HealthPartners Institute|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|161|||Both|7 Years|N/A|No|||October 2015|November 30, 2015|February 25, 2014||No||No|September 10, 2015|https://clinicaltrials.gov/show/NCT02074384||49573|This is a survey of patient and clinician preference and as such is subject to traditional survey biases (social desirability, hawthorne effect, etc.).
NCT02074956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C 006 404|A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as Different IC31 Adjuvant Amounts With Different AERAS-404 (HyVac4) Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection||Aeras|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02074956||49529|
NCT02066428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-005-404|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection||Aeras|Yes|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066428||50181|
NCT02075450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23697|Improving the Quality of Cardiopulmonary Resuscitation (CPR) During Pediatric Cardiac Arrest|Assessing and Improving the Quality of Cardiopulmonary Resuscitation (CPR) Delivered During Simulated Pediatric Cardiac Arrest Using a Novel Pediatric CPR Feedback Device|QCPR|Express Collaborative|Yes|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|4||Actual|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075450||49491|
NCT02075970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013EPO|Optimized Erythropoietin (EPO) Treatment|Optimized EPO Treatment of Neonatal Anemia|OETNA|University of Iowa|Yes|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|62|||Both|N/A|2 Days|No|||June 2015|June 15, 2015|May 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075970||49451|
NCT02068118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01672-41|Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology|OSICAT : Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology|OSICAT|Alere E-Sante|No|Recruiting|May 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|870|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068118||50053|
NCT02068131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-RC-006|Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer|Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capatabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Recruiting|February 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|January 4, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068131||50052|
NCT02068430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD2184|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection||Columbia University|No|Recruiting|November 2008|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|November 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068430||50029|
NCT02068664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-802-13|An Assessment of the Prevalence of Spatial Neglect in Stroke Survivors With Aphasia|An Assessment of the Prevalence of Spatial Neglect in Stroke Survivors With Aphasia With Option of Prism Adaptation Treatment (PAT) Protocol||Kessler Foundation|Yes|Active, not recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02068664||50011|
NCT02068924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0181|Vitrification and Slow Freezing for Cryopreservation of Blastocyst|Single Embryo Transfer: Comparison of Slow Freezing and Vitrification at Blastocyst Stage||University Hospital, Clermont-Ferrand||Recruiting|February 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||February 2014|February 21, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02068924||49991|
NCT02068417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU10/002|Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT)|A Prospective, Randomised, Blinded, Placebo-controlled Pilot Study of the Treatment of Erectile Dysfunction With Extracorporeal Shockwave Therapy (ESWT)||Storz Medical AG|Yes|Terminated|October 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|75 Years|No|||March 2015|March 5, 2015|February 19, 2014||No|It has been decided to improve the inclusion criteria for better study outcome|No||https://clinicaltrials.gov/show/NCT02068417||50030|
NCT02075801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-ODO-0207|10-years Clinical Trial of Sealed of Margin Failures|Longitudinal Results of a 10-years Clinical Trial of Sealed Margin Failures of Amalgam Restorations|Sealant|University of Chile|Yes|Completed|August 2003|February 2014|Actual|February 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients of the Operative Dentistry Clinics, School of Dentistry, University of Chile|February 2014|February 27, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02075801|10 Years|49464|
NCT02076048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCPUFA Supplementation|LCPUFA Supplementation: A Multi-Modality Imaging Study|LCPUFA Supplementation: A Multi-Modality Imaging Study||University of Kansas Medical Center|No|Completed|July 2013|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|Samples With DNA|cheek swab|Both|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who were originally enrolled as infants will be invited to participate in the        longitudinal follow up study.|October 2015|October 6, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076048||49445|
NCT02076061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOL 001|Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study|Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases in Smokers/Ex-Smokers Attending Primary Care - Longitudinal Study||Lund University|No|Recruiting|February 2014|||February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|300|||Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic in Malmö, Sweden|March 2016|March 14, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076061||49444|
NCT02076906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU3917|MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors|Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors||Children's Research Institute|No|Recruiting|April 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|21 Years|No|||August 2015|August 5, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076906||49379|
NCT02077530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS in KUMC|Metabolic Syndrome Cohort in Korea|||Korea University Anam Hospital||Active, not recruiting|November 2013|||November 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|30 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Patients with metabolic syndrome living in Seoul area|February 2016|February 23, 2016|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077530|10 Years|49331|
NCT02076334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3101|Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise|Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise||University of North Carolina, Chapel Hill|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|81|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076334||49423|
NCT02079844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-SCHZ_106|Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia||Takeda|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|No|||July 2015|July 16, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02079844||49153|
NCT02049320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00478|Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)|||Nationwide Children's Hospital|No|Enrolling by invitation|July 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients suffering a traumatic brain injury who were sedated in the PICU using        remifentanil.|March 2016|March 16, 2016|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02049320||51492|
NCT02065947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MURA 09-56-23|Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy|Three-level Injection Paravertebral Block Using Paravertebral Catheter Compared to General Anesthesia in Mastectomy Surgery||Ramathibodi Hospital|Yes|Completed|October 2013|||March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02065947||50217|
NCT02066753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTH48AG|The Cardiac Effects of Prolonged Hypothermia After Cardiac Arrest|The Cardiac Effects of Prolonged Hypothermia After Cardiac Arrest||University of Aarhus|No|Completed|February 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||November 2015|November 24, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066753||50156|
NCT02066766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4069|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam|DiabCare Asia|Novo Nordisk A/S|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1647|||Both|18 Years|N/A|No|Non-Probability Sample|People having been treated for at least a year are eligible for the study. The selection        of the patients will be done randomly by the individual physician involved in the study.|September 2015|September 10, 2015|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02066766||50155|
NCT02077478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15022014|Total Intravenous Anesthesia: TCI Versus MCI|Total Intravenous Anesthesia: TCI Versus MCI, Unresolved Question||Università degli Studi di Ferrara|Yes|Completed|March 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||September 2014|September 4, 2014|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077478||49335|
NCT02067039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-eSTAMP-41989|Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)|Evaluation of Rapid HIV Self-testing Among MSM in High Prevalence Cities||Centers for Disease Control and Prevention|No|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|3200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 20, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067039||50136|
NCT02077972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1216-7558|Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)|Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)|PTSD + WBH|University of Arizona|No|Terminated|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|February 28, 2014||No|Investigator transferred to the University of Wisconsin - Madison|No||https://clinicaltrials.gov/show/NCT02077972||49297|
NCT02073578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0240|Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|POEM|Ohio State University|No|Completed|August 2012|December 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||September 2015|September 22, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073578||49635|
NCT02066727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW002|Lidocaine Combined Dexmedetomidine for Obturator Nerve Block|Effects of Dexmedetomidine as an Adjuvant on the Median Effective Concentration of Lidocaine for Obturator Nerve Block — A Perspective, Randomized，Blind Study|ONB|Tianjin Medical University General Hospital||Completed|February 2014|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||December 2014|December 11, 2014|February 17, 2014|Yes|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT02066727||50158|
NCT02066740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1007|EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study|EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study||Medtronic Endovascular|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|February 16, 2014|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT02066740||50157|
NCT02075762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00083791|Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease|Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease||Johns Hopkins University|No|Recruiting|August 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|16|||Both|18 Years|99 Years|No|||February 2016|February 4, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02075762||49467|
NCT02074423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-026|A Human Clinical Trial Evaluating the Effect of MealShape™ on Blood Glucose Level Following Consumption of Standard Meal|A Randomized, Controlled, Double-blind, Cross-over Clinical Trial, Evaluating the Effect of MealShape™ on the Postprandial Glycemia After Eating Standard Food, in Healthy Volunteers.||Dialpha|Yes|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074423||49570|
NCT02074436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066504|PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)|Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies|PROBLEMA|Emory University|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||March 2016|March 13, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074436||49569|
NCT02074709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072013-080|TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management|Transversus Abdominis Plane (TAP) Block With Bupivacaine Versus Wound Infiltration With Liposomal Bupivacaine (Exparel) for Postoperative Pain Management After Open Total Abdominal Hysterectomy: a Prospective Randomized Controlled Trial||University of Texas Southwestern Medical Center|Yes|Completed|January 2014|February 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|May 26, 2015|February 26, 2014|Yes|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT02074709||49548|
NCT02074722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312M46727|Brain-Computer Interface and Mind-Body Awareness Training|Brain-Computer Interface and Mind-Body Awareness Training||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Healthy population in Minneapolis area|May 2015|May 26, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02074722||49547|
NCT02075008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031B2201E1|Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201|An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201||Novartis|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|76 Years|No|||March 2016|March 20, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075008||49525|
NCT02075268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAS-AM|Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers|An Open Label, Single Dose Study to Characterize the Pharmacokinetics and Pharmacodynamics of Prasugrel in Healthy Male Adult Subjects|PRAS-AM|Asan Medical Center|No|Recruiting|January 2014|February 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075268||49505|
NCT02069236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU 1302|Comparing G6PD Tests Using Capillary Blood Versus Venous Blood|Correlation of G6PD Activity Across Different Sample Sources, and Different G6PD Testing Platforms||PATH|No|Completed|February 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|August 18, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02069236||49967|
NCT02075814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1021-C1063|A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects|A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects||Human Genome Sciences Inc.|Yes|Completed|March 2008|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|322|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 27, 2014|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075814||49463|
NCT02076646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2DTIC-04-12|A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma|A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma||Philogen S.p.A.|No|Recruiting|October 2013|August 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||October 2014|October 20, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076646||49399|
NCT02076620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19TNFDOXO-01/12|L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours|Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours||Philogen S.p.A.|No|Recruiting|January 2013|February 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2014|October 20, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076620||49401|
NCT02076633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2TNF-02/12|Intratumoral Administration of L19IL2/L19TNF|A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions||Philogen S.p.A.|No|Completed|December 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2014|May 25, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076633||49400|
NCT02065635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-Artemis|Effect of Type of General Anesthesia Maintenance on Exhaled Nitric Oxide and Eosinophil Blood Count|Investigation of Changes in the Levels of Exhaled NO and Eosinophil Blood Count in Patients Undergoing Thyroidectomy by Two Different Methods of General Anesthesia Maintenance||Aretaieion University Hospital|Yes|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02065635||50241|
NCT02065934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI/2013/116|Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation|Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation|SIMACRIS|Centre Hospitalier Universitaire de Besancon|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Team members|July 2015|July 7, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065934||50218|
NCT02066467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rally X4-10-2013|Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study|Maximizing CRT Delivery by Using Multipolar Coronary Sinus Lead Family ACUITY® X4|RallyX4|Guidant Corporation|No|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|The BSC Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for        subjects with art failure who receive stable optimal pharmacologic therapy (OPT) for heart        failure and who meet any one of the following classifications:          -  Moderate to severe heart failure (New York Heart Association (NYHA) Class III-IV)             with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms          -  Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA             Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I)             ischemic heart failure BSCCRT-Ds are also intended to provide ventricular             antitachycardia pacing and ventricular defibrillation for automated treatment of             life-threatening ventricular arrhythmias.|June 2015|August 6, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02066467|12 Months|50178|
NCT02066155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PAF00455 PAF|Ongoing Diabetes Self-Management Support in Church-Based Settings|Ongoing Diabetes Self-Management Support in Church-Based Settings||University of Michigan|Yes|Not yet recruiting|January 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|21 Years|N/A|No|||December 2014|December 2, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02066155||50201|
NCT02077491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-013|The Effect of Protein and Resistance Training on Muscle Mass in Acutely Ill Old Medical Patients|The Effect of Protein and Resistance Training on Muscle Mass, Muscle Strength and Functional Ability in Acutely Ill Old Medical Patients; a Randomized Controlled Trial||Hvidovre University Hospital|Yes|Completed|April 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Both|65 Years|N/A|No|||May 2014|May 29, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02077491||49334|
NCT02073916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0813-0139|TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer|Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients|STELA|The Methodist Hospital System|No|Recruiting|October 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073916||49609|
NCT02077712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China4|Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children|A Randomised Comparison of Two Intranasal Dexmedetomidine Doses for Ophthalmic Examination Following Failed Chloral Hydrate Sedation in Children|DEX-EYE|Sun Yat-sen University|Yes|Recruiting|February 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|2 Months|6 Years|No|||May 2015|May 4, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077712||49317|
NCT02077725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0067|Measuring the Impact of an Interdisciplinary Polypharmacy Clinic Within a Patient-centered Medical Home|Measure the Impact of an Interdisciplinary Polypharmacy Clinic Within a Patient-entered Medical Home||Ohio State University|No|Recruiting|December 2013|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients within the general internal medicine patient-centered medical homes of The Ohio        State University Division of General Internal Medicine|October 2014|October 21, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077725||49316|
NCT02073591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYP2013/001|Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen|A Phase IV, Open Label, Single Arm, Multicenter, Observational Study to Evaluate the Correlation Between PEST and SCORAD Score in the Management of Atopic Dermatitis With Use of Ceradan® Regimen in Children Aged Six Months to Six Years|COPES|Hyphens Pharma Pte Ltd|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|58|||Both|6 Months|6 Years|No|Probability Sample|Children Aged Six Months to Six Years with Atopic Dermatitis|November 2015|November 4, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02073591||49634|
NCT02067026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFIS-13-001|Measuring the Impact of Dietary Supplementation With a High Fiber, High Antioxidant Aleurone on Biomarkers of Cardiovascular Disease and Gut Microbiota in Adults With High Body Mass Index|Measuring the Impact of Dietary Supplementation With a High Fiber, High Antioxidant Aleurone on Biomarkers of Cardiovascular Disease and Gut Microbiota in Adults With High Body Mass Index||Fondazione Edmund Mach|No|Completed|January 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02067026||50137|
NCT02067832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02890|Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease|Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease|ABLE-cGVHD|University of British Columbia|No|Recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|From recipient: whole blood From donor: bone marrow or apheresis product|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recipients and donors of allogeneic hematopoietic stem cell transplantation|December 2015|December 10, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02067832||50075|
NCT02074735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072012-088|Citicoline for Alcohol Dependence|Citicoline for Alcohol Dependence||University of Texas Southwestern Medical Center|Yes|Recruiting|April 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|75 Years|No|||November 2015|November 2, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074735||49546|
NCT02075034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-10|Three Dosing Schedules of Oral Rigosertib in MDS Patients|A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System||Onconova Therapeutics, Inc.|No|Suspended|May 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|February 27, 2014|No|Yes|Study suspended before enrollment and treatment of any patients; study potentially will resume    after evaluation of results from other studies|No||https://clinicaltrials.gov/show/NCT02075034||49523|
NCT02075047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281198|Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder|A Phase 3, Multicenter, Four Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)||Pfizer|Yes|Recruiting|May 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|10 Years|17 Years|No|||March 2016|March 16, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075047||49522|
NCT02075021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02519|Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma|rev/abraxane|New York University School of Medicine|Yes|Terminated|March 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 27, 2014|No|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT02075021||49524|
NCT02075281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-205|Effect of LAPS-Exendin on Body Weight in Obese Population|A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes||Hanmi Pharmaceutical Company Limited|No|Completed|February 2014|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|297|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075281||49504|
NCT02075489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH1210567|Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans|Effectiveness of Acupressure Treatment in Pain Management and Fatigue Relief for Gulf War Veterans||The Cleveland Clinic|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075489||49488|
NCT02076373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpoRepair|Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants|Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study|EpoRepair|University of Zurich|Yes|Recruiting|March 2014|December 2021|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|24 Weeks|31 Weeks|No|||December 2014|December 19, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076373||49420|
NCT02077556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312011MINA|Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients|Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients: Using Mycophenolate Mofetil as a Control||National Taiwan University Hospital|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|65 Years|No|||January 2016|January 24, 2016|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077556||49329|
NCT02077218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13385|Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant|Assessment of Coronary Artery Disease in Asymptomatic Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT): A Pilot Feasibility Study||City of Hope Medical Center|Yes|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|45 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 17, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077218||49355|
NCT02077231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlaucomaVitaminA|Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients|||Shanghai Jinshan Hospital||Completed|September 2011|September 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02077231||49354|
NCT02077244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1715|Follow up After Intensive Care. The FUTstudy|A Randomized Controlled Trial to Evaluate the Effect of Nurse Led Follow up After Being a Patient in the Intensive Care Unit.|FUT|Oslo University Hospital|No|Recruiting|March 2014|June 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077244||49353|
NCT02049008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/13260-8 FAPESP|Treatment of Aggressive Periodontitis With Repeated Adjunctive Antimicrobial Photodynamic Therapy|Clinical, Microbiological and Immunological Effects of Antimicrobial Photodynamic Therapy on Non-surgical Treatment of Aggressive Periodontitis: a Double-blind Split-mouth Randomized Controlled Clinical Trial.||University of Sao Paulo|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|35 Years|No|||April 2014|April 2, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02049008||51516|
NCT02066181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00264|Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis|A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)||National Cancer Institute (NCI)|No|Suspended|March 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|83|||Both|18 Years|N/A|No|||February 2016|March 23, 2016|February 17, 2014|Yes|Yes|Other - Nearing accrual goal|No||https://clinicaltrials.gov/show/NCT02066181||50200|
NCT02076607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314151|Thoracic And Lumbar Burst Fracture: Correlation Between Structural Changes And Clinical Outcome Of Treatment|Thoracic And Lumbar Burst Fracture: Correlation Between Structural Changes And Clinical Outcome Of Treatment||Hospital Ortopedico de Passo Fundo|No|Completed|March 2013|July 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|25|||Both|22 Years|69 Years|No|Probability Sample|Surgical treatment Group: 14 samples Conservative Treatment Group: 11 samples|February 2014|February 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076607||49402|
NCT02076880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9016|SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients|Investigation of Endocrin-metabolic Modifications Related to Diabetes Improvement After Sleeve Gastrectomy in Severly Obese|SLEEVEDIAB|University Hospital, Montpellier|No|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|14|||Both|18 Years|65 Years|No|||September 2013|December 2, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02076880||49381|
NCT02077179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGY-249-14|Health Improvement After Pregnancy (HIP) Program Randomized Control Trial|Health Improvement After Pregnancy (HIP) Program Randomized Control Trial|HIP|Queen's University|No|Active, not recruiting|September 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Female|N/A|N/A|No|||October 2015|October 14, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02077179||49358|
NCT02077192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-049|Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura||Rigel Pharmaceuticals|No|Recruiting|July 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077192||49357|
NCT02073929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr 2013-003862-15|LIPT - Liraglutide in Polycystic Ovary Syndrome|A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.|LIPT|Herlev Hospital|Yes|Completed|March 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|60 Years|No|||June 2015|March 3, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073929||49608|
NCT02074774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-NIAE2014001Reg|Aeolus vs Manual Control for Optimizing Oxygenation in Infants|||Vapotherm, Inc.||Not yet recruiting|June 2014|||September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|N/A|No|||February 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074774||49543|
NCT02077738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10216|HFCWO in Prolonged Mechanical Ventilation Patients|High-frequency Chest Wall Oscillation in Prolonged Mechanical Ventilation Patients-a Randomized Controlled Trial||Taichung Veterans General Hospital|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|N/A|No|||March 2014|March 2, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02077738||49315|
NCT02073565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-0601|HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt|Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome|HARMONEE|OrbusNeich|Yes|Recruiting|February 2014|November 2020|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|572|||Both|20 Years|N/A|No|||July 2015|July 27, 2015|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073565||49636|
NCT02067299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103409|A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants|A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants||Janssen Research & Development, LLC|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|64 Years|No|||February 2016|February 3, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02067299||50116|
NCT02067312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152|Effects of Traditional Thai Massage on Pain and Pain Related Parameters in Patients With Upper Back Pain|Effects of Traditional Thai Massage on Pain and Pain Related Parameters in Patients With Upper Back Pain||Mae Fah Luang University Hospital|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|40 Years|No|||May 2015|May 5, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02067312||50115|
NCT02074163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTNS088800|ASIS for Botox in Chronic Migraine|ASIS for Botox in Chronic Migraine|ASISinCM|ASIS Corporation|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|19||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074163||49590|
NCT02075294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YNKT201313|Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B|Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B||Beijing 302 Hospital|Yes|Completed|January 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|242|||Both|18 Years|N/A|No|Probability Sample|We retrospectively analyzed a consecutive cohort of chronic hepatitis B patients treated        with ADV, 10mg, daily, or with ETV，0.5mg，daily between January 2010 and December 2013 in a        single tererral referral hospital in Beijing. Data were retrieved from a prospectively        maintined database.|October 2014|October 26, 2014|February 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075294||49503|
NCT02075528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPP-2009-OLS|Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER|Early Prediction of Clinical Response, Metabolic Change, and Pharmacokinetics in Taiwanese Patients With Schizophrenia Patients Treated by Paliperidone ER: an Open-Label Study||Taipei City Hospital|Yes|Completed|July 2009|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|65 Years|No|||February 2014|February 27, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02075528||49485|
NCT02075502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mays-1|Community Walking Exercise for Patients With Peripheral Artery Disease|A Community-based Exercise Program to Improve Walking Outcomes in Patients With Peripheral Artery Disease|GAIT|International Heart Institute of Montana Foundation|No|Recruiting|February 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Anticipated|134|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02075502||49487|
NCT02075515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117177|Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age|Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older||GlaxoSmithKline||Active, not recruiting|August 2014|May 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|651|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|February 18, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075515||49486|
NCT02076919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-007|First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration|A Randomized, Double-Masked, Vehicle-Controlled, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Topically Delivered LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration||Alcon Research|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|110|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|February 28, 2014|Yes|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT02076919||49378|
NCT02076932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWS menopause, adipose tissue|Effects of Physical Training on Adipose Tissue Metabolism and Insulin Sensitivity in the Menopausal Transition Phase|A Training Intervention Study in Late Pre- and Early Postmenopausal Women Investigating the Changes in Adipose Tissue Metabolism and Peripheral Insulin Sensitivity||University of Copenhagen|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Female|45 Years|57 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076932||49377|
NCT02076971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUN-CMV-2013-01|Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive|A Multicenter Prospective Observational Study to Evaluate Cytomegalovirus (CMV)-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients With CMV-positive Serology (R+) Prior to Transplant and Its Involvement in the Development of CMV Infection|REIVI|Fundacio Catalana de Pneumologia|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|84|None Retained|Whole blood|Both|18 Years|N/A|No|Probability Sample|CMV-positive (R+) lung transplant patients|February 2016|February 18, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076971||49374|
NCT02077270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-9733-DC-CTIL|Pretreatment With Electroacupuncture to Reduce Discomfort|Pretreatment With Electroacupuncture to Reduce Discomfort||Sheba Medical Center|No|Not yet recruiting|January 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02077270||49351|
NCT02073669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0668-DS-CTIL|Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults|Better Identification of Latent Tuberculosis Infection Among Israeli Young Adults by Comparison Skin Tests and Interferon Gamma Releasing Assays (IGRA)||Sheba Medical Center|No|Not yet recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073669||49628|
NCT02073682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-D-U311|Cancer Venous Thromboembolism (VTE)|||Daiichi Sankyo Inc.|Yes|Recruiting|March 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073682||49627|
NCT02049021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT Schizo|Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia|Pilot Double Blind, Placebo Controlled and Randomized Study to Assess Electroconvulsive Therapy Efficacy as Augmenting Strategy to Clozapine in Super-refractory Schizophrenia|SSURECT|University of Sao Paulo|Yes|Recruiting|February 2010|||January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||January 2014|January 27, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02049021||51515|
NCT02077205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no funding|Manualised Cognitive Behavioral Therapy of Anxiety Disorders in Children and Adolescents in Routine Care Setting|||Ruhr University of Bochum|No|Recruiting|January 2012|December 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|4 Years|18 Years|No|||February 2014|February 28, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02077205||49356|
NCT02077504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONDUCTOME|Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"|Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature|CONDUCTOME|University Hospital, Grenoble|No|Recruiting|September 2013|August 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|28|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02077504||49333|
NCT02077517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBES-001|Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial|Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial|STAVHAS|Hospital Universitario Virgen de la Arrixaca|Yes|Recruiting|January 2007|||January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||March 2014|March 2, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02077517||49332|
NCT02077751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212345|BioRBC Survival in Adults With Prior Antibody Response to BioRBCs|BioRBC Survival in Adults With Prior Antibody Response to BioRBCs||University of Iowa|Yes|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077751||49314|
NCT02077764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sagsnr. 1-10-72-153-13|The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.|The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.||Aarhus University Hospital Skejby|Yes|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples Without DNA|At each visit blood samples are taken. These will include:      1 x 10 ml EDTA-blood      1 x 10 ml Lithiumheparin-blood      1 x 10ml Koagel -blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Design: A cross sectional study consisting of 50 stabile HTX patients. These will be        selected with 25 patients with no or light CAV and 25 patients with moderate or severe        CAV. 25 matched controls.|May 2015|May 18, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077764|5 Years|49313|
NCT02073604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-16|Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm|Rôle de la SMA Dans la préparation Des Mouvements Uni et Bi-manuels: le Paradigme Des Mouvements en Miroir|MOMIC2|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|15 Years|82 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02073604||49633|
NCT02073617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00804|Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography|Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography||New York University School of Medicine|Yes|Recruiting|January 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|23|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02073617||49632|
NCT02073955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D43TW008660-02|Validation of a Community Worker Administered Stroke Symptom Questionnaire|Adaptation and Validation of a Community Worker Administered Stroke Symptom Questionnaire in a Peri-urban Pakistani Community||Aga Khan University|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|322|||Both|40 Years|N/A|No|Non-Probability Sample|Adults (above 40 years of age) residing in Ibrahim Hyderi and willing to participate in        the all components of the study|February 2014|February 27, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073955||49606|
NCT02075060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPOI vs IPOP|Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer||IPOI vs IPOP|Poitiers University Hospital|Yes|Recruiting|February 2014|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075060||49521|
NCT02074176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008049R|Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder|Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Active, not recruiting|January 2011|||December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|mRNA,pre-pro-orexin gene|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects in this study will be recruited from Children's Mental Health Center, Department        of Psychiatry, National Taiwan University Hospital (NTUH). The sample will consist of 50        ADHD probands and 50 age- and sex- matched controls.|February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074176||49589|
NCT02074462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCZ-13O30|Effect of Inflammation on Voriconazole Concentration|Managing Voriconazole Exposure During Severe Infection; Effect of Inflammation on Voriconazole Metabolic Ratio||University Medical Center Groningen|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples With DNA|Whole blood, serum|Both|18 Years|N/A|No|Probability Sample|All patients admitted to the University Medical Center Groningen who receive voriconazole|August 2014|August 13, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02074462||49567|
NCT02073890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE 1021/14|Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage|Incidence and Outcomes of Traumatic Subarachnoid Haemorrhage Patients: A Cross Sectional Study||Macmillan Research Group UK|Yes|Completed|September 2012|June 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|117|||Both|N/A|N/A|No|Probability Sample|traumatic subarachnoid haemorrhage|February 2014|February 25, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02073890||49611|
NCT02074449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS|Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)|Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil|ISS|University of Arizona|No|Recruiting|December 2012|||December 2014|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Pulmonary Arterial Hypertension|February 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074449||49568|
NCT02075827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL0326011|Metabolic Response to Playing Video Games: Two Arm Trial|Metabolic Response to Playing Video Games: Two Arm Trial||University College, London|No|Recruiting|February 2014|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02075827||49462|
NCT02075840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO28984|ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants|Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer||Hoffmann-La Roche||Active, not recruiting|August 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075840||49461|
NCT02076087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02113|Immune Characterization of Subcutaneous Adipose Tissue|Immune Characterization of Subcutaneous Adipose Tissue|ATI|Washington University School of Medicine|Yes|Recruiting|February 2014|August 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|75|Samples With DNA|Serum and plasma samples will be obtained Abdominal and thigh subcutaneous adipose tissue      obtained during surgery|Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 women already scheduled to undergo liposcution/lipectomy procedure for breast        reconstruction associated with prophylactic mastectomy or mastectomy for in situ ductal        breast corcinoma, cosmetic surgery, or abdominal lipectomy for severe obesity at either        Barnes-Jewish Hospital or Barnes-Jewish West County Hospital. Subjects of all races and        ethnicity, with a body mass index (BMI) greater than or equal to 18.5 kg/m2 and between        the ages of 18 and 65 years of age will be included in the study.|March 2016|March 1, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076087||49442|
NCT02076100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8408-003|Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Participants With Hepatitis C Infection (MK-8408-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection||Merck Sharp & Dohme Corp.|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|February 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02076100||49441|
NCT02076386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201067|A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany|A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)|DOL-ART|ViiV Healthcare|No|Active, not recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|411|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 40 HIV treatment centers in Germany are planned to be involved in the        documentation. The participating study site will document a maximum of 20 patients for        this observation study. Overall, approximately 400 patients under dolutegravir-containing        ART are to be documented. This selection process is intended to achieve the documentation        of patients under dolutegravir-containing ART in routine daily practice representative for        Germany.|February 2016|February 18, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02076386||49419|
NCT02076074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401160|Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer|Evaluation of Single Fraction High-Gradient Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-Risk Stage 0 and I Breast Carcinoma||Washington University School of Medicine|No|Recruiting|April 2014|April 2027|Anticipated|April 2022|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|50 Years|N/A|No|||February 2016|February 29, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076074||49443|
NCT02077257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSE|LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients|A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes||Committee of Cardio-Cerebral-Vascular Diseases of GSC|No|Recruiting|March 2014|May 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1060|||Both|18 Years|80 Years|No|||November 2014|November 6, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077257||49352|
NCT02076984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11041974|Titanium vs Absorbable Tacks for Mesh Fixation in Laparoscopic Incisional and Ventral Hernia Repair|LAPAROSCOPIC VENTRAL HERNIA REPAIR BY LIGHTWEIGHT POLYPROPYLENE MESH. A PROSPECTIVE ITALIAN MULTICENTRIC RANDOMIZED STUDY COMPARING TWO FIXATION DEVICES: TITANIUM SPIRAL TACKS vs ABSORBABLE TACKS||University of Roma La Sapienza|No|Recruiting|June 2014|December 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2015|May 29, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076984||49373|
NCT02077569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12076|AKT Inhibitor in Oestrogen Positive Breast Cancer|The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study|STAKT|University of Nottingham|Yes|Recruiting|January 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|4||Anticipated|150|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02077569||49328|
NCT02049385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140041|Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in People With Major Depressive Disorder|A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|24|||Both|18 Years|65 Years|No|||June 2015|November 26, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049385||51487|
NCT02073630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-45|Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia|Contribution du Cervelet Dans l'Adaptation Sensori-motrice Via Les Oscillations Gamma : le Cas de la Dystonie|GAMMA|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02073630||49631|
NCT02073942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-050|Cologne Register of Wearable Defibrillator (CRWD)|||University of Cologne||Recruiting|February 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with an indication for wearable defibrillator|December 2015|December 10, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073942|1 Month|49607|
NCT02074189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012XLC02-1|Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer|Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer||Southwest Hospital, China|Yes|Enrolling by invitation|March 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074189||49588|
NCT02074488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG045661-01|Balancing Act: Impact on Falls in Older Adults With Vision Impairment|Balancing Act: Impact on Falls in Older Adults With Vision Impairment||University of Maine|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|62 Years|N/A|No|||December 2015|December 1, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074488||49565|
NCT02074761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 007-002|Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System|Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System||Zyga Technology, Inc.|No|Recruiting|January 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the Investigator's standard patient population diagnosed        with SIJ pain and representing candidates' for SIJ fusion.|March 2016|March 10, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074761||49544|
NCT02074800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015271|A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants|A Phase 1, Randomized Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Subjects||Centocor, Inc.|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|February 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02074800||49541|
NCT02074813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMI II (RB 13.124)|Inspiratory Muscle Training During Pulmonary Rehabilitation in COPD|Effects of Inspiratory Muscle Training (IMT) on Dyspnea in COPD During Pulmonary Rehabilitation: Randomized Controlled Trial|EMI II|University Hospital, Brest|No|Recruiting|March 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02074813||49540|
NCT02074501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44/2013|Intervention in Informal Caregivers Who Care Older People After a Stroke: a Pilot Study in Northern Portugal|Supporting Older People's Informal CAREgivers at Home Through InCARE Programme|InCARE|University of Minho|Yes|Enrolling by invitation|January 2014|October 2014|Anticipated|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|1||Actual|158|||Both|65 Years|N/A|No|||February 2014|February 26, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02074501||49564|
NCT02075307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-033|Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage|Highbush Blueberries, the DNA-damage of Obesity, Somatic Mutations and Metabolic Syndrome||Children's Hospital & Research Center Oakland|No|Enrolling by invitation|January 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|60 Years|No|||August 2014|August 22, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075307||49502|
NCT02073903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-042|The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC|The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2014|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073903||49610|
NCT02074748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|foot fluoro|Measurement of Arch Motion After Bunion Surgery|First Ray Kinematics Following Lapidus Bunion Surgery: A Fluoroscopic Gait Study||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|February 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients having bunion will be recruited from the surgical practice of the Co-I. The        surgeon will screen the patients, and invite those to participate identified as having an        unstable arch as a complication of bunion deformity.        Controls will be recruited from the community, group matched for age. Controls must have        normal foot posture and display no evidence of an unstable arch.|September 2014|September 4, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02074748||49545|
NCT02075567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExT1DM|Exercise in Type 1 Diabetes Mellitus|Exercise and Blood Glucose Levels in Patients With Type I Diabetes - a Pilot Study|ExT1DM|Medical University of Graz|Yes|Completed|January 2014|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|7|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02075567||49482|
NCT02075580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-PORT|Totally Implantable Venous Access Devices: Quality of Life and Body Image|Totally Implantable Venous Access Devices (TIVAD): Impact on Quality of Life and Body Image|BI-PORT|Istituto Oncologico Veneto IRCCS|No|Recruiting|September 2013|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|80 Years|No|||February 2016|February 29, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02075580||49481|
NCT02076399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-047|A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura|FIT|Rigel Pharmaceuticals|Yes|Active, not recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076399||49418|
NCT02076412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-048|A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura|FIT|Rigel Pharmaceuticals|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076412||49417|
NCT02076672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-ABOCA1|Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population|Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (The ABOCA Phase II Trial)|ABOCA1|Ontario Clinical Oncology Group (OCOG)|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076672||49397|
NCT02076659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F8IL10-02/08|Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients|A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis||Philogen S.p.A.|No|Recruiting|September 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|75 Years|No|||February 2014|October 17, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076659||49398|
NCT02076945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-40/14|Characteristics of Popliteal Sciatic Nerve Block in Patients With and Without Diabetic Neuropathy|||Centre Hospitalier Universitaire Vaudois|No|Recruiting|February 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|85 Years|No|||August 2015|August 4, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076945||49376|
NCT02076685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805015M|NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis|The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis||National Taiwan University Hospital|No|Recruiting|November 2007|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT02076685||49396|
NCT02076698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1317 FRANCE|Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy|Clinical and Medico-economical Assessment of Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for the Treatment of Pharmacoresistant Partial Epilepsy|FRANCE|University Hospital, Grenoble|Yes|Recruiting|March 2014|December 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|16 Years|60 Years|No|||December 2015|December 2, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02076698||49395|
NCT02076997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33119|Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate|Individualized High Dose Methotrexate for the Treatment of Malignancies in Children and Adolescents With a Significant Risk for Methotrexate Toxicities||Baylor College of Medicine|Yes|Recruiting|December 2013|June 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|22 Years|No|||December 2015|December 15, 2015|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02076997||49372|
NCT02077010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131273|Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population Awaiting Cardiac Transplantation|Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population Awaiting Cardiac Transplantation: A Randomized Controlled Trial|iMilrinone|Vanderbilt University|No|Suspended|July 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|February 25, 2014|Yes|Yes|Drug reformulation|No||https://clinicaltrials.gov/show/NCT02077010||49371|
NCT02077283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-KYKS-7-01|Urinary Metabonomics of Two Major Patterns of NAFLD|Urinary Metabonomics of Two Major Patterns of NAFLD||ShuGuang Hospital|Yes|Recruiting|January 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|114|Samples Without DNA|midstream urina sanguinis|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|All patients will be enrolled in NAFLD outpatient of Shuguang hospital. The healthy people        also will be enrolled in Shuguang hospital.|November 2015|November 19, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02077283|3 Months|49350|
NCT02048800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10MI28|Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT|Evaluation of Treosulfan Pharmacokinetics (PK) in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)|TreoPK|Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|Plasma will be stored for Treosulfan PK analysis.|Both|N/A|18 Years|No|Non-Probability Sample|Children affected by malignant or non-malignant diseases with an indication to allogeneic        HSCT.|August 2015|August 17, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02048800||51532|
NCT02077790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|684-a01|To Investigate the Precision and Agreement of SS-1000 and Pentacam in a Repeatability and Reproducibility Trial|To Investigate the Precision and Agreement of SS-1000 and the Predicate Device Pentacam in a Repeatability and Reproducibility Trial (PASP)|PASP|Tomey Corporation|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|22 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 2, 2014|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077790||49311|
NCT02073643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12051001|Study of Household Purchasing Patterns, Eating and Recreation|Delay Discounting and Household Food Choices|SHoPPER|Rush University Medical Center|No|Recruiting|November 2013|June 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|145|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Chicago households|May 2015|May 4, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073643||49630|
NCT02073656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-0115|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection||Gilead Sciences|Yes|Completed|February 2014|December 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073656||49629|
NCT02074228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112131MIB|Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD|A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder||National Taiwan University Hospital|No|Recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|7 Years|16 Years|No|||February 2014|February 26, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02074228||49585|
NCT02074540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0005-14|The Influence of Health Beliefs and Uncertainty on Diabetes Type II Patient Compliance|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|35 Years|70 Years|No|Probability Sample|Diabetes Type II patients who receive insulin and are hospitalized in the Hillel Yaffe        Medical Center in a variety of departments. Patients are both Hebrew and Arabic speaking.|February 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074540||49561|
NCT02075086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGIOSWITCH2011|Angiogenic Switch in Patients With Colorectal Cancer|Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer|ANGIOSWITCH|Grupo Hospital de Madrid|No|Active, not recruiting|July 2011|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||March 2015|March 13, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT02075086||49519|
NCT02075333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN - 0114|The Effect of Ingesting or Rinsing Sucrose and Sucralose on Self-control, Cognitive Performance, and Blood Glucose|The Effects of Ingesting or Rinsing Sucrose and Sucralose Solutions on Self-control, Cognitive Performance, and Blood Glucose Level||University of Leeds|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|40|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075333||49500|
NCT02074787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C&W13/090|Imaging of Adult Burn Injuries|A Comparison of Three Non-invasive Imaging Modalities (Thermography, Laser Doppler and SIAscope) for the Assessment of Adult Burns Injuries||Chelsea and Westminster NHS Foundation Trust|No|Not yet recruiting|March 2014|September 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|16 Years|N/A|No|Non-Probability Sample|Adult patients with burns injuries attending the regional burns unit at Chelsea &        Westminster hospital between 48 and 72 hours post burn will be invited to take part in the        study at the time of presentation to the unit.|February 2014|February 27, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02074787||49542|
NCT02074475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH2013-1|SPI Value Relevance in Clinical Practice|GE AOA Study Spin-off: Defining the Clinically Useful Range for Surgical Pleth Index|SPIrelevance|Tampere University Hospital|No|Recruiting|December 2013|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients assessed for operation lasting more than two hours and requiring intubation.|November 2014|November 24, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02074475||49566|
NCT02075541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200157|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients||GlaxoSmithKline||Active, not recruiting|July 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|40 Years|80 Years|No|||January 2016|January 18, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075541||49484|
NCT02075320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1337|Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules|Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis Versus Chest Radiographs in Patients With Known Lung Nodules||UNC Lineberger Comprehensive Cancer Center|No|Recruiting|February 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075320||49501|
NCT02075892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0062|Mushroom Blend on Oxygen Kinetics|Acute Effects of a Mushroom Blend on Oxygen Kinetics, Aerobic Power and Time to Fatigue||University of North Carolina, Chapel Hill|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|28|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|December 3, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075892||49457|
NCT02076958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA147313|Implementation of Evidence-Based Cancer Early Detection in Black Churches|Implementation of Evidence-Based Cancer Early Detection in Black Churches|Project HEAL|University of Maryland|No|Enrolling by invitation|March 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|574|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076958||49375|
NCT02076711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300114731|Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?|Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?|MELVAS|Aarhus University Hospital|Yes|Completed|June 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||November 2015|November 10, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076711||49394|
NCT02077309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-027|Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus|Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus|Lina-Plaque|RWTH Aachen University|No|Terminated|August 2014|November 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|50 Years|N/A|No|||December 2015|December 1, 2015|February 28, 2014||No|bad recruitment of suitable participants, just 4 patients in one year|No||https://clinicaltrials.gov/show/NCT02077309||49348|
NCT02077036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nervus11|Narcolepsy - New Potential Treatment|||Karolinska University Hospital||Recruiting||||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|30|||Both|16 Years|60 Years|No|||February 2014|February 28, 2014|February 11, 2014||||No||https://clinicaltrials.gov/show/NCT02077036||49369|
NCT02077296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46983.100.13/R13.044|The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|CYTORECT|St. Antonius Hospital|No|Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|An extra ethylene diamine tetra acetic acid blood tube of 4 ml will be withdrawn from the      patient during a regular venapuncture or after administration of an intravenous needle      specifically before, during and just after preoperative CRT, 1 day before and 2 days after      surgery and 6 weeks after surgery. Blood samples for determination of cytokines are directly      processed.      As standard medical treatment surgery will be performed and biopsies of resection specimen      will be collected by the department of pathology, frozen, and further examined. For this      study 4 extra biopsies will be taken from resection tissue for cytokine measurements. Two      from tumour tissue and 2 from normal mucosa of each patient. These biopsies will be      snap-frozen in liquid nitrogen. Subsequently, the frozen biopsies will be grinded with a      mortar and pestle, which were cooled in liquid nitrogen, and resuspended in 100 μl ice-cold      PBS containing 10 μl/ml of a cocktail of protease inhibitors.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced rectal cancer diagnosed in St. Antonius Hospital Nieuwegein        and Utrecht, 18 years or older, selected for preoperative chemoradiotherapy (chemotherapy:        oral capecitabine; radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery.        Rectal carcinoma is defined as <15 cm from the anal verge. They are already routinely        planned to undergo a regular venipuncture for blood collection and intravenous needle        before surgery.|December 2015|December 4, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02077296||49349|
NCT02049073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHL2014|Prevention of Noise-induced Hearing Loss|Zonisamide and Methylprednisolone to Prevent Noise-induced Temporary Hearing Loss||Washington University School of Medicine|Yes|Not yet recruiting|June 2017|January 2020|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049073||51511|
NCT02049086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AT008318-01|Pain Management for Veterans Filing Compensation Claims|Pain Management for Veterans Filing Compensation Claims|SBIRT LBP|Yale University|No|Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02049086||51510|
NCT02074202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111019MIB|To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma|A Phase III, Multi-center, Single-blind, Cross-over Study to Evaluate the Efficacy and Safety of 18Ffluorocholine (18F-FCH) Comparing With 18F-fluorodeoxyglucose (18F-FDG) for Detecting Hepatocellular Carcinoma||National Taiwan University Hospital|Yes|Not yet recruiting|February 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|20 Years|80 Years|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074202||49587|
NCT02074215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012136RB|Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Effects and Mechanisms of Aerobic Exercises Combined With Dual-task Training in Cognitive Function in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease||National Taiwan University Hospital|Yes|Completed|March 2011|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|60 Years|90 Years|No|||February 2014|February 26, 2014|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02074215||49586|
NCT02074514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0116|Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection|A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection||Gilead Sciences|No|Completed|March 2014|November 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074514||49563|
NCT02074527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE_08691912.8.1001.0060|CHAIN_brazilian Registry of Congenital HeArt Disease INtervention and Angiography|Phase 0 _ Brazilian Registry of Congenital HeArt Disease INtervention and Angiography|CHAIN|Hospital do Coracao|Yes|Recruiting|October 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted to the hemodynamic sector with diagnosed or suspected congenital        cardiopathy and undergoing diagnostic or therapeutic cardiac catheterization.|February 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074527|30 Days|49562|
NCT02074241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012XLC02-2|Molecular Markers of Chemosensitivity for Bladder Cancer|Molecular Markers of Chemosensitivity for Locally Advanced, Recurrent and Metastatic Bladder Cancer Based on the Adjuvant Chemotherapy of Gemcitabine and Cisplatin-a Prospective Control Study||Southwest Hospital, China|Yes|Enrolling by invitation|March 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|bladder cancer specimens|Both|18 Years|N/A|No|Probability Sample|1. The patients of locally advanced, recurrent, metastatic transitional cell carcinoma.          2. Gone through standardize radical cystectomy and pelvic lymphadenectomy or inoperable.          3. Experienced adjuvant chemotherapy(Gemcitabine and Cisplatin).|February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074241||49584|
NCT02074553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29040|A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers|A Randomized, Open-Label, Single Dose, Cross-Over Study to Investigate the Bioequivalence of Three RO5424802 Test Formulations Versus a Reference Formulation Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|97|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02074553||49560|
NCT02075346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0419|Bedside Respiratory Patient Monitoring System - Sensor Off Study|Sensor Off Studies Using a Nellcor Bedside Respiratory Patient Monitoring System, Configured With the Multi-functional Respiratory PCBA|BRPMS|Medtronic - MITG|No|Completed|November 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 20 subjects recruited from the Clinical Laboratory subject data base.|December 2013|February 27, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075346||49499|
NCT02075593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200336|ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection|ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women||GlaxoSmithKline|No|Recruiting|January 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075593||49480|
NCT02075554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC10-009-001-PL_H_2|Efficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach|Study of an Expandable Interbody Device for the Lumbar Spine|CALIBER|Globus Medical Inc|No|Recruiting|July 2012|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|80 Years|No|||February 2016|February 10, 2016|February 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075554||49483|
NCT02075359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12067|Energy Expenditure and Physical Activity in Preschoolers|Novel Models to Predict Energy Expenditure and Physical Activity in Preschoolers|LILCAL|Baylor College of Medicine|No|Active, not recruiting|May 2010|April 2015|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Child (3-5 years)|February 2014|February 27, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02075359||49498|
NCT02075853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0531|Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material|Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material||University of Colorado, Denver||Recruiting|September 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|4 Years|18 Years|No|Non-Probability Sample|Children receiving an Evans calcaneal lengthening procedure at Children's Hospital        Colorado.|November 2015|November 20, 2015|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075853||49460|
NCT02075866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uoulu-FinGesture|Finnish Genetic Study for Arrhythmic Events|Finnish Genetic Study for Arrhythmic Events|FinGesture|University of Oulu||Recruiting|January 1998|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|8000|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive victims of sudden cardiac death verified by medicolegal autopsy (cases).        Acute coronary event patients admitted to the Oulu University Hospital who survived to be        discharged from the hospital (controls).|March 2014|March 3, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075866|1 Day|49459|
NCT02075905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3843|Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management|Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management||University of North Carolina, Chapel Hill|No|Completed|March 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|111|Samples Without DNA|Paraffin embedded esophageal biopsies|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects with Barrett's Esophagus, coming into clinics for routine care surveillance upper        endoscopy procedures.|September 2015|September 21, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075905||49456|
NCT02076113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID: 2013-085|Cervical Spondylotic Myelopathy Surgical Trial|Cervical Spondylotic Myelopathy Surgical Trial||Lahey Clinic|Yes|Recruiting|April 2014|September 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|45 Years|75 Years|No|||March 2016|March 9, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076113||49440|
NCT02076126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holb.SJ-384|Determination of Lung Maturity and Prediction of RDS at Birth|Spectroscopic-chemometric Determination of Lecithin-sphingomyelin Ratio in Gastric Aspirates and Secretion From Hypopharynx at Birth, in Relation to Development of RDS||Holbaek Sygehus|Yes|Completed|March 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|145|Samples Without DNA|Gastric- and hypopharyngeal secretions|Both|N/A|30 Minutes|No|Probability Sample|135 preterm infants with gestational age 24-32 weeks (24+0 to 31+6)|January 2015|January 29, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076126||49439|
NCT02076425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH098454-02|A Randomized Controlled Trial of PCIT-ED for Preschool Depression|A Randomized Controlled Trial of PCIT-ED for Preschool Depression||Washington University School of Medicine|No|Recruiting|December 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|36 Months|83 Months|No|||December 2015|December 7, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076425||49416|
NCT02077023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13IC0865|An Observational Study of Natural History of Cardiovascular Diseases|An Observational Study of Natural History of Cardiovascular Diseases||Imperial College London|No|Recruiting|February 2014|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5200|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study consists of an observational, prospective study of the prevalence of and risk        factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended        cardiovascular screening appointments provided by Life Line Screening.        This cohort will include 1300 participants who are exposed to significant carotid artery        stenosis (more than 50% artery occlusion identified by ultrasound scan) and atrial        fibrillation. We also aim to recruit 3900 participants who do not have carotid artery        disease or atrial fibrillation as control group and for comparison purposes. The control        group will be drawn from a population that is similar to the exposed group in all respects        other than their carotid disease and atrial fibrillation. The data collected for the        control group will be the same and will be obtained in the same way as those on the        exposed group.|September 2014|June 4, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02077023||49370|
NCT02077322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synechiae-2014|Rates of Middle Meatal Synechia Formation Following Functional Endoscopic Sinus Surgery|Rates of Middle Meatal Synechia Formation Following Functional Endoscopic Sinus Surgery: A Double-Blind Randomized Controlled Trial Comparing Gloved Merocel and Silastic Middle Meatal Spacers.|SYNECHIAE|St. Paul's Hospital, Canada|No|Recruiting|March 2014|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|96|||Both|19 Years|N/A|No|||November 2014|November 19, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077322||49347|
NCT02074072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYI-14-004-1|Endotracheal Intubation Using Three Laryngoscopes in Maternal Cardiac Arrest: a Manikin Simulation Study|Comparison of Glidescope, Pentax-AWS and Macintosh Laryngoscope for Intubation During Chest Compression in 15-30 Degree Left-Lateral Tilt: A Manikin Simulation Study of Maternal Cardiopulmonary Resuscitation||Hanyang University Seoul Hospital|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074072||49597|
NCT02077621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP020|Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer|The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer||PhytoHealth Corporation|No|Not yet recruiting|July 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||November 2015|November 3, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02077621||49324|
NCT02049645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xiang-Ya 0001|The Suitability of Sniff Dog as a Tool in Screening Tumors|The Suitability of Sniff Dog as a Tool in Screening Tumors-- a Prospective Observational Study||Central South University|Yes|Recruiting|January 2014|March 2019|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples Without DNA|serum|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Third Xiang-Ya Hospital staff members and their adult family members who wish to        participate the study.|January 2014|January 28, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02049645||51467|
NCT02049658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xiang-Ya 0003|The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients|The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients||Central South University|No|Recruiting|January 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|2000|Samples Without DNA|Serum|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Healthy volunteers who have been examined by the currently used procedures and find             to be without tumors.          -  Patients in the breast surgery, thoracic surgery, gynecological and neurosurgery             departments with lesions with characteristics of tumors|January 2014|January 28, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02049658||51466|
NCT02077803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103257|A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02077803||49310|
NCT02077816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP 12632/2010|Using a Infrared Thermometer to the Early Detection of Catheter Related Infections|Using Non-contact Infrared Thermometry to Detection of Central Venous Catheter Related Infection.||University of Sao Paulo|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|39|||Both|N/A|N/A|No|Non-Probability Sample|Inpatient of the metabolic, clinical or intensive care wards with a CVC for medical care.|March 2014|March 2, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077816||49309|
NCT02073695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/01/049|Return of Function and External Rotation Post Proximal Humerus Fracture Fixation With Neutral Rotation Brace|Return of Function and External Rotation Post Proximal Humerus Fracture Fixation With Neutral Rotation Brace|ROTATE|South Devon Healthcare NHS Foundation Trust|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073695||49626|
NCT02073994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG120-C-002|Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation|A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation||Agios Pharmaceuticals, Inc.|No|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|N/A|No|||August 2015|November 13, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073994||49603|
NCT02074007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR01.007|Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)|A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years||Arbor Pharmaceuticals, Inc.|No|Terminated|December 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|2 Months|18 Years|No|||January 2015|January 8, 2015|January 16, 2014|Yes|Yes|primary outcome measure not met|No||https://clinicaltrials.gov/show/NCT02074007||49602|
NCT02074254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012E0196|Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors|Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors||Ohio State University|No|Recruiting|April 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|350|||Both|18 Years|70 Years|No|Non-Probability Sample|The study is being done to evaluate the safety of percutaneous tracheostomy in patients        taking antiplatelet agents such as aspirin and/ or clopidogrel or selective serotonin        reuptake inhibitors. We will identify all patients age 18 or older who have undergone        percutaneous tracheostomy by interventional pulmonology at OSUMC and access their PHI to        record variables (see data collection form).|February 2014|February 26, 2014|June 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074254||49583|
NCT02074579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100CPT6|A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome|A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome||Tsumura USA|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|65 Years|No|||May 2015|May 19, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074579||49558|
NCT02074566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47337.044.13|Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study|A Prospective Randomized Multicentre Efficacy Study on Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study||Thorax Centrum Twente|No|Enrolling by invitation|March 2014|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|222|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02074566||49559|
NCT02074826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-AFIB-REG|Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation|Analysis of the Interplay Between Genetic Risk Variants for Atrial Fibrillation and Pathological Changes That Associate With the Disease|LOGICAL|Technische Universität Dresden|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood samples in EDTA plastic vaccutainers will be collected from the study participants for      genetic testing|Both|18 Years|75 Years|No|Non-Probability Sample|Patients will be recruited from our primary care clinic|February 2015|February 12, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02074826|2 Years|49539|
NCT02075073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB3-G11-NHV|Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects|A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Trastuzumab (SB3, EU Sourced Herceptin® and US Sourced Herceptin®) in Healthy Male Subjects||Samsung Bioepis Co., Ltd.|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|109|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075073||49520|
NCT02075606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-97-52030-270|Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients|A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)|CALM-NET|Ipsen|No|Recruiting|May 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075606||49479|
NCT02075372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/094L|CrossBoss and Hybrid Registry on Coronary Chronic Total Occlusions|REgistry of CrossBoss and Hybrid Procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom|RECHARGE|Hasselt University|No|Active, not recruiting|January 2014|January 2017|Anticipated|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1177|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and        who will receive treatment via percutaneous coronary intervention (PCI)|February 2016|February 23, 2016|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02075372|1 Year|49497|
NCT02075619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200561|Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions|An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 10mg Tablet and Rosuvastatin 20mg Tablet to Two Fixed Dose Combination Tablet Formulations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Adult Male and Female Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075619||49478|
NCT02075879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20121105002|The Effects of a Nurse-led Case Management Programme on Home Exercise Training for Haemodialysis Patients|The Effects of a Nurse-led Case Management Programme on Home Exercise Training for Haemodialysis Patients||The Hong Kong Polytechnic University|Yes|Completed|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|113|||Both|19 Years|75 Years|No|||February 2014|February 27, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075879||49458|
NCT02076165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-058|Insomnia Treatment for Women Veterans|A Patient-Focused Approach to Insomnia Treatment for Women Veterans||VA Office of Research and Development|No|Recruiting|September 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076165||49436|
NCT02076139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYADATREG|Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis|Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection||Manresana de Micobacteriologia, SL|No|Completed|March 2014|July 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|51|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02076139||49438|
NCT02076438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2012002450|Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease|Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease in Hospitalized Adults-A Double Blind Placebo Controlled Trial||Rutgers, The State University of New Jersey|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|290|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076438||49415|
NCT02076750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061627|Weekly Vitamin D in Pediatric IBD|Weekly Vitamin D3 for Treatment of Hypovitaminosis D in Children and Adolescents With Inflammatory Bowel Disease||Emory University|No|Completed|March 2013|June 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|8 Years|21 Years|No|||November 2014|November 25, 2014|December 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076750||49391|
NCT02074085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.05/APO14.01|Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events|Measuring the Incidence of Hospital Readmissions, Caused by Adverse Drug Events (ADE) Due to Anticoagulants in Vzw Jessa Hospital (Belgium)||Hasselt University|No|Not yet recruiting|March 2014|||September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|450|||Both|N/A|N/A|No|Non-Probability Sample|patients who received an anticoagulant on their last day of admission|February 2014|February 25, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074085||49596|
NCT02077335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSSG-001|Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer|Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer||CSSS de Gatineau|Yes|Recruiting|April 2014|September 2022|Anticipated|September 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02077335||49346|
NCT02077634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARE-001/AP 67/11|Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)|Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)|SPARE|Association of Urogenital Oncology (AUO)|Yes|Recruiting|May 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|N/A|No|||November 2015|November 3, 2015|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02077634||49323|
NCT02050217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCHIDINI2014|NAVA Helmet in Pediatric Respiratory Failure|Patient Ventilator Interaction During Non-invasive Ventilation Delivered With Neurally Adjusted Ventilatory Assist (NAVA-NIV) in Infants Delivered by Helmet: a Pilot Short Term Physiological Study||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|June 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Month|24 Months|No|||January 2014|January 29, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050217||51423|
NCT02050490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201419701|Effect of a Symptom Diary on Symptom Care and Symptom Burden in Patients Treated With Chemotherapy: a Before-and-after-study|Effect of the Implementation of a Symptom Diary on the Symptom Care Received and the Symptom Burden Experienced by Adult Cancer Patients Treated With Chemotherapy: A Before-and-after-study||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Adult (>18) patients with (any type of) cancer treated with chemotherapy|November 2014|November 17, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02050490||51402|
NCT02077829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR 01/2014|Implementation of Illness Management and Recovery in Mental Health Services|Implementation of Illness Management and Recovery in Mental Health Services: Facilitators and Barriers in the Implementation Process.||University Hospital, Akershus|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02077829||49308|
NCT02073708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1665|A Population-based Investigation of Asthma in the Telemark Region of Norway|A Population-based Investigation of Asthma in the Telemark Region of Norway||Sykehuset Telemark|No|Recruiting|February 2014|December 2033|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Serum, citrate plasma, EDTA-plasma, whole blood, gene sequencing (next generation gene      sequencing)|Both|16 Years|50 Years|No|Probability Sample|The researchers have recently collected data on respiratory symptoms and physician        diagnosed asthma from 16.300 inhabitants of Telemark County (baseline study). A random        sample from the baseline study of 1000 asthma cases and 1000 controls will be asked to        take part in a medical examination in a case-control study.|November 2015|November 17, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02073708||49625|
NCT02074020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SLE3332|CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis||Anthera Pharmaceuticals|Yes|Withdrawn|December 2015|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074020||49601|
NCT02074605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0389-02|Cognitive Effects of Interferon in Patients With Melanoma|A Pilot Study of Neurocognitive Function in Patients Treated With Adjuvant Interferon Alpha-2b for High-Risk Melanoma||University of Arizona|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in one of these categories:          1. Are to receive adjuvant treatment with interferon alpha-2b after complete surgical             resection of high risk melanoma.          2. Have had a complete surgical resection of high risk melanoma, but have elected not to             receive interferon alpha-2b and will be observed for disease progression only.|February 2014|February 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074605||49556|
NCT02074592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR08021|Self Assessment of Fetal Ultrasound Images|Self Assessment Vs. Expert for Fetal Ultra Sound Biometry Images|SAVE US|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|320|||Both|N/A|N/A|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074592||49557|
NCT02074878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33624|CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer|A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer|CRIZENT|Baylor Breast Care Center|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074878||49535|
NCT02074839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG120-C-001|Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation|A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation||Agios Pharmaceuticals, Inc.|No|Recruiting|March 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|236|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02074839||49538|
NCT02074852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|urinary catheter following CS|Comparison of Immediate Versus Delayed Removal of Urinary Catheter Following Elective Cesarean Section|||Cairo University||Completed|November 2012|||December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|300|||Female|20 Years|40 Years|No|Probability Sample|Women admitted to the prenatal wards for primary or repeat elective cesarean section|March 2014|March 1, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02074852||49537|
NCT02075099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 53|Evaluation of the Efficiency of Hydration by Isotonic Solution in the Prevent of the Fainting Whole Blood Donors|Evaluation of the Efficiency of a Hydration by Isotonic Solution With or Without Muscular Exercise of the Fainting Whole Blood Donors|EVASION|Etablissement Français du Sang|No|Completed|January 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|4825|||Both|18 Years|71 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02075099||49518|
NCT02075385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|589/2012|Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer|Randomized Phase II Trial: Swallowing Speech Pathology Intervention During Radiochemotherapy on Patients With Head and Neck Cancer|Swallowing-1|Barretos Cancer Hospital|Yes|Completed|July 2012|August 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02075385||49496|
NCT02075632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2200440|Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream|A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream||GlaxoSmithKline|No|Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Both|12 Years|65 Years|No|||August 2014|August 28, 2014|January 28, 2014|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT02075632||49477|
NCT02076152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-482|FMISO PET Study of Glioblastoma|A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using FMISO PET and Vascular MRI||Massachusetts General Hospital|Yes|Recruiting|February 2014|January 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076152||49437|
NCT02076451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8273-A-U101|Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas|PHASE 1, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF DS-8273A IN SUBJECTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS||Daiichi Sankyo Inc.|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076451||49414|
NCT02076724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK 1-10-72-10-13|Reinforcement of the Abdominal Wall After Breast Reconstruction With the Pedicled TRAM-flap|Reinforcement of the Abdominal Wall With Acellular Dermal Matrix (Strattice™) After Breast Reconstruction With the Pedicled TRAM-flap||Aarhus University Hospital|No|Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076724||49393|
NCT02073773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB 2013/323/D|Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke|Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke||Singapore General Hospital|Yes|Recruiting|January 2014|August 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|N/A|No|||February 2014|February 26, 2014|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02073773||49620|
NCT02077920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-RCU-001|Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP)|Prevention of Ventilator-Associated Pneumonia by Oropharyngeal and Subglottic Decontamination Via Bronchoscopy|VAP|General Hospital of Shenyang Military Region|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|192|||Both|N/A|N/A|No|||February 2016|February 15, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077920||49301|
NCT02074293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTNS089268|ASIS for Botox in Cervical Dystonia|ASIS for Botox in Cervical Dystonia|ASISinCD|ASIS Corporation|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|22||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074293||49580|
NCT02074306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/13|Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes|Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes|lungshield|Shaare Zedek Medical Center|No|Not yet recruiting|April 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02074306||49579|
NCT02050789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST Trial|Flexibility In Duty Hour Requirements for Surgical Trainees Trial - "the FIRST Trial"|Allowing Flexibility in Surgical Resident Duty Hours Trial|FIRST|Northwestern University|Yes|Active, not recruiting|July 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|152|||Both|N/A|N/A|No|||December 2015|December 21, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02050789||51379|
NCT02050802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-114|Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects|A Double-blind, Randomized, Placebo-controlled, Four-way Crossover Phase 1 Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Effect of Repeated Daily Doses of 10 mg and 30 mg Macitentan on the QT/QTc Interval of the ECG in Healthy Male and Female Subjects||Actelion|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02050802||51378|
NCT02051075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB 0443-13|Fertilizations With Immotile Sperm: Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation|A Randomized Controlled Trial to Compare Fertilizations With Immotile Sperm After Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation|PXN|Rambam Health Care Campus|No|Withdrawn|March 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|35 Years|No|||May 2015|May 5, 2015|January 29, 2014||No|failure to recruit|No||https://clinicaltrials.gov/show/NCT02051075||51357|
NCT02077842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-192|Prophylactic nCPAP in the PACU Following Elective Laparotomy for Bowel Surgery|Prophylactic Nasal Continuous Positive Airway Pressure in the Post-Anaesthesia Care Unit Following Elective Laparotomy for Bowel Surgery||University of Saskatchewan|No|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077842||49307|
NCT02073721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260535|The Importance of Electrical Stimulation as a Treatment for Urinary Incontinence in Patients Prostatectomy|The Importance of Electrical Stimulation as a Treatment for Urinary Incontinence in Patients Undergoing Prostatectomy to Exercise the Pelvic Floor Muscles (MAPs): Randomised Controlled Trial, Double Blind|UI|Universidade Gama Filho|Yes|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Male|50 Years|80 Years|No|||February 2014|February 25, 2014|June 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02073721||49624|
NCT02074033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30121978|Errors in Prescription Antibiotics in Ventilator-associated Pneumonia|Determination of Errors in Prescription Antibiotics in Ventilator-associated Pneumonia in Unit of Intensive Care of Clinical Hospital of Federal University of Uberlandia - Brazil||Federal University of Uberlandia|Yes|Recruiting|March 2014|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|130||No samples will be retained for the study|Both|18 Years|N/A|No|Probability Sample|The study is a retrospective study to evaluate the use of antibiotics in the        ventilator-associated pneumonia (PAV) in the Intensive Care Unit of the Adult Clinical        Hospital of the Federal University of Uberlândia. The UnitAdult Intensive Care has        complexity level III and consists of 30 beds.O number of statistically significant sample        is 130 patients.|March 2014|March 26, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02074033||49600|
NCT02074618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMT2013|Physiotherapy in Patients With Chronic Kidney Disease|Impact of Physical Therapy on Functional Capacity and Quality of Patients With Chronic Kidney Disease||Hospital Regional Publico do Araguaia|No|Completed|May 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||March 2014|March 14, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074618||49555|
NCT02074904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP MRI|Topiramate's Effects on Heavy Drinking|Brain Mechanisms of Topiramate's Effects on Heavy Drinking|TOPMRI|University of Pennsylvania|Yes|Recruiting|May 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2016|February 19, 2016|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074904||49533|
NCT02074891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-6511|Sustainable Healthcenter Implementation PrEP Pilot Study|Sustainable Healthcenter Implementation PrEP Pilot Study|SHIPP|Centers for Disease Control and Prevention|No|Recruiting|October 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Dried blood spots|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1200 adult men who have sex with men, injection drug users, and heterosexually-active men        and women who are at substantial risk of acquiring HIV infection and initiate the use of        daily oral antiretroviral preexposure prophylaxis (PrEP) with TDF/FTC|February 2016|February 2, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02074891||49534|
NCT02075151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB/2013/00144|Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype|Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype||National University Hospital, Singapore|No|Not yet recruiting|February 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|64 Years|No|||February 2014|February 26, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02075151||49514|
NCT02074865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11 ChARLI|Children's Antibiotic Resistant Infections in Low Income Countries|Children's Antibiotic Resistant Infections in Low Income Countries|ChARLI|Institut Pasteur|No|Recruiting|September 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|At birth, for therapeutic management of the newborns in the presence of a risk factor for      infection :gastric fluid, external auditory canal swabs, anal swabs, placental biopsy.      Before empirical antibiotic treatment: blood cultures, blood sampling for CRP      determination.In the presence of particular warning signs of infection chest X ray and      lumbar puncture.      During the follow-up, for therapeutic management of the newborns if the child has a      suspected infection : urine samples, blood for blood cultures and Blood formula and      C-reactive protein (CRP) detrmination; rhinopharyngeal fluid samples, lumbar puncture in      febrile children under the age of three months; and thick blood smears if the child has a      fever.      Samples based on the presence of particular warning signs of infection: stool samples, eye      or ear swabbing, chest X|Both|N/A|3 Days|Accepts Healthy Volunteers|Probability Sample|newborns|February 2014|February 25, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02074865||49536|
NCT02075112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065591|Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck|A Pilot Study of Soy Isoflavone, Genistein, in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Emory University|Yes|Active, not recruiting|November 2013|April 2020|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075112||49517|
NCT02075684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-9312|Office-based Percutaneous Ultrasound-guided Renal Biopsy|Office-based Percutaneous Ultrasound-guided Renal Biopsy||University of California, Irvine|Yes|Enrolling by invitation|April 2013|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|180|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02075684||49473|
NCT02075697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biobadaderm|Spanish Registry of Systemic Treatments in Psoriasis|Spanish Registry of Systemic Treatments in Psoriasis|Biobadaderm|Fundación Academia Española de Dermatología|No|Recruiting|October 2008|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1887|||Both|N/A|N/A|No|Non-Probability Sample|Psoriasis patients requiring systemic therapy.|August 2015|August 10, 2015|January 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02075697|5 Years|49472|
NCT02075645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23264|Can Adherence to PALS Guidelines be Improved by Team Training of Pediatric Resuscitation Members?|Can Adherence to PALS Guidelines be Improved by Team Training of Pediatric Resuscitation Members?|Teams4Kids|University of Calgary|Yes|Completed|December 2010|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02075645||49476|
NCT02075658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-9088|A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation|A Comparative Study of the Physiological Response, Between AirSeal, an Integrated Insufflation and Access System, and Conventional Insufflation and Trocars||University of California, Irvine|Yes|Recruiting|January 2003|September 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|75|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02075658||49475|
NCT02075918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2016|Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis|Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis|InTeam|University of North Carolina, Chapel Hill|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Serum, Plasma, Whole Blood DNA, PBMCs, Urine, Stool, Liver Biopsy|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with an episode of alcoholic hepatitis fulfilling the inclusion criteria will be        eligible to participate in the study. Those patients who meet one or more exclusion        criteria will not be included. We will prospectively include patients with the following        inclusion criteria|February 2016|February 10, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075918||49455|
NCT02076464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100455|Using Technology to Improve Eating Disorders Treatment|Using Technology to Improve Eating Disorders Treatment||Washington University School of Medicine|Yes|Enrolling by invitation|May 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|650|||Female|18 Years|30 Years|No|||February 2014|February 27, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076464||49413|
NCT02076477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scch201402|The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）|The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）|OITROLC|Sichuan Cancer Hospital and Research Institute|Yes|Recruiting|January 2014|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076477||49412|
NCT02076737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0183|Model-based Iterative Reconstruction (MB-IR VEOTM) in Ultra Low-dose Abdominal CT Versus Adaptative Statistical Iterative Reconstruction (ASIR): A Prospective Study for Acute Renal Colic|Model-based Iterative Reconstruction (MB-IR VEOTM) in Ultra Low-dose Abdominal CT Versus Adaptative Statistical Iterative Reconstruction (ASIR): A Prospective Study for Acute Renal Colic|VEOLITH|University Hospital, Clermont-Ferrand||Completed|February 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|90 Years|No|||February 2014|February 28, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02076737||49392|
NCT02077686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH022014_2|Diabetes and Travel: Evaluation of a Diabetes Education Module - a Randomized Controlled Trial (PRIMO_Travel)|A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic "Diabetes and Travel" in a Randomized Controlled Trial|PRIMO_Travel|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077686||49319|
NCT02077933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719Z2102|Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors|A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.||Novartis|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|166|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02077933||49300|
NCT02051088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEDEPAD|Swedish Drug-elution Trial in Peripheral Arterial Disease|Swedish Drug-elution Trial in Peripheral Arterial Disease - a Multicenter, Prospective Randomized Controlled Clinical Trial Based on the Swedish Vascular Registry (SWEDVASC) Platform|SWEDEPAD|Sahlgrenska University Hospital, Sweden|Yes|Recruiting|November 2014|February 2021|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3800|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051088||51356|
NCT02073734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12136-12-081|Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP|Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial||TriHealth Inc.|No|Completed|February 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|63|||Female|18 Years|81 Years|No|||October 2015|October 19, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02073734||49623|
NCT02074046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-001|Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas||Fuda Cancer Hospital, Guangzhou|Yes|Completed|February 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|75 Years|No|||February 2014|June 1, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02074046||49599|
NCT02074267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S08174|Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain|||Nang Kuang Pharmaceutical Co., Ltd.||Completed|March 2009|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||February 2014|February 26, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02074267||49582|
NCT02075164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fru2.0|Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD|Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial||Medical University of Vienna|Yes|Recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|56|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02075164||49513|
NCT02075138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG003|Grass Observational Study|An Observational Multi-Centre Field Study to Assess Symptom Scores and Allergy Medication Usage in Subjects With a History of Grass-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|109|||Both|12 Years|65 Years|No|Non-Probability Sample|Subjects with a history of Grass induced Rhinoconjunctivitis|April 2015|April 7, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02075138||49515|
NCT02075125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANTASTIC|Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction|Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction||Dong-A University|Yes|Terminated|January 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|20 Years|80 Years|No|||February 2016|February 3, 2016|February 20, 2014||No|Enrolling participants has halted prematurely and will not resume|No|September 13, 2015|https://clinicaltrials.gov/show/NCT02075125||49516|For the present single-center pilot study, the small sample size was a major limitation, and as such was insufficiently powered to assess safety.
NCT02076204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2018.01.415.00|Mother and Infant Home Visiting Program Evaluation-Strong Start|Mother and Infant Home Visiting Program Evaluation (MIHOPE) - Strong Start||MDRC|No|Enrolling by invitation|February 2014|September 2017|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1059|||Female|15 Years|N/A|No|||October 2015|October 29, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02076204||49433|
NCT02076217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67314|Quick Start of Highly Effective Contraception|Rates of Contraceptive Failure When Unprotected Intercourse Has Occurred 6-14 Days Prior to Contraceptive Initiation||University of Utah|Yes|Recruiting|February 2014|February 2019|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1030|||Female|15 Years|45 Years|No|Non-Probability Sample|Women presenting to IRB approved clinics requesting highly effective contraception (an        IUD, Nexplanon®, or Depo-Provera) .|February 2016|February 18, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076217||49432|
NCT02076503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1513|Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status|Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status||St. Olavs Hospital|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|32|||Male|N/A|N/A|No|||August 2015|August 21, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02076503||49410|
NCT02076516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV-01|Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)|Pilot Evaluation Of CORACTO® (Rapamycin-Eluting Coronary Stent Delivery System) in The Treatment Of Patients With Coronary Artery Disease|PILOT-SECRET|Alvimedica|No|Recruiting|October 2013|May 2015|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076516||49409|
NCT02076763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIG-API-2011-01|Observational Study of Acute Intermittent Porphyria Patients|Observational Study of Acute Intermittent Porphyria Patients||Digna Biotech S.L.|No|Completed|August 2011|February 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Serum, urine|Both|18 Years|65 Years|No|Non-Probability Sample|Acute intermitent porphyria patients, with a severe condition. And genetic confirmation of        Porphobilinogen deaminase mutation.|February 2014|March 11, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076763||49390|
NCT02076776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD073566|Heart-Brain Retraining for Stroke Rehabilitation|Heart-Brain Retraining: Forced Aerobic Exercise for Stroke Rehabilitation||The Cleveland Clinic|Yes|Completed|August 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|85 Years|No|||June 2015|June 26, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076776||49389|
NCT02076178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201120|Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)|A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)||ViiV Healthcare|No|Active, not recruiting|March 2014|March 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|127|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|February 4, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076178||49435|
NCT02076191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1816|Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML|Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076191||49434|
NCT02076490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-GW02-035|Telerehabilitation Using Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation.|The PACT Trial - PAtient Centered Telerehabilitation: Effectiveness of Software-supported and Traditional Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation: Design of a Randomized Controlled Trial.||Zuyd University of Applied Sciences|Yes|Enrolling by invitation|May 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|105|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02076490||49411|
NCT02077647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR_Tomofix|Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee|A Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee||AO Clinical Investigation and Documentation|No|Active, not recruiting|March 2014|February 2017|Anticipated|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with Indication for open wedge HTO with the TomoFix™ Small presenting in the        orthopaedic department of the participating hospitals|May 2015|May 21, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02077647|24 Months|49322|
NCT02077660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Green Tea Effect on Anthropometric, Oxidation and Inflammation Parameters in Physically Active vs. Sedentary Elders|The Effect of Green Tea on Anthropometric, Oxidation and Inflammation Parameters in Physically Active Elderly Compared to Sedentary Elderly|GT|Rambam Health Care Campus|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|60 Years|76 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02077660||49321|
NCT02069210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 1|The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients||Mahidol University|No|Not yet recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood|Both|18 Years|60 Years|No|Non-Probability Sample|Patients underwent elective spine surgery|February 2014|February 19, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02069210||49969|
NCT02069223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21003|Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy|Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy||Laval University|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|60 Years|No|||May 2014|May 15, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02069223||49968|
NCT02065115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJH IRB 2012-05|Study of Ice Application to Reduce Pain From Arterial Punctures|Cryoanalgesia (Ice Pack) to Reduce the Pain Associated With Arterial Blood Gas Puncture||St. Joseph Hospital, New Hampshire|Yes|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065115||50281|
NCT02077894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140064|Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions|Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|February 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|310|||Both|N/A|N/A|No|||October 2015|February 5, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077894||49303|
NCT02077907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-016-Sierra Leone|Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition (MAM) in Children in Sierra Leone: a Cluster-randomised, Controlled Clinical Effectiveness Trial|||Tufts University|No|Terminated|January 2014|||July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1147|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 28, 2014||No|Due to Ebola virus disease outbreak|No||https://clinicaltrials.gov/show/NCT02077907||49302|
NCT02051855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS: 145205|NeoAdapt 2: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency|NeoAdapt 2: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency in Infants Older Than 33 Weeks Gestational Age||Brighton and Sussex University Hospitals NHS Trust|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|None Retained|Two blood samples of 400µl each will be obtained for each infant receiving dobutamine.      Samples for the pharmacokinetic studies will utilise micro assays to minimise the amount of      blood taken and will coincide with the taking of clinically indicated sample to reduce the      burden placed on neonates included in this study.|Both|N/A|3 Days|No|Non-Probability Sample|Infants aged older than 33 weeks gestational admitted to the neonatal intensive care unit|July 2015|July 13, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051855||51297|
NCT02073747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM 2014.01|The Various Effects of Gaseous Albuterol on Serum Lactate|The Various Effects of Gaseous Albuterol on Serum Lactate||University Medical Center of Southern Nevada|No|Completed|April 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073747||49622|
NCT02073760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAI_Umich_2|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2||University of Michigan|No|Recruiting|June 2014|||September 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinical providers and administrators working at any of 33 institutions performing cardiac        surgery in the state of Michigan|November 2015|November 7, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073760||49621|
NCT02074059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-CL-1201|Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates|A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension||Discovery Laboratories, Inc.|Yes|Completed|February 2014|November 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|80|||Both|29 Weeks|34 Weeks|No|||November 2015|November 19, 2015|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074059||49598|
NCT02074280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPDLCC-1|Rifaximin Predicts the Complications of Decompensated Cirrhosis|Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial||Shanghai Changzheng Hospital|Yes|Recruiting|October 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|250|||Both|18 Years|75 Years|No|||February 2014|February 26, 2014|February 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02074280||49581|
NCT02075411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009320|Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair|A Randomized, Controlled Trial to Evaluate Opioid Usage Associated With Femoral Continuous Perineural Infusion and Femoral Single Shot Peripheral Nerve Block After a Hamstring Autograft Anterior Cruciate Ligament Repair.||Children's Hospital of Philadelphia|Yes|Terminated|March 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1|||Both|14 Years|18 Years|No|||February 2015|February 3, 2015|February 25, 2014||No|Difficult to enroll, parents/subjects prefer to choose type of anesthetic block.|No||https://clinicaltrials.gov/show/NCT02075411||49494|
NCT02075424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02-CHRMT|Descriptive Study of Biological Stress and Perceived Stress at the Center 15|Descriptive Study of Biological Stress and Perceived Stress in Call Regulation Operators and Doctors When Processing a Call at the Center 15|RegulStress|Centre Hospitalier Régional Metz-Thionville|No|Active, not recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|August 27, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02075424||49493|
NCT02075723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepDep 02/14|Effect of Sleep Restriction on Metabolic Disturbances Caused by Overfeeding|Effect of Sleep Restriction on Metabolic Disturbances Caused by Overfeeding||University of Lausanne Hospitals|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|9|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075723||49470|
NCT02075736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/13/03/02/08|KTP Green Light Prostatectomy Compared With TUR-P in High Risk Patients|The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia in High Risk Patients, A Prospective Randomized Study||Helsinki University|No|Recruiting|March 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|90 Years|No|||February 2014|February 26, 2014|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075736||49469|
NCT02075710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nibble99|Dietary Treatment Study of Fat Synthesis and Risk of Cardiovascular Disease|Lipogenesis, Lipoprotein Flux, and CVD Risk: Role of Meal Composition and Frequency||University of California, San Francisco|No|Recruiting|July 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Anticipated|48|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075710||49471|
NCT02075398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0428|Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0|Evaluation of Respiration Rate Parameters During Motion in Healthy Volunteers Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0||Medtronic - MITG|No|Completed|December 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the available Covidien Boulder Clinical Laboratory subject        data base.|December 2013|February 27, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075398||49495|
NCT02075671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031416|Photodynamic Therapy for Papulopustular Rosacea|Photodynamic Therapy for Papulopustular Rosacea||George Washington University|No|Recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075671||49474|
NCT02076529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RamosetronPK|Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting|A Study About Pharmacokinetic and Pharmacodynamics of Ramosetron in Chemotherapy Induced Nausea and Vomiting||Chonnam National University Hospital|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|51|||Both|18 Years|75 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076529||49408|
NCT02076789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72/2013/O/Oss|DEtect Long-term Complications After icD rEplacement: a Multicenter Italian Registry|Detect Long-term Complications After ICD Replacement: a Multicenter Italian Registry - DECODE Registry|DECODE|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|March 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing ICD generator replacement, with and without a planned transvenous        lead addition for replacement or upgrade to a device capable of additional therapies        (consecutive patients)|January 2015|January 8, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02076789||49388|
NCT02077075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIP13001|MyHealthCheckup Wellness Program Among Canadian Forces Military Personnel|The Effectiveness of the MyHealthCheckup Wellness Program Among Canadian Forces Military Personnel||McGill University|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077075||49366|
NCT02077088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.090|Effect of Galactooligosaccharides on Incidence of Atopic Manifestations in Infants|Double Blind, Randomised Study on the Effect of Prebiotics on Incidence of Atopic Manifestations in Infants||Humana Co.Ltd.|No|Completed|June 2009|April 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|6 Weeks|8 Weeks|No|||February 2014|February 28, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077088||49365|
NCT02076802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHSY-20130814|Regular Physical Exercise and Salt Diet on Coronary Artery Disease in Patients With Prehypertension(RESTRAIN Pre-HT)|Regular Physical Exercise and Salt Diet Effect on Progression of Coronary Disease in Patients With Prehypertension||General Hospital of Shenyang Military Region|Yes|Recruiting|December 2012|September 2014|Anticipated|July 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|45 Years|75 Years|No|Probability Sample|Coronary atherosclerosis patients with prehypertension|February 2014|February 28, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02076802|5 Years|49387|
NCT02077049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KlinikenValens_Oesch_RCT-2013|Are Serious Games Promoting Mobility an Attractive Alternative to Conventional Self-training for Elderly People?|Are Serious Games Promoting Mobility an Attractive Alternative to Conventional Self-training for Elderly People? A Randomized Controlled Trial.||Klinik Valens|Yes|Recruiting|February 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|65 Years|N/A|No|||June 2014|June 4, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02077049||49368|
NCT02077062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbph|Study of Mediators of Post Hepatectomy Liver Regeneration|Prospective Non-randomized Trial to Study Expression of Mediators of Post Hepatectomy Liver Regeneration(PHLR) and Compare With a Non-hepatectomy Group: a Pilot Study||Govind Ballabh Pant Hospital||Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|liver regeneration in patient with hepatectomy|March 2014|March 3, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02077062||49367|
NCT02077348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-247-13|Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.|Metabolic Signalling in Muscle- and Adipose Tissue Following Insulin Withdrawal and Growth Hormone Injection in Type I Diabetes Mellitus, a Clinical Experimental Study.||University of Aarhus|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|9|||Male|18 Years|65 Years|No|||February 2016|February 23, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02077348||49345|
NCT02077387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD074987|Promoting Child Inhibitory Control Skills Around Food|Promoting Child Inhibitory Control Skills Around Food|CHIC Play|University of California, San Diego|No|Completed|June 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|72|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077387||49342|
NCT02077673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-101|Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections|Robotic Assisted Laparoscopy Versus Open Gastroesophageal Resection; Effects on the Mesenteric Traction Reflex and PGI2 Levels||Rigshospitalet, Denmark|Yes|Completed|December 2013|April 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Serum Tissue|Both|18 Years|N/A|No|Non-Probability Sample|The patients will be recruited at; The Department of Surgical Gastroenterology,        Rigshospitalet, Denmark|May 2015|May 3, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02077673|90 Days|49320|
NCT02065648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC-2011-MR-02-01-NATIVE-Mos|Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet|NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet||Cedars-Sinai Medical Center|No|Active, not recruiting|May 2012|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Consenting patients referred for standard of care contrast-enhanced abdominal MR        Angiography|February 2014|February 14, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02065648||50240|
NCT02065661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZ Product Validation Study|Product Validation Study of 2 New Devices, EZ-NG (RightSpot pH Indicator) and EZ-pH (RightLevel pH Indicator)|Product Validation Study of 2 New Devices, EZ-NG (RightSpot pH Indicator) and EZ-pH (RightLevel pH Indicator)||Florida Hospital Tampa Bay Division|No|Completed|September 2011|February 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Consented elective surgical candidates|February 2014|February 14, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065661||50239|
NCT02073812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 503|Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects|A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073812||49617|
NCT02073825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AA023123|Web Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse Abuse|Web Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse|PC|RAND|No|Recruiting|November 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02073825||49616|
NCT02047851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-122|Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis|Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|October 2014|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047851||51604|
NCT02048072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSG 1.8|Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS|Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose|ANSG|Cantonal Hospital of St. Gallen|Yes|Completed|July 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|60 Years|No|||July 2015|July 28, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048072||51587|
NCT02074917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFMUSP972|Comparison of Dynamic Knee Stability and Functional Outcomes in Anatomical ACL Reconstruction at AM or Central Position|Comparison of Dynamic Knee Stability and Functional Outcomes in Anatomical Single-bundle ACL at Anteromedial or Central Tunnel Position - Prospective, Randomized and Double-blind Clinical Trial in Athletes||University of Sao Paulo|No|Recruiting|October 2012|October 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|No|||March 2014|March 14, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02074917||49532|
NCT02074098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intubation with a bed height|Endotracheal Intubation Using Macintosh Laryngoscope, Glidescope, Airwayscope During Chest Compression With Adjustment Height of a Bed|||Hanyang University|Yes|Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02074098||49595|
NCT02075177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC-2014-001|Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma|Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma (IND#68,254)||South Plains Oncology Consortium||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||December 2014|December 9, 2014|February 27, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02075177||49512|
NCT02075190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28625|Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression|Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression||Stanford University|No|Recruiting|February 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075190||49511|
NCT02074657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005146-38|"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia|"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia|LYDIA|Hospital Universitario La Paz|No|Recruiting|April 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|23 Years|No|||February 2016|February 23, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074657||49552|
NCT02075203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-040-404|A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents (040-404)|A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents||Aeras|Yes|Active, not recruiting|February 2014|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|990|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02075203||49510|
NCT02051465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 2012-64|Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM|A Randomized Controlled Trial to Evaluate Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM (LR) as a Modified Colonic Overtube||Mercy Medical Center|Yes|Recruiting|May 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|17 Years|90 Years|No|||May 2015|May 6, 2015|January 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051465||51327|
NCT02047708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003200-39|Zibotentan Better Renal Scleroderma Outcome Study|A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma|ZEBRA|University College, London|Yes|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047708||51615|
NCT02051699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orthoTU04|One-Leg Standing Radiograph: A Novel Technique to Evaluate the Severity of OA Knee|One-Leg Standing Radiograph: A Novel Technique to Evaluate the Severity of Knee Osteoarthritis|OA knee|Thammasat University|No|Completed|June 2012|February 2013|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|50|||Both|40 Years|90 Years|No|Non-Probability Sample|the patients who came to our clinic which bilateral knee pain|January 2014|January 30, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051699|1 Day|51309|
NCT02047721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3252|The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals|The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals||University of Colorado, Denver|Yes|Recruiting|February 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02047721||51614|
NCT02047734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-201 (Part B)|Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients||Celgene|Yes|Active, not recruiting|November 2013|June 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1200|||Both|18 Years|55 Years|No|||April 2015|April 14, 2015|January 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047734||51613|
NCT02047916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS 145159|NeoAdapt 1: A Study of Circulatory Adaptation of Newborn Infants After Birth|NeoAdapt 1: A Study of Circulatory Adaptation of Newborn Infants After Birth||Brighton and Sussex University Hospitals NHS Trust|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|N/A|3 Days|Accepts Healthy Volunteers|Non-Probability Sample|Potential candidates for enrolment will be infants admitted to the postnatal ward for        routine post natal care and those admitted to the Trevor Mann Baby Unit for special care.        The infants will be greater than 33 weeks´ gestation, and postnatal age below 72 hours.|July 2015|July 13, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02047916||51599|
NCT02048436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78o944o|Perminova Respiratory Effort Accuracy Validation 09-12-2013-Rev 2|Perminova Respiratory Effort Accuracy Validation 09-12-2013-Rev 2||Clinimark, LLC|Yes|Completed|September 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy Male or female, ages 18-45|January 2014|January 27, 2014|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02048436||51559|
NCT02048215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THERMODIET|Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in Obesity|Evaluation of Diet and Treatment With a Combination of Ephedrine and Caffeine on Thermogenesis, Cardiac Function and on Uncoupling Proteins Expression in Adipose and Muscle Tissue of Morbid Obese Patients Undergoing Bariatric Surgery.||Istituto Auxologico Italiano|No|Completed|February 2000|November 2007|Actual|January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|13|||Female|18 Years|55 Years|No|||January 2014|January 27, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02048215||51576|
NCT02048449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChuncheonSHH 2013|Inter-rater Reliability of the Reflux Finding Score Among Gastroenterologists|Inter-rater Reliability of the Reflux Finding Score Based on Endoscopic Laryngeal Findings in the Diagnosis of Laryngopharyngeal Reflux Disease||Chuncheon Sacred Heart Hospital|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|||Both|N/A|N/A|No|Non-Probability Sample|not appliable|April 2014|April 4, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02048449||51558|
NCT02095665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAM|Ureteral Stent-related Pain and Mirabegron (SPAM) Trial|Ureteral Stent-related Pain and Mirabegron (SPAM) Trial|SPAM|Nova Scotia Health Authority|No|Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|236|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02095665||47941|
NCT02095951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2024.11|Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection|Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter Associated Bloodstream Infection: Impact on Length of Stay and Catheter Salvage||Children's Hospital of Michigan|Yes|Recruiting|June 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Months|21 Years|No|||February 2016|February 22, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02095951||47919|
NCT02048930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02411|Real Life Effectiveness of Easyhaler (Orion)|Effectiveness and Cost-effectiveness Evaluation of Easyhaler Versus Other Devices in a Real World Primary Care Population||Research in Real-Life Ltd||Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|24003|||Both|6 Years|80 Years|No|Non-Probability Sample|This will be a retrospective, observational study consisting of a one-year baseline period        immediately prior to an index prescription date (IPD), and a one-year outcome period        immediately following the index date.        At the IPD, patients either:          -  Initiation cohort: receive their first prescription for ICS therapy as one of the             study drugs          -  Step-up cohort: receive a prescription for one of the study drugs at a dose ≥50% that             of their prescribed ICS dose during baseline.          -  Switch cohort: switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other)             with no change in ICS dose|January 2014|January 28, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048930||51522|
NCT02049541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13027|Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma|A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|July 2014|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049541||51475|
NCT02080611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402M47947|Smart Textile Technology for Scoliosis|Smart Textile Technology for Scoliosis: Aim 1||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers will be used, recruited from the university community.|March 2014|March 4, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02080611||49094|
NCT02050373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382/2011|Low-level Laser Therapy on Inflammatory Mediators During Chemotherapy-induced Oral Mucositis|Effect of Low-level Laser Therapy on Inflammatory Mediators Release During Chemotherapy-induced Oral Mucositis: a Randomized Preliminary Study|LLLTHSCT|Universidade Federal de Goias|Yes|Completed|January 2012|August 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|14 Years|N/A|No|||January 2014|January 28, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02050373||51411|
NCT02050399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13287613.0.0000.5504|Cardiovascular Oscillations in Coronary Patients With and Without Type 2 Diabetes|Cardiovascular Oscillations at Rest and During Isometric Exercise in Coronary Patients With and Without Type 2 Diabetes||Universidade Federal de Sao Carlos|Yes|Recruiting|August 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|3||Anticipated|45|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02050399||51409|
NCT02050646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303011696|The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis|The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis||Yale University|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|1 Year|65 Years|No|||January 2016|January 6, 2016|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02050646||51390|
NCT02050958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXP001-002|Pilot Study of OXP001 and Brufen in Healthy Subjects|A Randomised, Open Label, Evaluator Blinded, Multiple Dose, Parallel Arm, Phase I Pilot Study of OXP001 Ibuprofen 400 mg Tablets and Brufen 400 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions to Assess The Incidence of Upper Gastrointestinal Irritation||Oxford Pharmascience Ltd|No|Completed|February 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|January 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02050958||51366|
NCT02051491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0276A|Non-invasive Ventilation for Extubation Success in Infants Less Than 1,250 Grams|A Randomized Controlled Trial of BiPhasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) vs. Non-invasive High Frequency Ventilation (NIHFV) Following NCPAP Failure: A Pilot Study|NOVEL|Mount Sinai Hospital, Canada|No|Recruiting|June 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||May 2014|May 15, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02051491||51325|
NCT02051712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZHK-HGW-001|Cardiovascular Effects of Preferred Home-based Exercise Training in Systolic Heart Failure|Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study|HOMEX-HF Pilot|University Medicine Greifswald|No|Recruiting|February 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|30 Years|75 Years|No|||November 2015|November 30, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051712||51308|
NCT02047747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130418|A Phase II Study of Dacomitinib in Progressive Brain Metastases|A Phase II Study to Evaluate the Efficacy, Safety, and Central Nervous System (CNS) Pharmacokinetics of the HER Family Inhibitor Dacomitinib in Progressive Brain Metastases||University of California, San Diego|Yes|Recruiting|February 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02047747||51612|
NCT02047760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147305|Neuroretinal Biomarkers in Neurodegenerative Diseases|Investigation Into the Role of Neuroretinal Biomarkers in the Phenotyping of Neurodegenerative Diseases, and Potential for Tracking Progression and Monitoring Impact of Interventions, Events and Therapies.||University of Edinburgh|No|Active, not recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|All MS patients attending the ARRNC research clinic|December 2015|December 1, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047760||51611|
NCT02048189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUDONI PARI 2011|Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes|Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment|TRICIDIA|Centre Hospitalier Universitaire Dijon||Recruiting|March 2012|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048189||51578|
NCT02048202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-2013.CTIL|Medical Clowning in the NICU (Neonatal Intensive Care Unit and Their Effects on Parents and Staff|Effects of Medical Clowning (Dream Doctors) on the Development of the Nervous System and the Relationship Between Preterm Premature Baby Parents and NICU Staff|clowns|The Baruch Padeh Medical Center, Poriya|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|4 Weeks|No|Non-Probability Sample|Premature neonates 32 weeks gestation|January 2015|May 3, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02048202||51577|
NCT02048462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47367.068.13|The Effect of Strenuous Exercise on Coagulation.|The Effect of Strenuous Exercise on Coagulation: Hemostatic Behaviour Before and After Amstel Gold Race||Synapse bv|Yes|Completed|April 2014|November 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants of the Amstel Gold Race for non-professionals will be asked to join        our study.|November 2014|November 24, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048462||51557|
NCT02048475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kotoe _ 2|Electroencephalogram During Desflurane Anaesthesia|Electroencephalogram During Increasing and Decreasing Desflurane Concentration||Tampere University Hospital|No|Withdrawn|January 2010|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|October 8, 2013||No|administrative reasons.|No||https://clinicaltrials.gov/show/NCT02048475||51556|
NCT02048813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00118|Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)|Yes|Recruiting|February 2014|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|519|||Both|18 Years|70 Years|No|||March 2016|March 18, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048813||51531|
NCT02048826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2008-6432|FINGER Robot Therapy Study|Study of Influence of Timing on Motor Learning||University of California, Irvine|No|Recruiting|November 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|80 Years|No|||November 2013|January 27, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048826||51530|
NCT02048839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiel 5Y|Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors|Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors||Helsinki University|No|Enrolling by invitation|January 2014|||February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|550|Samples With DNA|Blood, saliva, hair, urine and fecal samples|Both|3 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who participated the Radiel intervention study, and were originally randomly        assigned to either active lifestyle intervention group or control group. They were all        high risk women with BMI >30 or prior gestational GDM. To this follow up-study we invite        also the children born during the intervention.|August 2015|August 17, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048839||51529|
NCT02096211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12017|Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)|36mm CERAMAX® Ceramic Hip System PMA PAS STUDY: Short to Mid-Term Follow-up , New Study Subjects (Ceramic Hip System, Subjects Receive CERAMAX 36mm Ceramic Acetabular Bearing Insert That Articulates With a Ceramic Femoral Head for THA)|COC36mmPAS|DePuy Orthopaedics|No|Recruiting|June 2014|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|21 Years|75 Years|No|||December 2015|December 14, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02096211||47899|
NCT02096224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRBDSevoDes|Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort|Comparison of the Effects of Sevoflurane and Desflurane on Prevention of Catheter-related Bladder Discomfort||Seoul National University Hospital|Yes|Completed|May 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Both|18 Years|80 Years|No|||March 2014|September 30, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096224||47898|
NCT02096432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13110601|Suicide Prevention in Chinese Older Adults|Suicide Prevention in Chinese Older Adults||Rush University Medical Center||Not yet recruiting|April 2014|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|60 Years|N/A|No|||March 2014|April 14, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096432||47882|
NCT02096445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-13-02-009921|Neurocognitive Robot-assisted Rehabilitation of Hand Function After Stroke|Neurocognitive Robot-assisted Rehabilitation of Hand Function After Stroke||Swiss Federal Institute of Technology|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|90 Years|No|||March 2016|March 21, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096445||47881|
NCT02049281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-011|A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)|A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor||Endocyte|No|Terminated|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|20 Years|N/A|No|||February 2015|February 9, 2015|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049281||51495|
NCT02080325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|783 Soya|Vegetarian High Protein Weight Loss Diets|Vegetarian High Protein Weight Loss Diets|ALPROsoya|University of Aberdeen|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02080325||49116|
NCT02050100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKTCTCH0001|Biomarkers for Diagnosis of Lung Cancer|Biomarkers for Diagnosis of Lung Cancer||SK Medical (Beijing) Co., Ltd.|No|Recruiting|January 2014|February 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Two 10ml blood samples (serum and plasma) from the patient will be analyzed for protein      biomarkers associated with lung cancer diagnosis|Both|18 Years|N/A|No|Probability Sample|A total of 300 patients will be recruited from hospital pulmonary clinics. The study        participants will have pulmonary nodules suspicious for lung cancer and a bronchial biopsy        diagnosis of NSCLC or probable benign. Approximately half of the patients will be cases        and half controls.|September 2014|September 2, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02050100||51432|
NCT02050412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-Scratch-Cat-001|A Pilot Study for the Determination of Allergenicity of Cat Dander Samples Obtained by Different Methods|||University of Zurich||Completed|February 2014|April 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050412||51408|
NCT02050659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEGA|Omentectomy in Radical Gastrectomy for Gastric Cancer Trial|Omentectomy in Radical Gastrectomy for Gastric Cancer Trial|OMEGA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Completed|March 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|patients with a castric carcinoma who received an in potentially curative gastric        resection|March 2015|March 9, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050659||51389|
NCT02050672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI_ICSI|Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study|Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study|MI_ICSI|AGUNCO Obstetrics and Gynecology Centre||Recruiting|May 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||||||Male|30 Years|42 Years||||January 2014|January 29, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02050672||51388|
NCT02050971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPO 01|Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates|Safety and Effectiveness Phase 1 Study of Autologous Umbilical Cord Blood Transfusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates||Pomeranian Medical University Szczecin|No|Enrolling by invitation|October 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|30 Days|No|||January 2014|January 30, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050971||51365|
NCT02051231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01|Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization|Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051231||51345|
NCT02051244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0094-CTIL|Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?|Pilot Study That Investigates the Potential of Using OCT (Optical Coherence Tomography) Measurements of the Thickness of the Retinal Nerve Fiber Layer as a Biomarker for the Early Detection of Alzheimer's Disease.|SCI-OCT|Carmel Medical Center|No|Not yet recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subjects will be mainly recruited from the geriatric ward (patients, relatives, etc)        and the cognitive clinic of the Carmel Medical Center.|January 2014|January 30, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02051244||51344|
NCT02051738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103571|A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02051738||51306|
NCT02051751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719Z2101|A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer|A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy||Novartis|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|January 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02051751||51305|
NCT02051725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANC 104-1.5-11|Functional Impairments and Exercise in Older Adults With Low Physical Function,|Implementation of an "Active Life-style" Intervention in Older People With Low Physical Function: Effect on Functional Impairments, Pilot|HANC-Pilot|University of Southern Denmark|No|Recruiting|November 2013|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|76 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02051725||51307|
NCT02047981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1032340-A|Mortality Reduction After Oral Azithromycin: Mortality Study|Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Mortality Trial|MORDOR|University of California, San Francisco|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|227000|||Both|1 Month|60 Months|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047981||51594|
NCT02047942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOVE-AGE_09_2013|Telerehabilitation in Coronary Heart Disease|A Randomized Controlled Trial Comparing Home-based Training With Telemonitoring Guidance Versus Center-based Cardiac Rehabilitation in Patients With Coronary Heart Disease: the TRiCH-study|TRiCH|Katholieke Universiteit Leuven|No|Recruiting|February 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|40 Years|75 Years|No|||March 2016|March 3, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02047942||51597|
NCT02048228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01417884|Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS|Study of Clopidogrel and Ticagrelor Anti-Platelet Treatment Using an Individualized Strategy Based on Genotyping in Chinese ACS Patients|GI-CT|Chinese PLA General Hospital|Yes|Not yet recruiting|October 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048228||51575|
NCT02048488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-20-5006-C|A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas|A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas||Tesaro, Inc.|No|Active, not recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02048488||51555|
NCT02048852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORN004127HE|Manipulating Tobacco Constituents in Female Menthol Smokers|Manipulating Tobacco Constituents in Female Menthol Smokers|Menthol|University of Connecticut Health Center|Yes|Recruiting|July 2014|December 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|320|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048852||51528|
NCT02049099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.HAEM89-001|A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care|A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care||Swedish Orphan Biovitrum|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1658|||Male|2 Years|N/A|No|Non-Probability Sample|The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9        or haemophilia B D67.9.|March 2016|March 11, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049099||51509|
NCT02049112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN/2011/001|A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study|Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia.|NIAGARA|Unither Pharmaceuticals, France|No|Completed|January 2012|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049112||51508|
NCT02049424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-03/2011|Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow|Retrospective-prospective Observational Study for Data Collection of Patients Who Underwent an Haploidentical Transplantation After Non-myeloablative Conditioning Regimen||Istituto Clinico Humanitas|No|Terminated|March 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|patients who underwent a haploidentical transplantion after non-myeloablative conditioning        regimen|January 2014|January 28, 2014|June 28, 2013||No|low recruitment|No||https://clinicaltrials.gov/show/NCT02049424||51484|
NCT02096237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-IgE-01-A|Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)|First in Man Trial to Investigate Safety and Efficacy of the New IgE Adsorber|ESPIRA|Fresenius Medical Care Deutschland GmbH|No|Completed|December 2013|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|50 Years|No|||March 2015|March 5, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096237||47897|
NCT02096458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR(OD)_107|Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets|An Open-Label Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Subjects : TAK-390MR(OD)_107||Takeda|No|Completed|February 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 22, 2015|February 21, 2014|No|Yes||No|February 22, 2015|https://clinicaltrials.gov/show/NCT02096458||47880|
NCT02096471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI176190|MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1|A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas|MEK Inhibitor|University of Alabama at Birmingham|Yes|Active, not recruiting|June 2014|December 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|16 Years|N/A|No|||March 2016|March 19, 2016|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096471||47879|
NCT02049294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 14-008|Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis|Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis||McMaster University|No|Recruiting|March 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049294||51494|
NCT02049307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-007|Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial|Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial|LIFE-HIV|Minneapolis Medical Research Foundation|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||December 2015|December 21, 2015|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049307||51493|
NCT02049801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0030|MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of MEK Inhibitor MEK162 Combined With Idarubicin and Cytarabine Induction in Patients With Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia||Stanford University||Recruiting|December 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049801||51455|
NCT02050113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARPE-01|Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices|Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices|CARPE-CMD|University of Massachusetts, Worcester|Yes|Recruiting|March 2014|March 2024|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050113||51431|
NCT02050126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-UP-12-02|Caesarean Scar Revision With the UltraPulse|Caesarean Scar Revision With the UltraPulse||Lumenis Ltd.|No|Completed|April 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|22 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050126||51430|
NCT02050386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300392|The Brain Alerting Mechanism Study|The Role of Brain Arousal Systems in Cognitive and Physical Decline in Normal Aging||University of Florida|No|Not yet recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults 18 and older.|December 2015|December 14, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02050386||51410|
NCT02050685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REES-ASTES-2014|Comparison of Different Screening Score for Hypoxemic OSA (Obstructive Sleep Apnea) With the Results of a Polysomnography (PSG)|Comparison of Different Screening Score for Hypoxemic OSA||Astes|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|159|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All adults patients for an overnight polysomnography at SLBO.|January 2016|January 5, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02050685||51387|
NCT02050451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU-IRB-131560|Perioperative Oral Nutrition Intervention for Patients Undergoing Radical Cystectomy|A Pilot Study of Perioperative Oral Nutrition Supplementation to Improve Nutritional Status, Post-operative Complications, Length of Stay and Readmission Rates in Patients Undergoing Radical Cystectomy||Vanderbilt University|No|Recruiting|March 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|90 Years|No|||December 2014|December 10, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050451||51405|
NCT02050984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASBP|Effect of Bariatric Surgery on Blood Pressure|A Prospective Study on the Effects of Bariatric Surgery on Blood Pressure in Patients With Obesity and Diabetes|BASBP|Third Military Medical University|Yes|Recruiting|January 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood sample|Both|18 Years|60 Years|No|Non-Probability Sample|Patients with obesity and diabetes|January 2014|January 29, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02050984||51364|
NCT02050997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-31|Plasma Biomarkers P-DAC, V1|Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (P-DAC Plasma Biomarker Study)||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|October 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|All patients on this study must have pancreatic ductal adenocarcinoma.|October 2015|February 15, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02050997||51363|
NCT02051478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC2012/11|Thoracic Manipulation and Mobilization for Neck Pain|CHANGES IN PRESSURE PAIN SENSITIVITY AND NECK PAIN AFTER THORACIC THRUST MANIPULATION OR NON-THRUST MOBILIZATION IN PATIENTS WITH MECHANICAL NECK PAIN||Universidad Rey Juan Carlos|Yes|Completed|September 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|20 Years|65 Years|No|||January 2014|January 30, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02051478||51326|
NCT02047994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-36|Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality|Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality|GISTAR|International Agency for Research on Cancer|Yes|Recruiting|October 2013|December 2035|Anticipated|December 2033|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30000|||Both|40 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02047994||51593|
NCT02047773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLTBrIVStudy|Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations|Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study|BLTBrIV|University of Edinburgh|No|Recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02047773||51610|
NCT02048514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N09-01|The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms|The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms||Endologix|No|Active, not recruiting|December 2008|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048514||51553|
NCT02048527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Global versus Origio|Single-step Versus Sequential Media in Preimplantation Embryo Development and Pregnancy Rates|Comparison of Single-step (Global) Versus Sequential Media (Origio) in Preimplantation Embryo Development and Pregnancy Rates||Eugonia|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|131|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048527||51552|
NCT02047955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13B-T-SHOULDER-RM|Tornier Shoulder Outcomes Study to Examine Safety and Functional Outcomes in Shoulder Arthroplasty and Fracture Patients|Tornier Shoulder Outcomes Clinical Study||Tornier, Inc.|No|Recruiting|March 2014|||January 2054|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from United States, European, Canada, and Australia.|September 2015|September 23, 2015|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02047955|20 Years|51596|
NCT02047968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT12|Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences|Wake and Light Therapy to In-patients With Major Depression: A Randomized Controlled Trail, Efficacy, Predictors and Patient Experiences||University of Aarhus|Yes|Recruiting|February 2014|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02047968||51595|
NCT02048501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049254|Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y|Gut Hormone, Energy Expenditure and Body Composition Change in Subjects Who Succeed or Fail to Sustain Weight Loss After Roux-en-Y Gastric Bypass||Duke University|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|57|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048501||51554|
NCT02049671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED12/10391|Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet|||The Leeds Teaching Hospitals NHS Trust||Recruiting|July 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|16 Years|90 Years||Non-Probability Sample|Hypopituitary adults|September 2014|September 23, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02049671||51465|
NCT02049944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-13|Increased Cefazolin During Cesarean Delivery in Obese Population|Increased Cefazolin (Ancef) Dosing for Prophylaxis During Cesarean Delivery in the Obese Population||MemorialCare Health System|No|Completed|August 2013|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Female|N/A|N/A|No|||January 2015|January 7, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02049944||51444|
NCT02096809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-5-14|Stability of the Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery|Evaluation of Soft Tissue Healing and Implant Stability of Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery After Linear Incision Without Soft Tissue Reduction.||Aarhus University Hospital|No|Completed|March 2014|September 2015|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02096809||47854|
NCT02097069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITA01|Inositol Stereoisomers to Treat Gestational Diabetes|Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes||Università degli Studi 'G. d'Annunzio' Chieti e Pescara|Yes|Not yet recruiting|April 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Female|18 Years|45 Years|No|||March 2014|March 23, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02097069||47834|
NCT02097082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480-SFA2013-001|Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System|An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions|SPRINT|480 Biomedical, Inc.|Yes|Recruiting|October 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097082||47833|
NCT02080091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-01-13-003|Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies|ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien® (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies|ILUMINATE|Alimera Sciences|No|Terminated|December 2013|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with DME considered insufficiently responsive to available therapies in        approximately 25 ophthalmology centers (private practice or hospital) across Germany|August 2015|August 14, 2015|March 3, 2014||No||No|July 15, 2015|https://clinicaltrials.gov/show/NCT02080091||49134|
NCT02049554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00084255|Preconception Women's Health in Pediatric Practice Intervention|||Johns Hopkins University|No|Active, not recruiting|October 2013|March 2017|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|415|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02049554||51474|
NCT02049814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASCN1201|Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes|Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone: a Randomized, Open-label, Non-inferiority Study||Takeda|No|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049814||51454|
NCT02049827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-03|Evaluation of a Predictive Immunovirological Test Occurrence of BK Virus Nephropathy in Renal Transplant|Evaluation of a Predictive Immunovirological Test Occurrence of BK Virus Nephropathy in Renal Transplant||Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049827||51453|
NCT02049840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU016|The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence|The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence|EASY|Coloplast A/S|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|136|||Female|18 Years|N/A|No|||April 2015|April 22, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049840||51452|
NCT02050139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINDY|L-Cysteine in Peritoneal Dialysis|A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE RENAL AND BIOHUMORAL EFFECTS OF L-CYSTEINE COMPARED TO PLACEBO IN STABLE PERITONEAL DIALYSIS PATIENTS WITH RESIDUAL DIURESIS|CINDY|Mario Negri Institute for Pharmacological Research|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050139||51429|
NCT02050711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFRH/BD/84665/2012|Effects of Pulmonary Rehabilitation on Respiratory Sounds in Patients With COPD|Effects of Pulmonary Rehabilitation on Computerized Respiratory Sounds in Patients With Chronic Obstructive Pulmonary Disease||Aveiro University|No|Recruiting|May 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050711||51385|
NCT02050724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU 12/048|ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT|Thorakoskopische Handheld-SPECT Gesteuerte Ektomie Von Radioaktiv-markierten Pulmonalen Rundherden. Proof of Feasibility of Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With the Help of Free-hand SPECT.|ThoHSpEkt|Cantonal Hospital of St. Gallen|Yes|Recruiting|November 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02050724||51384|
NCT02050698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2014-OS01|Hard-soled Shoe Versus Short Leg Walking Cast for a Fifth Metatarsal Avulsion Fracture: A Randomized Multicenter Noninferiority Trial|Hard-soled Shoe Versus Short Leg Walking Cast for a Fifth Metatarsal Avulsion Fracture: A Randomized Multicenter Noninferiority Trial||Hallym University Kangnam Sacred Heart Hospital|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||October 2015|October 11, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050698||51386|
NCT02051257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13277|Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma|Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma||City of Hope Medical Center|Yes|Recruiting|May 2014|||June 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02051257||51343|
NCT02051504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_52|Muscle Oxygenation, Type 1 Diabetes, and Glycated Hemoglobin|Impact of Type 1 Diabetes and Glycated Haemoglobin Levels on Oxygen Delivery and Release to Active Muscle During Exercise and on Muscle Oxidation Capacity - Possible Impact on Aerobic Fitness|OXYDIAB|University Hospital, Lille|Yes|Completed|March 2010|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|79|Samples With DNA|Whole blood, plasma, serum, and skeletal muscle (vastus lateralis) samples|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The two groups of patients with Type 1 diabetes are recruited from primary care clinics        (university hospital of Lille and hospital of Roubaix, France) among patients with Type 1        diabetes for more than 1 year and free from micro and macrovascular complications.        Healthy participants are selected from a list (n=250) drawn up from patients' friends and        contacts. Each healthy control is chosen to strictly match a patient with type 1 diabetes        according to gender, age, physical activity levels, and tobacco status.|December 2014|December 11, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02051504||51324|
NCT02048267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/338/MS/9609-1|Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis|A Prospective Study of Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis||Postgraduate Institute of Medical Education and Research||Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|||Both|15 Years|65 Years|No|Non-Probability Sample|All patients of chronic pancreatitis with unremitting pain requiring surgery at primary        care clinic|November 2014|November 8, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02048267||51572|
NCT02049450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424X2201|Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.|A Single Arm, Multicenter, Phase IIa Study to Explore the Efficacy and Safety of Ruxolitinib (INC424) in Regularly Transfused Patients With Thalassemia||Novartis|No|Active, not recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049450||51482|
NCT02048241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6068|Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder|Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder||New York State Psychiatric Institute|Yes|Recruiting|July 2011|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|12 Years|No|||January 2014|January 27, 2014|December 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048241||51574|
NCT02048254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201308|Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer|A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer||Peking University|Yes|Recruiting|February 2014|June 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||May 2015|May 12, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048254||51573|
NCT02049437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDS 347|AIDS 347: IL-6 Blockade in Treated HIV Infection|AIDS 347: IL-6 Blockade in Treated HIV Infection|IL-6|Case Western Reserve University|Yes|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049437||51483|
NCT02049957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C31001|Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer|A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant||Millennium Pharmaceuticals, Inc.|No|Recruiting|February 2014|November 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02049957||51443|
NCT02050230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASG 2013-002316-27|Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients|Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients||Medical University of Vienna|Yes|Recruiting|January 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02050230||51422|
NCT02050516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOW-1|Comparison of Single vs Group Embryo Culture in Micro-well Group Culture Dish|Randomized Controlled Comparison of Single Embryo Culture Versus Group Culture Using a Micro-well Group Culture Dish in Humans||Eurofertil IVF Health Center|No|Recruiting|July 2013|July 2014|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|160|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050516||51400|
NCT02050503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP073|Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis|Ability of Intranasal Transmucosal Fentanyl Pectin Nasal Spray to Prevent Breakthrough Pain Episodes in Patients With Radiation-induced Oropharyngeal Mucositis|CP073|Grupo de Investigación Clínica en Oncología Radioterapia|Yes|Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|75 Years|No|Probability Sample|adults of either sex and over 18 and under 75 years of age, receiving continued treatment        with long half-life or controlled release opioids, experiencing breakthrough pain        secondary to mucositis in the context of radiotherapy or radio-chemotherapy for head and        neck tumors.|March 2015|March 16, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050503||51401|
NCT02097095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-041-972|Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)|Substudy of GSK Protocol TB-018: Collection and Storage of Biological Samples for Evaluation of Correlates of Tuberculosis||Aeras|No|Active, not recruiting|August 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|3253|Samples With DNA|Specimens for this sub-study are collected from an interventional Phase 2 study (TB-018 see      NCT 01755598) and later analyzed for correlates of risk to tuberculosis.      PBMC/Plasma; Whole Blood cell count; Intracellular RNA|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Subjects who have consented to participate in TB-018 will be approached for participation        in this sub-study. Subjects who have consented to participate in TB-018 are not required        to participate in this sub-study.|February 2016|February 3, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097095||47832|
NCT02096835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAS-PONV|Transcutaneous Electrical Acupoint Stimulation of P6 to Prevent Postoperation Nausea and Vomiting|Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron Both in Combination With Dexamethasone to Prevent Postoperation Nausea and Vomiting in Women|TEASP6PPONV|Huashan Hospital|Yes|Completed|January 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|157|||Female|18 Years|60 Years|No|||October 2015|October 9, 2015|March 24, 2014||No||No|January 5, 2015|https://clinicaltrials.gov/show/NCT02096835||47852|
NCT02049333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECPLateau10.1|Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome|Phacoemulsification Versus Phacoemulsification With Endoscopic Cycloplasty (ECPL) for Treatment of Plateau Iris Configuration or Syndrome: A Prospective Randomized Clinical and Surgical Study||Credit Valley EyeCare|No|Completed|November 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049333||51491|
NCT02049567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP01725|Evaluation of the FluidVision Accommodating Lens|Clinical Evaluation of the FluidVision Accommodating Intraocular Lens|AIOL-2009-1|PowerVision|No|Active, not recruiting|January 2014|July 2017|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|50 Years|N/A|No|||April 2015|April 13, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049567||51473|
NCT02049580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2011-005|Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas|Multi-center, Phase II Study to Assess the Safety and Efficacy of Haploidentical Bone Marrow Transplantation Using Reduced Intensity Conditioning(RIC)Regimen and Post-transplant Cyclophosphamide,in Patients With Poor Prognosis Lymphomas||Istituto Clinico Humanitas|No|Recruiting|July 2013|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049580||51472|
NCT02049853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TripleA01|The Triple A Initiative Study ("Aktionsbündnis Akute Atemnot")|A Prospective Randomized Study of Coordinated Diagnostic Pathways and Treatment Algorithms for Patients With Acute Dyspnea Including Point-of-care Testing of a Cardiac Biomarker by the Emergency Medical Service Team||Klinikum Nürnberg|No|Terminated|June 2013|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|67|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 28, 2014||No|recruitment numbers lower than expected|No||https://clinicaltrials.gov/show/NCT02049853||51451|
NCT02050425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-2013-0536|Breath Analysis in Obstructive Sleep Apnoea|Exhaled Breath Analysis by Mass Spectrometry in Patients With Obstructive Sleep Apnoea - a Randomised Placebo-controlled Trial.||University of Zurich|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|20 Years|75 Years|No|||November 2014|November 23, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050425||51407|
NCT02050438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COTCSPT1JV|How Total Knee Prosthesis Dessigns Influence in Quality of Live|||Corporacion Parc Tauli|No|Completed|January 2014|||July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|135|||Both|65 Years|80 Years|No|Non-Probability Sample|Patients operated Total Knee Arthroplasty 6 months previously the observational study|July 2014|July 25, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050438||51406|
NCT02051036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC1307|Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study|A Pilot Study on Effectiveness and Safety of Moxibustion for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome||Korean Medicine Hospital of Pusan National University|Yes|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Male|20 Years|80 Years|No|||March 2016|March 11, 2016|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02051036||51360|
NCT02051010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 13-01|ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?|ABC Survey: Are we Meeting the Needs of Patients With Advanced Breast Cancer (ABC) in Ireland? A Nationwide Survey||ICORG- All Ireland Cooperative Oncology Research Group|No|Completed|May 2013|||March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Female|18 Years|N/A|No|Non-Probability Sample|All patients must have metastatic breast cancer|March 2015|March 27, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02051010||51362|
NCT02051023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-CERLAB-003-2013|Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)|Randomized, Double-Masked, Vehicle-controlled Phase III Trial on the Safety/Efficacy of FML® 0.1% in the Treatment of the Inflammatory Exacerbation Provoked by Exposure to an Adverse Controlled Environment in Patients With Dry Eye Disease|FML|Instituto Universitario de Oftalmobiología Aplicada|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02051023||51361|
NCT02051764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A04|Imaging Characteristics of a Follow-up 18F-AV-1451 Scan|An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan||Avid Radiopharmaceuticals|No|Enrolling by invitation|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051764||51304|
NCT02051777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC801|Hospital Discharge Oral Nutrition Support Trial|||Nutricia UK Ltd|No|Completed|July 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|120|||Both|50 Years|N/A|No|||October 2015|October 6, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02051777||51303|
NCT02047786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRB13069-PGA|A Comparison of Appendicectomy Outcomes in Children Between Paediatric and General Surgical Centres in Scotland|A Comparison of Appendicectomy Outcomes in Children Between Paediatric and General Surgical Centres in Scotland||University of Edinburgh|No|Completed|January 2001|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|4000|None Retained|Please note that the investigators are not yet in receipt of the database required for this      study. Although the study period has ended, we are not able at present to state how many      patient episodes this database has captured.|Both|2 Years|12 Years|No|Probability Sample|All children resident in Scotland, who undergo appendicectomy during the study period        specified.|January 2014|January 24, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02047786||51609|
NCT02048865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSN-20130563-01H|Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients|Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial|AVERT|Ottawa Hospital Research Institute|Yes|Recruiting|January 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|574|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048865||51527|
NCT02049151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 63325-021|Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)|START2|EMD Serono|Yes|Terminated|March 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2015|October 8, 2015|January 27, 2014|Yes|Yes|The study is terminated prematurely as the sponsor decided to discontinue program with    Tecemotide in NSCLC|No||https://clinicaltrials.gov/show/NCT02049151||51505|
NCT02049164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR08.100|Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)|A Randomized, Double-blind, Placebo-controlled, Forced Titration, Dose-ranging Study of AR08 in the Treatment of Vasomotor Symptoms (VMS) in Menopausal Females: A Proof-of-Concept Study||Arbor Pharmaceuticals, Inc.|No|Terminated|January 2014|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Female|41 Years|N/A|No|||November 2015|November 10, 2015|January 28, 2014|Yes|Yes|Study stopping criteria met with regards to vital sign measurements post dose.|No||https://clinicaltrials.gov/show/NCT02049164||51504|
NCT02049697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100588|A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants|Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 (TPI 1062) After a Single Oral Dose in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|56 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049697||51463|
NCT02049125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAL01|Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis|Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response||University of Sao Paulo|No|Recruiting|June 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|We will store samples of urine and serum frozen at -80oC.|Both|18 Years|N/A|No|Non-Probability Sample|We will include cirrhotic patients admitted to hospitals participating centers with AKI        and/or bacterial infection.|November 2015|November 30, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049125||51507|
NCT02049138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-538|An Open-label Extension Study Evaluating the Safety and Efficacy of ABT-494 in Rheumatoid Arthritis Subjects|Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With ABT-494||AbbVie|No|Active, not recruiting|January 2014|July 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|470|||Both|18 Years|100 Years|No|||January 2016|January 27, 2016|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049138||51506|
NCT02049970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/107|Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade|Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade for Forearm Surgery.||TC Erciyes University|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049970||51442|
NCT02049983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV-TP-0010|Levita Magnetic Grasper Device Safety and Performance Study|Levita Magnetic Grasper Device Safety and Performance Study||Levita Magnetics||Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|No|||March 2015|March 10, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049983||51441|
NCT02050529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Labetalol in Severe preg HTN|Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.|Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi.||Dow University of Health Sciences|Yes|Recruiting|February 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|15 Years|49 Years|No|||January 2014|January 29, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050529||51399|
NCT02051101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2013-9396|Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples|Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples||University of California, Irvine|No|Recruiting|May 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02051101||51355|
NCT02050815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162A2104|MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function|A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment|MEK162|Array BioPharma|No|Recruiting|March 2014|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050815||51377|
NCT02097108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_HIV1|Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir|One Arm, Open Label, Interventional, Non-comparative Study to Assess Changes in Lipids and Lipoproteins in HIV Infected Women With Hyperlipidemia After Switch From Boosted Protease Inhibitor to Raltegravir||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Recruiting|May 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||June 2015|June 3, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097108||47831|
NCT02049346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11021/11|Comparison Among Erythropoietin Stimulating Agents|Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar.||Hamad Medical Corporation|Yes|Completed|March 2012|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|327|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049346||51490|
NCT02049359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49|Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics|Use of a Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetic Patients (SAMI TRIAL)|SAMI|Campbell University, Incorporated|No|Active, not recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|170|||Both|18 Years|80 Years|No|||January 2016|February 2, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049359||51489|
NCT02049593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO-US GI-07|PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|June 2014|||April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049593||51471|
NCT02050152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nitrous Oxide Amnesia Children|Nitrous Oxide Induction Induces Amnesia in Pediatric Patients|Dose Response Effect of Nitrous Oxide on Amnesia in Healthy Children||State University of New York at Buffalo|No|Completed|May 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|90|||Both|6 Years|12 Years|No|||March 2014|March 25, 2014|March 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02050152||51428|
NCT02049892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002050|A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements|A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements||Mayo Clinic|No|Active, not recruiting|December 2013|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|100 Years|No|Non-Probability Sample|Orthopedic patients with prior hip replacement.|December 2015|December 2, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02049892||51448|
NCT02049905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P3-STS-01|Phase 3 Study to Treat Patients With Soft Tissue Sarcomas|A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy||CytRx|Yes|Active, not recruiting|January 2014|February 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|433|||Both|15 Years|N/A|No|||January 2016|January 19, 2016|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049905||51447|
NCT02050165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01|Snacking, Satiety &Weight: A Randomized, Controlled Trial|Snacking, Satiety &Weight: A Randomized, Controlled Trial|Snack|Griffin Hospital|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|25 Years|75 Years|No|||January 2014|January 29, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02050165||51427|
NCT02051803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303-003|Women Engaging in Quitting Smoking Together (WE QUIT)|Distress Tolerance Treatment for Weight Concern in Smoking Cessation Among Women|WE QUIT|Butler Hospital|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|65 Years|No|||July 2015|July 30, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051803||51301|
NCT02051270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0050UG|Cognitive Impairment and Balance in Elderly|Mild Cognitive Impairment and Balance in Elderly||Universidad de Granada|Yes|Recruiting|January 2014|May 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|65 Years|N/A|No|Non-Probability Sample|Elders|December 2014|December 9, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051270||51342|
NCT02051517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303M30101|Vitreous Chemistry Analysis|Vitreous Chemistry Analysis||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples Without DNA|Vitreous fluid whole blood|Both|18 Years|90 Years|No|Probability Sample|Ophthalmology Clinic|December 2015|December 4, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02051517||51323|
NCT02048540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC neoadjuvant bev CTC|Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell|Phase 2 Study of Neoadjuvant Bevacizumab Plus DOF Versus DOF in Local Advanced Gastric Carcinoma and Its Association With Circulating Tumor Cell||Chinese PLA General Hospital|No|Completed|February 2009|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|70 Years|No|||April 2014|April 23, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02048540||51551|
NCT02048878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1214|Hyper-Arousal in Chronic Primary Insomnia|Multi-Level Assessment of Physiologic Hyper-Arousal in Chronic Primary Insomnia: A Case Control Study|MISP|University of Chicago|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|32|||Both|21 Years|65 Years|No|Non-Probability Sample|Insomniacs|December 2014|December 30, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048878||51526|
NCT02049177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/084/13|Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer|Alcohol Related Cancers and Genetic Susceptibility in Europe Follow-up - North-West England|ARCAGE-NWE|University of Aberdeen|No|Enrolling by invitation|November 2013|||April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|141|||Both|18 Years|N/A|No|Non-Probability Sample|Cases that were previously identified for the HPV-AHEAD case-control study.|January 2014|January 29, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049177||51503|
NCT02049190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR18-CT-102|Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer|A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer||Arno Therapeutics|Yes|Recruiting|February 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|75|||Male|18 Years|N/A|No|||June 2015|June 22, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049190||51502|
NCT02049463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311042RIND|Advanced Analysis of the Carotid Phonoangiography and Diseases|Advanced Analysis of the Carotid Phonoangiography and Diseases||National Taiwan University Hospital|No|Not yet recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|20 Years|90 Years|No|Non-Probability Sample|the patients who is going to have carotid angiography study and with informed consent        signed.|January 2014|January 29, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049463||51481|
NCT02050256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006802748|Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners|Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners in Denmark - an Intervention Study||University of Aarhus|No|Withdrawn|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|N/A|N/A|No|||December 2013|December 10, 2014|December 18, 2013||No|due to organisational changes|No||https://clinicaltrials.gov/show/NCT02050256||51420|
NCT02049684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR11/10063|SPARC: Shoulder PAtch for Rotator Cuff Tears|SPARC: Shoulder PAtch for Rotator Cuff Tears||The Leeds Teaching Hospitals NHS Trust||Recruiting|January 2013|||March 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|||||Both|18 Years|95 Years|No|Non-Probability Sample|Massive rotator cuff tear patients|September 2014|September 23, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02049684||51464|
NCT02050243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-JR-528-CTIL|The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors|The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors|5-ALA|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|3 Years|18 Years|No|||January 2014|January 28, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02050243||51421|
NCT02051348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRO-046|Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion|A Single-blinded, Placebo Controlled, Crossover Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion||Atlantia Food Clinical Trials|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051348||51336|
NCT02051569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL451-09-013 / 2|Serotonin and Everyday Social Interaction|Everyday Social Behavior and Mood in Individuals With a Family History of Depression. Investigating the Role of Serotonin||University of Groningen|No|Completed|August 2012|January 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02051569||51319|
NCT02097134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARET12P1|Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma|A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma||Children's Oncology Group|Yes|Recruiting|April 2014|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Months|N/A|No|||November 2015|November 30, 2015|March 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097134||47829|
NCT02049372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR/Helsinki/ORL/I|Complication Registry for Tonsil Surgery|Developing a Prospective Registry for Complications in Otorhinolaryngologic Surgery: Tonsil Surgery as a Pilot Cohort||Helsinki University|Yes|Completed|September 2011|December 2013|Actual|February 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|794|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|From September 2011 to February 2012, all patients undergoing tonsillectomy or        tonsillotomy with or without adenoidectomy were assessed for enrolment.|January 2014|January 31, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049372|1 Year|51488|
NCT02049866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN0161|Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP|Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis: a Phase IIB Study||Columbia University|Yes|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|41|||Female|20 Years|50 Years|No|||November 2015|November 2, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049866||51450|
NCT02049879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-2010|Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients|Quantification of Daily Physical Activity After an Intra-articular Corticosteroid Injection in Patients With Knee Osteoarthritis||Laval University|No|Completed|November 2008|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|50 Years|N/A|No|||February 2014|February 28, 2014|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049879||51449|
NCT02049918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP0006|Residual Sample Collection for Respiratory Viral Panel|De-identified Residual Sample Collection for the Respiratory Viral Panel on the GenMark Sample to Answer Platform (ARM 1)||GenMark Diagnostics|No|Completed|November 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1487|Samples With DNA|Nasopharyngeal Swab|Both|N/A|N/A|No|Probability Sample|Children and adults of any age suspected of having respiratory infection.|December 2015|December 23, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02049918||51446|
NCT02050178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54F28-002|Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||August 2015|August 31, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050178||51426|
NCT02050191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Griffin IRB # 2005-10|Community Web Health Portal for Diabetes Prevention|The Primary Goal of the Phase I Research Was to Demonstrate Feasibility of Creating and Running an Incentive-based Wellness Portal for a Local Community (Princeton, NJ) That Involved Designing the System, Building a Prototype, Testing the System, and Assessing User Acceptance.|NnoLEDGE|Griffin Hospital|No|Completed|July 2006|May 2012|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02050191||51425|
NCT02047799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SanchezC|Effect of Vitamin D Supplementation on Blood Pressure in Elderly People|Effect of Vitamin D Supplementation on Blood Pressure in Elderly People||Universidad de Colima|Yes|Completed|April 2013|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|60 Years|N/A|No|||April 2013|January 26, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047799||51608|
NCT02048280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCH02|Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support|Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support||ProMedica Health System|No|Completed|December 2012|April 2015|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|23 Weeks|40 Weeks|No|||July 2015|July 29, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02048280||51571|
NCT02048553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05092013|Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial|Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial|Tab-Guide|University Hospital, Geneva|No|Not yet recruiting|March 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02048553||51550|
NCT02048566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174/13|Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients|ImaCor II Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients - a Randomized Controlled Trial|ImaCor II|University Hospital Inselspital, Berne|No|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|500|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02048566||51549|
NCT02049476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-000443|Study of the Effectiveness of Ozurdex for the Control of Uveitis|Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy||Johns Hopkins University|No|Recruiting|January 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049476||51480|
NCT02049710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPP-TVS-01|Teen Video Study to Reduce Risky Driving and Sexual Behavior in Adolescents|Randomized Controlled Trial Evaluating the Effectiveness of Interactive Video Interventions to Reduce Teen Pregnancy and Teen Automobile Injuries|TVS|Carnegie Mellon University|No|Active, not recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1317|||Female|14 Years|19 Years|No|||October 2015|October 27, 2015|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02049710||51462|
NCT02050009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN-062|Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq||Fox Chase Cancer Center|Yes|Withdrawn||||October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||May 2015|May 1, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050009||51439|
NCT02050854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316-13-212|Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia|An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|47|Samples With DNA|Whole blood, Plasma|Both|18 Years|55 Years|No|Non-Probability Sample|Primary care clinic|January 2014|January 29, 2014|January 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02050854||51374|
NCT02050867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914044|Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting|Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|10 Years|21 Years|No|||October 2015|November 17, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050867||51373|
NCT02049996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13090-13-060|Difference in Pain, Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Versus Robotic Colpopexy?|Is There a Difference in Pain and Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Compared to Robotic Colpopexy? A Prospective Cohort Study||TriHealth Inc.|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|82|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have been scheduled for a vaginal hysterectomy with either vaginal or        robot-assisted prolapse repairs with Cincinnati Urogynecology Associates will be        approached for participation in the study.        Eligible subjects are patients of Cincinnati Urogynecology Associates, aged 18-90,        planning to undergo a vaginal hysterectomy with robotic or vaginal reconstructive surgery        for pelvic organ prolapse, as well as a posterior/rectocele repair, with or without a        suburethral sling or ovarian removal. All subjects will undergo general anesthesia.        Eligible subjects must be able to speak and read English, and be able to understand the        informed consent statement.|February 2016|February 29, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049996||51440|
NCT02050828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-9778-CI-2003|The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema|A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema|TIME-2|Aerpio Therapeutics|No|Completed|January 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050828||51376|
NCT02050841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-212|Octaplas Pediatric Plasma Replacement Trial|An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of octaplasLG in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.||Octapharma|Yes|Recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|16 Years|No|||August 2015|August 27, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050841||51375|
NCT02051582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300829|Role of the Laser Pointer in Budgeting Fluoroscopy Time and Radiation Exposure|Role of the Laser Pointer in Budgeting Fluoroscopy Time and Radiation Exposure||University of Florida|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|||Both|22 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty (30) orthopaedic surgeons (Attendings, Fellows, and Residents) from the Department        of Orthopaedics and Rehabilitation will be recruited and enrolled in the study|February 2015|February 24, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051582||51318|
NCT02051868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3847 InterAACT|International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel|An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease|InterAACT|Royal Marsden NHS Foundation Trust|Yes|Recruiting|December 2013|February 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051868||51296|
NCT02097420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL06404|HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|HALO Clinical Study: A Single Arm, Prospective, Non-randomized, Multi Center Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve||St. Jude Medical|Yes|Recruiting|July 2014|May 2022|Anticipated|May 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|5 Years|No|||August 2015|August 4, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097420||47807|
NCT02049606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAYLA_P4_NB|To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee|Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.||PMG Pharm Co., Ltd|Yes|Recruiting|February 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|40 Years|80 Years|No|||April 2014|April 13, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049606||51470|
NCT02049398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914047|Study of Variation Over Time in the Oral Microbiome|Temporal Variation In The Oral Microbiome||National Institutes of Health Clinical Center (CC)||Completed|January 2014|December 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|41|||Both|18 Years|100 Years|No|||December 2015|December 24, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049398||51486|
NCT02049619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC-PONV|Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting|Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting. A Prospective Randomized Double Blind Clinical Trial.||China Medical University, China|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|No|||February 2015|February 4, 2015|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049619||51469|
NCT02050737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-27|Plasma Biomarkers C-RAC, ICORG 12-27, V1|Identification of Plasma Biomarkers in Early Detection of Colorectal Adenocarcinoma Recurrence (C-RAC Plasma Biomarker Study)||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|October 2013|||December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy.        50 CRAC patients with stage II resectable disease for observation only.|February 2016|February 15, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02050737||51383|
NCT02050750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-30|TAILORx Tissue Bank|Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|December 2013|||June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|690|||Female|18 Years|75 Years|No|Non-Probability Sample|The study population will consist only of patients that participated in the TAILORx ICORG        06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31        study and have adequate tumour tissue available.|October 2015|October 23, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02050750||51382|
NCT02048007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1032340-B|Mortality Reduction After Oral Azithromycin: Morbidity Study|Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Morbidity Study|MORDOR2|University of California, San Francisco|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72000|||Both|1 Month|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02048007||51592|
NCT02048020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000915|Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer|Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)||Jonsson Comprehensive Cancer Center|Yes|Recruiting|December 2013|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|19 Years|N/A|No|||March 2016|March 4, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048020||51591|
NCT02048293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|326-3847-22|Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules|Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules Available in Colombia for Tracheal Intubation of Adult Patients, 2012-2013||Fundación Universitaria de Ciencias de la Salud|No|Completed|October 2012|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|50 Years|No|||January 2014|January 28, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048293||51570|
NCT02048891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0427-13|Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures|||Rambam Health Care Campus|No|Completed|October 2014|April 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Female|35 Years|44 Years|No|||May 2015|May 20, 2015|January 27, 2014||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT02048891||51525|
NCT02049203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005387|Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis|A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis||Mayo Clinic|No|Recruiting|January 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|50 Years|N/A|No|||February 2015|February 9, 2015|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049203||51501|
NCT02049723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERDclub2013-97|Assessment of GERD Knowledge Level Among Patients With it in Korea|How Much do Patients With Gastroesophageal Disease Know About Their Own Disease in Korea?|GERD|Chuncheon Sacred Heart Hospital|No|Recruiting|April 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|75 Years|No|Non-Probability Sample|Patients with GERD who visit the secondary or tertiary University hospital for their        treatment|April 2014|April 4, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02049723||51461|
NCT02050022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00786|Chronic Obstructive Pulmonary Disease Biomarker Study|Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for Chronic Obstructive Pulmonary Disease Management||University of British Columbia|No|Recruiting|April 2013|March 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Plasma, serum, whole blood, sputum|Both|19 Years|95 Years|No|Non-Probability Sample|Exacerbation cohort: COPD patients who present in emergency or are admitted to Vancouver        General Hospital or St. Paul's Hospital in Vancouver for a COPD exacerbation are        approached for participation in the study.        Non-exacerbation cohort: COPD patients who are seen in the hospital COPD clinic and are        not experiencing an exacerbation are approached for participation in the study.|December 2015|December 2, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050022||51438|
NCT02050269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO13-SE / IoxRea|Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study|Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study|IoxRea|University Hospital, Tours|Yes|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050269||51419|
NCT02050568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-069|Mechanism of Incontinence Before and After Genital Prolapse Surgery|Measuring the Mechanism of Incontinence With Urethral Pressure Reflectometry, Before and After Genital Prolapse Surgery||Herlev Hospital|No|Recruiting|October 2013|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|N/A|No|Non-Probability Sample|The suitable women are invited to volunteer at the outpatient clinic, at the Department of        Gynaecology, at Herlev hospital.|March 2015|March 17, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050568||51396|
NCT02051881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39168.068.12|Identification of Nutrient Receptors Gastrointestinal Tract|The Identification and Spatial Distribution of Different Nutrient Receptors Along the Gastrointestinal (GI) Tract||Maastricht University Medical Center|No|Completed|May 2012|June 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|65 Years|No|||January 2014|January 30, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051881||51295|
NCT02050542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00514-41|Study of Current Practice Which Compare the Rate of Prostate Cancer by Using 2 Kind of Transrectal Biopsies: 3 by IRM-echography Image Fusion and 12 Systematized Guided Echographies.|Comparison of Prostate Cancer Detection Rates Obtained With Multiparametric MRI Targeted Transrectal Ultrasound Biopsies and Systematic Transrectal Ultrasound Biopsies.|MURIELLE|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|108|||Male|45 Years|75 Years|No|||April 2015|April 20, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050542||51398|
NCT02050555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-867|Anti-obesity Effect of Koji-extracted Beverage Fermented With Pediococcus Pentosaceus LP28|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Koji-extracted Beverage Fermented With Pediococcus Pentosaceus LP28||Hiroshima University|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050555||51397|
NCT02051361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-CLOBES-EL-41|Antiplatelet Therapy Following Stent Implantation|Open Label, Non Interventional, Multi-center, Observational Study to Assess the Antiplatelet Treatment Pre and Post-operatively of Stent Implantation|Anti-Clot|Elpen Pharmaceutical Co. Inc.|No|Recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients on clopidogrel treatment following stent implantation|September 2015|October 9, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02051361||51335|
NCT02048371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC024|SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas|A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas||Sarcoma Alliance for Research through Collaboration|Yes|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02048371||51564|
NCT02097706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204-14|A Novel Drug for Borderline Personality Disorder|A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder||The Alfred|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02097706||47785|
NCT02097719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LUM-12-022|Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 25, 2014|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02097719||47784|
NCT02049047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2010-001|Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy|Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy|ONC-2010-001|Istituto Clinico Humanitas|No|Active, not recruiting|February 2011|January 2016|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02049047||51513|
NCT02049060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2011-001|Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin|Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy||Istituto Clinico Humanitas|No|Recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02049060||51512|
NCT02049632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SenOMic|Sentinel Node Biopsy in Breast Cancner: Omission of Axillary Clearance After Micrometastasis|Survival and Axillary Relapse in Breast Cancer Patients With Sentinel Node Micrometastases Who Have Not Undergone Completion Axillary Clearance - a National Cohort Study|SenOMic|Karolinska University Hospital|Yes|Recruiting|December 2013|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|452|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02049632||51468|
NCT02050464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207094|Computational Tools for Early Diagnosis of Memory Disorders|Virtual Physiological Human (VPH) Dementia Research Enabled by IT - Prospective Cohort Kuopio|ProsKuopio|University of Eastern Finland|No|Enrolling by invitation|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|120|Samples With DNA|whole blood, serum, plasma, white cells|Both|50 Years|85 Years|No|Non-Probability Sample|Control subjects with normal cognition        The Alzheimer's disease, Fronto-temporal dementia, Vascular dementia, and Mild Cognitive        Impairment will be recruited during their visit in the Neurological clinic at the Kuopio        University Hospital.|December 2015|December 14, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02050464|18 Months|51404|
NCT02050477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B707201214181|Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery|Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities||University Hospital of Liege|No|Active, not recruiting|June 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|75 Years|No|||January 2014|January 28, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02050477||51403|
NCT02051530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL451-09-013|Mood, Serotonin and Social Interaction|Mood, Serotonin and Social Interaction||University of Groningen|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02051530||51322|
NCT02051790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-RTP01|Evaluation of Reader Training Processes|Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads||Avid Radiopharmaceuticals|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|241|||Both|N/A|N/A|No|||August 2015|August 27, 2015|January 30, 2014|No|Yes||No|August 3, 2015|https://clinicaltrials.gov/show/NCT02051790||51302|
NCT02048033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 5037|Assessment of the Overstich Technique for the Management of Weight Regain After Gastric Bypass.|Medico-economic Evaluation of the Management of Weight Regain After Gastric Bypass by Gastrointestinal Narrowing of Jejunal Anastomosis by Endoscopic Suturing: Apollo Endosurgery OverStitch Technical||University Hospital, Montpellier|No|Not yet recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 24, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02048033||51590|
NCT02048306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPD/CIF/109502/2009|Impact of Family-based Pulmonary Rehabilitation (PR) on Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Family Members|Rehabilitation for Elderly Patients With COPD and Their Families: Promoting a Comprehensive, Integrated Intervention Based on the International Classification of Functioning, Disability and Health (ICF)||Aveiro University|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|56|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02048306||51569|
NCT02048579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH092466-01A1|Increasing Academic Success in Middle School Students With ADHD|Increasing Academic Success in Middle School Students With ADHD|STAND|Florida International University|No|Completed|February 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|11 Years|16 Years|No|||February 2016|February 8, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048579||51548|
NCT02049489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-121 DC-01|A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma|Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine||ImmunoCellular Therapeutics, Ltd.|Yes|Recruiting|December 2013|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|February 2, 2016|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049489||51479|
NCT02050880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-3000 series Protocol 1|OCT Agreement and Crossed Precision Study|Crossed Precision Design Study of the Nidek Optical Coherence Tomography RS-3000, RS-3000 Lite and RS-3000 Advance for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, and Pachymetry||Nidek Co. LTD.|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|119|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinic subjects, general population|September 2014|September 25, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02050880||51372|
NCT02051140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARS-2014-1|The Effect of Dietary Strawberry Supplementation on Older Adults|The Effect of Dietary Strawberry Supplementation on Older Adults||USDA Human Nutrition Research Center on Aging|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051140||51352|
NCT02051595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300857|The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery|The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery||University of Florida|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 29, 2014||No||No|June 23, 2015|https://clinicaltrials.gov/show/NCT02051595||51317|
NCT02051608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN28745|A Study of Gantenerumab in Patients With Mild Alzheimer Disease|A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE||Hoffmann-La Roche||Recruiting|March 2014|March 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1000|||Both|50 Years|90 Years|No|||March 2016|March 1, 2016|January 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051608||51316|
NCT02051114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOR-0833|Discovering the Antecedents of Rheumatoid Arthritis Flare|Discovering the Antecedents of Rheumatoid Arthritis Flare||Rockefeller University|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Blood samples|Female|40 Years|65 Years|No|Non-Probability Sample|Rheumatoid Arthritis|October 2015|October 26, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051114||51354|
NCT02051127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISM-01-2013|The Effects of Physical Training on Physiological and Psychological Stress-reactions and Cognitive Function.|Sustainable Working Life With Reduced Stress Levels - The Effects of Physical Training on Physiological and Psychological Stress-reactions and Cognitive Function.|ASTI|Vastra Gotaland Region|No|Recruiting|January 2013|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051127||51353|
NCT02048085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0224|Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis|A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours|TACAT|Medical Center of South Arkansas|No|Not yet recruiting|February 2014|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|70|||Both|18 Years|75 Years|No|||January 2014|January 31, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048085||51586|
NCT02048124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 13.030|Study Comparing the Diagnostic Yield of Solid Lesion Biopsies Performed by EUS-FNA Using the 25d ProCor Needle Versus the Standard 25g Needle|Prospective Study Comparing the Diagnostic Yield of Solid Lesion Biopsies Performed by EUS-FNA Using the 25d ProCor Needle Versus the Standard 25g Needle.||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Active, not recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|224|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02048124||51583|
NCT02048332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2777|Anti-virus Treatment Following Bone Marrow Transplant|Donor-Derived Anti-viral CTLs for Treatment of CMV, EBV and Adenovirus After Allogeneic Stem Cell Transplant|CTLs|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|February 2014|July 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||January 2016|January 26, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048332||51567|
NCT02048345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDD13POSA|Gastrointestinal Behavior of Posaconazol in Healthy Volunteers|Gastrointestinal Behavior of Posaconazol in Healthy Volunteers||Katholieke Universiteit Leuven|No|Recruiting|January 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|June 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02048345||51566|
NCT02048358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2B3-201-CR-001|Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients|Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201||BBB-Therapeutics B.V.|No|Terminated|November 2013|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study|9||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02048358||51565|
NCT02098031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100|Improving the Nutrition Status of Infants in South-Western Uganda|Improving the Nutrition Status of 6 to 8 Months Old Children Through Diet Diversification and Better Dietary Intakes in the Kabale and Kisoro Districts in South-Western Uganda||University of Oslo|No|Active, not recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|510|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098031||47760|
NCT02049411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2012-3601-56|Ketamine and Changes of the Short Portable Mental Status Questionnaire|Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.|SPMSQ-E|Instituto Mexicano del Seguro Social|No|Completed|June 2013|May 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 23, 2014|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049411||51485|
NCT02051049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF001|Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)|Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem||Promethera Biosciences|Yes|Active, not recruiting|March 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|N/A|23 Years|No|Non-Probability Sample|The SAF001 study will include all patients having received infusions of HepaStem in any        former interventional study conducted by Promethera Biosciences.|October 2014|October 2, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051049||51359|
NCT02051062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-011|BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients|Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT™) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Toxin.||Cangene Corporation|No|Enrolling by invitation|October 2014|April 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|N/A|16 Years|No|||April 2015|April 29, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051062||51358|
NCT02051283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sbis|Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC|Value of Pretreatment MRI Determined Parameters for Predicting Outcome After Radio-frequency Ablation of Hepatocellular Carcinoma||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|-  Documented and diagnosed liver confined hepatocellular carcinoma by existing imaging             criteria according to currently accepted international guidelines (< 4cm).          -  Treatment radio-frequency ablation - (percutaneous, laparascopy, laparatomy)          -  Availability of pretreatment MRI with three phase contrast enhanced images and             diffusion-weighted sequence prior to treatment.          -  Follow-up of at least 2 years.|January 2014|January 29, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051283||51341|
NCT02047825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0048UG|Upper Limbs Intervention in Multiple Sclerosis|Intervention Focused on Lower Limbs and Functionality in Patients With Multiple Sclerosis||Universidad de Granada|Yes|Active, not recruiting|January 2014|February 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047825||51606|
NCT02048904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207397|Use of Sitagliptin to Decrease Microalbuminuria|Clinical Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Urinary Albumin to Creatinine Ratio in Patients With Overt Kidney Disease||University of Missouri-Columbia|No|Recruiting|January 2014|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|75 Years|No|||January 2014|January 28, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048904||51524|
NCT02049216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTKOA|The Effect of Flexible Tape in Knee Osteoarthritis|The Effect of Flexible Tape Versus Placebo Tape in Patients Completing a Home Exercise Program With Knee Osteoarthritis|FTKOA|The Alfred|No|Recruiting|August 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|40 Years|N/A|No|||January 2015|January 14, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02049216||51500|
NCT02049229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-008|Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome|Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome|TIDES-ACS|The Hospital District of Satakunta|Yes|Recruiting|January 2014|October 2019|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1800|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049229||51499|
NCT02050581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012011459|A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone|"A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:"|Dex/Rituxan|Weill Medical College of Cornell University|No|Recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|3 Years|N/A|No|Non-Probability Sample|Patients who have received more than one course of dexamethasone together with rituximab        for relapsed or refractory ITP.|January 2014|January 30, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02050581||51395|
NCT02050893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fluid responsiveness|The Effect of Midazolam on Fluid Responsiveness in Septic Patients|||Southeast University, China|Yes|Completed|May 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|March 5, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02050893||51371|
NCT02051153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091967|Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls|Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls|ModCog|Cambridge University Hospitals NHS Foundation Trust|Yes|Completed|October 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|64|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051153||51351|
NCT02051634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140628|Papaya Study ID:20140628|Efficacy of Fermented Papaya Preparation on Markers of Systemic Inflammation||University of Florida|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051634||51314|
NCT02051374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/366|The NORDSTEN Study - Degenerative Spondylolisthesis|Degenerative Lumbar Spondylolisthesis: Is Only Decompression Good Enough? A Prospective Randomized Clinical Multi- Institutional Trial|NORDSTEN/DS|Haukeland University Hospital|Yes|Recruiting|February 2014|December 2026|Anticipated|December 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02051374||51334|
NCT02047864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300561|Effect of Creatine Supplementation and Exercise on Bone Health|Long-term Effects of Creatine Supplementation and Exercise Training on Bone Mineral Density and Bone Strength in Postmenopausal Women||University of Saskatchewan|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02047864||51603|
NCT02048098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atauni9|Misoprostol for Second Trimester Termination of Pregnancy|A Comparison Between Vaginal Misoprostol vs. Buccal Misoprostol For Second Trimester Termination of Pregnancy||Ataturk University|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02048098||51585|
NCT02048111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB1001-04|Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B|Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B||Cangene Corporation|Yes|Not yet recruiting|March 2014|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|18|||Both|12 Years|N/A|No|||January 2014|January 27, 2014|November 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02048111||51584|
NCT02048969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30DK034989|Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS|Treatment of Hepatic Encephalopathy With Benzodiazepine Antagonist (Flumazenil) and Change in Cortical GABA Levels in Localized 1H-MR Spectroscopy||Yale University|No|Recruiting|June 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048969||51519|
NCT02048982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bishop_stats_stories|What Influences Physicians' Decisions - Statistics or Stories?|What Influences Physicians' Decisions - Statistics or Stories?||Weill Medical College of Cornell University|No|Recruiting|February 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 4, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048982||51518|
NCT02048670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005525|Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness|A Pilot Project to Investigate the Use of an External Vestibular Prosthesis Potential to Improve Clinical Management of Chronic Subjective Dizziness (CSD)||Mayo Clinic|No|Recruiting|October 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048670||51541|
NCT02090725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16767|Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)|Controlled Trial of 3,4-Diaminopyridine in LEMS|3-4DAP|Dartmouth-Hitchcock Medical Center|Yes|Enrolling by invitation|February 2004|||December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|45 Years|65 Years|No|||August 2015|August 7, 2015|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02090725||48318|
NCT02049931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brace001|Comparison of Treatments of Osteoporotic Compression Fracture Using Rigid Brace, Soft Brace, and no Brace|The Comparative Study for Treatment Outcomes of Osteoporotic Compression Fracture Without Neurologic Injury Using Rigid Brace, Soft Brace, and no Brace||Seoul National University Hospital|No|Completed|December 2012|January 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|50 Years|N/A|No|||May 2015|May 22, 2015|January 28, 2014||No||No|April 15, 2014|https://clinicaltrials.gov/show/NCT02049931||51445|
NCT02050204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P16633|Evaluating the Health Benefits of Workplace Policies and Practices - Phase II|Evaluating the Health Benefits of Workplace Policies and Practices - Phase II|WFHS|Harvard School of Public Health|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|2753|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050204||51424|
NCT02051543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vamc-eak-1|Investigating Affective Mechanisms of Behavioral Sleep Treatment|||Minneapolis Veterans Affairs Medical Center|No|Withdrawn||||August 2016|Anticipated|N/A|Interventional|N/A|1||Actual|0|||Both|18 Years|N/A||||September 2015|September 23, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02051543||51321|
NCT02051816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131966|Facilitating EndotracheaL Intubation by Laryngoscopy Technique and Apneic Oxygenation Within the Intensive Care Unit: The FELLOW Study|Facilitating EndotracheaL Intubation by Laryngoscopy Technique and Apneic Oxygenation Within the Intensive Care Unit|FELLOW|Vanderbilt University|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051816||51300|
NCT02051829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEED-ASTES-2014|Comparison of Preoperative Screening Score for Obstructive Sleep Apnea (OSA)|Comparison of Preoperative Screening Score for OSA||Astes|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients (> 18 years) presenting for preoperative assessment before surgery at SLBO.|June 2015|June 22, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02051829||51299|
NCT02047812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRB13069-VEL|The Hospital Volume Relationship in Emergency Laparotomy Outcomes|The Hospital Volume Relationship in Emergency Laparotomy Outcomes||University of Edinburgh|No|Completed|January 2001|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||3|Anticipated|40000|None Retained|Please note with regard to enrollment: that although this study period has ended and data is      being collated, the actual number of subjects is not known at this point since data has yet      to be received. We requested data on all subjects meeting our criteria within the time frame      mentioned.|Both|18 Years|N/A|No|Probability Sample|All Scottish adult residents undergoing emergency laparotomy during the study period|January 2014|January 24, 2014|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02047812||51607|
NCT02048592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FN Motol-project 6008|Impact of Immunonutrition on the Patients With Cystic Fibrosis|Impact of Immunonutrition on the Patients With Cystic Fibrosis||University Hospital, Motol|Yes|Recruiting|September 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|40 Years|No|||January 2014|January 27, 2014|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048592||51547|
NCT02050035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAAP32212114000|Exercise and Vascular Function in Chronic Kidney Disease|Exercise and Vascular Function in Chronic Kidney Disease||University of Delaware|No|Recruiting|July 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050035||51437|
NCT02050282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-PHAD01|Prehospital Triage of Patients With Severe Shortness of Breath Using Biomarkers|Prehospital Triage of Patients With Severe Dyspnea Using Point-of-Care N-terminal Pro-Brain Natriuretic Peptide. PreBNP Trial.|PreBNP|University of Aarhus|No|Active, not recruiting|February 2014|April 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|700|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02050282||51418|
NCT02050594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-366|Ipilimumab 12-month Intensive Pharmacovigilance Protocol|Ipilimumab 12-month Intensive Pharmacovigilance Protocol||Bristol-Myers Squibb|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Bristol Myers de Venezuela S.A.C. has in place a Customer Model registry, which tracks        every Ipilimumab prescription in Venezuela. Therefore, any oncologist who treats a patient        with Ipilimumab will be identified by BMS. Use of this registry will ensure all patients        who are infused with Ipilimumab are included in this study|July 2015|July 3, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02050594||51394|
NCT02051166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-XXX-2013/1|Clinical Practice of AECOPD Management in China|A Non Interventional, Retrospective Study on AECOPD Treatment Status in China||AstraZeneca|Yes|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|5095|||Both|40 Years|95 Years|No|Non-Probability Sample|The patient population will be ≥40 years of age, received hospitalization due to AECOPD        since Sep, 2013. The patients should be diagnosed by GOLD 2013 as COPD at least 3 months        before AECOPD based on treating physician judgment.|August 2015|August 13, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02051166||51350|
NCT02051387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD-IS|Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study|Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo|CBD-IS|Central Institute of Mental Health, Mannheim|No|Recruiting|January 2013|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|74|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02051387||51333|
NCT02051920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REA-FO-2013-A00593-42|Cardiac Elastography Measurement : an Intraoperative Cardiac Surgery Study|Measurement of Cardiac Elastography: an Intraoperative Cardiac Surgery Study. Cardiac Elastography in Vivo|REA-FO|University Hospital, Caen|Yes|Recruiting|November 2013|||November 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Consecutive patients undergoing cardiac surgery|January 2015|January 9, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02051920|1 Month|51292|
NCT02060695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1109-081-378|Temporal Relationship Between Motor Fluctuations and Nonmotor Fluctuations|Temporal Relationship Between Motor Fluctuations and Nonmotor Fluctuations||Seoul National University Hospital|No|Recruiting|September 2012|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Probability Sample|movement disorder clinic|May 2015|May 28, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02060695|3 Years|50620|
NCT02051621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A201070|Therapy of Atrial Flutter by Afib Ablation|Isolated Atrial Fibrillation Ablation in Patients With Isolated Atrial Flutter|TripleA|University of Rostock|No|Recruiting|August 2010|August 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|21 Years|N/A|No|||January 2014|January 30, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02051621||51315|
NCT02051894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS: 145271|NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encephalopathy|NeoAdapt 3: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency in Infants Suffering From Hypoxic Ischemic Encephalopathy.||Brighton and Sussex University Hospitals NHS Trust|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|None Retained|Two blood samples of 400µl each will be obtained for each infant receiving dobutamine.      Samples for the pharmacokinetic studies will utilise micro assays to minimise the amount of      blood taken and will coincide with the taking of clinically indicated sample to reduce the      burden placed on neonates included in this study.|Both|N/A|3 Days|No|Non-Probability Sample|Infants older than 36 weeks gestational age suffering from hypoxic ischemic encephalopathy        receiving total body cooling|July 2015|July 13, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051894||51294|
NCT02057653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES04|Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol|Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol||University of California, Irvine|No|Recruiting|November 2013|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|The characteristics for inclusion of the proposed subject population will include those        adults patients who have undergone one or more of the following high risk surgeries: liver        resection, pancreatectomy, cancer debulking, colorectal surgery, and receive arterial line        as directed by the attending anesthesiologist as standard care of patient. Emergent        surgical procedures will not be considered for this study.|February 2016|February 9, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02057653||50854|
NCT02048384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13146|A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer|An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Metastatic Pancreatic Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02048384||51563|
NCT02048683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0174|A Pharmacokinetic Study of Sevoflurane Inhalation in Burn ICU Patients|A Pharmacokinetic Study of Sevoflurane Inhalation in Burn ICU Patients|SEVOBURN|University Hospital, Clermont-Ferrand||Completed|December 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02048683||51540|
NCT02087436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GH3.13|Taperloc Complete Microplasty vs Taperloc Complete Standard: Randomized Controlled Study on Bone Mineral Density|Taperloc Complete Microplasty vs Taperloc Complete Standard: Randomized Controlled Study on Bone Mineral Density|taperloc|Biomet, Inc.|Yes|Active, not recruiting|March 2013|March 2017|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||July 2015|July 20, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087436||48571|
NCT02050763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31MH095649-01A1|Assessing the Impact of an Intervention to Prevent Intimate Partner Violence and HIV in Uganda|A Cluster Randomized Trial of the Impact of an Intimate Partner Violence and HIV Prevention Intervention on Emotional, Physical and Sexual Abuse, Sexual Risk Behaviors and HIV Incidence in Rakai, Uganda|SHARE|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|February 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11451|||Both|15 Years|49 Years|Accepts Healthy Volunteers|||January 2014|October 12, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050763||51381|
NCT02050776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-07|Stem Cell Therapy in Limb Girdle Muscular Dystrophy|The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study||Neurogen Brain and Spine Institute|Yes|Completed|December 2008|December 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|15 Years|60 Years|No|||January 2014|January 30, 2014|January 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02050776||51380|
NCT02051556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPD-01|Working on Asymmetry in Parkinson's Disease|Working on Asymmetry in Parkinson's Disease: a Double Blind, Randomized, Controlled Rehabilitation Trial.||Neuromed IRCCS|No|Not yet recruiting|March 2014|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|42|||Both|55 Years|70 Years|No|||February 2014|February 14, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02051556||51320|
NCT02051842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-1081-13/14-1|Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis|Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Recruiting|January 2014|December 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051842||51298|
NCT02049736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telbivudine for CKD|Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases|The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases||Chinese University of Hong Kong|No|Recruiting|December 2013|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049736||51460|
NCT02050048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 13-130|High Volume Lactated Ringer's Solution and Pancreatitis|Perioperative Intravenous Administration of High Volume Lactated Ringer's Solution and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis||NorthShore University HealthSystem|Yes|Recruiting|January 2014|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1400|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02050048||51436|
NCT02050295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044120|Nerve Block Washout|A Novel Approach to Reverse and Titrate the Clinical Effects of a Nerve Block||University of Alberta|No|Active, not recruiting|February 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02050295||51417|
NCT02050308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13613|Web-based Smoking Cessation Program for Tribal College Students|Web-based Smoking Cessation Program for Tribal College Students||University of Kansas Medical Center|No|Recruiting|May 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050308||51416|
NCT02050906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12008|Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy|The Intensive Diet and Exercise Adherence Trial - Pilot (IDEA-P): A Feasibility Study of a Lifestyle Intervention in Men Undergoing Androgen Deprivation Therapy|IDEA-P|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2012|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Male|N/A|N/A|No|||March 2016|March 4, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050906||51370|
NCT02051179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUCH 2012/10/2|Longitudinal Results of a 10-Year Clinical Trial of Repair of Amalgam Restorations|Longitudinal Results of a 10-Year Clinical Trial of Repair of Amalgam Restorations|REPAMLG|University of Chile|Yes|Completed|August 2003|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A cohort of 20 patients between the ages of 18 to 80 years old (mean 26.5 years), female        (58%) and male (42%), with 40 (Class I and Class II) amalgam restorations, that presented        one or more clinical features that deviated from the ideal (Bravo or Charlie according to        modified United States Public Health Service USPHS criteria). All of them were recruited        at the Operative Dentistry Clinic at the Dental School, University of Chile|January 2014|January 30, 2014|January 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051179||51349|
NCT02051400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McGrath® MAC 1|Evaluation of McGrath® MAC Video Laryngoscope|Evaluation of McGrath® MAC Using Glidescope® Ranger for Novice Providers in a Simulated Difficult Airway: A Randomised Manikin Study|EMMVL|Hanyang University|Yes|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|39|||Both|22 Years|33 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02051400||51332|
NCT02051647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|325/13|Copeptin as a Stress Marker During a Written Examination|Copeptin as a Stress Marker During a Written Examination - the CoEXAM|CoEXAM|University Hospital, Basel, Switzerland|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|42||Serum, Li-Heparin|Both|18 Years|35 Years|No|Non-Probability Sample|42 healthy voluntary medical students studying in the 4th year at Basel University|December 2014|December 3, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051647||51313|
NCT02060708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000042023|Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography|Measuring the Stimulated Brain: Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography||The Hospital for Sick Children||Recruiting|January 2015|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02060708||50619|
NCT02051907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAM-RAD-01|Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis|A BLIND, CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KAM1403 GEL TREATMENT IN PATIENTS WITH RADIATION DERMATITIS|kam1403|Kamedis Ltd.|No|Not yet recruiting|March 2014|April 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2014|January 30, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02051907||51293|
NCT02048150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13405|Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer|Intra-operative Optical Imaging Utilizing Anti-PSMA (Prostate Specific Membrane Antigen) Fluorescent Antibody During Robotic Assisted Laparoscopic Prostatectomy||City of Hope Medical Center|Yes|Recruiting|March 2015|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|36 Years|74 Years|No|||December 2015|December 30, 2015|January 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02048150||51581|
NCT02048709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29753|IDO Inhibitor in Advanced Solid Tumors|A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors||Genentech, Inc.||Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048709||51538|
NCT02047877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2784|Airway Inflammatory Response During Illness in Children With Respiratory Failure|Investigation of Airway Inflammatory Response During an Acute Respiratory Illness in Pediatric Patients With Respiratory Failure||University of North Carolina, Chapel Hill|Yes|Not yet recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Will bank all remaining serum, tracheal secretion, and bronchial secretion de-identified for      purposes of future unknown scientific studies designed at examining respiratory secretions      in this defined pediatric population.|Both|N/A|17 Years|No|Non-Probability Sample|Previously healthy patients presenting to UNC with respiratory failure presumptively        caused by a primary lung infection will be screened. Only those patients intubated within        48-hours of potential enrollment and between the ages of ≥37 weeks gestation and 17 years        will be considered. For purposes of this study, acute respiratory illness is defined as        having upper respiratory infection symptoms and/or lower respiratory tract infection.        Patient should have fever (>38 oC) OR leukocytosis / leukopenia (>10,000 or <2,000) AND        any of the following: tachypnea, hypoxia (saturation <97%), cough, congestion, rhinorrhea,        abnormal lung exam findings, or infiltrate on chest x-ray.|March 2015|March 24, 2015|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02047877||51602|
NCT02048722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 13S02|Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma|Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma||Northwestern University|Yes|Recruiting|March 2014|||November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048722||51537|
NCT02079285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNASROSE|Prospective Evaluation of Diagnostic Accuracy of Endoscopic Ultrasound-guided Fine Needle Aspiration and Biopsy (EUS-FNAB) in the Absence of Rapid Onsite Evaluation|Prospective Evaluation of the Yield and Diagnostic Accuracy of Endoscopic Ultrasound-guided Fine Needle Aspiration and Biopsy in the Absence of Rapid Onsite Evaluation|FNASROSE|Kangbuk Samsung Hospital|Yes|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|19 Years|85 Years|No|Non-Probability Sample|Any patients who will undergo EUS-FNA for the diagnostic evaluation of pancreas lesion|February 2016|February 22, 2016|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02079285||49196|
NCT02088203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2|Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)|Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Complex as a Dietary Supplement to Improve Carbohydrate Metabolism; Dosing, Safety and Tolerability||Pennington Biomedical Research Center|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Anticipated|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02088203||48512|
NCT02051296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX000487|Minocycline to Reduce Pain After Carpal Tunnel Release|A Trial of Minocycline for Pain After Carpal Tunnel and Trigger Release||VA Palo Alto Health Care System|Yes|Active, not recruiting|January 2012|||April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02051296||51340|
NCT02051309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009133_B|Guanfacine Clinical Trial for Smoking Cessation|Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation||Yale University|Yes|Recruiting|March 2014|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02051309||51339|
NCT02051322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trunk|Comparison of Lung Administration With Three Different Nebulizer|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|January 2014|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051322||51338|
NCT02048046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V3 110613|Nutrition Therapy in Adult Patients Requiring ECMO in Australia and New Zealand|||Australian and New Zealand Intensive Care Research Centre|No|Completed|June 2012|||June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|109|||Both|16 Years|N/A|No|Probability Sample|Patients receiving VV or VA ECMO for longer than 72 hours|January 2014|January 27, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048046||51589|
NCT02048059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG1005-CLN-04|ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases|A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases||Angiochem Inc|Yes|Active, not recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048059||51588|
NCT02048319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDTW45115|Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts|Assessing Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Dominant Hepatic Cysts: a Randomized, Double-blind, Placebo-controlled Clinical Trial.|Sclerocyst|Radboud University|Yes|Recruiting|December 2013|May 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02048319||51568|
NCT02049502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071015|FMT in Ulcerative Colitis-Associated Pouchitis|The Use of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis-associated Pouchitis||Emory University|Yes|Recruiting|July 2014|August 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049502||51478|
NCT02049749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 13-010728|Parent Program to Improve Child Behavior Problems|Improving Child Behavior Problems in the Primary Care Setting||Children's Hospital of Philadelphia|No|Active, not recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|2 Years|N/A|No|||October 2015|October 14, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049749||51459|
NCT02050334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC100A|CC100: Safety and Tolerability of Single Doses|Protocol CC100A CC100: Safety and Tolerability of Single Doses||Chemigen, LLC|No|Completed|November 2013|February 2015|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|January 29, 2014|No|Yes||No|February 18, 2015|https://clinicaltrials.gov/show/NCT02050334||51414|
NCT02050607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTandMETs-001|Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome|Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome||Catholic University of the Sacred Heart|No|Not yet recruiting|January 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|30 Years|60 Years|No|||January 2014|January 29, 2014|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02050607||51393|
NCT02050919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9464|Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma|A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas||OHSU Knight Cancer Institute|Yes|Recruiting|December 2013|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050919||51369|
NCT02060136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUF LUTS|Electronic Method for Recording Lower Urinary Tract Symptoms|Validation of Electronic Recording of Lower Urinary Tract Symptoms (LUTS) in Men||University Hospital Ostrava|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|29|||Male|45 Years|90 Years|No|Non-Probability Sample|Men presenting to the urology clinic with lower urinary tract symptoms|February 2014|February 10, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02060136||50663|
NCT02060370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0944|Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)|A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)||M.D. Anderson Cancer Center|No|Recruiting|August 2014|||August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060370||50645|
NCT02060383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2219|Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly|A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly||Novartis|No|Recruiting|May 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|133|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02060383||50644|
NCT02051933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-19B|The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures|The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Plafond (Pilon) Fractures: A Pilot Study|Botox|Carolinas Healthcare System|Yes|Terminated|January 2013|January 2020|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 14, 2013|Yes|Yes|Low accrual rate|No||https://clinicaltrials.gov/show/NCT02051933||51291|
NCT02047890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15200|Japanese BAY1000394 Monotherapy Phase I Study|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies||Bayer|No|Active, not recruiting|May 2014|April 2017|Anticipated|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02047890||51601|
NCT02048137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/135/13|Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases||tDCS in IBD|Charite University, Berlin, Germany|No|Recruiting|January 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|February 7, 2015|January 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02048137||51582|
NCT02056860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821-2013|Detecting Lung Infections Through Vibration|Feasibility and Optimization of High Frequency Oscillation (HFO) for Detection of Lung Infections||University of Florida|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal adults age 18 to 50 Individuals with cystic fibrosis|March 2016|March 15, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02056860||50914|
NCT02057341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-231|A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy|||Array BioPharma|Yes|Active, not recruiting|February 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02057341||50877|
NCT02057354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00AG H-32635|Neuroimaging Study of Exercise and Memory Function|Aerobic Exercise, Neurotrophins, and fMRI of Hippocampal Function and Structure|EMF|Boston University|No|Recruiting|April 2014|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02057354||50876|
NCT02057367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE2556-01510|Scalp Nerve Block and Opioid Consumption in Brain Surgery|The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled||Chiang Mai University|Yes|Enrolling by invitation|March 2013|June 2014|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02057367||50875|
NCT02057640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4A13|MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma|A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Case Comprehensive Cancer Center|Yes|Suspended|May 2014|February 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 6, 2014|No|Yes|Working on Study Extension|No||https://clinicaltrials.gov/show/NCT02057640||50855|
NCT02048397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM-BRO-2013-01|Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis|A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial|FIM-BRO-2013|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|No|Completed|September 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2013|March 15, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02048397||51562|
NCT02048410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9/14|Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia|Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia||Federico II University|No|Completed|January 2012|June 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02048410||51561|
NCT02048995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010387|Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker|Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker|LightEyeBD|University of Pittsburgh|No|Active, not recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|91|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|community patient sample|February 2016|February 19, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02048995||51517|
NCT02089061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV205-029|Drug Interaction Statin|A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of BMS-919373 on the Single-dose Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects||Bristol-Myers Squibb|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089061||48446|
NCT02096692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120226 (Phase C)|ProMRI Study of the Iforia ICD System (Phase C)|ProMRI Study of the Iforia ICD System (Phase C)||Biotronik, Inc.|Yes|Completed|June 2014|June 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|154|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigators' general patient        population according to the inclusion and exclusion criteria.|February 2016|February 1, 2016|March 24, 2014|Yes|Yes||No|September 18, 2015|https://clinicaltrials.gov/show/NCT02096692||47862|
NCT02051335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-ALZ_102|Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults|A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults||Takeda|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|January 29, 2014|No|Yes||No|May 17, 2015|https://clinicaltrials.gov/show/NCT02051335||51337|
NCT02048917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCTN-1301|Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients|Optimization of Smoking Cessation Strategies in Community Cancer Programs for Newly Diagnosed Lung and Head and Neck Cancer Patients||University of Kentucky|Yes|Recruiting|July 2014|February 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048917||51523|
NCT02049242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atauni10|Uterine Tourniquet at Open Myomectomy|Triple Tourniquet vs. Single Tourniquet at Open Myomectomy to Reduce Blood Loss: A Prospective Randomised Controlled Trials||Ataturk University|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|16 Years|48 Years|Accepts Healthy Volunteers|||December 2014|December 21, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049242||51498|
NCT02049255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBES-ASTES-2013|Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.|Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.||Astes|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02049255||51497|
NCT02049515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-12|A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07|A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07||Infinity Pharmaceuticals, Inc.|No|Recruiting|December 2013|December 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049515||51477|
NCT02050061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|srd-873|Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life|Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life||Qassim University|No|Completed|November 2011|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|January 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02050061||51435|
NCT02050074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-010|The Role of Metformin and Colesevelam in Human GLP-1 Secretion|The Role of Metformin and Colesevelam in Human GLP-1 Secretion|ColMetInc|University Hospital, Gentofte, Copenhagen||Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|12|||Both|18 Years|80 Years|No|||October 2014|October 6, 2014|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050074||51434|
NCT02050321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312167559|A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma|A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma||University of Arizona|Yes|Completed|December 2013|July 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02050321||51415|
NCT02050347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33133 CARPASCIO|Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)|Phase I Study of Activated T Lymphocytes Expressing Chimeric Antigen Receptors for Therapy of Relapsed CD19-Positive Malignancies Post-Allogeneic Hematopoietic Stem Cell Transplantation Infused Only After Engraftment (CARPASCIO)|CARPASCIO|Baylor College of Medicine|Yes|Recruiting|April 2014|February 2033|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 25, 2015|January 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02050347||51413|
NCT02050620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050716|Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer|A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer||Duke University|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with biopsy proven ductal carcinoma in situ or invasive breast carcinoma        scheduled to receive definitive treatment in the Department of Radiation Oncology at Duke        will be potentially eligible for this study.|December 2015|December 1, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02050620||51392|
NCT02059889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13-09531|Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer|Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer||Virginia Commonwealth University|Yes|Recruiting|July 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|21 Years|N/A|No|||March 2016|March 22, 2016|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059889||50682|
NCT02051413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-25|Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)|Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder|DEPARRESTCLIN|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02051413||51331|
NCT02051660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKH-110746|German Evaluation of the Effectiveness of the Psychological Intervention Managing Cancer and Living Meaningfully (CALM)|German Randomized Controlled Trial of the Psychotherapeutic Intervention for Advanced Cancer Patients: Managing Cancer and Living Meaningfully (CALM)||University of Leipzig|Yes|Recruiting|March 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|262|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051660||51312|
NCT02051946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039988|Novel Drug Delivery Technique Via Retroject Device|Novel Drug Delivery Technique for Glaucoma Patients||Duke University|No|Completed|May 2014|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|9|||Both|55 Years|N/A|No|||March 2016|March 15, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02051946||51290|
NCT02056587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LRU02T|Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment|Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment||Kidney Cancer Research Bureau|Yes|Completed|November 2011|October 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|85 Years|No|||February 2014|February 5, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02056587||50935|
NCT02056600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DMCL004|BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers||LG Life Sciences|No|Completed|March 2014|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02056600||50934|
NCT02048163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCH 2013-034|Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis|A Comparison of the Effect of Intermittent and Continuous Infusion of Meropenem on the Prevalence of Nausea in Pediatric Cystic Fibrosis Patients||Dayton Children's Hospital|No|Withdrawn|December 2013|August 2015|Actual|August 2015|Actual|Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Blood|Both|7 Years|21 Years|No|Non-Probability Sample|Male and female patients with cystic fibrosis ages 7 to 21 who are admitted to Dayton        Children's Hospital and who will receive meropenem as part of their treatment regimen.|January 2015|February 4, 2016|January 27, 2014||No|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT02048163||51580|
NCT02048423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00445|An Open Prospective Trial of IV Ketamine in Suicidal Adolescents|An Open Prospective Trial of IV Ketamine in Suicidal Adolescents||Nationwide Children's Hospital|Yes|Recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|17 Years|No|||January 2014|January 27, 2014|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02048423||51560|
NCT02048761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2013-14/B|Locally Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Chronic Periodontitis|Locally Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Subjects With Chronic Periodontitis : A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore||Active, not recruiting|August 2013|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048761||51535|
NCT02048748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNN-NST-TeleCHF-01|Congestive Heart Failure Home Telemonitoring|Congestive Heart Failure Home Telemonitoring : A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial||University Hospital of North Norway|No|Not yet recruiting|February 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02048748||51536|
NCT02096705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-137|Phase III Insulin Add-On Asia Regional Program - ST|A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin||Bristol-Myers Squibb|No|Completed|March 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096705||47861|
NCT02096718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.216|Afatinib in Subjects With Kidney Dysfunction|Pharmacokinetics, Safety and Tolerability After Single Dose Administration of Afatinib in Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)||Boehringer Ingelheim||Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2015|December 9, 2015|March 24, 2014||||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02096718||47860|Two healthy volunteers were matched to 2 different groups i.e. subjects with moderate renal impairment and subjects with severe renal impairment.
NCT02047838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lillo 01/2014|Second Laparoscopic Surgery for Recurrent Unilateral Endometriomas.|Impact on Ovarian Reserve of Second Laparoscopic Surgery for Recurrent Unilateral Endometriomas: a Case-control Study.||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|January 2007|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|36|||Female|18 Years|50 Years|No|Non-Probability Sample|In this study were recruited women referred to an academic centre for the diagnosis and        treatment of endometriosis.        Cases were patients undergoing second surgery for recurrent unilateral endometrioma.        Controls were patients previously operated for unilateral endometrioma.|November 2014|November 22, 2014|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02047838||51605|
NCT02049268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000217|Neural Mechanisms Underlying Nicotine and Alcohol Combinations|Neural Mechanisms Underlying Nicotine and Alcohol Combinations|QfMRI|Mclean Hospital|No|Active, not recruiting|July 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|40|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049268||51496|
NCT02049762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0813-13-SMC|Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy|Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy||Sheba Medical Center|No|Recruiting|June 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02049762||51458|
NCT02050087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2288|The Role of Postoperative Immobilization After Arthroscopic Rotator Cuff Repair|The Role of Postoperative Immobilization After Arthroscopic Rotator Cuff Repair: A Prospective Randomized Controlled Non-inferiority Trial||Lovisenberg Diakonale Hospital|No|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050087||51433|
NCT02059109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1844|Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser|Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser||Children's Hospital Medical Center, Cincinnati|No|Recruiting|June 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|July 27, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02059109||50742|
NCT02059330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481032|A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects|A Phase 1, Open Label Study To Investigate The Effect Of Dose And Ethnicity On Palbociclib (PD-0332991) Pharmacokinetics In Japanese Healthy Volunteers||Pfizer|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059330||50725|
NCT02059590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0050|A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects|A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of BAL8728 After A Single Intravenous Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|April 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02059590||50705|
NCT02051205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCRD-I102-03|Parkinson's Disease Registry|Parkinson's Disease Registry（PDR）||Buddhist Tzu Chi General Hospital|Yes|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Probability Sample|Patients in community hospitals or medical centers|January 2014|January 30, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02051205|2 Years|51347|
NCT02051218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 96/12|Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks|Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial||Swiss Group for Clinical Cancer Research|No|Recruiting|July 2014|December 2022|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1380|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051218||51346|
NCT02051426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112-06|Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans|Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans|NMDAR|Herzog Hospital|No|Completed|April 2007|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|January 27, 2014||No||No|February 26, 2014|https://clinicaltrials.gov/show/NCT02051426||51330|
NCT02051673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-7392-Compassionate Use|Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)|Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)||University of Louisville||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|65 Years||||October 2015|October 29, 2015|January 29, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02051673||51311|
NCT02047929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-12-11-4276|Comparing Types of Implementation of a Shared Decision Making Intervention|Comparing Traditional and Participatory Dissemination of a Shared Decision Making Intervention|ADAPT-NC|Carolinas Healthcare System|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1500|||Both|1 Year|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02047929||51598|
NCT02047903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.205|GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations|An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.||Boehringer Ingelheim||Recruiting|March 2014|December 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|NSCLC-EGFR mutation positive|March 2016|March 16, 2016|January 27, 2014||||No||https://clinicaltrials.gov/show/NCT02047903||51600|
NCT02048176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14721|Posterior Fossa Mutism on Quality of Life|Long-Term Impact of Posterior Fossa Mutism on Quality of Life||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|8 Years|25 Years|No|Non-Probability Sample|Patients must be between 8 years and 25 years of age at the time of enrollment and have        completed treatment for their initial diagnosis of medulloblastoma.        We will identify a group of patients who developed PFM as well as a group of appropriately        matched controls with regard to age, sex and treatment protocol who did not develop PFM.|February 2016|February 3, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048176||51579|
NCT02048774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X131210007|Leader Partner Interactions|Leader Partner Interactions|LPI|University of Alabama at Birmingham|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|58|||Both|19 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048774||51534|
NCT02048787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120C2113|Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.|An Open-label, Single Dose, Multicenter Study to Evaluate the Pharmacokinetics and Safety of 50 mg Oral Buparlisib in Subjects With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Volunteers.||Novartis|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02048787||51533|
NCT02049034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIXISL06684|Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes|The Effect of Lixisenatide on Postprandial Lipid and Glucose Metabolism in Patients With Type 2 Diabetes||University of Surrey|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|12|||Male|40 Years|65 Years|No|||February 2016|February 15, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02049034||51514|
NCT02095639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074-2012|Inflammation and Electroconvulsive Therapy|Does Electroconvulsive Therapy Cause Neuroinflammation? An [18F]FEPPA Positron Emission Tomography Study in Treatment Resistant Depression||Centre for Addiction and Mental Health|Yes|Terminated|August 2012|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples With DNA|Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral      inflammatory markers and protein binding.|Both|18 Years|80 Years|No|Non-Probability Sample|Community and tertiary care clinic|July 2015|July 8, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095639||47942|
NCT02095938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sang-Hyuk Lee|Association of Amisulpride Response in Schizophrenia With Brain Image|Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging|ARB|CHA University|No|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|21 Years|60 Years|No|||March 2014|March 24, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095938||47920|
NCT02048605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSLTraining2|Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease|Basel Training Study II: Training of Psychosocial Skills for Patients With Parkinson's Disease|CBT|University Hospital, Basel, Switzerland|No|Active, not recruiting|February 2014|December 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|95 Years|No|||January 2016|January 21, 2016|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02048605||51546|
NCT02048618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-211|Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease|Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration||Galapagos NV|Yes|Completed|February 2014|February 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|75 Years|No|||February 2016|February 21, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02048618||51545|
NCT02049528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-CP-001|Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study|A Phase 1, Open-Label, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Single Oral Doses Of Formulated And Non-Formulated CC-122 Capsules And The Effect Of Food On The Pharmacokinetics Of CC-122 In Healthy Adult Male Subjects||Celgene|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02049528||51476|
NCT02049775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR13/10708|Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND)|Utility of Narrow Band Endoscopy in Predicting Short and Long Term Risk of Relapse in Patients With Quiescent Ulcerative Colitis||The Leeds Teaching Hospitals NHS Trust||Recruiting|April 2013|||April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|85 Years||||February 2016|February 18, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02049775||51457|
NCT02049788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGI-01|Effects of a Low Glycemic Index in Obese Children|Effects of a Low Glycemic Index Diet on Body Composition and Metabolic Syndrome Risks in Obese Thai Children: A Randomized Controlled Trial||Chulalongkorn University|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|9 Years|16 Years|No|||January 2014|January 28, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02049788||51456|
NCT02058862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0776-F2L|Effect of a Home-based Electrical Stimulation on Quadriceps Function After Knee Surgery|Effects of a Superimposed Electrical Stimulation Knee Garment on Strength, Function, Inhibition, Cortical Excitability, and Patient Reported Outcomes After Knee Surgery||University of Kentucky|No|Recruiting|May 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|12 Years|60 Years|No|Probability Sample|Patients from the University of Kentucky Orthopaedics and Sports Medicine Clinic who are        seeking surgical treatment for a disease/injury of the knee.|November 2015|November 30, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02058862||50761|
NCT02050360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC/12/26|"As Required" Oral Sildenafil in Raynaud's Phenomenon|Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)|PROFIL|University Hospital, Grenoble|Yes|Completed|November 2013|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02050360||51412|
NCT02050633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00881-44|PariS -TBI Study: Paris Severe Traumatic Brain Injury Study - 8 Years|Eight-year Outcome and Health Care After Severe Traumatic Brain Injury in the Parisian Area|TCS8|Assistance Publique - Hôpitaux de Paris|Yes|Enrolling by invitation|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|15 Years|N/A|No|Non-Probability Sample|Patients had severe TC in the Parisian area between 2005 and 2008 and were evaluated 4        years.|February 2016|February 24, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02050633||51391|
NCT02050932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-41|The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans|The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans: Effect of the Time of Administration and Consecutive Day Administration of Commonly Used Dosages||Swiss Federal Institute of Technology|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02050932||51368|
NCT02050945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-150|The Effects of Physical Exercise Training in Patients With Chronic Obstructive Pulmonary Disease|The Effects of Physical Exercise Training in Patients With Chronic Obstructive Pulmonary Disease||Rigshospitalet, Denmark|Yes|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|40 Years|80 Years|No|||April 2015|April 19, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02050945||51367|
NCT02051192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLET-13-0634|Brief Behavioral Treatment for Anxiety in Young Children|A Brief Behavioral Treatment for Anxiety in Young Children|PLET|University of South Florida|No|Active, not recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|7 Years|No|||December 2015|December 2, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051192||51348|
NCT02051439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRIRAJ11SU00030/028/11|The Party Balloon Assisted Valsalva in Diagnosis of Superficial Venous Valvular Reflux of Lower Limb|A Comparison of the Party Balloon Assisted Valsalva With Conventional Valsalva Maneuver in Diagnosis of Superficial Venous Valvular Reflux of Lower Limb||Mahidol University|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02051439||51329|
NCT02051452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001114|Reversal of General Anesthesia With Methylphenidate|Reversal of Propofol-Induced General Anesthesia With Intravenous Methylphenidate||Massachusetts General Hospital|Yes|Enrolling by invitation|November 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|55|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02051452||51328|
NCT02051686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208444|Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid|Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid: A Prospective, Randomized, Controlled Study|TXA|University of Missouri-Columbia|No|Recruiting|August 2013|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02051686||51310|
NCT02098954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKIRR001|Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers|Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment||Hunan Province Tumor Hospital|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 14, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02098954||47689|
NCT02099201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-073-102|Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects|A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects||Actelion|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|7||Actual|65|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099201||47670|
NCT02095990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM2013|Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study|Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study||Mesoestetic Pharma Group S.L.|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Female|18 Years|65 Years|No|||April 2015|April 9, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02095990||47916|
NCT02096276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201327|Boostrix® Pregnancy Registry|Boostrix® Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Boostrix® During Pregnancy or Within 28 Days Preceding Conception||GlaxoSmithKline||Active, not recruiting|March 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Female|12 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women, residing in the US, vaccinated with Boostrix during pregnancy or within 28        days preceding conception and who are volunteering to take part in the Pregnancy Registry        before the outcome of the pregnancy is known|December 2015|December 10, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02096276||47894|
NCT02096848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microbiology of Otitis Media|Microbiology of Otitis Media in Costarrican Children After PCV13 Introduction|IDENTIFICATION OF THE EFFECT OF THE INTRODUCTION OF THE PNEUMOCOCCAL CONJUGATED 13-VALENT VACCINE IN THE NATIONAL INMUNIZATION PROGRAM IN COSTA RICA ON THE INCIDENCE OF OTITIS MEDIA EPISODES CAUSED BY Haemophilus Influenzae AND ON THE Streptococcus Pneumonia SEROTYPE DYNAMICS||Instituto de Atención Pediátrica|No|Suspended|May 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|387|Samples With DNA|Bacteria isolated from children with otitis media|Both|3 Months|6 Years|No|Non-Probability Sample|Children aged more than 3 months to less than 6 years, visiting with otitis media and from        whom a middle ear fluid sample has been obtained.        A cohort of children with the first episode of otitis media occurring before or at the age        of 24 months of age and at least one month after completion of two doses of pneumococcal        13 valent vaccine will be followed until the participant completes 36 months of life.|March 2014|March 24, 2014|March 24, 2014||No|Due to lack of a law regulating clinical research in Costa Rica, the recruitment was stoped in    July 2013|No||https://clinicaltrials.gov/show/NCT02096848||47851|
NCT02096861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 3.4|Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease|A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease||Celltrion|Yes|Active, not recruiting|July 2014|February 2017|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|220|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096861||47850|
NCT02092246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008328|Ultrasound Guided vs Unguided Intra-articular Knee Injections|Accuracy of Ultrasound Guided Versus Unguided Intra-articular Knee Injections in a Difficult to Inject Population||Mayo Clinic|No|Withdrawn|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 13, 2014|No|Yes|Difficulty enrolling subjects|No||https://clinicaltrials.gov/show/NCT02092246||48201|
NCT02093104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-03704|TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)|Utilizing Intraprocedural Flow and Perfusion Dynamics as a Predictor of Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Chemoembolization and Radioembolization (Y90) "Liver Embolization Perfusion TACE Study (Version 1.0) EPTS 2013-1.0"|TACE|University of British Columbia|No|Enrolling by invitation|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|19 Years|N/A|No|Probability Sample|patients with unresectable hepatocellular carcinoma undergoing chemoembolization and        radioembolization|April 2015|April 7, 2015|March 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093104||48135|
NCT02093117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00009|Neurosurgery Recruitment Maneuver Study|Effect of an Alveolar Recruitment Maneuver on Subdural Pressure, Brain Swelling and Cerebral Perfusion Pressure in Patients Undergoing Supratentorial Tumour Resection||University of British Columbia|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|99 Years|No|||December 2015|December 2, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02093117||48134|
NCT02096198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11013|Ceramic On Ceramic (COC) 36mm PAS IDE Rollover Subjects; Ceramic Acetabular Bearing With Ceramic Femoral Head in Total Hip Replacement|36mm CERAMAX® Ceramic Hip System PMA PAS: Long-Term Follow-up of Previously Enrolled Investigational Device Exemption (IDE) Study Subjects|COC36mmPAS|DePuy Orthopaedics|No|Active, not recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|20 Years|75 Years|No|Non-Probability Sample|Subjects from the original IDE study who have already been implanted with a Ceramax 36mm        ceramic-on-ceramic system and who have given their consent for this study|December 2015|February 5, 2016|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02096198||47900|
NCT02097043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA7218_PK_I|Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers||Dong-A ST Co., Ltd.||Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|31|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097043||47836|
NCT02097355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH PPQI 52012|Using an Online Patient Monitoring System to Improve Care for Children With Chronic Conditions|Integrated Clinical Information Sharing System: Implementation and Mixed-Methods Evaluation of a Web-based Monitoring and Management System for Patients With Chronic Conditions|TriVoxHealth|Children's Hospital Boston|No|Active, not recruiting|December 2014|June 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|946|||Both|N/A|N/A|No|||January 2016|January 27, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02097355||47812|
NCT02097615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTSSA02101-298|Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water|Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome.||Universidad de Guanajuato|Yes|Recruiting|May 2014|December 2014|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097615||47792|
NCT02098161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0612|Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)|Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)||M.D. Anderson Cancer Center|No|Recruiting|December 2014|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098161||47750|
NCT02097589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400208|The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23|The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23|StatVax|University of Florida|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097589||47794|
NCT02098135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0182|ArmeoSenso - Home Therapy and Assessment for Patients With Arm Impairments Based on Wearable Movement Sensors|Phase 1 Study of a Home Therapy and Assessment for Patients With Arm Impairments||University of Zurich|No|Completed|November 2013|September 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02098135||47752|
NCT02098421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1279|Foley Labor Induction Trial at Term and in PROM|A Randomized Trial of Foley Bulb Induction With and Without Simultaneous Use of Oxytocin||Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098421||47730|
NCT02099474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 160 RalFE|Evaluation of Raltegravir During the Third Trimester of Pregnancy|Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy|ANRS 160 RalFE|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|July 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02099474||47649|
NCT02099487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139|Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma|Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma||Istituto Clinico Humanitas|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|20|||Both|70 Years|N/A|No|||January 2014|March 25, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02099487||47648|
NCT02095418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28170|Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept|Open Label, Multicenter Randomized Control Study to Investigate the Incidence of NODAT (New-Onset Diabetes After Transplantation), Safety and Efficacy of Corticosteroids Early Withdrawal in Liver Transplanted Recipients|NODAT|Samsung Medical Center|No|Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|20 Years|70 Years|No|||March 2014|March 20, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02095418||47959|
NCT02095431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10393|Acute Kidney Injury Biomarkers: Diagnosis and Application in Pre-operative Period of Liver Transplantation|Acute Kidney Injury Biomarkers: Diagnosis and Application in Pre-operative Period of Liver Transplantation|AKIB|University of Sao Paulo|No|Recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|122|Samples Without DNA|blood plasma and urine|Both|18 Years|80 Years|No|Non-Probability Sample|Patients submitted to liver transplantation .|March 2014|March 20, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02095431||47958|
NCT02099214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01843-42|Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis|Estimation of Myocardial Iron Overload by 3 Tesla MRI and Cardiac Functional Consequences in Patients With HFE Hereditary Haemochromatosis. Pilot Study|HEMOCOEUR|Rennes University Hospital|No|Recruiting|November 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02099214||47669|
NCT02095743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 13-01|Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer|Phase II Randomised Study Comparing the Tolerance of PICC Line (Peripherally Inserted Central Catheter) and Implanted Port for Adjuvant Chemotherapy in HER2-negative Early Breast Cancer|EPIC|Centre Henri Becquerel|No|Recruiting|April 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|256|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02095743||47935|
NCT02095756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICO-2013-01|Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma|A Randomized, Split-Face, Double-Blind Clinical Pilot Study of Combination Picosecond Alexandrite Laser and Non-Hydroquinone Topical Therapy Versus Topical Therapy Alone for the Treatment of Facial Melasma||Cynosure, Inc.|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|74 Years|No|||July 2015|July 29, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02095756||47934|
NCT02095769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|Pharmacogenomic Testing Of the Elderly To Reduce Morbidity|Pharmacogenomic Testing Of the Elderly To Reduce Morbidity|POETRY|General Genetics Corporation|No|Recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|280000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects aged 65 and above or subjects aged 18 and above who have a disability will be        eligible for inclusion in the study if they are receiving or are planned to receive at        least one medication with a metabolic pathway linked to genetic variations ("target        drug").|February 2015|February 20, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095769|90 Days|47933|
NCT02096003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1762|Intrathecal Hydromorphone for Pain Control After Cesarean Section|Comparison of Intrathecal Hydromorphone and Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096003||47915|
NCT02096016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Follow-up|HPV-test, Cervical Cancer and Follow-up|Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program.||University of Aarhus|No|Recruiting|January 2014|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Probability Sample|Patients treated for cervical cancer.|January 2014|December 5, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096016||47914|
NCT02096289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-THORIDAL|Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease|THORIDAL|Ontario Clinical Oncology Group (OCOG)|No|Recruiting|July 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|55 Years|80 Years|No|||October 2015|October 14, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02096289||47893|
NCT02096302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-INF-010|The Effects of an Infant Formula Containing Probiotic CECT7210 on Gastrointestinal Health|Evaluar el Efecto de Una fórmula Infantil Enriquecida Con el probiótico CECT7210 Sobre la Incidencia de Infecciones Gastrointestinales|GO-INF|Laboratorios Ordesa|Yes|Completed|January 2011|June 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|194|||Both|N/A|90 Days|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02096302||47892|
NCT02097147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-24|Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo||Forest Laboratories|No|Completed|March 2014|November 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|202|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097147||47828|
NCT02092805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS in malig. visceral pain|rTMS as a Treatment of Visceral Pain Secondary to Malignancy|Repetitive Transcranial Magnetic Stimulation in Visceral Pain Secondary to Malignancy||Assiut University|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years||||March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02092805||48158|
NCT02092818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16657|EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension|EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension|EXPERT|Bayer|No|Recruiting|May 2014|August 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|Probability Sample|Patients who have been prescribed Adempas® for a medically appropriate use|March 2016|March 18, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02092818||48157|
NCT02092558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/677/09|Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder|||Children's Hospital, Dziekanów Leśny, Poland|Yes|Completed|January 2005|December 2013|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2|||Both|5 Years|17 Years|No|Probability Sample|In all, 119 children (116 girls and 3 boys), aged between 5 and 17 years (mean age, 13.7        years), who were treated in the Pediatric Surgery Department during the period of        2005-2013 were included in this study|March 2014|March 19, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02092558||48177|
NCT02092571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR201-BE-10021|A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 2-Treatment, 2-Period Crossover Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings 20% (w/w) in Postmenopausal Women||Teva Pharmaceutical Industries|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092571||48176|
NCT02096783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13080|Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer|Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer||University of Wisconsin, Madison|No|Active, not recruiting|September 2014|April 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096783||47856|
NCT02097056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-M082-401|Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease|Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease|SAVE|Eisai Inc.|No|Active, not recruiting|February 2014|January 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|171|||Both|45 Years|90 Years|No|||December 2015|December 4, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097056||47835|
NCT02097927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127438-1|The Effect of Sensory-enhanced Beverages on Satiety Following Repeated Exposures|The Effect of Sensory-enhanced Beverages on Satiety Following Repeated Exposures||Leatherhead Food Research|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02097927||47768|
NCT02098174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORFM-1A|Pharmacokinetics of MP-3130 in Healthy Volunteers|Pharmacokinetics of MP-3180 in Healthy Volunteers|Pilot 1A|MediBeacon|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|22 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 24, 2014|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02098174||47749|
NCT02098460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-13-806-01|To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject|||Otsuka Beijing Research Institute|No|Recruiting|October 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|70 Years|No|||March 2014|March 27, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098460||47727|
NCT02097888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBLB: 252/11|Influence of Erythropoietin on Bone Marrow Microenvironment|Influence of Erythropoietin on Bone Marrow Microenvironment: A Pilot Study||Kantonsspital Baselland Bruderholz|No|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|120|Samples Without DNA|Samples Without DNA - samples retained, with no potential for DNA extraction from any      retained samples (e.g., fixed tissue, plasma)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents living < 400m over sea level and >1500m over sea level|March 2014|March 24, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02097888||47771|
NCT02097901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-370|Microfracture in Rotator Cuff Injury Repair|Microfracture in Rotator Cuff Injury Repair||Koege Sygehus|Yes|Suspended|March 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 17, 2014||No|Insufficient patient material|No||https://clinicaltrials.gov/show/NCT02097901||47770|
NCT02098148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001349|Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder|A RANDOMIZED PLACEBO-CONTROLLED CROSSOVER TRIAL OF LOW-DOSE XENON FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER||Mclean Hospital|No|Withdrawn|November 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||March 2014|March 24, 2014|January 10, 2014||No|Withdrawn. Unable to set up appropriate infrastructure to support study.|No||https://clinicaltrials.gov/show/NCT02098148||47751|
NCT02098434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19884|Ovarian Hormones and Stress Induced Drug Craving|Implication of Ovarian Hormones in the Neural Correlates of Stress Induced Drug Craving||Medical University of South Carolina|Yes|Completed|October 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT02098434||47729|
NCT02098447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS 01/2014|Pilot Study on Auricular Vagus Nerve Stimulation Effects in Chronic Diabetic Wounds|Evaluation of Electrical Auricular Vagal Nerve Stimulation Effects on Parameters of Wound Healing in Chronic Diabetic Wounds - Pilot Study||Medical University of Vienna||Active, not recruiting|February 2014|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02098447||47728|
NCT02099500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-CLIN-001|Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia|An Open-label, Non-Randomized, Patient Funded, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Via Intramuscular Injections for the Treatment of Critical Limb Ischemia||Ageless Regenerative Institute|No|Recruiting|March 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02099500||47647|
NCT02095444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEB-2014-2-20|Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection|Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients||S-Evans Biosciences Co.,Ltd.|Yes|Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095444||47957|
NCT02095457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHP-R-161-2013|Routine Outcome Monitoring in Mental Health Outpatient|A Randomized Trial of Routine Computerized Outcome and Process Clinical Measures Monitoring in Mental Health Outpatient Services: Preparing for the Planned Public Mental Health Reform in Israel|ROM-Shalvata|Shalvata Mental Health Center|Yes|Not yet recruiting|July 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|900|||Both|6 Years|N/A|No|||March 2014|March 20, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095457||47956|
NCT02095782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1307|Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation|Intercalated Combination of Chemotherapy and Erlotinib in 1st Line Setting for Patients Advanced Stage Non-small-cell Lung Cancer With Low Abundant Activating EGFR Mutation(INNOVATE)|INNOVATE|Guangdong Association of Clinical Trials|No|Active, not recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095782||47932|
NCT02095795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Habilita-RAR-05|Effectiveness of an Exoskeleton Gait Training Versus Manual Therapy in Subacute Post Stroke Patients.|Effectiveness of an Exoskeleton Gait Training Versus Manual Therapy in Subacute Post Stroke Patients.||Habilita, Ospedale di Sarnico|Yes|Recruiting|March 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|85 Years|No|||March 2014|March 28, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02095795||47931|
NCT02096029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019201|Tobacco Intervention in Primary Care Treatment Opportunities for Providers|Brief, Novel Smoking Cessation in Primary Care: A Comparative Effectiveness Trial|TipTop|Medical University of South Carolina|Yes|Enrolling by invitation|July 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1160|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096029||47913|
NCT02096042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0706|Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)|A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2014|||April 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|61|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096042||47912|
NCT02096055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0843|4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)|Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia||M.D. Anderson Cancer Center|Yes|Recruiting|April 2014|||April 2026|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|70 Years|N/A|No|||March 2016|March 14, 2016|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096055||47911|
NCT02096068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuprodex|Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (Neuprodex)|Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (NEUPRODEX)||Charite University, Berlin, Germany|No|Recruiting|July 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|87|||Both|60 Years|N/A|No|||September 2015|September 21, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096068||47910|
NCT02096315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL7080-002|Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.|A Phase II, Open-label, Multicenter Study to Assess the Tolerance, Safety, Efficacy and Pharmacokinetics/Pharmacodynamics (PK/PD) of POL7080 in the Treatment of Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection Requiring Intravenous Treatment||Polyphor Ltd.|No|Completed|December 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|79 Years|No|||November 2015|November 24, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02096315||47891|
NCT02096549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUH-14-0319-O10|Validity of Bispectral Index Monitoring During Deep Sedation|Validity of Bispectral Index Monitoring During Deep Sedation for Botulinum Toxin Injection in Children With Cerebral Palsy||Yeungnam University College of Medicine|Yes|Suspended|March 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|3 Years|18 Years|No|Non-Probability Sample|primary care clinic (rehabilitation)|July 2015|July 15, 2015|March 17, 2014||No|This study has suspended participant recruitment due to absence of operator.|No||https://clinicaltrials.gov/show/NCT02096549||47873|
NCT02097433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471051|Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers|A Phase 1 Open-label Study To Characterize The Pharmacokinetics Of A Single 45 Mg Oral Dose Of Dacomitinib (Pf-00299804) In Healthy Chinese Subjects||Pfizer|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097433||47806|
NCT02092272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140038H|Eccentric Exercises for Shoulder Pain|Does Providing Instructional Exercise Videos Increase Patient Adherence Compared to In-office Instruction by Physician When Using Eccentric Exercises to Treat Shoulder Pain in Adults?|Eccentric|Mike O'Callaghan Federal Hospital|No|Terminated|March 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|23|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|March 18, 2014||No|the PI left our facility and the new staff prefer alternate excersises|No||https://clinicaltrials.gov/show/NCT02092272||48199|
NCT02096796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56412|Arm Pump in Motorcross Training|Hand Strength Grip and Ergonomics of Driving as Risk Factors in the Etiology of Arm Pump in Motorcross Training||Universitaire Ziekenhuizen Leuven|Yes|Completed|April 2014|May 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|11|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recreational or competitive motor cycle athletes|September 2015|September 16, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096796||47855|
NCT02097628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wang002|Comparison of Two Ventilation Modes With Laryngeal Mask Airway Guardian|Comparison of Volume- and Pressure- Controlled Ventilation With Laryngeal Mask Airway Guardian in Obese Patients Undergoing Laparoscopic Gynecologic Surgery—A Perspective, Randomized, Blind Trial|wang002|Tianjin Medical University General Hospital|Yes|Not yet recruiting|April 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Female|18 Years|65 Years|No|||March 2014|March 26, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02097628||47791|
NCT02097641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-hMSC-ARDS-P2|Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)|Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome|START|University of California, San Francisco|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097641||47790|
NCT02098187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORFM-1B|Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers|Pilot 1B Study-Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy|ORFM-1B|MediBeacon|Yes|Active, not recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Both|22 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02098187||47748|
NCT02098486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCPMOXIVSCEF|Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP|Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis||Kangbuk Samsung Hospital|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|19 Years|80 Years|No|||February 2016|February 22, 2016|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02098486||47725|
NCT02097914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-13-0902|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households: Texas Effectiveness Trial|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households: Texas Effectiveness Trial|SFH|The University of Texas Health Science Center, Houston|No|Completed|March 2014|November 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|508|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097914||47769|
NCT02098473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC02-201|Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis|A Phase 2, Multi-center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis||Celgene||Active, not recruiting|August 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098473||47726|
NCT02098967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28903|A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.|A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)||Hoffmann-La Roche||Recruiting|April 2014|September 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098967||47688|
NCT02099227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC IRB 5577|Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections|Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections||Advocate Health Care|No|Recruiting|March 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|280|||Both|6 Months|19 Years|No|Non-Probability Sample|children presenting to participating pediatric emergency departments|February 2016|February 2, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099227||47668|
NCT02099240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0185|Patients Response to Early Switch To Oral:Osteomyelitis Study|Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics|PRESTO:Osteo|University of Louisville|Yes|Not yet recruiting|April 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|456|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02099240||47667|
NCT02099513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048816|The Mobile Health Platform|The Mobile Health Platform - Development and Feasibility Evaluation|mHealth|Duke University|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 13, 2015|March 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099513||47646|
NCT02095470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-4678|Video Laryngoscope, New Intubation Device|Advanced Video Laryngoscope, a New Practical Intubation Device: Randomized Clinical Trial in 401 Patients||Shiraz University of Medical Sciences|Yes|Completed|February 2013|February 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|19 Years|68 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02095470||47955|
NCT02095483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27425|Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder-Not Otherwise Specified|Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder NOS||Stanford University|No|Recruiting|March 2014|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|13 Years|18 Years|No|||March 2014|March 20, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095483||47954|
NCT02095808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052012-065|Feasibility Study Using Imaging Biomarkers in Lung Cancer|Feasibility Study Using Imaging Biomarkers in Lung Cancer||University of Texas Southwestern Medical Center|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|April 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02095808||47930|
NCT02096081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 60201_4096_1|The Treatment of Glabellar Frown Lines|||Merz Pharmaceuticals, LLC|No|Completed|February 2014|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|50 Years|No|||May 2015|May 11, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096081||47909|
NCT02096328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL7080-003|Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia|A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection.||Polyphor Ltd.|No|Recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02096328||47890|
NCT02096562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2013-0083|Knee Swelling Under Use of Compression Stockings After Outpatient Surgery|Prospective Randomized Assessment of Postsurgical Swelling Applying Compression Stockings vs. Conventional Wrapping After Outpatient Surgery||University of Rostock|No|Recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02096562||47872|
NCT02097732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.114|Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery|Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery||University of Michigan Cancer Center|Yes|Recruiting|April 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097732||47783|
NCT02097745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17531|A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies|An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies||Hoffmann-La Roche||Completed|June 2004|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|341|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|March 20, 2014|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT02097745||47782|
NCT02093741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061101|ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)|ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY||Baxalta US Inc.|No|Completed|September 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|||Both|N/A|12 Years|No|Non-Probability Sample|The study population will include 60 evaluable participants aged = 12 years with severe or        moderately severe hemophilia A (Factor VIII (FVIII) = 2%) with documented prior exposure        to FVIII concentrates.|February 2016|February 9, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093741||48088|
NCT02090205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPBVENT2014|Mechanical Ventilation During Cardiac Surgery|Mechanical Ventilation During Cardiac Surgery, a Randomized Controlled Trial||Ospedale San Raffaele|Yes|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|780|||Both|18 Years|100 Years|No|||February 2016|February 1, 2016|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02090205||48358|
NCT02090218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/984/REK-Vest.|I-Gel in Out-of-hospital Cardiac Arrest in Norway|I-Gel Versus Current Practice in Out-of-hospital Cardiac Arrest by Paramedics in Norway - a Prospective Stepped Wedge Crossover Trial|I-CAN|Haukeland University Hospital|No|Recruiting|February 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02090218||48357|
NCT02090231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-022OB|The Effect of Repetitive Transcranial Magnetic Stimulation for Poststroke Dysphagia Recovery|Phase 2 Study of rTMS on Poststroke Dysphagia||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|December 2011|August 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|70 Years|No|||March 2014|March 14, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090231||48356|
NCT02097368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00601-44|Bulbar Function in Neuromuscular Patients|Prospective Evaluation of Bulbar Function in Neuromuscular Patients|ORDEG|Centre d'Investigation Clinique et Technologique 805|Yes|Recruiting|April 2014|December 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|6 Years|70 Years|No|Probability Sample|patients affected by neuromuscular pathology|October 2015|October 14, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02097368||47811|
NCT02097940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Christiane Macedo|Influence of Sensorimotor Treatment in the Balance of Soccer|Influence of Sensorimotor Treatment in the Balance of Soccer||Universidade Estadual de Londrina|Yes|Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Male|14 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02097940||47767|
NCT02098200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENT_001/2013|Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™|Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™|PREVENT|4Tech Cardio Ltd.|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02098200||47747|
NCT02098499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCP.2012.0008|Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial|Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial||United States Naval Medical Center, Portsmouth|Yes|Completed|June 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098499||47724|
NCT02098720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902009|An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)|An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration|LAMP|Chengdu Kanghong Biotech Co.,Ltd.|No|Active, not recruiting|December 2011|||March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||July 2014|July 21, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098720||47707|
NCT02098980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDDIQAT Trial|Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar|Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar||Supreme Council Of Health, Qatar|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02098980||47687|
NCT02099253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX Pharmacodynamics|The Influence of Age on Dexmedetomidine Pharmacodynamic|The Influence of Age on Dexmedetomidine Pharmacodynamic in Lower Extremity Surgery||Guangzhou General Hospital of Guangzhou Military Command|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|80 Years|No|||December 2014|December 11, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099253||47666|
NCT02099526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051203|Older Cancer Caregiver Needs Post Hospital Discharge|Needs of Older Caregivers of Adults With Cancer In the First 2 Weeks Following Hospital Discharge||Duke University|No|Completed|June 2014|||June 2015|Actual|N/A|Observational|N/A||1|Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects include 30 informal caregivers and cancer patients dyads. Patients have been        admitted to either the hematological malignancy unit, or the non-hematological malignancy        unit for treatment of cancer, or treatment-related/cancer-related complications.|January 2015|July 21, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099526||47645|
NCT02095496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLuc|Efficacy of Closed-loop Ventilation to Reduced Sleep Disorders|Contribution to the Understanding of the Involvement of Mechanical Ventilation in ICU Patients Sleep Disorders|SleepICU|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|16|||Both|18 Years|94 Years|No|||January 2016|January 29, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02095496||47953|
NCT02095821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB-2110-2014|Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange|Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy||Hannover Medical School||Recruiting|February 2014|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Tertiary hospital patients after kidney transplantation, humoral rejection|September 2015|September 7, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02095821||47929|
NCT02095834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0162|Ph 1b, Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma|A Single Center Phase Ib Study of Carfilzomib, Bendamustine and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|April 2014|||April 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095834||47928|
NCT02096094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTSSA002101245|A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo|A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo||Universidad de Guanajuato|No|Completed|April 2014|January 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|November 30, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096094||47908|
NCT02096874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 1310|Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema|The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema||King Khaled Eye Specialist Hospital|No|Recruiting|June 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096874||47849|
NCT02097160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-14-01|How Much Vitamin D is Needed in Milk Products to Support Vitamin D Intake and Bone Health in Children?|How Much Vitamin D is Needed in Milk Products to Support Vitamin D Intake and Bone Health in Children?|D-KIDS|McGill University|No|Completed|December 2013|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|77|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097160||47827|
NCT02097173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-MTX.12/PK|Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen|Relative Bioavailability of Methotrexate (MTX) 50 mg/mL Administered Subcutaneously (SC) by a Disposable Autoinjector (Metoject® Prefilled Pen) Compared With Intramuscular (IM) Administration of the United States Reference Listed Drug Methotrexate Injection (USP 25 mg/mL [Hospira]) in Patients With Psoriasis||medac GmbH|No|Completed|May 2013|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|65 Years|No|||March 2015|March 13, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097173||47826|
NCT02090439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 062-13|Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.|Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.|SiloMET|Centre Hospitalier Departemental Vendee|Yes|Terminated|July 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|60 Years|No|||November 2015|February 10, 2016|March 14, 2014||No|Following difficulties in patient recruitment, we were forced to stop the study prematurely.|No||https://clinicaltrials.gov/show/NCT02090439||48340|
NCT02090452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRAA|Mobile Transmission of Prehospital Vital Signs to the Emergency Department|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and the Healthcare System: Study 1: "Mobile Transmission of Prehospital Vital Signs to the Emergency Department - Effect on Patient Outcomes, Treatment and Diagnosis"||University of Aarhus|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|15 Years|N/A|No|||April 2014|April 23, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02090452||48339|
NCT02090790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/400|Comparison of Analgesic Consumption Between Perioperative ıv Dexamethasone and Added to Femoral Block|The Compare the Effect of Peroperative Intravenous Single Dose Dexamethasone and the Addition of Dexamethasone to Femoral Nerve Block on Postoperative Analgesic Consumption Anf Patient Comfort in Unilateral Total Knee Arthroplasty Patients||TC Erciyes University|No|Recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||March 2014|March 20, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090790||48313|
NCT02090803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells|Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells , Prospective, Open, Multicenter Study|VIRAUTO6|Institut de Cancérologie de la Loire|No|Recruiting|August 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|196|||Both|18 Years|N/A|No|Probability Sample|consecutive patient|March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090803||48312|
NCT02097381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPHID-UniRoma01|Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy|HIV Infection and Gut Mucosal Immune Function: Longitudinal Analyses of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy||University of Roma La Sapienza|Yes|Active, not recruiting|April 2010|December 2014|Anticipated|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02097381||47810|
NCT02097654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF-C-12-05|Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons|Phase 1 of a Prospective, Multinational, Cluster‐Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects|SENATOR|University College Cork|Yes|Recruiting|March 2014|||March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|65 Years|N/A|No|Probability Sample|Elderly (age 65 years and older) hospitalized with acute illness.|March 2014|March 28, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02097654||47789|
NCT02097953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00069136|Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin|Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin||University of Utah|Yes|Active, not recruiting|May 2014|June 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097953||47766|
NCT02098213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOTHERMES|Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis|Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis, a Randomized, Controlled, Open Multicenter Study||Association Francaise pour la Recherche Thermale|No|Recruiting|January 2015|March 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02098213||47746|
NCT02098226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDAL-2013-001|Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts|Method Comparison Protocol: MALDI Biotyper-Clinical Applications (MBT-CA) Phase 2||Bruker Daltonics||Recruiting|September 2013|March 2015|Anticipated|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with infections from certain yeasts, Gram positive or certain Gram negative        bacteria (see Further Information / Target microorganisms of study)|February 2015|February 5, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098226||47745|
NCT02098512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC 564|Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients|A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)||New York Medical College|Yes|Recruiting|March 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|45 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098512||47723|
NCT02098772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N-CSM-AV-III/05/12|Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol|A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol|Custodiol-AV|Dr. F. Köhler Chemie GmbH|No|Recruiting|May 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|437|||Both|30 Years|85 Years|No|||January 2016|January 25, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02098772||47703|
NCT02098733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|097-011|Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus|Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for in Type 2 Diabetes Mellitus||Takeda|No|Completed|June 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1168|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes|August 2014|August 20, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098733||47706|
NCT02098993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS13090197|Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome|Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs. Standard of Care in Acute Chest Syndrome||University of Pittsburgh|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098993||47686|
NCT02099266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT-2011-08-01|Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment|A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment||University of Kansas Medical Center|Yes|Active, not recruiting|June 2013|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|17 Years|70 Years|No|||February 2015|March 31, 2015|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099266||47665|
NCT02095847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1080|High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection|Use of Fluorescence Imaging and High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection in Patients With Endometrial Cancer||M.D. Anderson Cancer Center|No|Withdrawn||March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||April 2015|April 7, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095847||47927|
NCT02096107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030099|Novartis Everolimus Transition|Safety and Efficacy of Everolimus Transition in Minimizing Progressive Graft Dysfunction and Interstitial Fibrosis in Adult Kidney Transplant Recipients||Medical University of South Carolina||Recruiting|February 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|March 23, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02096107||47907|
NCT02096341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-12-01|A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001|A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001||EpicentRx, Inc.|No|Terminated|April 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 20, 2014|No|Yes|Subcutaneous administration of RRx-001 is no longer of interest.|No||https://clinicaltrials.gov/show/NCT02096341||47889|
NCT02096575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMHSC12-313|Nitrous Oxide for Pain Management of First Trimester Surgical Abortion|Nitrous Oxide for Pain Management of First Trimester Surgical Abortion|NAB|University of New Mexico|Yes|Completed|August 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|March 20, 2014||No||No|February 12, 2016|https://clinicaltrials.gov/show/NCT02096575||47871|
NCT02096588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13160|Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin|Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|May 2014|April 2021|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096588||47870|
NCT02097186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVES-F|Preconditioning Shields Against Vascular Events in Surgery|Preconditioning Shields Against Vascular Events in Surgery: A Multi-centre Feasibility Trial of Preconditioning Against Adverse Events in Major Vascular Surgery (Preconditioning-SAVES)|SAVES-F|Mid Western Regional Hospital, Ireland|Yes|Recruiting|April 2014|August 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097186||47825|
NCT02097446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genewel1301|Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy|Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study|GUARDIX-FL|Genewel Co., Ltd|Yes|Not yet recruiting||January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|44 Years|No|||March 2014|March 24, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02097446||47805|
NCT02097459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-BREAST-AI|Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer|Prognostic Evaluation of Changing Endocrine Therapy in Perimenopausal and Recently Postmenopausal Women With Early-stage Hormone Receptor-Positive Breast Cancer||Peking Union Medical College Hospital|Yes|Active, not recruiting|March 2014|||March 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Female|45 Years|55 Years|No|||March 2014|March 24, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02097459||47804|
NCT02087124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-Premeal1|Dose-response Effect of Whey Protein Consumed as Pre-meal on Postprandial Lipaemia in Subjects With Metabolic Syndrome|Whey Protein, Postprandial Lipaemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipaemia in Persons With the Metabolic Syndrome and Type 2 Diabetes||Aarhus University Hospital|Yes|Completed|March 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|80 Years|No|||March 2014|July 18, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02087124||48594|
NCT02090816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver-lung-001|Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy|Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy||University of Milan|No|Completed|September 2004|December 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Tertiary care clinic|March 2014|March 14, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02090816||48311|
NCT02097121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-137|OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients|||Allergan|No|Recruiting|May 2014|June 2019|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|12 Years|17 Years|No|||January 2016|January 19, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097121||47830|
NCT02097394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJYYXHNK-002|The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps|A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps||RenJi Hospital|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|75 Years|No|||August 2015|August 27, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02097394||47809|
NCT02097667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0289|EVERREST Developing a Therapy for Fetal Growth Restriction|EVERREST - Developing a Therapy for Fetal Growth Restriction. A 6 Year Prospective Study to Define the Clinical and Biological Characteristic of Pregnancies Affected by Severe Early Onset Fetal Growth Restriction.|EVERREST|University College, London|No|Recruiting|March 2014|March 2021|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Plasma, serum, whole blood, fixed placenta, frozen placenta, fixed placenta bed.|Female|18 Years|60 Years|No|Non-Probability Sample|Pregnant women with FGR|May 2015|May 26, 2015|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02097667||47788|
NCT02097966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-237|EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C|A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C||Bristol-Myers Squibb||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2015|January 26, 2016|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097966||47765|
NCT02097979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer Canada NRA6110029|The Impact of a Brief Educational Intervention on Glaucoma Adherence|The Impact of a Brief Educational Intervention on Glaucoma Adherence||Maisonneuve-Rosemont Hospital|No|Completed|July 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||March 2014|March 24, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02097979||47764|
NCT02098525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVCM-01|Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy|Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy||Mahidol University|No|Completed|November 2013|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|195|||Both|15 Years|N/A|No|Probability Sample|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital,        Mahidol University.|March 2014|March 27, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02098525||47722|
NCT02098538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-244|Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2014|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098538||47721|
NCT02099032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.821|Milk Polar Lipids Consumption, Lipid Metabolism, and Inflammation in Menopausal Women|Influence of Milk Polar Lipids Intake on Lipid Metabolism, Body Composition, Inflammation and Intestinal Microbiota in Menopausal Women|VALOBAB-C|Hospices Civils de Lyon|No|Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|59|||Female|N/A|75 Years|No|||January 2016|January 26, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099032||47683|
NCT02099071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-073-101|Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949|Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Dose and Food Interaction Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Male Subjects||Actelion|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|65|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099071||47680|
NCT02098746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|097-012|Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone|Sonias Combination Tablets LD Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone||Takeda|No|Completed|June 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|294|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes|January 2016|January 11, 2016|March 25, 2014||No||No|January 11, 2016|https://clinicaltrials.gov/show/NCT02098746||47705|
NCT02099006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46905|Novel Topical Therapies for the Treatment of Genital Pain|Novel Topical Therapies for the Treatment of Genital Pain|Topicals|University of Rochester|No|Enrolling by invitation|November 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|65 Years|No|||May 2015|May 13, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099006||47685|
NCT02099019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0084|Usefulness of Coronary Computed Tomography Angiography for Therapeutic Decision- Making; Revascularization|||Yonsei University|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who visited the tertiary hospital for coronary angiography who are undergone CT        angiography prior to conventional coronary agniography|January 2015|January 7, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02099019||47684|
NCT02095509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004599-21|Pharmacokinetics of Enoxaparin in Intensive Care Patients|Pharmacokinetics of Enoxaparin in Intensive Care Patients||Tampere University Hospital|No|Recruiting|March 2014|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02095509||47952|
NCT02096120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130/13|Full Mouth Disinfection and Antibiotics for Periodontitis in High or Moderate Disease Activity Rheumatoid Arthritis|Single Arm Pilot Study of Antimicrobial Treatment of Active Rheumatoid Arthritis Associated With Manifest Periodontitis (Translated From German: Anti-mikrobielle Behandlung Der Aktiven Rheumatoiden Arthritis Bei Manifester Parodontitis - Eine Unkontrollierte Therapie-Pilotstudie)|FMD-ABRA|University Hospital Inselspital, Berne|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Each 5-10 ml of whole blood, serum and RNA specimen collected in RNA stabilization tubes      will be collected at screening and start, and subsequently 1, 3 and 6 months after      intervention. Gingival crevicular fluid samples will be collected at start of treatment,      after 3 and 6 months.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from inpatient and outpatient hospital rheumatology        departments.|September 2015|September 29, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096120||47906|
NCT02096354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-21-02|A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer|A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer|ROCKET|EpicentRx, Inc.|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096354||47888|
NCT02096601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612/004|A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients|A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD||NeuroDerm Ltd.|No|Not yet recruiting||||December 2014|Anticipated|Phase 1/Phase 2|Interventional|N/A|2||||||Both|30 Years|80 Years|No|||March 2014|March 23, 2014|March 18, 2014||Yes||||https://clinicaltrials.gov/show/NCT02096601||47869|
NCT02096614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201-01|Investigator Initiated Phase 1 Study of TBI-1201|Multi-center, Investigator Initiated Phase 1 Study of MAGE-A4 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors||Mie University|Yes|Recruiting|April 2014|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096614||47868|
NCT02096887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS964765|Effect of Patient Education on Compliance and Cardiovascular Risk Parameters|Effect of Patient Awareness and Education on Compliance and Cardiovascular Risk Factor Control|FAILAKA|Kuwait Institute for Medical Specialization|No|Not yet recruiting|June 2014|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096887||47848|
NCT02089607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009409|Clinical Outcomes and Quality of Life Measures in Patients Treated for Thoracoabdominal Aortic Aneurysms With Fenestrated and Branched Stent Grafts|Clinical Outcomes and Quality of Life Measures in Patients Treated for Thoracoabdominal Aortic Aneurysms With Fenestrated and Branched Stent Grafts||Mayo Clinic|Yes|Recruiting|March 2014|May 2025|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089607||48404|
NCT02089880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85951|Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis|Micro-processor Controlled Knee-Ankle-Foot Orthosis (C-Brace) Versus Stance-control Knee-Ankle-Foot Orthosis (SCO): Functional Outcomes in Individuals With Lower Extremity Impairment||Rehabilitation Institute of Chicago||Recruiting|February 2014|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089880||48383|
NCT02089893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRA-8504-1/2014/EKU|Study of the Incidence of Cilioretinal Arteries in the Hungarian Population|Study of the Incidence of Cilioretinal Arteries in the Hungarian Population||Semmelweis University|No|Recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young population|November 2015|November 16, 2015|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089893||48382|
NCT02090530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13053|Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing|Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|November 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Tumor Biopsy Whole Blood Serum Buccal Smear Plasma Formalin Fixed Paraffin Embedded (FFPE)      Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced or refractory cancer|October 2015|October 2, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02090530||48333|
NCT02090829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FaceStation|Intranasal Oxytocin and Learning in Autism|Promoting Social Perceptual Learning With Oxytocin in Autism||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2014|December 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Male|12 Years|17 Years|No|||December 2015|December 1, 2015|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090829||48310|
NCT02097407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreopDXM_PPF|Preoperative Dexmedetomidine & EC50 of Propofol|Preoperative Dexmedetomidine Reduces the EC50 of Propofol for Successful i-gelTM Insertion Without Muscle Relaxants|PreopDXM|Seoul National University Hospital|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|37|||Both|20 Years|65 Years|No|||March 2014|March 24, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097407||47808|
NCT02097680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/912|Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men|Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men|HEPAROB|University Hospital, Ghent|No|Recruiting|December 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|30|||Male|20 Years|60 Years|No|||June 2015|June 2, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02097680||47787|
NCT02098239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC2|Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.|An Open, Multiple Dose, Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.||Cancer Advances Inc.||Completed|August 1999|May 2002||April 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|90 Years|No|||March 2014|March 25, 2014|March 25, 2014||||||https://clinicaltrials.gov/show/NCT02098239||47744|
NCT02098785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-045|Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study|Phase I Clinical Trial Investigating the Effects of Caffeine Citrate on Serum Vascular Adhesion Protein -1 (VAP-1) Levels in Healthy Volunteers.|NOCTUA|University of Birmingham|No|Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|63|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098785||47702|
NCT02099058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-237|A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors||AbbVie||Recruiting|April 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|146|||Both|18 Years|99 Years|No|||February 2016|February 26, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099058||47681|
NCT02099292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mainz-135|Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma|Eine Phase II Studie Zur Beurteilung Der Wirksamkeit Von Rituximab in Der Salvage- Und Hochdosistherapie Mit Autologer Stammzelltransplantation Bei Patienten Mit B-Zell-Non-Hodgkin-Lymphom|Mz-135|Johannes Gutenberg University Mainz|No|Completed|May 2001|March 2014|Actual|May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02099292||47663|
NCT02098759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPISTOP|Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex|Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex|EPISTOP|Children's Memorial Health Institute, Poland|Yes|Recruiting|November 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|4 Months|No|||April 2014|April 3, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098759||47704|
NCT02099539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-803-02-13|A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma||Altor Bioscience Corporation|Yes|Recruiting|September 2014|January 2020|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099539||47644|
NCT02095860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-111|Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325|An Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Daclatasvir, Asunaprevir, and BMS-791325 Following Administration of a Single Fixed Dose Combination of DCV 3DAA FDC in Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095860||47926|
NCT02088411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-699412|The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults|The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: a Randomized, Double-blind, Placebo-controlled Trial.||Atrium Innovations|Yes|Completed|November 2000|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|40 Years|80 Years|No|||March 2014|March 13, 2014|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088411||48496|
NCT02088710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-2011|Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer|Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy||Philipps University Marburg Medical Center|No|Active, not recruiting|January 2011|January 2018|Anticipated|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|138|||Female|18 Years|80 Years|No|Non-Probability Sample|Primary care clinic|May 2015|May 5, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088710||48473|
NCT02089009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NonMydGyn|Comparison of Non-mydriatic Camera Systems in a Female Health Hospital|Comparison of Non-mydriatic Camera Systems for Screening and Follow-up Examinations -Focused on the Retinal Vessel Situation- in the Population of a Female Health Hospital||University Hospital Tuebingen|No|Recruiting|December 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|345|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 12, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02089009||48450|
NCT02089022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP 12788/2011|Analysis of Neuromuscular Responses and the Balance After the Application of Physiotherapy Resources|Analysis of Neuromuscular Responses and the Balance After the Application of Physiotherapy Resources||University of Sao Paulo|Yes|Completed|January 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02089022||48449|
NCT02089321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NelsonWong_LBP2013|Multiplanar Lumbopelvic Control in Patients With Low Back Pain|||Regis University|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|38|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with low back pain were recruited from the physical therapy clinic located at        Regis University as well as clinical practices from the surrounding area. Control subjects        were a community sample.|March 2014|March 13, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089321||48426|
NCT02089347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td536 (EFC12579)|Study of SP306 Given Intramuscularly Compared to DT BIK® Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old|Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) Given Intramuscularly Compared to Diphtheria and Tetanus Toxoids Adsorbed (DT) Given Subcutaneously in Japanese Adolescents 11 - 12 Years of Age||Sanofi|No|Completed|March 2014|March 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|534|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|March 13, 2014|No|Yes||No|September 9, 2015|https://clinicaltrials.gov/show/NCT02089347||48424|
NCT02089633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT-100-004|Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC|A Study of the Safety and Efficacy of Recombinant Human Arginase 1 (PEG-BCT-100) Combined With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|PACOX|Bio-Cancer Treatment International Limited|Yes|Recruiting|April 2014|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089633||48402|
NCT02089646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-001-IL-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||December 9, 2014|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089646||48401|
NCT02090491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Janssen Research & Development|MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation|MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation||Northeastern University|No|Recruiting|November 2013|||October 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|20|||Both|5 Years|20 Years|No|Non-Probability Sample|Group 1: Six (6) students from the Discovery School and their respective support staff.        Inclusion criteria include a diagnosis of ASD and enrollment in the Discovery School due        to frequently observed challenging behaviors. Reporters will include: 2 teachers, HCP and        parent/guardian.        Group 2: Fourteen (14) students receiving services from Center for Discovery (but outside        the Discovery School), their respective support staff, and, for those who live at home,        their parents. Inclusion criteria includes a diagnosis of ASD, seven (7) students who        reside in a CfD provided campus home, and seven (7) students who reside in the local        community with their parents. Reporters will include: 2 teachers, HCP, residential staff        and parents.        Stakeholders: Healthcare professionals, classroom teachers, residential staff, and parents        who support students with ASD in Groups 1 and 2 above.|November 2013|March 14, 2014|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02090491||48336|
NCT02086890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01311402F|Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for the Treatment of Vision Loss Due to Retinitis Pigmentosa|Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis Pigmentosa||Nova Southeastern University|Yes|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|21|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02086890||48612|
NCT02090543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17019|BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies|Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study||Bayer|No|Completed|January 2014|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|647|||Both|18 Years|N/A|No|Non-Probability Sample|Adult AF-patients, within 3 month of anticoagulation (VKA or rivaroxaban) therapy,        recruited by GPs|October 2015|October 15, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090543||48332|
NCT02090582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052239|H.O.P.E: Helping Ovarian Cancer Patients Cope|Pilot Study on H.O.P.E: Helping Ovarian Cancer Patients Cope During Disease Recurrence||Duke University|No|Recruiting|April 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|N/A|No|||August 2015|August 17, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02090582||48329|
NCT02097693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1603|Effect of DBS on Quality of Life in Dyskinetic Cerebral Palsy|Effect of Deep Brain Stimulation in the Globus Pallidus Internus on Quality of Life in Young Patients With Dyston-dyskinetic Cerebral Palsy|STIM-CP|University Hospital of Cologne|Yes|Recruiting|February 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|EDTA-plasma for DYT1-testing|Both|7 Years|18 Years|No|Non-Probability Sample|primary care clinic|March 2014|March 24, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097693||47786|
NCT02098005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/1133|Pain Neuroscience Education Combined With Cognition-targeted Motor Control Training|A Modern Neuroscience Approach to Chronic Spinal Pain: Pain Neuroscience Education Combined With Cognition-targeted Motor Control Training||University Ghent|No|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02098005||47762|
NCT02097992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120591|Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD|Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD||University of Miami|Yes|Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|21|||Both|45 Years|N/A|No|||October 2015|October 22, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02097992||47763|
NCT02098551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147/2009|Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments|Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments to Dissect the Contribution of IgE to Chronic Allergic Skin Inflammation||Medical University of Vienna|Yes|Completed|February 2011|April 2013|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Different types of individuals will be recruited and divided in four groups. A total of 30        allergic and non-allergic persons will be included in this study:        patients with Birch pollen-related atopic dermatitis (AD), Birch pollen allergic patients        without AD (group 2), allergic individuals without birch pollen allergy and non-allergic        individuals.|December 2015|December 6, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT02098551||47720|
NCT02099084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004866|Short Bowel Syndrome and Teduglutide Versus Placebo|Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition||Mayo Clinic|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|75 Years|No|||January 2016|January 25, 2016|March 25, 2014|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT02099084||47679|
NCT02099305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-wilcox|Randomized, School-based Effectiveness Trial of the Adolescent Depression Awareness Program|Impact of Increasing Adolescent Depression Literacy on Treatment-Seeking Behavior|ADAP|Johns Hopkins University|Yes|Enrolling by invitation|September 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|15000|||Both|12 Years|18 Years|No|||March 2014|March 25, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02099305||47662|
NCT02099318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-19|Evaluation of Effort and Time Efficiency of Surgical Theater's Surgery Rehearsal Platform (SRP) for Cerebral Aneurysm Clipping Surgery|Evaluation of Effort and Time Efficiency of Surgical Theater's Surgery Rehearsal|SRP|University Hospital Case Medical Center|No|Completed|February 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099318||47661|
NCT02099045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNVK1305018|Initial Patient Evaluation in the Emergency Department With Point-of-Care Ultrasonography|Initial Patient Evaluation in the Emergency Department With Point-of-Care Ultrasonography||Aarhus University Hospital||Recruiting|April 2014|January 2017|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|406|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Unselected consecutive patients in the Emergency Department.|January 2015|January 13, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099045||47682|
NCT02099279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|echo_COPD|Prognostic Value Cardiac Dysfunction Assessed by Bedside Echocardiography in Critically Ill COPD Patients Requiring Mechanical Ventilation|||Jinhua Central Hospital|No|Completed|January 2014|February 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|All patients meeting the diagnostic criteria of AECOPD and admitted to ICU are potentially        eligible for the present study. The diagnosis of AECOPD is based on that defined in Global        Initiative for Chronic Obstructive Pulmonary Disease. AECOPD is defined using definitive        criteria with at least two of the following major symptoms: increased dyspnea, increased        sputum purulence, increased sputum volume; or one major and one minor symptom: nasal        discharge/congestion, wheeze, sore throat and cough for at least two consecutive days.|March 2014|August 31, 2015|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02099279||47664|
NCT02095522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODEN|COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients|Does COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients?: A Prospective Randomized, Double-blind Placebo Controlled Study|CODEN|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|March 2014|December 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02095522||47951|
NCT02087904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-741|A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis|A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis||AbbVie|No|Active, not recruiting|May 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|35 Years|74 Years|No|||January 2016|January 15, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087904||48535|
NCT02088398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-HV-100|Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects|Open-Label, Randomized, Single Dose, 3-Period Crossover to Evaluate the Relative Bioavailability and Food-Effect on Pharmacokinetics of Alternative 10 mg/mL Liquid Formulation ACY-1215 (Ricolinostat) in Healthy Subjects||Acetylon Pharmaceuticals Incorporated|Yes|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088398||48497|
NCT02090972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FROP_BHL_Bochum|The Impact of Opioids in Fractures - a Case Control Study|Evaluation of Past Medications in Older Patients With Fractures and Patients Hospitalized for a Non-surgical Reason.|FROP|Ruhr University of Bochum|No|Recruiting|March 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|60 Years|N/A|No|Non-Probability Sample|hospitalized patients in University Hospital, surgical and internal department|March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090972||48299|
NCT02090985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1543/WSHT/2013|Lipomodelling for Symptomatic Peri-stomal Skin Contour Abnormalities: a Pilot and Feasibility Study|The Use of Lipomodelling Induced Skin Rejuvenation for the Management of Symptomatic Peri-stomal Skin Contour Abnormalities to Improve Quality of Life. A Pilot and Feasibility Study.|LiSPA|Western Sussex Hospitals NHS Trust|Yes|Recruiting|September 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 18, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02090985||48298|
NCT02087423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4191C00003|A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen|ATLANTIC|AstraZeneca|No|Active, not recruiting|February 2014|October 2017|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|453|||Both|18 Years|130 Years|No|||January 2016|January 25, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087423||48572|
NCT02087631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTPMS01|Safety and Tolerability of Quetiapine in Multiple Sclerosis|A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis||University of Calgary|No|Recruiting|December 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|65 Years|No|||July 2015|July 2, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087631||48556|
NCT02088450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syst-Eur|Systolic Hypertension in Europe|Systolic Hypertension in Europe Trial|Syst-Eur|Katholieke Universiteit Leuven|Yes|Terminated|February 1990|February 1997|Actual|February 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4695|||Both|60 Years|N/A|No|||March 2014|March 13, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088450||48493|
NCT02090192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaPLAGH-2013FC3009|Effects of Whole-body Vibration in the Frail Elderly|Acute and Chronic Effects of Whole-body Vibration on Mobility, Muscle Strength, Bone and General Health Status in the Frail Elderly||Chinese PLA General Hospital|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|75 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 16, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02090192||48359|
NCT02087956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-12-11-4261|Realizing Opportunities for Self Empowerment|Patient Priorities and Community Context: Navigation for Disadvantaged Women With Depression|ROSE|University of Rochester|Yes|Active, not recruiting|January 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||November 2015|November 13, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087956||48531|
NCT02090556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-348|Long-term Experience With Abatacept SC in Routine Clinical Practice|Long-term Experience With Abatacept SC in Routine Clinical Practice|ASCORE|Bristol-Myers Squibb|No|Recruiting|January 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2216|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Corhort 1: RA patients naive of Abatacept and any other biologic agents.        Corhort 2: RA patients naïve of Abatacept and who previously failed one or more biologic        agents.        In Germany, the study will be proposed to patients using syringe or pre-filled pen devices|February 2016|February 24, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02090556||48331|
NCT02090855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-026|Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem|A Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem.||GE Healthcare|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|108|Samples Without DNA|Brain specimen retained. Subjects who had previously been dosed with Flutemetamol (18F)      Injection and imaged in Study GE067-007.|Both|55 Years|N/A|No|Non-Probability Sample|Subjects who had previously been dosed with Flutemetamol (18F) Injection and imaged in        Study GE067-007.|September 2014|September 11, 2014|March 11, 2014|No|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT02090855||48308|The Clinical Trials NCT number is 01165554 for GE Healthcare study, GE-067-007.
NCT02086747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/33|Acetaminophen for Chronic Pain in Hysterectomy|The Management of Chronic Pain With Acetaminophen Four Times a Day||Mustafa Kemal University|No|Completed|March 2013|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|80 Years|No|||March 2015|March 12, 2015|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02086747||48623|
NCT02098018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AT007197|Comparison of Stress Reduction Techniques|||Massachusetts General Hospital|Yes|Recruiting|April 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02098018||47761|
NCT02098265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0469|A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device|A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device||University of Wisconsin, Madison|No|Recruiting|June 2010|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02098265||47742|
NCT02098252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.315|Treatment of Brain AVMs (TOBAS) Study|Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry|TOBAS|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|May 2014|||January 2035|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098252||47743|
NCT02098798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0960|Comparison of Surveillance Colonoscopy Techniques in Patients With IBD|||University of Calgary|No|Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|270|||Both|18 Years|80 Years|No|Non-Probability Sample|Inflammatory bowel disease patients undergoing surveillance colonoscopy|December 2015|December 6, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098798||47701|
NCT02098811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-NIF-JD-04|Evaluation of the Safety and Efficacy of a Non-Invasive Disruption of Fat and Skin Tightening Using 1064nm and 940nm Wavelengths|Evaluation of the Safety and Efficacy of a Non-Invasive Disruption of Fat and Skin Tightening Using 1064nm and 940nm Wavelengths||Cynosure, Inc.|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|55 Years|No|||July 2015|July 29, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098811||47700|
NCT02087397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-ED-001|Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction.||Ageless Regenerative Institute|No|Recruiting|March 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|80 Years|No|||July 2014|July 10, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087397||48574|
NCT02087410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ghrelin|Serum Ghrelin in Polycystic Ovary Syndrome|Ghrelin in Polycystic Ovary Syndrome||Ain Shams University|Yes|Not yet recruiting|April 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|84|Samples Without DNA|blood sample|Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty two patients with polycystic ovarian syndrome and forty two healthy subjects will be        recruited from the outpatient clinic Ain Shams University Maternity Hospital.|March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087410||48573|
NCT02099552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-015|Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia|Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia|ECP-015|Edimer Pharmaceuticals|No|Active, not recruiting|April 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|||Both|N/A|36 Months|No|Non-Probability Sample|Those with the condition of XLHED up to age 36 months|September 2015|September 3, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099552||47643|
NCT02095535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00623|Chlorhexidine Drying Time|The Minimum ChloraPrep Drying Time Before Neuraxial Anesthesia in Elective Cesarean Delivery Patients - Prospective Observational Study|Chlorhexidine|University of British Columbia|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Female|19 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Elective cesarean patients at BC Women's Hospital|September 2014|September 26, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095535||47950|
NCT02087891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11-254|Stress Free Now in a Corporate Call Center|Stress Free Now in a Corporate Call Center|SFN|The Cleveland Clinic|No|Completed|May 2011|September 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|161|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02087891||48536|
NCT02089620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 1|Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome|Calcium Supplements Versus Oral Contraceptive Pills Containing Drospirenone in Treating Mild to Moderate Premenstrual Syndrome: A Double Blind Randomized Placebo Controlled Trial|PMS|Beni-Suef University|Yes|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Female|18 Years|40 Years|No|||August 2015|August 7, 2015|March 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089620||48403|
NCT02090166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0105-CTIL|Lung Cancer Detection by Measuring Monocyte Activity|Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)|EDLC|Carmel Medical Center|No|Not yet recruiting|April 2014|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|950|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02090166||48361|
NCT02090179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGLU-CL01|Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging|Evaluation of Blood Brain Barrier Integrity and Relationship to Structural Brain Abnormalities in MPS IIIB Patients Using Cerebrospinal Fluid/Serum Albumin Index (CSF-AI) and Multimodal Magnetic Resonance Imaging||Alexion Pharmaceuticals|No|Active, not recruiting|December 2013|July 2014|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|5 Years|N/A|No|Non-Probability Sample|Up to six subjects with MPS IIIB. An attempt will be made to enroll equal numbers (three)        of MPS IIIB subjects with a classic (severe) disease presentation, and MPS IIIB subjects        with an attenuated phenotype.|June 2014|June 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090179||48360|
NCT02087111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9132|Telaprevir in Genotype 3 HCV|Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin|TIG3|Queen Mary University of London|Yes|Not yet recruiting|April 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||July 2014|July 11, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087111||48595|
NCT02087644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT003-QbG10 13|CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids|A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids||Cytos Biotechnology AG|No|Withdrawn|May 2014|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||May 2014|May 13, 2014|March 11, 2014|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT02087644||48555|
NCT02088190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-235|Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition|Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition||Ohio State University|Yes|Recruiting|April 2014|April 2019|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|22|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients scheduled to undergo laparoscopic sleeve gastrectomy (SG) at The Ohio State        University (OSU) Wexner Medical Center will be divided into two cohorts: 1). Greater than        or equal to 60 years of age and 2). Less than 60 years of age.|March 2014|April 20, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088190||48513|
NCT02089048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0101|Auranofin PK Following Oral Dose Administration|An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|April 2014|||September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|September 25, 2014|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089048||48447|
NCT02089659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-019|A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)|A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439||Merck Sharp & Dohme Corp.|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089659||48400|
NCT02086630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-8455|Timely Initiation of HIV Antiretroviral Therapy Among Those Who Delay/Decline|Intervention to Increase Timely Initiation of HIV Antiretroviral Therapy (ART) Among Those Who Delay or Decline|Heart to Heart|New York University|No|Completed|May 2012|April 2015|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086630||48632|
NCT02096393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16313|Patient Specific Instrumentation in TKR|A Prospective, Randomised Control Trial Assessing Clinical and Radiological Outcomes of Patient Specific Instrumentation In Total Knee Arthroplasty||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|September 2013|December 2024|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2014|March 22, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02096393||47885|
NCT02090296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBTSCA|Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study|Reticulocyte as Risk Marker: Targeted Therapy for Infants With Sickle Cell Anemia||Children's Research Institute|Yes|Terminated|February 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|6 Months|12 Months|No|||June 2015|June 19, 2015|February 4, 2014||No|Study PI moving to a different institution|No||https://clinicaltrials.gov/show/NCT02090296||48351|
NCT02090569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13-P007|High Resolution Imaging of Cerebral Vasculature by Functional Micro-Doppler Sonography During Brain Surgery|ULtrasound Imaging in Focal Cortical dYSplasia: a New Approach to Delineating the Dysplastic Cortex During Neurosurgery|ULYS|Centre Hospitalier St Anne|Yes|Suspended|April 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|65 Years|No|||March 2016|March 2, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02090569||48330|
NCT02087007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOA-1301i|A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Pletaal(Cilostazol) in Subjects With Vasospastic Angina|STELLA|Korea Otsuka Pharmaceutical Co.,Ltd.|Yes|Recruiting|November 2013|July 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|79 Years|No|||October 2014|October 17, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02087007||48603|
NCT02098278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2003-203|Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia|A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia||Catabasis Pharmaceuticals|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|74 Years|No|||May 2015|May 18, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098278||47741|
NCT02098564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHAB123|The Effect of Activity-based Training in Patients With Hand-related Injuries Grouped Using Sense of Coherence Scores|The Effect of Activity-based Training in Patients With Hand-related Injuries Grouped Using Sense of Coherence Scores||Odense University Hospital|No|Recruiting|February 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|420|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098564||47719|
NCT02088749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK081607-pilot|Comparison of Weight Management Programs Delivered in Large Versus Small Groups|Comparison of Weight Management Programs Delivered in Large Versus Small Groups||University of Alabama at Birmingham|No|Completed|May 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088749||48470|
NCT02090504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATE-I|Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome|The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome|GATE I|Catholic University of the Sacred Heart|No|Completed|February 2002|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|21 Years|75 Years|No|||March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090504||48335|
NCT02090751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-LB-0712-20001|Development of a Device to Measure Dark Adaptation|A Study to Evaluate the Sensitivity and Specificity of a Device to Measure Dark Adaptation in Subjects With and Without Early Macular Disease||University of Manchester|No|Completed|July 2014|April 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from a the greater manchester area by a call for        volunteers, through the local newspaper, a university email list and through the Hale        Barns Macular Disease Association|December 2015|December 1, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090751||48316|
NCT02090764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-110881-01|Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo|A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo||Ferrer Internacional S.A.|Yes|Recruiting|June 2014|||April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|412|||Both|2 Months|N/A|No|||March 2015|March 5, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090764||48315|
NCT02087930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/14|Microbiota as Potential Target for Food Allergy|Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy||Federico II University||Recruiting|March 2013|September 2014|Anticipated|May 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|60 Months|No|||March 2014|March 13, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02087930||48533|
NCT02099565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-CRE-2014/1|Observational Prospective Study OPTIMA II - Follow-up|Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI (Percutaneuos Coronary Intervention) With Drug Eluting Stent (DES) Implantation Who Take Statins (OPTIMA II) - Follow-up|OPTIMAII|AstraZeneca|No|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|572|||Both|18 Years|150 Years|No|Non-Probability Sample|Follow-up OPTIMA (NIS-GRU-NEX-2009/) study patients|February 2016|February 24, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099565||47642|
NCT02088723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apnea-PULMONAR-1|Testing the Elevation as Sleep Apnea Treatment|The Influence of Elevation of the Head of the Bed in Patients With Obstructive Sleep Apnea|TEST|Pulmonar|Yes|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088723||48472|
NCT02090465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-Picato NIS-2013|Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks|Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.||LEO Pharma|No|Recruiting|July 2013|April 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1080|||Both|18 Years|N/A|No|Non-Probability Sample|patients with actinic keratosis contacting their dermatologist|March 2014|March 17, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090465||48338|
NCT02090478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND039A01WISE|The Effect of Dietary Sugar Consumption on Sweet Taste Perception|The Effect of Dietary Sugar Consumption on Sweet Taste Perception||Monell Chemical Senses Center|No|Completed|October 2010|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02090478||48337|
NCT02090738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0941|A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide|||Yonsei University|Yes|Withdrawn|March 2014|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|70 Years|No|||March 2014|April 27, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02090738||48317|
NCT02087943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-AD-001|Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis|A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS||Celgene|Yes|Active, not recruiting|June 2014|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|189|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087943||48532|
NCT02088736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB 2013/676/C|Intraosseous vs Intravenous Access for Cardiac Arrest Treatment|Clinical Evaluation of Intraosseous and Intravenous Access for Cardiac Arrest Treatment in Emergency Ambulances In Singapore||Singapore General Hospital|No|Recruiting|June 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||November 2015|November 17, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088736||48471|
NCT02089932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-60-2013|Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.|The Effects of Different Dose Levels of Peri-neural Dexmedetomidine on the Pharmacodynamic and Side Effects Profiles of Bupivacaine-induced Ultrasound-guided Femoral Nerve Block||Cairo University|Yes|Completed|February 2014|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|60|||Both|15 Years|45 Years|No|||December 2015|December 22, 2015|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02089932||48379|
NCT02095925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICA|Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism|Microparticle's Procoagulant Activity to Identify Patients With Cancer and a High Risk for Venous Thrombosis|MICA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|July 2008|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|Samples Without DNA|citrated plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal        carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer,        urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have        started chemotherapy no more than 3 months ago|March 2016|March 14, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02095925||47921|
NCT02096172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002|Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA|Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA|UTOPIA|Renaissance RX|No|Withdrawn|March 2014|||July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female subjects who are considered candidates for UDT.|September 2014|September 22, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096172|24 Months|47902|
NCT02095327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130429|Families Affected by Dementia: A Survey of Caregivers|Religion and Free Will Perceptions as Coping Mechanisms in Caregivers of Individuals With Dementia|FAD|University of Miami|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample of caregivers for individuals with dementia|August 2015|August 26, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02095327||47966|
NCT02095626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-301-III-001|Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation|Pilot Study to Investigate the Clinical Effect of Orally Inhaled AP301 on Treatment of Primary Graft Dysfunction (PGD) in Mechanically Ventilated Patients After Primary Lung Transplantation||Apeptico Forschung und Entwicklung GmbH|Yes|Completed|June 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02095626||47943|
NCT02090595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-3124|Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar Disorder|Neurofunctional Effects of Mindfulness Based Cognitive Therapy for Youth With Symptoms of Anxiety and a Familial Risk for Developing Bipolar Disorder|Mindfulness|University of Cincinnati|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|39|||Both|10 Years|17 Years|No|||May 2015|May 26, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02090595||48328|
NCT02087020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIR-3|Debridement, Antibiotics and Implant Retention in Early Periprosthetic Joint Infection: A Retrospective Cohort Study|Debridement, Antibiotics and Implant Retention in Early Periprosthetic Joint Infection: A Retrospective Cohort Study|DAIR|Danderyd Hospital|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|51|||Both|N/A|N/A|No|Non-Probability Sample|Danderyd Hospital is a university hospital affiliated with the Karolinska Institute and is        one of the four emergency hospitals in Stockholm, with a catchment area of approximately        500.000 inhabitants. The index cohort was extracted from the local in-hospital surgery        database at the Department of Orthopaedic Surgery using ICD 10 coding and surgical        intervention coding for PJI treatment.|March 2014|March 8, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02087020||48602|
NCT02087332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOR-IIT-001|Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.|Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure||Society of Specialists in Heart Failure|No|Not yet recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|40 Years|70 Years|No|||March 2014|March 19, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087332||48579|
NCT02087657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Auto-HBO|Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation|Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant|Auto-HBO|University of Kansas Medical Center|Yes|Active, not recruiting|March 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||January 2015|January 22, 2015|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087657||48554|
NCT02086643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-175|The Retroclavicular Approach for Regional Anesthesia of the Upper Limb in Obese Patients|The Retroclavicular Approach for Regional Anesthesia of the Upper Limb in Patients With BMI ≥ 30 kg/m2 : A Descriptive Study||Université de Sherbrooke|No|Completed|December 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 3, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02086643||48631|
NCT02086656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COI-B|PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES|PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES|COI-B|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|June 2013|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02086656||48630|
NCT02086864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UToronto-29722|A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD|A Randomized, Double Blind, Placebo Controlled Study of Homeopathic Treatment of Children and Youth With Attention Deficit Hyperactivity Disorder||University of Toronto|Yes|Recruiting|March 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|177|||Both|6 Years|16 Years|No|||December 2015|December 1, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086864||48614|
NCT02087098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEST-001|A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics|Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare™ (Solifenacin) From Other Antimuscarinics|VEST|Astellas Pharma Inc|No|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients with OAB symptoms being treated by urologists in Czech Republic|March 2016|March 3, 2016|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087098||48596|
NCT02088437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32/14|High Intensity Physiotherapy for Hip Fractures|High Intensity Physiotherapy for Hip Fractures in the Acute Hospital Setting|HIP4hips|The Alfred|Yes|Completed|March 2014|September 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|65 Years|N/A|No|||December 2015|December 29, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02088437||48494|
NCT02089334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-0201-P2-A-09|Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer|A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma||Rexahn Pharmaceuticals, Inc.|No|Recruiting|August 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089334||48425|
NCT02089906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL22|Health and Nutrition Status of Chinese Elderly|Health Status of Chinese Elderly||Abbott Nutrition|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2834|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Multi-center cross-sectional study of community dwelling chinese|August 2015|August 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089906||48381|
NCT02098889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179|Safety Study of Hyoscine N Butyl Bromide in Active Management of Labor|Efficacy and Safety of Hyoscine N Butyl Bromide on the Augmentation of Labor: a Double-Blind, Placebo - Controlled Trial|HBB|Sisli Etfal Training & Research Hospital|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|382|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||May 2012|March 27, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02098889||47694|
NCT02099149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_28OB|Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days|Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.||Novartis|No|Withdrawn|May 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 18 years or older attending for antenatal care or delivery at 3        academic hospital centers in the Johannesburg area and the antenatal clinics serving those        hospital centers.|July 2014|July 23, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099149||47674|
NCT02086877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6425-BE|COGnitive Outcomes and WELLness in Survivors of Critical Illness|COGnitive Outcomes and WELLness in Survivors of Critical Illness|COGWELL|University of Toronto|Yes|Recruiting|January 2014|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|16 Years|N/A|No|Non-Probability Sample|Critically ill individuals who require mechanical ventilation for one week or greater|March 2014|March 11, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086877||48613|
NCT02095600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB-SRS|Radiosurgery for Drug Resistant Invalidating Tremor|Deep Brain Stimulation and Frameless Stereotactic Radiosurgery in the Treatment of Drug Resistant Invalidating Tremor|DB-SRS|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Active, not recruiting|April 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02095600||47945|
NCT02095613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002017/BWH|Tailored Nutrition and Food Security Interventions in Comprehensive HIV Care|A Randomized Trial of Ready-to-use-supplementary Food Compared to Corn-soy-blend+ as Food Rations for HIV-infected Adults on Antiretroviral Therapy in Rural Haiti||Brigham and Women's Hospital|No|Active, not recruiting|May 2010|||July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|623|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095613||47944|
NCT02095340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0035|Effects of Maternal Interpretation Biases on Child Anxiety and Related Responses|||University of Mississippi Medical Center||Recruiting|May 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|260|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095340||47965|
NCT02099435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007|Study of Hemospray for Lower Gastrointestinal Hemorrhage|A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)||Cook|No|Recruiting|January 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|No|Non-Probability Sample|clinical sites|January 2016|January 12, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099435||47652|
NCT02095353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|585-13|Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients|Gadobenate Dimeglumine Compared to Gadobutrol for MRI Perfusion Analysis in Brain Tumor Patients||University of Nebraska|No|Recruiting|September 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|24|||Both|19 Years|N/A|No|Non-Probability Sample|Adults with brain tumors who have had a brain MRI ordered.|January 2016|January 19, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02095353||47964|
NCT02090608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-FD|Paricalcitol in Fabry Disease|||Federico II University||Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||January 2014|March 17, 2014|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02090608||48327|
NCT02086773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13126|Red Cell Transfusion Goals in Patients With Acute Leukemias|Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients With Acute Leukemias||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02086773||48621|
NCT02087345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGRG-2414b|Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion|Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion: a Longitudinal Study With pH-impedance Monitoring||Brain-Gut Research Group|No|Recruiting|March 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|None Retained|gastric juice|Both|18 Years|N/A|No|Probability Sample|Successive male and female patients with dental erosions|February 2016|February 15, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02087345||48578|
NCT02088463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.T.REC/012/00368|Mobilization for Post Partum Low Back Pain|Efficacy of Lumbar Mobilization on Postpartum Low Back Pain in Egyptian Females: A Randomized Control Trial||Cairo University|No|Completed|December 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Female|25 Years|35 Years|No|||March 2014|March 14, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02088463||48492|
NCT02088476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUTF06|Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal|||Hacettepe University|No|Completed|January 2004|June 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|248|||Both|N/A|18 Years|No|Probability Sample|Children diagnosed with candidemia were included in our hospital between Jan 2004 and Dec        2012.|March 2014|March 14, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088476||48491|
NCT02089945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503-2013|Pilot Study of Cognitive and Functional Outcomes Following TAVI|Cognitive and Functional Outcomes Following Transcatheter Aortic Valve Implantation (TAVI): a Pilot Study||Sunnybrook Health Sciences Centre|No|Recruiting|March 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|31|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of severe symptomatic aortic stenosis (aortic valve area < 1        cm2, mean gradient across the aortic valve of 40 mm Hg or more and a peak aortic jet        velocity of 4.0 m/s or more) undergoing transcatheter aortic valve implantation|November 2015|November 26, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089945||48378|
NCT02087618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-05-H-02|The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment|The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)|KodroSol|Mt. Sinai Medical Center, Miami|No|Recruiting|March 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|No|||March 2014|March 13, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02087618||48557|
NCT02087917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-25-III|A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia|A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia||Zhejiang Hisun Pharmaceutical Co. Ltd.|No|Completed|March 2014|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|376|||Both|18 Years|65 Years|No|||January 2015|January 5, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087917||48534|
NCT02088177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6799|Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence|Open-Label Pilot Study of Long-Acting Injectable Naltrexone Treatment for Cannabis Dependence||New York State Psychiatric Institute|Yes|Recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|60 Years|No|||August 2015|August 31, 2015|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02088177||48514|
NCT02088424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mohd-1978|the Insulin Resistance in Recurrent Miscarriage IN RECURRENT ABORTION|Insulin Resistance and Recurrent Abortion||Ain Shams University|Yes|Not yet recruiting|March 2014|April 2015|Anticipated|November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples Without DNA|whole blood|Female|23 Years|40 Years|No|Non-Probability Sample|1. Women in the child bearing period between 23-40 years.          2. All patients are pregnant.          3. The gestational age of both groups 6-13 weeks|March 2014|March 13, 2014|March 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088424|6 Months|48495|
NCT02089035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/43|Replacement of Saturated Fat in Dairy on Total Cholesterol|Replacement of Saturated Fat in Dairy on Total Cholesterol, Vascular Function, Ambulatory Blood Pressure and Cardiovascular Risk Biomarkers|RESET|University of Reading|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02089035||48448|
NCT02089919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH-001|Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients|Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Liver||Fuda Cancer Hospital, Guangzhou|Yes|Completed|February 2014|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|75 Years|No|||March 2014|June 1, 2015|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02089919||48380|
NCT02098642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HalluxPD001|Hallux Mobilization in Patients With Parkinson's Disease|Passive Mobilization of the Metatarsophalangeal Joint of the Hallux During a Rehabilitation Treatment in Patients With Parkinson's Disease|HalluxPD001|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Completed|March 2013|February 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|49 Years|88 Years|No|Non-Probability Sample|PD|March 2014|March 24, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098642||47713|
NCT02098902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0547|Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5|Randomized Controlled Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5||University of North Carolina, Chapel Hill|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|3 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098902||47693|
NCT02095288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818658|Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A|Broad-spectrum Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in In Vitro Human Whole-blood Assay (hWBA)||University of Pennsylvania|No|Active, not recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|30|Samples Without DNA|Thirty (n=30) healthy, non-smoking male and female volunteers between the ages of 18-50 will      be included in this study. If all inclusion/exclusion criteria are met, a blood collection      of 104 ml will be obtained and the study visit will be completed. If eligible, a volunteer      may participate in this study up to four separate times, but not more than two times in the      same week.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal, healthy, non-smoking, male and non-pregnant female volunteers between the ages of        18 - 50|August 2015|August 17, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095288|1 Day|47969|
NCT02095301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1320|Herbal Extract Study|||PepsiCo Global R&D||Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|110|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|March 10, 2014||Yes||No||https://clinicaltrials.gov/show/NCT02095301||47968|
NCT02095314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Booster Penta 0413|Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine|Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age||PT Bio Farma|No|Completed|March 2014|December 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|399|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||December 2014|December 16, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095314||47967|
NCT02098915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000038585|Metoclopramide Pilot Trial|The Use of Metoclopramide vs. Placebo in Infants With Gastroschisis. A Pilot Double Blind Randomized Controlled Trial||The Hospital for Sick Children|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|33 Weeks|N/A|No|||May 2015|May 29, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098915||47692|
NCT02099383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPRPG6D0011|BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.|A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke|HYDO|Chang Gung Memorial Hospital|Yes|Recruiting|April 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|244|||Both|N/A|N/A|No|||January 2016|January 25, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099383||47656|
NCT02099396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaAOC-2014-001|A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma|||China Association of Osteosarcoma Chemotherapy||Not yet recruiting|April 2014|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|8 Years|40 Years|No|||March 2014|March 27, 2014|March 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099396||47655|
NCT02099409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIDLUX 4|Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg|Open Label Single Center Randomized Cross Over Study to Validate Current Algorithms and Evaluate Safety and Efficacy of Closed Loop Insulin Delivery (FlorenceD2 System) in Children With Type 1 Diabetes Between 6 - 12 Years of Age||Centre Hospitalier du Luxembourg|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|6 Years|12 Years|No|||September 2014|September 15, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099409||47654|
NCT02095678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3213|Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions|Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions||Case Comprehensive Cancer Center|Yes|Recruiting|December 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|170|||Both|18 Years|100 Years|No|||February 2016|February 19, 2016|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095678||47940|
NCT02095691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENABLATE-II|RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157|A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157)|RENABLATE-II|Biosense Webster, Inc.|Yes|Completed|October 2013|April 2015|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|85 Years|No|||October 2015|October 30, 2015|March 21, 2014||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT02095691||47939|
NCT02095964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYIEAH-281|HDL-C in Cardiac Syndrome X|HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X|HIRICS-X|Bursa Yüksek İhtisas Education and Research Hospital|Yes|Completed|March 2012|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Actual|710|||Both|47 Years|58 Years|Accepts Healthy Volunteers|Non-Probability Sample|CSX was defined as typical chest pain during rest or effort, abnormal test result for        exercise ECG and myocardial perfusion scintigraphy, and the presence of angiographically        normal epicardial coronary arteries. Control group was selected from volunteers presented        to our hospital with the complaint of typical anginal chest pain who had no ischemia on        myocardial perfusion scintigraphy or during the treadmill exercise test, had similar risk        profile with the patients (diabetes, hypertension, age, gender) and had normal epicardial        coronaries at coronary angiography.|March 2014|March 24, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02095964||47918|
NCT02086786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-RISP-2011-02|Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia|Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia|PRISMA-2|Rovi Pharmaceuticals Laboratories|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||May 2015|May 4, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086786||48620|
NCT02087579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103695|Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants|Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone||Janssen Research & Development, LLC|No|Completed|February 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|305|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02087579||48560|
NCT02089360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20140311|Adavanced Glycated Endproducts and Development of CAD|Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram|AGENDA|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2014|||January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood sample is taken for all patients underwent coronary angiogram after getting informed      consent, and stored in requested condition, for measuring serum levels of different kinds of      factors.|Both|18 Years|90 Years|No|Probability Sample|patients underwent coronary angiogram|March 2014|March 14, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089360|5 Years|48423|
NCT02089373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0392|A Pilot Study on Usefulness of Probe-based Confocal Laser Endomicroscopy Targeted Gastric Biopsy|||Yonsei University||Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|20 Years|80 Years|No|||August 2015|August 19, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089373||48422|
NCT02090959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-020e-DMD|Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy|A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy||PTC Therapeutics|Yes|Enrolling by invitation|March 2014|||June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Male|7 Years|18 Years|No|||October 2014|October 15, 2014|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02090959||48300|
NCT02097550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-28341|Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease|Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease|CKD eHealth|Stanford University|No|Not yet recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02097550||47797|
NCT02097563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R33MH097007|Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders|Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders|FFT|University of California, Los Angeles|No|Not yet recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|13 Years|25 Years|No|||March 2014|March 24, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097563||47796|
NCT02097524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6R88-RA-1309|Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)|||Regeneron Pharmaceuticals|Yes|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|105|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097524||47799|
NCT02097537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1002|Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma|Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma||Santen Pharmaceutical Co., Ltd.||Completed||||July 2014|Actual|Phase 3|Interventional|N/A|1||||||Both|6 Years|15 Years|No|||November 2015|November 11, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02097537||47798|
NCT02098083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092013-009|Evaluation of Physical Therapy Interventions and Patient Characteristics on Outcomes|Evaluation of Physical Therapy Interventions and Patient Characteristics on Functional Mobility Outcomes in Persons With Acute Stroke|PBE|University of Texas Southwestern Medical Center|No|Withdrawn|November 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|16 Years|80 Years|No|Non-Probability Sample|Persons post stroke admitted to inpatient rehabilitation units|July 2015|July 29, 2015|March 20, 2014||No|Unable to collect data|No||https://clinicaltrials.gov/show/NCT02098083||47756|
NCT02098356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-480|Comparison of High Versus Low Bicarbonate Hemodialysis|Intradialytic Acid-base Changes and Organic Anion Production With High Versus Low Bicarbonate Hemodialysis||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2015|January 13, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02098356||47735|
NCT02098629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCHC-14|Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction|Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction|COMET-AMI|Shantou University Medical College|Yes|Recruiting|May 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||November 2015|November 20, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098629||47714|
NCT02098109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403068|Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma|A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma||Washington University School of Medicine|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098109||47754|
NCT02098382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIS2013-002|Dilapan-S Osmotic Dilator in Pre-induction of Labor|Prospective Collection of Data About the Use of the Dilapan-S Osmotic Dilator in Pre-induction of Labor in Women With/Without Caesarean Section in Their History||Medicem International CR s.r.o.|Yes|Completed|May 2013|October 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Female|N/A|N/A|No|Probability Sample|All patients indicated in the centres involved in data collection for pre-induction of        labor with Dilapan-S who meet all inclusion and exclusion criteria.        In the above period, the Investigator will include consecutive patients in such a manner        that the numbers of those with and without a history of Caesarean section be balanced.|March 2014|July 28, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02098382||47733|
NCT02098395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9211-4083|The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes|A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial|ADJUNCT TWO™|Novo Nordisk A/S|No|Completed|May 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|835|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098395||47732|
NCT02099162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0030|Yonsei OCT (Optical Coherence Tomography) Registry for Evaluation of Efficacy and Safety of Coronary Stenting|||Yonsei University|No|Recruiting|April 2008|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who visited our tertiary hostpital (Severance Cardiovascular Hospital) for        coronary angiography (with coronary stents or planning for coronary stents)|March 2014|March 27, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099162||47673|
NCT02099188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINTART2|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Inoperable Patients||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|November 2013|January 2024|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02099188||47671|
NCT02099175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINTART1|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Surgery, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Operable Patients||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|November 2013|January 2024|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02099175||47672|
NCT02099422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APHM-011|Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome|The Randomized TOPIC Study : Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome|TOPIC|Hôpital de la Timone|No|Recruiting|January 2013|January 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|85 Years||Non-Probability Sample|Patients with ACS treated by coronary stent implantation|March 2014|March 26, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099422||47653|
NCT02095704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU-YXY-001|Pharmacokinetics of a Standard Paracetamol Tablet and Oral Solution After Oral Administration in Chinese Healthy Volunteers|||Central South University|Yes|Completed|May 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|19 Years|25 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095704||47938|
NCT02095717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002138-20|Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)||CURTAXEL|Centre Jean Perrin|No|Recruiting|March 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||December 2015|December 23, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095717||47937|
NCT02095730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-CHR 1|Corneal Cross-Linking Comparing Variables|Study of Safety and Efficacy of Photochemically Induced Collagen Cross-Linking at an Irradiance of 18 mW/cm2 as Constant or Pulsed Treatment in Eyes With Unstable Corneas Due to Keratoconus, Ectasia, or Post-Incisional Refractive Surgery||Crowd Health Research, LTD|No|Not yet recruiting|May 2014|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|12 Years|N/A|No|||March 2014|March 21, 2014|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095730||47936|
NCT02095977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZWEI003872|Insulation Failure in St. Jude Riata Leads|Insulation Failure in St. Jude Riata Leads: Screening and Predicting Impending Lead Failure||Hartford Hospital|Yes|Recruiting|July 2013|January 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02095977||47917|
NCT02096484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM145073|A Comparison of Metacognitive Group Therapy Versus Mindfulness Meditation Therapy in Generalized Anxiety Disorder|A Comparison of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy in Generalized Anxiety Disorder|MCT|University of Manchester|Yes|Active, not recruiting|August 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096484||47878|
NCT02087033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN-tvg-00313b|Use of Ritmonutra in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease|A Randomized, Double-blinded, Cross-over Study on the Use of Ritmonutra, a Nutraceutical Product Composed of Omega 3 Fatty Acids, Astaxanthin, Vitamin E and Hawthorn in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease||IRCCS Policlinico S. Donato|No|Recruiting|December 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||February 2014|March 7, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02087033||48601|
NCT02087046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-02|Deep Brain Stimulation (DBS) for the Suppression of Tremor|A Clinical Evaluation of the Advanced Neuromodulation System (ANS) Totally Implantable Deep Brain Stimulation System for the Suppression of Tremor in the Upper Extremities of Patients With Essential Tremor.||St. Jude Medical|Yes|Active, not recruiting|October 2005|December 2017|Anticipated|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087046||48600|
NCT02088151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/10|Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina|Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina||University Hospital Inselspital, Berne|No|Recruiting|June 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02088151||48516|
NCT02088164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809020|Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men|Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men||National Taiwan University Hospital||Completed|February 2012|||April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|27741|||Male|41 Years|N/A|No|Non-Probability Sample|Taiwanese healthy men who are older than 40 years|March 2014|March 13, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT02088164||48515|
NCT02089672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00069674|RF Lesion Monitoring With 8mm IntellaTip MiFi XP|Radiofrequency Ablation Lesion Monitoring Using Imbedded Micro-Electrodes Versus Standard Bipolar Electrograms||Emory University|Yes|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Enrollment will include 25 patients undergoing a radiofrequency ablation procedure in        which ablation of the cavotricuspid isthmus is planned.|November 2015|November 14, 2015|February 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089672||48399|
NCT02089685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-029|Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)|A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|March 2014|January 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|343|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089685||48398|
NCT02097277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB130-002|A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes||Bristol-Myers Squibb|No|Active, not recruiting|April 2014|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|120|||Both|21 Years|75 Years|No|||January 2016|March 11, 2016|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097277||47818|
NCT02097290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPTIVATE|Evaluation of Automatic Threshold Algorithms|CAPTure Information Via Automatic Threshold Evaluation|CAPTIVATE|Boston Scientific Corporation|No|Active, not recruiting|April 2014|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097290||47817|
NCT02096731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.526|Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events|Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events: A Population-based Observational Study||Boehringer Ingelheim||Completed|March 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|||||Both|55 Years|100 Years|No|Non-Probability Sample|Users of tiotropium or long-acting beta agonists|January 2016|January 26, 2016|March 24, 2014||||No||https://clinicaltrials.gov/show/NCT02096731||47859|
NCT02096744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253.2486|Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers|A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-Oppanol® Following Transdermal Administration in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|March 24, 2014||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT02096744||47858|
NCT02096991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPA-CAN-1|Associations of Exposure to Bisphenol A With Blood Pressure and Epigenetic Change|Associations of Exposure to Bisphenol A With Blood Pressure and Epigenetic Change||Seoul National University Hospital|Yes|Completed|February 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|60|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||March 2014|March 23, 2014|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02096991||47840|
NCT02097004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E+VIP|Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection|Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir|E+VIP|Seoul National University Hospital|Yes|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|75 Years|No|||August 2015|August 2, 2015|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02097004||47839|
NCT02098096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB01625|Negative Work Exercise for the Treatment of Knee Arthritis|Development of a Negative Work Exercise Regimen as an Intervention for Posttraumatic Osteoarthritis of the Knee|PTOA-ECC|Washington D.C. Veterans Affairs Medical Center|No|Recruiting|March 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|50 Years|70 Years|No|||January 2016|January 3, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02098096||47755|
NCT02098369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-CE 1304-6490|Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers|Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers (PELICAN)|PELICAN|University of Illinois at Chicago|Yes|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02098369||47734|
NCT02098408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2013-015|Effects of Neurocognitive and Social Cognitive Remediation in Patients at Ultra-High Risk of Psychosis|A Randomised Clinical Trial Examining Cognitive Remediation Plus Standard Treatment Versus Standard Treatment in Participants at Ultra-High Risk of Psychosis. - Effect on Cognitive Functioning, Functional Outcome and Symptomatology.|FOCUS|Mental Health Services in the Capital Region, Denmark|Yes|Recruiting|March 2014|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|40 Years|No|||March 2016|March 17, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02098408||47731|
NCT02098668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17721_PAEON|Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON|Model Driven Computation for Infertility Related Endocrinological Diseases - PAEON|PAEON|University of Zurich|Yes|Recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|110|Samples Without DNA|Probes to determine hormonal parameters|Female|18 Months|43 Years|Accepts Healthy Volunteers|Probability Sample|Women with normal and distrubed menstrual cycles Women receiving fertility treatment|January 2015|January 15, 2015|June 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02098668||47711|
NCT02098681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00010229|SPAIN Chest Wall Deformity Project (Pectus Repair)|Society for Pediatric Anesthesia Improvement Network (SPAIN) Chest Wall Deformity Project (Pectus Repair)||Children's Hospital Boston|No|Recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|8 Years|30 Years|No|Non-Probability Sample|Individuals undergoing surgical procedures on the chest wall region performed to correct        Pectus Excavatum deformities.|March 2014|March 25, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098681|3 Months|47710|
NCT02098655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP PD 001|Analysis of the Parameters Obtained on Stabilometric Platform in Patients With PD|Analysis of the Parameters Obtained on Stabilometric Platform in Patients With Parkinson's Disease: a Basis for a Rehabilitation Perspective|SPPD001|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|42|||Both|58 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease and healthy volunteers.|March 2014|March 27, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098655||47712|
NCT02099461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130349|Effect of Denosumab on Cellular Biomarkers in the Human Breast|A Randomized, Stratified, Open-label, No-treatment-controlled, Parallel Group, Multicenter Phase 1 Trial to Evaluate the Effect of Denosumab on Cellular Proliferation in the Human Breast||Amgen|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|82|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|February 25, 2014|No|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT02099461||47650|
NCT02099448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-01|Correlation of Non-invasive Assessment, Using C.A 2.0 Device, Versus Invasive Assessment of LVEDP|Correlation of Non-invasive Assessment, Using C.A 2.0 Device, Versus Invasive Assessment of Left Ventricular End Diastolic Pressure (LVEDP)||CorAlert Ltd.|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects undergoing elective cardiac catheterization, during which LVED and aortic        pressures are recorded|February 2016|February 8, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099448||47651|
NCT02095366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALGOFINE-2|Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting|Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting. A Multicenter,Randomized,Controled, Comparative, Double Blinded Study|ALGOFINE-2|University Hospital, Grenoble|Yes|Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02095366||47963|
NCT02096250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N43|Iron Absorption in Haiti|Iron Absorption From Wheat Flour in Haiti||Swiss Federal Institute of Technology|No|Completed|June 2014|July 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096250||47896|
NCT02096263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117119|Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants|Immunogenicity and Safety Study of GSK Biologicals' Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants||GlaxoSmithKline||Active, not recruiting|April 2014|November 2015|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|585|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||July 2015|August 20, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096263||47895|
NCT02096497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGU-001|Analysis of the Vascular Pattern of the Superficial Temporal Artery|In Vivo Analysis of the Vascular Pattern of the Superficial Temporal Artery Based on Digital Subtraction Angiography||University Hospital Tuebingen|Yes|Completed|January 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||11|Actual|93|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinic patients who underwent digital subtractions angiographie|March 2014|March 21, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096497||47877|
NCT02096822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K13802|Efficacy of Facilitated Tucking During Pain Procedure in Preterm Infants|Efficacy of Facilited Tucking and Non-nutritive Sucking of Sterile Water to Relieve Preterm Infants From Pain During Heel-stick Procedures.|BABYDOUL|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|N/A|48 Hours|No|||February 2016|February 23, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096822||47853|
NCT02087358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110908|Alcohol Consumption and Stress at Patients Alcohol-dependants|Alcohol Consumption and Stress at Patients Alcohol-dependants|CASPA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|CRHR1 gene polymorphisisme|Both|18 Years|65 Years|No|Non-Probability Sample|This study includes alcohol dependent inpatients participating in a 3 weeks detoxification        program.|November 2015|November 11, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02087358||48577|
NCT02087865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH AG022304|Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease|Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease||The Cleveland Clinic|No|Recruiting|May 2014|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|3||Anticipated|90|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087865||48538|
NCT02087878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F14-258|A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma|A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL)|HSTCL|AbbVie|No|Recruiting|March 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|40|Samples With DNA|1-10 mL blood (serum) for biomarker samples; separate consent for 1- 4 mL whole blood sample      for DNA isolation. Biopsy tissue and Fine Needle Aspirate also collected. Samples will be      shipped to a designated storage facility.|Both|1 Year|99 Years|No|Non-Probability Sample|The study population will include patients of any age with CD or UC in the US with HSTCL        who are identified through the Sponsor's adverse event reporting systems and who were        exposed to HUMIRA prior to the diagnosis of HSTCL.|January 2016|January 27, 2016|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087878||48537|
NCT02096978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100304|Comparing Implant Stability Using Two Accepted Techniques for Implant Sites|A Randomized Controlled Clinical Study Comparing Implant Stability Using Osteotome vs. Conventional Drilling Techniques by Resonance Frequency Analysis||Rutgers, The State University of New Jersey|No|Completed|October 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02096978||47841|
NCT02096406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042749|Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass|COMParison of Angiotensin Converting Enzyme Inhibitor managemenT Strategies Prior to Coronary Artery Bypass Surgery (the COMPACT Trial): a Pilot Randomized Controlled Registry Study|COMPACT|University of Alberta|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02096406||47884|
NCT02096757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13123|The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention|The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention|OMEGA-PVI|University of California, San Francisco|Yes|Recruiting|June 2014|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|90 Years|No|||June 2015|June 29, 2015|March 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096757||47857|
NCT02097017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-0801-AS-CTIL|Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation|Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation||Sheba Medical Center||Not yet recruiting||||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|160|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|March 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097017||47838|
NCT02097030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-46|Clinical Evaluation of Daily Disposable Contact Lenses|Single-Center Clinical Evaluation of Daily Disposable Contact Lenses||Coopervision, Inc.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|35|||Both|18 Years|40 Years|No|||January 2016|January 15, 2016|March 24, 2014|Yes|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT02097030||47837|
NCT02097329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481038|Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food|A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers||Pfizer|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097329||47814|
NCT02097823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401283326|Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy|A Pilot Study Comparing Olanzapine and Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Receiving Highly Emetogenic Chemotherapy||Indiana University|Yes|Recruiting|February 2014|||February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|4 Years|21 Years|No|||March 2014|March 24, 2014|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097823||47776|
NCT02097836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP_TT_2008|Targeted Training for Trunk Control_case Series Cerebral Palsy|Segmental Training for Trunk Control a Pilot Study for Children With Moderate to Severe Motor Impairment.|CP_TT|University of Oregon|Yes|Completed|September 2007|January 2010|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|4 Years|17 Years|No|||June 2014|June 12, 2014|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097836||47775|
NCT02097576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014Leon|Manuka Honey Nasal Rinse Study|Effectiveness of Manuka Honey/Saline Nasal Rinses as an Adjunct to Standard Medical Therapy for Chronic Rhinosinusitis: A Prospective Clinical Trial||University of Florida|No|Withdrawn|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|No|||July 2014|July 17, 2014|March 24, 2014|Yes|Yes|Funding withdrawn.|No||https://clinicaltrials.gov/show/NCT02097576||47795|
NCT02097849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS307|Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.|An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.||Biogen|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|55 Years|No|||December 2015|December 3, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097849||47774|
NCT02098694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1520 (REK)|Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis|Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis||Norwegian University of Science and Technology|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|45 Years|No|||February 2016|February 10, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098694||47709|
NCT02098941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620133760|Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment|A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment||Seoul National University Hospital|No|Recruiting|March 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|2500|||Both|15 Years|95 Years|No|Probability Sample|Subjects who newly visited to epilepsy center in a tertiary hospital during January 1st        2006 to December 31st of 2010|March 2014|March 25, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02098941||47690|
NCT02098928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01|Comparison Between Hand-acupuncture and Electro-acupuncture Stimulation in the Treatment of Menopause|Multicenter Randomized Controlled Trial on Comparison of Efficacy Between Hand Acupuncture and Electro-acupuncture in Treatment of Menopausal Hot Flashes Symptoms||The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Yes|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|242|||Female|40 Years|55 Years|No|||March 2014|October 31, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02098928||47691|
NCT02095405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009403-01H|A Study of Caffeine on Cardiac Arrhythmias|A Prospective Placebo Controlled Randomized Study of Caffeine in Patients With Supraventricular Tachycardia Undergoing Electrophysiologic Testing.|CACOA-HEART|Ottawa Heart Institute Research Corporation|No|Recruiting|February 2010|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||March 2014|March 20, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02095405||47960|
NCT02095379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02-055|Oligosecretary Myeloma: Prevalence and Its Clinical Significance|Oligosecretary Myeloma: Prevalence and Its Clinical Significance||Samsung Medical Center|No|Completed|October 2013|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|390|||Both|17 Years|90 Years|No|Non-Probability Sample|a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine        monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL,        a urine M protein ≥ 200mg/day)|March 2014|March 20, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02095379||47962|
NCT02095392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H55-14|Effects of Soluble Phosphate in Humans|The Effect of Soluble Phosphate in Combination With Different Calcium Doses on Calcium and Phosphorus Metabolism in Healthy Adults||University of Jena|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|62|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02095392||47961|
NCT02096510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1738|Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia|Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia||Haukeland University Hospital|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02096510||47876|
NCT02096523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002714- HMO-CTIL|Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder|Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder||Hadassah Medical Organization|No|Not yet recruiting|February 2017|||May 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|3 Years|85 Years|Accepts Healthy Volunteers|||February 2016|March 23, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02096523||47875|
NCT02096536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56376|Exploring Vancomycin Disposition in Neonates|Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Binding and Its Covariates in Neonates||Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|N/A|23 Months|No|||November 2015|November 2, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02096536||47874|
NCT02087605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2013|Automatic Image Analyzer to Assess Retinal Vessel Caliber|Validation of the Automatic Image Analyzer to Assess Retinal Vessel Caliber (ALTAIR)|ALTAIR|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Not yet recruiting|April 2014|December 2018|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|386|||Both|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|386 subjets of 30 to 75 years|March 2014|March 12, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02087605||48558|
NCT02092519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL2012/312/E|RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses|A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses||Changi General Hospital|Yes|Completed|April 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|21 Years|N/A|No|||July 2015|July 27, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02092519||48180|
NCT02096185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Specimen Imaging Ver3|Is Any Additional Information Gained Regarding Margins Using 3D Tomosynthesis Vs 2D Conventional Digital Imaging When Imaging Operative Breast Specimens?|Is Any Additional Information Gained Regarding Lesion to Margin Measurement Using 3D Tomosynthesis Imaging Versus 2D Conventional Digital Imaging When Imaging Specimens of Breast Tissue Removed at Therapeutic Surgery||Sandwell & West Birmingham Hospitals NHS Trust|No|Enrolling by invitation|May 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|50|||Female|30 Years|N/A|No|||March 2014|March 26, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096185||47901|
NCT02096419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108-1081875-1993-1|Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity|Effect of Continuous Clopidogrel Dosing Targeted After Platelet Function Testing in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention With High On-treatment Platelet Reactivity||University of Zagreb|No|Completed|February 2012|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||August 2014|August 14, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02096419||47883|
NCT02097342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Linagliptin|Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus|A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|December 2013|January 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|30 Years|65 Years|No|||April 2014|April 6, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097342||47813|
NCT02097602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RePOS|Correlation Between Reticulated Platelets and Major Adverse Cardiac and Cerebrovascular Events After Noncardiac Surgery|Can Reticulated Platelets Predict the Outcome After Noncardiac Surgery?||Technische Universität München|Yes|Completed|February 2014|January 2015|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|High-risk or intermediate-risk surgical patients older than 18 years undergoing noncardiac        surgery|March 2015|March 4, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02097602||47793|
NCT02097303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-PCA-01|Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis|Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis|eRADicAte|Carolina Research Professionals, LLC|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02097303||47816|
NCT02097316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00792-43|Feasibility Study of the JewelPump Version 3|Feasibility Study of the JewelPump Version 3||Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02097316||47815|
NCT02097862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-US-DDD-001|Adipose Cells for Degenerative Disc Disease|An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease||Bioheart, Inc.|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02097862||47773|
NCT02097875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-001|Safety Study of a Fluorescent Marker to Visualize Cancer Cells|A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer||Blaze Bioscience Australia Pty Ltd|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097875||47772|
NCT02098122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES2013|Upper Limb Activity in Human SCI Rehabilitation|Upper Limb Activity in Human SCI Rehabilitation||University of Zurich||Recruiting|March 2013|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Spinal Cord Injured Subjects|January 2016|January 6, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02098122||47753|
NCT02098707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP PD 002|Effects of a Rehabilitation Treatment on Balance in PD Evaluated With a Stabilometric Platform|Effects of a Multidisciplinary Intensive Rehabilitation Treatment (MIRT) on Balance in Patients With Parkinson's Disease Evaluated With a Stabilometric Platform|SPPD002|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|58 Years|74 Years|No|Non-Probability Sample|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr        (mean UPDRS III 18.8±10.5) according to the UK Brain Bank criteria.|March 2014|March 24, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098707||47708|
NCT02069392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058233|Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia|Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia||University of Maryland|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||April 2015|April 14, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02069392||49955|
NCT02069665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHLN-TCM-01|Effectiveness Study of Integrative Treatment for Pediatric Pneumonia|Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases||Liaoning University of Traditional Chinese Medicine|Yes|Completed|December 2011|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|451|||Both|6 Months|59 Months|No|||February 2014|February 20, 2014|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02069665||49934|
NCT02069925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310012846|STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.|STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.||Yale University|Yes|Recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|16 Years|35 Years|No|||July 2015|July 14, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069925||49914|
NCT02069912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCIRB-HS-06-00420|Multifaceted Depression and Cardiovascular Program|Multifaceted Depression and Cardiovascular Program for Low-Income Patients|MDCP|University of Southern California|Yes|Completed|November 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|108|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069912||49915|
NCT02070445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-859|Ventilation During Cardiopulmonary Bypass (CPB) for Cardiac Surgery|Ventilation During Cardiopulmonary Bypass (CPB) for Cardiac Surgery - Effect on Pulmonary Atelectasis Post-operatively, a Pilot Study||McMaster University|No|Suspended|June 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Probability Sample|Same Day Surgery Clinic|November 2014|November 10, 2014|February 21, 2014||No|One of the investigators left the institution.|No||https://clinicaltrials.gov/show/NCT02070445||49875|
NCT02070731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEFLECT III|DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI|A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation|TAVI|Keystone Heart|Yes|Completed|February 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070731||49853|
NCT02070744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX13-661-103|Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion|A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 in Combination With Ivacaftor for 12 Weeks in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation With an Open-Label Extension||Vertex Pharmaceuticals Incorporated|Yes|Active, not recruiting|April 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070744||49852|
NCT02071069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-ON-05|Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer|Efficacy and Tolerance of Cetuximab Combined With Irinotecan or Fluorouracil as Maintenance Therapy in Patients With RAS-wild-type Incurable Advanced Colorectal Cancer （Confirm Study）||Shanghai Zhongshan Hospital|No|Recruiting|July 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071069||49827|
NCT02071082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1249|Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults|A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults||Gilead Sciences|Yes|Active, not recruiting|March 2014|June 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071082||49826|
NCT02071355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018526|A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants|Phase I, Open Label Study to Examine the Pharmacokinetics, Safety and Tolerability of TMC435 Following Multiple Oral Doses of 100 and 150 mg q.d. in Healthy Chinese Subjects||Janssen Research & Development, LLC|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 28, 2014|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071355||49805|
NCT02074631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS023|Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation|Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|February 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|1 Year|18 Years|No|||February 2016|February 18, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074631||49554|
NCT02071238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2014-244|Factors Affecting Risk Recall in Open Carpal Tunnel Release Surgery|Factors Affecting Risk Recall in Open Carpal Tunnel Release Surgery||Nova Scotia Health Authority|No|Completed|May 2014|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|140|||Both|16 Years|N/A|No|||January 2016|January 12, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071238||49814|
NCT02071498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-527|A Spanish Pillbox App for Elderly Patients Taking Multiple Medications|Effectiveness and Utility of a Virtual Custom Tool to Reduce the Medication Errors of Patients Older Than 65 Years Pluripatologic With Complex Therapeutic Regimens|ALICE|Universidad Miguel Hernandez de Elche|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|99|||Both|65 Years|90 Years|No|||February 2014|February 21, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02071498||49794|
NCT02071485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312M46726|Non-Invasive Brain-Computer Interface for Virtual Object Control|Non-Invasive Brain-Computer Interface for Virtual Object Control||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Students and workers at the University of Minnesota - Twin Cities campus|December 2015|December 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02071485||49795|
NCT02072070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-TGC-01-3|Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis||Kolon Life Science|Yes|Completed|November 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|19 Years|N/A|No|||August 2015|August 31, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02072070||49751|
NCT02072083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/381|Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients|Intranasal Dexmedetomidine Versus Intranasal Midazolam-ketamine Combination for Premedication of Pediatric Patients Undergoing Strabismus Surgery||TC Erciyes University|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|2 Years|11 Years|No|||February 2014|April 11, 2015|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02072083||49750|
NCT02072694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Process HCRP: 12241/2010|Cerebral Blood Flow Changes in People With Obesity After Glucose Consumption|Cerebral Perfusion Changes in Obese Subjects After Administration of 75 Grams of Glucose. A SPECT, Controlled, Blinded and Randomized Study.||University of Sao Paulo|No|Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02072694||49703|
NCT02072915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F131108005|EUS-FNA With and Without Suction|Randomized Single Blind Controlled Trial of EUS-FNA With and Without Suction for Adequate Cellblock Sample Procurement of Solid Pancreatic Mass Lesions Using 25G Needle||University of Alabama at Birmingham|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|72|||Both|19 Years|N/A|No|||November 2014|November 7, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072915||49686|
NCT02073448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDT.07.SPR.27123|Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.|A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.||Galderma R&D|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|417|||Both|12 Years|N/A|No|||November 2014|November 17, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02073448||49645|
NCT02073461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDT.07.SPR.27124|Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.|A Multicenter, Randomized, Double-blinded, Vehicle-controlled Parallel Group Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.||Galderma R&D|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|236|||Both|12 Years|N/A|No|||November 2014|November 17, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02073461||49644|
NCT02073474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWSR10128|An Observational Post-Marketing Safety Registry of Sativex®|An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex®||GW Pharmaceuticals Ltd.|Yes|Enrolling by invitation|February 2011|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who are prescribed Sativex® in the UK and patients who are prescribed        Sativex® from selected specialist neurology centres in Germany and Sweden.|February 2014|February 25, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073474|2 Years|49643|
NCT02073487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1013-0164|Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel|Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients|TEAL|The Methodist Hospital System|No|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||October 2015|October 7, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073487||49642|
NCT02069405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6798-AE|Relaxation Music to Lower Heart Rate Prior to Cardiac CT|Relaxation Music to Lower Heart Rate Prior to Cardiac CT||University Health Network, Toronto|No|Completed|December 2013|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|197|||Both|18 Years|N/A|No|||December 2013|December 5, 2014|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02069405||49954|
NCT02069418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2012-01|Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient|Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?|FLT-THERA|University Hospital, Angers|No|Active, not recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02069418||49953|
NCT02070198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM001|Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF|Long Acting FSH Plus GnRH Antagonist Versus Daily FSH Plus GnRH Antagonist Versus Short Agonist Regimens in Poor Responder Patients Undergoing IVF: a Randomized Study.||Bioroma|Yes|Recruiting|December 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Female|25 Years|44 Years|No|||February 2014|February 21, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070198||49894|
NCT02070211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS 1|Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.|Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome Genetically at High Risk for Psychosis: A Randomised, Double Blind, Placebo-controlled Treatment Trial.||Bambino Gesù Hospital and Research Institute|Yes|Not yet recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|12 Years|26 Years|No|||February 2014|February 21, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02070211||49893|
NCT02070224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE|Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis|Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis|PRODIGE|Artialis|Yes|Recruiting|January 2014|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|45 Years|80 Years|No|||June 2015|June 23, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02070224||49892|
NCT02070458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7913|Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)||Case Comprehensive Cancer Center|Yes|Recruiting|October 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||December 2015|December 15, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070458||49874|
NCT02070757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-008|Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia|A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia|ASPECT-NP|Cubist Pharmaceuticals LLC|Yes|Recruiting|September 2014|February 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|726|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070757||49851|
NCT02070770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHS2014|The Effect of a Short-term Very Low Calorie Diet on Heart Rate Variability in Obese Individuals|The Effect of Short-term Adherence to a Very Low Calorie Diet on Heart Rate Variability: a Pilot Randomised Controlled Trial in Obese Men and Women||King's College London|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|31|||Both|32 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02070770||49850|
NCT02071095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0482|Enhancement by Poly-ICLC During HIV-1 Infection|Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection|Poly-ICLC|Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|55 Years|No|||January 2016|January 8, 2016|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071095||49825|
NCT02071108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0083|Safety and Performance Study of the Shockwave Lithoplasty System|Safety and Performance Study of the Shockwave Lithoplasty System|DISRUPT-PAD|Shockwave Medical, Inc.|Yes|Completed|January 2014|March 2015|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02071108||49824|
NCT02071121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231HV101|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect|A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect||Biogen|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2014|January 29, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071121||49823|
NCT02073786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optiscope_SNUH|Rigid Video Stylet Vs Conventional Lightwand Intubation|: Rigid Video Stylet Can Provide More Successful Intubation Than Conventional Lightwand Intubation in Patients With Cervical Spine Operation : A Prospective Randomized Study|Optiscope|Seoul National University Hospital|Yes|Recruiting|October 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|20 Years|80 Years|No|||February 2014|February 15, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073786||49619|
NCT02073799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaserP1|Storage Symptom After Laser Prostatectomy|Change in Storage Symptoms Following Laser Prostatectomy: Comparison Between Potassium-titanyl-phosphate Photoselective Vaporization of the Prostate (PVP) and Holmium Laser Enucleation of the Prostate (HoLEP)||Seoul National University Hospital||Recruiting|February 2014|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|486|||Male|40 Years|90 Years|No|Non-Probability Sample|Patients who underwent photoselective vaporization of the prostate or holmium laser        enucleation of the prostate and in whom 12-months follow-up data were available|February 2014|February 25, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02073799||49618|
NCT02070900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHOCHAIZIMBABWE-001|Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?|Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?|E4E|WHO, Department of Maternal, Newborn, Child and Adolescent Health|Yes|Recruiting|January 2014|July 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|704|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02070900||49840|
NCT02070913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDC-2191|COOL-AMI EU Case Series Clinical Study|COOL-AMI EU Case Series Clinical Study: A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction|COOL-AMI EU|ZOLL Circulation, Inc., USA|No|Recruiting|September 2013|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present with clinical signs and symptoms of acute myocardial infarction and        meet all Inclusion and Exclusion criteria will be considered for case study presentation        in this clinical trial without regard to age, gender or ethnicity.|January 2016|January 6, 2016|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02070913||49839|
NCT02071797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B626|Early Targeted Brain Cooling in the Cath Lab Following Cardiac Arrest|Early Targeted Brain Cooling in the Cath Lab Following Cardiac Arrest. Randomised Controlled Trial of RhinoChill Versus Blanketrol Intra-Hospital Induction of Therapeutic Hypothermia After Cardiac Arrest|COOLCATH|Basildon and Thurrock University Hospitals NHS Foundation Trust|Yes|Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02071797||49771|
NCT02071771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-007|Visual Assessment of DAILIES® AquaComfort Plus® for Astigmatism as Compared to 1-DAY ACUVUE® MOIST® for Astigmatism|DAILIES® AquaComfort Plus® Toric - Comparative Assessment of Visual and Mechanical Performance||Alcon Research|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 24, 2014|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT02071771||49773|
NCT02071784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-62|Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)|Etude Comparative en Imagerie Par résonnance magnétique et Par Enregistrement électroencéphalographique du Couplage Neurovasculaire Dans l'Angiopathie Cadasil|NEUROVASCAD|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|CADASIL patients compared to age-matched controls (two groups)|February 2016|February 23, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02071784||49772|
NCT02071823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-104|Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules|Single Dose Crossover Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules in Healthy Male Volunteers Following Administration of a 50 mg Dose / Fasted and Fed States||Bial - Portela C S.A.|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|January 19, 2012||No||No|December 31, 2014|https://clinicaltrials.gov/show/NCT02071823||49769|
NCT02071862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX-839-001|Study of the Glutaminase Inhibitor CB-839 in Solid Tumors|Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors||Calithera Biosciences, Inc|No|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|205|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071862||49766|
NCT02072109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267-13|Comparison of Regional Splanchnic Tissue Oxygenation Measured by NIRS in Preterm Babies Fed Bolus Versus Continuous Feeding|Evaluation of Regional Splanchnic Tissue Oxygenation Measured by NIRS (Near Infrared Spectroscopy) in Preterm Infants Receiving Bolus Versus Continuous Feeding||Meir Medical Center||Recruiting|June 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|6 Months|No|Probability Sample|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive        Care Unit.|June 2014|April 29, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072109||49748|
NCT02072122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOEDFT-2|Estrogen and the Outer Eye in Women During Fertility Treatment|The Influence of the Hormonal Fertility Treatment of Women, on the Eye Surface and the Eye Dryness||Meir Medical Center|Yes|Not yet recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood tests (hormones level)|Female|18 Years|37 Years|No|Non-Probability Sample|fertility clinic patients|February 2014|February 25, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072122|4 Weeks|49747|
NCT02072447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microdose_01(YH4808-110(I))|Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study|A Study to Determine the Absolute Bioavailability of YH4808 Using Simultaneous Oral Therapeutic- and [14C]-Labeled Intravenous Microdoses||Seoul National University Hospital||Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02072447||49722|
NCT02072460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00691-44|Vestibular and Multisensory Influence on Bodily and Spatial Representations|Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|February 2014|||July 2017|Anticipated|N/A|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02072460||49721|
NCT02073500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM_250913|Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies|Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.|PSM|Oslo University Hospital|No|Recruiting|September 2009|January 2023|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Metastatic tissue, blood specimens.|Both|18 Years|N/A|No|Non-Probability Sample|All patients with PSM that are referred to Oslo University Hospital and are candidates for        CRS with HIPEC may be included in the study.|October 2015|October 14, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02073500|5 Years|49641|
NCT02073227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103256|A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073227||49662|
NCT02073240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-DTBE-6498|Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand|Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand|EnTIC|Centers for Disease Control and Prevention|Yes|Active, not recruiting|February 2014|June 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|This study will be conducted at 22 hospitals, 10 in Thailand and 12 in Vietnam. The study        facilities will be hospitals that typically provide care to patients with confirmed or        suspected TB, namely TB or general hospitals.|May 2014|August 20, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02073240||49661|
NCT02073513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUT 09/24-47|Kinesiotaping the Hand in Cerebral Palsy|Effects of Kinesiotaping the Hand of Children With Cerebral Palsy||Hacettepe University|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|4 Years|14 Years|No|||February 2014|February 25, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02073513||49640|
NCT02069444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-12|Comparison of the Effects of Truview Laryngoscopy and Macintosh Larygonscopy on Intubation Difficulty Score, Intubation Duration and Intubation Quality in Pediatric Patients Between 2-12 Years|||Ankara University|No|Completed|January 2012|||October 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|2 Years|12 Years|No|Probability Sample|pediatric patients undergoing surgery which needs intubation|February 2014|February 21, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069444|1 Day|49951|
NCT02069938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312M46742|Brain Computer Interface Control of a Robotic Device|Brain Computer Interface Control of a Robotic Device||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects, primarily from individuals on the University of Minnesota Campus and        Minneapolis area|December 2015|December 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069938||49913|
NCT02070237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159-12|Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis|Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily||MemorialCare Health System|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|October 22, 2015|February 20, 2014||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02070237||49891|
NCT02070471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-CYCL002|Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)||LG Life Sciences||Active, not recruiting|January 2014|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|75 Years|No|||September 2015|September 17, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070471||49873|
NCT02070484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH2-13-0034|Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease|Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease||OhioHealth|Yes|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070484||49872|
NCT02070783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024364-18|Cognitive and Neural Effects of ARA290|The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers|CONEARA|Leiden University Medical Center|No|Completed|February 2012|February 2014|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 23, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02070783||49849|
NCT02070796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0011|Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations|Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations||UCB Pharma|Yes|Completed|February 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|February 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070796||49848|
NCT02071134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4010|Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry|Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry||Boston Scientific Corporation|No|Recruiting|February 2014|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptoms of Parkinson's disease that are not adequately controlled with        medication|December 2015|February 4, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071134|3 Years|49822|
NCT02074111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-08-098-003|Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke|Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke||Samsung Medical Center|Yes|Recruiting|January 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|400|Samples With DNA|Blood sample|Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Tertiary Hospital|January 2014|February 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074111||49594|
NCT02071264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Philstudy|Effects of an HIV Intervention Among Sex Workers in the Philippines|Effects of an HIV Intervention Among Female and Male Entertainers and Spa/Sauna Workers in the Philippines||University of California, San Diego|Yes|Enrolling by invitation|August 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 24, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02071264||49812|
NCT02071290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-RIC-01|Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock|Effect of Remote Ischemic Conditioning on Neutrophil Function and the Immune-Inflammatory and Coagulation Profiles in Trauma Patients With Hemorrhagic Shock||St. Michael's Hospital, Toronto|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|16 Years|N/A|No|||October 2015|October 13, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02071290||49810|
NCT02072096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14842|A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)|An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)|IMPERIUM|Eli Lilly and Company|No|Terminated|February 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|193|||Both|65 Years|N/A|No|||October 2015|October 21, 2015|February 24, 2014|Yes|Yes|The trial was terminated per protocol because of lack of feasibility|No||https://clinicaltrials.gov/show/NCT02072096||49749|
NCT02072421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPH00-Cohort|The MASS COMM Post-Randomization Phase Cohort Study|A Prospective, Multi-center, Non-Randomized, Single-arm, Open-label Study of Percutaneous Coronary Intervention in Community Hospitals Without Cardiac Surgery-On-Site||Harvard Clinical Research Institute|No|Completed|October 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|2879|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|February 24, 2014||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT02072421||49724|
NCT02071875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDCL100212-OCA|Comparing the Nautilus NeuroWaveTM to TCD or DSA for the Detection of Vasospasm|A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler or DSA as an Aid to Diagnosing Vasospasm||Jan Medical, Inc.|No|Recruiting|November 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with subarachnoid hemorrhage who are undergoing surveillance for vasospasm|February 2016|February 22, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02071875||49765|
NCT02072733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oncogeriatric feasibility|Suitability of an Organization With an Onco-geriatric Team to a Whole Region (Region Midt) of Denmark|Oncogeriatric Intervention and Follow-up at Home to Improve Quality of Life and the Possibility to Accomplish Cancer Treatment in Multimorbid Elderly||University of Aarhus|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|70 Years|130 Years|No|||December 2015|December 2, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02072733||49700|
NCT02072135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013003841|Exparel and Ankle Surgery|Exparel Use for Popliteal Nerve Block in Postoperative Pain Control; After Ankle Fracture Fixation or Ankle Fusion Surgery: a Case Series||Rutgers, The State University of New Jersey|No|Completed|February 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072135||49746|
NCT02072148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1662|The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)|The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA)||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072148||49745|
NCT02072473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-0716-13-RB-CTIL|Safety and Efficacy Aspects of a Standardized Stepwise Anatomical Approach for AVNRT Ablation|Safety and Efficacy Aspects of a Standardized Stepwise Anatomical Approach for Atrio-Ventricular Nodal Re-entrant Tachycardia Ablation||Sheba Medical Center|No|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Symptomatic AVNRT patients undergoing ablation procedure|June 2015|June 2, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02072473|6 Months|49720|
NCT02073019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-8040.02|A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers|A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.||BioLineRx, Ltd.|Yes|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|33|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073019||49678|
NCT02069431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801-2013|Oxytocin Aging Study|Effects of Oxytocin on Physical and Cognitive Functioning in the Elders||University of Florida|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|63 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069431||49952|
NCT02069717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_FAMI_001|Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)|Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome||Daewoong Pharmaceutical Co. LTD.||Terminated|October 2013|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|20 Years|N/A|No|Probability Sample|Subjects aged more than 20 with history of acute myocardial infarction and diagnosed with        metabolic syndrome|January 2016|January 21, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069717|24 Months|49930|
NCT02069730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMS-001|A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes|Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms||University Health Network, Toronto|Yes|Recruiting|June 2014|August 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069730||49929|
NCT02069678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stop Nuc|Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B|||Chinese University of Hong Kong|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|65 Years|No|Non-Probability Sample|HBeAg-negative patients on entecavir followed up in the liver clinics will be identified        from the existing database. All patients had HBV DNA testing every 6 months as a clinic        routine. Serum HBsAg levels will be tested in the residual serum samples at the        pre-treatment and last follow-up visits. Eligible patients will be discussed on the plan        of stopping entecavir therapy. All patients will have written informed consent before        recruited into this study. All patients will be followed up for 12 months after stopping        entecavir treatment.|February 2014|February 20, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02069678||49933|
NCT02069951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102169|Procedure-to-procedure Transfer Trial|A Randomised Educational Trial of Practicing One Versus Two Laparoscopic Procedural Modules in Simulator Training for Novices on Procedure-to-procedure Transferability||Rigshospitalet, Denmark|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|96|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 9, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069951||49912|
NCT02069964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3688|A Prospective Longitudinal Cohort Study Looking at the Difference in Carotid Intima-medial Thickness Between Irradiated and Unirradiated Carotid Arteries in Patients With Head and Neck Cancer|A Prospective Longitudinal Cohort Study Looking at the Difference in Carotid Intima-medial Thickness Between Irradiated and Unirradiated Carotid Arteries in Patients With Head and Neck Cancer||Royal Marsden NHS Foundation Trust|No|Recruiting|October 2011|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Adult patients with histologically confirmed canceror benign tumours of the head and neck        area requiring hemi-neck radiotherapy to ≥ 50Gy|February 2014|February 20, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069964||49911|
NCT02069977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031OTC1301|Study to Evaluate the Efficacy and Safety of Aripiprazole|A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems||Samsung Medical Center|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|6 Years|17 Years|No|||March 2014|March 10, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02069977||49910|
NCT02069990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAT12-730DS|Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients|||Semmelweis University|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069990||49909|
NCT02070250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13127|Stress Management for Cancer Patients: How Well Does it Work? (C2H-D)|Examination of a Stress Management Intervention for Cancer Patients as Delivered by Community Mental Health Professionals|C2H-D|Ohio State University Comprehensive Cancer Center|No|Recruiting|November 2013|August 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|21 Years|80 Years|No|||November 2015|November 17, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070250||49890|
NCT02070497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005083R|Effectiveness of Nursing Case Management for Lung Cancer Patients|The Effectiveness of Nursing Case Management for Lung Cancer Patients in a Taiwan Medical Center||National Taiwan University Hospital|No|Completed|July 2010|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|415|||Both|20 Years|N/A|No|||February 2014|February 24, 2014|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02070497||49871|
NCT02070809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013001|Rapid Construction of Tissue-engineered Skin for Repairing Wounds|Multicenter Clinical Randomized Controlled Trials on Rapid Construction of Tissue-engineered Skin for Repairing Wounds||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|December 2013|October 2023|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|386|||Both|N/A|81 Years|No|||August 2015|August 10, 2015|February 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070809||49847|
NCT02073851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEFLECT II|DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR|A Prospective, Single Arm Feasibility Pilot Study to Evaluate the Safety and Performance of the TriGuard™HDH Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)||Keystone Heart|No|Completed|January 2014|September 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02073851||49614|
NCT02073864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yale Neuro TAVR|A Study to Evaluate the Neuro-embolic Consequences of TAVR|Neurological Complications of Contemporary Unprotected TAVR (Yale Neuro TAVR)||Keystone Heart|No|Completed|November 2013|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for TAVR procedure|August 2015|August 26, 2015|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02073864||49613|
NCT02071511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4286|Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation|Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation|ARDEVAT|Universitätsklinikum Hamburg-Eppendorf|No|Terminated|January 2014|January 2017|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 10, 2014||No|results of the SYMPLICITY HTN 3 trial|No||https://clinicaltrials.gov/show/NCT02071511||49793|
NCT02071537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCI-EXP-13-01|Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors|A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors||University of Cincinnati|Yes|Recruiting|May 2014|December 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071537||49791|
NCT02071329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-01.1_CS_04|Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge|A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (Vaccine FP-01.1) in Healthy Volunteers Following Virus Challenge||Immune Targeting Systems Ltd|No|Active, not recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071329||49807|
NCT02071524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22012014|Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics|||Università degli Studi di Ferrara|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|85 Years|No|||May 2015|May 26, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02071524||49792|
NCT02071810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-102|Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers||Bial - Portela C S.A.|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|34|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|January 19, 2012||No||No|December 30, 2014|https://clinicaltrials.gov/show/NCT02071810||49770|
NCT02072512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307BC ET-01|The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer|The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer|PROOF|Hospital Affiliated to Military Medical Science, Beijing|Yes|Recruiting|January 2014|December 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|No|||February 2014|February 24, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02072512||49717|
NCT02072525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612|A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays|A Protocol to Collect Human Serum Samples From Healthy Adults||GlaxoSmithKline||Completed|April 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Actual|359|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072525||49716|
NCT02072967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-BEN-NI-001|Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma|Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma||Astellas Pharma Inc|No|Completed|May 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|No|Probability Sample|Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma with planned        combined Ribomustin and rituximab therapy|February 2016|February 19, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072967||49682|
NCT02072980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-002|DAILIES TOTAL1® Lubricity Post Wear|Evaluation of the Lubricity of DAILIES TOTAL1® Contact Lenses After Wear||Alcon Research|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|February 24, 2014|Yes|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT02072980||49681|
NCT02073526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1352|Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease|Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease||Oslo University Hospital|No|Recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|Samples With DNA|Serum, whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Inflammatory bowel disease treated with anti-TNF drug|February 2014|February 25, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02073526|3 Years|49639|
NCT02069470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BST-5.2013-PV|The Effect of CME on Early Cancer Diagnosis in General Practice|The Effect of Continuing Medical Education (CME) on Early Cancer Diagnosis in General Practice||University of Aarhus|Yes|Active, not recruiting|September 2012|August 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|689|||Both|N/A|N/A|No|||January 2014|September 29, 2014|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02069470||49949|
NCT02073266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1429, DR-002-1266|Impact of C3F8 or SF6 Use and Length of Face-down Positioning (7 vs 14 Days Respectively) in Macular Hole Surgery.|||Centre Hospitalier Universitaire de Québec, CHU de Québec||Completed|January 2010|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|51 Years|83 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073266||49659|
NCT02074150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTHD081800|ASIS for Botox in Upper Limb Spasticity|ASIS for Botox in Upper Limb Spasticity|ASISinULS|ASIS Corporation|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|23||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074150||49591|
NCT02069457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJFH20140220|Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis|Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis||Beijing Friendship Hospital|No|Completed|December 2013|June 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|Samples Without DNA|serum, plasma|Both|18 Years|80 Years|No|Non-Probability Sample|Cirrhosis of any etiology and severity|July 2015|July 26, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069457||49950|
NCT02069691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS11034|The Cycling Exercise With Virtual Reality Visual Stimulation for Rehabilitation in CVA Patients|Institutional Review Board of Chung Shan Medical University Hospital||Chung Shan Medical University|No|Completed|August 2012|May 2013|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|25 Years|80 Years|No|||August 2012|February 20, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02069691||49932|
NCT02069704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEVZ92-A-01-13|Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients|Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN®) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients||mAbxience S.A|Yes|Recruiting|October 2014|September 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02069704||49931|
NCT02070510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4065|A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects|An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide (NNC0113-0217) on Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects||Novo Nordisk A/S|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070510||49870|
NCT02074969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007406|Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures|Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures - Epidemiological Data and Rates of Complications||Medical University of Vienna|Yes|Completed|October 2007|May 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 28, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02074969||49528|
NCT02075229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAG-00107N|Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population|A Proposal to Evaluate Revised Indications for Cochlear Implant Candidacy for the Adult CMS Population||American Cochlear Implant Alliance|No|Recruiting|February 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This study will evaluate the benefits of cochlear implantation in up to 90 CMS-eligible        (medicare) adults from up to 10 study sites in the North America.|November 2015|November 6, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02075229||49508|
NCT02075463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114837|Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia|A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO||GlaxoSmithKline|Yes|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|March 17, 2016|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075463||49490|
NCT02075775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOON SI 2013|MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.|MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.|MOONSI|University of Iowa|Yes|Recruiting|August 2012|August 2037|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|12 Years|99 Years|No|Non-Probability Sample|Potential subjects are patients who have been diagnosed with shoulder instability        injuries.|November 2015|November 30, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075775|20 Years|49466|
NCT02071277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-362|APRV/BIPAP With Spontaneous Breathing on Lung Protection|Impact of the Type of Pressure Controlled Mode on Lung Protection in Mechanically Ventilated Patients With Spontaneous Breathing|APRV/BIPAP|St. Michael's Hospital, Toronto|No|Recruiting|March 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02071277||49811|
NCT02070978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700461-024|Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)|A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)||EMD Serono|Yes|Recruiting|July 2014|April 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|213|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070978||49834|
NCT02071303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gany-124|Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy|Tramadol Versus Celecoxib for Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial||Cairo University|Yes|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|210|||Female|18 Years|N/A|No|||December 2014|December 31, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02071303||49809|
NCT02072161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-009|Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy|A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy||Esperion Therapeutics|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072161||49744|
NCT02072174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-AD-004|Clinical Trial of Efficacy of Anaferon for Children® in the Treatment of Influenza and Acute Respiratory Viral Infections in Children|International Multicenter, Double-Blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy of Anaferon for Children® in the Treatment of Influenza and Acute Respiratory Viral Infections in Children||Materia Medica Holding|No|Recruiting|February 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|672|||Both|3 Years|12 Years|No|||August 2015|August 25, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02072174||49743|
NCT02071836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA 2R44020174|A Web Application to Reduce Heavy Drinking in First-time DWI Offenders|A Web Application to Reduce Heavy Drinking in First-time DWI Offenders||Behavior Therapy Associates, LLP|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02071836||49768|
NCT02071849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-01-025|HAART 200 Aortic Valve Annuloplasty During Bicuspid Aortic Valve Reconstruction|HAART 200 Aortic Valve Annuloplasty During Bicuspid Aortic Valve Reconstruction||Biostable Science & Engineering|Yes|Active, not recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02071849||49767|
NCT02072759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44572.068.13|Acetylcarnitine and Metabolic Flexibility|Preservation of Metabolic Flexibility by Acetylcarnitine Formation||Maastricht University Medical Center|Yes|Active, not recruiting|March 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|30|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2015|March 23, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072759||49698|
NCT02072772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA036445-01|A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers|A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers||Montefiore Medical Center|No|Not yet recruiting|May 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072772||49697|
NCT02072746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OICB10007|Zinc Supplementation in Alcoholic Cirrhosis|A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis||University of Louisville|No|Recruiting|February 2013|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02072746||49699|
NCT02073253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DissertaçãoLarissaPOE|Noninvasive Ventilation and Thoracic-abdominal Kinematics in Heart Failure Patients|Effect of Noninvasive Ventilation in Thoracic-abdominal Kinematics of Individuals With Heart Failure Associated With Cardiomegaly: a Randomized Controlled Trial||Universidade Federal de Pernambuco|Yes|Completed|March 2013|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||February 2014|February 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073253||49660|
NCT02077959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13128|Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma||Ohio State University Comprehensive Cancer Center|Yes|Suspended|March 2014|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 28, 2014|Yes|Yes|Pharmaceutical Companies decison|No||https://clinicaltrials.gov/show/NCT02077959||49298|
NCT02071667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17123|Association of Periostin Levels and Chronic Sinusitis|Association of Periostin Levels and Chronic Sinusitis||University of Virginia|No|Recruiting|September 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serum and paraffin embedded nasal polyp tissue samples|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who are recommended for sinus surgery as part of their care who self report no        asthma.|December 2014|December 4, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02071667||49781|
NCT02069483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048251|Testing Methods of Self-persuasion Involving Cigarette Smoking|Testing Methods of Self-persuasion Involving Cigarette Smoking||Duke University|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069483||49948|
NCT02072291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nifedipine-FET|Nifedipine Treatment on Uterine Contractility in IVF|The Influence of Nifedipine Treatment on Uterine Contractility During Frozen Embryo Transfer||Hadassah Medical Organization|No|Recruiting|March 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|45 Years|No|||February 2014|April 19, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072291||49734|
NCT02070003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26234|Perioperative Recovery of Moods, Opioids, and Pain Trial (PROMPT)||PROMPT|Stanford University||Enrolling by invitation|April 2014|March 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02070003||49908|
NCT02070016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27678|Transcranial Magnetic Stimulation for Low Back Pain|Clinical Applicaitons of Non-Invasive Brain Stimulation for the Treatment of Chronic Pain||Stanford University||Withdrawn|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070016||49907|
NCT02070263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110035|Mixed Tree Nut Food Challenges|Mixed Tree Nut Food Challenges||Arkansas Children's Hospital Research Institute|No|Enrolling by invitation|April 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|3 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients seen at Arkansas Children's Hospital between 3-21 years of age who have Tree Nut        food allergies.|February 2014|February 21, 2014|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02070263||49889|
NCT02074995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBVS857X2201|Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects|Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects||Novartis|Yes|Terminated|February 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|60 Years|No|||March 2016|March 3, 2016|February 27, 2014|No|Yes|The study was prematurely terminated due to recruitment issues|No|December 8, 2015|https://clinicaltrials.gov/show/NCT02074995||49526|Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided
NCT02075242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0900|TO Compare the Triple Drug Therapy and Dual Therapy .|Open Label, Multi-center, Randomized Study to Compare of Tacrolimus and Steroids in Combination With Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation With Hepatitis B Virus(HBsAg) Positive|OPTIMUS-A|Asan Medical Center|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|20 Years|65 Years|No|||February 2014|February 28, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075242||49507|
NCT02075255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00020|Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)||AstraZeneca|No|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02075255||49506|
NCT02075476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRALUX-34|the Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures or Fractures Luxation in Three or Four Fragments|Prospective, Randomized and Double Blind Study of Parallels Groups for Evaluating the Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures or Fractures Luxation in Three or Four Fragments of Neer's Classification.||Hospital General Universitario Gregorio Marañon|No|Recruiting|May 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|70 Years|N/A|No|||March 2014|March 4, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02075476||49489|
NCT02075788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13AP004|Millet Products Study - Investigation of Glycemic Index and Satiety|Millet Products Study - Investigation of Glycemic Index and Satiety||University of Guelph|No|Completed|January 2014|June 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02075788||49465|
NCT02076321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207111|The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study|The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study||University of Missouri-Columbia||Recruiting|January 2014|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|N/A|16 Years|No|||November 2015|November 20, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076321||49424|
NCT02070679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMSU-Cardiology-1|Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography|||Urmia University of Medical Sciences|Yes|Completed|February 2014|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|284|||Both|18 Years|N/A|No|||June 2015|June 13, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070679||49857|
NCT02070965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDS1307|DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis||BDS1307|Promius Pharma, LLC||Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|90 Years|No|||November 2015|November 24, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070965||49835|
NCT02071316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hexacap - 1|The Use of Hexacapron in Upper Gastrointestinal Bleeding|The Use of Hexacapron in Upper Gastrointestinal Bleeding|HEXUGI|Shaare Zedek Medical Center|No|Not yet recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02071316||49808|
NCT02071550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10869|10cmH2O Peep Application and Cerebral Oxygenation in Laparoscopic Surgery: a Comparative Study With Invos and Foresight Devices||NIRS AND PEEP|Turkiye Yuksek Ihtisas Education and Research Hospital|No|Completed|August 2013|||December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|65 Years|No|Probability Sample|Patients undergoing laparoscopic cholecystectomy|February 2014|February 21, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02071550|1 Day|49790|
NCT02072226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29093|A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS)|A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Neurologic Deficits (PRISMS)||Genentech, Inc.||Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|948|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072226||49739|
NCT02072239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP11-002|Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy|First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery||Neograft Technologies, Incorporated|Yes|Active, not recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02072239||49738|
NCT02072993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3930C00001|A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males|A Phase I, Single-center, Single-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral AZD1979 After Single-ascending Doses in Healthy Male Volunteers||AstraZeneca|No|Terminated|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|116|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|February 25, 2014|No|Yes|Study stopping criteria has been reached|No||https://clinicaltrials.gov/show/NCT02072993||49680|
NCT02073006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRO-048|A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation|A Randomised, Double-blind, Placebo-Controlled, Parallel Study to Evaluate the Effects of Lepicol® in Adults With Chronic, Functional Constipation||Atlantia Food Clinical Trials|No|Completed|February 2014|October 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073006||49679|
NCT02072785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUYESIKE-VSL-Ⅲ-01|Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia|Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia|LY01609|Nanjing Luye Sike Pharmaceutical Co.,Ltd.|Yes|Recruiting|June 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|65 Years|No|||November 2013|February 27, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072785||49696|
NCT02071979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-13-006|Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds|Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Skin Wounds|CMS|Arteriocyte, Inc.|No|Recruiting|April 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1500|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071979||49757|
NCT02073877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1-058.3|The Baha Microbiome Case Control Study|The Baha Microbiome Case Control Study A Molecular Bacterial Profile Of The Baha Part 1 of the Baha Microbiome Study|BMCCS1|Maastricht University Medical Center|Yes|Active, not recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|Bacterial samples are retained.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a Cochlear Baha system.|February 2014|September 22, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02073877|3 Months|49612|
NCT02072616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/141/HP|Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.|Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.|CTC-Pancreas|University Hospital, Rouen|No|Recruiting|September 2014|September 2021|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|142|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072616||49709|
NCT02074397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-465/13|Distant Extrafascial Injection vs Subfascial Injection for Interscalene Block: Acute Pain Outcomes and Rates of Complications|||Centre Hospitalier Universitaire Vaudois|No|Completed|February 2014|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||April 2015|April 29, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074397||49572|
NCT02074410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS824-HTD-002|Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease|Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease||Omeros Corporation|No|Suspended|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|65 Years|No|||October 2014|April 20, 2015|February 21, 2014|Yes|Yes|Enrollment has been suspended in this study.|No||https://clinicaltrials.gov/show/NCT02074410||49571|
NCT02072603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13793|Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya|Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya||University of Kansas Medical Center|Yes|Enrolling by invitation|August 2013|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072603||49710|
NCT02074696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401M46962|BDNF and Motor Learning|The Effect of BDNF on Motor Learning|BDNF|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2014|July 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|Saliva sample for BDNF testing|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|June 2015|June 9, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02074696||49549|
NCT02074982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2317|Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis|||Novartis|No|Active, not recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|676|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|February 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02074982||49527|
NCT02073318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011010RB|Effects of Balance Training in Older Adults With Dementia|Effects of Task-oriented Balance Training in Institutionalized Older Adults With Dementia||National Taiwan University Hospital|No|Completed|December 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|65 Years|N/A|No|||February 2014|February 25, 2014|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02073318||49655|
NCT02073331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PR-1095|Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)|A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix ECM for Pericardial Reconstruction|RECON|CorMatrix|No|Enrolling by invitation|March 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have received CorMatrix ECM for pericardial reconstruction|April 2015|April 22, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073331||49654|
NCT02073552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPREP1|Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.|Randomized Clinical Trial to Evaluate the Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid in Patients With Past Poor Colonic Preparation|REPREP1|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|Yes|Recruiting|May 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|438|||Both|N/A|N/A|No|||March 2015|March 24, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073552||49637|
NCT02069509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F2-2010- 242193|Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)|Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)|EFACTS|European Friedreich's Ataxia Consortium for Translational Studies|No|Recruiting|May 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|whole blood, urine, centrifugate of serum, EDTA, citrate blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a genetically confirmed diagnosis of FRDA and control research        participants with genetically excluded diagnosis of FRDA.|May 2015|May 12, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069509|2 Years|49946|
NCT02069756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-PPMD-2013|DuchenneConnect Registry|DuchenneConnect: An International, Patient-Report Registry for Individuals With Duchenne/Becker Muscular Dystrophy (Member of TREAT-NMD Neuromuscular Alliance)||DuchenneConnect|Yes|Recruiting|October 2007|October 2047|Anticipated|October 2027|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|DuchenneConnect is primarily a United States registry, but we do welcome participants from        other countries and we currently have over 100 countries represented in the registry.|February 2015|February 12, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02069756|40 Years|49927|
NCT02070991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055G201|Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension Due to Left Ventricular Dysfunction|A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction|MELODY-1|Actelion|No|Completed|July 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070991||49833|
NCT02071004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1040-A-E102|DS1040b/Aspirin Drug/Drug Interaction Study|A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS||Daiichi Sankyo Inc.|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071004||49832|
NCT02071017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1212-014-447|PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor|Application of the Simultaneous PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor From Differential Diagnosis to Prediction of Prognosis||Seoul National University Hospital|Yes|Enrolling by invitation|February 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|20 Years|N/A|No|Non-Probability Sample|primary brain tumors or metastatic, and evaluate the tumor grading efficiency and        prognosis prediction for the patients with high grade astrocytomas or oligodendrogliomas.|February 2014|February 21, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071017||49831|
NCT02071888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX-839-002|Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors|A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies||Calithera Biosciences, Inc|No|Recruiting|February 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071888||49764|
NCT02071901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4913|Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy||Case Comprehensive Cancer Center|Yes|Recruiting|August 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|31|||Both|60 Years|N/A|No|||February 2016|February 17, 2016|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071901||49763|
NCT02072486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 238913|Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC||Roswell Park Cancer Institute|No|Recruiting|November 2013|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||March 2016|March 1, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072486||49719|
NCT02072499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164/13/03/02/08|KTP Green Light Prostatectomy Compared With Open Prostatectomy|The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study||Helsinki University|No|Recruiting|September 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|95 Years|No|||February 2014|February 25, 2014|December 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072499||49718|
NCT02072577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01686312700005393|Effect of Educational Video in the Student's Knowledge|Effect of Educational Video in the Student's Knowledge About Oral Hygiene of Patients Undergoing Chemotherapy||University of Sao Paulo|No|Active, not recruiting|June 2012|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|February 26, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072577||49712|
NCT02072564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYP-HAB-2010-01|Influence of Diet and Lifestyle Factors on the Results of the IVF|Pilot Study on the Influence of the Different Components of the Diet and Different Habits (Tobacco, Alcohol, Physical Exercise, Occupation) Results of IVF-ICSI||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|April 2012|January 2015|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study sample is obtained from the population of infertile couples who meet the        criteria for inclusion in a protocol for controlled ovarian stimulation for IVF/ICSI.|March 2015|March 18, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02072564|9 Months|49713|
NCT02073279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-309JG|Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)||Chugai Pharmaceutical|Yes|Recruiting|August 2014|March 2019|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|74 Years|No|||December 2015|December 8, 2015|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073279||49658|
NCT02073292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1073|Cooled Radiofrequency Ablation vs. Thermal Radiofrequency Ablation|A Randomized Controlled Trial Comparing Thermal and Cooled Radiofrequency Ablation Techniques of Thoracic Facets' Medial Branches to Manage Thoracic Pain||The Cleveland Clinic|No|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|61|||Both|18 Years|90 Years|No|||October 2015|October 5, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073292||49657|
NCT02073357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1195|The BALANCED Anaesthesia Study|The BALANCED Anaesthesia Study A Prospective, Randomised Clinical Trial of Two Levels of Anaesthetic Depth on Patient Outcome After Major Surgery||The Cleveland Clinic|Yes|Withdrawn|July 2014|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|60 Years|N/A|No|||July 2014|July 29, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073357||49652|
NCT02071966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00028|Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS|Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes|TIGER-M|Catholic University of the Sacred Heart|Yes|Recruiting|November 2012|April 2015|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|50 Years|80 Years|No|||February 2014|February 25, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071966||49758|
NCT02069535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-X-03|An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy||ALK-Abelló A/S|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|65 Years|No|||January 2015|January 5, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069535||49944|
NCT02069782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSP23320095644 WC|Mother and Infant Home Visiting Program Evaluation|Mother and Infant Home Visiting Program Evaluation (MIHOPE|MIHOPE|MDRC|No|Enrolling by invitation|October 2012|September 2022|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|4232|||Female|15 Years|N/A|No|||September 2015|October 29, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069782||49925|
NCT02072824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081042|A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.|A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures||Pfizer|Yes|Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|123|||Both|1 Month|3 Years|No|||March 2016|March 23, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072824||49693|
NCT02073058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-US-VAL-13128|Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System|Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System||Abbott Diabetes Care|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with type 1 or type 2 diabetes who require multiple daily insulin injections        (MDI) or continuous subcutaneous insulin infusion (CSII). No more than 20 subjects will        have HbA1c > 8.5%, and no more than 20 subjects will have HbA1c < 7% based on the subject        screening.|May 2014|May 22, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073058||49675|
NCT02073071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA05|Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants|Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants||Abbott Nutrition|No|Completed|May 2014|November 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|139|||Both|N/A|21 Days|No|Probability Sample|Hospital based preterm infants|November 2015|November 25, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02073071||49674|
NCT02073344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRS-SASinHD_005|Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea in End Stage Renal Disease Patients|Prospective Interventional Study Investigating the Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea and Its Correlation With Overhydration, in End Stage Renal Disease Patients|SASinHD_005|Centre Hospitalier Universitaire Vaudois|No|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073344||49653|
NCT02069249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0425-13|Sleep, Nutrition and Psychological Functioning in Kindergarten Children|Sleep, Nutrition and Psychological Functioning in Kindergarten Children: A Longitudinal Intervention Study||Tel Aviv University|No|Recruiting|March 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|250|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02069249||49966|
NCT02069522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL13|Healthy Term Infants Fed Milk-Based Formulas|Healthy Term Infants Fed Milk-Based Formulas With A Supplemental Carotenoid||Abbott Nutrition|No|Terminated|February 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|91|||Both|N/A|28 Days|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 18, 2014||No|interim analysis findings|No||https://clinicaltrials.gov/show/NCT02069522||49945|
NCT02069769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-540|Ensuring Communication in Hospice by Oncology Study (ECHO)|Ensuring Communication in Hospice by Oncology Study (ECHO)||Massachusetts General Hospital|Yes|Active, not recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069769||49926|
NCT02070705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9694|DCE MRI in Diagnosing Patients With Pancreatic Cancer|The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer||OHSU Knight Cancer Institute|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|150|||Both|18 Years|85 Years|No|||February 2016|February 11, 2016|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070705||49855|
NCT02071563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-016-Burkina Faso|Effectiveness and Cost-Effectiveness of Four Formulations of Food Supplements for the Prevention of Wasting and Stunting in Burkina Faso|Food Aid Quality Review Phase II Effectiveness Study: Preventing MAM and Stunting in Burkina Faso|FAQR-Burkina|Tufts University|Yes|Recruiting|March 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|6000|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||November 2015|November 4, 2015|September 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02071563||49789|
NCT02071576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1215|A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK|A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK||Technolas Perfect Vision GmbH|No|Recruiting|February 2014|August 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|85 Years|No|||November 2014|November 19, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02071576||49788|
NCT02071589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006159-11|Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers|Crossover Randomised Bioavailability Clinical Study Of A Single Dose Of Nifedipine Oral Solution From Laboratorio Reig Jofre S.A. Compared To Adalat(R) Capsules In Healthy Female Volunteers|NIFEPAR_PK1|Reig Jofre Group|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 22, 2014|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02071589||49787|
NCT02072213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL2702-103|A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers||GL Pharm Tech Corporation|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072213||49740|
NCT02072187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Adjunctive Vitamin D in the Treatment of Non-remitted Depression|Adjunctive Vitamin D in the Treatment of Non-remitted Depression||START Clinic for Mood and Anxiety Disorders|Yes|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02072187||49742|
NCT02077153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03A901|Nostalgia Bits (NOBITS)|Nostalgia Bits Project|NOBITS|Istituto Auxologico Italiano|Yes|Recruiting|October 2012|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|No|||February 2014|February 28, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02077153||49360|
NCT02072798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20130117|Antibiotics and Gut Microbiota Among Newborn Infants|Antibiotic Prophylaxis for Postpartum Infections Following Caesarean Section||Odense University Hospital|Yes|Completed|February 2014|August 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||February 2014|August 10, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072798||49695|
NCT02073032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRA-refeed-1|Incidence and Risk Factors of Refeeding Syndrome|Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients - An Observational Study||University of Copenhagen|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|79|||Both|18 Years|N/A|No|Probability Sample|Referred for surgery with head and neck cancer|February 2014|February 26, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073032||49677|
NCT02077699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-DG 10|Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study|Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)||SOFAR S.p.A.|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||November 2014|November 27, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077699||49318|
NCT02072863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPZ006|A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma||Onyx Pharmaceuticals|Yes|Completed|January 2014|September 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072863||49690|
NCT02072304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-001|Study of Web- Based Cognitive Behavioral Therapy for Depressed Korean Adolescents|Study of Web-based Cognitive Behavioral Therapy in Adolescent Depression; Randomized Controlled Trial for Korean Adolescents|wogyeokdajim|Hallym University Medical Center|No|Recruiting|January 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|12 Years|18 Years|No|||February 2014|February 24, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072304||49733|
NCT02073370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010021R|Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics|Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics|EC0991002-E|National Taiwan University Hospital|No|Active, not recruiting|January 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|65 Years|N/A|No|Non-Probability Sample|Healthy subjects One thousand Taiwanese subjects aged 20-40 will be recruited equally        divided in both genders. Exclusion criteria includes (1) morbid obesity (BMI over 35) ;        (2) long term use of body composition modified medications, like steroid, medications for        endocrine diseases (hyperthyroidism, diabetes) and autoimmune diseases; (3) energy        consumption diseases, such as cancer, organ failure; (4) pregnant women.        Patient enrollment The research subjects will be culled from outpatients aged over 65 at        NTUH.|February 2014|February 26, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT02073370||49651|
NCT02072837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E.S.931/5-12-2006|Dyslipidemia-related Risk Factors in Dialysis|Dyslipidemia-related Variables as Risk Factor for Cardiovascular Disease in Patients on the End-stage of Renal Disease||National and Kapodistrian University of Athens|Yes|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|96|||Both|24 Years|87 Years|Accepts Healthy Volunteers|Non-Probability Sample|We studied 96 dialyzed patients at Nephrology Department of "Laiko, University General        Hospital of Athens" and Renal Unit of "Diagnostic and Therapeutic Center of Athens Hygeia        SA". 62 males and 34 females participated in this study.The treatment modalities which        were applied were : regular haemodialysis (HD, n=34), predilution haemodiafiltration (HDF,        n=42) and peritoneal dialysis (PD, n=20).|February 2014|February 27, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072837||49692|
NCT02073084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-102|A Thorough Corrected QT Interval Trial|||Kowa Research Institute, Inc.||Completed|January 2014|||March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073084||49673|
NCT02069548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01400-45|Analysis of Three-dimensional Movements of the Head in Cervical Dystonia|Analysis of 3-D Movements of the Head in Cervical Dystonia: Comparative Assessment of the Cervical Mobility With the Mean of 3D Sensors Motion Capture Between Patients With Cervical Dystonia and Control Subjects|STAC1|Fondation Ophtalmologique Adolphe de Rothschild|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|63|||Both|18 Years|70 Years|No|Non-Probability Sample|Study-group: 30 patients meeting the criteria for cervical dystonia (Spasmodic        Torticollis) and without botulinum toxin injections during the last 6 previous months        before baseline. Patients will be selected consecutively among the outpatients with        movement disorder of 3 study sites: Fondation OPH Rothschild, Salpetriere Hospital and        Sainte-Anne Hospital (Paris)        Control-group: 30 healthy volunteers matched in age (+/- 5 years) and gender with the 30        CD subjects. They will be selected in Sainte-Anne Hospital (Paris)|June 2015|June 8, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069548||49943|
NCT02070328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 0425|Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up|Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up|Registry|Center for Biomedical Research, LLC|No|Recruiting|December 2013|January 2022|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are seen/treated at proton therapy centers|April 2015|April 27, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02070328|25 Years|49884|
NCT02070588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2013-GES-0017|Advanced MRI Applications for Mild Traumatic Brain Injury|Advanced MRI Applications for Mild Traumatic Brain Injury|TBI|GE Healthcare|No|Terminated|February 2014|November 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|112|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 18, 2014|No|Yes|Sponsor terminated early as moving to a new larger study program|No||https://clinicaltrials.gov/show/NCT02070588||49864|
NCT02070601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123.01-2013-GES-0001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||October 16, 2014|February 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070601||49863|
NCT02076893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHC-IRGP-Gaba|Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen|A Comparison of Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen in Children Undergoing Tonsillectomy||Children's Hospitals and Clinics of Minnesota|Yes|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|4 Years|15 Years|No|||November 2015|November 2, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02076893||49380|
NCT02071342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350/O/13|Study of ABSORB Stent in Acute Myocardial Infarction|Study of ABSORB Stent in Acute Coronary Syndrome|ABSORB-ACS|Umberto I Hospital, Frosinone Italy|No|Recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with acute coronary syndrome who are undergoing coronary angioplasty.|February 2014|February 23, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02071342||49806|
NCT02071914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P27/2.1|To Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model||Celltrion|No|Active, not recruiting|February 2014|July 2014|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02071914||49762|
NCT02072200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOD13-KR-401|Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)|A New Modified-Release Tablet Formulation of Prednisone in Patients With Rheumatoid Arthritis- Multicenter, Phase IV, Interventional Study to Assess Reduction of Morning Stiffness||Mundipharma Korea Ltd|No|Completed|September 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|20 Years|80 Years|No|||July 2015|July 7, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02072200||49741|
NCT02071628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGVT-1301|Study for Validation of In-vitro Turbidometric Platelet Aggregation Assay Using Human Blood in Healthy Volunteers|||Asan Medical Center||Completed|December 2013|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult voulteers|February 2014|February 22, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02071628||49784|
NCT02072538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHHD-BM-002|Pre-discharge vs. Early Post-discharge Stress Testing and GRACE Score for Safe Discharge of ACS-patients With a Negative Hs-troponin T Result|Role of Pre-discharge vs. Early Post-discharge Stress Testing and Implementation of the GRACE Risk Score for Safe Discharge of Patients With an ACS and a Negative High Sensitivity Troponin T Result Within 3 Hours After Presentation to a Chest Pain Unit||University Hospital Heidelberg|No|Withdrawn|April 2014|April 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to our emergency department ("chest pain unit") with typical angina        pectoris are being screened for participation. Those meeting the inclusion criteria        (typical angina pectoris, absence of symptoms since presentation, low GRACE risk score)        are included.|May 2015|May 9, 2015|February 24, 2014||No|no Sponsor|No||https://clinicaltrials.gov/show/NCT02072538|24 Months|49715|
NCT02072551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUCONEO|Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes|Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal|GLUCONEO|Assistance Publique - Hôpitaux de Paris||Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|68|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|diabetic people|April 2015|April 20, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02072551||49714|
NCT02071199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-04-13|Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)|Treatment of Human Gingivitis With Topical ACCS: a Two Week Safety Dose-ranging and Proof-of-principle Trial||Stemnion, Inc.|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071199||49817|
NCT02077426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051711|Heart Failure and Regional Specific Exercise Training Stimulus|Heart Failure and Regional Specific Exercise Training Stimulus|HF-RSTS|Duke University|No|Withdrawn|June 2014|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|55 Years|90 Years|No|||March 2014|September 16, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077426||49339|
NCT02077439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITT/004/12GP|Interactive Intention-Driven Upper-Limb Training Robotic System|Trial: Interactive Intention-Driven Upper-Limb Training Robotic System||The Hong Kong Polytechnic University|Yes|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02077439||49338|
NCT02071186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-YL-0544-CTIL|The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With ADHD|The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With Attention Deficit Hyperactivity Disorder||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|8 Years|12 Years|No|||February 2014|February 23, 2014|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02071186||49818|
NCT02071433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLS|Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery|Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02071433||49799|
NCT02073136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-106|Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4|Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4||University of Copenhagen|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073136||49669|
NCT02069262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-2004-208|Angiography Combination Laparoscopy in Patients With Obscure Gastrointestinal Bleeding|Angiography Combination Laparoscopy in Patients With Obscure Gastrointestinal Bleeding||The Second People's Hospital of GuangDong Province|Yes|Completed|January 2003|January 2014|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|66|||Both|18 Years|75 Years|No|||January 2003|February 19, 2014|February 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069262||49965|
NCT02069288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-007971-18|Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock|Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response, Gastric Mucosal Perfusion and Arterial Stiffness in Septic Shock|FLUDRO|Rennes University Hospital|No|Withdrawn||February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|December 23, 2013||No|Problems of drugs supply by the manufacturer|No||https://clinicaltrials.gov/show/NCT02069288||49963|
NCT02069795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 1312958125|Speech Analysis as a Diagnostic Tool for Mild Traumatic Brain Injury|Utilization of Speech Analysis as a Diagnostic Tool to Objectively Evaluate Early Signs of Mild Traumatic Brain Injury: A Pilot Study||Methodist Sports Medicine|Yes|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|6 Years|21 Years|No|||March 2016|March 14, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02069795||49924|
NCT02069561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAUC/2013|Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer|Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease|EPAUC|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|January 2014|||August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|70 Years|No|||September 2015|September 17, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069561||49942|
NCT02069834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0322|Dolutegravir + Rilpivirine Switch Study (DORISS)|Dolutegravir + Rilpivirine Switch Study (DORISS): Pilot and Noninferiority Trial Comparing Dolutegravir + Rilpivirine vs. Continued HAART (Highly Active Antiretroviral Therapy) in Patients With Plasma HIV RNA ≤ 50 Copies/mL for at Least 2 Years|DORISS|Nantes University Hospital|Yes|Withdrawn|May 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|February 18, 2014||No|One of the both Funder partners decided to stop the study before the initiation : thus no    product provided and no funding to realize the study|No||https://clinicaltrials.gov/show/NCT02069834||49921|
NCT02070055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_12-251|Dietary Correlates of the Maximal Capacity for Fat Oxidation|Dietary Correlates of the Maximal Capacity for Fat Oxidation During Exercise in Males and Females.||University of Birmingham|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|306|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Local healthy population|June 2014|June 12, 2014|December 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02070055||49904|
NCT02069808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRM2014-1|Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation|Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct and GnRH Agonist Trigger for Egg Bank Donation||Michigan Reproductive Medicine|No|Recruiting|April 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|28 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069808||49923|
NCT02070068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP LBH 01|A Pilot Dosing and Timing Study to Optimize Imaging When Utilizing Endoscopic Fluorescence Imaging System During Laparoscopic Biliary and Hepatic Operations|A Pilot Study to Optimize Imaging When Utilizing the PINPOINT Endoscopic Fluorescence Imaging System for Identification of Biliary Anatomy During Laparoscopic Biliary and Hepatic Operations||University of California, Los Angeles|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070068||49903|
NCT02070341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hookey Picosalax PEG|Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG|A Randomized Controlled Trial Examining Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose Polyethylene Glycol||Queen's University|Yes|Terminated|February 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|5|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|February 20, 2014||No|Significant changes to protocol and study design, study stopped to further enrollment and new    study designed.|No||https://clinicaltrials.gov/show/NCT02070341||49883|
NCT02070627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0239S|Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study|Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy Sub-Study|NIRF-C Acute|Ohio State University|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|89 Years|No|||October 2014|October 30, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070627||49861|
NCT02077777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MES-CT 01|Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.|Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari "in Vivo" Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)||SOFAR S.p.A.|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077777||49312|
NCT02071602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006317|CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function|CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study|BELIEVE III|Mayo Clinic|Yes|Recruiting|October 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|November 15, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02071602||49786|
NCT02071940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11_DOG12_56|PLX3397 KIT in Acral aNd mucOsal Melanoma|A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma|PIANO|Christie Hospital NHS Foundation Trust|Yes|Recruiting|October 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|May 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02071940||49760|
NCT02071927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX-839-003|Study of the Glutaminase Inhibitor CB-839 in Leukemia|A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia||Calithera Biosciences, Inc|No|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071927||49761|
NCT02072317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guoweijian-2013-raltitrexed|Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer|Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies||Fudan University|Yes|Recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||February 2014|February 24, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072317||49732|
NCT02072629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-22746|HCU: Can VHVs Trained in ICCM Improve Care for Children|Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?|HCU:VHV/ICCM|University of Calgary|Yes|Completed|November 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|4071|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 25, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02072629||49708|
NCT02071680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140815-01H|Autonomic Innervation and MIBG Imaging|Cardiac Mapping of Autonomic Atrial Innervation and Its Relation to MIBG Nuclear Imaging in Patients With Atrial Fibrillation|MIBG-AF|Ottawa Heart Institute Research Corporation|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02071680||49780|
NCT02073110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41985.018.12|Optical Biopsy to Improve the Diagnosis of Kidney Cancer|Optical Biopsy to Improve the Diagnosis of Kidney Cancer: a Prospective, Observational, Multicentre, In-vivo Study||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|August 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|194|||Both|18 Years|N/A|No|Non-Probability Sample|Patients ≥ 18 years of age, with a solid enhancing renal mass suspected for renal cell        carcinoma (RCC) and candidates for active (surgical) treatment of the renal mass.|February 2014|February 26, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02073110||49671|
NCT02073123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2103|Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma|A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma||NewLink Genetics Corporation||Recruiting|July 2014|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073123||49670|
NCT02069587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074-13HYMC|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|44 Years|No|||January 2014|February 20, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02069587||49940|
NCT02069275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMOVAR 01|Immediate Mobilization After Cardiac Catheterisation|Patients Immediate Mobilization After Coronary Angiography and Percutaneous Coronary Intervention. Is it SAfe to MObilize Patients Very eARly After Cardiac Catheterisation?|SAMOVAR|Rigshospitalet, Denmark|No|Recruiting|April 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2000|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02069275||49964|
NCT02070081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO Bypass|Weight Loss Following Gastric Bypass or Sleeve Surgery|Patient Profiling for Successful Weight Loss After Gastric Bypass or Sleeve Surgery||University of Copenhagen|No|Active, not recruiting|March 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|25 Years|65 Years|No|||August 2014|August 7, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02070081||49902|
NCT02069821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_EXA_101|Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects|An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge® (Amlodipine Besylate/Valsartan) and Lipitor® (Atorvastatin Ca) in Healthy Male Volunteers||CJ HealthCare Corporation|No|Not yet recruiting|March 2014|August 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069821||49922|
NCT02070107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OICN130565|Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection|A Phase 2 Clinical Trial of A Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Chronic Genotype 1 Hepatitis C Infection||University of Louisville|No|Not yet recruiting|April 2014|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|52|||Both|18 Years|70 Years|No|||February 2014|February 20, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02070107||49901|
NCT02070354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0182|Physical Fitness and Nutrition Intake in Bariatric Surgery Population|Physical Fitness and Macro- and Micro- Nutrient Intake in a Morbidly Obese Bariatric Surgery Population||Geisinger Clinic|No|Completed|August 2009|||March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|73|||Both|18 Years|70 Years|No|Non-Probability Sample|Approximately 210 Geisinger subjects will participate in this study. Participants will be        volunteers from the patient population of the Center for Nutrition and Weight Management        between the ages of 18 and 70 years.|February 2016|February 11, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02070354||49882|
NCT02070640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0239|Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy|Near Infrared Fluorescence Cholangiography During Cholecystectomy|NIRF-C|Ohio State University|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|18 Years|89 Years|No|||September 2015|September 22, 2015|February 21, 2014||No||No|May 13, 2015|https://clinicaltrials.gov/show/NCT02070640||49860|
NCT02077543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProTool|Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma|Molecular and Cellular Print Medical Device Validation in Adult Glioma Tumors|ProTool|University Hospital, Grenoble|Yes|Recruiting|October 2013|August 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02077543||49330|
NCT02071615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003882-17|Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers|Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study|MKM|Charite University, Berlin, Germany||Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|48|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02071615||49785|
NCT02071368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103258|A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071368||49804|
NCT02071381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW340-1001|Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects|A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects||Daewon Pharmaceutical Co., Ltd.||Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|N/A|3||||||Male|20 Years|40 Years||||January 2014|March 26, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071381||49803|
NCT02071394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2013/4414|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Outcomes Study (COOLXENON3 Study)|CoolXenon3|University Hospitals Bristol NHS Foundation Trust|Yes|Recruiting|March 2014|March 2017|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|N/A|No|||September 2015|September 4, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071394||49802|
NCT02076568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH022014_4|Diabetes and Partnership: Evaluation of a Diabetes Education Module|A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic "Diabetes and Partnership" in a Randomized Controlled Trial|PRIMO_Partner|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2014|February 28, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02076568||49405|
NCT02076841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHE-AVX-12-10348|Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen|Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM)|SFERA|Biogen|No|Active, not recruiting|July 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Recruitment by participating clinicians in Switzerland and Czech Republic.|January 2016|January 28, 2016|February 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02076841||49384|
NCT02072252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00061284|Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men|Mobile Phone and Internet-Based Intervention for Vulnerable Youth|TODAY!|Northwestern University|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|17 Years|20 Years|No|||February 2016|February 2, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02072252||49737|
NCT02076854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31MH097308|A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa|||Boston University|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||February 2014|January 14, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02076854||49383|
NCT02072031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-06-IIA|Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）|A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC)||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||February 2015|February 14, 2015|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072031||49754|
NCT02070822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012077RB|3T MRI to Predict TACE Response of HCC|Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma||National Taiwan University Hospital|No|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Hospital patients, admitted for TACE treatment of HCC|February 2014|February 23, 2014|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT02070822||49846|
NCT02070835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-2013-048|Study of ReCell® Treating for Diabetic Foot Ulcers|ReCell® Versus Classic Skin Grafts in Treatment of Diabetic Foot Ulcers: a Comparative Randomized Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||August 2015|August 10, 2015|February 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070835||49845|
NCT02071173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1481|Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads|Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads: NAVIGATE X4|NAVIGATE X4|Boston Scientific Corporation|No|Active, not recruiting|March 2014|September 2022|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2242|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects included in the NAVIGATE X4 Clinical Study should be selected from the        investigator's general patient population indicated for CRT-D implantation. Investigators        are responsible for screening all potential subjects and selecting those who meet the        eligibility criteria for the study|February 2016|February 4, 2016|February 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071173||49819|
NCT02073097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3413|Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma|A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma||Case Comprehensive Cancer Center|Yes|Recruiting|October 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02073097||49672|
NCT02072876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D43TW008660-03|Asymptomatic Intracranial Atherosclerotic Disease in Pakistanis|Asymptomatic Intracranial Atherosclerotic Disease: Prevalence, Clinical and Lifestyle Determinants in Urban Pakistan|AICAD|Aga Khan University|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|N/A||2|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|This study recruited all adult Pakistani patients ≥ 18 yrs., with no previous clinical        history of stroke, (negative on QVSFS; Questionnaire to Verify Stroke Free Status),        presenting to the two tertiary care centers for MRI Brain for indications other than        stroke.|February 2014|February 27, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02072876||49689|
NCT02072889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220110074|Optimal Neck Angle for Internal Jugular Cannulation|Optimal Angle For Internal Jugular Cannulation||Rutgers, The State University of New Jersey|No|Completed|April 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02072889||49688|
NCT02073383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPaulo - USG Guided Block|Three Techniques for Ultrasound Guided Axillary Brachial Plexus Block|Prospective Randomized Study of Three Different Techniques for Ultrasound Guided Axillary Brachial Plexus Block||Federal University of São Paulo|No|Active, not recruiting|August 2013|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|313|||Both|18 Years|65 Years|No|||February 2014|February 25, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073383||49650|
NCT02069574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0940|Diagnosis of Periodontal Disease Using Genetic Marker in Saliva|Identification of Novel Periodontal Disease Biomarkers Using microRNA Expression in Saliva||Asan Medical Center|No|Not yet recruiting|March 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069574||49941|
NCT02070120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2013/10041|Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer|CALIBER - A Phase II Randomised Feasibility Study of Chemoresection and Surgical Management in Low Risk Non Muscle Invasive Bladder Cancer|CALIBER|Institute of Cancer Research, United Kingdom|Yes|Not yet recruiting|October 2014|July 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|174|||Both|16 Years|N/A|No|||September 2014|September 8, 2014|February 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070120||49900|
NCT02070367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-798|Somatosensory Assessment and Rehabilitation of Allodynia (SARA)|Somatosensory Assessment and Rehabilitation of Allodynia: the SARA Pilot Study|SARA|Hamilton Health Sciences Corporation|No|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02070367||49881|
NCT02070653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UpAAA - 2014 - 01|The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion|Does Ticagrelor Inhibit Growth of Small Abdominal Aortic Aneurysms? A Randomised Controlled Trial (TicAAA)|TicAAA|Uppsala University|Yes|Recruiting|March 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|50 Years|85 Years|No|||December 2015|December 3, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070653||49859|
NCT02070666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPALI|Preventive Strategies in Acute Respiratory Distress Syndrome (ARDS)|Preventive Strategies in Acute Respiratory Distress Syndrome|EPALI|Corporacion Parc Tauli|Yes|Recruiting|May 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02070666||49858|
NCT02070952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138830|CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer||Riverside Community Hospital, California|No|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|167|||Male|18 Years|N/A|No|||February 2014|February 21, 2014|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070952||49836|
NCT02073968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-252|PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer|PET-Adjusted IMRT for NSCLC Trial (PAINT)|PAINT|Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|July 2013|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02073968||49605|
NCT02073981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-FIRST|Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients|Japan-First-in Large Scale Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients.|J-FIRST|Kyowa Hakko Kirin Company, Limited|No|Active, not recruiting|March 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|Parkinson Disease|August 2015|August 31, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02073981||49604|
NCT02071147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/02/050|RCT of Follow up Following Cataract Extraction|Randomised Trial of Four to Six Week Follow Ups vs no Medical Follow up After Uncomplicated Cataract Extraction||South Devon Healthcare NHS Foundation Trust|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|400|||Both|40 Years|N/A|No|||May 2015|May 18, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071147||49821|
NCT02071407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014021801|A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury|||Subei People's Hospital of Jiangsu Province|Yes|Recruiting|October 2013|||March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071407||49801|
NCT02071641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/259|Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma|Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma||VU University Medical Center|No|Recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02071641||49783|
NCT02077166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1123-CA|Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||Pharmacyclics|Yes|Recruiting|February 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|129|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077166||49359|
NCT02077452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMM0102|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes|A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus||Hua Medicine Limited|No|Completed|March 2014|October 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|53|||Both|18 Years|65 Years|No|||March 2014|October 29, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02077452||49337|
NCT02077465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-368-1212|Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease||Gilead Sciences|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|40 Years|75 Years|No|||February 2015|February 9, 2015|February 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02077465||49336|
NCT02072044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-06-IIB|Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma（RCC）That Have Failed Or Are Intolerant To TKIs Therapy|A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 22, 2015|January 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072044||49753|
NCT02072057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOHTNC-02-2013|Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.|The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.||Kantonsspital Aarau|Yes|Active, not recruiting|April 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02072057||49752|
NCT02071446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3197|Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes|Local Field Potentials Recorded From Deep Brain Stimulating Electrodes Implanted for the Treatment of Parkinson's Disease, Essential Tremor or Dystonia|LFP in DBS|University of Colorado, Denver|No|Recruiting|March 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|Movement disorder patients from primary care clinic.|November 2015|November 18, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071446||49798|
NCT02072642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5063|Light Therapy in Parkinson's Disease|Light Therapy in Parkinson's Disease : Effect on Motor Symptoms, Sleep, Circadian Rhythms, and Mood||University Hospital, Strasbourg, France|No|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|45 Years|75 Years|No|||February 2014|February 25, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072642||49707|
NCT02069301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH094648-02|Evaluation of an Integrated Microfinance and Depression Care Program for Women|Development of an Integrated Microfinance and Depression Care Program for Women|LIFE-DM|RAND|Yes|Active, not recruiting|February 2014|April 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|55 Years|No|||March 2015|March 3, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02069301||49962|
NCT02073396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No 1.1; 4 Dec 2012|Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis|Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis||East and North Hertfordshire NHS Trust|Yes|Recruiting|January 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with coronary disease or atrial fibrillation. Participants will be        recruited from amongst in-patients or out-patients|October 2014|October 25, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073396||49649|
NCT02069314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203012093|Diet and Muscle Function In Older Adults|Diet and Muscle Function In Older Adults|S32|Purdue University|Yes|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2013|February 19, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02069314||49961|
NCT02069847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009467|Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy|Prospective Evaluation of the Clinical Utility of Budesonide for the Prevention of Esophageal Strictures After Endotherapy||Mayo Clinic|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069847||49920|
NCT02069860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12k002|BONE ANCHORED PORT for Hemodialysis Treatment|Bone Anchored Port - a Novel Vascular Access for Hemodialysis Treatment|BAP|Cendres+Mètaux|Yes|Not yet recruiting|November 2015|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02069860||49919|
NCT02069600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-elderly-OSA|Effect of CPAP Treatment in Elderly: Randomized Clinical Trial|OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY. ROLE OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT. A Randomized Controlled Trial||Hospital Universitario La Fe|Yes|Completed|January 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|70 Years|N/A|No|||February 2014|February 20, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069600||49939|
NCT02069873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0022|Effectiveness of Cognitive, Exposure, and Skills Group Manualized Treatments in Operations Iraqi (OIF)/Operation Enduring Freedom (OEF) Female Veterans|Phase II Efficacy Study on Group Delivery of Effective Treatments for PTSD||New Mexico VA Healthcare System|No|Completed|April 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|19 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02069873||49918|
NCT02070133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC08/00123|Efficacy of Simvastatin for the Treatment of COPD|Pilot Study on the Efficacy of Statins for the Treatment of Chronic Obstructive Pulmonary Disease||Hospital Universitari Son Dureta|No|Completed|May 2009|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Male|40 Years|80 Years|No|||February 2014|February 21, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02070133||49899|
NCT02070380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-148|Crossover Comparison of MultiHance and Dotarem|Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in Magnetic Resonance Imaging (MRI) of the Brain|BENEFIT|Bracco Diagnostics, Inc|No|Active, not recruiting|February 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|176|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070380||49880|
NCT02070393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUHPTC-01|Breast-Sparing Proton Therapy for Hodgkin's Disease|Breast-Sparing Proton Therapy for Hodgkin's Disease in Young Females Demonstrated By Positron Emission Tomograpy (PET) Scanning: A Pilot Study|Breast Sparing|Indiana University|Yes|Terminated|September 2011|February 2015|Actual|February 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|3|||Female|10 Years|30 Years|No|||February 2015|February 3, 2015|April 19, 2012||No|Closure of Indiana University Health Proton Center in December 2014|No||https://clinicaltrials.gov/show/NCT02070393||49879|
NCT02077582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOBI-BBB|Longitudinal MRI Examinations of Patients With Brain Ischemia and Blood Brain Barrier Permeability|Longitudinal Observation of Brain Ischemia and Blood Brain Barrier Permeability in the Acute Phase of Ischemic Stroke|LOBI-BBB|Charite University, Berlin, Germany|No|Recruiting|September 2013|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|410|Samples With DNA|2x 2ml plasma and 2x 2ml serum per patient|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic. Patients presenting with acute (<24h) transient ischemic attack or        stroke at the emergency ward, Charité Campus Benjamin Franklin|March 2014|March 3, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02077582||49327|
NCT02075996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-10280|Non-interventional Study With Pomalidomide (Imnovid®)|Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Poseidon|iOMEDICO AG|No|Recruiting|January 2014|January 2021|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with relapsing or refractory multiple myeloma previously treated with at        least two prior lines of therapy, including bortezomib and lenalidomide who have        progressed under their last therapy regimen|November 2015|November 12, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02075996||49449|
NCT02076581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS076052-1|MyoSense- Automated Muscle Hypertonicity Classification System|MyoSense- Automated Muscle Hypertonicity Classification System||Great Lakes NeuroTechnologies Inc.||Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|53|||Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sixty individuals, including individuals with and without abnormal muscle tone will be        recruited for this study.|May 2015|May 28, 2015|February 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02076581||49404|
NCT02076308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207036RIB|Acupuncture for Treatment of Frozen Shoulder Syndrome|Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: First Year Project- Verification of Acupuncture and Evaluation by Magnetic Resonance Imaging Examination|SMART|National Taiwan University Hospital|Yes|Recruiting|December 2012|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||March 2015|March 3, 2015|December 26, 2012||No||No||https://clinicaltrials.gov/show/NCT02076308||49425|
NCT02070549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00416|Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction|A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction||National Cancer Institute (NCI)||Suspended|February 2014|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||February 2016|March 8, 2016|February 21, 2014|No|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02070549||49867|
NCT02070562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR.1.C/A|Human Milk Profiles and Dietary Intake of Chinese Lactating Mothers During Early Lactation Period in Shanghai|Human Milk Profiles and Dietary Intake of Chinese Lactating Mothers During Early Lactation Period in Shanghai|MuRu|Dumex Baby Food Co., Ltd.||Active, not recruiting|February 2014|June 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|breast milk from 0-42 days postpartum|Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|General health lactating mothers|February 2015|February 5, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02070562||49866|
NCT02070848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5456|Muscle Blood Flow During Exercise|Muscle Blood Flow Control During Exercise in Humans: Contribution From Mechanical and Metabolic Signals and Role of the Erythrocyte.||University Hospital, Strasbourg, France|No|Recruiting|May 2013|||May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be students recruited in the Faculty, sports clubs...|October 2014|October 27, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02070848||49844|
NCT02072382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120406|The Hypotensive Effect of Metformin in Hypertensive Patients.|The Hypotensive Effect of Simvastatin in Hypertensive Patients: a Placebo-controlled Randomized Clinical Trial With 24-h Ambulatory Blood Pressure Monitoring||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|May 2013|December 2015|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02072382||49727|
NCT02072395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0003|Gastric Plication and Banding|Treatment of Morbid Obesity With Gastric Plication and Gastric Banding|GP and Band|Ohio State University|No|Active, not recruiting|February 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 15, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072395||49726|
NCT02072850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S0703/28|Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.|Cardiac Magnetic Resonance Imaging: New Pathological Insights and Their Functional and Clinical Significance in ST Elevation Acute Myocardial Infarction.|BHF MR-MI|NHS National Waiting Times Centre Board|No|Active, not recruiting|May 2011|May 2017|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|324|Samples With DNA|Blood and urine samples have been archived.|Both|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of ST-elevation myocardial infarction (STEMI).|August 2014|August 11, 2014|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02072850||49691|
NCT02072330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536TCH/CCT-001|Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.|A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension||Takeda|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|353|||Both|20 Years|N/A|No|||February 2014|February 24, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072330||49731|
NCT02072655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI PM 2012-12|Impact of Socio-aesthetic Care in the Quality of Life of Patients Treated for Lymphoma During and After Hospitalization|Impact of Socio-aesthetic Care in the Quality of Life of Patients Treated for Lymphoma During and After Hospitalization|CareSSE|University Hospital, Angers||Recruiting|January 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2014|February 24, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02072655||49706|
NCT02072928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/OAB/005|Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium|||Allergan|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with incontinence from NDO due to spinal injury or MS treated as per standard of        care in clinical practice.|January 2016|January 12, 2016|February 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02072928||49685|
NCT02073149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM-2542|Safe and Efficacious Iron for Children in Kenya|Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial|SEICK|London School of Hygiene and Tropical Medicine|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|338|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||February 2014|April 9, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073149||49668|
NCT02073162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1287|REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery|REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery||The Cleveland Clinic|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073162||49667|
NCT02073175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/2013|Development of Dietary Supplements for Mood Symptoms in Postpartum|Development of Dietary Supplements for Mood Symptoms in Postpartum||Centre for Addiction and Mental Health|No|Recruiting|February 2014|February 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|125|||Female|18 Years|45 Years|No|||December 2015|December 22, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02073175||49666|
NCT02073409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICK13A0|PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis|Cystic Fibrosis Nontuberculous Mycobacteria Diagnosis Protocol|PREDICT|National Jewish Health|Yes|Recruiting|December 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|serum sputum NTM isolates|Both|7 Years|82 Years|No|Non-Probability Sample|Male and female subjects with CF age 7 years and older who have a positive sputum culture        for NTM.|February 2016|February 22, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02073409||49648|
NCT02069340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-13-3|Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid|POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ)||University of Southern California|Yes|Not yet recruiting|January 2016|June 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|N/A|No|||October 2015|October 24, 2015|February 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069340||49959|
NCT02069327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fat Emboli|The Role of Fat Emboli in the Trauma Inflammatory Response|The Role of Fat Emboli in the Trauma Inflammatory Response||Poudre Valley Health System|No|Completed|November 2012|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Bone marrow Blood specimen (~4 teaspoons)|Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing a tibial or femoral fracture procedure in the operating room.|July 2015|July 22, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02069327||49960|
NCT02069886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AIT12|Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia|A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia|CENTAurus|Novartis|No|Withdrawn|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|2 Years|18 Years|No|||March 2015|March 18, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069886||49917|
NCT02070146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-510|Prospective Data Collection Initiative on Colorectal Cancer|Prospective Data Collection Initiative on Colorectal Cancer - a Prospective Observational Cohort Study -|PLCRC|Dutch Colorectal Cancer Group|No|Recruiting|May 2013|January 2051|Anticipated|January 2050|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood and tumor tissue will be stored.|Both|18 Years|N/A|No|Non-Probability Sample|All patients diagnosed with CRC who are treated in one of the participating hospitals will        be asked to participate in this cohort study.|October 2015|October 20, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02070146|50 Years|49898|
NCT02070406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001624|Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies|NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade||Jonsson Comprehensive Cancer Center|Yes|Recruiting|July 2014|||February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|16 Years|N/A|No|||March 2016|March 4, 2016|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070406||49878|
NCT02070692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF14-1|Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users|Tamoxifen for the Treatment of Unfavorable Bleeding Patterns in Etonogestrel Contraceptive Implant Users||Oregon Health and Science University|No|Active, not recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Female|15 Years|45 Years|No|||October 2015|October 13, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02070692||49856|
NCT02077595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-3624B|Effects of Transcutaneous Electrical Nerve Stimulation on Cortical Excitability in the Primary Motor Cortex in Healthy Adults|||Chang Gung University|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02077595||49326|
NCT02077608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SemmelweisU-002|Hyaluronan in Embryo Transfer Media|Effect of Hyaluronan Enriched Embryo Transfer Media on IVF Outcome||Semmelweis University|No|Completed|January 2010|December 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|580|||Female|18 Years|48 Years|No|Probability Sample|Patients entering in vitro fertilization and embryo transfer treatment|March 2014|March 3, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077608||49325|
NCT02076594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEGA|Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer|A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer||Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Recruiting|January 2013|July 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|69 Years|No|||November 2014|November 14, 2014|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02076594||49403|
NCT02076867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2014-274|Halifax Somatic Symptoms Disorder Trial|Halifax Somatic Symptom Disorder Trial: A Randomized Parallel Group Cross-Over Study of Intensive Short-Term Dynamic Psychotherapy Compared to Medical Treatment as Usual for Somatic Symptoms in the Emergency Department||Nova Scotia Health Authority|No|Not yet recruiting|March 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|65 Years|No|||February 2014|February 28, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02076867||49382|
NCT02071693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2008] 20|A Retrospective Study of the Relationship Between White Matter Hyperintensities(WMHs) Within the Cholinergic Pathways and the Cognition of PD Patients After Bilateral STN DBS|Cholinergic Pathways Hyperintensities Scale Could Not Predict the Change of Cognitive Status of Parkinson's Disease Patients After Bilateral STN DBS.||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|December 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|38|||Both|40 Years|75 Years|No|Non-Probability Sample|PD patients treated with bilateral STN DBS in the First Affiliated Hospital during the        year of 2008-2012.|March 2014|March 28, 2014|February 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02071693||49779|
NCT02071706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2013-GES-0010|Clinical Evaluation of an Integrated PET/MRI System|Clinical Evaluation of an Integrated PET/MRI System|PET/MR_ZURICH|GE Healthcare|No|Terminated|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|February 23, 2014|Yes|Yes|study terminated: the sponsor believes sufficient data has been collected to support    regulatory submissions.|No||https://clinicaltrials.gov/show/NCT02071706||49778|
NCT02072005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048974|Mobile App Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|Mobile Application Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|mSMART|Duke University|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|50 Years|No|Probability Sample|Participants will be 15 adult, nicotine dependent smokers for a target completion sample        of 9. Subjects will be allowed to meet criteria for a current comorbid psychiatric        disorder (e.g., Attention-Deficit/Hyperactivity Disorder [ADHD], Post-Traumatic Stress        Disorder, Major Depressive Disorder), though non-psychiatric smokers will be included as        well. Participants will be taking some form of prescribed psychiatric medication or        nicotine replacement therapy in pill form.|July 2014|July 29, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02072005||49756|
NCT02072018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDTP1|Peyronie's Disease Treatment Protocol|A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease||Hybrid Medical|Yes|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|70 Years|No|||February 2014|February 24, 2014|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02072018||49755|
NCT02072343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capnometry with DCCM|The Effect of 10 cm Catheter Mount on Malfunction of Capnometers Under the Conditions of Water|||Hanyang University||Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072343||49730|
NCT02072356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10036|Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery|A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|October 2010|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072356||49729|
NCT02072707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arrit-Incor-1|Efficacy and Safety of Epicardial VT Ablation Using Contact Force Irrigated Tip Catheter - Pilot Sutdy|Prospective and Randomized Study to Evaluate Efficacy and Safety of Epicardial Ventricular Tachycardia Ablation Using Contact Force Sensor Irrigated Tip Catheter - Pilot Study||University of Sao Paulo General Hospital|No|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072707||49702|
NCT02073188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBGST_L_05971|Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose|Comparative Efficacy of iBGStar Glucose Meter vs. Traditional Glucose Monitoring in Improving Metabolic Control and Compliance Towards Self-Monitoring of Blood Glucose in Young Patients With Type 1 Diabetes|iNew Trend|Sanofi|No|Completed|June 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|186|||Both|14 Years|24 Years|No|||March 2016|March 1, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073188||49665|
NCT02073201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300835|Development of Clinical Methods to Evaluate Neural Function in Aging|Development of Clinical Methods to Evaluate Neural Function in Aging|MIND|University of Florida|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|20 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|We propose to recruit 30 persons over 60 years of age who are classified as either high-        or low functioning based on performance on the Short Physical Performance Battery (SPPB).        Participants with a SPPB score ≥ 11 will be categorized as high-functioning, while the        low-functioning group will include participants with a SPPB score ≤ 8. We will also        recruit 15 persons between 20-30 years of age. We will target cognitively intact (3MSE >        80) older adults who are free of overt neuromuscular impairments (no dementias, brain        tumors, major depression, history of stroke, etc.).|November 2015|November 12, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073201||49664|
NCT02073422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRS-11-CA56, PG/11/55/28999|FAMOUS-NSTEMI MRI Sub-Study|Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes - A 3.0 Tesla Stress Perfusion MRI Sub-Study (FAMOUS-NSTEMI MRI)||NHS National Waiting Times Centre Board|Yes|Active, not recruiting|October 2011|December 2014|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|N/A|N/A|No|Non-Probability Sample|Medically stabilised patients with recent non-ST elevation myocardial infarction.|February 2014|February 25, 2014|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02073422||49647|
NCT02069613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27294/1|Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)|Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)||Huntington Medical Research Institutes|No|Recruiting|March 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood will be retained for future analysis.|Both|18 Years|50 Years|No|Non-Probability Sample|Study participants (control, mTBI) will be referred by the Huntington Hospital Emergency        Department staff. ED staff will determine the eligibility criteria. If consent is        achieved, testing will occur at pre-determined times: 1 day, 14 days, and 30 days        post-injury.|February 2016|February 17, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069613||49938|
NCT02069626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/214|The Effect of Compression Time for Secure Stapling With a Linear Stapler in Laparoscopic Gastric Bypass Surgery|||Inonu University||Active, not recruiting||||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years||||February 2014|February 21, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02069626||49937|
NCT02069639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARC|TARC After alloSCT in Hodgkin's Lymphoma|Serum Thymus and Activation-regulated Chemokine (TARC) Level Monitoring May Predict Disease Relapse Detected by PET Scan After Reduced Intensity Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma Patients|TARC|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|This study included 22 consecutive Hodgkin's lymphoma patients who underwent an alloSCT at        Fondazione IRCCS Istituto Nazionale dei Tumori and who were monitored by PET and TARC        before and after alloSCT.|February 2014|February 20, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02069639||49936|
NCT02069899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0501-05|Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody|A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody||NovImmune SA|Yes|Recruiting|June 2013|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|N/A|N/A|No|||March 2016|March 15, 2016|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069899||49916|
NCT02070159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRELOAD-LD|Prasugrel With Lower Dose - Loading Dose|Effect of Lower Loading Dose of Prasugrel Compared With Conventional Loading Dose of Clopidogrel and Prasugrel in Korean Coronary Artery Disease Patients Undergoing Coronary Angiography|PRELOAD-LD|Dong-A University|Yes|Completed|December 2011|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|80 Years|No|||February 2014|February 21, 2014|February 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02070159||49897|
NCT02070419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2212|TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer|Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)||Case Comprehensive Cancer Center|Yes|Withdrawn|April 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||December 2014|December 1, 2014|February 21, 2014|Yes|Yes|Principal Investigator left institution|No||https://clinicaltrials.gov/show/NCT02070419||49877|
NCT02077855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3964|Value of Sonographic Diagnosis of Toddler's Fracture of the Tibia|||Universitätsklinikum Hamburg-Eppendorf|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|5 Years|No|Probability Sample|Children with suspicion of Toddlers fractures.|July 2015|July 13, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT02077855||49306|
NCT02077868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGN1703-C06|Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment|Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment|IMPALA|Mologen AG|Yes|Recruiting|September 2014|June 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02077868||49305|
NCT02070042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13105-13-057|Oxybutynin and Omega-3 for OAB (Overactive Bladder)|Randomized Controlled Trial of Oxybutynin and Omega-3 Fatty Acid Supplementation Versus Oxybutynin and Placebo for Treatment of Overactive Bladder in Women||TriHealth Inc.|No|Terminated|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|February 13, 2014|Yes|Yes|Lack of participation|No||https://clinicaltrials.gov/show/NCT02070042||49905|
NCT02070289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431002|A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)||Pfizer|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070289||49887|
NCT02070302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85700|BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome|BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome||Arizona Arthritis & Rheumatology Research, PLLC.||Active, not recruiting|October 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||December 2015|December 28, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070302||49886|
NCT02071212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00063|Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With Coronary Artery Disease . The NOVELTY Study|A Single Center Phase II Assessor -Blinded RaNdomised Active Controlled Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in Patients With CoronarY Artery Disease. The NOVELTY Study|NOVELTY|Hellenic Cardiovascular Research Society|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|79 Years|No|||April 2015|April 15, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071212||49816|
NCT02071719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/109|Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients|Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients||VU University Medical Center|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|225|||Both|18 Years|N/A|No|Probability Sample|Patients with renal cell cancer|December 2015|December 8, 2015|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT02071719||49777|
NCT02072668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2607|The Effect of Rivaroxaban in Sickle Cell Disease|The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease||University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|55 Years|No|||October 2015|October 7, 2015|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072668||49705|
NCT02072681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120079|Mild and Rapidly Improving Stroke Study|Mild and Rapidly Improving Stroke Study|MaRISS|University of Miami|No|Recruiting|March 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2650|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ischemic stroke defined clinically as mild and/or rapidly improving and        confirmed by neuroimaging not to have a hemorrhagic stroke with symptom onset within 4.5        hours.|October 2015|October 7, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02072681|3 Months|49704|
NCT02072369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00032058|Simulated Home Therapy Program for the Hand After Stroke|Simulated Home Therapy Program for the Hand After Stroke||Rehabilitation Institute of Chicago|No|Completed|May 2011|December 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|23|||Both|21 Years|N/A|No|||February 2015|February 5, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02072369||49728|
NCT02072408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10-044-002|Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy|||Samsung Medical Center||Recruiting|February 2014|||December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|19 Years|N/A|No|||February 2014|February 24, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02072408||49725|
NCT02072720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/340|Angiogenic Factor Expression During Fractionated Irradiation|Pilot Study to Determine the Effect of Fractionated Radiotherapy on Expression of Pro-angiogenic Factors in Oesophagus Carcinoma||VU University Medical Center|Yes|Recruiting|February 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02072720||49701|
NCT02072954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARL/CT/13/003|Bioequivalence Fasting Study in Patients|A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRIS® (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male & Female Patients Under Fasting Condition.||Amneal Pharmaceuticals, LLC|Yes|Completed|November 2013|June 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|February 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072954||49683|
NCT02072941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0061026|Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making (PREPARE)|Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making||University of California, San Francisco|Yes|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|402|||Both|55 Years|N/A|No|||December 2015|December 1, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02072941||49684|
NCT02069379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00066696|Endogenous Opioid Activity and Affective State in Insulin Resistant Women|Endogenous Opioid Activity and Affective State in Insulin Resistant Women||University of Michigan|No|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|38|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069379||49956|
NCT02069652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-20130061|Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,|Chung-Ho Memorial Hospital Kaohsiung Medical University||Kaohsiung Medical University Chung-Ho Memorial Hospital||Available|July 2013|||December 2014|Anticipated|N/A|Expanded Access|N/A|||||||Male|15 Years|30 Years||||February 2014|February 20, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02069652||49935|
NCT02069353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13060260|Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest|Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest||University of Pittsburgh|No|Recruiting|July 2015|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02069353||49958|
NCT02069366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01MH101123-01A1|Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder|Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder||Wayne State University|Yes|Recruiting|November 2014|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|120|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069366||49957|
NCT02070172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMUSP2|Active and Passive Cervical Flexion-rotation Tests|A Comparison of Range of Motion During the Active and Passive Flexion-rotation Tests in Subjects Patients With Cervicogenic Headache||Des Moines University|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|24|None Retained|This study compares observation of neck range of motion measures during the flexion rotation      test (combining neck flexion with neck rotation) in two groups of subjects, one group has      headaches and one groups is a healthy, asymptomatic group.|Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|two groups of subjects were included; those with cervicogenic headaches and an        asymptomatic group of healthy volunteers|February 2014|February 21, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070172||49896|
NCT02070185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Energy|Effect of Energy Density on Liking and on Caloric Adjustment Conditioning|Effect of Energy Density on Liking and on Caloric Adjustment Conditioning After Sweet Beverage Exposure in Children Aged 8-11 y||Centre des Sciences du Goût et de l'Alimentation|Yes|Completed|March 2013|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|45|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||February 2014|February 21, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02070185||49895|
NCT02070432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUZ11-CDU-001|Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer|An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer||Luzitin SA|No|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070432||49876|
NCT02070718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43952-B|Effects of a Kappa Agonist on Hot Flashes in Menopausal Women|Effects of a Kappa Agonist on Hot Flashes in Menopausal Women||University of Washington|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02070718||49854|
NCT02071030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL nr.: 40492.091.12|The Efficacy of Cone Beam Computed Tomography (CBCT) Compared to Panoramic Radiography Prior to Third Molar Removal|The Efficacy of Cone Beam Computed Tomography (CBCT) Compared to Panoramic Radiography Prior to Third Molar Removal; a Multicentre Randomised Controlled Trial||Radboud University||Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|477|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 3, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02071030||49830|
NCT02071043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-ON-03|Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis|||Shanghai Zhongshan Hospital|No|Completed|November 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|80 Years|No|||February 2014|February 23, 2014|February 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071043||49829|
NCT02071056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13237|Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)|Tissue and Fluid Collection Pilot Study to Develop Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of LM in Patients With Metastatic Solid Tumor Cancer||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|May 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|22|||Both|18 Years|N/A|No|Non-Probability Sample|Neurology and Medical Oncology clinical practices|March 2016|March 2, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071056||49828|
NCT02077881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2104|Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas||NewLink Genetics Corporation|Yes|Recruiting|August 2014|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02077881||49304|
NCT02070861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1605|Non-invasive Evaluation of Volume Status Using End-tidal CO2 and Pulse Contour Analysis|Non-invasive Volume Evaluation With Endtidal CO2 and Pulse Contour Analysis (Nexfin)||Oslo University Hospital|No|Recruiting|March 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|95 Years|No|||May 2015|May 5, 2015|February 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02070861||49843|
NCT02070874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012450|Pain and Symptom Management in Rural Communities|Palliative Care Symptom Management in Rural Communities|TelePain|University of Washington|Yes|Recruiting|April 2012|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|288|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02070874||49842|
NCT02071225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29167|A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia|Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Recruiting|April 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071225||49815|
NCT02071251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108303|A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery|A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery||Washington University School of Medicine|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|89 Years|No|||August 2015|August 22, 2015|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02071251||49813|
NCT02071459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1255401|Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA|Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo|DOPS-AMS|University Hospital, Toulouse|No|Recruiting|February 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|30 Years|80 Years|No|||January 2016|January 17, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02071459||49797|
NCT02071472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 16|Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation|Evaluation of the Impact of an Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation|DP-CONCIL|University Hospital, Grenoble|No|Active, not recruiting|April 2014|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1076|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 25, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02071472||49796|
NCT02071732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002|Therapeutic Effect of Repetitive Transcranial Magnetic Stimulaton on Tinnitus|Repetitive Transcranial Magnetic Stimulation (rTMS) Effect on Tinnitus||Dongtan Sacred Heart Hospital|No|Recruiting|February 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02071732||49776|
NCT02071745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0041-13|Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results|||Ziv Hospital|No|Completed|July 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|70|||Both|18 Years|90 Years|No|Non-Probability Sample|patients undergoing navigated total knee replacement|February 2014|February 22, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02071745||49775|
NCT02071758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LVVPX-117|Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects||IDRI|Yes|Completed|April 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|39|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02071758||49774|
NCT02072434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-F-E308|Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation|A Prospective, Randomized, Open-Label Blinded Endpont Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation|ENSURE-AF|Daiichi Sankyo Inc.|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2199|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02072434||49723|
NCT02072902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-0050-RD-CTIL|Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort|Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort|DBCA|Sheba Medical Center|No|Active, not recruiting|March 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|2188669|||Both|21 Years|N/A|No|Non-Probability Sample|The cohort will include all individuals who were aged 21 years or older at study entry,        January 1, 2002, and who were insured by Clalit Health Services, from one year prior to        study entry, until the end of the study period, December 31, 2012, or until death, for        those who did not survive until the end of follow-up.|March 2014|March 2, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02072902||49687|
NCT02073435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2ALL Safety Study|A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation|A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant||Northwestern University|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|3000|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|CLINICIANS: All clinicians who are involved in the inpatient care provided to the LDLT        A2ALL donors and recipients are eligible for the study. The group of clinicians eligible        for the study involve all clinicians participating in the LDLT care between day of surgery        through discharge: OR personnel (nurses, technicians, anesthesiologists, surgeons,        research staff, cell saver staff, etc.), PACU/Intensive Care Unit personnel (nurses,        anesthesiologists, surgeons, pharmacists, etc.) and floor personnel (nursing,        coordinators, pharmacists, etc.).        PATIENTS: Living Donor Liver Transplant patients (donor and recipients) from 2008-2015.|December 2015|December 23, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02073435||49646|
NCT02073214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-DM/SBK-NEC-01/11|Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.|Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates. Multi-centre, Randomised, Double-blind, Placebo-controlled Clinical Study.||IBSS Biomed S.A.|No|Completed|April 2012|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|182|||Both|N/A|48 Hours|No|||February 2014|February 25, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02073214||49663|
NCT02093000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29261|A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma|A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin in Patients With Advanced Lung Adenocarcinoma||Hoffmann-La Roche||Recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving Avastin monotherapy as maintenance treatment|March 2016|March 1, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093000||48143|
NCT02093013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002-1077|Effectiveness of an Integrated Care Program on Asthma Control and Inhaled Corticosteroids Adherence|Impact of an Integrated Care Intervention Program on Asthmatic Patients.|RESPIRE|Laval University|No|Completed|May 2004|July 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|349|||Both|12 Years|45 Years|No|||March 2014|March 19, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093013||48142|
NCT02092454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT5675|Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media|Phase II, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Ages 2 Months to 12 Years Presenting With Acute Otitis Media||Otic Therapy, LLC||Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|2 Months|12 Years|No|||May 2015|May 7, 2015|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092454||48185|
NCT02093598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLO-TEM-2011-01/TEM IIG-4|POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus|"A Phase IIa Pharmacokinetic-pharmacodynamic Study to Confirm the Inhibitory Effect of Temsirolimus, Targeting the mTOR Pathway in Endometrial Carcinoma"|POEM|MedSIR|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|No|||March 2014|April 13, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02093598||48098|
NCT02092987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM5150|Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study|Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study|NHiCE|Columbia University|Yes|Active, not recruiting|March 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|221|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02092987||48144|
NCT02093936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-SK-0629-13-CTIL|Lymphocytes Cut Off Values of Induced Sputum Samples in Healthy and Non-healthy Patients- A Cross Sectional Study|Lymphocytes Cut Off Values of Induced Sputum Samples in Healthy and Non-healthy Patients- A Cross Sectional Study||Tel-Aviv Sourasky Medical Center|No|Completed|January 2005|||January 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||4|Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People who were sent to the Pulmonology and Allergy Laboratory in the Tel Aviv sourasky        medical center between the years 2005-2012. Some had a certain occupational or        environmental exposue, some had pulmunary symptoms or diseases and some had both of the        above. They were sent in order to examine through spirometry and induced sputum tests        wheather they suffer from a pulmonary pathology.|March 2014|March 19, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093936|10 Years|48073|
NCT02093949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUBSTRATE-HD|Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation|Substrate Ablation Guided by Automatic High Density Mapping for the Treatment of Atrial Fibrillation|SUBSTRATE DH|Hospital St. Joseph, Marseille, France|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patient from 18 à 75, with AF* (paroxysmal, and persistent AF) and indication of AF        ablation (including redos)*        *In accordance with the recommendation of European Society of Cardiology (2010).|March 2014|March 21, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02093949||48072|
NCT02094443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2233|Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon|A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.|ALtitude II|Novartis|Yes|Active, not recruiting|March 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094443||48034|
NCT02067715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFS001|Effectiveness of Sealed In-office Bleaching Technique: Randomized Controlled Clinical Trial|Effectiveness of Sealed In-office Bleaching Technique: Randomized Controlled Clinical Trial||Universidade Federal de Sergipe|No|Completed|February 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|February 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067715||50084|
NCT02067728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297832|Family Nutrition Physical Activity Tool Use During Well Child Visits|Family Nutrition, Physical Activity (FNPA) Tool: a Motivational Interviewing-based Practice Intervention to Address Pediatric Health Behaviors|FNPA|University of Illinois at Chicago|Yes|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|430|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 16, 2014||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT02067728||50083|
NCT02067741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 21/12|CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer|A Phase I and Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|April 2014|June 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02067741||50082|
NCT02069171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC_GO_2012_01_2|Cross-sectional and Questionnaire Study for Leg Lymphedema|The Cross-sectional and Questionnaire Study of Pelvic and Lower Extremity Lymphedema After Treatment of Gynecological Disease||National Cancer Center, Korea|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|333|||Female|18 Years|N/A|No|Non-Probability Sample|the patient who gynecologic cancer treatment at National Cancer Center (2001~2011)|February 2014|February 19, 2014|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02069171||49972|
NCT02068820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLN Mapping|Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG|Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging||Florida Hospital|No|Recruiting|September 2012|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|85 Years|No|||February 2014|February 20, 2014|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068820||49999|
NCT02094586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-VC-200-004|A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults|A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR||PaxVax, Inc.|No|Completed|May 2014|June 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3146|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094586||48023|
NCT02094833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L31|DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T Combined Vaccine at 2, 4, and 6 Months of Age Versus Sanofi Pasteur's DTaP IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age + Hep B Vaccine at 1 and 6 Months of Age, in South Korean Infants Primed With Hep B at Birth||Sanofi|No|Active, not recruiting|March 2014|November 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|310|||Both|1 Month|6 Months|Accepts Healthy Volunteers|||February 2016|February 16, 2016|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02094833||48004|
NCT02091908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87_25|Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions|Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.||Novartis|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|540|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02091908||48227|
NCT02091427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-2-074|Circadian Variation of Cardiac Troponin|||Maastricht University Medical Center||Completed|January 2013|December 2014|Actual|June 2014|Actual|N/A|Observational|N/A||1|Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals with no evidence of active cardiovascular disease|March 2015|March 2, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02091427||48264|
NCT02092168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-105|Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects|Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects||Bial - Portela C S.A.|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 20, 2012||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT02092168||48207|
NCT02091622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intervention-sv-pall|Increasing the Number of Patients Receiving Information About Transition to End-of-life Care|Increasing the Number of Patients Receiving Information About Transition to End-of-life Care: the Effect of a Half-day Physician and Nurse Training||Umeå University|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1431|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02091622||48249|
NCT02092480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jack-001|The If I Were Jack Feasibility Trial|Increasing Boys' and Girls' Intention to Avoid Teenage Pregnancy: Feasibility Trial of an Interactive Video-drama Based Intervention in Post-primary Schools in Northern Ireland||Queen's University, Belfast|No|Recruiting|September 2014|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|630|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02092480||48183|
NCT02092740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-UKMD-URO-0023|REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg|Retrospective Analysis of Testicular Cancer Patients With Histopathological Analysis or Urological Treatment at the University Magdeburg 1960-2012.|RETESTICAPUM|University of Magdeburg|Yes|Completed|November 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2000|||Male|N/A|N/A|No|Probability Sample|Testicular cancer histopathologically diagnosed at the University Magdeburg 1960-2012|March 2014|March 20, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02092740||48163|
NCT02093026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA16855|A Study to Assess the Efficacy and Safety of Retreatment With MabThera (Rituximab) in Patients With Active Rheumatoid Arthritis (RA)|A Randomized, Open-label Study of the Effect of MabThera Retreatment on Treatment Response in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|August 2002|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|472|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093026||48141|
NCT02093312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.A03.2014|Meals on Wheels, the Effect of a Home Food-delivery Service for Cancer Patients|Meals on Wheels, a Randomized Controlled Study on the Effect of a Home Food-delivery Service for Cancer Patients|RUMLE|Copenhagen University Hospital at Herlev|Yes|Completed|March 2014|April 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|N/A|N/A|No|||September 2015|September 1, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02093312||48120|
NCT02093611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2013-CS04|Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout|Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout||Metabolic Technologies Inc.|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|42|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093611||48097|
NCT02093884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM3457|A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department|Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)|T2I|Columbia University|No|Active, not recruiting|January 2014|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|14 Years|19 Years|No|||February 2015|February 2, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093884||48077|
NCT02093897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL627_3002|Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A|A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population With Severe Hemophilia A||CSL Behring|Yes|Completed|March 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Male|N/A|11 Years|No|||September 2015|September 10, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093897||48076|
NCT02085239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13027-13-033|Comparison of Long vs. Short Acting Anesthesia for Improving Pain Management After Breast Biopsy|Comparison of Long Acting vs. Short Acting Anesthetic Agents as a Tool for Improving Pain Management Post Ultrasound Guided Breast Biopsy||TriHealth Inc.|Yes|Terminated|August 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|90 Years|No|||April 2015|August 10, 2015|March 7, 2014|Yes|Yes|PI left the organization and did not arrange for replacement PI|No||https://clinicaltrials.gov/show/NCT02085239||48739|
NCT02094196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA707/6-1|The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders|The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders (LeAD P5)|LeAD P5|Technische Universität Dresden|Yes|Enrolling by invitation|December 2012|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Bloodsample are taken for genetic analysis|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Detoxified alcohol- dependent patients and age- and gender matched healthy controls living        in Germany|February 2016|February 4, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094196||48053|
NCT02068352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-12-205|A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis|A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|94|||Both|10 Years|70 Years|No|||January 2016|January 28, 2016|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068352||50035|
NCT02068833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20839|Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study|Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study||Laval University|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|Samples Without DNA|Plasma|Both|18 Years|60 Years|No|Non-Probability Sample|The study will include patients 18 years and older with microalbuminuria        (albumin/creatinine ratio between 2.0 and 20.0 mg/mmol in men and between 2.8 and 28.0        mg/mmol in women) planned to undergo either biliopancreatic diversion with sleeve        gastrectomy or sleeve gastrectomy alone.|May 2014|May 15, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02068833||49998|
NCT02069184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-07-144|IV Acetaminophen for Acute Post Operative Pain in C-Section Patients|Double Blinded Randomized Placebo Controlled Study in Evaluating the Effectiveness of IV Acetaminophen for Acute Post Operative Pain in C-Section Patients||Montefiore Medical Center|Yes|Recruiting|November 2013|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|N/A|No|||February 2014|February 19, 2014|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069184||49971|
NCT02065089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000584|Development of 'Emma'--a Pediatric IBD Quiz|Development of an Electronic Pediatric Inflammatory Bowel Disease Quiz||Mayo Clinic|No|Not yet recruiting|December 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|10 Years|18 Years|No|||December 2015|December 31, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065089||50283|
NCT02065609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307037|89ZrTrastuzumab Breast Imaging With Positron Emission Tomography|Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab||Washington University School of Medicine|Yes|Recruiting|February 2014|||February 2019|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|52|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065609||50243|
NCT02094859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05|GlucoClearTM System ICU Study|GlucoClearTM System ICU Study||Edwards Lifesciences|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with an anticipated ICU stay of at least 24 hours.|March 2014|March 21, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094859||48002|
NCT02095184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00057786|GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients|GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients||University of Maryland|Yes|Not yet recruiting||||March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||||||Female|18 Years|N/A|No|||March 2014|March 20, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095184||47977|
NCT02091167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS CRACK CEP_UFES 384281|Bilateral Prefrontal Modulation in Crack-cocaine Addiction|Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients.|tDCS_CRACK|Federal University of Espirito Santo|No|Recruiting|November 2013|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02091167||48284|
NCT02091180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012069|Mannitol Improves Cerebral Oxygen Saturation|Effect of Preoperative Mannitol Infusion on Cerebral Oxygen Saturation and Patients' Recovery After Laparoscopic Cholecystectomy||Dammam University|No|Completed|January 2013|February 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|50 Years|No|||March 2014|March 18, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02091180||48283|
NCT02091414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20055|A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.|An Open Label Study to Evaluate the Effect of CellCept in Combination With Cyclosporine A and Steroids on Renal Function and the Prevention of Acute Rejection in Heart Transplant Patients.||Hoffmann-La Roche||Completed|August 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|March 5, 2014|No|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT02091414||48265|
NCT02091674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15882|Management of Acute Ankle Sprain With Sodium Hyaluronate|Management of Acute Ankle Sprain With Sodium Hyaluronate (AdantTM) Periarticular Injections||Lawson Health Research Institute|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02091674||48245|
NCT02091648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34HL107613|A Pilot Stress Management Intervention Study for High Risk Children With Asthma|A Pilot Stress Management Intervention for High Risk Children With Asthma||University of Pittsburgh|Yes|Completed|January 2013|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|111|||Both|8 Years|14 Years|No|||January 2016|January 4, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02091648||48247|
NCT02092467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921133|Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis|Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis||Pfizer|Yes|Recruiting|March 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|4000|||Both|50 Years|N/A|No|||March 2016|March 7, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092467||48184|
NCT02092181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBPA-2013-01|A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)|A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)|Maestro|Burdick, Daniel, M.D.|No|Recruiting|March 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|85 Years|No|||October 2015|January 11, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02092181||48206|
NCT02092493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI1|The Effect of ScopeGuide on the Mental Workload of Endoscopist|The Effect of Magnetic Endoscopic Imaging (ScopeGuide) on the Mental Workload of Endoscopists During Colonoscopy||University Hospital Southampton NHS Foundation Trust.|Yes|Not yet recruiting|April 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|244|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02092493||48182|
NCT02092753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOLIBRI|Ketogenic Or LOGI Diet In a Breast Cancer Rehabilitation Intervention (KOLIBRI)|Ketogenic Or LOGI Diet In a Breast Cancer Rehabilitation Intervention (KOLIBRI)|KOLIBRI|Universitätsmedizin Mannheim|No|Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|150|||Female|18 Years|70 Years|No|||February 2016|February 25, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02092753||48162|
NCT02093052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 74374|Intervening Early With Neglected Children|Intervening Early With Neglected Children: Key Childhood Outcomes||University of Delaware|Yes|Active, not recruiting|March 2005|April 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|220|||Both|6 Years|8 Years|No|||January 2016|January 26, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093052||48139|
NCT02093039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01|Informed Decision Users of the Health System and Participation in Organized Screening for Breast Cancer|Informed Decision Users of the Health System and Participation in Organized Screening for Breast Cancer : a Qualitative Analysis|DECIDEO|Institut de Cancérologie de la Loire|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16000|||Female|50 Years|74 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093039||48140|
NCT02093325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-4363A3|A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer|A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|March 2014|August 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|83|||Female|18 Years|N/A|No|||September 2013|September 16, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093325||48119|
NCT02093338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P025|L.Fermentum CECT5716 in Treatment of Breast Pain|Study of Intervention Nutritional, Multicenter, Randomized, Blind, Parallel Group to Evaluate the Efficacy of Lactobacillus Fermentum CECT5716 to Reduce the Load Bacterial in Potential Pathogens in Milk of Mothers With Breast Pain||Biosearch S.A.|No|Completed|July 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|127|||Female|18 Years|45 Years|No|||March 2014|March 19, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02093338||48118|
NCT02093910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM1|Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy|Phase 2 Study of Concurrent Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy in Patients of Multiple Myeloma||Sun Yat-sen University|No|Recruiting|April 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|80 Years|No|||November 2014|November 17, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02093910||48075|
NCT02085252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-LEU-002|A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer|An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer||Takeda|No|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|50 Years|80 Years|No|||October 2014|October 2, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02085252||48738|
NCT02085512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-A1-00-001337|Prevention of PTSD III: Neurocognitive Training of Emotional Regulation|Prevention of PTSD by Neurocognitive Training of Emotional Regulation||New York University School of Medicine|Yes|Withdrawn|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085512||48718|
NCT02085733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311-107|Pro-calcitonin for Early Detection of Septic Arthritis|Pro-calcitonin for Early Detection of Septic Arthritis||Children's Hospitals and Clinics of Minnesota|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|N/A|16 Years|No|Non-Probability Sample|Emergency department patients.|November 2015|November 17, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02085733||48701|
NCT02068846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0036|BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent|BK Virus in Salivary Gland Disease||University of North Carolina, Chapel Hill|No|Recruiting|February 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068846||49997|
NCT02068859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPRSpecialty-0001-CC|Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%|Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%||FPR Specialty Pharmacy|No|Recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 20, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068859||49996|
NCT02068872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00076284|Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation|Pilot Study to Assess the Feasibility, Safety and Tolerability of Sleeve Gastrectomy in Morbidly Obese Patients Undergoing Orthotopic Liver Transplantation||Northwestern University|No|Completed|February 2014|May 2015|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068872||49995|
NCT02065908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZCO-2014-BD|Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer|Circulating microRNAs as a Novel Biomarker of Early Cardiotoxicity in Breast Cancer Patients Treated With Anthracyclines||West Pomeranian Cancer Center|No|Active, not recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|5 ml of blood will be collected, 2ml of serum will be isolated from the blood and stored      below -80C till completion of the study.|Female|18 Years|70 Years|No|Non-Probability Sample|Women with newly diagnosed breast cancer that will be treated with anthracyclines will be        recruited.|July 2015|July 8, 2015|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02065908||50220|
NCT02065921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB170/06|Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort|Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort COPD-Management: Eine Klinisch-epidemiologische Verlaufsbeobachtung in Hausarztpraxen||Cantonal Hosptal, Baselland|No|Recruiting|September 2006|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|265|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed or existing COPD, who are managed in primary-care practices.|February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065921||50219|
NCT02094625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-14-00270|NAC to Prevent Cisplatin-induced Hearing Loss|A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer||Children's Hospital Los Angeles|Yes|Recruiting|March 2016|October 2019|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|21 Years|No|||March 2016|March 18, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094625||48020|
NCT02094872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 1408014446|Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic|Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma||Yale University|Yes|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094872||48001|
NCT02094885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-13-003|The Bioseal Vascular Study|A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Manual Compression as an Adjunct to Hemostasis in the Patients Undergoing Elective Vascular Surgery||Ethicon, Inc.|No|Completed|February 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094885||48000|
NCT02091661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTV55/96|Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer|Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer||University of Rome Tor Vergata|Yes|Suspended|January 1997|May 2015|Anticipated|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Male|N/A|75 Years|No|||May 2015|May 26, 2015|March 13, 2014||No|accrual too slow|No||https://clinicaltrials.gov/show/NCT02091661||48246|
NCT02092194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSG-201301|High Versus Standard Volume Hemodiafiltration in Asia|Effectiveness of High-volume Online Hemodiafiltration Compared to Standard Volume Online Hemodiafiltration. A Prospective, Multicenter, Randomized, Open-labelled Interventional Study.||Korean Hemodialysis Study Group|Yes|Not yet recruiting|April 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||March 2014|March 19, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092194||48205|
NCT02084173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCueH-Elderly|Treatment of Alcohol Problems in the Elderly|Motivational Enhancement Therapy and Community Reinforcement Approach For Treating Alcohol Problems in the Elderly||University of Southern Denmark|No|Recruiting|January 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084173||48821|
NCT02093065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-CPRS-hemophilia A|Platelet Function in Patients With Hemophilia A|Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A||Children's Hospital Boston|No|Enrolling by invitation|March 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|Samples With DNA|whole blood|Male|2 Years|18 Years|No|Non-Probability Sample|Patients with severe hemophilia A who do not have inhibitors against FVIII and who have a        bleeding history of at least 6 months.|September 2015|September 4, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093065||48138|
NCT02084394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_0007115|Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium|Non Invasive Monitoring of Cerebral Blood Flow During and After Cardiopulmonary Bypass to Assess and Compare for the Presence of Delirium in Post Operative Patients (DELIRIUM)||Johns Hopkins University|No|Completed|June 2013|February 2016|Actual|October 2015|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|110|||Both|50 Years|N/A|No|Non-Probability Sample|Subjects who are under going cardiac bypass surgery with the use of cardiac perfusion|February 2016|February 5, 2016|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02084394||48804|
NCT02093637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20120024H|Rapid Extremity Pain Relief by Battlefield Acupuncture After Orthopedic Surgery|Rapid Extremity Pain Relief by Battlefield Acupuncture After Orthopedic Surgery: A Randomized Clinical Trial||Mike O'Callaghan Federal Hospital|No|Recruiting|August 2013|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02093637||48096|
NCT02093923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-2930-02|Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects|A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects||Dyax Corp.|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093923||48074|
NCT02085551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 7051|Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery|The Prism Trial: A Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery|PRISM|Penumbra Inc.|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||November 2014|November 6, 2014|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085551||48715|
NCT02085525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.018|A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation|A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation||University of Michigan Cancer Center|Yes|Withdrawn|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 10, 2014||No|Lack of funding.|No||https://clinicaltrials.gov/show/NCT02085525||48717|
NCT02068885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00009571|Framingham State Food Study|Dietary Composition and Energy Expenditure During Weight-Loss Maintenance|(FS)2|Children's Hospital Boston|No|Recruiting|February 2014|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 16, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02068885||49994|
NCT02095873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJT_HATFF|Healthy Aging Through Functional Food|Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.|HATFF|University of Warwick|Yes|Completed|May 2014|May 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02095873||47925|
NCT02065362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33954: RESIST-NPC|TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC|Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)||Baylor College of Medicine|Yes|Recruiting|February 2015|February 2033|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|N/A|No|||February 2016|February 26, 2016|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065362||50262|
NCT02065622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-033|Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis|A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis||AbbVie|No|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|605|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065622||50242|
NCT02096367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBR-AVC|Immediate Effect of Postural Muscle's Vibrations on Gait in Chronic Vascular Hemiplegia|Immediate Effect of Cervical Posterior Muscles' and Gluteus Medius Muscle's Vibrations on Gait in Chronic Vascular Hemiplegia|VIBR-AVC|Rennes University Hospital|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02096367||47887|
NCT02096640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1136-31/2|Postoperative Inflammation and Recovery After Tracheostomy|Randomized Controlled Trial on the Effect of Percutaneous Dilatation Tracheostomy Compared to Open Surgical Tracheostomy on Postoperative Inflammation, Pulmonary Function, Peri- and Postoperative Complications and Physical Mobilization.||Sormland County Council, Sweden|No|Not yet recruiting|March 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2014|March 23, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02096640||47866|
NCT02096913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibuprofen-SCI-Safety|Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury|The Rho-Inhibitor Ibuprofen for the Treatment of Acute Spinal Cord Injury: Investigation of Safety, Feasibility and Pharmacokinetics||Charite University, Berlin, Germany|Yes|Recruiting|June 2013|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096913||47846|
NCT02095223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130868|Effect of Electromyographic Biofeedback on Quadriceps Neuromuscular Function in Patients With Quadriceps Inhibition|Effect of Electromyographic Biofeedback on Quadriceps Neuromuscular Function||University of Miami|No|Terminated|December 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|40 Years|No|||September 2015|September 28, 2015|March 20, 2014|Yes|Yes|Difficulties with participant recruitment.|No||https://clinicaltrials.gov/show/NCT02095223||47974|
NCT02091388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03004 MD|Bioavailability of LY03004 and Risperdal® Consta®|A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder||Luye Pharma Group Ltd.|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||March 2015|March 3, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091388||48267|
NCT02091401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4002|A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen|A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen||Gynuity Health Projects|Yes|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|No|||February 2016|February 8, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091401||48266|
NCT02091440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW005/ Japan|Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan|Clinical Evaluation of the HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure|HW005|HeartWare, Inc.|No|Active, not recruiting|March 2014|October 2016|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|65 Years|No|||March 2016|March 22, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091440||48263|
NCT02091453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APT 1&2|Early Training of Attention After Acquired Brain Injury|The Protocol and Design of a Randomized Controlled Study on Attention Training in First Year After Acquired Brain Injury||Karolinska Institutet|No|Completed|January 2009|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|60 Years|No|||September 2015|September 2, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02091453||48262|
NCT02083341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVT-01|Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained Singers|Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained Singers||St. Michael's Hospital, Toronto|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083341||48885|
NCT02091921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00068//ISSBRIL0198|Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study|Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study|STT-CLIPS|University of Southern California|Yes|Recruiting|February 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091921||48226|
NCT02091934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford IRB #29233|Wavefront-guided PRK vs Wavefront-optimized PRK|A Prospective, Randomized Comparison of Fellow Eyes Undergoing Wavefront-guided PRK Versus Wavefront-optimized PRK Using the Alcon Allegretto Eye-Q 400 Excimer Laser||Stanford University|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|March 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091934||48225|
NCT02091947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010015OB|Efficacy of Functional Magnetic Stimulation in Urinary Incontinence|Efficacy of Functional Magnetic Stimulation in Urinary Incontinence|FMS|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|November 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||March 2014|March 17, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091947||48224|
NCT02092207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL7016_201|Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome||KT&G Life Sciences Corp|No|Completed|October 2012|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|147|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092207||48204|
NCT02092220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter Study|A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas|A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas||Massachusetts General Hospital|Yes|Active, not recruiting|April 2014|December 2015|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092220||48203|
NCT02083926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310012947|Ketamine Infusion for Social Anxiety Disorder|Ketamine Infusion for Social Anxiety Disorder||Yale University|No|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083926||48840|
NCT02084186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81303033|Moxibustion for Mild and Moderate Ulcerative Colitis|The Mechanism of Moxibustion in Treating Ulcerative Colitis Based on Metabonomics||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Recruiting|March 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084186||48820|
NCT02083627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-CL-2003|A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects|A Phase 1, Open Label, Randomized, Two-way Crossover Study to Evaluate the Effect of Multiple Doses of Fidaxomicin on the Single Dose Pharmacokinetics of Rosuvastatin in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083627||48863|
NCT02083640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481040|Relative Bioavailability For Palbociclib Formulations|A Phase 1, Open-Label, 6 Sequence, 3 Period, Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Relative Bioavailability Of 3 Palbociclib Formulations||Pfizer|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083640||48862|
NCT02083900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH (TRB) 2005-002|Use of Banana Leaf Dressing on Donor Site Wounds|Use of Banana Leaf Dressing on Donor Site Wounds: A Prospective Randomized Control Study||University of the Philippines|Yes|Active, not recruiting|October 2006|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|40 Years|No|||March 2014|March 6, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02083900||48842|
NCT02084160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIS-FU-EX-1213|Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation|The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis||Exalenz Bioscience LTD.|No|Recruiting|March 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|414|||Both|18 Years|N/A|No|Probability Sample|Chronic liver disease subjects from previous Exalenz trial "HIS-EX-408"|January 2016|January 20, 2016|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084160||48822|
NCT02084693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GE1|COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.||Biomet, Inc.|Yes|Active, not recruiting|December 2013|October 2019|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|60 Years|85 Years|No|Non-Probability Sample|Therefore, patients / cases to be included in this study shall utilize the following        inclusion criteria:          1. The patient must be anatomically and structurally suited to receive the implants and             a functional deltoid muscle is necessary.          2. Grossly deficient rotator cuff with severe arthropathy and/or               -  Previously failed shoulder joint replacement with a grossly deficient rotator                  cuff.               -  Primary total shoulder replacement for the relief of pain and significant                  disability due to gross rotator cuff deficiency, or               -  Fracture total shoulder replacement for the relief of pain and significant                  disability due to gross rotator cuff deficiency, or               -  Revision total shoulder replacement for the relief of pain and significant                  disability due to gross rotator cuff deficiency.|November 2015|November 9, 2015|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084693||48781|
NCT02084940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM002|Long Acting GnRH Antagonist in PCOS Women Undergoing IVF|The Use of a Long Acting GnRH Antagonist (Degarelix) in Controlled Ovarian Hyperstimulation in PCOS Women at a Risk to Developing OHSS Undergoing IVF : a Pilot Study||Bioroma|No|Recruiting|March 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|23 Years|37 Years|No|Non-Probability Sample|Women with PCOS with a previous IVF attempt cancelled due to the risk of OHSS|March 2014|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084940||48762|
NCT02084953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-112|Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects|A Randomized, Double-Blinded, Positive-Controlled, Placebo-Controlled, 3-Way Crossover Study to Determine the Electrocardiographic Effects of BMS-791325 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|59|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|March 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084953||48761|
NCT02085785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F6982-Wa|Weight Loss Intervention for Individuals With Lower Extremity Amputation|Home-based Weight Loss Intervention for Individuals With Lower Extremity Amputation|MOVE-LEAP|VA Office of Research and Development|No|Active, not recruiting|February 2014|June 2018|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|69 Years|No|||December 2015|December 22, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02085785||48697|
NCT02085772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WENDREMAIRE APJ 2013|Leukocytes - ObeSity - Spontaneous Labour|Is Impaired Activation and Migration of Circulating Leukocytes Associated With Overdue Birth in Obese Women?|LOST|Centre Hospitalier Universitaire Dijon||Recruiting|February 2014|||February 2016|Anticipated|N/A|Interventional|N/A|1||Anticipated|60|||Female|18 Years|N/A|No|||July 2013|March 11, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02085772||48698|
NCT02094924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200957|A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323|An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094924||47997|
NCT02094937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201135|A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects|201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR® Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects||GlaxoSmithKline|No|Completed|March 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|430|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094937||47996|
NCT02095236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The ESMERALDA Trial|Evaluation of Intrafractional Motion of Liver Tumors Using Markers|Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial|ESMERALDA|University Hospital Heidelberg|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02095236||47973|
NCT02091206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1332 Part A|A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome|A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome||GW Research Ltd|Yes|Completed|October 2014|November 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|34|||Both|4 Years|10 Years|No|||February 2016|February 15, 2016|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091206||48281|
NCT02082821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pure-Heart-1|A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy|Pure-Heart-1: A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy||Children's Hospital Boston|No|Active, not recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Peripheral blood mononulcear cells|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the CTOT-05 cohort of cardiac transplant recipients will be stratified        according to the genotype (P2X7R+/+, P2X7R+/- and P2X7R-/-) and compared for the        development of CAV|March 2014|March 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02082821||48924|
NCT02083107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9021344|Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss|COMPARISON BETWEEN RECTAL & SUBLINGUAL MISOPROSTOL BEFORE CAESARIAN SECTION TO REDUCE INTRA & POST-OPERATIVE BLOOD LOSS||Ain Shams University|Yes|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|636|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||November 2015|November 22, 2015|March 7, 2014|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT02083107||48903|
NCT02083380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_13_003|Phase IIb Study to Investigate the Efficacy of OZ439 & Piperaquine Phosphate Co-administered to Adults & Children With Uncomplicated Plasmodium Falciparum.|A Randomised, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine Phosphate in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.||Medicines for Malaria Venture|Yes|Completed|July 2014|November 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|438|||Both|6 Months|70 Years|No|||November 2015|November 11, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083380||48882|
NCT02091960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-1121|A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer|A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer||Astellas Pharma Inc|No|Recruiting|August 2014|November 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091960||48223|
NCT02091973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWC-004|MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation|MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Maintenance Immunosuppressive Regimens in Kidney Transplantation||Chulalongkorn University|No|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||March 2014|March 18, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02091973||48222|
NCT02083913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-209|Prebariatric Surgery Physical Exercise Training in Telehealth|Feasibility and Impacts of a Prebariatric Surgery Exercise Training in Telehealth: a Pilot Study|TelePreSET|Université de Sherbrooke|No|Active, not recruiting|February 2014|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|6|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083913||48841|
NCT02084446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR25T|Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant|Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study||Hospital Geral de Fortaleza|No|Active, not recruiting|December 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2015|March 18, 2015|December 7, 2012||No||No||https://clinicaltrials.gov/show/NCT02084446||48800|
NCT02084407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM1-Fibroblasts|Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients|Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients||Institut de Myologie, France|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2014|September 25, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02084407||48803|
NCT02084420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY-81149-HB03|Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment|PhaseⅢ Study of A Multicenter, Randomized, Double-blind, Active-controlled to Evaluate of Efficacy /Safety as H. Pylori Eradication Effect Between Ilaprazole/Pantoprazole||Il-Yang Pharm. Co., Ltd.|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084420||48802|
NCT02084719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care|||Centre hospitalier de l'Université de Montréal (CHUM)|No|Active, not recruiting|March 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|67|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084719||48779|
NCT02084706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002370|Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection|Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection|J-tip|Brigham and Women's Hospital|Yes|Active, not recruiting|March 2014|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|128|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084706||48780|
NCT02084966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK094877|Non-Invasive Evaluation of Transplant Kidney Using OCT|Non-Invasive Evaluation of Transplant Kidney Using OCT||Georgetown University|Yes|Recruiting|April 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 9, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02084966||48760|
NCT02084979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522696-1|A Controlled Trial of Patient Centered Telepsychiatry Interventions|A Controlled Trial of Patient Centered Telepsychiatry Interventions||University of California, Davis|Yes|Enrolling by invitation|April 2014|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084979||48759|
NCT02085577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-RS-2014|The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients|The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients||Rigshospitalet, Denmark|No|Active, not recruiting|May 2014|October 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||October 2015|October 29, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085577||48713|
NCT02086123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2011-8564|Randomized Study Comparing the Use of Epidural Analgesia to Intravenous Narcotics for Laparoscopic Colorectal Resection.|Randomized Clinical Trial Comparing the Use of Perioperative Epidural Analgesia to Conventional Intravenous Narcotics and NSAIDS for Patients Undergoing Laparoscopic Colorectal Resection||University of California, Irvine|No|Active, not recruiting|May 2012|April 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|87|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02086123||48671|
NCT02085798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-CELGENE-SP-006|Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)|Post-authorization, Observational Study to Assess the Evolution in the Normal Clinical Practise of Patients With Recent Diagnosis of Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Depending on the Time of Active Treatment Initiated||Celgene|No|Active, not recruiting|February 2013|August 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|503|||Both|18 Years|N/A|No|Non-Probability Sample|Patients recently diagnosed (within the last 3 months prior to entering the study) of SMD        or CMML, naïve to active treatment.|October 2015|October 15, 2015|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085798||48696|
NCT02096380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSHNG-1110|The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma||First People's Hospital of Foshan|Yes|Not yet recruiting|May 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|60 Years|No|Probability Sample|Patients diagnosed with locoregionally advanced nasopharyngeal carcinoma and agree to        receive anti-cancer treatment in our hospital|March 2014|March 22, 2014|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT02096380|3 Years|47886|
NCT02096666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120370|A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects|A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects||Amgen|No|Active, not recruiting|April 2014|May 2016|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096666||47864|
NCT02096133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200109_635|Vitamin D3 and the Stress-axis in MS|Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study||Academic MS Center Limburg|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|80|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096133||47905|
NCT02096146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT Fusion Plate|TMT Fusion Plate vs. Two Crossed Screws|TMT Fusion Plate vs. Two Crossed Screws - A Randomized Controlled Trial|TMT|AO Clinical Investigation and Documentation|No|Terminated|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|March 21, 2014||No|Lack of enrolment|No||https://clinicaltrials.gov/show/NCT02096146||47904|
NCT02095249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 13-7172-C|Prostate Hypoxia - TIC|Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer||University Health Network, Toronto|No|Recruiting|September 2014|||March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02095249||47972|
NCT02091193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02-34-334|Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus||Danbury Hospital||Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|Samples Without DNA|Only serum is retained and is discarded after specified assays are completed. No analysis      requires genetic information.|Both|18 Years|N/A|No|Probability Sample|The groups are selected from primary care offices, a diabetes and endocrine office, as        well as self-referrals and medical record confirmed cases of Type 2 Diabetes Mellitus.|March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091193||48282|
NCT02083081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008824|Community Intervention to Reduce Tobacco Use in Pregnant Women|Community Intervention to Reduce Tobacco Use Among Alaska Native Pregnant Women|Sisters|Mayo Clinic|No|Recruiting|May 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083081||48904|
NCT02083120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRVOhome|Efficacy and Physiology of Nasal High Flow Therapy|Efficacy and Physiology of Nasal High Flow Therapy (AIRVO2™, Fisher&Paykel) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Hypercapnic Respiratory Failure||Institut für Pneumologie Hagen Ambrock eV|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||February 2016|February 24, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083120||48902|
NCT02083393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoutheastUChina2011ZDllKY04|Changes of Dendritic Cells in Acute Lung Injury|Changes of Dendritic Cells in Acute Lung Injury||Southeast University, China|Yes|Completed|June 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Sepsis induced-ALI patients with mechanical ventilation including invasive aspergillosis|May 2015|May 26, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT02083393||48881|
NCT02083406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_13_007|Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)|Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects||Medicines for Malaria Venture|No|Completed|July 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 7, 2014|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT02083406||48880|
NCT02083653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200637-002|Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer|Open-label,Randomized,Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies||Symphogen A/S|Yes|Active, not recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|254|||Both|18 Years|N/A|No|||July 2015|October 29, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083653||48861|
NCT02083666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOBI002-001|Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers||Swedish Orphan Biovitrum|No|Terminated|December 2013|February 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|January 15, 2014||No|Transient adverse events observed|No||https://clinicaltrials.gov/show/NCT02083666||48860|
NCT02083679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200637-003|Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer|A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer||EMD Serono|Yes|Completed|May 2014|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083679||48859|
NCT02084433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75018|Comparison of Intraosseous Anaesthesia Using a Computerized System (QuickSleeper) to Conventional Anesthesia|Comparison of Intraosseous Anaesthesia Using a Computerized System (QuickSleeper) to Conventional Anesthesia|QUICK|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||April 2015|April 3, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02084433||48801|
NCT02085005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS13787|Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer|Phase II Study of First-line Capecitabine Plus Oxaliplatin Plus Aflibercept for 6 Cycles Followed by Capecitabine Plus Aflibercept as Maintenance Therapy in Patients With Metastatic Colorectal Cancer: DROP and GO Trial|Drop and Go|Sanofi|No|Withdrawn|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085005||48757|
NCT02084758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR-47701|Nitrate Supplementation in Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Dietary Nitrate Supplementation on Metabolic Efficiency in Patients With COPD||Maastricht University Medical Center|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02084758||48776|
NCT02084992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verizon2014|A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure|A Multicenter Randomized Controlled Evaluation of Heart Failure Disease Management Using Advanced Telecommunications Within a Diverse Provider Network: The Specialized Primary and Networked Care in HF (SPAN-CHF) III Trial|Span-CHF III|Tufts Medical Center|No|Recruiting|June 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|233|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084992||48758|
NCT02085265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARTAN-AD-001|Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients|The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients|SARTAN-AD|Sunnybrook Health Sciences Centre|No|Recruiting|March 2014|August 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|55 Years|N/A|No|||December 2015|December 21, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02085265||48737|
NCT02085538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481014|Study Of Palbociclib (PD-0332991) In Renal Impairment|A Phase 1, Open-Label, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Palbociclib (PD-0332991) In Subjects With Impaired Renal Function||Pfizer|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|28|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085538||48716|
NCT02092597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-282521-CUNI|Safety Evaluation of Adverse Reactions in Diabetes||SAFEGUARD|Charles University, Czech Republic||Recruiting|October 2013|March 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|35 Years|70 Years|No|||July 2015|July 27, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02092597||48174|
NCT02092610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAS5562|Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System|Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System||Cochlear Bone Anchored Solutions|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|N/A|N/A|No|||January 2016|January 12, 2016|March 14, 2014||No||No|October 26, 2015|https://clinicaltrials.gov/show/NCT02092610||48173|
NCT02085811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THOUANT-RICOLFI AOI 2012|Screening for Kyphosis in the Mean Term in Patients Treated With Kyphoplasty Alone in the Management of Stable Traumatic Compression Fractures of the Thoracolumbar Spine|Screening for Kyphosis in the Mean Term in Patients Treated With Kyphoplasty Alone in the Management of Stable Traumatic Compression Fractures of the Thoracolumbar Spine|KIPHO|Centre Hospitalier Universitaire Dijon||Recruiting|June 2013|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone kyphoplasty|June 2013|March 12, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02085811||48695|
NCT02066194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2011.324|Electroacupuncture Analgesia for EUS: a Randomized Controlled Trial|Electroacupuncture Analgesia for Endoscopic Ultrasound (EUS): a Prospective, Randomized, Double-blinded, Sham-controlled Study||Chinese University of Hong Kong|Yes|Recruiting|February 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|80 Years|No|||August 2014|August 19, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02066194||50199|
NCT02096679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00011|Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers|A Phase I, Single-centre, Non-Randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD9291 in Healthy Male Volunteers||AstraZeneca|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 24, 2014||No||No|July 2, 2015|https://clinicaltrials.gov/show/NCT02096679||47863|
NCT02096952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000501|Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD|Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder||Massachusetts General Hospital|No|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|40 Years|No|||February 2016|February 26, 2016|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02096952||47843|
NCT02094963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-14|Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management|A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial|TICA KOREA|Asan Medical Center|Yes|Recruiting|July 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02094963||47994|
NCT02095262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11IH001|Auditory Games for Tinnitus Benefit|Auditory Games for Tinnitus Benefit: Interactive Versus Reactive Auditory Discrimination Games|TAG|Nottingham University Hospitals NHS Trust|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02095262||47971|
NCT02082561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Florida State University|False Safety Behavior Elimination Therapy: A Randomized Study of a Brief Individual Transdiagnostic Treatment for Anxiety Disorders|||Florida State University|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082561||48944|
NCT02083419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300694|Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy|Study of the Effects of Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy||University of Florida|No|Enrolling by invitation|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083419||48879|
NCT02083718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-PBSC-MSC-2014|Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function|G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|65 Years|No|||March 2014|March 8, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02083718||48856|
NCT02083354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200104|Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Melanoma|An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous or Cutaneous Melanoma||GlaxoSmithKline|No|Recruiting|March 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083354||48884|
NCT02083367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF-14-001|Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome|Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome||OSF Healthcare System|No|Completed|January 2013|February 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community Hospital Gastroenterology Clinic.|May 2015|May 21, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083367||48883|
NCT02083952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131959|Impact of Swaddle Blanket on Gastroesophageal Reflux|Impact of Swaddle Blanket on Gastroesophageal Reflux||Valley Health System|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|180 Days|No|||January 2015|January 19, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083952||48838|
NCT02091024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVCM-HL-SEAPOLYNOL|Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava|Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava Extract in Hypercholesterolemic Korean Subjects: a Randomized Double-blind, Placebo-controlled Clinical Trial||Chonbuk National University Hospital|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091024||48295|
NCT02084199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-106|Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects|Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects||Galapagos NV|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|24|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084199||48819|
NCT02084212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAICO-MUSELIER AOI 2011|Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery|Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery||Centre Hospitalier Universitaire Dijon||Recruiting|March 2013|||August 2015|Anticipated|N/A|Interventional|N/A|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2012|March 7, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02084212||48818|
NCT02084225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB0001|Ultrasound Guided Regional Anesthesia for Acute Injury in Low Resource Settings|Feasibility, Perceived Utility and Sustainability of Using Ultrasound-guided Regional Anesthesia by Local Providers in a Limited Resource Conflict Setting||Salmon, Margaret, M.D.|No|Active, not recruiting|January 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Participants include medical doctors and orthopedic or trauma nurses (officers) who staff        the emergency department and/or orthopedic procedure area where acute injuries are        treated.|March 2014|March 19, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084225||48817|
NCT02084732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410-30610-258|Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study|Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study||Instituto Nacional de Cancerologia, Columbia|Yes|Recruiting|October 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084732||48778|
NCT02084745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE13.277|Timing of Glaucoma Drainage Device With Boston KPro Surgery|Timing of Glaucoma Drainage Device Implantation With Boston Keratoprosthesis Surgery|GDD-KPro|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02084745||48777|
NCT02084771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI-1777|Oral Salt and Water to Prevent Contrast Nephropathy|The Prevention of Acute Kidney Injury Following Contrast-Enhanced Computed Tomography: A Pilot Trial of Oral Fluid Versus Intravenous Saline||Ottawa Hospital Research Institute|Yes|Recruiting|October 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02084771||48775|
NCT02085278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL01|Safety of Apollo Micro Catheter in Pediatric Patients|Safety of Apollo Embolization Delivery Micro Catheter in Pediatric Patients With Vascular Malformations||St. Luke's-Roosevelt Hospital Center|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|21 Years|No|||August 2015|August 5, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085278||48736|
NCT02085564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050314-Rstrandby1|Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer|Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer||Rigshospitalet, Denmark|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|Samples With DNA|100ml of peritoneal washings will be obtained pr. patients x 2. The first at the staging      laparoscopy, and the second initially before esophagectomy. The specimen will be analyzed      for any malignant cancer cells by an authorized pathologist. Afterwards, the specimen will      be destroyed.|Both|18 Years|N/A|No|Probability Sample|Patients with biopsy verified GEJ-cancer referred from peripheral hospitals in the region        of Sjælland and the Capitol.        (The treatment of GEJ-cancer is centered at Rigshospitalet. All of our patients are        referred from other hospitals)|June 2015|June 1, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085564||48714|
NCT02085291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ZDllKY03.1|Targeting the Microcirculation in Resuscitation of Patients With Septic Shock|Targeting the Microcirculation in Resuscitation of Patients With Septic Shock||Southeast University, China|Yes|Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02085291||48735|
NCT02092883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25QNC|Evaluation of Neuroinflammation in Children With Infantile Spasms|Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH||Wayne State University||Recruiting|March 2013|||July 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|N/A|N/A|No|||January 2016|January 6, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092883||48152|
NCT02092896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002526-67|Liraglutide as add-on to Insulin in Type 1 Diabetes|Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia|T1DMLIRA|Hvidovre University Hospital|Yes|Completed|March 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|70 Years|No|||March 2015|March 31, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02092896||48151|
NCT02092857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005583|Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants|Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants||University of Alberta||Completed|December 2009|February 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|89|||Both|N/A|21 Days|Accepts Healthy Volunteers|||March 2014|March 24, 2014|March 18, 2014||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT02092857||48154|
NCT02092870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Adipose Derived Regenerative Cellular Therapy of Chronic Wounds|Adipose Derived Regenerative Cellular Therapy of Chronic Wounds||Tower Outpatient Surgical Center|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02092870||48153|
NCT02066818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECUEM-Synera|Injectable Lidocaine Versus Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses|Injectable Lidocaine Provides Similar Analgesia Compared to Transdermal Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses: A Randomized Controlled Trial||East Carolina University|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|November 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066818||50152|
NCT02066831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS|Diabetes Coaching Study|Diabetes Coaching Study|DCS|West German Center of Diabetes and Health|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|202|||Both|25 Years|79 Years|No|||February 2016|February 22, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066831||50151|
NCT02066480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 086-13|Improved Screening for Osteoporosis|Improved Screening for Osteoporosis in Women Between 50 and 80 Years Hospitalized in Hospital Departmental Vendee|ADOV|Centre Hospitalier Departemental Vendee|No|Completed|March 2014|May 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3226|||Female|50 Years|80 Years|No|Non-Probability Sample|women between 50 and 80 years hospitalized CHD Vendée|December 2014|May 18, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066480||50177|
NCT02066493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Giant|Giant Intracranial Aneurysm Registry|Giant Intracranial Aneurysm Registry||Charite University, Berlin, Germany|Yes|Recruiting|December 2008|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|February 2014|February 18, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066493|5 Years|50176|
NCT02086591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50370|A Phase II Study of Doxycycline in Relapsed NHL|A Phase II Study of Doxycycline in Relapsed NHL||University of Rochester|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086591||48635|
NCT02086604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404056|Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma||Washington University School of Medicine|No|Recruiting|September 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02086604||48634|
NCT02082548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049709|Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation|An International Multicenter Clustered Randomized Controlled Trial to imProve Treatment With AntiCoagulanTs in Patients With Atrial Fibrillation.|IMPACT-AF|Duke University|Yes|Enrolling by invitation|June 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082548||48945|
NCT02082808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102|Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects|A Phase 1, Open-Label, Crossover Study to Evaluate the Drug Interaction Between Dolutegravir and Daclatasvir in Healthy Adult Subjects||ViiV Healthcare|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02082808||48925|
NCT02082834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0184|Post EVAR Endoleak Detection : Model-based Iterative Reconstruction (MBIR) vs Adaptive Statistical Iterative Reconstruction (ASIR) CTA; a Prospective Study|Post EVAR Endoleak Detection : Model-based Iterative Reconstruction (MBIR) vs Adaptive Statistical Iterative Reconstruction (ASIR) CTA; a Prospective Study||University Hospital, Clermont-Ferrand||Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|90|||Both|18 Years|90 Years|No|||March 2014|March 6, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02082834||48923|
NCT02082847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2013-07-SEN-PROSF-PS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2013|||||N/A|N/A|N/A||||||||||||||March 6, 2014|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082847||48922|
NCT02094768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM7267|Soda and Milk Study|Effects of Replacing Sugar Sweetened Beverages With Milk on Metabolic Factors in Overweight and Obese Adolescents|SAMS|Children's Hospital & Research Center Oakland|No|Recruiting|April 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Male|13 Years|18 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094768||48009|
NCT02083692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.458|Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling|Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.||Thomas Jefferson University|Yes|Recruiting|September 2013|||September 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083692||48858|
NCT02083705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034524_CC|Chest Compression and Sustained Inflation|Chest Compression and Sustained Inflation for Asystole or Bradycardia in Newborn Infants||University of Alberta|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|3 Months|No|||March 2014|December 31, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02083705||48857|
NCT02083939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9550-DR-CTIL|Prophylactic Antibiotic Treatment for Laparoscopic Inguinal Hernia Mesh Repair: Necessary or Not?|Prophylactic Antibiotic Treatment for Laparoscopic Inguinal Hernia Mesh Repair: Necessary or Not?||Sheba Medical Center|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|100 patients undergoing elective hernia repair will be assigned randomly to the control        group; 100 patients will be assigned to the treatment group.|November 2015|November 21, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02083939||48839|
NCT02091037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5956|S. Aureus Colonization in Atopic Dermatitis|Staphylococcus Aureus Colonization in Atopic Dermatitis||Columbia University|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|114|Samples Without DNA|Skin culture specimens are retained|Both|N/A|18 Years|No|Non-Probability Sample|Subjects will be recruited from the pediatric dermatology faculty practices and resident        clinics at CUMC as well as from the units of the Morgan Stanley Children's Hospital of New        York. As per CUMC policy, the investigators will not directly approach potential subjects        until the subject's physician has ascertained and documented that their patient is willing        to discuss the research with the investigators.|January 2016|January 31, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091037||48294|
NCT02091271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903335|Screening Protocol to Evaluate Volunteers for NIA Approved Studies|Screening Protocol to Evaluate Volunteers for NIA Approved Studies||National Institutes of Health Clinical Center (CC)||Recruiting|October 2003|December 2018||December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 17, 2015|September 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02091271||48276|
NCT02084459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEH201300702085|Guided Self-determination in the Treatment of Chronic Pain to Promote the Life Skills of the Patient|The Use of Guided Self-determination in the Treatment of Chronic Pain Patients Will Increase Life Skills and Thereby Life Quality of the Chronic Pain Patient|GSD|Herlev Hospital|No|Recruiting|February 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02084459||48799|
NCT02091752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2407|A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)|The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.||Novartis|No|Terminated|September 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 6, 2014||No|The study was terminated due to low enrollment.|No|January 5, 2016|https://clinicaltrials.gov/show/NCT02091752||48239|
NCT02085018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAFIPF001|Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)|A Randomised, Placebo-controlled Trial of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)|PPIPF|Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|85 Years|No|||October 2015|October 8, 2015|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02085018||48756|
NCT02092311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMV|Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy|Assessing Post-operative Rates of Recurrence, Hydrocele and Testicular Atrophy in Patients Operated With a New Approach of Varicocelectomy Named Combined Mini-incision Microscopic Varicocelectomy (CMMV)|CMMV|Omid Fertility Center|No|Completed|January 2006|June 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|570|||Male|N/A|N/A|No|||June 2015|June 7, 2015|March 18, 2014||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT02092311||48196|
NCT02093195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCOPD-2014226|Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients|Phase Ⅱ Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients|BTCOPD|Fourth Military Medical University|Yes|Recruiting|December 2013|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||March 2014|March 18, 2014|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093195||48128|
NCT02093221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1302|Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus|A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus||Grifols Therapeutics Inc.|Yes|Active, not recruiting|March 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|76|||Both|6 Years|35 Years|No|||February 2016|February 10, 2016|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093221||48127|
NCT02093182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-007|An Innovative Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm|A Retrospective, Open-Label, Non-Randomized, Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Vasospasm Patients After Sub Arachnoid Hemorrhage||HeadSense Medical|No|Not yet recruiting|April 2014|November 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|SAH patients with an expected TCD test|March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093182||48129|
NCT02067091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2006|Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct|Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)|BVS in STEMI|Haukeland University Hospital|Yes|Recruiting|August 2014|August 2020|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02067091||50132|
NCT02067078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005010-36|Protracted Effect of Combined Nerve Blocks After Total Knee Arthroplasty|The Effect of Protracted Saphenous Nerve and Obturator Nerve Block Versus Saphenous Nerve Block Versus Local Infiltration Analgesia on Opioid Consumption, Pain, Block Duration of Action and Mobilization After Total Knee Arthroplasty.|Hobsali|Regionshospitalet Silkeborg|Yes|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|50 Years|N/A|No|||February 2015|February 3, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02067078||50133|
NCT02067377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000027289|Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD|A Randomized, Double Blinded, Placebo-controlled Pilot Study of Serum Bovine Immunoglobulin (SBI) for Cachexia in Patients With Advanced COPD|SBI for COPD|Medical University of South Carolina|No|Recruiting|December 2013|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|30 Years|80 Years|No|||August 2013|February 18, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02067377||50110|
NCT02086357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD13/10834|Investigation of Ultrasound Elastographic Techniques in Soft Tissue Pathology|||The Leeds Teaching Hospitals NHS Trust||Recruiting|July 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|16 Years|N/A|No|Non-Probability Sample|Musculoskeletal US department at Chapel Allerton Hospital|February 2015|February 19, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02086357||48653|
NCT02086617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-CAD-04|Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease||North Karelia Central Hospital|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Primary Purpose: Screening|1||||||Male|50 Years|N/A|No|||June 2014|June 25, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086617||48633|
NCT02083146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD(CTRP)|C1q/TNF-related Proteins in Coronary Artery Disease|||Korea University|Yes|Recruiting|September 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The subjects with stable angina or a history of acute coronary syndrome who visited for a        department of cardiology in Korea Univ. Guro hospital were enrolled using predefined        inclusion and exclusion criteria.|April 2014|April 28, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083146||48900|
NCT02094261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00002|Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours|Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive|AURA2|AstraZeneca|No|Active, not recruiting|May 2014|October 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|472|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02094261||48048|
NCT02094508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914073|Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda|Impact of Trimethoprim-sulfamethoxazole Prophylaxis on Malaria Infection and Immunity in Children in Uganda||National Institutes of Health Clinical Center (CC)||Completed|March 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||December 2015|December 30, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094508||48029|
NCT02094521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9926-4047|Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects|Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02094521||48028|
NCT02094781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200616|Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in Weight-training Adult Males|A Randomized, Double-blind, Placebo-controlled, Three-arm Trial to Evaluate the Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in Weight-training Adult Males||GlaxoSmithKline|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02094781||48008|
NCT02083965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997HA307|Pharmacokinetics of rFVIIIFc at Two Vial Strengths|A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A||Biogen|No|Completed|March 2014|May 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Male|12 Years|N/A|No|||August 2015|August 14, 2015|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083965||48837|
NCT02095041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOST|Trends In Oxygen Saturation In Healthy Term Infants In The First Few Days Of Life: The "TOST" Study|||University of Calgary|No|Recruiting|March 2014|||June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|625|||Both|N/A|8 Weeks|No|Non-Probability Sample|Helathy Term infants in the post partum unit .|March 2014|March 23, 2014|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02095041||47988|
NCT02095054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0833|Regorafenib and Cetuximab in Patients With Advanced Malignancy|A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Recruiting|March 2014|||March 2023|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095054||47987|
NCT02091518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-239|Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods|Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|March 2014|||March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02091518||48257|
NCT02091531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-143|Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients|A Phase 2 Study of the Dual mTOR Inhibitor MLN0128 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)||Memorial Sloan Kettering Cancer Center||Terminated|March 2014|||November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||November 2015|November 18, 2015|March 14, 2014|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT02091531||48256|
NCT02091505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKONDO-CRVO|Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO|Predictive Factors of Treatment Outcome After Intravitreal Injection of Lucentis (Ranibizumab) in Eyes With Macular Edema Associated With Central Retinal Vein Occlusion (CRVO)|CRVO|Mie University|No|Recruiting|December 2013|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|80 Years|No|||March 2014|March 17, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02091505||48258|
NCT02092064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Basal Proteinuria in FMF|Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Not yet recruiting|April 2014|April 2015|Anticipated|October 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|40|None Retained|maternal ürine protein level|Female|18 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|pregnant patients with FMF|March 2014|March 18, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092064|8 Months|48215|
NCT02092051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMMDI|CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections|A Randomized Trial of the Effect of Continuous Glucose Monitoring (CGM) in Individuals With Type 1 Diabetes Treated With Multiple Daily Insulin Injections (MDI)||Vastra Gotaland Region|Yes|Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092051||48216|
NCT02092623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/180/2010|Single Incision Transvaginal Mesh in Treatment of Posterior Vaginal Wall Prolapse|Single Incision Transvaginal Mesh (Elevate® Posterior) in Treatment of Posterior Vaginal Wall Prolapse Without Concurrent Surgery - National Prospective Multicenter Study||Turku University Hospital|No|Completed|September 2010|December 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Female|30 Years|90 Years|No|||May 2015|May 26, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092623||48172|
NCT02093533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE|Eculizumab in Primary MPGN|EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA|EAGLE|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|75 Years|No|||April 2015|April 8, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093533||48103|
NCT02066506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080609|Study of Adaptation of the Right Ventricle to Systemic Afterload|Study of Adaptation of the Right Ventricle to Systemic Afterload|STARS|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|March 31, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02066506||50175|
NCT02067403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-363|A Diaphragmatic Electrical Activity Based Optimization Strategy During Pressure Support Ventilation|A Diaphragmatic Electrical Activity Based Optimization Strategy During Pressure Support Ventilation. Effects on Work of Breathing, Patient-ventilator Synchrony and Comparison With Neurally Adjusted Ventilatory Assist||St. Michael's Hospital, Toronto|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02067403||50108|
NCT02067390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00075251|Urinary KIM-1 After Vancomycin or Linezolid Administration|Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury||Midwestern University|No|Recruiting|September 2013|January 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|urine|Both|18 Years|N/A|No|Non-Probability Sample|Critically/Terminally Ill (ER, ICU)|March 2016|March 16, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02067390||50109|
NCT02082340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S5 0399-01_GCC|Innovative Approach in Tuberculosis Care in Armenia|Innovative Approach in Tuberculosis Care in Armenia||American University of Armenia Fund|Yes|Completed|March 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|395|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082340||48961|
NCT02082574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR_2013-6|Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients|Prevalence of Cerebral Small Vessels Disease (CSVD) Among Patients Infected With HIV-1|MICROBREAK1|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|750|||Both|50 Years|N/A|No|Non-Probability Sample|HIV patients over 50 years old, infected for at least 5 years, treated with antiretroviral        (ARV) therapy|August 2015|August 11, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082574||48943|
NCT02094794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14012|Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia|Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Given in Combination With Cyclophosphamide and Etoposide as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia||City of Hope Medical Center|Yes|Recruiting|April 2014|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|16 Years|60 Years|No|||October 2015|October 7, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094794||48007|
NCT02094534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-D-010|A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics|A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics||Oramed, Ltd.|No|Completed|March 2014|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|No|||March 2014|October 29, 2014|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094534||48027|
NCT02091050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-G 01|2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy|Clinical and Dosimetric Comparison of 2D Versus 3D HDR Brachytherapy||AC Camargo Cancer Center|Yes|Active, not recruiting|June 2014|January 2018|Anticipated|March 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|85 Years|No|||August 2015|August 24, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02091050||48293|
NCT02095067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRAA2|Videoconferencing Between Ambulances and Physician at the Emergency Medical Dispatch Center, Effects on On-Site Patient Treatment and Patterns of Referral|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 2: Videoconferencing Between Ambulances and Physician at the Emergency Medical Dispatch Center,||University of Aarhus|Yes|Recruiting|June 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||March 2014|September 23, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095067||47986|
NCT02091284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS ALCOHOL CEP_UFES 384281|Bilateral Prefrontal Modulation in Alcoholism|Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Alcoholic Inpatients|tDCS_ALCOHOL|Federal University of Espirito Santo|No|Recruiting|November 2013|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02091284||48275|
NCT02091297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14074|Comparison of Different Methods of Pain Control After Cesarean Section for Patients on Buprenorphine or Methadone|Comparison of Transversus Abdominis Plane Block Versus Patient-controlled Epidural Analgesia for Patients on Buprenorphine or Methadone, After Cesarean Section||Dartmouth-Hitchcock Medical Center|No|Not yet recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|180|||Female|18 Years|N/A|No|||March 2014|March 18, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02091297||48274|
NCT02091544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COACH|Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight|Kijk op Overgewicht Bij Kinderen: Study Regarding Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight||Maastricht University Medical Center|No|Recruiting|April 2014|April 2023|Anticipated|April 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|-  urine        -  feces        -  DNA        -  liver ultrasound|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|overweight or obese children according to the International Obesity Task Force (IOTF)        criteria < 18 years old.|March 2016|March 15, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02091544||48255|
NCT02091778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEXU 01|Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU When Using Fast Gelling Dressing as Intended.|Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU When Using Fast Gelling Dressing as Intended.|CHEXU 01|Molnlycke Health Care AB|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2014|January 26, 2016|March 18, 2014||No||No|January 26, 2016|https://clinicaltrials.gov/show/NCT02091778||48237|
NCT02091765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI 2012-5388 / NL44153.031.13|A Randomized Study of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer.|A Randomized Study of an Internet-based Cognitive Behavioral Therapy Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer.|KIS|The Netherlands Cancer Institute|No|Recruiting|December 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|65 Years|No|||March 2016|March 22, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02091765||48238|
NCT02092337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706030R|Computer-Assisted Speech Training for Hearing Aid Users|Effect of Computer-Assisted Speech Training on Speech Recognition and Subjective Benefits for Hearing Aid Users With Severe to Profound Prelingual Hearing Loss||National Taiwan University Hospital|No|Completed|June 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|N/A|No|||March 2014|March 18, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02092337||48194|
NCT02092350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-052|Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)|A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease|C-SURFER|Merck Sharp & Dohme Corp.|Yes|Completed|March 2014|September 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|237|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092350||48193|
NCT02092324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10262|Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia|Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R||OHSU Knight Cancer Institute|Yes|Recruiting|May 2014|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2015|February 9, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092324||48195|
NCT02092909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8400-401|Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|8400-401|Idera Pharmaceuticals, Inc.||Recruiting|March 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092909||48150|
NCT02093546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1029|Translational Companion Protocol to GOG229O|A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2014|||August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25||Participant undergoes blood draw and biopsy prior to start of therapy. After 28 days of      therapy, a blood draw and an additional biopsy of the same site obtained prior to beginning      cycle 2. Blood draw obtained at first tumor assessment point at pre-cycle 3 and at      progression. Participants undergo an additional blood draw at 72 hours after initiation of      therapy.|Both|18 Years|N/A|No|Probability Sample|Patients enrolled on GOG0229O at UT MD Anderson Cancer Center in Houston, Texas|October 2015|October 12, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093546||48102|
NCT02066844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-0369|Navigator vs Standard Needle Injection for Hip|Phase II Study of Navigator vs Standard Needle Injection for Hip||Cartiva, Inc.|Yes|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066844||50150|
NCT02067923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herold.1310012954|AbATE Follow-Up Study|ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study||Yale University|No|Active, not recruiting|February 2014|July 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|44|Samples With DNA|blood urine|Both|10 Years|37 Years|No|Non-Probability Sample|The investigators will contact their patients who were originally on the ITN027AI (AbATE)        study. Subjects will be contacted via email or phone to see if they would be interested in        participating on this Abate follow-up study.|February 2016|February 9, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067923||50068|
NCT02068261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA02|Working Memory Training in Adults With Substance Abuse and Executive Function Deficits.|Computerized Working Memory Training in Adults With Substance Abuse and Executive Function Deficits: A Randomised Controlled Trial.||Örebro Läns Landsting|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2015|October 22, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068261||50042|
NCT02067624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152-4|Effects of Thai Massage on Patients With Wrist Extensor Muscles Latent Myofascial Trigger Points|Effects of Thai Massage on Patients With Wrist Extensor Muscles Latent Myofascial Trigger Points||Mae Fah Luang University Hospital|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|40 Years|No|||May 2015|May 5, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067624||50091|
NCT02067897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104906|Nonrandomized Assessment of Ingrown ToenaiLs Treated by Excision of Skinfold Rather Than Toenail|Nonrandomized Assessment of Ingrown ToenaiLs Treated by Excision of Skinfold Rather Than Toenail (NAILTEST): a Study of the Vandenbos Procedure in Children and Adolescents|NAILTEST|Western University, Canada|No|Enrolling by invitation|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|10 Years|18 Years|No|Non-Probability Sample|The study population include children and adolescents aged 10 to 18 years with one or more        ingrown toenails. They may have undergone previous surgical and/or non-surgical treatment        for this condition.|November 2014|November 11, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02067897||50070|
NCT02082587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCREB 14-006|Toronto BNB Pilot Study|Pilot Study of the Toronto Brief Neurocognitive Battery (BNB)||University Health Network, Toronto|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed brain metastases planned for whole brain radiotherapy|January 2016|January 26, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082587||48942|
NCT02082860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAVPBGD-AIP-001|Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria|Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria||Digna Biotech S.L.|Yes|Completed|November 2012|November 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|64 Years|No|||December 2014|December 17, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02082860||48921|
NCT02083133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-188|Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis|Dosing Strategies in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis (DOSE-HD Study)|DOSE-HD|John H. Stroger Hospital|No|Enrolling by invitation|October 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|496|||Both|18 Years|N/A|No|Probability Sample|In patient hospitalized greater than or equal to three days, diabetic with CKD 3-5 or on        dialysis on insulin therapy|March 2014|March 7, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083133||48901|
NCT02094807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hg481115|Pain as Indication for Operative Treatment of Traumatic Rib Fractures|A Prospective Randomized Controlled Trial of Pain as Indication for Operative Treatment of Traumatic Rib Fractures.|potf|Sahlgren´s University Hospital|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094807||48006|
NCT02095106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000218|Waterproof Casting for Pediatric Distal Radius Fractures|Waterproof Casting for Pediatric Distal Radius Fractures||University of California, Los Angeles|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|4 Years|14 Years|No|||May 2015|November 30, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095106||47983|
NCT02095093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intellijoint HIP|An Intelligent Instrument for Improved Leg Length and Hip Offset Accuracy in Total Hip Arthroplasty|Intellijoint HIP Limited Release Trial: An Intelligent Instrument for Improved Leg Length and Hip Offset Accuracy in Total Hip Arthroplasty||Mount Sinai Hospital, Canada|No|Recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 20, 2014|November 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02095093||47984|
NCT02095119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/CC/130/09|A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer|Phase I-II Study of Palliative Treatment With Nimotuzumab as a Second, Third Line or More of Treatment for Advanced or Metastatic Cervical Cancer||National Institute of Cancerología|Yes|Completed|July 2008|March 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||April 2015|April 13, 2015|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095119||47982|
NCT02091310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-113-9|Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers|A Two-part Phase I Study Composed of a Randomized, Double-blind, 4-parallel Group Study to Evaluate the Effect of Multiple Oral Doses of GFT505 on the QT/QTc Interval Compared to Placebo With Moxifloxacin (400 mg in Single Oral Dose) as a Positive Control, in Healthy Male and Female Volunteers, Preceded by a Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define the Supra-therapeutic GFT505 Dose in a Multiple Dosing Regimen.||Genfit|No|Completed|February 2014|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02091310||48273|
NCT02095080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00235|Determination of the UL of Leucine in Healthy Elderly Men|Determination of the Tolerable Upper Intake Level (UL) of Leucine in Healthy Elderly Men (70-75 Yrs)||University of British Columbia|Yes|Recruiting|August 2014|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Male|70 Years|75 Years|No|||November 2015|November 3, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02095080||47985|
NCT02091791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2754|High Versus Low Level of Lumbar Traction in Acute Lumbar Sciatica Due to Disc Herniation|High Versus Low Level of Lumbar Traction in Acute Lumbar Sciatica Due to Disc Herniation||University Hospital, Strasbourg, France|No|Completed|August 2002|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02091791||48236|
NCT02091804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45360-G|Beginning Relationships in a Native Community|Promoting First Relationships: A Strengths-based Primary Prevention Project in a Native Community|P20-RP3|University of Washington|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02091804||48235|
NCT02092090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSaSS|China Salt Substitute and Stroke Study|A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE: THE CHINA SALT SUBSTITUTE AND STROKE STUDY (SSaSS)|SSaSS|The George Institute|Yes|Active, not recruiting|March 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|21000|||Both|N/A|N/A|No|||June 2015|July 30, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02092090||48213|
NCT02092077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1106-IMM-20001|A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children|A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children||Teva Pharmaceutical Industries|Yes|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|3 Years|11 Years|No|||March 2016|March 24, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092077||48214|
NCT02092662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHai920130001|Objective Assessment of Upper Extremity Functioning of Stroke Patients Before and After Rehabilitation|Objective Assessment of Upper Extremity Functioning of Stroke Patients Before and After Rehabilitation|AssStrFunc|University of Haifa|Yes|Completed|January 2014|May 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort will be selected from Fliman Rehabilitation Geriatric Center. Healthy subjects, age        and gender-matched will be served as a control group.|June 2015|July 7, 2015|March 12, 2014||No||No|May 14, 2015|https://clinicaltrials.gov/show/NCT02092662|5 Weeks|48169|
NCT02092922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-215|A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)|||Array BioPharma|No|Active, not recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092922||48149|
NCT02092636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-194-6|Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring|Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring||University of Connecticut Health Center|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02092636||48171|
NCT02093234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI- IH-1304-6797|Changing the Healthcare Delivery Model|Changing the Healthcare Delivery Model:A Community Health Worker/Mobile Chronic Care Team Strategy|C4H|George Washington University|No|Active, not recruiting|April 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|200|||Both|21 Years|75 Years|No|||February 2016|February 8, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093234||48126|
NCT02093520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiDAS ENCORE|The MiDAS ENCORE Study|MILD® Percutaneous Image-Guided Lumbar Decompression Versus Epidural Steroid Injections in Patients With Lumbar Spinal Stenosis Exhibiting Neurogenic Claudication||Vertos Medical, Inc.|No|Active, not recruiting|May 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|65 Years|N/A|No|||October 2015|October 21, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093520||48104|
NCT02093559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA037194-01A1|Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients||REBOOT|San Francisco Department of Public Health|No|Active, not recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093559||48101|
NCT02067104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401183410|Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention|A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects||University of Arizona|Yes|Completed|February 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067104||50131|
NCT02067117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCFLU_P4|Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.|||Green Cross Corporation|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1139|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|January 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02067117||50130|
NCT02068287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004532-32|Esmolol Effects on Heart and Inflammation in Septic Shock|Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study|ESMOSEPSIS|Central Hospital, Nancy, France|Yes|Recruiting|December 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02068287||50040|
NCT02068300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1,5AG_Hypo|The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes|1,5-Anhydro-D-Glucitol Can Reflect Hypoglycemia in Patients With Well Controlled Type 2 Diabetes||Seoul National University Hospital|Yes|Enrolling by invitation|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|41|Samples Without DNA|blood, urine|Both|N/A|N/A|No|Probability Sample|primary care clinic|May 2015|May 19, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068300||50039|
NCT02068274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194/12|CO2 Monitoring Study|Continuous Monitoring of Patients Treated With Opioids for Chronic Pain and Its Impact on Patient Safety. A Feasibility Trial.||Cantonal Hosptal, Baselland|No|Recruiting|September 2013|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Pain patients treated with opioids|February 2014|February 19, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02068274||50041|
NCT02068508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-018|Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"|Actos Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"||Takeda|No|Completed|July 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1067|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes mellitus|August 2014|August 25, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068508||50023|
NCT02082600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010070050|Effects of Sleep Deprivation on Blood Hormones and Inflammatory Status After Exercise Induced-muscle Damage|Effects of Sleep Deprivation on Blood Hormones and Inflammatory Status After Exercise Induced-muscle Damage||Federal University of São Paulo|Yes|Active, not recruiting|July 2013|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|20 Years|31 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082600||48941|
NCT02082873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052133|Nonconvulsive Seizure Identification on Quantitative EEG by Neuro ICU Nurses|A Prospective Trial of Nonconvulsive Electrographic Seizure Detection by Nurses in the Adult Neuro ICU Using a Panel of Quantitative EEG Trends||Duke University|Yes|Enrolling by invitation|January 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|30 NeuroICU patients and 40 NeuroICU nurses|December 2015|December 7, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02082873||48920|
NCT02095145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00695|Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance|A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/POMx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance||National Cancer Institute (NCI)|Yes|Recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Male|21 Years|N/A|No|||October 2015|December 31, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095145||47980|
NCT02095158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-006|A Long-Term Safety and Efficacy Study of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea|||Allergan|No|Completed|April 2014|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|440|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095158||47979|
NCT02094846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evaluation with cell phones|Evaluation of an Intervention Based on Cell Phones|Evaluation of the Effect of an Intervention Based on Cell Phones on Glycemic Control in Adults With Type 2 Diabetes Mellitus||Instituto Nacional de Salud Publica, Mexico|No|Completed|October 2012|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|30 Years|69 Years|No|||March 2014|March 20, 2014|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02094846||48003|
NCT02091063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM4054|ACY-1215 for Relapsed/Refractory Lymphoid Malignancies|A Phase Ib/II, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies||Columbia University|Yes|Recruiting|March 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091063||48292|
NCT02091323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lrygb2014|Effect of Laparoscopic Roux-en-Y Gastric Bypass Surgery on Non-severe Obesity With Type 2 Diabetes Mellitus|Effect of Modified Laparoscopic Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetics With Lower Body Mass Index in China||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 25, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02091323||48272|
NCT02091557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA125_VAS_changes|CA 125 and VAS Pain Score Changes to Diagnose Endometriosis|CA 125 and VAS Pain Score Changes Following GnRH-analog Administration as ex Adiuvantibus Criteria to Diagnose Endometriosis as Cause of Chronic Pelvic Pain.||University Magna Graecia|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|118|||Female|18 Years|38 Years|No|Non-Probability Sample|Patients with chronic pelvic pain|June 2014|June 28, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02091557||48254|
NCT02091843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC121657|Deep Brain Stimulation of the Amygdala for Combat Post-Traumatic Stress Disorder|||VA Greater Los Angeles Healthcare System|Yes|Recruiting|January 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Male|25 Years|70 Years|No|||December 2015|December 11, 2015|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02091843||48232|
NCT02091856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUTimisoara-PsiTOD|Internet-delivered Psychotherapy for Depression|Internet-delivered Cognitive-Behavioral Therapy for Depression: A Randomized Controlled Trial (PsiTOD)|PsiTOD|West University of Timisoara|No|Active, not recruiting|March 2014|June 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02091856||48231|
NCT02092103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13094-14-012|Delayed Clamping and Milking the Umbilical Cord in Preterm Infants|Delayed Clamping and Milking the Umbilical Cord Prior to Clamping in Preterm Infants and the Effect of Neonatal Outcomes||TriHealth Inc.|No|Recruiting|March 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|240|||Both|N/A|N/A|No|||November 2015|November 8, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02092103||48212|
NCT02092363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54F28-003|Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|90 Years|No|||August 2015|August 31, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092363||48192|
NCT02092649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14JA044|Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate|Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate||University of Guelph|No|Completed|April 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|26|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 17, 2014||No||No|June 1, 2015|https://clinicaltrials.gov/show/NCT02092649||48170|
NCT02092675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED-1971-HR|Endothelial Dysfunction and Chronic Obstructive Pulmonary Disease|Endothelial Dysfunction and Frequent Exacerbator Phenotype in Patient With Chronic Obstructive Pulmonary Disease||Clinical Hospital Centre Zagreb|Yes|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|117|Samples Without DNA|plasma|Both|40 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patient with COPD, smokers and former smokers recruited in an ambulatory basis.|December 2014|December 22, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092675||48168|
NCT02092935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMT19969/C002|A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)|A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)||Summit Therapeutics|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||December 2015|December 18, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092935||48148|
NCT02093247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0006-14-HMO|Characterize Novel Pathogen- and Host- Related Factors in Hospitalized Patients and Patients on the Emergency Department Presenting With Lower Respiratory Tract Infections and/or Sepsis|||Hadassah Medical Organization|No|Not yet recruiting|June 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|1 Month|75 Years|No|Non-Probability Sample|Eligible subjects aged one month of age and older from both genders that attend the        hospital or the ED due to a suspected respiratory infections and/or sepsis (whose onset of        symptoms began ≤8 days prior to recruitment) or due to a non-infectious disease. These        subjects are expected to fall into one of the following categories:          1. Patients with an acute bacterial infection          2. Patients with an acute viral infection          3. Patients with an acute mixed co-infection (bacterial and viral)          4. Patients with a fungal infection          5. Patients with an undetermined disease etiology          6. Patients with a non-infectious disease (control group) Patients from subgroups 1-6             will also be classified based on the presence or absence of sepsis or severe sepsis.        Children in group 6 can only be included when blood sampling for this study can be        combined with blood sampling as part of standard of care.|March 2014|March 18, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02093247||48125|
NCT02093845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-3-14|Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII|Randomized Clinical Comparison of Everolimus-Eluting SYNERGY® and Biolimus-Eluting BioMatrix NeoFlex® Coronary Stents in Non-Selected Patients With Ischemic Heart Disease|SORT-OUT VIII|Aarhus University Hospital Skejby|Yes|Recruiting|February 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2800|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02093845||48080|
NCT02093858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRW|The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome|The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome||Central South University|Yes|Not yet recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|212|||Both|18 Years|45 Years|No|Probability Sample|All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth        Edition (DSM-IV) criteria for first episode schizophrenia.All of the patients and their        familier are know of the study and sign the informed consent.|March 2014|March 20, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02093858||48079|
NCT02067416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712-0127|PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer|Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting||The Methodist Hospital System|No|Terminated|July 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 17, 2014|Yes|Yes|Sponsor withdrawal of funding|No||https://clinicaltrials.gov/show/NCT02067416||50107|
NCT02067429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT135670|Limbal Relaxing Incision Versus Toric Intraocular Lens for Corneal Astigmatism During Cataract Surgery.|Limbal Relaxing Incisions Versus Toric Intraocular Lens for Keratometric Astigmatism <2.5 Diopters in Patients Undergoing Cataract Surgery and Intraocular Lens Implantation.||Sussex Eye Hospital|Yes|Recruiting|June 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02067429||50106|
NCT02067949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2014|Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient|The Clinical Outcome and the Cost-effectiveness Analysis of Simvastatin Plus Standard Therapy Versus Standard Therapy Alone in Critically Ill Septic Patient"||Ain Shams University|Yes|Completed|February 2014|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02067949||50066|
NCT02068521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13VR3|Versartis Long-Term Extension Study of VRS-317|An Open-Label, Long-Term Extension Study of the Safety and Efficacy of A Long-acting Human Growth Hormone (VRS-317) in Children With Growth Hormone Deficiency||Versartis Inc.|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|3 Years|12 Years|No|||October 2015|October 6, 2015|February 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068521||50022|
NCT02068534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102122-F|A Qualitative and Quantitative Analysis on the Living History of Survivors From Charcoal-burning Suicide|A Qualitative and Quantitative Analysis on the Living History of Survivors From Charcoal-burning Suicide||Far Eastern Memorial Hospital|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|20 Years|N/A|No|Non-Probability Sample|survivors from charcoal-burning suicide|February 2014|February 20, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068534||50021|
NCT02093754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECHAM|Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients|Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients: a European Multicentre Study|ANRS ECHAM|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|560|||Both|40 Years|N/A|No|||July 2015|July 23, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02093754||48087|
NCT02093767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP81396|Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis|Open-Label Trial of a Prebiotic Preparation Containing Inulin and Oligofructose (Synergy-1) for the Treatment of Mild to Moderate Acute Ulcerative Colitis||University of Alberta|No|Completed|August 2007|December 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||March 2014|March 23, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093767||48086|
NCT02094027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0707/67|Bariatric Surgery and Guided Self-help for Binge Eating Disorder|The Role of Self-help in the Pre-surgical Treatment of Binge Eating Disorder in Bariatric Surgery Candidates: Implications for Weight-related and Psychological Outcome.|BED|Imperial College London|No|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02094027||48066|
NCT02095171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX002-CL001|Single Ascending Dose Study of PRX002 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects||Prothena Biosciences Limited||Completed|March 2014|||December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095171||47978|
NCT02091102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PICO-LENS-DM|Evaluating the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles||Cynosure, Inc.|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091102||48289|
NCT02091128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-4-127|Pregnancy Chances in Classic Galactosemia|Pregnancy Chances in Classic Galactosemia||Maastricht University Medical Center|No|Recruiting|March 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Female|18 Years|N/A|No|Non-Probability Sample|Academic hospital|April 2015|April 15, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02091128||48287|
NCT02091076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-53-1|Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing|Efficacy and Safety of Wound Dressing Containing Silk Fibroin With Bioactive Coating Layer Versus Medicated Paraffin Gauze Dressing in the Treatment of Split-thickness Skin Graft Donor Sites||Chulalongkorn University|Yes|Recruiting|March 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||March 2015|March 10, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091076||48291|
NCT02091089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PICO-LENS-RW|Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles||Cynosure, Inc.|No|Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02091089||48290|
NCT02091336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAGM-001|Oral Antidiabetic Agents in Pregnancy|Oral Antidiabetic Agents on Gestational Diabetes: Modulating Effect on Fetal Growth - a Clinical Randomized Trial||Hospital de Clinicas de Porto Alegre|No|Recruiting|January 2014|December 2016|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||January 2014|March 18, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02091336||48271|
NCT02091570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1308|Effect of Nutrition Bars on Satiety in Women|A Randomized, Controlled, Double-Blind Crossover Pilot Trial to Assess the Effects of Nutrition Bars on Subjective Ratings of Hunger and Fullness in Women||PepsiCo Global R&D|No|Recruiting|December 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|42|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02091570||48253|
NCT02091817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor010712ctil|The Effect of Oxytocin on Face Perception|The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia||Soroka University Medical Center|No|Suspended|November 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|January 26, 2014||No|We are currently engaged in other behavioral study.|No||https://clinicaltrials.gov/show/NCT02091817||48234|
NCT02091830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The 07 - 11 cohort|Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients|Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients||Northern Orthopaedic Division, Denmark|No|Completed|January 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2262|||Both|N/A|N/A|No|Non-Probability Sample|2200 patients with knee osteoarthritis not eligible for at total knee arthroplasty|October 2015|October 16, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02091830||48233|
NCT02091869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202623|A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans|A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans|PEAK2|Arkansas Children's Hospital Research Institute|No|Active, not recruiting|March 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|January 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091869||48230|
NCT02092129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROL-BG-ACRO|Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.|Prognostic Value of Pituitary Histopathology and Plasma Hyperprolactinaemia in Predicting the Risk of Glucose Metabolic Disturbances in Patients With Acromegaly.||Rigshospitalet, Denmark|No|Active, not recruiting|September 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|79|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with acromegaly treated with surgery|October 2014|October 26, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02092129||48210|
NCT02092116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBC01-001|Safety and Efficacy of the Histone Deacetylase Inhibitor Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV‐1 Reservoir|An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation Using Romidepsin, on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART|REDUC|Bionor Immuno AS|No|Active, not recruiting|March 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092116||48211|
NCT02092415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Junctional Tourniquet|Assessment of Limb Perfusion During Junctional Tourniquet|Assessment of Limb Perfusion During Junctional Tourniquet||Oregon Health and Science University|Yes|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|January 6, 2014||No||No|April 22, 2015|https://clinicaltrials.gov/show/NCT02092415||48188|
NCT02092376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOAD|The Link Between Obesity And Vitamin D in Bariatric Patients With Omega-loop Bypass Surgery|The Link Between Obesity And Vitamin D in Bariatric Patients With Omega-loop Bypass Surgery: a Randomized Controlled, Double-blinded Clinical Supplementation Trial|LOAD|Medical University of Vienna|No|Active, not recruiting|March 2014|May 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|100 Years|No|||March 2016|March 15, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092376||48191|
NCT02092688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140/13|Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth|Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor in Comparison to a Control Group of Asymptomatic Women With the Same Gestational Age - a Multicenter Trial||University Hospital Inselspital, Berne|No|Recruiting|December 2013|October 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|N/A|No|Non-Probability Sample|pregnant women presenting with signs auf PTL at emergenca care and pregnant asymptomatic        women presenting for routine check-up|March 2014|March 18, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02092688||48167|
NCT02092948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNBD-PROT01|Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer|A Phase I Open Label Study to Evaluate the Tumor-targeting Properties and Safety of 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer.||Jonsson Comprehensive Cancer Center|No|Recruiting|August 2013|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092948||48147|
NCT02093260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Influenza 0213|Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)|Phase II b Study of Immunogenicity and Safety of Flubio Vaccine in Infants and Children||PT Bio Farma|No|Completed|May 2014|December 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|405|||Both|6 Months|11 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093260||48124|
NCT02093585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001685-42|Tenofovir Abacavir Platelet Activation Study|Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens|TAPAS|Rigshospitalet, Denmark|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|100|||Male|35 Years|70 Years|No|||December 2015|December 11, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093585||48099|
NCT02067936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WALIBI-001|Walking the Isobole of Drug Interaction|Walking the Isobole of Drug Interaction: Comparison of Hemodynamic Effects, Cerebral and Tissue Oxygenation for 4 Equipotent Combinations of Propofol and Remifentanil|Walibi|University Medical Center Groningen|No|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|87|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02067936||50067|
NCT02068326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-371|MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial|Mentalization-Based Treatment in Groups for Adolescents With Borderline Personality Disorder (BPD) or Subthreshold BPD Versus Treatment As Usual - the M-GAB Randomized Controlled Trial|M-GAB|Psychiatric Research Unit, Region Zealand, Denmark|Yes|Recruiting|September 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|14 Years|17 Years|No|||October 2015|October 6, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068326||50037|
NCT02068313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3301|Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers|Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers||Royal Marsden NHS Foundation Trust||Recruiting|March 2010|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically confirmed squamous cell cancer or undifferentiated cancer of        nasopharynx, oropharynx, larynx and hypopharynx and squamous cell carcinoma unknown        primary referred for primary or postoperative radiotherapy to the primary site and        bilateral neck irradiation requiring IMRT|February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068313||50038|
NCT02094274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-40468-10|A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid|A Single-dose, Randomised, Crossover, Placebo-controlled, Double-dummy, Pharmacodynamic Clinical Trial Assessing Two Fixed Dose Combinations of Long-acting Beta-agonist (LABA) and Inhaled Corticosteroid (ICS)||Almirall, S.A.|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|No|||March 2014|May 21, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094274||48047|
NCT02094547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC0G - 010|A Neurocognitive and Immunological Study of a New Formula for Healthy Infants|Evaluación Del Efecto de Una Nueva fórmula Infantil Con Ingredientes específicos Sobre el Desarrollo Neurocognitivo e inmunológico en Lactantes|COGNIS|Laboratorios Ordesa|No|Active, not recruiting|December 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|170|||Both|N/A|60 Days|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094547||48026|
NCT02091141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28897|A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients|My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents||Genentech, Inc.||Recruiting|April 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091141||48286|
NCT02091115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072013|Consumption of Milk Drink and Constipation|Influence of the Consumption of Milk Drink With Bifidobacterium Animalis in Symptoms of Constipation.||Centro Universitário Univates|Yes|Completed|July 2013|September 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Female|20 Years|50 Years|No|||March 2014|March 18, 2014|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02091115||48288|
NCT02091596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGN-1300|Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers|Randomized, Double-blind, Vehicle-controlled 2-Arm Trial of Topical PluroGel N for the Treatment of Patients With Mildly Infected Diabetic Foot Ulcer CLINICAL PROTOCOL PGN-1300||PluroGen Therapeutics, Inc|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091596||48251|
NCT02091609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:458|a Randomized Clinical Trial Evaluating Plaque Removal Around Dental Implants|Evaluation of Plaque Removal Using Different Plaque Control Therapies Around Single Crown Dental Implants and Splinted Implant Crowns in Patients Under 3 Months Maintenance;a Randomized Clinical Trial||University of Manitoba|Yes|Active, not recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|October 23, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02091609||48250|
NCT02091583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:029|Canola Oil, Fibre and DHA Enhanced Clinical Trial|Developing and Evaluating a Novel Food Supplement, Consisting of Canola Oil, Fibre and DHA, Aiming at the Management of CVD Risk in a Population With Metabolic Syndrome||University of Manitoba|No|Completed|November 2014|||November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|70 Years|No|||October 2015|January 25, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02091583||48252|
NCT02092142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-19|Safety and Immunogenicity of Q Fever Vaccine|Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii||U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|February 2006|December 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092142||48209|
NCT02091895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0942|Validation of Clinical Efficacy and Development of New Diagnostic Algorithm of Probe-based Confocal Laser Endomicroscopy in Patients With Lower Gastrointestinal Disorder|||Yonsei University|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|311|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02091895||48228|
NCT02092428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23311|Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)|Contrast- Enhanced Whole-Heart Coronary Magnetic Resonance Angiography (MRA) at 3.0T||Cedars-Sinai Medical Center|No|Recruiting|April 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|340|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092428||48187|
NCT02092389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-323|Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|AdaProQuo|AbbVie|No|Terminated|July 2014|March 2017|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with moderate to severe Ulcerative Colitis|December 2015|December 21, 2015|March 18, 2014||No|Recruitment below expectation|No||https://clinicaltrials.gov/show/NCT02092389||48190|
NCT02092402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/180|Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome|Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome||Örebro University, Sweden|No|Recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092402||48189|
NCT02092974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESO|Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin|Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin|LESO|Charite University, Berlin, Germany|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02092974||48145|
NCT02092961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00004Sub|Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study|A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study|OSKIRA 4 SS|AstraZeneca|Yes|Terminated|February 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||April 2014|May 28, 2014|March 19, 2014|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|April 25, 2014|https://clinicaltrials.gov/show/NCT02092961||48146|
NCT02093572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402039|Effect of Skipping Breakfast on Metabolic Function|Effect of Skipping Breakfast on Metabolic Function||Washington University School of Medicine|Yes|Recruiting|May 2014|March 2020|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093572||48100|
NCT02093299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004748-23|RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders|RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders|RISCLON|Roskilde County Hospital|Yes|Recruiting|December 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|50 Years|80 Years|No|Probability Sample|First time stroke patients|December 2015|December 16, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093299|2 Years|48121|
NCT02067676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-13-09|Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea|Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1)|CJCV1-01|U.S. Army Medical Research and Materiel Command|No|Recruiting|March 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067676||50087|
NCT02067689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300836|Cognitive Stimulation Study|Neuromodulation of Cognitive Function Using Transcranial Direct Current Stimulation|CogStim|University of Florida|No|Not yet recruiting|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|300|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults between ages 18-90|December 2015|December 14, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02067689||50086|
NCT02067975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00057861|Tryptophan MRI in People With Schizophrenia and Healthy Controls|Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls||University of Maryland|Yes|Recruiting|September 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067975||50064|
NCT02067988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45329.041.13|Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study|Adjuvant Hepatic Holmium-166-radioembolization in Patients With Unresectable Liver Metastases of Neuroendocrine Origin, Who Have Been Treated With Lutetium-177-dotatate|HEPAR_Plus|UMC Utrecht|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|N/A|N/A|No|||December 2015|December 4, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02067988||50063|
NCT02068560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenderDifferences|The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion|The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion||University of Aarhus|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|64|||Both|8 Years|80 Years|Accepts Healthy Volunteers|||February 2014|December 10, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068560||50019|
NCT02094287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PlacItch|Placebo Effect in the Treatment of Atopic Dermatitis|Placebo Effect in Atopic Dermatitis - Increase the Pharmacological Effect of Itching Caused by Classical Conditioning and Expectancy Processes: A Randomized Controlled Trial||Charite University, Berlin, Germany|No|Completed|September 2010|February 2015|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|166|||Both|18 Years|65 Years|No|||September 2015|September 17, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02094287||48046|
NCT02094300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-622|Zenith® Dissection Endovascular System|Zenith® Dissection Endovascular System|STABLE I|Cook||Active, not recruiting|December 2007|February 2017|Anticipated|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 21, 2014|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02094300||48045|
NCT02094560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPN710102|CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors|Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)|CAP7-1|CellAct Pharma GmbH|Yes|Recruiting|November 2011|December 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|N/A|N/A|No|||March 2014|March 19, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094560||48025|
NCT02095197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00089080|C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for Treatment of Cervical Radicular Pain|A Prospective Randomized Controlled Trial of Standardized C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for the Treatment of Cervical Radicular Pain||Northwestern University|No|Recruiting|March 2014|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02095197||47976|
NCT02091349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09491|Tolerance and Utilization of Polydextrose, Inulin, and Soluble Corn Fiber|Tolerance and Utilization of Polydextrose, Inulin, and Soluble Corn Fiber||University of Illinois at Urbana-Champaign|No|Completed|July 2010|July 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|25|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091349||48270|
NCT02091362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15261|A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus|The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|194|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091362||48269|
NCT02091375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1332 Part B|Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome|A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome||GW Research Ltd|Yes|Active, not recruiting|March 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|2 Years|18 Years|No|||December 2015|December 17, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091375||48268|
NCT02091882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316-13-206A|Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)|OSMITTER 316-13-206A Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period|OSMITTER|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|March 2014|May 2014|Actual|April 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091882||48229|
NCT02092727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056381|The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study|The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study|RaDIANT|Emory University|No|Active, not recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|134|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02092727||48164|
NCT02092155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086126|Biomarker Levels During Indwelling Pleural cAtheter Sample Testing|TGF-B as a Marker of Pleurodesis in Patients With Tunneled Pleural Catheters|BLAST|Johns Hopkins University|No|Recruiting|January 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|95|Samples Without DNA|Pleural fluid attained during drainage of indwelling pleural catheter|Both|18 Years|99 Years|No|Non-Probability Sample|Patients of the interventional pulmonology team who receive indwelling pleural catheters        for a malignant pleural effusion.|February 2016|February 4, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092155||48208|
NCT02092701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDB1|Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period|Effects of a One Year Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period||University Hospital of Liege|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|1||||||Both|18 Years|N/A|No|||March 2014|March 18, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092701||48166|
NCT02092441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMC 395266-1|Inhalation Intervention for Nausea in the Emergency Department|Inhalation Intervention for Nausea in the Emergency Department||Brooke Army Medical Center|Yes|Completed|April 2014|June 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|65 Years|No|||July 2015|July 3, 2015|March 18, 2014||No||No|July 3, 2015|https://clinicaltrials.gov/show/NCT02092441||48186|
NCT02092714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGI-061|Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors|A Pilot Study Utilizing Molecular Analysis Via Cancer CodeTM to Identify Therapeutic Targets for Patients With Advanced Neuroendocrine Tumors||Fox Chase Cancer Center|Yes|Recruiting|October 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|90|Samples With DNA|blood and tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with incurable neuroendocrine tumors, excluding small cell/large cell lung        cancers and Merkel cell carcinomas|March 2016|March 1, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092714||48165|
NCT02093273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPV 0213|Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)|Phase II, Randomized, Double Blind, Prospective Intervention Study to Evaluate the Immunogenicity and Safety Profile of tOPV (Bio Farma) With Different Batch Numbers in Indonesian Infants||PT Bio Farma|Yes|Completed|May 2013|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|N/A|1 Day|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093273||48123|
NCT02093286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS Penta 0414|Safety Profile Following Pentabio Vaccination in Indonesian Infants|Phase IV, Study of Safety Profile Following Pentabio Vaccination in Indonesian Infants||PT Bio Farma|No|Completed|May 2014|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4000|||Both|2 Months|11 Months|Accepts Healthy Volunteers|Probability Sample|4000 infants, 2-11 months old From 4 provincial health primary center|December 2014|December 16, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093286||48122|
NCT02094183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-134|The Interaction Between Appetite Hormones|The Interaction Between Appetite Hormones and Their Importance for Maintenance of Weight Loss After a Low Calorie Diet||University of Copenhagen|Yes|Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02094183||48054|
NCT02094430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGTW-1004|Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency|Clinical Pharmacology, Efficacy and Safety Study of FGTW in Paediatric Patients With Severe Congenital Fibrinogen Deficiency||Laboratoire français de Fractionnement et de Biotechnologies|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|12 Years|No|||February 2016|February 11, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02094430||48035|
NCT02094157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB 20080717|Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation|An Open-Label Randomized Control Trial of Pre-Operative Low Molecular Weight Heparin Versus Tapered Warfarin as Bridging Therapy for Patients With Implantation of Pacemaker or Defibrillator|PACEBRIDGE|McMaster University|No|Terminated|December 2007|March 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 19, 2014||No|Change of practice made further recruitment impossible|No||https://clinicaltrials.gov/show/NCT02094157||48056|
NCT02094170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA179977|Global Positioning System (GPS) Exposure to Environments & Relations With Biomarkers of Cancer Risk|Global Positioning System (GPS) Exposure to Environments & Relations With Biomarkers of Cancer Risk||University of California, San Diego|No|Recruiting|July 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|700|Samples With DNA|DNA and RNA will be collected from your blood. This may be used to look at genetic      components important to your health. DNA may be analyzed for important genetic determinants      that indicate unhealthy environment exposure and risk of obesity, cancer, and      cardiometabolic disease. Data from such analyses could guide and may help us learn more      about genetic markers of therapeutic or prevention effectiveness and risk of chronic disease      associated with obesity and unhealthy environment exposure, including cancer.|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|700 35 - 80 year old adults living in San Diego County|December 2015|December 1, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094170||48055|
NCT02067962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9258|Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing|Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing|GenesinJIA|University Hospital, Montpellier|Yes|Not yet recruiting|March 2014|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|1 Month|40 Years|No|||February 2014|February 17, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02067962||50065|
NCT02068586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.377|Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma|A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma||Thomas Jefferson University|Yes|Recruiting|November 2014|||February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068586||50017|
NCT02068599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-45070-CNS-20005|A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Primary Osteoarthritis Affecting a Single Knee||Teva Pharmaceutical Industries|No|Completed|February 2014|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|389|||Both|40 Years|85 Years|No|||July 2015|July 13, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068599||50016|
NCT02068339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-N01GI1_Phase 3|Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis||PharmaKing|Yes|Active, not recruiting|February 2014|February 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|276|||Both|19 Years|75 Years|No|||April 2015|April 27, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068339||50036|
NCT02094573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP26113-13-201|A Phase 2, Multicenter, Randomized Study of AP26113|A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib|ALTA|Ariad Pharmaceuticals|Yes|Active, not recruiting|March 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|N/A|No|||June 2015|October 5, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094573||48024|
NCT02094820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJ2012|Psychological Wellbeing in Chronic Fatigue Syndrome|Psychological Wellbeing in Adults With Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis||Royal Holloway University|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|Adults referred to a chronic fatigue syndrome service|January 2015|January 14, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094820||48005|
NCT02095132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00547|WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|March 2014|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|1 Year|21 Years|No|||February 2016|March 24, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095132||47981|
NCT02091635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Motilitone|Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method|Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method||Samsung Medical Center|No|Completed|August 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02091635||48248|
NCT02091154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202002824|How Environmental Interventions Influence Behavior in School Lunchrooms|Evaluating the Impact on Lunch Sales and Consumption of New School Lunch Guidelines and Behavioral Interventions in NYC Schools||Cornell University|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|43|||Both|5 Years|19 Years|No|||March 2014|March 18, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02091154||48285|
NCT02098850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAC-01|Staphylococcus Aureus Bacteraemia in Adults|A Prospective International Study of Staphylococcus Aureus Bacteraemia in Adults by the International Staphylococcus Aureus Collaboration|ISAC|University of Cologne|No|Recruiting|January 2013|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patient in tertiary care hospitals|December 2014|December 2, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098850|3 Months|47697|
NCT02099123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC 1068146|A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)|A Study of STAtins for Reducing Events in the Elderly (STAREE)|STAREE|Monash University|Yes|Enrolling by invitation|July 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|18000|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099123||47676|
NCT02064907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR(OD)_104|Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants|A Phase 1, Randomized, Open-Label, Single Center, Multiple-Dose, Two-Period, Crossover Study to Assess the Bioavailability, Safety, and Pharmacodynamics of Two 30 mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Administered on the Tongue Relative to Oral Administration of One 60 mg Dexlansoprazole Delayed-Release Capsule in Healthy Subjects||Takeda|No|Completed|February 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|February 14, 2014|No|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT02064907||50297|
NCT02064920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-318|Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)|A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients With Mild Alzheimer's Disease Treated With Donepezil||Merck Sharp & Dohme Corp.|No|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|36|||Both|55 Years|85 Years|No|||March 2016|March 18, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064920||50296|
NCT02095912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2013-0591|Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients|Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients||University of Zurich|No|Recruiting|March 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Organ Transplant Recipients with:          -  > 9 Squamous Cell Carcinoma (SCC) in total or          -  > 2 SCC per year (in any one year) or          -  any single "index" SCC that has a very poorly differentiated cell morphology or that             behaved aggressively in Terms of local recurrence or local/systemic metastasis|December 2014|December 2, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02095912||47922|
NCT02065427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIAS|Intervention to Improve Social and Family Support for Caregivers of Dependent Patients. (ICIAS)|Intervention to Improve Social and Family Support for Caregivers of Dependent Patients|ICIAS|Jordi Gol i Gurina Foundation|No|Completed|May 2010|December 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|282|||Both|19 Years|N/A|No|||February 2014|February 16, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02065427||50257|
NCT02065674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABROAGUS01|Therapeutic Efficacy of "Abroma Agusta" in HbA1c % in NIDDM|Therapeutic Efficacy of Homoeopathic Mother Tincture of "Abroma Agusta" in Changing the Level of Glycated Hb (HbA1c %) in Diabetes Mellitus Type II (NIDDM|ABOMNIDDM|Fr Muller Homoeopathic Medical College|Yes|Available|February 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Expanded Access|N/A|||||||Both|30 Years|85 Years|No|||June 2015|June 5, 2015|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065674||50238|
NCT02065687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0286B|Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer|A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer||Gynecologic Oncology Group|Yes|Suspended|March 2014|||September 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 14, 2014|Yes|Yes|Scheduled Interim Monitoring|No||https://clinicaltrials.gov/show/NCT02065687||50237|
NCT02065973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10-02-11-001|An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101|An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 in Subjects With Cervical Intraepithelial Neoplasia (CIN) and High-risk Human Papillomavirus (HPV) Infection||PDS Biotechnology Corp.|Yes|Enrolling by invitation|February 2014|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Female|21 Years|65 Years|No|||February 2014|February 16, 2014|February 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065973||50215|
NCT02115438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54416-01|A Cohort Study for Occupational Stress Induced Early Embryonic Death|||Peking University Third Hospital||Completed|March 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3405|||Female|N/A|N/A|No|Non-Probability Sample|pregnant women with job|April 2014|April 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115438||46426|
NCT02115711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-14-22|Study of a Community Based Approach to Control Cardiovascular Risk Factors in India|A Community Based Approach to Promote Cardiovascular Risk Factor Control in India, Project SEHAT: A Cluster Randomized Controlled Trial|SEHAT|University Hospital Case Medical Center|No|Recruiting|April 2014|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|35 Years|70 Years|No|||November 2015|November 30, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02115711||46405|
NCT02115945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARI-01|Femoral and Epidural Block After Total Knee Arthroplasty|COMPARISON OF CONTINUOUS FEMORAL NERVE BLOCK AND PATIENT CONTROLLED EPIDURAL ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY||Adnan Menderes University|Yes|Completed|February 2013|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 15, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02115945||46387|
NCT02116166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300790|Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia|Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia||University of Florida|Yes|Active, not recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|10|Samples With DNA|Skeletal muscle biopsy|Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young (age 20-35 years; N =10)|October 2015|October 22, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116166||46370|
NCT02065349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8477-CL-0020|A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety|A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain|MOBILE|Astellas Pharma Inc|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065349||50263|
NCT02066415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120295|A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Patients With Chronic Migraine.||Amgen|Yes|Active, not recruiting|February 2014|May 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|667|||Both|18 Years|65 Years|No|||February 2016|March 8, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066415||50182|
NCT02097199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1830/2013|IPHAAB-study Influence of Physical Activity on Atherosclerosis Biomarkers|Influence of Physical Activity on Promising Atherosclerosis Biomarkers||Medical University of Vienna|Yes|Completed|August 2014|December 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|98|Samples Without DNA|whole blood|Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of about 55 female and 55 male individuals aged 30-65        years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30        minutes quick walking/day).|January 2016|January 6, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097199||47824|
NCT02097472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-010|Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers|A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers||PATH|Yes|Completed|April 2014|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|304|||Both|12 Months|45 Years|Accepts Healthy Volunteers|||April 2015|January 7, 2016|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02097472||47803|
NCT02097485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha03-008|Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation|A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation||Hatchtech Pty Ltd|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|6 Months|N/A|No|||December 2014|December 15, 2014|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097485||47802|
NCT02097758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD_3D_device size|Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect||ASD|Asan Medical Center|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02097758||47781|
NCT02098603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e7925|Health Protection & Promotion for Oregon Correctional Officers|Health Protection & Promotion for Oregon Correctional Officers|DOC HEALTH|Oregon Health and Science University|Yes|Completed|January 2013|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|86|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02098603||47716|
NCT02098616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #1285|Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus|RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 ± Weight Based Ribavirin in Treatment-Naïve, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks|RHACE 1|Southern California Institute for Research and Education|No|Recruiting|July 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098616||47715|
NCT02098304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-01-2013|Post-Approval Clinical Study to Evaluate the Calcivis Caries Activity Imaging System|Post-Approval Clinical Study to Evaluate the Safety and Performance of the Calcivis Caries Activity Imaging System in a Clinical Setting||Calcivis Ltd|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|42|||Both|16 Years|25 Years|No|||February 2015|February 10, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02098304||47739|
NCT02099136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00525|Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers|Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation||National Cancer Institute (NCI)||Completed|September 1999|December 2004|Actual|September 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2015|March 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099136||47675|
NCT02099357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FADEUPAFA20132015|Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training|Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training||Universidade do Porto|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 1, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02099357||47658|
NCT02099370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-BGT-13-10458|Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients|A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.|ADIMS|University of South Florida|No|Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|community sample of Multiple Sclerosis patients started on Tecfidera|March 2016|March 17, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02099370||47657|
NCT02065440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2011-65|The Effect of Ebastine/Pseudoephedrine on Subacute Cough|The Effect of Ebastine/Pseudoephedrine on Subacute Cough :a Randomized Placebo-controlled Trial||Seoul National University Hospital|Yes|Active, not recruiting|September 2011|||February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|20 Years|70 Years|No|||February 2014|February 16, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02065440||50256|
NCT02065141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0758F|Method To Measure Protein Digestion & Absorption|Validation Of A New Method To Simultaneously Measure Protein Digestion And Absorption||Texas A&M University|No|Recruiting|November 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02065141||50279|
NCT02065414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAEBBA0005|A Clinical Trial to Test the Effect of Experimental Mouth Rinse on Gum Disease|Four Weeks Clinical Efficacy of an Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02065414||50258|
NCT02065986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002373-56|Pre-exposure Option for Reducing HIV in the UK.(PROUD)|Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD)|PROUD|Medical Research Council|Yes|Recruiting|October 2012|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02065986||50214|
NCT02066207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146DDI13024|CKD-337 Drug Interaction Study|Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Fenofibrate and Atorvastatin in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|March 2014|||June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2014|February 18, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02066207||50198|
NCT02115451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|685-06289|Nonsurgical or Surgical Treatment of ACL Injuries|Dynamic Stability of the ACL Deficient Knee||Oslo University Hospital|No|Completed|January 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|143|||Both|13 Years|60 Years|No|Non-Probability Sample|Athletically active anterior cruciate ligament injured patients|April 2014|April 24, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115451||46425|
NCT02115464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2014-ALMERA|Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy|A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer|ALMERA|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|September 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115464||46424|
NCT02115724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-Stress Pro00001887|Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)|Effect of Low Childhood Socioeconomic Status (SES) on Adult Endothelial Function and Nitric Oxide Bioavailability in Vivo and ex Vivo|NO-Stress|Georgia Regents University|Yes|Recruiting|April 2014|April 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02115724||46404|
NCT02116179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34DA031063|DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients|DVD-based HIV/HCV Intervention for Drug-Involved Latino Criminal Justice Clients||University of Delaware|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116179||46369|
NCT02065076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13089|Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients|Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Ambulatory Pre-dialysis Outpatients : a Randomized Triple-blind Placebo-controlled Trial|SKIP|Maisonneuve-Rosemont Hospital|No|Completed|February 2014|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065076||50284|
NCT02065336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2001|Study of ARC-520 in Patients With Chronic Hepatitis B Virus|A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection||Arrowhead Research Corporation|Yes|Recruiting|March 2014|June 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|58|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065336||50264|
NCT02066129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 008|Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations|Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations|STICS|Milton S. Hershey Medical Center|Yes|Recruiting|July 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|5 Years|11 Years|No|||April 2015|April 6, 2015|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066129||50203|
NCT02096900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140032|A Comparison of Midazolam and Zolpidem as Oral Premedication in Children|A Comparison of Midazolam and Zolpidem as Oral Premedication in Children|PedsPreMed|Loma Linda University|Yes|Recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|2 Years|9 Years|No|||February 2016|February 10, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02096900||47847|
NCT02097784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.831|Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury|Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury||Hospices Civils de Lyon|No|Recruiting|March 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097784||47779|
NCT02097797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 121104|Impact of the Fecal Flora Transplantation on Crohn's Disease|Impact of Fecal transPlantAtion on MiCrobotia and hosT in Crohn's Disease|IMPACT-Crohn|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02097797||47778|
NCT02098057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005160|Change in Permeability of the Small Intestine After Treatment With Gluten|A Pilot Study Barrier Function, Intestinal Permeability and Tight Junction Expression in Gluten Sensitive Patients With Functional Gastrointestinal Disorders||Mayo Clinic|Yes|Recruiting|April 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02098057||47758|
NCT02067845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR SRC - 4487453|A Group-level Intervention to Reduce HIV/STI Risk for Women Who Have Sex With Women in Calgary and Toronto|Pilot-testing a Group-level Intervention to Reduce Risk for Sexual Transmission of HIV/STIs Among Lesbian, Bisexual and Queer Women and Other Women Who Have Sex With Women in Calgary and Toronto||University of Toronto|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|44|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 4, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067845||50074|
NCT02068144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-047|The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans|The Effect of Daily Dietary Supplementation With Cranberry Extract on Modulation of Cardiovascular Risk Factors in Obese, Insulin Resistant Human Subjects||Pennington Biomedical Research Center|No|Recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|44|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068144||50051|
NCT02098590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMGF2b|Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection|Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection|BMGF2b|Radboud University|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02098590||47717|
NCT02068677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|456550|Evaluation of Injection Techniques in Celiac Plexus Neurolysis|Evaluation of Injection Techniques in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN)||Florida Hospital|No|Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|51|||Both|19 Years|89 Years|No|||February 2015|February 11, 2015|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02068677||50010|
NCT02068937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG/HCPA 10-0376|Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients|Effectiveness of a Diuretic Algorithm in Clinical Stability and Readmissions in Heart Failure Patients||Hospital de Clinicas de Porto Alegre|No|Recruiting|May 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||February 2014|February 23, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068937||49990|
NCT02065999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1107|Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients|Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients|SEARCH-C|Kirby Institute|No|Recruiting|November 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Stored serum and peripheral blood mononuclear cells.|Both|16 Years|N/A|No|Non-Probability Sample|An anticipated 100 participants will be recruited from 2 study sites: St Vincent's        Hospital, Sydney; St Vincent's Hospital, Melbourne.|March 2016|March 3, 2016|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02065999||50213|
NCT02065700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-205 (DARWIN3)|Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients|A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis|DARWIN3|Galapagos NV|Yes|Enrolling by invitation|February 2014|March 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065700||50236|
NCT02066519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111106|Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis|Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis|MGEX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066519||50174|
NCT02115139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM 1202|GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases|A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases|GRAY-B|Grupo Español Multidisciplinar de Melanoma|No|Recruiting|April 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02115139||46449|
NCT02115152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLiu|Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer|Phase II Neoadjuvant Trial of Capecitabine, Cyclophosphamide and Epirubicin for Patients With Axillary Lymph Node Positive Stage II-III Operable Breast Cancer||Guangxi Medical University|No|Not yet recruiting|June 2014|||June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|70 Years|No|||April 2014|April 14, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02115152||46448|
NCT02116192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K12HD055894|Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents|Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents|NAFLD|University of Wisconsin, Madison|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|11 Years|17 Years|No|||January 2016|January 20, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116192||46368|
NCT02116205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-01|Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever|A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Hemorrhagic Fever With Renal Syndrome||U.S. Army Medical Research and Materiel Command|No|Recruiting|May 2014|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|132|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116205||46367|
NCT02116452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPA|Prebiotics in Prevention of Atopy|Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy|PIPA|Federico II University|No|Completed|November 2011|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|380|||Both|N/A|24 Weeks|No|||February 2011|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116452||46348|
NCT02065882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biotest 984|Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency|A Prospective, Open-label, Phase I/II Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency||Biotest|No|Active, not recruiting|March 2013|October 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|75 Years|No|||July 2015|July 21, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02065882||50222|
NCT02065895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000401|Effect of Gain on Closed-Loop Insulin|Effect of Gain on Closed-Loop Insulin||Joslin Diabetes Center|No|Recruiting|December 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||September 2014|September 20, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02065895||50221|
NCT02096627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00089916|Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery|Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery on Corneal Endothelial Cell Loss||Johns Hopkins University|No|Not yet recruiting|May 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|720|||Both|18 Years|90 Years|No|Probability Sample|Patients who present to our center with visually significant cataract and who may benefit        from cataract surgery|March 2014|March 23, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02096627||47867|
NCT02097498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0226|Improving Patient Safety Through Simulation Research|Remote Expert Direction and Simulation Training in Airway Management With Paramedics|REDSTAMP|Ohio State University|No|Active, not recruiting|August 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|250|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02097498||47801|
NCT02097810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXDX-101-01|Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.|A Phase 1/2a, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations|STARTRK-1|Ignyta, Inc.|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097810||47777|
NCT02098070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14018|Knee Pain Phenotypes in the Community Study|Knee Pain and Related Health in the Community Study||University of Nottingham|Yes|Enrolling by invitation|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40000|Samples With DNA|Whole Blood Urine|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Community-derived sample|December 2015|December 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02098070||47757|
NCT02098330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVNHIT_kr|The Efficacy of Steroid Therapy in Vestibular Neuritis|The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study||Asan Medical Center|No|Active, not recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2015|January 26, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098330||47737|
NCT02098343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR-407|p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246|PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246||Aprea AB|Yes|Recruiting|March 2014|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02098343||47736|
NCT02068690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346.1|Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Male Subjects (Partially Randomised, Single-blind, Placebo-controlled) and Investigation of Relative Bioavailability and Food Effect of BI 425809 (Open-label, Randomised, Three-way Crossover)||Boehringer Ingelheim||Completed|March 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|83|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|February 20, 2014||||No||https://clinicaltrials.gov/show/NCT02068690||50009|
NCT02068703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075628|Sleep Enhancing Tools: Pilot Study|Use of Sleep Enhancing Tools Impact on Self-Reported Sleep Survey||University of Michigan|No|Enrolling by invitation|February 2014|February 2019|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2015|June 3, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068703||50008|
NCT02098863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCRIP|Sickle Cell Clinical Research and Intervention Program|Sickle Cell Clinical Research and Intervention Program||St. Jude Children's Research Hospital|No|Recruiting|March 2014|December 2044|Anticipated|December 2044|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|Samples With DNA|All participants will be offered the option of having biological specimens collected and      saved for future research. DNA, plasma, and urine will be collected from participants and      stored at Tissue Resources at St. Jude Children's Research Hospital. This will facilitate      future high quality genotype-phenotype studies and other genetic and proteomic studies      related to variability in disease severity, treatment response, and health outcomes.|Both|N/A|N/A|No|Non-Probability Sample|Participants with a diagnosis of sickle cell disease of any genotype.|November 2015|November 18, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02098863|30 Years|47696|
NCT02098876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066353|Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels|Evaluation of Wall Shear Stress and Neointimal Healing Following Percutaneous Coronary Intervention of Angulated Vessels With Resolute® Integrity Zotarolimus Eluting Coronary Stent Compared to XIENCE Xpedition® Everolimus Eluting Coronary Stent (SHEAR-STENT Study)|SHEAR-STENT|Emory University|No|Recruiting|May 2014|March 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|126|||Both|30 Years|80 Years|No|||January 2016|January 6, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02098876||47695|
NCT02064933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RDCRN PIDTC-6904|Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990|Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|June 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|541|Samples With DNA|Whole blood and tissue samples|Male|N/A|N/A|No|Non-Probability Sample|Male WAS participants treated at consortium centers Since 1990|March 2016|March 21, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064933||50295|
NCT02065154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1286|Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis|Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)||University of Alabama at Birmingham|Yes|Recruiting|August 2013|June 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|48|||Both|19 Years|65 Years|No|||March 2016|March 6, 2016|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02065154||50278|
NCT02065167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO -2|Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip|Evaluation of Safety and Feasibility of Bone Marrow Derived Autologous MSCs to Enhance Bone Healing in Patients With Avascular Necrosis of the Femoral Head|ORTHO-2|Universidad Autonoma de Madrid|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||February 2014|February 14, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065167||50277|
NCT02066246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-UKE-PV4374|Lung Function After Robot-assisted Radical Prostate Ectomy|Investigation of the Possible Advantages of the AirSeal-system Compared to Conventional CO2 Insufflation Systems in Terms of Lung Function and Hemodynamics in Robot-assisted Laparoscopic Radical Prostate Ectomy||Universitätsklinikum Hamburg-Eppendorf|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|192|||Male|18 Years|N/A|No|||October 2014|October 8, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02066246||50195|
NCT02066545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-003|Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Acne Vulgaris||Cutanea Life Sciences, Inc.||Completed|April 2014|||November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|327|||Both|12 Years|N/A|No|||September 2015|September 1, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066545||50172|
NCT02066220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOP PNET 5 MB|International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma|An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR)||Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|June 2014|April 2024|Anticipated|April 2024|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|3 Years|21 Years|No|||December 2015|December 2, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02066220||50197|
NCT02066233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008214|Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy|Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy||Mayo Clinic|No|Active, not recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066233||50196|
NCT02066857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071060|Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly|Use of Cast Versus Removable Splints for Minimally Displaced Distal Radius Fractures in Elderly Patients: A Prospective, Randomized Trial||Emory University|No|Enrolling by invitation|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|N/A|No|||April 2015|April 13, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066857||50149|
NCT02116218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-2014-ED|Assessment of Cancer Pain in Emergency Department in Traditional Chinese Medicine|Assessment of Cancer Pain in Emergency Department in Traditional Chinese Medicine (TCM): A Study Protocol for a Clinical Trial||Changhua Christian Hospital|Yes|Recruiting|March 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||April 2014|April 15, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02116218||46366|
NCT02115958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-001|The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic of the Nasopharynx||Fuda Cancer Hospital, Guangzhou|Yes|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||April 2014|June 1, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115958||46386|
NCT02115971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Balgrist 2009-124|Jumping Exercises Approach in Individuals With Chronic Ankle Instability|The Effect of a 12-week Training Jumping Exercises Program in Individuals With Chronic Ankle Instability: Randomized Controlled Trial Pilot Study||Balgrist University Hospital|No|Terminated|September 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|50 Years|No|||August 2015|August 27, 2015|April 3, 2014||No|The recruitment process could not provide us with enough participants|No||https://clinicaltrials.gov/show/NCT02115971||46385|
NCT02116738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMMA-LEC-001642|Modified Limberg Procedure Versus Lateral Advancement Flap With Burrow's Triangle Procedure in the Treatment of Pilonidal Sinus|Interventional Study of the Relatively New Surgical Techniques on the Treatment of Pilonidal Sinus Disease||Ankara Mevki Military Hospital|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 15, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116738||46326|
NCT02116751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 039/14|Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients|Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients: Role of Classical Factors, HIV Infection, and Antiretroviral Therapy|ComorVIH|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|306|||Both|18 Years|N/A|No|Non-Probability Sample|HIV infected patients in active follow up, receiving antiretroviral therapy|April 2014|December 6, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02116751||46325|
NCT02112942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7822-001|Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects|A Phase I Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects||Merck Sharp & Dohme Corp.|No|Terminated|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|April 10, 2014||No|Early termination of IDX21459 was due to integration of Merck's HCV antiviral pipeline has    resulted in revisions of the clinical development plan.|No||https://clinicaltrials.gov/show/NCT02112942||46618|
NCT02113228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Process HCRP: 1822/2013|Energy Metabolism in Patients With Short Bowel Syndrome|Assessment of Energy Metabolism in Patients With Short Bowel Syndrome Using the Doubly Labeled Water Method||University of Sao Paulo|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The recruitment of volunteers with short bowel syndrome (SIC) will be done in the Hospital        das Clinicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (HCFMRP /        USP). These individuals will be paired with volunteers without short bowel syndrome, which        will be selected at the clinics of the Hospital of the Faculty of Medicine of Ribeirão        Preto, and will constitute the control group.|December 2014|December 2, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113228||46596|
NCT02066142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRA20132014|Tomosynthesis (TS) Versus Ultrasonography (US) in Women With Dense Breast|Tomosynthesis (TS) Versus Ultrasonography (US) in Screening Women With Dense Breast|ASTOUND|University of Genova|No|Recruiting|December 2012|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|4000|||Female|18 Years|90 Years|No|||November 2015|November 30, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02066142||50202|
NCT02096926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-DEN-01C|Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery|Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery||Lotus Clinical Research, LLC|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096926||47845|
NCT02097212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#-2794|Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea|Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea||National Jewish Health|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|80 Years|No|Non-Probability Sample|In this pilot study we plan to recruit 30 consecutive patients with TBM/HDAC from the        interventional pulmonology clinic at National Jewish Health (NJH). These patients will        already have an established diagnosis of TBM and/or HDAC.|March 2016|March 23, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02097212||47823|
NCT02097511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI-102|Sarpogrelate Drug Interaction|A Randomized, Open-label, Three-sequence, Three-period Crossover Study to Investigate The Effect of Anplag on the Disposition of Betaloc in Healthy Male Volunteers||Ajou University School of Medicine|No|Completed|December 2013|December 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02097511||47800|
NCT02067858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003|An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System|An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System||University of Pittsburgh|Yes|Terminated|April 2011|March 2016|Actual|March 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|February 14, 2014|Yes|Yes|Unable recruit subjects|No||https://clinicaltrials.gov/show/NCT02067858||50073|
NCT02068170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV003|Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital|Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital|RISQ-PATH|Katholieke Universiteit Leuven|No|Completed|February 2014|June 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|178|Samples With DNA|-  1 blood sample (plasma) to measure the blood concentration of the drug        -  1 blood sample (DNA) to store in a biobank for additional research|Both|18 Years|N/A|No|Probability Sample|Patients treated with acute potentional QT-prolonging medication. In a university        hospital.|July 2015|July 27, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068170||50049|
NCT02064946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA175793-01A1|High-dose Vitamin D Supplementation for ADT-induced Side Effects|High-dose Vitamin D Supplementation for ADT-induced Side Effects||University of Rochester|Yes|Recruiting|February 2014|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|76|||Male|60 Years|99 Years|No|||October 2015|October 22, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064946||50294|
NCT02068157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 235613|Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer|Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II||Roswell Park Cancer Institute|Yes|Recruiting|April 2014|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068157||50050|
NCT02068443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-MET/CCT-001|Double-blind Comparative Study of SYR-322-MET.|Double-blind Comparative Study When Metformin Hydrochloride is Added on to SYR-322.||Takeda|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|374|||Both|20 Months|74 Years|No|||November 2015|November 13, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068443||50028|
NCT02065453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22548|Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy|Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy||St. Louis University|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|21 Years|80 Years|No|||August 2014|August 26, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02065453||50255|
NCT02065466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312169092|Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases|A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases||University of Arizona|Yes|Withdrawn|July 2014|August 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|February 6, 2014|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT02065466||50254|
NCT02065713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-50307|Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients|A Multicentre, Randomized, Double-blind, Parallel-group Study To Compare The Efficacy Of Golimumab In Combination With Methotrexate (MTX) Versus MTX Monotherapy, In Improving Dactylitis And Enthesitis, In MTX Naïve Psoriatic Arthritis Patients.|GO-DACT|Instituto de Medicina Molecular|Yes|Recruiting|August 2014|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||April 2015|April 11, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02065713||50235|
NCT02066558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-194|Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow|Basic Research on Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model||Danish Headache Center|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066558||50171|
NCT02066532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM1906|Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer|Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer||Columbia University|Yes|Recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066532||50173|
NCT02067130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02149|Utility of Fibroscan in Estimating Hepatic Iron Concentration|Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients With Transfusion Dependent Hemoglobinopathies||University of British Columbia|No|Active, not recruiting|October 2013|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|19 Years|N/A|No|||January 2016|January 13, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067130||50129|
NCT02116764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140091|Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995|Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|2 Years|N/A|No|||February 2016|February 23, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116764||46324|
NCT02116465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCD-018/K|Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration|Open-label, Two-treatment, 4-period Replicated Crossover Study in Healthy Subjects to Investigate the Plasma Pharmacokinetics of Levodopa and Carbidopa After Oral Administration of Single Doses of Two Fixed-dose Combination Products|LCD18K|Desitin Arzneimittel GmbH|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02116465||46347|
NCT02116478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2055|Gastrocnemius Recession vs. Conservative Treatment for Chronic Plantar Fasciitis|Gastrocnemius Recession vs. Conservative Treatment for Chronic Plantar Fasciitis. A Randomized Controlled Trial.||Oslo University Hospital|No|Recruiting|August 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||October 2014|October 22, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02116478||46346|
NCT02113241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPA-MS|Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion|Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion||University of Guadalajara|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|60 Years|No|||May 2015|May 26, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113241||46595|
NCT02096653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00092414|Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections|Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections||Johns Hopkins University|No|Recruiting|February 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02096653||47865|
NCT02096939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48364|Microvascular Function in Primary Aldosteronism|Microvascular Function in Patients With Primary Aldosteronism and Essential Hypertension||Maastricht University Medical Center|No|Withdrawn|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|70 Years|No|Non-Probability Sample|Twenty patients with primary aldosteronism and twenty patients with essential hypertension|August 2015|August 24, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02096939||47844|
NCT02097225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00615|Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in With BRAF-Mutant Melanoma and Other Solid Tumors||National Cancer Institute (NCI)|No|Suspended|May 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 24, 2014|No|Yes|CTEP Initiated Action|No||https://clinicaltrials.gov/show/NCT02097225||47822|
NCT02067052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vulvar protocol- Dr. Altamiro|New Strategy for the Treatment of Vulvar Cancer|New Strategy for the Treatment of Vulvar Cancer Employing Sentinel Scintigraphy, Surgery, Chemotherapy, and Radiotherapy||Instituto do Cancer do Estado de São Paulo|No|Recruiting|July 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|21|||Female|18 Years|N/A|No|Non-Probability Sample|Twenty one consecutive patients with a diagnosis of vulvar carcinoma (early and advanced        stages) will be studied.        All patients with tumors up to 4 cm in greatest diameter, uncompromised urethra or anus,        and lymph nodes smaller than 15 mm in greatest diameter in scan images will be considered        early-stage cases. Any other cases will be deemed advanced.|February 2014|February 18, 2014|August 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02067052||50135|
NCT02067338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 387/2012|Epidural Low Dose Morphine in Postoperative Pain After Posterior Lumbar Spinal Surgery|The Effect of Epidural Low-dose Morphine-soaked Microfibrillar Collagen Sponge in Postoperative Pain Control After Posterior Lumbar Spinal Surgery: a Randomized, Double-blind, Placebo-controlled||Mahidol University|No|Completed|August 2012|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02067338||50113|
NCT02068469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASA 4.0|In Vitro Diagnostic Device for the Detection of Strep A|Multi-Center Study of an In Vitro Diagnostic Device for the Detection of Strep A||IQuum, Inc.|No|Completed|December 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|799|Samples Without DNA|Throat culture swab|Both|3 Years|N/A|No|Non-Probability Sample|Adult and Pediatric primary care clinic, walk in clinic|April 2014|April 29, 2014|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068469||50026|
NCT02068716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAI_Umich|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery|HAI|University of Michigan|No|Active, not recruiting|March 2014|||October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|13925|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing adult cardiac surgery|November 2015|November 7, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068716||50007|
NCT02067559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:460|Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries|Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries||University of Manitoba|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|17 Years|N/A|No|||November 2015|November 18, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067559||50096|
NCT02067572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salvia|A Randomized Controlled Trial Evaluating the Effectiveness of a Salvia-based Mouthwash in Palliative Care|A Comparison of the Effectiveness of Normal Saline Mouthwash and Mouthwash Based on Tea Solution From Salvia Officinalis (SO) in Palliative Care. A Randomized Controlled Trial||Lovisenberg Diakonale Hospital|No|Not yet recruiting|February 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067572||50095|
NCT02064959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0762|To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients|HypOthermia for Patients Requiring Evacuation of Subdural Hematoma: a Multicenter, Randomized Clinical Trial|HOPES|The University of Texas Health Science Center, Houston|Yes|Recruiting|February 2014|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|22 Years|65 Years|No|||December 2015|December 1, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02064959||50293|
NCT02064972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 1574|CEC Count Changes to Support GvHD Diagnosis.|Evaluation of Circulating Endothelial Cells (CEC) as a Marker of Endothelial Damage in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): Correlation With the Occurrence of Graft-versus-Host Disease (GvHD)|ALLOCEC|Azienda Ospedaliera Spedali Civili di Brescia|Yes|Enrolling by invitation|April 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients, affected by hematologic disorders, undergoing allo-HSCT.|January 2016|January 26, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02064972||50292|
NCT02068950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH1401|Progressive Resistance Training Program in Head and Neck Cancer Patients|Feasibility of a 12-week Progressive Resistance Training Program in Head and Neck Cancer Patients During Concurrent Radiochemotherapy - a Pilot Trial||Herlev Hospital|Yes|Completed|February 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02068950||49989|
NCT02065726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130018046|Whey Protein Supplementation in Cancer Patients|Whey Protein Supplementation in Malnourished Cancer Patients: a Randomized, Controlled Trial||IRCCS Policlinico S. Matteo|Yes|Recruiting|October 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02065726||50234|
NCT02066012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0180|MEPHISTO (Macrophage Phenotype In Metabolic Syndrome With Iron Overload)|Impact of Dysmetabolic Iron Overload Syndrome on Polarization Capacity of Macrophages|MEPHISTO|University Hospital, Clermont-Ferrand||Recruiting|February 2014|October 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|metabolic syndrome|February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066012||50212|
NCT02067143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1913|MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate|National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|April 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|204|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02067143||50128|
NCT02067442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.685|Prospective, Randomized, Double Blind Study Comparing IV vs PO Acetaminophen in Patients Undergoing Lumbar Discectomy|Prospective, Randomized, Double-blind, Placebo-Controlled Study to Compare the Effects of Intravenous Versus Oral Acetaminophen on Postoperative Clinical Outcomes After Ambulatory Lumbar Discectomy||Thomas Jefferson University|No|Recruiting|August 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|January 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067442||50105|
NCT02066870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV55|Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI|Phase I Study of the Combination of Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|January 2014|January 2016|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|75 Years|No|||March 2015|March 12, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066870||50148|
NCT02067637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1761|Delayed Effects of Treatment in Cancer Survivors (DETECS)||DETECS|University of Colorado, Denver|No|Withdrawn|April 2016|December 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Blood and urine|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospective cohort study of female cancer survivors who are at least 2 years from        completion of cancer therapy and healthy controls age less than 45 years.|November 2015|November 9, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02067637||50090|
NCT02116504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-RA-P01|Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients|Multi-center Prospective European Cohort Study in Patients With Rheumatoid Arthritis or Juvenile Idiopathic Arthritis Planned to be Treated Independently of the Present Study, With the First Line of Adalimumab, Etanercept, Infliximab Therapy or With Rituximab or Tocilizumab (After Anti-TNF Therapy or Another Biotherapy or in First Line)|ABI-RA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|700|||Both|2 Years|N/A|No|||December 2015|December 8, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02116504||46344|
NCT02116517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100WFA2200449|Effects of Green Tea Extract on Obese Women With High Level of LDL|Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial|GTE-LDL|National Yang Ming University|No|Completed|August 2011|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|65 Years|No|||December 2013|April 15, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02116517||46343|
NCT02112955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SESSMP01|A Self-efficacy Enhancing Stroke Self-management Program for Community-dwelling Stroke Survivors|A Randomized Controlled Trial of the Effectiveness of a Nurse-led Self-efficacy Enhancing Stroke Self-management Program for Community-dwelling Stroke Survivors|SESSMP|Queensland University of Technology|No|Active, not recruiting|May 2014|May 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112955||46617|
NCT02112968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302|A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia|||Technolas Perfect Vision GmbH|No|Not yet recruiting|December 2014|May 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|97|||Both|18 Years|85 Years|No|||November 2014|November 19, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112968||46616|
NCT02112981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioM/RCT/12/03|BioMime Vs. Xience Randomised Control Clinical Study|A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of and Xience Everolimus Eluting Stent to Evaluate Efficacy and Safety in Coronary Artery Disease|meriT-V|Meril Life Sciences Pvt. Ltd.|No|Recruiting|June 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02112981||46615|
NCT02096965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001780|Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study|Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study||Mayo Clinic|No|Active, not recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02096965||47842|
NCT02097238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00621|Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma|A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma||National Cancer Institute (NCI)|Yes|Completed|August 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|12 Years|49 Years|No|||September 2015|December 18, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097238||47821|
NCT02097251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-606A|An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient|An Open-Label Treatment Protocol With UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy for an Advanced Stage Mucopolysaccharidosis Type 7 (MPS 7) Patient||Northwell Health||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Male|N/A|N/A||||April 2015|April 13, 2015|March 24, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02097251||47820|
NCT02097264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-4064|A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating the Mechanism of Action, of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate||Novo Nordisk A/S|No|Withdrawn|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||August 2014|August 13, 2014|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02097264||47819|
NCT02067325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152-2|Effects of Thai Massage on EMG|Effects of Thai Massage on EMG||Mae Fah Luang University Hospital|Yes|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|40 Years|No|||May 2015|May 5, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02067325||50114|
NCT02067351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008531|Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy|Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy||Mayo Clinic|No|Active, not recruiting|April 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Female|20 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02067351||50112|
NCT02067585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008986|An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery|An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery||University of Alberta|No|Completed|February 2010|September 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||February 2014|February 18, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02067585||50094|
NCT02068729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-002|Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine|A Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine: K2M RAVINE® Far Lateral System Versus NuVasive XLIF®|RAVINE|K2M, Inc.|Yes|Enrolling by invitation|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|222|||Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for study enrollment will have a primary diagnoses limited to        degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at L2-S1 requiring        surgical intervention at one or two contiguous levels. Qualified patients will have        confirmed failure of conservative therapy as well as plain film imaging studies. Subjects        must be ≥ 18 years old at the time of enrollment.|January 2016|January 28, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02068729||50006|
NCT02068456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-402-KR|Post Marketing Surveillance of Roflumilast in Korea|Post Marketing Surveillance of Roflumilast in Korea||Takeda|No|Recruiting|September 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|COPD patients prescribed roflumilast in the Republic of Korea.|February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068456||50027|
NCT02065180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|verhoevenhermans|The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome|The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol||Universiteit Antwerpen|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065180||50276|
NCT02065193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China SCORE study|Prevalence of Autism Spectrum Conditions in Mainland China|Social Communication Research and Epidemiological Study in China|China SCORE|University of Cambridge|Yes|Recruiting|April 2013|||January 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||14|Anticipated|280000|||Both|6 Years|11 Years|No|Probability Sample|Study population in each city is a defined region, usually a district or two districts. We        focus on urban populations in this study.|February 2014|February 14, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065193||50275|
NCT02065739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103432|A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants|A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects||Janssen Pharmaceutica N.V., Belgium|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02065739||50233|
NCT02066259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OctavaColon_001|OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol|OctavaColon Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol||Eventus Diagnostics Ltd|No|Recruiting|August 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1080|Samples With DNA|Human plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|There are 3 different populations that will participate in the study-          1. Any person with suspected colon abnormality, that will be classified after             colonoscopy/surgery as "colon cancer patient" will be a part of group1 - "Patient".          2. Any person with suspected colon abnormality, that will be classified after             colonoscopy as "benign polyp" will be a part of group2 - "benign".          3. Any person with suspected colon abnormality, that will be classified after             colonoscopy as "normal/healthy" will be a part of group0 - "healthy".|August 2014|August 4, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02066259||50194|
NCT02066909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601002|A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Western And Japanese Subjects||Pfizer|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|9||Actual|77|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02066909||50146|
NCT02067156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-202-004|Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma|An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma||GenSpera, Inc.|No|Recruiting|February 2014|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067156||50127|
NCT02067169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09013 ORPHAVIC|A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.|A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. Survey of Pharmacological and Virological Resistance of Cytomegalovirus to Antiviral Therapy in Transplantation.|ORPHAVIC|University Hospital, Limoges|No|Recruiting|January 2012|January 2017|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Detection of the CMV in sang, the leukocytes, or plasma with or without the viral      quantification and/or the sample of urine of saliva or tissues, positive for research of      CMV.|Both|N/A|N/A|No|Non-Probability Sample|allograft recipient or hematopoietic stem cell or solid organ.|February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02067169||50126|
NCT02067650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSUS|Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis|Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis||Children's Hospital of Eastern Ontario|No|Enrolling by invitation|September 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|2 Years|99 Years|No|Non-Probability Sample|Patients with MPS I and IV|January 2016|January 26, 2016|August 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02067650||50089|
NCT02067663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3264|Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study|Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study||University of Colorado, Denver|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|123|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women interested in an immediate postpartum IUD, or those who recently had one placed, who        are willing to be followed postpartum.|October 2015|October 8, 2015|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067663||50088|
NCT02116803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2X01B|An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective|An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator||Novartis|No|Active, not recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116803||46321|
NCT02116777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00804|Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies|A Phase 1/ 2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies||National Cancer Institute (NCI)|Yes|Recruiting|May 2014|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|172|||Both|13 Months|30 Years|No|||January 2016|March 24, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116777||46323|
NCT02116790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00083465|Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects|Study of the Efficacy of Co-administration of an NSAID With a Dopamine Agonist in the Alleviation of Acute Cutaneous Inflammatory Pain in Healthy Subjects||Northwestern University|No|Withdrawn|May 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 9, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02116790||46322|
NCT02113267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-226361|Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.|Treatment of Eosinophilic Esophagitis With Mometason Furoat Aerosol: a Randomised, Placebo-controled Phase II Study for Evaluation of Treatment Effect on Group Level Including Symtom Questionnaires||Vastra Gotaland Region|Yes|Enrolling by invitation|April 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113267||46593|
NCT02113735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC01-ARDS-01|Safety and Efficacy Study of Acthar in Subjects With ARDS|A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar® Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)||Mallinckrodt|Yes|Withdrawn||||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|April 8, 2014|Yes|Yes|A company decision was made not to proceed with the study.|No||https://clinicaltrials.gov/show/NCT02113735||46557|
NCT02066792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH099318|Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder|Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder||University of Texas at Austin|Yes|Recruiting|April 2014|||March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|156|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066792||50154|
NCT02066805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101335|Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark|Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark||Amgen|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|142|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include 108-200 patients who receive a prescription in secondary        care of XGEVA during the first year after the initial market availability. These patients        will be identified from the Danish National Registry of Patients and other sources in the        Northern Jutland Region and Copenhagen.|May 2015|May 27, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066805||50153|
NCT02067065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColonPropo-01|Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial|Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial||Hospital Beatriz Ângelo|Yes|Completed|January 2014|August 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|277|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02067065||50134|
NCT02067871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS - 20160|Treatment of Knee Osteoarthritis: Neuromuscular Electrical Stimulation and Low-level Laser.|Neuromuscular Electrical Stimulation and Low-level Laser: Combined Use for the Treatment of Knee Osteoarthritis in Elderly||Federal University of Rio Grande do Sul|No|Completed|March 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Female|60 Years|80 Years|No|||February 2014|February 18, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02067871||50072|
NCT02068183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03116|World Trade Center Adolescent Health Study|Early Identification of World Trade Center Conditions in Adolescents||New York University School of Medicine|Yes|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|450|Samples With DNA|A research assistant well trained in pediatric phlebotomy will collect 25 mL of blood at the      first visit, as one aliquot of 3 ml blood in a lavender top vacutainer for CBC, one aliquot      of 5 ml blood in a goldtop vacutainer for whole blood, and one 3 ml of blood in a PAX Gene      (PreAnalitycX - Hombrechtikon, Switzerland) tube for RNA isolation. One 4 ml cryovial of      whole blood will be reserved for future DNA analysis and heavy metal analysis, and another      10 ml vacutainer will be reserved for persistent organic pollutants, while the blood in the      PAX Gene will be stored for RNA isolation.|Both|12 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population for the present proposal will be drawn from the pediatric component        of the WTCHR, a cohort of 71,436 adults and children who were first interviewed in        2003-04. To further investigate the associations of WTC exposures with health outcomes, we        will compare health parameters in the cohort of WTCHR registrants with 225 subjects in a        control cohort drawn from pediatric and adolescent clinics in Manhattan and Brooklyn.|February 2016|February 25, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02068183||50048|
NCT02064985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00086|Ticagrelor China Pharmacokinetic/Pharmacodynamic Study|An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease||AstraZeneca|No|Completed|February 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02064985||50291|
NCT02068963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10433-HCVQPS-01|Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing|Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay||Hologic, Inc.|No|Completed|February 2014|December 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|352|Samples With DNA|Plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|Treatment naïve men and women ≥18 years of age with chronic HCV infection initiating        sofosbuvir-based treatment will be enrolled from medical facilities that may include        private and academic family practice, infectious disease, hepatology, gastroenterology,        and medical group clinics.|February 2016|February 2, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068963||49988|
NCT02068976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-IOP-2012-109|Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)|Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|November 2013|June 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|39 Years|No|Non-Probability Sample|Patients procedints of gynecology deparment of the centers participants|September 2015|September 14, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068976||49987|
NCT02066025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OctavaBreast_1|Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test|Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test||Eventus Diagnostics Ltd|No|Not yet recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1425|Samples With DNA|Human plasma samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The target population will be any women with a mammography result (positive or negative).        Women with negative mammography will be tested with the OctavaPink version to provide        additional information to the doctors following a negative mammography.        Women with a positive mammography will be tested with OctavaBlue version to provide        additional information to a physician.|February 2014|February 17, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02066025||50211|
NCT02065206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0848|Spreading Teen-Recorded Inspirational Videos to Engage Schoolmates|Spreading Teen-Recorded Inspirational Videos to Engage Schoolmates|STRIVES|University of Chicago|No|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|504|||Both|15 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|All subjects enrolled will be under 18 years of age. Subjects 18 and over will not be        enrolled. The subjects for this study include two populations of students age 15-17: (1)        Collegiate Scholars members to participate in focus groups and (2) feedback group        recruited by students involved in TEACH research to view the social media campaign.|December 2015|December 1, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065206||50274|
NCT02066571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeWitt01|Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease|A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease||Henry Ford Health System|Yes|Recruiting|March 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|N/A|No|||July 2015|July 13, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066571||50170|
NCT02066584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011-14HYMC|The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization (IVF) Outcome of Sibling Oocytes|The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization Outcome of Sibling Oocytes||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|600|||Female|18 Years|42 Years|No|Probability Sample|Sibling oocytes retrieved from women who have undergone IVF treatment in our IVF unit.|February 2014|February 18, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02066584||50169|
NCT02066896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLXS|Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome|Low Level Laser Therapy For The Treatment Of Xerostomia In Primary Sjogren`s Syndrome||Federal University of São Paulo|No|Recruiting|May 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||October 2015|February 1, 2016|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02066896||50147|
NCT02066610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD61|Effect of Selenium Supplementation on Trace Mineral Antioxidant Enzyme and Amino Acid Metabolism in Infants|Effect of Parenteral and Enteral Selenium Supplementation on Trace Mineral Antioxidant Enzyme and Amino Acid Metabolism in Low Birth Weight Infants||Abbott Nutrition|No|Completed|March 1991|June 1993|Actual|June 1993|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|47|||Both|N/A|N/A|No|||February 2014|February 18, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02066610||50167|
NCT02067182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED2-201301|Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation|Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation|ODIn-AF|University Hospital, Bonn|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|630|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067182||50125|
NCT02066935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHEREBZ-001|Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study|Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil: Diagnosis and Associations - ADHERE BRAZIL Multicenter Study|ADHEREBRAZIL|Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi|No|Recruiting|September 2015|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney Transplant patient|September 2015|September 22, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02066935||50144|
NCT02067468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111545921657|Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia|Evaluation of Strategies for Optimal Clinical Management of Women With Atypical Squamous Cells of Undetermined Significance (ASC-US)|ASCUS-COL|Universidad de Antioquia|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|3000|||Female|20 Years|69 Years|No|||July 2015|July 16, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067468||50103|
NCT02067455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01798-37|REVADE : Right Ventricular Function and Exercise in Left Ventricular Assist Device Patients : Echocardiographic Study|This is a Non-randomized, Single-center, Prospective Investigation on Exercise Capacities of Left Ventricular Assist Devices Recipients|REVADE|Rennes University Hospital|Yes|Active, not recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02067455||50104|
NCT02113280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH-DJK-2013|DEMAND - DEgenerative Meniscal Tears - Arthroscopy vs. Dedicated Exercise|Randomised Controlled Trial Comparing Arthroscopy With Physiotherapy for Degenerative Meniscal Tears|DEMAND|Northumbria Healthcare NHS Foundation Trust|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|N/A|No|||April 2015|April 13, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02113280||46592|
NCT02112994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL06|Safety and Efficacy Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency|A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency||Alexion Pharmaceuticals|Yes|Active, not recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Months|N/A|No|||November 2015|November 16, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112994||46614|
NCT02113748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML10278|Downhill Walking Training in COPD|Downhill Walking to Enhance Training Effects in Patients With COPD||Katholieke Universiteit Leuven|No|Recruiting|April 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|N/A|No|||April 2014|April 11, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113748||46556|
NCT02067364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDxDev-CRT-2015|CRT ShuntCheck "Fit & Function" Study|CRT ShuntCheck "Fit & Function" Exploratory Study||NeuroDx Development|Yes|Recruiting|January 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|3 Years|N/A|No|||June 2015|June 22, 2015|February 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02067364||50111|
NCT02067598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152-3|Effects of Scapular Exercise on Patients With Scapulocostal Syndrome|Effects of Scapular Exercise on Patients With Scapulocostal Syndrome||Mae Fah Luang University Hospital|Yes|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|50 Years|No|||May 2015|May 5, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067598||50093|
NCT02068196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipi4|A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.|Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma|Ipi4|Oslo University Hospital|No|Active, not recruiting|January 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02068196||50047|
NCT02068209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gany-123|Evaluation of the Role of Tramadol 50mg as an Analgesic During Outpatient Hysteroscopy|Role of Tramadol 50mg in Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial.||Cairo University|Yes|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Female|18 Years|N/A|No|||April 2015|April 3, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02068209||50046|
NCT02068482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDSNC2009|Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis|Evaluation of Immunohistological Pattern in Patients With Uncomplicated Symptomatic Diverticular Disease and Correlation Between Intraluminal Bacterial Flora and Phlogosis||Catholic University of the Sacred Heart|No|Completed|November 2010|August 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02068482||50025|
NCT02065492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIT|Amlodipine for Myocardial Iron in Thalassemia|Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study|AMIT|Aga Khan University|No|Completed|February 2014|November 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|6 Years|20 Years|No|||December 2015|December 28, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02065492||50252|
NCT02068989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301011408|Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus|Stress Hyperglycemia as an Indicator for Future Diabetes Mellitus: A Prospective Cohort Study||Yale University|No|Recruiting|February 2013|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Whole Blood|Both|18 Years|80 Years|No|Non-Probability Sample|Intensive Care Unit admissions who are not known to be diabetic|February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068989||49986|
NCT02069002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSR113076|Comparing Interventions for Indoor Air -Related Functional Symptoms|Psychosocial Interventions for Indoor Air -Related Functional Symptoms - Randomized Controlled Trial (RCT)|TOSI|Finnish Institute of Occupational Health|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|25 Years|58 Years|No|||August 2015|August 13, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069002||49985|
NCT02066298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 007|Steroids In Eosinophil Negative Asthma|Steroids In Eosinophil Negative Asthma|SIENA|Milton S. Hershey Medical Center|Yes|Recruiting|July 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|384|||Both|12 Years|N/A|No|||March 2016|March 11, 2016|February 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066298||50191|
NCT02066597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130329-01H|Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation|Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation|SPADE|Ottawa Hospital Research Institute|Yes|Terminated|November 2013|||December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 5, 2013||No|Recommendation from the DSMB following recurrent DVT in 3/4 participants who underwent the    thrombectomy procedure.|No||https://clinicaltrials.gov/show/NCT02066597||50168|
NCT02066922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-057|A Comparative Study of Two Daily Disposable Contact Lenses in Higher Myopia Subjects|||Alcon Research|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 8, 2013|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT02066922||50145|
NCT02066948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307013804|Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health|Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome|S38|Purdue University|No|Active, not recruiting|January 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02066948||50143|
NCT02067195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC20140222|Aggressive hydraTion in Patients With ST -Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to prevenT Contrast-Induced Nephropathy|Aggressive Hydration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to Prevent Contrast-Induced Nephropathy, A Randomized, Controlled Trial REduction of riSk of Contrast-Induced Nephropathy followINg carDiac Catheterization 1|ATTEMPT|Guangdong General Hospital|Yes|Recruiting|July 2014|July 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|560|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02067195||50124|
NCT02067702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300662|Limb Cooling in Essential Tremor|Effects of Limb Cooling on Essential Tremor.||University of Florida|Yes|Recruiting|October 2014|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|The investigators will enroll 24 subjects diagnosed with Essential Tremor (ET) and 24        subjects with no diagnosed of ET.|November 2015|November 30, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02067702||50085|
NCT02113033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVNS01|VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients|VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients|VANGUARD|LivaNova|Yes|Active, not recruiting|October 2014|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113033||46611|
NCT02113046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09131|Pancreatic Stump Closure After Distal Pancreatic Resection|Prospective Randomized Study to Decrease Pancreatic Fistula Rate||Tampere University Hospital|No|Terminated|October 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|March 26, 2014||No|interim analysis does not show good results|No||https://clinicaltrials.gov/show/NCT02113046||46610|
NCT02113514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0490|Community Awareness, Resources and Education (CARE I): Project 3|Community Awareness, Resources and Education (CARE I): Project 3||Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2394|Samples Without DNA|Cervical mucus will be collected for Human Papillomavirus (HPV) assays and stored for      potential other assays related to HPV. Serum will be drawn for HPV serology and stored for      future analysis.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Woman 18 years or older that are nonpregnant with intact cervix and no cervical cancer who        present for a Pap smear. Must be residents of an Appalacian Ohio county.|April 2015|April 27, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113514||46574|
NCT02113527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC192014|Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia|Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia|DYSMOT-RIII|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|No|Completed|April 2014|June 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|75|Samples With DNA|breath specimen, whole blood, serum, white cells.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited in this observational study from the out-patients of the        National Institute of Digestive Diseases, I.R.C.C.S. Saverio de Bellis, Castellana Grotte,        Bari, Italy.|September 2015|September 1, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02113527||46573|
NCT02067611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-X0002-21|A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis|A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study to Evaluate the Efficacy and Safety of X0002 Spray Versus Placebo in Subjects With Osteoarthritis||Techfields Pharma Co. Ltd|Yes|Active, not recruiting|February 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|35 Years|85 Years|No|||May 2015|May 12, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067611||50092|
NCT02067884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-13-8|Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery|Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer||University of Southern California|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||July 2015|July 6, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067884||50071|
NCT02068742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1048|Postoperative Cognitive Dysfunction in Elderly|Postoperative Cognitive Dysfunction in Elderly|ElderlyPOCD|Università degli Studi dell'Insubria|Yes|Recruiting|January 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|90|||Both|65 Years|N/A|No|||February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068742||50005|
NCT02069015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCBSMF 1956.11|Achieving Blood Pressure Control Through Enhanced Discharge|Achieving Blood Pressure Control Through Enhanced Discharge|AchieveBP|Wayne State University|No|Active, not recruiting|October 2013|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|89 Years|No|||December 2015|December 18, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069015||49984|
NCT02065505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19284013.6.0000.5503|Method Pilates X Pilates in Water Postural Alignment and Its Correlation With Respiratory Capacity With Hemiparesis Spastic|METHOD PILATES x PILATES IN WATER POSTURAL ALIGNMENT AND ITS CORRELATION WITH RESPIRATORY CAPACITY WITH HEMIPARESIS SPASTIC||Universidade do Vale do Paraíba|Yes|Recruiting|October 2013|December 2014|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|70 Years|No|||February 2014|February 14, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02065505||50251|
NCT02065219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-130-open|Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair|Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair|Trigger-open|University of Copenhagen|No|Completed|November 2013|May 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|February 10, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065219||50273|
NCT02065752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103254|A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC|Yes|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|February 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065752||50232|
NCT02065765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14945|International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer|An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy||Eli Lilly and Company||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2016|January 28, 2016|February 17, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02065765||50231|
NCT02065778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-08|Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke|A Clinical Study of Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Chronic Stroke||Neurogen Brain and Spine Institute|Yes|Completed|December 2008|January 2014|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||February 2014|February 18, 2014|February 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065778||50230|
NCT02065479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2014-12|A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:|A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing||University of Florida|Yes|Recruiting|March 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|74 Years|No|||October 2015|October 1, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065479||50253|
NCT02066272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29/2013|Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease|Safety of Anti-TNF Antibodies, Including Biosimilars, in Treatment of Inflammatory Bowel Disease: Multicentre Cohort Observational Study (SATIMOS)|SATIMOS|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|All IBD patients who start or re-start anti-TNF therapy within the study period.|April 2015|April 6, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066272|2 Years|50193|
NCT02066623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GABI-R|Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold|German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis|GABI-R|IHF GmbH - Institut für Herzinfarktforschung|No|Active, not recruiting|November 2013|March 2021|Anticipated|March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3329|||Both|18 Years|N/A|No|Probability Sample|All patients in Germany and Austria having been implanted with ABSORB scaffold system|February 2016|February 23, 2016|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02066623|5 Years|50166|
NCT02066636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-153|A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)|A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen||Bristol-Myers Squibb|No|Recruiting|February 2014|January 2023|Anticipated|January 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1380|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066636||50165|
NCT02066649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2013003729|Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding|A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding||Rutgers, The State University of New Jersey|No|Not yet recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066649||50164|
NCT02067494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-032|Myofascial Release and Kinesio Taping on Autonomic Nervous System in Low Back Pain|Myofascial Release and Kinesiotaping on Disability, Pain, Automic Nervous System and Oxidative Stress Indicators in Chronic Low Back Pain: A Randomized Controlled Clinical Trial|I|Universidad de Almeria|No|Completed|February 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067494||50101|
NCT02067754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-076|Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer|Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer||Samsung Medical Center|Yes|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|400|Samples With DNA|-  From each enrolled patient who meets the inclusion/exclusion criteria, blood samples           will be collected 10 mL blood sample will be collected at the baseline and every cycles           of tumor evaluation.        -  20 of 5µm unstained sections will be collected at the time of study entry.|Both|20 Years|N/A|No|Probability Sample|Pathologically confirmed cancer patients|January 2016|January 3, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02067754||50081|
NCT02067767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0230|Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)|Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults|SWAD|Nantes University Hospital|Yes|Completed|February 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||February 2015|February 19, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067767||50080|
NCT02067481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICOP-F|Effect of a Diet and Physical Activity Intervention in Breast Cancer Survivors|Effect of a Diet and Physical Activity Intervention on Body Weight and Nutritional Patterns in Overweight and Obese Breast Cancer Survivors|PREDICOP-F|Institut Català d'Oncologia|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067481||50102|
NCT02105428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007006|Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and Accumulation|Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and Accumulation||Mayo Clinic|No|Active, not recruiting|July 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105428||47192|
NCT02113293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYS-001|CyclASol® Phase 1 Study|A Phase 1, Two Period, Double-blind, Randomised, Placebo-controlled, Cross- Over Study Investigating the Safety, Local Tolerability and Systemic Exposure of Cyclosporine A and Placebo (Vehicle) Following Single and Multiple Ocular Doses of CyclASol® and Placebo in Healthy Volunteers (CYS-001).||Novaliq GmbH|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113293||46591|
NCT02105727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014079|Changing Population Salt Consumption in Lithgow, Australia|A Before After Comparison of the Effectiveness of a Community-based Salt Reduction Program Done in Lithgow, Australia||The George Institute|No|Completed|March 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|991|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02105727||47169|
NCT02105987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201147|A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen|201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.||ViiV Healthcare|No|Completed|April 2014|December 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|555|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 3, 2014|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT02105987||47149|
NCT02067910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-473|Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome|Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAP III Study = Abatacept Sjögren Active Patients Phase III Study)|ASAPIII|University Medical Center Groningen|Yes|Recruiting|August 2014|July 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067910||50069|
NCT02068222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-213|A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection|An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|No|||March 2015|March 13, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068222||50045|
NCT02068235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058-114|Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects|Single-center, Open-label, Randomized, Two-way Crossover Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects||Actelion|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|17|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068235||50044|
NCT02068248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cholesterol Meta|Effect of Dietary Fibre on Serum Cholesterol Levels|Effect of Dietary Fibre on Serum Cholesterol Levels|CHOL-META|St. Michael's Hospital, Toronto|No|Active, not recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|healthy, hypercholesterolemic|October 2015|October 6, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068248||50043|
NCT02068495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119-011|Candesartan Cilexetil/Amlodipine Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"|Unisia Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"||Takeda|No|Completed|June 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3409|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension|February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068495||50024|
NCT02064998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/278-31/2|Two Consecutive Randomized Controlled Trials Using Mobile Phone Applications for Risky Alcohol Use|Brief Alcohol Interventions With Mobile Phone Applications for University Students: Interventions Targeting Differing Risk Levels in Two Consecutive Randomized Controlled Trials||Karolinska Institutet|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|2166|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02064998||50290|
NCT02065232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLNPain01|Sentinel Lymph Node Mapping Post-Injection Site Pain|A Randomized, Double-blinded, Controlled Clinical Trial Comparing Post-injection Site Pain of Technetium-labeled Tilmanocept Versus Technetium-labeled Sulfur Colloid in Patients Undergoing Sentinel Lymph Node Mapping Procedure for Breast Cancer||University of California, San Diego|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|52|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065232||50272|
NCT02065258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breathing vs. aerobic exercise|Breathing Versus Aerobic Exercises on Asthma Control|Comparison Between Breathing and Aerobic Exercises on Clinical Control, Psychosocial Morbidity, Thoracoabdominal Kinematics, and Airway Inflammation in Patients With Moderate-to-severe Asthma: a Randomized Trial||University of Sao Paulo General Hospital|Yes|Recruiting|February 2013|June 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|25 Years|65 Years|No|||December 2013|February 14, 2014|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02065258||50270|
NCT02065518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU0001-10-1-TS04|Electromyostimulation and Strength Walking for Knee Injuries|Electromyostimulation and Strength Walking for Knee Injuries|KI|University of Tennessee|Yes|Recruiting|March 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|50 Years|No|||October 2015|October 13, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065518||50250|
NCT02066051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003814|IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD|Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD)||Mayo Clinic|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|99 Years|No|||October 2015|October 25, 2015|February 13, 2014|Yes|Yes||No|October 25, 2015|https://clinicaltrials.gov/show/NCT02066051||50209|
NCT02066038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-FXY-025|Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|A Multi-center, Open-labeled Phase 2 Study of First Line Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation||Sun Yat-sen University|Yes|Active, not recruiting|January 2014|March 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||February 2014|February 16, 2014|February 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02066038||50210|
NCT02066285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS-32|Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma|A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)||Grupo Espanol de Investigacion en Sarcomas|No|Recruiting|June 2014|June 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066285||50192|
NCT02066324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0062203|Urine Sample Collection From FOP Patients|Urine Sample Collection From Patients With Fibrodysplasia Ossificans Progressiva (FOP) for Biomarker Analysis|FOP|Novartis|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|N/A||1|Actual|25|Samples Without DNA|Urine samples|Both|5 Years|35 Years|No|Probability Sample|Patients with Fibrodysplasia Ossificans Progressiva.|March 2015|March 11, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02066324||50189|
NCT02067208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23731-01|Wedged Insoles for Management of Knee Osteoarthritis|Reduced Knee Joint Loading With Lateral and Medial Wedge Insoles for Management of Knee Osteoarthritis: a Randomized Controlled Trial||University of Calgary|Yes|Completed|October 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|85 Years|No|||November 2015|November 30, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067208||50123|
NCT02068040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 130398|Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)||HFPEF|University of California, San Diego||Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|40 Years|60 Years|No|||June 2015|June 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068040||50059|
NCT02068365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28486|An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy|An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy||Chinese University of Hong Kong||Recruiting|June 2013|||June 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02068365||50034|
NCT02068001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45837.081.13|Changes in Food Preference and Food Cue Responsivity After Bariatric Surgery|Changes in Food Preference and Food Cue Responsivity After Bariatric Surgery|Verrukkelijk|Wageningen University|No|Active, not recruiting|July 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|55 Years|No|Non-Probability Sample|Morbidly obese individuals (age 18-55 years) scheduled for Roux-en-Y gastric bypass        surgery at Rijnstate hospital, Arnhem|June 2015|June 5, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02068001||50062|
NCT02068014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA012014|Standarization for Stappler Application During Sleeve Gastrectomy|Implication and Factors Influencing the Decision to Select Srapplers During Laparoscopic Sleeve Gastrectomy.|LSG|Assuta Medical Center|No|Recruiting|May 2014|November 2014|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|patients underwnt laparoscopic sleev gastrectomy between 18 y.o. and 70 y.o.|May 2014|May 22, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068014|3 Months|50061|
NCT02105740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNB19739513900000030|Hypnosis in Pain Management, Anxiety and Depression in Oncological Patients|Hypnosis as a Complementary Practice in Pain Management, Anxiety and Depression in Oncological Patients|HPMADOP|University of Brasilia|No|Recruiting|July 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|40 Years|70 Years|No|||July 2015|July 14, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02105740||47168|
NCT02105766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140077|Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure|Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|August 2021|Anticipated|August 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|162|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||December 2015|March 10, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105766||47166|
NCT02106000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201248|A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour|An Enabling Study to Compare the Inhalation Profiles of Women in the Third Stage of Labour to Those of Non-pregnant Female Volunteers and to Explore Whether There Are Any Differences Which Could Impact the Delivery of an Inhaled Medicinal Product||GlaxoSmithKline|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106000||47148|
NCT02106013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS2|Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals|Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals||University of Campinas, Brazil|Yes|Completed|April 2008|March 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|101|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who sought governmental primary care centers of the city of Campinas, SP,        Brazil.|April 2014|April 2, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02106013||47147|
NCT02106286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NW/0810|Effects of Beta-blockade on Cardiopulmonary Exercise Testing|The Influence of Beta-blockade on Cardiopulmonary Function Measured by Cardiopulmonary Exercise Testing||Aintree University Hospitals NHS Foundation Trust|No|Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|55|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02106286||47126|
NCT02068755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiCS|Blood Products in Cardiac Surgery|The Use of Blood Products in Patients Undergoing Cardiac Surgery|BiCS|University of Turku|No|Completed|January 2002|December 2012|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31000|||Both|18 Years|N/A|No|Non-Probability Sample|We collected data from patients who visited underwent cardiac surgery in Finnish hospitals        during the years 2002 and 2012. Participating perform all the cardiac surgery in Finland        and hospitals were scattered to all geographical areas in Finland.|February 2014|February 19, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068755|1 Year|50004|
NCT02069028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0|Effectiveness of Different Interventions for Implementing Surviving Sepsis Campaign (SSC) Guidelines on Compliance and Mortality: Systematic Review and Meta-analysis|Effectiveness of Different Interventions for Implementing Surviving Sepsis Campaign (SSC) Guidelines on Compliance and Mortality: Systematic Review and Meta-analysis||King Abdullah International Medical Research Center|No|Active, not recruiting|February 2014|September 2014|Anticipated|June 2014|Anticipated|N/A|Observational|N/A||3|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Research articles|February 2014|February 20, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069028||49983|
NCT02065011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13619|A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B|An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B||Sanofi|Yes|Enrolling by invitation|September 2013|September 2032|Anticipated|September 2032|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065011||50289|
NCT02065024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2012-39503-C02-02|Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols|Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation|foodmagenpol|Puerta de Hierro University Hospital|No|Active, not recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||February 2014|March 3, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02065024||50288|
NCT02065245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130646|AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery.|A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty.|CRATUS|University of Miami|Yes|Recruiting|February 2014|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|60 Years|95 Years|No|||November 2015|November 9, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065245||50271|
NCT02065531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-021|Myofascial Release and Mobilization With Impulse Technique Torsion in Low Back Pain|Effects of Myofascial Soft Tissue Release and Mobilization With Impulse Technique Torsion in Subjects With Chronic Non-specific Low Back Pain: A Randomized Clinical Trial||Universidad de Almeria|No|Completed|January 2014|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|60 Years|No|||November 2014|November 23, 2014|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02065531||50249|
NCT02066077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDC12012109|The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy|The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy: A Randomized Clinical Trial And Its Standard Technology Promotion Research||Shanghai Mental Health Center|Yes|Recruiting|January 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066077||50207|
NCT02066311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISLE|Nelfinavir in Systemic Lupus Erythematosus|Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial|NISLE|Northwell Health|Yes|Recruiting|September 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066311||50190|
NCT02066961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-MA-1001|A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer|A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis|ASPIRE-PCa|Astellas Pharma Inc|No|Recruiting|January 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|||Male|N/A|N/A|No|Non-Probability Sample|Subjects will be selected from the offices of either a medical oncologist, radiation        oncologist, uro-oncologist, urologist, surgeon, or primary care physician.|February 2016|February 4, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02066961||50142|
NCT02067507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA154549-01A1|Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County|Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County||University of California, Los Angeles|No|Enrolling by invitation|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|70 Years|No|||February 2015|February 4, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02067507||50100|
NCT02068027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-290|Safety and Efficacy Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy|A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM PARALLEL-GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CLONIDINE HYDROCHLORIDE TOPICAL GEL, 0.1% IN THE TREATMENT OF PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY||BioDelivery Sciences International|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|85 Years|No|||December 2015|December 4, 2015|February 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02068027||50060|
NCT02068378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_DOG07_158|Visual Feedback With Optical Sensing - A Feasibility Study|Clinical Evaluation of Visual Feedback With Optical Sensing in Lung Cancer Patients Undergoing Radiotherapy: A Feasibility Study|ROSS-LC|Christie Hospital NHS Foundation Trust|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068378||50033|
NCT02068612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG043452-01A1|Enhancing Function in Later Life: Exercise and Functional Network Connectivity|Enhancing Function in Later Life: Exercise and Functional Network Connectivity|FORCE|University of Colorado, Boulder|Yes|Recruiting|April 2014|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|305|||Both|25 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068612||50015|
NCT02106026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACT-120413|Nursing Education Intervention for Maternal Breastfeeding|Effectiveness of a Nursing Education Intervention on Duration of Breastfeeding and on Post-natal Breast Complications in Primiparous Women: a Randomized Controlled Trial||Universidad Miguel Hernandez de Elche|No|Completed|December 2004|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|314|||Female|N/A|N/A|No|||April 2014|April 2, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02106026||47146|
NCT02106299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP201303|Safety and Efficacy Study of Regen Sling to Treatment SUI|A Multi-Center, Randomized, Controlled Clinical Trial of the Safety and Efficacy of Regen Sling Treatment for Female Patients With Stress Urinary Incontinence||Medprin Regenerative Medical Technologies Co.,Ltd.|No|Recruiting|January 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|178|||Female|18 Years|75 Years|No|||April 2014|April 3, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02106299||47125|
NCT02106559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12223|Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy|A Pilot Study of Pleural Photodynamic Therapy for Patients With Pleural Malignancy||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|September 2014|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106559||47105|
NCT02068768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AveL100|Multicenter Study of the Avenue L Interbody Spinal Fusion System Using VerteBRIDGE Plating and Posterior Fixation|A Prospective, Multicenter, Open Label Clinical Study of the Safety andEfficacy of the Avenue L Interbody Spinal Fusion System Using the VerteBRIDGE Plating System and Supplemental Posterior Fixation||LDR Spine USA|No|Recruiting|August 2013|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|N/A|No|Probability Sample|Subjects will be drawn from the patient populations of the physicians participating in the        study. The principal investigators include community physicians in private practice as        well as physicians affiliated with academic institutions.|February 2013|April 1, 2014|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068768|1 Year|50003|
NCT02069041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15233|A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer|Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma||Eli Lilly and Company|No|Recruiting|April 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|75 Years|No|||April 2015|April 29, 2015|February 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02069041||49982|
NCT02069054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPU-DIMPA-WUM13(2)|Airway Inflammation and Remodeling in Asthma and COPD.|Relationship Between Airway Inflammation and Remodeling in Asthma and COPD Patients.||Medical University of Warsaw|No|Recruiting|September 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|85|Samples With DNA|induced sputum, BALF, bronchial mucosa samples, exhaled breath condensate, serum|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|patients with stable asthma and COPD invited to Clinical Hospital in Warsaw|February 2014|February 21, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02069054||49981|
NCT02069067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Break-1|Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated|Multicenter Observational Study of the Incidence and Treatment Modalities of Breakthrough Cancer Pain in Patients With Chronic Cancer Pain|Break-1|National Cancer Institute, Naples|No|Recruiting|December 2011|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients with advanced cancer and chronic pain being controlled with opiods.|November 2015|November 25, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069067||49980|
NCT02069080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140050|Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor|Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor||National Institutes of Health Clinical Center (CC)||Suspended|January 2014|April 2018|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|99 Years|No|||October 2015|November 3, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069080||49979|
NCT02069093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JUS226|Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer|A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane||Novartis|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|92|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|February 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02069093||49978|
NCT02069106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001-PR-003-09092013|Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction|An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia|PrOteCT|Nordic Pharma, USA|No|Withdrawn|February 2014|July 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069106||49977|
NCT02065037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6011440|The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection|The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection: A Randomized Controlled Trial||Queen's University|Yes|Active, not recruiting|June 2014|November 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|229|||Both|40 Years|N/A|No|||December 2015|December 21, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02065037||50287|
NCT02065271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44919.081.13|Herbal Preparation and Glucose Homeostasis|Herbal Preparation and Glucose Homeostasis|Herbie|Wageningen University|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|22|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02065271||50269|
NCT02065830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROBOSCIEKSO|Safety Study of Outdoor and Indoor Mobility in People With Spinal Cord Injury (ROBOtics Spinal Cord Injury EKSO).|ROBOticsSpinalCordInjuryEKSO: Outdoor and Indoor Mobility in People With SCI.|ROBOSCIEKSO|IRCCS San Raffaele|No|Not yet recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065830||50226|
NCT02066363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN 01|Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer|Best Nutritional Care in Cancer Patients. A Comparative Randomized Study of Supplemental Parenteral Nutrition to Patients With GI Cancer Compared to Best Supportive Nutritional Care||Odense University Hospital|Yes|Enrolling by invitation|March 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066363||50186|
NCT02066376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-401|A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets|A Phase II/III Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Oral Administration of NE-58095NF Tablets Versus Once-daily Oral Administration of NE-58095 2.5-mg Tablets for the Treatment of Involutional Osteoporosis||Ajinomoto Pharmaceuticals Co., Ltd.|No|Completed|February 2014|November 2015|Actual|November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|760|||Both|50 Years|N/A|No|||November 2015|November 29, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02066376||50185|
NCT02065791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103517|Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy|A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy|CREDENCE|Janssen Research & Development, LLC|Yes|Recruiting|February 2014|June 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|4200|||Both|30 Years|N/A|No|||March 2016|March 18, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065791||50229|
NCT02065804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-130-lap|Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair|Trigger-point Blockade in Persistent Pain After Laparoscopically Assisted Groin Hernia Repair|Trigger-lap|University of Copenhagen|No|Not yet recruiting|May 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065804||50228|
NCT02066064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-EYE|G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist|G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate - Randomized Tandem Study With Different Endoscopist||Smart Medical Systems Ltd.|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|58|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02066064||50208|
NCT02067221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPCNL Study|Comparison of Surgical Outcomes Between MPCNL and RIRS|Comparison of Surgical Outcomes in the Treatment of Renal Stones Larger Than 1 Centimeters Between MPCNL and RIRS: a Single-center, Randomized, Prospective Study||Seoul National University Hospital|Yes|Completed|May 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|N/A|No|||June 2015|June 21, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02067221||50122|
NCT02067234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-14-027|A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families|A Multi-Disciplinary Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families: A Pilot Study||Seton Healthcare Family|Yes|Withdrawn|January 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|2 Months|12 Years|No|||May 2015|May 18, 2015|January 3, 2014||No|PI left institution; project closed.|No||https://clinicaltrials.gov/show/NCT02067234||50121|
NCT02068638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/14|Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes|Exercise-related Fuel Metabolism and Glucose Stability in Individuals With Type 1 Diabetes Mellitus|CARBEX1|University Hospital Inselspital, Berne|No|Enrolling by invitation|February 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|27|||Male|18 Years|35 Years|No|||February 2016|February 3, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02068638||50013|
NCT02067780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD levofloxacine Study|Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD|Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Treatment Guided by Markers of Inflammation|AECOPD|University of Monastir|Yes|Recruiting|September 2013|April 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2014|April 16, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02067780||50079|
NCT02067793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX1074-C-201|Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder|Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder||Naurex, Inc|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|151|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067793||50078|
NCT02068053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-006|Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020|Pharmacokinetics and Metabolism of [14C] BMS-986020 in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|February 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02068053||50058|
NCT02068066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260/12|Physical Workload and Work Capacity Across Occupational Groups|Physical Workload and Work Capacity Across Occupational Groups||Cantonal Hosptal, Baselland|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|337|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult full-time employees|November 2015|November 16, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068066||50057|
NCT02069197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maes 004|Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea|Evaluation of Efficacy and Safety of Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea.|KGDobesity|Mid-Atlantic Epilepsy and Sleep Center, LLC|No|Recruiting|January 2014|May 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||December 2014|December 12, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02069197||49970|
NCT02068625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/10|Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment|Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment||University Hospital Inselspital, Berne|No|Recruiting|September 2010|December 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068625||50014|
NCT02106572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB03|Therapeutic Instillation of Mistletoe|Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study|TIM|Abnoba Gmbh|No|Recruiting|February 2015|October 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|546|||Both|18 Years|80 Years|No|||October 2015|October 9, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106572||47104|
NCT02108093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP|The Effect on Cerebral Oxygenation of Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit in Cardiac Surgery Patients|The Effect on Cerebral Oxygenation of Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit in Cardiac Surgery Patients: a Randomized Controlled Trial|RAP|Amphia Hospital|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|70 Years|N/A|No|||December 2014|December 24, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108093||46989|
NCT02108106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG348-C-001|A Phase I Study of AG-348 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers|AG-348 SAD|Agios Pharmaceuticals, Inc.|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108106||46988|
NCT02104609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00602|Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill|Pharmacokinetics of the Levonorgestrel-only Emergency Contraception Regimen in Normal-weight, Obese and Extremely Obese Users: a Pilot Study||University of Southern California|Yes|Recruiting|April 2013|||April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Non-smoking women between ages 18-35 years with regular menstrual cycles (24-35 days) will        be enrolled, to include 10 normal weight (BMI = 18.5-24.9 kg/m2) women, 10 obese (BMI =        30-39.9 kg/m2) and 10 extremely obese (BMI ≥ 40 kg/m2) women|June 2015|June 20, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02104609|2 Months|47255|
NCT02068547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308043|Bone Marrow Aspirate Concentration in Posterior Cervical Fusion|Bone Marrow Aspirate Concentration in Posterior Cervical Fusion|BMAC|Washington University School of Medicine|Yes|Recruiting|February 2014|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068547||50020|
NCT02068781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47438/IMP10124|Aldosterone, Microvascular Function and Salt-sensitivity|Aldosterone-induced Microvascular Dysfunction as a Cause of Salt-sensitivity in Obesity?||Maastricht University Medical Center|No|Recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068781||50002|
NCT02065050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002461|Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)|Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With DM: COACH-DM|COACH-DM|Brigham and Women's Hospital|No|Recruiting|February 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02065050||50286|
NCT02065284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBWP and RAS|Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis|Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis.||The Cleveland Clinic|No|Completed|February 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065284||50268|
NCT02066090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMCOH 2013-01-020|Acupuncture for Obesity on Serum Metabolic Parameters|Effects of Acupuncture on Serum Metabolic Parameters in Pre-menopausal Obese Women: A Randomized Controlled Trial||Kyung Hee University Hospital at Gangdong|No|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|19 Years|55 Years|No|||March 2015|March 4, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066090||50206|
NCT02066402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16121|Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections||Bayer|No|Active, not recruiting|March 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066402||50183|
NCT02066701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001575|Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers|Utility of Aberrant Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers||Mayo Clinic|No|Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|253|Samples With DNA|Tissue and cytology brushes will be stored for the duration of the study|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled for clinically indicated upper endoscopy will be approached to        participate in this study|September 2015|September 4, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02066701||50160|
NCT02066337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mn1965|Effect of Ozone Gel on Treatment of Chronic Periodontitis|Effect of Ozone Gel on Alveolar Bone Density and Superoxide Dismutase in Chronic Periodontitis: A Randomized Controlled Clinical Study||October 6 University|Yes|Completed|March 2013|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02066337||50188|
NCT02066350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1062|Cardiovascular Risk Factors After Single Pancreas Transplantation|Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation|Diamant|Oslo University Hospital|No|Recruiting|January 2014|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066350||50187|
NCT02066662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001|Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification|Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)||RWTH Aachen University|No|Recruiting|July 2013|January 2018|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|253|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066662||50163|
NCT02066675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISG TR1US|Trabectedin First Line Therapy In Unfit Sarcoma Study|SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES|TR1US|Italian Sarcoma Group|Yes|Active, not recruiting|February 2014|December 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066675||50162|
NCT02067520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.611|Intrathecal Hydromorphone for Cesarean Section|Intrathecal (IT) Hydromorphone for Cesarean Section (C/S): A Dose Finding Study||Thomas Jefferson University|No|Completed|January 2014|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02067520||50099|
NCT02099097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-062|Quit IT: Preliminary Testing of a Web-based, 3D Coping Skills Game to Increase Quitting Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Quit IT: Preliminary Testing of a Web-based, 3D Coping Skills Game to Increase Quitting Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization||Memorial Sloan Kettering Cancer Center||Recruiting|March 2014|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099097||47678|
NCT02099110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-005|Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)|A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|1250|||Both|18 Years|N/A|No|||February 2016|March 16, 2016|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099110||47677|
NCT02068898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XS003_CT001|Pharmacokinetic Comparison of XS003 and Tasigna|A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of "XS003" and Originator in Healthy Male Subjects||XSpray Microparticles|No|Completed|December 2013|May 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|27|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068898||49993|
NCT02099578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.11762|The Effects of Strawberries on Blood Pressure in Postmenopausal Women|Daily Incorporation of Strawberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension||Florida State University|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Female|45 Years|65 Years|No|||February 2016|February 5, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099578||47641|
NCT02099591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00016|Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients|A Phase I Open-Label Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With Opioids|KODIAK16|AstraZeneca|No|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|48|||Both|6 Months|18 Years|No|||March 2016|March 23, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02099591||47640|
NCT02065102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/R/CAR/13|Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty|Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty||Royal Infirmary of Edinburgh|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing percutaneous coronary intervention requiring rotational atherectomy        and coronary stent implantation in South East Scotland.|March 2014|March 5, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02065102||50282|
NCT02107794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007708|Shared Decision Making in Graves Disease - Graves Disease (GD) Choice|Shared Decision Making in Graves Disease - Graves Disease (GD) Choice||Mayo Clinic|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|93|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02107794||47011|
NCT02107807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87_26|Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine|A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions||Novartis|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|539|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02107807||47010|
NCT02104310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002165|A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas|A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients||Mayo Clinic|Yes|Recruiting|April 2014|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104310||47278|
NCT02107261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1679|Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand|A Placebo-Controlled, Double-Blind, Randomized, Cross Over Pilot Study Of The Efficacy And Tolerability Of Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand||Icahn School of Medicine at Mount Sinai|No|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||September 2015|September 22, 2015|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107261||47052|
NCT02068794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1266|MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer|Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer||Mayo Clinic|Yes|Suspended|March 2014|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 19, 2014|Yes|Yes|Accrual met on dose level 1|No||https://clinicaltrials.gov/show/NCT02068794||50001|
NCT02069119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269-13-001|A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)|A Multicenter, Parallel-group-comparison, Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation||Otsuka Pharmaceutical Co., Ltd.||Active, not recruiting|February 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|85 Years|No|||March 2016|March 1, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069119||49976|
NCT02069132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIALE|Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity|Prospective Validation of IWPC Pharmacogenetic Algorithm for Estimating the Appropriate Initial Dose of Warfarin in Elderly People (65 or Older) With Heart Valves Prostheses or Non Valvular Atrial Fibrillation and Comorbidity|VIALE|Second University of Naples|No|Recruiting|March 2013|September 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples With DNA|Whole blood|Both|65 Years|N/A|No|Non-Probability Sample|prospective cohort of elderly people (≥65 years) with nonvalvular atrial fibrillation        and/or heart valve replacement, with at least one comorbid condition, presenting for        warfarin therapy|November 2015|November 16, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02069132||49975|
NCT02065297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUDIA-SAMSON HORTON TH17|Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)|Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)||Centre Hospitalier Universitaire Dijon||Recruiting||||January 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|240|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Horton' s disease Patients with an infectious disease Patients with        neoplasia ( solid tumor or hemopathy ) Healthy controls|July 2013|February 13, 2014|February 13, 2014||||No||https://clinicaltrials.gov/show/NCT02065297||50267|
NCT02065544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS: M11-198|Remission Rates of New Type 2 Diabetes With Weight Loss and Exercise|Remission Rates of New Type 2 Diabetes With Weight Loss and Exercise|Resolution|University of Vermont|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||February 2014|February 18, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02065544||50248|
NCT02065817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004890|Dose of Labeled Cholesterol for Kinetics: A Pilot Study|Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study||Mayo Clinic|No|Completed|February 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02065817||50227|
NCT02066103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSP0147|Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients|Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients|BROADWAY|Mercator MedSystems, Inc.|No|Recruiting|January 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066103||50205|
NCT02066116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1401|Kinect-based Upper Limb Rehabilitation System in Stroke Patients|||Seoul National University Bundang Hospital|No|Recruiting|November 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||February 2016|February 15, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02066116||50204|
NCT02066389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-537|A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate (MTX) in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone||AbbVie|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|300|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02066389||50184|
NCT02067273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25894-2|Transcranial Magnetic Stimulation (TMS) for CRPS|Transcranial Magnetic Stimulation for CRPS||Stanford University||Completed|February 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067273||50118|
NCT02067286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR4- v2.0|Detection of Influenza A, Influenza B, and RSV Using the Liat Analyzer|Multi-Center Study of In Vitro Diagnostic Devices for the Detection of Influenza A, Influenza B, and RSV||IQuum, Inc.|No|Recruiting|January 2014|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Nasopharyngeal swabs|Both|N/A|N/A|No|Non-Probability Sample|Subjects must be exhibiting symptoms characteristic of influenza or RSV|February 2014|February 19, 2014|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067286||50117|
NCT02066688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQ2011SF12RJ|Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer|A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|2400|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02066688||50161|
NCT02066974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC2-112|Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy|Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy||China Medical University, China|No|Enrolling by invitation|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|Fragmented DNA and RNA, Methylation|Both|21 Years|79 Years|No|Non-Probability Sample|Patient with advanced hepatoma requiring radiotherapy|February 2015|February 3, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02066974|2 Years|50141|
NCT02068391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISE2-2014-312185|Recovery Improved in Covert Stroke With Exercise|Achieving Brain Benefits in Covert Stroke Through Aerobic Exercise|RISE-2|Sunnybrook Health Sciences Centre|No|Not yet recruiting|May 2014|May 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|50 Years|95 Years||||November 2015|November 16, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068391||50032|
NCT02099344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCA-001|Artegraft Versus Propaten Dialysis Grafts|A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access||Kaiser Permanente|No|Terminated|April 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|November 13, 2013||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT02099344||47659|
NCT02099331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00090647|Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin|Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin|DREAM|Johns Hopkins University|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|March 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099331||47660|
NCT02095574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-363|A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma|Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration||AbbVie|No|Withdrawn|September 2014|January 2015|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|January 28, 2014|No|Yes|This study will now be conducted in healthy volunteers.|No||https://clinicaltrials.gov/show/NCT02095574||47947|
NCT02095548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM04690-01|Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)|A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects||Samumed LLC||Completed|March 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|61|||Both|50 Years|75 Years|No|||December 2015|December 8, 2015|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095548||47949|
NCT02095561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-1CU|Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake|Study of HPV Self Testing Evaluation in the Province of Jujuy, Argentina|EMA|Instituto Nacional del Cáncer, Argentina|Yes|Completed|July 2012|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|6013|||Female|30 Years|N/A|No|||March 2014|March 27, 2014|March 21, 2014||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT02095561||47948|
NCT02103985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015718|A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants|A Randomized, Open-Label, Two-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Male and Female Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103985||47302|
NCT02105207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLUS-RCT|Comparison Between Lung Ultrasound and Chest Radiography for Acute Dyspnea|Comparison Between Lung Ultrasound and Chest Radiography for Differential Diagnosis of Acute Dyspnea in the Emergency Department||University of Turin, Italy|No|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|504|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02105207||47209|
NCT02105831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU in LVAD|Skeletal Muscle Perfusion With LVAD|||Oregon Health and Science University|Yes|Recruiting|February 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Non-Probability Sample|1. Heart failure patients being referred for LVAD|October 2015|October 23, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105831||47161|
NCT02106091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFM11-101|Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL|A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.||Affimed GmbH|Yes|Recruiting|April 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106091||47141|
NCT02068573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AstmaVen - 1101|AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children|AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children|AsthmaVent|University of Aarhus|Yes|Recruiting|August 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|5 Years|18 Years|No|||February 2014|December 3, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02068573||50018|
NCT02068807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-LUT-2011|Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn|Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn||University of Siena|No|Completed|January 2011|October 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|N/A|5 Minutes|No|||February 2014|February 24, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02068807||50000|
NCT02069145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54F28-004|Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|January 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||August 2015|September 2, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02069145||49974|
NCT02065063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200344|A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors|A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, Trametinib, Combined With the CDK4/6 Inhibitor, Palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects With Solid Tumors||GlaxoSmithKline|No|Terminated|April 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 5, 2013|Yes|Yes|Part 1 of the trial completed and will not proceed to Parts 2 or 3. 3 patients remain in the    trial to receive study medication as long as they derive benefits.|No||https://clinicaltrials.gov/show/NCT02065063||50285|
NCT02065557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-290|Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis||AbbVie|Yes|Recruiting|October 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|245|||Both|4 Years|17 Years|No|||January 2016|January 20, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065557||50247|
NCT02065570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-115|Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration||AbbVie|No|Recruiting|March 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02065570||50246|
NCT02065843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSI-388.427|Three Anxiolytic Drugs Used in Third Molar Surgery|Comparative Study of the Effectiveness of Three Anxiolytic Drugs Used in Third Molar Surgery||Universidade Federal de Sergipe|No|Not yet recruiting|March 2014|||April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 15, 2014|February 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02065843||50225|
NCT02065856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001728-20|An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy|AV-X-02|ALK-Abelló A/S|No|Completed|December 2013|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02065856||50224|
NCT02066714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08RS|Neurodevelopment Outcomes Following Severe Hand Foot and Mouth Disease in Vietnam|A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease|08RS|Oxford University Clinical Research Unit, Vietnam|No|Recruiting|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hand foot and mouth disease patients admitted to Hospital of Tropical Diseases. Healthy        children form 3 kindergartens in District 8, HCMC and infants enrolled in Dengue Birth        cohort (Oxtrec 02-09)|February 2014|February 17, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02066714||50159|
NCT02097771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01852-43|Gastric Insufflation and Laryngeal Mask Airway|||Hôpital Edouard Herriot||Recruiting|November 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized|2||||||Both|18 Years|95 Years|No|||November 2014|November 18, 2014|March 21, 2014||||No||https://clinicaltrials.gov/show/NCT02097771||47780|
NCT02098044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13130|Knee Osteoarthritis Risk in Retired Professional Footballers|An Investigation of the Prevalence of Knee Osteoarthritis and Pain in Retired Professional Male Footballers in the United Kingdom||University of Nottingham|Yes|Enrolling by invitation|November 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1300|||Male|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Retired footballers will be recruited from a database of retired professional footballers.        (cases)        The members of the general public will be recruited from the general population in the        East Midlands region. (controls)|December 2015|December 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02098044||47759|
NCT02098291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC1|An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma|Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma|PC1|Cancer Advances Inc.||Completed|April 1999|February 2002|Actual|July 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02098291||47740|
NCT02066987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS-B23|The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents|The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents||Qazvin University Of Medical Sciences||Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1110|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||September 2014|September 14, 2014|February 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02066987||50140|
NCT02067000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-44|Patient Perception Questionnaire Validation|Validation of the Patient Perception Questionnaire||Fisher and Paykel Healthcare|No|Completed|April 2011|April 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|217|||Both|18 Years|N/A|No|Non-Probability Sample|OSA patients|February 2014|February 18, 2014|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02067000||50139|
NCT02067247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXA-SOS|Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease|Comparison of BMD Measurements by Dual Energy X-Ray Absorptiometry and Multiple Sites to BeamMed Speed-of-Sound Measurements at the Forearm in Patients With Gaucher Disease||Shaare Zedek Medical Center|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02067247||50120|
NCT02067260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02-31-161|A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males|A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males||Spencer Forrest, Inc.|No|Completed||||April 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Male|20 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02067260||50119|
NCT02068079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045015|A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma|A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma||Duke University|Yes|Withdrawn|April 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 19, 2014|No|Yes|Study is being revised|No||https://clinicaltrials.gov/show/NCT02068079||50056|
NCT02098837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEAT 22/SSAT 060|Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)|An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression||St Stephens Aids Trust|Yes|Active, not recruiting|April 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|415|||Both|18 Years|99 Years|No|||December 2015|December 22, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02098837||47698|
NCT02095587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-14|Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects|A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects|IPI-145-14|Infinity Pharmaceuticals, Inc.|No|Completed|March 2014|October 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095587||47946|
NCT02099604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12226 ViZIR|Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C|Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial|ViZIR|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Withdrawn|April 2014|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||March 2014|July 22, 2014|March 24, 2014||No|Study objectives were considered as obsolete regarding the new antiviral drugs arrival in    Egypt.|No||https://clinicaltrials.gov/show/NCT02099604||47639|
NCT02096159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC/Uro-MF-01|Prophylactic Antibiotics or Placebo After Hypospadias Repair|Trimethoprim-sulfamethoxazole vs. Placebo After Hypospadias Repair: a Multicenter, Double-blind, Randomized Trial|PROPHY|Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|March 2014|December 2023|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|630|||Male|N/A|5 Years|No|||August 2015|August 25, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02096159||47903|
NCT02095886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-034|Relative Bioavailability Study With BMS-955176|Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects||Bristol-Myers Squibb|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|8||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095886||47924|
NCT02095899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-253|Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome|Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome. A Prospective, Randomized, Double-blind, Placebo Controlled, Monocenter Study.|RUFPTPS|University of Zurich|Yes|Withdrawn|March 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||July 2015|July 20, 2015|February 14, 2014||No|Poor study patient recruitment|No||https://clinicaltrials.gov/show/NCT02095899||47923|
NCT02104882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRAGO-I/II|INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study|INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study||Universitätsmedizin Mannheim|No|Recruiting|March 2014|January 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|50 Years|N/A|No|||December 2015|December 1, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02104882||47234|
NCT02105519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-101-139|The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis|The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis||National Cheng-Kung University Hospital|No|Recruiting|October 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02105519||47185|
NCT02106884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s56122|Quality of Life Study in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel|Randomized Crossover Trial to Assess the Effects and Quality of Life in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel: QOLINPAC|QOLINPAC|Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02106884||47080|
NCT02106897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230LE101|Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus|A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus||Biogen|No|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|109|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106897||47079|
NCT02069158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOSI-NDU-001|Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor|DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR|IOSI-NDU-001|Oncology Institute of Southern Switzerland|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02069158||49973|
NCT02065310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13188|N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes|Evaluation of the Internal Consistency of Measurement and Potential of a DNA-adduct as a Biomarker of Glycemic Control||City of Hope Medical Center|Yes|Enrolling by invitation|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02065310||50266|
NCT02065323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCN-PC1301|A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT|A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy||Comprehensive Cancer Centers of Nevada|Yes|Withdrawn||||August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||January 2015|January 15, 2015|February 3, 2014|Yes|Yes|Terminated due to budgetary considerations and length of development.|No||https://clinicaltrials.gov/show/NCT02065323||50265|
NCT02065583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spiegel 0016|Predictive Validity of Acoustic Gastrointestinal Surveillance (AGIS) in Post-Operative Feeding|Predictive Validity of a Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Post-Operative Feeding|AGIS|VA Greater Los Angeles Healthcare System|Yes|Recruiting|December 2013|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators will recruit patients who are scheduled for GI abdominal surgery at        Cedars-Sinai Medical Center|December 2015|December 9, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02065583||50245|
NCT02065596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12Z13|Hematopoietic Stem Cell Transplant for Sickle Cell Disease|Hematopoietic Stem Cell Transplant for Sickle Cell Disease||Case Comprehensive Cancer Center|Yes|Suspended|April 2015|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 14, 2014|Yes|Yes|Pending protocol amendment|No||https://clinicaltrials.gov/show/NCT02065596||50244|
NCT02065869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-004|Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant|Phase I Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders||Bellicum Pharmaceuticals|No|Recruiting|December 2014|December 2018|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Months|21 Years|No|||July 2015|November 23, 2015|February 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02065869||50223|
NCT02067013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28894s|Analysis of Aqueous and Vitreous Humor|Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease|ARK|California Retina Consultants|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02067013||50138|
NCT02098317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD3_DHA_NAFLD|DHA and Vitamin D in Children With Biopsy-proven NAFLD|Efficacy and Tolerability of Vitamin D and Docosahexaenoic Acid (DHA) in Children With Biopsy Proven NAFLD|VitD_DHA|Bambino Gesù Hospital and Research Institute||Completed|January 2014|September 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|4 Years|16 Years|No|||January 2016|January 13, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02098317||47738|
NCT02067533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390187|Flexion Versus Extension Soft Tissue Repair in Total Knee Arthroplasty|||Isfahan University of Medical Sciences||Completed||||April 2014|Actual|N/A|Interventional|N/A|2||Actual|91|||Both|N/A|N/A||||May 2015|May 8, 2015|February 18, 2014||||No|December 25, 2014|https://clinicaltrials.gov/show/NCT02067533||50098|
NCT02067806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHL1/01-2012/M|Observational Prospective Study on 2-chloroprocaine Hydrochloride 1% Safety in Intrathecal Anaesthesia|OBSERVATIONAL PROSPECTIVE STUDY ON 2-CHLOROPROCAINE HYDROCHLORIDE 1% SAFETY IN INTRATHECAL ANAESTHESIA|PASS|Sintetica SA|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients scheduled for elective surgery will be informed about the aims, procedures and        possible risks of the study and will be asked to sign the informed consent form for the        inclusion in the trial, from day -14 to day of surgery (visit 1, Day 0).|October 2015|October 13, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02067806|7 Days|50077|
NCT02068092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713-0108|Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer|A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer|Olive Oil|The Methodist Hospital System|No|Recruiting|December 2013|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|N/A|No|||September 2015|October 7, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02068092||50055|
NCT02098577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDvsCOPD|Crossover Versus Stabilometric Platform in Parkinson's Disease|Effect of Two Different Rehabilitation Programs on Balance in Parkinsonian Patients: Crossover Versus Stabilometric Platform|PDvsCOPD|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|50 Years|75 Years|No|Non-Probability Sample|60 patients with PD in stage III Hoen&Yahr according to Gelb et la. with the ability to        walk without any assistance and with Mini Mental State Examination (MMSE) score > 26.|March 2014|March 27, 2014|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02098577||47718|
NCT02098824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45933.029.13|Symptomatic Treatment of Vascular Cognitive Impairment|Symptomatic Treatment of Vascular Cognitive Impairment|STREAM-VCI|VU University Medical Center|Yes|Recruiting|February 2014|December 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|30|||Both|N/A|N/A|No|||December 2014|December 23, 2014|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02098824||47699|
NCT02115217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CliniqueRR-02|Effect of Kinesiotaping on Ankle Stability|Effect of Kinesiotaping on Ankle Stability in a Population of Elite Basketball Players||Clinique Romande de Readaptation||Active, not recruiting|February 2014|May 2015|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|30|||Both|15 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115217||46443|
NCT02115555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-04, IRB00000219|Advancing Diabetes Management in Adolescents Using Health Information Technology|Advancing Diabetes Management in Adolescents Using Health Information Technology||Indiana University|Yes|Active, not recruiting|May 2014|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|90|||Both|12 Years|18 Years|No|||August 2015|August 24, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02115555||46417|
NCT02115529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-242|Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet|A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery|Cesamet|St. Michael's Hospital, Toronto|Yes|Completed|April 2014|November 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|331|||Both|18 Years|99 Years|No|||November 2015|December 1, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02115529||46419|
NCT02115542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17651|Single Agent Regorafenib in Refractory Advanced Biliary Cancers|Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|April 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115542||46418|
NCT02115776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIDIT05PXIB92501PR|A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures|A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures||University of Santiago de Compostela|No|Completed|January 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|266|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02115776||46400|
NCT02115789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346072|Perceptions of Aesthetic Outcomes of Zigzag and Linear Scars|Perceptions of Aesthetic Outcomes of Zigzag and Linear Scars||University of California, Davis|No|Completed|June 2012|April 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|876|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the dermatology clinic at UC Davis Medical Center.|April 2015|April 6, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115789||46399|
NCT02116010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAGOBURN|Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients|Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Patients Using Pherecydes Pharma Anti-Escherichia Coli and Anti-Pseudomonas Aeruginosa Bacteriophages GMP Produced Cocktails . This Project is a European Research & Development (R&D) Project Funded by the European Commission Under the 7th Framework Programme for Research and Development Involving 7 Clinical Sites in EU.|PHAGOBURN|Pherecydes Pharma|Yes|Recruiting|July 2015|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||||||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02116010||46382|
NCT02116023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1402|The Effects of Processed Whole Orange on Subjective Ratings of Satiety|The Effect of Different Doses of Processed Whole Orange on Subjective Ratings of Satiety|POAS|PepsiCo Global R&D|No|Completed|March 2014|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02116023||46381|
NCT02116530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221301|Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy|Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|August 2014|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|372|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116530||46342|
NCT02113020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-233/CPH-003|A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects|A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects||Takeda|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Female|20 Years|40 Years|No|||October 2014|October 20, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02113020||46612|
NCT02111720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH097486|Disclosure to Family|Maybe, Maybe Not: Deciding to Disclose HIV Status to Family|D2F|University of South Florida|Yes|Recruiting|July 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02111720||46712|
NCT02112032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-105|Treatment of Advanced Melanoma With MK-3475 and Peginterferon|Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma||University of Pittsburgh|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112032||46688|
NCT02112045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405057|A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation|A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation||Washington University School of Medicine|No|Recruiting|January 2015|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112045||46687|
NCT02108847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 13-314|Ultrasound Guided Fascia Iliaca Block for Pain Control After Elective Hip Replacement Surgery|Ultrasound Guided Fascia Iliaca Block for Postoperative Analgesia After Elective Total Hip Arthroplasty||University of Saskatchewan|No|Not yet recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2014|April 4, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02108847||46931|
NCT02108834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFPH-IRB-2013-085|Regional Anesthesia for Thyroidectomy|Randomized Controlled Trial of Regional Anesthesia in Combination With General Anesthesia for Thyroidectomy||Guangzhou First Municipal People’s Hospital|Yes|Recruiting|April 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|79|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02108834||46932|
NCT02116725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERS-2013-01-LDT|Zinc Gel and Epidermal Regeneration in Healthy Human Volunteers|Effects of Shower Gel With Zinc on Epidermal Regeneration|ZINGEL|Bispebjerg Hospital|No|Recruiting|March 2014|September 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116725||46327|
NCT02113917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10015|Children and Adult Hemophagocytic Syndrome (HLHa)|The Formation of a Cohort of HLHa Patients in Order to Study Their Physiopathological Characteristics|HLH-genes|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|whole blood and serum|Both|2 Years|N/A|No|Non-Probability Sample|Infant, Adolescent and adult patients who have a HLH syndrome regardless of etiology,        hospitalized in Internal Medicine, Critical Care, Hematology, Rheumatology Neurology or        Organ Transplantation|November 2015|November 30, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02113917||46543|
NCT02113436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200860|Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma|Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma||GlaxoSmithKline|No|Recruiting|May 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|296|||Both|6 Months|4 Years|No|||March 2016|March 10, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02113436||46580|
NCT02114437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Closed-Loop|Closed-Loop Target Controlled Infusion in Laparoscopic Cholecystectomy|Closed-Loop Target Controlled Infusion of Propofol and Remifentanil Guided by Narcotrend Index in Laparoscopic Cholecystectomy|CLTCI|Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|March 2014|March 2015|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|38|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02114437||46503|
NCT02114697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059784|Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging|Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging||Emory University|Yes|Enrolling by invitation|April 2014|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|22 Years|N/A|No|||December 2015|December 15, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114697||46483|
NCT02114944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11227|Treatment of Dyspnea in Do-not-intubate Patients|Treatment of Dyspnea in Do-not-intubate (DNI) Patients||Tufts Medical Center|No|Recruiting|April 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients admitted to study center will be screened for study entry.        Patients with dyspnea and/or acute respiratory failure (regardless the underlying        diagnosis) and with a DNI order will be evaluated to define study entry criteria.|January 2015|January 26, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114944||46464|
NCT02115802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activa PC+S|LFP Correlates of Movement Disorders|Local Field Potential Correlates of Motor Behavior and Pathological Signs in Movement Disorders for Development of Closed Loop Stimulation Systems||Colorado Neurological Institute|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|21 Years|75 Years|No|||February 2016|February 21, 2016|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115802||46398|
NCT02115815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-VA-MEDI7510-1134|A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults|A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults||MedImmune LLC|Yes|Completed|April 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|246|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115815||46397|
NCT02116036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-13-0002011|Rivaroxaban for Antiphospholipid Antibody Syndrome|Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis|RAPS|St. Joseph's Healthcare Hamilton|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116036||46380|
NCT02116257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0702|The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV|||Yonsei University|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|108|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116257||46363|
NCT02112292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44758.081.13|The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking|The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking|Sweed|Wageningen University|No|Recruiting|April 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|36|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02112292||46668|
NCT02112552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02-058|Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer|A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|May 2013|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Female|18 Years|N/A|No|||February 2015|February 10, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112552||46648|
NCT02112565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14023|COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists|A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists||City of Hope Medical Center|Yes|Not yet recruiting|September 2016|||September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112565||46647|
NCT02109666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-151|Long Term Experience With Abatacept in Routine Clinical Practice|Long Term Experience With Abatacept in Routine Clinical Practice|ACTION|Bristol-Myers Squibb|No|Completed|March 2008|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2364|None Retained|Whole blood (Spanish sub study only)|Both|18 Years|N/A|No|Non-Probability Sample|Crohn's Disease|February 2016|March 11, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109666||46868|
NCT02109081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH13-477|Dexamethasone and Postoperative Delirium|Dexamethasone and Postoperative Delirium||NorthShore University HealthSystem Research Institute|No|Recruiting|April 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|70 Years|N/A|No|||March 2015|March 11, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02109081||46913|
NCT02113670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TrendLinesSUI|Changes in ALPP in Women With SUI Following Air Instillation|Changes in Abdominal Leak Point Pressures in Women Stress Urinary Incontinence Following Intravesical Air Instillation During Urodynamic Study||Meir Medical Center|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02113670||46562|
NCT02113683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMS-tm14|Validation of MMS Test for Cancer Monitoring|Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods|MMS-TM|MedInnovation GmbH|No|Recruiting|May 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|patients with primary diagnosis of cancer|March 2016|March 15, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113683||46561|
NCT02113943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-03|Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation|Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation|MBBCitalopram|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113943||46541|
NCT02114190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34AT007843-01|Family-Based Mindful Eating Intervention for Overweight Adolescents|Adaptation and Evaluation of a Family-Based Mindful Eating Intervention for Overweight Adolescents||Oregon Research Institute|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|14 Years|17 Years|No|||May 2015|May 13, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02114190||46522|
NCT02114177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103430|Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve and -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis||Janssen Infectious Diseases BVBA|Yes|Completed|April 2014|April 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114177||46523|
NCT02114450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14107|Human-Machine System for the H2 Lower Limb Exoskeleton|Human Machine Interface System With the H2 Lower Limb Exoskeleton for Rehabilitation|H2-NeuroExo|University of Houston|No|Recruiting|March 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114450||46502|
NCT02114463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phantom limb pain|Comparison of Two Kinds of Postoperative Analgesia After Amputation|Comparison of Two Kinds of Postoperative Analgesia After Amputation:a Randomized Clinical Trial||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114463||46501|
NCT02114710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NLY078|Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock||Nanjing PLA General Hospital|No|Completed|May 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|78 Years|No|||April 2014|April 14, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02114710||46482|
NCT02114957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-3742|Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)|Single Oral Dose Pharmacokinetics of Decursin/Decursinol Angelate in Healthy Adult Men and Women||Texas Tech University Health Sciences Center|No|Completed|January 2013|||April 2013|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114957||46463|
NCT02115230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IncorRDN-ICFEN|Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction|Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter||InCor Heart Institute|No|Recruiting|April 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||April 2014|April 13, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115230||46442|
NCT02115243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046479|Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma|A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma||Duke University|Yes|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115243||46441|
NCT02115828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1423|A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy|A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||November 2015|November 17, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115828||46396|
NCT02115854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|granuloma1|Labial Biopsy in Patients With Tuberculosis Disease|The Value of Labial Biopsy in 65 Patients With Tuberculosis Disease||Hopital Lariboisière||Completed|December 2010|||April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|bacteriologically confirmed tuberculosis|April 2014|April 15, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02115854|1 Year|46394|
NCT02116049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH082639|Intervention to Assist MSM Disclose HIV Status to Casual Sex Partners|Intervention to Assist MSM Disclose HIV Status to Casual Sex Partners||University of South Florida|No|Completed|August 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|340|||Male|18 Years|N/A|No|||April 2015|April 6, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02116049||46379|
NCT02116270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS API/2012/28|Accelerated Immunosenescence and Chronic Kidney Disease|Accelerated Immunosenescence and Chronic Kidney Disease|IRIS|Centre Hospitalier Universitaire de Besancon|No|Recruiting|September 2013|May 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|282|||Both|18 Years|85 Years|No|||February 2016|February 4, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02116270||46362|
NCT02116543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110|TD-6450 MAD Study in HCV Infected Subjects|A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)||Theravance Biopharma R & D, Inc.|No|Completed|May 2014|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116543||46341|
NCT02113007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CNS 20|Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma|Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma||SCRI Development Innovations, LLC|No|Terminated|July 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|April 10, 2014|Yes|Yes|Closed early due to slow accrual.|No||https://clinicaltrials.gov/show/NCT02113007||46613|
NCT02116816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Version 2|Absorption Profiles of Three Polyphenol Preparations With and Without Pollen Shell Covering|Investigation Into Polyphenol Absorption Profiles||University of Hull|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116816||46320|
NCT02116829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A309|Is There Room for Butter in a Healthy Diet?|Is There Room for Butter in a Healthy Diet? - A Randomized Controlled Dietary Human Intervention||University of Copenhagen|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116829||46319|
NCT02112578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS 002/2013|Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin|" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"||Apsen Farmaceutica S.A.|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112578||46646|
NCT02108613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084902|Living Well on Androgen Deprivation Therapy|Living Well on Androgen Deprivation Therapy: A Comprehensive Approach to Prostate Cancer Survivorship||British Columbia Cancer Agency|Yes|Not yet recruiting|April 2014|March 2017|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Male|N/A|80 Years|No|||April 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108613||46949|
NCT02109887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-1999-0005|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)||Asan Medical Center|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|16 Years|99 Years|No|Non-Probability Sample|Non-HIV patients with PCP|February 2016|February 5, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02109887||46851|
NCT02113449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202181|Market Potential of Carbon Dioxide Nasal Spray|A Study to Assess the Market Potential of a Carbon Dioxide Nasal Spray in Congested Subjects||GlaxoSmithKline|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|February 6, 2014|No|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT02113449||46579|
NCT02113462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-012014|Triglyceride/High-density Lipoprotein Cholesterol Ratio in Chronic Kidney Disease|The Prospective Cohort Study to Investigate the Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio To Predict Cardiovascular Outcomes in Chronic Kidney Disease.||Gulhane School of Medicine|No|Completed|January 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Both|20 Years|80 Years|No|Probability Sample|renal unit|April 2014|April 10, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02113462||46578|
NCT02113696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|primary|Intake of Omega 3 in Morbidly Obese Patients|The Effect of ω-3 Polyunsaturated Fatty Acids (Eicosapentaenoic Acid and Docosahexanoic Acid) on Morbidly Obese Patients||Pontificia Universidade Católica do Rio Grande do Sul|Yes|Completed|May 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|60 Years|No|||July 2014|July 4, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02113696||46560|
NCT02113930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI08039|Idiopathic CD4 Lymphocytopenia|Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia|Lympho-4|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Serum; plasma, peripheral blood mononuclear cells and DNA.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200 patients will be included : 100 for which the diagnosis of ICL will be defined on a        basis in international classification criteria.|December 2015|December 21, 2015|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02113930||46542|
NCT02113956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007481|Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior|Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior|G2G|Center for Innovative Public Health Research|No|Active, not recruiting|June 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|302|||Male|14 Years|18 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113956||46540|
NCT02114203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401016|Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease|A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease||Pfizer|No|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|64|||Both|18 Years|65 Years|No|||March 2016|March 18, 2016|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02114203||46521|
NCT02114216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1211/180-003|Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease|TRPV1, NGF and GDNF Messenger Ribonucleic Acid(mRNA) Expression of the Esophageal Mucosa in the Erosive Reflux Disease With Esophageal Reflux Symptoms||Seoul National University Bundang Hospital|No|Recruiting|October 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|156|Samples With DNA|During the endoscopic examination, two biopsies of the distal esophagus are taken. Biopsies      are taken using standard biopsy forceps from between esophagitis erosions at a fixed      position 3cm above the squamo-columnar junction in order to achieve sample consistency in      all GERD subjects.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who visit SNUBH gastroenterology department mainly for evaluating the origin of        suspicious GERD symptoms or for screening of gastric cancer.|November 2014|November 17, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02114216||46520|
NCT02114970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401014708|Comparing Paper-based and Tablet-delivered Informed Consent for Older Adults|Comparing Paper-based and Tablet-delivered Informed Consent for Older Adults||Weill Medical College of Cornell University|Yes|Active, not recruiting|June 2012|July 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|42|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114970||46462|
NCT02115256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0636|Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline|Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women||Icahn School of Medicine at Mount Sinai|No|Terminated|July 2014|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Female|18 Years|35 Years|No|||April 2015|April 13, 2015|April 13, 2014|Yes|Yes|difficult recruitment|No||https://clinicaltrials.gov/show/NCT02115256||46440|
NCT02115568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-005|Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203|A Registry to Assess the Ongoing Safety for Subjects That Have Been Randomized and Completed a Juventas Sponsored Heart Failure Protocol Under IND # 14203||Juventas Therapeutics, Inc.|No|Active, not recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|165|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population eligible for the proposed Registry will be subjects who have        completed a Juventas sponsored heart failure study under IND 14203. The patient population        will primarily be comprised of symptomatic systolic heart failure patients due to ischemic        etiology.|April 2014|April 14, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115568|3 Years|46416|
NCT02116062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5540|Robotic Surgery of the Ocular Surface|Robotic Microsurgery of the Ocular surfaceProspective Human Feasibility Study||University Hospital, Strasbourg, France|No|Recruiting|June 2014|March 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02116062||46378|
NCT02116283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044941|Mobile Sensing of Smoking Behavior|Mobile Sensing of Smoking Behavior|Mobi-Smoke|Duke University|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02116283||46361|
NCT02116296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ToyBox-study|Multi-component, Kindergarten-based, Family-involved Intervention for the Prevention of Childhood Obesity:The ToyBox-study|Multifactorial Evidence Based Approach Using Behavioural Models in Understanding and Promoting Fun, Healthy Food, Play and Policy for the Prevention of Obesity in Early Childhood||Harokopio University||Completed|March 2010|||June 2013|Actual|N/A|Interventional|Primary Purpose: Prevention|1||||||Both|42 Months|66 Years||||April 2014|April 15, 2014|April 2, 2014||||No||https://clinicaltrials.gov/show/NCT02116296||46360|
NCT02116556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFA-AAH.|Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis|Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study|RIFA-AAH|Hospital Universitari Vall d'Hebron Research Institute|Yes|Recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||April 2014|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116556||46340|
NCT02116842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN10/9307|Minimum Effective Dose (MED) & Epidural Bupivacaine|Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.||University of Leeds|Yes|Recruiting|December 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|50 Years|No|||April 2014|April 16, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116842||46318|
NCT02113059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-AS-TG-CB|Platelets in Liver Regeneration|"Involvement of Platelets and Platelet Derived Growth Factors in Postoperative Liver Regeneration, Liver Dysfunktion and Morbidity in Patients Undergoing Hepatectomy"||Medical University of Vienna|No|Recruiting|January 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Plasma, serum, platelet and tissue preparation|Both|18 Years|85 Years|No|Probability Sample|40 patients undergoing elective hemihepatectomy.|September 2015|September 21, 2015|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02113059||46609|
NCT02113072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAraujo|Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics.|Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics, a Randomized Clinical Trial, Double-blind, Placebo Controlled.||Universidade Federal de Pernambuco|Yes|Completed|April 2014|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||December 2014|December 3, 2014|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113072||46608|
NCT02108626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/2014|Electronic Cigarettes in Daily Dependent Smokers|A Behavioral Assessment of Electronic Cigarettes in Reducing Cue- and Withdrawal-induced Craving in Daily Dependent Smokers||Centre for Addiction and Mental Health|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||May 2015|May 4, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108626||46948|
NCT02108860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABROGATE 5527|Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)|Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)||University of South Florida|Yes|Recruiting|April 2015|September 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|15 Years|N/A|No|||March 2016|March 1, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108860||46930|
NCT02109094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sherwin.Pregnancy.11.20.13|Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance|Investigating Markers of Energy Metabolism in the CNS and Periphery in Pregnant Women With Varying Degrees of Insulin Resistance||Yale University|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|Samples With DNA|whole blood, urine, cerebrospinal fluid, cord blood|Female|18 Years|45 Years|No|Non-Probability Sample|All pregnant subjects will be women recruited from the Women's Center, the high-risk        prenatal care unit at Tompkins, Long Wharf and L&D.        The target population in this study includes pregnant women with pregnancies complicated        by gestational diabetes, DM, and uncomplicated controls.        The Yale New Haven Hospital Lumbar puncture clinic, located in the Yale Physicians        Building, is a weekly referral clinic in the department of Neurology. The target        population for this study includes non-pregnant women, age greater than 18 who require        large volume lumbar puncture for medical purposes such as for symptomatic treatment of        pseudotumor cerebri.|March 2015|March 19, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02109094||46912|
NCT02109107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_EZ6_BC_001|Study of Low Level Laser Light Therapy on Circumference Reduction|An Evaluation of the Effect of the Erchonia® Zerona 6 Headed Scanner (EZ6) Six-week Treatment Protocol on Circumference Reduction of the Waist, Hips, Thighs and Upper Abdomen Clinical Study Protocol||Erchonia Corporation|No|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|April 7, 2014|Yes|Yes||No|December 31, 2015|https://clinicaltrials.gov/show/NCT02109107||46911|
NCT02109120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-0321|MMP-9 Monitoring Particulate Cerebral Embolisation|Dynamic Changes of MMP9 Concentration Cross Carotid Endarterectomy Monitoring Particulate Cerebral Embolisation|MMP9MPCE|Peking Union Medical College Hospital|Yes|Completed|February 2012|November 2013|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|Samples Without DNA|serum,Freeze-saving -80℃|Both|40 Years|90 Years|No|Non-Probability Sample|patients under CEA in the PUMCH|September 2013|April 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109120|7 Days|46910|
NCT02109133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0058|The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy|||Yonsei University|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|67|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 21, 2015|March 30, 2014||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT02109133||46909|
NCT02109146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-103|Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma|||Zhejiang University||Recruiting|January 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||April 2014|April 8, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02109146||46908|
NCT02113475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC14-1213-001|Venous Thrombectomy/Thrombolysis Outcome Registry|A Patient Outcome Study After Pharmacomechanical Catheter-directed Thrombolysis and Standard Treatment for Venous Thrombosis|VETTOR|Heart and Vascular Outcomes Research Institute|Yes|Recruiting|April 2014|January 2021|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Both|16 Years|75 Years|No|Non-Probability Sample|Participating study centers will enroll patients and enter data in the web-based registry        that include demographics, clinical features,|March 2015|March 18, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113475||46577|
NCT02113488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1978|Causes of Nonattendance at Scheduled Outpatient Appointments|Case-control Study: Causes of Nonattendance at Clinical Medicine Scheduled Outpatient Appointments in a University General Hospital|AU2|Hospital Italiano de Buenos Aires|No|Active, not recruiting|October 2013|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults with a scheduled appoitment at the Clinical Medicine Outpatient care system at the        Italian Hospital of Buenos Aires (HIBA)|April 2014|April 10, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02113488||46576|
NCT02113709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIrfanMEHT|Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at Different Ages|Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at All Ages||Mughal Eye Trust Hospital|Yes|Active, not recruiting|January 2010|June 2014|Anticipated|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|3 Years|N/A|No|||April 2014|April 14, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02113709||46559|
NCT02114476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM-Imp|Effect of Implantable Contraception on Type-2 DM and Metabolic Syndrome in Women With History of Gestational DM|Effect of Implantable Progestin-only Contraception on the Incidence of Type 2 Diabetes and Metabolic Syndrome in Thai Women With History of Gestational Diabetes||Mahidol University|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|260|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 4, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114476||46500|
NCT02114229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJATRT|Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors|Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT||St. Jude Children's Research Hospital|Yes|Recruiting|May 2014|May 2027|Anticipated|May 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|N/A|21 Years|No|||January 2016|January 29, 2016|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114229||46519|
NCT02114723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC-MITR-01-1|Effectiveness of Medical Taping Concept in Primary Dysmenorrhea|Assessment of Mediacal Taping Concept Self-applied, in the Treatment of Primary Dysmenorrhea||Universidad Miguel Hernandez de Elche|No|Completed|February 2014|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|129|||Female|18 Years|30 Years|No|||November 2014|November 11, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02114723||46481|
NCT02114983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-1|General Practitioner-performed Compression Ultrasound for Deep Vein Thrombosis|Precision and Diagnostic Accuracy of General Practitioner-performed Compression Ultrasound for Proximal Symptomatic Deep Vein Thrombosis||Azienda Sanitaria Locale ASL 6, Livorno|No|Recruiting|January 2015|January 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000||d-dimer|Both|18 Years|N/A|No|Probability Sample|All outpatients evaluated at home or at office by the GP with a first episode of suspected        DVT of the lower limbs will be screened with CUS. GP may use his/her own ultrasound, or        take advantage of the equipment of the Vascular Service of the Hospital. Shortly        afterward, (i.e., within 2 hours), all outpatients will be re-evaluated by a doctor with        expertize in vascular ultrasound|January 2015|January 3, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02114983||46461|
NCT02114996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3072|Can a Vocal Stimulus Provoke Spontaneous Breathing in an Ischemic Stroke Patient Dependent on Mechanical Ventilation?|Phase 1 - Vocal Stimuli to Provoke Spontaneous Breathing||The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|April 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|patients on mechanical ventilation|April 2014|April 13, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02114996||46460|
NCT02115269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-389|IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice|IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan|PRESTO|Abbott|No|Completed|June 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|759|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with migraine (with or without aura) and/or episodic TTH|November 2015|November 18, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02115269||46439|
NCT02115581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoenzymeQ10 and Cardiomyopathy|Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy|Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial||University of Tehran|Yes|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|6 Months|18 Years|No|||March 2014|March 14, 2014|December 22, 2008||No||No|December 22, 2008|https://clinicaltrials.gov/show/NCT02115581||46415|
NCT02115841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2266A3|Effect of Transcutaneous Nerve Stimulation on Primary Motor Cortex to Modulate Cortical Excitability and Hemodynamic Response During Implicit Motor Learning: A TMS and NIRS Study|||Chang Gung University|Yes|Recruiting|August 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|48|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02115841||46395|
NCT02116075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC2626|Caudal Corticosteroid vs. Dextrose Injection for Lumbosacral Radicular Pain.|||VA Long Beach Healthcare System||Recruiting|January 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02116075||46377|
NCT02116309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034715|A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis in High Risk Patients||INDIEH|Johns Hopkins University|Yes|Recruiting|August 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|948|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116309||46359|
NCT02116322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00090101|EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study|EUS-guided Fine Needle Tissue Acquisition of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study||Johns Hopkins University|Yes|Recruiting|April 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||September 2015|September 2, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116322||46358|
NCT02104505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1605|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS|Vitalps|University of North Carolina, Chapel Hill|No|Recruiting|July 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|No|||February 2016|February 15, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104505||47263|
NCT02116569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104072|A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma|A Phase I Study of JNJ-54761414 (Daratumumab) in Japanese Patients With Relapsed or Refractory Multiple Myeloma||Janssen Pharmaceutical K.K.|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|April 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116569||46339|
NCT02105103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001514|European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.|Accu-Chek® Insight Insulin Pump EU Study: A European Multicenter Study to Evaluate the Accu-Chek® Insight Insulin Pump in Routine Practice||Hoffmann-La Roche||Completed|October 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|May 11, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105103||47217|
NCT02105441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009050|Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss|Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss|CI and SSD|Mayo Clinic|No|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|N/A|No|||April 2014|April 2, 2014|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02105441||47191|
NCT02105454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-048|Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)|A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy||Merck Sharp & Dohme Corp.|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|April 2, 2014|Yes|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT02105454||47190|
NCT02108873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2262|Factors Associated With Nonattendance at Scheduled Outpatient Appointments in a University General Hospital|Factors Associated With Nonattendance at Scheduled Outpatient Appointments in a University General Hospital|AU1|Hospital Italiano de Buenos Aires|No|Completed|May 2014|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We included all requested appointments (random consecutive sampling) between 2012 and 2013        (24 month). The sample was randomized to allocate a generation cohort (two-thirds of the        sample) and a validation cohort (one third of the sample).|March 2015|March 19, 2015|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02108873||46929|
NCT02108652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29293|A Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor210]|A Phase II, Multicenter, Single-Arm Study of Atezolizumab (MPDL3280A) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer||Hoffmann-La Roche||Active, not recruiting|May 2014|August 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108652||46946|
NCT02108665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11AOI07|Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility|Magnetic Resonance Imaging Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2013|January 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|N/A|No|||November 2013|April 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108665||46945|
NCT02108886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-143|Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth|Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth.|EAU2-Mtlk|Université de Sherbrooke|No|Active, not recruiting|December 2011|December 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||March 2015|March 3, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02108886||46928|
NCT02113254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/17|Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine|Study of Modification of the Density of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine|MAIS|University Hospital, Bordeaux|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113254||46594|
NCT02113722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14_145|The Purpose of This Study is to Determine Whether the Incidence of Recurrent Life Threatening Ventricular Arrhythmias in Patients With an Implanted Cardiac Defibrillator (ICD) Can be Reduced if a Surgical Left Stellate Ganglionectomy is Performed|Does Left Cardiac Sympathectomy Stellate Ganglionectomy Confer an Additional Benefit Over Optimal Medical Treatment in the Reduction of Therapy Delivered From an Implanted Cardioverter Defibrillator (ICD) in Patients at High Risk of Sudden Cardiac Death (SCD)?|Reduce-SCD|Princess Alexandra Hospital, Brisbane, Australia|Yes|Not yet recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113722||46558|
NCT02113969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA12I2153|Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol|Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol||Servicio de Salud Metropolitano Sur Oriente|No|Recruiting|September 2013|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|294|||Female|18 Years|N/A|No|||November 2014|November 17, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02113969||46539|
NCT02114489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwissMedic 136/13|Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis|Double Blind Randomized Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Stage 1 and 2||University of Lausanne Hospitals|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|No|||June 2015|June 3, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114489||46499|
NCT02114502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0892|Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma|Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma||M.D. Anderson Cancer Center|No|Withdrawn|September 2014|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||July 2014|July 9, 2014|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114502||46498|
NCT02114736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-SKG-57/2013|Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke|A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke||University Hospital of Mont-Godinne|No|Recruiting|March 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||April 2014|April 12, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02114736||46480|
NCT02115009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0072-CTIL|The Sacroiliac Joint With SIJ Nerve Entrapments and Chronic Low Back Pain|Comparative Study of The Relationship Between the Sacroiliac Joint (SIJ) and Lumbopelvic Configurations With SIJ Nerve Entrapments and Chronic Low Back Pain|SARA31143|Carmel Medical Center|Yes|Not yet recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects (100 males and 100 females) with and without Low Back Pain|April 2014|May 5, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115009||46459|
NCT02115282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00746|Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic|A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer||National Cancer Institute (NCI)|Yes|Recruiting|March 2014|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115282||46438|
NCT02115295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0648|Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)|Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115295||46437|
NCT02115594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0305|Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer|A Phase 2, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer|ENCORE305|Syndax Pharmaceuticals|Yes|Withdrawn|April 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|N/A|N/A|No|||April 2014|October 6, 2014|April 4, 2014|No|Yes|Internal decision|No||https://clinicaltrials.gov/show/NCT02115594||46414|
NCT02115867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/1695|Effect of a Probiotic on Diverticular Symptoms|Assessment of the Probiotic Symprove as a Dietary Supplement in Patients With Symptomatic Diverticular Disease||King's College Hospital NHS Trust|No|Completed|April 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|20 Years|N/A|No|||April 2014|September 10, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02115867||46393|
NCT02104219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-HPP-502|Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)|A Retrospective, Non-interventional, Epidemiologic Study of the Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)||Alexion Pharma GmbH|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|32|||Both|5 Years|N/A|No|Non-Probability Sample|Juvenile-onset HPP (≥ 6 months and ˂18 years)|November 2015|November 16, 2015|March 25, 2014||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT02104219||47285|
NCT02104232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THPP-I MH095687|Thinking Healthy Program - Peer Delivered, India (THPP-I)|Thinking Healthy Program - Peer Delivered, India (THPP-I)|THPP-I|London School of Hygiene and Tropical Medicine|Yes|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|N/A|No|||November 2014|November 11, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104232||47284|
NCT02104518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eijkman-69|Evaluation of Different G6PD Testing Platforms|Evaluation of a Point-of-care G6PD Diagnostic Test||PATH|Yes|Completed|April 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|700|Samples With DNA|Left-over venous blood will be spun down and buffy coat and extracted DNA will be stored in      labeled tubes for later G6PD genotyping and characterization.|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll up to 700 volunteers from the SW Sumba region in Indonesia. The SW Sumba        region is inland, and isolated from other nearby villages. The general population of SW        Sumba are substance farmers.|October 2014|October 27, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104518||47262|
NCT02104791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCOG-1988|Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane|Procalcitonin Has a Role to Play in Prediction of Intra-amniotic Subclinical Infection.||Ain Shams Maternity Hospital|Yes|Enrolling by invitation|May 2014|||May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|100|Samples Without DNA|plasma|Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Study population          -  This study will be conducted at the department of Obstetrics and Gynecology             recruiting pregnant women selected from the attendees of antenatal clinic, emergency             department and from inpatient wards of Ain Shams University Maternity Hospital from             Mars2014.          -  This study will include 100 pregnant women these cases will be divided into 2 groups:          -  Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks             of gestational age .          -  Group 2: Preterm premature rupture of membrane Group: will include 50 pregnant             females all at 24-34 weeks of gestational age.|April 2014|April 3, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104791||47241|
NCT02104804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00010|Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control|A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin||AstraZeneca|No|Completed|May 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|953|||Both|18 Years|100 Years|No|||March 2016|March 15, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104804||47240|
NCT02105116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021208|AML Therapy With Irradiated Allogeneic Cells|AML Therapy With Irradiated Allogeneic Cells||Rutgers, The State University of New Jersey|No|Recruiting|February 2014|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105116||47216|
NCT02105129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-523-00AU1|A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523|A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523||Hutchison Medipharma Limited|Yes|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|118|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02105129||47215|
NCT02105467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-060|Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.||Merck Sharp & Dohme Corp.|No|Completed|June 2014|September 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105467||47189|
NCT02105753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0010|Tx Axillary Hyperhidrosis 1210nm Diode Laser|Treatment of Axillary Hyperhidrosis With a 1210nm Diode Laser||United States Naval Medical Center, San Diego|No|Enrolling by invitation|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|64 Years|No|||September 2014|February 9, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105753||47167|
NCT02112617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-443|Phase II Study of Proton Radiation Therapy for Neuroblastoma|Phase II Study of Proton Radiation Therapy for Neuroblastoma||Massachusetts General Hospital|Yes|Recruiting|June 2014|March 2028|Anticipated|March 2024|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Months|25 Years|No|||March 2016|March 4, 2016|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112617||46643|
NCT02108899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5305|Retrieval Practice and Schizophrenia|Retrieval Practice in Patients With Schizophrenia : an Exploratory Study Using Descriptive Stories||University Hospital, Strasbourg, France|No|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02108899||46927|
NCT02109159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA534|Dissemination of Findings Fast Using Online-videos Trial|A Randomize Controlled Trial of the Effect of Emotional Content on the Extent to Which an On-line Medical Educational Video is Forwarded.|DIFFUSION|London School of Hygiene and Tropical Medicine|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|7000|||Both|N/A|N/A|No|||May 2014|March 30, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109159||46907|
NCT02109172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0116|A 7-Day Cross-over Study of QD and BID TD-4208 in COPD|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease||Theravance Biopharma R & D, Inc.|No|Completed|April 2014|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|40 Years|N/A|No|||December 2014|December 1, 2014|April 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109172||46906|
NCT02113501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HighGradeT1 Bladder Cancer HVH|Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study|Optimized Treatment Strategy for HighGradeT1 (HGT1) Bladder Cancer Based on Substaging (Depth of Lamina Propria Invasion): a Prospective Observational Cohort Study||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|April 2005|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|Samples With DNA|paraffin embedded blocks of transurethral resection (TUR) samples|Both|N/A|N/A|No|Non-Probability Sample|Initial HGT1 bladder cancer patients that have undergone a complete TUR and are willing to        enter the protocol.|April 2014|April 10, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02113501||46575|
NCT02113982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-401-0114|SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia|SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)||Stemline Therapeutics, Inc.|Yes|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113982||46538|
NCT02114008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179.017/2012 CEP UFMT|Residual Gastric Volume in Morbidly Obesa Diabetics. A Comparison of 3 Hour Versus Hour Fasting.|Residual Gastric Volume in Morbidly Obesa Diabetics. A Comparison of 3 Hour Versus Hour Fasting.||Cuiaba University|Yes|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|8|||Both|18 Years|55 Years|No|||April 2014|April 14, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02114008||46536|
NCT02114515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-IH 1211-4365|PATient Navigator to rEduce Readmissions|PATient Navigator to rEduce Readmissions|PArTNER|University of Illinois at Chicago|Yes|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1130|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02114515||46497|
NCT02114528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130425|Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention|Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial|AVATAR|Ottawa Heart Institute Research Corporation|Yes|Terminated|October 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||November 2015|November 13, 2015|April 4, 2014||No|Low recruitment. Pilot trial.|No||https://clinicaltrials.gov/show/NCT02114528||46496|
NCT02114749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Hospital, Grenoble|Development of Tools for Respiration and Circulation Exploration|Development of Tools for Respiration and Circulation Studies and Exploration, Their Mutual Interactions and the Functions Involved in the Daily Life in Healthy Volunteers|MAPO-RCVQ|University Hospital, Grenoble|Yes|Recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02114749||46479|
NCT02108028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140079|Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer|An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer, and Other Life Threatening Illnesses||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|March 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108028||46993|
NCT02108340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ΕΣ 45/19-9-2013|Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis|Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis||Hippocration General Hospital|No|Recruiting|September 2013|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|No|||December 2015|December 6, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02108340||46970|
NCT02108574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401|Efficacy Park Study Assessing Rhinix™ Nasal Filters for Hay Fever|A Double-blind, Placebo-controlled, Randomized Single-centre Crossover Park Study Assessing Rhinix™ Nasal Filters||University of Aarhus|Yes|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||December 2014|December 19, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02108574||46952|
NCT02104245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-3150-1202|Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension|ORBIT-4|Aradigm Corporation|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|255|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104245||47283|
NCT02105142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305011436|Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD|Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD||Indiana University|Yes|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|81|||Both|6 Years|12 Years|No|||November 2015|November 6, 2015|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02105142||47214|
NCT02104531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403E49122|Shoulder Motion Guided Patient Diagnostic and Treatment Classification|Shoulder Motion Guided Patient Diagnostic and Treatment Classification||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with shoulder pain and rotator cuff disease, as well as age and gender matched        controls.|January 2016|January 4, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02104531||47261|
NCT02104817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5881C00004|Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia|A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)|STRENGTH|AstraZeneca|Yes|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|13000|||Both|18 Years|99 Years|No|||February 2016|February 24, 2016|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104817||47239|
NCT02106039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-201403.01|Pulmonary Tuberculosis Patients With Diabetes Mellitus|Concurrent Tuberculosis and Diabetes: Clinical Monitoring, and Microbiological and Immunological Effects of Diabetes During Tuberculosis Treatment|TANDEM|Universitas Padjadjaran|Yes|Recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02106039||47145|
NCT02106052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4887 A1/1|Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients|The Effect of Aerobic Exercise on Cognition in Multiple Sclerosis (MS Exercise Study)||University of Washington|No|Recruiting|March 2014|February 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|59 Years|No|||February 2016|February 16, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02106052||47144|
NCT02106312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N10DMY|Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas|Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas|DOREMY|The Netherlands Cancer Institute|No|Recruiting|November 2010|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2012|October 8, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02106312||47124|
NCT02108691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSWU-BF-GE|Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight|||Hanyang University|Yes|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|April 7, 2014||No||No|May 6, 2015|https://clinicaltrials.gov/show/NCT02108691||46943|
NCT02106663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 110531|Effectiveness Study of Circumferential vs. Segmental Ablation in Paroxysmal Atrial Fibrillation|Evaluating the Efficacy of Circumferential Pulmonary Vein Ablation (CPVA) Versus Segmental Pulmonary Vein Isolation (SPVI) in Paroxysmal Atrial Fibrillation|PAF|University of California, San Diego|No|Recruiting|July 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106663||47097|
NCT02106988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0367|Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma|Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|January 2015|||January 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106988||47072|
NCT02107001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPP08032014|Lung Ultrasound in Pleuritic Chest Pain|Lung Ultrasound in Pleuritic Chest Pain: a Multicenter, Prospective, Diagnostic Accuracy Study.|UPP|University of Milan|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Inpatients and outpatients presenting with pleuritic chest pain referred for medical        consultation to italian university and clinical hospitals.|November 2015|November 30, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107001||47071|
NCT02113995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018/CEP-UNIC/2011.|Clinical Evaluation, Organic Response in Obesity Patients Subjected to Vertical Videolaparoscopy Gastroplasty With or Without Perioperative Cares Recommended by the Acerto Project. Randomized Study.|Clinical Evaluation, Organic Response in Obesity Patients Subjected to Vertical Videolaparoscopy Gastroplasty With or Without Perioperative Cares Recommended by the Acerto Project.||Cuiaba University|Yes|Completed|April 2012|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|No|||April 2014|April 14, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02113995||46537|
NCT02106533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53/2010|Aerobic Exercise on Ventilatory Efficiency in CAD Patients|Effect of Aerobic Exercise Training on Ventilatory Efficiency in Patients With Coronary Artery Disease||Hospital TotalCor|Yes|Completed|August 2011|May 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Both|48 Years|77 Years|No|||April 2014|April 7, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02106533||47107|
NCT02106819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300595|Emotional Communication Disorders in Cerebellar Disease|Disorders of Emotional Communication in Patient With Cerebellar Dysfunction||University of Florida|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The ataxia subjects will be recruited from the University of Florida Medical Center. The        age matched controls will be recruited from the local community.|November 2015|November 30, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106819||47085|
NCT02114242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/27|Biomarkers in Parkinsonian Syndromes|Development of Biomarkers for the Diagnosis and Prognosis of Parkinsonian Syndromes Running Head: Biomarkers in Parkinsonian Syndromes|BIOPARK|University Hospital, Bordeaux|No|Recruiting|December 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|-  Cerebrospinal fluid        -  Whole blood        -  Plasma        -  Serum        -  Urine|Both|18 Years|N/A|No|Probability Sample|Patients suffering from parkinson disease or multiple system atrophy or progressive        supranuclear palsy.|October 2014|October 27, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02114242||46518|
NCT02107404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP003|Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial With Active Cellular Immunotherapy DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy||Sotio a.s.|No|Active, not recruiting|April 2012|June 2017|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|N/A|No|||June 2015|June 30, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107404||47041|
NCT02107677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC0094|Specificity Study of Diagnostic for Early Detection of Dengue Infection|Determination of Estimated Specificity of DENV Detect NS1 ELISAs||InBios International, Inc.||Completed|August 2012|||August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|300|Samples Without DNA|serum|Both|N/A|N/A|No|Probability Sample|Human males and females of varying ages and geographical locations where dengue fever is        non-endemic. We will use retrospective (archived) human serum samples, not collected        specifically for this study and not individually identifiable to the Investigators. These        samples will fall under the category of "leftover" specimens as described by FDA guidance.        These archived samples will have been collected from patients within 7 days after onset of        symptoms consistent with Dengue infection.|November 2014|November 7, 2014|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107677||47020|
NCT02103920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC01/06/11|A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors|||National University Hospital, Singapore|Yes|Recruiting|May 2011|||June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1400|||Both|21 Years|N/A|No|Probability Sample|Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH.|April 2014|April 1, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT02103920||47307|
NCT02108002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140067|Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)|Pilot Study of the Effect of Vorinostat on Nervous System Hemangioblastomas In Von Hippel-Lindau Disease||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|March 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|No|||December 2015|March 12, 2016|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108002||46995|
NCT02108015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140068|Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8|Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8||National Institutes of Health Clinical Center (CC)||Terminated|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 6, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108015||46994|
NCT02108301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK477/2011|Hepatitis C in Renal Transplant Recipients|Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.||Medical University of Vienna||Active, not recruiting|December 2011|||June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||April 2014|April 10, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02108301||46973|
NCT02108587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11811|Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer|Staging of Upper Tract Urothelial Cancer With Optical Coherence Tomography||Case Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108587||46951|
NCT02108600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29092|Tocilizumab for Renal Graft Inflammation|A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft||University of California, San Francisco|Yes|Recruiting|June 2014|December 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||January 2015|January 27, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108600||46950|
NCT02105155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 120907|Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation|Non-inferiority and Tolerance of Conversion From Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation|Conversion|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105155||47213|
NCT02105480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDLabs-AAAPN|Automated Algorithm Based Analysis of Phonocardiograms of Newborns|Automated Algorithm Based Analysis of Phonocardiograms of Newborns||CSD Labs GmbH|Yes|Recruiting|November 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|220|||Both|N/A|5 Days|Accepts Healthy Volunteers|Non-Probability Sample|Premature babies and newborns stationed at the department of neonatology|July 2015|July 29, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02105480|1 Day|47188|
NCT02105779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1MH082818|Optimizing Cognitive Remediation Outcomes in Schizophrenia|Optimizing Cognitive Remediation Outcomes in Schizophrenia|CAST|University of California, San Francisco|No|Recruiting|December 2009|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02105779||47165|
NCT02105805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-01-clinnutr|Weight Loss as Treatment in Heart Disease|Intentional Weight Loss as Treatment in Obese Patients With Ischaemic Heart Disease||University of Copenhagen|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105805||47163|
NCT02106611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-017|Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors|Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC|January 2016|January 5, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106611||47101|
NCT02106624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiNiCi|A Trial to Assess the Effect of High Nitrogen Intake in Critically Ill Patients|The Efficacy and Safety of High Nitrogen Intake in Critically Ill Patients: a Randomized and Controlled Trial||Shanghai Zhongshan Hospital|Yes|Recruiting|March 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02106624||47100|
NCT02107469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NADIAD 2014|A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy|A Randomized Placebo-compared Study on Efficiency of Two Different Administration Forms of Phyllanthus Niruri and Sida Cordifolia in Patients With Diabetic Peripheral Polyneuropathy|VEDICINE|Rosenberg European Academy of Ayurveda|Yes|Completed|June 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|98|||Both|20 Years|80 Years|No|||February 2016|February 23, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107469||47036|
NCT02106377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|537897|Using in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Steroid Treatment in Dry Eye Disease|The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease||Massachusetts Eye and Ear Infirmary|No|Recruiting|February 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|89 Years|No|||April 2014|April 7, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106377||47119|
NCT02107287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-519 GEN|Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer|Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer||McGill University Health Center|No|Recruiting|August 2011|June 2019|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT02107287||47050|
NCT02107508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2013-021|The Relationship Between Activity Energy Expenditure and Body Composition in School-age Children|||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|No|Recruiting|January 2013|||December 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children in Shanghai|April 2014|April 9, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107508||47033|
NCT02107846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-112-02a|An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112|A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease||Protalix|No|Not yet recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107846||47007|
NCT02113761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE77201318160|Non Invasive Mapping Before Ablation for Atrial Fibrillation.|Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.|AFACART|Brugmann University Hospital|Yes|Active, not recruiting|January 2014|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with persistent atrial fibrillation as described by the Consensus Statement and        with an indication for atrial fibrillation catheter ablation.|October 2015|October 21, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02113761||46555|
NCT02106858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16778|Stivarga Regulatory Post-Marketing Surveillance Study in Korea|Stivarga® Regulatory Post-Marketing Surveillance Study in Korea|StivargaPMS|Bayer|No|Recruiting|June 2014|August 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3750|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable locally        advanced GIST(Gastrointestinal stromal tumors) by physician|March 2016|March 7, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106858||47082|
NCT02107196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAK-06|12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea|IRIS-3|Menarini Group|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|No|||April 2015|July 14, 2015|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107196||47057|
NCT02114255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG_influenza|Effects of BCG on Influenza Induced Immune Response|The Effects of BCG-vaccination on the Immune Response Induced by Influenza-vaccination in Healthy Volunteers. A Pilot Proof-of-principle Study.||Radboud University|Yes|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|March 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02114255||46517|
NCT02107417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-2014-NPIQ|Study of TENS in Reducing Symptoms of Peripheral Neuropathy Induced by Chemotherapy|The Use of Transcutaneous Electrical Nerve Stimulation (Tens) in Reducing Symptoms of Peripheral Neuropathy Induced by Antineoplastic Chemotherapy|CIPN|University of Sao Paulo General Hospital|No|Recruiting|June 2014|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02107417||47040|
NCT02107690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2297|The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration|The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration||Norwegian University of Science and Technology|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107690||47019|
NCT02107703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15362|A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer|MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer|MONARCH 2|Eli Lilly and Company|Yes|Active, not recruiting|July 2014|February 2020|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|630|||Female|18 Years|N/A|No|||February 2016|February 19, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107703||47018|
NCT02105792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF112|PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|PROMASTER|NIHR Exeter Clinical Research Facility|Yes|Active, not recruiting|March 2013|May 2016|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|820|Samples With DNA|At Visit 1, a fasting blood sample (approximately 35 ml) will be collected for DNA      extraction, and to measure for markers of the progression of diabetes or response to      diabetes medication and for secondary markers that may predict response. A urine sample is      also collected to measure for biomarkers.      At Visit 2 a fasting blood sample and urine sample will be collected to measure for markers      of the response to diabetes medication and for secondary markers that may predict response.|Both|18 Years|90 Years|No|Non-Probability Sample|Participants will be identified in primary care and secondary care. The method for patient        identification may differ between sites and could involve:        GP Searches; Secondary Care Clinician Referral; Research Database Searches.|March 2016|March 22, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105792||47164|
NCT02108314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-494|Video-assisted Intervention for Increasing Mammography Uptake in Private Primary Care in Singapore|Physician-led Video-assisted Intervention for Increasing Mammography Uptake in Private Primary Care Practice in Singapore: A Cluster-Randomized Trial||National University Health System, Singapore|Yes|Active, not recruiting|February 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|448|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||April 2014|April 5, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108314||46972|
NCT02108327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orthoTU07|Blood Loss Between Surgical Blade and Unipolar Electrocautery in TKA|Comparison of Blood Loss Between Surgical Blade and Unipolar Electrocautery in Primary Total Knee Arthroplasty|TKA|Thammasat University|Yes|Recruiting|March 2014|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||April 2014|April 8, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02108327||46971|
NCT02104830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-017-3|Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients|International Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy||Biocad|No|Active, not recruiting|September 2013|February 2015|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Anticipated|135|||Female|18 Years|70 Years|No|||April 2014|April 3, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104830||47238|
NCT02104843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-115|Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin|Effect of Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Therapy on the Pharmacokinetics of Rosuvastatin||Bristol-Myers Squibb|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104843||47237|
NCT02108366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-009|Treatment of Severe Influenza A Infection|A Randomized Controlled Trial on the Treatment of Severe Influenza A Infection||The University of Hong Kong|Yes|Recruiting|March 2014|June 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108366||46968|
NCT02104583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-356-0101|Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|TEMPO|Gilead Sciences|Yes|Recruiting|September 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104583||47257|
NCT02104596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xylitol- HMO-CTIL|Intraarticular Xylitol Injections for Knee Osteoarthritis|Intraarticular Xylitol Injections for Knee Osteoarthritis||Hadassah Medical Organization||Not yet recruiting|May 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|45 Years|N/A|No|||April 2014|April 16, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104596||47256|
NCT02105818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAMECO_1|Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis|Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis: a Cross-sectional Cohort Study|SWAMECO|University Hospital, Basel, Switzerland|No|Completed|March 2014|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland        (European Centre for the Rehabilitation of Scleroderma)|May 2015|May 20, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105818||47162|
NCT02107235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-12|Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer|Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma||Onconova Therapeutics, Inc.|No|Active, not recruiting|January 2014|June 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02107235||47054|
NCT02107248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4670604413|Supine Sleeping After Total Hip Replacement|The Need for Supine Position Advise During Sleep in the First 8 Week After a Total Hip Replacement to Prevent Hip Dislocation||Orthopedisch Centrum Oost Nederland|Yes|Recruiting|June 2014|March 2020|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|456|||Both|N/A|N/A|No|||March 2016|March 7, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107248||47053|
NCT02106676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03|Androgen Metabolism and Reproductive Outcome|Androgen Metabolism and Reproductive Outcome||Medical University of Graz|No|Completed|March 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Polycystic ovary Syndrome (PCOS): According to ethnicity and the criteria used for        diagnosis, polycystic ovary syndrome (PCOS) affects between 2-13% of women of reproductive        age (Asunción et al., 2000; Azziz et al., 2009; ESHRE/ASRM, 2004; Wang and Alvero, 2013).|November 2015|November 24, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106676||47096|
NCT02107014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29911|Low Dose Naltrexone (LDN) Immune Monitoring|Low Dose Naltrexone (LDN) Immune Monitoring|LDN-IM|Stanford University|No|Recruiting|March 2014|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Anticipated|20|||Female|18 Years|65 Years|No|||April 2014|April 7, 2014|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107014||47070|
NCT02107300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP|NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy|NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy||Medical University of South Carolina|No|Recruiting|November 2013|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|32|||Both|18 Years|84 Years|No|||April 2014|April 4, 2014|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107300||47049|
NCT02107521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapi IMSI IF|IMSI in Couples With Previous Implantation Failures|The Effect of the Intracytoplasmic Morphologically Selected Sperm Injection in Couples With Previous Implantation Failure After Intracytoplasmic Sperm Injection||Sapientiae Institute|No|Terminated|April 2014|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|N/A|38 Years|No|||August 2014|November 17, 2014|April 3, 2014|No|Yes|broken equipment|No||https://clinicaltrials.gov/show/NCT02107521||47032|
NCT02107534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-480/2012|Group-based Training for Parents of Children With Dyslexia|Evaluation of a Group-based Training for Parents of Children With Dyslexia||University of Heidelberg Medical Center|Yes|Active, not recruiting|January 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|N/A|No|||April 2014|April 3, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107534||47031|
NCT02106273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si154/2011|The Use of LMA-Proseal and Endobronchial Blocker for One Lung Anesthesia, Case Series|The Use of LMA-Proseal and Endobronchial Blocker for One Lung Anesthesia, Case Series.||Mahidol University|No|Completed|April 2011|September 2013|Actual|June 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|75 Years|No|Non-Probability Sample|ASA class I-III patients age 18-75 years scheduled for thoracic surgery that required        one-lung ventilation|April 2014|April 3, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02106273||47127|
NCT02106949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIAM|Short Message System (SMS) Monitoring Intended for the Suicidal Patients|Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency||University Hospital, Brest|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|530|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106949||47075|
NCT02106962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-Boiskin|Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients|Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients||California Institute of Renal Research|No|Not yet recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106962||47074|
NCT02106975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20000917|Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury|Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury|CITRIS-ALI|Virginia Commonwealth University|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106975||47073|
NCT02106832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15626|Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)|Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.|RESPIRE 2|Bayer|No|Active, not recruiting|April 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|513|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106832||47084|
NCT02107170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAEV|Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.|Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|February 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02107170||47059|
NCT02107729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2297B|The Importance of Needle Gauge for Pain During Injection of Local Anaesthetic.|The Importance of Needle Gauge for Pain During Injection of Local Anaesthetic.||Norwegian University of Science and Technology|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107729||47016|
NCT02108041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914075|Personalized Medicine Decision-Making in a Virtual Clinical Setting|Medical Decision-Making in a Virtual Clinical Setting||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|260|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|October 27, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108041||46992|
NCT02106325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00794|Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients|A Randomized, Double-Blinded Controlled Trial of an N-Methyl D-Aspartate Antagonist as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients||New York University School of Medicine|Yes|Completed|December 2013|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||March 2016|March 24, 2016|December 12, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106325||47123|
NCT02103933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2014-0010|Pilot Study to Evaluate the Knowledge and Understanding on Surgery for Patients With Hysterectomy|||National Cancer Center, Korea|No|Not yet recruiting|April 2014|||June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|20 Years|N/A|No|Non-Probability Sample|The patients who underwent hysterectomy at National Cancer Center, Korea|April 2014|April 1, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02103933|1 Year|47306|
NCT02104258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAR47|Rehabilitation of Acute Hamstring Injuries in Male Athletes|Rehabilitation of Acute Hamstring Injuries in Male Athletes: A Prospective Single-site Randomized Controlled Clinical Trial Comparing Two Rehabilitation Protocols With Different Emphasis on Eccentric Exercises||Aspetar|Yes|Recruiting|March 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|50 Years|No|||March 2016|March 5, 2016|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02104258||47282|
NCT02107456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920114|Effect of Dry Needling on Myofascial Trigger Point|The Long Term Effect of Dry Needling on Myofascial Trigger Point in the Upper Trapezius Muscle.||University of Social Welfare and Rehabilitation Science|Yes|Completed|July 2012|June 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|40 Years|No|||April 2014|April 7, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107456||47037|
NCT02104284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mannitol-01|A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population|A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population||BL&H Co., Ltd|Yes|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|104|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02104284||47280|
NCT02104297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agitation|Effect of Deksmedetomidine and Remifentanil in Extubation Agitation|The Effect of Deksmedetomidin and Remifentanil Infusion on Extubation Agitation and Recovery Conditions on Nasal Septoplasty Operation|EA|Diskapi Yildirim Beyazit Education and Research Hospital|No|Not yet recruiting|April 2014|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104297||47279|
NCT02105506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38212|Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses|Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses|SAFE-T|UMC Utrecht|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105506||47186|
NCT02106338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0009|Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.|Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|April 2014|June 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|December 18, 2014|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106338||47122|
NCT02108379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002|Compliance and Usability Study Evaluating RHINIX™ Nasal Filters|An Open-label Outpatient In-season Study Assessing Compliance and Usability of Rhinix™ Nasal Filters||University of Aarhus|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1073|||Both|18 Years|65 Years|No|||March 2014|November 10, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02108379||46967|
NCT02108392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pending|Characterization of Pseudoxanthoma Elasticum|Characterization of Patients With Pseudoxanthoma Elasticum||University Hospital, Bonn|Yes|Recruiting|January 2014|||December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|whole blood samples|Both|N/A|N/A|No|Non-Probability Sample|Pseudoxanthoma elasticum|April 2014|April 8, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02108392||46966|
NCT02106689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03229|Needle-Free Injections of Gonadotropins for Superovulation|Needle Free Injections of Gonadotropins for Patients Undergoing Superovulation - A Randomized, Pilot Study||University of British Columbia|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|39 Years|No|||November 2015|November 30, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02106689||47095|
NCT02107027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVACIRC|Pulmonary Veins Circular Ablation Catheter Evaluation for Atrial Fibrillation|Pulmonary Veins Circular Ablation Catheter Evaluation for Atrial Fibrillation|EVACIRC|Association de Recherche pour le Traitement des Arythmies Cardiaques|Yes|Recruiting|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2014|April 4, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02107027||47069|
NCT02107053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0122-13|The Effect of Pomegranate Juice (PJ) on Oxidative Stress Biomarkers During Treatment With IV Iron During One Dialysis Session|The Effect of Pomegranate Juice on Oxidative Stress Biomarkers During Treatment With IV Iron During One Dialysis Session||Western Galilee Hospital-Nahariya|No|Completed|April 2014|January 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|25|||Both|20 Years|95 Years|No|||February 2016|February 7, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02107053||47068|
NCT02107313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT2-103|Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2|A Phase 1, Single Centre, Randomised, 2 Period Crossover Study to Determine the Effect of Food on the Pharmacokinetic Profile of a Single Dose of PBT2 Administered Orally to Healthy Volunteers||Prana Biotechnology Limited|No|Completed|May 2014|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107313||47048|
NCT02107547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 13-0085|Study Evaluating Outcomes After Biceps Tenodesis or Labral Repair for the Treatment of Type 2 Superior Glenoid Labrum Lesions|Evaluation of Biceps Tenodesis vs Labral Repair for Type 2 SLAP Lesions, A Randomized Controlled Trial||University of Chicago||Not yet recruiting|January 2015|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107547||47030|
NCT02107898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13672|Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Alirocumab in Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy||Sanofi|Yes|Completed|March 2014|September 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|20 Years|80 Years|No|||December 2015|December 23, 2015|April 4, 2014|Yes|Yes||No|December 23, 2015|https://clinicaltrials.gov/show/NCT02107898||47003|
NCT02106546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-089|Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer|Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)||AbbVie|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|975|||Both|18 Years|99 Years|No|||February 2016|February 22, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106546||47106|
NCT02106845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16674|Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.|A Phase I, Multi-center, Non-randomized, Open Label, Drug-drug-interaction Study to Determine the Effect of Multiple Doses of Regorafenib (BAY 73-4506) on the Pharmacokinetics of Probe Substrates of Transport Proteins P-gp (Digoxin; Group A) and BCRP (Rosuvastatin; Group B) in Patients With Advanced Solid Malignant Tumors||Bayer|No|Active, not recruiting|April 2014|June 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106845||47083|
NCT02107443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC13070|Improving Communication in Older Cancer Patients and Their Caregivers|Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers|COACH|University of Rochester|Yes|Recruiting|June 2014|August 2019|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1056|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107443||47038|
NCT02107183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trial120_A|Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial|Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial|RINO|Catholic University of the Sacred Heart|Yes|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107183||47058|
NCT02104271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662/2012|Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.|Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.||Barretos Cancer Hospital|Yes|Completed|January 2013|August 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02104271||47281|
NCT02104856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7086|Bronchial Thermoplasty Global Registry|Bronchial Thermoplasty (BT) Global Registry|BT Registry|Boston Scientific Corporation|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing BT according to labeled indications will be approached to        participate in the Registry.|July 2015|July 15, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104856|2 Years|47236|
NCT02105168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00373-52|Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment|Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma|MSN|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|July 2009|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2200|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02105168||47212|
NCT02106910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2618|Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy|Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy||University of North Carolina, Chapel Hill|No|Enrolling by invitation|October 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|374|Samples With DNA|Paraffin embedded esophageal tissue samples obtained by the cytosponge.|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects with a history of Barrett's Esophagus or Barrett's Esophagus with dysplasia (high        or low grade) who have achieved complete eradication via radiofrequency ablation (RFA) and        are returning to clinic for routine surveillance (upper endoscopy with biopsies) of their        condition.|February 2016|February 16, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106910||47078|
NCT02106923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.14|Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets|Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|April 4, 2014||||No||https://clinicaltrials.gov/show/NCT02106923||47077|
NCT02106585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT251-U-13-001|Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects|Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)||Akros Pharma Inc.|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|9||Actual|94|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106585||47103|
NCT02106598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-249|Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Cervical/Uterine Cancer Patients|Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Cervical/Uterine Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106598||47102|
NCT02108080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140080|Characterization Imaging Instruments in Alcoholics and Non-Alcoholics|Characterization Imaging Instruments in Alcoholics and Non-Alcoholics||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 19, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02108080||46990|
NCT02104869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-03-IB|Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients|Open Label Parallel Randomized Clinical Trial to Evaluate the Immunogenicity of Three Regimens of the Trivalent Influenza Vaccine (Inactivated and Fragmented) in Kidney Transplant Recipients||Butantan Institute|No|Completed|April 2014|March 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|195|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104869||47235|
NCT02105194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #6627|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||January 2015|January 1, 2015|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02105194||47210|
NCT02106078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH091284|Internet-Based Interventions for Bipolar Disorder|2/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder|MoodSwings 2|VA Palo Alto Health Care System|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|21 Years|65 Years|No|||September 2015|September 8, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02106078||47142|
NCT02106936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140070|Depotentiation in People With Focal Hand Dystonia|Depotentiation in Focal Hand Dystonia Patients||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|56|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106936||47076|
NCT02115126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042574|Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant|A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant||Duke University|No|Not yet recruiting|August 2016|January 2025|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115126||46450|
NCT02115425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Samsung|Calibrate Samsung's BIA to Meseaure Body Composition|Samsung Bioimpedance System Calibration Study||Pennington Biomedical Research Center|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|475|||Both|10 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Male or Female age 10-80 years of age.|August 2015|August 28, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115425||46427|
NCT02106702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA027209|The Navigator Project|Navigator-Enhanced Case Management for HIV-Infected Jail Inmates Reentering the Community|NAV|University of California, San Francisco|No|Completed|February 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|271|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02106702||47094|
NCT02106715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cycle_Dnr2014/42-31|Overuse Injuries in Road Cyclists, Prevalence and Prevention|Overuse Injuries in Road Cyclists, Prevalence and Prevention|Cycle|University Hospital, Linkoeping|No|Recruiting|March 2014|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02106715||47093|
NCT02107066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904004976|Women's Activity and Lifestyle Study in Connecticut|Impact of Exercise on Ovarian Cancer Prognosis|WALC|Yale University|Yes|Completed|May 2009|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|144|||Female|18 Years|75 Years|No|||April 2014|April 3, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT02107066||47067|
NCT02107560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-IMGPB-2014-01|Results of Bile and Blood Culture in Patients With Acute Cholangitis|A Comparison of Results With Bile and Blood Culture in Patients With Acute Cholangitis According to Severity||Seoul National University Hospital|Yes|Terminated|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Non-Probability Sample|The patients who visited to tertiary medical center(Seoul National University Bundang        Hospital) because of moderate or severe obstructive cholangitis|April 2014|November 18, 2014|April 3, 2014||No|Because of small number of enrolled patients, we terminated this study.|No||https://clinicaltrials.gov/show/NCT02107560||47029|
NCT02107911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 020|Factors Affecting the Intention to Take nPEP Among Thai MSM|Factors Affecting the Intention to Take Non-occupational HIV Post-exposure Prophylaxis Among Thai Men Who Have Sex With Men||South East Asia Research Collaboration with Hawaii|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|450|||Male|18 Years|N/A|No|Non-Probability Sample|MSM who seek voluntary HIV counseling and testing service at the Thai Red Cross AIDS        Research Centre, including those who describe risky sexual exposure to HIV within the        preceding 72 hours and meet nPEP criteria.|May 2015|May 27, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107911||47002|
NCT02106871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0409|Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer|Phase I Assessment of NO Mediated Signaling in Cancer Cachexia|PCC|The University of Texas Medical Branch, Galveston|No|Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|40 Years|75 Years|No|||September 2015|September 23, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02106871||47081|
NCT02108353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuRhythDia II|Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers|Multicenter, Randomized, Double-blind, Placebo Controlled Trial of 2 mg Melatonin for Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02108353||46969|
NCT02107430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP004|Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized High-risk Prostate Cancer After Primary Radiotherapy||Sotio a.s.|No|Active, not recruiting|March 2012|September 2018|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|N/A|No|||June 2015|June 29, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107430||47039|
NCT02107716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2297A|Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?|Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?||Norwegian University of Science and Technology|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107716||47017|
NCT02105493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORAO2014|Nitroglycerin Prevents Radial Artery Occlusion|A Novel Approach to Reduce Radial Artery Occlusion After Trans-Radial Catheterization: Post-Procedural/Pre-Hemostasis Intra-Arterial Nitroglycerin|NORAO|National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Completed|October 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|1706|||Both|18 Years|80 Years|No|||March 2014|April 2, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02105493||47187|
NCT02113618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGALC|Effect of Cognitive Training on Alcohol Use Outcomes|The Effects of Cognitive Training on Alcohol Consumption, Cognition and Craving in Alcohol Use Disorder|COGALC|Karolinska University Hospital|Yes|Completed|October 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||August 2015|August 31, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113618||46566|
NCT02113631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 11064-H40|Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir|Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir and Re-assessment of Treatment Duration in Patients With Chronic Hepatitis C||Louis Stokes VA Medical Center|Yes|Recruiting|September 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|April 10, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02113631||46565|
NCT02107222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAQ/COPD/PALP/2012|The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)|A Multicenter Randomized Control Trial (RCT) to Determine Safety and Efficacy of PALP™ for ECCO2-R in Conjunction With Liberation From Mechanical Ventilation (MV) Compared to MV Alone in COPD Exacerbation and Respiratory Failure|PALP-COPD|Maquet Cardiopulmonary AG|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02107222||47055|
NCT02107768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/396-31|Aerobic Exercise in Early Subacute Stroke|Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial.||Ostergotland County Council, Sweden|No|Completed|January 2011|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|50 Years|N/A|No|||February 2015|February 3, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107768||47013|
NCT02103959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX-2043-2aK|Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography|A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)|CARIN|Ischemix, LLC|No|Completed|June 2014|December 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|361|||Both|18 Years|N/A|No|||June 2014|February 22, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103959||47304|
NCT02103972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.46.NRC|Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis|||Nestlé|No|Recruiting|July 2014|November 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|4 Months|30 Months|Accepts Healthy Volunteers|||October 2015|October 20, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02103972||47303|
NCT02114346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392353|High Dose Atorvastatin for Preventing Contrast-induced Nephropathy|Evaluating the Effect of High Dose Atorvastatin (80 mg/d) Comparing With Placebo in Preventing Contrast-induced Nephropathy in Patients Undergoing Computed Tomography Coronary Angiography||Isfahan University of Medical Sciences|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114346||46510|
NCT02114359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140113/16-2014-9/021|Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer|Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study||Seoul National University Hospital|Yes|Recruiting|February 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|332|||Both|70 Years|N/A|No|||February 2016|February 2, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02114359||46509|
NCT02114619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920800|Comparative Study of Different I-131 Doses in Graves' Disease|The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease||Mashhad University of Medical Sciences|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|65 Years|No|||April 2014|April 14, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02114619||46489|
NCT02114853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4784.02|Oxidative Monitoring in ICU Patients.|Oxidative Monitoring in ICU Patients.|ORPICU|University of Thessaly|No|Recruiting|April 2014|April 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|plasma|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|All subjects who enter to the intensive care unit are candidates for this protocol|April 2014|April 12, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02114853||46471|
NCT02115113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001HIT34|REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy|Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up|REFLECT|Novartis|Yes|Recruiting|March 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|415|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02115113||46451|
NCT02114866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110/2012|Quality of Handover to a Post Anaesthesia Care Unit in a Children's Hospital|||University of Witten/Herdecke|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|441|||Both|N/A|17 Years|No|Probability Sample|The study population consists of patients (<18 years of age) at Children's Hospital        Cologne, being admitted to the main postoperative care unit (PACU), after they underwent        interventions within normal surgery hours|April 2014|April 12, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114866||46470|
NCT02114879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH099011A1|Enhanced Medical Rehabilitation in Older Adults|Enhanced Medical Rehabilitation in Older Adults|EMR|Washington University School of Medicine|No|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Both|65 Years|N/A|No|||February 2016|February 24, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02114879||46469|
NCT02107079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melaform|The Relative Bio-availability of Oral and Oromucosal Melatonin in Different Formulations in Healthy Human Volunteers.|The Relative Bio-availability of Oral and Oromucosal Melatonin in Different Formulations in Healthy Human Volunteers. A Three-phased Cross-over Study.|Melaform|Utrecht University||Completed|January 2012|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|April 3, 2014||||No||https://clinicaltrials.gov/show/NCT02107079||47066|
NCT02107326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER13-272|Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes|Webdia Study: Use of Smartphones to Improve Diabetes Control and Quality of Life in Children With Type 1 Diabetes||University Hospital, Geneva|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|10 Years|18 Years|No|||December 2015|December 1, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02107326||47047|
NCT02107586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0117|Comparison of Outcomes Between Biceps Tenotomy and Tenodesis in the Treatment of the Long Head of the Biceps Pathology|Biceps Tenotomy or Tenodesis in Treating Long Head of the Biceps Pathology: a Prospective Randomized Controlled Trial||University of Chicago||Not yet recruiting|January 2015|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107586||47027|
NCT02107937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV01|Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma|A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma||Sotio a.s.|Yes|Recruiting|November 2013|May 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107937||47000|
NCT02108236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture-Obesity-2014-3|Effectiveness and Safety of Acupuncture for Obesity and Over-weight People|||Heilongjiang University of Chinese Medicine|No|Recruiting|May 2014|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|45 Years|No|||March 2015|March 25, 2015|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02108236||46978|
NCT02107976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140060|Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes|Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes||National Institutes of Health Clinical Center (CC)||Recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|60 Years|No|||August 2015|September 10, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02107976||46997|
NCT02107989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140061|Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy|Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|February 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|8 Years|65 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02107989||46996|
NCT02108223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4085|The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI|In This Study, the Addition of rLH, Increasing the Dose of rFSH and the Control Groups Regarding the Results of IVF in These Patients.|LH|Sisli Etfal Training & Research Hospital|Yes|Completed|January 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|137|||Female|23 Years|39 Years|No|||March 2015|March 2, 2015|March 26, 2014||No||No|May 14, 2014|https://clinicaltrials.gov/show/NCT02108223||46979|
NCT02106104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2013RENALIS|Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes|A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM)|RENALIS|VU University Medical Center|No|Recruiting|March 2014|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|35 Years|70 Years|No|||April 2014|April 2, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02106104||47140|
NCT02106351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-153|Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children|A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT® Used In The Treatment Of Upper Limb Spasticity In Children|PUL|Ipsen|Yes|Recruiting|April 2014|October 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|2 Years|17 Years|No|||February 2016|February 26, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106351||47121|
NCT02116686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBS2014|ECG Derived Respiration for Automated Screening of Sleep Disordered Breathing in Chronic Heart Failure Patients|ECG Derived Respiration for Automated Screening of Sleep Disordered Breathing in Chronic Heart Failure Patients||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients with sleep apnea syndrom|March 2015|March 30, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02116686||46330|
NCT02107742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2297C|The Influence of Injection Speed on Pain During Administration of Local Anaesthetic.|The Influence of Injection Speed on Pain During Administration of Local Anaesthetic.||Norwegian University of Science and Technology|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107742||47015|
NCT02107755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12182|Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma|A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|July 2014|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107755||47014|
NCT02104544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.10.CN.INF|Investigation of DHA Intake in Pregnant and Lactating Women in China|Investigation of DHA Intake in Pregnant and Lactating Women in China||Peking University|Yes|Completed|April 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1254|Samples Without DNA|1. Collection of venous blood, pretreatment of blood sample, take the plasma and           erythrocyte respectively.        2. Collection of breast milk (only for women having lactated for 42±7 days)|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|816 pregnant (pregnant week 17±2 group and pregnant week 39±2 group; 408 cases in each        group) and 408 lactating women (post-natal lactation day 42±7 group)|December 2014|December 1, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104544||47260|
NCT02104557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6791036|Post Marketing Surveillance Study For Sayana®|Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana(Registered) Used For Contraception And Management Of Endometriosis-associated Pain|SAYANA|Pfizer|No|Recruiting|March 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|600|||Female|N/A|N/A|No|Probability Sample|Women subjects who are initiating treatment with Sayana® for the first time as per the        local product document for usage|March 2016|March 12, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104557||47259|
NCT02104570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09102013.011|Effects of Muscle Fatigue and Kinesio Taping on Shoulder Position Sense|Effects of Muscle Fatigue and Kinesio Taping on Shoulder Joint Position Sense||University of Oregon||Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02104570||47258|
NCT02106065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1240-W|VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers|Dementia Caregiver Rehabilitation: Enhancing Veteran and Family-Centered Care|VA CARES|VA Office of Research and Development|No|Recruiting|February 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02106065||47143|
NCT02113397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14010|Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung|Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Inhaled Colistimethate||Dartmouth-Hitchcock Medical Center|No|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|75 Years|No|||August 2015|August 12, 2015|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02113397||46583|
NCT02113410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|420926|Effect of Chair Yoga on Elders With Osteoarthritis|Effect of Sit 'N' Fit Chair Yoga on Community-Dwelling Elders With Osteoarthritis||Florida Atlantic University|Yes|Active, not recruiting|March 2014|January 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|N/A|No|||October 2015|October 9, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113410||46582|
NCT02107781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|r041998|Intra-abdominal Pressure Monitoring in Patients With Open Abdomen Undergoing Early Closure|A Prospective Observational Study of Continuous Intra-abdominal Pressure Monitoring in Patients With Postoperative Open Abdomen Undergoing Early Intervention and Closure||Michigan State University|No|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort of patients in ICU with open abdomen|July 2015|July 27, 2015|January 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107781||47012|
NCT02114125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112011RID|Effects of the Physical Activity and Cognitive Training Program|The Effects of Physical Activity and Cognitive Training in Improving Cognitive Function of Institutionalized Older Residents||National Taiwan University Hospital|Yes|Recruiting|February 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|270|||Both|65 Years|N/A|No|||April 2014|April 11, 2014|November 2, 2012||No||No||https://clinicaltrials.gov/show/NCT02114125||46527|
NCT02114138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400127|Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury|Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury Subtitle: Urinary Molecular and Metabolic Signature of Postoperative Acute Kidney Injury (NavigateAKI)|NavigateAKI|University of Florida|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|urine samples blood samples|Both|18 Years|N/A|No|Probability Sample|The population from which the cohort will be selected among patients undergoing major        in-hospital surgery.|November 2015|November 24, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02114138||46526|
NCT02114372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104383|Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study|Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort Study (PRO)|CHARIOT:PRO|Janssen Research & Development, LLC||Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||5|Anticipated|1200|Samples With DNA|Blood, saliva, and urine specimens will be collected.|Both|60 Years|72 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants without dementia who are considered at high, medium and low risk for        developing mild cognitive impairment (MCI) due to Alzheimer's disease (AD).|March 2016|March 11, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114372||46508|
NCT02114632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/154/2006|Supplementation of Polyunsaturated Fatty Acids in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|A Double Blind, Placebo Controlled Trial of Effectiveness of Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Treatment of Children With Attention Deficit/Hyperactivity Disorder||Medical University of Warsaw|No|Completed|January 2007|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|89|||Male|8 Years|16 Years|No|||April 2014|April 13, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02114632||46488|
NCT02115737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213-2012|Group Treatment for Adolescents With Depression|Group Treatment for Adolescents With Depression||Sunnybrook Health Sciences Centre|Yes|Terminated|December 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|14 Years|19 Years|No|||November 2015|November 16, 2015|April 14, 2014||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT02115737||46403|
NCT02107339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH14-113|Methadone and Hydromorphone For Spinal Surgery|Methadone and Hydromorphone For Spinal Surgery||NorthShore University HealthSystem Research Institute|No|Recruiting|March 2014|September 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107339||47046|
NCT02107573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0099|Comparing the Outcomes Between Traditional Rotator Cuff Repair and Rotator Cuff Repair With Suprascapular Nerve Decompression for the Treatment of Shoulder Rotator Cuff Tears|Will Routine Suprascapular Nerve Release During Arthroscopic Rotator Cuff Repair Improve Patient Outcomes?||University of Chicago||Not yet recruiting|January 2015|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107573||47028|
NCT02107599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-QP02|The Feasibility of Florbetapir Quantitation in Europe|A Study to Evaluate the Improvement in Reader Accuracy When Using a Read Method That Incorporates Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Visual Interpretation of Amyvid Brain Scans||Avid Radiopharmaceuticals|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|96|||Both|N/A|N/A|No|||June 2015|June 17, 2015|April 4, 2014||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT02107599||47026|
NCT02107924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112-0211|Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements|Use of Antibiotic Contained Calcium Sulfate Carrier in Acute Periprosthetic Infections(APPI) of Total Knee Replacements||Sharp HealthCare|No|Withdrawn|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Total knee replacement and have developed either APPI within 28 dyas of surgery, or an        acute onset of a hematogenous (blood-source ) infection in knee, more than 30 days after        surgery with symptoms present less than 28 days|November 2014|November 24, 2014|April 4, 2014|No|Yes|No Funding|No||https://clinicaltrials.gov/show/NCT02107924||47001|
NCT02108249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW-ANX1401|Annex™ Adjacent Level System for Treatment of Adjacent Level Disease|||Spine Wave||Recruiting|April 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|The subject population for both the treatment and control groups will include adult        (skeletally mature) men and women who were previously implanted with rigid posterior        fixation (pedicle screw/rod constructs) in the thoracolumbar spine and who later developed        adjacent level disease (ALD) at a lumbar level.|December 2014|December 8, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108249||46977|
NCT02108548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7657-CL-0001|A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects|A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort||Astellas Pharma Inc|No|Terminated|April 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|April 7, 2014||No|Gastrointestinal safety findings|No||https://clinicaltrials.gov/show/NCT02108548||46954|
NCT02108522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33903, CHARMS|Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant|Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant|CHARMS|Baylor College of Medicine|Yes|Recruiting|June 2014|March 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 4, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108522||46956|
NCT02106364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13564|A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study||Eli Lilly and Company|Yes|Not yet recruiting|February 2015|June 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|663|||Both|20 Years|N/A|No|||November 2014|November 17, 2014|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106364||47120|
NCT02106637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAMPIX (CHANTIX)|Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS|Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)||Sheba Medical Center|Yes|Not yet recruiting|June 2014|May 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||April 2014|April 3, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02106637||47099|
NCT02106650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-FOL-14-201|Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL|A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)||Spectrum Pharmaceuticals, Inc||Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|37|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106650||47098|
NCT02103946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI- Cairo|Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia|Serratus Anterior Muscle Plane Block Versus Paravertebral Block for Breast Cancer Resections.|SAM|National Cancer Institute, Egypt|No|Recruiting|April 2014|August 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|80 Years|No|||April 2014|April 17, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02103946||47305|
NCT02105181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-A00197-44|Fully Covered Self-expandable Metal Stents (FCMS) in Benign Biliary Strictures|Temporary Placement of Fully Covered Self-expandable Metal Stents in Benign Biliary Strictures||Société Française d'Endoscopie Digestive|No|Completed|March 2007|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|N/A|N/A|No|||April 2014|April 6, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105181||47211|
NCT02113163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-101-CS01|PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA|An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers||Thetis Pharmaceuticals LLC|Yes|Recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|April 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02113163||46601|
NCT02113384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Larc-Ex_09/2012|Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells|Prospective Observational Study of Exfoliated Peritoneal Tumor Cells in Locally Advanced Rectal Cancer|LARC-EX|Oslo University Hospital|No|Recruiting|September 2012|January 2028|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|Tumor tissue, peritoneal lavage samples, blood specimen.|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for surgical removal of a primary locally advanced rectal tumor at the        Radium Hospital.|October 2015|October 14, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113384|5 Years|46584|
NCT02114151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103431|Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis|A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis||Janssen Infectious Diseases BVBA|Yes|Completed|April 2014|April 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114151||46525|
NCT02113852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG 1308|Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients|Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients|CHOICE|Guangdong Association of Clinical Trials|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|250|Samples With DNA|blood,tumor and adjacent normal tissue samples|Both|18 Years|N/A|No|Probability Sample|The study aims to collect approximately 250 smoking induced lung cancer(NSCLC)        samples.Approximately 200 cases of treatment naive samples will be required. Samples will        be collected mainly from the investigational sites in Guangzhou, Shanghai and Beijing that        have expertise in lung cancer diagnosis.|April 2014|April 14, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02113852|2 Years|46548|
NCT02113865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMM115392013|Score System for Prediction Risk and Early Diagnosis of HCC in HIV/HCV Patients|Obtención de un Panel de puntuación ("Score System") Para la predicción de Riesgo Individualizado y la detección Precoz de Carcinoma Hepatocelular (HCC) en Sujetos Coinfectados VIH/VHC||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||Completed|October 2013|February 2015|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|45|Samples With DNA|Serum, plasma, white cells|Both|18 Years|80 Years|No|Non-Probability Sample|HIV/HCV coinfected patients from Infectious Diseases Department|April 2014|March 6, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113865||46547|
NCT02113878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008|Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck|A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck||Dana-Farber Cancer Institute|Yes|Recruiting|October 2014|March 2020|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113878||46546|
NCT02113891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101004|Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation|Treatment of Subclinical Antibody-mediated Acute Rejection in Kidney Transplant Recipients With the Complement Inhibitor Eculizumab.|TAMARCIN|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|February 2015|November 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|November 21, 2013||No|disengagement of the sponsor Alexion Pharmaceuticals|No||https://clinicaltrials.gov/show/NCT02113891||46545|
NCT02114892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESV-MS|Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion|Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion||University of Guadalajara|No|Completed|April 2012|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|50 Years|No|||December 2014|December 16, 2014|April 11, 2014||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT02114892||46468|
NCT02115165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000286-36|A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors|A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors|CABA-GCT|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|May 2014|May 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Male|15 Years|N/A|No|||February 2016|February 5, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02115165||46447|
NCT02115178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT22552|Haemodynamic Effects During Anorectal Surgery: a Comparison of the Jack -Knife and Lithotomy Position|Haemodynamic Effects During Anorectal Surgery in Spinal Anaesthesia With Low Dose Hyperbaric Bupivacaine : a Comparison of the Jack -Knife and Lithotomy Position||Lithuanian University of Health Sciences|No|Recruiting|August 2011|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|85 Years|No|Probability Sample|Patients admitted to department of surgery for minor anorectal surgery.|October 2015|October 13, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02115178||46446|
NCT02115477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2013-09-22/2014-03-21|Lymphedema After Primary Surgery for Endometrial Cancer|Prevalence, Complications and Risk Factors for Lymphedema After Pelvic and Paraaortic Lymphadenectomy in Primary Radical Surgery for Early Stage Endometrial Carcinoma.|LASEC|University Hospital, Linkoeping|No|Recruiting|April 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|260|||Female|18 Years|N/A|No|Probability Sample|All women admitted to the participating clinics for primary surgery of endometrial        carcinoma FIGO stage 1 and 2 will be asked to participate in the study.|February 2016|February 20, 2016|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115477||46423|
NCT02115750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-0214-02|Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate|CHS-0214-02|Coherus Biosciences, Inc.|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|620|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115750||46402|
NCT02115984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-bc-2|Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer|Double-blind Multicenter Placebo-controlled Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer||Panagen, Limited Liability Company|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||April 2014|June 11, 2014|April 7, 2014||No||No|May 12, 2014|https://clinicaltrials.gov/show/NCT02115984||46384|
NCT02107625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRIBS1|Traditional Dietary Advice Versus a Low FODMAP Diet Intake in IBS Patients|A Multi-centre, Randomized, Single-blind, Comparative Trial: Traditional Dietary Advice Versus a Low FODMAP Diet Intake in IBS Patients|KRIBS|Göteborg University|No|Completed|August 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|No|||August 2015|August 19, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107625||47024|
NCT02107950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV02|Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma|A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma||Sotio a.s.|Yes|Active, not recruiting|November 2013|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107950||46999|
NCT02107963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140059|A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors|A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|February 2014|December 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|1 Year|35 Years|No|||October 2015|February 3, 2016|April 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02107963||46998|
NCT02108561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505185|Breast Cancer Tumor Heterogeneity|Does Breast Tumor Heterogeneity Necessitate Additional HER2 Testing on the Surgical Specimens?||Anne Arundel Health System Research Institute|No|Recruiting|April 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Female|18 Years|100 Years|No|Probability Sample|Breast Cancer pre-surgical patients|January 2016|January 13, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108561||46953|
NCT02108535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNISO-2012|Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns|Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns|ARGENTUM|University of Sorocaba|No|Completed|November 2013|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108535||46955|
NCT02104180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINE4001|Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras|Evaluation of the Non-inferiority of TulleGras M.S.® Versus Urgotul® in Pain Associated With Removal of Wound Dressing During Care of Venous Leg Ulcer. An Open-label, Multicenter, Randomized, Controlled, Crossover Study With Blinded Reading of Healing Criteria.||Mylan Inc.|No|Recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|45 Years|N/A|No|||November 2015|November 26, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02104180||47287|
NCT02107209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD68|Low Cost Biological Lung Volume Reduction Therapy for Advanced Emphysema|Evaluation of Bronchoscopic Biological Lung Volume Reduction Therapy in Pulmonary Emphysema Patients|BLVR|Mansoura University|Yes|Completed|April 2013|August 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|40 Years|85 Years|No|||November 2015|November 10, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107209||47056|
NCT02116413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/CR-01|Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?|Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?|FC-Rev|Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|||Both|18 Years|N/A|No|Probability Sample|The study population consists of patients admitted to intensive care, sedated and under        controlled ventilatory support with septic shock criteria defined by severe sepsis        associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring        vascular filling according to the following criteria:          -  oliguria <0.5 ml / kg / h for at least 2h          -  skin mottling          -  Arterial Lactate > 2 mmol / l          -  SvcO2 <70% or SvO2 <65%          -  Patient on noradrenaline.        Severe sepsis is defined as a systemic inflammatory response associated with a suspected        or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ        dysfunction.|January 2016|January 18, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116413||46351|
NCT02116426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/PGC-01|Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome|The Role of Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome|SCA COP|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|||Both|18 Years|N/A|No|Probability Sample|The study population includes all adult patients taken in charge by the emergency        ambulance services of the participating centers for non-traumatic chest pain for suspected        Acute Coronary Syndrome (ACS) without ST segment elevation.|October 2015|October 15, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116426||46350|
NCT02112864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dexaPTPS|Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome|Impact of Dexamethasone on the Post Operative Inflammatory Response and on the Occurrence of Post Thoracotomy Pain Syndrome||Maisonneuve-Rosemont Hospital|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112864||46624|
NCT02112877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STE-HUM-004P|VIRTUS: An Evaluation of the Veniti Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction|VIRTUS-OUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment|VIRTUS|Veniti|Yes|Recruiting|April 2014|July 2021|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|November 12, 2015|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112877||46623|
NCT02113176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINO-SAH|Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage|||University at Buffalo|Yes|Recruiting|January 2010|December 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02113176||46600|
NCT02112890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201076|Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico|Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico||GlaxoSmithKline||Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|2000|Samples With DNA|Stored serum samples of the selected subjects obtained from the ENSANUT 2012|Both|10 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Subjects constituting adolescents and young adults (≥10 - ≤25 years of age) from the total        population that participated in the ENSANUT 2012 in Mexico.|February 2016|February 4, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112890||46622|
NCT02113189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD walking study|Impact of Walking Practice on Persons With PD|The Long Term Impact of Walking Practice on Functional Mobility and Quality of Life in Persons With Parkinson's Disease||University of Texas Southwestern Medical Center|No|Terminated|April 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|30 Years|90 Years|No|||February 2016|February 4, 2016|April 10, 2014||No|Inadequate funding to continue the study|No||https://clinicaltrials.gov/show/NCT02113189||46599|
NCT02113644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevent CardioKids|Prevent CardioKids|Prevent CardioKids||Maastricht University Medical Center|No|Recruiting|April 2014|April 2029|Anticipated|April 2029|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|240|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Overweight or obese children according to the International Obesity Task Force (IOTF)        criteria between 6-18 years old. Overweight and obese children will be recruited in the        COACH program. For the control group healthy, normal weight children between 6-18 years        old.|March 2016|March 15, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02113644||46564|
NCT02114645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB-5030|The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes|To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Not yet recruiting|April 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||April 2014|April 13, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114645||46487|
NCT02114905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012814|Dissemination of Comprehensive Behavioral Intervention for Tics (CBIT) to Occupational Therapists: A Feasibility Study|Dissemination of Comprehensive Behavioral Intervention for Tics (CBIT) to Occupational Therapists: A Feasibility Study||Weill Medical College of Cornell University|No|Recruiting|November 2013|||November 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|7 Years|17 Years|No|||April 2014|April 10, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02114905||46467|
NCT02115191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cyanoacrylate-2014-03|2-octyl Cyanoacrylate for Closure of Urethrocutaneous Fistula.|Use of 2-octylcyanoacrylate for Closure Urethrocutaneous Fistulas After Urethroplasty for Hypospadias||Instituto Mexicano del Seguro Social|Yes|Completed|April 2014|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Male|6 Months|5 Years|No|||March 2015|March 23, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115191||46445|
NCT02115490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OraMed-01-2014|Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women|The Effect of Orally Administered Bisphosphonates in the Treatment of Osteoporosis on the Alveolar Bone Using Panoramic and Cone-Beam CT Imaging: A Case-control Study||Damascus University|Yes|Completed|April 2014|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Female|45 Years|75 Years|No|Non-Probability Sample|Women who were referred to perform Dual Energy X-Ray Absorptiometry (DXA) examination will        be invited to participate in this study if they were diagnosed with osteoporosis. They may        be under bisphosphonates or not. They will be met in Alassd and Almowsat        University-Hospitals where DXA is available. If they meet inclusion criteria, mentioned        below, they will be invited.|September 2015|September 26, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02115490||46422|
NCT02116491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWu|Visual Sputum Suctioning System Tests in Mechanically Ventilated Patients|Test of a Novel Visual Sputum Suctioning System in Mechanically Ventilated Patients||First Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|March 2014|June 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||April 2014|April 15, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02116491||46345|
NCT02107365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC32 QUATTRO|Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)|Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|November 2013|September 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02107365||47044|
NCT02107638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-975|Effect of Osteopathic Manipulative Medicine on Parkinson Disease|Effect of Osteopathic Manipulative Medicine on Motor Function, Balance, and Neuroprotective Serum Markers in Parkinson Disease||New York Institute of Technology|No|Recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||October 2015|October 16, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107638||47023|
NCT02107651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01675-HVH-2012-010-999|Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants|Serious Adverse Events in Patients Treated With New Oral Anticoagulants Are Underreported||Hvidovre University Hospital|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted for GI bleeding while in treatment with NOAC|April 2014|April 23, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107651||47022|
NCT02112279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHC059|Reduction of C-Difficile Infection Using Stool Transplant|Reduction of C-Difficile Infection Using Fecal Microbiota Transplant|FMT|Providence Holy Cross Medical Center|No|Recruiting|April 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112279||46669|
NCT02104193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH CL 25|Simvastatin Effect on Radiation Therapy of Brain Metastases|The Effect of Simvastatin on the Clinical Outcome of Patients With Brain Metastases Treated With Radiation Therapy: a Pilot Study||Ain Shams University|No|Completed|April 2014|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104193||47286|
NCT02108054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140066|Behavioral and Functional MRI Task Development, Implementation, and Testing|Behavioral and Functional MRI Task Development, Implementation, and Testing||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|January 7, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02108054||46991|
NCT02116712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAM 7601|The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)|The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)||Baylor College of Medicine|Yes|Completed|August 2014|July 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116712||46328|
NCT02116699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-72393-360|Oropharyngeal Administration of Mother's Colostrum for Premature Infants|Oropharyngeal Administration of Mother's Colostrum: Health Outcomes of Premature Infants||NorthShore University HealthSystem|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|622|||Both|N/A|4 Days|No|||December 2015|December 28, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02116699||46329|
NCT02112903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15947A|Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women|Interventional, Randomised, Double-blind 4-way Crossover Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women||H. Lundbeck A/S|No|Completed|April 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112903||46621|
NCT02113423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJCH009911|Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma|Superiority of Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma||Fujian Cancer Hospital|No|Completed|January 1996|March 2011|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|16 Years|75 Years|No|||April 2014|April 10, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113423||46581|
NCT02113657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0444|T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer|A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma||M.D. Anderson Cancer Center|No|Recruiting|August 2014|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||December 2015|December 10, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113657||46563|
NCT02113904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100150|Clinical Trial Using Humira in Netherton Syndrome|Phase II Clinical Trial Using Humira in Netherton Syndrome|AntiTNF-SN|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|4 Years|N/A|No|||November 2015|November 11, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02113904||46544|
NCT02114164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-13-00489|Study of CO2 Exchange Patterns During Robotic Prostatectomies|A Comparative Study of CO2 Exchange Patterns Between Valve-free Trocar (AirSeal®) Versus Standard Trocar (Endopath®) During Robotic Prostatectomies||OhioHealth|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114164||46524|
NCT02114385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDS07C|A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men|A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men||Sanofi Pasteur MSD|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|500|||Both|16 Years|26 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114385||46507|
NCT02114398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9162|Physiotherapy Efficiency on Child Asthma|Physiotherapy Efficiency With Caycedian Sophrology on Child Asthma: Randomized, Controlled Study||University Hospital, Montpellier|No|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|74|||Both|6 Years|17 Years|No|||December 2014|December 3, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02114398||46506|
NCT02114411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biohit-001|Gastropanel for Gastric Atrophy and Cancer Risk Assessment|Gastropanel *for Early Detection of Gastric Atrophy and Gastric Cancer Risk||Biohit Healthcare Ltd|Yes|Not yet recruiting|June 2014|June 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|45 Years|N/A|No|Non-Probability Sample|Enrollment of the patients in the study will take place at Homerton Hospital including        consecutive patients over 45 years of age, referred for gastroscopy at the Outpatient        Department of Endoscopy. The estimated cohort to be screened is 250 subjects (both        genders), to reach a cohort of 100 patents enriched with equal numbers (n=25) of all        conditions classified as study endpoints.        Patient enrollment is taking place in a single step. In brief, the potentially eligible        patients are identified among the gastroscopy-referral outpatients by the members of the        research team. At this stage, every patient will be asked to consent the study and sign a        written consent to participate.|April 2014|April 14, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02114411||46505|
NCT02114658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17073|Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients|A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma||Bayer|No|Active, not recruiting|April 2014|August 2016|Anticipated|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114658||46486|
NCT02115516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUCHMI-002|Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis|Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis||Sanaria Inc.|Yes|Active, not recruiting|April 2014|March 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|12||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|April 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115516||46420|
NCT02115763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM4084|The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial|||University of Oklahoma||Not yet recruiting|May 2014|||August 2014|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115763||46401|
NCT02115997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28550|A Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoids in Patients With Wegener's Granulomatosis or Microscopic Polyangitis|AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS OR MICROSCOPIC POLYANGITIS||Hoffmann-La Roche||Recruiting|July 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115997||46383|
NCT02116231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHGX20140402|The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma|Phase II Study Comparing Intensity Modulated Radiotherapy (IMRT) in Combination With Concurrent Chemotherapy and IMRT Alone for Stage II Nasopharyngeal Carcinoma||Cancer Hospital of Guangxi Medical University|Yes|Not yet recruiting|April 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||April 2014|April 15, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02116231||46365|
NCT02116244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-08-02|Civamide Nasal Solution for Dry Eye|A PHASE II, OPEN-LABEL, TOLERABILITY AND EFFICACY STUDY OF CIVAMIDE NASAL SOLUTION 0.01%, IN PATIENTS WITH DRY EYE SYNDROME||Winston Laboratories|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116244||46364|
NCT02107664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1126|The Palliative Radiotherapy And Inflammation Study - PRAIS|The Palliative Radiotherapy And Inflammation Study: Palliative Radiotherapy of Bone Metastasis. Classification, Inflammatory Biomarkers, and Longitudinal Clinical Follow-up|PRAIS|Norwegian University of Science and Technology|No|Recruiting|December 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Genetic and Cytokine Analyses|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to palliative RT for bone cancer pain|November 2015|November 6, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107664||47021|
NCT02108262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-HDL-12-77|A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.|A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.||CSL Behring|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1200|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108262||46976|
NCT02108275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|699CLD|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2013|||||N/A|N/A|N/A||||||||||||||April 6, 2014|April 10, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108275||46975|
NCT02108288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1085EL-13-004|Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers|||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2014|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|March 27, 2014||No||No|March 23, 2015|https://clinicaltrials.gov/show/NCT02108288||46974|
NCT02112799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVR3-778-101|Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients|A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Healthy Volunteers and Patients With Chronic Hepatitis B||Novira Therapeutics, Inc.|Yes|Active, not recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112799||46629|
NCT02112526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-002|ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma|An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma||Acerta Pharma BV|No|Active, not recruiting|July 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|February 24, 2016|April 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112526||46650|
NCT02112539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Val 0072-B|Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument|||Aggredyne, Inc.|No|Recruiting|March 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|April 2014|April 10, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112539||46649|
NCT02116439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP/2013/MC-01|Evaluation of the Manifestation of Patient Aggresivity in an Emergency Department|Evaluation of the Manifestation of Patient Aggresivity in an Emergency Department|ASAU|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|Persons manifesting violence (and their victims) according to a pre-determined list of        watched-for events will be observed.|November 2015|November 17, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116439||46349|
NCT02112929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPX-2011-001|Regional Lung Imaging Using Hyperpolarized Xenon Gas|Regional Lung Imaging and Modelling to Quantify Anatomy, Ventilation and Perfusion Using Hyperpolarized Xenon Gas MR and Thoracic CT Imaging||Oxford University Hospitals NHS Trust|No|Recruiting|April 2012|||January 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02112929||46619|
NCT02112916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00712|Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma|A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)||National Cancer Institute (NCI)|Yes|Recruiting|September 2014|||February 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|2 Years|30 Years|No|||November 2015|March 24, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112916||46620|
NCT02113215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-318|Very Low Density Lipoprotein Turnover in Young and Elderly Individuals|Very Low Density Lipoprotein Turnover in Young and Elderly Individuals||The University of Texas Medical Branch, Galveston|No|Recruiting|December 2011|July 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|40|Samples With DNA|Blood samples and muscle biopsies will be collected.|Both|60 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy individuals from the Galveston area.|April 2014|April 10, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113215||46597|
NCT02113202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45148.042.13|Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW|Visualization of a VEGF-targeted Near-Infrared Fluorescent Tracer in Patients With Familial Adenomatous Polyposis During Fluorescence Endoscopy A Single Center Pilot Intervention Study|FLUOFAP|University Medical Center Groningen|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|17|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02113202||46598|
NCT02114424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-039|Night Balance for Positional Obstructive Sleep Apnea Syndrome (POSAS)|Night Balance for Positional Obstructive Sleep Apnea Syndrome (POSAS) A Prospective, Randomized, Controlled Open Trial in Daily Clinical Practice|POSAS|Glostrup University Hospital, Copenhagen|No|Not yet recruiting|May 2014|February 2016|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 13, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114424||46504|
NCT02114671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.42|A Study to Investigate the Phototoxic Potential of Faldaprevir|A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects||Boehringer Ingelheim||Withdrawn|April 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|April 11, 2014||||No||https://clinicaltrials.gov/show/NCT02114671||46485|
NCT02114684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP 011|Improving Retreatment Success (IMPRESS)|An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB|IMPRESS|Centre for the AIDS Programme of Research in South Africa|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|330|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02114684||46484|
NCT02114918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11-000195|Attention Training for Childhood Obsessive Compulsive Disorder|Attention Training for Childhood Obsessive Compulsive Disorder|AMP-OCD|University of California, Los Angeles|Yes|Active, not recruiting|April 2013|May 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|8 Years|17 Years|No|||March 2016|March 23, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114918||46466|
NCT02114931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130258|Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis|An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis||Amgen|No|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|467|||Both|18 Years|81 Years|No|||February 2016|February 3, 2016|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114931||46465|
NCT02115204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-Doc|4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF|Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes||West German Study Group|Yes|Completed|June 2000|August 2010|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2011|||Female|18 Years|65 Years|No|||June 2015|June 18, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02115204||46444|
NCT02115503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSA 3242014|A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients|A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients|DSA|Databean|Yes|Recruiting|July 2014|||June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|162|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|July 2015|July 30, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02115503|3 Years|46421|
NCT02088229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00064483|Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema|Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema||University of Michigan|No|Completed|September 2012|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|99 Years|No|Non-Probability Sample|Individuals undergoing treatment for diabetic macular edema at the University of Michigan        W.K. Kellogg Eye Center.|January 2016|January 25, 2016|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02088229||48510|
NCT02088502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392300|Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy|Comparative Evaluation of the Effect of Theophylline Plus N-acetylcysteine, Theophylline Alone, and N-acetylcysteine Alone in Preventing Contrast-induced Nephropathy in Patients With Moderate to High Risk Undergoing Coronary Angiographic Procedures||Isfahan University of Medical Sciences|No|Recruiting|September 2013|||April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|96|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088502||48489|
NCT02088515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5501068|Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma|Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|December 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|75 Years|No|||March 2014|March 13, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02088515||48488|
NCT02089438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200A|DPP-4 Inhibition, Incretins and Islet Function|Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes|CODI24|Lund University|Yes|Recruiting|May 2014|February 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|40 Years|75 Years|No|||March 2015|March 1, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089438||48417|
NCT02089412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-008|A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects|||Eisai Inc.|No|Completed|February 2014|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089412||48419|
NCT02089425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-103-IP-3.01US|An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.|||Kowa Research Institute, Inc.||Terminated|April 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|384|||Both|18 Years|70 Years|No|||April 2015|April 14, 2015|March 14, 2014|Yes|Yes|Interim futility analysis|No||https://clinicaltrials.gov/show/NCT02089425||48418|
NCT02089399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1351001|Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers|An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers||Daewoong Pharmaceutical Co. LTD.|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089399||48420|
NCT02089711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2013-2 NORM-jp|Optical Coherence Tomography (OCT) Normative Data Collection Study (S-2013-2)|Multi-center Study for Normal Database of Optic Nerve Head, Retinal Nerve Fiber Layer, and Macula Parameters With the Heidelberg Spectralis OCT, Study 2|S-2013-2|Heidelberg Engineering GmbH|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|392|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|At least 224 Japanese subjects (enrollment target: 249 subjects) will be selected from        qualifying normal volunteers. Age ranges will be from ≥18 to 90 years. Recruitment will be        from persons who respond to recruitment initiatives at the individual centers or have        signed a release saying that they are willing to be approached for participation in        research.|August 2015|August 19, 2015|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089711||48396|
NCT02093819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1345.1|To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 416970 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, Investigation of Relative Bioavailability of BI 416970 (Open-label, Randomised, Three-way Cross-over) and Assessment of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers (Open-label, Single-dose)||Boehringer Ingelheim||Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|60|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 20, 2014||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT02093819||48082|
NCT02094105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC01|Endoscopic Screening on Esophageal Cancer|Effect of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: 10-year Follow up of a Community-based, Controlled Study Among High Risk Population in China||Chinese Academy of Medical Sciences|Yes|Completed|November 1999|December 2013|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45386|||Both|40 Years|69 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094105||48060|
NCT02094118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005965|Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications|Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications||Mayo Clinic|No|Not yet recruiting|July 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|85|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094118||48059|
NCT02094326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAR-FAM-2013-01|Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)|A Retrospective, Multicentre Observational Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Real Life in Patients With Rheumatoid Arthritis|SAR-FAME|Fundación Andaluza de Reumatología|No|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|301|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with rheumatoid arthritis.|February 2016|February 9, 2016|March 18, 2014||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT02094326||48043|
NCT02094339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unilateral Knee Replacement|Comparison of Three Kinds of Postoperative Analgesia After Total Knee Arthroplasty|Comparison of Three Kinds of Postoperative Analgesia After Total Knee Arthroplasty :a Randomized Clinical Trial||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094339||48042|
NCT02094014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0503|Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech|Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech||University of North Carolina, Chapel Hill|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with aphasia (PWA) will be referred from existing referral sources (e.g. UNC        Stroke registry, Triangle Aphasia Project), clinicians in the community, and the Carolina        Data Warehouse for Health.|June 2015|June 23, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094014||48067|
NCT02090517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|430519|Laser Therapy Versus Electrosurgery For Nasal Telangiectasias|Evaluation of Laser Therapy Vs Electrosurgery For Nasal Telangiectasias Using A Novel Vascular Imaging Device||University of California, Davis|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02090517||48334|
NCT02093377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Version 6.0|ASV for Sleep Apnea After Myocardial Infarction|Treatment of Sleep Apnea Early After Myocardial Infarction With Adaptive Servo-Ventilation - a Randomized Controlled Trial|TEAM ASV-I|University Hospital Regensburg|Yes|Recruiting|February 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||December 2014|December 2, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093377||48115|
NCT02093390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C27005|A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects|A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Fluconazole and Atorvastatin on the Pharmacokinetics of a Single Oral Dose of TAK-385 in Healthy Subjects||Millennium Pharmaceuticals, Inc.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|March 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093390||48114|
NCT02093403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13182|Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|March 2014|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|19 Years|N/A|No|||October 2015|October 28, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093403||48113|
NCT02093429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 47986-201|Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)|A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)||Incyte Corporation|No|Terminated|January 2014|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|January 3, 2014|Yes|Yes|Business decision.|No||https://clinicaltrials.gov/show/NCT02093429||48111|
NCT02093728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00083|To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers|A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years||AstraZeneca|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093728||48089|
NCT02094235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6005-J081-102|A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis|||Eisai Inc.|No|Completed|January 2014|January 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|2 Years|15 Years|No|||April 2015|April 6, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094235||48050|
NCT02087462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0080|Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement|Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement||Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|January 2012|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|324|||Both|18 Years|65 Years|No|||March 2014|March 13, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02087462||48569|
NCT02087670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrupoRS0002|Natriuretic Brain Pro-peptid Changes in Patients With Chronic Heart Failure Within a Cardiac Rehabilitation Program|Natriuretic Brain Pro-peptid (Pro-BNP)Changes in Patients With Chronic Heart Failure Enroled in a Controlled, Supervised Exercise Protocol Within a Cardiac Rehabilitation Program||Grupo Rehabilitacion en Salud|No|Completed|March 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 12, 2014||No||No|April 22, 2014|https://clinicaltrials.gov/show/NCT02087670||48553|
NCT02087969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052299|Triceps Surae Trigger Point Size and Muscle Extensibility|Effectiveness of Dry Needling to Decrease Trigger Point Size and Increase Soft Tissue Extensibility in the Triceps Surae Muscle as Measured Via Musculoskeletal Ultrasound||Duke University|Yes|Completed|April 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02087969||48530|
NCT02089126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GGCL001|Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes|A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone||LG Life Sciences|No|Not yet recruiting|June 2014|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|19 Years|N/A|No|||March 2014|March 14, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089126||48441|
NCT02089139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13009|Treatment of Discogenic Back Pain|Intradiscal Injection of Gelified Ethanol for the Treatment of Discogenic Back Pain|EGID|University Hospital, Limoges|No|Terminated|May 2014|September 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||September 2015|September 9, 2015|March 13, 2014||No|The French medicines agency did not allow the continuation of the study (no patient enrolled    in this study)|No||https://clinicaltrials.gov/show/NCT02089139||48440|
NCT02089451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3949|A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects|A Trial Comparing the Pharmacokinetic Properties of FIAsp After Different Injection Regions and Routes of Administration in Healthy Subjects||Novo Nordisk A/S|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|January 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089451||48416|
NCT02089464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX92325|Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial|Pivotal Phase III, Prospective, Multicenter, Double Blinded, Randomized, Sham Controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 Hz rTMS Administered to the Contralesional Hemisphere as Adjuvant to Task Oriented Rehabilitation in Patients With Ischemic or Hemorrhagic Stroke|NICHE|Nexstim Ltd|Yes|Active, not recruiting|April 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089464||48415|
NCT02089724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|medint001|Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease|Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease|LOVE|Groupe Hospitalier Pitie-Salpetriere|Yes|Recruiting|March 2014|April 2019|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Study population description is patients with Erdheim-Chester disease who have been        treated with vemurafenib or other BRAF inhibitor for at least 6 months prioly to        enrollment|September 2015|September 22, 2015|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089724||48395|
NCT02090010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Modified seldinger|Subclavian Vein catheterization_Seldinger Vs Modified Seldinger|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Subclavian Venous Catheterization: Seldinger vs. Modified Seldinger Technique|MS|Seoul National University Hospital|Yes|Recruiting|April 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|418|||Both|20 Years|80 Years|No|||March 2014|May 11, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02090010||48373|
NCT02090023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309084RIND|Long Term Prognosis of Taiwanese Patients With OSA|Long Term Prognosis of Taiwanese Patients With Obstructive Sleep Apnea||National Taiwan University Hospital|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|4000|||Both|20 Years|N/A|No|Probability Sample|Obstructive sleep apnea (PSG apnea-hypopnea index (AHI)>5 or The International        Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM)        code:780.51,780.53,780.57, or 327.23) Community-based from NHIRD cohort Hospital-based        from NTUH cohort|March 2014|March 16, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02090023||48372|
NCT02090309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor0237-13ctil|Association Between Low Cortisol Levels and Whiplash Syndrome|The Association Between Low Cortisol Level and Whiplash Syndrome and the Effect of a Single Hydrocortisone Injection on Neck Symptoms Among Motor Vehicle Accident Victims: a Randomized Placebo Controlled Double Blinded Study||Soroka University Medical Center|No|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||January 2014|August 27, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02090309||48350|
NCT02090322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72-12|Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1|Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1|Bevacizumab|Universidad Autonoma de San Luis Potosí|Yes|Recruiting|September 2013|March 2014|Anticipated|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|1 Month|4 Months|No|||March 2014|March 17, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02090322||48349|
NCT02093832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-13-EMC|Does the Femoral Head Size Can Predict the Cup Size?|Does the Femoral Head Size Can Predict the Cup Size? Retrospective Study.||HaEmek Medical Center, Israel|Yes|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|83|||Both|15 Years|90 Years|No|Non-Probability Sample|Patients that underwent primary Total hip arthroplasty due to end-stage primary        osteoarthritis; Males and females between 15-90 years of age.|March 2014|March 19, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093832||48081|
NCT02094131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMR-01|Effects of Training Using Volume and Flow-oriented Incentive Spirometry in Healthy Subjects - Case-control Study|Effects of Training Using Volume and Flow-oriented Incentive Spirometry in Healthy Subjects - Case-control Study||Universidade Federal de Sao Carlos|No|Completed|October 2010|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094131||48058|
NCT02094352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003|Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome|Randomized Controlled Trial of Subanesthetic Intravenous Ketamine Infusion in Conjunction With Continuous Epidural Infusion for Treatment of Refractory Complex Regional Pain Syndrome||Hospital for Special Surgery, New York|Yes|Terminated|April 2014|||October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 23, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094352||48041|
NCT02094365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8176-502|A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model|A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model||Alios Biopharma Inc.|No|Completed|March 2014|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|December 22, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094365||48040|
NCT02094599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-13-017|A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users|A Single-dose, Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users||INSYS Therapeutics Inc||Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|March 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02094599||48022|
NCT02090777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052498|Health Coaching for Glaucoma Patients|Health Coaching for Glaucoma Patients, Pilot Study||Duke University|No|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|9|||Both|18 Years|N/A|No|||January 2016|February 17, 2016|March 14, 2014||No||No|November 6, 2015|https://clinicaltrials.gov/show/NCT02090777||48314|
NCT02093130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001644|Study of Pomegranate Juice on Memory in Older Adults|Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging||University of California, Los Angeles|No|Recruiting|January 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|212|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02093130||48133|
NCT02093416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13010529|Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study|Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study||University of Pittsburgh|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and Females undergoing endoscopy|January 2016|January 14, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093416||48112|
NCT02086903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLLATERAL|Clopidogrel And Ticagrelor in Healthy Subjects|Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects||Dong-A University|Yes|Completed|February 2014|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Male|19 Years|59 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02086903||48611|
NCT02087137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-21|Functional Impact of a Memory Intervention Program|Functional Impact of a Memory Intervention Program||Baycrest|No|Completed|May 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087137||48593|
NCT02087150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005029|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||December 10, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087150||48592|
NCT02088242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0471-BA-CTIL|Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans|Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans|Astaxanthin|Sheba Medical Center|No|Not yet recruiting|May 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|34|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02088242||48509|
NCT02087683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESVDIC2013-CINCO|Effect of Vitamin D Supplementation in Patients With Heart Failure and Vitamin D Deficiency|Effect of Vitamin D Supplementation in Patients With Heart Failure and Vitamin D Deficiency||Instituto Tecnologico y de Estudios Superiores de Monterey|No|Not yet recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|85 Years|No|||September 2014|September 3, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087683||48552|
NCT02087982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reperage - 23|Development of General Practitioners Screening Tool of Frail Older Old Community|Development of General Practitioners Screening Tool of Frail Older Old Community-dwellers: a Cohort Population-based Study|ReperAge|Gerontopôle des Pays de la Loire|Yes|Recruiting|January 2014|February 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adults aged 80 and over|March 2015|March 9, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02087982||48529|
NCT02087995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL901100|Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm|Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm||DexCom, Inc.|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|51|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087995||48528|
NCT02088775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP-RT-060|PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer|Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study||Fox Chase Cancer Center|Yes|Recruiting|February 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088775||48468|
NCT02088788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0140|Reduction in Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a Radiation Protection Board|Reduction in Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a Radiation Protection Board||Geisinger Clinic|No|Recruiting|June 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|89 Years|No|||March 2014|March 14, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088788||48467|
NCT02089152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO1307|A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand|A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand|PREMEL|University of Oxford|No|Recruiting|April 2014|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|9000|||Both|18 Years|65 Years|No|||September 2015|October 1, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089152||48439|
NCT02089178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0937|Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection|||Yonsei University|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Female|20 Years|65 Years|No|||March 2014|March 14, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02089178||48437|
NCT02089737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183-011|Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)|Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)||Takeda|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3091|||Both|N/A|N/A|No|Non-Probability Sample|Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene|March 2014|March 13, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089737||48394|
NCT02089750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS IRB_H-1203|Orthotic Use for Chronic Low Back Pain|Orthotic Use for Chronic Low Back Pain: A Randomized Controlled Trial||National University of Health Sciences|Yes|Active, not recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089750||48393|
NCT02089763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT-100-006|Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer|A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma||Bio-Cancer Treatment International Limited|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089763||48392|
NCT02094144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8189|Health Benefits of a 6-month Brisk Walking Program in Sedentary Postmenopausal Women|Health Benefits of a 6-month Brisk Walking Program in Sedentary Postmenopausal Women : a Randomized Controlled Trial|ACTIMARCH|University Hospital, Montpellier|Yes|Completed|January 2008|March 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|126|||Female|55 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094144||48057|
NCT02094378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103823|A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects||Janssen Research & Development, LLC|Yes|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094378||48039|
NCT02094391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001610-15|Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma|A Randomized, Open Label, Multicenter, Comparative Phase II Trial of Ipilimumab After Isolated Limb Perfusion (ILP), in Patients With In-transit Metastases Melanoma Stage IIIB and IIIC|ILP+/-IPI|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|March 2014|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094391||48038|
NCT02094612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1692-H|Effectiveness of the Quotient® ADHD Assessment in a System of Care|Effectiveness of the Quotient® ADHD Assessment in a System of Care||Kaiser Permanente|Yes|Terminated|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|206|||Both|6 Years|12 Years|No|||March 2016|March 4, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094612||48021|
NCT02086929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039(C)SC11063|Trazodone Once a Day in Major Depression Disorder|A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder.||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Completed|December 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|75 Years|No|||December 2015|December 29, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02086929||48609|
NCT02094248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO Study|rhTPO in Critical Patients With Thrombocytopenia|A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia||Jinling Hospital, China|Yes|Recruiting|March 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|85 Years|No|||June 2014|May 19, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094248||48049|
NCT02086916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007512QM|Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection|Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection||Barts & The London NHS Trust|No|Active, not recruiting|October 2011|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Stool samples from recruited participants are frozen and stored. They will be batch analysed      after completion of recruitment.|Both|16 Years|N/A|No|Non-Probability Sample|Patients admitted to Barts Health NHS Trust|March 2014|July 8, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02086916||48610|
NCT02087163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-700007-00|The Use of Clear Aligners With Movement Enhacement Techniques|The Use of Clear Aligners With Movement Enhacement Techniques||Align Technology, Inc.|Yes|Active, not recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|16 Years|46 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02087163||48591|
NCT02087176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6011C00001|A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer|A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients||AstraZeneca|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087176||48590|
NCT02088034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21273|Intervention to Promote Weight Loss in Latinas At-risk for Diabetes|Promotora-led Intervention to Promote Weight Loss in Latinas At-risk for Diabetes||Temple University|No|Active, not recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|20 Years|75 Years|No|||February 2016|February 18, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02088034||48525|
NCT02088528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCEC 044/13-14|The Ghana Primary Tube Versus Trabeculectomy Study|The Ghana Primary Tube Versus Trabeculectomy Study|GPTVT|Tema Christian Eye Center|Yes|Recruiting|March 2014|||March 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|298|||Both|18 Years|85 Years|No|||March 2014|March 14, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088528||48487|
NCT02088541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-008|Selinexor (KPT-330) in Older Patients With Relapsed AML|A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation|SOPRA|Karyopharm Therapeutics, Inc|Yes|Recruiting|March 2014|June 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|60 Years|N/A|No|||January 2016|January 27, 2016|March 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088541||48486|
NCT02088554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERIGON|PERIGON Pivotal Trial|Medtronic PERIcardial SurGical AOrtic Valve ReplacemeNt Pivotal Trial A Multi-center, Non-randomized Trial to Determine the Safety and Effectiveness of the Model 400 Aortic Valve Bioprosthesis in Patients With Aortic Valve Disease|PERIGON|Medtronic Cardiovascular|Yes|Recruiting|May 2014|December 2021|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1300|||Both|N/A|N/A|No|||February 2016|February 22, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088554||48485|
NCT02088801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/12_2|Evaluation of Videolaryngoscopes in Difficult Airway (SWIVITII)|Phase 2 Study of Evaluation of Videolaryngoscopes in Difficult Airway (SWIVITII)|SWIVITII|University Hospital Inselspital, Berne|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|480|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088801||48466|
NCT02088814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100014_149158|Prevention of Posttraumatic Stress Symptoms in Young Children With Burns: a Randomized Controlled Trial|Prevention of Posttraumatic Stress Symptoms in Young Children With Burns: a Randomized Controlled Trial|EPICAP|University Children's Hospital, Zurich|No|Recruiting|April 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|124|||Both|1 Year|4 Years|No|||December 2015|December 2, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088814||48465|
NCT02089165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISU 58/2013|Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.|Randomized, Single-center, Open-label, Blinded Endpoint Assessment Study (Cross-over Study With 3 Study Products) on Bioavailability of Fatty Acids (Plasma Lipid Fractions) From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.|RISU|Olympic Seafood AS|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089165||48438|
NCT02088840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGNB-GITMO-AMCLI-Survey|Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant|A Prospective, Multicenter Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Autologous and Allogeneic Stem Cell Transplant.|GITMO-SIGNB|Gruppo Italiano Trapianto di Midollo Osseo|No|Active, not recruiting|January 2014|September 2015|Anticipated|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3500|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing autologous or allogeneic Stem Cell Transplant for any underlying        disease will be monitored for SIGNB during the engraftment period.|September 2015|September 2, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088840|4 Months|48463|
NCT02089191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-006|Tear Film Stability of DAILIES® AquaComfort Plus® Contact Lenses vs. MyDay® Daily Disposable Contact Lenses|Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses Using Ring Mire Projection||Alcon Research|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|31|||Both|18 Years|44 Years|No|||April 2015|April 30, 2015|March 14, 2014|No|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT02089191||48436|There was a high censoring rate observed with the objective measurements and therefore there are limitations to the conclusions that may be drawn.
NCT02089477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterWalk - Validation|The Smart-phone as a Physical Fitness Monitor - Validity, Sensitivity and Motivation InterWalk|The Smart-phone as a Physical Fitness Monitor on a Population Level - Validity and Sensitivity and Improtance of Individual Motivation for Doing Interval Walking With the InterWalk Application||University of Copenhagen|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|30 Years|70 Years|No|||December 2014|December 2, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089477||48414|
NCT02089776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140069|fMRI Neurofeedback for Motor Rehabilitation|Real-time fMRI Neurofeedback for Motor Rehabilitation||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|February 5, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02089776||48391|
NCT02089789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140071|Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation|Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A|||Anticipated|100|||Both|1 Year|80 Years|No|||October 2015|October 6, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089789||48390|
NCT02090868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13IC0065|An Oral Intake Screening Tool for Patients Receiving Non-Invasive Ventilation|How the Introduction of an Oral Intake Screening Tool Can Benefit Patients Receiving Non-Invasive Ventilation||Imperial College London|No|Completed|April 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Patients; Medical High Dependency Unit Patients Staff; Full time employees on the Douglas        Acute Admission Unit|March 2013|March 17, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02090868||48307|
NCT02090881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0858|Transcranial Doppler Ultrasound in Children With Sickle Cell Disease|Comparison of a Portable and Non-Portable Ultrasound Machine in the Evaluation of Children With Sickle Cell Disease - A Pilot Study||Imperial College Healthcare NHS Trust|No|Not yet recruiting|March 2014|May 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|2 Years|16 Years|No|Non-Probability Sample|2-16 year olds under the care of consultant haematologist and attending outpatient clinic.|October 2013|March 17, 2014|October 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02090881||48306|
NCT02093871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thermalcore-01|A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer|A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer|PISH-2|ThermalCore Inc|Yes|Recruiting|August 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|69 Years|No|||December 2014|January 8, 2015|August 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093871||48078|
NCT02094404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSEH13|Triage of Children at the Emergency Department: Manchester Triage System or Pediatric Early Warning Score?|Triage of Children at the Emergency Department: Manchester Triage System or Pediatric Early Warning Score?||Isala|No|Completed|December 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|727|||Both|N/A|18 Years|No|Non-Probability Sample|- All children presenting at the emergency department of the Isala, Zwolle.|May 2015|May 28, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02094404||48037|
NCT02094638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-Pharmacy-003|Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study|Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study||Peking University Third Hospital|Yes|Completed|January 2014|||August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|30400|Samples With DNA|biospecimen including serum, plasma, blood cells with DNA.|Both|24 Months|N/A|No|Non-Probability Sample|Patients who use the Tanreqing Injection in selected hospitals in China (including the        inpatient and the outpatient(only in some hospitals which can get the information)).|February 2016|February 18, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094638|7 Days|48019|
NCT02094898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005152|Ketamine for Depression and Suicide Risk|Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt|Ketamine|Mayo Clinic|No|Enrolling by invitation|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|January 22, 2016|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094898||47999|
NCT02094911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37994.081.11|(Cost-)Effectiveness of SLIMMER Diabetes Prevention Intervention|Implementation and (Cost-)Effectiveness of Diabetes Prevention in Dutch Primary Health Care: From SLIM to SLIMMER|SLIMMER|Wageningen University|No|Active, not recruiting|October 2011|May 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|316|||Both|40 Years|70 Years|No|||March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094911||47998|
NCT02095210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA1021|HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025|Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025||Herlev Hospital|Yes|Recruiting|April 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|8|||Both|18 Years|N/A|No|||November 2013|March 20, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT02095210||47975|
NCT02086942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB20130806|Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.|Randomized, Multicenter Study of Tolerability and Efficacy of Modified Combinations of Bortezomib, Dexamethasone and Cyclophosphamide in Previously Untreated Multiple Myeloma.||Jinling Hospital, China|Yes|Recruiting|August 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02086942||48608|
NCT02086669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S500-00|Pneumatic Dilatation or Surgical Myotomy for Achalasia|Randomized Study to Compare Pneumatic Dilatation With Surgical Myotomy for Treatment of Achalasia - Long Term Follow up||Karolinska University Hospital|No|Completed|January 2000|January 2014|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||March 2014|March 11, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02086669||48629|
NCT02087189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA107|TD01 Master Study (Safety and Efficacy Study)|TD01 Master Study (Safety and Efficacy Study)||Biotronik SE & Co. KG|No|Active, not recruiting|August 2014|July 2020|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for the investigation should be from the investigator's general        patient population according to the inclusion and exclusion criteria.|October 2015|October 14, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02087189||48589|
NCT02087475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAH 5010 CRC|Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin|Randomized Open-label Phase III Study Comparing Perioperative FOLFIRI Versus Adjuvant FOLFIRI in Resectable Advanced Colorectal Cancer Failed to Oxaliplatin-containing Treatment||Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|January 2011|December 2024|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|80 Years|No|||March 2014|March 12, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02087475||48568|
NCT02087696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-TOC-2013-01|Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis|Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy||Spanish Foundation of Rheumatology|No|Recruiting|May 2014|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02087696||48551|
NCT02087709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0535.0.000.325-08|Effect of Low-calorie Diet on Serum Lipids, Adipokines, Insulin Resistance and Also Body Composition in Women With Metabolic Syndrome|Effect of Hypocaloric Diet on Biomarkers of Metabolic Profile, Insulin Resistance and Body Composition in Women With Metabolic Syndrome||Universidade Federal do Rio de Janeiro|No|Completed|May 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|30 Years|45 Years|No|||March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087709||48550|
NCT02088008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_IDCV_1303|A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers||IlDong Pharmaceutical Co Ltd|No|Not yet recruiting|May 2014|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088008||48527|
NCT02088021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL07045|Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access||PorticoALTEU|St. Jude Medical|Yes|Withdrawn|January 2014|December 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||April 2014|April 21, 2015|March 4, 2014||No|Business decision|No||https://clinicaltrials.gov/show/NCT02088021||48526|
NCT02088047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202241|The Effects of ProFoveate on Reducing Self-Stimulating Behaviors|The Effects of ProFoveate on Reducing Self-Stimulating Behaviors in Children Diagnosed With Autism Spectrum Disorders||University of Arkansas|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088047||48524|
NCT02087774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498505-2|Brief Physical Activity Program to Increase Physical Fitness in Elementary School Children|The Effects of a Brief Physical Activity Program on Elementary School Students' Physical Fitness||Marshall University|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 25, 2014|March 12, 2014||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT02087774||48545|Non-randomized, controlled design. Majority of subject were caucasian, from Appalachian region.
NCT02088255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/UCS-016/2013|Walking Training With Partial Body Weight Support on Static and Dynamic Surfaces in Stroke Survivers|Walking Training With Partial Body Weight Support on Static and Dynamic Surfaces in Individuals With Hemiparesis Due to Stroke||Universidade Cruzeiro do Sul|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2015|March 7, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088255||48508|
NCT02088567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFTKR001|Amniotic Membrane in Total Knee Replacements to Reduce Scarring|A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Total Knee Replacement Patients to Reduce Post-operative Scarring.||MiMedx Group, Inc.|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02088567||48484|
NCT02088580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronotherapy Pilot|Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients|Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients||Medical University of South Carolina|No|Completed|October 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2013|October 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02088580||48483|
NCT02088827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01886|Effects of Sedentary Behaviour on Metabolic Parameters|Effects of Sedentary Behaviour on Metabolic Parameters||University of British Columbia|No|Recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|65 Years|N/A|No|||December 2015|December 2, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088827||48464|
NCT02088853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUTTER|Diet Induced Intestinal Mucosal Adaptation|Small Intestinal Adaptation to Isocaloric Diets Dominated Either by Fats or Carbohydrates||Göteborg University|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088853||48462|
NCT02089204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H201021|Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma|Clinical Feasibility Study of Hypoxia Imaging -Guided IMRT on the Individualized Radiotherapy of Nasopharyngeal Carcinoma||Xuzhou Medical College|Yes|Enrolling by invitation|June 2010|December 2015|Anticipated|February 2014|Actual|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|70 Years|No|Probability Sample|Between June 2010 to June 2015, patients from Department of Radiation Oncology, Affiliated        Hospital of Xuzhou Medical College.|March 2014|March 13, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02089204||48435|
NCT02089802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IQUO/01 OPERA|Optimizing Pazopanib Exposure in RCC Patients|Optimizing Pazopanib Exposure in RCC Patients Through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation|OPERA|Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.|No|Recruiting|February 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2014|March 15, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02089802||48389|
NCT02089490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS2 NEVELIA|Evaluation of NEVELIA® in Terms of Safety and Efficacy for Third-degree Burns Treatment or Reconstructive Surgery|Prospective Follow-up Study for the Evaluation of the Safety and Efficacy of the Dermal Substitute NEVELIA® in the Treatment of Third-degree Burns and Reconstructive Surgery|NEVAL|Symatese|No|Not yet recruiting|April 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089490||48413|
NCT02090894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105005442|Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin|Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin|Laser Genesis|Indiana University||Active, not recruiting|March 2011|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|65 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02090894||48305|
NCT02086799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|354-13CTIL|Thyroid Hormones Treatment in Asthma Exacerbation|Is There a Role for Thyroid Hormones Treatment in the Set-up of Acute Moderate to Severe Asthma Exacerbation|THINAS|Rambam Health Care Campus|No|Not yet recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||July 2014|July 29, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086799||48619|
NCT02094417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|531-KR001|A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia|A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy||Kyowa Hakko Kirin Korea Co., Ltd.|No|Recruiting|March 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|19 Years|N/A|No|||February 2016|February 22, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094417||48036|
NCT02094651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00005744|Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium|Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium||Children's Hospital Boston|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|4 Years|8 Years|No|||May 2015|May 20, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02094651||48018|
NCT02086682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003161|A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients|A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients in a Large Medical Center||Mayo Clinic|No|Recruiting|February 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|The group includes adult hospitalized patients requiring hemodialysis at the inpatient        dialysis unit or the ICU during the recruitment period.|April 2015|April 6, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02086682||48628|
NCT02086955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320030_143863|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration||Zurich University of Applied Sciences|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02086955||48607|
NCT02087202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hyperalgesia|Hyperalgesia and NMDA Receptor Antagonist|Hyperalgesia and NMDA Receptor Antagonist||Seoul National University Bundang Hospital|Yes|Not yet recruiting|March 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|85 Years|No|||March 2014|March 12, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087202||48588|
NCT02087215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRDIAFOOTULCER|Effect of Local Application of Boron on Diabetic Foot Ulcers|Prospective Randomized Study of Local Application of Boron on Diabetic Foot Ulcers: Effect of Healing Process||Bezmialem Vakif University|No|Recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||November 2014|November 23, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02087215||48587|
NCT02087488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0302-3|Auricular Acupuncture for Primary Insomnia|Auricular Acupuncture for Primary Insomnia|AAPI|Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|64 Years|No|||February 2015|February 5, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02087488||48567|
NCT02087722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-CC-8303|Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients||Kuhnil Pharmaceutical Co., Ltd.|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|55 Years|N/A|No|||March 2014|March 12, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087722||48549|
NCT02087735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS-2013-SD|Measurement of Urinary Catabolites of PACs as Biomarkers of Consumption of Cranberry Extracts|Measurement of Urinary Catabolites of the Proanthocyanidines (PACs) in Healthy Young Women as Biomarkers of Consumption of Cranberry Extracts.|CUPACS|Laval University|Yes|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|15|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087735||48548|
NCT02087787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS112|Medical-legal Partnership (MLP) to Support Bone Marrow Transplant|Establishing a BMT Legal Clinic to Support Patients With Cancer Undergoing Blood or Marrow Transplant||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|March 2014|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|105|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087787||48544|
NCT02088268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC1-110|Treatment of PRP on Diabetes Wound|Treatment and Evaluation of Platelet-rich-plasma on Diabetes Wound Healing|PRP|China Medical University Hospital|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|70 Years|No|||October 2015|October 20, 2015|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02088268||48507|
NCT02088281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 101-2320-B-182-021-MY3|Mechanistic Study of Indigo Naturalis in Treating Psoriasis|Mechanistic Study of Indigo Naturalis in Treating Psoriasis: Local or Systemic Manipulation of Inflammation and Induction of Immunoregulation||Chang Gung Memorial Hospital|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2012|March 12, 2014|December 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02088281||48506|
NCT02088593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dawn|Simulated Dawn Med Students|The Effect of Improving Sleep and Circadian Rhythms on Affective Symptoms In First Year Medical Students||Medical University of South Carolina|No|Completed|July 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|March 14, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02088593||48482|
NCT02088606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-002 527 Version H|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol||St. Jude Medical|No|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088606||48481|
NCT02089503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELOUAN HSJ 2014|Monocentric Retrospective Observational Study on Patients With Macular Degeneration|Monocentric Retrospective Observational Study Describing the Visual Acuity of Patients With Exudative Age Related Macular Degeneration and Treated by Lucentis® Under Real Conditions of Care.|ELOUAN|Hospital St. Joseph, Marseille, France|Yes|Not yet recruiting|March 2014|December 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|patients with exudative Age-Related Macular Degeneration (ARMD), treated with Lucentis,        under real conditions of care|March 2014|March 17, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089503||48412|
NCT02090075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21183-01|Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque|Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque||Los Angeles Biomedical Research Institute|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|85 Years|No|||January 2016|January 8, 2016|March 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090075||48368|
NCT02090062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxhnk2014|Difference in H. Pylori Infection Rate of EGC Patients Before and After Endoscopic Resection|Difference in H. Pylori Infection Rate of EGC Patients Before and After Endoscopic Resection||Shanghai Jiao Tong University School of Medicine|No|Not yet recruiting|March 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|All the lesions will be removed endoscopically or surgically and examine histologically by      an independent gastrointestinal pathologist.      Each biospecimen after ER will be detected H pylori infection status.|Both|18 Years|90 Years|No|Non-Probability Sample|patients with early gastric lesions|March 2014|March 17, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02090062||48369|
NCT02090907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392349|Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism|Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism||Isfahan University of Medical Sciences|No|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||March 2014|March 17, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090907||48304|
NCT02086812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1324-BKEYE-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||March 11, 2014|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086812||48618|
NCT02086825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00665|A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure|A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure||New York University School of Medicine|No|Withdrawn|October 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086825||48617|
NCT02087059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424AJP01|A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis|A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis||Novartis|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087059||48599|
NCT02094664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-066|Heated Humidified Oxygen Compared to Dry Oxygen Therapy in Children With Bronchiolitis|HHOT AIR Study (a Pilot Study): Heated Humidified Oxygen Therapy Compared to Standard Dry Oxygen: An Assessment in Infants With bRonchiolitis||Children's Hospital & Research Center Oakland|Yes|Active, not recruiting|January 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|24 Months|No|||March 2015|March 23, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094664||48017|
NCT02094950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11513|Acupuncture Feasibility Trial for Dyspnea in Lung Cancer|Acupuncture Feasibility Trial for Dyspnea in Lung Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094950||47995|
NCT02086695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005362|Early Detection of Broken Hearts in Cancer Patients|Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib and Heart Failure|ASPER|Mayo Clinic|No|Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples Without DNA|Blood will be drawn to measure blood biomarkers to determine your heart biomarker [High      sensitivity TnT and NT-proBNP] as an indicator of early heart failure.|Both|18 Years|90 Years|No|Non-Probability Sample|A total of 100 individuals with advanced metastatic renal cell carcinoma or colorectal        cancer (50 receiving BVZ and 50 receiving Sunitinib) will be prospectively enrolled . (80        at Mayo Clinic( Any subject presenting who will be treated for cancer recieving Pazopanib,        Sutent, or Bevacizumab] and 20 at St. Boniface General Hospital (SBGH)).|January 2016|January 27, 2016|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02086695||48627|
NCT02086734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP NK 2012|Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma|Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma||Ludwig-Maximilians - University of Munich|No|Recruiting|January 2012|January 2018|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic renal cell cancer eligible for AAT (antiangiogenic therapy) with        either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) presenting at the        Departement of Urology. LMU, meeting the inclusion/exclusion criteria|March 2014|March 11, 2014|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02086734||48624|
NCT02087228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-053|Evaluation of the Endometrial Cavity After Endometrial Ablation|Evaluation of the Endometrial Cavity After Endometrial Ablation|Postablation|Baylor Research Institute|No|Terminated|September 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|51 Years|No|||January 2016|January 15, 2016|March 10, 2014||No|Sponsor and Principle Investigator mutually agreed to terminate study and patients are no    longer examined/treated|No||https://clinicaltrials.gov/show/NCT02087228||48586|
NCT02087241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6011C00002|Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer|Double-Blind Randomised Phase II Trial of Carboplatin and Pemetrexed With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer||AstraZeneca|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087241||48585|
NCT02087501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP003.00|HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm|A Prospective Open-label Non-randomized Pivotal Study to Evaluate the Safety and Performance of the Horizon™ Abdominal Aortic Aneurysm (AAA) Stent Graft System||Endospan Ltd.|No|Active, not recruiting|April 2014|April 2020|Anticipated|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02087501||48566|
NCT02087748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-VOL-01C|An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS|A Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness||Lotus Clinical Research, LLC|No|Completed|March 2014|May 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|March 12, 2014||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT02087748||48547|
NCT02087761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-FLU-01-CS-001|A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients||Luminex Molecular Diagnostics|No|Active, not recruiting|December 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Nasal-pharyngeal swabs|Both|N/A|N/A|No|Probability Sample|All comers|March 2016|March 1, 2016|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087761||48546|
NCT02088073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-004|Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.|Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.||ZS Pharma, Inc.|Yes|Completed|March 2014|January 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|258|||Both|18 Years|N/A|No|||August 2014|June 1, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088073||48522|
NCT02088060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD-FEP|A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients|A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients||Central Institute of Mental Health, Mannheim|Yes|Recruiting|March 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088060||48523|
NCT02088619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028869|Positive Therapy for Autonomic Function & Mood in ICD Patients|Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients|PAM-ICD|Medical University of South Carolina|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|April 10, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02088619||48480|
NCT02088866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|515576|Commercial Lidocaine Patch as a Treatment for Ear-ringing|Transdermal Lidocaine as a Treatment for Tinnitus||University of California, Davis|No|Completed|March 2014|September 2015|Actual|August 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088866||48461|
NCT02088879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMG CPR-freq1|Physical Workload Identify in Chest Compression Position Using Surface Electromyogram|||Hanyang University|Yes|Completed|March 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|36|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088879||48460|
NCT02088892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB031|A Clinical Challenge Study of BCG in Healthy Volunteers|A Clinical Challenge Study to Quantify BCG at the Challenge Site of Healthy Volunteers Receiving Either Intradermal BCG SSI or BCG TICE at Standard or High Dose||University of Oxford|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088892||48459|
NCT02090088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080046|Nplate® Pregnancy Exposure Registry|Nplate® Pregnancy Exposure Registry (NPER)|NPER|Amgen|Yes|Terminated|May 2009|January 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|||Both|N/A|N/A|No|Non-Probability Sample|The study population consists of two cohorts of women and their offspring who reside in        the U.S. The exposed cohort is defined as pregnant women who have received at least one        dose of Nplate® during pregnancy and their offspring up to one year of age. The unexposed        cohort is defined as women unexposed to Nplate® during pregnancy matched on disease status        (cITP) and age (childbearing) to the exposed. In order to provide context for any possible        Nplate® exposed women without cITP, comparators from published literature will be used.|December 2014|December 23, 2014|March 14, 2014|No|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT02090088|21 Months|48367|The number of infants born to participants was too low to draw conclusions or make comparisons to the Systematic Tracking of Real Kids (STORK) analysis or to the background rates of congenital anomalies or preterm infants in the general population.
NCT02090101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003367-55|Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer|Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study|IRAFU|Centre Georges Francois Leclerc|Yes|Recruiting|June 2014|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|80 Years|No|||June 2015|June 23, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02090101||48366|
NCT02090335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boston In SHAPE|Health Promotion and Fitness for Younger and Older Adults With SMI|Health Promotion and Fitness for Younger and Older Adults With SMI|InSHAPE|Dartmouth-Hitchcock Medical Center|Yes|Completed|May 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|210|||Both|21 Years|N/A|No|||March 2014|March 14, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02090335||48348|
NCT02090621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEC-TH|Extracorporeal Photopheresis After Liver Transplant|Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Completed|October 2012|March 2015|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2014|March 11, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02090621||48326|
NCT02090634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEA Award ID09-SD-047|Texting to Improve Adherence in HIV+ With Bipolar Disorder|Texting to Improve Adherence in HIV+ With Bipolar Disorder|iTAB|University of California, San Diego|No|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02090634||48325|
NCT02087371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR12132|Prognosis Factors of Cardiac Complications After Liver Transplantation|Prognosis Factors of Cardiac Complications After Liver Transplantation|PROCOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Plasma and urines samples will be collected on 3 separate days (inclusion in the study, the      day before liver transplantion and 7 days after).|Both|18 Years|N/A|No|Non-Probability Sample|Patients with end-stage liver failure and registered on transplantation list can        participate to the study.|November 2015|November 30, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02087371||48576|
NCT02087592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBRE-F-110013|Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers|Prospective Randomized Multicenter Trial to Assess the Feasibility of a Structured Physical Exercise Training and Mediterranean-style Diet in Women With BRCA1/2 Mutations|LIBRE|Technische Universität München|No|Active, not recruiting|February 2014|June 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|69|||Female|18 Years|69 Years|No|||July 2015|July 14, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087592||48559|
NCT02094456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0032|Prophylactic Elective Clipping of Colonic Diverticula|Prophylactic Elective Clipping of Colonic Diverticula in Patients Who Have Had Sustained Lower Gastrointestinal Haemorrhage||King's College Hospital NHS Trust|No|Not yet recruiting|October 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094456||48033|
NCT02094677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-50|Daily Disposable Comparison Study|Daily Disposable Comparison Study||Coopervision, Inc.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|70|||Both|17 Years|40 Years|No|||March 2016|March 9, 2016|March 13, 2014|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT02094677||48016|
NCT02086708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000705|Ultrasound Method to Measure Fibrosis of the Liver in Children|Sonoelastography: Ultrasound Method to Measure Fibrosis of the Liver in Children||Massachusetts General Hospital|Yes|Recruiting|June 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086708||48626|
NCT02086721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L19-IL2|Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor|Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor.|L19-IL2|Maastricht Radiation Oncology|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02086721||48625|
NCT02086994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid77|Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol|Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia.|carbetocin|Benha University|Yes|Completed|March 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Female|19 Years|42 Years|No|||November 2015|November 25, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02086994||48604|
NCT02087540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_Telotan_1203|Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia|A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia||IlDong Pharmaceutical Co Ltd||Recruiting|May 2013|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|310|||Both|19 Years|80 Years|No|||March 2014|March 13, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02087540||48563|
NCT02086968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT13035|Treatment Response of Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass|A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass||Luitpold Pharmaceuticals|No|Recruiting|January 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086968||48606|
NCT02087267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITONA_01/2014|Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™|Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™||Sitona AG|No|Recruiting|March 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary care clinic of selected spine centers|May 2015|May 19, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087267||48584|
NCT02087280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHaas|Metabolic Phenotyping in Anorexia Nervosa|Metabolic Phenotyping to Predict Risk of Relapse in Patients With Anorexia Nervosa||Charite University, Berlin, Germany|No|Not yet recruiting|October 2014|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|72|Samples Without DNA|Biomarkers of energy metabolism|Female|12 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Female adolescents with Anorexia Nervosa|March 2014|March 12, 2014|January 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02087280||48583|
NCT02087514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0835|Duration of Red Blood Cell Storage Prior to Transfusion and Non-Transferrin-Bound Iron|Duration of Red Blood Cell Storage Prior to Transfusion and Non-Transferrin-Bound Iron||Columbia University|Yes|Recruiting|January 2014|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|6||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087514||48565|
NCT02088905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0031588|Efficacy of Parent-Child Interaction Therapy With ASD|Efficacy of Parent-Child Interaction Therapy With ASD|PCIT|University of Pittsburgh|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Months|83 Months|No|||January 2016|January 7, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02088905||48458|
NCT02088918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_Fasticmet_1201|A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects|||IlDong Pharmaceutical Co Ltd|No|Completed|October 2012|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02088918||48457|
NCT02088294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM 1 RO1 AT008330-01|Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth|Imagine HEALTH (Healthy Eating Active Living Total Health) Study: Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth||University of Southern California|No|Recruiting|May 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|240|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02088294||48505|
NCT02088307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIOLIFE--001|Study of the Cardiovascular Vitamin, CardioLife|Evaluation of the Metabolic and Physiological Profiles of Patients Diagnosed With Cardiovascular Disease (CVD) Following Administration of the Novel Cardiovascular Vitamin, CardioLife||University of Utah|Yes|Completed|June 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|90 Years|No|||March 2016|March 21, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088307||48504|
NCT02089516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DynaPort I|Activity Monitoring in Frail Elderly Patients|Activity Monitoring in Frail Elderly Patients. A Methods Comparison Study.||Medical Research Foundation, The Netherlands|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|18|||Both|75 Years|N/A|No|Non-Probability Sample|Home-dwelling frail elderly (GFI score ≥ 4) of 75 years and older.|April 2015|April 10, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089516||48411|
NCT02089815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-56-37|Home Based Exercise in Preventing Fall and Improving Balance in Older People|Effectiveness of a Simple Designed Programme of Home Based Exercise in Preventing Fall and Improving Balance and Strength in Older People With Mild to Moderate Balance Dysfunction: A Randomized Controlled Trials||Mahidol University|Yes|Completed|August 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|439|||Both|65 Years|N/A|No|||April 2015|April 9, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02089815||48388|
NCT02090114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1416|RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)|A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies|Restore|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|June 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090114||48365|
NCT02090127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-299-13-103S|Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient|Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412||AVEO Pharmaceuticals, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||July 2015|July 27, 2015|March 14, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02090127||48364|
NCT02090348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS405|Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate|A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)|TECNERGY|Biogen|No|Withdrawn|June 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|March 14, 2014|Yes|Yes|The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not    a result of any safety or efficacy concerns.|No||https://clinicaltrials.gov/show/NCT02090348||48347|
NCT02090361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/008/HP|Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts|Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts|MATRIGREFFE|University Hospital, Rouen|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02090361||48346|
NCT02090647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTM001|Aesthetic Evaluation of Different Abutment Materials for OsseoSpeed Implants|Aesthetic Outcome of Osseospeed Implants With Three Different Abutment Materials. A Randomized Controlled Clinical Study||University of Siena|No|Completed|January 2012|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02090647||48324|
NCT02090660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5454|Technique for Localization of Pulmonary Nodules Using Spy Thoracoscope System|Feasibility of a Novel Minimally Invasive Technique for Localization of Pulmonary Nodules Using the Spy Thoracoscope System||University Health Network, Toronto|No|Recruiting|April 2014|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090660||48323|
NCT02087085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-038|A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration||BEACON|Allergan|Yes|Recruiting|May 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|55 Years|N/A|No|||February 2016|February 9, 2016|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087085||48597|
NCT02091687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401S47261|Longitudinal Outcomes in Pediatric rTMS and CIT|Longitudinal Outcomes in Pediatric rTMS and CIT|Longitudinal|University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2014|||May 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|19|||Both|N/A|N/A|No|Non-Probability Sample|Previous participants in a randomized controlled study (RCT) rTMS/CIT (Pediatric        Hemiparesis: Synergistic Treatment using rTMS and CIT (NIH Grant Number: 1RC1HD063838-01;        PI: Dr. James Carey)|January 2016|January 4, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091687||48244|
NCT02087384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45200.018.13|HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)|Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men|VACCAIN-P|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|March 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|125|||Male|18 Years|N/A|No|||December 2015|December 22, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02087384||48575|
NCT02085746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015065|Defining Sexual Activity|Defining Sexual Activity: How Demographics May Impact Our Definition||University of South Florida|Yes|Recruiting|January 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or female patient over 18 years of age seeking urogynecological/urological treatment        at one of the participating clinical sites.|March 2014|March 12, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085746||48700|
NCT02086058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeneOAB|Gene Expression in the Overactive Bladder in Children|Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence||University of Aarhus|No|Recruiting|November 2013|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|46|Samples With DNA|Bladder biopsies from the back-wall og the bladder.|Both|5 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|We will include 3 groups of patients Group 1: children with an overactive bladder and        daytime urinary incontinence Group 2: Children and adults with a neurogenic bladder Group        3: children and adults who have a healthy bladder|December 2015|December 17, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02086058||48676|
NCT02086071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC-REBIOP|Feasibility of re Biopsies at Progression|Feasibility of New Biological and Histological Samples at Progression for Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)|GFPC-REBIOP|Groupe Francais De Pneumo-Cancerologie|Yes|Completed|May 2012|May 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|October 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02086071||48675|
NCT02086344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS_hysterectomy|Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy|The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer||University Magna Graecia|Yes|Recruiting|February 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|167|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 22, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086344||48654|
NCT02090842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/40|Milk Proteins, Ambulatory Blood Pressure and Vascular Function|Investigating the Acute and Chronic Effects of Dietary Proteins on Markers of Vascular Function, Ambulatory Blood Pressure, Insulin Resistance and Lipid Metabolism.||University of Reading|Yes|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|38|||Both|30 Years|77 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02090842||48309|
NCT02086760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5580|Ultrasonography Sensibilized by Oral Hydration and Hydronephrosis in Children.|Ultrasonography Sensibilized by Oral Hydration and Hydronephrosis in Children. Is it Useful for Diagnosis and Follow up?||University Hospital, Strasbourg, France|No|Withdrawn|May 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|30 Days|No|||October 2015|October 1, 2015|February 18, 2014||No|no subject enrolled within one year following EC and IRB approvals.|No||https://clinicaltrials.gov/show/NCT02086760||48622|
NCT02087813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-27176|Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses|A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks|A1AT for NMO|Stanford University||Recruiting|March 2014|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|18 Years|75 Years|No|||March 2014|March 12, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087813||48542|
NCT02087293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P000210|e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions|e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions|CEDAR|Brigham and Women's Hospital|No|Active, not recruiting|June 2013|August 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|38400|||Both|21 Years|N/A|No|||August 2015|August 3, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02087293||48582|
NCT02087527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-128-2013|Use of Corticosteroids in Children With Cellulitis|Use of Corticosteroids in Children Hospitalized With Cellulitis: Randomized, Double Blind, Placebo Controlled Trial||Hospital General de Niños Pedro de Elizalde|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|1 Month|18 Years|No|||February 2016|February 26, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02087527||48564|
NCT02087800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS120|Smoking, Stress & Allopregnanolone Response|Effect of Smoking on Stress-Induced Allopregnanolone Response in Women by Menstrual Phase||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|43|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 18 and 40 who either smoke or do not smoke.|August 2015|November 25, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087800||48543|
NCT02088658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015064|Technology Intensified Diabetes Education Study in African Americans|Technology Intensified Diabetes Education Study in African Americans With Type 2 Diabetes|TIDES|Medical University of South Carolina|Yes|Recruiting|May 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|100 Years|No|||September 2015|October 1, 2015|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088658||48477|
NCT02089217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004051|Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial|CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL|CREST-2|Mayo Clinic|Yes|Recruiting|December 2014|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2480|||Both|35 Years|N/A|No|||March 2016|March 24, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089217||48434|
NCT02089230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0116|Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy|Phase I/II Trial of MEK Inhibitor MEK162 in Patients With Relapsed and or Refractory Acute Myeloid Leukemia and Patients With Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy||M.D. Anderson Cancer Center|No|Recruiting|August 2014|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089230||48433|
NCT02089243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-009|Controlled Randomized Vagus Nerve Stimulation (VNS) Therapy Versus Resection (CoRaVNStiR)|Prospective Randomized Controlled Study of Vagus Nerve Stimulation Therapy in the Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Vagus Nerve Stimulation Versus Resection (CoRaVNStiR)|CoRaVNStiR|Xijing Hospital|Yes|Not yet recruiting|June 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|60 Years|No|||March 2014|March 13, 2014|April 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02089243||48432|
NCT02089529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2528(REK)|Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs|Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs: Application of Pharmacotherapeutic Conditioning in Clinical Practice.||University Hospital of North Norway|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|8|||Both|20 Years|N/A|No|||December 2015|December 16, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089529||48410|
NCT02089828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014-021|Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia|Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia||Shanghai Zhongshan Hospital|No|Recruiting|March 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2014|March 17, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089828||48387|
NCT02090699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSNA-RR1318|MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias|Quantification of Diffuse Myocardial Iron Overload Related Interstitial Fibrosis With Cardiac Magnetic Resonance Imaging in Patients With Transfusion-Dependent Anemias|MAFIO|University Health Network, Toronto|No|Completed|July 2013|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with transfusion dependent anemias Age-matched healthy subjects|July 2014|July 16, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02090699||48320|
NCT02090374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM1837|Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen|Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen: Monophosphoryl lipidA, Poly-inosine-cytosine, Poly-inosine-cytosine Stabilised With Poly-L-lysine and Carboxymethylcellulose, Resiquimod, Tuberculin and Timothy Grass Pollen||Imperial College London|No|Recruiting|March 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|174|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|January 12, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02090374||48345|
NCT02090387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL20|Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.|Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.||Abbott Nutrition|No|Recruiting|March 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|76|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090387||48344|
NCT02090673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB001-078|Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea|Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea||AstraZeneca|No|Completed|February 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1711|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, hospital and teaching hospitals|August 2015|August 19, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090673||48322|
NCT02090686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cupping-LBP|Pulsatile Cupping in Low Back Pain|Efficacy of Pulsatile Cupping in Patients With Chronic Low Back Pain - a Randomized Controlled Study.|Cupping-LBP|Charite University, Berlin, Germany||Recruiting|March 2014|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|65 Years|No|||March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090686||48321|
NCT02092259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-NOR-01-CS-001|A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay|A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay in Patients With Signs and Symptoms of Acute Gastroenteritis||Luminex Molecular Diagnostics|No|Recruiting|January 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Stool|Both|N/A|N/A|No|Probability Sample|All comers|June 2015|July 10, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092259||48200|
NCT02091986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589GC00003|A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg|A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma|CHASE 3|AstraZeneca|No|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|279|||Both|6 Years|11 Years|No|||January 2016|January 12, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091986||48221|
NCT02085759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC# 4729|T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects|Th2 Cytokine Responses in Overweight/Obese Subjects||West Penn Allegheny Health System|No|Completed|May 2009|||December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be male or female, aged 18-50 years, and of any race. Subjects must be        healthy with no history of allergies or asthma. Subjects will be placed in one of three        groups based on their BMI: normal, overweight, or obese.|March 2014|March 11, 2014|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT02085759||48699|
NCT02086084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECCO2R in AECOPD|ECCO2R as an Adjunct to NIV in AECOPD|Extra-corporeal CO2 Removal as an Adjunct to Non-Invasive Ventilation in Acute Severe Exacerbations of COPD||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|May 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086084||48674|
NCT02086097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIFE-019-013|Dexketoprofen Trometamol in Postoperative Endodontic Pain|Effectiveness of Dexketoprofen Trometamol in the Management of Postoperative Endodontic Pain. Controlled Clinical Trial of Multiple Doses|DTPEP|Universidad Autonoma de San Luis Potosí|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 6, 2014|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086097||48673|
NCT02086981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSS.13.070|The DETEcT Study - Delirium in Elderly paTiEnts Admitted to Trauma|The DETEcT Study - Delirium in Elderly paTiEnts Admitted to Trauma|DETEcT|Azienda Ospedaliero-Universitaria Careggi|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|672|||Both|65 Years|N/A|No|Non-Probability Sample|Patients admitted to the Department of Orthopedics and Traumatology and in the High        Dependency Unit in the postoperative phase|December 2015|December 25, 2015|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02086981|12 Months|48605|
NCT02087306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001 304|Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection|A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (Chimerix Study CMX001-304)|CMX001 Adv|Chimerix||Active, not recruiting|March 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Months|75 Years|No|||August 2015|August 7, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087306||48581|
NCT02087553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM5050|PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions|Harmful Effects of Red Blood Cell Transfusions Are Mediated by Iron: Pediatric ICU Aim||Columbia University|No|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|Samples Without DNA|Serum and plasma samples both pre- and post-transfusion samples of the transfusate|Both|N/A|21 Years|No|Non-Probability Sample|Hospitalized pediatric patients admitted to the Columbia University Medical Center's        Pediatric ICU|May 2015|May 15, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087553||48562|
NCT02088086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07-4472|BMI Screening and Reporting in Schools: The Fit Study|Randomized Controlled Trial of BMI Screening: Effects on Obesity, Disparities, and Body Satisfaction||University of California, Berkeley|Yes|Active, not recruiting|March 2014|July 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38830|||Both|7 Years|N/A|No|||June 2015|June 18, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02088086||48521|
NCT02088099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008525|Mayo Clinic Traumatic Brain Injury Model System Center: The CONNECT Trial|The CONNECT Trial: A Randomized Pragmatic Clinical Trial Measuring the Effectiveness of a Remotely Provided Complex Brain Rehabilitation Intervention in Improving Participation Outcomes of Individuals With TBI, Their Families, and Local Primary Providers|CONNECT|Mayo Clinic|No|Recruiting|March 2014|September 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088099||48520|
NCT02088320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131355|Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI|Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI||Vanderbilt University|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female sex, age >18 years who are having an echocardiogram done for clinical        reasons.|December 2015|December 8, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088320||48503|
NCT02088632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEO/SDS/01|Botulinum Toxin for the Treatment of Trigeminal Neuralgia|A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia||Thomas Jefferson University|No|Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088632||48479|
NCT02088645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFS-3170-02-2013|177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.|177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.|Lumed|University Hospital, Basel, Switzerland|Yes|Recruiting|April 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02088645||48478|
NCT02088957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01394|Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures|A Randomized, Open-label, Multicenter, Parallel-group, Exploratory Study to Evaluate the Efficacy of Intravenous Brivaracetam and Intravenous Phenytoin in Subjects Experiencing Nonconvulsive Electrographic Seizures||UCB Pharma|Yes|Terminated|March 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|16 Years|N/A|No|||September 2015|September 22, 2015|February 20, 2014|Yes|Yes|Termination of study due to low enrollment. There were no safety issues.|No||https://clinicaltrials.gov/show/NCT02088957||48454|
NCT02088970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0004|Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)|Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.|CXL|Nantes University Hospital|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088970||48453|
NCT02088931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFTX412ST|Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation|A Pilot Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy in Renal Transplant Recipients|TASK|University of California, San Francisco|Yes|Recruiting|March 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|50 Years|No|||January 2015|January 27, 2015|January 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088931||48456|
NCT02088944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yimi-2|a Single-center Registered Clinical Research of Chinese Patients With Moderate to Severe Crohn's Disease|||Nanfang Hospital of Southern Medical University||Not yet recruiting|March 2014|||October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|142|||Both|18 Years|75 Years|No|Probability Sample|moderate to severe CD patients|March 2014|March 13, 2014|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088944|8 Weeks|48455|
NCT02089542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17176|Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery|Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089542||48409|
NCT02089841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.0.2011|Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.|Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania.|ALE|Muhimbili University of Health and Allied Sciences|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|6 Months|120 Months|No|||March 2014|March 17, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089841||48386|
NCT02094989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFH-001|ECG and VCG in Dependence of Body Posture|Prospective, Observational Controlled Trial to Assess the Statistical and the Visual Accuracy of the Individual VCG-ECG-Transformation in Dependence of Posture|EVER|Bern University of Applied Sciences|Yes|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|46|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy men without history of cardiac disorder|March 2014|March 21, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094989||47992|
NCT02086838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9020058|Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy|Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy||Ain Shams University|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Female|20 Years|35 Years|No|||March 2015|March 17, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086838||48616|
NCT02087072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0185|Collaborative Home Visits to Reduce Hospital Readmissions and Improve Medication Use During Transitions of Care|COLLABORATIVE HOME VISITS TO REDUCE HOSPITAL READMISSIONS AND IMPROVE MEDICATION USE DURING TRANSITIONS OF CARE||Ohio State University|No|Active, not recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from the OSU Healthy at Home program that have been recently        discharged from the hospital.|October 2014|October 21, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087072||48598|
NCT02091713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0529-BA-CTIL|Musculoskeletal Injuries' Prediction Tool for Military Combatants in the Israeli Defense Force|Musculoskeletal Injuries' Prediction Tool for Military Combatants in the Israeli Defense Force (FMS)|FMS|Sheba Medical Center|No|Not yet recruiting|August 2014|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|300 soldiers in 3 units will be recruited and will undergo medical evaluation and        functional movment screening as describes in the protocol.|March 2014|March 17, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02091713||48242|
NCT02092532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-AMD-1401|Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)|Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV)|RIVAL|Southeast Retina Center, Georgia|No|Recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 14, 2014|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092532||48179|
NCT02092545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH0002|Heart Obesity Prevention Education|Heart Obesity Prevention Education: Retired NFL Players Weight Management Study|HOPE|Tampa General Hospital|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|25 Years|64 Years|No|||December 2014|December 18, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02092545||48178|
NCT02086110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450072|Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism|A Pilot Study Examining Microbiota Composition in Children With Autism and Gastrointestinal Symptoms After Use of Bifidobacterium Infantis and Milk Oligosaccharides||University of California, Davis|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|10|||Both|2 Years|11 Years|No|||December 2014|December 2, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086110||48672|
NCT02086370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radical_PBS|Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques|Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques. A Randomized Controlled Trial|Rad_PBS|University Magna Graecia|Yes|Completed|March 2014|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|177|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 19, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086370||48652|
NCT02087319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC1-111|Effect of PRP on the Therapy for Hair Growth|Application and Evaluation of PRP on the Therapy for Hair Loss Disorder||China Medical University Hospital|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|70 Years|No|||February 2016|February 29, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087319||48580|
NCT02087839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0787 Phase II|Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC): Phase II|A Phase II Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Withdrawn|October 2008|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|March 12, 2014|Yes|Yes|Original study did not progress to Phase II.|No||https://clinicaltrials.gov/show/NCT02087839||48540|
NCT02087826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000255|Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test|A Study to Understand the Influence of Common Variation at SLC16A11 and Other Genes on the Physiologic Response to a Mixed Meal Tolerance Test (SIGMA2 MGH)|SIGMA2MGH|Massachusetts General Hospital|Yes|Recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087826||48541|
NCT02088112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791PC00001|MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)||MedImmune LLC|No|Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|100 Years|No|||March 2016|March 2, 2016|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088112||48519|
NCT02088333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 59A13|Effectiveness of an mHealth Colorectal Cancer Screening Intervention|A Primary Care Multilevel mHealth Colorectal Cancer Screening (mCRC) Intervention|mCRC|Wake Forest School of Medicine|No|Recruiting|June 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|450|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088333||48502|
NCT02089555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066145|African American Alzheimer's Progression Markers - CSF and Neuro-Imaging||A3PM|Emory University|No|Active, not recruiting|September 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|135|Samples With DNA|Cerebrospinal fluid, plasma, and DNA will be saved.|Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|African American and non-Hispanic white seniors with normal cognition, mild cognitive        impairment (MCI), or mild Alzheimer's disease.|December 2015|December 3, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089555||48408|
NCT02089568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POWAR|Prophylaxis Of Wound Infections- Antibiotics in Renal Donation|Are Prophylactic Antibiotics Necessary Before Laparoscopic Living Kidney Donation? A Double Blind, Randomised, Controlled Trial.|POWAR|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|July 2012|April 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089568||48407|
NCT02089256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LI20/1101|Effect of Repeated Administration of Liraglutide on Insulinogenic Indices|Effect of Repeated Administration of Liraglutide on Insulinogenic Indices||University of Tartu|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089256||48431|
NCT02089269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOM-01281|Tumor Registry Pancreatic Cancer|Clinical Registry on Treatment Reality and Therapy Sequences in Patients With Metastatic or Locally Advanced Pancreatic Cancer.||iOMEDICO AG|No|Recruiting|December 2013|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pancreatic cancer undergoing antineoplastic treatment.|February 2016|February 23, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089269||48430|
NCT02090140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27561|Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects|Randomized Controlled Trial of Microfracture Versus Adipose Derived Stem Cells for the Treatment of Isolated Articular Cartilage Defects||Stanford University|No|Recruiting|November 2015|December 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|50 Years|No|||November 2015|November 25, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02090140||48363|
NCT02090400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-2012-01|Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women|Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates||Instituto Palacios|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|110|||Female|55 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 8, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02090400||48343|
NCT02090413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS406|Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis|A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules|ASSURE|Biogen|No|Active, not recruiting|May 2014|December 2015|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|241|||Both|18 Years|N/A|No|||June 2015|September 17, 2015|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090413||48342|
NCT02086851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13833|Study of a Structured Parent Intervention on Adolescent Weight Loss Modification Program.|Impact of a Structured Parent Intervention on Weight Loss and Behavioral Change in Overweight Adolescents Enrolled in a Lifestyle Modification Program||Virginia Commonwealth University|Yes|Completed|September 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086851||48615|
NCT02092844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-102|Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause|Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause||The University of Texas Medical Branch, Galveston|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|40 Years|65 Years|No|||September 2015|September 23, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02092844||48155|
NCT02092025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279-011|Azilsartan Tablets Special Drug Use Surveillance: Long-term Use|Azilsartan Tablets Special Drug Use Surveillance: Long-term Use||Takeda|No|Active, not recruiting|June 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3432|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension|August 2014|August 20, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02092025||48218|
NCT02093143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2008/78|Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia|Evaluation of the Impact of Adding Remifentanil to Propofol on the Conditions of the Diagnostic Panendoscopy of the Upper Airway Under General Anesthesia With Tubeless Spontaneous Ventilation.|ENDOTANIL|Centre Hospitalier Universitaire de Besancon|No|Completed|June 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|256|||Both|18 Years|80 Years|No|||November 2008|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093143||48132|
NCT02086383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5380/001|Physical Activity and Self-Efficacy After Pulmonary Rehabilitation|Short Term Effects of Pulmonary Rehabilitation on Level of Physical Activity and Self-Efficacy in Patients With Chronic Obstructive Pulmonary Disease.||University College, London|No|Recruiting|April 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|90 Years|No|Non-Probability Sample|This study involves patients with chronic obstructive pulmonary disease (COPD), whose        diagnosis is confirmed by spirometry|May 2014|May 27, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086383|10 Weeks|48651|
NCT02082353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RDCRN PIDTC-6903|Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995|Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|June 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|1480|Samples With DNA|Peripheral blood, skin swabs and/or stool samples|Both|N/A|N/A|No|Non-Probability Sample|Institutions participating in Rare Diseases Clinical Research Network (RDCRN)|March 2016|March 24, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082353||48960|
NCT02082366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-RR-560-CTIL|Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)|Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082366||48959|
NCT02086396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACarvalho|Effect of Weight Loss Diet and Pumpkin Seed Flour Consumption on Obese Women|Effect of Hypoenergetic Diet Combined With Pumpkin Seed Flour Consumption on Obese Women||Universidade Federal do Rio de Janeiro|No|Completed|October 2011|September 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086396||48650|
NCT02087566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LZDPPT6|Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)|Single-Dose Linezolid Pharmacokinetics In Critically Ill Patients With Impaired Renal Function Especially Chronic Haemodialysis Patients|LZDPPT6|Damanhour University|Yes|Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Male|22 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02087566||48561|
NCT02088138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FESCP01|Functional Electrical Stimulation in Cardiac Patients|Effects of Functional Electrical Stimulation on Physical Performance of Patients in Cardiac Rehabilitation||Universidade Federal de Santa Maria|Yes|Completed|September 2010|June 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|80 Years|No|||March 2014|March 12, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02088138||48517|
NCT02088125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke|Dynamic Ventilatory and Asymmetry of the Chest Wall During Breath Stacking and Volume-oriented Incentive Spirometer|Dynamic Ventilatory and Asymmetry of the Chest Wall During Breath Stacking and Volume-oriented Incentive Spirometer in Patients After Stroke: Crossover Clinical Trial||Universidade Federal de Pernambuco|No|Recruiting|September 2013|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|80 Years|No|||March 2014|March 12, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02088125||48518|
NCT02088346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-Tele-001|Acute Stroke Advancing Program Using Telemedicine|Intravenous Thrombolysis Guided by Telemedicine Consultation System for Acute Ischemic Stroke Patients in China|ASAP-Tel|Xijing Hospital|Yes|Recruiting|August 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|80 Years|No|Non-Probability Sample|Ischemic stroke patients arriving in the local hospitals within 4.5 hours of symptom onset|September 2014|June 23, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02088346||48501|
NCT02088359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB000123|Compare of Effectiveness Cycled Light or Near Darkness on Growth Parameters in Preterm Infants|||Zekai Tahir Burak Women's Health Research and Education Hospital||Completed|June 2012|January 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|N/A|24 Hours|Accepts Healthy Volunteers|Probability Sample|Preterm infant (<32 gestational weeks) were enrolled in this study.|June 2012|July 7, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02088359||48500|
NCT02088671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|925-0701-DCI|Effectiveness of the NeuroSENSE for Monitoring the Hypnotic Depth of Anesthesia|A Prospective, Blinded, Clinical Study for Assessing the Effectiveness of the NeuroSENSE for Monitoring the Hypnotic Depth of Anesthesia (DOA)||NeuroWave Systems Inc.|No|Recruiting|May 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|76|||Both|18 Years|75 Years|No|||May 2014|May 21, 2014|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02088671||48476|
NCT02089867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 632|Plant Sterols Effect on Previous Statin Therapy|A Randomized Open Label Trial to Assess the Effect of Plant Sterols Associated With Ezetimibe in LDL-cholesterol Levels in Coronary Patients Previously on Statin Therapy||Pontifícia Universidade Católica do Paraná|No|Completed|October 2006|January 2008|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089867||48384|
NCT02089854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-breast-TNBC|Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer|Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients|AETNBC|Peking Union Medical College Hospital||Recruiting|November 2014|||April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|80 Years|No|||January 2015|January 3, 2015|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089854||48385|
NCT02090426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPAL-763|Health Care Hotspotting: A Randomized Controlled Trial|Health Care Hotspotting: A Randomized Controlled Trial||Abdul Latif Jameel Poverty Action Lab|No|Recruiting|March 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|800|||Both|19 Years|80 Years|No|||January 2016|January 8, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090426||48341|
NCT02090712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838/11|Sao Paulo ST Segment Elevation Myocardial Infarction (STEMI) Registry|Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.||Federal University of São Paulo|No|Enrolling by invitation|January 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to an emergency room included in the network or being attended by        ambulances in this same area, with acute ST segment elevation myocardial infarction will        be assesed for thrombolysis (preferable) or primary angioplasty (if within 90' patient        would be in the cath lab or when thrombolysis is not possible or contra-indicated) and        immediately sent to a tertiary center for catheterization and angioplasty of the culprit        artery.|March 2014|March 17, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02090712|5 Years|48319|
NCT02094703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-SOL-01-2012|The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females|The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females||Dr Cipto Mangunkusumo General Hospital||Recruiting|April 2013|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|65 Years|No|||March 2014|March 19, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02094703||48014|
NCT02095275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111012RIB|Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients|Exploring the Relationship Among Brain Natriuretic Peptide, Fluid Status and Acute Kidney Injury in Critically Ill Patients||National Taiwan University Hospital|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Serum BNP|Both|18 Years|N/A|No|Probability Sample|Critically ill patients in intensive care unit(older than 18 y/o)|March 2014|March 20, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02095275||47970|
NCT02091232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The ONE Study|Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)|Renal Transplantation Followed By Infusion of T-Regulatory Cells Made With Belatacept Ex-Vivo||Massachusetts General Hospital|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091232||48279|
NCT02090920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106006106|Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor|Individualized Dosing of Nifedipine for Tocolysis in Preterm Labor||Indiana University|Yes|Recruiting|July 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Plasma for determination of nifedipine and oxidized nifedipine concentrations Blood for DNA|Female|18 Years|N/A|No|Probability Sample|Pregnant Women with preterm labor who have been prescribed immediate release nifedipine        and admitted at Eskenazi Health Hospital or Indiana University Methodist Hospital.|February 2016|February 22, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02090920||48303|
NCT02090933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00524|Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers|Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation||National Cancer Institute (NCI)||Completed|March 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2015|March 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02090933||48302|
NCT02090946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507/WSHT/2012 and 11/163/WIL|The Experiences of Parents Learning Physiotherapy Techniques for Their Child|The Experiences of Parents Learning Physiotherapy Techniques for Their Child||Western Sussex Hospitals NHS Trust|No|Completed|October 2012|September 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|6|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|convenience sample from the Arun, Adur and Worthing region, UK.|March 2014|March 14, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02090946||48301|
NCT02091466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388/08 - FCMSCSP|Pre-warming Prevents Hypothermia in Elective Cesarean Section|Pre-warming With Thermal Gown Prevents Maternal Hypothermia in Elective Cesarean Section|hypothermia|Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|40 Years|No|||September 2014|October 1, 2015|March 13, 2014||No||No|March 20, 2014|https://clinicaltrials.gov/show/NCT02091466||48261|
NCT02089698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.03|Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification|Mini-flared Kelman Tip and Reverse Tip With Torsional Phaco: Prospective Randomized Comparative Study||Hospital Oftalmologico de Brasilia|Yes|Completed|September 2013|February 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 15, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02089698||48397|
NCT02093442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:03292412.0.0000.5440|Endometrial Scratching for Cryopreserved Embryo Transfer|Endometrial Scratching for Cryopreserved Embryo Transfer: a Randomized Controlled Trial||University of Sao Paulo|No|Enrolling by invitation|July 2014|February 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Female|18 Years|40 Years|No|||May 2015|May 28, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093442||48110|
NCT02089958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AE 003|Standardization of Laparoscopic Hernia Repair|Standardization of Laparoscopic Intraperitoneal Onlay Mesh Augmentation for Incisional Hernia Repair: Impact on Clinical Outcomes and Quality-of-Life - Open Prospective Observational Multicentre Cohort Study|LIPOM|Klinikum Fulda|Yes|Recruiting|September 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Pts. with incisional hernia following prior abdominal surgery|December 2014|December 12, 2014|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02089958||48377|
NCT02089971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL23|Muscle Mass and Function in Chinese Adults|Muscle Mass and Function in Chinese Adults||Abbott Nutrition|No|Completed|March 2014|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|412|||Both|25 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cross-sectional, observational study of young Chinese adults|January 2015|January 16, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089971||48376|
NCT02086136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection|Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study|ADVISED|Azienda Ospedaliero-Universitaria Careggi|No|Recruiting|September 2014|September 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive adult patients with suspected AD presenting to Emergency Departments will be        enrolled at the time of initial medical evaluation and before the establishment of a final        diagnosis|November 2015|November 23, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086136||48670|
NCT02082379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202438|In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route|In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route||Arkansas Children's Hospital Research Institute||Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|21|||Both|N/A|8 Months|Accepts Healthy Volunteers|||January 2016|January 6, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02082379||48958|
NCT02087852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-218|Kidney Cancer DNA Registry|Kidney Cancer DNA Registry||Memorial Sloan Kettering Cancer Center||Recruiting|March 2014|||March 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|750|Samples With DNA|saliva specimen      tissue (when available)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urologists, clinical geneticists, and medical oncologists at MSKCC, along with study        personnel will identify patients, family members, and unaffected controls that may be        eligible for the registry. Patients and families may also be directly referred to the        MSKCC study team by any MSKCC physician, external physician, or by the family itself.|January 2016|January 5, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02087852||48539|
NCT02088372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GK4|Prospective Multi-Center Study on Vanguard With E1 Bearing|Evaluate Clinical Performance of Vanguard Knee With E1 Bearing in Korean Patient Population|VGRDE1|Biomet, Inc.|Yes|Active, not recruiting|November 2012|December 2023|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|Painful and disabled knee joint resulting from osteoarthritis or traumatic arthritis where        one or more compartments are involved, varus, valgus, or posttraumatic deformity, and        revision of unsuccessful osteotomy at Chungnam Nat'l Univ. Hospital, Kangwon Nat'l Univ.        Hospital, Gacheon Uni. Gil Medical Center, and Chonbuk Nat'l Univ. Hospital.|July 2015|July 20, 2015|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02088372||48499|
NCT02088684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2108|Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer|A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer||Novartis|No|Recruiting|May 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|216|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02088684||48475|
NCT02088983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013031|Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia|Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia||University of Ottawa||Not yet recruiting|April 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|18 Years|35 Years|No|||March 2014|March 14, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088983||48452|
NCT02089282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-369|Clavicular Shortening Post-fracture - Does it Change? - a Prospective Study of 70 Patients|||Holbaek Sygehus|Yes|Recruiting|March 2014|||August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|17 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Clavicular fractures|March 2014|March 14, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089282|21 Days|48429|
NCT02089295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501035|Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions|An Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Dose Proportionality of 5 Mg, 20 Mg and 40 Mg of PF-00345439 Formulation K Under Intermediate-fat Fed Conditions in Healthy Volunteers||Pfizer|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089295||48428|
NCT02089594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #7381|Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)|Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)||Louisiana State University Health Sciences Center in New Orleans|Yes|Recruiting|May 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||June 2014|June 9, 2014|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089594||48405|
NCT02093650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081/56|Black Cohosh Extract for Treatment of Moderate to Severe Menopausal Symptoms|Black Cohosh Extract for the Treatment of Moderate to Severe Menopausal Symptoms: a Randomized-placebo Controlled Trial|BCOMS|Navamindradhiraj University|Yes|Recruiting|March 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|40 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093650||48095|
NCT02093663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-319|Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases|PACE|Shire||Recruiting|April 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|5 Years|17 Years|No|||November 2015|November 23, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093663||48094|
NCT02090153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL for AGC|Study of S-1 Plus LV for Advanced Gastric Cancer|Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer||Sun Yat-sen University|No|Completed|July 2011|March 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090153||48362|
NCT02094469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOA-1302i|Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina|A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)|STELLA_Ext|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|December 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|20 Years|80 Years|No|||January 2016|January 27, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094469||48032|
NCT02094690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259.691|Physiotherapy for Radiation-induced Trismus|Prophylactic Physiotherapy Development Of Radiation-Induced Trismus In Patients With Head And Neck Cancer: Randomized Controlled Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Completed|June 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|July 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02094690||48015|
NCT02094976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP_protocol|Comparison of Intraabdominal Pressure|Comparison of Intraabdominal Pressure and Respiratory Parameter Changes According to Positional Apparatus in the Prone Position|IAP|Seoul National University Hospital|Yes|Recruiting|September 2013|||September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|138|||Both|20 Years|80 Years|No|||March 2014|March 20, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094976||47993|
NCT02091245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-563|Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML|Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.||Dana-Farber Cancer Institute|Yes|Recruiting|March 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Months|21 Years|No|||February 2016|February 11, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091245||48278|
NCT02091219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000124-1954|Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function|The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function||University of California, Los Angeles|No|Recruiting|June 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091219||48280|
NCT02091999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASG-22CE-13-2|A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4||Astellas Pharma Inc|No|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02091999||48220|
NCT02092012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/489|Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on Abdominal Hysterectomy Patients|Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on the Patients That is Undergoing Abdominal Hysterectomy||TC Erciyes University|No|Recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||March 2014|March 20, 2014|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092012||48219|
NCT02089997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-001|Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)|Benet 75 mg Tablets Special Drug Use Surveillance: Long-term Use (12-month Treatment Survey)||Takeda|No|Active, not recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|Osteoporosis|August 2015|August 24, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02089997||48374|
NCT02090270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-13-0275-CTIL|Hair Cortisol and the Risk of Stroke|Hair Cortisol and the Risk of Stroke||Meir Medical Center|No|Completed|March 2014|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Hair|Male|18 Years|N/A|No|Non-Probability Sample|Cases - Consenting patients admitted to internal medicine wards with acute ischemic (non        cardioembolic) stroke.        Controls - Consenting patients admitted to internal medicine wards due to indications        other than stoke or acute myocardial infarction.|January 2015|March 22, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02090270||48353|
NCT02089984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH086951|Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders|Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders||Center for Psychological Consultation|No|Completed|September 2011|December 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089984||48375|
NCT02090244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH spinal stenosis|Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?|Förbättrar PTH Postero-lateral fusionsläkning Vid Ryggkirurgi?||University Hospital, Linkoeping|Yes|Recruiting|August 2012|May 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||December 2014|December 9, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02090244||48355|
NCT02093156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130910-3|A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy|A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy||Fourth Military Medical University|Yes|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|605|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective study involving two tertiary centers in China. The patients of the        training cohort were enrolled from the Endoscopy Center of Xijing Hospital of Digestive        Diseases in China. The patients of the validation cohort were enrolled from the Shaanxi        Second People's Hospital in China.|March 2014|March 19, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093156|1 Week|48131|
NCT02093169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15868A|D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound|Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound||H. Lundbeck A/S|No|Completed|February 2014|||June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093169||48130|
NCT02093455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007023|Effects of Chardonnay Seed Flour on Vascular Health|Effects of Chardonnay Seed Flour on Vascular Health||Mayo Clinic|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||May 2014|May 9, 2014|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093455||48109|
NCT02092233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-HSV-01-CS-001|A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients|A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients||Luminex Molecular Diagnostics|No|Completed|January 2014|||March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1963|Samples With DNA|Patient lesion swab specimens|Both|N/A|N/A|No|Probability Sample|Clinical lesions from pediatic or adult patients suspected of having herpes infection|March 2014|July 9, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092233||48202|
NCT02092779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHD2014|Growth Hormone Deficiency and Empty Sella Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study|Growth Hormone Deficiency, Empty Sella and Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study.||University of Roma La Sapienza|No|Completed|March 2007|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|447|||Both|18 Years|65 Years|No|Non-Probability Sample|Obese|March 2014|March 18, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02092779||48160|
NCT02088385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/575/E|Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study|Pilot Study of a Randomized Controlled Trial Comparing Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers||Changi General Hospital|No|Recruiting|November 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||February 2015|February 4, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02088385||48498|
NCT02088697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-13-003|A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects|||Otsuka Pharmaceutical Co., Ltd.||Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02088697||48474|
NCT02088996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studie 3|Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy|Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy.||Uppsala University|No|Active, not recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02088996||48451|
NCT02089308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00116 TD 1 06|Nicotine Patch - Bioequivalence Study|||Pierre Fabre Medicament||Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|74|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089308||48427|
NCT02089581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMX1508|A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication|An Open-label, Randomised, Crossover, Single-dose, Study in Healthy Subjects to Compare the Pharmacokinetics of Two Formulations of a Strong Pain Killer With a Marketed Reference Product in a Fasted or Fed State||Mundipharma Research Limited|No|Completed|April 2014|July 2015|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02089581||48406|
NCT02093351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081CC00001|To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer|An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect of the Anti-hormonal Agents on Olaparib, Following Administration in Patients With Advanced Solid Cancer||AstraZeneca|No|Active, not recruiting|September 2014|May 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|97|||Both|18 Years|130 Years|No|||March 2016|March 11, 2016|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093351||48117|
NCT02093364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR Radial Head Prosthesis|A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)|A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)||AO Clinical Investigation and Documentation|No|Withdrawn|July 2015|||May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care centers|January 2016|January 5, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093364|12 Months|48116|
NCT02093962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-415|Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer|A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer||Threshold Pharmaceuticals|Yes|Active, not recruiting|March 2014|April 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093962||48071|
NCT02093975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRAA3|Videoconferencing Between Ambulances and Physician Manned Rapid Response Vehicles, Effects on On-site Patient Treatment and Patterns of Referral|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 3: Videoconferencing Between Ambulances and Physician Manned Rapid Response Vehicles, Effects on On-site Patient Treatment and Pattern of Referral||University of Aarhus|Yes|Withdrawn|May 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||December 2015|December 7, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02093975||48070|
NCT02095002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014315V|The Effect of Modified Valsalva Maneuver on Filling Degree of Internal Jugular Vein|The Effect of Modified Valsalva Maneuver on Filling Degree of Internal Jugular Vein||Fudan University||Completed|January 2014|||March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|60 Years|No|Probability Sample|female genecology patients, age 18-60 years old; weight 45-70 kg; body mass index (BMI)>20        kg/m2 and <30 kg/m2; American Society of Anesthesiologists (ASA) grade I-II.        The exclusion criteria were as follows: a history of chronic throat disease; upper        respiratory tract infection within two weeks before surgery; and history of mental illness        or communication barriers.|March 2014|March 21, 2014|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02095002||47991|
NCT02090998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012002610|Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines|A Comparison of the Efficacy of 5% Lidocaine Anesthetic to Provide SPGB Vs. Elavil for the Treatment of Transformed Migraine||Rutgers, The State University of New Jersey|No|Enrolling by invitation|May 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02090998||48297|
NCT02091739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3090_1|Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions|SIAXI|Merz Pharmaceuticals GmbH|Yes|Active, not recruiting|April 2014|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|184|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02091739||48240|
NCT02091700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT1010|ObseRvation of PeripHEral rEtinal Morphology in Normals|ObseRvation of PeripHEral rEtinal Morphology in Normals|ORPHEE|Optos, PLC.|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal subjects with no known retinal disease.|August 2015|August 24, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02091700||48243|
NCT02090283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004|Open Label Extension Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa|An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa||Scioderm, Inc.|No|Active, not recruiting|March 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|6 Months|N/A|No|||February 2016|February 26, 2016|March 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02090283||48352|
NCT02090257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HL111492|Pediatric Heart Transplantation: Transitioning to Adult Care|Pediatric Heart Transplantation: Transitioning to Adult Care|TRANSIT|Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|March 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02090257||48354|
NCT02093468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-188-07|Evaluation of MST-188 in Acute Lower Limb Ischemia|Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy of MST-188 in Subjects With Acute Lower Limb Ischemia Receiving Catheter-Directed Recombinant Tissue Plasminogen Activator||Mast Therapeutics, Inc.|Yes|Terminated|June 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|4|||Both|30 Years|80 Years|No|||December 2015|December 11, 2015|March 18, 2014|Yes|Yes|Program discontinued to persue alternate indications.|No||https://clinicaltrials.gov/show/NCT02093468||48108|
NCT02093780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035413|Personalized "Alberta" Diet for Prevention of Relapse in Ulcerative Colitis|A Dietary Approach to Reduce the Frequency of Relapse in Ulcerative Colitis Patients: a Randomized Controlled Clinical Trial Study||University of Alberta|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|75 Years|No|||April 2015|April 28, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093780||48085|
NCT02094040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3800H0.52-0059|Municipality-based Post-discharge Follow-up Visits|Effect of Municipality-based Post-discharge Follow-up Visit Including the Primary Physician on Early Re-hospitalization in High Risk People of 65+ Years. A Randomised Controlled Trial.||Holbaek Sygehus|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|531|||Both|65 Years|N/A|No|||March 2014|March 19, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02094040||48065|
NCT02094053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-345|A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.|A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.||Eisai Inc.|No|Active, not recruiting|September 2013|June 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|15 Years|39 Years|No|||March 2016|March 10, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094053||48064|
NCT02092792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29146|A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors|A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS||Genentech, Inc.||Recruiting|April 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092792||48159|
NCT02092506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/389/E|RCT: Triple vs Sequential vs Concomitant Therapy H Pylori|A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection||Changi General Hospital|Yes|Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|462|||Both|21 Years|N/A|No|||July 2014|July 6, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02092506||48181|
NCT02092766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIMORU005|Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria|Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria|DHART|University of Oxford|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|6 Months|14 Years|No|||May 2015|May 29, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02092766||48161|
NCT02093078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120926-01H|Cognitive Aids With Roles Defined (CARD) for Obstetrical Crises: A Multisite Cohort Study|Cognitive Aids With Roles Defined (CARD) for Obstetrical Crises: A Multisite Cohort Study||Ottawa Hospital Research Institute|No|Recruiting|January 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twelve obstetrical unit teams (4 registered nurses (RN), 1 operating room attendant, 1        respiratory therapist (RT) assisting anesthesia, 1 RT assisting neonatal, 2 neonatal RNs)        will be recruited for the study|October 2015|October 21, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02093078||48137|
NCT02094222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13110219|Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease|Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease||University of Pittsburgh||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|130 Days|21 Years||||February 2016|February 12, 2016|March 19, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02094222||48051|
NCT02094209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSmartFix|Focused Registry SmartFix|Clinical Data Collection With a Novel Biofeedback Technology for Continuous Monitoring of Bone Healing|FRSmartFix|AO Clinical Investigation and Documentation|Yes|Recruiting|January 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Tibia shaft fracture and external fracture fixation (AO large external        fixator).        Patients capable of at least partial weight-bearing (or expected to do so in the course of        healing).|January 2015|January 5, 2016|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094209|6 Months|48052|
NCT02094482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08138.1|Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)|Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)||Medartis AG||Recruiting|April 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094482||48031|
NCT02094716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185-7851-201|A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of PF-045 and PF-055 for the Treatment of Scabies|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison Study of the Safety and Efficacy of PF-055 Versus PF-045 Versus Vehicle in Subjects With Sarcoptes Scabiei||Renaissance Pharma, Inc.|Yes|Active, not recruiting|March 2014|June 2015|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Both|6 Months|65 Years|No|||May 2015|May 6, 2015|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02094716||48013|
NCT02095015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-001-801|Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)|Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project)||Shire|No|Terminated|March 2014|September 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|160|||Male|N/A|7 Years|No|Non-Probability Sample|Males of any ethnic background or race, <7 years of age or under, who have had or are        scheduled for adenoidectomy and/or tonsillectomy and/or tympanostomy (alone or in        combination), will be enrolled. In addition, the subjects must have previous surgical        repair or presence of inguinal and/or umbilical hernia.|June 2015|June 24, 2015|March 20, 2014||No|terminated for not meeting enrollment goals|No||https://clinicaltrials.gov/show/NCT02095015||47990|
NCT02091492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vinforce_006|Teriparatide for Fracture Repair in Humans|Teriparatide for Fracture Repair in Humans: A Prospective, Randomized, Double-blind Placebo-controlled Pilot Study in Female and Male Patients With Proximal Humerus Fracture: The TERAFRAP Study|TERAFRAP|Medical University of Vienna|Yes|Withdrawn|June 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|60 Years|90 Years|No|||September 2015|September 16, 2015|March 13, 2014|Yes|Yes|no participants|No||https://clinicaltrials.gov/show/NCT02091492||48259|
NCT02091726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicirc 003|Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive|Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive|Unicirc003|Simunye Primary Health Care|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Male|18 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 14, 2014||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT02091726||48241|
NCT02088762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-08-10|Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)|Impact of the Excision of Melanoma > 2mm in Thickness With 1cm Surgical Margins on Survival of the Patients in Comparison to 2 cm Surgical Margins||University Hospital Inselspital, Berne|No|Active, not recruiting|January 1997|June 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|Patient with melanom of a tumourthickness above 2 mm admitted to the University Hospital        of Bern, Inselspital|March 2014|March 14, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02088762||48469|
NCT02092038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH0001|Preoperative Chemoradiation for Glioblastoma|Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma||Tampa General Hospital|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||November 2015|November 7, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02092038||48217|
NCT02091479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108097|Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage|Randomized Assay Evaluating the Risk/Benefit of Early Versus Late Resumption of Anticoagulation in Patients With Major, Non-trauma Related Hemorrhage Occurring While on Anticoagulant Treatment for a High Risk of Thrombosis.|RATHER|Centre Hospitalier Universitaire de Saint Etienne|Yes|Terminated|January 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|90 Years|No|||March 2016|March 9, 2016|March 7, 2014||No|inclusion rate insufficient|No||https://clinicaltrials.gov/show/NCT02091479||48260|
NCT02092285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8259-032|Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)|Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis|GO-COLITIS|Merck Sharp & Dohme Corp.|No|Active, not recruiting|May 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092285||48198|
NCT02090036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0.2014|Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes|Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes.||Muhimbili University of Health and Allied Sciences|Yes|Completed|July 2014|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|220|||Both|1 Year|N/A|No|||December 2014|December 5, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02090036||48371|
NCT02093481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2013/241|Effects of Dietary Fibre on Glucose Metabolism and Satiety|Intrinsic Indigestible Carbohydrates as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety||Lund University|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|19|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02093481||48107|
NCT02093494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT1303|Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device When Collected Through Peripheral Intravenous Catheters|A Randomized, Open Label Study to Evaluate the Effectiveness of the MMT Initial Specimen Diversion Device in Reducing Blood Culture Contamination Compared to Laboratory Standard Procedures When Collected Through Peripheral Intravenous Catheters (PIVC)||Magnolia Medical Technologies, Inc.|No|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|4444|||Both|19 Years|N/A|No|||March 2014|April 12, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093494||48106|
NCT02093793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4007|Safety and Effectiveness Study of the Precision SCS System Adapted for High-Rate Spinal Cord Stimulation|A Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Precision Spinal Cord Stimulator System Adapted for High-Rate Spinal Cord Stimulation|ACCELERATE|Boston Scientific Corporation|Yes|Recruiting|March 2014|October 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|406|||Both|22 Years|N/A|No|||December 2015|December 3, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02093793||48084|
NCT02094066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/683|The Effect of Tranexamic Acid for Total Hip Arthroplasty|The Effects of High Doze Tranexamic Acid Application on Hemorrhage, Blood Transfusion, Fibrin Degradation Products, and Kidney Functions for Total Hip Arthroplasty||TC Erciyes University|No|Recruiting|March 2014|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094066||48063|
NCT02094079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pregnant hypo|Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism|Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women||Herlev Hospital|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|||Female|18 Years|45 Years|No|Probability Sample|A retrospective study of consecutive pregnant women with L-T4 treated hypothyroidism        followed at the outpatient clinic at the Endocrinology Unit, Herlev Hospital, Denmark        during 2012|March 2015|March 17, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02094079||48062|
NCT02092831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29284|A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers|A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS||Genentech, Inc.||Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092831||48156|
NCT02093091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TantaU-Nano|Clinical Evaluation of Nanoionomer Filling in Primary Teeth|Two-year Clinical Performance in Primary Teeth of Nano-filled Versus Conventional Resin Modified Glass Ionomer Restorations|CENFPT|Tanta University|Yes|Completed|June 2011|October 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|5 Years|8 Years|No|||March 2014|March 17, 2014|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02093091||48136|
NCT02093676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0770-YRK-CTIL|Applying the "New Authority" Model in the Treatment of Poorly Controlled Diabetic Adolescents and Their Families|Development and Assessment of a Treatment Protocol for Poorly Controlled Diabetic (Type 1) Adolescents, Based on "The New Authority" Model||Sheba Medical Center|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|12 Years|17 Years|No|||November 2015|November 19, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02093676||48093|
NCT02093689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS302-ILR-006|A Randomized, Placebo-controlled Study in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery||Omeros Corporation|No|Terminated|February 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|N/A|No|||August 2014|April 20, 2015|March 18, 2014|Yes|Yes|Pupil measurement methodology determined not to be appropriate in this population.|No||https://clinicaltrials.gov/show/NCT02093689||48092|
NCT02093988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00595|Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial|Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial||University of British Columbia|Yes|Not yet recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|8 Years|21 Years|No|||November 2015|November 30, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02093988||48069|
NCT02094755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00047/ISSBRIL0152|ASA/Plavix Resistance CLI|Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia||University of Southern California||Recruiting|June 2013|June 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood Draw|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The patient population will include one-hundred patients with a diagnosis of CLI. We will        only include in the study CLI patients who as part of their medical treatment are        receiving dual antiplatelet therapy with aspirin 81 mg and clopidogrel 75 mg daily.|October 2014|October 28, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02094755||48010|
NCT02094495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC 2014-0112-0001|Pilot Study About Tamoxifen Therapy for Breast Cancer Patients|Pilot Study to Evaluate the Knowledge and Understanding on Tamoxifen Therapy for Breast Cancer Patients||National Cancer Center, Korea|No|Recruiting|June 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|breast cancer patients who take tamoxifen at National Cancer Center|June 2014|June 24, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02094495||48030|
NCT02094729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAN2401-J081-104|A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease||Eisai Inc.|No|Completed|September 2013|May 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|26|||Both|50 Years|90 Years|No|||June 2015|June 4, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02094729||48012|
NCT02094742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.2|BIG Molecular Screening Feasibility Study|The BIG Molecular Screening Feasibility Study:Testing the IT Infrastructure and Logistics of a Molecular Screening Program|BIG MS Pilot|Jules Bordet Institute|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|October 14, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02094742||48011|
NCT02091258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 14/0110|Tooth Loss in Periodontitis Patients|Tooth Loss in Periodontitis Patients on Long-term Maintenance in Private Practice||University College, London|No|Recruiting|June 2014|December 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|16 Years|75 Years|No|Probability Sample|200 patients with periodontitis on maintenance therapy (after initial/ corrective        periodontal therapy) will be included in the study|September 2015|September 1, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091258||48277|
NCT02088489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF vs Tc|Thermocool SF Catheter Versus Thermocool Catheter in Isthmus-dependent Atrial Flutter Ablation|Effectiveness and Safety of Porous Tip Irrigated Ablation Catheter Versus Conventional Irrigated Catheter in Isthmus Dependent Atrial Flutter Ablation: a Randomized Study|Cathena|Hospital Clinic of Barcelona|No|Active, not recruiting|November 2012|April 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02088489||48490|
NCT02089100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00142-43|Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer|Multicentric Phase III Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Metastatic Breast Cancer in First-line Treatment|STEREO-SEIN|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|February 2014|February 2020|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089100||48443|
NCT02089113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-14-003|Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery|||Ocular Therapeutix, Inc.|No|Completed|April 2014|April 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||October 2014|May 15, 2015|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02089113||48442|
NCT02089074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1224a|Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack|Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months||Norwegian University of Science and Technology|No|Active, not recruiting|November 2012|June 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|No|||November 2015|November 26, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02089074||48445|
NCT02089087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFZ533X2101|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients||Novartis|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089087||48444|
NCT02092298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0989|Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer|A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02092298||48197|
NCT02092584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5144|Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.|Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease.||Tehran University of Medical Sciences|Yes|Completed|December 2011|October 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Male|45 Years|65 Years|No|||March 2014|March 18, 2014|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02092584||48175|
NCT02089386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404013|Tamoxifen to Treat Barrett's Metaplasia|Tamoxifen to Treat Barrett's Metaplasia||Washington University School of Medicine|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02089386||48421|
NCT02090049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUR-3825|Appetite Regulation by a Breakfast Soft Bread|Appetite Ratings, Postprandial Glucose, Insulin and Gastrointestinal Hormone Responses After the Intake of an Enriched Fiber and Protein Breakfast Soft Bread in Healthy Adults||Puratos|No|Completed|October 2012|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02090049||48370|
NCT02093507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 172/2|Effectiveness of Parent's Manipulation in Newborn With Metatarsus Adducts. a Randomized Controlled Trial|Effectiveness of Parent's Manipulation in Newborn With Metatarsus Adducts.a Randomized Controlled Trial||Mahidol University|No|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|1 Month|No|||March 2014|March 20, 2014|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02093507||48105|
NCT02093806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0140-13-BNZ|Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery|Clinical Applications of Round Window High Resolution Computerised Tomography Anatomy in Cochlear Implant Surgery||Bnai Zion Medical Center|Yes|Active, not recruiting|January 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|20 Years|N/A|No|Non-Probability Sample|100 patient who were suffering from profound sensory neural hearing loss and underwent a        high resolution computerized tomography of the temporal bone prior to cochlear        implantation surgery|December 2014|December 15, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02093806||48083|
NCT02094092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZSPBT001|Role of ProTectis on Infant Colic and Its Effect on Infant Crying Time and Maternal Mental Health|L.Reuteri ProTectis DSM 17938 to Relieve Infant Colic and Its Effects on Infant Sleep Pattern & Maternal Mental Health. PRIC-SMM Trial|PRIC-SMM|Ferozsons Laboratories Ltd.|Yes|Not yet recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|3 Months|No|||March 2014|March 19, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02094092||48061|
NCT02094313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0185|Effects of Atorvastatin on Human Semen and Gonadal Hormones|Effects of Decrease in Cholesterol Levels Induced by a Statin on Sperm Quality||University Hospital, Clermont-Ferrand||Completed|January 2008|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02094313||48044|
NCT02093702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AW-100-SD|Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus|Impact of Structured Physical Activity Education Delivery on Hemoglobin A1c (HbA1c) Levels, Blood Pressure, Lipid Profile, Body Mass Index (BMI), Waist Circumference, and Adherence to Clinical Practice Guidelines Weekly Physical Activity Recommendations in Patients With Type 2 Diabetes Mellitus||Royal Victoria Hospital, Canada|No|Active, not recruiting|April 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|64 Years|No|||October 2015|October 26, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02093702||48091|
NCT02093715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-YS-07-075-CTIL|FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma|FeNO and Cytokines in RSV and Non RSV Bronchiolitis in Relation to Future Asthma||Tel-Aviv Sourasky Medical Center||Recruiting|July 2007|||August 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|400|Samples Without DNA|blood|Both|N/A|2 Years|Accepts Healthy Volunteers|Probability Sample|Children ages 2 weeks to 2 years who will arrive to Dana Children's hospital, Tel-Aviv        Medical Center due to first episode of shortness of breath and working diagnosis of        bronchiolitis.|June 2014|August 31, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02093715|7 Years|48090|
NCT02094001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130903-01H|Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH|Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio||Ottawa Heart Institute Research Corporation|No|Recruiting|May 2014|November 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02094001||48068|
NCT02087449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.GH5.13|Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population|A Prospective Multi-center Study on E1 Acetabular Liner in THA|E1Hip|Biomet, Inc.|Yes|Recruiting|February 2013|February 2026|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|65 Years|No|Non-Probability Sample|Patients who are treated to have Total Hip Arthroplasty at Daegu Catholic University        Hospital, Kyung Pook Nat'l Univ. Hospital, Yeonsei Univ. College of Medicine, and Gangdong        Kyung Hee Univ. Hospital|February 2016|February 16, 2016|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02087449||48570|
NCT02095028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2011-02|Dietary and Lifestyle Interventions in Obese Pregnant Women|Effects of Dietary and Lifestyle Interventions in Obese Pregnant Women From the First Trimester on Gestational Weight Gain and Pregnancy Outcomes||Capital Medical University|Yes|Completed|April 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|373|||Female|18 Years|45 Years|No|||March 2014|March 21, 2014|March 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02095028||47989|
NCT02091011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDM 90912475|LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices|LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices.||Boston Scientific Corporation|No|Active, not recruiting|January 2014|May 2021|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1600|||Both|N/A|N/A|No|Non-Probability Sample|Subject has been implanted within 30 days with a commercially available Boston Scientific        ICD or a CRT-D device according to current guidelines and/or center's current practice|March 2016|March 2, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02091011||48296|
NCT02088216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCFB-FLS-01|Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis|Effect of Long-term, High-dose N-acetylcysteine on Acute Exacerbations of Patients With Non-cystic Fibrosis Bronchiectasis: the BENE Randomized, Controlled Trial|BENE|Qilu Hospital||Active, not recruiting|March 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02088216||48511|
NCT02112708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13/035|Cognitive Behavioral Therapy (REBT/CBT) Evaluation for Dysthymia in the Practice of Clinical Social Work at Primary Care|Evaluation of the Effectiveness of Rational Emotive Behavioral Therapy (REBT/CBT) as an Intervention Tool in Clinical Social Work Consultation to Primary Care.||Jordi Gol i Gurina Foundation|No|Completed|October 2009|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|14 Years|N/A|No|||March 2014|April 11, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112708||46636|
NCT02108769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024336|Yogic Breathing Changes Salivary Components|Induction of Salivary Neuromodulators by Chanting and Breathing Exercise||Medical University of South Carolina|Yes|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02108769||46937|
NCT02108964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEGF816X2101|A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies|A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies||Novartis||Recruiting|June 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|490|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108964||46922|
NCT02108977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-364|Evaluation of Videoconferencing Versus Telephone Genetic Counseling|Evaluation of Videoconferencing vs Telephone Genetic Counseling Consultations|EVTGC|VA Office of Research and Development|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|42|||Both|50 Years|N/A|No|||July 2015|July 14, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108977||46921|
NCT02109250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200R00001|CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice|CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice|CaprelsaReg|AstraZeneca|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Actual|10|||Both|18 Years|130 Years|No|Probability Sample|It is planned to include all Belgian sites which have patients diagnosed with aggressive        and symptomatic unresectable locally advanced or metastatic MTC who have been prescribed        vandetanib and fulfilling the criteria for reimbursement.|January 2016|January 28, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02109250|16 Months|46900|
NCT02082418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0065|Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly|Effects of Alpha-lactalbumin on Metabolic and Cognitive Functions in Healthy Older Adults||Texas A&M University|No|Recruiting|March 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|40|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082418||48955|
NCT02082990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI042924|Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption|A Randomised Controlled Non-inferiority Trial of Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption (EFAR-Spain)|EFAR-Spain|Hospital Clinic of Barcelona|No|Recruiting|December 2014|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02082990||48911|
NCT02082964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|training|The Effect of SCIM on Neonatal Resuscitation|||Mashhad University of Medical Sciences|Yes|Completed|December 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|48|||Both|22 Years|32 Years|Accepts Healthy Volunteers|||March 2014|March 8, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02082964||48913|
NCT02082977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117208|A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma||GlaxoSmithKline|No|Recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|169|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082977||48912|
NCT02083263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF2012-1|Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis|Study of Non Invasive Ventilation With High Pressure as Airways Clearance Technique in Adults Patients With Cystic Fibrosis||Karolinska University Hospital|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||July 2014|July 3, 2014|November 16, 2012||No||No|March 11, 2014|https://clinicaltrials.gov/show/NCT02083263||48891|
NCT02083822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN11-ES / EPIRMEX|Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions|Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions|EPIRMEX|University Hospital, Tours|Yes|Active, not recruiting|June 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|600|||Both|25 Weeks|32 Weeks|No|||September 2014|September 18, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02083822||48848|
NCT02083510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6293|Apolipoprotein CIII Reduction Via Colchicine|A Translational Study to Understand the Mechanism of Apolipoprotein CIII Reduction Via Colchicine||Scripps Translational Science Institute|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 28, 2014|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083510||48872|
NCT02110823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10HL068270-4a|Single Ventricle Reconstruction Extension Study (SVR II) - Pediatric Heart Network|Single Ventricle Reconstruction Extension Study (A Study Conducted by the Pediatric Heart Network)|SVRII|New England Research Institutes|Yes|Active, not recruiting|March 2008|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|325|Samples With DNA|The SVR II study will collect biological specimens to bank in an established biorepository      as a resource for future, hypothesis-driven studies from families who provide separate      informed consent. When possible, blood will be drawn, processed, and stored in such a way as      to permit both genetic studies and studies of serum biomarkers. The intent is to obtain      blood from study subjects and parents (i.e., "trios"). When obtaining blood is not possible,      however, saliva will be obtained so that at least genetic information can be stored for      future studies.|Both|2 Years|6 Years|No|Probability Sample|Follow up of subjects originally enrolled in the SVR trial|April 2014|December 19, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110823||46781|
NCT02111070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_101|Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects|Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects||Il-Yang Pharm. Co., Ltd.|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|44|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111070||46762|
NCT02111395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3556192|Psychotherapy for Anxiety in Children With Autism Spectrum Disorder|3/3 Treatment of Anxiety in Autism Spectrum Disorder|TAASD|Temple University|Yes|Recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|201|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111395||46737|
NCT02112253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-120|Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome|Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study||The University of Western Australia|Yes|Recruiting|March 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|10|||Both|14 Years|60 Years|No|||December 2014|December 30, 2014|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02112253||46671|
NCT02111642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHRI 2014-073|Effect of a Risk Calculator on Patient Satisfaction With the Decision for Midurethral Sling During Prolapse Surgery|Effect of a New Risk Calculator on Patient Satisfaction With the Decision for Concomitant Midurethral Sling During Prolapse Surgery||Medstar Research Institute|No|Active, not recruiting|June 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|42|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111642||46718|
NCT02112240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16746|Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients|Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer||University of Virginia|Yes|Suspended|May 2013|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02112240||46672|
NCT02112487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-311|Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH|An Extension of AC-055-310, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™||Actelion|No|Active, not recruiting|June 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02112487||46653|
NCT02112461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33122-SCP|Hospice and End-of-life Symptom Monitoring & Support Using an Automated System Designed for Family Caregivers|Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Symptom Care by Phone for Hospice Caregiver Support and Cancer Symptom Relief|SCP|University of Utah|Yes|Active, not recruiting|May 2010|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|430|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02112461||46655|
NCT02112474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-HF-2013|The Pain Suppressive Effect of Alternative Spinal Cord Stimulation Frequencies|The Pain Suppressive Effect of Low Frequency Spinal Cord Stimulation Versus High Frequency Spinal Cord Stimulation||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|November 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2015|June 30, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02112474||46654|
NCT02112721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1047897|Can Vitamin D Supplementation Prevent Type 2 Diabetes?|Can Vitamin D Supplementation Prevent Type 2 Diabetes by Improving Insulin Sensitivity and Secretion in Overweight Humans?||Monash University|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112721||46635|
NCT02108782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU021205I|Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors|Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy||Academic and Community Cancer Research United|Yes|Withdrawn|October 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|January 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108782||46936|
NCT02108990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012HO294|Acetaminophen and Social Processes|Acetaminophen and Social Pain in Borderline Personality Disorder||Ohio State University|No|Active, not recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|18 Years|50 Years|No|||December 2015|December 21, 2015|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108990||46920|
NCT02082431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-001-13|Long QT and Hearing Loss Registry|Long QT & Hearing Loss Prospective Study Registry||Mednax Center for Research, Education and Quality|No|Recruiting|August 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|90 Days|Accepts Healthy Volunteers|Non-Probability Sample|Newborn infants|July 2015|July 30, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082431||48954|
NCT02083276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1917|Mecillinam for Treatment of Genital Chlamydia Infection|Mecillinam for Treatment of Genital Chlamydia Infection in Asymptomatic Men|MecillinamCT|Oslo University Hospital|No|Terminated|March 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||June 2015|June 18, 2015|March 5, 2014||No|Treatment failure on study medication observed|No||https://clinicaltrials.gov/show/NCT02083276||48890|
NCT02083549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR- MTP-TEG|Evaluating URMC's Massive Transfusion Protocol|Evaluating the Efficacy of the University of Rochester Medical Center's Massive Transfusion Protocol in Trauma Level 1 Patients Utilizing Thromboelastography|MTP-TEG|University of Rochester|No|Recruiting|April 2013|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Study population includes level 1 trauma patients brought to the trauma bay for        resusitation and are initiated under the Massive Transfusion Protocol.|September 2015|September 18, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083549||48869|
NCT02083835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7 223590|PAIN OUT: Improvement in Postoperative PAIN OUTcome|Improvement in Postoperative Pain Outcome|PAN-OUT|University of Jena|No|Recruiting|January 2009|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|200000|||Both|4 Years|N/A|No|Probability Sample|adult post-surgical patients in hospitals on post-op day 1|June 2015|June 1, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02083835|1 Day|48847|
NCT02083523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smith13356|Project CHOICE: Efficacy Testing of CHOICE and CHOICE+Normative Feedback Interventions|PROJECT CHOICE: Efficacy Testing of Motivational Interviewing (MI) for Adolescents Referred for Substance Use Concerns|CHOICE|University of Illinois at Urbana-Champaign|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|13 Years|19 Years|No|||March 2014|March 10, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02083523||48871|
NCT02083536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110671|LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma|A Phase I Study Using Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) As A Docetaxel Chemo-Potentiator for Patients With Platinum-Resistant Recurrent Ovarian Carcinoma||University of Miami|Yes|Recruiting|May 2014|||May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|80 Years|No|||February 2016|February 1, 2016|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083536||48870|
NCT02110836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSUCA|The Impact of Sucrose Ingestion During Exercise on Liver and Muscle Glycogen Concentration.|||Northumbria University|No|Completed|April 2014|April 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02110836||46780|
NCT02111083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15418|A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants|Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|April 8, 2014|No|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT02111083||46761|
NCT02111096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15286|A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Terminated|April 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|174|||Both|18 Years|79 Years|No|||December 2015|December 23, 2015|April 8, 2014|Yes|Yes|The overall benefit-risk profile did not support continued development of LY2409021 for type 2    diabetes.|No||https://clinicaltrials.gov/show/NCT02111096||46760|
NCT02111109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/YH/0078|An Observational Pilot Study of the Effects of Traumatic Haemorrhagic Shock and Resuscitation on the Microcirculation||MICROSHOCK|King's College Hospital NHS Trust|No|Recruiting|July 2014|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood / plasma / urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with traumatci injury, haemorrhae and impaired perfusion|May 2015|May 29, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111109||46759|
NCT02112513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108006470|The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome|The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome||Indiana University|Yes|Recruiting|November 2012|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|200|Samples With DNA|We will obtain serum and saliva for estriol measurement before or within 2 hours of      antenatal corticosteroid administration and about 24 hours after each dose is given.      Women who consent to an optional PK portion of the study will have plasma samples obtained      pre-dose and then on a schedule of approximately 0.5-2, 4-8, 10-15, 22-24 hours after the      first dose and then 6-8, 24, and 48 hours after the 2nd dose. One sample will be collected      in each of these times.      A sample of whole blood will be obtained for DNA isolation. At the time of delivery,      umbilical cord blood will be collected before being discarded for DNA and plasma. If we are      unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA      extraction.|Female|18 Years|N/A|No|Probability Sample|Mothers with preterm labor (23 - 34 weeks) on antenatal corticosteroid for prevention of        neonatal respiratory distress syndrome will be recruited|January 2016|January 29, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112513||46651|
NCT02111655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210443-031132-261233|Second Generation Surveillance Methods To Prevent Thrombosis And Increase Assisted Primary Patency Survival In Native Arteriovenous Fistulae|SECOND GENERATION SURVEILLANCE TECHNIQUES (METHODS) TO PREVENT THROMBOSIS AND INCREASE ASSISTED PRIMARY PATENCY SURVIVAL IN NATIVE ARTERIOVENOUS FISTULAE. A PROSPECTIVE CONTROLLED TRIAL|METTRO|Hospital Infanta Sofia|Yes|Completed|September 2012|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|212|||Both|18 Years|95 Years|No|||August 2014|August 11, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02111655||46717|
NCT02112214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS13716|Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population|Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial|HELPER|National Cancer Center, Korea|Yes|Recruiting|February 2014|December 2026|Anticipated|December 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|11000|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02112214||46674|
NCT02109016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-3810-II-02|A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations|A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations||Clovis Oncology, Inc.|Yes|Active, not recruiting|April 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109016||46918|
NCT02112734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC # 34168 A|Can Vitamin D Supplementation in Infants Prevent Food Allergy in the First Year of Life? The VITALITY Trial|Can Vitamin D Supplementation in Infants Prevent Food Allergy in the First Year of Life? The VITALITY Trial.|VITALITY|Murdoch Childrens Research Institute|Yes|Recruiting|December 2014|December 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3012|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||September 2015|September 23, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112734||46634|
NCT02112747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12230|Adherence to Colon Cancer Screening (ACCS)|Ohio Colorectal Cancer Prevention Initiative: Adherence to Colon Cancer Screening (ACCS) Project:Your Personal Prescription For Colorectal Cancer Screening.||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|September 2013|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|12000|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112747||46633|
NCT02108795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj20140331|The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium|The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery||Yeungnam University College of Medicine|Yes|Recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|86|||Both|3 Years|7 Years|No|||July 2015|July 14, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108795||46935|
NCT02109003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPREI|Efficiency of a Mechanical Device in Controlling Tracheal Cuff Pressure in Intubated Critically Ill Patients|Efficiency of PressureEasy in Controlling Tracheal Cuff Pressure in Intubated Critically Ill Patients||Corporacion Parc Tauli|No|Completed|April 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||May 2015|May 30, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109003||46919|
NCT02109276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTH-151-14|Study of the Effect of Aspheric Lenses in Patients With Fuch's Dystrophy|Contrast Sensitivity and Higher Order Aberrations After Spheric and Aspheric Intraocular Lens Implantation for Patients With Mild to Moderate Fuch's Endothelial Dystrophy.||Queen's University|No|Recruiting|April 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109276||46898|
NCT02109523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28/20/7200|Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults|||Qazvin University Of Medical Sciences||Recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Both|65 Years|N/A|No|||April 2014|April 9, 2014|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109523||46879|
NCT02082717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 13-060|The Impact of Neut During KCL Replacement on Pain and Incidence of Phlebitis|The Impact of 4% Sodium Bicarbonate Additive During Potassium Chloride Replacement on Pain and Incidence of Phlebitis for Adult Patients in a Medical Surgical Unit: A Randomized Double Blinded Controlled Study|Neut-WKBH|Baptist Health South Florida|No|Enrolling by invitation|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|21 Years|N/A|No|||January 2016|January 28, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02082717||48932|
NCT02083289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-9054IOU003|A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)|A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)||Ono Pharmaceutical Co. Ltd|No|Completed|May 2014|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|85 Years|No|||January 2016|January 26, 2016|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083289||48889|
NCT02083302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-412M|Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention|Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention||Rutgers, The State University of New Jersey|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|4385|||Both|18 Years|21 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02083302||48888|
NCT02083562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD-2014_UKBB|Biomarkers and Volumetric Capnography in BPD|Plasma Biomarkers for the Prediction of Bronchopulmonary Dysplasia and Volumetric Capnography for Severity Assessment of Lung Disease in Preterm Infants|BPD-2014|University Hospital, Basel, Switzerland|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples Without DNA|Plasma|Both|N/A|9 Days|No|Non-Probability Sample|Preterm infants born below 32 weeks PMA and admitted to the neonatal intensive care units        in Basel and Berne, Switzerland.|November 2015|November 23, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02083562||48868|
NCT02083848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41056.041.13|Detection of Loco-regional Invasion of Cervical Cancer With 7 Tesla MRI|Detection of Loco-regional Invasion of Cervical Cancer With 7 Tesla MRI (DETECT)|DETECT|UMC Utrecht|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Female|18 Years|N/A|No|||November 2015|November 2, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083848||48846|
NCT02084069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMSU-Cardiology-2|Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair|||Urmia University of Medical Sciences||Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|58|||Both|25 Years|N/A|No|||February 2015|February 13, 2015|March 8, 2014|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT02084069||48829|The sample size of this study was small
NCT02084082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.9|Bioequivalence of a High, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (5 mg/1000 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)||Boehringer Ingelheim||Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|March 7, 2014||||No||https://clinicaltrials.gov/show/NCT02084082||48828|
NCT02110849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUHPTC-03|Prostate Cancer Parameters for Patients Receiving Proton Treatment|Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)||Indiana University|Yes|Active, not recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prostate cancer patients who are receiving proton radiation therapy|February 2015|February 3, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02110849|12 Months|46779|
NCT02110862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skipo-2013|Scintigraphic Evaluation of IPAA Function in Patients With Ulcerative Colitis|Scintigraphic Evaluation of IPAA Function in CU Patients|SKIPO|Odense University Hospital|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|21|||Both|18 Years|100 Years|No|Probability Sample|Ulcerative colitis|January 2016|January 27, 2016|April 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02110862||46778|
NCT02110875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e9576|Strength and Balance in Gender- and Age-Matched Controls|Strength and Balance in Gender- and Age-Matched Controls: SubStudy to "The Effects of Vitamin D on Balance in Parkinson's Disease"|VITDC|Oregon Health and Science University|No|Completed|June 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Elderly (over 59 years old) without Parkinson's disease or Parkinsonism.|October 2014|October 17, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110875||46777|
NCT02111993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110647|Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation|Evaluating Myocardial Injury During ICD Implantation Using the Upper Limit of Vulnerability (ULV) Method vs. Standard Defibrillation Threshold Testing|ULV|University of California, San Diego|No|Completed|August 2011|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111993||46691|
NCT02112006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soberon Forearm|Comparing Two Injection Sites of Local Anesthetic for Hand Surgery|A Comparison Of Distal Peripheral Nerve Blockade Versus Traditional Proximal Approaches For Hand Surgery||Ochsner Health System|No|Completed|April 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|March 21, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02112006||46690|
NCT02100085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-188E-FU|Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation|A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)||Genexine, Inc.|No|Active, not recruiting|February 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9|Samples Without DNA|plasma and PBMC (peripheral blood mononeuclear cells)|Female|20 Years|50 Years|No|Non-Probability Sample|The subjects who have completed the DNA vaccine administration of each dosage (1, 2 and 4        mg).        The subjects in the period less than 48 weeks after the final administration of GX-188E|April 2015|April 21, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100085||47602|
NCT02112500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STELLAR-Pilot|Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure|A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.|STELLAR|Asan Medical Center|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years|No|||January 2016|January 8, 2016|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02112500||46652|
NCT02111954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402/12|Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients|PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT||University of Lausanne Hospitals|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|18 Years|N/A|No|||January 2016|January 24, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111954||46694|
NCT02109289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6032|Etanercept in Rheumatoid Arthritis and Vascular Inflammation|Pilot Open-label Study of the Effect of Etanercept on Vascular Inflammation in Patients With Active Rheumatoid Arthritis||Innovaderm Research Inc.|No|Recruiting|April 2014|December 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02109289||46897|
NCT02109536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1639-13|The Use of Magnetic Endoscopic Imagers During Colonoscopy for Loop Recognition and Resolution|The Use of Magnetic Endoscopic Imagers During Colonoscopy for Loop Recognition and Resolution||Queen's University|No|Recruiting|February 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive male and female patients, 18 years or older, undergoing outpatient colonoscopy        in the MEI room at Hotel Dieu Hospital in Kingston, Ontario, Canada will be considered for        the study.|September 2015|September 16, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02109536||46878|
NCT02109549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin NSCLC|Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.|Influence of Metformin Use on Treatment Outcome in NSCLC Patients|Metformin|Maastricht Radiation Oncology|No|Active, not recruiting|March 2014|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|70|||Both|N/A|N/A|No|Probability Sample|Patients with advanced stage non-small cell lung cancer|September 2015|January 21, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02109549||46877|
NCT02109809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97114|Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant|A Phase I Study: Low-Dose Total Lymphoid Irradiation in the Treatment of Refractory Chronic Graft Versus Host Disease||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|July 2014|||July 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109809||46857|
NCT02110082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-018|Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer|A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck||Bristol-Myers Squibb|No|Active, not recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||October 2015|January 6, 2016|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110082||46836|
NCT02110095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN14-PICO-MULTI-JD|Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos|Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos||Cynosure, Inc.|No|Active, not recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||July 2015|February 16, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110095||46835|
NCT02110108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN14-REV-REJUV-NS|Study for the RevLite Laser System for Facial Solar Lentigines|Study for the RevLite Laser System for Facial Solar Lentigines||Cynosure, Inc.|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|60 Years|No|||July 2015|July 29, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110108||46834|
NCT02083003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/68|Polyamine-low Diet to Prevent Postoperative Pain After Cholecystectomy|Polyamine-low Diet to Prevent Postoperative Pain After Cholecystectomy||Hopital Foch|No|Terminated|January 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|76 Years|No|||April 2015|April 14, 2015|March 7, 2014||No|End of commercialization of low polyamin diet|No||https://clinicaltrials.gov/show/NCT02083003||48910|
NCT02083601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288993|Caring for Caregivers: Supporting Caregivers of Youth With Spinal Cord Injury|Caring for Caregivers: Supporting Caregivers of Youth With Spinal Cord Injury||Shriners Hospitals for Children|No|Active, not recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|88|||Both|7 Years|N/A|No|||November 2014|November 20, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083601||48865|
NCT02083575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitamin c and iron chelator|Role of Vitamin C to Augment Iron Chelation With DFP or DFX|Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation||Ain Shams University|No|Not yet recruiting|April 2014|April 2014|Anticipated|April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|18 Years|No|||March 2014|March 7, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083575||48867|
NCT02083588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS_01|A Prospective Trial to Explore the Efficacy of dTMS in Subjects With Fibromyalgia|A Prospective Trial to Explore the Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Fibromyalgia||Shalvata Mental Health Center||Not yet recruiting|March 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2014|March 10, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02083588||48866|
NCT02084134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110174|Peri-Operative Steriod Management in Patients|The Use of Perioperative Steroids in Patients Undergoing Transsphenoidal Resection of Pituitary Tumors or Cysts|Steroid|Washington University School of Medicine|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02084134||48824|
NCT02084095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28332|IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly|The Role of Insulin-like Growth Factor-I (IGF-I) and Free Fatty Acids in Insulin Resistance, Insulin Secretion and Glucose Metabolism Abnormalities in Acromegaly||Carol Davila University of Medicine and Pharmacy|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Probability Sample|The study will prospectively include patients with active acromegaly assessed in a        tertiary center. All patients who meet inclusion and exclusion criteria will be invited        consecutively to participate in the study until the proposed number of patients is        reached.|February 2015|February 3, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084095||48827|
NCT02110602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002607|Dietary Intake and Circulating Levels of Branched Chain Amino Acids|Short-term Dietary Intake and Branched Chain Amino Acids||Massachusetts General Hospital|Yes|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|5|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 3, 2014|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110602||46798|
NCT02111668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110238|Thoracic Aortic Dilatation Syndromes|Thoracic Aortic Dilatation Syndromes - Diagnostic, Incidences, Morbidity, Mortality and Socioeconomical Observations.||University of Aarhus|No|Active, not recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|300|Samples With DNA|Biobank with plasma, serum and Whole blood.|Both|N/A|N/A|No|Non-Probability Sample|Patients with thoracic aorta dilatation|February 2013|December 2, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111668|1 Day|46716|
NCT02111681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-174|Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer|Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02111681||46715|
NCT02112266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICBT|Depression Online Assessment and Therapy|Online Assessment for Therapy Expectation and Quality of Life and Online Therapy of Depression||University of Zurich|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|18 Years|65 Years|No|||January 2015|February 4, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02112266||46670|
NCT02099838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tongji201202|Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients|The Randomized Multiple Center Trial for The Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients Who Have Bad Glycemic Control With the Initial Treatment of Sulfonylureas||Huazhong University of Science and Technology|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|70 Years|No|||June 2014|June 11, 2014|March 24, 2014|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT02099838||47621|
NCT02103907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00587|Randomized Controlled Trial of Dynamic Balance Training in People With Knee Osteoarthritis|The Effect of Dynamic Balance Training on Balance and Physical Function in Those With Knee Osteoarthritis||University of British Columbia|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|80 Years|No|||December 2015|December 2, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103907||47308|
NCT02112773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVISE UK|ADenoVirus Initiative Study in Epidemiology in UK|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis||NicOx|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|31|||Both|1 Year|N/A|No|Non-Probability Sample|Any female and male patients from one year of age with signs and symptoms of acute        conjunctivitis either seen during ophthalmology consultations or who are in the emergency        room or hospitalized, can be enrolled in the study|April 2014|October 19, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112773||46631|
NCT02111967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRG_Metformin_CMG|Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin|Adequacy of Serum Vitamin B12 Measurement in Type 2 Diabetic Patients Treated With Metformin in Comparison to Holotranscobalamin Measurement||University Hospital, Basel, Switzerland|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|None Retained|All blood samples investigated in this study will be destroyed one week after withdrawal.      All patient information obtained as a result of the study will be regarded as confidential      and made anonymous using a unique study ID number instead of name and surname of the      patient.|Both|18 Years|N/A|No|Probability Sample|Patients with diabetes mellitus type 2 treated with and without Metformin.|August 2015|August 12, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111967||46693|
NCT02111980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131198|RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators|Compatibility of Radiofrequency Detection Technology With Cardiac Internal Electronic Devices (RF Assure Study)|RF|University of California, San Diego|No|Completed|March 2014|May 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111980||46692|
NCT02108808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRAS CARDIOLOGY 18|Effect of Ticagrelor on Fractional Flow Reserve|Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve||University of Patras|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|80 Years|No|||January 2015|January 4, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02108808||46934|
NCT02109029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14873|A Study of LY2505541 and Human Insulin Concentrations in Fat Tissue|Use of Open-Flow Microperfusion to Measure LY2605541 and Human Insulin Concentrations in Adipose Tissue Interstitial Fluid||Eli Lilly and Company|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|65 Years|No|||May 2015|May 14, 2015|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02109029||46917|
NCT02109042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15172|A Study of Blosozumab ( LY2541546) in Postmenopausal Female Participants|A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women||Eli Lilly and Company|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|60 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 6, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02109042||46916|
NCT02109302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-32|Primary Premature Ejaculation Genetics|Identification Des Bases moléculaires de l'éjaculation prématurée Primaire||Institut National de la Santé Et de la Recherche Médicale, France||Not yet recruiting||||April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 2, 2014||||No||https://clinicaltrials.gov/show/NCT02109302||46896|
NCT02109562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-09-0010|Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study t and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)||Indivior Inc.|No|Completed|April 2014|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|259|||Both|18 Years|55 Years|No|||August 2015|August 7, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109562||46876|
NCT02109575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/83|Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)|Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)|DTRT|Medical College of Wisconsin|No|Recruiting|September 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|480|Samples With DNA|Whole Blood|Both|N/A|N/A|No|Non-Probability Sample|Study population will include people of any age who have undergone heart transplant or who        are "listed" to undergo heart transplant.|October 2015|October 27, 2015|February 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02109575||46875|
NCT02100943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00026736|Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum|Exhaled Nitric Oxide as a Biomarker of Gestational Obstructive Sleep Apnea and Persistence Postpartum||Wake Forest School of Medicine|No|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|65|||Female|18 Years|45 Years|No|Probability Sample|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation|December 2015|December 10, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100943||47536|
NCT02101476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-MNK-01C|An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.|A Randomized, Open Label,Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP (Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain||Lotus Clinical Research, LLC|No|Completed|May 2014|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2014|November 19, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101476||47495|
NCT02083016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PentaRay|Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation|Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation||Hospital Clinic of Barcelona|No|Active, not recruiting|April 2014|||December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083016||48909|
NCT02084147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE16Z12|PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases|PET-MRI: Evaluation, Optimization and Clinical Implementation||Case Comprehensive Cancer Center|No|Recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|530|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084147||48823|
NCT02083861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZetrOZ-01|Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial|ZetrOZ Wearable Ultrasound Clinical Study||ZetrOZ, Inc.|Yes|Active, not recruiting|March 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Years|80 Years|No|||January 2015|January 21, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083861||48845|
NCT02084667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03062013|Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis|Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis||Mount Sinai Hospital, Canada|No|Not yet recruiting|June 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|38 Years|No|||June 2013|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084667||48783|
NCT02084680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaNB|Intervention Trial to Measure the Effect of Individual Prenatal Information Combined With Mobile Phones|A Community Trial to Measure the Effect of Individual Prenatal Education With Mobile Phone Consultations Offered to Pregnant Women in Masindi and Kiryandongo, Western Uganda||Makerere University|No|Recruiting|June 2013|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 14, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084680||48782|
NCT02110329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/040/HP|Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study|Simultaneous Detection of Somatic Quantitative Molecular Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study|Code Barre|University Hospital, Rouen|No|Completed|May 2010|November 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|401|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110329||46819|
NCT02111122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0239|Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease|A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease|PD-Xyrem|University of Zurich|Yes|Recruiting|April 2014|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|90 Years|No|||April 2014|April 8, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111122||46758|
NCT02111421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cesarean Surgery|The Median Effective Dose (ED50) of Dexmedetomidine in Cesarean Surgery|The Median Effective Dose (ED50) of Dexmedetomidine in Cesarean Surgery With Respect to the Loss of Consciousness||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|40 Years|No|||March 2015|March 11, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02111421||46735|
NCT02112019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44018.029.13|Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome|Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome; A Randomised Controlled Pilot Study||VU University Medical Center|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|January 18, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02112019||46689|
NCT02099851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1003-CIBIEM|Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study|Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study.||Noblewell|Yes|Active, not recruiting|March 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099851||47620|
NCT02099617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-389|Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.|Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.|SENIOR|Ceric Sàrl|Yes|Recruiting|May 2014|June 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1200|||Both|75 Years|N/A|No|||January 2016|January 11, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02099617||47638|
NCT02100345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bowel Endometriosis|Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound|Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound||University of Aarhus|No|Recruiting|October 2014|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Female|18 Years|80 Years|No|Non-Probability Sample|Women with bowel endometriosis|March 2014|June 10, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02100345||47582|
NCT02100683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP126|Nit-Occlud PDA Post-Approval Study|Nit-Occlud PDA Post-Approval Study||PFM Medical, Inc|Yes|Recruiting|August 2014|April 2022|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|215|||Both|6 Months|21 Years|No|Non-Probability Sample|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA        with a minimum diameter of <4 mm.|July 2015|July 21, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100683||47556|
NCT02112760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903075R|Specific Stabilization Exercise With Ultrasound Feedback For Patient With Recurrent Low Back Pain|Specific Stabilization Exercise With Ultrasound Feedback For Patient With Recurrent Low Back Pain||National Taiwan University Hospital|No|Completed|June 2011|||December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112760||46632|
NCT02100956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00027272|Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain|Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain||Wake Forest School of Medicine|Yes|Recruiting|April 2014|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100956||47535|
NCT02100709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMD_NIV_COPD_001|The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program|The Effect of BiLevel Pressure Support NonInvasive Ventilation on Quality of Life and Exercise Capacity in a COPD Exercise Rehabilitation Program||ResMed||Not yet recruiting|April 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2014|March 31, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100709||47554|
NCT02101515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.590|Randomized Control Trial of Second Stage of Labor|Randomized Control Trial of Usual Labor Versus Extended Second Stage||Thomas Jefferson University|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101515||47492|
NCT02101814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNetto|Energy Balance and Inflammation in Obese Adults Bariatric Surgery Follow-up|Analysis of Neuroendocrine Regulation of Balance Energy and Inflammatory Factors in Obese Adults Submitted to Bariatric Surgery||Federal University of São Paulo|Yes|Active, not recruiting|March 2013|||May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|20 Years|60 Years|No|||April 2014|April 11, 2014|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101814||47469|
NCT02083029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU070813|Vagal Nerve Stimulation Assessed by the Diving Reflex: An Investigation Into Mechanisms of Asthma Death|Vagal Nerve Stimulation Assessed by the Diving Reflex: An Investigation Into Mechanisms of Asthma Death||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02083029||48908|
NCT02083315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-1003|Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Explore the Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Adult Male Subjects||Trevena Inc.|No|Completed|July 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|February 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083315||48887|
NCT02114541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHICC-31052012|Correlation Between Coronary and Carotid Atherosclerotic Disease and Links With Clinical Outcomes|Global Observational Study to Evaluate the Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|MHICC3ROW|Montreal Heart Institute|No|Recruiting|May 2012|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|87 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have successfully undergone baseline imaging in the dal-PLAQUE 2 study|April 2015|April 13, 2015|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02114541||46495|
NCT02084381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502|PERCI- Medium Cut Off (MCO)|Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)|PERCI-MCO|Gambro Dialysatoren GmbH|No|Completed|February 2014|February 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084381||48805|
NCT02115308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Astellas CMR Tagging|Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging|Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging||Aspire Foundation|No|Recruiting|August 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|19 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115308||46436|
NCT02111434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-022014|Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment|Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism||Gulhane School of Medicine|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|150|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02111434||46734|
NCT02111694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBS-1303001967|Influence of Bottle-Type on Infant Feeding Behaviors|Influence of Bottle-Type on Infant Feeding Behaviors|OBS|Drexel University|No|Completed|June 2013|June 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|N/A|6 Months|Accepts Healthy Volunteers|||October 2015|October 28, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02111694||46714|
NCT02111707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041158|Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)|Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)||University of Alberta||Recruiting|April 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|534|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111707||46713|
NCT02103101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pgp NOAC|Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events|Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events|Pgp NACO|Centre Hospitalier Universitaire de Besancon|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103101||47370|
NCT02103374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN10-PD/Nebuadom|Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State|Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State|Nebuadom|University Hospital, Tours|Yes|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Both|18 Years|80 Years|No|||March 2014|March 31, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02103374||47349|
NCT02103894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-777|Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects|Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects||Molecular NeuroImaging|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103894||47309|
NCT02103634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5113|NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer|NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|March 2014|July 2025|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103634||47329|
NCT02100124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-1304-6117|MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning|Reducing Unintended Pregnancies Through Reproductive Life Planning and Contraceptive Action Planning|MyNewOptions|Milton S. Hershey Medical Center|No|Active, not recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|972|||Female|18 Years|40 Years|No|||March 2016|March 14, 2016|November 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02100124||47599|
NCT02099864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10241|Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy|Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment||OHSU Knight Cancer Institute|Yes|Recruiting|January 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|46|Samples With DNA|Whole blood, serum|Male|18 Years|N/A|No|Non-Probability Sample|Men with prostate cancer as they are seen in oncology clinic|February 2016|February 11, 2016|March 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099864||47619|
NCT02100696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA28950|A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors|PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS||Hoffmann-La Roche||Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|800|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|March 27, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02100696||47555|
NCT02100358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403462|Functional MRC With Eovist for Acute Cholecystitis|Accuracy of Functional MRC With Gadoxetate Disodium in the Diagnosis of Acute Cholecystitis: Comparison With Hepatobiliary Scintigraphy|MRC|University of California, Davis|No|Recruiting|February 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have recently (within 12 hours) undergone a clinically-indicated nuclear        medicine hepatobiliary scan not involving sedation or anesthesia for suspected acute        cholecystitis|December 2015|December 1, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02100358||47581|
NCT02100982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH101236|Improving Communication About Patient Priorities in Multimorbidity|Developing a Customized Care Intervention to Improve Mental Health Outcomes in Multimorbidity|ICOM-APP|University of Rochester|Yes|Enrolling by invitation|June 2015|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|70|||Both|40 Years|N/A|No|||July 2015|March 11, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02100982||47533|
NCT02101242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReCOSA|Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study|Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study||Charite University, Berlin, Germany|No|Active, not recruiting|May 2014|July 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients of both genders, over 18 years of age, undergoing elective surgery in general        anesthesia.|February 2016|February 1, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02101242||47513|
NCT02101255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4-RACL|Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions|Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Split-mouth, Post-marketing Study||Credentis AG|No|Active, not recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02101255||47512|
NCT02101528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CybexPD001|Determination of Muscle Strength in Parkinsonian Patients Through the Use of an Isokinetic Dynamometer|Determination of Muscle Strength in Parkinsonian Patients Through the Use of an Isokinetic Dynamometer|CybexPD001|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Completed|January 2013|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|40|||Both|55 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed with PD in stage 2-3 of Hoen&Yahr according to the United Kingdom Brain        Bank criteria.        Healthy Volunteers|March 2014|April 1, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02101528||47491|
NCT02083614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIUCGY-1|The Effect of Clamping the Indwelling Urethral Catheter Before Removal From Patients After Type III Radical Hysterectomy|||First Affiliated Hospital of Chongqing Medical University||Recruiting|November 2013|November 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|N/A|N/A|No|||March 2014|March 8, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02083614||48864|
NCT02083874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCPIC2014001|Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study|Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study||The University of New South Wales|No|Active, not recruiting|March 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02083874||48844|
NCT02083887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC058|A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants|A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants|VAC058|University of Oxford|Yes|Completed|February 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|65|||Both|N/A|16 Weeks|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02083887||48843|
NCT02115022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Col-gastro 5|EUS vs. MDCT in Pancreatic Malignancy|Endoscopic UltraSound in Potentially Resectable PAncreatic Malignancy - Does it Bear the Weight of the Rapidly Evolving Technology of Computer Tomography?|EUSPACT|Clinical Hospital Colentina|No|Recruiting|July 2014|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients with a confirmed pancreatic mass (suspected neoplastic) deemed        resectable or borderline resectable on multislice (at least 16 simultaneously acquired        slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery        with a curative (R0) intent.|September 2015|September 5, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115022|2 Years|46458|
NCT02114762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120437|Balloon Dilation in Selected Subjects With Refractory Eustachian Tube Dysfunction|Balloon Dilation in Selected Subjects With Refractory Eustachian Tube Dysfunction||University of Pittsburgh|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|50 Years|No|||February 2016|February 23, 2016|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02114762||46478|
NCT02115620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-165A|Telemedicine Technology Demonstration Project for Heart Failure|Demonstration Project Using Technology to Improve Health Outcomes for Hospitalized Patients With Heart Failure Discharged to Skilled Nursing Homes||Providence Health & Services|No|Active, not recruiting|March 2014|December 2016|Anticipated|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Both|65 Years|N/A|No|||March 2016|March 8, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115620||46412|
NCT02115633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RxF-NIA-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||May 4, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115633||46411|
NCT02102854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003442|Single Dose rATG for Renal Allograft Rejection|Single Dose rATG for Treatment of Acute Renal Allograft Rejection||The Methodist Hospital System|No|Recruiting|March 2014|September 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||March 2016|March 22, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102854||47389|
NCT02103387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060496|Five Sessions Intervention to Facilitate Adaptation to Breast Cancer|Five Sessions Intervention to Facilitate Adaptation to Breast Cancer||University of Miami||Active, not recruiting|December 2006|June 2019|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|184|||Female|21 Years|75 Years|No|||May 2015|May 17, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02103387||47348|
NCT02103400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP2014|Physical Training Program in Patients Hospitalized for Community-acquired Pneumonia|Physical Training Program in Patients Hospitalized for Community-acquired Pneumonia||University of Nove de Julho|Yes|Completed|March 2014|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||August 2015|August 15, 2015|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02103400||47347|
NCT02103647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-PRMD-1202|Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation|A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects||IlDong Pharmaceutical Co Ltd||Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|19 Years|44 Years|Accepts Healthy Volunteers|||April 2013|August 28, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02103647||47328|
NCT02103660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-6512|Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women|A Randomized Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women||Centers for Disease Control and Prevention|Yes|Active, not recruiting|April 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|131|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103660||47327|
NCT02100150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-TBI-003|A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)||Neuren Pharmaceuticals Limited|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|16 Years|55 Years|No|||January 2016|January 21, 2016|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100150||47597|
NCT02100423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5913|Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Case Comprehensive Cancer Center|No|Recruiting|September 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100423||47576|
NCT02099877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.SS.11|μ-opioid Receptor Polymorphism and Opioid Analgesia|Observational Study: The Effect of μ-opioid Receptor Genetic Polymorphism on Neuraxial Opioid Labor Analgesia||American University of Beirut Medical Center||Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated        course of singleton vertex pregnancy requesting epidural analgesia for pain relief|January 2016|January 22, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02099877||47618|
NCT02100098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAnFractRebound-01|Peripheral Nerve Block Anaesthesia for Ankle Fracture Surgery - an Exploratory Study: Is Rebound Pain a Problem?|Peripheral Nerve Block Anaesthesia for Ankle Fracture Surgery - an Exploratory Study: Is Rebound Pain a Problem?||Herlev Hospital|No|Completed|March 2014|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for internal fixation of an ankle fracture under PNB-anaesthesia at        Herlev Hospital identified from the operation booking system via consecutive screening.        Eligible ankle fractures will be those of anatomically uni-, bi- or trimalleolar        composition including syndesmotic injury with distal but not proximal fibular fracture.        The "third malleolus" is the distal posterior edge of the tibia. Fractures needing        external fixation or causing ankle dislocation in need of imminent surgery is not        eligible.|April 2015|April 17, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100098||47601|
NCT02100371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-103|Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome|Extension Protocol of BMS-833923 in Subjects With Basal Cell Nevus Syndrome||University Health Network, Toronto|No|Active, not recruiting|February 2014|August 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02100371||47580|
NCT02100995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP# 4100057688|Simultaneously Targeting Obesity and Pain: The STOP Trial|A Randomized Clinical Trial of an Integrated Behavioral Self-management Intervention Simultaneously Targeting Obesity and Pain: The STOP Trial|STOP|University of the Sciences in Philadelphia|No|Recruiting||||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100995||47532|
NCT02101008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI37833|Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy|||University of Utah|Yes|Completed|March 2010|||February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 10, 2014|Yes|Yes||No|May 23, 2014|https://clinicaltrials.gov/show/NCT02101008||47531|
NCT02100969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001041|Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis|Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis||University of Kansas Medical Center|Yes|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100969||47534|
NCT02101541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/627|FIRM as a Stand-alone Procedure in the Treatment of Atrial Fibrillation|Focal Impulse and Rotor Modulation (FIRM) as a Stand-alone Procedure in the Treatment of Atrial Fibrillation||Oslo University Hospital|No|Recruiting|February 2014|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|74 Years|No|||October 2014|October 22, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101541||47490|
NCT02101840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043-2013|Abuse Liability of Controlled-Release Oxycodone Formulations|Abuse Liability of Controlled-Release Oxycodone Formulations||Centre for Addiction and Mental Health|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02101840||47467|
NCT02114268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5290C00001|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults||MedImmune LLC|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|342|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02114268||46516|
NCT02115035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07|A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib|A Phase II Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib (VMRB) in Patients With Relapsed or Refractory Multiple Myeloma Who Have Activated BRAF Mutation||University of Arkansas|Yes|Withdrawn|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|April 9, 2014|Yes|Yes|Funding issues|No||https://clinicaltrials.gov/show/NCT02115035||46457|
NCT02115048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO 020|Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone|A Randomized Open-label Phase II Study of Letrozole Plus Afatinib (BIBW2992) Versus Letrozole Alone in First Line Treatment of Advanced ER+, HER2- Post-menopausal Breast Cancer With Low ER Expression||Translational Research in Oncology|Yes|Active, not recruiting|July 2014|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115048||46456|
NCT02115321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-059|Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)|A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection With Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|May 2014|June 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 14, 2014|Yes|Yes||No|February 19, 2016|https://clinicaltrials.gov/show/NCT02115321||46435|
NCT02115334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0996A3|Development and Effectiveness of Home-based Programs for Preschool Children With Developmental Delay|Development and Effectiveness of Home-based Programs for Preschool Children With Developmental Delay:a Randomized Controlled Trial.||Chang Gung Memorial Hospital|Yes|Completed|May 2011|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|N/A|6 Years|Accepts Healthy Volunteers|||June 2011|February 25, 2015|September 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02115334||46434|
NCT02115347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-014|Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)|A Phase 1, Non-randomized, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Hepatic Impairment and the Healthy Subjects With Normal Hepatic Function||Merck Sharp & Dohme Corp.|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02115347||46433|
NCT02103114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051186|Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery|Double Blind Randomized Placebo-controlled Study in Children (<6mo) Comparing the Effects of Anti-thrombin III (ATIII) or Placebo on the Coagulation System in Infants With Known Low ATIII Levels Undergoing Open Congenital Cardiac Surgery||Duke University|No|Recruiting|June 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|7 Months|No|||August 2015|October 15, 2015|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103114||47369|
NCT02103127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PCAP-AS-SK02|Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars|Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars||Cynosure, Inc.|No|Completed|July 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103127||47368|
NCT02103140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-012 Georgetown Lombardi|An Exercise RCT Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer|An Exercise Randomized Controlled Trial Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer||Georgetown University|No|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|February 8, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103140||47367|
NCT02099630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOKET-103/13|Functional and Metabolic Changes in the Course of Antidepressive Treatment|||Charite University, Berlin, Germany|No|Enrolling by invitation|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|whole blood|Both|18 Years|65 Years|No|Non-Probability Sample|depressive patients from a primary care clinic|January 2016|January 26, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02099630|3 Months|47637|
NCT02099890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-192 - DITOR|The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury|Neural Consequences of Chronic Inflammation in Individuals With Spinal Cord Injury and the Influence of an Anti-inflammatory Diet||Brock University|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02099890||47617|
NCT02100163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43654-J|Virtual Reality Orthopedic Trauma|Controling Pain After Orthopedic Trauma|VROT|National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|March 2014|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02100163||47596|
NCT02100384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:174|Long Term Comparison of Ultrasonic and Hand Instrumentation in the Maintenance of Peri-implant Tissues: A Randomized Clinical Trial|Long Term Comparison of Ultrasonic and Hand Instrumentation in the Maintenance of Peri-implant Tissues: A Randomized Clinical Trial||University of Manitoba|No|Active, not recruiting|April 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02100384||47579|
NCT02100397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2013/07|Understanding Paratyphoid Infection|Development of a Human Model of Salmonella Enterica Serovar Paratyphi A Challenge in Healthy Adult Volunteers||University of Oxford|Yes|Active, not recruiting|March 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02100397||47578|
NCT02100410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-061|On-Eye Evaluation of Contact Lens Axis Location|||Alcon Research|No|Completed|April 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|March 27, 2014|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT02100410||47577|
NCT02100111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28682|An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Patients|RONNIE - A Multi-Center, Multi-National, Retrospective Medical Record Review to Describe Treatment Patterns and Outcomes for Patients With Locally Advanced or Metastatic Basal Cell Carcinoma||Hoffmann-La Roche||Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|134|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced or metastatic basal cell carcinoma|March 2016|March 1, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02100111||47600|
NCT02101021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-370-1296|Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase||Gilead Sciences|Yes|Recruiting|June 2014|August 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101021||47530|
NCT02101294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997-01|Study Protocol for CTS and Keyboard Controlled Randomized Trial|Study Protocol for Carpal Tunnel Syndrome and Typing Keyboard: Controlled Randomized Trial||Finger Relief|No|Completed|January 1997|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|12 Years|85 Years|No|||September 2014|September 23, 2014|March 24, 2014|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT02101294||47509|Recruitment was a challenge and the budget to conduct the study was extremely limited. It took ten years to collect 20 participants who completed the protocol.
NCT02101268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-352-1214|Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF|A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib|Simplify 2|Gilead Sciences|Yes|Active, not recruiting|June 2014|January 2021|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101268||47511|
NCT02101281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF0213|Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye|An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye||Dompé Farmaceutici S.p.A|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02101281||47510|
NCT02101853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00631|Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia|Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)||National Cancer Institute (NCI)|No|Recruiting|December 2014|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|598|||Both|1 Year|30 Years|No|||March 2016|March 24, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101853||47466|
NCT02101866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA798-103|A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers|A Randomized, Single-Center, Open-Label, Two-Period, Two-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Product Formulations in Healthy Volunteers||Biota Scientific Management Pty Ltd|Yes|Completed|March 2014|||May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|June 17, 2014|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101866||47465|
NCT02102139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXM_Hydrodissection|Preop Dexmedetomidine Attenuates Haemodynamic Responses to Hydrodissection|A Single Preoperative Injection of Dexmedetomidine Attenuates Haemodynamic Responses to Hydrodissection in Patients Undergoing Robotic Thyroidectomy: a Prospective Randomised Double-blinded Study|DXM_Hydro|Seoul National University Hospital|Yes|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|41|||Both|20 Years|65 Years|No|||March 2014|March 30, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102139||47444|
NCT02115360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2308/1/14|Epidural Calcitonin in Lower Limb Amputation|The Pre-emptive Value of Epidural Calcitonin in Patients With Lower Limb Amputation. A Double Blinded Randomized Study||Tanta University|Yes|Active, not recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2015|January 30, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02115360||46432|
NCT02115373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200095_005|c-Met Second-Line Hepatocellular Carcinoma|A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment||Merck KGaA||Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115373||46431|
NCT02115386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ARU02|Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib|Open-label Multicenter Trial to Evaluate the Improvement of Chronic Low-grade Adverse Events Experienced by Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) With Optimal Response to Imatinib When Switched From Imatinib to Nilotinib Treatment|MACS1532|Novartis|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115386||46430|
NCT02115061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02621613100000068|Gastric Varices Treatment: Coil + Cyanoacrylate Versus Cyanoacrylate|Gastric Varices Treatment: Coil + Cyanoacrylate Versus Cyanoacrylate||University of Sao Paulo General Hospital|Yes|Recruiting|August 2013|October 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|N/A|N/A|No|||August 2012|April 11, 2014|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115061||46455|
NCT02102893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1214|Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan|A Multi-center, Registration Study for Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan||National Health Research Institutes, Taiwan|Yes|Recruiting|March 2014|February 2024|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|20 Years|75 Years|No|Probability Sample|2.1 To establish the database for GEP-NET by register the clinical presentation,        diagnosis, stages, treatment and clinical outcome of GEP-NET patients.        2.2 To analyze the risk and prognostic factors of GEP-NET patients. 2.3 To make a        treatment consensus for GEP-NETs|March 2014|April 2, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02102893||47386|
NCT02103166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001921-19|Role of Hyoscine Bromide in Latent and Active Labor|Randomized, Masked, Placebo-controlled Clinical Trial to Evaluate the Effects of a Single Intravenous Dose of Hyoscine Bromide on the Duration and Pain in Latent and Active Labor||Hospital Clinic of Barcelona|No|Suspended|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|180|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 1, 2014||No|Conditions of recruitment changed|No||https://clinicaltrials.gov/show/NCT02103166||47365|
NCT02103426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-CL-0004|An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients|A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients||Astellas Pharma Inc|No|Active, not recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|10||Actual|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103426||47345|
NCT02103673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-0035C|DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia|||Chang Gung Memorial Hospital||Recruiting|February 2014|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|50 Years|N/A|No|||July 2015|July 27, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103673||47326|
NCT02099656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB29260|A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma|A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION||Hoffmann-La Roche||Recruiting|November 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099656||47635|
NCT02099669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCCMDS-005|Red Blood Cell Transfusion Thresholds and QOL in MDS|Red Blood Cell Transfusion Thresholds and QOL in MDS (EnhanceRBC): a Pilot, Feasibility Study|EnhanceRBC|Sunnybrook Health Sciences Centre|No|Not yet recruiting|March 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099669||47634|
NCT02099903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18400613.1.0000.0068|Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease|Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study.||InCor Heart Institute|No|Recruiting|March 2014|August 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||March 2014|March 26, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02099903||47616|
NCT02100137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO 12|Women With Asymptomatic Endometrial Hyperplasia|Women With Asymptomatic Endometrial Hyperplasia|FAME-ENDO|Medical University of Vienna|No|Completed|September 2006|July 2012|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|asymptomatic women with endometrial hyperplasia diagnosed using a vaginal ultrasound|March 2014|March 26, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02100137||47598|
NCT02100462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16785|Chlorthalidone and HCTZ Impacts on Platelet Activation|Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide||Creighton University|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100462||47573|
NCT02100475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4119|A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification|A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)|DUAL™|Novo Nordisk A/S|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100475||47572|
NCT02100436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0016|Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations|A Phase II Open-Label Study in Healthy Pediatric Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|270|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||December 2014|October 29, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100436||47575|
NCT02100748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-2001|A Study of TRV130 for the Treatment of Pain After Bunionectomy|A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy||Trevena Inc.|Yes|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|333|||Both|18 Years|75 Years|No|||July 2014|October 15, 2014|March 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100748||47551|
NCT02101034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404139|PD 0332991 and Cetuximab in Patients With Incurable SCCHN|Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN||Washington University School of Medicine|No|Recruiting|June 2014|July 2021|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101034||47529|
NCT02100761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYLL-2014(KS)-085|CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients|Impact of Cytochrome P450 2C19 Genotype Polymorphism on Voriconazole Trough Concentration in Chinese Adult Patients With Invasive Pulmonary Aspergillosis: a Prospective Multicenter Research||Qilu Hospital|No|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|The susceptibility test of aspergillosis strains to voriconazole, serum galactomannan (GM)      test, voriconazole trough levels and genotyping of CYP2C19 will be measured.|Both|18 Years|80 Years|No|Probability Sample|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole        according to their physician decision|March 2014|March 31, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02100761||47550|
NCT02100722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME 3|A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease|Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease|FAME 3|Stanford University|Yes|Recruiting|August 2014|August 2021|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|21 Years|N/A|No|||September 2015|September 22, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100722||47553|
NCT02101307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28429|Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)|A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with rheumatoid arthritis starting RoActemra/Actemra treatment|March 2016|March 1, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101307||47508|
NCT02101580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-002|Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer|Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer||Polaris Group|No|Recruiting|November 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101580||47487|
NCT02101593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-005|Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer|A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)||Polaris Group|No|Completed|November 2014|March 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101593||47486|
NCT02101554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4541006|Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain|An Open-label Study To Evaluate The Safety And Pharmacokinetics Of Pf-06412528 In Children 7-17 Years For The Treatment Of Moderate-to-severe Pain||Pfizer|No|Recruiting|April 2015|July 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|7 Years|17 Years|No|||March 2016|March 24, 2016|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101554||47489|
NCT02101567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 3|Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Haemorrhage Following Caesarean Section|A Comparison Between Carbetocin, Oxytocin and Ergometrine in Prevention of Postpartum Haemorrhage Following Caesarean Section||Beni-Suef University|Yes|Completed|May 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|30 Years|No|||April 2015|April 9, 2015|March 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101567||47488|
NCT02101606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009050|Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke|Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke|TAIS|University of Alberta|No|Recruiting|October 2009|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101606||47485|
NCT02101892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-14|Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation|Prediction of Migraine Prevention Efficacy: Individualization of Treatment by Coupling Drug's Mode of Action With Patient's Mechanism of Pain Modulation||Rambam Health Care Campus|No|Recruiting|April 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Female|18 Years|75 Years|No|||September 2015|September 16, 2015|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101892||47463|
NCT02102152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCBH147441|Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection|Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection|TOBI|Rabin Medical Center|Yes|Not yet recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2014|March 30, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02102152||47443|
NCT02115087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGRSB-123|Efficacy Study of Rectus Sheath Block to Control Postoperative Pain|The Effect of Ultrasound Guided Rectus Sheath Block on Postoperative Analgesia After Laparotomy With Transverse Incision in Children|UGRSB|Cukurova University|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|3 Years|15 Years|No|||April 2014|April 14, 2014|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115087||46453|
NCT02114775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0324|Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)|Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI||The University of Texas Medical Branch, Galveston|No|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2015|December 3, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02114775||46477|
NCT02114788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNS100013_130030/1|Interactive Sections Of An Internet-Based Intervention Increase Patient Empowerment: A Study With Chronic Back Pain Patients|INTERACTIVE SECTIONS OF AN INTERNET-BASED INTERVENTION INCREASE PATIENT EMPOWERMENT: A RANDOMIZED CONTROLLED STUDY WITH CHRONIC BACK PAIN PATIENTS||University of Lugano||Completed|March 2013|||September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Participants are screened through their healthcare provider at selected clinics and        rehabilitation centers in the Canton Ticino (Switzerland).|April 2014|April 12, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02114788||46476|
NCT02115685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS079751|Sympathetic-Somatomotor Coupling in Human Spinal Cord Injury|Sympathetic-Somatomotor Coupling in Human Spinal Cord Injury||Rehabilitation Institute of Chicago|No|Recruiting|April 2014|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115685||46407|
NCT02115906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THIGHT_2|Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly|Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly - a 31P/1H Magnetic Resonance Spectroscopy Pilot Study||Medical University of Vienna|Yes|Recruiting|August 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|acromegalic patients and healthy controls matched for sex, age and body mass index|March 2016|March 15, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02115906||46390|
NCT02103413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS-BD-002|EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP|Multicenter Study of EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP||Asan Medical Center|Yes|Completed|October 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103413||47346|
NCT02103439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-016-4|An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients|Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC "BIOCAD", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients||Biocad|No|Active, not recruiting|September 2013|July 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|April 1, 2014|Yes|Yes||No|May 21, 2015|https://clinicaltrials.gov/show/NCT02103439||47344|
NCT02103686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-PRSD-1201|Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects||IlDong Pharmaceutical Co Ltd||Completed|November 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|19 Years|44 Years|Accepts Healthy Volunteers|||September 2012|August 28, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02103686||47325|
NCT02099643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJ-2013-03|Crucial Areas on AF Termination|Crucial Areas on Atrial Fibrillation Termination by Substrate Ablation: Relevance to Anatomy||Hospital St. Joseph, Marseille, France|No|Completed|December 2008|March 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|patients with symptomatic Atrial Fibrilation undergoing EGM-based substrate ablation were        included.|March 2014|March 28, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099643|5 Days|47636|
NCT02099682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|467-712|Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin|Takepron Capsules 15/ Orally Dispersing (OD) Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin||Takeda|No|Completed|August 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3366|||Both|N/A|N/A|No|Non-Probability Sample|Gastric or duodenal ulcers|June 2015|June 5, 2015|March 26, 2014||No||No|June 5, 2015|https://clinicaltrials.gov/show/NCT02099682||47633|
NCT02099916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV04222014|Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF|Prospective Randomized Trial on the Effect of DHEA Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and and Pregnancy Outcome.|DHEA|University of Athens|Yes|Not yet recruiting|October 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099916||47615|
NCT02100176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRT-RT|MIRT and Rotigotine in the Early Stage of PD|Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.|MIRT-RT|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Recruiting|January 2013|June 2014|Anticipated|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|50 Years|75 Years|No|Probability Sample|Parkinson's disease "de novo" Patients|March 2014|March 26, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100176|18 Months|47595|
NCT02110758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-4383|Evaluating the Impact of Patient-Centered Oncology Care|Evaluating the Impact of Patient-Centered Oncology Care||National Committee for Quality Assurance|No|Enrolling by invitation|February 2014|January 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1876|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with cancer who receive their cancer care        from oncology practices. We plan to attribute patients to the study practices based on the        plurality of office visits for cancer diagnoses, but in sensitivity analyses, we will        investigate other attribution rules, such as the majority of such office visits. The study        population also consists of physicians/leadership and nursing/administrative staff at each        of the practices implementing Patient-Centered Oncology Care|April 2015|April 29, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02110758||46786|
NCT02100449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.005|Role of Lung Ultrasound and Pulsed-wave Doppler in Lung Consolidations in Mechanically Ventilated Patients|Role of Lung Ultrasound Imaging and Pulsed-wave Doppler in the Assessment of Lung Consolidations in Mechanically Ventilated Patients.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|June 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|62|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100449||47574|
NCT02101060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O0667-R|Strength Training and Endurance Exercise for LIFE|Effect of Exercise Training on Inflammation and Function in HIV Infected Veterans|STEEL|VA Office of Research and Development|No|Recruiting|September 2014|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Male|50 Years|N/A|No|||December 2015|December 11, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02101060||47527|
NCT02100735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016830|Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients|Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients||Tampa General Hospital|No|Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|100 Years|No|||November 2015|November 2, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02100735||47552|
NCT02101047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 26872|Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension|Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery||Wake Forest School of Medicine|Yes|Enrolling by invitation|August 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Female|18 Years|45 Years|No|||August 2015|August 31, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02101047||47528|
NCT02101320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120704|Hand-held Gamma Camera in the SNOLL Procedure|Contribution of a Hand-held Gamma Camera (TreCam) to the SNOLL(Occult Breast Lesion Localization Plus Sentinel Node Biopsy) Procedure in Breast Cancer|TRECAM|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|19 Years|N/A|No|||July 2015|July 7, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02101320||47507|
NCT02101879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiotoxicity|Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes|Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen||Rambam Health Care Campus|No|Recruiting|May 2014|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood samples for TNI & BNP will be sent before every cycle for the first 5 cycles of      treatment|Female|18 Years|N/A|No|Probability Sample|Patients with Metastatic Breast Cancer Her2 Positive|May 2014|May 1, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02101879|12 Months|47464|
NCT02101905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00634|Lapatinib Tosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma|Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma||National Cancer Institute (NCI)||Suspended|March 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|March 28, 2014|No|Yes|CTSU requested the status update|No||https://clinicaltrials.gov/show/NCT02101905||47462|
NCT02102711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITA-1-OS|Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g|Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g Efficacy and Tolerability in the Prevention of Bronchopulmonary Dysplasia (BDP) and Retinopathy of the Prematurity (ROP)||IRCCS Policlinico S. Matteo|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|4 Days|No|||August 2014|August 29, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02102711||47400|
NCT02102165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIG 14-01|AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.|AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.|AURORA|Breast International Group|Yes|Recruiting|April 2014|January 2027|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02102165||47442|
NCT02115412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhilipsResearch-2007-0116|Validation of Medication Non-adherence Model (UK)|Validation of Medication Non-adherence Model (UK)||Philips Healthcare|No|Recruiting|July 2014|||April 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|750|||Both|18 Years|89 Years|No|Non-Probability Sample|patients with chronic illness taking more than 3 medications. These patients will be        between the age of 18 - 89|July 2014|July 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115412||46428|
NCT02115659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZKIPLA-ADPKD-002|Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD)||Shanghai Changzheng Hospital|Yes|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|75 Years|No|||April 2014|April 16, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115659||46409|
NCT02115672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0575-AN-CTIL|Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia|Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib.||Sheba Medical Center|No|Not yet recruiting|May 2014|November 2018|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||May 2014|May 8, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115672||46408|
NCT02115932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/TA/0022/2013|Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy|The Effectiveness of Strength and Balance Training in Patients With Diabetic Peripheral Neuropathy on Quality of Life and Functional Status: a Randomized Controlled Trial With Cost-utility Analysis|DPN-QoL|National University Health System, Singapore|Yes|Enrolling by invitation|July 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|260|||Both|45 Years|69 Years|No|||March 2016|March 24, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02115932||46388|
NCT02115919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2013.0080|Safety Study of Multikine in the Treatment of Perianal Warts|Phase 1 Study of Multikine in the Treatment of Perianal Warts||United States Naval Medical Center, San Diego|No|Recruiting|April 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|August 15, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115919||46389|
NCT02103452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17819555|Edessy Stem Cell Score (ESS), Endometrium, Endometrioma|Edessy STEM CELL SCORE (ESS), Endometrium, Endometrioma||Al-Azhar University|Yes|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Female|20 Years|40 Years|No|||March 2014|April 1, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02103452||47343|
NCT02103699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101973|A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir|A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings||Janssen Scientific Affairs, LLC|No|Completed|February 2014|January 2016|Actual|November 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|315|||Both|18 Years|N/A|No|Non-Probability Sample|Hepatitis C virus (HCV) infected patients receiving simeprevir.|February 2016|February 19, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02103699||47324|
NCT02099929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GliCafé|Effects of Coffee Consumption on Glucose Metabolism|Coffee and Glucose Metabolism: Clinical, Crossover and Randomized Glucose Disposal Assay Using Stable Isotopes||University of Brasilia|Yes|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|5||Actual|14|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099929||47614|
NCT02100189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9213|Esophageal Cytology With FISH in Detecting Esophageal Cancer in Participants Undergoing Esophago-Gastro-Duodenoscopy or Upper Endoscopy.|Esophageal Cancer (10030139, 10066354) Screening With FISH in Esophageal Cytology||OHSU Knight Cancer Institute|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|310|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100189||47594|
NCT02111031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDX-2014-001|Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients|Registry to Demonstrate the Clinical Utility of CELLSEARCH® Circulating Tumor Cell (CTC) Test in Medicare-Eligible Metastatic Breast Cancer Patients||Janssen Diagnostics, LLC|No|Withdrawn|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|65 Years|N/A|No|Probability Sample|"Cases" of CTC-tested mBC patients being cared for by physicians who routinely (i.e., test        at least once every quarter) incorporate CTC testing in their management of mBC patients.|June 2015|June 18, 2015|April 8, 2014||No|The company decided not to start the study.|No||https://clinicaltrials.gov/show/NCT02111031|9 Months|46765|
NCT02100774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00955-50|Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability|Effect of Genetic Variants of Intestinal Transporters of Lipophilic Micronutrients (Vitamins D, E and Carotenoids) on Absorption Efficiency of These Compounds.|VITAGENES|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|January 2009|December 2013|Actual|July 2010|Actual|N/A|Observational|N/A||1|Actual|45|Samples With DNA|blood, adipose tissue|Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy male adults.|March 2014|March 27, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100774||47549|
NCT02100787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR_PM_102_13|Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears|Evaluation of Tear Osmolarity Over Time With Sustained Use of TheraTears Lubricating Drops|BENTLEY|Jenkins Eye Care|No|Not yet recruiting|April 2014|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|21 Years|N/A|No|||March 2014|March 27, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100787||47548|
NCT02111330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2013-155|Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers|Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02111330||46742|
NCT02111564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103834|A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients|Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk|MARINER|Janssen Research & Development, LLC|Yes|Recruiting|June 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|8000|||Both|40 Years|N/A|No|||March 2016|March 9, 2016|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111564||46724|
NCT02101333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130404|Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis|Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study|TOCITAKA|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|April 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|77 Years|No|||December 2013|March 27, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02101333||47506|
NCT02111577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP005|Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer|A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy|VIABLE|Sotio a.s.|Yes|Recruiting|April 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1170|||Male|18 Years|N/A|No|||January 2016|January 5, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111577||46723|
NCT02101632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/07/B/ST6/01238|Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With RDC/TMD Ia and Ib|Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With Research Diagnostic Criteria/Temporomandibular Disorder Ia and Ib (RDC/TMD) Randomized, Double Blinded Study|BV/TMD|Medical University of Silesia|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|79|||Both|18 Years|79 Years|No|||April 2014|April 1, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02101632||47483|
NCT02101619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-004385|Assessment of Myocardial Tissue Damage in Aortic Stenosis|Assessment of Myocardial Tissue Damage in Aortic Stenosis for Risk Stratification||Mayo Clinic||Recruiting|August 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|||Both|65 Years|N/A|No|Non-Probability Sample|Patients referred for echocardiography in Mayo Clinic.|January 2016|January 4, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101619||47484|
NCT02102984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242/13|Covered Versus Uncovered Biliary Stents for Biliary Malignancies|Covered Versus Uncovered Metal Stents for Biliary Malignancies - A Randomized Controlled Trial||Nuovo Ospedale Civile S.Agostino Estense|Yes|Not yet recruiting|April 2014|October 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102984||47379|
NCT02112643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL9502|Selenium in Mild Thyroid Eye Disease in North America|Selenium - ITEDS: A North American Study|S-ITEDS|Columbia University|No|Recruiting|June 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|151|||Both|18 Years|N/A|No|||August 2014|August 2, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02112643||46641|
NCT02082886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDW120613A|HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry||Edward Hospital|No|Recruiting|February 2014|January 2034|Anticipated|January 2034|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|The sole inclusion criteria for this study will be those consenting patients who are to        undergo cytoreductive surgery followed by HIPEC performed by the PI at Edward Hospital.|September 2014|September 11, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02082886|10 Years|48919|
NCT02115399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADRN-04|ADRN Barrier/Immunoprofiling Exploratory Pilot Study|ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|April 2014|June 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|150|Samples With DNA|Whole blood, skin tissue|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants enrolled in the ADRN Registry study (NCT01494142) who fulfill eligibility        criteria for this (ADRN04) study|July 2015|July 23, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115399||46429|
NCT02116153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHHD-BM-003|Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients|Clinical Use of Mi-RNAs to Improve Specificity of High-sensitivity Troponin T in Symptomatic Patients Presenting to the ED||University Hospital Heidelberg|No|Not yet recruiting|June 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department with symptoms suggestive of acute coronary        syndrome.|April 2014|April 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116153||46371|
NCT02103465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number: 2013-000827-15|Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease|Late Onset Parkinson's Disease in Subjects 70 Years and Older: Possible Use of Rotigotine|PARROT|Azienda Ospedaliera Cardinale G. Panico|No|Terminated|December 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|70 Years|N/A|No|||January 2016|January 22, 2016|March 26, 2014||No|Because the rate of recruitment was very slow|No||https://clinicaltrials.gov/show/NCT02103465||47342|
NCT02099695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT069|Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis|Clinical Trial Phase III, Prospective, Randomized, Double-blind, Multicenter, National, Comparative Between Oxybutynin Chloride With Placebo to Evaluate the Efficacy and Safety for Systemic Treatment of Primary Hyperhidrosis.||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Not yet recruiting|December 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02099695||47632|
NCT02110251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEARL study|Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease|Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease With Critical Limb Ischemia or Tissue Loss. A Pilot Study|PEARL|Catharina Ziekenhuis Eindhoven|No|Recruiting|September 2011|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||April 2015|April 3, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02110251||46825|
NCT02110524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP1027|CVI Drug Coated Balloon First In Human Trial|Prospective, Controlled, Multi-Center, Open, Single Arm Study for the Treatment of Subjects Presenting De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Angioplasty Catheter||Spectranetics Corporation|No|Completed|December 2011|December 2014|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02110524||46804|
NCT02110771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00793-38|Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia|Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia||Hôpital le Vinatier|No|Completed|May 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|45 Years|No|||September 2015|March 2, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02110771||46785|
NCT02111005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-01-2014|Smoking Influence on Apoptosis in Periodontitis|Influence of Smoking on Fibroblast Apoptosis in Patients With Chronic and Aggressive Periodontitis||Damascus University|Yes|Completed|April 2015|March 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 80 subjects will be invited to participate in this study from the patients        referred to the Department of Periodontology, Faculty of Dentistry, University of        Damascus. Patients should have a diagnosis of periodontitis (either chronic or        aggressive). Any candidate will be approached and informed about this clinical study with        the relevant information sheet. Informed consent forms will be obtained.Using five        clinical parameters and full mouth or panoramic radiographs, the participants will be        allocated to four groups according to their condition as well as their smoking habit. The        description of these groups has given before.|March 2016|March 15, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02111005||46767|
NCT02111850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140052|T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive|Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin||National Institutes of Health Clinical Center (CC)||Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|107|||Both|18 Years|70 Years|No|||February 2016|February 20, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111850||46702|
NCT02111863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140062|Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||May 2015|February 26, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111863||46701|
NCT02111876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11-238|Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU|Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU||Ligue Pulmonaire Genevoise|No|Recruiting|September 2012|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients surviving an episode of acute hypercapnic respiratory failure in the ICU|April 2014|April 9, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02111876||46700|
NCT02111902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK090363|Vitamin D Ancillary Study in 5 Populations of African Origin|Determinants and Consequences of Low Vitamin D in Populations of African Descent|VIDA|Loyola University|No|Active, not recruiting|September 2011|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples With DNA|Blood Serum Urine|Both|25 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|A community-based probability sampling strategy is being used to recruit 500 adults, ages        25-44, from metropolitan Chicago, Spanish Town Jamaica, rural Ghana near Kumasi, Cape Town        South Africa, and the Seychelles in the Indian Ocean|April 2014|April 10, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02111902||46698|
NCT02111824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009873|A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy|A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy|MIMIG|The Methodist Hospital System|Yes|Recruiting|November 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111824||46704|
NCT02112175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-026|Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM|Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma|ARUMM|Celgene|Yes|Active, not recruiting|April 2014|October 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112175||46677|
NCT02111837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.16.INF.B|Effects of Specific Lipid Fractions-enriched Infant Formulae|Multicenter, Randomized, Double-blind, Parallel-group, Reference-controlled, Safety Pilot Study to Evaluate the Effects of Specific Lipid Fractions-enriched Infant Formulae in Infants Aged 0-4 Months||Nestlé|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|199|||Both|N/A|14 Days|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111837||46703|
NCT02101918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00642|Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery|Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors||National Cancer Institute (NCI)|No|Recruiting|June 2014|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101918||47461|
NCT02112396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF-01GX0702|Community Reinforcement and Family Training (CRAFT) for Treatment-resistant Individuals With Alcohol Use Disorders|Psychosocial Intervention for Relatives of Individuals Suffering From Chronic Alcohol Dependence|CRAFT|University of Luebeck|No|Completed|August 2008|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02112396||46660|
NCT02109198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-NINM pilot|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Phase)||U.S. Army Medical Research and Materiel Command|No|Withdrawn|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|18 Years|50 Years|No|||May 2015|May 29, 2015|April 7, 2014||No|protocol withdrawn|No||https://clinicaltrials.gov/show/NCT02109198||46904|
NCT02082626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3812|Study of Eribulin in Children With Cancer to Determine Safety|A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors|ERIBULIN|University of Oklahoma|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|20 Years|No|||December 2014|December 2, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082626||48939|
NCT02082639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117099|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years|Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix™) (GSK-580299) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) (GSK-208109) in Healthy Female Adolescents Aged 9-14 Years||GlaxoSmithKline||Withdrawn|February 2015|November 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|March 6, 2014|Yes|Yes|Because the Russian Authorities already approved the 2‐dose Cervarix™ schedule, the study was    no longer needed for registration and hence it was cancelled.|No||https://clinicaltrials.gov/show/NCT02082639||48938|
NCT02115698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-070.3|Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)|Counteracting Age-related Loss of Skeletal Muscle Mass|CALM|Bispebjerg Hospital|Yes|Recruiting|April 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|68|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02115698||46406|
NCT02083432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/63|Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and Adolescents|Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and Adolescents||University of Bergen|Yes|Active, not recruiting|December 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|10 Years|16 Years|No|||December 2015|December 4, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02083432||48878|
NCT02083445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP2010-222005-C02-02|Exercise, Hypoxia and CPC in TBI Patients|Exercise, Muscle Electro-stimulation and Intermittent Hypobaric Hypoxia Program and Circulating Progenitor Cells in Traumatic Brain Injured Patients|TCECAM|University of Barcelona|Yes|Completed|November 2011|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|21|||Male|20 Years|60 Years|No|||March 2014|March 7, 2014|March 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02083445||48877|
NCT02083744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05030|Project Fluido: Fluid Watchers|A Self-Care Intervention for Hispanic Patients With Heart Failure||University of California, San Francisco|No|Active, not recruiting|June 2013|June 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02083744||48854|
NCT02103712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR12/10496|Long Term Outcome of Hypospadias Repair|Long Term Outcome of Hypospadias Repair: A Comparative Study||The Leeds Teaching Hospitals NHS Trust|No|Completed|October 2012|||September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|||Male|3 Years|17 Years|No|Non-Probability Sample|Patients with hypospadias|April 2014|April 3, 2014|November 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02103712||47323|
NCT02109952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000285/11|Biomechanics of Metastatic Defects in Bone|The Purpose of This Study is to Monitor Fracture Risk Associated With Bone Tumors in Cancer Patients||Beth Israel Deaconess Medical Center|No|Recruiting|January 2009|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|245|||Both|20 Years|90 Years|No|Non-Probability Sample|When a patient presents to the orthopaedic oncologist with lower appendicular skeletal        skeletal metastasis, as per standard clinical practice biplanar radiographs and CT scans        of the involved bone(s) plus the contralateral limb will be obtained. Informed consent        will be obtained for CT scan with the contralateral limb (Both limbs are in the gantry and        are imaged together-this is not an additional step, as this is how patients are scanned        for general care of lesions in the lower limbs) to provide a patient specific internal        control and calcium hydroxyapatite phantom for standardizing bone density estimates.        Post-processing of the image data will be conducted by the Orthopaedic Biomechanics Lab at        BIDMC to calculate fracture risk associated with the bone lesion.|November 2015|November 13, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02109952|12 Months|46846|
NCT02110537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI13C0580|Acupuncture in Persistent Atrial Fibrillation|Clinical Trial to Evaluate the Antiarrhythmic Effects of Acupuncture for Drug Resistant Persistent Atrial Fibrillation: Randomized, Participant and Assessor Blinded, Sham-controlled, Clinical Trial||Kyunghee University Medical Center|No|Recruiting|March 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|No|||April 2014|April 8, 2014|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02110537||46803|
NCT02110784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST3073-ST3074-DM13-001|Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria|Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria||sigma-tau i.f.r. S.p.A.|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110784||46784|
NCT02111018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CytoSorb 2013-001|Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis|||CytoSorbents, Inc|No|Recruiting|March 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111018||46766|
NCT02111343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/09/485|The Effectiveness of Computerized Auditory Training Programme on Children With Auditory Processing Disorder|Pilot Study: The Effectiveness of Computerized Auditory Training Programme on Children With Auditory Processing Disorder|CBAT|National University Health System, Singapore|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|7 Years|12 Years|No|||April 2014|April 7, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02111343||46741|
NCT02111356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-001|Determine Functions of Pinhole Glasses on the Eyes|Quantative Analysis of Functional Changes by the Pinhole Glasses|PH001|Chung-Ang University Hospital|Yes|Active, not recruiting|April 2014|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02111356||46740|
NCT02111590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-400-RH|Immunoglobulin Dosage and Administration Form in CIDP and MMN|The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN||Rigshospitalet, Denmark|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|36|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with CIDP or MMN in maintenance treatment with immunoglobulins|September 2015|September 18, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111590||46722|
NCT02112695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208051|Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study|Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|March 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112695||46637|
NCT02112188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-076|Adaptation of Individual Meaning-Centered Psychotherapy for Chinese Immigrant Cancer Patients|Adaptation of Individual Meaning-Centered Psychotherapy for Chinese||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|80 Years|No|Non-Probability Sample|Participants will be recruited from MSKCC, QCC, CCHC, ACS Asian Initiatives, CBWCHC, NYHQ        and NYCAAMH and the Cheung and Kan Medical Group,.|December 2015|December 4, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02112188||46676|
NCT02112409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 201312-0621|Intraoperative Cell Salvage and Hemodilution Technique in Scoliosis Surgery|Autologous Blood Transfusion Technique in Idiopathic Scoliosis Surgery - a Comparison Between Intraoperative Cell Salvage With Hemodilution Techniques Versus Cell Salvage Technique Alone||University of Malaya|Yes|Completed|February 2014|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|10 Years|25 Years|No|||June 2015|June 3, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02112409||46659|
NCT02112162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401064|Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery|Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer||Washington University School of Medicine|No|Recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112162||46678|
NCT02108717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|The Feasibility Study for Real-time Remote CT Reading for Suspected Acute Appendicitis Using iPhone|The Feasibility Study for Remote CT Reading for Suspected Acute Appendicitis Using iPhone With Remote Control System in Realtime Under the Ambient Bright.|Telemedicine|Hanyang University|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Male|33 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108717||46941|
NCT02108925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2396|Effect of Oxygen Supplementation During Exercise in Chronic Obstructive Pulmonary Disease Patients|Oxygen Supply and Ventilation During Physical Exercise in Patients With Chronic Obstructive Pulmonary Disease||LHL Helse|No|Recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|95 Years|No|||March 2016|March 1, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108925||46925|
NCT02082405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3A13|Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma|A Phase II Trial of Weekly Bortezomib and Dexamethasone With Oral Metronomic Cyclophosphamide in Elderly Patients With Plasma Cell Myeloma||Case Comprehensive Cancer Center|Yes|Withdrawn|April 2015|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||April 2015|April 23, 2015|March 6, 2014|No|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT02082405||48956|
NCT02082652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010195|A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy|A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women||University of Pittsburgh|No|Active, not recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|45 Years|No|||January 2016|January 15, 2016|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082652||48937|
NCT02082899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-AC-1|A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)|A Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model||Eleven Biotherapeutics|No|Completed|February 2014|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082899||48918|
NCT02082912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035176|NMDA Receptors in Motor Learning in Humans|||Emory University|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|95 Years|No|||April 2015|April 9, 2015|March 5, 2014||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT02082912||48917|
NCT02082925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVIE_SD6|Dyspnea Threshold During 6 Minutes Walk Test|Self-perception of Dyspnea Threshold During the 6-minute Walk Test (DT6): A New Tool for Individualized Exercise Training With Chronic Obstructive Pulmonary Disease Patients (COPD)|SD6|5 Santé|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|82|||Both|N/A|N/A|No|||March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082925||48916|
NCT02083211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMO 001-09 MX|Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma|Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma"||National Institute of Cancerología|Yes|Completed|July 2010|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Female|18 Years|70 Years|No|||April 2015|April 13, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02083211||48895|
NCT02109705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG001|Porphyromonas Gingivalis and Alzheimer`s Disease|Porphyromonas Gingivalis - a Responsible Pathogen in Alzheimer`s Disease?|PGNEURO|University Hospital Muenster|No|Recruiting|March 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|GCF, Liquor, Serum|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 Patients with Dementia (30 with Alzheimer`s and 30 with another Dementia) 30 cognitive        healthy patients|December 2014|December 8, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02109705||46865|
NCT02109939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX1006|Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic|A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic|RCT|Assurex Health Inc.|No|Recruiting|April 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||October 2015|December 4, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02109939||46847|
NCT02110264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034743|Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)|Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs|IPOD|University of California, Los Angeles|Yes|Not yet recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110264||46824|
NCT02111044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/13/2984/05|Phase II Study With ITF2984 in Acromegalic Patients|A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients|POC|Italfarmaco|No|Active, not recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|80 Years|No|||August 2015|August 28, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111044||46764|
NCT02111616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC HENC LCCC 1325|Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study|Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study||UNC Lineberger Comprehensive Cancer Center|No|Completed|December 2013|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|37|||Both|21 Years|90 Years|No|||January 2016|January 19, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02111616||46720|
NCT02111629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309010018168|Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge|Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia.||Universidad Nacional de Colombia|Yes|Completed|May 2012|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Female|18 Years|50 Years|No|||March 2014|April 10, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02111629||46719|
NCT02111915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THPP-P MH095687|Thinking Healthy Program - Peer Delivered (Pakistan)|Thinking Healthy Program - Peer Delivered in Pakistan|THPP-P|University of Liverpool|Yes|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111915||46697|
NCT02111603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000384|Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids|Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome||Mayo Clinic|No|Completed|April 2014|September 2015|Actual|August 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|April 9, 2014|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT02111603||46721|
NCT02111889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/478|Tumor Kinase Inhibitor Concentrations Measured by PET|Measurement of Tumor Kinase Inhibitor Concentrations Using PET Imaging in Patients With Advanced Solid Malignancies|PIKTURE|VU University Medical Center|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111889||46699|
NCT02112448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5900208|Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery|Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery||Advocate Health Care|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Months|4 Months|No|||January 2016|January 14, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112448||46656|
NCT02112201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA025857|The ProGirls Study|Preventing HIV/STI Risk Behavior in Girls With Delinquency, Drug Abuse, & Trauma||Oregon Research Institute|No|Recruiting|September 2013|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02112201||46675|
NCT02112422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:159|The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.|The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.||University of Manitoba|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|50 Years|No|||April 2015|April 29, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02112422||46658|
NCT02112682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOG 2013-07|Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy|The Value of Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy. A Dutch Randomized Controlled Multicentre Trial.||Maastricht University Medical Center|Yes|Recruiting|June 2014|||June 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|878|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112682||46638|
NCT02112656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-13-302|Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)|A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm|OPTIMA|Celsion|Yes|Recruiting|June 2014|December 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112656||46640|
NCT02112669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laminate CD0006|A Multi Center, Study to Evaluate the Safety and Efficacy of the Laminate External Support Device for Arteriovenous Fistulas|A Prospective, Multi Center, Study to Evaluate the Safety and Efficacy of the Laminate External Support Device for Brachiocephalic Arteriovenous Fistula||Laminate Medical Technologies||Recruiting|April 2014|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|50 Years|N/A|No|||October 2015|October 20, 2015|April 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112669||46639|
NCT02108938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0131|Brain-Gut Interactions in Crohn's Disease|Characterizing Brain-Gut Interaction in Patients With Crohn's Disease Using Advanced Neuroimaging Tools||University of Wisconsin, Madison|No|Active, not recruiting|April 2014|December 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients 18 years of age or older diagnosed with CD, as determined by endoscopy or        radiographic imaging, will be targeted for enrollment. Patients with CD in symptomatic        remission as defined by a Harvey-Bradshaw score of 3, will be eligible.|June 2015|June 3, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02108938||46924|
NCT02082392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6652|Developing New Clinical Management Strategies|Developing New Clinical Management Strategies for Antidepressant Treatments||New York State Psychiatric Institute|No|Active, not recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||August 2014|March 20, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082392||48957|
NCT02082678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112013-075|Ondansetron for Bipolar Disorder and Alcohol Use Disorders|Ondansetron for Bipolar Disorder and Alcohol Use Disorders||University of Texas Southwestern Medical Center|Yes|Recruiting|April 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082678||48935|
NCT02082691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 13-0040|Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma|Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit||The University of Texas Health Science Center at San Antonio||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2014|March 6, 2014|March 6, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02082691||48934|
NCT02082665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200919|Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam|An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects With BRAF V600 Mutation Positive Tumors||GlaxoSmithKline|No|Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|March 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02082665||48936|
NCT02082938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eder01|The Use of Brace to Retrain Hemiparetic Gait|The Use of a Brace to Retrain Hemiparetic Gait in Patients With Genu Recurvatum: Effects on Plantar Pressure Distribution||Federal University of Health Science of Porto Alegre|No|Completed|March 2012|January 2014|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082938||48915|
NCT02083224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/00511|Familial Cancer Registry and DNA Bank|Familial Cancer Registry and DNA Bank||National University Hospital, Singapore|Yes|Recruiting|January 2000|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood for DNA banking and future genotyping Questionnaires regarding family history of      cancer and personal medical history will be taken.|Both|13 Years|N/A|No|Probability Sample|Patients are recruited from the National University Hospital. All cancer patients seen in        the Cancer Centre, NUH, are screened using a basic family history form.The family history        is reviewed by the Principal Investigator with the cancer genetics counselor. Eligible        patients who fulfil the eligibility criteria as described below are invited to        participate. Written informed consent is obtained. Demographic characteristics and cancer        history of the study subject is prospectively recorded. Participants are invited to fill        out a family history questionnaire providing cancer history information on their first-        and second-degree relatives. Participants are also invited to donate 10ml blood for DNA        banking and future genotyping. Permission will be obtained from participants to contact        family members who may be eligible to participate in the study.|March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083224|5 Years|48894|
NCT02083172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-658|Comparing USCOM and Echocardiographic Hemodynamic Measurements in Children (CUE Study)|Evaluating Agreement Between USCOM and 2D-echocardiographic Hemodynamic Measurements in Pediatric Patients||McMaster University|No|Completed|July 2014|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|78|||Both|1 Month|18 Years|No|Non-Probability Sample|1. The hemodynamically stable group: will be screened from pediatric in-patients on             McMaster Children's Hospital general pediatric wards and those scheduled for elective             2D-echo through cardiology and sedation clinic.          2. The hemodynamically unstable patients and 3. those requiring mechanical ventilation             will be screened from McMaster Children's Hospital Pediatric Critical Care Unit.|November 2015|March 14, 2016|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02083172||48898|
NCT02083185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C27002|A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer|A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|April 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|125|||Male|18 Years|N/A|No|||July 2015|July 1, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083185||48897|
NCT02083198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bax-BSP-HiLoCl|Effects of IV Chloride Content on Outcomes|A Comparison of High and Low Chloride Containing IV Fluid Solutions in Patients Undergoing Major Surgery and/or ICU Admission||Baxter Healthcare Corporation|No|Recruiting|September 2013|||April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients with SIRS needing fluid replacement|March 2014|March 10, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083198||48896|
NCT02083471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTU-ClinAll-0112|Cow's Milk and Hen's Egg Hyposensitization in Adults|Cow's Milk and Hen's Egg Hyposensitization in Adults||Turku University Hospital|No|Not yet recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|65 Years|No|||October 2015|October 29, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083471||48875|
NCT02109718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUR-2009-06-11-033|A Trial Comparing the Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine|A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic||University of the Philippines|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|No|||April 2014|April 9, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02109718||46864|
NCT02110797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071230|Osteoporosis in RETT Syndrome|Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.|OSRETT|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2009|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|98|||Female|5 Years|45 Years|No|||July 2015|July 20, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02110797||46783|
NCT02111369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072929|Propranolol and Botulinum Toxin for Essential Vocal Tremor|Propranolol and Botulinum Toxin for Essential Vocal Tremor||Emory University|Yes|Completed|May 2014|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|45 Years|N/A|No|||May 2015|May 8, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111369||46739|
NCT02111928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-001|NovaTears® Eye Drops Observational Study|NovaTears® Observational Study||Novaliq GmbH|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with mild to moderate hyper-evaporative dry eye disease|October 2015|October 5, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02111928||46696|
NCT02111941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1361|Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy|A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer||Mayo Clinic|Yes|Recruiting|April 2014|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02111941||46695|
NCT02112435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011-CERES-D|Comparative Efficacy Study of Titratable Versus Active Mandibular Advancement Splint in Sleep Apnea|Comparative Study of Efficacy of Titratable Mandibular Advancement Splint Versus Active Mandibular Advancement Splint to Treat Patients With Obstructive Sleep Apnea|SOMNYX|Université de Montréal|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02112435||46657|
NCT02112227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT-HF|Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster Randomized Trial|Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster|PACT-HF|Population Health Research Institute|No|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|16 Years|N/A|No|||September 2015|September 21, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112227||46673|
NCT02108743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB8603|Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension|Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension||American Medical Association Foundation|Yes|Withdrawn|June 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||December 2015|December 29, 2015|April 7, 2014|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02108743||46939|
NCT02108756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-CTTQ-SPAN|Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding|||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|February 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|272|||Both|18 Years|65 Years|No|||April 2014|April 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108756||46938|
NCT02108951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AAU04|Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.|A Multicenter, Single Arm Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Intolerant to Prior Tyrosine Kinase Inhibitors (TKIs).|ENESTswift|Novartis|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02108951||46923|
NCT02108730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism|Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism|non-focal CHI|University Medicine Greifswald||Completed|March 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|N/A|N/A|No|Probability Sample|13 children and one adult (30 years)|April 2014|April 8, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02108730||46940|
NCT02109237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/13/QPCH/217|Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3|The Prevalence and Treatment of Sleep Disorders in Lung Transplant Recipients With BOS 2 & 3 and the Influence on Quality of Life and Daytime Activity.||The Prince Charles Hospital|Yes|Recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|75|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109237||46901|
NCT02109471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#9282|Observational Study of Corneal Opacities in Adults|Observational Study of Corneal Opacities in Adults||Oregon Health and Science University|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Adult patients presenting in OHSU Casey Eye Clinic with corneal opacities (scar and        stromal dystrophy)|April 2015|April 21, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02109471||46883|
NCT02109484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-013|Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants|Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability & Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers & Infants||PATH|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|15||Anticipated|204|||Both|6 Weeks|35 Months|Accepts Healthy Volunteers|||January 2016|January 15, 2016|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02109484||46882|
NCT02086448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13080159|Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)|Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)|SOAP|University of Pittsburgh|Yes|Recruiting|September 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02086448||48646|
NCT02086461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/896-31/4|Pylorus Dysfunction After Esophagectomy and Gastric Tube Reconstruction. Effect of Pneumatic Pylorus Dilatation During Hospital Stay, Surgical Complications During in Hospital Stay|Pylorus Dysfunction After Esophagectomy. Effect of Pneumatic Dilatation.||Karolinska University Hospital|No|Enrolling by invitation|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||August 2015|August 31, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086461||48645|
NCT02082704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ 1R01HS019708-01A1|Interactive Spaced Education to Optimize Diabetes Care|Interactive Spaced Education to Optimize Diabetes Care||Boston VA Research Institute, Inc.|No|Active, not recruiting|June 2014|August 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|N/A|N/A|No|||December 2015|December 11, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082704||48933|
NCT02082951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP23|Family Empathic Behaviour Versus Nurse Empathic Behaviour|Family Empathic Behaviour Versus Nurse Empathic Behaviour: Comparison of Anxiety Symptoms in the Preoperative Cardiac Surgery Patients||Federal University of São Paulo|Yes|Completed|May 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|66|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02082951||48914|
NCT02083237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB0650|Evaluation of an Intervention for Living With Mild Cognitive Impairment|Evaluation of a Behavioural Intervention for People Living With Mild Cognitive Impairment||Baycrest|No|Recruiting|January 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 7, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02083237||48893|
NCT02083250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0999|Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia|Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia||M.D. Anderson Cancer Center|No|Recruiting|March 2014|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|N/A|60 Years|No|||February 2016|February 8, 2016|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02083250||48892|
NCT02083484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-030|Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)|Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options||Merck Sharp & Dohme Corp.||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Years|N/A||||April 2015|April 20, 2015|March 7, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02083484||48874|
NCT02083497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20559113.0.0000.5503|Comparison Between Rigid Functional And Elastic Bandage For Stabilizing Ankle Support During The Member Of The Chute Football|COMPARISON BETWEEN RIGID FUNCTIONAL AND ELASTIC BANDAGE FOR STABILIZING ANKLE SUPPORT DURING THE MEMBER OF THE CHUTE FOOTBALL||Universidade do Vale do Paraíba|Yes|Recruiting|October 2013|December 2014|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2014|March 10, 2014|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02083497||48873|
NCT02110550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-FixPro-01-2014|Evaluation of a New Design of Crowns in the Posterior Teeth|Evaluation of IPS E.Max-CAD Endocrown in Molars Compared to the Conventional Design||Damascus University|Yes|Completed|May 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|60 Years|No|||October 2015|October 2, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110550||46802|
NCT02111057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13146|Perioperative Flare in RA: Characterization of Clinical and Biological Features|Perioperative Flare in RA: Characterization of Clinical and Biological Features|Periop Flare|Hospital for Special Surgery, New York|No|Recruiting|September 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|The study population will comprise of 100 patients with Rheumatoid Arthritis undergoing a        primary or secondary total hip replacement.|April 2014|April 8, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111057||46763|
NCT02111382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cv4-2014|Electroencephalography Activity in Individuals With Nonspecific Chronic Low Back Pain After Cranial Osteopathic Manipulative Treatment|Electroencephalography Activity in Individuals With Nonspecific Chronic Low Back Pain After Cranial Osteopathic Manipulative Treatment: Study Protocol of a Randomized, Controlled Crossover Trial||University of Brasilia|Yes|Recruiting|August 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02111382||46738|
NCT02111408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK: H-2-3013-091|Stroke - Sleep Disorders, Dysfunction of the Autonomic Nervous System and Depression|Stroke - Sleep Disorders, Dysfunction of the Autonomic Nervous System and Depression||Glostrup University Hospital, Copenhagen|No|Recruiting|March 2014|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|335|Samples With DNA|Whole blood, plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|The study population is recruited among patients admitted at the acute stroke unit at        Glostrup university hospital.|February 2016|February 11, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02111408||46736|
NCT02113540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant number: 392172|Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography|Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography|CIN|Isfahan University of Medical Sciences||Recruiting|January 2012|||May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||||||Both|N/A|N/A||||April 2014|April 10, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02113540||46572|
NCT02113774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7687|The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients|||Rabin Medical Center||Not yet recruiting|April 2014|||April 2019|Anticipated|Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||April 2014|April 14, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02113774||46554|
NCT02082795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|breechqualyv1|Investigating Women's Views on the Management of a Breech Pregnancy|Investigating Women's Views on the Management of a Breech Pregnancy||Chelsea and Westminster NHS Foundation Trust|No|Not yet recruiting|March 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Female|18 Years|N/A|No|Non-Probability Sample|Women found to have a fetus in a breech presentation at >34 weeks gestation following a        presentation scan in Chelsea and Westminster Hospital.|March 2014|March 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02082795||48926|
NCT02083055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-DT/PY-IRB 2012/021.1904|Anesthetic Advantages of Dexmedetomidine for Hypotensive Anesthesia|Anesthetic Advantages of Dexmedetomidine Compared With Nitroglycerin for Hypotensive Anesthesia in Orthognathic Surgery. A Randomized Clinical Trial.||Mahidol University|No|Completed|December 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||March 2014|March 6, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02083055||48906|
NCT02083068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2304-493-26202|Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax|Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax||Malaria Vaccine and Drug Development Center|No|Not yet recruiting|May 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02083068||48905|
NCT02114554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307058RINB|Mitochondrial nt3243 A>G Mutation in Taiwan|Clinical Characteristics and Prognostic Factors of Mitochondrial nt3243 A>G Mutation in Taiwan||National Taiwan University Hospital|No|Recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients with mitochondrial DNA nt3243 A>G mutation detected at National Taiwan University        Hospital.|April 2014|April 13, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02114554||46494|
NCT02122393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2001/01263|A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression|A Randomised, Controlled Evaluation of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression||University of Melbourne|No|Completed|April 2002|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|40 Years|No|||April 2014|April 27, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122393||45892|
NCT02122406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31748\2009 progetto lorhen|Depression and Anxiety in Rheumatoid Arthritis|Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity|DEAR|University of Pavia|No|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with rheumatoid arthritis currently treated with biological drugs.|December 2015|December 4, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122406||45891|
NCT02123797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Milestone Project|Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology|Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology||Baptist Memorial Health Care Corporation|No|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|450|||Both|N/A|N/A|No|Non-Probability Sample|Lung Cancer Patients coming through the Baptist health care system|January 2016|January 11, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123797||45786|
NCT02123251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDFA93.536 -CMS-MIPCD-HI|Hawaii Patient Reward And Incentives to Support Empowerment|A Randomized Incentive-Based Diabetes Self-Management Study (Hawaii Patient Reward And Incentives to Support Empowerment Project)|HI-PRAISE|University of Hawaii|No|Active, not recruiting|May 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|320|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02123251||45827|
NCT02122718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12MT494|Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack|Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack|XILO-FIST|NHS Greater Glasgow and Clyde|Yes|Not yet recruiting|May 2014|March 2019|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|464|||Both|50 Years|N/A|No|||April 2014|April 23, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122718||45867|
NCT02133040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2013-236-13|Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue|Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases||Aarhus University Hospital|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Serum and fat tissue|Both|50 Years|N/A|No|Non-Probability Sample|10 patients with hyperthyroidism, reffered to our hospital from their primary caretakers        will be investigated before and after 3 to 5 months in a proven euthyroid state.|January 2016|January 11, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133040||45079|
NCT02133339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRN-157-101|Single Ascending Dose Study of TRN-157 in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects||Theron Pharmaceuticals, Inc.||Completed|May 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02133339||45056|
NCT02083809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxyDE|Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation|A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use||University of Hawaii|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Female|14 Years|50 Years|No|||July 2015|July 12, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083809||48849|
NCT02084043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synchro-Neb|In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation|In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses.|Synchro-Neb|University Hospital St Luc, Brussels|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02084043||48831|
NCT02084875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921180|A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers|A Phase 1, Randomized, Open Label, Single Dose, 2-Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (MR) 11 Mg Tablets In Healthy Western And Japanese Volunteers||Pfizer|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|March 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084875||48767|
NCT02085161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.16|To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways|An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|March 2014|October 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|304|||Both|40 Years|75 Years|No|||November 2015|November 3, 2015|March 7, 2014||||No||https://clinicaltrials.gov/show/NCT02085161||48745|
NCT02085174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|radis 1-3_REV_01_CTIL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2008|||||N/A|N/A|N/A||||||||||||||March 10, 2014|January 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085174||48744|
NCT02085408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2906|Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years)||Eastern Cooperative Oncology Group||Recruiting|December 2010|||February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|747|||Both|60 Years|N/A|No|||September 2014|September 16, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085408||48726|
NCT02085200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04111311|Scapular Stabilization During Manual Horizontal Adduction Stretches and Its Effect on Increasing Posterior Shoulder Flexibility|The Effect of Scapular Stabilization During Horizontal Adduction Stretching on Passive Internal Rotation and Posterior Shoulder Tightness in Young Female Volleyball Athletes.||Nova Southeastern University|Yes|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|60|||Female|15 Years|21 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085200||48742|
NCT02085460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-12-001|A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|75 Years|No|||December 2015|December 18, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085460||48722|
NCT02085473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2210C00011|A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers|||MedImmune LLC|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|149|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085473||48721|
NCT02086006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-1002|Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial|A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS||Elixir Medical Corporation|Yes|Active, not recruiting|February 2011|June 2016|Anticipated|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02086006||48680|
NCT02086305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolyU5492|Transitional Palliative Care in End-stage Heart Failure|Effects of a Transitional Palliative Care Model on Patients With End-stage Heart Failure||The Hong Kong Polytechnic University|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|176|||Both|N/A|N/A|No|||February 2016|February 18, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086305||48657|
NCT02086318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OvAge|A New Algorithm to Predict Ovarian Age|A New Algorithm to Predict Ovarian Age Combining Clinical, Biochemical and 3D-ultrasonographic Parameters: OvAge|OvAge|University Magna Graecia|Yes|Recruiting|January 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women|April 2015|April 19, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086318||48656|
NCT02086578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-028|Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions|Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions||Memorial Sloan Kettering Cancer Center||Recruiting|March 2014|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|155|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086578||48636|
NCT02113787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620140190 (2013-2172)|Switchability Study Between Brand and Generic Topiramate|A Clinical Pharmacokinetics Comparing Brand and Generic Topiramate in Epilepsy Patients : A Open-label,Randomised, Three-period Crossover Study||Seoul National University Hospital|No|Active, not recruiting|February 2014|February 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02113787||46553|
NCT02114034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI12004|Cohort Analysis of Clinical and Biological Severe Childhood Asthma|Cohort Analysis of Clinical and Biological Severe Childhood Asthma|COBRAPed|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2013|September 2031|Anticipated|September 2031|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|676|Samples With DNA|-  whole blood        -  serum        -  Bronchoalveolar lavage fluid        -  bronchial brushing and washing specimens|Both|3 Years|18 Years|No|Non-Probability Sample|Primary Care Clinic|November 2015|November 25, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02114034||46534|
NCT02114047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013D002300|Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging|Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging||Massachusetts General Hospital|No|Recruiting|February 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|70 Years|No|Probability Sample|Chronic thromboembolic pulmonary hypertension|April 2015|April 6, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02114047||46533|
NCT02114281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/11|Oral and Dental Health Status in Patients Suffering From Chronic Kidney Disease|Oral and Dental Health Status in Patients Suffering From Chronic Kidney Disease|NEPHRODENT|University Hospital, Bordeaux|No|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02114281||46515|
NCT02114567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPDNAVA|Is it Necessary to Set External PEEP in AECOPD Patients|Neural Triggering and Cycling-off of Pressure Support Ventilation Improves Synchrony and Reduces Inspiratory Effort in Chronic Obstructive Pulmonary Disease.||Southeast University, China|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|85 Years|No|||July 2014|July 15, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02114567||46493|
NCT02123511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC13C2|Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy|A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies||Mayo Clinic||Active, not recruiting|April 2014|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|April 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02123511||45807|
NCT02124889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027050|Multivitamin Adherence Following Bariatric Surgery|Adherence to Multivitamin Use Following Bariatric Surgery for Weight Loss||Wake Forest Baptist Health|No|Recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124889||45703|
NCT02124902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404107|Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity|A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery||Washington University School of Medicine|No|Recruiting|July 2014|April 2022|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124902||45702|
NCT02124915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37575-1|Influence of Socket Volume on Prosthesis Performance|Influence of Socket Volume on Prosthesis Performance|CAD|University of Washington|No|Recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Transtibial amputees|April 2014|April 24, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124915||45701|
NCT02122185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1235|Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer||University of Chicago|Yes|Recruiting|June 2014|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|77 Years|No|||November 2015|November 16, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122185||45908|
NCT02133053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL-042|Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray|Non Interventional Study of Ectoin Allergy Nasal Spray Compared to Beclomethasone Nasal Spray||Bitop AG|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|70 Years|No|Non-Probability Sample|Primary Care Clinic|May 2014|May 6, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02133053||45078|
NCT02133066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010667|The Effect of Bedside Ultrasound Assistance on the Proportion of Successful Infant Spinal Taps|The Effect of Bedside Ultrasound Assistance on the Proportion of Successful Infant Lumbar Punctures in a Pediatric Emergency Department: A Randomized Controlled Trial||Children's Hospital of Philadelphia|No|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|128|||Both|N/A|6 Months|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133066||45077|
NCT02084316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA CTN 0056|Testing and Linkage to HIV Care in China|Testing and Linkage to HIV Care in China: A Clustered Randomized Trial|CTN 0056|University of California, Los Angeles|Yes|Completed|March 2014|January 2016|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084316||48810|
NCT02084602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U.2012.0008|Assessment of Artesunate/Mefloquine in the Peruvian Amazon|Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon|Artesunate|Instituto Nacional de Salud. Peru|Yes|Not yet recruiting|June 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|5 Years|65 Years|No|||March 2014|June 4, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084602||48788|
NCT02084615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0976|Prospective Study Investigating Aspirin and Intraoperative Blood Loss and Complications Following Inguinal Hernia Repair|A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.||Jesse Brown VA Medical Center|No|Enrolling by invitation|August 2014|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Male|18 Years|N/A|No|||June 2015|June 16, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084615||48787|
NCT02084888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAAR-CTO-01|Prognostic Impact of Chronic Total Occlusions|Prognostic Impact of Chronic Total Occlusions - A Report From the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)||Sahlgrenska University Hospital, Sweden|No|Completed|January 2005|January 2012|Actual|January 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|91154|||Both|N/A|N/A|No|Probability Sample|The study is based on all patients who underwent diagnostic coronary angiography and were        registered in SCAAR during the period 2005 to January 2012 . Only patients who were        diagnosed with significant coronary artery disease were included in the analyses.|March 2014|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084888|3 Years|48766|
NCT02084901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0083|Comparison of Biodegradable Stents: Orsiro and BioMatrix|Comparison of Biodegradable Stents: Orsiro and BioMatrix||Yonsei University|No|Recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084901||48765|
NCT02085707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akershus UH|Complications and Functional Outcome of Displaced Femoral Neck Fractures in Patients Younger Than 70 Years|Complications and Functional Outcome of Displaced Femoral Neck Fractures Treated With Internal Fixation vs Total Hip Arthroplasty in Patients Younger Than 70 Years. A Randomized Controlled Double Blind Multi Center Trial.||University Hospital, Akershus|Yes|Recruiting|December 2013|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|118|||Both|55 Years|70 Years|No|||January 2015|January 14, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02085707||48703|
NCT02086019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-AdB-RINCAL-2013|Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes|A Prospective Randomised Controlled Trial|RINCAL|Brighton and Sussex University Hospitals NHS Trust|Yes|Recruiting|May 2014|May 2019|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|80 Years|N/A|No|||January 2016|January 12, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02086019||48679|
NCT02086331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0943|Evaluation of Musculoskeletal Microcirculation With Ultrasound|Evaluation of Musculoskeletal Microcirculation With Ultrasound|EMMU|Imperial College London|Yes|Enrolling by invitation|December 2013|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|June 1, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086331||48655|
NCT02113306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|t-VNS extinction|Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans|Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans|t-VNSext|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|July 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|50|||Both|16 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113306||46590|
NCT02114307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH0768|REVITIVE for the Treatment of Patients With Venous Insufficiency|REVITIVE for the Treatment of Patients With Venous Insufficiency|RVI|Imperial College London|Yes|Recruiting|March 2014|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2014|April 11, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114307||46513|
NCT02114060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-003-002|Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine|A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection||Genocea Biosciences, Inc.|Yes|Completed|July 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|310|||Both|18 Years|50 Years|No|||March 2016|March 7, 2016|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02114060||46532|
NCT02114294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1860REK|Hip Strengthening Versus Quadriceps Based Training for Patellofemoral Pain Syndrome|Does Isolated Hip Strengthening for Patellofemoral Pain Syndrome Give Better Long Term Results Than Traditional Quadriceps Based Training? A Randomised Controlled Trial.||Sorlandet Hospital HF|Yes|Recruiting|October 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|16 Years|40 Years|No|||April 2014|March 4, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02114294||46514|
NCT02115074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVABREX-1208|Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas|Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults|FLUVABREX|Centre Oscar Lambret|Yes|Recruiting|June 2014|August 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|6 Years|21 Years|No|||January 2016|January 5, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02115074||46454|
NCT02124551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES05|Comparing Pleth Variability Index (PVI) Measurements at Different Sensing Locations|Comparing PVI Measurements at Different Sensing Locations||University of California, Irvine|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|55|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be patients who undergo any form of surgery, where he/she is        mechanically ventilated, preferably cases that require arterial line placement, use of        cardiac output measurement, and where fluid administration will occur perioperatively.|February 2016|February 9, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124551||45728|
NCT02124564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0057|A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures|Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without Secondary Generalization||UCB Pharma|No|Active, not recruiting|April 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|N/A|No|||December 2015|December 16, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124564||45727|
NCT02121080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2222-HV-1326|Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers|||Regeneron Pharmaceuticals|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|132|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121080||45993|
NCT02121353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF582-CLIN-001|Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration|A Pilot Phase 1/2, Double Blind, Parallel Group, Controlled Study of the Safety, Tolerability and Preliminary Efficacy Evaluation of Intravitreally Administered Pfenex Ranibizumab Biosimilar Versus Lucentis for the Treatment of Neovascular AMD||Pfenex, Inc|Yes|Completed|November 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|50 Years|N/A|No|||January 2016|January 11, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121353||45972|
NCT02132520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF CBET-1264562|A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training|A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132520||45119|
NCT02122666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311988|Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome|Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome|COMP-SR|Washington University School of Medicine|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|whole blood and frozen tissue|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, community sample|December 2015|December 7, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122666||45871|
NCT02122679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073642|Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass|A Randomized Trial Investigating the Effect of Tranexamic Acid on Platelet Aggregation Following Infant Cardiopulmonary Bypass||Emory University|Yes|Withdrawn|December 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|6 Months|No|||December 2015|December 9, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122679||45870|
NCT02123472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15315|A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 125 mg/5 ml of Cephalexin (Keflex® Pediatrico Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Pediatrico Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers||Eli Lilly and Company|No|Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|April 23, 2014|No|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT02123472||45810|
NCT02132832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|buspirone, stress, marijuana|Buspirone, Stress, and Attentional Bias to Marijuana Cues|Buspirone, Stress, and Attentional Bias to Marijuana Cues||The University of Texas Health Science Center, Houston|Yes|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|45 Years|No|||June 2015|June 10, 2015|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132832||45095|
NCT02133079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-CIH-Li-01|Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96|Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96||Cure&Sure Biotech Co., LTD|Yes|Active, not recruiting|March 2012|November 2019|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02133079||45076|
NCT02084329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104865|Balance and Mild Traumatic Brain Injury: The Effect of a Weighted Compression Vest|Balance and Mild Traumatic Brain Injury: The Effect of a Weighted Compression Vest||Lawson Health Research Institute|No|Not yet recruiting|March 2014|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||March 2014|March 11, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084329||48809|
NCT02084628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16078|Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent|Open-label, Multi-center Study to Evaluate the Safety, Efficacy, and Plasma Gadolinium Concentrations After an Intravenous Injection of 0.1 mL/kg Body Weight Eovist/Primovist for Enhanced Magnetic Resonance Imaging (MRI) of the Liver in Children 0 to 2 Months of Age||Bayer|No|Terminated|February 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|N/A|2 Months|No|||October 2015|October 19, 2015|February 6, 2014|Yes|Yes|Enrollment discontinued due to rare medical condition in the age group 0 to 2 months|No||https://clinicaltrials.gov/show/NCT02084628||48786|
NCT02085486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000515|Ultrasound Assisted Puncture of AV Fistulas in Chronic Hemodialysis Patients|Ultrasound Assisted Puncture of AV Fistulas in Chronic Hemodialysis Patients After a Short Learning Program in Bed-side Ultrasound for Hemodialysis Nurses by an Index Nurse - an Outcome Study||University Hospital Inselspital, Berne|No|Not yet recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02085486||48720|
NCT02085720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elderly OSA/Ng/2011|Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance|Prevalence of Obstructive Sleep Apnea Syndrome and CPAP Adherence in the Elderly Chinese Population||Chinese University of Hong Kong|No|Completed|September 2007|August 2011|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|819|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|March 7, 2014||No||No|March 13, 2014|https://clinicaltrials.gov/show/NCT02085720||48702|Subjects were chosen from the community centers and it is possible that those with more symptoms would be more eager to join the study; mre females than males; those who participated in the home sleep study were younger, with slightly higher ESS.
NCT02086032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBG-2556-02070|The Effect of Different Types of Progestin on Sleeping of Menopausal Women|The Effect of Different Types of Progestin on Sleeping of Menopausal Women||Chiang Mai University|Yes|Not yet recruiting|March 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086032||48678|
NCT02086045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-1003|Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial|A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS||Elixir Medical Corporation|Yes|Active, not recruiting|November 2011|June 2017|Anticipated|June 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02086045||48677|
NCT02113085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD064854-02|My Life: Evaluation of Self-determination Enhancement for Adolescents in Foster Care|My Life: Evaluation of Self-Determination Enhancement for Adolescents in Foster Care||Portland State University|No|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|186|||Both|198 Months|246 Months|No|||April 2014|April 10, 2014|December 11, 2012||No||No||https://clinicaltrials.gov/show/NCT02113085||46607|
NCT02113553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2012-002|Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve|ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE||Istituto Clinico Humanitas|Yes|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Female|N/A|40 Years|No|||August 2015|August 5, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02113553||46571|
NCT02114099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612128M|Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease|An Open Label, Non-comparative Phase II Trial to Evaluate the Effects of Atorvastatin on the Persistent Coronary Arterial Aneurysm in Children With Kawasaki Disease: Safety and Efficacy||National Taiwan University Hospital|No|Recruiting|June 2007|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|10 Years|N/A|No|||April 2014|April 14, 2014|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT02114099||46529|
NCT02114580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0051-14-TLV|Brain Plasticity Following Aerobic Exercise in Patient With Mild Cognitive Impairment: Neuroimaging Study|Brain Plasticity Following Aerobic Exercise in Patient With Mild Cognitive Impairment: Neuroimaging Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||March 2014|April 13, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02114580||46492|
NCT02114801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|358.350/2013|Mechanical Control of Plaque in Patients With Cerebral Palsy: A Randomized Clinical Trial|Mechanical Control of Plaque in Patients With Cerebral Palsy: A Randomized Clinical Trial||Federal University of the Valleys of Jequitinhonha and Mucuri|Yes|Completed|March 2012|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Both|4 Years|16 Years|No|||April 2014|April 11, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02114801||46475|
NCT02114814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MD002289-02|A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community|A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community||University of North Carolina, Greensboro|Yes|Recruiting|November 2011|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|N/A|No|||April 2014|April 12, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02114814||46474|
NCT02121067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0202|LNG-IUS at 2 Weeks Postpartum|Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes|LNG-IUS|University of North Carolina, Chapel Hill|Yes|Recruiting|September 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121067||45994|
NCT02121912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-89|Laboratory Assessment of Pilairo Q CPAP Mask Performance and Ease of Use.|Pilairo Q In-lab Market Research - Europe||Fisher and Paykel Healthcare|No|Completed|June 2014|||November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121912||45929|
NCT02132260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFTC 1301|Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis|A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) and the Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) in Patients With Tinea Pedis||Taro Pharmaceuticals USA|No|Completed|August 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|890|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132260||45138|
NCT02132533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122013-063|Nifedipine for Acute Tocolysis of Preterm Labor|Nifedipine for Acute Tocolysis of Preterm Labor|Nifedipine|University of Texas Southwestern Medical Center|Yes|Recruiting|May 2014|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|16 Years|44 Years|No|||November 2015|November 9, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132533||45118|
NCT02123485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-509-12|the Antidepressant Effect of rTMS as add-on to ECT|The Antidepressant Efficacy of Repetitive Transcranial Magnetic Stimulation ( rTMS) as add-on to Electroconvulsive Therapy (ECT). A Double Blind Randomized Controlled Trial.|TMS|University of Aarhus|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|March 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123485||45809|
NCT02132806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNITS01-2014|Piezosurgery in the Treatment of Class II Furcation Involvement|Piezosurgery in the Treatment of Class II Furcation Involvement||University of Trieste|Yes|Recruiting|March 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132806||45097|
NCT02133105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000986-36|Levosimendan Versus Dobutamine for Renal Function in Heart Failure|Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure|ELDOR|Göteborg University|No|Enrolling by invitation|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133105||45074|
NCT02084342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDS-SYSU-2013|Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery|Efficacy and Safety of Desmopressin Combined With Tranexamic Acid on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery||First Affiliated Hospital, Sun Yat-Sen University|Yes|Active, not recruiting|December 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|18 Years|No|||March 2014|March 10, 2014|December 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02084342||48808|
NCT02085213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 12/29/01|GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta|GOT-IT Trial: A Pragmatic Group Sequential Placebo Controlled Randomised Trial to Determine the Effectiveness of Glyceryl Trinitrate for Retained Placenta.|GOT-IT|University of Edinburgh|Yes|Recruiting|September 2014|January 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1087|||Female|16 Years|N/A|No|||December 2015|December 9, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02085213||48741|
NCT02085499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130844|Flow-synchronized Nasal IMV in Preterm Infants|Effects of Flow-synchronized Nasal Intermittent Mandatory Ventilation in Preterm Infants||University of Miami|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|N/A|N/A|No|||November 2015|November 18, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085499||48719|
NCT02116595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPH&DNAE|Urine pH and Diet Net Acid Load|Alterations in Urine pH With Differing Diet Net Acid Loads||University of California, San Francisco|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116595||46337|
NCT02116855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-20140415|Individualized Prophylaxis for Severe Hemophilia A Children|Individualized Tertiary Low Dose Prophylaxis for Severe Hemophilia A Children With Arthropathy in China||Beijing Children's Hospital||Not yet recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Male|6 Years|10 Years|No|||April 2014|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116855||46317|
NCT02113319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUpromoteur2006-08|Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia|An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique|DasaCBF|University Hospital, Angers|No|Completed|April 2007|||May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Both|18 Years|60 Years|No|||January 2009|April 11, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02113319||46589|
NCT02113332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDILiraglutide|Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections|Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control||Vastra Gotaland Region|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|80 Years|No|||December 2014|February 1, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113332||46588|
NCT02114073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMS-911251|Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure|Comparison of Effect of Cyclosporine Ophthalmic Emulsion 2% and Betamethasone Eye Drop on Intraocular Pressure, Conjunctival Hyperemia and Subjective Dry Eye Symptoms Following Trabeculectomy in Open Angle Glaucoma Patients|BCATS|Mashhad University of Medical Sciences|Yes|Completed|April 2014|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||April 2015|April 17, 2015|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02114073||46531|
NCT02114333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3192|Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds|A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the GSK Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients||University of Colorado, Denver|No|Active, not recruiting|May 2014|December 2019|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|160|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|April 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02114333||46511|
NCT02114320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS-BD-001|Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents|Multicenter Study of EUS-guided Biliary Drainage Using Partially Covered With a Dedicated Introducer or Fully Covered Antimigration Metallic Stents||Asan Medical Center|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02114320||46512|
NCT02114593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ladnaan123|Ladnaan - an Evaluation of a Parent Support Program for Somali Parents|Evaluation of a Parent Support Program to Promote Somali Parent's and Children's Mental Health||Karolinska Institutet|Yes|Completed|June 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|130|||Both|11 Years|16 Years|No|||October 2015|October 17, 2015|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02114593||46491|
NCT02114827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13-10228|Efficacy of a Patient Education Video|Efficacy of a Patient Education Video||Virginia Commonwealth University|Yes|Terminated|April 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|9|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|April 3, 2014||No|study closed due to slow accrual|No||https://clinicaltrials.gov/show/NCT02114827||46473|
NCT02115100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9206|Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation, Renal Artery Denervation or Both.|Treatment of Atrial Fibrillation in Patients With High Sympathetic Activity by Pulmonary Vein Isolation, Renal Artery Denervation or Both; a Randomized, Controlled Trial|ASAF|Diagram B.V.|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115100||46452|
NCT02131987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMASN|Radiological Riskfactors for Dislocation of Hip Hemiarthroplasty|Radiological Riskfactors for Dislocation of Hip Hemiarthroplasty Through a Posterolateral Approach as Treatment for Femoral Neck Fracture|RRDHHR|Sundsvall Hospital|No|Completed|January 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|324|||Both|60 Years|N/A|No|Non-Probability Sample|Between January 1 2006 and December 31 2013, at our department 324 patients underwent        hemiarthroplasty (HA) for displaced femoral-neck fracture with a bipolar prosthesis        (Variokopf, Link®, Germany) by the use of the posteriolateral approach. Patients with        pathological fractures and HA performed with anterolateral approach were excluded.|October 2015|October 28, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131987||45158|
NCT02132208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRcitadelle-trauma-01|Evaluation of the TICCS Capacity to Identify Trauma Patients With Acute Coagulopathy and Massive Bleeding|Pre-hospital Identification of Trauma Patients With Early Acute Coagulopathy and Massive Bleeding: Results of a Prospective Non-interventional Clinical Trial Evaluating the Trauma Induced Coagulopathy Clinical Score (TICCS).||Centre Hospitalier Régional de la Citadelle|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|Samples Without DNA|Whole blood sample for Thromboelastometry and standard coagulation tests.|Both|12 Years|N/A|No|Probability Sample|Severe trauma patients admitted in the resuscitation room of our emergency department.|June 2013|May 6, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02132208||45142|
NCT02132221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Partners IRB 2013P000881|Cessation of Long-term Opioid Therapy in Chronic Pain Patients|Long-term Opioid Therapy in Chronic Pain Patients: Investigation of Tapering Strategies and Impact on Hyperalgesia||Massachusetts General Hospital|No|Recruiting|October 2013|March 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02132221||45141|
NCT02132559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC30901601|Effect of Dehydroepiandrosterone Administration in Patients With Poor Ovarian Response According to the Bologna Criteria|||Chinese Medical Association|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|386|||Female|23 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|All patients were stratified according to the Bologna criteria for poor ovarian response.        Poor responders were classified with at least two of the three following criteria: (I)        advanced maternal age (≥40 years) or any other risk factor for POR; (II) a previous POR(≤3        oocytes with a conventional ovarian stimulation protocol); and (III) an abnormal ovarian        reserve test (ORT): antral follicle count (AFC) < 5-7 or serum anti-Mullerian hormone        (AMH) <0.5-1.1 ng/mL, as described by the Bologna criteria|July 2013|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132559||45116|
NCT02132819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sahin1|Withholding Feeds During Red Blood Cell Transfusion and TRAGI|The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants|Tx-TRAGI|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|February 2014|April 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|3 Months|No|||May 2014|May 5, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02132819||45096|
NCT02132546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-0001-TS|Spectrophotometric Evaluation of Chlorhexidine Pigmentations After Oral Surgery: a Prospective Randomized Clinical Trial|Spectrophotometric Evaluation of Chlorhexidine Pigmentations After Periodontal Flap Surgery: a Prospective Randomized Clinical Trial||University of Trieste||Completed|February 2011|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Actual|60|||Both|N/A|N/A|No|||April 2014|May 2, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02132546||45117|
NCT02084108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-128 and 08-06|Efficacy of Integrated Care to Reduce Hospitalization and Nursing Home Placement in Community Dwelling Frail Elderly|Efficacy of Integrated Care to Decrease Hospitalization and Institutionalization in Community Dwelling Frail Elderly, With Care Coordination Between Physicians, Home Nursing Services and a Community Geriatrics Unit.||University Hospital, Geneva|No|Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|301|||Both|60 Years|N/A|No|||March 2014|March 10, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02084108||48826|
NCT02084121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-13080-Compassionate Use|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)||University of Louisville||No longer available||||||N/A|Expanded Access|N/A|||||||Male|3 Years|N/A||||November 2015|November 2, 2015|March 7, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02084121||48825|
NCT02084641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20281|Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans|Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans||Stanford University|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 9, 2014|March 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02084641||48785|
NCT02084654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9946|Exenatide and Weight Loss for Diabetes Prevention|Randomized Trial Investigating Exenatide for Diabetes Prevention in Obese, Insulin-Resistant Individuals With Prediabetes||Stanford University|No|Completed|November 2007|February 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|66|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 9, 2014|December 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084654||48784|
NCT02085226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011GM01|Art as Creative Engagement for Stroke|Can an Arts Based Creative Engagement Intervention Following Stroke Improve Psychosocial Outcomes? A Feasibility Trial of a Creative Engagement Intervention for In-patient Rehabilitation|ACES|University of Dundee|No|Completed|July 2013|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|N/A|N/A|No|||December 2015|December 4, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02085226||48740|
NCT02116335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001874|Endothelin Receptor Function and Acute Stress|Endothelin Receptor Function and Acute Stress (End-Stress)|End-Stress|Georgia Regents University|Yes|Recruiting|June 2015|April 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116335||46357|
NCT02116582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0410|A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer|A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate||Astellas Pharma Inc|No|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116582||46338|
NCT02116868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01002-43|Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery|Usefulness of Pupillary Reflex on Remifentanil and Morphine Consumption During Laparoscopic Surgery. A Bicentric, Prospective, Randomized, Controlled Trial.||Central Hospital, Nancy, France|No|Recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02116868||46316|
NCT02113098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|488.293|Effects of Treadmill Gait Training With Loading in Individuals With Stroke|Effects of Treadmill Gait Training With Adding Load on Lower Limb of Individuals With Stroke||Universidade Federal do Rio Grande do Norte|Yes|Recruiting|February 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||April 2014|April 10, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113098||46606|
NCT02113800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-NET-0112|Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study|Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study|EVINEC|AIO-Studien-gGmbH|No|Recruiting|August 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113800||46552|
NCT02113813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8273-CL-0102|A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations||Astellas Pharma Inc|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02113813||46551|
NCT02113826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200240|Pazopanib for Metastatic Alveolar Soft Part Sarcoma|A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma||Seoul National University Hospital|No|Recruiting|April 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||April 2014|March 7, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02113826||46550|
NCT02114086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROKSM 01/12|IORT-Boost-Study, Prospective Observational Study for Intraoperative Radiotherapy of the Breast as a Boost|Prospective Observational Study for Intraoperative Radiotherapy (IORT) of the Breast as a Boost||Kantonsspital Münsterlingen|No|Recruiting|January 2013|February 2028|Anticipated|January 2027|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Female|N/A|N/A|No|Non-Probability Sample|women with breast cancer breast-conserving therapy|September 2015|September 14, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02114086||46530|
NCT02085824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPX-2012|Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.|Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.||Medical Centre of Postgraduate Education, Poland|No|Recruiting|July 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085824||48694|
NCT02085837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-033|Healthy Transitions in Late Stage Kidney Disease|An Open Label Randomized Controlled Study to Compare the Impact of Patient Centered Nursing Services in Addition to a Nephrologist's Usual Patient Care With Usual Nephrologist's Care in Late Stage Chronic Kidney Disease Patients.||Northwell Health|No|Recruiting|October 2013|April 2016|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085837||48693|
NCT02085850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCEC 066/13-14|Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort|Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort||Tema Christian Eye Center|No|Enrolling by invitation|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1375|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2014|March 11, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085850|1 Day|48692|
NCT02114606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3521|Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge|Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge||University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Paraffin embedded esophageal tissue samples obtained by the cytosponge.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with Eosinophilic Esophagitis (EoE) who are currently on treatment or        are not currently being treated.|February 2016|February 16, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02114606||46490|
NCT02114840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQP-9CH|Pronator Quadratus Preservation Following Volar Plate Fixation. RCT|IN PATIENS WITH DISTAL RADIUS FRACTURE FOLLOWING VOLAR PLATE FIXATION, DOES PRONATOR QUADRUTUS PRESERVATION HAVE CLINICAL IMPACT IN PRONOSUPINATION AND PROPRIOCEPTION? MULTICENTER RANDOMIZED CONTROLLED CLINICAL TRIAL|PROQUAP|Universidad de la Frontera|No|Recruiting|April 2014|September 2015|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|270|||Both|15 Years|65 Years|No|||April 2014|April 11, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02114840||46472|
NCT02082613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLL-378961|Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study|Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study.||Umeå University|No|Recruiting|February 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|40 Years|N/A|No|||June 2014|February 4, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082613||48940|
NCT02131753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL 3-2004|Therapy Optimisation for the Treatment of Hairy Cell Leukemia|Therapy Optimisation for the Treatment of Hairy Cell Leukemia||University of Giessen|No|Recruiting|May 2004|December 2025|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|18 Years|90 Years|No|||June 2015|June 17, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02131753||45176|
NCT02132000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCSCO002|Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients|||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|April 2014|May 2020|Anticipated|May 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3036|||Female|18 Years|60 Years|No|||May 2014|May 3, 2014|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132000||45157|
NCT02132234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJ-KChWiMWsi-Reu|Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis||Jagiellonian University||Recruiting|June 2013|||July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02132234||45140|
NCT02132247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08US/Fp03|Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries|An Open-label, Prospective, Uncontrolled Study of the Safety and Local Tolerability of the Diclofenac Epolamine Patch (Flector Patch) in Pediatric Patients With Minor Soft Tissue Injuries||IBSA Institut Biochimique SA|No|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|6 Years|16 Years|No|||August 2015|August 7, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132247||45139|
NCT02133118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZODIAC|Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.|A Prospective Observational Cohort Study; The Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.|ZODIAC-39|Medical Research Foundation, The Netherlands|No|Completed|January 1998|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16293|||Both|N/A|N/A|No|Non-Probability Sample|Patients with T2DM who received monotherapy with metformin and needed treatment        intensification by receiving add-on therapy next to metformin|March 2015|March 14, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133118|5 Years|45073|
NCT02132845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGI-065|Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer|A Prospective Randomized Trial Comparing the Effectiveness of Physician Discretion Guided Therapy Versus Physician Discretion Guided Plus Next-Generation Sequence Directed Therapy||Fox Chase Cancer Center|No|Recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||January 2016|January 19, 2016|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132845||45094|
NCT02084355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNUH-2013-07-014|Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain|Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study||Gyeongsang National University Hospital||Not yet recruiting|April 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|136|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02084355||48807|
NCT02084368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nerve Block|Application of Combined Lumbar Plexus and Sciatic Nerve Block|Application of Combined Lumbar Plexus and Sciatic Nerve Block in Unilateral Knee Replacement||Guangzhou General Hospital of Guangzhou Military Command|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02084368||48806|
NCT02116088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01JH1204B|Prevention and Intervention of Externalizing Problem Behavior in School: Development and Evaluation of a Teacher Coaching.|Prevention and Intervention of Externalizing Problem Behavior in School: Development and Evaluation of a Teacher Coaching.||University of Cologne|Yes|Active, not recruiting|October 2012|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|53|||Both|6 Years|11 Years|No|||April 2014|April 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116088||46376|
NCT02116608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2819|Treatment of Tracheostomy Granulomas|||University of Colorado, Denver|Yes|Enrolling by invitation|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|31 Days|17 Years|No|||November 2015|November 9, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116608||46336|
NCT02113111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5522 TheraFast|Effects of Fasting on Self Efficacy|The Effects of Therapeutic Fasting on Self Efficacy Measures - a Prospective Observational Trial|TheraFast|Universität Duisburg-Essen|No|Completed|April 2014|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being treated in an integrative clinic for internal medicine Patients recommended        for fasting therapy during the inpatient treatment|September 2015|September 3, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02113111||46605|
NCT02113345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082010Deb|The Relationship Between Metamemory and Memory in Old Age|The Relationship Between Metamemory and Memory in Old Age|M&Mresearch|The University of Hong Kong|No|Enrolling by invitation|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113345||46587|
NCT02113566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR-001|A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness|A Double-Blind, Repeat-Dose, Parallel Group Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness.|DOMS|Jean Brown Research|Yes|Completed|February 2013|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113566||46570|
NCT02113579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOXDHY0009|Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity|Assessment of a Potassium Oxalate Containing Formulation for the Relief of Dentinal Hypersensitivity||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|375|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 8, 2014|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT02113579||46569|
NCT02114112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23596|E-23596 - Use of NCPAP Cycling to Wean Preterm Infants|Randomised Controlled Trial to Study the Effect of Nasal Continuous Positive Airway Pressure (NCPAP) Cycling on Successful Weaning When Compared With Nasal Continuous Positive Airway Pressure (NCPAP) in Premature Infants of 25-28 Weeks Gestation||University of Calgary|No|Terminated|January 2011|March 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|75 Days|No|||April 2014|April 10, 2014|April 6, 2014||No|Due to new respiratory quality control initiative introduced in the NICU, recruitment for the    study was stopped.|No||https://clinicaltrials.gov/show/NCT02114112||46528|
NCT02085876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAMZA APJ 2013|Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy|Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy|IRM Stéatose|Centre Hospitalier Universitaire Dijon||Not yet recruiting||||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Probability Sample|Overweight patients or patients with type 2 diabetes or obese patients (who present a        liver anomaly and should undergo bariatric surgery)|July 2013|March 12, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02085876||48690|
NCT02086162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FED14095|Randomized Controlled Trial (RCT) of a Motivational Decision Support System|RCT of a Motivational Decision Support System for Smokers With Severe Mental Illnesses|RCTEDSS|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|70 Years|No|||February 2015|February 24, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086162||48668|
NCT02086149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304-001|Exercise for Depressed Smokers|Aerobic Exercise for Smokers With Depressive Symptomatology||Butler Hospital|No|Recruiting|February 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086149||48669|
NCT02086409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01499-36|GAit, MEmory, Dietary and Vitamin D|Dairy Product, Calcium & Vitamin D Supplementation and Congnitive-motor Function|GAME-D2|University Hospital, Angers|Yes|Not yet recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Female|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 11, 2014||||No||https://clinicaltrials.gov/show/NCT02086409||48649|
NCT02131467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFE-PER-CD|Safety and Tolerability of Perampanel in Cervical Dystonia|An Open-label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel (E2007) in Subjects With Cervical Dystonia (SAFE-Per CD)||University Health Network, Toronto|No|Not yet recruiting|September 2014|September 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||February 2014|May 2, 2014|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131467||45198|
NCT02131766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17351|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Oversight Control in Type 1 Diabetes|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Oversight Control in Type 1 Diabetes||University of Virginia|Yes|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|21 Years|65 Years|No|||May 2015|May 11, 2015|May 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131766||45175|
NCT02132013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48079.042.14|SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology|SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology|SUBLIME|University Medical Center Groningen|No|Active, not recruiting|June 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132013||45156|
NCT02132273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-EP-13|Use of an Educational Story to Prepare Children With Developmental Disabilities for Sleep Study|Use of an Educational Story to Prepare Children With Developmental Disabilities for Overnight Polysomnography||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|4 Years|17 Years|No|||September 2015|September 24, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132273||45137|
NCT02133677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-102072-F|A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases|A Phase II, Open-label, Single-arm, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Whole-brain Radiotherapy With Concomitant Temozolomide in Lung Cancer and Breast Cancer Patients With Brain Metastases||Far Eastern Memorial Hospital||Not yet recruiting|May 2014|May 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|65 Years|No|||February 2014|May 6, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133677||45030|
NCT02115607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-1-0066|Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy|Quantitative Subharmonic Breast Imaging: Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy||Thomas Jefferson University|Yes|Active, not recruiting|March 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|21 Years|N/A|No|||February 2016|February 8, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02115607||46413|
NCT02084914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBPOPRIUI|Endometrial Scratching by Pipelle on Pregnancy Rate in Unexplained Infertility|The Effect of Endometrial Scratching by Pipelle on Pregnancy Rate in Couples With Unexplained Infertility||Ain Shams University|Yes|Recruiting|December 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|158|||Female|20 Years|35 Years|No|||March 2014|March 10, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084914||48764|
NCT02084927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/14|Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery|Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery -Randomized Prospective Trial||Assaf-Harofeh Medical Center|No|Not yet recruiting|April 2014|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084927||48763|
NCT02116348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA 000017585|Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy|Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy||Ain Shams University|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Months|18 Years|No|||April 2014|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116348||46356|
NCT02116361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-135|OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females|||Allergan|No|Recruiting|April 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|248|||Female|18 Years|65 Years|No|||November 2015|November 12, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116361||46355|
NCT02112812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF0452012|Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease|A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease||National University of Malaysia|No|Completed|December 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|17 Years|N/A|No|||April 2014|April 10, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112812||46628|
NCT02113124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC IRB #200|Association of Amino Acid Prevalence and Chronic Brain Injury|Association of Amino Acid Prevalence and Chronic Brain Injury||The Transitional Learning Center, Galveston, TX|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|43|Samples Without DNA|Whole blood, oral tissue swab, fecal matter|Both|35 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals in the chronic brain injured group are recruited from traumatic brain injury        rehabilitation facilities. These facilities include Tideway in Galveston, Texas, Centre        for Neuro Skills in Bakersfield, CA, and Centre for Neuro Skills in Dallas, TX. The        cohorts for this study will be recruited from the communities surrounding the        rehabilitation facilities.|November 2015|November 17, 2015|April 8, 2014||No||No|August 27, 2015|https://clinicaltrials.gov/show/NCT02113124||46604|No limitations reported
NCT02113358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312116RINC|Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial|Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial||National Taiwan University Hospital|No|Recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|70 Years|No|||December 2014|December 2, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02113358||46586|
NCT02113839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DysPerEx|Dyspnea in COPD: Relationship With Exacerbations Frequency|Breathlessness Perception in COPD: Relationship With Exacerbation Frequency|DPE|Hospital Clinic of Barcelona|No|Completed|April 2014|May 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|34|||Both|18 Years|80 Years|No|||April 2014|August 19, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02113839||46549|
NCT02085590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG-LPS|Effects of BCG on Immune Response|The Effects of BCG-vaccination on the Innate Immune Response in Healthy Volunteers. Pilot Proof-of-principle Studie||Radboud University|Yes|Completed|March 2014|November 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085590||48712|
NCT02085616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRL00-367|Effectiveness of the Swedish National Tobacco Quitline|Smoking Cessation by Telephone. Effectiveness and Cost-effectiveness of Proactive and Reactive Services at the Swedish National Tobacco Quitline (SNTQ).|SNTQ|Uppsala University||Terminated|February 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|586|||Both|N/A|N/A|No|||March 2014|March 10, 2014|March 10, 2014||No|Interim analysis, revealed no additional effect of proactive over reactive service.|No||https://clinicaltrials.gov/show/NCT02085616||48710|
NCT02086175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-398|A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma|A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma||Dana-Farber Cancer Institute|Yes|Recruiting|December 2014|August 2021|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086175||48667|
NCT02086422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD13/10799|Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure|||The Leeds Teaching Hospitals NHS Trust||Recruiting|July 2013|||July 2015|Actual|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||February 2016|February 25, 2016|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02086422||48648|
NCT02086435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SafeMorcellation|Intracorporeal Versus Extracorporeal Morcellation: Clinical Efficacy and Safety Outcomes|A Randomized Controlled Trial on Intracorporeal Versus Extracorporeal Morcellation With Endobag Extraction in Patients Undergoing Laparoscopic Myomectomy: Clinical Efficacy and Safety Outcomes|IEME|University Magna Graecia|Yes|Completed|March 2014|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|93|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 19, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086435||48647|
NCT02132286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00037|Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression|Serotonin Transporter Genetic Variation and Amygdala Responses to Quetiapine and Selective Serotonin Reuptake Inhibitor Treatment in Major Depression||University of Calgary|No|Completed|December 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|57|||Both|18 Years|65 Years|No|||May 2014|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132286||45136|
NCT02132572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-MED-BRE-003|Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants|Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle® Breast Implants in Primary Augmentation (RANBI)|RANBI|Allergan||Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|206|||Female|18 Years|N/A|No|Probability Sample|Subjects that have undergone a primary breast augmentation for aesthetic reasons with a        BIOCELL™ textured 410 cohesive implant|June 2015|June 22, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02132572||45115|
NCT02132585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spk-001|Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction|Cross Sectional Study of Use of Speckle Tracking Echocardiography in the Early Diagnosis of Cardiovascular Dysfunction and Performance in Sjogren Patients|SPEEDCARS|University of Roma La Sapienza|Yes|Active, not recruiting|January 2010|May 2014|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|700|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients enrolled from cardiovascular clinic|February 2014|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132585||45114|
NCT02132858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGI-066|Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation|Assessing Intratumoral Heterogeneity and Chemoradiation Response in Locally Advanced Rectal Cancer Utilizing Sequencing and PET/CT||Fox Chase Cancer Center|Yes|Recruiting|July 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient clinic|September 2015|September 3, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132858||45093|
NCT02133417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013001|Non-Inferiority Quantitative Transmission Ultrasound Case Collection Study|A Prospective Multi-center Case Collection Study of Breast Imaging Examinations From Women With Mammographically-detected Lesion(s) to Evaluate the Non-inferiority of Digital Mammography (XRM) and Quantitative Transmission Ultrasound (QTUS) Together Compared to XRM and Hand Held Ultrasound (HHUS) Together in the Evaluation of Lesion(s) Detected With Diagnostic Mammography.|QTUS|QT Ultrasound LLC|No|Completed|July 2014|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|287|||Female|25 Years|N/A|No|Probability Sample|Eligibility for enrollment will be open to women of all races and ethnicities who have        completed a diagnostic XRM with a mammographically-detected lesion(s) in at least one        mammographic view and have a lesion seen on HHUS corresponding to the XRM lesion(s). Women        with a normal mammogram at the time of this evaluation are not eligible to participate.        Women younger than 25 years of age will not be eligible to participate. Potential subjects        must not be breastfeeding at the time of diagnostic breast imaging. Patients who have had        breast cancer, breast surgeries, or interventional breast procedures in the past 12 months        will not be eligible to enter the study.|March 2016|March 9, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133417||45050|
NCT02133690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTA:03/12|A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants|Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Live Attenuated Bovine-Human Rotavirus Reassortant Pentavalent Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants||Serum Institute of India Limited|Yes|Active, not recruiting|May 2014|April 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|7500|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||November 2015|November 5, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133690||45029|
NCT02133703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-611|Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility|Decision Making Interventions for Women Receiving Uninformative BRCA1/2 Test Results or Positive BRCA1/2 Test Results||Georgetown University|Yes|Enrolling by invitation|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|600|||Female|21 Years|75 Years|No|||October 2015|October 9, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02133703||45028|
NCT02129803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20001217|Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis|Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis||Virginia Commonwealth University|No|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|10 Years|50 Years|No|||November 2015|November 3, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02129803||45325|
NCT02115893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC13-3-059|Nitrate Supplementation; Duration|The Effect of Nitrate Supplementation on Sports Performance: Duration of Supplementation|NO-how|Maastricht University Medical Center|No|Completed|April 2014|March 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|March 15, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02115893||46391|
NCT02115646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001310|Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance|Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance||Massachusetts General Hospital|Yes|Recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|5 Years|70 Years|No|||May 2015|May 28, 2015|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02115646||46410|
NCT02115880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP00216_PRODO|PRimary Prevention Of Depression in Offspring of Depressed Parents|PRimary Prevention Of Depression in Offspring of Depressed Parents|PRODO|Ludwig-Maximilians - University of Munich|No|Recruiting|May 2014|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02115880||46392|
NCT02116621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|496804|N-of-1 Trials Using mHealth in Chronic Pain|N-of-1 Trials Using mHealth in Chronic Pain Aka PREEMPT (Personalized Research for Monitoring Pain Treatment)|PREEMPT|University of California, Davis|No|Enrolling by invitation|July 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|244|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116621||46335|
NCT02112825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207M17821|Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease|Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease|PACE|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||December 2014|December 9, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112825||46627|
NCT02113150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TurkiyeYIH|A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery|A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery||Turkiye Yuksek Ihtisas Education and Research Hospital|Yes|Completed|May 2013|September 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|March 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02113150||46602|
NCT02113371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e5473|Evaluation of COMmunity of Practice And Safety Support (COMPASS) for Home Care Workers|Creating Health and Safety Communities of Practice for Home Care Workers||Oregon Health and Science University|No|Active, not recruiting|October 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02113371||46585|
NCT02113592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4UH3NS088731-02|Pain Program for Active Coping & Training|Collaborative Care for Chronic Pain in Primary Care|PPACT-UH3|Kaiser Permanente|Yes|Enrolling by invitation|March 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113592||46568|
NCT02113605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGID Child Pilot-0|Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders|Exposure-Based CBT for Children With Functional Gastrointestinal Disorders - Development of a Protocol|CBT|Karolinska Institutet|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|8 Years|12 Years|No|||December 2015|December 1, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02113605||46567|
NCT02085304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12BN101|Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM|Phase I/II Randomized Prospective Trial for Newly Diagnosed GBM, With Upfront Gross Total Resection, Gliadel®, Followed by Temodar® With Concurrent IMRT Versus GK||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||April 2015|April 30, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085304||48734|
NCT02085603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16404|SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain|SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain|SarCaBon|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|March 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|16 Years|N/A|No|||November 2014|November 11, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085603||48711|
NCT02085863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV5600-PK-10017|A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together|A Randomized, Double-Blind, Placebo-Controlled, Two-way Crossover Drug-drug Interaction Study to Assess the Effect of Laquinimod 0.6 mg on the Pharmacokinetics and Pharmacodynamics of Ethinylestradiol and Levonorgestrel in Healthy Young Women||Teva Pharmaceutical Industries|Yes|Completed|February 2014|November 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085863||48691|
NCT02085902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 079-13|Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?|Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?|VesiRop|Centre Hospitalier Departemental Vendee|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|120|||Both|18 Years|N/A|No|||March 2015|May 18, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085902||48688|
NCT02085889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGRG-2415b|Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders|Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders||Brain-Gut Research Group|No|Active, not recruiting|March 2014|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|blood, urine and stool|Both|18 Years|N/A|No|Probability Sample|Successive patients referred to our gastroenterology practice with functional GI disorders        according to ROME 3 criteria.|July 2015|July 27, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085889||48689|
NCT02086188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRB2013|Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis|Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)|MIRROR|EvergreenHealth|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086188||48666|
NCT02132871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5516|Preload Dependency by Impedance Cardiography After Cardiac Surgery|Noninvasive Assessment of Preload Dependency by Passive Leg Raising Test and Impedance Cardiography Compared to Echocardiographic Measurements After Cardiac Surgery||University Hospital, Strasbourg, France|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring cardiac surgery|January 2016|January 4, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132871||45092|
NCT02132611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-0005-P|Coronary Orbital Atherectomy System Study|Coronary Orbital Atherectomy System Study|COAST|Cardiovascular Systems Inc|Yes|Active, not recruiting|June 2014|August 2018|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132611||45112|
NCT02133131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-074|Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)|A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection||Merck Sharp & Dohme Corp.|No|Completed|June 2014|February 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|143|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02133131||45072|
NCT02133430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-2556-01778|Optimized Anesthesia to Reduce Incidence of Postoperative Delirium|Optimized Anesthesia to Reduce Incidence of Postoperative Delirium in Elderly Undergoing Elective, Non-cardiac Surgery: a Randomized Controlled Trial (POD-II)||Chiang Mai University|No|Recruiting|January 2014|April 2015|Anticipated|February 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|65 Years|95 Years|No|||May 2014|May 8, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02133430||45049|
NCT02133443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01835-40|NAVASET: Nava Level Titration Using Comfort Scales|Neurally Adjusted Ventilatory Assist (NAVA) Levels Titration During Weaning Using Ventilatory Comfort Scales: a Physiological Evaluation||University Hospital, Caen|No|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02133443||45048|
NCT02133716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTEET|Efficacy of Breast Milk Expressed and Sucrose in Procedural Pain in Preterm|Efficacy of Breast Milk Expressed Versus Sucrose Relief Procedural Pain of Venipuncture in Preterm.|LACTEET|Hospital General Universitario Gregorio Marañon|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|25 Weeks|37 Weeks|No|||May 2014|March 17, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02133716||45027|
NCT02129816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BryoSoliP-2014|Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder|Treatment of Patients With Overactive Bladder With Bryophyllum Pinnatum Versus Solifenacinsuccinat Versus Placebo: Multicenter, Prospective, Double-blind Randomized, Placebo-controlled Cross-over Study, Phase III Trial|BryoSoliP|University of Zurich|Yes|Recruiting|May 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|40 Years|N/A|No|||December 2015|December 1, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02129816||45324|
NCT02116114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/11|Effects of Aquatic Physical Training Program on Cardiorespiratory Variables in Patients With COPD|Effects of Aquatic Physical Training Program on Cardiorespiratory Variables in Patients With COPD||Universidade Metodista de Piracicaba|Yes|Not yet recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Male|50 Years|70 Years|No|||April 2011|April 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116114||46374|
NCT02116101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-SC-11-BRD-001|Intestinal Health and Blood Lipid Adjustment|Evaluation of the Effect of Momchilovtsi Yogurt on Intestinal Health and Blood Lipid Adjustment in Human Subjects||Bright Dairy & Food Co., Ltd|Yes|Completed|March 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|30 Years|60 Years|No|||April 2014|April 15, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02116101||46375|
NCT02116374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP55 MICROGUT|Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients|Correlation Between Microbiota Biodiversity of HIV Seropositive Patients With Their Clinical and Immunological Status (ANRS EP 55 MICROGUT).|MICROGUT|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|December 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Stool sample|Both|18 Years|N/A|No|Non-Probability Sample|HIV-1 seropositive patients|July 2015|July 23, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116374||46354|
NCT02116634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rokhsareh|Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis|Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients||Alzahra Hospital, Iran|Yes|Withdrawn|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 6, 2014||No|Because economic problems|No||https://clinicaltrials.gov/show/NCT02116634||46334|
NCT02116647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 1130|Role of Psychoanalysis in Prevention of Girl Child Maltreatment and Neglect|Role of Psychoanalysis in Prevention of Girl Child Maltreatment and Neglect: A Randomized Controlled Trial||Macmillan Research Group UK|Yes|Completed|November 2012|November 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|134|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|September 27, 2015|April 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116647||46333|
NCT02112851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1326|Processed Orange and the Glycemic Response|A Randomized, Placebo-controlled, Double-blind, Crossover Trial to Investigate the Effects of Acute Processed Whole Orange Consumption on Postprandial Glycemic Responses in Healthy Men|POGR|PepsiCo Global R&D|No|Recruiting|March 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|33|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112851||46625|
NCT02113137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHP-018-EI|Oral Hygiene Procedures on Reduction of Oral Malodor|Effects of Various Oral Hygiene Procedures on the Reduction of Oral Malodor in Periodontally Healthy Patients||Tokyo Medical and Dental University|Yes|Completed|September 2013|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02113137||46603|
NCT02084784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB707700|Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research|Study of Surgical Navigation System in Detection of Sentinel Lymph Node of Early Breast Cancer Patients||Chinese Academy of Sciences|Yes|Enrolling by invitation|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|N/A|N/A|No|||November 2015|November 17, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02084784||48774|
NCT02085031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFGS-OrVil-01|Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer|Randomized Controlled Trial on Surgical Safety of Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer||Nanfang Hospital of Southern Medical University|Yes|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|19 Years|74 Years|No|||April 2014|April 8, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085031||48755|
NCT02085317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biovasc-1|Microcirculatory Impairment in Patients With Leprosy|Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis||Rio de Janeiro State University|Yes|Completed|March 2006|February 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02085317||48733|
NCT02085330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69/13|Hyperbaric Oxygen Therapy for Mild Cognitive Impairment|Hyperbaric Oxygen Therapy in Patients Suffering From Mild Cognitive Impairment and Vascular Subcortical Ischemia||Assaf-Harofeh Medical Center|No|Recruiting|March 2014|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|90 Years|No|||October 2014|October 1, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085330||48732|
NCT02085343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02-0023|Anti-phobic and Safety Behaviors in the Treatment of Acrophobia|Anti-phobic and Safety Behaviors in the Treatment of Acrophobia||University of Texas at Austin|No|Recruiting|February 2013|May 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|No|||February 2015|February 18, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02085343||48731|
NCT02085915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 065-13|Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis|Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis|Per-DRISLA|Centre Hospitalier Departemental Vendee|No|Completed|March 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|670|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085915||48687|
NCT02086201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENGAGE|The Engage Project|Stepped, Reward-exposure Based Therapy vs. PST in Late Life Depression||University of California, San Francisco|Yes|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|342|||Both|60 Years|N/A|No|||March 2015|March 4, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02086201||48665|
NCT02086474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-2014|Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients|Daily Activity Quantification and Gait Pattern Analysis Before and After Intra-articular Injection of Viscosupplement Among Hip Osteoarthritis Patients||Laval University|Yes|Recruiting|May 2014|August 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|65 Years|No|||March 2016|March 3, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02086474||48644|
NCT02133157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-012-00CH1|Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|HMPL|Hutchison Medipharma Limited|Yes|Completed|April 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|70 Years|No|||May 2014|October 29, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02133157||45070|
NCT02132884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGI-068|Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer||Fox Chase Cancer Center|Yes|Recruiting|March 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|N/A|N/A|No|||March 2016|March 1, 2016|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132884||45091|
NCT02133144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322013|Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation|Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation||Helsinki University|No|Recruiting|February 2014|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133144||45071|
NCT02133729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.649|Metabolic Risk Following Gestational Diabetes Mellitus|IMAGE (Metabolic Risk During Gestation) : Prospective Study of Women With Gestational Diabetes|IMAGE|Hospices Civils de Lyon|Yes|Completed|June 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|255|||Female|18 Years|N/A|No|||July 2015|July 24, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02133729||45026|
NCT02129829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMDH-P34114|PROLIFICA - West African Treatment Cohort for Hepatitis B|Prevention of Liver Fibrosis and Cancer in Africa. Observational Study of Screening, Assessment and Treatment for Chronic Hepatitis B Virus Infection|WATCH|Imperial College London|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Serum, plasma, urine and DNA|Both|18 Years|N/A|No|Probability Sample|All adults are included for community screening. Selection criteria (below) are applied        for recruitment into cohorts|June 2011|June 1, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129829||45323|
NCT02122289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9172|Muco Smartphone Exacerbation|Interest of the New Technologies to Detect précocément a Respiratory Exacerbation at Patients Reached by Cystic Fibrosis.|MUSE|University Hospital, Montpellier|No|Terminated|April 2014|January 2016|Anticipated|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|14 Years|25 Years|No|||November 2015|November 27, 2015|April 22, 2014||No|Sufficient number of patients for statistical analysis|No||https://clinicaltrials.gov/show/NCT02122289||45900|
NCT02116127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14-020|Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study|Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study||Women's College Hospital|No|Recruiting|April 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02116127||46373|
NCT02116387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/AD-01|Traditional Rehabilitation Versus Rehabilitation With the Imoove® Device for Spinal Musculoskeletal Disorders|Traditional Rehabilitation Versus Rehabilitation With the Imoove® Device for Spinal Musculoskeletal Disorders: a Randomised Controlled Trial|IMOOVE IT|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|July 2014|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 19, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116387||46353|
NCT02116660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-284|Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)|Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02|RANIA|Merck Sharp & Dohme Corp.|No|Active, not recruiting|September 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116660||46332|
NCT02116673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHED0001|Influence of Cognitive Rest on Minor Traumatic Brain Injury|The Influence of Cognitive Rest and Graduated Return to Usual Activities on Minor Traumatic Brain Injury||Mount Sinai Hospital, Canada|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|17 Years|64 Years|No|||September 2015|September 22, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116673||46331|
NCT02112838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-050|Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy|A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy||Rigel Pharmaceuticals|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|70 Years|No|||July 2015|July 24, 2015|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112838||46626|
NCT02084472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/2013|Accessible and Affordable Moisturizers for Atopic Eczema|Accessible and Affordable Moisturizers for Atopic Eczema: the 2am Atopic Eczema Study||Red Cross War Memorial Childrens Hospital|No|Completed|February 2013|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|120|||Both|6 Months|12 Years|No|||March 2014|March 9, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02084472||48798|
NCT02084485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631010|PH-797804 LPS Study in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Effects of a Single Oral Dose of Ph-797804 on Induced Sputum Inflammatory Markers Following Inhaled Lipopolysaccharide (Lps) Challenge in Healthy Volunteers||Pfizer|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084485||48797|
NCT02084797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM#4713|V2 Receptor Effects on Fluid Regulation and Performance|Revisiting the Human Sweat Gland - Does Arginine Vasopressin Modulate Sweat Sodium Concentration Via the V2 Receptor?||Oakland University|No|Completed|June 2011|October 2012|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084797||48773|
NCT02085044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Médecins Sans Frontières-OCG|Non Randomized Controlled Intervention Study Comparing Two Interventions of Nutritional Supplement on Malnutrition, Health and Mortality|Non Randomized Controlled Intervention Study Comparing Two Interventions of Nutritional Supplement on Malnutrition, Health and Mortality in Children Aged 6 to 24 Month Hadjer-Lamis Region - Chad|NRCI-ASPE|Médecins Sans Frontières, Switzerland|No|Completed|February 2012|December 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5700|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||October 2013|March 11, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02085044||48754|
NCT02085057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18888|Neural Links Between OCD and Anorexia|Shared and Unique Neural Links Between OCD and Anorexia: Investigating Biological Mechanisms of Phenotypic Expression||Stanford University|No|Recruiting|January 2013|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Female|12 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent females ages 12-19 drawn from clinic and community populations. With diagnosis        of anorexia nervosa or obsessive-compulsive disorder or no psychiatric diagnosis.|January 2016|January 4, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085057||48753|
NCT02085070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401013290|MK-3475 in Melanoma and NSCLC Patients With Brain Metastases|A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases||Yale University|Yes|Recruiting|March 2014|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|99 Years|No|||January 2016|January 28, 2016|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085070||48752|
NCT02085083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-IBD|Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease|Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease|IMPACT-IBD|Mount Sinai Hospital, Canada|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|210|||Both|16 Years|18 Years|No|||September 2015|September 29, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02085083||48751|
NCT02085629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONEmreg12|The ONE Study M Reg Trial|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M Reg Trial|ONEmreg12|University of Regensburg|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085629||48709|
NCT02085928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-005|Clinical and Ultrasonographic Results of Intratissue Percutaneous Electrolysis in Lateral Epicondylitis|Clinical and Ultrasonographic Results of Intratissue Percutaneous Electrolysis (EPI Technique) in Chronic Lateral Epicondylitis: a Case Series With Prospective 12 Months Follow up||CEU San Pablo University|Yes|Completed|March 2012|September 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|45 Years|No|Non-Probability Sample|36 participants with lateral epicondylitis|March 2014|March 12, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02085928||48686|
NCT02085941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-458|Image-guided Cryoablation of Head, Neck and Spine Tumors|Image-guided Cryoablation of Head, Neck and Spine Tumors||Dana-Farber Cancer Institute|Yes|Recruiting|February 2015|February 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085941||48685|
NCT02086214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_01|Pressure Therapy in the Treatment of Upper Arm of Cerebral Palsy Children|Pressure Therapy in the Treatment of Upper Arm of Cerebral Palsy Children|PROPENSIX|University Hospital, Lille|No|Recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|5 Years|10 Years|No|||December 2015|December 3, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02086214||48664|
NCT02086487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12/052|Efficacy and Safety Assessment of NIlotinib in Patients With Suboptimal Response on Imatinib Therapy|Efficacy and Safety Assessment of NIlotinib in Patients With Suboptimal Response on Imatinib Therapy (NISRI)|NISRI|King Abdullah International Medical Research Center|Yes|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|90 Years|No|||February 2016|February 24, 2016|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02086487||48643|
NCT02121483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.87|Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus|An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|June 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|10 Years|17 Years|No|||March 2016|March 22, 2016|April 22, 2014||||No||https://clinicaltrials.gov/show/NCT02121483||45962|
NCT02133456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201401|A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older|A Post-marketing Safety Study of SIBP's Inactivated, Split-virion Influenza Vaccine Administered in Chinese Subjects Aged 3 Years and Older||Centers for Disease Control and Prevention, China|Yes|Completed|January 2014|April 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community||1|Actual|166240|||Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Beijing subjects aged 3 years or older, at the time of routine visit to a participating        clinic or hospital for influenza vaccination.|May 2014|May 7, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02133456||45047|
NCT02133469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201201|PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae|Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children.||Centers for Disease Control and Prevention, China|Yes|Completed|June 2012|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3281|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02133469||45046|
NCT02122042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64/14|Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery|Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial||Assaf-Harofeh Medical Center|No|Not yet recruiting|May 2014|||May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122042||45919|
NCT02122302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027150|Online Health Assessment to Support Comprehensive Care|Online Health Assessment to Support Comprehensive Care||Cedars-Sinai Medical Center|Yes|Enrolling by invitation|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|80|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122302||45899|
NCT02123134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-13-28|Safety Study of ATX-101 for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age|A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age||Kythera Biopharmaceuticals|No|Completed|April 2014|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123134||45836|
NCT02116140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011469-01|ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.|Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study|AMEND|Ottawa Heart Institute Research Corporation|No|Recruiting|July 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02116140||46372|
NCT02116400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/FC-02|Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt|Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt|DECISIDAIRE|Centre Hospitalier Universitaire de Nīmes|No|Suspended|January 2017|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples Without DNA|Leftover serum samples will be stored in the Nîmes University Hospital Biothèque.|Both|18 Years|60 Years|No|Probability Sample|Patients are recruited via the Bipolar Expert Centres (BEC) at the participating        hospitals. Euthymic bipolar patients requiring a lithium or divalproex -based mood        stabilizer will be included.|October 2015|October 20, 2015|April 15, 2014||No|The primary investigator moved.|No||https://clinicaltrials.gov/show/NCT02116400||46352|
NCT02083978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105453|Bipolar Research Study Using MR Imaging|Neuromorphometry of Psychosis in Bipolar Disorder||Washington University Early Recognition Center|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|75|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|June 2015|June 1, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083978||48836|
NCT02084511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.13|Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain|Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)||Boehringer Ingelheim||Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|80|||Male|18 Years|55 Years|No|||November 2014|November 5, 2014|March 10, 2014||||No||https://clinicaltrials.gov/show/NCT02084511||48795|
NCT02084264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN108|Robotic vs. Freehand Corrective Surgery for Pediatric Scoliosis|Multicenter, Prospective, Partially Randomized, Controlled Trial of Robotic-guided vs. Freehand Corrective Surgery for Pediatric Scoliosis|PEDSCOLI|Mazor Robotics|No|Recruiting|October 2014|October 2024|Anticipated|October 2024|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|||Both|10 Years|21 Years|No|Non-Probability Sample|Pediatric/adolescent patients (age 21 years and younger) undergoing a primary surgery for        the correction of a scoliotic curve of 40 degrees or greater|January 2016|January 5, 2016|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084264||48814|
NCT02084524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.703|ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.|ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.|ANC1|Hospices Civils de Lyon|No|Recruiting|June 2013|June 2016|Anticipated|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|150|||Both|70 Years|N/A|No|||June 2013|March 11, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02084524||48794|
NCT02084537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577235|Minimally Invasive Surgery vs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis|Minimally Invasive Surgeryvs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis|MISER|Florida Hospital|Yes|Recruiting|April 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084537||48793|
NCT02084810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7777-4087|Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects|A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven®||Novo Nordisk A/S|No|Withdrawn|March 2014|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|January 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02084810||48772|
NCT02085096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5180|Problem Solving Therapy|Problem-Solving Therapy for Prostate Cancer Patient's Spousal Caregivers||University of California, San Diego|No|Completed|July 1997|||December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|2||Actual|338|||Both|21 Years|N/A||||June 2014|June 9, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085096||48750|
NCT02085356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130238|Implementing a Comprehensive Prevention of Mother-to-Child Transmission of HIV Program for South African Couples|Implementing Comprehensive PMTCT and HIV Prevention for South African Couples||University of Miami|No|Recruiting|April 2014|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2160|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085356||48730|
NCT02085642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSCSTROKEACPILOT1|Investigation of the Use of Acupuncture for the Treatment of Spasticity in Chronic Stroke Participants|Investigation of the Use of Acupuncture for the Treatment of Spasticity in Chronic Stroke Participants|HHSCSTROKEAC|Hamilton Health Sciences Corporation|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02085642||48708|
NCT02086227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUC-002-CP1|Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)|Bioequivalence of a Test Formulation of Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories) Under Fasted Conditions||Fresenius Kabi USA, LLC|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02086227||48663|
NCT02086240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13HH1842|Reproducibility of the 11C-PBR28 PET Signal|Reproducibility of the 11C-PBR28 PET Signal||Imperial College London|No|Recruiting|March 2014|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086240||48662|
NCT02082444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogPlus201314|Cognition Intervention Study PLUS (CogniDO PLUS)|Cognition Intervention Study PLUS (CogniDO PLUS): Short-term Effects of Lunch on Children's Executive Cognitive Functions|CogniDo|Research Institute of Child Nutrition, Dortmund||Completed|November 2013|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|193|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082444||48953|
NCT02122055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMATJHICU|Sequential Use of Propofol/Midazolam and Dexmedetomidine for Sedation in Mechenical Ventialtion Patients in ICU.|Sequential Use of Propofol/Midazolam and Dexmedetomidine for Sedation in Mechenical Ventialtion Patients in ICU, A Randomized Controlled Study.||Tianjin Third Central Hospital|No|Not yet recruiting|June 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02122055||45918|
NCT02122068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMIT003|Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers|Central Meditation and Imagery Therapy for Major Depressive Disorder in Family Dementia Caregivers||University of California, Los Angeles|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|45 Years|N/A|No|||March 2016|March 24, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02122068||45917|
NCT02121769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omegaven Expanded Access|Omegaven Expanded Access Protocol|Protocol for Patients With Parenteral Nutrition Associated Liver Disease (PNALD) to Access Parenteral Fish Oil (Omegaven®) - Omegaven IND 122375||St. Luke’s Health System, Boise, Idaho||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|17 Years||||November 2015|November 17, 2015|April 21, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02121769||45940|
NCT02122614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFRH/BD/81328/2011|Home-monitoring and Adherence of Patients With COPD to Long-term Rehabilitation|The Role of Home-monitoring in the Adherence of Patients With Chronic Obstructive Pulmonary Disease to Long-term Rehabilitation||Aveiro University|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||January 2015|April 14, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122614||45875|
NCT02122861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-LV305-2013-001|A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1|A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1||Immune Design|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122861||45856|
NCT02122874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003|Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients|||Hospital General Universitario Elche||Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02122874||45855|
NCT02122627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.1.13.033|Vitamin D Supplementation in Patients With COPD|Prevention of Exacerbations in Patients With COPD Through Vitamin D Supplementation: a Randomized Controlled Trial|PRECOVID|VU University Medical Center|No|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|N/A|No|||April 2015|April 8, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122627||45874|
NCT02083159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD(CTRP)|C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease|||Korea University|Yes|Recruiting|March 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The subjects who visited for a routine health check-up at the Health Promotion Center of        Korea University Guro Hospital were enrolled using predefined inclusion and exclusion        criteria.|February 2016|February 29, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083159||48899|
NCT02083731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSC-CMV-2014|MSC for Treatment of CMV Infection|Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant||Nanfang Hospital of Southern Medical University|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|65 Years|No|||January 2015|January 6, 2015|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02083731||48855|
NCT02084550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-48-14|Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis|Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled Trial|AMINOPOUCH|Aarhus University Hospital|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|50 Years|No|||September 2015|September 30, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02084550||48792|
NCT02084823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-001|Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Lung||Fuda Cancer Hospital, Guangzhou|Yes|Completed|March 2014|December 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|20 Years|80 Years|No|||March 2014|June 1, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084823||48771|
NCT02085109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-3-049|The Effects of Fat and Theobromine on apoA-I|The Effects of a Diet Rich in Fat or Theobromine on Intestinal apoA-I mRNA and Protein Expression||Maastricht University Medical Center|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02085109||48749|
NCT02085122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Larissa_ergo_vni_2|Exercise and Noninvasive Ventilation in Heart Failure Patients|Impact of Noninvasive Ventilation With Two Levels of Pressure on Exercise Tolerance in Subjects With Heart Failure: Randomized and Controlled Clinical Trial.||Universidade Federal de Pernambuco|Yes|Completed|March 2013|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||December 2013|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085122||48748|
NCT02085369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH2014|Effect of Gastric Bypass Surgery on Cognition and Genetics|Effect of Gastric Bypass Surgery on Cognition and Genetics||Uppsala University|No|Recruiting|January 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|A fasted blood sample (50 mL) will be taken before and 2h after a standardized meal.      Through epigenetic study, we will analyze the changes in DNA methylation after surgery in      genes related to metabolism (at the Science for Life Laboratory (SciLifeLab) with 450K Human      Meth arrays).      In addition, blood samples from these obese patients analyzed (before and after surgery)      after ingestion of a predetermined test meal (for example, high protein) to explore changes      in metabolites profile. Metabolites in the samples will be quantified by the SciLifeLab.|Both|18 Years|65 Years|No|Non-Probability Sample|Obese patients with gastric bypass surgery|June 2015|June 1, 2015|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02085369||48729|
NCT02085382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 2011-014|Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Neonates|A Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Low Birth Weight Neonates Admitted in Level II Neonatal Intensive Care Unit of the Philippine General Hospital||University of the Philippines|Yes|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|N/A|28 Days|Accepts Healthy Volunteers|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02085382||48728|
NCT02085655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT-SYSUCC-2013|PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma|PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study||Sun Yat-sen University|Yes|Recruiting|April 2013|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|75 Years|No|||April 2013|March 12, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085655||48707|
NCT02086500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH1320080 IND 121102|Study of Tranexamic Acid During Air Medical Prehospital Transport Trial (STAAMP Trial)|Study of Tranexamic Acid During Air Medical Prehospital Transport Trial For Trauma Patients At Risk Of Hemorrhage (STAAMP Trial); Phase III Multicenter, Prospective, Randomized, Double Blind, Interventional Trial|STAAMP|University of Pittsburgh|Yes|Recruiting|July 2015|March 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|90 Years|No|||September 2015|September 28, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086500||48642|
NCT02086513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-598|Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT|Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT||Massachusetts General Hospital|Yes|Recruiting|April 2014|February 2020|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086513||48641|
NCT02082457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP10811_IBS_II_2013|Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation|Multi-center, Randomized, Double Blinded, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation|YKP|SK Chemicals Co.,Ltd.|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|273|||Both|19 Years|N/A|No|||June 2015|June 10, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02082457||48952|
NCT02082470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14001|Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer|Feasibility and Preliminary Outcomes of Survivorship Care Planning in Ovarian Cancer||City of Hope Medical Center|Yes|Active, not recruiting|April 2014|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Female|21 Years|N/A|No|||February 2016|February 15, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082470||48951|
NCT02082730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASARM001|The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Population|An Initial Trial of ASARM: an Advanced Sleep and Rest Monitoring System for Treating Paediatric CFS/ME: Assessing Acceptability and Adaptation Into Current CBT Treatment Protocols|ASARM|Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|January 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|35|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02082730||48931|
NCT02122315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP13-060|Dry Needling in Post-operative Shoulder Pain|EFFECTIVENESS OF THE INCLUSION OF TRIGGER POINT DRY NEEDLING INTO A MULTIMODAL PHYSICAL THERAPY PROGRAM FOR POST-OPERATIVE SHOULDER PAIN||Universidad Rey Juan Carlos|Yes|Completed|February 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||April 2014|April 22, 2014|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02122315||45898|
NCT02122328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-09-00680|Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome|USFetus Randomized Clinical Trial: Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome||University of Southern California|Yes|Recruiting|June 2010|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|542|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02122328||45897|
NCT02122081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13219|Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients With High-Risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2015|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122081||45916|
NCT02122341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00714|Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy|Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial||University of Southern California|No|Recruiting|April 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02122341||45896|
NCT02122913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOXO-TRK-14001|Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors|A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors||Loxo Oncology, Inc.|No|Recruiting|April 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02122913||45852|
NCT02083991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000451-13|Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation|A Controlled Randomized, Open-label, Multi-centre Study Evaluating if a Steroid-free Immunosuppressive Protocol, Based ATG-induction, Low Tacrolimus-dose and Therapeutic Drug Monitoring of Mycophenolate Mofetil, Reduces the Incidence of New Onset Diabetes After Transplantations, in Comparison With Standard Steroid-based Protocol With Low-dose Tacrolimus.|SAILOR|Vastra Gotaland Region|Yes|Recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02083991||48835|
NCT02083757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ZDllKY03.0|Fluid Responsiveness Predicted by PtcO2 in Critically Ill Patients|Fluid Responsiveness Predicted by Transcutaneous Partial Pressure of Oxygen in Critically Ill Patients|PtcO2-FR|Southeast University, China|No|Completed|September 2011|May 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients for whom the attending physician decided to perform a fluid challenge or presence        of at least one clinical sign of inadequate tissue perfusion in the absence of        contraindication for fluid infusion for less than 24 hours were eligible to participate in        the study.|May 2015|May 26, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02083757||48853|
NCT02084238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03|Low-dose IL-2( Interleukin-2) Treatment in SLE|Safety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus Erythematosus||Peking University People's Hospital|Yes|Completed|August 2013|October 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||October 2015|October 2, 2015|March 8, 2014||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT02084238||48816|
NCT02084251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-I-2013-08|Clinical Trial for PB-119 in Healthy Subjects (Phase I)|Safety, Tolerability and Pharmacokinetics of Single Dose of PB-119 in Healthy Volunteers||PegBio Co., Ltd.|Yes|Recruiting|January 2014|January 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02084251||48815|
NCT02084498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StenoABC|Advanced Carbohydrate Counting and Automated Bolus Calculation|A Randomized Controlled Large Study of Flexible Intensified Insulin Therapy (FIIT) With Carbohydrate Counting (CHC) Versus FIIT With Carbohydrate Counting and Automated Bolus Calculation (ABC)||Steno Diabetes Center|No|Completed|September 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02084498||48796|
NCT02084563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA Brasil|Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms|Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms||Hospital Israelita Albert Einstein|Yes|Active, not recruiting|October 2012|December 2019|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|450|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02084563||48791|
NCT02084576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.02|Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification|Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study||Hospital Oftalmologico de Brasilia|Yes|Completed|August 2013|February 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02084576||48790|
NCT02084836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK080760|Relation of Consummatory & Anticipatory Food Reward to Obesity|Relation of Consummatory & Anticipatory Food Reward to Obesity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|June 2009|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|Samples With DNA|Saliva|Both|14 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|162 lean adolescents between 14-17 years old with BMIs between the 25th and 75th        percentile at baseline|March 2014|March 11, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084836||48770|
NCT02085135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-210|A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)|A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)||Alkermes, Inc.|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085135||48747|
NCT02085148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15906|A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy|A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy.||Bayer|No|Recruiting|April 2014|December 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|6 Months|18 Years|No|||February 2016|February 29, 2016|March 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085148||48746|
NCT02085395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCD06003A|Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis|An Open Phase II Study to Assess the Efficacy and Safety of Topical SR-T100® Gel in the Treatment of Human Cutaneous Squamous Cell Carcinoma in Situ (Actinic Keratosis and Bowen's Disease)|AK|G&E Herbal Biotechnology Co., LTD|Yes|Completed|November 2007|November 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A|No|||March 2014|March 13, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085395||48727|
NCT02086266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILUI1|The Efficacy of Pilates in the Recovery of Post-prostatectomy Urinary Incontinence|The Efficacy of Pilates Compared to Pelvic Floor Muscle Training Associated With Electrical Stimulation in the Recovery of Post-prostatectomy Urinary Incontinence: a Randomized Clinical Trial.||Universidade Estadual de Londrina||Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|50 Years|75 Years|No|||March 2014|March 11, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086266||48660|
NCT02086526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000692|Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)|Targeting Pathophysiologic Pathways in Polycystic Ovary Syndrome Using a Response to Metformin Phenotype||Mayo Clinic|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|150|||Female|18 Years|50 Years|No|||August 2015|August 11, 2015|March 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02086526||48640|
NCT02082483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00141|Coronary Artery Disease Screening in Kidney Transplant Candidates|Pilot Study to Determine Feasibility of a Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates|CADScreening|University of British Columbia|Yes|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082483||48950|
NCT02082743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1020515|Vision Care Intervention for Lower Grade School Children in Taiwan|Intervention Program for Vision Care in Lower Grade Schoolchildren||Chang Gung Memorial Hospital|Yes|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1020|||Both|6 Years|7 Years|No|||July 2015|August 5, 2015|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02082743||48930|
NCT02082756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013KTZB03-02-01B|Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment|Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study||Xijing Hospital|Yes|Not yet recruiting|June 2014|September 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|400|||Both|18 Years|70 Years|No|||March 2014|March 7, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082756||48929|
NCT02082769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFDA2010L04287|Safety and Efficacy of Oral Febuxostat in Subjects With Gout|A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout||Xijing Hospital|Yes|Completed|July 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|504|||Both|18 Years|70 Years|No|||March 2014|December 30, 2015|March 6, 2014||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT02082769||48928|
NCT02121496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6889|Social Circumstances, Parenting Techniques, and Infant Development|Social Circumstances, Parenting Techniques, and Infant Development||New York State Psychiatric Institute|Yes|Recruiting|March 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|May 7, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02121496||45961|
NCT02121509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.10|Bioequivalence of a Low, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/750 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)||Boehringer Ingelheim||Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|April 22, 2014||||No||https://clinicaltrials.gov/show/NCT02121509||45960|
NCT02121795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-311-1089|Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF|A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF||Gilead Sciences|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121795||45938|
NCT02121808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ 21054|EPO2-PV: Evaluation of Pre-Oxygenation Conditions in Morbidly Obese Volunteer: Effect of Position and Ventilation Mode|Evaluation of Different Pre-Oxygenation Conditions in Morbid Obesity: Position and Ventilation Mode, in a Respiratory Physiology Laboratory, on Voluntary Subjects|EPO2-PV|Laval University|No|Completed|April 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121808||45937|
NCT02122354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-14-00222|Triggers and Responses to Simulator Sickness in Videogame Players|Data Collection and Analysis on Simulator Sickness Case Parameters in Susceptible Videogame Players||University of Southern California|No|Completed|April 2014|||June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02122354||45895|
NCT02122640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECO/TOR|Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department|Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department|ECO/TOR|Comitato Etico di Area Vasta Sud Est|No|Completed|September 2012|September 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|All the patients admitted to our Emergency Department from January 2011 to February 2013        with acute non-traumatic dyspnea. We included patients carried by ambulance and patients        who came autonomously.|April 2014|April 23, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122640||45873|
NCT02122653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10044|Evaluation and Training of Muscle Fitness in Pre-frail Individuals|||Chang Gung University|Yes|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122653||45872|
NCT02123173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401037RINB|Hemodynamic Changes During One Lung Ventilation in Non-intubated Vedio-assisted Thoracoscopic Operations|Hemodynamic Changes and Fluid Responsiveness During One Lung Ventilation: Comparison in Non-intubated and Intubated Vedio-assisted Thoracoscopic Operations||National Taiwan University Hospital|No|Completed|May 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|||Both|20 Years|70 Years|No|Non-Probability Sample|patients scheduled to receive video-assisted thoracoscopic (VATS) operations with one lung        ventilation(OLV)        Inclusion criteria:          1. age over 20 y/o, less than 70 y/o          2. scheduled to receive VATS operations with OLV        Exclusion:          1. previous thoracic surgery          2. cardiac disease ( including arrhythmias, congestive heart failure, coronary cardiac             disease, etc.)          3. pulmonary disease|December 2014|December 3, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02123173||45833|
NCT02083458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Axillary vein - WCM|An Infraclavicular Landmark-based Approach to the Axillary Vein|A New Infraclavicular Landmark-based Approach to the Axillary Vein as an Alternative Method of Central Venous Cannulation||Publiczny Samodzielny Zaklad Opieki Zdrowotnej Wojewodzkie Centrum Medyczne|No|Completed|February 2010|February 2014|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|153|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083458||48876|
NCT02084017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRG-104871|Negative Pressure Wound Therapy for the Prevention of Surgical Site Infection Following Lower Limb Revascularization|Single Center Prospective Randomized Control Trial on Negative Pressure Wound Therapy for Primarily Closed Groin Incisions Following Lower-limb Re-vascularization to Reduce Surgical Site Infection||Western University, Canada|No|Recruiting|July 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084017||48833|
NCT02084004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013KTZB03-02-01A|Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment|Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study||Xijing Hospital|Yes|Not yet recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|310|||Both|18 Years|70 Years|No|||March 2014|March 6, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02084004||48834|
NCT02084277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10MMHIS068|A RCT to Compare OHRQoL Outcome for SLB and CB|A Randomized Clinical Trial to Compare Oral Health Related Quality of Life Outcome for Patients With Malocclusion Receiving Orthodontic Treatment: Before Treatment vs. During Initial Treatment; Self-ligating Brackets vs. Conventional Brackets||Mackay Memorial Hospital|Yes|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|40 Years|No|||March 2014|March 9, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02084277||48813|
NCT02084589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|A Comparison Study of Patient Controlled Epidural Analgesia (PCEA) With and Without Basal Infusion Using Ropivacaine 0,15% and Fentanyl μg/ml for Pain Relief in Labor, Assessment of Efficacy and Maternal Satisfaction.|||Attikon Hospital||Completed|June 2012|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 6, 2014|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02084589||48789|
NCT02084849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041117|ADPKD Cohort Study|The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cohort Study||Emory University|No|Completed|June 1998|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|624|Samples With DNA|Whole blood, serum, urine, tissue|Both|N/A|60 Years|No|Non-Probability Sample|ADPKD individuals at risk for progression to End Stage Renal Disease (ESRD)|June 2015|June 23, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02084849|84 Months|48769|
NCT02085967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-004|A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion|||Eisai Inc.|No|Completed|February 2014|June 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02085967||48683|
NCT02086253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/161/HP|Role of Endothelin-1 in Flow-mediated Dilatation|Role of Endothelin-1 in Mediating Flow-mediated Dilatation of Conduit Arteries During Sustained Hyperemic Stimulation|Endothelin|University Hospital, Rouen|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02086253||48661|
NCT02086279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMHunderGnRH|AMH Levels Change During Treatment With GnRh Agonist|AMH Levels Change During Treatment With GnRh Agonist: A Prospective Observational Study.||University Magna Graecia|Yes|Completed|March 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|67|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 22, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02086279||48659|
NCT02086292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2297D|The Influence of Lidocaine Volume on Discomfort During Administration of Local Anesthetic|The Influence of Lidocaine Volume on Discomfort During Administration of Local Anesthetic||Norwegian University of Science and Technology|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086292||48658|
NCT02086539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816003|Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study|A Randomized Controlled Trial of Outreach Approaches to Increase Enrollment in the Habit Formation for Adherence to Statin Use and LDL Reduction Study||University of Pennsylvania|Yes|Enrolling by invitation|April 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Anticipated|100|||Both|18 Years|80 Years|No|||March 2014|May 29, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086539||48639|
NCT02086552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC128B|Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma||Mayo Clinic||Recruiting|January 2014|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02086552||48638|
NCT02082496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC4R-2014|GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations|Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations||University of Copenhagen|Yes|Active, not recruiting|June 2014|May 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082496||48949|
NCT02083328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03|Influence of Caffeine on HRV and Exercise Performance in Spinal Cord Injury|Influence of Caffeine on Heart Rate Variability and Exercise Performance in in Tetraplegic and Paraplegic Subjects Compared to Able-bodied Subjects||Swiss Paraplegic Centre Nottwil|No|Completed|July 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02083328||48886|
NCT02121821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH-001|Impact Evaluation of the Pilot SMS Mother Reminder System|Impact Evaluation of the Pilot SMS Mother Reminder System||African Strategies for Health|Yes|Not yet recruiting|May 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|11454|||Female|N/A|N/A|No|||April 2014|April 22, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121821||45936|
NCT02122094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033673|Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities|Implementation of a Sexual Health Intervention for YMSM in Two Vietnamese Cities||National Development and Research Institutes, Inc.|Yes|Recruiting|May 2013|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Male|16 Years|29 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02122094||45915|
NCT02122380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131969|The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome|The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome||Vanderbilt University|Yes|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|34|||Female|18 Years|40 Years|No|||February 2016|February 1, 2016|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122380||45893|
NCT02122926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010A056508|Intensive Discharge Intervention in Diabetes|Effects of an Intensive Discharge Intervention on Medication Adherence, Glycemic Control, and Readmission Rates in Patients With Type 2 Diabetes|IDID|Brigham and Women's Hospital|No|Completed|December 2011|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|180|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02122926||45851|
NCT02122939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECTE|A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers|An Open-label, Single Dosing Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram After Oral Administration in Elderly Volunteers||Seoul National University Hospital||Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 30, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122939||45850|
NCT02122991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-13-024|Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury|Cardiovascular, Cerebrovascular, and Cognitive Function in SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|130|||Both|30 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|80 subjects with chronic SCI and 50 age-matched non-SCI controls will be recruited from        out-patient clinics at the JJP VAMC and the Center of Excellence. This includes subjects        who have completed various protocols in the Cardiovascular autonomic testing laboratory or        patients referred by their physicians following routine physical examinations. Physicians        will be informed of the inclusion and exclusion criteria for this study and will be able        to provide us with the assurance that the patient is an appropriate candidate for the        study and that he/she was willing to speak with the study coordinators.|February 2016|February 22, 2016|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02122991||45846|
NCT02083770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT2525|Clinical Trials Education Program for Hispanic Americans and Asian Pacific Islanders|Randomized Controlled Clinical Trials Education Program for Hispanic Americans and Asian Pacific Islanders||University of California, San Diego|No|Recruiting|March 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|950|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083770||48852|
NCT02084030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DONG2014POCD|Screening of Susceptibility Genes in Postoperative Cognitive Dysfunction(POCD)|Screening of Susceptibility Genes in Postoperative Cognitive Dysfunction After On-pump Cardiac Surgery||Xijing Hospital|Yes|Recruiting|March 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120||blood collected one day before surgery|Both|60 Years|75 Years|No|Probability Sample|Old patient(>60 y) who are schedule to receive of-pump cardiac surgery.|August 2014|August 14, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02084030||48832|
NCT02084290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQR01 HS21747|Evaluating a Shared Decision Making Program for Crohn's Disease|Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|March 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02084290||48812|
NCT02085421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNPI-256|Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis|Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|64 Years|No|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02085421||48725|
NCT02085668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE-ADAPT-HF|Renal Denervation in Patients With Chronic Heart Failure|A Prospective, Multicenter, Randomized, Open-label, Feasibility, Safety and Efficacy Study of Renal Denervation in Patients With Chronic Heart Failure (CHF)||University Hospital, Saarland|Yes|Not yet recruiting|May 2014|May 2019|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2014|March 17, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085668||48706|
NCT02085954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12077|Evaluation of a Training in the Walking With Exosquelette||LOKOMAT|Centre d'Investigation Clinique et Technologique 805|No|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13|||Both|18 Years|N/A|No|Probability Sample|stroke patients follow in our rehabilitation hospital, able to walk alone|October 2015|March 1, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02085954||48684|
NCT02085681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT097685MA|Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases|Effectiveness of Tele-medicine in Identifying Diabetic Retinopathy Cases Attending Diabetologists' Clinics Compared to the Conventional Referral System|DRTM|Aravind Eye Care System|Yes|Completed|May 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|801|||Both|50 Years|N/A|No|||April 2015|April 21, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02085681||48705|
NCT02085980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELEN13-VVA-MK01|Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy|Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy||El. En. SpA|Yes|Completed|March 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||November 2015|January 19, 2016|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02085980||48682|
NCT02082509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAIN-TBI|Therapeutic Resources for Attention Improvement With Neuroimaging for TBI|Therapeutic Resources for Attention Improvement With Neuroimaging for Traumatic Brain Injury|TRAIN-TBI|University of California, San Francisco|Yes|Recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|8 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with TBI will be recruited from the Bay Area Concussion and Head Injury Program        at UCSF or referred to us by colleagues. Healthy controls will be recruited via flyers and        referred to us.|March 2014|March 7, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02082509||48948|
NCT02082782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLDFIRE-2 study|Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases|Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - a Phase II Clinical Trial (COLDFIRE-2 Study)|COLDFIRE-2|VU University Medical Center|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082782||48927|
NCT02083042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB-A2(Urea-CMV)|Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients|Clinical Validation of Lophius Biosciences Kit T-Track® CMV to Assess the Functionality of CMV-specific Cell-mediated Immunity (CMI) and Its Suitability to Determine a Protective Cut-off Value for CMV Reactivations/Disease in Kidney Transplant Recipients|CMValue|Lophius Biosciences GmbH|Yes|Completed|August 2013|December 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|N/A|N/A|No|Non-Probability Sample|Kidney transplant recipients of intermediate risk groups for CMV serostatus (D+/R+;        D-/R+), and scheduled for the preemptive antiviral strategy|February 2016|February 5, 2016|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02083042||48907|
NCT02114021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/13/1019|Effect of Betamethasone Gel and Lidocaine Jelly on Sore Throat, Cough and Hoarseness of|Effect of Betamethasone Gel and Lidocaine Jelly Applied Over Tracheal Tube Cuff on Post Operative Sore Throat, Cough and Hoarseness of Voice on the Patients||Tehran University of Medical Sciences|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|99|||Both|15 Years|50 Years|No|||April 2014|April 14, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02114021||46535|
NCT02121834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14936|A Study of LY3050258 in Healthy Participants|A Multiple-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258||Eli Lilly and Company|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|120|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121834||45935|
NCT02121847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-RES-014-001|Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy||IMPACT|Allergan|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121847||45934|
NCT02122107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-071|Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History|Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|240|Samples With DNA|Blood, saliva or buccal sample for APOE analysis|Female|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We propose to enroll 480 participants into the study across the 2 sites: 240 participants        (160 patients, 80 controls) from MSKCC and 240 participants from City of Hope (160        survivors, 80 controls).|December 2015|December 3, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02122107||45914|
NCT02122367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chung-Ang UH|Study of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness|Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy||Chung-Ang University Hospital||Recruiting|April 2014|||March 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|20 Years|70 Years|No|||April 2014|April 23, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122367||45894|
NCT02125201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0089-13 - CTIL|Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention|Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention||HaEmek Medical Center, Israel|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|3 Months|No|||March 2016|March 10, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02125201||45679|
NCT02122471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-03|12-Week Study of Plecanatide for CIC (The National CIC3 Study)|A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation|CIC|Synergy Pharmaceuticals Inc.|No|Active, not recruiting|April 2014|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1350|||Both|18 Years|80 Years|No|||January 2015|January 29, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122471||45886|
NCT02122952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00627|Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1|Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering the Survival Motor Neuron Gene by Self-Complementary AAV9||Nationwide Children's Hospital|Yes|Active, not recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|N/A|6 Months|No|||December 2015|December 16, 2015|April 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02122952||45849|
NCT02083783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI102-ADD-001|TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study||Tris Pharma, Inc.|Yes|Completed|March 2014|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|6 Years|12 Years|No|||June 2015|June 12, 2015|March 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02083783||48851|
NCT02083796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haik-0607|Short-term Effects of Thoracic Manipulation in Shoulder Impingement|Short-term Effects of Thoracic Manipulation on Scapular Kinematics, Muscle Activity and Pain in Shoulder Impingement. A Randomized Controlled Trial||Universidade Federal de Sao Carlos|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02083796||48850|
NCT02084056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.11|Bioequivalence of a Medium, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects.|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/1000 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)||Boehringer Ingelheim||Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|March 7, 2014||||No||https://clinicaltrials.gov/show/NCT02084056||48830|
NCT02084862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11410|Ultrasound Guided Percutaneous Tracheostomy Compared to Bronchoscopy Guided Percutaneous Tracheostomy|Ultrasound Guided Percutaneous Tracheostomy Compared to Bronchoscopy Guided Percutaneous Tracheostomy - A Randomized Non-inferiority Trial|TRACHUS|University of Sao Paulo|No|Completed|March 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|N/A|N/A|No|||October 2015|October 26, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02084862||48768|
NCT02084303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14089|Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI|Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI|IRONMAN|Dartmouth-Hitchcock Medical Center|No|Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|70 Years|No|||August 2014|August 4, 2014|March 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02084303||48811|
NCT02085187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110036|Early Telemedicine Training in Patients With COPD|Early Telemedicine Training and Counselling After Hospitalization in Patients With Severe Chronic Obstructive Pulmonary Disease: A Feasibility Study||Odense University Hospital|No|Completed|January 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|40 Years|N/A|No|||March 2014|March 10, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02085187||48743|
NCT02085434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H00000948|Pediatric Practice-based Obesity Intervention to Support Families: FITLINE|||University of Massachusetts, Worcester|No|Completed|February 2013|||November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02085434||48724|
NCT02085447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R092670SCH4031|A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness|A Concierge Model of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAL-C) in Individuals With Schizophrenia at Risk for Treatment Non-adherence and for Homelessness|CAL-C|University Hospital Case Medical Center|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02085447||48723|
NCT02085694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/14|Lactobacillus Brevis CD2 Preventing Oral Mucositis|A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation||Catholic University of the Sacred Heart|Yes|Recruiting|March 2014|December 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2014|March 8, 2014|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02085694||48704|
NCT02085993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120269|Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training|A Cross-sectional Study of Patients With Immune Thrombocytopenic Purpura and Caregivers to Estimate the Proportion Who Administer Romiplostim Correctly After Receipt of Home Administration Training Materials||Amgen|No|Completed|July 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|100 Years|No|Non-Probability Sample|ITP patients being treated with romiplostim will be approached for possible study        participation. At each participating site, patients that meet the following criteria will        be enrolled as a study subject. Adult ITP patients, treated per EU Summary of product        characteristics (SmPC), or caregiver new (or at least a 3 month gap) to administering        romiplostim, that has received HAT pack training and is available at a standard-of-care        medical visit 4 weeks (range 2 to 8 weeks) after HAT pack training, the patient provides        informed consent.|December 2015|December 21, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02085993||48681|
NCT02086565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-1307-05218|Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults|Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults||University of Pennsylvania|Yes|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02086565||48637|
NCT02082522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIN-PHO1201|Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)|Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma||Concordia Laboratories Inc.|Yes|Recruiting|August 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2014|March 15, 2016|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02082522||48947|
NCT02082535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0044-0B-CTIL|S100B as a Marker of Brain Injury of Preterm Infants|S100B as a Marker of Brain Injury of Preterm Infants|PTS100B|Sheba Medical Center|No|Recruiting|February 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|2 Days|No|Non-Probability Sample|Very early preterm infants born before 30 weeks gestational age|March 2014|March 8, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02082535||48946|
NCT02130687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121253|Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure|Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition||Vanderbilt University|Yes|Recruiting|June 2014|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02130687||45257|
NCT02131519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13968|Utility of Ultrasonography During Internal Jugular Vein Catheterisation in Pediatric Patients|||Ankara University|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|180|||Both|1 Month|16 Years|No|Non-Probability Sample|pediatric patients aged more than 1 month|May 2014|May 5, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02131519||45194|
NCT02131779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0095|Men's Prostate Awareness Church Training|Prostate Cancer Education in African American Churches|M-PACT|University of Maryland|No|Enrolling by invitation|July 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|480|||Both|40 Years|69 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131779||45174|
NCT02128256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeramentG-CH-2014|CERAMENT™/G - Bone Healing and Re-infection Prophylaxis|CERAMENT™/G - Bone Healing and Re-infection Prophylaxis||University of Lausanne Hospitals|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 1, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02128256||45444|
NCT02128516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN1118|NUTRALYS® Pea Protein Oral Supplementation Effects on Muscle Mass|Controlled, Randomized, Parallel, Double-blind Study of the Effect of NUTRALYS® Pea Protein Supplementation Versus Whey Protein and Placebo on the Muscle Mass and Strength of Volunteers Engaged in Training|nutralys|University of Burgundy|No|Completed|January 2012|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|150|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02128516||45424|
NCT02128763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn IRB Protocol 816490|Dry Eye Assessment and Management Study|Dry Eye Assessment and Management Study|DREAM|University of Pennsylvania|Yes|Recruiting|November 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128763||45405|
NCT02129062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00886|Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)||National Cancer Institute (NCI)|Yes|Terminated|April 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129062||45382|
NCT02129075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00898|CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma|A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2014|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|February 10, 2016|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129075||45381|
NCT02129361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0424|Screening and Brief Intervention for Substance Misuse Following Traumatic Brain Injury|Brief Intervention for Substance Misuse Following Moderate or Severe Traumatic Brain Injury (TBI): A Randomized Controlled Trial||Ohio State University|No|Enrolling by invitation|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129361||45359|
NCT02125396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTC-HCC|Adjuvant Radiotherapy Comparing TACE for Curative HCC|Adjuvant Radiotherapy Comparing Transarterial Chemoembolization for Curative Hepatocellular Carcinoma: a Randomized Controlled Trials|ARTC-HCC|Guangxi Medical University|Yes|Recruiting|May 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125396||45664|
NCT02125916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Driving simulation COLD & ILD|Evaluating the Effect of Oxygentherapy on Concentration at Chronic Lung Patients|Evaluating the Effect of Oxygentherapy on Concentration at Chronic Lung Patients||University of Aarhus||Completed|July 2014|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|65 Years|No|||September 2014|September 11, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125916||45624|
NCT02125929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHGS2013|Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms|Comparative Study of the Efficacy and Safety Outcomes of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neuroendocrine Tumors||Peking Union Medical College Hospital|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02125929||45623|
NCT02124278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUL-042-001|Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects||Pulmotect, Inc.|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124278||45749|
NCT02125175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD547|BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer|BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer|BIOPROP20|The Clatterbridge Cancer Centre NHS Foundation Trust|Yes|Active, not recruiting|January 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Male|18 Years|80 Years|No|||January 2016|January 26, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125175||45681|
NCT02129959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401041RINC|Cardiovascular Effects of the Degree of Head-down and Pneumoperitoneum During Laparoscopy|Cardiovascular Effects of the Degree of Head-down and Pneumoperitoneum During Laparoscopy||National Taiwan University Hospital||Not yet recruiting|May 2014|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|20 Years|80 Years|No|Non-Probability Sample|180 ASA physical status I to III patients undergoing laparoscopic surgery are enrolled in        this study.|May 2014|May 1, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02129959||45313|
NCT02129738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOF-0028|Reuse of Intermittent Urethral Catheters|Is Reuse of Intermittent Urethral Catheters Safe and Preferred? A Prospective, Observational Study Evaluating Reuse of Catheters and Switch to Single-use.||Wellspect HealthCare|No|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02129738||45330|
NCT02129751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-BUPA-401|Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder|A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder||Valeant Pharmaceuticals International, Inc.|No|Not yet recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|7 Years|17 Years|No|||April 2014|January 20, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129751||45329|
NCT02129985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2014-005|Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy|Effect of Short-term Intensive Insulin Sequential Exenatide Therapy on Beta Cell Function and Glycaemic Control in Patients With Newly Diagnosed Type 2 Diabetes :a Multicenter Prospective Randomized Control Study|T2DMRS|Huashan Hospital|Yes|Recruiting|February 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|70 Years|No|||April 2014|April 30, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02129985||45311|
NCT02130232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1628|Appropriate Gestational Weight Gain in Overweight/Obese Women|Appropriate Gestational Weight Gain in Overweight/Obese Women||Kaiser Permanente|Yes|Recruiting|April 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|45 Years|No|||October 2015|October 22, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02130232||45292|
NCT02130466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-022|A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)|A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma||Merck Sharp & Dohme Corp.|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|177|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 1, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02130466||45274|
NCT02130479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA034064-01A1|Testing a Promising Treatment for Youth Substance Abuse in a Community Setting|Testing a Promising Treatment for Youth Substance Abuse in a Community Setting||Medical University of South Carolina|No|Recruiting|April 2014|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||October 2015|November 2, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130479||45273|
NCT02131792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH2014-02|Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness|Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness; A Prospective Study||Kyungpook National University|Yes|Completed|June 2010|April 2014|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|4 Years|12 Years|No|||May 2014|May 4, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02131792||45173|
NCT02132299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSPZV1|Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults|Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults||Sanaria Inc.|Yes|Completed|April 2014|August 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|67|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132299||45135|
NCT02132312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS302-ILR-007|A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement|A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement|ILR7|Omeros Corporation|No|Recruiting|July 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|47 Months|No|||October 2015|December 8, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132312||45134|
NCT02132039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11121441|A Randomised Controlled Trial of Home-based Exercise Intervention for Caregivers of Persons With Dementia|A Randomised Controlled Trial of Home-based Exercise Intervention for Caregivers of Persons With Dementia||The University of Hong Kong|No|Recruiting|May 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|272|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02132039||45154|
NCT02132325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001857|Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer|Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer||Mayo Clinic|No|Recruiting|April 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|19 Years|N/A|No|||December 2015|December 30, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02132325||45133|
NCT02128282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S4-13-001|Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma|A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma||Senhwa Biosciences, Inc.|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128282||45442|
NCT02128529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-401-BE|Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Cross-sectional Observational Study in Pulmonology Departments in Belgium and Luxembourg to Investigate the Epidemiology of Chronic Bronchitis in Patients Suffering From Moderate to Very Severe COPD||Takeda|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|976|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients with or without chronic bronchitis in Belgium and Luxembourg.|April 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128529||45423|
NCT02128542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1379|Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis|A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV|VALOR-HCV|Gilead Sciences|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128542||45422|
NCT02128776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0658|An Enhanced Medical Home for High-Risk Chronically Ill Children|Comprehensive Care Provided in an Enhanced Medical Home to Improve Outcomes and Reduce Costs for High-Risk Chronically Ill Children||The University of Texas Health Science Center, Houston|No|Completed|March 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|201|||Both|N/A|18 Years|No|||April 2014|April 29, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02128776||45404|
NCT02129049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9095|Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children|Enhancing Connections Telephone Program: A Cancer Education Program for Parents||University of Washington|Yes|Completed|April 2014|||July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129049||45383|
NCT02129088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103806|A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Elderly and Adult Subjects||Janssen Research & Development, LLC|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129088||45380|
NCT02125656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475074/2011-4|Use of High Intensity Interval Training as a Strategy to Minimize the Insulin Resistance Observed in Sleep Deprivation|Use of High Intensity Interval Training as a Strategy to Minimize the Insulin Resistance Observed in Sleep Deprivation|HIIT|Federal University of São Paulo|Yes|Active, not recruiting|February 2014|May 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125656||45644|
NCT02125422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-1200|Neurophysiological Study of tDCS Effects in Healthy Volunteers|Neurophysiological Study of tDCS Effects in Healthy Volunteers|tDCSHV|University Hospital of Liege|Yes|Completed|November 2013|April 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02125422||45662|
NCT02125435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408-CL-0101|A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects||Astellas Pharma Inc|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125435||45661|
NCT02126761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V133_01EXP|Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above|A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage-Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age||Novartis|Yes|Completed|June 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|196|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126761||45559|
NCT02126774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02865|The Human Epilepsy Project|The Human Epilepsy Project|HEP|New York University School of Medicine|No|Recruiting|July 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood, plasma, urine|Both|12 Years|60 Years|No|Non-Probability Sample|Epilepsy/Neurology clinical centers|October 2015|October 5, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126774|3 Years|45558|
NCT02126787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN402464340|Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment|Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment of Anxiety Disorders and Comorbid Depressive or Personality Disorders||Medical University of Warsaw|No|Not yet recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|123|||Both|18 Years|65 Years|No|||April 2014|April 28, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02126787||45557|
NCT02133352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30217|Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction|Proof of Concept Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction||Boston University|No|Completed|July 2011|May 2014|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||May 2014|May 6, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133352||45055|
NCT02133365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000363|Atrial Fibrillation, Cardiac Symptoms, and Anxiety|Atrial Fibrillation, Cardiac Symptoms, and Anxiety||Brigham and Women's Hospital|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133365||45054|
NCT02133625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-096|A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors|A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2011|August 2016|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|February 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133625||45034|
NCT02129725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110206-substudy|Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.|Renin- Angiotensin and Fibrinolysis Interaction in Humans: Effect of Long-term PDE-5 Inhibition on Glucose Homeostasis. Sub-study||Vanderbilt University||Recruiting|April 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129725||45331|
NCT02133651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00069524|Mucosal Versus Fecal Microbiota in FMT|Characterization of the Microbial Genomics of Fecal Bacteriotherapy (FBT): Intestinal Microbiota Transplantation (IMT) for Recurring Clostridium Difficile||Emory University|Yes|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Fecal matter from the consented donor, consented recipient at 3 time points will be stored      in a -80 freezer.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Clostridium difficile infection at least twice and will be undergoing        intestinal microbiota transplantation (IMT) via a colonoscopy for treatment from Emory        University Hospital and Emory University Midtown.|December 2015|December 8, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133651||45032|
NCT02130492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 13-382A|A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)|A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)||Northwell Health|Yes|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|21 Years|N/A|No|||October 2015|October 19, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130492||45272|
NCT02130700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-VT-464-CL-002|Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide|A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide||Innocrin Pharmaceutical|No|Recruiting|April 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|N/A|No|||October 2015|October 16, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130700||45256|
NCT02131805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma|A Pilot Study of Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|60 Years|N/A|No|||January 2016|January 20, 2016|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131805||45172|
NCT02132624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003:TCELL|CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.|CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.||Uppsala University|Yes|Recruiting|April 2014|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132624||45111|
NCT02132637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14288|A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes|A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study|IMAGINE 8|Eli Lilly and Company|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|70 Years|No|||September 2015|September 3, 2015|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132637||45110|
NCT02132897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDBEQ-CBZ400/EUFUY-023|Fed Bioequivalence Study of CBZ Formulations|Fed Bioequivalence Study of Carbamazepine Controlled Release Formulations in Healthy Male Uruguayan Subjects||Center for Clinical Pharmacology Research Bdbeq S.A.|Yes|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 14, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02132897||45090|
NCT02121210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13752|To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)|An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis|SARIL-RA-ONE|Sanofi|Yes|Completed|June 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121210||45983|
NCT02128295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12NT04|Trial of Two Electric Breast Pumps in Mothers of Term Infants.|Randomised Trial Comparing the Efficacy and Acceptability of Two Single Electric Breast Pump in Mothers Exclusively Breast Feeding Their Healthy Term Infants.||University College, London|Yes|Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|228|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|December 2, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128295||45441|
NCT02128555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0518|Total Ankle Replacement Versus Arthrodesis Trial|A Randomised, Multi-centre, Non-blinded, Prospective, Parallel Group Trial of Total Ankle Replacement (TAR) Versus Ankle Arthrodesis in Patients With End Stage Ankle Osteoarthritis, Comparing Clinical Outcomes and Cost-effectiveness.|TARVA|University College, London|Yes|Recruiting|January 2015|May 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02128555||45421|
NCT02128789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0171|Bring Communities and Technology Together for Healthy Aging|Bring Communities and Technology Together for Healthy Aging|ElderTree|University of Wisconsin, Madison|Yes|Active, not recruiting|June 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|600|||Both|65 Years|N/A|No|||February 2016|February 3, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02128789||45403|
NCT02129387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA036032-01|EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers|EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers||Southern Illinois University Carbondale|Yes|Recruiting|April 2014|May 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|128|Samples With DNA|blood, saliva|Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of young light smokers|November 2015|November 16, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129387||45357|
NCT02125682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDLPROTECT|The HDL Particle Protection Study|Atorvastatin Action on Oxidative Stress and Inflammation in Type II Diabetes: The HDL Particle Protection Study|HDL PROTECT|Hotel Dieu de France Hospital|Yes|Recruiting|January 2012|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|16|||Both|21 Years|80 Years||||April 2014|April 28, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02125682||45642|
NCT02123810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG-CAN|Quality of Chest Compressions After a Night Shift|Weaker Chest Compression After Nightshift : The We CAN Study.|WeCAN|Bistro Study Group|No|Completed|April 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|46|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123810||45785|
NCT02123823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.4|BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer|A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer||Boehringer Ingelheim||Recruiting|May 2014|January 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|174|||Female|18 Years|99 Years|No|||March 2016|March 8, 2016|April 22, 2014||||No||https://clinicaltrials.gov/show/NCT02123823||45784|
NCT02133378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Prospective Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery|Prospective, Randomized Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery.||Cardiochirurgia E.H.|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|N/A|N/A|No|||January 2016|January 26, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133378||45053|
NCT02133638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sev003|Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery|Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery||Negovsky Reanimatology Research Institute|No|Recruiting|May 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|65 Years|80 Years|No|||May 2014|May 6, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133638||45033|
NCT02129998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progesterone/PIF_Skive|The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology|The Role of Luteal Progesterone and Preimplantation Factor (PIF) for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology||Regionshospitalet Viborg, Skive|No|Enrolling by invitation|May 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|Samples Without DNA|Serum, Embryo culture media|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients undergoing IVF/ICSI treatment at 4 Danish Fertility Centres.|November 2015|November 4, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02129998||45310|
NCT02130245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Early cholecystectomy|Acute Cholecystitis: Early Versus Delayed Laparoscopic Cholecystectomy; Randomized Prospective Study|Acute Cholecystitis: Early Versus Delayed Laparoscopic Cholecystectomy; Randomized Prospective Study||Mansoura University|Yes|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02130245||45291|
NCT02130713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1611380961111745|Treatment of Chronic Bacterial Prostatitis|Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®)||University of Roma La Sapienza|No|Completed|January 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Male|19 Years|54 Years|No|||May 2014|May 2, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02130713||45255|
NCT02130960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC027|Resting Metabolic Rate Reliability|Resting Metabolic Rate Reliability||USDA Grand Forks Human Nutrition Research Center|No|Completed|April 2014|December 2015|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will include up to 15 men and 15 women age 18 -65 years old with a BMI of 19        - 40 kg/m2.|December 2015|December 31, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02130960||45236|
NCT02130934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0315|Cardiac 3D MRI in Pediatric Cancer Patients|Left Ventricular Strain Assessment Using 3d Cardiac Magnetic Resonance Technique In Asymptomatic Pediatric Patients Who Received Cardiotoxic Chemotherapy||University of Kentucky|No|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|8 Years|26 Years|No|Non-Probability Sample|Subjects will come from the Kentucky Children's Hospital Hematology/Oncology clinic. The        study team will ask the subject's primary physician to introduce the study in clinic to        any patient who is identified by the study team as meeting the enrollment criteria. If the        patient and his/her family are interested in participating, a member of the study team        will be notified, and will then consent / assent the patient and family for the study.        Patients who wish to consider the study and potentially enroll later will be given contact        information to call the study personnel if they wish to enroll later.|June 2015|June 26, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130934||45238|
NCT02131207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6813|MRI Before Biopsy in Diagnosing Patients With Prostate Cancer|Novel Screening MRI for the Detection of Prostate Cancer||Case Comprehensive Cancer Center|No|Recruiting|September 2014|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|40 Years|75 Years|No|Non-Probability Sample|This is a pilot study of patients from the University Hospitals urology clinics who have        not previously been given a diagnosis of prostate cancer but who are awaiting a prostate        biopsy due to an elevated PSA or abnormal digital rectal exam|March 2016|March 2, 2016|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131207||45218|
NCT02131220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhongshan 2012-134|Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction|A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON|ERUPTION|Fudan University|Yes|Recruiting|November 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02131220||45217|
NCT02131233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-292|Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects|onceMRK|Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131233||45216|
NCT02130921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DA33609-01|Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled Trial|Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled Trial||University of California, Los Angeles|Yes|Recruiting|July 2014|May 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130921||45239|
NCT02131493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYMedOncoPAC01|S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer|A Open-label, Randomized Study of S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer||Zhejiang University||Recruiting|January 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||November 2015|November 21, 2015|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02131493||45196|
NCT02131506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST174.01|A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer|A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer|CAELYX|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Terminated|December 2009|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|May 5, 2014||No|Safety reasons|No||https://clinicaltrials.gov/show/NCT02131506||45195|
NCT02132338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 22372013.2.000.5149|Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment|Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment||Federal University of Minas Gerais|No|Enrolling by invitation|June 2014|November 2017|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|191|||Both|30 Years|N/A|No|||May 2014|May 5, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02132338||45132|
NCT02125344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 84|A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)|A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)||German Breast Group|Yes|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|950|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02125344||45668|
NCT02121223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU CT002|POST-dilatation to Improve Outcomes in Acute STEMI Patients Undergoing Primary With OCT Assessment|A Prospective, Multi-center,Randomized Controled Trial of POST-dilatation to Improve Outcomes in Acute STEMI Patients Undergoing Primary PCI After Thrombus Aspiration and DES Implantation With OCT Assessment|POST-STEMI|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Not yet recruiting|April 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02121223||45982|
NCT02121470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLIN 12-005|NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care|The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US||BioPorto Diagnostics|No|Completed|February 2014|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|252|Samples Without DNA|Urine, K3-EDTA Plasma, Li-Heparin Plasma|Both|18 Years|N/A|No|Probability Sample|Patients admitted to intensive care or critical care unit (all-comers)|August 2015|August 10, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121470||45963|
NCT02128815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coaching2014#|Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes|Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes|DiabCoach|McMaster University|No|Recruiting|January 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|370|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02128815||45401|
NCT02129101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1389|Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies|Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies||Mayo Clinic|Yes|Recruiting|May 2014|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|April 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02129101||45379|
NCT02129374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-001|Direct Repair Surgery for Spondylolysis of Lumbar in Young Population|||Seoul National University Hospital|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|20 Years|30 Years|No|||May 2014|May 2, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129374||45358|
NCT02125409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-13-01|Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action|Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action.||Aragon Institute of Health Sciences|Yes|Not yet recruiting|May 2014|||May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|69 Years|No|||May 2014|May 2, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125409||45663|
NCT02125448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42022.041.13|PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer|Preoperative Identification of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer (PRIOR)|PRIOR|UMC Utrecht|No|Recruiting|October 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|At the UMC Utrecht, the resection specimens after esophagectomy will be kept in our      institute's biobank, according to standard clinical practice.      At M.D. Anderson Cancer Center biopsy and blood samples will be collected for all patients.|Both|18 Years|N/A|No|Probability Sample|The research population consists of patients with resectable esophageal carcinoma,        scheduled to receive preoperative chemoradiation according to the CROSS-regimen. The        participants will be recruited from the surgical outpatient clinic or the radiation        oncology department of the UMC Utrecht or M.D. Anderson Cancer Center. In total 50        participants with available histopathologic data of the resection specimen are required        for this study.|November 2015|November 6, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02125448||45660|
NCT02126488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-04798|Effect of Adaptive Training for Balance Recovery|Perturbation Training for Fall-risk Reduction Among Older Adults||University of Illinois at Chicago|No|Recruiting|January 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|394|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02126488||45580|
NCT02126501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 13/01/VA03|Comparing Weaning of Nasal Continuous Positive Airway Pressure (CPAP) From Preterm Infants|Randomized Control Trial of Weaning NCPAP From Preterm Infants: Sudden Wean Versus Weaning by Gradually Decreasing Pressure||Maimonides Medical Center|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|26 Weeks|32 Weeks|No|||July 2015|July 6, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02126501||45579|
NCT02133092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103179|A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections|Prospective Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections||Janssen Research & Development, LLC|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|N/A|5 Years|No|Non-Probability Sample|Pediatric patients hospitalized with a laboratory confirmed Respiratory Syncytial Virus        (RSV) lower respiratory tract infection.|March 2016|March 8, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133092||45075|
NCT02133391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2395|Accountable Care Organizations/ Public Health Collaborative|Agency for Healthcare Research and Quality R18: Accountable Care Organizations (ACO)/ Public Health Collaborative Preventive Care Delivery to Priority Populations|ACO/PH|University of Colorado, Denver|Yes|Recruiting|October 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|66264|||Both|19 Months|N/A|No|||October 2015|October 12, 2015|December 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02133391||45052|
NCT02130505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL17100.101.07|Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes|Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes|INFORM|Sint Franciscus Gasthuis|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|51|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02130505||45271|
NCT02130973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG 10-05|The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab|The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab||Health Research, Inc.|No|Active, not recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|45 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02130973||45235|
NCT02123966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-090|An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease|An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease||Dana-Farber Cancer Institute|Yes|Recruiting|May 2014|October 2021|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|31|||Both|4 Years|N/A|No|||October 2014|October 14, 2014|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123966||45773|
NCT02130947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1339|Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide|Randomized, Controlled Study of an Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Either Abiraterone or Enzalutamide||UNC Lineberger Comprehensive Cancer Center|No|Withdrawn|April 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Male|18 Years|N/A|No|||February 2016|February 10, 2016|May 1, 2014||No|We were not able to accrue any participants.|No||https://clinicaltrials.gov/show/NCT02130947||45237|
NCT02131246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3921|A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|64 Years|No|||August 2014|August 4, 2014|May 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131246||45215|
NCT02131259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.181|Long-term Observation PMS for Afatinib|Post Marketing Surveillance on Long Term Drug Use of GIOTRIF Tablets in Patients With Epidermal Growth Factor Receptor Mutation-positive Inoperable or Recurrent Non-small Cell Lung Cancer.||Boehringer Ingelheim||Active, not recruiting|May 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|1500|March 2016|March 21, 2016|May 5, 2014||||No||https://clinicaltrials.gov/show/NCT02131259||45214|
NCT02131532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSF-14/SS/0093|A Rehabilitation Therapy for Post-stroke Fatigue|A Feasibility Study of a Brief Psychological Intervention for Post-stroke Fatigue||University of Edinburgh|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|April 28, 2014||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT02131532||45193|The aim of this single-arm pilot study was to test the feasibility of the intervention programme. This study can not inform the sample size calculation or efficacy of the intervention, which should be investigated in randomised controlled trials.
NCT02131545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000896|Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine|A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults||Mayo Clinic|No|Enrolling by invitation|June 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131545||45192|
NCT02125019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13010|Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer|Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|September 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|N/A|No|Probability Sample|Men and women diagnosed with breast cancer stages I-III|March 2016|March 7, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125019||45693|
NCT02121236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OraMed-02-2014|Diagnostic Accuracy of Ultrasonography in Detecting Benign Radiolucent Lesions|Diagnostic Accuracy of Ultrasonography in Detecting Benign Radiolucent Lesions Compared to CBCT Imaging and Histological Examination||Damascus University|Yes|Completed|April 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|20 Years|50 Years|No|Probability Sample|Patients who are primarily diagnosed as having a benign lesion in one of the two jaws are        going to be included in the study. Patients are usually referred to the Oral and        Maxillofacial Department at our University Dental School to confirm their primary        diagnosis. A database of these referred patients will be created and a random sample from        this database will be withdrawn.|March 2015|March 14, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121236||45981|
NCT02121782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3110A_P1/2a|A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)|A Randomized, Open-label (Part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/IIa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3110A (Quadrivalent Influenza Vaccine)||Green Cross Corporation|Yes|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|84|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121782||45939|
NCT02128594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-299|Serosorting Intervention for HIV Negative MSM|Serosorting Intervention for HIV Negative MSM||University of Connecticut|Yes|Completed|January 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|600|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128594||45418|
NCT02128828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H020|Effect of Cenicriviroc on HIV Neurocognitive Impairment|Randomized, Placebo-Controlled, Double-Blind, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)||University of Hawaii|No|Recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|September 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128828||45400|
NCT02129114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CT-RK2014|Study to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical Repairs|A Multi-Center,Randomized,Non-Inferiority and Positively Controlled Clinical Trial to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical Repairs||Medprin Regenerative Medical Technologies Co.,Ltd.|No|Recruiting|April 2014|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129114||45378|
NCT02126202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80+|Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes|Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study|80+|Sahlgrenska University Hospital, Sweden|Yes|Recruiting|August 2009|January 2016|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|80 Years|N/A|No|||January 2014|April 27, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02126202||45602|
NCT02126215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:057-AAA|An MRI Study of Post-op Cognitive Deficit in Patients Undergoing Major Surgery|"Blue" Cerebrovascular Reactivity (CVR) Maps as a Marker for Post- Operative Delirium (POD) in Patients Undergoing Abdominal Aortic Aneurysm (AAA) Surgery: A Pilot Study: Addition of Other Patients Being Admitted to SSCU After Major Surgery||University of Manitoba|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled to undergo open abdominal aortic aneurysmectomy.|July 2015|July 6, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02126215||45601|
NCT02123524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-RASET|Rivaroxaban Anticoagulation for Superficial Vein Thrombosis|A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis|RASET|McMaster University|Yes|Recruiting|November 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02123524||45806|
NCT02123537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSFD2014|Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation|Functional Electrical Stimulation to Treat Foot Drop in People With Multiple Sclerosis||University of Manitoba|No|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123537||45805|
NCT02129790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000988|Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder|Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder||University of California, Los Angeles|Yes|Recruiting|January 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|13 Years|21 Years|No|||April 2014|April 30, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02129790||45326|
NCT02133404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7991-CL-1004|A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis|Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -||Astellas Pharma Inc|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|20 Years|79 Years|No|||November 2014|November 26, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02133404||45051|
NCT02133664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP2190|Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis|Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis||Oregon Health and Science University|Yes|Not yet recruiting|June 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|65 Years|No|||June 2014|June 5, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133664||45031|
NCT02129764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUSH-PATH 2|Prednisone for Heart Failure Patients With Hyperuricemia|Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2)|PUSH-PATH-2|Hebei Medical University|Yes|Recruiting|December 2013|April 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||April 2014|April 30, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129764||45328|
NCT02129777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1-1188_203|Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis|A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilumab/MT203 At 4 Different Subcutaneous Doses in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Takeda|No|Recruiting|June 2014|April 2017|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|120|||Both|18 Years|70 Years|No|||June 2015|June 30, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02129777||45327|
NCT02130726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOMACH trial|Surgical Technique, Open Versus Minimally-invasive Gastrectomy After CHemotherapy|The STOMACH Trial: Surgical Technique, Open Versus Minimally-invasive Gastrectomy After CHemotherapy|STOMACH|VU University Medical Center|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02130726||45254|
NCT02123654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-117|UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C|A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Treatment-Naive and IFN Experienced Subjects With Genotype 1 Chronic Hepatitis C||Bristol-Myers Squibb|No|Completed|April 2014|August 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|297|||Both|20 Years|N/A|No|||August 2015|September 16, 2015|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123654||45796|
NCT02123667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-01535AC1-01|AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)|AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.|ATLANTIS|Chiesi Farmaceutici S.p.A.|Yes|Recruiting|May 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|900|Samples With DNA|Optional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in      selected sites only in EU and US. Total number of inflammatory cells and quantification of      specific cells including eosinophils, T cells and macrophages will be performed. Gene      expression profiles (including RNA) will be performed at a later date for future analysis on      the pathobiology of asthma which will be defined in future specific protocols|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|900 subjects divided into 800 asthmatic patients and 100 healthy controls will be        included. Recruitment will be balanced, at the extent possible, in order to achieve at        least > 150 patients each for steps 1 - 4 and > 50 patients for step 5 as indicated in the        international guidelines (GINA 2012) on the basis of their previous therapy. The 150        healthy controls will be recruited on the basis of absence of respiratory symptoms, airway        obstruction and hyper responsiveness.|February 2015|February 3, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123667||45795|
NCT02131272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-4093|A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin|A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin||Novo Nordisk A/S|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|358|||Both|10 Years|17 Years|No|||December 2015|December 30, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131272||45213|
NCT02131571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FractaVIH 117/13|Prevalence of Vertebral Fractures in HIV Infected Patients Older Than 50 Years|Prevalence of Vertebral Fractures in HIV Infected Patients Older Than 50 Years: Importance of Bone Mineral Density and Bone Biomarkers|FractaVIH|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Recruiting|May 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|50 Years|N/A|No|Non-Probability Sample|HIV infected patients older than 50 years|February 2016|February 2, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131571||45190|
NCT02131584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0044|Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II|Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): A Phase II Study||M.D. Anderson Cancer Center|No|Recruiting|September 2014|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131584||45189|
NCT02131597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0901|SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)|Phase 2 Study of SGI-110 in Patients With Higher Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131597||45188|
NCT02131558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-017|Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer|The Feasibility and Benefits of Using Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer||Lahey Clinic|No|Enrolling by invitation|May 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|90 Years|No|||May 2014|May 5, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02131558||45191|
NCT02125032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-PEMF14|Transcranial Low Voltage Pulsed Electromagnetic Fields (T-PEMF) in Patients With Parkinson's Disease|||Odense University Hospital||Enrolling by invitation||||April 2016|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||April 2014|April 24, 2014|April 23, 2014||||No||https://clinicaltrials.gov/show/NCT02125032||45692|
NCT02125357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUTG-001|Sequencing Abiraterone and Enzalutamide in mCRPC|A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer||British Columbia Cancer Agency|No|Recruiting|August 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|118|||Male|18 Years|N/A|No|||January 2016|February 12, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02125357||45667|
NCT02121262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-026|A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema|||Allergan|No|Withdrawn|April 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|April 22, 2014|Yes|Yes|This study was withdrawn prior to enrollment due to company decision.|No||https://clinicaltrials.gov/show/NCT02121262||45979|
NCT02121275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUS|Lung Ultrasound for the Detection of Pulmonary Atelectasis in the Perioperative Period|Lung Ultrasound for the Detection of Pulmonary Atelectasis in the Perioperative Period||Medical University of Vienna|No|Recruiting|January 2012|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing elective laparoscopic surgery at the Medical University of Vienna|March 2016|March 15, 2016|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121275||45978|
NCT02121522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1313.20|A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration|A Single Arm Open Label Study to Evaluate the Pharmacodynamics and Safety of a 4 wk Treatment With BI 144807 in Patients With Newly Diagnosed Wet Age Related Macular Degeneration (wAMD)||Boehringer Ingelheim||Completed|June 2014|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|50 Years|N/A|No|||May 2015|May 10, 2015|April 22, 2014||||No||https://clinicaltrials.gov/show/NCT02121522||45959|
NCT02121535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348.3|Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use|Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study||Boehringer Ingelheim||Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|April 22, 2014||||No||https://clinicaltrials.gov/show/NCT02121535||45958|
NCT02128841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154/10|Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.|This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mechanical Aortic Heart Valve Replacement.|CATHAR|University Hospital Inselspital, Berne|Yes|Recruiting|September 2012|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||July 2015|July 22, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02128841||45399|
NCT02129413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLT-CL-PR-01|Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm|Safety and Performance of the Delta System in the Treatment of Vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH) Patients||Samson NeuroSciences|No|Recruiting|May 2014|||August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|75 Years|No|||April 2014|February 4, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02129413||45355|
NCT02129127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP004|Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial|First in Human Evaluation of the Drug-Coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease|ENDURE|TriReme Medical, LLC|Yes|Active, not recruiting|March 2014|August 2017|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129127||45377|
NCT02129400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-026|Influence on Erythropoetin-level by Xenon|Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers|XEPO|RWTH Aachen University|Yes|Terminated|May 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|16||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|April 15, 2014||No|The analysis of the blood samples was much expensive than calculated. The recruitment had to    be stopped after 36 study participants.|No||https://clinicaltrials.gov/show/NCT02129400||45356|
NCT02126228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2ndhsdu-ob|no Antibiotics for Elective Cesarean With Low Risk of Infection|A Randomized Controlled Trial on Antibiotics Application For Low Infection-risked Elective Cesarean||Shandong University|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|212|||Female|20 Years|45 Years|No|Probability Sample|antibiotics group:202 none antibiotics group:212|April 2014|April 27, 2014|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126228|1 Month|45600|
NCT02126241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-1176-14-MG-CTIL|Non-Invasive Cardiac Output Measurement for CRT Optimization|The Use of Impedance-Based Non-invasive Cardiac Output Measurement (NICaS) for Optimizing Cardiac Resynchronization Therapy: a Pilot Clinical Trial.|NICaS-CRT|Sheba Medical Center|No|Completed|April 2014|May 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|90 Years|No|||August 2015|August 5, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126241||45599|
NCT02123849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01006|Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers|The Effect of Intermittent Versus Continuous Dose Aspirin (ASA) on Nasal Epithelium Gene Expression in Current Smokers||National Cancer Institute (NCI)|Yes|Recruiting|June 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123849||45782|
NCT02124616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGYPT PED-NMD 2014|National Registry for Egyptian Pediatric Neuromuscular Diseases|National Registry for Egyptian Pediatric Neuromuscular Diseases||Ain Shams University|Yes|Recruiting|April 2014|December 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|1 Month|18 Years|No|Non-Probability Sample|All children from birth to 18 years of age with inherited or acquired neuromuscular        diseases.|April 2014|April 25, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124616|5 Years|45723|
NCT02130024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AAU17|A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients|Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept|RIVAL|Novartis|No|Recruiting|April 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|278|||Both|50 Years|N/A|No|||March 2016|March 10, 2016|March 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130024||45308|
NCT02130037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1001-EG-CTIL|Cognitive Behavioral Therapy Via a Smartphone Application on Bulimia Nervosa and Binge Eating Disorder Symptoms|The Effect Size of Cognitive Behavioral Therapy Via a Smartphone Application on Bulimia Nervosa and Binge Eating Disorder Symptoms||Sheba Medical Center|No|Recruiting|May 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|60 Years|No|||May 2014|May 1, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130037||45307|
NCT02130284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 272 PLGM|In Clinic Evaluation of the PLGM Feature|In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor|PLGM|Medtronic Diabetes|Yes|Completed|October 2014|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|14 Years|75 Years|No|||September 2015|September 3, 2015|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130284||45288|
NCT02130011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGRT|Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose|Managing the Real Dose: Evaluating the Impact on Gastric Filling on the Delivered Radiation Dose in Gastrooesophageal Junction Tumors|DGRT|Maastricht Radiation Oncology|No|Completed|March 2014|September 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02130011||45309|
NCT02130258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002234|Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome|Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome||Massachusetts General Hospital|No|Recruiting|May 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02130258||45290|
NCT02130271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-002174|PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients|PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients||Massachusetts General Hospital|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|A saliva sample will be taken from healthy subjects only at Visit 1. The saliva sample will      be taken fro genotyping. Genotyping will identify if the subject makes proteins that will      bind the radioactive tracer.      A blood sample will be drawn for Genotyping at Visit 2 from all subjects.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Subject is currently diagnosed with lower extremity radicular/sciatica pain.          2. Healthy subjects with no pain from the local community.|September 2015|September 21, 2015|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130271||45289|
NCT02130739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-Tepi|Horner's SD After Thoracic Epidural Block|Incidence of Transient Horner's Syndrome Following Thoracic Epidural Anesthesia for Mastectomy||Soonchunhyang University Hospital|Yes|Completed|September 2010|April 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Female|20 Years|80 Years|No|Non-Probability Sample|Patients, who scheduled for mastectomy with/without breast reconstruction|May 2014|May 1, 2014|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130739|3 Days|45253|
NCT02124200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Personal Vape Pilot (Vapecig)|High Cessation Rates in Smokers Using Personal Vaporizers|High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study|VAPECIG|Universita degli Studi di Catania||Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124200||45755|
NCT02124213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441005|A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers|Open Label Adaptive Design Study To Evaluate D1 Receptor Occupancy (ro) Following Single Dose Of Pf-06412562, Using Positron Emission Tomography (Pet) With Ligand [11c]sch23390 In Healthy Male Subjects|PET|Pfizer|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|5|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124213||45754|
NCT02124174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203835|Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS|Maintenance Therapy With Azacitidine and Valproic Acid After Allogeneic Stem Cell Transplant in Patients With High-Risk Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)(Version 1_06 Jan 2012)||Loyola University|Yes|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|89 Years|No|||April 2014|April 24, 2014|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124174||45757|
NCT02124434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC14062-13CTIL|Laparoscopic Sleeve Gastrectomy - A Prospective Study of Weight Loss, Comorbidities and Patients' Quality of Life|Laparoscopic Sleeve Gastrectomy - A Prospective Study of Weight Loss, Comorbidities and Patients' Quality of Life||Meir Medical Center|Yes|Recruiting|February 2014|||October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity.|April 2014|April 24, 2014|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02124434|1 Year|45737|
NCT02131818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-OBG-CEU-01-2014|Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term|Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term||Mahidol University|No|Terminated|May 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|5|||Female|18 Years|50 Years|No|||December 2015|December 1, 2015|April 28, 2014||No|The enrollment process is too difficult to complete|No||https://clinicaltrials.gov/show/NCT02131818||45171|
NCT02131831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDO 123 TRX|Telomeres Parameters in Cirrhosis|||Meir Medical Center||Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|patients with cirrhosis|September 2014|September 15, 2014|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02131831||45170|
NCT02120963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FatigueRA-RCT|Fatigue in People With Rheumatoid Arthritis- Randomized Controlled Trial|The Effect of Person-centered Physical Therapy on Fatigue Related Variables in Persons With Rheumatoid Arthritis- Randomized Controlled Trial|RAFatigueRCT|Göteborg University|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|65 Years|No|||January 2016|January 7, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120963||46002|
NCT02121249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mazor_001|Clinical Trial of Minimally Invasive Robotic Spine Surgery|Randomized Comparative Trial of Minimally Invasive Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries||Seoul National University Hospital|No|Active, not recruiting|December 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|85 Years|No|||April 2015|April 6, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121249||45980|
NCT02121288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5135L00001|Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients|A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients|PAD|AstraZeneca|No|Withdrawn|December 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|59 Years|No|||October 2014|October 14, 2014|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121288||45977|
NCT02121301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-110-0006|A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome|A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome||Mitotech, SA|No|Completed|April 2014|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121301||45976|
NCT02121548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100834|Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations|Research Project of the South Florida Center for Reducing Cancer Disparities (SUCCESS): Testing CHWs and HPV Self-Sampling to Increase Cervical Cancer Screening Among Minority Immigrants in Miami-Dade County:|SUCCESS|University of Miami|Yes|Active, not recruiting|June 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|600|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121548||45957|
NCT02125461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4191C00001|A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer|A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)|PACIFIC|AstraZeneca|Yes|Recruiting|May 2014|January 2020|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|702|||Both|18 Years|130 Years|No|||February 2016|February 11, 2016|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125461||45659|
NCT02125695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999LE003|Pilot Tape Harvesting Study|A Pilot Study to Evaluate Using Tape Harvesting to Collect RNA From the Upper Epidermis of Healthy Volunteers, Subjects With Discoid Lupus, Subjects With Subacute Cutaneous Lupus, Subjects With Systemic Sclerosis, and Subjects With Atopic Dermatitis||Biogen|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|55|Samples With DNA|Specimens collected from skin taping and blood sampling.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants are enrolled at selected investigational sites in a standard clinical        practice setting|October 2015|October 16, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125695||45641|
NCT02125942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMIT1044|Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment|Pilot Study of Central Meditation and Imagery Therapy for Borderline Personality Disorder||University of California, Los Angeles|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02125942||45622|
NCT02123550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swanson01|Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection|Doppler Ultrasound Imaging of Plastic Surgery Patients for Deep Venous Thrombosis Detection: A Prospective Controlled Study.||Swanson Center|Yes|Recruiting|January 2014|January 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200 study patients consisting of consecutive elective patients undergoing outpatient        plastic surgery.|November 2014|November 18, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123550||45804|
NCT02123836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKEXPSIN-2013/01|Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome|Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Acute Leukaemia and Myelodysplastic Syndrome||National University Hospital, Singapore|No|Recruiting|April 2014|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|80 Years|No|||June 2015|June 17, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123836||45783|
NCT02124642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASUPPPREG-2014|Folic Acid Supplementation in Pregnant Women: Dose Response|Folic Acid Supplementation in Pregnant Women: Dose Response|FAPREG|University of Georgia|No|Active, not recruiting|May 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124642||45722|
NCT02130050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401106RINB|Metabolic Profiling in Patients With Obstructive Sleep Apnea: From Plasma to Hypoxic Cell Model of Peripheral Monocyte|Metabolic Profiling in Patients With Obstructive Sleep Apnea: From Plasma to Hypoxic Cell Model of Peripheral Monocyte||National Taiwan University Hospital|Yes|Active, not recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|24|Samples Without DNA|Human plasma|Male|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|moderate to severe OSA from primary care clinic friends and families from recommendation        of OSA patients|April 2014|April 30, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02130050||45306|
NCT02130297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0387|Post Excision/Mohs Scar Laser Resurfacing|Post Excision/Mohs Fractional CO2 Resurfacing: A Quantitative and Qualitative Scar Analysis Study||Icahn School of Medicine at Mount Sinai|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130297||45287|
NCT02130518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1401|Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency|A Multicenter, Randomized, Double-Blind, Efficacy Study of Auriclosene Irrigation Solution on Indwelling Urinary Catheter Patency||NovaBay Pharmaceuticals, Inc.|No|Active, not recruiting|September 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130518||45270|
NCT02123641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-017|Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function|Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function|LISA|Bispebjerg Hospital|Yes|Recruiting|April 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|450|||Both|62 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123641||45797|
NCT02124226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METGINA-005|Low-dose Methotrexate for Reduction GINA 5 Medications in Chronic Severe Asthma|Low-dose Methotrexate for Reduction of GINA Step 5 Medications in Chronic Severe Asthma: a Randomized Controlled Trial||Universita degli Studi di Catania|Yes|Not yet recruiting|April 2015|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|75 Years|No|||April 2014|April 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124226||45753|
NCT02124187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCARID|Smoking Cessation And Reduction in Depression||scarid|Universita degli Studi di Catania|Yes|Not yet recruiting|December 2016|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|129|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124187||45756|
NCT02124447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00022505|Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy|Comparison of Efficacy and Patient Tolerability of Four Commercially Available Bowel Purgatives for Screening and Surveillance Colonoscopy: A Single Tertiary Medical Center Experience.||Medical College of Wisconsin|No|Withdrawn|June 2014|June 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|4||Actual|0|||Both|18 Years|90 Years|No|||July 2015|July 9, 2015|April 23, 2014|Yes|Yes|Protocol issues. Modifications potentially will be undertaken and resubmitted to IRB|No||https://clinicaltrials.gov/show/NCT02124447||45736|
NCT02124707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1330|Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN|LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|April 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124707||45717|
NCT02120976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT252-U-14-001|Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252|A Phase 1, Randomized, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Single Oral Doses of JTT-252 in Healthy Subjects (Part I); in Conjunction With an Open-label Study to Evaluate the Effect of Food on the PK of JTT-252 in Healthy Subjects (Part II); and an Open-label Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics (PD) of Single Oral Doses of JTT-252 in Type 2 Diabetic Subjects (Part III)||Akros Pharma Inc.|No|Terminated|April 2014|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|9||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120976||46001|
NCT02121860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-08|PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers|An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers||Conatus Pharmaceuticals Inc.|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|April 18, 2014|Yes|Yes||No|September 25, 2015|https://clinicaltrials.gov/show/NCT02121860||45933|
NCT02121873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-503|The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage|The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage||Atossa Genetics, Inc.|No|Completed|July 2011|August 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|Samples With DNA|Whole blood, nipple aspirate fluid, ductal lavage fluid|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women will be recruited from our local pool of volunteers who have participated in        previous studies of ductal lavage and/or ductoscopy at the Foundation.|April 2014|April 22, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02121873||45932|
NCT02122120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEN1|The Value of Aritficial Diet and Complex Care in Home Nutrition|Home Enteral Nutrition (HEN) Reduces Complications, Length of Stay and Health-care Costs: Results From the Multicenter Study.||Stanley Dudrick's Memorial Hospital|Yes|Completed|January 2007|January 2013|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|456|||Both|N/A|N/A|No|Probability Sample|456 patients during home tube feeding|April 2014|April 23, 2014|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02122120|12 Months|45913|
NCT02129426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ket-Dex/M-Dex MRI|Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine|COMPARISON OF OUTCOMES DURING MRI SEDATION WITH MIDAZOLAM-DEXMEDETOMIDINE VERSUS KETAMINE-DEXMEDETOMIDINE||University of Louisville|No|Recruiting|August 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|N/A|18 Years|No|||December 2015|December 8, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02129426||45354|
NCT02125708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012014|Core-temperature Monitoring in Patients With PPROM|Core-temperature Monitoring in Patients With PPROM for Early Detection of Chorioamnionitis - a Pilot Study||Medical University of Vienna|Yes|Active, not recruiting|April 2014|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125708||45640|
NCT02125955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-1026386|Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children|Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children||University of Calgary|Yes|Active, not recruiting|February 2014|April 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125955||45621|
NCT02124096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914092|Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs|Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|March 2025|Anticipated|March 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 27, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124096||45763|
NCT02124655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393/2012|Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth.|Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth: a Randomised Clinical Trial.||University of Santiago de Compostela|No|Completed|September 2012|||June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|15|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 26, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124655||45721|
NCT02124668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0122|A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Astellas Pharma Inc|No|Active, not recruiting|September 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|N/A|N/A|No|||January 2016|January 27, 2016|April 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124668||45720|
NCT02124408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H20132175|Mobile Phone Personalized Intervention for Diabetes|||Ningbo Beilun District Traditional Chinese Medicine Hospital||Recruiting|November 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|20 Years|N/A|No|||April 2014|April 27, 2015|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02124408||45739|
NCT02122822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-TT-G-01|Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96|Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96||Cure&Sure Biotech Co., LTD|Yes|Active, not recruiting|July 2013|January 2018|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122822||45859|
NCT02122835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032063|Exercise, Heart Failure, and Type 2 Diabetes|Vascular and Metabolic Responses to Exercise Training in Heart Failure With or Without Type 2 Diabetes||Duke University||Withdrawn|February 2012|||September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||May 2015|November 11, 2015|April 18, 2014||No|Lack of funding/patient availability|No||https://clinicaltrials.gov/show/NCT02122835||45858|
NCT02130310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-105|Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers|A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers||Macrocure Ltd.|Yes|Active, not recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130310||45286|
NCT02130531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4429-101|Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration||Acucela Inc.|No|Completed|April 2014|November 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|65 Years|N/A|No|||January 2016|January 14, 2016|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130531||45269|
NCT02123368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM/ART|Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells|Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells||Clinica Universidad de Navarra, Universidad de Navarra|Yes|Active, not recruiting|May 2012|February 2015|Anticipated|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|50 Years|80 Years|No|||April 2014|January 5, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02123368||45818|
NCT02123381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scch2014019|Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma|Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma||Sichuan Cancer Hospital and Research Institute|Yes|Recruiting|April 2014|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02123381||45817|
NCT02124239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0105-1034|Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions|A Phase I, Multi-centre, Open-label, Uncontrolled, Non-randomised Study to Evaluate the Systemic Exposure and Safety of Ingenol Mebutate When Applied to Full Face, Balding Scalp or an Area of Approximately 250 cm2 on the Arm in Subjects With Actinic Keratosis||LEO Pharma|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|N/A|No|||March 2014|January 8, 2015|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124239||45752|
NCT02124252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA188428|Community-Driven Cervical Cancer Prevention in Western Kenya|Evaluation of a Community-Driven Cervical Cancer Prevention Strategy in Western Kenya||University of California, San Francisco|No|Not yet recruiting|October 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|7200|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124252||45751|
NCT02124460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-6739|Connect 4 Health: An Intervention to Improve Childhood Obesity Outcomes|Improving Childhood Obesity Outcomes: Testing Best Practices of Positive Outliers||Massachusetts General Hospital|No|Active, not recruiting|June 2014|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|721|||Both|2 Years|12 Years|No|||September 2015|September 22, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02124460||45735|
NCT02124746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-352-1154|Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia|Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia||Gilead Sciences|No|Active, not recruiting|April 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|105|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124746||45714|
NCT02124759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130459H|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)|MicroB1|The University of Texas Health Science Center at San Antonio|Yes|Recruiting|April 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124759||45713|
NCT02125045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215_062013|Sublingual L-GSH Supplementation in Male Subjects With Smoking Habit and/or Hypertension|Medium Term Effect of Sublingual L-glutathione (L-GSH) Supplementation on Flow Mediated Dilation and Oxidative Stress Markers in Male Subjects With Smoking Habit and/or Arterial Hypertension||Niguarda Hospital|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|November 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125045||45691|
NCT02124720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERFAS-2014-15-030-P|Using Mobile Technology to Reduce Stereotypy|Using Mobile Technology to Reduce Stereotypy in Children With Autism Spectrum Disorders||Université de Montréal|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|12 Years|No|||December 2015|December 3, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124720||45716|
NCT02124733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-374|Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses|Simultaneous Incubation/Illumination Versus Short Aminolevulinate Preincubation for Painless Photodynamic Therapy of Actinic Keratoses||The Cleveland Clinic|No|Recruiting|April 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124733||45715|
NCT02120989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H140059|Researching Effective Sleep Treatments (Project REST)|A Pilot Study Examining the Effectiveness of Partner-Assisted Cognitive Behavioral Therapy for Insomnia|REST|University of California, San Diego|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02120989||46000|
NCT02121002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-DCG-001|Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee|A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in the Treatment of Subjects With Osteoarthritis of the Knee||Amneal Pharmaceuticals, LLC|Yes|Completed|April 2014|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1176|||Both|35 Years|N/A|No|||June 2015|June 23, 2015|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121002||45999|
NCT02122458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1164-R|Blast-exposed Veterans With Auditory Complaints|Blast-exposed Veterans With Auditory Complaints||VA Office of Research and Development|No|Not yet recruiting|August 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|468|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02122458||45887|
NCT02123238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-549|Positioning of Surgical Patients With Sleep Apnea|Non-Supine Positioning in Treatment of Surgical Patients With Obstructive Sleep Apnea||Englewood Hospital and Medical Center|No|Withdrawn|April 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 14, 2015|April 23, 2014||No|no funding|No||https://clinicaltrials.gov/show/NCT02123238||45828|
NCT02122731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-017033|Amiloride for Resistant Hypertension|Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride||Odense University Hospital|No|Completed|November 2010|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|30 Years|75 Years|No|||April 2014|April 23, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122731||45866|
NCT02123004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0249|Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function|Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention|TIGERCAVE|Jinan Central Hospital|Yes|Not yet recruiting|April 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|80 Years|No|||February 2015|February 24, 2015|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02123004||45845|
NCT02123264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGV222|Zoledronic Acid in Rheumatoid Arthritis|Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity|AZAR|Hospital Universitari de Bellvitge|Yes|Recruiting|May 2014|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02123264||45826|
NCT02125331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123.04-2013-GES-0008|Measurement of NonInvasive Blood Pressure in Neonates Through Adults and Special Populations|Measurement of NonInvasive Blood Pressure With DINAMAP SuperSTAT and Datex-Ohmeda With Intra-arterial Blood Pressure in Neonates Through Adults and Special Populations|MISSION|GE Healthcare|No|Enrolling by invitation|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|N/A|N/A|No|||February 2016|February 8, 2016|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125331||45669|
NCT02123082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1060|Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes|Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes||University of California, Irvine|Yes|Not yet recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02123082||45839|
NCT02123355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPPHA01|The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery|The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery,A Randomized Controlled Study||Shaanxi Provincial People's Hospital|No|Not yet recruiting|August 2014|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|65 Years|N/A|No|||April 2014|April 24, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02123355||45819|
NCT02124824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1418-P|Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure|Contribution of Endothelin-1 to Exercise Intolerance in HF||VA Office of Research and Development|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|February 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124824||45708|
NCT02125149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202954|The Expecting Study|Prenatal Physical Activity Intervention||Arkansas Children's Hospital Research Institute|No|Recruiting|September 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|234|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02125149||45683|
NCT02124473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 1120|Addition of Homeopathy in Patients With Resistant Arterial Hypertension|Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Homeopathy in Resistant Arterial Hypertension||Macmillan Research Group UK|Yes|Completed|August 2013|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|85 Years|No|||April 2014|April 24, 2014|April 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124473||45734|
NCT02124772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116540|Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations||GlaxoSmithKline|No|Recruiting|January 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|94|||Both|1 Month|17 Years|No|||July 2015|July 16, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124772||45712|
NCT02124785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116763|Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®|Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix® (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)||GlaxoSmithKline||Withdrawn|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|April 24, 2014|Yes|Yes|This study has been cancelled before initiation due to company's prioritisation decisions    linked to resources restrictions.|No||https://clinicaltrials.gov/show/NCT02124785||45711|
NCT02124811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071195|Minocycline Augmentation to Clozapine|A Pilot Study of Minocycline Augmentation to Clozapine in Individuals With Treatment Resistant Schizophrenia||Emory University|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|65 Years|No|||November 2015|November 14, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124811||45709|
NCT02125058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46056.068.13|Intracutaneous Versus Transcutaneous Sutures in the Face (IC vs TC Sutures)|Randomized Controlled Trial for the Cosmetic Result of Intracutaneous Versus Transcutaneous Sutures After Dermatologic Surgery in the Face||Maastricht University Medical Center|No|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02125058||45690|
NCT02120950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16995|Aflibercept in Polypoidal Choroidal Vasculopathy|A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy|PLANET|Bayer|No|Active, not recruiting|May 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Both|50 Years|N/A|No|||March 2016|March 14, 2016|April 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120950||46003|
NCT02121561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMississippi2014-0010|Examining the Effectiveness of Self-Acceptance Group Therapy|Examining the Effectiveness of Self-Acceptance Group Therapy||University of Mississippi Medical Center|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121561||45956|
NCT02122978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/12/12 mind derm|Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy in a Psoriasis Sample|Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy: Understanding What Works Psychologically and Physiologically in a Randomized Study in Dermatology||St Vincent's University Hospital, Ireland|No|Active, not recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|94|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122978||45847|
NCT02123017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-KR-005|Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy|An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults||Cumberland Pharmaceuticals|Yes|Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|April 23, 2014|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT02123017||45844|
NCT02123277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9259|Long Term Evaluation of Tubal Expansion on Obstructive Dysfunctions of Eustachian Tube|Long Term Evaluation of Tubal Expansion on Obstructive Dysfunctions of Eustachian Tube||University Hospital, Montpellier|Yes|Recruiting|May 2014|May 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02123277||45825|
NCT02123290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_DSM265_13_02|DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax|A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period||Medicines for Malaria Venture|Yes|Completed|January 2016|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|60 Years|No|||January 2016|January 29, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123290||45824|
NCT02123563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/20424-1|Mechanical-chemical Gingival Therapy in Diabetics and/or Obese|Evaluation of Mechanical-chemical Gingival Therapy in Diabetic, Obese or Diabese Subjects: Quantitative and Qualitative Analysis of Local and General Aspects.|MCGTDO|University of Taubate|No|Completed|June 2012|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02123563||45803|
NCT02123862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.08.002|Cultured Circulating Tumor Cells in Prostate and Other Cancers|Cultured Circulating Tumor Cells - Development of a Novel Platform for Drug Discovery and in Vitro Chemosensitivity Testing in Prostate and Other Cancers||Comprehensive Cancer Centers of Nevada|No|Recruiting|April 2014|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|220|Samples With DNA|-  Fifteen (15) cc whole blood (two - 7.5 cc tubes) will be collected and processed for           research tests.        -  Patients with prostate, breast or colorectal cancer will have an additional ten (10) cc           whole blood collected for commercial CTC assay as part of standard care.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be having blood drawn at Comprehensive Cancer Centers of Nevada as part        of their routine care.|January 2015|January 15, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02123862||45781|
NCT02124343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WA/0022|Exercise and Neutrophil Function in COPD|A Pilot Study to Examine the Effect of Acute Exercise on Neutrophil Function in Patients With Chronic Obstructive Pulmonary Disease||Hywel Dda Health Board|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02124343||45744|
NCT02124356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-AHA-FYS-01|Functional Performance Following Emergency High-risk Abdominal Surgery|Functional Performance Following Emergency High-risk Abdominal Surgery||Hvidovre University Hospital|Yes|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|19 Years|N/A|No|Probability Sample|Patients (19 years and older) undergoing Emergency High-risk Abdominal Surgery at the        Hvidovre University Hospital.|October 2014|October 2, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02124356||45743|
NCT02129569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5A13|Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers|Family-Centered Intervention for the Transition to Living With Multiple Myeloma as a Chronic Illness||Case Comprehensive Cancer Center|Yes|Active, not recruiting|November 2013|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129569||45343|
NCT02122575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140103|Effect of Fasting on the NLRP3 Inflammasome|Pilot Study to Evaluate the Effect of Fasting on the NLRP3 Inflammasome||National Institutes of Health Clinical Center (CC)||Completed|April 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|23|||Both|21 Years|37 Years|No|||February 2016|February 27, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122575||45878|
NCT02122588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORU-XXX-2014/1|OVArian Cancer Non-Interventional Study - OVATAR|OVArian Cancer Non-Interventional Study. Treatment hAbits and Epidemiology of BRCA in Russian Federation - OVATAR.|OVATAR|AstraZeneca|No|Recruiting|June 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|N/A|N/A|No|Non-Probability Sample|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18        years and older, diagnosed 3 months before enrolment into the study or later, consented to        participate in this non-interventional study, who are being treated for OC, FTC and PC in        the oncology hospitals/departments in the Russian Federation.|March 2016|March 1, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122588||45877|
NCT02122601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL013|A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee|An Open-label, Single Arm, Multi-center, Phase 3 Study to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee||LG Life Sciences||Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|174|||Both|40 Years|N/A|No|||September 2015|September 7, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02122601||45876|
NCT02122848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsl 2013-48|Exercise Tolerance in Patients With Decompensated Heart Failure|Effects of Bilevel Positive Airway Pressure on Exercise Tolerance in Patients With Decompensated Heart Failure||Hospital Sirio-Libanes|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02122848||45857|
NCT02123108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA: CCHI621AUS17T|Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver Transplantation|Safety and Efficacy of Immunosuppression With Basiliximab, Delayed Dose Tacrolimus Plus Enteric Coated Mycophenolic Acid, Versus Standard Dose Tacrolimus, Enteric Coated Mycophenolic Acid Plus Corticosteroids in Patients Undergoing Orthotopic Liver Transplantation (OLT)||University of California, Los Angeles|No|Recruiting|January 2011|June 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||April 2014|April 23, 2014|February 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123108||45838|
NCT02123121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT007564-01A1|Resveratrol to Enhance Vitality and Vigor in Elders|Phase IIa Study of Resveratrol to Enhance Mitochondrial and Physical Function in Older Adults|REVIVE|University of Florida|Yes|Recruiting|September 2015|June 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123121||45837|
NCT02123979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000723|Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Opioid Analgesia Using the Oral Surgery Model of Acute Pain in Healthy Volunteers||East Carolina University|No|Not yet recruiting|November 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02123979||45772|
NCT02123992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR1206|Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse|A Prospective, Safety and Efficacy Cohort Study of Elevate® Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair|Harmony 522|ASTORA Women’s Health|No|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|494|||Female|18 Years|N/A|No|||October 2015|February 15, 2016|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02123992||45771|
NCT02123719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304197302|Laparoscopic Incisional Hernia Repair in Liver Transplant Patients|Outcomes Analysis of Laparoscopic Incisional Hernia Repair and Risk Factors for Hernia Recurrence in Liver Transplant Patients||Medical University Innsbruck|No|Completed|January 2013|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|112|||Both|18 Years|80 Years|No|Non-Probability Sample|Patient with incisional hernia post liver transplantation|April 2014|April 24, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123719||45792|
NCT02122419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDPHPOSITION|The Effect of Patient Position on Postdural Puncture Headache|Phase IV Study of Application Position During Spinal Anesthesia||Diskapi Yildirim Beyazit Education and Research Hospital|No|Completed|April 2014|June 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|100|||Female|18 Years|45 Years|No|Probability Sample|Patients records form patients who experienced headache after caesarean section with        spinal anesthesia were retrospectively evaluated|August 2015|August 4, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122419||45890|
NCT02122432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMG002|Teledermatology Versus Usual Care on Delay Before Diagnosis and Treatment of Dermatologic Conditions|Impact of Teledermatology Versus Usual Care on Delay Before Diagnosis and/or Treatment of Dermatologic Conditions in General Practice|TELEDERMATO|University Paris 7 - Denis Diderot|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|109|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122432||45889|
NCT02124486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_12-089|An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH|A Randomised Controlled Trial of Bariatric Surgery Versus a Community Weight Loss Programme for the Sustained Treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial|IIH:WT|University of Birmingham|Yes|Recruiting|March 2014|February 2022|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|85|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02124486||45733|
NCT02124798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200339|A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector|An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector That Administers Belimumab Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)||GlaxoSmithKline|No|Completed|May 2014|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|95|||Both|18 Years|N/A|No|||May 2015|August 13, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124798||45710|
NCT02125097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Barrel OUS VRD-001|The Reverse Barrel™ VRD Intracranial Aneurysm Trial|Multi-center Non-randomized Clinical Investigation of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide Neck Intracranial Bifurcation and Branch Aneurysms|Barrel|Reverse Medical Corporation|Yes|Recruiting|December 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 5, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02125097||45687|
NCT02125110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01420-45|PERINE : Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain : an MRI Study|Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain: an MRI Study|PERINE|Rennes University Hospital|Yes|Recruiting|April 2014|October 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|110|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02125110||45686|
NCT02125123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL15|Oral Nutritional Supplementation in Children|Oral Nutritional Supplementation in Children With Picky Eating Behaviors||Abbott Nutrition|No|Terminated|April 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|36 Months|109 Months|Accepts Healthy Volunteers|||July 2015|July 24, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125123||45685|
NCT02125071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I.V. Hepabig injection_IIT|Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation|An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation|LT|Seoul St. Mary's Hospital|No|Recruiting|November 2013|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Those who receiving I.V. Hepabig injection for prevention of hepatitis B relapse after        liver transplantation|April 2014|April 24, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02125071||45689|
NCT02125084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 99|Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer|Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort||SCRI Development Innovations, LLC|No|Active, not recruiting|August 2014|May 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125084||45688|
NCT02121587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsteoMAP 1|Osteopathy, Mindfulness and Acceptance-based Programme for Patients With Persistent Pain|Stage 2 Delivery and Evaluation of an Integrated Osteopathy, Mindfulness and Acceptance-based Programme for Patients With Persistent Pain|OsteoMAP|The British School of Osteopathy|Yes|Recruiting|September 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with musculoskeletal pain for more than six months Pain or pain-related beliefs        limit activity Suitable for osteopathic manual therapy Able to attend the British School        of Osteopathy in London or Attend selected National Health Service doctors' surgeries in        South East London|January 2015|January 15, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121587||45954|
NCT02124070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140101|Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis|Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||November 2015|November 7, 2015|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124070||45765|
NCT02124304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR04|Cervical Activation During Elastic and Manual Resistance|EMG Activation of Cervical Musculature During Therapeutic Exercise With Thera-Band(R) Resistance Versus Manual Resistance|CervEMG|Sport and Spine Rehab Clinical Research Foundation|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 22, 2014||No||No|September 22, 2015|https://clinicaltrials.gov/show/NCT02124304||45747|
NCT02123576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17365|Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline|Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study||University of Virginia|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02123576||45802|
NCT02123875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|ATTEND-Family-led Rehabilitation After Stroke in India|Family-led Rehabilitation After Stroke in India|ATTEND|Christian Medical College and Hospital, Ludhiana, India|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02123875||45780|
NCT02123888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10_RADIO_94|Simultaneous CBCT Acquisition During Arc Radiotherapy|Simultaneous Cone Beam Computed Tomography (CBCT) Acquisition During Arc Radiotherapy|SCART|Christie Hospital NHS Foundation Trust|No|Recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123888||45779|
NCT02124109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914098|The Genetic Basis of Acquired Heart Disease in Africa|The Genetic Basis of Acquired Heart Disease in Africa||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|N/A|100 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124109||45762|
NCT02124122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA IND# 13710-Protocol 2|Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru|Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru||Tulane University School of Medicine|Yes|Not yet recruiting|February 2015|||June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124122||45761|
NCT02124369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092497|Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)|Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) - A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer|PRICKLE|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02124369||45742|
NCT02124382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIRPEDMG2012|Living Donor Liver Transplantation in Children|Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Université Catholique de Louvain.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|March 2012|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|500|||Both|N/A|57 Years|Accepts Healthy Volunteers|Non-Probability Sample|250 pediatric living donor liver transplant recipients 250 corresponding adult living        donors|April 2014|April 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124382||45741|
NCT02129595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3-058|Resveratrol and First-degree Relatives of Type 2 Diabetic Patients|Effects of Resveratrol on Insulin Sensitivity, Brown Adipose Tissue and Metabolic Profile in First-degree Relatives of Type 2 Diabetic Patients||Maastricht University Medical Center|Yes|Recruiting|April 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Male|40 Years|70 Years|No|||September 2015|September 30, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02129595||45341|
NCT02125617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uPARCRPC|Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer|uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?|uPARCRPC|Rigshospitalet, Denmark|Yes|Terminated|January 2014|February 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples Without DNA|Blood plasma|Male|18 Years|120 Years|No|Non-Probability Sample|Patients eligible for this study include patients with CRPC in progression after therapy        with a taxane who are candidates for therapy with standard second line therapy        abiraterone.|November 2015|November 18, 2015|April 25, 2014||No|Poor recruition|No||https://clinicaltrials.gov/show/NCT02125617||45647|
NCT02123394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP200755|Efficacy of the Mckenzie Method in Patients With Chronic Non-Specific Low Back Pain|Efficacy of the Mckenzie Method in Patients With Chronic Non-Specific Low Back Pain: A Randomized Placebo-Controlled Trial|Mckenzie|Universidade Cidade de Sao Paulo|No|Recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|80 Years|No|||January 2015|January 14, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02123394||45816|
NCT02122887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIU901305|Peace-Building Interventions for Israeli and Palestinian Youth|Peace-Building Interventions for Israeli and Palestinian Youth: Effects on Biological and Behavioral Markers of Empathy, Prejudice, and Dialogue||Bar-Ilan University, Israel|Yes|Completed|March 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|118|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122887||45854|
NCT02123680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55-O13|Chronic Low Back Pain Patients' Expectations Toward Physiotherapy|Non-specific Chronic Low Back Pain Patients' Expectations Toward Physiotherapy and Physiotherapists: An Interpretive Socio-anthropological Study on Ill Persons' Experience|CLBPEXPECT|Haute Ecole Cantonale Vaudoise de Santé|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|A purposive sample will be used. The investigators will aim at the recruitment of a        diversified sample of patients following an intensive chronic low back pain rehabilitation        program. The sample will include as many men as women, as many young than older        participants (3 age groups: 18-30, 30-50, 50-65), as much variety in educational level and        occupation as possible. The type of work (physical demand of employment) and career track        will also be taken into account, as well as having a representation of migrants (since        they are overrepresented in the back pain population58). It is estimated that data        saturation should be reached with 20 participants.|June 2015|June 1, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02123680||45794|
NCT02123407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA2014001|Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer|Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer：a Prospective Randomized Study||Peking University|Yes|Recruiting|December 2013|||June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|80 Years|No|||April 2014|April 23, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02123407||45815|
NCT02123693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYNOST-01|The Role of Osteopathic Treatment in the Axial Variations of the Lumbar Spine: RCT|||European Institute for Evidence Based Osteopathic Medicine||Recruiting|June 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|35 Years|No|||September 2014|September 15, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123693||45793|
NCT02124005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC50 femoral block bupivacaine|Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery|Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery||Federal University of São Paulo|Yes|Recruiting|July 2013|September 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02124005||45770|
NCT02122965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01815|The Effect of Medication Review in High-risk Emergency Department Patients|The Effect of Medication Review in High-risk Emergency Department Patients: Evaluation of a Quality Improvement Program||University of British Columbia|No|Completed|December 2012|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10805|||Both|19 Years|N/A|No|||April 2014|April 23, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02122965||45848|
NCT02125162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4161-104|A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161|A Single-dose, Randomized, 3-period, Crossover Study to Evaluate the Relative Bioavailability of BCX4161 Formulated as a Soft Gelatin Capsule to BCX4161 Formulated as a Hard Gelatin Capsule and the Effect of Food on BCX4161 Pharmacokinetics||BioCryst Pharmaceuticals|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125162||45682|
NCT02123212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527-11 SC|Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C|Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C|Best-C|National Opinion Research Center|No|Completed|February 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|29607|||Both|47 Years|69 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123212||45830|
NCT02121015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH102478-01|Online Collaborative Learning Intervention to Prevent Perinatal Depression|Online Collaborative Learning Intervention to Prevent Perinatal Depression||Northwestern University||Not yet recruiting|February 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Female|18 Years|N/A|No|||January 2015|January 5, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02121015||45998|
NCT02121028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140056|Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease|Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease|MyRIAD|University of Miami|No|Recruiting|January 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|175|||Both|30 Years|99 Years|No|Non-Probability Sample|Eligible patients will have a recent stroke or TIA due to intracranial Atherosclerotic        Disease (IAD) of 70-99% .|January 2016|January 18, 2016|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02121028||45997|
NCT02125136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-PAK-0113|Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer|Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer|NEOLAP|AIO-Studien-gGmbH|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02125136||45684|
NCT02121314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGM-RuG-UMCG-TB-001|HRZE Fasted/Fed in Newly Diagnosed TB|The Influence of Fasting and Food on the Pharmacokinetics of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol in Newly Diagnosed TB Patients|FASTFOOD|University Medical Center Groningen|No|Completed|July 2013|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02121314||45975|
NCT02122172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0540|Afatinib in Advanced Refractory Urothelial Cancer|Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer||University of Chicago|Yes|Active, not recruiting|October 2013|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122172||45909|
NCT02122445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR03|Cramer Sports Motion Tape and Low Back Pain EMG|Effectiveness of Cramer Sports Motion Tape on Low Back Pain Patients' Pain and Muscle Activation|KT_LBP_EMG|Sport and Spine Rehab Clinical Research Foundation|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|April 21, 2014||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02122445||45888|
NCT02131740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140622|Eye Rubbing and Transient Change in Corneal Parameters|Relationship Between Eye Rubbing and Transient Changes in Corneal Parameters in Healthy Volunteers: A Randomised-Controlled Trial||Sussex Eye Hospital|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 28, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02131740||45177|
NCT02123316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRL12008-003680-39|Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis|Assessment of the Effectiveness of a Dermatophagoides Pteronyssinus Extract, Rated in Units of Mass and Administered Subcutaneously for the Treatment of Local Allergic Rhinitis. Randomized, Double-blind, Placebo-controlled Study.|ECRL1|Plaza del Hospital Civil|Yes|Completed|January 2010|||April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|No|||April 2014|April 23, 2014|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02123316||45822|
NCT02123589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West ChinaH Sedation|The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults.|The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill adults-a Prospective, Randomized and Controlled Trial||West China Hospital|No|Not yet recruiting|April 2014|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|85 Years|No|||April 2014|April 23, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123589||45801|
NCT02123602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#093-2014|Core Stabilization for the Treatment of Anterior Knee Pain|The Effects of a Trunk Strengthening Program on Anterior Knee Pain in an Adolescent Athletic Population: a Randomized Clinical Trial||Youngstown State University|No|Recruiting|April 2014|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|13 Years|20 Years|No|||January 2016|January 25, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02123602||45800|
NCT02123901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPSC-1|The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes|THE EFFECT OF WALKING MEDITATION TRAINING ON GLYCEMIC CONTROL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES||Chulalongkorn University||Completed|December 2013|February 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|75 Years|No|||August 2013|September 15, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02123901||45778|
NCT02123914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPSC-2|The Effect of Exercises on Physiological Changes and Clinical Symptoms in Allergic Rhinitis Patients|Effects of Chronic Exercise Training and Vitamin C Supplementation on Physiological Changes and Symptoms in Allergic Rhinitis Patients||Chulalongkorn University|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|45 Years|No|||August 2015|August 1, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123914||45777|
NCT02124135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004774|Eat Out With KP: A Pilot to Improve the Impact of Dietary Advice for Families|Eat Out With KP: A Pilot to Improve the Impact of Dietary Advice for Families||Kaiser Permanente|No|Not yet recruiting|May 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|160|||Both|8 Years|64 Years|No|||April 2014|April 28, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124135||45760|
NCT02124148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15295|A Study of LY2606368 With Chemotherapy or Targeted Agents in Participants With Advanced Cancer|A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors||Eli Lilly and Company|No|Recruiting|June 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|185|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124148||45759|
NCT02124395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6408|Health-related Quality of Life in Rare Kidney Stone|Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium||New York University School of Medicine|Yes|Recruiting|August 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|320|||Both|5 Years|N/A|No|Non-Probability Sample|Sample will be selected from the Rare Kidney Stone Consortium registries|October 2015|October 26, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02124395|5 Years|45740|
NCT02129309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPHa-COPD|Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures|Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures.||Cambridge University Hospitals NHS Foundation Trust|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|June 23, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129309||45363|
NCT02122900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #013-142|Prospective Balloon Aortic Valvuloplasty|Assessment of the Role of Balloon Aortic Valvuloplasty in the Management of Patients With Aortic Stenosis|BAV|Baylor Research Institute|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Aortic Stenosis|January 2016|January 13, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02122900||45853|
NCT02123160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6687|Dyadic Therapy for Mothers and Children|Dyadic Therapy for Mothers and Children||New York State Psychiatric Institute|Yes|Terminated|November 2013|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|3 Years|40 Years|No|||May 2015|May 14, 2015|March 31, 2014||No|Loss of staff|No||https://clinicaltrials.gov/show/NCT02123160||45834|
NCT02123147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400079|Examining the Immunological Process of Autoimmune Patients|Examining the Immunological Process of Autoimmune Patients||University of Florida|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|9 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|150 Sjogren's syndrome patients and 50 healthy controls.|June 2015|June 9, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02123147||45835|
NCT02123732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DbXell1234|Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus|Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus||Laniado Hospital|No|Recruiting|July 2014|||August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||July 2014|July 29, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02123732||45791|
NCT02123745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVW400CS-06|ivWatch Model 400: Device Validation for Infiltrated Tissues|||ivWatch, LLC|Yes|Completed|February 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 27, 2014|April 22, 2014|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT02123745||45790|
NCT02124018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-PRESERVE1|Risk Stratification in Patients With Preserved Ejection Fraction|Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients With Preserved Ejection Fraction: PRESERVE-EF|PRESERVE-EF|University of Athens|Yes|Recruiting|April 2014|April 2019|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|80 Years|No|Probability Sample|1000 asymptomatic post-MI patients>40%, at least 40 days post-MI, revascularized or        without needing further revascularization (in any case without any evidence of ischemia)        The patients will be divided into two categories:          1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit             vessels <70%) at 40 days post-MI (when LVEF>40% will be re-assessed)          2. Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q)             with LVEF>40% right after a negative stress test or right after a negative for             stenoses control coronary catheterization|December 2014|December 14, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124018|3 Years|45769|
NCT02123498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETDLPR2014|The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux|The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR)|ETDLPR|Loma Linda University|Yes|Not yet recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||April 2014|April 23, 2014|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123498||45808|
NCT02123225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2013.0045|Is the STOP-BANG Predictive of Worsening OSA in the Early Postop Period in Patients Undergoing TJA?|Is the STOP-BANG Predictive of Worsening Obstructive Sleep Apnea in the Early Postoperative Period in Patients Undergoing Total Joint Arthroplasty?||United States Naval Medical Center, San Diego|No|Recruiting|December 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|168|||Both|18 Years|90 Years|No|Non-Probability Sample|The subject population will be N = 168 patients scheduled for primary or revision TKA        between the ages of 18-90, at Naval Medical Center San Diego.|October 2015|October 14, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02123225||45829|
NCT02124057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140099|Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy|Evaluation of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02124057||45766|
NCT02124863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVG002|Influence of IPV on GOR in Infants From 0 to 12 Months.|Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR) in Infants From 0 to 12 Months.||Vrije Universiteit Brussel|Yes|Completed|September 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|N/A|12 Months|Accepts Healthy Volunteers|||March 2015|June 25, 2015|April 24, 2014||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT02124863||45705|
NCT02124876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43418-1|Accommodating for Residual Limb Fluid Volume Change|Accommodating for Residual Limb Fluid Volume Change|AM-PM|University of Washington|No|Recruiting|June 2013|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Transtibial amputee currently using prosthetic limbs|April 2014|April 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124876||45704|
NCT02122705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB/2012/264/D|A Case Series of VPIA Using Remifentanil for Labour and Delivery|A Case Series of Vital Signs-controlled, Patient Assisted Intravenous Analgesia (VPIA) Using Remifentanil for Labour and Delivery|VPIA|KK Women's and Children's Hospital|Yes|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Female|18 Years|45 Years|No|Non-Probability Sample|Term parturients presenting to the hospital delivery suite in labour|September 2015|September 3, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122705||45868|
NCT02131168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD EPI|Epidemiology of IBD in Hong Kong: An Inception Cohort and Follow up Study|Investigating the Epidemiology of Inflammatory Bowel Disease in Hong Kong: An Inception Cohort and Follow up Study (IBD EPI Study)|ACCESS|Chinese University of Hong Kong|Yes|Recruiting|January 2011|September 2021|Anticipated|March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|One stool sample will be collected for microbiology tests 10 ml of blood will be stored for      genetic analysis|Both|N/A|N/A|No|Non-Probability Sample|Newly diagnosed IBD patients in the local area|October 2015|October 5, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02131168|5 Years|45221|
NCT02131181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-131366-FB|Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients|Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients (POD-I)|POD-I|Chiang Mai University|No|Completed|December 2013|February 2015|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|60 Years|N/A|No|Non-Probability Sample|Patients undergoing scheduled non-cardiac operation|February 2015|February 2, 2015|November 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02131181|6 Months|45220|
NCT02123329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPRP 4 - 716 - 3 - 203|Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar|Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar||Qatar University|No|Recruiting|February 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02123329||45821|
NCT02123615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTEB017805|ASIS for GAMMAGARD in Primary Immunodeficiency|ASIS for GAMMAGARD in Primary Immunodeficiency|ASISinPI|ASIS Corporation|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|20||Anticipated|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123615||45799|
NCT02123927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CPH-001|Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Subjects||Takeda|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|13||Actual|108|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123927||45776|
NCT02124421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2014-17|Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer|CRS/HIPEC|Mercy Medical Center|No|Recruiting|April 2014|April 2020|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|80 Years|No|||November 2015|November 4, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02124421||45738|
NCT02124694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH097834-01A1|Iwankapiya-Healing: Historical Trauma Practice and Group IPT for American Indians|Iwankapiya-Healing: Historical Trauma Practice and Group IPT for American Indians|HTUG-IPT|University of New Mexico|Yes|Recruiting|April 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124694||45718|
NCT02125006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130525-01H|The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain|The Effect of an Inter-Disciplinary Program, Including Mindfulness-Based Stress Reduction, on Psychosocial Function, Pain Perception, Disability and Quality of Life in Breast Cancer Survivors With Chronic Neuropathic Pain|InDepth|Ottawa Hospital Research Institute|No|Recruiting|October 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|108|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125006||45694|
NCT02129322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYMedOncoLT01|Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1|Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study||Zhejiang University||Not yet recruiting|July 2015|December 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 9, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129322||45362|
NCT02129335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGETHER|Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner|Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner (TOGETHER-study): a Prospective Multicenter Cohort Study.|TOGETHER|University Hospital, Basel, Switzerland|Yes|Recruiting|April 2014|August 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Newly diagnosed GBM with one Partner.|November 2015|November 23, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02129335||45361|
NCT02129348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6915|Treatment of Psychosis and Agitation in Alzheimer's Disease|Treatment of Psychosis and Agitation in Alzheimer's Disease||New York State Psychiatric Institute|Yes|Recruiting|June 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|55 Years|95 Years|No|||December 2015|December 1, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129348||45360|
NCT02123433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004518-40|Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults|Serological Response to Antipneumococcal Vaccination and Consequent Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Positive Adults: a Prospective Study Using 13-valent Conjugate Vaccine|PCV13HIV2011|University of Siena||Completed|December 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|65 Years|No|||April 2014|April 23, 2014|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02123433||45813|
NCT02123446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15313|A Study of Cephalexin Capsules in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Capsules With 250 mg of Cephalexin (Keflex® Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers||Eli Lilly and Company|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|April 23, 2014|No|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT02123446||45812|
NCT02123459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15314|A Study of Cephalexin Suspension in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex® Liquido Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers||Eli Lilly and Company|No|Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|April 23, 2014|No|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT02123459||45811|
NCT02123420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS vs RP|Platform Switching vs Regular Platform Implants. One Year Results From a RCT|Platform Switching vs Regular Platform Implants. One Year Results From a RCT||Università degli Studi di Sassari|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|24 Years|72 Years|No|||April 2014|April 23, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02123420||45814|
NCT02124265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00038778|Oral Rehydration Therapy in Burn Patients|Oral Rehydration Therapy in Burn Patients Phase 1|ORT|Johns Hopkins University|Yes|Enrolling by invitation|May 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124265||45750|
NCT02124499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041/09|Genetic Variants and Perioperative Morbidity and Mortality|Genetic Variants and Perioperative Morbidity and Mortality||University Hospital Inselspital, Berne|Yes|Recruiting|January 2012|January 2028|Anticipated|January 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|whole blood (plasma and cells) or mucosal swab|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled for elective surgery|April 2014|April 24, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02124499||45732|
NCT02123784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W 522 MARK GEROT|Biomarkers for the Surgical Treatment of Rotator Cuff Tears|Biomarkers for the Surgical Treatment of Rotator Cuff Tears|MARK-GEROT|Balgrist University Hospital|No|Recruiting|April 2014|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, muscle, tendon, capsule, synovial liquid|Both|40 Years|80 Years|No|Non-Probability Sample|Regular patients from Balgrist University Hospital, Zurich (Switzerland)|April 2014|April 24, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02123784||45787|
NCT02124525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEL 33553/2011|N-acetylcysteine for Tobacco Smoking|The Efficacy of N-acetylcysteine as a Cessation Treatment for Tobacco Smoking and Oxidative Stress Reduction|NACNOS|Universidade Estadual de Londrina|Yes|Recruiting|February 2013|May 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|January 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02124525||45730|
NCT02124538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShaheedBMU|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2013|||||N/A|N/A|N/A||||||||||||||April 25, 2014|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124538||45729|
NCT02124850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRXP-A106|A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab|A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab||VentiRx Pharmaceuticals Inc.|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02124850||45706|
NCT02121340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34EY024299|Collaborative Care for Depression and Diabetic Retinopathy in African Americans|Collaborative Care for Depression and Diabetic Retinopathy in African Americans|CC-DDR|Thomas Jefferson University|No|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|No|||August 2015|August 4, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121340||45973|
NCT02131454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUM-TI|Efficacy of Inhalation Technique Training.|Impact of Inhalation Technique Training on the Course of Asthma and Chronic Obstructive Pulmonary Disease (COPD).||Medical University of Warsaw|No|Active, not recruiting|September 2013|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02131454||45199|
NCT02131480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-012430-70|Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma|A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse|LMS02|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|June 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|70 Years|No|||May 2014|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02131480||45197|
NCT02123342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM.C/625/1/HIR/MOHE/ASH/02-PA|SMS Reminders for Exercise Among Older Adults. Malaysian Physical Activity for Health Study|Promoting Exercise Among Older Malaysians Using SMS Reminders. The Malaysian Physical Activity for Health Study (myPAtHS): A Randomized Controlled Trial|myPAtHS|University of Malaya||Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|43|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02123342||45820|
NCT02123628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-00625-14|Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis|Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study|C H R O N O S|Tourcoing Hospital|No|Completed|June 2007|September 2012|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02123628||45798|
NCT02123940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0187|Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy|Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy|WIN IN WEAN|University Hospital, Clermont-Ferrand||Recruiting|February 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02123940||45775|
NCT02123953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CPH-002|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Subjects||Takeda|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|60|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123953||45774|
NCT02124161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851138|Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.|A Phase 4, Randomized, Double-blind Trial To Evaluate The Immunogenicity And Safety Of A 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine In Adults 50 Years And Older Who Received 1 Or More Doses Of 23-valent Pneumococcal Polysaccharide Vaccine Prior To Study Enrollment.||Pfizer|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|883|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124161||45758|
NCT02129010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICPTS-Sma-2012|The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage|The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage||Cantonal Hospital of St. Gallen|Yes|Completed|April 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Cerebrospinal fluid|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with aneurysmatic subarachnoid hemorrhage requiring CSF-diversion and/or        intracranial pressure monitoring|March 2016|March 7, 2016|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02129010||45386|
NCT02129257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 6A/13|﻿Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer|﻿Single-arm Phase II Study of Maintenance Therapy With Aflibercept After First-line Treatment With FOLFIRI Plus Aflibercept in Metastatic Colorectal Cancer Patients|AMALTHEA|Hellenic Cooperative Oncology Group|No|Recruiting|May 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129257||45367|
NCT02129270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158-13-EMC|Hematoma Block for Reduction of Distal Radius Fractures|Phase 4 Study of Hematoma Block for Reduction of Distal Radius Fractures||HaEmek Medical Center, Israel||Not yet recruiting|May 2014|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|N/A|No|||April 2014|April 30, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02129270||45366|
NCT02125643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM4088|The Effects of Caffeine on Force Loss Following Exercise-induced Muscle Damage|The Effects of Caffeine on Force Loss Following Exercise-induced Muscle Damage||University of Oklahoma|No|Not yet recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125643||45645|
NCT02123186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308058RIN|Newborn Screening for Spinal Muscular Atrophy|Newborn Screening for Spinal Muscular Atrophy||National Taiwan University Hospital|No|Active, not recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60000|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|newborns whose parents agree to be tested|April 2014|April 23, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02123186||45832|
NCT02123199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BGB01|Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD|Prospective Observational Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD|INHALE|Novartis||Completed|April 2012|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited only after indacaterol has been prescribed and is being used        for the patients first maintenance therapy for COPD symptoms.|April 2014|April 24, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123199||45831|
NCT02124031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACTAR|Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis (IMPACTAR)|Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis|IMPACTAR|Iniciativa Mexicana de Pacientes con Osteoartritis y Artritis Reumatoide|No|Completed|December 2013|October 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|10241|||Both|18 Years|N/A|No|Probability Sample|The Registry will include male and female patients older than 18 years with knee and/or        hand OA and/or RA diagnosis according with the American College of Rheumatology criteria.        It will include consecutive outpatients that are treated in any of the participant        specialties of the study (orthopedics, rheumatology, internal medicine, rehabilitation        medicine).|October 2015|October 22, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124031|1 Year|45768|
NCT02124837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257682SA|Intervention Study on Break Activities and Workers´ Psychological and Physiological Health & Performance|An Intervention Study to Investigate the Effect of Different Types of Break Activities on Workers´ Psychological and Physiological Health & Job Performance||University of Tampere|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124837||45707|
NCT02121327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21171401|The Effects of Disease Management Programs for Prevention of Recurrent Ischemic Stroke|Disease Management Program (DMP) Stroke Trial||Hiroshima University|No|Active, not recruiting|September 2010|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|321|||Both|40 Years|80 Years|No|||April 2014|April 22, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02121327||45974|
NCT02121574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WKR0-2013-0051|Accuracy of Zero-flux and Ingestible Thermometers|A Study To Determine The Accuracy Of Zero-Flux And Ingestible Thermometers In The Perioperative Setting||Brighton and Sussex University Hospitals NHS Trust|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Participants will be patients undergoing elective gynaecological, vascular or urological        surgery at the Royal Sussex County Hospital, and as such will be seen at a pre-operative        assesment clinic as part of their normal work up for theatre.|January 2016|January 11, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121574||45955|
NCT02130180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402-020|DKA Optic Ultrasound|Measurement of the Optic Nerve Sheath Diameter by Optic Ultrasound in Diabetic Ketoacidosis and the Relationship to Cerebral Edema|DKA Optic US|Children's Hospitals and Clinics of Minnesota|No|Recruiting|April 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|108|||Both|7 Years|18 Years|No|Non-Probability Sample|We will conduct a cross-sectional study of pediatric patients aged 7-18 years. This study        will involve recruitment of patients from both the Endocrinology Clinic and the ED. We        will recruit patients from the Children's Endocrinology Clinic with well-controlled T1DM,        defined as having a hemoglobin A1c <8% at time of the clinic visit, no previous episodes        of DKA other than at the time of diagnosis, and no previous hemoglobin A1c values >10%.        This study will also involve recruitment of two subsets of patients from the Children's        ED: those with DKA and those with T1DM and hyperglycemia without criteria for DKA.|May 2014|July 29, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02130180||45296|
NCT02130193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200163|Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations|A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations||GlaxoSmithKline|No|Active, not recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|40 Years|70 Years|No|||January 2016|February 4, 2016|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130193||45295|
NCT02124291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitHatSZMC|Effect of Assisted Hatching on Vitrified Embryo Transfer Clinical Outcome|Effect of Assisted Hatching on Vitrified Embryo Transfer Clinical Outcome|VitHatSZMC|Shaare Zedek Medical Center|Yes|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|42 Years|No|||April 2015|April 21, 2015|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124291||45748|
NCT02125188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|desmopressinFESS|Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery|Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|January 2014|||August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|60 Years|No|||April 2014|April 25, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02125188||45680|
NCT02121054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0873|Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease|Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease||Asan Medical Center|No|Recruiting|September 2013|December 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Probability Sample|Patients with coronary artery disease, Patients with peripheral artery disease|January 2016|January 3, 2016|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121054||45995|
NCT02121899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|myPlan ONC006|Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)|LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Treatment Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)|ONC006|Myriad Genetic Laboratories, Inc.|No|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic      adenocarcinoma biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|Recently diagnosed treatment-naïve patients with early stage NSCLC (lung adenocarcinoma)|September 2015|September 30, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121899|3 Years|45930|
NCT02122159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEI MA09-hRPE MMD|Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration|A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Geographic Atrophy Secondary to Myopic Macular Degeneration||University of California, Los Angeles|Yes|Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|40 Years|N/A|No|||February 2016|February 4, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122159||45910|
NCT02130908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2011/572|A Study on the Possible Health Effects of Lean Fish, Fatty Fish and Lean Meat Intake in Non-obese Adults||FISK1|University of Bergen|No|Completed|March 2011|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|70|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130908||45240|
NCT02132026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALTIRE2-2014|Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.|SALTIRE II and RANKL Inhibition in Aortic Stenosis|SALTIRE II|University of Edinburgh|No|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132026||45155|
NCT02128230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134668|UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission|A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host -Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance||University of Arkansas|Yes|Recruiting|August 2014|May 2025|Anticipated|May 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128230||45446|
NCT02128490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEB-XR_201|Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment|A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout and Moderate Renal Impairment||Takeda|Yes|Completed|May 2014|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|200|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128490||45426|
NCT02128737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810896|Neurobehavioral Effects of Partial Sleep Deprivation|Neurobehavioral Effects of Partial Sleep Deprivation||University of Pennsylvania|No|Completed|December 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|300|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2014|June 9, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02128737||45407|
NCT02129023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPD3D0021|The Impact of Exergame on User Health|The Impact of Exergame on User Health: A Randomized Controlled Trial||Chang Gung University|No|Active, not recruiting|January 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|116|||Both|20 Years|N/A|No|||June 2014|June 10, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02129023||45385|
NCT02129283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126-14-HMO|Can We Improve the Quality of Care at the End of Life in Israel?|Can We Improve the Quality of Care at the End of Life in Israel?|ISRAEOLC|Hadassah Medical Organization|No|Not yet recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 30, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129283||45365|
NCT02129296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastric balloon|Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study|Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study||Mansoura University|Yes|Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02129296||45364|
NCT02129582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9Z13|Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies|Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation||Case Comprehensive Cancer Center|No|Suspended|June 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 30, 2014|No|Yes|Administrative Hold: Protocol Amendment needed|No||https://clinicaltrials.gov/show/NCT02129582||45342|
NCT02124044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140065|Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV|Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|99 Years|No|||December 2015|December 15, 2015|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124044||45767|
NCT02121041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0670|Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study|Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|May 2014|June 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|30 Years|65 Years|No|||December 2015|December 1, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02121041||45996|
NCT02122133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 7495|CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400|CARE: A Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400|CARE|Penumbra Inc.|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Both|N/A|N/A|No|Non-Probability Sample|Up to 90 patients treated with the PC 400 or conventional coils (2:1) at up to 15 centers        in the USA will be enrolled.|March 2016|March 14, 2016|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02122133|3 Days|45912|
NCT02122146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7401001|A Study Of PF-06664178 In Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors||Pfizer|No|Terminated|August 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|April 17, 2014|No|Yes|The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The    decision to terminate the trial was based on the overall results.|No||https://clinicaltrials.gov/show/NCT02122146||45911|
NCT02130440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESV_01|Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis|Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis||Second University of Naples|No|Completed|November 2012|April 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|4 Years|17 Years|No|||May 2014|May 1, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02130440||45276|
NCT02130661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201274|Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers|A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers||GlaxoSmithKline|No|Not yet recruiting|October 2017|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130661||45259|
NCT02130895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00797|Testing CDS in OSCAR EMR Using STOPP Criteria|A Mixed-method Study to Explore, Assess, and Explain the Translation of a Complex Set of Evidence-based Rules Into Practice Through Electronic Medical Record Based Decision Support: How Can STOPP Effectively be Deployed in Primary Care?|STOPP-RCT|University of British Columbia|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130895||45241|
NCT02131194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-tunis|The Post-Vitrectomy Lenstatin™ Study|The Post-Vitrectomy Lenstatin Study: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy||Lenstatin LLC|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131194||45219|
NCT02132598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-182|Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases|A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification||University of Pittsburgh|Yes|Recruiting|December 2015|June 2028|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132598||45113|
NCT02128243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-YMO-0111|Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer|Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer|MATEO|AIO-Studien-gGmbH|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128243||45445|
NCT02128503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD-RA HBV|Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease|Prevalence and Clinical Course of Chronic Hepatitis B Infection in Patients With Inflammatory Bowel Disease and Rheumatologic Disease on Immunosuppressive Therapy||Chinese University of Hong Kong|Yes|Recruiting|February 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128503||45425|
NCT02128750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBCS1|Contrast Enhanced Ultrasound and Muscle|Echographie de Contraste Pour l'Analyse de la Perfusion Musculaire Dans l'ischémie Critique|Echomuscle|University Hospital, Grenoble|No|Completed|February 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|32|||Both|18 Years|N/A|No|||April 2014|March 4, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128750||45406|
NCT02129036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGOG-127|Ovarian Clear Cell Adenocarcinoma Review|Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients|OCCA|Cathay General Hospital|No|Completed|April 2008|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|5|||Female|30 Years|70 Years|No|Non-Probability Sample|total 300 patients of ovarian clear cell carcinoma post operation from 8 institution.|April 2014|May 1, 2014|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT02129036||45384|
NCT02125370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14024|Experiences of Pregnant Women Who Use NRT in Pregnancy as Part of a Quit Attempt|Experiences of Pregnant Women Who Use NRT in Pregnancy as Part of a Quit Attempt||University of Nottingham|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|15|||Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be identified through two identification sites; New Leaf Stop Smoking        Services in Nottinghamshire and Nottingham City. The study will consist of a short survey        focussing on how NRT is used during pregnancy. As well as providing information the survey        responses will also be able to distinguish who is eligible to participate in qualitative        telephone interviews. A subsection of these women will be asked to participate in an        interview. The survey and interviews will be conducted as close as possible after        participants have had an appointment with a smoking cessation advisor and, have given        consent for the researcher to contact them, this is likely to be within a two week period.|December 2014|December 3, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125370||45666|
NCT02125864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000103-27|Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept|Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration|Eylea-2014|Oslo University Hospital|Yes|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|60 Years|N/A|No|||January 2015|January 19, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125864||45628|
NCT02125877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670F2201|Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)|A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)||Novartis|No|Active, not recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|10 Years|N/A|No|||December 2015|December 21, 2015|April 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125877||45627|
NCT02125890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-13-91|Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms|The Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms|TARAA|Regina Qu'Appelle Health Region|No|Recruiting|July 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125890||45626|
NCT02125669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF57/2012|Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas|The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial||Hautklinik Darmstadt|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2014|April 27, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02125669||45643|
NCT02123758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104358|A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer|A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer||Aragon Pharmaceuticals, Inc.|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Male|18 Years|99 Years|No|||March 2016|March 7, 2016|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02123758||45789|
NCT02123771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/00113|Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections|Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections||National University Hospital, Singapore|No|Recruiting|May 2013|||March 2014|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Stool samples(solid/semi-solid) between 1-5 g will be collected and tested using ELISA for      the presence of the H. pylori GGT antigen using monoclonal antibodies against GGT.|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 100 patients seen in Gastro clinic will be recruited for this study. Patient        should 21 years and above and agreeable for study. Patient should not have been treated        for H. pylori prior to stool collection.|April 2014|April 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02123771||45788|
NCT02124512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0136-F1V|Blood Lipopolysaccharide (LPS) Rifaximin Study|Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance||University of Kentucky|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|65 Years|No|||November 2015|November 30, 2015|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124512||45731|
NCT02121886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Departement of HPB surgery|The Parietal Peritoneum as a Substitute Graft for Venous Reconstruction in HPB Surgery|To Evaluate the Safety and Outcome of the Parietal Peritoneum as a Substitute Graft for Venous Reconstruction in Hepatobiliary and Pancreatic Surgery||Beaujon Hospital|No|Recruiting|December 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02121886||45931|
NCT02122692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15820A|Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects|Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects||H. Lundbeck A/S|No|Completed|March 2014|||June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02122692||45869|
NCT02129972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-823|Colon Capsule Endoscopy in Children|Evaluation of the Video Capsule Colonoscopy for the Detection and the Control of Colon Lesions in Children Presenting Confirmed or Suspected Inflammatory Bowel Disease|VICCOINBODI|Hospices Civils de Lyon|No|Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|8 Years|18 Years|No|||September 2015|September 21, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02129972||45312|
NCT02130206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|665-2008|The Microbiology of Caries Resistance|The Microbiology of Caries Resistance. Subtitle: Functional Amyloid Formation in Streptococcus Mutans||University of Florida|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|79|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02130206||45294|
NCT02130219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-3-SMM-01/06|Clinical Value of Noninvasive Intracranial Pressure Measurement|Scientific Research and Development of Innovative Evidence Based Non-invasive Brain Diagnostic and Monitoring Solutions for Neurological and Traumatic Brain Injury Patients|Braincare|Lithuanian University of Health Sciences|No|Recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|4||Anticipated|45|||Both|18 Years|80 Years|No|||March 2014|July 25, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02130219||45293|
NCT02130453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0881|Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking|Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging||M.D. Anderson Cancer Center|No|Recruiting|August 2014|||August 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130453||45275|
NCT02130674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 111782|Optimized Therapy in Severe Traumatic Brain Injured Patients|Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs||University of Zurich|No|Completed|January 2005|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||May 2014|May 4, 2014|April 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130674||45258|
NCT02104895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APBI-IMRT-Florence|Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation|Randomised Phase 3 Trial Of Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation||Azienda Ospedaliero-Universitaria Careggi|Yes|Active, not recruiting|March 2005|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|520|||Female|40 Years|N/A|No|||April 2014|April 4, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104895||47233|
NCT02105545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1306|Genome Sequencing of Human Cancer Tissues|Genome Sequencing of Human Cancer Tissues||New Mexico Cancer Care Alliance|Yes|Recruiting|January 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|N/A|N/A|No|||January 2016|January 15, 2016|March 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02105545||47183|
NCT02105558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0023|Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)|Outcomes of Epidural Versus Combined Spinal and Epidural (CSE) Anesthetic Technique on the Success of Trial of Labor After Cesarean (TOLAC): A Pilot Study||The University of Texas Health Science Center, Houston|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Community sample from the area surrounding Houston and LBJ hospital|June 2015|June 1, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105558||47182|
NCT02105896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2235|Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall|Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall||University of North Carolina, Chapel Hill|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|25 Years|82 Years|No|Non-Probability Sample|Subjects who participated in a 2007 study entitled "Clinical Evaluation of New Total-Etch        and Self-Etch Dental Adhesives" (UNC IRB Study #07-0673).|June 2015|June 18, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02105896||47156|
NCT02106156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21645|Observational Study Evaluating the Quality of Pegasys and Copegus Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)|Noninterventional Study for Quality Assurance in Therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa-2a (Pegasys) and Ri-bavirin (i.e. Copegus) at Hepatology Centers- a Project in Cooperation With BNG (Association of German Resident Gastroenterologists, Part III)||Hoffmann-La Roche||Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9729|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CHC eligible for Pegasys treatment|March 2016|March 1, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106156||47136|
NCT02106143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009|RejuvenAir™ System Lobectomy Safety and Histology Study|A Prospective Study of RejuvenAir™ System Radial Spray Cryotherapy to Determine Safety and Histological Effect in the Lung|Lobectomy|CSA Medical, Inc.|Yes|Terminated|September 2014|October 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|21 Years|75 Years|No|||February 2016|February 1, 2016|April 2, 2014|Yes|Yes|sufficient data collected to meet study objectives|No||https://clinicaltrials.gov/show/NCT02106143||47137|
NCT02106390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_56|Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants|A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants||Novartis|No|Active, not recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|750|||Both|85 Days|119 Days|Accepts Healthy Volunteers|||November 2015|November 9, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02106390||47118|
NCT02109731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24149|Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea|Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea||University of Rochester|Yes|Completed|January 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 9, 2012|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT02109731||46863|
NCT02109991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD-001|Safety, Tolerability and Performance Profile of the Cologuard Device CG-100 in Patients Undergoing Colorectal Surgery|A Prospective, Multi-center, Single-arm, Open-label Study Designed to Evaluate Safety, Tolerability and Performance Profile of the Cologuard Device CG-100 in Patients Undergoing Colorectal Surgery||Cologuard Ltd.||Recruiting|March 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109991||46843|
NCT02110004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-152|Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man|Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man||Biosense Webster, Inc.|Yes|Completed|March 2014|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110004||46842|
NCT02109965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311031MINB|The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis|The Effect of Dexmedetomidine on the Microcirculation in Patients With Severe Sepsis and Septic Shock||National Taiwan University Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|N/A|No|||October 2015|October 25, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109965||46845|
NCT02109978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF117|RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes:|RetroMASTER|NIHR Exeter Clinical Research Facility|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|562|Samples With DNA|At Visit 1 a fasting blood sample (approximately 35 mls) will be taken for DNA extraction,      and to measure for markers of the progression of diabetes or response to diabetes medication      and for secondary markers that may predict response. A urine sample is also collected to      measure for biomarkers.|Both|18 Years|90 Years|No|Non-Probability Sample|Participants will be identified in primary care and secondary care. The method for patient        identification may differ between sites and could involve:        GP Searches; Secondary Care Clinician Referral; Research Database Searches.|March 2016|March 21, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109978||46844|
NCT02110277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-139S-3|Photoacoustic Imaging of the Ovary|Photoacoustic Imaging of the Ovary||University of Connecticut Health Center|Yes|Recruiting|March 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|21 Years|N/A|No|||January 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110277||46823|
NCT02110212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-C-3.0|Femtosecond Laser for Cataract Surgery|A Prospective, Randomized Study of Cataract Surgery With the Assistance of the OptiMedica Femtosecond Laser System Compared to Standard Surgical Procedure of Continuous Curvilinear Capsulorhexis and Ultrasonic Phacoemulsification||Abbott Medical Optics|No|Terminated|April 2011|February 2014|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|50 Years|80 Years|No|||June 2014|June 27, 2014|April 8, 2014|Yes|Yes|FDA approval received for product, no additional study subjects required.|No||https://clinicaltrials.gov/show/NCT02110212||46828|
NCT02109653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818A2202|Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC|A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy||Array BioPharma|No|Withdrawn|June 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 25, 2014|No|Yes|Study never started - transferred to Array.|No||https://clinicaltrials.gov/show/NCT02109653||46869|
NCT02109874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-011-404|A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as a Single Adjuvant Amount With Different Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|C-011-404|Aeras|Yes|Completed|December 2008|September 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02109874||46852|
NCT02110693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 0059|The Tobacco, Alcohol, Prescription Medication and Other Substances Tool|The TAPS Tool: Screen and Brief Assessment Tool Validation Study|CTN 0059|Friends Research Institute, Inc.|No|Active, not recruiting|March 2014|December 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02110693||46791|
NCT02110238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SUP301|Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA|Multicenter, Randomized, Double-Blind, Parallel Controlled Non-Inferiority Clinical Trial Comparing 3 Weekly Intra-articular Injections of SUPARTZ® vs 3 Weekly Intra-articular Injections of Euflexxa® for Treatment of Knee OA||Bioventus LLC|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|40 Years|80 Years|No|||August 2014|March 10, 2015|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110238||46826|
NCT02110498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00084662|Early Detection of Pancreatic Cystic Neoplasms|Early Detection of Pancreatic Cystic Neoplasms||Johns Hopkins University|No|Recruiting|March 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Pancreatic cyst fluid, blood|Both|18 Years|N/A|No|Non-Probability Sample|Any individual with a pancreatic cyst seen at the Johns Hopkins Hospital or other        participating Institutions.|February 2016|February 26, 2016|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02110498||46806|
NCT02110511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107011010|Body Responses to Bean Physical Form and "Beano"|Effects of Bean Form and Digestive Enzyme Availability on Postprandial Responses|BFE|Purdue University|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110511||46805|
NCT02110719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REAG00414HU|A Multimodal Pain Pathway in Urogynecologic Surgery|A Multi-modal Pain Pathway in Urogynecologic Surgery: A Randomized Study|Pain|Hartford Hospital|Yes|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110719||46789|
NCT02110732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HelsinkiUCH|Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil|Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil After Randomized, Double-blind, Placebo-controlled Oral Administration||Helsinki University Central Hospital|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02110732||46788|
NCT02104648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29269|A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval|A 2 PART STUDY IN HEALTHY SUBJECTS: PART A: A MULTIPLE DOSE, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SUPRA-THERAPEUTIC DOSES OF RO4602522; PART B: A MULTIPLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, POSITIVE-CONTROL, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECT OF RO4602522 ON THE QTC INTERVAL||Hoffmann-La Roche||Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|203|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104648||47252|
NCT02105246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR13-10887|The Healthy Heart Study|The Healthy Heart Study||University of California, San Francisco|No|Enrolling by invitation|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|454|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105246||47206|
NCT02105259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-ANX2014-APT|Internet-delivered Psychodynamic Therapy for Social Anxiety Disorder (SOFIA)|Internet-delivered Psychodynamic Therapy for Social Anxiety Disorder: A Randomized Controlled Trial|SOFIA|Linkoeping University|Yes|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105259||47205|
NCT02104908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARA-2014|Study of Nerve Block Anesthesia for Surgery of Hip Fracture in the Elderly|Target-controlled Propofol Infusion as a Technique of Anesthesia for Surgery of Hip Fracture Under Ultrasound Guidance Lumbar and Sacral Plexus Block or Lumbar, Sacral and Paravertebral Nerve Block in the Elderly||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Enrolling by invitation|March 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|80 Years|N/A|No|||January 2014|December 30, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02104908||47232|
NCT02106169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01104-41|Impact of the Therapeutic Education on the Quality of Life of the Child Suffering of Food Allergy IgE-mediated|Impact of the Therapeutic Education on the Quality of Life of the Child From 8 to 12 Years Old (and His Family) Suffering of Food Allergy IgE-mediated.|EducAA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|220|||Both|8 Years|12 Years|No|||November 2015|November 11, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106169||47135|
NCT02106182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-SDS-406|Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia|A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia|BPH|JW Pharmaceutical|Yes|Recruiting|December 2013|||December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|126|||Male|50 Years|N/A|No|||April 2014|April 7, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02106182||47134|
NCT02106403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202273|A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray|A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray||GlaxoSmithKline|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|March 27, 2014||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT02106403||47117|
NCT02109445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8641019|Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies|Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma||Pfizer|Yes|Terminated|September 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 2, 2014|Yes|Yes|The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No    safety/efficacy concerns were behind the reason of trial termination|No||https://clinicaltrials.gov/show/NCT02109445||46885|
NCT02109211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-250|Does Altering Magill Forceps Affect Nasal Intubation Time|Does Altering The Magill Forceps Angle By 45 Degrees Alter Nasal Intubation Time In Pediatric Dental Surgery Patients?||University of Saskatchewan|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|133|||Both|N/A|15 Years|No|||December 2014|December 5, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109211||46903|
NCT02109458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086035|Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy|Navigational Bronchoscopy and Transthoracic Needle Biopsy for the Diagnosis of Peripheral Pulmonary Nodules: A Safety and Feasibility Pilot||Johns Hopkins University|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|99 Years|No|||February 2016|February 4, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02109458||46884|
NCT02110017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2013-A00064-41|Exploration of Neural Bases in Social Cognition|Exploration of Neural Bases in Social Cognition|IRM-COG|University Hospital, Caen|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|September 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02110017||46841|
NCT02110290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1111|Effects of an Adapted Ski/Snowboarding Program on Quality of Life in Children With Physical Disabilities|Effects of Adapted Skiing and Snowboarding on Quality of Life in Children With Physical Disabilities||University of Colorado, Denver|No|Enrolling by invitation|October 2010|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|78|||Both|8 Years|18 Years|No|Probability Sample|The Hospital Sports Program at Children's Hospital Colorado only has the capability to        accommodate 60 to 65 children a year. This study contacts all of the subjects who meet the        study inclusion criteria from the enrolled HSP participant list. It should be noted that        the investigators will only be recruiting from children already participating in HSP; they        will not be recruiting for children to join HSP.|July 2015|July 24, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110290||46822|
NCT02110563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCR-MYC-101|Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma|Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma||Dicerna Pharmaceuticals, Inc.|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110563||46801|
NCT02110810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Indomethacin-2014-02|Indomethacin Decreases Post-ERCP Pancreatitis|Rectal Indomethacin Decreases the Incidence of Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography in High-risk Patients|Indomethacin|Instituto Mexicano del Seguro Social|Yes|Completed|January 2014|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110810||46782|
NCT02110446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2481A|Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome|Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome - A Randomized Control Trial|SS-1|Chang Gung Memorial Hospital|Yes|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||January 2016|January 31, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02110446||46810|
NCT02110459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL7080-005|Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment|An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment||Polyphor Ltd.|No|Completed|February 2013|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|36|||Both|18 Years|79 Years|No|||November 2015|November 24, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110459||46809|
NCT02110472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-12-001|Investigation of the Presbia Flexivue Microlens™|Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens™ for the Improvement of Near Vision in Emmetropic Presbyopes||PresbiBio, LLC|No|Active, not recruiting|May 2014|February 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|412|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110472||46808|
NCT02110706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401013253-0|Phase II Trial of Rituximab In Myasthenia Gravis|A Phase II Trial of Rituximab In Myasthenia Gravis||Yale University|Yes|Recruiting|May 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|90 Years|No|||November 2015|November 24, 2015|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110706||46790|
NCT02109900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OpudayPivfOutcome|Prognostic Value of Progesterone on Oocyte Retrieval Day for In Vitro Fertilization Outcome|Prognostic Value of Progesterone Levels on Oocyte Retrieval Day for Outcome of Intracytoplasmic Sperm Injection||Acibadem University||Active, not recruiting|February 2014|||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|||Female|18 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Patients who are referred to Acibadem Kayseri Hospital IVF Unit|April 2014|April 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109900||46850|
NCT02108405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020/02/13|The Value of Memory B Cells Marker (CD27) and Howell Jelly Bodies Detrection in Critically Ill Patients|The Value of Memory B Cells Marker (CD27) and Howell Jelly Bodies Detrection in Critically Ill Patients||Tanta University|Yes|Completed|May 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|96|||Both|18 Years|70 Years|No|Probability Sample|A total of ninety five patients were included in the study. fifty eight patients developed        septic complication during ICU stay (sepsis group). fifty seven patients were critically        ill without evidence of infectious organism (SIRS group). At admission, the patient's age,        sex, height and weight were recorded.|April 2014|April 8, 2014|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02108405||46965|
NCT02103998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THOP2 - NYMC - CCC|Study of Thyroid Hormones in Prematures|Phase III Study of Thyroid Hormones in Prematures|THOP2|New York Medical College|No|Not yet recruiting|July 2014|May 2021|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1224|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||April 2014|April 3, 2014|May 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02103998||47301|
NCT02110745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267|The Effect of Induction Technique on Postoperative Pain and Agitation|THE EFFECT OF DIFFERENT INDUCTION TECHNIQUES ON POSTOPERATIVE PAIN AND AGITATION IN CHILDREN||Mustafa Kemal University|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|2|||Both|2 Years|12 Years|No|||March 2015|March 12, 2015|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110745||46787|
NCT02110992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCI-HN-13-001|Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck|A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck||University of Cincinnati|Yes|Recruiting|April 2014|December 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110992||46768|
NCT02105272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1085EL-13-002|Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension|||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|237|||Both|20 Years|80 Years|No|||November 2015|November 18, 2015|March 27, 2014||No||No|October 15, 2015|https://clinicaltrials.gov/show/NCT02105272||47204|
NCT02105298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001704|Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)|Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)||Massachusetts General Hospital|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|104000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All surgical patients aged 18 upwards receiving general anesthesia at Massachusetts        General Hospital between January 2007 and November 2012|August 2015|August 19, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105298||47202|
NCT02105584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCC201202|Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation|Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage in Patients With Atrial Fibrillation|OLAAC|Occlutech International AB|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|85 Years|No|||April 2014|October 15, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02105584||47180|
NCT02106429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00531|Platelet Activity in Vascular Surgery and Cardiovascular Events|Platelet Activity in Vascular Surgery and Cardiovascular Events|PACE|New York University School of Medicine|Yes|Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|385|Samples With DNA|Blood will be obtained from the patient using standard aseptic phlebotomy techniques at 3      time points throughout the study. This will be pre-operatively, at post-op day 2 and at the      30-day follow up. A questionnaire, urine specimen and endothelial function test will be      performed as well.|Both|21 Years|N/A|No|Non-Probability Sample|The study's population will be obtained form NYU Langone Medical Center, Bellevue Hospital        and the VA Hospital.|November 2015|November 4, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02106429||47115|
NCT02106416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00394|Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development|Development of a Novel Technique for PET/MRI Tracer Kinetic Analysis for Urologic Pelvic Malignancy||New York University School of Medicine|Yes|Recruiting|August 2013|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|October 25, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02106416||47116|
NCT02109224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00707|Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection|Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma||National Cancer Institute (NCI)||Terminated|September 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||April 2015|August 18, 2015|April 7, 2014|No|Yes|Inadequate accrual rate|No||https://clinicaltrials.gov/show/NCT02109224||46902|
NCT02110030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCJC-13|Effectiveness of Two Electrotherapy Techniques to Treat Subacromial Impingement Syndrome|Effectiveness of Two Electrotherapy Techniques to Treat Subacromial Impingement Syndrome|TENSIC|Camilo Jose Cela University|No|Completed|January 2013|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02110030||46840|
NCT02110303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAMOND-14/SS/0055|DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury|Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease|DIAMOND|University of Edinburgh|No|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|40 Years|N/A|No|||December 2015|December 1, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110303||46821|
NCT02110576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100343|Procedure For The Reference Range Study For Absolute MA|Procedure For The Reference Range Study For Absolute MA||Haemonetics Corporation|No|Completed|May 2014|March 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|161|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|community sample|March 2015|March 31, 2015|March 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110576||46800|
NCT02109367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRARD-SIUSOM-14-001|Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass|Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass||Southern Illinois University|Yes|Recruiting|February 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|None Retained|fluid sample infused and collected from the cul-de-sac|Female|30 Years|N/A|No|Non-Probability Sample|Adult women with suspected ovarian cancer who are scheduled for oophorectomy, bilateral        salpingo-oophorectomy (BSO), hysterectomy via laparotomy or laparoscopy, hysterectomy/BSO,        staging or debulking.|February 2016|February 17, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109367||46891|
NCT02109380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 14-3-013|Bed-rest, Muscle Mass and Insulin Sensitivity|The Impact of Short-term Bed-rest on Skeletal Muscle Mass and Insulin Sensitivity in Healthy, Young Men||Maastricht University Medical Center|No|Completed|June 2014|||April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02109380||46890|
NCT02109679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.7|Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects|Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects (an Open-label, Randomised, Two-sequence Crossover Study)||Boehringer Ingelheim||Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 8, 2014||||No||https://clinicaltrials.gov/show/NCT02109679||46867|
NCT02109913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2013-004120-11|Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane|Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole||VU University Medical Center|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|175|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02109913||46849|
NCT02108418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-2349-02|Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers|A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution||TaiGen Biotechnology Co., Ltd.|No|Completed|April 2014|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108418||46964|
NCT02108431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1155-1458|Prospective Randomized Trial Comparing Urinary Diversion After Robot-assisted Radical Prostatectomy|Superior Postoperative Patient Comfort in Suprapubic Drainage Versus Transurethral Catheterization Following Robot-assisted Radical Prostatectomy: A Prospective Randomized Clinical Trial||St. Antonius Hospital Gronau|No|Completed|February 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Male|18 Years|N/A|No|||April 2014|April 6, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108431||46963|
NCT02104011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/35|Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers|Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial|STBETA|University Hospital, Bordeaux|Yes|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104011||47300|
NCT02104336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI743-13-024|Phase 2 Study of EPI-743 in Children With Pearson Syndrome|An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome||Edison Pharmaceuticals Inc|No|Terminated|August 2014|February 2016|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|18 Years|No|||November 2015|March 18, 2016|April 2, 2014|Yes|Yes|Results from other studies did not support continuation of this trial|No||https://clinicaltrials.gov/show/NCT02104336||47276|
NCT02104323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tian-drug-neuro001|Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping|Endostatin|Beijing Tiantan Hospital|Yes|Active, not recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|30 Years|No|||January 2016|January 11, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02104323||47277|
NCT02105571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e3061|Evaluation of Safety and Health Involvement For Truck Drivers|Social Support During a Randomized Trial of a Trucker Weight Loss Intervention|SHIFT|Oregon Health and Science University|No|Active, not recruiting|April 2011|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|452|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105571||47181|
NCT02105597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iADHERE-01|A Smartphone Application to Improve Medication Adherence Among People With Type 2 Diabetes Mellitus in Singapore|A Smartphone Application to Improve Medication Adherence Among People With Type 2 Diabetes Mellitus in Singapore: A Randomized Controlled Trial|iADHERE|Singapore General Hospital|No|Withdrawn|August 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|40 Years|N/A|No|||May 2015|May 18, 2015|March 28, 2014||No|Poor patient recruitment|No||https://clinicaltrials.gov/show/NCT02105597||47179|
NCT02105909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH P20 RR-016464|GWAS in a Small Group of Metabolically Healthy Obese White Adults|Genome Wide Association Studies (GWAS) to Identify Candidate Obesity Susceptibility Genes in a Carefully Phenotyped, Metabolically Healthy Population of Obese White Adults||University of Nevada, Las Vegas|No|Completed|May 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|81|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02105909||47155|
NCT02106195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD025-205|A Safety and Tolerability Study of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris|A Phase 2a, Open-Label Study to Evaluate the Safety and Tolerability of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-Line Therapy||Kadmon Corporation, LLC|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||October 2014|October 9, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02106195||47133|
NCT02106442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-002|36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate Tablets|36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets||Takeda|No|Active, not recruiting|May 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|275|||Both|N/A|N/A|No|Non-Probability Sample|Osteoporosis|April 2015|April 15, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106442||47114|
NCT02106741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAK|Acupressure for Fatigue and Low Back Pain|Randomized Pilot Study of Self-Administered Acupressure for Patients With Low Back Pain||University of Michigan|No|Recruiting|May 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02106741||47091|
NCT02106728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1012-AE (UHN REB ID NUMBER)|Multi-Family Group Therapy for Adult Eating Disorders|A Comparison of Family Supportive Counseling and Multi-Family Therapy Group for People With Eating Disorders and Their Family Members: A Randomized Controlled Trial|MFGT|University Health Network, Toronto|No|Enrolling by invitation|January 2012|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||April 2014|April 3, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02106728||47092|
NCT02109497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT2-104|Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine|A Phase 1, Single Centre, Open Label, Two-period Study in Healthy Volunteers to Determine the Effect of PBT2 on the Pharmacokinetics of Caffeine||Prana Biotechnology Limited|No|Completed|May 2014|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109497||46881|
NCT02109263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.143|Prevention of the Procedural Pain in the Newborn|Breastfeeding Versus Saccharose for Prevention of the Procedural Pain in the Newborn|ACTISUCROSE|University Hospital, Brest|Yes|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|114|||Both|37 Weeks|42 Weeks|No|||April 2015|April 21, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02109263||46899|
NCT02109744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48721|Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients|A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients|AML|University of Rochester|Yes|Recruiting|February 2014|December 2020|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109744||46862|
NCT02109757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWR20130114H|Evaluation of Hearing Protection Fit Testing Program|Evaluation of Hearing Protection Fit Testing Program||United States Air Force|Yes|Recruiting|March 2014|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||April 2014|April 7, 2014|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02109757||46861|
NCT02109783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4168733312-CAF|Caffeine, Genetic Variation and Athletic Performance|Genetic Modifiers of Caffeine Intake and Athletic Performance|GMC-AP|University of Toronto|No|Active, not recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|100|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02109783||46859|
NCT02110316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47955|Bioavailability of Voriconazole|Bioavailability of Voriconazole in Critically Ill Patients||University Medical Center Groningen|No|Recruiting|June 2015|||July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|13|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110316||46820|
NCT02110589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIKEL CT001|Tonicity Monitor For Epilepsy and Hypertonic Disorders|Investigation Into the Efficacy and Application of Non-invasive Sensor Technology to Produce a Community-based Seizure Alarm/Monitor for Epilepsy and Episodic Hyperexcitability Disorders.||Vikel Ltd|No|Not yet recruiting|August 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|35|||Both|7 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110589||46799|
NCT02109393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSPLOKOMAT|Use of Lokomat in Patients With Progressive Supranuclear Palsy|Use of the Electromechanicaldriven Orthosis (Lokomat) for Gait Disturbances and Imbalance in Patients With Progressive Supranuclear Palsy|PSPLOKOMAT|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Recruiting|January 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|55 Years|75 Years|No|Non-Probability Sample|Patients with a diagnosis of clinically probable PSP according to NINDS criteria:        gradually progressive disorder, age of onset >40 and either vertical supranuclear gaze        paresis or both slowing of vertical saccades and prominent postural instability with falls        in the first year.|April 2014|April 4, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02109393||46889|
NCT02109406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZD2115 D3060C00006|Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD|A Randomized, Double Blind, Chronic Dosing (14 Days), Three Period, Placebo Controlled, Cross Over, Multi Center Study to Assess Efficacy and Safety of Two Dose Levels of AZD2115 MDI in Subjects With Moderate to Severe COPD||Pearl Therapeutics, Inc.|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|40 Years|80 Years|No|||October 2014|October 16, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109406||46888|
NCT02109692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9184|Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies|Quantification of Muscle Specific microRNAs in the Serum of Patients With Duchenne Muscular Dystrophy (DMD) and Becker (BMD) : Evaluation of the Inters-est of These Biomarkers in Patients Care|biodystromirs|University Hospital, Montpellier|Yes|Recruiting|May 2014|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|186|||Both|18 Months|80 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02109692||46866|
NCT02109926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESTIS|A Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures and the Risk of Testicular Germ Cell Tumor|A Multicentric Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures During Antenatal and Early Postnatal Periods and the Risk to Develop a Testicular Germ Cell Tumor During Adulthood|TESTIS|Centre Leon Berard|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|1500|Samples With DNA|plasma and buffy coat|Male|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases are patients with a testicular germ cell tumor. They will be recruited in the French        infertility centers at the moment of sperm cryopreservation.        Group A controls are sperm donors and husbands of women with fertility troubles. They will        be recruited in the French infertility centers and in the medically assisted procreation        centers.        Group B controls are husbands of women followed for a pathological pregnancy. This group        of controls will be recruited in the level III maternities.|October 2015|October 12, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109926||46848|
NCT02104362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01514-41|Single Fraction Early Prostate Irradiation (SiFEPI)|A Phase I-II Study to Evaluate Exclusive Single-fraction Irradiation by Interstitial High Dose Rate Brachytherapy in Patients With Prostate Cancer at Low Risk or at Low Intermediate Risk of Local Recurrence|SiFEPI|Centre Antoine Lacassagne|Yes|Recruiting|February 2014|July 2019|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|18 Years|N/A|No|||November 2015|November 13, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02104362||47274|
NCT02104661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8722|Protective Role of Oxcarbazepine in Multiple Sclerosis|OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial|PROXIMUS|Queen Mary University of London|Yes|Recruiting|October 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||August 2015|August 21, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104661||47251|
NCT02104674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29249|A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma|A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA||Hoffmann-La Roche||Active, not recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|313|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104674||47250|
NCT02104349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1322|Mindfulness Meditation for Spine Surgery Pain|Mindfulness Meditation for Spine Surgery Pain||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104349||47275|
NCT02104635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saving Lives at Birth|Postpartum Empowerment: an Integrated Approach Driving Demand and Delivery of High Quality, Low-cost Postnatal Services in Kenya|||Harvard School of Public Health|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Basic Science|3||Actual|109|||Female|18 Years|40 Years||||December 2014|December 1, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104635||47253|
NCT02105610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLATILE/38/OSR|Volatile Anesthetics to Reduce Mortality in Cardiac Surgery|Volatile Anesthetics to Reduce Mortality in Cardiac Surgery: A Multicentre Randomized Controlled Study||Università Vita-Salute San Raffaele||Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105610||47178|
NCT02106208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2013-251|Study of the Impact of Dairy Fat on Cardiovascular Health.|Study of the Impact of Dairy Fat on Cardiovascular Health.|HDL|Laval University|No|Active, not recruiting|April 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02106208||47132|
NCT02106455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067-211|Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance −|Benet 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance −||Takeda|No|Recruiting|September 2008|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|Osseous Paget's disease|August 2015|August 24, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106455||47113|
NCT02106754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA021855|Alcohol Screening & Brief Lntervention in Juvenile Justice: Filling the Gap|Alcohol Screening & Brief Lntervention in Juvenile Justice: Filling the Gap||University of Rhode Island||Recruiting|September 2012|September 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|700|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02106754||47090|
NCT02106767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-12970|The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin|The Effects of Single-Dose Rifampin on the Pharmacokinetics of Rosuvastatin in Healthy White and Asian Volunteers||University of California, San Francisco|No|Active, not recruiting|November 2014|March 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02106767||47089|
NCT02107105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0631|Quality of Life (QOL) Following Surgical Treatment for Rectal Cancer|Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer||M.D. Anderson Cancer Center|No|Recruiting|May 2014|||May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Rectal cancer participants at UT MD Anderson Cancer Center in Houston, Texas|February 2016|February 8, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107105||47064|
NCT02107092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-004E|Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.|Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]||ZS Pharma, Inc.|Yes|Completed|May 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|123|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107092||47065|
NCT02107352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003877-24|Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study|||Brugmann University Hospital|Yes|Recruiting|December 2013|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|||Both|18 Years|65 Years|No|Probability Sample|Patients (age-range 18-65 years) undergoing a three-weeks detoxification cure in Alcohol        Unit of CHU Brugmann, diagnosed with alcohol dependence, according to the DSM-IV-TR        (diagnostic and statistical manual of mental disorders, 4th revision)|February 2016|February 11, 2016|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02107352|3 Months|47045|
NCT02109796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00219-38|Effects of tDCS on Quadriceps Strength After Stroke|a Controlled, Randomized Study Evaluating the Immediate Effect of One tDCS Session on Quadriceps Strength in Hemiparetic Patients.|tDCS(HE)|Centre d'Investigation Clinique et Technologique 805|Yes|Recruiting|February 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|February 12, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109796||46858|
NCT02109770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSN014|Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA|Development of Non-invasive Prenatal Test for Microdeletion/Duplication and Other Genetic Syndromes Based on Fetal DNA Isolated From Maternal Blood|Microdel Triad|Natera, Inc.|No|Recruiting|October 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|-  Maternal blood sample        -  Affected child blood sample        -  Unaffected sibling blood sample        -  Father buccal or blood sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families with a child affected by a chromosomal abnormality.|October 2015|October 15, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109770||46860|
NCT02110342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371009|A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PF-04449913 In Healthy Male Volunteers||Pfizer|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110342||46818|
NCT02110043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCATO-MCI-tDCS|Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS|Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms||Charite University, Berlin, Germany|No|Recruiting|March 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|22|||Both|50 Years|90 Years|No|||March 2016|March 15, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02110043||46839|
NCT02110056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCATO-OA-tDCS|Modulation of Visual-Spatial Learning in Healthy Older Adults by tDCS|Modulation of Visual-Spatial Learning in Healthy Older Adults by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms||Charite University, Berlin, Germany|No|Completed|March 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|32|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02110056||46838|
NCT02109419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-040|Feasibility and Validity of A Novel Computer Based Battery of Assessments in the Elderly|Feasibility and Validity of A Novel Computer Based Battery For Analysis of Cognition, Mood, and Mobility-Independence in the Elderly|HHT|Pennington Biomedical Research Center|No|Completed|March 2014|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|57|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will undergo screening to confirm eligibility, completion of initial        screening form, and MMSE evaluation. Study subjects meeting study criteria will then be        categorized as being in the control (MMSE 29-30: inclusive), mild cognitive impairment        (MMSE 25-28: inclusive), or dementia (MMSE 10-24: inclusive) categories.|January 2016|January 15, 2016|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02109419||46887|
NCT02107482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levia|Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis|Bilateral Comparator, Sham-Light Source Controlled, Assessor Blinded Clinical Trial of Localized Narrow Band-Ultraviolet B (NB-UVB) (Levia®) Treatment for Plaque-type Psoriasis||Tufts Medical Center|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107482||47035|
NCT02107820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/036|Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders|Does Bladder Training (BT) Improve the Efficacy of Percutaneous Tibial Nerve Stimulation (PTNS) in Women With Refractory Overactive Bladder (OAB) - A Randomised Controlled Study||Plymouth Hospitals NHS Trust|No|Recruiting|May 2014|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|N/A|N/A|No|||November 2015|November 4, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107820||47009|
NCT02108119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO008|The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome|||Probi AB||Recruiting|April 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||||||Both|18 Years|70 Years||||May 2015|May 29, 2015|April 1, 2014||||No||https://clinicaltrials.gov/show/NCT02108119||46987|
NCT02108132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-HEM|Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia|Allogenic Mesenchymal Stem Cells in Hemophilia: a Pilot Study||Cairo University|Yes|Not yet recruiting|August 2014|February 2016|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|40 Years|No|||April 2014|April 5, 2014|February 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108132||46986|
NCT02104388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJP-0035/2-01|Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders|A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders||Senju Pharmaceutical Co., Ltd.|No|Active, not recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|75 Years|No|||June 2015|June 16, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104388||47272|
NCT02104700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Near Rwanda|Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir|Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)"|Near-Rwanda|Stanford University|No|Active, not recruiting|April 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104700||47248|
NCT02104687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KARIM-1|Intraoperative Haemodynamic Optimization Comparing Flow and Pressure Parameters|The Influence of Intraoperative Goal-directed Hemodynamic Therapy Based on Cardiac Index Trending on the Volume of Intraoperatively Administered Fluids and Vasoactive Agents in Comparison to Standard Pressure Monitoring in Patients Undergoing Major Elective Abdominal Surgery|Flow-press|University Hospital Ostrava|No|Recruiting|April 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104687||47249|
NCT02104921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2K24NS060951|Innovative Ultrasound Technology in Neuromuscular Disease||AQUIRe|Beth Israel Deaconess Medical Center|No|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with any neuromuscular disorder (i.e. primary nerve or muscle disease), both        localized and generalized, producing some degree of weakness or disability.|November 2015|November 13, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02104921||47231|
NCT02104934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGHLIAACB2013|A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty|A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty||Changi General Hospital|No|Recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|85 Years|No|||July 2015|July 28, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02104934||47230|
NCT02106221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMF2908|Transforming Outcomes for Patients Through Medical Home Evaluation & reDesign|Transforming Outcomes for Patients Through Medical Home Evaluation & reDesign|TOPMED|Care Management Plus|Yes|Completed|July 2011|February 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|65500|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02106221||47131|
NCT02106468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elgendy - 1|The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus|The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study||October 6 University|Yes|Completed|May 2013|February 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||March 2014|April 26, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02106468||47112|
NCT02106481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1-M-255|Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery|Comparison of a Single Shot Femoral Nerve Block to Femoral Nerve Block Shot Plus Continuous Femoral Nerve Catheter for Total Knee Replacement Surgery; a Randomized, Blinded Controlled Trial.||Eastern Maine Medical Center|Yes|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|80 Years|No|||August 2015|August 5, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02106481||47111|
NCT02106494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2013-01|A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC|A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy||Heron Therapeutics|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|942|||Both|18 Years|75 Years|No|||July 2015|July 18, 2015|March 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106494||47110|
NCT02106780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-CL-0021|A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707|An Open Label Study to Evaluate the Pharmacokinetics of ASP1707 After a Single Oral Dose of 14C-labeled ASP1707 in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106780||47088|
NCT02107612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDEF V09E0007|Randomized Study For Minimally Invasive Splinted Implants|Development of Minimally Invasive Splinted Dental Implants to Stabilize Mandibular Overdentures, a Randomized Clinical Trial||University of Concepcion, Chile|No|Completed|July 2004|July 2007|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|45 Years|90 Years|No|||April 2014|April 8, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107612||47025|
NCT02110355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120238|A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma|A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma||Amgen|No|Recruiting|December 2014|September 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110355||46817|
NCT02101489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU#206041|Precise Transvaginal Tape Placement Trial|Precise Transvaginal Tape Placement Trial||Loyola University|Yes|Active, not recruiting|March 2014|May 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02101489||47494|
NCT02109510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISIVATS01|Comparative Study of Nonintubated Anesthesia Versus Intubated General Anesthesia in Single Port Thoracoscopic Bullectomy|Comparative Study of Single Port Thoracoscopic Bullectomy Under Nonintubated Local and Sedation Anesthesia Versus Intubated General Anesthesia for Primary Spontaneous Pneumothorax.||Korea University|Yes|Completed|November 2012|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|13 Years|30 Years|No|||April 2014|April 7, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02109510||46880|
NCT02110901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-310|A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)|Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease||Proteon Therapeutics|Yes|Active, not recruiting|July 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|100 Years|No|||November 2015|November 10, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110901||46775|
NCT02110615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U18DP003370|Mass in Motion Kids in the Clinical Setting|MA Childhood Obesity Research Demonstration (CORD) Project||Massachusetts General Hospital|No|Enrolling by invitation|December 2011|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3000|||Both|2 Years|12 Years|No|||April 2014|April 8, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02110615||46797|
NCT02110888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMPNS|Subcutaneous Peripheral Nerve Stimulation (PNS) as "Hybrid Stimulation" After Failure of Spinal Cord Stimulation (SCS) to Control the Back Pain Component in Failed Back Surgery Syndrome (FBSS) Patients.(CUMPNS Study)|||Poitiers University Hospital||Recruiting|February 2013|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|18 Years|80 Years|No|||February 2015|February 25, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02110888||46776|
NCT02107274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-09-1075-5016|Efficacy of Azithromycin in Treatment of Bronchiectasis|Efficacy of Azithromycin in Treatment of Bronchiectasis||Penang Hospital, Malaysia|Yes|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|April 3, 2014||No||No|May 6, 2014|https://clinicaltrials.gov/show/NCT02107274||47051|
NCT02107495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A20-01|Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting|Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting||Samsung Electronics|No|Terminated|March 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|191|Samples Without DNA|Retaining plasma specimens|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects to be recruited for this study will be presenting to one of five point of care        sites located in the USA. The sites will be emergency room or POL sites, and will include        primary care facilities representative of those typically serving the intended use        population for the test.|February 2015|February 18, 2015|April 3, 2014|Yes|Yes|Optimize calibration|No||https://clinicaltrials.gov/show/NCT02107495||47034|
NCT02107833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-106-001|Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers|A Phase 1, Randomized, Parallel-Design, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers||Protalix|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02107833||47008|
NCT02108145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHDD-004|Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma|Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial||Fourth Military Medical University|No|Recruiting|July 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||April 2014|December 19, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108145||46985|
NCT02104713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120925|Stem Cell Therapy to Improve Burn Wound Healing|A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds||University of Miami|Yes|Recruiting|April 2014|February 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104713||47247|
NCT02105337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013002781|Tegaderm and Visual Evoked Potentials|A Pilot Study: Does Tegaderm Placement on Eyes to Prevent Lagophthalmos Affect Visual Evoked Potentials Data Latency and Amplitude||Rutgers, The State University of New Jersey|No|Terminated|July 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|70 Years|No|Non-Probability Sample|undergoing transsphenoidal pituitary tumor resection with visual evoked potential|September 2014|March 10, 2015|January 15, 2014||No|PI leaving institution|No||https://clinicaltrials.gov/show/NCT02105337||47199|
NCT02104960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308003|Study of Skin Parameters in the PROOF Cohort|Study of Skin Parameters in the PROOF Cohort|PEAU PROOF|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2013|December 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|Samples Without DNA|Skin|Both|75 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|PROOF cohort (NCT00759304)|January 2015|January 13, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02104960||47228|
NCT02104973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-785-060|Obesity Prevention in Schoolchildren|Design and Evaluation of a Strategy to Prevent Overweight and Obesity in Schoolchildren in Mexico City|CRECES|Coordinación de Investigación en Salud, Mexico|No|Active, not recruiting|January 2012|February 2015|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|8 Years|12 Years|No|||January 2014|April 2, 2014|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02104973||47227|
NCT02104947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1321.3|Reversal of Dabigatran Anticoagulant Effect With Idarucizumab|A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial||Boehringer Ingelheim||Recruiting|May 2014|July 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 2, 2014||||No||https://clinicaltrials.gov/show/NCT02104947||47229|
NCT02105285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1085EL-13-003|Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension|||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|20 Years|80 Years|No|||November 2015|November 24, 2015|March 27, 2014||No||No|October 15, 2015|https://clinicaltrials.gov/show/NCT02105285||47203|
NCT02106234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47173.068.14|A Maastricht Contrast-Induced Nephropathy Guidelines Study: CIN Prevention Guidelines: Appropriate & Cost-effective?|Randomised Controlled Trial Evaluating Prophylactic Intravenous Hydration for the Prevention of Contrast Induced Nephropathy|AMACING|Maastricht University Medical Center|Yes|Recruiting|April 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1300|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02106234||47130|
NCT02106247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344.20|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)||Boehringer Ingelheim||Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|April 1, 2014||||No||https://clinicaltrials.gov/show/NCT02106247||47129|
NCT02106793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MitomicinC_PostopESS|Mitomicin C for Prevention Postoperative Endoscopic Sinus Surgery Synechia and QOL in Chronic Rhinosinusitis|Comparing Effect of Mitomicin C Versus Placebo for Prevention of Postoperative Endoscopic Sinus Surgery Synechia and Impact on Quality of Life in Thai Patients With Chronic Rhinosinusitis||Mahidol University|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|388|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02106793||47087|
NCT02106806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2011/07867-4|Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles|Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles||University of Sao Paulo|No|Completed|May 2011|December 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 3, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02106806||47086|
NCT02107144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM - CARD - 002|The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease|The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease|PATMOS|Clinical Hospital Center Zemun|Yes|Recruiting|April 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||March 2016|March 5, 2016|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02107144||47061|
NCT02107157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PICO-CAPHST-ET|Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation|Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation||Cynosure, Inc.|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02107157||47060|
NCT02107118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34570 No.11-13-40-07|Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men|H-34570: PHASE I Study: The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men||Baylor College of Medicine|No|Withdrawn|May 2015|February 2022|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Male|40 Years|N/A|No|||May 2015|May 22, 2015|April 3, 2014|No|Yes|Contract issues|No||https://clinicaltrials.gov/show/NCT02107118||47063|
NCT02107131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29184s|Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab|Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab|ERASER|California Retina Consultants|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02107131||47062|
NCT02101502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1781955|Quality Assurance of Obstetrics and Gynecology Department|Quality Assurance of Obstetrics and Gynecology Department||Al-Azhar University|Yes|Completed|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|2300|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 7, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02101502||47493|
NCT02110069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIR-DA-1202|A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors|A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|January 2015|September 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|31 Years|No|||May 2015|May 29, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110069||46837|
NCT02110368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL1401|Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions|An Open-Label, Randomized, Balanced, Single-Dose, Two Treatment, Four Period, Two Sequence Replicate Design, Bioequivalence Study Of Testosterone Topical Gel, 1.62% Metered Pump, Manufactured By Amneal Pharmaceuticals LLC With AndroGel (Testosterone Gel) 1.62% Metered-Dose Pump, Marketed By Abbvie Inc., In Testosterone-Deficient (Hypogonadal) Adult Male Subjects Under Fasting Conditions||Amneal Pharmaceuticals, LLC|Yes|Completed|March 2014|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|65 Years|No|||June 2014|June 25, 2014|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110368||46816|
NCT02102087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT1302|Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device|A Matched, Open Label Study to Evaluate the Effectiveness of the MMT Initial Specimen Diversion Device in Reducing Blood Culture Contamination When Compared to Laboratory Standard Procedures||Magnolia Medical Technologies, Inc.|No|Recruiting|July 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|5308|||Both|19 Years|N/A|No|||April 2015|April 12, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102087||47448|
NCT02102347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24568013.0.0000.5511|Effect of Phototherapy Incorporated Into an Exercise Program on Osteoarthritis of the Knee|Effect of Phototherapy Incorporated Into an Exercise Program on Osteoarthritis of the Knee||University of Nove de Julho|Yes|Completed|April 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|20|||Both|40 Years|80 Years|No|||December 2015|December 2, 2015|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02102347||47428|
NCT02111135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV005ABMG|Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life|Phase II, Observer-blind, Randomized Study on the Safety, Reactogenicity, Immunogenicity and Impact on Intestinal Shedding of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) or a Single Dose of Standard Trivalent Inactivated Poliovirus Vaccine (t-IPV) When Given Concomitantly With the Third Dose of Bivalent Oral Poliovirus Vaccine (b-OPV) to Infants Early in Life|IPV005|Vaxtrials S.A.|Yes|Completed|April 2014|March 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|6 Weeks|6 Weeks|Accepts Healthy Volunteers|||July 2015|July 16, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111135||46757|
NCT02107859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-023-CF|Study of Ataluren (PTC124®) in Cystic Fibrosis|An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)||PTC Therapeutics|Yes|Enrolling by invitation|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|6 Years|N/A|No|||June 2015|June 2, 2015|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02107859||47006|
NCT02107872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1500-CL-1321|Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500|||Regeneron Pharmaceuticals|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|55|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02107872||47005|
NCT02107885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E101|Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.|A Phase 1, Double-blind, Randomized, Placebo-controlled Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male Subjects||Daiichi Sankyo Inc.|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107885||47004|
NCT02108158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PF1311|A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines|A Randomized, Evaluator-blinded, Comparative Study to Evaluate the Efficacy and Safety of Different Injection Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines||Q-Med AB|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|64 Years|No|||August 2015|November 5, 2015|March 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108158||46984|
NCT02108444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU 2013-Autonomous-9|Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients|Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection||Peking University|Yes|Completed|January 2007|March 2014|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|107|Samples With DNA|serum hepatitis B virus DNA|Both|18 Years|80 Years|No|Probability Sample|lymphoma patients with hepatitis B virus infection diagnosed in Peking University Cancer        Hospita|July 2014|July 22, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02108444||46962|
NCT02104024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAK 1.0|CEUS in Kidney and Pancreas Transplantation|Contrast Enhanced Ultrasound Scanning of Kidney and Pancreas Transplantation (Proof of Principle Study)||University of Manchester|No|Recruiting|October 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|65|||Both|18 Years|N/A|No|Probability Sample|Kidney and pancreas transplant recipients|April 2014|April 3, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02104024||47299|
NCT02104037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-027|Liraglutide in Spinal Fluid|Liraglutide in Spinal Fluid|LIRA-CSV|University Hospital, Gentofte, Copenhagen|No|Completed|January 2012|||December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104037||47298|
NCT02105350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biliary GEMOX / MEK|A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer|A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer||University Health Network, Toronto|Yes|Suspended|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105350||47198|
NCT02105012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT008001|Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma|A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma||Pearl Therapeutics, Inc.|No|Active, not recruiting|April 2014|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|150|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105012||47224|
NCT02105623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2013-09|EARly Prevention of aTHeroma Progression|EARly Prevention of aTHeroma Progression|EARTH|Asan Medical Center|Yes|Recruiting|June 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|35 Years|N/A|No|||November 2015|November 16, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02105623||47177|
NCT02105636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-141|Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)|An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Bristol-Myers Squibb|Yes|Active, not recruiting|May 2014|September 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||September 2015|March 11, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105636||47176|
NCT02105311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC57-020-02-1|Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure|A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation||Prince of Songkla University|Yes|Recruiting|March 2014|July 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105311||47201|
NCT02105324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000630|The Summer Camp Study 2:Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas|The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps||Massachusetts General Hospital|Yes|Active, not recruiting|June 2014|December 2015|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|11 Years|No|||September 2015|September 10, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105324||47200|
NCT02105935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-23|Investigator Initiated Protocol for the: Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion and the Establishment of Normative Data in Youth and Adolescents Athletes|Investigator Initiated Protocol for the: Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion and the Establishment of Normative Data in Youth and Adolescents Athletes.||ElMindA Ltd|No|Recruiting|April 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|male and female athletes|January 2016|January 25, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02105935||47153|
NCT02105948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117106|Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients|Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients||GlaxoSmithKline|Yes|Active, not recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105948||47152|
NCT02106520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.827|Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|ALEGORI|Hospices Civils de Lyon|Yes|Terminated|April 2014|September 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|April 1, 2014||No|DSMB's decision following the first step analysis|No||https://clinicaltrials.gov/show/NCT02106520||47108|
NCT02111174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1384|Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy|A Pilot Randomized Sham-Controlled Trial of MC5-A Calmare Therapy (Scrambler Therapy) in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|March 2015|July 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|March 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111174||46754|
NCT02111148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 2|Vaginal Fluid Wash in Pre-labour Rupture of Membranes|Urea and Creatinine Versus Nitrazine Test in Vaginal Fluid Wash in Diagnosed Pre Labour Rupture of Membranes|PROM|Beni-Suef University|No|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|105|||Female|30 Years|40 Years|No|||December 2015|December 26, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111148||46756|
NCT02111161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH4131-03|Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial|Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial|INSTINCT|Rigshospitalet, Denmark|No|Active, not recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02111161||46755|
NCT02107378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV03|Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma|A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma||Sotio a.s.|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107378||47043|
NCT02107391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP002|Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer||Sotio a.s.|No|Active, not recruiting|March 2012|September 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Male|18 Years|N/A|No|||June 2015|January 5, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02107391||47042|
NCT02102100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309012678|The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users|Menthol's Effects on Nicotine Reinforcement in Smokers||Yale University|Yes|Recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|160|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|October 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02102100||47447|
NCT02101788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00629|Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer|A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer||National Cancer Institute (NCI)|Yes|Suspended|February 2014|||February 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|19 Years|N/A|No|||February 2016|March 16, 2016|March 28, 2014|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02101788||47471|
NCT02101801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orap2014-HMO-CTIL|Urine Drug Levels Related to Source of Water for Irrigation for Vegetable Crops Among Healthy Israeli Volunteers|||Hadassah Medical Organization|No|Completed|September 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|35|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|February 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101801||47470|
NCT02102607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intrathecal ropivacaine|Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine|Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine|Spinal|China Three Gorges University, Yichang, China|Yes|Completed|January 2014|June 2015|Actual|March 2015|Actual|N/A|Observational|N/A||1|Actual|120|||Both|20 Years|80 Years|No|Non-Probability Sample|Adult patients who were undergoing transurethral, urological or lower limb surgery,        primarily under the spinal anesthesia|October 2015|October 23, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02102607||47408|
NCT02102594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVAB|Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)|Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)|TAVAB|Charite University, Berlin, Germany|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02102594||47409|
NCT02102867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11968|Developing Rectal USPE Measures|Evaluating User Perceptions and Experiences of Dual Compartment Microbicide Formulations. Project 5.1: Developing Rectal USPE Measures|Project DRUM|The Miriam Hospital|Yes|Active, not recruiting|April 2014|May 2017|Anticipated|March 2015|Actual|N/A|Observational|N/A||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals residing in the greater Providence, RI and southeastern, MA metropolitan areas|October 2015|October 5, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102867||47388|
NCT02108184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSungmin|Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy|Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea||Incheon St.Mary's Hospital|Yes|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|264|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108184||46982|
NCT02108197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-56-39|Sleep Apnea and Gestational Diabetes|Obstructive Sleep Apnea and Gestational Diabetes : Incidence and Effects of Continuous Positive Airway Pressure Treatment on Glucose Metabolism||Ramathibodi Hospital|No|Recruiting|April 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|50 Years|No|||May 2015|May 7, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108197||46981|
NCT02108171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFPH-IRB-2013-086|Intranasal Dexmedetomidine Premedication|A Randomised Controlled Trial of Intranasal Dexmedetomidine as Premedication for Suspension Laryngoscopy||Guangzhou First Municipal People’s Hospital|Yes|Completed|March 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|60 Years|No|||February 2016|February 13, 2016|March 30, 2014||No||No|February 10, 2015|https://clinicaltrials.gov/show/NCT02108171||46983|
NCT02108457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 28813|[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers|[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Primary Purpose: Treatment|2||Anticipated|17|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108457||46961|
NCT02104050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLT1177-03|Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain|A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy||Olatec Industries LLC||Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|45 Years|80 Years|No|||August 2015|August 27, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104050||47297|
NCT02104063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008956QM|Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]|Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]|MRI-PET|Queen Mary University of London|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|107|Samples Without DNA|Whole blood, serum, biopsy tissue of primary penile cancer lesions and metastatic lesions.|Male|18 Years|N/A|No|Non-Probability Sample|Patients referred to UCLH presenting with penile cancer will be approached for        consideration of inclusion into the study.|January 2015|January 23, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02104063||47296|
NCT02104375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.11742|L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia|The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia||Florida State University|No|Completed|March 2013|December 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104375||47273|
NCT02105025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131023-3|A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy|A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy||Fourth Military Medical University|Yes|Completed|December 2013|February 2014|Actual|February 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|612|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective study involving only one tertiary center in China. The patients were        enrolled from the Endoscopy Center of Xi jing Hospital of Digestive Diseases in China.|May 2014|May 5, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105025|1 Week|47223|
NCT02105389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga Pilot|Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy|A Feasibility Study of Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy||The Hospital for Sick Children|No|Completed|January 2013|||October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|7 Years|18 Years|No|||November 2015|November 27, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105389||47195|
NCT02105363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013003345|How Much Can the Thoracic and Lumbar Skin Slide?|How Much Can the Thoracic and Lumbar Skin Slide? Unrecognized Cause of Epidural Catheter Placement Failure||Rutgers, The State University of New Jersey|No|Enrolling by invitation|April 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||20|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All individuals age 0-100|April 2014|April 2, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02105363||47197|
NCT02105376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS_depression|TNS for Major Depressive Disorder: a Phase II Randomized Controlled Trial|The Effects of Trigeminal Nerve Stimulation (TNS) for the Treatment of Major Depressive Disorder: a Phase II, Randomized, Sham Controlled Clinical Trial||Santa Casa Medical School|Yes|Recruiting|May 2014|||June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|69 Years|No|||May 2015|May 3, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02105376||47196|
NCT02105922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-070.2|Effect of Strength Training and Protein Ingestion in Old Versus Very-old|Effect of Strength Training and Protein Ingestion in Old Versus Very-old||Bispebjerg Hospital|Yes|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02105922||47154|
NCT02106260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS003-CO-PR-001|First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts|A Phase I/IIa Open-label First-in-Human Study to Assess Safety and Pharmacokinetics and Explore Biomarker Effects of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Subjects With Cutaneous Warts||Cutanea Life Sciences, Inc.|No|Completed|March 2014|||April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02106260||47128|
NCT02106507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-025|ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate|Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Male|18 Years|N/A|No|||January 2016|January 5, 2016|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02106507||47109|
NCT02111187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1402|A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer|A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.|LDE225|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|100 Years|No|||November 2015|November 17, 2015|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111187||46753|
NCT02110628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCGCC-1202|Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy|Jejunal Pouch for Postoperative Quality of Life Following Roux-en-Y Reconstruction of Radical Total Gastrectomy: a Multicenter Randomized Controlled Trial (WCGCC-1202)|WCGCC-1202|West China Hospital|No|Recruiting|August 2014|August 2019|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|588|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110628||46796|
NCT02110641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012007780_1|Lifestyle, Exercise and Nutrition Study 2 (LEAN 2)|Lifestyle, Exercise and Nutrition (LEAN) Study 2|LEAN 2|Yale University|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|75 Years|No|||July 2015|July 14, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110641||46795|
NCT02110914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-FSP01|A Coaching Intervention to Young Adults With Cystic Fibrosis|Coach to Cope. A Motivational Interviewing Inspired Coaching Intervention for Young Adults With Cystic Fibrosis: A Randomized Controlled Feasibility Study||Rigshospitalet, Denmark|No|Active, not recruiting|May 2014|November 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|30 Years|No|||November 2015|November 20, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02110914||46774|
NCT02111733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnT-HD|Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?|Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?|TnT-HD|Université de Sherbrooke|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|43|||Both|50 Years|N/A|No|||April 2014|April 8, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02111733||46711|
NCT02111746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTVS-KC02|PAIN - Postoperative Analgesia INvestigation|A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control|PAIN|The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111746||46710|
NCT02111447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|412889-6|Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI|Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI: Comparative Study Using Propofol, Sevoflurane and Isoflurane||State University of New York at Buffalo|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|180|||Both|2 Years|12 Years|No|||April 2014|April 9, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111447||46733|
NCT02101827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103006-E|Safety and Efficacy of Distending Media Infusion by Manual Syringe Method for Hysteroscopic Procedures|Safety and Efficacy of Distending Media Infusion by Manual Syringe Method for Hysteroscopic Procedures||Far Eastern Memorial Hospital||Completed|March 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Female|20 Years|N/A|No|Non-Probability Sample|Patients had hysteroscopic procedures for either diagnostic or therapeutic purpose|July 2015|July 4, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02101827||47468|
NCT02102360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mist2014|Conventional or Minimally Invasive Surgical Technique for the Treatment of Furcation Defects Using Enamel Matrix Derivative and Anorganic Bovine Bone - a Randomized Controlled Clinical Trial.|||University of Sao Paulo||Completed|March 2012|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 29, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102360||47427|
NCT02102373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mytyk2014|Evaluation of Two Different Diet Regimen Prior to Colonoscopy in Children|||Medical University of Warsaw||Recruiting|March 2014|August 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|6 Years|18 Years|No|||March 2014|March 29, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102373||47426|
NCT02102386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312041|Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|CerOx|Washington University School of Medicine|No|Terminated|February 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to undergo elective carotid endarterectomy at Barnes Jewish Hospital.|January 2015|January 27, 2015|March 29, 2014||No|Technical issues with the device under study. Sponsor terminated.|No||https://clinicaltrials.gov/show/NCT02102386||47425|
NCT02102880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040214|The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects|The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects||Medical University of Vienna||Recruiting|March 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|220|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02102880||47387|
NCT02108210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0002198|Cytokine Inhibition in Chronic Fatigue Syndrome Patients|Cytokine Inhibition in Chronic Fatigue Syndrome Patients|CiCFS|Radboud University|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|59 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108210||46980|
NCT02108470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER020-2012A|A Randomized Cross-over Clinical Trial to Evaluate the Use of Oral Health-Related Quality of Life in Dental Practice|A Randomized Cross-over Clinical Trial to Evaluate the Use of Oral Health-Related Quality of Life in Dental Practice|OHRQoL|University of Malaya|No|Completed|March 2014|June 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|144|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02108470||46960|
NCT02108483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-010|Phototoxicity Test of Dapsone Gel in Healthy Volunteers|||Allergan|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108483||46959|
NCT02104076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-014|Evolution® Biliary Stent System-Fully Covered|Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered||Cook||Recruiting|September 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104076||47295|
NCT02104089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-017|Post-market Observational Study Zenith® t-Branch™|Post-market Observational Study Zenith® t-Branch™ Thoracoabdominal Endovascular Graft||Cook||Recruiting|January 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals|November 2015|November 16, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104089||47294|
NCT02104401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000|Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood|Pilot Study: Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood||Georgetown University|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104401||47271|
NCT02104414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0062|Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy|Comparison of Rectal Infiltration of Exparel vs. 0.25% Bupivacaine With Epinephrine vs. Placebo for Analgesic Benefit Following Hemorrhoidectomy||St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|April 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02104414||47270|
NCT02105675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP001|Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Castrate-resistant Prostate Cancer||Sotio a.s.|No|Active, not recruiting|February 2012|March 2017|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||June 2015|June 29, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02105675||47173|
NCT02105688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-062|An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are on Opiate Substitution Therapy|C-EDGE CO-STAR|Merck Sharp & Dohme Corp.|No|Active, not recruiting|September 2014|December 2018|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105688||47172|
NCT02105701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-068|Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection||Merck Sharp & Dohme Corp.|No|Completed|June 2014|June 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|420|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|April 2, 2014|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT02105701||47171|
NCT02105649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Calf Muscle Strength and Standing Efficiency in Children With Spastic Diplegia|CALF MUSCLE STRENGTH AND STANDING EFFICIENCY IN CHILDREN WITH SPASTIC DIPLEGIA: A RANDOMIZED CONTROLLED TRIAL||Cairo University|Yes|Completed|April 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|4 Years|No|||February 2015|February 2, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02105649||47175|
NCT02105662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-061|An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)|A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen Grazoprevir (GZR) and Elbasvir (EBR) in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are Co-Infected With HIV||Merck Sharp & Dohme Corp.|No|Completed|June 2014|May 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|April 2, 2014|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT02105662||47174|
NCT02110381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00086973|Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial|Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial||University of Michigan||Terminated|September 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|N/A|No|||December 2015|December 11, 2015|April 7, 2014||No|It was a pilot study and we enrolled sufficient numbers to evaluate the proposed outcomes.|No||https://clinicaltrials.gov/show/NCT02110381||46815|
NCT02111200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33157|Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders|Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders|BPA/Benzoate|Baylor College of Medicine|No|Recruiting|September 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|9|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111200||46752|
NCT02111460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC5010|Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma|Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity||Sun Yat-sen University|Yes|Recruiting|October 2013|December 2022|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111460||46732|
NCT02111473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-032014|The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism|Phase 4 Study of Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism||Gulhane School of Medicine|No|Completed|May 2009|April 2014|Actual|May 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Male|18 Years|28 Years|No|||April 2014|April 9, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02111473||46731|
NCT02111759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTOSM0001|The Effect of Knee Flexion Angle for Graft Fixation During Single-Bundle Anterior Cruciate Ligament Reconstruction|The Effect of Knee Flexion Angle for Graft Fixation During Single-Bundle Anterior Cruciate Ligament Reconstruction - A Multicentre, Patient and Assessor Blinded, Stratified, Two-arm Parallel Group Superiority Trial|FIRM|University of Toronto Orthopaedic Sports Medicine|No|Recruiting|May 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|16 Years|N/A|No|||December 2015|December 7, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02111759||46709|
NCT02112058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS-233-03-0034|The Supporting Healthy Marriage Evaluation|The Supporting Healthy Marriage Evaluation|SHM|MDRC||Completed|February 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|6298|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02112058||46686|
NCT02112071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905M66282|Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.|Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.|DKD-EXT|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|October 2009|October 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|90 Years|No|||July 2015|July 23, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112071||46685|
NCT02102126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENSURE|Effect of Renal deNervation on Arterial Stiffness and Haemodynamics in Patients With UncontRolled hypErtension (ENSURE)||ENSURE|Shanghai 10th People's Hospital||Not yet recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||March 2014|March 30, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02102126||47445|
NCT02102113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310012948|Probing the Cannabinoid System in Individuals With a Family History of Psychosis|Probing the Cannabinoid System in Individuals With a Family History of Psychosis||Yale University|No|Recruiting|January 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02102113||47446|
NCT02102633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871043|Drug Interaction Study Between Bosutinib And Dabigatran|An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Bosutinib On The Pharmacokinetics Of Dabigatran Etexilate Mesylate Administered Orally To Healthy Subjects||Pfizer|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|March 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02102633||47406|
NCT02102646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kk2013 MRI|MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism|MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin||Herlev Hospital|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|90 Years|No|||October 2015|October 27, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02102646||47405|
NCT02102620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPauloRheum01|Corticosteroid Intra-articular Injection in Hands Osteoarthritis|Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients||Federal University of São Paulo|No|Completed|August 2011|June 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|N/A|No|||March 2014|April 2, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02102620||47407|
NCT02108509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113-14-FB|Bone Disease in Chronic Pancreatitis: A Complex Phenomenon|Bone Disease in Chronic Pancreatitis: A Complex Phenomenon||University of Nebraska|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|19 Years|75 Years|No|Non-Probability Sample|Both males and females with diagnosis of chronic pancreatitis|December 2015|December 1, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02108509||46957|
NCT02108496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000249|Verifying the Effectiveness of the NUsurface® System|The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) A Multi-centered, Prospective, Randomized, Interventional, Superiority Clinical Study|VENUS|Active Implants|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|30 Years|75 Years|No|||January 2016|January 14, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02108496||46958|
NCT02104102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24581613.0.0000.5503|Biomedical Instrumentation in the Study of Mirror Therapy in Elderly's Hands Motor Activity|Biomedical Instrumentation in the Study of Mirror Therapy in Elderly's Hands Motor Activity||Universidade do Vale do Paraíba|Yes|Recruiting|January 2014|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2014|April 3, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02104102||47293|
NCT02104115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12122013 SoM NDDC EEG|Effects of Bread Gluten Content on Gastrointestinal Volumes|Effects of Bread Gluten Content on Gastrointestinal Volumes|EGG|University of Nottingham|No|Completed|March 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02104115||47292|
NCT02104427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-0054-04|PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients|A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease||TaiGen Biotechnology Co., Ltd.||Completed|February 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||January 2016|January 10, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104427||47269|
NCT02104440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/CIT|Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro|||Red de Terapia Celular|No|Recruiting|October 2013|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||April 2014|April 3, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02104440||47268|
NCT02104726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026934|"Blind" vs. Fluoroscopy-Guided Steroid Injections for Knee Osteoarthritis|Prospective Randomized-Controlled Two-Arm Study of "Blind" vs. Fluoroscopy-Guided Steroid Injections for Knee Osteoarthritis||Johns Hopkins University||Not yet recruiting||||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|80 Years|No|||April 2014|April 2, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104726||47246|
NCT02104986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGM 2013-NS|A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent|A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent||Centre Leon Berard|Yes|Recruiting|May 2014|May 2024|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|94|||Both|N/A|18 Years|No|||March 2015|March 11, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02104986||47226|
NCT02104999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-NH0414|Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein Device in a Nursing Home Setting|Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein (CRP) Device in Comparison With Laboratory CRP Testing in Nursing Home Residents.||Katholieke Universiteit Leuven|No|Completed|June 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02104999||47225|
NCT02105402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMPT-29142|Treatment Efficacy for Developmental Motor Speech Disorders|Treatment Efficacy for Developmental Motor Speech Disorders: A PROMPT Randomized Control Trial||The Prompt Institute|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02105402||47194|
NCT02105714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP2-01-DIG|Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders|Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal|NIDIAGDigest|Swiss Tropical & Public Health Institute|No|Active, not recruiting|July 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|4000|||Both|1 Year|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals aged ≥1 year presenting with persistent diarrhoea (≥3 loose stools per days        for ≥2 weeks; symptomatic group) and/or children (aged 1-18 years) with persistent        abdominal pain (localized or diffuse abdominal pain lasting for ≥2 weeks, with possible        intermittence/recurrence) will be recruited together with matched controls.|January 2016|January 25, 2016|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02105714||47170|
NCT02105961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117113|Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)|Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level||GlaxoSmithKline|Yes|Active, not recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|660|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105961||47151|
NCT02105974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200820|Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared With Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|April 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1621|||Both|40 Years|N/A|No|||December 2015|February 25, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105974||47150|
NCT02110927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-003|Microcurrent and Aerobic Exercise Effects in Abdominal Fat|Microcurrent and Aerobic Exercise Effects in Glycerol, Catecholamines, Energetic Source and Muscle Activity||Escola Superior de Tecnologia da Saúde do Porto|Yes|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02110927||46773|
NCT02111512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CHI 0714|Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study|Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study|SNIFFLE-2|Imperial College London|Yes|Completed|September 2014|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|779|||Both|2 Years|17 Years|No|||May 2015|May 27, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02111512||46728|
NCT02112344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 2823|A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck|A Phase I Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck||Royal Marsden NHS Foundation Trust|No|Active, not recruiting|July 2007|July 2015|Anticipated|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02112344||46664|
NCT02111486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:027|Effect of Certain Breakfasts on Appetite Control|A Randomized, Controlled, Cross-over Study of the Effect of Certain Breakfasts on Appetite Control.||St. Boniface General Hospital Research Centre|No|Withdrawn|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|April 9, 2014||No|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT02111486||46730|
NCT02111499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H553000-1308|Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test|A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis||Almirall, S.A.|No|Completed|March 2014|June 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|75 Years|No|||June 2014|June 6, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02111499||46729|
NCT02112097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTAR066986|ASIS for Enbrel in Plaque Psoriasis|ASIS for Enbrel in Plaque Psoriasis|ASISinPP|ASIS Corporation|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|13||Anticipated|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112097||46683|
NCT02112084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33122-DPM|An Individualized Grief Intervention for Spouses of Cancer Patients After the Patient's Death|Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Individualized Dual Process Intervention for Bereaved Partners After Cancer Death|DPM|University of Utah|Yes|Active, not recruiting|May 2010|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|210|||Both|45 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02112084||46684|
NCT02112305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 104/2557|Compare Efficacy Nebulized and Intravenous Magnesium Sulphate in Thai Children|Comparison Efficacy of Nebulized Magnesium Sulphate to Intravenous Magnesium Sulphate in Children With Severe Acute Asthma||Queen Sirikit National Institute of Child Health|No|Active, not recruiting|January 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|15 Years|No|||November 2014|November 15, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02112305||46667|
NCT02102412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053 CLD ars 08|First in Man Aer-O-Scope|A Single-center Study to Evaluate the Safety & Performance of the Aer-O-Scope for Traveling Through the Colon in Healthy Volunteers||GI View Ltd.|Yes|Terminated|February 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|101|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|April 1, 2014|March 30, 2014||No|Changes made to device.|No||https://clinicaltrials.gov/show/NCT02102412||47423|
NCT02102399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1152-9129|Vocal Warm-up and Respiratory Muscle Training|Vocal Warm-up and Respiratory Training in Teachers: a Randomized Clinical Trial||Federal University of Bahia|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|March 30, 2014||No||No|January 24, 2015|https://clinicaltrials.gov/show/NCT02102399||47424|Small and not probabilistic sample; type I error; type II error; strike in the last week of the study; healthy worker effect.
NCT02102919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Main study (PhD)- part I|Innovative Training Program for Elderly in Need of Care Individuals|Skilling-up Exercise for Elderly in Need of Care||Bern University of Applied Sciences|No|Completed|January 2013|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102919||47384|
NCT02102932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.23|Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers|Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study||Boehringer Ingelheim||Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|March 31, 2014||||No|August 21, 2015|https://clinicaltrials.gov/show/NCT02102932||47383|
NCT02102906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS|TMS and Attentional Bias in Functional Motor Disorder|TMS and Attentional Bias in Functional Motor Disorder||University of Edinburgh|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|75 Years|No|||December 2014|February 8, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102906||47385|
NCT02103153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PICO532-RG5|Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos|Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos||Cynosure, Inc.|No|Active, not recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103153||47366|
NCT02104141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROIA100|Retrospective/Prospective Data Collection on the LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating|||LDR Spine USA|No|Enrolling by invitation|November 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|50|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects will be drawn from community surgeon practices in which the subjects have already        received the device and who meet the Inclusion/Exclusion criteria.|April 2014|April 3, 2014|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104141||47290|
NCT02104128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bup_dep_1|Effects of Bupropion in Depression|Effects of Bupropion in Depression||University of Oxford|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02104128||47291|
NCT02104453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-103-05-029|Comparative Evaluation of Three Airway Maneuvers in the Unconscious Apneic Person|Comparative Evaluation of One-handed E-C Clamp Mask Holding Technique, Two-handed Mask Ventilation With Jaw Thrust, and Two-handed Mask Ventilation With Triple Airway Maneuver in the Unconscious Apneic Person||Tri-Service General Hospital|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|80 Years|No|||November 2014|November 13, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02104453||47267|
NCT02104739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0791|Effects of Antidiabetic Medications on the Postprandial State in Prediabetes|Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes||The University of Texas Health Science Center, Houston|No|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104739||47245|
NCT02109588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevention childhood obesity|Early Prevention of Childhood Obesity: an Active Pregnancy|Early Prevention of Childhood Obesity: an Active Pregnancy||Technical University of Madrid|Yes|Recruiting|March 2014|April 2018|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|November 13, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02109588||46874|
NCT02109601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09854|Patient-Centered Tablets: Applications for Inpatient Admissions|Tablet Computers for Hospitalized Adults: a Novel Approach to Increasing Patient Engagement With Their Electronic Personal Health Records||University of California, San Francisco|No|Completed|November 2013|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|98|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02109601||46873|
NCT02110134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-REV-TOP-MEL-AK|A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma|A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma||Cynosure, Inc.|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110134||46832|
NCT02110394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-BEN-NI-003|Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia|Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia|NORMA|Astellas Pharma Inc|No|Active, not recruiting|June 2012|February 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|190|||Both|18 Years|N/A|No|Probability Sample|Patients with В-cell chronic lymphocytic leukemia under the care of a physician in the        haematology/chemotherapy departments in 20-25 centers in the Russian Federation|October 2015|October 19, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110394||46814|
NCT02110407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCATO-YA-tDCS|Modulation of Visual-Spatial Learning in Healthy Young Adults by tDCS|Modulation of Visual-Spatial Learning in Healthy Young Adults by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms||Charite University, Berlin, Germany|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02110407||46813|
NCT02111538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130026923|Body Composition in Systemic Amyloidosis|Prognostic Value of Phase Angle in Systemic Immunoglobulin Light-chain (AL) Amyloidosis|BIVAmyloid|IRCCS Policlinico S. Matteo|Yes|Recruiting|February 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL)        amyloidosis attending the Amyloidosis Research and Treatment Center (Fondazione IRCCS        Policlinico San Matteo)|February 2016|February 23, 2016|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02111538||46726|
NCT02111772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12673|Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic|Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic Host||University of Virginia|No|Recruiting|September 2013|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111772||46708|
NCT02112318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASAF20090610|CArdioversion of Short Duration Atrial Fibrillation|Study of ECG-derived Atrial Fibrillatory Rate for Prediction of the Outcome of Cardioversion of Short Duration Atrial Fibrillation|CASAF|Region Skane||Recruiting|January 2011|May 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with recent onset persistent atrial fibrillation admitted for cardioversion|March 2014|April 9, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02112318||46666|
NCT02102425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130076|Effects by Omission of Bandage Over Exit Site|Effects by Omission of Bandage Over Exit Site at Patients in Peritoneal Dialysis (PD).Randomized Controlled Cross-over Study|EXIT|Aalborg Universitetshospital|Yes|Recruiting|March 2014|November 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Probability Sample|Nurses in the PD clinic at Aalborg University Hospital might have observed that patients        without bandage do not get more infections around the exit site in relation to the        patients using bandage. However, the study should develop evidence guidelines.|January 2016|January 18, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02102425||47422|
NCT02102659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ-20130803|Biological Assessment of Clinical Nutrition and Its Application|This Preliminary Study Was Designed to Explore a New Biological Method for Nutritional Assessment by Measuring Oral Mucosal Epithelial Cell Apoptosis Rate and Guideline to Clinical Nutrition Support Therapy for Improving Clinical Outcome of Malnourished Patients.||Huazhong University of Science and Technology|Yes|Active, not recruiting|March 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|167|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||March 2014|April 2, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02102659||47404|
NCT02102945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP2|Special Imaging Technique to Aid in the Diagnosis of Patients in Coma After Cardiac Arrest|CT Perfusion in the Prognostication of Patients in Coma Following Cardiac Arrest- A Pilot Study||Nova Scotia Health Authority|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02102945||47382|
NCT02103179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k0113011-2013ECC|VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)|VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway|VEGF ECC|First Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|July 2006|September 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|Samples Without DNA|Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces      individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial.      Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.|Both|16 Years|80 Years|No|Non-Probability Sample|Extrahepatic cholangiocarcinoma patients underwent surgical therapy|March 2014|March 31, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103179||47364|
NCT02103192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1319|Nutrient-Fortified Beverage Study|||PepsiCo Global R&D||Completed|December 2013|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 31, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02103192||47363|
NCT02104154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T10-02|Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting|Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting||Samsung Electronics|No|Terminated|November 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|Retaining serum and plasma specimens|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinics|February 2015|February 18, 2015|December 13, 2013|Yes|Yes|To conduct interim analysis and assess whether assay changes are recommended.|No||https://clinicaltrials.gov/show/NCT02104154||47289|
NCT02104167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROIC100|Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating|An Open-Label Clinical Study of the Safety and Efficacy of the ROI-C Anterior Cervical Interbody Fusion Device Using the VerteBRIDGE Plating System||LDR Spine USA|No|Enrolling by invitation|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects will be drawn from community surgeon practices in which the subjects have already        received the device and who meet the Inclusion/Exclusion criteria|April 2014|April 3, 2014|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104167||47288|
NCT02104466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-12822|Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)|Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy|GATE-PDN|University of California, San Francisco|Yes|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104466||47266|
NCT02104752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-121701|Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia|Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia||VA Greater Los Angeles Healthcare System|No|Recruiting|July 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||July 2014|July 19, 2014|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104752||47244|
NCT02105038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026777|Effects of Upper Extremity Immobilization and Use of a Steering Wheel Spinner Knob Following Distal Radius Fracture|Effects of Upper Extremity Immobilization and Use of a Steering Wheel Spinner Knob Following Distal Radius Fracture||Greenville Health System|No|Completed|April 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|80 Years|No|||February 2016|February 10, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02105038||47222|
NCT02105064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0426|Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia|||Hospital de Clinicas de Porto Alegre|No|Completed|July 2011|February 2016|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|September 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02105064||47220|
NCT02109822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46256-EA|Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF|Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis|STOP-OB-13|University of Washington|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with Cystic Fibrosis who are hospitalized with a pulmonary exacerbation treated        with intravenous antibiotics.|August 2015|September 16, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02109822||46856|
NCT02109835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCRT/3277/PROCEED|Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects|Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects: Evaluation of the Role of CT Coronary Angiography and Novel Bio-markers of Endothelial Dysfunction and Vascular Inflammation|PROCEED|British Cardiac Research Trust|Yes|Recruiting|September 2012|July 2017|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Plasma and serum will be separated from the blood sample collected within half an hour.      These samples will be labelled with the unique random number assigned to each patient      recruited to the study. The link file with the random numbers and patient identifiers will      be kept on single computer with restricted access to only members of the research team. Only      the completely anonymised samples will be sent to the labs for analysis. 5 mls of whole      blood with cells will also be stored.|Both|35 Years|N/A|No|Non-Probability Sample|Patients with type 2 diabetes recruited from hospital clinics and one community faith        based cardiovascular disease prevention clinic run under the aegis of a lipidologist|May 2015|May 18, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02109835||46855|
NCT02110121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PICOREVLITE|Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos|Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos||Cynosure, Inc.|No|Active, not recruiting|February 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110121||46833|
NCT02110953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-063|Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver|Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease||Fox Chase Cancer Center|Yes|Recruiting|January 2016|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110953||46771|
NCT02110654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140329|Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery|Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery: a 9-month Randomized, Open-label, Controlled Study||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|June 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2014|April 8, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02110654||46794|
NCT02110667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-170|Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy|||University of Vermont Medical Center|Yes|Not yet recruiting|April 2014|||April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Male|18 Years|N/A|No|Non-Probability Sample|Fletcher Allen Health Care- Radiation Oncology Patient Prostate cancer w/ prostatectomy|April 2014|April 8, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02110667||46793|
NCT02110940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20140401001|The Effect of Neurodynamic Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.|The Effect of Neural Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.||The Hong Kong Polytechnic University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110940||46772|
NCT02111811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1132-R|Reducing the Burden of Depression Related Disability|Reducing the Burden of Depression on Employment: Improving Function and Work||VA Office of Research and Development|No|Recruiting|May 2014|November 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02111811||46705|
NCT02111798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034-047|Bupropion-Enhanced Contingency Management for Cocaine Dependence|Bupropion-Enhanced CM for Cocaine Dependence||Johns Hopkins University|Yes|Recruiting|July 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02111798||46706|
NCT02112591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-CNIC-2012-160|Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence|Efficacy and Safety of Transobturator Subtrigonal Tape vs Transobturator Tension-free Suburethral Tape for the Correction of Stress Urinary Incontinence|S-TOTvsTOT|Coordinación de Investigación en Salud, Mexico|No|Recruiting|July 2015|June 2017|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Female|21 Years|80 Years|No|||July 2015|July 29, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112591||46645|
NCT02112604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001919B|Predictors of Upper Airway Function and Sleep-disordered Breathing in the Critically Ill|Determining Predictors of Adequate Upper Airway Function in Ventilated Patients||Massachusetts General Hospital|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Ventilated patients in the surgical intensive unit (SICU)|March 2016|March 16, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02112604||46644|
NCT02108639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-110|To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet|An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction||Bristol-Myers Squibb|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|July 9, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108639||46947|
NCT02102438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 477|Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer|Neoadjuvant or Adjuvant Chemotherapy Without Anthracyclines for Elderly Patients Diagnosed With HER2 Positive Breast Cancer||Instituto do Cancer do Estado de São Paulo|No|Not yet recruiting|April 2014|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|65 Years|N/A|No|||April 2014|April 2, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102438||47421|
NCT02102672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-229|Trimetazidine in Pulmonary Artery Hypertension|Comprehensive Evaluation of Right Ventricular Function, Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension: Effects of a Fatty Acid Oxidation Inhibitor||Pontificia Universidad Catolica de Chile|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|75 Years|No|||March 2014|April 2, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102672||47403|
NCT02102958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR012513|Nonvisual Foot Examination for People With Diabetes and Visual Impairment|Nonvisual Foot Examination for People With Diabetes and Visual Impairment||Case Western Reserve University|Yes|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102958||47381|
NCT02102971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400182|Observational Study of Biomarker During Liver Surgery|Autophagy in Liver Injury: Changes in Autophagy Biomarkers During Liver Surgery||University of Florida|No|Recruiting|October 2014|December 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|liver tissues during liver surgery|Both|18 Years|70 Years|No|Probability Sample|Liver Disease Requring Liver Resection Surgery|November 2015|November 2, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102971||47380|
NCT02103205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIME2014|Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function|Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function|LIME|Umeå University|No|Recruiting|June 2014|December 2023|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|252|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103205||47362|
NCT02104492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMA_RMTP_2014/SM|Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis|Clinical Research on the Effect of a 12-week Respiratory Muscles Training Program in Persons With Relapsing-remitting Multiple Sclerosis||University of Malaga|Yes|Active, not recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02104492||47264|
NCT02104479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFU-ASP 2014|Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing|Open Multicenter Diagnostic Study on the Accuracy of Biomarker Testing (Galactomannan (GM), (1-3)-β-D-glucan (BDG), Aspergillus-specific Polymerase Chain Reaction (PCR) Assay) in Pleural Effusion Samples of Immunocompromised Patients With Suspected Invasive Pulmonary Aspergillosis (IPA)|EFFU-ASP|Heidelberg University|No|Enrolling by invitation|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|only fungal DNA is investigated, no human DNA|Both|18 Years|N/A|No|Probability Sample|- Immunocompomised Patients based on the following conditions: prolonged neutropenia > 10        d, patients after allogeneic stem cell transplantation or solid organ transplantation,        Patients wth acute leukemia in induction treatment, patients witrh        graft-versus-host-disease, patients under chronic immunusuppressive therapy such as        ciclosporin, patients with HIV, patients with chronic steroid treatment,|December 2015|December 8, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02104479||47265|
NCT02104778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj20140401|Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine|Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine in Ankle and Foot Surgery||Yeungnam University College of Medicine|Yes|Recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02104778||47242|
NCT02104765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15435|A Study of LY2951742 in Healthy Japanese and Caucasian Participants|A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects||Eli Lilly and Company|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|45|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|April 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02104765||47243|
NCT02105051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChNN-001|A Population-based Investigation of Related Factors of Birth Weight in China|||Chinese Neonatal Network|No|Recruiting||||April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|1 Day|No|Non-Probability Sample|We continuously collected the information of live births in participating hospitals of        Chinese neonatal network during the study period|April 2014|April 2, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105051||47221|
NCT02105415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000506|Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial|Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial|KEEP PACE|Mayo Clinic|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105415||47193|
NCT02110147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401.13.001|Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria|Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria||Wellstat Therapeutics|No|Active, not recruiting|April 2014|August 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Months|19 Years|No|||April 2015|February 11, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110147||46831|
NCT02110160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17113|18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer|18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|A total of up to 75 subjects, age 18 years, with a diagnosis or estrogen receptor positive        (ER+) breast cancer, with clinical evidence of bone dominant stage IV disease will be        enrolled in this study. This study will enroll both women and men but it is anticipate        that the majority of subjects will be women due to the small percentage of breast cancer        patients that are male.|December 2015|December 14, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110160||46830|
NCT02109848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00006820|Observational Study of Keratoconus and Post-keratoplasty Eyes|Observational Study of Keratoconus and Post-keratoplasty Eyes||Oregon Health and Science University|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Post Operative surgical patients at Oregon Health & Science University for keratoconus,        keratoplasty, DSAEK|April 2015|April 21, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02109848||46854|
NCT02111785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17294|Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma|The DECS Trial: DExamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma|DECS|University of Virginia|Yes|Recruiting|March 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111785||46707|
NCT02112110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-109|Absolute Bioavailability of BMS-791325|Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||April 2014|June 25, 2014|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02112110||46682|
NCT02111213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL116448|Virtual Advisors for Physical Activity Promotion in Underserved Communities|Virtual Advisors for Physical Activity Promotion in Underserved Communities|COMPASS2|Stanford University|No|Recruiting|June 2014|June 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|530|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02111213||46751|
NCT02111226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182-2013|Detecting and Treating High Blood Pressure in Aboriginal Population and Low and Middle Income Countries|DREAM-GLOBAL: Diagnosing hypeRtension - Engaging Action and Management in Getting LOwer Bp in Aboriginal and LMIC - A Research Proposal|DREAM-GLOBAL|Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2012|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|90 Years|No|||April 2014|April 8, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02111226||46750|
NCT02105220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001413|Chest Wall Influence on Respiratory System Mechanics in Morbidly Obese Patients|Chest Wall Influence on Respiratory System Mechanics in Morbidly Obese Patients||Massachusetts General Hospital|No|Completed|August 2013|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Probability Sample|We will enroll morbidly obese intubated patients and/or patients affected by        intraabdominal hypertension admitted to medical ICUs and surgical ICUs at Massachusetts        General Hospital. Patients with contraindication to esophageal balloon placement or with        severe respiratory failure will be excluded from the study.|March 2015|March 24, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02105220||47208|
NCT02112149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301011291|Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors|Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors||Yale University|Yes|Active, not recruiting|February 2013|December 2015|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||July 2015|July 14, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112149||46679|
NCT02112136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB14.017 GeneQuest|Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD|Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in Autosomal Dominant Polycystic Kidney Disease (ADPKD): The GeneQuest Study|GeneQuest|University Hospital, Brest|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1450|||Both|16 Years|N/A|No|||December 2015|December 15, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02112136||46680|
NCT02112357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3994|Feasibility of a Molecular Characterisation Approach to Treatment|FOrMAT - Feasibility of a Molecular Characterisation Approach to Treatment|FOrMAT|Royal Marsden NHS Foundation Trust|No|Recruiting|February 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Both fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) tumour samples will be      obtained.      Biopsies may be taken at entry to the study and/or at the time of radiological response      assessment. Each patient can have a maximum of 3 research biopsies in this study.      Up to 35 ml of blood will be collected at study entry to provide normal germline DNA and for      possible additional biomarker analysis. If the patient has consented to optional blood      sample collection, then additional blood samples will also be collected at the time of      radiological response assessment to study molecular changes that occur during treatment.|Both|18 Years|N/A|No|Probability Sample|Locally advanced or metastatic gastrointestinal cancer (including gastroesophageal,        pancreatic, biliary tract and colorectal cancer)|April 2014|April 16, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02112357||46663|
NCT02112630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL5200|Boceprevir in End Stage Renal Disease (ESRD)|Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic HCV With End Stage Renal Disease||Columbia University|No|Withdrawn|May 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|April 2, 2014|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT02112630||46642|
NCT02102685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACOTOL-012|Vacuum Assisted Closure in Neck Abscess|Vacuum Assisted Closure in Deep Neck Abscess||Instituto Mexicano del Seguro Social|Yes|Completed|September 2010|September 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 21, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02102685||47402|
NCT02102698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY302|Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years|Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years||Psyadon Pharma|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|17 Years|No|||October 2015|October 20, 2015|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102698||47401|
NCT02099708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|467-713|Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs|Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs||Takeda|No|Completed|October 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3502|||Both|N/A|N/A|No|Non-Probability Sample|Gastric or duodenal ulcers|September 2015|September 8, 2015|March 26, 2014||No||No|August 6, 2015|https://clinicaltrials.gov/show/NCT02099708||47631|
NCT02103478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTX727-01|Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS|A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)||Astex Pharmaceuticals|Yes|Recruiting|May 2014|February 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||December 2015|January 5, 2016|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103478||47341|
NCT02112786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIM-1|Neuromodulation Implantation Settings Variation for Overactive Bladder|Intermittent Versus Continuous Stimulation in Bilateral Sacral Neuromodulation for Overactive Bladder||Loma Linda University|Yes|Withdrawn|January 2015|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||January 2015|January 22, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112786||46630|
NCT02105077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014032273|Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans|Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans||Heinrich-Heine University, Duesseldorf|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Whole-blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing xenon-based general anesthesia as part of routine care at University        Hospital Düsseldorf, Germany|March 2015|March 30, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02105077||47219|
NCT02105090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005528-13|Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy|Comparison of Novel Articaine Lozenge Versus Placebo for Upper Gastrointestinal Endoscopy in Adults. A Randomized Double-blinded Controlled Study||Helsinki University Central Hospital|No|Recruiting|October 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|75 Years|No|||October 2014|October 8, 2014|March 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105090||47218|
NCT02109315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAB-01|Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.|Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.|DIAB-01|Fundacion Clinic per a la Recerca Biomédica|No|Not yet recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||April 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109315||46895|
NCT02110433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRD0414|Heart Failure Educational and Follow up Platform|Heart Failure Educational and Follow up Platform|HELP|Centre Hospitalier René Dubos|Yes|Active, not recruiting|December 2013|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|330|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110433||46811|
NCT02110420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90001-CP-001|First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001|A Phase 1, Randomized, Two-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 in Healthy Subjects||Celgene|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|14||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|February 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02110420||46812|
NCT02110979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-1036-015|Validation of a Patient Decision Aid for Type 2 Diabetes|Validation of a Patient Decision Aid for Type 2 Diabetes||EPI-Q|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02110979||46769|
NCT02111291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-034|Santyl Applications to Diabetic Foot Ulcers|Clinical Outcomes Associated With Enzymatic Debridement of Diabetic Foot Ulcers for Up To 12 Weeks With Clostridial Collagenase (Santyl®) Ointment||Healthpoint|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111291||46745|
NCT02112123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102012-052|Icariin to Prevent Corticosteroid-related Memory Changes|Icariin to Prevent Corticosteroid-related Memory Changes||University of Texas Southwestern Medical Center|Yes|Recruiting|April 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02112123||46681|
NCT02112331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01460-45|Influence of Physical Treatments of Human Milk on the Kinetics of Gastric Lipolysis in Preterm Newborns|Influence of Physical Treatments of Human Milk on the Kinetics of Gastric Lipolysis in Preterm Newborns|ARCHILACT|Rennes University Hospital|No|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Both|N/A|21 Days|No|||May 2015|May 26, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02112331||46665|
NCT02105233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1266|Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid|Brain Mimicking Fluid. Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid: a Preliminary Technical and Safety Study|BMF|St. Olavs Hospital|Yes|Recruiting|February 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02105233||47207|
NCT02105532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-09-CSU|Transfusion in Gastrointestinal Bleeding|A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding|TRIGGER|NHS Blood and Transplant|Yes|Completed|September 2012|August 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|936|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT02105532||47184|
NCT02112370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1403/242-006|Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy|Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy|REBT|Seoul National University Hospital|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02112370||46662|
NCT02112383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-KI-STUDENT|Group Versus Internet-based Cognitive Behavior Therapy for Procrastination|Group Versus Internet-based Cognitive Behavior Therapy for Procrastination||Stockholm University||Active, not recruiting|September 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02112383||46661|
NCT02108678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23MH097827-02|One-Day Intervention for Depression and Impairment in Migraine Patients|One-Day Intervention for Depression and Impairment in Migraine Patients|ACT|University of Iowa|No|Recruiting|September 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02108678||46944|
NCT02106117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AENEAS II|Exhaled Breath Analysis in the Early Detection of Aspergillosis|The Application of an Electronic Nose in the Early Detection of Aspergillosis II|AENEASII|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|December 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Throat Swabs for microbiome analysis Serum samples for Galactomannan detection.|Both|18 Years|N/A|No|Non-Probability Sample|All patients aged 18 or older, admitted at the hematology department of the AMC or UMCU,        that will undergo treatment for a hematological malignancy expected to result in prolonged        neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).|April 2015|April 1, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02106117||47139|
NCT02103218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MD002289-1|A Risky Sex Prevention Intervention for Middle School Age Minority Girls|A Risky Sex Prevention Intervention for Middle School Age Minority Girls|GEMM|University of North Carolina, Greensboro|Yes|Recruiting|November 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|215|||Female|11 Years|99 Years|No|||September 2015|September 29, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103218||47361|
NCT02103491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCJC-14|Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman|Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman|SALTED|Camilo Jose Cela University|Yes|Completed|June 2013|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02103491||47340|
NCT02103725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1092|A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis|A Phase I, Multi-Centre, Randomised, Vehicle-Controlled, Double-Blinded, Explorative Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis Over a Treatment Period of Three Weeks||LEO Pharma|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Both|18 Years|N/A|No|||December 2013|September 18, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02103725||47322|
NCT02103738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ACA06|Canadian Treat and Extend Analysis Trial With Ranibizumab|Canadian Treat and Extend Analysis Trial With Ranibizumab|CAN-TREAT|Novartis|No|Recruiting|May 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|580|||Both|50 Years|50 Years|No|Probability Sample|The study population will consist of male and female Canadian patients diagnosed with        visual impairment due to wAMD and for whom Ranibizumab has been prescribed as their        standard of care by the treating physician. Eligibility for Ranibizumab will be determined        by the study physician according to the current prescribing information. A total of 580        patients will be enrolled from approximately 20 to 25 centers.|November 2015|November 6, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02103738||47321|
NCT02109185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMT-12084|A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers|A Randomized, Double-Blind, Multiple-Dose Trial of Mometasone Nasal Spray, 50 μg (Mylan), Nasonex® Nasal Spray, 50 μg (MSD-US), Nasonex® Nasal Spray Suspension, 50 μg (MSD-EU) & Placebo for Treatment of the Signs & Symptoms of Seasonal Allergic Rhinitis in 1,520 Male & Female Volunteers||Mylan Pharmaceuticals|No|Completed|September 2013|November 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1307|||Both|12 Years|N/A|No|||April 2014|April 8, 2014|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02109185||46905|
NCT02099942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1058-001|Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device|Transluminal Aortic Balloon Valvuloplasty Registry (TAB-R)|TAB-R|InterValve, Inc.|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|103|||Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic - Patients at each enrolling clinic who are to be treated with the        InterValve V8 device for balloon aortic valvuloplasty (BAV) are eligible for enrollment.|February 2016|February 29, 2016|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02099942|6 Months|47613|
NCT02109068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012007780|Lifestyle, Exercise and Nutrition Study 1|Lifestyle, Exercise and Nutrition (LEAN) Study 1|LEAN|Yale University|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Female|18 Years|75 Years|No|||April 2014|April 8, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02109068||46914|
NCT02109328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-Aurora_INT01|Alisertib in Chemotherapy-pretreated Urothelial Cancer|A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Not yet recruiting|April 2014|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02109328||46894|
NCT02108821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13030081|Fecal Microbiota Transplantation in Pediatric Patients|A Study of Fecal Microbiota Transplantation in Pediatric Patients With Relapsed Inflammatory Bowel Disease.|FMT|University of Pittsburgh|Yes|Recruiting|September 2014|October 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|22 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02108821||46933|
NCT02109055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILATESCRM1|Application of Exercises Based on the Pilates in Coronary Artery Bypass Grafting|Application of Exercises Based on the Pilates Method on the Functional Capacity in Postoperative Surgery Coronery Artery Bypass Grafting: Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Recruiting|April 2014|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||April 2014|April 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02109055||46915|
NCT02109627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139510|Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML|Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML||University of California, San Francisco|Yes|Recruiting|January 2015|January 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02109627||46871|
NCT02110186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU—ORTHO—2012—001|Lumbar Intervertebral Disc Herniation|A Prospective, Comparative Study to Evaluate Effectiveness and Safety of Dynamic Stabilization in Treatment of Lumbar Disc Herniation|LIDH|Third Military Medical University|No|Recruiting|July 2012|June 2019|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|195|||Both|20 Years|60 Years|No|||April 2014|April 7, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02110186||46829|
NCT02111239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunnybrook106-2011|Preoperative Imaging in DIEP Flap Breast Reconstruction|Preoperative Imagining in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial Evaluating Cost and Patient-Reported Outcomes||Sunnybrook Health Sciences Centre|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 9, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02111239||46749|
NCT02111252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-850/CPH-001|A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects|An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects||Takeda|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|March 11, 2014||No||No|April 14, 2015|https://clinicaltrials.gov/show/NCT02111252||46748|
NCT02110680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENSOAB|Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms|Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms|TENSOAB|Meir Medical Center||Withdrawn|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02110680||46792|
NCT02111304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC Study (DDP CFT PO 202)|Efficacy of iOWH032 in Dehydrating Cholera|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Trial to Evaluate the Efficacy, Safety, and Tolerability of iOWH032 in the Treatment of Acute Dehydrating Diarrhea in Adult and Pediatric Patients With Cholera|POC|PATH|Yes|Withdrawn|June 2014|May 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|55 Years|No|||April 2014|September 24, 2014|April 1, 2014|Yes|Yes|Trial was never initiated due to PATH executive decision.|No||https://clinicaltrials.gov/show/NCT02111304||46744|
NCT02111317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK04|A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects|A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02111317||46743|
NCT02111265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHXJTUA01|THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients|The Comparison of Efficacy and Safety of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients ——A Randomized Controlled Trial.||Second Affiliated Hospital of Xi'an Jiaotong University|No|Not yet recruiting|April 2014|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|60 Years|75 Years|No|||April 2014|April 10, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111265||46747|
NCT02111278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00262|Lumbar Manipulation and Exercise for the Treatment of Acute Low Back Pain in Adolescents|Lumbar Manipulation and Exercise for the Treatment of Acute Low Back Pain in Adolescents: a Randomized Controlled Trial||Nationwide Children's Hospital|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|13 Years|17 Years|No|||December 2014|December 22, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02111278||46746|
NCT02105870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVH 001|A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function|A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function|Intracor|University of Melbourne|No|Active, not recruiting|February 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||April 2014|April 2, 2014|December 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02105870||47158|
NCT02105883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEB-2014|The Effect of Identification Badge on Situation Awareness During High Fidelity Simulation|The Effect of Identification Badge on Situation Awareness During High Fidelity Simulation||Université de Montréal|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|28|||Both|N/A|N/A||||December 2014|December 1, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02105883||47157|
NCT02105844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWISS-AF|Swiss Atrial Fibrillation Cohort Study|Swiss Atrial Fibrillation Cohort Study - SWISS AF|SWISS-AF|University Hospital, Basel, Switzerland|No|Recruiting|March 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2600|||Both|65 Years|N/A|No|Non-Probability Sample|Consecutive patients with atrial fibrillation|January 2016|January 19, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105844||47160|
NCT02105857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULausanneH|The Effects of End-of-range Grade A+ Mobilization Following Acute Primary TKA|The Effects of End-of-range Grade A+ Mobilization Following Acute Primary TKA||University of Lausanne Hospitals|No|Completed|March 2011|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02105857||47159|
NCT02106130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_MotiReb_1201|A Drug Interaction Study of Mosapride and Rebamipide|A Randomized, Open-label, Multiple Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Mosapride Citrate and Rebamipide After Oral Administration in Healthy Volunteers||IlDong Pharmaceutical Co Ltd|No|Completed|May 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|April 3, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02106130||47138|
NCT02108704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPPD|Helicobacter Pylori Eradication Study in Parkinson's Disease|Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial||University of Malaya|No|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02108704||46942|
NCT02108912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA CV study|Metabolic Costs of Walking Post Stroke|The Impact of Gait Training on the Metabolic Costs of Walking and Cardiorespiratory Capacity in Persons Post Stroke||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02108912||46926|
NCT02109432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-051|Short-term Behavior Change With Pedal Desk Installation|Short-term Behavior Change With Pedal Desk Installation|PD-ST|Pennington Biomedical Research Center|No|Terminated|May 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|March 12, 2014||No|Continued development of technology|No||https://clinicaltrials.gov/show/NCT02109432||46886|
NCT02109354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 097|Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults|Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa|HVTN 097|HIV Vaccine Trials Network|Yes|Active, not recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02109354||46892|
NCT02109640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005327-16|A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery|A Randomized Blinded Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function After Colorectal Surgery|TACS|University of Edinburgh|Yes|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02109640||46870|
NCT02109341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goirc 01-2013|Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer|Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer|NabucCO|Gruppo Oncologico Italiano di Ricerca Clinica|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02109341||46893|
NCT02109614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00-M105-13A|Early Aortic Valve Lipoprotein(a) Lowering Trial|A Pilot,Randomized Controlled-trial of Lipoprotein(a) Lowering for the Prevention of Aortic Valve Disease-translating Genomic Knowledge for Cardiovascular Prevention|EAVaLL|McGill University Health Center|No|Recruiting|May 2014|September 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|238|||Both|50 Years|85 Years|No|||April 2015|April 10, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02109614||46872|
NCT02109861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFE2011.06|Microdose Study of Melphalan, Bortezomib and Dexamethasone|Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma|Phase-0-MM|Aalborg Universitetshospital|Yes|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02109861||46853|
NCT02110966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIFE-008-014|Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis|Efficacy of the Combination Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: a Randomized Clinical Trial.||Universidad Autonoma de San Luis Potosí|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02110966||46770|
NCT02110225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF0113|A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)|A 24 Week Phase Ib/II, Multicenter, Randomized, Double-masked, Vehicle Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of Two Doses (60 and 180 µg/ml) of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Typical Retinitis Pigmentosa (RP)|Lumos|Dompé Farmaceutici S.p.A|Yes|Active, not recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02110225||46827|
NCT02110485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00335|Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)|Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis to Determine Choice Between Antibiotics Alone vs. Appendectomy|Appy-PAT|Nationwide Children's Hospital|No|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|7 Years|17 Years|No|||August 2015|August 14, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02110485||46807|
NCT02111525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-000030|Fluid Status of Outpatients With Dyspnea|Fluid Status of Outpatients With Dyspnea|FLOOD|Intersection Medical, Inc.|No|Completed|June 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|45 Years|N/A|No|Probability Sample|Patients who present with shortness of breath to an emergency department or urgent care        facility are possible candidates for the study and shall be screened for suitability based        on the inclusion and exclusion criteria.|October 2015|October 13, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02111525||46727|
NCT02104622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89259|Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation|Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation||Rehabilitation Institute of Chicago|Yes|Active, not recruiting|February 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|85 Years|No|||February 2016|February 12, 2016|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02104622||47254|
NCT02111551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0614|Phase I Nicotinic Agonist Treatment Trial for Autism|Phase I Nicotinic Agonist Treatment Trial for Autism||University of Colorado, Denver|Yes|Recruiting|June 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|50 Years|No|||December 2015|December 8, 2015|April 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02111551||46725|
NCT02128906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 13-056|Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design|A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design|(UPCI)13-056|University of Pittsburgh|Yes|Recruiting|December 2013|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|January 14, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128906||45394|
NCT02129439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB012/01/2013|Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients|SB012 for Treatment of Active Ulcerative Colitis: Prospective Single-centre Randomised Double-blind Placebo-controlled Phase IIa Clinical Trial to Evaluate Efficacy, Pharmacokinetics, Tolerability and Safety of SB012 Enema Administered OD|SECURE|Sterna Biologicals GmbH & Co. KG|Yes|Recruiting|April 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|75 Years|No|||April 2014|May 19, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129439||45353|
NCT02128919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309320|Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic|Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic|TDCSSCHIZ|Nathan Kline Institute for Psychiatric Research|No|Recruiting|April 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||April 2014|April 29, 2014|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02128919||45393|
NCT02129478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000040306|Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study|Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study||The Hospital for Sick Children||Active, not recruiting|March 2014|March 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|4 Years|18 Years|No|||January 2016|January 19, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129478||45350|
NCT02103257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV62|Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma|Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|March 2014|September 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|75 Years|No|||April 2015|April 27, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103257||47358|
NCT02103270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AADCRC-STAN-001|The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery|Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects|POISED|Stanford University|Yes|Recruiting|March 2014|June 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|8 Years|55 Years|No|||December 2015|December 7, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103270||47357|
NCT02099760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13100170|Cepheid Rectal Sample Validation Study|A Validation Study of the Cepheid Xpert CT/NG for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples||University of Pittsburgh|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|402|Samples Without DNA|Any leftover specimens including genital, rectal, pharyngeal, or urine may be retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects presenting for routine clinical care in an STD Clinic and/or subjects who are        aware of the study and meet the inclusion/exclusion criteria.|June 2015|June 17, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02099760||47627|
NCT02103790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01817-38|Installation of Non-invasive Ventilation at Home Using Telemedicine : a Pilot Study on Feasibility and Impact on Ventilation Compliance|Installation of Non-invasive Ventilation at Home Using Telemedicine : a Pilot Study on Feasibility and Impact on Ventilation Compliance|Tele-VAD|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103790||47317|
NCT02100592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERIGO-1|Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study|Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study||Ospedale Generale Di Zona Moriggia-Pelascini|No|Completed|October 2012|March 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100592||47563|
NCT02100605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_PhytosunDecon_Cardiff_UK|Study on Hypertonic Saline Nasal Spray|A Study to Assess the Speed of Relief From Nasal Congestion With a Hypertonic Saline Nasal Spray (Phytosun Decongestant)|PhytosunDecon|Omega Pharma|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02100605||47562|
NCT02100579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00088239|Ultrasound-guided Adductor Canal Block for Total Knee Replacement|Ultrasound-guided Adductor Canal Block for Total Knee Replacement: a Randomized, Double-blind Placebo Controlled Trial.||Northwestern University|No|Recruiting|March 2014|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|75 Years|No|||October 2015|October 1, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02100579||47564|
NCT02102048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPHID-UniRoma02|ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir|ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Boosted or Unboosted Atazanavir|ATAGLU|University of Roma La Sapienza|Yes|Active, not recruiting|January 2009|July 2014|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02102048||47451|
NCT02101151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDIS|Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)|Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)|VDIS|Rashid Centre for Diabetes and Research|Yes|Completed|June 2012|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|30 Years|60 Years|No|||March 2014|March 29, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02101151||47520|
NCT02118649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-10788|Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game|||Yale University|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02118649||46180|
NCT02118935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6023|Nutritive Effects of Prebiotics on Early Postnatal Behavioral Measures of Tolerance|Nutritive Effects of Prebiotics on Early Postnatal Behavioral Measures of Tolerance||Mead Johnson Nutrition|No|Active, not recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|153|||Both|N/A|35 Days|Accepts Healthy Volunteers|||February 2016|February 10, 2016|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02118935||46158|
NCT02119169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mohamed Sharaf-Eldin|Pigtail Catheter: a Less Invasive Option for Pleural Drainage of Recurrent Hepatic Hydrothorax|Pigtail Catheter: a Less Invasive Option for Pleural Drainage of Recurrent Hepatic Hydrothorax|HH|Tanta University|Yes|Recruiting|March 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 25, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119169||46140|
NCT02127593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104172|A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities||Janssen Research & Development, LLC|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127593||45495|
NCT02119416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DA030386|Gender Difference in Response to Caffeine in Children and Adolescents|Sex and Pubertal Stage Differences in Cardiovascular Responses to Caffeine in Children||State University of New York at Buffalo|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|101|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119416||46121|
NCT02119429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17411a|Pumpkin Seed Oil Supplementation in Premenopausal Women|The Effect of Pumpkin Seed Oil Supplementation on Blood Pressure in Premenopausal Women||Texas Woman's University|Yes|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|June 17, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02119429||46120|
NCT02119637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140100|Effects of Transcranial Magnetic Stimulation (TMS) on Somatosensory Perception|Effects of Transcranial Magnetic Stimulation (TMS) on Somatosensory Perception||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 5, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119637||46104|
NCT02119858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14015|Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery|A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer||City of Hope Medical Center|Yes|Active, not recruiting|July 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|80 Years|No|||January 2016|January 25, 2016|April 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02119858||46087|
NCT02128659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13559|Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention|Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention|SHE Project|University of Kansas Medical Center|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 10, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128659||45413|
NCT02128893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0054|A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole|A Phase 1 Randomized Open Label, Parallel Group Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole||Astellas Pharma Inc|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|April 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02128893||45395|
NCT02128932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3625|Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes|SUSTAIN™ 4|Novo Nordisk A/S|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1089|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128932||45392|
NCT02128945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002796-18|Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies|Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies|FLUDATEP|University Hospital, Caen|Yes|Recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02128945||45391|
NCT02129205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7501001|A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06650808 In Patients With Advanced Solid Tumors||Pfizer|No|Recruiting|June 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02129205||45371|
NCT02125539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMJ 2R44DA026645-02A1|Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment|Navigating My Journey (NmJ): A Relapse Prevention Program for Adolescents -- Field Trial||Inflexxion, Inc.|Yes|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|13 Years|21 Years|No|||June 2015|July 24, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02125539||45653|
NCT02103803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009632|Assessing Eye Tracking Features Following Sports-Related Concussion|Assessing Eye Tracking Features Following Sports-Related Concussion||Mayo Clinic|No|Completed|February 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|8 Years|N/A|No|Non-Probability Sample|Twenty subjects with diagnosed concussion will be recruited from the adolescent and adult        population seen in the Comprehensive Concussion Program at Mayo Clinic Arizona.|November 2015|November 11, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02103803||47316|
NCT02103816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-PRECIS-ACNE-BD|The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars|The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars||Cynosure, Inc.|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103816||47315|
NCT02100020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSProject2001|Implementing Physical Activity Guidelines for Adults With MS|A Community-based Randomized Controlled Trial Testing Implementation of the New Canadian Physical Activity Guidelines for Adults With Multiple Sclerosis.||McMaster University|No|Not yet recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Both|18 Years|60 Years|No|||March 2014|March 26, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100020||47607|
NCT02100267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1001|A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Primary Purpose: Diagnostic|2||||||Both|20 Years|64 Years||||March 2014|November 13, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100267||47588|
NCT02099981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 22503|Restoration of Retinal Vascular Responses in Diabetic Patients|Restoration of Retinal Vascular Responses in Diabetic Patients||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with type 1 diabetes between the ages of 18 and 65 will be recruited for        particiation.|January 2016|January 12, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099981||47610|
NCT02099994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-CORE 004/IAVI N004|Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults|A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.|HIV-CORE 004|University of Oxford|Yes|Active, not recruiting|March 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099994||47609|
NCT02101450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAYA-2013-1|Extra-abdominal Removal of Placenta During CS|Evaluation of the Effects of Extra-abdominal Removal of the Placenta During Cesarean Section on the Amount of Bleeding Into the Abdominal Cavity.||Near East University, Turkey|Yes|Completed|March 2014|December 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|March 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02101450||47497|
NCT02100891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIR Trial|Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors|Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial|STIR|Medical College of Wisconsin|Yes|Recruiting|March 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||February 2016|February 25, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100891||47540|
NCT02101164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120127|Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease|An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada||Amgen|No|Withdrawn|November 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||January 2015|February 16, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02101164||47519|
NCT02102061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Health and Wellness in Obesity|Health and Wellness in Obesity|Health and Wellness in Obesity: Exploring the Efficacy of a New Multidisciplinary Intervention||University of Sao Paulo|No|Recruiting|January 2013|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2014|April 1, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02102061||47450|
NCT02102074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036|Intra-peritoneal Environmental Changes Following Surgery|Intra-peritoneal Environmental Changes Following Colorectal Surgery for Cancer|CRC|Meir Medical Center|Yes|Recruiting|May 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Fluids from abdomen drain system|Both|18 Years|N/A|No|Probability Sample|colon and rectal cancer patients|February 2013|December 9, 2014|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02102074||47449|
NCT02101437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-I021003|The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment|||Taipei City Hospital|Yes|Recruiting|January 2014|May 2016|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|miRNA in platelet(Platelet Rich Plasma)|Both|18 Years|90 Years|No|Probability Sample|stable angina who received routine dual antiplatelet agents therapy.|November 2015|November 3, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101437||47498|
NCT02127086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00053272|Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients|Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients||University of Maryland|Yes|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127086||45534|
NCT02127320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROZE-101|Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Not yet recruiting|June 2014|November 2014|Anticipated|September 2014|Anticipated|Phase 1|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||6|Anticipated|24|||Male|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteer|April 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127320||45516|
NCT02127333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD_pO2|Role of Oxygen for Vascular Dysfunction|Role of Acute and Chronic Hypoxemia for Vascular Function||Heinrich-Heine University, Duesseldorf|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|38|||Male|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|CAD patients with or without COPD; healthy volunteers|December 2014|December 14, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127333||45515|
NCT02127606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-811-14|The Effect of Whole Body Vibration on Spasticity in Persons With Spinal Cord Injury|The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients||Kessler Foundation|No|Recruiting|April 2014|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||November 2014|November 25, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02127606||45494|
NCT02127619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602-ROCC|Total Knee Replacement With the ROCC Knee|Prospective Study of Total Knee Replacement With the ROCC Knee||Bercovy, Michel, M.D.|Yes|Completed|January 2001|March 2014|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|42 Years|90 Years|No|||April 2014|April 28, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02127619||45493|
NCT02127892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-06-00243|SCID Bu/Flu/ATG Study With T Cell Depletion|Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor||Children's Hospital Los Angeles|Yes|Enrolling by invitation|July 2011|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|15|||Both|N/A|21 Years|No|||September 2015|January 29, 2016|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127892||45472|
NCT02128139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoDev|Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study|Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study|EndoDev|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|1 Year|N/A|No|Non-Probability Sample|Hospital-based population.|April 2014|April 30, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02128139||45453|
NCT02128386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/328/13|Medication Adherence and "True" Resistance in Patients With Resistant Hypertension|A Study on Medication Adherence and "True" Resistance in Patients Referred to a Medical Outpatient Department in Germany With the Diagnosis "Resistant Hypertension".||Charite University, Berlin, Germany|No|Recruiting|February 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Blood samples for therapeutic drug monitoring|Both|18 Years|N/A|No|Probability Sample|Adult male or female patients referred to the Medical Outpatient Department of the Charité        - Universitätsmedizin Berlin with the diagnosis "Resistant hypertension".|February 2015|February 20, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128386||45434|
NCT02128399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDRO|Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients|||Southeast University, China||Completed|June 2012|December 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|978|||Both|N/A|N/A|No|Probability Sample|patients who admitted into intensive care unit|July 2012|April 29, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02128399||45433|
NCT02128672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003985|Spinal Stimulation to Treat Low Back Pain|Extraforaminal Spinal Stimulation Compared to Conventional Spinal Cord Stimulation to Treat Axial Low Back Pain-A Pilot Study||Mayo Clinic|No|Withdrawn|July 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 18, 2014|Yes|Yes|stopped because of competing studies|No||https://clinicaltrials.gov/show/NCT02128672||45412|
NCT02129491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NENPSHR|National Egyptian Network Pediatric Stroke and Hemiplegia Registry|National Egyptian Network Pediatric Stroke and Hemiplegia Registry||Ain Shams University|Yes|Recruiting|January 2014|December 2021|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|18 Years|No|Non-Probability Sample|All children from birth to 18 years of age with acute stroke presented by focal        neurological signs confirmed by neuroradiology CT or MRI. All children with hemiplegia        till the age of 18 years.|May 2014|May 1, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02129491|10 Years|45349|
NCT02129504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCM|Two Techniques for Root Coverage With a Xenogeneic Collagen Matrix|Comparison of Two Surgical Techniques to Optimize the Treatment of Gingival Recessions Using a Gingival Graft Substitute.||University of Sao Paulo|Yes|Completed|September 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129504||45348|
NCT02125773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 599|Pre-exposure Prophylaxis Accessibility Research and Evaluation 2|CCTG 599: Pre-exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE) 2|CCTG 599|California Collaborative Treatment Group|No|Recruiting|April 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125773||45635|
NCT02099773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56517|Support Staff-client Interactions With Augmentative and Alternative Communication|Support Staff's Interactions With Adults With Intellectual Disability Who Use Augmentative and Alternative Communication||Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|January 2015|September 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Support workers who work in residential facilities or day-centres for adults with        intellectual disability, in Flanders.|March 2014|April 13, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02099773||47626|
NCT02100007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-344-002|ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors|A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors||MEI Pharma, Inc.|No|Active, not recruiting|April 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||August 2015|March 14, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100007||47608|
NCT02100904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13325|Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry|Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry|ULTRA Registry|University of California, San Francisco||Recruiting|May 2014|||June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with uterine fibroids who are planning to undergo or have undergone radiofrenquency        ablation (Acessa) treatment.|December 2015|December 1, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100904||47539|
NCT02100280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-NMB|The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy|A Double-blinded, Randomized, Parallel Design Study to Compare the Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy|suga-SH|Seoul National University Bundang Hospital|Yes|Enrolling by invitation|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|96|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02100280||47587|
NCT02101463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 997|MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts|Surgeon-Modified Fenestrated/Branched Stent-Grafts for Treatment of Complex Aortic Aneurysms in High-Risk Patients|MOSTEGRA|Northside Hospital, Inc.|Yes|Recruiting|March 2012|December 2022|Anticipated|March 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|March 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101463||47496|
NCT02101749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elderly Flu vaccine|Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.|Comparative Immune Response of Intradermal and Intramuscular Preparations of||Mahidol University|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|221|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|December 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02101749||47474|
NCT02131844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC Study Code 13-329-SDR|Early Mobilization After Colorectal Surgery|Facilitation of Early Mobilization After Colorectal Surgery: A Randomized Controlled Trial||McGill University Health Center|No|Active, not recruiting|August 2014|May 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131844||45169|
NCT02102321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW0001|Does Treating Hookworm Improve Productivity of Small Subsistence Farmers|A Randomized Effectiveness Trial of Hookworm Treatment of Women Smallholder Farmers to Evaluate Improved Productivity of Their Farming and/or Household Labor||Salmon, Margaret, M.D.|No|Recruiting|March 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Female|17 Years|50 Years|No|||March 2014|April 1, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02102321||47430|
NCT02127099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017.8|The Incidence of Undiagnosed OSA Compared in Multi-ethic Races of Malaysia & the Associated Postoperative Complications|The Incidence of Undiagnosed OSA in Multi-ethic Races of Malaysia and the Associated Postoperative Complications||University of Malaya|Yes|Not yet recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients over age 18 undergoing non-cardiac surgery|May 2014|May 6, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02127099||45533|
NCT02127346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-04-2014|Relationship Between Chronic Periodontitis and Vitamin D and Calcium in Men|Relationship Between Chronic Periodontitis and Vitamin D and Calcium in Men||Damascus University|Yes|Completed|May 2014|October 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|||Male|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are referred to the Periodontics Department at University of Damascus Dental        School (Damascus, Syria) will be recruited in this research project. Healthy volunteers        will be invited to participate in this research.|October 2015|October 2, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02127346||45514|
NCT02127359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-078|Whole-Exome Sequencing (WES) of Cancer Patients|CanSeq: Whole-Exome Sequencing (WES) of Cancer Patients||Dana-Farber Cancer Institute|No|Recruiting|September 2012|August 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Dana-Farber Cancer Institute patients who are identified as oncology patients or patients        suspected to have an eligible cancer diagnosis as defined by their providers.|February 2015|February 9, 2015|February 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02127359|99 Years|45513|
NCT02127632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|533-GOA|Comparison of Laryngeal Mask Airway Supreme and Endotracheal Tube In Patients Undergoing Gynecological Laparoscopy Surgery|Comparison of Laryngeal Mask Airway Supreme and Endotracheal Tube In Patients Undergoing Gynecological Laparoscopy Surgery||Dokuz Eylul University|No|Completed|April 2012|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|100|||Female|18 Years|65 Years|No|||April 2014|April 30, 2014|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02127632||45492|
NCT02127905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-10-00176|Unrelated HSCT in Patients With Fanconi Anemia|A Study of Total Body Irradiation, Cyclophosphamide and Fludarabine Followed by Alternated Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia||Children's Hospital Los Angeles|Yes|Enrolling by invitation|March 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|8 Weeks|21 Years|No|||July 2015|July 27, 2015|October 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127905||45471|
NCT02128152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00089523|Mobility Training Using Exoskeletons for Functional Recovery After Stroke|Effect of Mobility Training Using Robotic Exoskeletons on Functional Recovery in Individuals With Severe Stroke||Rehabilitation Institute of Chicago|Yes|Recruiting|February 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||December 2015|December 29, 2015|February 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128152||45452|
NCT02128165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Air gastric balloon|Effect of Gastric Balloon in Morbid Obesity: Prospective Study|Effect of Gastric Balloon in Morbid Obesity: Prospective Study||Mansoura University|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02128165||45451|
NCT02128412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/167|IVUS Controlled Stenting|Expansion of Intracoronary Stents by Low Pressure Oversizing Versus High Pressure Inflation: A Randomised Intracoronary Ultrasound Controlled Study||Sydney South West Area Health Service|No|Recruiting|February 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||November 2015|November 19, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02128412||45432|
NCT02128685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-292|Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage|A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester||The University of Hong Kong||Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|40 Years|No|||November 2015|November 21, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128685||45411|
NCT02128958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF102-201HCC|Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)|A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis||Can-Fite BioPharma|No|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|April 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128958||45390|
NCT02129192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348.4|Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use|Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Amlodipine 5 mg Capsule in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study), With Influence of Food on the Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet||Boehringer Ingelheim||Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|April 30, 2014||||No||https://clinicaltrials.gov/show/NCT02129192||45372|
NCT02125552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010758|Ultrasound Guided IV Access in a Pediatric Emergency Department|A Randomized Control Trial of Ultrasound Guided IV Access in the Pediatric Emergency Department|USgIV|Children's Hospital of Philadelphia|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|N/A|18 Years|No|||November 2015|November 23, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125552||45652|
NCT02125565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liodcaine_ABG_RCT_2011|Radial ABG Sampling: A RCT of Lidocaine Local Anaesthesia|Radial Artery Blood Gas Sampling: A Randomised Controlled Trial of Lidocaine Local Anaesthesia||James Paget University Hospital NHS Foundation Trust|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125565||45651|
NCT02125578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105HV102|A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers||Biogen||Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125578||45650|
NCT02100618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200255|Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study|Evaluation of Antibody Persistence for GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study||GlaxoSmithKline||Withdrawn|January 2015|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|15 Years|32 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|March 27, 2014|Yes|Yes|Due to late study start, the possibility to enroll enough subjects dropped below the limit to    provide scientifically acceptable data, hence study was cancelled.|No||https://clinicaltrials.gov/show/NCT02100618||47561|
NCT02100631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-VC-200-005|A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults|A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR||PaxVax, Inc.|No|Completed|May 2014|June 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|398|||Both|46 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100631||47560|
NCT02100917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMB-3111-2|Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults|||Meiji Seika Pharma Co., Ltd.|No|Completed|January 2014|December 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|70|||Male|20 Years|39 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100917||47538|
NCT02101203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB90a extension|Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder|A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms||Emotional Brain NY Inc.|No|Completed|July 2013|October 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 23, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101203||47516|
NCT02101216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIX-14-03|Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers|A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol™) and Oral Abacavir Sulfate (Ziagen®) in Healthy Volunteers||Cellceutix Corporation|Yes|Completed|March 2014|October 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101216||47515|
NCT02131285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG_Falls_01|Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis|Stabilometric Assessment of Context Dependent Balance Recovery in Persons With Multiple Sclerosis: a Randomized Controlled Study||Fondazione Don Carlo Gnocchi Onlus||Completed|January 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02131285||45212|
NCT02101762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MII-001|Study to Compare CAUTI Rates Following ERASE CAUTI Tray Non-Silver vs Silver Coated Foley Catheters|A Clinical Study to Compare the CAUTI Rates Following ERASE CAUTI Tray Non-Silver Coated Foley Catheters Verse Silver Coated Foley Catheters||Medline Industries|No|Not yet recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Subjects requiring urinary Foley catheters.|March 2014|March 27, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT02101762||47473|
NCT02101775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00620|Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers||National Cancer Institute (NCI)|Yes|Recruiting|July 2014|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101775||47472|
NCT02131298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481016|Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib|A Phase 1, Open-Label, Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Itraconazole On The Single Dose Pharmacokinetics of Palbociclib (PD-0332991) In Healthy Volunteers||Pfizer|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|May 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131298||45211|
NCT02102334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMVL|Validity, Reliability and Reproducibility of Plain Radiographic Measurements After Total Hip Arthroplasty|Validity, Reliability and Reproducibility of Plain Radiographic Measurements After Total Hip Arthroplasty||Sundsvall Hospital|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|N/A|N/A|No|Probability Sample|90 consecutive patients with primary unilateral osteoarthritis (OA) who underwent THA        between September 2010 and June 2012 were recruited into the study.|March 2014|March 29, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02102334||47429|
NCT02127112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0265|Ridge Augmentation Comparing a Block Allograft to a Demineralized Bone Matrix Allograft.|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Plus Optecure Containing Cortico-Cancellous Chips Versus Optecure Containing Cortico-Cancellous Chips Alone.||University of Louisville|Yes|Recruiting|May 2014|May 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127112||45532|
NCT02127372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008205|Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571|A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer||Duke University|No|Terminated|November 2004|December 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|April 24, 2014|Yes|Yes|The study was closed due to poor accrual|No|September 5, 2014|https://clinicaltrials.gov/show/NCT02127372||45512|
NCT02127385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001-14|The Type of Hepatoglobin in IUGR|The Type of Hepatoglobin in IUGR||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2014|||April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|None Retained|Blood test for H-p genotype|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients adimitted with IUGR|March 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127385||45511|
NCT02128191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-129|No Treatment Versus Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants|Efficacy and Safety of No Treatment Compared With Ibuprofen Treatment for Patent Ductus Arteriosus in Extremely Low Gestational Newborns: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial||Samsung Medical Center|Yes|Recruiting|July 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|N/A|14 Days|No|||June 2015|June 19, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02128191||45449|
NCT02127918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-P00003255|Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment|Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment|ESES-Clobazam|Children's Hospital Boston|Yes|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|2 Years|21 Years|No|Non-Probability Sample|Investigators will enroll patients with ESES studied at our centers and treated with        high-dose clobazam treatment as decided by the clinical epileptologist. Patients with ESES        are monitored once or twice a year in the long-term electroencephalogram monitoring unit        to assess epileptiform activity. Patients with very active discharges and        neuropsychological regression require a change in their treatment regimen. If the treating        epileptologist decides that high-dose cloblazam treatment is indicated for clinical        reasons, then the patient will be offered to participate in the study. The research team        will not be responsible for or influence the treatment decisions in any way.|July 2015|July 28, 2015|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127918|3 Months|45470|
NCT02127931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01711372B|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults||CogCubed, Corp|No|Active, not recruiting|March 2014|||February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127931||45469|
NCT02128178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enoxaparin|Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study|Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study||Mansoura University|Yes|Recruiting|November 2013|May 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02128178||45450|
NCT02128425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU06|FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer|Phase II Randomized Controlled Trial of FOLFOXIRI Compared to FOLFOX in First Line Treatment of Chemo-naive Metastatic Colorectal Cancer||Sun Yat-sen University|No|Recruiting|April 2014|April 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|75 Years|No|||April 2014|May 6, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02128425||45431|
NCT02128971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-FEB-INDO-2013-01|A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo|A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo||Albion|No|Recruiting|April 2014|August 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|108|||Female|18 Years|50 Years|No|||May 2014|May 5, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02128971||45389|
NCT02129218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7213|Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer|A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer||Case Comprehensive Cancer Center|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02129218||45370|
NCT02129530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2062|Effect of Community Social Mobilization for the Prevention of HIV in Young South African Women|Effect of Community Social Mobilization for the Prevention of HIV in Young South African Women||University of North Carolina, Chapel Hill|No|Completed|March 2012|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2502|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129530||45346|
NCT02129543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080899|Immune Reconstitution in Stem Cell Transplant Recipients|Collection of Peripheral Blood Samples From Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution||University of Miami|No|Recruiting|August 2011|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood Samples Marrow Samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include subjects selected from all patients presenting to the        clinical services of the Adult Cell Transplant Program as donors or recipients for SCT. As        a result, this group will consist of a diverse assortment including subjects ranging in        age from late adolescence to approximately age 75; individuals of both sexes; and a wide        variety of ethnic backgrounds. All donors will have been cleared for clinical marrow or        peripheral blood stem cell donation, and will be expected to be generally healthy.|June 2015|June 22, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129543||45345|
NCT02129556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 45-13/BIG 4-13|Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer|A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers|PANACEA|International Breast Cancer Study Group|Yes|Recruiting|December 2014|December 2023|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02129556||45344|
NCT02120911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCMEDONC 2013-377|Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma|Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study|TRAP|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120911||46006|
NCT02100657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-A-012-13|Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma|Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma||PharmaMar|No|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02100657||47558|
NCT02100930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-260|Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma|Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|March 2014|||March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|N/A|N/A|No|||January 2016|January 5, 2016|March 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02100930||47537|
NCT02101229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01657-38|Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital|Diabeloop WP6-1 : Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital|WP6-1|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|17|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02101229||47514|
NCT02131610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01475421|Epigenetics Modifications in Obstructive Sleep Apnea|Epigenetics Modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA Study|EPIOSA|Aragon Institute of Health Sciences|No|Recruiting|March 2013|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|350|Samples Without DNA|serum and plasma samples.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that will be study because suspected OSA|April 2014|May 4, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02131610|5 Years|45187|
NCT02127398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053348|Stool Transplants to Treat Refractory Clostridium Difficile Colitis|Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis||Duke University|No|Not yet recruiting|August 2014|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|April 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127398||45510|
NCT02127645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAES-4|Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer|PILOT OBSERVATIONAL STUDY OF NEOADJUVANT 5 x 5 RADIOTHERAPY FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY FOR T1-T2 EXTRAPERITONEAL RECTAL CANCER WITH CURATIVE INTENT|NERATEM|European Association for Endoscopic Surgery|Yes|Active, not recruiting|June 2011|May 2017|Anticipated|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|90 Years|No|||January 2016|January 20, 2016|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02127645||45491|
NCT02127944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS1|Assessment of Ovarian Reserve Tests in Unexplained Infertile Women|Assessment of Ovarian Reserve Tests in Unexplained Infertile Women||Karadeniz Technical University|No|Recruiting|April 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|SERUM SAMPLES OF PATIENTS WILL BE STORED .THE SERUM SAMPLES DO NOT CONTAIN DNA.|Female|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALL STUDY PARTICIPANTS SHOULD BE LESS THAN 35 YEARS OLD, MARRIED , SHOULD HAVE REGULAR        MENSES AND SHOULD HAVE AT LEAST A YEAR OF UNPROTECTED SEX.|April 2014|April 28, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02127944||45468|
NCT02128451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1350/14|The Value of Adding Either Meperdine or Fentanyl to Clonidine-bupivacaine|The Value of Adding Either Meperdine or Fentanyl to Clonidine-bupivacaine Mixture in Patients With Lower Limb Orthopedic Surgery Using Combined Spinal Epidural Anesthesia||Tanta University|Yes|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|90|||Both|18 Years|60 Years|No|||April 2015|April 5, 2015|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02128451||45429|
NCT02128438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mohanty0202|Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study|Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study||Swami Vivekanand National Institute of Rehabilitation Training and Research|No|Completed|February 2007|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|940|||Both|30 Years|60 Years|No|Non-Probability Sample|Persons with low back pain who had attended our hospital and sub centres with a complaint        of low back pain|April 2014|April 29, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02128438||45430|
NCT02128698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM_Minigrad_CH|Physical Activity and Protein Supplementation After Bariatric Surgery (PAPAB)|Physical Activity and Protein Supplementation After Bariatric Surgery|PAPAB|University of Hohenheim|No|Active, not recruiting|March 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|50|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128698||45410|
NCT02129231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAT/DPN_2014|Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy|Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial||University of Guadalajara|Yes|Completed|February 2012|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129231||45369|
NCT02129517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Z14|Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials|Oncology Nurse IMPACT: Improving Communication With Patients About Clinical Trials||Case Comprehensive Cancer Center|No|Recruiting|November 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1262|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129517||45347|
NCT02120677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00077461|Topical Itraconazole in the Treatment of Basal Cell Carcinoma|A Pilot Study Investigating Antitumorigenic Potential of Topical Itraconazole in the Treatment of Basal Cell Carcinoma||Johns Hopkins University|Yes|Recruiting|May 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|100 Years|No|||December 2015|December 3, 2015|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120677||46024|
NCT02120690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS-FMA|Trigeminal Nerve Stimulation (TNS) in the Treatment of Fibromyalgia|Trigeminal Nerve Stimulation (TNS) as a Complementary Strategy in the Treatment of Fibromyalgia, Open Label Study|TNS-FMA|Santa Casa Medical School|No|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|69 Years|No|||April 2014|April 22, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02120690||46023|
NCT02117154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 988.5|Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control|Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control in Malaysian Type 2 Diabetes Mellitus Patients||University of Malaya|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited from Diabetes Clinic, University of Malaya Medical Center|October 2014|October 20, 2014|April 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02117154||46294|
NCT02100670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202179|A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain|A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain||GlaxoSmithKline|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|385|||Both|16 Years|65 Years|No|||April 2015|April 9, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100670||47557|
NCT02130544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403039RIND|Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection|Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection||National Taiwan University Hospital|No|Recruiting|November 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|20 Years|N/A|No|Non-Probability Sample|Selected patients are from the hospital patients who are arranged to have video-assisted        thoracoscopic surgery for lobectomy or wedge resection|December 2014|December 3, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130544||45268|
NCT02130986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01GM101197|Procalcitonin Antibiotic Consensus Trial (ProACT)|Procalcitonin Antibiotic Consensus Trial (ProACT)|ProACT|University of Pittsburgh|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1514|||Both|18 Years|N/A|No|||May 2015|October 30, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130986||45234|
NCT02130752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGCT-01|Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery|Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery: a Multicenter Randomized Controlled Trial|CGCT-01|West China Hospital|No|Not yet recruiting|October 2014|October 2019|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|430|||Both|18 Years|75 Years|No|||September 2014|September 5, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02130752||45252|
NCT02130765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-0005|Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia|Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) - G130132|STAR-VT|St. Jude Medical|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1453|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130765||45251|
NCT02130778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCZagreb|Natriuretic Effect of GLP-1in Healthy Non Obese Subjects|Natriuretic Effect of GLP-1 in Healthy Non Obese Subjects Followed by Oral Sodium Load: A Randomized, Placebo-controlled, Cross-over Study||Clinical Hospital Centre Zagreb|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02130778||45250|
NCT02130999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-4101|Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)|A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)||Vanda Pharmaceuticals|No|Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|July 28, 2014|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130999||45233|
NCT02131623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM1038|Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease|Validation of the ItchRO Diaries in Pediatric Cholestatic Liver Disease||Shire|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|5 Years|N/A|No|Non-Probability Sample|Subjects (children) with ALGS or PFIC and/or caregivers of subjects with ALGS or PFIC|June 2015|June 10, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131623||45186|
NCT02131636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-004|Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea|||Allergan|No|Completed|May 2014|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|May 5, 2014|Yes|Yes||No|December 29, 2015|https://clinicaltrials.gov/show/NCT02131636||45185|
NCT02127658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R24HS022434-01, 1305011439|Abscess Surgery With and Without Decolonization in Pediatric MRSA Patients|Abscess Surgery With and Without Decolonization in Pediatric MRSA Patients||Indiana University|Yes|Not yet recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|108|||Both|3 Years|64 Years|No|||November 2015|November 5, 2015|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127658||45490|
NCT02127957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKEX_12.356|Effects of an Exercise Program Among CF Patients With Dysglycemia|Effects of a Program of Aerobic and Resistance Exercises Combined in Patients With Cystic Fibrosis (CF) With Impaired Glucose Tolerance or Diabetes Related to CF Without Medication|FKEX|Institut de Recherches Cliniques de Montreal|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02127957||45467|
NCT02128204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCT-YDL|The Safety and Efficacy of Using HYADERMIS LA for Wrinkle Correction|The Safety and Efficacy of Using HYADERMIS LA for Wrinkle Correction||SciVision Biotech Inc.|Yes|Completed|April 2014|January 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02128204||45448|
NCT02127970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-303|Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections||Durata Therapeutics Inc., an affiliate of Allergan plc|Yes|Completed|April 2014|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|85 Years|No|||August 2015|August 5, 2015|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127970||45466|
NCT02128217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5327|Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection|Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)|SWIFT-C|AIDS Clinical Trials Group|Yes|Recruiting|April 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128217||45447|
NCT02128711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404M49426|Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens|Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Explanted lung specimens from cystic fibrosis patients. This tissue, that would otherwise be      discarded, is being retained for microbiological analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will include those undergoing single or double lung transplantation as part of        their normally scheduled therapy for cystic fibrosis disease.|December 2015|December 1, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02128711||45409|
NCT02128984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-2572-011|Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children|Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children|VITJUNIOR|Laboratorios Ordesa|Yes|Completed|January 2012|May 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|1 Year|N/A|No|||March 2016|March 7, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02128984||45388|
NCT02128997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819579|PROphylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population|Prophylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population|PROVAC|University of Pennsylvania|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128997||45387|
NCT02129244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104488-01A1|A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes|A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes||Johns Hopkins University|Yes|Recruiting|October 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|3000|||Both|13 Years|N/A|No|||March 2016|March 23, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02129244||45368|
NCT02120937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0453|Mindfulness in Mood Dysregulated Youth|Neural Basis of Mindfulness in Mood Dysregulated Youth||University of Cincinnati|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|10 Years|17 Years|No|||September 2015|September 16, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120937||46004|
NCT02117141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN-0302002|To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules|A Pilot Study in Healthy Volunteers to Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules, in Both Fed and Fasted States||Zogenix, Inc.|No|Completed|June 2002|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 15, 2014|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117141||46295|
NCT02117947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA105183|Counseling to Reduce Children's SHS Exposure: A Trial With Maternal Smokers|Behavioral Counseling to Reduce Children's Secondhand Smoke Exposure: A Trial With Maternal Smokers||Temple University|No|Completed|July 2004|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|50 Years|No|||March 2014|August 27, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117947||46234|
NCT02130323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP#NMCSD.2014.0040|Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix|Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix||United States Naval Medical Center, San Diego|Yes|Recruiting|February 2015|||August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130323||45285|
NCT02130791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812523|Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss|Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss||University of Pennsylvania|No|Completed|October 2010|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|170|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02130791||45249|
NCT02131012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND for Celecoxib|Intraviteral Celecoxib for Chronic Uveitis|Intravitreal Celecoxib for Chronic Uveitis: A Phase I Investigational Safety Study|Celecoxib|Vanderbilt University|Yes|Not yet recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|N/A|No|||December 2015|December 7, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131012||45232|
NCT02131038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rep-25|Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis|Non Interventional, Open Label Trial of Ectoine Containing Nasal Spray in Comparison With Cromoglycic Acid Containing Nasal Spray in Patients With Allergic Rhinitis||Bitop AG|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|May 2014|May 5, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02131038||45231|
NCT02131311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012118|A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)|A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence||Procter and Gamble|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|May 2, 2014|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT02131311||45210|
NCT02131324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFD06-CD-007|DFD06 Cream vs Comp01 Cream HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis|A Randomized, Parallel Group, Open Label, to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD06 Cream Versus Comp01 Cream in Subjects With Moderate to Severe Plaque Psoriasis||Promius Pharma, LLC|No|Active, not recruiting|May 2014|April 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||March 2016|March 9, 2016|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131324||45209|
NCT02131649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAP02-01.1|PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy|PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)|PROPS|Lawson Health Research Institute|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Male|18 Years|N/A|No|||September 2015|September 1, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131649||45184|
NCT02131896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc7800ctil|The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes|The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes||Rabin Medical Center|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|5 Years|18 Years|No|||November 2015|November 26, 2015|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02131896||45165|
NCT02127424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K130601|Targeted Nurse-driven HIV Screening in Emergency Departments|Targeted Nurse-driven HIV Screening Using Rapid Tests in Emergency Departments in the Metropolitan Paris Region|DICI-VIH|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2014|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|140000|||Both|18 Years|64 Years|No|||October 2015|October 23, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02127424||45508|
NCT02127671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL112299|Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness|Comprehensive CVD Risk Reduction Trial in Persons With Serious Mental Illness|IDEAL|Johns Hopkins University|Yes|Recruiting|December 2013|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127671||45489|
NCT02127983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriagePlus|Engaging Informal Health Care Providers on Case Detection and Treatment Initiation Rates for TB and HIV in Rural Malawi (Triage Plus)|Engaging Informal Health Care Providers on Case Detection and Treatment Initiation Rates for TB and HIV in Rural Malawi (Triage Plus): a Cluster Randomised Health System Intervention Trial|Triage|Liverpool School of Tropical Medicine|Yes|Completed|January 2009|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2012|April 30, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127983||45465|
NCT02119507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4-APCL|Effect of Curodont Repair in Patients With Early Approximal Carious Lesions|Effect of Curodont Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Post-marketing Study||Credentis AG|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119507||46114|
NCT02128464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrthoTu-02|Outcome of TKA Using Customized Cutting Block Compared With Conventional Intramedullary Cutting Guide|Comparison of Customized Cutting Block (Visionaire™) and Conventional Total Knee Arthroplasty: A Prospective Randomized Control Trial||Thammasat University|Yes|Recruiting|October 2012|December 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|November 25, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128464||45428|
NCT02128477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO012014|Predictive Value of Periodic Repolarization Dynamics in Post-Infarction Patients|Predictive Value of Periodic Repolarization Dynamics in Post-Infarction Patients: Validation Study|PRD-MI|Thebiosignals.com|No|Recruiting|October 2010|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|myocardial infarction|April 2014|April 29, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02128477||45427|
NCT02128724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_031|Palliative Thoracic Radiotherapy Plus BKM120|A CR-UK Phase I Study of BKM120 in Patients With Non-small Cell Lung Cancer (NSCLC) Receiving Thoracic Radiotherapy|BKM120|University of Oxford|Yes|Recruiting|April 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02128724||45408|
NCT02120196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asem Ahmed Elfert|Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis|Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis|SBP|Tanta University|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|April 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120196||46061|
NCT02120209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/24|Prediction of Falls in Older Inpatients Hospitalized at Angers University Hospital|Nurse Screening Tool for Fall Risk : Prediction of Falls in Older Inpatients Hospitalized at Angers University Hospital|EPRIC|University Hospital, Angers|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1300|||Both|65 Years|N/A|No|Non-Probability Sample|All patients hospitalized in acute care units participating in study in Angers University        Hospital with respect to the eligibility criteria|April 2014|April 17, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120209||46060|
NCT02120469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14036|Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer|Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer||City of Hope Medical Center|Yes|Recruiting|October 2014|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|April 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120469||46040|
NCT02117700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NemoursCC|Fatty Liver Disease in Obese Children|Effect of N-acetyl Cysteine on Non Alcoholic Fatty Liver Disease in Obese Children||Nemours Children's Clinic|Yes|Not yet recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|7 Years|18 Years|No|||March 2015|March 30, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117700||46253|
NCT02118259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/GL-01|Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly|Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly|Rev-EHPAD|Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|49|||Both|65 Years|N/A|No|||April 2015|May 5, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118259||46210|
NCT02118272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-06 Physica KR|Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism|A Multicentre, Prospective Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism|K-06|Limacorporate S.p.a|No|Recruiting|July 2014|May 2021|Anticipated|May 2021|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|22 Years|80 Years|No|||March 2016|March 2, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02118272||46209|
NCT02130557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV001|A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase (CP) Chronic Myelogenous Leukemia (CML)||Avillion Development 1 Limited|Yes|Active, not recruiting|June 2014|May 2020|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130557||45267|
NCT02130804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00017|Using Salsalate to Target Adipocyte Macrophage Infiltration|Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults|TAMI|University of Southern California|No|Completed|July 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02130804||45248|
NCT02131051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP-85|Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis|Non-interventional Study: Application of Ectoin® Rhinitis Nasal Spray and Eye Drops in Patients With Allergic Rhinitis||Bitop AG|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|70 Years|No|Non-Probability Sample|Primary Care Clinic|May 2014|May 5, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02131051||45230|
NCT02131064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO28408|A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer|A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER||Hoffmann-La Roche||Active, not recruiting|June 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|444|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131064||45229|
NCT02131337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFICAS II Version B|TactiCath® Prospective Effectiveness Pilot Study|Efficacy Study on Atrial Fibrillation Percutaneous Catheter Ablation With Contact Force Support 2|EFFICAS II|St. Jude Medical|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|18 Years|75 Years|No|||May 2014|May 2, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131337||45208|
NCT02131350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2617|Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema|||Shinshu University|Yes|Recruiting|April 2014|||March 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||May 2014|May 2, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02131350||45207|
NCT02131363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPD21402|A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail|A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail||Reckitt Benckiser Healthcare (UK) Limited|No|Completed|August 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2014|January 12, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131363||45206|
NCT02131376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0459|Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy|Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy||Indiana University|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131376||45205|
NCT02131389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-1001|Multi-Site, Post-Market Study of the ICONACY I-Hip System|Non-Randomized, Multi-Site, Post-Market Study of the ICONACY I-Hip System (Protocol No. PS-1001)||Iconacy Orthopedic Implants, LLC.|Yes|Recruiting|April 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|30 Years|80 Years|No|||May 2014|May 2, 2014|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131389||45204|
NCT02131662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15788|Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap|A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months|ASTEROID 1|Bayer|No|Active, not recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|305|||Female|18 Years|50 Years|No|||March 2016|March 7, 2016|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131662||45183|
NCT02118753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLICARD|The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium|The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)|EPLICARD|Radboud University|No|Completed|March 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02118753||46172|
NCT02119013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPKD-heart|Effects of Somatostatin on ADPKD Heart|EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A MATCHED-COHORT, SPECKLE-TRACKING ECHOCARDIOGRAPHIC STUDY||Federico II University|No|Completed|January 2009|||September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|80 Years|No|||January 2014|April 17, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119013||46152|
NCT02119026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25153_PASSION|Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer|A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer|PASSION|Medical University of Vienna|No|Recruiting|February 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02119026||46151|
NCT02119273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140031|Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)||Loma Linda University|No|Recruiting|September 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119273||46132|
NCT02119728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 246513|Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity|A Randomized Multicenter Phase II Study Using HPPH With PDT Versus Standard of Care Surgery for Patients With T1/T2 Squamous Cell Carcinoma of the Oral Cavity||Roswell Park Cancer Institute|Yes|Not yet recruiting|March 2016|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119728||46097|
NCT02119715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHPG-19K-II-01|A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy|A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF as Supportive Therapy to Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|February 2011|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|70 Years|No|||April 2014|April 17, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119715||46098|
NCT02119936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2051|Feasibility of Heart Rate Variability Biofeedback With Impatient Pregnant Women at UNC-CH|Feasibility of Heart Rate Variability Biofeedback as a Stress Reduction Tool for Hospitalized Pregnant Women.|HRVB|University of North Carolina, Chapel Hill|No|Active, not recruiting|May 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119936||46081|
NCT02120482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2123/2013|Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study|Semiselective Immunoadsorption and Membrane Filtration for Desensitization in ABO-incompatible Kidney Transplantation - a Phase 2 Pilot Study||Medical University of Vienna|Yes|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120482||46039|
NCT02120703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173-SUR-ERC-10|Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery|Gabapentin vs. Pregabalin for Post Operative Pain in Lumbar Microdiscectomy: a Randomized Controlled Trial.||Aga Khan University|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|78|||Both|30 Years|60 Years|No|||April 2014|April 22, 2014|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02120703||46022|
NCT02120924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1014|A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea|A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.||Actavis Inc.|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1008|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02120924||46005|
NCT02117960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2486|Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD|Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With Coronary Artery Disease||Tehran University of Medical Sciences|Yes|Completed|December 2011|October 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|45 Years|65 Years|No|||April 2015|April 7, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117960||46233|
NCT02117973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-13-HMO|iAssist vs. Conventional Instrumentation in Total Knee Arthroplasty Using the Persona Knee System Among Patients With BMI>=30: Radiographic, Clinical and Economic Outcomes|||Hadassah Medical Organization|No|Not yet recruiting|June 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||February 2014|April 16, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02117973||46232|
NCT02118844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000289-23|Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions|Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade|BaChiBloPro1|Central Hospital, Nancy, France|Yes|Recruiting|July 2014|April 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|92|||Both|18 Years|64 Years|No|||July 2015|July 29, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118844||46165|
NCT02118857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIN-2014-GB|Microbiota and Related Metabolome in Omnivore, Vegetarian or Vegan Diets|Microorganisms in Foods and in Humans: Study of the Microbiota and the Related Metabolome as Affected by Omnivore, Vegetarian or Vegan Diets|MRMOVVD|University of Bari|No|Recruiting|January 2013|January 2016|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|150|Samples With DNA|Feces, urine and saliva samples|Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study focused on enrolling of 150 healthy volunteers including an equal number of        omnivores, vegetarians and vegans (age 18-59 years, male/female ratio ca. 1:1). Recruited        volunteers will be asked to sign a consensus document, to record their dietary habits and        to collect biological samples (saliva, feces and urine).|April 2014|April 18, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02118857|3 Weeks|46164|
NCT02130349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDSL biobank project|IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD.|IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD. A Prospective Population Based Biobank of Inflammatory Bowel Disease Patients in Zuid Limburg, The Netherlands.|IBDSL|Maastricht University Medical Center|Yes|Recruiting|February 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|5000|Samples With DNA|DNA Serum Plasma Stool Exhaled air Biopsies|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All adult IBD patients (>18 years) residing permanently in South Limburg are eligible. IBD        was diagnosed by certified gastroenterologists according to the Lennard-Jones criteria,        and was proven by endoscopic and/or radiologic evidence and by histologic evidence.        To capture the full South Limburg IBD population, a multifaceted approach was used.        Incident cases were prospectively identified through the three hospitals. Missed patients        were retrospectively identified using PALGA, the nationwide histopathology registry        containing data on all endoscopic biopsies.|March 2016|March 15, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02130349|25 Years|45283|
NCT02130817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-327|Belatacept in Kidney Transplantation of Moderately Sensitized Patients|Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)|BelatPilot|University of Wisconsin, Madison|Yes|Recruiting|May 2014|April 2022|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 9, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130817||45247|
NCT02131077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-TI-201|Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis|A Multi-center, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase I/II Clinical Study to Evaluate Safety and Efficacy of Allogeneic Adipose-derived Stem Cells for the Treatment of Lateral Epicondylitis||Anterogen Co., Ltd.|Yes|Active, not recruiting|January 2014|May 2015|Anticipated|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|27|||Both|19 Years|90 Years|No|||May 2014|March 6, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02131077||45228|
NCT02131090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epi devices RCT|A Comparison of Intrapartum Epidural Fixation Devices: A Randomised Controlled Trial|A Comparison of Intrapartum Epidural Fixation Devices: A Randomised Controlled Trial||St George's, University of London|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|160|||Female|18 Years|50 Years|No|||November 2014|November 25, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02131090||45227|
NCT02131675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1425|Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus|Observational Study of C-peptide Levels in Youth With Longstanding Type 1 Diabetes Mellitus as Detected by an Ultrasensitive Assay||Icahn School of Medicine at Mount Sinai|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|Samples Without DNA|serum|Both|1 Year|21 Years|No|Non-Probability Sample|Subjects will be recruited from the population of patients seen in the Division of        Pediatric Endocrinology and Diabetes. These patients must have type 1 diabetes and must        have been diagnosed more than 1 year prior to their recruitment. Potential subjects will        be identified by reaching out to the physicians in the division and asking that they        inform the investigators of patients that they see with type 1 diabetes. Those patients        will have their information reviewed by the investigators using EPIC, the electronic        medical record at The Mount Sinai Hospital.|May 2014|May 2, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02131675||45182|
NCT02131935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120|Impaired Peripheral Endothelial Function and In-stent Restenosis|Impaired Peripheral Endothelial Function as Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis||Kumamoto University|No|Completed|January 2010|May 2014|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|513|||Both|20 Years|90 Years|No|Probability Sample|consecutive patient sampling This is a prospective observational study of all consecutive        patients with coronary artery disease (CAD) treated with PCI at Kumamoto University        Hospital between January 2010 and September 2012. Inclusion criteria consisted of patients        who were symptomatic for myocardial ischemia and who were undergoing stent implantation        for significant CAD.|May 2014|May 24, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131935|1 Year|45162|
NCT02118766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-AD-301|Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis||Anacor Pharmaceuticals, Inc.|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|763|||Both|2 Years|N/A|No|||December 2015|December 28, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118766||46171|
NCT02119975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals|A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals: A Double-blind Randomized Controlled Trial||Erasmus Medical Center||Completed|August 2011|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|67 Years|No|||April 2014|April 18, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02119975||46078|
NCT02119039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070214|Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus|Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus||Medical University of Vienna||Completed|July 2014|December 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02119039||46150|
NCT02119286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200110|Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2|A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2||GlaxoSmithKline|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|620|||Both|40 Years|N/A|No|||August 2014|December 4, 2014|April 17, 2014|Yes|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT02119286||46131|
NCT02119299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2014|||||N/A|N/A|N/A||||||||||||||May 19, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119299||46130|
NCT02119520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2011-2012/D|PLATELET RICH FIBRIN COMBINED WITH 1.2% ATORVASTATIN FOR TREATMENT OF INTRABONY DEFECTS IN CHRONIC PERIODONTITIS|||Government Dental College and Research Institute, Bangalore||Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|25 Years|45 Years|No|||April 2014|April 17, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119520||46113|
NCT02120716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD0756658|The Health Check-Up for Expectant Moms|Computer Intervention for HIV/STI Risk and Drug Use During Pregnancy||Butler Hospital|Yes|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|50 Years|No|||July 2015|July 31, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120716||46021|
NCT02119949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Working Memory Training for Substance Dependent Individuals|A Randomized Double-blind Placebo-controlled Trial to Working Memory Training in Substance Abusers||Erasmus Medical Center|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|16 Years|67 Years|No|||August 2014|August 20, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02119949||46080|
NCT02119962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|A Working Memory Training in Burnout Patients|||Erasmus Medical Center||Recruiting|June 2013|||September 2014|Anticipated|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|67 Years|No|||April 2014|April 18, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02119962||46079|
NCT02120222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13124|Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery|A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma|KPT-330|Ohio State University Comprehensive Cancer Center|Yes|Recruiting|April 2014|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120222||46059|
NCT02117453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120127|Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides|Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides|STATVAS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2014|April 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|162|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117453||46271|
NCT02118584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA28951|Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies|AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES||Hoffmann-La Roche||Recruiting|September 2014|November 2021|Anticipated|November 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1850|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 16, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02118584||46185|
NCT02118831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28032|Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF|Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients With Neovascular Age-related Macular Degeneration||California Retina Consultants|No|Completed|March 2012|April 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|145|||Both|N/A|N/A|No|||April 2014|April 17, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118831||46166|
NCT02119130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3358597|Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa|Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in South Africa||Johns Hopkins University|No|Recruiting|November 2014|May 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02119130||46143|
NCT02130596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/2013|An Acceptance-Based Behavioral Intervention vs. Nutritional Counselling for Weight Loss in Psychotic Illness|A Pilot Study of an Acceptance-Based Behavioral Intervention Versus Nutritional Counseling for Weight Loss in Psychotic Illness||Centre for Addiction and Mental Health|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||November 2014|November 6, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130596||45264|
NCT02130570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000096|Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions|Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions||Brigham and Women's Hospital|No|Active, not recruiting|June 2013|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|1679|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130570||45266|
NCT02130583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH101272|Skills to Enhance Positive Affect in Suicidal Adolescents|Skills to Enhance Positive Affect in Suicidal Adolescents|STEP|Brown University|Yes|Recruiting|August 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|12 Years|18 Years|No|||February 2016|February 3, 2016|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130583||45265|
NCT02131103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-2556-01631|The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.|The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.||Chiang Mai University|Yes|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|75 Years|No|||May 2014|January 30, 2016|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02131103||45226|
NCT02131402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-47|Clinical Performance of Hydrogel vs. Silicone Hydrogel Contact Lenses|Non-Dispensing Fitting Study Comparing the Clinical Performance of Hydrogel vs. Silicone Hydrogel Sphere Design Contact Lenses||Coopervision, Inc.|No|Completed|May 2014|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|60|||Both|18 Years|40 Years|No|||February 2015|February 9, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131402||45203|
NCT02132169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-100-0006|A Multi-Center Study Evaluating the Safety of AC-170 0.24%|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)||Aciex Therapeutics, Inc.|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|512|||Both|2 Years|N/A|No|||April 2015|April 30, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132169||45145|
NCT02132455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E14017|The Utility of Timed Segmental Withdrawal During Screening Colonoscopy|The Utility of Timed Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate. A Randomized Controlled Clinical Trial||Texas Tech University Health Sciences Center||Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|4||Anticipated|400|||Both|18 Years|80 Years|No|||November 2014|November 13, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132455||45124|
NCT02132767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-00007|Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation|Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132767||45100|
NCT02120235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-CFCT-11|Investigating Lysosomal Storage Diseases in Minority Groups|||O & O Alpan LLC||Recruiting|February 2014|||February 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|20000|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will comprise of patients of healthcare institutions in the        Washington, D.C. metro area .|September 2015|September 4, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120235||46058|
NCT02120248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY04 WIC Special Project Grant|The Effect of Varied Intensities of Breastfeeding Peer Support on Duration of Breastfeeding Among Oregon WIC Participants|The Effect of Varied Intensities of Breastfeeding Peer Support on Duration of Breastfeeding Among Oregon WIC Participants||Oregon WIC Program|No|Completed|July 2005|December 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Prevention|3||Actual|1948|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 21, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120248||46057|
NCT02120495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wxiaoxia1|Application of Digital Techniques in Intraoral Condylectomy Via Coronoid Process Resection|Application of Digital Techniques in Intraoral Condylectomy Via Coronoid Process Resection||Peking University|Yes|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|15 Years|70 Years|No|||November 2014|November 19, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120495||46038|
NCT02120508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207007AC|Functional Neuroimage in Assessment of Post-stroke Aphasia|Phase 2 Study of rTMS Application in Aphasic Patients Evaluated With fMRI||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|August 2012|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|80 Years|No|||April 2014|April 18, 2014|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120508||46037|
NCT02120729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUAN004090HE|Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT|Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT|CYP-GUIDES|Hartford Hospital|Yes|Recruiting|March 2014|October 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|95 Years|No|||April 2015|April 7, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02120729||46020|
NCT02116881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-261|Incisional Hernia and Adhesion-Related Bowel Obstruction|Incisional Hernia and Adhesion-Related Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Cohort Study||The Cleveland Clinic|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|320|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled for an elective colorectal operation in the Department of Colorectal        Surgery at Cleveland Clinic|August 2015|August 3, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02116881||46315|
NCT02116894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051541|Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer|Phase Ib Study of the Combination Regorafenib With PF-03446962 in Patients With Refractory Metastatic Colorectal Cancer (REGAL-1 Trial)|REGAL-1|Duke University|Yes|Active, not recruiting|August 2014|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02116894||46314|
NCT02117167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 0105-1305 / IFCT 1301|SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients|Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer|SAFIR02_Lung|UNICANCER|Yes|Recruiting|April 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|650|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02117167||46293|
NCT02117180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CdeK2014|Nutritional Adequacy of a FODMAP Diet in Children|Evaluation of the Nutritional Adequacy of a Diet Low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP's) in Children With Functional Gastrointestinal Disorders.||University of Plymouth|Yes|Recruiting|February 2014|August 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|10 Years|16 Years|No|||June 2015|June 3, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02117180||46292|
NCT02117193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS 366465|Combined and Isolated Effects of Sleep Deprivation and Alcohol Intake on Exercise Performance in Humans.|Combined and Isolated Effects of Sleep Deprivation and Alcohol Intake on Cardiorrespiratory, Neuromuscular and Hormonal Responses in Healthy Males.||Federal University of Rio Grande do Sul||Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02117193||46291|
NCT02117986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA13I20317|Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients|Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients||Hospital Barros Luco Trudeau|Yes|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02117986||46231|
NCT02117440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRU CC-13-24C|Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer|GRU CC-13-24C: Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer||Georgia Regents University|Yes|Recruiting|April 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|buffy coat, plasma and serum samples|Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients|July 2015|July 26, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117440||46272|
NCT02117713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-305|An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome|A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome|IMAGINE-II|Shire|No|Recruiting|March 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|12 Months|18 Years|No|||January 2016|January 15, 2016|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117713||46252|
NCT02118597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29278|An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Pegasys and Ribivarin in the Re-Treatment of Chronic Hepatitis C Patients|Non-interventional Study to Observe Triple Combination Therapy With Boceprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary||Hoffmann-La Roche||Not yet recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Blood serum used to analyze levels of hepatitic c virus (HCV) RNA|Both|18 Years|N/A|No|Non-Probability Sample|Patients with genotype 1 chronic hepatitis C (CHC) infection taking triple combination        therapy (boceprevir, Pegasys and ribavirin)|April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118597||46184|
NCT02120326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC13/48|Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine|Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine|Medis|University Hospital, Grenoble|No|Recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|December 1, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120326||46051|
NCT02131415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15914N|Real Life Assessment of Abilify Maintena|Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena ™ in Schizophrenia|ReLiAM|Lundbeck Canada Inc.|No|Recruiting|May 2014|June 2018|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|252|||Both|18 Years|N/A|No|Non-Probability Sample|patients treated with Abilify Maintena™ for schizophrenia|September 2015|September 16, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02131415||45202|
NCT02131688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HE14Ⅰ|Phase I Study of Mitoxantrone Hydrochloride Liposome Injection|Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|May 2013|October 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2014|May 4, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02131688||45181|
NCT02130830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-038|Topical Anesthesia Versus Placebo to Decrease Pain in Rubber Band Ligation for Treatment of Internal Hemorrhoids|Topical Anesthesia Versus Placebo to Decrease Post Procedure Pain in Rubber Band Ligation for the Treatment of Grade I - III Symptomatic Internal Hemorrhoids. A Single Institution, Double Blinded, Placebo Controlled Trial.||Pontificia Universidad Catolica de Chile|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130830||45246|
NCT02130843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-13-0717|Tiemann Mounted Urodynamic Catheter Technique for Difficult Bladder Catheterization|RETROSPECTIVE STUDY ABOUT A TECHNIQUE OF INSERTION OF TIEMANN MOUNTED URODYNAMIC CATHETER FOR DIFFICULT BLADDER CATHETERIZATION IN MALES|TMUC|Sheba Medical Center|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Male|18 Years|80 Years|No|Non-Probability Sample|MALE PATIENTS 18-80 Y/O WHO UNDERWENT URODYNAMIC STUDY, AND HAD DIFFICULT CATHETERIZATION|May 2014|May 2, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130843||45245|
NCT02131948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 12-5032A|Regulation of Endogenous Glucose Production by Brain Insulin Action|Regulation of Endogenous Glucose Production by Brain Insulin Action|Nasal insulin|University Health Network, Toronto|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131948||45161|
NCT02132182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050745|Monocyte Phenotypic and Functional Differences|A Canine/ Human Translational Model of Phenotypic and Functional Differences Between Monocytes in Patients With and Without Sarcoma||Duke University|Yes|Recruiting|October 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Whole blood samples (~15 to 20 mls) will be obtained from 90 humans over 3 years presenting      to Duke with osteosarcoma. Only patients who would normally have blood drawn as part of      standard care will be included. Research blood will be in addition to what is normally      collected. Samples will be de-identified and then transferred to researchers as NC State's      College of Veterinary Medicine. These researchers will use the samples to perform a CBC and      evaluate monocyte phenotype and function. These results will be compared to published      historical normal values for healthy human monocytes. This data will also be compared with      canine data already gathered.|Both|6 Years|N/A|No|Non-Probability Sample|The patient population for this study will be comprised of individuals who present to        clinic with newly diagnosed osteosarcoma with or without infection and without known        metastasis to the lung. Potential subjects will be 10 years or older.|August 2015|August 5, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02132182||45144|
NCT02132468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX4218s|A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers|A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers|GI-NETorPNET|OXiGENE|No|Active, not recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132468||45123|
NCT02132481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRSS Experiment|Using Smartphones to Provide Recovery Support Services|Using Smartphones to Provide Recovery Support Services Experiment|SRSS|Chestnut Health Systems|Yes|Recruiting|June 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132481||45122|
NCT02132494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISF_2014|Active Smarter Kids: A Cluster-randomized Controlled Trial|Active Smarter Kids: A Cluster-randomized Controlled Trial Investigating the Effect of Daily Physical Activity on Children's Academic Performance and on Risk Factors for Lifestyle-related Non-communicable Diseases|ASK|Sogn og Fjordane University College|Yes|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1256|||Both|8 Years|11 Years|No|||November 2015|November 16, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02132494||45121|
NCT02132780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000058|Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease|The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance|AD-NAFLD|Virginia Commonwealth University|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|33|||Both|35 Years|65 Years|No|Probability Sample|Adults with NAFLD who are patients at the NAFLD Clinic at VCU Health Systems in Richmond,        VA.|December 2015|December 9, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132780||45099|
NCT02119546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912126R|Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease||National Taiwan University Hospital|Yes|Completed|May 2010|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|45 Years|85 Years|No|||April 2014|April 18, 2014|November 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02119546||46111|
NCT02119754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGN-1300X|Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers|Open Label Trial of Topical PluroGel PN for the Treatment of Patients With Mildly Infected Diabetic Foot Ulcer CLINICAL PROTOCOL PGN-1300X||PluroGen Therapeutics, Inc|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119754||46095|
NCT02119988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPS-Variceal embolization|TIPS Combined With Variceal Embolization for the Prevention of Variceal Rebleeding in Patients With Cirrhosis|Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using Covered Stents Combined With Variceal Embolization in the Prevention of Variceal Rebleeding for Patients With Cirrhosis : a Prospective, Open-labeled, Randomized, Controlled Trial||Fourth Military Medical University|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|118|||Both|18 Years|75 Years|No|||January 2016|January 23, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119988||46077|
NCT02120261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0072|Using Saline for Myofascial Pain Syndromes (USAMPS)|Using Saline for Myofascial Pain Syndromes (USAMPS)|USA MPS|The University of Texas Health Science Center, Houston|Yes|Recruiting|May 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02120261||46056|
NCT02117206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3262|Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans|Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans||University Hospital, Strasbourg, France|No|Completed|November 2005|November 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02117206||46290|
NCT02116907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-049|An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects|||Eisai Inc.|No|Completed|May 2014|September 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116907||46313|
NCT02117466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.265|Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer|Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer|IMPACT-CRC|VU University Medical Center|Yes|Recruiting|April 2014|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02117466||46270|
NCT02117726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDS2014|Impact of Various Sedation Regimens on the Incidence of Delirium|Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation||Shandong Provincial Hospital||Not yet recruiting|May 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|70 Years|No|||July 2014|July 15, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117726||46251|
NCT02117999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA_27|Transepithelial Corneal Cross-linking Using Iontophoresis|Randomized Clinical Trial Comparing Transepithelial Corneal Cross-linking Using Iontophoresis and Standard Corneal Cross-linking for the Treatment of Keratoconus|T-ionto CL|Fondazione G.B. Bietti, IRCCS|No|Active, not recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|46 Years|No|||January 2016|January 12, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02117999||46230|
NCT02118285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS101|Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|April 2014|April 2020|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|March 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02118285||46208|
NCT02118870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9207|Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent|Randomized Evaluation of Short-term DUal Anti Platelet Therapy in Patients With Acute Coronary Syndrome Treated With the COMBO Dual-therapy stEnt|REDUCE|Diagram B.V.|Yes|Recruiting|April 2014|May 2018|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118870||46163|
NCT02120586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1382044172319|Preventive Physiotherapy Intervention in Elderly People With Sarcopenia|Effects and Costs of Preventive Physiotherapy Intervention in Institutionalized Elderly People With Sarcopenia: A Randomized Controlled Trial||University of Valencia|No|Active, not recruiting|January 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|70|||Both|65 Years|N/A|No|||February 2016|February 9, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02120586||46031|
NCT02131142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14US01|BioFreedom US IDE Feasibility Trial|To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent in Patients With Native, de Novo Coronary Artery Disease||Biosensors Europe SA||Active, not recruiting|August 2014|July 2019|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02131142||45223|
NCT02131428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052933|Depression and Heart Failure Disease Progression|Depression and Heart Failure Disease Progression||Duke University|No|Recruiting|November 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples With DNA|Samples with DNA are optional.|Both|21 Years|N/A|No|Non-Probability Sample|Men and women aged 21 years or older with diagnosed heart failure.|November 2015|November 23, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131428||45201|
NCT02131701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPP2007|PPP-Botnia Exercise Intervention Study|PPP-Botnia Exercise Intervention Study||Folkhälsan Researech Center|No|Completed|October 2006|August 2013|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|290|||Both|30 Years|70 Years|No|||May 2014|May 5, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02131701||45180|
NCT02131961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140171|EZCast-DFU Study With Portal for Application of Topical Medications|A Study to Evaluate the Feasibility of Using a Modified Cast Walker With a Portal for Application of Topical Medications in Diabetic Foot Ulcers|EZCast-DFU|University of Miami|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|May 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02131961||45160|
NCT02132793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-C-0067|Remote Exercise for Learning Anger and Excitation Management|Remote Exercise for Learning Anger and Excitation Management (RELAX)|RELAX|VA Pacific Islands Health Care System|No|Active, not recruiting|March 2014|November 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|January 6, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132793||45098|
NCT02100202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLS-SH/02-14 Ver 01|Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Efficacy and Safety Study of Dietary Supplements (BioTurmin, BioTurmin-WD and MaQxan) on Cotinine Level and Oxidative Stress Marker in Chronic Smokers Having Mild to Moderate Hyperlipidemia||Olive Lifesciences Pvt Ltd|Yes|Not yet recruiting|April 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|60|||Male|20 Years|65 Years|No|||March 2014|March 26, 2014|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02100202||47593|
NCT02100488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL4M Controls|Improving Postprandial Glycaemia by a New Developed Closed-loop Control System - Closedloop4meals|Improving Postprandial Glycaemia by a New Developed Closed-loop Control System (Closedloop4meals). An Interdisciplinary, Investigator's Initiated Project for Optimization of Glucose Control in Type1 Diabetic Subjects|CL4M-Controls|Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|March 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||November 2015|November 14, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100488||47571|
NCT02100501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0003|Prospective Study of Comparison Between the Modified Atkins Diet and Classic Ketogenic Diet for Intractable Childhood Epilepsy|||Yonsei University|No|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|104|||Both|1 Year|18 Years|No|Probability Sample|the patients were recriuted from the Pediatric Neurology Outpatient Clinic, Severance        Children's Hospital. This study conducted on 104 (Ketogenic diet - 51, Atkin's diet - 53)        patients diagnosed with intractable epilepsy which shows frequency with more than 1 per        week, 4 per month even though at least more than 2 antiepileptic drug treatment.|February 2015|February 24, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02100501||47570|
NCT02120521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1637/02/13|Serum STREM and MNDA Mointoring in ICU|The Predictive Values of Serum STREM and Its Correlation With MNDA Monitoring in Critically Ill Patients.||Tanta University|Yes|Completed|April 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|60 Years|No|Probability Sample|120 critically ill patients, sixty patients are critically ill with evidence of sepsis        during ICU stay (sepsis group) and sixty patients are critically ill without evidence of        infectious organism (SIRS group). At admission, Patients data include clinical status;        SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis        are measured. Routine cultures will be obtained. The attending physician will evaluate the        patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum        level of sTREM-1 and MNDA will be monitored.|December 2014|December 14, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120521||46036|
NCT02120742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14103|The Impact Of Text Message (SMS) Reminders On Helmet Use Among Motorcycle Drivers In Dar Es Salaam, Tanzania|The Impact Of Text Message (SMS) Reminders On Helmet Use Among Motorcycle Drivers In Dar Es Salaam, Tanzania||Amend|Yes|Completed|April 2014|September 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|391|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02120742||46019|
NCT02116920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT/PR6121/SPD/11/1401/2012|HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening|Evaluation of the Diagnostic Performance of HPV E6/E7 mRNA Versus Oncogenic HPV DNA as a Secondary Triage Test for VIA Positive Women in Cervical Cancer Screening Program|PODBT|Tata Memorial Hospital|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Cervical Biopsy and Endo-cervical Brushing|Female|30 Years|65 Years|No|Non-Probability Sample|Women in the age group of 30 to 65 years (non pregnant and with intact uterus) in urban        slum colonies of Mumbai city|April 2014|April 15, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02116920||46312|
NCT02117219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00007|Phase 1 Study to Evaluate MEDI4736 in MDS|A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents||MedImmune LLC|No|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|99 Years|No|||October 2015|October 22, 2015|April 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117219||46289|
NCT02117479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-362|Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)|A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)||Incyte Corporation|Yes|Active, not recruiting|March 2014|August 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|318|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117479||46269|
NCT02117739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-011|Photoallergy Potential of Dapsone Gel in Healthy Volunteers|||Allergan|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117739||46250|
NCT02117752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-009|Dermal Tolerability of Dapsone Gel in Healthy Volunteers|||Allergan|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117752||46249|
NCT02118311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS091|Treg Cells for AGVHD in Non-myeloablative UCB Transplant|T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Not yet recruiting|June 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|18|||Both|18 Years|69 Years|No|||January 2016|January 22, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118311||46206|
NCT02118298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401013272|Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI|||Yale University|No|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with relapsing remitting Multiple Sclerosis and demographically matched controls        will be recruited for this study. The MS subjects will consist of patients who were        referred for a neuropsychological evaluation and neuroimaging as part of standard practice        of care to evaluate for cognitive difficulties and/or track disease progression.|August 2015|August 20, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118298||46207|
NCT02120053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111116|Interest of Bone Substitute Material in Immediate Complete Denture|Interest of Bone Substitute Material in Immediate Complete Denture: a Controlled Randomized Clinical Trial|PANORAMIX|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2013|April 2018|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||July 2015|August 4, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120053||46072|
NCT02120833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140206110636-SBCT|A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin|A Multi-Center Clinical Trial to Evaluate the Efficacy of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Infants and Toddlers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|2 Months|35 Months|No|||August 2015|August 6, 2015|March 28, 2014|No|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT02120833||46012|
NCT02131974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCMS130324|Ultrasound Confirmation of Endotracheal Tube Location Using a Saline Filled Cuff|Ultrasound Confirmation of Endotracheal Tube Location Using a Saline Filled Cuff|ET_Tube|The University of Texas Health Science Center, Houston|Yes|Recruiting|September 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|21 Years|No|Non-Probability Sample|Patients scheduled to undergo elective cardiac catherization procedures will be screened        for eligibility.|February 2015|February 11, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131974||45159|
NCT02131714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD-2003|Pressure Pain Threshold of Jaw Muscles in TMD Patients Submitted to a Conservative Treatment|Pressure Pain Threshold of Jaw Muscles in Patients With Facial Myofascial Pain Submitted to a Conservative Treatment : a Short-term Evaluation|PPT|Federal University of São Paulo|No|Active, not recruiting|March 2014|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2014|May 4, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02131714||45179|
NCT02132507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EB006433|Multimodal Functional Neuroimaging in Epilepsy Patients|Multimodal Functional Neuroimaging in Epilepsy Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|January 2011|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who are seen at the epilepsy center of School of medicine, University of        Minnesota|January 2016|January 27, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132507||45120|
NCT02100527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731019|Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris|A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects||Pfizer|No|Withdrawn|April 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||May 2014|May 12, 2014|March 27, 2014|Yes|Yes|Study canceled|No||https://clinicaltrials.gov/show/NCT02100527||47568|
NCT02100228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661025|Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)|A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion|EMANATE|Pfizer|Yes|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1500|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100228||47591|
NCT02100540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-RCN3028-01|A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women|A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women|RDC|Yung Shin Pharm. Ind. Co., Ltd.|No|Recruiting|March 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|N/A|N/A|No|||March 2014|March 31, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02100540||47567|
NCT02120287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-063|Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme|Multicenter Phase II Study of Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Multiforme||University of Pittsburgh|Yes|Recruiting|May 2014|December 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120287||46054|
NCT02120534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1638/02/13|Serum CD14 and CD88 Mointoring in ICU|The Predictive Values of Serum Soluble CD14 Subtype and CD88 Monitoring in Critically Ill Patients.||Tanta University|Yes|Completed|March 2013|October 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|60 Years|No|Probability Sample|A total of ninety-four patients will be included in the study. Forty seven patients are        critically ill with evidence of sepsis during ICU stay (sepsis group) and forty seven        patients are critically ill without evidence of infectious organism (SIRS group). At        admission, Patients data include clinical status; SOFA score; central venous pressure;        laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be        obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or        septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be        monitored.|December 2014|December 14, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120534||46035|
NCT02120755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amn-DFU-01|A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds|A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds||Liventa Bioscience|Yes|Withdrawn||||October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 21, 2014||No|Never Started|No||https://clinicaltrials.gov/show/NCT02120755||46018|
NCT02116933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCC001|Grafting of Autologous Adipose Stromal Cell Trial|Grafting of Autologous Adipose Stromal Cell Trial|GAASC|Tower Outpatient Surgical Center|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02116933||46311|
NCT02117492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000143|A Randomized Trial Comparing Horizontal and Vertical Vaginal Cuff Closure|A Randomized Trial Comparing Horizontal and Vertical Vaginal Cuff Closure||Milton S. Hershey Medical Center|No|Enrolling by invitation|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||July 2015|July 13, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117492||46268|
NCT02117765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00939|Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D|Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes|UST1D|University of British Columbia|Yes|Recruiting|March 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|35 Years|No|||July 2015|July 16, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02117765||46248|
NCT02118012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140084|Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C|Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118012||46229|
NCT02119611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140086|Deep Brain Stimulation Therapy in Movement Disorders|Deep Brain Stimulation Therapy in Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119611||46106|
NCT02119832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLEX-1-002-IR|A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)|A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction||TVA Medical Inc.|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||April 2014|April 21, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119832||46089|
NCT02118610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058491|Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity|Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity||University of Maryland|Yes|Recruiting|September 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||June 2015|June 9, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118610||46183|
NCT02120339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH|Carvedilol PAH A Pilot Study of Efficacy and Safety|Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|99 Years|No|||November 2015|November 13, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120339||46050|
NCT02103751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS06-01|Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers|A Multi-center Study to Determine the Levels of Biomarkers of Potential Harm and Biomarkers of Exposure to Cigarette Smoke in Asian Adult Smokers and Non-smokers||Philip Morris Products S.A.|Yes|Completed|July 2007|February 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1069|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy male and female Japanese smokers and non smokers, 30 years of age or older.|June 2014|June 18, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02103751||47320|
NCT02103764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG-SIAUB|Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB|The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial|SI-AUB-RCT|Mahidol University|No|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||July 2015|July 4, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02103764||47319|
NCT02132195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068101|Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome|Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome||Emory University|Yes|Recruiting|May 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|20 Years|No|||February 2016|February 11, 2016|December 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02132195||45143|
NCT02100215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPtSim-Ashland|Quantifying the Influence of Expert Modeling|Quantifying the Influence of Expert Modeling on Novice Nurse Competence and Self-Efficacy||Oregon Health and Science University|No|Recruiting|November 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|60 Years|No|||March 2014|March 26, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02100215||47592|
NCT02100514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481045|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events|A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|SPIRE-LL|Pfizer|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|690|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100514||47569|
NCT02100566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ 71476|Behavioral Economics for Advance Care Options|Behavioral Economics for Advance Care OptioNs|BEACON|Genesys Regional Medical Center|No|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|350|||Both|50 Years|N/A|No|||November 2015|November 2, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100566||47565|
NCT02100800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/09|Assessment of Emphysema Using 1.5T MRI With UTE Pulse Sequences|Assessment of Emphysema in COPD Patients Using 1.5T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences|EMPHYREM|University Hospital, Bordeaux|No|Recruiting|May 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|40 Years|N/A|No|||January 2015|January 8, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02100800||47547|
NCT02100813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1014|Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis||LEO Pharma|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|220|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100813||47546|
NCT02100826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15312|A Study of Cephalexin in Healthy Participants|Randomized, Open-label, 2-period, 2-treatment, 2-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of 2 Oral Preparations in Tablets With 1g of Cephalexin (Keflex® Made in Mexico by Eli Lilly vs. Keflex® Made in Italy by Facta) in Fasting Healthy Participants||Eli Lilly and Company|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|March 27, 2014||No||No|May 8, 2015|https://clinicaltrials.gov/show/NCT02100826||47545|
NCT02120768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310128-1-1312|Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas|Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas||Fudan University|Yes|Recruiting|March 2014|December 2018|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|14 Years|80 Years|No|||April 2014|April 22, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02120768||46017|
NCT02116946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00254|Plasma Injections Plus Exercise for Patellar Tendinopathy|Intratendinous Injections of Platelet Rich Plasma With or Without Leukocyte Enrichment for Patellar Tendinopathy: a Randomized Controlled Trial|PHS|University of British Columbia|Yes|Recruiting|March 2014|April 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|50 Years|No|||April 2015|April 22, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116946||46310|
NCT02117232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-001|Effectiveness and Safety of the Colonoscopy With "Visualization" Balloon|A Randomized Controlled Trial to Evaluate Effectiveness and Safety of the Colonoscopy With the "Visualization" Balloon||Mercy Medical Center|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|216|||Both|17 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117232||46288|
NCT02118623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH091384|Internet-Based Interventions for Bipolar Disorder (MoodSwings 2)|1/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder||University of Melbourne|Yes|Active, not recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|21 Years|65 Years|No|||April 2015|April 1, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118623||46182|
NCT02118883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESSHOV102|Dehydration, Rehydration, and Blood Viscosity|Randomized, Double-blind, Parallel Arm Study of the Effect of Essentia Water, an Electrolyzed High-pH Bottled Water, on Serial Blood Viscosity and Other Hydration Biomarkers in Healthy Subjects||Essentia Water, LLC|No|Completed|April 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|100|||Both|25 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118883||46162|
NCT02118896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0857|Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant|A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen||Astellas Pharma Inc|No|Completed|January 2003|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|850|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 17, 2014|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT02118896||46161|No Kaplan-Meier estimates for PMR-EC-1210 due to the short subject participation period and the low number of subjects.
NCT02119143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-151 ex 13/14|Micronutrient Supplementation and Incidence of Common Cold|Influence of Micronutrient Supplementation on Duty Days Lost Due to Flu/Common Cold, Immune System, Oxidative Stress and Wellbeing in a Cohort of Middle Management Employees||Green Beat|Yes|Active, not recruiting|April 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|82|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119143||46142|
NCT02119403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smi7531|Hand Held Nitrous Oxide Delivery Device|Safety and Efficacy of Hand Held Nitrous, a Device That Delivers 16 Grams of Nitrous Oxide Over 120 Seconds of Inhalation Time.|HHN|Strata Medical Innovations|Yes|Recruiting|July 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|250|||Both|3 Years|N/A|No|||April 2014|April 17, 2014|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119403||46122|
NCT02119845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLEX-1-001|A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-001|A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol FLEX-1-001||TVA Medical Inc.|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|80 Years|No|||April 2014|April 21, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119845||46088|
NCT02120066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye015|Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm|||Kyorin University|No|Completed|January 2011|April 2014|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|40 Years|95 Years|No|||April 2014|April 18, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120066||46071|
NCT02119819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15062|A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes|Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes||Eli Lilly and Company|No|Completed|April 2014|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|420|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119819||46090|
NCT02120079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-150H|The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease|The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease||Massachusetts Eye and Ear Infirmary||Completed|February 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|89 Years|No|||April 2014|October 28, 2015|February 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120079||46070|
NCT02120599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401112|Interventions for Moderate Malnutrition in Pregnancy|Randomized Controlled Trial of the Impact of Treating Moderately Malnourished Women in Pregnancy|Mamachiponde|Washington University School of Medicine|No|Recruiting|March 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1800|||Female|14 Years|N/A|No|||December 2015|December 17, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120599||46030|
NCT02129166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400056|Explore the Synergy of Combination TKI Therapy|Explore the Synergy of Combination TKI Therapy - A Pilot Study to Evaluate the Effect of Imatinib on Dasatinib Pharmacokinetics in Healthy Volunteers||University of Florida|No|Withdrawn|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|April 30, 2014|Yes|Yes|PI resigned|No||https://clinicaltrials.gov/show/NCT02129166||45374|
NCT02129179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO1860|The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure|The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure||Papworth Hospital NHS Foundation Trust|No|Not yet recruiting|June 2014|||June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2014|May 1, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129179||45373|
NCT02103777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICU MUCH 2013|High Versus Low Dose of Caffeine for Apnea of Prematurity|High Versus Low Dose of Caffeine for Apnea of Prematurity: A Double Blind Randomized Control Trial||Mansoura University Children Hospital|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|N/A|10 Days|No|||April 2014|April 3, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02103777||47318|
NCT02099721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Improve SCA|Improve Sudden Cardiac Arrest Study|Improve Sudden Cardiac Arrest Study||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|4800|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099721||47630|
NCT02099747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT-RACE|hATG+CsA vs hATG+CsA+Eltrombopag for SAA|A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.|RACE|European Group for Blood and Marrow Transplantation|Yes|Recruiting|May 2015|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|N/A|No|||October 2015|October 14, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099747||47628|
NCT02099968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORONA|Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial|Intensivierte Ernährungs- Und Lebensstilmodifikation Bei Patienten Mit Bluthochdruck Und Kardiometabolischer Risikokonstellation. Eine Zweizentrische Randomisiert-kontrollierte Interventionsstudie über 6 Monate||Universität Duisburg-Essen|No|Active, not recruiting|April 2014|December 2015|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|25 Years|75 Years|No|||December 2015|December 1, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099968||47611|
NCT02099955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAU-11-092|Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI|Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|December 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02099955||47612|
NCT02100878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1107|Exercise and Neural Response to Food Cues in Children|Effect of Exercise on the Neural Response to Food Cues and Energy Intake in Lean and Obese Adolescents||Université Blaise Pascal, Clermont-Ferrand|No|Withdrawn|March 2014|March 2015|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|0|||Male|12 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Lean and obese adolescents will be recruited accodring to the international curves for        obesity. they will be between 12 to 15 years old and will have no medical limitations to        complete exercise testings.|April 2014|April 1, 2014|March 27, 2014||||No||https://clinicaltrials.gov/show/NCT02100878||47541|
NCT02100553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2311065|Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women|A Phase 1, Open Label, Two Period, Fixed Sequence, Parallel Group Study To Estimate The Effects Of Multiple Dose Administration Of Itraconazole On The Single Dose Pharmacokinetics Of Conjugated Estrogens/Bazedoxifene In Non Obese (Bmi <30 Kg/m2) And Obese (Bmi ≥30 Kg/m2) Postmenopausal Women|CE/BZA|Pfizer|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Female|40 Years|64 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100553||47566|
NCT02100852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGR-GA-106|TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)||TG Therapeutics, Inc.|Yes|Active, not recruiting|March 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02100852||47543|
NCT02117505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104088|A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Two JNJ-54781532 Tablet Formulations Under Fed Conditions in Healthy Adult Subjects||Janssen Research & Development, LLC|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117505||46267|
NCT02117778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI IRB13086|Comparison of Pulmonary Function and Efficacy of Different Nerve Block Catheters for Shoulder Surgery|A Comparative Pulmonary Function Study of Continuous Supraclavicular, Suprascapular, and Interscalene Nerve Catheters After Total Shoulder Arthroplasty||Benaroya Research Institute|Yes|Active, not recruiting|January 2014|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02117778||46247|
NCT02118025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECC-1|Coronary Bypass Grafting With Minimal Extracorporeal Circulation System Versus Off-pump Coronary Surgery|Prospective Randomized Comparison of Coronary Bypass Grafting With Minimal Extracorporeal Circulation System (MECC) Versus Off-pump Coronary Surgery. New Insights Into Inflammatory Cytokines.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|January 2006|June 2013|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|230|||Both|18 Years|90 Years|No|Probability Sample|230 patients with indication for coronary surgery established on the basis of current        published guidelines. All patients provided written consent to enter the study.|March 2014|April 16, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02118025||46228|
NCT02118324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS119|Exergaming Intervention in ALL Patients|The Effect of a Home-based Fitness Intervention on Cardiometabolic Risk Profile in Acute Lymphoblastic Leukemia (ALL) Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|35|||Both|5 Years|17 Years|No|||June 2014|June 5, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02118324||46205|
NCT02118337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6020C00001|A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies|A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies||MedImmune LLC|No|Recruiting|May 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|99 Years|No|||December 2015|December 22, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118337||46204|
NCT02118922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002178|A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia|A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia||Massachusetts General Hospital|No|Recruiting|June 2013|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|28|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|General population|April 2014|April 17, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118922||46159|
NCT02119156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116027|Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.|An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects.||GlaxoSmithKline|No|Recruiting|May 2014|February 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|163|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119156||46141|
NCT02119624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140094|Neural Substrates of Approach-Avoidance Conflict|Neural Substrate of Approach-Avoidance Conflict||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2015|March 24, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119624||46105|
NCT02120105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6402|Cystine Capacity Clinical Study (CysCap)|Cystine Capacity Clinical Study (CysCap)||New York University School of Medicine|No|Recruiting|September 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|8 Years|80 Years|No|Non-Probability Sample|For patients to be enrolled in this study they must have a diagnosis of cystinuria.|March 2016|March 24, 2016|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02120105||46068|
NCT02120092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClopidogrelTicagrelorASA|The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man|The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man||Medical University of Vienna|Yes|Completed|October 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|89|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120092||46069|
NCT02120352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200056|A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects|A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects||ViiV Healthcare|Yes|Active, not recruiting|April 2014|December 2020|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|310|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120352||46049|
NCT02129452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301056458|Olfactory Neuroepithelial Tissue of Alzheimer Disease|Research of Olfactory Neuroepithelial Tissue as a Potential Biomarker of Alzheimer Disease||Seoul National University Hospital|No|Completed|January 2013|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|40|Samples With DNA|Tissue including olfactory neuroepithelium from nasal cavity|Both|18 Years|85 Years|No|Non-Probability Sample|primary care clinic|May 2015|May 26, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129452||45352|
NCT02103517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI37B04|Fish Oil and Cardiovascular Suboptimal Health|Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 Fatty Acids in Subjects at High Cardiovascular Risk and Suboptimal Health Status||Chinese PLA General Hospital|Yes|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|422|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 2, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02103517||47338|
NCT02103530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC13MISI0184|Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT|Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT||The Catholic University of Korea|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|19 Years|N/A|No|||January 2016|January 31, 2016|February 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103530||47337|
NCT02103543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061868|Comparison of the Order of Treatment in Lumbar Spinal Stenosis|A Randomized Trial in Patients With Lumbar Spinal Stenosis, Comparing the Order of Treatment With Epidural Corticosteroid Injections and Physical Therapy||Emory University|Yes|Suspended|January 2014|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|March 27, 2014||No|Haven't been able to recruit any cases so far|No||https://clinicaltrials.gov/show/NCT02103543||47336|
NCT02099734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-016|Germ Cell Tumor and Testicular Tumor DNA Registry|Germ Cell Tumor and Testicular Tumor DNA Registry||Memorial Sloan Kettering Cancer Center||Recruiting|January 2014|||January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|blood saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|At MSKCC, the following outpatient clinics will be used to recruit GCT and testicular        tumor cases and controls: Urology (Department of Surgery), Gynecologic Oncology        (Department of Surgery) Clinical Genetics, Genitourinary Oncology (Department of        Medicine), and Gynecologic Medical Oncology (Department of Medicine).|February 2016|February 11, 2016|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099734||47629|
NCT02100254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 159309|Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities|CRC Screening Thoughts and Feelings: Increasing Engagement of African Americans||Roswell Park Cancer Institute|No|Recruiting|October 2009|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02100254||47589|
NCT02100241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPR2012|Effectiveness Analysis of Active Stretching Versus Active Stretching With Low Frequency Currents|Effectiveness Analysis of Active Stretching Versus Active Stretching With Low Frequency Currents||Rodríguez, Francisco Piqueras, M.D.|Yes|Completed|April 2012|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Male|10 Years|16 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02100241||47590|
NCT02101177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12291|Evaluation of the National Treatment Program of Hepatitis C in Egypt|Evaluation of the National Treatment Program of Hepatitis C in Egypt, Using Data Coming From Two Treatment Centres.|eNTC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Withdrawn|April 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|0|Samples With DNA|-  Plasma        -  Serum        -  PBMC|Both|18 Years|60 Years|No|Non-Probability Sample|Patients included in the study will be those with prior approval from the Ministry of        Health to begin the bi-therapy and attending two centres of the National Treatment        Program.|March 2014|July 22, 2014|March 26, 2014||No|Study objectives were considered as absolete regarding the arrival of new antiviral drugs in    Egypt.|No||https://clinicaltrials.gov/show/NCT02101177||47518|
NCT02101190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-106|Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment|Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment||Bial - Portela C S.A.|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|January 20, 2012||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT02101190||47517|
NCT02100865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0206-01|Solar Powered Oxygen Delivery|Solar Powered Oxygen Delivery: An Open-label Non-inferiority Comparison to Standard Oxygen Delivery Using Oxygen Cylinders||University of Alberta|Yes|Recruiting|March 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|13 Years|No|||April 2015|April 20, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02100865||47542|
NCT02118038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111013|Emotional and Cardiac Impact of Postpartum Haemorrhage|Emotional and Cardiac Impact of Postpartum Haemorrhage. Observational Study HELP-MOM.|HELP-MOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|November 2020|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|Samples Without DNA|Serum and plasma|Female|18 Years|N/A|No|Non-Probability Sample|Patients with postpartum hemorrhage|November 2015|November 30, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02118038||46227|
NCT02118350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilates|Effect of Mat Pilates Training on Blood Pressure of Hypertensive Individuals|Effect of Mat Pilates Training on Blood Pressure of Hypertensive Individuals||Federal University of São Paulo|Yes|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|30 Years|59 Years|No|||April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118350||46203|
NCT02118363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13101|INTERACTION, Monitoring of Stroke Patients in Hospital and Home Environment|Proof of Concept Study of the INTERACTION Technology, Monitoring of Stroke Patients in Hospital and Home Environment|INTERACTION|University of Zurich|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|subakut or chronic stroke patients|December 2015|December 1, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02118363||46202|
NCT02118636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009.057|Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms|Prospective Observational Study of Breast Cancer Patients Starting Therapy With an AI to Evaluate Mechanisms Underlying Development of Aromatase Inhibitor Associated Musculoskeletal Symptoms||University of Michigan Cancer Center|No|Completed|October 2009|September 2015|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|Whole blood is being collected at baseline for DNA extraction. Serum is being collected at      baseline and after 3, 6, and 12 months.|Female|21 Years|N/A|No|Non-Probability Sample|Postmenopausal women with hormone receptor positive breast cancer who are initiating        therapy with an aromatase inhibitor|March 2016|March 3, 2016|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118636||46181|
NCT02118909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI-007|Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects|A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects||MEI Pharma, Inc.|No|Completed|May 2014|August 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|April 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02118909||46160|
NCT02100033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC1-090|How Acupuncture Sensation Propagated to Effect the Energy of Channels|||China Medical University Hospital||Recruiting|October 2013|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02100033||47606|
NCT02103829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-PAU-1|"Quit Smoking on Your Own" Brief Online Study|"Quit Smoking on Your Own" Brief Online Study|TC-PAU-1|i4Health|No|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103829||47314|
NCT02100293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1307/209-006|Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium|||Seoul National University Hospital|No|Recruiting|October 2013|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|75 Years|No|||June 2014|June 12, 2014|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02100293||47586|
NCT02142049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1124-CA|Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma|A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma||Pharmacyclics|No|Recruiting|May 2014|June 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142049||44388|
NCT02142062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-13|Venogram vs. Intravascular Ultrasound (IVUS) for Diagnosing Iliac Vein Obstruction|Prospective, Single-arm, Multi-center, Pilot Study of IVUS Imaging Used as an Adjunct to Multiplanar Venography During Iliac-common Femoral Vein Assessment for Possible Endovascular Intervention|VIDIO|Volcano Corporation|No|Active, not recruiting|July 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects with iliac compression disease CEAP classification 4-6. Hospitals, venous clinics|July 2015|July 20, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142062||44387|
NCT02142309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGM 7-2006|Glycemic Durability After Metformin Failure|Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes|AMAZING|Second University of Naples|No|Recruiting|October 2005|January 2017|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|450|||Both|30 Years|70 Years|No|||November 2015|November 17, 2015|April 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142309||44368|
NCT02139085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPC 2014|Great Saphenous Vein Electrocoagulation|A Prospective Double Blind Randomized Controlled Trial Of Electrocoagulation Versus Radiofrequency Treatment Of The Great Saphenous Vein In Patients With Varicose Veins.||Instituto Dante Pazzanese de Cardiologia|No|Recruiting|August 2014|July 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139085||44615|
NCT02138760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-MRI-2014|Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy|Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy||Kaiser Permanente|No|Not yet recruiting|August 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Male|30 Years|79 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138760||44640|
NCT02139059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61179|Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria|Staged Ureteroscopy After Initial Urinary Drainage Versus Direct Ureteroscopy in the Treatment of Pediatric Obstructive Calcular Anuria||Cairo University|Yes|Recruiting|June 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|12 Years|No|||February 2015|February 2, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139059||44617|
NCT02139072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400096|CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients|Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome||University of Florida|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139072||44616|
NCT02139423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC12025|Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening|Feasibility to Achieve, Before One Month of Age, the Diagnosis of Congenital CMV Diagnosis and the Formal Audiologic Assessment in Newborns Who Failed Newborn Hearing Screening|CymeAudit|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|November 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|624|||Both|N/A|10 Days|No|||November 2015|November 30, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02139423||44589|
NCT02140255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1115|IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission|IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Recruiting|January 2015|December 2023|Anticipated|December 2023|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|472|||Both|N/A|10 Days|No|||October 2015|October 6, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140255||44526|
NCT02102581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orthopedic deparment|Evaluation of Short-term Effects of Tourniquet Use in Different Ways During Total Knee Arthroplasty|Evaluation of Short-term Effects of Tourniquet Use in Different Ways During Total Knee Arthroplasty: a Randomized Controlled Trial||Peking Union Medical College Hospital|Yes|Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|N/A|N/A|No|Probability Sample|60 consecutive patients who underwent routine TKA were included in this prospective        randomized study.|March 2014|March 30, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02102581|14 Days|47410|
NCT02102035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen8992|Direct and Reversed Dorsal Digital Island Flaps: A Review of 65 Cases|||The Second Hospital of Tangshan|Yes|Completed|January 2011|February 2014|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|65|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||October 2013|March 28, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02102035||47452|
NCT02103088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCAN|Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners|PROCAN: Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners: A Randomized Controlled Intervention Study|PROCAN|Danish Cancer Society|No|Recruiting|May 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|320|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103088||47371|
NCT02103335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-0052-107|Combination Study of Pomalidomide, Marizomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma|A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma||Triphase Research and Development I Corporation|No|Recruiting|June 2014|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 3, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103335||47352|
NCT02103348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13242|Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program|Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program|CAESAR|University of California, San Francisco|No|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|75|Samples With DNA|Samples of induced sputum and blood for DNA and RNA extraction, plasma, and serum will be      banked in the UCSF Airway Tissue Bank.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|A diverse sample of subjects with asthma is needed to gain better understanding of asthma        and its endotypes. CAESAR will therefore enroll subjects between 18 and 65 years with a        physician diagnosis of asthma as well as a group of healthy subjects. The target        recruitment goal for UCSF is 50 adults with asthma and 25 healthy controls (age 18 and        older). Within the asthma group, an attempt will be made to enroll 60% of subjects with        severe with the rest of the subjects mild to moderate asthma.Within the cohort, an attempt        will be made to enroll at least 50% females and 10% minorities.|September 2015|September 15, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02103348||47351|
NCT02103608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO105306A|Clinical Evaluation of Silk'n Glide for Face|Clinical Evaluation of Silk'n Glide for Face||Home Skinovations Ltd.|Yes|Active, not recruiting|September 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||March 2014|April 3, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02103608||47331|
NCT02103621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402-002|Assisting Obsessive Compulsive Disorder (OCD) Patients With Discontinuing Long-term Serotonin Reuptake Inhibitors (SRIs)|Discontinuation of Long-term SRIs in Obsessive Compulsive Disorder||Butler Hospital|Yes|Recruiting|May 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103621||47330|
NCT02103868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMHPOZariW2013|Medium Vs Low Intensity Intervention in Tobacco Cessation and Control in Zari Workers|Interventional Study to Determine the Effectiveness of Medium Intensity Verses Low Intensity Tobacco Use Prevention and Cessation Intervention in the Unorganized Sector of Zari Workers in Mumbai|ZARI|Tata Memorial Hospital|Yes|Recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|400|||Both|15 Years|90 Years|No|||February 2015|February 4, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02103868||47311|
NCT02103881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR #13-3682|Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital|A Double Blinded Randomized Trial of Ketamine Versus Haloperidol for Severe Prehospital Agitation||Minneapolis Medical Research Foundation||Withdrawn|April 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103881||47310|
NCT02099812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT-12-483|Web-based Collection of Data on Obesity and Health Behavior|||Virginia Polytechnic Institute and State University||Completed|December 2012|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1585|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Amazon Mechanical Turk users|March 2014|March 28, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02099812||47623|
NCT02099825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306084|Medication Enhanced Rapid Therapy|Medication Enhanced Rapid Therapy|MERiT|Washington University School of Medicine|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02099825||47622|
NCT02100046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0186|Assessment of the Effectiveness of Ethosuximide in the Treatment of Traumatic Neuropathic Pain|Assessment of the Effectiveness of Ethosuximide in the Treatment of Traumatic Neuropathic Pain.|EDONOT|University Hospital, Clermont-Ferrand||Recruiting|March 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Male|18 Years|N/A|No|||September 2014|September 5, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02100046||47605|
NCT02100306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCH-1234-SF|The Role of Auditory Feedback in Guiding Upper Extremity Movements|||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|26|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02100306||47585|
NCT02142322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0406-127-007|Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer|A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer||Seoul National University Hospital|No|Completed|June 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT02142322||44367|
NCT02138188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISP-DT1-ITA13 (CE-2393)|Psychological Aspects and Insulin Pump Therapy|Psychological Aspects and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Adults.||Universita di Verona||Recruiting|September 2013|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|65 Years|No|Non-Probability Sample|Outpatient setting|May 2014|May 13, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138188||44684|
NCT02138786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-010|Selinexor in Initial or Relapsed/Refractory Richter's Transformation|A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Richter's Transformation (RT)|SIRRT|Karyopharm Therapeutics, Inc|Yes|Recruiting|November 2014|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138786||44638|
NCT02139436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL117037|Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI|Hybrid-FES Exercise to Prevent Cardiovascualr Declines in Acute SCI||Spaulding Rehabilitation Hospital|No|Recruiting|December 2013|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|20 Years|40 Years|No|||November 2015|November 16, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139436||44588|
NCT02139449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0098|Prospective Study on Prognosis of Cardiac Resynchronized Therapy (CRT), Implantable Cardioverter Defibrillator (ICD) Implantation in Patients With Congestive Heart Failure (CHF)|||Yonsei University|No|Recruiting|May 2014|May 2025|Anticipated|May 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients with congestive heart failure (CHF) who are undergone cardiac resynchronized        therapy (CRT), implantable cardioverter defibrillator (ICD) implantation|May 2014|May 13, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139449||44587|
NCT02139748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0387|The Clinical Effect of Implant Placement With a Simultaneous Soft Tissue Allograft|The Clinical Effect of Implant Placement and Simultaneous Grafting Using Acellular Dermal Matrix Allograft vs. Acellular Dermal Matrix Allograft Plus Bovine-Derived Xenograft||University of Louisville|Yes|Not yet recruiting|July 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02139748||44564|
NCT02139982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A145-1|The Study of Regional Hemodynamic Changes After Specific Brachial Plexus Block by Ultrasound Guidance|The Study of Regional Hemodynamic Changes After Specific Brachial Plexus Block by Ultrasound Guidance||Wenzhou Medical University|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|10||Actual|110|||Both|18 Years|70 Years|No|||July 2014|July 25, 2014|May 7, 2014||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT02139982||44546|
NCT02139995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics-42|West-China Transfusion Score for Critically-ill Patients|West-China Transfusion Score for Critically-ill Patients||West China Hospital|No|Not yet recruiting|May 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02139995||44545|
NCT02140268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5613C00003|To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers|A Phase 1, Single-center, Fixed-sequence, Open Label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers||Ardelyx|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|65|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02140268||44525|
NCT02102828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14045-14-008|Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty|Efficacy of Prolonged Distal Calf Compression as Part of a Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty: a Randomized Clinical Trial in 100 Patients||TriHealth Inc.|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102828||47391|
NCT02132650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1149-R|Rehabilitating Corticospinal Control of Walking|Rehabilitation of Corticospinal Control of Walking Following Stroke|ABC of Walking|VA Office of Research and Development|No|Recruiting|June 2014|June 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02132650||45109|
NCT02132663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3386-1|The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants|The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants||Mead Johnson Nutrition|No|Completed|May 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|315|||Both|N/A|14 Days|Accepts Healthy Volunteers|||April 2015|April 30, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132663||45108|
NCT02103361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTO1275PSO4037|Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project|Stelara® Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project||University of California, San Diego|No|Recruiting|November 2013|July 2020|Anticipated|November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|Women who have had exposure to Stelara (ustekinumab) within 3 months of the last menstrual        period, or anytime during pregnancy, and who reside in the U.S. or Canada.|January 2016|January 26, 2016|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02103361|2 Years|47350|
NCT02133170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP: 4094|"Mindfulness vs Psychoeducation in Bipolar Disorder"|Comparative Efficacy of Two Adjunctive Psychosocial Interventions (Mindfulness or Psychoeducation) Versus Treatment as Usual in Bipolar Patients With Subsyndromal Deppresive Symptoms: A Pilot Randomized Trial|BI-MIND|Instituto de Investigación Hospital Universitario La Paz|No|Not yet recruiting|September 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|60 Years|No|||May 2014|May 6, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02133170||45069|
NCT02133183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00907|TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma|Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients||National Cancer Institute (NCI)|No|Suspended|May 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 6, 2014|No|Yes|Scheduled Interim Monitoring|No||https://clinicaltrials.gov/show/NCT02133183||45068|
NCT02133482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1352.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)||Boehringer Ingelheim||Withdrawn|July 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|May 7, 2014||||No||https://clinicaltrials.gov/show/NCT02133482||45045|
NCT02133742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061079|A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer|A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (AG-013736) In Combination With Pembrolizumab (MK-3475) In Patients With Advanced Renal Cell Cancer||Pfizer|No|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02133742||45025|
NCT02100059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-16795|Motor and Sensory Deficits Following Partial Meniscectomy|Motor and Sensory Deficits Following Partial Meniscectomy||Creighton University|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02100059||47604|
NCT02100072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-MK-HH01|Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis|Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis||Cynosure, Inc.|No|Completed|June 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|55 Years|No|||July 2015|July 29, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02100072||47603|
NCT02100319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279-012|Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "|Azilva Tablets Special Drug Use Surveillance "Hypertension Complicated by Diabetes "||Takeda|No|Active, not recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension|January 2016|January 20, 2016|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02100319||47584|
NCT02100644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200776|Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -|Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -||GlaxoSmithKline|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|15 Years|N/A|No|||November 2015|December 24, 2015|March 27, 2014||No||No|November 5, 2015|https://clinicaltrials.gov/show/NCT02100644||47559|
NCT02138500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431004|A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865|A Phase 1, Open-label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gabaa Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of Pf-06372865 In Healthy Subjects||Pfizer|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|5|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138500||44660|
NCT02138773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|617-CL-CN3|A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects|A Randomized, Single Dose, Open-label, Cross-over Study on Bioequivalence of Two Formulations of Tamsulosin Hydrochloride Prolonged Release Capsule (Tamsulosin Pellet From Meppel Plant and Nishine Plant) Under Fed and Fasted Conditions in Chinese Healthy Male Subjects||Astellas Pharma Inc|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|80|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138773||44639|
NCT02139488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N13OME|Organ Motion and Early Tumor Response Measurement|Organ Motion and Early Tumor Response Measurement During Chemotherapy for Esophageal Cancer||The Netherlands Cancer Institute|No|Recruiting|December 2013|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|54|||Both|18 Years|N/A|No|Non-Probability Sample|-  Histologic evidence of invasive adenocarcinoma or squamous cell cancer of the             esophagus          -  Patient eligible for trimodality treatment (chemoradiotherapy and surgery) or             definitive chemoradiotherapy|October 2015|October 8, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02139488||44584|
NCT02139098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOR1328-SP8|Alternative Dosing Regimens in the Pharmacotherapy of Insomnia|Phase III Study on Alternative Dosing Regimens in the Pharmacotherapy of Mild to Moderate Insomnia|ALPHASOM|Philipps University Marburg Medical Center|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|150|||Both|18 Years|69 Years|No|||June 2014|June 5, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02139098||44614|
NCT02139462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH096779-01|Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa|Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa||Stanford University|Yes|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 10, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139462||44586|
NCT02139475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0772|Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study|||Yonsei University|No|Recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|20 Years|N/A|No|Non-Probability Sample|patients undergoing colonoscopy after colorectal cancer surgery|May 2014|May 14, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139475||44585|
NCT02139761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00059193|L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder|L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder||University of Maryland|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|50 Years|No|||March 2015|March 25, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139761||44563|
NCT02140580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.3, 6th June 2013|OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP|Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure|OPTIMIST-A|Menzies Institute for Medical Research|Yes|Recruiting|December 2011|December 2019|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|606|||Both|N/A|6 Hours|No|||September 2015|September 21, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140580||44501|
NCT02140593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lap2014NMB|The Laparotomy Study|Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized?||Herlev Hospital|Yes|Recruiting|September 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140593||44500|
NCT02132052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0952|Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography|Defining Cognitive and Motor Phenotypes of Parkinson's Disease (PD) With Magnetoencephalography|PHENO|University of Colorado, Denver|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|18|||Both|40 Years|N/A|No|Non-Probability Sample|University of Colorado Hospital Movement Disorders Clinic Patients|February 2016|February 1, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132052||45153|
NCT02132065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-386|Unilateral Dual TAP (Transverses Abdominal Plane) Blok i Forbindelse Med Laparoskopisk Nyre Operation|Unilateral Dual TAP (Transverses Abdominal Plane) Blok i Forbindelse Med Laparoskopisk Nyre Operation||University Hospital Roskilde|Yes|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 15, 2015|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02132065||45152|
NCT02102841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0410|Investigating Immune Mechanisms in Atopic Eczema|Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge||University College, London|No|Active, not recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 5, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102841||47390|
NCT02132923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103420|A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections|Prospective Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections||Janssen R&D Ireland|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|N/A|5 Years|No|Non-Probability Sample|Pediatric patients hospitalized with a laboratory confirmed Respiratory Syncytial Virus        (RSV) lower respiratory tract infection.|October 2015|October 2, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02132923||45088|
NCT02132910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380491|Restorative Exercise for Strength Training and Operational Resilience (RESTORE) for Chronic or Recurrent Low Back Pain||RESTORE|Defense and Veterans Center for Integrative Pain Management||Active, not recruiting|December 2013|February 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Both|18 Years|68 Years|No|||January 2016|January 27, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02132910||45089|
NCT02133196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140104|T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer|A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|February 2020|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|70 Years|No|||November 2015|December 2, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133196||45067|
NCT02133495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMBella1|An Outcomes Assessment of the Utility of Belladerm Acellular Dermal Allograft in Ocular Lower Lid Retraction Repair|Use of Non-Cadaveric Human Acellular Dermal Tissue (BellaDerm®) in Lower Eyelid Retraction Repair||SGM Physician Research Consortium|No|Completed|January 2011|January 2014|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|95 Years|No|||May 2014|May 7, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133495||45044|
NCT02133508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28891|A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)|Observational Trial on Long Responses in Patients With Advanced Non-Small Cell Lung Cancer Treated in Second-Line With Erlotinib||Hoffmann-La Roche||Recruiting|April 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with non-small cell lung cancer (NSCLC)|May 2014|May 7, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02133508||45043|
NCT02133755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS-Pilot|Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study|Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study|PCOS-Pilot|IWK Health Centre|No|Not yet recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Female|18 Years|45 Years|No|||May 2014|May 6, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133755||45024|
NCT02129855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-2013|Metabolic Costs of Daily Activities in Older Adults|Metabolic Costs of Daily Activities in Older Adults|CHORES-XL|University of Florida|Yes|Recruiting|July 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community dwelling population|October 2015|October 29, 2015|February 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02129855||45321|
NCT02129842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-AFib-001|Is Endothelial Function a Predictor of Successful Ablation Therapy Provided to Patients With Atrial Fibrillation?|A Prospective, Non-randomized, Double Blind Multicenter Study to Assess Endothelial Function Using Endo-PAT2000 and Its Correlation to Clinical Outcome Following Ablation in Patients With Atrial Fibrillation||Itamar-Medical, Israel|No|Active, not recruiting|May 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|AFib patients eligible for ablation treatment|December 2014|February 24, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129842||45322|
NCT02100332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-402-IT|A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)|Prevalence of Comorbidities of COPD in the Exacerbator Phenotype - A Cross Sectional Disease/Condition Focused Observational Study on COPD|PREFER|Takeda|No|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|45 Years|85 Years|No|Probability Sample|Patients with COPD will be enrolled at hospital and pulmonology departments in Italy.|March 2014|March 26, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02100332||47583|
NCT02138214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13115|Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer|Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer||University of Wisconsin, Madison||Recruiting|June 2014|December 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|21 Years|73 Years|No|||March 2016|March 18, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138214||44682|
NCT02138513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.WO14.C153|(Cost-)Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in Cancer Patients|(Cost-) Effectiveness of Mindfulness Based Cognitive Therapy (MBCT) in Cancer Patients: a Superiority Trial of Online and Face-to-face Treatment Versus Treatment as Usual (TAU).|BeMind|Radboud University|Yes|Active, not recruiting|April 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02138513||44659|
NCT02140034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPL Study|Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial|Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial (EPL Study)|EPL|National University Hospital, Singapore|Yes|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|600|||Both|21 Years|80 Years|No|||May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140034||44542|
NCT02139774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1320|Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer|Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|October 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|15|||Male|65 Years|N/A|No|Non-Probability Sample|Men aged 65 and older with Prostate Cancer|December 2015|December 2, 2015|February 26, 2014||No|inadequate accrual|No||https://clinicaltrials.gov/show/NCT02139774||44562|
NCT02140008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0011|A Comparison of the I-gel and the Self-pressurised Air-Q Intubating Laryngeal Airway in Children|||Yonsei University|Yes|Completed|May 2014|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|80|||Both|1 Month|108 Months|No|||September 2014|September 21, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02140008||44544|
NCT02140021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0021|Prevalence of Anal Dysplasia and Cancer in Women|Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|All patients undergo anal Pap and anal HPV testing.|Female|18 Years|N/A|No|Non-Probability Sample|Women with high-grade dysplasia or squamous cell carcinoma of the cervix, vagina, or vulva        at The University of Texas MD Anderson Cancer Center, Houston, Texas, and Lyndon Baines        Johnson Hospital, Houston, Texas|March 2016|March 1, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140021||44543|
NCT02140294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ALD-01|Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease|Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease - A Randomized Control Trial||Institute of Liver and Biliary Sciences, India|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02140294||44523|
NCT02141113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129704 ADINT|Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).|Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD|ADINT2012|Rochester Center for Behavioral Medicine|No|Completed|November 2012|November 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|November 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141113||44460|
NCT02132078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTR_Diverticulitis|Epidemiology of Diverticulitis in Lung Transplant Recipients|Long-term Follow-up of Lung Transplant Recipients With Diverticulitis||University of Zurich|Yes|Completed|January 1992|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|18|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We want to retrospectively analyse our prospective database of lung transplant recipients        at our institution between 1992 and 2013 with diverticulitis episodes.|May 2014|May 5, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02132078||45151|
NCT02132351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-1|Non-invasive Methods Questionnaire|Acceptability, Reliability and Applicability of Liver Biopsy and Noninvasive Methods for Assessment of Hepatic Fibrosis and Cirrhosis Among Hepatologists; a Web Based Survey||Al-Azhar University|No|Recruiting|August 2013|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|90 Years|No|Probability Sample|Hepatologists|May 2014|May 5, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132351||45131|
NCT02133235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212175RINC|The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker|The Need and the Effectiveness of Fiberoptic Bronchoscopy for Better Lung Collapse in Vedio-assisted Thoracic Operations Using Endobronchial Blockers||National Taiwan University Hospital|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|112|||Both|20 Years|80 Years|No|||October 2015|October 20, 2015|April 28, 2014||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT02133235||45064|
NCT02133547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-PNE-nNO-01|Determination of Normal Values of Nasal Nitric Oxide in Adults|Determination of Normal Values of Nasal Nitric Oxide Measured With the NIOX MINO Analyzer in Adults: a Pilot Study||Centre Hospitalier Universitaire Vaudois|No|Completed|February 2014|April 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|July 2015|July 27, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02133547||45040|
NCT02133209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR 91884|MRI Outcomes of Mindfulness Meditation for Migraine|MRI Outcomes of Mindfulness Meditation for Migraine||Johns Hopkins University|Yes|Recruiting|May 2014|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02133209||45066|
NCT02132936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-1003|LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris|LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris||LEO Pharma|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|463|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132936||45087|
NCT02132949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29217|A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.|A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer||Hoffmann-La Roche||Active, not recruiting|July 2014|November 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132949||45086|
NCT02132962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-162|Sarcopenia and Cirrhosis|||Rigshospitalet, Denmark||Completed|May 2014|||October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||September 2015|October 28, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02132962||45085|
NCT02133222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-04|Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy|Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy.|AMMAM|Centre Hospitalier Universitaire de Nice|No|Recruiting|May 2014|July 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02133222||45065|
NCT02133521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-0111|DLBS1033 for Acute Ischemic Stroke Patients|Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients|ADDLIST|Dexa Medica Group|Yes|Recruiting|October 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02133521||45042|
NCT02133534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011172|The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease|The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease||Duke University||Terminated|February 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||June 2014|June 3, 2014|May 6, 2014|Yes|Yes|failure to enroll|No|June 3, 2014|https://clinicaltrials.gov/show/NCT02133534||45041|Early termination of trial due to lack of enrollment.
NCT02130076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM11-0103|Interruption of TNFinhibitors and Endothelial Function|The Effect of Interruption of TNFi on Endothelial Function in Patients With Rheumatoid Arthritis|POET-VEF|Radboud University|Yes|Active, not recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stable rheumatoid arthritis who are included in another study (POEET) to        stop or continue their TNFi therapy.|April 2014|May 1, 2014|January 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02130076||45304|
NCT02130063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-IDA-01|IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose|A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)|Provide|Pharmacosmos A/S|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|511|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130063||45305|
NCT02130336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112105RIC|The Effects of High-intensity Aerobic Training in Patients With Metabolic Syndrome|The Effects of High-intensity Aerobic Training in Patients With Metabolic Syndrome and Its Dose Response Study||National Taiwan University Hospital|No|Recruiting|November 2012|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|45 Years|75 Years|No|||December 2014|December 2, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02130336||45284|
NCT02138799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0405|A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men|A Phase I, Randomized, Open-label, 2-arm Parallel-design Study to Determine the Effect of Multiple-dose Rifampin on the Pharmacokinetics, Safety and Tolerability of Single-dose Enzalutamide in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138799||44637|
NCT02139111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-009|PRC-063 in Adolescent ADHD|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients||Rhodes Pharmaceuticals, L.P.|No|Completed|April 2014|May 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|360|||Both|12 Years|17 Years|No|||July 2015|July 7, 2015|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139111||44613|
NCT02139124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-010|The Efficacy and Safety of PRC-063 in Adult ADHD Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients||Rhodes Pharmaceuticals, L.P.|No|Completed|April 2014|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|360|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139124||44612|
NCT02140307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR-MHP-OC13|Relaxation-Response-based Mental Health Promotion - Open and Calm 2013|Study of Potential Health Effects of a Relaxation-response-based Mental Health Promotion Course (RR-MHP) and the Possibilities for Its Applications in the Danish Public Health Sector|RR-MHP OC13|Rigshospitalet, Denmark|Yes|Active, not recruiting|January 2013|September 2014|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|60 Years|No|||May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140307||44522|
NCT02140320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STN003|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days||Respivert Ltd|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140320||44521|
NCT02140606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10159-I-01|Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)|An Open Phase I Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Cafusertib Hydrochloride in Combination With Subcutaneous Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)||Jiangsu Hansoh Pharmaceutical Co., Ltd.||Recruiting|May 2014|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 12, 2014||||No||https://clinicaltrials.gov/show/NCT02140606||44499|
NCT02140619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYY-20131201|Multiple Health Education Interventions for Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients|Multiple Health Education Interventions for Secondary Prevention Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients: a Prospective Cohort Study||Ministry of Science and Technology of the People´s Republic of China|Yes|Not yet recruiting|May 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Both|18 Years|80 Years|No|||May 2014|May 14, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02140619||44498|
NCT02140879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMBS|LA Moms and Babies Study (LAMBS) for Nutrition and Growth|LA Moms and Babies Study (LAMBS) for Nutrition and Growth||Pennington Biomedical Research Center|No|Recruiting|April 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02140879||44478|
NCT02131857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-0321-12-ctil|The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic|The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic|Mindfulness|Rabin Medical Center|No|Recruiting|May 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|24|||Both|8 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 4, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131857||45168|
NCT02132091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB772011|Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress|The Effect of Intermittent Fasting on Adaptive Oxidative Stress Response and Mitochondrial Biogenesis||University of Florida|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|37|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132091||45150|
NCT02132364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_34|Controlled Education Of Patients After Stroke|Controlled Education Of Patients After Stroke|CEOPS|University Hospital, Lille|No|Recruiting|January 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|60 Years|90 Years|No|||November 2015|November 3, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132364||45130|
NCT02132741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SS/0069|Optical Coherence Tomography (OCT) in Hypertension & Chronic Kidney Disease (CKD)|ASSESSMENT OF RETINAL VASCULATURE USING OPTICAL COHERENCE TOMOGRAPHY IN HEALTH, HYPERTENSION & CHRONIC KIDNEY DISEASE||University of Edinburgh|No|Recruiting|May 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers will be recruited from a research database. CKD and patients with        hypertension will be recruited from these respective clinics in secondary care.|August 2014|August 13, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02132741||45102|
NCT02129634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINGA-PACLI_01|Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial|Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial|SINGA-PACLI|Singapore General Hospital|No|Recruiting|December 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|21 Years|N/A|No|||November 2015|November 20, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02129634||45338|
NCT02129647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-00004|Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas|Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas||New York University School of Medicine|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129647||45337|
NCT02133248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0076|Identification of Donor Specific B Cells and Antibody Mediated Rejection|Identification of Donor Specific B Cells Will Positively Affect Monitoring and Treatment of Donor Specific Antibodies and Antibody Mediated Rejection||University of Wisconsin, Madison|No|Recruiting|May 2014|May 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|50|Samples With DNA|Frozen peripheral blood mononucleated cells and plasma|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Aim 1: Subjects on the wait list for kidney transplantation who are patients of the        University of Wisconsin Hospital and Clinics (UWHC) and are identified as sensitized Aim        2: Kidney transplant recipients who are having a clinically indicated biopsy due to        suspected antibody mediated rejection and are patients of the UWHC Both aims: Control        subjects recruited from the University of Wisconsin Office of Clinical Trials control        recruitment database|October 2015|October 9, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133248||45063|
NCT02133573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010710|Randomized Trial of Maternal Progesterone Therapy|Randomized Trial of Maternal Progesterone Therapy to Improve Neurodevelopmental Outcomes in Infants With Congenital Heart Disease||Children's Hospital of Philadelphia|Yes|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|N/A|No|||March 2016|March 4, 2016|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133573||45038|
NCT02129608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002370|Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management|A Feasibility Pilot Comparing a Non-invasive Low Level Laser Therapy (LLLT) With Lorcaserin to Reduce Central Adiposity in Overweight Individuals.||Mayo Clinic|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129608||45340|
NCT02130089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-186|Can Dietitians Reduce Interdialytic Weight Gain in at Risk Hemodialysis Patients Through Tailored Education on Dietary Sodium and Fluid Intake?|Can Dietitians Reduce Interdialytic Weight Gain in at Risk Hemodialysis Patients Through Tailored Education on Dietary Sodium and Fluid Intake?||Academy of Nutrition and Dietetics|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02130089||45303|
NCT02130102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFG Registration Nr. 835863|ModuLAAr - A Module Based and Scalable System for Silver-ager in Austria|Evaluation of ModuLAAr - a Module Based and Scalable System for Silver-ager Located in Assisted Living Homes in Austria|ModuLAAr|AIT Austrian Institute of Technology GmbH|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|38|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|elderly residents of assisted living homes aged 60 and above|December 2015|December 30, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02130102||45302|
NCT02139150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-050|Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy|Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139150||44610|
NCT02139501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Thrombopoietin|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) With Different Frequencies in the Management of ITP|A Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|May 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|60 Years|No|||November 2014|November 18, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139501||44583|
NCT02139787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSHTNOBESE|Radio Stories About Children's Healthy Eating and Exercise|Somali, Latino & Hmong Radio Stories About Children's Healthy Eating and Exercise: A SoLaHmo Pilot Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02139787||44561|
NCT02140047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-2301-J01|Exploratory Clinical Study of MT-2301|Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|April 2014|September 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|157|||Both|2 Months|7 Months|Accepts Healthy Volunteers|||October 2015|October 15, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140047||44541|
NCT02140333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20130819|Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC|Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|August 2013|December 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|October 5, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140333||44520|
NCT02140346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STN002|A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled RV1729 in Patients With COPD||Respivert Ltd|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|75 Years|No|||July 2015|July 1, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140346||44519|
NCT02140632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-13-018(64-16)|Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome|Local Steroid Injection vs Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Clinical Trial||Kwong Wah Hospital|No|Enrolling by invitation|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02140632||44497|
NCT02140645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.162|Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy|Association of Clinical Covariates With Non-insulin Diabetes Medication Initiation Using Electronic Medical Records (EMR)||Boehringer Ingelheim||Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Actual|4800|||Both|18 Years|N/A|No|Non-Probability Sample|T2DM patients aged 18 or older, initiating antidiabetic treatment after at least 6 months        of continuous enrollment|April 2015|April 15, 2015|May 14, 2014||||No||https://clinicaltrials.gov/show/NCT02140645||44496|
NCT02140892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0697-YO-CTIL|A Comparison Study of Two Respiratory Physical Therapy Methods and Standard Medical Treatment for Treating COPD Patients During Acute Exacerbation|||Sheba Medical Center|No|Not yet recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|50 Years|80 Years|No|||May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140892||44477|
NCT02131870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProIron|Study of the Iron Absorption From Capsules Containing Lactobacilli and Iron|||Probi AB|No|Completed||||July 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Primary Purpose: Basic Science|2||||||Female|19 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02131870||45167|
NCT02131883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-374|Outcome of Cognitive Behavioral Therapy for Patients With Severe Health Anxiety Treated in Groups|Outcome of Cognitive Behavior Therapy for Patients With Severe Health Anxiety Treated in Groups A Randomised Controlled Trial The CHAG-Trial. Categorical and Dimensional Characteristics of Personality and Predictors of Outcome|CHAG|Psychiatric Research Unit, Region Zealand, Denmark|No|Active, not recruiting|February 2014|December 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131883||45166|
NCT02132416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ec761218|Operative Treatment of Unstable Thoracic Cage Injuries and Chest Wall Deformity in Trauma|Prospective Controlled Study of Surgical Management of Unstable Thoracic Cage Injuries and Chest Wall Deformity in Trauma||Sahlgren´s University Hospital|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02132416||45127|
NCT02132715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400300|KAATSU Training to Enhance Physical Function of Older Adults With Osteoarthritis|KAATSU Training to Enhance Physical Function of Older Adults With Osteoarthritis|KAATSU-OA|University of Florida|Yes|Recruiting|September 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|60 Years|N/A|No|||September 2015|September 17, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02132715||45104|
NCT02132728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP 4244/2007|Impact of Flaxseed on the Syndrome Metabolic Inflammation|Flaxseed and Lignans: Effect of Consumption on Nutritional and Inflammatory Markers||University of Sao Paulo|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|52|||Male|20 Years|60 Years|No|||May 2014|May 21, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132728||45103|
NCT02132390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Breast-CIA|Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea|Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea||Peking Union Medical College Hospital|Yes|Not yet recruiting|May 2014|||May 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Female|18 Years|45 Years|No|||June 2014|June 2, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132390||45129|
NCT02132403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1115|(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer|PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer|PM-01|University of Illinois at Chicago|Yes|Terminated|August 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|May 5, 2014|Yes|Yes|Drug Recall|No||https://clinicaltrials.gov/show/NCT02132403||45128|
NCT02133586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDZONE|Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.|Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.|ENDZONE|Environmental Protection Agency (EPA)|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133586||45037|
NCT02132676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 15-321|Peer Support to Enhance Diabetes Shared Medical Appointments: Examining Comparative Effectiveness in VA Health Systems|Peer Support to Enhance Diabetes Shared Medical Appointments: Examining Comparative Effectiveness in VA Health Systems||VA Office of Research and Development|No|Active, not recruiting|March 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|896|||Both|18 Years|N/A|No|Non-Probability Sample|VA outpatients with uncontrolled diabetes receiving care at a participating VA Medical        Center during implementation of a P2P program for diabetes management in conjunction with        SMAs|November 2015|November 12, 2015|August 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02132676||45107|
NCT02132689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KVO-3|Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism|Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability|CONTACT-SPE|University Hospital Ostrava|No|Recruiting|March 2011|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02132689||45106|
NCT02132702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-082|Performance Attributes and User Progression While Using Ekso|Performance Attributes and User Progression While Using Ekso Robotic Exoskeleton in an Eight Week, Over Ground, Locomotor Program in Individuals With Spinal Cord Injury||Ekso Bionics||Enrolling by invitation|August 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|15 Years|65 Years|No|||April 2015|April 27, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132702||45105|
NCT02129920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M25-113|RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke|Recurrent Embolism Lessened by Rivaroxaban, an Anti-Xa Agent of Early Dosing for Acute Ischemic Stroke and Transient Ischemic Attack With Atrial Fibrillation Study (RELAXED)|RELAXED|Japan Cardiovascular Research Foundation|Yes|Recruiting|February 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Non-Probability Sample|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and        treated with rivaroxaban|April 2014|May 1, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02129920|3 Months|45316|
NCT02130154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 42422.018.12 METC 2012.319|Brown Adipose Tissue Activity and Age|Brown Adipose Tissue Activity Young and Older Individuals||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|May 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Caucasian Males|April 2014|April 30, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02130154||45298|
NCT02129868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCam09|Automated Closed-loop in Children and Adolescents With Type 1 Diabetes|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of a Novel Automated Overnight Closed-loop Glucose Control System on Day 1 of Continuous Glucose Monitoring Sensor Insertion in Comparison to Day 3 to 4 After Sensor Insertion in Children and Adolescents With Type 1 Diabetes|APCam09|University of Cambridge|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|6 Years|18 Years|No|||April 2015|April 30, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02129868||45320|
NCT02130115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 40|LungPoint ATV for Biopsy in Patients Undergoing Lobectomy|LungPoint ATV for Biopsy in Patients Undergoing Lobectomy|LABEL|Broncus Medical Inc|No|Completed|March 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|21 Years|75 Years|No|||May 2014|May 2, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02130115||45301|
NCT02130128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 42|Continuing Evaluation of the LungPoint ATV System|Continuing Evaluation of the LungPoint ATV System||Broncus Medical Inc|No|Terminated|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|21 Years|75 Years|No|||June 2015|June 3, 2015|April 28, 2014||No|Sufficient clinical evidence was gathered|No||https://clinicaltrials.gov/show/NCT02130128||45300|
NCT02129894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN-50-14|The Use of Abdominal Binders in Patients Undergoing Cesarean Sections|The Use of Abdominal Binders in Patients Undergoing Cesarean Sections: A Randomized Controlled Trial||St. Luke's Hospital, Pennsylvania|No|Recruiting|November 2013|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|50 Years|No|||April 2014|May 1, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129894||45318|
NCT02130362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-292|A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)|A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE|CAPE|AbbVie|No|Recruiting|August 2014|April 2030|Anticipated|April 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1300|||Both|6 Years|30 Years|No|Probability Sample|Pediatric patients with moderately to severely active Crohn's Disease (CD) who have been        prescribed HUMIRA according to the local label and pediatric patients being prescribed and        treated with IMM (azathioprine, 6-mercaptopurine, or methotrexate). Patients being        prescribed and treated with immunosuppressant therapy with no concurrent biologic use will        be enrolled as a reference group.|March 2016|March 1, 2016|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130362||45282|
NCT02139514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211011083|Virtual Reality Social Cognition Training for Adults With Autism Spectrum Disorders|||Yale University||Recruiting|January 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139514||44582|
NCT02141451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS081|INCB7839 With Rituximab After Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Non-Hodgkin Lymphoma|Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|May 2014|May 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141451||44434|
NCT02142218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-168|Expanded Access Program With Nivolumab to Treat Melanoma|Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)|Checkmate 168|Bristol-Myers Squibb||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2015|November 19, 2015|May 16, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02142218||44375|
NCT02142517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatic reconstruction|Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy:|Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Study|PJ|Mansoura University|Yes|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||June 2011|May 19, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142517||44352|
NCT02142530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-096|Carfilzomib Plus Belinostat in Relapsed/Refractory NHL|Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study||Massachusetts General Hospital|Yes|Recruiting|October 2014|January 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142530||44351|
NCT02139865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 14-333|The Effects of Lifting Light or Heavy Weights on Muscle Growth and Strength in Trained Young Men|The Effects of Resistance Training Intensity on Muscular Hypertrophy and Strength in Young, Resistance Trained Men||McMaster University|No|Completed|May 2014|March 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02139865||44555|
NCT02140411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DCL01|Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.|Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.||Novartis||Not yet recruiting|June 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140411||44514|
NCT02140905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERM-IRB-0001|Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis|Validation of Neck-Worn Monitoring System - A Study for Monitoring Subjects With Fluid-Management Issues Using Repeated Measurements During Hemodialysis||toSense, Inc.|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|49|||Both|21 Years|90 Years|No|Non-Probability Sample|Subjects will be volunteers, solicited using accepted recruitment methods, such as through        clinicians associated with dialysis centers. Subjects will have a clinical diagnosis of        Kidney Failure and will be currently undergoing Hemodialysis with possible related        co-morbidity of Heart Failure.|May 2014|May 19, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02140905||44476|
NCT02132104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-FXH-14-06|Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery|Amnion Graft for Preventing Intrauterine Adhesions Following Hysteroscopic Surgery||Capital Medical University|Yes|Not yet recruiting|November 2014|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|208|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132104||45149|
NCT02132117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-005|Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea|||Allergan|No|Completed|June 2014|May 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|445|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02132117||45148|
NCT02132130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCGF166X2201|Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Severe-to-profound Hearing Loss|A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss||Novartis|No|Recruiting|June 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|45|||Both|21 Years|75 Years|No|||March 2016|March 8, 2016|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132130||45147|
NCT02132442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC Docket # H00002866|Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes|Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes|VDLS|University of Massachusetts, Worcester|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|10 Years|50 Years|No|||October 2015|October 28, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02132442||45125|
NCT02132975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 14 05|Motorised Probe Holder Assisting Prostate Biopsies|Pilot Study of a Motorised Probe Holder Assisting Prostate Biopsies|PROSBOT-Apollo|University Hospital, Grenoble|Yes|Recruiting|May 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Male|18 Years|N/A|No|||June 2015|June 18, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02132975||45084|
NCT02132988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-OPT822-OC001|Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer|An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Mackay Memorial Hospital|No|Recruiting|November 2013|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Female|21 Years|N/A|No|||May 2014|May 6, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02132988||45083|
NCT02133599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 14CC06|Prediction of Delayed Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL|Prediction of Delayed Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With Acute Lymphoblastic Leukemia||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|2 Years|21 Years|No|||July 2015|July 30, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133599||45036|
NCT02133560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052665|Use of Mobile Technology for Intensive Training in Medication Management|Use of Mobile Technology for Intensive Training in Medication Management||Duke University|No|Recruiting|May 2014|||May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|5 Years|N/A|No|||January 2016|January 20, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133560||45039|
NCT02129621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01008-45|Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human|Prospective Study of Neutrophil Gelatinase Associated Lipocalin (NGAL)as a Biomarker of Mineralocorticoid Receiver Activity in Human: Proof of Concept.||Central Hospital, Nancy, France|No|Completed|May 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2013|May 1, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129621||45339|
NCT02129933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45554.042.14|VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions|A Pilot Intervention Study for the Use of VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions|VICE|University Medical Center Groningen|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02129933||45315|
NCT02130167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8C0601|Low Concentration Atropine for Myopia Progression in School Children|Low Concentrations of Atropine for Controlling Myopia Progression in School Children||Chang Gung Memorial Hospital|Yes|Recruiting|August 2012|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|12 Years|No|||August 2012|May 1, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02130167||45297|
NCT02130401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-DIA-01|Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes|Device: Investigational Study to Examine the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes||Scion NeuroStim|No|Completed|June 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|April 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130401||45279|
NCT02130648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9039|Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis|Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR||University Hospital, Montpellier|No|Recruiting|October 2012|April 2016|Anticipated|July 2015|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Samples with DNA|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women with a risk of cystic fibrosis for the foetus|April 2014|December 30, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02130648||45260|
NCT02129881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONETreg1|The ONE Study UK Treg Trial|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation|ONETreg1|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|April 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02129881||45319|
NCT02129907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thrombingeneration- anemia|The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.|The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.||HaEmek Medical Center, Israel|Yes|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|men and women over age 18 suffering from iron deficiency anemia that wasnt responded to        oral iron treatment or there is contraindication for oral iron therapy.|December 2015|December 15, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02129907|10 Weeks|45317|
NCT02130141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-RAV-FAZ-01|The Effects of Dark Chocolate on Blood Pressure in Individuals With Mildly Elevated Blood Pressure|The Effects of Dark Chocolate on Blood Pressure in Mildly Hypertensive Individuals|CHOKO|Helsinki University|No|Completed|November 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|30|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130141||45299|
NCT02130375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402021RINB|Clinical and Urodynamic Effects of Minimally Laser (IncontiLaseTM) Procedure for Female Stress Urinary Incontinence|Clinical and Urodynamic Effects of Minimally Laser (IncontiLaseTM) Procedure for Female Stress Urinary Incontinence||National Taiwan University Hospital|Yes|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|20 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02130375||45281|
NCT02139800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819208|Sustained Aeration of Infant Lungs Trial|Sustained Aeration of Infant Lungs Trial|SAIL|University of Pennsylvania|Yes|Recruiting|August 2014|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|23 Weeks|26 Weeks|No|||March 2016|March 7, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02139800||44560|
NCT02138656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGO 4866|CHiropractic for Infantile Colic Study|The Effectiveness of Chiropractic in the Treatment of Infantile Colic|CHIC|University of Southampton|Yes|Suspended|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|N/A|12 Weeks|No|||May 2014|June 17, 2015|April 28, 2014||No|Review of recruitment methods|No||https://clinicaltrials.gov/show/NCT02138656||44648|
NCT02140697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-BF-HLE|Efficacy and Safety of Hippophae Rhamnoides L. Leaf Extract on Body Fat|||Chonbuk National University Hospital|Yes|Recruiting|May 2014|||May 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140697||44492|
NCT02140125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408-CL-9101|A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects|Phase I Study of ASP2408 -Subcutaneous Single-dose, Placebo-controlled Study in Non-elderly Healthy Adult Male Subjects||Astellas Pharma Inc|No|Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02140125||44535|
NCT02140138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9104-007|An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer|An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer||CureVac AG|No|Active, not recruiting|June 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|N/A|No|||January 2016|January 18, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02140138||44534|
NCT02140658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYY20140312|Health Education Interventions for Statins Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients|Affect of Multiple Health Education Interventions for Statins Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients: a Prospective Cohort Study||Ministry of Science and Technology of the People´s Republic of China|Yes|Not yet recruiting|May 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|80 Years|No|||May 2014|May 14, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02140658||44495|
NCT02141646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 NR0113332|DASH - Decision Making in Adolescent Sexual Health|Adolescent Decision Making and HIV Risk Avoidance: Neurocognitive Factors|DASH|University of New Mexico|No|Active, not recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|300|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02141646||44419|
NCT02141659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385/TB-AK160108|This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.|A Phase 1, Randomized, Open-Label Study of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist in Japanese Patients With Androgen Deprivation Treatment-Naïve Nonmetastatic Prostate Cancer||Takeda|No|Active, not recruiting|May 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|20 Years|N/A|No|||January 2016|January 6, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141659||44418|
NCT02131909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01325-40|PC MIROIR : Effects of Mirror Therapy in Children With Hemiplegic Cerebral Palsy|PC MIROIR : Effects of Mirror Therapy in Children With Hemiplegic Cerebral Palsy|PC MIROIR|Rennes University Hospital|No|Recruiting|February 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|32|||Both|7 Years|17 Years|No|||January 2016|January 5, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131909||45164|
NCT02131922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMT-01A|Study of the Effects of Intensive Treatment of Periodontitis on Blood Pressure Control|Study of the Effects of Intensive Treatment of Periodontitis on Blood Pressure Control and Vascular Function|PerioBP|Jagiellonian University|No|Recruiting|September 2009|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|65 Years|No|||May 2014|May 5, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02131922||45163|
NCT02132754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4166-001|Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)|Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies||Merck Sharp & Dohme Corp.|No|Recruiting|June 2014|September 2019|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02132754||45101|
NCT02132429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130246|Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects|Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Migraine Subjects||Amgen|No|Terminated|May 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|May 5, 2014|No|Yes|The study was stopped due to an administrative decision not safety.|No||https://clinicaltrials.gov/show/NCT02132429||45126|
NCT02129712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121214|Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors|Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors|CRPBT|Vanderbilt University|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|16 Years|No|||June 2015|June 4, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129712||45332|
NCT02133001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103162|A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide|A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide||Janssen Research & Development, LLC|No|Completed|May 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|64 Years|No|||March 2016|March 18, 2016|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133001||45082|
NCT02130427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08909|A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy|A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|September 2010|||August 2014|Actual|N/A|Interventional|Primary Purpose: Diagnostic|4||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130427||45277|
NCT02130635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115119|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-Blind, Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients||GlaxoSmithKline|No|Completed|July 2014|August 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|75 Years|No|||September 2015|September 3, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130635||45261|
NCT02130882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140081|Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome|A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|April 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02130882||45242|
NCT02129660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM04-HH02|Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis|A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of DRM04B and DRM04 in Subjects With Axillary Hyperhidrosis||Dermira, Inc.|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|105|||Both|18 Years|N/A|No|||October 2015|January 19, 2016|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129660||45336|
NCT02129673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS101-CS201|A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension||ViSci Ltd.|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|85 Years|No|||December 2015|December 9, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129673||45335|
NCT02130609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYN13-SkinTel-Elite+-01|Skintel Integration Study|Skintel Integration Study for Use With the Elite+ Laser System||Cynosure, Inc.|No|Active, not recruiting|December 2013|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130609||45263|
NCT02130856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000042963|Newborn Kit to Save Lives in Pakistan|An Integrated Toolkit to Save Newborn Lives in Pakistan||The Hospital for Sick Children|Yes|Recruiting|April 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5250|||Female|N/A|N/A|No|||May 2015|May 20, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130856||45244|
NCT02131116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401410369|Integrated Metacognitive Therapy in First Episode Psychosis|An Integrated Metacognitive Approach to Improve Insight and Outcomes in Early Psychosis|IMT|Indiana University|No|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|35 Years|No|||February 2016|February 25, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131116||45225|
NCT02131129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401416429|rTMS in First Episode Psychosis|Cortical Activation and Cognitive Performance During Repetitive Transcranial Magnetic Stimulation in First-Episode Psychosis: A Pilot Study|EmeraldThunder|Indiana University|Yes|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|40 Years|No|||February 2016|February 25, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02131129||45224|
NCT02141178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14040418|Comparison of Bupivacaine and Exparel for Carpal Tunnel Release|Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?||University of Pittsburgh|No|Withdrawn|May 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|No|||January 2016|January 4, 2016|May 12, 2014||No|No IRB approval|No||https://clinicaltrials.gov/show/NCT02141178||44455|
NCT02141191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-D201|A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device|A Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCl Solution Administered Overnight by the tPAD Device to Subjects With Cystic Fibrosis||University of Pittsburgh|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141191||44454|
NCT02139280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13179|Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy|A Prospective Randomized Trial Examining Low- or Intermediate-Dose Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139280||44600|
NCT02139592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-011|Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"|ADCETRIS IV Infusion − Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"||Takeda|No|Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|N/A|N/A|No|Non-Probability Sample|Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma|August 2015|August 24, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02139592||44576|
NCT02140060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-14-003|6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|327|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|May 14, 2014|Yes|Yes||No|November 24, 2015|https://clinicaltrials.gov/show/NCT02140060||44540|
NCT02140359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA034855|Enhancing Housing First Programs With a Social Network Substance Use Intervention|Enhancing Housing First Programs With a Social Network Substance Use Intervention||RAND|No|Not yet recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140359||44518|
NCT02141412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.MA.10|Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia|Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia: A Dose-Finding Study||American University of Beirut Medical Center|No|Recruiting|September 2009|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|216|||Both|18 Years|80 Years|No|||April 2015|April 15, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141412||44437|
NCT02141425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-HV07|A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects|A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Doses in Healthy Subjects||Astellas Pharma Inc|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141425||44436|
NCT02132143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2014-XW|Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2|||People's Hospital of Guangxi|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|May 5, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02132143||45146|
NCT02133261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7 day study|BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study|BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study||Bardy Diagnostics, Inc.|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|80 Years|No|Non-Probability Sample|cardiac patients followed at the study site's location|June 2014|June 25, 2014|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02133261||45062|
NCT02133274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPQual-001|A Psychosocial Intervention Plus Early Palliative Care in the Reduction of Depression of Advanced Cancer Patients|A Phase II Randomized Controlled Trial to Evaluate a Brief Psychosocial Intervention Together With Early Palliative Care in Reducing Depressive Symptoms of Patients With Advanced Cancer Starting First Line Palliative Chemotherapy|PREPArE|Barretos Cancer Hospital|No|Recruiting|August 2014|August 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133274||45061|
NCT02133287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFECT-II|To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization|A Prospective, Multi-center, Randomized Trial To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization||Beijing AmsinoMed Medical Device Co., Ltd|Yes|Recruiting|August 2013|August 2020|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|80 Years|No|||August 2013|May 6, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133287||45060|
NCT02129686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-067|A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients|A Randomized Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients||Dana-Farber Cancer Institute|Yes|Recruiting|June 2014|March 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02129686||45334|
NCT02102724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P20MD006886|Fish Oil for HIV-Related Inflamm-aging and Immune Senescence|Fish Oil for HIV-Related Inflamm-aging and Immune Senescence||Rush University Medical Center|Yes|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|50 Years|65 Years|No|||May 2015|May 4, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102724||47399|
NCT02130388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0127|The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis|The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis||Ohio State University|Yes|Recruiting|May 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02130388||45280|
NCT02130622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14076|Study of Promethazine for Treatment of Diabetic Gastroparesis|A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.||Dartmouth-Hitchcock Medical Center|No|Recruiting|July 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02130622||45262|
NCT02130869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCIST|A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas|A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas||St. Jude Children's Research Hospital|No|Recruiting|September 2014|September 2020|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|N/A|21 Years|No|||October 2015|October 15, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02130869||45243|
NCT02141932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH_Card2014-1|Pocket-size Cardiovascular Ultrasound in Stroke|Clinical Influence of Pocket-size Ultrasound Examinations of the Carotid Arteries and Heart in Patients Admitted With Stroke||Levanger Hospital|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02141932||44397|
NCT02148393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-128|Implantation Enhancement by Elective Cryopreservation of All Viable Embryos|Elective Blastocyst Vitrification for Endometrial Receptivity Enhancement in High-responder Patients Undergoing in Vitro Fertilisation/Intracytoplasmatic Sperm Injection (IVF/ICSI)|ICE|Universitair Ziekenhuis Brussel|No|Recruiting|May 2014|June 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Female|18 Years|40 Years|No|||December 2015|December 8, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02148393||43900|
NCT02148653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-JT-MFD|An Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Subjects|Efficacy of an Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Overweight Subjects: Studies of Mechanisms Involving Metabolomics and Gut Microbiota Mapping||Lund University|No|Completed|February 2014|November 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|50 Years|73 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148653||43880|
NCT02140073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM2013|Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity|Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity||Belarusian Medical Academy of Post-Graduate Education||Active, not recruiting|December 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2014|May 15, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02140073||44539|
NCT02141152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10-017|Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model|Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model: The Master Protocol|NEXT-1|Samsung Medical Center|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||5|Actual|895|Samples With DNA|fresh tissue or FFPE|Both|20 Years|N/A|No|Probability Sample|patients with treatment-refractory malignancy|December 2015|December 28, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02141152||44457|
NCT02149784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140413|Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients|Palliative Resection of Asymptomatic Primary Tumor Following Effective Induction Chemotherapy in Colorectal Cancer Patients With Unresectable Distant Metastasis: a Multi-center, Prospective, Randomized Controlled Study||Sun Yat-sen University|Yes|Recruiting|September 2015|July 2019|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02149784||43794|
NCT02149797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILC-PR vs. LC|Comparison of "Pick'n Roll" Single-incision Laparoscopic Cholecystectomy Technique, and Laparoscopic Cholecystectomy|Prospective Randomized Comparative Study of New Single-incision Laparoscopic Cholecystectomy Technique, "Pick'n Roll", Versus Conventional Four-port Laparoscopic Cholecystectomy||Samsun Education and Research Hospital|Yes|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02149797||43793|
NCT02141893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC- 0160609-CALMA|Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial|Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial||University of Puerto Rico|Yes|Completed|December 2009|July 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|404|||Both|5 Years|12 Years|No|||May 2014|May 19, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02141893||44400|
NCT02141906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012014-079|A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin|A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin for the Treatment of Patients With Unresectable Hepatocellular Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02141906||44399|
NCT02142166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 14-004|The Role of Biomarker in Serum, Cerebrospinal Fluid and Parenchyma in the Context of Aneurysmal Subarachnoid Hemorrhage.|Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -|bioSAB|RWTH Aachen University|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02142166||44379|
NCT02133027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fanyingfang3|Role of the Right Portal Pedicle and Rouviere's Sulcus as an Anatomic Landmark in Laparoscopic Cholecystectomy|Role of the Right Portal Pedicle and Rouviere's Sulcus as an Anatomic Landmark in Laparoscopic Cholecystectomy in Chinese Population||Zhujiang Hospital|Yes|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||May 2014|May 3, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02133027||45080|
NCT02133014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fanyingfang1|The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis|The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis in Chinese Population.||Zhujiang Hospital|Yes|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|70 Years|No|||April 2014|May 3, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02133014||45081|
NCT02133300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|u0064027|NMES in Critically Ill Patients|Neuromuscular Electrical Stimulation in Critically Ill Patients|NESCI|Katholieke Universiteit Leuven|No|Recruiting|May 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133300||45059|
NCT02133313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-X140206005|Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis|Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis||University of Alabama at Birmingham|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Biospecimens will be retained. Cells harvested from spent peritoneal dialysate will have RNA      isolated and then cDNA will be preserved.      Supernatent of spent peritoneal dialysate will be kept.|Both|19 Years|100 Years|No|Non-Probability Sample|All patients over the age of 19 on Peritoneal Dialysis at the University of Alabama at        Birmingham|October 2015|October 21, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02133313|3 Years|45058|
NCT02102178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7683857344959085|Occupational Therapy Modulates the Pain in Cancer Patient Under Palliative Care|Occupational Therapy Modulates the Pain in Cancer Patient Under Palliative||Barretos Cancer Hospital|Yes|Completed|July 2007|November 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02102178||47441|
NCT02102191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972CE|Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking|Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking: a RCT||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 5, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02102191||47440|
NCT02129699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP 5-12 / EORTC 08111|Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy|A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC|SPLENDOUR|European Thoracic Oncology Platform|Yes|Recruiting|January 2015|April 2020|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129699||45333|
NCT02102451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1208|Control and Elimination Within Australia of Hepatitis C From People Living With HIV|A Five Year Plan of Enhanced HCV Monitoring, Primary Care-based Workforce Development, Rapid Scale-up of HCV Treatment and Public Health Policy Action in HIV Positive Individuals in Australia.|CEASE|Kirby Institute|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02102451||47420|
NCT02102464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF006|Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers|Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers||TearScience, Inc.|No|Completed|April 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102464||47419|
NCT02102204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130213|To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis|A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis||Amgen|No|Active, not recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|902|||Both|18 Years|110 Years|No|||March 2016|March 10, 2016|March 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102204||47439|
NCT02130414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC102|PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects|A Multiple Dose, Multi-stage Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Colon Tissue Distribution of Cyclosporine Capsules (CyCol®) Compared to Intravenous Cyclosporine in Healthy Male Volunteers|CYC102|Sigmoid Pharma|No|Completed|July 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02130414||45278|
NCT02131441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLLLR-001|Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection|||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|July 2013|August 2023|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|70 Years|No|||May 2014|May 2, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02131441||45200|
NCT02131727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-050|Hand Hygiene Randomized Cluster Intervention to Reduce Infections|The Kent State-Cuyahoga County Health Promotion Study||Kent State University|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 4, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02131727||45178|
NCT02138357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013D004946|Butrans for Treatment of Restless Legs Syndrome|Butrans for Treatment of Restless Legs Syndrome|Butrans|Massachusetts General Hospital|No|Withdrawn|December 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|25 Years|75 Years|No|||January 2015|January 6, 2015|May 9, 2014||No|No funding|No||https://clinicaltrials.gov/show/NCT02138357||44671|
NCT02148406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1416|Programs to Support You During Chemotherapy (Pro-You)|Programs to Support You During Chemotherapy (Pro-You): Feasibility|Pro-You|Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148406||43899|
NCT02148679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00083272|Geriatric Out of Hospital Randomized Meal Trial in Heart Failure|Effects of Home-delivered Low-sodium Meals in Older Adults Following Heart Failure Hospitalization.|GOURMET-HF|University of Michigan||Recruiting|May 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|65 Years|N/A|No|||June 2014|June 9, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148679||43878|
NCT02148939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke|Antiplatelet Effects in Stroke-Patients|Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients||Heinrich-Heine University, Duesseldorf|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|patients with ischemic stroke|March 2015|March 9, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02148939||43858|
NCT02149238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|New Drink|Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects|Acute Study to Investigate the Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects|New Drink|Heinrich-Heine University, Duesseldorf|No|Completed|February 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|36|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02149238||43835|
NCT02149251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gany 125|Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles?|Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles?||Cairo University|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|11006|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|All women who had IVF/ICSI over the past 3 years in Dar AlTeb subfertility centre will be        included in the study|November 2014|January 20, 2015|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02149251||43834|
NCT02149537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU205449|Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment|Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea||Loyola University|Yes|Enrolling by invitation|December 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149537||43813|
NCT02149810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB|Automatic Self Transcending Meditation Versus Treatment as Usual|Automatic Self-transcending Meditation (ASTM) Therapy Versus Treatment as Usual (TAU) in Late Life Depression: Implications for Cardiovascular Health and Cross-fertilization Across Different Levels of Care.||Lawson Health Research Institute|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|60 Years|85 Years|No|||March 2015|March 31, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149810||43792|
NCT02149563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Oxygen Therapy in Depression|Oxygen Therapy in Depression||Meir Medical Center|Yes|Recruiting|January 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||March 2015|March 15, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02149563||43811|
NCT02101073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0061-C102|ALX-0061 Phase I Bioavailability Study in Healthy Volunteers|A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.||Ablynx|No|Completed|April 2014|||August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02101073||47526|
NCT02133326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caldolor vs. Orfimev Clinical|Efficacy Study of IV Ibuprofen vs IV Acetaminophen Post Surgical Extraction|Assessment of Preemptive Analgesic Effect of Caldolor® vs. Ofirmev® on Third Molar Surgery: A Prospective, Randomized, Double-blinded Clinical Trial|Caldolor|Tufts University School of Dental Medicine|No|Recruiting|March 2014|November 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 19, 2014|September 17, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02133326||45057|
NCT02133612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-026|Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma|Phase 2 Study of Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Patients With Advanced Esophageal Cancer||Chinese Academy of Medical Sciences||Completed|December 2007|May 2014|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133612||45035|
NCT02129946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MY041|The Effect of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer|Human Clinical Trial to Investigate the Effects of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer in Adults at Risk for Type 2 Diabetes||University of Guelph|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|25|||Both|40 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02129946||45314|
NCT02101957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC2004-03bis|Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)|||University Hospital, Angers||Active, not recruiting|October 2010|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|65 Years|No|||July 2013|April 1, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02101957||47458|
NCT02102490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15419|A Study Of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread|A Phase 2 Study Of LY2835219 For Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer|MONARCH 1|Eli Lilly and Company|No|Active, not recruiting|June 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102490||47417|
NCT02131155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.162|LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy|A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma||Boehringer Ingelheim||Recruiting|July 2014|August 2020|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 5, 2014||||No||https://clinicaltrials.gov/show/NCT02131155||45222|
NCT02103231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YACHT|Young Adult Cardiovascular Health Trial|Young Adult Cardiovascular Health Trial|YACHT|University of Oxford|No|Recruiting|May 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|132|Samples With DNA|Whole blood, serum, plasma|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged between 18 and 40 years old, recruited from the local community and Oxford        University Hospitals Hypertension clinic, participants will have a history of preterm (<37        weeks) or full term (>37 weeks) birth.|March 2014|December 2, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103231||47360|
NCT02103504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP ATT|DePuy Attune Total Knee Arthroplasty RSA Study|Roentgen Stereophotogrammetric Analysis (RSA) of the ATTUNETM Posterior Stabilized Fixed Bearing Knee System||Nova Scotia Health Authority|No|Active, not recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|80 Years|No|||August 2015|August 6, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02103504||47339|
NCT02148146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105591|Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis|Clinical Trial of Omegaven™ Therapy for Parenteral Nutrition Associated Cholestasis||University of California, San Diego|Yes|Recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|18 Years|No|||May 2014|May 22, 2014|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148146||43919|
NCT02148692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-PROBESE|Protective Ventilation With Higher Versus Lower PEEP During General Anesthesia for Surgery in Obese Patients||PROBESE|Technische Universität Dresden|Yes|Recruiting|July 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|748|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148692||43877|
NCT02148666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMR 80/1/2014- BMS|Study of Homing of Labelled Stem Cells in Human Heart.|Labelling of Stem Cells With Technetium 99- m Hexamethylene Propylene Amine Oxide ( Tc99m HMPAO)to Monitor Homing in the Human Heart. Bench to Bedside Studies [ COLT -- COronary Labelling Trial ]|COLT|All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|August 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|10|||Both|20 Years|70 Years|No|Non-Probability Sample|patients within 3 months following myocardial infarction|June 2014|June 6, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148666||43879|
NCT02148952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPH OPP1017378|BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program|A Matched-pair, Cluster Randomized Trial to Measure the Efficacy of the WHO Safe Childbirth Checklist Program on Severe Maternal, Fetal and Newborn Harm|BetterBirth|Harvard School of Public Health|Yes|Recruiting|November 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|171964|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02148952||43857|
NCT02149264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000127|A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males|A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males||Ferring Pharmaceuticals|No|Completed|July 2014|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Male|18 Years|75 Years|No|||December 2015|December 2, 2015|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149264||43833|
NCT02149550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMGF2a|Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains|Controlled Human Malaria Infection After Bites From Mosquitoes Infected With NF135.C10 or NF166.C8 Plasmodium Falciparum Parasites (BMGF2a)||Radboud University|Yes|Completed|August 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149550||43812|
NCT02149849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/406|Surgical Positioning of the Arm During Thoracic Surgery -Effect on Shoulder Pain After Surgery?|Lateral Surgical Positioning for Thoracic Surgery -Effect on Ipsilateral Shoulder Pain?||Oslo University Hospital|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149849||43789|
NCT02149862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00038-37|FIRBladd - Use of Infrared Spectroscopy in the Diagnosis of Bladder Tumors|FIRBladd - Use of Infrared Spectroscopy in the Diagnosis of Bladder Tumors|FIRBladd|Rennes University Hospital|No|Not yet recruiting|May 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 23, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02149862||43788|
NCT02101086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankara University-06|Autologous Cord Blood Transfusion in Preterm Infants|Evaluation of the Efficacy and Safety of Autologous Cord Blood Transfusions in Premature Infants||Ankara University|No|Completed|March 2009|January 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|N/A|1 Year|No|||March 2014|March 28, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101086||47525|
NCT02101346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipophage-14|A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake|A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake|Lipophage14|Imperial College London|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02101346||47505|
NCT02101372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2010/BMD-2422|Intervention Module AGES|Gene and Environment in Schizophrenia- Research Groups in Madrid|AGES-CM|Hospital General Universitario Gregorio Marañon|No|Completed|January 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|14 Years|19 Years|No|||October 2015|October 6, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02101372||47503|
NCT02101385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE12-158|Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer|A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158||Hoosier Cancer Research Network|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101385||47502|
NCT02101645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13148|Proof-of-concept Study for Bioimpedance Based Monitoring of Venous Ulcers During Galvanic Stimulation|Proof-of-concept Study for Bioimpedance Based Monitoring of Venous Ulcers During Galvanic Stimulation||Tampere University Hospital|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|80 Years|No|||May 2015|May 12, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02101645||47482|
NCT02101658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB-NORC-expectancy pilot|Evaluating Expectancy Effects in Weight Loss Measurement|||University of Alabama at Birmingham|No|Completed|March 2014|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|59|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|undergraduate students|October 2014|October 27, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02101658||47481|
NCT02101671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/522|Inadequate Emergence After Laparoscopic Surgery in Trendelemburg Position|Inadequate Emergence After Anaesthesia in Laparoscopic Surgery in Trendelemburg Position||Corporacion Parc Tauli|Yes|Not yet recruiting|May 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|140|||Both|15 Years|N/A|No|Non-Probability Sample|Patient undergone surgery|March 2014|March 29, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02101671||47480|
NCT02101970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000703|Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women|Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention||University of Kansas Medical Center|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101970||47457|
NCT02101983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35606|Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)|A Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia||University of Rochester|Yes|Completed|May 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|55 Years|65 Years|No|||April 2015|April 3, 2015|October 14, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101983||47456|
NCT02101931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-1019|A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine|A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine|ALA|Princess Al-Johara Al-Ibrahim Cancer Research Center|No|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|April 30, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02101931||47460|
NCT02101944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00643|Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma|Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma||National Cancer Institute (NCI)||Suspended|September 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|March 28, 2014|No|Yes|Scheduled interim monitoring|No||https://clinicaltrials.gov/show/NCT02101944||47459|
NCT02103023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 14-016|Intradermal Influenza Vaccine in the Young|Intradermal Trivalent Influenza Vaccine in Young Adults, a Double-blind Randomized Controlled Trial||The University of Hong Kong|Yes|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|160|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02103023||47376|
NCT02102997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTS.DE Register V 1.2|Deutsches Dual Therapy Stent Register|Deutsches Dual Therapy Stent Register|DTS Register|OrbusNeich|Yes|Recruiting|July 2013|November 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients in Germany who have undergone PCI with the COMBO Dual Therapy Stent.|October 2015|October 15, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02102997|12 Months|47378|
NCT02102737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-14|Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique|Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose.|GLUCIMAG2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|May 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02102737||47398|
NCT02102750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201350|A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension|A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension||Santen Oy|Yes|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Month|17 Years|No|||September 2015|September 2, 2015|March 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02102750||47397|
NCT02103244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBMI|Validation of an Adjusted Dosing Algorithm of Carboplatin|Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function||Rijnstate Hospital|No|Not yet recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2014|April 2, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02103244||47359|
NCT02148159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400340|Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer|Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients With Cachexia||University of Florida|Yes|Recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|21 Years|N/A|No|||November 2015|November 23, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02148159||43918|
NCT02149290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0120|LifeVest Trends Validation Protocol|LifeVest Trends Validation Protocol|TRENDS|Zoll Medical Corporation|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with heart failure who are being cared for in an outpatient environment|July 2015|July 27, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149290||43831|
NCT02149303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.200|Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa|A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate||Boehringer Ingelheim||Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|191|||Both|18 Years|N/A|No|Non-Probability Sample|AF patients with bleeding event using Dabigatran etexilate|April 2015|April 15, 2015|May 19, 2014||||No||https://clinicaltrials.gov/show/NCT02149303||43830|
NCT02148965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMELA-649.244|Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial|Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial|PAMELA|Federal University of Pelotas|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 24, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148965||43856|
NCT02148978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016-14-HMO|Cystic Fibrosis Related Diabetes|DPP-IV Inhibition in Patients With Cystic Fibrosis||Hadassah Medical Organization||Recruiting|March 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|65 Years|No|||May 2014|May 23, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02148978||43855|
NCT02149277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ovo-12-06|Effects of Exogenous Recombinant GCSF (Granulocyte Colony-stimulating Factor ) in Patients With Repeated Implantation Failure|Effects of Exogenous Recombinant GCSF in Patients With Repeated Implantation Failure - A Randomized Single-blind Trial||OVO R & D|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|290|||Female|18 Years|37 Years|No|||October 2015|October 13, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149277||43832|
NCT02149576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_IntenseCT_Pilot|Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery|Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery: A Pilot Study for the Intense-CT Trial|Intense-CT|McMaster University|Yes|Recruiting|August 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|620|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149576||43810|
NCT02150629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2011 0257|Investigating Kinematic and Electromyographic Changes After SCI and Their Relation to Clinical and Functional Outcome|||University of Zurich|Yes|Recruiting|January 2011|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Spinal cord injury patients and healthy control subjects|January 2016|January 6, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02150629||43729|
NCT02100839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPMX-112|Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia||LipimetiX Development, LLC|Yes|Completed|March 2014|December 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|November 23, 2015|March 27, 2014||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT02100839||47544|
NCT02101359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2380-PIII-05/10|Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery|Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery Versus Reference Group (Topical Mydriatics and Anaesthetic)||Laboratoires Thea|No|Completed|June 2011|May 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|609|||Both|40 Years|88 Years|No|||November 2014|November 4, 2014|September 4, 2013||No||No|September 19, 2014|https://clinicaltrials.gov/show/NCT02101359||47504|
NCT02101996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211238|Pilot Study to Test Dietary Fat Delivery|Pilot Study to Test Dietary Fat Delivery||University of Missouri-Columbia|No|Recruiting|June 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and insulin resistant subjects.|December 2015|December 2, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101996||47455|
NCT02101684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETHI 2013-01|Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.|Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.|Greko II|Grupo Español de Tumores Huérfanos e Infrecuentes|No|Recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02101684||47479|
NCT02101697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH093257|Reducing AIDS Stigma Among Health Professionals in India|Reducing AIDS Stigma Among Health Professionals in India|DRISTI|University of California, San Francisco|Yes|Recruiting|July 2014|July 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|3640|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02101697||47478|
NCT02102503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLAS-1-2013|Motivational Interviewing and Medication Review in Coronary Heart Disease|Motivational Interviewing and Medication Review in the Secondary Prevention of Coronary Heart Disease|MIMeRiC|Linneaus University|No|Recruiting|October 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|585|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102503||47416|
NCT02102516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1SPR11002|SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures|A Single Arm, Open Label Study of the Safety, Efficacy, and Pharmacokinetics of SPRIX (Intranasal Ketorolac Tromethamine) in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures||Luitpold Pharmaceuticals|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|11 Years|No|||November 2015|November 17, 2015|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102516||47415|
NCT02102217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro14/23|the PRECious Trial: PREdiction of Complications|PREdiction of Complications: A Step-up Approach, CRP First Followed by CT-scan Imaging to Ensure Quality Control After Major Abdominal Surgery|PRECious|VU University Medical Center|Yes|Recruiting|December 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1050|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02102217||47438|
NCT02102230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-016-13F|The Impact of CBT-I on Cannabis Cessation Outcomes|The Impact of CBT-I on Cannabis Cessation Outcomes||VA Office of Research and Development|Yes|Recruiting|November 2014|July 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02102230||47437|
NCT02103036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOLUM|Valuation of the Low Back Pain Treated With Different Types of Active Exercises in Women|Valuation of the Low Back Pain Treated With Different Types of Active Exercises in Women|ECOLUM|University Rovira i Virgili|Yes|Recruiting|March 2014|October 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02103036||47375|
NCT02102477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPCG-15|Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer|Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial|SPCG-15|Karolinska University Hospital|Yes|Recruiting|October 2014|December 2027|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Male|18 Years|75 Years|No|||February 2016|February 23, 2016|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102477||47418|
NCT02147886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-MJD-201|Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease|A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease||Bioblast Pharma Ltd.|No|Recruiting|July 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||July 2015|July 23, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147886||43939|
NCT02148419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0331|Psychosocial Development of Maltreated Children: A Prospective Study|Psychosocial Development of Maltreated Children: A Prospective Study||University Children's Hospital, Zurich|No|Recruiting|February 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|15 Years|No|Non-Probability Sample|The sample is drawn from in- and outpatients reported to CPTs at University Children's        Hospital Zurich and Children's Hospital Baden AG between July 2013 and August 2015.|June 2015|June 16, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02148419||43898|
NCT02142036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetAction|N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy|N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy|MetAction|Oslo University Hospital|No|Recruiting|May 2014|January 2022|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02142036||44389|
NCT02142283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4024|Trevo and Medical Management Versus Medical Management Alone in Wake Up and Late Presenting Strokes|Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention|DAWN|Stryker Neurovascular|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142283||44370|
NCT02149589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0192|Lung Imaging for Ventilatory Setting in ARDS|Lung Imaging for Ventilatory Setting in ARDS||University Hospital, Clermont-Ferrand||Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|420|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149589||43809|
NCT02149602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 2588|A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck|A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck|PARSPORT-II|Royal Marsden NHS Foundation Trust|No|Completed|July 2005|January 2014|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Midline pharyngeal squamous cell cancers (excluding nasopharyngeal cancers)|May 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149602||43808|
NCT02149875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605872|Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke|A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.||Shanghai 6th People's Hospital|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|30 Years|90 Years|No|||October 2015|October 20, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02149875||43787|
NCT02150135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-IMGPB-2014-02|Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients|||Seoul National University Hospital|No|Recruiting|June 2014|May 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||August 2014|August 19, 2014|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02150135||43767|
NCT02150421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWGHs|Impact of Electronic Devices on Myopia Development and Progression|Impact of School Curriculum Engaging Electronic Devices on Myopia Development and Progression in Primary Schoolchildren||The Hong Kong Polytechnic University|Yes|Active, not recruiting|September 2013|March 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|6 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary schoolchildren in Hong Kong|February 2016|February 2, 2016|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150421||43745|
NCT02138721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B670201420709|Local Treatment With RP for Newly-diagnosed mPCa|Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).|LoMP|University Hospital, Ghent|No|Recruiting|May 2014|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|85 Years|No|||September 2015|September 29, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02138721||44643|
NCT02101125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-122|Drug Interaction Study With Rosuvastatin|A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Concomitant Administration of BMS-986020 on the Single-dose Pharmacokinetics of Rosuvastatin in Healthy Subjects||Bristol-Myers Squibb|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|March 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101125||47522|
NCT02101138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140063|Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome|An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|February 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101138||47521|
NCT02101398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-09|Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke|Etude de l'Effet de Stimulations transcrâniennes en Courant Continu (tDCS) Sur Les Performances en dénomination Chez le Sujet Aphasique à Moins d'un an de Son Accident Vasculaire cérébral : Comparaison de 5 Configurations de Stimulation||Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting||||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Anticipated|5|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|March 21, 2014||||No||https://clinicaltrials.gov/show/NCT02101398||47501|
NCT02101099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFM-04|Effect of Anesthesia on Force Application During Colonoscopy|Effect of Anesthesia on Force Application During Colonoscopy|CFM|Artann Laboratories|Yes|Completed|March 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|78|||Both|30 Years|75 Years|No|Non-Probability Sample|All adult male and female patients between the ages of 30 and 75 presenting to the        participating sites for screening or diagnostic colonoscopy to be performed by any of the        investigators will be considered for inclusion.|January 2016|January 20, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101099||47524|
NCT02101112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-292|Bioavailability of Apixaban Crushed Tablet|Relative Bioavailability of Crushed Apixaban Tablets Administered With Water or Apple Sauce Compared With Intact Tablet in Healthy Subjects||Bristol-Myers Squibb|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|69|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|March 28, 2014|No|Yes||No|February 29, 2016|https://clinicaltrials.gov/show/NCT02101112||47523|
NCT02102009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFOS-01-012|Nutritional Supplementation in Adults With Chronic Respiratory Disease|Impact of Nutritional Support With an Complete Formula on Nutritional Status and Respiratory Function in Adult Patients Malnourished or at Risk of Malnutrition and Chronic Respiratory Disease..|OFOS|Laboratorios Ordesa|Yes|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|80 Years|No|||May 2015|May 28, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02102009||47454|
NCT02102022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2013-001|Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies|Phase 1 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies||Polaris Group|No|Recruiting|November 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102022||47453|
NCT02102243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102010-063|Neural Mechanism of Aldosterone-induced Insulin Resistance|The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity||University of Texas Southwestern Medical Center|Yes|Recruiting|November 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|March 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102243||47436|
NCT02102529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCO-014|Survey: Clinical Outcome After Bowel Resection in Women Due to Endometriosis|Survey: Clinical Outcome After Bowel Resection in Women Due to Endometriosis||Ludwig Boltzmann Institute for Operative Laparoscopy|No|Recruiting|April 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with typical symptoms including pelvic pain, infertility and endometriotic bowel        lesions who underwent laparoscopic surgery including colonic resection performed from 2009        to 2012|April 2014|April 14, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02102529||47414|
NCT02102789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frozen-2|A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis|Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study||Sun Yat-sen University|Yes|Recruiting|March 2014|December 2024|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102789||47394|
NCT02102776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014015|Intraoperative Mitomycin C, Amniotic Membrane Transplantation and Conjunctival Autograft for Primary Pterygium|Intraoperative Mitomycin C Application, Amniotic Membrane Transplantation and Conjunctival Autograft After Primary Pterygium Excision: A Multi-center Randomized Clinical Trial||Sun Yat-sen University|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102776||47395|
NCT02103595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001494|A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.|Perception of Insertion Pain With Soft Cannula Infusion Sets: A Multicenter, Randomized, Cross-over Study to Evaluate Accu-Chek FlexLink Plus and Accu-Chek FlexLink Under Real Life Conditions.||Hoffmann-La Roche||Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|99 Years||||October 2013|March 1, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103595||47332|
NCT02102763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AgriculturalUA|Greek Childhood Obesity (GRECO) Study|Greek Childhood Obesity Study|GRECO|Agricultural University of Athens|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|5000|||Both|10 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|A nationwide cross-sectional sample of 10-12 years old Greek schoolchildren|April 2014|April 7, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102763||47396|
NCT02103283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DME01RV|A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)|Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)||River Vision Development Corporation|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103283||47356|
NCT02103010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/895|Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer||PRETOXIS|University Hospital, Ghent|No|Recruiting|January 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|patients with head and neck cancer|December 2014|December 4, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103010||47377|
NCT02103556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/06605-9|Edible Oils in the Treatment of Constipation of Hemodialysis Patients|Double-blind Randomized Trial on the Effect of Olive Oil and Flaxseed Oil on Constipation of Hemodialysis Patients||Federal University of São Paulo|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02103556||47335|
NCT02148172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM IRB 282-13|Optimizing Plyometric Training for Functional Recovery Post-ACL Reconstruction|Optimizing Plyometric Training for Functional Recovery Post-ACL Reconstruction||University of Montana|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|35 Years|No|||December 2015|December 12, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148172||43917|
NCT02148718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W13-984|Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease|Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)|RAPIDA|AbbVie|No|Recruiting|May 2014|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148718||43875|
NCT02148991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAR-IIS-2014|Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction|Observational Clinical Trial to Assess Irbesartan Alone or in Combination With Amlodipine and Carvedilol Effectiveness in Patients With Hypertension and Left Ventricular Dysfunction||Elpen Pharmaceutical Co. Inc.|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|The study will recruit 100 patients with hypertension.|October 2015|October 9, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148991||43854|
NCT02142634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUG-3/MIC|Budesonide for Induction of Remission in Incomplete Microscopic Colitis|Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis||Dr. Falk Pharma GmbH|Yes|Recruiting|May 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|80 Years|No|||August 2015|January 20, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142634||44343|
NCT02142296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bayer-001-PED|Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)|A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration||Lawson Health Research Institute|No|Not yet recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142296||44369|
NCT02142608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR55-105|A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer|A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2||Bracco Diagnostics, Inc|No|Recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|21|||Male|50 Years|70 Years|No|||March 2015|March 17, 2015|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142608||44345|
NCT02142621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010924|Transpyloric Feeding in Severe Bronchopulmonary Dysplasia|Pilot N-of-1 Multiple Crossover Randomized Trial of Gastric and Transpyloric Feeds in Infants With Severe Bronchopulmonary Dysplasia||Children's Hospital of Philadelphia|Yes|Recruiting|June 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|24 Weeks|No|||March 2016|March 15, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02142621||44344|
NCT02138448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD302893|Implementing Personal Health Records to Promote Evidence-Based Cancer Screening|Implementing Personal Health Records to Promote Evidence-Based Cancer Screening||Virginia Commonwealth University|No|Recruiting|February 2014|September 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|46|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138448||44664|
NCT02138461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-ALG-MDB-1301|Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops|Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.||MDbackline, LLC|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|211|None Retained|Note patients will be recruited to fill out a questionnaire, describing their symptoms      related to glaucoma use drops. In this study, we are examining only patients taking either      bimatoprost or latanoprost, thus 2 cohorts. However, this is not an interventional study,      and there will be only one study visit (enrollment and questionnaire at the same time) and      no change in the patient's prescribed therapy.|Both|18 Years|N/A|No|Probability Sample|Patients taking either study medication for glaucoma.|September 2014|September 16, 2014|May 9, 2014||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT02138461||44663|
NCT02139410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGF-001|IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment|Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment|ISAAC|University of Roma La Sapienza|Yes|Completed|June 2008|November 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|589|||Both|65 Years|90 Years|No|Non-Probability Sample|Consecutive patients were enrolled from orthopedics clinic (IRCCS Galeazzi Milan) and        geriatric day service (Sapienza University of Rome)|September 2013|May 13, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139410||44590|
NCT02139709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001371|Milk-derived Gangliosides for Inflammatory Bowel Disease|Milk-derived Gangliosides as Novel Anti-inflammatory Therapy for Inflammatory Bowel Disease||University of Alberta|No|Active, not recruiting|January 2007|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|17 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02139709||44567|
NCT02101424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3179|Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department|Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department||Minneapolis Medical Research Foundation||Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department at an urban county hospital.|October 2014|October 23, 2014|October 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02101424||47499|
NCT02101736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-IST14|Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)|A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 Age 16 Years or Greater|XL184|University of Alabama at Birmingham|Yes|Recruiting|June 2014|October 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|16 Years|N/A|No|||March 2016|March 8, 2016|March 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02101736||47475|
NCT02101411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-1011207-E-F|Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)|||Taipei City Hospital|Yes|Recruiting|January 2015|May 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|90 Years|No|Probability Sample|stable angina who received routine dual antiplatelet agents therapy.|November 2015|November 3, 2015|March 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101411||47500|
NCT02101710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD0001|Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects|A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release)||UCB Pharma|Yes|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|March 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02101710||47477|
NCT02102295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LionSDP-6|Effects of Antioxidant Dentifrice on Gingivitis|Clinical Study of an Ascorbic Acid Derivative Dentifrice in Patients With Gingivitis||Lion Corporation|Yes|Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 29, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02102295||47432|
NCT02102308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|elderly1|Exercise Improves Executive Function and Dual-task Decrements|A Multicomponent Exercise Improves Executive Function and Dual-task Decrements in Gait Among Older Adults||National Yang Ming University|Yes|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 29, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02102308||47431|
NCT02102256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSOM-ABI 001|A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients|A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients||University of Southern California|Yes|Recruiting|March 2014|||February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|6 Years|No|||December 2014|December 1, 2014|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102256||47435|
NCT02102269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/991|Sonographic Evaluation of the Effect of Shoulder Orthosis on the Subluxation in Stroke Patients|Sonographic Evaluation of the Effect of Shoulder Orthosis on the Subluxation in Stroke Patients|SinSbyS&Co|University Hospital, Ghent|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02102269||47434|
NCT02102282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AMI)83/2012|Breast Cancer During Pregnancy|Observational Study of Breast Cancer Diagnosed During Pregnancy|BRCAPRE|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|October 2012|||December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood and tissue samples|Female|18 Years|60 Years|No|Non-Probability Sample|Patients with breast cancer diagnosed during pregnancy|March 2014|April 1, 2014|March 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02102282||47433|
NCT02103049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCL-2014-TX|The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients|The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients||University Medical Centre Ljubljana|No|Not yet recruiting|April 2014|May 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103049||47374|
NCT02102802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP8-S1|Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD|Exploring Mechanisms of Action of ±3,4-methylenedioxymethamphetamine (MDMA)- Assisted Psychotherapy for Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|January 2014|March 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102802||47393|
NCT02103296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393720-1|Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial|Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight (VLBW) Preterm Neonates: A Multi-center Randomized Clinical Trial||San Antonio Military Medical Center|Yes|Recruiting|February 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|225|||Both|N/A|1 Day|No|||January 2015|January 8, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02103296||47355|
NCT02103309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-13-050|Comparative Evaluation of Contact Lens Centering of DAILIES® AquaComfort Plus® Versus 1-DAY ACUVUE® MOIST® in Japan|Comparative Evaluation of Contact Lens Centering of DAILIES® AquaComfort Plus® Versus 1-DAY ACUVUE® MOIST®||Alcon Research|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|29 Years|No|||October 2014|October 24, 2014|April 1, 2014|No|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT02103309||47354|
NCT02103569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-016|Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325|Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects||Bristol-Myers Squibb|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103569||47334|
NCT02141516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_62|Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects|A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Immunocompromised Patients From 2 to 17 Years of Age Who Are at Increased Risk of Meningococcal Disease Because of Complement Deficiency or Asplenia Compared to Matched Healthy Controls||Novartis|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|239|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141516||44429|
NCT02141776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-2013|Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression|A Randomized Blinded Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation of Left Prefrontal Cortex in Patients With Treatment-resistant Depression||University of Florida|Yes|Recruiting|May 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|65 Years|No|||October 2015|October 13, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141776||44409|
NCT02142023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5505|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2014|||||N/A|N/A|N/A||||||||||||||January 28, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142023||44390|
NCT02138487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00084995|Restricted Convalescence: Outcomes Following Urogynecologic Procedures|Restricted Convalescence: Outcomes Following Urogynecologic Procedures|ReCOUP|Northwestern University|Yes|Recruiting|August 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|104|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02138487||44661|
NCT02138474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maimela200904978|The Efficacy of Lacticum Acidum Homaccord in the Treatment of Chronic Tension-type Headaches|The Efficacy of Lacticum Acidum Homaccord in the Treatment of Chronic Tension-type Headaches||University of Johannesburg|Yes|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138474||44662|
NCT02138734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-803-01-14|A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer|A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer||Altor Bioscience Corporation|Yes|Recruiting|July 2014|October 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|115|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138734||44642|
NCT02138747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-MA-1001|A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)|A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)|PREFER|Astellas Pharma Inc|No|Completed|July 2014|November 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|376|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138747||44641|
NCT02139046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEB-XR_301|Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout|A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout||Takeda|Yes|Completed|May 2014|November 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1750|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139046||44618|
NCT02139735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSM-MO-01|Therapeutic Response of Ultrasound and Muscular Stretching in Temporomandibular Disorder Patients|Therapeutic Response of Ultrasound and Muscular Stretching in Temporomandibular Disorder Patients: Clinical Trial||Universidade Federal de Santa Maria|Yes|Completed|March 2012|March 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|18|||Female|20 Years|35 Years|No|||May 2014|May 13, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02139735||44565|
NCT02102555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2013-25|A Single Dose of Intravenous (IV) Acetaminophen Verses Placebo in the Pre-operative Setting and Outcomes on Post-operative Pain, Nausea and Vomiting|A Double-blind Randomized, Placebo-controlled Study to Determine the Effectiveness of Pre-operative IV Acetaminophen Administration in Reducing Post-operative Pain, Nausea, and Vomiting in the Outpatient Setting|IV|Catholic Health Initiatives|No|Recruiting|October 2013|||October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||March 2014|March 31, 2014|January 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02102555||47412|
NCT02102568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01284-41|Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer||menocor|Centre Jean Perrin|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Female|18 Years|45 Years|No|Probability Sample|premenopausal women with age between 18 to 45 years. premenopausal women with breast        cancer non metastatic.|December 2015|December 23, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02102568||47411|
NCT02101723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0227|Effect of Sprinkles With and w/o Fe on Zn Absorption in Kenyan Toddlers|Effects of Sprinkles With and Without Iron on Zinc Absorption From Local Foods in Kenyan Toddlers, Including the Gut Microbiome||University of Colorado, Denver|No|Active, not recruiting|April 2011|December 2016|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|63|||Both|5 Months|10 Months|Accepts Healthy Volunteers|||January 2016|January 8, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02101723||47476|
NCT02103062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-COLO-001|Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer|A SINGLE ARM PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Nab®-PACLITAXEL, IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER||Celgene|No|Completed|May 2014|January 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|March 31, 2014|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT02103062||47373|
NCT02103075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-221|Neuromuscular Electrical Stimulation on Median Nerve Facilitates Low Motor Cortex Excitability in Human With Spinocerebellar Ataxia|||Chang Gung University|Yes|Completed|August 2002|October 2005|Actual|October 2005|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|29|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 31, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02103075||47372|
NCT02102542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/2555(EC3)|Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service||Mahidol University|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|65|||Both|18 Years|N/A|No|Non-Probability Sample|Participants:- 100 adult male or female patients, over 18 year old who consent to the        study.        Exclusion Criteria : Children < 18 yo, pregnant or parturient of breast feeding patients,        patients who refused or unable to give consent, patients who has co-existing problems with        dry secretion i.e. Sjögren's syndrome, glaucoma, myasthenia gravis, patient whom baseline        heart rate is > 100 bpm|March 2014|April 2, 2014|March 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02102542||47413|
NCT02102815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrthoTU06|Efficacy of Preoperative Intravenous Dexamethasone in Primary Total Knee Arthroplasty|Efficacy of Preoperative Intravenous Dexamethasone in Controlling Postoperative Pain After Primary Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial|TKA|Thammasat University|Yes|Recruiting|March 2014|September 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||April 2014|April 4, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02102815||47392|
NCT02103855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS 103-337|Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients|Calcineurin Inhibitors to Belatacept Switch Study to Prevent the Progression of Kidney Disease in Pancreas Transplant Alone Recipients||Indiana University|Yes|Active, not recruiting|June 2014|||April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103855||47312|
NCT02103322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARL/CT/13/001|Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions|A Randomized, Open Label, Two-Treatment, Multiple Dose, Steady State, Two-period, Cross-over, Multi-Centre Comparative Bioequivalence Study of Imatinib Mesylate Tablet 400 mg of Amneal Pharmaceuticals, USA With GLEEVEC® (Imatinib Mesylate) Tablets 400 mg Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions||Amneal Pharmaceuticals, LLC|Yes|Completed|February 2014|June 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|No|||June 2014|June 25, 2014|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02103322||47353|
NCT02099786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0239-R|Randomized Trial Comparison of Ototoxicity Monitoring Programs|Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial|COMP-VA|VA Office of Research and Development|Yes|Recruiting|March 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|440|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02099786||47625|
NCT02099799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1150-R|The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD|The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD|WEB|VA Office of Research and Development|Yes|Recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|185|||Both|40 Years|N/A|No|||November 2015|November 20, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02099799||47624|
NCT02103582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1516 Georgetown Lombardi|Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans|Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans|Quit and Fit|Georgetown University|No|Active, not recruiting|April 2013|December 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Female|18 Years|69 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|March 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103582||47333|
NCT02103842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000639|Omega-3 Fatty Acids to Combat Sarcopenia|Omega-3 Fatty Acids to Combat Sarcopenia||Mayo Clinic|Yes|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|March 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02103842||47313|
NCT02140112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNDO 201-101|Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder|A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER||Coronado Biosciences, Inc.|No|Terminated|May 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|5 Years|17 Years|No|||November 2015|November 3, 2015|May 13, 2014|Yes|Yes|A preliminary analysis of data from this trial failed to demonstrate any signal of activity.|No||https://clinicaltrials.gov/show/NCT02140112||44536|
NCT02140931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 12-01|Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia|A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia||Hemostemix|Yes|Recruiting|August 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140931||44474|
NCT02143557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011037|Dietary Treatment of Infants With Chylothorax|The Effectiveness of Low Fat Breast Milk for the Treatment of Chylothorax in Infants Following Cardiothoracic Surgery: A Pilot Study||The Hospital for Sick Children|No|Completed|January 2008|||February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|N/A|12 Months|No|||May 2014|May 17, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02143557||44272|
NCT02143791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-13-038-ID-SC|Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs|A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.|Prodigy-I|St. Jude Medical|No|Active, not recruiting|June 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|123|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are indicated for Spinal Cord Stimulation (SCS) and with Failed Back Surgery        Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.|June 2015|January 19, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143791||44254|
NCT02140957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000032247|Office Based Intervention to Reduce Bottle Use in Toddlers: TARGet Kids! Pragmatic Randomized Trial|Office Based Intervention to Reduce Bottle Use in Toddlers: TARGet Kids! Pragmatic Randomized Trial||The Hospital for Sick Children|No|Completed|January 2007|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|251|||Both|6 Months|1 Year|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 19, 2013||No||No|November 23, 2015|https://clinicaltrials.gov/show/NCT02140957||44472|
NCT02144363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14057|Electrical Activity of Diaphragm as a Means to Predict Extubation Success in Preterm Infants|A Prospective Study of Diaphragmatic Electrical Activity in Preterm Infants as a Means to Predict Extubation Success|Edi|Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|N/A|28 Days|No|Non-Probability Sample|A convenience sample of forty(40) preterm infants less than 35 week gestation admitted in        the ICN with the need for intubation and mechanical ventilation for respiratory distress        in the first 24 hours of life will be recruited for this study.|March 2016|March 10, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02144363||44210|
NCT02145377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00059690|PXVX0200 (CVD103-HgR) vs Shanchol in Mali|A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol™ Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator||University of Maryland|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145377||44132|
NCT02141984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-362|Surveillance of Humira in Korean JIA Patients|Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination||AbbVie|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|2 Years|17 Years|No|Probability Sample|General hospital|January 2016|January 27, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02141984||44393|
NCT02146118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-001|A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma|A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma||MedicalLogic|Yes|Recruiting|April 2014|March 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|30 Years|80 Years|No|||May 2014|May 20, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02146118||44075|
NCT02146638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFN-6932-AS|Post Operative Pain Control: Morphine vs Fentanyl|Post Operative Pain Control: Continuous Infusion of Morphine vs Fentanyl. Clinical Outcomes||Catholic University of the Sacred Heart|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|35 Years|59 Years|No|||May 2014|May 21, 2014|January 10, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02146638||44035|
NCT02140281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5613C00004|To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers|A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers||Ardelyx|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|71|||Both|N/A|50 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02140281||44524|
NCT02140567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syncope Prediction Study|Syncope Prediction Study|Syncope Prediction Study|SPS|Medtronic Bakken Research Center|No|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|90 Years|No|Probability Sample|Vasovagal syncope patients|April 2015|April 10, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02140567||44502|
NCT02140827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140508-5|Instant Messaging Program (Wechat) Improve the Quality of Bowel Preparation|Communication Through Instant Messaging Program for the Improvement of Bowel Preparation: a Two Centers Study||Fourth Military Medical University|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|770|||Both|18 Years|80 Years|No|||December 2014|December 20, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140827||44482|
NCT02140840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202550|UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib|A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma||University of Arkansas|Yes|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140840||44481|
NCT02141880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211233|The Tailgate Study: A Pilot Study Measuring the Impact of Acute Alcohol Intake on Intrahepatic Lipid|The Tailgate Study: A Pilot Study Measuring the Impact of Acute Alcohol Intake on Intrahepatic Lipid||University of Missouri-Columbia|No|Not yet recruiting|June 2014|January 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|21 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and overweight sedentary men.|May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02141880||44401|
NCT02140918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004794-27|Fludrocortisone in Healthy Volunteers (AFLUCO4)|Hemodynamic and Biological Effects of 3 Increasing Doses of Fludrocortisone in Healthy Volunteers|AFLUCO4|Rennes University Hospital|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|12|||Male|20 Years|25 Years|Accepts Healthy Volunteers|||May 2015|October 28, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02140918||44475|
NCT02142413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/033/14|HEart and BRain Interfaces in Acute Ischemic Stroke|HEart and BRain Interfaces in Acute Ischemic Stroke (HEBRAS) - A Prospective Oberservational Cohort Study|HEBRAS|Charite University, Berlin, Germany|Yes|Recruiting|May 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|475|Samples Without DNA|Biomarkers indicating myocardial damage (cardiac Troponin T), autonomic function      (Norepinephrine), prediction of atrial fibrillation (BNP).|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the specialized stroke unit at the Charité - Universitätsmedizin        Berlin, Campus Benjamin Franklin (CBF), due to an acute ischemic stroke.|January 2016|January 29, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142413||44360|
NCT02142426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-021|A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients|A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients||Southwest Regional Wound Care Center|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2000|Samples Without DNA|To pursue statistical analysis on a series of molecular laboratory results obtained from      chronic wounds|Both|N/A|N/A|No|Non-Probability Sample|Chronic wound patients|November 2015|November 24, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT02142426||44359|
NCT02139553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULRM-001|Effect of Rhythmic Upper-limb Training in Stroke Patients|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|May 2014|August 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02139553||44579|
NCT02139566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065333|Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention|Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention||Emory University|No|Completed|July 2014|September 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|2405|||Male|18 Years|34 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02139566||44578|
NCT02139579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-FXY-032|Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer|An Open-labeled, Single Arm, Multicenter Phase II Study to Evaluate Efficacy and Safety of Bevacizumab Plus Chemotherapy for Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer With EGFR-TKI Resistance||Sun Yat-sen University|Yes|Active, not recruiting|May 2014|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||May 2014|May 13, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02139579||44577|
NCT02139267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-188E_CIN3_P2|Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia|A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)||Genexine, Inc.|No|Recruiting|May 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|19 Years|50 Years|No|||July 2015|July 29, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139267||44601|
NCT02140684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/12|Exhaled Nitric Oxide in Asthma Management|Exhaled Nitric Oxide in Asthma Management: a Retrospective Real-life Observational Evaluation of the Use of Exhaled Nitric Oxide Measurements for Asthma Management in a UK Primary Care Population||Research in Real-Life Ltd||Suspended|March 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Both|6 Years|80 Years|No|Non-Probability Sample|Asthma patients who either:          -  Use eNO monitoring in their asthma management          -  Do not use eNO monitoring|May 2014|May 14, 2014|May 14, 2014||No|suspended due to lack of data.|No||https://clinicaltrials.gov/show/NCT02140684||44493|
NCT02139891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTVCARDIO022014|Effects of Multipoint Pacing CRT-D on Neurohormonal Activation.|Randomized, Crossover Study of the Effects of MultiPoint Left Ventricular Pacing on Neurohormonal Activation.||University of Rome Tor Vergata|No|Recruiting|May 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||April 2015|April 17, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139891||44553|
NCT02140424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000985|Bone Health in Youth With Type 1 Diabetes|Bone Mineral Accrual and Microarchitecture in Youth With Type 1 Diabetes||Massachusetts General Hospital|No|Recruiting|August 2013|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|66|Samples Without DNA|serum, plasma, urine|Female|10 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|youth with type 1 diabetes and healthy controls|September 2015|September 22, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140424||44513|
NCT02140437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2014-14|Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC|An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer||Fudan University|Yes|Withdrawn|March 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|80 Years|No|||December 2015|December 24, 2015|May 9, 2014||No|The progress of enrollment is too slow.|No||https://clinicaltrials.gov/show/NCT02140437||44512|
NCT02140710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST2010|Impact of Visceral Osteopathic Treatment on Meconium Evacuation in Preterm Infants|The Impact of Visceral Osteopathic Treatment on the Meconium Evacuation in Very Low Birth Weight Infants||Medical University of Vienna|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||May 2014|May 14, 2014|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02140710||44491|
NCT02140723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PART1|p53 and Response to Preoperative Radiotherapy for T2 and T3|PART1 - a Prospective Phase II Study to Evaluate the Impact of TP53 Gene Mutations in Patients With Preoperative Radiotherapy for T2 and T3 Rectal Cancer|PART1|Medical University of Vienna|No|Recruiting|August 2011|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|whole blood diagnostic tumor biopsy|Both|18 Years|99 Years|No|Non-Probability Sample|Rectal cancer patients with clinical staging T2/T3 Nx M0|March 2016|March 17, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02140723||44490|
NCT02140736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1_09.04.2009|Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology|Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study|ORHEO|Hospira, Inc.|No|Completed|September 2009|||August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2333|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have        developed symptomatic anaemia due to their chemotherapy.|July 2015|July 27, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140736||44489|
NCT02141230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202157|Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.|Evaluation of the Characteristics of Alli® Purchasers in the European Union Following the Revision to the Alli® Pack Information.||GlaxoSmithKline|No|Not yet recruiting|September 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|N/A|1||Anticipated|1524|||Both|N/A|N/A|No|||August 2015|August 27, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141230||44451|
NCT02146131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00029233|Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 )|Multicenter, Prospective, Randomized Trial of Bronchoscopy With Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) With Fluoroscopy for Biopsy of Pulmonary Lesions||Medical University of South Carolina|No|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|214|||Both|22 Years|N/A|No|||August 2014|January 19, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02146131||44074|
NCT02141503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140106|Clinical Biomarkers in Alpha-mannosidosis|Clinical Biomarkers in Alpha-Mannosidosis||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|N/A|||Anticipated|15|||Both|5 Years|60 Years|No|||February 2016|March 8, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141503||44430|
NCT02141750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENASICA III|THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES|THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES|RENASICA_III|Third National Registry of Acute Coronary Syndromes|Yes|Completed|November 2012|November 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8296|||Both|18 Years|N/A|No|Probability Sample|It will include patients older than 18 years with ACS final diagnosis and objective        evidence of atherosclerotic coronary disease. Patients will be identified in the emergency        department, coronary care units, intensive care units, hospital and hemodynamic        laboratories|May 2014|May 15, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141750||44411|
NCT02140853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1993136|MDR Bacilli Surveillance and Clinical Feature in China|Multi-drug Resistant Gram-negative Bacilli-surveillance and Clinical Feature in China|MDR|Sun Yat-sen University|Yes|Recruiting|November 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|Samples Without DNA|sputum, pleural effusion or blood|Both|18 Years|80 Years|No|Probability Sample|3000|May 2014|May 14, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140853||44480|
NCT02140866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109|Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Trial|Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Randomized Controlled Trial|RAHExercise|Parker Research Institute|No|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02140866||44479|
NCT02141100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMC-2014-6TG/6MP|Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma|A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood Non-Hodgkin's Lymphoma||Rigshospitalet, Denmark|Yes|Not yet recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|18 Years|No|||May 2014|May 28, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02141100||44461|
NCT02141373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-CTU-0912/03 Version 5.0|Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection|Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection||King Hussein Cancer Center|No|Recruiting|October 2013|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|136|||Female|18 Years|N/A|No|||April 2015|April 2, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02141373||44440|
NCT02142153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F901318-01-01-14|F901318 Single Ascending Dose Study in Healthy Male Volunteers|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects||F2G Ltd.|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|August 10, 2015|May 13, 2014||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT02142153||44380|
NCT02139813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.851|Omega Loop Versus Roux-en-Y Gastric Bypass|Prospective Multicentric Randomized Trial of Efficiency and Safety of Laparoscopic Omega Loop Bypass Versus Roux-en-Y Gastric Bypass|YOMEGA|Hospices Civils de Lyon|No|Active, not recruiting|May 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139813||44559|
NCT02139826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX-0102|Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men|A Randomised, Single-dose, 3-way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Capsule Formulation Compared With the IX-01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Capsule Formulation, in Healthy Male Subjects||Ixchelsis Limited|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139826||44558|
NCT02141438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16913|Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer|Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation|REASSURE|Bayer|No|Recruiting|August 2014|December 2023|Anticipated|September 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1334|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with histologically or cytologically confirmed castration resistant        adenocarcinoma of the prostate with bone metastases for whom the treatment decision to        Radium-223 has been made independent from and before patient enrolment in the study.|March 2016|March 3, 2016|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141438||44435|
NCT02141672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUR-VCS2012-01|AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin|A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis|AURA-LV|Aurinia Pharmaceuticals Inc.|Yes|Active, not recruiting|June 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|258|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141672||44417|
NCT02138279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCON-TON-US-0001|Comparative Study of Non-contact Tonometers for Intraocular Pressure and Corneal Cell Thickness Measurements|Comparative Study of the Topcon Tonometers - CT-800, CT-1, CT-1P and TRK-2P to Demonstrate Conformance to ANSI Z80.10-2009 Ophthalmic Instruments -Tonometers, to the FDA Guidance for Industry and FDA Staff, Tonometer-Premarket Notification [510(k)] Submissions, and to the Applicable Supplemental Information Sheet and Comparison of Pachymetry Values for CT-1P and TRK-2P With the Konan CellChek Plus (Predicate)||Topcon Medical Systems, Inc.|No|Completed|April 2014|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology practice|November 2014|April 22, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02138279||44677|
NCT02138292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012014-007|A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma|A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma||University of Texas Southwestern Medical Center|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||October 2015|October 9, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138292||44676|
NCT02139852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAHTCAPX-003-2014|Capsaicinoid Ingestion, Human Metabolism and Exercise|The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance|Phase 1|University of Prince Edward Island|No|Active, not recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02139852||44556|
NCT02141685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-AUX-011|Correlating Time-Lapse Parameters With aCGH Testing in IVF Treatment (aCGH Study)|Correlating Time-Lapse Parameters Detected by Eeva™ With Array-Comparative Genomic Hybridization Results and Ongoing Pregnancy Rates (aCGH Study)||Progyny, Inc.|No|Active, not recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|43 Years|No|Non-Probability Sample|Women undergoing fresh IVF treatment and undergoing aCGH testing, as recommended based on        medical need by the clinical site reproductive endocrinologist.|July 2015|July 9, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02141685||44416|
NCT02140177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140109|Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients|Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ'em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|430|||Both|18 Years|N/A|No|||April 2015|January 14, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140177||44531|
NCT02140164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140108|Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa|Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|12 Years|N/A|No|||February 2016|February 23, 2016|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140164||44532|
NCT02140450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910292|Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection|Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents||Mashhad University of Medical Sciences|No|Completed|February 2012|May 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|70|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02140450||44511|
NCT02140996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUC-1|Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers|Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers|MUC-1|Singapore Clinical Research Institute|Yes|Recruiting|September 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|21 Years|N/A|No|||February 2016|February 11, 2016|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140996||44469|
NCT02140970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0514|Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal|Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population||University of Colorado, Denver|Yes|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|4 Years|17 Years|No|||December 2015|December 8, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140970||44471|
NCT02140983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25076|Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes|Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes|LGT|Stanford University|Yes|Recruiting|August 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|80|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02140983||44470|
NCT02145598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMAIN|Treatment Optimization in Patients With Untreated Multiple Myeloma|Phase II Study of Bortezomib, Melphalan, Prednisone (VMP) Followed by Lenalidomide Maintenance vs. VMP Without Maintenance in Myeloma Patients Not Eligible to High-dose Chemotherapy and Autologous Stem Cell Transplantation|GERMAIN|University of Jena||Recruiting|August 2013|December 2021|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|August 13, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145598||44115|
NCT02145871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-069|A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy|A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|282|||Both|21 Years|N/A|No|||January 2016|January 21, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145871||44094|
NCT02146404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1H_lac_acc|The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow|The Effect of Insulin-induced Hypoglycemia on Brain Lactate Accumulation and Regional Cerebral Blood Flow in Patients With Type 1 Diabetes Mellitus With and Without Hypoglycemia Unawareness and Non-diabetic Controls||Radboud University|No|Completed|August 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146404||44053|
NCT02146417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP#51414|Comparison of Low Versus Normal Pressure Pneumoperitoneum - With Profound Low Versus Normal Pressure Pneumoperitoneum -With Profound Muscle Relaxation- During Laparoscopic Donor Nephrectomy|A Phase IV, Blinded, Randomized Controlled Trial to Compare the Effectiveness of Low Pressure Pneumoperitoneum - With Profound Muscle Relaxation - During Laparoscopic Donor Nephrectomy to Optimize the Quality-of-recovery During the Early Post-operative Phase|LEOPARD2|Radboud University|No|Completed|August 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146417||44052|
NCT02146430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-E309|Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia||Daiichi Sankyo Inc.|Yes|Active, not recruiting|October 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1294|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146430||44051|
NCT02141386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG4808A81|Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis|Plasticity-based, Adaptive, Computerized Cognitive Remediation Treatment (PACR) for Adults With Multiple Sclerosis (MS)||Stony Brook University||Active, not recruiting|September 2013|||September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|February 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141386||44439|
NCT02141620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA035376|n-Acetylcysteine and Cocaine|Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis||University of Kentucky|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141620||44421|
NCT02139839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-10-0002|Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14|A Single-Center Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 on Subjects With Intermediate Nugent Scores||Kimberly-Clark Corporation|No|Completed|September 2012|May 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Female|40 Years|80 Years|No|||May 2014|May 13, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02139839||44557|
NCT02140086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBT_03|Buteyko Based Remedial Breathing Therapy With Children With Asthma|||ARCIM Institute Academic Research in Complementary and Integrative Medicine||Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140086||44538|
NCT02140671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORO3112|Launching an Asthma Initiative Designed to Improve Asthma Management and Outcomes|To Deliver a Pilot Project on Effective Interventions to Ensure: Diagnostic Accuracy, Management of Risk and Control and Self-management for Asthma Patients.||Research in Real-Life Ltd||Active, not recruiting|May 2012|August 2015|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|33370|||Both|3 Years|65 Years|No|Non-Probability Sample|The patient questionnaire will be subject to local refinement in line with local needs,        targets and priorities but will assess -          -  Asthma Control e.g. ACT, or ACQ or RCP3          -  Lifestyle - i.e. smoking status          -  Comorbidities          -  Patient perceived adherence          -  Side effects        The practice and patient reports will be used to characterise the patient in terms of risk        and control. They will give a complete picture of the patient's asthma and will be used to        identify patients for diagnostic assessment, medical management and education. Patients        will then be stratified into Group 1 (patients with asthma) or Group 2 (Patients        identified for further diagnostic assessment and/or with diagnostic doubt).|May 2014|May 14, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140671||44494|
NCT02142192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS207|Natalizumab Subcutaneous Immunogenicity and Safety Study|A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis|SIMPLIFY|Biogen|No|Terminated|December 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||July 2015|July 2, 2015|May 16, 2014|No|Yes|Sponsor's decision.|No||https://clinicaltrials.gov/show/NCT02142192||44377|
NCT02142205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUS-TYS-11-10158|Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)|A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).||Biogen|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|60 Years|No|||May 2014|May 16, 2014|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142205||44376|
NCT02141919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 122013-030|Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer|A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141919||44398|
NCT02147392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140117|Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People|Assessment of [11C]ER-176 to Image Translocator Protein in Brain and Whole-Body of Healthy Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147392||43977|
NCT02140398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92013|Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women|Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial.|ESLOD|Mansoura University|Yes|Recruiting|April 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|39 Years|No|||May 2014|May 14, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02140398||44515|
NCT02147873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-RAN-0094-PTL|Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia||TetraLogic Pharmaceuticals|Yes|Terminated|June 2014|June 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 13, 2014|Yes|Yes|Study terminated due to lack of efficacy|No||https://clinicaltrials.gov/show/NCT02147873||43940|
NCT02143869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01346-39|Evolution of Corporeal Composition in the PeriOperative Period|Perioperative Body Composition Changes in Patients Undergoing Gastrointestinal or Lung Cancer Surgery|ECCOP|Hôpital Européen Marseille|No|Recruiting|December 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|346|||Both|18 Years|N/A|No|Probability Sample|Patients with gastrointestinal cancer (esophagus, gastric, pancreatic, hepatic, colorectal        and anal) or lung cancer undergoing curative surgical resection as part of their disease        management.|August 2015|August 24, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143869||44248|
NCT02140463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-014|Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)|Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)||Samsung Medical Center|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|165|Samples With DNA|circulating free DNA|Both|20 Years|N/A|No|Probability Sample|pathologically confirmed cancer patient|December 2015|December 28, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02140463||44510|
NCT02140749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46640.081.14|Trial on Short-chain Fructooligosaccharides, Microbiota, and Constipation in Adults|Randomized, Placebo-controlled Double-blind Cross-over Study to Evaluate the Effects of Short-chain Fructooligosaccharides on Stool Frequency in Constipated Subjects|TOMCAT|NIZO Food Research|Yes|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02140749||44488|
NCT02144896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-2013|Effect of Ankle Splinting on Vascular Function in Aging|Ankle Dorsiflexion Splinting Enhances Endothelial Function of Aged Leg Muscles||University of Florida|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|90|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144896||44169|
NCT02141256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45883.081.13|Can Protein Intake be Increased by Offering Protein-enriched Foods and Drinks?|Can Protein Intake be Increased by Offering Protein-enriched Foods and Drinks? Evaluation of a Pilot in a Local Residential Care Home.|EET-studie|Wageningen University|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|24|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 4, 2014|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02141256||44449|
NCT02145884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED3560|Topical Timolol Gel for the Treatment of Infantile Hemangiomas|Topical Timolol Gel for the Treatment of Infantile Hemangiomas||Rady Children's Hospital, San Diego|No|Not yet recruiting|May 2014|May 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|90 Days|No|||May 2014|May 22, 2014|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145884||44093|
NCT02145897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/CLI/11-12/001|To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI|A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intramuscular and Intravenous Administration of Autologous ADMSCS for Treatment of Critical Limb Ischemia (CLI).||Kasiak Research Pvt. Ltd.|Yes|Recruiting|August 2014|||August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||May 2014|May 20, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02145897||44092|
NCT02145910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.480|Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases|Phase I Study of Vemurafenib Combined With Whole Brain Radiation Therapy (WBRT) or Radiosurgery (SRS) for Melanoma Patients With BRAF Mutation Presented With Brain Metastases||Thomas Jefferson University|Yes|Withdrawn||||June 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|May 13, 2014|No|Yes|Study never opened to enrollment. There is no clinical benefit to patients as Vemurafenib +    SRS is the standard of care for this patient population.|No||https://clinicaltrials.gov/show/NCT02145910||44091|
NCT02146144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0026|Prospective, Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery (Peeling)|Prospective, Randomized, Controlled and Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery|Peeling|Nantes University Hospital|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02146144||44073|
NCT02146443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-222|Validation and Test-retest Study of the Star-shaped Manual Dexterity Test.|||Herlev Hospital|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|31|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146443||44050|
NCT02141139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-036|Perioperative Inflammation and Breast Cancer Outcome|Suppression of Inflammation by Using NSAIDs During Peri-operative Period Can Affect the Prognosis of Breast Cancer.||Samsung Medical Center|No|Not yet recruiting|September 2014|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1568|||Female|18 Years|75 Years|No|||May 2014|May 14, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02141139||44458|
NCT02141399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-208|A Long-Term Safety Study of ALKS 5461|A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)||Alkermes, Inc.|No|Enrolling by invitation|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141399||44438|
NCT02142465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAZ-012-0002SA|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2014|||||N/A|N/A|N/A||||||||||||||May 19, 2014|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142465||44356|
NCT02141633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120896|Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment|Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment|smoker3|University of Miami|No|Completed|April 2013|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|31|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141633||44420|
NCT02141165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/0238|Home Nasal Pressure for Sleep Apnea Management in Primary Case|Efficacy and Cost-Effectiveness of a Supersimplified System for the Management of Patients With Sleep Apneas in Primary Healthcare.|Primary|Sociedad Española de Neumología y Cirugía Torácica|No|Not yet recruiting|March 2016|March 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|70 Years|No|||November 2013|June 3, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02141165||44456|
NCT02146872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIHS-KMA|Premature Coronary Artery Disease - Clinical and Molecular Genetic Aspects|Premature Coronary Artery Disease - Clinical and Molecular Genetic Aspects|PIHS|Aarhus University Hospital Skejby|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||3|Anticipated|400|Samples With DNA|2 samples of EDTA blood (4ml glass) and 1 sample of serum (4ml glass) will be retained in a      biobank.|Both|18 Years|N/A|No|Probability Sample|Patients who has received a coronary intervention procedure at Aarhus University Hospital,        Skejby (all interventions are registered in the West Denmark Heart Registry)|May 2014|May 23, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02146872||44017|
NCT02142491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluMist240713|Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs|Pilot Project on Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in the Context of Influenza Vaccination in a Population Allergic to Eggs.||St. Justine's Hospital|Yes|Completed|November 2013|May 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|124|||Both|2 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population will be a group of 75 egg allergic children (2 to 17 years old) and a group        of 75 non-allergic children (2 to 17 years old). Egg allergic children will be selected        from the allergy clinic of a university children hospital and non-egg allergic children        will be selected from the community.|May 2014|May 19, 2014|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02142491||44354|
NCT02142504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-201|Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults|Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults||Takeda|Yes|Active, not recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|650|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142504||44353|
NCT02147639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANO3|Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy|||Cedars-Sinai Medical Center||Recruiting|September 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|20|||Male|15 Years|45 Years|No|||May 2014|May 22, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02147639||43958|
NCT02147652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7490-DE|Personalized Music Therapy and Agitation in Dementia|Assessing the Effects of a Personalized Music Therapy With Headphones on Agitation in Patients With Dementia||University Health Network, Toronto|No|Enrolling by invitation|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|60 Years|90 Years|No|||May 2015|May 26, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147652||43957|
NCT02144155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120005|Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia|Open-label Study of the Long-Term Efficacy of Intranasal Oxytocin in Patients With Schizophrenia||University of California, San Diego|No|Suspended|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|May 19, 2014|Yes|Yes|Break in funding|No||https://clinicaltrials.gov/show/NCT02144155||44226|
NCT02144415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-1020 IR-103|A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users|||Euthymics BioScience, Inc.|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|80|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144415||44206|
NCT02145403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.010|Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies|Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies||University of Michigan Cancer Center|Yes|Recruiting|September 2014|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145403||44130|
NCT02145637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0405|Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)|||Yonsei University|Yes|Not yet recruiting|July 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||April 2014|May 27, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02145637||44112|
NCT02145117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000864|Brain Biomarkers w/Mind-Body Tx in Veterans With Post Traumatic Headache (PTH)|Neuroimaging Biomarkers of Mind-Body Treatment in Veterans With Post Traumatic Headache (PTH)|Biomarkers PTH|University of California, Los Angeles|No|Recruiting|September 2013|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|60 Years|No|||May 2014|May 21, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145117||44152|
NCT02145923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-FMBC-05-01-14|Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis|Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.||Burnasyan Federal Medical Biophysical Center|No|Enrolling by invitation|May 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|16|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02145923||44090|
NCT02146157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012110|Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes|A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes||NewChapter, Inc.|No|Completed|February 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02146157||44072|
NCT02146456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colloid_tranexamic acid|Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion|The Effect of Tranexamic Acid on Blood Coagulation After Colloid Infusion During Surgery: Rotational Thromboelastography Measurement||Seoul National University Bundang Hospital||Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|80 Years|No|||May 2014|June 16, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146456||44049|
NCT02141126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI-SJH|Lower Limb Resistance Training in Older Inpatients|Can Lower Limb Resistance Training Improve Strength, Muscle Mass and Functional Outcomes in Older Inpatients in a Post-acute Rehabilitation Unit? A Randomised Controlled Trial||Royal College of Surgeons, Ireland|No|Recruiting|June 2013|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||May 2014|May 14, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02141126||44459|
NCT02142478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPS-14-01|Evaluation of Two Different Delivery Approaches of a GP Exercise Referral Scheme|Theory-informed Evaluation of Two Delivery Approaches of a GP Exercise Referral Scheme||Liverpool John Moores University|No|Active, not recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|16 Years|N/A|No|Non-Probability Sample|Inactive adults (16+ years) who have, or are at risk of developing, a medical condition        (e.g. hypertension, obesity, depression).|March 2015|March 31, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142478||44355|
NCT02138305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCIRB 13-001949|Correlation Study of Imaging Data Acquired During CABG With Data Acquired in the Cath Lab|Collaborative Pilot Study to Determine the Correlation Between Intra-Operative Observations Using SPY® Near Infra-Red Imaging and Cardiac Catheterization Laboratory Physiological Assessment of Lesion Severity (PERSEUS I Pilot Study)|PERSEUS|East Carolina University|No|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138305||44675|
NCT02138877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61178|Dismembered Pyeloplasty With and Without After Coming Stent|Dismembered Pyeloplasty With and Without After Coming Stent in Neonatal Ureteropelvic Junction Obstruction||Cairo University|Yes|Completed|January 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|6 Months|No|||January 2016|January 19, 2016|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02138877||44631|
NCT02138890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI.CR.APS1.14|APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution (APS) in Patients With Osteoarthritis (OA) of the Knee|PROGRESS II|Biomet, Inc.|No|Active, not recruiting|May 2014|April 2020|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|40 Years|75 Years|No|||December 2015|December 30, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138890||44630|
NCT02150850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00-M23-12A|Quebec Registry for Atypical Femur Fractures|Quebec Registry for Atypical Femur Fractures||McGill University|No|Recruiting|April 2012|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|AFF patients only will be asked to deposit 2 ml of saliva into a collection tube using a      standardized protocol. Individuals unable to produce 2ml of saliva will be asked to perform      at least two buccal swabs.|Both|45 Years|N/A|No|Non-Probability Sample|Patients who have sustained an AFF.|May 2014|May 27, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02150850|3 Years|43712|
NCT02146885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2012-9158|The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention|The Use of Diffuse Optical Spectroscopy to Characterize Adipose Tissue Oxygenation and Vascular Reactivity in Response to Weight-Loss Intervention||University of California, Irvine|No|Recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from University of California Irvine Medical Center        Department of Cardiology, preventive cardiology intervention program.|February 2016|February 5, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146885|3 Months|44016|
NCT02146898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000171|The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery|The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery||Beth Israel Deaconess Medical Center|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Female|18 Years|50 Years|No|||November 2015|November 16, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146898||44015|
NCT02138630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAHTCAPX-003-2014-2|Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)|The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance||University of Prince Edward Island|No|Active, not recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02138630||44650|
NCT02138643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23460613000000068|Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM)|Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM)||University of Sao Paulo General Hospital|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||February 2014|May 12, 2014|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138643||44649|
NCT02147171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/F017227/1|Carotenoid Supplementation and Normal Ocular Health|The Bioavailability of Retinal Carotenoids in the Older Human Eye and Their Effects on Photoreceptor Performance||University of Manchester|Yes|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||April 2014|May 21, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02147171||43994|
NCT02147184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH090072|Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents|Serotonin Reuptake Inhibitors and Bone Mineralization in Adolescents|SSRI_BMD|University of Iowa|No|Active, not recruiting|July 2010|May 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|280|Samples With DNA|serum plasma DNA whole blood|Both|15 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients within one month of initiating treatment with SSRIs will be recruited, regardless        of the indication for SSRIs.        Unmedicated controls will be also recruited.|June 2015|June 2, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02147184||43993|
NCT02147405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140124|PET Imaging and Lymph Node Assessment of IRIS in People With AIDS|PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|March 16, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147405||43976|
NCT02147899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM-1219-201|A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis|A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis||Symbiomix Therapeutics|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|215|||Female|18 Years|N/A|No|||November 2015|November 16, 2015|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147899||43938|
NCT02147912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCatania|Evaluation of Depression In Chronic Obstructive Pulmonary Disease|Evaluation of Depression In Chronic Obstructive Pulmonary Disease: a Longitudinal Randomized Controlled Trial.|EDIC|University Hospital, Catania|Yes|Not yet recruiting|November 2014|November 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|40 Years|80 Years|No|||May 2014|May 27, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147912||43937|
NCT02144662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM3247|Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion|To Investigate Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion||St. Marianna University School of Medicine|Yes|Active, not recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02144662||44187|
NCT02144675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020803|Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia|A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia||Rutgers, The State University of New Jersey|No|Active, not recruiting|January 2009|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144675||44186|
NCT02144909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-21514|Partners in Care With Semi-Structured Support Group|||University of Hawaii|No|Completed|November 2013|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02144909||44168|
NCT02145130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuroSkinGraft / ESG-01-2011|Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects|A Phase I, Two Armed, Open, Prospective and Multicentre Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adults||University Children's Hospital, Zurich|Yes|Recruiting|May 2014|October 2021|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|1 Year|70 Years|No|||February 2016|February 22, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145130||44151|
NCT02145390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130896|Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy|A Phase II Study of Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy||University of Miami|Yes|Recruiting|June 2014|||August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145390||44131|
NCT02145650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-SPAS-001|Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs||STRETCh|Allergan|No|Withdrawn|May 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|2 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI in clinical practice evaluated        for spasticity.|November 2015|November 2, 2015|May 21, 2014||No|Study suspended due to company decision prior to enrollment.|No||https://clinicaltrials.gov/show/NCT02145650||44111|
NCT02145611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ABR07T|Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension|12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension||Hospital de Base|No|Recruiting|July 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|N/A|No|||August 2015|August 17, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02145611||44114|
NCT02145624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iMAP2|A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants|A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants|iMAP2|Public Health England|No|Recruiting|October 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|360|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02145624||44113|
NCT02142686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyst 1|Comparison Between Different Filling Pressures in Diagnostic Outpatient Hysteroscopy|Comparison Between Different Filling Pressures in Diagnostic Outpatient Hysteroscopy: A Double Blinded Randomised Controlled Trial.||Cairo University|Yes|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|240|||Female|18 Years|60 Years|No|||January 2016|January 26, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142686||44339|
NCT02142946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-026|Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study|Quantified Balance Measures During Stance and Gait: Clinical Relevance for Multiple Sclerosis Patients in Comparison to Patients With Inner Ear Balance Problems. A Longitudinal Clinical Study.|MS-Gait|University Hospital, Basel, Switzerland|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||10|Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with MS or UVL|November 2015|November 30, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142946||44319|
NCT02142179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KARE-001|Impact of a Curriculum Intervention on Asthma Knowledge in Adolescents of a Public School in Salvador-Bahia-Brazil|Impact of a Curriculum Intervention on Asthma Knowledge in Adolescents of a Public School in Salvador-Bahia-Brazil|KARE|Federal University of Bahia|No|Completed|November 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|181|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02142179||44378|
NCT02142452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28810|Cardiovascular Health in Postpartum Women Diagnosed With Excessive Gestational Weight Gain|Cardiovascular Health in Postpartum Women Diagnosed With Excessive Gestational Weight Gain||Stanford University|No|Recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02142452||44357|
NCT02138604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dp/dt to detect AMD in ED|Non Invasive dP/dt to Detect an Acute Ischemic Myocardial Dysfunction in Emergency Department|Non Invasive dP/dt is Not a Good Index to Detect an Acute Ischemic Myocardial Dysfunction in Emergency Department (ED)|dP/dtAMDED|University of Monastir|Yes|Recruiting|June 2013|June 2016|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients presenting to the emergency department with acute chest pain|May 2014|May 12, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02138604|12 Months|44652|
NCT02138617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1317|Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer|Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|May 2014|May 2022|Anticipated|May 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138617||44651|
NCT02139540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204023|Nitrous Oxide as Treatment for Major Depression - a Pilot Study|Nitrous Oxide as Treatment for Major Depression - a Pilot Study||Washington University School of Medicine|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139540||44580|
NCT02150863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000121|Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study|Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study||Massachusetts General Hospital|Yes|Not yet recruiting|August 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|85 Years|No|||May 2014|May 29, 2014|March 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150863||43711|
NCT02150876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The SWEET registry|SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent|SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent The SWEET Registry||University of Freiburg|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients treated with SYNERGY stents at Bern and Fribourg university        hospitals and La Tour Hospital in Geneva until June 30, 2014 will be retrospectively        included in the study.|December 2015|December 1, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150876||43710|
NCT02146911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200/2012|The MATCH (Medication Aids for Tobacco Cessation and Health) Study|Evaluating the Real-world Effectiveness of Varenicline and Bupropion for Long-term Smoking Cessation|MATCH|Centre for Addiction and Mental Health|No|Recruiting|May 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|19 Years|90 Years|No|||November 2015|November 12, 2015|May 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146911||44014|
NCT02146924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13447|Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia|Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia||City of Hope Medical Center|Yes|Recruiting|September 2014|||September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146924||44013|
NCT02147197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1309|A Study of the Efficacy and Safety of a Single Ulipristal Treatment Course for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas||Watson Pharmaceuticals||Active, not recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|50 Years|No|||December 2015|December 23, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147197||43992|
NCT02147418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1310|Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma|An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma||New Mexico Cancer Care Alliance|Yes|Recruiting|February 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|All oropharyngeal rinse (gargle) specimens will be processed within 24 hours of collection.      Any remaining material after testing will be stored for a period not to exceed 1 year in a      secure location.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patient population will consist of adults presenting to the Division of Otolaryngology        - Head and Neck Surgery at the University of New Mexico with previously untreated OPSCC.        Both HPV-positive and HPV-negative malignancies will be collected as the study and control        groups, respectively. In addition, saliva samples will be collected from patients        presenting with benign conditions as a further negative control.|January 2016|January 6, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147418||43975|
NCT02147665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031150|Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin||Cedars-Sinai Medical Center|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02147665||43956|
NCT02148185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-J02|Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease|A Phase I, Open-label Study to Evaluate PK, PD, and Safety of a Single Oral Dose of MT-1303 in Subjects With Moderate to Severe Crohn's Disease||Mitsubishi Tanabe Pharma Corporation|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|65 Years|No|||September 2014|September 10, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02148185||43916|
NCT02148432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0232|Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome|||Yonsei University|No|Recruiting|May 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148432||43897|
NCT02148445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000666|Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers|Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers||University of Kansas Medical Center|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|398|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148445||43896|
NCT02148705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW 2010-03-02|A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns|A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care||MediWound Ltd|Yes|Recruiting|April 2015|November 2019|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|70 Years|No|||January 2016|January 27, 2016|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148705||43876|
NCT02144688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT 015|COMO: Cognition Study With HIV+ Patients (CTNPT 015)|CTNPT 015 - Pilot Project to Implement a Step-wise Investigation That Includes Cerebrospinal (CSF) Analysis as a Standard of Care for HIV+ Individuals With Cognitive Symptoms|COMO|McGill University Health Center|Yes|Terminated|June 2011|March 2016|Actual|March 2016|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 29, 2014||No|In 14 participants who had LP, very low level viremia was found in only 1|No||https://clinicaltrials.gov/show/NCT02144688||44185|
NCT02145143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-031|Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study|Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2014|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02145143||44150|
NCT02145156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0402|Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination|Educational Intervention to Minimize Disparities in HPV Vaccination|HPV|University of Colorado, Denver|No|Active, not recruiting|June 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|1205|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145156||44149|
NCT02145416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO-051|ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy|Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy|ART|University of Oxford|No|Recruiting|October 2014|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients receiving radical CRT for anal cancer within Oxford University Hospitals|November 2015|November 2, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145416||44129|
NCT02145429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH096997-01A1|Preventing Depression in Late Life: A Model for Low and Middle Income Countries|Preventing Depression in Late Life: A Model for Low and Middle Income Countries||University of Pittsburgh|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|60 Years|N/A|No|||November 2015|November 30, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145429||44128|
NCT02145663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUSBS2013|Helsinki Ultra-acute Stroke Biomarker Study|Helsinki Ultra-acute Stroke Biomarker Study||Helsinki University Central Hospital||Recruiting|May 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Human Serum and Plasma|Both|18 Years|N/A|No|Probability Sample|Patients with suspected acute stroke, being transported by emergency medical services        (EMS) to a tertiary hospital stroke center, as candidates for thrombolytic treatment of        acute ischemic stroke.|March 2015|March 24, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02145663||44110|
NCT02145676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-127|OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity|||Allergan|Yes|Terminated|May 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|80 Years|No|||January 2016|January 30, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145676||44109|
NCT02142699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE01047|Heme Arginate in Cardiac Surgery Patients|Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery|HACS|University of Edinburgh|No|Not yet recruiting|July 2014|November 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|60 Years|N/A|No|||May 2014|May 15, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02142699||44338|
NCT02143466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00006|AZD9291 in Combination With Ascending Doses of Novel Therapeutics|A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON)||AstraZeneca|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|198|||Both|18 Years|100 Years|No|||March 2016|March 4, 2016|May 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143466||44279|
NCT02143479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-ADV-NI-002|A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year|A Cohort Study in Liver Transplant Patients Converted From a Tacrolimus Twice a Day (Prograf®) to Tacrolimus Once a Day (Advagraf®). French, Multisite, Observational Study|COBALT|Astellas Pharma Inc|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Liver transplant patients|March 2016|March 3, 2016|May 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143479||44278|
NCT02138318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA12/10210|High Definition Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis (UC)|Randomized Controlled Trial of High Definition White Light Endoscopy Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|May 2012|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02138318||44674|
NCT02139228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V37_07E2|Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children|A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine||Novartis|No|Completed|November 2014|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|426|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|May 13, 2014||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT02139228||44604|
NCT02139241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramosetron_opcab|The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery|The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery||Seoul National University Hospital|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|114|||Both|20 Years|80 Years|No|||May 2014|November 17, 2015|November 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02139241||44603|
NCT02140099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/2013|Evaluation of the Healthy Relationships Plus Program for Youth|Evaluation of the Healthy Relationships Plus Program for Youth||Centre for Addiction and Mental Health|No|Completed|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|238|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140099||44537|
NCT02140372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00747|Anti-platelet Effects of Colchicine in Healthy Volunteers|Anti-platelet Effects of Colchicine in Healthy Volunteers||New York University School of Medicine|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 14, 2014|No|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT02140372||44517|
NCT02140385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120289|Role of Preservation of Scarpa's Fascia in Abdominoplasty|Role of Preservation of Scarpa's Fascia in Abdominoplasty: a Prospective Trial||Loma Linda University|Yes|Withdrawn|July 2014|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02140385||44516|
NCT02150603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9231|Patient-Reported Outcomes in Adults With Congenital Heart Disease|Assessment of Patterns of Patient-reported Outcomes in Adults With Congenital Heart Disease - International Study|APPROACH-IS|Universitaire Ziekenhuizen Leuven|No|Completed|April 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with congenital heart disease who are in continuing follow-up at an adult        congenital heart disease center or included in a national/regional registry.|March 2015|March 11, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02150603||43731|
NCT02147431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3684|A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes|A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|64 Years|No|||May 2015|May 22, 2015|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147431||43974|
NCT02147678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140522|A Comparison Between Propofol and Etomidate in Hysteroscopy on Effect of Postoperative Sedation and Cognitive Function in Elderly Patients|||Shaanxi Provincial People's Hospital|No|Not yet recruiting|December 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|80 Years|No|||May 2014|May 27, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147678||43955|
NCT02147925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS201404|Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects|Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease|LIGHT-ON|Sun Yat-sen University|No|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|30 Years|75 Years|No|||November 2014|November 5, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02147925||43936|
NCT02147938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-ADV-NI-003|A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)|French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)|OPALE|Astellas Pharma Inc|No|Recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Renal transplant patients|March 2016|March 3, 2016|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147938||43935|
NCT02147951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120166|Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma|A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma||Amgen||No longer available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|95 Years|No|||February 2016|February 26, 2016|May 1, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02147951||43934|
NCT02148198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRO-041-part 1|Effect of NWT-03 on Blood Pressure - Part 1|A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects. Part 1: A Dose Ranging, Cross-over Study to Determine the Effect of 1g, 2g & 5gs of NWT-03 Versus Placebo on Blood Pressure in Healthy Subjects.||Newtricious R&D BV|Yes|Completed|May 2013|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|92|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|November 6, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148198||43915|
NCT02141269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5906|Comparitive Effectiveness of PME Versus Transthoracic Echocardiogram (TTE)|Comparative Effectiveness of Pocket, Mobile, Hand-held Echocardiography and Conventional Transthoracic Echocardiography in an Inpatient and Outpatient Clinical Setting||Scripps Translational Science Institute|No|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Inpatient and outpatient subjects with an order for a routine transthoracic echocardiogram        based on clinical indications.|May 2015|May 19, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT02141269||44448|
NCT02141542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-613|Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma|Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma||Dana-Farber Cancer Institute|Yes|Recruiting|May 2014|February 2019|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141542||44427|
NCT02145442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBEX-IFG-2014|Effects of Obex in Overweight and Obese Patients|Effects and Safety of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose||Catalysis SL|Yes|Completed|June 2014|November 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|60 Years|No|||June 2014|February 4, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145442||44127|
NCT02145169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4507FBD|Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study|Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study||Albert Einstein Healthcare Network|Yes|Recruiting|October 2013|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145169||44148|
NCT02146170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140105|Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors|Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|April 2025|Anticipated|April 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|18 Years|100 Years|No|||March 2016|March 19, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02146170||44071|
NCT02146469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH2012VAR|Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine|Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine||Shanghai Municipal Center for Disease Control and Prevention|Yes|Enrolling by invitation|December 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|1200|||Both|1 Year|7 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146469||44048|
NCT02143193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11082-11-058|Skin-to Skin Contact on Newborn Temperature|THE EFFECTS OF SKIN-TO-SKIN CONTACT ON NEWBORN TEMPERATURE, INITIAL BATH AND EARLY BREASTFEEDING||TriHealth Inc.|Yes|Completed|August 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|325|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143193||44300|
NCT02143492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-NTS-020|Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC|Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC||Argos Therapeutics|No|Completed|August 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|Samples With DNA|Excess kidney cancer tumor specimen|Both|18 Years|N/A|No|Non-Probability Sample|Subject with advanced renal cell carcinoma (kidney cancer)|July 2015|July 27, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02143492||44277|
NCT02150356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEURONE Prot 209/2013|Effects of Aleurone-enriched Products on Cardiovascular Risk Factors|Effects of Aleurone-enriched Products on Fasting and Postprandial Glycemic Homeostasis and Lipid Metabolism in High Cardiovascular Risk Subjects||Federico II University|No|Completed|January 2014|January 2016|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|70 Years|No|||June 2015|March 3, 2016|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150356||43750|
NCT02150577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH085104|Implementation Trial of Evidence Based Practices for Mood Disorders|Partnership for Implementation of Evidence-Based Practices in Rural Primary Care||University of Arkansas|No|Active, not recruiting|May 2014|May 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|100 Years|No|||March 2016|March 15, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150577||43733|
NCT02139917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23 January 2014|Effects of a Transitional Palliative Care Model on Patients With End-stage Renal Failure|Effects of a Transitional Palliative Care Model on Patients With ESRF|ESRF|The Hong Kong Polytechnic University|Yes|Recruiting|August 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|176|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02139917||44551|
NCT02150889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209M20741|Training Effects on Fuel Metabolism|Training Effects on Fuel Metabolism|TrainMeUpMN|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|July 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|64|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02150889||43709|
NCT02146937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1408|A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance|A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|May 2014|June 2017|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Male|18 Years|N/A|No|||May 2014|May 23, 2014|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146937||44012|
NCT02140476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-1151-13/13-1|Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy|Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Recruiting|May 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|160|||Both|18 Years|65 Years|No|||May 2014|May 27, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02140476||44509|
NCT02140762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_16|Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents|A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.||Novartis|No|Completed|May 2014|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|305|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140762||44487|
NCT02141009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44924.100.13|Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status|Response to Pneumococcal Vaccination in Patients After Community Acquired Pneumonia With Streptococcus Pneumoniae Compared to Pneumonia Patients With Another Pathogen.|CAPolista|St. Antonius Hospital|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02141009||44468|
NCT02141789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKonstanzMOdenwald2014-1|Outpatient Psychotherapeutic Treatment for Alcohol Dependent Individuals With Comorbid Psychiatric Disorders|||University of Konstanz|No|Recruiting|November 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141789||44408|
NCT02145455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP2013-08|Unity Total Knee Replacement Using Two Different Surgical Techniques|Unity Total Knee Replacement: Prospective Single-centre Clinical Study||Corin|Yes|Recruiting|June 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145455||44126|
NCT02144922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1091|Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients|Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|EPOCH|Asan Medical Center|No|Active, not recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|35 Years|80 Years|No|||December 2015|December 29, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144922||44167|
NCT02145689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-129|Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity|||Allergan|Yes|Withdrawn|August 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2014|August 12, 2014|May 21, 2014|Yes|Yes|The study was withdrawn prior to enrollment due to corporate decision.|No||https://clinicaltrials.gov/show/NCT02145689||44108|
NCT02145936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1541 - Fatty Acid Pilot|Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation|Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation.||Tufts University|No|Recruiting|January 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|20|||Female|50 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02145936||44089|
NCT02145949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12272013.024|Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults|Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults||University of Oregon|Yes|Recruiting|January 2015|February 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|50 Years|80 Years|No|||March 2015|March 16, 2015|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145949||44088|
NCT02146183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aarhus University|Steviol Glycoside for Use in Restoring Muscle Glycogen by Increasing the Rate of Glycogen Re-synthesis in Muscles|Compositions Comprising a Steviol Glycoside for Use in Restoring Muscle Glycogen by Increasing the Rate of Glycogen Re-synthesis in Muscles|steviagly|Aarhus University Hospital|No|Recruiting|September 2013|July 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146183||44070|
NCT02146196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZH_2011_0119|Robotic Assisted Rehabilitation for Heart Failure Patients and Patients After Cardiac Surgery|Roboter-unterstützte Kardiale Rehabilitation Herzinsuffzienter Patientinnen Und Patienten||University of Zurich|Yes|Recruiting|February 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02146196||44069|
NCT02146482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSCWStanford|Access to a Sit-stand Computer Workstation and Back Pain|Evaluating Change in Back Pain From Access to a Sit-stand Workstation||Stanford University|Yes|Completed|April 2013|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 21, 2014||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT02146482||44047|
NCT02142959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1306|RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE|A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis||Reata Pharmaceuticals, Inc.|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|187|||Female|18 Years|75 Years|No|||January 2016|January 27, 2016|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142959||44318|
NCT02143206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12026-12-024|Modifying Exercise for the COPD Patient|Modifying Exercise for the COPD Patient With Arthritic Limitations to Improve Compliance in a Pulmonary Rehab Program||TriHealth Inc.|Yes|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|99 Years|No|Non-Probability Sample|A cohort of 25 COPD patients (total N = 50) with osteoarthritis undergoing an exercise        plan in a pulmonary rehab program.|October 2015|October 20, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143206||44299|
NCT02143505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014BAI09B05|Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence|Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|March 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|900|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 17, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143505||44276|
NCT02150057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREG72609|Efficacy Study of an Unloading Brace for Knee Osteoarthritis|Efficacy of Medial Compartment Unloading Brace Use for Osteoarthritis of the the Knee: A Prospective Randomized Study||Andrews Research & Education Institute|Yes|Completed|February 2010|May 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|30 Years|80 Years|No|||May 2014|May 27, 2014|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02150057||43773|
NCT02150070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408-CL-0102|A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Intravenous Administration of ASP2408 Manufactured From a New Production Clone and Following Single Ascending Doses of Subcutaneous Injections in Healthy Subjects||Astellas Pharma Inc|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02150070||43772|
NCT02150369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053989|Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms|Investigating Cognitive/Affective/Sleep Symptoms During High-dose Interleukin-2 Therapy||Duke University|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|16 Years|65 Years|No|Non-Probability Sample|Eligible participants will be recruited from Duke University Hospital (Duke North) in        Durham, NC.|January 2016|January 5, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150369||43749|
NCT02150096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 390/10|Laser and Therapeutic Ultrasound in the Management of the Chronic Non-specific Low Back Pain|Laser and and Ultrasound Effect on Pain and Disability in Women With Chronic Non-specific Low Back Pain: a Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Not yet recruiting|May 2014|July 2014|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 25, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02150096||43770|
NCT02150590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0088V2A3B|Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep|Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep in||University of Zurich|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02150590||43732|
NCT02139930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54 DA031659-P2|Project 2: Strategies for Reducing Nicotine Content in Cigarettes|Project 2: Strategies for Reducing Nicotine Content in Cigarettes||University of Pittsburgh|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|1250|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139930||44550|
NCT02140216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 081/2557 (EC3)|Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients||Mahidol University|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood|Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing elective spine surgery/|November 2015|November 3, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02140216||44529|
NCT02140203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetsYoga|Effects of Yoga on Metabolic Syndrome|Effect of Yoga on Metabolic Abnormalities Outcomes in Middle-Aged and Older Adults With Metabolic Syndrome||The Hong Kong Polytechnic University|Yes|Completed|July 2010|August 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|182|||Both|30 Years|80 Years|No|||May 2014|May 14, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02140203||44530|
NCT02140489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALRO-101|Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin|An Open-label, Randomized, Single-dose Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Recruiting|February 2014|August 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02140489||44508|
NCT02140775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6911|Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS|Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS||New York State Psychiatric Institute|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02140775||44486|
NCT02141022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DUS26T|Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya|A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya||Stony Brook University||Active, not recruiting|August 2013|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02141022||44467|
NCT02141282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-032|A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy|A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy||AbbVie|No|Recruiting|September 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141282||44447|
NCT02141529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAPRF01|Intraarticular Pulse Radiofrequency to Treat Chronic Knee Pain|Bipolar Versus Unipolar Intraarticular Pulsed Radiofrequency Thermocoagulation in Chronic Knee Pain Treatment: A Prospective Randomized Study||Cukurova University|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|70 Years|No|||March 2016|March 15, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141529||44428|
NCT02142075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002338-19|Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure||DAPTOREA|Poitiers University Hospital||Recruiting|March 2014|||March 2014|Actual|Phase 3|Interventional|N/A|1||||||Both|18 Years|85 Years|No|||May 2014|May 15, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02142075||44386|
NCT02145468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116197|A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)|A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.|LATITUDE|GlaxoSmithKline|Yes|Active, not recruiting|June 2014|December 2018|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|3505|||Both|35 Years|N/A|No|||March 2016|March 10, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145468||44125|
NCT02145715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12/10174|Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma|A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients|MUKsix|University of Leeds|Yes|Active, not recruiting|January 2013|January 2016|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02145715||44106|
NCT02145702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000284|Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease|Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease||University of Kansas Medical Center|No|Recruiting|May 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|20 Years|N/A|No|||August 2015|August 10, 2015|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02145702||44107|
NCT02145962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELF-MF-2006-001|Open Multi-center Safety & Efficacy Study of Low Frequency Magnetic Fields to Treat Unresponsive Diabetic Foot Ulcers.|Application of Extremely Low Frequency Electromagnetic Fields in the Cicatrization of Ulcers With Diabetic Origin as a Method of Preventive and Complementary Treatment||Autonomous University of Morelos|Yes|Completed|December 2006|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|N/A|No|||May 2014|May 20, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02145962||44087|
NCT02146495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-HS-0044-CTIL|Neurofeedback for Fibromyalgia|Pain and Sleep Quality Measures Before and After a Course of EEG Neurofeedback in Fibromyalgia Patients||Tel-Aviv Sourasky Medical Center|No|Recruiting|May 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|85 Years|No|||May 2014|May 21, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146495||44046|
NCT02142972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/28|Low Back Pain and Depression: Cohort Study|Low Back Pain Disability, Intensity and Widespread Pain and Relationship to Postpartum Depression||Universidad Rey Juan Carlos|No|Completed|October 2011|May 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|236|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cohort comprised all pregnant women who were registered consecutively at this primary        health care center|May 2014|May 16, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02142972||44317|
NCT02143219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-N-2014-01|Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer|Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of "FOLFIRINOX " Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.|PAMELA70|Institut Cancerologie de l'Ouest|Yes|Recruiting|June 2014|July 2020|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|70 Years|N/A|No|||October 2015|October 5, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02143219||44298|
NCT02144051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5860C00001|Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors|A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor||AstraZeneca|No|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|130 Years|No|||January 2016|January 12, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144051||44234|
NCT02144311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-061|Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics|Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144311||44214|
NCT02150083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1950|Trial of Two Techniques to Assess Postoperative Voiding Function|Diagnostic Accuracy of Two Techniques for Assessing Postoperative Voiding Function - A Randomized Trial||University of North Carolina, Chapel Hill|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|59|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02150083||43771|
NCT02150109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2014-002-01|Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study)|User Performance of the Karajishi Contour Blood Glucose Monitoring System (ISO/FDA Study)||Ascensia Diabetes Care|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|372|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|January 29, 2016|May 27, 2014|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT02150109||43769|
NCT02150382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China Medical University|China Rural Hypertension Control Project|Effectiveness of a Standardized Protocol-based Treatment Program on Hypertension Control in Rural China.|CRHC|First Hospital of China Medical University||Recruiting|February 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|52800|||Both|40 Years|N/A|No|Probability Sample|All study patients will be recruited from rural areas in Liaoyang County from blood        pressure screening. Liaoyang County, Liaoning Province is located in Northeast China.|May 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150382||43748|
NCT02150395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 199-13|Impact of Music Therapy on Anxiety in Patients With Cancer Undergoing Simulation for Radiation Therapy|The Impact of Music Therapy on Anxiety in Patients Newly Diagnosed With Cancer & Undergoing Simulation for Radiation Therapy||Beth Israel Medical Center|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|82|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150395||43747|
NCT02140788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027822|Effects of Metformin and Fish Oil on Treatment With Clozapine|A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder||Duke University||Terminated|May 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|34|||Both|18 Years|60 Years|No|||May 2014|November 6, 2014|May 14, 2014|Yes|Yes|PI left institution|No|November 6, 2014|https://clinicaltrials.gov/show/NCT02140788||44485|Patients were not randomized per protocol and the study was terminated. Data analysis was not performed.
NCT02140502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate Biopsy Infections|Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy|Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy||Helsinki University Central Hospital|No|Active, not recruiting|May 2015|December 2016|Anticipated|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|rectal culture swabs|Male|18 Years|95 Years|No|Non-Probability Sample|Men undergoing prostate biopsy|October 2015|October 26, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02140502|2 Years|44507|
NCT02141295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29262|A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)|A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER||Hoffmann-La Roche||Recruiting|June 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141295||44446|
NCT02141568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-016312-CTIL|The Effect of Clinic Intervention in Frequent Attenders Suffering From Unexplained Medical Symptoms|The Effect of Multidisciplinary Clinic Intervention in Frequent Attenders Suffering From Unexplained Medical Symptoms, Cost-Effectiveness Analysis. Randomized Control Trial.||Soroka University Medical Center|No|Enrolling by invitation|March 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||May 2014|March 19, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141568||44425|
NCT02141555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140250|Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss|Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss: a Pilot Randomized Controlled Trial||University of California, San Diego|Yes|Not yet recruiting|July 2014|June 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|May 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141555||44426|
NCT02141802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 13/SW/0228|Clinical Effectiveness of Increased Standing Time in Non-ambulant Children With Cerebral Palsy:a Pilot Study|Clinical Effectiveness of Increased Standing Time in Non-ambulant Children With Cerebral Palsy:a Pilot Study||University of Plymouth|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Months|48 Months|No|||May 2014|May 15, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141802||44407|
NCT02142335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29065|Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma|A Phase II Trial of the Combination of Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma||California Cancer Assocaties for Research & Excellence|No|Recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|March 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142335||44366|
NCT02138201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-25|Representation of the Bladder Innervation Using Diffusion Tensor Imaging Fiber Tracking With MRI - a Pilot Study|||Swiss Paraplegic Centre Nottwil|No|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|individuals with and without neurogenic lower urinary trat dysfunction|November 2015|November 16, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02138201||44683|
NCT02145988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-0312|DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease|Improvement of Ankle-Brachial Index by DLBS1033 Treatment in Diabetic Patients With Peripheral Arterial Disease||Dexa Medica Group|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Both|40 Years|65 Years|No|||December 2015|December 10, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02145988||44085|
NCT02145975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDEAFEN001|Efficacy of Fentanyl to Reduce the Time of Severe Postoperative Pain Relief Compared to Morphine|Efficacy of Fentanyl to Reduce the Time of Severe Postoperative Pain Relief Compared to Morphine: a Randomized Parallel-group, Double-blind Clinical Trial||Universidad de Antioquia|No|Completed|January 2014|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02145975||44086|
NCT02146209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-GST006|Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.|Comparative Randomized, Single Dose, Three-Period Crossover Open-Label Study to Determine the Bioequivalence Of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules (Formula A)) Relative to 500 mg From Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension (Formula B)) and Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets (Formula C)) , After an Oral Administration to Healthy Adults Under Fasting Conditions||Verisfield UK Ltd. Greek Branch||Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02146209||44068|
NCT02146222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13112|VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors|Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel||University of Wisconsin, Madison|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146222||44067|
NCT02142985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ScvO2 Flo-Trac study|ScvO2 Based Vascular Filling Test in Patients With Hemodynamic Instability|ScvO2 and Cardiac Output Variation After a Vascular Filling Test in Patients With Hemodynamic Instability|VOS-HI|University of Monastir|Yes|Recruiting|April 2014|October 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02142985||44316|
NCT02143739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-XXX-2013/2|The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China|The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China.|INITIAL|AstraZeneca|No|Recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|The patient population will be outpatients, men or women, ≥18 years of age, Newly        diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The        patient population should not have COPD history, or asthma exacerbation.|March 2016|March 24, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143739|12 Weeks|44258|
NCT02144324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Ortho-01-2014|Changes Following the Treatment of Lower Jaw Protrusion Using Two Appliances|A Comparison of the Skeletal and Dento-alveolar Changes After Treatment of Class III Malocclusion With a Modified Tandem Appliance Versus the Face Mask||Damascus University|Yes|Completed|May 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|10 Years|No|||April 2015|April 20, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02144324||44213|
NCT02149823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0340|Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations|Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149823||43791|
NCT02149836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0597|Study to Treat Major Depressive Disorder (MDD) With a New Medication|A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder||Icahn School of Medicine at Mount Sinai|No|Recruiting|August 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02149836||43790|
NCT02150408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-27|Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors|Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors|DOTATATENET|Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150408||43746|
NCT02150616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 2013-0088V2A3D|Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep|Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep||University of Zurich|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02150616||43730|
NCT02141035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045538|Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome|Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.||University of Alberta|No|Recruiting|September 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02141035||44466|
NCT02141581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-21987- 2011|Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021)- Year 1, 2011|Vaccination and Infection: Indicators of Immunological Health and Responsiveness. Project 1: Plasmablast Trafficking and Antibody Response in Influenza Vaccination; Year 1, 2011||Stanford University|No|Active, not recruiting|August 2011|December 2015|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|70|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141581||44424|
NCT02141854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-AS-30017|Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma|A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy||Teva Pharmaceutical Industries|No|Completed|May 2014|October 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|728|||Both|12 Years|N/A|No|||December 2015|December 8, 2015|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141854||44403|
NCT02141815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55578|The Effect of Arabinoxylan-oligosaccharides (AXOS) on Intestinal Generation of Microbial Metabolites in Chronic Kidney Disease|||Universitaire Ziekenhuizen Leuven||Recruiting|May 2014|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||December 2014|December 2, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141815||44406|
NCT02142088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.01.CE|Comparative Study of GlySure Continuous Intra-vascular Glucose Monitoring and Intermittent Monitoring in Medical ICU|A Clinical Study to Evaluate the Safety of the GlySure Continuous Intra-vascular Glucose Monitoring System, and Its Performance in Comparison to Intermittent Blood Glucose Monitoring in Adult Intensive Care Unit Patients|MICU|GlySure|Yes|Not yet recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142088||44385|
NCT02142348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai OP Survey|Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women|Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women||Shanghai University of Traditional Chinese Medicine|Yes|Not yet recruiting|June 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Basal whole blood is collected for serum and DNA extraction.|Female|50 Years|N/A|No|Probability Sample|Randomly selected two communities in Xuhui District to investigate.|May 2014|May 15, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142348||44365|
NCT02146001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pitt Pepper 124078|Reducing Sedentary Behavior vs. Increasing Physical Activity in Older Adults|Reducing Sedentary Behavior vs. Increasing Physical Activity in Older Adults|RISE|University of Pittsburgh|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|38|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02146001||44084|
NCT02146235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081-08|Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease|The Effects of Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease||Beth Israel Medical Center|No|Completed|June 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|45 Years|N/A|No|||May 2014|May 22, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146235||44066|
NCT02146508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P62/02/2013|Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital|Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia|EXPECT|Tenwek Hospital|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|85 Years|No|||May 2014|May 21, 2014|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146508||44045|
NCT02146521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050303|Limited Abdominal CT in ED Patients With Abdominal Pain|Prospective Study of Z-axis-limited Abdominal CT Guided by Region of Tenderness in the Diagnosis and Management of Adult Emergency Department Patients With Acute Nontraumatic Abdominal Pain and Tenderness|LACTINEDAP|Duke University|No|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients of the emergency department undergoing CT evaluation for acute abdominal pain and        tenderness|March 2016|March 14, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02146521||44044|
NCT02142712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400353|Histamine Glutamate Antagonism in Stroke|Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy.||University of Florida|No|Completed|December 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|80 Years|No|||November 2015|November 10, 2015|May 9, 2014|Yes|Yes||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02142712||44337|
NCT02143518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-GST-03|Safety and Immunogenicity Study of Na-GST-1 With or Without CpG|Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel, With or Without a CpG ODN Adjuvant, in Healthy Adults||Albert B. Sabin Vaccine Institute|Yes|Active, not recruiting|October 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143518||44275|
NCT02144064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed 3|Pregnancy Outcomes in Women With Recurrent Miscarriage Treated With Low Dose Aspirin and Unfractionated Heparin|Pregnancy Outcomes in Women With Recurrent Miscarriage Treated With Low Dose Aspirin and Unfractionated Heparin||Benha University|No|Completed|June 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|140|||Female|21 Years|46 Years|No|||March 2015|March 6, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02144064||44233|
NCT02150122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODIN/1213|Dietary Requirement for Vitamin D in Adolescents Aged 14-18 Years|A Dose-response, Double-blind Randomised Placebo-controlled Trial to Estimate the Dietary Requirement for Vitamin D in Caucasian Male and Female Adolescents Aged 14-18 Years (The ODIN Study)||University of Surrey||Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02150122||43768|
NCT02146950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2013_10|European Active Surveillance Study of LCS12|European Active Surveillance Study of LCS12|EURAS_LCS12|Center for Epidemiology and Health Research, Germany|Yes|Recruiting|June 2014|June 2021|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|38000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using an intrauterine system/device (hormonal IUS or copper IUD)|December 2015|December 21, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02146950||44011|
NCT02139683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU-F|Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU|High Intensity Focused Ultrasound for the Treatment of Fibroadenomata (HIFU-F)||Theraclion|No|Active, not recruiting|January 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02139683||44569|
NCT02140515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Emb-018|Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism|Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism||Royan Institute|Yes|Recruiting|November 2012|November 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||August 2012|May 5, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140515||44506|
NCT02140528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-012|Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures|Evaluation the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures||Royan Institute|Yes|Recruiting|August 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|December 3, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140528||44505|
NCT02140801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0361|Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel|A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|May 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|352|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140801||44484|
NCT02141048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1952 Lester|Evaluation of the Parent Centre's Positive Parenting Skills Training.|Evaluation of the Parent Centre's Positive Parenting Skills Training: A Randomised Controlled Trial.||University of Cape Town|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02141048||44465|
NCT02142387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-heros-01|Before and After Community Intervention Trial With Dispatcher Assisted CPR Program|Layperson Training of Dispatcher Assisted Basic Life Support for Improving Outcomes After Out-of-Hospital Cardiac Arrest; a Nonradomized before-and After- Community Intervention Trial|HEROS|Seoul National University Hospital|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4000|||Both|15 Years|N/A|No|||August 2015|August 4, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02142387||44362|
NCT02142400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1093-A-E102|Multiple Ascending Dose Study of DS-1093 in Healthy Subjects|A Double Blind, Randomised, Placebo-controlled, Multiple Ascending-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DS 1093a in Healthy Male Subjects||Daiichi Sankyo Inc.|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|31|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142400||44361|
NCT02141828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPZ-5676-12-002|A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene|A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene||Epizyme, Inc.|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|3 Months|18 Years|No|||November 2015|November 3, 2015|May 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141828||44405|
NCT02142101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1798|Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease|Gut Microbiota of Renal Patients||Icahn School of Medicine at Mount Sinai|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|18|Samples With DNA|Serum and urine will be saved for metabolite analysis; stool will be used to extract      bacterial DNA for sequencing.|Both|18 Years|N/A|No|Non-Probability Sample|o All subjects with diagnosis for cystic kidney disease, who were evaluated at Mount Sinai        Hospital, Renal clinic, Internal Medicine Associates clinic and Faculty Practice        Associates clinics will be identified via the electronic medical system (EPIC).|January 2016|January 4, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02142101||44384|
NCT02138526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF-13.05|Pazopanib Tolerability When Given With Food|Improving the Tolerability of the Oral Targeted Anticancer Drug Pazopanib by Food Intake (DIET)|DIET|Radboud University|No|Recruiting|June 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|79|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02138526||44658|
NCT02146261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6011-J081-002|A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects|||Eisai Inc.|No|Completed|September 2013|April 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|32|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2014|October 20, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146261||44064|
NCT02146274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049705|Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research|Observational Study of Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research|PROSPER|Duke University|No|Enrolling by invitation|November 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|Ischemic Stroke patients|August 2015|August 3, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146274|6 Months|44063|
NCT02146248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 10103|HSG and Tubal Patency Study|Tubal Patency During the Menstrual Cycle and During Treatment With Hormonal Contraceptives: a Pilot Study in Women||Oregon Health and Science University|No|Completed|May 2014|April 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146248||44065|
NCT02142998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|A Prospective Blinded Randomized Study Comparing Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-y Gastric Bypass and Their Effect on Gastro-Esophageal Reflux Disease Using 24 Horus pH Monitoring|A Prospective Blinded Randomized Study Comparing Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-y Gastric Bypass and Their Effect on Gastro-Esophageal Reflux Disease Using 24 Horus pH Monitoring|GERD|McMaster University|No|Recruiting|October 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02142998||44315|
NCT02142725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCG-2/UCA|Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis|Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine|PROTECT-1|Dr. Falk Pharma GmbH|Yes|Recruiting|July 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|762|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02142725||44336|
NCT02143752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001|Meriter Mindfulness Training for Smokers Program and Study|Meriter Mindfulness Training for Smokers Program and Study||University of Wisconsin, Madison|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|93|||Both|18 Years|N/A|No|Non-Probability Sample|Study subjects will be drawn from the Meriter Smoking Cessation Program, which is made up        of two interventions: the Mindfulness Training for Smokers (MTS) intervention and the Quit        Line (QL) Intervention|April 2015|September 30, 2015|January 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02143752||44257|
NCT02141217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117044|AUGMENTIN™ in Dental Infections|Efficacy, Safety and Tolerability of Amoxicillin + Clavulanic Acid (875mg/125mg) Two Times a Day Compared to Clindamycin (150mg) Four Times a Day for 5-7 Days in Treatment of Acute Odontogenic Infection With or Without Abscess|AUGDENT|GlaxoSmithKline|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|472|||Both|18 Years|75 Years|No|||August 2014|September 11, 2014|May 15, 2014||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT02141217||44452|
NCT02144844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8045091|A Public Health Program to Reduce Risk of Antepartum Depression|A Behavioral Intervention to Reduce Risk of Antepartum Depression|APD|East Carolina University|No|Completed|December 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|146|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 21, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144844||44173|
NCT02145052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000393; MGH|Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy|Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy: A Prospective Randomized Study||Massachusetts General Hospital|No|Recruiting|July 2008|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|388|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145052||44157|
NCT02150902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS 2771|Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence|AUGMENTED WIDE AREA CIRCUMFERENTIAL CATHETER ABLATION FOR REDUCTION OF ATRIAL FIBRILLATION RECURRENCE - A RANDOMIZED CLINICAL TRIAL (The AWARE Trial)|AWARE|Ottawa Heart Institute Research Corporation|Yes|Recruiting|March 2015|December 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|342|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150902||43708|
NCT02139384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110327|Clinical Pediatric Pneumonia Score in Critically Ill Children|Development of a Clinical Pediatric Pneumonia Score in Critically Ill Children Admitted With Acute Respiratory Failure||Loma Linda University|No|Withdrawn|August 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|21 Years|No||critically ill children admitted the the LLU PICU with acute respiratory failure with        suspected community-acquired pneumonia|May 2014|May 12, 2014|May 8, 2014||No|The study was withdrawn due to inability to enroll patients in a timely fashion.|No||https://clinicaltrials.gov/show/NCT02139384||44592|
NCT02139397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC010|Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma|A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma||Spectrum Health Hospitals|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|N/A|21 Years|No|||February 2016|February 16, 2016|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139397||44591|
NCT02139696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINGOPET|Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation|Does Targeting of Sphingosine-1 Phosphate Receptors Reduce Microglial Activation in Multiple Sclerosis? A [11C]PK11195 Brain PET Study|FINGOPET|Turku University Hospital|No|Not yet recruiting|May 2014|December 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|58 Years|No|Non-Probability Sample|10 patients with multiple sclerosis who will be initiated on Gilenya in the neurology        outpatient clinic of the Turku University hospital in Turku, Finland.|May 2014|May 13, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02139696||44568|
NCT02141347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4880C00010|Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma|A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma||AstraZeneca|No|Active, not recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label|3||Anticipated|62|||Both|20 Years|130 Years|No|||January 2016|January 15, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02141347||44442|
NCT02141360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2014-GES-0001|Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|TBI-2|GE Healthcare|No|Terminated|July 2014|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|15 Years|50 Years|No|||November 2015|November 30, 2015|May 12, 2014|No|Yes|Sponser terminated early to start a larger feasability study|No||https://clinicaltrials.gov/show/NCT02141360||44441|
NCT02138253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-07|A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV|A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy|POLT-HCV-SVR|Conatus Pharmaceuticals Inc.|Yes|Active, not recruiting|May 2014|March 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138253||44679|
NCT02138266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCON-SP-1P-US-0001|Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements|Comparative Study of the Topcon Specular Microscope SP-1P and the Konan Specular Microscope CELLCHEK XL (Predicate Device) for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area, ％ Hexagonality, Central Corneal Thickness||Topcon Medical Systems, Inc.|No|Completed|February 2014|September 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|65|||Both|18 Years|80 Years|No|Non-Probability Sample|Ophthalmology Practice|November 2014|April 22, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02138266||44678|
NCT02138552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002708-14|Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo|Phase II Study to Assess Bacterial Count Reduction of Three Octenidine Mouthwash Concentrations in Comparison to a Placebo in Patients With Mild Gingivitis|OML0113|Schülke & Mayr GmbH|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02138552||44656|
NCT02142114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29182|Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles|Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles||Retina Health Center|No|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02142114||44383|
NCT02142361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-48|Clinical Performance of Habitual Hydrogel vs. Silicone Hydrogel Toric Contact Lenses|Clinical Performance of Habitual Wearers of Hydrogel Toric Lenses When Refitted With Avaira Toric Silicone Hydrogel Lenses||Coopervision, Inc.|No|Completed|May 2014|July 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|60|||Both|18 Years|40 Years|No|||February 2015|February 9, 2015|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142361||44364|
NCT02142374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAZ-012-0001-SA|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2014|||||N/A|N/A|N/A||||||||||||||May 19, 2014|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142374||44363|
NCT02138227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK081118|A Randomized Trial of the Early Referral and Request Approach (ERRA) Intervention to Increase Consent to Organ Donation|A Randomized Trial of the Early Referral and Request Approach (ERRA) Intervention to Increase Consent to Organ Donation||Temple University|No|Completed|January 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1680|||Both|16 Years|N/A|No|||May 2014|May 12, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02138227||44681|
NCT02138812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16804|Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies||Bayer|No|Recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138812||44636|
NCT02138825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13605|Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)|A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).|RISE-IIP|Bayer|Yes|Recruiting|June 2014|June 2023|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138825||44635|
NCT02139137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31MH088170|Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD|Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD||San Diego State University|No|Completed|January 2010|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Female|18 Years|65 Years|No|||May 2014|May 13, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139137||44611|
NCT02142738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-024|Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)|A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|August 2014|May 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|305|||Both|18 Years|N/A|No|||January 2016|February 17, 2016|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142738||44335|
NCT02142751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOREST|Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli|Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli|FOREST|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|July 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|198|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02142751||44334|
NCT02143258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIancu_IIH|Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension|Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension||Ottawa Hospital Research Institute|Yes|Recruiting|March 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|80 Years|No|||July 2015|July 29, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02143258||44295|
NCT02143271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-004|Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis|A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis||Kyowa Hakko Kirin Company, Limited|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|74 Years|No|||March 2015|March 3, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02143271||44294|
NCT02143232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130412-01H|Post Op Home Monitoring After Joint Replacements|Postop Home Monitoring After Joint Replacements (POHM)|POHM|Ottawa Hospital Research Institute|Yes|Recruiting|April 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|54|||Both|18 Years|80 Years|No|||January 2015|January 7, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02143232||44297|
NCT02143245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140167-01H|Diagnostic Accuracy of Synovial Biopsy for Implant-Related Shoulder Infections|Diagnostic Accuracy of Synovial Biopsy for Implant-Related Shoulder Infections||Ottawa Hospital Research Institute|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|90 Years|No|||October 2015|October 21, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143245||44296|
NCT02144597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1668|Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass|The Effect of a 2-week vs. 6-week Low-calorie Diet (LCD) Followed by Roux-en-Y Gastric Bypass (RYGB) on Body Composition and Surgery Outcomes in Obese Humans: a Dietary Intervention and Magnetic Resonance Imaging Study|LCD|Imperial College London|Yes|Completed|August 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|60 Years|No|||May 2014|May 19, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02144597||44192|
NCT02144610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-CLI-0206|Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia|A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia|AGILITY|AnGes|Yes|Recruiting|October 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|40 Years|90 Years|No|||February 2016|February 15, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144610||44191|
NCT02141464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10622|Energy Balance and Weight Gain With Ivacaftor Treatment|Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations||Children's Hospital of Philadelphia|No|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|Samples Without DNA|serum, urine, stool|Both|6 Years|N/A|No|Non-Probability Sample|24 subjects ≥6 years old with CF with a gating mutation before treatment (baseline) and        after three months treatment with Ivacaftor.|November 2015|November 23, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141464||44433|
NCT02141698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438_101|Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects||Takeda|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|15||Actual|73|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141698||44415|
NCT02139033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-110-0008|A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome|A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye||Ocusoft, Inc.||Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139033||44619|
NCT02139722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-11-4615|Patient-Centered Care and Asian Americans|A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans||University of California, San Francisco|Yes|Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|416|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 29, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02139722||44566|
NCT02139943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104173|A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)|A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus||Janssen Research & Development, LLC|Yes|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|352|||Both|25 Years|65 Years|No|||June 2015|June 15, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139943||44549|
NCT02140229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130401|Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?|REVECHO Study (REmission Véritable en ECHOgraphie) Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?|REVECHO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|450|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02140229||44528|
NCT02141061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-101|Comparison of Two Formulations of Proellex for Oral Administration|A Double-Blind Crossover Study in Healthy Volunteers to Compare Two Formulations of Proellex for Oral Administration||Repros Therapeutics Inc.|Yes|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141061||44464|
NCT02141867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASOS|South African Surgical Outcomes Study|South African Surgical Outcomes Study|SASOS|University of KwaZulu|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3927|||Both|16 Years|N/A|No|Non-Probability Sample|Seven day, South African national multi-centre cohort study of adult (≥16 years) patients        undergoing in-patient non-cardiac surgery.|January 2016|January 11, 2016|May 13, 2014||No||No|January 11, 2016|https://clinicaltrials.gov/show/NCT02141867|1 Month|44402|
NCT02141308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010511|OCT in Rare Chorioretinal Diseases|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases||Oregon Health and Science University||Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals 18 years of age and older presenting to the Retina Service within the        Department of Ophthalmology at the Casey Eye Institute of Oregon Health & Science        University with signs and symptoms of rare choroidal or retinal diseases will be evaluated        for enrollment into this study.|April 2015|April 21, 2015|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141308||44445|
NCT02141321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9010023|Sub Lingual Misoprostol Before IUD Insertion in Women With Only Previous Cesarean Section|SUB LINGUAL MISOPROSTOL PRIOR TO IUD INSERTION IN WOMEN WITH ONLY PREVIOUS CESARIAN SECTION: A Randomized Controlled Trial||Ain Shams University|Yes|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|124|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141321||44444|
NCT02141334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-007|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||May 6, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141334||44443|
NCT02138591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-149|Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.|Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.||University of Missouri, Kansas City|No|Not yet recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138591||44653|
NCT02138240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL116601|Reducing Obesity Among Public Housing Residents: an Ecological Approach|Reducing Obesity Among Public Housing Residents: an Ecological Approach||Johns Hopkins University||Not yet recruiting|August 2016|||October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02138240||44680|
NCT02138539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRG-EPI-1|Evaluation of an Herbal-Based De-Pigmenting System|A Clinical Usage Study to Evaluate the Safety and Efficacy of an Herbal-Based De-Pigmenting System||Sadick Research Group|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|February 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138539||44657|
NCT02139163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1147-8393|Epidemiological Study on Community Acquired Pneumonia|Epidemiological Study on Community Acquired Pneumonia|CAPNETZ|Hannover Medical School|No|Recruiting|October 2002|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10150|||Both|18 Years|N/A|No|Non-Probability Sample|patients with pneumonia|May 2014|May 12, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02139163|6 Months|44609|
NCT02139176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3707|Assessing Strategies for Increasing Male Involvement in Malawi's Antenatal Program|Assessing Strategies for Increasing Male Involvement in Malawi's Antenatal Program||University of North Carolina, Chapel Hill|No|Recruiting|March 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|330|||Both|16 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139176||44608|
NCT02139189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PR-1083|Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)|RESTORE Myocardial Function With CorMatrix® ECM® Particulate (P-ECM) Implantation in Subjects With LVEF 25 to 40% Study||CorMatrix Cardiovascular, Inc.|No|Active, not recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||August 2015|August 5, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139189||44607|
NCT02146534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-FMP-13-10507|Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients|Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study.||Clinique Neuro-Outaouais|No|Completed|December 2013|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02146534||44043|
NCT02142764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/01|Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients|Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).|IMMUNOSEP|University Hospital, Bordeaux|No|Active, not recruiting|November 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02142764||44333|
NCT02143011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574149|Stress and Sugar Synergy|Synergistic Effects of Stress and Sugar Feeding on Metabolism|SSS|University of California, Davis|No|Recruiting|April 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143011||44314|
NCT02143765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhongdaH-Match|Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus|An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China|Match-101|Zhongda Hospital|Yes|Active, not recruiting|May 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|70 Years|No|||July 2015|July 20, 2015|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02143765||44256|
NCT02143778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPH-EX-4014|Assessing Portal Hypertension With Methacetin Breath Test|Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis||Exalenz Bioscience LTD.|No|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143778||44255|
NCT02144077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA-BCC-CT008|Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy|A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)||Biofrontera Bioscience GmbH|No|Active, not recruiting|January 2014|September 2020|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|277|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144077||44232|
NCT02143531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.MA 09|Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting|Intravenous Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting in Patients Undergoing Surgery With General Anesthesia: A Randomized Clinical Trial||American University of Beirut Medical Center|No|Completed|September 2008|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||May 2014|May 21, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02143531||44274|
NCT02140944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1107|IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence|IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Recruiting|February 2015|March 2023|Anticipated|March 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|For consenting participants, blood and tissue samples|Both|12 Months|N/A|No|Non-Probability Sample|HIV-1 infected children and adults who undergo cord blood stem cell transplantation for        treatment of cancer, hematopoietic disease, or other underlying disease|October 2015|October 6, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140944||44473|
NCT02141204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116566|Immunogenicity and Safety Study of Two Different Formulations of Human Rotavirus Vaccine, Rotarix in Healthy Infants|Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants||GlaxoSmithKline||Not yet recruiting|February 2017|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|308|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||November 2015|November 19, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141204||44453|
NCT02141477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0812|Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|70 Years|N/A|No|||March 2016|March 16, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141477||44432|
NCT02141490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140107|Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers|Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney)Cancers||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|December 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|56|||Both|18 Years|99 Years|No|||March 2016|March 17, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141490||44431|
NCT02141711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438_107|TAK-438 - Safety, Blood Levels & Effects of Repeated Doses|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Multiple Repeat Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Non-Japanese Male Subjects|TAK-438_107|Takeda|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141711||44414|
NCT02139956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mekky|Assessment of the Internal Urethral Sphincter and the Vagina by Three Dimensional Ultrasound|Ultrasonic Assessment of the Urethra and the Vagina in Normal Continent Women and Women Suffering From Stress Urinary Incontinence||Ain Shams University||Active, not recruiting|May 2014|||May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|140|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|out patient [clinics] and in patient|May 2014|May 15, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139956|2 Days|44548|
NCT02139969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE1401|GreenLight XPS Laser System Retrospective Chart Review|GreenLight XPS Laser System for the Treatment of Benign Prostatic Hyperplasia: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review||American Medical Systems|No|Active, not recruiting|May 2014|||November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Male|N/A|N/A|No|Non-Probability Sample|The study population will consist of males who have had the GreenLight XPS procedure with        the MoXy fiber on or after 01-Aug-2010. The cohort will be selected from six pre-selected        urology clinics in the US and one pre-selected urology clinic in Canada.|May 2014|October 29, 2014|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139969||44547|
NCT02140242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-2DAUNO-058|Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML|Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤60 Years|DaunoDouble|Technische Universität Dresden|No|Recruiting|April 2014|August 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02140242||44527|
NCT02141074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3895|Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B|An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)|paradigm™6|Novo Nordisk A/S|No|Recruiting|July 2014|October 2020|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|N/A|6 Years|No|||February 2016|February 11, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02141074||44463|
NCT02141087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-031|Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone|A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone||Genentech, Inc.||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||July 2015|July 9, 2015|May 15, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02141087||44462|
NCT02142140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 123412|Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder||McGill University Health Center|No|Recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|326|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142140||44381|
NCT02141594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT PPAA in early glaucoma|Posterior Pole Asymmetry Analysis (PPAA) for Early Glaucoma|Diagnostic Ability of Posterior Pole Asymmetry Analysis Parameters (PPAA) of Spectralis Optical Coherence Tomography (OCT) in Detecting Early Glaucoma|PPAA|Dr T V Patel Eye Institute|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|156|||Both|49 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive 80 eyes of 80 normal subjects and 76 eyes of 76 patients with early glaucoma        were included for the study.|May 2014|May 16, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02141594||44423|
NCT02141841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China Three Gorges University|Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine|Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine||China Three Gorges University, Yichang, China|Yes|Withdrawn|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|0|||Both|20 Years|80 Years|No|Probability Sample|This study was performed in 131 adult patients undergoing transurethral, urological or        lower limb surgery under combined spinal and epidural anesthesia.|October 2015|October 23, 2015|May 13, 2014||No|because the study is very complicated and cannot be performed in the practice|No||https://clinicaltrials.gov/show/NCT02141841|2 Years|44404|
NCT02138331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|666666|Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)|Phase 1 Study of The Effect of Cell-Free Cord Blood Derived Microvesicles On β-cell Mass in Type 1 Diabetes Mellitus (T1DM) Patients||General Committee of Teaching Hospitals and Institutes, Egypt|Yes|Enrolling by invitation|April 2014|September 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||May 2014|May 12, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138331||44673|
NCT02138344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 04 2006|Assessment of Neuropathic Pain|||University of Zurich|Yes|Recruiting|April 2006|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|SCI|January 2016|January 25, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138344||44672|
NCT02138565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005|Effect of Bariatric Surgery on Kidney Function|Effect of Bariatric Surgery on Kidney Function|GAS|Steno Diabetes Center|Yes|Recruiting|March 2014|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|80 Years|No|||September 2015|September 7, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02138565||44655|
NCT02138578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2013.069|A Ph II Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma|A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma (RCC)||University of Michigan Cancer Center|Yes|Recruiting|May 2014|||February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138578||44654|
NCT02138851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YGF-CON-FIG2|The Effects of a Ficus Carica in Subjects With Functional Constipation|Randomized, Double-Blind, Placebo-Controlled, Parallel Trial in Subjects With Functional Constipation, to Evaluate the Improvement in Constipation of Ficus Carica||Chonbuk National University Hospital|Yes|Recruiting||||June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|19 Years|39 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138851||44633|
NCT02138838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130356|A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis|A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis||Amgen|No|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|6 Years|17 Years|No|||January 2016|January 19, 2016|April 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138838||44634|
NCT02139202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819466|Heartstrong Pilot Program|HeartStrong Pilot Program - Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients||University of Pennsylvania|No|Active, not recruiting|May 2014|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|17|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139202||44606|
NCT02139527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-CAD-01|CARES Lumbar Artificial Disc Registry|The Centers for Arthroplasty Research and Education in Spine (CARES) Lumbar Artificial Disc Registry Protocol||DePuy Spine|No|Terminated|May 2007|August 2009|Actual|August 2009|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that undergo lumbar total disc replacement (TDR); this includes patients treated        with either the CHARITE disc or the ProDisc-L disc|May 2014|May 13, 2014|February 11, 2014|No|Yes|Low enrollment and follow-up data on enrolled patients.|No||https://clinicaltrials.gov/show/NCT02139527|5 Years|44581|
NCT02143284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-1715|A Study of EndoChoice's Upper&Lower Endoscopic Systems Utilizing a Full Spectrum Optical Technology|Single-Center, Exploratory Study of EndoChoice's Upper&Lower Endoscopic Systems Utilizing EndoChoice's Full Spectrum Optical Technology|FUSE|EndoChoice Innovation Center, Ltd.|No|Recruiting|May 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|280|||Both|18 Years|70 Years|No|||May 2014|May 20, 2014|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143284||44293|
NCT02143544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart Institute|Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery|Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial|IABCS|University of Sao Paulo|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||February 2016|February 3, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02143544||44273|
NCT02144090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2 Pilot Study|Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study|Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study|O2|Laval University|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144090||44231|
NCT02144337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14005|Physical Activity in Children With Type 1 Diabetes Study|The Feasibility of a Physical Activity Intervention for Children With Type 1 Diabetes Mellitus: Steps To Active Kids (STAK)||University of Nottingham|No|Completed|May 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13|||Both|9 Years|11 Years|No|||July 2015|July 20, 2015|January 16, 2014||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT02144337||44212|Analysis and interpretation of secondary outcomes ongoing.
NCT02144350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Broad-IBD-0372|Hyperbaric Oxygen for Ulcerative Colitis|Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-center Randomized Double Blind Sham Controlled Trial||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|77|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02144350||44211|
NCT02141243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRENOTOMY|Prospective Evaluation of Lingual Frenotomy in Newborns With Simultaneous Lip Tie for the Relief of Breastfeeding Pain.|Randomized, Controlled Trial Evaluating Lingual Frenotomy in Newborns With Simultaneous Lip Tie for the Relief of Breastfeeding Pain.||University of South Florida|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|2 Weeks|No|||December 2015|December 10, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02141243||44450|
NCT02141724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0946927B|Wheelchair Positioning and Pain in Neuromuscular Patients|Assessment of Wheelchair Positioning and Pain in Adults Patients With Neuromuscular Disorder||Centre d'Investigation Clinique et Technologique 805|No|Completed|April 2014|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Adults patients with neuromuscular disordres using wheelchair.|March 2015|March 31, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02141724||44413|
NCT02141737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140514|Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia|Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia||Tang-Du Hospital|Yes|Recruiting|May 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|272|||Both|60 Years|81 Years|No|||May 2014|May 16, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141737||44412|
NCT02141971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSBI|Down Syndrome Biomarker Initiative (DSBI)|Down Syndrome Biomarker Initiative: A Natural History Study of Alzheimer's Disease in Down Syndrome (Pilot Study)|DSBI|Alzheimer's Disease Cooperative Study (ADCS)|No|Active, not recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|12|Samples With DNA|blood, urine, cerebrospinal fluid|Both|30 Years|60 Years|No|Probability Sample|Community sample|September 2014|May 13, 2015|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141971||44394|
NCT02141763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA0007|Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis|A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis||UCB Pharma|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|53|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02141763||44410|
NCT02140541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05812|The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils|The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils||Research in Real-Life Ltd|No|Active, not recruiting|February 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|130248|||Both|12 Years|80 Years|No|Non-Probability Sample|A retrospective database analysis of asthma patients with a valid eosinophil count (where        valid: numeric value expressed as /µl at least one year prior to last data extraction)        with at least one year of data of prior to the date of eosinophil count (baseline period)        and one year of data post recorded eosinophil count (outcome period).|May 2014|May 14, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02140541||44504|
NCT02140554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGB-206|A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease|A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease||bluebird bio|Yes|Recruiting|August 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140554||44503|
NCT02140814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000874|Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease|Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease|NIAC-PKD1|University of Kansas Medical Center|No|Active, not recruiting|May 2014|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|50 Years|No|||December 2015|December 10, 2015|May 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140814||44483|
NCT02141607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7#602706|Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock|Multiscale Approach to Describe the Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock|Shockomics|Shockomics Consortium|No|Recruiting|October 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|115|Samples With DNA|whole blood, serum, urine|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|All the patients admitted to ICU|November 2015|November 26, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02141607||44422|
NCT02142439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STERK|STERK - Strength Training and Eating Disorders|Strength Training and Eating Disorders (STERK - Styrketrening og Spiseforstyrrelser)||Telemark University College|No|Recruiting|January 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02142439||44358|
NCT02142127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-114-10|Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers|An Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labelled GFT505 and Its 14C-Metabolites) and to Investigate the Metabolic Profile and Pharmacokinetics of GFT505||Genfit|No|Completed|April 2014|April 2015|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|55 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142127||44382|
NCT02138903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-189|A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial|A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial|CARWEAN|University Hospital, Clermont-Ferrand||Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients|November 2014|November 28, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02138903||44629|
NCT02138916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3251C00003|Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History|Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations|GALATHEA|AstraZeneca|Yes|Recruiting|June 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1626|||Both|40 Years|85 Years|No|||February 2016|February 22, 2016|March 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138916||44628|
NCT02138929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0838|LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma|A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138929||44627|
NCT02138864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4350A|Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication|Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|August 2013|||July 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|20 Years|65 Years|No|||January 2016|January 28, 2016|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138864||44632|
NCT02139254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030/13|First Trimester Glycosylated Haemoglobin Und Plasma Glucose in Women at High Risk for Gestational Diabetes|First Trimester Glycosylated Haemoglobin Und Plasma Glucose in Women at High Risk for Gestational Diabetes|GDM HbA1c|University Hospital Inselspital, Berne|No|Recruiting|August 2013|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples Without DNA|Serum|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who receive antenatal care at the Department of Obstetrics in our Hospital        and have the first vist between 8. and 12. week of pregnancy. Women with pregestational        diabetes are excluded.|March 2015|March 25, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139254||44602|
NCT02139215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMPC-01|Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients|A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes and Economic Impact of Panitumumab Versus Standard-of-care in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer||PeriPharm|No|Active, not recruiting|April 2014|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chemotherapy-refractory metastatic colorectal cancer from participating        hospitals in Quebec.|January 2016|January 13, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139215||44605|
NCT02128100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-RAD-13|Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer|The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer|BCC-RAD-13|James Graham Brown Cancer Center|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128100||45456|
NCT02128347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eportal 2014-316|Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients|Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients||Nova Scotia Health Authority|No|Active, not recruiting|October 2014|October 2015|Anticipated|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2015|April 4, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128347||45437|
NCT02128607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IoNS-UCL-Hidalgo-02|A Randomized Placebo Controlled Trial on the Efficacy of Sustained Natural Apophyseal Glide (SNAG) in Low Back Pain Patients|Immediate and Short-term Effects of Mulligan "Sustained Natural Apophyseal Glides" for a Subgroup of Low Back Pain Patients: A Randomized Placebo Controlled Trial||Université Catholique de Louvain|Yes|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|20 Years|55 Years|No|||August 2014|August 13, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128607||45417|
NCT02128620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-40656|A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour|Study on Sexually Transmitted Diseases Prevention - Introduction of a Novel Game-based Appointment System for Youth||University Hospital of North Norway|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|996|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128620||45416|
NCT02120573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-1345|Efficacy of CPR Teaching in Mass Training|Evaluation of Teaching Methods in Mass CPR Training in Different Groups of the Society||Shiraz University of Medical Sciences|Yes|Completed|January 2010|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|2000|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120573||46032|
NCT02120807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-063|Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas|A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120807||46014|
NCT02119806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delirium 13-001412|Decreasing the Incidence of Delirium After Cardiac Surgery|Decreasing the Incidence of Delirium After Cardiac Surgery||University of California, Los Angeles|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119806||46091|
NCT02120040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System||PsychoVHL|Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|42|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02120040||46073|
NCT02120313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESAR|Inpatient Versus Outpatient Rehabilitation After TKA|Inpatient Versus Outpatient Rehabilitation Following Total Knee Arthroplasty: a Double-blinded Non-inferiority Trial||University of Rostock|No|Recruiting|April 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|70 Years|85 Years|No|||December 2014|December 2, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120313||46052|
NCT02117284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130344|Rubidium Elution System Performance Testing|Rubidium Elution System Performance Testing|REST-PET|Ottawa Heart Institute Research Corporation|Yes|Recruiting|January 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7500|||Both|18 Years|N/A|No|Probability Sample|All patients present to participating nuclear imaging facilities for diagnosis of CAD        and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the        clinical indications listed in the approved Ruby-Fill product monograph.|January 2016|January 4, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02117284|1 Day|46284|
NCT02118051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POR-ELONVA|Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.|Prospective Randomized Study for the Evaluation of Controlled Ovarian Stimulation With Corifollitropin Alpha in Patients With Expected or Poor Ovarian Response in IVF Cycles||Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|September 2013|April 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Female|18 Years|40 Years|No|||July 2015|July 21, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02118051||46226|
NCT02118064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC6|Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma|A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.|CC6|Cancer Advances Inc.||Completed|March 2001|||December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|N/A|No|||January 2014|April 17, 2014|April 16, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02118064||46225|
NCT02118389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucerna|Effect of Meal Replacement Beverage(Glucerna) on Body Composition,Lipid Metabolism and Blood Pressure|The Effect of Meal Replacement Beverage(Glucerna) on Body Composition,Lipid Metabolism and Blood Pressure in Patients With Obesity||Shanghai 10th People's Hospital|Yes|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|14 Years|65 Years|No|||October 2013|April 17, 2014|April 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02118389||46200|
NCT02125903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 06/13|Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy|Randomized Controlled Study: Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy Relating to Early Mobilization and Analgesia||Philipps University Marburg Medical Center|No|Completed|May 2013|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|80 Years|No|||January 2015|January 23, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02125903||45625|
NCT02126176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUNHDM-adherence|Protopic Adherence and Efficacy in Korean Eczema Patient|||Pusan National University Hospital|No|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|No|Probability Sample|patient with atopic dermatitis|November 2014|November 3, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126176|2 Weeks|45604|
NCT02126462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-001|Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults|Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults||Albert B. Sabin Vaccine Institute|Yes|Active, not recruiting|November 2014|July 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126462||45582|
NCT02126735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121525|Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans|Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans||Vanderbilt University|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|28|Samples With DNA|serum, white cells|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|we will recruit subjects locally|December 2015|December 10, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02126735||45561|
NCT02126748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVG003|The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.|The Effectiveness of Assisted Autogenic Drainage (AAD) and Intrapulmonary Percussive Ventilation (IPV) to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis: a Randomised Clinical Trial.||Vrije Universiteit Brussel|No|Completed|December 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|N/A|24 Months|No|||March 2015|March 10, 2015|April 24, 2014||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT02126748||45560|
NCT02121093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|janaina de moraes silva|Effect of Vibration Stimulation Applied to Different Frequencies in Cortical Excitability and Muscular Function: Randomised Clinical Trial|Effect of Vibration Stimulation Applied to Different Frequencies in Cortical Excitability and Muscular Function: Randomised Clinical Trial||Universidade do Vale do Paraíba|Yes|Not yet recruiting|May 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02121093||45992|
NCT02121106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361958|Remote Cognitive Remediation|Remote Cognitive Remediation for Psychosis||Queen's University|No|Recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02121106||45991|
NCT02127268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-CRF|Thymosin-α1 in Cancer-Related Fatigue|Thymosin-α1 for Cancer-Related Fatigue in Cancer Patients Who Undergo Chemotherapy: A Randomized Controlled Trial||Zhejiang University|Yes|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||April 2014|April 29, 2014|April 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127268||45520|
NCT02128113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1309|RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD|A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery||Reata Pharmaceuticals, Inc.|No|Completed|May 2014|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|304|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128113||45455|
NCT02128126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA-HPV-01-12|Study of the Therapeutic Vaccine (ISA101) to Treat Advanced or Recurrent Cervical Cancer|Phase I/II Study With Extension Cohorts to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101) at Different Doses With or Without IFNα as Combination Therapy With Carboplatin and Paclitaxel in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer|CervISA|ISA Pharmaceuticals|Yes|Recruiting|September 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02128126||45454|
NCT02127853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SerialCataractGaba|Effect of Gabapentin on Pain of the Second Cataract Surgery|The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery||Seoul National University Hospital|Yes|Recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2014|May 10, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127853||45475|
NCT02127866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1206-PR-0088|Triple in Asthma Dose Finding|A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF CHF 5259 (GLYCOPYRROLATE) PLUS FOSTER® 100/6 µg (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL) IN A METERED DOSE INHALER FOR THE TREATMENT OF PATIENTS WITH UNCONTROLLED ASTHMA UNDER MEDIUM DOSES OF INHALED CORTICOSTEROIDS PLUS LONG-ACTING β2-AGONISTS|Triskel|Chiesi Farmaceutici S.p.A.|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|211|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02127866||45474|
NCT02128360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1034-SD-CTIL|Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve|Analysis of IVF Outcome After Minimal Stimulation vs. High Dose Stimulation for Patients With Low Ovarian Reserve||Sheba Medical Center|No|Not yet recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|43 Years|No|||November 2014|November 19, 2014|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02128360||45436|
NCT02128633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_DH_2014|Effectiveness of a Homecare Dentin Hypersensitivity Gel|EFFECTIVENESS OF A HOMECARE DESENSITIZER FOR PATIENTS WITH DENTIN HYPERSENSITIVITY|ECR|Universidade Federal de Santa Maria|Yes|Completed|November 2009|March 2014|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|90 Years|No|||April 2014|April 29, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02128633||45415|
NCT02128854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021502|Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills|Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills|TABLETS|Medical University of South Carolina|Yes|Recruiting|May 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|100 Years|No|||September 2015|October 1, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02128854||45398|
NCT02128867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVG001|Safety Study of Airway Clearance Techniques in Infants.|Influence of Bouncing, Assisted Autogenic Drainage (AAD) and Bouncing and AAD (BAAD) on Gastro-oesophageal Reflux ( GOR ), Oxygen Saturation (SaO2) and Heart Rate in Infants From 0 to 12 Months||Vrije Universiteit Brussel|Yes|Completed|September 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|159|||Both|N/A|365 Days|Accepts Healthy Volunteers|||March 2015|March 10, 2015|April 23, 2014||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT02128867||45397|
NCT02129140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0377|Observational Study to Evaluate Ventral Incisional Hernia Repair Using a Biologic Mesh (Cook Biodesign)|Observational Study to Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biologic Mesh (Cook Biodesign) for Midline Fascial Closure Reinforcement||Icahn School of Medicine at Mount Sinai|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|The study team will screen the office schedules of the investigators for patients        presenting for open bowel resection at the Mount Sinai Medical Center. Patients who meet        the eligibility criteria will be asked if they are interested in volunteering to        participate in the study.|December 2015|December 22, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129140||45376|
NCT02120820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HongKongPU|An Evaluation of Massage Therapy in a Multisensory Environment for Residents With Intellectual Disabilities|An Evaluation of the Clinical Efficacy of Massage Therapy in a Multisensory Environment for Residents With Severe and Profound Intellectual Disabilities|MassageID|The Hong Kong Polytechnic University|Yes|Active, not recruiting|April 2013|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|240|||Both|18 Years|64 Years|No|||August 2015|August 17, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02120820||46013|
NCT02116985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dual-loop|Dual-Loop Target Controlled Infusion in Laparoscopic Cholecystectomy (DLTCI)|Dual-Loop Target Controlled Infusion of Propofol and Remifentanil Guided by Narcotrend Index in Laparoscopic Cholecystectomy|DLTCI|Guangzhou General Hospital of Guangzhou Military Command|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02116985||46307|
NCT02117544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-057|Multifocal High ADD Contact Lens Proof of Concept Trial|Evaluation of Visual Performance With a Multifocal High ADD Soft Contact Lens Design||Alcon Research|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|50 Years|N/A|No|||August 2015|August 14, 2015|April 16, 2014|Yes|Yes||No|July 21, 2015|https://clinicaltrials.gov/show/NCT02117544||46265|
NCT02117804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002495|Early Screen for Discharge Planning in Community Hospitals|Validating Discharge Planning Decision Support in a Regional Community Hospital||Mayo Clinic|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|225|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study targets adults hospitalized for a variety of medical and surgical conditions in        a rural regional community hospital that is part of a large health system in the Midwest.        The sample will be limited to adults who are returning home in the community, because the        investigators are primarily interested in the problems and unmet needs encountered after        discharge during the recovery period at home. To enhance the generalizability of the        results, the sample will be stratified based on 2010 national estimates of age categories        for hospitalized adults.|May 2015|May 20, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117804||46245|
NCT02126514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5010C00007|A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293|A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects|AZD3293hADME|AstraZeneca|No|Completed|May 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126514||45578|
NCT02126800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3995|Rapid Medical Donation Programme for Breast Cancer|Rapid Medical Donation Programme for Breast Cancer to Examine Tumour Heterogeneity|LEGACY|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2014|March 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Metastatic breast cancer|Both|18 Years|N/A|No|Non-Probability Sample|Patients with proven metastatic breast cancer|April 2014|April 28, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126800||45556|
NCT02126189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC13QPAH36|The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study|An Epidemiological Study of Mucosal Squamous Cell Carcinomas of the Head and Neck||Queensland Centre of Excellence for Head and Neck Cancer|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|600|Samples With DNA|Participants are asked to give their consent for researchers to obtain tissue from tumour      blocks. This tissue is taken as part of their normal care and treatment. If consent is      given, formalin-fixed paraffin embedded (FFPE) tissue samples will be used to determine HPV      status.|Both|N/A|N/A|No|Probability Sample|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra        Hospital, Brisbane, Australia. Patients may be be new patients or old patients and may        have a new diagnosis or they may have a recurrence.|April 2015|April 20, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02126189||45603|
NCT02126475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-45|Temporal Expectations in Parkinson's Disease|L'Expectation Temporelle Dans la Maladie de Parkinson : étude Oculomotrice Psychophysique et Par électroencéphalographie|PEDUPARK|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|April 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and Parkinson patients, non fluctuent|February 2015|February 3, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126475||45581|
NCT02127580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASE-IT|Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve|Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry|EASE-IT|Institut für Pharmakologie und Präventive Medizin|No|Recruiting|April 2014|November 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from aortic Stenosis undergoing transapical trans-catheter heart valve        implantation|January 2016|January 26, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127580|6 Months|45496|
NCT02127281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 14-273|Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.|Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.||The Cleveland Clinic|No|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127281||45519|
NCT02121392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1438|Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty|||University of Chicago|No|Not yet recruiting||||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|85 Years||||April 2014|April 22, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121392||45969|
NCT02121626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3921|The FOCCUS Study: "Focusing on Cancers Chemotherapys' Untreated Symptoms"|The FOCCUS Study: "Focusing on Cancer Chemotherapys' Untreated Symptoms"|FOCCUS|Royal Marsden NHS Foundation Trust|Yes|Recruiting|April 2014|April 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood and Stool Samples will be collected for translational analysis.|Both|18 Years|90 Years|No|Non-Probability Sample|Patients at The Royal Marsden NHS Foundation Trust who have been diagnosed with cancer and        are receiving chemotherapy as part of their treatment. This study will recruit men and        women who will receive chemotherapy for cancers of the oesophagus, stomach, pancreas,        liver, biliary tree or bowel.|February 2016|February 9, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02121626||45951|
NCT02128373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Z11|A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer|A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer||Case Comprehensive Cancer Center|No|Terminated|November 2011|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 16, 2015|April 29, 2014||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT02128373||45435|
NCT02128646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000101|Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair|Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair||University of Kansas Medical Center|No|Recruiting|April 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128646||45414|
NCT02128880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17319|Contraception and Alcohol Risk Reduction Internet Intervention Randomized Trial|A Randomized Clinical Trial of the Contraception and Alcohol Risk Reduction Internet Intervention to Reduce AEP Risk in Community Women|CARRII|University of Virginia|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128880||45396|
NCT02129153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#13-001638|Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring|Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring|LIFT|University of California, Los Angeles|Yes|Enrolling by invitation|September 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02129153||45375|
NCT02117011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1377 Georgetown Lombardi|Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer|Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer||Georgetown University|No|Active, not recruiting|June 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Female|18 Years|74 Years|No|||December 2013|December 4, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02117011||46305|
NCT02120781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-V-002|Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia||Fibrocell Technologies, Inc.|No|Active, not recruiting|March 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120781||46016|
NCT02120794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP287|Threshold Suspend in Pediatrics at Home|Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System in Pediatric Patients With Type 1 Diabetes||Medtronic Diabetes|Yes|Enrolling by invitation|June 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|7 Years|15 Years|No|Non-Probability Sample|US population only. 200 will be eligible to participate in the study, with up to 300        subjects enrolled.|October 2015|October 8, 2015|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120794||46015|
NCT02117557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFGS-SILS-01|Safety Study of Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer|A Prospective Randomized Controlled Trial Comparing Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer||Nanfang Hospital of Southern Medical University|Yes|Recruiting|April 2014|April 2022|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|80 Years|No|||April 2014|April 17, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117557||46264|
NCT02117583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501039|Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers|An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study To Estimate The Effects Of Food On Oxycodone Pharmacokinetics Following Oral Administration Of 40 Mg Doses Of Pf 00345439 Formulation K Taken Whole Or After Chewing In Healthy Volunteers||Pfizer|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117583||46262|
NCT02117817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101305|Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer|A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane®) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer||Rutgers, The State University of New Jersey|No|Withdrawn|February 2015|||February 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|April 16, 2014|Yes|Yes|Research cancelled|No||https://clinicaltrials.gov/show/NCT02117817||46244|
NCT02118077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC6|Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer|A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.|PC6|Cancer Advances Inc.||Completed|April 2001|||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02118077||46224|
NCT02126527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1213|Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer|Phase I Study of Auranofin and Sirolimus in Adult Patients With Non-Small Cell Lung Cancer||Mayo Clinic|Yes|Withdrawn|August 2013|||September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|April 28, 2014|No|Yes|no participants enrolled|No||https://clinicaltrials.gov/show/NCT02126527||45577|
NCT02126540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0638|Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries|A Non-randomized, Multi-center Feasibility Trial of the Avinger Pantheris System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries|COMBINE-II|Avinger, Inc.|Yes|Withdrawn|September 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126540||45576|
NCT02126813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POUR-RCT|When to Perform Bladder Catheterization in Fast-track Hip and Knee Arthroplasty|Urinary Bladder Catheterization in Fast-track Hip and Knee Arthroplasty - What is the Optimal Bladder Volume? A Randomized, Controlled Study|POUR-RCT|Rigshospitalet, Denmark|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|800|||Both|18 Years|125 Years|No|||October 2015|October 27, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126813||45555|
NCT02126826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)||Boehringer Ingelheim||Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|58|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|April 28, 2014||||No||https://clinicaltrials.gov/show/NCT02126826||45554|
NCT02127073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL5203|Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer|Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer||Columbia University|Yes|Suspended|March 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|September 7, 2015|April 28, 2014|Yes|Yes|Enrollment on hold|No||https://clinicaltrials.gov/show/NCT02127073||45535|
NCT02127294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFO-1shsf|Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine|Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine|EASTFORM|First Hospital of Jilin University|No|Completed|January 2013|January 2016|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127294||45518|
NCT02127307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-122-016|Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.|An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.||GE Healthcare|No|Recruiting|March 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|860|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Failure patients (NYHA Class II or III) with left ventricular ejection fraction ≤35%        at time of enrolment in MBG311 or MBG312.|September 2014|September 17, 2014|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127307||45517|
NCT02125214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fractal-01|Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness|Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness|Fractal|University Hospital, Geneva|Yes|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|40 Years|No|||May 2015|May 29, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125214||45678|
NCT02124928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUCAP|Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis|Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis|VUCAP|Wilhelminenspital Vienna|No|Recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|whole blood serum carotid artery plaque|Both|18 Years|N/A|No|Probability Sample|Four hundred patients with symptomatic or asymptomatic carotid artery stenosis undergoing        carotid endarterectomy, after written informed consent will be included in this study. The        inclusion would be done through our ambulatory care clinic.|September 2015|September 17, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02124928||45700|
NCT02125227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14755-102|Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers|A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755||Yuhan Corporation|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|56|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125227||45677|
NCT02121366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS0511|EUS-guided Ethanol Ablation of an Insulinoma|Endoscopic Ultrasound (EUS)-Guided Ethanol Ablation of an Insulinoma - A Multi-center Prospective Cohort Study|EUS|Guangxi Medical University|Yes|Active, not recruiting|March 2014|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||April 2014|April 22, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02121366||45971|
NCT02122224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PU-IRB1310014050|Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory|||Purdue University|No|Recruiting|December 2013|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122224||45905|
NCT02121925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|myPlan ONC003|Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up|LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients|ONC003|Myriad Genetic Laboratories, Inc.|No|Recruiting|May 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic      adenocarcinoma biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|Recently diagnosed treatment-naïve patients with early stage NSCLC (lung adenocarcinoma)|September 2015|September 30, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121925|3 Years|45928|
NCT02122198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0193|Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women|Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women||University of Colorado, Denver|No|Recruiting|June 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|34|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122198||45907|
NCT02122484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.CABG|Colchicine in Coronary Artery Bypass Graft (CABG)|Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage||G.Gennimatas General Hospital|Yes|Completed|November 2013|November 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2014|November 8, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122484||45885|
NCT02116998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-004-002|Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae||Genocea Biosciences, Inc.|Yes|Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|98|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116998||46306|
NCT02117297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-504|SCT Plus Immune Therapy in Average Risk AML/MDS|Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)(IND 111024)||New York Medical College|No|Recruiting|November 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|N/A|30 Years|No|||March 2016|March 10, 2016|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117297||46283|
NCT02125981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMA_001|The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy|A Prospective Randomized Double-blinded Clinical Trial About the Efficacy of Oral Limaprost Administration Following Surgery for Cervical Myelopathy||Seoul National University Hospital|No|Recruiting|September 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|N/A|No|||May 2015|May 20, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125981||45619|
NCT02125994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulder 0.5 vs 0.375|Effect of 0.5% vs 0.375% Ropivacaine on Autonomous Nervous System|Comparison of the Effect of Ropivacaine 0.5% vs 0.375% on the Autonomous Nervous System During Shoulder Surgery in Beach Chair Position||Larissa University Hospital|No|Recruiting|March 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02125994||45618|
NCT02126254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-YA-055-CTIL|Optimization of the Treatment of Acute HF by a Non Invasive Cardiac System-a Randomized Control Trial|Optimization of the Treatment of Acute Heart Failure by a Non Invasive Cardiac System-Randomized Control Trial|HFNICAS|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2014|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 27, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02126254||45598|
NCT02126553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0116|Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission|Phase II Study of Lenalidomide Maintenance in Patients With High Risk Acute Myeloid Leukemia (AML) in Remission||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126553||45575|
NCT02126839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-303|A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics|A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics||Teva Pharmaceutical Industries|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|4 Years|11 Years|No|||January 2016|January 6, 2016|April 28, 2014|Yes|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT02126839||45553|
NCT02126852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMEM|Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia|Comparison of AMG (Acceleromyography) and EMG (Electromyography) to Avoid Postoperative Residual Paralysis After General Anesthesia|CAMEM|Technische Universität München|No|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126852||45552|
NCT02124317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABXS001|Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer|Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer|NAPSPAC|Chinese PLA General Hospital|Yes|Recruiting|April 2014|December 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2014|August 12, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124317||45746|
NCT02124577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140338|Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD|Development of Kinetic Biomarkers of Liver Fibrosis Based on Stable Isotope Mass Spectrometry Techniques for Measuring Nonalcoholic Fatty Liver Disease NAFLD)||University of California, San Diego|No|Not yet recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Stored specimen The specimens (serum, plasma, urine, stool, saliva, liver tissue, and DNA)      collected as part of this study will be kept in Dr. Loomba' s locked research freezer at the      Clinical Teaching Facility (CTF-building A).All collected data and patient charts will be      maintained at the CTF building in a locked computer file with access available to the      principal and study investigators only.      All samples and data will be labeled with a code number. The name, address, social security      number, date of birth and other personal identifiers will not be available on the sample,      and we will not give out any information that identifies the patient to the researchers who      use these samples and data.|Both|18 Years|N/A|No|Probability Sample|Adults, age 18 or above, may have NAFLD or NASH-related cirrhosis or may serve as a        control participant without this condition.|April 2014|December 17, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124577|8 Weeks|45726|
NCT02121405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCCZ-R01|Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM|Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy Versus Conventional Preoperative Radiochemotherapy for Locally Advanced Rectal Cancer With MRI Negative Circumferential Margin|PSSR|Zhejiang University|Yes|Not yet recruiting|December 2014|December 2022|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|75 Years|No|||April 2014|April 22, 2014|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121405||45968|
NCT02121665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLOZ/PG/PERIO/2013|Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.|Effect of Probiotic Lozenges as an Adjunct to Non Surgical Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Double Blind Placebo Controlled Clinical and Biochemical Study.||CD Pharma India Pvt. Ltd.|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|65 Years|No|||February 2015|February 4, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121665||45948|
NCT02121678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-200|Effect of Resistance and Aerobic Exercise in CIDP or MMN|Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN)||University of Aarhus|No|Enrolling by invitation|April 2014|January 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|80 Years|No|||August 2015|December 22, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02121678||45947|
NCT02121119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-289|Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump|Sciatic Popliteal Nerve Block in Foot Surgery: Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump||Pontificia Universidad Catolica de Chile|Yes|Completed|September 2013|September 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|70 Years|No|||September 2015|September 22, 2015|November 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02121119||45990|
NCT02121379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1401-116-549|Randomized Clinical Trial of 8 Weeks Pulmonary Rehabilitation in Advanced Stage Lung Cancer Patients With COPD During Cytotoxic Chemotherapy|||Seoul National University Hospital||Recruiting|May 2014|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||May 2014|May 30, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02121379||45970|
NCT02122237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-1289|Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial|Cathodal Transcranial Direct Current Stimulation in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial|CATCHROMIG|University Hospital of Liege|No|Completed|September 2013|September 2014|Actual|April 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122237||45904|
NCT02121600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET CRPC|18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer|Assessment of CRPC Response Through Comprehensive Characterization Using Novel Biomarkers (PET CRPC)||Lawson Health Research Institute|Yes|Recruiting|September 2014|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|66|||Male|18 Years|N/A|No|||October 2014|October 2, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02121600||45953|
NCT02121613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00048 GP 4 04|PERmixon® in LUTS Evaluation Study (PERLES)|PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|PERLES|Pierre Fabre Medicament||Active, not recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|833|||Male|45 Years|85 Years|No|||December 2015|December 8, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02121613||45952|
NCT02121938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051659|Dynamics of the Microbiome in the Premature Infant|Dynamics of the Microbiome in the Premature Infant||Duke University|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Blood, stool, serum, breastmilk|Both|N/A|1 Week|No|Non-Probability Sample|Very low birth weight infants|August 2015|August 18, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121938||45927|
NCT02122211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2424|Choline Dehydrogenase and Sperm Function: Effects of Betaine|Choline Dehydrogenase and Sperm Function: Effects of Betaine||University of North Carolina, Chapel Hill|Yes|Recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02122211||45906|
NCT02122497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIAS1.0|The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery|The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery: Possibility of Risk Assessment and Stratification|BIAS|Wilhelminenspital Vienna|No|Recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|whole blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from abdominal aortic aneurysm or abdominal aortic occlusive disease        scheduled either for open surgical repair or endovascular procedure|April 2014|April 22, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122497||45884|
NCT02122744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-1331|RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine|Randomised Placebo Controlled Trial of rTMS Quadri Pulse Over Visual Cortex for the Prevention of Chronic Migraine||University Hospital of Liege|Yes|Completed|September 2013|September 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122744||45865|
NCT02125474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41030610-041|Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate|Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate||Instituto Nacional de Cancerologia, Columbia|Yes|Recruiting|November 2013|November 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|90 Years|No|||May 2014|May 6, 2014|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125474||45658|
NCT02125487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.RS1.03|Hybrid Simulation in Teaching Clinical Breast Examination|The Use of Hybrid Simulation (HS) of the Breast in Teaching Clinical Breast Examination (CBE) to Medical Students.|HS-CBE|American University of Beirut Medical Center|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|82|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 22, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02125487||45657|
NCT02117310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0414|ICG Use in Angiography for Nasoseptal Flap Harvest|Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Sphenopalatine Artery Location and Patency in Harvesting and Positioning a Pedicled Nasoseptal Mucosal Flap in Endoscopic Endonasal Cranial Base Surgery|ICG|Ohio State University|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|March 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117310||46282|
NCT02117570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5091003|A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.|A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years||Pfizer|Yes|Active, not recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|749|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117570||46263|
NCT02126280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAR-MAPA|Monocyte Activation in Preclinical Atherosclerosis|Cross-sectional Clinical Study of the Individual Profile of Activation of Circulating Blood Monocytes in Subjects With Preclinical Atherosclerosis.|MAPA|Institute for Atherosclerosis Research, Russia|Yes|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|170|Samples Without DNA|Whole blood taken with anticoagulants for immediate monocyte isolation to be seeded in cell      culture, and for preparation of plasma samples to be frozen for lipid analysis.|Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|The inclusion of healthy individuals, of apparently healthy persons with a predisposition        to atherosclerosis, and subjects with subclinical atherosclerosis, according to the        results of ultrasonographic examination of carotids, to achieve 80% statistical power (up        to 50 study participants per group).        Conducting experiments on obtaining the individual cultures of blood monocytes and        stimulation of cells by proinflammatory and anti-inflammatory stimuli|April 2014|April 28, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02126280||45596|
NCT02126579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15931|Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists|Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)|MEL60|University of Virginia|Yes|Recruiting|April 2014|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|58|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126579||45573|
NCT02126267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07172212.3.0000.5149|Evaluation of Techniques for Scaling and Root Planing and One Stage Full Mouth Disinfection|Clinical and Microbiological Evaluation of Techniques for Scaling and Root Planing Per Quadrant and One Stage Full Mouth Disinfection Associated With Azithromycin or Chlorhexidine: Randomized Controlled Trial||Centro Universitario de Lavras|No|Completed|January 2013|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|77|||Both|18 Years|60 Years|No|||April 2014|April 27, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02126267||45597|
NCT02126865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.2|Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 1060469 Tablets in Healthy Subjects and Otherwise Healthy Patients With Asthma up to GINA Treatment Step 2 (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)||Boehringer Ingelheim||Completed|May 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|131|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|April 28, 2014||||No||https://clinicaltrials.gov/show/NCT02126865||45551|
NCT02127125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130458H|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)|MicroB2|The University of Texas Health Science Center at San Antonio|Yes|Recruiting|April 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127125||45531|
NCT02124083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140102|Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1|Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1||National Institutes of Health Clinical Center (CC)||Recruiting|April 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||December 2015|January 15, 2016|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02124083||45764|
NCT02124330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 06-13|Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models|Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models||IRCCS Burlo Garofolo|No|Recruiting|June 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|25|||Both|25 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02124330||45745|
NCT02124590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053117|The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function|The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function||Duke University|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|60 Years|80 Years|No|||June 2015|June 15, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124590||45725|
NCT02124603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041SI|Microbiological Evaluation of the Ocular Flora Before Cataract Surgery|Evaluation of Ocular Flora in Patients Undergoing Cataract Surgery. An Observational Study||SIFI SpA|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|120|Samples Without DNA|Conjunctival and palpebral swab of the eye undergoing surgery|Both|18 Years|N/A|No|Probability Sample|Patients undergoing routine cataract surgery|December 2015|December 15, 2015|April 23, 2014||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT02124603||45724|
NCT02121418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9019|Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm|Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)||University of Washington|No|Recruiting|June 2014|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|N/A|No|||March 2016|March 1, 2016|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121418||45967|
NCT02121691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-085|Faith-Based Initiative to Promote Health in Appalachia|Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia||University of Kentucky|Yes|Active, not recruiting|April 2013|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02121691||45946|
NCT02121951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quadratus Lumborum Block|Quadratus Lumborum Block for Percutaneous Nephrostomy|Quadratus Lumborum Block Versus Local Anesthetic Infiltration Combined With Monitored Anesthesia Care for Percutaneous Nephrostomy|QLB|National Cancer Institute, Egypt|Yes|Not yet recruiting|May 2014|August 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2014|April 22, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02121951||45926|
NCT02122250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4746|Web-based Support for People With Type 2 Diabetes|Developing and Testing Accessible Web-based Support for Patient Self-management of Diabetes||University of Southampton||Completed|October 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1041|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02122250||45903|
NCT02121639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMCAN0935|Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy|An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)|ProCAID|University Hospital Southampton NHS Foundation Trust.|Yes|Recruiting|January 2014|December 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Male|18 Years|N/A|No|||November 2014|November 3, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02121639||45950|
NCT02121652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517176-3|Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer|Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT||State University of New York at Buffalo|Yes|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|21 Years|N/A|No|||January 2016|January 13, 2016|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02121652||45949|
NCT02122757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-1300|Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine|Randomised Sham-controlled Trial of Anodal Transcranial Direct Current Stimulation (tDCS) for the Prevention of Episodic Migraine|ANODEM|University Hospital of Liege|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|November 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122757||45864|
NCT02123030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0642|A Micro/Nano Device for Exhaled Breath Analysis|A Micro/Nano Device for Exhaled Breath Analysis||James Graham Brown Cancer Center|Yes|Recruiting|January 2011|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Breathe samples|Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those fitting inclusionary criteria between 20 and 85 years of age, with or without        history of pulmonary disease or cancer.|February 2016|February 29, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02123030||45843|
NCT02123303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-10-038|Orthostatic Hypotension Among Veterans|The Incidence of Orthostatic Hypotension Among Veterans|OH|James J. Peters Veterans Affairs Medical Center|No|Completed|November 2010|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|Any able-bodied veteran (able to independently stand for 10 minutes) that presents for a        routine clinical visit or a neurological clinic visit at the James J. Peters VA Medical        Center and does not have an acute illness or infection is eligible to participate in the        study.|August 2015|August 31, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02123303||45823|
NCT02129465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV_transmission.CTIL|Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy|Correlates of Maternal Characteristics in CMV Infection in Pregnancy With Maternal-fetal Transmission.|CMV|Shaare Zedek Medical Center|No|Recruiting|June 2014|July 2018|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|whole blood, serum, plasma, peripheral blood mono-nuclear cells , DNA, RNA|Female|18 Years|42 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women with CMV infection who are referred to the 'CMV in Pregnancy clinic' in        Shaare Zedek Medical Center.|June 2015|June 18, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02129465||45351|
NCT02125500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC31 SOFTRIH|Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection|Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|September 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125500||45656|
NCT02125513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOGER-01|Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer|Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma|GOGER-01|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|January 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|No|||October 2014|October 3, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02125513||45655|
NCT02125721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6413|Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria|Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria||Northwell Health|Yes|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125721||45639|
NCT02125968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-103-DR-36|Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain|Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain:Randomized-Controlled Clinical Trail||Taipei Medical University|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|85 Years|No|||April 2014|April 26, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125968||45620|
NCT02126592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12XJ10015|The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome|The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome||RenJi Hospital|No|Recruiting|March 2013|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|only plasma|Female|13 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|January 2014|April 28, 2014|January 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02126592||45572|
NCT02126566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00518|Multiclear Treatment for Striae Distensae - A Pilot Study|Phase 2 Study of Multiclear Treatment for Striae Distensae - A Pilot Study||National University Hospital, Singapore|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126566||45574|
NCT02127411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBRP BZD|Effectiveness of Mindfulness Based Relapse Prevention for Chronic Users of Benzodiazepines|Adaptation and Evaluation of the Mindfulness-Based Relapse Prevention Program for Cessation and/or Reduction of Benzodiazepine Chronic Use to Induce Sleep Among Women|MBRP|Federal University of São Paulo|No|Recruiting|October 2013|October 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||September 2014|September 3, 2014|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02127411||45509|
NCT02124941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311013082|Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 13C-MRS|||Yale University||Recruiting|February 2014|||January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02124941||45699|
NCT02125240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV-59|Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma|Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|September 2014|December 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||May 2015|May 21, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02125240||45676|
NCT02125253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-MMS-001|Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Blinded, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg (Amneal Pharmaceuticals LLC) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis||Amneal Pharmaceuticals, LLC|Yes|Completed|January 2014|June 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|811|||Both|12 Years|N/A|No|||October 2015|October 5, 2015|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125253||45675|
NCT02121132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-7127|Pediatric Obesity Weight Evaluation Registry (POWER) Study|Establishment of the Pediatric Obesity Weight Evaluation Registry (POWER): A Prospective Pilot Project of Children and Adolescents Presenting for Weight Management|POWER|Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2014|October 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|18 Years|No|Non-Probability Sample|Participants will be overweight and obese patients (18 years of age or younger) who are        seen for an initial medical evaluation in a pediatric weight management program from March        1, 2014 through April 30, 2020.|February 2016|February 1, 2016|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121132|6 Months|45989|
NCT02121431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH097699|Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention|Online vs Staff Delivery: Child & Family Outcomes, Value Analysis, Satisfaction|TPAS|University of South Carolina|No|Recruiting|April 2014|August 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|3 Years|7 Years|No|||November 2015|November 18, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121431||45966|
NCT02121704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXICO|Magnetic Endoscope Imaging in Colonoscopy: Influence on Propofol Dosage||MEXICO|Technische Universität München|No|Completed|May 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|334|||Both|18 Years|90 Years|No|||November 2015|November 5, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02121704||45945|
NCT02121717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGZ301|Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients|Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial|CMAP|Chipscreen Biosciences, Ltd.|Yes|Recruiting|May 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|534|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121717||45944|
NCT02121964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054340|Capsulectomy vs Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty|Anterior Capsulectomy Versus Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty||Emory University|No|Recruiting|August 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02121964||45925|
NCT02121977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR1205|Study of the Elevate Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse|A Prospective, Safety and Efficacy Cohort Study of Elevate® Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair|Embrace 522|ASTORA Women’s Health|No|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|494|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121977||45924|
NCT02121990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-220|Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|April 2014|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02121990||45923|
NCT02122263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007-14-ZIV|Transient Elastography of the Liver ( Fibroscan ) and Bariatric Surgery|Transient Elastography of the Liver ( Fibroscan ) and Bariatric Surgery||Ziv Hospital|No|Not yet recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|65 Years|No|Probability Sample|60 obese NAFLD patients after sleeve gastrectomy surgery|April 2014|April 22, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02122263||45902|
NCT02122510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004/02/12|Transverse Abdominal Block for Analgesia in Casarean Section|The Value of Preemptive Dexmedetomidine Transversus Abdominis Plane (TAP) Block in Patients Undergoing Elective Cesarean Section Under General Anesthesia.||Tanta University|Yes|Completed|March 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|21 Years|40 Years|No|||December 2014|December 14, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122510||45883|
NCT02122770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15011|Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|April 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122770||45863|
NCT02123043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00253|Motor Learning-based Wheelchair Propulsion Training for Older Adults|The Effect of Motor Learning-based Wheelchair Propulsion Training on Wheeling Biomechanics and Gross Mechanical Efficiency in Older Adults: A Randomized Controlled Trial||University of British Columbia|No|Recruiting|October 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02123043||45842|
NCT02125526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IABPinPI|Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia|Survival Improvement in Extensive Myocardial Infarction With PERsistent Ischemia Following Intra-aortic Balloon Pump Implantation|SEMPER FI|Catharina Ziekenhuis Eindhoven|Yes|Recruiting|August 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125526||45654|
NCT02125747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM/RHB/CR/05|Respiratory Therapy in COPD Exacerbations|Effectiveness of Respiratory Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease|TRESEPOCAS|Parc de Salut Mar|No|Completed|December 2011|November 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125747||45637|
NCT02125734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ADE04|Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients|A Randomized, Multicenter, Open-label, Cross-over Study to Assess Lung Function and Patient Preference After a 4 Week Treatment Each With QVA149 vs. Tiotropium in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) and Moderate to Severe Airflow Limitation Who Are on a Tiotropium Therapy (FAVOR Study)|FAVOR|Novartis|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|40 Years|N/A|No|||December 2015|December 14, 2015|April 24, 2014||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT02125734||45638|
NCT02126891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01524-41|FACEFI : Cardiac Fatigue During Intense Exercises - Pilot Study|FACEFI : Cardiac Fatigue During Intense Exercises - Pilot Study|FACEFI|Rennes University Hospital|Yes|Recruiting|January 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|23|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|January 23, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126891||45549|
NCT02126904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310006|Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept|Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration||Yokohama City University Medical Center|Yes|Recruiting|January 2012|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|50 Years|N/A|No|Probability Sample|All the patients were treated at Yokohama City University Medical Center between January        2012 and October 2013.|April 2014|April 28, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126904||45548|
NCT02126878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401174207|Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection|Prospective, Randomized, Double-blinded Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection||West Virginia University|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02126878||45550|
NCT02124954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-05|A Preliminary Drug Drug Interaction Study With TA-8995|A Phase I, Open Label Study to Assess the Effects of TA-8995 on the Pharmacokinetics of Midazolam and Digoxin in Healthy Male Subjects||Xention Ltd|No|Completed|April 2014|||July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|February 23, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02124954||45698|
NCT02125266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V4041|Safety and Preliminary Efficacy Study of V404 PDS in Uveitis|A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis||Forsight Vision4|No|Terminated|April 2014|March 2015|Actual|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125266||45674|
NCT02125279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18131|Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis|A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 17 Years of Age) With Mild to Moderate Plaque Psoriasis||Galderma|Yes|Recruiting|May 2014|||October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|2 Years|17 Years|No|||January 2016|January 18, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125279||45673|
NCT02125292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP429-102|Taste Assessment Study of SHP429 in Healthy Adult Subjects|A Phase 1, Open-label, Randomized, 3-period Crossover Taste Assessment Study to Characterize the Palatability of SHP429 When the Contents Are Sprinkled Onto Soft Foods or Emptied Into a Cup and Administered With Water in Healthy Adult Subjects||Shire||Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|April 1, 2015|April 25, 2014|No|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT02125292||45672|
NCT02121145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ty21a-ASC|Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines|Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae|Ty21a-ASC|Helsinki University Central Hospital|Yes|Recruiting|October 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2014|April 19, 2014|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02121145||45988|
NCT02121184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00074673|Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes|A Clinical Trial Evaluating the Interaction of Rapid Hydration and the Rate of Oxytocin Labor Augmentation on Fetal Heart Rate Changes and Maternal Fetal Outcomes||Northwestern University|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|380|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 9, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02121184||45985|
NCT02121444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17101|BAY86-5046 (Betaseron), Non Interventional Studies|BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®|BETAEVAL|Bayer|No|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with relapsing remitting multiple sclerosis        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with        Betaferon or will be treated with Betaferon according to the attending physician's        decision and for whom the patient and the physician have agreed to use the BETACONNECT        device.|March 2016|March 8, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121444||45965|
NCT02122003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP2|Second Line Sorafenib After Pazopanib in Patients With RCC|Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)|SOAP|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Not yet recruiting|May 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02122003||45922|
NCT02126917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX002-0901|A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)|Single-center, Open-Label, 3-Period Crossover, Phase 1 Study to Evaluate the Pharmacokinetics of Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules 50 mg When Co-Administered With Alcohol in Healthy Subjects Under Fasted Conditions||Zogenix, Inc.|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126917||45547|
NCT02127177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2009|Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients|Long-term Effects of Continuous Positive Airway Pressure on Lipidemia and High-sensitivity C-reactive Protein Levels in Nonobese Patients With Coronary Heart Disease and Obstructive Sleep Apnea||Chinese Pulmonary Vascular Disease Research Group|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|45 Years|75 Years|No|||April 2014|April 28, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02127177||45527|
NCT02127190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-10-001|Study of CXA-10 in Healthy Volunteers|A Randomized, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers||Complexa, Inc.|No|Recruiting|April 2014|November 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|March 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127190||45526|
NCT02122523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLN|Sentinel Lymph Node (SLN) in Colorectal Carcinoma (CRC) With a Near-infrared (NIR)-Dye|In Vivo Study to Determine the Efficacy of Sentinel Node Mapping in Patients With Colon Carcinoma Using Near-infrared Laparoscopy||VU University Medical Center|No|Completed|January 2013|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122523||45882|
NCT02122783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4422|Comparison of the Functional Walking Outcomes of Two Settings of a Commercially Available Ankle Foot Orthosis in Adult Stroke Patients|Comparison of the Functional Walking Outcomes of Two Settings of a Commercially Available Ankle Foot Orthosis in Adult Stroke Patients||Albert Einstein Healthcare Network|Yes|Recruiting|January 2013|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|9|||Both|21 Years|70 Years|No|||January 2016|January 19, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122783||45862|
NCT02123056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POST 5|Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects|Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects||University of Calgary|Yes|Recruiting|October 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|40 Years|N/A|No|||December 2014|December 1, 2014|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02123056||45841|
NCT02125760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM/RHB/NR/14|Respiratory Muscle Training in Subacute Stroke Patients|The RETORNUS Study: Dual Training to Restore the Function of Respiratory Muscles in Stroke Patients|RETORNUS|Parc de Salut Mar|No|Completed|March 2011|September 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02125760||45636|
NCT02126020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEI 13-110H|Topical Infliximab in Autoimmune Eyes With Keratoprosthesis|Topical Infliximab in Autoimmune Eyes With Keratoprosthesis||Massachusetts Eye and Ear Infirmary|No|Enrolling by invitation|November 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|4|||Both|18 Years|80 Years|No|||November 2014|November 2, 2014|April 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126020||45616|
NCT02126033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Telomeres Parameters in Celiac Disease|||Meir Medical Center||Not yet recruiting||||December 2015|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 27, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126033||45615|
NCT02126007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-fatigue|Fatigue Management in HIV|Fatigue Management in HIV: A Sleep and Circadian Rhythm Pilot Intervention||University of California, San Francisco|No|Enrolling by invitation|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||November 2014|November 5, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02126007||45617|
NCT02126293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZICKD13-827|Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant|Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant||Hamilton Health Sciences Corporation|No|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|4 Years|18 Years|No|||March 2015|March 18, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02126293||45595|
NCT02126618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403054RIND|The Effect of Diuresis During 20-minute Pad Test on the Estimation of the Severity of Stress Urinary Incontinence|The Effect of Diuresis During 20-minute Pad Test on the Estimation of the Severity of Stress Urinary Incontinence||National Taiwan University Hospital|Yes|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|3000|||Female|20 Years|N/A|No|Non-Probability Sample|Women with lower urinary tract symptoms and underwent urodynamic testing|July 2015|July 5, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126618||45570|
NCT02118207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264816-02|Exercise and Repetitive Diving|The Impact of Predive Exercise on Repetitive SCUBA Diving||University of Split|No|Completed|October 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118207||46214|
NCT02127138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATP 01|The Study of Active Transfer of Plaque Technique for Unprotected Distal Left Main Bifurcation Lesions|A Prospective Multicenter Randomized Trial Assessing the Efficacy and Safety of Active Transfer of Plaque vs. Provisional T Stenting for the Treatment of Unprotected Distal Left Main Bifurcation Lesions||Beijing Anzhen Hospital|No|Not yet recruiting|June 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02127138||45530|
NCT02127151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0045|A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer|A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis|PANDA|University College, London|No|Withdrawn||||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|April 14, 2014||No|Withdrawal of Industry support for the study|No||https://clinicaltrials.gov/show/NCT02127151||45529|
NCT02127164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAKCI2014|Vacuum Assisted Therapy in Emergent Contaminated Abdominal Surgeries|Prospective Evaluation of Wound Management Using Vacuum Assisted Instillation Therapy in Emergent Contaminated Abdominal Surgeries||University of Arizona|No|Recruiting|May 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02127164||45528|
NCT02124967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0029-B|A Mosque-Based Intervention to Promote Physical Activity in South Asian Muslim Women|Exploring the Feasibility, Acceptability, and Effectiveness of a Mosque-Based Intervention to Promote Physical Activity in South Asian Muslim Women: A Pilot Study||Women's College Hospital|No|Completed|April 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124967||45697|
NCT02125305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME01|Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly|A Phase I Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in Elderly Healthy Male Volunteers|ME01|Seoul National University Hospital|No|Completed|August 2013|||January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125305||45671|
NCT02121158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|592|Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly|CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly|I-70|VA Office of Research and Development|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|70 Years|N/A|No|||March 2016|March 4, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02121158||45987|
NCT02121171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trab+Trab+Ologen|Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma|Comparative Evaluation of Combined Trabeculotomy-trabeculectomy Versus Combined Trabeculotomy-trabeculectomy With Subconjunctival Implantation of Collagen Matrix Implant for Primary Congenital Glaucoma.||National Centre of Ophthalmology named after academician Zarifa Aliyeva|Yes|Active, not recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Months|12 Years|No|||July 2015|July 18, 2015|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02121171||45986|
NCT02126358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GSCL002|Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3|A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia||LG Life Sciences|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|290|||Both|19 Years|N/A|No|||January 2016|January 13, 2016|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02126358||45590|
NCT02126371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0058-1005|LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects|LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation||LEO Pharma|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|March 10, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02126371||45589|
NCT02121730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0006|Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions|Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions|FRISC|Centre Hospitalier Universitaire, Amiens|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who had undergone renal transplantation for 10 years in the French interregion        Northwest (Normandy, Picardy and Nord-Pas de Calais).|July 2015|July 28, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121730||45943|
NCT02126930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/HF-01|Pharmaceutical Consultation at Hospital Discharge and Adherence to Anti-infective Treatment|Impact of a Pharmaceutical Consultation at Hospital Discharge on Adherence to Anti-infective Treatment After Returning Home|CPS-INFECTIO|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|174|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126930||45546|
NCT02122536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318060-3|Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles|Split-Face, Double-blind, Single Center, Prospective Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA||YMD Eye and Face||Completed|July 2012|November 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 22, 2014|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02122536||45881|
NCT02122796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S121301|A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope|A Pilot Randomized Controlled Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope.||Allina Health System|No|Recruiting|May 2014|May 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||July 2014|July 8, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02122796||45861|
NCT02122809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR101|Phase I Study of Chiauranib in Patients With Advanced Solid Tumors|Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors||Chipscreen Biosciences, Ltd.|No|Active, not recruiting|February 2014|April 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02122809||45860|
NCT02123069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000596|Vascular Function and Uterine Fibroids|Sympathetic Nerve Activity and Vascular Function in Women With Uterine Leiomyomata||Mayo Clinic|No|Recruiting|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|Whole blood and serum      No DNA extraction from samples is planned.|Female|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Premenopausal women, ages 25-50 years old, who have and have not been diagnosed with        uterine fibroids. Women will be recruited from Rochester, Minnesota and the surrounding        area (including locations in Iowa and Wisconsin). Women eligible to participate will be in        good health and not taking medications.|March 2016|March 23, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02123069||45840|
NCT02126046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFTM20130101|Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major|||Nanfang Hospital of Southern Medical University||Recruiting|September 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Months|18 Years|No|||April 2015|April 15, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02126046||45614|
NCT02126059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sellin127|Complementary Interventions on Patients With Dementia: Comparative and Longitudinal Research|The Health Effects of Cognitive Stimulation, Reminiscence, and Aroma-massage Complementary Interventions on Different Behavior Patterns of Patients With Dementia: Comparative and Longitudinal Research||National Cheng-Kung University Hospital|Yes|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|4||Actual|120|||Both|65 Years|N/A|No|||February 2016|February 14, 2016|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02126059||45613|
NCT02126332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0188|Epidural Analgesia for Pancreatitis (Epipan Study)|A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS|EPIPAN|University Hospital, Clermont-Ferrand||Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||May 2014|May 26, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02126332||45592|
NCT02126306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YI1958|Beta Glucosylceramide for Treatment of NASH|Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis||Hadassah Medical Organization|No|Completed|January 2006|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||January 2006|October 22, 2014|April 9, 2014||No||No|April 30, 2014|https://clinicaltrials.gov/show/NCT02126306||45594|
NCT02126319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB97-811|Facilitating Participation in a Prostate Cancer Risk Assessment Program|Facilitating Participation in a Prostate Cancer Family Risk Assessment Program||Fox Chase Cancer Center|No|Completed|October 1998|April 2002|Actual|April 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|128|||Male|34 Years|69 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126319||45593|
NCT02117895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI002|Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail|A Prospective RCT Study of Distal Pancreatectomy Combined With Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail||Fudan University|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02117895||46238|
NCT02117908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP-RFP|Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment|Application of CPAP to Reduce Complications and Improve Treatment of Radiofrequency Ablation of Lung Cancer Under Conscious Sedation. A Randomized Study|CPAP-RFP|Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|November 2014|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02117908||46237|
NCT02118220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00011568|Effects of Anesthesia on Pediatric Surgical Patients With a History of Concussion - Phase I|Effects of Anesthesia on Pediatric Surgical Patients With a History of Concussion - Phase I||Children's Hospital Boston|No|Recruiting|May 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|250|||Both|5 Years|21 Years|No|||October 2014|October 27, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118220||46213|
NCT02118480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSMC-001-UD|Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial|Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial||University of Deusto|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|75 Years|No|||February 2016|February 9, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118480||46193|
NCT02124681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13060248|Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer|Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer|REHNIS|University of Pittsburgh|Yes|Recruiting|April 2014|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|34|||Both|21 Years|69 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124681||45719|
NCT02124980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010744|Automated Recovery Line for Medication Assisted Treatment|Automated Recovery Line for Medication Assisted Treatment||Yale University|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02124980||45696|
NCT02124993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 13029|The Effect of Sleeve Gastrectomy on Food Preference|The Effect of Sleeve Gastrectomy on Food Preference|FPQ|Pennington Biomedical Research Center|No|Completed|April 2013|September 2015|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Dr. Drake Bellanger sleeve gastrectomy surgery|January 2016|January 7, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02124993||45695|
NCT02125318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALE-401-201|A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders|A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)||Galena Biopharma, Inc.|No|Active, not recruiting|May 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125318||45670|
NCT02126384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSERM-C12-10|Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response|Analysis of the Response of Healthy Adults to a 23-valent Pneumococcal Polysaccharide Vaccine to Identify the B Cell Subsets Responsible for the Production of IgM, IgG2 and IgA Anti-pneumococcal Capsular Polysaccharides|PNEUMOVACB|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|May 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02126384||45588|
NCT02122016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmartCare\HIAE11|Comparison of Two Different Types of Mechanical Ventilation Weaning in Patients in the ICU|Weaning With Smartcare in Mechanically Ventilated Patients in the ICU - a Controlled and Randomized Study||Hospital Israelita Albert Einstein|No|Completed|June 2011|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02122016||45921|
NCT02122029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVS|Lifestyle vs.Surgery for Morbid Obesity Treatment|A Nine-Year Follow-up of Intensive Lifestyle Intervention vs Surgery to Treat Morbidly Obese Women: a Non-randomized Human Subject Research.||Harokopio University|Yes|Completed|February 2003|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Female|21 Years|51 Years|No|||April 2014|April 22, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02122029||45920|
NCT02122276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-1434B|Effects of Continuous Passive Motion on the Spinal Circuitries and Its Adaptation in Patients With Spasticity Resulting From Upper Motor Neuron Lesions|||Chang Gung University|Yes|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|N/A|No|||April 2014|April 23, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02122276||45901|
NCT02126631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6147|Sternal ECG Patch Comparison Trial|Comparison of a Sternal ECG Patch With a Standard Recording System for Holter Monitoring||Bardy Diagnostics, Inc.|No|Not yet recruiting|July 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac patients at Auckland City Hospital, Auckland, New Zealand|June 2014|June 25, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126631||45569|
NCT02127203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-03-2014|Nitro-oxidative Stress in Periodontitis|Assessment of Nitro - Oxidative Stress in Periodontal Disease||Damascus University|Yes|Completed|May 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 80 subjects will be invited to participate in this study from the patients        referred to the Department of Periodontology, Faculty of Dentistry, University of        Damascus.        The study has been pproved by our local Review Board. Subjects will be recruited according        to specific inclusion criteria after completion of medical and dental history        questionnaires. Patients will sign a consent form after being advised about the nature of        the study.        The selection of patients will be made according of the criteria approved by the 1999        international world workshop for a classification system of periodontal diseases and        conditions (Armitage 1999) using five clinical parameters and full mouth or panoramic        radiographs for diagnosis.|October 2015|October 2, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02127203||45525|
NCT02127216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIDS-MOSES|Motivation Psychology-based Smart Engagement System|Motivation Psychology-based Smart Engagement System for Improved Older Adult Chronic Disease Management|MOSES|Baltimore Research & Education Foundation, Inc.|Yes|Active, not recruiting|June 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Anticipated|88|||Both|60 Years|N/A|No|||March 2015|March 16, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127216||45524|
NCT02122549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0118|Hospital Wearable Defibrillator Inpatient Study|Hospital Wearable Defibrillator Inpatient Study|HWD|Zoll Medical Corporation|No|Completed|April 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122549||45880|
NCT02122562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140085|The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder|The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|65 Years|No|||November 2015|December 15, 2015|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02122562||45879|
NCT02127684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29381|Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing|Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard AntiVEGF Dosing||Maturi, Raj K., M.D., P.C.|No|Withdrawn||November 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|April 29, 2014|Yes|Yes|sponsor determined study design would not produce useful results|No||https://clinicaltrials.gov/show/NCT02127684||45488|
NCT02127697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237B2301|Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma|A Randomized, Double-blind, Parallel Group, 52-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 in Patients With Poorly Controlled Asthma||Novartis|No|Withdrawn|March 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 10, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127697||45487|
NCT02127710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5082C00002|A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)|A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)||AstraZeneca|No|Active, not recruiting|April 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|99 Years|No|||February 2016|March 1, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127710||45486|
NCT02127996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01799|GLP-1 Loading During Elective Percutaneous Coronary Intervention|A Study to Investigate the Protective Effects of Glucagon-like Peptide-1 (GLP-1) in Patients Undergoing Elective Angioplasty and Stenting (GOLD-PCI)|GOLD-PCI|Papworth Hospital NHS Foundation Trust|Yes|Recruiting|March 2015|July 2021|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02127996||45464|
NCT02125786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RERTEP|A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma|A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma||St. Jude Children's Research Hospital|No|Recruiting|April 2014|September 2025|Anticipated|September 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|1 Year|21 Years|No|||November 2015|November 3, 2015|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02125786||45634|
NCT02126072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/262|Effects of Ethanol on Gut Wall Integrity|The Effects of Ethanol on Gut Wall Integrity as Measured by I-FABP and LBP|E-GUT|University Medical Center Groningen|No|Completed|January 2012|March 2014|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02126072||45612|
NCT02117427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-EP-RF-02|TARGTEPO Treatment for Anemia in CKD and ESRD|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO||Medgenics Inc.|No|Recruiting|April 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117427||46273|
NCT02126605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17296|Accuracy of Blood Glucose Detection by Diabetes Alert Dogs|Accuracy of Blood Glucose Detection by Diabetes Alert Dogs||University of Virginia|Yes|Not yet recruiting|July 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|6 Years|65 Years|No|Non-Probability Sample|Diabetes Alert Dog (DAD) owners who have obtained their dogs from a specific training        organization.|April 2014|April 28, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126605||45571|
NCT02119312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-002|Malaria Clinical Trials Center General Screening|General Screening for Eligibility to Participate in Treatment, Prevention and Vaccine Trials at the Seattle Malaria Clinical Trials Center|GS|Fred Hutchinson Cancer Research Center|No|Recruiting|June 2010|||December 2025|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Men and non-pregnant women who are in general good health.|February 2016|February 9, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119312|1 Year|46129|
NCT02119533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPIT|Concussion and Post Traumatic Stress in Traumatic Brain Injury|Prospective Study of Concussion and PTSD in Structurally Brain Injured, Non-Structurally Brain Injured and Non-Brain Injured Trauma Victims in Bellevue HHC|CAPIT|New York University School of Medicine|No|Terminated|May 2013|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|5 Years|N/A|No|Probability Sample|There are three populations being studied:          1. structural traumatic brain injury          2. non-structural traumatic brain injury          3. non-brain injured (bodily or extremity injured)|February 2016|February 25, 2016|July 8, 2013||No|PI has left the institution.|No||https://clinicaltrials.gov/show/NCT02119533||46112|
NCT02118493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400129|Endo-biliary Laser Excision of Biliary Stenoses|Endo-biliary Laser Excision of Biliary Stenoses: Initial Experience and Feasibility||University of Florida|No|Withdrawn|December 2015|May 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 8, 2014|Yes|Yes|The protocol has been withdrawn for re-evaluation.|No||https://clinicaltrials.gov/show/NCT02118493||46192|
NCT02121197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-RET-2014-07|Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.|A Collaborative Retrospective Trial on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients With Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES)|ARTES|Association for Innovation and Biomedical Research on Light and Image|No|Completed|August 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|321|||Both|18 Years|N/A|No|Non-Probability Sample|300-400 patients who have received at least 2 Ozurdex injections for the treatment of DME,        were followed for at least 6 months after the last injection and with a minimal BCVA of        20/200 at baseline (before Ozurdex treatment).|January 2016|January 19, 2016|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121197||45984|
NCT02121457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doutorado-2014|Brazil Nuts Effects on Selenium Status and Cognitive Performance|Effects of Brazil Nuts Consumption on Selenium Status and Cognitive Performance in Older Adults With Mild Cognitive Impairment: a Randomized Controlled Pilot Trial||University of Sao Paulo|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|60 Years|N/A|No|||April 2014|April 22, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121457||45964|
NCT02121743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2014_843_0001|Use of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy|Prospective, Multicenter, Randomized, Parallel Group Clinical Study Evaluating the Efficacy of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy|PROBIOCOL|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|February 2014|September 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|108|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02121743||45942|
NCT02121756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS-ES ID 11987|Dipyridamole for Immune Activation in HIV|A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987||University of Pittsburgh|Yes|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02121756||45941|
NCT02126670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP1401|ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis|||Promius Pharma, LLC||Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|30 Years|85 Years|No|||January 2016|January 25, 2016|April 25, 2014|Yes|Yes||No|November 24, 2015|https://clinicaltrials.gov/show/NCT02126670||45566|
NCT02126683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312121MINA|The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis|The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis||National Taiwan University Hospital|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|35 Years|No|||April 2014|April 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126683||45565|
NCT02126644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01229|The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging|Phase 2 Study of the Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging||National University Hospital, Singapore|No|Not yet recruiting|May 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126644||45568|
NCT02126943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-503|OPsumit USers Registry|US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice|OPUS|Actelion|No|Recruiting|April 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Patients newly treated with Opsumit|February 2016|February 17, 2016|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126943||45545|
NCT02126956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058-106|Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects|Single-center, Open-label Study With 14C-labeled ACT-128800 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects||Actelion|No|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02126956||45544|
NCT02126969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-HN-24|A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN|A Phase II Study of Docetaxel, Carboplatin With and Without Low Dose Radiation as Induction Therapy in Locally Advanced Head and Neck Cancer||University of Kentucky|Yes|Recruiting|October 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126969||45543|
NCT02127463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-1101-003|Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration|Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration|McCP2/3|MacuCLEAR, Inc.|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||April 2014|April 29, 2014|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127463||45505|
NCT02127437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPS-01|Lanreotide In Polycystic Kidney Disease Study|Lanreotide In Polycystic Kidney Disease Study|LIPS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2014|April 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02127437||45507|
NCT02127723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GC1202|(Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring|An Open, Non-comparative Single Center Study to Evaluate Efficacy and Safety of HA (Macrolane VR30) in Buttocks Reshaping and Contouring||Q-Med AB|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|30 Years|N/A|No|||January 2016|January 12, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127723||45485|
NCT02127736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSG40|Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin|Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin||Philipps University Marburg Medical Center||Completed||September 2014|Actual|September 2014|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|69 Years||||September 2014|September 1, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127736||45484|
NCT02128009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2-73|Study on the microRNA Expression Level in Postmenopausal Osteoporosis|Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1|microRNA|Fujian Institute Of Trational Chinese Medicine|Yes|Recruiting|February 2014|January 2015|Anticipated|December 2014|Anticipated|Phase 1|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Female|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|outpatient clinic|March 2014|April 30, 2014|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02128009|6 Months|45463|
NCT02117128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJODCT2014001|The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement|The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement: a Randomized, Double-blind, Controlled Trial||Xijing Hospital|Yes|Completed|April 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02117128||46296|
NCT02118506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UFRN 275.155|Effects of Mental Practice in Gait of Individuals With Parkinson Disease: Randomized Clinical Trial|Immediate Effects of Mental Practice in Gait of Individuals With Parkinson Disease: Randomized Clinical Trial||Universidade Federal do Rio Grande do Norte|No|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|44 Years|75 Years|No|||April 2014|April 16, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02118506||46191|
NCT02118519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KneeUJCTC|Mesenchymal Stem Cells in Knee Cartilage Injuries|Use of Mesenchymal Stem Cells for the Repair of Articular Cartilage Disorder of Knee Using Intra-articular Injection of Mesenchymal Cells Alone or Mesenchymal Cells With Platelet Lysate||University of Jordan|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|40 Years|68 Years|No|||February 2016|February 23, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02118519||46190|
NCT02126345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14|MASTER SL Clinical Study|A Prospective, Observational, Multi-centre, Cohort Study of the MASTER SL Femoral Stem and the DELTA TT Acetabular Cup in Patients With Degenerative Disease of the Hip||Limacorporate S.p.a||Recruiting|May 2014|December 2021|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Requiring Hip Replacement|January 2016|January 28, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126345||45591|
NCT02118792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-AD-302|Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis||Anacor Pharmaceuticals, Inc.|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|764|||Both|2 Years|N/A|No|||December 2015|December 28, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118792||46169|
NCT02118805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000204/1|Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders|Quantitative Ultrasonography and Electrical Impedance Myography: Speech and Swallowing Technologies for Use in Neurological Disorders|QUESST|Beth Israel Deaconess Medical Center|No|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||6|Anticipated|200|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited principally from the BIDMC outpatient clinics and inpatient        ward service. Healthy volunteers will be recruited through online advertising.|July 2015|July 21, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02118805||46168|
NCT02119065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13176|Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT|PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|January 2014|||July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|The target population includes patients with unresectable liver metastases or malignancy        who are referred to The Ohio State University Wexner Medical Center for Yttrium-90        microsphere radioembolization therapy.|July 2015|July 7, 2015|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119065||46148|
NCT02119741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-02-2014|Reconstruction of Interdental Papilla Using Hyaluronic Acid|The Role of Hyaluronic Acid in Reconstruction of Interdental Papilla in The Esthetic Zone||Damascus University|Yes|Completed|May 2014|October 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|20 Years|35 Years|No|Probability Sample|Patients will be recruited from the database of Periodontics Department at University of        Damascus. A random sample of 30 patients will be included in this evaluation study from        those who have been identified with defected interdental papillae.|October 2015|October 2, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02119741||46096|
NCT02125591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-NINM full|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Full Trial)|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury: A Randomized, Double-Blinded, Sham-Controlled, Prospective Trial|CN-NINM|U.S. Army Medical Research and Materiel Command|No|Withdrawn|August 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||October 2014|May 21, 2015|April 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125591||45649|
NCT02125799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERB12/38|Accelerated rTMS for Treatment-Resistant Major Depression|A Pilot Trial on the Effectiveness and Tolerability of Accelerated High Frequency Repetitive Transcranial Magnetic Stimulation for Treating Resistant Major Depression||Douglas Mental Health University Institute|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||October 2014|October 2, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125799||45633|
NCT02126085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIESTA|Sedation vs. Intubation for Endovascular Stroke TreAtment|Sedation vs. Intubation for Endovascular Stroke TreAtment|SIESTA|University Hospital Heidelberg|No|Recruiting|April 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02126085||45611|
NCT02126137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-199|Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection|A Pilot Study of the Effect of Ezetimibe in Patients With Chronic Hepatitis C Infection|EZE-1|Pontificia Universidad Catolica de Chile|No|Recruiting|October 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126137||45607|
NCT02126657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01230|The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars|Phase 2 Study of the The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars||National University Hospital, Singapore|No|Not yet recruiting|May 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126657||45567|
NCT02126696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CART-1|Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho|Study on Non-communicable and Selected Communicable Chronic Comorbidities Among HIV-positive Patients on Anti-retroviral Therapy in Rural Lesotho and Their Association to Virologic Outcome||Swiss Tropical & Public Health Institute|No|Active, not recruiting|May 2014|December 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples Without DNA|Frozen human plasma|Both|6 Months|N/A|No|Non-Probability Sample|Patients on anti-retroviral therapy ≥ 6 months followed at one of the facilities involved        in the study.|November 2015|November 29, 2015|April 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02126696||45564|
NCT02127450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 12025|Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases|Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases|E-CARB|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1050|Samples Without DNA|Enterobacteriaceae Isolates non-susceptible to carbapenem (NS -CARB)|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patient hospitalised for more than 24 hours , with a clinical sample positive for a             NS-CARB Enterobacteriaceae          -  Patient hospitalised for more than 24 hours with clinical sample positive for a             non-NS-CARB Enterobacteriaceae and hospitalised in the same type of ward as that case          -  Patient hospitalised for more than 24 hours having had clinical sample(s) being             stayed negative since the beginning of his admission and up to 3 days after the             detection of the case, hospitalised in any type of ward in the hospital|June 2015|June 12, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02127450||45506|
NCT02127749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45198.018.13|The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia|The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia|MISSION-2|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127749||45483|
NCT02128022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01900|Cardioprotective Effects of GLP-1 and Their Mechanisms|Investigation Into Cardioprotective Effect of Glucagon-like Peptide-1 and it's Mechanism of Action During Myocardial Ischaemia||Papworth Hospital NHS Foundation Trust|No|Not yet recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02128022||45462|
NCT02117687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-OPH-DE-016|A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye|||Allergan|No|Completed|May 2014|March 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 16, 2014|Yes|Yes||No|January 22, 2016|https://clinicaltrials.gov/show/NCT02117687||46254|
NCT02117921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000315|Mind Body Syndrome (MBS) Therapy for the Treatment of Chronic Pain|Mind Body Syndrome (MBS) Therapy for the Treatment of Chronic Pain||Beth Israel Deaconess Medical Center|No|Recruiting|February 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117921||46236|
NCT02117934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-23|Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine|A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age||Dynavax Technologies Corporation|Yes|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8374|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117934||46235|
NCT02117674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSE-001|Full Spectrum vs. Standard Forward-viewing Colonoscopy|Full Spectrum vs. Standard Forward-viewing Colonoscopy With and Without Right-colon Retroflexion: a Randomized, Bicentric Back-to-back Study||Attikon Hospital|No|Completed|April 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|246|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02117674||46255|
NCT02119338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11BN092|5-ALA in Recurrent Glioma|Barrow ALA Trial for Recurrent Gliomas||St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119338||46127|
NCT02119767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE002|Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System|Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System|CS1|PlaqueTec Ltd|No|Recruiting|July 2014|June 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited at secondary care cardiology facilities. All subjects who need        a percutaneous transluminal interventional coronary procedure (excluding those with an ST        elevation myocardial infarction) will be considered for this study.        Potential participants will be identified from pre-admission clinic lists and screened for        suitability by members of the clinical team. Eligible patients will be approached for        participation in the study.|April 2015|April 27, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119767||46094|
NCT02119325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202180|The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population|The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population||GlaxoSmithKline|No|Completed|September 2013|||October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|96|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|May 11, 2015|April 17, 2014||No||No|June 5, 2014|https://clinicaltrials.gov/show/NCT02119325||46128|
NCT02120001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN1000AM|Efficacy Study on Silver-coated ETT Cleaned With a Novel Device|Silver-coated Endotracheal Tube Cleaned With a Novel Mechanism for Secretion Removal: a Randomized Controlled Clinical Study.||Massachusetts General Hospital|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120001||46076|
NCT02125604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS407|Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany|A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)|TOLERATE|Biogen|No|Recruiting|June 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|April 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125604||45648|
NCT02125812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis|Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial||Facultad Nacional de Salud Publica|No|Completed|August 2011|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125812||45632|
NCT02125825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KinesiaDPhaseIIYear1|Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration|Kinesia-D Phase II In-Clinic Continuous Assessment Study|Kinesia-D|Great Lakes NeuroTechnologies Inc.||Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|14|||Both|21 Years|N/A|No|Non-Probability Sample|Individuals with Parkinson's disease and a history of levodopa-induced dyskinesia|January 2016|January 8, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02125825||45631|
NCT02126098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-PULMONARY DISEASES|Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis|Cohort Study of Chinese Patients With Pulmonary Vasculitis||Peking Union Medical College Hospital|Yes|Not yet recruiting|May 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|serum lymphocytes urine|Both|18 Years|75 Years|No|Probability Sample|Patients who newly diagnosed ANCA-vasculitis|April 2014|April 27, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126098|30 Months|45610|
NCT02126982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-Clo-U-Io-01|Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence|Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.|SCIENCE|University of Ioannina|No|Completed|October 2012|November 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Suitable for the study will be every patient eligible to receive clopidogrel based on the        international guidelines. In particular, in the study will participate patients with an        acute coronary syndrome (ACS) or having a stable coronary artery disease (CAD). Patients        who have experienced an acute ischemic stroke or a transient ischemic attack (TIA) during        the previous 6 months or having a history of peripheral artery disease (PAD) or carotid        artery disease, will be also eligible for enrollment. Finally, patients with atrial        fibrillation (AF) who will refuse or will not be eligible to use of any oral anticoagulant        will be included in the study. The study will include at least 1,500 patients (at least        750 will receive clopidogrel hydrogen sulfate and at least 750 clopidogrel besylate).|December 2015|December 15, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126982||45542|
NCT02127528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1101137|Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care|Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care: Pharmacodynamic Evaluation and Impact.|TARGET-REA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Pneumonia acquired in mechanically ventilated patients (PAVM)|September 2015|September 24, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02127528||45500|
NCT02127229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574462|Cost Analysis for Endoscopic Retrograde Cholangiopancreatography (ERCP)|The Impact of Cost Itemization on Resource Utilization With ERCP|ERCP|University of Oklahoma|No|Active, not recruiting|April 2014|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|142|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 28, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02127229||45523|
NCT02127476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6640-001|A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease|A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease||Kyowa Hakko Kirin Pharma, Inc.|Yes|Recruiting|July 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|55 Years|N/A|No|||March 2016|March 2, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02127476||45504|
NCT02127762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120541-01H|The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy|The Effect of an Inter-Disciplinary Program, Including Mindfulness Based Stress Reduction, on Psychosocial Function, Pain and Metabolism in Patients With Painful Diabetic Peripheral Neuropathy|AWARE|Ottawa Hospital Research Institute|No|Recruiting|September 2012|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127762||45482|
NCT02128035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIATION PROTECT|RADIATION PROTECTion With a Pelvic Lead Shield and a Radiation Protection Cap for Operators Performing Coronary Angiography or Intervention|Radiation Protection With a Pelvic Lead Shield and a Radiation Protection Cap for Operators Performing Coronary Angiography or Intervention, a Randomized Controlled Trial||Population Health Research Institute|No|Completed|December 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|230|||Both|19 Years|N/A|No|||April 2015|April 27, 2015|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT02128035||45461|
NCT02128269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1007-APS-201|Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome|An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome||Alexion Pharmaceuticals|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128269||45443|
NCT02118558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-14-HMO-CTIL|Negative Pressure Wound Therapy -PREVENA in Prevention of Infections After Total Knee Arthroplasty (TKA)|||Hadassah Medical Organization|No|Not yet recruiting|June 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||||||Both|18 Years|80 Years|No|||April 2014|April 17, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118558||46187|
NCT02118571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1533|Schizophrenia Cognition Scale Development|Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application|CIAS PRO|New England Research Institutes|No|Active, not recruiting|November 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|125|None Retained|No biospecimens collected|Both|18 Years|55 Years|No|Non-Probability Sample|Adults with formal dx of schizo aged 18-55, stabe (non-acute phase), on stable medications|February 2014|December 2, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02118571||46186|
NCT02118233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-009|Cognitive Outcome After Carotid Surgery|Cognitive Outcome After Carotid Surgery||Lahey Clinic|Yes|Recruiting|April 2014|April 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|56|||Both|18 Years|N/A|No|Probability Sample|Patients with unilateral, asymptomatic, significant carotid artery stenosis who are ≥18        years of age who do not present with past or current significant cerebrovascular and        neuropsychological disease.|March 2016|March 1, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118233||46212|
NCT02118246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930127|The Effects of Dry Needling & Kinesio Tape on Anterior Knee Pain|The Clinical Effects of Dry Needling & Kinesio Tape on Myofascial Trigger Point in the Vastus Lateralis Muscle in Subjects With PFPS||University of Social Welfare and Rehabilitation Science|Yes|Completed|October 2012|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|57 Years|No|||April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118246||46211|
NCT02118779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NE/0342|Observational Prolonged Trial in Myotonic Dystrophy Type 1|Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life Standards, a Target Identification Collaboration|OPTIMISTIC|Radboud University|Yes|Active, not recruiting|April 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02118779||46170|
NCT02119052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPKD-liver|Effects of Somatostatin on Liver in ADPKD|Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease||Federico II University|No|Completed|January 2009|||September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2014|April 18, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119052||46149|
NCT02119780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL014|Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar Region|||LG Life Sciences||Active, not recruiting|May 2014|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|83|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119780||46093|
NCT02120274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB12SHCV|Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C|Randomized Clinical Trial to Assess the Effectiveness of Vitamin D and Vitamin B12 Supplementation in Combination With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C.||Federal University of São Paulo|No|Active, not recruiting|March 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|70 Years|No|||August 2015|August 11, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120274||46055|
NCT02125838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|859-GOA|Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery|Application of Endotracheal Intubation and Laryngeal Mask Supreme Without Neuromuscular Blocker in Laparoscopic Gynecologic Surgery||Dokuz Eylul University|No|Recruiting|May 2013|December 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|100|||Female|18 Years|65 Years|No|||April 2014|April 28, 2014|January 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02125838||45630|
NCT02126111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG6043179|Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis|Efficacy of a Depigmented Extract of Phleum in the Treatment of Local Allergic Rhinitis|GRAMAL|Plaza del Hospital Civil|Yes|Active, not recruiting|October 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|No|||April 2014|April 27, 2014|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02126111||45609|
NCT02126124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-SMOK-01|Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.|A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (With the H-ADD Coil) Intended as an Aid to Smoking Cessation.||Brainsway|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|224|||Both|22 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 26, 2015|April 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126124||45608|
NCT02126397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230485|Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint and Laser Diode. A Randomised Controlled Trial.|Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint and Laser Diode. A Randomised Controlled Trial.||Maimónides Biomedical Research Institute of Córdoba|Yes|Completed|May 2013|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|98|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 8, 2014|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126397||45587|
NCT02126709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01233|The Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy|Phase 2 Study of the Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy||National University Hospital, Singapore|No|Not yet recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|13 Years|60 Years|No|||April 2014|April 29, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126709||45563|
NCT02127034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-107|Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects|A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects||Astellas Pharma Inc|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127034||45538|
NCT02126410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402038RINB|Associations Between Self-Reported Sleep Duration and Sarcopenia in Community-Dwelling Older Adults|Associations Between Self-Reported Sleep Duration and Sarcopenia in Community-Dwelling Older Adults||National Taiwan University Hospital|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|488|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|community-dwelling elderly (>= 65 years old)|August 2014|August 11, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126410||45586|
NCT02127255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBM@BUCM-1|Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail||ACTIN|Beijing University of Chinese Medicine|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||April 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127255||45521|
NCT02126995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL014|A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome|A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome||Alcobra Ltd.|Yes|Active, not recruiting|June 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|55 Years|No|||December 2014|March 26, 2015|April 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02126995||45541|
NCT02127489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.KTU.0.01.00.01/372|The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery|The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery, Sedation, and Analgesia in Children Given Caudal Anesthesia Plus Bupivacaine||Karadeniz Technical University|No|Completed|June 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|2 Years|10 Years|No|||April 2014|April 28, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02127489||45503|
NCT02127775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-132|Lesinurad Tablet Bioequivalence|A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Bioequivalence of Lesinurad Tablets From Two Manufacturing Sites in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|Yes|Completed|April 2014|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|54|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|April 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127775||45481|
NCT02127788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-MYC-NI-003|Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology|National, Longitudinal, Multicentre and Prospective, Observational Study of the Use of Micafungin (Mycamine®) in Antifungal Prophylaxis of Invasive Fungal Infections in Medical Practice in Haematology and Onco-haematology|OLYMPE|Astellas Pharma Inc|No|Recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Probability Sample|Hospitalized, adult patients with haemopathy or paediatric patients with haemopathy or        solid tumor, under antifungal prophylaxis with micafungin.|December 2015|December 18, 2015|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127788||45480|
NCT02128048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 01 Dated 27-March-2012|The Effect of Cigarette Smoking / Smoking Cessation on Skeletal Muscle Mass, Strength and Functional Capabilities|The Effect of Cigarette Smoking / Smoking Cessation on Skeletal Muscle Mass, Strength and Functional Capabilities||Rambam Health Care Campus|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were recruited from support groups of smoking cessation conducted at "Clalit        Health Services" at Haifa and Western Galilee district.|April 2014|April 29, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02128048||45460|
NCT02119091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH_CTC_2013_001|Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers|A Double-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study: Comparison of Single Oral Dose 400mg Moxifloxacin-induced QT Prolongation Between Healthy Chinese Volunteers and Caucasian Volunteers||Peking University Third Hospital|No|Recruiting|April 2014|December 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02119091||46146|
NCT02118818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002682/BWH|RhEumatiC Heart diseAse Genetics|Next Generation Sequencing Approach to the Study of Rheumatic Heart Disease|RECHARGE|Brigham and Women's Hospital|No|Recruiting|February 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|The investigators are collecting blood for DNA analysis from all subjects as well as heart      valve tissue from subjects who undergo cardiac surgery.|Both|5 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The investigators will include patients aged between 5-40 years in Rwanda presenting with        an initial diagnosis of RHD and whose echocardiographic findings meet the criteria for        definite RHD. World Heart Federation's criteria for echocardiographic diagnosis of        definite RHD will be used, utilizing a combination of pathological criteria and        morphological features.|January 2016|January 11, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118818|5 Years|46167|
NCT02119351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ViaValve Study|A Study Evaluating the Clinical Performance of the ViaValve™ Safety IV Catheter|A Post-market, Randomized Study Evaluating the Clinical Performance of the ViaValve™ Safety IV Catheter|ViaValve-001|Smiths Medical, ASD, Inc.|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|July 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02119351||46126|
NCT02118532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN.PACT SFA China|The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population|The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population||Medtronic Endovascular|Yes|Active, not recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|143|||Both|18 Years|85 Years|No|||January 2016|January 25, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02118532||46189|
NCT02118545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vie-Sal-Ber|Von Willebrand Factor to Predict Postoperative Outcome|Preoperative Von Willebrand Factor to Predict Postoperative Liver Dysfunction and Morbidity After Liver Resection||Medical University of Vienna|No|Completed|April 2014|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|85 Years|No|Probability Sample|Patients undergoing liver resections for either hepatocellular carcinoma,        cholangiocellular carcinoma or colorectal cancer liver metastasis. vWF-Ag will be        evaluated prior to liver resection|September 2015|March 7, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118545||46188|
NCT02119559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825|Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma|Assessment of Circulating Tumor Cells as an Early Predictive Marker of Response to a First Line Treatment Based on an Anti-Human Epidermal Growth Factor Receptor (HER), Cetuximab, in Patients With Inoperable Recurrent and/or Metastatic Head-and-neck Squamous-cell Carcinoma.|CIRCUTEC|University Hospital, Montpellier|No|Recruiting|September 2012|March 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|115|||Both|18 Years|N/A|No|||September 2012|December 2, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02119559||46110|
NCT02120300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1274|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders|A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders||Gilead Sciences|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|122|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120300||46053|
NCT02120014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003912|Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure|A Prospective Study to Determine the Association of Quantitated Blood and Plasma (Intravascular) Volume to Right Heart Hemodynamics, Venous Capacitance, and Regulatory Neurohormones in Patients With Chronic Heart Failure of Reduced and Preserved Ejection Fraction||Mayo Clinic|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120014||46075|
NCT02125383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43NS077652-01A1|ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease|ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I|ParkinStim|Great Lakes NeuroTechnologies Inc.|No|Completed|April 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|40 Years|70 Years|No|||March 2015|March 9, 2015|April 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02125383||45665|
NCT02125630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOMET MF14-01|Bone Metastasis and Surgery in Breast Cancer|The Effect of Primary Surgery in Patients With Stage IV Breast Cancer With Bone Metastasis Only||Federation of Breast Diseases Societies|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Female|20 Years|80 Years|No|||March 2015|March 5, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02125630||45646|
NCT02125851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385682-2|Comparison of Esophageal Clearance Times of Oral Budesonide Preparations|Comparison of Esophageal Clearance Times of Oral Budesonide Preparations||Walter Reed National Military Medical Center|Yes|Completed|January 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|April 25, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02125851||45629|
NCT02127047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 349/12|Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes|Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes|EXTYPE-1|University Hospital, Basel, Switzerland||Recruiting|November 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|No|||November 2015|November 23, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127047||45537|
NCT02127554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_21_01_2014|Long Term Results and Complications After Epistaxis Treatment|Langzeitresultate Und Komplikationen Nach Einer Epistaxisbehandlung||University of Zurich|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|591|||Both|14 Years|80 Years|No|Non-Probability Sample|All patients treated between March 29, 2007 and April 1st, 2008 for epistaxis at the ENT        Dept. of the Zurich University Hospital|December 2015|December 1, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127554||45498|
NCT02127801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1908-1909-ALG-1325|Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants|||Regeneron Pharmaceuticals|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|74|||Both|18 Years|55 Years|No|||January 2016|January 8, 2016|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02127801||45479|
NCT02127502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENUS-1024931|VENUS: Septic Gene Expression Using SeptiCyte||VENUS|Intermountain Health Care, Inc.|No|Recruiting|April 2014|||April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|89 Years|No|Non-Probability Sample|Critically ill subjects, admitted to an Intensive Care Unit|November 2014|November 28, 2014|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127502||45502|
NCT02127515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130601|Non Invasive Prenatal Testing of Down Syndrome|Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample|SAFE 21|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2450|||Female|18 Years|N/A|No|||November 2015|November 11, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02127515||45501|
NCT02128308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBPK|Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents|A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers||Seoul National University Hospital|No|Completed|November 2013|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02128308||45440|
NCT02128321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0053|A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine|A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine||Astellas Pharma Inc|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02128321||45439|
NCT02128568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCGA-YRI-21003-Bio|Sub-Trial of the Youth Readiness Intervention (YRI): Treatment of Control Group and Addition of Stress Biomarkers|A Feasibility Trial of the Youth Readiness Intervention: A Group Psychosocial Intervention for War-affected Youth in Sierra Leone||Harvard School of Public Health|Yes|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|218|||Both|15 Years|24 Years|No|||July 2015|July 21, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128568||45420|
NCT02128581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002150|A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake|A Dose-response Study of the Effects of Exendin-9,39 on Gastrointestinal Symptoms and Food Intake.||Mayo Clinic|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|3|||Both|20 Years|70 Years|No|||September 2015|September 23, 2015|April 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02128581||45419|
NCT02128802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130912|Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure|Weight Reduction Surgery Followed by Kidney Transplantation for Patients With Class III Obesity and Renal Failure||Vanderbilt University|Yes|Recruiting|April 2014|||April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|55 Years|No|||December 2015|December 9, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02128802||45402|
NCT02119104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851122|Prevenar (13v) Infant Drug Use Investigation|Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Active, not recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1100|||Both|2 Months|6 Months|No|Probability Sample|Vaccinees who meet all of the following conditions at the time of the first vaccination        among infants who use Prevenar 13 in accordance with the indication, and dosage and        administration of the vaccine will be included in the investigation.|February 2016|February 9, 2016|March 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02119104||46145|
NCT02119117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACh-002|Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study|Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study||Reproductive Endocrinology Associates of Charlotte|No|Recruiting|April 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Female|36 Years|42 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02119117||46144|
NCT02119364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2/00/14|Working Memory Training for Children With Cerebral Palsy|Computer Based Working Memory Training in Children With Cerebral Palsy (CP)||Sorlandet Hospital HF|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|115|||Both|7 Years|15 Years|No|||April 2014|April 17, 2014|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02119364||46125|
NCT02119377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB:gc:6722|First Australian National Trans Mental Health Study|A Mixed-Methods Study of Mental Health and Associated Factors in Transgender and Transsexual (Trans) People||Curtin University of Technology|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|946|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a study of trans people living in Australia aged 18 years or older. The        investigators used the term trans in an inclusive way, and included people who use (or        used) words like transsexual, transgender, sistergirl, brotherboy, androgynous, or        genderqueer to describe themselves. All trans people, including those who just describe        themselves as men or women were encouraged to participate.|May 2014|May 5, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119377||46124|
NCT02119078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB00010420|Acute Care for Elders (ACE) Program at OHSU Hospital|Acute Care for Elders (ACE) Program at OHSU Hospital||Oregon Health and Science University|No|Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|N/A|N/A|No|||April 2014|April 17, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02119078||46147|
NCT02120027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAK-07|52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)|IRIS-4|Menarini Group|No|Active, not recruiting|March 2014|May 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120027||46074|
NCT02116959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13087|Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma|A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma||University of California, San Francisco|Yes|Recruiting|April 2014|July 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|4 Months|N/A|No|||January 2015|January 9, 2015|February 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116959||46309|
NCT02116972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2014-006|Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|310|||Both|40 Years|N/A|No|||December 2015|December 15, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02116972||46308|
NCT02117245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-105|Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers|Phase I Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers||Mirati Therapeutics Inc.|No|Completed|December 2011|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples With DNA|Pharmacodynamic analysis|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female volunteers.|January 2015|January 6, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT02117245||46287|
NCT02120547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBR 652-1-121|Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment|An Open Label, Phase 1 Study to Evaluate the Effect of Mile and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)||Tobira Therapeutics, Inc.|No|Completed|March 2014|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|April 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120547||46034|
NCT02117258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-360-01|Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma|Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )|ZIPANG|Zeria Pharmaceutical|Yes|Active, not recruiting|April 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02117258||46286|
NCT02117271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068|The Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure on Appearance and Age|"BEAUTY CPAP": The Impact of the Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure on Appearance and Age: a Randomized Crossover Placebo-controlled Study||Nucleo Interdisciplinar da Ciencia do Sono|No|Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|60 Years|No|||March 2016|March 22, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02117271||46285|
NCT02126150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-183|United Coronary Biobanks|United CORoNary Biobanks|UNICORN|UMC Utrecht|No|Completed|September 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|Samples With DNA|Plasma, peripheral blood mononuclear cells and whole blood is stored.|Both|21 Years|N/A|No|Non-Probability Sample|All patients that undergo coronary catheterization for any reason are eligible to enroll        in the study.|December 2015|December 7, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02126150||45606|
NCT02126423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Resistance to Antibiotics in Patients Receiving Eye Injections|Prospective Study on Antimicrobial Resistance Rates Following Repeated Courses of Topical Antibiotics for Intravitreal Injection||NJ Retina|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|40|Samples Without DNA|Conjunctival and nasopharyngeal swabs are procured from each patient.|Both|18 Years|N/A|No|Non-Probability Sample|Outpatient setting|April 2015|April 20, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02126423||45585|
NCT02127008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDSC-001|The Impact of Epidural Fat Resection on Postoperative Outcomes in Posterior Surgery of Lumbar Spine|||Seoul National University Hospital|No|Completed|February 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|185|||Both|20 Years|80 Years|No|||November 2015|November 17, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127008||45540|
NCT02127060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITC-001|The Effectiveness of Vitamin C in Postoperative Pain Management of Single-level Posterior Lumbar Interbody Fusion (PLIF)|||Seoul National University Hospital|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|20 Years|80 Years|No|||November 2015|November 17, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02127060||45536|
NCT02127242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fanyingfang2|Laparoscope Combined Ureteroscopic Air-pressure Ballistic Lithotripsy to Treat Patients With Hepatolithiasis|The Study of Laparoscope Combined Ureteroscopic Air-pressure Ballistic Lithotripsy to Treat Patients With Hepatolithiasis||Zhujiang Hospital|Yes|Recruiting|April 2014|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|70 Years|No|||April 2014|April 29, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02127242||45522|
NCT02127567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV009|The Evaluation of a CONSORT Based Online Writing Tool|The Evaluation of a CONSORT Based Online Writing Tool: a Randomized Controlled Trial|COBWEB|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|March 7, 2015|April 29, 2014||No||No|November 27, 2014|https://clinicaltrials.gov/show/NCT02127567||45497|
NCT02127541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 163/12|New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells|New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells||University Hospital, Basel, Switzerland|Yes|Recruiting|January 2014|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02127541||45499|
NCT02128061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENIOR|Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+|Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association||The Lymphoma Academic Research Organisation|Yes|Recruiting|August 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|80 Years|N/A|No|||February 2016|February 16, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02128061||45459|
NCT02128074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-207|A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia|A Phase 2 Pilot Study of KRX-0502 (Ferric Citrate Coordination Complex) in Treating Iron-deficiency Anemia in Patients With Stage 3-5 Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD)||Keryx Biopharmaceuticals|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||November 2014|October 2, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02128074||45458|
NCT02128087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD074925-01|Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders|Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders|RATA|RAND|Yes|Active, not recruiting|February 2013|January 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|330|||Both|15 Years|24 Years|No|||July 2015|July 14, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02128087||45457|
NCT02128334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-EGD-NI-001|An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation|Prospective Multicenter Observational Program for Evaluation of Efficacy and Tolerability of the 6-month Depot Eligard 45 mg in Patients With Advanced Prostate Carcinoma in Routine Clinical Practice of Uro-Oncologists in the Russian Federation||Astellas Pharma Inc|No|Active, not recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Male|18 Years|N/A|No|Probability Sample|Male patients >18 years of age with advanced prostate cancer (PCa) to whom Eligard 45 mg        was prescribed|October 2015|October 7, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02128334||45438|
NCT02119390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1TEAM|Medication Adherence in Human Immunodeficiency Virus (HIV)|Targeting Enhanced Adherence to Medication: A Pilot Study in Adolescents and Young Adults With Human Immunodeficiency Virus (HIV)||St. Jude Children's Research Hospital|No|Active, not recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|33|||Both|13 Years|24 Years|No|||February 2016|February 18, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02119390||46123|
NCT02119572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhongdaendo1|Impact of Peer Support on Diabetes in China|Impact of Peer Support on Diabetes in China: a Multi-center, Cluster Randomized Controlled Trial||Zhongda Hospital|Yes|Recruiting||||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02119572||46109|
NCT02119598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201317990|Feasibility of AmbulanCe-based Telemedicine (FACT) Study|Technical and Clinical Feasibility of Third Generation In-ambulance Telemedicine: Feasibility of AmbulanCe-based Telemedicine (FACT) Study|FACT|Universitair Ziekenhuis Brussel|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|N/A|No|Probability Sample|Any patient older than 18 years requesting ambulance-based emergency care.|December 2014|December 1, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02119598||46107|
NCT02119585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0077687|Analysis of Respiratory System Mechanics and Inflammatory Response During Orthotopic Liver Transplantation (SPPLIT Trial)|Observational Study to Analyze Respiratory System Mechanics Changes and Inflammatory Responses During Orthotopic Liver Transplantation (SPPLIT Trial)|SPPLIT|University of Turin, Italy|No|Recruiting|February 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood samples at four time points during OLT|Both|18 Years|90 Years|No|Non-Probability Sample|patients with end stage liver diseases undergoing to liver transplantation|December 2014|December 15, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02119585||46108|
NCT02119793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL015|Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE® Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study|||LG Life Sciences||Enrolling by invitation|May 2015|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119793||46092|
NCT02120560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13595|Anticoagulation in AF Ablation and Effects on Neurocognitive Function|Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance||University of California, San Francisco|Yes|Withdrawn|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120560||46033|
NCT02117518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-13|Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients|Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients||Migal Galilee Research Institute|No|Not yet recruiting|May 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|None Retained|Blood samples|Both|N/A|25 Years|No|Non-Probability Sample|T1D patients who were diagnosed up to 3 years prior to recruitment|April 2014|April 22, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117518||46266|
NCT02117791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16843|Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|JPMS-CTEPH|Bayer||Recruiting|July 2014|January 2024|Anticipated|September 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|420|||Both|N/A|N/A|No|Non-Probability Sample|Study population includes patients treated with Riociguat for inoperable CTEPH/ persistent        or recurrent CTEPH after surgical treatment. This study is performed as an all-case        investigation. Therefore, all patients who have been treated with Riociguat for CTEPH need        to be registered in principle, until the target number of patients reached.|March 2016|March 18, 2016|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117791||46246|
NCT02118376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1|Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status|Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity||Shanghai 10th People's Hospital|Yes|Not yet recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|65 Years|No|||December 2013|April 16, 2014|December 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118376||46201|
NCT02126163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AA01733-02|Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention|Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention||Pro-Change Behavior Systems|No|Completed|April 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1000|||Both|21 Years|N/A|No|||March 2016|March 23, 2016|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02126163||45605|
NCT02126436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLP001|Acupuncture for the Treatment of Phantom Limb Syndrome|Acupuncture for the Treatment of Phantom Limb Syndrome: A Randomised Controlled Trial (Feasibility Study)||London South Bank University|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02126436||45584|
NCT02126449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44684.058.13|DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer|DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer|DIRECT|Leiden University Medical Center|Yes|Recruiting|February 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|70 Years|No|||January 2016|January 8, 2016|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02126449||45583|
NCT02126722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy|Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy: Prospective Validation||Niso Biomed S.R.L.|No|Not yet recruiting|June 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|65 Years|No|Non-Probability Sample|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred        for gastroscopy at Homerton University Hospital (London, United Kingdom). A control group        of 50 patients with dyspepsia, not on PPI, will be also enrolled in the study.|April 2014|April 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02126722||45562|
NCT02127879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSRPMMLA1|Intensive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia|High-frequency Repetitive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia: The Double-blind Sham-controlled Study||Brno University Hospital|Yes|Recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|60 Years|No|||May 2014|May 2, 2014|April 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02127879||45473|
NCT02127021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1401-145-552|The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy|Prospective Study for the Effects of High Dose Pancreatic Enzyme Replacement Therapy on Body Weight, Quality of Life, and Nutritional Assessment After Pancreatoduodenectomy||Seoul National University Hospital|Yes|Recruiting|April 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|490|||Both|18 Years|75 Years|No|||April 2014|April 28, 2014|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02127021||45539|
NCT02127827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0834-OC-CTIL|Multiday Fully Closed Loop Insulin Delivery in Monitored Outpatient Conditions|||Sheba Medical Center||Not yet recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||April 2014|April 29, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02127827||45477|
NCT02127840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAAVS1143|Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism|Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism|ISIRA|Charles University, Czech Republic|No|Recruiting|March 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02127840||45476|
NCT02127814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES504803|Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile|Efficacy and Safety of the Probiotic Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile Related Infections in Hospitalized Adult Patients||Case Western Reserve University|No|Recruiting|May 2010|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT02127814||45478|
NCT02136563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1318|Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents|oBservational Clinical Research In Chronic Kidney Disease Patients With Renal Anemia : Renal proGnosis in Patients With Hyporesponsive Anemia To Erythropoiesis Stimulating Agents, darbepoetiN Alfa|BRIGHTEN|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Enrolling by invitation|April 2014|||March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Probability Sample|Chronic renal disease patients without dialysis who are diagnosed with renal anemia and        are administered darbepoetin alfa at enrollment|June 2015|June 18, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136563||44809|
NCT02147457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREMATCH|Prematurity as Predictor of Children's Cardiovascular-renal Health|Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH)|PREMATCH|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|400|Samples With DNA|Urine collection Blood collection|Both|7 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|ELBW (birth weight below 1000 g) neonates and have been well characterized and documented        in the postnatal period, survivors (n = 140) will be matched with two controls. One        control will be matched to sex, birth year and residential area and will be suggested by        the index patient, the second control will be age and sex matched from the area of the        field center. All children considered are currently between 8 and 13 years of age.        Based on GCP guidance and national law, parents or custodians will provide informed        written consent, while the child has to provide informed assent.|February 2014|May 21, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02147457||43972|
NCT02147444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPAND study|Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation|Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice|EXPAND|Tohoku University|Yes|Recruiting|November 2012|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|||Both|20 Years|N/A|No|Probability Sample|Non-valvular atrial fibrillation (In the present study, non-valvular atrial fibrillation        refers to atrial fibrillation without a history of prosthetic valve replacement or mitral        valve stenosis.)|May 2014|May 21, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02147444|2 Years|43973|
NCT02147964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47124-A|ITT-5 Mechanisms of Spermatogenesis|Mechanisms of Hormonal Control of Spermatogenesis in Man|ITT-5|University of Washington|No|Not yet recruiting|January 2017|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147964||43933|
NCT02147977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20140013|Effects of Marine n-3 Fatty Acids on Heart Rate Variability and Arrhythmias in Patients Receiving Chronic Dialysis|Effects of Marine n-3 Fatty Acids on Heart Rate Variability and Arrhythmias in Patients Receiving Chronic Dialysis (Renal Rhythm Study II)||Aalborg Universitetshospital|Yes|Active, not recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|112|||Both|18 Years|90 Years|No|||January 2016|January 5, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147977||43932|
NCT02147990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-019 (TIGER-2)|TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)|TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)||Clovis Oncology, Inc.|No|Active, not recruiting|April 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147990||43931|
NCT02148458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404045|Short Term Intermittent Fasting and Mediterranean Diet|Metabolic and Molecular Effects of a Mediterranean Diet and Intermittent Fasting||Washington University School of Medicine|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148458||43895|
NCT02148471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0505-A|Fatty Acids, Genes and Microbiota in Fatty Liver|Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?||University Health Network, Toronto|No|Recruiting|October 2003|June 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|165|Samples With DNA|DNA - samples retained, with potential for extraction of DNA from at least one of the types      of samples retained (e.g., frozen tissue, whole blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy living liver donors from the Multiorgan transplant program at the University        Health Network Patients with nonalcoholic fatty liver disease (SS or NASH on liver biopsy)        or patients with elevated liver enzymes but no significant findings on liver biopsy.|November 2014|November 25, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148471||43894|
NCT02148484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00417300|Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse|Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse||University of Pennsylvania|Yes|Completed|February 2006|March 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|13 Years|18 Years|No|||June 2013|May 29, 2014|July 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02148484||43893|
NCT02149017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-NM-333(18F)|Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)|Phase 1 and Phase 2 Clinical Trials for the Evaluation of Pharmacokinetics, Safety, and Efficacy of SNUBH-NM-333(18F) in Alzheimer's Disease Patients and Healthy Volunteers.||Seoul National University Hospital|Yes|Terminated|December 2010|December 2012|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 24, 2014|May 19, 2014||No|SNUH-NM-333 ligand effect was judged to be insufficient.|No||https://clinicaltrials.gov/show/NCT02149017||43852|
NCT02149030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-004|Effectiveness of Cervical Screening in HPV Vaccinated Women|Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial|HPV-004|University of Tampere|No|Enrolling by invitation|March 2014|January 2024|Anticipated|January 2024|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Anticipated|7500|||Female|22 Years|22 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149030||43851|
NCT02134353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-303|A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects|Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects||Pharmaxis|Yes|Recruiting|October 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|99 Years|No|||October 2015|October 19, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134353||44978|
NCT02134366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC-1|Clobazam Use in Epilepsia Partialis Continua - Pilot Study|A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam||The Cooper Health System|No|Not yet recruiting|July 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134366||44977|
NCT02134314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1INH (Berinert) for DGF|C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI|Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert®) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI|C1INHDGF|Cedars-Sinai Medical Center|Yes|Recruiting|September 2014|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134314||44981|
NCT02134613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP-711/2008|99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity|99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity||Universidade Federal do Rio de Janeiro|Yes|Recruiting|January 2009|March 2015|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02134613||44958|
NCT02134860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-017|Bed Rest, Alternate Daily Fasting and Incretin Effect|A Randomized Controlled Study on the Incretin Effect, Cognitive Function and Controlled Fasting During Bed Rest in Healthy Male Volunteers||Rigshospitalet, Denmark|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02134860||44939|
NCT02135146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1900|Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach|Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach||University of Colorado, Denver|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|No|||January 2016|January 4, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135146||44917|
NCT02135159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA2012/38|Patients With Brain Metastases From HER2-positive Breast Cancer|A Phase I Study to Evaluate the Feasibility of Different Sequences of Combined Trastuzumab Emtansine (T-DM1) and Whole-brain Radiotherapy in Patients With Brain Metastases From HER2-positive Breast Cancer|BIRTH|Institut du Cancer de Montpellier - Val d'Aurelle|No|Active, not recruiting|February 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135159||44916|
NCT02135471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.1.590.58.4|Root Coverage in Smokers With Acellular Dermal Matrix Graft and Enamel Matrix Derivative|A 12-month Randomised Controlled Prospective Clinical Study for Root Coverage in Smokers With Acellular Dermal Matrix Graft and Enamel Matrix Derivative||University of Sao Paulo|Yes|Completed|June 2009|November 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|30 Years|50 Years|No|||May 2014|May 9, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02135471||44892|
NCT02135484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0933|Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases|An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|N/A|No|||May 2015|May 11, 2015|May 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02135484||44891|
NCT02135770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLDS01|Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis|Randomized Control Trial to Assessed the Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Severe Sepsis||Indonesia University|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|90 Years|No|||July 2014|July 6, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135770||44870|
NCT02136017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cnbg-002|Post-License Safety Evaluation of Influenza Virus Vaccine|Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine||Sichuan Center for Disease Control and Prevention|Yes|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|400000|||Both|3 Years|N/A|No|Non-Probability Sample|all the people immunized by influenza vaccine of Changchun Institute of Biological Product        in Sichuan province in 2013.|May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136017||44851|
NCT02147249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-0613|Cytokines and Chemokines in Erythema Migrans|Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans||University Medical Centre Ljubljana|No|Recruiting|July 2013|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02147249||43988|
NCT02147262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-0613|Laboratory Characteristics in Chronic Atrophic Acrodermatitis|Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis||University Medical Centre Ljubljana|No|Recruiting|July 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02147262||43987|
NCT02147275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJH-AD-12888|Monitoring Hypertensive Patients's Cerebral Oxygen Saturation|Monitoring Cerebral Oxygen Saturation in Hypertensive Patients Undergoing Major Abdominal Surgery|MHPCOS|Huazhong University of Science and Technology|Yes|Completed|May 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|30 Years|80 Years|No|Probability Sample|patients scheduled for major abdominal surgery such as gastrectomy, colon resection ,liver        resection and duodenocephalo-pancreasectomy|November 2014|November 10, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147275||43986|
NCT02147704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUMC-FMS-NA|Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan|Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan||DongGuk University|No|Recruiting|May 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147704||43953|
NCT02147470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16603|Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study|Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study||University of Virginia|No|Recruiting|February 2013|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|December 17, 2013|Yes|Yes||||https://clinicaltrials.gov/show/NCT02147470||43971|
NCT02147691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN1302|Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study|Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study||Derm Research, PLLC|No|Completed|May 2014|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|85 Years|No|||August 2015|August 28, 2015|May 16, 2014|Yes|Yes||No|May 7, 2015|https://clinicaltrials.gov/show/NCT02147691||43954|Pilot study. Small number of participants.
NCT02148237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD077057|Increase Breastfeeding Duration Among Puerto Rican Mothers|Intervention to Increase Breastfeeding Duration Among Puerto Rican Mothers|BFCM|Treatment Research Institute|No|Active, not recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|15 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148237||43912|
NCT02148224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-NRC-04-2014|Relationship of Glycemic Index Values and Subjects' Body Composition Parameters|Correlation of Glycemic Index Values and Subjects' Body Composition Parameters||Nutrifood Research Center, Jakarta, Indonesia|No|Active, not recruiting|April 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be selected from a group of office workers fulfilling inclusion        criteria.|May 2014|May 22, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02148224||43913|
NCT02148744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XmAb7195-01|Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis|A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195||Xencor, Inc.|No|Active, not recruiting|May 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148744||43873|
NCT02148757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10093|Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT|Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT||Hospital for Special Surgery, New York|No|Recruiting|June 2011|October 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|112|||Both|N/A|N/A|No|||May 2014|May 27, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148757||43872|
NCT02148497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51771|Multi-Colored Placido Disk Viability|Viability Study of a Multi-Colored Videokeratoscope With Extended Timescale Data||University of Rochester|No|Active, not recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|April 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02148497||43892|
NCT02148783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402693-1|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI||Uniformed Services University of the Health Sciences|No|Not yet recruiting|September 2014|June 2017|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||May 2014|May 27, 2014|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148783||43870|
NCT02149043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THERMO-01|Thermography in Surveillance of Ulcerative Colitis|Prototype Study on Association Between Clinical, Laboratory and Thermographic Findings in Patients With Ulcerative Colitis|Thermo|University Hospital Dubrava|No|Recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Stool sample for calprotectin mesures|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be recruited among hospitalized active ulcerative colitis patients        in University Hospital Dubrava Healthy individuals matching age, sex and BMI to the those        of patients with UC will be asked to volunteer.|June 2015|June 19, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149043||43850|
NCT02134379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000596|Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation|Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation: A Pilot Trial of the "Dynamic Thoracic Impedance Bed Rest Test"||University of Kansas Medical Center|No|Recruiting|April 2014|||April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be identified from the KU Hospital Cardiology clinic.|August 2015|August 17, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134379||44976|
NCT02134392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00691|Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection|Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection (CDI) in Pediatric and Young Adult Patients|FMT|Nationwide Children's Hospital|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|21 Years|No|||May 2014|May 8, 2014|May 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134392||44975|
NCT02134340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPD1028-01|A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours|A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection||Centre for Probe Development and Commercialization|No|Suspended|June 2014|January 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|No|||July 2014|November 4, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02134340||44979|
NCT02134886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00684|Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection|A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection||National Cancer Institute (NCI)||Terminated|July 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2015|October 5, 2015|May 7, 2014|No|Yes|No Accrual|No||https://clinicaltrials.gov/show/NCT02134886||44937|
NCT02134873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000038052|Sucrose Practices for Pain in Neonates|Sucrose Practices for Pain in Neonates: A Program of Research: Part A (Trial 1 and 2): Determining the Minimally Effective Dose of Sucrose for Procedural Pain in Infants|SPiN|The Hospital for Sick Children|Yes|Completed|July 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|291|||Both|N/A|2 Weeks|No|||May 2015|May 26, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02134873||44938|
NCT02135172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0376|Breaks in Sedentary Time and Glucose Regulation in Women|Does Breaking Sedentary Time Improve Glucose Regulation in Women With Impaired Glucose Tolerance? A Balanced Incomplete Block Design Study|ACUTE|University of Leicester|Yes|Completed|October 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|22|||Female|50 Years|74 Years|No|||December 2014|December 9, 2014|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02135172||44915|
NCT02135796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Echo in Septic Shock-1009957|ICU Echocardiography in Septic Shock|ICU Echocardiography in Resuscitation of Severe Sepsis and Septic Shock||Intermountain Health Care, Inc.|No|Recruiting|October 2008|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|172|||Both|13 Years|N/A|No|Non-Probability Sample|Patients admitted to an Intensive Care Unit (ICU) with an initial diagnosis of severe        sepsis or septic shock.|February 2015|February 24, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135796||44868|
NCT02135783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurosurg 01|Decompressive Craniectomy Combined With Hematoma Removal to Treat ICH|A Randomised Trial to Establish the Efficacy and Safety of Decompressive Craniectomy Combined With Hematoma Removal in Patients With Intracerebral Hemorrhage|CARICH|Southwest Hospital, China|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02135783||44869|
NCT02136043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC14.|Kinetic Oscillation Stimulation (KOS) of Nasal Mucosa in Non-allergic Rhinitis: Investigation of Treatment Procedure|A Randomized Study (With Active Treatment in Both Treatment Groups) to Evaluate How a New Vibration Treatment in the Nose in Patients With Non-allergic Rhinitis Can be Done as Convenient as Possible to the Patient||Halmstad County Hospital|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||May 2015|May 25, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02136043||44849|
NCT02135978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N110018|Maintenance of Shoulder Health and Function After Spinal Cord Injury|Southern California Spinal Cord Injury Model System: A Randomized Clinical Trial to Evaluate Two Prevention Programs for Maintenance of Shoulder Health and Function After Spinal Cord Injury||Rancho Research Institute, Inc.|No|Active, not recruiting|April 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|166|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135978||44854|
NCT02135991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1AA022353|Preparing to Run Effective Prevention|Preparing to Run Effective Prevention|PREP|RAND|No|Recruiting|September 2013|June 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|990|||Both|10 Years|14 Years|No|||May 2015|May 5, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135991||44853|
NCT02136004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REX-US-2027-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||May 4, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136004||44852|
NCT02147288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 1010007535|Prevention of Seroma Formation and Wound Complications Using NPWT Devices|Prevention of Seroma Formation and Wound Complications Using NPWT Devices||Yale University|No|Enrolling by invitation|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Anticipated|150|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147288||43985|
NCT02147301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC#124520|TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve|Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve||University of California, San Francisco|Yes|Enrolling by invitation|December 2014|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147301||43984|
NCT02147483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16363|Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission|Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study|MBRP|University of Virginia|Yes|Recruiting|August 2012|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|104|||Both|21 Years|N/A|No|||May 2014|May 23, 2014|November 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02147483||43970|
NCT02148003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1470|Effect of the Temperature Used in Thermal Radiofrequency Ablation|Effect of the Temperature Used in Thermal Radiofrequency Ablation on Outcomes of Lumbar Facets Medial Branches Denervation Procedures: A Randomized Double-Blinded Trial||The Cleveland Clinic|No|Recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|237|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148003||43930|
NCT02148016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013SKL005|Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation|Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation||Sun Yat-sen University|No|Recruiting|December 2012|September 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|10 Years|70 Years|No|||May 2014|May 27, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02148016||43929|
NCT02148250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140019|PK/PD STUDY OF U-500 REGULAR INSULIN|DURATION OF ACTION AND PEAK EFFECT OF HIGH DOSE OF U-500 REGULAR INSULIN IN SEVERELY INSULIN RESISTANT SUBJECTS WITH TYPE 2 DIABETES MELLITUS.||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|July 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|65 Years|No|||January 2016|January 12, 2016|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148250||43911|
NCT02148510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apnea-2|Oral Appliance in Obstructive Sleep Apnea. A Randomized Controlled Blinded Multicenter Study Comparing Two Devices|Oral Appliance in the Treatment of Obstructive Sleep Apnea. A Randomized Controlled Blinded Multicenter Study Comparing the Efficacy of Two Devices||Uppsala University|No|Enrolling by invitation|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02148510||43891|
NCT02148796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORBEX-BV2014/06|Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness|Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)|ORBEX|University of Arizona|Yes|Not yet recruiting|September 2015|August 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1076|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148796||43869|
NCT02149056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40170393-8|Can Platelets/Lymphocytes Rate Be New Serological Index for Prognosis of Coronary Heart Disease Complicated With Impaired Glucose Tolerance: Basic Principles and Experimental Design|Can Platelets/Lymphocytes Rate Be New Serological Index for Prognosis of Coronary Heart Disease Complicated With Impaired Glucose Tolerance: Basic Principles and Experimental Design||Affiliated Hospital of Hebei University|Yes|Completed|August 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|447|||Both|30 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|1. Inclusion criteria:          1. confirmed CHD by coronary angiography          2. IGT according to WHO standard (1999) as fasting blood-glucose of 6.1~7.0mmol/L and             blood-glucose of 7.8~11.1mmol/L at 2 h after oral administration of 75g glucose          3. accessible complete data of routine blood test and serum glucose before admission.        2. Exclusion criteria:          1. ≥75 years of age          2. patients of pregnancy, nursing, possible gestation and desiring gestation;          3. recent acute infection;          4. previous history of systemic inflammatory diseases (like chronic hepatitis),             malignant tumors and hematologic diseases;          5. acute or chronic diseases of immune system;          6. end-stage liver disease, kidney dysfunction (creatinine>2.0mg/dL, 176.8μmol/L) or             accompanied nephrosis syndrome.|May 2014|May 28, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149056||43849|
NCT02149069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMP - TRASFU1|Blood Management Program in the Post - Operative Period.|Blood Management Program: Appropriateness of Transfusion Therapy in the Post - Operative Period.||Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|November 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|patients undergoing complex surgical procedures|June 2015|July 31, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149069||43848|
NCT02135237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-204H-2|Contingency Management for Alcohol Use Disorders|Contingency Management for Alcohol Use Disorders||University of Connecticut Health Center|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02135237||44910|
NCT02134964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLT1177-04|Phase 1 Safety and PK Study of OLT1177 Capsules|A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects||Olatec Industries LLC||Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|May 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134964||44931|
NCT02134626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|simvhp01|Simvastatin Effect on Portal Hypertension|Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy||Universidade Federal do Rio de Janeiro|No|Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||May 2014|May 7, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02134626||44957|
NCT02134899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 090804|The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients|An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease|EVERKYSTE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 8, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02134899||44936|
NCT02134912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1300|S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib|S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy||Southwest Oncology Group|Yes|Recruiting|August 2014|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134912||44935|
NCT02135185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA2011/43|Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent|Phase II Study, Multicentric, Randomized Studying the Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent|NUTRIMOUV|Institut du Cancer de Montpellier - Val d'Aurelle|No|Recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|75 Years|No|||March 2015|March 2, 2015|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135185||44914|
NCT02135198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0231|Effects of GABA Modulator AZD7325 on Cortical Excitability|A Phase I Single Site, Single Dose, Randomised, Double-blind, Placebo Controlled 3-way Cross-over Biomarker Study Investigating the Effect of the GABA Modulator AZD7325 on Short Interval Intracortical Inhibition (SICI) in Healthy Volunteers||University College, London|Yes|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|August 27, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02135198||44913|
NCT02135510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/366|MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy|MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial|MEDEA|VU University Medical Center|Yes|Recruiting|June 2013|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02135510||44890|
NCT02136082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHMS098729|Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children|Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children|Asha II|University of California, Los Angeles|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|600|||Female|18 Years|50 Years|No|||November 2015|November 30, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136082||44846|
NCT02136095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFC_Feasibility_study|Promising Initial Experience With Intra-operative Fluorescent Cholangiography|Promising Initial Experience With Intra-operative Fluorescent Cholangiography||Hvidovre University Hospital|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|75 Years|No|||May 2014|May 8, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136095||44845|
NCT02136069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA29103|A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors|PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAÏVE TO TNF INHIBITORS||Hoffmann-La Roche||Recruiting|December 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|April 15, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02136069||44847|
NCT02136030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYLA0701|Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis|A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis||TTY Biopharm|No|Recruiting|February 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2010|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136030||44850|
NCT02147314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOFiMeter 2013-1|Evaluation of the YOFiMeter Glucometer|Evaluation of the YOFiLife Blood Glucose Monitoring System With YOFiMeter Glucometer||YofiMeter, LLC|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals over 18 years of age with diabetes who currently use blood glucose monitors.|December 2014|December 16, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147314||43983|
NCT02147496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC kids 25804|Fluid Dairy Products Consumed Before and Within a Pizza Meal on Glycemic Response, Food Intake and Satiety in Children|The Effect of Fluid Dairy Products Consumed Before and Within a Pizza Meal on Glycemic Regulation, Food Intake and Satiety in Normal Weight and Overweight/Obese Children||University of Toronto|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|5||Actual|57|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|December 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02147496||43969|
NCT02147509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCL-018-SS|Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome|Evaluation of the Therapeutic Effect of Bandage Contact Lenses on Dry Eye Caused by Sjogren's Syndrome|BCL|Wenzhou Medical University|Yes|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|70 Years|No|||July 2014|July 20, 2014|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147509||43968|
NCT02147717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 130602|Laser Acupuncture and Pain Management in Preterm Infants Undergoing Patent Ductus Arteriosus Ligation|Laser Acupuncture and Pain Management in Preterm Infants Undergoing Patent Ductus Arteriosus Ligation|ELAPPS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|24 Weeks|32 Weeks|No|||February 2016|February 23, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02147717||43952|
NCT02147730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-12-Alice|ALICE-Regional Anesthesia in Italy: Complications and Outcomes|ALICE-Regional Anesthesia in Italy: Complications and Outcomes|ALICE|IRCCS Policlinico S. Matteo|No|Recruiting|January 2013|July 2016|Anticipated|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, allux valgus        surgery, hernia repair, safenectomy, cesarean section,colectomy, hysterectomy, nephrectomy        mastectomy during study period|May 2014|May 27, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02147730|3 Years|43951|
NCT02148029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F0995-R|Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome|Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome|EFFORT2|VA Office of Research and Development|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148029||43928|
NCT02148263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0074|Contact Lens Adaptation in Neophytes|Contact Lens Adaptation in Neophytes|CLAN|Ohio State University|No|Recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148263||43910|
NCT02148523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819129-B|Social Forces to Improve Statin Adherence (Study B)|Using Social Comparison To Improve Medication Adherence In Statin Users With Diabetes||University of Pennsylvania|No|Completed|January 2014|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|N/A|No|||December 2014|June 9, 2015|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02148523||43890|
NCT02148809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 13193|Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia|Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia||Hospital for Special Surgery, New York|No|Recruiting|May 2014|||November 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|50 Years|75 Years|No|||March 2015|March 10, 2015|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02148809||43868|
NCT02149082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010812|Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection in Children|Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection in Children||Children's Hospital of Philadelphia|Yes|Recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|328|||Both|N/A|18 Years|No|Non-Probability Sample|Emergency Department (ED), Pediatric Intensive Care Unit (PICU)|January 2016|January 22, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149082||43847|
NCT02135250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013022|Study on Therapeutic Effect of Treating Mental Stress Induced Myocardial Ischemia|Study on Therapeutic Effect of Treating Mental Stress Induced Myocardial Ischemia With Conventional Therapy for Coronary Heart Disease Combined With Traditional Chinese Medicine :Design and Methods||Beijing Anzhen Hospital|Yes|Recruiting|January 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135250||44909|
NCT02134639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2012/28|PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation|Development of an Innovative Gallium 68 Radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation|GALTEP|University Hospital, Bordeaux|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patient who is suspected of endocrine tumors|November 2014|November 10, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02134639||44956|
NCT02135822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-LR001|Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer|Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer|NAPGAP|Chinese PLA General Hospital|Yes|Recruiting|May 2014|December 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135822||44866|
NCT02135211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-150|Healthy Directions After Lung Surgery Pilot|Feasibility and Acceptability of a Lifestyle Intervention for Patients Receiving Surgical Treatment for Lung Surgery||Dana-Farber Cancer Institute|No|Active, not recruiting|September 2012|June 2016|Anticipated|October 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|21 Years|N/A|No|||February 2015|October 26, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135211||44912|
NCT02135224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M79|the Effects of Epidural Fentanyl on Vaginal Delivery|The Effects of Fentanyl Added to Ropivacaine for Labour Epidural Analgesia on the Progress, Duration or Mode of Delivery: a Randomized, Double Blind Study.|EFVD|University of Athens||Recruiting|December 2011|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|20 Years|40 Years|No|||May 2014|May 7, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135224||44911|
NCT02135523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0896|The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial|||Yonsei University|No|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|19 Years|N/A|No|||April 2014|May 6, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02135523||44889|
NCT02135536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0104|Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis|A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103||NGM Biopharmaceuticals, Inc|No|Recruiting|May 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|75 Years|No|||May 2014|May 8, 2014|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135536||44888|
NCT02135809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90895329|Pancreatic Metal Stents in Chronic Pancreatitis|Fully Covered Self Expanding Metal Stents (FCSEMS) for Refractory Pancreatic Duct Strictures in Patients With Chronic Pancreatitis||Boston Scientific Corporation|No|Active, not recruiting|June 2014|December 2016|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135809||44867|
NCT02136654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00693|Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care|Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care|Namaste|University of British Columbia|Yes|Recruiting|July 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|600|||Both|19 Years|N/A|No|||August 2015|August 24, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02136654||44802|
NCT02136056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|auh_JOS_sfi-01|Effects of a Self-management Course for Adults on Sick-leave|Effects of a Self-management Course for Adults on Sick-leave; Outcomes in Registry Based Measures of Return to Work and Questionnaire Based Measures of Well-being and Quality of Life|jos|University of Aarhus|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136056||44848|
NCT02136316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7962-CL-0002|A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Oral Multiple Doses of ASP7962 in Healthy Male and Female Subjects|MAD|Astellas Pharma Inc|No|Completed|May 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136316||44828|
NCT02147782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Osteodystrophy|Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency|Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|October 2012|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|300|Samples Without DNA|Serum and plasma of cases and controls|Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases groups (CKD-5) are recruited from inpatients and outpatients in the 4 centers.        Controls are recruited from community samples and physical examination population.|November 2015|November 16, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02147782|1 Day|43947|
NCT02147522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1304-7364|A Helping Hand Among Low-Income Patients|A Helping Hand (AHH) to Activate Patient-Centered Depression Care Among Low-Income Patients|AHH|University of Southern California|No|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02147522||43967|
NCT02147535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDICES-WP2-2|Impact of CES1 Genotype on Metabolism of Methylphenidate|Impact of CES1 Genotype on Metabolism of Methylphenidate||Bispebjerg Hospital||Completed|March 2014|||August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|78|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147535||43966|
NCT02147743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080174|Preventing Adolescents From Entering the Juvenile Justice System|Preventing Adolescents From Entering the Juvenile Justice System: Testing An Empirically-Supported, Family-Based Diversion Model|CCP|University of Miami|No|Completed|May 2009|January 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147743||43950|
NCT02148042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312M46141|Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa|Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Fifteen adults with anorexia nervosa and 15 healthy, age- and sex- matched control        participants will be recruited.|January 2016|January 8, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02148042||43927|
NCT02148276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408|Improving Identification of Social Harm Among Substance Abusers in HIV Trials|Improving Identification of Social Harm Among Substance Abusers in HIV Trials||Treatment Research Institute|No|Recruiting|May 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|We anticipate that the sample will be representative of the populations in our ongoing        trials of clients with substance use disorders and of the substance abuse treatment        population, which is approximately 70% male, 60% African-American, 35% Caucasian, and 30%        Hispanic. This distribution is similar to the gender and racial distributions of publicly        funded drug abuse treatment patients in Philadelphia and other large cities located in        Mid-Atlantic States.|August 2015|August 11, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148276||43909|
NCT02149095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCP-PH-101|Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers|A Phase I, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose and Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers||United Therapeutics|No|Withdrawn|July 2014|||November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|May 20, 2014|No|Yes|Study will not be conducted|No||https://clinicaltrials.gov/show/NCT02149095||43846|
NCT02149446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgisis-001|Does Reinforcement of the Staple Line in Left Pancreatectomy Reduce the Rate of Pancreatic Fistula?|Pancreas Fistula After Distal Pancreatic Resection: Prevention and Treatment in a Randomized Controlled Trial||Karolinska University Hospital|No|Recruiting|April 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02149446||43820|
NCT02149459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0712-YL-CTIL|Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy|Improving the Response of Recurrent Glioma to Radiation Therapy Through Metabolic Intervention|SMC 0712-13|Sheba Medical Center|No|Recruiting|June 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||May 2014|September 2, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149459||43819|
NCT02148822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opt1228|Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia|Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia|VL&MNEthio|Instituto de Salud Carlos III|No|Completed|December 2009|February 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|520|||Both|4 Years|15 Years|No|Probability Sample|School age children from VL high prevalent communities of Libo Kemkem and Fogera districts        in Amhara Regional State, Ethiopia|May 2014|May 27, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148822||43867|
NCT02149706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immune Response 2020|A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis|A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination||Immune Response BioPharma, Inc.|Yes|Not yet recruiting|March 2017|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|May 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149706||43800|
NCT02134938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KJM-G|Effects of Viscous Fibre Containing Foods on Satiety (Gel Form)|Effects of High-Fibre, Low-Energy Density Viscous Gel Meals on Satiety, Appetite Regulation and Subsequent Food Intake in Healthy Individuals||St. Michael's Hospital, Toronto|No|Recruiting|July 2013|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|May 7, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02134938||44933|
NCT02134678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH090414-01A1|Assessing Change in Short Term Therapy for Depression|Assessing Change in Short Term Therapy for Depression Using ESM||University of North Carolina, Greensboro|Yes|Completed|May 2011|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|60 Years|No|||April 2015|April 30, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02134678||44953|
NCT02135263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDICES-WP2|Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype|Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype||Bispebjerg Hospital|Yes|Completed|April 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02135263||44908|
NCT02135276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-014|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects||Tetraphase Pharmaceuticals, Inc.|No|Completed|December 2013|May 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02135276||44907|
NCT02135549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-002|Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin|Randomized, Dose-Ranging, Cross-over, Placebo-controlled Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin||Boston Therapeutics|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|25 Years|75 Years|No|||July 2015|July 17, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135549||44887|
NCT02135562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1814|Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors|A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors||Case Comprehensive Cancer Center|No|Recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Female|18 Years|70 Years|No|||February 2016|February 17, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135562||44886|
NCT02135835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312-Z-SHFU-ZS-RE|A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure|A Multicentre, Parallel-Group, Randomised, Double-Blind Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure.||China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.|No|Recruiting|August 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|356|||Both|18 Years|80 Years|No|||May 2014|August 1, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02135835||44865|
NCT02136108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS -1306-02960|Optimizing Patient Engagement in a Novel Pain Management Initiative (OPEN)|Optimizing Patient Engagement in a Novel Pain Management Initiative (OPEN)|OPENtext|Inflexxion, Inc.|No|Recruiting|September 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|19 Years|65 Years|No|||February 2016|February 24, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136108||44844|
NCT02136121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Prospective Investigation of Robotic Single-port System|||Intuitive Surgical|Yes|Completed|June 2010|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|75 Years|No|||May 2014|May 8, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02136121||44843|
NCT02136394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OE006B|The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis|Investigation Into the Role of Gastroesophageal Reflux in Pulmonary Fibrosis in Scleroderma||Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|February 2014|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen in the department of respiratory medicine or rheumatology of two teaching        hospitals in London.|May 2014|October 28, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02136394||44822|
NCT02136368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M4W18858|Body and Brain Exercise for Older Adults With Memory Complaints|A Combined Exercise Program Plus Cognitive Training for Older Adults With Self-reported Cognitive Complaints: The Multi-modal, Mind-motor (M4) Study||Lawson Health Research Institute|No|Active, not recruiting|January 2014|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02136368||44824|
NCT02136381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiveWell_00745/2014|Lifestyle Interventions at Retirement|Pilot Randomised Controlled Trial of an Internet-based Lifestyle Intervention for People Around Retirement||Newcastle University|No|Recruiting|May 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|90|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02136381||44823|
NCT02136667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98372017|Preeclampsia and Circulating Biomarkers|||University of Aarhus|Yes|Recruiting|April 2014|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|64|Samples With DNA|Blood serum Blood plasma Urine|Female|N/A|N/A|No|Probability Sample|Participants will be recruited from a well-characterised cohort, previously assembled at        the Department of Obstetrics at Randers Regional Hospital in 2001-2005.|May 2014|January 5, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02136667||44801|
NCT02136680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058180|CASA: Care and Support Access in HIV Disease|CASA: Care and Support Access Study for Implementation of a Palliative Approach With HIV Treatment|CASA|University of Maryland|Yes|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|204|||Both|18 Years|35 Years|No|||March 2016|March 5, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02136680||44800|
NCT02136355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISSILE NSCLC|A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer|A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer||Lawson Health Research Institute|Yes|Recruiting|September 2014|September 2021|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136355||44825|
NCT02148068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310819|Changes in Body Composition Following Bariatric Surgery|Roux-en-y Gastric Bypass Versus Sleeve Gastrectomy - Analysis of the Disparate Effects on Body Composition and Associated Comorbidity Resolution||University of Iowa|Yes|Recruiting|May 2014|August 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|136|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population consists of individuals who meet the NIH consensus statement for the        surgical treatment of obesity. These individuals will have a BMI greater than 35 kg/m2 and        a medical comorbidity or 40 kg/m2. These subjects will have voluntarily initiated a        consultation for bariatric surgery and completed the pre-bariatric surgery weight        management program. After failing this program, the patients will undergo surgical        consultation for bariatric surgery. It is only after this consultation that the subjects        will be approached for enrollement in the study.|November 2015|November 30, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148068|1 Year|43925|
NCT02148055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/169/HP|Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death|Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death.|COMPER|University Hospital, Rouen|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148055||43926|
NCT02147756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF12531|Histology Evaluation of the CO2RE Device Versus the RePair Device|In Vivo Histology Evaluation of the CO2RE Device Versus the RePair Device in Pre- Abdominoplasty Patients||Syneron Medical|No|Active, not recruiting|May 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147756||43949|
NCT02147769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23894|Cerebral Oxygenation and Autoregulation in Preterm Infants|Cerebral Oxygenation and Autoregulation in Preterm Infants: Association With Morbidity and Mortality|Early NIRS|Stanford University|No|Recruiting|May 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|24 Hours|No|Probability Sample|All inborn preterm infants with birth weight <=1250 grams and with an indwelling arterial        catheter already in place are eligible for study enrollment if they are <24 hours old at        the time of enrollment. These preterm infants are at risk for impaired cerebral        autoregulation and may undergo non-invasive monitoring of cerebral oxygenation using        near-infrared spectroscopy (NIRS).|November 2015|November 18, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147769||43948|
NCT02148835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543-13|Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals|Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals||Ludwig-Maximilians - University of Munich|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|44|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148835||43866|
NCT02149108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.52|Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer|A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer Refractory to Standard Therapies.||Boehringer Ingelheim||Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|764|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 26, 2014||||No||https://clinicaltrials.gov/show/NCT02149108||43845|
NCT02149719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2492|Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study|Phase 2 Randomised Study of Oral Immunotherapy Using Boiled Peanut to Induce Desensitisation in Children With Challenge-proven, IgE-mediated Peanut Allergy|BOPI-1|Imperial College London|Yes|Recruiting|May 2015|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|8 Years|16 Years|No|||January 2016|January 21, 2016|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02149719||43799|
NCT02149992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1676|Glycemic Impact of Myo-inositol in Pregnancy|Glycemic Impact of Myo-inositol in High Risk and Gestational Diabetic Pregnancies: a Pilot Study||Oregon Health and Science University|No|Active, not recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|13 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149992||43778|
NCT02134951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6925|Biomarker Assessment of Glutamatergic Target Engagement|Biomarker Assessment of Glutamatergic Target Engagement||New York State Psychiatric Institute|Yes|Completed|May 2014|November 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134951||44932|
NCT02135627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-251-BMD|TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.|||McGill University Health Center|No|Recruiting|April 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135627||44881|
NCT02135575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWS-WP2CV|Effects of Exercise Training on Cardiovascular Health in Middle-aged Women|Effects of Exercise Training on Cardiovascular Health in Middle-aged Women||University of Copenhagen|No|Active, not recruiting|May 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Female|45 Years|57 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02135575||44885|
NCT02135588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMC 13-29|Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions|||Eastern Regional Medical Center|No|Recruiting|October 2013|||June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|99 Years|No|||January 2016|January 28, 2016|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135588||44884|
NCT02135848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114272|3 Month PHI PAD PoM Study|A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).||GlaxoSmithKline|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|46|||Both|40 Years|N/A|No|||May 2014|May 29, 2014|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135848||44864|
NCT02135861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201137|A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure|An Evaluation of DCE-MRI Measures of Pulmonary Oedema and Vascular Permeability in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure||GlaxoSmithKline|No|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02135861||44863|
NCT02136134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103995|Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma|Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma||Janssen Research & Development, LLC|Yes|Active, not recruiting|August 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|497|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136134||44842|
NCT02136420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497997|Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels|Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels||Massachusetts Eye and Ear Infirmary|No|Active, not recruiting|June 2014|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136420||44820|
NCT02136693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|psyllium_STARR|Psyllium Fiber Versus Placebo in Early Treatment After STARR for Obstructed Defecation: a Double-blind RCT|Efficacia Della Fibra di Psyllium Versus Placebo Nella Gestione Dell'Alvo in Pazienti Sottoposti ad Intervento Chirurgico Per Ostruita Defecazione||University of Milano Bicocca|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|N/A|No|||May 2014|May 10, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02136693||44799|
NCT02136706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-14A01|Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol|Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study||VA St. Louis Health Care System|No|Withdrawn|December 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|88 Years|No|||December 2015|December 14, 2015|May 4, 2014||No|Sponsor and site were unable to complete a final contract to support the study|No||https://clinicaltrials.gov/show/NCT02136706||44798|
NCT02136966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSS0002|Joint Infant and Young Child Nutrition Program and Malnutrition Prevention|Joint Infant and Young Child Nutrition Program in Burkina Faso : Impact Evaluation||Institut de Recherche en Sciences de la Sante, Burkina Faso|Yes|Recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2212|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||August 2015|August 25, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136966||44778|
NCT02137187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMCV-01-14|Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure|A Randomized Controlled Trial of Atrioventricular (AV) Junction Ablation and Biventricular Pacing Versus Optimal Pharmacological Therapy in Patients With Permanent Atrial Fibrillation|APAF-CRT|Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella|Yes|Recruiting|October 2014|May 2019|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1830|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|May 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02137187||44761|
NCT02148081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-214|Functional Recovery in Critically Ill Children, the Wee-Cover Multicentre Study|Functional Recovery in Critically Ill Children - a Longitudinal Multicentre, Mixed-Methods Study||McMaster University|No|Active, not recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|182|||Both|12 Months|17 Years|No|Probability Sample|In order to enrol children at potential risk for the outcomes of interest, and avoid        "healthier" participants with short PICU stays, we considered the following: the patient        should have: a) a minimum age (when one is expected to be ambulatory/mobilizing), and b) a        threshold severity of illness. In order to understand how different subsets of PICU        populations are affected by critical illness, we chose not to restrict the selection of        patients to a specific diagnosis, nor did we exclude patients with underlying functional        or cognitive abnormalities at baseline. This study will evaluate the epidemiology of        recovery in a general critically ill pediatric population over time.|March 2016|March 15, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02148081||43924|
NCT02148302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELLUTOME-VLU-013|Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers|A Multi-center Randomized Open-Label Controlled Clinical Trial Evaluating Suction Blister Grafting Utilizing a Novel Harvesting Device (CelluTome©) and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers|Cellutome|SerenaGroup, Inc.|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02148302||43907|
NCT02148315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWFJ 69550|School Gardens and Physical Activity|School Gardens and Physical Activity||Cornell University|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|234|||Both|8 Years|12 Years|No|||May 2014|May 23, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148315||43906|
NCT02148289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-BRJ-COPD|Dietary Nitrate in COPD|Dietary Nitrate in COPD: A Double-blind, Randomized, Placebo-controlled, Crossover Trial|CHB-BRJ-COPD|Royal College of Surgeons, Ireland|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|12|||Both|N/A|N/A|No|||June 2014|June 4, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02148289||43908|
NCT02148536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH-2014-034|Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome|Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome||West China Hospital|No|Recruiting|June 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Cirrhotic patients with hepatopulmonary syndrome undergoing transjugular intrahepatic        portosystemic shunt for any indication at West China Hospital.|June 2014|June 2, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148536||43889|
NCT02149121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 3.2|PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis|A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis|rituximab|Celltrion|No|Active, not recruiting|May 2014|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||November 2015|November 3, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02149121||43844|
NCT02149134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMETE13|Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy|Cow's Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula (TeHF2013-01) in Infants With Confirmed Cow's Milk Protein Allergy||Federico II University||Recruiting|October 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|1 Month|12 Months|No|||May 2014|May 23, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02149134||43843|
NCT02149472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.46563.058.13|Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage|Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage|TeMpOH-2|Leiden University Medical Center|No|Recruiting|February 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9500|Samples With DNA|Blood samples will be drawn for conventional haemostatic parameters and ROTEM profiles.      Remaining plasma will be frozen and stored for further evaulation.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women in participating hospitals are asked for their informed consent (n =        9.500). All women will complete a bleeding score generating questionnaire duing their        pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will        be drawn (n = 600) during the course of postpartum haemorrhage for evaluation of changes        in haemostatic parameters and ROTEM profiles.        3 months postpartum a nested case cohort study will be performed to compare the incidences        of underlying bleeding disorders in the haemorrhage and non-haemorrhage group. This        outcome will also be related to the obtained bleeding scores during pregnancy.|March 2015|March 31, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02149472||43818|
NCT02149147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9492 B|Variety of Physical Activity in Normal to Overweight Adults Who Are Regularly Active|Variety of Physical Activity in Normal to Overweight Adults Who Are Regularly Active||University of Tennessee|No|Active, not recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be 50 men and women, recruited from flyers posted on the University of        Tennessee-Knoxville campus and in local gyms.|January 2016|January 26, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149147||43842|
NCT02149160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRM-0334-002|Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation||FORUM Pharmaceuticals Inc||Active, not recruiting|October 2014|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|21 Years|75 Years|No|||May 2015|March 22, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149160||43841|
NCT02149732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMET trial|Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation|An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients||Seoul National University Hospital|Yes|Available|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||May 2014|May 20, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02149732||43798|
NCT02134977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-211|Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"|Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"||Takeda|No|Completed|October 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2816|||Both|N/A|N/A|No|Non-Probability Sample|Breast cancer|April 2015|April 1, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02134977||44930|
NCT02145819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLUS|Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?|Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?|PLUS|Universitair Ziekenhuis Brussel||Recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|39 Years|No|||May 2014|May 20, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02145819||44098|
NCT02135601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140408-7|The Effects of the Water-exchanged Colonoscopy on Adenoma Detection Rate|The Effects of the Water-exchanged Colonoscopy on Adenoma Detection Rate: a Multicenter, Randomized, Single Blind, Control Trial||Fourth Military Medical University|Yes|Completed|April 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|3303|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|November 8, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135601||44883|
NCT02135614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-1227|Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection||Gilead Sciences|Yes|Recruiting|July 2014|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135614||44882|
NCT02136160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rakuns|Population-based Intervention to Promote Health in Elementary Schools|Rakuns: Setting-based Prevention Program to Promote Positive Experiences in Health Promoting Lifestyle Choices||Ludwig-Maximilians - University of Munich|No|Completed|March 2013|||May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Prevention|||Actual|249|||Both|N/A|N/A||||May 2014|May 8, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02136160||44840|
NCT02136173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sequential balloons|Study of Weight Loss Effect of the Sequential Balloons|Study of Weight Loss Effect of the Sequential Balloons||Mansoura University|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136173||44839|
NCT02146352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP201303|AXIOS Stent With Electrocautery Enhanced Delivery System|AXIOS Stent With Electrocautery Enhanced Delivery System||Xlumena, Inc.|Yes|Completed|June 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|May 13, 2014|Yes|Yes||No|September 2, 2015|https://clinicaltrials.gov/show/NCT02146352||44057|
NCT02136147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT|ADHD Medication and Predictors of Treatment Outcome|Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome|ADAPT|Karolinska Institutet|No|Enrolling by invitation|June 2015|||March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2000|Samples With DNA|Whole blood and saliva|Both|6 Years|18 Years|No|Non-Probability Sample|All children/adolescents starting ADHD medication at the child and adolescent psychiatry        services in Stockholm|September 2015|September 8, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02136147|12 Months|44841|
NCT02136407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN399-09|Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort|Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort||Sahlgrenska University Hospital, Sweden|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|615|Samples Without DNA|Serum|Both|16 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Blood donors|May 2014|May 12, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02136407||44821|
NCT02136745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000757/19|Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD|Genomic and Clinical Effects Associated With a Relaxation Response Mind-Body Intervention in Patients With Irritable Bowel Syndrome and Inflammatory Bowel Disease||Massachusetts General Hospital|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||May 2014|May 9, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136745||44795|
NCT02136719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed 2|Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery|Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery||Benha University|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|320|||Female|19 Years|49 Years|No|||May 2015|May 10, 2015|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02136719||44797|
NCT02136732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG042467-01A1|Chronic Care Management for Adults at FQHCs|Chronic Care Management Model Translation to Multimorbid Aging Adults at FQHCs||Washington State University|Yes|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|45 Years|N/A|No|||June 2015|June 3, 2015|November 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02136732||44796|
NCT02136979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160064|Effect of Cardiopulmonary Bypass on Serum CD39 and CD73 Level|Effect of Cardiopulmonary Bypass on Serum CD39 and CD73 Level||Konkuk University Medical Center|No|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1|Samples Without DNA|whole blood, urine|Both|19 Years|90 Years|No|Probability Sample|Patients undergoing CPB for cardiac surgery|December 2015|December 9, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136979||44777|
NCT02137226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.2|BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis|Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial||Boehringer Ingelheim||Active, not recruiting|January 2015|October 2016|Anticipated|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|645|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|May 12, 2014||||No||https://clinicaltrials.gov/show/NCT02137226||44758|
NCT02137213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|083/2013|Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation|Oral Naloxone for Treatment of Opioid-induced Constipation in Patients Receiving Methadone Maintenance Treatment||Centre for Addiction and Mental Health|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137213||44759|
NCT02148341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP-09-160|Implementation of the Hospital to Home (H2H) Heart Failure Initiative|Implementation of the Hospital to Home (H2H) Heart Failure Initiative||VA Palo Alto Health Care System|No|Completed|January 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|122|||Both|N/A|N/A|No|||February 2013|May 27, 2014|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02148341||43904|
NCT02148354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|Internet Delivered Intervention Program for the Prevention and Treatment of Depression|Differential Efficacy of an Internet Delivered Intervention Program for the Prevention and Treatment of Mild to Moderate Depression With or Without Support by the Therapist||Universitat Jaume I|Yes|Completed|March 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|65 Years|No|||May 2014|May 22, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02148354||43903|
NCT02148328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104114|Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults|A Phase 1, Double-blind, Active-controlled, Randomized Study in Healthy Adults to Evaluate Safety, Tolerability, and Immunogenicity of a Trivalent and Quadrivalent Cell-based Virosomal Subunit Influenza Vaccine||Crucell Holland BV|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|240|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148328||43905|
NCT02148848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229/2556(EC4)|Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty|A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures||Mahidol University|Yes|Recruiting|June 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|50 Years|N/A|No|||September 2015|September 21, 2015|May 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02148848||43865|
NCT02148861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1436-4057|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|64 Years|No|||June 2015|June 5, 2015|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02148861||43864|
NCT02148874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0260|Immune Responses to the Flu Shot During Pregnancy|Immune Responses to the Flu Shot During Pregnancy||Ohio State University|No|Recruiting|September 2013|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|serum whole blood plasma|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample, prenatal clinic|October 2015|October 15, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148874||43863|
NCT02149758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sum2141|EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).|EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).||Tatyasaheb Kore Dental College|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|May 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149758||43796|
NCT02150044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005008|Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media|inVENT2|Acclarent|No|Completed|February 2010|November 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|N/A|No|||September 2014|September 25, 2014|May 27, 2014|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT02150044||43774|
NCT02135289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGRA|The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID|The Role of Interferon Gamma Releasing Assays (IGRA) in Screening and Monitoring for Tuberculosis During Anti-TNF Therapy in Patients With Immune-mediated Inflammatory Disease (IMID)|IGRA|Chinese University of Hong Kong|Yes|Recruiting|March 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|560|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending Prince of Wales Hospital|October 2015|October 5, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02135289||44906|
NCT02146092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_Spirometry001|Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery|Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery: A Prospective Blinded Randomized Trial||McMaster University|No|Recruiting|August 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02146092||44077|
NCT02135874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0073|A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL)|A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135874||44862|
NCT02146573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-010987|Pediatric Continuity Care Intensivist|Pediatric Continuity Care Intensivist: Role Implementation and Randomized Control Trial|CCI|Children's Hospital of Philadelphia|No|Enrolling by invitation|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|333|||Both|N/A|N/A|No|||January 2016|January 25, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146573||44040|
NCT02146599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPRO-101-SIVQ|Patient Perception of Visual Quality and Function|||Abbott Medical Optics|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|301|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bilaterally-implanted pseudophakic subjects over 22 years of age who meet the inclusion        criteria.|September 2015|September 10, 2015|May 20, 2014||No||No|July 7, 2015|https://clinicaltrials.gov/show/NCT02146599||44038|
NCT02136433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0125-RK-CTIL|Using Tablets for Upper Extremity Rehabilitation Post Acquired Brain Injury|Using Tablets for Upper Extremity Rehabilitation Post Acquired Brain Injury|TBL|Sheba Medical Center|No|Recruiting|February 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||September 2014|September 17, 2014|September 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02136433||44819|
NCT02146586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0713|Clinical Evaluator Outcomes Reliability Study|Cooperative International Neuromuscular Research Group (CINRG) Clinical Evaluator Outcomes Reliability Study||Cooperative International Neuromuscular Research Group|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|55|||Male|6 Years|N/A|No|Non-Probability Sample|Dystrophinopathies (Duchenne Muscular Dystrophy and Becker Muscular Dystrophy)|February 2016|February 1, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02146586||44039|
NCT02143050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-MEL-14-01|Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients|A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients||James Graham Brown Cancer Center|Yes|Recruiting|September 2014|June 2020|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||May 2014|February 29, 2016|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143050||44311|
NCT02143063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-090H-2|Extending Long-term Outcomes Through an Adaptive Aftercare Intervention|Extending Long-term Outcomes Through an Adaptive Aftercare Intervention||University of Connecticut Health Center|Yes|Recruiting|September 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02143063||44310|
NCT02136992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH01312|Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|IPF|Shanghai Pulmonary Hospital, Shanghai, China|Yes|Completed|December 2011|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|N/A|75 Years|No|||May 2014|May 12, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02136992||44776|
NCT02137239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-177|Regimen Optimization Study|Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression||Bristol-Myers Squibb|Yes|Recruiting|December 2015|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137239||44757|
NCT02137499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/WM/0027|Venous Insufficiency and Neuromuscular Stimulation|Venous Insufficiency and Neuromuscular Stimulation|VeINS|Imperial College London|Yes|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|August 5, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137499||44737|
NCT02148107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.2|Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects||Boehringer Ingelheim||Terminated|May 2014|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|May 19, 2014||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT02148107||43922|The trial was terminated prematurely because the sponsor decided to discontinue the development of BI 691751, also no PK blood samples were analysed because of the trial termination.
NCT02148120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-01535BA1-01|A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler|A Phase II, Multicentre, Double-blind, Randomised, 5-way Crossover Study to Test the Non-inferiority of the Acute Bronchodilator Effect of CHF 1535 200/6 µg NEXThaler Versus CHF 1535 100/6 µg NEXThaler in Partially Controlled and Uncontrolled Adult Asthmatic Patients.||Chiesi Farmaceutici S.p.A.|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|65 Years|No|||October 2014|October 27, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148120||43921|
NCT02148575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307012400|Integrating Palliative Care Into Self-Management of Breast Cancer|Integrating Palliative Care Into Self-Management of Breast Cancer||Yale University|No|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|21 Years|N/A|No|||July 2015|July 14, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148575||43886|
NCT02148588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404|Peripheral Sensory Input in Central Post Stroke Pain (CPSP)|How "Central" is Central Post-stroke Pain? Investigating the Role of Peripheral Sensory Input in Maintaining Central Pain||Washington University School of Medicine|No|Recruiting|August 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02148588||43885|
NCT02148887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013 0559|Spinal Cord White and Grey Matter Changes in Patients With Spinal Injury|||University of Zurich|Yes|Recruiting|April 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with spinal injury|January 2016|January 6, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148887||43862|
NCT02148549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRINOX|Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study|The Pilot Study of Neoadjuvant Chemotherapy of FIRINOX for Patients With Borderline Resectable Pancreatic Cancer|FIRINOX|Wakayama Medical University|Yes|Active, not recruiting|April 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|74 Years|No|||July 2015|July 22, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02148549||43888|
NCT02148562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56121|Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity|Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity With Next-generation Sequencing: From Chronic Infection to End-stage Liver Disease and Liver Cancer||Universitaire Ziekenhuizen Leuven|Yes|Enrolling by invitation|April 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|274|Samples With DNA|serum whole blood|Both|N/A|N/A|No|Non-Probability Sample|Patients with liver disease related to Hepatitis B in a pre-advanced (chronic infection)        and advanced stage (end-stage liver diseases) treated at the Hepatology Department of        University Hospital of Leuven|May 2014|May 22, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02148562||43887|
NCT02149498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-MAG-01|Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease|||Sheba Medical Center|Yes|Not yet recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 patients with idiopathic Parkinson's disease (PD) 50 Healthy controls (HC)|April 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149498||43816|
NCT02149485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2010|Follow-up of 5-year Old Children Born After PGD|Long-term Safety of Preimplantation Genetic Diagnosis. Follow-up of 5-year Old Children Born After PGD.||Maastricht University Medical Center|Yes|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|5 Years|5 Years|Accepts Healthy Volunteers|Probability Sample|5 years old children born after preimplantatio genetic diagnosis|May 2014|May 28, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149485||43817|
NCT02149745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSeo_Calling|Effect of Calling the Patient's Name on Recovery From General Anesthesia|||Seoul National University Hospital||Completed|May 2014|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|101|||Both|20 Years|70 Years|No|||November 2015|November 16, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02149745||43797|
NCT02150343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH005|Phase II HDM-SPIRE Safety and Efficacy Study|A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis||Circassia Limited|Yes|Active, not recruiting|September 2014|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|660|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02150343||43751|
NCT02145559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0614|A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors|A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors||University of Chicago|Yes|Active, not recruiting|April 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02145559||44118|
NCT02146079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3634|A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects|A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects||Novo Nordisk A/S|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146079||44078|
NCT02146339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.828|Impact of Milk Polar Lipids on Lipids Digestion, Absorption and Metabolism|Impact of Milk Polar Lipids Content in a Test Meal on Lipid Composition of Ileostomy Fluid and Consequences on Postprandial Dietary Cholesterol and Fatty Acid Metabolism.|VALOBAB-D|Hospices Civils de Lyon|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|4|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146339||44058|
NCT02146612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTK1202|Amino Acid Usage Patterns in Daily Practice|An Observational Study to Evaluate Amino Acid Usage Patterns in Daily Practice||Abbott Nutrition|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|354|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects receiving amino acid supplement prior to enrollment|May 2014|May 21, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02146612||44037|
NCT02143596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-4630C|Neuroprotective Therapy and Therapeutic Target in Emergency Department|Neuroprotective Therapy and Therapeutic Target in Emergency Department||Chang Gung Memorial Hospital|No|Completed|November 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|N/A|N/A|No|||May 2014|May 23, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143596||44269|
NCT02142829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball|Pain Control in Bariatric Patients: A Prospective Trial Comparing the Effectiveness of EXPAREL(R) Versus the On-Q(R) Pain Ball||Pacira Pharmaceuticals, Inc|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|80 Years|No|||May 2014|May 20, 2014|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142829||44328|
NCT02143323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILI_Healthy|A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)|A Clinical Study to Evaluate the Effect of Glutathion S-transferase Polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Amoxicillin/Clavulanate and Explore Biomarkers for Drug-induced Liver Injury (DILI)||Seoul National University Hospital|Yes|Completed|December 2013|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|January 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143323||44290|
NCT02143583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN005T|Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment|Long-term Follow-up of a Multicentre, Randomized, Double-blind, Placebo-controlled Trial (AN004T) Assessing the Efficacy and Tolerability of 2 Dosing Regimens of AllerT in Adult Subjects Allergic to Birch Pollen||Anergis|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|Phase 2|Observational|Time Perspective: Prospective||3|Actual|196|||Both|18 Years|55 Years|No|Probability Sample|Subjects with moderate to severe allergic rhiniconjunctivitis to birch pollen|June 2015|June 22, 2015|May 2, 2014||No||No|March 23, 2015|https://clinicaltrials.gov/show/NCT02143583||44270|
NCT02143297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPAR-265/2012|Automatic Estimation of the Apnea-hypopnea Index Using Neural Networks to Detect Sleep Apnea|Automatic Estimation of Apnea-hypopnea Index (AHI) Using Neural Networks to Assist in the Diagnosis of Sleep Apnea-hypopnea Syndrome (SAHS)||Sociedad Española de Neumología y Cirugía Torácica|Yes|Active, not recruiting|July 2013|July 2014|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|322|||Both|18 Years|N/A|No|Probability Sample|Subjects derived to the reference sleep unit from primary care with suspicion of suffering        from SAHS due to daytime hypersomnolence, loud snoring, nocturnal choking and awakenings,        and/or apnoeic events|May 2014|May 20, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02143297||44292|
NCT02137512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot 3 Outpatient CTR|Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use|Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use|CTR3|Juvenile Diabetes Research Foundation Artificial Pancreas Project Consortium|Yes|Completed|August 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|69 Years|No|||February 2016|February 16, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137512||44736|
NCT02148367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-N-2695|Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI|Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI|TBI-EPO|Uniformed Services University of the Health Sciences|Yes|Withdrawn|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|May 22, 2014|Yes|Yes|Publication of recent trials showing no effect of EPO in TBI substantially reduced equipoise    about this study.|No||https://clinicaltrials.gov/show/NCT02148367||43902|
NCT02148900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79135|Development of a Blood Test for Marfan Syndrome|Development of a Blood Test for Marfan Syndrome||Shriners Hospitals for Children|No|Recruiting|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|336|Samples With DNA|Plasma Frozen Cells|Both|4 Years|26 Years|Accepts Healthy Volunteers|Probability Sample|The study population includes 3 groups: (1) individuals with Marfan syndrome; (2)        individuals with Marfan-related disorders; (3) unaffected controls. Both genders, ages 4        to 26, will be included. Geographic locations will include the Pacific Northwest, Texas,        and the Salt Lake City/Denver areas.|May 2014|May 27, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148900|5 Years|43861|
NCT02148913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-067|Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma|A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma||Spectrum Health Hospitals|Yes|Recruiting|May 2014|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148913||43860|
NCT02149173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7184|F-18 FES PET in Measuring Hormone Expression in Patients With Primary, Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy|Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy||University of Washington||Recruiting|September 2010|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02149173||43840|
NCT02149186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 24 2009|Interactive Motor Imagery in Virtual Reality|||University of Zurich|Yes|Recruiting|October 2009|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|72|||Both|16 Years|80 Years|No|||January 2016|January 6, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02149186||43839|
NCT02118090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC_Pv_CQR_RTK|Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:|Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area|CRePViCam|Institut Pasteur, Cambodia|No|Completed|May 2014|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|15 Years|N/A|No|||March 2015|March 23, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02118090||46223|
NCT02118402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSM-2-70790-11|Iron and Prebiotics Fortification in Kenyan Infants|In Home Iron Fortification in Kenyan Infants: Effect of Co-supplementation With Galactooligosaccharides (GOS) on the Gut Microbiota Composition and the Effectiveness of Iron Supplementation|Iro'n'Pre|Swiss Federal Institute of Technology|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|155|||Both|6 Months|14 Months|Accepts Healthy Volunteers|||June 2015|January 15, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02118402||46199|
NCT02149771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-IR 2013|Combination Treatment for Advanced Liver Cancer|Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of Bare Stent and Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone||Shanghai Zhongshan Hospital|No|Recruiting|May 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|20 Years|70 Years|No|||November 2015|November 16, 2015|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149771||43795|
NCT02118948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH095362|Development of a Novel HIV Risk Reduction Intervention for Abused Women|Development of a Novel HIV Risk Reduction Intervention for Abused Women||The Miriam Hospital|No|Enrolling by invitation|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02118948||46157|
NCT02145832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-11|Fluconazole Versus Micafungin in Neonates With Candidiasis|Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates)|TINN|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Not yet recruiting|June 2014|May 2017|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|24 Weeks|42 Weeks|No|||May 2014|May 20, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02145832||44097|
NCT02143076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISEP|Medication Adherence in Youth With Sickle Cell Disease (SCD)|Use of WISE Device Technology to Measure Medication Adherence in Youth With Sickle Cell Disease (SCD): A Pilot Study||St. Jude Children's Research Hospital|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|N/A|17 Years|No|Non-Probability Sample|Participants will have a diagnosis of sickle cell disease,be receiving treatment with        hydroxyurea, and meet eligibility criteria.|May 2015|May 26, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143076||44309|
NCT02143089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSM28-10-12|Catheterization During Second Elective Caesarean Delivery|Evaluation OF Use Versus Non Use of Urinary Catheterization During Second Elective Caesarean Delivery|CDSECD|Ain Shams University|No|Recruiting|August 2013|September 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02143089||44308|
NCT02134236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSLED004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||May 7, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134236||44987|
NCT02146365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-011|Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers|Prospective Study to Assess the Nasopharyngeal Carriage of SPn, Long Term Safety and Immune Persistence in Healthy Kenyan PCV-primed Toddlers Who Received PATH-wSP Compared to Controls||PATH|No|Active, not recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|300|||Both|12 Months|15 Months|Accepts Healthy Volunteers|Probability Sample|Healthy PCV- primed Kenyan toddlers; some of whom have participated in VAC-010 (n=250) and        some of whom have not (n=50)|January 2016|January 7, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146365||44056|
NCT02146378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461042|Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer||Active, not recruiting|January 2014|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|The subjects of this surveillance are all patients who received Vyndaqel.|March 2016|March 2, 2016|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146378||44055|
NCT02143830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-7501|HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy|A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|RAFA|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2014|May 2020|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|3 Months|N/A|No|||December 2015|December 4, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143830||44251|
NCT02142842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1438/QDBYT|Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis|Phase I/II Study of Transplantation of Autologous Adipose Stem Cells and Activated Platelet Rich Plasma in Knee Osteoarthritis Treatment||University of Science Ho Chi Minh City|Yes|Completed|April 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142842||44327|
NCT02135354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s55829|Belgian Trial With Azithromycin During Acute COPD Exacerbations|Azithromycin for Acute COPD Exacerbations With Hospitalization|BACE|Katholieke Universiteit Leuven|No|Recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135354||44901|
NCT02143310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP G1 S3|A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years|A Multi-Centre Study to Evaluate the Safety of Use of Electronic Vapour Products for Two Years||Fontem Ventures BV|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|420|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02143310||44291|
NCT02143570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|635|Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women|Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women||Universidad de Valparaiso|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|16 Years|N/A|No|||December 2015|December 1, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143570||44271|
NCT02143804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exBOND 2.1|Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer|Phase II Safety and Efficacy Study of CG0070 Oncolytic Vector Regimen in Patients With High Grade Non-Muscle Invasive Bladder Carcinoma Disease (NMIBC) Who Have Failed BCG and Refused Cystectomy|exBOND|Cold Genesys, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2015|January 27, 2015|May 19, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02143804||44253|
NCT02144103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-FMBC-02-01-14|Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration|Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration||Burnasyan Federal Medical Biophysical Center|No|Enrolling by invitation|May 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|35 Years|75 Years|No|||June 2015|June 9, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02144103||44230|
NCT02148601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1192013|Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection|Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection: an Open-label Randomized Clinical Trial||Catholic University of the Sacred Heart||Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|95 Years|No|||November 2014|November 19, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148601||43884|
NCT02148614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392CEP|Effects of Intake of a Polysaccharides Mix on Metabolism, Hormones and Satiety in Obese Children.|Intake of a Polysaccharides Mix (LibraMedR) in Obese Children. 1. Postprandial Effects on Metabolism, Hormones and Satiety; 2. Effects on Body Fat, Glucide and Fat Metabolism After a 60-day Treatment.||Azienda Ospedaliera Universitaria Integrata Verona|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|8 Years|12 Years|No|||December 2015|December 29, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148614||43883|
NCT02148627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15164|Safety Study of LY3041658 in Healthy Participants|A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects||Eli Lilly and Company|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02148627||43882|
NCT02148640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA2014-01|The NOR-SWITCH Study|A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY|NOR-SWITCH|Diakonhjemmet Hospital|No|Active, not recruiting|October 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148640||43881|
NCT02148926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCM-011213-28037|Clinical and Genetic Examinations of Dilated Cardiomyopathy|Clinical and Genetic Examinations of Dilated Cardiomyopathy||University of Southern Denmark|Yes|Recruiting|February 2014|March 2017|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|480|Samples With DNA|DNA for genetic testing|Both|N/A|N/A|No|Probability Sample|Families in Denmark with history of dilated cardiomyopathy. Patients mainly from Funen and        Jutland.|January 2015|January 30, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148926|1 Year|43859|
NCT02118116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013:380|The Safety and Effectiveness of Gatekeeper Training in First Nations Communities|||University of Manitoba|No|Recruiting|June 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|300|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2014|December 9, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118116||46221|
NCT02149212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPC_2 2014|Iliac Vein Stenting in Advanced Chronic Venous Insufficiency|Randomized Double-blind Trial Between Clinical and Endovascular Treatment in Patients With Advanced Chronic Venous Insufficiency and Iliac Venous Obstruction||Instituto Dante Pazzanese de Cardiologia|Yes|Completed|February 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149212||43837|
NCT02149225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAPVAC-101|GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients|A Phase I Trial of Actively Personalized Peptide Vaccinations Plus Immunomodulators in Patients With Newly Diagnosed Glioblastoma Concurrent to First Line Temozolomide Maintenance Therapy||immatics Biotechnologies GmbH|Yes|Recruiting|October 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02149225||43836|
NCT02149199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589SC00001|A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.|A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.|SYGMA1|AstraZeneca|No|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|3750|||Both|12 Years|130 Years|No|||February 2016|February 24, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02149199||43838|
NCT02118961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKD1A|Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents|Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|446|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02118961||46156|
NCT02118662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-Work 2013-033|Energy Expenditure During Seated, Seated Cycling, and Treadmill Walking Work Conditions (EE-Work)|Energy Expenditure During Seated, Seated Cycling, and Treadmill Walking Work Conditions (EE-Work)|EE-Work|Pennington Biomedical Research Center|No|Recruiting|March 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02118662||46179|
NCT02119455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OATI-20130635|Biomarkers of Orthodontic Tooth Movement With Fixed Appliances and Vibration Appliance Therapy|Biomarkers of Orthodontic Tooth Movement With Fixed Appliances and Vibration Appliance Therapy: A Randomized Clinical Trial||University of Connecticut Health Center|Yes|Recruiting|April 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|15 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02119455||46118|
NCT02133963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3229|Determining Relationships Among Maternity Stress & Sleep|Sleep Dysregulation and Neuroendocrine Stress Reactivity: Towards a Biopsychosocial Model of Vulnerability to Postpartum Depression|DREAMSS|University of North Carolina, Chapel Hill|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|17|Samples Without DNA|Serum, Plasma, Adrenocorticotropic hormone (ACTH), Cortisol|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of pregnant women|May 2015|May 15, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133963||45008|
NCT02134249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed|Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|infertility|Benha University|Yes|Completed|April 2014|October 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|200|||Female|23 Years|48 Years|No|||January 2016|January 29, 2016|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02134249||44986|
NCT02143336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-3961|Subcuticular Continuous Suture Versus Skin Staples to Reduce Surgical Site Infections in Colorectal Surgery Patients|Prospective and Comparative Pilot Study Between Subcuticular Continuous Suture Versus Skin Staples to Reduce Surgical Site Infections in Colorectal Surgery Patients.||Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|September 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143336||44289|
NCT02143843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-003|An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product|An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002||ForSight Vision5, Inc.|No|Completed|May 2014|January 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143843||44250|
NCT02135068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013588|Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop|Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop||Yale University|Yes|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|13 Years|44 Years|No|||January 2015|January 20, 2015|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135068||44923|
NCT02134769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIONECT-2014|Influence of Bionecteurs on Catheter-associated Infection|Incidence of Catheter-related Bloodstream Infections Using Bionecteur Device|Bionect|University Hospital Tuebingen|Yes|Recruiting|May 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02134769||44946|
NCT02135328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSDiabetes|SoLaHmo Radio Stories About Children's Healthy Eating and Exercise|Somali, Latino & Hmong Radio Stories About Children's Healthy Eating and Exercise: A SoLaHmo Pilot Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|123|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 6, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02135328||44903|
NCT02135341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL010|Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility|Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility||Buddhist Tzu Chi General Hospital|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|85 Years|No|||May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135341||44902|
NCT02135679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12512|The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy|The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|NSCLC patients|November 2014|November 6, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02135679||44877|
NCT02143817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2012.9674|Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition|The Effect of Whole-body Vibration Training Combined With L-cit Supplementation on Cardiovascular, Autonomic Function and Body Composition in Postmenopausal Women||Florida State University|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|60|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143817||44252|
NCT02144129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS_COL|Effects of WB-EMS in Ulcerative Colitis Patients|Effects of Different Types of Whole Body Electromyostimulation (WB-EMS) Application on Body Composition, Muscle Strength and Quality of Life in Patients With Ulcerative Colitis||University of Erlangen-Nürnberg Medical School|No|Recruiting|March 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|N/A|No|||December 2015|December 1, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144129||44228|
NCT02144142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 131244.3|Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients|Phase 2 Study Evaluating the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients||University of California, San Diego|No|Not yet recruiting|January 2015|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144142||44227|
NCT02144402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1069|Growth of Healthy Term Infants Fed Formula Containing DHA-B|||DSM Nutritional Products, Inc.|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|159|||Both|N/A|14 Days|Accepts Healthy Volunteers|||August 2015|August 3, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02144402||44207|
NCT02117830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-108|A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects|A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects||Repros Therapeutics Inc.|No|Completed|April 2014|||May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|54|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117830||46243|
NCT02117843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFECT-I|The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization|A Prospective, Multi-center, Single Armed Registry to Evaluate The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization||Beijing AmsinoMed Medical Device Co., Ltd|Yes|Recruiting|July 2013|June 2020|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|18 Years|76 Years|No|||April 2014|April 19, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117843||46242|
NCT02118103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:079|The Impact of Spinal Manipulation on Leg Movement in Lumbar Spinal Stenosis Patients|The Impact of Spinal Manipulation on Lower Extremity Motor Control in Lumbar Spinal Stenosis Patients: a Single-blind Randomized Before-after Trial||University of Manitoba|No|Enrolling by invitation|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|85 Years|No|||April 2015|April 16, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118103||46222|
NCT02118129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014GoodmanVitD|Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.|Knowledge, Attitudes, Intake and Blood Levels of Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.||University of Guelph|No|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118129||46220|
NCT02118415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC-TKD/IL-2|Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)|Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)||Technische Universität München|Yes|Recruiting|March 2014|February 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|February 25, 2014||||No||https://clinicaltrials.gov/show/NCT02118415||46198|
NCT02149511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2010 0271|Longitudinal Morphometric Changes Following SCI|||University of Zurich|Yes|Recruiting|September 2010|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Acute and chronic patients with spinal cord involvement|January 2016|January 25, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02149511||43815|
NCT02149524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB3-G31-BC|A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer|A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB3 (Proposed Trastuzumab Biosimilar) and Herceptin® in Women With Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting||Samsung Bioepis Co., Ltd.|Yes|Active, not recruiting|April 2014|November 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|806|||Female|18 Years|65 Years|No|||September 2015|September 23, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149524||43814|
NCT02118974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000164|Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy|Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy||Milton S. Hershey Medical Center|No|Completed|May 2014|April 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Female|18 Years|80 Years|No|||April 2015|April 10, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118974||46155|
NCT02119195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUCH2012/10-3|Increasing Composite Restorations Sealants|Increasing Longevity of Composite Restorations With Defective Margins With Sealants. Controlled Clinical Trial 10 Years Follow-up|SEALCOMP|University of Chile|Yes|Completed|May 2003|December 2013|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 16, 2014|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119195||46138|
NCT02119468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12267|Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma||City of Hope Medical Center|Yes|Recruiting|June 2014|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119468||46117|
NCT02137915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N02-AMD|Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|Long-Term Follow-up Study of the Phase I/II Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration||StemCells, Inc.|Yes|Enrolling by invitation|April 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Both|51 Years|N/A|No|Non-Probability Sample|All subjects with age-related macular degeneration (AMD) with GA who received        transplantation of HuCNS-SC in Study CL-N01-AMD.|May 2015|May 18, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02137915||44705|
NCT02138175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-14-02E|Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective|Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective||Carolinas Healthcare System|Yes|Withdrawn|January 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Adult (>18 years) patients admitted to the surgical intensive care unit for hemodynamic        monitoring and serial hemoglobin measurements at high risk for bleeding (known solid        organ/vascular/orthopedic injury, unexplained hypotension/tachycardia following        trauma/surgery, suspected ongoing blood loss-postoperative or gastrointestinal bleeding)|February 2015|February 3, 2015|May 12, 2014||No|Sponsor (Masimo) suspended trial due to change in corporate ownership|No||https://clinicaltrials.gov/show/NCT02138175||44685|
NCT02133976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12101001|Mechanisms of Psychosocial Chronic Pain Treatments|Mechanisms of Psychosocial Chronic Pain Treatments||Rush University Medical Center|Yes|Recruiting|June 2014|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|75 Years|No|||February 2015|February 17, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02133976||45007|
NCT02134535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120447|Optimization of the ex Vivo Challenge|Optimization of the ex Vivo Challenge||University of Pittsburgh|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|73|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, non-pregnant, HIV negative women|January 2016|January 26, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134535||44964|
NCT02134756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF-NS.Active-2014|Impact of Nutritional Supplementation on Aerobic Performance and Fatigue|Impact of Nutritional Supplementation on Aerobic Performance and Fatigue||University of South Florida|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134756||44947|
NCT02135081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006166|Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction|A Magnetic Resonance Imaging Study to Determine Cerebral Blood Flow Changes in Single Ventricle Patients During Staged Reconstruction as Compared to Normal Children|CBF|Children's Hospital of Philadelphia|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|260|||Both|4 Months|10 Years|No|Non-Probability Sample|Single ventricle patients will be recruited from the cohort of patients treated and/or        followed at The Children's Hospital of Philadelphia in the cardiology program and        surrounding hospitals/institutions. In specific, patients will be approached to        participate in the study during clinic visits or visits to the hospital for other reasons.        Children for the normal control group will be recruited from children who are undergoing        clinical MRIs at CHOP. A full understanding of all study related procedures and processes        will be explained to the subject, including all MRI scans, how the MRI scanner works and        how the proposed research will help medical practice. Children likely to have a normal        brain MRI will be asked to participate and sign an informed consent form.|August 2015|August 4, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02135081||44922|
NCT02134795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-PD-01|A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease|A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease||Scion NeuroStim|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134795||44944|
NCT02135107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-311|A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients|A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients||Eisai Inc.|No|Active, not recruiting|September 2013|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Both|20 Years|N/A|No|||March 2015|March 31, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02135107||44920|
NCT02135705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-025|LOWER: Lomitapide Observational Worldwide Evaluation Registry|LOWER: Lomitapide Observational Worldwide Evaluation Registry|LOWER|Aegerion Pharmaceuticals, Inc.|No|Enrolling by invitation|March 2014|September 2028|Anticipated|March 2028|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients treated with lomitapide who agree to participate in the study.|May 2014|May 8, 2014|April 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02135705|10 Years|44875|
NCT02135692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312|A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects|Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial||GlaxoSmithKline|Yes|Active, not recruiting|May 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|375|||Both|12 Years|N/A|No|||February 2016|February 25, 2016|May 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02135692||44876|
NCT02117622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4129|A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India||Novo Nordisk A/S|No|Enrolling by invitation|July 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus requiring insulin therapy who qualify for starting        treatment with Tresiba® based on the clinical judgment by their treating physician during        enrolment period.|January 2016|January 22, 2016|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117622||46259|
NCT02117635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN01-CP-0002|Pilot Investigation of Stem Cells in Stroke Phase II Efficacy|A Phase II Simon Two-Stage Efficacy Study of Intracerebral CTX0E03 DP in Patients With Stable Paresis of the Arm Following an Ischaemic Stroke.|PISCES-II|ReNeuron Limited|Yes|Recruiting|June 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|40 Years|89 Years|No|||October 2015|October 9, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117635||46258|
NCT02118142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2548|Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21|Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21||UNC Nutrition Research Institute|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02118142||46219|
NCT02118428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5031|Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria|AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria|AIMS|Terumo BCTbio|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|226|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02118428||46197|
NCT02118701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258883|SHARED DECISION MAKING IN LONG-TERM CARE FACILITIES|SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES||Radboud University||Enrolling by invitation|January 2014|||May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|N/A|N/A|No|||May 2015|May 13, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02118701||46176|
NCT02118675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tanita|Tanita BIA System Validation|Tanita® BIA System Validation||Pennington Biomedical Research Center|No|Active, not recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|150|||Both|5 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Male or Female age 5 - 80 years of age.|August 2015|August 28, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02118675||46178|
NCT02118688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICUDelirium|Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium|Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study||Rochester General Hospital|Yes|Terminated|March 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 9, 2014||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT02118688||46177|
NCT02118727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAME-ALS FD003937-01|Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)|Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS Currently Taking Riluzole|TAME|University of Kansas Medical Center|Yes|Not yet recruiting|April 2016|October 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||August 2015|August 6, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118727||46174|
NCT02119260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117387|A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients|A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients||GlaxoSmithKline|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 25, 2016|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119260||46133|
NCT02119208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-135-CERES-P|Effects of the Intensity and the Timing of the Physical Activity in a Primary School|||Université de Montréal|Yes|Not yet recruiting|May 2014|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|30|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02119208||46137|
NCT02119221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16353|Copanlisib Mass Balance Study|Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects||Bayer|No|Completed|February 2014|October 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119221||46136|
NCT02119234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-04|Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients|Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer|TRIPLE 4|Chiesi Farmaceutici S.p.A.|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|45 Years|70 Years|No|||March 2015|March 20, 2015|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02119234||46135|
NCT02119247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-06001AA1-07|Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device|OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, SINGLE DOSE STUDY IN HEALTHY VOLUNTEERS TO INVESTIGATE THE PHARMACOKINETICS OF CHF 6001 DPI ADMINISTERED USING THE MULTI-DOSE RESERVOIR NEXThaler® DEVICE OR THE CAPSULE FOR ORAL INHALATION VIA AEROLIZER® DEVICE||Chiesi Farmaceutici S.p.A.|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02119247||46134|
NCT02137928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanghs2014|Carboplatin Periocular Injection for Retinoblastoma|Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma||Sun Yat-sen University|Yes|Recruiting|January 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||August 2014|December 18, 2014|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02137928||44704|
NCT02137941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n° EudraCT 2010-A00212-37|Stress Management Programs in Fire-fighters|Stress Management Programs in Fire-fighters of Paris: a Randomized Controlled Trial||French Defence Health Service|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|180|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02137941||44703|
NCT02133768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bladder cathererisation|Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences?|Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences?||Lundbeck Foundation|No|Recruiting|May 2014|May 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participating patients may help to clarify the consequences of using fixed bladder        catheterisation of patients undergoing planned deployment of an artificial hip or knee.        This will provide a basis to compare the effects of these practices with other treatment        regimens, such as. intermittent once-bladder catheterisation in the postoperative period,        which may contribute to the prevention and treatment of POUR can be optimized for all        patients.        The study is conducted as a non-interventional, observational study and all participants        will receive the department's standard treatment.|September 2015|September 2, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02133768||45023|
NCT02133989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-123|Clopidogrel Resistance and Embolism in Carotid Artery Stenting|Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement|CRECAS|Samsung Medical Center|Yes|Recruiting|June 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|20 Years|N/A|No|||June 2014|June 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02133989||45006|
NCT02134002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121006|A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts|Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts|RAPID|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|June 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|65 Years|No|||December 2014|December 7, 2014|May 7, 2014||No|Too selective recrutment criteria, none eligible patients|No||https://clinicaltrials.gov/show/NCT02134002||45005|
NCT02134262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMU-CD19CAR|Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes|Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen||Jichi Medical University|Yes|Recruiting|May 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|18|||Both|20 Years|70 Years|No|||November 2014|November 4, 2014|April 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134262||44985|
NCT02134548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC0226|Sensitivity Study of Diagnostic for Detection of Chagas Infection|Determination of Estimated Sensitivity for Chagas Detect Plus Rapid Tests||InBios International, Inc.||Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1601|Samples Without DNA|serum|Both|N/A|N/A|No|Probability Sample|Human males and females of varying ages and geographical locations where Chagas infection        is endemic. We will use retrospective (archived) and prospective human serum and blood        samples.        Retrospective (archived) serum samples are not collected specifically for this study and        are not individually identifiable to the Investigators. These samples will fall under the        category of "leftover" specimens as described by FDA guidance.        Prospective whole blood samples will be collected in compliance with human subject        protection. The first sample will be collected from finger prick; the second sample will        be collected from venous puncture.|December 2015|December 4, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134548||44963|
NCT02135744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6174|Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions|Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions and Emergency Department Visits: a Randomized, Controlled Trial.||Henry Ford Health System|No|Completed|February 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|172|||Both|40 Years|N/A|No|||May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135744||44872|
NCT02135094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-02|Low Intensity Ultrasound Therapy for Upper Back Pain Relief|Short Term Effects of Long Duration Low Intensity Continuous Ultrasound for Trapezius Muscle Pain||ZetrOZ, Inc.|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2015|November 17, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135094||44921|
NCT02135939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00292|Vegan vs AHA Diet on Inflammation and Glucometabolic Profile After PCI|Effects of a Whole-food Plant-based Vegan Diet on Markers of Inflammation and Glucometabolic Profile After Percutaneous Coronary Intervention||New York University School of Medicine|No|Recruiting|March 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|No|||September 2015|September 22, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02135939||44857|
NCT02117648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15173|A Study of LY2835219 in Participants With Cancer|Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients||Eli Lilly and Company|No|Completed|April 2014|August 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117648||46257|
NCT02117882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|misfe|Minimally Invasive Lateral Approach for Sinus Augmentation: a Split-mouth Randomized Clinical Trial.|Minimally Invasive Lateral Approach for Sinus Augmentation: a Split-mouth Randomized Clinical Trial.||University of Firenze and Siena, Napoli, Italy|Yes|Completed|January 2013|April 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|15 patients edentulous in maxillary posterior area have been treated with a bilateral        sinus lift procedure.|April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117882||46239|
NCT02117596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI Withdrawal|Calcineurin Inhibitor Based Immunosuppression Withdrawal|Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression|CNI-W|Pediatric Nephrology of Alabama|Yes|Completed|November 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|N/A|19 Years|No|||April 2014|April 16, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117596||46261|
NCT02117609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRD-2011-PRESAGE|Effect of a New High-protein Oral Supplement on Functional Parameters in Patients in Nursing Homes|Effet d'Une supplémentation Avec Une Nouvelle préparation hyperprotéinée et Hypercalorique Sur l'évolution Des paramètres Fonctionnels, Nutritionnels et Cognitifs Chez la Personne âgée en Institution|PRESAGE-T2|Lactalis|Yes|Completed|May 2012|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|110|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117609||46260|
NCT02118155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0978412.5.0000.0077|Low-intensity Laser Therapy in the Treatment of Gingival Recession|Connective Tissue Graft Associated or Not With Low Intensity Laser Therapy: A Randomized Clinical Trial|LILT|UPECLIN HC FM Botucatu Unesp|Yes|Completed|October 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118155||46218|
NCT02118168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS T-002 EF-UP|Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002|OBSERVATIONAL STUDY FOR THE EXTENDED FOLLOW-UP OF THE PATIENTS ENROLLED IN THE PHASE II THERAPEUTIC CLINICAL TRIAL ISS T-002|ISST-002 EF-UP|Istituto Superiore di Sanità|No|Active, not recruiting|September 2013|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|92|Samples With DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|HAART-treated patients who participated to the therapeutic phase II trial of the Tat        vaccine "ISS T-002" and received at least 3 immunizations and reached 48-weeks of        follow-up.|March 2016|March 3, 2016|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118168||46217|
NCT02118714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-919|Atrasentan Spermatogenesis and Testicular Function|A Single-Country, Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function||AbbVie|No|Recruiting|April 2015|May 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Male|30 Years|75 Years|No|||February 2016|February 3, 2016|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118714||46175|
NCT02148731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASRO101|MOST: Mediterranean Oncology Senior Tests|Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer|MOST|Association Sud pour la Recherche en Oncogériatrie|No|Active, not recruiting|January 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|70 Years|N/A|No|Non-Probability Sample|Elderly colon cancer patients, recruited from 6 different oncology centers in France.|May 2014|May 27, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02148731||43874|
NCT02118987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-485|Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization|Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization||Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118987||46154|
NCT02119702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD052102 - PH300|Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)|Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)|AMP Up|Harvard School of Public Health|No|Recruiting|April 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|850|Samples With DNA|Plasma, serum, peripheral blood monocuclear cells (PBMCs), urine, throat wash/gargle,      saliva, and vaginal swabs.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected and -uninfected young adults 18 years of age or older at the time of        enrollment born to HIV-infected mothers.|January 2016|January 14, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02119702||46099|
NCT02134015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31287-A-U301|Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)|Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy|HER3-Lung|Daiichi Sankyo Inc.|Yes|Recruiting|March 2014|September 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|724|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134015||45004|
NCT02134028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS12551|Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)|Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study||Sanofi|Yes|Enrolling by invitation|July 2014|November 2019|Anticipated|November 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2082|||Both|12 Years|N/A|No|||July 2015|July 16, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134028||45003|
NCT02134288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-336|Belatacept for Renal Transplant Recipients With Delayed Graft Function|Prospective, Randomized Trial of Belatacept Switch in Renal Transplant Recipients With Delayed Graft Function||Ohio State University|No|Recruiting|April 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||May 2014|May 7, 2014|April 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134288||44983|
NCT02134808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00073442|Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder|Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study||University of Utah|Yes|Recruiting|October 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|12 Years|21 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134808||44943|
NCT02134821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSQ_001|Influence of Pain Sensitivity on Lumbar Surgery Outcomes|Influence of Pain Sensitivity on Surgical Outcomes After Lumbar Spine Surgery in Patients With Lumbar Spinal Stenosis||Seoul National University Hospital|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|171|||Both|40 Years|80 Years|No|Probability Sample|The inclusion criteria were the following: 1) patients aged 40-80 years; 2) an lumbar        spinal stenosis diagnosis and scheduled spine surgery at a tertiary-care teaching        institution between June 2012 and April 2013|May 2014|May 7, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02134821||44942|
NCT02134275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10504|Whole Body Vibration Training for Healthy Body Composition in Young Adults|Whole Body Vibration Training for Healthy Body Composition in Young Adults||Oregon Health and Science University|Yes|Recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|176|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02134275||44984|
NCT02134561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00088-37|Assessment of the Psychological, Cognitive and Social Resources of Applicants for Huntington's Disease and Presymptomatic Genetic Testing||PREHUNT|University Hospital, Angers||Recruiting|September 2013|||September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2013|May 6, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02134561||44962|
NCT02134574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9011|Prospective Cohort With Hemopathy in Languedoc-Roussillon|Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon|DataDiag2012|University Hospital, Montpellier|No|Recruiting|February 2014|June 2033|Anticipated|June 2033|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood and marrow|Both|18 Years|N/A|No|Probability Sample|patient for suspected haematological disease and justifying further exploration|September 2015|September 4, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02134574||44961|
NCT02134782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga RCT|Yoga Fatigue Study|A Randomized Controlled Trial of Individualized Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy||The Hospital for Sick Children|No|Recruiting|October 2014|||October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|210|||Both|8 Years|18 Years|No|||November 2015|November 27, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02134782||44945|
NCT02135419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-A01|Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions|ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study||AIDS Malignancy Consortium|Yes|Recruiting|September 2014|June 2022|Anticipated|June 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5058|||Both|35 Years|N/A|No|||September 2015|October 2, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135419||44896|
NCT02135757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMPC-02|Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients|A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes, Economic Impact and Resistance Mechanisms of Panitumumab in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer||PeriPharm||Active, not recruiting|August 2014|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chemotherapy-refractory metastatic colorectal cancer from participating        hospitals in Quebec.|January 2016|January 13, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135757||44871|
NCT02135393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK CRN 5085|Where is the Initial Site of Biotransformation of Folates in Humans?|Folic Acid Handling by the Human Gut: Implications for Food Fortification and Supplementation|FOLTIPS|Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|April 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135393||44898|
NCT02135406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02413|CART-19 for Multiple Myeloma|Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|May 2014|September 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135406||44897|
NCT02135367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-KNEE 012|Platelet-rich Plasma (PRP) vs Viscosupplementation for the Treatment of Early Knee Articular Degenerative Pathology|Platelet-rich Plasma (PRP) vs Viscosupplementation for the Treatment of Early Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial|PRP-012|Istituto Ortopedico Rizzoli|Yes|Recruiting|January 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|55 Years|No|||December 2015|December 2, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02135367||44900|
NCT02135380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/IPF/11-12/002|Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis|A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF).||Kasiak Research Pvt. Ltd.|Yes|Recruiting|August 2014|||August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|70 Years|No|||May 2014|May 12, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135380||44899|
NCT02147210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 194 02|Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1|Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1|GARRE|University Hospital, Toulouse|No|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Biopsies from patients corresponding to eligibility criteria (see below) will be selected        from the list of kidney transplant patients followed up in the Toulouse University        Hospital. They will be divided into two groups matched for age, sex and time of kidney        transplantation (n = 30 for each group). Iterative biopsies are conserved in the        collection of tissue samples of the CHU|August 2015|August 24, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02147210||43991|
NCT02117869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300728|The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics|The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics||University of Florida|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117869||46240|
NCT02117856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-70082|Complete Lower Dentures on 1 or 2 Implants|A Randomized Clinical Trial Comparing Patient Satisfaction and Prosthetic Outcomes With Mandibular Implant Overdentures Retained by 1 or 2 Implants||University of British Columbia|No|Active, not recruiting|November 2002|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02117856||46241|
NCT02118181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not Avalaible|Assessment of Physical Performance With A Supplementation Containing HMB in a Sample of Old Women in Good Health|Role of Oral Supplementation of Proteins and β-hydroxy-β-methyl Butyrate (HMB) in a Sample of Older Women in Good Health|HMB|University of Padova|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|December 2, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02118181||46216|
NCT02118740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44976.068.13|Bone Marrow Collection in Healthy Volunteers (iCell)|Bone Marrow Collection in Healthy Volunteers|iCell|Amarna Stem Cells BV|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|A stem cell specimen will be retained to enable verification in the future|Both|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young healthy volunteers|December 2015|December 29, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02118740|1 Week|46173|
NCT02118441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00494|Ultrasound-guided Versus Direct Palpation Radial Artery Catheter Insertion Among Cardiac Anesthesiologists|A Comparison of Ultrasound-Guided Versus Direct Palpation For Radial Artery Catheterization Among Cardiac Anesthesiologists|art-line|University of British Columbia|No|Completed|August 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|129|||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 15, 2014||No||No|March 3, 2015|https://clinicaltrials.gov/show/NCT02118441||46196|
NCT02118454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AI094666|Antiretroviral Adherence and Quality-of-life Support for HIV+ Patients in India With Twice-daily Interactive Voice Response (IVR) Calls With Health and Mental Health Messaging Compared to Weekly IVR Survey Only Control Condition: The Mobile-messaging Adherence and Support for Health Study, India.|ART Adherence Behaviour and Practices Among HIV Positives in Kolkata, India-a Pilot Project|MASHIndia|University of California, Los Angeles|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02118454||46195|
NCT02148770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|646/2013BO2|The Effect of Neurofeedback on Eating Behaviour|Modulating Functional Connectivity Between Eating-related Brain Areas by Neurofeedback||University Hospital Tuebingen|No|Recruiting|November 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|120|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|December 2, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02148770||43871|
NCT02119494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.529|Phenotypes of COPD in Central and Eastern Europe|POPE-Study: Phenotypes Of COPD in Central and Eastern Europe Study|POPE|Masaryk University|Yes|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|3500|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with COPD who visit selected specialised pulmonology clinics in the given time        period.|March 2015|March 24, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119494|7 Months|46115|
NCT02149329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000735|Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO|Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial.|SHORT|VU University Medical Center|Yes|Recruiting|December 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149329||43828|
NCT02149615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2013-0433 AAMPTC|Antiacne Medications Pseudotumor Cerebri|Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment|AAMPTC|University of Zurich|Yes|Recruiting|April 2014|December 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|310|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 26, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02149615||43807|
NCT02134067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS-119-101|Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|No|Recruiting|August 2014|May 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134067||45000|
NCT02134834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP0595-1|A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.||Meiji Seika Pharma Co., Ltd.|No|Completed|May 2014|November 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134834||44941|
NCT02134847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001346|Multi-center Clinical Trial of Limiting Resident Work Hours on ICU Patient Safety|Multi-center Clinical Trial of Limiting Resident Work Hours on ICU Patient Safety|ROSTERS|Brigham and Women's Hospital|Yes|Recruiting|July 2013|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02134847||44940|
NCT02135120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.GK.09|The Efficacy of Peripheral Nerve Blocks With Intrathecal Morphine in Improving Analgesia After Unilateral Total Knee Arthroplasty|Do Peripheral Nerve Blocks When Used as Part of a Multimodal Regimen Inclusive on Intrathecal Morphine Improve Analgesia After Unilateral Total Knee Arthroplasty? A Randomized Controlled Trial||American University of Beirut Medical Center||Recruiting|March 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02135120||44919|
NCT02135432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140319002|TOPIC Trial for COPD|A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)||University of Alabama at Birmingham|Yes|Completed|May 2015|November 2015|Actual|October 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|65 Years|No|||November 2015|November 30, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135432||44895|
NCT02135445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C27003|Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer|A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||November 2015|November 30, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135445||44894|
NCT02135458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 61|Evaluation of the AUTONOM@DOM Telemonitoring System for People With Heart Failure|Clinical and Medico-economic Assessment of Conventional Care Plus the "Autonom@Dom" Telemonitoring System Versus a Conventional Care Package Alone, for People With Heart Failure in Several French Structures.|AUTONOM@DOM|University Hospital, Grenoble|No|Recruiting|April 2014|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|60 Years|N/A|No|||December 2014|December 8, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02135458||44893|
NCT02136264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCFADASH-HT|Study of Personalized Dietary Intervention for the Control of Essential Hypertension|Randomized Controlled Trial of a Personalized Dietary Intervention Approach for the Control of Essential Hypertension|PCFADASH-HT|University of Nigeria, Enugu Campus|Yes|Recruiting|June 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||November 2015|November 10, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136264||44832|
NCT02135731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0308|APHID- Primary Care Accuracy Study|APHID- Sensitivity and Specificity of a Medication Reconciliation Technology - A Primary Care Randomized Controlled Trial||Portland VA Medical Center|No|Completed|February 2009|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 9, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135731||44873|
NCT02147223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRANDED|Sex-dependent Effects of Flavanols on Vascular Status|Sex-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status||Heinrich-Heine University, Duesseldorf|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147223||43990|
NCT02118194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJPVAMC ReWalk2|Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI|Assessment of Home/Work Simulation Tasks and Community Mobility Skills in the ReWalk Powered Exoskeleton in Persons With Spinal Cord Injury|VA_ReWalk2|James J. Peters Veterans Affairs Medical Center|No|Recruiting|October 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|Males and females with paraplegia (T1 and below) who are unable to walk on their own will        be eligible for participation in this study.|April 2015|April 8, 2015|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118194||46215|
NCT02118467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0047|Vasoactive Drugs in Intensive Care Unit|A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU||University of Chicago|Yes|Recruiting|May 2014|June 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|836|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02118467||46194|
NCT02148211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201476|Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Vaccine Pregnancy Registry|Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Fluarix® or Fluarix® Quadrivalent or FluLaval® or FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception.||GlaxoSmithKline||Active, not recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women, residing in the US, vaccinated with any of the 4 GSK sIIVs during        pregnancy or within 28 days preceding conception and who are volunteering to take part in        the Pregnancy Registry before the outcome of the pregnancy is known.|October 2015|October 29, 2015|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02148211||43914|
NCT02119000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN 13-148|Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy|||McGill University Health Center|No|Recruiting|August 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|January 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02119000||46153|
NCT02149004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZIF_HIV|German Centre for Infection Research HIV Translational Platform|Translational Research Platform of the TTU HIV of the German Center for Infection Research (DZIF)||University Hospital of Cologne|Yes|Recruiting|April 2015|January 2035|Anticipated|January 2035|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|10000|Samples With DNA|Liquids, tissue, and pathogens from consenting patients will be stored in a decentral      biobank.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients HIV positive and who are treated in one of the six partner sites|August 2015|August 24, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02149004||43853|
NCT02149316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FW2012-863B-C|Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery|Cardioprotective Effects of Remote Ischemic Preconditioning With Postconditioning of the Recipient on Donor Heart in Heart Transplantation Surgery||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|February 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|14 Years|70 Years|No|||February 2016|February 1, 2016|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149316||43829|
NCT02149342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-001389-40|Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2% and 2%HAL With 16%MAL|Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% and 2% Hexylaminolaevulinate With 16% Methylaminolaevulinate||Joint Authority for Päijät-Häme Social and Health Care|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 3, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149342||43827|
NCT02149355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2013-0342|Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy|Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy|IVPareseZahn|University of Zurich|Yes|Recruiting|March 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients suffering from congenital fourth nerve palsy|May 2014|May 23, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02149355||43826|
NCT02134080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013669|FAAH Inhibitor Trial for Adults With Tourette Syndrome|FAAH Inhibitor Trial for Adults With Tourette Syndrome||Yale University||Suspended|May 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|May 6, 2014|Yes|Yes|Clinical hold placed on the study pending results from another study|No||https://clinicaltrials.gov/show/NCT02134080||44999|
NCT02134327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB004-1|Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion|Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion: A Randomized, Blinded Study||Nemours Children's Clinic|Yes|Not yet recruiting|August 2014|||April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||April 2014|May 7, 2014|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134327||44980|
NCT02134587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E015/10|Educational Intervention in Pharmacovigilance for Hospital Health Professionals|Implementation of a Hospital Pharmacovigilance Service and Comparison of Algorithms for Adverse Drug Reaction Causality Assessment|EIPhv|Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|February 2012|May 2014|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|203|||Both|N/A|N/A|No|||July 2015|July 26, 2015|May 5, 2014||No||No|March 29, 2015|https://clinicaltrials.gov/show/NCT02134587||44960|
NCT02134600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130321|OmegaChild - Omega-3 Supplementation to Children Previously Treated for Cancer|OmegaChild - Omega-3 Supplementation to Children Now in Full Remission From a Previous Cancer; an Early Phase Dose-finding Study.|OmegaChild|Karolinska Institutet|No|Recruiting|May 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|2 Years|18 Years|No|||May 2014|May 22, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134600||44959|
NCT02135133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-309|A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL|A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL)||Dana-Farber Cancer Institute|Yes|Recruiting|June 2014|March 2021|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|September 2, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135133||44918|
NCT02148094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:050|Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India|Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India|PrEP-India|University of Manitoba|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148094||43923|
NCT02156986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.03.INF|Chewing Capability Study for Infants and Toddlers|Effect of Food Structural Properties on Infants and Toddlers Mastication Abilities||Nestlé|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||5|Actual|68|||Both|9 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|The subjects investigated will be healthy infants and toddlers ranging from 9 to 36 months        in 5 groups:          -  9 months (±2 weeks),          -  12 months (±1 month),          -  18 months (±2 months),          -  24 months (±2 months),          -  36 months (±3 months).|August 2014|August 4, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156986||43242|
NCT02156999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2014|Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment|Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients||Shinshu University|Yes|Recruiting|June 2014|||February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156999||43241|
NCT02156700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBD-IG1|Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors|Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWE™) for Characterisation of Liver Tumors||University Hospital Dubrava|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients and inpatients in a tertiary care hsopital|December 2015|December 23, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02156700||43264|
NCT02156713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00197|Constraint Induced Movement Therapy Summer Camp|Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7||Nationwide Children's Hospital|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|7 Years|No|||February 2015|February 3, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156713||43263|
NCT02158975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.031|Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas|Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas||University of Michigan Cancer Center|Yes|Recruiting|September 2014|||September 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158975||43089|
NCT02159521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKOS-11|Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System|ACCelerated ThrombolySiS for Post-Thrombotic Syndrome Using EKOS|ACCESS PTS|EKOS Corporation|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||January 2015|January 26, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159521||43047|
NCT02159469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QST-13-003|Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism|A Double-blind, Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism|STEADY|Antares Pharma Inc.|No|Completed|July 2014|November 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|150|||Male|18 Years|N/A|No|||November 2015|November 11, 2015|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159469||43051|
NCT02156063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-05|A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)|A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)|RESPONSE|Nora Therapeutics, Inc.|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|37 Years|No|||July 2015|July 13, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156063||43313|
NCT02159053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2320|16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis|MEASURE4|Novartis|Yes|Recruiting|May 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|324|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159053||43083|
NCT02159066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818X2109|LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma|A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma|LOGIC-2|Array BioPharma|No|Active, not recruiting|July 2014|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159066||43082|
NCT02158455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTSVGRA|Vein vs Arterial Grafts for Coronary Artery Bypass Grafting Surgery|No-touch Saphenous Vein Grafts vs Radial Artery Grafts; A Randomized Trial.||University Hospital Orebro|No|Active, not recruiting|February 2004|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|N/A|65 Years|No|||June 2014|June 4, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02158455||43129|
NCT02158754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX_000021|Clinician Utilization of CORUS® CAD in Primary Care Provider Decision Making|Clinician Utilization of CORUS® CAD in Primary Care Provider Decision Making|(CU-PCP)|CardioDx|No|Withdrawn|May 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|This study is a retrospective chart review, in which only de-identified clinical data will        be collected and analyzed. The main criterion for inclusion is the occurrence of chest        pain (or anginal equivalent) in a subject without known significant CAD or a history of        prior myocardial infarction, and the utilization of CORUS® CAD for the CORUS® CAD Arm.        Additionally, CORUS® CAD eligible subjects with similar chest pain (or angina equivalent)        who did not undergo CORUS® CAD testing will be included as a control group.|May 2015|May 5, 2015|June 5, 2014||No|Study halted due to low investigator involvement; no patients enrolled in study.|No||https://clinicaltrials.gov/show/NCT02158754||43106|
NCT02149394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16707313.5.0000.5231|Ice Popsicle for Thirst Relief of the Surgical Patient|Efficacy of Ice Popsicle in the Management of Thirst in the Immediate Postoperative Period: Randomized Clinical Trial||Universidade Estadual de Londrina|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|65 Years|No|||May 2014|May 26, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02149394||43824|
NCT02149407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0752|Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants|Efficacy and Safety of Glycerin Suppositories for Treatment of Feeding Intolerance in Very Low Birth Weight Infants||King Saud Medical City|Yes|Recruiting|May 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|230|||Both|N/A|N/A|No|||April 2015|April 2, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02149407||43823|
NCT02149680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAP-2013|Long-term Effects of Accidental Dural Puncture in Patients Having Had an Epidural Blood Patch (LEAP)|Long-term Follow-up of Patients Having Had an Epidural Blood Patch Following Accidental Dural Puncture During Labour or Caesarean Section|LEAP|Örebro University, Sweden|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|60|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Women who had delivered during the years 2005 - 2011. Experimental group: 60 patients who        had an accidental dura puncture during labour or caesarean section and developed post-dura        puncture headache and required an epidural blood patch would constitute the experimental        group Contro group: 600 patients, identical to the above except that they had no dura        puncture and therefore no post-dural puncture headache|September 2015|September 26, 2015|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149680||43802|
NCT02150252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC1-122|Evaluate the Efficacy of Bu-Yang- Huan-Wu Tang（BYHWT）on Ischemic Stroke|Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Bu-Yang-Huan-Wu Tang（BYHWT）on Ischemic Stroke||China Medical University Hospital||Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|120|||Both|40 Years|75 Years|No|||May 2014|May 27, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150252||43758|
NCT02146742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-CL-0002|A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects|A Double Blind, Randomized and Placebo Controlled Ascending Single Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ASP1707 in Healthy Young Japanese Male Subjects||Astellas Pharma Inc|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02146742||44027|
NCT02146768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #013-234|Low-dose-contrast Cardiac Computed Tomography|A Novel Low-dose-contrast Cardiac Computed Tomography Method for Pre-Procedural Guidance in Transcatheter Aortic Valve Replacement|CCTA|Baylor Research Institute||Completed|January 2014|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|142|||Both|18 Years|N/A|No|Probability Sample|The study is a retrospective study of 150 consecutive patients > 18 years of age (75        patients who received low-dose contrast matched by body mass index with 75 patients who        received traditional dose contrast) seen at THHBP between January 1, 2011 and June 30,        2013. Patients with MDRD eGFR < 25 will be excluded. The cutoff of 25 was chosen as the        maximal allowable dose of contrast for eGFR of 25 would be about 90 ml (3.7 x eGFR of 25),        and half of that maximal allowable contrast would be 45 ml (the minimum we require to        obtain a CCTA with acceptable SNR for post-processing).|January 2016|January 15, 2016|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02146768||44025|
NCT02147054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rocuronium Pilot May 14|A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning|Pilot Study - Assessing the Impact of Using a Neuromuscular Blocking Agent to Reduce Neuromuscular Junction Damage and Intermediate Syndrome in Organophosphorus (OP) Insecticide Poisoned Patients Requiring Ventilation||University of Edinburgh||Recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|17 Years|N/A|No|||June 2015|June 4, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147054||44003|
NCT02147574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhuanlone0001|Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation|Laparoscope Subtotal Colectomy With Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation||First Affiliated Hospital of Harbin Medical University|Yes|Completed|December 2009|April 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||May 2014|May 20, 2014|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147574||43963|
NCT02147847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006H-AUD|Computer-Based Auditory Rehabilitation|Neurological Treatment to Improve the Hearing in Noise Abilities of Older Adults With Hearing Impairments.||Massachusetts Eye and Ear Infirmary|No|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|85 Years|No|||September 2015|September 21, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02147847||43942|
NCT02158195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUDIA APJ 2012|Immunopathology of Autoimmune Hemolytic Anemia|Immunopathology of Autoimmune Hemolytic Anemia. Open, Prospective, Multicentre Study.|IAHAI|Centre Hospitalier Universitaire Dijon||Recruiting|July 2013|||July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed with warm primary or secondary Autoimmune Hemolytic Anemia|March 2013|June 5, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02158195||43149|
NCT02157038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00090769|Neuromuscular Mechanisms Underlying Poor Recovery From Whiplash Injuries|Neuromuscular Mechanisms Underlying Poor Recovery From Whiplash Injuries||Northwestern University|No|Recruiting|July 2014|July 2019|Anticipated|July 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02157038||43238|
NCT02159209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121651|The Drug Induced Renal Injury Consortium|The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)|DIRECT|University of California, San Diego|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|-  Plasma, serum, and urine stored for further analysis of biomarkers        -  Urinary chemistry        -  Urinary microscopy        -  DNA sample|Both|2 Years|N/A|No|Non-Probability Sample|This is a prospective observational cohort study of patients who have developed DIRI.        Patients will be identified through two main approaches;          1. Recall and review of medical records of patients who were suspected to have DIRI          2. Concurrent identification of patient under active treatment.        Patients who developed DIRI in their previous care provided will be identified through a        review of kidney biopsy logs or nephrology consults previously made.|June 2014|June 5, 2014|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02159209||43071|
NCT02157012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xeljanz2014|Evaluation of the Condition of Rheumatoid Arthritis After Treatment|Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients||Shinshu University|Yes|Recruiting|May 2014|||February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157012||43240|
NCT02159482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014489|Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines|Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines||Duke University|No|Terminated|November 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2014|July 21, 2014|June 6, 2014|Yes|Yes|Low enrollment|No|June 17, 2014|https://clinicaltrials.gov/show/NCT02159482||43050|Low accrual was due to a drug manufacturing issue.
NCT02155816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0160|Omega 7 + 3 Combination and Systemic Inflammation|Influence of Omega 7 + 3 Combination on Systemic Inflammation and Plasma Lipoproteins in Women: a 2-month, Double Blind, Placebo-Controlled, Randomized Community Trial||Appalachian State University|No|Completed|May 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02155816||43332|
NCT02155829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380797|Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)|Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder||Uniformed Services University of the Health Sciences|Yes|Recruiting|July 2013|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||July 2014|July 21, 2014|November 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02155829||43331|
NCT02166242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBSKE001|Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers|Phase 1c Single Arm Study of Thioredoxin Reductase Inhibitor Ethaselen, for the Treatment of Thioredoxin Reductase High Expressed Advanced Non-small Cell Lung Cancers Who Have Received More Than Two Lines Standard Treatment.||Hunan Province Tumor Hospital|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 14, 2016|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02166242||42533|
NCT02159612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-163 (fsh)|1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy|Disease Progression in Facioscapulohumeral Muscular Dystrophy - 1 Year MRI Follow-up|FSHD|Rigshospitalet, Denmark|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|80 Years|No|Non-Probability Sample|Persons in Denmark diagnosed with Facioscapulohumeral muscular dystrophy is invited to the        study.|May 2015|May 13, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159612||43040|
NCT02158208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMSON APJ 2013|Study of the T CD8 Immune Response in Horton's Disease|Study of the T CD8 Immune Response in Horton's Disease|Horton CD8|Centre Hospitalier Universitaire Dijon||Recruiting|July 2013|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients presenting Horton's disease at the diagnosis before any treatment|May 2013|June 5, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02158208||43148|
NCT02158468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPSIA-Conditioning|Effect of Conditioning on Myocardial Damage in STEMI|Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.|LIPSIA-COND|University of Leipzig|Yes|Recruiting|October 2011|September 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02158468||43128|
NCT02149420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736X2201|PD of VAY736 in Patients With Primary Sjögren's Syndrome|A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome|CVAY736X2201|Novartis|No|Active, not recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149420||43822|
NCT02149693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401065RIND|Paradigm Shift in Medical Education: Applications of High-Fidelity Simulation, Teamwork Model Development, and Concept of Flipped Classroom in Innovation and Revolution of Resuscitation Training|Paradigm Shift in Medical Education: Applications of High-Fidelity Simulation, Teamwork Model Development, and Concept of Flipped Classroom in Innovation and Revolution of Resuscitation Training||National Taiwan University Hospital|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 7, 2015|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149693||43801|
NCT02150499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP051-361|A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects|A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting||Sunovion|No|Terminated|July 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|48 Months|No|||January 2016|January 4, 2016|May 27, 2014|Yes|Yes||No|November 18, 2015|https://clinicaltrials.gov/show/NCT02150499||43739|
NCT02150512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReSSeS-2014|Resuscitation Strategies in Septic Shock|Resuscitation Strategies in Septic Shock. A Randomized Controlled Trial of Two Different Fluid Loading Strategies in ICU Patients With Early Septic Shock|ReSSeS|Medisch Spectrum Twente|No|Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02150512||43738|
NCT02146781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI PH IC- 2014|A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device|A Safety and Immunogenicity Phase IC Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device||Immunomic Therapeutics, Inc.|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|63 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|April 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146781||44024|
NCT02150720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-FAT-2011-103|Prevention of Postoperative Bleeding in Subcapital Femoral Fractures: a Multicenter, Randomized, Controlled, Parallel Clinical Trial|Prevention of Postoperative Bleeding in Femoral Fractures: a Multicenter, Randomized, Controlled, Parallel Clinical Trial to Assess the Efficacy of Tranexamic Acid and Fibrin Glue|TRANEXFER|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|February 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02150720||43722|
NCT02150733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-A-U160|Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment|A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Active, not recruiting|April 2014|January 2017|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150733||43721|
NCT02147340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130004180 del 24/09/2013|External Sensors for remoTe MoniToring of Heart Failure Patients With Implantable Defibrillators|External Sensors for remoTe MoniToring of Heart Failure Patients With Implantable Defibrillators: the ESTIMATE-HF Study|ESTIMATE-HF|IRCCS Policlinico S. Matteo|No|Not yet recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|186|||Both|18 Years|N/A|No|Non-Probability Sample|All Heart failure patients implanted with cardiac Resynchronization therapy-defibrillator        (CRT-D) or ICD (mono-VR- or dual chamber-DR) will receive an RPM system equipped with        sensors for the measurement of weight and pressure for remote management.|May 2014|May 23, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147340||43981|
NCT02147587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921237|A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment||Pfizer|Yes|Completed|June 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|50 Years|N/A|No|||July 2015|July 31, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147587||43962|
NCT02147808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-108-NRM|A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects|A Phase 1, Open-Label, Single-Center, 2-Period, Single-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Multiple-Dose Telotristat Etiprate on the Pharmacokinetics of Single-Dose Midazolam, a Sensitive P450-3A4 Substrate, in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|May 2014|||August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147808||43945|
NCT02117323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-10-00084|Corneal Opacities in Children|Observational Study on Corneal Opacities in Children|OCT|Oregon Health and Science University|No|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|1 Month|18 Years|No|Probability Sample|Infants and children (1 month to 18 years of age) with corneal opacity requiring a        thorough eye examination.|April 2015|April 21, 2015|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02117323||46281|
NCT02117336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1446A-05/79/13|Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I/Ib Study of P1446A-05 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).||Piramal Enterprises Limited|No|Suspended|June 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|April 8, 2014|No|Yes|Sponsor decision not related to patient safety|No||https://clinicaltrials.gov/show/NCT02117336||46280|
NCT02164370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43603-A|Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach|Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach||University of Washington|No|Completed|October 2013|October 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|120|Samples Without DNA|VBGs|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with mild pre-eclampsia and admitted on the labor and delivery unit at        the UWMC will be included consecutively and their clinical course will be followed, until        25 cases have progressed to severe pre-eclampsia. At each state of the disease a blood gas        will be drawn (mild disease, severe disease, beginning labor or with decision for cesarean        delivery). However, some women will deliver before severe pre-eclampsia develops        (continuing mild pre-eclampsia), because disease is either late or only slowly progressing        (study flow chart).        Analyzing the number of women treated for mild and severe pre-eclampsia in 2011 and 2012,        we are expecting to see a 3x higher number of mild than severe cases of pre-eclampsia,        which means we will need to enroll approximately 100 women with mild pre-eclampsia in        order to have 25 who develop severe pre-eclamsia..|October 2014|October 14, 2014|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02164370||42676|
NCT02156739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1157|Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)|Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02156739||43261|
NCT02157025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KID_VF|A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics|||Nova Southeastern University|No|Recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02157025||43239|
NCT02157311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS162-4D|4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients|Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent Maintenance Therapy After a Successful Continuous Induction Therapy.|ANRS162-4D|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|July 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02157311||43217|
NCT02157324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-002|ACP-196 in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia|A Multicenter, Open-label, Phase 1 Pilot Study of ACP 196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia||Acerta Pharma BV|No|Active, not recruiting|August 2014|||September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157324||43216|
NCT02157597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1677|NIRS Guidance Trail in Children's Heart Surgery|Randomized Trial of Near-infrared Spectroscopy to Guide Intraoperative and Intensive Care Management in Children's Heart Surgery Requiring Cardiopulmonary Bypass|NIRS|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|November 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2015|August 4, 2015|November 15, 2012||No||No||https://clinicaltrials.gov/show/NCT02157597||43195|
NCT02159339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Methylation-14414|DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma|A Cohort Study on Prediction of Metastasis of Gastric Carcinoma by DNA Methylation Biomarkers||Beijing Cancer Hospital|Yes|Completed|December 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|Samples With DNA|Tissue specimens are surgically collected from inpatients with pN0M0-stage gastric      carcinoma. Genomic DNA sample is extracted from tissues. Unmethylated cytosine residues in      DNA are converted into uracil residues with bisulfite modification.|Both|N/A|N/A|No|Probability Sample|198 early stage gastric carcinoma (GC) inpatients that underwent surgical treatment at        Peking University Cancer Hospital & Institute between 2002 and 2012 were enrolled in the        cohort. All of the enrolled patients had been diagnosed pathologically by senior        pathologists. The 2010 UICC-TNM (tumor-node-metastasis) system was used for the        classification of GCs. All cases involved primary lesions without neoadjuvant        chemotherapy. Genes methylation status of GC samples was analyzed with MethyLight combined        with denatured high performance liquid chromatography. 191 eligible cases with        gene-methylated or gene-methylated GC were enrolled into the cohort study.|June 2015|June 17, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159339||43061|
NCT02158221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-043|PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load|PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load||Danish Headache Center||Completed|June 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|32|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158221||43147|
NCT02159027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H024|Maraviroc and NeuroAIDS Pathogenesis|Maraviroc and NeuroAIDS Pathogenesis||University of Hawaii|Yes|Recruiting|May 2015|December 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||March 2016|March 11, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159027||43085|
NCT02159040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS47|Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.|A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes||Novartis|Yes|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159040||43084|
NCT02149433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pneumocystis and Steroids|Pneumocystis Jerovici Pneumonia in Infants and Steroids|Early Steroid Use in Infants With Clinical Pneumocystis Jiroveci Pneumonia (PCP) in the Queen Elizabeth Central Hospital, Blantyre, Malawi||University of Malawi College of Medicine|Yes|Completed|May 2012|February 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|78|||Both|2 Months|6 Months|No|||December 2015|December 9, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT02149433||43821|
NCT02150759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-027|Dexmedetomidine-ketamine in Femur Proximal Fracture Patients|Comparison Study of Analgesic Effects for Dexmedetomidine-fentanyl vs Dexmedetomidine-ketamine in Femur Proximal Fracture Patients||Inje University|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|46|||Both|20 Years|N/A|No|||December 2015|December 9, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02150759||43719|
NCT02150772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWE-diag 042014|The Diagnostic Value of Shear Wave Elastography|Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study||University of Aarhus||Recruiting|April 2014|April 2020|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02150772||43718|
NCT02146794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCH-10/065|Renal Denervation in Chronic Heart Failure|Renal Denervation in Chronic Heart Failure|REACH|Imperial College London|Yes|Completed|May 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||May 2014|May 21, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146794||44023|
NCT02150746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-00271|Circulating Tumor Cells in Operative Blood|Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence||University of Florida|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|Samples With DNA|Whole blood Buffy coat isolated from collected whole blood|Both|18 Years|85 Years|No|Non-Probability Sample|Patients between the ages of 18-85 years with a confirmed tissue diagnosis of pancreatic        ductal adenocarcinoma who are scheduled to undergo curative surgery.|February 2016|February 22, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150746||43720|
NCT02146755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #013-178|Improving Echo Measurements in the Diagnosis of Aortic Stenosis|Improving The Quality Of Echocardiographic Imaging Measurements In The Diagnosis Of Severe Aortic Stenosis||Baylor Research Institute|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|396|||Both|18 Years|N/A|No|Non-Probability Sample|This study is an observational, retrospective review of data collected as standard of        care. The study intends to review the charts of up to 400 patients over the last 5 years        who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve        stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center        (BUMC).|January 2016|January 12, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02146755||44026|
NCT02147067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072996|Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)|Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis|MARINA|Emory University|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147067||44002|
NCT02147080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA154928-01|A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults|A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults|UV4me|Fox Chase Cancer Center|No|Completed|March 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1234|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147080||44001|
NCT02147093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5175|CLARITI (TM) 1Day Multifocal Contact Lenses Performance and Acceptance Evaluation|||Johnson & Johnson Vision Care, Inc.|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 6, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147093||44000|
NCT02147353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0860|Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment|An Investigator-Initiated Study to Assess the Safety and Efficacy of Sinecatechins 15% Ointment When Used in Conjunction With Cryotherapy in the Treatment of External Genital Warts||Icahn School of Medicine at Mount Sinai|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147353||43980|
NCT02147834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400100|Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents|Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)|IMWELL3|North Florida Foundation for Research and Education|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|99 Years|No|||October 2015|October 5, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147834||43943|
NCT02147613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mayo-ArizonaSU Seed 93016001|High Intensity Interval Exercise in Diastolic Heart Failure|High-intensity Aerobic Interval Training vs. Moderate-intensity Continuous Exercise Training in Heart Failure With Preserved Ejection Fraction||Arizona State University||Completed|November 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|80 Years|No|||May 2014|May 27, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147613||43960|
NCT02117362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004A|Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma|Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma||Providence Health & Services|No|Recruiting|March 2014|March 2020|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117362||46278|
NCT02156388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tmab-GW003-NP-01|Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors|A Single-center, Uncontrolled, Open, Phase 1 Study of Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein For Injection(GW003)to Metastatic Tumors||Jiangsu T-Mab Biopharma Co.,Ltd|No|Completed|August 2013|December 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|31|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02156388||43288|
NCT02156726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-lite|Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project|Observational Study of Low Dose FCR in the Treatment of Elderly/Comorbid Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: The Q-lite Project|Q-lite|Czech CLL Study Group|No|Active, not recruiting|March 2011|July 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with CLL or SLL deemed unfit for full-dose FCR. Both untreated and        relapsed/refractory setting.|May 2014|June 3, 2014|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02156726||43262|
NCT02157337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0551|The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery|The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery||Yonsei University|No|Recruiting|August 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|20 Years|80 Years|No|||June 2014|June 5, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02157337||43215|
NCT02157610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0204|Smoking Cessation for Cervical Cancer Survivors|Smoking Cessation for Cervical Cancer Survivors in a Safety Net Healthcare System||University of Oklahoma|No|Recruiting|January 2015|||January 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157610||43194|
NCT02157623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE 2614|Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome|Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome||The Cleveland Clinic|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3|||Both|N/A|N/A|No|||August 2015|August 18, 2015|June 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157623||43193|
NCT02157974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0542|Liver and Fat Regulation in Overweight Adolescent Girls|Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls||University of Colorado, Denver|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|Samples Without DNA|Serum and urine samples.|Female|12 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese, non-diabetic, sedentary adolescent females with or without diagnosed polycystic        ovarian syndrome.|December 2015|December 7, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157974||43166|
NCT02159352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-093|Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants|A Phase 1 Clinical Study to Assess the Effect of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Subjects||Bristol-Myers Squibb|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|49|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 6, 2014|No|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT02159352||43060|
NCT02159365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-112|Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients|A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients||Bristol-Myers Squibb|No|Active, not recruiting|March 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159365||43059|
NCT02158780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPRESSO|Expertise-Based Randomized Control Trial of Scrotal Versus Inguinal Orchidopexy on Post-operative Pain|Expertise-Based Randomized Control Trial of Scrotal Versus Inguinal (Standard) Orchidopexy on Postoperative Pain: EXPRESSO Trial|EXPRESSO|McMaster University|Yes|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Male|10 Months|7 Years|No|||March 2016|March 21, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02158780||43104|
NCT02159586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKG/Vagal Nerve|Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve|Cardiac Vagal Effects of Gastric Electrical Stimulation and Vagal Nerve Action Potentials in Vagus Nerve in Patients With Gastroparesis|GES|Indiana University|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|This study will evaluate male and female patients at least 18 years of age, with        gastroparesis, who will or have already undergone the implantation of a GES device        (Enterra, Medtronic, Minneapolis, MN)|January 2015|January 28, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159586|2 Years|43042|
NCT02159599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA 8014|Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject|An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia|DUAL|Fundacion SEIMC-GESIDA|No|Active, not recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||May 2015|January 22, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02159599||43041|
NCT02150278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENCON|Effectiveness of an Intervention to Reduce Driving Under the Influence of Alcohol Among Drivers|Effectiveness of an Intervention to Reduce Driving Under the Influence of Alcohol Among Drivers|PREVENCON|Jordi Gol i Gurina Foundation|Yes|Enrolling by invitation|April 2012|September 2014|Anticipated|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02150278||43756|
NCT02150785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AASIST|Asia Africa Streptokinase Trial|The Effectiveness of Administering Streptokinase as a Thrombolytic Agent in the Management of Acute Stroke|AASIST|University of Alberta|Yes|Not yet recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||December 2014|December 28, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02150785||43717|
NCT02150798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC001|The Effects of a High Fat and Low Carbohydrate Diet on Clinical Status in Patients With Heart Failure|The Effects of a High Fat and Low Carbohydrate Diet on Clinical Status in Patients With Heart Failure||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|May 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02150798||43716|
NCT02146807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH132802|Laser Treatment of Tattoos With Pico Laser|LASER TREATMENT OF TATTOOS WITH A DUAL WAVELENGTH PICOSECOND LASER||Syneron Medical|No|Completed|October 2013|||May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146807||44022|
NCT02146820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF13661|Picosecond Laser for Ttreatment of Benign Pigmented Lesions|LASER TREATMENT OF BENIGN PIGMENTED LESIONS WITH A DUAL WAVELENGTH PICOSECOND LASER||Syneron Medical|No|Completed|December 2013|||May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146820||44021|
NCT02147106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDEO-NET-2014|Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study|Use of Video Consultation in Follow-up Care for Patients With a NeuroEndocrine Tumor: a Feasibility Study (VIDEO-NET Study)|VIDEO-NET|University Medical Center Groningen|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Neuroendocrine tumor patients (grade 1 and 2) whose medical condition allows        videoconsultation.|December 2015|December 1, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02147106||43999|
NCT02147366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-13440|Indian Instrumental Music in Hypertension|Role of Music in Non Pharmacological Management of Hypertension|MIH|MS Ramaiah Medical College & Hospitals|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 24, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147366||43979|
NCT02147600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC UZG 2013/1148|Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients|Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients||University Hospital, Ghent|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|75|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|-  Primary care clinic          -  University Hospital          -  Private dermatology practice|June 2015|June 3, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147600|1 Day|43961|
NCT02148380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chest20140001|Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial|Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial||Shanghai Chest Hospital|No|Recruiting|May 2014|July 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02148380||43901|
NCT02156401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCM-2013EPI02|VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE|VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism|VTEval|Johannes Gutenberg University Mainz|No|Recruiting|April 2013|July 2023|Anticipated|July 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|Serum, Na-Citrated Plasma, EDTA-Plasma, Lit-Heparin, DNA, RNA, Urine|Both|18 Years|N/A|No|Probability Sample|Individuals either with clinically suspected or incident diagnosis of VTE|April 2015|April 23, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02156401||43287|
NCT02156414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-2013|Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer|Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer in Bogota Colombia.|LNIEPLCLPC|Javeriana University|Yes|Completed|March 2013|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Male|18 Years|N/A|No|Probability Sample|Patients with clinical localized prostate cancer who undergo a radical prostatectomy in        the 3 centers. Hospital Universitario San Ignacio, Hospital Fundacion Santa fe de Bogota,        Fundacion Cardioinfantil.|April 2015|April 21, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02156414|1 Month|43286|
NCT02156427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13INT/VIT01|A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism)|||Laboratoires Genévrier|Yes|Recruiting|May 2014|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02156427||43285|
NCT02157987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004390-27|Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose|Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose|EROSB|University Hospital, Caen|Yes|Recruiting|December 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2015|January 26, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157987||43165|
NCT02158247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJSMAN-01|Determining the Depth of Endotracheal Tube Insertion|||The Catholic University of Korea||Completed|January 2012|||July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|176|||Both|20 Years|90 Years|No|Probability Sample|Patients who are taking operation in the university hospital|June 2014|June 23, 2014|June 5, 2014||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT02158247||43145|
NCT02157051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9140|Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients||University of Washington|No|Recruiting|June 2015|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|June 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157051||43237|
NCT02157350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-4202-ID-2018|The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT|A Prospective Study to Identify Predictive Factors for Progression and Regression of Proliferative Diabetic Retinopathy in Patients Receiving Standard Panretinal Laser Photocoagulation.|IMPETUS-D|Odense University Hospital|Yes|Active, not recruiting|August 2014|May 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|90 Years|No|||December 2015|December 11, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157350||43214|
NCT02157636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610-03|A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma|A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma||Constellation Pharmaceuticals|No|Recruiting|July 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157636||43192|
NCT02157649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGU506|Single Dose Trial of Extended Release Combination Tablet Codeine and Guaifenesin|An Open-Label, Single-Dose, Crossover Comparative Bioavailability and Pharmacokinetic Study of Codeine Phosphate/Guaifenesin Extended-Release Tablet With Immediate-Release Tablet||Nexgen Pharma, Inc|No|Completed|June 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157649||43191|
NCT02158234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17799|Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck|A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|November 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02158234||43146|
NCT02155699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU 14-0200|Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis|Exercise and Markers of Medial Temporal Health in Youth at Ultra High-risk for Psychosis||University of Colorado, Boulder|Yes|Recruiting|July 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|16 Years|24 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02155699||43341|
NCT02159326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17309|Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women|Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold Crossover Design||Bayer|No|Completed|June 2014|July 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|31|||Female|52 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159326||43062|
NCT02149979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Katzir #1|Closure of Skin Incision Using CO2 Laser|Closure of Skin Incision Using CO2 Laser||Tel Aviv University|No|Completed|March 2007|January 2009|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02149979||43779|
NCT02150525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09145|Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors|A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|August 2010|||January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|52|||Female|45 Years|65 Years|No|||May 2014|May 26, 2014|August 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150525||43737|
NCT02150304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDPHAMINOPHYLLINE|Aminophylline Prophylaxis For Postdural Puncture Headache|Phase IV Study of Intravenous Aminophylline During Spinal Anesthesia||Diskapi Yildirim Beyazit Education and Research Hospital|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|100|||Female|18 Years|45 Years|No|Probability Sample|patient records form who experinced headache after caserean section with spinal anesthesia        were retrospectively evaluated|August 2015|August 4, 2015|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02150304||43754|
NCT02150811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131119|Observational Study of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome|Longitudinal Change of Distribution Pattern of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome||Asan Medical Center|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|N/A|No|Non-Probability Sample|Tertiary care clinic|December 2015|December 29, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02150811|1 Year|43715|
NCT02150824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.4|Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Three BI 187004 Doses Given Once Daily as Mono-therapy and of the Highest BI 187004 Dose Given Once Daily as Add on Treatment to Metformin Over 28 Days in Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|July 2014|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|103|||Both|18 Years|80 Years|No|||August 2015|August 12, 2015|May 28, 2014||||No||https://clinicaltrials.gov/show/NCT02150824||43714|
NCT02146833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-007|SHIP (Selinexor in Hormone Insensitive Prostate Cancer)|A Multi-Center, Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|SHIP|Karyopharm Therapeutics, Inc|No|Terminated|May 2014|July 2017|Anticipated|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|May 13, 2014|Yes|Yes|Due to enrollment challenges. The termination is not a consequence of any safety concern.|No||https://clinicaltrials.gov/show/NCT02146833||44020|
NCT02146846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kerman-001-FOPPT|Population Pharmacokinetics of Imatinib in CML Patients in Iran|Population Pharmacokinetics of Imatinib in CML Patients in Iran||Kerman University of Medical Sciences|Yes|Enrolling by invitation|October 2012|July 2014|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|70 Years|No|Probability Sample|Patients with approved diagnosis of chronic myeloid leukemia taking Imatinib as treatment|May 2014|May 21, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02146846||44019|
NCT02147119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG13/32/30205|Radial Artery Function Following Trans-radial Cardiac Catheterisation|Radial Artery Function Following Trans-radial Cardiac Catheterisation||University of Edinburgh|No|Recruiting|March 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|51|||Both|18 Years|85 Years|No|Non-Probability Sample|Stable outpatient population attending for angiography|March 2014|May 23, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02147119||43998|
NCT02147132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-7275|Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients|A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients||University of Cincinnati||Enrolling by invitation|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147132||43997|
NCT02147379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00290|Lurasidone and Cognition in Bipolar I Disorder|Changes in Cognitive Functioning in Euthymic Bipolar Patients Treated With Lurasidone Versus Treatment as Usual; A Randomized, Open-Label Study.||University of British Columbia|No|Completed|May 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|19 Years|65 Years|No|||December 2015|December 2, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02147379||43978|
NCT02117024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS110-201|A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer|A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease||Heat Biologics|Yes|Active, not recruiting|July 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|123|||Both|18 Years|N/A|No|||June 2015|September 1, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117024||46304|
NCT02156141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-035|High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy|High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy|HIT in Kennedy|Rigshospitalet, Denmark|No|Not yet recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156141||43307|
NCT02156154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-241|Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications|Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications||The Cleveland Clinic|No|Recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|528|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156154||43306|
NCT02158013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-020|Treatment Of Chronic Anal Fissure|Treatment Of Chronic Anal Fissure (TOCA): a Randomized Clinical Trial on Levorag® Emulgel Versus Diltiazem Gel 2%|TOCA|Bispebjerg Hospital|No|Recruiting|September 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158013||43163|
NCT02158273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA012602-14A1|Medication Development in Alcoholism: Investigating PPAR Agonists|Medication Development in Alcoholism: Investigating PPAR Agonists||The Scripps Research Institute|No|Recruiting|May 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|November 24, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158273||43143|
NCT02158286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS2010|Paracetamol Absorption Technique as a Method for Measuring Gastric Tube Outlet|Validation of Paracetamol Absorption Technique as a Method for Measuring Gastric Tube Outlet to Golden Standard, to Scintigraphy. A Pilot Study||Region Skane||Completed|January 2012|March 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients where it had past at least two years since they had underwent an Ivor Lewis        esophagectomy with gastric pull-up reconstruction.|May 2014|June 4, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158286||43142|
NCT02158520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCRU RU261206I|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery|Randomized Phase II Study of AB (Nab-paclitaxel [Abraxane™], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma||Academic and Community Cancer Research United|Yes|Active, not recruiting|October 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||November 2015|December 30, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158520||43124|
NCT02158260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|capsule endoscopy20140107|A New Method To Reduce Gastric Missing Areas in Capsule Endoscopy|A New Method To Reduce Gastric Missing Areas in Capsule Endoscopy: a Single Center, Prospective and Self-controlled Trial||Nanfang Hospital of Southern Medical University|Yes|Recruiting|September 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|71|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02158260||43144|
NCT02158494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0002|Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury|Cranial Nerve Noninvasive Neuromodulation Using the PoNS for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury||University of Wisconsin, Madison|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02158494||43126|
NCT02158507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F131219003 (UAB 1372)|Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer|An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer||University of Alabama at Birmingham|Yes|Recruiting|July 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|19 Years|N/A|No|||October 2015|October 20, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158507||43125|
NCT02158793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00550|Craniomaxillofacial Allotransplantation|Craniomaxillofacial Allotransplantation||New York University School of Medicine|Yes|Recruiting|June 2014|June 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|64 Years|No|||December 2015|December 1, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158793||43103|
NCT02159625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G120243/S001|Abdominal Compression Elastic Support (ACES)|A Study of the Use of Abdominal Compression Elastic Support (ACES) for Hemodialysis Patients|ACES|Global Monitors, Inc.|Yes|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159625||43039|
NCT02155374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47135.048.13|Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy|Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy|GluCon-Chemo|Slotervaart Hospital|No|Completed|May 2014|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02155374||43366|
NCT02150291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2107|A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.|A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.||British University In Egypt|Yes|Recruiting|May 2014|November 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|120|||Both|N/A|N/A|No|||May 2014|May 27, 2014|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150291||43755|
NCT02150317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2013-001-08|Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma|TACE|Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||May 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150317||43753|
NCT02150538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parere Unico 86/13|BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study|BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study|REAL-CRT|S. Anna Hospital|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||May 2014|May 26, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02150538||43736|
NCT02150551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOMP|Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease|Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease||Children's Research Institute|No|Recruiting|February 2015|November 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|5 Years|22 Years|No|||September 2015|September 26, 2015|January 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150551||43735|
NCT02147145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProGIST 1|Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs)|Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs)||Washington University School of Medicine||Completed|August 2008|January 2014|Actual|August 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|187|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (>18 years of age) referred for EUS evaluation of incidentally discovered        foregut SEL at a two tertiary care centers between 8/2008 and 8/2012.|May 2014|May 23, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147145|3 Years|43996|
NCT02147158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1208|A Study of the Safety and Efficacy of Intermittent Ulipristal Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas||Watson Pharmaceuticals||Active, not recruiting|January 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|400|||Female|18 Years|50 Years|No|||December 2015|December 23, 2015|May 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147158||43995|
NCT02147626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001953|Heart Health 4 Moms|Heart Health 4 Moms: Engaging Women With a Recent History of Preeclampsia to Reduce Their Cardiovascular Disease Risk|HH4M|Brigham and Women's Hospital|Yes|Recruiting|July 2014|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02147626||43959|
NCT02147860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17375|Full Day and Night Closed-Loop With DiAs Platform|Full Day and Night Closed-Loop With DiAs Platform||University of Virginia|Yes|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|10 Years|35 Years|No|||November 2015|November 9, 2015|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02147860||43941|
NCT02148133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200926|A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia|A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia||Novartis|No|Active, not recruiting|July 2014|September 2017|Anticipated|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|79 Years|No|||March 2016|March 9, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02148133||43920|
NCT02117037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04|Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes|Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes||Assistance Publique Hopitaux De Marseille|No|Recruiting|June 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|180|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02117037||46303|
NCT02117050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136-586|RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate|RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)|RESOunD|EMD Serono||Terminated|June 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|April 15, 2014|Yes|Yes|recruitment challenges|No||https://clinicaltrials.gov/show/NCT02117050||46302|
NCT02117349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-007|Safety and Efficacy Study of Fibrocaps to Treat Surgical Bleeding in Children|A Phase 2, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ (Raplixa™) in Intraoperative Surgical Hemostasis in a Pediatric Population||ProFibrix, Inc.|Yes|Recruiting|July 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Both|N/A|17 Years|No|||August 2015|August 6, 2015|April 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02117349||46279|
NCT02157662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K10|GISSI Outliers CAPIRE|Coronary Atherosclerosis in Outlier Subjects: Protective and Individual Risk Factor Evaluation|CAPIRE|Gruppo di Ricerca GISSI|No|Active, not recruiting|January 2011|July 2018|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|544|Samples With DNA|whole blood and serum. Lipid profile Metabolic profile (HbA1c, HOMA index) inflammatory      profile (CRP, LP-PLA, pentraxine 3, MCP-1, IL-8, IL-10, IL-5, P-selectin, ICAM, VCAM-1,      CD40L, TIMP-1, MMP Genetic profile: chromosome polymorphism 9 (9p21)|Both|45 Years|75 Years|No|Probability Sample|Male and female subjects between 45 and 75 years old who, in the absence of any previous        clinical manifestations of ischemic heart disease, will undergo coronary arteries study.|May 2014|June 4, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157662||43190|
NCT02158026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 3|Evaluation of the Role of Follicular Sensitivity Index in the Prediction of Pregnancy in Women Undergoing ICSI/IVF Without Polycystic Ovarian Syndrome|Evaluation of the Role of Follicular Sensitivity Index in the Prediction of ICSI/IVF Outcome in Women Without Polycystic Ovarian Syndrome||Cairo University|Yes|Recruiting|June 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|20 Years|40 Years|No|Non-Probability Sample|1000 women with infertility without polycystic ovarian syndrome who are already decided to        be treated with ICSI will be recruited from Cairo university hospitals and Dar Al-Teb        subfertility centre.|January 2016|January 26, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158026||43162|
NCT02158299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinical trail003|Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer|Contrast The Role of Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||Recruiting|October 2013|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|3|||Female|18 Years|N/A|No|||June 2014|June 4, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02158299||43141|
NCT02158533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-205|A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study)||Alkermes, Inc.|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|385|||Both|18 Years|70 Years|No|||February 2016|February 3, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158533||43123|
NCT02158806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspirin4VLU|Low Dose Aspirin for Venous Leg Ulcers|Low Dose Aspirin for Venous Leg Ulcers: a Randomised Trial|Aspirin4VLU|University of Auckland, New Zealand|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|354|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158806||43102|
NCT02159079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140582|A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)|A Phase II/III Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction|BALANCE|Vanderbilt University|No|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159079||43081|
NCT02159638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-387191|Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes|Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes||Vastra Gotaland Region|No|Recruiting|May 2013|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159638||43038|
NCT02159651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGI01|A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia|Specified Drug Use-results Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis||Astellas Pharma Inc|No|Recruiting|April 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with interstitial pneumonia associated with polymyositis/dermatomyositis who        treated with Prograf|March 2016|March 23, 2016|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159651||43037|
NCT02159664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/14-03-25/4354|Influence of Didgeridoo Pratice on UA Obstruction Levels in Moderate OSA|Influence of Didgeridoo Pratice on Upper Airways Obstruction Levels in Moderate Obstructive Sleep Apnea Patients||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|December 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159664||43036|
NCT02155959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|toric_rotation_acrylic|Performance of a Single-piece Toric Acrylic Intraocular Lens|Rotational Stability of a Single-piece Toric Acrylic Intraocular Lens: a Pilot Study||Vienna Institute for Research in Ocular Surgery|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|21 Years|N/A|No|Probability Sample|patients who were scheduled for cataract surgery and had corneal astigmatism|June 2014|June 2, 2014|June 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02155959||43321|
NCT02155400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-28535|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||June 2, 2014|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155400||43364|
NCT02150005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA71/06|Non-surgical Periodontal Treatment on Hemogram, Lipid and Glycemic Profiles in Patients With Coronariopathies|Effects of Non-surgical Periodontal Treatment on Hemogram, Lipid and Glycemic Profiles of Patients With an Indication for Surgical Coronary Revascularization||Universidade Veiga de Almeida|No|Completed|January 2009|||December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|35 Years|N/A|No|||May 2014|May 25, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02150005||43777|
NCT02150018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0193|Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography|Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography|NIVIT|University Hospital, Clermont-Ferrand||Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients requiring non invasive ventilation|July 2015|July 30, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150018||43776|
NCT02150031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/202 CHX bacteraemia|Bacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols|Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols||University of Santiago de Compostela|No|Completed|December 2010|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 25, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02150031||43775|
NCT02150837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED 017|Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans|A Retrospective Chart Review to Assess Weight Loss in Overweight and Obese Adults Using Either the 5 & 2 & 2 Meal Replacement Plan or the 4 & 2 & 1 Meal Replacement Plan at Medifast Weight Control Centers||Medifast, Inc.|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|372|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is a systematic retrospective chart review of existing MWCC charts located in        Maryland, Texas, Florida or Pennsylvania for MWCC members who used either the Medifast 5 &        2 & 2 Plan or the Medifast 4 & 2 & 1 Plan for weight loss.        Charts will be reviewed for members that started either the 5 & 2 & 2 Plan or the 4 & 2 &        1 Plan on or after January 1, 2012. This start date was chosen because it represents the        date when Medifast began using the current versions of the 5 & 2 & 2 Plan and the 4 & 2 &        1 Plan. Only charts of those members who are no longer in the active weight loss phase of        their program at the MWCC will be considered for the study.|May 2014|May 27, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02150837||43713|
NCT02146859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si123|Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia|Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia||Mahidol University|No|Recruiting|May 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|222|||Both|18 Years|N/A|No|Non-Probability Sample|patient who are schedule for general anesthesia and use neuromuscular blocking agents        (NMBAs)|April 2015|April 11, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02146859||44018|
NCT02119871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKML-004|Comparative Effectiveness of Unilateral vs. Bilateral Pulmonary Collapse in Cardiac De-airing|Comparative Effectiveness of Unilateral Versus Bilateral Pulmonary Collapse in De-airing During Open Left Heart Surgery.||Lund University|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 21, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119871||46086|
NCT02120365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014397|Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence|Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence||Yale University|No|Recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|21 Years|55 Years|No|||March 2016|March 23, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120365||46048|
NCT02120378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WH142014|Fetal Viability Estimation in Egypt|Correlation Between Fetal Gestational Age, Viability and Survival Rates in Egypt||Woman's Health University Hospital, Egypt|No|Recruiting|April 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|40 Years|No|Non-Probability Sample|females presenting to the causality department in kasr el Aini hospital presenting with        signs of preterm labor ( uterine contractions before completing 38 weeks of gestation)|March 2015|March 27, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120378|3 Months|46047|
NCT02120612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOH32414|Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program|Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program||Edward Hospital|No|Recruiting|April 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects who have been diagnosed with a DSM opioid use disorder enrolled in an        outpatient treatment program for the substance use disorder.|April 2014|April 22, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02120612||46029|
NCT02120846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flywheel stroke|Effects of Flywheel Resistance Training on Cognitive Function in Stroke Patients|Effects of Flywheel Resistance Training on Cognitive Function in Stroke Patients|KAROL|Karolinska Institutet|Yes|Completed|January 2014|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Both|40 Years|N/A|No|||August 2014|August 7, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02120846||46011|
NCT02117375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00333-42|EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients|EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients|EMISEP|Rennes University Hospital|Yes|Recruiting|January 2014|July 2022|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02117375||46277|
NCT02157688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFE Folliculitis Decalvans|Impact of Staphylococcus Aureus on Folliculitis Decalvans|Role of Staphylococcus Aureus on Folliculitis Decalvans. A Comparative Bacteriological Study.|SAFE|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with Folliculitis Decalvans|March 2015|March 17, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02157688||43188|
NCT02158000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed 5|Aspiration of Excessive Endometrial Fluid at the Day of Ovum Retrieval Plus Diosmin in (ICSI) Cycles|Aspiration of Excessive Endometrial Fluid at the Day of Ovum Retrieval Plus Diosmin in (ICSI) Cycles||Benha University|Yes|Completed|July 2013|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|23 Years|48 Years|No|||January 2016|January 31, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158000||43164|
NCT02158559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH-140318-01|the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.|A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI(ST- Elevation Myocardical Infarction) After the PTCA Surgery.|Danhong|Beijing Bozhiyin T&S Co., Ltd.|Yes|Active, not recruiting|March 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||June 2014|June 5, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02158559||43121|
NCT02158546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-206|A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)||Alkermes, Inc.|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|70 Years|No|||February 2016|February 3, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158546||43122|
NCT02158819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISHE.13|Visionaire Health Economics Study Comparing Economic Outcomes Between Visionaire and Standard Instrumentation|A Prospective, Randomised Pilot Study to Compare Health Economic Outcomes Using a Patient-matched Cutting Guide Versus Standard Instrumentation in Total Knee Arthroplasty.|VISHE13|Smith & Nephew, Inc.|Yes|Recruiting|June 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02158819||43101|
NCT02155387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICSLUWA2014|Extravascular Lung Water and Pulmonary Vascular Permeability After Minimally Invasive Cardiac Surgery|Extravascular Lung Water Index and Pulmonary Vascular Permeability Index Assessed by the Transpulmonary Thermodilution Method in Patients After Minimally Invasive Cardiac Surgery With Cardiopulmonary Bypass and One Lung Ventilation||University Hospital Freiburg|No|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients between 18 and 75 years who need one of following surgeries: coronary artery        bypass graft surgery with CPB, resection of pulmonary metastases with OLV, or minimally        invasive mitral valve surgery with CPB and OLV.|June 2014|June 1, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02155387||43365|
NCT02159690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neoadj enz/abi/dut/deg|A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy|A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy||Johns Hopkins University||Withdrawn|September 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||January 2015|January 22, 2015|June 6, 2014|No|Yes|loss of funding|No||https://clinicaltrials.gov/show/NCT02159690||43034|
NCT02155413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14-284|Audit of Tolerability and Safety of Acute Pain Service|Retrospective Study to Evaluate the Tolerability and Safety of Acute Pain Service at Queen Mary Hospital Between 2009 to 2012||The University of Hong Kong|No|Recruiting|June 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|7500|||Both|N/A|N/A|No|Non-Probability Sample|Postoperative patients who were cared by the Acute Pain Service, Pain Management Team,        Department of Anaesthesiology, Queen Mary Hospital between 2009 to 2012.|June 2014|June 3, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155413||43363|
NCT02150330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS13-CT11-17|Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve|Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve||Taipei Veterans General Hospital, Taiwan|Yes|Completed|January 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|May 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150330||43752|
NCT02119442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001008|Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves|Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves||University of California, Los Angeles|No|Recruiting|August 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||November 2015|November 30, 2015|April 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02119442||46119|
NCT02119650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-266|Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer|A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent||Incyte Corporation|Yes|Active, not recruiting|March 2014|February 2017|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119650||46103|
NCT02120144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00829-36|Effect of Observation Plus Imagination of Gait on Stride Variability in Young and Older Adults|Effect of Observation Plus Imagination of Gait on Stride Variability in Young and Older Adults|OBI|University Hospital, Angers|Yes|Recruiting|May 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2014|July 30, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02120144||46065|
NCT02120118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140101D|Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors|A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Withdrawn|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|85 Years|No|||October 2014|June 8, 2015|March 17, 2014||No|Taiwan FDA asked for seperating this protocol into one disease site per protocol.|No||https://clinicaltrials.gov/show/NCT02120118||46067|
NCT02120391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 - 0726|Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application|Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application||University of Wisconsin, Madison|No|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|99|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02120391||46046|
NCT02120404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120912|Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock|Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock|THANE|Assistance Publique - Hôpitaux de Paris|Yes|Suspended|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||May 2015|September 4, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120404||46045|
NCT02120625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NimbusConcepts - LRFNV|Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies|Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies - an MRI and EMG Confirmation Study||Nimbus Concepts, LLC|No|Enrolling by invitation|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Appropriate study subjects will be identified, upon initiation of care (MD/DO). They will        have pain of greater than three months duration, within the current pain episode. They        will have no radicular/neurological deficits or focal disc herniation and/or stenosis,        with correlating radicular symptoms. They will not have any known history of ongoing        radiculopathy, prior epidural spinal injections relieving their current pain, or prior        lumbar surgery. These prospective patients will then undergo diagnostic medial branch        blocks to determine if they are appropriate candidates for radiofrequency neurotomies and,        furthermore, might also be candidates for study inclusion.|October 2015|October 8, 2015|April 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120625||46028|
NCT02120859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKJ-TCP-2|Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty|Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography|OCTOPUS-2|University of Jena|Yes|Completed|October 2012|April 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 20, 2014|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02120859||46010|
NCT02117388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27264|Treatments for Insomnia: Mediators, Moderators and Quality of Life|Treatments for Insomnia: Mediators, Moderators and Quality of Life||Stanford University|No|Enrolling by invitation|September 2013|December 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 29, 2014|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02117388||46276|
NCT02157701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEWC2600|Polyherbal Capsule Formulation for Joint Health|Polyherbal Capsule Formulation for Joint Health: a Multicenter, 2-arm, Randomized, Double-blind, Placebo-controlled Study||NewChapter, Inc.|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|108|||Both|25 Years|75 Years|No|||October 2015|October 12, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157701||43187|
NCT02157714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX002-CL002|Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease||Prothena Biosciences Limited||Recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|40 Years|80 Years|No|||March 2016|March 22, 2016|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157714||43186|
NCT02158338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|389127|Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?|Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?||State University of New York - Upstate Medical University|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|May 2015|May 29, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158338||43138|
NCT02158832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIREB 14-089|Acupuncture for Lymphedema Secondary to Breast Cancer Treatment|Rehabilitation of Breast Cancer Treatment Related Lymphedema Using Electro-acupuncture: A Randomized Controlled Trial||McMaster University|No|Recruiting|April 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02158832||43100|
NCT02159378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD008-14|Fructosamines and Gestational Diabetes (FRUCTO)|Fructosamines and Gestational Diabetes (FRUCTO)|FRUCTO|Centre Hospitalier Departemental Vendee|No|Recruiting|July 2014|March 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159378||43058|
NCT02159417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00704-41|Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail|Feasibility of the Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail "La Santé" (Maison d'arrêt Paris La Santé)"|EPRIDIA|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2013|February 2015|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Male|18 Years|N/A|No|||June 2014|April 20, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159417||43055|
NCT02159677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBP-001-2012|Electrical Impedance Myography of Neck and Low Back Pain|Electrical Impedance Myography for the Assessment of Neck and Low Back Pain|EIM|Skulpt, Inc.|Yes|Completed|January 2014|November 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|178|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Neck and Low Back Pain Subjects|January 2016|January 20, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159677|1 Day|43035|
NCT02155738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFD-C-14-009|IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair|The Impact of IV Acetaminophen on Postoperative Pain in Women Undergoing Pelvic Organ Prolapse Repair: A Double-Blind Randomized Placebo Controlled Trial||University of Pittsburgh|No|Recruiting|July 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155738||43338|
NCT02150564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-ACTREC 101|3D Ultra Sound for Resection of Brain Tumors|Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study|Sono RCT|Tata Memorial Hospital|Yes|Recruiting|March 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02150564||43734|
NCT02119884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LB-2014|Hemodynamic Effects of Terlipressin and High Dose Octreotide|Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial|HEofT&O|Shanghai Zhongshan Hospital|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||April 2014|April 22, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02119884||46085|
NCT02120157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13161|Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies|A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T Cell Replete Bone Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2014|January 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|31|||Both|6 Months|25 Years|No|||December 2015|December 17, 2015|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120157||46064|
NCT02120170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIPO|Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation|The Effect of Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation: Prospective Randomized Controlled Trial||Soonchunhyang University Hospital|Yes|Not yet recruiting|April 2014|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|356|||Both|20 Years|N/A|No|||April 2014|April 21, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02120170||46063|
NCT02120131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcttm|Trapezoidal Flap vs. Envelope Flap in Mandibular Third Molar Extraction.|Trapezoidal Flap Versus Envelope Flap in Impacted Mandibular Third Molar Extraction||University of Firenze and Siena, Napoli, Italy|No|Completed|February 2012|March 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|a sample of 50 patients requiring mandibular third molar extracion was selected for the        study. Healthy patients with mild symptoms of pericoronitis affecting at least 1        mandibular third molar were included in the study|April 2014|April 17, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02120131||46066|
NCT02120638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2013-260|Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide|Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide||Huashan Hospital|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||April 2014|April 21, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02120638||46027|
NCT02120872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2011-2012/E|Platelet Rich Fibrin Combined With Simvastatin for Treatment of Intrabony Defect in Chronic Periodontitis|Platelet - Rich Fibrin Combined With 1.2mg Simvastatin for the Treatment of 3 - Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|February 2013|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 19, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120872||46009|
NCT02117063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16132|Go Girls! Fitness Support Group Intervention Effectiveness Study|Go Girls! Fitness Support Group Intervention Effectiveness Study|CBS002|University of Virginia|No|Recruiting|April 2012|April 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|10 Years|18 Years|No|||April 2014|April 15, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02117063||46301|
NCT02117076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLS and Gabapentin or Horizant|Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome|Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome||University of South Florida|No|Recruiting|April 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02117076||46300|
NCT02117661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-Carnitine-01|Carnitine for the Treatment of Atherosclerosis.|ECoM Study: Effect of Carnitine Supplementation on Progression of Carotid Plaque in the Metabolic Syndrome.|ECoM|Queen's University|Yes|Recruiting|January 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02117661||46256|
NCT02158312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-006C|Bihemispheric Modulation of the Motor Cortex by Transcranial Direct Current Stimulation in Subacute Stroke Patients|Bihemispheric Modulation of the Motor Cortex by Single-session Transcranial Direct Current Stimulation During Training in Subacute Stroke Patients||Taipei Veterans General Hospital, Taiwan|No|Recruiting|May 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|20 Years|80 Years|No|||June 2014|June 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158312||43140|
NCT02158884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-2-0032|PRIORITI-MTF Study- Testing Patient Response to the IDEO|Patient Response to an Integrated Orthotic and Rehabilitation Initiative for Traumatic Injuries for the Military Treatment Facilities (PRIORITI-MTF)|PRIORITI-MTF|Major Extremity Trauma Research Consortium|Yes|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|60 Years|No|||February 2016|February 4, 2016|June 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02158884||43096|
NCT02158845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIU-LNG 001|Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis|Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial|SIU-LNG|University of Sao Paulo|No|Completed|February 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|44|||Female|18 Years|40 Years|No|||January 2015|January 17, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02158845||43099|
NCT02159092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01DA037661-02|The Role of Contingency Management in Waterpipe Smoking Cessation|The Role of Contingency Management in Waterpipe Smoking Cessation||Washington State University|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159092||43080|
NCT02159105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00080804|Abdominal Ultrasound Assessment in the Post-cesarean Patient|Abdominal Ultrasound Assessment in the Post-cesarean Patient||Northwestern University|No|Recruiting|June 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|12 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing non-emergent cesarean delivery at Prentice Women's Hospital, who speak        English and are able to provide consent, will be eligible to participate.|February 2016|February 1, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159105||43079|
NCT02159118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012|A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children|A Trial of the Vidacare Powered Bone Marrow Aspiration and Core Biopsy System (OnControl by Vidacare) Compared to Traditional Manual Devices in Children||Vidacare Corporation|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|44|||Both|2 Years|18 Years|No|||August 2014|August 8, 2014|May 15, 2014|No|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT02159118||43078|
NCT02159391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 0691-2013|The Efficacy of Brief Motivational Interviewing for Trauma Patients Related to Alcohol or Other Abuse Drugs.|The Efficacy of Brief Motivational Interviewing for Trauma Patients Related to Alcohol or Other Abuse Drugs.|MOTIVA|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental|No|Active, not recruiting|June 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|86|||Both|18 Years|55 Years|No|||September 2015|September 24, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159391||43057|
NCT02159404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtOmicsSeasons01|Seasonal Differences in Nasal Mucus Proteome and Impact of Immunotherapy|||Medical University of Graz||Recruiting|April 2015|||August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|88|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Allergic Rhinoconjunctivitis Healthy controls|March 2016|March 3, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159404||43056|
NCT02159443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATA|Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody|Characterization of Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody||St. Jude Children's Research Hospital|No|Recruiting|July 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|DNA from tumor tissue. Blood serum samples.|Both|N/A|N/A|No|Non-Probability Sample|Participants will have a diagnosis within the Ewing family of tumors, melanoma,        neuroblastoma, or osteosarcoma and will receive treatment with hu14.18K322A.|February 2016|February 3, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159443||43053|
NCT02155426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLCCTC-SUMS01|Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy|A Multicenter, Prospective, Observational Trial on the Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With 1st or 2nd Line Line Chemotherapy and Targeted Therapy||Sun Yat-sen University|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Subjects' blood sample will be retained to evaluate the dynamic CTC count during the      treatment|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with histologically documented, locally advanced or recurrent (stage IIIb and not        amenable or combined modality treatment) or metastatic (stage IV) non-small cell lung        cancer, who will receive routine first or second line chemotherapy, or EGFR-TKI for those        with EGFR sensitive mutant type.|April 2015|April 22, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155426|2 Years|43362|
NCT02155439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140260M|Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study|Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study||Tampere University Hospital|Yes|Not yet recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|June 2, 2014|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02155439||43361|
NCT02159729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-08-12|Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|Long-term Follow-up Study of Subjects Who Completed Kythera-sponsored Trials of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Active, not recruiting|February 2009|February 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|205|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159729||43031|
NCT02155751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102573|Bringing NELIP for Obese Pregnant Women Into Clinical Practice|Bringing an Evidence-based Nutrition and Exercise Lifestyle Intervention Program (NELIP) for Obese Pregnant Women Into Clinical Practice||Lawson Health Research Institute|No|Recruiting|July 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Female|18 Years|N/A|No|||May 2015|May 5, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02155751||43337|
NCT02156011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-90|Comprehensive Assessment of the Musculoskeletal System|Kinematics and Joint Loading in Total Knee Arthroplasty|CAMS-Knee|Swiss Federal Institute of Technology|No|Active, not recruiting|June 2014|December 2017|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|6|||Both|50 Years|80 Years|No|Non-Probability Sample|Patients after total knee replacement surgery from the Charité- Universitätsmedizin in        Berlin, Germany|November 2015|November 16, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156011||43317|
NCT02119182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01NS086090-01|Transforming Research and Clinical Knowledge in Traumatic Brain Injury|Transforming Research and Clinical Knowledge in Traumatic Brain Injury|TRACK-TBI|University of California, San Francisco|No|Recruiting|February 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3000|Samples With DNA|Plasma, Serum, DNA, and RNA will be collected at the time of injury. Plasma, Serum, and RNA      will be collected at Day 3 and Day 5 if patient is in the hospital, and at 2 weeks and 6      months post-injury. Samples will be banked at -80 degrees Celsius.|Both|N/A|100 Years|No|Non-Probability Sample|We will enroll adult patients of all ages presenting to the Emergency Department with a        history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria,        in which the patient has sustained a traumatically induced* physiological disruption of        brain function, as manifested by ≥ one of the following:        Any period of loss of consciousness Any loss of memory for events immediately before or        after the accident Any alteration of mental state at the time of the accident (feeling        dazed, disoriented, and/or confused) Focal neurologic deficits that may or may not be        permanent        *Traumatically induced includes the head being struck, the head striking an object, or the        brain undergoing an acceleration/deceleration movement without direct external trauma to        the head.|December 2015|December 7, 2015|March 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02119182||46139|
NCT02119897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-611|Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation|Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2014|May 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|4 Years|25 Years|No|||October 2014|October 14, 2014|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119897||46084|
NCT02120456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1015|Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis||LEO Pharma|No|Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|224|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120456||46041|
NCT02120417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-268|A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer|A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer||Incyte Corporation|No|Active, not recruiting|March 2014|October 2017|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02120417||46044|
NCT02120651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TISSUCOL-012|Fibrin Monomer Compared With Hemostatic Sponge in the Integrity of the Graft During Tympanoplasty|Effect of the Fibrin Monomer in the Integrity of the Graft During Tympanoplasty Compared With the Effect of the Hemostatic Sponge|TISSUCOL|Instituto Mexicano del Seguro Social|Yes|Completed|January 2012|January 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|16 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02120651||46026|
NCT02120885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0215|An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial||Gastric cancer|Yonsei University|No|Recruiting|May 2013|December 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|20 Years|70 Years|No|||March 2014|April 22, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02120885||46008|
NCT02117089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITS/033/12|Upper Limb Rehabilitation After Stroke Assisted With a Hybrid Electrical Stimulation (ES)-Robot System|Biomechatronic System Using Electromyography (EMG)-Driven Neuromuscular Electrical Stimulation (NMES) for Upper Limb Rehabilitation||The Hong Kong Polytechnic University|Yes|Recruiting|October 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2015|March 22, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02117089||46299|
NCT02117102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLSTJEJUNUH|Effect of Use of a New Technique for Pediatric Urine Collection in ER|Effect of Use of a New Technique for Pediatric Urine Collection on the Length of Stay in the Emergency Department: Prospective Randomized Controlled Trial|BLST|Jeju National University Hospital|Yes|Not yet recruiting|May 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|170|||Both|6 Months|36 Months|No|||April 2014|April 15, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02117102||46298|
NCT02147236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402026356|Social Skills in Children With Autism Spectrum Disorders|A Randomized Trial of a Structured Social Skills Development Progam for Children With Autism Spectrum Disorders|SSD_ASD|Yale University|No|Completed|July 2003|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|44|||Both|8 Years|11 Years|No|||May 2014|May 21, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147236||43989|
NCT02158572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL23|Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System|A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)||Agile Therapeutics|No|Recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2100|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 2, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158572||43120|
NCT02158585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhang-001|Study of Lamotrigine to Treat Ménière's Disease|Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study||Dent Neuroscience Research Center|Yes|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158585||43119|
NCT02158364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247-012|Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination|Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Specified Drug-use Survey of Vaccinees After the Second Vaccination||Takeda|No|Completed|March 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3331|||Both|N/A|N/A|No|Non-Probability Sample|Measles/rubella|June 2014|June 4, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158364||43136|
NCT02158377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2011-08D|TM vs TSV Implants Loaded Early vs Conventional in Anterior and Posterior Areas|A Randomized Controlled Multicenter Study of Trabecular Metal Dental Implants vs.Tapered Screw-Vent Dental Implants Loaded Early vs. Conventionally in the Maxilla and Mandible.|TMEL|Zimmer, Inc.|No|Recruiting|March 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158377||43135|
NCT02158598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14-03-1896|Comparison of Changes in Serum 25(OH)D Concentrations Following Vitamin D Supplementation With Chewable Tablets Versus Pills|||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158598||43118|
NCT02158611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102081-F|Whole Person Care Research Program of the Suicide Cases Consultative Services|Whole Person Care Research Program of the Suicide Cases Consultative Services||Far Eastern Memorial Hospital|No|Enrolling by invitation|January 2014|||July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|20 Years|N/A|No|||June 2014|June 5, 2014|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02158611||43117|
NCT02159131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117011|Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects|An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects||ViiV Healthcare|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|July 2, 2015|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159131||43077|
NCT02158858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610-02|A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis|A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis||Constellation Pharmaceuticals||Recruiting|June 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02158858||43098|
NCT02159144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014Wze088|Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults|Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02159144||43076|
NCT02159456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|feed520|Continuous Versus Intermittent Enteral Feeding in Critically Ill Patients|Continuous Versus Intermittent Enteral Feeding in Critically Ill Patients: a Prospective, Randomized Controlled Trial||Seoul National University Hospital|Yes|Recruiting|May 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|20 Years|N/A|No|||June 2014|June 8, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159456||43052|
NCT02159742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06911|Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases|Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2011|||July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Prospective/retrospective data will be collected from medical records of patients who have        received PDT for neoplastic diseases.|January 2016|January 12, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159742||43030|
NCT02155465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-043|Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib|A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|19 Years|N/A|No|||October 2015|October 28, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155465||43359|
NCT02155452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC- ACTREC IRB project no 139|Fluorescence and Glioma Heterogeneity|Understanding the Mechanisms of ALA-induced Fluorescence in Malignant Gliomas - Exploring the Biological Basis of Tumoral Heterogeneity.|ALA glioma|Tata Memorial Hospital|Yes|Recruiting|May 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|25|Samples With DNA|The heterogeneity of fluorescence within malignant gliomas by sampling tissues from these      variable areas within the same tumor. These tissue samples will then be subjected to      pathological and biological analysis to assess proteins related to ALA metabolism and      correlated with the fluorescence emitted as well as levels of protoporphyrin IX in the      tissues.|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with malignant glioma|November 2015|November 3, 2015|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02155452||43360|
NCT02119663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-363|A Study of Ruxolitinib in Pancreatic Cancer Patients|A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)||Incyte Corporation|Yes|Active, not recruiting|April 2014|August 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119663||46102|
NCT02119910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072609|Technology-supported Behavioral Feeding Intervention|Development of a Manual-based, Technology-supported, Behavioral Feeding Intervention||Emory University|No|Completed|January 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Months|6 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02119910||46083|
NCT02150148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182508|Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors|Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors||University of Alabama at Birmingham|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|46|||Both|60 Years|N/A|No|||November 2015|February 5, 2016|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02150148||43766|
NCT02120430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 60/07|Promoting Child Development Practices in the First Year of Life Through a Video Administered at Two Different Times|Promoting Effective Child Development Practices in the First Year of Life Through a Video Administered at Two Different Times. A Randomized Controlled Trial||IRCCS Burlo Garofolo|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|105|||Both|N/A|N/A|No|||April 2014|April 18, 2014|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02120430||46043|
NCT02120443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVW400CS-05|ivWatch Model 400: Device Validation for Non-Infiltrated Tissues|ivWatch Model 400: Device Validation for Non-Infiltrated Tissues||ivWatch, LLC|Yes|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 23, 2014|April 18, 2014|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT02120443||46042|
NCT02120898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-3153-301|A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara® (Imiquimod) Cream, 2.5% in Subjects With Actinic Keratoses||Actavis Inc.|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|600|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02120898||46007|
NCT02117115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404063|Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|GVHD|Washington University School of Medicine|No|Completed|June 2014|May 2015|Actual|October 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|21|||Both|20 Years|60 Years|No|||June 2015|June 10, 2015|April 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02117115||46297|
NCT02150928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006|An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma||Jazz Pharmaceuticals||Withdrawn|May 2014|||June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|40 Years|No|||May 2015|May 11, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150928||43706|
NCT02117401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121101|A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients|A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients||Jiangsu Nhwa Pharmaceutical Co., Ltd.|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|16||Actual|1152|||Both|2 Months|14 Years|No|||July 2014|July 14, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02117401||46275|
NCT02117414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evera MRI|Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access|Evera MRI Clinical Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|April 2014|October 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|April 16, 2014|Yes|Yes||No|July 20, 2015|https://clinicaltrials.gov/show/NCT02117414||46274|
NCT02147002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB305/2012|Omega-3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3|Omega 3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3|Omega-3 acids|Collegium Medicum w Bydgoszczy|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147002||44007|
NCT02158065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9814|Impact of "Telecoaching Program" on Physical Activity in Patients With COPD|A 3-month Multicenter Randomized Trial to Evaluate the Efficacy of a Physical Activity Promotion Program on the Experience of Physical Activity in Patients With COPD (Mr PAPP)|MrPAPP|Katholieke Universiteit Leuven|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|40 Years|N/A|No|||April 2015|April 30, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158065||43159|
NCT02158390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05302014|Phenotypic Specific Communication Intervention for Children With Down Syndrome|Phenotypic Specific Communication Intervention for Children With Down Syndrome|Merck|Vanderbilt University|No|Recruiting|June 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|30 Months|54 Months|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158390||43134|
NCT02159157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12030|A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer|A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|June 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|99 Years|No|||October 2015|October 15, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159157||43075|
NCT02158871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSi14-385|Impact Study of Workplace Mental Health Education on Early Intervention for Healthcare Workers With Mental Health Issues|Beyond Silence: Comparing the Impact of Contact-based Education With Mental Health Literacy Training on Early Intervention for Healthcare Workers With Mental Health Issues||McMaster University|No|Completed|May 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|216|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02158871||43097|
NCT02159703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 40313|A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer|A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159703||43033|
NCT02159716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 31213|CART-meso in Mesothelin Expressing Cancers|Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||June 2014|February 5, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159716||43032|
NCT02155478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXF|Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study|Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study||Vienna Institute for Research in Ocular Surgery|No|Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|21 Years|N/A|No|||June 2014|June 3, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155478||43358|
NCT02156609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPCEMark|HeartMate PHP™ CE Mark Clinical Investigation Plan|HeartMate PHP™ CE Mark Clinical Investigation Plan|HM PHP CE Mark|Thoratec Corporation|Yes|Completed|June 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02156609||43271|
NCT02156622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0852|CID 0911 - Adaptation of A Depression Treatment Intervention for HIV Patients in Cameroon|CID 0911 - Adaptation of A Depression Treatment Intervention for HIV Patients in Cameroon|ADEPT|University of North Carolina, Chapel Hill|Yes|Completed|July 2009|November 2012|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|Assessed CD4 counts and viral loads|Both|18 Years|65 Years|No|Non-Probability Sample|HIV-infected patients attending the Bamenda Regional Hospital AIDS Treatment Center|June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156622|12 Months|43270|
NCT02155790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI 12-001|The Peregrine Study: A Safety and Performance Study of Renal Denervation|A Safety and Performance Study of Renal Denervation by Neurolysis Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter||Ablative Solutions, Inc.|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||January 2016|January 18, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02155790||43334|
NCT02155803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCMAJCA2014|ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study|ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study||Albany Medical College|No|Not yet recruiting|February 2015|November 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02155803||43333|
NCT02119676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB18424-267|Study of Ruxolitinib in Colorectal Cancer Patients|A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer||Incyte Corporation|Yes|Active, not recruiting|March 2014|October 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|373|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02119676||46101|
NCT02120183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR13NMR139MP|Investigating the Effects of a Psycho-educational Support Group Therapy on Cancer Caregivers' Burden and Quality of Life|Investigating the Effects of a Psycho-educational Support Group Therapy on Cancer Caregivers' Burden and Quality of Life||National University Hospital, Singapore|No|Recruiting|September 2013|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|21 Years|64 Years|No|||July 2014|July 3, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02120183||46062|
NCT02150161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56csm2014001|Opioid vs. Opioid-free Anesthesia for Hip Arthroscopy|Fentanyl vs. Lidocaine/Ketamine Infusion for Hip Arthroscopy||Clinica Santa Maria||Terminated|May 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|May 26, 2014||No|DSMB estimated futility of the trial and safety risk|No||https://clinicaltrials.gov/show/NCT02150161||43765|
NCT02150174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5806|Testing Effect and Schizophrenia|Retrieval Practice in Patients With Schizophrenia : an Exploratory Study Using Word Pairs||University Hospital, Strasbourg, France|No|Recruiting|July 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150174||43764|
NCT02120664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A22|Florbetapir Calibration to the Centiloid Scale|A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB||Avid Radiopharmaceuticals|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|36|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02120664||46025|
NCT02150642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 11 2004|Probing Neural Circuitry for the Control of Movement|||University of Zurich|No|Recruiting|May 2004|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|control subjects without neurological movement disorder AND patients with neurological        movement disorder|January 2016|January 6, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02150642||43728|
NCT02150915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT-ACUP-2014|Acute Effects of Acupuncture in the Response of the Median Neurodynamic Test|Acute Effects of Acupuncture in the Response of the Median Neurodynamic Test: a Randomised, Double-blind, Non-inferiority Trial||Universidade do Porto|Yes|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 24, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150915||43707|
NCT02146963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00613-44|Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal|Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal||Centre Hospitalier Esquirol|No|Recruiting|May 2014|April 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|alcohol-dependent subjects hospitalized for alcohol withdrawal|July 2015|July 31, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02146963||44010|
NCT02146976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140522|Postoperative Sleep Quality of Patients Anesthesia With Propofol or Sevoflurane Undergoing Thyroidectomy|Postoperative Sleep Quality of Patients Anesthesia With Propofol or Sevoflurane Undergoing Thyroidectomy||China Medical University, China|Yes|Completed|October 2014|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|65 Years|No|||November 2015|January 28, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02146976||44009|
NCT02146989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45430.068.13|Upper Extremity Strength in Cerebral Palsy|Upper Extremity Strength in Children and Adolescents With and Without Unilateral Cerebral Palsy||Maastricht University Medical Center|No|Not yet recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|400|||Both|7 Years|18 Years|No|Non-Probability Sample|Spastic unilateral Cerebral Palsy and Healthy Controls|June 2014|June 17, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146989||44008|
NCT02147015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP|Personalized Variable Versus Experiential or Fixed Dose Glucocorticoid Therapy in AECOPD|Personalized Variable Versus Experiential or Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|No|Recruiting|May 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|40 Years|N/A|No|||June 2014|June 6, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147015||44006|
NCT02147028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0512|Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases|A Randomized Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-4 Brain Metastases|HIPPO|University College, London|No|Not yet recruiting|July 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|16 Years|N/A|No|||August 2015|August 4, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147028||44005|
NCT02158624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-E-09|Ranibizumab Treatment for Age-Related Macular Degeneretion|The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients|QUATRO|Kyushu University|No|Recruiting|December 2013|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|N/A|No|||June 2014|June 5, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158624||43116|
NCT02158104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-004|Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point|||CEU San Pablo University||Completed|October 2013|||February 2014|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjetct. Community sample from university.|January 2014|June 5, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158104||43156|
NCT02156362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.665|Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)|Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)||Hospices Civils de Lyon|No|Recruiting|May 2012|May 2022|Anticipated|May 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2015|May 28, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02156362||43290|
NCT02157298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00013|Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.|A 16-week Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin||AstraZeneca|No|Completed|June 2014|November 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|20 Years|130 Years|No|||February 2016|February 18, 2016|June 2, 2014||No||No|February 18, 2016|https://clinicaltrials.gov/show/NCT02157298||43218|For HbA1c, FPG and TBW: excluding data after insulin up-titration and for Mean Daily Insulin Dose: including data after insulin up-titration were used. For participants who did not complete week 16 last observation carried forward (LOCF) was used.
NCT02158637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002504 / MC1091|Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)||Mayo Clinic|No|Active, not recruiting|August 2010|||March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1100|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients initiating or receiving chemotherapy, radiation therapy, or both at nine        U.S.-based cancer centers and community oncology practices were approached in clinical        waiting areas and invited to participate in this questionnaire-based study.|June 2015|June 23, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158637||43115|
NCT02159430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCatania1|Hereditary AngioEdema, Neurobiology and Psychopathology||HAENP|University Hospital, Catania|No|Not yet recruiting|November 2014|May 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|35|||Both|18 Years|65 Years|No|Non-Probability Sample|This population-based cross-sectional study will include all Hereditary AngioEdema (HAE)        patients from the Eastern Sicily HAE register.|June 2014|June 5, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02159430|1 Day|43054|
NCT02159170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGIN_NGF|Cortical Representation of Hyperalgesia Induced by Nerve Growth Factor|Cortical Representation of NGF-induced Hyperalgesia|LOGIN_NGF|Central Institute of Mental Health, Mannheim|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159170||43074|
NCT02159183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/11|Controlled Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface|A Controlled Clinical Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface||Institut Straumann AG|No|Active, not recruiting|January 2012|September 2017|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159183||43073|
NCT02156323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29333|A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)|A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, TWO SEQUENCE, 3-WAY CROSSOVER STUDY TO INVESTIGATE THE INTERACTION BETWEEN MULTIPLE DOSES OF COLISTIN METHANESULFONATE SODIUM (CMS) AND MULTIPLE DOSES OF RO7033877 IN HEALTHY SUBJECTS||Hoffmann-La Roche||Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156323||43293|
NCT02156336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPG-CLIN-2014-01|Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)||Horizons International Peripheral Group|No|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02156336||43292|
NCT02157272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2013-004575-13|Rivaroxaban in Thrombotic Antiphospholipid Syndrome|A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome|TRAPS|University of Padova|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|536|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02157272||43220|
NCT02157870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-321 Phase II|A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Phase II of Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn|December 2004|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||August 2012|June 5, 2014|June 4, 2014|Yes|Yes|NCT00102622 Phase I/II study did not progress to Phase II.|No||https://clinicaltrials.gov/show/NCT02157870||43174|
NCT02157519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-055|Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer|Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer||Massachusetts General Hospital|No|Recruiting|June 2014|August 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157519||43201|
NCT02119481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI-MBSR-Main-BC|Effects of Mindfulness Meditation and Stress Management After Breast Cancer|Effects of Mindfulness Meditation and Stress Management Training on Perceived Stress, Psychological Well-being, and Sleep Quality Among Patients Diagnosed With Breast Cancer||Karolinska Institutet|No|Recruiting|May 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|210|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02119481||46116|
NCT02119689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308798827|Vascular Reparative Mechanism in Diabetes|Vascular Reparative Mechanism by ACE2/Ang-(1-7) in Diabetes|RAAS|Indiana University|No|Recruiting|October 2011|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Ophthalmology and Primary Care Clinics|February 2015|February 5, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02119689|4 Years|46100|
NCT02149888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPARATORY-5|PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5|A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study|PREP-5|St. Michael's Hospital, Toronto|Yes|Active, not recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02149888||43786|
NCT02149914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC103-20|The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients|The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients||Taichung Tzu Chi Hospital|No|Enrolling by invitation|May 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Both|20 Years|75 Years|No|||November 2014|November 19, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02149914||43784|
NCT02150434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FreeO2-Rehab-1|Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD|Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD|FreeO2rehab|Laval University|No|Completed|November 2009|June 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|40 Years|N/A|No|||May 2014|May 28, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150434||43744|
NCT02150655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102886|Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women|Pilot Study Investigating Bacteria (Microbiota), Their By-products (Metabolome) and Environmental Toxins in Relation to Reproductive Health in Rwandan Women.|RVMM|Western University, Canada|No|Completed|September 2012|December 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|July 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150655||43727|
NCT02150668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R305A130011|Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD|Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD||Virginia Commonwealth University|Yes|Enrolling by invitation|September 2013|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|11 Years|15 Years|No|||December 2015|December 4, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02150668||43726|
NCT02150941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105394|Effectiveness Study of the BioVac Direct Suction Device in Upper Gastrointestinal Bleeding|Does the BioVac Direct Suction Device Increase Identification of the Bleeding Source in Upper Gastrointestinal Bleeding: a Randomized Clinical Trial||Lawson Health Research Institute|Yes|Recruiting|April 2015|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02150941||43705|
NCT02146677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-Pa 1|Effect of Osteopathic Manipulative Treatment on Pain in Preterms|||European Institute for Evidence Based Osteopathic Medicine|Yes|Recruiting|June 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|26 Weeks|37 Weeks|No|||February 2015|February 12, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02146677||44032|
NCT02146690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-Pa 2|Effect of Osteopathic Manipulative Treatment on Reduction of Pain in Complicated Newborns: RCT|||European Institute for Evidence Based Osteopathic Medicine|Yes|Recruiting|June 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|26 Weeks|40 Weeks|No|||September 2014|September 15, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02146690||44031|
NCT02147041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100XDAA00110|The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides|The Effect of Extract of Green Tea on Obese Women Obese Related Hormone Peptides||Taipei City Hospital|Yes|Enrolling by invitation|May 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Female|20 Years|60 Years|No|||May 2014|May 21, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02147041||44004|
NCT02158117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI-13-001|Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use|Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use||Norwegian University of Science and Technology|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 2, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158117||43155|
NCT02157558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-106-NRM|An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects|A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Telotristat Etiprate on the Pharmacokinetics of Single-dose Fexofenadine, a Sensitive P Glycoprotein Substrate, in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|July 2014|||August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157558||43198|
NCT02157571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prulifloxacin AECB ZK-004|A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control|||Lee's Pharmaceutical Limited|No|Recruiting|June 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|70 Years|No|||June 2014|June 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157571||43197|
NCT02158650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058881|Video-Based Treatment Options for Basal Cell Carcinoma|The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients||Emory University|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|32|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158650||43114|
NCT02158663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAH TMS 15863|Study Testing if Fast or Slow rTMS is Better for the Treatment of Posttraumatic Stress Disorder (PTSD)|Randomized Trial of 1 Hz Versus 10 Hz Right Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Posttraumatic Stress Disorder (PTSD)||James A. Haley Veterans Administration Hospital|No|Recruiting|June 2014|June 2018|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|No|||February 2016|February 23, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158663||43113|
NCT02157584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-107-NRM|An Open-Label Food Effect Study of Telotristat Etiprate|A Phase 1, Randomized, Single Center, Open Label, 2 Sequence, 2 Period, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of Telotristat Etiprate (LX1606 Hippurate) in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|June 2014|||July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157584||43196|
NCT02158897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-00391|Multi-cycle Prolon Diet|Effect of a Periodic Fasting-mimicking Diet on Risk Factors for Metabolic Syndrome and Age-related Diseases||University of Southern California||Active, not recruiting|March 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|102|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158897||43095|
NCT02159196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nebulae|Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation|Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators in Mechanically Ventilated Intensive Care Patients'|Nebulae|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|July 2014|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|950|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159196||43072|
NCT02156934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Kidney-002|Paraurethral Transplantation of Autologous Muscle Derived Stem Cells for Treatment of Stress Incontinency|Evaluation the Effect of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Stress Urinary Incontinency,The Randomized Clinical Trial Phase II||Royan Institute|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|40 Years|60 Years|No|||October 2013|December 3, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156934||43246|
NCT02157883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00012|Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)|A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI||AstraZeneca|No|Active, not recruiting|November 2014|January 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|47|||Both|N/A|N/A|No|||November 2015|November 20, 2015|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157883||43173|
NCT02158156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2-2013-066(A)|Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy|Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy||Rigshospitalet, Denmark|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|8|||Both|18 Years|75 Years|No|||June 2014|June 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158156||43152|
NCT02158169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synergy|Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology|Pharmaco-epidemiological Study on the Effect of Retacrit® on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation|SYNERGY|Hospira, Inc.|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2167|||Both|18 Years|N/A|No|Non-Probability Sample|Patients for whom the oncologist decides to initiate epoetin alpha biosimilar treatment        (curative or prophylactic) will be asked to participate from treatment initiation        (baseline visit) up to 12-16 weeks after inclusion.|July 2015|July 27, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158169||43151|
NCT02119923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Tackling Depression and Anxiety: A Working Memory Intervention|Effects of Working Memory Training in a Depressed and Anxious Sample||Erasmus Medical Center|Yes|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|16 Years|68 Years|No|||April 2014|April 18, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02119923||46082|
NCT02149901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140547|Water and Sudafed in Autonomic Failure|Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure||Vanderbilt University|No|Recruiting|October 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|35|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|May 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02149901||43785|
NCT02149940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55301|Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.|Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.|RASP-HF|Universitaire Ziekenhuizen Leuven|No|Completed|April 2013|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|29|||Both|75 Years|N/A|No|||May 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149940||43782|
NCT02150213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2216|Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492|A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212||Novartis|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02150213||43761|
NCT02150447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS09420|The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding|Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicenter Trial||National Cancer Center, Korea|Yes|Active, not recruiting|June 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|394|||Both|18 Years|90 Years|No|||May 2014|April 4, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150447||43743|
NCT02150460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NECKAD/TRIALS/001/2012|A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria|A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at National Eye Centre, Kaduna. Nigeria||National Eye Centre, Kaduna|No|Completed|October 2012|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2014|March 15, 2015|May 26, 2014||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT02150460||43742|
NCT02150681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003212|Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders|MBCT for Perinatal Women With Mood Disorders|MBCT|University of California, Los Angeles|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||May 2014|May 29, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150681||43725|
NCT02146703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-0501|Gemcitabine and S-1 for Advanced Biliary Tract Cancer|Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer||Hallym University Medical Center|No|Completed|August 2005|December 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||May 2014|May 21, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146703||44030|
NCT02146716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-840|Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.|Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.|RESC|Hospices Civils de Lyon|No|Not yet recruiting|May 2014|January 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|80 Years|No|||September 2014|September 16, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146716||44029|
NCT02147548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETILANCE - ETI 175|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo||Biocodex|No|Recruiting|December 2013|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|30|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147548||43965|
NCT02147561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-148|A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine|||Allergan|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02147561||43964|
NCT02158923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iPROVE|Individualized Perioperative Open Lung Ventilatory Strategy|Postoperative Complication and Hospital Stay Reduction With a Individualized Perioperative Lung Protective Ventilation. A Comparative, Prospective, Multicenter, Randomized Controlled Trial.|iPROVE|Fundación para la Investigación del Hospital Clínico de Valencia|Yes|Recruiting|September 2014|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|920|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158923||43093|
NCT02158442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-PILP-C01 - Part B|Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients|Randomized Study Comparing Clinical and Microbiological Efficacy of Timentin Delivered Via Percutaneous Isolated Limb Perfusion (PILP) or Intravenous Infusion in Diabetic Subjects With Moderate to Severe Lower Limb Infection||Osprey Medical, Inc|No|Recruiting|October 2013|February 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||June 2014|June 5, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02158442||43130|
NCT02157922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2984|A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis|A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis|SMR-2984|AlgiPharma AS|Yes|Recruiting|October 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157922||43170|
NCT02157935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589UC00001|Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease|A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.|RISE|AstraZeneca|No|Completed|June 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1136|||Both|40 Years|95 Years|No|||March 2016|March 7, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157935||43169|
NCT02158910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-M082-601|A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients|A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients|AID|Eisai Inc.|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|6660|||Both|N/A|N/A|No|Probability Sample|Patients with Alzheimer's disease|March 2016|March 8, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158910||43094|
NCT02159807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0210|Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects|Randomized Double-blinded Study Designed to Optimize the Dose of Bupivacaine in Combined Spinal Epidurals to Reduce the Incidence of Fetal Bradycardia and Maternal Hypotension||St. Luke's-Roosevelt Hospital Center|No|Not yet recruiting|March 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||June 2014|January 2, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159807||43025|
NCT02157948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120187|A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis|A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis||Amgen|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|394|||Female|55 Years|100 Years|No|||November 2015|November 10, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157948||43168|
NCT02157961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4058-04/14|Doctor's Health - Health Behavior of General Practitioners in Germany|Doc's Health - Doctor as a Patient - An Observational Study on Health Behavior of General Practitioners in Germany|Doc'sHealth|University of Jena|No|Recruiting|April 2014|April 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|General Practitioners in Germany|June 2014|June 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157961||43167|
NCT02166502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000029134|Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection|Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection||The Hospital for Sick Children|No|Completed|February 2012|November 2015|Actual|May 2015|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|N/A|72 Hours|Accepts Healthy Volunteers|Non-Probability Sample|The patients in this study are newborn infants clinically prescribed combination        antiretroviral treatment with nevirapine for prevention of mother-to-child HIV        transmission. These infants are routinely referred to the SickKids and CHEO HIV clinics in        Toronto and Ottawa, respectively, for ongoing management. The majority of referrals are        from Mount Sinai Hospital and St. Michael's Hospital in Toronto, and the Ottawa General        Hospital in Ottawa.|November 2015|November 17, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02166502||42513|
NCT02158702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00498|Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib|Prospective Follow-up of Relapse Myeloma Patients After Previous Exposure to Bortezomib and Lenalidomide Treated on Pomalidomide and Dexamethasone||National University Hospital, Singapore|No|Recruiting|November 2014|November 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|21 Years|N/A|No|||May 2015|May 5, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158702||43110|
NCT02166749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETMK:41/180/2010|Clinical Follow up After Subtotal and Total Hysterectomy|Ultra Long-term Follow-up of the Outcome After Subtotal Versus Total Abdominal Hysterectomy||Turku University Hospital|No|Completed|March 1997|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|212|||Female|N/A|N/A|No|Non-Probability Sample|The study population included 212 patients operated on during February 1978 and May 1979        in Turku University Hospital. 107 women underwent subtotal and 105 women total abdominal        hysterectomy.|June 2014|June 27, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166749||42494|
NCT02149628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0098|The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide|The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery||Yonsei University|Yes|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Male|20 Years|70 Years|No|||July 2015|July 27, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02149628||43806|
NCT02149641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2608|Parotid-sparing IMRT for Nasopharyngeal Cancer|Phase II Study of Parotid Sparing IMRT for Nasopharyngeal Cancer||Royal Marsden NHS Foundation Trust|No|Completed|February 2006|April 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|16 Years|N/A|No|Non-Probability Sample|nasopharyngeal cancers|May 2014|May 26, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149641||43805|
NCT02149654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAE00937|Engager Align Study|The Engager ALIGN Study. To Characterize the Safety and Clinical Benefit of the Engager Transcatheter Aortic Valve Implantation System in a Real World Environment.||Medtronic Cardiovascular|Yes|Active, not recruiting|May 2014|October 2016|Anticipated|August 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|38|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe aortic stenosis requiring treatment, who are selected by a heart team        to be treated electively with the Engager Transcatheter Aortic Valve Implantation System        are eligible to be included in this study.|October 2015|October 12, 2015|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02149654|12 Months|43804|
NCT02149953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00495|Determination of Glycine Requirement in Pregnancy|Determination Glycine Requirements During Healthy Pregnancy Using the Indicator Amino Acid Oxidation (IAAO) Technique||University of British Columbia|Yes|Recruiting|June 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|18|||Female|20 Years|40 Years|No|||November 2015|November 30, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02149953||43781|
NCT02150187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProHair01|Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss|Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Family Marketing|No|Active, not recruiting|May 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150187||43763|
NCT02150200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5717|Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.|Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.||University Hospital, Strasbourg, France|Yes|Not yet recruiting|May 2014|||February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|44|||Female|35 Years|70 Years|No|||July 2014|July 3, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150200||43762|
NCT02150473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-ERA|The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients|Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients||Heinrich-Heine University, Duesseldorf|No|Recruiting|October 2014|June 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||May 2015|May 7, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150473||43741|
NCT02150694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEAP Study|Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo|Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo|HEAP|University of Cambridge|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|52|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150694||43724|
NCT02146729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 5903|Treatment of Thoracolumbar Spine Fractures: Percutaneously Placed Pedicle Screws Versus Open Treatment|Treatment of Thoracolumbar Spine Fractures: Percutaneously Placed Pedicle Screws Versus Open Treatment||Allegheny Singer Research Institute|No|Enrolling by invitation|July 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146729||44028|
NCT02147795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBM01|The German Patient Blood Management Network|Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients||Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|200000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult surgical patients|February 2016|February 22, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02147795||43946|
NCT02155855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-037|Telemedicine for Adolescents With Insulin-dependent Diabetes|Effectiveness of and Satisfaction With Remote Blood Glucose Monitoring and Telemedicine for Adolescents With Insulin-dependent Diabetes||Texas Tech University Health Sciences Center|No|Active, not recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155855||43329|
NCT02156089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140120|Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial|Neuroimaging Omega-3 and Reward in Adults With ADHD (NORAA) Trial||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|1||Anticipated|150|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 4, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156089||43311|
NCT02158741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCT-06669|Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes|A Client-Driven Intervention to Support Self-Management Among Community-Living Older Adults With Type 2 Diabetes and Multiple Chronic Conditions||McMaster University|No|Recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|65 Years|N/A|No|||September 2015|September 24, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02158741||43107|
NCT02155530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0185|COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial|||Yonsei University|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|762|||Both|20 Years|N/A|No|||January 2015|January 6, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02155530||43354|
NCT02155543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223575-001|A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects|||Allergan|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155543||43353|
NCT02159248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.017|Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation|09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy||Orlando Health, Inc.|Yes|Withdrawn|March 2014|December 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|June 5, 2014|No|Yes|The study closed prior to enrolling any participants.|No||https://clinicaltrials.gov/show/NCT02159248||43068|
NCT02159755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01202|Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma|A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|May 2014|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|January 12, 2016|June 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159755||43029|
NCT02158481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BNH-0751|Effects of Dietary Ingredients on Vascular Function|Investigating the Effects of Dietary Ingredients on Vascular Function During Acute Glucose Load||Unilever R&D|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|35 Years|65 Years|No|||June 2015|June 23, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02158481||43127|
NCT02166515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor|The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor||Third Military Medical University|Yes|Enrolling by invitation|October 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|The sample of blood, urine, cervical exfoliated cells and cancer tissue of patient should be      used only in this research with informed consent. The remaining part will be Safekeeping.All      information is strictly confidential.|Female|16 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The experiment group are patients with cervical cancer, ovarian cancer or endometrial        cancer.While the control group are volunteers on the basis of informed consent.|June 2014|June 17, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166515||42512|
NCT02166762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121099|Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.|Mapping of the Coronary Venous System in Patients With Heart Failure Presenting for CRT-D (Cardiac Resynchronization Therapy) Implantation. Correlating QLV Interval to Fluoroscopic LV (Left Ventricular) Lead Position.|QLV|University of California, San Diego|No|Active, not recruiting|May 2013|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166762||42493|
NCT02149381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsySysNe|Psychosocial Group Interventions for Depression|Psychosocial Group Interventions for Depression: Systemic and Neurophysiological Correlates of Treatment Effect. A Randomized, Controlled Trial|PsySysNe|University of Eastern Finland|No|Recruiting|May 2014|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|384|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02149381||43825|
NCT02149667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002C|Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components|Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components||MicroPort Orthopedics Inc.|No|Enrolling by invitation|December 2014|December 2028|Anticipated|December 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|21 Years|N/A|No|Non-Probability Sample|Patients previously implanted with DYNASTY® BioFoam® Acetabular Components|October 2015|October 16, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02149667||43803|
NCT02149927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56012/12|Neural Mechanisms of Sevoflurane Induced Anesthesia: an EEG fMRI Study in Healthy Volunteers|||Technische Universität München|No|Completed|June 2013|January 2014|Actual|December 2013|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02149927||43783|
NCT02149966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG348-C-002|A Phase I Study of AG-348 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers|AG-348MAD|Agios Pharmaceuticals, Inc.|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02149966||43780|
NCT02150265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1937|Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway|Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway. A Randomized Controlled Study|SMART|University of Tromso|No|Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|18 Years|No|||December 2015|December 10, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150265||43757|
NCT02150226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZ001|Y-TZP and In-mouth Low Thermal Degradation A Prospective Clinical Study|Y-TZP and In-mouth Low Thermal Degradation: A Prospective Clinical Study||University Hospital of Liege|No|Recruiting|February 2014|February 2021|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||January 2015|January 27, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150226||43760|
NCT02150239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20144-137|A Survey on Postoperative Pain (POP) Experience in Asian Patients.|A Survey on Postoperative Pain (POP) Experience in Asian Patients.||University of Malaya|No|Recruiting|May 2014|November 2014|Anticipated|September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Adult with age ≥ 18 who undergo operation|June 2014|June 9, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02150239|2 Weeks|43759|
NCT02150486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39172.100.11|Myocardial Injury and Postoperative Complications|Postoperative Myocardial Injury and Non-cardiac Complications After Major Abdominal Surgery in Patients at Risk for Coronary Artery Disease|MICOLON|St. Antonius Hospital|No|Completed|June 2012|March 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|||Both|45 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective abdominal surgery at risk for coronary artery disease|June 2014|June 3, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150486||43740|
NCT02150707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPP4201401|The Differential Effects of Diabetes Therapy on Inflammation|The Differential Effects of Diabetes Therapy on Inflammation||University College Dublin|No|Recruiting|May 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|30 Years|N/A|No|Non-Probability Sample|This study will be a prospective cohort study with 120 participants: 40 per group. I have        calculated this sample size to achieve a 90% power based on a 50% reduction in urinary        chemokines and circulating pro-inflammatory immune cells 1-4. This power calculation        anticipates a 10% dropout rate.        Patients with DKD presenting to the diabetes service of St Vincent's University Hospital        (SVUH) and Mater Misericordiae University Hospital (MMUH) who are commenced on GLP-1,        DPP4i or insulin for the first time will be invited to participate in the study.|July 2015|July 6, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02150707||43723|
NCT02147327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sevit25D3|Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|October 2013|May 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|N/A|30 Minutes|No|Probability Sample|Newborns which are hospitalized in the Neonatal Intensive Care Unit of our hospital|May 2014|May 27, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02147327||43982|
NCT02147821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-1374|Necessity of Using Pleural Drainage Tubes After IMA Harvesting During Cardiac Surgery|Necessity of Using Pleural Drainage Tubes After IMA Harvesting During Cardiac Surgery||University of Calgary|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02147821||43944|
NCT02161289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 120|Behavioral and Biomedical HIV Prevention Interventions for Thai Men Who Have Sex With Men|Behavioral and Biomedical HIV Prevention Interventions for Thai Men Who Have Sex With Men.|HIV-NAT 120|Thai Red Cross AIDS Research Centre|No|Completed|September 2010|||September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Male|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|men who have sex with men in Thailand|June 2014|June 9, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02161289||42911|
NCT02161302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0092|THE EFFECT OF tDCS IN THE TREATMENT OF CHRONIC PELVIC PAIN ASSOCIATED WITH ENDOMETRIOSIS|THE EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS) IN THE TREATMENT OF CHRONIC PELVIC PAIN ASSOCIATED WITH ENDOMETRIOSIS|tDCS|Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|June 2014|May 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|55 Years|No|||June 2014|June 10, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161302||42910|
NCT02161315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-SYH-201205001|Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer|A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|April 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Female|N/A|N/A|No|Probability Sample|80|February 2012|December 21, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161315||42909|
NCT02161536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MCC-SA-0214|Evaluation of the Performance of the CleanC System|||Motus GI Medical Technologies Ltd||Active, not recruiting|July 2014|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161536||42892|
NCT02161549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MCU-SP-1211|Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy|||Motus GI Medical Technologies Ltd||Completed|August 2012|||October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|71|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161549||42891|
NCT02161848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-163 (CPEO)|MRI Study - Chronic Progressive External Ophthalmoplegia|Magnetic Resonance Imaging Study of Patients With Chronic Progressive External Ophthalmoplegia|CPEO|Rigshospitalet, Denmark|No|Recruiting|June 2014|October 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Danish patients with verified single large-scale mtDNA deletions and chronic progressive        external ophthalmoplegia.|June 2014|June 11, 2014|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161848||42868|
NCT02163590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFCSPA-FXA-02|Immediate Effects of Different Rates of Thoracic Mobilization on Pressure Pain Thresholds in Asymptomatic Individuals|A Preliminary Investigation Into the Immediate Effects of Different Rates of Thoracic Mobilization on Pressure Pain Thresholds in Asymptomatic Individuals||Federal University of Health Science of Porto Alegre|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163590||42736|
NCT02163044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-HPLS-IIS|The Hellenic Postprandial Lipemia Study (HPLS)|A Study to Assess the Consequences of Postprandial Lipemia in CRP as Inflammatory Marker in High-risk Adults, to Investigate Whether Hypolipidemic, Hypoglycemic or Antihypertensive Medication May Lessen the Exaggerated Postprandial Lipemia and Evaluate the Influence of Gene Polymorphisms Involved in Lipid and Glucose Metabolism on Postprandial Lipemia and Cardiovascular Outcomes.|HPLS|Hellenic College of Treatment of Atherosclerosis|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|90 Years|No|Non-Probability Sample|The study aims to recruit 1200 patients that are characterized either as high risk or        very-high risk for Coronary Heart Disease. It is assumed that an equal number of high risk        and very high risk patients will be included in the study. Patients will be invited to        participate in the study from outpatient clinics in the 14 centers in Athens, Greece.|February 2016|February 22, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02163044||42777|
NCT02161133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-009-13S|Cognitive Rehabilitation for Gulf War Illness|Cognitive Rehabilitation for Gulf War Illness||VA Office of Research and Development|No|Recruiting|January 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|No|||December 2015|December 4, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02161133||42923|
NCT02161146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229666-006|AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis|||Allergan|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|240|||Both|20 Years|N/A|No|||February 2016|February 8, 2016|June 9, 2014|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT02161146||42922|
NCT02161159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/OAB/002|An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder||GRACE|Allergan|No|Completed|June 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|515|||Both|18 Years|N/A|No|Non-Probability Sample|Patients With Urinary Incontinence Due to iOAB|March 2016|March 8, 2016|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161159||42921|
NCT02164084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC101|A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris|A Phase 1, Single-center, Double-blind, Randomized, Cross-over, Pharmacokinetics, Safety and Tolerability Study of SB204 8% (NVN1000 Gel) and Vehicle Gel||Novan, Inc.|No|Completed|June 2014|December 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164084||42698|
NCT02164097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-165|ODSH + ICE Chemotherapy in Pediatric Solid Tumors|A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving "ICE" Chemotherapy||New York Medical College|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|1 Year|21 Years|No|||January 2015|April 27, 2015|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164097||42697|
NCT02164071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-GAH-2011-01|Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies|Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies|GAH|Celgene|Yes|Completed|April 2012|July 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|363|||Both|65 Years|N/A|No|Non-Probability Sample|Eligible patients, even being naïve to treatment, are eligible to receive treatment at any        time as per clinical practice. Patients ≥ 65 years old, newly diagnosed, naïve to        treatment, belonging to one of the 3 following groups. 1.- Patients with Myelodysplastic        Syndromes (any risk according to) or Acute myeloid leukemia; 2.- Patients with Multiple        Myeloma, either symptomatic or asymptomatic; or 3.- Patients with Chronic lymphocytic        leukemia (including stadium A).|February 2016|February 5, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164071||42699|
NCT02158988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastripec I|Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis|Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction|GASTRIPEC|Charite University, Berlin, Germany|Yes|Recruiting|March 2014|September 2020|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|May 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158988||43088|
NCT02159573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS412|Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)|A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)|STRATEGY|Biogen|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|530|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with a diagnosis of RRMS receiving at least 12 months of continuous treatment        with Tysabri monotherapy prior to initiation of Tecfidera. Additionally, participants must        have initiated treatment with Tecfidera at least 12 months prior to enrollment into the        study.|April 2015|April 30, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02159573||43043|
NCT02159547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41/10|IV Dexketoprofen vs Placebo in Migranie Attack|Study of Comparing Dexketoprofen to Placebo in Migraine Attack||Akdeniz University|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|65 Years|No|||June 2015|June 27, 2015|May 31, 2014||No||No|March 16, 2015|https://clinicaltrials.gov/show/NCT02159547||43045|
NCT02159560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000085|Uniport and Multiport Epidural Catheters in Post-surgical Patients|Uniport and Multiport Epidural Catheters in Post-surgical Patients||Beth Israel Deaconess Medical Center|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02159560||43044|
NCT02159833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM2069|Intranasal Diagnostics in Food Allergy: a Feasibility Study|Phase 1/2 Study to Determine the Intranasal Allergen Threshold to Food Proteins in Children With Food Allergy|INDY|Imperial College London|No|Enrolling by invitation|October 2014|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|6 Years|17 Years|No|||October 2015|October 20, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159833||43023|
NCT02155595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AR062103-01A1|Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy|Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy|NIH fracture|Henry Ford Health System|Yes|Recruiting|May 2014|August 2018|Anticipated|May 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Bone & serum to be retained per institutional guidelines and clinical practice|Female|50 Years|N/A|No|Non-Probability Sample|Patients will be found within the Henry Ford Health System Division of Endocrinology,        Diabetes, Bone & Mineral Disorders|March 2015|March 17, 2015|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155595||43349|
NCT02157064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF01MS|Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis|Autologous Adipose Stromal Vascular Fraction Outcomes Research Study||StemGenex|No|Recruiting|May 2014|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample|June 2015|June 17, 2015|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02157064||43236|
NCT02157363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW-001|POsitioning for Esophageal Cancer Resection|POsitioning for Esophageal Cancer Resection - a Randomized Controlled TRIal (POETRI)|POETRI|Technische Universität Dresden|Yes|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02157363||43213|
NCT02161068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308014251|Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping|Chart Review/PKD Genotyping|ADPKD|The Rogosin Institute|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|700|Samples With DNA|After informed consent is obtained, blood samples for PKD genotyping will be obtained from      the study patient. Genotype results will be made available to the patient and they will be      referred to a genetic counselor at their request. This service would not be a part of the      study and therefore, genetic counseling would be done at the patient's expense.|Both|18 Years|N/A|No|Non-Probability Sample|All patients enrolled in this study will have the diagnosis of ADPKD|February 2016|February 8, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02161068||42928|
NCT02161575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AGB17|Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD|A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.|SAFARI|Novartis|No|Recruiting|August 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|162|||Both|50 Years|N/A|No|||March 2016|March 8, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161575||42889|
NCT02161861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071002|Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study|Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study|Fertiline|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2014|March 2017|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|43 Years|No|||March 2015|March 26, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02161861||42867|
NCT02162160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI DS 2013|Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women|Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women||Karolinska Institutet|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Female|45 Years|65 Years|No|||November 2015|November 25, 2015|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02162160||42845|
NCT02162485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106009|Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus|Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µG/Inhalation; A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|Yes|Completed|June 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|129|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02162485||42820|
NCT02164110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBC301|To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children|A Randomized, Single Blind, Multicenter, Therapeutic Confirmatory Study to Assess the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children||EuBiologics Co.,Ltd|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3632|||Both|1 Year|40 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02164110||42696|
NCT02160015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01157|Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL||National Cancer Institute (NCI)||Suspended|May 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 30, 2014|No|Yes|Other - Per CTEP Action Letter|No||https://clinicaltrials.gov/show/NCT02160015||43009|
NCT02160626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-202|Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis.||Aclaris Therapeutics, Inc.|No|Active, not recruiting|June 2014|December 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||June 2014|October 7, 2014|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160626||42962|
NCT02160639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS-DSMES-2014|Evaluating the Impact of Year Long, Augmented Diabetes Self Management Support|Evaluating the Impact of Year Long, Augmented Diabetes Self Management Support||American Association of Diabetes Educators|No|Not yet recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|512|||Both|21 Years|85 Years|No|||January 2015|January 12, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02160639||42961|
NCT02160002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0054|Incubator Weaning of Moderately Preterm Infants|Incubator Weaning of Moderately Preterm Infants: A Randomized Controlled Trial||NICHD Neonatal Research Network|Yes|Recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|29 Weeks|34 Weeks|No|||March 2016|March 22, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02160002||43010|
NCT02160301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2669|Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients|Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients||University of North Carolina, Chapel Hill|No|Suspended|November 2017|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|June 6, 2014|Yes|Yes|Insufficient infrastructure/funding for enrollment|No||https://clinicaltrials.gov/show/NCT02160301||42987|
NCT02158767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE16Z13|Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.|Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.||Case Comprehensive Cancer Center||Available|December 2013|||December 2019|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|80 Years|No|||February 2016|February 17, 2016|June 5, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02158767||43105|
NCT02155933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13502|Assessment of Day-night Secretion of Progesterone and LH Across Puberty|Assessment of Day-night Secretion of Progesterone and LH Across Pubertal Maturation in Girls With and Without Hyperandrogenemia (JCM023)|LH|University of Virginia|No|Recruiting|February 2008|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|75|Samples Without DNA|Serum Urine|Female|7 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Adolescent females|November 2015|November 11, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02155933||43323|
NCT02156193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clip control|Effect of Prophylactic Clip|Effect of Prophylactic Clip Application for the Prevention of Postpolypectomy Bleeding in Large Pedunculated Colonic Polyps: a Randomized, Controlled Trial||The Catholic University of Korea|Yes|Not yet recruiting|July 2014|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|80 Years|No|||June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156193||43303|
NCT02156167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL5441|Clinical Assessment of the External Sound Processor Worn by Patients Implanted With Codacs|Clinical Validation of the Nucleus® CP810 Sound Processor for the Codacs™ System||Cochlear|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||July 2015|July 20, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156167||43305|
NCT02156440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SOHS|Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee|A Double Blind, Placebo Controlled Cross Over Study to Explore the Efficacy of SierraSil® Joint Formula 14™ in Adults With Osteoarthritis of the Knee|11SOHS|KGK Synergize Inc.||Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|150|||Both|18 Years|65 Years|No|||June 2014|June 4, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156440||43284|
NCT02156752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23KDK097143|Using Novel Behavioral Approaches to Improve Long-Term Weight Loss Outcomes|||The Miriam Hospital|No|Active, not recruiting|January 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|190|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2014|October 2, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02156752||43260|
NCT02157077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIC-ARI2|Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration|A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)|ARI2|Centre Hospitalier Intercommunal Creteil|Yes|Active, not recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|50 Years|N/A|No|||September 2015|September 21, 2015|March 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02157077||43235|
NCT02157090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herpes patch study 32583|Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.|Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS (Hansaplast®) Based on Hydrocolloids Without Active Substances in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product (Herpes Vesicle Patch of COMPEED®)||Technische Universität Dresden||Completed|August 2009|June 2010|Actual|January 2010|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||June 2014|June 2, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT02157090||43234|
NCT02157376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961OC00002|Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients|Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study|SUP|AstraZeneca|No|Completed|January 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|343|||Both|18 Years|70 Years|No|||March 2016|March 18, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02157376||43212|
NCT02157675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEWC2700|Effects of a Polyherbal Supplement on the Signs and Symptoms of Delayed Onset Muscle Soreness|The Effects of a Polyherbal Supplement on the Signs and Symptoms of Delayed Onset Muscle Soreness: a 2-arm, Randomized, Double-blind, Placebo-controlled, Crossover Design Study||NewChapter, Inc.|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157675||43189|
NCT02161341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1146/48/2014|Ocular Surface Microbiome in Dry Eye Patients|Exploratory Study on the Ocular Surface Microbiome and Correlation to Clinical Parameters||Singapore National Eye Centre|No|Recruiting|June 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|90|Samples Without DNA|Microbiome swab will be collected from the inferior fornix of the lower eyelids to determine      composition of the bacterial microbiome of the human ocular surface in normal volunteers and      dry eye patients|Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Dry eye patients and healthy normal volunteers|June 2014|May 18, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02161341||42907|
NCT02161562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ECA01|OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients|OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients|OPTIMA|Novartis|No|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161562||42890|
NCT02161588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4140|A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects|A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects||Novo Nordisk A/S|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161588||42888|
NCT02161874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3023|Evaluation of Integration Success and Crestal Bone Preservation Biomet 3i's T3 Implant System|A Prospective, Randomized-controlled Evaluation of Biomet 3i's T3 Implant System for Integration Success and the Preservation of Crestal Bone|OAK|Biomet, Inc.|No|Active, not recruiting|April 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161874||42866|
NCT02162173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP007|Dual Focus NBI and pCLE in FAP Related Duodenal Adenoma|Diagnostic Values of Dual Focus Narrow Band Imaging and Probe-based Confocal Laser Endomicroscopy in FAP Related Duodenal Adenoma|PIVI|King Chulalongkorn Memorial Hospital|Yes|Completed|December 2012|||November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02162173||42844|
NCT02162498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD075090-02|Study to Determine Impact of Feeding Buddies on Adherence to WHO PMTCT Guidelines in South Africa|Effect of Feeding Buddies on Adherence to WHO PMTCT Guidelines in South Africa||PATH|No|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|932|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|October 19, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162498||42819|
NCT02162511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28663|CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function|An Expanded Access Study Using the CliniMACS System to Offer Therapeutic Manipulated Grafts That Are CD34 Cell Enriched and T Cell Depleted for Allogeneic Stem Cell Recipients With Mismatched Related Donors or Borderline Organ Function||Stanford University|Yes|Recruiting|May 2014|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|35 Years|No|||May 2015|May 19, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162511||42818|
NCT02162784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTB012|Efficacy Study of SYN006 HFA MDI in Asthma Patients|An Open-Label, Randomized, Cross-Over Study to Evaluate the Dose Response of SYN006 HFA MDI in Asthma Patients||Intech Biopharm Ltd.|Yes|Completed|February 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|16 Years|N/A|No|||June 2015|June 2, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162784||42797|
NCT02160912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EctMRS/aLR/2014|Non Interventional Study (NIS) Regarding the Application of Ectoin Mund- & Rachenspray in Patients With Acute Laryngitis and/or Acute Pharyngitis|Non Interventional Study Regarding the Application of Ectoin Mund- & Rachenspray in Patients With Acute Laryngitis and/or Acute Pharyngitis||Bitop AG|Yes|Completed|February 2014|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|95|||Both|6 Years|N/A|No|Non-Probability Sample|Primary care unit In this non interventional study the therapy process of a total of 90        patients with acute pharyngitis and/or laryngitis for which the physician has planned a        therapy with Ectoin Mund- & Rachenspray 1% (60 Patients) or Emser Pastillen (30 patients)        shall be observed in 8 clinical centers|January 2015|January 8, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160912||42940|
NCT02160925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1412|Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma|Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma||Johns Hopkins University|No|Recruiting|May 2014|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|February 6, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02160925||42939|
NCT02156102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140125|Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers Study (INSIGHTS Study)|Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156102||43310|
NCT02160652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0185-14-RMC|Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction|Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction||Rabin Medical Center|Yes|Enrolling by invitation|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral        re-implantation, who have a life expectancy of over 6 months and are willing and able to        participate in the study.|June 2015|June 15, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160652||42960|
NCT02161406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-344|A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis|A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.|ASSET|University of Michigan|Yes|Recruiting|September 2014|July 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161406||42902|
NCT02160886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFR-296311|Effects of a Task Oriented Intervention With Two Goal-setting Approaches|Effects of a Task Oriented Intervention for Children With Disabilities, Based on Children's or Parent's Goals, a Randomized Study.||Region Gävleborg|No|Completed|October 2011|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|5 Years|12 Years|No|||June 2014|June 9, 2014|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02160886||42942|
NCT02160899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 494372-CS3|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a)|A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)||Ionis Pharmaceuticals, Inc.|No|Completed|June 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160899||42941|
NCT02159313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17306|Relative Bioavailability Study|Relative Bioavailability Study of Riociguat Given Orally as a Crushed 2.5 mg Tablet Suspended in Applesauce, Crushed 2.5 mg Tablet Suspended in Water, and Whole 2.5 mg Tablet After a Continental Breakfast in Comparison to a Whole 2.5 mg Tablet Given in the Fasted State to Characterize the Pharmacokinetic Properties in Healthy Male Adult Subjects in a 4-fold Crossover Design||Bayer|No|Completed|June 2014|January 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159313||43063|
NCT02155660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3251C00004|Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History|A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.|TERRANOVA|AstraZeneca|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|2168|||Both|40 Years|85 Years|No|||March 2016|March 8, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155660||43344|
NCT02155608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMH R34MH101282|Trigeminal Nerve Stimulation for ADHD|Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD|TNS for ADHD|University of California, Los Angeles|Yes|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|8 Years|12 Years|No|||January 2016|January 8, 2016|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155608||43348|
NCT02155621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POG 2.0|Personalized Oncogenomics (POG) Program of British Columbia|Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution||British Columbia Cancer Agency|No|Recruiting|July 2014|June 2025|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5000|||Both|18 Years|85 Years|No|||October 2015|October 29, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155621||43347|
NCT02155634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-027|Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma|Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma||Celgene|Yes|Withdrawn|July 2014|March 2021|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|June 2, 2014|Yes|Yes|The study was terminated due to poor feasibility and lack of interest at the participating    sites.|No||https://clinicaltrials.gov/show/NCT02155634||43346|
NCT02155647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100070-003|Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)|A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma||EMD Serono|Yes|Active, not recruiting|June 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||August 2015|September 9, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155647||43345|
NCT02156479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB-B1|Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients|Clinical Validation of an Improved T-Track® CMV Assay to Assess the Functionality of CMV Protein-reactive Cell-mediated Immunity (CMI) and Its Suitability to Determine a Protective Cut-off Value for Recurrent CMV Reactivations in Allo-HSCT Recipients|AlloProtectCMV|Lophius Biosciences GmbH|No|Recruiting|July 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first        time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or        both, donor and recipient are CMV seropositive|February 2016|February 5, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02156479||43281|
NCT02156453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126/2556(EC2)|Functional Recovery After Total Knee Arthroplasty|The Evaluation of Short-term Functional Recovery of Total Knee Arthroplasty Patients||Mahidol University|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|40 Years|N/A|No|Non-Probability Sample|Patients who receive uncomplicated total knee replacement by a single surgeon|September 2015|September 21, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156453|1 Year|43283|
NCT02156765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYY-20140410|China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients|China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients|CRIST|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|October 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients with ischemic stroke that are diagnosed definitely|June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156765|6 Days|43259|
NCT02157103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062998|A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma|A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma||Emory University|Yes|Recruiting|January 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157103||43233|
NCT02157389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fl156/33-1_chrBP|Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain|Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain||Central Institute of Mental Health, Mannheim|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02157389||43211|
NCT02161601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPESO-01|Effect of Incorrectly Applied Cricoid Pressure During Rapid Sequence Induction. Evaluation With High-resolution Manometry.|Effect of Incorrectly Applied Cricoid Pressure During Rapid Sequence Induction. Evaluation With High-resolution Manometry||Örebro University, Sweden|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161601||42887|
NCT02161887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006453-3|The Healing Context in Complementary and Alternative Medicine (CAM): Initial Validation Study|The Healing Context in CAM: Instrument Development and Initial Validation - Phase 3 Validation Study|HEAL|University of Pittsburgh|No|Recruiting|June 2014|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are beginning or about to begin CAM or Conventional Medicine treatments for        chronic back pain or chronic neck pain in Pittsburgh, Pennsylvania at University of        Pittsburgh Medical Center (UPMC).|November 2015|November 30, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161887||42865|
NCT02161900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH Project No. 735|Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer|Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer||Tata Memorial Hospital|No|Recruiting|November 2010|April 2025|Anticipated|May 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|850|||Female|18 Years|65 Years|No|||November 2015|November 24, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02161900||42864|
NCT02162186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP2013-12|Clinical and Radiographic Outcomes of the Corin Tri-Fit Total Hip Replacement|Analysis of Clinical Outcome and Implant Migration of the Cementless Tri-Fit Total Hip Replacement System||Corin|Yes|Recruiting|October 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|The first 100 patients Dr. Paul Beaule undergoing a total hip replacement with Corin's        TriFIT Total Hip replacement system that meet the eligibility requirements and consent to        do the study.|October 2015|October 6, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162186||42843|
NCT02162524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-045|Effects of Images Following Long-term Aerobic Exercise on Brain Activation|Effects of Images Following Long-term Aerobic Exercise on Brain Activation (E-Mechanic Ancillary II)|E-Mech Anc II|Pennington Biomedical Research Center|No|Withdrawn|January 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02162524||42817|
NCT02163304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2013-031|Effects of Images Following Beverage Ingestion on Brain Activation|Effects of Images Following Beverage Ingestion on Brain Activation|Sweety|Pennington Biomedical Research Center|No|Withdrawn|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02163304||42758|
NCT02160340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11221319Exp|Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older|Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies|VAST|Nova Southeastern University|No|Active, not recruiting|May 2014|May 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1584|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be selected from primary eye care clinics within academic settings, tertiary        care clinics, and veterans administration medical centers.|December 2015|January 4, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02160340||42984|
NCT02160353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 13-23|Neo-adjuvant Abiraterone Prostate Study|Phase II Single-arm Study Evaluating Neo-adjuvant (Pre-radical Radiotherapy) Abiraterone Acetate (Plus Prednisolone) and Gonadotropin-Releasing Hormone (GnRH) Agonist in High Risk Localised Prostate Carcinoma||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|May 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160353||42983|
NCT02160379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219/09|Effects of Roux-en-Y Gastric Bypass on Gastro-intestinal Hormone Secretion and Brain Responses Food Pictures|Dynamic Effect of Gastrointestinal Hormones on Cerebral Mechanisms Involved in Brain Perception of Food Pictures After Bariatric Surgery||University of Lausanne|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|31|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Formerly obese patients attending the obesity clinics of Lausanne University Hospital and        healthy subjects resident in the Lausanne area|June 2014|June 6, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160379||42981|
NCT02156375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104186|A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations|A Phase 1, Randomized, Open-label, Parallel-design Study to Compare Single-dose Pharmacokinetics of Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations||Janssen Research & Development, LLC|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|June 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02156375||43289|
NCT02160938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL0100|Prenatal Microarray Follow-Up Study|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis: Follow-Up||Columbia University|No|Recruiting|February 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|390|||Both|18 Years|N/A|No|Non-Probability Sample|Women undergoing prenatal microarray testing during pregnancy.|July 2015|July 28, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02160938|3 Years|42938|
NCT02161172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|658214|Cognitive and Psychosocial Outcome After Mild Traumatic Brain Injury|Cognitive, Functional, and Psychosocial Outcome After Mild Traumatic Brain Injury: a Cross-sectional Study at a Tertiary Care Trauma Center.||Shanghai 6th People's Hospital|No|Completed|April 2012|May 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|360|||Both|18 Years|60 Years|No|Non-Probability Sample|360 patients with mild traumatic brain injury were enrolled in this study. Their age        ranged from 18 to 60 years, with mean age of 54.3 years. Types of trauma included scalp        hematoma, scalp laceration, cerebral contusion, subarachnoid hemorrhage, cerebral        concussion, epidural hematoma, subdural hematoma and skull fracture. Mechanisms of injury        contained traffic accident, fall, industrial accident, etc. Occupation of patients        included cadres, workers, farmers, individual, unemployed. Education: college or above,        middle school, primary school.|June 2014|June 10, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161172|6 Months|42920|
NCT02152228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT-03-2014|A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism|A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism||Entera Bio Ltd.|No|Completed|July 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152228||43607|
NCT02155673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS-100-CS-4003|A Phase 2 Extension Study of Study GCS-100-CS-4002|A Phase 2 Extension Study of Study GCS-100-CS-4002||La Jolla Pharmaceutical Company|No|Active, not recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155673||43343|
NCT02156206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN/MG-13064-RG ECO 577-2|Impact Evaluation of the 123 Women Emergency Phone Line in Medellín, Colombia|Building Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of the 123 Women Emergency Phone Line in Medellín (Colombia), Component of the Program "Seguridad Pública".||Econometría Consultores|No|Active, not recruiting|June 2014|February 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|900|||Female|18 Years|65 Years|No|Probability Sample|Women that call the 123 emergency line in Medellín, Colombia|January 2016|January 19, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156206||43302|
NCT02157155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-98-14|A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis|The Role of ATGL and G0/G1 Switch Gene Complex in Lipopolysaccaride (LPS) Induced Ketosis - a Controlled, Randomised, Clinical Experimental Study||University of Aarhus|No|Completed|June 2014|September 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|9|||Male|18 Years|45 Years|No|||June 2014|December 1, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02157155||43229|
NCT02156518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-027|The Efficacy of Vocal Function Exercises for Early Glottic Cancers|Investigating the Efficacy of Vocal Function Exercises in the Treatment of Voice Problems in Adults Treated With Radiation Therapy for T1NOMO-T2NOMO (Early) Glottic Cancers||University of Kentucky|Yes|Recruiting|June 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|40 Years|N/A|No|||December 2015|December 6, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156518||43278|
NCT02156466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200574-003|Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects|Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis||Merck KGaA||Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|70 Years|No|||November 2015|November 9, 2015|May 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02156466||43282|
NCT02156778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN2013-0045|Post-Stroke Disease Management - Stroke Card|Phase 3 Study of Multifaceted Intervention to Reduce Recurrent Cardiovascular Events and Improve Quality-of-Life After Ischemic Stroke and High-Risk Transient Ischemic Attack (TIA)|Stroke Card|Medical University Innsbruck|No|Recruiting|January 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2400|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156778||43258|
NCT02156791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT007|Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM|Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients||BioTech Tools S.A.|Yes|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|70 Years|No|||May 2014|June 5, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02156791||43257|
NCT02157402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYTO-SPAIN|EYTO (European Youth Tackling Obesity): A Randomized Controlled Trial in Catalonia (Spain)|A Youth Led Social Marketing Campaign to Encourage Healthy Lifestyles. EYTO (European Youth Tackling Obesity): A Randomized Controlled Trial in Catalonia (Spain)|EYTO-SPAIN|University Rovira i Virgili|Yes|Active, not recruiting|May 2014|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02157402||43210|
NCT02157727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-DITEROP|Cost-effectiveness of Tele-expertise for Premature Infants for Retinopathy|Effectiveness and Cost-effectiveness of Tele-expertise for the Screening Examination of Premature Infants for Retinopathy of Prematurity|Dite-ROP|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2014|October 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|843|||Both|N/A|N/A|No|Non-Probability Sample|Infants hospitalized in neonatology unit|October 2015|October 13, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157727||43185|
NCT02157740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-EVLINE|Assessment of Teleconsulting in Nursing Homes|Assessment of Teleconsulting in Nursing Homes|EVLINE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Nursing home residents|October 2015|October 13, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157740||43184|
NCT02158039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498-04|Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms|Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms||Mayo Clinic|Yes|Completed|June 2004|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 30, 2013||No||No|December 22, 2015|https://clinicaltrials.gov/show/NCT02158039||43161|Sample size was small, and a control group was not included. Neither cyst histology not degree of epithelial ablation was assessed by surgical resection in any of the study participants.
NCT02161913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHNF-288318|Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers|Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers||St. Luke's Rehabilitation Institute|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161913||42863|
NCT02162537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METAL 2|Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases|A Multicentric, Randomized, Phase III Trial Comparing Two Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases:a Systematic Initial Brain Radiotherapy Followed by Chemotherapy and Initial Chemotherapy Associated to Brain Radiotherapy Only in Case of Cerebral Progression.|METAL2|Centre Hospitalier Intercommunal Creteil|Yes|Recruiting|December 2013|January 2019|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|18 Years|N/A|No|||November 2015|November 29, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02162537||42816|
NCT02162797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPL002|Zinc Supplementation Effect on Immune Recovery in HIV Patients|EFFECT OF ZINC SUPPLEMENTATION ON IMMUNE RECOVERY PROGRAM HIV PATIENTS WITH AN IPS MEDELLIN||CES University|No|Recruiting|October 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 12, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02162797||42796|
NCT02163057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-005|Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma|Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)||Inovio Pharmaceuticals|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163057||42776|
NCT02163837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/14-02-14/4343|Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy|||Centre Hospitalier Universitaire Saint Pierre|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|100 Years|No|||December 2015|December 16, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02163837||42717|
NCT02160041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398XUS04|BGJ398 for Patients With Tumors With FGFR Genetic Alterations|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations|CBGJ398XUS04|Novartis|No|Recruiting|July 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160041||43007|
NCT02155868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-in-CS|Role of Cerebral Oximetry in Reducing Postoperative Morbidity Following Cardiac Surgery|Cerebral Near-Infrared Spectroscopy Monitoring in High-Risk Cardiac Surgery Patients: A Prospective, Randomised, Single-Blinded Study||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02155868||43328|
NCT02161224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0513|A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function|A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of FG-4592 in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function||Astellas Pharma Inc|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 9, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02161224||42916|
NCT02161445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STI in AHF|Systolic Time Intervals in the Diagnosis of Heart Failure in Emergency Departement|Systolic Time Intervals: a Diagnostic Tool of Acute Heart Failure in Emergency Departement Settings|STA/AHF|University of Monastir|Yes|Recruiting|October 2012|March 2016|Anticipated|January 2015|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients aged more than 18 years old presenting at the ED with non traumatic dyspnea.|June 2014|June 9, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02161445||42899|
NCT02160665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM 2013-01|Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis|A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,Multi-Center Study Comparing a Generic Tazarotene Cream, 0.05% to RLD Tazorac® Cream, 0.05% and Both Treatments to a Vehicle in the Treatment of Plaque Psoriasis||G & W Laboratories Inc.|No|Recruiting|May 2014|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|804|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160665||42959|
NCT02160678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM 2014-01|Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris|A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,MulticenterStudy ComparingaGenericTazaroteneCream,0.1%toReference Listed Drug Tazorac® Cream, 0.1% and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris||G & W Laboratories Inc.||Completed|May 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1741|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|March 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160678||42958|
NCT02156674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LS014|Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome|Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|January 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|N/A|No|||January 2016|January 27, 2016|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156674||43266|
NCT02156687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-354|Randomized Trial of Y Mesh vs Dual Mesh|A Prospective Randomized Trial Comparing Restorelle Y Mesh vs. Restorelle Dual Flat Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy||The Cleveland Clinic|No|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|100 Years|No|||January 2016|January 29, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156687||43265|
NCT02155946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1534-R|Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment|Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment||VA Office of Research and Development|No|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|50 Years|88 Years|No|||January 2016|January 21, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02155946||43322|
NCT02156830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOGMA2|Multidisciplinary Approach and Counseling of the Obese Patient Before and After Bariatric Surgery|Multidisciplinary Approach and Counseling of the Obese Patient Before and After Bariatric Surgery: Qualitative Interviews||Katholieke Universiteit Leuven|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The different health care professionals of the obesity team|February 2015|February 4, 2015|August 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02156830||43254|
NCT02157129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNO-TUM-LT1|LipoAerosol© Inhalation After Tracheostomy|LipoAerosol© Inhalation to Maintain the Functional Integrity of the Tracheo-bronchial System in Patients After Tracheostomy||Technische Universität München|Yes|Recruiting|May 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||March 2016|March 16, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157129||43231|
NCT02157142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLT1301|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON|HORIZON|HLT Inc.|Yes|Terminated|August 2014|March 2020|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|75 Years|N/A|No|||March 2015|March 24, 2015|June 2, 2014||No|HLT determined that design changes are necessary before reopening the study|No||https://clinicaltrials.gov/show/NCT02157142||43230|
NCT02156531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH101118-01A1|Cognitive Bias Modification for Youth Anxiety|An Efficacy-Effectiveness Trial of Cognitive Bias Modification for Youth Anxiety|TeenCBM|Kaiser Permanente|Yes|Recruiting|September 2014|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|498|||Both|12 Years|17 Years|No|||September 2015|September 1, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156531||43277|
NCT02156804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-172|A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)|A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody||Bristol-Myers Squibb|No|Active, not recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||September 2015|March 11, 2016|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156804||43256|
NCT02157116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004682|Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer|Dose-Dense Induction/Neoadjuvant Chemotherapy in the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer With Additional Genomic Analyses to Identify Signatures Predictive of Chemotherapy Response.||Duke University|No|Terminated|May 2006|January 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|May 29, 2014|Yes|Yes|Insufficient accrual to meet analysis goals|No|June 5, 2014|https://clinicaltrials.gov/show/NCT02157116||43232|
NCT02158052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KdBMT-2|Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease|Combined HLA-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma or Other Hematologic Disorders With End Stage Renal Disease||Massachusetts General Hospital|Yes|Recruiting|February 2015|February 2021|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02158052||43160|
NCT02158325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China6|Capsulorhexis Size and Capsular Outcome|Appropriate Capsulorhexis Size Results in Better Capsular Outcome When Treating Pediatric Cataract: A Randomized Controlled Trial||Sun Yat-sen University|Yes|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|38|||Both|N/A|2 Years|No|||June 2014|June 6, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158325||43139|
NCT02162810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010275|Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair|Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair||Children's Hospital of Pittsburgh|No|Recruiting|May 2014|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|200|||Male|3 Months|22 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|March 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162810||42795|
NCT02163070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-6424|Effect of Vitamin E Fortified Whey Drink on Nutritional, Inflammatory and Oxidative Markers in Hemodialysis Patients|Effect of Vitamin E Fortified Whey Drink on Nutritional Status, Inflammatory Markers and Oxidative Stress in Hemodialysis Patients|EVEWD|Shiraz University of Medical Sciences|Yes|Completed|September 2013|June 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|92|||Both|17 Years|65 Years|No|||January 2015|January 8, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163070||42775|
NCT02163317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11813|Magnetic Resonance Guided Focal Stereotactic Radiosurgery in Treating Patients With Low- or Intermediate-Risk Localized Prostate Cancer|Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|No|||March 2016|March 8, 2016|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163317||42757|
NCT02163603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangzhouWCMC|A Trial on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip|A Multi-center Study on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip||Guangzhou Women and Children's Medical Center||Not yet recruiting|September 2014|||December 2024|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2|||Both|1 Year|14 Years|No|Probability Sample|The south of China|March 2016|March 18, 2016|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163603||42735|
NCT02160327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312127RINB|The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye|The Role of Cytokines and Mast Cell in the Pathogenesis of Ocular Surface Inflammation Diseases Including Superior Limbic Keratoconjunctivitis, Conjunctivochalasis, and Dry Eye||National Taiwan University Hospital|No|Active, not recruiting|March 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|105|Samples Without DNA|-  tear        -  conjunctival tissue|Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Part I. Tear sample diagnosed as a patients of superior limbic keratoconjunctivitis (SLK)        or conjunctivochalasis or keratoconjunctivitis sicca (KCS) Part II. Surgical conjunctiva        specimen disease group: SLK or conjunctivochalasis patients refractory to medical        treatment and receiving conjunctival resection surgery|June 2014|June 23, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02160327||42985|
NCT02160093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404030RIND|Impact of Chronic Disease Control and Aging Psychology on Outcomes of Frailty-Sarcopenia Syndrome in Ambulatory Geriatric Patients|Impact of Chronic Disease Control and Aging Psychology on Outcomes of Frailty-Sarcopenia Syndrome in Ambulatory Geriatric Patients||National Taiwan University Hospital|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory geriatric outpatients aged 65 and over from NTUH|August 2015|August 7, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02160093||43003|
NCT02160366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAB10-0441|Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients|Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients||M.D. Anderson Cancer Center|No|Recruiting|September 2010|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural      fluid, ascites, skin or hair follicle.|Both|N/A|N/A|No|Non-Probability Sample|Patients referred to the Clinical Center for Targeted Therapy at UT MD Anderson Cancer        Center in Houston, Texas|February 2016|February 19, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160366||42982|
NCT02161471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atrial function in CHD by CMR|Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance|Haemodynamics and Function of the Atria in Patients With Congenital Heart Defects - Pilot Study by Cardiovascular Magnetic Resonance||University Children's Hospital, Zurich|No|Recruiting|October 2009|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|50|||Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants for the study will be recruited among patients, children and adults, with CHD        (groups 1-4) undergoing cardiac magnetic resonance examination for clinical reasons.          1. Patients after repair of coarctation of the aorta          2. Patients after repair of tetralogy of Fallot          3. Patients with transposition of the great arteries after atrial switch (Senning             procedure)          4. Patients with transposition of the great arteries after arterial switch operation          5. Children without cardiovascular anomalies undergoing CMR for other clinical reasons             not influencing cardiac function (control group)|January 2016|January 19, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161471||42897|
NCT02161458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG041502|Escitalopram Effects on CSF Amyloid Beta|Escitalopram Effects on CSF Amyloid Beta Total Concentrations||University of Pennsylvania|No|Recruiting|June 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02161458||42898|
NCT02161757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2210C00007|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist|STRATOS1|AstraZeneca|Yes|Active, not recruiting|June 2014|July 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1140|||Both|12 Years|75 Years|No|||February 2016|February 9, 2016|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161757||42875|
NCT02160951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGH447X1101|Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies|A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies||Novartis||Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02160951||42937|
NCT02161198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-75|Efficacy and Safety Study of Ginseng Polysaccharide Extract|A Single-center, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety After 14-week of Ginseng Polysaccharide Extract||Seoul St. Mary's Hospital|No|Completed|September 2012|December 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 9, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02161198||42918|
NCT02155348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lentis|Comparison Between Bilateral Multifocal Intraocular Lenses and Pseudophakic Monovision|Comparison Between Bilateral Multifocal Intraocular Lenses and Pseudophakic Monovision: a Randomised Controlled Trial||Vienna Institute for Research in Ocular Surgery|No|Recruiting|June 2013|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|N/A|No|||June 2014|June 3, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155348||43368|
NCT02155361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-9377-7007|Evaluation of Topical Citrullus Colocynthis Fruit Oil Efficacy in Treatment of Painful Peripheral Diabetic Neuropathy|Evaluation of Topical Citrullus Colocynthis Fruit Oil Efficacy in Treatment of Painful Peripheral Diabetic Neuropathy||Shiraz University of Medical Sciences|Yes|Completed|June 2014|September 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||November 2014|November 14, 2014|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02155361||43367|
NCT02156505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTSMD12009|Outcome Study of Double Bare Stent for Malignant Gastric Outlet Obstruction|Phase IV Study of Double Bare Self-expandable Metallic Stent for Malignant Gastric Outlet Obstruction||National Cancer Center, Korea|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|N/A|No|||June 2014|June 4, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02156505||43279|
NCT02156817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0052|Neurophysiologic Maturation Index for Moderate and Late Preterm Infants|Neurophysiologic Maturation Index: NEMO Project for Moderate and Late Preterm Infants|NEMO Project|Brown University||Recruiting|March 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|171|||Both|N/A|4 Days|No|Probability Sample|Neonatal intensive care unit Newborn nursery|June 2014|June 2, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02156817||43255|
NCT02156232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPS-SPSS|Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Refractory Hepatic Encephalopathy|Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Refractory Hepatic Encephalopathy: a Prospective、Open-labeled、Randomized、Controlled Trial||Fourth Military Medical University|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 23, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156232||43300|
NCT02156245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASILLAS DB 2011|Evaluation of the Effects of Eccentric Training on a Cycle Ergometer, Versus Conventional Concentric Training|Evaluation of the Effects of Eccentric Training on a Cycle Ergometer, Versus Conventional Concentric Training||Centre Hospitalier Universitaire Dijon||Recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2012|June 3, 2014|March 5, 2014||||No||https://clinicaltrials.gov/show/NCT02156245||43299|
NCT02157181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL 4-2004|Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab|Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia||University of Giessen|No|Completed|June 2004|January 2013|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|90 Years|No|||June 2014|June 3, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02157181||43227|
NCT02157194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLK-EBUS-2|Endobronchial Ultrasound-transbronchial Needle Aspiration (EBUS-TBNA) Sample Division|||University Hospital, Essen||Recruiting|February 2013|||March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A||Probability Sample|Subjects suspected to have lung cancer and enlarged mediastinal lymph nodes|June 2014|June 3, 2014|June 1, 2014||||No||https://clinicaltrials.gov/show/NCT02157194||43226|
NCT02157415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-1101|Prospective Cohort Study on Tolerability & Safety of Uro-Tainer® Polihexanide 0.02%|Prospective Cohort Study on the Tolerability and Safety of Uro-Tainer® Polihexanide 0.02% in Long-term Indwelling Catheterized Patients.||B. Braun Ltd. Centre of Excellence Infection Control|No|Recruiting|August 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02157415||43209|
NCT02156843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYR-311|Pyridorin in Diabetic Nephropathy|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)|PIONEER|NephroGenex, Inc.|Yes|Terminated|June 2014|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156843||43253|
NCT02157753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/036|Quality of the Detection & Treatment of Osteoporotic Fractures in a Swiss Trauma Center|Osteoporotic Fractures in a Swiss Trauma Center - Observational Study to Improve the Diagnosis and Management of and the Persistence to Therapy.||Kantonsspital Aarau|No|Recruiting|July 2012|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|Every patient with fracture over age of 49, admitted to the Kantonsspital Aarau and        treated by the traumatology department, whom a treatment for osteoporosis was suggested        according to national guidelines|February 2016|February 23, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02157753||43183|
NCT02157766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0116|Wisconsin Center for the Neuroscience and Psychophysiology of Meditation|Wisconsin Center for the Neuroscience and Psychophysiology of Meditation||University of Wisconsin, Madison|Yes|Recruiting|September 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|6||Anticipated|793|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157766||43182|
NCT02157428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|984/10|Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane|Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane: a Randomized Controlled Trial||University of Sao Paulo|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02157428||43208|
NCT02157779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1146-R|Treatment of Trauma-Related Anger|Treatment of Trauma-Related Anger in OEF/OIF/OND Veterans|TOTRA|VA Office of Research and Development|No|Recruiting|March 2015|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02157779||43181|
NCT02157792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-970-001|An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy|An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors||Vertex Pharmaceuticals Incorporated||Recruiting|December 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|129|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|June 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157792||43180|
NCT02163616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3003|Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study|Treatment of Postpartum Hemorrhage With Misoprostol: Who do we Treat? Who Will Develop Fever?||Gynuity Health Projects|No|Recruiting|September 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1400|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02163616||42734|
NCT02163850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 011, G12160|Transcatheter Aortic Valve Replacement System Pivotal Trial|SALUS Trial TranScatheter Aortic Valve RepLacement System Pivotal Trial The Safety and Effectiveness of the Direct Flow Medical Tanscatheter Aortic Valve System|SALUS|Direct Flow Medical, Inc.|Yes|Recruiting|June 2015|July 2020|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1262|||Both|N/A|N/A|No|||July 2015|July 28, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163850||42716|
NCT02163863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mimics|BioMimics 3D Stent Clinical Investigation: The Mimics Study|BioMimics 3D Stent Clinical Investigation: The Mimics Study|Mimics|Veryan Medical Ltd.|Yes|Active, not recruiting|February 2010|July 2014|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163863||42715|
NCT02164123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFCSPA-FXA-01|Autonomic Effects of T4 Mobilization in Asymptomatic Subjects|Autonomic Effects of T4 Mobilization in Asymptomatic Subjects: Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Completed|July 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02164123||42695|
NCT02160028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2615/SGK|Pain and Placebo Analgesia. Does Extended Information About Dental Procedures Reduce Pain Induced by Dental Treatment?|Pain and Placebo Analgesia. A Double Blinded, Randomized, Clinical Study About the Impact of Information About Anesthesia, and the Experience of Pain and Stress During Dental Treatment.||Norwegian University of Science and Technology|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02160028||43008|
NCT02160054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRA006|Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)|Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)||Astellas Pharma Inc|No|Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|289|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after        kidney transplantation.|September 2015|September 25, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160054||43006|
NCT02160067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1506|A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches|A Four-period, Randomised, Open-label, Crossover, Pharmacokinetic Study to Assess the Dose Proportionality and Relative Bioavailability of Buprenorphine Transdermal Delivery System Second Generation Patches Compared to First Generation Patches, in Healthy Volunteers||Mundipharma Research Limited|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|September 29, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160067||43005|
NCT02160080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB:102-4331A|Boceprevir Treatment in Liver Pre-transplant HCV Patients|Boceprevir Treatment in Liver Pre-transplant HCV Patients||Chang Gung Memorial Hospital|Yes|Recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||June 2014|June 10, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02160080||43004|
NCT02160964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC14-0610-002|Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters (iRetrieve Study)|A Prospective Multi-center Study Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters Placed Across the US|iRetrieve|Heart and Vascular Outcomes Research Institute||Not yet recruiting|May 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1786|||Both|18 Years|80 Years|No|Non-Probability Sample|Participating study centers will enroll patients and enter data in the web-based platform        that include demographics, clinical features, and clinical pathway|March 2015|March 18, 2015|June 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02160964||42936|
NCT02162069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI Ulm TAVR 1.0|Coronary and Structural Interventions Ulm - Transcatheter Aortic Valve Replacement|Coronary and Structural Interventions Ulm - Transcatheter Aortic Valve Replacement|CSI-Ulm-TAVR|University of Ulm|No|Recruiting|June 2014|December 2025|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02162069||42851|
NCT02162082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI Ulm - CTO 1.0|Coronary and Structural Interventions Ulm - Coronary Chronic Total Occlusions|Coronary and Structural Interventions Ulm - Coronary Chronic Total Occlusions|CSI-Ulm-CTO|University of Ulm|No|Recruiting|June 2014|December 2026|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02162082||42850|
NCT02161783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OC003|Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation|Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 2014|July 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 21, 2016|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161783||42873|
NCT02161770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00008|Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment||AstraZeneca|No|Recruiting|December 2014|June 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|99 Years|No|||March 2016|March 24, 2016|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161770||42874|
NCT02162017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X14-0044|Head Position in Stroke Trial (HeadPoST)|An Investigator Initiated, International Collaborative, Multicentre, Cluster Randomised Controlled Trial to Establish the Effects of Head Positioning on Death or Disability in Patients With Acute Stroke|HeadPoST|The George Institute|Yes|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16800|||Both|18 Years|N/A|No|||November 2015|November 8, 2015|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02162017||42855|
NCT02155686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13027|Elderly Chronic Diseases Online Biometric Analysis Home Living Technology|Etude de l'Impact Clinique de la télésurveillance à Domicile Par télémédecine de paramètres biométriques de la Personne âgée Polypathologique|e-COBAHLT|University Hospital, Limoges|No|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|536|||Both|65 Years|N/A|No|||February 2015|March 8, 2015|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02155686||43342|
NCT02155972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179489|The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression|The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial|ALIGN|Women's College Hospital|No|Recruiting|May 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02155972||43320|
NCT02155985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5331|Modulation of Immune Activation by Aspirin|Modulation of Immune Activation by Aspirin||AIDS Clinical Trials Group|Yes|Completed|August 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155985||43319|
NCT02156869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMG1|Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening|Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening: a Multicenter Pragmatic Randomized Controlled Trial|PSAMG|University Paris 7 - Denis Diderot|No|Completed|November 2012|June 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1170|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156869||43251|
NCT02156856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/060/13|Stroke Volume Analysis During Aortic Valve Replacement Trial||standart|Charite University, Berlin, Germany|No|Recruiting|May 2014|||May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|68|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac surgery at a university hospital|August 2014|August 7, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02156856||43252|
NCT02157168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS-1306-04356|Connections for Healthy Women|Connections for Healthy Women||University of Arizona|No|Recruiting|June 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2100|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||June 2014|April 15, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02157168||43228|
NCT02158078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQR13002|A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus||CeQur Corporation|No|Terminated|June 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Probability Sample|Twenty five (25) individuals with T2DM who have an A1C of 7.0% to 11.0%, inclusive, at        Screening (Visit 1) will be recruited at one investigative site.|April 2015|April 14, 2015|June 4, 2014|Yes|Yes|Terminated to allow continued optimization of the product.|No||https://clinicaltrials.gov/show/NCT02158078||43158|
NCT02158091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-193|A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL|A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.||Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|July 2021|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|65 Years|No|||August 2015|August 20, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158091||43157|
NCT02158351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2943/14.11.2013|Gut Microbiota and Modulation of Liver Damage in NAFLD|Role and Pathogenetic Mechanisms of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Severity in Obese and Non-obese Subjects||University of Roma La Sapienza|No|Recruiting|November 2013|October 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|55|Samples With DNA|Stool samples, serum, plasma, liver and (only in the obese patients) adipose tissue|Both|18 Years|65 Years|No|Probability Sample|two groups of patients with morbid obesity undergoing sleeve gastrectomy will be enrolled.        Grouping in patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH)        will be performed based on the histological diagnosis of the type of NAFLD obtained at        operation. Two groups of non-obese patients undergoing cholecystectomy for gallstone        disease will be enrolled. Grouping in patients with simple steatosis (SS) or non-alcoholic        steatohepatitis (NASH) will be performed based on the histological diagnosis of the type        of NAFLD obtained at operation.|June 2014|June 6, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158351||43137|
NCT02163629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-842|Impact of Stress Management Training After Cardiac Transplantation|Impact of Stress Management Training on Quality of Life and Cardiac Post-transplantation Complications in a Controlled Multicentric Comparative Study.|QUIET|Hospices Civils de Lyon|No|Recruiting|April 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02163629||42733|
NCT02163876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SCI-201|Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury|A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury||StemCells, Inc.|Yes|Recruiting|October 2014|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163876||42714|
NCT02164136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUSTOMER-01|Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients|Comparisons of Urinary and Sexual Function Protection and Long-term Outcomes Between Laparoscopy-assisted and Open Pelvic Autonomic Nerve Preservation Total Mesorectum Excision for Male Mid-low Rectal Cancer Patients: a Randomized Controlled Clinical Trial||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|June 2014|June 2023|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Male|20 Years|60 Years|No|||November 2015|November 7, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02164136||42694|
NCT02164149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT121177|Length of Tumour Feeding Artery After Colon Cancer Surgery|Length of Tumour Feeding Artery After Colon Cancer Surgery|ColonCT|University of Aarhus|No|Recruiting|May 2014|November 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|65|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over 18 years with primary colon cancer, who are to have surgery at Randers        Regional Hospital, Denmark.|June 2014|June 12, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02164149||42693|
NCT02160691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANXMT_RCT1|Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder|Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder||Holland Bloorview Kids Rehabilitation Hospital|No|Not yet recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|14 Years|No|||June 2014|June 10, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160691||42957|
NCT02161237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-MA-1001|Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation|A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf® Kidney Transplantation in Asia.|OPTIMIZE|Astellas Pharma Inc|Yes|Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|20 Years|65 Years|No|||January 2016|January 12, 2016|June 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161237||42915|
NCT02162394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-022A|A Study to Determine the Feasibility of Wireless Electrocardiography|Study to Determine the Feasibility of Wireless Electrocardiography||Peerbridge Health, Inc||Not yet recruiting|June 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects referred for 24 hour Holter monitoring|June 2014|June 11, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162394||42827|
NCT02162407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1196|A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin|A Randomised, Three-period Crossover Trial in Healthy Subjects Investigating the Relationship Between the Pharmacodynamic Steady State and the Pharmacokinetic Steady State in the Interstitial Fluid Following iv Infusion of Insulin Detemir and Human Insulin Using Microperfusion Technique||Novo Nordisk A/S|No|Completed|October 1999|December 1999|Actual|December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Male|19 Years|50 Years|No|||June 2014|June 10, 2014|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162407||42826|
NCT02162030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139593|A Component Analysis of Acceptance and Commitment Therapy|The Impact of Self as Context in the Treatment of Long-term Health Conditions With Acceptance and Commitment Therapy; a Feasibility Pilot Study||University of Sheffield|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02162030||42854|
NCT02156219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN/MG-13064-RG ECO577-1|Impact Evaluation of Separating Women and Men in the Metro of Mexico City|Building Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of Separating Women and Men in the Metro of Mexico City, Component of the Program "Viajemos Seguras"||Econometría Consultores|No|Suspended|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2360|||Female|18 Years|65 Years|No|Non-Probability Sample|Women aged 18-65 who reside in Mexico City or the metropolitan area of the Valley of        Mexico and that are users on the Metro lines 4, 5 and 6 between 7 and 9 or 11 and 1pm at        baseline|January 2016|January 19, 2016|June 3, 2014||No|The STC has had financial limitations to start implementing the intervention.|No||https://clinicaltrials.gov/show/NCT02156219||43301|
NCT02156492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14467|A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants|A Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Study of Evacetrapib With Selected Statins in Healthy Chinese Subjects||Eli Lilly and Company|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02156492||43280|
NCT02156258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2013-004A|Acquisition of Breast Mammography Images|Acquisition of Digital Mammography and Breast Images for Clinical Evaluation of FujifilmDigital Breast Tomosynthesis||Fujifilm Medical Systems USA, Inc.|No|Active, not recruiting|June 2014|December 2016|Anticipated|January 2016|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1232|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of at least 200 cancer, 175 recall cases and 350 negative/benign cases will be        accumulated|February 2016|February 1, 2016|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156258||43298|
NCT02156544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148HPS14001|Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519|A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers|CKD-519 FIH|Chong Kun Dang Pharmaceutical|No|Completed|June 2014|August 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|41|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||May 2014|September 9, 2015|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02156544||43276|
NCT02156284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U111111568736|Nurse Empathic Behaviour to Reduce the Fear in Patients of Preoperative Cardiac Surgery|Nurse Empathic Behaviour to Reduce the Fear in Patients of Preoperative Cardiac Surgery||Federal University of São Paulo|No|Completed|May 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|44|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156284||43296|
NCT02156557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00086259|Study of KCC Peptide Application in the Colon|Phase 1B Study of KCC Peptide Application in the Colon|KCC 1B|University of Michigan|Yes|Recruiting|June 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Both|18 Years|100 Years|No|||December 2015|December 1, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156557||43275|
NCT02157441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed 4|the Treatment of Postpartum Hemorrhage Due to Placenta Previa Complete Centralis|Lower Uterine Compression Sutures for the Treatment of Postpartum Hemorrhage Due to Placenta Previa Complete Centralis; Prospective Study|PPH|Benha University|No|Completed|July 2012|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|21 Years|46 Years|No|||October 2015|October 9, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02157441||43207|
NCT02157805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1024|Technological Processes on Quality of Meat|Effect of Technological Processes on Nutritional Quality of Meat Proteins||Institut National de la Recherche Agronomique|No|Completed|August 2013|January 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Male|70 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 5, 2014|January 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02157805||43179|
NCT02157454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP-332-041|Effect of a Website Offering Individual Patients' Experiences for Cancer Patients|Randomized Controlled Trial to Evaluate the Effect of a Website Offering Individual Patient's Experiences on Patient Competence of Colorectal Cancer Patients|DIPExRCT|Berlin School of Public Health|No|Completed|June 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|212|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02157454||43206|
NCT02157467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-041|Study of Combined Oral Contraceptive Effects in Female Subjects|The Effect of Coadministration of BMS-955176 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Female Subjects||Bristol-Myers Squibb|No|Completed|June 2014|||August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|February 9, 2015|June 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157467||43205|
NCT02157818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dex512|A Comparison of Sedative Drugs for Conscious Sedation During Ultrasound Guided Transbronchial Needle Aspiration|A Comparison of Dexmedetomidine Versus Midazolam for Conscious Sedation During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)||Seoul National University Hospital|Yes|Recruiting|June 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|100|||Both|18 Years|75 Years|No|||June 2014|June 4, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02157818||43178|
NCT02154789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005338-39|An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst|An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cysts||University of Edinburgh|No|Not yet recruiting|June 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02154789||43411|
NCT02154802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA037129-01A1|Increasing HIV Testing in Urban Emergency Departments Via Mobile Technology|||National Development and Research Institutes, Inc.||Not yet recruiting|July 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02154802||43410|
NCT02155062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDM/13/14-78|Biomarkers of Whole Grain Wheat and Rye Intake|Urinary Alkylresorcinol Metabolites as a Biomarker of Whole Grain Wheat and Rye Intake||King's College London|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02155062||43390|
NCT02155296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD072235-01|RCT of the Restorative Practices Intervention|Reducing Problem Behaviors Through PYD: An RCT of Restorative School Practices|RPI|RAND|No|Recruiting|August 2014|August 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2680|||Both|12 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02155296||43372|
NCT02160704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33673|Androxal in Male Infertility|PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08)||Baylor College of Medicine|No|Recruiting|December 2014|August 2019|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|35 Years|No|||September 2015|September 16, 2015|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02160704||42956|
NCT02160977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QS-YU|Proprioception of the Knee Post MIS TKA and MIS-QS TKA|Prospective Randomized Comparative Study on the Proprioception of the Knee Post MIS TKA (Minimally Invasive Surgery Total Knee Arthroplasty) and MIS-QS(Quadriceps Sparing ) TKA||Peking University Third Hospital|Yes|Completed|October 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|70 Years|No|||July 2014|July 11, 2014|June 5, 2014||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT02160977||42935|Limitation was that the position reconstruction measurement mainly measures the difference of the reconstructed flex angle, while the reflex circuit and motion perception of the knee was not measured.
NCT02162355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-110|Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects|Randomized, Double-blind, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Multiple Oral Doses of GLPG0634 in Japanese and Caucasian Healthy Subjects||Galapagos NV|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 14, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162355||42830|
NCT02162368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCB/2014/0097|Laryngeal Mask Use in Knee-chest Position in Lumbar Surgery in Neurosurgical Patients|Laryngeal Mask Use in Knee-chest Position in Lumbar Surgery in Neurosurgical Patients||Fundacion Clinic per a la Recerca Biomédica|No|Completed|January 2008|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|358|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent scheduled spine surgery in prone position|June 2014|June 11, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162368||42829|
NCT02162745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 35/12|Nasal Irrigation in Infants With Bronchiolitis.|Randomized Controlled Trial to Evaluate the Efficacy of Nasal Irrigation in Infants With Bronchiolitis||IRCCS Burlo Garofolo|No|Completed|October 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|N/A|365 Days|No|||June 2014|June 12, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162745||42800|
NCT02162992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICOR-2014-01|Systemic Lupus Erythematous and Heart Conduction Disorders|Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous||Germans Trias i Pujol Hospital|No|Recruiting|April 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with SLE visited in the rheumatology outpatient's area.|August 2015|August 10, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02162992||42781|
NCT02162654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131101-823|Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment|The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study|RIPAT|Medical University Innsbruck|No|Recruiting|November 2013|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162654||42807|
NCT02162667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P6 3.2|Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer|Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer||Celltrion|Yes|Active, not recruiting|June 2014|June 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|562|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162667||42806|
NCT02162927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2014|Dietary Nitrate Supplementation and Crossfit Athletes|The Effects of Six-day Dietary Nitrate Supplementation on Strength and Endurance Measurements in Male CrossFit Athletes||Florida State University|No|Completed|August 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02162927||42786|
NCT02155712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74|Triathlon Tritanium Knee Outcomes Study|Triathlon Tritanium Knee Outcomes Study||Stryker Orthopaedics|No|Recruiting|October 2014|May 2026|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155712||43340|
NCT02155725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDEL|Fibrinogen in Haemorrhage of Delivery|Study on the Efficacy and Safety of a Therapeutic Strategy of PPH Comparing Early Administration of Human Fibrinogen vs Placebo in Patients Treated With IV Prostaglandins Following Vaginal Delivery|FIDEL|Laboratoire français de Fractionnement et de Biotechnologies|Yes|Recruiting|April 2014|October 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|434|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02155725||43339|
NCT02156271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013501|Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance|Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance||Duke University||Completed|July 2007|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|65 Years|No|||May 2014|July 9, 2015|May 30, 2014|Yes|Yes||No|October 20, 2014|https://clinicaltrials.gov/show/NCT02156271||43297|
NCT02156596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSAI vs Morphine|IV NSAI Versus Nebulized Morphine Analgesia for First-line Renal Colic|Intravenous Treatment With NSAIDs Versus Nebulized Morphine Analgesia for First-line Renal Colic: Randomized Controlled Double-blind Single-center Study.|NSAI vs NM|University of Monastir|Yes|Recruiting|February 2013|January 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|No|||June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156596||43272|
NCT02156921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-FSP17|App-based Training in eFAST Ultrasound|The Effect of Prompting Self-Regulated Learning Processes on App-Based Ultrasound Training. Study 1||Rigshospitalet, Denmark|No|Completed|May 2014|October 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|34|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02156921||43247|
NCT02156570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1206|DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)|An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection|DARE-CII|Kirby Institute|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156570||43274|
NCT02156583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14C.146|Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients|Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients||Thomas Jefferson University|No|Recruiting|May 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|60 Years|N/A|No|Probability Sample|Consecutive heart failure patients 60 years old or older undergoing left ventricular        assist device implantation.|December 2015|December 11, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156583||43273|
NCT02157246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_043|RHYTHM-I: Investigating Hypoxia in Rectal Tumours|RHYTHM-I: Modulation of Radiotherapy According to HYpoxia: Exploiting Changes in the Tumour Microenvironment to Improve Outcome in Rectal Cancer.|RHYTHM-I|University of Oxford|Yes|Recruiting|October 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02157246||43222|
NCT02156882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaTuTU-TB-01|Establishment of a Clinical Trial Unit in Mavalane, Maputo, in Mozambique|Maputo Tuberculosis Trial Unit- Project (MaTuTU- Project)|MaTuTU|Ludwig-Maximilians - University of Munich|No|Recruiting|June 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Sputum, Urine, Blood|Both|18 Years|N/A|No|Non-Probability Sample|TB patients and TB suspects who present themselves or are referred to theTB clinic at the        Mavalane Health center|March 2016|March 10, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156882||43250|
NCT02156895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061075|Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Inlyta||Pfizer|No|Not yet recruiting|December 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Korea who has a disease for which Axitinib is indicated|March 2016|March 2, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02156895||43249|
NCT02157207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0980|Racial and Aging Effects of Acute Antioxidant Supplementation|Racial and Aging Effects of Acute Antioxidant Supplementation|RACE|University of Illinois at Chicago|Yes|Completed|April 2014|June 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|93|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02157207||43225|
NCT02157480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00231-46|Effect of Electrostimulation on Glucose Profile of Patients With Type 2 Diabetes|ELECTRODIAB2: Effect of an Outpatient Program of Bi-quadricipital Electrostimulation on Glucose Profile of Sedentary Patients With Type 2 Diabetes.|ELECTRODIAB2|University Hospital, Caen|No|Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|80 Years|No|||January 2016|February 9, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02157480||43204|
NCT02157493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U261IHS0080-01-00|Evaluation of an Entrepreneurship Program for American-Indian Youth|Evaluation of an Entrepreneurship Program on Psychosocial, Behavioral Health, Educational and Economic Outcomes Among American-Indian Youth||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||May 2014|January 20, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157493||43203|
NCT02157831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 10904|Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Redosing With CP-870,893 in Patients With Clinical Benefit After a Single Infusion of CP-870,893 From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2005|February 2008|Actual|February 2008|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157831||43177|
NCT02157844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0878F|Fat Metabolism in OSA and COPD|Fat Metabolism and Digestion in Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease||Texas A&M University|No|Recruiting|April 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|65|Samples With DNA|Urine, adipose tissue, serum, plasma|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with OSA or COPD will be recruited when visiting a medical or pulmonary clinic in        and outside the surrounding area of College Station. Patients and healthy subjects will        also be recruited by responding to distributed flyers in the community in the College        Station area; for example in hospital/clinic waiting areas, clinic rooms and bulletin        boards at Scott & White and the CSMC or any other hospital. Other general recruitment        material in relation to the nutrition research that the research group performs at Texas        A&M can be placed on bulletin boards at Scott & White and the CSMC.|February 2016|February 8, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157844||43176|
NCT02163382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-3388|Impact of NAVA (Neurally Adjusted Ventilatory Assist) on Ventilatory Demand During Pediatric Non-Invasive Ventilation|Impact of NAVA (Neurally Adjusted Ventilatory Assist) on Ventilatory Demand During Pediatric Non-Invasive Ventilation|NAVANI|St. Justine's Hospital|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|N/A|18 Years|No|||November 2015|November 20, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163382||42752|
NCT02163642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-BRO-2013-154|Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis|Bronchial Infections in Patients With Non-Cystic Fibrosis (CF) Bronchiectasis; Role of Innate Lung Defense Mechanisms and Utility of an Electronic Nose for Its Diagnosis||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Enrolling by invitation|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|-  Serum samples        -  Sputum samples and cultures|Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of non-CF bronchiectasis will be recruited from the outpatient        clinic of the Pneumology Service of the Sant Pau Hospital in Barcelona|May 2014|June 11, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02163642||42732|
NCT02163889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00254|Serial Therapeutic and Antifungal Monitoring Protocol|Serial Therapeutic and Antifungal Monitoring Protocol|STAMP|T2 Biosystems|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|At each time point, three 4 ml whole blood specimens will be collected. One sample will be      tested, and the remaining samples will be available for use in investigating discrepant      T2Candida assay and blood culture results, or may be used for research purposes|Both|18 Years|95 Years|No|Non-Probability Sample|Patients receiving treatment with antifungal therapy for 1 of 5 Candida species:          -  Candida albicans          -  Candida tropicalis          -  Candida glabrata          -  Candida parapsolosis          -  Candida krusei|September 2015|September 25, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02163889||42713|
NCT02160990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002683 Exenatide|Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying|Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying||Mayo Clinic|No|Active, not recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160990||42934|
NCT02162043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2366|Development and Evaluation of a Self-administered/Assisted Visual Field Screening Tool for Glaucoma|Development and Evaluation of a Self-administered/Assisted Visual Field Screening Tool for Glaucoma||University of Manchester|No|Recruiting|November 2014|July 2017|Anticipated|June 2015|Anticipated|N/A|Observational|N/A||3|Anticipated|300|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|For the usability trials, volunteers with no previous perimetric experience will be        recruited. Subjects will be based at Greater Manchester area.        For the hospital- and community- based trials subjects will be recruited by Manchester        Royal Eye Hospital's outpatient clinic|June 2015|June 3, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02162043||42853|
NCT02163005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002535a|A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography|Gadolinium Enhanced Dual-Energy Computed Tomography: A Feasibility Study to Assess Image Quality and Diagnostic Confidence||Massachusetts General Hospital|No|Not yet recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|20 Years|N/A|No|||January 2015|January 28, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02163005||42780|
NCT02163018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-MPE1/0043|HAL-MPE1 First-in-human|A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy|HAL-MPE1/0043|HAL Allergy|Yes|Completed|June 2014|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||July 2015|July 9, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02163018||42779|
NCT02162381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105-14-RMC|Methylphenidate Effect on Humphrey Visual Fields|Methylphenidate Effect on Performing Humphrey Visual Fields||Rabin Medical Center|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162381||42828|
NCT02162680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015861|An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion|An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion||Duke University||Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||June 2014|July 29, 2014|June 11, 2014|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT02162680||42805|
NCT02155998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORU-XXX-2014/2|Non-Interventional Study PREVENT|A Non-interventional Study of Postoperative or Post-Radiation trEatment Habits in Locally adVanced Prostate Cancer patiENTs (High Risk)- PREVENT|PREVENT|AstraZeneca|No|Active, not recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|N/A|N/A|No|Non-Probability Sample|Male patients with locally advanced prostate cancer with high and very high risk of        recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18        years and older, consented to participate in this non-interventional study, being treated        for prostate cancer in the oncology institutions / departments in the Russian Federation.|January 2016|January 11, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02155998||43318|
NCT02156037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diabetesdashboardrct|An RCT Evaluation of a Diabetes Dashboard Team Model in Primary Care|Case Management for Underserved Hispanic Type 2 Diabetes Populations||Baystate Medical Center|Yes|Completed|July 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|399|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156037||43315|
NCT02156297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ3201|Sorafenib to Treat FLT3-ITD AML|Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study||The First Affiliated Hospital of Soochow University|No|Recruiting|June 2014|August 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who diagnosed as AML with FLT3-ITD mutation and accepting the prescription of        sorafenib.|October 2015|October 7, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02156297||43295|
NCT02155491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI08889|Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events|Global Anticoagulant Registry in the Field Observing Treatment and Outcomes in Patients With Treated Acute Venous Thromboembolic Events in the Real World|GARFIELD-VTE|Thrombosis Research Institute|Yes|Recruiting|March 2014|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Sites will be selected at random from a representative list reflecting treatment patterns        in each country. Consecutive male and female VTE patients at the randomly selected sited        will be included in the registry if they meet the eligibility criteria.|December 2014|December 10, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02155491|3 Years|43357|
NCT02157259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA-050 Sepsis Study|An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia|An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia|SEA050|University of Oxford|No|Completed|December 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2250|Samples With DNA|Whole blood|Both|N/A|N/A|No|Probability Sample|Male and female patients, age 30 days on the day of enrollment with community-acquired        sepsis or severe sepsis in Southeast Asia. Of the 2,250 enrolled patients, 1,125 will be        adults and 1,125 will be children.|February 2016|February 17, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02157259||43221|
NCT02157506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-1427-02|A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure|A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure||Cardioxyl Pharmaceuticals, Inc|Yes|Completed|June 2014|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Anticipated|48|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02157506||43202|
NCT02156908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601945|D-serine and Cognitive Remediation in Schizophrenia|D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot and D-serine and Cognitive Remediation in Schizophrenia: Double Blind||Nathan Kline Institute for Psychiatric Research|No|Active, not recruiting|August 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|64 Years|No|||June 2014|March 18, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156908||43248|
NCT02157220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC12098|Prospective Double-blinded Randomised Comparison of Profix Mobile to Fixed Bearing Knee Replacements|||The University of New South Wales|No|Completed|May 2005|May 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|N/A|N/A|No|||June 2014|June 3, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02157220||43224|
NCT02157233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/N/01|Post-exercise Food Intake Regulation in a Hot Environment|Post-exercise Food Intake Regulation in a Hot Environment|APPA|University of the French West Indies and French Guiana|No|Completed|October 2013|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02157233||43223|
NCT02158403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC05232014|PREVENtion of HeartMate II Pump Thrombosis|PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management|PREVENT|Thoratec Corporation|No|Active, not recruiting|September 2014|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|300|||Both|N/A|N/A|No|||March 2016|March 18, 2016|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02158403||43133|
NCT02158676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96156587|Effect of Prebiotic and Synbiotic Supplementation in Individuals Undergoing Roux-en-y Gastric Bypass.|Effect of Prebiotic and Synbiotic Supplementation on Inflammatory Markers, Metabolic Parameters and Nutritional Status After Roux-en-y Gastric Bypass.||Universidade Federal de Santa Catarina|Yes|Completed|October 2013|July 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02158676||43112|
NCT02163902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-13-35|Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|A Multicenter, Double-blind, Nontreatment, Long Term Follow up Study of Subjects Who Completed ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Active, not recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|224|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163902||42712|
NCT02163915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-137_102|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder||Takeda|No|Terminated|June 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|47|||Both|18 Years|55 Years|No|||April 2015|April 3, 2015|June 12, 2014|No|Yes|To allow evaluation of emerging non-clinical data (see detailed description below)|No||https://clinicaltrials.gov/show/NCT02163915||42711|
NCT02164162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAR06|Efficacy of a Robotic-assisted Gait Training in Addition to a Conventional Physical Therapy in Parkinson's Disease|Interventional Double Blinded Randomized and Controlled Trial on the Efficacy of a Robotic-assisted Gait Training in Addition to a Conventional Physical Therapy in Parkinson's Disease||Habilita, Ospedale di Sarnico|Yes|Recruiting|June 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|80 Years|No|||June 2014|June 20, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02164162||42692|
NCT02160106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-001|First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors|First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects With Advanced Stage Solid Tumors||MedPacto, Inc.|No|Recruiting|June 2014|April 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02160106||43002|
NCT02160392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUGTS2010|Female Upper Genital Tract in HIV-infected Women|Virologic, Pharmacologic, and Immunologic Characterization of the Female Upper Genital Tract in HIV-infected Women|FUGTS|University of North Carolina, Chapel Hill|No|Completed|May 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|26|Samples Without DNA|Endometrial and cervical lavage specimens|Female|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|We enrolled HIV-1 positive menstruating women between ages 25-48 years.|June 2014|June 6, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160392||42980|
NCT02160405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74282013|Effect on Iron Levels by the Inclusion of Native Potato in the Diet of Children From 2 to 5 Years, ICBF Beneficiaries. Nariño. Colombia. Cluster Randomized Controlled Trial|Effect on Iron Levels by the Inclusion of Native Potato in the Diet of Children From 2 to 5 Years, ICBF Beneficiaries in the Municipalities of Carlosama, Cumbal, Guachucal, Túquerres y Pasto. Nariño. Colombia. Cluster Randomized Controlled Trial||Universidad Nacional de Colombia||Completed|February 2014|||April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|212|||Both|2 Years|5 Years|No|||June 2014|June 6, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02160405||42979|
NCT02162056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI-Ulm-BVS 1.0|Coronary and Structural Interventions Ulm - Bioresorbable Vascular Scaffold|Coronary and Structural Interventions Ulm - Bioresorbable Vascular Scaffold|CSI-Ulm-BVS|University of Ulm|No|Recruiting|November 2013|December 2028|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02162056||42852|
NCT02161796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0525|A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, 4-way Crossover Study to Evaluate the Dose-proportionality and Pharmacokinetics of FG-4592 in Healthy Young and Elderly Male and Female Subjects||Astellas Pharma Inc|No|Completed|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 10, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161796||42872|
NCT02161809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD079372-01A1|Turn up the HEAT - Healthy Eating and Activity Time in Summer Day Camps|Turn up the HEAT - Healthy Eating and Activity Time in Summer Day Camps|HEPA|University of South Carolina|Yes|Recruiting|January 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1000|||Both|6 Years|14 Years|No|||August 2015|August 25, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161809||42871|
NCT02163551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-07-09|Respiratory Event-Related Potentials in Patients With Spinal Cord Injury|Respiratory Event-Related Potentials in Patients With Spinal Cord Injury: An Evaluation of Somatosensory Afferents||University of North Carolina, Charlotte|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with spinal cord injury will participate in an initial enrollment session at        Carolinas Rehabilitation. Patients will be recruited from a registry managed by Dr.        Lieberman. Healthy volunteers will be recruited through e-mail solicitation for volunteers        for a project examining breathing sensations distributed to faculty, students, and staff        in the College of Health and Human Services.|December 2015|December 2, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163551||42739|
NCT02162693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMG-KOA-Ⅱb|Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis|A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis||Cellular Biomedicine Group Ltd.|Yes|Recruiting|November 2013|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||June 2014|December 21, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02162693||42804|
NCT02163213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002151|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D|An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)||Mayo Clinic|No|Active, not recruiting|June 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163213||42765|
NCT02156024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDZX2012115|The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension|||Shanghai Institute of Hypertension||Recruiting|March 2014|||March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||June 2014|June 4, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02156024||43316|
NCT02156310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMFUSA001|Mechanisms of Anti-VEGF Induced Hypertension|Associations Between Antihypertensive Drugs and Patterns of Blood Pressure Changes: a Strategy to Reduce the Burden of Anti-VEGF Induced Hypertension||Flinders University|No|Completed|January 2009|||December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2000|||Both|N/A|N/A|No|Probability Sample|Patients with renal cancer randomised to active treatment, active comparator or placebo in        two finished randomised controlled trials|June 2014|June 3, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02156310||43294|
NCT02159222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-HUM00073474|Sepsis Trial of Early Physical Therapy Outside the ICU|Sepsis Trial of Early Physical Therapy Outside the ICU: A Pilot Feasibility Study|STEP TO IT|University of Michigan|No|Enrolling by invitation|April 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02159222||43070|
NCT02156076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV205-005|A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation|A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation||Bristol-Myers Squibb|No|Recruiting|July 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|80|||Both|18 Years|85 Years|No|||January 2016|March 11, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156076||43312|
NCT02156349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001732|A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.|Integrated Personalized Diabetes Management (Integrated PDM): Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Intergrated PDM in the Care of People With Type 2 Diabates in Diabetes Specialized Medical Practices in Germany (DSP)||Hoffmann-La Roche||Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|540|||Both|18 Years|N/A||||March 2014|October 1, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156349||43291|
NCT02157857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSNA in EBUS-TBNA|One Step Nucleic Acid Amplification in Endobronchial Ultrasound-guided Needle Aspiration Samples|A Molecular Test for Rapid On-site Evaluation in EBUS-TBNAsamples of Lung Cancer Patients||University Hospital, Essen|No|Recruiting|February 2014|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|Endobronchial ultrasound-guided needle-aspiration samples|Both|18 Years|95 Years|No|Non-Probability Sample|Patients with CT-scans suspicious for primary diagnosis of lung cancer and enlarged        mediastinal lymph nodes Patients with known diagnosis of lung cancer and newly enlarged        mediastinal lymph nodes|June 2014|June 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157857||43175|
NCT02158130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-028|Effects of Aerobic Exercise Detraining|Effects of Aerobic Exercise Detraining on Energy Balance in Overweight Persons|E-Mechanic_Fol|Pennington Biomedical Research Center|No|Completed|September 2014|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|25|Samples With DNA|serum, plasma|Both|18 Years|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants that successfully enrolled and completed the E-Mechanic study and are not        past 88 weeks study randomization.|March 2016|March 21, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158130||43154|
NCT02158143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-KY1301|A Single High-dose Oral Supplement of Vitamin D in Young Chinese|||Chinese Academy of Sciences||Completed|October 2013|||April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|25 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158143||43153|
NCT02159235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2010/910|Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)|Heavy Metals (Cadmium, Lead, Mercury, Zinc), Angiogenesis Factors (Endostatin, Angiostatin, VEGF) and Osteopontin in Patients With Coronary Artery Disease||Medical University of Vienna|Yes|Completed|September 2010|April 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|200|Samples With DNA|Blood, Urine|Both|18 Years|80 Years|No|Non-Probability Sample|Population will be recruited during their in-patient stay at the General Hospital of        Vienna|June 2014|June 6, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02159235||43069|
NCT02159781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1476.CTIL|Effect of Periodontal Treatment on Salivary Biomarkers|Effect of Periodontal Treatment on Salivary Biomarkers.||The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|July 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02159781||43027|
NCT02155517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019CBCEA032013|Clinical Effect of Two Pharmacokinetics Model of Propofol|Phase 4: CLINICAL EVALUATION OF TWO PHARMACOKINETICS MODELS OF PROPOFOL IN HEALTHY PEOPLE||Tiva Group|Yes|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|September 21, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02155517||43355|
NCT02160119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-26|Emotional and Change-related Attention in Autism|Emotional and Change-related Attention in Autism|AUTATTEN|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|140|||Both|5 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children/ adults with ASD and healthy children/ adults|February 2015|February 5, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02160119||43001|
NCT02160418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819853|Incentives for Daily Tooth Brushing to Reduce Gingivitis|||University of Pennsylvania|No|Enrolling by invitation|June 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|4||Anticipated|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02160418||42978|
NCT02160431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004-0024|Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD)|Investigating the Neuropsychological Profile of Youth With Obsessive Compulsive Disorder (OCD)||University of Texas at Austin|No|Not yet recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|25|||Both|8 Years|16 Years|No|||June 2014|June 29, 2014|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02160431||42977|
NCT02160717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC-906|Risk of Diabetes in Young Turner Syndrome Patients|Beta-Cell Function in Young Turner Syndrome Patients||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|120|Samples Without DNA|Whole blood|Female|6 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic Turner Syndrome Center of Cincinnati Community Sample|September 2015|September 25, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160717||42955|
NCT02161822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03-056|Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients|A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients||Samsung Medical Center|No|Recruiting|December 2014|April 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|20 Years|N/A|No|||March 2014|May 3, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02161822||42870|
NCT02162095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000995|Is COPD a Risk Factor for Cardiovascular Disease?|Is Chronic Obstructive Pulmonary Disease a Risk Factor for Cardiovascular Disease?||University of Zurich|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|162|||Both|N/A|N/A|No|Probability Sample|Patients with a history of smoking underdoing SPECT-CT imaging due to preoperative        assessmentat the University Hospital Zurich between 01.01.2007 and 31.07.2013.|June 2015|June 2, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02162095||42849|
NCT02163291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-01-2013|Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer|Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer||Peking University|Yes|Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||June 2014|June 11, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02163291||42759|
NCT02163486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-11.1/30|Comparison Between the I-gel and the LMA-Unique|The Influence of Head and Neck Position On The Oropharyngeal Leak Pressure of LMA Unique ™ and I-GEL™||Dokuz Eylul University|No|Completed|December 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|103|||Both|18 Years|65 Years|No|||December 2010|June 11, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163486||42744|
NCT02155764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-13|Ridge Preservation With New Class of Osteoplastic Materials|Comparison of Octacalcium Phosphate Synthetic Bone Graft (OctoFor) and Bovine-derived Bone (Bio-Oss) for Ridge Preservation After Tooth Extraction: Open, Prospective, Non-Randomised Clinical Trial|RP|I.M. Sechenov First Moscow State Medical University|No|Not yet recruiting|November 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|17 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02155764||43336|
NCT02155777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC Prevention|Why do Oral Contraceptives Prevent of Ovarian Cancer?|Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives||University of Southern California|No|Not yet recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Female|30 Years|45 Years|No|||April 2014|June 2, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02155777||43335|
NCT02159768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00376|Visualization of the Larynx With the Airtraq Laryngoscope and Image Transmission|Visualization of the Larynx With the Airtraq Laryngoscope and Image Transmission||National University Hospital, Singapore|No|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|80 Years|No|||January 2016|January 24, 2016|June 9, 2014||No||No|October 25, 2015|https://clinicaltrials.gov/show/NCT02159768||43028|
NCT02156635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS 001|Stroke Treatment Associate to Rehabilitation Therapy and Transcranial DC Stimulation|A Double-blind, Sham-controlled, Randomized Clinical Trial on Stroke Treatment Using Transcranial Direct Current Stimulation|START-tDCS|Federal University of Paraíba|No|Not yet recruiting|February 2016|July 2017|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02156635||43269|
NCT02156947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doppler-Acute Cholecystitis|Correlation Between Power Doppler and Intraoperative Findings of Chronic and Acute Cholecystitis|Correlation Between Preoperative Power Doppler Sonography and Intraoperative Findings - Postoperative Outcomes of Chronic and Acute Cholecystitis Patients: Prospective Clinical Study||Samsun Education and Research Hospital|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|Samples Without DNA|Resected gallbladders pathology|Both|18 Years|N/A|No|Non-Probability Sample|A total of 80 cholecystitis patients (40 symptomatic chronic, 40 acute).|June 2014|June 3, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02156947||43245|
NCT02156960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deno-PTH2365|Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients|||Shinshu University||Recruiting|May 2014|||May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02156960||43244|
NCT02156973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/059|Using Media to Reduce Anxiety for Cardiac Computed Tomography|Using Media to Reduce Anxiety for Cardiac Computed Tomography||Plymouth Hospitals NHS Trust|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|130|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02156973||43243|
NCT02157532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 12.224|Endovascular Acute Stroke Intervention Trial - the EASI Trial|Intra-arterial Thrombectomy as an Acute Treatment Intervention for Stoke: the Endovascular Acute Stoke Intervention (EASI) Trial|EASI|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|January 2013|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02157532||43200|
NCT02157285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816769|Influence of Peer Mentoring on Adolescent Contraceptive Decision Making|The Influence of Peer Mentoring on Contraceptive Decision Making Among Adolescents|ImPACCT|University of Pennsylvania|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|110|||Female|13 Years|21 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|March 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02157285||43219|
NCT02158182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI/14/107/03/028|Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding|Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients||Hospital General de Mexico|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02158182||43150|
NCT02158429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USParentalbonding|Study of Ultrasound To Increase Parental Bonding in Women With Substance Use Disorders|Comparison Study of Three-Dimensional vs. Two-Dimensional Ultrasound in Measures of Maternal and Paternal Bonding||University of Hawaii|Yes|Recruiting|April 2011|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Female|18 Years|50 Years|No|||June 2015|June 8, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02158429||43131|
NCT02159794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLT1401|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADA|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADA|HORIZON CANADA|HLT Inc.|Yes|Withdrawn|August 2014|March 2020|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|75 Years|N/A|No|||March 2015|March 24, 2015|June 4, 2014||No|HLT determined that design changes are necessary before reopening a study|No||https://clinicaltrials.gov/show/NCT02159794||43026|
NCT02155504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3700-CL-0001|A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects|A Phase 1, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects, Including a Drug-drug Interaction Part With Itraconazole||Astellas Pharma Inc|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02155504||43356|
NCT02163655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUPRE|Diuretics for Postpartum High Blood Pressure in Preeclampsia|Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial|DIUPRE|Instituto Materno Infantil Prof. Fernando Figueira|No|Completed|March 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|N/A|N/A|No|||August 2015|August 24, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163655||42731|
NCT02161003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Azhar52980070|Stem Cells Therapy for Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty|Therapeutic Effect of Stem Cells in Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty||Al-Azhar University|Yes|Recruiting|October 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|2 Years|12 Years|No|||June 2014|June 8, 2014|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161003||42933|
NCT02161250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312014354|Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses|Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses||Purdue University|No|Completed|April 2014|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02161250||42914|
NCT02161484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13030184|Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement|A Prospective, Randomized, Blinded, Controlled Study Evaluating the Efficacy of Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement||University of Pittsburgh|No|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2014|June 9, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02161484||42896|
NCT02162433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-019H|The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation|Does Dexmedetomidine Decrease the Incidence of Untoward Airway Events After Deep or Awake Extubation in Patients Undergoing Adenotonsillectomy?||Massachusetts Eye and Ear Infirmary|Yes|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|336|||Both|3 Years|16 Years|No|||September 2015|October 1, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162433||42824|
NCT02162706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salivary Cortisol|Salivary Cortisol Measurements by Mass Spectrometry|Pilot Study of Salivary Cortisol Measurements by Mass Spectrometry||Stanford University|Yes|Recruiting|June 2013|June 2025|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples Without DNA|Saliva was collected using Salivabio children's swab (SCS).|Both|3 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with possible endocrine disorders seen during outpatient pediatric endocrinology        visit or inpatient consultations. Healthy controls were open to the general public in        California.|June 2014|June 12, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162706||42803|
NCT02162719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29227|A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer|A RANDOMIZED, PHASE II, MULTI-CENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER||Genentech, Inc.||Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162719||42802|
NCT02162953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008089|Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.|Development of Induced Pluripotent Stem Cells From Patients With Best Disease and Other Inherited Retinal Degenerative Diseases.||Mayo Clinic|No|Recruiting|February 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood (10 ml) for DNA/RNA extraction      Dermal Tissue from Skin punch biopsy|Both|5 Years|N/A|No|Non-Probability Sample|Children (as well as their parents) and adults with mutations in the gene BEST1 resulting        in one of the five bestrophinopathies.|March 2016|March 16, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162953||42784|
NCT02162966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSMC-CCD-AFM-002|Safety and Efficacy Study of High Dose Colistin|Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial||King Saud Medical City|No|Recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02162966||42783|
NCT02162979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR#52031|Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease|A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease||Loma Linda University|Yes|Terminated|February 2002|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||June 2014|June 20, 2014|December 26, 2007|Yes|Yes|Not enough subjects.|No|June 20, 2014|https://clinicaltrials.gov/show/NCT02162979||42782|
NCT02156050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-O2|Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant|Utilisation du Dispositif BBloo® Pour le Traitement de l'ictère néonatal : Satisfaction Des Parents et Des Personnels Soignants|ICT-O2|Association Pédiatrique des Groupes d'Acuueil et de Recherche|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Weeks|42 Weeks|No|||June 2014|June 3, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02156050||43314|
NCT02155842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.12327|Exercise Training in Treating Diastolic Heart Failure|High Versus Moderate Intensity Endurance Exercise Training in Treating Diastolic Heart Failure|TREND-HF|Norwegian University of Science and Technology|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02155842||43330|
NCT02159534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU15/neuro/primebrain|Primebrain Stimulation|Multicentric Prospective Randomised-Controlled Clinical Study Assessing the Efficacy in Single-blind and the Safety of NOBEPPI (Norwegian-Belgian Physical Programme for Preterm Infants) Sensorimotor Stimulation on Neuropsychological Development of Preterm Infants (Born Before 32 Weeks' Gestation) or Infants Born Weighing Less Than 1500 g||Queen Fabiola Children's University Hospital|No|Recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|N/A|No|||October 2015|October 20, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159534||43046|
NCT02157545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pyridostigmine|The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine|The Dose-response Relationship of Rocuronium in Patients Taking Pyridostigmine Preoperatively Compared With Age and Sex Matched Controls||University of Toledo Health Science Campus|No|Recruiting|March 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects taking pyridostigmine for any reason who are scheduled for surgery under general        anesthia.|February 2016|February 2, 2016|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02157545||43199|
NCT02157896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1583-660110|Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke|Dynamic Changes of Vascular Endothelial Growth Factor and Endostatin in Association With Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke||Shanghai 6th People's Hospital|No|Completed|May 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Peripheral blood samples|Both|45 Years|74 Years|No|Probability Sample|The patient group comprised twenty male and ten female. Their age ranged from 45 to 74        years, with mean age of 54.3 years. Locations of infarct, as evidenced by radiologic and        neurologic symptoms or signs, included the territories of the middle cerebral artery (9        cases), the posterior cerebral artery (8 cases) the anterior cerebral artery (6 cases),        vertebrobasilar area (5 cases), and watershed area (2 cases with cortical and subcortical        low densities crossing typical vascular territories).|October 2015|October 20, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02157896||43172|
NCT02157909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-055|DW Evaluation of Lotrafilcon B Lenses in a Modified Design|Daily Wear (DW) Evaluation of Lotrafilcon B in a Modified Design||Alcon Research|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|134|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|June 4, 2014|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT02157909||43171|
NCT02158962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[460913-1]|Empowered Sisters Project Making Choices Reducing Risks|An Integrated Risk Reduction Intervention for Abused African Caribbean Women|ESP|University of the Virgin Islands|Yes|Recruiting|August 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02158962||43090|
NCT02156648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140259-01H|A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma|A Feasibility Study for Women Receiving Adjuvant or Neo-adjuvant Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma|OTT 14-01|Ottawa Hospital Research Institute|Yes|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Female|19 Years|N/A|No|||January 2016|January 27, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02156648||43268|
NCT02156661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT-FC-14|Oxytocin and Emotion Processing|||University Hospital, Bonn|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156661||43267|
NCT02159846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC14-1287|Effects of Mixed Herbs on Blood Glucose and Lipid Profile in T2DM Patients|The Effects of Mixed Herbs on Blood Glucose and Lipid Profile of Patients With Established Type II Diabetes Mellitus|T2DM|International Islamic University Malaysia|Yes|Completed|August 2013|October 2013|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|80 Years|No|Non-Probability Sample|In the present study, 20 patients with established T2DM were recruited from the M-OPD,        HTAA, Kuantan; and equally divided into the control and the test groups (10 patients in        each group).These patients were either fed with placebo (maize starch) or 4 g daily mixed        herbs (on wet weight basis).|June 2014|June 7, 2014|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159846|6 Months|43022|
NCT02160756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104824|Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 3 Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|75|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|June 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02160756||42952|
NCT02161016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|map3-2014|A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft|A Radiographic and Clinical Outcomes Study Evaluating map3® Cellular Allogeneic Bone Graft in Patients Undergoing Bone Grafting in the Foot/Ankle||RTI Surgical|No|Terminated|June 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||February 2015|March 31, 2015|June 6, 2014||No|slow recruitment|No|February 26, 2015|https://clinicaltrials.gov/show/NCT02161016||42932|
NCT02161029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/97|Flexible Endoscopy Biopsies for Submucous Tumors With a New Drill Instrument|Flexible Endoscopy Biopsies With the New Drill Biopsy Instrument for Submucous Tumors||Region Skane|No|Recruiting|June 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Both|N/A|N/A|No|||January 2015|January 12, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02161029||42931|
NCT02161263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30301|Quality of Vision and Quality of Life With LASIK|Patient Quality of Vision and Quality of Life With LASIK Surgery||Stanford University|No|Recruiting|March 2014|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Adults over the age of 21 with healthy eyes and nearsightedness, farsightedness and/or        astigmatism|November 2015|November 22, 2015|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161263||42913|
NCT02161497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0313-13-MMC|Clinical History Taking Versus the Addition of an Electronic File Consultation in Pediatric Pre-operative Assessments|Comparison of Clinical History Taking Versus the Addition of an Electronic Patient File Consultation in Pediatric Pre-operative Assessments||Meir Medical Center|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|N/A|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parents of children being interviewed at pre anesthesia assessment|June 2014|April 27, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161497||42895|
NCT02162147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/70X|How Safe Are Our Pediatric Emergency Departments?|How Safe Are Our Pediatric Emergency Departments? A National Prospective Cohort Study||Children's Hospital of Eastern Ontario|No|Active, not recruiting|November 2014|August 2017|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6385|||Both|N/A|18 Years|No|Non-Probability Sample|Subjects presenting to one the nine participating Canadian pediatric hospitals (BC        Children's Hospital (BC), CHU Sainte-Justine (PQ), Children's Hospital of Eastern Ontario        (ON), The Hospital for Sick Children (ON), Children's Hospital of Western Ontario (ON),        Children's Hospital of Winnipeg (MB), Janeway Children's Health and Rehabilitation Centre        (NL), Stollery Children's Hospital (AB) and Alberta Children's Hospital (AB)) Emergency        Departments|February 2016|February 7, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162147||42846|
NCT02162446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPS-B-001|68Ga-OPS202 Study for Diagnostic Imaging of GEP NET|An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)||Ipsen|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02162446||42823|
NCT02162459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 dated January 2014|Strength-enhancing Effect of Whey Protein Supplementation Following Resistance Exercise in Adolescent Males|Strength-enhancing Effect of Whey Protein Supplementation Following Resistance Exercise in Adolescent Males||Olympia Eye Clinic|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|||Male|16 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|male high school athletes|June 2014|June 10, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02162459||42822|
NCT02162732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC009|Molecular-Guided Therapy for Childhood Cancer|Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers||Spectrum Health Hospitals|Yes|Recruiting|June 2014|June 2021|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|13 Months|21 Years|No|||January 2016|January 18, 2016|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162732||42801|
NCT02163811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1143-R|Self-management to Improve Function Following Amputation|Self-management to Improve Function Following Amputation|VETPALS|VA Office of Research and Development|No|Recruiting|July 2014|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02163811||42719|
NCT02163824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPI-121-C-001|Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation|A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation|Hawaii-1|Kala Pharmaceuticals, Inc.|No|Completed|May 2014|March 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|380|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163824||42718|
NCT02163252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211699_5|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies: Study 5|Does Early Intervention Improve Weight Loss Outcomes Among Individuals Enrolled in an Internet-based Weight Loss Program?||The Miriam Hospital|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|70 Years|No|||February 2015|February 18, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163252||42762|
NCT02163265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130111-621|Impact of Surgical Treatments of Thoracic Deformation on Cardiopulmonary Functions|Impact of Surgical Treatments of Thoracic Deformation on Cardiopulmonary Functions||Medical University Innsbruck|No|Not yet recruiting|July 2014|January 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|10 Years|50 Years|No|||June 2014|June 11, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02163265||42761|
NCT02163226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0640|A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms|A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms||M.D. Anderson Cancer Center|Yes|Recruiting|August 2014|||August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163226||42764|
NCT02163239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRT-0001|Post Market Study for FloShield 10mm Reusable Cannula and Blunt Obturator and Robotic FloShield|Post Market Study: Use of the Reusable FloShield 10mm Endoscopic Cannula and Blunt Obturator and the Robotic FloShield System During Robot-assisted Laparoscopic Single-Site Surgery. A Multicenter Historical Control Comparison||Minimally Invasive Devices, Inc.|No|Terminated|March 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Subjects will be recruited from a population of patients who are from the medical practice        of the study investigator and who are scheduled to undergo robot-assisted laparoscopic        single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy|September 2015|September 25, 2015|June 10, 2014|No|Yes|Not meeting primary objective of the study|No||https://clinicaltrials.gov/show/NCT02163239||42763|
NCT02163499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-005|Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months Including Randomized Withdrawal|Multicenter, Multi-Dose, Open-Label Maintenance of Long-Term Safety and Efficacy of Sodium Zirconium Cyclosilicate (ZS) in Hyperkalemia, Including a Randomized, Double-Blind, Placebo-Controlled Withdrawal||ZS Pharma, Inc.|No|Active, not recruiting|June 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163499||42743|
NCT02158416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLXPRO017|Platelet Products Tested With the ThromboLUX® Platelet Quality Test|Blinded Study on Consecutive Transfusable Platelet Products Tested With the ThromboLUX® Platelet Quality Test||LightIntegra Technology|No|Completed|December 2013|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|||Both|18 Years|N/A|No|Probability Sample|The study population consists of adults who require treatment of a blood cancer with        platelet transfusion(s). Patients will be stable and thrombocytopenic, however treatment        center will intervene for bleeding. Adult hematology-oncology outpatients.|March 2015|March 30, 2015|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158416||43132|
NCT02158689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10017|Comparison of Treatment Modalities in Poor Responders Undergoing IVF|||Istanbul University|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|42 Years|No|||January 2016|January 7, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02158689||43111|
NCT02167243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013607|A Reinforcement Approach to Improve Diabetes Management|A Reinforcement Approach to Improve Diabetes Management - Randomized Trial||Yale University|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|21 Years|No|||July 2015|July 20, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167243||42456|
NCT02159287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-01-01-5667|Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke|Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation||Shiraz University of Medical Sciences|Yes|Recruiting|January 2014|September 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 6, 2014|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02159287||43065|
NCT02159300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS697348|Brain Rhythms in Fibromyalgia: A Magnetoencephalography (MEG) Study|Brain Rhythms in Fibromyalgia: A Magnetoencephalography (MEG) Study|FMP|New York University School of Medicine|No|Completed|December 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with fibromyalgia pain in the greater New York City area.        Pain-free women in the greater New York City area.|October 2015|October 5, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02159300||43064|
NCT02155322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4031-400|A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)|A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia||Merck Sharp & Dohme Corp.|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|June 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02155322||43370|
NCT02155335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8259-027|Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)|Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis|SMART|Merck Sharp & Dohme Corp.|No|Completed|July 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155335||43369|
NCT02158715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PocketCPR|Assessment of Validity of Depth by PocketCPR as Sites of Smartphone on Arm|Assessment of Validity of Depth by PocketCPR as Sites of Smartphone on Arm||Hanyang University|No|Completed|April 2014|August 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Basic Life Support certtification licenced by American Heart Association        Clinical experience more than 3 years associated with CPR|August 2015|August 31, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02158715||43109|
NCT02158728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVT Collect Study|Supraventricular Tachycardia Collection Study|||Medtronic Cardiac Rhythm Disease Management||Recruiting|June 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|ICD indicated|June 2014|June 6, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02158728||43108|
NCT02159508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322-E9-05|Intensive Nutrition Counselling in Patients With Head and Neck Cancer|An Intervention Study Comparing Intensive Nutrition Counselling With On-demand Counselling in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy||Helsinki University Central Hospital|No|Active, not recruiting|November 2007|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|80 Years|No|||May 2014|June 9, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02159508||43048|
NCT02168270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|735-13|Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma|A Phase I Study of Metronomic Temozolomide and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma||University of Nebraska|Yes|Terminated|June 2014|||December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|N/A|No|||December 2015|December 3, 2015|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168270||42378|
NCT02160730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035720|Treatment of Cushing's Disease With R-roscovitine|Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine||Cedars-Sinai Medical Center|Yes|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160730||42954|
NCT02160743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_ATM_104|The Food Effect on Pharmacokinetics and Safety of Fixed-dose Combination of CJ-30056 in Healthy Male Subjects|||CJ HealthCare Corporation|No|Recruiting|May 2014|September 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 9, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02160743||42953|
NCT02161042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100344|The Effect of Blood Transfusion on Endothelial Function|The Effect of Blood Transfusion on Endothelial Function||Lawson Health Research Institute|No|Active, not recruiting|August 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients who come to IV therapy or Oncology day Unit requiring a blood transfusion|November 2015|November 25, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161042||42930|
NCT02161276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNTL-14-01|Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule|Phase 2 Study of The Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes|TNTL|Guizhou Bailing Group Pharmaceutical Co Ltd|Yes|Completed|April 2014|September 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|70 Years|No|||September 2014|September 10, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02161276||42912|
NCT02161510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2248-002|Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Subjects With Hepatitis C Infection||Merck Sharp & Dohme Corp.|No|Completed|July 2014|April 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|13|||Both|18 Years|65 Years|No|||June 2015|June 5, 2015|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161510||42894|
NCT02162472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU78102|Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis|Videocapillaroscopy Assessment During Systemic Agent Therapy in Patients With Psoriasis||Northwestern University|Yes|Recruiting|July 2015|September 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Thirty patients with a confirmed diagnosis of "active" psoriasis treated with a single        systemic agent will be recruited from the Northwestern Medical Faculty Foundation        Dermatology clinic. The study population will include 15 patients receiving adalimumab and        15 patients receiving methotrexate.|February 2016|February 19, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162472||42821|
NCT02162758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-P4-003|Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation|A Randomized, Double-Blind, Phase 4 Study to Evaluate the Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation||Takeda|No|Recruiting|July 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||August 2014|August 18, 2014|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162758||42799|
NCT02163031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0187635|Left vs. Right Radial Approach for Routine Catheterization of Heart Transplant Patients|RADIAL 2 Heart Transplant Study: Left vs. Right Radial Approach Randomized Comparison for Routine Catheterization of Heart Transplant Patients||Hospital Clinic of Barcelona|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163031||42778|
NCT02160314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012119|A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence|A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence||Procter and Gamble|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|June 4, 2014|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT02160314||42986|
NCT02163798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSRF 02030511|Evaluation of Energy Expenditure and Cardiovascular Health Effects From Tai Chi and Walking Exercise|Evaluation of Energy Expenditure and Cardiovascular Health Effects From Tai Chi and Walking Exercise||Chinese University of Hong Kong|No|Completed|January 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|374|||Both|36 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163798||42720|
NCT02164045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-042|Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529|Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 From an Extended-Release Formulation of BMS-663068 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164045||42701|
NCT02163538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Energy Devices-UL|Articulating Enseal Versus Ligasure Energy Devices|A Comparison of Industry Leading Energy Devices for Use in Gynecologic Laparoscopy: Articulating Enseal Versus Ligasure Energy Devices||University of Louisville|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163538||42740|
NCT02163785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPRO|Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position|Estudio A.P.PRO: Estrategia quirúrgica en la amputación Abdominoperineal cilíndrica Del Recto Por cáncer: posición de litotomía vs. Prono-navaja|APPRO|Hospital Universitario La Fe|No|Recruiting|June 2014|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02163785||42721|
NCT02158936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112121|A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)|A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine||GlaxoSmithKline|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02158936||43092|
NCT02158949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00335|Study of Mobile Phone Delivered Intervention to Reduce Alcohol Consumption|Mobilizing to Reduce Overuse of Alcohol in Emergency Department Patients|mROAD|University of Southern California|No|Completed|June 2014|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02158949||43091|
NCT02159261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17177|Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles|A Prospective Multicenter Non-interventional Study on Patients and Physicians Satisfaction of Yaz Plus||Bayer|No|Recruiting|July 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female patients ≥ 18 years old requiring contraception, treated with Yaz Plus for the        first time and for which the inclusion and exclusion criteria are fulfilled, are eligible        for enrolment into the study.|March 2016|March 7, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02159261||43067|
NCT02159274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRH-2014|Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery|Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery||University of Aarhus|Yes|Not yet recruiting|June 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|495|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients, who are undergoing breast conserving surgery (including or without oncoplastic        surgical techniques) for invasive breast cancer or carcinoma in situ by one of the three        breast surgical units in Central Denmark (Viborg, Randers and Aarhus).        And surviving patients from the study by Husted Madsen et. al in 2003-4 ("Sentinel Node        Biopsy and Breast Cancer - Aspects of introducing the method in Denmark") are invited to a        new evaluation of shoulder and arm function.|January 2014|June 5, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02159274|18 Months|43066|
NCT02155920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CUS224T|Everolimus for Children With Recurrent or Progressive Ependymoma|Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma||University of Texas Southwestern Medical Center|Yes|Recruiting|February 2015|December 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|2 Years|21 Years|No|||February 2016|February 5, 2016|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155920||43324|
NCT02167464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34HL105880|Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study|Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study|TRH|Medical University of South Carolina|Yes|Active, not recruiting|June 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|80 Years|No|||September 2014|September 3, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167464||42440|
NCT02167477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/NW/0805|Comparison of Indirect and Direct Laryngoscopy in Obese Patients|Comparison of the C-MAC Video Laryngoscope With Conventional Direct Laryngoscopy in Morbidly Obese Patients Using a Photographic Overlay Technique||Aintree University Hospitals NHS Foundation Trust|No|Recruiting|January 2013|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167477||42439|
NCT02167711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTC001|Treatment for Bile Duct Cancer in the Liver|Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study||Chinese University of Hong Kong|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167711||42421|
NCT02168023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACC-1|Study to Evaluate DACC Dressings for the Prevention of Surgical Site Infections in Women Undergoing Caesarean Section.|Randomised Controlled Trial Evaluating Dialkylcarbamoyl Chloride (DACC) Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Caesarean Section.||Medical University of Warsaw|No|Completed|June 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|543|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168023||42397|
NCT02156115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140127|Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders|Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|2 Years|90 Years|Accepts Healthy Volunteers|||April 2015|September 25, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02156115||43309|
NCT02156128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100878|Subjective Memory Complaints, Objective Memory Performance and Cognitive Training|Study of Subjective Memory Complaints, Objective Memory Performance and Cognitive Training in Patients With Complex Symptom Disorders||Norwegian University of Science and Technology|No|Completed|October 2013|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|59 Years|No|||November 2015|November 30, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02156128||43308|
NCT02160457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120162|Gait Analysis and Interdisciplinary Interventions for Children With Cerebral Palsy|Instrumented Gait Analysis and Individually Tailored Interdisciplinary Interventions for Children With Cerebral Palsy: A Randomized Controlled Trial|CPinMotion|University of Southern Denmark|No|Enrolling by invitation|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|8 Years|No|||November 2015|November 30, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02160457||42975|
NCT02160769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1075/90/2013|Tear Layer Lipid Thickness in Pterygium Patient Before and After Surgery|The Assessment of Tear Layer and Tear Layer Lipid Distribution Pre and 1 Month Post Pterygium Surgery Using a LipiView Ocular Surface Interferometer (LipiView)||Singapore National Eye Centre|No|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|21 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal volunteers and Pterygium patients undergoing surgery to remove Pterygium|February 2016|February 22, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160769||42951|
NCT02161523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059-14-MMC|The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation|||Meir Medical Center||Not yet recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Biopsy from lung tissue|Both|N/A|N/A|No|Probability Sample|Patient with non small cell lung carcinoma that need a surgery without connection to this        experiment|July 2014|July 13, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161523||42893|
NCT02161835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-026|Relations Between Myotonia and Fitness|Relations Between Fitness Status and the Severity of Myotonia in Patients With Congenital Myotonia||Rigshospitalet, Denmark|No|Completed|April 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|75 Years|No|||May 2015|May 13, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161835||42869|
NCT02162121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC06-14|Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?|Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?||ASST Gaetano Pini-CTO|No|Recruiting|May 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|February 9, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02162121||42848|
NCT02162134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BenazirBH|Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy|Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy||Benazir Bhutto Hospital, Rawalpindi|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 11, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02162134||42847|
NCT02162420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OC127|Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia|Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|January 2015|July 2024|Anticipated|July 2024|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|70 Years|No|||January 2016|January 21, 2016|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162420||42825|
NCT02162771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 3.3|To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan|A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma|rituximab|Celltrion|No|Active, not recruiting|June 2014|June 2020|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02162771||42798|
NCT02163278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBPR108-102|A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DBPR108 in Healthy Male Subjects||National Health Research Institutes, Taiwan|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163278||42760|
NCT02163564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501|Development of an Insomnia Treatment for Depressed Adolescents|Development of an Insomnia Treatment for Depressed Adolescents||University of Michigan|No|Completed|April 2012|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|13 Years|19 Years|No|||January 2016|January 28, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02163564||42738|
NCT02163577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX023-CL201|Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against FGF23, in Pediatric Subjects With X-linked Hypophosphatemia (XLH)|A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)||Ultragenyx Pharmaceutical Inc|Yes|Active, not recruiting|June 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|5 Years|12 Years|No|||August 2015|August 17, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163577||42737|
NCT02164058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA 2011-01|TandemHeart to Reduce Infarct Size (TRIS Trial)|A Randomized Controlled Multicenter Study on the Use of the TandemHeart to Reduce Infarct Size|TRIS|CardiacAssist, Inc.|Yes|Withdrawn|January 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 12, 2014|Yes|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT02164058||42700|
NCT02159495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13272|Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With Relapsed or Refractory CD123+ Acute Myeloid Leukemia||City of Hope Medical Center|Yes|Recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159495||43049|
NCT02167022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401195212|Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy|Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy||University of Arizona|Yes|Recruiting|November 2014|||November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|12 Months|36 Months|No|||January 2016|January 5, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02167022||42473|
NCT02159001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22014|Electroconvulsive Therapy in Clozapine-resistant Schizophrenia|Efficacy and Cognitive Effects of Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia||Niuvanniemi Hospital|No|Recruiting|June 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|64 Years|No|||October 2015|October 15, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02159001||43087|
NCT02159014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DanceFit Prime|DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study|DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention to Reduce the Risk of Heart Disease, Stroke, Diabetes, and Dementia in Inactive Adults, in Primary Care Settings - A Feasibility Study|DanceFit|North Essex Partnership NHS Foundation Trust|No|Completed|August 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|17 Years|N/A|No|||October 2015|October 13, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159014||43086|
NCT02156180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC14QPAH10|Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma|A Prospective Cohort Study to Determine Specific Volatile Organic Compounds Present in Breath Samples of Patients With Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Using Gas Chromotography-mass Spectrometry||Queensland Centre of Excellence for Head and Neck Cancer|No|Suspended|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who attend the Head and Neck Cancer Clinic at the Princess Alexandra Hospital,        Brisbane, Australia|April 2015|April 20, 2015|June 3, 2014||No|Awaiting funding to facilitate selected-ion flow-tube mass spectrometry (SIFT/MS)|No||https://clinicaltrials.gov/show/NCT02156180||43304|
NCT02159820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-BT-010|Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer|Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial|DAC and CT|Chinese PLA General Hospital|Yes|Recruiting|June 2014|June 2024|Anticipated|June 2024|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|80 Years|No|||June 2014|June 9, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02159820||43024|
NCT02155556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIU|Diurnal Changes of the Cornea - a Pilot Study|Diurnal Changes of the Cornea - a Pilot Study||Vienna Institute for Research in Ocular Surgery|No|Recruiting|June 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 volunteers/patients (10 patients >50 years old; 5 patients with a corneal astigmatism        of >1 D)|June 2014|June 2, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155556||43352|
NCT02155569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atauni8|Extraperitoneal Versus Transperitoneal Cesarean Section|Extraperitoneal Versus Transperitoneal Cesarean Section: A Prospective Randomized Comparison||Ataturk University|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155569||43351|
NCT02155582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16790|Copanlisib Pharmacodynamic Study|A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors||Bayer|No|Recruiting|August 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|100 Years|No|||February 2016|February 29, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155582||43350|
NCT02155881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIC-RR-001|Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia|A Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Phase III (Registration) Study to Assess the Efficacy and Safety of Ciclesonide Nasal Spray (Omnaris®) 200 mcg Once Daily in the Treatment of the Patients With Seasonal Allergic Rhinitis (SAR) in Russia||Takeda|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155881||43327|
NCT02155894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeRA_15-05-14|Tight Control of Disease Activity Among Patients With RA Based on a Systematic Telemedicine Treatment Strategy|Tight Control of Disease Activity Among Patients With Rheumatoid Arthritis Based on a Systematic Telemedicine Treatment Strategy|TeRA|University of Aarhus|Yes|Completed|May 2014|July 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|300|||Both|18 Years|N/A|No|||April 2014|July 8, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155894||43326|
NCT02155907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rtest|Detection of Atrial Fibrillation in Patients With Recent Stroke or TIA: Validity of Automated Loop-recording (Rtest) Compared to Holter Recording and Predictive Value of Short Runs of Atrial Fibrillation and an Excess Supraventricular Extra Systoles for a New Stroke|Detection of Atrial Fibrillation in Patients With Recent Stroke or TIA: Validity of Automated Loop-recording (Rtest) Compared to Holter Recording and Predictive Value of Short Runs of Atrial Fibrillation and an Excess Supraventricular Extra Systoles for a New Stroke||University of Aarhus|No|Recruiting|June 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|430|||Both|60 Years|N/A|No|Non-Probability Sample|Stroke and TCI patients admitted to the Regional Hospital Holstebro|November 2013|December 2, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155907|1 Year|43325|
NCT02160782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-304|A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome|Long-Term, Open-Label Study With a Double-Blind, Placebo-Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Alagille Syndrome|ICONIC|Shire|Yes|Active, not recruiting|September 2014|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Months|18 Years|No|||March 2016|March 14, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160782||42950|
NCT02145195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D214|The Effect of Vitamin D Supplements on Vitamin D Status, Cardiometabolic Health and Immune Defense in Danish Children|Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN) Junior|ODIN Junior|University of Copenhagen|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|130|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145195||44146|
NCT02136277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13115|Vascular Changes During Colorectal Surgery|Measurement of Changes in Macro- and Microvascular Blood Flow During Major Colorectal Surgery|MaMiFlo|University of Nottingham|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with colorectal cancers, scheduled to undergo open resectional surgery.|January 2015|January 25, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136277||44831|
NCT02137096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400316|Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma|High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma||University of Florida|Yes|Recruiting|June 2014|May 2022|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|30 Years|No|||November 2015|November 20, 2015|May 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02137096||44768|
NCT02136875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC-08-001|Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation|Phase IV Study; Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation||McGill University Health Center|Yes|Completed|July 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|40 Years|N/A|No|||May 2014|May 13, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02136875||44785|
NCT02137109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS028|Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri|Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis||Biogen|No|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|400|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric MS patients who have received at least 1 dose of natalizumab prior to the age of        18 years where the first dose was administered prior to 31 March 2015.|October 2015|October 16, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02137109||44767|
NCT02137967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105091RB|Sodium Hypochlorite Pulpotomies in Primary Molars: Comparison With Conventional 20% Formocresol Pulpotomies|Clinical Evaluation of Sodium Hypochlorite Pulpotomies in Primary Molars: A Long-Term Follow-Up in Comparison With Conventional 20% Formocresol Pulpotomies||National Taiwan University Hospital|No|Recruiting|August 2011|June 2016|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Months|9 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT02137967||44701|
NCT02133807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01200953720|Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis|A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level.|LaRCA|Russian Cardiology Research and Production Center|Yes|Completed|September 2009|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||May 2014|May 9, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133807||45020|
NCT02137616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002003|Antipsychotic to Treat Psychosis Syndrome|Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study||Central South University|Yes|Recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|300|||Both|16 Years|30 Years|No|||May 2014|May 12, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02137616||44728|
NCT02137954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-50|Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.|Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.|LIDOSP|Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||August 2015|August 27, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02137954||44702|
NCT02134054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSI-CS_1|Stavanger IBD Study - Cross Sectional|Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics|SUSI-CS|Helse Stavanger HF|No|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|Samples Without DNA|Standard blood sampling Serum sampling - trough/antibodies of biological agent|Both|16 Years|N/A|No|Non-Probability Sample|Patients with inflammatory bowel disease established (minimum 3 doses) on treatment with        infliximab or adalimumab|November 2015|November 30, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02134054||45001|
NCT02142257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/12|Comparison of Gastric Bypass and AspireAssist Aspiration Therapy for Treatment of Morbid Obesity|Gastric Bypass Procedure and AspireAssist Aspiration Therapy System for the Treatment of Morbid Obesity, Observational Study Over 5 Years||Blekinge County Council Hospital|Yes|Active, not recruiting|May 2014|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|20 Years|60 Years|No|Non-Probability Sample|The study is a prospective investigation of patients in Blekinge with a diagnosis of        obesity. A total of 100 patients will be included consecutively in the study. The        distribution will be 50 patients for each group. Recruitment for Gastric Bypass is made        from the clinic's waiting list for obesity surgery and for AspireAssist those individuals'        self-reported interest for treatment with AspireAssist.|January 2016|January 26, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142257||44372|
NCT02142569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOCO-CRYR-118824|Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood|Effects of a Tocotrienol-Enriched Fraction of Palm Oil and Chinese Red Yeast Rice on Serum Lipids in Hypercholesterolemic Subjects|TOCO-CRYR|University of California, Los Angeles|No|Suspended|December 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||September 2014|December 15, 2015|May 14, 2014|Yes|Yes|We were unable to procure the supplement for this study.|No||https://clinicaltrials.gov/show/NCT02142569||44348|
NCT02142270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCAR|Epidemiology of Sudden Cardiac Arrest in Sub-Saharan Africa: Rationale and Design|||Cameroon Resuscitation Council||Not yet recruiting|January 2015|January 2018|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250000|||Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All residents of districts of interest will be surveyed during 3 years. premature deaths        occurring in residents of districts of interest will be checked for past medical history,        circumstances of death, and autopsy report (if possible). Investigators will also analyze        the employment of resuscitation attempts during the timeframe of sudden cardiac arrest        (SCA) in various patient populations throughout African countries.        The arm group of the study is every resident of the district of interest|May 2014|May 19, 2014|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02142270|3 Years|44371|
NCT02143141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 17294|Low Pain Prediction in Cesarean Section Patients|Eliminating Long Acting Spinal Narcotic Use and Its Associated Side Effects for Those Who do Not Need it After Cesarean Delivery||Wake Forest School of Medicine|Yes|Terminated|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|13|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|March 27, 2014||No|feasibility of population needed to complete study|No||https://clinicaltrials.gov/show/NCT02143141||44304|
NCT02143102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305|Non-invasive Computer-Aided Phenotyping of Vasculopathy|vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy|Q-CAMP|Elucid Bioimaging Inc.|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|After endarterectomy during surgery, the excised plaque specimens will be sent to the      hospital's pathology lab to be analyzed.|Both|18 Years|N/A|No|Non-Probability Sample|Individuals must meet one of the following inclusion criteria in order to be eligible to        participate in the study:          -  Case subjects will be patients with documented carotid atherosclerosis, scheduled for             magnetic resonance or CT angiography and subsequent elective endarterectomy with 30             days of enrollment in the study          -  Case subjects will be patients with peripheral arterial disease (PAD) with clinical             symptoms, scheduled for magnetic resonance or CT angiography and indicated             endarterectomy of diseased areas of femoral arteries within 30 days of enrollment in             the study|August 2015|August 24, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02143102||44307|
NCT02143115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA155347|Comparative Effectiveness of CTC & OC|Comparative Effectiveness of Virtual and Optical Colonoscopy for Colorectal (CRC) Surveillance||Fox Chase Cancer Center|Yes|Recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a history of colorectal cancer|September 2015|September 2, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143115||44306|
NCT02144467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNU_CCBD_LargeSampleCollection|The Establishment of Large-sample Database of "Multiple-MRI/Gene/Cognition"|The Establishment of Large-sample Database of "Multiple-MRI/Gene/Cognition"||Hangzhou Normal University|Yes|Recruiting|April 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|Peripheral Venous Blood|Both|6 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Residents of Hangzhou, China.|March 2015|March 18, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02144467||44202|
NCT02144480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-3049A3|Efficacy of Early Short-term Training on Thrombogenesis in Patients Following Coronary Bypass Surgery|Efficacy of Early Short-term Training on Thrombogenesis in Patients Following Coronary Bypass Surgery||Chang Gung Memorial Hospital|No|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|90 Years|Accepts Healthy Volunteers|||October 2013|May 21, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02144480||44201|
NCT02144194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRG SE036|Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca|TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer|TNM|Cancer Research Group - Collaborative Group, Beirut, Lebanon.|No|Recruiting|March 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||May 2015|July 28, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144194||44223|
NCT02143895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI175|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo||Biocodex|No|Recruiting|December 2013|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|30|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143895||44246|
NCT02143908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-020|Lysine Trial in Adults With Diarrhoea|Efficacy of Lysine Supplementation in Reducing Attack Rates of Diarrhea in Adults: a Community-based Randomized Trial in Urban Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|December 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143908||44245|
NCT02144948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUNiDIA-2014|Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II|Pilot Study to Investigate the Effect of E-coli-nissle as Probiotic Adjuvant to Antidiabetic Standard Care in Patients With Diabetes Mellitus Type II|PUNiDIA|GWT-TUD GmbH|No|Active, not recruiting|August 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|45 Years|80 Years|No|||August 2015|August 18, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144948||44165|
NCT02145208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-02|Study to Assess the Efficacy of Medi-Tate TIND Device|One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-Tate Temporary Implantable Nitinol Device (TINDTM) in Subjects With Benign Prostatic Hypertrophy (BPH).||Medi-Tate Ltd.|No|Recruiting|October 2014|August 2018|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Male|18 Years|80 Years|No|||March 2016|March 21, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145208||44145|
NCT02136290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140047|Prepackaged Foods to Promote Weight Loss|Randomized Clinical Trial of Portion-Controlled Prepackaged Foods to Promote Weight Loss - CHOICES Study.|CHOICES|University of California, San Diego|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|184|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136290||44830|
NCT02136303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO 1511/8-1|Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients|Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of Patients With Age-related Macular Degeneration - an Alternative to Supplements With Isolated Xanthophylls|KALESIGHT|University of Jena|No|Recruiting|February 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|14||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136303||44829|
NCT02136576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11184|Caries Prevention Products & Dentinal Hypersensitivity|Comparing Three Caries Prevention Products on Dentinal Hypersensitivity - A Pilot Study||Tufts University School of Dental Medicine|No|Recruiting|May 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|TUSDM clinics and the greater-Boston community.|June 2015|June 29, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136576||44808|
NCT02136888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058-110|Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects|A Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group, Multiple-dose, Up-titration Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects||Actelion|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|116|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02136888||44784|
NCT02136901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00356|The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System)|The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) A Multi-center, Prospective, Randomized, Interventional, Superiority Clinical Study|VENUS|Active Implants|No|Recruiting|June 2014|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|30 Years|75 Years|No|||June 2015|June 22, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136901||44783|
NCT02137122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400328|Neuromodulation of Cognition in Older Adults|Neuromodulation of Cognition in Older Adults: The Stimulated Brain Study||University of Florida|No|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137122||44766|
NCT02137369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073702|The ISLAND Study: InSuLa Assessed Needs for Depression|Testing an Imaging Biomarker for Treatment Stratification in Major Depression|ISLAND|Emory University|Yes|Recruiting|September 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|55 Years|No|||October 2015|October 30, 2015|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137369||44747|
NCT02137382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC3004|A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Abbott|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|12 Years|N/A|No|||January 2016|January 21, 2016|February 12, 2014||No||No|September 18, 2015|https://clinicaltrials.gov/show/NCT02137382||44746|
NCT02137395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXSX01|The Effect of Dexamethasone on Sugammadex Reversal|The Effect of Dexamethasone on Sugammadex Reversal in Pediatric Patients Undergoing Adenotonsillectomy: a Randomized, Placebo-controlled Study||Cukurova University|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|3 Years|15 Years|No|||August 2015|August 12, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137395||44745|
NCT02137655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-005|Recovery After Fast Track THA / TKA|Prospective Descripive Study of Subacute Function After Total Hip or Knee Arthroplasty|0-21|Rigshospitalet, Denmark|No|Completed|May 2014|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|||Both|55 Years|75 Years|No|Probability Sample|Patients with hip or knee osteoarthritis referred for total joint arthroplasty.|March 2016|March 8, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137655||44725|
NCT02137668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Davies 1|Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin|The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin||Sacramento Pediatric Gastroenterology||Recruiting|July 2010|||May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|40 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137668||44724|
NCT02134041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH101-TD-PB-111-NSC017|Amyloid Accumulation After Mild Traumatic Brain Injury|Observational Study for Amyloid Accumulation After Mild Traumatic Brain|TBI|Taipei Medical University Shuang Ho Hospital|Yes|Recruiting|October 2012|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|150|Samples With DNA|peripheral blood for APOE genotyping|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients aged over 55 years with/without traumatic brain injury 1, 5, 10, 15 years ago|May 2014|May 6, 2014|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT02134041||45002|
NCT02133833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11zyy|Quantum Spectrum Radiation Emitter for Adhesive Capsulitis|Quantum Spectrum Radiation Emitter for Adhesive Capsulitis (Frozen Shoulder or Stiff Painful Shoulder): a Prospective, Self-controlled Trial||Nanjing Junxie Hospital|No|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||July 2014|July 3, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02133833||45018|
NCT02141997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-963|A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate|A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate||AbbVie|Yes|Completed|February 2014|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|222|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02141997||44392|
NCT02142010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY-TM-LPS-2014-01|Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer|||Nanjing Luye Sike Pharmaceutical Co.,Ltd.|Yes|Recruiting|August 2014|||June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Female|18 Years|65 Years|No|||August 2014|August 26, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02142010||44391|
NCT02142881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404M49925|Treatment of Masked Hypertension|Treatment of Masked Hypertension||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|June 2014|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||July 2015|July 23, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142881||44324|
NCT02142894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST001_USA1|Evaluation of the QuantiFERON-TB Test.|||QIAGEN Gaithersburg, Inc|No|Recruiting|May 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with bacteriologically confirmed and untreated TB disease.|January 2016|January 26, 2016|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02142894||44323|
NCT02143934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07200734|Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity|Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province||Papua New Guinea Institute of Medical Research|No|Completed|August 2009|May 2014|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|524|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143934||44243|
NCT02143388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRT-AC-LAHR-NPC|Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial|Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial||Sun Yat-sen University|Yes|Recruiting|May 2014|May 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|70 Years|No|||February 2016|February 20, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02143388||44285|
NCT02144207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAH-RS/2014-LAW|Optimal Laryngoscopic View to Enable GlideScope-assisted Tracheal Intubation|||Nova Scotia Health Authority||Active, not recruiting|September 2014|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|160|||Both|18 Years|75 Years|No|||August 2015|August 12, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144207||44222|
NCT02144233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1134-0832|Restoring Masticatory Function to Treat Chronic Pain|Restoring Masticatory Function as Treatment for Chronic Pain: a Randomized Placebo-controlled Trial|MAP|University of Santiago de Compostela|Yes|Recruiting|September 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||June 2015|June 27, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144233||44220|
NCT02144714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB5-G11-NHV|Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects|A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira® and US Sourced Humira®) in Healthy Subjects||Samsung Bioepis Co., Ltd.|No|Completed|May 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|189|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144714||44183|
NCT02144454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|024/0036|Impact of Meal Fatty Acids on Postprandial Vascular Reactivity|The Acute Effects of Meals Rich in Saturated, Monounsaturated and n-6 Polyunsaturated Fatty Acids on Vascular Function|DIVAS-2|University of Reading|Yes|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|32|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144454||44203|
NCT02145221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221-08|Effects of Music Therapy on the Recovery of Patients Undergoing Spine Surgery|The Effects of Music Therapy in the Recovery of Patients Undergoing Spine Surgery||Beth Israel Medical Center|No|Completed|January 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Both|40 Years|55 Years|No|||May 2014|May 21, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02145221||44144|
NCT02136329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Revaki-001|A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery|A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery|Revaki-001|University of Leicester|Yes|Completed|June 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Both|18 Years|N/A|No|||December 2014|June 12, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136329||44827|
NCT02136342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYS-I-01|Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer|Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer||Chinese Academy of Medical Sciences|No|Terminated|May 2014|||August 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||October 2014|October 19, 2014|May 9, 2014||No|Study site change|No||https://clinicaltrials.gov/show/NCT02136342||44826|
NCT02136628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-HRAEB_2013-020|Hernia Prevention. Effectiveness of Reinforced Tension Line (RTL) Technique Compared With the Conventional Method|Posincisional Hernia Prevention. Effectiveness of Reinforced Tension Line (RTL) Technique Compared With the Conventional Method|Herniapreven|Universidad de Guanajuato|Yes|Enrolling by invitation|July 2014|July 2015|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 14, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136628||44804|
NCT02136589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-097|Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes|Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes|ENTICHIR|Tokyo University|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02136589||44807|
NCT02136602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hct 4321|Interventricular Cardiac Septal Thickness in Fetus of Diabetic Mother Correlated to Postnatal Outcome|Interventricular Cardiac Septal Thickness in Fetus of Diabetic Mother Correlated to Postnatal Outcome||Ain Shams University|No|Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|None Retained|pregnant over 35 weeks. medically free.single intrauterine pregnancy|Female|20 Years|45 Years|No|Non-Probability Sample|pregnant women with diabetes mellites|May 2014|May 9, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02136602|2 Months|44806|
NCT02136914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-AMT-PD301|ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)|Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)|EASE LID|Adamas Pharmaceuticals, Inc.|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|30 Years|85 Years|No|||February 2016|February 9, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136914||44782|
NCT02136927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_12_10|Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer|||Sun Pharma Advanced Research Company Limited|No|Terminated|August 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Female|18 Years|65 Years|No|||March 2016|March 8, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136927||44781|
NCT02137135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARI-05|Menstrual Phase and Postoperative Pain|The Influence of the Menstrual Cycle on Acute and Persistent Pain After Laparoscopic Cholecystectomy||Adnan Menderes University|Yes|Completed|August 2012|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|64|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137135||44765|
NCT02137148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-542|Sonic Window Study Evaluation Plan|Observational Study of the Sonic Window Handheld Ultrasound System for Assistance With Vascular Access and Needle Placement||Analogic Corporation|No|Withdrawn|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|50 adults who require vascular access|March 2015|March 2, 2015|May 12, 2014||No|Study was cancelled|No||https://clinicaltrials.gov/show/NCT02137148||44764|
NCT02137408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-7329|Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health|Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health and Reduce the Risks of Preterm Delivery|DHA-2|Children's Hospital Medical Center, Cincinnati|Yes|Withdrawn|December 2014|April 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|No|||August 2014|September 17, 2014|May 12, 2014|Yes|Yes|PI no longer at Institution|No||https://clinicaltrials.gov/show/NCT02137408||44744|
NCT02137681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-RTX2vs4|A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|2 Cycles Rituximab Compared With Standard Regimen in Management of ITP||Shandong University|Yes|Recruiting|May 2014|January 2016|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2014|November 17, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137681||44723|
NCT02137980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046362|Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site|Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site|CPORT|Johns Hopkins University|Yes|Recruiting|April 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28000|||Both|18 Years|95 Years|No|Non-Probability Sample|The patient population includes inpatients and outpatients undergoing diagnostic cardiac        catheterization for suspected coronary artery disease (CAD) at hospitals without SOS.|April 2015|April 10, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02137980|1 Week|44700|
NCT02134093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tangdu sedation|Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients|Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial||Tang-Du Hospital||Not yet recruiting|July 2014|December 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|120|||Both|55 Years|75 Years|No|||July 2014|July 9, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02134093||44998|
NCT02146651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT008|A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes||Adocia|No|Completed|May 2014|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|38|||Male|18 Years|64 Years|No|||May 2014|December 9, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02146651||44034|
NCT02142907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD|Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast|Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2013|January 2020|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|75 Years|No|Non-Probability Sample|Stage I , stage II of breast carcinoma with breast conservative surgery|February 2015|February 9, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02142907|5 Years|44322|
NCT02143414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01047|Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients &gt;/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients &gt;/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL||National Cancer Institute (NCI)|No|Recruiting|January 2015|||July 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|65 Years|N/A|No|||February 2016|March 14, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143414||44283|
NCT02143427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ScouT-Study 1|Treatment of Children With Peer Related Aggressive Behavior (ScouT)|Treatment of Children With Peer Related Aggressive Behavior With the Computer Based Treatment Program ScouT - a Randomized Controlled Trial||University of Cologne|No|Recruiting|May 2014|September 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|6 Years|12 Years|No|||May 2014|May 20, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143427||44282|
NCT02144220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB-50627|Remote Access to Care, Everywhere, for Parkinson Disease|Remote Access to Care, Everywhere: Using Telemedicine to Deliver Patient-centered Care to Patients With Parkinson Disease|RACE-PD|University of Rochester|No|Active, not recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|287|||Both|30 Years|120 Years|No|||February 2016|February 18, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144220||44221|
NCT02144506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37715|Home-based Program "T&E" for Fall Prevention and QoL in Elderly: a Randomised Control Pilot-study|Tests and Exercises Home-based Program "T&E" for Fall Prevention and Quality of Life in Elderly: a Randomised Control Pilot-study|"T&E"elderly|HES-SO Valais-Wallis|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144506||44199|
NCT02144493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJH-1|Risk Factors for Recurrence of Primary Bile Duct Stones|Case-control Study of Risk Factors for Recurrence of Primary Bile Duct Stones||Chuncheon Sacred Heart Hospital|No|Recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who were diagnosed as CBD stone or calculous cholangitis will be enrolled. These        patients will be divided by patienst with recurrent CBD stone (devlopment of CBD stone        after 1 year from the first development of CBD stone) or not .|May 2014|May 19, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02144493||44200|
NCT02144753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR-2013-NTX|Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)|Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)||Nutrabiotix, LLC|Yes|Recruiting|March 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2015|April 1, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144753||44180|
NCT02144935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012014-077|Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study|Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study|TMCAPTURE|University of Texas Southwestern Medical Center|No|Recruiting|May 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric Transverse Myelitis. The diagnosis of TM needs to be within 3 months of symptom        onset at the time of consent.|February 2016|February 18, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144935|12 Months|44166|
NCT02145728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-14-UL|The Effect of Cognitive Functional Therapy on Patients With Non-specific Chronic Low Back Pain|The Effect of Cognitive Functional Therapy on Patients With Non-specific Chronic Low Back Pain: a Multi-centre Randomized Trial||University of Limerick|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02145728||44105|
NCT02136641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01651989|Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia|Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia||Universidad de Cartagena|Yes|Completed|June 2011|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|May 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136641||44803|
NCT02136615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/14/RAH/118|Does Hyperbaric Oxygen Therapy Lead to a Sustained Increase in Insulin Sensitivity?|Does Hyperbaric Oxygen Therapy Lead to a Sustained Increase in Insulin|HOTAIR3|University of Adelaide|No|Completed|July 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Serum, adipose tissue|Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|November 2015|November 30, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02136615||44805|
NCT02137161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002066-39|Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery|The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study|REPEX|Arcispedale Santa Maria Nuova-IRCCS|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|60 Years|N/A|No|||October 2014|October 28, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137161||44763|
NCT02137174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH-diab013|Home and School Visits Intervention for Children With DM TYPE 1|The Efficacy of Constructed Intervention by Home and School Visits on Glycemic Control in Children With Type I Diabetes||Ben-Gurion University of the Negev|No|Completed|January 2012|February 2014|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Both|4 Years|18 Years|No|||May 2014|May 12, 2014|May 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02137174||44762|
NCT02137434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute calcium|Calcium Over Postprandial Effects of Fatty Meal on Metabolism, Blood Pressure, Oxidative Stress, Endothelial Function.|Influence of Dietary and Supplementary Calcium Over the Postprandial Effects of a Fatty Meal on Metabolism Profile, Blood Pressure, Oxidative Stress, and Endothelial Function of Obese Women.||Rio de Janeiro State University|Yes|Recruiting|February 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|15|||Female|25 Years|50 Years|No|||May 2014|May 9, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137434||44742|
NCT02137421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17001-30-01-91|A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome|Effects of Resveratrol on Crosstalk Between Canonical β-catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients With Metabolic Syndrome: A Case Control Study||Tehran University of Medical Sciences|Yes|Recruiting|April 2012|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Male|40 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137421||44743|
NCT02137694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 13.161 PapU-APV|Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer|Comparison of the Urinary and Vaginal Auto-takings for the Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer.|PapU-APV|University Hospital, Brest|Yes|Completed|April 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|460|||Female|25 Years|65 Years|No|||December 2015|December 15, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02137694||44722|
NCT02138006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN-2012|Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes|Stockholm Diabetes Intervention Study|SDIS|Karolinska Institutet|No|Completed|September 1982|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|102|||Both|18 Years|52 Years|No|Probability Sample|A total of 102 patients with type 1 diabetes mellitus were randomised to ICT (n=48) or ST        (n=54) with insulin between September 1982 and March 1984. The original SDIS study lasted        for an average of 7.5 years and ceased in 1990, by which time 96 patients had been fully        evaluated. Thereafter, all patients were assigned to their regular clinical visits, mainly        at one hospital (Södersjukhuset, Stockholm, Sweden).|November 2015|November 16, 2015|May 9, 2014||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT02138006||44698|
NCT02137993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_OLZ_401|Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia|A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder||CJ HealthCare Corporation|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|65 Years|No|||May 2014|May 11, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02137993||44699|
NCT02134106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00609 (XDR-GNB)|Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria|Multi-center, Open-label Randomized Controlled Trial on the Efficacy of Combination Antibiotic Therapy for Serious Infections Caused by Extensively Drug-resistant Gram-negative Bacteria (XDR-GNB)|XDR-GNB|Tan Tock Seng Hospital|Yes|Not yet recruiting|January 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|90 Years|No|||December 2014|December 12, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02134106||44997|
NCT02146664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-0513|DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization|The Role of DLBS1033 in The Management of Acute Non-ST Elevation of Myocardial Infarction (NSTEMI) Without Early Coronary Revascularization||Dexa Medica Group|Yes|Recruiting|November 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|30 Years|75 Years|No|||November 2015|November 25, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02146664||44033|
NCT02142920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151006|Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers|A Phase One, Open-Label Single-Radiolabeled Dose Study To Investigate The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers||Pfizer|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142920||44321|
NCT02143128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVHF-KS001|Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery|Safety and Quality for Inpatients After Surgery at the Ward. Development and Evaluation of a New Tool: Efficacy Side-effect Score (ESS)|ESScore|Vestre VikenHF Kongsberg Sykehus|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All inpatients after surgery.|December 2015|December 18, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02143128||44305|
NCT02143947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC 1404|Custom Molded Foot Orthoses Effect on Foot Kinematics and Lower Extremity Electromyography During Walking and Running.|The Effect of Two Different Custom Molded Foot Orthoses on Inter-segmental Foot Kinematics and the EMG Activity of Selected Lower Leg Muscles During Walking and Running.|SOLE|Quinnipiac University|No|Completed|September 2008|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|May 19, 2014||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT02143947||44242|
NCT02143960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC85471|VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction|Clinical Study to Evaluate the Performance of the VelaShape III Device in Comparison to Cryolipolysis for Reduction in Waist / Love Handles / Flanks.||Syneron Medical|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143960||44241|
NCT02144974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9R025|Reconstruction of the Pelvic Floor After Total Pelvic Exenteration Using the TMG Flap|Reconstruction of the Pelvic Floor and the Vagina After Total Pelvic Exenteration Using the Transverse Musculocutaneous Gracilis Flap||Tampere University Hospital|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|12|||Female|N/A|N/A|No|Non-Probability Sample|Patients in the department of Gynecology in the University hospital of Tampere, who        underwent total pelvic exenteration with reconstruction of the pelvic floor (no:12)|May 2014|May 21, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144974||44163|
NCT02144766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060717|Prevention of Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block|Prevention of Pro-inflammatory Cytokines-associated Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|April 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|1 Year|5 Years|No|||August 2014|August 24, 2014|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02144766||44179|
NCT02144779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1NRO11179|Family Communication and Support in the Pediatric Intensive Care Unit|Improving Family Outcomes With a Communication Intervention in the Pediatric ICU||Seattle Children's Hospital|Yes|Completed|September 2009|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|220|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02144779||44178|
NCT02144727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-13-712|A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer|A Multicenter Randomized Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer|ADDICT|National Cancer Center, Korea|Yes|Recruiting|January 2014|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1880|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02144727||44182|
NCT02144740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRO-041 - Part 2|Effect of NWT-03 on Blood Pressure|A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects||Newtricious R&D BV|No|Completed|October 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|63|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02144740||44181|
NCT02145754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKP,BSK-0613|Culture Media for Borrelia Burgdorferi Sensu Lato|Comparison of Two Culture Media for Cultivation of Borrelia Burgdorferi Sensu Lato||University Medical Centre Ljubljana|No|Completed|July 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|235|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 24, 2013||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT02145754||44103|
NCT02145767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRMT15|Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial|Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Recruiting|December 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|850|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02145767||44102|
NCT02137447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002484|Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions|A Prospective Observational Study of the Use of Negative Pressure Wound in High Risk Surgical Closed Incisions.||Massachusetts General Hospital|Yes|Recruiting|May 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|95 Years|No|||March 2016|March 23, 2016|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137447||44741|
NCT02136940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA0076-S-202|Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|A Phase 2a, Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Amakem, NV|No|Completed|April 2014|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|103|||Both|30 Years|85 Years|No|||January 2015|January 16, 2015|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136940||44780|
NCT02138058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topiramate for oniomania|Topiramate Trial for Compulsive Buying|Double Blind Controlled Trial of Topiramate for Compulsive Buying|TFO|University of Sao Paulo|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138058||44694|
NCT02137460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBASE01|Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease|Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease|KBASE|Seoul National University Hospital|Yes|Recruiting|May 2014|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|920|Samples With DNA|Plasma, Serum, DNA, RNA|Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young and elderly normal controls: community-based population AD and MCI: clinic or        community-based population|November 2014|November 24, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02137460||44740|
NCT02133872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-00102 Study 1|Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients|Angiotensin and Neuroimmune Activation in Hypertension||University of Florida|No|Recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133872||45015|
NCT02137707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DCA04T|Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya|An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 5 Years|IGLOO|McGill University|No|Recruiting|November 2012|June 2020|Anticipated|November 2019|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|serum, peripheral blood mononuclear cells, DNA|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with relapsing-remitting multiple sclerosis deemed by their treating physician to        be a suitable candidate for Gilenya therapy|May 2014|May 13, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137707||44721|
NCT02138019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910010M|The Application of Fibrin Glue (Tissucol Duo Quick) in External Eye Surgeries|The Application of Fibrin Glue (Tissucol Duo Quick) in External Eye Surgeries||National Taiwan University Hospital|Yes|Completed|December 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|12 Years|85 Years|No|||May 2014|May 13, 2014|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT02138019||44697|
NCT02138032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUNN-001-RCT|Effects of Message Content on Intention to Quit Smoking|Effects of Message Content on Intention to Quit Smoking in Smokers With Peripheral Artery Disease - a Randomised Controlled Trial||University of Stirling|Yes|Terminated|May 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|17|||Both|N/A|N/A|No|||December 2014|December 5, 2014|May 12, 2014||No|Student study which ended at the end of their course.|No||https://clinicaltrials.gov/show/NCT02138032||44696|
NCT02133846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI287-4RT-001|Safety Study of TPI-287 to Treat CBS and PSP|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy|TPI-287-4RT|University of California, San Francisco|Yes|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|44|||Both|50 Years|85 Years|No|||January 2016|January 26, 2016|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133846||45017|
NCT02142673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyst 2|The Impact of Altering Filling Pressures in Operative Outpatient Hysteroscopy on the Procedure Success Rates and Associated Pain.|The Impact of Altering Filling Pressures in Operative Outpatient Hysteroscopy on the Procedure Success Rates and Associated Pain. A Randomized Double Blind Controlled Trial||Cairo University|Yes|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|240|||Female|18 Years|60 Years|No|||June 2015|June 17, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142673||44340|
NCT02142647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0139|Effect of Protein From Complementary Foods on Infant Growth, Body Composition and Gut Health|Effects of Dietary Protein From Meat vs. Dairy on Infant Growth, Body Composition and Gut Health||University of Colorado, Denver|No|Active, not recruiting|March 2014|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|1 Month|5 Months|Accepts Healthy Volunteers|||March 2016|March 21, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02142647||44342|
NCT02142660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8744|Sprayshield as Adhesion Barrier System for Obese Patients|Prospective Study Evaluating the Usefulness of Sprayshield as Adhesion Barrier System in Two Steps Laparoscopic Bariatric Surgery for Obese Patients|Sprayshield|University Hospital, Montpellier|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Probability Sample|Obese male or female who would benefit from a gastric band removal and for whom a second        surgical step with conversion to sleeve gastrectomy or bypass is scheduled|April 2014|December 30, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02142660||44341|
NCT02143648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02|Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus||Trevi Therapeutics|No|Completed|June 2014|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143648||44265|
NCT02143661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitality|eValuatIon of The ALl New Environment for crITicallY Ill Patients (VITALITY)|eValuatIon of The ALl New Environment for crITicallY Ill Patients (VITALITY)||Charite University, Berlin, Germany|No|Recruiting|May 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|74|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients|December 2015|December 4, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143661||44264|
NCT02143674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPernambuco|Muscle Strengthening Exercises and Global Stretching in Elderly|MUSCLE STRENGTHENING EXERCISES AND GLOBAL STRETCHING: IMPACT ON BALANCE, FEAR OF FALLING AND FUNCTIONAL CAPACITY OF ELDERLY||Universidade Federal de Pernambuco|Yes|Completed|September 2012|January 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Female|60 Years|N/A|No|||May 2014|May 20, 2014|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02143674||44263|
NCT02143973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02ext|Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus|An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus||Trevi Therapeutics|No|Completed|September 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|184|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143973||44240|
NCT02144246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819889|Contraceptive Hormones and Women With Cystic Fibrosis|Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease||University of Pennsylvania|Yes|Terminated|May 2014|||July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|5|||Female|18 Years|40 Years|No|||January 2016|January 6, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144246||44219|
NCT02144987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-C-092-JS|Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy|New Therapeutic Approaches to Treat Asherman's Syndrome and Endometrial Atrophy Based in BM Stem Cells Autologous Transplantation|BMSCT|Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|April 2013|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|45 Years|No|||April 2015|April 21, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144987||44162|
NCT02145234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN001-001|Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects|A Randomized, Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects||Bristol-Myers Squibb|No|Completed|June 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|12||Actual|140|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 11, 2016|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02145234||44143|
NCT02144961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45728-A|The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis|Observational Study to Compare Research-only Breast Ultrasound to Standard of Care Physical Exam for Identifying Tissue Necrosis in Post-mastectomy Patients Undergoing Planned Breast Reconstruction.|SPY|University of Washington|No|Active, not recruiting|January 2014|September 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|25 Years|65 Years|No|Non-Probability Sample|Females pursuing breast reconstruction after having undergone mastectomy. In the        overwhelming majority of cases, this procedure is indicated for breast cancer treatment.        Eligible patients will have their breast reconstruction done at the University of        Washington Medical Center.|March 2016|March 22, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144961||44164|
NCT02146014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB-69168|Effects of Transcranial Direct Current Stimulation on Cigarette Addiction|Effects of Transcranial Direct Current Stimulation of the Prefrontal Cortex on Cigarette Smoking||University of Brasilia|No|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02146014||44083|
NCT02137720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK098742-01A1|Translating Telephonic Diabetes Self-management Support to Primary Care Practice|||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2014|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|875|||Both|21 Years|N/A|No|||December 2015|December 29, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02137720||44720|
NCT02137733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ji 012-0386|The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)|The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)||Mebix Inc||Recruiting|June 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|85 Years|No|||May 2014|May 10, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02137733||44719|
NCT02138045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TODINELI|Treatment of Diabetic Neuropathy With Liraglutide|A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.|TODINELI|Aalborg Universitetshospital|Yes|Enrolling by invitation|May 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138045||44695|
NCT02137473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000044263|Bovine vs. Human Milk-Based Fortifier Study|Optimizing Mothers' Milk for Preterm Infants (OptiMoM) Program of Research: Study 2-Bovine vs. Human Milk-Based Fortifier Study||The Hospital for Sick Children|Yes|Active, not recruiting|August 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|127|||Both|N/A|2 Weeks||||March 2016|March 4, 2016|May 6, 2014||||No||https://clinicaltrials.gov/show/NCT02137473||44739|
NCT02137746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP010|Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer|Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression||Sotio a.s.|No|Active, not recruiting|December 2013|April 2017|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||June 2015|June 30, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137746||44718|
NCT02137759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065425|MRSI to Predict Response to RT/TMZ ± Belinostat in GBM|Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)||Emory University|Yes|Recruiting|May 2014|June 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|87|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137759||44717|
NCT02134119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL-23C403|Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes|Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes||Texas Tech University|Yes|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|45|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02134119||44996|
NCT02134405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-OTC-1203i|Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia|Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study||University of Malaya|No|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134405||44974|
NCT02134418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126-13-COM|Evaluation of Social Skills Intervention on Cognitive Function in Schizophrenia|Evaluation of an Intervention Program Designed to Improve Understanding of Irony on the Hemispheric Processing of Ambiguous Figurative Language in Adults With Schizophrenia||Clalit Health Services|Yes|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|35|||Both|18 Years|75 Years|No|||February 2015|February 3, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02134418||44973|
NCT02134431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000124-1955|Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents|Dose-response Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Model of Tissue Infectibility in Adolescents||University of California, Los Angeles|No|Recruiting|May 2014|||May 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|24|||Both|10 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive adolescents already taking tenofovir in their antiretroviral regimen. Must be        10-14 years (n=6) and 18-21 years (n=6). HIV negative adolescents who are otherwise        healthy ages10-14 years (n=6) and 18-21 years (n=6). Recruitment will be voluntary from        the city/community and outpatient clinics.|December 2014|December 3, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02134431||44972|
NCT02133859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA220414|Adaptive Servo-ventilation Monitoring Study|Feasibilty of Respiratory Monitoring With Adaptive Servoventilation (PaceWave™) to Predict Worsening of Heart Failure in Patients With Severe Heart Failure and Sleep-disordered Breathing||ResMed|No|Completed|May 2014|March 2016|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Heart Failure patients using adaptive servo ventilation|March 2016|March 4, 2016|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02133859||45016|
NCT02134652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS-3325|Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever|Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever||University of Massachusetts, Worcester|Yes|Withdrawn|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|3 Months|16 Years|No|Probability Sample|Study subjects will include children 16 years or less, who present during the annual        Dengue Fever outbreak with suspected Dengue fever. Subjects include children with an acute        febrile illness, and two of the following: headache, retro-orbital pain, myalgias,        arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath,        abdominal distention/pain)|June 2015|June 10, 2015|April 29, 2014||No|Unable to conduct study because of political issues in host country.|No||https://clinicaltrials.gov/show/NCT02134652||44955|
NCT02143401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01043|Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors||National Cancer Institute (NCI)|No|Recruiting|November 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143401||44284|
NCT02143154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vancomycin for Group B Strept|Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis|Intrapartum Vancomycin in GBS-positive Women: The Effect on Vaginal Group B Streptococcus Colony Counts||Women and Infants Hospital of Rhode Island|No|Recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|None Retained|vaginal swabs collected during labor plated for GGBS bacteria and then discarded|Female|18 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with documented GBS-positive antenatal screening culture or documented GBS        bacteruria during pregnancy with plan to receive vancomycin for intrapartum antibiotic        prophylaxis|June 2015|June 2, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143154||44303|
NCT02144519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL112787-01A1|Physical Activity and Nutrition Intervention in Afterschool Programs|Nutrition and Physical Activity Policies, Obesogenic Behaviors and Weight Outcomes||University of South Carolina|Yes|Active, not recruiting|August 2012|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1200|||Both|6 Years|12 Years|No|||June 2015|June 24, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02144519||44198|
NCT02144792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0720130520|Development and Clinical Application of [11C]Verapamil-PET|Development and Clinical Application of [11C]Verapamil-PET, a Surrogate Marker on P-glycoprotein Expression||Seoul National University Hospital|Yes|Recruiting|May 2013|December 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|16 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|April 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144792||44177|
NCT02145000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R822388|Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger|Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger|ROSE|Epicentre|Yes|Recruiting|June 2014|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|7770|||Both|6 Weeks|2 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145000||44161|
NCT02145247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-140260|Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)|Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)||University of California, San Diego|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02145247||44142|
NCT02145481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL114918-01A1|Decisional Quality for Patients With Coronary Artery Disease|Decisional Quality for Patients With Stable Coronary Artery Disease|DeQCAD|University of California, San Francisco|No|Enrolling by invitation|May 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|846|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02145481||44124|
NCT02143024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|in process|A Family-based Primary Care Intervention to Enhance Older Men's Depression Care|A Family-based Primary Care Intervention to Enhance Older Men's Depression Care||University of California, Davis|No|Not yet recruiting|June 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Male|60 Years|N/A|No|||May 2014|May 16, 2014|June 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02143024||44313|
NCT02136953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP133452|Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change|An Examination of Structured Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change||Sunnybrook Health Sciences Centre|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136953||44779|
NCT02137486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-1030209-E|Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques|Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques|MV:main branch|Taipei City Hospital|No|Recruiting|April 2015|May 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|57|||Both|18 Years|95 Years|No|Probability Sample|patients revceived coronary intervention between 2009-2014/3.|November 2015|November 3, 2015|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02137486||44738|
NCT02137200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB ID #:201312123|Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial|Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial|OMSS|Washington University School of Medicine|Yes|Recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3184|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137200||44760|
NCT02133911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHFTX-UMCLJ-1|A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy|Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy|RAMP-DCM|University Medical Centre Ljubljana|Yes|Recruiting|May 2014|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||May 2014|May 6, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133911||45012|
NCT02138071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/2012|Psychological Variables in Physiotherapy Treatment of Low Back Pain: A Comparison of Group and Individual Treatment|Psychological Variables in Physiotherapy Treatment for LBP: a Comparison Between Individual and Gruop Treatment||Bait Balev Hospital|Yes|Active, not recruiting|April 2014|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|180|||Both|18 Years|80 Years|No|Probability Sample|adults (18 years old and older) seeking for physiotherpy treatment for low back pain in        one of the 15 clinics participating in this study|June 2015|February 18, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138071||44693|
NCT02134132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-PVD-003|Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers|Utilization of Umbilical Cord Blood-derived Platelet Gel for Treatment of Diabetic Foot Ulcers,a Randomized Double Blind Clinical Trial||Royan Institute|Yes|Completed|January 2012|April 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|65 Years|No|||November 2011|December 3, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134132||44995|
NCT02134925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01080|Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps|Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas||National Cancer Institute (NCI)|Yes|Recruiting|June 2014|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|40 Years|70 Years|No|||October 2015|October 2, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134925||44934|
NCT02134444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not yet conducted|Game Based Vestibular Exercise for Home Rehabilitation|Comparison of Clinical and Game-based Rehabilitation for Balance Impairments and Gaze Dysfunction in Clients With Vestibular Disorders||University of Manitoba|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|65 Years|No|||April 2014|January 6, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134444||44971|
NCT02142933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ-2014-087|Simplified GBS Screening and Prevalence of ESBL in Pregnant Women|1) Accuracy of the Vagino-perineal Versus the Standard Dual Swab for Detection of Group B Streptococcus in Pregnancy 2) Prevalence and Risk Factors of Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in Pregnancy||University Hospital, Basel, Switzerland||Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|480|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142933||44320|
NCT02143180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThirdSunYatSen|Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study|Accuracy of Real-time Tissue Elastography for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study.||Third Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|May 2014|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|5 Years|70 Years|No|Non-Probability Sample|Patients with chronic hepatitis|May 2014|May 16, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02143180||44301|
NCT02143453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIIT in Juvenile Obesity|Comparative Study of High Intensity Interval Training and Endurance Training in Juvenile Obesity|Comparative Study of High Intensity Interval Training and Endurance Training in Juvenile Obesity||University of Sao Paulo|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|8 Years|12 Years|No|||May 2014|May 20, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143453||44280|
NCT02143167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETRAP|Resistance Training and Amino Pyridine in Multiple Sclerosis|RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis|RETRAP|University of Southern Denmark|No|Recruiting|May 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||May 2014|May 16, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02143167||44302|
NCT02144532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-755|Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos Syndrome|Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome|VETCOSED|Hospices Civils de Lyon|No|Recruiting|May 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02144532||44197|
NCT02144805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-29|Closure of Uterine Incision by Single or Double Layer Technique|Evaluation of Single Versus Double-layer Technique by Closure of Cesarean Uterine Incision. A Randomized Controlled Study||Roskilde County Hospital|No|Completed|January 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Female|N/A|N/A|No|||May 2015|May 5, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144805||44176|
NCT02145780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-807|Polyphenols and Overfeeding|Polyphenols: Protection From Overfeeding-induced Insulin Resistance?|Poly-Nut|Hospices Civils de Lyon|No|Recruiting|February 2014|January 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|42|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02145780||44101|
NCT02146040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T137/2012|Atrial Fibrillation as a Cause of Stroke and Intracranial Hemorrhage Study (The FibStroke Study)|Incidence and Clinical Predictors of Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation. A Retrospective Multicenter Study|FibStroke|University of Turku|No|Active, not recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients aged 18 or over, hospitalized or having emergency unit visit during the study        period because of thromboembolic event (stroke, TIA) or intracranial hemorrhage and having        the diagnosis of atrial fibrillation.|May 2014|May 20, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02146040||44081|
NCT02145260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000629|Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients|Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients||Brigham and Women's Hospital|No|Recruiting|July 2014|July 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145260||44141|
NCT02145494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0109|The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife|Stereotactic Prostate Augmented Radiotherapy With Cyberknife|SPARC|Royal Marsden NHS Foundation Trust|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|N/A|N/A|No|||May 2014|May 20, 2014|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02145494||44123|
NCT02145741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.15|Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours||Boehringer Ingelheim||Active, not recruiting|June 2014|April 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|20 Years|N/A|No|||January 2016|January 28, 2016|May 21, 2014||||No||https://clinicaltrials.gov/show/NCT02145741||44104|
NCT02143037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-040-2|CM Treatment for Alcohol Dependence Using New Technology|CM Treatment for Alcohol Dependence Using New Technology||University of Connecticut Health Center|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02143037||44312|
NCT02137772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8228-001|MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)|A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2014|January 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137772||44716|
NCT02137785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0108|Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities|A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities||DUSA Pharmaceuticals, Inc.|No|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|May 7, 2014|Yes|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02137785||44715|
NCT02138084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-041|Drug-drug Interaction (DDI) Rifabutin|Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138084||44692|
NCT02138097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.161|Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns|A Description of Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns Including Initiation, Switching, and Discontinuation||Boehringer Ingelheim||Completed|May 2014|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||8|Actual|615067|||Both|18 Years|N/A|No|Non-Probability Sample|T2DM patients aged 18 years or older, initiating antidiabetic treatment after at least 6        months of continuous enrollment|September 2015|September 2, 2015|May 13, 2014||||No|July 29, 2015|https://clinicaltrials.gov/show/NCT02138097||44691|
NCT02133924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.051|Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease|PHASE II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|November 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|12 Years|N/A|No|||September 2015|September 15, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133924||45011|
NCT02133885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-00102 Study 2|Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients|Angiotensin and Neuroimmune Activation in Hypertension||University of Florida|No|Not yet recruiting|April 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|80 Years|No|||October 2015|October 2, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133885||45014|
NCT02133898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400170|The Use Of L-Methylfolate As A Treatment For Depression|The Use Of A Genetic Marker To Predict Response To L-Methylfolate As A Treatment For Depression||University of Florida|No|Recruiting|February 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02133898||45013|
NCT02134145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scanadu|Scanadu Consumer Health Outcomes (SCOUT) Study|Usability Study of the Scanadu Scout|SCOUT|Scripps Translational Science Institute|No|Active, not recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|5000|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of a select cohort of crowdfunding backers for the        Scanadu Scout Crowdfunding campaign.|November 2015|November 5, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134145||44994|
NCT02134457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE-ROP|Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity|Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)|CARE-ROP|University Hospital Freiburg|Yes|Recruiting|August 2014|December 2021|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||December 2015|December 1, 2015|April 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02134457||44970|
NCT02134665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hejuanwin19811119|Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia|Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia||Ruijin Hospital|No|Recruiting|May 2013|May 2014|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|85 Years|No|Probability Sample|patients who used vancomycin and who had diagnosed as severe acute pancreatitis (SAP        group), and patients who had diagnosed as pneumonia (pneumonia group) . meanwhile, the        fluorescence polarization immunoassay method was used to measure vancomycin serum trough        concentrations in these patients 30 min before the next administration.|May 2014|May 7, 2014|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02134665||44954|
NCT02143440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012273|The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes|The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes||RenJi Hospital|Yes|Active, not recruiting|March 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|30 Years|70 Years|No|||March 2012|May 17, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143440||44281|
NCT02143986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-FERRITGLY01|Glycosylated Ferritin in Macrophagic Activation Syndromes|Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes.|FERRITGLY01|Brugmann University Hospital|No|Recruiting|May 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|Samples Without DNA|Serum|Both|N/A|85 Years|No|Probability Sample|All consecutive patients admitted in our hospital with inclusion criteria with a suspicion        of sepsis or macrophagic activation syndrome.|May 2014|May 20, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143986||44239|
NCT02144259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813000|The Impact of Contraception on Postpartum Weight Loss|The Impact of Contraception on Postpartum Weight Loss: a Prospective Study|PPWL|University of Pennsylvania|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144259||44218|
NCT02144545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-RES-2012-178|Impact of Size of Gastric Sleeve on the Weight Loss. Correlation With Gastric Function and Endocrine-metabolic Changes.|Study of Impact of the Size of Gastric Sleeve o the Weight Loss in Patients Submitted to Bariatric Surgery. Evaluation of Changes in Gastric Motility and Endocrine-metabolic Function.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|October 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02144545||44196|
NCT02144818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0438-JH-CTIL|GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response|GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian||Sheba Medical Center|No|Recruiting|January 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|May 19, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02144818||44175|
NCT02146053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symptoms KCL|Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron.|Validation of a Simple Questionnaire to Assess Gastrointestinal Symptoms After Oral Ferrous Sulphate Supplementation.||Medical Research Council|No|Completed|March 2004|December 2004|Actual|December 2004|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|May 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02146053||44080|
NCT02146027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAKULT|Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients|Immunological Effects of Continuous, Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients on Suppressive Antiretroviral Treatment With Poor CD4+ T-cell Recovery||University of Sao Paulo General Hospital|Yes|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|48|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02146027||44082|
NCT02145507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100331C|Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution|Clinical Investigation to Evaluate the Haemonetics LeukoSep Leukocyte Reduction Filtration System for Whole Blood With CPD Anticoagulant and SOLX Additive - Pivotal Trial||Haemonetics Corporation|No|Completed|April 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02145507||44122|
NCT02146287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011520|Preterm Infants: Light Effects on Health and Development|Preterm Infants: Light Effects on Health and Development||Duke University|Yes|Completed|June 2003|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|23 Weeks|28 Weeks|No|||May 2014|May 21, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146287||44062|
NCT02139878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPEI HS 01|Short-term Health Effects of Wild Blueberry Juice Consumption|Short-term Health Effects of Wild Blueberry Juice Consumption||University of Prince Edward Island|Yes|Recruiting|May 2014|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02139878||44554|
NCT02140151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29258|Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration|Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study|PREVENT|Southern California Desert Retina Consultants, MC|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2016|January 20, 2016|April 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02140151||44533|
NCT02137798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK474122013|Reduction of Fluoroscopy Exposure During Atrial Fibrillation Ablation|Atrial Fibrillation Ablation Facilitated by Fluoroscopy Image Integrated 3-dimentional Electroanatomical Mapping System|AF-FII|Technische Universität Dresden|Yes|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|75 Years|No|||October 2014|October 7, 2014|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137798||44714|
NCT02138110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InVivo-100-101|The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury|The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury||InVivo Therapeutics|Yes|Recruiting|April 2014|||June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|70 Years|No|||March 2016|March 7, 2016|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138110||44690|
NCT02144636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|herbalife.2014|Protein Supplementation and Weight Loss|Effect of Protein Supplementation on Weight Loss and Cardio Metabolic Profile of Overweight/Obese Subjects||Diabetes Foundation, India|Yes|Completed|November 2012|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144636||44189|
NCT02134158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120135 / AOM12126|Impact of tDCS on Locomotion and Equilibrium in Hemiplegic Patients|Impact of Transcranial Direct Current Stimulation (tDCS) on Locomotion and Bipedal Equilibrium in Hemiplegic Patients: a Crossover Randomized Controlled Trial|HEMILOCOSTICOR|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||February 2016|February 10, 2016|December 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02134158||44993|
NCT02134470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BISP-SALIVA-2014|Diagnostic Relevance of Salivary Testosterone Concentrations in Doping Control.|Diagnostic Relevance of Salivary Testosterone Concentrations After Exogene Low-dose Hormone Application as a Screening Method for in Doping Control.||Paracelsus Medical University|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02134470||44969|
NCT02134704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOUVSCO-DCIC-1411|MOUVSCO: Kinematic Analysis of the Trunk in Patients With Moderate Scoliosis|Kinematic Analysis of the Trunk in Patients With Moderate Scoliosis|MOUVSCO|University Hospital, Grenoble|No|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|66|||Female|9 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02134704||44951|
NCT02134990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-LC-P2a-01|Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer|A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer||Oshadi Drug Administration|No|Recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||April 2015|April 21, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134990||44929|
NCT02134691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1MH090599|Randomized Trial of Prolonged Exposure for the Treatment of Posttraumatic Stress Disorder (PTSD)|||University of Puerto Rico|No|Recruiting|August 2013|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|64 Years|No|||December 2015|December 31, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134691||44952|
NCT02135003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110|Non-enrolment and Non-adherence to HIV Care in a Community-based Program, Rakai, Uganda|Non-enrolment and Non-adherence to HIV Care in a Community-based Program, Rakai, Uganda||Rakai Health Sciences Program|No|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1209|||Both|15 Years|N/A|No|||May 2014|May 8, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02135003||44928|
NCT02143687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 2013-0088V2A3C|Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance|Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance||University of Zurich|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143687||44262|
NCT02143999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29031|An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma|||Hoffmann-La Roche||Active, not recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|394|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed unresectable or metastatic melanoma|March 2016|March 1, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02143999||44238|
NCT02144012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28405|A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer|||Hoffmann-La Roche||Active, not recruiting|July 2014|December 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144012||44237|
NCT02144272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15098|Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis|A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis||Eli Lilly and Company|No|Completed|June 2014|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|41|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144272||44217|
NCT02145273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90YR0074-01-00|Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children|Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children||University of Southern California|No|Not yet recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Female|N/A|N/A|No|||May 2014|May 19, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02145273||44140|
NCT02145520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12216/12|Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis|Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis.||Hamad Medical Corporation|Yes|Recruiting|October 2012|December 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|1 Month|18 Months|Accepts Healthy Volunteers|||March 2015|March 30, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02145520||44121|
NCT02146300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diary number 15/2014|Effect of the Nasal Provocation on the Breathing Style|Effect of the Nasal Provocation on the Breathing Style and on the Calibration of Respiratory Effort Belts||Oulu University Hospital|No|Not yet recruiting|March 2014|June 2016|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146300||44061|
NCT02142777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001228|S-Equol in Alzheimer's Disease (SEAD) Trial|S-Equol in Alzheimer's Disease (SEAD) Trial|SEAD|University of Kansas Medical Center|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|15|||Female|60 Years|90 Years|No|||February 2016|February 1, 2016|May 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142777||44332|
NCT02142790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY-TM-LPS-2014-02|Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer|||Nanjing Luye Sike Pharmaceutical Co.,Ltd.||Recruiting|May 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||July 2014|July 20, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142790||44331|
NCT02139618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01INT|Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage|A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage||Fundación Dermabase|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|35 Years|75 Years|No|||March 2015|March 5, 2015|April 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139618||44574|
NCT02137811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1143088|Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)|Chart Review of Demographics and Clinical Outcomes and Physician Attitudes in Patients Who Have Received the Microculture Kinetic (MiCK) Apoptosis Test||DiaTech Oncology|No|Recruiting|April 2014|January 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay        (CorrectChemo) performed|May 2014|May 12, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02137811||44713|
NCT02137824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients|||Medical University of Vienna||Recruiting|May 2014|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137824||44712|
NCT02138123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China5|Intraocular Lens-shell Technique in Phacoemulsification|Intraocular Lens-Shell Technique: An Adjustment of Surgical Procedure Makes Differences in Treating Dense Nucleus Cataract||Sun Yat-sen University|Yes|Completed|December 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|90 Years|No|||June 2014|June 6, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138123||44689|
NCT02145585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX RNI 01/2014|Robotic Pharmacological Anesthesia System for Elective Cardiac Surgery|Completely Automated Robotic Pharmacological Anesthesia System for Patients Undergoing Elective Cardiac Surgery: a Pilot Study||University Hospital, Bordeaux|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing elective cardiac surgery with extracorporeal circulation|December 2014|December 17, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02145585||44116|
NCT02134171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p120118|Early Predictive Factors of Cardiac and Cerebral Involvement in TMA|Identification of Early Predictive Factors of Cardiac and Cerebral Involvement in Thrombotic Microangiopathies|MATRISK|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02134171||44992|
NCT02144623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.2|Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia|Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia|PREVAIL|Lund University Hospital|No|Recruiting|January 2015|||May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144623||44190|
NCT02144857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/19-6-12|Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis|Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.||University of Athens|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02144857||44172|
NCT02145065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAX-0314|First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)|Prospective, Pivotal, First - in Man Clinical Trial of the Safety and Efficacy of a Novel Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease|PAX|Balton Sp.zo.o.|Yes|Recruiting|September 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||May 2014|October 29, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145065||44156|
NCT02145325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00091850|Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients|A Phase I, Single Center Trial of Adoptive Immunotherapy With T-reg Adoptive Cell Transfer (TRACT) to Prevent Rejection in Living Donor Kidney Transplant Recipients|TRACT|Northwestern University|Yes|Active, not recruiting|April 2014|December 2021|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145325||44136|
NCT02143700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0051UG|Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients|Clinical Profile and Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients|COPD|Universidad de Granada|Yes|Recruiting|April 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed of chronic obstructive pulmonary disease.|May 2014|May 17, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143700||44261|
NCT02143713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-821|Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain|Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||AbbVie|Yes|Active, not recruiting|May 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|50 Years|No|||January 2016|January 25, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143713||44260|
NCT02144025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU-EICHO|Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT|Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen|HSCT|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|May 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02144025||44236|
NCT02144038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGH447X2103C|Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma|A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma||Novartis|No|Completed|July 2014|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144038||44235|
NCT02144285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15200|A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis||Eli Lilly and Company|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144285||44216|
NCT02145013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIM Chetana|Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma|Assessment and Impact of Portal Hypertension Before and During Liver Resection in Patients With Hepatocellular Carcinoma||Henri Mondor University Hospital|Yes|Recruiting|November 2013|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|All patients with hepatocellular carcinoma|February 2016|February 9, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145013||44160|
NCT02145533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURVAS|Matrix Metalloproteinases (MMPs),Neutrophil Gelatinase-associated Lipocalin (NGAL) Tissue and Plasma Levels and Aneurysms|Evaluation of Plasma and Tissue Levels of Metalloproteinases and Neutrophil Gelatinase-associated Lipocalin in Arterial Aneurysms.||University of Cantanzaro|Yes|Completed|January 2010|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|307|||Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with diagnosis of aneurysmal disease (central and peripheral, ruptured and        non-ruptured).|May 2014|May 22, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02145533||44120|
NCT02145793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204008526|Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home|Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home||Indiana University|Yes|Completed|June 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|56|||Both|6 Years|18 Years|No|||May 2014|May 22, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02145793||44100|
NCT02138942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2012/JYL-01|Automated Administration of Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia|Automated Administration of Intravenous Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia: a Pilot Feasibility Study|LIR|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|75 Years|No|||October 2015|November 3, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138942||44626|
NCT02138955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipocurc1002/P-1-010|A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer|: A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER||SignPath Pharma, Inc.|Yes|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|85 Years|No|||November 2015|November 16, 2015|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02138955||44625|
NCT02138968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17/13|Clinical and Economic Assessment of a Pre-frail Screening Program|Clinical and Economic Assessment of an Opportunistic Screening Program for Pre-frailty State in Elderly Population.||Consorci Sanitari del Maresme||Completed|September 2013|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|170|||Both|70 Years|N/A|No|||August 2015|August 31, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138968||44624|
NCT02142816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOR-A02089|Fluid Requirement During Surgery PVI v Doppler|Non-invasive Assessment of Fluid Requirement During Surgery: a Comparison of Oesophageal Doppler and Pleth Variability Index|PVIvDoppler|York Teaching Hospitals NHS Foundation Trust|Yes|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02142816||44329|
NCT02144649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13166|Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery|A Comparison of Tangerine and Red Tomato Juice in Men With Prostate Cancer: A Pilot Study||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Male|21 Years|N/A|No|||July 2015|July 30, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02144649||44188|
NCT02144116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0052UG|Dance-movement Therapy Programme in Fibromyalgia.|Effects of a Dance-movement Therapy Programme in Patients With Fibromyalgia.||Universidad de Granada|Yes|Recruiting|May 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2014|December 9, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144116||44229|
NCT02144376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UON14011|MRI and Microbiota Analysis in Constipation|Validation of Magnetic Resonance Imaging to Characterise Gastrointestinal Physiology, Gut Luminal Content and Its Interaction With Colonic Microbiota in Patients With Chronic Constipation|MIMIC|University of Nottingham|No|Active, not recruiting|March 2014|April 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02144376||44209|
NCT02144389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1054|Arachidonic Acid Treatment Against Schistosomiasis Infection in Children|Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children||DSM Nutritional Products, Inc.|No|Completed|January 2013|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|335|||Both|6 Years|15 Years|No|||May 2014|May 19, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02144389||44208|
NCT02145104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_IDCV_1302|Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension|Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study||IlDong Pharmaceutical Co Ltd|No|Recruiting|May 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|279|||Both|20 Years|75 Years|No|||May 2014|May 20, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145104||44153|
NCT02137031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27225|Continuous Glucose Monitoring and Metabolic Control in Children With Type 1 Diabetes|Continuous Glucose Monitoring and HbA1c in Children for Longterm Diabetes Management|CHILD|University of Toronto|Yes|Completed|September 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02137031||44773|
NCT02144870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THICS-Study|Efficacy of Psychotherapy Treatment of Children With Tics|Randomized Control Trial on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents - a Comparison With Resource Activation Treatment||University of Cologne|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|8 Years|18 Years|No|||May 2014|May 19, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02144870||44171|
NCT02145078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-177|Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer|A Pilot Trial of Platinum, Gemcitabine, or Pemetrexed Single- or Multi-Agent Therapy With Serial Tumor Specimen Collection in Patients With Advanced Non-Small-Cell Lung Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|June 2014|||April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145078||44155|
NCT02145091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA__00047665|Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators||Johns Hopkins University|Yes|Recruiting|May 2014|May 2019|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|100|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145091||44154|
NCT02145572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-IRB-140054|Metabolomic Profiling in Adolescents With Obesity and Diabetes|Metabolomic Profiling in Adolescents With Obesity and Diabetes||University of California, San Diego|No|Active, not recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|90|Samples Without DNA|Plasma and urine|Both|13 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from clinical practices affiliated with Rady Children's        Hospital.|December 2015|December 6, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02145572||44117|
NCT02143726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091302|Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer|Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer||Alliance for Clinical Trials in Oncology|Yes|Recruiting|October 2014|||August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02143726||44259|
NCT02144558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130703|Fertility of Spinal Cord Injured Men|Evolution of Sperm Parameters and Study of Risk Factors of Impairment of Sperm Quality in Spinal Cord Injuries. Longitudinal Prospective Study.|FertiSCI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2014|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Male|18 Years|60 Years|No|||December 2015|December 15, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144558||44195|
NCT02144831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENA-TIA study|The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack|The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study|MENA-TIA|University of Alberta|Yes|Not yet recruiting|July 2014|October 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|2400|||Both|N/A|N/A|No|||December 2014|December 28, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02144831||44174|
NCT02145286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16964|Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow|A Phase I/II Single Arm Prospective Single Fraction Real-time Stereotactic Body Radiation Therapy Dose Escalation Trial of Rapid Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease||University of Virginia|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02145286||44139|
NCT02145806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC_UI_2014|Validation of Korean Version of ICIQ-SF|||The Catholic University of Korea|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|134|||Female|18 Years|N/A|No|Non-Probability Sample|130|February 2015|February 12, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02145806|1 Week|44099|
NCT02146066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202EA|Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221|An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221|DCVax-L EAP|Northwest Biotherapeutics||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|70 Years||||February 2016|February 25, 2016|May 21, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02146066||44079|
NCT02146313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29213|A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer||Genentech, Inc.||Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146313||44060|
NCT02146326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-6597|The Impact of Burnout on Patient-Centered Care: A Comparative Effectiveness Trial in Mental Health|The Impact of Burnout on Patient-Centered Care: A Comparative Effectiveness Trial in Mental Health||Indiana University|No|Active, not recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|678|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146326||44059|
NCT02146547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR49490|European Long-acting Antipsychotics in Schizophrenia Trial|European Long-acting Antipsychotics in Schizophrenia Trial|EULAST|UMC Utrecht|Yes|Recruiting|February 2015|August 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146547||44042|
NCT02146560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6378-A|TEAMS (Troponin Elevation After Major Surgery) Study|Clinical Characteristics and Functional Outcomes of Postoperative Myocardial Injury: a Prospective Cohort Study. TEAMS (Troponin Elevation After Major Surgery) Study|TEAMS|University Health Network, Toronto|No|Active, not recruiting|August 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood|Both|45 Years|N/A|No|Non-Probability Sample|Adult patients undergoing elective non-cardiac non-transplant surgery|November 2015|January 27, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02146560||44041|
NCT02142803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01118|TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors|A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|May 2014|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|May 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02142803||44330|
NCT02139605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87|"Phase III Randomized Trial Comparing D2 Versus D3 Lymphadenectomy in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy-ELANCe Trial|Phase III Randomized Controlled Trial Comparing D2 Versus D3 Lymphadenectomy on Outcomes of Non-metastatic, Resectable, But Locally Advanced, Gastric Cancer Following Neoadjuvant (Perioperative) Chemotherapy (ELANCe Trial)|ELANCe|Tata Memorial Centre|Yes|Active, not recruiting|August 2013|July 2020|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|574|||Both|18 Years|85 Years|No|||May 2014|May 13, 2014|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02139605||44575|
NCT02135913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0348-P3H|Roles of Vitamin D and HDL in Obese Children|Roles of Vitamin D and HDL in Obese Children||University of Kentucky|No|Not yet recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|5 Years|18 Years|No|||November 2015|November 30, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02135913||44859|
NCT02135926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-Heidelberg-THRILL|Comparison of Thrombectomy and Standard Care for Ischemic Stroke in Patients Ineligibility for Tissue Plasminogen Activator Treatment|Thrombectomy in Patients Ineligible for iv tPA|THRILL|University Hospital Heidelberg|Yes|Suspended|March 2014|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||January 2015|January 30, 2015|April 30, 2014||No|Recruitment is on hold until MR CLEAN, ESCAPE, EXTEND-IA, and SWIFt PRIME have been evaluated.|No||https://clinicaltrials.gov/show/NCT02135926||44858|
NCT02144883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #030310|Telephone Counseling for Pregnant Smokers|Telephone Counseling for Pregnant Smokers||University of California, San Diego|No|Completed|September 2000|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1173|||Female|18 Years|45 Years|No|||May 2014|May 19, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02144883||44170|
NCT02145364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-139|Ultherapy® for the Treatment of Acne Scars|Evaluation of the Ulthera® System for Correction of Moderate to Severe Atrophic Acne Scars||Ulthera, Inc|No|Completed|May 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145364||44133|
NCT02145845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-013|Pilot Safety Study of Injectable SIS for Critical Limb Ischemia|Pilot Safety Study of Injectable Small Intestine Submucosa (SIS) for Critical Limb Ischemia|CLIC|Cook|No|Recruiting|April 2014|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||December 2015|December 1, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02145845||44096|
NCT02145858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2014001|Prevention of Retained-Blood Outcomes With Active Clearance Technology|Prevention of Retained-Blood Outcomes With Active Clearance Technology. ACT Registry||ClearFlow, Inc.|No|Recruiting|June 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects 18 years or older who received a PleuraFlow System following heart surgery (Track        A) or VAD surgery (Track B)|October 2015|October 21, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02145858|1 Month|44095|
NCT02146105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga_KneeOA|Yoga as an Intervention for Women With Knee Osteoarthritis|A Yoga Exercise Intervention Designed for Women With Knee Osteoarthritis||McMaster University|Yes|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|50 Years|N/A|No|||February 2015|February 3, 2015|May 16, 2014||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT02146105||44076|
NCT02145338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnTIC:6672|Antibiotic Prophylaxis for Clean Intermittent Catheterisation|Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis|AnTIC|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|372|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145338||44135|
NCT02145351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008306|Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure|Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)|RAPID-HF|Mayo Clinic|No|Recruiting|June 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145351||44134|
NCT02146391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-107|Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal|AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL||Repros Therapeutics Inc.|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02146391||44054|
NCT02142855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B13032014 SoMSGEM BBSRC3|Structural and Metabolic Determinants of Sarcopenia and the Efficacy of Concentric vs. Eccentric Exercise Training|Structural and Metabolic Determinants of Sarcopenia and the Efficacy of Concentric vs. Eccentric Exercise Training: a Novel Temporospatial Approach||University of Nottingham|No|Recruiting|May 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|60|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142855||44326|
NCT02142868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481034|Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate|An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate||Pfizer||Available||||||Phase 3|Expanded Access|N/A|||||||Female|18 Years|N/A|No|||March 2016|March 11, 2016|May 16, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02142868||44325|
NCT02144298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATADEK 2013-540|The Sublingual Microcirculatory Alterations in Patients Undergoing Extracorporeal Flow Conditions|The Perioperative Course of Sublingual Microcirculatory Alterations in Patients Undergoing Extracorporeal Flow Conditions: Cold Blood Compared With Cristalloid Cardioplegia||Medical Centre Leeuwarden|No|Completed|March 2014|February 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|of patients undergoing coronary artery bypass grafting (CABG) using cristalloid (n=10) or        cold blood (n=10) cardioplegia|February 2015|February 12, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144298||44215|
NCT02145026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29005|An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic Syndrome|A Prospective Open-label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-risk Myelodysplastic Syndrome (MDS)||Hoffmann-La Roche||Recruiting|August 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02145026||44159|
NCT02145039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OC116|Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases|Reduced Intensity Conditioning (RIC) and Transplantation of HLA-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|74 Years|No|||January 2016|January 21, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145039||44158|
NCT02142543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCDOrtho1|The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer|The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer||Texas A&M University|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|12 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02142543||44350|
NCT02138370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immuno_CRC_001|Comprehensive Immune-landscape in Localized Colorectal Cancer|Tissue Und Liquid Immune Biopsies to Predict Clinical Outcome in Localized Colorectal Cancer Patients - Retrospective Clinical Observational Study.||University of Zurich|No|Active, not recruiting|April 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with histopathologically confirmed stage II and III colon cancer consecutively        enrolled at the Division of Clinical Oncology, Department of Medicine, Medical University        of Graz (Graz, Austria) between 1995 and 2011.|May 2015|May 27, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138370||44670|
NCT02138994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-001|Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care|Clinical Assessment of the Next Science Wound Gel Efficacy in Chronic Wound Compared to Standard of Care||Next Science TM|No|Recruiting|July 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138994||44622|
NCT02138669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intacs Protocol_Version 1.0|Intacs for Keratoconus|INTACS® Prescription Inserts Used to Treat Patients With Keratoconus as a Humanitarian Use Device||University of Texas Southwestern Medical Center|No|Recruiting|January 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138669||44647|
NCT02138682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-DAT-014|Validation of DaTscan for Detection of Parkinson Disease Related Disorders|Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue||Wisconsin Institute for Neurologic and Sleep Disorders S.C.|No|Enrolling by invitation|July 2014|||April 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Fixed brain tissue|Both|75 Years|N/A|No|Probability Sample|Parkinson disease patients from Wisconsin Institute for Neurologic and Sleep Disorders,        SC.|July 2014|July 15, 2014|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138682||44646|
NCT02139293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS 02/2014|Pilot Study - Auricular Vagus Nerve Stimulation Effects on Cardiovascular Parameters|Functional Mapping of Auricular Vagal Stimulation Points on Cardiovascular Parameters in Healthy Subjects - Pilot Study||Medical University of Vienna||Not yet recruiting|May 2014|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139293||44599|
NCT02139306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-021-CF|Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)|A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis||PTC Therapeutics|Yes|Active, not recruiting|June 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Both|6 Years|N/A|No|||November 2015|November 25, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139306||44598|
NCT02139319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43QM1309|Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee|||Q-Med AB|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|25 Years|80 Years|No|||August 2014|August 4, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139319||44597|
NCT02139332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45359-G|A Primary Prevention Trial to Strengthen Child Attachment in a Native Community|A Primary Prevention Trial to Strengthen Child Attachment in a Native Community|FPT PFR|University of Washington|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139332||44596|
NCT02136225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2829|Reducing Youth Access to Firearms Through the Health Care Setting|Reducing Youth Access to Firearms Through the Health Care Setting||University of Colorado, Denver|No|Enrolling by invitation|March 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136225||44835|
NCT02136212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R00MH090243|Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia|Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia - New Data||University of California, San Diego|No|Recruiting|April 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136212||44836|
NCT02136485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14CH078|Mindfulness-based Stress Reduction in Multiple Sclerosis|Mindfulness-based Stress Reduction in Multiple Sclerosis - a Randomised Controlled Trial||NHS Greater Glasgow and Clyde|No|Recruiting|June 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02136485||44815|
NCT02136784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001175|Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals|Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals||University of California, Los Angeles|No|Recruiting|April 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|7||Anticipated|12|||Male|20 Years|50 Years|No|||May 2014|May 9, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02136784||44792|
NCT02136797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-070|Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|N/A|N/A|No|||March 2016|March 14, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136797||44791|
NCT02136810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509016399|Perioperative Blood Pressures and Chronic Hypertension|The Association Between Home Blood Pressures and Clinic Blood Pressures in Patients Presenting for Surgery.||Yale University|No|Recruiting|October 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|21 Years|N/A|No|Non-Probability Sample|Ambulatory surgical patients >= 21 years of age presenting for preadmission testing to a        tertiary care hospital and who demonstrate elevated clinic blood pressures greater than or        equal to 150/95mmHg.|January 2016|January 6, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136810||44790|
NCT02137278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASL4/CARD/01|Stop Vasodepressor Drugs in Reflex Syncope|Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope|STOP-VD|Gruppo Italiano Multidisciplinare per lo Studio della Sincope|No|Completed|March 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02137278||44754|
NCT02137564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-089|Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma|A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients With AIDS-Associated Kaposi Sarcoma||AIDS Malignancy Consortium|No|Withdrawn|July 2015|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|May 9, 2014|Yes|Yes|Drug supply unavailable|No||https://clinicaltrials.gov/show/NCT02137564||44732|
NCT02146625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_HGH_101|Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects|A Dose-block Randomized, Single-blind, Placebo-controlled, Single-dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CJ-40002 After Subcutaneous Injection in Healthy Adult Male Volunteers|hGH|CJ HealthCare Corporation|No|Not yet recruiting|June 2014|April 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02146625||44036|
NCT02138162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0404|A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men|A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Enzalutamide in Male Subjects With Severe Hepatic Impairment and Normal Hepatic Function||Astellas Pharma Inc|No|Completed|August 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|69 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138162||44686|
NCT02137590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SEHS|An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes|An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes in Healthy Male Subjects|11SEHS|KGK Synergize Inc.||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137590||44730|
NCT02144571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54CA153461-01|Sistas Inspiring Sistas Through Activity and Support|SCCDCN-II: Research Project (Breast Cancer)|SISTAS|University of South Carolina|No|Completed|November 2010|June 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|350|||Female|30 Years|90 Years|Accepts Healthy Volunteers|||December 2015|February 26, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02144571||44194|
NCT02144584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00068751|Memantine for Enhanced Stroke Recovery|Pilot Study of Memantine for Enhanced Stroke Recovery||University of Utah|Yes|Recruiting|January 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02144584||44193|
NCT02145546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2013-013-2|Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation|Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation|ADA-PAF|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145546||44119|
NCT02142556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00046|The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics|The Efficacy and Safety of Once-daily Quetiapine Extended Release in Patients With Schizophrenia Switched From Other Antipsychotics||Tri-Service General Hospital|No|Completed|November 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|20 Years|65 Years|No|||May 2014|May 15, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02142556||44349|
NCT02138383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17696|Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer|A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|May 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138383||44669|
NCT02138396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-13-019|Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions|Single-Dose, Open-Label, Two-Period, Two-Treatment, Two-Sequence Crossover Exploratory Bioavailability Study of Subsys® (Fentanyl Sublingual Spray), 400 mcg, and Fentanyl Citrate Injection 2 mL x 0.05 mg/mL (Total Dose 100 mcg) Under Fasted Conditions||INSYS Therapeutics Inc|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138396||44668|
NCT02138708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120910|Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt|Pharmacological Test of Pulmonary Endothelium-dependent Vascular Reactivity to Acetylcholine in Pulmonary Arterial Hypertension With Congenital Cardiac Shunt Child and Adult|ReVAch|Assistance Publique - Hôpitaux de Paris|No|Suspended|January 2016|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|N/A|No|||July 2015|July 20, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02138708||44644|
NCT02139345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4060-04|TC-A Registration Study|A Prospective, Randomized, Multicenter Clinical Study to Compare the Safety and Efficacy of TC-A PS Total Knee System With TC-PLUS Solution PS Total Knee System in Chinese Subjects||Smith & Nephew Medical (Shanghai) Ltd|No|Active, not recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|50 Years|75 Years|No|||November 2015|November 30, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02139345||44595|
NCT02139358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17656|Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer|Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139358||44594|
NCT02138981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC_S012|Hepatectomy Versus Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria|Hepatic Resection Versus Transarterial Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria||Sun Yat-sen University|Yes|Recruiting|May 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|436|||Both|18 Years|70 Years|No|||May 2014|May 14, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02138981||44623|
NCT02139904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0329|Vinorelbine in Mesothelioma|A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma|VIM|Velindre NHS Trust|Yes|Not yet recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02139904||44552|
NCT02135718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201344|ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma|A Preference Study of Inhaler Attributes Between Two Inhalers; ELLIPTA and MDI, in Adult Subjects With Asthma||GlaxoSmithKline|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135718||44874|
NCT02136498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA034612|Internet-based Medication Adherence Program for Nicotine Dependence Treatment|Internet-based Medication Adherence Program for Nicotine Dependence Treatment||Group Health Cooperative|No|Completed|October 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|May 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02136498||44814|
NCT02136511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-1325|Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia|An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia||Gilead Sciences||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2014|October 27, 2014|May 9, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02136511||44813|
NCT02136238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro0013189|Functional Performance of Voluntary Opening and Closing Body Powered Prostheses|A Clinical Trial Comparing Functional Performance of Voluntary Opening and Closing Body Powered Prosthetic Terminal Devices||University of South Florida|Yes|Completed|September 2013|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|February 17, 2014||No||No|November 18, 2014|https://clinicaltrials.gov/show/NCT02136238||44834|
NCT02136524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28370|A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation|A PHASE 1, OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, 2-PERIOD, 2-TREATMENT SEQUENCE CROSS-OVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF COBIMETINIB ADMINISTERED AS A TABLET FORMULATION COMPARED TO A CAPSULE FORMULATION IN HEALTHY SUBJECTS||Genentech, Inc.||Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136524||44812|
NCT02136537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0854|Electrical Stimulation in Peripheral Arterial Disease|Electrical Stimulation in Peripheral Arterial Disease|PAD|Imperial College London|Yes|Not yet recruiting|August 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136537||44811|
NCT02137044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46597-G|Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study|Improving the Quality of Care for Pain and Depression in Persons With Multiple Sclerosis|MS-CARE|University of Washington|No|Enrolling by invitation|July 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02137044||44772|
NCT02137057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0167|The Effect of Spinal Anesthesia on Heart Rate Variability in Diabetic Patients|||Yonsei University|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|||Both|40 Years|80 Years|No|Non-Probability Sample|patients undergoing lower limb surgery with spinal anesthesia|June 2015|June 12, 2015|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02137057||44771|
NCT02137291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-20952|IPg2 Study: Left-sided Lung Isolation|IPg2 Study - Left-sided Lung Isolation: Comparison of Twodevices|IPg2|Laval University|No|Recruiting|May 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|||Both|21 Years|N/A|No|Non-Probability Sample|Patients undergoing an elective left VATS requiring OLV|October 2015|October 7, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02137291||44753|
NCT02137304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01771-44|A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases|A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases|COUGHELP|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|February 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02137304||44752|
NCT02137876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00092183|Effects of Thymoglobulin on Human B Cells|Effects of Thymoglobulin on Proliferation, Activation, and Differentiation of Human B Cells||Northwestern University|No|Recruiting|April 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|20ml of whole blood will be drawn from each subject each time they are asked to have blood      drawn. The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups)      within any eight week period throughout the two year timespan patients may be asked to      participate in this study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will consist of healthy volunteers who meet the inclusion/exclusion        criteria.|January 2016|January 6, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02137876||44708|
NCT02137889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736Y2101|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients|A Phase 1, Muticenter, Open-label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 When Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients|VAY736Y|Novartis|No|Terminated|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|April 29, 2014|No|Yes|Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early    termination was not due to safety concerns.|No||https://clinicaltrials.gov/show/NCT02137889||44707|
NCT02137902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HL117736|Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study|Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study|HEALTHH|Stanford University|No|Recruiting|June 2015|March 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02137902||44706|
NCT02137603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0660|Fast Track Appendectomy for Suppurative Appendicitis|Fast Track Appendectomy in Pediatric Patients With Intraoperative Findings of Suppurative Appendicitis||All Children’s Hospital Johns Hopkins Medicine|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|36|||Both|5 Years|18 Years|No|||August 2015|August 12, 2015|May 7, 2014||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT02137603||44729|The small number of patients enrolled in each arm and the low number of 30-day patient follow up limit the interpretation of the current results.
NCT02145299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC140101333|The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)|A Prospective, Multicenter, Open Label Randomized Study to Evaluate the Safety, Performance and Intraluminal Crossing of the TruePath™ CTO Device Versus The Crosser System in Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)||Yale University|No|Terminated|May 2014|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|100 Years|No|||January 2016|January 7, 2016|May 19, 2014||No|The study was stopped due to insufficient numbers of subjects to meet study design objectives.|No||https://clinicaltrials.gov/show/NCT02145299||44138|
NCT02145312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0147|An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.|||Yonsei University|No|Not yet recruiting|March 2016|March 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02145312||44137|
NCT02142231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuTA|AcuTA: Acupuncture in Test Anxiety|Acupuncture Randomized Trial for Preventing Test Anxiety|AcuTA|Goethe University|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 6, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02142231||44374|
NCT02138409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-13-021|Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting|A Pilot, Randomized, Double-blind, Placebo-controlled Single-center Study to Evaluate the Safety and Efficacy of SUBSYS™ (Fentanyl Sublingual Spray) for the Treatment of Acute Procedure-related Pain in a Monitored Setting||INSYS Therapeutics Inc|No|Not yet recruiting|May 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138409||44667|
NCT02138695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0104|The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study|||Yonsei University||Recruiting|May 2014|April 2024|Anticipated|April 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3100|||Both|19 Years|N/A|No|Probability Sample|Consecutive patients with atrial fibrillation who undergoing catheter ablation in Yonsei        Cardiovascular hospital, Yonsei university health system, Seoul, Korea.|January 2015|January 7, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02138695||44645|
NCT02138435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSDBAA2014|Longterm Outcome After Ventricular Septal Defect Closure|Cardiac Output During Exercise in Young Adults Operated for Ventricular Septal Defect as Children||University of Aarhus|No|Active, not recruiting|March 2014|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Of 182 children who in the years 1990 to 1995 underwent surgical closure of a congenital        VSD at Aarhus University Hospital (AUH), Denmark, a small group of 20 is randomly selected        to participate. These children form a homogenous group of patients comparing surgeons,        anesthetists, surgical procedures and post-surgical period. An equal amount of healthy        controls, matched on age and gender, form the control group.|September 2015|September 11, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02138435||44665|
NCT02143882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV Immuno|A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).|A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).|LAIV Immuno|Public Health England|No|Recruiting|September 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02143882||44247|
NCT02139007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F120404006|Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study|Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study|EDGE|University of Alabama at Birmingham|Yes|Active, not recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Female|65 Years|100 Years|No|||January 2016|January 12, 2016|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139007||44621|
NCT02139020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 2013-01|Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients|Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|February 2013|January 2023|Anticipated|January 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|One EDTA tube is collected at the beginning of the study and there are only plasma samples      at baseline, during treatment, and at progression.|Both|18 Years|N/A|No|Probability Sample|PATIENTS TREATED WITH MOLECULAR TARGETED THERAPIES FOR SQUAMOUS CELL CARCINOMA OF THE HEAD        AND NECK|May 2015|May 18, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02139020||44620|
NCT02139631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070490|Hemodynamic Repercussions of Noninvasive Ventilation|Evaluation of the Hemodynamic Repercussions of Non Invasive Ventilation in Healthy Individuals by Doppler Echocardiography||Federal University of Uberlandia|Yes|Completed|May 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 13, 2015|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02139631||44573|
NCT02139644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-AS-301|Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma|A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy||Teva Pharmaceutical Industries|No|Completed|May 2014|October 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|625|||Both|12 Years|N/A|No|||January 2016|January 12, 2016|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02139644||44572|
NCT02139670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thrombin generation- pregnancy|Thrombin Generation and Gestational Outcome|Thrombin Generation and Gestational Outcome in Women With Recurrent Pregnancy Loss||HaEmek Medical Center, Israel|Yes|Recruiting|October 2013|December 2016||September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|4 cc of serum will be retain until all blood samples will be collected|Female|18 Years|N/A|No|Probability Sample|pregnant women with recurrent miscarriages undergoing investigation for Thrombophilia .|December 2015|December 15, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02139670|9 Months|44570|
NCT02143856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1205-CL-102|Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food|A Randomized, Open-label, Two-way Cross-over Study to Determine the Oral Bioavailability of GLPG1205 After Single-dose Intake in Healthy Male Subjects as a Solid Formulation, With and Without Food||Galapagos NV|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143856||44249|
NCT02135965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28026|Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate|Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate.|CALM|Pennington Biomedical Research Center|No|Completed|April 2009|August 2011|Actual|August 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02135965||44855|
NCT02135952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP/697|Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis|Metronidazole and Amoxicillin as Adjuncts to Scaling and Root Planing for the Treatment of Type 2 Diabetic Subjects With Periodontitis: a Randomized Placebo-controlled Clinical Trial||University of Guarulhos|Yes|Active, not recruiting|September 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|35 Years|N/A|No|||May 2014|May 6, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02135952||44856|
NCT02136550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 147/13|Smoking Cessation on the Human Airway: Mucus Secretion, Inflammatory and Proteomic Profile in Nose and miRNAs in Blood|Smoking Cessation on the Human Airway: Mucus Secretion, Inflammatory and Proteomic Profile in Nasal Lavage and miRNAs in Blood||University of Sao Paulo|No|Recruiting|February 2013|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136550||44810|
NCT02136836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSCH-STO13-01|Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer||HER2|Yonsei University||Active, not recruiting|May 2014|||March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|860|||Both|N/A|N/A|No|Non-Probability Sample|gastric cancer patients in Gangnam Severance Hospital|April 2014|May 12, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136836||44788|
NCT02136849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0107|Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic|Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic|HUGODIMS|Nantes University Hospital|No|Completed|July 2014|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|228|Samples With DNA|2 tubes of 5 ml EDTA blood|Both|N/A|N/A|No|Non-Probability Sample|We planned to include 50 trios (patients + parents) in the study. This number appears to        be sufficient to achieve the defined objectives and according to the literature data        (Rauch et al, 2012).        The study population is the population affected by severe intellectual disability        according to the commonly accepted definition (IQ <35), and patients with severe or        moderate ID (IQ <50) associated with other clinical signs but no obvious syndromic form        known . In 2 cases, the parents of patients will not be affected by DI. The recruitment        will be made during genetic counseling. Many patients with DI meet the criteria of the        study are already being explored in different centers. For these patients, the DNA of the        index case and parents is already available. Families will therefore re-contacted to        invite them to participate in this study.|March 2016|March 24, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136849||44787|
NCT02136823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00012823|Impact of Persistent Conductances on Motor Unit Firing in SCI|Impact of Persistent Conductances on Motor Unit Firing in SCI||Rehabilitation Institute of Chicago||Active, not recruiting|June 2009|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02136823||44789|
NCT02137070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400034|The WISE (Weightloss Intervention Surgical Effects) Brain Study|Obesity and Type 2 Diabetes, Bariatric Surgery Effects on Brain Function|WISEBrain|University of Florida|No|Recruiting|August 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood samples will be retained for biomarker analysis.|Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential bariatric surgery patients will have study specific information made available        to them for their consideration at the bariatric or diabetes clinics at UFHealth & Shands        Hospital, or at other community locations. Flyers will be posted in many community        advertising locations in the North Florida region.|September 2015|September 4, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137070||44770|
NCT02137577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acotec-03|AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China|Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of the Infrapopliteal Artery||Acotec Scientific Co., Ltd|Yes|Recruiting|May 2014|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||December 2015|January 4, 2016|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02137577||44731|
NCT02133781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-17218- 2009|B-cell Immunity to Influenza (SLVP017)- Year 1, 2009|U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 1, 2009||Stanford University|No|Active, not recruiting|July 2009|December 2014|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|8 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133781||45022|
NCT02133794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parasu-001|Tomosynthesis Use in Detecting Subtle Occult Hip Fractures|Tomosynthesis Use in Detecting Subtle Occult Hip Fractures||Medical Imaging Informatics Research Centre at McMaster|No|Not yet recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A||||April 2014|May 6, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02133794||45021|
NCT02141945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-01|Microbiome Test for the Detection of Colorectal Polyps and Cancer|Metabiomics Neoplasia Clinical Research Study||Metabiomics Corp|No|Suspended|March 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|gut microbiome samples from stool, rectal and colonic mucosa|Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients at average risk of developing colorectal cancer, scheduled for colonoscopy.|September 2015|September 22, 2015|May 14, 2014||No|Recruiting suspended but potentially may resume|No||https://clinicaltrials.gov/show/NCT02141945||44396|
NCT02142244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHNIR01|Fluorescence Surgery for Sentinel Node Identification in Melanoma|Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma||Barretos Cancer Hospital|Yes|Recruiting|May 2014|December 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|318|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02142244||44373|
NCT02142595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140515|Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing TURP|Comparison of the Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing Transurethral Prostatic Resection(TURP)||China Medical University, China|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|111|||Male|60 Years|85 Years|No|||May 2014|September 22, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02142595||44346|
NCT02138422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-PT026|A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer|A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy||XBiotech, Inc.|Yes|Active, not recruiting|July 2014|March 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02138422||44666|
NCT02143609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0088V2A3|Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance|Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance||University of Zurich|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143609||44268|
NCT02143375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mbakhshi|Gingival Depigmentation by Diode Laser|Efficacy of810 nm Diode Laser on Gingival Pigmentation||hahid Beheshti University of Medical Sciences|Yes|Completed|April 2013|March 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|May 18, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02143375||44286|
NCT02144168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG127-2013A|The Effect of Enteral Nutrition Supplemented With Prebiotics on Colonic Microbiota in the Critically Ill Patients|The Effect of Enteral Nutrition Supplemented With Prebiotics on Colonic Microbiota in the Critically Ill Patients: A Randomized Controlled Trial|PrebioticFOS|University of Malaya|No|Recruiting|January 2014|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02144168||44225|
NCT02139371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-574|Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography|64Cu-DOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor) for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Man.||Rigshospitalet, Denmark|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|80 Years|No|||December 2014|December 11, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02139371||44593|
NCT02139657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1301|An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)|An Open-label, Single-arm Study to Evaluate the Safety and Antibody Titers Specific to the Rabies Virus in Healthy Subjects After Receiving a Single Dose of Intramuscularly Administered Rabies Immune Globulin (Human)||Grifols Therapeutics Inc.|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|April 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02139657||44571|
NCT02144181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-138|Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea|Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea||Ulthera, Inc|Yes|Active, not recruiting|May 2014|October 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144181||44224|
NCT02144441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819840|Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy|Proof-of-concept Trial of Clinician-supported Patient Self-management of Hospital Insulin Therapy||University of Pennsylvania|Yes|Withdrawn|June 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|March 13, 2015|May 13, 2014||No|Very few patients met eligibility criteria, none of whom elected to enroll.|No||https://clinicaltrials.gov/show/NCT02144441||44204|
NCT02136862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG012-01|ATHENA: Natural History of Disease Study in Alport Syndrome Patients|A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients|RG012-01|Regulus Therapeutics Inc.|No|Recruiting|August 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|16 Years|N/A|No|Non-Probability Sample|Alport syndrome patients with GFR between 30-75 ml/min|February 2016|February 17, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136862||44786|
NCT02136251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067-14-FB|Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.|Five Year Outcome Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty.|Glenoid|University of Nebraska|No|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|48|||Both|N/A|N/A|No|Non-Probability Sample|Orthopaedic Surgery clinic patients|May 2014|May 8, 2014|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02136251||44833|
NCT02137343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120142|A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|RILOMET-2|Amgen|Yes|Terminated|July 2014|July 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|20 Years|100 Years|No|||January 2016|January 18, 2016|April 28, 2014|Yes|Yes|All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data    Monitoring Committee safety review of study 20070622.|No||https://clinicaltrials.gov/show/NCT02137343||44749|
NCT02137356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1061-YL-CTIL|Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer|An Investigator Sponsored Phase I Trial of Selinexor Combined With Standard Capecitabine Based Chemoradiation as a Neoadjuvant Treatment in Locally Advanced Rectal Cancer||Sheba Medical Center|No|Recruiting|December 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02137356||44748|
NCT02137629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-Celgene-KOR-001|Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea|VIDAZA® Drug Use Examination||Celgene|No|Active, not recruiting|August 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|510|||Both|18 Years|N/A|No|Non-Probability Sample|All Korean patients who are intended to be treated with VIDAZA® according to the approved        package insert|January 2016|January 15, 2016|February 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02137629||44727|
NCT02137642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-008|Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation|A Single-center, Placebo-controlled, Double-blind, Study to Evaluate the Effects of RM-131 on Colonic Motor Functions in Patients With Chronic Constipation||Rhythm Pharmaceuticals, Inc.|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02137642||44726|
NCT02137083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2014-13|A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer|A Prospective Single-center Randomized Phase 3 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer||Fudan University|No|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||December 2015|December 24, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02137083||44769|
NCT02137330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539/RA|Obalon in Children With Severe Obesity|Tolerance and Efficacy of the Swallowable Obalon® Gastric Balloons System in Children With Severe Obesity|Obalon|Bambino Gesù Hospital and Research Institute|Yes|Completed|January 2014|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|9 Years|17 Years|No|||July 2015|July 21, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02137330||44750|
NCT02137317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPPEN|Farming, Personal Protective Equipment, Nepal|Prevention of Farmers' Exposure to Pesticides With Relevant Personal Protective Equipment in Chitwan District of Nepal||Bispebjerg Hospital|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02137317||44751|
NCT02134301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-ORI-11-01|Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections|An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)||The Medicines Company|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|18 Years|No|||November 2015|November 4, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134301||44982|
NCT02133820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMX1507|A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.|A 4-part, Single-dose, Open-label, Randomised, Crossover, Exploratory Study in Healthy Subjects to Assess the Influence of an Opioid Antagonist on How the Body Processes a Strong Painkiller, When Co-administered in a Fasted and Fed State.||Mundipharma Research Limited|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02133820||45019|
NCT02141958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGU-4HPR-13-01|Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis|An Adaptive Phase I Intra-patient Dose Escalation Study of Fenretinide in Adult Cystic Fibrosis Patients||McGill University Health Center|Yes|Active, not recruiting|April 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02141958||44395|
NCT02142582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008346|Comparison of Different Oral Rehydration Solutions|Comparison of Different Oral Rehydration Solutions (ORS) in Short Bowel Syndrome (SBS) Patients on Home Parenteral Nutrition (HPN): A Prospective Double-blinded Randomized Controlled Trial.|ORS|Mayo Clinic|No|Recruiting|May 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|90 Years|No|||October 2015|October 14, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02142582||44347|
NCT02143349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12614000305628|The Effect of Coleus Forskohlii Extract on the Risk Factors of Metabolic Syndrome|Investigation of Appetite Suppressant Properties Associated With Coleus Forskohlii in Overweight and Obese Individuals||Olive Lifesciences Pvt Ltd|Yes|Recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|60 Years|No|||May 2014|May 17, 2014|May 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02143349||44288|
NCT02143362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex anesthesia|Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake up|Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake Up-single Center,Random,Controlled Trial||Second Affiliated Hospital of Xi'an Jiaotong University|No|Not yet recruiting|June 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2014|July 3, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02143362||44287|
NCT02143635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDM201X2101|Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt|A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53||Novartis|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|164|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143635||44266|
NCT02143921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-051|Impact of Training on Diarrhoea Management|Impact of an NGO Training and Support Intervention on Private Sector Provider Diarrhea Management Practices||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|January 2008|August 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|1160|||Both|6 Months|5 Years|No|||May 2014|May 20, 2014|May 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02143921||44244|
NCT02143622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJM716X2104|Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients|A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma||Novartis|No|Withdrawn|March 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|May 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02143622||44267|
NCT02144428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/14|Hypoallergenicity To Substitutive Formulas In Children With Cow's Milk Allergy|DETERMINATION OF HYPOALLERGENICITY TO SUBSTITUTIVE FORMULAS IN CHILDREN WITH COW'S MILK ALLERGY||Federico II University||Recruiting|April 2011|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|36 Months|No|Probability Sample|Subjects with cow's milk allergy diagnosed by family pediatrician operating in Italy|May 2014|May 19, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02144428||44205|
NCT02144701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021202|Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant|A Randomized Trial Testing a Probiotic Enteric Regimen for Easing Complications of Transplant (Randomized PERFECT Trial)||Rutgers, The State University of New Jersey|No|Recruiting|February 2013|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|68|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02144701||44184|
NCT02145182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-DGF-201|Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)|A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.||Alexion Pharmaceuticals|Yes|Active, not recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|286|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02145182||44147|
NCT02168218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218/13|Effects of Milk Proteins on Protein Synthesis in Healthy Male Subjects Fed a Hypercaloric, High Sucrose Diet|Effects of Milk Proteins on Whole Body Protein Synthesis and Ectopic Lipid Deposition During Sucrose Overfeeding in Healthy Male Subjects|FruMilk|University of Lausanne|No|Recruiting|December 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02168218||42382|
NCT02164617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-2012-01-02(II)|Wheelchair-bound Senior Elastic Band (WSEB) Exercise Program for the Demented Seniors|Development and Evaluation of an Evidence-based Intervention Guideline of the Wheelchair-bound Senior Elastic Band (WSEB) Exercise Program for the Demented Seniors in Long-term Care Facilities|WSEB|Kaohsiung Medical University|Yes|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|65 Years|N/A|No|||June 2015|June 13, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02164617||42657|
NCT02164630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400260|Optimizing Resilience In Orofacial Pain and Nociception|Assessing the Efficacy of a Hope Intervention in Temporomandibular Disorder|ORION|University of Florida|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164630||42656|
NCT02135055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014021801|Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status|Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status.||Xiangya Hospital of Central South University|No|Not yet recruiting|May 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|80 Years|No|||May 2014|May 7, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02135055||44924|
NCT02165904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-LEM2|Subarachnoid Administration of Adult Autologous Bone Marrow Mesenchymal Cells Expanded in Incomplete (SCI)|Phase I.Subarachnoid Administration of Adult Autologous Mesenchymal Bone Marrow Cells Expanded in Incomplete Spinal Cord Injury (SCI)||Puerta de Hierro University Hospital|No|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||August 2015|August 25, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02165904||42558|
NCT02134184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-25199|The Influence of Chronic CMV Infection on Influenza Vaccine Responses|The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses|SLVP025|Stanford University|No|Active, not recruiting|August 2012|March 2015|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|78|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 7, 2014||Yes||No||https://clinicaltrials.gov/show/NCT02134184||44991|
NCT02134509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14CRP18200010|Smartphone Application for Smoking Cessation|Smartphone Application for Smoking Cessation||Yale University|Yes|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134509||44966|
NCT02134522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013732|The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease|The Role of Obstructive Sleep Apnea in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents||Yale University|No|Recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|9 Years|21 Years|No|||March 2015|March 16, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02134522||44965|
NCT02134717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL112711|Impact of CCR5 Inhibition on Sarcoidosis Immunophenotypes|An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis|GRADS|University of Pittsburgh|Yes|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|3|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02134717||44950|
NCT02135016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140415|The Effect of Thoracic Epidural Anesthesia With Different Block Level on Propofol Induction|The Effect of Thoracic Epidural Anesthesia With Different Block Level on Propofol Concentration During General Anesthesia Induction||First Hospital of China Medical University|Yes|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|40 Years|60 Years|No|||August 2014|August 28, 2014|April 30, 2014||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT02135016||44927|
NCT02135029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481030|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins|A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of PF-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins|SPIRE-SI|Pfizer|Yes|Completed|June 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|184|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135029||44926|
NCT02135900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-046|The Use of Heliox in Obstructive Sleep Apnea Syndrome|The Use of Heliox in Obstructive Sleep Apnea Syndrome.|HOSA|Northwell Health|No|Completed|December 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|July 4, 2012||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT02135900||44860|
NCT02136199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002055|Use of Decision Aids in Clinical Encounters|Patient-centered Dissemination of Evidence-based Medicine: Share EBM||Mayo Clinic|No|Enrolling by invitation|September 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02136199||44837|
NCT02154763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|717602410|The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery|A Pilot Study to Assess the Feasibility of a Future Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Role of Intra-Peritoneal Ropivacaine in Gastric Bypass Surgery: INOPAIN Trial|INOPAIN|Ottawa Hospital Research Institute|Yes|Recruiting|June 2014|May 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02154763||43413|
NCT02154776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2112C|Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.|A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.|LeeBLet|Novartis|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154776||43412|
NCT02155023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACTforSENSOR|Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors|An Open, Single-centre, Non-controlled Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors Used for Continuous Glucose Monitoring in Patients With Type 1 Diabetes|REACT4SENSOR|Medical University of Graz|Yes|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02155023||43393|
NCT02153359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00082646|Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response|Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response|INHALE 2|Johns Hopkins University|No|Recruiting|February 2014|||February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|50 Years|No|||September 2015|September 14, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02153359||43520|
NCT02153632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS320-3006|Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|ALLAY-LID II|Osmotica Pharmaceutical Corp.|No|Recruiting|June 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|162|||Both|30 Years|85 Years|No|||February 2016|February 9, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153632||43499|
NCT02153645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS320-3005|Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.|A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|ALLAY-LID I|Osmotica Pharmaceutical Corp.|No|Recruiting|June 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|162|||Both|30 Years|85 Years|No|||February 2016|February 9, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153645||43498|
NCT02151708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-026|Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method|Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia:||Samsung Medical Center|No|Not yet recruiting|June 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|78|||Both|20 Years|70 Years|No|||November 2014|November 24, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151708||43647|
NCT02183818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301013416|Integrative-omics of the Disordered COPD Small Airway Epithelium|Integrative-omics of the Disordered COPD Small Airway Epithelium||Weill Medical College of Cornell University|No|Active, not recruiting|April 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|717|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan Area residents|April 2015|December 9, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02183818||41187|
NCT02152215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0430|Ridge Preservation Comparing a Polylactic Acid Membrane vs. an Acellular Dermal Matrix Membrane|Ridge Preservation Comparing the Clinical and Histologic Healing of a Bioabsorbable Membrane Made of Polylactic Acid and a Citric Acid Ester vs. an Acellular Dermal Matrix Allograft GBR||University of Louisville|No|Not yet recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02152215||43608|
NCT02164344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPHID-UniRoma03|Effects of Probiotics on Microbial Translocation and Immune Activation Markers in HIV-positive Patients on Combined Antiretroviral Therapy|Effects of Probiotics on Microbial Translocation and Immune Activation Markers in HIV-positive Patients on Combined Antiretroviral Therapy and Non-virological Study of the Effects of Therapy|PROBIO-HIV|University of Roma La Sapienza|Yes|Active, not recruiting|January 2013|July 2014|Anticipated|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|June 12, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02164344||42678|
NCT02165449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS001796|Biomarkers of Fast Acting Therapies in Major Depression|Translational Biomarkers of Fast Acting Therapies in Major Depression||University of California, Los Angeles|Yes|Recruiting|June 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||December 2015|December 5, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165449||42593|
NCT02138136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG/0211PFC-11S1|Long-term Safety and Efficacy of Lubiprostone in Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation||Sucampo Pharma Americas, LLC|Yes|Recruiting|March 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|6 Years|17 Years|No|||February 2016|February 29, 2016|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02138136||44688|
NCT02165475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 02-220|Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents|Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents is Effective for the Treatment of Fecal Incontinence in Women - a Randomized Controlled Trial||University Hospital, Linkoeping|No|Completed|May 2002|||March 2005|Actual|N/A|Interventional|Primary Purpose: Treatment|3||||||Female|18 Years|N/A|No|||June 2014|June 17, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165475||42591|
NCT02134197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16044|Dose-escalation Study of BAY1129980|An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a||Bayer|No|Recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02134197||44990|
NCT02165670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASIC VALIDATE|BASIC VALIDATE Coronary Stent Registry|BioMatrix NeoFlex Post Marketing Surveillance in Validate (the BASIC VALIDATE) Registry)||University Hospital Orebro|No|Active, not recruiting|June 2014|July 2021|Anticipated|June 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Probability Sample|Patients with ischemic heart disease|June 2014|June 16, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165670|5 Years|42576|
NCT02134730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGJA-01|School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial|School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial Using the FRIENDS for Life Manual||Uppsala University|No|Completed|September 2013|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|695|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02134730||44949|
NCT02135042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-HN001|Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA|Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)||NRG Oncology|Yes|Recruiting|April 2014|||July 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|924|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135042||44925|
NCT02135666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117307|Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)|Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)||GlaxoSmithKline||Withdrawn|May 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|May 8, 2014|Yes|Yes|This study has been cancelled before initiation due to company's prioritisation decisions    linked to resources restrictions.|No||https://clinicaltrials.gov/show/NCT02135666||44878|
NCT02166775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5541|Correlation Between Sagittal Balance of the Spine and Psychopathological Profile|||University Hospital, Strasbourg, France|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|70 Years|No|Non-Probability Sample|Kyphosis in Depressed or Anxious Patients - Lordosis in Patients With Manic|June 2015|June 18, 2015|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166775||42492|
NCT02166788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZMTG 01.12|Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma|Inguinal or Ilio-inguinal Lymphadenectomy for Patients With Metastatic Melanoma to Groin Lymph Nodes and no Evidence of Pelvic Disease on PET/CT Scan - A Randomised Phase III Trial (EAGLE FM)|EAGLE FM|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|January 2015|August 2030|Anticipated|August 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|634|||Both|15 Years|N/A|No|||January 2016|January 6, 2016|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02166788||42491|
NCT02167035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEP001|Comparison of Combigan BID Versus Simbrinza TID|Pilot Study Comparison of Combigan BID vs Simbrinza TID in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension||Cornerstone Health Care, PA|No|Recruiting|August 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 18, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167035||42472|
NCT02186808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-116|T-116_Procera-Bridge Zirconia - A Clinical Study|Procera-Bridge Zirconia - A Clinical Study||Nobel Biocare|No|Completed|May 2005|||December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 8, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02186808||40957|
NCT02155036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH11-123|Effect of Exercise on Renal Function in Predialysis|The Effect of Exercise on Renal Function and Cardiovascular Disease in Pre-dialysis (Chronic Kidney Disease Stage 3-4) Patients With Chronic Kidney Disease; a Randomised Controlled Trial Pilot Study.||King's College Hospital NHS Trust|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02155036||43392|
NCT02155049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-01|Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues|Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.||Rabin Medical Center|No|Recruiting|November 2014|||December 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 14, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02155049||43391|
NCT02153658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odor Study (RMC-10)|An Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Methods With PrePexTM|A Prospective, Randomized, Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Techniques When Using the PrePexTM Device|RMC-10|Ministry of Health, Rwanda|No|Completed|November 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|101|||Male|21 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02153658||43497|
NCT02153671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-H5N2-02|Immunogenicity of H5N1 Vaccine Following H5N2|Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects||PATH|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|51 Years|Accepts Healthy Volunteers|||May 2014|August 26, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02153671||43496|
NCT02153918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140112|Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy|A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Male|18 Years|100 Years|No|||March 2016|March 11, 2016|May 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153918||43477|
NCT02183376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.27|Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects|Pharmacokinetics and Pharmacodynamics of BI 1356 5 mg Once Daily in Male and Female Subjects With Different Degrees of Liver Impairment (Child Pugh Classification A-C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)||Boehringer Ingelheim||Completed|July 2008|||March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183376||41221|
NCT02183389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.28|Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of Warfarin (10 mg qd) After Coadministration With Multiple Oral Doses of BI 1356 (5 mg qd) Compared to the Bioavailability of a Single Oral Dose of Warfarin (10 mg qd) Alone in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study)||Boehringer Ingelheim||Completed|May 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183389||41220|
NCT02183402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.29|Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers|Relative Bioavailability of Digoxin After Co-administration of Multiple Oral Doses of Digoxin (0.25 mg qd) and Multiple Oral Doses of BI 1356 (5 mg qd) Compared to the Bioavailability of Multiple Oral Doses of Digoxin (0.25 mg qd) Alone in Healthy Male and Female Volunteers (an Open-label, Randomized, Two-way Crossover Clinical Phase I Study)||Boehringer Ingelheim||Completed|June 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02183402||41219|
NCT02183415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.3|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses (2.5, 5, and 10 mg q.d. for 28 Days) of BI 1356 BS as Tablet in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups)||Boehringer Ingelheim||Completed|August 2005|||January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|77|||Both|21 Years|70 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183415||41218|
NCT02154217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR-BLT|Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures|Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures||University of Milan|No|Completed||||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02154217||43454|
NCT02154516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-ODHH166|Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System|||Smith & Nephew, Inc.||Active, not recruiting|October 2011|June 2022|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|N/A|No|||March 2015|March 30, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02154516||43432|
NCT02184143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140057|Postoperative Management for Degenerative Spinal Conditions|Comparative Effectiveness of Postoperative Management for Degenerative Spinal Conditions||Vanderbilt University|Yes|Recruiting|August 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|21 Years|90 Years|No|||January 2016|January 11, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184143||41162|
NCT02184403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0579B|Quality of Life After Laser Cordectomy in Early Glottic Cancer|Quality of Life After Laser Cordectomy in Early Glottic Cancer||Chang Gung Memorial Hospital|Yes|Recruiting|May 2010|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|20 Years|95 Years|No|Non-Probability Sample|Patients with early glottic cancer without neck or distant metastasis and were managed by        Laser cordectomy in a tertian referral hospital in Taiwan.|July 2014|July 8, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02184403||41142|
NCT02154529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD019-204|Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer|A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer||Kadmon Corporation, LLC|Yes|Active, not recruiting|May 2014|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|80|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02154529||43431|
NCT02165163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCAMP_123|Virtual Reality-Based Exercise in Cancer Patients|Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy||University of Arizona|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165163||42615|
NCT02165176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035394|Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis|Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis||Johns Hopkins University|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165176||42614|
NCT02134743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18911913.7.0000.0075|Evaluation of the Stability of Implants With Two Different Surface Treatments|Evaluation of the Stability of Implants With Two Different Surface Treatments: a Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|April 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02134743||44948|
NCT02165462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPRIO-HE|Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy|Assessment of Bilateral Deficit Phenomenon During Dynamic Plantar Flexion Task in Patients With Haemophilic Arthropathy|PROPRIO-HE|Universidad Católica San Antonio de Murcia|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Male|18 Years|50 Years|No|Probability Sample|Patients with haemophilia|September 2015|November 11, 2015|June 1, 2014||No||No|October 7, 2015|https://clinicaltrials.gov/show/NCT02165462|1 Month|42592|
NCT02166255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99114|APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02166255||42532|
NCT02166268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-G-03|Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber|Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber|AV-G-03|ALK-Abelló A/S|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02166268||42531|
NCT02166528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|The Study of Genes Localization for Female Pelvic Floor Dysfunction|The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction|PFD POP UI|Third Military Medical University|Yes|Enrolling by invitation|November 2013|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|The sample of blood, urine, cervical exfoliated cells and tissue of patients with POP, UI or      genital tract injury should be used only in this research with informed consent. The      remaining part will be Safekeeping. All information is strictly confidential.|Female|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The experiment group are patients with PFD. While the control group are volunteer patients        without PFD on the basis of informed consent.|June 2014|June 14, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166528||42511|
NCT02166801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smallstep|Small Step Intervention for Infants With Cerebral Palsy and Other Neurodevelopmental Disorders|A Small-step Program for Development of New Treatment Principles for Children With Cerebral Palsy and Other Neurodevelopmental Disorders|smallstep|Karolinska Institutet|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Months|10 Months|No|||March 2016|March 7, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02166801||42490|
NCT02166814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FRC-CT-301|A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia|||Boryung Pharmaceutical Co., Ltd|No|Not yet recruiting|June 2014|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|135|||Both|20 Years|75 Years|No|||June 2014|June 17, 2014|June 16, 2014||Yes||||https://clinicaltrials.gov/show/NCT02166814||42489|
NCT02167048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00224|Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Children With ADHD|Effects of Low-dose Versus Normal-dose Psychostimulants on Executive Functions in Children With Attention-Deficit Hyperactivity Disorder||University of British Columbia|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|52|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02167048||42471|
NCT02167061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA1229_01_BE_I|A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers|A Randomized, Open-label, Crossover, Single Dose Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 5/1000 mg) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 After Single Oral Administration in Healthy Male Volunteers||Dong-A ST Co., Ltd.|Yes|Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02167061||42470|
NCT02152475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPQ2013|Photodynamic Therapy (PDT) for Oral Disinfection|PDT With Blue Light and Curcumin for Oral Disinfection||University of Sao Paulo|Yes|Completed|May 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02152475||43588|
NCT02187081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHB008|Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC|Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)||Southwest Hospital, China|Yes|Not yet recruiting|June 2014|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|70 Years|No|||December 2015|December 21, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02187081||40936|
NCT02155114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-053|Iron Homoeostasis in Inflammation|Iron Homoeostasis in Inflammation: A Single Center Observational Cross-sectional Study||University Hospital, Basel, Switzerland|No|Completed|April 2014|||October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|472|Samples Without DNA|blood samples (serum and heparinized plasma)|Both|N/A|N/A|No|Non-Probability Sample|Consecutive internal medicine inpatients with laboratory signs of inflammation|November 2014|November 11, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155114||43386|
NCT02150967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398X2204|A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma|A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy||Novartis|No|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|May 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02150967||43703|
NCT02153892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3870|Feasibility of the Accucinch System for Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function|Clinical Protocol - A Feasibility Study Using the Accucinch System in the Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function|LVRECOVER|Guided Delivery Systems Inc.|Yes|Active, not recruiting|August 2014|November 2018|Anticipated|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153892||43479|
NCT02153905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140110|T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive|Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|November 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|70 Years|No|||December 2015|February 20, 2016|May 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153905||43478|
NCT02154204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRF2014|A Validation Study of Near Infrared Fluorescence Imaging of Lymphatic Vessels in Humans.|||University of Aarhus||Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Male|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants are young healthy males.|May 2014|January 18, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02154204||43455|
NCT02154542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-3688|Study to Improve Treatments and Follow-up of Children Who Need Respiratory Support|Validation of the Measurement of Respiratory Work Using Diaphragm Electrical Activity in Infant and Children During Weaning|Edi-PTP|St. Justine's Hospital|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|18 Years|No|||November 2015|November 20, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02154542||43430|
NCT02154815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0078|Pre-emptive Kidney Transplantation Quality of Life|Evaluation of the Benefits Associated With Pre-emptive Kidney Transplantation. Prospective, Multicenter and Controlled Study of Quality of Life, Psychological Adjustment Processes and Medical Outcomes of Patients Receiving a Pre-emptive Kidney Transplant Compared to a Similar Population of Recipients After a Dialysis Period of Less Than Three Years|PreKiTQoL|Nantes University Hospital|No|Recruiting|September 2014|September 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|390|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients waiting a kidney transplantation|July 2015|July 2, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154815||43409|
NCT02137837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1222|S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer|Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients||Southwest Oncology Group|Yes|Active, not recruiting|May 2014|May 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|825|||Female|18 Years|N/A|No|||May 2015|May 20, 2015|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137837||44711|
NCT02137850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7088-3908|Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A|An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A|pathfinder™6|Novo Nordisk A/S|No|Enrolling by invitation|June 2014|November 2021|Anticipated|November 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Male|N/A|6 Years|No|||January 2016|January 26, 2016|March 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137850||44710|
NCT02165189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104281|An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant|A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin|GALAXY|Janssen Scientific Affairs, LLC|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165189||42613|
NCT02165202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 076|Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis|HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)|TMC278LA|PATH|Yes|Active, not recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|132|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 14, 2016|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165202||42612|
NCT02165683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0468-F3r|Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans|Investigation of Propranolol Premedication to Reduce FDG Uptake in Brown Adipose Tissue on PET Scans of Pediatric Cancer Patients||University of Kentucky|Yes|Not yet recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|11|||Both|12 Years|29 Years|No|Probability Sample|11 Male and female participants from all races and ethnic backgrouns who are receiving        treatment by the University of Kentucky Medical Center, Pediatric Oncology divsion.|September 2014|September 2, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165683||42575|
NCT02165943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-0014|Evaluation of Vitoss With and Without BMA for Benign Cavitary Lesions|A Combined Retrospective and Prospective Protocol to Evaluate Vitoss With and Without Bone Marrow Aspirate for Benign Cavitary Lesions||Orthovita d/b/a Stryker|No|Enrolling by invitation|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from retrospective records from the investigators specialty        practice.|June 2014|June 12, 2014|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165943||42555|
NCT02165956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEOBE-01-011|Effect of a New Infant Cereal on Weight Gain|Effect of a New Food Product on Weight Gain During First Infancy|CEOBE|Laboratorios Ordesa|No|Completed|March 2011|April 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|195|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165956||42554|
NCT02166294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE-2001|NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers|A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks|CONDUCT I|Amniox Medical, Inc.|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 26, 2015|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166294||42529|
NCT02165917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDW-003|Study to Compare Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesion Barrier|Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier||Pius-Hospital Oldenburg|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||November 2015|November 2, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02165917||42557|
NCT02165930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501037|Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers|An Open Label, Single Dose, Randomized, Two Way Crossover Study to Estimate Oxycodone Relative Bioavailability in Healthy Volunteers Following Administration of PF 00345439 Formulation K 40 Mg Under Fasting Conditions With 40% Ethanol Compared With Water||Pfizer|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165930||42556|
NCT02166281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Comfort|Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer|||Azienda Ospedaliera Spedali Civili di Brescia|No|Recruiting|May 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal Women with early stage endocrine responsive breast cancer|June 2014|June 16, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02166281||42530|
NCT02166541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Forssberg_KI_1|Evaluation of INRS With BCSK in Children With Spastic Bilateral Cerebral Palsy: a Randomized Controlled Trial.|Evaluation of "Intensive Neurophysiological Rehabilitation System" (INRS) With "Biomechanical Correction of the Spine According to Kozyavkin" (BCSK) in Children With Spastic Bilateral Cerebral Palsy: a Randomized Controlled Trial.||Karolinska Institutet|No|Recruiting|January 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|12 Years|No|||February 2015|February 18, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02166541||42510|
NCT02167516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301042211|A Clinical Study of Xin'an Medicine in the Treatment of Knee Osteoarthritis|Efficacy and Safety of Xinfeng Capsule in the Treatment of Knee Osteoarthritis (KOA) :A Randomized, Double-blind, Double-dummy, Multi-center Trial||The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Yes|Completed|October 2014|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|40 Years|75 Years|No|||August 2015|August 18, 2015|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02167516||42436|
NCT02167776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107011800|From Obstacles to Opportunities for Male Circumcision in Tanzania|Cluster-randomized Study of Church-Based Intervention to Promote Male Circumcision in Tanzania||Weill Medical College of Cornell University|No|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|900|||Male|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167776||42416|
NCT02167789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITSY02|Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device|Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT|CLEPSYDRA|LivaNova||Completed|September 2009|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|520|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167789||42415|
NCT02153060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Dexamethasone|An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)|A Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Different Doses of Dexamethasone for Management of Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|May 2014|March 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153060||43543|
NCT02153047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01962|Multicentric Randomized Clinical Trial to Evaluate the Long-term Effectiveness of a Motivational Intervention Against Smoking, Based on the Information Obtained From Spirometry in Primary Care.|Multicentric Randomized Clinical Trial to Evaluate the Long-term Effectiveness of a Motivational Intervention Against Smoking, Based on the Information Obtained From Spirometry in Primary Care.|RESET-ESPITAP2|Jordi Gol i Gurina Foundation|No|Active, not recruiting|November 2011|November 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1100|||Both|35 Years|70 Years|No|||May 2014|May 30, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02153047||43544|
NCT02154568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16885|Study of Airflow in the Lungs Using Helium MRI|Flow Quantification in the Human Airways Using Hyperpolarized Helium 3 MRI||University of Virginia|No|Recruiting|November 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154568||43428|
NCT02154854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO2011/YL/ADEQUATE-A|Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)|Effect of Advagraf on Arterial Stiffness and on Vascular Fibrosis Plasma Markers on de Novo Renal Transplant Patients|ADEQUATEartère|University Hospital, Tours|Yes|Recruiting|July 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|70 Years|No|||May 2014|May 30, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02154854||43406|
NCT02154867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/971/REK|Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.|Recalibrating Intestinal Microflora in IBS by Fecal Transplantation|REFIT|University Hospital of North Norway|No|Active, not recruiting|December 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|November 16, 2015|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02154867||43405|
NCT02154230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2488/14.06.2012|Sulphate-bicarbonate-calcium Water, Body Weight and Gut Microbiota|Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet||University of Roma La Sapienza|No|Recruiting|November 2013|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Female|18 Years|65 Years|No|||June 2014|June 4, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154230||43453|
NCT02151500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU.HIC.036514B3E|Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms|Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms||Wayne State University|No|Completed|May 2014|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151500||43663|
NCT02154828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0029|Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)|Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)|AUTISM|Nantes University Hospital|No|Recruiting|September 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|3 Years|6 Years|No|Non-Probability Sample|Children 3 to 6 years with a diagnosis F84.0 and F84.1 according to CIM-10, supported in        care units that meet the criteria defined integrative practices.|December 2015|December 21, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02154828||43408|
NCT02155088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17815|BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer|A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2014|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02155088||43388|
NCT02155101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChantalIRCB|Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS|Monotherapy in Africa: Evaluation of New Therapy|MANET|University of Liverpool|Yes|Recruiting|May 2014|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|70 Years|No|||July 2014|July 16, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155101||43387|
NCT02134210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-0214-04|Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)||Coherus Biosciences, Inc.|Yes|Active, not recruiting|June 2014|May 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|496|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134210||44989|
NCT02134223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH103-80|Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD|Changes in Methylation Status of BDNF Gene After Receiving Dialectical Behavior Therapy in Patients With Borderline Personality Disorder||Mackay Memorial Hospital|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|180|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02134223||44988|
NCT02165696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMA_CBM_2014/LYMP|Compression Bandaging and Manual Lymph Drainage in Women With Lymphedema|Effectiveness of the Combination of Compression Bandaging and Manual Lymph Drainage in Women With Secondary Lymphedema After Breast Cancer.|LYMPHATIC|University of Malaga|Yes|Not yet recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Female|45 Years|65 Years|No|||June 2014|June 13, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165696||42574|
NCT02165969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0063|Olfactory Function Following Endoscopic Endonasal Skull Base Surgery|Olfactory Function Following Endoscopic Endonasal Skull Base Surgery: Clinical and Histological Outcomes|UPSIT|Ohio State University|No|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|160|||Both|18 Years|N/A|No|||September 2015|September 13, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02165969||42553|
NCT02166307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deng02|Clinical Verification of Peptide Biomarkers for Human Aging|Clinical Verification of Peptide Biomarkers for Human Aging by Standard-Free, Label-Free LC-MS/MS Quanification of Aldehyde-modified Peptides||Beijing Institute of Technology|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|253|||Both|23 Years|72 Years|Accepts Healthy Volunteers|Non-Probability Sample|university hospital, plasma samples of physical examination, faculties and staff of a        certain university|June 2014|June 17, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166307||42528|
NCT02166554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNL-2011-05|The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions|The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial|BAP|BioRegen Biomedical (CHangzhou) Co., Ltd|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|216|||Female|18 Years|45 Years|No|||June 2014|June 16, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02166554||42509|
NCT02166827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX-LT1|Effects of a NeuroAD System, for the Treatment of Alzheimer Disease|Effects of a NeuroAD System, for the Treatment of Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study||Neuronix Ltd|No|Terminated|November 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|60 Years|90 Years|No|||November 2015|November 23, 2015|June 15, 2014||No|Administrative decision|No||https://clinicaltrials.gov/show/NCT02166827||42488|
NCT02167074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPRO-2014-01|A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device|A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device|ASPRO|Foundation for Liver Research|No|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|672|||Both|18 Years|100 Years|No|||October 2015|October 16, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167074||42469|
NCT02167815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RedEgg 01|A Multicenter, Post Marketing Clinical Follow up (PMCF) Investigation to Evaluate the Performance and Safety of a Soft Silicone Foam Dressing and to Evaluate the Performance of Standard Care in Exuding Venous Leg Ulcers|A Multicenter, Post Marketing Clinical Follow up (PMCF) Investigation to Evaluate the Performance and Safety of a Soft Silicone Foam Dressing and to Evaluate the Performance of Standard Care in Exuding Venous Leg Ulcers||Molnlycke Health Care AB|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|September 7, 2015|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02167815||42413|
NCT02154243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-114|An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty|An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine in Patients With Preserved Cardiac Output (CO) and an Intravenous Fluid Bolus for Patients With Low CO Following Total Hip Arthroplasty||Hospital for Special Surgery, New York|No|Terminated|June 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|90 Years|No|||January 2015|August 31, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154243||43452|
NCT02154555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POD_001|A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery|||St. Michael's Hospital, Toronto||Recruiting|May 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02154555||43429|
NCT02153944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140114|Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety|Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Anticipated|159|||Both|18 Years|50 Years|No|||December 2015|December 31, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153944||43475|
NCT02153372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC2012|Cell Therapy by Bone Marrow-derived Mononuclear Cells (BMC) for Large Bone Defect Repair: Phase-I Clinical Trial|Cell Based Therapy by Implanted Bone Marrow-derived Mononuclear Cells (BMC) for Bone Augmentation of Plate-stabilized Proximal Humeral Fractures|BMC2012|Goethe University|Yes|Recruiting|July 2013|||July 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|90 Years|No|||May 2014|May 29, 2014|February 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02153372||43519|
NCT02154880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13050317|Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)|Translation Evaluation of Aging, Inflammation and HIV in Lung Function|TEAL|University of Pittsburgh|No|Recruiting|February 2014|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02154880||43404|
NCT02154893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP2013|Synergic Effects of Ultrasound and Laser on the Pain Relief and Functionality|Synergic Effects of Ultrasound and Laser on the Pain Relief and Functionality in Women With Hand or Knee Osteoarthritis.||University of Sao Paulo|Yes|Completed|January 2014|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Female|60 Years|80 Years|No|||May 2014|December 3, 2015|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02154893||43403|
NCT02151253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028116|A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia|A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia||Duke University|No|Completed|May 2011|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|90 Years|No|||January 2016|January 20, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151253||43681|
NCT02151227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC14EISI0086|Magnesium and Metabolic Syndrome: A Dose-response Meta-analysis|Association of Dietary Magnesium Intake and Circulating Magnesium Concentration With Metabolic Syndrome: A Dose-response Meta-analysis||The Catholic University of Korea|No|Completed|June 2014|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|12|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Adult population: 18 years old and older|December 2014|December 25, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151227||43683|
NCT02150980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INORMUS_INTERNATIONAL|INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)|INORMUS 40,000: Large Observational Cohort Study of Orthopedic Trauma Patients|INORMUS|McMaster University|Yes|Recruiting|April 2014|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients 18 years of age or older who are admitted to a recruiting hospital in        low-middle income countries in Africa, Asia, and Latin America|March 2016|March 14, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02150980||43702|
NCT02133950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201420647|Efficacy Study of Segmentation of PGD Treatment|A Single Centre Randomised Controlled Study Into the Segmentation of Preimplantation Genetic Diagnosis (PGD) Treatment by Comparing Cumulative Pregnancy Rates Following Cryopreservation of All Genetically Transferable Embryos After PGD, Compared to Fresh Embryo Transfer Cumulative With Frozen Embryo Transfer of Genetically Transferable Embryos.||Universitair Ziekenhuis Brussel|Yes|Not yet recruiting|May 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Female|20 Years|40 Years|No|||May 2014|May 6, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02133950||45009|
NCT02164955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-015|A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.|A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy||Celgene|No|Recruiting|June 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic, measurable relapsed and refractory multiple myeloma who have        received at least two prior treatment regimens, including both bortezomib and lenalidomide        and have demonstrated disease progression on the last therapy and are commencing a        pomalidomide based treatment.|January 2016|January 21, 2016|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164955|5 Years|42631|
NCT02165722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13070205|4 Pillars Toolkit for Adolescent Vaccination|An Enhanced 4 Pillars Toolkit for Increasing Adolescent Immunization: A Randomized Controlled Cluster Trial in Pediatrics and Family Medicine||University of Pittsburgh|No|Active, not recruiting|September 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|21|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165722||42572|
NCT02166606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENTLE-1013|INGEVITY™ Observational Trial|INGEVITY™ Observational Trial: Assessment of Routine Experience and Magnet Resonance Imaging (MRI) Usage With a New Lead for Bradycardia Pacing|Gentle|Boston Scientific Corporation|No|Active, not recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1177|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects will be coming from the general patient population of the participating        centers who are indicated for implantation of a BSC (Boston Scientific) ImageReady Pacing        System (pulse generator [PG] & leads) and who are fulfilling all inclusion criteria and        none of the exclusion criteria.|March 2016|March 2, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02166606||42505|
NCT02165982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|Characteristics of Intensity and Dependence to Physical Activity in Anorexia Nervosa|Intensity and Dependence to Physical Activity and Its Links With Clinical and Emotional Statuses in Comparison With Healthy Controls.|HAP-AM|Institut Mutualiste Montsouris|No|Recruiting|February 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|13 Years|23 Years|Accepts Healthy Volunteers|Probability Sample|Pour l'échantillon clinique (patients témoins et contrôles) : prise en charge pour        Anorexie Mentale (selon les critères DSM-IV) dans le département de psychiatrie de        l'enfant et de l'adolescent de l'Institut Mutualiste Montsouris.        Pour l'échantillon individus sains témoins : Sujets issus de la population générale        (collégiens lycéens étudiants).|May 2014|June 12, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02165982||42552|
NCT02166320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1034-31/3|Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent.|The Importance of Stent Design|StentMig|Karolinska University Hospital|Yes|Completed|October 2010|April 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166320||42527|
NCT02166333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063914|Study To Understand Fall Reduction and Vitamin D in You|Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial|STURDY|Johns Hopkins University|Yes|Recruiting|July 2015|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|1200|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166333||42526|
NCT02166567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB178/12|Effect of Sorting of Apoptotic Spermatozoa on the Outcome of Assisted Reproduction|The Effect of Sorting of Non-apoptotic and Apoptotic Spermatozoa Using Flow Cytometry on the Outcome of Intracytoplasmic Sperm Injection.|Spermsorting|University of Basel|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|22 Years|39 Years|No|||June 2014|June 17, 2014|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166567||42508|
NCT02166840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/220-31/4|Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.|Self Expanding Metal Stents (SEMS) or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.|SEMS|Karolinska University Hospital|No|Completed|March 2007|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|90 Years|No|||October 2015|October 21, 2015|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02166840||42487|
NCT02167087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENSE2014|Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.|Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.|SENSE|Herlev Hospital|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02167087||42468|
NCT02168101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 42|Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma|Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study||SCRI Development Innovations, LLC|No|Recruiting|August 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168101||42391|
NCT02164227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025972/2013|Effective Use of Respiratory Patterns in the First Period of Labor in Control of Maternal Anxiety|EFFECTIVE USE OF RESPIRATORY PATTERNS IN THE FIRST PERIOD OF LABOR IN CONTROL OF MATERNAL ANXIETY: A CLINICAL TRIAL||Universidade Federal de Pernambuco|Yes|Recruiting|March 2014|April 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|30|||Female|12 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02164227||42687|
NCT02153684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1674-14|Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform|Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform||Queen's University|No|Recruiting|March 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will include 30 participants from each of the following four subgroups: GOLD        grade 1A COPD, GOLD grade 1B COPD, symptomatic smokers who do not meet spirometric        criteria for COPD, and age- and sex-matched healthy non-smoking controls. Subjects will be        recruited from the Canadian Chronic Obstructive Lung Disease (CanCOLD) study cohort and,        once that source has been exhausted, from each site's database of previous or potential        research study participants. The CanCOLD Study cohort was recruited from the COLD Study        sample, which was a random sample of adults ≥40 years of age who had pre- and        post-bronchodilator spirometry performed in order to estimate the prevalence of COPD in        Canada.|November 2015|November 19, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02153684||43495|
NCT02153957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140116|Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors|A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in ChildrenTreated With Cranial Radiation for BrainTumors||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|April 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|156|||Both|8 Years|17 Years|No|||March 2016|March 24, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153957||43474|
NCT02154256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM14I001|Incentive Disbursement Pattern|Increasing, Decreasing, and Stable Incentives in a Health App Aggregator Website||University of Pennsylvania|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|3519|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02154256||43451|
NCT02154282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAJAJ0013|iPod Games in Hepatic Encephalopathy|||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Recruiting|January 2013|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02154282||43449|
NCT02154841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/P/009|Changes in Taste Perception and Preference in the Peri-operative Patient|Changes in Taste Perception and Preference in the Peri-operative Patient|TASTE|Plymouth Hospitals NHS Trust|No|Completed|February 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||May 2014|June 2, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154841||43407|
NCT02155153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cg1|Role of Chewing Gum in Reducing Post Operative Ileus After Reversal of Ileostomy|The Effect of Gum Chewing on the Duration of Postoperative Ileus and Total Length of Hospital Stay After Reversal of Ileostomy||Services Hospital, Lahore|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|15 Years|60 Years|No|||January 2016|January 29, 2016|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02155153||43383|
NCT02155127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00064407|Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility|Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study||University of Utah|Yes|Not yet recruiting|July 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|N/A|No|||June 2014|June 2, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155127||43385|
NCT02151812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTQ002-Agent-ISR|Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)|A Prospective Randomized Multicenter Non-inferiority Clinical Study to Determine the Safety and Performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter (Hemoteq) Compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter (B.Braun) for the Treatment of Coronary In-Stent Restenosis (AGENT-ISR)|AGENT-ISR|Hemoteq AG|Yes|Recruiting|August 2014|March 2019|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151812||43639|
NCT02164669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130225-8|Exploration of Neuroimaging and Biochemical Prognostic Indicators for POCD|Exploration of Neuroimaging and Biochemical Prognostic Indicators for Post-operative Cognitive Dysfunction After Coronary Artery Bypass Graft||Xijing Hospital|Yes|Recruiting|May 2013|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|4ml venous blood will be collected, and serum IL-6， IL-8，TNF-α，NSE，S100β will be detected.|Both|18 Years|80 Years|No|Probability Sample|Patients will selective undergo Coronary Artery Bypass Grafting (CABG) surgery. Health        adult|May 2013|June 13, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164669|7 Days|42653|
NCT02165488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14-237|Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae|Gastrointestinal, Hepatic and Biliary Sequelae of Frequent Ketamine Use: a Prospective Observational Study||The University of Hong Kong|No|Recruiting|June 2014|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Saved plasma samples Gastric antral and duodenal histology obtained by upper GI endoscopy|Both|18 Years|60 Years|No|Non-Probability Sample|Recreational use of ketamine with frequency at least twice per month over 6 months within        the last 2 years, with or without other illicit psychotropic drug.|November 2015|November 30, 2015|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02165488||42590|
NCT02166879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11-0591|Undetected Sleep Apnea in the Postanesthesia Acute Care Unit (PACU)|Undetected Sleep Apnea in the Postanesthesia Acute Care Unit||M.D. Anderson Cancer Center|No|Recruiting|August 2012|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants undergoing elective surgical procedures at UT MD Anderson Cancer Center in        Houston, Texas|February 2016|February 8, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02166879||42484|
NCT02167360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07414|Study of Efficacy and Safety of CTL019 in Adult ALL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia||Abramson Cancer Center of the University of Pennsylvania|Yes|Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167360||42448|
NCT02166866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1295|Phase I/II Cancer Caregiver Interventions to Improve Quality of Life and Prevent Burnout|||Mayo Clinic||Suspended|September 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Caregivers will be recruited through the Mayo Clinic inpatient and outpatient services,        including but not limited to referrals from staff of the Divisions of Medical Oncology,        Hematology, and Radiation Oncology and other clinics in the outpatient setting, and        Divisions of HospitalMedicine, Hospice and Palliative Medicine, and other inpatient        services in the hospital setting. This population was chosen as they are likely to        experience caregiver-related distress for which the intervention will be beneficial.|January 2016|January 7, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02166866||42485|
NCT02167113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V10434-HBVQPS-CSP-01|Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay|Collection of Plasma Samples From Individuals Initiating Therapy With Entecavir or Tenofovir for Chronic Hepatitis B Virus Infection for the Clinical Evaluation of the Aptima HBV Quant Assay|HBVQuant|Hologic, Inc.|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Treatment naïve men and women ≥18 years of age with chronic HBV infection initiating        entecavir or tenofovir treatment.|March 2016|March 22, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167113||42466|
NCT02166580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP 2012_2|Accuracy of CNAP PPV Under General Anaesthesia|Comparison of the Non-invasive CNAP Pulse Pressure Variation With the Invasive Gold Standard||University of Schleswig-Holstein|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|99 Years|No|Probability Sample|Patients undergoing major surgery with the need for invasive arterial pressure monitoring|August 2015|December 5, 2015|December 4, 2012||No||No||https://clinicaltrials.gov/show/NCT02166580||42507|
NCT02166593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YYP-Pravafenix-C31301|A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy|A Multicenter, Double Blind, Randomized, Active Controlled, Parallel-design, Phase 3 Study to Evaluate the Efficacy and Safety of Pravafenix Cap. (Pravastatin Sodium/Fenofibrate) in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy||Yooyoung Pharmaceutical Co.,Ltd.|Yes|Recruiting|May 2014|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|366|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02166593||42506|
NCT02166853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0195|Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)|Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study.|SEGA|University Hospital, Clermont-Ferrand||Completed|April 2014|March 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|99 Years|No|||March 2016|March 3, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166853||42486|
NCT02167100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retention in Care Audit|Patient Retention in HIV Medical Care in a Primary Care Practice in Australia|Patient Retention in HIV Medical Care in a Primary Care Practice in Australia|RiC|Holdsworth House Medical Practice|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1537|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients attending HHMP from 1st January 2009 to 31st March 2014 inclusive,        who had at least 2 practice visits separated by ≥90 days in a year involving HIV        laboratory monitoring whilst attending HHMP.|September 2015|September 17, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02167100||42467|
NCT02167308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-1403A3|Effect of Laser Acupuncture on Obesity|Effect of Laser Acupuncture on Obesity: a Patient-Assessor-Blinded, Randomized, Sham-controlled Crossover Trial||Chang Gung Memorial Hospital|Yes|Recruiting|June 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|20 Years|75 Years|No|||June 2014|June 17, 2014|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02167308||42452|
NCT02167555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-020|Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period|Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period|WBB|Institute for Food Safety and Health, United States|No|Active, not recruiting|June 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167555||42433|
NCT02164240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-149|Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST|A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors|SURE|Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|May 2020|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164240||42686|
NCT02153697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0435|Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream|Comparative Study Investigating the Therapy of of Solar Lentigines With the Q-switched SINON Rubin 694nm Laser Versus Pigmanorm® Cream||University of Zurich|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02153697||43494|
NCT02154295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126|In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems|Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study|SAVOIR2|InfraReDx|No|Recruiting|May 2014|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|16|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02154295||43448|
NCT02154607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TechnischeUM|Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in Patients|Clinical Trial Analyzing the Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus||Technische Universität München|No|Completed|January 2004|December 2013|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|263|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02154607||43425|
NCT02154269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL07/12|Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy|Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy||Hospital Sao Rafael|Yes|Recruiting|September 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|70 Years|No|||October 2015|October 9, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154269||43450|
NCT02154581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI 799_2011|Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone|Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone: A Controlled Clinical Trial||The University of Texas Health Science Center at San Antonio|No|Enrolling by invitation|January 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 12, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154581||43427|
NCT02154659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0680|The Difference of Reflux Pattern Between the Patients Who Have Postprandial Reflux Symptoms|||Yonsei University|No|Recruiting|June 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|51|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154659||43421|
NCT02155140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D 11/P/022|Enteral Feeding in Discharged Patients|Randomised Trial of Enteral Feeding in Patients Discharged From Hospital Following Surgical Resection of an Upper Gastrointestinal Malignancy||Plymouth Hospitals NHS Trust|No|Terminated|February 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|June 2, 2014||No|Failed to recruit full number of patients|No||https://clinicaltrials.gov/show/NCT02155140||43384|
NCT02151539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 1401|Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)|Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)|POSTAGE|Vanderbilt-Ingram Cancer Center|Yes|Recruiting|August 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|No|Non-Probability Sample|This study targets patients with acute graft-versus-host disease previously treated with        extracorporeal photopheresis or other systemic therapies. Patients can be enrolled by all        participating locations.|July 2015|July 15, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151539||43660|
NCT02165215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA29102|A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors|PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAÏVE TO TNF INHIBITORS||Hoffmann-La Roche||Recruiting|August 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165215||42611|
NCT02165501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3218-08/11|Jena Sepsis Registry|Jena Sepsis Registry - a Sepsis-registry for Long Term Outcomes|JenaSepsisReg|University of Jena|No|Recruiting|January 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|patients will be selected from Jena University Hospital, Germany|June 2014|June 13, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165501|60 Months|42589|
NCT02165514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00029355|Cobb Angle Measurement of Kyphosis and Scoliosis|Traditional Cobb Angle Measurement of Kyphosis and Scoliosis Using Lunar IDXA||University of Michigan|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165514||42588|
NCT02167373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH100748|Dashboards for Clinician Monitoring of Patients Through a Mobile Sensing Platform|Dashboards for Clinician Monitoring of Patients Through a Mobile Sensing Platform||Cogito Health Inc|No|Recruiting|November 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02167373||42447|
NCT02167594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A09|Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers|18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers"||Avid Radiopharmaceuticals|No|Active, not recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02167594||42430|
NCT02167126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFranca02|Kinesio Taping Effects on Knee Extension Force Among Soccer Players|Kinesio Taping Effects on Knee Extension Force Among Soccer Players||University of Franca|No|Completed|July 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167126||42465|
NCT02167347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINT-PSY-02|Culturally Adapted Family Intervention For Psychosis|Pilot Study of Culturaly Adapted Family Intervention for Psychosis||Pakistan Institute of Learning and Living|No|Completed|February 2012|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|36|||Both|18 Years|65 Years|No|||August 2015|August 22, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167347||42449|
NCT02167321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0239|Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin With Oxaliplatin), Total Mesorectal Excision (TME)|Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial||Yonsei University|No|Recruiting|December 2014|May 2021|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|580|||Both|19 Years|80 Years|No|||July 2015|July 14, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02167321||42451|
NCT02167334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12 Dr DIMOV|Using Positive Pressure Ventilation for Preoxygenation During Panendoscopy.|Non Invasive Ventilation (NIV) Versus Spontaneous Breathing for Preoxygenation During Ear, Nose, and Throat (ENT) Panendoscopy. A Controlled, Prospective, Randomized Study.|PANNIV|Centre Hospitalier Universitaire, Amiens|No|Completed|September 2013|June 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02167334||42450|
NCT02167568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081260|Corpus Callosum Agenesis and Intellectual Disability|Corpus Callosum Agenesis and Intellectual Disability: Genetic and Phenotypic Characterization|ACCREM|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|360|Samples With DNA|blood sample|Both|3 Months|N/A|No|Non-Probability Sample|patient with corpus callosum agenesis (complete or partial) or dysgenesis associated to        mental retardation recruted through pediatric neurology and genetics consultations in the        reference and competence centers " intellectual disabilities of rare cause" and associated        network called "DéfiSciences".|June 2014|June 18, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02167568||42432|
NCT02167828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00021451|Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia|Increasing Social Support to Improve HIV Care Engagement and Adherence||Medical College of Wisconsin|No|Enrolling by invitation|June 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02167828||42412|
NCT02167841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0265-13-MMC|Comparison of Efficiency Between Practicing of Knee Chest Position and External Cephalic Version in Cases of Breech Presentation.|||Meir Medical Center||Not yet recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02167841||42411|
NCT02167854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-057|Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer|A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02167854||42410|
NCT02165059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI Neuromuscular Pathology|GI Neuromuscular Pathology Prospective Registry|Indiana University GI Neuromuscular Pathology Prospective Registry||Indiana University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Full thickness biopsies of Gastric body and proximal jejunum obtained.|Both|6 Months|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have been diagnosed with gastropareiss and are undergoing surgery for full        thickness biopsy GES implantation willl serve as our study group, Patients who are        undergoing surgery on the digestive system but do not have gastroparesis, will serve as        our control group.|October 2015|October 23, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165059|2 Years|42623|
NCT02153970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140118|Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy|The Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|8 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 7, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153970||43473|
NCT02153983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140119|Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome|Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 13, 2016|May 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153983||43472|
NCT02154620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70|Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster|Dorsally Displaced Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster - A Prospective Randomized Trial|70|Karolinska Institutet|Yes|Recruiting|April 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02154620||43424|
NCT02154594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHANASHREE289|"The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients.|||Tatyasaheb Kore Dental College|Yes|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|60|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02154594||43426|
NCT02154906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130439H|Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans|Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02154906||43402|
NCT02154919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPVsSPCI|Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction|Conservative Pharmacotherapy Versus Staged Percutaneous Coronary Intervention on Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease|CPVsSPCI|Beijing Shijitan Hospital||Completed|April 2011|||December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|306|||Both|18 Years|75 Years|No|Probability Sample|STEMI patients after culprit vessels treated by PPCI|May 2014|May 31, 2014|May 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02154919||43401|
NCT02154386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130440H|Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft|Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft||The University of Texas Health Science Center at San Antonio|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|May 28, 2014||No||No|September 30, 2015|https://clinicaltrials.gov/show/NCT02154386||43442|
NCT02151019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 12-38|Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer|Randomised Phase II Study of Pre-operative 3-D Conformal Radiotherapy (3-DCRT) Versus Intensity Modulated Radiotherapy (IMRT) for Locally Advanced Rectal Cancer|TRI-LARC|ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|August 2014|July 2030|Anticipated|August 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151019||43699|
NCT02151279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAP study|Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients|Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients|SWAP|Universidade do Porto|Yes|Recruiting|March 2014|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|15|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02151279||43679|
NCT02150993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12294 FIT-2|First-Line Treatment for HIV-2|A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa|FIT-2|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|January 2016|February 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02150993||43701|
NCT02151006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub 2|Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?|Does DHEA Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response According to the Bologna Criteria? A Randomized Controlled Study||Cairo University|Yes|Completed|May 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|20 Years|45 Years|No|||May 2015|May 16, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151006||43700|
NCT02165228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10GRNT260013|Strategies for Inflammation and Cardiovascular Disease (CVD) Prevention|A Stress Reduction Strategy for Decreasing CVD Risk Through C-reactive Protein Reduction|SICVDP|Montana State University|No|Completed|January 2010|December 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|108|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165228||42610|
NCT02165527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM29462|Evaluation of Bone Length Measurement|Evaluation of Bone Length Measurement Using Lunar iDXA||University of Michigan|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165527||42587|
NCT02165709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0337|Cohort Study of Risk Reducing Salpingectomy|Cohort Study of Risk Reducing Salpingectomy (RRS) Versus Standard Tubal Sterilization Among Women Who Desire Sterilization|RRS|University of North Carolina, Chapel Hill|No|Recruiting|June 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165709||42573|
NCT02167386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO0852|PrEPared and Strong: Clinic-Based PrEP for Black MSM|PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment|P&S|Columbia University|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02167386||42446|
NCT02167607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-033|A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans|A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans|PPT|Institute for Food Safety and Health, United States|No|Active, not recruiting|June 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|12|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167607||42429|
NCT02167893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-021|Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"|Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"||Takeda|No|Completed|October 2005|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11288|||Both|N/A|N/A|No|Non-Probability Sample|Prostate cancer|June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167893||42407|
NCT02168127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-012|Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD|A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD||Rhodes Pharmaceuticals, L.P.|No|Completed|May 2014|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|360|||Both|12 Years|N/A|No|||July 2015|July 7, 2015|June 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168127||42389|
NCT02167581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081259|Confrontation Phenotypes and Genotypes of Epithelial Odontogenic Tumors of the Jaws|Confrontation Phenotypic (Clinical, Radiological, Histological) and Genotypic Epithelial Odontogenic Tumors Isolated or Syndromic Jaws|TEIOS|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|319|Samples With DNA|serum bank and tissue bank|Both|5 Years|N/A|No|Non-Probability Sample|Patient with an osteolytic lesion of the jaws resulting of an epithelial odontogenic tumor|April 2015|April 23, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02167581||42431|
NCT02167867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_Z6_OTC|Study of Over-The-Counter Use of Low Level Laser Light Therapy for Body Contouring of the Waist, Hips and Thighs|Evaluation of Efficacy, Usability and Labeling Comprehension for Over-the-Counter Use of the Erchonia Corporation ZERONA® Z6 for Body Contouring of the Waist, Hips and Thighs||Erchonia Corporation|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 15, 2014|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167867||42409|
NCT02167880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-123|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||July 31, 2014|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167880||42408|
NCT02168114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|536-2012|Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle|Optical Imaging of Dystrophic and Damaged Muscle||University of Florida|No|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Male|10 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168114||42390|
NCT02165072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-052|IVC Collapsibility Index in Patients With Acute Kidney Injury|IVC Collapsibility Index in Patients With Acute Kidney Injury||Texas Tech University Health Sciences Center|No|Active, not recruiting|February 2014|July 2016|Anticipated|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|39|||Both|18 Years|89 Years|No|Non-Probability Sample|subjects ages 18-89 years with AKI (creatinine of 2mg/100ml or higher for less than 24        hours from baseline creatinine ≤1.2 or with unknown baseline creatinine). Standard of care        treatment will not be different for patients taking part in this study. Participants will        have bedside ultrasounds on days 0, 1, and 3, and baseline and follow-up data will be        collected from medical records.|October 2015|October 21, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165072||42622|
NCT02165306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214588|Enhancing Antiepileptic Drug Adherence|||Qazvin University Of Medical Sciences|No|Completed|June 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|280|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165306||42604|
NCT02154308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_AD_301|Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults|A Multicenter, Open-Label, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of IL-YANG Inactivated Split Influenza Vaccine in Healthy Adults 18 to < 65 Years of Age and in Healthy Adults ≥ 65 Years of Age.||Il-Yang Pharm. Co., Ltd.|No|Completed|November 2012|August 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|787|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 2, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154308||43447|
NCT02154633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ68039|Family Gene Toolkit|Development of a Family Communication and Decision-support Intervention for Women That Carry a BRCA1 or a BRCA2 Mutation and Their At-Risk Female Family Members|FGT|University of Michigan|Yes|Suspended|September 2010|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154633||43423|
NCT02154932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB123|Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy|Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study||Mansoura University|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|69|||Female|20 Years|50 Years||||May 2014|May 31, 2014|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02154932||43400|
NCT02154360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn 819693|Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects|A Phase IB, Open Label Study to Examine the Safety, Pharmacokinetic Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir|Emend-IV|University of Pennsylvania|Yes|Recruiting|May 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||May 2015|July 20, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02154360||43443|
NCT02154672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402013376|Prostate Cancer Screening in Men With Germline BRCA2 Mutations|Prostate Cancer Screening in Men With Germline BRCA2 Mutations||Yale University|No|Recruiting|May 2014|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|30 Years|90 Years|No|Non-Probability Sample|Study participants will be identified because of their BRCA2 mutation that places them at        increased risk for developing prostate cancer. Because this is a pre-selected high-risk        population, and our goal is to establish the incidence of cancer and association of risk        factors with developing disease, all men ≥30 years of age, able to give informed consent,        and with at least a 5-10 year life expectancy will have PSA testing, prostate examination,        Pelvic MRI, and Artemis fusion prostate biopsy.        Men identified to have prostate cancer will be treated according to current standards of        care. Treatment for prostate cancer at the Yale Cancer Center is largely based on clinical        risk; options include, but are not limited to, active surveillance for appropriate men        with low risk disease, treatment with curative intent for men with localized intermediate        and high risk prostate cancer, and systemic therapy for men with metastatic disease.|August 2015|August 20, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154672||43420|
NCT02154945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-2013.CTIL|Retinal Nerve Fiber Layer and Macular Thickness Changes During Pregnancy|Retinal Nerve Fiber Layer and Macular Thickness Changes During Pregnancy by Optical Coherence Tomography: Prospective, Observational, Nonrandomized Controlled Study||The Baruch Padeh Medical Center, Poriya|Yes|Withdrawn|January 2016|January 2016|Actual|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant patients|June 2014|January 12, 2016|May 28, 2014||No|Did not go through with the study for logistical reasons|No||https://clinicaltrials.gov/show/NCT02154945||43399|
NCT02155166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNG-IUS-2|Effect of Intracervical on the Pain Associated With the Insertion of the LNG-IUS|Effect of Injectable Intracervical Anesthesia on the Pain Associated With the Insertion of the Levonorgestrel-releasing Intrauterine System in Women Without Previous Vaginal Delivery: a Randomized Controlled Trial||University of Sao Paulo|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 17, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155166||43382|
NCT02151032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0632|Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial|Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2012|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|201|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Participants from MD Anderson Cancer Prevention Center (CPC), Literacy Advance of Houston        (LAH), Ephiphany Community Health Outreach Services (ECHOS), and Bethel's Heavenly Hands|May 2015|May 28, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151032||43698|
NCT02165241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMB01|Immunological Profile in Relation to Cardiac Geometry in Hypertension|Characterization of the Immunological Profile in Relation to Cardiac Geometry Variations in Hypertensive Patients||Neuromed IRCCS||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|30 Years|65 Years|No|Probability Sample|Patients will be selected from the outpatient cardiac centre of the IRCCS Mediterranean        Neurological Institute Neuromed, according to specific inclusion criteria. Approximately        100 subjects aged between 30 and 65 years will be included in the study. At the present 30        subjects have been enrolled.|April 2015|April 15, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165241||42609|
NCT02165995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0711|Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery|Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery and Plasticity Following Brain Tumor Surgery in or Adjacent to Eloquent Cortex||M.D. Anderson Cancer Center|No|Recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|N/A|N/A|No|||November 2015|November 23, 2015|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165995||42551|
NCT02166346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPYRA-TM-2|Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)|Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)||Johns Hopkins University|Yes|Active, not recruiting|February 2014|June 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166346||42525|
NCT02167932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1334|The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer|Impact of a Physical Activity Program on Biomarkers of Aging During Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|Samples With DNA|Blood samples will be taken collect p16 levels, CBC + Differential and senescence markers.|Female|21 Years|59 Years|No|Non-Probability Sample|Breast Cancer Patients age 21-59|October 2015|October 29, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167932||42404|
NCT02167906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9356|Impact of Hand Osteoarthritis on Arterial Stiffness|Impact of Hand Osteoarthritis on Arterial Stiffness||University Hospital, Montpellier|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|80|||Both|45 Years|65 Years|No|||June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167906||42406|
NCT02168140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 28314|CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma|Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|September 2014|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168140||42388|
NCT02164253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_69|Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients|Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis|SAFEFAIRALS|University Hospital, Lille|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|18|||Both|18 Years|85 Years|No|||December 2015|December 3, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02164253||42685|
NCT02164266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29205|A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477|||Hoffmann-La Roche||Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02164266||42684|
NCT02164526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPHDLHD|Registry for Pulmonary Hypertension Due to Left Heart Disease in China|National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|520|||Both|18 Years|80 Years|No|Probability Sample|Consecutive patients who were diagnosed as pulmonary hypertension due to the left heart        disease in 35 participating institutions in China|June 2014|June 13, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02164526|3 Years|42664|
NCT02164539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200699|Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component|200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component||GlaxoSmithKline|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|338|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164539||42663|
NCT02164799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000357|The Epidemiology and Approach to Differentiating Etiologies of Shock in the Emergency Department|Establishing a Tool to Increase the Accuracy of Emergency Physicians Diagnosing Etiologies of Shock||Beth Israel Deaconess Medical Center|No|Completed|November 2012|||September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2500|||Both|18 Years|N/A|No|Probability Sample|Emergency Department patients|June 2014|June 13, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164799||42643|
NCT02165085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110907|Biomarkers in Vascular Ehlers-Danlos Syndrome|Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome|MEDIC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|211|Samples Without DNA|Serum, Plasma|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with vascular Ehlers-Danlos syndrome and patients with spontaneous dissection(s)        will be recruited from the French National Referral Centre for Rare arterial diseases,        Hopital Europeen Georges Pompidou, Paris, France. Healthy volunteers will be recruited by        the clinical investigations center, Hopital Europeen Georges Pompidou, Paris, France        (random community sample).|March 2016|March 16, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02165085||42621|
NCT02154321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00081947|Electroencephalogram and Attention Deficit Hyperactivity Disorder Study|EEG and ADHD Study||University of Michigan|No|Active, not recruiting|February 2014|||February 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 adult participants will be recruited for this study: 50 adults diagnosed with        Attention Deficit Hyperactivity Disorder and 50 healthy controls.|April 2015|April 21, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154321||43446|
NCT02154334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104359|Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine|An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine||Janssen Research & Development, LLC||Completed|June 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154334||43445|
NCT02154022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140128|Collection of Pharmacokinetic Samples From People With Unanticipated Response or Toxicity|Collection of Pharmacokinetic Samples From Patients With Unanticipated Response or Toxicity||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|May 2020|Anticipated|May 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|2 Years|N/A|No|||April 2015|April 23, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02154022||43469|
NCT02154347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAD6401|Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||April 2016|Anticipated|Phase 4|Interventional|N/A|2||||||Both|20 Years|N/A||||June 2014|June 4, 2014|May 30, 2014||||No||https://clinicaltrials.gov/show/NCT02154347||43444|
NCT02154646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14855|A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body|A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer||Eli Lilly and Company|Yes|Completed|May 2014|July 2015|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||February 2016|February 9, 2016|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154646||43422|
NCT02154971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR_2013-10|Assessment of Age-related Hearing Loss in HIV-1 Patients|Assessment of Age-related Hearing Loss in HIV-1 Patients|HELO|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|November 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|70|||Both|40 Years|N/A|No|Non-Probability Sample|Patients followed for HIV infection in the department of infectious diseases of        Saint-Antoine hospital or Bichat hospital and/or by a private HIV-specialized physician in        Paris, France|October 2015|October 27, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02154971||43397|
NCT02155192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103877|An Exploratory Genetic Study in Participants With Psoriasis|Exploratory Genetic Study in Subjects With Moderate to Severe Psoriasis||Janssen Research & Development, LLC|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|712|Samples With DNA|Two buccal swab samples will be collected to extract Deoxyribonucleic acid (DNA).|Both|18 Years|N/A|No|Non-Probability Sample|Participants who were treated in the CNTO1959PSO2001 study, C0743T08 study, C0743T09 or        C0743T12 study will be assessed.|October 2014|October 31, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155192||43380|
NCT02155205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-105-NRM|A Thorough QT Study of Telotristat Etiprate|Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study||Lexicon Pharmaceuticals|No|Completed|May 2014|||August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|June 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02155205||43379|
NCT02154958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub 1|Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility|Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection Outcome in Women With Unexplained Infertility||Cairo University|Yes|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Female|20 Years|40 Years|No|Non-Probability Sample|300 women with unexplained infertility who are already decided to be treated with ICSI        will be recruited|February 2015|February 16, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154958||43398|
NCT02155179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|semen-esd|Sperm Pathology Samples and Morphokinetics|Embryo Kinetics and Sperm Quality. Depends on the Sperm Quality the Embryo Cleavage Rate?||IVI Madrid|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sperms samples of assisted reproduction treatments|February 2016|February 23, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155179||43381|
NCT02151045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8708|Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica|Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica - Controlled Randomized Trial With Double Blind Evaluation|EPI-AMELIE|University Hospital, Montpellier|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151045||43697|
NCT02151331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH099898-01A1|Improving Mental Health Outcomes: Building an Adaptive Implementation Strategy|Improving Mental Health Outcomes: Building an Adaptive Implementation||University of Michigan|No|Enrolling by invitation|August 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1600|||Both|21 Years|99 Years|No|||December 2015|December 4, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151331||43676|
NCT02151344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 293|Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals|Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151344||43675|
NCT02151357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCBCI 0901 101|Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor|Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor||Standard Chem. & Pharm. Co., Ltd.|No|Recruiting|June 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|20 Years|80 Years|No|||May 2014|August 1, 2014|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151357||43674|
NCT02151604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPX-2011-003|Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy|A Study to Determine Regional Lung Function in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Radiotherapy Using Hyperpolarized Xenon Gas MR Imaging||Oxford University Hospitals NHS Trust|No|Recruiting|April 2014|||October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02151604||43655|
NCT02166008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP006|Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT|Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study||King Chulalongkorn Memorial Hospital|Yes|Suspended|September 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|70 Years|No|||June 2014|June 12, 2014|September 30, 2013|No|Yes|Wait for the placebo|No||https://clinicaltrials.gov/show/NCT02166008||42550|
NCT02166034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-CGP-11-0047|Effects of School Gardens on Children's Diet, Nutritional Knowledge, Etc.|Healthy Gardens, Healthy Youth (HGHY): A People's Garden School Pilot Program|HGHY|Cornell University|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3531|||Both|6 Years|14 Years|No|||May 2014|June 15, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02166034||42548|
NCT02166619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChronicStroke_tDCS_rehab|tDCS in Poststroke on Upper Limb Rehabilitation|Transcranial Direct Current Stimulation in Rehabilitation of Chronic Stroke Patients: Multicenter Clinical Trial||Universidade Federal de Pernambuco|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|80 Years|No|||May 2014|June 17, 2014|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166619||42504|
NCT02168192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-08-275|Breaking Bad News in Obstetrics: A Trial of Simulation-Debrief Based Education|Breaking Bad News in Obstetrics: A Trial of Simulation-Debrief Based Education||Montefiore Medical Center|No|Completed|November 2010|July 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168192||42384|
NCT02168205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-CP-011|Food Effect and CYP1A2 Induction Study in Healthy Subjects|Hase I Open-Label Two-Part Study To Evaluate The Effect Of Food and Of CYP1A2 Induction On Pomalidomide (CC-4047) Pharmacokinetics in Healthy Subjects||Celgene|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|55|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168205||42383|
NCT02167919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3445|Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)|Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH) As an Alternative to Open Prostatectomy||University of North Carolina, Chapel Hill|No|Active, not recruiting|July 2014|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|40 Years|N/A|No|||March 2016|March 23, 2016|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02167919||42405|
NCT02164279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 356 03|Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children|Identification and First Validation of Early Non-invasive Biomarkers of Diabetic Nephropathy in Type I Diabetic Children|peeDIAB2|University Hospital, Toulouse|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|140|||Both|6 Years|30 Years|No|||January 2016|January 11, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02164279||42683|
NCT02164552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEOR-04-08|Vitamin D Status in Relation to Insulin Sensitivity Among Saudi Women With Polycystic Ovary Syndrome|Vitamin D Status in Relation to Insulin Sensitivity, Resistance and Inflammatory Response Among Saudi Women With Polycystic Ovary Syndrome|CEOR-04-08|King Abdulaziz University|Yes|Recruiting|January 2009|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Observational|Time Perspective: Prospective||2|Anticipated|340|||Female|20 Years|45 Years|No|Probability Sample|Women were recruited through Infertility clinics at King Abdulaziz University Hospital,        New Jeddah Clinic Hospital and Dr S Fakeeh Hospital, Jeddah area during general health        survey and consecutively referred to a special clinic at the Center of Excellence for        Osteoporosis Research for enrollment at the present study|June 2014|June 12, 2014|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164552||42662|
NCT02164812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-959|Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects|A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms||Bristol-Myers Squibb|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|58|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164812||42642|
NCT02164825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTSA001|Total Knee Arthroplasty Analgesia: Single-shot Femoral Nerve Block or Epidural?|Comparison Between Single-shot Femoral Nerve Block and Epidural Techniques for Total Knee Arthroplasty: a Randomized Controlled Trial||Centro Hospitalar do Tâmega e Sousa|Yes|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||June 2014|February 4, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02164825||42641|
NCT02165358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-035 (MRI BMD/LGMD2I)|Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I|Muscle MRI Study of Patients With Becker Muscular Dystrophy and Limb-girdle Muscular Dystrophy Type 2I||Rigshospitalet, Denmark|No|Recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Danish patients genetically verified with either becker muscular dystrophy or limb-girdle        muscular dystrophy type 2I|June 2014|June 16, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165358||42600|
NCT02153749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC #1210010970|Effects of Brief Training on Craving Regulation|Regulation of Craving: Brief Neurocognitive Training and Neural Mechanisms||Yale University|Yes|Recruiting|September 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|60 Years|No|||October 2015|October 5, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02153749||43490|
NCT02154035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914123|Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans|Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|January 12, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02154035||43468|
NCT02154698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00030500|22-gauge ProCore Needle v. Standard 22-gauge (P00030500)|A Multi-center Study Comparing Standard 22-gauge and 22-gauge ProCore Needles for Endobronchial Ultrasound||Medical University of South Carolina||Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|January 19, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02154698||43418|
NCT02154984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 13CC12|Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants|A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women||Northwestern University|Yes|Recruiting|July 2014|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02154984||43396|
NCT02151058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-131219112750-CTOC|A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal|Whitening Action of a Hydrogen Peroxide/Sodium Fluoride Containing Mouth Rinse: A 2 Week Randomized Controlled Trial||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|227|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|May 28, 2015|May 27, 2014||No||No|May 7, 2015|https://clinicaltrials.gov/show/NCT02151058||43696|
NCT02151071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-002|The Breast Surgery EnLight and LightPath Imaging System Study|A Pilot Study to Evaluate Molecular Imaging Using a BetaScope and a Specimen Analyser for Determining Margin and Lymph Node Status During Breast Conserving Surgery in Women With Breast Cancer||Lightpoint Medical Limited|No|Not yet recruiting|September 2016|August 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|30 Years|N/A|No|||October 2015|October 6, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151071||43695|
NCT02151370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28428|An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer|Ascites Control Treating Ovarian Cancer With Bevacizumab: "ACT-OB"||Hoffmann-La Roche||Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Female|18 Years|N/A|No|Probability Sample|Female patients with Advanced FIGO Stage (IIIb to IV) Ovarian Epithelial Cancer with        measurable residual disease after surgery|May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151370||43673|
NCT02151630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393219|Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts|Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart||Isfahan University of Medical Sciences|No|Recruiting|May 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|N/A|No|||May 2014|May 29, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151630||43653|
NCT02151890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al Azhar University|Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure|Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure (POF)|POF|Al-Azhar University|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|20 Years|40 Years|No|||May 2014|May 30, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02151890||43633|
NCT02166359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXIT study|Effect of Extraneal (Icodextrin) on Triglyceride Levels in PD Patients|||Dong-A University|No|Recruiting|June 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|80 Years|No|||August 2015|August 16, 2015|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166359||42524|
NCT02166892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc0042-14CTIL|Specially Designed Eating Plates Effects on Food Intake in Normal Weight and Overweight Children|The Effect of Specially Designed Eating Plates on Self-served Portions and Caloric Intake in Normal Weight and Overweight Children||Meir Medical Center|No|Recruiting|July 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|4 Years|13 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02166892||42483|
NCT02167139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB5-G31-RA|A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy||Samsung Bioepis Co., Ltd.|Yes|Completed|May 2014|November 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|544|||Both|18 Years|75 Years|No|||June 2014|December 2, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167139||42464|
NCT02167620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007/2014|Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness|Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness||Centre for Addiction and Mental Health|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|17 Years|45 Years|No|||December 2015|December 21, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167620||42428|
NCT02167633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-050|Stereotactic Radiosurgery in Metastatic Spinal Cord Compression|A Randomized Trial of Stereotactic Radiosurgery Versus Decompressive Surgery Followed by Postoperative Radiotherapy in Metastatic Spinal Cord Compression|Stereocord|Rigshospitalet, Denmark|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167633||42427|
NCT02167646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen10512|Bilaterally Innervated Sensory Dorsal Digital Flaps for Sensory Reconstruction of the Fingers|||The Second Hospital of Tangshan|Yes|Completed|January 2008|August 2013|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|73|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||February 2012|June 18, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167646||42426|
NCT02164305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07252013.032|The Effects of Exercise Training on Shoulder Neuromuscular Control|The Effects of Exercise Training on Shoulder Neuromuscular Control||University of Oregon|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02164305||42681|
NCT02168153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0352|Assessment of Chiropractic Treatment Using Reaction and Response Times in Members of the Special Operation Forces (ACT2)|Assessment of Chiropractic Treatment Using Reaction and Response Times in Members of the Special Operation Forces (ACT2)||RAND|Yes|Recruiting|August 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02168153||42387|
NCT02164292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1942|ALPPS: Safety, Feasibility and Efficacy at a Single Center|Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): Safety, Feasibility and Efficacy at a Single Center||Hospital Italiano de Buenos Aires|No|Completed|June 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|85 Years|No|Non-Probability Sample|High-Volume University Hospital population|June 2014|June 12, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02164292||42682|
NCT02164565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-12-EMC|The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery|The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery||HaEmek Medical Center, Israel|Yes|Withdrawn|June 2014|March 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|60 Years|N/A|No|||June 2015|June 25, 2015|May 29, 2014||No|Enrollment difficulties|No||https://clinicaltrials.gov/show/NCT02164565||42661|
NCT02164838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1315|VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors|A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors||Children's Oncology Group|Yes|Recruiting|September 2014|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|12 Months|17 Years|No|||January 2016|January 14, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164838||42640|
NCT02164851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000004|Non-Invasive Shock: Differentiating Shock in the Emergency Department|Non-Invasive Shock: Differentiating Shock in the Emergency Department|NIS|Beth Israel Deaconess Medical Center|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|50 mLs of whole blood will be collected at enrollment for biomarker analysis|Both|18 Years|100 Years|No|Non-Probability Sample|Patients found to have shock and "near-shock" physiology in the emergency department.|September 2015|November 13, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164851||42639|
NCT02166164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-MSH-2014|Characterization of Secondary Hyperalgesia in Healthy Volunteers|Characterization of Secondary Hyperalgesia in Healthy Volunteers||Rigshospitalet, Denmark|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02166164||42538|
NCT02166177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treg Liver Trial|Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients|Pilot Study Evaluating the Safety and Efficacy Profile of Regulatory T Cell Therapy in Liver Transplant Recipients|ThRIL|Guy's and St Thomas' NHS Foundation Trust||Recruiting|June 2014|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|70 Years|No|||July 2014|July 1, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166177||42537|
NCT02153762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1932|Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream|Assessment of Application Order When Utilizing Locoid Lotion and Hylatopic Plus Cream in the Treatment of Atopic Dermatitis||Icahn School of Medicine at Mount Sinai|No|Completed|April 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|3 Months|N/A|No|||June 2014|June 3, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02153762||43489|
NCT02153775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB031/55|Progressive Muscle Relaxation and Cigarette Craving|Preliminary Study of Effects of Progressive Muscle Relaxation on Cigarette Craving and Withdrawal Symptoms of Experienced Smokers in Acute Cigarette Abstinence : A Randomised Control Trial||Chulalongkorn University|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 31, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153775||43488|
NCT02154685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25623|Extinction Updating in Reconsolidation|Reducing Smoking Cue Reactivity and Behavior Via Retrieval-Extinction Mechanism||Medical University of South Carolina|Yes|Completed|December 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|October 1, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154685||43419|
NCT02154711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819440|Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease|Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease||University of Pennsylvania|No|Recruiting|May 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups of subjects: 1) mitochondrial disease and 2) healthy individuals|January 2016|January 6, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02154711||43417|
NCT02154997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0071-14|The Effect of Different Food Products on Post Prandial Blood Glucose in Pregnant Woman With Diabetes|||Hadassah Medical Organization||Recruiting|November 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women perticapting in this study will be from the high risk pregnancy clinic of hadassah        Ein Kerem.|February 2016|February 28, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02154997||43395|
NCT02155218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47155-A|Improving the Concentration of MR Contrast in the Arteries|Contrast Dynamics of the Thoracic Vasculature and Heart||University of Washington|No|Enrolling by invitation|June 2014|May 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155218||43378|
NCT02151084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIL-MEK|A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer|A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer||University Health Network, Toronto|Yes|Recruiting|November 2014|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151084||43694|
NCT02151383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2208|Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure|Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure|RELAX-PEDS-PK|Novartis|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|17 Years|No|||February 2016|February 23, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151383||43672|
NCT02166372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSIRB2014009|Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery|Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery|TDS|Min-Sheng General Hospital|Yes|Recruiting|March 2014|December 2034|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|Diabetic patients in Taiwan|June 2014|June 16, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166372||42523|
NCT02167152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000718|Ischemic Preconditioning to Prevent Acute Kidney Injury|Ischemic Preconditioning to Prevent Acute Kidney Injury||University of Kansas Medical Center|No|Completed|June 2014|February 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|115|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167152||42463|
NCT02164318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054388|Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation|Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation||Duke University|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|80|||Both|12 Years|N/A|No|||August 2015|August 5, 2015|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164318||42680|
NCT02164331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HL117801|Blood Pressure (BP) Visit Intensification Study|A Multimodal Quality Improvement Intervention Using the JNC Guidelines to Promote Control of Patients' BP in Federally Qualified Health Centers||University of Rochester|Yes|Active, not recruiting|October 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 12, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02164331||42679|
NCT02168166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPSYC-651-14|Short-term Working Memory and Executive Training|Short-Term Executive Functioning Training|STExFx|Queen's University|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02168166||42386|
NCT02168179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98114|KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer|Safety of Treatment With KeraStat Skin Therapy in Breast Cancer Patients Developing Radiation Dermatitis||Comprehensive Cancer Center of Wake Forest University|No|Withdrawn|December 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Female|18 Years|N/A|No|||November 2014|November 28, 2014|June 18, 2014||No|No longer pursuing study at our site.|No||https://clinicaltrials.gov/show/NCT02168179||42385|
NCT02164877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pectin-2014|Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease|A Randomized, Controlled Study of Soluble Dietary Fiber on Bacterial Translocation in Adults Patients With Crohn's Disease||Jinling Hospital, China|Yes|Recruiting|June 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|17 Years|40 Years|No|||June 2014|June 13, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164877||42637|
NCT02164578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicroVasc-DIVA|Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease|Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation|MicroVasc-DIVA|GWT-TUD GmbH|No|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|40 Years|75 Years|No|||February 2016|February 29, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164578||42660|
NCT02164864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.186|Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)|A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting||Boehringer Ingelheim||Recruiting|July 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2500|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 13, 2014||||No||https://clinicaltrials.gov/show/NCT02164864||42638|
NCT02165098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-188-101|Cariprazine: Comparison of Slow- and Immediate-release Forms|A Single-Dose Study to Evaluate the Pharmacokinetic, Safety, Tolerability Profile and the Effects of Food on the Pharmacokinetics of Different Formulations of Cariprazine in Healthy Male Subjects||Gedeon Richter Plc.|No|Completed|June 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|160|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165098||42620|
NCT02165631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0362|The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure|The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure||University of Colorado, Denver|No|Completed|August 2014|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Open angle glaucoma, Ocular hypertension,Pigment dispersion        glaucoma, or Pseudoexfoliation glaucoma|March 2016|March 10, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165631||42579|
NCT02154048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019301|Analgesic Efficacy of Perineural Dexamethasone During Supraclavicular Block for Hand Surgery|Analgesic Efficacy of Perineural Dexamethasone Added to Ropivacaine 0.5% With 1:400,000 Epinephrine During Single-injection Supraclavicular Block for Outpatient Hand Surgery||Duke University|No|Terminated|April 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|May 30, 2014|Yes|Yes||No|June 2, 2014|https://clinicaltrials.gov/show/NCT02154048||43467|
NCT02155010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003|Dexmedetomidine in Spinal Anesthesia|Hemodynamic Effect of Dexmedetomidine on Heavy Bupivacaine Spinal Anesthesia||Inje University|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|74|||Both|20 Years|60 Years|No|||August 2015|August 9, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02155010||43394|
NCT02155244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR-1234|Common Bile Duct Stone Management: What Have we Learned?||CBDS|Ospedale Regionale di Mendrisio|No|Completed|January 2006|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|101|||Both|18 Years|94 Years|No|Non-Probability Sample|Primary care clinic|June 2014|June 3, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02155244||43376|
NCT02155257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00028525|Pain Expectations in Subjects With Osteoarthritis|A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip||Wake Forest School of Medicine|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155257||43375|
NCT02151110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5100C00001|A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults|||MedImmune LLC|No|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|56|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151110||43692|
NCT02155231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anal HPV and AIN among MSM|Study on Anal Human Papillomavirus Infection and Anal Intraepithelial Neoplasia Among Men Who Have Sex With Men in Indonesia, Malaysia, and Thailand|The Thai Red Cross AIDS Research Centre||Thai Red Cross AIDS Research Centre|No|Recruiting|February 2013|||March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|430|||Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|An approximately 75 HIV-positive and 75 HIV-negative MSM who attended the study clinic in        Kuala Lumpur, Jakarta, and Bangkok will be enrolled. The study will also enroll 185        HIV-positive and 95 HIV-negative MSM who are previous participants of the MSM VCT study.        There will be approximately 260 HIV-positive and 170 HIV-negative MSM in total in this        study.|November 2015|November 2, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02155231||43377|
NCT02151097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-003|PRIME - PRostate Imaging for Margin Evaluation|A Feasibility Study to Evaluate 18F-choline Cerenkov Luminescence Imaging for Measuring Margin Status in Radical Prostatectomy Specimens|PRIME|Lightpoint Medical Limited|No|Recruiting|November 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Male|18 Years|N/A|No|Non-Probability Sample|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage        ≥T2c, or PSA>20 ng/ml, or Gleason Score 8-10, undergoing radical prostatectomy.|March 2016|March 11, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151097||43693|
NCT02151396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD061915|Effect of Working Memory Training on ADHD Brain Function|Effect of Working Memory Training on ADHD Brain Function||Hartford Hospital|No|Completed|July 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|13 Years|17 Years|No|||May 2014|May 29, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151396||43671|
NCT02151409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8209-1940|Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.||Novo Nordisk A/S|No|Completed|June 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151409||43670|
NCT02166905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 248613|DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission|A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||Roswell Park Cancer Institute|Yes|Recruiting|August 2014|||February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166905||42482|
NCT02167165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF/DIGOXIN|Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients|Role of Genetic Factors in the Response to Digoxin in the Acute Treatment of Atrial Fibrillation||University of Monastir|No|Recruiting|July 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|arterial blood samples collected in EDTA tubes and stored in - 20°C envirement for DNA      extraction with salting out methods.|Both|20 Years|N/A|No|Non-Probability Sample|All patients presenting at the ED with acute onset AF documented by ECG.|June 2014|June 16, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167165||42462|
NCT02167399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00222|Smart Phone as a Screening and Evaluation Tool to Identify Knee Valgus During Dynamic Activities|Evaluation of the Use of the Smart Phone as a Screening and Evaluation Tool to Identify Knee Valgus During Dynamic Activities.||Nationwide Children's Hospital|No|Completed|June 2014|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|25|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|physical therapy clinic|December 2014|December 22, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02167399||42445|
NCT02164916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1406|S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer|Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer||Southwest Oncology Group|Yes|Recruiting|November 2014|January 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164916||42634|
NCT02164929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047810|Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy|A Prospective, Randomized, Single-Blind Study to Evaluate the Efficacy of Transversus Abdominis Plane Versus Paravertebral Regional Blockade in Patients Undergoing Laparoscopic Colectomy||Duke University|No|Recruiting|December 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|February 22, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164929||42633|
NCT02164591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Temp GES|Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis|Escalating Temporary Gastric Electrical Stimulation for Severe Gastroparesis|TempGES|Indiana University|Yes|Recruiting|February 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Serum to be frozen|Both|18 Years|90 Years|No|Non-Probability Sample|Subjects who have been diagnosed with gatroparesis.|March 2015|March 2, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02164591||42659|
NCT02164890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13025|Pharmacokinetics of Micafungin in Patients of Intensive Care Units|Pharmacokinetics of Micafungin in Patients of Intensive Care Units|MI-K|University Hospital, Limoges|No|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2014|June 17, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164890||42636|
NCT02164903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoL-CML0713|LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients|Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|479|||Both|18 Years|N/A|No|Non-Probability Sample|Adult chronic myeloid leukemia patients in first line treatment with either dasatinib or        imatinib for no more than 3 years.|July 2015|July 9, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02164903||42635|
NCT02165111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00087346|Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome|A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome||Johns Hopkins University|Yes|Active, not recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165111||42619|
NCT02165371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinovuyo_RCT|The Sinovuyo Caring Families Project: a Randomized Controlled Trial of a Parenting Programme|Sinovuyo Caring Families Project||University of Cape Town|No|Active, not recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165371||42599|
NCT02165839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0042|Brief Behavioral Intervention for Insomnia During Chemotherapy|Brief Behavioral Intervention for Insomnia During Chemotherapy||Stanford University|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Female|21 Years|N/A|No|||September 2015|September 30, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165839||42563|
NCT02165852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Papillectomy Study|Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal Injection|A Prospective Comparative Study of Papillectomy||Soon Chun Hyang University|Yes|Completed|January 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02165852||42562|
NCT02165865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-SIUSOM-13-001|Vascularized Composite Allotransplantation of the Hand and Upper Extremity (Hand Transplant)|Vascularized Composite Allotransplantation of the Hand and Upper Extremity for the Restoration of Form and Function in Hand Amputees||Southern Illinois University|No|Recruiting|January 2014|May 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|69 Years|No|||October 2015|October 22, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02165865||42561|
NCT02154100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF02406|Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk|Tart Cherry Improves Cardiovascular Risk Factors Associated With Metabolic Syndrome||Florida State University|No|Recruiting|April 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|28|||Both|20 Years|40 Years|No|||October 2015|October 15, 2015|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154100||43463|
NCT02154113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-CA 02|Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction|Baseline Controlled Two-arm Multi-Center Study to Evaluate the Safety and Efficacy of Combined Multi-Focus Treatments of UltraShape® Contour I V3 System and VelaShape II Device for Non-Invasive Circumference Reduction||Syneron Medical|No|Completed|October 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02154113||43462|
NCT02154399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01169|EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer|Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Completed|May 2002|April 2014|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2014|April 10, 2015|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154399||43441|
NCT02154412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0286 Ovechkin|Mechanisms of Arterial Hypotension in Chronic Spinal Cord Injury|Mechanisms of Arterial Hypotension in Chronic Spinal Cord Injury||University of Louisville|No|Recruiting|June 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154412||43440|
NCT02154425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0016|A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers|A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)|CRADLE|UCB Pharma|No|Completed|September 2014|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02154425||43439|
NCT02155270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Precut|Impact of a Corneal Pre-cut on Wound Architecture and Astigmatism in Cataract Surgery - a Pilot Study|Impact of a Corneal Pre-cut on Wound Architecture and Astigmatism in Cataract Surgery - a Pilot Study||Vienna Institute for Research in Ocular Surgery|No|Recruiting|June 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|21 Years|N/A|No|||June 2014|June 2, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02155270||43374|
NCT02151136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/20E|Be Sweet to Toddlers: Does Sugar Water Reduce Pain During Blood Work?|Be Sweet to Toddlers During Needles: RCT of Sucrose Compared to Placebo||Children's Hospital of Eastern Ontario|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|12 Months|36 Months|No|||February 2016|February 9, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151136||43690|
NCT02151435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM HUM00004076|Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis|Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis||University of Michigan|No|Active, not recruiting|August 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples Without DNA|Peripheral blood plasma obtained from individuals at 6-month intervals for up to 2 years|Both|35 Years|80 Years|No|Non-Probability Sample|The study population includes subjects with IPF identified via the University of Michigan        Interstitial Lung Disease Clinical-Radiologic-Pathologic Conference. The investigators        will only enroll subjects in whom an IPF diagnosis is firmly established.|March 2016|March 18, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151435||43668|
NCT02151123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-02_CU|Metabiomics Colon Cancer Clinical Research Study|Metabiomics Colon Cancer Clinical Research Study||Metabiomics Corp|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|gut microbiome samples from stool, rectal and colonic mucosa|Both|18 Years|95 Years|No|Non-Probability Sample|Patients diagnosed with colonic adenocarcinoma undergoing colectomy at University of        Colorado|April 2015|April 6, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151123||43691|
NCT02151422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00081294.|Breathing Exercises for Asthma|||University of Michigan||Recruiting||||June 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151422||43669|
NCT02151682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503-66|An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension.|An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension.||Grünenthal GmbH|Yes|Recruiting|December 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Both|6 Years|17 Years|No|||March 2016|March 15, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151682||43649|
NCT02151968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USG123|Traditional Blind Versus Ultrasound-guided Peribulbar Blockade|Traditional Blind Versus Ultrasound-guided Peribulbar Blockade||Sunnybrook Health Sciences Centre|No|Not yet recruiting|July 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02151968||43627|
NCT02151955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAJ120702|Social-emotional Under 4's Screening & Intervention S.U.S.I.|Social-emotional Under 4's Screening & Intervention; A Study of Emotional Health and Development in Babies and Young Children|SUSI|South London and Maudsley NHS Foundation Trust|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|185|||Both|3 Months|4 Years|No|||January 2016|January 14, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02151955||43628|
NCT02167412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00252|EEG Characteristics in Youth POTS and/or Syncope|Electroencephalographic (EEG) Characteristics of Postural Tachycardia Syndrome (POTS) and Syncope (Without POTS) During Head-upright Tilt Table Testing||Nationwide Children's Hospital|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|9 Years|21 Years|No|||March 2015|March 21, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02167412||42444|
NCT02167659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCBRE1438|Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema|A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement in the Prevention of Lymphedema Following Locoregional Treatment for Breast Cancer||ImpediMed Limited|No|Recruiting|June 2014|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1100|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02167659||42425|
NCT02165657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-13-33|Excimer Laser, Serum Markers & Psoriasis|Effects of UVB Excimer Laser on Serum Inflammatory Markers in Patients With Psoriasis||University Hospital Case Medical Center|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165657||42577|
NCT02164604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSA22-05-2014|Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease|Intravitreal Ranibizumab to Treat Retinopathy of Prematurity Stage 3 Plus Disease||Kantonsspital Aarau|No|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|32 Weeks|40 Weeks|No|||June 2014|June 13, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02164604||42658|
NCT02165423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 14/66|Discharge to Home and Chronic Illness Care Pilot|Discharge to Home and Chronic Illness Care Pilot||Medical College of Wisconsin|No|Recruiting|June 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165423||42595|
NCT02165436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X090615006|Chewing Gum Facilitates an Earlier Return to Bowel Function in Pediatric Scoliosis Patients: A Prospective Randomized Study|The Use of Chewing Gum Reduces Post-operative Ileus and Gastrointestinal Complications in Pediatric Scoliosis Patients.||University of Alabama at Birmingham|No|Completed|July 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|10 Years|18 Years|No|||June 2014|June 13, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165436||42594|
NCT02165124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093563|Bariatric Embolization of Arteries for the Treatment of Obesity|Bariatric Embolization of Arteries for the Treatment of Obesity|BEAT Obesity|Johns Hopkins University|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||January 2016|January 21, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165124||42618|
NCT02165137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-008|Management of Major Trauma Patients at Aarau Trauma Center - Evaluation of Processes and Patient Outcome|Quality Control in the Management of Major Trauma Patients at Aarau Cantonal Hospital - Evaluation of Processes and Patient Outcome||Kantonsspital Aarau|No|Recruiting|January 2010|July 2019|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1800|||Both|N/A|N/A|No|Non-Probability Sample|All emergency patients treated at Aarau Cantonal Hospital following trauma (<24h        postinjury) with suspected major trama|February 2016|February 23, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165137|2 Years|42617|
NCT02165384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preceptis Alpha|Hummingbird TTS Ear Tube Delivery Study|Continued Evaluation of the Preceptis Medical, Inc. Tympanostomy Ear Tube Introducer||Preceptis Medical, Inc.|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|6 Months|N/A|No|||April 2015|April 27, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165384||42598|
NCT02165397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1127-CA|Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia|iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia||Pharmacyclics|Yes|Active, not recruiting|July 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|181|||Both|18 Years|N/A|No|||September 2015|March 24, 2016|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165397||42597|
NCT02165410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120204|MRI Study of Cerebral Blood Flow in Development Disorders in Children|MRI Study of Cerebral Blood Flow in Development Disorders in Children|IRM-Aut|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Months|18 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02165410||42596|
NCT02166216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS2013ORST01|The North Sea Race Endurance Exercise Study|The North Sea Race Endurance Exercise Study|NEEDED|Helse Stavanger HF|No|Active, not recruiting|June 2013|June 2034|Anticipated|June 2034|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Serum EDTA Whole blood|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers participating in the bicycle race "Northsea race" 2013 (pilot) and 2014        (main study), males and females.|June 2014|June 19, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02166216||42535|
NCT02166229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013775|Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma|||Yale University|No|Recruiting|June 2014|||May 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166229||42534|
NCT02166736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-2013-044|Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome|Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina Pectoris or Acute Coronary Syndrome. A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the Swedish Angiography and Angioplasty Registry (SWEDEHEART) Platform|iFR Swedeheart|Uppsala University|Yes|Active, not recruiting|May 2014|October 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|99 Years|No|||December 2015|December 3, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02166736||42495|
NCT02154464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR 0024-14 CTIL|Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients|Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients||Soroka University Medical Center|Yes|Not yet recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|June 2, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02154464||43436|
NCT02154737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121359|Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer|A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer||University of California, San Diego|Yes|Recruiting|July 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|June 14, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02154737||43415|
NCT02154438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0062|The Effect of Ketamine Infusion on Lumbar Surgery|The Effect of Ketamine Infusion for Reduction of Neuropathic Pain and Improvement of Quality of Life After Lumbar Surgery||Yonsei University|Yes|Recruiting|May 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|70 Years|No|||May 2014|May 29, 2014|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02154438||43438|
NCT02154451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-304|Transient Infrared Imaging for Early Detection of Skin Cancer|Transient Infrared Imaging for Early Detection of Skin Cancer||Skinfrared LLC|Yes|Recruiting|August 2013|||December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Anticipated|400|||Both|18 Years|N/A||||May 2014|May 30, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02154451||43437|
NCT02155283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBP-2|The Efficacy of the Kyrobak for Chronic Low Back Pain (LBP-2)|The Kyrobak Continuous Passive Motion Device for the Treatment of Chronic Low Back Pain: A Pilot Study|LBP-2|Radiancy|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2014|June 28, 2015|December 11, 2013|Yes|Yes||No|June 28, 2015|https://clinicaltrials.gov/show/NCT02155283||43373|
NCT02151149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-NSCL-005|Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly|Safety and Efficaty of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)|ABOUND 70+|Celgene|No|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|70 Years|N/A|No|||March 2016|March 1, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151149||43689|
NCT02151448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-110|αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies|A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies||University of Pittsburgh|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151448||43667|
NCT02151695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mEdICARE|Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.|Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.||Poitiers University Hospital||Recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|N/A|2||||||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151695||43648|
NCT02151981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00003|AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3)|AURA3|AstraZeneca|No|Active, not recruiting|August 2014|January 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151981||43626|
NCT02151994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-51058-101|Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.|A Double-blind, Randomised, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058, in Healthy Male Volunteers||Bial - Portela C S.A.|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|May 26, 2014||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT02151994||43625|
NCT02152202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol version july 17, 2011|Semi-up Right Position Study|Does a Semi-upright Position During Sleep Prevent Worsening of Severity of Obstructive Sleep Apnea (OSA) on the Second Postoperative Night in Patients Following Elective Inpatient Surgery? A Two Arm, Parallel, Randomized, Controlled, First Stage Proof of Concept Trial||University Health Network, Toronto|No|Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152202||43609|
NCT02167672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIgHT|Barriers for the Uptake of LaparoScopic Hysterectomy|What Would it Take to Reduce the Proportion of Women Who Have a Hysterectomy Via an Open Abdominal Approach in Australia?|LIgHT|Queensland Centre for Gynaecological Cancer|No|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|1200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members of RANZCOG community sample|April 2015|April 20, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167672||42424|
NCT02167945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-222|A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)|(TOPAZ II)|AbbVie|No|Active, not recruiting|June 2014|March 2020|Anticipated|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02167945||42403|
NCT02167958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-131|Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source|Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source||University of Pittsburgh|Yes|Recruiting|November 2014|July 2020|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167958||42402|
NCT02133937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29113|A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers|A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers||Hoffmann-La Roche||Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02133937||45010|
NCT02165150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYH-IRB-098-12-02|Senior Elastic Band (SEB) on Institutional Elders|Development, Application , and Evaluation of the Senior Elastic Band (SEB) Exercise Program for Elderly Residents in Long-term Care Facilities|SEB|Kaohsiung Medical University|Yes|Completed|August 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|127|||Both|65 Years|N/A|No|||June 2014|June 13, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165150||42616|
NCT02134483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567|Parathyroid Allo-transplantation With a New Technique|Parathyroid Allo-transplantation With a New Technique||SB Istanbul Education and Research Hospital||Recruiting|September 2013|||May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02134483||44968|
NCT02134496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-012|PACU Discharge Without Motorfunction Assessment After Spinal Anaesthesia|PACU Discharge Without Motorfunction Assessment After Spinal Anaesthesia for Total Hip or Knee Arthroplasty - a Multicenter Randomized Controlled Trial||Rigshospitalet, Denmark|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1511|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02134496||44967|
NCT02165644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014000419|Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage|Targeting Carbonic Anhydrase Mediated Coupling as a Novel Vasospasm Prophylaxis in Aneurysmal Sub Arachnoid Hemorrhage||University of Florida|No|Withdrawn|September 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|June 13, 2014|Yes|Yes|The PI is leaving the University of Florida.|No||https://clinicaltrials.gov/show/NCT02165644||42578|
NCT02165878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013E3301601|KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease|KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease : A 10-year Longitudinal Cohort Study of the Chronic Kidney Disease|KNOW-PedCKD|Seoul National University Hospital|Yes|Recruiting|March 2011|December 2021|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|A biobank is also established for the DNA, serum and urine taken at regular interval.|Both|N/A|20 Years|No|Probability Sample|CKD stage 1 through 5 Ages below 20|January 2016|January 10, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165878||42560|
NCT02165891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2013/PE1|Comparison of Intrapleural Urokinase and Video-Assisted Thorascopic Surgery in the Treatment of Parapneumonic Pleural Effusion in Children|Prospective Randomized Study Comparing the Efficacy and Safety of Pleural Drainage by Video-Assisted Thoracoscopic With Pleural Drainage by Percutaneous Drain Associated With Urokinase in the Treatment of Parapneumonic Pleural Effusion in Children|UROVATS|Queen Fabiola Children's University Hospital|No|Recruiting|February 2015|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|16 Years|No|||October 2015|October 20, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02165891||42559|
NCT02135302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-013|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects||Tetraphase Pharmaceuticals, Inc.|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02135302||44905|
NCT02135315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAPREC|Intensive Arterial Pressure Control in Acute Coronary Syndrome|Interest of an Intensive Arterial Pressure Control in Acute Coronary Syndrome|IAPREC|University of Monastir|Yes|Recruiting|October 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|30 Years|N/A|No|||May 2014|May 16, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02135315||44904|
NCT02135640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114197|China HVT Safety, PK, PD|A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China||GlaxoSmithKline|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02135640||44880|
NCT02135653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 05813|A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer|A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Adults with stage I or II prostate cancer undergoing radiation therapy. Enrolled subjects        will not have smoked nor taken any regular yoga classes in the 6 months preceding their        participation in the study.        Additionally they will have not undergone a surgical prostatectomy|January 2016|January 12, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02135653||44879|
NCT02154750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD20120783|AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals|Evaluation of AV Delay Optimization vs. Intrinsic Conduction in Patients With Long PR Intervals Receiving Dual Chamber Pacemakers for Symptomatic Bradycardia|AV Delay|University of California, San Diego|No|Recruiting|June 2013|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154750||43414|
NCT02154724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADBS-2013-IRCCSMaggioreH|Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease|Clinical Investigation for Adaptive Deep Brain Stimulation (aDBS)Closed-loop Device Controlled by Local Field Potentials in Parkinson's Disease.|ADBS|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||May 2014|May 30, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02154724||43416|
NCT02187315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140501|Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study|Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With Intensity-modulated Radiotherapy In The Treatment Of Locally Advanced Nasopharyngeal Carcinoma PhaseⅡClinical Randomized Study||Guiyang Medical University|No|Recruiting|May 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187315||40918|
NCT02187328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ben-0614a|Effects of Fruit Juices on Hormone Metabolism|Effect of Grapefruit Juice and Exercise on Cortisol Levels||Benedictine University|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02187328||40917|
NCT02187692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTPOLAND|The Effectiveness of the Meta-cognitive Training Among Patients With Chronic Schizophrenia|The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland.||Medical University of Warsaw|No|Completed|August 2012|September 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||October 2013|July 10, 2014|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02187692||40889|
NCT02187705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.322|Micardis® in Patients With Essential Hypertension|Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals||Boehringer Ingelheim||Completed|May 1999|||May 2000|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1688|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02187705||40888|
NCT02187718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49489.094.14|Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial|A Prospective Single-centre Randomised Controlled Clinical Trial Comparing Sentinel Node Procedure Under Local Anaesthesia to Traditional Sentinel Node Procedure Under General Anaesthesia in Patients <60 Years With a Breast Carcinoma >20 mm.|AMBULANT|Medical Center Alkmaar|No|Not yet recruiting|January 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Female|18 Years|60 Years|No|||July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187718||40887|
NCT02175576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GK9B|Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System|Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System|GK9B|Biomet, Inc.|No|Enrolling by invitation|October 2014|October 2026|Anticipated|October 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175576||41816|
NCT02175589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-14-RMB|Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation|Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation||Rambam Health Care Campus|No|Enrolling by invitation|June 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|2 Years|18 Years|No|||June 2014|June 25, 2014|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175589||41815|
NCT02176772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fe_TB_Study_TZ|Iron Absorption and Utilization During Tuberculosis and After Treatment|The Effects of Tuberculosis on Dietary Iron Absorption and Systemic Iron Utilization: a Double Stable Isotope Study in Bagamoyo, Tanzania||Swiss Federal Institute of Technology||Recruiting|April 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|45 Years|No|Probability Sample|18 tuberculosis cases recruited at the Bagamoyo District Hospital and surrounding TB        diagnostic centres.|November 2015|November 27, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02176772||41725|
NCT02176460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-01|Colchicine for Symptom and Inflammation in Knee Osteoarthritis|A Randomized Controlled Trial of Colchicine for Symptom and Inflammation Modification in Knee Osteoarthritis||Singapore General Hospital|No|Active, not recruiting|October 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|No|||June 2015|June 18, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02176460||41749|
NCT02176408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31MH100773-01A1|Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression|Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression||Boston University|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176408||41752|
NCT02176421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-MED-FIL-020|A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area|||Allergan|No|Completed|May 2014|July 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 25, 2014||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT02176421||41751|
NCT02176746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-001|A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Colorectal|CSC|Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||June 2014|June 1, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176746||41727|
NCT02177019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050263|Assessment of a Personalized Health Care Intervention for Frequent Headache|Assessment of a Personalized Health Care Intervention for Frequent Headache||Duke University|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|N/A|No|||May 2015|July 17, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177019||41707|
NCT02177032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V49_30|Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age|Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New "4-sites, 1-week" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended "2-sites, TRC" Intradermal Regimen in Children and Adults Subjects.||Novartis|No|Completed|June 2014|August 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|885|||Both|1 Year|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177032||41706|
NCT02177292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate Cancer|High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)|A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients|SIB|Medical College of Wisconsin|Yes|Active, not recruiting|June 2010|December 2060|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||August 2015|March 7, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02177292||41686|
NCT02177305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.138|Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers|A Single Increasing Dose Tolerance Study After Ocular Administration of Tiotropium (Single Doses: 0.02 - 0.4 mcg) in Healthy Male Volunteers (Randomised, Placebo-controlled, Double-blind, Parallel Groups).||Boehringer Ingelheim||Completed|October 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02177305||41685|
NCT02177643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07943212.5.2002.0053|Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin|Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin||University of Campinas, Brazil|Yes|Recruiting|January 2013|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177643||41659|
NCT02136472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-2-001|Female Subfertility: a Metabolic and Vascular Profile|Female Subfertility: a First Sign of Metabolic and Cardiovascular Anomalies?||Maastricht University Medical Center|Yes|Recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|512|||Female|18 Years|42 Years|Accepts Healthy Volunteers|Probability Sample|Study 1:          -  Study group: subfertile women between 18 and 41 years who visit our fertility clinic             in the Maastricht University Medical Centre with a primary or secondary subfertility,             independent of the cause of their subfertility          -  Control group: women with a history of an uneventful spontaneous pregnancy        Study 2: Women who finished the basic fertility work up and are diagnosed with:          -  an unexplained subfertility: study group 1          -  an "expected" decreased ovarian reserve: study group 2 Control group: women with a             history of an uneventful spontaneous pregnancy        Study 3: Women who received an IVF treatment in the period of 2010 - 2012 and:          -  study group: had a "proven" decreased ovarian response, defined as retrieving 3             oocytes or less at an ovum pick-up, despite maximal ovarian stimulation          -  control group: received and IVF/ICSI treatment because of a severe male subfertility|January 2016|January 6, 2016|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02136472||44816|
NCT02167256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013830|A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease|A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease||Yale University|Yes|Recruiting|December 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|55 Years|85 Years|No|||February 2016|February 19, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167256||42455|
NCT02167490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S637/311|Sentinel Node Vs Observation After Axillary Ultra-souND|A Randomized Trial Comparing Sentinel Lymph Node Biopsy Vs no Axillary Surgical Staging in Patients With Small Breast Cancer and a Negative Preoperative Axillary Assessment (IEO S637/311)|SOUND|European Institute of Oncology|No|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1560|||Female|N/A|N/A|No|||December 2015|March 11, 2016|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02167490||42438|
NCT02167763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM2010.01|Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD|Study of the VeraCept Intrauterine Device for Long Acting Reversible Contraception||ContraMed LLC|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167763||42417|
NCT02168049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR14-000670|Heart and Lung Function Monitoring System|Heart and Lung Function Monitoring System Evaluation||University of California, Los Angeles|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02168049||42395|
NCT02168296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1602|Pharmacokinetics of Plant-based Ingredient|Exploratory Study to Assess the Pharmacokinetics in Relation to Blood Glucose and Insulin Levels After Intake of a Plant-based Ingredient in Healthy Subjects||Unilever R&D|No|Completed|June 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2014|February 17, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02168296||42376|
NCT02168283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPBCM|Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients|Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients||Chinese University of Hong Kong|No|Not yet recruiting|December 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168283||42377|
NCT02164968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14027|Assessment of Respiratory Symptoms After Corticosteroid Treatment Period Using Impedance Pneumography|Assessment of Respiratory Symptoms After Corticosteroid Treatment Period Using Impedance Pneumography|IP-ASTMA_2|Tampere University Hospital|No|Enrolling by invitation|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|1 Year|5 Years|No|Non-Probability Sample|1-5 year old patients who have visited the TAYS emergency room due to obstructive        bronchitis and have been instructed to begin a three-month period of inhaled        corticosteroid (ICS) treatment as per national guidelines.|March 2016|March 7, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164968|2 Months|42630|
NCT02164981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001204|A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia|A Randomized Double-Blind, Placebo-Controlled, Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia||Massachusetts General Hospital|No|Recruiting|May 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164981||42629|
NCT02175264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC12074|Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia|Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia|HCD GENE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|78|||Both|3 Months|N/A|No|Non-Probability Sample|Babies with CDH who delivered if centers included in the "Centre For Rare Disease for        Congenital Diaphragmatic Hernia"|December 2015|December 15, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175264||41840|
NCT02175277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130113|Darbepoetin Alfa MDS Companion Protocol|Single Arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin Alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome||Amgen|No|Active, not recruiting|June 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175277||41839|
NCT02175290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC140006CTIL|Machado-Joseph Disease in Israel|Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation||Meir Medical Center|No|Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Spinocerebellar Ataxia 3 Yemenite Jews patients|June 2014|May 19, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02175290|3 Years|41838|
NCT02176434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|swisstolerance.ch|Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease|Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease||University of Zurich|Yes|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||December 2015|December 2, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02176434||41750|
NCT02176473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013837|Computerized Cognitive Behavioral Therapy and Electroconvulsive Therapy|Evaluating the Feasibility and Efficacy of Computerized Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Electroconvulsive Therapy||Yale University|No|Recruiting|June 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||June 2015|June 10, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176473||41748|
NCT02176135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUR-001|Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection|A Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Oral Auranofin Therapy in HIV-infected Subjects Receiving Suppressive Antiretroviral Therapy|Goldrake|Vaccine and Gene Therapy Institute, Florida|Yes|Withdrawn||January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|No|||February 2015|February 25, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176135||41773|
NCT02177045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0164-14-RMB CTIL|Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation|Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation||Rambam Health Care Campus|No|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2014|September 30, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177045||41705|
NCT02177344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2484|Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease|A Six Month, Randomized, Double-blind (Within Formulation), Multiple Dose Trial to Compare the Safety and Efficacy of 20 mcg and 40 mcg of Ipratropium Bromide, as Delivered by the RESPIMAT Device, to 18 mcg ATROVENT® Inhalation Aerosol (x 2 Puffs) and Respective Placebos in Adults, With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|August 1998|||October 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|646|||Both|40 Years|N/A|No|||June 2014|July 16, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02177344||41682|
NCT02177357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.362|Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients|Pramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational Study||Boehringer Ingelheim||Completed|November 1998|||January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|150|||Both|30 Years|N/A|No|||June 2014|June 26, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02177357||41681|
NCT02177656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITI-HF_EGKMF|Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)|Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)|MITI-HF|University of Pennsylvania|No|Completed|January 2012|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02177656||41658|
NCT02177981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57./3./1.|Impact of Remote Ischemic Preconditioning Preceding Coronary Artery Bypass Grafting on Inducing nEuroprotection|A Randomized, Double-Blind, Controlled Clinical Trial: Impact of Remote Ischemic Preconditioning Preceding Coronary Artery Bypass Grafting on Inducing Neuroprotection|RIPCAGE|University of Zagreb|No|Recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|No|||May 2015|May 28, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02177981||41633|
NCT02177994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOAPFECSACT|Antibiotic Prophylaxis for Elective Cesarean Section|Timing of Antibiotic Prophylaxis for Elective Cesarean Section: A Randomized Controlled Trial|TOAPFECSACT|Ain Shams Maternity Hospital|Yes|Completed|September 2013|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|328|||Female|18 Years|35 Years|No|||June 2015|June 24, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02177994||41632|
NCT02173548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM2000118|Interleukin-1 Blockade in HF With Preserved EF|Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2)|D-HART2|Virginia Commonwealth University|Yes|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173548||41972|
NCT02173561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0116-1|Group vs. Individual Cognitive Processing Therapy for Combat-related PTSD|Group vs. Individual Cognitive Processing Therapy for Combat-related PTSD||VA Boston Healthcare System|Yes|Active, not recruiting|June 2012|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02173561||41971|
NCT02167269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE531147|Comparison of Minimal Fresh Gas Requirements of Baby EAR and Jackson Rees Anesthetic Circuit|Comparison of Minimal Fresh Gas Requirements of Baby EAR and Jackson Rees Anesthetic Circuit for General Anesthesia in Spontaneously Breathing Children Undergoing Surgery||Khon Kaen University|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||March 2015|March 30, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167269||42454|
NCT02167503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-08|Observational Study on Patients With Chronic Hepatitis B|A Retrospective-prospective Observational Study to Evaluate the Effect of Anti-viral Treatment on the Long-term Outcome in Patients With Chronic Hepatitis B (SEARCH-B Study)||Nanfang Hospital of Southern Medical University|Yes|Recruiting|May 2014|||May 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|||Both|30 Years|N/A|No|Non-Probability Sample|Patients with chronic hepatitis B from hospital|June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167503||42437|
NCT02167750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1404|Effect of Phytochemicals on Aspects of Cognitive Performance|Effects of Phytochemicals on Aspects of Cognitive Performance||PepsiCo Global R&D||Recruiting|April 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|24|||Both|17 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02167750||42418|
NCT02164422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308012557|Does Guanfacine Attenuate Stress-Induced Drinking?|||Yale University|Yes|Recruiting|June 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02164422||42672|
NCT02164435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-12-044-AU-HT|Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation|Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation|RDN|University of Adelaide|No|Recruiting|January 2013|October 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||June 2014|June 12, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164435||42671|
NCT02164695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR314003|Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction|Cardioprotective Effects of Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention|CAPRI|Yonsei University|No|Recruiting|June 2014|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||January 2015|January 21, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164695||42651|
NCT02164409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203012274|Changes Associated With H. Pylori and Gastric Carcinogenesis|Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated With H. Pylori Infection and Gastric Cancer Carcinogenesis|IIT H pylori|Weill Medical College of Cornell University|No|Recruiting|July 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 12, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02164409||42673|
NCT02164721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADIT-CHIC|Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy|Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy|MADIT-CHIC|University of Rochester|Yes|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164721||42649|
NCT02164994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402|Prospective Evaluation of the Long-term Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions|Prospective Evaluation of the Long-term (18 Months) Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions Following Cataract Surgery||Technolas Perfect Vision GmbH|No|Recruiting|April 2014|November 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Only the patients who were previously treated with VICTUS™ femtosecond laser-assisted        arcuate incisions and successfully pass the eligibility criteria are eligible for this        follow-up extension study.|April 2015|April 23, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164994||42628|
NCT02175004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 420915-CS3|Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)|An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)||Ionis Pharmaceuticals, Inc.|Yes|Enrolling by invitation|June 2014|August 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|172|||Both|N/A|N/A|No|||March 2016|March 23, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175004||41860|
NCT02175017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-09|ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer||Ono Pharmaceutical Co. Ltd|No|Active, not recruiting|June 2014|||November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|20 Years|N/A|No|||June 2014|January 16, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02175017||41859|
NCT02176148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00026573|Cutaneous Lupus Medication Experience Study|Cutaneous Lupus Medication Experience Study||Wake Forest School of Medicine|No|Recruiting|December 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Dermatology clinic patients with a diagnosis of active cutaneous lupus confirmed by a        dermatologist|December 2015|December 9, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176148||41772|
NCT02175901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls2014006|Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication|Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication||Shanghai Jiao Tong University School of Medicine|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175901||41791|
NCT02176161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14015|Metformin Prostate Cancer Adjuvant Trial|Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time||Winthrop University Hospital|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|N/A|No|||January 2016|January 4, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176161||41771|
NCT02177318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.314|Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease|Drug Use Results Survey of Tiotropium Bromide|COPD|Boehringer Ingelheim||Completed|April 2005|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3588|||Both|N/A|N/A|No|Non-Probability Sample|COPD patients in daily clinical settings.|June 2014|June 26, 2014|January 31, 2008||||No||https://clinicaltrials.gov/show/NCT02177318||41684|
NCT02177331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.215|Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension|Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions During Long-term Treatment. 3rd Follow-up Study - Long-term Use in the 4th and 5th Year Treatment Years||Boehringer Ingelheim||Completed|June 1995|||January 1998|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|20 Years|85 Years|No|||July 2014|July 11, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02177331||41683|
NCT02177370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260.716|Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma|Effect of Fenoterol Metered Dose Inhaler (0.1 mg) on the Beta-receptor Population on Lymphocytes and the Clinical Findings Compared With Treatment With DSCG Metered Dose Inhaler in Patients With Bronchial Asthma.||Boehringer Ingelheim||Terminated|February 1990|||October 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||June 2014|July 17, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02177370||41680|
NCT02177682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115960|Study of Afuresertib Monotherapy and in Combination With Bortezomib and Dexamethasone in Japanese Relapsed Multiple Myeloma Patients|An Open-Label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy and in Combination With Bortezomib and Dexamethasone in Japanese Relapsed Multiple Myeloma Patients||Novartis|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|20 Years|N/A|No|||March 2016|March 16, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02177682||41656|
NCT02177669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05291468Exp|Test-Retest Variability of Quick Contrast Sensitivity Function Testing|||Nova Southeastern University|No|Recruiting|June 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|20 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals between the ages of 20-89 without ocular disease will be recruited from among        patients seen in the Primary Eye Care Clinic at the Nova Southeastern University's The Eye        Care Institute in Davie-Ft. Lauderdale, FL, as well as faculty, students and staff at this        institution.|October 2015|October 5, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177669||41657|
NCT02178020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05017.0501399RC05|Outcome Study of Highly-cross Linked Polyethylene vs. Standard Polyethylene for Primary Posterior Stabilized (PS) Total Knee|Prospective, Randomized Study of Highly-cross Linked Polyethylene vs. Compression Molded Polyethylene for Primary Posterior-stabilized Total Knee Arthroplasty||Chapel Hill Orthopedics Surgery & Sports Medicine|No|Enrolling by invitation|July 2009|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|all female and male patients with arthritis of knee that requires total knee arthroplasty|July 2015|July 28, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02178020|10 Years|41631|
NCT02173925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1101/119-010|Gut Hormone, Nociceptors, Neurotrophic Factors Expression in Functional Dyspepsia|Ghrelin, Leptin, Serotonin, TRPV1, NGF and GDNF Expression in the Patients With Functional Dyspepsia|FD|Seoul National University Bundang Hospital||Completed|February 2011|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|314|Samples With DNA|Blood sample (plasma and serum), samples with DNA and paraffin-embedded tissue. During the      endoscopic examination, one pair of biopsies was obtained from the greater curvature of high      body. Biopsies are taken using standard biopsy forceps.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who had epigastric pain or discomfort with normal upper endoscopy and no evidence        for explaining these symptoms were prospectively enrolled in Seoul National University        Bundang Hospital. All participants underwent esophagogastroduodenoscopy. During endoscopy,        biopsies were taken from both antrum and body for histological evaluation, determining H.        pylori infection status.        Participants were divided into control and patients according to the Rome III criteria.        Patients group were subclassified into 3 categories; PDS (postprandial distress syndrome),        EPS(epigastric pain syndrome) or mixed (PDS+EPS)|January 2015|January 5, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02173925||41943|
NCT02168062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135513|Multidisciplinary Study of Androgen Deprivation Therapy (ADT) in Prostate Cancer|A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: a Randomized Phase 2|STAND|University of California, San Francisco|No|Recruiting|June 2014|May 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168062||42394|
NCT02164175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRG1301.000-M|Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis|Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis||Hemosphere, Inc.|No|Recruiting|May 2014|December 2029|Anticipated|December 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients eligible for HeRO Graft for dialysis access|December 2015|December 23, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164175|5 Years|42691|
NCT02168075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mannitol|Mannitol Brain Relaxation Effect|Can Mannitol Increments Provide More Brain Relaxation in Patients Undergoing Craniotomy for Supratentorial Brain Tumor Removal?|MANNITOL|Seoul National University Hospital|Yes|Recruiting|June 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|124|||Both|20 Years|80 Years|No|||October 2014|October 23, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02168075||42393|
NCT02164188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIAE_Florescer|The Flourishing Project: Evaluation of the Effectiveness of a Well-being Program|The Flourishing Project: Evaluation of the Effectiveness of a Well-being Program in the Personal and Relational Dimensions|Flourishing|Hospital Israelita Albert Einstein|Yes|Active, not recruiting|April 2014|June 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|120|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02164188||42690|
NCT02164448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0249|The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy|||Yonsei University|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|92|||Both|20 Years|70 Years|No|||May 2015|May 26, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02164448||42670|
NCT02164461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lm-LLO-E7-1401|ADXS11-001 High Dose HPV+ Cervical Cancer|PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX||Advaxis, Inc.|No|Recruiting|January 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164461||42669|
NCT02164708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 - 170|Healthy Student Initiative|Healthy Student Initiative||York University|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|71|||Both|17 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164708||42650|
NCT02165735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1306-03104|Get Ready And Empowered About Treatment|Addressing HIV Tx Disparities Through Patient Empowerment|GREAT|University of Rochester|No|Recruiting|June 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|360|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165735||42571|
NCT02165748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IntraopHypegl&Infections|Severe Intraoperative Hyperglycemia During Craniotomy and Postoperative Infections|||University of Roma La Sapienza||Recruiting|November 2013|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|||Both|18 Years|85 Years|No|Probability Sample|Adult patients undergoing craniotomy for brain surgery|June 2014|June 16, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165748||42570|
NCT02175888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeSupp_Hep-1|The Optimization of Bioavailability From Iron Supplements: Study 1|The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles||Swiss Federal Institute of Technology||Active, not recruiting|October 2015|January 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|January 4, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175888||41792|
NCT02175615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA Cyclosporine PK Study|Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT|PHARMACOLOGICAL PREDICTORS OF SUCCESSFUL CYCLOSPORINE ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT||The Hospital for Sick Children||Completed|October 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|||Both|N/A|18 Years|No|Non-Probability Sample|ALLOGENEIC Hematopoietic stem cell transplant recipients|January 2016|January 19, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175615||41813|
NCT02176538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-01-05|Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects||Fougera Pharmaceuticals Inc.|No|Withdrawn|June 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|3 Months|17 Years|No|||June 2014|June 26, 2014|June 17, 2014|Yes|Yes|Business Reasons|No||https://clinicaltrials.gov/show/NCT02176538||41743|
NCT02176824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronotherapy RCT|Chronotherapy Randomized Controlled Trial|Adjunct Total Sleep Deprivation, Sleep Phase Advance, and White Light Therapy Vs. Partial Sleep Deprivation, Sleep Phase Delay, and Amber Light Therapy as Adjunctive Treatments in Acutely Suicidal and Depressed Inpatients.||Medical University of South Carolina|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|90 Years|No|||August 2015|October 1, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176824||41722|
NCT02176785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Power Nap|The Effect of Pre-Frontal tDCS on Sleep Propensity During an Afternoon Nap: RCT|The Effect of Pre-Frontal tDCS on Sleep Propensity During an Afternoon Nap: RCT||Medical University of South Carolina|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|October 1, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176785||41724|
NCT02176811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-052014|Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease|The Cross Sectional Study to Investigate the Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease and Healthy Controls||Gulhane School of Medicine|No|Completed|June 2009|February 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Male|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Outpatient clinics of gastroenterology|May 2014|June 25, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02176811||41723|
NCT02177084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTNS BO-01|Percutaneous Tibial Nerve Stimulation in the Treatment of Anterior Resection Syndrome After Rectal Cancer Surgery|||St. Orsola Hospital||Not yet recruiting|July 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|80 Years|No|||June 2014|June 26, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02177084||41702|
NCT02177058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304897|Reducing Hospitalizations of Nursing Home Residents|Implementing Interventions to Reduce Hospitalizations of Nursing Home Residents||Florida Atlantic University|Yes|Active, not recruiting|September 2012|February 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|264|||Both|N/A|N/A|No|||July 2015|July 14, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177058||41704|
NCT02177071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2014-03|A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy|A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy|SPARE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|Yes|Recruiting|October 2015|January 2020|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||November 2015|November 20, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177071||41703|
NCT02177695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1314|S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer|A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer|COXEN|Southwest Oncology Group|Yes|Recruiting|July 2014|||February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177695||41655|
NCT02178033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Split dose-ADR|The Impact of Split Dose of Low-volume Polyethylene Glycol on Adenoma Detection Rate|The Impact of Split Dose of Low-volume Polyethylene Glycol on Adenoma Detection Rate: a Randomized, Investigator Blind, Controlled Trial||Valduce Hospital|No|Recruiting|January 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|514|||Both|50 Years|69 Years|No|||June 2014|June 27, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02178033||41630|
NCT02173574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2119|Two-way Interaction Between Alisporivir and EDP239|An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects||Enanta Pharmaceuticals|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|June 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02173574||41970|
NCT02174237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP/LNP1892/2014/001|A Study to Test the Safety/Tolerability of Increasing Doses of LNP1892 Versus Placebo in Healthy Male/Female Subjects|LNP1892 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects||Lupin Ltd.|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174237||41919|
NCT02174510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1070002|A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects|A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects||Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|37|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02174510||41898|
NCT02167542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BroncoNIVCPAP|Positive Pressure During Bronchoscopy|Positive Pressure During Bronchoscopy: Noninvasive Positive Pressure Ventilation vs Continuous Positive Airway Pressure Valve||Hospital Sao Joao|No|Completed|February 2010|February 2014|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT02167542||42434|
NCT02167802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0119|Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)|Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)|DIABACT IV|Nantes University Hospital|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|782|||Both|N/A|15 Years|No|Non-Probability Sample|Patients included in this study will be children admitted to pediatric intensive care unit        for a severe bacterial infection community.        Retrospective inclusions (data DIABACT III study) of children from 1 month to 15 years and        3 months and prospective inclusions concern for children from 0 months to 15 years and 3        months.|July 2015|November 30, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02167802||42414|
NCT02164734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3768|Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome|Efficacy of Rescue Surfactant Delivery Via Endotracheal Intubation (INSURE Technique) Versus Laryngeal Mask Airway (LMA) for Respiratory Distress Syndrome (RDS) in Preterm Neonates||Albany Medical College|Yes|Recruiting|June 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|48 Hours|No|||December 2015|December 30, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164734||42648|
NCT02164747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-TMG91|Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units|Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units|TMG91|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|360|||Both|N/A|N/A|No|Non-Probability Sample|Nursing home residents|February 2016|February 24, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164747||42647|
NCT02165254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AT007569|The Gentle Cardiac Rehabilitation Study|Development of A Tai-Chi Program To Overcome Barriers To Cardiac Rehabilitation||The Miriam Hospital|Yes|Active, not recruiting|October 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|21 Years|90 Years|No|||March 2016|March 14, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165254||42608|
NCT02165540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819173|The Impact of Doulas in Early Pregnancy Management|The Impact of Doulas in the Surgical Management of Early Pregnancy Failure and Abortion Care||University of Pennsylvania|No|Completed|May 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02165540||42586|
NCT02165761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVG 13-01|Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients|Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.||W.L.Gore & Associates|No|Enrolling by invitation|July 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165761||42569|
NCT02166021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCMS-001-IL|Optimal Administration Mode of Autologous Mesenchymal Bone Marrow Stem Cells in Active and Progressive Multiple Sclerosis|Phase IIA Trial to Investigate the Optimal Way of Administration (Based on the Immunological, Clinical and Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) in Active and Progressive Multiple Sclerosis (MS)||Hadassah Medical Organization|No|Recruiting|June 2014|April 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|25 Years|65 Years|No|||June 2015|June 24, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02166021||42549|
NCT02175329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD-On|Clinical Investigation on Zirconia-ceramic Three-unit Bridges With CAD-on Veneering|A Randomized Clinical Trial of 3-unit Posterior Zirconia-ceramic Fixed Dental Prosthesis (FDPs) Veneered With Layered and Milled (CAD-on) Veneering Ceramics||Ivoclar Vivadent AG||Active, not recruiting|January 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||September 2015|February 23, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02175329||41835|
NCT02175342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.127|Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, 3-week Multiple-dose, Placebo Controlled, Intraformulation Double-blind, Parallel Group Study||Boehringer Ingelheim||Completed|March 1998|||April 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|202|||Both|40 Years|N/A|No|||June 2014|June 25, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02175342||41834|
NCT02176486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN9708_101|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects With ISN / RPS Class III or IV Lupus Nephritis||Takeda|No|Recruiting|July 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02176486||41747|
NCT02176499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.255|Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension|Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension On a Controlled Sodium Diet (100 mmol/Day)||Boehringer Ingelheim||Completed|February 1999|||July 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02176499||41746|
NCT02176837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-03-01|Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage|Evaluation of Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage From a Cerebral Aneurysm||Hope Pharmaceuticals|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176837||41721|
NCT02177097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110022|Chronic Pain, Inflammation and Infection After Joint Replacement|Extended Biochemical Analysis and Bacteriologic Diagnosis in Patients With Loose Joint Replacements, Chronic Pain and Infection.||Northern Orthopaedic Division, Denmark|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|180|Samples With DNA|4 x 10 ml blood samples for each patient.|Both|18 Years|80 Years|No|Probability Sample|Primary care clinic.|April 2015|April 9, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177097||41701|
NCT02177396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.256|MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring|A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.||Boehringer Ingelheim||Completed|April 1998|||December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|18 Years|N/A|No|||June 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177396||41678|
NCT02177409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.258|Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension|A Prospective Randomized Open-Label, Blinded-Endpoint (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Amlodipine (5 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.||Boehringer Ingelheim||Completed|April 1998|||December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177409||41677|
NCT02177708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34781|Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy|Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy Measured by MR||University of Aarhus|Yes|Recruiting|January 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Type C HE|June 2014|June 26, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177708||41654|
NCT02177383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 994/08 PI|Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance|Scientific Basis of the Action of Foods Rich in Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance||University of the Balearic Islands||Completed|September 2011|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Male|16 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02177383||41679|
NCT02173587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSFC81273064|Study Evaluating the Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis|Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis||Zhejiang University|Yes|Active, not recruiting|February 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|56|||Both|18 Years|75 Years|No|||June 2014|June 23, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02173587||41969|
NCT02173938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINJ#131217|Novel Psychosocial Influences on Smoking Cessation|Novel Psychosocial Influences on Successful Tobacco Cessation Among Treatment Seekers||Rutgers, The State University of New Jersey|No|Completed|August 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult smokers 18 years and older seeking treatment for quitting smoking|May 2015|May 1, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173938||41942|
NCT02174224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OJJDP-2013-3579|At-risk Intervention and Mentoring Evaluation|Program Evaluation of a Hospital-based Violence Intervention Program (At-risk Intervention and Mentoring)|AIM|Denver Health and Hospital Authority||Recruiting|June 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|14 Years|24 Years|No|||September 2015|September 16, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174224||41920|
NCT02174497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMB No 0925-0586|One-Day Versus Three-Day Bowel Preparation for Colonoscopy in Children|One-Day Bowel Preparation With Polyethylene Glycol 3350 (Miralax®) is as Effective and Safe as Three-Day Preparation for Colonoscopy in Children||St. John Health System, Michigan|Yes|Completed|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|2 Years|21 Years|Accepts Healthy Volunteers|Probability Sample|Children between 2 and 21 years of age undergoing elective colonoscopy were enrolled into        the study.|June 2014|June 23, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02174497||41899|
NCT02167295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB1-258(CR-2)|Biobehavioral and Cultural Determinants of Betel Quid Chewing, Dependence, and Withdrawal in Taiwan|Biobehavioral and Cultural Determinants of Betel Quid Chewing, Dependence, and Withdrawal in Taiwan|BCDBQCDWT|China Medical University Hospital|Yes|Completed|December 2012|April 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|77|Samples Without DNA|The urine of participants for self-report questionnaire study will be retained|Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|1. 47 participants will be invited to participate in a qualitative study that includes             focus group and in-depth structured interviews that examine the social and cultural             context that surrounds continued use and cessation of betel quid consumption.          2. 30 male and female healthy individuals who currently both chew betel quid and smoke             cigarettes will be invited to attend 3 separate sessions at CMUH and complete a             self-report questionnaire specifically designed to measure betel quid withdrawal             symptoms, and the relationship between betel quid chewing and cigarette smoking             withdrawal. This application represents the first step in the development of a             multi-phase, multidisciplinary betel quid chewing research program.|December 2015|December 13, 2015|February 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02167295||42453|
NCT02164201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFM1301.000-M|Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular Surgery|Post Market Surveillance Study Evaluating the Operative Management of Anastomotic Bleeding by Means of an Adjunctive Application of BioFoam Surgical Matrix in Cardiovascular Surgery||CryoLife Europa|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac or cardiovascular procedures, including, but not limited to:        Thoracic Aortic Aneurysm Aortic Valve Replacement Type A Aortic Dissection (where BioFoam        is limited to the anastomotic site)|July 2015|July 27, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164201||42689|
NCT02164474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02268|Small Steps for Big Changes|Time-efficient High-intensity Interval Training Versus Moderate-intensity Continuous Aerobic Training for Promoting Exercise Adherence: A Randomized-controlled Trial||University of British Columbia|No|Active, not recruiting|September 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164474||42668|
NCT02165280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206481|Guided IMagery and Patient Satisfaction (GIMPS) Following Urogynecological Surgery|Guided IMagery and Patient Satisfaction Following Urogynecological Surgery|GIMPS|Loyola University|No|Active, not recruiting|June 2014|December 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Female|21 Years|N/A|No|||March 2016|March 1, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02165280||42606|
NCT02165267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 104|Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2014|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|88|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165267||42607|
NCT02165553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/40|Impact of Hibiscus on Cardiovascular Disease Risk|Acute Impact of Hibiscus Sabdariffa Calyces (HSC) Extract Consumption on Blood Pressure, Vascular Function and Other Cardiovascular Risk Factors|PHYTOVAS|University of Reading|Yes|Completed|January 2014|March 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|25|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02165553||42585|
NCT02166047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-283-1059|Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B||Gilead Sciences|Yes|Active, not recruiting|June 2014|October 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|162|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166047||42547|
NCT02176174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 13-14|Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study|Ethnicity and Incidence of Twelve Cardiovascular Diseases: A CALIBER Study||University College, London|Yes|Active, not recruiting|December 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1000000|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the CALIBER database who have a record of ethnic group while registered at one        of 225 general practices contributing data to CPRD (the Clinical Practice Research        Datalink) and consenting to data linkage.|July 2015|July 1, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176174||41770|
NCT02176187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1360|Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease|A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique||Boehringer Ingelheim||Terminated|April 2003|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02176187||41769|
NCT02176200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1361|Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Terminated|April 2003|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02176200||41768|
NCT02176512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.136|Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects|Relative Oral Bioavailability of 80 mg Telmisartan / 12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Subjects. A 4 Period Cross-over, Open, Randomized, Replicate Design Study.||Boehringer Ingelheim||Completed|September 1998|||October 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02176512||41745|
NCT02176525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.2|Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients|Safety, Antiviral Activity, and Pharmacokinetics of Multiple Oral Doses of BI 207127 NA Administered q8H for 5 Days as Monotherapy, a Randomised, Double-blind, Placebo Controlled Study||Boehringer Ingelheim||Completed|December 2007|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|70 Years|No|||June 2014|June 26, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02176525||41744|
NCT02176876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-373-1276|Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis||Gilead Sciences|No|Completed|August 2014|June 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|70 Years|No|||June 2015|June 25, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02176876||41718|
NCT02177136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-207|Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis|AESOP|Intercept Pharmaceuticals|Yes|Recruiting|December 2014|June 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177136||41698|
NCT02177110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 13-22|A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma|A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)|SYS-ACT|ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|September 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Fresh frozen and FFPE tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients must have a diagnosis of advanced or metastatic melanoma of the skin|October 2015|October 23, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177110||41700|
NCT02177123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-007|Post Market Study of the InnFocus MicroShunt|Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma||InnFocus Inc.|No|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||August 2014|May 4, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177123||41699|
NCT02177422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.260|Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension|Open-Label Follow-up Trial on Efficacy and Safety of Chronic Administration of Telmisartan 80 mg (Micardis®) Tablets as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension||Boehringer Ingelheim||Completed|June 1998|||November 1999|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|489|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177422||41676|
NCT02177435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.261|Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension|An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.||Boehringer Ingelheim||Completed|February 1999|||September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|491|||Both|18 Years|80 Years|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177435||41675|
NCT02178046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2014-1167|Non-Invasive Oral Biofilm Characterization|Non-Invasive Oral Biofilm Characterization||University of California, Irvine|No|Recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|25 Years|No|Non-Probability Sample|Study population will be selected from UCI Medical Center a referral base for dentists in        the greater Orange County area for diagnosis of patients with suspected intra-oral        lesions. The UCI student dental health clinic caters to UCI students, staff and faculty.|February 2016|February 5, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178046|1 Month|41629|
NCT02178059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4711C00002|Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Current Version of Turbohailer With Inhalation Via a New Version.|An Open-label, Single-dose, 2-period Cross Over Study in Healthy Male and Female Volunteers to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg After Inhalation Via the M3 Turbuhaler (New Version) Compared With the M2 Turbuhaler (Current Version)||AstraZeneca|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178059||41628|
NCT02173600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0969-12|Cardiovascular Risk Factors And Intensive Dietary Counselling|Estimation of Cardiovascular Risk After Intensive Dietary Counselling in a Primary Care Setting||Andalusian Regional Ministry of Health|Yes|Enrolling by invitation|May 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|630|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02173600||41968|
NCT02173613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120|Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)|Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized|PROPAGE|University Hospital, Grenoble|Yes|Recruiting|August 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|340|||Both|80 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02173613||41967|
NCT02173951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|start of ICT in young BTM|An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients|A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study||Ain Shams University|Yes|Not yet recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|6 Months|36 Months|No|||January 2015|January 13, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173951||41941|
NCT02167529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0194|Quality of Life After Thyroidectomy (ThyrQol)|A Prospective, Multicenter and Observational Trial to Evaluate Evolution of Quality of Life (SF-36) After Total Thyroidectomy.|ThyrQol|Nantes University Hospital|No|Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|780|||Both|18 Years|N/A|No|Non-Probability Sample|A prospective, non randomized, open, multicenter trial to evaluate quality of life (SF 36)        and voice function (VHI questionnaire) before and after totalthyroidectomy|April 2015|April 14, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167529||42435|
NCT02164487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/12|Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients|Evaluating the B1 Status in Eating Disorder Female Adolescent Patients||Assaf-Harofeh Medical Center||Recruiting|March 2013|||September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Female|12 Years|19 Years|No|Non-Probability Sample|adolescent girls with eating disordes aged 12-18|June 2014|June 13, 2014|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02164487||42667|
NCT02164500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JeRiCHO|JAK-inhibition in Recurrent Classical Hodgkin Lymphoma|A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|JeRiCHO|University of Cologne||Recruiting|October 2015|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|99 Years|No|||October 2015|October 30, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164500||42666|
NCT02164760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESG-09-2012|The Safety of a Novel Acellular Dermal Template as Treatment for Burns and Scars|A Phase 1, Randomized, Multicentre Multinational Study to Evaluate the Safety and Feasibility of an Acellular Dermal Template Novomaix for the Treatment of Full Thickness Skin Defects in Human Patients.||Association of Dutch Burn Centres|No|Active, not recruiting|June 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02164760||42646|
NCT02166060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IvaCRT KB/111/2014|Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy|Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy|IvaCRT|Medical University of Warsaw|Yes|Not yet recruiting|August 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||June 2014|June 13, 2014|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166060||42546|
NCT02166073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_HFT_PS_JACKSON|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||July 1, 2015|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166073||42545|
NCT02165007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPSICKLE|Haploidentical Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease and Thalassemia Using CD34+ Positive Selected Grafts|HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE AND THALASSEMIA USING CD34+ POSITIVE SELECTED GRAFTS||Children's Research Institute|Yes|Recruiting|January 2015|December 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|22 Years|No|||September 2015|September 26, 2015|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165007||42627|
NCT02165020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-606|Hyaluronic Acid for Hypofractionated Prostate Radiotherapy|Hypofractionated Radiotherapy for Prostate Cancer (62 Gy in 20 Fractions of 3.1 Gy) With Hyaluronic Acid Injection|RPAH1|Hospices Civils de Lyon|Yes|Active, not recruiting|November 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|80 Years|No|||May 2014|June 13, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02165020||42626|
NCT02165774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2012 0048|Sacral Neuromodulation for Neurogenic LUT Dysfunction|Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial||University of Zurich|Yes|Recruiting|April 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02165774||42568|
NCT02175927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls2014007|High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection|Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection||Shanghai Jiao Tong University School of Medicine|No|Completed|July 2014|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|75 Years|No|||December 2015|February 29, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175927||41789|
NCT02175940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF001|VEGF and PEDF in Patients With Myopic Choroidal Neovascularization|Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.||Università degli Studi di Brescia||Completed|July 2013|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with myopic Choroidal Neovascularization treated with intravitreal ranibizumab at        the Medical Retina Department, University of Molise, Campobasso, Italy|June 2014|June 25, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02175940||41788|
NCT02176551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-01-06|Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects||Fougera Pharmaceuticals Inc.|No|Withdrawn|June 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|3 Months|17 Years|No|||June 2014|June 26, 2014|June 17, 2014|Yes|Yes|Business Reasons|No||https://clinicaltrials.gov/show/NCT02176551||41742|
NCT02176564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.40|Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|COPD, Inhaled Bronchodilators Association, and Quality of Life||Boehringer Ingelheim||Completed|June 1999|||October 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2639|||Both|N/A|N/A|No|Non-Probability Sample|Patients with COPD|June 2014|July 17, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02176564||41741|
NCT02176577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-01-07|Study to Determine the Pharmacokinetics of Product 0405|An Open-Label, Multi-Center Study to Determine the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects||Fougera Pharmaceuticals Inc.|No|Withdrawn|June 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Months|17 Years|No|||June 2014|June 26, 2014|June 17, 2014|Yes|Yes|Business Reasons|No||https://clinicaltrials.gov/show/NCT02176577||41740|
NCT02177149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00078062|Nurse Management of Neuromodulation Therapy|Mobile Computing Platform to Improve Outcomes From Deep Brain Stimulation Therapy|DBS|Medical College of Wisconsin|No|Withdrawn|February 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|June 26, 2014||No|PI is no longer at MCW, study has been closed|No||https://clinicaltrials.gov/show/NCT02177149||41697|
NCT02177448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.267|BIBR 277 Capsule in Patients With Essential Hypertension|A Double-blind, Parallel-group Comparison Study of BIBR 277 Capsule in Patients With Essential Hypertension||Boehringer Ingelheim||Completed|September 1998|||September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|225|||Both|25 Years|N/A|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177448||41674|
NCT02177461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.317|Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension|A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension||Boehringer Ingelheim||Completed|April 2000|||August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|374|||Both|65 Years|N/A|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177461||41673|
NCT02177474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frauenherz - 284|Effects of a Telephone Based Peer Support to Reduce Depressive Symptoms and Improve Social Support in Women With CHD|Randomized Controlled Trial of a Telephone Based Peer Support Intervention to Reduce Depressive Symptoms and Improve Social Support in Women With Coronary Heart Disease (CHD)||University of Göttingen|No|Completed|October 2010|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|108|||Female|18 Years|N/A|No|||June 2014|June 26, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02177474||41672|
NCT02177734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age||GlaxoSmithKline||Not yet recruiting|March 2016|May 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|420|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02177734||41652|
NCT02177747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART001|Smartphone-based Ophthalmoscopy|Comparison of Smartphone-based Ophthalmoscopy Versus Dilated Ophthalmic Examination for Diabetic and Nondiabetic Eye Disease||Università degli Studi di Brescia||Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|1||Actual|120|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02177747||41651|
NCT02177721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200137|An Open Label, Phase IV Study Evaluating the Clinical Benefit, Safety and Pharmacokinetics of Raxibacumab in Subjects Exposed to Bacillus Anthracis|A Phase 4, Open-label Field Study (200137) to Evaluate the Clinical Benefit, Safety and Pharmacokinetics in Subjects Treated With Raxibacumab (GSK3068483) Following Exposure to Bacillus Anthracis||GlaxoSmithKline|No|Not yet recruiting|September 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|N/A|No|||May 2015|May 11, 2015|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02177721||41653|
NCT02178072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013771|Window Trial 5-aza in HNSCC, T-tare|A Pilot Study to Assess the Activity of Demethylation Therapy in Patients With HPV Positive Compared With HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)||Yale University|Yes|Not yet recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178072||41627|
NCT02173626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME13.17|Effect of Video-Module Based Mindfulness Training on Physician Stress and Well Being|Effect of Video-Module Based Mindfulness Training on Physician Stress and Well Being||MultiCare Health System Research Institute|No|Completed|October 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02173626||41966|
NCT02173639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.47|Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects|Relative Oral Bioavailability of a Fixed Dose Combination Tablet of BI 1356 2.5 mg / Metformin 1000 mg, Compared With Single BI 1356 2.5 mg and Metformin 1000 mg Tablets Administered Together to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial||Boehringer Ingelheim||Completed|April 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173639||41965|
NCT02173964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pin-2014-SNUBH|Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)|Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT||Seoul National University Hospital|No|Recruiting|July 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|19 Years|80 Years|No|||July 2014|July 16, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173964||41940|
NCT02168088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-6386|Molecular Autopsy Study|Molecular Autopsy for Sudden Cardiovascular Death||Scripps Translational Science Institute|No|Recruiting|June 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Blood and/or tissue will be collected on the deceased individual. Saliva samples will be      collected on family members who have consented to participate.|Both|N/A|45 Years|No|Non-Probability Sample|The study population is limited to cases of sudden unexplained death in San Diego County        and their living, biologically-related family members.|October 2015|October 14, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02168088||42392|
NCT02164773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|use of magnesium sulfate|Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.|Addition of Magnesium Sulfate to Caudal for Prevention of Emergence Agitation in Children||Ain Shams University|Yes|Recruiting|October 2013|August 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|70|||Male|1 Year|6 Years|No|||June 2014|June 13, 2014|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164773||42645|
NCT02164786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetaLab_2014_001|Metabolomics Dynamics Study for Severe Patient|Modeling Metabolomic Dynamics Based on Nuclear Magnetic Resonance and High Performance Liquid Chromatography for Severe Patient: a Cohort Study||Sichuan Academy of Medical Sciences|Yes|Recruiting|June 2014|December 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|plasma,urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffering from acute severe disease|August 2015|August 9, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02164786||42644|
NCT02165033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPK10002J1|Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers|Multiple-dose Pharmacokinetics and Tolerability of "SYN006 HFA MDI" (Budesonide 180ug + Procaterol Hydrochloride 10ug/Dose HFA MDI) Administered Orally to Healthy Volunteers||Intech Biopharm Ltd.|Yes|Completed|November 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165033||42625|
NCT02165046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPK09003J1|Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.|Randomized, Single-dose, Three-way Crossover Study to Assess the Bioavailability of Using SYN006 HFA MDI (Budesonide/Procaterol 180/10mcg) vs Pulmicort pMDI (Budesonide 200 μg) and Meptin Air (Procaterol 10mcg)" in Healthy Volunteer.||Intech Biopharm Ltd.|Yes|Completed|February 2012|August 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02165046||42624|
NCT02166086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111012020|Advanced Imaging Registry for Diagnosing Pancreatico-biliary Disorders|Advanced Imaging for Diagnosing Pancreatico-biliary Disorders: A Multicenter Registry.||Weill Medical College of Cornell University|No|Recruiting|September 2011|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment        of a pancreatico-biliary disorder.|June 2015|June 1, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166086|1 Year|42544|
NCT02166099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206012450|Choledochoscopy Multicenter Registry|Choledochoscopy For Diagnosing Pancreatico-Biliary Disorders: A Multicenter Registry|SPY|Weill Medical College of Cornell University|No|Recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or        treatment of a pancreatico-biliary disorder|June 2015|June 1, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166099|1 Year|42543|
NCT02165566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HlogHlin|Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit|||University of Roma La Sapienza|Yes|Completed|March 2013|May 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||June 2014|June 16, 2014|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02165566||42584|
NCT02166658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-ZNS-0113|A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)|A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)|CaBaMet|AIO-Studien-gGmbH|Yes|Recruiting|August 2015|September 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166658||42501|
NCT02166671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV_VAX_DUR_2014|Immune Response to HBV Booster Vaccination After 20-23 Years|Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 20-23 Years After Neonatal Immunization||Seoul National University Hospital||Recruiting|May 2014|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166671||42500|
NCT02166632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH130401|Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty|Prospective, Randomized Comparison of Postoperative Pain Control Results of Peri-articular Local Injection and Intra-capsular Injectinon of Bupivacaine Liposome Injectable Suspension After Total Knee Arthroplasty||Broward Health|No|Completed|April 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||February 2016|February 8, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02166632||42503|
NCT02166645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT|Comparison Between Preterm Infants Who Are Placed on Their Back or Stomach in the Immediate Postextubation Period|Comparison of Prone and Supine Positioning in the Immediate Postextubation Period of Preterm Infants: a Randomized Controlled Trial Protocol||Uniao Metropolitana de Educacao e Cultura|Yes|Recruiting|March 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|N/A|36 Weeks|No|||May 2014|June 14, 2014|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166645||42502|
NCT02176213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0825|Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176213||41767|
NCT02176590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90YR0075|Improving Family Well-Being and Child School Readiness: Power PATH Dual Generation Intervention|Improving Family Well-Being and Child School Readiness: Power PATH Dual Generation Intervention With Head Start Preschoolers and Their Parents||University of Alabama, Tuscaloosa|Yes|Enrolling by invitation|August 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|3 Years|8 Years|No|||November 2015|November 30, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176590||41739|
NCT02176850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.314|Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension|Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension||Boehringer Ingelheim||Completed|January 1999|||May 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19870|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of general practioners, cardiologists and specialist in internal medicine in        non-hospital practice|July 2014|July 7, 2014|June 25, 2014||||No||https://clinicaltrials.gov/show/NCT02176850||41720|
NCT02176863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1104|Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome|A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome|FORCE|Grifols Biologicals Inc.|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|75 Years|No|||November 2015|November 20, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176863||41719|
NCT02180646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|b2d2-01|Impact of Breakfast Composition on Glycemic and Incretin Responses to the Subsequent Meal in Individuals With Type 2 Diabetes|||University of Missouri-Columbia|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180646||41431|
NCT02180659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Braeburn PRO-814|A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants|A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants|PRO-814|Braeburn Pharmaceuticals|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180659||41430|
NCT02177487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.321|Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension|An Open-Label, Six Month Safety Evaluation of the Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Mild-to-Moderate Hypertension||Boehringer Ingelheim||Completed|June 1999|||January 2000|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177487||41671|
NCT02177500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.323|Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy|An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg||Boehringer Ingelheim||Completed|January 2000|||May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|327|||Both|18 Years|80 Years|No|||July 2014|July 7, 2014|June 26, 2014||||No||https://clinicaltrials.gov/show/NCT02177500||41670|
NCT02177773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-DOTA-TOC|Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies|Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies|DOTA-TOC|University of California, San Francisco|No|Recruiting|June 2014|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177773||41649|
NCT02173652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.45|Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers|Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers. A Monocentric, Open Label, Cross-over Trial||Boehringer Ingelheim||Completed|March 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173652||41964|
NCT02177760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13024|Sirolimus Prophylaxis for aGVHD in TME SCID|Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)||University of California, San Francisco|Yes|Withdrawn|July 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|N/A|1 Year|No|||December 2015|December 1, 2015|June 19, 2014|Yes|Yes|Preliminary data suggested a better approach available|No||https://clinicaltrials.gov/show/NCT02177760||41650|
NCT02173665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution||Boehringer Ingelheim||Completed|October 2004|||December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|64|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173665||41963|
NCT02173678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.24|Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects|A Randomized, Placebo-controlled, Double-blind, 3 Way Cross-over Safety and Tolerability Study of Single and Repetitive Dosing of COMBIVENT® HFA Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects (Cumulative Dose: 1600 mcg (HFA) or 1648 mcg (CFC) of Salbutamol Sulfate, 288 mcg of Ipratropium Bromide)||Boehringer Ingelheim||Completed|October 1999|||November 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|12|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|July 3, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173678||41962|
NCT02173977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1078-RO-CTIL|Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF|Ultrashort Flare GnRH Agonist Combined With Flexible Multidose GnRH Antagonist Versus Flexible Multidose GnRH Antagonist for Good-prognosis IVF Patients||Sheba Medical Center|No|Not yet recruiting|June 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02173977||41939|
NCT02174289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013PS003H|LV Endocardial Cardiac Resynchronisation Therapy|A Randomised Double-blinded Cross Over Study to Evaluate the Improvement of Left Ventricular Systolic Failure Using Targeted Left Ventricular Endocardial Lead Placement in Cardiac Resynchronisation Therapy.|ENDO-CRT|Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|April 2014|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174289||41915|
NCT02174562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK102609-01|Improving Medication Adherence in Older African Americans With Diabetes|Improving Medication Adherence in Older African Americans With Diabetes||Thomas Jefferson University|No|Recruiting|July 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|65 Years|N/A|No|||September 2015|September 3, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02174562||41894|
NCT02164214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002954-29|Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?|DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?||Assistance Publique Hopitaux De Marseille|No|Completed|September 2011|September 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02164214||42688|
NCT02165579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers for Osteomyelitis|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis||University of Texas Southwestern Medical Center|No|Not yet recruiting|June 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|21 Years|N/A|No|Non-Probability Sample|Age > 21, diabetes, Infectious Disease Society of America stage 3 infection        (osteomyelitis)|June 2014|June 16, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02165579||42583|
NCT02165787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2014 0004|Investigation of Gait Parameters in Health and Neurological Disease Under Varying Locomotor Conditions|||University of Zurich|Yes|Recruiting|April 2014|||March 2017|Anticipated|N/A|Observational|N/A||2|Anticipated|340|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients aged 18-80 with spinal cord injury, hemispheric stroke, multiple sclerosis,        Parkinson disease, vestibular disease, cerebellar disease. Healthy control subjects aged        18-80.|January 2016|January 15, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02165787||42567|
NCT02166112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Permacol Dutch Cohort Study|The Permacol Dutch Cohort Study|The Permacol Dutch Cohort Study||Erasmus Medical Center|No|Completed|April 2013|May 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|77|||Both|18 Years|N/A|No|Probability Sample|The design of the trial will be a cross sectional cohort study. We will be gathering        information from all the centers in the Netherlands who have used the Permacol© mesh in        the past to treat complicated abdominal wall defects. Patients will be asked to return to        the hospitals outpatient clinic. A total of around 70 patients will be included into the        study.|June 2014|June 17, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166112||42542|
NCT02166125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207012584|Endoscopic Sutures For Gastrointestinal Tract Disorders: A Prospective Multicenter Registry|Endoscopic Sutures For Gastrointestinal Tract Disorders: A Prospective Multicenter Registry.||Weill Medical College of Cornell University|No|Recruiting|May 2013|August 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Any patient who has undergone clinically indicated and/or standard of care endoscopic        suturing within the Gastrointestinal tract.|June 2015|June 1, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02166125|1 Year|42541|
NCT02166385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11C3|Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel|RC11C3, Pilot Placebo-Controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome||Mayo Clinic|Yes|Active, not recruiting|January 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02166385||42522|
NCT02166684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9608|The Potential of Do-it-yourself Devices for Obtaining Personal Health Data|The Potential of Do-it-yourself Devices for Obtaining Personal Health Data - P4@TNO Pilot Study|P4@TNO|TNO|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166684||42499|
NCT02166931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306043|BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition|The Effectiveness of BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition||Taipei Medical University Shuang Ho Hospital|No|Recruiting|March 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02166931||42480|
NCT02166918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010XP2XR4|Factors Influencing Social Functioning of People With Schizophrenia|Multicenter Study on Factors Influencing Real-life Social Functioning of People With a Diagnosis of Schizophrenia|PRIN2014|Second University of Naples|Yes|Recruiting|June 2013|July 2016|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|760|Samples With DNA|In all subjects a blood sample of 20 ml will be withdrawn from a peripheral vein for genetic      analyses.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three-hundred-twenty patients (80 in each of the 4 recruitment units) with a diagnosis of        schizophrenia according to DSM-IV criteria, confirmed by the Structured Clinical Interview        for DSM-IV - Patient Version (SCID -IP), will be included in the study. One-hundred-twenty        unaffected parents of the recruited patients (15 pairs of parents in each center), 120        unaffected siblings and 320 healthy control subjects, meeting the criteria listed below,        will also be recruited.|June 2014|June 16, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02166918||42481|
NCT02176226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100482-01|IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)|Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)||Northwestern University|Yes|Recruiting|March 2015|July 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|19 Years|N/A|No|||September 2015|September 29, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176226||41766|
NCT02176889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PSHS|A Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals|A Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals|14PSHS|KGK Synergize Inc.|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 8, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176889||41717|
NCT02178696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00033328|Predictors of Antidepressant Response|||University of Michigan|No|Recruiting|January 2011|||October 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|80|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178696||41579|
NCT02178709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0473|A Phase II Study of Neoadjuvant FOLFIRINOX|A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection||Indiana University|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02178709||41578|
NCT02182583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54.560|Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Study of Ba253BINEB in Patients With COPD - Double-blind, Randomised, Double Dummy, Multiple Dose Study in Comparison With MDI||Boehringer Ingelheim||Completed|October 1998|||June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|163|||Both|40 Years|N/A|No|||July 2014|July 10, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182583||41282|
NCT02178423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1059/2014|Feasibility Study of CVC Diagnosis Via Ultrasound in Children|Ultrasound Guided Diagnosis of Central Venous Catheters in Children: A Feasibility Study|CVC|Medical University of Vienna|Yes|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|20|||Both|N/A|8 Years|No|||June 2015|June 8, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02178423||41600|
NCT02173704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_60|Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.|A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.||Novartis|No|Active, not recruiting|September 2014|June 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|225|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||January 2016|January 4, 2016|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173704||41960|
NCT02173691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.137|Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)|A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 1999|||May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|584|||Both|40 Years|N/A|No|||June 2014|June 25, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02173691||41961|
NCT02173990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULSAR-1303|Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).|A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.|PULSAR|Centre Oscar Lambret|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173990||41938|
NCT02179515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140142|Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)|An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|June 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02179515||41517|
NCT02180308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00434|Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI|Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI||New York University School of Medicine|Yes|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180308||41456|
NCT02181153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01072014|Genetic, Serological Fecal and Clinical Markers in Siblings of Children With Inflammatory Bowel Disease|GENETIC, SEROLOGICAL, FECAL AND CLINICAL MARKERS IN SIBLINGS OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE||University of Roma La Sapienza|No|Recruiting|December 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|6 Years|18 Years|No|||July 2013|July 2, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181153||41392|
NCT02164513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116855|A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|Yes|Recruiting|June 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|10000|||Both|40 Years|N/A|No|||March 2016|March 10, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164513||42665|
NCT02165592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCAM-2|Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia|Assessment and Identification of Proprioceptive and Functional Changes in Patients With Hemophilia of the Region of Murcia.|HE-BALANCE|Universidad Católica San Antonio de Murcia|No|Recruiting|September 2015|October 2015|Anticipated|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|||Male|6 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Murcia Regional Hemophilia Association|September 2015|October 7, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02165592|2 Days|42582|
NCT02165800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUSTOMER-001|Multicenter Study on Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients|Multicenter Study on Outcomes and Protection of Urinary and Sexual Function of Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|January 2014|December 2023|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|667|||Male|20 Years|60 Years|No|||November 2015|November 7, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02165800||42566|
NCT02166697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460-015|Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"|Candesartan Cilexetil Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"||Takeda|No|Completed|June 2006|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14151|||Both|20 Years|74 Years|No|Non-Probability Sample|Hypertension|June 2014|June 16, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166697||42498|
NCT02166398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUP-UNSD-101|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers|Phase 1 Study of Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg|UI15AML055MT|Korea United Pharm. Inc.|No|Completed|June 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166398||42521|
NCT02166411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lap.myomectomy|Laparoscopic Myomectomy Using Barbed or Conventional Sutures|Laparoscopic Myomectomy Using Barbed or Conventional Sutures . A Randomized Controlled Trial||Cairo University|Yes|Recruiting|December 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|55 Years|No|||July 2015|July 27, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166411||42520|
NCT02167191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT|HIT in the Healthy Elderly Population|Determining the Effectiveness of a High Intensity Interval Training Exercise Programme in the Healthy, Elderly Population|HIT|University of Nottingham|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167191||42460|
NCT02167178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12012012|The Relationship Between Cardiac Output and Microvascular Visceral Blood Flow|Investigation of the Relationship Between Oesophageal Doppler Assessed Increases in Cardiac Output and Microvascular Visceral Blood Flow in Healthy Volunteers||University of Nottingham|No|Completed|January 2013|August 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|24|||Male|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteers, aged 18-80.|January 2015|January 26, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167178||42461|
NCT02176603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-EnDys|Observational Study of Endothelial Dysfunction in Phenylketonuria|Observational, Investigator Initiated, Monocentric Study of the Endothelial Dysfunction in Adolescent and Adult Patients With Phenylketonuria Due to Phenylalanine Hydroxylase Deficiency||Charite University, Berlin, Germany|No|Enrolling by invitation|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples Without DNA|Plasma, serum, urine will be retained. All blood samples will be destroyed immediately after      having analyzed the above mentioned parameters.|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged ≥ 16 years with PKU diagnosed by newborn screening who are followed up in        the Metabolic Unit of the Charité University Medical Center Berlin (Interdisciplinary        Center for Metabolic Diseases, Dept. of Hepatology and Gastroenterology, as well as Dept.        of Pediatric Endocrinology, Gastroenterology and Metabolic Diseases).|January 2016|January 26, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02176603||41738|
NCT02179541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.BAV.0.05.05/467|A Novel Objective Diagnostic Test for Otitis Media With Effusion|RGB Measurements as a Novel Objective Diagnostic Test for Otitis Media With Effusion||Bezmialem Vakif University|No|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|52|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Endoscopic images of the tympanic membranes of 52 patients (Group 1) and 52 healthy        controls (Group 2) were taken during their otologic examinations. RGB values of specific        points were measured on the tympanic membrane images of both groups. Additionally, in        Group 1 viscosity of each effusion taken by paracentesis during surgery was also measured        intraoperatively with a viscometer. Patients with viscosity values lower than 450 cP        (centipoise) were subdivided into Group 1a, and those with values higher than 450 cP into        Group 1b.|January 2013|July 1, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179541||41515|
NCT02182089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IntelomedTufts11231|Measuring Cardiovascular Stress in Patients on Hemodialysis Study II|Measuring Cardiovascular Stress in Patients on Hemodialysis Study II||Intelomed, Inc.|No|Active, not recruiting|April 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|||Both|20 Years|N/A|No|Non-Probability Sample|Study Population:        The sample will be enriched for subjects prone to IDH, defined as patients who experience        IDH for greater than 20% of HD treatments in the past 2 months. The study population will        consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with        less than 10% of IDH during the last two months (n=12).|July 2015|July 20, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02182089||41320|
NCT02178150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18201|Effect of Magnesium Supplementation on Polycystic Ovary Syndrome|Effect of Magnesium Supplementation on Metabolic Profile and Sex Hormone Levels in Overweight Women With Polycystic Ovary Syndrome.||Isfahan University of Medical Sciences|Yes|Recruiting|June 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|20 Years|45 Years|No|||June 2014|March 8, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178150||41621|
NCT02173717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.100|Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers|Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule)When Administered Alone, After Seven Days of Dosing With 600 mg Rifampicin(Tablet), and Seven Days and Fourteen Days After Last Administration of Rifampicin in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)||Boehringer Ingelheim||Completed|June 2009|||July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02173717||41959|
NCT02173730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.10|BIBR 953 ZW in Healthy Elderly Subjects|Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects||Boehringer Ingelheim||Completed|November 2002|||February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02173730||41958|
NCT02174575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMDU-1490|Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery|Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study||Tokyo Medical and Dental University|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|20 Years|N/A|No|||May 2015|May 12, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02174575||41893|
NCT02174874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND - 0001|Ondansetron Oral Versus Orally Disintegrating Tablets (ODT)|Comparison of Ondansetron Oral Solution to Orally Disintegrating Tablets for the Management of Suspected Viral Gastroenteritis in a Pediatric Emergency Department||Alberta Children's Hospital|No|Completed|June 2011|June 2014|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|462|||Both|3 Months|10 Years|No|Probability Sample|Alberta Children's Hospital Emergency department, all patients presenting with acute        gastroenteritis|June 2014|June 24, 2014|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT02174874||41870|
NCT02179983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHSTayside|Tayside Rehabilitation in Bronchiectasis Exacerbations (TRIBE) : a Randomized Controlled Trial|A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis|TRIBE|NHS Tayside|No|Recruiting|June 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02179983||41481|
NCT02180893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02774|The Use of Paravertebral Block for Cardiac Surgery|Study of Paravertebral Block for Cardiac Surgery||New York University School of Medicine|Yes|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||February 2016|February 16, 2016|July 1, 2014|Yes|Yes||No|February 16, 2016|https://clinicaltrials.gov/show/NCT02180893||41412|
NCT02181686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015|Iperia/Sentus QP Study|Iperia Family / Sentus QP Master Study||Biotronik SE & Co. KG|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|The patient collective consists mainly of heart failure patients with CRT-D indication        according to current guidelines. In addition 50 patients with an indication for single or        dual chamber ICD will be enrolled in the study. The investigator will select patients who        are appropriate for particiation from his general patient population.|July 2015|July 14, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181686||41351|
NCT02181998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.11|A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting|A Phase IIIb-IV, Randomised, Open Label Trial on Efficacy and Safety of 2 Parallel Groups: Full Dose Tenecteplase Combined With Unfractionated Heparin or Enoxaparin in Acute Myocardial Infarction in the Prehospital Setting (ASSENT 3 Plus) ASSENT 3 Plus Was a Satellite Study to ASSENT 3 (Main Study) ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens)|ASSENT 3 Plus|Boehringer Ingelheim||Completed|July 2000|||August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1606|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181998||41327|
NCT02165293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29332|A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers|||Hoffmann-La Roche||Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165293||42605|
NCT02165605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092012-058|HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer|Randomized, Double-Blind, Vehicle-Controlled Pilot Study of the Efficacy and Safety of HylaCareTM in the Treatment of Acute Skin Changes in Patients Undergoing External Beam Radiotherapy for Tumors of the Breast.||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Female|18 Years|N/A|No|||September 2015|September 12, 2015|December 19, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165605||42581|
NCT02165813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICEGUT|Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children|A Randomised, Placebo-controlled Trial of Oral Nitazoxanide for the Empiric Treatment of Acute Gastroenteritis Among Australian Indigenous Children|NICEGUT|Telethon Kids Institute|Yes|Recruiting|November 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|3 Months|4 Years|No|||June 2015|June 30, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02165813||42565|
NCT02167204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7754|18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors|Cellular Proliferation Imaging Using [18F]Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors||University of Washington|No|Recruiting|November 2012|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02167204||42459|
NCT02166424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNCHRO-RCT|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)||Tokyo Medical University|Yes|Recruiting|June 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Female|20 Years|N/A|No|||August 2015|August 26, 2015|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02166424||42519|
NCT02167685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-333|The Chimerix CMX001 Registry|A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.|CMX001|Chimerix|No|Recruiting|January 2014|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|550|||Both|6 Months|100 Years|No|Non-Probability Sample|Subjects previously enrolled in selected clinical studies of CMX001|February 2016|February 29, 2016|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167685|3 Years|42423|
NCT02167971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-01|Brain Stimulation for Traumatic Brain Injury|Evaluation of Repetitive Transcranial Magnetic Stimulation on the Cognitive Rehabilitation After Traumatic Diffuse Axonal Injury.|TMS/DAI|University of Sao Paulo|Yes|Recruiting|January 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167971||42401|
NCT02167425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAT-01|Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs|Reducing Failure-to-Initiate ART Among People Who Inject Drugs: the IMAT Strategy|IMAT|Pangaea Global AIDS Foundation|No|Enrolling by invitation|February 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|The study sites will include the methadone clinics at Muhimbili National Hospital,        Mwananyamala Regional Hospital, and Temeke Regional Hospital. The study population        includes methadone patients and the providers of clinical services at these facilities.|November 2015|November 19, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167425||42443|
NCT02177786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-223-1015|Efficacy, Safety, and Tolerability of GS-4997 in Participants With Diabetic Kidney Disease|A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease||Gilead Sciences|Yes|Active, not recruiting|June 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|334|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177786||41648|
NCT02180347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAM_602929|Contact Lenses and Myopia||CLAM|State University of New York College of Optometry||Recruiting|June 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|7 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes children and teens that are recruited from the University        Eye Center at SUNY College of Optometry and from the greater New York City area.|May 2015|May 31, 2015|June 30, 2014||||No||https://clinicaltrials.gov/show/NCT02180347||41453|
NCT02180360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Capoeira Training and Flexibility|Eight Weeks of Basic Training in Capoeira Increases Flexibility of Beginners in the Sport||Universidade Federal do vale do São Francisco|Yes|Completed|February 2012|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02180360||41452|
NCT02174354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H0802/7|Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis|Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis|MTXPG|King's College London|Yes|Enrolling by invitation|January 2011|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|350|Samples With DNA|Longitudinal study design. Serum samples will be retained with consent.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with psoriasis taking methotrexate recruited in outpatient dermatology clinics|June 2014|June 24, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02174354||41910|
NCT02174640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-008|Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study|Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study|COF1|Institute for Food Safety and Health, United States|No|Active, not recruiting|June 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02174640||41888|
NCT02174588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0801|Moderate Sedation for Elective Upper Endoscopy With Balanced Propofol Versus Propofol Alone: a Randomized Clinical Trial|||Yonsei University|No|Recruiting|December 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 6, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174588||41892|
NCT02174926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASERtrial|LASER Trial. LAparoscopic Elective Sigmoid Resection Following divERticulitis - a Multicenter, Prospective, Randomized Clinical Trial|LASER Trial. LAparoscopic Elective Sigmoid Resection Following divERticulitis - a Multicenter, Prospective, Randomized Clinical Trial|LASER|Helsinki University Central Hospital||Recruiting|September 2014|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label|2||Anticipated|133|||Both|18 Years|75 Years||||March 2015|March 16, 2015|June 22, 2014||Yes||No||https://clinicaltrials.gov/show/NCT02174926||41866|
NCT02179775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-64-3456|Effect of "Sekanjabin e Safarjali" (Quince Oxymel) in the Prevention of Migraine Attacks|Comparison of Effectiveness of "Sekanjabin e Safarjali" (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction||Shiraz University of Medical Sciences|Yes|Recruiting|July 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|18 Years|70 Years|No|||July 2014|July 9, 2014|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179775||41497|
NCT02180607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH085035|Neuronal Responses to Social Feedback in Major Depressive Disorder|Neuronal Responses to Social Feedback in Major Depressive Disorder||University of Michigan|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|58|Samples With DNA|saliva|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Individuals diagnosed with major depressive disorder (MDD), and healthy controls|May 2015|May 27, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180607||41434|
NCT02180620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exertime|Pre-dinner vs. Post-dinner Exercise on Glycemic Control|||University of Missouri-Columbia|No|Completed|September 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|13|||Both|25 Years|55 Years|No|||June 2014|July 1, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180620||41433|
NCT02181400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRD|Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema|Pilot Study of Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema|NIRD|University of Sydney|No|Not yet recruiting|July 2014|May 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|N/A|No|||June 2014|July 2, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02181400||41373|
NCT02182505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1105|Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma|A Randomized, Double-blind Study to Compare the Safety and Efficacy of Berodual® Inhaled Via the Respimat® Device in Two Dosages (50 µg Fenoterol Hydrobromide + 20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide + 10 µg Ipratropium Bromide, 1 Puff t.i.d.) With That of Berodual® Inhaled Via the MDI With Aerochamber® (50 µg Fenoterol Hydrobromide + 21 µg Ipratropium Bromide, 2 Puffs t.i.d.) in Pediatric Patients With Asthma Over a 4 Week Period||Boehringer Ingelheim||Completed|September 1998|||July 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|535|||Both|6 Years|15 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182505||41288|
NCT02182518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.254|Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis|Double-blind, Randomized, Parallel Trial to Evaluate the Clinical Efficacy and Safety of Epinastine 10 mg + Pseudoephedrine 120 mg SR, Twice a Day, Versus Epinastine 10 mg Alone, Twice a Day, in the Treatment of Outpatients With Perennial Allergic Rhinitis||Boehringer Ingelheim||Completed|May 2000|||July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|101|||Both|12 Years|N/A|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182518||41287|
NCT02182531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.255|Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers|Study of the Pharmacokinetic Interactions and Relative Bioavailability of Epinastine and Pseudoephedrine in Healthy Volunteers, Comparing Tablets Containing the Fixed Combination of the Two Substances With Tablets Containing Each of the Two Substances Separately||Boehringer Ingelheim||Completed|August 1999|||October 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182531||41286|
NCT02165319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LateralTaperedCuff-phpkhc|The Cuff Pressure of an Endotracheal Tube After Supine-to-lateral Position Change|Comparison of the Cuff Pressure of an Endotracheal Tube After Supine-to-lateral Position Change: Barrel-shaped vs. Taper-shaped Cuff|LateralCuff|Seoul National University Hospital|Yes|Not yet recruiting|July 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|58|||Both|18 Years|80 Years|No|||June 2014|June 13, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02165319||42603|
NCT02165332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29334|A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval|A Two-part, Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of RO7033877 on the QT/QTc Interval in Healthy Subjects||Hoffmann-La Roche||Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02165332||42602|
NCT02166138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13045|Non-Ablative Fractional Resurfacing of Total Knee Replacement Scars|Non-Ablative Fractional Resurfacing of Total Knee Replacement Scars||Hospital for Special Surgery, New York||Recruiting|November 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02166138||42540|
NCT02166151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0550-31 -RMC|Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria|Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria||Rabin Medical Center|No|Not yet recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||June 2014|June 17, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02166151||42539|
NCT02166710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.093|Effect of Adductor Canal Nerve Block Compared to a Simulated Block on Quadriceps Strength Following Knee Arthroplasty|Effect of Adductor Canal Femoral Nerve Block Compared to a Simulated Block on Knee Extensor Muscle Strength Following Total Knee Arthroplasty||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||January 2016|January 11, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02166710||42497|
NCT02166437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH No 6-3|Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese|Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study||Tomidahama Hospital|No|Recruiting|November 2013|November 2018|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|500|||Both|45 Years|N/A|No|Probability Sample|tion Osteoporotic patients who admit to our hospital|November 2015|November 3, 2015|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02166437||42518|
NCT02166450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRS-001|Effects of Denture-Related Stomatitis on Blood Pressure in Denture Wearers|Effects of Denture-Related Stomatitis on Blood Pressure, Endothelial Function and Systemic Immune Response in Patients With Dentures||Jagiellonian University|No|Recruiting|October 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Dental clinic patients wearing dentures|June 2014|June 18, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02166450||42517|
NCT02167217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308062|Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy|Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy||Washington University School of Medicine|Yes|Recruiting|February 2014|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|1 Month|30 Months|No|||December 2015|December 9, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02167217||42458|
NCT02166944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307022|Tamoxifen Treatment in Patients With Motor Neuron Disease|The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease||Taipei Medical University Shuang Ho Hospital|No|Recruiting|April 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|80 Years|No|||June 2014|June 16, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02166944||42479|
NCT02167997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17155|EffectiveNess and SAfety of Small ANeurysm COiling Trial|EffectiveNess and SAfety of Small ANeurysm COiling Trial|NANO|University of Virginia|Yes|Recruiting|November 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|252|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with cerebral aneurysms less than 4mm|June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167997|24 Months|42399|
NCT02167984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|swallow-01|Esophageal Bolus Transit in Newborns With Gastroesophageal Reflux Disease|Esophageal Bolus Transit in GERD Newborns: a Multichannel Intraluminal Impedance Study||University of Turin, Italy|No|Completed|January 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|61|||Both|N/A|90 Days|No|Probability Sample|newborns consecutively admitted to the Torino University NICU who underwent 24-hour MII/pH        for suspected GERD|June 2014|June 17, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167984||42400|
NCT02168231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASE cohort study|Abdominal Wall Repair With Strattice in Germany: a Cohort Study|Abdominal Wall Repair With Strattice in Germany: a Cohort Study (BASE Cohort)|BASE cohort|Erasmus Medical Center|No|Enrolling by invitation|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients operated by members of the ROKI group (Arbeitsgruppe für Rekonstruktion komplexer        Inzisionaler Hernien); i.e. a group of German hernia surgeons using Strattice for complex        abdominal wall surgery. This group of surgeons is willing to share their patient cases        with the investigators to achieve more knowledge on this delicate topic.|February 2015|February 9, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02168231||42381|
NCT02178995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPH in epilepsy|Methylphenidate Treatment of Attention Deficits in Epilepsy|Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy||Stanford University|No|Not yet recruiting|August 2014|May 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178995||41556|
NCT02181426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketorolac Knee Arthroscopy|Dose Response of Ketorolac in Knee Arthroscopy|Dose Response of Ketorolac in Out-Patients Undergoing Knee Arthroscopy||Medical University of South Carolina|No|Recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|112|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02181426||41371|
NCT02181439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0126|Study Evaluating the Laser Diode Effect on the Kinetics of Orthodontic Tooth Movement (Protocol CINELASER)|Single-center, Controlled, Randomized and Double-blind Study Evaluating the Laser Diode Effect on the Kinetics of Orthodontic Tooth Movement.|CINELASER|Nantes University Hospital|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|10 Years|18 Years|No|||July 2014|July 3, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02181439||41370|
NCT02178085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2014_843_0007|Ocular Blood Flow Assessment in Glaucoma|Ocular Blood-flow Assessment by Magnetic Resonance Angiography in Glaucoma|OBAMAg|Centre Hospitalier Universitaire, Amiens|No|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02178085||41626|
NCT02178098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-014|Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension||Esperion Therapeutics|No|Completed|June 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178098||41625|
NCT02178111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPISIO|Comparison of Never Performing Episiotomy to Performing it in a Selective Manor|Not Performing Episiotomy Versus Selective Episiotomy: a Randomized Clinical Trial|EPISIO|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|July 2013|August 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|237|||Female|N/A|N/A|No|||December 2014|December 10, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02178111||41624|
NCT02175212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DART01/05|Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer|Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.|AADLPC|Hospital Universitario de la Princesa|No|Active, not recruiting|November 2005|||June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|358|||Male|19 Years|N/A|No|||June 2014|June 25, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02175212||41844|
NCT02175511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 100-2622-E-038-001-CC2|A Randomized Controlled Trial for Hypertension Control by Integrating Cloud BP System and CPOE|Cloud BP System Integrated With CPOE Improves Self-Management of the Hypertensive Patients: A Randomized Controlled Trial Study||Taipei Medical University|No|Completed|December 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|382|||Both|18 Years|85 Years|No|||June 2012|June 24, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02175511||41821|
NCT02175810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0217|Impact of Bariatric Surgery on Cardiorespiratory Function|Impact of Bariatric Surgery on Cardiorespiratory Function: an Observational Study||St George's, University of London|No|Recruiting|June 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients with scheduled bariatric surgery at St George's Healthcare NHS Trust.|June 2014|June 30, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175810||41798|
NCT02176057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETS-13-10961|Nepal Elimination of Trachoma Study|Nepal Elimination of Trachoma Study|NETS|University of California, San Francisco||Withdrawn|August 2014|||August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|9 Years|No|||May 2015|May 19, 2015|June 24, 2014|No|Yes|Nepal Ministry of Health implemented public drug treatment prior to the proposed start date|No||https://clinicaltrials.gov/show/NCT02176057||41779|
NCT02176317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052449|Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)|Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)||Duke University|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|24 Months|72 Months|No|||February 2016|February 4, 2016|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02176317||41759|
NCT02176330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14733|Does Using a 'Virtual Clinic' in Urogynaecology Improve Patient Experience and Reduce Cost?|Assessing the Impact of Using ePAQ on Quality and Cost of Patient Care in Uro-gynaecology: a Randomised Controlled Trial||University of Sheffield|No|Completed|June 2008|August 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|195|||Female|18 Years|N/A|No|||June 2014|June 25, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02176330||41758|
NCT02176343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-14-005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||September 5, 2014|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176343||41757|
NCT02165345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29231|Extension Study Evaluating the Safety and Efficacy of Subcutaneous RoActemra/Actemra Administration in Patients With Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis|Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis||Hoffmann-La Roche||Recruiting|July 2014|November 2020|Anticipated|November 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|2 Years|18 Years|No|||March 2016|March 3, 2016|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02165345||42601|
NCT02165618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-54896|Rationalisation of Polypharmacy by the Geriatric Consultation Team|Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study|RASP-GCT|Universitaire Ziekenhuizen Leuven|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|75 Years|N/A|Accepts Healthy Volunteers|||May 2014|June 13, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02165618||42580|
NCT02166957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OESORDV|Evaluation of the Effectiveness of Endoscopic "Rendez-vous" Technique Foresophageal Reconstructions for the Treatment of a Total and Extensive Disruption of the Esophagus|Evaluation of the Effectiveness of Endoscopic "Rendez-vous" Technique for Esophageal Reconstructions for the Treatment of a Total and Extensive Disruption of the Esophagus||Société Française d'Endoscopie Digestive|Yes|Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|This is a retrospective report about six patients referred for complete esophageal        disruption|November 2015|November 23, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02166957||42478|
NCT02166970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hilar stenting|Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction|Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study||Soon Chun Hyang University|Yes|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2014|June 16, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02166970||42477|
NCT02166983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0037|Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors|Cognitive Enhancement Program||Stanford University||Withdrawn|January 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|0|||Female|21 Years|N/A|No|||November 2014|November 21, 2014|December 16, 2013||No|PI left Stanford|No||https://clinicaltrials.gov/show/NCT02166983||42476|
NCT02167438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_004|Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer|Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer||Plexus Biomedical, Inc.|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|May 11, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02167438||42442|
NCT02168257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303-032|Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates|Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates||Children's Hospitals and Clinics of Minnesota|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 5, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168257||42379|
NCT02164357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUN-TPA-2012-01|Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset|Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset: A Prospective Cohorts Study|FUN-TPA|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Yes|Completed|September 2012|December 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|124|||Both|18 Years|80 Years|No|Probability Sample|Patients younger than 80 with acute ischemic stroke produced by a main artery oclussion        with a NIHSS > 6 (National Institute of Health Stroke Scale) receiving IVT or EVT within        4.5 hours after onset.|June 2015|December 17, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164357||42677|
NCT02168244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0535|Reduction of Pain Caused by Biologic Drugs in Psoriasis|Reduction of Injection-related Pain Caused by Subcutaneous Administration of Biologic Drugs in Psoriasis||Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|124|||Both|N/A|N/A|No|||December 2015|December 29, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168244||42380|
NCT02164643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/47 A|Longitudinal Study of Brain Amyloid imaGing in MEMENTO|Longitudinal Study of Brain Amyloid imaGing in MEMENTO|MEMENTOAmyGing|University Hospital, Bordeaux|No|Recruiting|June 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164643||42655|
NCT02164656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0247|Mindfulness Training for Smokers Online Feasibility Study|Mindfulness Training for Smokers Online Feasibility Study|MTS3|University of Wisconsin, Madison|No|Completed|April 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164656||42654|
NCT02180022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onion-EPC|Effects of Onion Peel Extract on Endothelial Function|Effect of Onion Peel Extract on Endothelial Function and Endothelial Progenitor Cells in Overweight and Obese Subjects||Kyunghee University Medical Center|Yes|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|62|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2014|July 1, 2014|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02180022||41478|
NCT02180035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq- 478741/2008-1|Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS|Effect of Treatment Nutritional With Supplementation About Biochemical Profile and Anthropometry in Adult Patients With HIV/AIDS|PRECOR-NUT|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|290|||Both|19 Years|N/A|No|||July 2014|July 16, 2014|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180035||41477|
NCT02181712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000025|Mesenchymal Stem Cell Therapy for Lung Rejection|A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells to Induce Remission in Lung Transplant Patients Experiencing Treatment-refractory Moderate Lung Rejection||Mayo Clinic|No|Active, not recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181712||41349|
NCT02181725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47323.068.13/METC13-3-062|2B Active: Outpatient Rehabilitation for Adolescents With Chronic Pain|Effectiveness and Cost-effectiveness of a Multimodal Rehabilitation Programme (MRP) for Adolescents With Chronic Musculoskeletal Pain (12-21 Years) Compared to Care as Usual (CAU); a Randomized Clinical Trial (2B Active)||Maastricht University Medical Center|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|12 Years|21 Years|No|||March 2016|March 15, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181725||41348|
NCT02174939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-102-076|Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease||National Cheng-Kung University Hospital|No|Recruiting|February 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||October 2015|October 11, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02174939||41865|
NCT02174952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12031|Self-help in Adjunct to Pharmacotherapy|Efficacy of a Self-help Parenting Intervention for Parents of Children With ADHD in Adjunct to Pharmacotherapy|SHIP|University of Nottingham|No|Active, not recruiting|July 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|10 Years|No|||June 2014|June 24, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174952||41864|
NCT02174302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6|Ì-SPIES, Comparison of Cystoscopy Images in Four Different SPIES Modalities|Ì-SPIES, Comparison of Cystoscopy Images in Four Different SPIES Modalities||Clinical Research Office of the Endourological Society|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|88|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|urologists and resident urologist|June 2014|June 24, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174302||41914|
NCT02174653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701079.01.013|Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)|Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides) A Prospective, Monocentric, Randomised, Double-blind, Placebo-controlled Clinical Trial||Dr. Willmar Schwabe GmbH & Co. KG|No|Active, not recruiting|March 2014|January 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02174653||41887|
NCT02175524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF13341|The Association Between Areca-nut Chewing Habit and Metabolic Syndrome|||Taichung Veterans General Hospital|No|Recruiting|April 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients with oral and oesophageal carcinoma.|June 2014|June 24, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175524||41820|
NCT02175823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401056RIND|Health Status Evaluation for Cancer Survivors by Non-intrusive Sensing System|Health Status Evaluation for Cancer Survivors by Non-intrusive Sensing System||National Taiwan University Hospital|No|Not yet recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Elderly cancer survivors|July 2014|July 3, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175823||41797|
NCT02176070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5531|Reproductive Health in Men and Women With Vasculitis|Reproductive Health in Men and Women With Vasculitis||University of South Florida|Yes|Completed|February 2011|March 2012|Actual|March 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|467|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with vasculitis included in the VCRC Contact Registry were invited to        participate. Data was included for all patients who provided a vasculitis diagnosis,        estimated date of diagnosis, confirmed that the diagnosis was made by a rheumatologist,        and reported having taken at least one appropriate anti-rheumatic medication. Other        participants were excluded as the likelihood that they have a true vasculitis condition is        low.|June 2014|June 25, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02176070|1 Year|41778|
NCT02176356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-CMB-14-001|Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)|||Allergan|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|35 Years|65 Years|No|||July 2015|July 16, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176356||41756|
NCT02176681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5706|A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM|A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM||University Hospital, Strasbourg, France|Yes|Recruiting|June 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|83 Years|No|||August 2015|August 6, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02176681||41732|
NCT02165826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-302-RD|Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD|A Multicenter, Randomized, Double-blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-titration Regimen in COPD, Including an Open-label Down-titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-daily|OPTIMIZE|Takeda|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1323|||Both|40 Years|N/A|No|||October 2015|October 22, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02165826||42564|
NCT02166463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01223|Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma|A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents||National Cancer Institute (NCI)|No|Recruiting|March 2015|||November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|2 Years|18 Years|No|||February 2016|March 24, 2016|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02166463||42516|
NCT02166723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIUH13-007|Persistent Atrial Fibrillation Cryoballoon Ablation|Treatment of Long Persistent Atrial Fibrillation by Single Cryoballoon Ablation of the Pulmonary Veins, Left Atrial Roof Line and Ablation of Left Lateral Ridge From Within the Appendage|PAFCA|Staten Island University Hospital|Yes|Active, not recruiting|January 2013|April 2015|Anticipated|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|62|||Both|18 Years|80 Years|No|Non-Probability Sample|The study population includes patients with persistent atrial fibrillation who present to        staten island university hospital. Those who are listed treatment by cryoballoon ablation        at the discretion of the operating physician will be included in the study.|June 2014|June 16, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02166723|1 Year|42496|
NCT02166996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011-56-31M|A Prospective Comparison of Suture Removal Time for Simple Surgical Defects of the Head and Neck|A Prospective Comparison of Suture Removal Time for Simple Surgical Defects of the Head and Neck||Sundsvall Hospital|No|Completed|April 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|19 Years|N/A|No|||December 2012|June 16, 2014|March 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02166996||42475|
NCT02167698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI/2014/06/004677|Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia|A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome|APRiCE|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|February 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|1 Month|12 Years|No|||February 2016|February 1, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02167698||42422|
NCT02167451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1221|Maraviroc as GVHD Prophylaxis in Transplant Recipients|Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2014|December 2021|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|65|||Both|5 Years|40 Years|No|||December 2015|December 10, 2015|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167451||42441|
NCT02137252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-056|Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer|Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|May 2014|April 2022|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137252||44756|
NCT02164942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-GU-BLA-SPEC-001|LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer|LCI-GU-BLA-SPEC-001: Expression of the Aurora Kinase Family and Chemoresistance in Muscle-Invasive Bladder Cancer||Carolinas Healthcare System|Yes|Terminated|June 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with muscle-invasive urothelial carcinoma of the bladder|February 2016|February 20, 2016|June 13, 2014||No|Futility|No||https://clinicaltrials.gov/show/NCT02164942||42632|
NCT02137525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-14-022|Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain|A Randomized, Multicenter, Double-Blind, Double Dummy, Active Comparator, Dose-Ranging Study to Explore the Efficacy of SUBSYS® in Emergency Department Patients With Acute Pain||INSYS Therapeutics Inc||Not yet recruiting|May 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|176|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02137525||44735|
NCT02180919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0704/19|Implementation of Telemonitoring in Chronic Heart or Lung Failure|Implementation of Telemonitoring in the Management of Acute Exacerbations of Chronic Heart Failure and Respiratory Failure/Chronic Obstructive Pulmonary Disease|TELECRAFT|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|June 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|85|||Both|18 Years|N/A|No|||May 2010|July 2, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02180919||41410|
NCT02174029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013130|Serial Daily Diaphragm Ultrasounds in Ventilated Patients|Serial Ultrasonographic Evaluation Of Diaphragm Thickness During Mechanical Ventilation In ICU Patients||Fraser Health|No|Completed|June 2014|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|61|||Both|19 Years|N/A|No|Probability Sample|Mechanically ventilated critical ill patients|March 2015|March 9, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02174029||41935|
NCT02175251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120909|Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia|Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia: a Double Blind Sham-controlled Randomised Study|rTMS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||May 2014|June 25, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02175251||41841|
NCT02175225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000005/11|Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial|Study of Deferoxamine Mesylate in Intracerebral Hemorrhage||Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175225||41843|
NCT02175537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPRP2014-2017|Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar|Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar||Microclinic International|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02175537||41819|
NCT02175836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17/25-10-2006|Arrhythmia Prediction Trial|Arrhythmia Prediction Trial and Risk Stratification in Heart Failure Patients - Athens.|APRET|University of Athens|No|Recruiting|October 2007|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|82 Years|No|Probability Sample|Heart Failure Patients with Myoacardial Infarction and Dilated Cardiomyopathy maintaining        sinus rhyhtm.|January 2016|January 27, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175836||41796|
NCT02176083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-1|Reproductive Health Survivorship Care Plan Pilot|Intervening on Reproductive Health in Young Breast Cancer Survivors||University of California, San Diego|No|Completed|March 2014|December 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|45 Years|No|||December 2015|December 2, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02176083||41777|
NCT02176096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-097|Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial|Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial|Glycosade GSD|University of Manitoba|Yes|Active, not recruiting|July 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|5 Years|18 Years|No|||August 2015|August 20, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176096||41776|
NCT02176369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-MANILA12|Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial|Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial|ONC-MANILA12|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|February 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02176369||41755|
NCT02176382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000853|Denosumab and Teriparatide Study (DATA-2)|Denosumab and Teriparatide Study (DATA-2)|DATA-2|Massachusetts General Hospital|Yes|Recruiting|August 2014|||October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|45 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176382||41754|
NCT02176694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1184|Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care|Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care.|ACT Me|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|29|||Both|12 Years|21 Years|No|||February 2016|February 1, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02176694||41731|
NCT02166476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 505|Efficacy, Safety, Tolerability of Carbavance Compared to Piperacillin/Tazobactam in cUTIs, Including AP, in Adults|A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/RPX7009) Compared to Piperacillin/Tazobactam in the Treatment of cUTIs, Including AP, in Adults||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|Yes|Recruiting|July 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02166476||42515|
NCT02166190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014843|RFA RCT for Pancreatic or Bile Duct Cancer|Randomized Controlled Trial Comparing Radiofrequency Ablation and Stenting vs. Stenting Alone for Biliary Obstruction Due to Unresectable Cholangiocarcinoma and Pancreatic Cancer|RFA RCT|Weill Medical College of Cornell University|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02166190||42536|
NCT02167230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBT|Jailed-balloon Technique in Coronary Bifurcation Lesion PCI|Effect of Jailed-Balloon Technique in Percutaneous Coronary Intervention for Non-Left Main Coronary Bifurcation Lesions: A Prospective, Randomized Study.|JBTinCBL|Guangdong General Hospital|Yes|Not yet recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|75 Years|No|||June 2014|June 17, 2014|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167230||42457|
NCT02136446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EchoCath|Prospective Post-market Evaluation of an Echogenic Catheter|Prospective Post-market Evaluation of an Echogenic Catheter Used in a Peripheral Nerve Block Procedure|EchoCath|Smiths Medical, ASD, Inc.|Yes|Recruiting|September 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02136446||44818|
NCT02136459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIVUH1|Non-neural Vocal Changes After Thyroidectomy|Assessment of Non-neural Voice Changes in Thyroidectomy Patients: A Randomized Control Trial||South Infirmary-Victoria University Hospital|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02136459||44817|
NCT02136758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-07|Cardiovascular Risk Clinic|Cardiovascular Risk Clinic|CRC|Windber Research Institute|No|Terminated|April 2009|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|207|||Both|18 Years|85 Years|No|||May 2014|May 8, 2014|May 8, 2014||No|Funding cut due to government sequestration|No||https://clinicaltrials.gov/show/NCT02136758||44794|
NCT02168010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vw1401|Analgecine for Treatment of Low Back Pain|Efficacy and Safety of Analgecine for Low Back Pain: a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial||VanWorld Pharmaceutical (Rugao) Company Limited|Yes|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|584|||Both|18 Years|70 Years|No|||August 2014|December 8, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02168010||42398|
NCT02137863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/345|Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy|Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy||TC Erciyes University|No|Completed|June 2011|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02137863||44709|
NCT02164383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1606|A Quit Smoking Study Using Smartphones|A Quit Smoking Study Using Smartphones||University of Wisconsin, Madison|No|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02164383||42675|
NCT02164396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005277|Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds|Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds||Johnson & Johnson Vision Care, Inc.|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|May 2, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02164396||42674|
NCT02137538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI growth study|Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole|Randomization to Letrozole vs. Anastrozole in Short Pubertal Males||Stanford University|No|Recruiting|November 2009|||November 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|10 Years|17 Years|No|||November 2014|November 17, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02137538||44734|
NCT02138149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-22|Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?|||Swiss Paraplegic Centre Nottwil|No|Completed|November 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|47|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|individuals suffering from neurogenic lower urinary tract dysfunction, namely neurogenic        detrusor overactivity|November 2015|November 16, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02138149||44687|
NCT02173769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.56|Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy|AKTIV: Changes in Physical Functioning in Patients With COPD During Therapy With a Combination of Spiriva® Respimat® + Striverdi® Respimat® or Spiriva® 18 Mikrogramm + Striverdi® Respimat®||Boehringer Ingelheim||Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1845|||Both|40 Years|N/A|No|Probability Sample|Patients|April 2015|April 29, 2015|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173769||41955|
NCT02173782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1349|Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Placebo-controlled, Within-device, Double-blind Tri-national Study to Compare the Safety and Efficacy of Berodual® Administered Via the Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d) in COPD Patients Over a 12-week Period||Boehringer Ingelheim||Completed|February 1998|||April 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|892|||Both|40 Years|N/A|No|||June 2014|July 11, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173782||41954|
NCT02174965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiniHip|Wear and Migration in the Corin Mini-Hip/Metafix and ECIMA Polyethylene|RSA-measured in Vivo Wear, Migration and Micromotion in the Corin Mini-Hip/Metafix and ECIMA Polyethylene.|MiniHip|University of Oxford|Yes|Recruiting|September 2012|September 2022|Anticipated|September 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||June 2014|June 24, 2014|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02174965||41863|
NCT02174978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-02|Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults|Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults||U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|August 2014|September 2019|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174978||41862|
NCT02176122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12613000532707|RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.|Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.|MERINO|The University of Queensland|Yes|Recruiting|February 2014|December 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|454|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176122||41774|
NCT02175238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.28|Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects|Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects||Boehringer Ingelheim||Withdrawn|July 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|June 25, 2014||||No||https://clinicaltrials.gov/show/NCT02175238||41842|
NCT02175849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10TB|Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis|Contact Tracing by Social Network Analysis to Enhance Multi-Drug Resistant Tuberculosis Case Finding in Hanoi, Vietnam|SNAP|Oxford University Clinical Research Unit, Vietnam|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|780|Samples With DNA|Sputum Gastric Aspirate|Both|N/A|N/A|No|Non-Probability Sample|Patients with newly detected rifampicin resistant TB or MDR-TB and their contacts|July 2014|July 15, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175849||41795|
NCT02176720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009857|Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma|Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT||The Methodist Hospital System|No|Terminated|May 2014|March 2016|Actual|March 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|31|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 24, 2014|Yes|Yes|PI left HMRI|No||https://clinicaltrials.gov/show/NCT02176720||41729|
NCT02176109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gre-lam-fer|Metabolism Des LAM|Rôle Pronostique Des métabolismes du Stress Oxydatif et du Fer Dans Les Leucémies Aiguës Myéloblastiques|LAM-ROS|University Hospital, Grenoble|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|leukemic cells in order to rna and proteins study medullar plasma|Both|18 Years|N/A|No|Non-Probability Sample|de novo acute myeloid leukemic patient from 18 years to 99 years. promyelocytic leukemia        excluded|June 2013|June 25, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176109||41775|
NCT02176395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH20140604|Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke|Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke||China Academy of Chinese Medical Sciences|Yes|Recruiting|June 2014|||August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|46|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 27, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02176395||41753|
NCT02176707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014RESP03L|Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis|Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis||University of East Anglia|Yes|Not yet recruiting|June 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|40 Years|N/A|No|Non-Probability Sample|Patients will be identified by hospital databases, patient registries and clinical notes        and approached by the patients' attending physician or clinical team.|June 2014|June 26, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176707||41730|
NCT02176993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201215226|Effects of Surface Cooling On Stroke Outcome triaL (COOL)|Effects of Surface Cooling On Stroke Outcome triaL: a Feasibility and Safety Study|COOL|Universitair Ziekenhuis Brussel|No|Recruiting|April 2014|August 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient older than 18 year presenting with an acute stroke and onset < 24 hours.|July 2014|July 2, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176993||41709|
NCT02177266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008553|Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation|Colchicine Versus Placebo in Post-Cardiac Surgery Patients to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation||Mayo Clinic|Yes|Not yet recruiting|June 2014|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|242|||Both|40 Years|N/A|No|||June 2014|June 25, 2014|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177266||41688|
NCT02166489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Kidney-003|Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease|Evaluation the Effect of Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease||Royan Institute|Yes|Completed|March 2014|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||November 2015|January 3, 2016|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02166489||42514|
NCT02136186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003548|Home Telemonitoring in Patients at High Risk for Readmission|Home Telemonitoring in Patients at High Risk for Readmission||Mayo Clinic|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1900|||Both|18 Years|99 Years|No|||September 2015|September 25, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02136186||44838|
NCT02137018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36Pa|"Nanotechnologies Applied to General Surgery and Emergency Surgery: Buckypaper as a New Fixing Method for Prosthetic Materials for the Treatment of Hernia and Incisional Hernia in Laparotomy and Laparoscopic|"Nanotechnologies Applied to General Surgery and Emergency Surgery: The Buckypaper as a New Fixing Method for Prosthetic Materials in the Treatment of Abdominal Wall Hernias, Diaphragmatic Hernias, Diaphragmatic Rupture, Incisional Hernia and Abdominal Wall Disaster in Laparotomy Procedure and Laparoscopic Procedures".|36P|University of Roma La Sapienza|Yes|Active, not recruiting|March 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Female|3 Months|6 Months|Accepts Healthy Volunteers|||May 2014|June 12, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02137018||44774|
NCT02167724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENIS CHS 2014|Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or|Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or|BUCCODOR|Centre Hospitalier Universitaire Dijon||Recruiting|September 2014|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A||||July 2015|August 19, 2015|June 17, 2014||||No||https://clinicaltrials.gov/show/NCT02167724||42420|
NCT02137265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0343|Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism|A Randomized, Double-blind, Placebo-controlled Trial of Clomiphene Citrate of Clomiphene Citrate in Hypoandrogenism and Azoospermia||University of Illinois at Chicago|No|Not yet recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|158|||Male|18 Years|N/A|No|||February 2015|February 25, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02137265||44755|
NCT02137005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0367|Cerebral Palsy Adult Transition Longitudinal Study|Walking and Its Effect on Health and Function in Individuals With Cerebral Palsy as They Transition to Adulthood: A Health Outcomes Study|CPAT|University of Colorado, Denver|Yes|Recruiting|May 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|||Both|18 Years|45 Years|No|Non-Probability Sample|Cohort will be selected from a larger cohort of 400 patients that received full,        instrumented gait analyses as children at the Center for Gait and Movement Analysis at        Children's Hospital Colorado and who are now older than 18.|January 2016|January 4, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02137005||44775|
NCT02164682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0294|The Effect of Caudal Block on the Postoperative Complications in Pediatric Patients After Hypospadias Repair|||Yonsei University|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|404|||Male|N/A|7 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric patients who underwent the first hypospadias surgery at our institution between        January, 2010 and December, 2014 (for 5 years).|August 2015|August 25, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164682||42652|
NCT02174367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1851782|An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis|An Observational Cohort Study to Evaluate Factors Affecting Prevalence of Fatty Liver Disease and Fibrosis and Factors Affecting Response to Treatment in Patients With Psoriasis|CORE|King's College London|Yes|Recruiting|November 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|Samples With DNA|Serum stored for analysis of non-invasive markers of fibrosis and DNA analysis|Both|18 Years|N/A|No|Probability Sample|Hospital outpatient clinic|June 2014|June 24, 2014|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174367||41909|
NCT02174081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDS Prediction system|ARDS Prediction Score in Critically Ill Patients in China|ARDS Prediction Score in Critically Ill Patients in China||Southeast University, China|No|Recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1|||Both|18 Years|80 Years|No|Probability Sample|patients have the risk of ARDS|May 2014|June 23, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02174081||41931|
NCT02174666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLKN 14-04-2014|Isoflavone Treatment for Postmenopausal Osteopenia.|The Effects of Red Clover Treatment on Bone Tissue Regulation in Postmenopausal Osteopenia.||University of Aarhus|Yes|Active, not recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|87|||Female|50 Years|85 Years|No|||December 2015|December 14, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02174666||41886|
NCT02175862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALH1-KF-2014|Long-term Evaluation of Patients Treated by an Emergency Medical Helicopter|Long-term Evaluation of Patients Treated by an Emergency Medical Helicopter||Rigshospitalet, Denmark|Yes|Completed|December 2009|May 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1791|||Both|N/A|N/A|No|Probability Sample|All trauma patients treated in the catchment area of PS-HEMS in a 17-month period from 1        December 2009 to 30 April 2011 (1791 patients).|October 2015|October 27, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175862|3 Years|41794|
NCT02175875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2013-005529-22|Ticagrelor for the Comatose|The Effect of Antithrombotic Treatment Administrated Through Nasogastric Tubes to Comatose Patients Undergoing Acute Percutaneous Coronary Intervention|TICOMA|Rigshospitalet, Denmark|Yes|Active, not recruiting|September 2014|February 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|plasma and urine|Both|18 Years|100 Years|No|Probability Sample|The study population consists of 50 unconscious patients, primary due to cardiac arrest or        cardiogenic shock. All patients have been undergoing recent percutaneous coronary        intervention (PCI) and are hospitalized at the cardiac intensive care unit.|October 2015|October 26, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175875||41793|
NCT02176759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rice_SFePP|Iron Absorption From Rice Fortified With Ferric Pyrophosphate|||Swiss Federal Institute of Technology||Completed|September 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|December 23, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176759||41726|
NCT02175550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-179|A 5-year Clinical Evaluation Study on NobelReplace Conical Connection Implants|An Open, Prospective, Single Cohort, Multi-centre Study Evaluating the NobelReplace Conical Connection Implants Supported Single -Unit Crowns in the Maxilla.||Nobel Biocare|No|Active, not recruiting|March 2011|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 12, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02175550||41818|
NCT02175563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tilt CPR|Tilt Cardiopulmonary Resuscitation With a Feedback Device|||Hanyang University||Completed|August 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175563||41817|
NCT02176733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2010-05|Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy||CICLO-NOHL|University Hospital, Angers||Recruiting|July 2011|||October 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2014|June 26, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176733||41728|
NCT02177006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00094207|Helping Children be Safe Outdoors With Sun Protection|Helping Children be Safe Outdoors With Sun Protection||Northwestern University|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|840|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lake Forest Pediatric Associates clinics in Lake Bluff, IL, Lindenhurst, IL and Vernon        Hills, IL|June 2015|June 15, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177006||41708|
NCT02177279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wheat Bran 2001|Bioactive Phytochemicals From Wheat Bran|Identification of Novel Bioactive Compounds in Wheat Bran|WB2001|University of Aberdeen||Completed|December 2011|||February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02177279||41687|
NCT02177630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456123456|Magnetic Resonance Imaging in Myocarditis|Myocarditis and the Role of Advanced Magnetic Resonance Imaging|MyoRacer|University of Leipzig|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Probability Sample|Patients with clinical suspicion of myocarditis|November 2015|November 30, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02177630||41660|
NCT02177929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 18353613.0.0000.5503|Study About Acting of Adaptive Sport in Musculoskeletal, Cardiovascular System and the Quality of Life of Individuals With Spinal Cord Injury Through Biomedical Instrumentation|Study About Acting of Adaptive Sport in Musculoskeletal, Cardiovascular System and the Quality of Life of Individuals With Spinal Cord Injury Through Biomedical Instrumentation|Adaptive sport|Universidade do Vale do Paraíba||Recruiting|April 2013|||June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|15 Years|40 Years|No|||June 2014|June 26, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02177929||41637|
NCT02177942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202155|A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children|A Double Blind Randomised Controlled Trial in Pre-school Age Children to Evaluate the Impact of a Nutritional Beverage Powder on Cognitive Performance Measures||GlaxoSmithKline|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|528|||Both|36 Months|65 Months|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177942||41636|
NCT02167009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH0003|Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams|Phase II, Single Arm Prospective Study to Evaluate Safety and Efficacy of Prostate Artery Embolization in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams||Tampa General Hospital|Yes|Recruiting|December 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|50 Years|85 Years|No|||June 2015|June 12, 2015|May 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02167009||42474|
NCT02135887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB104CLCT02|A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.|The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.|MB-6|Microbio Co Ltd|Yes|Recruiting|November 2013|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Observational|Time Perspective: Prospective||2|Anticipated|184|||Both|20 Years|80 Years|No|Probability Sample|A total of 184 patients with stage III colorectal cancer underwent surgery will be        recruited into the study for receiving adjuvant therapy over 18 weeks.|November 2015|November 23, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02135887||44861|
NCT02136771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no:2009-018125-70|Styrian Vitamin D Hypertension Trial|Styrian Vitamin D Hypertension Trial: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Systolic Ambulatory Blood Pressure in Vitamin D Deficient Hypertensive Patients||Medical University of Graz|Yes|Completed|June 2011|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2014|November 23, 2014|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02136771||44793|
NCT02167737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#PRO-00001450|The Emergency Department Stopping Elderly Accidents, Deaths and Injuries Program|"ED-STEADI:" The Emergency Department Stopping Elderly Accidents, Deaths and Injuries Program (A Pilot Study)|ED-STEADI|Lehigh Valley Hospital|No|Recruiting|May 2014|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|65 Years|N/A|No|||March 2016|March 1, 2016|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02167737||42419|
NCT02168036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104011629|Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.|Evaluation of the Mediastinal Lymph Nodes With Endobronchial-Guided Transbronchial Needle Aspiration in Individuals With Lung Diseases||Weill Medical College of Cornell University|Yes|Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Mediastinal tissue/ Lung biological samples|Both|18 Years|70 Years|No|Probability Sample|Patients with diseases of organs with known association with lung disease and mediastinal        lymph node involvement.|April 2015|April 20, 2015|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168036||42396|
NCT02137551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012|ABM for ACO Beneficiaries|Appointment Based Model (ABM) for Accountable Care Organization (ACO) Beneficiaries|ABM|American Pharmacists Association Foundation|No|Completed|August 2014|February 2016|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|595|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02137551||44733|
NCT02174380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-235353|Effectiveness of Active Case Finding of Household Contacts in a Routine Tuberculosis (TB) Control Program|Cost-effectiveness of a Population-based Active TB Control Program for Tuberculosis, Lima, Peru||McGill University|No|Recruiting|October 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1900|||Both|15 Years|N/A|No|||July 2014|July 7, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174380||41908|
NCT02174679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOTATATE12-001920EA|68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)|68Ga-DOTATATE Imaging in Neuroendocrine Tumors||University of California, Los Angeles||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|December 1, 2015|June 20, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02174679||41885|
NCT02179450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cognition_Facial palsy|Cognitive Function and Emotional Possessing in Bilateral Facial Palsy|Pilot Study Assessing Cognitive Function and Emotional Possessing in Patients With Bilateral Facial Palsy||Medical University of Vienna|No|Completed|August 2012|December 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|84|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Two patient groups with bilateral facial palsy, 31 patients each (group A: BEB, , group C:        BF), recruited from the Botulinum toxin outpatient's clinic and general outpatient's        clinic of the Medical University of Vienna. Two control groups, 31 patients with CD,        recruited from the Botulinum toxin outpatient's clinic of the Medical University of        Vienna, and and 31 age-and education-matched HC, will perform neuropsychological testing        of approximately 60 minutes duration at time of prominent facial palsy (baseline) and at        remission (visit 1). HC age and education matched, will be tested twice.        A total of 124 persons will be tested. All participants will sign an informed consent        form. Group A: 31 BEB Group B: 31 CD Group C: 31 BF Group D: 31 HC|June 2014|June 30, 2014|December 31, 2012||No||No||https://clinicaltrials.gov/show/NCT02179450||41522|
NCT02179463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-NeoCT-Evaluation-2014|Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer|A Multicenter Clinical Registry to Compare Different Patterns of Response Evaluation to Neoadjuvant Chemotherapy for Gastric Cancer||Peking University|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Tumor, Blood Sample|Both|18 Years|N/A|No|Probability Sample|Locally advanced Gastric Cancer(cT2-4NanyM0)，estimated to do neoadjuvant chemotherapy|December 2014|December 6, 2014|June 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179463|5 Years|41521|
NCT02179723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSNMedicalC09962|Clinical Study Into the Cosmetic Results of Leukosan Adhesive|Clinical Study Into the Cosmetic Results of Leukosan Adhesive vs. Transcutaneous Wound Suture With Laparoscopic Trocar Incision||BSN Medical GmbH|No|Completed|March 2012|July 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|60 Years|No|||June 2014|June 30, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179723||41501|
NCT02179736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1312|A Post Market Evaluation After Treatment of Nasolabial Folds|||Q-Med AB|No|Completed|July 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|January 12, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02179736||41500|
NCT02179944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014p000824|Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion|Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion: A Prospective Physiologic Study||Planned Parenthood League of Massachusetts|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adult patients seeking medication abortion from an outpatient health center|August 2015|August 14, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179944||41484|
NCT02171195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-101|A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093|A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 When Given to Healthy Male Adult Volunteers.||Bial - Portela C S.A.|No|Completed|July 2000|October 2000|Actual|October 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|64|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 20, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02171195||42153|
NCT02171598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.83|Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects|Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic and Pharmacodynamic Parameters, and Additionally the Impact of Single Oral Doses of 300 mg and 600 mg of Clopidogrel Administered Under Steady State Conditions of Dabigatran of 75 mg and 150 mg in Healthy Male Subjects||Boehringer Ingelheim||Completed|February 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171598||42122|
NCT02181361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-4-3|The Secondary Prevention of Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke|The Effectiveness and Safety of Aspirin Plus Hirudin in the Secondary Prevention of Cardioembolic Stroke|CE|Xijing Hospital|Yes|Recruiting|June 2014|October 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|85 Years|No|||September 2013|January 21, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02181361||41376|
NCT02172001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-IDA-02|A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo|A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy||Pharmacosmos A/S|No|Withdrawn||||March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 21, 2014|Yes|Yes|Study design not adequate|No||https://clinicaltrials.gov/show/NCT02172001||42091|
NCT02172495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.278|Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice|Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice||Boehringer Ingelheim||Completed|June 2002|||October 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4700|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172495||42053|
NCT02181959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1114.10|Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers|Safety and Tolerability of PHARMATON Capsules vs PHARMATON Capsules With DMAE vs Placebo in Healthy Volunteers (A Double-blind, Controlled Multicentre Study)||Boehringer Ingelheim||Completed|December 1998|||April 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|138|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181959||41330|
NCT02181972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118.2|Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults|Efficacy and Safety of Gingko Biloba Film-coated Tablets (2 x 60 mg Daily p.o.) in Improving Cognitive Functions and Neuropsychological Functioning of Middle-aged Cognitively Intact Adults: a Double-blind, Placebo-controlled, Parallel Group, Randomised Trial||Boehringer Ingelheim||Completed|May 2002|||November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181972||41329|
NCT02181985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.10|Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)|A Phase IIIb, Randomised, Open Label Trial With 3 Parallel Groups: Full Dose TNK-tPA Together With Heparin Sodium, Full Dose TNK-tPA Together With Enoxaparin, and Half Dose TNK-tPA Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction: ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens)|ASSENT 3|Boehringer Ingelheim||Completed|May 2000|||April 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5989|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181985||41328|
NCT02180373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCures|PREDICT-PVI Understanding Peripheral Restenosis: Genomic and Proteomic Determinants of Vascular Intervention|Understanding Peripheral Restenosis: Genomic and Proteomic Determinants of Vascular Intervention||Vascular Cures|No|Enrolling by invitation|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Whole blood from 3 timepoints plus 1 tube of plasma; for vein graft bypass arm, otherwise      discarded vein tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced peripheral artery disease already undergoing treatment by        participating vascular surgeons, who are either having vein graft (VG) bypass or        superficial femoral artery (SFA) stenting. These procedures are unrelated to this study.        Enrollment is at the discretion of the participating vascular surgeon in addition to        meeting inclusion criteria.|July 2014|July 1, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180373|2 Years|41451|
NCT02173860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVEIT351|Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery Disease|Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery Disease. AngIography vs Fractional Flow Reserve|SAVE-IT|Portuguese Society of Cardiology|Yes|Not yet recruiting|March 2016|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|502|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173860||41948|
NCT02173873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV 2014-194|Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I|Ziv-aflibercept in Eyes With Eyes With Retinal Diseases and Poor Vision-phase I|ZIV|Rafic Hariri University Hospital|Yes|Recruiting|June 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|95 Years|No|||June 2014|June 23, 2014|June 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173873||41947|
NCT02173886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP|A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery|||North Dakota State University|No|Active, not recruiting|June 2014|December 2015|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02173886||41946|
NCT02174146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|leptin_visfatin_diabetes|Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy|Effect of Non-surgical Periodontal Therapy on Leptin and Visfatin Expression in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Utilizing ELISA and Real Time PCR||Cairo University|Yes|Completed|September 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|50|||Both|35 Years|54 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174146||41926|
NCT02174159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8507-003|Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of MK-8507 in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|60 Years|No|||August 2015|August 4, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174159||41925|
NCT02174172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29322|A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors|A PHASE I STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH IPILIMUMAB OR INTERFERON-ALPHA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS||Hoffmann-La Roche||Recruiting|August 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174172||41924|
NCT02174458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC_QoL_EK_311/13|Body Contouring Surgery After Massive Weight Loss|Outcome in Body Contouring Surgery After Major Weight Loss - a Prospective Matched Single Blind Study||University Hospital, Basel, Switzerland|No|Completed|January 2014|June 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|||Both|18 Years|90 Years|No|Non-Probability Sample|Post-bariatric male and female patients and patients with no history of bariatric surgery        but after natural weight loss and some degree of skin laxity who underwent body-contouring        surgery between February 1999 and October 2009 at the Department of Plastic,        Reconstructive and Aesthetic Surgery, Handsurgery, University Hospital of Basel will be        included. Patients after BS with equal distributions and demographic characteristics but        no secondary reconstructive procedures served as a control group.|March 2015|March 17, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174458|10 Years|41902|
NCT02174757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUL_SMIDS_PERIO_01|Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis|A Comparative Evaluation of the Effect of Probiotic Inersan and Doxycycline on Chronic Periodontitis - A Clinical and Microbiological Study||CD Pharma India Pvt. Ltd.|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|25 Years|60 Years|No|||December 2014|December 12, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02174757||41879|
NCT02175680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140_CD 01|Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection|A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection||CytoDyn, Inc.|Yes|Recruiting|May 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175680||41808|
NCT02175914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-RK-0519-CTIL|Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis|Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough.||Tel-Aviv Sourasky Medical Center|No|Recruiting|June 2014|June 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|November 26, 2012||No||No||https://clinicaltrials.gov/show/NCT02175914||41790|
NCT02179190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRD-001|Study of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/ Branching Aneurysms|Prospective, Multi-Center, Single-Arm Study of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/ Branching Aneurysms of Middle Cerebral and Basilar Arteries||Medtronic Neurovascular Clinical Affairs|Yes|Recruiting|June 2014|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|164|||Both|18 Years|85 Years|No|||September 2015|September 3, 2015|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179190||41542|
NCT02179476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUET 001-003|A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome - DUET|A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome (DUET)|DUET|Zyga Technology, Inc.|Yes|Recruiting|June 2014|December 2024|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|22 Years|N/A|No|||February 2016|February 23, 2016|January 28, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179476||41520|
NCT02179749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA023152|Mifepristone Treatment of Alcohol Use Disorder|Glucocorticoid Antagonist Treatment of Alcohol Use Disorder||The Scripps Research Institute||Recruiting|September 2014|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179749||41499|
NCT02179957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/066|Visual Estimation of Coronary Fractional Flow Reserve From High-definition Computed Tomographic Coronary Angiography|Visual Estimation of Coronary Fractional Flow Reserve From High-definition Computed Tomographic Coronary Angiography||Plymouth Hospitals NHS Trust|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|85|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary stenoses which have been analysed with both CT and FFR|June 2014|July 1, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179957||41483|
NCT02180555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 12/2/22|Diabetes Mellitus After Intensive Care Admission|Incidence and Predisposing Factors for the Development of Glucose Metabolism Disturbances and Diabetes Mellitus After Intensive Care Admission|DIAFIC|University Hospital, Antwerp||Recruiting|February 2012|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients|July 2014|July 7, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180555||41437|
NCT02180867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01340|Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery|Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)||National Cancer Institute (NCI)|Yes|Recruiting|July 2014|||June 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|340|||Both|2 Years|N/A|No|||October 2015|March 24, 2016|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180867||41414|
NCT02171208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV112|A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers|A Randomized, Double-Blind, Crossover Study in Healthy Volunteers to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers (Vifor SA and Biogen Idec OSD)||Biogen|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|June 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02171208||42152|
NCT02171221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13-11038|Phase I Study of Oral DFP-11207 in Solid Tumors|A Phase I Study of Once-Daily Oral DFP-11207 in Patients With Solid Tumors||Delta-Fly Pharma, Inc.||Recruiting|June 2014|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02171221||42151|
NCT02181374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-25|The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation.|The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation|CE|Xijing Hospital|Yes|Recruiting|January 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|NT-proBNP|Both|18 Years|85 Years|No|Probability Sample|18 ≤ Age ≤ 85; meet the clinical diagnostic criteria for acute ischemic stroke; onset        within 24 hours at the same time more than one hour; it was diagnosed with experiential        doctor.|December 2015|December 30, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02181374|5 Years|41375|
NCT02181387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 23934|Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?|Does Acetaminophen Reduce Neuraxial Analgesic Requirement During Labor||Wake Forest School of Medicine|Yes|Enrolling by invitation|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|55 Years|No|||August 2015|August 31, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02181387||41374|
NCT02172859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2B-05|Dietary Influence on Serotonin in Cognitive and Emotional Functioning in Women|Dietary Influence on Serotonin in Cognitive and Emotional Functioning in Women Using a Tryptophan-rich Protein Over 19 Days|P2B_UK|DSM Nutritional Products, Inc.|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|59|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02172859||42025|
NCT02181673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103796|A Study of Golimumab in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2014|April 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181673||41352|
NCT02172456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.238|Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)|γ-Scintigraphic Evaluation of the Lung Deposition Rate and Distribution Pattern of a 99mTc-Labelled Tiotropium Powder Formulation Following Multiple Dose Inhalation of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With COPD||Boehringer Ingelheim||Completed|May 2002|||October 2002|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172456||42056|
NCT02172833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312061RINB|Antibiotic-associated Coagulopathy|Antibiotic-associated Coagulopathy||National Taiwan University Hospital|No|Recruiting|January 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|500|||Both|20 Years|N/A|No|Probability Sample|Patients aged older than 20 years old using antibiotics for more than 48 hours in the        emergency department in National Taiwan University Hospital and in in LHID 2000, 2005, and        2010 cohort derived from National Health Insurance Research Database|December 2014|December 30, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02172833||42027|
NCT02180061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-041|Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)|Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma||Merck Sharp & Dohme Corp.|No|Active, not recruiting|July 2014|March 2017|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|35|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180061||41475|
NCT02173899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02079605|Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine|A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine||Changchun Keygen Biological Products Co., Ltd.|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|716|||Both|1 Year|7 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02173899||41945|
NCT02173912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CCA_102|Bioequivalence Study of CJ-30059|Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers.|CCA|CJ HealthCare Corporation|No|Recruiting|June 2014|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|32|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02173912||41944|
NCT02174185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-18-530605|Compare the Quality of Life Between Patients With Conduit Diversions or Orthotopic Neobladders|A Prospective and Comparative Study of Health-related Quality of Life (HRQoL) in Patients With Conduit Diversion or Orthotopic Neobladder||Huazhong University of Science and Technology|No|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All eligible patients in Wuhan Union Hospital, Huazhong University of Science and        Technology.|August 2014|August 1, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02174185||41923|
NCT02174471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306102|Regression of Myocardial Fibrosis After Aortic Valve Replacement|REgression in Left Ventricular Interstitial Expansion and Fibrosis After Aortic Stenosis Surgery|RELIEF-AS|University College, London|No|Recruiting|October 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Serum and Plasma; myocardial biopsy obtained intra-operatively.|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with severe aortic stenosis awaiting valve replacement recruited from cardiology        outpatient department or as cardiology inpatients.|May 2015|May 26, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174471||41901|
NCT02174770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|395166|Blood Flow Restriction Training in Rehabilitation Patients|Blood Flow Restriction Training Versus Standard Physical Therapy in Post-Operative and Post-Traumatic Rehabilitation Patients||Brooke Army Medical Center|No|Not yet recruiting|July 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|160|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174770||41878|
NCT02175095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT-PET-regorafenib|[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib|3'-Deoxy-3'-18F-fluorothymidine Positron Emission Tomography ([18F] FLT-PET) for the Prediction of Response to Regorafenib in the Metastatic Colorectal Cancer Patients Who Progressed After All Standard Therapies||Asan Medical Center|No|Recruiting|July 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|68|||Both|20 Years|N/A|No|||January 2016|January 12, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02175095||41853|
NCT02175381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.04|Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC|A Phase I/II Trial of the Carboplatin/Gemcitabine Combination as First Line Treatment for Elderly Patients With Stage IV NSCLC.||Hellenic Oncology Research Group|No|Completed|February 2011|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|70 Years|N/A|No|||May 2015|May 14, 2015|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02175381||41831|
NCT02175394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.44|Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects|An Open, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1356 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel||Boehringer Ingelheim||Completed|July 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|June 25, 2014||||No||https://clinicaltrials.gov/show/NCT02175394||41830|
NCT02175407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-CL-0030|A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects|A Phase 1, One Sequence, Cross-over Pharmacokinetic Study to Assess the Interaction Between ASP1707 and Itraconazole, a CYP3A and P-gp Inhibitor in Healthy Female Subjects||Astellas Pharma Inc|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175407||41829|
NCT02175706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.6|DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity|DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All-Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2).|DUTCHPEERS|Thorax Centrum Twente|No|Active, not recruiting|November 2010|June 2017|Anticipated|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1811|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02175706||41806|
NCT02175719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB02T|Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A|||Eisai Inc.||Recruiting|April 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Probability Sample|Patients with cervical dystonia who was treated by botulinum toxin type A in the past.|November 2015|November 20, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175719||41805|
NCT02175992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/546|Quality of Life After Surgery for Pancreatic Carcinoma|Quality of Life After Surgery for Pancreatic Carcinoma||UMC Utrecht|No|Recruiting|March 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients with a suspected pancreatic malignancy|June 2014|June 25, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175992|24 Months|41784|
NCT02175641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN5207|Peer-Led Healthy Lifestyle Program in Supportive Housing|Peer-Led Healthy Lifestyle Program in Supportive Housing Agencies||Columbia University|Yes|Recruiting|July 2015|June 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175641||41811|
NCT02175654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-14-01|Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab|Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab|PREVIUM|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02175654||41810|
NCT02179203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP021|Changes in Doppler Signals From the Lung Due to Cardiac Resynchronization in Heart Failure Patients|Lung Doppler Signals Changes in Response to Cardiac Resynchronization in Heart Failure Patients||Echosense Ltd.|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with indication for cardiac snchronization therapy|June 2014|August 12, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179203|1 Day|41541|
NCT02180568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEV2013-0740|Lipiodol Localization for Ground-glass-opacity Minimal Surgery|Validation Study to Evaluate the Safety and Efficacy of Preoperative Computed Tomography-guided Localization Technique Using Lipiodol for Patients With Ground Glass Opacity Pulmonary Lesions: A Prospective Multicenter Study|LOGIS|Severance Hospital|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|20 Years|70 Years|No|||July 2014|July 1, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180568||41436|
NCT02180581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-032|Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare|Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare|ProbiComp|University of Copenhagen|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|270|||Both|8 Months|14 Months|Accepts Healthy Volunteers|||September 2014|September 10, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180581||41435|
NCT02180880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuropathicPain|Symptom Based Treatment of Neuropathic Pain|Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial||CHA University|No|Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|20 Years|N/A|No|||August 2014|August 18, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02180880||41413|
NCT02170766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.15|Bioavailability of BIBR 953 ZW in Healthy Subjects|Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 25, 50 or 100 mg BIBR 1048 MS Film-coated Tablet With and Without Pre-treatment With Pantoprazole to Healthy Subjects. Four Groups, 2-way Crossover, Randomised, Open Trial.||Boehringer Ingelheim||Completed|October 2000|||December 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170766||42186|
NCT02172014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV_fentanyl|Safety and Efficacy of Fentanyl Citrate in Children|Safety and Efficacy of Fentanyl Citrate in Combination With Midazolam in Critically Ill Children With Mechanical Ventilation||Seoul National University Hospital|Yes|Completed|June 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|44|||Both|2 Months|18 Years|No|||November 2015|November 23, 2015|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02172014||42090|
NCT02171611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.87|Bioavailability of Different Applications of Dabigatran in Healthy Volunteers|Relative Bioavailability of Dabigatran After Administration of Different Application Forms of a Single Oral Dose of 150 mg Dabigatran Etexilate (Capsule, Powder for Reconstitution Into Solution, Pellets on Food) in Healthy Male and Female Volunteers (an Open-label, Randomised, Three-way Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|March 2009|||May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171611||42121|
NCT02171624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.90|Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate|A Two-way Crossover Study to Evaluate the Safety and Pharmacokinetics of Quinidine Sulfate Alone (200 mg Orally q2h to a Maximum of 1,000 mg), Dabigatran Etexilate Alone (150 mg BID for Three Days), and the Co-administration of Dabigatran Etexilate (150 mg BID) With Quinidine Sulfate (200 mg q2h)||Boehringer Ingelheim||Completed|March 2009|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171624||42120|
NCT02171637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.1|Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|November 2003|||February 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171637||42119|
NCT02171650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.17|BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open-label Extension Study of 1200.1 and 1200.2 of Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|December 2004|||May 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171650||42118|
NCT02172469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.243|Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of 18 µg of Tiotropium Inhalation Capsules and Atrovent® Metered Dose Inhaler (2 Puffs of 20 µg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|May 2001|||April 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|215|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172469||42055|
NCT02172482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.277|Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice||Boehringer Ingelheim||Completed|June 2002|||October 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63127|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172482||42054|
NCT02172508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.289|Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation|A Randomised, Double-blind, Placebo-controlled 7-week Trial to Investigate the Effects of Tiotropium Inhalation Capsules (18 μg) Once Daily on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation.||Boehringer Ingelheim||Terminated|January 2004|||March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|15|||Both|40 Years|75 Years|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172508||42052|
NCT02173132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2010|Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy|||University of Catania||Completed|April 2010|||November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|33 Years|68 Years|No|||June 2014|June 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173132||42004|
NCT02173392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130307|A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab|A Bioequivalence Study Comparing a Single Subcutaneous Injection With a 1.5 mL Prefilled Syringe Versus 2 Subcutaneous Injections of 1 mL and 0.5 mL Prefilled Syringes of Brodalumab 140 mg/mL to Healthy Subjects||Amgen|No|Completed|September 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|June 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02173392||41984|
NCT02181478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Z14|Intra-Osseous Co-Transplant of UCB and hMSC|Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study||Case Comprehensive Cancer Center|No|Recruiting|July 2015|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181478||41367|
NCT02181491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811004457|PET Imaging in Cocaine Self Administration|||Yale University|Yes|Active, not recruiting|July 2014|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181491||41366|
NCT02174198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM4053|Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting|The Esthetic Effect of Bio-OSS Collagen® on the Mid-facial Gingival Dimensions When Placed Into Gaps Between 3i® Implants Placed Into Fresh Extraction Sockets and the Labial Plate of Bone||Columbia University|No|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174198||41922|
NCT02174211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number: 2012-005500-18|Effect of Vitrectomy and Posterior Vitreous Detachment on Intravitreal Ranibizumab Pharmacokinetics|A Study of the Effect of Vitrectomy and Posterior Vitreous Detachment on Ranibizumab Pharmacokinetics.|VITCLEAR|King's College Hospital NHS Trust|No|Recruiting|June 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|55 Years|N/A|No|||January 2016|January 22, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174211||41921|
NCT02174484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS057|Assessment of Intracardiac Electrograms Transmitted by Home Monitoring for the Remote Follow-up of Pacemaker (PREMS)|Pacemaker Remote Electrogram Monitoring Study (PREMS)|PREMS|Biotronik SE & Co. KG|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|571|||Both|18 Years|N/A|No|Probability Sample|Patient implanted with a single or dual chamber pacemaker and with the Biotronik        Home-Monitoring® system activated|January 2016|January 6, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174484||41900|
NCT02175108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00093759|Diet and Activity in Cerebral Palsy|DIET, ACTIVITY AND MEDICAL CO-MORBIDITIES IN ADOLESCENTS and ADULTS WITH CEREBRAL PALSY: WHAT ARE THE EFFECTS ON THE METABOLIC PROFILE?||Rehabilitation Institute of Chicago|No|Recruiting|June 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|16 Years|89 Years|No|Non-Probability Sample|Adolescents (16-17) and adults with cerebral palsy|September 2015|September 1, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02175108||41852|
NCT02175121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4801011|Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus||Pfizer|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|172|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175121||41851|
NCT02175420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG-TFV1|Role of BCG as Booster Vaccination|Role of BCG Vaccination as Booster on Salmonella Typhi Vaccine||Radboud University|No|Completed|July 2012|November 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02175420||41828|
NCT02175693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB01S|Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia|||Eisai Inc.||Recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Patients with cervical dystonia|November 2015|November 20, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175693||41807|
NCT02176005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAV132-CL-1002|Safety and Efficacy Study of DAV132 in Healthy Volunteers|Influence of the Administration of DAV132 7.5g Tid for 7 Days on the Fecal Levels of Moxifloxacin During and After a 5-day Oral Treatment With Moxifloxacin 400mg Oad in Healthy Volunteers||Da Volterra|No|Completed|March 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176005||41783|
NCT02176252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00005|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects|A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722||Ardelyx|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|83|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|November 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02176252||41764|
NCT02175953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO020|Short-term Caregiver Psychotherapy|Psychotherapeutical Short-term Intervention for Caregivers of Persons With Dementia||University of Rostock|No|Active, not recruiting|June 2014|May 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|13|||Both|18 Years|100 Years|No|||December 2015|December 9, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175953||41787|
NCT02179216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00695-42|Evaluation of the Effect of Hydration About Orthostatic Hypotension in the Elderly. Difference With Venous Compression|Evaluation of the Effect of Hydration About Orthostatic Hypotension in the Elderly. Difference With Venous Compression. A Randomized Controlled Crossover Trial.|CHHO|Central Hospital, Nancy, France|Yes|Recruiting|July 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|75 Years|N/A|No|||October 2015|October 1, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179216||41540|
NCT02180269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104614|A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Japanese Male Subjects||Janssen Pharmaceutical K.K.|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Male|55 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180269||41459|
NCT02180282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-M22-IPL-14-01|Impact of the M22-IPL Acne Filter on Acne Vulgaris|Impact of the M22-IPL Acne Filter on Acne Vulgaris||Lumenis Ltd.|No|Terminated|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|July 1, 2014|Yes|Yes|Low recruiting rate|No||https://clinicaltrials.gov/show/NCT02180282||41458|
NCT02180295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-014|A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)|A Phase III, Double-Blind, Lot-To-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults||Merck Sharp & Dohme Corp.|No|Withdrawn|July 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|50 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180295||41457|
NCT02170441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0099|Global Consortium for Drug-resistant Tuberculosis Diagnostics|Global Consortium for Drug-resistant Tuberculosis Diagnostics|GCDD|University of California, San Diego|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1128|Samples With DNA|Cultured isolates, processed sputum, extracted DNA (crude lysate from sputum)|Both|5 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed or previously treated tuberculosis who are at risk for        drug-resistant tuberculosis|June 2014|June 17, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02170441||42211|
NCT02170779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1401-P|Developing and Testing a Comprehensive MS Spasticity Management Program|Developing and Testing a Comprehensive MS Spasticity Management Program||VA Office of Research and Development|No|Not yet recruiting|July 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02170779||42185|
NCT02170792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.16|Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS|Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial.||Boehringer Ingelheim||Completed|February 2001|||March 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170792||42184|
NCT02170805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.17|Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects|Bioavailability of BIBR 953 ZW After Single Oral Doses of Two Different 50 mg Capsules of BIBR 1048 MS With and Without Coadministration of Pantoprazole to Healthy Subjects Relative to Solution. Two Groups, 3-way Crossover, Randomised, Open Trial||Boehringer Ingelheim||Completed|April 2001|||June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170805||42183|
NCT02179008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-003|Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||SEE-1|Santen Inc.|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|184|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179008||41555|
NCT02178722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-202|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers||Incyte Corporation|Yes|Recruiting|June 2014|November 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|374|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178722||41577|
NCT02171663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.2|Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study of Once-daily Oral Treatment With BIBF 2992 for 21 Days in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|March 2004|||February 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171663||42117|
NCT02171676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.20|BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|May 2005|||March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171676||42116|
NCT02172521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.320|Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation|Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With COPD and Proven Hyperinflation||Boehringer Ingelheim||Completed|January 2006|||October 2006|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1536|||Both|N/A|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172521||42051|
NCT02179294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_12-151|A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour|A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour|RESPITE|University of Birmingham|Yes|Recruiting|May 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02179294||41534|
NCT02179554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03463|Does Cardiopulmonary Bypass Change Olfaction?|Does Cardiopulmonary Bypass Change Olfaction?|Anosmia|Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|50 patients undergoing elective surgery requiring cardiopulmonary bypass (study group)|February 2015|February 9, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02179554||41514|
NCT02172846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404047|Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer|A Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Proton Therapy and Chemotherapy for Non-small Cell Lung Cancer||Washington University School of Medicine|No|Recruiting|May 2014|July 2021|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02172846||42026|
NCT02168309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro34034|Oral Nifedipine Versus Oral Labetalol|Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension||Cedars-Sinai Medical Center|Yes|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2015|February 2, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02168309||42375|
NCT02168556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1351|Interventions to Decrease Anxiety in Patients Undergoing Urodynamic Testing|Interventions to Decrease Anxiety in Patients Undergoing Urodynamic Testing||The Cleveland Clinic|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|98|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02168556||42356|
NCT02181244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-059|Egg Effects on Atherogenic Dyslipidemias, Glucose Metabolism and Inflammation in Diabetic Subjects|Egg Effects on Atherogenic Dyslipidemia, Glucose Metabolism and Inflammation in Diabetic Subjects||University of Connecticut|No|Completed|May 2013|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|33|||Both|35 Years|65 Years|No|||July 2014|July 1, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02181244||41385|
NCT02174783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTMS-9500|Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients|The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial||The Cleveland Clinic|No|Recruiting|June 2014|December 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174783||41877|
NCT02175082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00093757|Cycling in Parkinson's Disease|A Forced Cycling Exercise Program in Individuals With Parkinson's Disease: Can it Improve Gait Parameters?||Rehabilitation Institute of Chicago|No|Recruiting|June 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|80 Years|No|||September 2015|September 1, 2015|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02175082||41854|
NCT02175433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS67E-14-1|A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies|A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies||Astellas Pharma Inc|No|Recruiting|August 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02175433||41827|
NCT02175732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK094863|Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes|Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes|T1REDEEM|University of California, San Francisco|Yes|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|19 Years|N/A|No|||June 2015|June 2, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02175732||41804|
NCT02176616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0279|Evaluation of Proper Radiofrequency Catheter Ablation Strategy for the Patients Who Were Changed to Paroxysmal Atrial Fibrillation From Persistent Atrial Fibrillation|||Yonsei University|Yes|Not yet recruiting|June 2014|February 2024|Anticipated|February 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|19 Years|N/A|No|||June 2014|June 25, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02176616||41737|
NCT02177162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56904|Knee Osteoarthritis Care: A Quality Improvement Intervention in Physiotherapists|Knee Osteoarthritis Care: A Quality Improvement Intervention in Physiotherapists||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|September 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2014|September 11, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177162||41696|
NCT02182050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.10|Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer|A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-small-cell Lung Cancer||Boehringer Ingelheim||Completed|August 2005|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182050||41323|
NCT02182063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.11|A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer|An Open Label Randomized Phase II Study of Oral Treatment With BIBF 1120 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen||Boehringer Ingelheim||Completed|November 2005|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Male|N/A|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182063||41322|
NCT02175966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-131|Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)|Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)|FOURward|Bristol-Myers Squibb|No|Completed|July 2014|December 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||July 2015|January 6, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175966||41786|
NCT02175979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45640.060.13|SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition|SANICS II Trial: A Multicenter Prospective Double-blind Randomized Controlled Trial Investigating the Effect of Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition|SANICSII|Catharina Ziekenhuis Eindhoven|Yes|Recruiting|August 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175979||41785|
NCT02169934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-1007|A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects|A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 Following Single Intravenous Dose Administration in Healthy Male Subjects||Trevena Inc.|No|Completed|June 2014|May 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169934||42250|
NCT02170207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254-012|Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]|Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]||Takeda|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|N/A|N/A|No|Non-Probability Sample|Acute stress ulcer and acute gastric mucosal lesions|February 2016|February 8, 2016|June 19, 2014||No||No|February 8, 2016|https://clinicaltrials.gov/show/NCT02170207||42229|
NCT02170220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_401|Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment|A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment||Takeda|No|Completed|July 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 19, 2014|No|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02170220||42228|
NCT02170454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/055/HP|Effect of Pharyngeal Inhibition by rTMS on Swallowing Function|Effect of Pharyngeal Cortical Area Inhibition Induced by rTMS on Swallowing Function in Healthy Subject: Video Fluoroscopic Study.|rTMSvideoSS|University Hospital, Rouen|No|Completed|June 2008|June 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT02170454||42210|
NCT02170467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/174/HP|Study of Intestinal Permeability in Patients With Anorexia Nervosa|Study of Intestinal Permeability in Patients With Anorexia Nervosa|PIANO|University Hospital, Rouen|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|69|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02170467||42209|
NCT02170818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001015|Improving Faculty's Ability to Speak Up to Others in the Operating Room|Improving Faculty's Ability to Speak Up to Others in the Operating Room: A Simulation Based Randomized Controlled Trial of an Educational Intervention||Massachusetts General Hospital|No|Completed|March 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|310|||Both|N/A|N/A|No|||June 2014|June 20, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02170818||42182|
NCT02171715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.35|BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers|Relative Bioavailability of a Single Dose 20 mg BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) Following Oral Administration to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Phase I Study)||Boehringer Ingelheim||Completed|January 2009|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171715||42113|
NCT02178735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404024RINC|Clinical Outcomes and Urodynamic Effects After Vaginal Tailored Mesh Surgery for Pelvic Organ Prolapse|Clinical Outcomes and Urodynamic Effects After Vaginal Tailored Mesh Surgery for Pelvic Organ Prolapse||National Taiwan University Hospital|Yes|Completed|May 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Female|20 Years|99 Years|No|||January 2016|January 27, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02178735||41576|
NCT02178748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB036|Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents|A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents|TB036|University of Oxford|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02178748||41575|
NCT02172534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.338|Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single and Multiple Doses (28-day Dosing) of Tiotropium Bromide Administered Once Daily Via the Respimat® Device in Cystic Fibrosis Patients||Boehringer Ingelheim||Completed|September 2006|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|113|||Both|N/A|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172534||42050|
NCT02172547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.364|Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.|Effect of Spiriva® 18 Microgram on Health-related Quality of Life in COPD Patients Who Stopped Smoking During Treatment.||Boehringer Ingelheim||Completed|April 2006|||January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10821|||Both|18 Years|N/A|No|Non-Probability Sample|General Practioner|June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172547||42049|
NCT02179307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trainsome 2014#002|Individual Response to Different Volumes of Resistance Training|Determinants of Intra-individual Variation in Adaptability to Resistance Training of Different Volumes||Lillehammer University College|Yes|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179307||41533|
NCT02173145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/14|Azithromycin in Idiopathic Pulmonary Fibrosis|Azithromycin for the Treatment of Cough in Idiopathic Pulmonary Fibrosis- a Clinical Trial||University Hospital Inselspital, Berne|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173145||42003|
NCT02180048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5130411|"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"|"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"||Loma Linda University|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|3||Anticipated|85|||Female|58 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02180048||41476|
NCT02179827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|362559|Performance of Non-Invasive Monitors During ANH|The Evaluation of Minimally Invasive Hemodynamic Monitors for the Assessment of Volume Responsiveness to Various Standard Replacement Fluids During Acute Normovolemic Hemodilution||University of California, Davis|No|Recruiting|October 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients scheduled for elective procedures requiring normovolemic hemodilution|June 2015|June 30, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02179827||41493|
NCT02174250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-015|The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.|Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|June 2014|December 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174250||41918|
NCT02174523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1070003|Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects|Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects||Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|No|Completed|April 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02174523||41897|
NCT02174536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCHC002|A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis|||Karolinska Institutet||Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||June 2014|June 24, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174536||41896|
NCT02174796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01811-44|Hemodynamic Repercussions of the Correction (Surgical and Non Surgical) of Pectus Excavatum-type Thoracic Deformities|Hemodynamic Repercussions of the Correction (Surgical and Non Surgical) of Pectus Excavatum-type Thoracic Deformities|PECTUS|Centre Jean Perrin|No|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|40 Years|No|||August 2015|August 11, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174796||41876|
NCT02174809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12PiccVall|Gestational Weight Gain in Primary Care|Curbing Gestational Weight Gain in Primary Care: Using Technology Based on Behaviour Change Theory||Nova Scotia Health Authority|No|Not yet recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|June 25, 2014|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02174809||41875|
NCT02174822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AVP-786-101|A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects|A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects||Avanir Pharmaceuticals|No|Completed|January 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174822||41874|
NCT02175745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRN0024|18F FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly Diagnosed or Recurrent Gliomas|18F FDOPA PET/CT or PET/MRI in Patients With Gliomas||Stanford University|Yes|Suspended|December 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|16 Years|N/A|No|||May 2015|May 22, 2015|June 24, 2014|Yes|Yes|Need to analyze recruitment strategy|No||https://clinicaltrials.gov/show/NCT02175745||41803|
NCT02176018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001AV|Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine|A Randomized Pilot Study of Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine||Cady, Roger, M.D.|No|Recruiting|August 2014|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176018||41782|
NCT02182076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.17|Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers|Safety and Pharmacokinetics/Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules With and Without Food to Healthy Male Volunteers in an Open, Randomised, Intra-individual Crossover Comparison Design||Boehringer Ingelheim||Completed|October 2005|||November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182076||41321|
NCT02182544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.258|WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis|Phase III Double-blind Comparative Study of WAL801CL Dry Syrup in Paediatric Perennial Allergic Rhinitis||Boehringer Ingelheim||Completed|June 2001|||December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|151|||Both|N/A|15 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182544||41285|
NCT02178397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLARE /GFPC 03-2013|A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR|A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR|FLARE|Centre Francois Baclesse|Yes|Terminated|June 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|June 25, 2014||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT02178397||41602|
NCT02176239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS1-13-003|Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting|Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting||AxelaCare Health Solutions, LLC|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|15 Years|85 Years|No|Non-Probability Sample|Males and Females between 15-85 years of age with any form of PIDD who are considered 5%        IVIg treatment naïve and whose physician has decided to prescribe Gammaplex® IVIg therapy.|November 2015|November 16, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176239||41765|
NCT02169674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-00049|Hepatitis B Booster Study in Adolescence|Sustaining Protection Against Hepatitis B From Infancy to Adulthood: Assessing the Case for a Booster Dose in Adolescence||University of British Columbia|No|Active, not recruiting|September 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|10 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community based, healthy children who have received 3 doses of Hepatitis B vaccine as        infants in British Columbia|November 2015|November 30, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02169674||42270|
NCT02169947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134125|Weight Loss and Maintenance for Rural, African American Communities of Faith (The WORD)|Weight Loss and Maintenance for Rural, African American Communities of Faith (The WORD)|WORD|University of Arkansas|Yes|Recruiting|March 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169947||42249|
NCT02170844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.28|Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin|Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of 50, 150 and 350 mg BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin. Double-blind at Each Dose Level, Placebo-controlled, Randomised Study||Boehringer Ingelheim||Completed|June 2004|||August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170844||42180|
NCT02171247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004492|Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)|Comparison of the Use of High Iodine Concentration Contrast Material (Isovue 370) vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)||Duke University||Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|35|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|June 12, 2014|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT02171247||42149|
NCT02171689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.25|Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 After Administration of Single Doses of 15 mg [14C]- BIBW 2992 MA2 Oral Solution in Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 2006|||August 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|35 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171689||42115|
NCT02171702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.3|Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours|A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 28 Days in Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|November 2004|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171702||42114|
NCT02171728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.4|Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open Label Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|November 2004|||September 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171728||42112|
NCT02171767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.80|Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers|Pharmacokinetics, Safety and Tolerability of BIBW 2992 Administered Orally as 20 mg, 30 mg, 40 mg, and 50 mg Tablets (Final Formulation) to Healthy Male Volunteers in an Open-label, Single Rising Dose, Phase I Trial||Boehringer Ingelheim||Completed|August 2009|||October 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171767||42109|
NCT02171780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.1|A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat®) of BI 1744 CL in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|February 2005|||July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|122|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171780||42108|
NCT02171793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.19|Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Peroral Doses (15, 30, 40 μg Free Cation) BI 1744 CL in Healthy Male Volunteers||Boehringer Ingelheim||Completed|June 2007|||July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171793||42107|
NCT02179580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH103-REC2-016|A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome|A Randomized Double Blind Placebo Control Study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT)in Patients With Irritable Bowel Syndrome||China Medical University Hospital|Yes|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|65 Years|No|||June 2014|June 30, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179580||41512|
NCT02179021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0022|Haemostasis and Therapeutic Hypothermia|Is Haemostasis Impaired in Cardiac Arrest Patients During Therapeutic Hypothermia?||University of Aarhus|No|Completed|January 2014|May 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Whole blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with mild therapeutic hypothermia for 24-48 hours due to cardiac arrest.|June 2014|November 30, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02179021||41554|
NCT02179034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307012312|Flavors and E-cigarette Effects in Adolescent Smokers|Flavors and E-cigarette Effects in Adolescent Smokers||Yale University|Yes|Recruiting|October 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|60|||Both|18 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02179034||41553|
NCT02180412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-203|Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria|A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria||The University of Texas Medical Branch, Galveston|Yes|Recruiting|April 2014|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 5, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180412||41448|
NCT02179814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/10|Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls|Neuronal Correlates of Catecholamine Depletion in Patients With Bulimia Nervosa Off Medication and Healthy Controls||University of Bern|No|Suspended|February 2012|May 2020|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 25, 2014||No|Conduct of the first analyses|No||https://clinicaltrials.gov/show/NCT02179814||41494|
NCT02180958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-ONY-002|ONYX Evaluation in the Endovascular Treatment of Cerebral Arteriovenous Malformations (cAVM)|Assessment of ONYX in Endovascular Cerebral AVM. Prospective, Multi-centre and Observational French Study.|cAVM|Medtronic - MITG|Yes|Recruiting|July 2014|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|6 Years|N/A|No|Probability Sample|All the patients from participating centres for whom a cerebral AVM (not already treated)        has to be treated (whatever treatment method anticipated) and who do not object to the        collection and transmission of data concerning them, will be included in the so-called        "screened" population.|August 2014|August 28, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02180958|36 Months|41407|
NCT02181231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406016|Buprenorphine Used With Treatment Resistant Depression in Older Adults|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|IRL Grey B|Washington University School of Medicine|Yes|Not yet recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||July 2014|July 3, 2014|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181231||41386|
NCT02174263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9130|Tocilizumab for Chronic Graft-versus-Host Disease Treatment|Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|February 2016|||August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 23, 2014|No|Yes|Study never opened due to lack of funds.|No||https://clinicaltrials.gov/show/NCT02174263||41917|
NCT02174276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-330-1401|Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment||Gilead Sciences|Yes|Active, not recruiting|August 2014|August 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|195|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174276||41916|
NCT02174549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT001|Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer|Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma||Teclison Ltd.|Yes|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|75 Years|No|||August 2015|August 25, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174549||41895|
NCT02174835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AVR-134|A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers|A Phase 1, Single-center, Randomized, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide/Quinidine Sulfate) in Healthy Volunteers||Avanir Pharmaceuticals|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174835||41873|
NCT02174848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIRCON2012V1-EXT|Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration|Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)|TIRCON-EXT|ApoPharma|Yes|Enrolling by invitation|June 2014|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|5 Years|N/A|No|||September 2015|September 11, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174848||41872|
NCT02175134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0616|IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis|IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis||Asan Medical Center|No|Recruiting|July 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|16 Years|N/A|No|||July 2014|July 4, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175134||41850|
NCT02180321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0274|Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled Trial|||Yonsei University|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|6 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180321||41455|
NCT02180334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1311-104-537|The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones|The Effect of Combination of Mosapride and Dipeptidyl Peptidase-4 (DPP-4) Inhibitor on Plasma Concentration of Incretin Hormones||Seoul National University Hospital|Yes|Not yet recruiting|July 2014|April 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|20 Years|65 Years|No|||June 2014|June 30, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180334||41454|
NCT02181166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1158-7302|Diagnosis and Management of Myofascial Pain Syndrome in Women With Mastectomies|||University of Sao Paulo||Not yet recruiting|August 2014|December 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|35 Years|70 Years|No|||July 2014|July 1, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181166||41391|
NCT02178410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL116690|VITAL Rhythm Study|Vitamin D and Omega-3 Trial (VITAL Rhythm Study)||Brigham and Women's Hospital|Yes|Active, not recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178410||41601|
NCT02177513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914135|Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics|Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|October 1, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02177513||41669|
NCT02170480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57624|Pin Size Influence the Incidence of Knee Pain|Does Pin Size Influence the Incidence of Knee Pain in Patients Undergoing Temporary Skeletal Traction?||University of Utah|No|Enrolling by invitation|April 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the University of Utah Trauma and/or Orthopaedic Trauma services        indicated for skeletal traction pin placement based on the presence of a femoral        diaphyseal fracture and/or certain pelvic and acetabular fractures.|January 2016|January 4, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170480||42208|
NCT02170831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.2|Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers|Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 50, 100, 200, and 400 mg BIBR 1048 MS Solution Administered TID for 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level||Boehringer Ingelheim||Completed|May 1999|||July 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170831||42181|
NCT02171234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-102|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093, in Young Healthy Male Volunteers.||Bial - Portela C S.A.|No|Completed|February 2001|June 2001|Actual|June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 20, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02171234||42150|
NCT02171260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-113 (ADVL1314)|This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas.||BOLD 113|Eisai Inc.|No|Recruiting|July 2014|August 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|17 Years|No|||November 2015|December 11, 2015|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171260||42148|
NCT02171741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.6|Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors|A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days||Boehringer Ingelheim||Completed|April 2005|||December 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171741||42111|
NCT02171754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.79|Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers|Relative Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) After Coadministration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Two-way Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|September 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171754||42110|
NCT02178436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-133|Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer|A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|October 2014|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|43|||Both|19 Years|N/A|No|||February 2016|February 11, 2016|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178436||41599|
NCT02178449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXATrial1|Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade|The Effect of Dexamethasone Used Together With Low Volume Ropivacaine in a Single Shot Interscalene Block on the Pain Free Time Experienced by the Patient||Landesklinikum Sankt Polten|No|Recruiting|March 2014|May 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|109|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|May 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178449||41598|
NCT02180074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRKH2SPOOLS|Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease|Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease||Louisiana State University Health Sciences Center Shreveport||Recruiting|September 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|230|Samples With DNA|Plasma.|Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects scheduled to undergo left heart catheterization or peripheral angiography        at LSUHSC Shreveport cardiac catheterization laboratory will be given the opportunity to        participate. Controls will be recruited via flyers posted in various parts of LSUHSC        Shreveport.|June 2014|June 30, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02180074||41474|
NCT02180425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|531506|The Lipid Profile of the Skin Surface in Acne|The Lipid Profile of the Skin Surface in Acne|Acne|University of California, Davis|No|Completed|November 2013|July 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|Sebum collections from sebutapes|Both|12 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be from the UC Davis Dermatology Clinic, surrounding dermatology clinics,        from the UC Davis undergraduate campus, and from the California State University        Sacramento campus.|October 2015|October 31, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180425||41447|
NCT02180438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46565-A|An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal|An Open Label Trial of STRIBILD™ (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naïve HIV-2 Infected Adults in Dakar, Senegal|Stribild HIV-2|University of Washington|Yes|Active, not recruiting|September 2014|||January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02180438||41446|
NCT02179567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.03|Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC|First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab||Hellenic Oncology Research Group|No|Terminated|March 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|70 Years|N/A|No|||September 2015|September 25, 2015|June 30, 2014||No|Terminated due to poor accrual|No||https://clinicaltrials.gov/show/NCT02179567||41513|
NCT02180971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOMINATION|Multidetector Coronary CT In Vasospastic Angina|Diagnostic Usefulness of Multidetector Coronary CT in Vasospastic Angina||Dong-A University|Yes|Recruiting|April 2014|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02180971||41406|
NCT02174861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130255|A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.|An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334||Amgen|No|Active, not recruiting|June 2014|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|612|||Both|18 Years|66 Years|No|||March 2016|March 16, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174861||41871|
NCT02182011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.5|A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)|An Open-label, Randomised, Parallel-group Comparison to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With AMI||Boehringer Ingelheim||Completed|May 2000|||June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182011||41326|
NCT02182024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.23|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group Trial||Boehringer Ingelheim||Completed|April 2005|||March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182024||41325|
NCT02175147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305555|Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease|Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease|InSup-C|Radboud University|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|576|||Both|18 Years|N/A|No|Non-Probability Sample|In Belgium, Germany, Hungary, The Netherlands and United Kingdom 3-5 'model initiatives'        of palliative care were selected. From each initiative, patients with advanced cancer,        COPD and CHF, their family and professional caregivers are recruited. Patients (and if        presented the family caregiver) are recruited by their main responsible doctor or        (research) nurse involved in the initiative under examination. Participants need to meet        the inclusion and exclusion criteria in order to be eligible for the study. A family        caregiver is defined as the person who takes care and supports the patient for most of the        time. Family caregivers are not necessarily a family member. Professional caregivers        involved in the IPC initiatives under examination are invited for the group interviews.|June 2014|June 25, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02175147|3 Months|41849|
NCT02175446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM11-BERGI|Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients|A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel|GIM11-BERGI|Consorzio Oncotech|Yes|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02175446||41826|
NCT02180906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIONEC1-MBH-2014|Biomarkers in Patients With Flesh-eating Bacterial Infections|Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response|BIONEC|Rigshospitalet, Denmark|Yes|Completed|February 2013|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|169|Samples Without DNA|Whole blood and plasma/serum|Both|18 Years|N/A|No|Probability Sample|All NSTI patients treated at the University Hospital of Copenhagen, Rigshospitalet|February 2016|February 14, 2016|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02180906||41411|
NCT02181699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2823-001|Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.||Kyowa Hakko Kirin Pharma, Inc.|Yes|Recruiting|June 2014|||March 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181699||41350|
NCT02179801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GES_SCAN|Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)|Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)|SCAN|Technische Universität München|No|Recruiting|March 2014|December 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|||Both|65 Years|N/A|No|Non-Probability Sample|Women and men with recent coronary artery bypass graft (CABG) and at least 1 risk factor        for AAA (hypertension, hyperlipidaemia, hyperuricemia, diabetes, nicotine abuse,positive        family history.|June 2014|June 30, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02179801||41495|
NCT02178683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCI-157|Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression|Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT||Colorado Blood Cancer Institute|No|Recruiting|November 2010|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||June 2014|June 27, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02178683||41580|
NCT02182154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.20|Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BIBF 1120 After Administration of Single Doses of 100 mg [14C]-BIBF 1120 Oral Solution in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2005|||November 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182154||41315|
NCT02170493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58956|Insole Sensor to Determine Optimal Limb Loading|Development and Clinical Trial of an Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of OTA Type 42IIIB and IIIC Lower Extremity Fractures||University of Utah|No|Enrolling by invitation|January 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who present to the University of Utah with an Open Tibial Fractures.|January 2016|January 4, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170493||42207|
NCT02170857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-05-2014|Effect of Hyaluronic Acid in the Treatment of Periodontal Pockets|A Randomized Controlled Trial to Evaluate the Effect of Hyaluronic Acid on Infra-bony Defects: A Radiographic and Clinical Study.||Damascus University|Yes|Active, not recruiting|June 2014|February 2017|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|65 Years|No|||March 2016|March 11, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02170857||42179|
NCT02178163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002|Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer|A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178163||41620|
NCT02178176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K18HS023445-01|Participatory Design of Patient-centered Depression and Diabetes Care|||University of Pennsylvania|Yes|Not yet recruiting|July 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178176||41619|
NCT02179320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-GDOR-MIOFASCIAL|Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome|Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome||University of Sao Paulo General Hospital|No|Active, not recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||January 2014|June 30, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179320||41532|
NCT02179840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-Brain|Assessment of Cerebral Microvascular Circulation|Assessment of Coherent Hemodynamics Spectroscopy (CHS) as a New Tool for Monitoring Cerebral Blood Flow and Autoregulation at the Microvascular Level|CHS-Brain|University of California, San Francisco|No|Not yet recruiting|March 2015|March 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02179840||41492|
NCT02179606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-13-01|Clinical Study to Evaluate the Efficacy and Safety of Dermalax Implant Plus|A Multi-Center, Randomized, Subject and Evaluator Blind, Split-Face Comparative Medical Device Clinical Study to Evaluate the Efficacy and Safety of Dermalax Implant Plus to Restylane® Sub-Q for Correction of Nasolabial Folds||Across Co.,Ltd.||Completed|July 2013|||March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||March 2014|July 4, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179606||41510|
NCT02180087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0198|Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy|Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy|LoDoNSAID|University Hospital, Clermont-Ferrand||Recruiting|February 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|75 Years|No|||July 2014|July 1, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180087||41473|
NCT02180100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUSH-GNY-2013-01|Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis|A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe||Peking University Shenzhen Hospital|No|Completed|August 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|48 Years|No|||April 2015|April 27, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180100||41472|
NCT02180711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-003|An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma|An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma||Acerta Pharma BV|No|Recruiting|July 2014|||August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180711||41426|
NCT02180763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAN-03|Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps|A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.||Octapharma|Yes|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180763||41422|
NCT02182037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1193.1|Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects|Safety, Pharmacodynamics, and Pharmacokinetics After Single Oral Administration of 1, 5, 10, 30, 100, 200 and 400 mg BIBT 1011 BS as Drinking Solution in Healthy Subjects. An Open, Placebo-controlled, Randomised Study, Double Blind at Each Dose Level||Boehringer Ingelheim||Completed|August 2001|||September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182037||41324|
NCT02182908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004852-19|FDG PET-Scan Analysis of Evolutivity of Non-surgical Aneurysm of Abdominal Aorta|ANALYSE EN MORPHO-TEP AU FDG DE L'EVOLUTIVITE DES ANEVRISMES ABDOMINAUX AORTIQUES NON CHIRURGICAUX UNE ETUDE MULTICENTRIQUE DE L'INTER-REGION NORD-EST|AAA|Central Hospital, Nancy, France|Yes|Completed|March 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|51|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02182908||41257|
NCT02182921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC/YOUNG-81100653|Evaluation of Cataract Surgery Outcome|Evaluation of Surgical Outcomes of Cataract Surgery||Evidence Based Cataract Study Group||Recruiting|August 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|90 Years|No|Probability Sample|Medical centre: Eye and ENT Hospital of Fudan University|January 2016|January 20, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02182921||41256|
NCT02178384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-RemPro-01-2014|Management of Loading Forces Distribution in Mandibular Distal-extension Prostheses|An In-vivo Study to Evaluate Three Methods of Managing the Distribution of Loading Forces in Mandibular Distal-extension Prostheses (Class I Kennedy's Classification)||Damascus University|Yes|Completed|June 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|35 Years|75 Years|No|||October 2015|October 2, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178384||41603|
NCT02179528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCHDTC001|Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)|Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer||Beijing Cancer Hospital||Not yet recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||June 2014|September 10, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02179528||41516|
NCT02181413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16019|A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|July 2014|July 2023|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|652|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181413||41372|
NCT02182557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.259|WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients|Phase III Double-Blind Comparative Study of WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients||Boehringer Ingelheim||Completed|June 2001|||January 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|162|||Both|N/A|15 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182557||41284|
NCT02182570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.260|WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients|Phase III Open-labeled Study of WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients||Boehringer Ingelheim||Completed|June 2001|||February 2002|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|N/A|15 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182570||41283|
NCT02182934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020.11|Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People|Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Recreational Sports People: a Double-blind, Placebo Controlled Pilot Study||Boehringer Ingelheim||Completed|November 1999|||April 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02182934||41255|
NCT02173418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002844-25|The Effect of Phrenic Nerve Blockade on Acute and Chronic Shoulder Pain in Patients for Lobectomy and Pneumonectomy|The Effect of Phrenic Nerve Blockade on Acute and Chronic Shoulder Pain in Patients for Lobectomy and Pneumonectomy.|TOPBLOC|Odense University Hospital|Yes|Completed|November 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02173418||41982|
NCT02173431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO0414|Recognize High Pressure Areas in Human Body to Prevent Decubitus Ulcers|Mapping Pressure of Human Body to Prevent Bedsores|BEDSORES|Assuta Medical Center|No|Not yet recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|300|None Retained|messure of pressure of patients resting on the buttres with pressure sensors|Both|18 Years|N/A|No|Non-Probability Sample|Patients from 18 y.o. before elective operation will be recruited for the study/ Any        patient will be enroled in each group' seven in total according the BMI.|June 2014|June 23, 2014|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02173431|30 Days|41981|
NCT02182609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers|A Phase I Study of Safety, Tolerance, Pharmacokinetics and Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 Administered Intravenously in Healthy Adult Volunteers||Advanced Accelerator Applications|No|Completed|April 2013|August 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02182609||41280|
NCT02182622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-LDE225|LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel|Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel||Hackensack University Medical Center|Yes|Not yet recruiting|July 2014|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|34|||Male|18 Years|N/A|No|||July 2014|July 7, 2014|June 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02182622||41279|
NCT02182115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HS022912-01|S. Aureus Screening and Decolonization|Effectiveness of Screening and Decolonization of S. Aureus in Surgery Outpatients||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02182115||41318|
NCT02182128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.19|A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours|A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|June 2006|||June 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182128||41317|
NCT02182596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYLOFRANCE 2|DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML|A Dose-finding Phase I/II Trial of Daunorubicin and Cytarabine Combined to Fractionated Mylotarg® as Re-induction Treatment in Patients With First Relapse of Acute Myeloid Leukemia|MYLOFRANCE2|Acute Leukemia French Association|Yes|Completed|June 2006|January 2011|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|70 Years|No|||July 2014|July 2, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT02182596||41281|
NCT02179047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-1030509-E|Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases|||Taipei City Hospital|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|ELISA kit for Human Galectin-3 Quantikine ELISA Kit (R&D system, Minneapolis, Mn)、Human      ST2/IL-1 R4 Quantikine ELISA Kit(R&D system, Minneapolis, Mn)、Human Cystatin C Quantikine      ELISA Kit(R&D system, Minneapolis, Mn)、 Human Lipocalin-2/NGAL Quantikine ELISA Kit(R&D      system, Minneapolis, Mn)、Human midregional pro-atrial natriuretic peptide(MR-proANP) ELISA      Kit(Cusabio, China, Cn)、Soluble ST2/IL-1R4 (HUMAN) Elisa Kit(AvisceraBioscience, Santa      Clara,Ca)|Both|20 Years|95 Years|No|Probability Sample|patients with stable angina who received coronary angiography.|November 2015|November 3, 2015|May 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02179047||41552|
NCT02179593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|464.869|Effectiveness of SARPE With 3 and 2-Segment Technique: A Randomized Clinical Trial|Effectiveness of Surgically Assisted Rapid Palatal Expansion (SARPE) With 3 and 2-Segment Technique: A Randomized Clinical Trial|3S/2S_SARPE|Federal University of São Paulo|Yes|Active, not recruiting|September 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|50|||Both|17 Years|50 Years|No|||March 2016|March 14, 2016|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02179593||41511|
NCT02179346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1304|Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects|Observational Study on the Feasibility, Safety and Efficacy in the Biological Reconstruction of the Hip Joint With Full Thickness Cartilage Defects With an in Situ Polymerizable and Chondrocyte Populated Biomaterial (NOVOCART® Inject)|HIP-ACTION|Tetec AG|No|Recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|60 Years|No|Non-Probability Sample|specialist clinical centre|December 2014|October 30, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179346||41530|
NCT02179619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HG-HADNSF-12103|Clinical Study to Evaluate the Efficacy and Safety of Dermalax(Deep) in Correction of Nasolabial Folds|A Randomized, Multi-center, Patient & Evaluator-blind, Matched Pairs, Active-controlled Design Clinical Study to Evaluate the Efficacy and Safety of Injection With Dermalax(Deep) as Compared to Restylane® in Correction of Nasolabial Fold||Across Co.,Ltd.||Completed|December 2012|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179619||41509|
NCT02179853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD Anakinra|Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease|Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease||University of California, San Diego|Yes|Recruiting|November 2014|December 2020|Anticipated|October 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Months|17 Years|No|||September 2015|September 28, 2015|June 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179853||41491|
NCT02179866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29279|A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers|SINGLE-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO5285119 IN HEALTHY MALE SUBJECTS||Hoffmann-La Roche||Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|35 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02179866||41490|
NCT02180464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 553 000- 1309|A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis|A Phase IIa, 28-day Treatment, Multi-center, Randomized, Comparator-controlled, Observer-blind Trial With Intra-individual Left/Right Comparison to Investigate the Anti-psoriatic Efficacy and the Safety of an LAS41004 Formulation in Comparison to an Active Reference in Patients With Mild to Moderate Plaque Psoriasis|Left/Right|Almirall, S.A.|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180464||41444|
NCT02180724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-WM-001|An Open-label, Phase 1b/2 Study of ACP 196 in Subjects With Waldenström Macroglobulinemia|An Open-label, Phase 1b/2 Study of ACP 196 in Subjects With Waldenström Macroglobulinemia||Acerta Pharma BV|No|Active, not recruiting|July 2014|January 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180724||41425|
NCT02180737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexmedetomidine sedation|Dexmedetomidine for Sedation During Radiological Interventional Procedures|Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures|Dexmed|National Cancer Institute, Egypt|Yes|Recruiting|January 2014|January 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||July 2014|July 1, 2014|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180737||41424|
NCT02180997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP-1207-P1-DI|Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin|A Randomized, Open-label, Six-sequence, Three-period, Three-treatment, Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin 10mg 1 Tablet and Tamsulosin 0.2mg 2 Tablets After Oral Administration in Healthy Male Volunteers||Jeil Pharmaceutical Co., Ltd.|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||July 2014|March 31, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180997||41404|
NCT02178670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-001|Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Ovarian||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2014|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|75 Years|No|||June 2014|June 1, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178670||41581|
NCT02176655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001VI|Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches|Multi-Center, Double-Blind, Placebo Controlled Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches||Cady, Roger, M.D.|No|Completed|July 2014|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|N/A|No|||February 2016|February 5, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02176655||41734|
NCT02178982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDS protocol treatments|Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome|Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome|APT|Southeast University, China|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|134|||Both|18 Years|80 Years|No|Probability Sample|ARDS patients|June 2015|June 23, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02178982||41557|
NCT02179281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-01|Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children|Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Medtronic MiniMed™ 640G Sensor Augmented Insulin Pump in Children - The SportGuard Study|SportGuard|University of Ljubljana, Faculty of Medicine|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|8 Years|18 Years|No|||March 2015|March 9, 2015|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02179281||41535|
NCT02180009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS2012009|Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis|Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis||Chinese PLA General Hospital|No|Completed|December 2013|December 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1|Samples With DNA|peripheral blood|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients with sepsis|January 2016|January 26, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180009|12 Months|41479|
NCT02177578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1426|Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme|A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|May 2014|||June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2014|June 25, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177578||41664|
NCT02173457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGZ302|Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients|Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial|CMAS|Chipscreen Biosciences, Ltd.|Yes|Recruiting|June 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|738|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02173457||41979|
NCT02177851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeSupp_Hep-2|The Optimization of Bioavailability From Iron Supplements: Study 2|The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles||Swiss Federal Institute of Technology||Completed|June 2015|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|January 20, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02177851||41643|
NCT02177864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202731|Fiber Health Benefits|Health Benefits and Tolerance of Dietary Fiber Supplements in Children||University of Iowa|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177864||41642|
NCT02174042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNTL-14-03|The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis|The Effect of Tang Ning Tongluo Formula, a Traditional Chinese Miao Medicine, in Type 2 Diabetics: A Retrospective Clinical Analysis||Guizhou Bailing Group Pharmaceutical Co Ltd|No|Completed|March 2014|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|70 Years|No|||September 2014|September 9, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174042||41934|
NCT02174055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-101|Identifying and Measuring Depression in Older Cancer Patients|Identifying and Measuring Depression in Older Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|330|||Both|70 Years|N/A|No|Non-Probability Sample|Recruitment of patients will take place at MSKCC, in ambulatory care areas (i.e.,        prostate, breast, lung, colorectal, hepatobiliary, head and neck cancers, and palliative        medicine) or through the mail using letter recruitment procedures for letter recruitment.|November 2015|November 5, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02174055||41933|
NCT02178462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-2014-1|Biomarkers for Gynecologic Cancer|Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population||Ajinomoto Co., Inc.|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|160|Samples Without DNA|Subject blood samples (plasma and serum) will be collected for testing at a single visit|Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this study will be patients with Primary endometrial and ovarian cancer,        benign gynecological diseases (such as uterine fibroids, endometriosis, dysplasia, and        benign ovarian tumors), and healthy subjects that meet the following eligibility criteria:|January 2016|January 19, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02178462||41597|
NCT02178189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09120457|RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants|Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants||University of Pittsburgh|No|Completed|April 2010|December 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|N/A|3 Days|No|||June 2014|June 26, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178189||41618|
NCT02178202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qs-2012-05-05|McKenzie Exercise Vs Harmonic Technique in Chronic Low Back Pain|Prescription of Two Exercise Therapy Protocols for Treating Chronic Low Back Pain|CLBP|University of Tehran||No longer available||||||N/A|Expanded Access|N/A|||||||Both|20 Years|65 Years||||June 2014|June 27, 2014|June 26, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02178202||41617|
NCT02178761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402003RINA|Imaging and Interventional Study for Erectile Dysfunction and Lower Urinary Tract Symptoms|Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: A Multi-modality, Multi-Specialty Collaborative Study (PERFECT Program)|PERFECT|National Taiwan University Hospital|Yes|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Male|20 Years|N/A|No|||June 2014|June 30, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02178761||41574|
NCT02179632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0727|Disclosure of Industry Payments to Physicians and the Patient-Doctor Relationship|Disclosure of Industry Payments to Physicians and the Patient-Doctor Relationship||Harvard Medical School|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|278|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|July 1, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02179632||41508|
NCT02179879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM4(U)01/10/13|Development and Validation of Metrics Lumbar Labor Epidural Catheter Placement|Protocol for Development and Validation of Metrics for Conventional Lumbar Epidural Catheter Placement for Labor Analgesia in Obstetric Patients||Cork University Hospital|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|20 Years|70 Years|No|Probability Sample|Expertes and novice anaesthetist perfoming labor epidural analgesia|August 2015|August 26, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179879||41489|
NCT02180113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M116|Spleen Stiffness Measurement With FibroScan|Feasibility and Performances of Spleen Stiffness Measurement as Surrogate Marker for Oesophageal Varices in Cirrhotic Patients.||Echosens|No|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2014|August 10, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180113||41471|
NCT02180126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC0041-14|Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|August 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Patients with borderline positive ANCA test results who had been hospitalized at the        Hillel Yaffe Medical Center.|July 2014|July 1, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180126||41470|
NCT02180789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAURO-1201-TW|A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation|An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg||Astellas Pharma Inc|No|Completed|March 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|45 Years|N/A|No|||November 2015|November 17, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180789||41420|
NCT02180451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-1401|Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)|Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)||Vanda Pharmaceuticals|No|Active, not recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Melatonin and Cortisol samples will be collected|Both|6 Years|50 Years|No|Non-Probability Sample|Smith-Magenis patients|March 2016|March 24, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02180451||41445|
NCT02180750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWT01|Phase II Randomised Controlled Trial of Memory Work Therapy at PASADA, Tanzania|An Evaluation of a Psychosocial Intervention for Orphans With HIV Infection: a Phase II Randomised Controlled Trial of Memory Work Therapy at PASADA, Tanzania|MWT|Pastoral Activities and Service for AIDS Dar-Es-Salaam Archdiocese|No|Active, not recruiting|June 2013|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|48|||Both|14 Years|18 Years|No|||July 2014|July 1, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02180750||41423|
NCT02176668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-111|The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects|A Randomized, Open-label, Multiple-dose, Partial Crossover Study to Explore the Pharmacokinetics and the Pharmacodynamics of YH4808 New Formulation in Healthy Subjects||Yuhan Corporation|Yes|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|82|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 16, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02176668||41733|
NCT02176954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP247|The Influence of Adhesive Wafer Design on Fit to the Body|||Coloplast A/S|No|Completed|July 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02176954||41712|
NCT02179788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cin_002_MALMS|Metformin to Augment Low Milk Supply (MALMS) Study|Metformin to Augment Low Milk Supply in Pre-diabetic Mothers, a Phase I/II Randomized Clinical Trial|MALMS|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|20 Years|N/A|No|||February 2016|February 2, 2016|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179788||41496|
NCT02179996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01377-28|Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates|Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study|VacciPrema|Central Hospital, Nancy, France|Yes|Active, not recruiting|January 2014|September 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|160|||Both|N/A|6 Months|No|||July 2015|July 27, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02179996||41480|
NCT02180633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBB-BMD/2739/2012|Unveiling Preclinical Idiopathic Macular Hole Formation|Unveiling Preclinical Idiopathic Macular Hole Formation|IMH_2012|University of Coimbra||Recruiting|May 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with unilateral idiopathic macular hole and no other visible retinal pathologies.|July 2014|July 2, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180633||41432|
NCT02173795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1357|Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition|Berodual® Respimat® Inhaler Versus Berodual® MA Using HFA (Hydrofluoroalkane) 134a as Propellant in Adult Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Conditions, an Open-label, Crossover Trial Over a 7-week Treatment Period With Each Formulation: ' A Study to Compare Patient Preference'||Boehringer Ingelheim||Completed|October 2002|||June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|245|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 24, 2014||||No||https://clinicaltrials.gov/show/NCT02173795||41953|
NCT02173808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN011|A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception|A Phase I Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile of a Single Injection of Levonorgestrel Butanoate (LB) for Female Contraception|CCN011|Health Decisions|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||April 2014|February 19, 2016|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173808||41952|
NCT02173821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000134|A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency|A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Randomised, Open-label, Parallel-group, Multi-centre Trial (FE 999905 CS07) in Which the Efficacy and Safety of 12 Months' Treatment With One Daily Dose of ZOMACTON Were Compared to One Daily Dose of GENOTROPIN||Ferring Pharmaceuticals|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study|||Actual|23|||Both|2 Years|17 Years|No|||May 2015|May 4, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173821||41951|
NCT02174068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0191|A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam|A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam|PARA-NEF|University Hospital, Clermont-Ferrand||Completed|July 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02174068||41932|
NCT02178475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120214|Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy|Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy||Amgen|No|Recruiting|July 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients with NHL or breast cancer who have initiated treatment with a permitted        standard-dose chemotherapy regimen that has a high FN risk (> 20%) per published studies        or international guidelines, and who started pegfilgrastim in Cycle 1|March 2016|March 16, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02178475||41596|
NCT02178774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401059RIND|Evaluation the Perfusion of Uterus and Lower Extremities During Cesarean Section With NIRS and Color Doppler|Using Non-invasive Near-infrared Spectroscopy and Color Doppler to Evaluate the Relationship Between the Perfusion of Uterus and Gastrocnemius Muscles of the Parturients Receiving Cesarean Section||National Taiwan University Hospital|No|Not yet recruiting|June 2014|||January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|20 Years|40 Years|No|Non-Probability Sample|Parturients who are going to receive an elective cesarean section in NTUH will be        enrolled.|June 2014|June 30, 2014|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178774||41573|
NCT02179333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAND2012|Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)|Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)|STAND|University of South Florida|No|Active, not recruiting|October 2012|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Community members, support group members or clinic patients with ataxia.|May 2015|May 26, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179333||41531|
NCT02179086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-BN001|Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma||NRG Oncology|Yes|Recruiting|November 2014|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|576|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179086||41549|
NCT02179060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14025|Prehospital Resuscitation Intranasal Cooling Effects Seen in MRI of the Brain After Cardiac Arrest|Prehospital Resuscitation Intranasal Cooling Effects Seen in Magnetic Resonance Imaging of the Brain After Cardiac Arrest|COOLCAMRI|Tampere University Hospital|No|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|80 Years|No|Probability Sample|The subjects will be derived from the prehospital cardiac arrest patients from Tampere        area treated by the Tampere Area Emergency Medical Service (EMS) led by physician. The        study population (N=10) is from Pirkanmaa area. The paramedics are allowed to start        intra-arrest cooling by RhinoChill whenever they meet an adult SCA patient in VF/VT. The        third group of control subjects are same as used in "Effect of Xenon, in Combination with        Therapeutic Hypothermia, on the Brain and on Neurological Outcome following Brain Ischemia        in Cardiac Arrest Patients (EudraCT number 2009-009505-25)" -study running in Turku and        Helsinki, Finland. They are the prehospital cardiac arrest patients from Turku and        Helsinki area treated by the Turku or Helsinki Area Emergency Medical Service.|January 2016|January 12, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02179060||41551|
NCT02179073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-25|Health-related Quality of Life of Patients With Neurogenic Bladder|Effects of Bladder Management on Health-related Quality of Life in Patients With Neurogenic Bladder||Swiss Paraplegic Centre Nottwil|No|Enrolling by invitation|December 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|individuals with neurogenic bladder dysfunction|September 2015|September 1, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02179073||41550|
NCT02179645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 27864-101|GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers|A Three-Part, Phase I Study Of Orally Administered GRC 27864, A Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, To Evaluate The Safety, Tolerability And PK Of Single Ascending Doses In Healthy, Adult Subjects (Part 1a), And Of A Single Dose In Elderly Subjects (Part 2); The Effect Of Food On PK (Part 1b) In Healthy, Adult Subjects; And To Compare The Effects On Prostanoid Metabolism With Celecoxib (Part 3) In Healthy, Adult Subjects.||Glenmark Pharmaceuticals Ltd. India|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|December 29, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02179645||41507|
NCT02180139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS-2014|tDCS in Cervical Dystonia|Optimizing tDCS in Cervical Dystonia||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|96|||Both|21 Years|65 Years|No|||September 2015|September 30, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180139||41469|
NCT02180152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caminhadas2014|Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial|Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial||Professor Fernando Figueira Integral Medicine Institute||Not yet recruiting|March 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|132|||Female|18 Years|40 Years|No|||March 2015|March 10, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180152||41468|
NCT02180477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.251|Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers|Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation||Boehringer Ingelheim||Completed|November 2001|||December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 1, 2014||||No||https://clinicaltrials.gov/show/NCT02180477||41443|
NCT02180490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.252|Bioequivalence Study of UHAC 62 XX Tablets Compared With Capsules in Healthy Volunteers|Bioequivalence Study of UHAC 62 XX 10 mg Tablets Compared With 10 mg Capsules Following Single Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)||Boehringer Ingelheim||Completed|May 2002|||July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 1, 2014||||No||https://clinicaltrials.gov/show/NCT02180490||41442|
NCT02180503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.8|Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS|Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) Reconstituted With 0.1% Tartaric Acid Compared to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers (Separately at Each Dose Level) Including the Influence of Food (Standardised High Fat Breakfast) on the Bioavailability of 10 mg BI 1356 BS as Tablet in a Single Dose, Open-label, Randomised, Two-way (1 mg) and Three-way (10 mg) Crossover Trial||Boehringer Ingelheim||Completed|August 2005|||October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||24|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 1, 2014||||No||https://clinicaltrials.gov/show/NCT02180503||41441|
NCT02180776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-ORTHO01-2012|Effectiveness of Inelastic LSO Versus Standard Medical Treatment for Back Pain Associated With Kyphosis|A Randomized Crossover Pilot Study To Determine Clinical Effectiveness and Patient Wellness of Inelastic Lumbosacral Orthoses Versus Standard Medical Treatment in Patients With Back Pain AssociatEd With Kyphosis (The ARISE Study)|ARISE|Aspen Medical Products|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|N/A|No|||July 2014|July 1, 2014|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180776||41421|
NCT02181283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA023122|MiSSION STRONG - Preventing AOS Misuse in the National Guard|Preventing Alcohol/Prescribed Drug Misuse in the National Guard: Web and Peer BI||University of Michigan|No|Recruiting|April 2015|June 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|750|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02181283||41382|
NCT02181296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820072|Pulmonary Function and Interscalene Block|Effect of Local Anesthetic Concentration (0.2% Ropivacaine vs 0.1% Ropivacaine) on Phrenic Nerve Function, Pulmonary Function, and Analgesia After Ultrasound-guided Interscalene Brachial Plexus Block for Shoulder Arthroscopy||University of Pennsylvania|No|Not yet recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||June 2014|July 2, 2014|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02181296||41381|
NCT02181309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.254|Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers|An Open, Randomised, Four-way Crossover Study in Healthy Volunteers to Evaluate the Effect of Food on the Pharmacokinetics of Meloxicam After a Single p.o. Administration of 22.5 mg Meloxicam Oral Suspension and Dose-proportionality Over a Dosage Range of 7.5 mg to 22.5 mg||Boehringer Ingelheim||Completed|January 2002|||April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181309||41380|
NCT02176967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL1232|Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma|Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-risk Neuroblastoma||Children's Oncology Group|Yes|Recruiting|July 2014|||June 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|621|||Both|N/A|17 Months|No|||March 2016|March 18, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176967||41711|
NCT02177227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attune TruMatch|Attune With TruMatch TM Personalized Solutions Instruments|Attune With TruMatch TM Personalized Solutions Instruments: A Prospective Randomized Controlled Trial Comparing Clinical and Economic Outcomes in Patients With a BMI Between 30 and 50||Lawson Health Research Institute|No|Recruiting|August 2014|August 2024|Anticipated|August 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|20 Years|70 Years|No|||March 2016|March 9, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177227||41691|
NCT02176941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00298-39|Telomeres and Arterial Aging|Short Telomere in Patients at High Cardiovascular Risk: a Simple Marker or a Major Determinant of Accelerated Arterial Aging|TELARTA|Central Hospital, Nancy, France|No|Recruiting|June 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|340|Samples With DNA|Skeletal Muscle, skin, fat (as surgical waste) and Blood sampling DNA extractions and      telomere length measurements (Southern) in muscular cells, white blood cells and endothelial      progenitor cells.      Determination, isolation and characterization of endothelial progenitor cells Microparticle      (MP) von Willebrand Factor : vWF, CD146, CD31 Tissue plasminogen activator/plasminogen      activator inhibitor-1 complexes thrombomodulin, endothelial protein C receptor, free tissue      factor pathway inhibitor sirtuin proteins Biological phenotyping of inflammatory factors in      plasma : IL2, IL4, IL6, IL8, IL10, VEGF, IFNG, TNFA, IL1A, IL1B, MCP1, EGF, CRP,      Haptoglobine|Both|20 Years|N/A|No|Non-Probability Sample|Individuals will be recruited among patients admitted to the hospital either for surgery        or for installing pacemakers/ defibrillators. Informed consent will be signed at the        beginning of the hospitalization.|June 2014|June 26, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02176941||41713|
NCT02177214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAP STUDY|Magnetic Resonance Imaging of Mesh Position After Ventral Hernia Repair|Prospective Study to Visualize Dynamesh ® IPOM Visible Mesh With MRI After Laparoscopic Intraperitoneal Ventral Hernia Repair.||Algemeen Ziekenhuis Maria Middelares|No|Active, not recruiting|June 2014|April 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with        inclusion of primary and incisional hernias.|January 2016|January 4, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177214|13 Months|41692|
NCT02177890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Farmer|Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers|Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers||Wingate Institute of Neurogastroenterology|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177890||41640|
NCT02173470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47293.041.13|Chest CT With Iterative Reconstruction as an Alternative to Conventional Chest X-ray Prior to Heart Surgery|Ultra Low-dose Chest CT With Iterative Reconstructions as an Alternative to Conventional Chest X-ray Prior to Heart Surgery|CRICKET|UMC Utrecht|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1724|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173470||41978|
NCT02174991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.15|A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention||New York Glaucoma Research Institute||Active, not recruiting|June 2014|||February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|10|||Both|N/A|N/A|No|||April 2015|April 23, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174991||41861|
NCT02178488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-STAPH-EXT-01|Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers|Vitamin D Supplementation to Persistent Carriers of MRSA - A Double Blind, Randomised Controlled Trial|D-STAPH|Karolinska University Hospital|No|Active, not recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02178488||41595|
NCT02178501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/03/B/NZ5/05767|Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.|The Effect of Omega-3 Polyunsaturated Acids Supplementation on Endothelial Function, Oxidative Stress, Platelet Aggregation, Blood Coagulation and Inflammation in Patients With Type 2 Diabetes and Cardiovascular Disease||Jagiellonian University|No|Recruiting|January 2013|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|50 Years|N/A|No|||June 2014|June 27, 2014|April 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02178501||41594|
NCT02178787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000027|UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation|UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation|UTLight|Beth Israel Deaconess Medical Center|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population sample|November 2015|November 17, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178787||41572|
NCT02178800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 077|Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults|A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2015|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|194|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178800||41571|
NCT02179099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-OAB-02|Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients|Pilot Study Evaluating Safety and Efficacy of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in OAB Patients||UroGen Pharma Ltd.|No|Terminated|July 2014|February 2016|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|85 Years|No|||February 2016|February 28, 2016|June 29, 2014||No|Decision to open a randomized controlled trial with two groups receiving different Botulinum    Toxin in comparison to placebo group.|No||https://clinicaltrials.gov/show/NCT02179099||41548|
NCT02179359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014OC034|Stem Cell Transplant for Patients With Sickle Cell Disease (SCD), Thalassemia, Diamond Blackfan Anemia (DBA) and Other Non-malignant (Non-cancerous) Hematologic Disorders|MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders||Masonic Cancer Center, University of Minnesota|No|Recruiting|September 2014|August 2021|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179359||41529|
NCT02180204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H000|Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)|Phase IIb Study Comparing Tenecteplase to Alteplase in Acute Ischemic Stroke Within 3 to 4.5 Hours From Symptom Onset|TALISMAN|Ohio State University|No|Withdrawn|January 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 22, 2015|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02180204||41464|
NCT02180217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C2301|Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease|Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease||Novartis|No|Recruiting|November 2011|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180217||41463|
NCT02180178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICAT|Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registery|Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.|MICAT|Johannes Gutenberg University Mainz|No|Recruiting|September 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1000|Samples Without DNA|serum samples from patients with slow flow|Both|N/A|N/A|No|Non-Probability Sample|Patients with clinical indication for coronary angiography.|February 2016|February 23, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180178|10 Years|41466|
NCT02180191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-2012/48|Gut Microbiota in Obesity and Diabetes|Comparison of Gut Microbiota in Obese, Diabetic and Healthy Control Individuals||Gulhane School of Medicine||Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Tertiary referral center|July 2014|July 1, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180191||41465|
NCT02181010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111189|B'More Healthy; Communities for Kids (BHCK)|B'More Healthy: Communities for Kids (BHCK)|BHCK|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|January 2012|January 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|890|||Both|9 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 1, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02181010||41403|
NCT02181634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0204|Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma|A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma|PrE0204|PrECOG, LLC.|Yes|Recruiting|September 2014|October 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181634||41355|
NCT02181647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21HD069628|Safe Touches: A Rigorous Evaluation of a Sexual Abuse Prevention Program for Children|Safe Touches: A Rigorous Evaluation of a Sexual Abuse Prevention Program for Children|Safe Touches|The New York Society for the Prevention of Cruelty to Children|Yes|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|492|||Both|7 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 3, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181647||41354|
NCT02176980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046518|Hepatitis C Alcohol Reduction Treatment|Hepatitis C Alcohol Reduction Treatment - Randomized Controlled Trial (Hep ART-RCT)|Hep ART-RCT|Duke University|Yes|Recruiting|October 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|230|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02176980||41710|
NCT02177591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-141|Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease|Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease||Texas Tech University Health Sciences Center|No|Completed|June 2014|December 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|77|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients from ages 18-89 years who are being seen in the Cardiology clinic at TTUHSC        who meet inclusion and exclusion criteria, and who will consent to participating in the        study. There will be 20 to 30 patients in each group.|January 2016|January 20, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02177591||41663|
NCT02177877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-29027|A Biosensor for Tracking Seizures: Linking a Wrist Accelerometer to an Online Epilepsy Diary|A Biosensor for Tracking Seizures: Linking a Wrist Accelerometer to an Online Epilepsy Diary||Stanford University|Yes|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|90 Years|No|Non-Probability Sample|Adults with epilepsy over the age of 18 enrolled at the Stanford Epilepsy Monitoring Unit.|May 2015|May 22, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177877||41641|
NCT02173444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234-DHYD|Comparison of the Accuracy and Reliability of AMH, FSH and AFC in Predicting Ovarian Response|Comparison of the Accuracy and Reliability of AMH, FSH and AFC in Predicting Ovarian Response|AMH FSH AFC|Vietnam National University|Yes|Completed|January 2013|||October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|820|||Female|18 Years|45 Years|No|||June 2014|June 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173444||41980|
NCT02173834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41577.018.12 METC 2012.214|Brown Adipose Tissue and Body Mass Index|Activation of Brown Adipose Tissue in Lean and Obese Men||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02173834||41950|
NCT02174094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14362A|Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome||H. Lundbeck A/S|Yes|Withdrawn|March 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|16 Years|No|||September 2015|September 23, 2015|June 2, 2014|Yes|Yes|The study was terminated due to recruitment challenges|No||https://clinicaltrials.gov/show/NCT02174094||41930|
NCT02174393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-555|Microneedling Plus the Universal Peel For Acne Scarring|Efficacy of Combination Therapy With Microneedling and the Universal Peel For Acne Scarring in Skin Types III-VI||Englewood Hospital and Medical Center|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02174393||41907|
NCT02178241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01294|Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery|Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder||National Cancer Institute (NCI)|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178241||41614|
NCT02178813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120002|The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization|The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization. A Phase I Study||University of Pittsburgh|Yes|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||May 2015|May 26, 2015|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178813||41570|
NCT02178826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUL-2012/379|Nocturnal Enuresis and Rapid Maxillary Expansion|Nocturnal Enuresis and Rapid Maxillary Expansion - Long Term Effect, Prognostic Factors, Quality of Life and Sleep Quality|NERME|Uppsala University Hospital|No|Recruiting|January 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|7 Years|14 Years|No|||March 2016|March 9, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02178826||41569|
NCT02179112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR/1404AB12|Determining Universal Processes Related to Best Outcome in Emergency Gastrointestinal Surgery: an International Evaluation||GlobalSurg-1|University of Edinburgh|No|Recruiting|July 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will be recruited from all acute surgical units worldwide which        provide an emergency surgery service.|July 2014|July 2, 2014|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02179112|30 Days|41547|
NCT02179125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACTION|Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema|Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema|REACTION|University Medical Center Groningen|Yes|Recruiting|March 2015|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||May 2015|May 31, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02179125||41546|
NCT02179372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA/CALPRO|Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases|Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|June 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||December 2015|December 29, 2015|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02179372||41528|
NCT02180230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-127|Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use|Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use||Nobel Biocare|No|Active, not recruiting|October 2007|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|April 13, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02180230||41462|
NCT02179892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071635|Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block|Comparison Between Bupivacaine Extended-Release Liposome Injection (Exparel) Versus Bupivacaine With Dexamethasone in Transversus Abdominis Plane Block: A Prospective Randomized Controlled Trial|TapBlock|Emory University|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179892||41488|
NCT02179905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-102-DR-14|Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome|Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome||Shin Kong Wu Ho-Su Memorial Hospital|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|69|Samples Without DNA|Serum|Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Irritable bowel syndrome patients, Control|June 2014|July 1, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02179905||41487|
NCT02180165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5592-101|Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)|A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection||Merck Sharp & Dohme Corp.|No|Recruiting|July 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180165||41467|
NCT02180841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE SOY|Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness|Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness|SOY|Penn State University|No|Active, not recruiting|March 2014|December 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|20|||Both|35 Years|60 Years|No|||September 2015|September 16, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02180841||41416|
NCT02181023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960CEC|Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients|Acute Effect of Aclidinium on Hyperinflation and Lung Volume Distribution in Severe COPD Patients||University of Milan|Yes|Completed|June 2014|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|50 Years|85 Years|No|||October 2014|October 28, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181023||41402|
NCT02181036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH-SKH-103-07|Effects of Work Shop for Children With Developmental Delays|Effects of Family Work Shop for Children With Speech Developmental Delays||Taipei Medical University|No|Active, not recruiting|June 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Months|36 Months|No|||June 2014|July 2, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02181036||41401|
NCT02180802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3287|Parental Involvement Improves the Effect of Motivational Interviewing on Weight Loss in Obese Adolescents: A Randomized Controlled Trial Study|||Qazvin University Of Medical Sciences|No|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|408|||Both|13 Years|18 Years|No|||August 2014|August 30, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180802||41419|
NCT02180815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV 002|REV 002 Observational Study of the ReVENT Sleep Apnea System: Minimally Invasive Treatment for Obstructive Sleep Apnea|ReVENT Sleep Apnea System, a Minimally Invasive Approach to Treat Obstructive Sleep Apnea: a Prospective Multicenter Post-Market Observational Study||Revent Medical International B.V.|No|Recruiting|September 2014|January 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Obstructive Sleep Apnea due to primary tongue base closure|February 2016|February 7, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02180815||41418|
NCT02181660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0102|Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of ASP2215 - A Phase 1 Open-Label, Dose-Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia||Astellas Pharma Inc|Yes|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181660||41353|
NCT02177617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400343|Neurotoxin and Physical Therapy|Synergistic Effects of Neurotoxin and Physical Therapy||University of Florida|No|Recruiting|December 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177617||41661|
NCT02177240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cér 14013|A Comparison of the Flex-it® to the GlideRite® Stylet for GlideScope® in Simulated Difficult Intubations.|A Randomized Comparison of the Flex-it® Articulating Stylet to the GlideRite® Rigid Stylet for Orotracheal Intubation Using the GlideScope® in Simulated Difficult Intubations. A Double Blinded Randomized Controlled Trial.||Maisonneuve-Rosemont Hospital|Yes|Recruiting|May 2014|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02177240||41690|
NCT02177253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.46|Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease|A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-blind, Safety and Efficacy Study in Adults With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|October 2002|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|1118|||Both|40 Years|N/A|No|||June 2014|June 26, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02177253||41689|
NCT02177604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140319|Can Brief High-intensity Interval Training Mitigate the Adverse Consequences of High-fat Overfeeding?|Can Brief High-intensity Interval Training Mitigate the Adverse Consequences of High-fat Overfeeding?|GAINHIT|University of Adelaide|No|Not yet recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02177604||41662|
NCT02173483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish EC - 110728514|Anterior Cruciate Ligament-reconstruction: Quadriceps Tendon or Hamstrings Tendon? A Prospective Trial|Anterior Cruciate Ligament-reconstruction: Quadriceps Tendon or Hamstrings Tendon? A Prospective Randomised Controlled Trial||Aarhus University Hospital|Yes|Recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173483||41977|
NCT02174406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-119|Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis|Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Female|30 Years|N/A|No|Non-Probability Sample|All women scheduled for a WBUS and a FFDM on the same day or within the following 30 days        of each other will be identified by the investigators/research staff at MSKCC clinic.|February 2016|February 22, 2016|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174406||41906|
NCT02174419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR03|Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis|A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients||Trevi Therapeutics|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174419||41905|
NCT02174731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5740C00002|Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis|A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients||AstraZeneca|Yes|Recruiting|July 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1425|||Both|18 Years|130 Years|No|||February 2016|February 29, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174731||41881|
NCT02175303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCINF001|A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting|||Karolinska Institutet||Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||June 2014|June 25, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02175303||41837|
NCT02175316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20130045H|Enhanced External Counterpulsation on Delayed Onset Muscle Soreness|Effects of Enhanced External Counterpulsation on Delayed Onset Muscle Soreness, a Pilot Study||David Grant U.S. Air Force Medical Center|No|Recruiting|April 2014|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|25 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175316||41836|
NCT02174692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS|Study of Muscle Repair Following Exercise in Young and Elderly People|Exploring the Metabolic and Molecular Basis of Age-related Declines in Human Skeletal Muscle Regenerative Capacity|MDS|University of Nottingham|Yes|Completed|February 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02174692||41884|
NCT02174705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30427|Rotavirus vs. Sucrose for Vaccine Injection Pain|A Randomized Controlled Trial of Rotavirus Vaccine vs. Sugar Water for Vaccine Injection Pain Management in Infants||University of Toronto|No|Recruiting|June 2014|September 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||August 2014|August 13, 2014|June 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174705||41883|
NCT02174718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0766|Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME|Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME|D3forME|University of Wisconsin, Madison|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|220|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|October 1, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174718||41882|
NCT02178839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umsu.rec.1393.48|The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease|The Effect of Oral β- Glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver Echogenicity and Enzymes in Non Alcoholic Fatty Liver Disease Treating With Hypocaloric Diet and Vitamin E||Urmia University of Medical Sciences||Not yet recruiting|July 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|No|||June 2014|June 27, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02178839||41568|
NCT02179398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-162 (MatPed 09-032)|Impact of the Lab-score on Antibiotic Prescription Rate in Children With Fever Without Source|Impact of the Lab-score on Antibiotic Prescription Rate in Children Aged 7 Days to 3 Years Old With Fever Without Source.||University Hospital, Geneva|No|Completed|September 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|278|||Both|N/A|3 Years|No|||October 2014|October 26, 2014|June 27, 2014||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT02179398||41526|heterogeneity in the total number of participating physicians (30)recruitment in a tertiary care center (recruitment bias)
NCT02179658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-CL-3002|A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|OPT-80 Phase III Study -A Multi-center, Double Blinded, Randomized, Parallel Group Study To Compare The Safety, Pharmacokinetics And Efficacy of OPT-80 With Vancomycin In Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)||Astellas Pharma Inc|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02179658||41506|
NCT02180243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-013-13S|CAM in Veterans With Gulf War Illnesses|CAM in Veterans With Gulf War Illnesses|GW-CAM|VA Office of Research and Development|Yes|Recruiting|August 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180243||41461|
NCT02180256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 30504514.6.0000.5440|Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial|||University of Sao Paulo|Yes|Enrolling by invitation|September 2014|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|600|||Female|18 Years|N/A|No|||May 2015|May 28, 2015|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180256||41460|
NCT02180516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.246|Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome|Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome||Boehringer Ingelheim||Completed|October 2001|||September 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|9984|||Both|N/A|N/A|No|Non-Probability Sample|Patients from hospitals or general practioners (Internal Medicine, Orthopedics)|July 2014|July 4, 2014|July 1, 2014||||No||https://clinicaltrials.gov/show/NCT02180516||41440|
NCT02180828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pkuszh-2014-02|Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis|An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis||Peking University Shenzhen Hospital|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|48 Years|No|||April 2015|October 18, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180828||41417|
NCT02180854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delstudie4|Correlation Between Monitoring Frequency and Clinical Deterioration in Hospitalized Patients|Correlation Between Monitoring Frequency and Clinical Deterioration in Hospitalized Patients||Bispebjerg Hospital|No|Completed|September 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02180854||41415|
NCT02181049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVSS-study|Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS)|Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS): a Multidisciplinary Clinical, Epidemiological and Genetic Approach|CVSS|Johannes Gutenberg University Mainz|No|Active, not recruiting|October 2013|December 2017|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1000|Samples With DNA|blood (serum, plasm, DNA, RNA), urine, tear fluid|Both|24 Years|49 Years||Non-Probability Sample|Survivors of a oncological disease according to ICCC-3 aged <15 years at diagnosis,        diagnosed 1980-1990 while resident in Germany|February 2016|February 29, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02181049||41400|
NCT02181322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.243|Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range|An Open, Randomised, Four-way Crossover Study in Healthy Volunteers to Evaluate the Effect of Food on the Pharmacokinetics of Meloxicam After a Single p.o. Administration of 22.5 mg Meloxicam Oral Suspension and Dose-proportionality Over a Dosage Range of 7.5 mg to 22.5 mg.||Boehringer Ingelheim||Completed|June 2001|||September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181322||41379|
NCT02181335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1047.16|Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy|A Twelve-week, Efficacy and Safety Study Comparing Respimat ® Budesonide (100 and 200 mcg, 2 Puffs Bid) With Turbohaler ® Budesonide (200 mcg, 2 Puffs Bid) in Symptomatic Adult Moderate to Severe Asthmatic Requiring Inhaled Corticosteroids and Bronchodilator Therapy.||Boehringer Ingelheim||Completed|October 1998|||June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|684|||Both|18 Years|65 Years|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181335||41378|
NCT02181621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE048IOD|A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs|A Prospective, Open, Comparative, Randomized, Single-centre Study to Evaluate the Effect of Cadexomer Iodine Gel (IODOSORB) Compared to Standard Dressings (SOLOSITE) on Biofilm Disruption in Infected Diabetic Foot Ulcers (DFUs)||Smith & Nephew Medical Ltd|No|Terminated|August 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2015|November 16, 2015|July 2, 2014||No|Recruitment challenges|No||https://clinicaltrials.gov/show/NCT02181621||41356|
NCT02178358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15065|A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma|A Randomized Phase 2 Study of LY2157299 Versus LY2157299 - Sorafenib Combination Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma||Eli Lilly and Company|No|Recruiting|August 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178358||41605|
NCT02173509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-ESA/105530/2008|An Educational Intervention to Improve the Use of Antibiotics in Portuguese Health Professional|An Educational Intervention to Improve the Use of Antibiotics in Portuguese Health Professional: Cluster-randomized Trial||Aveiro University|No|Completed|May 2013|||October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2300|||Both|N/A|N/A|No|||June 2014|June 24, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173509||41975|
NCT02177903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-013093|Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes|Randomized, Prospective Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Perioperative Surgical Outcomes||3M|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|213|||Both|19 Years|85 Years|No|||December 2015|December 9, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02177903||41639|
NCT02177916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH0004|Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation|"A Comparison of 2 Different Methods of Patient Education to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation"||Tampa General Hospital|No|Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 7, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02177916||41638|
NCT02173496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDAR001|Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)|Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration|CEDAR|Aston University|No|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|210|Samples With DNA|Blood Samples|Both|50 Years|N/A|No|Non-Probability Sample|Unilateral wet ARMD|January 2015|January 13, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02173496||41976|
NCT02174432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR03ext|Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis|An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients||Trevi Therapeutics|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174432||41904|
NCT02174445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ADE18T|An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years|Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years|DECLINE|University Hospital Freiburg|No|Recruiting|March 2014|December 2024|Anticipated|October 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174445||41903|
NCT02175628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1405|Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound|Comparison of the Sensitivity and Specificity of Acoustic Angiography (Micro-tumor Detection by Quantifying Tumor-induced Vascular Abnormalities) to the Sensitivity and Specificity of Conventional Ultrasound||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2014|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||October 2015|October 7, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02175628||41812|
NCT02175602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-116|Study of Drug Combination on Pharmacokinetics in Healthy Volunteers|Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of Selective Serotonin Reuptake Inhibitors in Healthy Subjects||Bristol-Myers Squibb|No|Completed|June 2014|||August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|41|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02175602||41814|
NCT02178514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.20.INF|BabyNes Nutrition System Growth Study|Do Infants Fed With BabyNes™ System Grow in Agreement With the World Health Organization (WHO) Reference?||Nestlé|No|Recruiting|December 2014|August 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|N/A|4 Months|Accepts Healthy Volunteers|||November 2015|November 5, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178514||41593|
NCT02178527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010GR10|Podiatry Intervention to Reduce Falls in Elderly Care Trial (PIRFECT)|A Podiatry Intervention to Reduce Falls in Care Home Residents: Development, Feasibility and Acceptability Study With Exploratory Randomised Controlled Trial|PIRFECT|NHS Tayside|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|65 Years|N/A|No|||October 2015|October 7, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02178527||41592|
NCT02179385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0130-13-COM|Empowerment and Support for the Diabetic Patient|Coaching for Health to Achieve New Goals in Empowerment for Diabetes|CHANGE-D|Clalit Health Services||Active, not recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|21 Years|75 Years|No|||August 2015|August 4, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02179385||41527|
NCT02179671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4191C00011|Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)||AstraZeneca|No|Active, not recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|130 Years|No|||January 2016|January 11, 2016|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179671||41505|
NCT02179684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bell´sPalsy|Surgery or Clincial Follow up, in Patients With Bell' s Palsy|Surgery or Clinical Follow-up in Patients With Bell's Palsy. A Prospective, Parallell, Single Center, Randomized , Open Surgery Clinical Study.||Karolinska Institutet|No|Enrolling by invitation|November 2013|November 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|55 Years|No|||June 2014|June 30, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179684||41504|
NCT02179918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1641003|A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)|A Phase 1b Study Of The 4-1BB Agonist PF-05082566 In Combination With The PD-1 Inhibitor MK-3475 In Patients With Advanced Solid Tumors||Pfizer|No|Active, not recruiting|August 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02179918||41486|
NCT02181088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC057|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5||University of Oxford|Yes|Completed|August 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181088||41397|
NCT02181101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUCCESS-A|Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial|||Ludwig-Maximilians - University of Munich|Yes|Completed|September 2005|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3754|||Female|18 Years|N/A|No|||July 2014|July 1, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02181101||41396|
NCT02181114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK088711-1|Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant|Computer Tailored Education Program to Reduce Disparities in Living Donor Kidney Transplant||University of California, Los Angeles|Yes|Recruiting|May 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|900|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02181114||41395|
NCT02181127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001663/MGH|Closed-Loop Glucagon Administration For Hypoglycemia Treatment|CLOSED-LOOP GLUCAGON ADMINISTRATION FOR THE AUTOMATED PREVENTION AND TREATMENT OF HYPOGLYCEMIA||Massachusetts General Hospital|Yes|Active, not recruiting|November 2014|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 9, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181127||41394|
NCT02180529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC0642013|The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment|The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment: a Randomized, Placebo Controlled, Double-blind Trial.||Meir Medical Center|No|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|N/A|No|||November 2015|November 16, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180529||41439|
NCT02181933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1287|Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women|A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labour After 35 Weeks Gestation and Who Are Anti-retroviral Naive, Will be Included.||Boehringer Ingelheim||Completed|April 1999|||January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2648|||Both|N/A|N/A|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181933||41332|
NCT02181946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1361|Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients|An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®)||Boehringer Ingelheim||Completed|May 2001|||July 2001|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181946||41331|
NCT02181062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-NS-12-007|Culturally Tailoring a Stroke Intervention in Community Senior Centers|Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers|SPIRP|University of California, Los Angeles|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|244|||Both|60 Years|N/A|No|||May 2015|May 29, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02181062||41399|
NCT02181075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_040|Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours|A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin From Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients With Primary or Secondary Liver Tumours|TARDOX|University of Oxford|Yes|Recruiting|July 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181075||41398|
NCT02181348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJilani|Effect of Vitamin E Supplementation on Hemoglobin Levels in Healthy Adults|Role of Vitamin E in Enhancing Erythropoiesis and the Molecular Mechanism of the Action of Vitamin E on Erythropoietin-secreting Cells||Aga Khan University|No|Completed|November 2008|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181348||41377|
NCT02182492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTDrug-001|Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery ( ESS)|Comparison of Different Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery||Huazhong University of Science and Technology|Yes|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|70 Years|No|||January 2014|April 19, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02182492||41289|
NCT02173405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCMC IRB 04-13-45|Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain|Pelvic Floor Trigger Point Injection With OnabotulinumtoxinA for the Treatment of Severe Myofascial Pelvic Pain (MPP) - A Randomized, Controlled Trial|BotoxMPP|University Hospital Case Medical Center|No|Recruiting|August 2014|September 2016|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|65 Years|No|||June 2015|June 10, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173405||41983|
NCT02177955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001.0.097.000-08|Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery|Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study||University of Pernambuco|Yes|Completed|January 2011|September 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|June 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177955||41635|
NCT02177968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP9879/2011|Public Health Concerns of Elderly Fallers and Non-fallers in a Community|Public Health Concerns of Elderly Fallers and Non-fallers in a Southeastern Community of Brazil||University of Sao Paulo|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|June 2014|June 27, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02177968||41634|
NCT02173847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL-PO-001|Laser Assisted Procedures in Penetrating Keratoplasty|Laser Assisted Procedures in Penetrating Keratoplasty: Femtosecond Laser Anvil-shaped Cuts and Laser Welding of the Surgical Wounds||Ospedale Santo Stefano|No|Completed|January 2011|September 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|75 Years|No|||June 2014|June 23, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02173847||41949|
NCT02174107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIOINTER01|Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.|Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.|Radiointer|Centre Leon Berard|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174107||41929|
NCT02174744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0190|Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales|Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales.|CALDOL|University Hospital, Clermont-Ferrand||Recruiting|January 2014|September 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|210|||Both|65 Years|N/A|No|Non-Probability Sample|elderly patients|June 2014|June 23, 2014|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174744||41880|
NCT02179138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 070|Paper Applicator Acceptability Study|EVALUATION OF A USER-FILLED, PAPER APPLICATOR FOR DELIVERY OF TENOFOVIR 1% GEL AMONG WOMEN IN RURAL KWAZULU-NATAL, SOUTH AFRICA||CONRAD|No|Withdrawn||||March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 27, 2014|Yes|Yes|Study no longer relevant based on change in regulatory pathway for TFV 1% gel|No||https://clinicaltrials.gov/show/NCT02179138||41545|
NCT02179411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P2009-01|Study of the Renal Perfusion in Healthy Volunteers and Renal Transplant Recipients During an Orthostatic Stress|Study of the Renal Perfusion in Healthy Volunteers and Renal Transplant Recipients During an Orthostatic Stress|ortho_rein|University Hospital, Angers|Yes|Completed|April 2009|March 2013|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|June 27, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179411||41525|
NCT02179424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSTWPLACE|Promoting Tobacco Control and Smoking Cessation in Workplaces|Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong||The University of Hong Kong|Yes|Recruiting|December 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179424||41524|
NCT02179697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0100|Randomized Trial With an Observational Component of Non-operative Versus Operative Treatment for AO Type A3 Fractures|Radiographic and Clinical Outcomes Following Non-operative Versus Operative Treatment of AO Type A3 Fractures: A Prospective, Randomized Clinical Trial With an Observational Component||Ohio State University|Yes|Recruiting|August 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02179697||41503|
NCT02179710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M.O.M.M.I.1|Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study|Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study||Landon Pediatric Foundation|No|Enrolling by invitation|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|12 Years|30 Years|No|||January 2015|January 2, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179710||41502|
NCT02179931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15972A|Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)|Interventional, Single Dose, Open-label, Randomised, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)||H. Lundbeck A/S|No|Completed|June 2014|||July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02179931||41485|
NCT02181140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV 3835|Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro-core® Needle|Prospective Evaluation of the Significance of the Pro-core® Needle in Differential Diagnosis of Tumorous and Inflammatory Processes|COS|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|August 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 15, 2015|July 8, 2013||No||No|May 21, 2015|https://clinicaltrials.gov/show/NCT02181140||41393|
NCT02180542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pacific|Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke.|Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke: Prevalence, Characteristics and Prognosis|Pacific|Odense University Hospital|No|Active, not recruiting|March 2012|October 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|264|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ischemic stroke patients admitted to the hospital|October 2015|October 15, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02180542||41438|
NCT02171988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401091550|Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)|Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment|POTS|Seoul National University Hospital|No|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|15 Years|85 Years|No|||June 2015|June 2, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171988||42092|
NCT02172443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.232|Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease|Comparison of 18 mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 mcg) in a Double Blind, Double Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|June 2001|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172443||42057|
NCT02182466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265/13|German Colon Capsule Registry|Documentation of Colon Capsule Endoscopies in a National Observational Study [Dokumentation Von Kolonkapsel-Endoskopien im Rahmen Einer Bundesweiten Studie]|DEKOR|Johann Wolfgang Goethe University Hospitals|No|Active, not recruiting|June 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with indication for endoscopic investigation of the colon|July 2014|July 2, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02182466||41291|
NCT02182479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1104|Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients|Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d.) in Asthma Patients Over a 12-week Period||Boehringer Ingelheim||Completed|April 1998|||June 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|631|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182479||41290|
NCT02182882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020.10|Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People|Efficacy of Ginsana in Improving Half -Time Hemoglobin Re-oxygenation in Recreational Sportspeople: a Double Blind, Placebo Controlled Pilot Study||Boehringer Ingelheim||Completed|March 1999|||October 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02182882||41259|
NCT02168530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB29298|A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)|||Hoffmann-La Roche||Withdrawn|October 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168530||42358|
NCT02168569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/CNBS/11|In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children|In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite, Open-label, Two-cohort Clinical Trial in Mozambique.|MEFI|Centro de Investigacao em Saude de Manhica|No|Completed|June 2011|January 2013|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|6 Months|59 Months|No|||June 2014|June 19, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02168569||42355|
NCT02168582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBP2014|Improvement After Physiotherapy for Low Back Pain: The Good Responders|Improvement After Physiotherapy for Low Back Pain: The Good Responders. An Observational Study in Primary Care||Norwegian University of Science and Technology|No|Recruiting|May 2014|April 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|70 Years|No|Non-Probability Sample|Persons seeking primary care physiotherapy because of low back pain.|January 2016|January 7, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168582||42354|
NCT02173522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131034, G130237|Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients|Phase II Open Label Investigation of the Safety and Efficacy of Pre-Operative Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients||University of Miami|Yes|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|45 Years|79 Years|No|||October 2015|October 8, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173522||41974|
NCT02173535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5590|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||June 23, 2014|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173535||41973|
NCT02174120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140623|The Application of Target Controlled Infusion of Etomidate Combined With Propofol in the Maintenance of Anesthesia During Brain Surgeries|||Henan Provincial Hospital|Yes|Not yet recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|60 Years|No|||June 2014|June 24, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174120||41928|
NCT02174133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVAD|Impact of LVAD Implantation on Micro- and Macrovascular Function|Impact of LVAD Implantation on Micro- and Macrovascular Function|LVAD|Heinrich-Heine University, Duesseldorf|No|Completed|January 2014|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with end stage heart failure|March 2015|March 9, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174133||41927|
NCT02175355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.254|Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)|A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)|ARAMIS|Boehringer Ingelheim||Completed|October 1999|||August 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|1039|||Both|35 Years|84 Years|No|||July 2014|July 7, 2014|June 25, 2014||||No||https://clinicaltrials.gov/show/NCT02175355||41833|
NCT02175368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOFU 2012|Adhese One F Upgrade in Direct Filling Therapy|Clinical Evaluation of AdheSE One F Upgrade in Direct Filling Therapy||Ivoclar Vivadent AG|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02175368||41832|
NCT02175069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-ISB-1|Magnetic Resonance Imaging of Interscalene Plexus Block|Magnetic Resonance Imaging of Local Anesthetic Distribution: A Comparison of 5 and 15 Milliliters of Ropivacaine 0,75% for Ultrasound Guided Interscalene Plexus Blockade||Paracelsus Medical University|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||July 2014|July 9, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02175069||41855|
NCT02175667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC-CLQ-001-12|Influence of the Global Postural Reeducation and the Personality in the Posture|Influence of the Global Postural Reeducation and the Personality Traits in the Range of Motion, in the Stabilometry and in the Postural Sway.|RPG-POSTURE|Universidad Miguel Hernandez de Elche|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|December 15, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02175667||41809|
NCT02175030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73554|RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC|RAPID EC - Randomized Controlled Trial Assessing Pregnancy With Intrauterine Devices for Emergency Contraception||University of Utah|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|777|||Female|18 Years|35 Years|No|||January 2016|January 5, 2016|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02175030||41858|
NCT02175043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0282|Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial Fibrillation|||Yonsei University|Yes|Recruiting|June 2014|June 2024|Anticipated|June 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|19 Years|N/A|No|||January 2015|January 6, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02175043||41857|
NCT02175056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_C101|A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study|A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study to Investigate the Tolerability, and Pharmacokinetics/Pharmacodynamics of HL2351 After a Single Subcutaneous Administration in Healthy Male Subjects||Handok Pharmaceuticals Co., Ltd.|No|Completed|May 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|58|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02175056||41856|
NCT02179151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-311|Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome|Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months|bestPWS|Zafgen, Inc.|Yes|Active, not recruiting|September 2014|June 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|12 Years|65 Years|No|||January 2016|January 4, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179151||41544|
NCT02179177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048953|Apixaban in Patients With Sickle Cell Disease|Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease||Duke University|Yes|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 18, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179177||41543|
NCT02179437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14-356|Intraoperative TIVA With Propofol on Postoperative Pain and Side Effects After Liver Resection Surgery|Retrospective Study to Investigate Intraoperative TIVA With Propofol on Postoperative Pain and Side Effects After Liver Resection Surgery||The University of Hong Kong|No|Not yet recruiting|July 2014|March 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patient undergone liver resection surgery between 2010 to 2012 in Queen Mary Hospital|June 2014|June 27, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179437||41523|
NCT02184637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200951|A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate|A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine Tetraphosphate (DHA+PQP)||GlaxoSmithKline|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02184637||41124|
NCT02184936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24416|Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke|Precise and Rapid Assessment of Collaterals Using Multi-phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy|PRove-IT|University of Calgary|No|Recruiting|September 2012|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke presenting within 12 hours of stroke symptom onset        with evidence of intracranial occlusion on routine CTA.|July 2014|July 23, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184936||41101|
NCT02185222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC12-TC / D-COG|Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint|Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint|D-COG|University Hospital, Tours|Yes|Not yet recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|60 Years|N/A|No|||July 2014|July 3, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02185222||41079|
NCT02153021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.286|New Therapeutic Perspectives in Obesity|New Therapeutic Perspectives in Obesity||Universidade Federal de Sao Carlos|Yes|Not yet recruiting|September 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Female|20 Years|40 Years|No|||May 2014|May 27, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02153021||43546|
NCT02153320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105721|Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers|A Long-term Follow-up of a Phase I/II Study to Compare the Persistence and to Perform in Depth Characterisation of the Cellular and Humoral Immune Response Following Vaccinations With GSK Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers||GlaxoSmithKline||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|93|||Both|22 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02153320||43523|
NCT02153307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARE|Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The "MARE" Study|Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The "MARE" Study|MARE|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Recruiting|January 2014|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 7, 2016|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153307||43524|
NCT02152969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH22162-101|Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)|An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers||Yuhan Corporation|No|Completed|May 2014|November 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|66|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152969||43550|
NCT02152982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00616|Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation||National Cancer Institute (NCI)|Yes|Recruiting|December 2014|||June 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2015|March 24, 2016|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152982||43549|
NCT02153840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105|Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis|A Double-blind, Randomized, Placebo-controlled Trial of PSORI-CM01（YXBCM01） Granule for Stable Plaque Psoriasis||Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Terminated|December 2013|October 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|May 24, 2014|Yes|Yes|Paitents were unwilling to be randomly assigned to a placebo group.|No||https://clinicaltrials.gov/show/NCT02153840||43483|
NCT02186548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ÖLL-2013/091|The Impact of Surgical Technique on PDC|Closed Versus Open Surgical Exposure of Palatally Displaced Canines (PDC); Treatment and Treatment Outcome Including Aspects of Cost-benefit and Patients´Perceptions. A Multicenter Prospective Randomized Clinical Trial|PDC|Örebro County Council|No|Recruiting|November 2013|December 2020|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||April 2015|April 26, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186548||40977|
NCT02160873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMK-1415|Nighttime Feeding and Morning Endurance Performance|Effect of Nighttime Feeding on Morning Performance in Female Endurance Athletes||Florida State University|Yes|Completed|June 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|12|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02160873||42943|
NCT02161120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTN-2014-rye|Effect of Two Different Rye Bread Types in Irritable Bowel Syndrome|Effects of Traditional and Low-FODMAP Rye Bread in Irritable Bowel Syndrome.||Oy Karl Fazer Ab|No|Completed|April 2014|||February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|No|||March 2015|March 28, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161120||42924|
NCT02161653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI/10/107/3/43|Metadoxine as a Therapy for Severe Alcoholic Hepatitis|Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis||Hospital General de Mexico|Yes|Completed|April 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|135|||Both|18 Years|65 Years|No|||November 2014|November 8, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161653||42883|
NCT02162563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIRO5|Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases|Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)|CAIRO5|Dutch Colorectal Cancer Group|Yes|Recruiting|July 2014|July 2025|Anticipated|July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|640|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02162563||42814|
NCT02162836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103653|A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer||Janssen Pharmaceutical K.K.|No|Active, not recruiting|June 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|20 Years|N/A|No|||January 2016|January 20, 2016|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162836||42793|
NCT02162849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0207|Reward Sensitivity and Pharmacotherapy for Smoking Cessation|The Effects of Behavioral Counseling Plus Nicotine Replacement Therapy (NRT) or Varenicline on Smoking Cessation Among Smokers High and Low in Intrinsic Reward Sensitivity||M.D. Anderson Cancer Center|No|Recruiting|December 2015|||December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162849||42792|
NCT02154191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:176|Level of Activity in Lumbar Spinal Stenosis Patients Pre- and Post-surgery|Level of Activity in Lumbar Spinal Stenosis Patients Pre- and Post-surgery: a Non-randomized Controlled Before-after Trial||University of Manitoba|No|Enrolling by invitation|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||June 2015|June 3, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02154191||43456|
NCT02163369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-031-1|The Use of Aromatherapy for Symptom Management|The Use of Aromatherapy for Symptom Management||Central DuPage Hospital|No|Recruiting|July 2014|||June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163369||42753|
NCT02155075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960-CSP-ISR_ImplantsMC_ILS3|Evaluation of a Novel Infra-red Breast Imaging System for Breast Cancer Risk Assessment in Women With Breast Implants|Data Collection Study for the Evaluation of REAL IMAGING'S 3D Functional Metabolic Imaging and Risk Assessment ("3D MIRA") System in Women With Breast Implants.||Real Imaging Ltd.|No|Recruiting|January 2015|August 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Female|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 30 years and older, who have breast implants and who, regardless of this        clinical trial are summoned for routine breast cancer screening exam or breast biopsy due        to suspicious finding in recent screening exam.|May 2015|May 4, 2015|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02155075||43389|
NCT02155309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMRUD.2013.0004|Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray|Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness||Repurposed Therapeutics, Inc.|Yes|Enrolling by invitation|June 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02155309||43371|
NCT02184923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|verticality_percept_stroke_zrh|Verticality Perception in Stroke Patients|Verticality Perception in Patients With Acute Lateralized Lesions Along the Central Graviceptive Pathways- Acute Assessment on the Ward and the Stroke Center||University of Zurich|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|180|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184923||41102|
NCT02185196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13088|Vitamin-D Supplementation: Impact on Severe Pneumonia Among Under-five Children|Vitamin D Supplementation: Impact on Severe Pneumonia Among Under-five Children|Vitamin-D|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|June 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|3 Months|59 Months|No|||June 2014|June 11, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02185196||41081|
NCT02185209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERI-IMPL|Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics|Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics A Prospective, Double Blind, Randomized, Three Armed, Parallel, Placebo Controlled Clinical Trial||Karolinska Institutet|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02185209||41080|
NCT02153606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walton-MSA14-GlycerinSupp|Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial|Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial||McMaster University|Yes|Recruiting|January 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||March 2016|March 15, 2016|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153606||43501|
NCT02153866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cnbg-001|The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine|The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine||Sichuan Center for Disease Control and Prevention|Yes|Enrolling by invitation|December 2013|August 2014|Anticipated|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|2800|||Both|8 Months|9 Months|No|||May 2014|June 2, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153866||43481|
NCT02153567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS|SSRI Study for Functional Dyspepsia (SS)|Effect of Selective Serotonin Reuptake Inhibitor on Satiety Function in Patients With Functional Dyspepsia||Chinese University of Hong Kong||Recruiting|November 2013|May 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02153567||43504|
NCT02153580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13351|Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia|Phase I Study to Evaluate Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms||City of Hope Medical Center|Yes|Active, not recruiting|September 2014|||September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02153580||43503|
NCT02153593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-EVI-2011-138|Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial|Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis|TRANEXTUM|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|March 2013|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||May 2014|June 2, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02153593||43502|
NCT02153853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMIandRectalCancer|Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?|Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?||Hvidovre University Hospital|No|Enrolling by invitation|June 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|335|||Both|N/A|N/A|No|Non-Probability Sample|Patients with rectal cancer treated with laparoscopic surgery at the Department of        Gastrointestinal Surgery, Hvidovre Hospital, Denmark.|January 2015|January 22, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153853||43482|
NCT02152241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:155|Long-term Functional Outcome of Children With Inflammatory Bowel Disease|Long-term Functional Outcome of Children With Inflammatory Bowel Disease||University of Manitoba|No|Active, not recruiting|September 2014|||December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|105|||Both|24 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|The participant population will be comprised of adult patients who were initially        diagnosed with IBD in childhood or adolescence (diagnosis was made < age of 18 years) and        who were followed by the Section of Pediatric Gastroenterology at the Winnipeg Children's        Hospital from 1974 - 2009.        Controls: age and sex-matched control group will be generated using the Canadian Community        Health Survey (CCHS) 2012 (16) with access through the local Research and Data Centre        (RDC).|September 2015|September 8, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02152241||43606|
NCT02161679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-132-02|Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer|Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer||Immunomedics, Inc.||Not yet recruiting|August 2016|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||October 2015|October 9, 2015|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161679||42881|
NCT02161692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT48/96|Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors|Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|December 1996|April 2009|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Male|18 Years|75 Years|No|||June 2014|June 11, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161692||42880|
NCT02161705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00075957|Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate TE Reconstruction|Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy With Immediate Tissue Expander Reconstruction||Johns Hopkins University|No|Recruiting|July 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161705||42879|
NCT02162225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wake-58091|Study of Beet Juice for Patients With Sickle Cell Anemia|Phase 2 Study of Effects of Plasma Nitrite in Sickle Cell Anemia||Wake Forest School of Medicine|No|Suspended|September 2014|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|19 Years|65 Years|No|||December 2015|December 4, 2015|June 9, 2014|Yes|Yes|Enrollment was very slow. Hope to reopen as multi-site study|No||https://clinicaltrials.gov/show/NCT02162225||42840|
NCT02162238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kisumu dietary Zn Study|Assessment of Zinc Intake From Enriched Water and Other Dietary Sources in Kisumu, Kenya|Assessment of Zinc Intake From Enriched Water and Other Dietary Sources in Kisumu, Kenya||Wageningen University|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|186|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02162238||42839|
NCT02162576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH LVL - 40202|Asthma Data Innovation Demonstration Project|Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management|ADID|Reciprocal Labs|Yes|Completed|June 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|299|||Both|5 Years|N/A|No|||June 2014|June 11, 2014|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162576||42813|
NCT02153879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISPV-HUSJR-LOWHDL|Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment|Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population|LOWHDL|Institut Investigacio Sanitaria Pere Virgili|No|Completed|February 2009|December 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|30 Years|70 Years|No|||May 2014|June 2, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153879||43480|
NCT02162862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFA 13050045|Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease|Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness||University of Pittsburgh|Yes|Recruiting|July 2013|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162862||42791|
NCT02154503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03501|Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia|Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia- Pilot Study||Vancouver General Hospital|Yes|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|June 2, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154503||43433|
NCT02151201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1157|Impact of Influenza Vaccination in Pregnancy Video Education|Impact of Video Education on Influenza Vaccination Rate in Pregnancy||The Cleveland Clinic|No|Completed|November 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|105|||Female|N/A|N/A|No|||May 2014|May 30, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151201||43685|
NCT02151214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALIM-K|Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.|Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.|ALIM-K|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|May 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151214||43684|
NCT02151487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102013-068|A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block|A Comparison of Ropivacaine Alone Versus Ropivacaine With Dexamethasone or Clonidine Versus a Combination of Ropivacaine, Dexamethasone, and Clonidine for Supraclavicular Brachial Plexus Block Using Ultrasound: A Prospective, Observer-blinded, Randomized Clinical Trial to Assess the Duration of Block||University of Texas Southwestern Medical Center|No|Recruiting|March 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|80 Years|No|||June 2014|December 4, 2014|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151487||43664|
NCT02151760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1418|A Safety Study of 18F-DCFPyL, a PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer|Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center||Recruiting|May 2014|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151760||43643|
NCT02185235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MMHIS031|A Randomized Controlled Trial of Electrical Stimulation to Treat Pelvic Floor Disorder|To Evaluate The Efficacy of Electrical Stimulation and Biofeedback Treatment for Pelvic Floor Disorder Women||Mackay Memorial Hospital|Yes|Recruiting|June 2014|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02185235||41078|
NCT02185521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2917-05-12-433|Hemodynamic Instability Index: The Impact to Care With a New Predictive Indicator|Hemodynamic Instability Rules Based Advisor: The Impact to Care With a New Predictive Indicator (HIRBA 2.0)|HII|Philips Healthcare|Yes|Recruiting|November 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3000|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185521||41056|
NCT02185534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00131|Clopidogrel Bioequivalence Study in Healthy Subjects|An Open-label, Randomised, Three-way Crossover Study in Healthy Subjects to Assess the Bioequivalence of European Source Generic Clopidogrel Tablets and US and Japanese Source Branded Clopidogrel (Plavix®) Tablets.||AstraZeneca|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|144|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|July 4, 2014||No||No|September 18, 2015|https://clinicaltrials.gov/show/NCT02185534||41055|
NCT02185547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWMP001|Effects and Consequences for Mother and Child From Treatment for Depression|Effects and Consequences for Mother and Child From Treatment for Depression, A Prospective Randomized, Placebo- Controlled, Trial With Internet-based Cognitive Behavior Therapy and Sertraline or Placebo for Moderate Depression in Pregnancy|MAGDALENA|Karolinska University Hospital|No|Not yet recruiting|October 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|55 Years|No|||September 2015|September 2, 2015|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02185547||41054|
NCT02185508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-14-06|Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Lumbar Radiculopathy.|Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Radiculopathy Associated to Lumbar Disk Disease. Two Years Follow-up||American British Cowdray Medical Center||Active, not recruiting|January 2011|August 2014|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients diagnosed with lumbar disk disease with radiculopathy, undergoing neurological        surgery of the spine at the ABC Neurological Center|July 2014|July 4, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185508||41057|
NCT02185742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064852|Planning for SUCCESS|Planning for Sustained, Unbroken Connections to Care, Entry Services, and Suppression (SUCCESS)-- A Project to Improve the Connection to Community Care for HIV Infected Persons Leaving Jail in Atlanta|SUCCESS|Emory University|No|Active, not recruiting|July 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|112|||Both|18 Years|N/A|No|||July 2015|July 25, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185742||41039|
NCT02186002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-071-101|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)|Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose, With Nested Cross-over for Food Effect, to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)||Actelion|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|6||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186002||41019|
NCT02154165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKV 2013|Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes|Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes||University of Aarhus|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|33 Weeks|N/A|No|||May 2014|June 2, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154165||43458|
NCT02154178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_53|Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)|Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study|STAFE|University Hospital, Lille|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02154178||43457|
NCT02186301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-022 (TIGER-1)|TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy|TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC||Clovis Oncology, Inc.|No|Active, not recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186301||40996|
NCT02152748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI 394|Disease Progression and Treatment-induced Alterations in Glioblastoma|Analysis of Disease Progression and Treatment-Induced Alterations in Glioblastoma - an Integrative Morphological and Molecular Approach||Medical University of Vienna|Yes|Active, not recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|60|Samples With DNA|Tissue|Both|N/A|N/A|No|Non-Probability Sample|All newly diagnosed GB patients will be identified in the Austrian population since 2007 -        after the current firstline therapy has become standard, in order to warrant a        homogenously treated patient cohort. GB patients with multiple resections will be        identified.|September 2015|September 22, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152748||43567|
NCT02152462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000116 Georgetown Lombard|Exergaming Intervention and Breast Cancer Biomarkers in Black Women|Exergaming Intervention and Breast Cancer Biomarkers in Black Women|POWER|Georgetown University|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|40 Years|59 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02152462||43589|
NCT02161393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT12/20|Physical Activity Versus Pulmonary Rehabilitation in COPD|PhysicaL actIvity interVention vErsus puLmonarY Rehabilitation in COPD: The LIVELY COPD Project.|LIVELY|University of Ulster|Yes|Active, not recruiting|February 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02161393||42903|
NCT02161965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005354-27|Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation|The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa.|VICTORIA|University Hospital, Angers|Yes|Recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02161965||42859|
NCT02162251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART07T|Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease|||Eisai Inc.||Active, not recruiting|June 2013|February 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Probability Sample|Patients with Alzheimer's Disease|April 2015|April 7, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162251||42838|
NCT02162264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART08T|Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice|||Eisai Inc.||Active, not recruiting|June 2013|February 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with Alzheimer's Disease|April 2015|April 7, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162264||42837|
NCT02162277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Showa-Hitachi2014|Therapeutic Strategy in Postmenopausal Women Using Osteoporotic Diagnostic Kits|Phase 1 Study of Osteoporotic Diagnosis Using Osteoporotic Diagnostic Kits||Shinshu University|Yes|Recruiting|January 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|20 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are over 20 years old|February 2016|February 9, 2016|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162277||42836|
NCT02153619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-102|Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer|Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|May 2014|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|76|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02153619||43500|
NCT02162602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN-001_Bone Mineral Accretion|Bone Mineral Accretion in Young Children|Bone Mineral Accretion in Young Children||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|520|||Both|1 Year|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|September 2015|September 25, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162602||42811|
NCT02162615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU014|Restorelle® Mesh Versus Native Tissue Repair for Prolapse|Restorelle® Transvaginal Mesh Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Restorelle 522 Study||Coloplast A/S|No|Recruiting|August 2014|April 2019|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|892|||Female|18 Years|N/A|No|Non-Probability Sample|Adult female patients with pelvic organ prolapse who are candidates for transvaginal        surgical repair.|February 2016|February 15, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162615||42810|
NCT02163148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSDIRB-130313|Predictors of Exposure Success in Public Speaking Anxiety|Predictors of Exposure Success in Public Speaking Anxiety||University of California, San Diego|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|24|||Both|18 Years|55 Years|No|Non-Probability Sample|Community sample|May 2015|May 26, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02163148||42770|
NCT02163109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EE/0003|Oxygen Consumption in Critical Illness|Measurement of Oxygen Consumption in Critical Illness Using Optical Gas Analysis||University of Oxford|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients requiring intubation and mechanical ventilation on an adult intensive care        unit|October 2015|October 1, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163109||42772|
NCT02151513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00057738|Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain|Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain||University of Utah|No|Enrolling by invitation|April 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cancer-associated pain who are receiving an intrathecal pump for management        of cancer pain|May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151513||43662|
NCT02151526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGB-205|A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease|A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Beta-Hemoglobinopathies (Sickle Cell Disease and Beta-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral Beta-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)||bluebird bio|Yes|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|5 Years|35 Years|No|||January 2016|January 19, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02151526||43661|
NCT02151175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX001|Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy|LIFUP for Treatment of Temporal Lobe Epilepsy||BrainSonix Inc.||Recruiting|May 2014|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|60 Years|No|||January 2016|January 22, 2016|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151175||43687|
NCT02151188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00036|Liquid Protein Preloads With Different Carbohydrate Types Effects on the Glycaemic and Insulinaemic Response|Liquid Protein Preloads With Different Carbohydrate Types Effects on the Glycaemic and Insulinaemic Response||Clinical Nutrition Research Centre, Singapore|No|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151188||43686|
NCT02151474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 47986-202|INCB047986 in Rheumatoid Arthritis|A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis||Incyte Corporation|No|Terminated|May 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|May 28, 2014|Yes|Yes|Business decision.|No||https://clinicaltrials.gov/show/NCT02151474||43665|
NCT02151461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-0100-01|Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients|A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes||NuSirt Biopharma|No|Active, not recruiting|July 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|102|||Both|18 Years|N/A|No|||April 2015|August 20, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151461||43666|
NCT02186015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206519|Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)|Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)|SAFE-D|Loyola University|No|Recruiting|February 2015|August 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186015||41018|
NCT02152007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD201 - CS01|Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)|Phase 1b Clinical Trial Using Topical Sirolimus for the Treatment of Pachyonychia Congenita||TransDerm, Inc.|No|Completed|January 2014|November 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|16 Years|N/A|No|||February 2016|February 3, 2016|February 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152007||43624|
NCT02152761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338D2201|Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery|A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture||Novartis|Yes|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|245|||Both|60 Years|N/A|No|||September 2015|September 25, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152761||43566|
NCT02152774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.12|A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma|ROCK - CACG|New York Glaucoma Research Institute||Active, not recruiting|May 2014|||February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|50 Years|85 Years|No|||April 2015|April 23, 2015|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152774||43565|
NCT02161419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14615|RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer|A Randomized, Double Blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects With Extensive-stage Disease Small Cell Lung Cancer (SCLC) Who Are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-line Therapy|CONCEPT-SCLC|Bayer|Yes|Active, not recruiting|July 2014|October 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161419||42901|
NCT02161978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00441-40|Vascular Dysfunction and Antiangiogenic Therapy|Micro and Macro Vascular Dysfunction Induced by Antiangiogenic Therapy: Identification of New Vascular Biomarkers (DYVA-AAGG)|DYVA-AAGG|University Hospital, Angers|Yes|Recruiting|May 2011|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for a solid tumor (kidney, pancreas, intestinal, breast, lungs, skin)        requiring a first or second line antiangiogenic therapy|April 2014|November 26, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02161978||42858|
NCT02153333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114793|Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following the Administration of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus Vaccine (444563)||GlaxoSmithKline||Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|Samples With DNA|Serum samples|Both|6 Weeks|12 Weeks|No|Probability Sample|Infants aged 6 to 12 weeks from 6 previously completed clinical trials, who received 2        doses of either Rotarix™ or Placebo.|April 2015|April 2, 2015|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02153333||43522|
NCT02153346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200347|Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec|Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec||GlaxoSmithKline||Active, not recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02153346||43521|
NCT02162290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2*175/10|Comparison Between Moderate-high Interval Exercise and Moderate Continuous Exercise in an Advanced Cardiac Rehabilitation Program|Comparison Between Moderate-high Interval Exercise and Moderate Continuous Exercise in an Advanced Cardiac Rehabilitation Program - Nine Months Follow up||Assaf-Harofeh Medical Center|No|Recruiting|May 2011|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|86|||Both|40 Years|75 Years|No|||February 2015|February 24, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162290||42835|
NCT02162589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014292|Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Registry|Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Retrospective And Prospective Multicenter Registry.|POEM Registry|Weill Medical College of Cornell University|No|Recruiting|February 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Any patient who has undergone clinically indicated and/or standard of care POEM for the        treatment of Achalasia and above or equal to 18 years of age|June 2015|June 1, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162589|1 Year|42812|
NCT02162875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAN-score|Schistosoma Mansoni in Mwanza Region, Tanzania|Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above|SCORE_PAR|DBL -Institute for Health Research and Development|No|Enrolling by invitation|March 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|37500|||Both|7 Years|55 Years|No|||June 2014|June 12, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02162875||42790|
NCT02163122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN061AD|Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)|A Pilot Study to Compare Responses to Cat Allergen Exposure Using the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|32|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02163122||42771|
NCT02163928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-128|Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions|Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions||Texas Tech University Health Sciences Center|No|Active, not recruiting|June 2014|June 2016|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Medical students from Texas Tech University School of Medicine.|January 2016|January 20, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02163928||42710|
NCT02163395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/07|Performance Evaluation of FullCeram Implants in Single Tooth Gaps|A Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Monotype FullCeram (Zirconium Dioxide) Implants in Single Tooth Gaps in the Maxilla and Mandible||Institut Straumann AG|No|Active, not recruiting|October 2011|September 2022|Anticipated|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|June 10, 2014||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT02163395||42751|
NCT02152046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5900211|ROP Screening: Comparison of Pain Using Two Eyelid Retractors|Retinopathy of Prematurity Screening: Comparison of Pain Using Two Eyelid Retractors||Advocate Health Care|No|Enrolling by invitation|June 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|10|||Both|23 Weeks|37 Weeks|No|Probability Sample|Preterm infants, who need an ROP exam based on clinical indication.|June 2015|June 22, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152046||43621|
NCT02152033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA036818|Home-based Continuing Care for Young Adults Leaving Residential Substance Abuse Treatment|Feasibility and Acceptability of Home-based Continuing Care|HCC|Treatment Research Institute|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|19 Years|N/A|No|||December 2015|December 9, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02152033||43622|
NCT02151786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254-011|Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]|Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]||Takeda|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1120|||Both|N/A|N/A|No|Non-Probability Sample|Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesions|January 2016|January 24, 2016|May 28, 2014||No||No|January 24, 2016|https://clinicaltrials.gov/show/NCT02151786||43641|
NCT02151162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRG-NP-NCNP-25-8|Happy Nurse Project: Lifestyle Interventions to Maintain Healthy Mental State in Hospital Nurses|Mindfulness-Based Stress Management Program and Omega-3 Fatty Acids to Maintain Healthy Mental State in Hospital Nurses: Multi-Center Factorial-Design Randomized Controlled Trial Happy Nurse Project|HNP|National Center of Neurology and Psychiatry, Japan|Yes|Recruiting|June 2014|March 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|120|||Female|20 Years|59 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151162||43688|
NCT02152020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01914|Patient-Centered Acupuncture for Pain (PCAP)|Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Probability Sample|Cancer survivors 18 years or older with pain ratings of 4 or greater on a 0-10 numerical        rating scale; primary diagnosis of cancer (stages I-III); finished primary cancer        treatment; Karnofsky score 60 or greater; and who have been taking pain medications daily.|January 2015|January 13, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152020||43623|
NCT02151721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H25-S-I-005|Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer|Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer|VICTORY-J|Kanazawa University|Yes|Recruiting|June 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||February 2016|February 23, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151721||43646|
NCT02153931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140113|Internet Support Group for Parents of a Child With Neurofibromatosis Type 1|Effects of an Internet Support Group for Parents of a Child With Neurofibromatosis Type 1||National Institutes of Health Clinical Center (CC)||Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|33|||Both|18 Years|99 Years|No|||March 2016|March 12, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153931||43476|
NCT02161185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P261-408|A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters|An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters||Upsher-Smith Laboratories|No|Terminated|May 2014|||June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Years|65 Years|No|||April 2015|April 17, 2015|June 9, 2014|Yes|Yes|Study terminated due to slow enrollment. There were no safety concerns.|No||https://clinicaltrials.gov/show/NCT02161185||42919|
NCT02161432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.3|Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers|Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Bioavailability of the Tablet Formulation (a Randomised, Open-label, Single Dose, Three-way Crossover Trial in Healthy Subjects)||Boehringer Ingelheim||Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 10, 2014||||No||https://clinicaltrials.gov/show/NCT02161432||42900|
NCT02152735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU IRB# 14-459|Intrauterine Cleaning After Placental Delivery at Cesarean Section: RCT|Intrauterine Cleaning After Placental Delivery at Cesarean Section: a Randomized Controlled Trial||Michigan State University|Yes|Completed|July 2014|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|206|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152735||43568|
NCT02153034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/J01477X/1|Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer|A Study of the Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer|Buruli_Path|Kwame Nkrumah University of Science and Technology|No|Recruiting|May 2013|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|450|||Both|5 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with confirmed Buruli ulcer and healthy contacts of patients with Buruli ulcer|August 2015|August 2, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02153034||43545|
NCT02161991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACINV|Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers|Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy||Hunan Province Tumor Hospital|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||February 2016|February 14, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02161991||42857|
NCT02162303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIPS-002|Colchicine in Vascular Inflammation Assessed With PET Imaging|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET)|COLPET|Montreal Heart Institute|Yes|Completed|May 2014|January 2016|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|106|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162303||42834|
NCT02162628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU019|Exair® Versus Native Tissue Repair for Prolapse|Exair® Prolapse Repair System Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Exair 522 Study||Coloplast A/S|No|Terminated|August 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|79|||Female|18 Years|N/A|No|Non-Probability Sample|Adult female patients with pelvic organ prolapse who are candidates for transvaginal        surgical repair.|December 2015|December 11, 2015|June 11, 2014|Yes|Yes|Device voluntarily withdrawn from commercial use by manufacturer|No||https://clinicaltrials.gov/show/NCT02162628||42809|
NCT02163668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUYogaStudy|Effects of Yoga on Bone Metabolism in Premenopausal Women|Effects of an 8-month Yoga Intervention on Bone Metabolism in Healthy Middle-aged Premenopausal Women: A Randomized Controlled Study||University of Oklahoma|No|Completed|September 2009|April 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163668||42730|
NCT02160444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-0009|Investigating the Effects of Parent Component to Cognitive Behavior Therapy (CBT) for Youth With Anxiety Disorders|Investigating the Effects of an Added Parent Component to Cognitive Behavior Therapy for Youth With Anxiety Disorders||University of Texas at Austin|No|Recruiting|June 2012|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|35|||Both|7 Years|17 Years|No|||June 2015|June 5, 2015|July 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02160444||42976|
NCT02150954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001312|Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor|A Randomized Comparison of Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor||Duke University||Completed|December 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Female|18 Years|N/A|No|||June 2014|August 4, 2014|May 23, 2014|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT02150954||43704|
NCT02152059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBF-SCLC-001|A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy|A Phase II Study of BIBF1120 in Recurrent and Platinum-Sensitive Small Cell Lung Cancer (SCLC)||AHS Cancer Control Alberta|No|Not yet recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152059||43620|
NCT02152306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FAC-CT-301|Fimasartan/Amlodipine Combination Phase III|A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.||Boryung Pharmaceutical Co., Ltd|Yes|Completed|April 2014|July 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|20 Years|75 Years|No|||July 2015|July 24, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152306||43601|
NCT02151799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09166|The Effects of Body Contouring: Abdominoplasty and Liposuction|Body Contouring - the Analysis of Non-invasive and Invasive Methods and Their Interventional Effects on Quality of Life||Tampere University Hospital||Completed|January 2010|November 2015|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Female|18 Years|65 Years|No|||November 2015|November 3, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151799||43640|
NCT02152280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V2.0|A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke|A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke||Beijing Bozhiyin T&S Co., Ltd.|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152280||43603|
NCT02152488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar4|Cerebral Blood Flow During Flexion and Rotation of the Cervical Spine|Cerebral Blood Flow During Flexion and Rotation of the Cervical Spine|TCDPOS|University of Schleswig-Holstein|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|80 patients presenting in the pre-anaesthesia ambulance of the University Hospital        Schleswig-Holstein, Campus Kiel were enrolled in the study. Exclusion criteria were        cranial spine pathology and known cerebral vascular disease.|May 2014|May 28, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02152488||43587|
NCT02152501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC028|Exercise and Weight Control|Exercise and Weight Control: A Search for Biological and Neurobehavioral Compensatory Mechanisms That Defend Against Exercise-Induced Negative Energy Balance||USDA Grand Forks Human Nutrition Research Center|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152501||43586|
NCT02151734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUP-KLM_301|Safety and Efficacy of KALOMIN™ Tab. in Patients With Acute Bronchitis|||Korea United Pharm. Inc.||Completed|August 2013|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|12 Years|75 Years|No|||May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151734||43645|
NCT02151747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0889|Testing BRCA 1/2 Mutation Using Next Generation Sequencing|Pilot Study of Validation of Testing BRCA 1/2 Mutation Using Next Generation Sequencing|BRCANGS|Severance Hospital|No|Completed|February 2014|||February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|12|||Both|19 Years|80 Years|No|Non-Probability Sample|Patients with breast cancer|July 2015|July 14, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151747||43644|
NCT02153073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142-011|Evaluation of the Safety and Efficacy of Long-term Use of Lotriga|Lotriga Granular Capsules Special Drug Use Surveillance (Long-term Use Survey)||Takeda|No|Active, not recruiting|May 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3084|||Both|N/A|N/A|No|Non-Probability Sample|Hyperlipidemia|November 2015|November 17, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153073||43542|
NCT02153086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293-011|Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> − Transitional Survey From the Preceding Drug-use Survey −|Rozerem 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Associated With Sleep-onset Difficulty > − Transitional Survey From the Preceding Drug-use Survey −||Takeda|No|Completed|March 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|236|||Both|N/A|N/A|No|Non-Probability Sample|Insomnia|August 2014|August 1, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153086||43541|
NCT02152254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA12-1161|IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer|Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2)||M.D. Anderson Cancer Center|Yes|Recruiting|May 2014|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1362|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02152254||43605|
NCT02152267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29515714.6.0000.5543|Analgesic Effect of Cathodal tDCS Over Right DLPFC in Subjects With Muscular TMD: a Double Blind Crossover RCT|ANALGESIC EFFECT OF CATHODAL TRANSCRANIAL CURRENT STIMULATION OVER RIGHT DORSOLATERAL PREFRONTAL CORTEX IN SUBJECTS WITH MUSCULAR TEMPOROMANDIBULAR DISORDERS: A Double Blind Crossover Randomized Clinical Trial||Federal University of Bahia|Yes|Completed|July 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|60 Years|No|||February 2016|February 3, 2016|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02152267||43604|
NCT02153710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1183-R|Speech Therapy for Aphasia: Comparing Two Treatments|A Prospective, Controlled Study of Rehabilitation of Anomia in Aphasia|PMvSFA|VA Office of Research and Development|No|Recruiting|March 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02153710||43493|
NCT02153996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140121|Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States|Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States||National Institutes of Health Clinical Center (CC)||Terminated|May 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153996||43471|
NCT02161211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404S49427|Dismantling the Components and Dosing of CBT for Co-Occurring Disorders|Dismantling the Components and Dosing of CBT for Co-Occurring Disorders|CBT|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||September 2015|September 17, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02161211||42917|
NCT02162316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyFu|A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia|A Multicenter, Randomized, Double-blind Comparative Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia||Chung-Ang University Hospital|Yes|Not yet recruiting|July 2014|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|20 Years|70 Years|No|||June 2014|June 23, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162316||42833|
NCT02162641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_DOG03_261|Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer|R-SeNSAR Feasibility Study: The Role of Sentinel Node Biopsy in Patients With Anal Cancer|R-SeNSAR|Christie Hospital NHS Foundation Trust|Yes|Withdrawn|September 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with squamous cell carcinoma (SCC) of the anus with clinically negative or        equivocal nodal involvement; and for consideration of chemo-radiotherapy, local excision        or salvage surgery treatment. The majority will be initial presentations, but patients        with recurrent disease may also be considered.|June 2015|June 2, 2015|June 11, 2014||No|The study was terminated early as it failed to recruit.|No||https://clinicaltrials.gov/show/NCT02162641||42808|
NCT02161718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK3831-401|A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder|A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder||Alkermes, Inc.|No|Recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161718||42878|
NCT02161731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15366|Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161731||42877|
NCT02162004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC2014|Continuous Correction|Sensor-Augmented Continuous Correction in Insulin Pump-Treated Type 1 Diabetes||Hvidovre University Hospital|No|Terminated|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|June 2, 2014||No|Technical problems|No||https://clinicaltrials.gov/show/NCT02162004||42856|
NCT02163408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35762|3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery|3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery||Cedars-Sinai Medical Center|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 healthy volunteers and 40 patients with carotid artery disease will be recruited for        this technical development study.|January 2015|January 13, 2015|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163408||42750|
NCT02160132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usix-IgAN-001|A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.|Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.||Sun Yat-sen University|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|14 Years|65 Years|No|||March 2015|March 2, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160132||43000|
NCT02160145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-13-210|Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease|A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1300|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160145||42999|
NCT02151773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247-011|Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination|Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Special Drug Use Surveillance of Vaccinees After the First Vaccination||Takeda|No|Completed|February 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3493|||Both|N/A|N/A|No|Non-Probability Sample|Measles/rubella|May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151773||43642|
NCT02152072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609459-1|Using Simulation-Based Training to Incorporate Lung Ultrasound Into Physical Examination|||Tulane University Health Sciences Center||Not yet recruiting|July 2014|||September 2014|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical Students|May 2014|May 28, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152072||43619|
NCT02152319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MD004049|Automated Telehealth Diagnostics for Remote Parkinson Monitoring|PDRemote Phase II: Automated Telehealth Diagnostics for Remote Parkinson Monitoring|PDRemote|Great Lakes NeuroTechnologies Inc.|No|Active, not recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|21|||Both|N/A|N/A|No|||January 2016|January 8, 2016|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152319||43600|
NCT02152293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOCK|Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery|Pharmacoepidemiology Study on Real Life Impact of Chloroprocaine (CLOROTEKAL®) on the Eligibility for Discharge From Hospital of Patients Requiring Short Outpatient Surgery Under Spinal Anesthesia|CLOCK|Nordic Pharma SAS|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|620|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for surgery under spinal anesthesia of short duration will be informed        about the study and will be asked to participate, from about day -14 (pre-anesthesia        consultation) to 24h after the day of surgery.|May 2015|May 22, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02152293||43602|
NCT02152514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epimorph for VATS|RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo|Randomized Controlled Trial Comparing Post-VATS Analgesia Between Patients With an Intrathecal Injection of Morphine and Sufentanil Versus Placebo.||Université de Sherbrooke|No|Terminated|April 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|75 Years|No|||January 2016|January 18, 2016|May 23, 2014||No|Due to technical details recruitment was unreasonably slow|No||https://clinicaltrials.gov/show/NCT02152514||43585|
NCT02152787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0028|Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia|Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia||Yonsei University|No|Recruiting|May 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|3 Years|12 Years|No|||July 2014|July 7, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02152787||43564|
NCT02152800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-RCH3002P02|A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster|A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster|Vacyless®|Yung Shin Pharm. Ind. Co., Ltd.|No|Completed|April 2011|November 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|20 Years|80 Years|No|||May 2014|May 28, 2014|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02152800||43563|
NCT02153099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENV8058_101|Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects||Takeda|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|May 29, 2014|No|Yes||No|November 13, 2015|https://clinicaltrials.gov/show/NCT02153099||43540|
NCT02153112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-202|Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children|A Phase II, Randomized, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide, With and Without Monophosphoryl Lipid A Adjuvant in Children, Toddlers, and Infants||Takeda|Yes|Recruiting|June 2015|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Anticipated|1210|||Both|6 Weeks|8 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153112||43539|
NCT02153385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-Q099012|Effects of Yoga on Heart Rate Variability and Mood in Women|Effects of Yoga on Heart Rate Variability and Mood in Women: A Randomized Controlled Trial||Kaohsiung Medical University|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02153385||43518|
NCT02154009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140122|Clinical Autonomic Disorders: A Training Protocol|Clinical Autonomic Disorders: A Training Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|8 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 10, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02154009||43470|
NCT02162329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0156|Meditation on Cognitive Function|Effects of Meditation on Cognitive Function and Quality of Life||M.D. Anderson Cancer Center|No|Recruiting|October 2013|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|140|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162329||42832|
NCT02162342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Upper_Extremety- HMO-CTIL|Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities|Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities||Hadassah Medical Organization||Enrolling by invitation|July 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control||1|||||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, spina bifida,        poliomyelitis, neuropathy|July 2014|July 16, 2014|June 11, 2014||||No||https://clinicaltrials.gov/show/NCT02162342||42831|
NCT02163174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Pentoxifylline and Late Onset Sepsis in Preterm Infants|Pentoxifylline Therapy of Late-onset Sepsis in Preterm Infants: A Randomized Controlled Trial.||Mansoura University|No|Completed|May 2011|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|7 Weeks|No|||June 2014|June 12, 2014|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02163174||42768|
NCT02161744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMS-2013-25|Safety, Tolerability and Preliminary Efficacy of Adipose Derived Stem Cells for Patients With Chronic Obstructive Pulmonary Disease|A PHASE I OPEN- LABEL STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF AUTOLOGOUS ADIPOSE STEM CELL (ADULT HUMAN) TO SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE||Arkansas Heart Hospital|Yes|Recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02161744||42876|
NCT02162888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGL-BDM-C-1301|A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients|||Eagle Pharmaceuticals, Inc.|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|81|||Both|18 Years|N/A|No|||June 2014|November 5, 2014|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162888||42789|
NCT02163161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7451004|AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects|A Phase 1, Open Label, Single Dose 3 Way Crossover Study to Evaluate the Bioavailability of a Solid Dose Formulation of PF 04965842 Relative to a Suspension Formulation Under Fasting Conditions and the Effect of Food on the Bioavailability of the Solid Dosage Formulation of Pf 04965842 in Healthy Subjects||Pfizer|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163161||42769|
NCT02159859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH-D-Ertapenem-HD|Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients|Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients||Oakwood Hospital and Medical Center|No|Not yet recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|88 Years|No|||May 2014|June 7, 2014|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159859||43021|
NCT02159872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0870|Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure|A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159872||43020|
NCT02159885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01473|Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)|Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)||Philadelphia Veterans Affairs Medical Center|No|Recruiting|April 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|90 Years|No|||August 2015|September 4, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02159885||43019|
NCT02160470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-0012|Enhancing Exposure Therapy for Snake and Spider Phobias|Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction|Snake/Spider|University of Texas at Austin|No|Recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 6, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02160470||42974|
NCT02151240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cttq-focus-101|Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster|A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China|Focus-101|Cttq|Yes|Not yet recruiting|May 2014|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151240||43682|
NCT02151578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMMP001|Home Management of Malaria and Pneumonia|Home and Community Management of Fevers/Malaria and Pneumonia in Children Under-five: a Cluster Randomised Controlled Trial of an Integrated Approach in a Rural District of Burkina Faso|HMM/P|World Health Organization|No|Completed|January 2009|September 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11500|||Both|6 Months|59 Months|No|||May 2014|May 29, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151578||43657|
NCT02151591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AA020000-01A1|New Approaches to Smoking Cessation in Heavy Drinkers|New Approaches to Smoking Cessation in Heavy Drinkers||Yale University|Yes|Recruiting|May 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||May 2014|May 29, 2014|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151591||43656|
NCT02152332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104508|A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants|A Randomized, Double-blind, Placebo- and Positive-controlled, Multiple-dose, Four-way, Cross-over Study to Evaluate the Effects of Repeated Oral Doses of JNJ-54861911 on Electrocardiogram Intervals in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152332||43599|
NCT02152540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1416-P|rTMS to Improve Cognitive Function in TBI|Repetitive Transcranial Magnetic Stimulation to Improve Cognitive Function in TBI|rTMS TBI|VA Office of Research and Development|Yes|Recruiting|October 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|65 Years|No|||November 2015|November 4, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152540||43583|
NCT02152527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMZHHV|Prospective Observational Study of Trimetazidine Influence on Mitochondrial Metabolism in Human Heart Ventricle|Myocardial Energetics as a Target for Treatment of Ischemic Heart Disease: A Translational Approach From Patient to Mitochondria||University of Split, School of Medicine|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|55|Samples With DNA|Parts of human left ventricular muscle|Both|30 Years|80 Years|No|Probability Sample|Patients with coronary artery disease planned for coronary artery bypass grafting|May 2015|May 27, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152527||43584|
NCT02152813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_GRF_NG|Efficacy of Bilateral Stimulation With Task-oriented Training in Improving Lower Limb Motor Functions in Patients With Stroke|Efficacy of Bilateral Stimulation With Task-oriented Training in Improving Lower Limb Motor Functions in Patients With Stroke: a Randomized, Placebo-controlled Clinical Trial|RCT|The Hong Kong Polytechnic University|Yes|Recruiting|May 2014|December 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|No|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152813||43562|
NCT02153125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-13-TLV|Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy|||Tel-Aviv Sourasky Medical Center||Recruiting|April 2014|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153125||43538|
NCT02153398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961TC00002|A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases|An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases||AstraZeneca|No|Active, not recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|1 Year|14 Years|No|||March 2016|March 4, 2016|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02153398||43517|
NCT02153411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RME-XXX-2014/1|Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population|Evaluation of aSthma Management in Middle EAst Adult Population|ESMAA|AstraZeneca|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7294|||Both|18 Years|130 Years|No|Non-Probability Sample|Asthmatic since at least one year before inclusion. Patient's informed consent obtained.|January 2016|February 1, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02153411||43516|
NCT02153476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMA-202|A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion|A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion||Allegro Ophthalmics, LLC|Yes|Completed|February 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||May 2014|June 22, 2015|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153476||43511|
NCT02153489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/47|A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A Pilot, Double-blind, Placebo-controlled, 2-period Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|N/A|No|||December 2015|December 15, 2015|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02153489||43510|
NCT02162914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005626-30|Regorafenib Versus Placebo to Treat Cholangiocarcinoma|REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.|REACHIN|Erasme University Hospital|No|Recruiting|March 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02162914||42787|
NCT02163447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMOTE-BC1|Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants|Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)|PROMOTE-BC1|University of California, San Francisco|No|Active, not recruiting|June 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|300|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 16, 2014|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163447||42747|
NCT02162901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK091811-01A1|The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs|The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs|DiaBEAT-it|Virginia Polytechnic Institute and State University|Yes|Active, not recruiting|March 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162901||42788|
NCT02163421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002SC_101|Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration|A Phase 1, Open Label, Randomized, Parallel Group Study to Assess the Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration||Takeda|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163421||42749|
NCT02163681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15720|MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children|||University of Virginia||Recruiting|January 2011|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|77|||Both|4 Months|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163681||42729|
NCT02163694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-914|A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer|A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer||AbbVie|Yes|Recruiting|July 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|May 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163694||42728|
NCT02160158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221099|Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers|Open-label, Single-dose, Randomized, Crossover Study To Estimate The Relative Bioavailability Compared To Commercial Extended-release Tablet Formulation And The Effects Of Food Or Sprinkling On Applesauce For Fesoterodine Sustained-release Beads-in-capsule Formulations In Healthy Adult Volunteers||Pfizer|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160158||42998|
NCT02160171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB0113UCC|ANSeR- The Algorithm for Neonatal Seizure Recognition Study|A Multicentre Clinical Evaluation of a Decision Support Algorithm for Neonatal Seizure Detection|ANSeR|University College Cork|No|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Both|36 Weeks|N/A|No|Probability Sample|Term neonates who are undergoing continuous video aEEG/EEG monitoring for clinical        purposes (e.g. because seizures were suspected, or the neonate is being treated with        therapeutic hypothermia)|August 2015|August 10, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02160171||42997|
NCT02161055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYG-1401-WW|Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury|Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury||Lianyungang Oriental Hospital|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|80 Years|No|||July 2014|July 22, 2014|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02161055||42929|
NCT02151266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060752|Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.|The Feasibility of Exercise and Cognitive Retraining to Improve Memory, Attention and Concentration in Heart Failure.|EXCITE|Emory University|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|67|||Both|40 Years|75 Years|No|||January 2016|January 15, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151266||43680|
NCT02151864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131053|LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis|Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis||University of California, San Diego|Yes|Recruiting|July 2014|January 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151864||43635|
NCT02151877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5900209|Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass|Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass.||Advocate Health Care|Yes|Recruiting|July 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|30 Days|No|||January 2015|January 13, 2015|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151877||43634|
NCT02152553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOCORT|Biomarker(s) for Glucocorticoids|Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal Insufficiency|BIOCORT|Vastra Gotaland Region|No|Active, not recruiting|May 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|20 Years|60 Years|No|||January 2016|January 4, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02152553||43582|
NCT02152839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physoc_D20|The Implementation of Novel 'Heavy' Water Techniques for Determining Modulation of Muscle Protein, DNA and Lipid Synthesis Due to Ageing|||University of Nottingham||Completed|May 2013|||July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152839||43560|
NCT02152826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013145|Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity|A Clinical Study Comparing the Safety and Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Existing Dentinal Hypersensitivity||Procter and Gamble|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|May 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152826||43561|
NCT02153450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4213|Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer|A Pilot Trial of Stereotactic Body Radiation Therapy and Metformin for Borderline-Resectable and Locally-Advanced Pancreatic Adenocarcinomas||Case Comprehensive Cancer Center|No|Recruiting|May 2015|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02153450||43513|
NCT02153424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-330|Early Post-marketing Study of Eliquis (Apixaban)|Early Post-marketing Study of Eliquis (Apixaban)||Bristol-Myers Squibb|No|Active, not recruiting|April 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|The sentinel site for the CNFV in Mexico|July 2015|July 3, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02153424||43515|
NCT02153437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV205-006|Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers|A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker||Bristol-Myers Squibb|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|85 Years|No|||February 2016|February 11, 2016|May 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02153437||43514|
NCT02153502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AVP-786-201|Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment||Avanir Pharmaceuticals|Yes|Recruiting|July 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153502||43509|
NCT02153515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426/2014/340|Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood|Fingerprick Fresh Blood for Treatment of Chronic Corneal Ulcers, Persistent Epithelial Defects and Dry Eyes|FAB|Bedford Hospital NHS Trust|No|Enrolling by invitation|April 2014|August 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|16 Years|N/A|No|||May 2014|May 30, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02153515||43508|
NCT02163187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-100|Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation|Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163187||42767|
NCT02163200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-14|Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores|Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores||Assuta Medical Center|Yes|Not yet recruiting|June 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|||Both|60 Years|N/A|No|Non-Probability Sample|Patient 60 y.o. or more both sexs, schedule for total hip replacement, without previous        bedsore|June 2014|June 11, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163200|4 Months|42766|
NCT02163460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/2011-CEP|Repair of Large Incisional Hernias - To Drain or Not to Drain Randomised Clinical Trial|Comparative Study Between the Use of Tubular Drains in Closed Suction System and the Use of Progressive Tension Sutures in Prevention of Infection and Seromas After Surgical Repair of Large Incisional Hernias||Universidade Estadual do Oeste do Paraná|Yes|Completed|May 2012|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163460||42746|
NCT02163434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|496486-3|Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum|Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum||University at Buffalo|Yes|Recruiting|June 2014|May 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||August 2015|August 2, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163434||42748|
NCT02163707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0998|UW Psilocybin Pharmacokinetics Study|Pharmacokinetics of Psilocybin in Normal Adult Volunteers||University of Wisconsin, Madison|Yes|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163707||42727|
NCT02163954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIANO3|ONSET and OFFSET of Ticagrelor in ESRD|Platelet Reactivity in Patients With End Stage Renal Disease Receiving Clopidogrel Compared With Ticagrelor||Kyunghee University Medical Center|Yes|Completed|January 2013|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|80 Years|No|||June 2014|June 12, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02163954||42708|
NCT02163941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070643|Meditation for Emotional Numbing in Post-Traumatic Stress Disorder|Meditation Training for Emotional Numbing in Post-traumatic Stress Disorder||Emory University|No|Recruiting|May 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02163941||42709|
NCT02160795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914093|Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.|Feasibility of Identifying the Chinese Community Intervention Program (CIP) Population and Eligible Incident Pediatric Cancer Cases, and Linking the Cases to the Population to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer (Pilot #N3)||National Institutes of Health Clinical Center (CC)||Not yet recruiting|March 2014|December 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|124500|||Both|17 Years|20 Years|No|||February 2016|March 9, 2016|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02160795||42949|
NCT02160808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBG-01|Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection|Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|May 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160808||42948|
NCT02152150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1107002349|Feeding Trial of Bio-fortified Pearl Millet|Efficacy of Iron Bio-fortified Pearl Millet in Improving the Iron Status of Adolescents in India||Cornell University|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|246|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02152150||43613|
NCT02151916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDP-103988|Preventing Early Childhood Caries in Indigenous Children: the Baby Teeth Talk Study|Reducing Disease Burden and Health Inequalities Arising From Chronic Dental Disease Among Indigenous Children: an Early Childhood Caries Intervention|BTT|University of Toronto|Yes|Active, not recruiting|June 2011|July 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|544|||Female|N/A|N/A|No|||May 2014|May 29, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151916||43631|
NCT02151825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011F7611|Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects|Pilot Study on the Influence of a Synbiotic Formulation (ProSynbiotic) on Gut Microbiota Composition, Adiposity and Selected Markers of Cardiometabolic Health in Overweight or Moderately Obese Individuals||Texas State University, San Marcos|No|Completed|September 2011|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|54|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151825||43638|
NCT02151838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRCS PMTCT|The Thai Red Cross Society Prevention of Mother-To-Child Transmission of HIV (TRCS PMTCT) Program|The Thai Red Cross AIDS Research Centre||Thai Red Cross AIDS Research Centre|No|Recruiting|September 2008|December 2022|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|15 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The study population will be HIV-infected pregnant women who request HAART from the TRCS        PMTCT program. These pregnant women will be under the care of the health care teams in 30        hospitals throughout Thailand which have registered with the TRCS PMTCT program since        April 2004|November 2015|November 2, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151838||43637|
NCT02152085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0720|Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis|Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis||University of Colorado, Boulder|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||June 2014|June 3, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02152085||43618|
NCT02152852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18DK088072|Peer Support for Achieving Independence in Diabetes|Peer Support for Achieving Independence in Diabetes (Peer AID)|Peer-AID|Public Health - Seattle and King County|No|Active, not recruiting|November 2011|August 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|287|||Both|30 Years|70 Years|No|||October 2015|October 22, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02152852||43559|
NCT02152865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anti-acne product|Clinical Trial of Lupeol for Mild-moderate Acne|||Seoul National University Hospital||Completed|December 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|15 Years|N/A|No|||May 2014|May 28, 2014|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02152865||43558|
NCT02153138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-VN-0085-CTIL|The Effect of Plant-based Diets (Vegetarian and Vegan) on Endothelial Function and Atherogenic Parameters|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|150|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153138||43537|
NCT02153463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/72X|Activity in Tourette Syndrome|Enhancing Physical Activity in Children With Tics and Tourette Syndrome: Impact on Tic Severity and Quality of Life||Children's Hospital of Eastern Ontario|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|8 Years|16 Years|No|||August 2015|August 5, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02153463||43512|
NCT02153723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rett Syndome Copaxone|Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)|Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)||Montefiore Medical Center|No|Active, not recruiting|August 2013|June 2015||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|10 Years|N/A|No|||April 2015|April 19, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153723||43492|
NCT02153801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number 986|Genito Urinary Function With High or Low Inferior Mesenteric Artery Ligation in Laparoscopic Anterior Rectal Resection|Sexual Urinary Function in Patients Undergoing Laparoscopic Low Anterior Resection With Total Mesorectal Excision With High Or Low Ligation of the Inferior Mesenteric Artery With Preservation of Left Colic Artery Multicentre Randomized Trial||Niguarda Hospital|No|Recruiting|September 2014|September 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||September 2014|February 19, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02153801||43486|
NCT02154061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074239|Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics|Systems Biology of Inactivated Influenza Vaccine (IIV) in Healthy Adults With or Without Use of Broad Spectrum Antibiotics|VAX-002|Emory University|No|Completed|April 2015|January 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02154061||43466|
NCT02162940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARI-06|Statin and Epidural Steroid Injection|Effect of Statin Use on Low Back Pain Steroid Injections.||Adnan Menderes University|Yes|Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 0|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|All patients coming to the Algology Department with complaints of low back pain and        scheduled to receive Transforaminal epidural steroid injection. Statin users (Group 1) and        non-statin users (Group 2) will be record.|June 2014|June 12, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02162940|6 Months|42785|
NCT02163967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMC1209013001|Effect of CES on Parasympathetic Tone|Effect of Cranial Electrical Stimulation (CES) on Autonomic Regulation||Weill Medical College of Cornell University|No|Completed|January 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|February 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02163967||42707|
NCT02163980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0111|Effect of Dexmedetomidine on the Characteristics of High Volume/Low Concentration Ropivacaine in a Caudal Block in Pediatrics|||Yonsei University|No|Completed|May 2011|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Male|1 Year|6 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02163980||42706|
NCT02163720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSPECTYON (GINECO-OV229)|Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)|Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse||ARCAGY/ GINECO GROUP|No|Recruiting|June 2014|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with epithelial ovarian cancer, fallopian tube or peritoneal with treatment        receiving in relapse platinum-sensitive|August 2015|October 21, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02163720|12 Months|42726|
NCT02163733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00009|Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer|An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI||AstraZeneca|No|Active, not recruiting|November 2014|April 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|43|||Both|18 Years|99 Years|No|||February 2016|February 8, 2016|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02163733||42725|
NCT02160184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIGHT CONTROL|Nocturnal Insulin-Glucose in Hospital: Tight Control||NIGHT CONTROL|Corporacion Parc Tauli||Not yet recruiting||||February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1|||12|||Both|18 Years|70 Years|No|||June 2014|June 9, 2014|June 9, 2014||||No||https://clinicaltrials.gov/show/NCT02160184||42996|
NCT02160197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142804|Outcome of Rehabilitation Following Internally Fixed Ankle Fractures|A Randomised Controlled Trial of Outcome of Different Post Operative Rehabilitation Regime Following Internally Fixed Ankle Fractures||Countess of Chester NHS Foundation Trust|Yes|Not yet recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|50 Years|No|||June 2014|June 9, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160197||42995|
NCT02159898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-P3-12-02|EndoMAXX EVT Compared to EndoMAXX|Prospective, Multicenter, Single Blind, Randomized Study Comparing the EndoMAXX EVT Fully Covered Esophageal Stent With Valve to the EndoMAXX Fully Covered Esophageal Stent for Malignant Strictures Requiring Stent Placement Across the Gastroesophageal Junction||Merit Medical Systems, Inc.|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159898||43018|
NCT02160496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEICA;PI13/00108|A Study to Assess the Effect of Diets With Different Protein Composition - Mainly Coming From Lean Red Meat - in Body Weight and Lipid Profile in Overweight and Obese Women|A Randomized Study to Assess the Effect of Diets With Different Protein Composition - Mainly Coming From Lean Red Meat - in Body Weight and Lipid Profile in Overweight and Obese Women||Instituto Aragones de Ciencias de la Salud||Completed|April 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|90|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160496||42972|
NCT02160821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1610841001|TAPB vs. Caudal for Lower Abdominal Surgery in Children: A Double-Blinded Randomized Controlled Trial|Transversus Abdominis Plane Block Versus Caudal Epidural for Lower Abdominal Surgery in Children: A Double-Blinded Randomized Controlled Trial||Nemours Children's Clinic|No|Completed|January 2011|May 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|45|||Both|1 Year|9 Years|No|||June 2014|June 9, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02160821||42947|
NCT02161328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT2014|Electric Impedance Tomography Before and After Dilatative Tracheotomy|EIT: Changes of Pulmonary Ventilation Before and After Tracheotomy||Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|February 2014|||December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|85 Years|No|Non-Probability Sample|ICU patients undergoing an elective dilatative tracheotomy. Before and after tracheotomy        the results of EIT will be compared.|March 2015|March 24, 2015|January 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02161328||42908|
NCT02151552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF 2010060|Assessing NOS Uptake With PET Imaging in Lung Inflammation|Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation||Washington University School of Medicine|Yes|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Both|19 Years|44 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151552||43659|
NCT02151565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTEMS|High-tone External Muscle Stimulation for Pain Reduction|High-tone External Muscle Stimulation for Treatment of Chronic Pain|HTEMS|West German Center of Diabetes and Health|Yes|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151565||43658|
NCT02151929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM_BVS1|Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction|Bioresorbable Vascular Scaffold in Patient With ST Elevation Myocardial Infarction: a Randomized Comparison With Everolimus Eluting Stent||San Giuseppe Moscati Hospital|No|Completed|May 2013|April 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|85 Years|No|||May 2014|May 30, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02151929||43630|
NCT02151851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0044|A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis|A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel Group, Randomized 24-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol (CZP) as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate|RAPID-C|UCB Pharma|Yes|Active, not recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151851||43636|
NCT02152098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-114|Skeletal Muscle Strain Injuries and the Connective Tissue: Characterization, Recovery and Optimal Treatment|Skeletal Muscle Strain Injuries and the Connective Tissue: Characterization, Recovery and Optimal Treatment||Bispebjerg Hospital|No|Recruiting|April 2014|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02152098||43617|
NCT02152345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL7011|Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients|A Randomized Clinical Trial of Efficacy and Safety on the Use of Belatacept as Compared to Tacrolimus in the Setting of Rabbit Antithymocyte Globulin Induction and Rapid Steroid Discontinuation in Deceased Donor Renal Transplant Recipients With a Focus on Ameliorating Delayed Graft Function||Columbia University|No|Recruiting|April 2014|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2014|May 30, 2014|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152345||43598|
NCT02153151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.374|Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy|A Pilot Study to Evaluate the In-vitro Effect of AMP-514, a PD-1 Inhibitor, on Peripheral Blood T Cell Proliferation and Cytokine Production From Patients With Solid Malignancies Treated With Radiotherapy (RT)||Thomas Jefferson University|Yes|Suspended|November 2013|||November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|PBMCs|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with solid malignancies to be treated with RT|December 2015|December 14, 2015|May 29, 2014||No|Withdrawn by PI|No||https://clinicaltrials.gov/show/NCT02153151||43536|
NCT02153164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|589602|Effect of the Steep Trendelenburg Position on Respiratory Gas Heat Content|Effect of the Steep Trendelenburg Position on Respiratory Gas Heat Content||University of California, Davis|No|Enrolling by invitation|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Elective surgery requiring steep Trendelenberg position.|May 2014|May 29, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153164||43535|
NCT02152878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT01|Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression|Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression|TDCS-BD|University of Sao Paulo|Yes|Recruiting|April 2014|February 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152878||43557|
NCT02153736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUIRB HM20001308|Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention|Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention (SPEEDI) - Phase 1 Clinical Trial|SPEEDI|Virginia Commonwealth University|No|Active, not recruiting|April 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|18 Weeks|No|||November 2015|November 4, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02153736||43491|
NCT02153177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-0540|The Effect of NSAIDs After a Rotator Cuff Repair Surgery.|The Effect of NSAIDs After a Rotator Cuff Repair Surgery. A Prospective Randomized Controlled Trial||University of Chicago||Not yet recruiting|January 2015|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|75 Years|No|||December 2014|December 5, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153177||43534|
NCT02154074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexmedetomidine 20140527|Dexmedetomidine Influence on the Level of Perioperative Blood Glucose and Insulin of Elderly Diabetes Patients|||Second Affiliated Hospital of Xi'an Jiaotong University|No|Recruiting|May 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|92|||Both|60 Years|80 Years|No|||May 2014|May 30, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02154074||43465|
NCT02154087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-034|A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers|A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers|MOA 034|Smith & Nephew, Inc.|No|Terminated|July 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|May 28, 2014|Yes|Yes|based on outcome of previous study|No||https://clinicaltrials.gov/show/NCT02154087||43464|
NCT02163473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201200142|Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock|Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock||University of Florida|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|63|Samples With DNA|whole blood, serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy controls recruited from the community. Subjects with sepsis admitted to the        University of Florida Hospital.|September 2015|September 17, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02163473||42745|
NCT02163512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALB-BET-2011-01|Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites|Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites|ALB-BET|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|46|||Both|18 Years|75 Years|No|Probability Sample|Patients with hepatic cirrhoris and refractory or non-refractory ascites. These patients        are going to be treated with beta blockers as primary or secondary prophylaxis of variceal        bleeding|April 2015|June 24, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163512||42742|
NCT02159911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USJ-002|Oral Misoprostol for Cervical Priming Before Hysteroscopy|Use of Oral Misoprostol for Cervical Priming Before Hysteroscopy: a Randomized Comparison of Two Dosages||Saint-Joseph University|Yes|Completed|June 2004|November 2004|Actual|November 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|||Female|N/A|N/A|No|Probability Sample|All patients admitted for hysteroscopy were offered participation in the study, and those        choosing to participate were assessed according to the inclusion and exclusion criteria of        the study protocol|June 2014|June 7, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02159911||43017|
NCT02159924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROM_iPhone_2014|Posture and Mobility Measurements of the Upper Quadrant in Asymptomatic Subjects by Means of a Smartphone|Posture and Mobility Measurements of the Upper Quadrant in Asymptomatic Subjects by Means of a Smartphone||Universidade do Porto|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Asymptomatic subjects from scholar community|September 2014|September 24, 2014|June 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02159924||43016|
NCT02159937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDCX|In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides|In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides||Recepta Biopharma|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically confirmed metastatic malignant neoplasia.|August 2015|August 3, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02159937||43015|
NCT02160483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/728/D|Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain|Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain||KK Women's and Children's Hospital|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Female|21 Years|70 Years|No|||September 2015|September 3, 2015|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02160483||42973|
NCT02160210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-001|Ultrafine Endoscope for Colonoscopy in Diagnosis of Colorectal Diseases|Ultrafine Endoscope for Unsedated Colonoscopy is an Effective Method to Reduce Abdominal Pain:a Prospective Randomized Study.||First Affiliated Hospital of Harbin Medical University|Yes|Not yet recruiting|June 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|June 9, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02160210||42994|
NCT02160522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00215|Endotracheal Tube (ETT) Cuff Pressure Study in the Emergency Department (ED)|Endotracheal Tube Cuff Pressure in the Pediatric Emergency Department: A Pilot Study||Nationwide Children's Hospital|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|N/A|N/A|No|Non-Probability Sample|Patients that are intubated with a cuffed endotracheal tube in the emergency department of        Nationwide Children's Hospital.|June 2015|June 5, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02160522||42970|
NCT02151305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTEM_anesthesia|Different Hemostasis According to the Anesthetic Agents|The Influence of Propofol and Sevoflurane on Hemostasis During Ophthalmic Surgery: Rotational Thromboelastographic Study.||Seoul National University Bundang Hospital||Completed|August 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|66|||Both|20 Years|80 Years|No|||May 2014|May 27, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02151305||43678|
NCT02151318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15309|Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies|Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies||University of South Florida|No|Recruiting|December 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|20|Samples Without DNA|The ophthalmologist will collect samples from the tissue that is removed during patients eye      surgery that would otherwise be discarded or thrown away. Researchers will collect the      sample and grow in the laboratory conditions. These cells will then be studied for further      research on glaucoma.|Both|18 Years|N/A|No|Non-Probability Sample|Patients having glaucoma and undergoing a trabeculotomy|June 2015|June 25, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02151318||43677|
NCT02151942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRS-001|Patient-Specific Simulation Used for EVAR Procedure Rehearsal - Evaluation of Clinical Performance With and Without Prior Rehearsal|Patient-Specific Simulation Used for Case Rehearsal Prior to EVAR Procedure - Evaluation of Clinical Performance With and Without Prior Rehearsal Using the Procedure Rehearsal Studio. Multi-center Randomized Study|PRS|Simbionix US Corporation|No|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Subjects admitted for elective endovascular AAA repair will be randomized|June 2015|June 16, 2015|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151942||43629|
NCT02152111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05155812.2.0000.5257|Hipoenergetic Effect of Diet Associated or Not With the Consumption of Coconut Flour in Women With Overweight|Effect of Hipoernergetic Diet Combined or Not With Coconut Flour on Overweight Women||Universidade Federal do Rio de Janeiro|No|Completed|February 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Female|20 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 22, 2014|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02152111||43616|
NCT02152124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/857|Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?|Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?||University Hospital, Ghent|No|Recruiting|June 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|Serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Groups 1-3 and 5: outpatient clinic attendants Group 4: recruted from community (by        placard)|June 2015|June 3, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02152124||43615|
NCT02152384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15406|A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements|The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.||Eli Lilly and Company|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|65 Years|No|||December 2014|December 9, 2014|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152384||43595|
NCT02152358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20126003312-30|PTH - Preemptive Treatment for Herpesviridae|Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial|PTH|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|March 2014|July 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|March 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02152358||43597|
NCT02152371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13195|A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes|A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine|AWARD-9|Eli Lilly and Company|No|Completed|May 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152371||43596|
NCT02152566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-117|Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep|Study of the Effects of Nasal High Flow Therapy as a Treatment Option for Patients With Respiratory Insufficiencies During Sleep.||Fisher and Paykel Healthcare|Yes|Terminated|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 29, 2014||No|Difficulty with recruitment|No|August 19, 2015|https://clinicaltrials.gov/show/NCT02152566||43581|
NCT02152891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-133563|A Community Paramedicine Initiative for Older Adults Living in Subsidized Housing|A Community Paramedicine Initiative for Older Adults Living in Subsidized Housing|CHAP-EMS|McMaster University|No|Recruiting|October 2014|August 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1900|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152891||43556|
NCT02152904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPUB|Risk Factors of Rebleeding After Peptic Ulcer Bleeding: a Nationwide Cohort Study|Risk Factors of Rebleeding After Peptic Ulcer Bleeding: a Nationwide Cohort Study|KPUB|Incheon St.Mary's Hospital|Yes|Recruiting|April 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients who visit the hospital with symptoms suggestive of peptic ulcer bleeding such as        melena or hematemesis. These patients recieve endoscopy and when they are diagnosed with        peptic ulcer bleeding are eligible for enrollment.|March 2015|March 24, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152904|1 Year|43555|
NCT02153190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628 4|Hybrid Artificial Pancreas in Home Setting|Assessment of Hybrid Use of an Artificial Pancreas in a Home Setting for Two Months in Patients With Type 1 Diabetes|AP Hybrid|University Hospital, Montpellier|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153190||43533|
NCT02153203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERFAS-2014-15-058-P|Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders|Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders||Université de Montréal|No|Recruiting|October 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|12 Years|No|||December 2015|December 3, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153203||43532|
NCT02153827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12111308exp|Shoulder Eccentric External Rotator Training for Subacromial Pain Syndrome|Shoulder External Rotator Eccentric Training for Subacromial Impingement Syndrome||Nova Southeastern University|No|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02153827||43484|
NCT02163525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0025|Post Market TRUST - U.S.A. Study|The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study||Halt Medical, Inc|Yes|Recruiting|June 2014|December 2022|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|No|||December 2015|January 11, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02163525||42741|
NCT02163746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8606|Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing|A Prospective, Randomized, Controlled Clinical Trial Comparing the Efficacy Carbon Dioxide (CO2) Laser Excision Versus Surgical Deroofing in the Treatment of Hidradenitis Suppurativa||Henry Ford Health System|Yes|Recruiting|March 2014|||February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|13 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02163746||42724|
NCT02163993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15414|A Study of LY2951742 in Participants With Migraine Headache|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine||Eli Lilly and Company|Yes|Completed|July 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|410|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163993||42705|
NCT02164006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGR-BV-107|Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma||TG Therapeutics, Inc.|Yes|Active, not recruiting|June 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164006||42704|
NCT02159950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 250813|Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2015|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|N/A|No|||August 2015|August 14, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02159950||43014|
NCT02160223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sugammadex-OSA|Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea|Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea||Diskapi Teaching and Research Hospital|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|19 Years|70 Years|No|||January 2012|December 7, 2014|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02160223||42993|
NCT02160236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/469|Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam|Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam in Lumbar Disc Surgery||TC Erciyes University|No|Recruiting|November 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02160236||42992|
NCT02161367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simethicone-CRSurgery-1415|Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery|A Randomized Controlled Trial of the Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery: A Pilot Study||McMaster University||Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161367||42905|
NCT02161081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC2011-05-032-023|A Study on Improved Dynamic Myocardial Perfusion With Less Effective Radiation Dose in CT (SIMPLE CT)|Adenosine-induced Stress Myocardial Perfusion Imaging With Dual-source 128-slice CT: a Study on the Comparison of Diagnostic Performance of Dynamic Scanning Protocols||Samsung Medical Center|Yes|Recruiting|January 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|30 Years|80 Years|No|||March 2014|July 6, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02161081||42927|
NCT02161354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTC-510-004|Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510 and NTC-510A) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.||Nanotherapeutics, Inc.|No|Recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|66|||Both|18 Years|45 Years|No|||February 2016|February 23, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161354||42906|
NCT02151617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7911001|A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 With Or Without Food In Healthy Adult Subjects||Pfizer|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02151617||43654|
NCT02151903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO-101-EXT|Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL|An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)||Alopexx Oncology, LLC|Yes|Enrolling by invitation|November 2014|August 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151903||43632|
NCT02152436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-32|Simulation-based Curriculum to Enhance Culture of Safety in Operating Rooms||PROPECS|University Hospital, Grenoble|No|Active, not recruiting|November 2013|July 2016|Anticipated|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|259|||Both|N/A|N/A|No|Probability Sample|Surgical interventions in Grenoble University Hospital|December 2015|December 7, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02152436||43591|
NCT02152397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA035331-01A1|Safety and Health Intervention Project|Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment|SHIP|University of Michigan|No|Active, not recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02152397||43594|
NCT02152618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSP23320095655WC-KS|Kansas Intensive Permanency Project|Permanency Innovations Initiative- Kansas Intensive Permanency Project|PIIKIPP|Westat|No|Enrolling by invitation|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|720|||Both|3 Years|16 Years|No|||June 2014|June 6, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02152618||43577|
NCT02152631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15296|A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer|JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy|JUNIPER|Eli Lilly and Company|Yes|Recruiting|September 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152631||43576|
NCT02152592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11524|Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial|Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial||Maastricht University Medical Center|No|Completed|October 2007|||March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|70 Years|No|||May 2014|May 28, 2014|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02152592||43579|
NCT02152605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211|A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD||GlaxoSmithKline|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|498|||Both|40 Years|N/A|No|||February 2016|February 25, 2016|May 29, 2014|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT02152605||43578|
NCT02152579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATC 001/14|Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci|Open Monocentric Clinical Study for the Evaluation of Efficacy and Safety of 20 mg Monocordil Tablets Manufactured by Laboratórios Baldacci in Patients With Stable Angina||Laboratórios Baldacci S.A|No|Not yet recruiting|July 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|80 Years|No|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152579||43580|
NCT02153242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B596|The Effects of Selective Site Right Ventricular Pacing|Does a Surrogate Marker Exist That Can be Used as A Predictor For Left Ventricular Dysfunction In Patients Undergoing Right Ventricular Pacing|PacingRV|Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Completed|September 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing SVT studies|July 2015|July 20, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02153242||43529|
NCT02153216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0225|Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load|Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load: An RCT in ART Clinics in Vietnam|F-REDART|University of North Carolina, Chapel Hill|No|Recruiting|May 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|49 Years|No|Non-Probability Sample|ART clients with hazardous alcohol use; PWID in general population with hazardous alcohol        use|September 2015|September 14, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02153216||43531|
NCT02153229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14513|MPM PDT Phase II Trial|A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153229||43530|
NCT02154126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0004|PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor|PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor|PRECISE|Senseonics, Inc.|No|Completed|May 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|81|||Both|18 Years|N/A|No|||May 2015|January 19, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02154126||43461|
NCT02164032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTO_humans|The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS|The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS a Randomized, Controlled, Double Blinded Trial|INTO_humans|Medical University of Vienna|Yes|Recruiting|September 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|26|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02164032||42702|
NCT02163759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA28948|A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis in Patients Naive to TNF Inhibitors (Study #1)|PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS IN PATIENTS WHO ARE NAÏVE TO TNF INHIBITORS||Hoffmann-La Roche||Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163759||42723|
NCT02163772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC100-2314-B-182-021|Early Intracordal Hyaluronic Acid Injection During Spontaneous Reinnervation for Unilateral Recurrent Laryngeal Nerve Paralysis|Early Intracordal Hyaluronic Acid Injection During Spontaneous Reinnervation for Unilateral Recurrent Laryngeal Nerve Paralysis||Chang Gung Memorial Hospital|No|Completed|August 2011|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||July 2013|June 12, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163772||42722|
NCT02164019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-287|A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur|A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02164019||42703|
NCT02160535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46614-A|Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA|Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA||University of Washington|Yes|Recruiting|May 2014|December 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|60 Years|No|||June 2014|June 6, 2014|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160535||42969|
NCT02160509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Telementoring for Emergency Ultrasonography Performed by Emergency Physicians With Low Experience.|Telementoring for Emergency Ultrasonography Performed by Emergency Physicians||Hanyang University|No|Completed|June 2014|April 2015|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|N/A|N/A|No|Probability Sample|The patients who undergo the ultrasonography in the emergency department|April 2015|April 16, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160509|6 Months|42971|
NCT02160834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03KD095740-02|Reducing Sedentary Time in Obese Adults (Study 2)|A Mobile Health Approach to Reducing Sedentary Time in Bariatric Surgery Patients|B-MOBILE|The Miriam Hospital|No|Withdrawn|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2014|March 19, 2015|June 9, 2014||No|study not initiated|No||https://clinicaltrials.gov/show/NCT02160834||42946|
NCT02161926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 149 03|Assessments of Dietary Restrictions in Young and Elderly Obese Men : Metabolism Obesity Nutrition Age|Dietary Restrictions Implications on Metabolic Changes in Obese Men : Comparison Between Two Groups of Different Ages (60-70 Years Old Versus 30-40 Years Old)|MONA|University Hospital, Toulouse|No|Recruiting|May 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|32|||Male|30 Years|70 Years|No|||April 2015|April 24, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02161926||42862|
NCT02161614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILA V E2|Vascular Effect of Estradiol Valerate Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|Flow-mediated Evaluation of the Brachial Artery of Climacteric Women Using Estradiol Valerate and Placebo. Randomized, Double Blinded, Placebo Controlled Study.|VEDILA|Federal University of Minas Gerais|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161614||42886|
NCT02161627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBWSH1302|Safety and Effectiveness of Spinal Cord Stimulation With Automatic Control to Treat Chronic Pain in an Extended Trial|Prospective, Multicenter, Randomized Double-blind Crossover Study Examining the Safety and Effectiveness of Spinal Cord Stimulation Incorporating Feedback to Treat Patients With Chronic Pain of the Trunk and/or Limbs in an Extended Trial|Panorama|Saluda Medical Pty Ltd|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02161627||42885|
NCT02152137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091305|Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer|A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination With Paclitaxel Versus Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer||Alliance for Clinical Trials in Oncology|Yes|Recruiting|September 2014|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152137||43614|
NCT02152722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR 2012 TBI|Breath Test for Biomarkers in Humans Receiving Total Body Irradiation|Breath Test for Biomarkers in Humans Receiving Total Body Irradiation||Menssana Research, Inc.|No|Recruiting|September 2013|November 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing total body irradiation prior to chemotherapy.|April 2015|April 6, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02152722||43569|
NCT02152163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB Protocol #20121749|Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients|Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients||Delray Medical Center|Yes|Recruiting|October 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|134|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|May 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152163||43612|
NCT02152410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture Morphine in RC|Acupuncture Versus IV Morphine in the Treatment of Acute Renal Colic|Comparison of Two Antalgic Strategies: Acupuncture Versus Intravenous Morphine in the Treatment of Acute Renal Colic in Emergency Departement|AcuMoRC|University of Monastir|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 28, 2014|September 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02152410||43593|
NCT02152930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46719.029.13|The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication|The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication|FISHTIC|Medical Center Alkmaar|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152930||43553|
NCT02152917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/11297|Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty|Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study||University of Sao Paulo General Hospital|No|Recruiting|February 2014|May 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 30, 2014|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02152917||43554|
NCT02153541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREWS01|Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults|Assessing the Efficacy of Antipyrine Benzocaine Otic Solution in the Ear Canal to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults.|CREWS01|Global United Pharmaceutical Corporation|Yes|Not yet recruiting|July 2014|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|June 2, 2014|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153541||43506|
NCT02153528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OneRIF|Optimization of the TB Treatment Regimen Cascade|Optimization of the TB Treatment Regimen Cascade|OneRIF|Damien Foundation|Yes|Active, not recruiting|November 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|946|||Both|15 Years|N/A|No|||November 2015|November 16, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02153528||43507|
NCT02153788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018356|Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia|A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia||Duke University||Completed|September 2009|||September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|69 Years|No|||January 2015|February 24, 2015|May 30, 2014|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT02153788||43487|
NCT02154139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-201|Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"|Leuplin SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"||Takeda|No|Completed|December 2005|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|651|||Female|N/A|N/A|No|Non-Probability Sample|Breast cancer|January 2016|January 19, 2016|April 23, 2014||No||No|January 19, 2016|https://clinicaltrials.gov/show/NCT02154139||43460|
NCT02154152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|enuresishmc|A Clinical Study on Causticum 200 Centesimal Potency in Primary Enuresis|A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS|PE|Fr Muller Homoeopathic Medical College|No|Recruiting|May 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|5 Years|15 Years|No|||May 2014|June 2, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154152||43459|
NCT02159976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1403/243-003|Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea|A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea||Seoul National University Bundang Hospital|No|Recruiting|July 2014|July 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02159976||43012|
NCT02159963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-035 (FSH)|High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy|High Intensity Interval Training in Patients With Facioscapulohumeral Muscular Dystrophy|HIT-FSHD|Rigshospitalet, Denmark|No|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02159963||43013|
NCT02160249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7035|RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)|RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia): a Cluster-randomised Trial|RISE|London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|166|||Both|18 Years|N/A|No|||December 2015|March 18, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02160249||42991|
NCT02160262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-304|Open-label Safety Study in Adults With ADHD|A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Sunovion|Yes|Active, not recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|700|||Both|18 Years|55 Years|No|||February 2016|February 11, 2016|June 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160262||42990|
NCT02160847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14356|Development of the DRIVE Curriculum to Address Childhood Obesity Risk Factors|Pilot Trial of the DRIVE Parent Training Curriculum to Target Risk Factors for Childhood Obesity||Georgia State University|No|Completed|September 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|2 Years|65 Years|No|||March 2016|March 24, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02160847||42945|
NCT02161094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD-019|Diabetes Incentive Performance Study (DIPS) at Shanghai Jiading District|Diabetes Incentive Performance Study（DIPS）at Shanghai Jiading District||Shanghai Jiao Tong University School of Medicine|Yes|Enrolling by invitation|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|1300|||Both|40 Years|74 Years|No|||December 2014|December 1, 2014|May 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02161094||42926|
NCT02162212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_DM_LJM|Diabetic Shoulder Mobility|Diabetic Upper Extremity Pathophysiology, Limited Joint Mobility and Disability||Washington University School of Medicine|Yes|Recruiting|September 2014|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|40 Years|70 Years|No|||January 2015|January 9, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02162212||42841|
NCT02162199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1450-102|A Single Dose Study of Debio 1450 in Healthy Subjects|A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Escalating Oral Doses of Debio 1450 in Healthy Subjects||Debiopharm International SA|No|Completed|June 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02162199||42842|
NCT02151643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT20-201|Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease|Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease||Phosphate Therapeutics|Yes|Completed|May 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1503|||Both|18 Years|90 Years|No|||October 2015|October 20, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02151643||43652|
NCT02151656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F17464 GE 2 01|F17464 in Acute Schizophrenia Trial|Effects of F17464 in Acute Exacerbation of Schizophrenia|FAST|Pierre Fabre Medicament||Completed|June 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|64 Years|No|||January 2016|January 26, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02151656||43651|
NCT02152176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2013-08|Morphine Titration by Patient Self-controlled by a Mechanical Device Versus Administration by the Nurse for Patients With Severe Acute Pain in the Emergency Department|Titration Morphinique autocontrôlée Par le Patient Par un Dispositif mécanique à Usage Unique Versus Administration Par l'infirmière Chez Les Patients Ayant Une Douleur aiguë sévère Aux Urgences.|TACIDOU|University Hospital, Angers|Yes|Not yet recruiting|July 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152176||43611|
NCT02152423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXAMED|Enoxamed Study in the Treatment of Acute Coronary Syndromes|Comparison of the Anti Xa Activity in the Enoxaparin for Acute Coronary Syndromes Admitted to the Emergency. Randomized Clinical Trial ENOXAMED Versus LOVENOX|ENOXAMED|University of Monastir|Yes|Completed|June 2013|June 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02152423||43592|
NCT02152670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013567|Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET|||Yale University|Yes|Recruiting|May 2014|||May 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|May 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152670||43573|
NCT02152644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1589|Prevalence of Amyloidosis and Carpal Tunnel|Prevalence of Amyloidosis in Carpal Tunnel Surgery||Hospital Italiano de Buenos Aires|No|Not yet recruiting|June 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients older than 21 years with carpal tunnel syndrome with surgical indication        (moderate to severe symptoms that do not respond to conservative treatment physiotherapy,        splinting, activity modification) for more than 6 months.|December 2015|December 16, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02152644||43575|
NCT02152657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-002|Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study|||Hospital Sao Rafael|Yes|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02152657||43574|
NCT02153255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WM/0120|Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa|||Birmingham Children's Hospital NHS Foundation Trust|No|Suspended|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|6 Years|18 Years|No|Non-Probability Sample|Children With Mucopolysaccharidosis Type IVa|January 2015|January 26, 2015|May 28, 2014||No|Closure of Gait Analysis Laboratory - currently identifying alternative facilities and if    identified then recruitment will commence|No||https://clinicaltrials.gov/show/NCT02153255||43528|
NCT02153268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-BNS-02|Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration|Phase I/II Open Label FIH Single Center Clinical Study Aimed to Evaluate the Safety and the Efficacy of BonoFill in Reconstructing the Bone.||BonusBio Group Ltd|No|Recruiting|February 2014|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||May 2014|June 2, 2014|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02153268||43527|
NCT02153281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETB-071-13|Detecting Central and Peripheral Biomarkers in MDD|Detecting Central and Peripheral Biomarkers in Major Depressive Disorder (MDD)|DETB|Centre for Addiction and Mental Health|Yes|Recruiting|June 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02153281||43526|
NCT02153814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-STU00075489|Endometrial Injury and in Vitro Fertilization Outcomes|Pilot Study on the Effect of Endometrial Injury in Patients Undergoing in Vitro Fertilization (IVF)||Northwestern University|No|Recruiting|August 2014|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|600|||Female|18 Years|45 Years|No|||February 2016|February 21, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02153814||43485|
NCT02159989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01107|Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of MLN0128 (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers||National Cancer Institute (NCI)|No|Recruiting|June 2014|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02159989||43011|
NCT02160275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43469.018.13|Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format|Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, APPEL 4|APPEL4|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||October 2015|October 1, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02160275||42989|
NCT02160548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicine SOMCH|Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning|Effect of Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen During Resuscitation of OP Pesticide Poisoned Patients|SalbutamolOP|Sylhet M.A.G.Osmani Medical College|Yes|Completed|April 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02160548||42968|
NCT02160561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00023156|Feasibility of Upright Bed Position in ARDS Patients|Feasibility of Upright Bed Position in ARDS Patients||Wake Forest School of Medicine|Yes|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02160561||42967|
NCT02161107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG004|Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Grass-SPIRE in Subjects With Asthma and Grass-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161107||42925|
NCT02161380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140248|Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy|An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA|LHON|University of Miami|Yes|Recruiting|July 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|60 Years|No|||December 2015|December 14, 2015|June 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02161380||42904|
NCT02161640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13ID11|Vascular Dysfunction in Paediatric IBD|Investigation of Vascular Endothelial Dysfunction, Thromboembolism and Structural Arterial Disease in Paediatric and Adolescent Inflammatory Bowel Disease (IBD)||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples Without DNA|Platelet poor plasma (PPP)|Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be identified by the Clinical Nurse Specialists (CNS's) for Inflammatory        Bowel Disease (IBD), on-call Gastroenterology registrars and consultants as well as the        Pre-admission Nurses (PAN) within Great Ormond Street Hospital (GOSH). The lead        consultants for IBD would also alert us of suitable patients for the study, as well as any        suitable patients attending their regular gastroenterology clinics.|February 2016|February 9, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161640||42884|
NCT02163083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1157-6624|Detection of Lymphnodes Using ICG During RARP|Detection of Lymph Nodes by Means of Intraoperative Fluorescence Lymphography Using Indocyanine Green (ICG) During the Radical Robot-assisted Prostatectomy||St. Antonius Hospital Gronau|No|Active, not recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Male|18 Years|75 Years|No|||May 2015|May 18, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163083||42774|
NCT02162550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026|Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus|Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM||Phoenix VA Health Care System|No|Recruiting|June 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|21 Years|75 Years|No|||July 2015|July 9, 2015|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02162550||42815|
NCT02151669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R13/068|Diet Intervention Spirometry and Tobacco|Effect of a Mediterranean Diet Intervention Pulmonary Function in Smokers:A Multicenter Randomized Clinical Trial in Primary Care Centers|DIET|Jordi Gol i Gurina Foundation|No|Active, not recruiting|November 2013|November 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02151669||43650|
NCT02184624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200301|Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices|An Open-label Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|569|||Both|40 Years|N/A|No|||September 2015|November 19, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184624||41125|
NCT02152696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTorNOT|Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location|Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment|ACTorNOT|Yale University|Yes|Recruiting|May 2014|May 2019|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|276|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02152696||43571|
NCT02152709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEPI-003|Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine|A Phase 3, Randomized, Controlled, and Blinded Clinical Trial to Evaluate Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine for Infants and Other Age Groups.||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|November 2008|October 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1537|||Both|N/A|75 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02152709||43570|
NCT02152995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01106|Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer|A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers||National Cancer Institute (NCI)|No|Suspended|August 2014|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|May 29, 2014|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02152995||43548|
NCT02153008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0142-07|Strep A FIA Field Study, Sofia|Sofia Strep A FIA Field Study||Quidel Corporation|No|Recruiting|April 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1200|||Both|3 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the general population as they present to the clinical        facility. Subjects must be exhibiting symptoms characteristic of pharyngitis, possibly        GAS.|September 2015|September 30, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02153008||43547|
NCT02152683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LISW-NY|Linear Focused Shockwave Treatment for Erectile Dysfunction|Linear Focused Shockwave Treatment for Erectile Dysfunction||Initia||Terminated|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Male|20 Years|80 Years|No|||September 2015|September 1, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152683||43572|
NCT02152943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0119|Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients|Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance||M.D. Anderson Cancer Center|No|Recruiting|July 2014|||July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152943||43552|
NCT02152956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGD006-01|Safety Study of MGD006 in Relapsed/Refractory AML|A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia|MGD006-01|MacroGenics|No|Recruiting|May 2014|January 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||May 2015|July 1, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02152956||43551|
NCT02153294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PReVENT-NL|PRotective VENTilation in Patients Without ARDS|PRotective VENTilation in Patients Without ARDS at Start of Ventilation - PReVENT, a Randomized Controlled Trial|PReVENT-NL|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|August 2014|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|952|||Both|18 Years|100 Years|No|||March 2016|March 21, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02153294||43525|
NCT02153554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN/MG-13064-RG ECO 577-3|Impact Evaluation of Training Civil Servants on Violence Against Women in Medellín, Colombia|Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of Training Civil Servants on Violence Against Women in Medellín (Colombia), Component of the Program "Seguridad Pública"||Econometría Consultores||Active, not recruiting|May 2014|February 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|900|||Female|18 Years|65 Years|No|||January 2016|January 19, 2016|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02153554||43505|
NCT02154477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-075|Effect of Intranasal Insulin on LH Concentrations in Man|Effect of Intranasal Insulin on LH Concentrations in Man||Texas Tech University Health Sciences Center|No|Recruiting|December 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|18 Years|75 Years|No|||October 2015|October 6, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02154477||43435|
NCT02154490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1400|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer|A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)||Southwest Oncology Group|Yes|Recruiting|June 2014|||April 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Anticipated|10000|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02154490||43434|
NCT02160600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IESC/T-457/29.11.2013|Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial|Role of Split Bolus Dual Energy Single Acquisition CT in Evaluation of Urological Diseases of the Upper Urinary Tract.||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|April 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02160600||42964|
NCT02160613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPG_OFD|Osteoprotegerin Before and After Periodontal Surgery|Effect of Periodontal Surgery on Osteoprotegerin Levels in Gingival Crevicular Fluid, Saliva and Gingival Tissues.||Cairo University|Yes|Completed|April 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|30|||Both|32 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 7, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02160613||42963|
NCT02160288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH2014-P-000406|Effects of Botox in Obstructed Defecation Syndrome|Effects of Type A Botulinum Toxin in Obstructed Defecation Syndrome: a Phase II Randomized, Parallel-Group, Triple-Blind, Placebo-Controlled Trial||Massachusetts General Hospital|No|Not yet recruiting|September 2015|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|90 Years|No|||September 2015|September 8, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160288||42988|
NCT02160574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130820-302 (ZX-ZP-0017)|Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA|A 21-Day Evaluation of the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers||Zurex Pharma, Inc.|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 24, 2014|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160574||42966|
NCT02160587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130821-303 (ZX-ZP-0018)|Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA|A Clinical Evaluation of the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers||Zurex Pharma, Inc.|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 11, 2015|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02160587||42965|
NCT02160860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY201405-HP|Epidemiology of Helicobacter Pylori Infection Among Shanghai Children|Epidemiology of Helicobacter Pylori Infection Among Shanghai Children||Fudan University|No|Recruiting|May 2014|May 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples Without DNA|serum will be storage in to -80℃ fridge for further test. other biospecimen will be test at      site and disposed.|Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Age 3~18 children|June 2014|June 10, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02160860||42944|
NCT02161666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-CD-10-2Y|Effect of Gastric Bypass Surgery on Pancreatic Islet and Incretin Function - Follow-up Study|||Hvidovre University Hospital|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|7|Samples Without DNA|Plasma and serum specimens are retained|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are recruited from the population undergoing gastric bypass surgery at Hvidovre        Hospital (Denmark)|April 2015|April 3, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161666||42882|
NCT02161939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-257|A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C|A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence||Bristol-Myers Squibb||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2016|January 28, 2016|June 10, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02161939||42861|
NCT02161952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMMTG.05|Pirfenidone, an Antifibrotic and Antiinflammatory Drug|Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study||University of Guadalajara|Yes|Completed|May 2005|August 2007|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|July 7, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02161952||42860|
NCT02162823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/1089-31/4|Clinical Trial of Pancreatic Cancer in Stockholm.|Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors.|SPP|Karolinska University Hospital|No|Enrolling by invitation|May 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Germline DNA and tumour DNA (PDAC patients). Saliva and urine (DNA).|Both|18 Years|85 Years|No|Non-Probability Sample|Population based cohort of all patients with pancreatic cancer within the district of        Stockholm and age and gender matched healthy controls.|March 2016|March 10, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02162823|5 Years|42794|
NCT02163096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0447|A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma|||University of Louisville|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|||Both|6 Years|16 Years|No|Non-Probability Sample|Children ages 6-16 in Primary Care Clinic and Pediatric Subspecialty Clinics of Pulmonary        and Allergy/Immunology.|January 2016|January 7, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02163096||42773|
NCT02163356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC-2013-001|Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma|Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254)|SPOC-2013-001|South Plains Oncology Consortium|Yes|Recruiting|May 2014|||May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|30 Years|No|||July 2014|July 8, 2014|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02163356||42754|
NCT02163330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS 05 - 12|Normal Pressure Hydrocephalus Treatment by Acetazolamide|||Rabin Medical Center|No|Not yet recruiting|June 2014|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|80 Years|No|||April 2014|June 12, 2014|April 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02163330||42756|
NCT02163343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WS/0060|Serum Metal Ion Levels in Patients Who Underwent Cathcart/Corail Hemiarthroplasty for Fractured Neck of Femur|Serum Metal Ion Levels in Patients Who Underwent Cathcart/Corail Hemiarthroplasty for Fractured Neck of Femur||Royal Berkshire NHS Foundation Trust|No|Recruiting|June 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 patients receiving a Cathcart Hemiarthroplasty for intracapsular fractured neck of        femur at the Royal Berkshire Hospital|June 2014|May 8, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02163343||42755|
NCT02152189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry screening 02202014|Screening for Fabry Disease in a Pediatric Population at Risk|||University Hospital Heidelberg|No|Recruiting|May 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|N/A|18 Years|No|Probability Sample|Children with rheumatological disorders or chronic abdominal pain|June 2014|June 3, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02152189||43610|
NCT02152449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12025|Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients|Impact on Functional Status of Early Oral Nutritional Supplementation (ONS) in Amyotrophic Lateral Sclerosis (ALS) Patients|NUTRALS|University Hospital, Limoges|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||March 2015|March 8, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02152449||43590|
NCT02186132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si158/2012|0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant|The Effect of 0.6 vs. 1.2 Milligram Atropine Together With Neostigmine 2.5 Milligram on Heart Rate in Patient Receiving Muscle Relaxant During General Anesthesia||Mahidol University|No|Completed|March 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186132||41009|
NCT02186145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJ 3002-13|Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections|Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections||Marjan Industria e Comercio ltda|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|50 Years|No|||July 2014|April 8, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186145||41008|
NCT02185885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-110|Perfusion Pressure Cerebral Infarction Trial (PPCI)|The Importance of Mean Arterial Pressure During Cardiopulmonary Bypass to Prevent Cerebral Complications After Cardiac Surgery - a Randomised Clinical Trial.|PPCI|Rigshospitalet, Denmark|No|Recruiting|July 2014|July 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185885||41028|
NCT02186626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 290|Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age|Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´Δ30 Chimeric Virus Vaccine (WN/DEN4Δ30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|February 2014|July 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|July 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186626||40971|
NCT02186665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18132|Plaque Psoriasis Study in Pediatric Subjects|A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis||Galderma||Active, not recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|2 Years|12 Years|No|||January 2016|January 18, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186665||40968|
NCT02186678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-26|Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation|Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation: Monocentric Prospective Study|DOTATATE|Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|July 2014|February 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186678||40967|
NCT02187198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP0040|Buprenorphine Treatment for Opioid Dependence|Buprenorphine Treatment for Prescription Opioid Dependence||Yale University|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187198||40927|
NCT02183090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.217|Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects|Pharmacokinetics and Tolerability of a Single 15mg Meloxicam Dose Injected Intramuscularly Compared to a Single Oral 15 mg Meloxicam Tablet in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study.||Boehringer Ingelheim||Completed|November 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183090||41243|
NCT02183103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.224|Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects|Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU (Rapid Release Tablet) Given as an Oral Single Dose of 7.5 mg in Healthy Subjects (Two Way, Crossover, Randomized, Open)||Boehringer Ingelheim||Completed|April 1999|||May 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183103||41242|
NCT02183116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.228|A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee|Open Study to Access the Efficacy and Safety of Meloxicam 7.5mg in Patients With Osteoarthritis of the Knee||Boehringer Ingelheim||Completed|October 1998|||February 1999|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|34 Years|74 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183116||41241|
NCT02183129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.229|Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee|Open Label Study to Assess the Efficacy and Safety of Meloxicam 7.5mg vs. Diclofenac 100mg SR in Patients With Osteoarthritis of the Knee||Boehringer Ingelheim||Completed|April 1999|||November 1999|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|N/A|N/A|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183129||41240|
NCT02187445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF2014086|Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial|Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial||Vanderbilt University|Yes|Recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|1 Year|4 Years|No|||April 2015|April 14, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02187445||40908|
NCT02187458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USVT-3|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2013|||||N/A|N/A|N/A||||||||||||||August 6, 2014|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187458||40907|
NCT02183025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.191|Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea|Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea||Boehringer Ingelheim||Completed|January 1998|||April 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|337|||Female|18 Years|40 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183025||41248|
NCT02183038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.193|Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis|Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days||Boehringer Ingelheim||Completed|July 1998|||February 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|390|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183038||41247|
NCT02183051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.197|Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar|A Short Term Double-blind Trial to Compare the the Analgesic Efficacy and Tolerability of Meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg Oral (Quick Tablet) Versus Placebo and Ibuprofen 400 mg and 200 mg Oral in the Treatment of Pain After Surgery of the Third Molar||Boehringer Ingelheim||Completed|April 1998|||October 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|381|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183051||41246|
NCT02183064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.210|Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis|A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine||Boehringer Ingelheim||Completed|October 1998|||November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1309|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183064||41245|
NCT02170298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402395|Lisdexamfetamine's Effect In ADHD in the Brain and Cognition|Effects of Lisdexamfetamine on Cognitive Control and Reward Response in Adolescents and Young Adults With ADHD: Neural and Clinical Outcomes|LEIA|University of California, Davis|Yes|Recruiting|February 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|12 Years|30 Years|No|||June 2015|June 27, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02170298||42222|
NCT02170545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20000037|CT Imaging Evaluation of Humerus Fractures|Computed Tomography Evaluation of Humeral Head Perfusion in Displaced Proximal Humerus Fractures in Predicting Rates of Avascular Necrosis||Virginia Commonwealth University|No|Recruiting|March 2014|March 2019|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|For those patients who undergo shoulder replacement, the humeral head bone will be collected      and processed for any evidence of avascular necrosis. Once processing and data collection is      done, the bone will be disposed of.|Both|18 Years|N/A|No|Non-Probability Sample|Consenting adult patients with proximal humerus fractures.|January 2016|January 6, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02170545||42203|
NCT02171390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-042014|Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy|Phase 4 Study That Evaluates the Presence of Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism and Effects of Two Different Testosterone Replacement Regiments on These Parameters.||Gulhane School of Medicine|No|Completed|August 2008|||June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||March 2014|June 20, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02171390||42138|
NCT02172248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.6|Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Metformin After Coadministration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Metformin (1000 mg b.i.d.) Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|January 2009|||March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172248||42072|
NCT02172261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.7|Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Glimepiride After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and a Single Dose of Glimepiride (1 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|April 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172261||42071|
NCT02173288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mido-tolvaptan 1|Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites|Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites||Postgraduate Institute of Medical Education and Research|Yes|Active, not recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|70 Years|No|||March 2016|March 13, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02173288||41992|
NCT02173301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-H-093|A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis|A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis||XenoPort, Inc.|No|Completed|June 2014|August 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|N/A|No|||September 2014|September 16, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173301||41991|
NCT02173275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014313|Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia|Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia (The CREDENCE Trial)|CREDENCE|Weill Medical College of Cornell University|Yes|Recruiting|May 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|618|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive consenting adult patients who meet all of the inclusion criteria and none of        the exclusion criteria will be asked to participate in the study.|July 2015|July 29, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173275||41993|
NCT02185326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHE062013|Microflare Protocol in Poor Responders|Growth Hormone Co-treatment With the Microflare Stimulation Protocol in IVF/ICSI, Can it be a New Hope for Poor Responders?||Woman's Health University Hospital, Egypt|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Female|20 Years|45 Years|No|||January 2015|January 26, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02185326||41071|
NCT02185339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dNMBonResp|Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics|Effects of Deep Versus Moderate Neuromuscular Blockade on Intraoperative Respiratory Mechanics in Patients Undergoing Laparoscopic Renal Surgery: a Prospective, Randomized, Parallel Design Study||Seoul St. Mary's Hospital|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|61|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02185339||41070|
NCT02185859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0375|Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy|||Yonsei University|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|126|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185859||41030|
NCT02185872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6058|CrossFit Exercise to Improve Glucose Control for Overweight and Obese Adults|The Influence of a CrossFit Exercise Program on Glucose Control in Overweight and Obese Individuals||Kansas State University|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185872||41029|
NCT02186418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2588|Gene Transfer for Patients With Sickle Cell Disease|Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector: An Open Label Phase I/II Pilot Study||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|35 Years|No|||September 2015|September 2, 2015|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186418||40987|
NCT02186379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009540|Eating RePace Study|Eating Pace Retraining in Childhood Obesity Prevention|REPACE|Children's Hospital of Philadelphia|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186379||40990|
NCT02186392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-114|The Impact of Ergonomic Circadian Light on Hospitalized Stroke Patients in a Rehabilitation Unit|The Impact of Ergonomic Circadian Light on Hospitalized Stroke Patients in a Rehabilitation Unit||Glostrup University Hospital, Copenhagen|No|Active, not recruiting|May 2014|May 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02186392||40989|
NCT02186639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0088|Breath Analysis in Chronic Obstructive Lung Disease (COPD)|Exhaled Breath Analysis in Patients With COPD by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS)||University of Zurich|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited in primary, secondary and tertiary care clinics. Healthy        controls will be recruited from a community sample.|December 2015|December 9, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186639||40970|
NCT02186652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048765|PK Study With Pantoprazole in Obese Children and Adolescents|The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children and Adolescents|PAN01|Duke University|Yes|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|6 Years|17 Years|No|||October 2015|February 9, 2016|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186652||40969|
NCT02187224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER0023|Progesterone Effect on Individuals Diagnoses With AD and PTSD.|Progesterone Treatment in Reducing Trauma and Alcohol Induced Craving in Individuals Diagnoses With Alcohol Dependence (AD) and Post-tramatic Stress Disorder (PTSD).||Yale University|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|45 Years|No|||July 2015|July 14, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187224||40925|
NCT02187471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-E310|Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia||Daiichi Sankyo Inc.|Yes|Recruiting|October 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1200|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187471||40906|
NCT02186912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-185|All-On-4® Treatment Concept|A Clinical Evaluation of All-On-4® Treatment Concept in the Mandible or Maxilla on 4 NobelActive®Implants With a Fixed NobelProcera® Implant Bridge||Nobel Biocare|No|Recruiting|January 2014|August 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|April 13, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186912||40949|
NCT02186925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ren001|A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.|||Meir Medical Center|Yes|Recruiting|August 2014|August 2025|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from kidney, bladder or prostate cancer who are being treated at the        Meir Medical Center.|July 2014|April 20, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186925||40948|
NCT02187484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.266|BIBR 277 Capsules in Hypertensive Patients With Nephropathy|BIBR 277 Capsules Clinical Study on Hypertension With Nephropathy||Boehringer Ingelheim||Completed|August 1998|||August 1999|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|20 Years|N/A|No|||July 2014|July 9, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02187484||40905|
NCT02183142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.234|Study of Relative Bioavailability of Mobic Manufactured in China in Comparison With Mobic Manufactured in Germany in Chinese Healthy Volunteers|Relative Bioavailability of 7.5 mg Mobic Tablet Manufactured in China in Comparison With 7.5 mg Tablets Manufactured in Germany After a Single Oral Dose in Chinese Healthy Volunteers, Open, Randomized, Two Way Crossover Trial||Boehringer Ingelheim||Completed|March 2001|||April 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183142||41239|
NCT02183155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.236|Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects|A Double Blind, Randomized, Parallel Group Trial to Compare the Effect of Three Doses of Meloxicam Tablets (7.5, 15 and 30 mg) With Placebo on Bleeding Time in Healthy Subjects; With Extended-release Indomethacin Capsules 75 mg (Open-label) as an Active Control to Assess Trial Sensitivity.||Boehringer Ingelheim||Completed|May 2000|||September 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|82|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183155||41238|
NCT02183675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348.5|Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers|Pharmacokinetics of Multiple Oral Doses of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet, Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet at Steady State in Healthy Male Subjects: an Open-label, Randomised, Multiple-dose, Three Treatment, Three-period, Six-sequence Crossover Study||Boehringer Ingelheim||Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183675||41198|
NCT02183688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155.8|Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients|A Double-blind, Randomized, Placebo-controlled Clinical Trial to Confirm the Rationale of the ASA + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients||Boehringer Ingelheim||Completed|September 1998|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|1889|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183688||41197|
NCT02183701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.257|Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension|A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring||Boehringer Ingelheim||Completed|April 1998|||December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|715|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183701||41196|
NCT02183987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0083_MOD1|Preventing Early Dialysis Starts|Knowledge Translation Interventions to Prevent the Early Initiation of Dialysis: A Cluster Randomized Trial||University of Manitoba|No|Active, not recruiting|September 2014|September 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02183987||41174|
NCT02184000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Real-Time Elasto|The Role of Strain Elastography in Staging Liver Fibrosis|Usefulness of the Strain Elastography in the Assessment of Liver Fibrosis in Chronic Hepatopathy|SELF|University of Medicine and Pharmacy Craiova|Yes|Recruiting|March 2014|September 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The patients included in the study will be healthy voluntaries, patients with chronic        hepatitis B or C and patients with liver cirrhosis. ARFI and Hitachi elastography will be        performed for each patient and the results will be compared with final diagnosis. The        final diagnosis (the stage) will be established based on Transient elastography and or        liver biopsy.|June 2014|July 2, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184000||41173|
NCT02170584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.5|Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males|Tolerability of Single Rising Doses of 0.1 mg, 1 mg, and 5 mg BIBR 953 ZW IV (Placebo-controlled in Each Dose Group; Substudy 1) and Absolute and Relative Bioavailability of 100mg BIBR 1048 Tablet and of Solution and of 1 mg or 5 mg BIBR 953 ZW IV (Randomized, Three-way Crossover; Substudy 2).||Boehringer Ingelheim||Completed|January 2001|||March 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170584||42200|
NCT02170597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.40|Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Capsule Relative to a Gelatine Capsule, and Bioavailability of the HPMC Capsule Under the Influence of Food in Healthy Subjects. A Three-way Crossover, Randomised, Open Trial||Boehringer Ingelheim||Completed|August 2003|||September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170597||42199|
NCT02170987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.54|Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.|Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Positive Control (Moxifloxacin)||Boehringer Ingelheim||Completed|March 2006|||May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170987||42169|
NCT02171000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.55|Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects|Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule (150 mg b.i.d., 7 Days) in Healthy Japanese Male Subjects (Open Label Study)||Boehringer Ingelheim||Completed|April 2005|||May 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171000||42168|
NCT02172287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.130|Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|COPD|Boehringer Ingelheim||Completed|February 1999|||May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|623|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172287||42069|
NCT02172300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.131|Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized Double-Blind, Placebo Controlled, Parallel Group Study)||Boehringer Ingelheim||Completed|June 1999|||November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|198|||Both|40 Years|70 Years|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172300||42068|
NCT02172313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4154|Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects||Novo Nordisk A/S|No|Completed|June 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|June 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02172313||42067|
NCT02172677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-46|The Influence of Collective Schemas on Individual Memory|ETUDE D'IMAGERIE PAR RESONANCE MAGNETIQUE FONCTIONNELLE CHEZ LE SUJET SAIN DES RELATIONS ENTRE MEMOIRE COLLECTIVE ET INDIVIDUELLE|MULTIBRAIN_1|Institut National de la Santé Et de la Recherche Médicale, France||Recruiting|October 2014|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|20 Years|38 Years|Accepts Healthy Volunteers|||November 2015|January 6, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02172677||42039|
NCT02172690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-LStaging-2014|Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients|Laparoscopic Staging in Patients With Locally Advanced Gastric Cancer in Chinese Patients||Peking University|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Both|18 Years|N/A|No|||December 2014|December 6, 2014|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172690||42038|
NCT02172703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aICP_CH_TBI_SAH|Non-invasive Brain Pressure Monitoring After Trauma or Hemorrhage|Validation of Non-invasive Absolute Intracranial Pressure Monitoring in Patients After Traumatic Brain Injury and Subarachnoid Hemorrhage||Kantonsspital Aarau|No|Completed|February 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02172703||42037|
NCT02173054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne and adjuctive moisturizer|An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne|An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects||Mahidol University|Yes|Completed|July 2014|July 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 18, 2014||No||No|July 29, 2015|https://clinicaltrials.gov/show/NCT02173054||42010|
NCT02168439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120431|Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair|Double Blinded Randomized Controlled Trial of Intranasal Dexmedetomidine Versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department||University of Pittsburgh|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|1 Year|5 Years|No|||January 2016|January 13, 2016|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168439||42365|
NCT02173314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8977-2|Nevada Initiative to Reduce Long-Term Foster Care|Permanency Innovations Initiative- Nevada Initiative to Reduce Long-Term Foster Care||Westat|No|Enrolling by invitation|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||||||Both|N/A|18 Years|No|||June 2014|June 23, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173314||41990|
NCT02185352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402059MIPD|Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases|Randomized Phase II Study of Induction Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy (WBRT) Versus WBRT Alone in Breast Cancer With Untreated Brain Metastases|A-Plus|National Taiwan University Hospital|Yes|Recruiting|September 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Female|20 Years|75 Years|No|||January 2016|January 21, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02185352||41069|
NCT02185066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_ATM_103|Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR|||CJ HealthCare Corporation|No|Not yet recruiting|July 2014|November 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185066||41091|
NCT02185079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM4(i)06/05/2014|The Effect of Metrics Based Performance Based Progression in Provision of Labor Epidural Analgesia|The Effect of Metrics Based Performance Based Progression in Provision of Labor Epidural Analgesia on Clinical Performance and Clinical Outcome||Cork University Hospital|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|16|||Both|23 Years|60 Years|No|||August 2015|August 26, 2015|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02185079||41090|
NCT02185365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140371-01H|Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia|Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia||Ottawa Hospital Research Institute|No|Not yet recruiting|July 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|February 8, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185365||41068|
NCT02185638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B258|Appetite Suppression Effects of an Herbal Combination of Yerba maté, Guarana, Damiana (YGD), and 12 Other Herbal Components, Versus YGD Supplementation Alone|Appetite Suppression Effects of an Herbal Combination of Yerba maté, Guarana, Damiana (YGD), and 12 Other Herbal Components, Versus YGD Supplementation Alone|YGD|University of Copenhagen|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|19|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02185638||41047|
NCT02185612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30641|The EARN-Health Trial of Financial Savings and Health|EARN-Health: A Randomized Controlled Trial of the Effects of an Incentivized Savings Program on Depression, Anxiety, Substance Abuse, and Locus of Control|EARN-Health|Stanford University|No|Not yet recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185612||41049|
NCT02185625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU201407|Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana|Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana: a Cluster Randomized Trial||University of Aarhus|No|Recruiting|July 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2800|||Female|N/A|N/A|No|||July 2014|August 4, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02185625||41048|
NCT02186444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17455|Navigator Guided e-Psychoeducational Intervention|Navigator Guided e-Psychoeducational Intervention for Prostate Cancer Patients and Their Caregivers||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|August 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Male|40 Years|80 Years|No|Probability Sample|Patients from Moffitt Cancer Center Genitourinary Clinic, University of South Florida        Genitourinary Clinic, or community-based urologists and primary care providers.|November 2015|November 19, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186444||40985|
NCT02186158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/09|Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.|Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.|PNEUMO-VITA-C|University Hospital, Bordeaux|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|75 Years|N/A|No|||February 2015|February 13, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186158||41007|
NCT02186405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-03|Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism|Effects of Levothyroxine Treatment on Hemodynamic and Isotopic Renal Functions in Subclinical Hypothyroidism||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2015|June 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186405||40988|
NCT02187237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YTCSP-2013-YOLO-REDUCE|Safety and Effectiveness of the "YOLO TOUCH" LLLT for Circumference Reduction of the Waistline|A RandomizEd DoUble Blinded Controlled Study to Evaluate the Safety and Effectiveness of the "YOLO TOUCH" Low Level Laser Therapy (LLLT) for Circumference Reduction of he Waistline - REDUCE|REDUCE|Yolo Medical Inc.|Yes|Completed|September 2013|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||July 2014|July 9, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187237||40924|
NCT02187497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.268|Pharmacokinetics of BIBR 277 in Hypertensive Patients|BIBR 277 Capsules Pharmacokinetics Study of Hypertensive Patients||Boehringer Ingelheim||Completed|June 1998|||September 1998|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|20 Years|N/A|No|||July 2014|July 9, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02187497||40904|
NCT02187510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPTNeonat2014_01|Umbilical Cord Milking vs Delayed Cord Clamping in Preterm Infants Born by Cesarean Section|Umbilical Cord Milking Compared With Delayed Cord Clamping to Increase Plancental Transfusion in Preterm Infants Less Than 34 Weeks' Gestation Born by Cesarean Section. Randomised Clinical Trial||Corporacion Parc Tauli|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|N/A|No|||January 2016|January 26, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02187510||40903|
NCT02183740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiST05|Effect of an Educational Program for Staff in Nursing Homes Concerning Patients Fecal Incontinence|Effect of an Educational Program for Staff in Nursing Homes Concerning Patients Fecal Incontinence: a Cluster-randomized Controlled Trial|EPSPFI|Norwegian University of Science and Technology|Yes|Completed|April 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02183740||41193|
NCT02183714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|582.1|The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances|The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances||Boehringer Ingelheim||Completed|May 1998|||December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183714||41195|
NCT02183727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC1060|L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction|L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction: A Prospective, Randomized Controlled Trial||Soft Tissue Regeneration, Inc.|Yes|Not yet recruiting|September 2014|September 2020|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|No|||July 2014|July 2, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02183727||41194|
NCT02184013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140623|Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study|Correlation of Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation:A Pilot Study|COAST-AF|Ottawa Heart Institute Research Corporation|Yes|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184013||41172|
NCT02171052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.59|Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Digoxin After 150 mg BID Dabigatran Etexilate and Digoxin at 0.25 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|June 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171052||42164|
NCT02171065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSPECT II & PROSPECT ABSORB|PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.|A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients With Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined With a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)|P2|Uppsala University|Yes|Recruiting|June 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|900|||Both|N/A|N/A|No|||December 2015|December 15, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171065||42163|
NCT02172768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATADOR|Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease|Pharmacokinetics of Micafungin (Mycamin ®) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease.|MATADOR|Radboud University|No|Recruiting|October 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172768||42032|
NCT02172716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26793214.9.0000.0075|Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis|Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis||University of Sao Paulo|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 22, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02172716||42036|
NCT02172729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-PJ-14|The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2|The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2||Rigshospitalet, Denmark|Yes|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172729||42035|
NCT02173327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHPOTA-01|Helm CPAP Versus Mask CPAP After Major Abdominal Surgery|Continuously Helm CPAP Versus Intermittent Mask CPAP After Major Abdominal Surgery||Rigshospitalet, Denmark|No|Recruiting|November 2013|April 2016|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02173327||41989|
NCT02173340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0247|Population Pharmacodynamic Modeling of the Sedative and Side Effects of Propofol|Population Pharmacodynamic Modeling of the Sedative and Side Effects of Propofol in Patients Undergoing Spinal Anesthesia||Yonsei University|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|20 Years|80 Years|No|Probability Sample|patients who have lower extremity surgery under spinal anesthesia at Gangnam Severance        Hospital|July 2015|July 27, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02173340||41988|
NCT02168465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21NR012763-02|Internet Self-Management for People With Intermittent Urinary Catheters|Web-Based Self-Management Intervention for Intermittent Urinary Catheter Use|Internet CIC|University of Rochester|Yes|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|34|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02168465||42363|
NCT02185651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400461|A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction|A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy||University of Florida|No|Recruiting|November 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02185651||41046|
NCT02185911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130301|Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis|Observational Study of Correction of Anaemia With Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian Patients With Chronic Kidney Disease Not on Dialysis|ADAPTATION|Amgen|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|308|||Both|18 Years|100 Years|No|Probability Sample|The study population comprises CKD patients not on dialysis, ESA-naïve at time of        initiation of darbepoetin alfa QM, and treated at nephrology clinics in EU and Australia        from 01 May 2013. Eligible patients will have received at least three consecutive doses of        darbepoetin alfa for correction of anaemia at a QM dosing interval. At each participating        study site, all potentially elgible patients are to be considered for enrolment.|March 2016|March 4, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02185911||41026|
NCT02185898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSD1302|Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes|A Single-Center Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes||R.J. Reynolds Vapor Company|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|71|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185898||41027|
NCT02186171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110174|A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis|BRIDGE|Amgen|No|Active, not recruiting|June 2014|April 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|245|||Male|55 Years|90 Years|No|||March 2016|March 1, 2016|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186171||41006|
NCT02186717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-065|Does Chewing Gum Hasten Return of Bowel Function Post-Operatively in Patients Undergoing Spinal Surgery|||Hospital for Special Surgery, New York|No|Enrolling by invitation|June 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186717||40964|
NCT02186691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06|Right and Left Ventricle Remodeling Predictors After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot|Right and Left Ventricle Remodeling Predictors After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot.||Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2014|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|14 Years|90 Years|No|||July 2014|July 8, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186691||40966|
NCT02186938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT FloTrac|A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps|Does the Intraoperative Use of the FloTrac Device to Guide Fluid and Vasopressor Management Affect Postoperative Morbidity in Patients Receiving a Head and Neck Microvascular Free Tissue Transfer||Medical University of South Carolina|Yes|Completed|December 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186938||40947|
NCT02187575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.259|Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers|Bioequivalence Study of UHAC62XX 10 mg Tablets Compared With 10 mg Capsules Following Multiple Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)||Boehringer Ingelheim||Completed|July 2002|||September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 10, 2014||||No||https://clinicaltrials.gov/show/NCT02187575||40898|
NCT02183168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.237|Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis|A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis||Boehringer Ingelheim||Completed|July 2001|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|192|||Both|N/A|N/A|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183168||41237|
NCT02187523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.324|Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects|Relative Oral Bioavailability of 40 mg Telmisartan / 12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Subjects. A 4 Period Cross-over, Open, Randomized, Replicate Design Study||Boehringer Ingelheim||Completed|October 1999|||December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02187523||40902|
NCT02187536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.341|Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects|Pharmacokinetics of Single Oral Doses of 40 mg Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan 80 mg Daily, Given Orally Over 6 Days. A Randomised, Placebo Controlled, Double Blind (for Telmisartan), Two Way Cross Over Trial in Healthy Subjects||Boehringer Ingelheim||Completed|April 2000|||May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02187536||40901|
NCT02187549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQE7-13-01|Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee|||Fidia Farmaceutici s.p.a.|No|Active, not recruiting|June 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|332|||Both|40 Years|N/A|No|||October 2015|October 2, 2015|June 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187549||40900|
NCT02183181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.274|Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers|A Randomized, Single-dose, Two-way Crossover Study to Assess the Bioequivalence of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) Administered to Healthy Adult Volunteers||Boehringer Ingelheim||Completed|November 2008|||January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02183181||41236|
NCT02184325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129.2|Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children|Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets, Comparing the Marketed Formula With an Improved One With a Reduced Mineral Amount, and a Comparator Product: a Double-blind, Controlled, Randomised, Three Arm Cross-over Study in Children||Boehringer Ingelheim||Completed|November 1999|||February 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|96|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184325||41148|
NCT02184338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1187.1|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS (5, 25, 100, 250, 500, and 800 mg) as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects. Placebo Controlled and Blinded at Each Dose Level||Boehringer Ingelheim||Completed|August 2004|||November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184338||41147|
NCT02184026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA-778|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child|ERRT-C|University of Montana|No|Recruiting|December 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|13 Years|No|||July 2014|July 2, 2014|July 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02184026||41171|
NCT02184039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.264|Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases|Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases||Boehringer Ingelheim||Completed|May 2003|||July 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12687|||Both|12 Years|N/A|No|Non-Probability Sample||July 2014|July 8, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02184039||41170|
NCT02184299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1286|Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients|A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash.||Boehringer Ingelheim||Completed|April 1999|||January 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184299||41150|
NCT02184312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1517|Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers|An Open-label, Non-randomised, Single-dose, Parallel-group Study of Pharmacokinetic Properties of 200 mg (2 x 100 mg Tablets Once Daily) and 300 mg (3 x 100 mg Tablets Once Daily) Nevirapine Extended Release Formulations Compared to 200 mg VIRAMUNE® Tablet as Well as to 400 mg Nevirapine Extended Release Tablet Following Oral Administration in Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2008|||July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184312||41149|
NCT02172183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-RV|CBT Group for Adolescents With ADHD: a Randomized Controlled Trial|Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: a Randomized Multicenter Controlled Trial||Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|April 2012|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|15 Years|21 Years|No|||June 2014|June 20, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02172183||42077|
NCT02172196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.27|Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Sitagliptin After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Sitagliptin (100 mg q.d.) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|May 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172196||42076|
NCT02172209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.3|Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers|The Effect of Food on the Bioavailability and Pharmacokinetics of BI 10773 Tablet, Administered as a Single Dose of 50 mg With and Without Food to Healthy Male Volunteers in an Open-label, Randomised Intraindividual Crossover Comparison Design||Boehringer Ingelheim||Completed|January 2008|||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172209||42075|
NCT02173093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-171|Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma|Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study||Barbara Ann Karmanos Cancer Institute|Yes|Suspended|November 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|13 Months|29 Years|No|||February 2016|February 15, 2016|June 22, 2014|Yes|Yes|Study on hold due to primary co-investigator leaving the institution.|No||https://clinicaltrials.gov/show/NCT02173093||42007|
NCT02172742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-107|The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin|The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|May 2002|||July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|June 23, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02172742||42034|
NCT02172755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-105|Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites|Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites in Healthy Elderly Subjects Compared With Those in Healthy Young Subjects||Bial - Portela C S.A.|No|Terminated|June 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|June 23, 2014||No|occurrence of a serious adverse event|No|November 28, 2014|https://clinicaltrials.gov/show/NCT02172755||42033|
NCT02168478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTWC01-001|Neo-Synalar Modified 48 Hour Patch Test|A Modified 48 Hour Patch Test of Neo-Synalar Cream, Sodium Lauryl Sulfate (Positive Control) and Saline (Negative Control)||Medimetriks Pharmaceuticals, Inc|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|206|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|June 17, 2014|Yes|Yes||No|September 25, 2015|https://clinicaltrials.gov/show/NCT02168478||42362|
NCT02168764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway CH-2|Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache|Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache||Autonomic Technologies, Inc.|Yes|Recruiting|July 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|22 Years|N/A|No|||March 2016|March 16, 2016|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168764||42340|
NCT02168777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17064|Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer|A Phase 1b/2, Multi-center, Uncontrolled, Open-label, Dose Escalation Study of Refametinib (BAY86-9766) in Combination With Regorafenib (BAY73-4506) in Patients With Advanced or Metastatic Cancer||Bayer|No|Active, not recruiting|June 2014|March 2016|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168777||42339|
NCT02185664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F.2/IEC/MAMC/11/No.96|Use of Static Ultrasound Guidance for Internal Jugular Vein Cannulation in Adult Cardiac Surgical Patients|Comparison of the Landmark Technique and the Static Ultrasound Guided Technique for Internal Jugular Vein Cannulation in Adult Cardiac Surgical Patients.||Govind Ballabh Pant Hospital|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|201|||Both|15 Years|N/A|No|||July 2014|July 14, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185664||41045|
NCT02185924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-138/15-06-10|Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty|COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY.||Asklepieion Voulas General Hospital|No|Completed|January 2009|February 2014|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|90|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185924||41025|
NCT02186184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB504601|Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial|Effect of Orthokeratology on Myopia Progression in Chinese Children||Beijing Tongren Hospital|Yes|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02186184||41005|
NCT02186431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIK_601933|Contact Lenses and Infiltrative Keratitis|Contact Lenses and Infiltrative Keratitis|CLIK|State University of New York College of Optometry|No|Active, not recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186431||40986|
NCT02187263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZHK TORCH 001|German Centre for Cardiovascular Research Cardiomyopathy Register|DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK)|TORCH|Heidelberg University|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|2300|Samples With DNA|EDTA, serum, urine|Both|18 Years|79 Years|No|Non-Probability Sample|Patients with hereditary and inflammatory cardiomyopathies|March 2016|March 24, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187263|12 Months|40922|
NCT02186704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401014661|Sensing Atrial High Rate Episodes With Implantable Cardioverter-Defibrillators Trial (The SENSE Trial)|Sensing Atrial High Rate Episodes With DX System in Implantable Cardioverter Defibrillators Trial|SENSE|Weill Medical College of Cornell University|Yes|Recruiting|July 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with standard indications for implantable cardioverter-defibrillator implantation        and no prior history of atrial fibrillation|July 2015|July 14, 2015|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186704||40965|
NCT02186951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13018 ANTHARTIC|Antibiotherapy During Therapeutic Hypothermia to Prevent Infectious Complications|Prevention of Early Ventilator-associated Pneumonia With Antibiotic Therapy in Patients Treated With Mild Therapeutic Hypothermia After Cardiac Arrest.|ANTHARTIC|University Hospital, Limoges|No|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||September 2015|February 23, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186951||40946|
NCT02183753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3076|Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers|Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers|Woodsies|University of North Carolina, Chapel Hill|Yes|Completed|July 2014|April 2015|Actual|March 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|39|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02183753||41192|
NCT02183766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|366/2009|GOS Prebiotic Effect in Children Constipation|Effect of the Prebiotic 4'Galactooligosaccharides in Children and Adolescents With Functional Constipation||University of Campinas, Brazil|Yes|Completed|April 2010|July 2013|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|16 Years|No|||July 2014|July 2, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02183766||41191|
NCT02183194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0021-01|Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts|A Prospective, MultiCenter, Single-arm, Post-market Study of Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts (ACCESS)|ACCESS|C. R. Bard|No|Withdrawn|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 25, 2014||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT02183194||41235|
NCT02184052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.267|Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions|Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study||Boehringer Ingelheim||Completed|July 2003|||March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|||Both|N/A|N/A|No|Non-Probability Sample||July 2014|July 8, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02184052||41169|
NCT02184065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.272|Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases|Clinical and Therapeutic Evaluation of Meloxicam in Mexican Patients With Rheumatic Diseases||Boehringer Ingelheim||Completed|January 2004|||April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22639|||Both|12 Years|N/A|No|Non-Probability Sample||July 2014|July 8, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02184065||41168|
NCT02184078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1258|Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients|An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®)||Boehringer Ingelheim||Completed|October 1998|||December 1998|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184078||41167|
NCT02184598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125002|Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With ADHD|Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder||Hospital de Clinicas de Porto Alegre|No|Enrolling by invitation|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|13 Years|No|||December 2015|December 21, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02184598||41127|
NCT02184585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117057|Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States|An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg Tablets in Healthy Male Subjects in the Fed and Fasted States||GlaxoSmithKline|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|84|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184585||41128|
NCT02171429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA28949|A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis in Patients Naive to TNF Inhibitors (Study #2)|PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS IN PATIENTS WHO ARE NAÏVE TO TNF INHIBITORS||Hoffmann-La Roche||Recruiting|July 2001|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171429||42135|
NCT02171442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.6|Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of 5 mg [14C]-BIBR 953 ZW Intravenously or 200 mg [14C]-BIBR 1048 Oral Solution in a Group Comparison Design in 12 Healthy Male Volunteers.||Boehringer Ingelheim||Completed|April 2002|||May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171442||42134|
NCT02171923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110139|Multicenter Comparative Study of the Activity of the Medial Prefrontal Cortex in Vulnerability to Depression|Medial Prefrontal Cortex and Vulnerability for Depression|CORVAD|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|77|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Formerly depressed patients and healthy controls matched for age and sex|October 2015|October 5, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02171923||42097|
NCT02172222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.30|Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers|Relative Bioavailability of Multiple Doses BI 10773 50 mg and Linagliptin 5 mg After Concomitant Administration Compared to Multiple Doses of BI 10773 50 mg and Linagliptin 5mg Administered Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|July 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172222||42074|
NCT02172235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.50|Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers|Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|April 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172235||42073|
NCT02173366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11244|Change Clubs for African American Women|Preliminary Investigation of Civic Engagement as a Novel Approach to Behavior Change and Body Weight Improvement in African American Females||Tufts University|No|Active, not recruiting|December 2013|February 2016|Anticipated|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|1||Actual|26|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02173366||41986|
NCT02173067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odonto - Diabetes|Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective|Local Anesthesia With Epinephrine for Oral Surgery in Type 2 Diabetes Mellitus With Corornary Disease is Safe and Effective||University of Sao Paulo General Hospital|Yes|Completed|September 2009|November 2012|Actual|November 2012|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|70|None Retained|Type 2 diabete mellitus (in use of insulin and/or hypoglicemic agents) with coronary disease      adults patients who needes to have at least one posterior maxillary tooth extracted,      according to oral examination and panoramic radiography.|Both|18 Years|N/A|No|Probability Sample|We enrolled pharmacologically controlled type 2 diabetes mellitus (in use of insulin        and/or hypoglycemic agents) and with coronary disease adult patient who needed to have at        least one posterior maxillary tooth to be extracted.|October 2012|June 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173067|1 Week|42009|
NCT02173080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003832|Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).|Development and Assessment of the Psychometric Properties of a Polycystic Liver Disease-specific Patient Reported Outcomes Questionnaire (PLD-Q).||Mayo Clinic|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|544|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with polycystic liver disease|April 2015|April 6, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02173080||42008|
NCT02168790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKC002AR01|Safety Study of a Sutureless Amniotic Membran Transplantation to Treat Ocular Surface Disorders (Expanded Access)|Interventional Study to Investigate the Safety of a Combination of Amniotic Membrane and a Holder Device (AmnioClip) in the Therapy of Ocular Surface Disorders (Sutureless Amniotic Membrane Transplantation)|AmnioClip|Klinikum Chemnitz gGmbH|No|Completed|February 2011|August 2013|Actual|August 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||June 2014|June 18, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02168790||42338|
NCT02169050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD2014|Association Between Vitamin D and Inflammation and Diabetes Risk in Morbidly Obese Pre-Menopausal Women|Vitamin D, Inflammation, and Relations to Insulin Resistance in Morbidly Obese Pre-Menopausal Women||University of Illinois at Chicago|Yes|Completed|May 2011|February 2013|Actual|February 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|76|Samples With DNA|Plasma Adipose tissues|Female|21 Years|49 Years|No|Non-Probability Sample|Study subjects are drawn from women seeking surgical treatment for their morbid obesity at        the University of Illinois at Chicago Medical Center (UICMC) Bariatric surgery clinics.|June 2014|June 18, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169050|2 Months|42318|
NCT02186470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13282|Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer|Feasibility of Assessing Radiation Response With MRI/CT Directed Preoperative Accelerated Partial Breast Irradiation in the Prone Position for Hormone Responsive Early Stage Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Suspended|June 2015|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|60 Years|N/A|No|||February 2016|February 23, 2016|July 7, 2014|Yes|Yes|Additional equipment needed for trial|No||https://clinicaltrials.gov/show/NCT02186470||40983|
NCT02186730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITADAL|Computerised Intervention/Treatment for Adolescent Depression and Low Mood:|Computerised Intervention/Treatment for Adolescent Depression and Low Mood: Feasibility Phase 2|CITADAL|Leeds and York Partnership NHS Foundation Trust|Yes|Active, not recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|12 Years|18 Years|No|||March 2016|March 4, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02186730||40963|
NCT02186197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206-13|The Impact of Fellow-performed Cardiopulmonary Ultrasound Exams|The Impact of Fellow-performed Cardiopulmonary Ultrasound Exams on the Diagnosis and Management of Shock and Respiratory Failure||Beth Israel Medical Center|Yes|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|112|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to our intensive care unit with shock and/or respiratory failure|July 2015|July 14, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02186197||41004|
NCT02186457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14036644165|Antibiotic Irrigation for Pancreatoduodenectomy|Routine Antibiotic Irrigation in Patients Undergoing Pancreatoduodenectomy to Reduce Infection and Fistula Rates||Indiana University|Yes|Recruiting|November 2014|August 2024|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|88 Years|No|||February 2016|February 6, 2016|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186457||40984|
NCT02187029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7911002|Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.|A Randomized, Double Blind, Third Party Open, Placebo Controlled Multi-center Study Of Efficacy, Safety And Tolerability Of Pf-06743649 In Gout Subjects||Pfizer|No|Terminated|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|60 Years|No|||March 2015|March 6, 2015|July 8, 2014|No|Yes|B7911002 was prematurely discontinued due to a safety concern that led to decision to    terminate the study on 10 Nov 2014|No||https://clinicaltrials.gov/show/NCT02187029||40940|
NCT02187627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29409|Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease Participants|||Hoffmann-La Roche||Completed|August 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Both|25 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02187627||40894|
NCT02186964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS42|Comparison of Tension Free Primary Closure, Karydaks and Limberg Flap Methods|Randomised Prospective Comparison of Tension-free Primary Closure, Karydakis and Limberg Flap Methods in Treatment of Pilonidal Sinus Disease||Konya Training and Research Hospital|No|Completed|February 2011|May 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186964||40945|
NCT02186977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP140465_2014_001_v2|Proof Of Concept Study: Immunogenicity and Safety of Hepatitis B Injection in the Dermis in Healthy Volunteers Using an Intradermal Injection Device (VAX-ID)|Proof Of Concept Study: Immunogenicity and Safety of Hepatitis B Injection in the Dermis in Healthy Volunteers Using an Intradermal Injection Device (VAX-ID)|POC VAX-ID|Novosanis NV||Not yet recruiting|July 2015|||September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|33|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|February 18, 2015|July 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186977||40944|
NCT02187250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAXAS 2|PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome|Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome||University Medical Centre Ljubljana|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|55 Years|No|||June 2014|July 8, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187250||40923|
NCT02187562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.255|Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females|Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.||Boehringer Ingelheim||Completed|July 2002|||August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 10, 2014||||No||https://clinicaltrials.gov/show/NCT02187562||40899|
NCT02184104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT11351938|Caffeine Disposition After Inhalation|Pharmacokinetics and Pharmacodynamics of a 100 mg Caffeine Dose After Oral Consumption of an Energy Drink or Inhalation Using the Aeroshot Administration Device||University of Tennessee|No|Recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184104||41165|
NCT02184091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1259|Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine|An Open-Label, Single Dose Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine (VIRAMUNE®)||Boehringer Ingelheim||Completed|January 1999|||July 1999|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184091||41166|
NCT02184351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1190.1|Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis|A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis||Boehringer Ingelheim||Completed|May 2001|||November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184351||41146|
NCT02184611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117410|A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)|A 24 Week Randomised, Double Blind and Placebo Controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184611||41126|
NCT02184871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21/2014/U/Tess|Next Generation Sequencing in Intrahepatic Cholangiocarcinoma|Next Generation Sequencing in Intrahepatic Cholangiocarcinoma (ICC) According to the Stratification of the Risk Factors|EtherBil|University of Bologna|No|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|Tumor tissue samples will be immediately collected after surgery: one part will be suspended      in RNAlater to prevent RNA degradation and stored at -20°C, the other will be formalin-fixed      and paraffin-embedded for histopathology examination and evaluation of asbestos fibers. For      each patient enrolled, peripheral blood will be also collected and stored at -20°C. Total      RNA and genomic DNA will be extracted from tumor tissue and peripheral blood and stored at      -80°C until use.|Both|18 Years|N/A|No|Non-Probability Sample|ICC patients candidate for curative-intent surgery, for a total of 45 subjects. For each        patient enrolled, histological examination of tumor tissue specimen will be performed in        order to confirm ICC diagnosis.|July 2014|July 8, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184871||41106|
NCT02171949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL 03/13|Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases|Randomized, Open and Controlled Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases||Hospital Sao Rafael|Yes|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||April 2015|April 10, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02171949||42095|
NCT02172326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.133|Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)|The Pharmacokinetics, Safety and Tolerability of Tiotropium in Elderly COPD Patients (Open Label, Monocenter Study).||Boehringer Ingelheim||Completed|February 1998|||September 1998|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||29|||Both|N/A|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172326||42066|
NCT02171936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0194|Chronic Pain and Social Vulnerability: Prevalence and Predictive Factors of the Social Vulnerability in Evaluation and Treatment of the Pain Center (CETD)|Chronic Pain and Social Vulnerability: Prevalence and Predictive Factors of the Social Vulnerability in Evaluation and Treatment of the Pain Center (CETD)|PRECAPAIN|University Hospital, Clermont-Ferrand||Recruiting|May 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|800|||Both|N/A|18 Years|No|Non-Probability Sample|Patients follow-up in a CETD|June 2014|June 23, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02171936||42096|
NCT02172274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.8|BI 10773 Administered as Oral Solution to Healthy Male Volunteers|A Phase I, Open-label, Single-dose Trial to Investigate the Metabolism and Pharmacokinetics of 50 mg [14C]-BI 10773 When Administered as Oral Solution to Healthy Male Volunteers||Boehringer Ingelheim||Completed|June 2008|||July 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172274||42070|
NCT02204540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-033|Feasibility of Using Webcams in Clinical Studies|Validation of Video Monitoring to Assess Compliance in Clinical Interventions|WEBCAM|Pennington Biomedical Research Center|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02204540||39597|
NCT02173353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ultrasound for Pancreas Motion|Feasibility of Using Ultrasound to Track Pancreas Motion|Feasibility of Using Ultrasound to Track Pancreas Motion||Medical College of Wisconsin|Yes|Recruiting|February 2014|December 2024|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173353||41987|
NCT02168491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LixiBIT_V3|Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin|Feasibility of Once-daily Administered GLP-1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin in Patients With Type-2 Diabetes Mellitus Not Achieving Therapeutic Targets With Premixed Insulin|LixiBIT|Medical University of Vienna|Yes|Completed|November 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02168491||42361|
NCT02201108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11759|Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis|A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension|TERIKIDS|Sanofi|Yes|Recruiting|July 2014|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|165|||Both|10 Years|17 Years|No|||January 2016|January 20, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201108||39861|
NCT02201394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1802|Reversing Ticagrelor's Effects With Fresh Platelets|Normalizing Platelet Reactivity After Treatment With Ticagrelor||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201394||39839|
NCT02186223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QD-230|The Angel® Catheter Clinical Trial|The Angel® Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects||BiO2 Medical|Yes|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|172|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186223||41002|
NCT02186483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP_1310-P1-DI|Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin|An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Drug-drug Interaction Following Coadministration of Metformin and Rosuvastatin in Healthy Male Volunteers||Jeil Pharmaceutical Co., Ltd.|No|Not yet recruiting|August 2014|February 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186483||40982|
NCT02186496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144BE14002|Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|July 2014|November 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|November 27, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186496||40981|
NCT02186990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odu-2|Comparison of Etomidate, Propofol and Etomidate-propofol Combination in Terms of Effects on Haemodynamic Response to Intubation|||T.C. ORDU ÜNİVERSİTESİ||Completed|May 2014|||August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|65 Years|No|||August 2014|August 12, 2014|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02186990||40943|
NCT02187003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5201002|Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease||Pfizer|Yes|Recruiting|June 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|6 Years|N/A|No|||March 2016|March 23, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187003||40942|
NCT02187016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAH-13-0151|Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health|A Randomized, Parallel Design Study to Assess the Effects of Three Interproximal Cleaning Modalities Versus a Manual Toothbrush Control on Gingivitis and Plaque Following a Period of Home Use||Philips Oral Healthcare|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|290|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|July 1, 2014|Yes|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT02187016||40941|
NCT02187588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120.3|Study to Assess the Kinetic of the Analgesic Effect and Tolerability of Eschscholtzia Californica Versus Ibuprofen and Placebo in the Treatment of Pain After Surgery of the Third Molar|Short Term Double Blind Randomised Controlled Study to Assess the Kinetic of the Analgesic Effect and the Tolerability of Eschscholtzia Californica 500 mg and 1000 mg Versus Ibuprofen 200 mg and Placebo in the Treatment of Pain After Surgery of the Third Molar||Boehringer Ingelheim||Completed|February 1998|||May 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|60 Years|No|||July 2014|July 11, 2014|July 10, 2014||||No||https://clinicaltrials.gov/show/NCT02187588||40897|
NCT02187601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-BETA-EX-0614|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2014|||||N/A|N/A|N/A||||||||||||||March 17, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187601||40896|
NCT02187614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Number: 14-00059|Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management|A Double Blind, Multi-arm Randomized Control Trial, for Efficacy of Intramuscular Diclofenac Versus Intravenous Morphine Versus Intravenous Paracetamol, in Renal Colic Emergency Department Pain Management||Hamad Medical Corporation|No|Completed|August 2014|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1645|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187614||40895|
NCT02183207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG by EG Scan|PEG by Introducer Method Via EG Scan|Percutaneous Endoscopic Gastrostomy by Introducer Method Via Visualization Through E.G. ScanTM||The Catholic University of Korea|No|Recruiting|August 2013|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||July 2014|July 2, 2014|August 11, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02183207||41234|
NCT02183220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093.16|Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache|A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.||Boehringer Ingelheim||Completed|October 1998|||July 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|417|||Both|18 Years|65 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183220||41233|
NCT02183233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120.2|Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia|A Double-blind Randomized, Placebo Controlled Study to Assess the Efficacy and the Safety of Eschscholtzia Californica 1000 mg Per Day in Treating Primary Insomnia During a 28 Day Treatment Duration.||Boehringer Ingelheim||Terminated|January 1998|||June 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|65 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183233||41232|
NCT02183792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00705|Aquaresis Utility for Hyponatremic Acute Heart Failure Study|Aquaresis Utility for Hyponatremic Acute Heart Failure Study|AQUA-AHF|University of Southern California|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02183792||41189|
NCT02184364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|563.1|Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints|Double-blind Dose/Response Study Comparing Klimadynon® With Conjugated Oestrogens in Women Suffering From Menopausal Complaints||Boehringer Ingelheim||Completed|November 1998|||September 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|161|||Female|40 Years|60 Years|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184364||41145|
NCT02184884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0172|Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery|||Yonsei University|No|Recruiting|July 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|195|||Both|20 Years|90 Years|No|Non-Probability Sample|patients with acute coronary syndrome (ACS) undergoing off-pump coronary artery bypass        surgery|January 2015|January 6, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02184884||41105|
NCT02172365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 14-7493-AE|Allogeneic SCT for CML, TKI Failure After TKI Failure|Retrospective Analysis of Treatment Outcomes of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia After TKI Failure||University Health Network, Toronto|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|350|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients treated with allogeneic stem cell transplantation (SCT) since 2000 till 2013 for        any of tyrosine kinase inhibitor (TKI) failure due to resistance or intolerance during        chronic myeloid leukemia (CML) management with tyrosine kinase inhibitor|June 2015|June 19, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172365||42063|
NCT02172378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.215|12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales|Effect of a 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe COPD Patients. Correlation to Dyspnoea Scales. A Double-blind, Placebo-controlled, Randomized, Parallel Group Study||Boehringer Ingelheim||Completed|May 2000|||January 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|116|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172378||42062|
NCT02172391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.218|Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Tiotropium Therapy on Airway Diameter in Patients With COPD (a Randomized, Double-blind, Placebo-controlled, Parallel-group Study)||Boehringer Ingelheim||Completed|November 2000|||August 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||81|||Both|40 Years|75 Years|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172391||42061|
NCT02172339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.134|The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects|The Pharmacokinetic, Safety and Tolerability of Tiotropium (4.8 mcg, Single i.v. Dose) in Outpatients With Renal Impairment in Comparison to Healthy Subjects (Open Label, Group Comparison, Two-center Study)||Boehringer Ingelheim||Completed|April 1998|||December 1998|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172339||42065|
NCT02172352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.139|Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients|Dose Ranging Study of Ba 679 BR Inhalation Powder Following Single Inhalation in COPD Patients - Double-blind, Placebo-controlled, 4 Treatment, 4 Period Crossover Study-||Boehringer Ingelheim||Completed|July 1998|||May 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|28|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172352||42064|
NCT02172781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.239|Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment|A Double-blind, Randomised, Two-way Cross-over Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of a Single Additional Dose of 500 µg Ipratropium Bromide Unit Dose Vial Inhaled Via Nebuliser Versus Placebo After 19 Days of Treatment With Tiotropium Inhalation Capsules 18 µg q.d. in Male Healthy Volunteers.||Boehringer Ingelheim||Completed|January 2001|||April 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|36|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172781||42031|
NCT02172794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.261|Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Comparison of the Effect of 6-Week Treatment Periods of Tiotropium Inhalation Capsules (18 μg) and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|May 2002|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172794||42030|
NCT02172807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.226|Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|December 2000|||September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|201|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172807||42029|
NCT02168504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBPD_170614|Electromyography Signals as Biomarkers for Parkinson's Disease|Electromyography Signals as Biomarkers for Parkinson's Disease||Norconnect Inc|Yes|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|20|||Both|25 Years|82 Years|Accepts Healthy Volunteers|Non-Probability Sample|PD patients will be selected from the primary care clinic in Claxton - Hepburn Medical        Center, Ogdensburg NY. The healthy participants will be selected from the population of        St. Lawrence County, NY.        Selection of PD patients: PD confirmed, but with mild symptoms Selection of healthy        controls: match in age/gender/education level/profession/etc. if possible.|October 2015|October 7, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168504||42360|
NCT02204787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9257|Treatment of Negative Symptoms and Schizophrenia|A Double Blind Sham Controlled Trial of tDCS for Treatment of Negative Symptoms in Patients With Schizophrenia|STICCS|University Hospital, Montpellier|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||December 2014|December 3, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204787||39578|
NCT02201407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29062|An Open-Label, Multicenter, National Observational Study in Patients With Chronic Hepatitis B Receiving Therapy With PEGASYS (Peginterferon Alfa-2a 40kD) - The PRO B Study|Peginterferon Alfa-2a (PEGASYS) in theRapy of Patients With chrOnic Hepatitis B (CHB) - PRO B||Hoffmann-La Roche||Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients receiving treatment for chronic hepatitis B with PEGASYS according to        standard of care and in line with the current summary of product characteristics and local        labeling who have no contraindication to PEGASYS therapy as per the local label. Target        population are naïve subjects (who have never received any hepatitis B virus treatment)        and previously treated subjects with nucleos(t)ide analogs (NAs).|March 2016|March 1, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201407||39838|
NCT02201615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBF - 005|The Effect of Perineal Massage in Childbirth|The Effect of Perineal Massage in Childbirth: the Rate of Episiotomy Procedures, Perineal Tears and the Length of the Second Stage of Labour||Cumhuriyet University|No|Completed|January 2010|||May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Actual|284|||Female|19 Years|49 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02201615||39822|
NCT02186756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-FMBFBack|A Randomized Controlled Trial to Evaluate the Effectiveness of Electromyography (EMG)-Biofeedback in Patients With Fibromyalgia|Biofeedback in Patients With Fibromyalgia - a Randomized Controlled Trial||Ludwig-Maximilians - University of Munich|No|Completed|April 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|No|||July 2014|July 8, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186756||40961|
NCT02186769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03004/CT-USA-104|An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder|A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder||Luye Pharma Group Ltd.|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||June 2015|June 17, 2015|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186769||40960|
NCT02187042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181213|Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line|Pragmatic Study Evaluating The Impact Of A Therapy Management Platform On The Management Of Patients Suffering From Advanced/Metastatic Renal Cell Carcinoma And Receiving First Line Treatment With Sunitinib, Versus Standard Follow-up|RENACALL|Pfizer|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|186|||Both|18 Years|99 Years|No|Probability Sample|The 220 metastatic and/or advanced patients of the study will come from the population of        patients under the care of French renal cell carcinoma oncologists|March 2016|March 7, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187042||40939|
NCT02186743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013784|Irritable Bowel Syndrome and Food Sensitivity|Irritable Bowel Syndrome and Food Sensitivity: Assessing Clinical Outcomes and Inflammatory Cellular Pathways||Yale University|Yes|Completed|July 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186743||40962|
NCT02187276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172/2010|The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia|The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer Disease and Mixed Dementia: a Naturalistic Study||Federal University of Minas Gerais|Yes|Completed|June 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|129|Samples With DNA|Genetic and biochemical analyzes A blood sample (5 mL) was withdrawn from all patients on      the first consultation for DNA extraction and APOE genotyping in its different allelic forms      (Ɛ2, Ɛ3, Ɛ4). An additional blood sample (10 mL) was withdrawn from patients who took      donepezil (51 patients) and was kept in a tube with heparin and frozen at - 70 ° C. In this      group of patients, we genotyped the APOE and assessed the polymorphism of CYP 2D6      (*3,*4,*5,*6 and*10). This procedure was done when they came at 3, 6 and 12 months      consultation, respectively.|Both|59 Years|92 Years|No|Non-Probability Sample|Eligible patients were those who spontaneously went to the outpatient units to be        diagnosed and presented cognitive, functional, and in many cases, behavioral symptoms.|September 2014|September 10, 2014|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02187276||40921|
NCT02187653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOC 1002|Intraoperative Monitoring (IOM) Patient Registry|Spine Registry Exposure for: Lumbar and Cervical Surgery Utilizing IOM|IOM|DC2 Healthcare|No|Recruiting|September 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cervical or lumbar surgery in which intraoperative monitoring has been        utilized.|July 2014|July 9, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187653|6 Weeks|40892|
NCT02183246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1164.4|Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients||Boehringer Ingelheim||Terminated|May 2000|||December 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183246||41231|
NCT02183259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1172.1|Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers|Absolute Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL 1 mg Capsule Compared to 0.015 mg Solution i.v. as Single Administration in Healthy Male Subjects (Open-labelled, 2-way Cross-over Study)||Boehringer Ingelheim||Completed|November 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183259||41230|
NCT02183779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 14 02|PORH and Response to Cold in Raynaud's Phenomenon.|Rôle Des Acides Epoxy-eicosatriénoïques et du Monoxyde d'Azote Dans l'hyperhémie Post-occlusive cutanée Digitale et la réponse cutanée au Froid Dans le phénomène de Raynaud Primaire|REFRAIN|University Hospital, Grenoble|Yes|Recruiting|June 2014|June 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02183779||41190|
NCT02184130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tms_percept_zurich|Altered Vestibular Perception and Transcranial Magnetic Stimulation|Altered Vestibular Perception by Virtual Lesions of Cerebral and Cerebellar Structures Using Repetitive Transcranial Magnetic Stimulation - Implications for Human Vestibular Dysfunction||University of Zurich|No|Recruiting|October 2011|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184130||41163|
NCT02184117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0399|CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)|CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)|CONTRAST|The University of Texas Health Science Center, Houston|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing FFR assessment for standard clinical indications|May 2015|May 15, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184117||41164|
NCT02184377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101_4920A3|The Function of Cricothyroid Muscle and Its Impaction on Mandarin Lexical Tones in Unilateral Vocal Fold Paralysis|The Function of Cricothyroid Muscle and Its Impaction on Mandarin Lexical Tones in Unilateral Vocal Fold Paralysis: a Quantified Laryngeal Electromyography Based Research||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|August 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|Patients from a tertian referral medical center.|July 2014|July 8, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02184377||41144|
NCT02184390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44MH086936|Parenting Your Young Child With Autism: A Web-Based Tutorial|Parenting Your Young Child With Autism: A Web-Based Tutorial||Center for Psychological Consultation|No|Completed|May 2013|September 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|104|||Both|18 Months|6 Years|No|||February 2016|February 1, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184390||41143|
NCT02184897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_MM01|Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoetic Stem Cell Mobilization|Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoetic Stem Cell Mobilization in Patients With Multiple Myeloma||Asan Medical Center|No|Recruiting|July 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|65 Years|No|||February 2016|February 20, 2016|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02184897||41104|
NCT02184910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0722|Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea|||Yonsei University|No|Recruiting|December 2013|November 2018|Anticipated|October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|108|||Female|19 Years|N/A|No|Non-Probability Sample|Over 19 years, the patients who have gastrointestinal discomfort or get        esophagastroduodenoscopy (EGD) for health check up, the patients who got the procedure,        endoscopic submucosal resection (ESD) for early gastric cancer|July 2014|July 8, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02184910|4 Years|41103|
NCT02172404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.220|HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD.||Boehringer Ingelheim||Completed|October 2000|||June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172404||42060|
NCT02172417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.222|Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects|The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Male and Female Subjects of 50-65 Years (Randomized, Open Label, Two Independent Two-fold Crossover)||Boehringer Ingelheim||Completed|July 2000|||November 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172417||42059|
NCT02172430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.227|Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of Tiotropium 18 μg Inhalation Capsules and Oxitropium MDI (2 Puffs of 100 μg) in a One-year, Open-Label, Safety and Efficacy Study in Patients With COPD||Boehringer Ingelheim||Completed|September 2000|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|40 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172430||42058|
NCT02172820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRINCN9874|Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees|Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees||University of Vermont|No|Recruiting|April 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172820||42028|
NCT02205034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 391 02|Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants|Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants|OTBB2|University Hospital, Toulouse|Yes|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|1 Month|5 Months|No|||February 2015|February 27, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02205034||39559|
NCT02205047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1203-GITCG|Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma|INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL|INNOVATION|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|September 2015|September 2024|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|N/A|No|||October 2015|December 22, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02205047||39558|
NCT02205060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01253-42|Virtual Reality Cue Exposurefor the Relapse Prevention of Tobacco Consumption|Interventionnal and Randomized Study Measuring Virtual Reality Cue Exposure for the Relapse Prevention of Tobacco Consumption Versus Cognitive and Behavioral Approaches Therapy||Assistance Publique Hopitaux De Marseille|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02205060||39557|
NCT02201121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|plaghran001|Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation|Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation||Chinese PLA General Hospital|Yes|Completed|March 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|94|||Both|18 Years|60 Years|No|||October 2013|July 24, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201121||39860|
NCT02201134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0199|SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia|SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia|SEVOCAR|University Hospital, Clermont-Ferrand||Recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||March 2015|March 26, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02201134||39859|
NCT02201147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-041|Cold Snare Polypectomy Vs. Cold Forceps Polypectomy Using Narrow-band Imaging Endoscopy for Removal of Diminutive Colorectal Polyps|Prospective Comparison of Cold Snare Polypectomy and Cold Forceps Polypectomy Using Narrow-band Imaging Endoscopy for Diminutive Colorectal Polyps||Soonchunhyang University Hospital|Yes|Completed|July 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|146|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 2, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201147||39858|
NCT02201420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV3-12|Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging|Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.||Navidea Biopharmaceuticals|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201420||39837|
NCT02186782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1|Concomitant CC and E2 Versus CC Alone in Ovulation Induction|Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial||Mansoura University|No|Recruiting|June 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Female|20 Years|39 Years|No|||June 2015|November 18, 2015|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02186782||40959|
NCT02187055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921187|An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate|A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis|ORAL STRATEGY|Pfizer|Yes|Recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1080|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187055||40938|
NCT02187289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA CC-14-0066|A Study to See Whether Adding Night-time Compression to the Standard Care Will Result in Improved Control of Arm Swelling (Lymphedema) in Breast Cancer Subjects|Night-time Compression for Breast Cancer Related Lymphedema (LYNC): A Randomized Controlled Efficacy Trial|LYNC|AHS Cancer Control Alberta|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|N/A|N/A|No|||December 2015|December 29, 2015|July 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02187289||40920|
NCT02183285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209.1|Tolerability of Pharmaton PHL 00747 in Healthy, Young Female Subjects of Child-bearing Potential|A 30 Day, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre Safety Trial to Evaluate the Tolerability Profile of Pharmaton PHL 00747 Soft Gelatine Capsules (Multivitamin, Multimineral + Omega-3 Fatty Acids) 1/Day p.o. and Pharmaton PHL 00747 Film-coated Tablets (Multivitamin, Multimineral Without Omega-3 Fatty Acids) 1/Day p.o. in Healthy, Young Female Subjects of Child-bearing Potential||Boehringer Ingelheim||Completed|November 2003|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|203|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183285||41228|
NCT02187640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hkpusn01|Effects of Self-administered Acupressure in Psychiatric Patients With Constipation|A Randomised Controlled Trial of Self-administered Acupressure in Adult Psychiatric Patients With Constipation||The Hong Kong Polytechnic University|Yes|Completed|June 2013|July 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|60 Years|No|||August 2015|August 17, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187640||40893|
NCT02183272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketamine IIT|Emergency Ketamine Treatment of Suicidal Ideation|Ketamine as an Adjunctive Treatment of Acute Suicidal Ideation in the Emergency Setting.||University of Cincinnati|Yes|Not yet recruiting|July 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02183272||41229|
NCT02175758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1112|Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection|A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection||Gilead Sciences|Yes|Recruiting|July 2014|April 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|100|||Both|3 Years|17 Years|No|||February 2016|February 5, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175758||41802|
NCT02175771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-AS-305|Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma|A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|June 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|674|||Both|12 Years|N/A|No|||October 2015|October 15, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175771||41801|
NCT02176031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-140|Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract|Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract||Dana-Farber Cancer Institute|Yes|Recruiting|January 2015|March 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176031||41781|
NCT02176265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUEST I|Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation|Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation||Qvanteq AG|Yes|Active, not recruiting|September 2014|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||July 2015|November 17, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176265||41763|
NCT02176278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2013.609-T|Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)|Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) (DKD-TMT)|DKD-TMT|Asia Diabetes Foundation|No|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3000|||Both|N/A|N/A|No|||August 2015|August 17, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02176278||41762|
NCT02176629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-03|Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease|Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. MeMO-RV2|MeMO-RV2|Centre Hospitalier Universitaire de Nice|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|60 Years|N/A|No|||August 2015|August 31, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176629||41736|
NCT02203994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07|Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Spasticity in Persons With Spinal Cord Injury|The Effect of Extracorporeal Shock Wave Therapy (ESWT) on Lower Limb Spasticity in Persons With an Incomplete Spinal Cord Injury|ESWT|Swiss Paraplegic Centre Nottwil|Yes|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203994||39639|
NCT02204267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MonDAFIS|Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke|Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke|MonDAFIS|Charite University, Berlin, Germany|No|Recruiting|December 2014|October 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3470|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204267||39618|
NCT02204813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861F|To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery|To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery||Washington University School of Medicine|Yes|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204813||39576|
NCT02200861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/389|Tooth Extraction With Deep Sedation in Children: A Retrospective Study|Tooth Extraction With Deep Sedation in Children: A Retrospective Study||TC Erciyes University|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|885|||Both|1 Year|15 Years|No|Probability Sample|children|November 2014|November 4, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200861||39880|
NCT02169986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02932|Atopic Dermatitis Adherence Study|Family Practice Resident Research Project: Do Electronic Reminders Increase Adherence of Moisturizer Utilization in Paediatric Atopic Dermatitis?||University of British Columbia||Not yet recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|10 Years|No|||June 2014|June 19, 2014|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02169986||42246|
NCT02169999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0045|Personalized Decision Support for Older Patients With Diabetes|Personalized Decision Support for Older Patients With Diabetes||University of Chicago|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Both|65 Years|N/A|No|||February 2016|February 17, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169999||42245|
NCT02187068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-142|Dexmedetomidine Pharmacokinetics in the Obese|Dexmedetomidine Pharmacokinetics in the Obese||Pontificia Universidad Catolica de Chile|Yes|Completed|April 2012|May 2014|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02187068||40937|
NCT02187302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX101-208|CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)|A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)||Cerulean Pharma Inc.|Yes|Active, not recruiting|July 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02187302||40919|
NCT02187666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOC 1001|NOC2 Spine Registry|National Neurosurgical and Orthopedic Optimum Care Continuum Spine Registry Exposure for Various Implants/Products||DC2 Healthcare|No|Recruiting|December 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Approximately 10,000 patients undergoing lumbar or cervical surgery will be screened to        decide whether they meet the inclusion and exclusion criteria of the study/patient        registry. Patients who meet the study criteria will be informed by the investigator and        should read the 'patient information' document. Patients must give their written informed        consent to be enrolled into this study.|July 2014|July 9, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187666|2 Years|40891|
NCT02187679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCRC-ISP0016888|Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome|An Open Label, One Arm Pilot Study to Measure the Efficacy and Safety of Dysport in the Treatment of Vocal Tics in Patients With Tourette's Syndrome and Chronic Tic Disorders||Detroit Clinical Research Center||Recruiting|January 2014|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187679||40890|
NCT02183324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.12|BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled, Multiple Dose Phase II Study of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg in Tablet q.d. Administered Orally for 28 Days) to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|February 2007|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|72|||Both|21 Years|70 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183324||41225|
NCT02183337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.13|Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers|Relative Bioavailability of Both BI 1356 and Pioglitazone After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 10 mg qd Alone and Pioglitazone 45 mg qd Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|February 2007|||April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183337||41224|
NCT02183350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (1, 2.5, 5, 10 and 25 mg q.d. for 12 Days) of BI 1356 BS as Powder in the Bottle (PIB) in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups).||Boehringer Ingelheim||Completed|April 2005|||August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|47|||Male|21 Years|65 Years|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183350||41223|
NCT02183363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.25|Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers|Bioavailability of BI 1356 After Single Oral Administration of 5 mg BI 1356 Given as Tablet Formulation TF IIb Relative to Tablet Formulation TF II and Tablet Formulation iFF in Healthy Male Volunteers (an Open Label, Randomised, Single-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|February 2007|||May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183363||41222|
NCT02174887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOAnab1-IPC 2012-010|Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer|A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma|MOAnab1|Institut Paoli-Calmettes|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02174887||41869|
NCT02183298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.10|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.5 mg to 10 mg) of BI 1356 BS as Formulation for Intravenous Administration in Healthy Male Volunteers. A Randomised, Single-blind, Placebo-controlled Trial, Including a Crossover Intra-subject Bioavailability Comparison of 5 mg BI 1356 BS iv Solution and 10 mg BI 1356 BS as Tablet.||Boehringer Ingelheim||Completed|May 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183298||41227|
NCT02183311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.11|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses (1 to 10 mg) and Multiple Rising Oral Doses (2.5 to 10 mg Once Daily for 12 Days) of BI 1356 BS in Healthy Male Volunteers (a Randomised, Double-blind, Placebo Controlled Within Dose Groups Clinical Trial)||Boehringer Ingelheim||Completed|June 2006|||October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|56|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183311||41226|
NCT02183805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-004|Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer|Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer||Sun Yat-sen University|Yes|Recruiting|June 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02183805||41188|
NCT02175459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14081985|Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy|||Catholic University of the Sacred Heart|Yes|Recruiting|August 2010|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|PANCREAS SAMPLES|Both|18 Years|69 Years|No|Probability Sample|Patients scheduled for elective pancreaticoduodenectomy for periampullary neoplasms will        be enrolled in the study. Indications for surgery will be periampullary neoplasms, i.e.        tumors of the Vater's ampulla, distal CBD and periampullary duodenum. Patients with        pancreatic cancer will be excluded from the study. The metabolic features of all patients        will be assessed before and after surgery. The patients will visit the Division of        Endocrinology for studies at least 1 week before surgery. Only patients with normal        cardiopulmonary and kidney functions, as determined by medical history, physical        examination, screening blood tests, electrocardiogram and urinalysis, and not on any        antidiabetic medications will be enrolled for metabolic assessments before and after        surgery. Each subject will undergo, on separate days, a hyperinsulinemic euglycemic clamp,        a hyperglycemic clamp and a mixed meal test one week before and after a variable period of        recovery from the surgical procedure.|August 2015|August 2, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02175459||41825|
NCT02175784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0131|A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus|Post-marketing Clinical Study of Ipragliflozin -Study to Assess the Efficacy, Safety and Tolerability of Ipragliflozin in Combination With Insulin Preparation in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy-||Astellas Pharma Inc|No|Completed|March 2014|December 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175784||41800|
NCT02175797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMR02 - IKONE|Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System|Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System|IKONE|LivaNova|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|June 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02175797||41799|
NCT02176044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOSMEM01|The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study|The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study||King's College London|No|Completed|August 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|60 Years|No|||March 2016|March 8, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176044||41780|
NCT02176291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120236|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|IRLGREY-B|University of Pittsburgh|Yes|Recruiting|August 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2016|January 5, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176291||41761|
NCT02176304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Knee Injections|Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes.|Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes.||University of Puerto Rico|No|Recruiting|June 2014|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 26, 2014|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176304||41760|
NCT02176642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052742|Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.|Double-Blind Randomized Controlled Trial of Extended Release Oxybutynin Versus Placebo in Women Receiving Posterior Tibial Nerve Stimulation for Treatment of Urgency Urinary Incontinence|APP|Duke University|No|Recruiting|August 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176642||41735|
NCT02204800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312013110|Active Surveillance of the Small Renal Mass|Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial||Yale University|No|Recruiting|August 2014|||August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|N/A|No|Probability Sample|This is a trial of active surveillance in patients with a solitary, small (1.0-2.7 cm)        renal mass.|September 2015|September 29, 2015|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204800||39577|
NCT02204566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001952|Using the Optical Frequency Domain Imaging (OFDI) Capsule to Image the Esophagus in Patients Who Have Atrial Fibrillation and Have Undergone Radio Frequency (RF) Ablation|Pilot Study of OFDI Capsule Imaging of the Esophagus of Patients With Atrial Fibrillation Following RF Ablation||Massachusetts General Hospital|No|Recruiting|January 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02204566||39595|
NCT02200874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM_NST_KET|Investigation of the Effectiveness and Efficiency of a Structural Clinical Nutrition Support|Investigation of the Effectiveness and Efficiency of a Structural Clinical Nutrition Support by an Interdisciplinary Nutrition Support Team at the University Hospital Tübingen||University of Hohenheim|No|Recruiting|November 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|840|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from University Hospital Tübingen. 420 patiens in each group. Patients from three        general wards and two intensive care units. From all patients written informed consent is        needed. From sedated and/or ventilated patients, consent from their advisor is needed.|September 2015|September 3, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200874||39879|
NCT02200887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC-NSI.12.01|Sleep Homeostasis in Parkinson's Disease|Ruolo Della Sleep Homeostasis Nello Sviluppo Delle Discinesie Indotte Della L-Dopa Nei Pazienti Affetti da Malattia di Parkinson in Fase Avanzata. The Role of Sleep Homeostasis in the Progress of Dyskinesi, Induced by L-Dopa in Patients With Advanced Parkinsons Disease.||Ospedale Civico, Lugano|No|Recruiting|September 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|48|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers and patients with parkinson disease|July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200887||39878|
NCT02201160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD-2188|Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients|Impact of n-3 Fatty Acid Supplementation on the Metabolic Abnormalities in Children With NAFLD||St. Justine's Hospital|Yes|Active, not recruiting|January 2009|December 2015|Anticipated|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Male|8 Years|18 Years|No|||July 2014|July 23, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02201160||39857|
NCT02170272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 1431|Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors|Development and Pilot Testing of a Home-Based Program for Head and Neck Cancer Survivors With Lymphedema||Vanderbilt-Ingram Cancer Center|Yes|Terminated|June 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 13, 2014|Yes|Yes|loss of funding|No||https://clinicaltrials.gov/show/NCT02170272||42224|
NCT02201628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SG04|Correlation of Nasopharyngeal (NP) and Lower Oesophageal (LO) Temperatures in Ventilated Children|Comparison of Nasopharyngeal and Lower Oesophageal Temperatures Under General Anaesthesia With an Endotracheal Tube With Leak||Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Recruiting|July 2014|April 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|8 Months|7 Years|No|||July 2014|July 24, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02201628||39821|
NCT02201641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-LO-1893|Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial|Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial||King's College London|Yes|Active, not recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|53|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02201641||39820|
NCT02174003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406365027|Whole Body Hyperthermia Registry Study|||University of Arizona|No|Terminated|June 2014|||August 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|For the purposes of this study we will enroll subjects 18 years and older to undergo a        Hyperthermia session in an open fashion. We expect approximately 20-30 subjects per year        to undergo this open hyperthermia treatment. Subjects must be medically healthy enough to        be able to undergo the Hyperthermia session, all exclusion criteria listed below address        what is deemed "medically healthy".        Inclusion into this study will require that the minimum safety standards described in the        eligibility criteria, there will be no inclusion of children, pregnant women, mentally        impaired individuals, or prisoners in this registry. Subjects who appear to have Major        Depressive Disorder will be referred to Protocol 12-0147-01 due to the specific aims        pertaining directly to depressive symptoms.|July 2015|July 23, 2015|June 23, 2014||No|Investigator transferred to the University of Wisconsin - Madison|No||https://clinicaltrials.gov/show/NCT02174003|1 Week|41937|
NCT02174315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46593-G|Motivational Incentives for Alcohol Abstinence in American Indian and Native Alaskan Adults|Contingency Management Treatment of Alcohol Abuse American Indian People||Washington State University||Recruiting|October 2014|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A||||September 2015|September 3, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02174315||41913|
NCT02174328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrOvAS001|Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.|Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.|PROVAS|Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|June 2014|June 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|372|||Female|18 Years|50 Years|No|||July 2015|July 21, 2015|September 11, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174328||41912|
NCT02174601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0292|A Pre-endoscopic Prediction Model for Inadequate Bowel Preparation in Patients Receiving Split Dose Polyethylene Glycol Preparation|||Yonsei University|No|Recruiting|July 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects, more than 20 years old, who admitted to the health promotion center for        performing colonoscopy.|January 2015|January 6, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174601||41891|
NCT02174900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFEPRIM|Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)|Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM)||London School of Hygiene and Tropical Medicine|Yes|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|70|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02174900||41868|
NCT02174913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099/2557|Awakening in Spine Surgery: A Comparison Between Clinical Signs and Bispectral Index|Awakening in Spine Surgery Patients Having Neurophysiologic Monitoring: A Comparison Study Between Clinical Signs and Bispectral Index (BIS) Guided Target Controlled Infusion(TCI) of Propofol||Mahidol University|No|Recruiting|May 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|34|||Both|18 Years|80 Years|No|||June 2015|June 25, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02174913||41867|
NCT02175160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|619/2013BO2|Predictability of the Ability to Perform an Emergency Stop|Predictability of the Ability to Perform an Emergency Stop in Knee Osteoarthritis and Patients With Total Knee Arthroplasty||University Hospital Tuebingen|No|Completed|July 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2014|February 1, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02175160||41848|
NCT02175173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO01T|Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome|||Eisai Inc.||Recruiting|May 2013|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Lennox-Gastaut Syndrome|November 2015|November 5, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02175173||41847|
NCT02175472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT1301|Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease|Sixty Minute Exposure of Specific Bandwidth Light for the Treatment of Idiopathic Parkinson's Disease||PhotoPharmics, Inc.|No|Active, not recruiting|June 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|45 Years|N/A|No|||January 2016|January 5, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02175472||41824|
NCT02175485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXHYL06934|Evaluation of Efficacy of Dellegra in Exposure Unit|Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen Exposure in Japanese Population. Open Label Study||Sanofi|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|65 Years|No|||December 2015|December 17, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02175485||41823|
NCT02175498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APB123|Effectiveness of Homeopathic Treatment in Female Infertility|A Clinical Study to Assess the Effectiveness of Homeopathic Treatment in Female Infertility||Fr Muller Homoeopathic Medical College|Yes|Recruiting|June 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02175498||41822|
NCT02186314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4381|Effect of Right Bifocal Ventricular Cardiac Pacing on Serum Level Natriuretic Peptides in Patients With Heart Failure|Effect of Right Bifocal Ventricular Cardiac Pacing on Serum Level Natriuretic Peptides in Patients With Heart Failure and Pacemaker Indication||Instituto Dante Pazzanese de Cardiologia|No|Recruiting|February 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02186314||40995|
NCT02186561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PED-07|Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device|PREMIER PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE™ EMBOLIZATION DEVICE|PREMIER|Medtronic Neurovascular Clinical Affairs|No|Recruiting|July 2014|October 2019|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|141|||Both|22 Years|80 Years|No|||August 2015|August 26, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186561||40976|
NCT02186574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF62014|Tenofovir to Prevent HBV Reactivation|A Multi-centre Phase III Study to Evaluate Preemptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Rituximab-based Chemotherapy for Non-Hodgkin's Lymphoma||University Health Network, Toronto|Yes|Recruiting|May 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186574||40975|
NCT02186821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378AUS23|Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1|SIGNATURE|Novartis|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186821||40956|
NCT02186834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17814|Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma|Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|September 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186834||40955|
NCT02187094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-6499-12-CLP-005|Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis|||Targacept Inc.|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|70 Years|No|||May 2015|May 11, 2015|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187094||40935|
NCT02204826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRG-infertility|Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study|Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study||Pusan National University Hospital|Yes|Completed|April 2011|December 2013|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Male|25 Years|45 Years|No|||July 2014|July 29, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02204826||39575|
NCT02169427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-122|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration||Bial - Portela C S.A.|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 24, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02169427||42289|
NCT02169440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-116|Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin|Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|January 24, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02169440||42288|
NCT02169713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-109|Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects|A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169713||42267|
NCT02169726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2013-9473|A Pilot Study Non-Invasive Guidance for Therapeutic Ultrasound Treatment of Lower Back Muscle Injuries|A Pilot Study to Investigate Non-Invasive Metabolic Guidance for Improving Therapeutic Ultrasound Treatment of Lower Back Muscle Injuries||University of California, Irvine|No|Completed|December 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study population will be selected from Univesity of California Irvine Medical Center|January 2016|January 12, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02169726||42266|
NCT02170948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6795-A|The Effectiveness of the Addition of Dexmedetomidine to Analgesia for Ankle Surgery.|The Analgesic Efficacy of Dexmedetomidine as a Local Anesthetic Adjunct in Ankle Blocks for Forefoot Surgery. A Dose Ranging Study.||University Health Network, Toronto|No|Recruiting|April 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170948||42172|
NCT02170259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVtensiontype|Manual Therapy for Tension Headache With Psychological Disorders|Efficacy of Manual Therapy for the Treatment of Tension-type Headache in Patients With Anxiety and Depressive Disorders. A Randomized Controlled Clinical Trial||University of Valencia|Yes|Completed|January 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02170259||42225|
NCT02173756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5092|Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults||MorphinOgel|University Hospital, Strasbourg, France|No|Not yet recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|25 Years|No|||June 2014|June 20, 2014|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02173756||41956|
NCT02174016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001156A|The Ketogenic Diet for Pediatric Acute Brain Injury|The Ketogenic Diet for Pediatric Acute Brain Injury||University of California, Los Angeles|No|Recruiting|January 2015|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|1 Year|17 Years|No|||November 2015|November 30, 2015|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02174016||41936|
NCT02174341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20110428|The Pilot Study of Chikungunya Virus Infections in Southern Taiwan|Investigate the Prevalence of Serum Chikungunya Virus Infection, and Against Those Suspected Dengue Fever, Chikungunya Disease-related Tests Conducted||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|300|Samples With DNA|blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples are obtained from the Kaohsiung Medical University Chung-Ho Memorial Hospital        in Kaohsiung, Taiwan.|March 2015|March 31, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02174341||41911|
NCT02185248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363990-4|Wellness Action Plan Trial Addressing Childhood Obesity|Randomized Controlled Trial of a Wellness Action Plan to Address the Childhood Obesity Epidemic||Medical College of Wisconsin|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|181|||Both|30 Months|14 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185248||41077|
NCT02174614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14050 13937|The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)|The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)|Project 1|Yale University|Yes|Recruiting|April 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02174614||41890|
NCT02174627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5740C00001|Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis||AstraZeneca|Yes|Recruiting|June 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2600|||Both|18 Years|130 Years|No|||March 2016|March 3, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02174627||41889|
NCT02175186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV 2014-05|Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|DAPT ALBIS|Asan Medical Center|Yes|Recruiting|January 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||January 2016|January 3, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02175186||41846|
NCT02175199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-008|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers||Alcon Research|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|151|||Both|16 Years|N/A|No|||September 2015|September 14, 2015|June 24, 2014|Yes|Yes||No|September 14, 2015|https://clinicaltrials.gov/show/NCT02175199||41845|
NCT02186028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/094/2012/VitD|Effect of Oral Daily Supplementation With 400 IU Vs 200 IU of Vitamin D in Term Healthy Neonates|Effect Of Oral Daily Supplementation With 400 IU Vs 200 IU Of Vitamin D In Term Healthy Newborns: A Randomised Control Trial||Lady Hardinge Medical College|Yes|Completed|July 2014|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||September 2015|September 26, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186028||41017|
NCT02186327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054909|Integrative Health Coaching in Community Settings|Community Coaching: Integrative Health Coaching Initiative for Behavior Change and Assessment of Perceived Needs in the Community Setting||Duke University|No|Completed|August 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|74|||Both|5 Years|N/A|Accepts Healthy Volunteers|||January 2015|July 22, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02186327||40994|
NCT02186340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52852-2|Effects of Inspiratory Muscle Training on Breathing Pattern in Patients With Chronic Obstructive Pulmonary Disease|||Katholieke Universiteit Leuven||Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|40 Years|90 Years|No|||August 2015|August 28, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02186340||40993|
NCT02186587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206872|iTotal Pilot Study of ConforMIS Custom Total Knee Implant|CT-navigated, Patient-specific Custom Total Knee Replacement Versus Standard Total Knee Replacement: Comparison With a Marker-less Gait Analysis System and Validated Outcome Scores||University of Missouri-Columbia|Yes|Enrolling by invitation|June 2014|||March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186587||40974|
NCT02186847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-LU001|Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC||NRG Oncology|Yes|Recruiting|August 2014|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186847||40954|
NCT02187107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005848|A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials|An Open Label Trial of TMC114/Rtv in HIV-1 Infected Subjects Who Were Randomized in the Trials TMC114-C201, TMC114-C207 or in Sponsor Selected Phase I Trials||Tibotec Pharmaceuticals, Ireland|No|Completed|January 2005|March 2009|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||August 2014|August 22, 2014|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02187107||40934|
NCT02187354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130320|Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|RIALTO|Amgen||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|17 Years||||February 2016|February 10, 2016|July 9, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02187354||40915|
NCT02204280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HebeiMUTH|The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy|Urine UbA52 is a Biomarker of Early Diabetic Nephropathy||Hebei Medical University Third Hospital|Yes|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|120|Samples Without DNA|morning urine|Both|18 Years|70 Years|No|Non-Probability Sample|patients with type 2 diabetic,diabetic with macro-or microalbuminuria and proteinuria due        to nondiabetic renal disease from Hebei Medical University the Third Hospital.|July 2014|July 20, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02204280||39617|
NCT02204293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885GDE01T|Canakinumab for Treatment of Adult Onset Still's Disease|Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation|CONSIDER|Charite University, Berlin, Germany|Yes|Recruiting|June 2012|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204293||39616|
NCT02204306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000 Talents-CSU-GC|Genotype Guided Chemotherapy in Gastric Cancer Patients|TSER Genotype Guided Chemotherapy in Metastatic Gastric Cancer Patients: A Phase II Study in China||Central South University|Yes|Recruiting|April 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|70 Years|No|||August 2014|August 12, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02204306||39615|
NCT02169154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202187|A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel|A Cumulative Skin Irritation Study Investigating the Skin Irritancy Potential of MFC51123 Diclofenac-Menthol Gel||GlaxoSmithKline|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|7||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169154||42310|
NCT02169739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA-000-376|Remote Preconditioning Over Time To Empower Cerebral Tissue|Pilot, Randomized, Controlled, Staggered Start, Feasibility Trial of Ischemic Preconditioning, a Promising Novel Treatment for Stroke Prevention|REM-PROTECT|University of California, Los Angeles|Yes|Recruiting|November 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|40 Years|N/A|No|||February 2016|February 1, 2016|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169739||42265|
NCT02170012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7911004|A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 In Healthy Elderly Subjects||Pfizer|No|Terminated|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|24|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|June 19, 2014|No|Yes|The study was prematurely terminated on 17th December 2014 due to safety concerns.|No||https://clinicaltrials.gov/show/NCT02170012||42244|
NCT02170025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17020|Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta ∆F508 Homozygous Cystic Fibrosis Patients||Bayer|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02170025||42243|
NCT02170519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013737|Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide|Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide||Duke University|No|Terminated|September 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|N/A|No|||June 2014|August 25, 2014|June 19, 2014|Yes|Yes|Project was completed|No|August 11, 2014|https://clinicaltrials.gov/show/NCT02170519||42205|
NCT02170909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.29|Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin|Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)||Boehringer Ingelheim||Completed|December 2004|||June 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170909||42175|
NCT02184650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 13016|Nutrition and Neurological Development of Very Preterm Infants|Early Nutrition and Neurological Development of Very Preterm Infants|EPINUTRI_3|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|July 2014|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|None Retained|saliva, whole blood|Both|3 Years|3 Years|No|Non-Probability Sample|Subsample of infants born very preterm (before 32 weeks of gestation), otherwise included        in the French national cohort EPIPAGE 2, and previously included in EPINUTRI study.|May 2015|October 5, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184650||41123|
NCT02184949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOR-PCI-VolOut|Exploring the Volume-Outcome Relationship for PCI Procedures Undertaken in a UK Context: A NICOR Study|Percutaneous Coronary Interventions in the UK: The Relationship Between Procedural Volumes and Patient Outcomes in a Changing Context (A NICOR Study)||University College, London|No|Completed|January 2014|April 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|427467|||Both|18 Years|N/A|No|Non-Probability Sample|Percutaneous coronary interventions undertaken in UK hospitals are recorded in the UK        National Audit of Percutaneous Coronary Intervention. Patients who contribute data to this        audit will be eligible for inclusion in this study. Additional inclusion criteria, as        described below, will be applied to ensure that data are appropriate for the intended        analysis.|May 2015|May 26, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184949||41100|
NCT02185261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|Interferon α for the Therapy of Minimal Residual Disease|Interferon α for the Therapy of Minimal Residual Disease Following Hematopoietic Stem Cell Transplantation||Peking University People's Hospital|Yes|Recruiting|June 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|1 Year|60 Years|No|||July 2014|July 6, 2014|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02185261||41076|
NCT02185560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17391|Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib|Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC)|JPMS-DTC|Bayer|No|Recruiting|June 2014|June 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Sorafenib for Unresectable Differentiated Thyroid Carcinoma (DTC).|March 2016|March 7, 2016|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185560||41053|
NCT02185755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBGMS standalone|Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes|Investigating if an Internet-Based Glucose Monitoring System is as Effective as Medication at Reducing HbA1c Levels in Type 2 Diabetes Mellitus||Endocrine Research Society|No|Active, not recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 10, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185755||41038|
NCT02185768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 1307|Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II|Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II|IDASPHERE II|Federation Francophone de Cancerologie Digestive|Yes|Recruiting|December 2014|January 2020|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|91|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185768||41037|
NCT02186041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.05.7008|Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study|Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS):an Observational Study|SOUNDS|Medtronic International Trading Sarl|No|Recruiting|August 2014|August 2021|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are eligible for Interstim® therapy for the treatment of intractable        urinary voiding dysfunctions will be proposed to participate to the registry in a        representative selection of French centers.|December 2015|December 3, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186041||41016|
NCT02186054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2 Weighted MRI Liver|T2 Weighted Imaging of the Liver With Fast Spin Echo MRI|Enhancement of T2 Weighted Imaging of the Liver With Fast Spin Echo Magnetic Resonance Imaging (MRI).||Ottawa Hospital Research Institute|No|Terminated|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 17, 2015|July 4, 2014||No|Trial Logistics|No||https://clinicaltrials.gov/show/NCT02186054||41015|
NCT02186860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-CAR T|Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia|Treatment of Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia by Third Generation Chimeric Antigen Receptor (CAR)-Modified T Cells||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|December 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186860||40953|
NCT02187120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP1044894|Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)|A Multi-centre Randomised, Double-blinded, Placebo-controlled Trial of Pre-hospital Treatment With Tranexamic Acid for Severely Injured Patients at Risk of Acute Traumatic Coagulopathy.|PATCH|National Trauma Research Institute|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1184|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187120||40933|
NCT02187172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820124|Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)|A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS|VIP-U|University of Pennsylvania|No|Recruiting|July 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||June 2015|September 10, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187172||40929|
NCT02187133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14251|Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma||University of California, San Francisco|Yes|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187133||40932|
NCT02187367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV-NSCLC-002|Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients|Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care|EGF|Bioven Sdn. Bhd.|Yes|Recruiting|May 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|418|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187367||40914|
NCT02187380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220109082|Studying the Impact of Medication Counselling by Community Pharmacists in Patients Starting a Treatment With Antidepressants|Studying the Impact of Medication Counselling by Community Pharmacists in Patients Starting a Treatment With Antidepressants|SIMCA|Katholieke Universiteit Leuven|No|Completed|June 2010|||August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|223|||Both|18 Years|N/A|No|Non-Probability Sample|primary care patients with a new prescription for antidepressants in Flanders, Belgium.|July 2014|July 9, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187380||40913|
NCT02204579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-C13-001|A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations|Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study||Shire|Yes|Completed|July 2014|October 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2015|November 10, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204579||39594|
NCT02204592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBO101|Level of Burn Out of Surgical Residents Working in Government Hospitals of Lahore|Burn Out Among Surgical Residents Working at Government Institutes in Lahore: An Area of Grave Concerns||Services Hospital, Lahore|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|133|||Both|25 Years|40 Years|No|Non-Probability Sample|General surgical residents of All the government Hospitals Of Lahore|January 2016|January 29, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02204592||39593|
NCT02169453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-110|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects||Bial - Portela C S.A.|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 20, 2012||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT02169453||42287|
NCT02169466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-109|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects||Bial - Portela C S.A.|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|January 20, 2012||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT02169466||42286|
NCT02170285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E24720|Enhancing Motor Plasticity After Perinatal Stroke Using tDCS|Enhancing Developmental Motor Plasticity After Perinatal Stroke With Transcranial Direct Current Stimulation|tDCS|University of Calgary|Yes|Completed|May 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|6 Years|18 Years|No|||May 2015|May 27, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02170285||42223|
NCT02170532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013822|Aerosolized Beta-Agonist Isomers in Asthma|Aerosolized Beta-Agonist Isomers in Asthma||Duke University||Completed|July 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|10|||Both|18 Years|N/A|No|||June 2014|August 11, 2014|June 19, 2014|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT02170532||42204|
NCT02171312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075343|Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool|Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool||Emory University|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|126|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A cohort of patients presenting to the Sports Concussion Institute with persistent post        concussive dizziness and imbalance will be enrolled in this study.|October 2015|February 8, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171312||42144|
NCT02171325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1402|Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment|A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment||Guangdong Association of Clinical Trials|Yes|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|65 Years|No|||June 2014|June 20, 2014|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171325||42143|
NCT02171338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-342|Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections|Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics?||Holbaek Sygehus|No|Active, not recruiting|October 2013|September 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|55|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02171338||42142|
NCT02184962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEV-2030|Periodontal Disease and Post-menopausal Osteoporosis|"Levels of RANKL and OPG in Gingival Crevicular Fluid of Patients With Post-menopausal Osteoporosis / Osteopenia and Periodontal Disease."||Universidad Nacional de Córdoba|Yes|Completed|May 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|81|||Female|45 Years|70 Years|No|Probability Sample|Patients with osteopenia / osteoporosis and controls with normal osseous condition. Both        groups with chronic periodontitis|July 2014|July 8, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184962||41099|
NCT02185274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPIP-ENDO1|Observational Study on Metabolism and Psychopathology in Transsexual Patients|Observational Study on the Short- and Long-term Effects of Cross-sex-hormone Treatment on Metabolism and Psychopathology in Transsexuals Patients.||Max-Planck-Institute of Psychiatry|No|Recruiting|October 2013|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|-  2 x 10ml serum        -  10ml urine        -  Hair sample        -  7,5ml EDTA-Blood for DNA and plasma        -  2,5ml blood for mRNA-Analysis        -  8,5ml stabilized serum        -  Stool sample (2-5ml)|Both|18 Years|70 Years|No|Non-Probability Sample|Patients will be recruited from the outpatient clinics of the corresponding centres. Every        patient is eligible who has not yet received any cross-sex hormone treatment. Patients        will be invited to participate at the regular visit after which it is planned to start        hormone treatment. Further visits will follow the regular check-up visits in the        corresponding centers.|July 2014|July 3, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02185274||41075|
NCT02185573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OperDent-01-2014|Evaluation of Two Different Methods of Resin Composite Application In Class II Restorations|Evaluation of Two Different Methods of Resin Composite Application Using Bulk-fill Technique In Class II Restorations||Damascus University|Yes|Completed|July 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|15 Years|60 Years|No|||October 2015|October 2, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185573||41052|
NCT02185287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2199/13 Prot.N.1625/13/ON|"The Urological Dysfunctions in Young Women: Inheritance of Childhood?"|||University of Roma La Sapienza|No|Recruiting|April 2013|March 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the outpatient clinic of the Urogynecology Urology Clinic,        University of Perugia, while the healthy controls will be recruited by submitting a        questionnaire to the women chosen to sample a healthy population of Graduate Schools found        in the framework of Urology, Pediatrics and Pediatric Surgery, University of Perugia.|May 2015|May 27, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02185287||41074|
NCT02185794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-338-1121|Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection|Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection||Gilead Sciences|No|Completed|June 2014|September 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|100|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02185794||41035|
NCT02186067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13102013FM|Developing an Integrated System Approach for the Management of Hypertension: A Pilot Study|Developing an Integrated System Approach for the Management of Hypertension: A Pilot Study||Aga Khan University|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|40 Years|N/A|No|||June 2015|June 24, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02186067||41014|
NCT02185781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL 2013|Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)|Phase I Protocol of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission (CHR) But With Persistent/Recurrent Minimal Residual Disease (MRD) ≥60 Years or Not Eligible for Other Post-CHR Treatment Modalities||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|November 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|60 Years|N/A|No|||April 2015|April 28, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185781||41036|
NCT02186600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XXXX-14|Study Comparing Bone Loss in Women Who Take Calcium and Vitamin D With Women Who Also Take Risedronate or Exercise|Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women|HOPE|University of Nebraska|Yes|Recruiting|February 2015|August 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|309|||Female|19 Years|N/A|No|||June 2015|June 8, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186600||40973|
NCT02186613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R14/015|Telephone Support From Primary Care for Breastfeeding Mothers|Telephone Support From Primary Care to Breastfeeding Mothers: A Randomized and Multicenter Clinical Trial||Jordi Gol i Gurina Foundation|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|434|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02186613||40972|
NCT02187146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_13-100|The Effects of Serum Vitamin D and IVF Outcome|The Effects of Serum Vitamin D and IVF Outcome: a Prospective Cohort Study|VIDIO|University of Birmingham|Yes|Active, not recruiting|September 2013|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|490|||Female|23 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing IVF, ICSI and FET treatment cycles at the Birmingham Womens        Fertility Centre|December 2015|December 1, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187146||40931|
NCT02187159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-E311|Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia||Daiichi Sankyo Inc.|Yes|Active, not recruiting|October 2014|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1270|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187159||40930|
NCT02187185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0627|Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease|Studies of Salivary Inflammatory Biomarkers During Biofilm Overgrowth: Confirmation of Predictors and Comparative Effects of Sonicare/Elite-Flexcare in Various Stages of Periodontal Disease||University of North Carolina, Chapel Hill|No|Completed|April 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|175|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187185||40928|
NCT02187406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-007|Ankle Athletic Taping Fatigue After a Standard Tennis Warm up|||CEU San Pablo University|No|Completed|June 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|10|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02187406||40911|
NCT02187393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3027|Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis|Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis||University of Colorado, Denver|No|Withdrawn|July 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples With DNA|-  (3) tubes of blood        -  sample of cells from the nose|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|normal healthy volunteers|November 2015|November 25, 2015|March 13, 2014||No|Technical difficulties with the wet bench side of proposed studies.|No||https://clinicaltrials.gov/show/NCT02187393||40912|
NCT02182973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAS 052014|Donor Human Milk in Neonatal Abstinence Syndrome|Donor Human Milk for Infants With Neonatal Abstinence Syndrome|DHM&NAS|Neolac Inc dba Medolac Laboratories|No|Recruiting|January 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|38 Weeks|42 Weeks|No|Non-Probability Sample|Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to        opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan        scoring tool when compared to (historic) infants fed formula.|January 2015|January 13, 2015|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02182973||41252|
NCT02168842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEADY-PD III|Efficacy of Isradipine in Early Parkinson Disease|Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease||University of Rochester|Yes|Active, not recruiting|September 2014|March 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|336|||Both|30 Years|N/A|No|||January 2016|January 12, 2016|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168842||42334|
NCT02170038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17004|Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol|Open Label, One-way Crossover Study to Assess the in Vivo Formation of Ethinylestradiol Following Single Intramuscular Administration of 200 mg Norethisterone Enantate Compared to Ethinylestradiol Pharmacokinetics After Multiple Doses of a Combined Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Women||Bayer|No|Completed|June 2014|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02170038||42242|
NCT02170961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRA-MMP|Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure|Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)|PRA-MMP|University of Monastir|No|Recruiting|February 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|arterial blood samples collected in EDTA tubes and stored in - 20°C envirement for DNA      extraction with salting out methods.|Both|18 Years|N/A|No|Probability Sample|Acute onset dyspnea patients|June 2014|June 19, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170961||42171|
NCT02170974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.52|Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Polymorph II Capsule Relative to 150 mg HPMC Polymorph I Capsule in Healthy Subjects. A Two-way Crossover, Randomised, Open Trial||Boehringer Ingelheim||Completed|July 2004|||August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170974||42170|
NCT02172092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDKA|Fluid Kinetics in Patients With Diabetic Ketoacidosis|Fluid Kinetics in Patients With Diabetic Ketoacidosis|FDKA|University Hospital, Linkoeping|No|Not yet recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|17 Years|80 Years|No|||June 2014|June 23, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02172092||42084|
NCT02172105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.21|Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers|A Double-blind, Randomised, Placebo Controlled (Within a Dose Group) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (5 μg, 10 μg and 20 μg) of BI 1744 CL for 14 Days in Healthy Male Volunteers||Boehringer Ingelheim||Completed|January 2008|||May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172105||42083|
NCT02172118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.35|BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function|Pharmacokinetics, Safety and Tolerability of Single Dose of BI 1744 CL (30 μg Administered With the Respimat® Inhaler) in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open Label, Parallel Group Phase I Trial||Boehringer Ingelheim||Completed|August 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172118||42082|
NCT02172664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVOC2014|Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions|Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions||Indiana University|No|Active, not recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172664||42040|
NCT02184676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130405|T1D Risk Assessment in Kids With Relatives|Early Immunological, Metagenomic, Metabolic and Environmental Factors in the Progression to Type 1 Diabetes: the TRAKR Cohort|TRAKR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2015|February 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1200|||Both|N/A|N/A|No|||December 2015|January 5, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184676||41121|
NCT02184975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conization1|Cold Knife Conization With and Without Lateral Hemostatic Sutures|Randomized Clinical Trial Comparing Cold Knife Conization of the Cervix With and Without Lateral Hemostatic Sutures||Barretos Cancer Hospital|No|Completed|March 2009|October 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Female|15 Years|80 Years|No|||July 2014|July 5, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02184975||41098|
NCT02184988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evolus - CLIN004|Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines|A Multi-center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines.|EV-004|Evolus, Inc.|No|Completed|August 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|353|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|December 17, 2015|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184988||41097|
NCT02185300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200401|Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers|A Phase 1, Single Dose, Crossover, Relative Bioavailability Study of a Dolutegravir Dispersible Tablet as Compared to a Dolutegravir Pediatric Granule Formulation and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers(200401)||ViiV Healthcare|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|November 26, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185300||41073|
NCT02185586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-21|A Prospective Randomized Controlled Trial of Lower Abdominal Three-port Laparoscopic Cholecystectomy|A Prospective Randomized Controlled Trial of Traditional Three-port Laparoscopic Cholecystectomy Versus Lower Abdominal Three-port Laparoscopic Cholecystectomy||China-Japan Friendship Hospital|Yes|Completed|May 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|70 Years|No|||February 2016|February 27, 2016|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02185586||41051|
NCT02185833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRI502/PRO-00|Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition|Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions.||Pharmaceutical Research Unit, Jordan||Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|July 9, 2014|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02185833||41032|
NCT02185807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFPH-IRB-2013-087|Video-assisted Informed Consent for Cataract Surgery|Does Video-assisted Informed Consent for Cataract Surgery Improve Patients' Satisfaction||Guangzhou First Municipal People’s Hospital|No|Recruiting|July 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||February 2015|February 10, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185807||41034|
NCT02185820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN07/IST-CAR-538|Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)|A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS|CPD|Stichting Hemato-Oncologie voor Volwassenen Nederland|Yes|Recruiting|June 2014|June 2019|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185820||41033|
NCT02186353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00009343|Processing Responses of Grains (PRO-Grains) Study|Effect of Intact vs. Highly Processed Whole Grains on Insulin Sensitivity and Other Cardiometabolic Risk Factors in Hyperinsulinemic Adults||Children's Hospital Boston||Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|6|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02186353||40992|
NCT02186366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECF 20120210|Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type|Study of Abdominal Massage Therapy for Generalized Anxiety Disorder Based on the " Essence Fosters Spirit " Theory||First Teaching Hospital of Tianjin University of Traditional Chinese Medicine|No|Recruiting|September 2014|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 1, 2014|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186366||40991|
NCT02187432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eurocyst|The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe|The Eurocyst Initiative: Building a Reference Center Network Across EUROpe to Establish a Large-scale Longitudinal Observational Cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) Patients||University of Zurich|No|Recruiting|August 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples With DNA|The following samples will be collected: blood, spot urine and 24h urine|Both|18 Years|N/A|No|Probability Sample|The study will include 1,100 participants aged 18 and above with a diagnosis of ADPKD,        diagnosed via imaging and family history. The assessment of participants is based on        defined inclusion and exclusion criteria.|May 2015|May 26, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02187432||40909|
NCT02187419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AT008246-01|Hypnosis to Improve Sleep In Menopause|Hypnosis to Improve Sleep in Menopause: Determination of Optimal Dose and Method||Baylor University|Yes|Recruiting|January 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|80|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187419||40910|
NCT02182999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWI-HVS|Continuous Wound Infiltration After Hallux Valgus Surgery|Continuous Wound Infiltration After Hallux Valgus Surgery A Prospective, Randomized, Double-blind and Placebo-controlled Single-center Trial|CWI-HVS|Medical University Innsbruck|Yes|Recruiting|May 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02182999||41250|
NCT02182986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-06|Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children|Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (CTOTC-06)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1277|Samples With DNA|Blood and tissue samples.|Both|N/A|21 Years|No|Non-Probability Sample|Pediatric Candidates for or recipients of heart, liver, heart with liver, small intestine,        or liver with small intestine at participating major pediatric solid organ transplant        programs|September 2015|September 21, 2015|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02182986||41251|
NCT02183532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.58|Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers|Pharmacokinetics of Single and Multiple Oral Doses of 5 mg BI 1356 in Healthy Chinese Volunteers||Boehringer Ingelheim||Completed|July 2009|||July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183532||41209|
NCT02169167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKBBN/75/2014|Comparison of Resin Salve and Octenidine in Patients With Neuropathic Diabetic Foot Ulcers|Comparison of Resin Salve and Conventional Octenidine in Patients With Neuropathic Diabetic Foot Ulcers - a Prospective, Randomized and Controlled Clinical Trial||Helsinki University Central Hospital|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 23, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169167||42309|
NCT02169180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104615|Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma|A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)||Janssen Pharmaceutical K.K.|No|Active, not recruiting|August 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169180||42308|
NCT02170558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2013-05S|Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With TM-Ardis|Evaluating Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With Trabecular Metal Implants (TM-Ardis)||Zimmer, Inc.|No|Recruiting|June 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|85 Years|No|Probability Sample|All patients who are having a spinal fusion procedure with TM-Ardis and meet the        requirements below are eligible for this study.|February 2016|March 14, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170558||42202|
NCT02171013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.56|Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers|Bioequivalence of Two Different Drug Product Batches of 150 mg of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double Blind, Randomised, Single-dose, Replicate Design in a Two-treatments, Four Periods Crossover Study)||Boehringer Ingelheim||Completed|April 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171013||42167|
NCT02171026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.57|Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of 150 mg Dabigatran Etexilate b.i.d. With or Without 600 mg Amiodarone as Single Dose in Healthy Male and Female Volunteers (an Open-Label, Multiple-Dose, Group-Comparison Study)||Boehringer Ingelheim||Completed|April 2006|||June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171026||42166|
NCT02171364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0536|Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Prospective Randomized Study|||Yonsei University|No|Recruiting|June 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|19 Years|N/A|No|||January 2015|January 6, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171364||42140|
NCT02171884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAUQUE DB 2013|Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans|Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans||Centre Hospitalier Universitaire Dijon||Recruiting||||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|152|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|4 groups of infants:          -  conceived naturally          -  born following ART with IVF/ICSI (short culture)          -  born following ART with IVF/ICSI and freezing/thawing of the embryo          -  born following ART with IVF/ICSI (prolonged culture)|December 2013|June 20, 2014|June 18, 2014||||No||https://clinicaltrials.gov/show/NCT02171884||42100|
NCT02172157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.9|Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects|Investigation of the Metabolism and Pharmacokinetics of 20 μg (Calculated as Free Base) [14C]BI 1744 CL Administered as a 3-hour Infusion and 40 μg (Calculated as Free Base) [14C]BI 1744 CL Administered as an Oral Solution.||Boehringer Ingelheim||Completed|February 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172157||42079|
NCT02172170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 800 mg) of BI 10773 as Tablets Administered to Healthy Male Subjects. A Randomised Placebo-controlled (Within-dose Groups) and Double-blind Trial.||Boehringer Ingelheim||Completed|January 2007|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172170||42078|
NCT02173015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000605|Fall Recovery Training for Older Adults in Continuous Care Facilities|Compensatory Step Training for Reducing the Fall Incidence of Older Adults Residing in Continuous Care Facilities||Mayo Clinic|No|Active, not recruiting|April 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02173015||42013|
NCT02172989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1410202-1|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Benign Breast Neoplasm.|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Benign Breast Neoplasm ; Observational Pilot Study for 20 Patients.||National Cancer Center, Korea|Yes|Completed|June 2014|May 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Female|20 Years|70 Years|No|Probability Sample|nonpalpable benign breast lesion ≤ 2cm in patients with breast cancer.|June 2015|June 17, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02172989|1 Week|42015|
NCT02173002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|myIBDcoach|Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled Trial|Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled Trial|myIBDcoach|Maastricht University Medical Center|Yes|Recruiting|July 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|75 Years|No|||August 2014|August 4, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173002||42014|
NCT02185001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLKC-0001|Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation|Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation; A Randomized Prospective Trial||Orthopedic Specialty Institute|No|Recruiting|October 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|N/A|No|||December 2014|December 30, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185001||41096|
NCT02185014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-347|Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115|A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease||AbbVie|No|Enrolling by invitation|August 2014|October 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|270|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185014||41095|
NCT02185313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gaze_holding_cerebellar_zurich|Gaze Holding in Cerebellar Patients|Verticality Perception and Gaze Holding in Healthy Human Subjects and Patients With Acute and Chronic Cerebellar Disorders||University of Zurich|No|Recruiting|August 2013|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185313||41072|
NCT02185599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE-100|IMproved PRactice Outcomes and Value Excellence in Colposcopy|IMproved PRactice Outcomes and Value Excellence in Colposcopy|IMPROVE-COLPO|DySIS Medical Inc.|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|N/A||2|Anticipated|11000|||Female|21 Years|N/A|No|Probability Sample|Women referred for colposcopy after an abnormal screening test for prevention of cervical        cancer|February 2016|February 5, 2016|July 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185599||41050|
NCT02185846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRI503/PRO-00|Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition|Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions.||Pharmaceutical Research Unit, Jordan||Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|July 9, 2014|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02185846||41031|
NCT02186106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-094|Dosage Calculation for Vitamin D Treatment|The Effect of Oral Loading Doses of Cholecalciferol on the Serum Concentration of 25-OH-vitamin-D||Bispebjerg Hospital|No|Completed|January 2012|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02186106||41011|
NCT02186119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-004|A Study of Abicipar Pegol in Patients With Diabetic Macular Edema|||Allergan|Yes|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|151|||Both|19 Years|N/A|No|||July 2015|July 10, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186119||41010|
NCT02186080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1401-089-550|Evaluation of the Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia Induced by High Fat Diet in Patients With Type 2 Diabetes|Evaluation of the Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia Induced by High Fat Diet in Patients With Type 2 Diabetes||Seoul National University Hospital|Yes|Not yet recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|10|||Both|20 Years|75 Years|No|||July 2014|July 9, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186080||41013|
NCT02186093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404-057-573|Clinical, Physiological and Prognostic Implication of Microvascular Status|Clinical, Physiological and Prognostic Implication of Index of Microcirculatory Resistance||Seoul National University Hospital|Yes|Recruiting|April 2014|||November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||4|Anticipated|1197|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stable angina|July 2014|July 9, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186093|2 Years|41012|
NCT02186886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50831-PIMS-Golimumab-UC|Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab|Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi)||Kliniken im Naturpark Altmuehltal|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02186886||40951|
NCT02186899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSOvsGA|Peripheral Nerve Block (Femoral - Sciatic - Obturator) Versus General Anesthesia for Arthroscopic ACL Repair|Comparison of Femoral - Sciatic - Obturator Nerve Block vs General Anesthesia in Combination With Continuous or Bolus Femoral Nerve Block for Arthroscopic ACL Repair Regarding the Time of Patient Mobilasation||Larissa University Hospital|No|Recruiting|March 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|80 Years|No|||July 2014|July 7, 2014|April 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02186899||40950|
NCT02186873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103795|A Study of Golimumab in Participants With Active Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2014|July 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02186873||40952|
NCT02187211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER0098|Minocycline's Effects on Alcohol Responses in Humans|Minocycline's Effects on Alcohol Responses in Humans||Yale University|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|50 Years|No|||July 2015|July 14, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02187211||40926|
NCT02183077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.214|Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects|Pharmacokinetics and Tolerability of 2 x 15 mg Meloxicam (2 x 0.3 g Topical Gel) Over 7 Days Compared to 7.5 mg Meloxicam Tablet (Single Oral Dose) in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study||Boehringer Ingelheim||Completed|September 1998|||November 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183077||41244|
NCT02183012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024.5|Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers|Open-label, Randomised, Single Dose, Four-way Crossover Study to Investigate the Relative Bioavailability of a 400 mg Ibuprofen Extrudate Tablet Compared to a 400 mg Ibuprofen Lysinate Tablet (Dolormin Extra®) and a 400 mg Ibuprofen Tablet (Brufen® 400 mg, Denmark) in Fasted Condition and After Ingestion of a Standardised Meal in Healthy Male and Female Volunteers.||Boehringer Ingelheim||Completed|August 2002|||October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183012||41249|
NCT02183584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.67|Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers|An Open Label, Two-period, Fixed Sequence, Phase 1 Trial to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin||Boehringer Ingelheim||Completed|September 2009|||October 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183584||41205|
NCT02183597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUC-2013-WBMRI-Sitter|Whole-body MRI for the Detection of Metastasis|Whole-body MRI for the Detection of Metastasis|WBMRI|Norwegian University of Science and Technology|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Female|18 Years|95 Years|No|Non-Probability Sample|Women in Mid Norway living with advanced breast cancer|February 2016|February 11, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02183597||41204|
NCT02183610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.7|Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design||Boehringer Ingelheim||Completed|July 2006|||September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183610||41203|
NCT02183623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.9|The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers|The Effect of Multiple Oral Doses of BI 1356 BS as Tablets Once Daily for Six Days on the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of 40 mg Simvastatin Given Once Daily for 20 Days and on the Pharmacokinetics of Its Metabolite Simvastatin Acid. An Open-label Study in Healthy Male Volunteers.||Boehringer Ingelheim||Completed|September 2005|||October 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183623||41202|
NCT02169752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2716|Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension|Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension|AMERICA-PAH|National Jewish Health|Yes|Recruiting|September 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||June 2014|June 19, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169752||42264|
NCT02171351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00559-38|Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)|Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)|ELECTROSYMP2|University Hospital, Caen|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|February 9, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02171351||42141|
NCT02171377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/091/HP|Quadricipital Electrical Stimulation in COPD Patients Rehabilitation|Quadricipital Electrical Stimulation in COPD Patients Rehabilitation|Reha-Res|University Hospital, Rouen|Yes|Completed|August 2010|December 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT02171377||42139|
NCT02171897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREMLET AOI 2013|Pertrochanter Arthroplasty Versus Osteosynthesis|Comparison of Functional Recovery After Pertrochanter Fracture Treated With Either Total Hip Replacement or Centromedullary Nailing|PAVO|Centre Hospitalier Universitaire Dijon||Not yet recruiting||||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|70 Years|N/A||||May 2014|June 20, 2014|June 18, 2014||||No||https://clinicaltrials.gov/show/NCT02171897||42099|
NCT02172131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.7|Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects|Safety, Tolerability and Pharmacokinetics of Single Rising Doses of 0.5 μg, 2.5 μg, 5 μg, 10 μg, 15 μg, 20 μg, 25 μg and 30 μg BI 1744 CL (Calculated as Free Base) Given as Intravenous Infusion Over 30 Minutes to Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.||Boehringer Ingelheim||Terminated|October 2006|||February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|64|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||May 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172131||42081|
NCT02172144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.8|Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers|A Double-blind, Randomised, Placebo Controlled, Six-way Crossover Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Influence of Via Respimat® Inhaled BI 1744 CL (Single Doses of 10 μg, 20 μg, 30 μg and 50 μg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|June 2007|||October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172144||42080|
NCT02173028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rif. n. 89/11 - 2011/0043537|RESynchronizaTiOn theRapy and bEta-blocker Titration|RESynchronizaTiOn theRapy and bEta-blocker Titration : RESTORE|RESTORE|University of Florence|No|Recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients successfully implanted with CRT-D according to current European guidelines, on        optimal therapy for heart failure (diuretics, ACE inhibitors and aldosterone antagonists),        with stable dose in the previous month.|July 2014|July 30, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173028||42012|
NCT02173041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 1216|Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User|Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User: Results of the Randomized Controlled Trial||Macmillan Research Group UK|Yes|Completed|August 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|65 Years|No|||May 2015|May 15, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02173041||42011|
NCT02199626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCE-2 in pediatric CD|SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).|SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).||Azienda Policlinico Umberto I|No|Completed|September 2013|July 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|6 Years|18 Years|No|||July 2014|July 23, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02199626||39973|
NCT02199925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMXAUT01|An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum|A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum||IMMUNOe International Research Centers|Yes|Active, not recruiting|June 2013|July 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|12 Years|No|||March 2015|April 15, 2015|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199925||39951|
NCT02200185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMORNEB|Titrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings|Efficacy and Safety of Nebulized Morphine Given at Two Different Doses Compared to Intravenous Morphine in Post-traumatic Acute Pain: a Randomized Controlled Double Blind Study|TIMORNEB|University of Monastir|Yes|Completed|April 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|300|||Both|8 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02200185||39931|
NCT02200848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI#9540|Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL||Georgetown University|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200848||39881|
NCT02196441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234656|Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia Procedure|Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia in Patients Undergoing Implantable Contact Lens Procedure||Cairo University|Yes|Not yet recruiting|August 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|102|||Both|18 Years|90 Years|No|||July 2014|July 18, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196441||40217|
NCT02196688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-013-00CH1|Study of Fruquintinib in Patients With Metastatic Colorectal Cancer（CRC）|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With CRC as 3rd or Above Therapy||Hutchison Medipharma Limited|Yes|Completed|April 2014|November 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02196688||40198|
NCT02198365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGOG-128|Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia|Comparison of Human Papillomavirus Integrated DNA and Messenger RNA for Detection and Prediction in Progression of Cervical Neoplasia||Cathay General Hospital|No|Completed|January 2007|March 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|250|Samples With DNA|HPV DNA and mRNA|Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will examine 250 baseline liquid-based cytology specimens from women with 100 low-grade        squamous intraepithelial lesions (LSILs), 100 high-grade squamous intraepithelial lesions        (HSILs), 10 microinvasions and 40 invasive cervical cancers.|July 2014|July 22, 2014|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT02198365||40070|
NCT02199171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 13-54|Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.||University of California, Irvine|Yes|Recruiting|July 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||September 2014|September 17, 2014|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199171||40008|
NCT02199964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33276|The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface|The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye|CsA|Baylor College of Medicine|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02199964||39948|
NCT02200250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/10/6.2(3838)QA|Long Term Barrett's Endoscopic Mucosal Resection Study|Long Term Outcomes of Patients Undergoing Endoscopic Resection of Barrett's Oesophagus (BO) With High Grade Dysplasia (HGD) and Early Adenocarcinoma|CBE|Western Sydney Local Health District|Yes|Recruiting|October 2013|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who have or have had Barrett's Oesophagus with high grade dysplasia or        adenocarcinoma.|December 2015|December 15, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02200250||39926|
NCT02196740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tri-antibiotic-2014|Research of the Application of Triple Antibiotic Paste in Primary Teeth With Pericpical Periodontitis|Randomized Controlled Research of the Application of Triple Antibiotic Paste in Primary Teeth With||Sun Yat-sen University|Yes|Active, not recruiting|June 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|8 Years|No|||July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196740||40194|
NCT02184273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093.18|Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery|Randomized, Double Blind, Comparative Trial of the Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children of 6 and 11 Years Old Undergoing Minor Surgery||Boehringer Ingelheim||Completed|March 2002|||March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|122|||Both|6 Years|11 Years|No|||July 2014|July 9, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184273||41152|
NCT02184286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1280|Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®) and Saquinavir-sgc (Fortovase®) in HIV-1 Infected Patients||Boehringer Ingelheim||Terminated|May 1999|||February 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184286||41151|
NCT02184793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080407|Impact of an Electronic Monitoring Device on Maintaining a Correct Elevation of Head of Bed for Mechanically-ventilated Patients in Intensive Care Unit|Impact of an Electronic Monitoring Device on Maintaining a Correct Elevation of Head of Bed for Mechanically-ventilated Patients in Intensive Care Unit|Inclinometre2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|343|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02184793||41112|
NCT02185092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4258|Probiotic Use in Patients With Prior COPD Exacerbation|Probiotic Use in Patients With Prior COPD Exacerbation||University of Oklahoma|Yes|Withdrawn|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|July 3, 2014|Yes|Yes|Lost funding|No||https://clinicaltrials.gov/show/NCT02185092||41089|
NCT02185105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-14-04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||July 16, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185105||41088|
NCT02185378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0302|Effects of 1:1 Inspiratory to Expiratory Ratios on Oxygenation and Intrapulmonary Shunt Fraction During One Lung Ventilation in the Obese Patients|Effects of 1:1 Inspiratory to Expiratory Ratios on Oxygenation and Intrapulmonary Shunt Fraction During One Lung Ventilation in the Obese Patients||Yonsei University|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|36|||Both|40 Years|80 Years|No|||April 2015|April 16, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185378||41067|
NCT02185391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ParacelsusHCBS 2013-125|Interactive Education of Patients With Coronary Heart Disease|Development of Sustainable Methods in Interactive Patient Education to Improve Adherence After Cardiac Rehabilitation|INSERT|Paracelsus Harz Clinic Bad Suderode.|No|Active, not recruiting|May 2014|November 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|260|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02185391||41066|
NCT02194010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC 6610|Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)|Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)|DSI and HMSN|University of Iowa|No|Recruiting|April 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|415|||Both|10 Years|N/A|No|Non-Probability Sample|Participants enrolled in INC protocol 6601 and being seen at a participating site for an        evaluation of CMT will be asked if they would like to participate in this protocol. The        individuals being recruited will have already signed consent forms and be enrolled in        6601. They will be informed that it is completely voluntary to participate in this        protocol, and they can still be enrolled in INC 6601 without participating in this        project.        Alternative participants who are registered with our INC Patient Registry will be alerted        to the form through an email and asked to participate due to their diagnosis of suspected        diagnosis of CMT.|May 2015|May 15, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02194010||40404|
NCT02194712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAA48780|Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact|Detection of Schistosomiasis Circulating Anodic Antigen (CAA) in Travellers After High-risk Water Contact||Leiden University Medical Center|No|Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|155|Samples With DNA|serum, urine and faeces|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Travellers with reported high-risk water contact <12 weeks before inclusion.|September 2015|September 3, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02194712||40350|
NCT02199938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 10/2007 (5)|Identification and Characterization of Molecular Markers in Musculoskeletal Tumors|Identification and Characterization of Molecular Markers in Musculoskeletal Tumors||Balgrist University Hospital|No|Recruiting|January 2010|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|blood serum blood plasma tumor tissue tumor free tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients who receive a biopsy or surgery because of confirmed or suspected        musculoskeletal tumor.|September 2015|February 18, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02199938|5 Years|39950|
NCT02200198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0613/07|Respiratory Muscle Training in Malnourished Patients Undergoing Abdominal Surgery|Effect of Respiratory Muscle Training in Malnourished Patients Undergoing Upper Abdominal Surgery||University of Sao Paulo General Hospital|No|Completed|February 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|45|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200198||39930|
NCT02200211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS18|Study of Binocular Computer Activities for Treatment of Amblyopia|Study of Binocular Computer Activities for Treatment of Amblyopia|ATS18|Jaeb Center for Health Research|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|512|||Both|5 Years|16 Years|No|||February 2016|February 22, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200211||39929|
NCT02200523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ns053116_SARA_electrode|Self Abrading Rapidly Applied Electrode Validation|Self Abrading Rapidly Applied (SARA) Electrode Phase II|SARA|Cleveland Medical Devices Inc|No|Completed|June 2014|December 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|48|||Both|12 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200523||39906|
NCT02196454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-011091|Video to Promote HPV Vaccination|Educating Pre/Teens and Their Parents on the Importance of HPV Vaccination||Children's Hospital of Philadelphia|No|Recruiting|July 2014|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|11 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196454||40216|
NCT02197533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-PtEdOAB-01|Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions|Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions||St. Michael's Hospital, Toronto|No|Recruiting|July 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|No|||March 2016|March 9, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197533||40133|
NCT02198872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/13|Aquatic and Land Aerobic Training, Cardiorespiratory and Metabolic Variables in Cardiorespiratory Diseases|Effects of Aquatic and Land Aerobic Training on Body Composition and Cardiorespiratory and Metabolic Variables in Patients With Cardiorespiratory Diseases||Universidade Metodista de Piracicaba|No|Not yet recruiting|September 2014|February 2018|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|50 Years|70 Years|No|||July 2014|July 23, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198872||40031|
NCT02199665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0033|Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|SINE|University of Chicago|Yes|Recruiting|June 2014|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199665||39970|
NCT02196467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRUL 104501|Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients|Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|May 2014|February 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Male|16 Years|N/A|No|||February 2016|February 12, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02196467||40215|
NCT02196480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPV23JIA-aTNF|23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy|Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy||University of Sao Paulo|No|Completed|January 2008|June 2012|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Both|5 Years|18 Years|No|||July 2014|July 18, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196480||40214|
NCT02197312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-159|NobelProceraTM Bridge Shaded Zirconia|A Clinical Evaluation of NobelProceraTM Bridge Shaded Zirconia||Nobel Biocare|No|Terminated|June 2010|||November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02197312||40150|
NCT02184572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115650|Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age|Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age||GlaxoSmithKline||Completed|August 2014|December 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1743|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184572||41129|
NCT02184832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001226|Dietary Intake of Tryptophan and Metformin Response|||Massachusetts General Hospital|No|Completed|August 2014|March 2016|Actual|March 2016|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184832||41109|
NCT02184845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T 176|A 5 Year Clinical Study on NobelActive 3 mm Implants|Open, Prospective, Single Cohort, Multi-centre Study Evaluating the NobelActive 3 mm Implant Immediately Restored With Single Crowns in the Maxillary Lateral Incisor Area or Mandibular Central or Lateral Incisor Area|NA 3 MM|Nobel Biocare|No|Active, not recruiting|January 2011|May 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184845||41108|
NCT02185131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA022123|Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.|Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.|PT-MAD|University of Pittsburgh|No|Active, not recruiting|September 2013|March 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|55 Years|No|||January 2016|January 7, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02185131||41086|
NCT02184806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080802|Autograft of Human Ovarian Tissue : Efficiency and Safety|Autograft of Human Ovarian Tissue: Efficiency and Safety Evaluation|CAROLéLISA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||April 2015|April 23, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02184806||41111|
NCT02184819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110138|Preoperative Levosimendan in CABG Patients With Poor LV Function|Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial|LICORN|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2013|November 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|335|||Both|18 Years|N/A|No|||November 2015|February 24, 2016|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02184819||41110|
NCT02185118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81171839|Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis|In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis||Fourth Military Medical University|No|Recruiting|June 2014|July 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 6, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02185118||41087|
NCT02185404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moterum-GEMS-1|Gait Enhancing Mobile Shoe for Stroke Rehabilitation|||University of South Florida|No|Recruiting|April 2015|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|21 Years|80 Years|No|||December 2015|December 16, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02185404||41065|
NCT02194413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111724|Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant|Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant||University of Iowa|Yes|Active, not recruiting|March 2012|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194413||40373|
NCT02195258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC Paris centre|Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis|Pharmacogenetic of the Salbutamol Efficacy in Asthma Crisis for Children in Emergency Department|Pegase|Hôpital Necker-Enfants Malades|Yes|Completed|November 2010|June 2013|Actual|May 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|95|Samples With DNA|Saliva from patient were collected using Oragen®.DNA OG-500 kit, (DNA Genotek, Kanata,      Canada) or swabs (Catch-All™ sample collection swabs from Epicentre Biotechnologies,      Madison, WI), and stored at room temperature or -20°C, respectively.|Both|6 Years|16 Years|No|Non-Probability Sample|children 6-16 years old asthmatic patients consulting for an exacerbation in a pediatric        emergency department|July 2013|July 17, 2014|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02195258|1 Day|40308|
NCT02198638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.814|Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units|Influenza Vaccination of HCW and Hospital Acquired Influenza in Patients||Hospices Civils de Lyon|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|541|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198638||40049|
NCT02199990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49850254-1|The Effect of Propofol or Etomidate on Cognitive Function for 1-3 Years Old Children|the Study of Propofol or Etomidate Affecting to the Cognitive Function for 1-3 Years Old Children in the 7 Days and 3 Months.||Guilin Medical University, China|Yes|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|1 Year|3 Years|Accepts Healthy Volunteers|Probability Sample|1.Guilin 1-3 years due to hernia surgery to receive propofol or etomidate total        intravenous anesthesia in children.        2.1-3 years old healthy children in 4 kindergartens of different level of teachers in the        Guilin city.|July 2014|July 23, 2014|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02199990|3 Months|39946|
NCT02200276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00092365|Influenza Immunization in Adults Over Age 75|Influenza Immunization in Adults Over Age 75||Johns Hopkins University|No|Recruiting|March 2014|June 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|525|||Both|76 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200276||39924|
NCT02200614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17712|Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)|A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER|ARAMIS|Bayer|Yes|Recruiting|September 2014|June 2020|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200614||39899|
NCT02197299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EM/0136|Improving Glycaemic Control With L-carnitine|Increasing Skeletal Muscle Carnitine Content to Improve Glycaemic Control in Type 2 Diabetes Mellitus||University of Nottingham|No|Recruiting|August 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|60 Years|No|||December 2015|December 1, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197299||40151|
NCT02198105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBTRAK-Registry|Registry of Cutting Balloon and DCB Intervention in Femoropopliteal Stenosis/Occlusion.|Registry of Cutting Balloon and DCB Intervention in Femoropopliteal Stenosis/Occlusion.|DEBTRAK|Caritasklinik St. Theresia|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis or        occlusion.|March 2015|March 11, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02198105|1 Year|40089|
NCT02198599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13DPD6_132090|Mobility Enhancing Nursing Intervention|Effects of Mobility-Enhancing Nursing Intervention in Patients With MS and Stroke: Randomised Controlled Trial|MFP|Zurich University of Applied Sciences|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02198599||40052|
NCT02199418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-BC-001|Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer|Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients|SHPD001|RenJi Hospital||Recruiting|January 2013|October 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|70 Years|No|||July 2014|July 23, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02199418||39989|
NCT02200549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX13902205193|Effects of Combined Cycle Training and Inspiratory Muscle Training in Patients With COPD|Effects of Combined Cycle Training and Inspiratory Muscle Training on Exercise Performance ,Health-related Quality,Dyspnoea ,Body Composition,Depressive Symptomatology in Patients With Chronic Obstructive Pulmonary Disease(COPD)||Zhujiang Hospital|Yes|Recruiting|December 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|75 Years|No|||July 2015|July 26, 2015|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02200549||39904|
NCT02197052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11032|iScreen Study: Best Methods for Social Screening in Pediatric Caregivers|iScreen Study: Best Methods for Social Screening in Pediatric Caregivers||University of California, San Francisco|No|Completed|June 2013|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|552|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants were drawn from adult caregivers seeking treatment for a child in a fast        track arm of a large, urban children's hospital emergency department in Oakland, CA (CHO        ED Annex).|July 2014|July 18, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197052||40170|
NCT02194855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TingtingWang|Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis|Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis.||Fudan University|Yes|Not yet recruiting|November 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|120|||Female|18 Years|60 Years|No|||July 2014|July 16, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02194855||40339|
NCT02197858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMPR1|Comparability of Invasive and Non-invasive Haemodynamic Monitoring|Clinical Comparison of Hemodynamic Parameters Using Invasive Versus Non-invasive Continuous Blood-pressure Technology During a Total Intravenous Anaesthesia (TIVA).|HMPR1|University of Erlangen-Nürnberg Medical School|No|Completed|July 2014|October 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Patients that get an elective surgery under general anesthesia|December 2015|December 3, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02197858||40108|
NCT02195375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3510|Flutiform® Compared With Seretide® in the Treatment of COPD|A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID Versus Salmeterol / Fluticasone (Seretide®) 50/500 µg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Mundipharma Research Limited||Recruiting|September 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|912|||Both|40 Years|N/A|No|||September 2015|September 25, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195375||40299|
NCT02185443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-01/2014|Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases|Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors||University of Sao Paulo|No|Recruiting|May 2014|May 2021|Anticipated|May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185443||41062|
NCT02185703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM004|Chordate System S020 Acute Migraine Clinical Investigation|A Randomized, Placebo-controlled, Double-blind, Multi-center Clinical Investigation to Evaluate the Performance and Safety of the Chordate System When Used in the Treatment of Acute Migraine Attacks of Moderate to Severe Intensity|Amici|Chordate Medical|No|Terminated|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|July 4, 2014||No|Too slow recruitment rate|No||https://clinicaltrials.gov/show/NCT02185703||41042|
NCT02185677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/07|Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy|Comparison of Cognitive and Behavioral Dysexecutive Syndrome Between Parkinsonian Form and Cerebellar Form of Multiple System Atrophy and Analysis of Correlates With an Imaging Study.|CogAMS|University Hospital, Bordeaux|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|30 Years|N/A|No|Probability Sample|Patients suffering from MSA-P or MSA-C|January 2015|January 8, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02185677||41044|
NCT02185937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABILITY|Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy|Influence of an Acidic Beverage (Coca-Cola) on the Exposure to Imatinib (GLIvec) After Major gastrecTomY in Patients With Gastrointestinal Stromal Tumors (ABILITY)|ABILITY|Radboud University|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185937||41024|
NCT02186210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prewarming_OPCAB|Effect of Prewarming on Microcirculatory Response|Effect of Prewarming on Microcirculatory Response||Seoul National University Hospital|Yes|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|85 Years|No|||August 2014|January 13, 2016|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186210||41003|
NCT02194985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-042|Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease|An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease||Amicus Therapeutics|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194985||40329|
NCT02195622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305011478R001|Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures|Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures||Indiana Kidney Stone Institute|No|Completed|September 2013|February 2016|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195622||40280|
NCT02195635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-109-NRM|Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects|A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Octreotide Acetate Injection (Sandostatin®) on the Pharmacokinetics of Single-dose Telotristat Etiprate in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Active, not recruiting|July 2014|||October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02195635||40279|
NCT02199704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NW/0126|Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series|Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series||University of Manchester|No|Recruiting|June 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|18 Years|35 Years|No|||July 2014|July 23, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199704||39967|
NCT02200601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEIPHER_CLIN_002|Pre-Market Algorithm Validation Study|Pre-Market Algorithm Validation Study||Heart Force Medical Inc.|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200601||39900|
NCT02200224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHUIRB00026782|Clinical Utility of Rapid CT/NG Testing in the ED|Clinical Utility of Rapid CT/NG Testing in the ED||Johns Hopkins University|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200224||39928|
NCT02200536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM20AM18|Impact of Providing Free Preventive Dental Health Products on Infant's Tooth Brushing and Bottle-feeding Termination Practices|Effectiveness of an Oral Health Promotion Program in Infant's Tooth Brushing and Bottle-feeding Termination Practices: a Randomized Controlled Trial||Damascus University|Yes|Completed|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|92|||Both|12 Months|12 Months|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 22, 2014||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT02200536||39905|
NCT02197013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H-1207|Evaluation of Introcan Safety 3 Closed IV Catheter|Evaluation of Introcan Safety 3 Closed IV Catheter||B. Braun Melsungen AG|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients in need for intravenous access|July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02197013||40173|
NCT02197845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HL112737-01|Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators|Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators|SHiP HU|Virginia Commonwealth University|Yes|Recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|270|||Both|15 Years|N/A|No|||February 2016|February 3, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197845||40109|
NCT02193893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPO 02|Biological Treatment of Amyotrophic Lateral Sclerosis|Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells|NeuStem-ALS|Pomeranian Medical University Szczecin|No|Enrolling by invitation|January 2010|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193893||40413|
NCT02193906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSR-2013|Neuropsychological Profile of a Patient's Group With Multiple Sclerosis and Effect of a Cognitive Rehabilitation Program|Neuropsychological Profile of a Portuguese Patient's Group With Multiple Sclerosis and Results of a Cognitive Rehabilitation Program|MS_Rehab|Aveiro University|No|Active, not recruiting|December 2012|December 2014|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|September 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02193906||40412|
NCT02194127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1147.2|Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision|Efficacy and Tolerability of a Treatment Over 28 Days With a Bilberry Extract Standardised to a Content of 25% Anthocyanidines in Volunteers With Impaired Twilight and Night Vision||Boehringer Ingelheim||Completed|November 1998|||June 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|195|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194127||40395|
NCT02194140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028-14|Improvement of Appendix Identification and Appendicitis Diagnosis in us After Administration of Oral Contrast Medium|Improvement of Appendix Identification and Appendicitis Diagnosis in Ultrasound After Administration of Iodinated Oral Contrast Medium|us|Hillel Yaffe Medical Center|No|Not yet recruiting|July 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02194140||40394|
NCT02194153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.16|Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse|Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Prehospital or Early Inhospital (Emergency Department) Thrombolysis With Metalyse ®||Boehringer Ingelheim||Completed|May 2001|||March 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|||Both|18 Years|N/A|No|Non-Probability Sample|prehospital or emergency room patients|July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194153||40393|
NCT02194543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0002|High-Definition 3D Visualization System for Ophthalmic Surgery|||Yonsei University|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cataract|July 2014|July 16, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194543||40363|
NCT02194556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV69|Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC|Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194556||40362|
NCT02194569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDOUT|Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.|Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.||Ziekenhuis Oost-Limburg|No|Recruiting|July 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|N/A|N/A|No|||December 2015|December 2, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194569||40361|
NCT02195102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV 2013-12|The Asian Pacific TAVR Multicenter Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement in the Asian Population The Asian Pacific TAVI Multicenter Registry A MULTICENTER, OBSERVATIONAL STUDY|AP TAVR|Queen Elizabeth Hospital, Hong Kong|Yes|Not yet recruiting|December 2014|December 2021|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who had undergone transcatheter aortic valve replacement on the basis of        inclusion criteria were prospectively&retrospectively included in the registry|November 2014|November 17, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02195102||40320|
NCT02195752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIS001|Lexington Observational Study of Treatment With Compounded Pain Creams|Observational Study of Patient and Physician Experiences During Treatment of Pain With Compounded Pharmaceuticals|TrackingCPC|Lexington Independent Studies, LLC|No|Terminated|November 2014|May 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Males and females at least 18 years of age residing in the United States|May 2015|May 7, 2015|July 15, 2014||No|Sponsor financial decision stemming from low recruitment|No||https://clinicaltrials.gov/show/NCT02195752|2 Years|40270|
NCT02185456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AI111103-01|Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis|Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis|BV-LbRC|Wayne State University|Yes|Recruiting|September 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|5||Anticipated|200|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185456||41061|
NCT02185469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECC001|Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment|Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment||Sunnybrook Health Sciences Centre|No|Not yet recruiting|July 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02185469||41060|
NCT02185716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-414|Transversus Abdominis Plane Block (TAP) for Laparoscopic Cholecystectomy Surgery|Comparison Of Ultrasound Guided Transversus Abdominis Plane Block (TAP) and Local Infiltration Analgesia During Laparoscopic Cholecystectomy Surgery||Duzce University||Active, not recruiting|January 2014|August 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|20 Years|60 Years|No|||January 2016|January 25, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185716||41041|
NCT02185430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0306|Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease|||Yonsei University|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|63|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185430||41063|
NCT02185690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 1 Version 27 March 2014|A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung|A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung|MEK162|University Health Network, Toronto|Yes|Not yet recruiting|November 2016|December 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||December 2015|December 2, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02185690||41043|
NCT02185950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1146-7342|The Effects of Therapeutic Resources on Structure and Function of Normal and Burned Skin|||University of Sao Paulo|Yes|Recruiting|June 2012|March 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|80 Years|No|||July 2014|July 9, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02185950||41023|
NCT02195271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130155|Neuroplasticity:Melatonin and Transcranial Current Stimulation in Healthy Subjects.|Effect of Melatonin and Transcranial Direct Current Stimulation (tDCS) on Neuroplasticity and the Heat-pain Detection Threshold in Healthy Subjects:Randomized, Double-blind,Crossover Trial||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|March 2014|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02195271||40307|
NCT02199379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-005|A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects||Eisai Inc.|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||January 2015|April 13, 2015|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199379||39992|
NCT02199951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INESS 02/2012|Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania|Observational Study to Evaluate the Clinical Safety After Introduction of the Fixed Dose Artemisinin-based Combination Therapy Eurartesim® (Dihydroartemisinin/Piperaquine [Dha/Pqp]) in Public Health Districts in Sub-Saharan Africa.||INDEPTH Network|Yes|Recruiting|September 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|6 Months|N/A|No|Non-Probability Sample|Patients with uncomplicated malaria except pregnant women|July 2014|July 24, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02199951||39949|
NCT02193191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-229|Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease|Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193191||40467|
NCT02200237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-EV-21|A Clinical Study for Inactivated Vaccine Against EV71||EV71|Medigen Vaccinology Corp.|Yes|Recruiting|September 2014|December 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|365|||Both|2 Months|12 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02200237||39927|
NCT02196701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W14-406|Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study|Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study|CLEAR|AbbVie|No|Recruiting|July 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196701||40197|
NCT02197026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139.4|Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis|A Multicentre, Open-label and Randomized Clinical Trial to Compare in Patient With Knee Osteoarthritis the Medicoeconomic Benefits as Well as Effectiveness and Safety of Synvisc® Versus Usual Treatments.||Boehringer Ingelheim||Completed|October 1998|||February 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|518|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02197026||40172|
NCT02197039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ER-103-112|The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers|The Selection Criteria for Deciding Who Needs the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers|CSE|National Cheng-Kung University Hospital|Yes|Recruiting|August 2011|July 2016|Anticipated|July 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|350|Samples With DNA|whole blood, serum, white cells, gastric tissue|Both|20 Years|95 Years|No|Probability Sample|We developed the study with data collected in an audit of admissions for acute peptic        ulcer hemorrhage at the inpatient wards of National Cheng Kung University Hospital, a        tertiary health care center in Tainan, Taiwan. Patients who receive gastroscopy for        melena, hematochezia, or hematemesis in whom bleeding peptic ulcers with major stigmata of        recent hemorrhage are detected are consecutively enrolled.|July 2014|July 20, 2014|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02197039|3 Days|40171|
NCT02193672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0591|A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy|A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy||M.D. Anderson Cancer Center|No|Withdrawn|August 2014|||August 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|July 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193672||40430|
NCT02194582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000430|Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure|Molecular and Genetic Analysis of Inherited Kidney Dysfunction|FSGS / NS|Beth Israel Deaconess Medical Center|No|Recruiting|April 2010|||January 2035|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|2050|Samples With DNA|Usually saliva In some cases, a blood sample may be obtained In some cases, a urine sample      may be requested|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are recruiting subjects who have kidney disease, family members of a person with kidney        disease, and healthy controls.|November 2015|November 12, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194582||40360|
NCT02194595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0128-A|Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)|Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)|PREVAIL|Mount Sinai Hospital, Canada|No|Recruiting|September 2014|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|80 Years|No|||March 2016|March 15, 2016|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194595||40359|
NCT02194868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 12036|Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)|Role and Interactions Between Immunoregulatory T Lymphocytes Subtypes After Allogeneic Haematopoietic Stem Cell Transplantation (HSCT): Identification of New Partners Implicated on the Development of GVT (Graft Versus Tumor) and Anti-infectious Responses Without GVHD (Graft Versus Host Disease)|REG-Allo|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|September 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|Samples Without DNA|Whole blood, hematopoietic stem cell of bone marrow|Both|N/A|N/A|No|Non-Probability Sample|The eligible patients will be select by the responsible physicians from clinical teams        involved in this study at their BMT staff. These physicians will propose the study to        selected patients and provide the informed consent.        Grafts and blood from donors of patients involved in this study will be provided by the        different cell therapy departments related to the clinical groups.        Peripheral blood from healthy donors will be obtained from volunteer donations to the        "Etablissement Français du Sang" (EFS).|December 2015|December 8, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194868||40338|
NCT02195115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULJRR033173|Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia|Randomized Controlled Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia||CAMC Health System|Yes|Recruiting|February 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2014|March 4, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195115||40319|
NCT02195388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOREVER-1|Focus On Stiffness Reduction, Endothelial Function and Autonomic Nervous System|Phase 1 Study - Focus On Stiffness Reduction, Endothelial Function and Autonomic Nervous System improVement in Patients After MI With or Without hypErtension After Cardiovascular Rehabilitation.|FOREVER|Medical Universtity of Lodz|Yes|Completed|December 2009|March 2015|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|120|Samples Without DNA|VEGF-A, ADMA, NT-proBNP, creatinine, uric acid, LDL, HDL, total cholesterol, trigliceride,      ALT,GGTP, CRP, fibrinogen,|Both|20 Years|85 Years|No|Probability Sample|Patient after troponin-positive acute coronary syndrome (ACS) with or without arterial        hypertension.|September 2015|September 21, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195388|5 Years|40298|
NCT02184858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC project number: 2012/498|Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension|Dose Titration Study to Test Efficacy and Safety of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension.|Lisi-ped|University Ghent|Yes|Recruiting|June 2014|January 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|1 Year|18 Years|No|||July 2014|July 10, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02184858||41107|
NCT02185482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adwin112|Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus|Physician Led Counseling for Depression in Type 2 Diabetes Mellitus: A Randomized, Controlled Trial||Adwin Life Care|Yes|Completed|August 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|150|||Both|35 Years|60 Years|No|||January 2016|February 4, 2016|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185482||41059|
NCT02185495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13411950100|Screening for Early Lung Cancer in Shanghai, China|Screening and Diagnosing for Early Lung Cancer in Shanghai Communities With Imaging Procedures||Shanghai Changzheng Hospital|Yes|Recruiting|July 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|3000|||Both|35 Years|74 Years|Accepts Healthy Volunteers|||November 2014|December 16, 2014|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02185495||41058|
NCT02185729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007543|Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers|Randomized Study Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function, Autonomic Nervous System, Insulin Sensitivity and Carbohydrate Metabolism|TPN1|Emory University|Yes|Completed|June 2008|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|July 7, 2014|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT02185729||41040|Short duration and involved healthy volunteers--not clear whether the use of olive oil-based lipid emulsions may result in improved clinical outcomes over traditional lipid emulsions in hospitalized patients with medical and surgical illness.
NCT02185963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_ENDO05|Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes|Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes||Seoul National University Bundang Hospital|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|80 Years|No|||October 2015|October 23, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02185963||41022|
NCT02186236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-114|Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung Cancer Patients|A Pilot Study Testing the Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|July 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|230|Samples With DNA|periphera blood sample and urine sample|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|September 2015|September 16, 2015|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186236||41001|
NCT02186249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-218|Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)|Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma||Bristol-Myers Squibb||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2016|March 17, 2016|July 8, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02186249||41000|
NCT02186509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.528|Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas|Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas||Thomas Jefferson University|Yes|Recruiting|January 2015|||July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02186509||40980|
NCT02199106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ti-cTBS|Effectiveness of Neuronavigated Continuous Theta Burst Stimulation of the Left Heschl's Gyrus in Chronic Tinnitus|Effectiveness of Neuronavigated Continuous Theta Burst Stimulation of the Left Heschl's Gyrus in Chronic Tinnitus||University of Regensburg|No|Completed|January 2009|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199106||40013|
NCT02199639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ibHEro|Transcultural Multidisciplinary Evaluation of Patients With Hemophili|Multidisciplinary Evaluation of Patients With Hemophilia of Spain, El Salvador and Bolivia. An Observational Study|ibHEro|Universidad Católica San Antonio de Murcia|No|Recruiting|March 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Male|6 Years|65 Years|No|Non-Probability Sample|Patients with haemophilia from Spain, El Salvador and Bolivia|March 2014|April 29, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199639||39972|
NCT02193451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPSTREAM 3250|Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods|A Randomised Controlled Trial to Determine the Clinical and Cost Effectiveness of Invasive Urodynamic Studies for Diagnosis and Management of Bladder Outlet Obstruction in Men in the United Kingdom National Health Service (NHS)|UPSTREAM|North Bristol NHS Trust|Yes|Recruiting|October 2014|March 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Male|N/A|N/A|No|||March 2016|March 22, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193451||40447|
NCT02193464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICODE|Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk|Observational Study Using Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk, Southeastern Area of Korea|EPICODE|Keimyung University Dongsan Medical Center|No|Recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|All patients with inflammatory bowel disease from primary, secondary, and tertiary        hospital in Daegu-Gyeongbuk province of Korea.|October 2015|October 15, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193464|10 Years|40446|
NCT02196714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003010-00|PK Study of PT003 and PT001 in Japanese Healthy Subjects|A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001 in Japanese Healthy Subjects||Pearl Therapeutics, Inc.|No|Completed|July 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|October 14, 2014|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196714||40196|
NCT02193425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140144|Reliability of the Human Brain Connectome|Reliability Of The Human Brain Connectome||National Institutes of Health Clinical Center (CC)||Recruiting|June 2014|March 2021|Anticipated|March 2021|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|180|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193425||40449|
NCT02193932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-100|Electroencephalogram (EEG) Triggered Functional Magnetic Resonance Imaging (fMRI) in Epilepsy Patients|EEG-triggered fMRI in Epilepsy Patients||Baptist Health South Florida|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|1 Year|75 Years|No|||January 2016|January 29, 2016|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193932||40410|
NCT02194166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28839|An Open-Label Randomized Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Patients With HER2-Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration|||Hoffmann-La Roche||Active, not recruiting|July 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194166||40392|
NCT02194179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1489|Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects|Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)||Boehringer Ingelheim||Completed|December 2006|||May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|92|||Both|18 Years|60 Years|No|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194179||40391|
NCT02194608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-347|Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)|A Randomized Clinical Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Individuals With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Both|45 Years|N/A|No|||June 2015|June 23, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194608||40358|
NCT02194621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-1113-BACT-PS-NJ|Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria|A Randomized, Single Center, Three Cell, Double Blind and Parallel Groups Clinical Study Conducted in Newark, NJ to Evaluate the Antibacterial Effects of Two Toothpastes Containing 0.3% Triclosan/2% Copolymer/0.243% Sodium Fluoride in a Silica Base as Compared to a Control Regular Fluoride Toothpaste on Oral Bacteria 12 Hours After 13 Days Product Use.||Colgate Palmolive|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|107|||Both|22 Years|58 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194621||40357|
NCT02194881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTIRS 13.652|Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation|Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.|IVACAFTOR1|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2014|November 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|57|||Both|6 Years|N/A|No|Non-Probability Sample|Patients with CF aged 6 or older and cared in French CF centres|December 2015|December 15, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194881||40337|
NCT02195128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-03-2013|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||September 30, 2015|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195128||40318|
NCT02195141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2014-ST02|Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer|Randomized Phase II Tiral of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer||Chinese Academy of Medical Sciences|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02195141||40317|
NCT02195154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4624A|18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism|18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism: Investigating the Correlation Between Cerebral Structural and Functional Changes, and Clinical Manifestation||Chang Gung Memorial Hospital|Yes|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 1, 2015|February 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02195154||40316|
NCT02195401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-131|The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism|The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children and Adolescents With Autism Spectrum Disorders||The Children's Institute|Yes|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|3 Years|21 Years|No|Non-Probability Sample|Ten children confirmed to have autism through ADOS|July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195401||40297|
NCT02195414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-201401|NeoVas Bioresorbable Coronary Scaffold First-in-Man Study|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a First-in-Man Study||Lepu Medical Technology (Beijing) Co.,Ltd|Yes|Active, not recruiting|July 2014|September 2019|Anticipated|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|75 Years|No|||December 2015|February 16, 2016|July 16, 2014||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT02195414||40296|
NCT02195427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEO-RHA-1302|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||March 23, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195427||40295|
NCT02195440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-724-1101|An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis|An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis||Komagome Hospital|No|Recruiting|August 2014|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|75 Years|No|||June 2015|June 10, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02195440||40294|
NCT02185144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA036503-01A1|PATH For Triples Study: Medication and Lifestyle Adherence for HIV+ Patients|The PFT Intervention: Linking Triply Diagnosed Inpatients to Community Care|PFT|University of Pennsylvania|Yes|Recruiting|February 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02185144||41085|
NCT02177526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Malignant Prostate 100|Imaging of High Grade Prostate Cancer|Detection of Malignant Calcifications in High Grade Prostate Cancer With Comedo-type Necrosis Using Thin Section Computed Tomography and Susceptibility Weighted Magnetic Resonance Imaging||Ottawa Hospital Research Institute|No|Terminated|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|30|||Male|N/A|N/A|No|||November 2015|November 17, 2015|June 18, 2014||No|trial logistics|No||https://clinicaltrials.gov/show/NCT02177526||41668|
NCT02177539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-344|A New More Efficient Cycloplegia Scheme|A New More Efficient Cycloplegia Scheme||Pontificia Universidad Catolica de Chile|No|Recruiting|May 2014|September 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02177539||41667|
NCT02185976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/051|Effect of Cartoons on Preoperative Anxiety in Paediatric Patients.|Preoperative Anxiety in Paediatric Patients; do Cartoons Help?||Balikesir University|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|60|||Both|3 Years|9 Years|No|||February 2016|February 9, 2016|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185976||41021|
NCT02186262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas|Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas|RODIG|Turku University Hospital|No|Recruiting|March 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Whole blood, frozen tumor tissue|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with a brain tumor scheduled for a surgical resection at the Turku University        Hospital, Finland.|November 2015|November 3, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186262||40999|
NCT02186522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/0208|Immune Failure in Critical Therapy (INFECT) Study|Immune Failure in Critical Therapy(INFECT) Study: Phenotyping Immune Cell Dysfunction to Predict Outcomes in Critically Ill Adults|INFECT|University of Edinburgh|No|Recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples Without DNA|Samples of serum and plasma stored frozen|Both|16 Years|N/A|No|Probability Sample|Critical Care patients who are expected to remain in ICU for at least 48 hours, and        require the external support of one or more organs (invasive ventilation,        inotropes/vasopressors or renal replacement therapy) and who are not expected to die        within 48 hours of study entry.|November 2015|November 9, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02186522||40979|
NCT02199392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-007|A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers|||Eisai Inc.|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|February 12, 2015|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199392||39991|
NCT02197559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST-VAOS|Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis|A Prospectie Cohort Study of Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis||Xuanwu Hospital, Beijing|Yes|Recruiting|January 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|172|||Both|35 Years|75 Years|No|Probability Sample|Symptomatic status: as evidenced by TIA or non-severe stroke within the past 12 months        attributed to 70% to 99% stenosis of vertebral artery ostium are eligible. Degree of        stenosis: >70% and <99%; stenosis may be diagnosed by TCD, MRA, or CTA to qualify for        angiogram performed as part of the study protocol, but must be confirmed by catheter        angiography for enrollment in the trial. All the patients should be performed with PTAS        beyond a duration of 3 weeks from the latest ischemic symptom onset. No fresh infarctions        identified on MRI (indicated as high signals on DWI series) upon enrollment.Patient is        willing and able to return for all follow-up visits required by the protocol Patient        understands the purpose and requirements of the study, can make him/herself understood,        and has signed informed consent.|July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197559||40131|
NCT02193477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gjian|Effect of TEAS on the Incidence Rate of SIRS in Patients Undergoing Abdominal Surgery|Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS)on the Incidence Rate of Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Radical Surgery for Gastric Cancer||Fourth Military Medical University|No|Completed|July 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|105|||Both|30 Years|75 Years|No|||March 2015|March 5, 2015|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02193477||40445|
NCT02193438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.24.MET|Physiologic Effect of Spices Ingestion|Physiologic Effect of Spices Ingestion||Nestlé|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|19|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193438||40448|
NCT02193685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers of HAEC|Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease|Identification of Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease|HAEC|Cedars-Sinai Medical Center|No|Recruiting|February 2010|December 2025|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Procedures include prospective data collection from medical records venipuncture and stool      collection. 4 cc of blood will be drawn at the screening visit for genetic and immune      testing. Additional 8.5 cc of blood will be drawn for CSMC patients for establishment of      cell lines.      1. Stool sample collected at screening or follow-up if patient unable to provide at      screening.      DNA will be prepared from blood for Genome Wide Association Study and mutational analysis 2.      Serological immune markers for inflammatory bowel disease (IBD) including ANCA, ASCA, OMPC,      I2, and CBir1 and any newly identified markers. These tests will only be performed on      patients who consent to the immune response sub-study. No additional blood sample required.      3. Collect and store fresh fecal specimens for future evaluation by molecular methodologies      to determine relative proportions of enteric microflora.|Both|N/A|17 Years|No|Probability Sample|Children with Hirschsprung disease under the age of 17 years.|December 2015|December 17, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02193685||40429|
NCT02193919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO-001|A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|A Single-Center, Prospective, Single-Blind, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy||Bagel, Jerry, M.D.|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|30 patients, males, females, over 18 yo with moderate-to-severe psoriasis|July 2014|July 16, 2014|February 4, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193919||40411|
NCT02194192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810/2556(EC2)|Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section|Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section; a Randomized, Double Blinded, Placebo Controlled Trial||Mahidol University|Yes|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|168|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194192||40390|
NCT02194205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.11|Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A One-year Randomized, Double-blind, Placebo and Active-controlled Parallel Design Safety and Efficacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients With COPD||Boehringer Ingelheim||Terminated|October 2000|||June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|360|||Both|40 Years|N/A|No|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194205||40389|
NCT02194647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406077RINA|Anti-osteoporosis Medication Monitoring and Management Service|Anti-osteoporosis Medication Monitoring and Management Service||National Taiwan University Hospital|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|500|||Both|50 Years|N/A|No|Non-Probability Sample|Adults treated with anti-osteoporosis medicines (AOMs)|September 2015|September 2, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194647||40355|
NCT02194894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00771|The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients|The Effect of Daily Acetaminophen on Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Compared to Healthy Controls||University of Southern California|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|July 18, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02194894||40336|
NCT02195167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-105|Dasotraline SEP360-105 Pediatric PK/PD Study|A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age With Attention Deficit Hyperactivity Disorder||Sunovion|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|6 Years|17 Years|No|||March 2015|March 30, 2015|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02195167||40315|
NCT02195180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPANC 2013-03|Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma|Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma||ERYtech Pharma|Yes|Recruiting|July 2014|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195180||40314|
NCT02195453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yl-yxb08-lcsyfa-201302|Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer||Shandong Cancer Hospital and Institute|No|Not yet recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|70 Years|No|||July 2014|July 17, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02195453||40293|
NCT02195466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.10|Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers|A Single Centre, Open-label Study, in Healthy Adult Volunteers, to Determine the Effects of Single-dose and Steady-state TPV/RTV 500/200 mg on the Steady-state Pharmacokinetics of Fluconazole 100 mg qd (200 mg Loading Dose)||Boehringer Ingelheim||Completed|June 2003|||July 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02195466||40292|
NCT02195479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104761|A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma|A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy||Janssen Research & Development, LLC|Yes|Recruiting|December 2014|October 2021|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195479||40291|
NCT02185157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECAGGOMESUFMG -001|Effects of Dual-task Exercises on Gait Parameters and Cognitive Function in Elderly Women: A Randomized Controlled Trial|Effects of Dual-task Versus Aerobic Training on Gait Stride Variability and Cognitive Function of Independent Community-dwelling Elderly Women: A Randomized Controlled Trial||Federal University of Minas Gerais|Yes|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|69 Years|79 Years|Accepts Healthy Volunteers|||July 2014|July 6, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02185157||41084|
NCT02176902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000432|Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer|A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer||Jonsson Comprehensive Cancer Center|Yes|Recruiting|November 2014|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Male|50 Years|80 Years|No|||March 2016|March 4, 2016|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176902||41716|
NCT02176915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P60MD006912|Trial of Fresh Start Weight Loss Intervention in WIC Participants|Fresh Start: A Randomized Clinical Trial||University of Massachusetts, Worcester|Yes|Active, not recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02176915||41715|
NCT02185989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRO 2014-001|Electrical Muscle Stimulation and Bicycling Combined to Early Standard Rehabilitation in the ICU|Early Rehabilitation Combining Daily Electrical Muscle Stimulation and Early Bedside Cycling Exercise, Compared to Early Standard Rehabilitation. A Randomized, Assessor-blinded, Single-center Study in Intensive Care Patients.|PROMOREA1|Centre Hospitalier Régional d'Orléans|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|314|||Both|18 Years|N/A|No|||September 2015|September 26, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02185989||41020|
NCT02186275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP2014|The Vitamin D in Pediatric Crohn's Disease|Randomized Controlled Trial of High Dose Vitamin D in Children With Newly Diagnosed Crohn's Disease for the Prevention of Relapses|ViDiPeC|St. Justine's Hospital|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|316|||Both|9 Years|18 Years|No|||November 2015|November 2, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02186275||40998|
NCT02186288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0196|Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography|Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography|OXIDIA|University Hospital, Clermont-Ferrand||Completed|July 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult ICU patients|July 2015|July 23, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02186288||40997|
NCT02186535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-131|The Role of Vitamin D in Female Reproductive Tract Immunity|The Role of Vitamin D in Female Reproductive Tract Immunity||CONRAD||Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02186535||40978|
NCT02186795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA Retrospective Analysis|Total Hip Arthroplasty Outcomes With Regional and Multimodal Analgesia|Improvement in Total Hip Arthroplasty Patient Outcomes With Regional Anesthesia and Multimodal Analgesia: A Retrospective Analysis|THA|Medical University of South Carolina|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|117|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing primary total hip arthroplasty|June 2015|June 25, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02186795||40958|
NCT02199405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13066|Study on the Early Warning and Treatment of Cervical Spondylosis of Cervical Type on Young People Based on the " Move Generate Yang " Theory|Study on the Early Warning and Treatment of Cervical Spondylosis of Cervical Type on Young People Based on the " Move Generate Yang " Theory||First Teaching Hospital of Tianjin University of Traditional Chinese Medicine|No|Recruiting|September 2014|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|15 Years|18 Years|No|||September 2014|September 1, 2014|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199405||39990|
NCT02199652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001365|Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)|Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD|REST-ON PTSD|Georgia Regents University|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199652||39971|
NCT02198391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920158|Study of Echinaforce Junior Tablets in Children With Acute Colds|Multicenter Open-label, Randomized Clinical Trial to Assess the Safety and Efficacy of Echinaforce® Junior Tablets in Two Dosages for the Therapy of Common Cold Symptoms in Children (4-12 Years)||Bioforce AG|No|Not yet recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|4 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|children aged 4 - 12 years recruited in pediatrics practice|July 2014|July 22, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198391||40068|
NCT02198625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18826410080|Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication|||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|20 Years|60 Years|No|||July 2014|July 22, 2014|July 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198625||40050|
NCT02193971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOST III REDUCE POLYTECH RCT|Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases III Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST III Trial - REDUCE POLYTECH RCT)|Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases III Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST III Trial - REDUCE POLYTECH RCT) Comparison of the Efficacy and Safety of Biostable Polymer Everolimus-eluting Coronary Stent System (Promus PremierTM) With Biodegradable Polymer Biolimus-eluting Coronary Stent System (Biomatrix®, Biomatrix Flex® and Nobori®) and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention.||Seoul National University Hospital|Yes|Not yet recruiting|July 2014|June 2020|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3384|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193971||40407|
NCT02193698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G26007|Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial|Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome||Chiba University|Yes|Recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||July 2015|July 27, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193698||40428|
NCT02193945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-022|A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA|OZONE: Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study|OZONE|ThromboGenics|No|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|134|||Both|18 Years|N/A|No|Probability Sample|Patients who have been treated with JETREA® for Symptomatic vitreomacular adhesion (VMA)|July 2015|July 8, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02193945||40409|
NCT02194244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP28978|Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662|A Randomized, Open-Label, Four Period, Four-Treatment Crossover Study to Investigate the Comparative Bioavailability of Film-Coated Tablet and Granule Formulations of RG1662 Under Fed and Fasted Conditions in Healthy Volunteers||Hoffmann-La Roche||Completed|August 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02194244||40386|
NCT02194634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902010|Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)|||Chengdu Kanghong Biotech Co.,Ltd.|No|Recruiting|July 2014|September 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||June 2015|January 5, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02194634||40356|
NCT02194907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300814|Emotion Study -- A Neurofeedback Approach|Emotion Study -- Improving Neural Dysregulation in Advanced Age: A Neurofeedback Approach||University of Florida|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194907||40335|
NCT02195193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-CARE|Integrating Depression Care in Acute Coronary Syndromes Care in China|Integrating Depression Care in Acute Coronary Syndromes Patients in Low Resource Hospitals in China|I-Care|The George Institute for Global Health, China|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|20 Years|79 Years|No|||February 2016|February 15, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02195193||40313|
NCT02195492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139.7|Retrospective Follow-up of Synvisc® in Active Patients With Knee Osteoarthritis|Synvisc® in With Knee Osteoarthritis: Retrospective Follow-up in Active Patients||Boehringer Ingelheim||Completed|April 2002|||March 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|41|||Both|N/A|N/A|No|Non-Probability Sample|rheumatological practice|July 2014|July 18, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02195492||40290|
NCT02195505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139.1|Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study|Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study (U.S.A.G.E. Médico-Economique)||Boehringer Ingelheim||Completed|September 2001|||April 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|374|||Both|N/A|N/A|No|Non-Probability Sample|rheumatological practice|July 2014|July 18, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02195505||40289|
NCT02195791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHW103-TDU-B-212-113001 S|Neuroprotection of Pioglitazone in Acute Ischemic Stroke|Mechanism of Hyperglycemia and Neuroprotection Effect of Pioglitazone in Acute Ischemic Stroke||Taipei Medical University Shuang Ho Hospital|No|Recruiting|July 2014|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|20 Years|N/A|No|||July 2014|July 16, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02195791||40267|
NCT02195804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1144.3|Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers|A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formulations Following Oral Administration in Fasting, Healthy Male Volunteers||Boehringer Ingelheim||Completed|May 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02195804||40266|
NCT02196051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71000-3207|Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.|Lipid and Carbohydrate Metabolism: Effects of Exercise||Yale University|No|Recruiting|November 2007|December 2019|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02196051||40247|
NCT02196311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34336|Treatment Of Supracondylar Fractures Closed Reduction And Circular Ring External Fixation Versus Open Reduction and Internal Fixation|TREATMENT OF SUPRACONDYLAR FRACTURES IN ADOLESCENTS: CLOSED REDUCTION AND CIRCULAR RING EXTERNAL FIXATION VERSUS OPEN REDUCTION AND INTERNAL FIXATION||Baylor College of Medicine|No|Recruiting|March 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|12 Years|18 Years|No|Non-Probability Sample|Patients at Texas Children Hospital will undergo either an open reduction with internal        fixation or a closed reduction and circular ring external fixation based on the operating        surgeon's preference. We do not plan on randomizing or assigning patients that present to        Texas Children's Hospital with a supracondylar humerus fracture. Children that consent to        participate will strictly continue their follow-up with the physician that performed the        surgery. Post-operative course will be noted, physical exam and x-rays followed and        outcome surveys obtained and measured intervals.|January 2016|January 21, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196311||40227|
NCT02185170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 12 03|DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections|Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections.||University Hospital, Grenoble|No|Terminated|July 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Male|18 Years|N/A|No|||September 2015|September 21, 2015|June 23, 2014||No|Results of 5 first patients show that chips' cauterization interferes the signal|No||https://clinicaltrials.gov/show/NCT02185170||41083|
NCT02185183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YI2014-HMO-CTIL|Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)|Phase 2 Clinical Trial for Oral Administration of Alequel for Patients With IBD||Hadassah Medical Organization|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||January 2008|September 21, 2014|April 28, 2014||No||No|September 7, 2014|https://clinicaltrials.gov/show/NCT02185183||41082|
NCT02187731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120209|Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma|FULIMA - A Prospective Study of Dual Time PET/CT and Diffusion Weighted MRI in Multiple Myeloma|FULIMA|Odense University Hospital|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|50 Years|N/A|No|Non-Probability Sample|Prospective study with 60 patients referred to Haematological Department under the        suspicion of having treatment demanding multiple myeloma. Patients will be included from        two centres of Haematology.|April 2015|April 21, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02187731||40886|
NCT02177175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-099|Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification|Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|June 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02177175||41695|
NCT02177188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHAT2012|HEAVy HAT-HEAlthy Volunteers Heart to Arm Time. Haemorrhage Simulation Protocol in Healthy Volunteers|HEAVy HAT-HEAlthy Volunteers Heart to Arm Time. Haemorrhage Simulation Protocol in Healthy Volunteers.|HEAvyHAT|University of Milano Bicocca|Yes|Completed|April 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 26, 2014|March 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02177188||41694|
NCT02177201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/255|Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting|Effect of Intravenous Crystalloid Volume on Postoperative Nausea and Vomiting After Tonsillectomy and/or Adenoidectomy: a Prospective, Randomized, Controlled Study|EICVPV|Adnan Menderes University|Yes|Completed|August 2013|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|160|||Both|2 Years|15 Years|No|||August 2015|December 30, 2015|June 26, 2014||No||No|January 19, 2015|https://clinicaltrials.gov/show/NCT02177201||41693|
NCT02177799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHH12014|Surveillance Study of Acute Gastroenteritis in Hospitalized Children in Rural Area in Lebanon|Surveillance Study of Acute Gastroenteritis in Hospitalized Children|SAGE|Shaikh Ragheb Harb Hospital|No|Recruiting|July 2014|||October 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|2 Months|10 Years|No|Non-Probability Sample|Children male and female from 2 months to 10 year old|June 2014|June 30, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02177799||41647|
NCT02177812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200200|A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Acute Myeloid Leukemia||GlaxoSmithKline|No|Recruiting|August 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02177812||41646|
NCT02178124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-002|A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.|||Icure Pharmaceutical Inc.||Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178124||41623|
NCT02173743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47402.044.13|Platelet-rich Plasma in Calcific Tendinitis|Calcific Tendinitis of the Rotator Cuff: a Randomized Controlled Trial to the Effects of the Adjuvant Application of Platelet-rich Plasma After Needle Aspiration of Calcific Deposits||Orthopedisch Centrum Oost Nederland|Yes|Recruiting|July 2014|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|No|||March 2016|March 7, 2016|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02173743||41957|
NCT02197065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAR4398|Pilot Study of Atorvastatin for Orthopedic Surgery Patients|The Post-Operative Statin for Thromboprophylaxis & Cardiovascular Outcomes Protection (POST-OP) Pilot Trial|POST-OP Pilot|Hospital for Special Surgery, New York|No|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|65 Years|99 Years|No|||February 2016|February 19, 2016|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197065||40169|
NCT02199210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPROJECT-MT|Exploring Self-regulatory Processes in Anesthesiologists During Massive Transfusion|Optimizing Intra-Operative Massive Transfusion: Probing for Forethought||St. Michael's Hospital, Toronto|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|40|||Both|N/A|N/A|No|||November 2015|December 1, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02199210||40005|
NCT02199223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI72561|Regorafenib + Panitumumab for Colorectal Cancers|Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers||University of Utah|Yes|Active, not recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199223||40004|
NCT02194322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.35|Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Volunteers After Intranasal Administration of BIBN 4096 BS (Dosage: 6.25 mg - 200mg )||Boehringer Ingelheim||Completed|November 2001|||January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|38|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194322||40380|
NCT02194335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.34|Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study (Parallel Groups) in Healthy Male and Female Volunteers After Oral Administration of BIBN 4096 BS Drinking Solution (Dosage: 20 - 200 mg)||Boehringer Ingelheim||Completed|October 2000|||December 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194335||40379|
NCT02194348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.31|Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Randomized, Placebo-controlled Single Increasing Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Subcutaneous Administration of BIBN 4096 (Dosage: 2.5 - 30 mg)||Boehringer Ingelheim||Completed|February 2000|||March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194348||40378|
NCT02193711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delivra-001|Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The Knee|Randomized, Double Blind, Placebo Controlled Trial With Open Label Extension Of Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The Knee||Delivra, Inc.||Recruiting|January 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|100 Years|No|||January 2016|January 19, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193711||40427|
NCT02193958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS FF1050101US01|Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies|A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies||Fujifilm Pharmaceuticals U.S.A., Inc.|No|Recruiting|July 2014|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193958||40408|
NCT02194218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1531|Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers|An Open-label, Randomised, Single Dose, Parallel-group Phase I Study to Investigate the Pharmacokinetic Properties of 200 mg Nevirapine Extended Release Tablets When Administered Orally as 2x100 mg Tablets or as 4x50 mg Tablets in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2009|||November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194218||40388|
NCT02194231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-MPM-6077|ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)|ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM)|ATREUS|Mario Negri Institute for Pharmacological Research|No|Recruiting|July 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|18 Years|N/A|No|||October 2013|April 21, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194231||40387|
NCT02194920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06072011|Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function|Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function||University of Roma La Sapienza||Completed|October 2014|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|All patients receiving thyroid surgery with accidental removal or devascularization of        normal parathyroid gland|November 2014|November 4, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02194920||40334|
NCT02194933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-009|Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity|Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Recruiting|February 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||October 2015|January 29, 2016|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194933||40333|
NCT02195817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15892A|Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care|Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care||H. Lundbeck A/S|No|Completed|August 2014|||February 2016|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|378|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195817||40265|
NCT02196064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hEPAtic|Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."|Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort." hEPAtic Study.|hEPAtic|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|519|||Both|18 Years|N/A|No|Probability Sample|A total of 176 patients will be included in this study, as well as 352 patients naive for        RPV who initiated any ART that does not include RPV, who will serve as control group.|August 2015|August 4, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02196064||40246|
NCT02196077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT009001|Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD|PT009001|Pearl Therapeutics, Inc.|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|180|||Both|40 Years|80 Years|No|||February 2016|February 16, 2016|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196077||40245|
NCT02196324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCP-102|A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist VPD-737 Prurigo Nodularis (PN)|A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist VPD-737 in Subjects With Prurigo Nodularis||Tigercat Pharma, Inc.|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2014|July 21, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02196324||40226|
NCT02192268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP/HFOO|Assesment of the Effectiveness of High Frequency Oral Oscillation and Mask of PEP in Children With Pneumonia|ASSESSMENT OF THE EFFECTIVENESS OF HIGH FREQUENCY ORAL OSCILLATION AND MASK OF PEP IN CHILDREN WITH PNEUMONIA|PEP/HFOO|Hospital Sirio-Libanes|Yes|Not yet recruiting|August 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|3 Years|11 Years|No|||July 2014|July 15, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192268||40537|
NCT02192528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008|Vitamin D and Outcome in Cardiac Surgery|25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D and Postoperative Outcome in Cardiac Surgical Patients|Calcitop|Heart and Diabetes Center North-Rhine Westfalia|No|Completed|June 2012|July 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3852|||Both|18 Years|N/A|No|Probability Sample|cardiac surgical patients|July 2014|July 15, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192528||40518|
NCT02192775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203081|UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus|A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma||University of Arkansas|Yes|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192775||40499|
NCT02176928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130161|Sleep-Disordered Breathing in Chronic SCI|Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease||University of Miami|No|Recruiting|May 2014|February 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02176928||41714|
NCT02183454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-0639|MASCOT - Post Marketing Registry|Multinational Abluminal Sirolimus Coated BiO-Engineered StenT - The MASCOT Post Marketing Registry|MASCOT|OrbusNeich|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients who undergo PCI with (attempted) placement of at least one Combo        Stent as part of routine clinical care are entered into the registry. PCI with a Combo        Stent is considered attempted when the operator has passed the Combo Stent across the        guiding catheter.|April 2015|April 30, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02183454|12 Months|41215|
NCT02183467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.32|Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 5 mg and 100 mg of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Study With Moxifloxacin as Positive Control||Boehringer Ingelheim||Completed|January 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|44|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183467||41214|
NCT02183493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.34|Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects|Relative Bioavailability of a 5 mg BI 1356 Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single Dose, Two-way Crossover, Phase I Trial||Boehringer Ingelheim||Completed|October 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183493||41212|
NCT02183428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.30|Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers|Relative Bioavailability of BI 1356 and Glyburide After Concomitant Administration of Multiple Oral Doses of BI 1356 5 mg Once Daily and a Single Oral Dose of Glyburide 1.75 mg Compared With the Bioavailability of BI 1356 and Glyburide After Each Treatment Given Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Two-way Crossover Study of Phase I)||Boehringer Ingelheim||Completed|May 2008|||July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183428||41217|
NCT02183441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.31|Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of BI 1356 (5 mg) After Co-administration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BI 1356 (5 mg) Alone in Healthy Male Volunteers (an Open-label, Randomized, Two-way Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|April 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183441||41216|
NCT02183831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0010|Comparison of Clinical Outcomes After Cataract Surgery With and Without Capsular Tension Ring|||Yonsei University|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|52|||Both|40 Years|79 Years|No|Probability Sample|The patients who were planned to undergo the cataract surgery in Department of        Ophthalmology, Yonsei University College of Medicine|June 2014|July 2, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02183831||41186|
NCT02177552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01052014|Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma|Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial.|SEED|Rigshospitalet, Denmark|No|Recruiting|June 2014|January 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|75 Years|No|||May 2015|May 6, 2015|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177552||41666|
NCT02177565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL1 254|Autologous Stem Cell Therapy for Fracture Non-union Healing|Autologous Stem Cell Therapy for Fracture Non-union Healing||Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust|No|Completed|January 2000|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|76 Years|No|||June 2014|June 25, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02177565||41665|
NCT02177825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLNEU SJ 01|Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas|Phase II Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas||St. Justine's Hospital|Yes|Recruiting|June 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|21 Years|No|||June 2015|June 12, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02177825||41645|
NCT02177838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031204|Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer|Selecting for Cetuximab Responders in Advanced Head and Neck SCC||Rutgers, The State University of New Jersey|Yes|Recruiting|May 2015|||June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02177838||41644|
NCT02178137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIH-Ortho-001|Effect of Interventions on the Progression of Knee Osteoarthritis|Effect of Interventions on Progression of Knee Osteoarthritis - a Comparison of Effect of Glucosamine/Chondroitin or Diacerin Vs Placebo: Measured by Clinical, Radiological and Biochemical Parameters|KAPS|Indus Hospital|Yes|Active, not recruiting|June 2014|October 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|322|||Both|40 Years|65 Years|No|||February 2016|February 24, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178137||41622|
NCT02198131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98214|Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia|Pulsed Dye Laser for Treatment of Post Radiation Dysphonia||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2009|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|No|||September 2015|September 22, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198131||40087|
NCT02199457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMD_CT_001|A Study to Demonstrate the Clinical Accuracy of the Smartphone Vital Signs System (SVSS)|An Open Label, Clinical Performance Study to Demonstrate the Clinical Accuracy of the Smartphone Vital Signs System (SVSS)||Léman Micro Devices SA|No|Not yet recruiting|December 2016|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02199457||39986|
NCT02192697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8273-CL-0101|An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|Phase I and II Study of ASP8273 — An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations —||Astellas Pharma Inc|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|124|||Both|20 Years|N/A|No|||August 2015|August 18, 2015|May 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192697||40505|
NCT02194257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.494|Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of an Open Label Single Dose of 20 mg Ambroxol Administered as a Lozenge Together With an Oral Solution of 0.4 mg [14C]-Ambroxol in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194257||40385|
NCT02194270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.488|Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers|Relative Bioavailability of Ambroxol Hydrochloride Following Oral Administration of Soft Pastilles 15 mg (Test) Compared to 15 mg of Syrup (15mg/5mL, Reference I) and Compared to 15 mg of Syrup (30mg/5mL) (Reference II) in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, 3-way Crossover Study||Boehringer Ingelheim||Completed|September 2004|||February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194270||40384|
NCT02194283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.493|Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo Controlled Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges (Dosage: 20, 40, 80 mg Three Times Daily) Over 4 Days in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2009|||November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194283||40383|
NCT02194296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.479|Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers|An Open Label, Randomised, Two-way Crossover Study in Healthy Female and Male Volunteers to Evaluate the Relative Bioavailability of a 20 mg Ambroxol Hydrochloride Lozenge in Comparison to 30 mg Ambroxol Hydrochloride Syrup (Mucosolvan®)||Boehringer Ingelheim||Completed|June 1999|||July 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194296||40382|
NCT02194660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311048RIN|Fragility Fracture Liaison Service Project|Fragility Fracture Liaison Service Project||National Taiwan University Hospital|No|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|600|||Both|50 Years|N/A|No|Non-Probability Sample|new fragility fracture|August 2015|August 26, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194660|24 Months|40354|
NCT02195830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AE14/11038|Inferior Vena Cava Collapsibility Index in Severe Sepsis|Bedside Ultrasound of Inferior Vena Cava Collapsibility in Emergency Department Patients Presenting With Severe Sepsis and Septic Shock||Teesside University|No|Not yet recruiting|July 2014|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|112|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195830||40264|
NCT02196090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAM-RD-001|Application of Vagal Stimulation in Exposure and Response Prevention for Obsessive Compulsive Disorder|Application of Vagal Stimulation by Cold Face Mask in Exposure and Response Prevention for Obsessive Compulsive Disorder||King's College London|No|Recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02196090||40244|
NCT02196337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-82|Salt Iodization: Meeting the Needs of Pregnancy, Lactation and Infancy|Salt Iodization and the 1st 1000 Days: Does a USI Program Cover the Iodine Requirement of Pregnant and Lactating Women and Infants?|SIMPLIFY|Swiss Federal Institute of Technology|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||6|Anticipated|9600|Samples With DNA|Urine, dried blood spots, breast milk|Both|N/A|44 Years|Accepts Healthy Volunteers|Probability Sample|In each of the four study countries, six population groups will be studied:          -  women of reproductive age          -  pregnant women          -  lactating women          -  young infants          -  toddlers          -  school-aged children|November 2015|November 27, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02196337||40225|
NCT02192281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR-06758|Randomized Experiment of Playworks|Randomized Experiment of Playworks||Mathematica Policy Research, Inc.|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|2278|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 14, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192281||40536|
NCT02192294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871044|Absolute Bioavailability Of Bosutinib|An Open-label, Randomized, 2-period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects||Pfizer|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|July 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192294||40535|
NCT02192541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140150|Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas|Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas||National Institutes of Health Clinical Center (CC)||Completed|July 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|120 Years|No|||May 2015|February 26, 2016|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192541||40517|
NCT02187341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ben-0614b|Effects of Exercise and 5-HTP on Cortisol Levels|Effects of Exercise and 5-HTP on Cortisol Levels||Benedictine University|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02187341||40916|
NCT02182947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13080263|Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children|Comparison of the Use of Wireless Capsule Endoscopy With Magnetic Resonance Enterography in Children With Inflammatory Bowel Disease|CE|Children's Mercy Hospital Kansas City|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|34|||Both|4 Years|17 Years|No|||July 2014|July 2, 2014|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02182947||41254|
NCT02183506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.4|Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers|Bioavailability of Both BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 BS 10 mg Daily Alone and Metformin 850 mg Three Times a Day Alone in Healthy Male Volunteers (an Open-label, Randomized, Crossover Study)||Boehringer Ingelheim||Completed|September 2005|||December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183506||41211|
NCT02183883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/14/0131|Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity|Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity|DARWIN1|University College, London|Yes|Not yet recruiting|May 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02183883||41182|
NCT02183857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.SS.12|Ultrasound-Guided vs Landmark Technique for Femoral Arterial Cannulation in Pediatric Cardiac Surgery|Femoral Arterial Cannulation Performed by Residents: A Comparison Between Ultrasound-Guided and Landmark Technique in Infants and Children Undergoing Cardiac Surgery||American University of Beirut Medical Center|No|Completed|July 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|106|||Both|N/A|12 Years|No|||January 2016|January 14, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02183857||41184|
NCT02183870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUCROSS|EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer|EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations|EUCROSS|University of Cologne|Yes|Active, not recruiting|May 2014|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02183870||41183|
NCT02183844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH100565|A System for Preference Assessment in Mental Health|Implementing Patient-Centered Decision Support for Mental Health|SPA|University of California, Los Angeles|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|95|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02183844||41185|
NCT02184169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00006630|Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)|Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)|Oxy-CAHN|Children's Hospital Boston|No|Recruiting|December 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|N/A|6 Months|No|||July 2014|July 3, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184169||41160|
NCT02184156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-007|Study to Evaluate Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion in the Knee of Adults With Pain Due to Osteoarthritis|A Prospective Phase I/II Study to Evaluate the Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion™ (4 ML) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee||Ampio Pharmaceuticals. Inc.|No|Completed|June 2014|October 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|40 Years|85 Years|No|||February 2016|March 2, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184156||41161|
NCT02184416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061078|Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting|Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-Interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (ADONIS)|ADONIS|Pfizer|No|Recruiting|October 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll adv/mRCC patients when they start a treatment with Sutent in 1st        line or Inlyta in 2nd line post Sutent treatment.|March 2016|March 2, 2016|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02184416||41141|
NCT02198898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMCGC1301|Anti-adhesion Effect of GUARDIX-SGⓇ in Gastric Cancer Surgery|Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer.||The Catholic University of Korea|Yes|Recruiting|July 2013|August 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|224|||Both|20 Years|80 Years|No|||July 2014|July 21, 2014|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02198898||40029|
NCT02192931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73034|A Feasibility Placebo-Controlled Study of Creatine in Depressed Meth-Using Females|A Feasibility Placebo-Controlled Study of Creatine in Depressed Meth-Using Females||University of Utah|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Female|18 Years|55 Years|No|||February 2016|February 16, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192931||40487|
NCT02194946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BAI02B04|Chinese Medicine on Deferring Dialysis Initiation|Effectiveness of Chinese Medicine on Deferring Dialysis Initiation for Stage 5 Chronic Kidney Disease|C-MODDI|Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Enrolling by invitation|July 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|875|||Both|18 Years|75 Years|No|||July 2014|July 30, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194946||40332|
NCT02194673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH 00112|Acute Effects of Natural and Interesterified Fats-margarine on Lipemic and Insulinemic Response|Acute Effects of Natural and Interesterified Fats-formulated Margarine on Lipemic and Insulinemic Response||Malaysia Palm Oil Board|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02194673||40353|
NCT02195206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000041669|Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Healthy Adult Volunteer Pilot Study|Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging Hardware and Software: Healthy Adult Volunteer Pilot Study||The Hospital for Sick Children|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Adults from the general population|July 2015|August 19, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02195206||40312|
NCT02195518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201215|Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study|A Multi-centre, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate(TDF) Treatment in Chinese Chronic Hepatitis B (CHB) Subjects Following Failure of Multiple Nucleos(t)Ide Analogues(NAs)||GlaxoSmithKline|No|Recruiting|March 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||July 2015|October 29, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195518||40288|
NCT02195843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-2014-07-10|Quadripolar Leads for the Management of Heart Failure Patients in the Middle East|Quadripolar Leads for the Management of Heart Failure Patients in the Middle East|QUADRA-ME|King Abdullah International Medical Research Center||Not yet recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|389|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195843||40263|
NCT02196103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019-14-HYMC|Management of Labor in Patients With Previous Cesarian Section|Management of Labor in Patients With Previous Cesarian Section and Premature Rupture of Membranes Who Desire TOLAC: Comparison Between the Use of Standard Expectant Management and the Double-balloon Catheter Device. A Prospective Randomized Study||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2014|September 2018|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|45 Years|No|||July 2014|July 17, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02196103||40243|
NCT02196350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9607|P4 Approach in Diabetes Type 2|The Impact of the P4 Approach, Preventive, Predictive, Personalized and Participatory in Newly Diagnosed Type 2 Diabetics in Hillegom|P4P-Hillegom|TNO|No|Enrolling by invitation|September 2014|July 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|60|||Both|30 Years|80 Years|No|||August 2015|August 3, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196350||40224|
NCT02192567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5573-A-J101|Open Label Study of DS-5573a|Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors||Daiichi Sankyo Inc.|Yes|Recruiting|September 2014|March 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192567||40515|
NCT02192307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014047|Effectiveness of Two Water-Based Potassium Oxalate Desensitizers|||Procter and Gamble|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 12, 2014|July 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192307||40534|
NCT02192554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-211|Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo|A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Enrolling by invitation|June 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|360|||Both|N/A|N/A|No|Non-Probability Sample|Subjects must have completed a previous double-blind trial of brexpiprazole or placebo;        neither drug or placebo will be administered in the trial|April 2015|April 1, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192554||40516|
NCT02182960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024.3|Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers|An Open Two Way Cross Over Study to Relative Bioavailability of Ibuprofen Enantiomers After Single p.o. Administration of 200 mg Syrup (T) Compared With 200 mg Standard Brufen Sirup (R)||Boehringer Ingelheim||Completed|September 1998|||October 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02182960||41253|
NCT02183480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.33|Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers|Assessment of Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers in an Open, Randomised, Multiple-dose, Three-period Crossover, Phase I Trial||Boehringer Ingelheim||Completed|July 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183480||41213|
NCT02183909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI12-EBACA-003|Connecting Resources for Urban Sexual Health|Connecting Resources for Urban Sexual Health|CRUSH|University of California, San Francisco|No|Recruiting|May 2013|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|670|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02183909||41180|
NCT02183896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0080|Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip|Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip||University of Colorado, Denver|No|Enrolling by invitation|July 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|No|||July 2015|July 24, 2015|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02183896||41181|
NCT02184182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2934P|Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)|Liver Resection After Portal Vein Ligation / Embolization and Transection Plane Devascularization With Radio Frequency / Microwave: Pilot Study on Primary and Secondary Liver Tumors|LAPS|Azienda Ospedaliera di Padova|No|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||July 2014|July 8, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02184182||41159|
NCT02184429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7821001|A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions|A Phase 1, Double Blind, Sponsor Open, Placebo Controlled Combined Single And Multiple Ascending Dose Study To Investigate The Safety, Tolerability And Food Effect On Pharmacokinetics Of Pf-06669571 Following Oral Doses In Healthy Subjects||Pfizer|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02184429||41140|
NCT02184442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-THV-01-US /2012-THV-01-US|The PARTNER Post Approval Study Part II|Assessment of Safety, Effectiveness, Adherence to Indication and Learning Curve of the SAPIEN™ THV With Retroflex for Inoperable Patients and With RetroFlex or Ascendra for High Risk Operable Patients Post Approval Period (US)|PAS II|Edwards Lifesciences|No|Active, not recruiting|September 2013|February 2018|Anticipated|February 2014|Actual|Phase 4|Interventional|Primary Purpose: Treatment|1||Actual|5000|||Both|N/A|N/A|No|||July 2014|July 8, 2014|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02184442||41139|
NCT02184663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APACaP D13-1|Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer|Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|February 9, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184663||41122|
NCT02192450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypoDeg|Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia|The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia|HypoDeg|Nordsjaellands Hospital|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02192450||40524|
NCT02192463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1485|Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers|Relative Bioavailability of Different Oral Viramune Extended Release Formulations Containing 300 mg or 400 mg Compared to 200 mg or 400 mg as One or Two 200 mg IR Tablets Following Administration in Healthy Male Volunteers - an Openlabel, Non-randomized, Parallel Group Study||Boehringer Ingelheim||Completed|April 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|204|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02192463||40523|
NCT02193204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111009349|Chronic Alcohol, Stress Inflammatory Response and Relapse Risk|Chronic Alcohol, Stress Inflammatory Response and Relapse Risk||Yale University|No|Completed|September 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|116|||Both|18 Years|50 Years|No|||July 2015|July 14, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193204||40466|
NCT02194959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0594|Peer Patient Navigation for Colon Cancer Screening|Training African American Peers as Patient Navigators for Colon Cancer Screening||Icahn School of Medicine at Mount Sinai|No|Completed|July 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|800|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 25, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194959||40331|
NCT02195219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLUX-3|Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Dislocations|Clinical Trial to Compare the Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Grade III Dislocations||Hospital General Universitario Gregorio Marañon|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|50 Years|No|||July 2014|July 16, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02195219||40311|
NCT02195531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI-BIG4-1331-MS|BIG4 CPAP Study Educational Materials and Usage Feedback to Promote CPAP Adherence|BIG4 CPAP Educational Materials and Usage Feedback to Promote CPAP Adherence||Philips Respironics|No|Recruiting|January 2014|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|21 Years|80 Years|No|||July 2014|July 16, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02195531||40287|
NCT02195544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139.5|Use of Synvisc® in Knee Osteoarthritis - Survey on Practice|Use of SYNVISC in Knee Osteoarthritis. Survey on Practice. "U.S.A.G.E Pratique"||Boehringer Ingelheim||Completed|October 1998|||April 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|N/A|N/A|No|Non-Probability Sample|rheumatological practice|July 2014|July 18, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02195544||40286|
NCT02195557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139.6|Retrospective Follow-up Study of Synvisc® in Patients With Knee Osteoarthritis|Synvisc® in Knee Osteoarthritis: Retrospective Follow-up in Treated Patients Since at Least Three Years||Boehringer Ingelheim||Completed|April 2002|||March 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|rheumatological practice|July 2014|July 21, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02195557||40285|
NCT02196363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1013/9|New Ultrasound Parameters for Predicting Birthweight|New Ultrasound Parameters for Predicting Birthweight|NUPS|Central Manchester University Hospitals NHS Foundation Trust|No|Completed|July 2010|July 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|253|||Female|N/A|N/A|No|Non-Probability Sample|Participants will be identified by screening booked scan appointments in regular antenatal        clinics. The first approach will be by either the named local investigators|February 2016|February 1, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196363||40223|
NCT02192320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDH2014|The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders|The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders||Oriental Neurosurgery Evidence-Based-Study Team|No|Not yet recruiting|July 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|No|||March 2015|March 25, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192320||40533|
NCT02192580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shahid Behesti University|Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children|||Shahid Beheshti University|Yes|Recruiting|July 2014|September 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|1 Month|10 Years|No|||July 2014|July 16, 2014|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02192580||40514|
NCT02192840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0|POLish Bifurcation Optimal Stenting Study|Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study|POLBOS|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland|Yes|Completed|October 2010|March 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|90 Years|No|||July 2014|July 15, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192840||40494|
NCT02193061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rota/CeNSIA|Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs|Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between Rota Vaccine 5 and Rota Vaccine 1 Using Seven Combined Anti-rotavirus Prevention Programs: ROTA 1,ROTA 2,ROTA 3,ROTA 4,ROTA 5,ROTA 6,ROTA 7 in Infants at 2, 4 and 6 Months of Age in Mexico City.||National Institute of Pediatrics, Mexico|Yes|Recruiting|November 2013|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Anticipated|1498|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193061||40477|
NCT02183519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400477|Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease|Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease||University of Florida|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02183519||41210|
NCT02183922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181/10|Microencapsulated Fish Oil or Conjugated Linoleic Acid in Metabolic Syndrome|Hypocaloric Diet With or Without Microencapsulated Fish Oil or Conjugated Linoleic Acid on Oxidative Stress and Cardiovascular Risk Factors in Women With Metabolic Syndrome Genotyped for Polymorphisms in the Genes PPAR Gamma 2 (Pro12Ala) and Adiponectin (G276T)||Universidade Federal do Rio de Janeiro|No|Completed|May 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|37|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02183922||41179|
NCT02183935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-AD-39/03/14|Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner|Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner - a Study on Efficacy and Pathophysiologic Mechanisms||University Medical Centre Ljubljana|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|20 Years|No|||July 2014|July 2, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02183935||41178|
NCT02184208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P000011819|Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.|Retrospective Review of Mechanically Ventilated Patients|T3|Children's Hospital Boston|No|Active, not recruiting|July 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|All mechanically ventilated patients in our medical surgical ICU.|May 2015|May 26, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184208||41157|
NCT02184481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Franken 5|Working Memory Training for Dysphoric Students|Working Memory Training to Decrease Depression, Anxiety and Rumination in Dysphoric Students||Erasmus Medical Center|No|Completed|September 2013|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|17 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 8, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184481||41136|
NCT02184195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081FC00001|Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy|POLO|AstraZeneca|Yes|Recruiting|December 2014|August 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|145|||Both|18 Years|130 Years|No|||March 2016|March 14, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184195||41158|
NCT02184455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeCell-001|Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment|A Feasibility Study of DermGEN Dermal Regeneration Scaffold for the Treatment of Diabetic Foot Ulcers||DeCell Technologies Inc.|Yes|Not yet recruiting|March 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02184455||41138|
NCT02184689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiHATFEX006|Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study|Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study||Drugs for Neglected Diseases|Yes|Recruiting|May 2014|||March 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|6 Years|14 Years|No|||July 2014|July 8, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02184689||41120|
NCT02184702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-2014-192|Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy|||Inje University||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|65 Years|No|Probability Sample|Patints who undergoing shoulder arthroscopy American Society of Anesthesiologists (ASA)        1,2|January 2016|January 26, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184702||41119|
NCT02192710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.794|Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam|Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam|IPAD|Hospices Civils de Lyon|No|Completed|May 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|4 Years|10 Years|No|||April 2014|July 15, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02192710||40504|
NCT02192944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1401|Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine|Comparison of the Electrocardiographic Effects in Relation to Pharmacokinetic Profile of Chloroquine and Piperaquine in Healthy Thai Subjects||University of Oxford|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02192944||40486|
NCT02193217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E12|A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303|||Mitsubishi Tanabe Pharma Corporation||Completed||January 2015|Actual|December 2014|Actual|Phase 1|Interventional|N/A|4||Actual|81|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193217||40465|
NCT02195245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMF-CLIN-14-01|A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate|A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate||DMF Medical Incorporated|No|Recruiting|August 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|N/A|N/A|No|||September 2014|September 26, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02195245||40309|
NCT02195232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-114|Cancer Associated Thrombosis and Isoquercetin (CAT IQ)|Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.|CAT IQ|Dana-Farber Cancer Institute|Yes|Recruiting|January 2015|April 2023|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|618|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195232||40310|
NCT02195570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130654|Contingency Management for Smoking Cessation in Pregnant Minority Women|Contingency Management for Smoking Cessation in Pregnant Minority Women||University of Miami|Yes|Not yet recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195570||40284|
NCT02195583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202194|The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ|The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ||GlaxoSmithKline|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|April 9, 2015|July 17, 2014|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT02195583||40283|
NCT02196376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140671|Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome|Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Blood will be drawn for future assay and analysis of the following tests:      Antibodies regulating cardiovascular function      The clinical significance of these antibodies is unknown. We will share the results of the      antibody panel with the subject, but with the caveat that no clinical interpretation or      comment on significance can be made.      Inflammatory markers|Both|13 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic orthostatic intolerance, sometimes known as the postural tachycardia syndrome        (POTS), is the most common disorder among patients seen at several centers specializing in        diseases of the autonomic nervous system.        excessive increase in heart rate [>30 min-1] on standing associated with orthostatic        symptoms [including palpitation, chest pain syndrome, dyspnea on standing, mental clouding        and difficulties with concentration], in the absence of orthostatic hypotension.        Orthostatic tachycardia can produce substantial disability among otherwise healthy people.        Patients typically feel tired and run down. Many also report a myriad of symptoms that are        hard to categorize, often involving fatigue. We and others have reported that patients had        a diminished quality of life.|December 2015|December 7, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02196376||40222|
NCT02192593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ComputerCBTPsychosis|Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations|Randomized Controlled Trial of Computerized Cognitive Behavioral Therapy for Auditory Hallucinations in Persons With Psychosis||Boston University|No|Completed|November 2011|February 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||July 2015|July 20, 2015|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02192593||40513|
NCT02192853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-149|Correlation Between Plasma- and Endothelial DPP-4 Activity|Plasma and Endothelial Activity of Dipeptidyl Peptidase 4 During Different Doses of Sitagliptin||University Hospital, Gentofte, Copenhagen|Yes|Completed|May 2013|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|January 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02192853||40493|
NCT02193074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS3B|A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants With Spinal Muscular Atrophy|A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy||Ionis Pharmaceuticals, Inc.|Yes|Recruiting|July 2014|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|111|||Both|N/A|210 Days|No|||December 2015|March 16, 2016|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193074||40476|
NCT02193308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.4|Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers|Bioequivalence of 80 mg Telmisartan / 10 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Sequence, Two-period Crossover Study||Boehringer Ingelheim||Completed|September 2007|||November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 16, 2014||||No||https://clinicaltrials.gov/show/NCT02193308||40458|
NCT02193321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405313630|Safety and Efficacy Study of Amniotic Membrane Patch to Treat Postoperative Atrial Fibrillation|Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving an Amniotic Membrane Patch Placed on the Epicardial Surface||University of Arizona|Yes|Withdrawn|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193321||40457|
NCT02183545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.3|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers in a Randomized, Double-blind, Placebo-controlled Design||Boehringer Ingelheim||Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02183545||41208|
NCT02183558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM OBK|Screening for GDM in Women With PCOS and Controls|Glucose Metabolism and Screening for Gestational Diabetes Mellitus According to Different Sets of Criteria in Women With Polycystic Ovary Syndrome and Controls||Odense University Hospital|No|Completed|January 2010|June 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02183558||41207|
NCT02183571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.57|Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects|Bioequivalence of Two Strengths (1000 mg and 500 mg) of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-period Crossover, Phase I Trial||Boehringer Ingelheim||Completed|February 2009|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183571||41206|
NCT02183974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-OME Restech|Suitable Method for Routine Diagnostics of EER in Children With Otitis Media With Effusion|Suitable Method for Routine Diagnostics of EER in Children With Otitis Media With Effusion||University Hospital Ostrava|No|Completed|June 2012|May 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Both|1 Year|7 Years|No|||July 2014|July 2, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02183974||41175|
NCT02184728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-2014-215|Comparison of End-tidal Carbon Dioxide (ETCO2) Measured by Transportable Capnometer (EMMATM) and the Arterial pCO2 in General Anesthesia|||Inje University|No|Completed|June 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|20 Years|85 Years|No|||March 2015|March 23, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184728||41117|
NCT02184468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMS 242-11|Survival Study After Out-of-hospital Cardiac Arrest|Dual Dispatch of EMS, Fire Fighters and/or Police in Out-of-hospital Cardiac Arrest Implemented in Nine Counties in Sweden - Can More Lives be Saved by Using This Method?|SAMS|Karolinska Institutet|Yes|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6000|||Both|8 Years|N/A|No|||July 2014|July 8, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02184468||41137|
NCT02184715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-01|Effects of Virtual Reality System in Children With Developmental Delays|The Additional Therapeutic Effects of Virtual Reality System in Children With Developmental Delays||Taipei Medical University|No|Completed|January 2009|December 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|157|||Both|2 Years|12 Years|No|||July 2014|July 8, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184715||41118|
NCT02192723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project863|A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia|Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study||Beijing HuiLongGuan Hospital|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|550|||Both|25 Years|60 Years|No|||July 2014|July 16, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192723||40503|
NCT02192957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140415|The Ottawa AF Cardioversion Protocol|Developing a Standardized Atrial Fibrillation Cardioversion Protocol||Ottawa Heart Institute Research Corporation|No|Recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|389|||Both|18 Years|85 Years|No|||March 2016|March 3, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192957||40485|
NCT02193724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETCELL|Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma|Feasibility, Validation and Differentiation of Induced Pluripotent Stem Cells Produced From Patients With Heritable Retinoblastoma||St. Jude Children's Research Hospital|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Skin samples or peripheral blood samples to be used to generate pluripotent stem cells.|Both|N/A|N/A|No|Non-Probability Sample|Participants will have a diagnosis of heritable retinoblastoma.|October 2015|October 6, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193724||40426|
NCT02195856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF163|Effects of Nitrate on Liver Perfusion and Sugar Control|The Effect of Dietary Nitrate on Hepatic Perfusion and Incretin Secretion|DiMPLe|NIHR Exeter Clinical Research Facility|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02195856||40262|
NCT02196116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/02|Amyloïd Load in Elderly Population: Effect of Cognitive Reserve|Amyloïd Load in Elderly Population: Effect of Cognitive Reserve|EDUMA|University Hospital, Bordeaux|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196116||40242|
NCT02192606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3DRCT|Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?|Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy|3DRCT|Brigham and Women's Hospital|No|Enrolling by invitation|November 2013|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|2||Anticipated|42|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02192606||40512|
NCT02192866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2102|Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies|Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies||University of Colorado, Denver|Yes|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|270|Samples With DNA|Blood samples.|Both|1 Year|75 Years|Accepts Healthy Volunteers|Probability Sample|Adults and children who are allergic to peanuts and/or tree-nuts and individuals with no        known food allergies.|December 2015|December 10, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02192866||40492|
NCT02193087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEN-106|Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults||Takeda|No|Completed|August 2014|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|1002|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193087||40475|
NCT02193334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-100-ND002|Phase I/II Study of KP-100IT in Acute Spinal Cord Injury|A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury||Kringle Pharma, Inc.|Yes|Recruiting|June 2014|March 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02193334||40456|
NCT02193347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054746|IDH1 Peptide Vaccine for Recurrent Grade II Glioma|Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine|RESIST|Duke University|Yes|Recruiting|December 2015|June 2019|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193347||40455|
NCT02183948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESTC-SCAN-01|Effect of Oxytocin on Masked Facial Expressions: a fMRI Study|||University of Electronic Science and Technology of China||Active, not recruiting|June 2014|July 2014|Anticipated|July 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|86|||Both|18 Years|29 Years|No|||July 2014|July 7, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02183948||41177|
NCT02183961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-EER Peptest Restech|Three Methods Used in the Diagnosis of EER in Children With OME|Comparison of Three Methods Used in the Diagnosis of Extraesophageal Reflux in Children With Chronic Otitis Media With Effusion||University Hospital Ostrava|No|Completed|June 2012|May 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|1 Year|7 Years|No|||July 2014|July 2, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02183961||41176|
NCT02184533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0047|Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Prostate Cancer|A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer||Stanford University|Yes|Recruiting|July 2014|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Male|18 Years|N/A|No|||July 2014|July 18, 2014|July 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02184533||41132|
NCT02184546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF01PD|Outcomes Data of Adipose Stem Cells to Treat Parkinson's Disease|||StemGenex||Recruiting|July 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|June 2015|June 17, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184546||41131|
NCT02184741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B211-11|Evaluation of the Safety and Efficacy of GB-0998 in Unexplained Primary Recurrent Miscarriage|A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage||Japan Blood Products Organization|No|Recruiting|April 2014|June 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|N/A|41 Years|No|||February 2016|February 3, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184741||41116|
NCT02184754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2014|Magnetic Endoscope Imaging in Single-balloon-enteroscopy||Magenta|Technische Universität München|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|endoscopy unit|January 2015|January 28, 2015|January 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02184754||41115|
NCT02185027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 18|Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants|Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants|GIHP-NACO|University Hospital, Grenoble|No|Recruiting|June 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|842|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects managed in view of surgery or an invasive procedure, emergency or not managed and        hospitalized for active bleeding with a long-term therapy (in the indication atrial        fibrillation or treatment of pulmonary embolism or deep vein thrombosis) by one        antithrombotic agent (Dabigatran, Rivaroxaban, Apixaban)|July 2015|July 28, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02185027||41094|
NCT02193230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0073|Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence|Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence.|DACE|Nantes University Hospital|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|3 Years|15 Years|No|Probability Sample|Multicenter prospective nonrandomized uncontrolled open-label study|June 2015|June 5, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193230||40464|
NCT02193490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-CNBL-1001|DNase Treatment for Dry Eyes|Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease||University of Illinois at Chicago|No|Recruiting|July 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193490||40444|
NCT02193737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-DRINC|Effects of Drinking at PACU Discharge After General Anaesthesia With Airway Control on Aspiration, Vomiting and Patients Comfort|Effects of Drinking at PACU Discharge After General Anaesthesia With Airway Control on Aspiration, Vomiting and Patients Comfort.|I-DRINC|Poitiers University Hospital||Not yet recruiting||||September 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||July 2014|July 17, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02193737||40425|
NCT02193984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G00007943|Alliance to Control Diabetes|Alliance to Control Diabetes||San Diego State University|Yes|Active, not recruiting|February 2009|September 2016|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|336|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193984||40406|
NCT02194309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.9|Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine (Free Dose Combination) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194309||40381|
NCT02195596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011111100|Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.|Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.|EFA-P|Basque Health Service|Yes|Recruiting|April 2013|December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|55 Years|85 Years|No|||July 2014|July 18, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02195596||40282|
NCT02195609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-2013-01|Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms|Randomized Open Label Study to Evaluate the Effect of (Omega-3) EPA + Docosahexaenoic Acid (DHA) vs Soy Isoflavones in 100 Postmenopausal Women Between 45-65 Years With Moderate to Severe Vasomotor Symptoms.|OMEGASI|Instituto Palacios|Yes|Active, not recruiting|March 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02195609||40281|
NCT02195869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1129-CA|Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease|A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease||Pharmacyclics||Recruiting|July 2014|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|39|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195869||40261|
NCT02195882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-008|Effect of an Exercise Program of the Scapular Muscle Stabilizers in Amateur Kayakers Shoulder Pain|||CEU San Pablo University||Completed|May 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|14 Years|30 Years|No|||July 2014|July 3, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02195882||40260|
NCT02196129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2014-02|Immediate Pain Relieving Effects of Sinbaro-3 for Low Back Pain|Immediate Pain Relieving Effects of Sinbaro-3 Pharmaco-acupuncture in Low Back Pain Patients; A Randomized Controlled Trial||Jaseng Hospital of Korean Medicine|Yes|Completed|July 2014|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|69 Years|No|||November 2014|November 17, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02196129||40241|
NCT02192333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9161|Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors|Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)||Fred Hutchinson Cancer Research Center|No|Recruiting|August 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|455|||Both|18 Years|39 Years|No|||January 2016|January 29, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192333||40532|
NCT02192346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-043A|α-TEA in Advanced Cancer|Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer||Providence Health & Services|No|Recruiting|July 2014|July 2021|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|62|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|July 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192346||40531|
NCT02196675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-13-003|Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea||Ethicon Endo-Surgery|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|19 Years|N/A|No|Non-Probability Sample|Individuals with suspected or confirmed of NSCLC (up to and including Stage II), or        individuals undergoing VATS diagnostic wedge resection in accordance with their        institution's Standard of care (SOC);|December 2015|December 28, 2015|July 19, 2014||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT02196675||40199|
NCT02196987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/14|Does the Act of Urination During Urethral Catheterisation in Males Reduce Pain?|Pain Level During Male Urethral Catheterisation - Does Patient Attempted Urination During Catheterisation Reduce Pain? A Prospective Randomized Study||Assaf-Harofeh Medical Center|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|96|||Male|18 Years|N/A|No|Non-Probability Sample|Men who will be referred to Urodynamic study|July 2014|July 21, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196987||40175|
NCT02197260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320030-122089|Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing|Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing on Clinical, Microbiological and Systemic Response|GAR|University of Geneva, Switzerland|No|Completed|September 2008|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|25 Years|70 Years|No|||July 2014|July 21, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197260||40154|
NCT02197494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042-14|Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two Period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Two Formulations of Valsartan 320mg Tablet in Healthy, Adult, Human Subjects Under Fed Condition.||Ranbaxy Inc.|No|Completed|January 2014|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197494||40136|
NCT02183636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1264.1|Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects|Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin 5 mg/Pioglitazone 45 mg Compared With Single Linagliptin 5 mg and Pioglitazone 45 mg Tablets Administered Together to Healthy Male and Female Subjects (Open, Randomised, Single Dose, Three-period Crossover Phase I Trial)||Boehringer Ingelheim||Completed|August 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183636||41201|
NCT02183649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1265.1|Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers|A Phase I, Single-dose, Two-way Crossover Study to Investigate Tolerability and Potential ECG Effects After a Single Oral Dose of 192 mg Pentoxyverine Citrate (Corresponding to 121.5 mg Pentoxyverine Base) in Healthy Male and Female Volunteers (Randomised, Single-blind, Placebo-controlled)||Boehringer Ingelheim||Completed|November 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02183649||41200|
NCT02183662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1277.1|Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.|Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW at 6.2 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg Dose Levels in Healthy Male Volunteers (Randomized, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|November 2009|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|105|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 7, 2014||||No||https://clinicaltrials.gov/show/NCT02183662||41199|
NCT02184559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005690-23|Postoperative Analgesia After Caesarean Section Under ALR: TAP Block Versus Catheter Scar Infiltration|Postoperative Analgesia After Caesarean Section Under ALR: TAP Block Versus Catheter Scar Infiltration||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2012|February 2015|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||July 2014|July 8, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02184559||41130|
NCT02184221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS-2010|Deep-brain Magnetic Stimulation (DMS) in the Treatment of Major Depressive Disorder|The Effectiveness of Deep-brain Magnetic Stimulation in the Treatment of Major Depressive Disorder：a Preliminary Study|DTMS|Capital Medical University|Yes|Completed|May 2010|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|No|||July 2014|July 3, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02184221||41156|
NCT02184494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014:12658|Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients|Phase 1 Study of A Double-Blind Placebo-Controlled Study of the Effect of Beta-Alanine and Whole Body Vibration on Neurologic Motoric Function, Vascular Function, and Quality of Life in Parkinson's Disease|PDMSLac|Florida State University|No|Completed|August 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|July 2, 2014||No||No|July 2, 2015|https://clinicaltrials.gov/show/NCT02184494||41135|
NCT02184767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV571-CNS-10018|Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication|A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE® (STACCATO® Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication||Teva Pharmaceutical Industries|Yes|Completed|July 2014|May 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|10 Years|17 Years|No|||February 2016|February 26, 2016|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184767||41114|
NCT02185040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-220-SLE-001|A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.|A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus||Celgene|No|Recruiting|September 2014|April 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185040||41093|
NCT02185053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC-001-07|A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia|A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia||Chase Pharmaceuticals Corporation|Yes|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|50 Years|79 Years|No|||July 2015|February 1, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02185053||41092|
NCT02193503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVX-2011-01|MVX-ONCO-1 in Patients With Solid Tumor|An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy||Maxivax SA|Yes|Recruiting|March 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02193503||40443|
NCT02194686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-BR-101-121|Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease||National Cheng-Kung University Hospital|No|Completed|January 2013|August 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|20 Years|N/A|No|||October 2015|October 11, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194686||40352|
NCT02194699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2210C00008|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist|STRATOS2|AstraZeneca|Yes|Recruiting|October 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|770|||Both|12 Years|75 Years|No|||February 2016|February 25, 2016|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194699||40351|
NCT02194972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NLY084|Clinical Effects of Soluble Dietary Fiber Supplementation|Study of Soluble Dietary Fiber on Colonic Transit Time and Clinical Symptoms in Adults With Slow-transit Constipation||Nanjing PLA General Hospital|No|Completed|May 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|78 Years|No|||July 2014|July 18, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194972||40330|
NCT02196142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068/14|Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence|Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence|CAR-Bern 2013|University Hospital Inselspital, Berne|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196142||40240|
NCT02196389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dec2013|Comparison Between 4 Different Nasal Dilators|Comparison Between 4 Different Nasal Dilators: Objective vs Subjective Parameters||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196389||40221|
NCT02196402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/2014|Narrow Band Imaging in the Prediction of Surveillance Intervals After Polypectomy in Community Practice: Ready for (a European) Prime Time|||Valduce Hospital|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|||Both|18 Years|80 Years|No|Probability Sample|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications        (screening, symptoms, surveillance).        Exclusion criteria:          -  patients with CRC history or hereditary polyposis syndromes or hereditary             non-polyposis colorectal cancer          -  patients with inadequate bowel preparation          -  patients in which cecal intubation was not achieved or scheduled for partial             examinations          -  polyps could not be resected due to ongoing anticoagulation or could not be retrieved             for pathologic assessment|July 2014|July 18, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196402||40220|
NCT02200510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K07HL108720|Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease|Patient-Provider Interventions to Improve Transition to Adult Care in SCD|iTransition|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|June 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|13 Years|24 Years|No|||July 2015|July 30, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200510||39907|
NCT02200835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHBeijing-20140701|Gender-related Differences in Chinese Patients With AAD|||General Hospital of Beijing PLA Military Region|Yes|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2015|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Chinese pupolation and foreign citizen of Chinese origin from 15 major hospitals in China|January 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200835||39882|
NCT02200822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOL-STOP-CRT|Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients|Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding Patients to Cardiac Resynchronization Therapy: the STOP-CRT Trial|STOP-CRT|Hasselt University|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200822||39883|
NCT02197000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0117-14-RMC|A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers|A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial||Rabin Medical Center|Yes|Recruiting|September 2014|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|36|||Female|18 Years|70 Years|No|||March 2016|March 17, 2016|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02197000||40174|
NCT02197273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1-14-00529|Liposomal Bupivacaine Versus Standard Analgesia in TJA|Efficacy of Liposomal Bupivacaine Versus Standard Analgesia in Pain Management of Total Joint Arthroplasty||OhioHealth|No|Recruiting|July 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197273||40153|
NCT02197286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-01127|Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia|Vitamin-D Treatment Targeted to Hyperprolinemia-Associated Schizophrenia.||New York University School of Medicine|No|Withdrawn|February 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|July 16, 2014|Yes|Yes|Personnel changes at study site.|No||https://clinicaltrials.gov/show/NCT02197286||40152|
NCT02197507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9385|Digitized Grip Strength|Evaluation of Grip Strength With Digitized Sensor in Adults With Rheumatoid Arthritis||University Hospital, Montpellier|Yes|Not yet recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|18 Years|85 Years|No|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197507||40135|
NCT02197520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15407|A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics|The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197520||40134|
NCT02197832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-VL-FETEA|A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles|A Randomized Controlled Trial on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing Frozen-thawed Embryo Transfer Treatment Cycles||The University of Hong Kong|No|Terminated|September 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|45 Years|No|||December 2015|December 10, 2015|July 20, 2014||No|Difficulty in recruiting participants.|No||https://clinicaltrials.gov/show/NCT02197832||40110|
NCT02196727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPP|Evaluation of Postoperative Pain Following Bascom Cleft Lift Operation|Evaluation of Post-operative Pain in Bascom Cleft Lift Operation Receiving Multimodal Analgesia and Spinal Saddle Block in Day Case Surgery Setting.||Hvidovre University Hospital|No|Completed|May 2013|April 2014|Actual|January 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing Bascom Cleft Lift operation in a day-case surgery setting|May 2013|July 21, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196727|1 Month|40195|
NCT02184247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1071.10|Bioavailability of Two Sustained-release Theophylline Products in Healthy Males|A Study to Compare the Bioavailability of Two Sustained-release Theophylline Products||Boehringer Ingelheim||Completed|April 1998|||May 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184247||41154|
NCT02184260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093.15|Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke|A Randomized, Multicentre, Double-blind Clinical Trial of Metamizole 2 g /8 h, I.V. Ampoules, Versus Placebo Each 8 h, I.V. Ampoules, Administered During 3 Days Consecutively as Antithermic Therapy in the Acute Phase of Ischemic Stroke. A 30-day Study. (ATIS Study)|ATIS|Boehringer Ingelheim||Terminated|December 1998|||May 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 8, 2014||||No||https://clinicaltrials.gov/show/NCT02184260||41153|
NCT02185417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|597|Diuretic Comparison Project|CSP #597 - Diuretic Comparison Project|DCP|VA Office of Research and Development|No|Not yet recruiting|April 2016|April 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|13500|||Both|65 Years|N/A|No|||February 2016|February 29, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02185417||41064|
NCT02184234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.5|Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)|A 6-week, Open, Multicentre Safety Trial to Evaluate the Tolerability Profile of Antistax® Film Coated Tablets (Extr. Vitis Viniferae Siccum), 360 mg/Day Per os, in Male and Female Patients Suffering From Chronic Venous Insufficiency||Boehringer Ingelheim||Completed|June 2001|||October 2001|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|25 Years|75 Years|No|||July 2014|July 11, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02184234||41155|
NCT02184507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-6447|Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress|Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress|ECIRRA|Shiraz University of Medical Sciences|Yes|Completed|June 2013|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|92|||Both|30 Years|70 Years|No|||October 2014|October 23, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184507||41134|
NCT02184520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS090007/A10|A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System|A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System||Globus Medical Inc|Yes|Recruiting|May 2012|||May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02184520||41133|
NCT02184780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB/2013/644/D|Impact of Perinatal Anaesthesia and Analgesia on Neurocognitive Outcomes in Early Childhood|Impact of Perinatal Anaesthesia and Analgesia on Neurocognitive Outcomes in Early Childhood (PANO Study)|PANO|KK Women's and Children's Hospital|No|Active, not recruiting|September 2013|September 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|468|||Both|2 Years|4 Years|No|Non-Probability Sample|This study involves retrospective analysis of data from an existing cohort of 600 infants        who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore        Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in        Singapore, where subjects were followed up from in-utero up to 36 months of age and        beyond. The infants have already undergone a rigorous battery of neurocognitive tests at        6, 18, 24 and 36 months of age and their detailed demographic and medical information are        available.|July 2014|February 28, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02184780||41113|
NCT02193997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203734|Constipation Fiber Trial|Double-blind, Placebo-controlled Study to Examine the Effects of Dietary Fiber in Treating Childhood Constipation||University of Iowa|Yes|Recruiting|June 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02193997||40405|
NCT02194361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1147.3|Efficacy of a Standardised Bilberry Extract in Improving the Night Vision of Healthy Volunteers|Efficacy of a Bilberry Extract Standardised to a Content of 25% Anthocyanosides in Improving the Night Vision of Healthy Volunteers: a Double-blind, Randomized, Placebo Controlled, Cross-over Trial Over 2 x 28 Days||Boehringer Ingelheim||Completed|December 1999|||July 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194361||40377|
NCT02194374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0932|Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)|A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2015|||January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194374||40376|
NCT02194387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0230|Pilot Tests to Optimize the Delivery of Energy Balance Interventions|Pilot Tests to Optimize the Delivery of Energy Balance Interventions||M.D. Anderson Cancer Center|No|Recruiting|September 2014|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|16||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194387||40375|
NCT02194400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132-02|Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus|A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus||Resolve Therapeutics|Yes|Completed|July 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194400||40374|
NCT02195895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00083759|Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide|12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide||Northwestern University|No|Enrolling by invitation|April 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||October 2015|October 7, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02195895||40259|
NCT02200731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMOS|FAMOS: Psychosocial Intervention for Childhood Cancer Survivors and Their Families|FAMOS: The Effect of Psychosocial Intervention for Childhood Cancer Survivors and Their Families: A Randomized Controlled Trial||Danish Cancer Society|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|N/A|75 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200731||39890|
NCT02197182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA 0801|LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study|An Open-Label, Randomized Study to Determine the Safety and Efficacy of LUXSOL(TM) Cream for the Treatment of Bacterial Vaginosis: A Proof of Concept Study||CDA Research Group, Inc.|No|Suspended|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||March 2015|March 20, 2015|July 20, 2014|Yes|Yes|Not for safety reasons|No||https://clinicaltrials.gov/show/NCT02197182||40160|
NCT02197195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2013-251|Sugars-sweetened Beverages and Exercise on Glycaemic Response and Subjective Appetite in Children|The Role of Chocolate Milk and Fruit Drink on Subjective Appetite and Glycaemic Response With or Without Exercise in Normal Weight 9-14 Year Old Boys||Ryerson University|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|8|||Male|9 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 20, 2014|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02197195||40159|
NCT02197429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-10-01|Acupuncture for the Treatment of Vulvodynia|Acupuncture for the Treatment of Vulvodynia||Schlaeger, Judith M., CNM, LAc, PhD|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|N/A|No|||July 2014|July 18, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02197429||40141|
NCT02197442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044-14|Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Two Formulations of Valsartan 320 mg Tablet in Healthy, Adult, Human Subjects Under Fasting Condition||Ranbaxy Inc.|No|Completed|January 2014|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197442||40140|
NCT02197715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3075|Sex and Female Empowerment|Improving Women's Sexual Health While in Drug Addiction Treatment|SAFE|University of North Carolina, Chapel Hill|Yes|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197715||40119|
NCT02197728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hohl vs Colpo Probe|Comparing Two Devices of Uterine Manipulation and Vaginal Fornix Delineation at Total Laparoscopic Hysterectomy|Comparing Two Devices of Uterine Manipulation and Vaginal Fornix Delineation at Total Laparoscopic Hysterectomy||St. Michael's Hospital, Toronto|No|Completed|February 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|91|||Female|18 Years|80 Years|No|||March 2016|March 2, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02197728||40118|
NCT02198014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTHROPATHY|Manual Therapy in Haemophilic Arthropathy of the Knee|Effectiveness of Manual Therapy and Educational Physiotherapy in the Treatment of Hemophilic Arthropathy of the Knee. A Randomized Pilot Study|ARTHROPA|Universidad Católica San Antonio de Murcia|No|Completed|January 2012|June 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Male|18 Years|75 Years|No|||June 2014|July 22, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198014||40096|
NCT02198261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-IVD-MINOXIDIL-003|Minoxidil Response Testing in Males With Androgenetic Alopecia|Minoxidil Response Testing in Males With Androgenetic Alopecia||Applied Biology, Inc.|No|Active, not recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Plucked hair follicles with visible bulbs|Male|18 Years|49 Years|No|Non-Probability Sample|Males with androgenetic alopecia|January 2016|January 29, 2016|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198261||40078|
NCT02198781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B729|Right Ventricle (RV) Markers of Future Pacing Induced Ventricular Dysfunction - Pilot|Does a Measure Exist in the Right Ventricle Which Can Act as a Surrogate Marker for Future Ventriclar Sysfunction When Pacing - a Pilot Study||Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|80 Years|No|Probability Sample|Patients who are due to undergo permanent pacemaker (PPM) implantation will be recruited        to undergo RV Pressure/Volume loop assessment and RV strain ECHO at the same time as PPM        implant for pilot data regarding the acute effects of RV pacing on RV haemodynamics|September 2015|September 18, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198781||40038|
NCT02199041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPCORD|Combined Cord Blood and Haploidentical Transplantation for Patients With Hematologic Malignancies|Combined Haploidentical and Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Reduced-Intensity Preparative Regimen||St. Jude Children's Research Hospital|Yes|Recruiting|July 2014|August 2020|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|N/A|21 Years|No|||March 2016|March 13, 2016|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199041||40018|
NCT02199054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0045|Functional Snack Foods With Safflower Oil and Soy in Postmenopausal Women Having Metabolic Syndrome|Evaluation of Functional Snack Foods Containing Safflower Oil and Soy on Endpoints of Energy Metabolism in Postmenopausal Women With Metabolic Syndrome||Ohio State University|Yes|Active, not recruiting|July 2014|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|20|||Female|45 Years|70 Years|No|||October 2015|October 2, 2015|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02199054||40017|
NCT02198118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01940107|Domiciliary Physiotherapy During Breast Cancer Radiation|Domiciliary Physiotherapy During Breast Cancer Radiation||University of Sao Paulo|Yes|Completed|January 2010|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Female|30 Years|80 Years|No|||July 2014|July 22, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02198118||40088|
NCT02199431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14380A|Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.|Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects||H. Lundbeck A/S|No|Completed|July 2014|||February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199431||39988|
NCT02199444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-C Sev|Effect of Sevelamer on P-cresol Levels in CKD|||Federico II University||Recruiting|June 2014|||May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|February 17, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199444||39987|
NCT02199678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET003|A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction|A Randomized,Double Blind, Parallel Group, Placebo Controlled Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction||Lotus Clinical Research, LLC|No|Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||July 2014|November 19, 2014|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199678||39969|
NCT02199691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET50|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents|A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents||Sanofi|No|Active, not recruiting|July 2014|November 2017|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1700|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199691||39968|
NCT02200575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.359|Pharmacovigilance and Patient Compliance in Hypertensive Patients|Pharmacovigilance and Patient Compliance in Hypertensive Patients. Observational Study||Boehringer Ingelheim||Completed|May 1999|||December 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10333|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients over 18 years of age suffering non-secondary, essential hypertension, treated        by general practitioners and/or specialists|July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02200575||39902|
NCT02200588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10PAFIP|Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP|A Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program (PAFIP)|10PAFIP|Fundación Marques de Valdecilla|No|Recruiting|September 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|277|Samples With DNA|Whole blood, plasma and serum.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the        University Hospital Marqués de Valdecilla (Santander - Cantabria).|August 2015|August 7, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200588|2 Days|39901|
NCT02199756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0370|Nanovectors to Prevent Placental Passage of Tocolytic Agents|Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent||The University of Texas Health Science Center, Houston|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|Samples Without DNA|Uterine biopsy|Female|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who will undergo elective cesarean section at term|December 2015|December 3, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199756||39964|
NCT02200055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP# 12-0050|Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need|The Use of Multifrequency Bioimpedance Assessments as an Estimate of Perioperative Total Body Volume and Postoperative Fluid Resuscitation||United States Naval Medical Center, Portsmouth|No|Completed|May 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|86|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02200055||39941|
NCT02200718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR902-007|A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis|A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis||Immune Response BioPharma, Inc.|Yes|Not yet recruiting|November 2017|November 2019|Anticipated|November 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|5 Years|17 Years|No|||February 2016|February 22, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200718||39891|
NCT02200354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEM-RE-2014|The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab|The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab for Patients With Advanced Non-squamous Non-small Cell Lung Cancer||Kobe City General Hospital|No|Recruiting|July 2014|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||January 2016|February 22, 2016|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02200354||39918|
NCT02196610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140457|Feasibility Study of Arterial Stiffness in Hemodialysis Patients|Arterial Stiffness in Healthy Subjects and Patients With End‐Stage‐ Renal Disease: A Feasibility Study||Ottawa Hospital Research Institute|No|Terminated|November 2014|October 2015|Actual|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HEALTHY SUBJECTS: 20 healthy staff volunteers.        ESRD group: 20 patients with stage 5 CKD (estimated GFR <15 ml/min/m2), who attend chronic        hemodialysis treatments at The Ottawa Hospital (TOH).|October 2015|October 21, 2015|July 18, 2014||No|Limited funds available to complete full recruitment. Enrolment achieved: 90%.|No||https://clinicaltrials.gov/show/NCT02196610||40204|
NCT02197208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-VL-NChCGFET|A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET|A Randomized Controlled Comparison of Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in Frozen-thawed Embryos Transfer||The University of Hong Kong|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|43 Years|No|||December 2015|December 10, 2015|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02197208||40158|
NCT02197455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014260|Tofacitnib for the Treatment of Alopecia Areata and Variants|Tofacitnib for the Treatment of Alopecia Areata and Variants||Yale University|No|Active, not recruiting|July 2014|||July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|90 Years|No|||December 2014|December 7, 2014|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197455||40139|
NCT02197741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schmerz_2011|The Effect of an Additional Bolus Application in Patients With Intrathecal Opiate Administration - a Pilot Study|The Effect of an Additional Bolus Application in Patients With Intrathecal Opiate Administration - a Pilot Study||Swiss Paraplegic Centre Nottwil|No|Completed|February 2012|July 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|99 Years|No|Non-Probability Sample|individuals with chronic pain syndrome|November 2015|November 16, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02197741||40117|
NCT02197754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS46|Adaptation in Polyphenol Bioavailability and Bioactivity During Long Term Exposure to Polyphenol-Rich Foods|||USDA Beltsville Human Nutrition Research Center|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197754||40116|
NCT02198027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIH-Urology-001|Peritubal Infiltration of Bupivacaine in PCNL|Role of Peritubal Infiltration of 0.25% Bupivacaine in Percutaneous Nephrolithotomy (PCNL) in Postoperative Pain Control||Indus Hospital|Yes|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|68|||Both|18 Years|60 Years|No|||September 2014|September 20, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198027||40095|
NCT02198040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELBOW|Physiotherapy in the Haemophilic Arthropathy of the Elbow.|Physiotherapy in the Treatment of Elbow Hemophilic Arthropathy: Manual Therapy vs Educational Physiotherapy. A Randomized Clinical Trial|ELBOW|Universidad Católica San Antonio de Murcia|No|Completed|January 2012|June 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Male|18 Years|75 Years|No|||June 2014|July 22, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198040||40094|
NCT02189642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00008050|Boston Children's Hospital Post Anesthesia Care Unit Outcomes Study|Evaluation of Perioperative Outcomes in Children: Creation of the Boston Children's Hospital Perioperative Outcomes Registry||Children's Hospital Boston|No|Recruiting|July 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1000|||Both|6 Months|30 Years|No|Non-Probability Sample|The investigators will enroll all patients ages 6 months to 30 years undergoing the        following qualifying surgeries:        • Genito-Urinary/Urology Department        Circumcision, Orchidopexy, Hypospadias Repair, Hernia Repair, Cystoscopy, Pyeloplasty, and        Ureteral Reimplants or Ureteral Stents        • Otolaryngology Department        Tonsil and/or Adenoid Removal, Tympanostomy, Tympanoplasty, and Mastoidectomy        • Orthopaedics Department        Hip and Knee Arthroscopies, Hardware Removal, and Tendon Lengthening        • Plastic Surgery Department        Alveolar Cleft Repair|July 2014|July 11, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189642||40739|
NCT02198248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G25051|Low-dose Glucocorticoid Vasculitis Induction Study|Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial|LoVAS|Chiba University|Yes|Recruiting|October 2014|September 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|N/A|No|||July 2015|July 27, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02198248||40079|
NCT02198521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001019 AME 339|Staged Bilateral Carpal Tunnel Release: Which Side Hurts More?|Staged Bilateral Carpal Tunnel Release: Which Side Hurts More?||Massachusetts General Hospital|No|Enrolling by invitation|July 2014|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|52|||Both|18 Years|N/A|No|Non-Probability Sample|Bilateral CTS patients undergoing bilateral carpal tunnel release|August 2015|August 4, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02198521|6 Months|40058|
NCT02198794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-20|Reducing Involuntary Movements in Tardive Dyskinesia|An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|RIM-TD|Teva Pharmaceutical Industries|No|Recruiting|October 2014|August 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198794||40037|
NCT02199067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIAG1|Measurement of Exhaled Propofol|Measurement of Exhaled Propofol During a Total Intravenous Anesthesia With Propofol and Remifentanil|PIAG1|University of Erlangen-Nürnberg Medical School|No|Suspended|July 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|arterial blood samples (serum)|Both|18 Years|80 Years|No|Probability Sample|-  patients undergoing elective surgery          -  total intravenous anaesthesia|December 2015|December 3, 2015|July 22, 2014||No|technical difficulties of probe measurement|No||https://clinicaltrials.gov/show/NCT02199067||40016|
NCT02199080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/P02/001|D-dimer Assay for the Exclusion of Intra-atrial Thrombus Risk Before Ablation of Atrial Fibrillation|Etude du Dosage Des d-dimères sériques Pour le Diagnostic d'Exclusion Des Thrombi Intra-atriaux Avant Ablation Endocavitaire de Fibrillation Atriale||Groupe Hospitalier de la Rochelle Ré Aunis|No|Recruiting|July 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199080||40015|
NCT02198612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0226|FREEDOM: "Pilot Study of the Feasibility and Safety of Resuming Early Walking After Manual Compression in Patients Treated for Peripheral Artery Disease by Endovascular Technique Involving Retrograde Femoral Puncture"|FREEDOM: "Pilot Study of the Feasibility and Safety of Resuming Early Walking After Manual Compression in Patients Treated for Peripheral Artery Disease by Endovascular Technique Involving Retrograde Femoral Puncture"|FREEDOM|Nantes University Hospital|No|Completed|March 2015|September 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198612||40051|
NCT02195999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300420|Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy|Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy|CPI|University of Florida|No|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Male|5 Years|13 Years|No|Non-Probability Sample|As the focus of this study is on validating novel measures of cardiac and respiratory        function in individuals with DMD, this study will utilize a single-group design with up to        60 males with DMD between 5 and 13 years old upon entry to the study. The participant        selection is limited to children since the detrimental effects of DMD begin in early        childhood, and the life expectancy of these boys is shortened to the early- to mid-20s.        Only males will be eligible to participate in the study because DMD is an X-linked        recessive genetic disorder that only leads to the characteristic disease in males.        Although females may be carriers, they do not exhibit the same phenotype as males.|October 2015|October 14, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195999||40251|
NCT02200263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00088335|The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism|A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)|LUVIA|Johns Hopkins University|Yes|Recruiting|November 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|12 Years|N/A|No|||August 2015|August 11, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200263||39925|
NCT02200562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI68132|Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma|A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma||University of Utah|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200562||39903|
NCT02197871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX20140718|Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD|Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial||Zhujiang Hospital|Yes|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|90 Years|No|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197871||40107|
NCT02200068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00105-40|CARNet : Self-Monitoring and Co-driving in Rheumatology With Internet : Rheumatoid Arthritis Cohort (Usual Care Study)|Usual Care Randomized Study Measuring the Impact of an Online Personal Health Record (Sanoia) in Rheumatoid Arthritis Patients on Reported Outcomes|CARNet|Association Accompagnement pour un Internet en Médecine et Santé au Service des Usagers|No|Active, not recruiting|June 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02200068||39940|
NCT02200328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA14-061|Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients|Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients: A Randomized Clinical Trial||Cleveland Clinic Florida|Yes|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|600|||Both|55 Years|N/A|No|||December 2015|December 7, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200328||39920|
NCT02200367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100205|E-mental Health Support for Rural Areas|AN e- MENTAL HEALTH COLLABORATIVE PROGRAMME TO DEPRESSION MANAGEMENT IN RURAL PRIMARY CARE IN CHILE:A PILOT CLINICAL STUDY.||University of Chile|No|Completed|January 2011|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|70 Years|No|||July 2014|July 23, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02200367||39917|
NCT02200744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/CHU/08|Incidence of Recall After Procedural Sedation With Propofol in the Emergency Department|Incidence of Recall After Procedural Sedation With Propofol in the Emergency Department|MEMOPROPO|Centre Hospitalier Universitaire de la Réunion|No|Recruiting|April 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Adults patients managed in emergency department with a procedural sedation protocol using        propofol|February 2015|February 3, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200744||39889|
NCT02196896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK-97880|Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy|Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy||Johannes Gutenberg University Mainz|No|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196896||40182|
NCT02196909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinBio-GNE|Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)||ClinBio-GNE|Institut de Myologie, France|No|Active, not recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02196909||40181|
NCT02197221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7045 01|Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma|IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma|IFM2014-02|University Hospital, Toulouse|No|Recruiting|January 2015|September 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197221||40157|
NCT02197468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/930 (REK)|Preterm Infant Gut (PINGU) - a Norwegian Multi Centre Study|Gut Microbiome Study in Preterm Infants - a Norwegian Multi Centre Study|PINGU|University Hospital of North Norway|No|Recruiting|March 2015|October 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Fecal samples for bacterial DNA analyses|Both|N/A|12 Months|No|Non-Probability Sample|Preterm infants hospitalized in 6 Norwegian NICUs; divided in one group extremely preterm        infants receiving probiotics and one group moderate preterm infants not receiving        antibiotics. A group of helathy infants from the post-natal ward will also be included|June 2015|June 1, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197468|1 Year|40138|
NCT02189044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFTM2014|Pilates and Muscle Strength Respiratory|Effects of the Method Pilates Exercises in Muscle Strength Respiratory of Elderly Women: a Clinical Trial||Universidade Federal do Triangulo Mineiro|Yes|Completed|August 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02189044||40785|
NCT02189382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014029|Evaluation of the Safety and Efficacy of an Oxalate Gel or Negative Control on Dentinal Hypersensitivity|||Procter and Gamble|Yes|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 28, 2014|July 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189382||40759|
NCT02190188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602010072014|The Influence of Wedge Insoles After Partial Meniscectomy|Effect of Orthotic Devices in the Recovery After Partial Meniscectomy||Medical University Innsbruck||Recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190188||40697|
NCT02198534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-2014-049|Comparison of the Freiburg Visual Acuity Test (FrACT) With the EDTRS- and Landoltring Charts|Comparison of the Freiburg Visual Acuity Test (FrACT) With the EDTRS- and Landoltring Charts: a) Assessment of the Inter-test Agreement and the Test-retest Reliability b) Analysis of Examinees' / Examiner's Subjective Rating and of Test Durations|FEL|Aalen University|No|Recruiting|June 2014|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|None Retained|None applicable|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmologically normal subjects|July 2014|July 22, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198534||40057|
NCT02198807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP017|Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria|A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria|FOSPIP|Jomaa Pharma GmbH|No|Active, not recruiting|March 2014|December 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|1 Year|60 Years|No|||June 2015|June 12, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198807||40036|
NCT02198820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNF-SLBO|Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome|Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome in the Saint-Luc Bouge Hospital||Astes|No|Withdrawn|October 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|All patients admitted at the Saint-Luc Bouge Hospital for a femoral neck fractures|June 2015|June 22, 2015|July 23, 2014||No|lack of investigators|No||https://clinicaltrials.gov/show/NCT02198820|1 Month|40035|
NCT02199093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Upper_limb_apraxia|Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke|Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke: Randomized Clinical Trial||Universidad de Granada|Yes|Recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|95 Years|No|||October 2015|October 21, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02199093||40014|
NCT02195739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E02311|Nicotine Replacement Therapy and Cardiovascular Disease|A Retrospective, Real-life Evaluation of the Cardiovascular Disease Risk Associated With Exposure to Pharmacological Smoking Cessation Interventions in a Representative UK Primary Care Patient Population.||Research in Real-Life Ltd|No|Active, not recruiting|September 2013|December 2014|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|61050|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|EXPOSED PATIENTS: include smokers with no recorded smoking cessation attempts using        pharmacological aids in the prior year, whose index smoking cessation attempt was assisted        by one of the following pharmacological interventions:        (i) nicotine replacement therapy as any, or a combination, of transdermal patches, nasal        spray, gum and tablets, inhaler.        (ii) Other (e.g. bupropion, varenicline).        NON-EXPOSED PATIENTS: include smokers with no recorded smoking cessation attempts using        pharmacological aids in the prior year, whose index smoking cessation attempt involved        receipt of smoking cessation advice that resulted in a quit attempt unaided by        pharmacological therapies.|September 2014|September 30, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02195739||40271|
NCT02196246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol-004|Moletest Clinical Study in Scotland|A Clinical Study to Evaluate the Ability of an iPad Based Photographic Image Analysis System to Discriminate Benign Skin Lesions From Those Considered Suspect for Melanoma||Moletest Scotland Ltd|No|Not yet recruiting|August 2014|||August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Sample of suspect lesion taken for Biopsy, sample is only retained from initial inspection      until Biopsy, not other Biospecimen retention is required|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients referred to the Dermatology Department, Lanarkshire Hospitals for assessment        of suspicious skin lesions are eligible for inclusion|July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196246||40232|
NCT02196259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U028860-MICHR-Pilot|Anesthesia and Functional Connectivity: An Analysis of fMRI Changes|Anesthesia and Brain Functional Connectivity: An Analysis of fMRI Changes in Chronic Pain and Refractory Depression||University of Michigan|No|Terminated|February 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|July 17, 2014|No|Yes|Funding cessation.|No||https://clinicaltrials.gov/show/NCT02196259||40231|
NCT02196233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60239|Surgical Treatment of Adult Trigger Finger|A Prospective, Randomized Trial Evaluating the Type of Incision on Outcomes and Patient Satisfaction in the Surgical Treatment of Trigger Finger||University of Utah|No|Enrolling by invitation|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|95 Years|No|Non-Probability Sample|All patients over the age of 18 presenting to the four attending surgeons with Trigger        Finger|February 2016|February 2, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196233||40233|
NCT02192203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202186|A Safety Study to Investigate the Skin Sensitization Potential of MFC51123|Safety Study to Investigate the Skin Sensitization Potential of MFC51123||GlaxoSmithKline|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|227|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|May 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192203||40542|
NCT02199782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCUHB - PS - CAWS - 1|Pilot Study of Cognitive Assessment in Welsh Speakers|Pilot Study of Cognitive Assessment in Welsh Speakers||National Health Service, United Kingdom|No|Not yet recruiting|February 2015|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 23, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02199782||39962|
NCT02199795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD060689|Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke|Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|May 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|21 Years|75 Years|No|||May 2014|July 22, 2014|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199795||39961|
NCT02200081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGN1703-C03|Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC|Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy|IMPULSE|Mologen AG|Yes|Active, not recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|November 5, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02200081||39939|
NCT02200341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000223|Effects of Mindfulness-based Cognitive Therapy on Brain Mechanisms in Depression|MBCT Effects on Brain Mechanisms of Interoceptive Awareness and Rumination in MDD||Massachusetts General Hospital||Recruiting|August 2015|||May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|21 Years|65 Years|No|||March 2016|March 14, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200341||39919|
NCT02200757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P2-SCLC-01|Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer|A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy||CytRx|Yes|Recruiting|September 2014|July 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200757||39888|
NCT02196623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA 7037/2-1|Hypoxia and Exercise in the Elderly|Hypoxia and Aerobic Exercise Interactions in Age-related Metabolic Muscle Dysfunction||Hannover Medical School|No|Recruiting|June 2015|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196623||40203|
NCT02196935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00369|Los Angeles Prospective GI Biliary and EUS Series|Prospective Evaluation of Pancreatic, Biliary, and Gastrointestinal Neoplasia by Endoscopic Retrograde Cholangiopancreatography (ERCP) and Endoscopic Ultrasound (EUS)||University of Southern California|No|Recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing ERCP or EUS for clinical indications|July 2014|July 19, 2014|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02196935||40179|
NCT02196948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 22/2014|Electrolysis Percutaneous Therapeutic (EPTE) for Supraspinatus Tendinopathy|Electrolysis Percutaneous Therapeutic (EPTE) for the Management of Supraspinatus Tendinopathy||Universidad Rey Juan Carlos|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02196948||40178|
NCT02197481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahykdxdefsyy10|Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial|BiClamp Forceps Liver Transection Versus Clamp Crushing Technique in Liver Resections: A Randomized Clinical Trial||The Second Hospital of Anhui Medical University|Yes|Recruiting|September 2014|February 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02197481||40137|
NCT02197767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006694|Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis|A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis||Mayo Clinic|No|Recruiting|November 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|79 Years|No|||September 2015|September 22, 2015|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197767||40115|
NCT02197780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG-2013N636|Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD|Calprotectin or Calgranulin C-test Before Undergoing Endoscopy: a Prospective Diagnostic Accuracy Study Comparing Two Fecal Biomarkers for Pediatric IBD|CACATU|University Medical Center Groningen|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|335|Samples Without DNA|Feces|Both|6 Years|18 Years|No|Probability Sample|Eligible for inclusion are consecutive children and teenagers who consult their        pediatrician and have gastro-intestinal symptoms suggestive of IBD. Participating centers        are located in the Northern and Southern region of the Netherlands and the        Flemish-speaking region of Belgium.|October 2015|October 23, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197780|6 Months|40114|
NCT02189668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00218|Non-operative Management of Pediatric Appendicitis With an Appendicoltih|Non-operative Management of Uncomplicated Appendicitis With an Appendicolth in Children||Nationwide Children's Hospital|No|Terminated|July 2014|July 2025|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|7 Years|17 Years|No|||August 2015|August 14, 2015|July 3, 2014||No|High failure rate|No||https://clinicaltrials.gov/show/NCT02189668||40737|
NCT02189941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA43-0114|Pilot Study of the Pharmacokinetic Profile of a Single Dose of Deferiprone Sustained-Release Formulation in Healthy Volunteers|Pilot Study of the Pharmacokinetic Profile of a Single Dose of Deferiprone Sustained-Release Formulation in Healthy Volunteers||ApoPharma|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189941||40716|
NCT02189954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269-GOA|Effect of Laryngeal Mask Cuff Pressure in Geriatric Patients|Effect of Laryngeal Mask Cuff Pressure on Postoperative Pharyngolaryngeal Complications in Geriatric Patients||Dokuz Eylul University|No|Completed|July 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|90|||Both|65 Years|N/A|No|||August 2015|August 5, 2015|June 28, 2014||No||No|April 26, 2015|https://clinicaltrials.gov/show/NCT02189954||40715|Limitations of our study include the lack of imaging with a fiberoptic bronchoscope after LMU placement and not evaluating the position in the hypopharynx of the supraglottic airway device in the geriatric age group.
NCT02190175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFLEC|Management of Atrial Fibrillation With Flecainide : the AFFLEC Study|Multicentre Non Interventional Study in the Management of Atrial Fibrillation With Flecainide||Hellenic Cardiovascular Research Society|No|Recruiting|June 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|144|||Both|18 Years|80 Years|No|Probability Sample|Patients with history of atrial fibrillation who are under treatment with per os        flecainide|April 2015|April 15, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02190175||40698|
NCT02189967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-PORTAF-2014|Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation|Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation||Technische Universität Dresden|Yes|Recruiting|August 2014|August 2023|Anticipated|August 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02189967||40714|
NCT02189928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC IR AOR13032|RESCUE BRAIN (REmote iSchemic Conditioning in acUtE BRAin INfarction Study)|Lower Limb Ischaemic Per-conditioning in Acute Cerebral Infarction (<H6): Multicenter Randomized Study With Stratification on IV Thrombolysis and PROBE Design (Prospective Randomized Open Trial With Blinded End-Point)|RESCUE-BRAIN|Central Hospital, Versailles|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 14, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189928||40717|
NCT02190162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-14-NHR|The Influence of Tantum Verde® on Recovery Following Tonsillectomy|A Prospective Double-blined Randomized Trial to Evaluate The Influence of Tantum Verde® on Recovery Following Tonsillectomy||Western Galilee Hospital-Nahariya|Yes|Recruiting|July 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|12 Years|N/A|No|||June 2015|June 10, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02190162||40699|
NCT02190370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THICS-Study 3|Efficacy of a Resources Activation Treatment on Tic-symptoms|Within Subject Design on the Efficacy of a Resources Activation Treatment Programme in Children and Adolescents With Tics||University of Cologne|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|18 Years|No|||July 2014|July 12, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02190370||40683|
NCT02190383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THICS-Study 2|Efficacy of a Habit Reversal Treatment on Tic-symptoms|Within Subject Design on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents With Tics||University of Cologne|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|18 Years|No|||July 2014|July 12, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02190383||40682|
NCT02196012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9271B|A Technology-Based Intervention for the Reduction of Overweight and Obesity Among College Students|"The UTK Health Study" A Technology-Based Weight Loss Intervention for the Reduction of Overweight and Obesity Among College Students."||The University of Tennessee Knoxville|No|Completed|September 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02196012||40250|
NCT02196272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAPS-001|Nurse-led Reminder Program for Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients|The Efficacy of a Nurse-led Reminder Program on Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients.||Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti||Not yet recruiting|July 2014|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02196272||40230|
NCT02196285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN 002/2014|Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella|A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults|MR|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Active, not recruiting|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196285||40229|
NCT02192216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKDM2014|The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy|The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy||Department of Public Health, Denmark|Yes|Terminated|February 2014|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 4, 2014||No|Recruiting issues and limited personel ressources|No||https://clinicaltrials.gov/show/NCT02192216||40541|
NCT02192476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPT|Efficacy of CTPT Method in the Treatment of Post Stroke Shoulder Subluxation|Efficacy of California Tri-pull Taping Method in the Treatment of Post Stroke Shoulder Subluxation- A Randomized Clinical Trial.|CTPT|Maharishi Markendeswar University|Yes|Completed|June 2013|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|70 Years|No|||July 2014|July 18, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192476||40522|
NCT02200107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-knee 015/2014|Integrated Treatment Program for Osteoarthritis of the Knee|Implementing and Evaluating Integrated Medical and Physiotherapy Treatment Program for Osteoarthritis of the Knee by Family Doctors in Primary Care Clinics||Meir Medical Center||Recruiting|September 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|155|||Both|50 Years|N/A|No|||July 2014|April 12, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02200107||39937|
NCT02200380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX301-03|A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs|A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs||Celldex Therapeutics|No|Recruiting|July 2014|September 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200380||39916|
NCT02200393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11NE458|Abdominal Functional Electrical Stimulation (AFES) to Assist Ventilator Weaning in Tetraplegia|Feasibility Study Using Abdominal Functional Electrical Stimulation (AFES) to Assist Ventilator Weaning in Tetraplegia||University of Glasgow|Yes|Completed|February 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|16 Years|N/A|No|||July 2014|July 24, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02200393||39915|
NCT02196636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29276|A Phase 1 Study of RO6806127 in Healthy Male Volunteers|A Single-center, Randomised, Double-blind, Adaptative, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics or RO6806127 in Healthy Male Subjects||Hoffmann-La Roche||Completed|July 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|37|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196636||40202|
NCT02196922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telehealth CHF Disparities|Telehealth Self-Management Program in Older Adults Living With Heart Failure in Health Disparity Communities|Telehealth Self-Management Program in Older Adults Living With Heart Failure in Health Disparity Communities||Northwell Health|No|Recruiting|January 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196922||40180|
NCT02196961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-205|Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation|Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With 3 mg/kg BW Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation|ADMEC|University Hospital, Essen|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02196961||40177|
NCT02197234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00014|Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI||AstraZeneca|No|Active, not recruiting|December 2014|April 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|150 Years|No|||February 2016|February 8, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197234||40156|
NCT02188836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FemurEMG|Electromagnetic Stimulation as Coadjuvant in the Healing of Diaphyseal Femoral Fractures|Electromagnetic Stimulation as Coadjuvant in the Healing of Diaphyseal Femoral Fractures: a Randomized Controlled Trial||Fundacion Clinica Valle del Lili|Yes|Completed|January 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|60 Years|No|||July 2014|July 11, 2014|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188836||40801|
NCT02189057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007981|A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression|A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management of Depression|MOD|Mayo Clinic|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|65 Years|No|||January 2016|January 22, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02189057||40784|
NCT02189655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140630|Diluting With Cerebrospinal Fluid Versus Traditional Intrathecal Administration: Antishivering Effects|Diluting With Cerebrospinal Fluid Versus Traditional Intrathecal Administration: Antishivering Effects||China Medical University, China|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02189655||40738|
NCT02189681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L5S1 study|Landmark Guided Midline Versus Pre-procedural Ultrasound Guided Paramedian at L5S1 for Spinal Anaesthesia|Comparison of Conventional Landmark Guided Midline (Group C) Versus Pre-procedural Ultrasound Guided Paramedian at L5S1 (Group P) Technique for Spinal Anaesthesia||Cork University Hospital|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|120|||Both|20 Years|N/A|No|||August 2015|August 26, 2015|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02189681||40736|
NCT02189980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHp2014-001|Aromatherapy Using a Nasal Clip After Surgery|Aromatherapy Using a Nasal Clip After Surgery||Balanced Health plus|Yes|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189980||40713|
NCT02189993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPN-01|Limited Long Term Survival in Patients After In-hospital Intestinal Failure Requiring Total Parenteral Nutrition|Limited Long Term Survival in Patients After In-hospital Intestinal Failure Requiring Total Parenteral Nutrition||VU University Medical Center|No|Completed|January 2010|October 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|437|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring total parenteral nutrition during in hospital admission.|July 2014|July 15, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189993||40712|
NCT02190396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT D PLACENTAL CALCIFICATION|Vitamin D Deficiency and Placental Calcification in Low-risk Obstetric Population - Are They Related?|Vitamin D Deficiency and Placental Calcification in Low-risk Obstetric Population - Are They Related?||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|None Retained|Maternal venous and umbilical cordon blood|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who admitted our clinic without foreknown systemic diseases or multiple        pregnancy.|July 2014|July 12, 2014|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02190396||40681|
NCT02190643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA035629|Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers|Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers||RAND|No|Not yet recruiting|August 2014|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190643||40662|
NCT02195765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD24|Randomized Clinical Trial of Enamel Matrix Derivative: Radiographic Analysis|Two-year Randomized Clinical Trial of Enamel Matrix Derivative Treated Infrabony Defects: Radiographic Analysis||University of Sao Paulo|No|Completed|June 2002|October 2005|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195765||40269|
NCT02196025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400335|Transcranial Magnetic Stimulation for Treatment of Insomnia|An Open Label Trial of Sequential Bifrontal Low Frequency Repetitive Transcranial Magnetic Stimulation (r-TMS) in the Treatment of Primary Insomnia|TMSI|University of Florida|Yes|Recruiting|May 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|65 Years|No|||November 2015|November 24, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196025||40249|
NCT02196298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-293|A Randomized Trial Comparing the Lokomat® With a Gait-related Physiotherapy Program in Children With Cerebral Palsy|A Randomized Cross-over Clinical Trial Comparing the Impact of the Lokomat® Gait Training System With a Gait-related Physiotherapy Program in Children With Cerebral Palsy||Holland Bloorview Kids Rehabilitation Hospital|Yes|Active, not recruiting|October 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|5 Years|12 Years|No|||August 2015|August 20, 2015|April 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196298||40228|
NCT02192242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Investigating a Model for Acute Ischemic Pain in Humans|Investigating a Model for Acute Ischemic Pain in Humans||Ludwig-Maximilians - University of Munich|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|40 Years|N/A|No|||July 2014|July 15, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192242||40539|
NCT02192229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1150-5248|Efficacy of the Dose Regimen of Oral Vitamin D 50,000 IU in the Treatment of Vitamin D Deficiency|Safety and Efficacy Evaluation of the Dose Regimen of Vitamin D 50,000 IU(Biodal) Tablet Supplementation in the Treatment of Population With Vitamin D Deficiency.||Hayat Pharmaceutical Co. PLC|Yes|Not yet recruiting|August 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02192229||40540|
NCT02192489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-220-SAR-001|A Phase 2 Study With CC-220 in Skin Sarcoidosis|A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis||Celgene|No|Withdrawn|November 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|July 15, 2014|Yes|Yes|Administrative|No||https://clinicaltrials.gov/show/NCT02192489||40521|
NCT02192983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zswy002|A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.|A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer||Shanghai Zhongshan Hospital|No|Completed|November 2008|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|242|||Both|18 Years|80 Years|No|Probability Sample|242|November 2015|November 30, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192983|5 Years|40483|
NCT02200406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI187002|Desvenlafaxine in Opioid-Dependent Patients|An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|July 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02200406||39914|
NCT02200770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-MEDI-551-1155|A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders|A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders||MedImmune LLC|Yes|Recruiting|January 2015|November 2019|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02200770||39887|
NCT02196649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2014/5/4.2(3971)|Clip Placement Following Endoscopic Mucosal Resection - Randomised Trial|Prophylactic and Endoscopic Clip Placement to Prevent Clinically Significant Post Wide Field Endoscopic Mucosal Resection Bleeding - a Randomised Controlled Trial.|CuRB|Western Sydney Local Health District|No|Recruiting|October 2014|November 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|99 Years|No|||December 2015|December 15, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196649||40201|
NCT02197247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00013|Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of Rifampicin (a CYP3A4 Inducer) on the Pharmacokinetics of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI||AstraZeneca|No|Active, not recruiting|December 2014|March 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|18 Years|130 Years|No|||January 2016|January 11, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197247||40155|
NCT02188316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNEAH-KAEK 2014/22|Comparison of Jumbo and Hot Biopsy Forceps|The Histological Quality and Adequacy of Diminutive Colorectal Polyps Resected Using Jumbo Versus Hot Biopsy Forceps||Camlıca Erdem Hospital|Yes|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02188316||40841|
NCT02189070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K13-28|The PAtient Preference Analysis of Yearly Follow-up After PCI (PAPAYA)|What Patients Really Want - Patient Preferences Regarding Annual Follow-up After Medical Interventions: The PAPAYA Study|PAPAYA|Thorax Centrum Twente|No|Completed|July 2013|September 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2566|||Both|18 Years|N/A|No|Non-Probability Sample|All patients enrolled in the percutaneous coronary intervention (PCI) studies TWENTE trial        (a broad study population reflecting real-world PCI patients) and DUTCH PEERS trial (an        all-comers populatoin), who were treated at Thoraxcentrum Twente in Enschede between June        2008 and May 2012|May 2015|May 13, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189070|1 Year|40783|
NCT02189083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-SCM-TSD2014|Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids|A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids||The University of Hong Kong|Yes|Recruiting|May 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|52 Years|No|||July 2014|July 10, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02189083||40782|
NCT02189096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VELPS|Validation of Early Warning Score & Lactate in Prehospital Screening|Validation of Early Warning Score & Lactate in Prehospital Screening|VELPS|University of the West of Scotland|No|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|705|||Both|16 Years|N/A|No|Probability Sample|Patients from five Scottish healthboard areas.|December 2015|December 4, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189096||40781|
NCT02189395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437860|Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting|Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting||Riverside County Regional Medical Center|Yes|Active, not recruiting|April 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||May 2015|May 6, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189395||40758|
NCT02189408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-Bochum|Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration|Effect of Platelet Rich Plasma ( PRP ) Applied During Knee Arthroscopy on Pain, Function and Quality of Life - A RCT With a Follow up of 12 Months|PRP-Bochum|Ruhr University of Bochum|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189408||40757|
NCT02189694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-08|Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Overnight Glucose Levels in Children With Type 1 Diabetes in a Diabetes Camp||Institut de Recherches Cliniques de Montreal|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|8 Years|17 Years|No|||September 2014|September 1, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02189694||40735|
NCT02190006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 4|Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)|Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)||Cairo University|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|20 Years|40 Years|No|Non-Probability Sample|300 women with Polycystic ovarian syndrome who are already decided to be treated with ICSI        will be recruited.|January 2016|January 26, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190006||40711|
NCT02190201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK201405001|Comparison of McGrath and Macintosh Laryngoscope for DLT Intubation|A Randomised Controlled Trial Comparing McGrath Series 5 Videolaryngoscope and Macintosh Laryngoscope for Double Lumen Tube Intubation||Huazhong University of Science and Technology|Yes|Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|70 Years|No|||November 2014|November 19, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190201||40696|
NCT02190409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-KA11/06|An Invivo Study to Compare the Stability of Dental Implants With or Without Platelet Rich Fibrin Application|The Effect Of Platelet Rich Fibrin on Implant Stability||Necmettin Erbakan University|Yes|Completed|December 2011|December 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190409||40680|
NCT02195778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 262/13|Assessment of Health Literacy Among Adult Patients in the United Arab Emirates to Facilitate Clinical Trials Recruitment.|Assessment of Health Literacy Among Adult Patients in the United Arab Emirates to Facilitate Clinical Trials Recruitment.|LIT|Tawam Hospital|No|Active, not recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||3|Anticipated|1500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult 18+|July 2014|July 18, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195778|2 Years|40268|
NCT02196038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT11443659|A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients|REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients|REHAB-HF|Wake Forest School of Medicine|Yes|Recruiting|September 2014|||November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|60 Years|N/A|No|||November 2015|November 19, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02196038||40248|
NCT02192736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-MTFAS-001|Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma|Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma||Translational Biosciences|Yes|Active, not recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|60 Years|No|||February 2016|February 4, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192736||40502|
NCT02192749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-UCMSC-ASD001|Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism|Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)||Translational Biosciences|Yes|Active, not recruiting|July 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|16 Years|No|||September 2015|September 15, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02192749||40501|
NCT02192970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW-BEARRD|Bevacizumab Against Recurrent Retinal Detachment||BEARRD|University of Wisconsin, Madison|Yes|Not yet recruiting|August 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192970||40484|
NCT02192996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP3551|Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study|Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight, a Pilot Study||Hospital Universitario La Paz|No|Completed|December 2012|July 2014|Actual|February 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|N/A|1 Week|No|||July 2014|July 16, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02192996||40482|
NCT02193243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Six-Minute Walk Test|Value of 6-minute Walk Test in Grown Ups With Congenital Heart Defects (GUCH)|The Diagnostic Value of Six-Minute Walk Test in Grown-Up Patients With Congenital Heart Disease (GUCH)||Heinrich-Heine University, Duesseldorf|No|Completed|June 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patient with Congenital Heart Disease|December 2014|December 14, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193243||40463|
NCT02200419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7495-A|POC - Transfusion Algorithm Cardiac Study|Blood Conservation in Cardiac Surgery Using a Novel Transfusion Algorithm Based on Point-of-care Testing-A Stepped-wedge Cluster Randomized Controlled Trial|TACS|University Health Network, Toronto|Yes|Active, not recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|7000|||Both|18 Years|N/A|No|||November 2015|November 28, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02200419||39913|
NCT02200783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|718016|Randomized Comparison of Radiological Exposure With TRIPTable® in Patients With Acute Coronary Syndromes|Randomized Comparison of Radiological Exposure Between Radial and Femoral Technique Assessing Use of Protective Device Dedicated TRIPTable® in Patients With Acute Coronary Syndromes Undergoing Cardiac Catheterization|TRIPTABLE|Marilia Medicine School|No|Active, not recruiting|July 2014|December 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200783||39886|
NCT02196974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24185|Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy|Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy||University of Calgary|No|Recruiting|January 2013|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|99 Years|No|||February 2016|February 8, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196974||40176|
NCT02188004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-EPI-001|The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases|The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases In Male and Female Aged Over 18 Years In China||Xiamen University|No|Active, not recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Male:Two swabs were used to collect exfoliated skin cells from the coronal sulcus      /glans/shaft and anal      Female:Three swabs were used to collect exfoliated skin cells from the vagina，vulva and anal|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|5000 healthy volunteers will be recruited from the residents of Liuzhou through        advertisment.|July 2014|December 30, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188004||40865|
NCT02188563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1407|A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers|Efficacy and Impact of a Comprehensive Smoking Cessation Intervention During Radiation for Upper Aerodigestive Cancers||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|May 2014|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188563||40822|
NCT02188862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACIFICRHDGEN|Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region|Genome-wide Association Study of Susceptibility to Rheumatic Heart Disease in Fiji and New Caledonia||University of Oxford|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2372|Samples With DNA|Blood collected from all participants for extraction of DNA|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases:          -  Prevalent and incident cases of rheumatic heart disease ascertained from disease             registers, primary care clinics and hospital services.        New Controls:          -  Individuals volunteering from communities where cases were identified.        Existing Controls:          -  Individuals from this region who have previously been recruited to population             genetics research studies.|July 2014|July 14, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188862||40799|
NCT02189122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140707|Comparative Effects of Aspirin and NHP-544C|Comparative Effects of Rapid-Release Aspirin and NHP-544C on Basal and Bradykinin Stimulated Prostacyclin Production||Vanderbilt University|Yes|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|61|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189122||40779|
NCT02189135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRFAST|Making Ramadhan Fasting a Safer Experience With Technology Study|Making Ramadhan Fasting a Safer Experience With Technology Study||Monash University|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189135||40778|
NCT02189421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHBC 2014-06-012-001|Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy|Comparison of Multibending and Conventional Ultra-slim Upper Endoscope for the Direct Advance Into the Bile Duct Without Assisting Accessory in Peroral Cholangioscopy||Soonchunhyang University Hospital|No|Active, not recruiting|April 2014|February 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Anticipated|110|||Both|20 Years|80 Years|No|||October 2015|October 30, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189421||40756|
NCT02189720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAP-001|Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients|An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus|EAP-001|Catalyst Pharmaceuticals, Inc.||Available||||||N/A|Expanded Access|N/A|||||||Both|10 Years|N/A||||February 2016|February 27, 2016|July 5, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02189720||40733|
NCT02189733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0681-C102|Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.|A Phase I, Single Center, Open-Label, Randomized, Single Dose Cross-Over Study in Healthy Male Subjects to Investigate the Bioequivalence and Tolerability of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.||Ablynx|No|Completed|July 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|November 13, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189733||40732|
NCT02190448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS2013|Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation|A Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation|SLS|Medical University of South Carolina|Yes|Completed|March 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02190448||40677|
NCT02190214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyEndo-Thyroid|Thyroid Disorders in Malaysian: A Nationwide Multicentre Study|Thyroid Disorders in Malaysian: A Nationwide Multicentre Study|MyEndo|International Islamic University Malaysia|Yes|Enrolling by invitation|August 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|2500|Samples With DNA|Whole Blood White Cell Serum Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult (aged equal or more than 18 years old ) Malaysian citizen living in Malaysia at the        time of sampling|August 2015|August 26, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02190214||40695|
NCT02190422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB944902|Effect of Assisted Reproductive Technology on Cardiac Development in Childhood Assessed by Echocardiography|Effect of Assisted Reproductive Technology on Cardiac Development in Childhood Assessed by Echocardiography|Heart and ART|Nanjing Medical University|Yes|Recruiting|June 2014|September 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|2 Years|6 Years|No|Probability Sample|ART group will be ART children conceived in Clinical Centre of Reproductive Medicine and        born in Maternal-Fetal Medicine Unit (MFMU). The controls will be the spontaneous        conception children born in the MFMU during the same period as ART group for prenatal        screening and subsequent delivery.|July 2014|July 11, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190422|3 Months|40679|
NCT02192255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-018|SUPREME-DM (Diabetes Mellitis) Treatment Study|An Intervention to Feedback 'Early' Non-Adherence Data to ImproveCardiovascular Disease Risk Factor Outcomes in Patients With Diabetes||HealthPartners Institute|No|Completed|January 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2378|||Both|18 Years|75 Years|No|||July 2014|July 15, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02192255||40538|
NCT02193009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA154364|SipSmarter: A Nutrition Literacy Approach to Reducing Sugary Beverages|SipSmarter: A Nutrition Literacy Approach to Reducing Sugary Beverages||Virginia Polytechnic Institute and State University|No|Active, not recruiting|July 2011|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|304|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02193009||40481|
NCT02192502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-973|Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients|A Randomized Controlled Investigation of the Effects of 6% Hydroxyethylstarch 130/0.4 (Voluven) on Renal Function in Patients Having Aortic Valve Replacement With or Without Coronary Artery Bypass Grafting|SHARP|The Cleveland Clinic|Yes|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|40 Years|85 Years|No|||October 2015|October 5, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192502||40520|
NCT02192515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-J081-101|A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects|A Phase 1 Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects||Eisai Inc.|No|Completed|July 2014|January 2016|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Male|20 Years|54 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192515||40519|
NCT02192762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110601002|Withdrawal Exposure With Withdrawal Regulation Training for Smoking Cessation|A Pilot Study of Withdrawal Regulation Training vs. Relaxation Training for Smoking Cessation (Withdrawal Exposure With Withdrawal Regulation Training for Smoking Cessation)||University of Alabama at Birmingham|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|April 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192762||40500|
NCT02193750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01420|Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease|Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease: A Randomized, Controlled Trial||University of British Columbia|No|Recruiting|August 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|48|||Both|19 Years|N/A|No|||February 2016|February 1, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193750||40424|
NCT02200432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14762|Patient Experience Recommender System for Persuasive Communication Tailoring|PERSPECT: Patient Experience Recommender System for Persuasive Communication Tailoring|PERSPECT|University of Massachusetts, Worcester|No|Completed|May 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|972|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 7, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02200432||39912|
NCT02200445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00009599|Low Dose IL-2 for Ulcerative Colitis|A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.||Children's Hospital Boston|Yes|Recruiting|February 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02200445||39911|
NCT02200458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1019|Near-infrared Software Performance Study|Near-Infrared Software Performance Study||Christie Medical Holdings, Inc.|No|Completed|November 2012|December 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 21, 2014|No|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT02200458||39910|
NCT02200796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tempID|Role of Dietary Protein on Satiety, Food Intake and Thermic Effect of Food|Role of Dietary Protein in a Familiar Breakfast Meal on Subjective Satiety, Food Intake and Thermic Effect of Food in Normal Weight and Overweight/Obese Children||Ryerson University|No|Recruiting|April 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|36|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02200796||39885|
NCT02188303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15247|A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants|A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of the Oxyntomodulin Analog, LY2944876, in Healthy Japanese Subjects and Healthy Non-Japanese Subjects||Eli Lilly and Company|No|Terminated|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|July 10, 2014|No|Yes|The termination criteria of the protocol was met during dose escalation.|No||https://clinicaltrials.gov/show/NCT02188303||40842|
NCT02188849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creatine elderly|Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training|Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training||University of Chile|Yes|Completed|October 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|July 10, 2014||No||No|October 1, 2015|https://clinicaltrials.gov/show/NCT02188849||40800|
NCT02188875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130024|Fitbit One and Text Messaging Prompts to Promote Physical Activity in Overweight/Obese Adults|Wearable Sensor/Device With Website (Fitbit One) and SMS Text Messaging Prompts to Increase Physical Activity in Overweight/Obese Adults: A Randomized Controlled Pilot Trial|Text2bfit|University of California, San Diego|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188875||40798|
NCT02189109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX108-GBM1B|The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma|A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme|GBM|NuvOx Pharma Pty Ltd|Yes|Recruiting|May 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|70 Years|No|||August 2014|August 25, 2014|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02189109||40780|
NCT02189148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-MOP-133672|First-trimester Prediction of Preeclampsia|First-trimester Prediction of Preeclampsia and Other Placenta-mediated Pregnancy Complications|PREDICTION|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|November 2014|March 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7600|Samples Without DNA|Maternal serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous women who will deliver in one of the participating center:        CHUL Hospital, Quebec city, QC Hôpital Saint-François-d'Assise, Quebec city, QC CHU        Ste-Justine, Montreal, QC|February 2015|February 16, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189148||40777|
NCT02189161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-253|A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia|A Safety and Tolerability Trial of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia Using the Barrx™ Ablation System||Medtronic - MITG|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189161||40776|
NCT02189434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMC 14-14|A Pilot Study to Determine the Correlation of Serum Procalcitonin Levels and Development of Sepsis in Patients Undergoing Cytoreductive Surgery|||Eastern Regional Medical Center|No|Recruiting|June 2014|||June 2016|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Collection of serum blood specimens|Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients having undergone cytoreductive surgery with or without HIPEC|November 2015|November 13, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189434||40755|
NCT02189447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC 126|Photorefractive Keratectomy and Corneal Cross-linking in Keratoconus|||The Eye Center and The Eye Foundation for Research in Ophthalmology|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02189447||40754|
NCT02189707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bifido transit 3|Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation.|Effects of 4-week Bifidobacterium-lactis HN019 Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial||Danisco Sweeteners Oy|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|228|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02189707||40734|
NCT02190240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006518-01|Effect of Complementary and Alternative Medicine on Pain Among Inpatients|Effect of Complementary and Alternative Medicine on Pain Among Inpatients||Allina Health System|Yes|Active, not recruiting|January 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|4500|||Both|18 Years|N/A|No|Non-Probability Sample|Abbott Northwestern Hospital Inpatients|January 2015|January 16, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02190240||40693|
NCT02190227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJGH-RDA|RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment|Tumor RNA Disruption Assay as a Tool to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer: Optimizing Timing of Biopsy||Jewish General Hospital|No|Completed|May 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Female|18 Years|N/A|No|||February 2015|February 2, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190227||40694|
NCT02190435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-111|Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures|Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures||William Beaumont Hospitals|Yes|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190435||40678|
NCT02190682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2062014|Data Collection for Prediction of Postoperative Chronic Pain for a Software|Data Collection for Prediction of Postoperative Chronic Pain for Establishing a Software by Using Data Mining Technology||Istanbul University|Yes|Recruiting|October 2014|December 2015|Anticipated|April 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|all cases undergoing surgery|February 2015|February 15, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190682|4 Months|40659|
NCT02192788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBRT-SG 05|Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer|Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer||Grupo de Investigación Clínica en Oncología Radioterapia|No|Recruiting|August 2014|August 2019|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Male|18 Years|N/A|No|||September 2015|September 15, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02192788||40498|
NCT02192801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-RC-0022-13-CTIL|Kidney Function in Patients With Bladder Exstrophy|Evaluation of Long-term Renal Function in Patients After Surgical Repair of Classical Bladder Exstrophy||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|1 Year|30 Years|No|Non-Probability Sample|Patients with calssic bladder exstrophy|January 2014|July 16, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02192801||40497|
NCT02193022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13045|Miltefosine for Children With PKDL|A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|730 Days|6569 Days|No|||March 2016|March 24, 2016|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193022||40480|
NCT02193256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K05AA014715|Varenicline + Prazosin for Heavy Drinking Smokers|Pilot Trial of Varenicline and Prazosin to Treat Heavy Drinking Smokers||Yale University|Yes|Recruiting|July 2014|June 2015|Anticipated|January 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193256||40462|
NCT02193516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC1413-0250CTIL|Identification of Corticomedullary Differentiation Along Different Stage of Pregnancy|||Meir Medical Center||Not yet recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|330|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women 14-24 gestational age|July 2014|July 15, 2014|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02193516||40442|
NCT02193763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC 4746|Bedside Ultrasound Assisted Pediatric Lumbar Puncture|Bedside Ultrasound Assisted Pediatric Lumbar Puncture--A Randomized Controlled Trial||Advocate Health Care|No|Suspended|August 2009|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|120|||Both|N/A|12 Months|No|||March 2016|March 1, 2016|July 13, 2014||No|PI has relocated to another institution, no other site PI to take over|No||https://clinicaltrials.gov/show/NCT02193763||40423|
NCT02193776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-005-(J-M-Pa-Z)|A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.|A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide During 8 Weeks of Treatment in Adult Subjects With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis.|NC-005|Global Alliance for TB Drug Development|Yes|Active, not recruiting|November 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|75 Years|No|||December 2015|January 12, 2016|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193776||40422|
NCT02200471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN - 13 / 04 - 01|Cosmetic Dermatology Study|Evaluation of VeinViewer in Cosmetic Dermatology||Christie Medical Holdings, Inc.|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02200471||39909|
NCT02200484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14864|Project HERA (Health, Education, and Relationship-building for Adolescents- Moms and Tots)|Helping Ethnically Diverse Teen Moms Prevent Obesity in Their Preschool Children|Project HERA|University of Massachusetts, Worcester|Yes|Completed|April 2013|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|16 Years|20 Years|No|||April 2015|April 9, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02200484||39908|
NCT02200809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/185|MR-guided Focal Laser Ablation of the Prostate|MR-guided Focal Laser Ablation of the Prostate||Radboud University|No|Recruiting|July 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||July 2015|July 1, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200809||39884|
NCT02196662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110200|Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers|Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers|IBD98-M|Holy Stone Healthcare Co., Ltd|Yes|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196662||40200|
NCT02188576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00008434|The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery|The Efficacy and Population Pharmacokinetics/ Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery||Children's Hospital Boston|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|3 Months|6 Years|No|||February 2015|February 2, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188576||40821|
NCT02188602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27752|Effect of Cumulative Chloride Dose on Development of Acute Kidney Injury in Critically Ill Children|Retrospective Investigation of Chloride Dosing and Its Effect on Acute Kidney Injury||Stanford University|Yes|Active, not recruiting|July 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1500|||Both|1 Month|18 Years|No|Non-Probability Sample|Children < 18 yo admitted to the Pediatric Intensive Care Unit at Lucile Packard        Children's Hospital with admitting diagnosis of sepsis, respiratory failure, or liver        failure|July 2014|July 10, 2014|July 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02188602||40819|
NCT02188888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2309|Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients|Heart Rate Reduction With Esmolol is Associated With Improved Arterial Elastance in Patients With Septic Shock. A Prospective Observational Study||University of Roma La Sapienza|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Septic shock patients with heart rate > of 95 bpm and requiring norepinephrine to maintain        mean arterial pressure (MAP) between 65 and 75 mmHg after at least 24 hours of hemodynamic        optimization.|August 2015|August 6, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188888||40797|
NCT02196766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVJ-EX-MKTG-1818|BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens|BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens: A Two Week Crossover Study||Coopervision, Inc.|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196766||40192|
NCT02189460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-AZ00569-38|Effect of Normal Aging on Language Processing|Cognitive Mechanisms and Cerebral Substrate of Naming Impairment During Aging. Behavior and Neuroimaging Approaches.|SEMVIE|University Hospital, Grenoble|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|60 healthy adults will participate to the study. There will be 3 age groups: 30-50, 50-70,        > 70 years. Ech group will contain 20 volunteers.        The volunteers are recruited by means of ads on Laboratory websites and Universities.|March 2016|March 4, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02189460||40753|
NCT02189746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 011|Kangaroo Mother Care to Prevent Hypothermia in Preterm Infants|A Randomized Trial of Kangaroo Mother Care to Prevent Neonatal Hypothermia - Trials 1A & 1B||University of Alabama at Birmingham|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|220|||Both|N/A|8 Weeks|No|||March 2016|March 7, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189746||40731|
NCT02197910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACCHUS_PASTATREND_2014|Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects|Association Between Consumption of Different Dosages of Bioactive Wheat Peptides and Blood Pressure (BP) Level and Other Biomarkers of Cardiovascular Disease Risk in Healthy Subjects With High-normal BP: a Double-blind, Cross-over, RCT||University of Bologna|No|Recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02197910||40104|
NCT02197325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP2014-03|Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome.|Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome. (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to pPCI in Patients With Anterior NSTEMI or Following pPCI in STEMI)||Miracor Medical Systems|No|Recruiting|January 2015|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|75 Years|No|||September 2015|September 30, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02197325||40149|
NCT02190968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH102229-01A1|Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance|Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance.||University of Toronto|Yes|Recruiting|March 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190968||40637|
NCT02190981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|615362-1|Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department|Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department||WellSpan Health|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|106|||Both|18 Years|N/A|No|Non-Probability Sample|Adult emergency department patients at a university-affiliated, community teaching        hospital with suspected small bowel obstruction|December 2015|December 8, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190981||40636|
NCT02191319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1395|Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens|Observational Study With Antiretroviral Treated Patients Switching Therapy Because of Therapeutic Reasons From Protease Inhibitor- or NNRTI-containing Regimens to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens||Boehringer Ingelheim||Completed|January 2002|||August 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|HIV treatment centres and HIV out-patient facilities|July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191319||40610|
NCT02191332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1305|Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen|Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen||Boehringer Ingelheim||Completed|December 1999|||November 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|||Both|18 Years|N/A|No|Non-Probability Sample|HIV treatment centres and HIV out-patient facilities|July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191332||40609|
NCT02192814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0024|Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures|A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization||UCB Pharma|No|Completed|June 2014|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|16 Years|N/A|No|||January 2016|January 12, 2016|July 11, 2014|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT02192814||40496|
NCT02193035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31446114.1.0000.0068|Microparticles in Severe Aortic Stenosis|Microparticles as an Inflammatory Marker in Severe Aortic Stenosis.||InCor Heart Institute|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02193035||40479|
NCT02193048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000150|Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease||PROGNOS|Ferring Pharmaceuticals||Recruiting|September 2014|July 2022|Anticipated|July 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Specialist gastroenterological centres|October 2015|October 16, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193048||40478|
NCT02193269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304011871|The Effects of Minocycline in Humans|Cognitive Effects of Minocycline in Humans||Yale University|Yes|Recruiting|July 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|21 Years|50 Years|No|||January 2016|January 8, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02193269||40461|
NCT02193529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-LSG|Dietary Intake After Laparoscopic Sleeve Gastrectomy —a 5 Year Study|Weight Loss and Metabolic Surgery Center Min-Sheng General Hospital||Min-Sheng General Hospital|Yes|Recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|morbid obesity patients received laparoscopic sleeve gastrectomy for more then 5 years.        BMI above 40 kg/m2 when operation. Age 18-65 years old.|July 2014|July 15, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02193529||40441|
NCT02193555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTC2014-02|Visual Performance of Prototype Contact Lens Designs|Visual Performance of Prototype Contact Lens Designs||Brien Holden Vision|No|Completed|July 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|91|||Both|7 Years|N/A|Accepts Healthy Volunteers|||July 2014|November 4, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193555||40439|
NCT02194023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER-ECL-2011-06-NF|Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.|Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.||Universitat Internacional de Catalunya|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|200|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02194023||40403|
NCT02191826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOMCT01-C|Study of SOM0226 in Familial Amyloid Polyneuropathy|Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity||SOM Biotech SL|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02191826||40571|
NCT02192086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fluid Kidney Transplants|Goal Directed Fluid Administration for Kidney Transplantation|The Effect of Non-Invasive Goal Directed Fluid Administration on Graft Function in Kidney Transplantation||Medical University of South Carolina|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02192086||40551|
NCT02192099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYX13-C-203|Open Label Extension for GLYX13-C-202, NCT01684163|Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)||Naurex, Inc|No|Active, not recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192099||40550|
NCT02188342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HITCa|Assessing The Effectiveness of a Preoperative High Intensity Interval Training Programme In Older Colorectal Cancer Patients|Effectiveness of Short Term, High Intensity, Interval Exercise Training in Older Colorectal Cancer Patients in Improving Preoperative Fitness|HITCa|University of Nottingham|No|Recruiting|November 2014|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|55 Years|75 Years|No|||July 2015|July 21, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188342||40839|
NCT02188589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-NVC-13001|Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse|Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse||Spirox, Inc.|No|Active, not recruiting|May 2014|November 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|ENT clinics|July 2014|November 16, 2015|July 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188589||40820|
NCT02188615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZhang|Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer|A Single Institution Prospective Randomized Controlled Clinical Trial of Neo-adjuvant Chemoradiotherapy Followed by Mckeown Minimally Invasive Esophagectomy (MIE) Versus Mckeown MIE for Locally Advanced Squamous Cell Esophageal Carcinoma|NACRFMIE|Taizhou Hospital|Yes|Recruiting|June 2011|July 2019|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|No|||July 2014|July 9, 2014|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02188615||40818|
NCT02197338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biliary Cannulation Trial|Randomized Trial of Wire and Sphincterotome Systems for Biliary Cannulation|Randomized Controlled Trial of Short Versus Long Wire and Small Versus Standard Sphincterotomes for Initial Biliary Cannulation||University of Southern California|Yes|Active, not recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|498|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197338||40148|
NCT02197078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.163|Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin|Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin||Boehringer Ingelheim||Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|500000|||Both|18 Years|N/A|No|Non-Probability Sample|T2DM patients aged 18 or older, initiating antidiabetic treatment after at least 6 months        of continuous enrollment|March 2016|March 8, 2016|July 21, 2014||||No||https://clinicaltrials.gov/show/NCT02197078||40168|
NCT02197923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/637b|Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnosis, Part 2|NAPPED II|Oslo University Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|whole blood and biopsies from uterine myometria and uterine endometria|Female|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|women referred to our clinic and volunteering to participate|January 2016|January 15, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02197923||40103|
NCT02198157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45-14-EMC|Urinary Catheterization and Second Stage of Labor|Effect of Intermittent Versus Continuous Bladder Catheterization During Labor on Second Stage Duration|cath2stage|HaEmek Medical Center, Israel|Yes|Completed|July 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 20, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198157||40085|
NCT02197572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C31002|Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197572||40130|
NCT02197585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHU|Comparison of Mesh Fixation Wit Cyanoacrylate vs Suture in Inguinal Hernia Surgery|Cyanoacrylate vs Suture for Mesh Fixation in Inguinal Hernia Surgery|UHU|Hospital del Mar|Yes|Completed|June 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Male|18 Years|N/A|No|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197585||40129|
NCT02197598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15871A|Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use|Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment||H. Lundbeck A/S|No|Completed|September 2014|||December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197598||40128|
NCT02197884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104763|A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants|An Open-Label, Fixed-Sequence Study to Assess Effects of Clarithromycin on the Single-Dose Pharmacokinetics of JNJ-54861911 in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02197884||40106|
NCT02197897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25233|Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors|Phase II Trial of Estrogen Receptor Targeted Treatment of Non-Muscle Invasive Bladder Cancer With Tamoxifen.|BCTamoxifen|Baylor College of Medicine|Yes|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|21 Years|N/A|No|||February 2016|February 23, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02197897||40105|
NCT02192827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|647430-4|Use of Dexamethasone in Pediatric Asthma Exacerbations|Efficacy of Single vs. Double Dose Dexamethasone for Mild to Moderate Asthma in a Pediatric Emergency Department||University at Buffalo|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|254|||Both|2 Years|20 Years|No|||November 2015|November 30, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192827||40495|
NCT02193568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12161|Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy|A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|April 2014|December 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|19 Years|N/A|No|||October 2015|October 21, 2015|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193568||40438|
NCT02193282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01508|Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)|Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Recruiting|August 2014|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||September 2015|January 6, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193282||40460|
NCT02193542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bwhobanes-DADB|Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients|Prospective Observation Study of Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients|DADB|Brigham and Women's Hospital|Yes|Recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant woman presenting for vaginal or cesarean delivery|July 2015|July 20, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02193542||40440|
NCT02193789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-MDB-14-059|Covered Self-expandable Metallic Stents Insertion Using Clips and Suture Materials for Preventing Migration|The Effect of Newly Designed Covered Self-expandable Metallic Stents Insertion Using Clips and Suture Materials for Preventing Migration in Benign Stricture of Gastroduodenal Anastomosis: a Pilot Study||Ajou University School of Medicine|Yes|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||February 2016|February 19, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02193789||40421|
NCT02194036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/393 (REK)|Learning Oriented Physiotherapy - a New Approach|The Effect of Learing Oriented Physiotherapy on Health-Related Functioning and Quality of Life in Patients With Various Anxiety Disorders|LOF|Central Norway Regional Health Authority|No|Enrolling by invitation|August 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02194036||40402|
NCT02194725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914149|Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy|Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy||National Institutes of Health Clinical Center (CC)||Completed|July 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194725||40349|
NCT02188017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPS|Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)|ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)|ACPS|University of Cincinnati|Yes|Recruiting|June 2014|September 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||December 2015|December 4, 2015|April 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188017||40864|
NCT02188329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHHSP23320095647WC, 23337017T|National Survey of Early Care and Education|National Survey of Early Care and Education|NSECE|National Opinion Research Center|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||4|Actual|31436|||Both|18 Years|N/A|No|Probability Sample|Households with children under 13 years. Individuals providing at least 5 hours' weekly        care to children under 13 years not their own in a home-based setting. Early care and        education centers serving children not yet in kindergarten. Individuals working in        center-based classrooms.|July 2014|July 9, 2014|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02188329||40840|
NCT02188355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T123E2|Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry|Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice|e-Ultimaster|Terumo Europe N.V.|No|Recruiting|October 2014|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|17000|||Both|18 Years|N/A|No|Probability Sample|patient 18 years or older eligible for percutaneous coronary intervention using DES|March 2016|March 15, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188355|1 Year|40838|
NCT02188368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO-CL-MM-PI-003854|Pomalidomide for Lenalidomide for Failures|A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen||Oncotherapeutics|Yes|Recruiting|August 2014|August 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188368||40837|
NCT02188628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00122|Refinement and Clinical Evaluation of the H-Man for Arm Rehabilitation After Stroke|Refinement and Clinical Evaluation of the H-Man: A Novel, Portable, Inexpensive Planar Robot for Arm Rehabilitation After Stroke||Tan Tock Seng Hospital|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|85 Years|No|||May 2015|May 12, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02188628||40817|
NCT02196493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13031|An Open Label Trial of Azithromycin in Chronic Productive Cough|An Open Label Trial of Azithromycin in Chronic Productive Cough|AZCC|University of Nottingham|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02196493||40213|
NCT02196506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-214|Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Active, not recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|837|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196506||40212|
NCT02197351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00418|Narrow Band Imaging for Gastric Neoplasia|Prospective Controlled Trial of Narrow Band Imaging for Detection of Gastric Cancer Precursors||University of Southern California|Yes|Recruiting|July 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|220|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197351||40147|
NCT02197611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haemo Adhaesione|Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia.|Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia. The Haemo-Adhaesione Questionnaire|ADHAESIONE|Universidad de Murcia|No|Recruiting|September 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Male|18 Years|65 Years|No|Non-Probability Sample|Patients with haemophilia|September 2015|October 19, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02197611|1 Day|40127|
NCT02197650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPALL 2012-10-EAP|Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase|Expanded Access Program for a Multicentre, Open, Non Randomized Study, Evaluating Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase|EAP|ERYtech Pharma||Available|February 2013|December 2016|Anticipated|December 2014|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|N/A|55 Years|No|||March 2016|March 17, 2016|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02197650||40124|
NCT02198170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-004|A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers|||Eisai Inc.|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|February 11, 2015|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02198170||40084|
NCT02198417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000911|Metformin Treatment in Polycystic Ovary Syndrome (PCOS)|Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome||Massachusetts General Hospital|No|Recruiting|July 2014|December 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|18 Years|40 Years|No|||October 2015|October 5, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198417||40066|
NCT02198677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP vs LAT|Cardiovascular Response to Two Manual Techniques for Neck Pain|Randomized Trial of Cardiovascular Response to Two Manual Techniques Non-thrust Joint Manipulation of the Cervical Spine in Patients With Non-traumatic Mechanical Neck Pain.||Azusa Pacific University|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|50 Years|No|||January 2016|January 5, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198677||40046|
NCT02198937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2014-0078|Investigation on the Effect of Smoking on the Expression of Pro- and Anti-thrombotic, Anti-oxidative, and Inflammatory Markers in Humans|||University of Zurich||Suspended|June 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150||Blood sample|Both|25 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Smokers and non-smokers|May 2015|December 3, 2015|July 21, 2014||No|Funding unclear|No||https://clinicaltrials.gov/show/NCT02198937||40026|
NCT02198950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00870-57|Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis|Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis: a Prospective, Bicentric Study||Central Hospital, Nancy, France|No|Completed|November 2009|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples Without DNA|plasmas|Both|18 Years|N/A|No|Non-Probability Sample|All patient admitted into the ICU|July 2014|July 23, 2014|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT02198950||40025|
NCT02193295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020290-20997|The Effects of a Moderate Weight Loss on Insulin Resistance|The Effects of a Moderate Weight Loss on Muscle and Liver Fat Content and Reversal of Insulin Resistance||Yale University|No|Recruiting|October 2002|October 2022|Anticipated|October 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|35|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02193295||40459|
NCT02193815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5391003|A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis|A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test||Pfizer|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193815||40419|
NCT02193802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2012-3|Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease|Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease|CHANCE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Suspended|May 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|July 16, 2014||No|Lack of enrollment, amendment to colon capsule|No||https://clinicaltrials.gov/show/NCT02193802||40420|
NCT02194426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP0250-CP101|First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients|A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours||Molecular Partners AG|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02194426||40372|
NCT02194738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01509|Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)|Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)|ALCHEMIST|National Cancer Institute (NCI)|Yes|Recruiting|August 2014|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|8000|||Both|18 Years|N/A|No|Non-Probability Sample||March 2016|March 22, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194738||40348|
NCT02195011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 189|Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases|A Two Arm Safety Study of Regorafenib Before or After SIR-Spheres Microspheres (90Y) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases||SCRI Development Innovations, LLC|No|Recruiting|June 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02195011||40327|
NCT02187757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prelip/Nutra001/PMI13|Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels|A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Safety, Efficacy and Tolerability of PreLipid®, a Twice-daily Nutritional Supplement in Subjects With Higher Than Normal Blood Lipid Levels|Prelip|PreEmptive Meds, Pvt. Ltd|Yes|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||May 2015|May 14, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02187757||40884|
NCT02187770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-000040|Precision of IMED-4 Lung Fluid Measurements|Precision of IMED-4 Lung Fluid Measurements||Intersection Medical, Inc.|Yes|Completed|July 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are admitted for inpatient management with acute heart failure syndrome with        pulmonary congestion are possible candidates for the study and shall be screened for        suitability based on the inclusion and exclusion criteria.|October 2015|October 13, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187770||40883|
NCT02188030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480.968|Individual and Group Exercise Program for Industrial Workers With CANS: Randomized Controlled Trial|Individual Exercise Program for Industrial Workers With Complaints of the Arm, Neck, or Shoulder (CANS): Study Protocol for a Randomized Controlled Trial.|Exercise|Universidade Cidade de Sao Paulo|Yes|Recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|No|||June 2014|July 9, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02188030||40863|
NCT02188381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400233|The Role of Gut Microbiota in Hypertension|The Role of Gut Microbiota in Hypertension||University of Florida|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|123|Samples With DNA|Stool Samples|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will initially enroll 10 patients without hypertension as normal controls, and        10 patients with controlled hypertension and 10 patients with resistant hypertension to        characterize gut microbiota. In addition, all patients enrolled in IRB# 102-2013 will be        approached for possible participation.|October 2015|October 1, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188381||40836|
NCT02196792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|project-ID S-20080151|Assessment of Polyethylene Wear, Migration and Clinical Outcome in Total Hip Replacement|Assessment of Polyethylene Wear, Migration and Clinical Outcome in Total Hip Replacement - A Prospective Randomized Control Trial||Odense University Hospital|Yes|Active, not recruiting|May 2009|June 2017|Anticipated|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|40 Years|70 Years|No|||July 2014|July 20, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02196792||40190|
NCT02196818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01.014.08/00|A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup|A Multi-centre, Prospective Post Marketing Surveillance Study to Assess Mid-term Performance of the Mpact Cup in Subjects Requiring Primary Total Hip Arthroplasty||Medacta International SA||Recruiting|March 2013|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||April 2015|April 14, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02196818||40188|
NCT02197091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99514|Communication Effectiveness in Cancer Treatment|A Health Services Research Study to Evaluate Communication Effectiveness in Oncology Treatment||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adults receiving cancer treatment|February 2016|February 10, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197091||40167|
NCT02197117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERIC-LYSIS|Effect of Remote Ischemic Conditioning in Heart Attack Patients|Effect of Remote Ischaemic Conditioning in STEMI Patients Treated by thromboLYSIS: A Randomised Controlled Clinical Trial (the ERIC-LYSIS Study)|ERIC-LYSIS|University College, London|Yes|Recruiting|March 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|519|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197117||40165|
NCT02197624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1206003117|Genetic Variants and Iron Absorption|Metabolic Adaptation to Plant-based Diets in Asian Populations||Cornell University|No|Completed|June 2012|May 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|57|Samples With DNA|Two 10 mL blood samples and one 3 mL blood sample were collected.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women were eligible for the study if they met the following criteria: 1) non-pregnant and        between the ages of 18~35 y; 2) of East Asian descent with both maternal and paternal        grandparents from East Asia, including China, Japan, South Korea, Vietnam, Thailand,        Malaysia and Singapore; 3) not taking any vitamin or mineral supplements for at least 1        month before the study and during the 2-week study interval; 4) no pre-existing medical        problems including malabsorption, blood disorders, ulcers, joint diseases or asthma that        might impact inflammation or Fe status; 5) not taking any prescribed medications known to        affect iron homeostasis.|July 2014|July 21, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02197624||40126|
NCT02197949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELISA|Preoperative and Intraoperative Quantification of Axillary Tumoral Load|Preoperative and Intraoperative Quantification of Axillary Tumoral Load to Reduce the Need of Axillary Lymph Node Dissection in Breast Cancer Patients With Positive Lymph-nodes at Diagnosis||Parc de Salut Mar|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer|February 2016|February 25, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197949||40101|
NCT02197962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radial Shockwave|Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis|Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis||University of Sao Paulo|Yes|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|60 Years|N/A|No|||July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02197962||40100|
NCT02197936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/637c|Norwegian Adenomyosis Study III: Peristalsis|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part III|NAPPEDIII|Oslo University Hospital|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women suffering from adenomyosis and healthy control group|August 2015|August 25, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02197936||40102|
NCT02198430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemo-HOLISTIC|Multidisciplinary Evaluation of Patients With Hemophilia|Multidisciplinary Assessment of the Physical, Functional and Psychosocial Alterations in Patients With Hemophilia. An Observational Study.|HOLISTIC|Universidad de Murcia|No|Recruiting|May 2014|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Male|8 Years|60 Years|No|Non-Probability Sample|Patients with haemophilia attending hemophilia shelters organized by the Federación        Española de Hemofilia (Fedhemo) in the Centro de Formación Permanente en Hemofilia La        Charca (Murcia, Spain).|September 2015|October 19, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198430||40065|
NCT02198690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA181357 2014P-000108|Trial of a Mammography Decision Aid for Women Aged 75 and Older|Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older||Beth Israel Deaconess Medical Center|No|Recruiting|September 2014|June 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|550|||Female|75 Years|89 Years|No|||January 2016|January 12, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02198690||40045|
NCT02198703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-Life study #3|A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia|RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOR EVALUATING THE EFFICACY OF AB-LIFE PROBIOTIC PRODUCT ON THE LDL-CHOLESTEROL REDUCTION IN THE MODERATE HYPERCHOLESTEROLEMIA||AB Biotics, SA||Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02198703||40044|
NCT02193581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS 001_HMO|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)||Orlucent, Inc|Yes|Not yet recruiting|August 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|21 Years|N/A|No|Probability Sample|Individual referred by a dermatologist or plastic surgeon for a skin biopsy or lesion        excision.|July 2014|July 15, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02193581||40437|
NCT02197793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13575|Activating Treatment as Prevention Through Community Mobilization in South Africa|Activating Treatment as Prevention Through Community Mobilization in South Africa||University of California, San Francisco|No|Recruiting|July 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2510|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197793||40113|
NCT02198053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|azliquan|the Effect Between Platelet Reactivation and Antiplatelet Drugs|Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.||Beijing Anzhen Hospital|No|Active, not recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|74|Samples Without DNA|Platelet reactivity|Both|N/A|N/A|No|Non-Probability Sample|Chinese|July 2015|July 20, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198053|1 Year|40093|
NCT02198274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152.10|Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer|A Phase II Uncontrolled Sudy to Evaluate the Antitumour Activity and Safety of Intravenous BIBH 1, Administered in a Weekly Dose of 100 mg in 12 Weeks, in Patients With Metastatic Colorectal Cancer||Boehringer Ingelheim||Completed|February 2000|||October 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198274||40077|
NCT02194049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#239|Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer|Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer||University of California, Davis|Yes|Active, not recruiting|July 2014|December 2016|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194049||40401|
NCT02194998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5329|Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy|Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Subjects With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|August 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194998||40328|
NCT02198547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarGalMg|Magnesium as Adjuvant for Sciatic Block|Evaluation of Magnesium as Adjuvant to Ropivacaine for Sciatic Block at Popliteal Level.|Mg|Campus Bio-Medico University|No|Recruiting|March 2014|March 2015|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|July 22, 2014|March 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198547||40056|
NCT02198833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC120028|Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection|Clinical Study to Assess the Efficacy of a Novel Micro-Patterned Foley Catheter to Reduce Catheter-Associated UrinaryTract Infection Among Spinal Cord Injury Patients||Baylor College of Medicine|Yes|Terminated|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|13|||Both|21 Years|N/A|No|||July 2015|July 30, 2015|July 21, 2014||No|Study catheter manufacturing issues. Poor enrollment.|No||https://clinicaltrials.gov/show/NCT02198833||40034|
NCT02187783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011XUS03|LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors|SIGNATURE|Novartis|No|Recruiting|August 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187783||40882|
NCT02188043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCueH_Relay|Project Relay Model for Recruiting Alcohol Dependent Patients in General Hospitals|Relay Model for Recruiting Alcohol Dependent Patients in General Hospitals - A Single-blind Pragmatic Randomised Trial|Relay|University of Southern Denmark|Yes|Recruiting|November 2013|October 2020|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188043||40862|
NCT02188056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-14|Observational Prospectif Monocentric Registry of Patients Suffering From VIE|Observational Prospectif Monocentric Registry of Patients Suffering From VIE|REMOTEV|University Hospital, Strasbourg, France|No|Not yet recruiting|October 2014|||August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|All patients with a venous thromboembolic event, hospitalized in the Department of        Vascular Diseases and Hypertension, UF 1311 will included in the registry prospectively.|July 2014|October 20, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02188056|1 Year|40861|
NCT02189759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 012|Kangaroo Mother Care to Prevent Hypothermia in Term Infants|A Randomized Trial of Kangaroo Mother Care to Prent Neonatal Hypothermia - Trials 2A & 2 B||University of Alabama at Birmingham|Yes|Active, not recruiting|June 2014|December 2017|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|N/A|2 Weeks|No|||January 2016|January 29, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189759||40730|
NCT02189772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL015|Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects|Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention Deficit Hyperactivity Disorder||Alcobra Ltd.|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|13 Years|17 Years|No|||December 2014|March 3, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189772||40729|
NCT02196545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTDEM-001|Physical Activity Training Program for Patients With Alzheimer's Dementia|An Easily Accessible Physical Activity Training Program for Patients With Alzheimer's Dementia: Effect on Clinical and Neurobiological Parameters (MOTODEM)|MOTODEM|Technische Universität Dresden|No|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|55 Years|N/A|No|||July 2014|July 18, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02196545||40209|
NCT02196558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6011-J081-103|A Phase 1/2 Study of E6011 in Japanese Subjects With Rheumatoid Arthritis|A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis||Eisai Inc.|No|Recruiting|June 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|33|||Both|20 Years|64 Years|No|||January 2016|January 19, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196558||40208|
NCT02197104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITO-123|Citocoline for Treatment of FXTAS|Phase 2 Study of Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome||Rush University Medical Center|Yes|Not yet recruiting|September 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197104||40166|
NCT02197377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/2009|The Laryngeal Mask Airway in Edentulous Geriatric Patients|Comparison of The Laryngeal Mask Airway Supreme™ Versus Unique™ in Edentulous Geriatric Patients||Dokuz Eylul University|No|Completed|August 2009|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|60|||Both|65 Years|N/A|No|||July 2014|July 22, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197377||40145|
NCT02197364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL-6_20140715|The Role of KL-6 in the Clinical Diagnosis of ILD|The Role of KL-6 as a Serum Biomarker in the Clinical Diagnosis of Interstitial Lung Diseases (ILD) in China||Shanghai Pulmonary Hospital, Shanghai, China|Yes|Completed|December 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1190|Samples Without DNA|The residual serums in the clinical laboratory.|Both|14 Years|90 Years|No|Non-Probability Sample|The serums from clinical laboratory of Shanghai Pulmonary Hospital, Nanjing Drum Tower        Hospital and Beijing Chaoyang Hospital.|July 2014|July 18, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02197364||40146|
NCT02197637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVIMA-1210|Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma|Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma|OVIMA-1210|Centre Oscar Lambret|Yes|Recruiting|May 2014|November 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|6 Years|17 Years|No|||January 2016|January 5, 2016|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02197637||40125|
NCT02197676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-110|A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response|A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response||Groupe Francophone des Myelodysplasies|No|Recruiting|August 2014|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02197676||40122|
NCT02198196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT007845-01A1|Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs|Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs||Alere Wellbeing|Yes|Completed|August 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198196||40082|
NCT02198183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003|Total Shoulder Arthroplasty Near-infrared Spectroscopy|The Effects of Positive-pressure Ventilation on Cerebral Oxygenation and Cardiac Output in Total Shoulder Arthroplasty.|TSA NIRS|Hospital for Special Surgery, New York|No|Completed|July 2014|October 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Total shoulder arthroplasty patients who are receiving surgery at the Hospital for Special        Surgery|February 2016|February 11, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02198183||40083|
NCT02198443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRIB-PEP|Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.|Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.|STRIB-PEP|Fundacion Clinic per a la Recerca Biomédica|No|Not yet recruiting|October 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198443||40064|
NCT02198456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol PARIS3D|Imaging Control Study, 3D Echo, MR and RHC.|Prostanoid Therapy in Severe Pulmonary Arterial Hypertension - Imaging Control Study, 3D Echo, MR and RHC.|PARIS|Elisabethinen Hospital|No|Recruiting|July 2014|September 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|pulmonary arterial hypertension WHO group I|August 2014|August 1, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198456||40063|
NCT02197806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-007|Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia|||Allergan|No|Completed|July 2014|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|65|||Both|40 Years|55 Years|No|||October 2015|October 30, 2015|July 21, 2014|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT02197806||40112|
NCT02198066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-2014-1|A Comparison of Post-Sternotomy Dressings|A Comparison of Post-Sternotomy Dressings||Carilion Clinic|No|Completed|July 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|351|||Both|21 Years|N/A|No|||March 2014|July 21, 2014|March 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02198066||40092|
NCT02198079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090499|A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida|A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida||University of Miami|No|Completed|March 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|85|None Retained|one sputum, throat, or bronchoalveolar lavage|Both|N/A|18 Years|No|Non-Probability Sample|Patients with Cystic Fibrosis aged from 0 to 18 years.|May 2015|May 22, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02198079||40091|
NCT02198287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1150.7|Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers|A Single Increasing Dose Safety and Tolerability Study (Dose Extension) After Inhalational Administration of BIIX 1 XX (Single Doses: 800 - 2000 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)||Boehringer Ingelheim||Completed|January 1999|||April 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198287||40076|
NCT02198560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL-1|RS-3000 Lite Agreement Study|||Nidek Co. LTD.|No|Completed|August 2014|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal (Eyes without pathology)|September 2014|September 9, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02198560||40055|
NCT02198573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHO_3DF_2013_day3|Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar|Molecular Assessment of Artemisinin Resistance Markers, K13 Kelch Propeller and Multi-drug Resistant Gene Polymorphism in Eastern and Western Border Areas of Myanmar||Department of Medical Research, Lower Myanmar|Yes|Completed|July 2013|June 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|91|Samples With DNA|dried blood spot|Both|2 Years|N/A|No|Probability Sample|All of the malaria suspected cases were invited to participated in this study from        Myanmar-Thailand border and Myanmar-Bangladesh border.|July 2014|July 22, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198573||40054|
NCT02199119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2013-120|Effect of Television Viewing and Exercise on Appetite, Satiety, and Food Intake in Children|Effect of Television Viewing During Exercise on Subjective Appetite, Satiation, and Food Intake in 9 to 14 Year Old Children||Ryerson University|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|13|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02199119||40012|
NCT02199132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT_ORL14_YE1|Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli|Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli||Corporacion Parc Tauli|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed of Nasopharyngeal Carcinoma at Ear-Nose-Throught Department at        Corporació Sanitària Parc Taulí from 1993 to 2013|July 2015|July 31, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199132||40011|
NCT02187796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0214.24s|Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic|PREVALENCE of HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) in a SCHOOL of MEDICINE HIV/AIDS OUTPATIENT CLINIC|HAND|East Tennessee State University|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|50|||Both|25 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|HIV+ individuals and Healthy controls (HIV-, age and gender matched)|August 2015|August 3, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187796||40881|
NCT02187809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14362B|Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome||H. Lundbeck A/S|Yes|Terminated|March 2015|||October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|1 Year|16 Years|No|||January 2016|January 29, 2016|July 9, 2014|Yes|Yes|The study was terminated due to recruitment challenges|No||https://clinicaltrials.gov/show/NCT02187809||40880|
NCT02188069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00968|Canadian SCAD Study|Canadian Spontaneous Coronary Artery Dissection (SCAD) Cohort Study||Cardiology Research UBC|No|Recruiting|June 2014|December 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|N/A|No|Probability Sample|Prospective patients presenting with Spontaneous coronary artery dissection (SCAD)|September 2015|September 24, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188069|3 Years|40860|
NCT02188082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSQYFBLDHF2013|Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）|Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）|FIRST|Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|May 2014|||August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|75 Years|No|||May 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188082||40859|
NCT02188095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1401|Post Market Clinical Follow-Up Study of Excia T® Hip Prosthesis|Post Market Clinical Follow-Up Study of Excia T® Hip Prosthesis||Aesculap AG|No|Active, not recruiting|September 2014|July 2018|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2016|January 14, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02188095||40858|
NCT02196519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-106-0028|Clinical Evaluation of Cohera Sylys Surgical Sealant as an Adjunct to Standard Bowel Anastomosis Closure|||Cohera Medical, Inc.|Yes|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196519||40211|
NCT02196779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swanson 003|Laser Fluorescent Imaging of Abdominal Skin During Abdominoplasty|Laser Fluorescent Imaging of Abdominal Skin During Abdominoplasty||Swanson Center|No|Completed|July 2014|November 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult men and women undergoing abdominoplasty.|November 2014|November 18, 2014|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02196779|6 Months|40191|
NCT02196844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0036|Yoga Program for Lung Cancer Patients and Caregivers|Couple-Based Yoga Program for Patients Receiving Thoracic Radiation and Their Family Caregivers||M.D. Anderson Cancer Center|Yes|Recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196844||40186|
NCT02196857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0076|Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation|Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196857||40185|
NCT02196831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01AI115711|Tesamorelin Effects on Liver Fat and Histology in HIV|Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant||Massachusetts General Hospital|Yes|Recruiting|July 2015|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196831||40187|
NCT02197130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241021|Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease|A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease||Pfizer|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|260|||Both|30 Years|65 Years|No|||March 2016|March 22, 2016|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197130||40164|
NCT02197143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDhayri84|A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain|A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain: A Double-Blind, Randomized, Controlled Trial||Pamukkale University|Yes|Completed|March 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|286|||Both|18 Years|60 Years|No|||July 2014|July 18, 2014|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197143||40163|
NCT02197156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN154088-201|A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Active Comparator Study of Hydrocodone Bitartrate Extended Release (HC-ER) in Adults Following Bunionectomy Surgery||Zogenix, Inc.|No|Completed|August 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|241|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197156||40162|
NCT02197663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC2-015|Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident|Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident||China Medical University Hospital|No|Terminated|April 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|N/A|No|||October 2015|October 20, 2015|June 8, 2014||No|the numbers of drop-out patients are more than we anticipate|No||https://clinicaltrials.gov/show/NCT02197663||40123|
NCT02198235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-017|Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)|Prolonged Popliteal Fossa Nerve Blockade||Hospital for Special Surgery, New York|No|Completed|October 2012|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|90|||Both|18 Years|75 Years|No|||July 2015|January 29, 2016|September 21, 2012||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT02198235||40080|
NCT02197975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010003-00|Randomized, Crossover Safety and Pharmacokinetics Study of PT010|A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days||Pearl Therapeutics, Inc.|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197975||40099|
NCT02198469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUderma-03|Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis|A Randomized, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment for Actinic Cheilitis||Dong-A University|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|92 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198469||40062|
NCT02198729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/10/4.2(3830)|Comparison Rectal Endoscopic Submucosal Dissection to Endoscopic Mucosal Resection|Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection for Sessile Polyps and Laterally Spreading Lesions of the Rectum - a Prospective Randomised Trial|RESDEMR|Western Sydney Local Health District|Yes|Recruiting|July 2014|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|99 Years|No|||December 2015|December 15, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02198729||40042|
NCT02198742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H28224|A Comparison Between Two Video Laryngoscopes,in Successfully Intubating Pediatric Mannequins w/wo Difficult Airways|A Comparison Between Two Video Laryngoscopes,the Truview PCD and the Glidescope Cobalt AVL, in Successfully Intubating Pediatric Mannequins With and Without Difficult Airways||Baylor College of Medicine|No|Completed|June 2013|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198742||40041|
NCT02197819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EERAADS|A Randomized Evaluation of Emergent Immobilization in External Rotation in the Management of Acute Anterior Dislocations of the Shoulder||EERAADS|St. Michael's Hospital, Toronto|No|Recruiting|February 2013|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|40 Years|No|||December 2015|December 2, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197819||40111|
NCT02198339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.2|Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache|A Phase II a, Double-Blind, Randomised, Group Sequential Adaptive Assignment Design Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Seven Fixed Doses of Intravenous BIBN 4096 BS Ranging From 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attach of Acute Migraine Headache||Boehringer Ingelheim||Completed|February 1999|||December 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||July 2014|July 22, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198339||40072|
NCT02198352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.1|Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind, Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intravenous Administration of BIBN 4096 BS (Dosage: 0.1 - 10 mg)||Boehringer Ingelheim||Completed|June 1998|||August 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198352||40071|
NCT02198300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.1|DES Versus BiOSS LIM - POLBOS II Study|Regular Drug Eluting Stent Versus Dedicated Bifurcation Sirolimus-eluting Stent BiOSS LIM in Coronary Bifurcation Treatment - Randomized POLBOS II Study.|POLBOS II|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland|No|Completed|November 2012|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|90 Years|No|||July 2015|July 28, 2015|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02198300||40075|
NCT02198313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1150.3|A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers|A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX (100 µg, 200 µg, 400 µg b.i.d. for 14 Days ) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel-group)||Boehringer Ingelheim||Terminated|April 1999|||April 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|8|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198313||40074|
NCT02198846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU_PUMP1|A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes|A Study to Compare the Efficacy and Safety of Insulin Pump Treatment in Patients With Uncontrolled Type 2 Diabetes Mellitus||Konkuk University Medical Center|No|Recruiting|June 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|85 Years|No|||July 2014|July 23, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198846||40033|
NCT02199145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-05|Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy|Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA|SOURIS|Centre Hospitalier Universitaire de Nice|No|Recruiting|July 2015|October 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199145||40010|
NCT02199158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iridoplastiaeca|Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent Iridotomies|Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent Iridotomies An Anterior Segment Optical Coherence Tomography Study|ALPIECA|Instituto de Oftalmología Fundación Conde de Valenciana|No|Completed|July 2012|January 2013|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02199158||40009|
NCT02189187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34AT006963|Keeping Weight Off: Brain Changes Associated With Healthy Behaviors|Keeping Weight Off: Brain Changes Associated With Healthy Behaviors||University of Massachusetts, Worcester|Yes|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02189187||40774|
NCT02189473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO 200901|Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression|Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression (10 x 3 Gy Versus 5 x 4 Gy)|SCORE-2|University of Schleswig-Holstein|Yes|Completed|September 2010|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|89 Years|No|||September 2015|September 21, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02189473||40752|
NCT02196532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYF20140717|Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies|Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies||Wenzhou Medical University|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Migraine patients and healthy subjects were included and underwent OCT examinations|July 2014|July 21, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196532||40210|
NCT02196805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-09-801-01|A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers|||Otsuka Beijing Research Institute|No|Completed|March 2009|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 20, 2014|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT02196805||40189|
NCT02196584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00021075|Clinical Evaluation of the RAVI-Guide|Clinical Evaluation of the Rapid Access Vitreal Injection Guide (RAVI-Guide)||Medical College of Wisconsin|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years of age or older who undergo intravitreal injection|December 2015|December 4, 2015|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02196584||40206|
NCT02196597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGNM_ARM|Value of Anorectal Manometry Before Ileo- or Sigmoidostomy Closure After Rectal Resection|Prospective Multi-center Evaluation of the Value of Anorectal Manometry Before Closure of Protective Ileostomy or Sigmoidostomy After Rectal Resection in Patients With Rectal Carcinoma||German Society for Neurogastroenterology and Motility|No|Recruiting|January 2013|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|all patients operated for rectal carcinoma in three German centers|July 2014|July 18, 2014|November 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02196597||40205|
NCT02196870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chest wall Elastance in ARF|Effects of Chest Wall Elastance on Pulmonary Mechanics of Acute Respiratory Failure (ARF)|Physiological Effects of Chest Wall Elastance on Pulmonary Mechanics of Acute Respiratory Failure Patientstranspulmonary Pressure||Southeast University, China|Yes|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|85 Years|No|Probability Sample|acute respiratory failure patients|June 2015|June 23, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02196870|3 Years|40184|
NCT02197403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|an00543|Paradoxical Excitement Response During Sedation Between Dexmedetomidine and Propofol in Hazardous Alcohol Drinker|Comparative Study on Development of Paradoxical Excitement Response During Sedation Using Dexmedetomidine or Propofol in Hazardous Alcohol Drinkers|DEX|Chonnam National University Hospital|Yes|Recruiting|December 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|110|||Both|19 Years|65 Years|No|||March 2015|March 6, 2015|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197403||40143|
NCT02197416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.108|Safety of Dabigatran Etexilate in Blood Clot Prevention in Children|Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years||Boehringer Ingelheim||Recruiting|September 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|N/A|17 Years|No|||March 2016|March 21, 2016|July 21, 2014||||No||https://clinicaltrials.gov/show/NCT02197416||40142|
NCT02197390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18DP003377-03|An Ecological Approach to Addressing Childhood Obesity Issues in Imperial County|An Ecological Approach to Addressing Childhood Obesity Issues in Imperial County|Our Choice|San Diego State University|Yes|Active, not recruiting|May 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1184|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02197390||40144|
NCT02198495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPEFER|Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients|Continuous Versus Periodic Intravenous Iron Supplementation in Maintenance Hemodialysis Patients|COPEFER|Medical University of Vienna|No|Recruiting|September 2014|||November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02198495||40060|
NCT02198209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1138-7223|Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation|Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation||Cedars-Sinai Medical Center|No|Recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|65 Years|No|||July 2014|July 22, 2014|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198209||40081|
NCT02198482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 20-13|Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)||University of Ulm|Yes|Not yet recruiting|February 2016|August 2021|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|264|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198482||40061|
NCT02198755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-Osteo-HRUS-0601|Detection of Osteomyelitis Using High Resolution Ultrasound|Sensitivity, Specificity and Predictive Value of High Resolution (B-Mode) Ultrasonography (HRUS) for the Detection of Osteomyelitis in Chronic Wound Patients||Calvary Hospital, Bronx, NY|No|Not yet recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|85 Years|No|||July 2014|July 23, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198755||40040|
NCT02198092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816593|Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes|Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes|Septin9|University of Pennsylvania|No|Recruiting|July 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|46|Samples With DNA|Blood samples will be used as per the study protocol. Consented subjects will provide at      least 10 ml but not more than 20 ml (for repeating testing) of blood at each time point for      Epi proColon testing. An additional volume of up to 10 ml anticoagulated blood will be drawn      for circulating colonic epithelial cell analysis at each time point. Blood samples will be      stored and will only be used in future research with the express written permission of study      subjects. Subjects may withdraw consent from the study or for future use of blood samples at      any time.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Age > or = to 18 years of age Clinical diagnosis of familial adenomatous polyposis        Clinical diagnosis of Lynch syndrome Clinical diagnosis of MYH-associated polyposis and        presence of more than 20 colon polyps Genetically related family member of patients with        clinical diagnosis of FAP for Control group|December 2015|December 1, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198092||40090|
NCT02198326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.3|Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intranasal Administration of BIBN 4096 BS (Dosage: 2.5 - 20 mg)||Boehringer Ingelheim||Completed|July 1999|||August 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 22, 2014||||No||https://clinicaltrials.gov/show/NCT02198326||40073|
NCT02198378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7050 01|Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.|Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.|SCADOLII|University Hospital, Toulouse|No|Recruiting|November 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|684|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02198378||40069|
NCT02198586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI/FBB 2014|Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old|Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old||Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Completed|April 2014|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|575|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population of this study is 45 to 75 years old at the time of inclusion in the parent        study (ClinicalTrials.gov ID: NCT01835717), mostly sons and daughters of AD patients.|January 2016|January 19, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02198586||40053|
NCT02198859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13582|Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer|Phase 1 Study of Evaluation of Lithium and it's Effect on Clinically Localized Prostate Cancer.||University of Kansas Medical Center|Yes|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||July 2014|March 31, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02198859||40032|
NCT02196753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.32/V/2014|PET CT in Suspected CIED Infection, a Pilot Study - PET Guidance I|Positron Emission Tomography Combined With Computed Tomography (PET CT) in Suspected Cardiovascular Implantable Electronic Device Infection, a Pilot Study - PET Guidance I|PET Guidance I|Institute of Cardiology, Warsaw, Poland|No|Recruiting|March 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Study group - twenty pts with implanted CIEDs and suspected or diagnosed CIED-related        infection or fever of unknown origin.        Control group - twenty pts with implanted CIEDs who underwent PET CT due to non infectious        indications and have no data for infectious process in follow-up.|May 2015|May 27, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02196753||40193|
NCT02200289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1215|In Utero Household Air Pollution Exposure and Lung Development in Ghana|In Utero Biomass Smoke Exposure, Pro-oxidant/Antioxidant Imbalance and Lung Function in Rural Ghana||Icahn School of Medicine at Mount Sinai|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Cord blood, placenta|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mother-infant pairs are recruited from the Ghana Randomized Air Pollution and Health Study        (GRAPHS). GRAPHS participants are from the Kintampo Health Research catchment area in        rural Ghana, which comprises a population of 146,000 people.|November 2015|November 23, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200289||39923|
NCT02200627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00015|Forxiga Tablets Specific Clinical Experience Investigation for Elderly|Forxiga Tablets Specific Clinical Experience Investigation for Elderly||AstraZeneca|No|Active, not recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Forxiga for the first time during three months after the launch due        to type 2 diabetes mellitus, which is the indication of the drug, aged 65 or over at the        time when Forxiga was started.        In addition, patients receiving the study drug of Forxiga before the launch should be        included also.|January 2016|January 11, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200627||39898|
NCT02200640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.343|A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring||Boehringer Ingelheim||Completed|March 2000|||December 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|333|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02200640||39897|
NCT02200692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/607|Allergic Transfusion Reactions in Plasma Transfusion|Risk Factors for Allergic Transfusion Reactions in Patients Receiving Plasma Transfusion||Haukeland University Hospital|No|Active, not recruiting|June 2014|June 2016|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Samples from patients receiving plasma transfusion and samples from plasma units transfused.|Both|N/A|N/A|No|Non-Probability Sample|Patients receiving plasma transfusion, mainly in relation to cardiac surgery|January 2016|January 28, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02200692||39893|
NCT02200705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMBC-02|Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial|Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)||IceCure Medical Ltd.||Recruiting|October 2014|July 2021|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|65 Years|N/A|No|||January 2016|January 17, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02200705||39892|
NCT02196883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|593154-1|Steroid Injections Given at the "Level of MRI Pathology" Versus at the "Level of Clinical Symptoms" to See if One is More Effective Than the Other.|A Prospective, Randomized, Single Blind Study Comparing Transforaminal Epidural Steroid Injections at the Level of MRI Pathology vs Clinical Symptoms||State University of New York - Upstate Medical University|Yes|Recruiting|May 2014|||May 2015|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|2||||||Both|21 Years|N/A||||July 2014|July 21, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02196883||40183|
NCT02197169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2401BT-IFN-001|DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors|A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)|TARGET-I|DNAtrix, Inc.|No|Recruiting|August 2014|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02197169||40161|
NCT02197702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVA|Vitamin D in Preschoolers With Viral-induced Asthma|Vitamin D In the Prevention of Viral-induced Asthma of Preschoolers: a Randomised Controlled Trial (RCT)- (DIVA)|DIVA|St. Justine's Hospital|Yes|Not yet recruiting|September 2014|August 2018|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|1 Year|5 Years|No|||July 2014|July 22, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02197702||40120|
NCT02197689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 99-2218-E-038-001|A Trial for a Personalized Medication Management Platform to Improve Medication Adherence|Mobile Intelligent Personal Medication Management Platform||Taipei Medical University|No|Completed|January 2010|November 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|763|||Both|20 Years|N/A|No|||June 2014|July 22, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02197689||40121|
NCT02197988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-218|TAP Versus Thoracic Epidural in Major Abdominal Resections|Efficacy and Safety of Transversus Abdominis Plane Blocks Versus Thoracic Epidural Anesthesia in Patients Undergoing Major Abdominal Resections: A Prospective, Randomized Controlled Trial||Spectrum Health Hospitals|No|Recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02197988||40098|
NCT02198001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B403201318408|Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction|Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy|PRF|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|50 Years|N/A|No|||July 2014|July 22, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198001||40097|
NCT02198508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-096-IRB-037|Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients|The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.||China Medical University Hospital|Yes|Completed|July 2007|||July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02198508||40059|
NCT02198768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12-03A|Ankle Fracture vs Ankle Fracture-Dislocation|Functional Outcome After Ankle Fractures and Ankle Fracture-Dislocations: A Prospective Study||Carolinas Healthcare System|Yes|Active, not recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Population will be selected from Carolinas Medical Center Level I Trauma Center.|February 2016|February 11, 2016|March 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02198768||40039|
NCT02199028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28949|Hyaluronidase Effect on Infusion Set Life|Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Hyaluronidase Study||Stanford University|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|45 Years|No|||September 2014|March 31, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199028||40019|
NCT02197546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB 57/10|Acupuncture for Pain During Injection of Local Anaesthetic|Acupuncture Reduces Pain and Autonomous Distress During Injection of Local Anaesthetic in Children - a Randomised Crossover Investigation|AcuDent|University Medicine Greifswald|No|Completed|July 2010|November 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|4 Years|17 Years|No|||July 2014|July 21, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02197546||40132|
NCT02198885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST-01|Comparing Use of a Prehospital Ultrasound System and Standard Prehospital Care in Thoracoabdominal Trauma|Post-marketing, Single-center, Controlled, Open-Label, Feasibility Study Comparing Use of a Prehospital Ultrasound System and Standard Prehospital Care in Patients With Thoracoabdominal Trauma.|FAST-01|University of Saskatchewan|No|Enrolling by invitation|August 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients, presenting with blunt or penetrating trauma to the thorax or abdomen, that        are being transported by MD Ambulance to Royal University Hospital where the hospital trip        is expected to take longer than 10 minutes.|December 2015|December 2, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02198885||40030|
NCT02199184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0123|Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)|Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia||M.D. Anderson Cancer Center|No|Recruiting|January 2015|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||February 2016|February 8, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199184||40007|
NCT02199197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI68770|Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer|A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer||University of Utah|Yes|Recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|April 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199197||40006|
NCT02199977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052602|Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector|Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector||Duke University|No|Completed|June 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|444|||Both|1 Year|N/A|No|||December 2015|December 14, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199977||39947|
NCT02200302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF - 02|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|MID-C|Apifix|No|Not yet recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|11 Years|20 Years|No|Non-Probability Sample|The study is designed as a European, observational study with a 12-month follow-up period.        Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice        will be included during a 6-month enrollment period.|January 2015|January 13, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200302|1 Year|39922|
NCT02200653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.344|A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomised, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 or 80 mg p.o. Once Daily) and COZAAR® / LORZAAR® (Losartan) (50 or 100 mg p.o. Once Daily) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (TOPAS STUDY = Telmisartan and LOsartan ComParative ABPM Study)|TOPAS|Boehringer Ingelheim||Completed|May 2000|||February 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|387|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02200653||39896|
NCT02200666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00014|Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use|Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use||AstraZeneca|No|Recruiting|October 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Forxiga for the first time due to type 2 diabetes mellitus, which is        the indication of the drug.|March 2016|March 2, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200666||39895|
NCT02200679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302002|National Study on Autism Spectrum Disorder in China|Study on Approach and Standards for Diagnosis, Prevention and Control of Autism Spectrum Disorder in Children in China||Fudan University|Yes|Recruiting|January 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|120000|Samples With DNA|whole blood 2*5ml, (isolate Plasma, Serum and white cell) Hair, Urine(biosample will be      collected only for Cases 1200 +Controls 1200)|Both|6 Years|12 Years|No|Non-Probability Sample|Community-based populations aged 6-12 years old form 8 cities in China|October 2014|October 30, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200679||39894|
NCT02200315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSWEET-01|No Antimicrobial Prophylaxis for Laparoscopic Distal Gastrectomy|Phase II Study of the Efficacy of no Antimicrobial Prophylaxis Use for Laparoscopic Distal Gastrectomy for Gastric Carcinoma|KSWEET-01|Korean South West East Gastric Surgery Group|Yes|Completed|May 2014|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200315||39921|
NCT02196571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impuls001|Structured Aerobic and Resistance Exercise and Gestational Diabetes|The Impact of Structured Aerobic and Resistance Exercise on the Course and Outcome of Gestational Diabetes Mellitus||Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse|No|Active, not recruiting|January 2014|May 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02196571||40207|
NCT02171819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVAC A/H5N1|Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC in Healthy Adult Volunteers in Vietnam||Institute of Vaccines and Medical Biologicals, Vietnam|Yes|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2014|November 17, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02171819||42105|
NCT02172053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|454.709|Resistance Exercise to Improve Fatigue in Workplace (REW)|Effectiveness of a Resistance Training Program in the Workplace to Muscle Fatigue Control in Industrial Workers: Cluster Randomized Controlled Trial.|REW|Universidade Cidade de Sao Paulo|Yes|Active, not recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|352|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02172053||42087|
NCT02172612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0461-F3R|A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly|Evaluation of a Patient-Centered Medication Therapy Management Intervention to Reduce Inappropriate Anticholinergic Prescribing in the Elderly||University of Kentucky|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|65 Years|N/A|No|||September 2015|September 28, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172612||42044|
NCT02172625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0614|The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance|The Effect of 90 Days of Protandim Supplementation on Markers of Oxidative Stress, Athletic Performance, and Recovery||University of Louisville|Yes|Active, not recruiting|November 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02172625||42043|
NCT02172898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT Observational|Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium|Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium||Indiana University|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1260|Samples With DNA|serum/plasma, peripheral mononuclear cells, genomic DNA, stool samples, urine, and liver      tissue (where available)|Both|21 Years|N/A|No|Non-Probability Sample|Individuals with AH and suitable controls will be enrolled at Indiana University and        affiliated hospitals. In addition, the enrollment will be conducted simultaneously at Mayo        Clinic and Virginia Commonwealth University with the same target enrollment.|August 2015|August 24, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02172898||42022|
NCT02172911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-004|A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer|Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease||Inovio Pharmaceuticals|No|Recruiting|May 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|May 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02172911||42021|
NCT02172599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSWH|Take A Stand for Workplace Health: A Sit-stand Workstation Project Evaluation|The Influence of Sit-stand Workstations Upon Total Physical Activity: a 12 Month Randomised Controlled Trial||Brunel University|Yes|Active, not recruiting|May 2014|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|June 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172599||42045|
NCT02168647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-199|The Blossom Project: "Be-Well" Behavioral Wellness Study in Pregnancy|The Blossom Project: "Be Well" Behavioral Wellness Study in Pregnancy to Prevent Excessive Gestational Weight Gain|Be-Well|Iowa State University|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168647||42349|
NCT02169206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910177|Clinical Trial on Frozen Shoulder Using Bilateral Shoulder Radiography in Different Position|Clinical Trial on Frozen Shoulder Using Bilateral Shoulder Radiography in Different Position||Mashhad University of Medical Sciences|Yes|Completed|October 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|40 Years|N/A|No|||June 2014|June 19, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169206||42306|
NCT02169505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0351|Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)|Safety and Efficacy of Brentuximab Vedotin Maintenance After Allogeneic Stem Cell Transplantation in High Risk CD30+ Lymphoma (Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma ((ALCL))||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169505||42283|
NCT02169778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/754|Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction|Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction||Norwegian University of Science and Technology|No|Active, not recruiting|August 2013|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169778||42262|
NCT02170311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z213-01|Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia|"Phase Ib Study of Z-213 in Subjects With Iron-deficiency Anemia - To Investigate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics -"||Zeria Pharmaceutical|No|Completed|June 2014|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|64 Years|No|||March 2015|March 19, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02170311||42221|
NCT02170571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.51|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design||Boehringer Ingelheim||Completed|July 2005|||December 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170571||42201|
NCT02170623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.33|Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days in Healthy Subjects. Intraindividual Comparison (3-way Crossover) With and Without Pantoprazole, Randomised, Open.||Boehringer Ingelheim||Completed|February 2002|||April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170623||42197|
NCT02173106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usix-IMN-001|A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy|Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial||Sun Yat-sen University|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|14 Years|75 Years|No|||June 2014|June 30, 2014|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173106||42006|
NCT02173119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO22746|Can Quantitative MRI After cTACE Help Predict Survival ?|Can Quantitative MRI After Conventional Transarterial Chemoembolization (cTACE) Help Predict Survival ?||Medical College of Wisconsin|No|Enrolling by invitation|August 2014|August 2020|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients with hepatocellular carcinoma (HCC or cancer of the liver) and will soon undergo        one or more transcatheter arterial chemoembolization (TACE) procedure(s).|September 2015|September 22, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02173119||42005|
NCT02173379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-392 C|Absorb IV Randomized Controlled Trial|A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions||Abbott Vascular|Yes|Recruiting|July 2014|March 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173379||41985|
NCT02169089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57047|Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis (MIRACULOUS) Trial|Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis (MIRACULOUS) Trial|MIRACULOUS|University of Maryland|Yes|Not yet recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|56 Years|N/A|No|||June 2014|June 18, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169089||42315|
NCT02169102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08509912.3.0000.0075|Effect of Low Power Laser in Tooth Pain Modulation Caused by Irreversible Inflammation|Effect of Low Power Laser in Pain Modulation During Irreversible Inflammation of Tooth Pulp||University of Sao Paulo|No|Completed|February 2013|October 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169102||42314|
NCT02169115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EDE17T|Urticaria Facticia Treatment With Omalizumab (UFO)|Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment|UFO|Charite University, Berlin, Germany|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|June 12, 2014||No||No|October 28, 2015|https://clinicaltrials.gov/show/NCT02169115||42313|
NCT02169700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2014|Ischemic Compression on Post-needling Soreness|Ischemic Compression After Dry Needling of a Latent Myofascial Trigger Point Reduces Post-needling Soreness Intensity and Duration.||Universidad Rey Juan Carlos|Yes|Completed|December 2013|May 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169700||42268|
NCT02169973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103601|A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279|An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279||Janssen Research & Development, LLC|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02169973||42247|
NCT02181751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LW2014|A 1-year Program to Treat Children Who Have Been Victims of Child Sexual Abuse|A 1-year Program to Treat Children Who Have Been Victims of Child Sexual Abuse||Little Warriors|No|Not yet recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181751||41346|
NCT02182141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.2|An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma|An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|April 2003|||March 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182141||41316|
NCT02170922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.3|Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food|Relative Bioavailability of 200 mg Film Coated Tablets of BIBR 1048 MS With or Without Food Compared to 200 mg Solution of BIBR 1048 MS Given as Single Oral Administrations to Healthy Subjects. A 3-way Crossover, Open, Partly Randomized Study.||Boehringer Ingelheim||Completed|July 1999|||August 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170922||42174|
NCT02171299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10103|Intraoperative Local Anaesthetic and Postoperative Pain|Intraoperative Wound Infiltration With Local Anaesthetic in Surgical Patients; Is There Any Late Effect on the Postoperative Pain and the Requirements of Analgesia ? A Randomized Control Trial.|Pain-1|Hellenic Red Cross Hospital|Yes|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|16 Years|N/A|No|||June 2014|June 23, 2014|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171299||42145|
NCT02172638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AMI)136/2014|Postoperatory Recovery in Advanced Ovarian Cancer, Fast-Track Protocol vs. Classical Management|Ensayo clínico Comparando Recuperación Postoperatoria Tras Protocolo FAST- TRACK Vs. Manejo Clásico en Cáncer de Ovario Avanzado|PROFAST|Hospital Universitari Vall d'Hebron Research Institute||Recruiting|June 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||September 2014|September 11, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02172638||42042|
NCT02172924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCGVHD001|A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease|A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease||Karolinska Institutet||Not yet recruiting|January 2017|December 2019|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||November 2014|November 8, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02172924||42020|
NCT02172937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCGVHD002|Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study|Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease||Karolinska Institutet||Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||November 2014|November 8, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02172937||42019|
NCT02173210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820143|Precision Medicine for Preterm Birth|Precision Medicine In Segregating Endotypes in Preterm Birth|PRoMISE|University of Pennsylvania|No|Recruiting|June 2014|January 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women with a singleton gestation who have had a prior spontaneous preterm birth.|October 2014|October 2, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173210||41998|
NCT02173197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO_Pilota|Effectiveness of Occupational Therapy Intervention in Complex Patients|Study on the Effectiveness of Occupational Therapy Intervention in Complex Patients.|OT|University of Modena and Reggio Emilia|No|Completed|July 2014|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|In-hospital complexes patients as defined by way of the Rehabilitation Complexity Scale,        regardless of the diagnosis and in charge of the rehabilitation ward|May 2015|May 26, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173197||41999|
NCT02168907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 28114|CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168907||42329|
NCT02169219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001427|Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis|Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis|SCOUT|Massachusetts General Hospital|No|Recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||June 2014|June 19, 2014|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169219||42305|
NCT02169791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 1074|Nonmyeloablative Haploidentical Transplant Followed by MLN9708|A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies||Northside Hospital, Inc.|No|Recruiting|September 2014|June 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169791||42261|
NCT02169804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-111|An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal|An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal||Repros Therapeutics Inc.|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169804||42260|
NCT02169817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTERR06929|Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children|Bacillus Clausii in the Treatment of Acute Community-acquired Diarrhea Among Latin American Children (cadiLAc)|cadiLAc|Sanofi|No|Completed|July 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|629|||Both|6 Months|5 Years|No|||January 2016|January 20, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169817||42259|
NCT02170064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-202|Pharmacokinetics, Efficacy and Tolerability of BIA 2-093|Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy||Bial - Portela C S.A.|No|Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|2 Years|17 Years|No|||August 2014|August 29, 2014|June 20, 2014||No||No|July 18, 2014|https://clinicaltrials.gov/show/NCT02170064||42240|
NCT02170077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-201|A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093|A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 in Controlling Refractory Partial Seizures When Added to Ongoing Therapy||Bial - Portela C S.A.|No|Completed|April 2002|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|18 Years|65 Years|No|||July 2014|July 18, 2014|June 20, 2014||No||No|July 18, 2014|https://clinicaltrials.gov/show/NCT02170077||42239|
NCT02170636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.32|Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).||Boehringer Ingelheim||Completed|January 2002|||March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170636||42196|
NCT02170649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-103|The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093|The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093 in Healthy Male Volunteers||Bial - Portela C S.A.|No|Completed|September 2001|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|June 20, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02170649||42195|
NCT02171039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.58|Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Atorvastatin After 150 mg BID Dabigatran Etexilate and Atorvastatin at 80 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open-label, Randomised, Multiple-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|June 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171039||42165|
NCT02168543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI-09-03|1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers|Clinical Efficacy of Subgingivally Delivered 1% Alendronate in the Treatment of Smokers With Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial.||Government Dental College and Research Institute, Bangalore|Yes|Completed|March 2009|April 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|30 Years|50 Years|No|||June 2014|June 18, 2014|June 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168543||42357|
NCT02168816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206209|Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis|Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)|CRO-OSTEO|Loyola University|No|Recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|228|||Both|18 Years|N/A|No|||April 2015|May 1, 2015|June 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168816||42336|
NCT02169401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-SMI-2012 - PREDICT|A Multi-centre Observational Study of the Axium Neurostimulator as a Treatment for Chronic Pain|a PRospEctive Post Market Trial of Drg stImulation With the Commercially Available Axium|PREDICT|St. Jude Medical||Active, not recruiting|November 2012|August 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Pain Patients|December 2015|December 15, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02169401||42291|
NCT02169414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-123|Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics|Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects||Bial - Portela C S.A.|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|January 24, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02169414||42290|
NCT02181452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE1|Liver Fibrosis Assessment With ShearWave Elastography|Evaluation of SWE Performances for the Non-Invasive Diagnosis of Liver Fibrosis in Patients With Chronic Liver Diseases||SuperSonic Imagine|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2333|||Both|18 Years|N/A|No|Non-Probability Sample|Population will consist of patients who have confirmed or suspected liver fibrosis and        will be assessed with ultrasound, +/- blood analysis, +/- other non-invasive imaging,        and/or measurements, and biopsy|May 2015|May 11, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02181452||41369|
NCT02170935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.30|Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery|Multicenter, Open-label-study to Assess PK Profile of a Single Oral Dose of 150 mg BIBR 1048 (Capsule) in Patients Shortly After Primary Elective Total Hip Replacement Surgery.||Boehringer Ingelheim||Completed|April 2002|||June 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170935||42173|
NCT02171286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01212|The Oncopanel Pilot (TOP) Study|The Oncopanel Pilot (TOP) Study||British Columbia Cancer Agency|No|Recruiting|October 2014|||June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|Samples With DNA|Whole blood, plasma and tissues|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and        candidates for clinical trials.|February 2016|February 11, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02171286||42146|
NCT02172066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCR2014|Narrative Exposure Therapy (NET) for Victims of the Recent Flood Disaster in Burundi|Evaluation of the Narrative Exposure Therapy (NET) as Means to Reduce Psychological Impairment in the Aftermath of the Recent Flood Disaster in Bujumbura, Burundi||University of Konstanz|Yes|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02172066||42086|
NCT02172950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL627_3001|An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A|A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII‑SingleChain, CSL627) in Subjects With Severe Hemophilia A||CSL Behring|Yes|Recruiting|June 2014|||June 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Male|N/A|N/A|No|||March 2016|March 8, 2016|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172950||42018|
NCT02173223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.14|A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt||New York Glaucoma Research Institute||Active, not recruiting|June 2014|||February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173223||41997|
NCT02168387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026503|Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient|Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient||Duke University|No|Completed|December 2010|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|N/A|18 Years|No|||March 2015|March 2, 2015|June 18, 2014|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT02168387||42369|Small sample size in a single center study. Children who were extubated prior to the end of the study were not accounted for, as this was not a primary endpoint.
NCT02168361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHC-21|The SIM-SOF Trial for Hepatitis C|The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis||Center For Hepatitis C, Atlanta, GA|No|Completed|December 2013|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 17, 2014||No||No|February 5, 2016|https://clinicaltrials.gov/show/NCT02168361||42371|
NCT02168374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGICACD|Properties of Glass Ionomer Cements Associated With Chlorhexidine or Doxycycline|Biological and Physicomechanical Properties of Glass Ionomer Cements Associated With Chlorhexidine or Doxycycline||University of Campinas, Brazil|No|Completed|March 2008|October 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02168374||42370|
NCT02170337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110236|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps||Amgen|No|Active, not recruiting|July 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|June 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02170337||42219|
NCT02170129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINUS LIFT|SINUS LIFT 100% Anorganic Bovine Bone vs. 50% Anorganic Bovine Bone + 50% Autologous Bone|Sinus Lift Grafting With Anorganic Bovine Bone vs 50% Autologous + 50% Bovine Bone. One Year Results From a Randomized Controlled Trial.||Università degli Studi di Sassari|No|Completed|February 2013|||February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|No|||June 2014|June 19, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02170129||42235|
NCT02170090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTICCA-1|Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer|Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)|ACTICCA-1|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|April 2014|April 2022|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170090||42238|
NCT02170324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014Wze091|GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men|||Wuhan General Hospital of Guangzhou Military Command|Yes|Completed|June 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|20 Years|30 Years|No|||August 2015|August 15, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02170324||42220|
NCT02170610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.34|Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule With and Without Coadministration of Pantoprazole as Well as Under the Influence of Food in Healthy Subjects. A Threeway Crossover, Randomised, Open Trial.||Boehringer Ingelheim||Completed|March 2002|||May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170610||42198|
NCT02171910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doxa1|Doxapram as an Additive to Propofol Sedation in Sedation for ERCP|Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography||Helsinki University Central Hospital|No|Not yet recruiting|April 2016|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02171910||42098|
NCT02168829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327494|Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial|The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial|OCEAN|Ottawa Heart Institute Research Corporation|Yes|Not yet recruiting|January 2016|December 2021|Anticipated|September 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1452|||Both|19 Years|N/A|No|||November 2015|November 13, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168829||42335|
NCT02169128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSTI|Severe Soft Tissue Infections: Perspectives of Patients and Significant Others|Severe Soft Tissue Infections: Perspectives of Patients and Significant Others||Göteborg University||Recruiting|January 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for necrotizing fasciitis at the three study sites|January 2016|January 7, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169128||42312|
NCT02169141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC-20|Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients|Pharmacokinetics of Levofloxacin and Capreomycin in MDR-TB Patients||University Medical Center Groningen|No|Completed|November 2012|November 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|MDR-TB patients|June 2014|June 20, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02169141||42311|
NCT02180945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-ONY-001|ONYX Evaluation in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulae|ONYX Evaluation in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulae. A French, Observational, Prospective, Multicentric, Single Arm and Open Study|dAVF|Medtronic - MITG|Yes|Active, not recruiting|July 2013|||November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|All patients presenting at the participating centers for whom an intracranial dAVF (not        previosly treated) needs to be treated (unrelated to the planned treatment) and who agree        to the collection and transmission of related data.|December 2014|December 18, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02180945|12 Months|41408|
NCT02181205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-024|Sphenopalatine Ganglion Block for Post-Dural Puncture Headache|Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache: A Prospective Randomized Double Blind Placebo Controlled Study||Wake Forest School of Medicine|Yes|Enrolling by invitation|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||August 2015|August 31, 2015|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181205||41388|
NCT02181179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014040107|Examining Yoga's Effects on Smoking|Examining Yoga's Effects on Aspects Related to Stress and Smoking Behavior||University of Texas at Austin|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181179||41390|
NCT02181192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROST-I|Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate Carcinoma|Postoperative Prostate Carcinoma Recurrence: Instant Radiotherapy Versus Radiotherapy With Additional Imaging With PSA Value >= 1|PROST-I|University of Erlangen-Nürnberg Medical School|No|Not yet recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Male|18 Years|N/A|No|||July 2014|July 1, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02181192||41389|
NCT02181465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC1A&B|Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.|Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma.|CC1A&B|Cancer Advances Inc.||Completed|October 1993|May 1994|Actual|May 1994|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|81 Years|No|||July 2014|July 3, 2014|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181465||41368|
NCT02171832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.20|Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Pharmacokinetics, Safety and Tolerability of a Single Dose of BI 1744 CL (20 μg Administered With the Respimat® Inhaler) in Patients With Mild and Moderate Hepatic Impairment (Child Pugh Classifications A and B) in Comparison to a Single Dose of BI 1744 CL (30 μg Administered With the Respimat® Inhaler) in Subjects With Normal Hepatic Function in a Monocentric, Open Label, Parallel Group Phase I Trial||Boehringer Ingelheim||Completed|July 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171832||42104|
NCT02171845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAUQUE ANR 2011|Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans|Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans||Centre Hospitalier Universitaire Dijon||Recruiting||||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Male|10 Weeks|37 Weeks|No|Probability Sample|Male foetuses of 10 to 37 weeks of amenorrhea obtained following medical termination of        pregnancy or voluntary termination of pregnancy.|November 2013|June 23, 2014|June 18, 2014||||No||https://clinicaltrials.gov/show/NCT02171845||42103|
NCT02172079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USAL201000048540|Mobilization With Movement for Shoulder Impingement|Effects of Mobilization-with-Movement on Pain and Range of Motion in Unilateral Shoulder Impingement Syndrome: A Randomized Controlled Trial||Universidad Rey Juan Carlos|Yes|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||June 2014|June 23, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02172079||42085|
NCT02172651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-091|Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.|Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.||Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|May 2020|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172651||42041|
NCT02168400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406M51241|Clinical Intervention in Alcohol Use Disorder|Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Alcohol Use Disorder||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02168400||42368|
NCT02168673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102011549|Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke|Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke||Weill Medical College of Cornell University|No|Completed|April 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|Samples With DNA|Blood and cells obtained from the study may be kept for future genetic studies.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study will involve healthy nonsmokers and healthy smokers.|April 2015|April 20, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02168673||42347|
NCT02168920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-13-001|Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type||Otsuka Pharmaceutical Co., Ltd.|Yes|Recruiting|June 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|880|||Both|55 Years|89 Years|No|||August 2015|August 20, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168920||42328|
NCT02168933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP00004323|308nm Excimer Laser for Treatment of Fingernail Psoriasis|Randomized Controlled Trial of 308 nm Excimer Laser for Treatment of Nail Psoriasis|NAPSI|University of Utah|Yes|Recruiting|January 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168933||42327|
NCT02168660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT092010-217|Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth|Normalization of Vitamin D Levels and Its Effect on Glucose Homeostasis in Obese Youth||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|March 2011|December 2014|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|6 Years|17 Years|No|||June 2014|June 17, 2014|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168660||42348|
NCT02170142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT4104938095|Characterization of the Functional and Structural Development of the Human Neonatal Brain From 30 Wks to 45 Wks ga|The Major Goal of This Project is to Characterize the Structural and Functional Development of Cortical Plate and White Matter of the Human Neonatal Brain From the Equivalent 30 Gestational Weeks to 45 Gestational Weeks.||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|102|||Both|30 Weeks|45 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Neonates in the neonatal intensive care unit at Parkland Hospital|June 2014|June 20, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02170142||42234|
NCT02170155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2012 343|MRI-changes in Morphometry and Cerebro Spinale Fluid (CSF)|||University of Zurich|Yes|Recruiting|December 2012|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with spinal cord disorder|January 2016|January 6, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02170155||42233|
NCT02169518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PON2011|Paraoxonase and HDL Qualities in Glycaemia and Inflammation|Changes in Paraoxonase Activity, HDL Properties, Inflammatory Markers and Corneal Innervation in Post-bariatric Surgery Patients, Type 1 Diabetics With and Without Nephropathy, Type 2 Diabetics, and During an Oral Glucose Tolerance Test.|PON1|Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|600|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 patients with type 1 diabetes 60 control subjects for type 1 diabetics 60 patients with        type 2 diabetes 60 control subjects for type 2 diabetics 60 patients undergoing oral        glucose tolerance test 120 patients scheduled for bariatric surgery - lipoprotein group        120 control subjects for bariatric patients 60 patients scheduled for bariatric surgery -        nerve function & structure group|January 2016|January 28, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169518||42282|
NCT02170662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017573|Topical Bimatoprost Effect on Androgen Dependent Hair Follicles|Topical Bimatoprost Effect on Androgen Dependent Hair Follicles||Duke University|No|Completed|November 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Male|18 Years|45 Years|No|||July 2014|August 27, 2014|June 20, 2014|Yes|Yes||No|July 31, 2014|https://clinicaltrials.gov/show/NCT02170662||42194|
NCT02170675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.101|Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers|Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Ketoconazole (Tablet) or in Combination With 400 mg q.d. Ketoconazole (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)||Boehringer Ingelheim||Completed|June 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170675||42193|
NCT02171078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0742|Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance|Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance||University of Wisconsin, Madison|No|Active, not recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|N/A||3|Anticipated|50881|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Research Aim 1: Patients who have participated in 1 of 15 closed clinical trials; Research        Aim 2: National Cancer Database (NCDB); Research Aim 3: Purposive sample of breast cancer        survivor, breast cancer treatment provider, and cancer health services researcher        stakeholders|July 2015|July 22, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171078||42162|
NCT02171403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201421130|Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls|Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls||Katholieke Universiteit Leuven|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|34|Samples Without DNA|Fecal samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a positive test (reduced lactose digestion and increased H2-excretion) and        complaints will be included in the group of lactose-intolerant patients and patients with        a positive result without complaints will be included in the group of        lactose-malabsorption patients. Subjects with a normal breath test will be recruited as        controls.|July 2015|July 28, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02171403||42137|
NCT02171091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404106|Intubated ICU Patients|Impact of the Endotracheal Tube on Airway Inflammation: Prospective Analysis in Intubated ICU Patients||Washington University School of Medicine|Yes|Recruiting|June 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|225|Samples With DNA|blood and tracheal sample|Both|18 Years|85 Years|No|Non-Probability Sample|patients receiving endotracheal intubation in the ICU|August 2015|August 11, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171091||42161|
NCT02171416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cures|Cold Contact Urticaria Treatment With Rilonacept|A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)|Cures|Charite University, Berlin, Germany|No|Recruiting|January 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02171416||42136|
NCT02180672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010942|Steroids for Pediatric Apnea Research in Kids|Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea|SPARK|Children's Hospital of Philadelphia|Yes|Recruiting|September 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|318|||Both|5 Years|10 Years|No|||October 2015|October 5, 2015|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02180672||41429|
NCT02180685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish EC 1-10-72-194-14|Reconstruction of the Medial Patellofemoral Ligament - A Randomised Controlled Trial Comparing Two Surgery Technics|Reconstruction of the Medial Patellofemoral Ligament - A Randomised Controlled Trial Comparing Two Surgery Technics||Aarhus University Hospital|Yes|Recruiting|January 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|40 Years|No|||January 2016|January 4, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02180685||41428|
NCT02180386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-ODP-3|Effect of PlayStation Distraction in the Dental Setting|Effect of PlayStation Distraction on Children's Behavior and Pain in the Dental Setting||Universitat Internacional de Catalunya|Yes|Recruiting|June 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|34|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02180386||41450|
NCT02180932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-GIRCI-01|Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers|||Centre Hospitalier Universitaire de Nice|No|Completed|June 2014|||July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|80 Years|No|||May 2014|October 23, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02180932||41409|
NCT02182635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54.561|Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Long-term Study of Ba253BINEB in Patients With COPD||Boehringer Ingelheim||Completed|August 1998|||March 1999|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|40 Years|N/A|No|||July 2014|July 10, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182635||41278|
NCT02182648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|etomidate children 20140625|Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction|||Henan Provincial Hospital|Yes|Not yet recruiting|October 2014|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|3 Years|10 Years|No|||June 2014|July 2, 2014|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02182648||41277|
NCT02181218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407160|Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas|A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas||Washington University School of Medicine|Yes|Recruiting|February 2015|April 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181218||41387|
NCT02178215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si479/2013|Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients|Effect of Holly Mangrove Shower Gel Containing Acanthus Ebracteatus Vahl. on Skin Barrier Function in Atopic Dermatitis Patients||Mahidol University|Yes|Completed|July 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178215||41616|
NCT02178228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-2235|Observational Analysis of the Cause of Leaks When Bowel is Cut and Reconnected|Prospective Assessment of Anastomotic Leak||Icahn School of Medicine at Mount Sinai|No|Recruiting|October 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|15 Years|N/A|No|Non-Probability Sample|Patients who are scheduled to have a small or large bowel surgery and reconnection of        bowel will be selected from the operating room schedule at Icahn School of Medicine at        Mount Sinai.|February 2016|February 17, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178228||41615|
NCT02171858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-S1|Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke|Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke|MAASP|Hospital Central Sur de Alta Especialidad|Yes|Enrolling by invitation|June 2013|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|Samples Without DNA|serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients affiliated to Petróleos Mexicanos medical system of any gender between 18 and 80        years old suspected of acute phase stroke who arrive to emergency room at our hospital|June 2014|June 21, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02171858||42102|
NCT02171871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBCS003|Effects Of Passive Smoking On The Respiratory System Mechanics Of Healthy Non-Smokers In Different Body Positions|Effects Of Passive Smoking On The Respiratory System Mechanics Of Healthy Non-Smokers In Different Body Positions||Hellenic Anticancer Society|Yes|Completed|January 2010|May 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 21, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02171871||42101|
NCT02173236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-|The Effect of Platform Switching on Single Implants in the Esthetic Zone, Following Flapless Surgery and Early-Loading Protocols|||University of Michigan|Yes|Completed|June 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02173236||41996|
NCT02173249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-100-0007|A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%|||Aciex Therapeutics, Inc.||Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|55 Years|No|||January 2015|January 14, 2015|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173249||41995|
NCT02169531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCOVER 1|Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus|Pilot Study of a Cell-Based Therapy for Treatment of Hyperglycemia in Type 2 Diabetes Mellitus|DISC|B & Y Technologies|No|Completed|March 2014|January 2016|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|25 Years|N/A|No|||January 2016|January 12, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169531||42281|
NCT02169258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-BR-103-023|Routine Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty|Prognostic Impact of ROUtine Coronary CathETerization in Low Extremity ArTEry Disease Undergoing Percutaneous Transluminal Angioplasty (PIROUETTE-PTA Study)|PIROUETTEPTA|National Cheng-Kung University Hospital|No|Recruiting|June 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|700|||Both|20 Years|N/A|No|||September 2015|September 23, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169258||42302|
NCT02169544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-488|Post-marketing Study Assessing the Long-Term Safety of Abatacept|Post-marketing Study Assessing the Long-Term Safety of Abatacept||Bristol-Myers Squibb|No|Active, not recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100000|||Both|18 Years|N/A|No|Probability Sample|Patients will be selected from 4 US claims databases|January 2016|January 27, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02169544||42280|
NCT02169232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-443-SDR|Videolaryngoscope Versus Fiberoptic Bronchoscope for the Awake Intubation|||McGill University Health Center|Yes|Recruiting|May 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|55 Years|No|||June 2014|June 20, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169232||42304|
NCT02170389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 250113|Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer|Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer &lt;pT2||Roswell Park Cancer Institute|Yes|Recruiting|October 2014|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02170389||42215|
NCT02170402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061301|China ADVATE PTP Study|Study to Evaluate Efficacy and Safety of ADVATE in the Treatment of Previously Treated Patients With Hemophilia A||Baxalta US Inc.|No|Active, not recruiting|June 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|82|||Male|N/A|N/A|No|||May 2015|June 26, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02170402||42214|
NCT02170350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.272|Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy|Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy||Thomas Jefferson University|No|Recruiting|June 2014|||June 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170350||42218|
NCT02170688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010850|Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT|Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT||Duke University||Completed|February 2004|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Actual|139|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|June 20, 2014|Yes|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT02170688||42192|
NCT02171104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS104|MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis|MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG||Masonic Cancer Center, University of Minnesota|No|Recruiting|July 2014|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|55 Years|No|||January 2016|January 22, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171104||42160|
NCT02180984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26164614.7.0000.5505|The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED|The Effects of Repetitive Transcranial Magnetic Stimulation in Obese Females With Binge Eating Disorder: a Protocol for a Double-blinded, Randomized, Sham-controlled Trial.||Federal University of São Paulo|Yes|Not yet recruiting|July 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02180984||41405|
NCT02180399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sepsis MI-05-02-14|Serial Measurement of Capillary Blood Lactate in the Management of Sepsis|Role of the Serial Measurement of Capillary Blood Lactate in the Management of Sepsis Outside the Intensive Care|SepsisMI|University Hospital, Strasbourg, France|No|Not yet recruiting||||February 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over age 18 with an acute systemic inflammatory response syndrome array of        presumed infectious not yet been treated.|February 2014|June 30, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02180399||41449|
NCT02180698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9145|TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery|A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) With Radiation in Patients With Metastatic Sarcoma||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2014|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02180698||41427|
NCT02182180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC2I SUR902506|SCCI Tissue and Data Repository Protocol|Surgical Critical Care InitiativeTissue and Data Acquisition Protocol|SC2I|Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Recruiting|November 2014|October 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with injury or illness requiring surgical care or treatment in a critical care or        emergency setting who are being cared for at SC2I sites, including Grady Memorial        Hospital, Emory University Hospital, and Duke University Health System. Also, healthy        volunteer control subjects to include individuals without any known injury or end-stage        organ disease and patients who have recovered from prior injury.|February 2016|February 17, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02182180||41313|
NCT02182661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54.562|A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma|A Phase III Long-term Study of Ba253BINEB in Patients With Bronchial Asthma||Boehringer Ingelheim||Completed|July 1998|||May 2000|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|20 Years|N/A|No|||July 2014|July 10, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182661||41276|
NCT02182674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.25|A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Crossover, Placebo- and Active Controlled Dose Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With COPD||Boehringer Ingelheim||Completed|October 2000|||August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|40 Years|N/A|No|||July 2014|July 3, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182674||41275|
NCT02182687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID 2014-026|Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant|A Randomized Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) With DEBDOX Beads as a Bridge to Transplant in Hepatocellular Carcinoma.|SBRTvsTACE|Lahey Clinic|Yes|Recruiting|June 2014|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02182687||41274|
NCT02182700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.32|Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis|Open Study on the Efficacy and Safety of Combivent® Aerosol (120 mcg Salbutamol Sulfate Plus 20 mcg Ipratropium Bromide) + Spacer, 12 to 24 Puffs, in Adult Patients With Moderate to Severe Asthma Crisis||Boehringer Ingelheim||Terminated|July 1998|||December 1999|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|40 Years|No|||July 2014|July 3, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182700||41273|
NCT02182713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.36|Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm|Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm||Boehringer Ingelheim||Completed|May 1998|||September 1998|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|7 Years|12 Years|No|||July 2014|July 7, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182713||41272|
NCT02172963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCHC001|A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis|||Karolinska Institutet||Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||June 2014|June 23, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02172963||42017|
NCT02172976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPAFOX|Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma|Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer||Krankenhaus Nordwest|Yes|Recruiting|November 2014|June 2020|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02172976||42016|
NCT02168946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 506|Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults|A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/RPX7009) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|Yes|Recruiting|July 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168946||42326|
NCT02169245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208012603|Effects of Protein and Fiber at Breakfast on Appetite, Blood Sugar, and Cholesterol|Relative Effects of Chronic Consumption of Egg Protein at Breakfast With and Without Fiber on Brain Neural Activation, Appetite, Glycemic and Lipemic Control and Self-selected Energy Intake|PFB|Purdue University|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02169245||42303|
NCT02168699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTIK12112|Ultrasonographic Detection of Musculocutaneous Nerve in Children|Ultrasound Imaging of Musculocutaneous Nerve in Infants, Preschoolers and Children||Attikon Hospital|No|Completed|December 2010|||March 2012|Actual|N/A|Interventional|N/A|1||||||Both|N/A|12 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168699||42345|
NCT02169271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01311|Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules|A Randomized Phase II Trial of Low Dose Aspirin Versus Placebo in High-Risk Individuals With CT Screen Detected Subsolid Lung Nodules||National Cancer Institute (NCI)|Yes|Recruiting|November 2014|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Both|50 Years|N/A|No|||November 2015|November 19, 2015|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169271||42301|
NCT02169830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24482_ Vest_Migraine|Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine|A Prospective Randomized Cross-over Trial of Nortryptyline and Topiramate in the Initial Treatment of Vestibular Migraine.||St. Louis University|Yes|Recruiting|June 2014|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2016|February 10, 2016|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169830||42258|
NCT02169843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140523 Dexmedetomidine|Small Doses of Dexmedetomidine for Emergence Agitation|Influence of Small Doses Dexmedetomidine to the Elderly Patients' Emergence Agitation||Tang-Du Hospital||Recruiting|May 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|65 Years|N/A|No|||June 2014|June 19, 2014|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02169843||42257|
NCT02170103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRUSMI TRIAL|Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL)|Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL)|MRUSMI|University of Nebraska|Yes|Recruiting|May 2014|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|30 Years|N/A|No|||June 2014|June 19, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02170103||42237|
NCT02170363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC02212014|HeartMate 3™ CE Mark Clinical Investigation Plan|HeartMate 3™ CE Mark Clinical Investigation Plan|HM3 CE Mark|Thoratec Corporation|No|Active, not recruiting|June 2014|November 2016|Anticipated|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170363||42217|
NCT02170376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-124|The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics|The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects||Bial - Portela C S.A.|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|117|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170376||42216|
NCT02170701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.11|BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery|Multicenter, Open-label, Ascending Dose Study of BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery. Bistro I||Boehringer Ingelheim||Completed|October 2000|||June 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|289|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170701||42191|
NCT02171117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMCG-EAML2014|Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia|Phase III Clinical Trial of Microtransplantation to Treat Elderly Acute Myeloid Leukemia|IMCG-EAML|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Recruiting|March 2014|June 2017|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|60 Years|85 Years|No|||June 2014|June 20, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02171117||42159|
NCT02171468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.61|Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects|Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)||Boehringer Ingelheim||Completed|May 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171468||42132|
NCT02171481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.66|Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers|Bioequivalence of Two Different Polymorphs of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)||Boehringer Ingelheim||Completed|May 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171481||42131|
NCT02181569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140143|Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study|Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study||National Institutes of Health Clinical Center (CC)||Recruiting|June 2014|April 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|215|||Both|18 Years|75 Years|No|||April 2015|August 6, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181569||41360|
NCT02181764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN23-001|A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia|A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.||Kyowa Hakko Kirin Company, Limited|Yes|Completed|July 2014|||December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181764||41345|
NCT02181777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D2014/018|Group Training for Social Skills in Psychosis|Exploring the Feasibility of Social Skills Training in People With Psychosis.|GRASP|King's College London|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||July 2014|July 3, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181777||41344|
NCT02182167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130808|A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis|A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis|NAC in TB DIH|University of Cape Town|Yes|Recruiting|May 2014|July 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02182167||41314|
NCT02181803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8189-003|MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Patients (MK-8189-003)|A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients||Merck Sharp & Dohme Corp.|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02181803||41342|
NCT02181816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212-011|Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"|Zacras Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"||Takeda|No|Recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension|December 2015|December 16, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181816||41341|
NCT02182193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.21|Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers|Safety and Relative Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules Charge 1 Compared to BIBF 1120 Soft Gelatine Capsules Charge 2 Compared to BIBF 1120 Administered as Drinking Solution Following Oral Administration to Healthy Male Volunteers in an Open, Randomised, Intra-individual, Crossover Comparison Design||Boehringer Ingelheim||Completed|September 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182193||41312|
NCT02182206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.3|An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours|A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|June 2003|||June 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182206||41311|
NCT02182219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.4|Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer|A Phase I Open Label Dose Escalation Study of Continuous (Except on the Days of Chemotherapy Infusion) Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer||Boehringer Ingelheim||Completed|November 2005|||April 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|N/A|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182219||41310|
NCT02182232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.5|A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer|A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer||Boehringer Ingelheim||Completed|June 2005|||May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182232||41309|
NCT02178852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS-nicotine|TNS for Treating Nicotine Craving|Effect of Trigeminal Nerve Stimulation (TNS) on Nicotine Craving: Phase II, Cross-over, Randomized, Sham-controlled Clinical Trial|TNS-nicotine|Santa Casa Medical School|No|Not yet recruiting|August 2014|||August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|69 Years|No|||June 2014|June 27, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178852||41567|
NCT02173262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140380-01H|REaCT Integrated Consent Model to Compare Two Standard of Care Regimens|Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia|OTT14-03|Ottawa Hospital Research Institute|Yes|Recruiting|August 2014|September 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|35|||Female|19 Years|N/A|No|||February 2016|February 18, 2016|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02173262||41994|
NCT02168686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401014659|Safety Study of Gene Transfer Vector to Treat alpha1-antitrypsin Deficiency|Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human alpha1-antitrypsin cDNA to Individuals With alpha1-antitrypsin Deficiency||Annapurna Therapeutics|Yes|Not yet recruiting|July 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|June 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168686||42346|
NCT02169284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01320|Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery|Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery||National Cancer Institute (NCI)|Yes|Recruiting|October 2014|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169284||42300|
NCT02169557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiHATFEX005|Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study|Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study||Drugs for Neglected Diseases|Yes|Recruiting|May 2014|||December 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|202|||Both|15 Years|N/A|No|||June 2014|June 19, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02169557||42279|
NCT02169856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy|A Randomized Controlled Trial: Role of EFTs (Emotional Freedom Techniques) in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy.|EFT|Benazir Bhutto Hospital, Rawalpindi|No|Completed|July 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02169856||42256|
NCT02170116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.1|Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers|Pharmacodynamics, Safety and Pharmacokinetics After Single Oral Administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as Drinking Solution in Healthy Subjects. An Open Study, Placebo Randomized Double Blind at Each Dose Level.||Boehringer Ingelheim||Completed|November 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170116||42236|
NCT02170168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/212|The Orkdal Model. Collaboration Between Specialist and Community Care Within Palliative Cancer Care|The Orkdal Model. Development, Implementation and Evaluation of Collaboration Between Specialist and Community Care Within Palliative Cancer Care||St. Olavs Hospital|No|Recruiting|October 2013|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1600|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients in need of palliative care, inhabitants of one of 22 municipalities in        Central Norway, carers (1 per patient) and health care providers (community care and 2        regional hospitals)|December 2015|December 2, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170168||42232|
NCT02170181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 012014-039|Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation|UTSW SBRT Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2014|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||4|Anticipated|5000|Samples With DNA|Tissue Procurement|Both|18 Years|N/A|No|Non-Probability Sample|patients receive SBRT|September 2015|September 12, 2015|June 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02170181|5 Years|42231|
NCT02170714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16062014|Efficacy of Infliximab as a Rescue Therapy in Pediatric Acute Severe Colitis|Managing Pediatric Acute Severe Colitis According to the 2011 ECCO-ESPGHAN Guidelines: Efficacy of Infliximab as a Rescue Therapy||University of Roma La Sapienza|No|Completed|May 2010|May 2014|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|1 Year|18 Years|No|Non-Probability Sample|Consecutive children hospitalized for an episode of ASC, defined as a PUCAI>65|June 2014|June 20, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02170714||42190|
NCT02170415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4116|Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery|Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery||Royal Marsden NHS Foundation Trust|Yes|Active, not recruiting|June 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|154|||Female|18 Years|N/A|No|||June 2014|June 20, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170415||42213|
NCT02171130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG108|Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia|A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes||Locemia Solutions ULC|No|Active, not recruiting|May 2014|April 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02171130||42158|
NCT02171455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.60|Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects|Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of 600 mg, 750 mg and 900 mg Dabigatran Etexilate as Capsule in Healthy Subjects. A Randomised, Placebo-controlled Study, Double Blind at Each Dose Level||Boehringer Ingelheim||Completed|January 2006|||January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171455||42133|
NCT02171494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.68|Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers|Bioequivalence of 2x5 mg of IVAX Warfarin /Formulation Tablet Compared to 10 mg of Coumadin /Formulation Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-treatment, Two-sequence Crossover Study) Under Fasted Conditions||Boehringer Ingelheim||Completed|September 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171494||42130|
NCT02171520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.70|Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers|Bioequivalence of Two Different Generations of Drug Product of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)||Boehringer Ingelheim||Completed|May 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171520||42128|
NCT02171533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.74|Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers|Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate Given With or Without Single Oral Doses of 120 mg (IR) or 240 mg (ER) of Verapamil Administered at Different Time Points Relative to Dabigatran Etexilate Dosing in Healthy Male and Female Volunteers (Open-label, Randomised, Five-way Crossover Design, Phase I Study)||Boehringer Ingelheim||Completed|June 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171533||42127|
NCT02181504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-002|A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration|||Allergan|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|50 Years|N/A|No|||December 2015|December 18, 2015|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181504||41365|
NCT02181517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-003|A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration|||Allergan|Yes|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|50 Years|N/A|No|||January 2016|January 14, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181517||41364|
NCT02181530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/016|Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®|||Allergan|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|43|||Both|N/A|N/A|No|Non-Probability Sample|Patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion        (CRVO) who received OZURDEX® as part of routine clinical practice.|May 2015|May 21, 2015|July 2, 2014|No|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT02181530||41363|
NCT02181790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0580|Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles|Addition of 308-nm Excimer Laser to Acitretin Therapy in the Management of Palmoplantar Psoriasis||Icahn School of Medicine at Mount Sinai|No|Terminated|June 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181790||41343|
NCT02182726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.245|Postmarketing Surveillance Study With MOBEC®|COX-2 Postmarketing Surveillance Study With MOBEC® 15 mg Tablets||Boehringer Ingelheim||Completed|May 2001|||December 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4760|||Both|N/A|N/A|No|Non-Probability Sample|primarily internal and general medical practices|July 2014|July 8, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182726||41271|
NCT02182739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.249|Observational Study of Meloxicam in Any Labeled Indication|Programa de Experiencia Therapéutica Personalizada (Personalized Therapeutic Experience Program)||Boehringer Ingelheim||Completed|January 2001|||December 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13039|||Both|N/A|N/A|No|Non-Probability Sample|primary care|July 2014|October 28, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182739||41270|
NCT02182752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3694/27-3-13|The Effect of Tramadol on Interscalene Brachial Plexus Block|The Effect of Tramadol on Interscalene Brachial Plexus Block With Ropivacaine in Shoulder Surgery.||Asklepieion Voulas General Hospital||Completed|April 2013|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|79 Years|No|||January 2016|January 2, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02182752||41269|
NCT02178254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0064|Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects|A Randomized, Safety, Tolerability and Pharmacokinetics 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|February 5, 2015|June 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178254||41613|
NCT02178865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2014-01|Predicting Normal vs. Carrier Status in Euploid Embryos of Translocation Carriers|Evaluation of the Accuracy of Predicting Normal or Carrier Status in Euploid Embryos Produced by Patients With Balanced Translocations||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|Samples With DNA|buccal swabs and whole blood|Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with balanced translocations|November 2015|November 16, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178865||41566|
NCT02178878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17054|Genetic and Demographic Factors That Influence the Pain and Progress of Labor|Genetic and Demographic Factors That Influence the Pain and Progress of Labor||University of Virginia|No|Recruiting|May 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Blood sample for DNA|Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant in active labor|June 2014|June 27, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02178878||41565|
NCT02178891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-163|Extra Short Implants Brånemark System® RP Ø4.5x4.5 mm Implants|A 5-year Clinical Evaluation on Brånemark System® RP Ø4.5x4.5 mm Implants||Nobel Biocare|No|Active, not recruiting|January 2010|August 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 30, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178891||41564|
NCT02168712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EO31/2013-HIE|Interval Versus Continuous Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease|Interval Versus Continuous Exercise Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease: a Randomized Clinical Trial||Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02168712||42344|
NCT02168413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01734-41|Cortical Excitability Using Robotised and Neuronavigated Transcranial Magnetic Stimulation|Development of New Cortical Excitability Methodologies Using Robotised and Neuronavigated Transcranial Magnetic Stimulation.|ROBEXCI|University Hospital, Grenoble|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ealthy subjects|March 2016|March 4, 2016|May 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02168413||42367|
NCT02168426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDIRB2013-15|Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus|Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus||Gachon University Gil Medical Center|No|Completed|August 2013|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|25 Years|90 Years|No|||August 2015|August 28, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168426||42366|
NCT02168959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56481|Continuous Femoral Nerve Block With a Tibial Plateau Fracture|Postoperative Pain Management With a Continuous Femoral Nerve Block in Patients With a Tibial Plateau Fracture||University of Utah|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168959||42325|
NCT02168972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOC-19996|Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)|A Prospective, Non-randomized Clinical Study to Assess Safety and Performance of a Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation|GLOBAL-AF|Kardium Inc.|No|Recruiting|November 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168972||42324|
NCT02169609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJD-HR-NB-Ch14.18|Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma|Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials||Fundació Sant Joan de Déu|No|Not yet recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|18 Years|No|||June 2014|June 18, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02169609||42275|
NCT02169622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH12-009|CABG REVEAL: Atrial Fibrillation After Coronary Artery Bypass Graft|A Prospective Look at Incidence of Atrial Fibrillation After Coronary Artery Bypass Graft and Related Morbidity/Mortality Utilizing the Reveal XT||Saint Thomas Health Services|No|Enrolling by invitation|September 2012|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|60 Years|N/A|No|Non-Probability Sample|Patients 60 years of age or older undergoing coronary artery bypass grafting (CABG).|June 2014|June 18, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02169622||42274|
NCT02169570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH-P02|Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis|Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial|EVIDENT|Dow University of Health Sciences|Yes|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|435|||Both|30 Years|60 Years|No|||June 2014|June 19, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02169570||42278|
NCT02169869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #10473|Immediate Postplacental IUD Insertion|Immediate Postplacental Intrauterine Device Insertion in High-risk Patient Populations||Oregon Health and Science University|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|55 Years|No|||May 2015|May 21, 2015|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169869||42255|
NCT02170753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042014-066|Regional Manual Therapy and Motor Control Exercise for Chronic Low Back Pain|Regional Manual Therapy and Motor Control Exercise for the Management of Chronic Low Back Pain With Hip and Spine Motion Loss: A Randomized Clinical Trial||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170753||42187|
NCT02170727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-123|A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1|A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1|UNITY 4|Bristol-Myers Squibb|No|Completed|June 2014|September 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|18 Years|N/A|No|||January 2016|February 25, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02170727||42189|
NCT02170740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.14|Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects|Bioavailability of BIBR 953 ZW After Multiple Oral Doses of 50 and 200 mg BIBR 1048 MS Film-coated Tablet Administered BIDfor 3 Days or 200 mg BIBR 1048 MS With and Without Pre-treatment With Pantoprazole to Healthy Volunteer Subjects. Two Groups, 2-way Crossover, Randomised, Open Trial||Boehringer Ingelheim||Completed|November 1999|||January 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170740||42188|
NCT02171143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2409-CL-0104|A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate||Astellas Pharma Inc|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|75 Years|No|||June 2014|June 20, 2014|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02171143||42157|
NCT02171156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.177|Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)|Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis||Boehringer Ingelheim||Available|August 2014|May 2015|Actual|May 2015|Actual|N/A|Expanded Access|N/A|||||||Both|40 Years|N/A|No|||June 2015|June 1, 2015|June 18, 2014||||||https://clinicaltrials.gov/show/NCT02171156||42156|
NCT02171507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.7|Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Diclofenac After 150 mg b.i.d. Dabigatran Etexilate and Diclofenac at 50 mg Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple- Dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|May 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171507||42129|
NCT02171962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008|Zilver® PTX® in China|Evaluation of the Zilver® PTX® Drug-Eluting Peripheral Stent for Treatment of Lesions of the Above-the-Knee Femoropopliteal Artery||Cook||Active, not recruiting|June 2014|July 2017|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02171962||42094|
NCT02181270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHEEX|Changes in Intrahepatic Lipids With Exercise|||University of Missouri-Columbia|No|Recruiting|October 2013|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment|2||Anticipated|30|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02181270||41383|
NCT02181842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-019|Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>|Actos Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>||Takeda|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|246|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes mellitus|July 2014|July 2, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181842||41339|
NCT02182297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.13|Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses (40 mg to 480 mg) of BI 201335 NA as Capsule(s) Administered to Healthy Male Subjects - a Randomised, Placebo-controlled (Within Dose Groups) and Double-blind Trial||Boehringer Ingelheim||Completed|April 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182297||41304|
NCT02181257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAG-00324R2|Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts|Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts|ECP Registry|Washington University School of Medicine|Yes|Recruiting|January 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Lung allograft patients with progressive bronchiolitis obliterans syndrome|February 2016|February 4, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02181257|1 Year|41384|
NCT02181543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1157-8852|Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.|Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.||Professor Fernando Figueira Integral Medicine Institute|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|2 Years|12 Years|No|||December 2014|December 8, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181543||41362|
NCT02181556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 1302|Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer|Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer||Federation Francophone de Cancerologie Digestive|Yes|Recruiting|October 2014|November 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181556||41361|
NCT02182245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.6|Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies|A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies||Boehringer Ingelheim||Completed|October 2005|||January 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182245||41308|
NCT02178267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kurt - 1|Probiotics On Resistant Bacteria Colonization In Preterm Receiving Antibiotics|Effect Of Probiotics On Resistant Bacteria Colonization Preterm Newborn Infants Receiving Antibiotics In Neonatal Intensive Care Unit||Baskent University|No|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|N/A|28 Days|No|||June 2014|June 27, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02178267||41612|
NCT02178540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2412|Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients|A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules||Novartis|No|Recruiting|August 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|6 Years|N/A|No|||October 2014|October 3, 2014|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178540||41591|
NCT02178904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014314|Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques|Dual Energy Computed Tomography for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques|DECIDE-Gold|Weill Medical College of Cornell University|Yes|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|156|||Both|18 Years|N/A|No|Probability Sample|Hospitals in Argentina, Beijing, Seattle, Vancouver, New York|July 2015|July 29, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02178904||41563|
NCT02168452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1410201-1|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy; Observational Pilot Study||National Cancer Center, Korea|Yes|Completed|June 2014|January 2015|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Female|20 Years|70 Years|No|Probability Sample|Breast cancer patients who receive neoadjuvant chemotherapy|February 2016|February 4, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168452|3 Months|42364|
NCT02168725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 08-02|Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors|A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients With Advanced Solid Tumors||Onconova Therapeutics, Inc.|No|Suspended|June 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168725||42343|
NCT02168738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.778|Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules|Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human|AceDoPC|Hospices Civils de Lyon|No|Recruiting|March 2014|March 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|6|||Male|60 Years|70 Years|Accepts Healthy Volunteers|||March 2014|June 19, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02168738||42342|
NCT02168985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFTZ-C&VECF|Impact Evaluation Study of The Faithful House Programme on Violence Reduction in Families|Impact Evaluation for the Faithful House Program in Reducing Violence in Families in Which Couples Are Discordant or HIV/AIDS Positive in Arusha Region, in Tanzania|TFHEVAL|Savannas Forever Tanzania|No|Not yet recruiting|July 2014|February 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||July 2014|July 5, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168985||42323|
NCT02168998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0261-14-TLV|Cortisol Measurement During Intravenous Access With a Medical Clown|Level of Cortisol in Stress Response During Intravenous Access in the Pediatric Emergency Department With a Medical Clown: a Randomized Prospective Pilot Study||Tel-Aviv Sourasky Medical Center||Not yet recruiting|August 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|10 Years|No|||June 2014|June 19, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168998||42322|
NCT02169921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVJ-12-02-01|TurboHawk™ Japan Trial|Determination of Safety and Effectiveness of the TurboHawk® Peripheral Plaque Excision System and the SpiderFX Embolic™ Protection Device (SpiderFX) for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan||Medtronic Endovascular||Active, not recruiting|June 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|N/A|No|||January 2016|January 26, 2016|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02169921||42251|
NCT02169583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201022|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects|A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022||GlaxoSmithKline|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|June 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169583||42277|
NCT02169596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLATE NOX|Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?|a Single Centre Open Pilot Study to Explore if the Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?|PLATE NOX|Hull and East Yorkshire Hospitals NHS Trust|Yes|Recruiting|June 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169596||42276|
NCT02169895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-107|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects||Bial - Portela C S.A.|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|January 20, 2012||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT02169895||42253|
NCT02169882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-201406.01|High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study|A Randomized Double Blinded Phase 2b Clinical Trial Comparing Standard Dose With Two Higher Doses of Rifampicin for Treatment of Adults With Tuberculous Meningitis|ReDEFINe|Universitas Padjadjaran|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|15 Years|N/A|No|||December 2015|December 1, 2015|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02169882||42254|
NCT02171169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-07875|Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures|Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures||Baxano Surgical, Inc.|No|Enrolling by invitation|June 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subject candidates are those that have been treated with either the transsacral or        transforaminal lumbar interbody fusion procedure at least one year prior to this        evaluation.|September 2014|September 2, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171169||42155|
NCT02171182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805-MA-1001|A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain|A Non-interventional Post-registration Clinical Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain||Astellas Pharma Inc|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|319|||Both|18 Years|N/A|No|Probability Sample|patients with post-operative peripheral neuropathic pain|February 2016|February 5, 2016|June 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02171182||42154|
NCT02171546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.75|Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers|A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)||Boehringer Ingelheim||Terminated|November 2007|||January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171546||42126|
NCT02171559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.78|Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers|Relative Bioavailability and Pharmacodynamics of Dabigatran After a Single Dose of 220 mg Dabigatran Etexilate and After 40 mg Enoxaparin s.c. for 3 Days Followed by a Single Dose of 220 mg Dabigatran Etexilate in Healthy Male and Female Volunteers (an Open-label, Randomised, Single and Multiple Dose, Two Way Crossover Phase I Study)||Boehringer Ingelheim||Completed|August 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171559||42125|
NCT02171572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.81|Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects|Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study)||Boehringer Ingelheim||Completed|October 2009|||November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171572||42124|
NCT02171585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.82|Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers|Relative Bioavailability of Dabigatran After Single Oral Administration of 150 mg Dabigatran Etexilate (Capsule) With or Without Multiple Oral Administration of 500 mg Clarithromycin (Tablet) Bid in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Clinical Phase I Study)||Boehringer Ingelheim||Completed|June 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171585||42123|
NCT02171975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM 4(j) 04/02/14|Ultrasound - Guided Paramedian Techniques in Spinal Anesthesia|A Comparison of Conventional Landmark Guided Midline Versus Pre-procedure Ultrasound - Guided Paramedian Techniques in Spinal Anesthesia||Cork University Hospital|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02171975||42093|
NCT02181829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-075|Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases|Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung||Memorial Sloan Kettering Cancer Center||Recruiting|July 2014|||July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|N/A|No|||January 2016|January 11, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181829||41340|
NCT02182258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.75|Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects|Safety and Tolerability of Single Rising Doses of 1 mg, 3 mg, 10 mg and 20 mg of BIBF 1120 as Intravenous Infusion (Single-blind, Placebocontrolled at Each Dose Group) and Absolute Bioavailability of 100 mg BIBF 1120 as Soft Gelatine Capsule (Intra-individual Comparison)||Boehringer Ingelheim||Completed|June 2009|||August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182258||41307|
NCT02182271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.1|Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 150 mg, 300 mg, 600 mg, 1000 mg, and 1500 mg BI 201335 ZW (PEG 400/TRIS/Water Solution) in Healthy Male Subjects, in a Randomised Double Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Two-stage Crossover Pilot Bioavailability Comparison of 600 mg BI 201335 ZW in a PEG 400/TRIS/Water Solution Co-administered With Food||Boehringer Ingelheim||Terminated|October 2004|||October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182271||41306|
NCT02182284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.10|Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers|An Open-label, Randomized, Crossover Relative Bioavailability Study of a New Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Current Solution Formulation (Powder in Bottle (PIB), After Single Dose Oral Administration in Healthy Volunteers||Boehringer Ingelheim||Completed|January 2008|||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182284||41305|
NCT02178280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140615|Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma|Phase 1 Study of Liver Transplantation Combined With Neoadjuvant Radiochemotherapy for Unresectable Hilar Cholangiocarcinoma||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2014|June 26, 2014|June 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178280||41611|
NCT02178553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002940|Study of Exparel Versus Epidural for Pain Control After Thoracotomy|Randomized Non-inferiority Trial of Continuous Thoracic Epidural Analgesia Versus Single Intercostal Nerve Block After Thoracotomy||Mayo Clinic|No|Enrolling by invitation|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178553||41590|
NCT02178566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inova-TY-PR-001|Pulmonary Rehab in COPD: Response to Tyvaso|Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)||Inova Health Care Services|Yes|Recruiting|August 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|40 Years|N/A|No|||August 2015|August 27, 2015|June 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178566||41589|
NCT02178917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14NE311|Neurofeedback for Treatment of Central Neuropathic Pain (CNP) in Sub-acute Spinal Cord Injury (SCI)|Neurofeedback Treatment of Central Neuropathic Pain (CNP) in Sub-acute Patients With Spinal Cord Injury (SCI)||NHS Greater Glasgow and Clyde|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||October 2014|April 27, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178917||41562|
NCT02168751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBHGM-ECNC003-2011|Inflammatory Response Secondary Using Intravenous Anesthesia Versus Inhalation Anesthesia With Halogenated Agents|STUDY OF PULMONARY AND SYSTEMIC INFLAMMATORY RESPONSE SECONDARY TO LUNG RESECTION SURGERY USING INTRAVENOUS ANESTHESIA VERSUS INHALATION ANESTHESIA WITH HALOGENATED AGENTS||Hospital General Universitario Gregorio Marañon|No|Recruiting|September 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02168751||42341|
NCT02169011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120207|Secondary Breast Reconstruction With a Flap of Skin From the Back|Delayed Breast Reconstruction With Skin Flap From the Back||Vejle Hospital|Yes|Recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||November 2015|November 24, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169011||42321|
NCT02169024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304011772|Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me"|Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me"||Yale University|No|Recruiting|February 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1400|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169024||42320|
NCT02169297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-10841-002|Sub-Paraspinal Block in Nuss Patients. A Pilot Project|A Novel Ultrasound-Guided Extrathoracic Sub-Paraspinal Block Utilizing Multi- Perforated Soaker Catheters for Control of Perioperative Pain: A Prospective Randomized Pilot Project in Nuss Patients||Nemours Children's Clinic|Yes|Completed|November 2011|April 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|10|||Both|12 Years|17 Years|No|||May 2014|June 20, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169297||42299|
NCT02202317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120092|Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging|Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging: A Prospective Case Series||University of Miami||Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202317||39768|
NCT02169908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPIDOXA|Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin|LIPIDOXA, a Pilot Study of Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin-based Regimen|LIPIDOXA|Groupe Hospitalier Paris Saint Joseph||Completed|May 2014|March 2016|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169908||42252|
NCT02170428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D201|Diet and Well-being of Young Danish Children|The SKOT I Cohort - a Prospective Cohort Study of Diet and Well-being in Young Danish Children|SKOT I|University of Copenhagen|No|Completed|May 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|263|Samples With DNA|Urine, faeces, white cells, plama/serum|Both|9 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young Danish Children selected through the National Civil Registry and invited to        participate by letter.|June 2014|June 17, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02170428||42212|
NCT02202876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060962|Redox Imbalance and the Development of Cystic Fibrosis Diabetes|Redox Imbalance and the Development of Cystic Fibrosis Diabetes|Redoxy|Emory University|No|Recruiting|November 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|98|||Both|1 Year|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202876||39725|
NCT02202889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-52102-9696|Improving Bone Health in Adolescence Through Targeted Behavioral Intervention|Improving Bone Health in Adolescence Through Targeted Behavioral Intervention||Purdue University|No|Completed|September 2000|September 2004|Actual|September 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|848|||Female|10 Years|13 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202889||39724|
NCT02203084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01278|Social Determinants in Chronic Disease in British Columbia|The Influence of Social Determinants and Access to Health Care on the Outcome of Children With Chronic Health Problems in British Columbia||University of British Columbia|No|Recruiting|September 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|1 Year|17 Years|No|Non-Probability Sample|Participants will be sampled from the cystic fibrosis clinic (150) patients and the        chronic kidney disease clinic (150 patients). For the larger type 1 diabetes clinic the        sample will be purposefully stratified. Recruitment will be monitored to ensure adequate        representation from all the health authorities in BC.|August 2015|August 27, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203084||39709|
NCT02203370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CerbralOximetry_01|Cerebral Oximetry for Carotid EEA|||Salzburger Landeskliniken|No|Recruiting|July 2014|December 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|126|Samples Without DNA|S100B and NSE blood samples taken twice, before and after the surgical procedure|Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for CTEA at the University Hospital Salzburg|July 2014|May 19, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02203370||39687|
NCT02203656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-038|Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults|Feasibility Study of Post-hospitalization Interventions to Improve Physical Function|PACE|The University of Texas Medical Branch, Galveston|No|Recruiting|October 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|100|||Both|65 Years|N/A|No|||September 2015|September 8, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02203656||39665|
NCT02203669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTPT2014|Occupational/Physical Therapy to Reduce Morbidity Post-Operative Bilateral Breast Reconstruction|The Use of Occupational/Physical Therapy to Reduce Upper Extremity Morbidity Post-Operative Bilateral Breast Reconstruction||University of Tennessee|No|Enrolling by invitation|July 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|75|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02203669||39664|
NCT02181582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140141|Specific PET Radioligand Binding to Translocator Protein|Evaluation of Specific PET Radioligand Binding To Translocator Protein||National Institutes of Health Clinical Center (CC)||Recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|February 11, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181582||41359|
NCT02181855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atyGERD-X|Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms|Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms.||Technische Universität München|No|Recruiting|June 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|23|||Both|18 Years|80 Years|No|||January 2015|January 28, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181855||41338|
NCT02182310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.16|Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control||Boehringer Ingelheim||Completed|June 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182310||41303|
NCT02182323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.3|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 4 mg, 16 mg, 48 mg, 120 mg, 240 mg, 480 mg, 800 mg, and 1200 mg BI 201335 NA (PEG 400/TRIS/Meglumine/Water Solution) in Healthy Male Subjects, in a Randomised Single Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Two-stage Crossover Pilot Bioavailability Comparison of 480 mg BI 201335 NA in a PEG 400/TRIS/Meglumine/Water Solution Coadministered With Food||Boehringer Ingelheim||Completed|September 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|74|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182323||41302|
NCT02182336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.32|Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers|Evaluation of the Effects of Single Oral Dose and Multiple Oral Doses of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail. An Open-label, Single-arm Phase I Study in Healthy Human Volunteers||Boehringer Ingelheim||Completed|June 2008|||September 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182336||41301|
NCT02182349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.33|Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of a Single Dose of 240 mg [14C]-BI 201335 Given as Oral Solution to Healthy Male Volunteers at Steady State of BI 201335 NA Maintained With Oral Capsules of 240 mg BI 201335, a Phase I, Single-arm, Open-label Trial||Boehringer Ingelheim||Completed|June 2009|||July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182349||41300|
NCT02182765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1244|Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®), Abacavir and Amprenavir in HIV-1 Infected NNRTI Naive Adults||Boehringer Ingelheim||Terminated|April 1999|||July 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182765||41268|
NCT02182778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1401|GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer|Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Enrolling by invitation|June 2014|May 2019|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|N/A|No|||July 2014|July 7, 2014|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02182778||41267|
NCT02178293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087.7|Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride|MISTRAL (Mouthwash In Sore Throat Relief: Antiinflammatory vs. Local Anesthetic Therapy) "Efficacy and Tolerability of Ketoprofen Lysine Salt as a Mouthwash in Acute Phlogosis of the Pharyngeal Cavity; Multicentre, Randomized, Single-blind, Parallel-group Comparison Versus Benzidamine Hydrochloride"|MISTRAL|Boehringer Ingelheim||Completed|September 1998|||May 1999|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|70 Years|No|||July 2014|July 4, 2014|June 27, 2014||||No||https://clinicaltrials.gov/show/NCT02178293||41610|
NCT02178306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.339|Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis|An Open-labeled, Placebo run-in, Multicentre Study to Investigate the Efficacy and Safety of Telmisartan (40 and 80 mg QD p.o.) in 3 Strata of Mild to Moderate Hypertensive Patients (Sitting Diastolic Blood Pressure ≥ 90 mmHg and ≤ 109 mmHg From Office Cuff Measurement) With Mild/Moderate or Severe Renal Impairment or Requiring Maintenance Hemodialysis. (ESPRIT Study = Efficacy and Safety in Patients With Renal Impairment Treated With Telmisartan)|ESPRIT|Boehringer Ingelheim||Completed|September 2000|||April 2002|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|June 27, 2014||||No||https://clinicaltrials.gov/show/NCT02178306||41609|
NCT02178579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140404|Prospective Observation of Cardiac Safety With Proteasome Inhibition|Prospective Observation of Cardiac Safety With Proteasome Inhibition|PROTECT|Vanderbilt University|Yes|Recruiting|November 2014|December 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|Samples With DNA|Blood sample banked for future research.|Both|18 Years|N/A|No|Non-Probability Sample|Multiple Myeloma patients being treated with bortezomib or carfilzomib, per oncology        physician decision.|December 2014|December 8, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178579||41588|
NCT02178592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117175|Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection|ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naïve Adults Starting Treatment for Rifampicin-sensitive Tuberculosis||ViiV Healthcare|No|Recruiting|January 2015|June 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||October 2015|November 12, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178592||41587|
NCT02178930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1150-6489|HealthMap: an Interactive Health Plan Randomised Trial to Prevent Cardiovascular Disease in People With HIV|HealthMap: a Cluster Randomised Trial of Interactive Health Plans and Self-management Support to Prevent Cardiovascular Disease in People With HIV||Monash University|No|Active, not recruiting|August 2014|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|731|||Both|30 Years|N/A|No|||March 2016|March 17, 2016|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02178930||41561|
NCT02169037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAR083359|Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation|Substrate Ablation (Focal Impulse and Rotor Modulation) Compared to Pulmonary Vein Isolation to Eliminate Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial|SUBSTRATE|University of California, San Diego|Yes|Recruiting|February 2016|September 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169037||42319|
NCT02169310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140083|Neural Basis of Decision-Making Deficits in Traumatic Brain Injury|Neural Basis of Decision Making Deficits in Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|March 2, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02169310||42298|
NCT02169635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013meky013|Macular Buckle With Three-armed Silicone|Safety and Efficacy Study of Macular Buckle With A Three-armed Silicone Capsule to Support the Posterior Staphyloma in High Myopia.|MBTAS|Sun Yat-sen University|Yes|Completed|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||June 2014|June 18, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02169635||42273|
NCT02202655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13501185982|Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer|Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer|NSCLC|Beijing Chao Yang Hospital|Yes|Recruiting|May 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with non-small cell lung cancer who accept chemotherapy for the first time are        acceptable.|July 2014|July 28, 2014|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202655||39742|
NCT02170194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388404|GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience|GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience|GETSmart|Walter Reed National Military Medical Center|Yes|Active, not recruiting|May 2014|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention|2||Actual|144|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02170194||42230|
NCT02203097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030167-006/2014/OTIG|The Effect of Different End-tidal Carbon-dioxide Levels on Cerebral CO2 Vasoreactivity and the Stiffness of Systemic Arteries During Propofol Anesthesia|The Effect of Different End-tidal Carbon-dioxide Levels on Cerebral CO2 Vasoreactivity and the Stiffness of Systemic Arteries During Propofol Anesthesia||University of Debrecen|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|50 Years|No|||January 2016|January 12, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203097||39708|
NCT02203383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0078|The Effect of CRT on the Hypercapnic Ventilatory Response|Sleep Disordered Breathing in Patients With Implanted Cardiac Devices: Assessment of the Change in Sensitivity to Carbon Dioxide With Cardiac Resynchronization Therapy.||Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with heart failure with reduced ejection fraction (<40% on echocardiography) due        to undergo implantation of a biventricular pacemaker, with either no significant sleep        disordered breathing or moderate to severe CSA.|February 2014|July 28, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203383||39686|
NCT02203682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013MEKY033|Doxycycline Treatment in Mild Graves' Orbitopathy|The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy||Sun Yat-sen University|Yes|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2014|July 28, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203682||39663|
NCT02204007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-555|Real Time 3D Imaging and Surrogate Bone Model|Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial||The Cleveland Clinic|Yes|Recruiting|June 2014|April 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204007||39638|
NCT02204553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589DUS94X|Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma|An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy||Novartis||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 28, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02204553||39596|
NCT02181595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140139|Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency|Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency: An Exporatory Pilot Study.||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|5|||Female|18 Years|45 Years|No|||March 2016|March 18, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181595||41358|
NCT02181608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140137|Traits Associated With Early Life Stress Among Treatment-Seeking Alcoholics|Traits Associated With Early Life Stress Among Treatment-Seeking Alcoholics||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Actual|0|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181608||41357|
NCT02182362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.6|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of 20 mg, 48 mg, 120 mg, and 240 mg Once a Day of BI 201335 NA (Oral Solution) in Healthy Male Subjects, in a Randomized Double Blind, Placebo Controlled Study||Boehringer Ingelheim||Completed|May 2007|||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|39|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182362||41299|
NCT02182375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.9|Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers|An Open Label Fixed Sequence Phase I Study to Investigate the Effect of BI 201335 Mediated UGT1A1 Inhibition on the Multiple Oral Dose Pharmacokinetics of Raltegravir (Isentress®) in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|January 2010|||March 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182375||41298|
NCT02182388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.1|Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses (5 mg to 3000 mg) of BI 207127 NA as Powder in the Bottle Reconstituted With PEG 400/Tris/SDS in Healthy Male Subjects. A Randomised, Placebo-controlled and Within Dose Groups Double-blinded Trial. Followed by an Intra-individual, Partially Randomised, Open Comparison of Powder in the Bottle and Tablet Without and With Food.||Boehringer Ingelheim||Completed|January 2007|||May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|82|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182388||41297|
NCT02182791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1245|Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE® ) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM® 1/35 (21 Pack)] in HIV-1 Infected Women||Boehringer Ingelheim||Completed|April 1998|||April 1999|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|65 Years|No|||July 2014|July 11, 2014|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182791||41266|
NCT02182804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP008|A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer|Diagnostic Values of Probe-based Confocal Laser Endomicroscopy (pCLE) and Magnifying Narrow Band Imaging (M-NBI) for Early Neoplasms Detection in Esophageal Lugol'S-voiding Lesions.||King Chulalongkorn Memorial Hospital|No|Completed|February 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|44|||Both|20 Years|N/A|No|||July 2014|July 7, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02182804||41265|
NCT02182414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.9|Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers|Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I Administered Orally as Tablet in Single Doses of 800 mg to Healthy Volunteers, and Evaluation of the Effect of Food on the Bioavailability of a Selected Prototype (an Open-label, Two-stage, Within Parts Randomised Six-way and Two-way Crossover Phase I Study)||Boehringer Ingelheim||Completed|May 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|42|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182414||41295|
NCT02178319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|portal hypertension|Laparoscopic Versus Open Devascularization for Portal Hypertension, a Randomized Controlled Trial|Randomized Clinical Trial Comparing Laparoscopic and Open Esophagogastric Devascularization and Splenectomy for Portal Hypertension||Second Affiliated Hospital of Xi'an Jiaotong University|No|Recruiting|June 2014|September 2021|Anticipated|June 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 26, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02178319||41608|
NCT02178332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL/455/6.00.00/2014|Yhteispeli - Effectiveness Study on Promoting Childrens' Socio-emotional Skills in School|Yhteispeli: Intervention Effectiveness on Elementary School Childrens' Socio-emotional Skills and Psychiatric Symptoms||National Institute for Health and Welfare, Finland|No|Active, not recruiting|March 2013|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4400|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02178332||41607|
NCT02178605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-07|rhBMP-2 in Cervical Arthrodesis|A Prospective Non-Randomized Investigation Of The Use Of Infuse® (rhBMP-2) In Cervical Arthrodesis||Virginia Spine Institute|No|Recruiting|October 2008|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting at a single site and candidates for cervical arthrodesis|June 2014|June 26, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178605||41586|
NCT02178618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE3-14-001|Partially Covered and Uncovered Metal Stent for Malignant Distal Biliary Stricture|A Randomized Trial of Partially Covered Versus Uncovered Self Expandable Metal Stents for the Palliation of Malignant Distal Biliary Stricture||Ajou University School of Medicine|Yes|Completed||||January 2006|Actual|N/A|Interventional|N/A|2||||||Both|20 Years|N/A|No|||June 2014|June 27, 2014|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02178618||41585|
NCT02179970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-PLEX|To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers|To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.|CAM-PLEX|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|16 Years|N/A|No|||January 2016|January 4, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02179970||41482|
NCT02169323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-98|Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics|Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics||University Hospital of Liege|No|Recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169323||42297|
NCT02169648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4|Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion|Study on the Correlation Between the Treatment Effectiveness of Ranibizumab and the Role of the Cytokines in Macular Edema With Retinal Vein Occlusion||Tokyo Medical University|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|30 Years|90 Years|No|||June 2014|June 18, 2014|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02169648||42272|
NCT02202083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCSH2014|The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor|The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor||West China Second University Hospital|Yes|Recruiting|June 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator)|1||Anticipated|300|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02202083||39786|
NCT02202096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0336|A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients|A Pilot Randomized Trial of the Comprehensive Transitional Care Program for Medically Underserved Colorectal Cancer Surgery Patients||The University of Texas Health Science Center, Houston|No|Not yet recruiting|February 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02202096||39785|
NCT02202109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140249|Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida|Addressing Cervical Cancer Disparity in South Florida: CBPR in Action||University of Miami|No|Recruiting|January 2015|April 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|700|||Female|30 Years|65 Years|No|||January 2016|January 11, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02202109||39784|
NCT02202642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007032D|The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells|The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells||National Taiwan University Hospital|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||July 2014|July 24, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT02202642||39743|
NCT02203110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Severe pneumonia|The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia|The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia|SCAHAVAP|University Medical Centre Ljubljana|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Whole blood, two 7 ml samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admited to Intensive Care Unit Department of Infectious Diseases University        Medical Centre Ljubljana due to severe pneumonia or pneumonia will develop during their        stay in ICU.|July 2014|July 25, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203110||39707|
NCT02203123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ultrasound_01|Ratio of Inferior Vena Cava and Aorta Diameter in Dehydrated Children|||Seoul National University Hospital||Recruiting|March 2014|||April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|226|||Both|3 Months|15 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02203123||39706|
NCT02203396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATGIIT201401|A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia|A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia|OSP|Institute of Hematology & Blood Diseases Hospital|Yes|Recruiting|August 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|70 Years|No|||August 2014|August 10, 2014|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02203396||39685|
NCT02203695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1454|Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy|Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2014|August 2025|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Male|18 Years|100 Years|No|||March 2016|March 8, 2016|June 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203695||39662|
NCT02204020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 13-165|Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS|Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|UPCI 13-165|University of Pittsburgh|Yes|Recruiting|April 2015|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204020||39637|
NCT02204319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-13-21|Cold Laser: A Modality to Promote Vulvar Healing and Pain Relief|Cold Laser: A Modality to Promote Vulvar Healing and Pain Relief||ProHealth Care, Inc|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||July 2015|July 1, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02204319||39614|
NCT02181881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR010187|DuoPACT Pilot Intervention|Relationship Factors and HIV Treatment Adherence||University of California, San Francisco|Yes|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Male|18 Years|N/A|No|||October 2014|October 21, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181881||41336|
NCT02181894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1117|Identifying the Most Accurate Method for Predicting the Safe Depth of Orally Placed Neonatal Endotracheal Tubes (ETT).|Identifying the Most Accurate Method for Predicting the Safe Depth of Orally Placed Neonatal Endotracheal Tubes.||University of Colorado, Denver|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|372|||Both|N/A|72 Hours|No|Non-Probability Sample|Infants <72 hours of age and orally intubated|November 2015|November 30, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181894||41335|
NCT02181868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBTF110|Comparison of Biodegradable and Titanium Fixation Systems in Mandibular Symphysis or Parasymphysis Solitary Fractures|||Tianjin Medical University General Hospital||Approved for marketing|January 2008|||December 2013|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|60 Years||||July 2014|July 3, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02181868||41337|
NCT02182401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.18|Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers|An Open-label, Fixed Sequence Phase I Study in Healthy Male Volunteers to Assess Sequentially the Effects of Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA, on the Single Dose Pharmacokinetics of Midazolam and Tolbutamide and on the Systemic Exposure of BI 207127 NA and BI 201335 NA||Boehringer Ingelheim||Terminated|July 2009|||August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182401||41296|
NCT02182817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGAIN 2013/552/D|Exposure to General Anaesthesia in Infancy and Neurocognitive Development|Prospective Cohort Study of Effects of Exposure to General Anaesthesia in Infancy on Neurocognitive Development|EGAIN|KK Women's and Children's Hospital|No|Recruiting|November 2013|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|Samples With DNA|Buccal swabs|Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|Full-term infants with no significant co-morbidities presenting for minor surgery at KK        Womens' and children's hospital, Singapore|July 2014|February 28, 2016|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02182817||41264|
NCT02178345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-126|Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer|Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical Head and Neck Cancer clinic MSKCC|December 2015|December 3, 2015|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178345||41606|
NCT02178631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVIDENTplus|Effectiveness of Internet-based Depression Treatment (EVIDENT) in Severe Depression|||University of Luebeck|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02178631||41584|
NCT02179502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1690-CL-101|First-in-Human Single and Multiple Dose of GLPG1690|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects||Galapagos NV|No|Completed|June 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 20, 2015|June 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02179502||41518|
NCT02169661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNU 2000|Burger and Beetroot Study - Lipid Oxidation Study|Lipid Oxidation of Ready Meals: Reformulation With Antioxidant Phytochemicals|BABS|University of Aberdeen|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|16|||Male|21 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT02169661||42271|
NCT02201602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gliclazide|Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study|Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study||Khoo Teck Puat Hospital|No|Recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|21 Years|65 Years|No|||September 2015|September 6, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201602||39823|
NCT02201836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142-04|The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma|The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma||Beth Israel Medical Center|No|Completed|January 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|200|||Both|7 Years|18 Years|No|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201836||39805|
NCT02201849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK8700-001|A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults||Alkermes, Inc.|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02201849||39804|
NCT02202122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNF-OSA|Interest of the OSA (Obstructive Sleep Apnea) Predictive Scores in the Prognosis of Postoperative Mortality of Femoral Neck Fractures|Interest of the OSA (Obstructive Sleep Apnea) Predictive Scores in the Prognosis of Postoperative Mortality of Femoral Neck Fractures.||Astes|No|Withdrawn|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|All patients with femoral neck fractures|June 2015|June 22, 2015|July 25, 2014||No|lack of investigators|No||https://clinicaltrials.gov/show/NCT02202122|1 Month|39783|
NCT02202356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8176-503|A Study of ALS-008176 in Infants Hospitalized With RSV|A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection||Alios Biopharma Inc.|Yes|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|168|||Both|1 Month|12 Months|No|||March 2016|March 18, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202356||39765|
NCT02202330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC132001MED|Using 5 Minute Videos for Numeracy and Literacy Challenged Stroke Survivors to Improve Outcomes|Translating Knowledge for Action Against Stroke - Using 5 Minute Videos for Numeracy and Literacy Challenged Stroke Survivors and Caregivers to Improve Outcomes||Aga Khan University|Yes|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202330||39767|
NCT02202343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHNP/2013|Effectiveness of School-based Health and Nutrition Education to Improve Health and Dietary Practices of Primary School Children From Jimma Zone|||Jimma University|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1000|||Both|12 Years|19 Years|No|||April 2015|April 9, 2015|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02202343||39766|
NCT02202902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR12017|Cardiac Steatosis in Cushing's Syndrome|Evaluation of Cardiac Steatosis in Cushing's Syndrome. A 1H-Magnetic Resonance Spectroscopy Study|CORTICOEUR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202902||39723|
NCT02203136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA13-0942|Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging|Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging||M.D. Anderson Cancer Center|No|Recruiting|June 2014|||June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|At the time of biopsy, a portion of the fresh human tumor biopsy samples utilized for DNA      and RNA extraction.|Both|N/A|N/A|No|Non-Probability Sample|Participants scheduled for bladder cancer surgery and biopsy from the Department of        Urology at MD Anderson Cancer Center in Houston, Texas.|February 2016|February 8, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203136||39705|
NCT02203149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-058|Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)|A Phase II, Randomized Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C and a Phase III, Randomized Placebo-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|399|||Both|20 Years|80 Years|No|||February 2016|February 19, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203149||39704|
NCT02203409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHZSG005|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy||Southwest Hospital, China|Yes|Recruiting|July 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Non-Probability Sample|30|July 2014|July 8, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02203409||39684|
NCT02203708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 199 08|Supportive Program for Mother With BPD|Effect on Relationship of a Brief Preventive Program: Pragmatic Pilot Randomized Controlled Trial." - Supportive Program for Mother With BPD|PAM-B|University Hospital, Toulouse|No|Completed|July 2012|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|January 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02203708||39661|
NCT02203721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EROV-106-ZXRC|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2014|||||N/A|N/A|N/A||||||||||||||October 29, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203721||39660|
NCT02204033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1170.1|Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer|A Phase I Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Head and Neck Cancer||Boehringer Ingelheim||Completed|March 1999|||June 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02204033||39636|
NCT02204046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1170.2|Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast|A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Adenocarcinoma of the Breast||Boehringer Ingelheim||Completed|January 2000|||February 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02204046||39635|
NCT02168595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1271-101|Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects||GlycoMimetics Incorporated|Yes|Completed|June 2014|April 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|28|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|June 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168595||42353|
NCT02168608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2013-003-006|Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy|Remote Ischemia Precondition for Hepatic Protection in Patients Undergoing Hepatectomy: A Single-center Randomized Controlled Trial||Eastern Hepatobiliary Surgery Hospital|Yes|Not yet recruiting|September 2014|June 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|70 Years|No|||June 2014|June 18, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02168608||42352|
NCT02181907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.260|Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers|Bioequivalence Study of UH-AC 62 XX Tablets 10 mg (TF4) Compared With the 10 mg Capsule Formulations Following Single Peroral Administration in Healthy Volunteers||Boehringer Ingelheim||Completed|March 2003|||April 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181907||41334|
NCT02181920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093.14|Metamizol for the Treatment of Neoplastic Chronic Pain|Analgesic Effect of a New Metamizol Oral Pharmaceutical Form for the Treatment of the Neoplastic Chronic Pain: Randomized, Double-blind Crossover Clinical Trial Between Metamizol, Diclofenac and Placebo||Boehringer Ingelheim||Terminated|March 2000|||November 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02181920||41333|
NCT02182427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-Pilot|Malnutrition Clinical Characteristics Validation Study|Malnutrition Clinical Characteristics Validation Study|MCC|Academy of Nutrition and Dietetics|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|N/A|No|Probability Sample|All eligible patients (according to the inclusion and exclusion criteria seen below) who        are admitted to one of the following acute care facilities: University Hospitals Case        Medical Center, Cleveland Clinic, and St. John's Westshore in Cleveland, Ohio, United        States, and Princess Alexandra Hospital in Brisbane, Queensland, Australia.|January 2016|January 26, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02182427|30 Days|41294|
NCT02182830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.29|24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, Once Daily Over 24 Weeks in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Recruiting|July 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 3, 2014||||No||https://clinicaltrials.gov/show/NCT02182830||41263|
NCT02182843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-092|Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn)|Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn)|VCBM/ACDF|Biomet, Inc.|No|Active, not recruiting|March 2014|September 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|February 26, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02182843||41262|
NCT02179489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCCZ-C01|Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis|Randomized Multicentric Phase III Trial Comparing Simple Surgery to Surgery Plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy) With MMC in Colorectal Patients Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis||Zhejiang University|Yes|Recruiting|October 2014|October 2023|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||July 2015|January 19, 2016|June 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02179489||41519|
NCT02179762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9814|Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer|Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors|EASE|Case Comprehensive Cancer Center|No|Suspended|August 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|30|||Male|18 Years|75 Years|No|||January 2016|January 14, 2016|June 30, 2014||No|Insufficient staff|No||https://clinicaltrials.gov/show/NCT02179762||41498|
NCT02169336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-13-012|Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy||Recro Pharma, Inc.|No|Terminated|June 2014|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|June 17, 2014|Yes|Yes|Lack of observed efficacy|No|October 6, 2015|https://clinicaltrials.gov/show/NCT02169336||42296|An interim analysis was performed that focused on the primary efficacy endpoint (SPID48). Observed effect size was determined for purposes of final sample size determination. The study was terminated following the interim analysis.
NCT02169349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00426-41|Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer|Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA|ANTiCIPe|Rennes University Hospital||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited from patients receiving treatment for NSCLC at the Rennes        Hospital|October 2015|October 27, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02169349||42295|
NCT02169362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART 13-005|Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries|Phase I, Double-Blind, Randomized, Controlled Study to Demonstrate the Safety of Applying Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™) to Acute Deep Partial Thickness Thermal Injuries||Arteriocyte, Inc.|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|86 Years|No|||March 2016|March 11, 2016|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169362||42294|
NCT02201862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD201|Non-Invasive Chromosomal Evaluation of Trisomy Study|Non-Invasive Chromosomal Evaluation of Trisomy Study|NICHE|Ariosa Diagnostics, Inc|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Plasma|Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women planning to undergo chorionic villus sampling (CVS) and/or amniocentesis        for the purpose of genetic evaluation of the fetus.|August 2015|August 12, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201862||39803|
NCT02202135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00001sub|Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.|A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.||AstraZeneca||Terminated|June 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|July 25, 2014|Yes|Yes|Study terminated due to sponsor decision|No||https://clinicaltrials.gov/show/NCT02202135||39782|
NCT02202369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9080|Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study|Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|February 2015|August 2018|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02202369||39764|
NCT02202681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-1405|Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule|Pilot Study for Imaging of the Duodenum Using an OFDI Capsule||Massachusetts General Hospital|No|Recruiting|August 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02202681||39740|
NCT02202668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00083401|Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers|Transcutaneous Raman Spectroscope Analyses of Diabetic Foot Ulcers||University of Michigan|No|Suspended|September 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|July 24, 2014||No|TRS probe performance does not meet primary outcome data requirements|No||https://clinicaltrials.gov/show/NCT02202668||39741|
NCT02202915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R33MH096828-03|CBT for Pediatric OCD: Community Training Pilot|CBT for Pediatric OCD: Community Training Pilot||Rhode Island Hospital|Yes|Recruiting|September 2014|May 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|5 Years|17 Years|No|||July 2014|May 10, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202915||39722|
NCT02172560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.392|A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler|A Retrospective Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler||Boehringer Ingelheim||Completed|March 2007|||January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|441|||Both|N/A|N/A|No|Probability Sample|Patients with COPD who withdrew prematurely from the randomised treatment phases of        studies 205.254 and 205.255|June 2014|November 17, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172560||42048|
NCT02172573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.505|Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease|A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease||Boehringer Ingelheim||Completed|April 1999|||July 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|315|||Both|20 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172573||42047|
NCT02172872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1301|"InDACtion" vs "3+7" Induction in AML|10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|November 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|60 Years|N/A|No|||January 2016|January 29, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02172872||42024|
NCT02173158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-030|Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy|A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy||Aegerion Pharmaceuticals, Inc.|Yes|Active, not recruiting|April 2014|November 2015|Anticipated|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02173158||42002|
NCT02168322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al Azhar universty|Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels|Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels During Treatment of Intrabony Defects: An In Vivo Proof-of-Principle Study||Al-Azhar University|Yes|Completed|October 2013|March 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|26 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02168322||42374|
NCT02168855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA034629|Cessation in Non-Daily Smokers|Cessation in Non-Daily Smokers: A RCT of NRT With Ecological Momentary Assessment|QUITS|University of Pittsburgh|Yes|Recruiting|July 2014|June 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|21 Years|N/A|No|||July 2014|July 22, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168855||42333|
NCT02178644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404013708|Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer|Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer||Yale University|Yes|Recruiting|July 2014|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|June 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02178644||41583|
NCT02178943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-C-00004|Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling|Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)|D-OAR|XDx|No|Recruiting|June 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|donor derived cf-DNA|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Heart allograft recipients undergoing scheduled surveillance visits that are part of a        long-term management plan.|March 2015|March 23, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02178943|3 Years|41560|
NCT02182440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-recAP-AKI-02-01|A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI|A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI|STOP-AKI|AM-Pharma|Yes|Recruiting|December 2014|September 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|290|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02182440||41293|
NCT02182453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.5|Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 to 100 mg) of BI 10773 in Healthy Male Volunteers||Boehringer Ingelheim||Completed|June 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182453||41292|
NCT02182856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.39|Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD|A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on Arterial Oxygen Saturation in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|February 1998|||July 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|33|||Both|40 Years|N/A|No|||July 2014|July 4, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02182856||41261|
NCT02182869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.43|Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)|Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients||Boehringer Ingelheim||Terminated|April 2001|||August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|7|||Both|40 Years|N/A|No|||July 2014|July 7, 2014|July 4, 2014||||No||https://clinicaltrials.gov/show/NCT02182869||41260|
NCT02179242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH Cardiac Rehab for HF|Study to Evaluate the Effectiveness of Cardiac Rehabilitation (Rehab) for Acute Decompensated Heart Failure Patients on 6 Minute Walk Test and Quality of Life|Randomized, Single Center Study to Determine if a Cardiac Rehabilitation Program Immediately Following Hospitalization Reduces Hospital Readmissions and Improves Quality of Life Outcomes in Heart Failure Patients.||Sanford Health|No|Terminated|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 27, 2014||No|Lower than expected accrual|No||https://clinicaltrials.gov/show/NCT02179242||41538|
NCT02178969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-608-002|Short Term Observational Study in DEB Patients|A Prospective Short-term Study to Evaluate Methodologies for the Assessment of Disease Extent, Impact, and Wound Evolution in Patients With Dystrophic Epidermolysis Bullosa (DEB)||Shire|No|Completed|June 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|Samples With DNA|Optional genetic test for DEB diagnosis|Both|N/A|N/A|No|Non-Probability Sample|Patients with DEB.|March 2015|May 28, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02178969||41558|
NCT02179255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04082014-02|Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF|An Open-Label Randomized Controlled Trial (RCT) of 6 Weeks of Human Growth Hormone (HGH) Prior to Ovulation Induction for In Vitro Fertilization (IVF)||Center for Human Reproduction|No|Enrolling by invitation|August 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|44 Years|No|||June 2015|June 24, 2015|June 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02179255||41537|
NCT02179268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2012] NO31260237/C090103|Antidepressants and Bone Mineral Density|International Committee of Medical Journal Editors||Guiyang Medical University|Yes|Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|203|||Both|20 Years|48 Years|No|||June 2014|June 28, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02179268||41536|
NCT02170233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014123|SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography|SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography||Yale University|No|Recruiting|August 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to one of three Yale New Haven Hospital emergency departments, York        Street Campus, St. Raphael's Campus, and Shoreline Medical Center who meet criteria for        severe sepsis or septic shock during their emergency department visit. A number of healthy        patients will also be enrolled to act as controls for this study.|August 2014|August 18, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02170233||42227|
NCT02201875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERHYP1|Intrinsic Periodic Pattern of Breathing|Study of Periodic Breathing in Healthy Humans|PERHYP1|Association pour la Recherche en Physiologie de l'Environnement|No|Not yet recruiting|September 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects Patients with obstructive sleep apneas Patients with cardiac failure|July 2014|July 24, 2014|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201875||39802|
NCT02202148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00854-43|Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal|||Centre Hospitalier Esquirol|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|195|||Both|18 Years|N/A|No|Non-Probability Sample|alcohol-dependent subjects hospitalized for alcohol withdrawal|July 2015|July 31, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202148||39781|
NCT02202161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201351|A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients|A Randomized, Placebo Controlled, Repeat Dose, Double Blind (Sponsor Unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients||GlaxoSmithKline|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|64|||Both|30 Years|64 Years|No|||May 2015|June 11, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202161||39780|
NCT02202382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGR study|Effects of Korean Red Ginseng on Male Infertility|||Pusan National University Hospital||Completed|April 2011|||January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Male|25 Years|45 Years|No|||July 2014|July 29, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02202382||39763|
NCT02202395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS-201-P1.0|Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|T8|Shanghai Pharmaceuticals Holding Co., Ltd|Yes|Recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Female|35 Years|65 Years|No|||July 2014|July 28, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02202395||39762|
NCT02202694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-PSY-01|Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan|Feasibility Study of Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan||Pakistan Institute of Learning and Living|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||July 2014|July 28, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02202694||39739|
NCT02202928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Colorectal Cancer|Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer|Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery||Shenzhen Hornetcorn Bio-technology Company, LTD|No|Active, not recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||July 2015|December 23, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202928||39721|
NCT02172885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number:2012-002553-38|Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta|Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta|TERCELOI|Hospital de Cruces|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|6 Months|12 Years|No|||March 2015|March 17, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02172885||42023|
NCT02173171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120139|Registry Study for Talimogene Laherparepvec|A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec||Amgen|No|Enrolling by invitation|December 2014|March 2023|Anticipated|March 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|99 Years|No|Non-Probability Sample|Subjects who have received at least one dose of talimogene laherparepvec on an Amgen or        BioVEX-sponsored clinical trial.|February 2016|March 14, 2016|June 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02173171|2 Years|42001|
NCT02173184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATVAC 1-2013-HU|Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis|Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis||Amvac Kft.|No|Recruiting|June 2014|July 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|55 Years|No|||October 2014|October 28, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02173184||42000|
NCT02168335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaSilva200814363|The Efficacy of OrasaltsTM in the Treatment of Gingivitis|The Efficacy of OrasaltsTM in the Treatment of Gingivitis||University of Johannesburg|Yes|Completed|May 2014|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02168335||42373|
NCT02168621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGR 2013-2|Intervention Study of Two Protocols for Non-surgical Treatment of Chronic Periodontitis|Approaches to Pocket/Root Debridement for Periodontal Infection Control - a Study on Effectiveness.||Göteborg University|No|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|30 Years|N/A|No|||January 2016|January 7, 2016|April 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02168621||42351|
NCT02169479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-108|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects||Bial - Portela C S.A.|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 20, 2012||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT02169479||42285|
NCT02169492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PMK-1203|Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke|Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke: An Observational, Prospective and Multicenter Study|Re-ACT|Codman & Shurtleff|Yes|Recruiting|January 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|103|||Both|18 Years|80 Years|No|Non-Probability Sample|subjects requiring mechanical thrombectomy|February 2016|February 9, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02169492||42284|
NCT02182895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001095|Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient|Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient||Brigham and Women's Hospital|No|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|110 Years|No|||February 2016|February 8, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02182895||41258|
NCT02178956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-336|A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer|A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma|BRIGHTER|Boston Biomedical, Inc|Yes|Recruiting|August 2014|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02178956||41559|
NCT02179229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syn-Graft Study|Effect of Pre- and Probiotics on P-cresol Plasma Levels in Patients Bearing a Kidney Allograft|Effect of Pre- and Probiotics on P-cresol Plasma Levels in Patients Bearing a Kidney Allograft||Federico II University|No|Recruiting|June 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||June 2014|July 1, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02179229||41539|
NCT02178657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2013-002135-15|Intra-arterial Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke|Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke. A Phase II, Open-label, Multicenter, Randomized and Controlled Clinical Trial.||Andalusian Initiative for Advanced Therapies|No|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|76|||Both|18 Years|80 Years|No|||July 2015|July 7, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02178657||41582|
NCT02168803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15340|A Study of Evacetrapib in Participants With Abnormal Cholesterol|A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks||Eli Lilly and Company|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02168803||42337|
NCT02169063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8021|Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer|PET Imaging as a Biomarker of Systemic Treatment Response for Men With Metastatic Castration-Resistant Prostate Cancer||University of Washington|No|Recruiting|December 2015|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|June 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02169063||42317|
NCT02169076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0338|Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients|Cardiac Resynchronization Therapy in Patients With Left Ventricular Assist Devices|CRT-LVAD|University of Louisville|Yes|Not yet recruiting|September 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2014|June 18, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169076||42316|
NCT02170246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS084911-01|Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection|Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of Central Nervous System Reservoirs of HIV and Lymph Node Fibrosis [Southeast Asia Research Collaboration With Hawaii (SEARCH) 018]|SEARCH018|Yale University|Yes|Recruiting|August 2014|February 2019|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|21|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|May 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02170246||42226|
NCT02201888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-2009-15|Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study|Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study||FIDMAG Germanes Hospitalàries|No|Completed|January 2010|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201888||39801|
NCT02202174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15832|The Safety and Efficacy of Supraglottic Airway Use in Children|The Safety and Efficacy of Supraglottic Airway Use in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients undergoing anesthesia with use of a supraglottic airway device as        primary means of oxygenation and ventilation.|July 2015|July 27, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202174||39779|
NCT02170870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002098|Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus|Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus||Mayo Clinic|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|104|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02170870||42178|
NCT02171273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000243|Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism|Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism||Brigham and Women's Hospital|No|Enrolling by invitation|June 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|50|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02171273||42147|
NCT02171806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 μg, 10 μg, and 30 μg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Doubleblind, Randomised, Placebo Controlled [at Each Dose Level] Study)||Boehringer Ingelheim||Completed|January 2006|||September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|47|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02171806||42106|
NCT02172040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIT-302-03-01|Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy|A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy||Kitov Pharmaceuticals, Ltd.|No|Completed|June 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|152|||Both|40 Years|75 Years|No|||February 2016|February 2, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02172040||42088|
NCT02172586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.316|Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients|A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg Once Daily Compared With Losartan 100 mg Once Daily + HCTZ 12.5 mg Once Daily Over a Period of Further 12 Weeks in Mild to Moderate Hypertensive Patients (Grade 1 and Grade 2 WHO-ISH Guidelines 1999)||Boehringer Ingelheim||Completed|January 2000|||January 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|363|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02172586||42046|
NCT02172027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImmunoMag-Det LC 00432014|Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool|Novel Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool||Meir Medical Center|Yes|Not yet recruiting|July 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients with pleural effusion at the Meir Medical Center Oncology Department        or Lung Department.|June 2014|June 22, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02172027||42089|
NCT02168348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOUILLET 2013|Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients|Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients||Centre Hospitalier Universitaire Dijon||Recruiting||||November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|N/A|No|Probability Sample|Patients with type 1 or 2 diabetes who have a lesion situated on a toe or on the plantar        or dorsal side of the foot|October 2013|June 19, 2014|June 18, 2014||||No||https://clinicaltrials.gov/show/NCT02168348||42372|
NCT02168634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS13-CT12-23|The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial|The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial||Kaohsiung Veterans General Hospital.||Recruiting|November 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||October 2015|October 7, 2015|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02168634||42350|
NCT02168881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Misoprostol-2014|Oral Misoprostol Versus Vaginal Dinoprostone For Induction Of Labour: A Randomized Controlled Clinical Trial|||Ain Shams University||Recruiting|May 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|342|||Female|N/A|N/A|No|||June 2014|June 19, 2014|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168881||42331|
NCT02168894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0930|SINF: Peripheral Neuropathy in Cancer Survivors|A Phase I-II Study of Acupuncture for the Treatment of Chronic, Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors||M.D. Anderson Cancer Center|Yes|Withdrawn|March 2016|||March 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02168894||42330|
NCT02168868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CellEL-920130030|Immune Tests in Blood Samples From Children With ASD|In Vitro Immune Tests in Blood Samples From Children With ASD||Cell El Ltd|Yes|Recruiting|May 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|450|Samples Without DNA|serum|Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children diagnosed with Autism Spectrum Disorder according to DSM-4 from hospital or kupat        cholim (local HMO's)|December 2014|December 24, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02168868|1 Day|42332|
NCT02169193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_09|Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium|Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium||University Hospital, Lille|No|Withdrawn|September 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169193||42307|
NCT02169765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRFA-HCC|HR Versus RFA for Early Stage HCC|Hepatic Resection Versus Radiofrequency Ablation for Early-stage Hepatocellular Carcinoma: a Randomized Controlled Trial|ARTC-HCC|Guangxi Medical University|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02169765||42263|
NCT02170051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130424|Improving Negative Symptoms of Psychosis In Real-world Environments|Improving Negative Symptoms of Psychosis In Real-world Environments|INSPIRE|University of California, San Diego|Yes|Recruiting|July 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02170051||42241|
NCT02178371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-006|Effects of Modified Constraint Induced Movement Therapy on Infantile Hemiplegia|||CEU San Pablo University|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|3 Years|10 Years|No|||February 2015|February 2, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02178371||41604|
NCT02168517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20140025|Correlation of Pain, Obesity and Fertility Potential.|Obesity, Pain and Fertility: is There Any Association?||Northern Orthopaedic Division, Denmark|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Anticipated|120|Samples With DNA|A research biobank will be established during the project period. Majority of each sperm      sample will be analyzed immediately but approximately 250 ul seminal plasma will be frozen      and later analyzed at Aalborg University Biotechnology Department.|Male|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|May 2015|May 27, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02168517||42359|
NCT02169375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I0004|Sensorimotor Based Brain Computer Interface|Effect of Normalizer Adaptation on Accuracy in a Sensorimotor Based Brain-Computer Interface||University of Michigan|No|Terminated|November 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 18, 2014|June 16, 2014||No|Insufficient improvement in primary measures under either condition.|No||https://clinicaltrials.gov/show/NCT02169375||42293|
NCT02169388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014SDU-QILU-G03|Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy|Effects of Gut Microflora on the Immune and Nutritional Status of CRC Patients After Chemotherapy||Shandong University|Yes|Recruiting|June 2014|January 2015|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2014|June 24, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02169388||42292|
NCT02169687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/F/02.01/Protocol V0|High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules|Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules||Theraclion|No|Terminated|June 2006|October 2007|Actual|October 2007|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|May 5, 2014||No|Protocol's modifications requested by IRB weren't feasible to continue the study|No||https://clinicaltrials.gov/show/NCT02169687||42269|
NCT02169960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH-SCN-02|Comprehensive Program for Youth Mental Health|Comprehensive Program for Youth Mental Health|EMPATHY|University of Alberta|Yes|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|5514|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02169960||42248|
NCT02181738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-205|Study of Nivolumab in Subjects With Classical Hodgkin's Lymphoma (Registrational)|Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects|CheckMate 205|Bristol-Myers Squibb|No|Recruiting|July 2014|December 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|294|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|July 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02181738||41347|
NCT02182102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.18|Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer|A Phase I Open Label Study of Continuous Oral Treatment With BIBF 1120 Together With Pemetrexed in Previously Treated Patients With Non-small Cell Lung Cancer||Boehringer Ingelheim||Completed|September 2005|||May 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|July 2, 2014||||No||https://clinicaltrials.gov/show/NCT02182102||41319|
NCT02170506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/176/HP|Effect of Sub-mental Sensitive Transcutaneous Electrical Stimulation on Pharyngeal Muscles Control : TENSVIRT Study|Effect of Sub-mental Sensitive Transcutaneous Electrical Stimulation on Pharyngeal Muscles Control|TENSVIRT|University Hospital, Rouen|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170506||42206|
NCT02170883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01451|EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS|EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS||University of British Columbia|No|Recruiting|May 2015|September 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|370|||Both|14 Years|N/A|No|||February 2016|February 25, 2016|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02170883||42177|
NCT02170896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.31|Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).||Boehringer Ingelheim||Completed|October 2001|||December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|June 20, 2014||||No||https://clinicaltrials.gov/show/NCT02170896||42176|
NCT02192905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK098556-01|Feasibility Trial of a Problem-Solving Weight Loss Mobile Application|Feasibility Trial of a Problem-Solving Weight Loss Mobile Application||University of Massachusetts, Worcester|Yes|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192905||40489|
NCT02193152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201408009|Pazopanib in Molecularly Selected Patients With Advanced NSCLC|A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Washington University School of Medicine|No|Recruiting|April 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193152||40470|
NCT02193399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRASFIS|Physiotherapy in Hematopoietic Stem Cell Transplantation|Effectiveness of Physiotherapy in the Prevention of Physical Sequelae in Patients Treated With Hematopoietic Stem Cell Transplantation. A Pilot Study.|TRAS|Universidad Católica San Antonio de Murcia|No|Not yet recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2014|August 28, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193399||40451|
NCT02193646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA-2014|Endoscopic Size Assessment of Advanced Adenomatous Polyps|Endoscopic Size Assessment of Advanced Adenomatous Polyps; Inter Observer Variations||Rush University Medical Center|No|Recruiting|November 2010|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Subjects undergoing screening colonoscopies at Rush University Medical Center.|October 2015|October 26, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02193646||40432|
NCT02193854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaipeiMU|Teledermatology Solution Through Mobile Phone in Rural Mongolia|Teledermatology Solution Through Mobile Phone in Rural Mongolia||Taipei Medical University|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|441|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|June 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193854||40416|
NCT02194101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFPH-IRB-2013-049|Supernormal Goal for Proximal Femur Fracture|Supernormal Oxygen Delivery May Not be a Valid Goal for Patients With Proximal Femur Fracture. An Observational Pilot Study||Guangzhou First Municipal People’s Hospital|No|Not yet recruiting|August 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|70 Years|N/A|No|Non-Probability Sample|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur        fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.|July 2014|July 16, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02194101||40397|
NCT02194517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELKA-01|Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.|Impact of ELKa, the Toolset for Prandial Insulin Dose Calculation on Metabolic Control in Children and Adolescent With Diabetes Type 1.||Medical University of Warsaw|No|Completed|April 2013|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|106|||Both|N/A|18 Years|No|||July 2014|March 16, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194517||40365|
NCT02194829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01425|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase I and Randomized, Double-Blinded Phase II Study of Nab-paclitaxel/Gemcitabine Plus AZD1775 or Placebo in Treatment-Naïve Metastatic Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)|Yes|Suspended|July 2014|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|133|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 16, 2014|Yes|Yes|Temporarily stopped for assessment.|No||https://clinicaltrials.gov/show/NCT02194829||40341|
NCT02194842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1333|Phase III Radium 223 mCRPC-PEACE III|A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|October 2015|April 2021|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Male|18 Years|N/A|No|||March 2016|March 11, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194842||40340|
NCT02204345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29360|A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology|Open Label Phase Ib/II, Multi-center Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for the Metastatic Disease or Targeted Therapy for NSCLC||Hoffmann-La Roche||Suspended|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204345||39612|
NCT02204618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7053 10|Cochlear Implantation in Single Sided Deafness and Asymmetrical Hearing Loss: a Cost/Utility Study.|Cochlear Implantation in Single Sided Deafness and Asymmetrical Hearing Loss: a Cost/Utility Study.|CISSD|University Hospital, Toulouse|Yes|Recruiting|October 2014|August 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204618||39591|
NCT02204839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West-Walker3|Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM|The Metabolic and Glycaemic Effects of a Combined Basal-Bolus Insulin Reduction And Carbohydrate Feeding Strategy For Evening Exercise in Type 1 Diabetes Mellitus||Northumbria University|Yes|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|50 Years|No|||January 2015|January 14, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02204839||39574|
NCT02204852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-ILEPSS|Co-administration of Iloprost and Eptifibatide in Septic Shock Patients|Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated Trial|CO-ILEPSS|Rigshospitalet, Denmark|Yes|Recruiting|September 2014|November 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204852||39573|
NCT02219100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.3.1|Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus|Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus||Gynuity Health Projects||Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|613|||Female|18 Years|55 Years|No|||August 2014|August 18, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02219100||38481|
NCT02219113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-CCH-03-02-14|Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular Cartilage|Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Degenerative Damage of Knee Articular Cartilage||Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati|No|Enrolling by invitation|July 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|85 Years|No|||September 2015|September 30, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02219113||38480|
NCT02218853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH077851|Psychosis and Affective Research Domains and Intermediate Phenotypes|Psychosis and Affective Research Domains and Intermediate Phenotypes|PARDIP|University of Texas Southwestern Medical Center|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|350|Samples With DNA|DNA will be extracted from blood (or buccal swab) and stored at the UT Southwestern Human      Genetic Center in a departmental freezer at -80 degrees. Part of the blood sample will be      used to create an immortalized lymphocyte culture (a lymphoblastoid cell line) for future      genetic analysis, and will be stored in a Cell Bank at the UT Southwestern Human Genetic      Center. The blood samples will be labeled by a coded identifier (number) and will not be      personally identifiable. Only specifically designated research staff from Dr. Tamminga's      group and from the UT Southwestern Human Genetic Center will have an access to stored DNA      samples. All samples will be de-identified. The genetic data will be in password-protected      computers in the Investigators' research offices.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|The study population will be comprised of individuals between the ages of 18-60 years old        who meet DSM-IV criteria for Bipolar I disorder, read/speak/understand the English        language, and are deemed capable of completing the study procedures by the research        investigators.|July 2014|August 14, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02218853||38500|
NCT02219659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25613|Pilot Study on Pairing Sedation Strategies and Weaning|Comparing Strategies of Pairing Sedation and Weaning Protocols on Outcomes of Mechanical Ventilation: A Pilot Study||MemorialCare Health System|Yes|Recruiting|April 2014|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|June 10, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02219659||38438|
NCT02192437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-13-2014|Dietary Methionine and Cysteine Restriction in Healthy Adults|Dietary Methionine and Cysteine Restriction in Healthy Adults||Milton S. Hershey Medical Center|Yes|Recruiting|June 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|24 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192437||40525|
NCT02192684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01HL108647-04|Obesity, Sleep Apnea, and Insulin Resistance|Interfacing Adiposity, Sleep Apnea, and Insulin Resistance||Stanford University|Yes|Enrolling by invitation|September 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02192684||40506|
NCT02193165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2014-07-PG-REG-PR-BS|The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis|The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis.||Colgate Palmolive|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 15, 2014|Yes|Yes||No|November 14, 2014|https://clinicaltrials.gov/show/NCT02193165||40469|
NCT02193178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-14-05|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||August 10, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193178||40468|
NCT02193412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01645-40|Influence of Variations of Systemic Venous Return on Analgesia Nociception Index (ANI) During General Anaesthesia|Influence of Variations of Systemic Venous Return on Analgesia Nociception Index (ANI) During General Anaesthesia||University Hospital, Lille|No|Recruiting|January 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 10, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193412||40450|
NCT02193659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elena García-García 3|Changes Induced by Breakfast Cereals Enriched With Omega-3 in the Lipidic Profile|Changes Induced by Breakfast Cereals Enriched With Omega-3 in the Lipidic Profile: a Randomized Simple Controlled Trial|cereals|Universidad Miguel Hernandez de Elche|Yes|Completed|September 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|96|||Female|25 Years|75 Years|No|||August 2015|August 24, 2015|February 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02193659||40431|
NCT02193867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL08|Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency|A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency||Alexion Pharmaceuticals|Yes|Recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|8 Months|No|||November 2015|November 16, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193867||40415|
NCT02194114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10602|Dietary Protein Requirements in Hemodialysis Patients|Dietary Protein Intake and Its Effect on Nitrogen Balance in Maintenance Hemodialysis (MHD) Patients||Los Angeles Biomedical Research Institute|Yes|Completed|January 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|25 Years|65 Years|No|||July 2014|July 16, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194114||40396|
NCT02194530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405015102|Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy|Pilot Study to Collect Blood From Research Subjects Allergic and Non-allergic to Peanut to Study Immune Modulation With Anti-IgE Therapy in Mice||Weill Medical College of Cornell University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|Whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|December 2015|December 18, 2015|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194530||40364|
NCT02204358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012022|Treatment of Infertility by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells|Clinical Study of the Treatment of Infertility Caused by Severe Intrauterine Adhesions by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|January 2012|December 2015|Anticipated|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02204358||39611|
NCT02201212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-229|Everolimus for Cancer With TSC1 or TSC2 Mutation|A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations||Dana-Farber Cancer Institute|Yes|Recruiting|September 2014|January 2022|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201212||39853|
NCT02201225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201133|A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.|A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children Aged 6 to 12 Years Receiving Nutritional Supplement With or Without Micronutrient Fortification||GlaxoSmithKline|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|109|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201225||39852|
NCT02204865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0077|Validation of the ApneaScan Algorithm in Sleep Disordered Breathing|Sleep-Disordered Breathing in Patients With Implanted Cardiac Devices: Validation of the ApneaScan Algorithm and Implications for Prognosis|ApneaScan|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|March 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with heart failure with reduced ejection fraction (EF <40%) due to receive a        Boston Scientific ICD/CRTD/P with ApneaScan function.|May 2014|July 28, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02204865||39572|
NCT02219373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00008001|Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study|Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study.||Children's Hospital Boston|Yes|Not yet recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|8 Years|18 Years|No|||August 2014|August 15, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02219373||38460|
NCT02219360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-K-115|Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease|TripAE|Beijing Chao Yang Hospital|No|Not yet recruiting|August 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|25-(OH)-VD3 and glycated albumin will be tested|Both|40 Years|N/A|No|Non-Probability Sample|Patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease        from 1st July, 2014 from Beijing Chao Yang Hospital|August 2014|August 15, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02219360||38461|
NCT02188121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS IRB pending|Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients|Fixed Dose Intervention Trial of New England Enhancing Survival in Serious Mental Illness Patients|FITNESS|Mclean Hospital|Yes|Recruiting|February 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|89 Years|No|||October 2015|October 17, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188121||40856|
NCT02220426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7733|Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study|Phase 1 Study: Detection of Brown Adipose Tissue in Normal Volunteers Using a 3 Tesla (3T) Magnetic Resonance Imaging System and Hyperpolarized (HP) Xenon Gas||University of North Carolina, Chapel Hill|Yes|Recruiting|September 2014|September 2020|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 30, 2015|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220426||38379|
NCT02188407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKC-TOR-1|Inflammation After One Lung Ventilation|Phase 1 Study of Antiinflammatory Effect of Sevoflurane in Open Lung Surgery With One-Lung Ventilation||University Medical Centre Ljubljana|Yes|Completed|July 2008|January 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|70 Years|No|||July 2014|July 8, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02188407||40834|
NCT02201654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093452|Stylet vs No Stylet During EBUS TBNA|Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)||Johns Hopkins University||Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|121|||Both|18 Years|100 Years|No|||February 2016|February 4, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02201654||39819|
NCT02201667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0208|Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI|An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II）||RenJi Hospital|Yes|Not yet recruiting|August 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|444|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201667||39818|
NCT02201901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1137|Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis|ASTRAL-4|Gilead Sciences|Yes|Completed|July 2014|November 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|268|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201901||39800|
NCT02201914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM003|Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF|Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF: a Randomized Study||Bioroma|Yes|Recruiting|January 2014|November 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|250|||Female|25 Years|44 Years|No|||July 2014|July 24, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02201914||39799|
NCT02202954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100114|Comparison of Two Rehabilitation Strategies in Patients With Hemiparesis One Year or More After Stroke|Comparison of Two Rehabilitation Strategies in Patients With Hemiparesis One Year or More After Stroke. Efficacy and Cost After One Year Treatment. A Randomized, Controlled, Multicenter, Single Blind Study|NEURORESTORE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202954||39719|
NCT02202408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKI2670_EMSD_I_2013|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670|A Phase I, Double-blind, Randomized, Placebo-controlled, Single-Dose Escalation, First-in-human Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SKI2670 After Oral Administration in Healthy Female Subjects||SK Chemicals Co.,Ltd.|No|Recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Female|20 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02202408||39761|
NCT02202707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002024|Vasomotor Symptoms and Cardiovascular Control|Vasomotor Symptoms and Cardiovascular Control||Beth Israel Deaconess Medical Center||Withdrawn|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|45 Years|58 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|July 22, 2014|Yes|Yes|No funding obtained to conduct study|No||https://clinicaltrials.gov/show/NCT02202707||39738|
NCT02202941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODA-2014|Procalcitonin-guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients|Effect of Procalcitonin-guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients in Korea|PRODA|Seoul National University Hospital|No|Recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||October 2014|October 16, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202941||39720|
NCT02203162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-IRB-2014-3288|Effect of Electronic Cigarette Use on Cough Reflex Sensitivity|Effect of Electronic Cigarette Use on Cough Reflex Sensitivity||Montefiore Medical Center|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203162||39703|
NCT02203175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-26.01.2011|Prevention of Propofol Injection Pain|The Effect of Fentanyl-propofol Mixture on Propofol Injection Pain.|VRS|Yeditepe University Hospital|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|65 Years|No|||September 2014|September 23, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02203175||39702|
NCT02193880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1397|Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant|Phase I/II Study of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide|ABD|University of Alabama at Birmingham|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|65 Years|No|||December 2015|December 17, 2015|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193880||40414|
NCT02203734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080617|Massage To Improve Uterine Artery Blood Flow|Massage to Reduce Intrauterine Artery Resistance, Prematurity and Low Birthweight||University of Miami|Yes|Completed|February 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02203734||39659|
NCT02203747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIOL-201-VPAS|Patient Perception of Visual Distortions|||Abbott Medical Optics|No|Completed|August 2014|January 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|79|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bilaterally-implanted pseudophakic subjects over 22 years of age with astigmatism who meet        the inclusion criteria.|September 2015|November 18, 2015|July 10, 2014||No||No|September 30, 2015|https://clinicaltrials.gov/show/NCT02203747||39658|
NCT02204059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1170.3|Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer|A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Non-small Cell Lung Cancer||Boehringer Ingelheim||Completed|December 1999|||February 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02204059||39634|
NCT02204332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLL-CAB-2011-01|Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment|Phase II-b Randomized Study of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment|COMETA|Hospital Clinico Universitario de Santiago|No|Terminated|March 2013|||September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|July 23, 2014||No|Interim analysis performed on the first 10 patients showed no efficacy of cabazitaxel|No||https://clinicaltrials.gov/show/NCT02204332||39613|
NCT02200939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.05.12|Post-Market Evaluation of the Rotation Medical Rotator Cuff System|Post-Market Evaluation of the Rotation Medical Rotator Cuff System||Rotation Medical, Inc.|No|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||May 2015|May 4, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200939||39874|
NCT02200952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luveris75UI|Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS|Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS||San Carlo Public Hospital, Potenza, Italy|No|Recruiting|June 2013|||July 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|16|||Female|18 Years|43 Years|No|Probability Sample|Infertile patients undergoing controlled ovarian hyperstimulation|July 2014|July 25, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200952|9 Months|39873|
NCT02201459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.837|Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients|Randomized Multicenter Phase III Study Comparing the Rate of Molecular Response 4.5 at 12 Months in Newly Diagnosed Philadelphia Positive Chronic Phase Chronic Myelogenous Leukemia Patients Receiving Either Frontline Nilotinib 600 mg Daily or Nilotinib 600 mg Daily Combined to Pegylated Interferon-alfa 2a (Peg-IFN)|PETALs|Hospices Civils de Lyon|Yes|Recruiting|August 2014|August 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2014|August 6, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201459||39834|
NCT02219152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0321-14|Topical Instillation of Tranexamic Aacid in Bronchoscopy to Decrease Bleeding During Entobronchial & Transbronchial Biopsiy: a Prospective Double Blind Placebo Controlled Study|||Hadassah Medical Organization|No|Not yet recruiting|September 2014|February 2017|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|75 Years|No|||August 2014|August 15, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02219152||38477|
NCT02219646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2009-014137-25|Diabetes & Vardenafil|Monitoring of Endothelial Dysfunction During Chronic Administration of Vardenafil in Patients With Type 2 Diabetes Mellitus: A Longitudinal, Randomised, Placebo-controlled, Double Blind, Phase II b, Clinical Trial|DiVa|Azienda USL Modena|Yes|Completed|March 2010|February 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|54|||Male|40 Years|65 Years|No|||August 2014|August 18, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02219646||38439|
NCT02187874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AMI)18/2014|Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.|Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.|CODE-P|Hospital Universitari Vall d'Hebron Research Institute|Yes|Not yet recruiting|July 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187874||40875|
NCT02188134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU14-679|Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection|Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection||Michigan State University|No|Completed|October 2014|April 2015|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|82|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|65 and older self administer medication Purchase OTCs|April 2015|April 6, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02188134||40855|
NCT02188147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0119|Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study|Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study Protocol|ASAP|Zoll Medical Corporation|No|Recruiting|August 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188147||40854|
NCT02202421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF IRB 14-429|T-ABA Group Based Early Intervention For Parents of Children With ASD|Targeted Applied Behavior Analysis (T-ABA) Group Based Early Intervention for Parents of Children With Autism Spectrum Disorder (ASD)|T-ABA|The Cleveland Clinic|No|Enrolling by invitation|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|24 Months|71 Months|No|||January 2016|January 28, 2016|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02202421||39760|
NCT02202434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2282|Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement|REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation|REPRISE III|Boston Scientific Corporation|Yes|Enrolling by invitation|September 2014|January 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1032|||Both|N/A|N/A|No|||December 2015|December 14, 2015|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202434||39759|
NCT02203448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT13/01|Facet Wedge Post Market Study|A Multi-centre, Prospective, Single-arm Post Market Clinical Follow up Study (PMCF) of the FACET WEDGE Spinal System to Assess Outcomes in Subjects With Chronic Low Back Pain Due to Degenerative Disc Disease (DDD), Facet Joint Disease and/or Pseudo Arthrosis Post Anterior Instrumentation||Synthes GmbH|Yes|Recruiting|May 2014|July 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|The cases in the cohort are selected from patients treated in hospitals.|November 2015|November 19, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203448||39681|
NCT02202720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0200|Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients|Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients|SEVORASS|University Hospital, Clermont-Ferrand||Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202720||39737|
NCT02203188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000|Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome||TOYOTA|University of Waterloo|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|17 Years|N/A|No|||December 2014|December 18, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203188||39701|
NCT02203422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Cyclosporin A|A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）||Shandong University|Yes|Recruiting|July 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||July 2014|July 27, 2014|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02203422||39683|
NCT02203760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PazoDoble|Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -|Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -||University Medicine Greifswald|No|Recruiting|September 2013|June 2016|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|107|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02203760||39657|
NCT02203773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-358|Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)|A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy||AbbVie|No|Recruiting|November 2014|February 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|65 Years|99 Years|No|||February 2016|February 15, 2016|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203773||39656|
NCT02204072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.8|BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)|A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone||Boehringer Ingelheim||Recruiting|November 2014|January 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|151|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02204072||39633|
NCT02204891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO01|Probiotics in Intestinal Bacterial Overgrowth|A Clinical Study of the Efficacy of a Formulation of Four Probiotics in Patients With Syndrome of Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome||University of Athens|No|Recruiting|September 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204891||39570|
NCT02200965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCRN-14324|Impact of Individualized Structured Information Provision to the Patients, on Diabetes Related Outcomes|The National Health Service (NHS) Choice and Information Revolution - Exploring the Utilization of High Quality Clinical Data Governance Processes to Promote Informed Patient Driven Care in a Locally Integrated English Diabetes Health Economy.|WICKED|The Royal Wolverhampton Hospitals NHS Trust|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|17002|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02200965||39872|
NCT02201238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202188|Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium|A Pharmacokinetics Study Comparing Systemic Exposure of Topical Diclofenac/Menthol Gels Versus Voltaren Gel and Oral Diclofenac Sodium in Healthy Volunteers at Steady State||GlaxoSmithKline|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|July 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02201238||39851|
NCT02201251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104425|A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy|A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy||Janssen Research & Development, LLC|Yes|Recruiting|October 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|282|||Both|2 Years|15 Years|No|||March 2016|March 11, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201251||39850|
NCT02219919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUFA-12/14|Nociceptive Gain Processing After Physical Therapy in Carpal Tunnel Syndrome|Changes in Nociceptive Gain Processing After Physical Therapy and Surgery in Carpal Tunnel Syndrome: A Randomized Clinical Trial||Universidad Rey Juan Carlos|Yes|Active, not recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|No|||February 2016|February 25, 2016|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219919||38418|
NCT02219386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44/11Comision of investigation|Dry Needling of the Trapezius Muscle in Office Workers With Neck Pain|Dry Needling of the Trapezius Muscle in Office Workers With Neck Pain. Randomised, Single Blinded Clinical Trial||University of Alcala|Yes|Completed|January 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||August 2014|August 30, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02219386||38459|
NCT02202200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D20121106|Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma|An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib|OPTIMUM|Assistance Publique - Hôpitaux de Paris||Recruiting|May 2014|August 2018|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202200||39777|
NCT02202213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15698A|Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia|Interventional, Randomised, Double-blind, Placebo Controlled, Multiple-dose Study Investigating the Safety, Tolerability, PK and PD Properties of Lu AF11167 in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|October 2013|||February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|60 Years|No|||February 2015|February 17, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202213||39776|
NCT02202759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26002|A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction|A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|July 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202759||39734|
NCT02202733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-5379|Skill-based Cooking Intervention to Reduce Eating Out|A Caretaker Cooking Skills Intervention to Reduce Eating Out||Children's Hospital Medical Center, Cincinnati|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|3 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202733||39736|
NCT02202746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-3810-025|A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer|A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer||Clovis Oncology, Inc.|Yes|Recruiting|July 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|201|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202746||39735|
NCT02202967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN09CA403|Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs|Misoprostol for the Healing of Small Bowel Ulceration in Patients With Obscure Blood Loss While Taking Low-dose Aspirin or Nonsteroidal Antiinflammatory Drugs [MASTERS Trial]|MASTERS|NHS Greater Glasgow and Clyde|Yes|Recruiting|January 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02202967||39718|
NCT02202980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1468|Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection|A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection||Gilead Sciences|No|Active, not recruiting|August 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|273|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202980||39717|
NCT02203201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM04|Diagnostic Significance of Positive EmA Antibodies in the Duodenal Culture Medium of Not-Celiac Wheat Sensitivity (NCWS)|Diagnostic Significance of Positive Anti-endomysium Antibodies in the Culture Medium of the Intestinal Biopsies in Not-Celiac Wheat Sensitivity (NCWS)|NCWS|University of Palermo|No|Recruiting|January 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|65 Years|No|Probability Sample|The investigators will include exclusively patients who had been previously fully        evaluated for suspected celiac disease in our Hospitals (Department of Internal Medicine,        Giovanni Paolo II Hospital of Sciacca, Agrigento, and of Internal Medicine of the        University of Palermo) from January 2002 to December 2012. In all patients NCWS diagnosis        had been posed by means of a double-blind placebo-controlled (DBPC) challenge with wheat        flour.|November 2015|November 30, 2015|June 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02203201||39700|
NCT02203786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-2009|D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement|Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls|HFDEX|Centre for Addiction and Mental Health|No|Completed|September 2009|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203786||39655|
NCT02204085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-222|A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia||Dana-Farber Cancer Institute|Yes|Recruiting|September 2014|July 2021|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204085||39632|
NCT02203435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK1|The Patient Characteristics and Mortality of Code Blue Calls|The Characteristics of the Blue-code Calls; Five Years Survey.||Umraniye Education and Research Hospital|Yes|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1050|||Both|N/A|N/A|No|Non-Probability Sample|This study aimed to retrospectively examine patients evaluated by the Code Blue team on a        Code Blue call in our hospital between 2009 and 2013.Retrospective examination was made of        the Code Blue notification forms which were completed by the anaesthesiologist as Code        Blue team leader of the hospital.|August 2014|August 5, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02203435||39682|
NCT02204631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-244|2 Phase Use Of Educational Materials In Head And Neck Cancer Center|A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center||Massachusetts General Hospital|Yes|Recruiting|August 2014|July 2019|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204631||39590|
NCT02204878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Liver-Dynastat|Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy|A Randomized, Phase IV Study Exploring the Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy||Peking Union Medical College Hospital|Yes|Recruiting|July 2014|||August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|70 Years|No|||July 2014|July 29, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204878||39571|
NCT02200926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSangthong|Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly|Effects of Slow Loaded and Unloaded Breathing Training||Khon Kaen University|Yes|Active, not recruiting|July 2014|December 2015|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|60 Years|85 Years|No|||December 2015|December 21, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200926||39875|
NCT02204904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD-103|Observational Study to Evaluate Allogeneic HSCT Outcomes for CCALD|A Prospective and Retrospective Data Collection Study to Evaluate Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Childhood Cerebral Adrenoleukodystrophy||bluebird bio|No|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|35|||Male|N/A|17 Years|No|Non-Probability Sample|Boys aged 17 or younger receiving allogeneic hematopoietic stem cell transplantation for        the treatment of Childhood Cerebral Adrenoleukodystrophy prospectively or partially        prospective/retrospective|May 2015|August 25, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204904||39569|
NCT02201498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIODENT1|Randomized Clinical Trial for Primary Molar Pulpotomy, Biodentine Vs Formocresol-ZOE|A New Technique for Primary Molar Pulpotomy : A Randomized Clinical Trial Comparing the Radiographic and Clinical Success of the Formocresol-zinc Oxide Eugenol Technique and the Biodentine Technique||Université de Montréal||Not yet recruiting|September 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|10 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201498||39831|
NCT02219672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACT140816|Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection|Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection||Peking Union Medical College|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|65 Years|No|||August 2014|August 18, 2014|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219672||38437|
NCT02187848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED13751|Evaluation of SAR408701 in Patients With Advanced Solid Tumors|A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors||Sanofi|No|Recruiting|July 2014|September 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187848||40877|
NCT02220179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-res-care|Resilience for Children and Young People in Foster Care and Residential Care in Denmark|Resilience for Children and Young People||University of Aarhus|No|Active, not recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|9000|||Both|N/A|23 Years|No|||June 2015|June 1, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220179||38398|
NCT02187861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29337|A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma|A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT-199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON HODGKIN'S LYMPHOMA||Hoffmann-La Roche||Recruiting|December 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|156|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187861||40876|
NCT02188420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPT_PAS|Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke|Effect of Different Interpulse Intervals of Paired Associative Stimulation on Cortical Excitability in People With Chronic Stroke||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|September 2014|December 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|3|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02188420||40833|
NCT02188433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTW2014|Promoting Smoking Cessation in the Community Via QTW 2014|Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2014: a Randomized Controlled Trial||The University of Hong Kong|Yes|Recruiting|May 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1307|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188433||40832|
NCT02202460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rrw2014|The Potential Biomark of Serious Psychosis:a Prospective,Case-controled Study|The Potential Biomark of Serious Psychosis: Including the Variation of Brain MRI, BDNF and Oxidative Stress-related Immunological Factors in Different Phases.||Central South University|Yes|Not yet recruiting|August 2014|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood|Both|18 Years|65 Years|No|Non-Probability Sample|Schizophrenia , Bipolar Disorder , Major Depression|July 2014|July 25, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02202460|18 Months|39757|
NCT02202772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM8506|Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder|A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer|CGC|Columbia University|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02202772||39733|
NCT02202993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014067|TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM|TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)||Cavion LLC|Yes|Recruiting|August 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||August 2014|August 22, 2014|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02202993||39716|
NCT02203253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOG1302|Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting|Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial||China Medical University, China|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|820|||Both|18 Years|70 Years|No|||July 2014|July 27, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02203253||39696|
NCT02203214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V03_29082013|Induced ACL Healing With the Ligamys Technique: a Prospective, Multicenter Observational Case Series|Induced ACL Healing With the Ligamys Technique: a Prospective, Multicenter Observational Case Series|Ligamys|Mathys Ltd Bettlach|No|Recruiting|August 2013|December 2025|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|154|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients with an acute rupture of the anterior cruciate ligament|October 2015|October 21, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203214||39699|
NCT02203461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-1383--0030-I|Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication|Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication - A Controlled, Mono Center, Three-arm, Randomized Phase I Study.||Technische Universität München|Yes|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203461||39680|
NCT02203474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBB-COPD-20009|A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose-Ranging Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), Placebo HFA BAI, and Open-Label SPIRIVA® HandiHaler® (18 mcg) in Patients With Chronic Obstructive Pulmonary Disease||Teva Pharmaceutical Industries|No|Withdrawn|August 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|40 Years|80 Years|No|||August 2014|August 26, 2014|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203474||39679|
NCT02203799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26819|Peanut Oral Immunotherapy in Children With Peanut Allergy|IMMUNE RESPONSES IN PEANUT ALLERGIC SUBJECTS UNDERGOING PEANUT ORAL IMMUNOTHERAPY|Peanut Flour|Baylor College of Medicine|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|5 Years|16 Years|No|||December 2015|December 16, 2015|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203799||39654|
NCT02204098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407100|Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy|A Phase 1B Randomized Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy||Washington University School of Medicine|No|Recruiting|January 2015|October 2024|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204098||39631|
NCT02204371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201128|Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia|A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia||Novartis|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204371||39610|
NCT02204384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140161|Glycemic and Insulinemic Response With Different Sources of Soluble Fiber in Patients Type 2 Diabetes Mellitus|Evaluation of Glycemic and Insulinemic Response After Consumption of Breakfasts With Different Sources of Soluble Fiber (Food vs. Supplement) in Patients With Type 2 Diabetes Mellitus: a Randomized Crossover Trial||Hospital de Clinicas de Porto Alegre|Yes|Not yet recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|19|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204384||39609|
NCT02204644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10096-301|The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML|Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|75 Years|No|||July 2014|July 27, 2015|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204644||39589|
NCT02204657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|961.7|The Effect of Continuous Glucose Monitoring on Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus|The Effect of Professional Continuous Glucose Monitoring on Diabetes Management,Hypoglycemia and Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus||University of Malaya|Yes|Recruiting|April 2013|August 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204657||39588|
NCT02201277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 14-13307|ODEN Trial: Option vs. Denali IVC Filters|Prospective Randomized Evaluation of the Denali and Option Inferior Vena Cava Filters|ODEN|University of California, San Francisco|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02201277||39848|
NCT02201290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117366|A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)||Novartis|No|Recruiting|June 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|17 Years|No|||March 2016|March 11, 2016|June 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02201290||39847|
NCT02201745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD-UdeM-EE-2012a|Palatal Brushing for Denture Stomatitis|||University of Sao Paulo||Completed|June 2012|December 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201745||39812|
NCT02191930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-CAP|Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma|Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -|B-CAP|University of Cologne||Recruiting|September 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|60 Years|99 Years|No|||December 2015|December 2, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02191930||40563|
NCT02191644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBMC_Lp-PLA2_metabolite|Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes|Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes||Yonsei University|Yes|Completed|January 2013|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|82|||Both|40 Years|70 Years|No|||July 2014|July 15, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191644||40585|
NCT02191943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHARM|Lesion Progression of Approximal Caries After Resin Infiltration|Long-term Bi-center Trial to Compare the Radiological Cavity Progression of Approximal Caries Following Infiltration or Standard Treatment||DMG Dental Material Gesellschaft mbH|No|Withdrawn|November 2014|December 2019|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2014|January 22, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02191943||40562|
NCT02191956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0078|Technology to Enhance Treatment for Early Conduct Problems in Low Income Families|Technology to Enhance Treatment for Early Conduct Problems in Low Income Families|TE-HNC|University of North Carolina, Chapel Hill|No|Recruiting|April 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|102|||Both|3 Years|7 Years|No|||October 2015|November 2, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02191956||40561|
NCT02187900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNXY201401|Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.|Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f||Second Xiangya Hospital of Central South University|Yes|Recruiting|June 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|16 Years|65 Years|No|||July 2014|July 10, 2014|June 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02187900||40873|
NCT02188186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triple|Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients|Therapeutic Efficacy of Triple Combination of Metformin, DPP4 Inhibitor and Thiazolidinedione in Drug-naïve Korean Type 2 Diabetic Patients||Seoul National University Bundang Hospital|Yes|Recruiting|July 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|80 Years|No|||October 2015|October 23, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02188186||40851|
NCT02188199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3 1001|C3 Total Joint Patient Registry|Clinical Care Continuum (C3) Total Joint Patient Registry||DC2 Healthcare|No|Recruiting|May 2012|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will come from cohorts of patients undergoing either knee or hip        replacement in accordance with a nationwide multicenter observational study design.        Eligibility criteria require only that patients are undergoing knee or hip replacement,        are able to sign informed consent and are 18 years of age or older. Approximately 10,000        patients will be enrolled|July 2014|July 10, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188199|1 Year|40850|
NCT02202473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxymatrine|Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects|||Southeast University, China|Yes|Completed||||February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|60 Years|No|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202473||39756|
NCT02203266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC004|Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting|A Randomised, Parallel-group, Multi-centre Trial Using a Novel INCA Tracker Device to Measure and Monitor Compliance and Technique of Seretide Diskus Inhaler in a Community Pharmacy Setting||Beaumont Hospital|No|Recruiting|February 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02203266||39695|
NCT02203279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-RemPro-02-2014|Evaluation of Three Hard Relining Materials in Complete Dentures|Evaluation of Three Hard Relining Materials in Complete Dentures: An In-vivo Study||Damascus University|Yes|Completed|July 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Male|47 Years|78 Years|No|||September 2015|September 26, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203279||39694|
NCT02203292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32520914.3.0000.0068|Transfusion Requirements After Head Trauma|Transfusion Requirements After Head Trauma|TRAHT|University of Sao Paulo|No|Recruiting|August 2014|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||July 2014|August 13, 2014|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02203292||39693|
NCT02203227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLS-SH/06-14 VER 01|Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Efficacy and Safety Study of Dietary Supplements (BioTurmin, BioTurmin-WD and MaQxan) on Cotinine Level and Oxidative Stress Marker in Chronic Smokers Having Mild to Moderate Hyperlipidemia||Olive Lifesciences Pvt Ltd|Yes|Not yet recruiting|August 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Male|20 Years|65 Years|No|||July 2014|July 28, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203227||39698|
NCT02203240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT13261005|Cocoa and Metabolic Health in Prediabetes|Dietary Cocoa for Inhibition of Metabolic Endotoxemia and Glucose Intolerance||Virginia Polytechnic Institute and State University|No|Recruiting|June 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Both|40 Years|75 Years|No|||July 2015|July 20, 2015|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02203240||39697|
NCT02203487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1157.3|Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers|A Double-blind (Within Dose Groups), Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Preliminary Pharmacokinetics of Increasing Repeated Oral Doses (Nine Days Treatment of 5 mg and 10 mg and Eighteen Days Treatment of 25 mg and 40 mg) of BIIF 1149 BS in Healthy Male Volunteers||Boehringer Ingelheim||Completed|November 1999|||June 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02203487||39678|
NCT02203500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173.2|Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects|Tolerability and Pharmacokinetics of 80 mg Telmisartan and 6 mg Lacidipine Alone and in Combination After 7 Days Treatment. An Open Randomised Three-way Cross-over Trial in Female and Male Healthy Subjects||Boehringer Ingelheim||Completed|October 1998|||January 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02203500||39677|
NCT02203513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140156|A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer|A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, And Metastatic Castrate-Resistant Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|99 Years|No|||June 2015|March 9, 2016|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203513||39676|
NCT02203812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIJ_GIN-PRO 01|Effect of Probiotic Lozenge on Gingivitis and Periodontitis|The Effect of Probiotic Lozenge Administration on Gingivitis and on Mild & Moderate Periodontitis: A Randomized Controlled Clinical Trial.||CD Pharma India Pvt. Ltd.|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|50 Years|No|||July 2015|July 27, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203812||39653|
NCT02204124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311146|Whipple Procedure: Standard of Care vs. Thunderbeat|Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial||Washington University School of Medicine|No|Enrolling by invitation|May 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|22 Years|75 Years|No|||September 2015|September 30, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204124||39629|
NCT02204111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YonLife-2014|Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma|Patient Directed Intervention Towards a Multidimensional Recommendation Guideline to Improve the Quality of Life for Patients With Soft Tissue Sarcoma Under Palliative Treatment With Trabectedin|YonLife|GWT-TUD GmbH|No|Recruiting|September 2014|December 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|77|||Both|18 Years|N/A|No|Probability Sample|Patients with Soft Tissue Sarcoma under palliative treatment with Trabectedin|January 2016|January 21, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02204111||39630|
NCT02204397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JewishGH|Exploratory Study on Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus|A Single-center, Open-Label, Exploratory Study to Assess the Tolerability and Safety of the Addition of Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus||Jewish General Hospital|No|Recruiting|November 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|19 Years|40 Years|No|||November 2015|November 13, 2015|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204397||39608|
NCT02204410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000015|Omega-3 Supplementation to ADHD Medication in Children|A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation||Massachusetts General Hospital|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|17 Years|No|||January 2016|January 12, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204410||39607|
NCT02204670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:064|EXIT: Prospective Study of the Response to Exercise|Exercise and Irisin Trial (EXIT): Prospective Cohort Study of the Determinants of the Metabolic Response to Exercise in Obese Adolescents|EXIT|University of Manitoba|No|Recruiting|July 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|A community-based convenient sample of overweight adolescents aged 12-18 years with a BMI        > 95th centile for age and sex.|March 2015|March 18, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204670||39587|
NCT02201511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441006|A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions|A Phase 1, Open-label Study In Healthy Subjects To Investigate the Pharmacokinetics Of Pf-06412562 Following Single Oral Administration Of Modified Release Formulation In Fasted And Fed States||Pfizer|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|July 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02201511||39830|
NCT02201524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7451005|Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-04965842 In Subjects With Moderate To Severe Psoriasis||Pfizer|No|Terminated|November 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|July 24, 2014|No|Yes|Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was    not terminated for reasons of safety and/or efficacy|No||https://clinicaltrials.gov/show/NCT02201524||39829|
NCT02201537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01070-43|Kidney Disease and Ultrasound Imaging|Non-invasive Diagnosis of Chronic Kidney Disease in Renal Transplants Kidney Transplanted Using Ultrasound Functional Imaging|Imag-NCT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|160|||Both|18 Years|N/A|No|||July 2014|November 18, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02201537||39828|
NCT02191358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genelex 2014-01|YouScript IMPACT Registry|YouScript IMPACT (Improving Medication Protocols and Abating Cost of Treatment) Registry|IMPACT|Genelex Corporation|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|800|||Both|65 Years|N/A|No|Non-Probability Sample|The study consists of patients age 65 and older who are currently on or initiating        treatment with at least one oral form of medication (excluding medications taken PRN) with        a significant drug-gene interaction as defined by black box warning, FDA cautionary        labeling, clinical literature or a YouScript algorithm-predicted significant effect. Those        meeting eligibility criteria and undergoing YouScript testing according to their        provider's usual care practice will be eligible for prospective enrollment into the        "tested" group. Those included in Inovalon's MORE2 healthcare database meeting enrollment        criteria between January 1, 2013 and June 30, 2013 will be eligible for inclusion in the        "untested" group.|September 2015|September 10, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191358|4 Months|40607|
NCT02188160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPI-121-C-002|Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease|A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease|Kauai|Kala Pharmaceuticals, Inc.|No|Completed|June 2014|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188160||40853|
NCT02188173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-US-EYE-0272|An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)|||Allergan|No|Active, not recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetic macular edema (DME) treated with (OZURDEX®) in clinical practice.|January 2016|January 21, 2016|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188173||40852|
NCT02187913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014929|Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response|Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response||Purdue University|No|Recruiting|July 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187913||40872|
NCT02188212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-158|Nobel Procera Crown Shaded Zirconia and NobelProceraTM Full Contour Crown IPS e.Max CAD|A Clinical Evaluation of Hand-veneered, Porcelain-fused NobelProceraTM Crown Shaded Zirconia and NobelProceraTM Full Contour Crown IPS e.Max CAD on Molars||Nobel Biocare|No|Terminated|March 2010|||November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02188212||40849|
NCT02202486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-073|Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI|Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI||Glostrup University Hospital, Copenhagen|Yes|Recruiting|September 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|600|Samples Without DNA|Creatinine, blood glucose, potassium, haemoglobin, erytrocyte profile|Both|18 Years|80 Years|No|Non-Probability Sample|Migraine patients.|July 2014|July 25, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02202486||39755|
NCT02203019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-136|Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure|PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis|PRO-DEFENSE|Texas Tech University Health Sciences Center|Yes|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|326|||Both|18 Years|89 Years|No|||October 2015|October 2, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203019||39714|
NCT02203565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0039|Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy|Pilot Study to Investigate the Impact of Hypochlorite in the Prevention of Radiation Dermatitis||Stanford University|Yes|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Female|18 Years|N/A|No|||January 2015|January 30, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203565||39672|
NCT02203578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021309|Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease|A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease||Rutgers, The State University of New Jersey|No|Recruiting|November 2014|||January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203578||39671|
NCT02203526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140157|Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma|Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|June 2023|Anticipated|June 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203526||39675|
NCT02203539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-056|The Influence of Light Exposure on Exercise Performance Dependent on Chronotype.|The Influence of Different Light Exposures on Endurance Performance, Handgrip Strength and Reaction Time in Consideration of the Chronotype.|EX-Light|University of Basel|Yes|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|74|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02203539||39674|
NCT02203825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-14-001|Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands|A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma.||Celdara Medical, LLC|Yes|Recruiting|March 2015|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203825||39652|
NCT02204150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002619|Study to Image the Esophagus Using the OFDI Capsule|Pilot Study for Imaging of the Esophagus Using an OFDI Capsule||Massachusetts General Hospital|No|Recruiting|February 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|54|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02204150||39627|
NCT02204163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HGCL007|Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome|A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome||LG Life Sciences||Recruiting|June 2014|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|N/A|N/A|No|||September 2015|September 11, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02204163||39626|
NCT02204423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45613.101.13|Upper Extremity Dysfunction Post Radial Percutaneous Coronary Intervention|Upper Extremity Dysfunction Post Radial PCI: A Cohort Study Evaluating Upper Extremity Dysfunction After Percutaneous Coronary Intervention Using the Radial Artery as Access Route||Albert Schweitzer Hospital|Yes|Recruiting|February 2014|November 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02204423||39606|
NCT02204683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334-14-FB|A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).|A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (the DRAW Study)|DRAW|University of Nebraska|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|15|||Both|50 Years|N/A|No|||August 2015|August 11, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204683||39586|
NCT02204137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407080|Falls Risk Questionnaire in Older Adults With Cancer|Pilot Study of the Falls Risk Questionnaire in Older Adults With Cancer||Washington University School of Medicine|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|65 Years|N/A|No|Non-Probability Sample|Cancer patients aged 65 years of age or older|November 2014|November 20, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02204137||39628|
NCT02204696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00794|Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea|The Role of Tonsillectomy in Adults With Marked Tonsillar Hypertrophy and Obstructive Sleep Apnea||University of Southern California|No|Withdrawn|December 2010|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|17 Years|N/A|No|Non-Probability Sample|Adults with obstructive sleep apnea and tonsillar hypertrophy|November 2015|November 30, 2015|July 28, 2014||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT02204696||39585|
NCT02204917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 13-010618|CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children|Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children.|ceVUS|Children's Hospital of Philadelphia|Yes|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|N/A|18 Years|No|||November 2015|November 9, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204917||39568|
NCT02200978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010001|A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia|A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia||South China Children's Leukemia Group|Yes|Recruiting|September 2011|September 2022|Anticipated|September 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|N/A|16 Years|No|||February 2014|June 4, 2015|February 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200978||39871|
NCT02201329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.35|Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia||Boehringer Ingelheim||Completed|August 2014|September 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|80 Years|No|||September 2015|September 30, 2015|July 25, 2014||||No||https://clinicaltrials.gov/show/NCT02201329||39844|
NCT02201342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHN-Udenafil-01|Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents|A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation||Mezzion Pharma Co. Ltd|Yes|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|14 Years|18 Years|No|||April 2015|April 24, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201342||39843|
NCT02202577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPR-13-01063|Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis|Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical Site Antisepsis Prior to Cesarean Delivery|CAPICA|Case Western Reserve University|No|Recruiting|March 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|932|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202577||39748|
NCT02202850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801379|Defining Remission With Etanercept in AS in Real Life Clinical Practice|Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered))|REACH AS|Pfizer|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|||Both|18 Years|N/A|No|Probability Sample|Patients visiting Rheumatologist for which the decision has been taken to prescribe        Etanercept as first or second line|March 2016|March 9, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202850||39727|
NCT02187887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AA022400|Online Program for Young Adult Veteran Drinkers|Brief Online Intervention to Reduce Heavy Alcohol Use Among Young Adult Veterans||RAND|No|Recruiting|May 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187887||40874|
NCT02191982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1402|The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older|A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)|S-PACT|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|65 Years|N/A|No|||October 2015|October 29, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02191982||40559|
NCT02187926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-401-GR|Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece|Observational Study for the Evaluation of Clinical Effectiveness in Routine Practice of Daxas® (Roflumilast), in Approximately 2700 Patients With Severe and Very Severe COPD (Chronic Obstructive Pulmonary Disease) in Greece|ATLAS|Takeda|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2577|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients prescribed roflumilast in Greece.|July 2014|July 8, 2014|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02187926||40871|
NCT02188225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMU.REC.1393.56|Comparison of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women|Comparison of the Effects of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women||Gonabad University of Medical Sciences|Yes|Enrolling by invitation|July 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188225||40848|
NCT02188498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Electrocardiography Study|Electrocardiography Data Analysis in Sleep Disorders|Electrocardiography Data Analysis in Sleep Disorders|Holter|Weill Medical College of Cornell University|No|Recruiting|September 2013|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing overnight sleep studies|July 2014|July 9, 2014|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188498||40827|
NCT02203006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB : 2010-A00417-32|HIV Patients Cohort|Constitution of an Open Monocentric Cohort of HIV Infected Patients|OVIHD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2011|August 2028|Anticipated|February 2028|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|764|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203006||39715|
NCT02202811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA 00010101|Circadian Rhythms and Cardiovascular Risk|Circadian Rhythms and Cardiovascular Risk||Oregon Health and Science University|No|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02202811||39730|
NCT02203318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0385|Can the Hypertrophy of Contralateral Testis Predict the Absence of the Non-palpable Testis in the Boys Aged From 6months to 18months of Age ?|||Yonsei University|No|Recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|72|||Male|6 Months|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|totally, 72 children : unpalpable testis : 24 children, palpable undescended testis : 24        children, normal control : 24 children|June 2015|June 23, 2015|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02203318||39691|
NCT02204462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13162|FBnTP Imaging of Breast Cancer|FBnTP Positron Emission Mammography Imaging of Mitochondria Function - Breast Cancer||Sidney Kimmel Comprehensive Cancer Center||Recruiting|April 2015|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|26 Years|N/A|No|||April 2015|April 15, 2015|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204462||39603|
NCT02203552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13165|Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer|Randomized Placebo Controlled Study of Minocycline for Amelioration of Chemotherapy Induced Affective Disorders||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|36|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203552||39673|
NCT02203877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P032|Evaluation of Lactobacillus Fermentum CECT5716 on the Incidence of Mastitis|Nutritional Intervention Study, Randomized, Double-blind, Parallel Group to Evaluate the Effect of Lactobacillus Fermentum CECT5716 Consumption on the Incidence of Mastitis||Biosearch S.A.||Recruiting|August 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02203877||39648|
NCT02203838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB US 13-0005|Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia|An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia||Indivior Inc.|No|Active, not recruiting|June 2014|July 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203838||39651|
NCT02203851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.13|Extension Trial Assessing the Safety and Efficacy of BI 655066 in Patients With Moderate to Severe Chronic Plaque Psoriasis|An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis.||Boehringer Ingelheim||Active, not recruiting|November 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02203851||39650|
NCT02203864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1155.2|Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma|An Open-label, Multicenter, Controlled, Combined Parallel Group and Dose Escalation (0, 0.12, 1.2, 12.0 µg IL-2/10**8 Cells/24 Hours) Study, to Evaluate the Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 Containing Melanoma Cells Transfected With the Human IL-2 Gene in Patients With Advanced Malignant Melanoma||Boehringer Ingelheim||Completed|August 1998|||February 2001|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02203864||39649|
NCT02204436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3013|Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin|Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin||Derming SRL|Yes|Completed|November 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||March 2014|July 29, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02204436||39605|
NCT02204709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC029|Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)|Disease Risk Reduction and n-3 Rich Rainbow Trout (Fish for Health)||USDA Grand Forks Human Nutrition Research Center|No|Recruiting|June 2015|December 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|43|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204709||39584|
NCT02204930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX-01-UK|PeproStat Haemostat Study in Subjects Undergoing Liver Surgery|A Multi-centre, Open-label, Uncontrolled, First-in-Human Study to Evaluate the Safety and Tolerability and Explore the Efficacy of PeproStat in Gelita-Spon® Gelatin Sponge in Subjects Undergoing Open Liver Resection Surgery||Haemostatix Ltd|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204930||39567|
NCT02204943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053925|Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer|Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer||Duke University|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204943||39566|
NCT02204956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH104562|Smoking Cessation Following Psychiatric Hospitalization|Extended Care for Smoking Cessation Following Psychiatric Hospitalization||University of Texas at Austin|Yes|Not yet recruiting|April 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|422|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204956||39565|
NCT02200991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIXISL06651|Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine|A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus||Sanofi|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|20 Years|75 Years|No|||November 2015|November 13, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200991||39870|
NCT02201303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200591|Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression|A Single-Center In Vitro Study to Evaluate GSK1325756 Inhibition of CD11b Cell Surface Expression in Healthy Adults and Respiratory Syncytial Virus-Infected Children <2 Years (200591)||GlaxoSmithKline|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|40|||Both|N/A|64 Years|Accepts Healthy Volunteers|||July 2015|September 24, 2015|January 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201303||39846|
NCT02201316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200940|A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions|An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (Gasmotin) in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02201316||39845|
NCT02202070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAHEJB|Botox for Treatment of TMJ Disorder With Bruxism|Phase 1 Study of Role of Botox in Myofascial Temporomandibular Disorder|TMJ|Washington University School of Medicine|Yes|Not yet recruiting||||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02202070||39787|
NCT02191683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309-00003B|Foetal Exposure and Epidemiological Transition: Role of Anaemia in Early Life for Non-communicable Diseases Later|Foetal Exposure and Epidemiological Transition: the Role of Anaemia in Early Life for Non-communicable Diseases in Later Life|FOETALforNCD|University of Copenhagen|No|Recruiting|July 2014|June 2017|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|8343|Samples With DNA|Periperal vein blood, umbilical cord blood, placentas|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Amendment October 2014: replacement of two-phase case-control study by two sub-projects,        running in parallel, and following two distinct groups of women, 1) a cohort of 1500        non-pregnant women, disregarding Hb level, of whom 270 followed throughout pregnancy        disregarding Hb level and gestational age at first contact, and 2) a case control study of        480 pregnant women followed from 1st trimester with a 160:160:160 ratio of women with        Hb≤8g/dL: 8.1-10.9g/dL: ≥11g/dL.        The Danish Council for Strategic Research notified and accepted in November 2014.|June 2015|June 9, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02191683|21 Months|40582|
NCT02191995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEP yoga|Yoga in the Treatment of Eating Disorders: a Randomized Trial|Yoga in the Treatment of Eating Disorders: a Randomized Trial|TEP|University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02191995||40558|
NCT02192008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2014/01|Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study|Investigating the Mechanisms and Determinants of Systemic and Mucosal Immunity to Salmonella Typhi and Salmonella Paratyphi A in naïve and Previously Exposed Individuals - A Challenge and Rechallenge Study||University of Oxford|Yes|Recruiting|December 2014|September 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02192008||40557|
NCT02187939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111081|Get in the GROOVE!|Get in the GROOVE (Girls Realizing Options Through OpenSim Virtual Experiences)!|GROOVE|University of Miami|No|Recruiting|May 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|480|||Female|11 Years|14 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02187939||40870|
NCT02188992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/0267|Early PREdiction of Severe Sepsis I (ExPRES-Sepsis I) Study|Early Prediction of Severe Sepsis (ExPRESSepsis) Study|ExPRES|University of Edinburgh|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|Samples of serum and plasma will be stored frozen.|Both|16 Years|N/A|No|Probability Sample|Patients in the initial 12 hours following presentation to hospital with suspected sepsis,        i.e. patients with signs of systemic inflammation (i.e. meeting criteria for SIRS) where        the treating clinician takes microbial samples and/or starts empiric antibiotics.|July 2014|January 28, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02188992||40789|
NCT02189005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Precre/Nutra001/PMI13|Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels|A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Efficacy and Safety of PreCrea®, a Twice-daily Dietary Supplement in People With Higher Than Normal Blood Sugar Levels.|Precrea|PreEmptive Meds, Pvt. Ltd|Yes|Completed|November 2013|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|65 Years|No|||May 2015|May 14, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189005||40788|
NCT02202824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096620-S1|Measuring Beliefs and Norms About Violence Against Women|Measuring Beliefs and Norms About Violence Against Women in Rural Uganda: A Randomized Controlled Trial||Massachusetts General Hospital|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|1557|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 29, 2015|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02202824||39729|
NCT02204202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL121218-01|PET Assessment of Acute Lung Transplant Rejection|Positron Emission Tomography Assessment of Acute Lung Transplant Rejection||Washington University School of Medicine|No|Recruiting|February 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples Without DNA|cells from bronchoalveolar lavage specimen; tissues from biopsy specimens|Both|19 Years|N/A|No|Non-Probability Sample|Any patient within 7 months of double-lung transplantation and who is scheduled for        bronchoscopy with biopsy will be eligible. Patients will be identified via the        bronchoscopy schedule through the Lung Transplant Center at Barnes-Jewish Hospital /        Washington University School of Medicine and approached for potential participation prior        to their scheduled bronchoscopy. PET/CT imaging with [18F]FDG will be performed, if        consented, no more than 3 days after results from the biopsy are reported. [18F]ISO-1        PET/CT imaging will be performed the day after [18F]FDG PET and can be performed after        treatment for acute rejection has been initiated. We intend to image 30 lung transplant        recipients with no evidence of rejection (grade A0) and 30 recipients with mild to        moderate (grades A2-3) rejection.|June 2015|June 1, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204202||39623|
NCT02204228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0960-001|TITAN™ Reverse Shoulder System|A Post-market Clinical Follow-up Study of the TITAN™ Reverse Shoulder System Used in Primary or Revision Total Shoulder Arthroplasty||Integra LifeSciences Corporation|No|Recruiting|September 2014|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who require reverse shoulder replacement due to the inclusions below.|March 2016|March 23, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02204228||39621|
NCT02204241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-601|Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients|A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients|CCD|Stichting Hemato-Oncologie voor Volwassenen Nederland|No|Recruiting|June 2014|June 2019|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|65 Years|N/A|No|||July 2014|July 29, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02204241||39620|
NCT02203903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESOLVE|Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies|Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies||Children's Research Institute|Yes|Recruiting|January 2015|December 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|6 Months|65 Years|No|||September 2015|September 26, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203903||39646|
NCT02203916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_307|Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension||Takeda|No|Completed|August 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|299|||Both|19 Years|N/A|No|||February 2016|February 3, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203916||39645|
NCT02203890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeSSIAM_02|Normative State and Variation in Growth, Hematology, Hydration, Oxidation, Infection, Inflammation, Guatemalan Children|Study on the Normative State and Inter- and Intra-individual Variation in Growth, Hematology, Hydration and Markers of Oxidation, Infection and Inflammation in Preschool Children With a Similar Dietary Intake||Center for Studies of Sensory Impairment, Aging and Metabolism|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|91|Samples Without DNA|Urine, feces, saliva and blood|Both|23 Months|84 Months|Accepts Healthy Volunteers|Non-Probability Sample|Apparently healthy children who attend 3 daycare centers (one semi-urban, one        urban-marginal and one rural) from the Secretariat of Beneficial Works of the First Lady        (SOSEP) system in the Western Highlands in Quetzaltenango, Guatemala.|July 2014|July 28, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203890||39647|
NCT02204722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA_CML_IV|A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients|A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase|IDEAL|Dong-A ST Co., Ltd.|No|Recruiting|September 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204722||39583|
NCT02204969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822429989|LIWA for Treatment of Alzheimer Patients|Transcranial Magnetic Stimulation (TMS) and Lithium Water for Treatment of Alzheimer Patients|LIWA|American Society Of Thermalism And Climatology Inc|Yes|Recruiting|January 2015|December 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|80 Years|No|||January 2015|January 5, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204969||39564|
NCT02201004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOFOGL07061|TOFO Insulin Combination Trial|A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus||Sanofi|No|Active, not recruiting|June 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|20 Years|75 Years|No|||January 2016|January 5, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02201004||39869|
NCT02201017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1194-IG-CTIL|HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia|HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia||Sheba Medical Center|No|Recruiting|June 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|621|||Both|21 Years|N/A|No|Non-Probability Sample|A total of 621 consecutive male and female subjects, without established CAD, referred to        exercise stress testing (EST) due to 1) chest pain syndromes or equivocal/equivalent        angina with intermediate pretest probability for CAD; 2) , or asymptomatic subjects with        diabetes mellitus who are referred EST for risk assessment prior to initiation of an        exercise program.        Pretest probability of CAD will be based on the ACC 2002 guideline update on exercise        stress testing1.|July 2014|July 23, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02201017||39868|
NCT02194439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405976232|Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease|Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease||Indiana University|Yes|Enrolling by invitation|January 2014|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|430|Samples With DNA|Whole Blood, Plasma, Peripheral Blood Mononuclear Cells (PBMC), Saliva, Bronchoalveolar      lavage (BAL)|Both|N/A|N/A|No|Non-Probability Sample|patients receiving an allogeneic hematopoietic stem cell transplant, cord blood        transplant, bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion        (DLI), or donor cellular infusion (DCI) from Dana-Farber Cancer Institute and Boston        Children's Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred        Hutchinson Cancer Research Center, Texas Children's Hospital, Children's National Medical        Center, and Indiana University Simon Cancer Center|September 2015|September 14, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02194439||40371|
NCT02202291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0086|Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon|Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon|RAY-GENE|Nantes University Hospital|No|Not yet recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02202291||39770|
NCT02191696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-000050|Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation|Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation||Intersection Medical, Inc.|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present for CRM device follow-up are possible candidates for the study and        shall be screened for suitability based on the inclusion and exclusion criteria.|January 2015|January 28, 2015|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191696||40581|
NCT02191709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1134.2|Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects|A Phase I, Single Dose, Controlled Two-way Crossover Study to Evaluate the Relative Bioavailability of Orally Administered Dextromethorphan Syrup (21 mg Dextromethorphan Hydrobromide Monohydrate) in Comparison to Dextromethorphan Soft Pastilles (21 mg Dextromethorphan Hydrobromide Monohydrate) in Healthy Male and Female Subjects Who Are Extensive Metabolisers for Cytochrom P450 (CYP) 2D6||Boehringer Ingelheim||Completed|January 2009|||February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191709||40580|
NCT02192021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14030589|Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)|Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)|MNA-D|University of Pittsburgh|Yes|Recruiting|January 2016|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192021||40556|
NCT02188771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROC- 1|A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis|||ProCore Ltd.|No|Recruiting|February 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|45 Years|75 Years|No|||July 2014|July 13, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188771||40806|
NCT02188784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054061|Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure|Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure|IRONOUT|Duke University|Yes|Recruiting|August 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188784||40805|
NCT02188797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA034813|Substance Use and Sexual Risk Reduction Intervention for Homeless Youth|Brief AOD Use and Sexual Risk Reduction Group MI Intervention for Homeless||RAND|Yes|Recruiting|January 2014|April 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188797||40804|
NCT02202837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801378|Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice|Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))|REACH RA|Pfizer|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients presenting with moderate-to-severe RA in daily clinical practice|March 2016|March 22, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202837||39728|
NCT02203305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1544|Cochlear Implantation in Cases of Single-Sided Deafness|Cochlear Implantation in Cases of Single-Sided Deafness|CI in SSD|University of North Carolina, Chapel Hill||Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203305||39692|
NCT02204215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-ICUAW|Electric Acupuncture for ICU-acquired Weakness in Mechanical Ventilation Patients|Phase 1 Study of Electric Acupuncture for ICU-acquired Weakness in Mechanical Ventilation Patients With Sepsis/Multiple Organ Dysfunction Syndrome|EA-ICUAW|Jiangsu Province Hospital of Traditional Chinese Medicine|Yes|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||July 2014|July 28, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02204215||39622|
NCT02204501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA798-102|A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers|A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy Male and Female Volunteers||Biota Scientific Management Pty Ltd|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|July 29, 2014|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204501||39600|
NCT02204514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgery for ext. snapping hip|The Effects of Surgery for Painful External Snapping Hip|||Northern Orthopaedic Division, Denmark|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing surgery for painful external snapping hip in The North Denmark        Region between 2008-2013 with at least 1 year follow-up time.|October 2015|October 16, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02204514||39599|
NCT02204527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140415|Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension|Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Not yet recruiting|August 2014|December 2017|Anticipated|August 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|154|||Both|30 Years|80 Years|No|||July 2014|July 29, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204527||39598|
NCT02204475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-066|Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)|A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1 Infection||Merck Sharp & Dohme Corp.|No|Withdrawn|November 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204475||39602|
NCT02204488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47755.075.14|Surgical Treatment for Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 2-3|Total Joint Arthroplasty or Trapeziectomy for Treating Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 2 and 3: a Randomized Clinical Trial||Isala|No|Recruiting|September 2014|September 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Female|40 Years|N/A|No|||February 2016|February 25, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204488||39601|
NCT02204449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7183|Cardiac Rehabilitation Peer Mentorship|Mentorship to Promote Cardiac Rehabilitation Enrollment: A Randomized Controlled Trial||University Health Network, Toronto|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|94|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 28, 2014||No||No|June 3, 2015|https://clinicaltrials.gov/show/NCT02204449||39604|
NCT02204982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-08|Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma|DYNAMO + R|Infinity Pharmaceuticals, Inc.|Yes|Active, not recruiting|September 2014|January 2024|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02204982||39563|
NCT02201030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP606_PCVI_III_2013|Study Immunogenicity and Safety of NBP606 in Healthy Infants|Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Primary Vaccination With NBP606 in Healthy Infants||SK Chemicals Co.,Ltd.||Not yet recruiting|September 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|534|||Both|1 Month|3 Months|Accepts Healthy Volunteers|||April 2014|July 23, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02201030||39867|
NCT02204176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072613B3F|Exercise Behavior Among Young Adults Study|Exercise Behavior Among Young Adults Study|EBYA|Wayne State University|Yes|Recruiting|August 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|200|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02204176||39625|
NCT02204189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|z141100002114004|The Clinical Study of Acute Pancreatitis Treated by TongFuSan|The Clinical Study of Acute Pancreatitis With Gastrointestinal Dysfunction Treated by TongFuSan for External Application on ShenQue Acupoint||Beijing Friendship Hospital|Yes|Recruiting|March 2014|February 2017|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204189||39624|
NCT02201550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-148-KLB|Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide|Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)||Hvidovre University Hospital|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Blood samples|Male|18 Years|80 Years|No|Non-Probability Sample|Patients with type 2 diabetes undertaking treatment with liraglutide|July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201550||39827|
NCT02201563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14020381|Minocycline Therapy for Management of Adverse Radiation Effects|A Safety and Feasibility Study of Minocycline Therapy for Management of Adverse Radiation Effects After Brain Metastases Radiosurgery||University of Pittsburgh|No|Recruiting|November 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 23, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201563||39826|
NCT02201771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-ISSBRIL0211|Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery||DACAB-1|Ruijin Hospital||Active, not recruiting|July 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201771||39810|
NCT02202044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1359.cc|Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection|Adjuvant Sequential Intravesical BCG (Bacillus Calmette-Guérin) and Electromotive Mitomycin-C (EMDA/MMC) After Transuretheral Resection (TUR) in Patients With Primary High Risk Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder||University of Colorado, Denver|No|Recruiting|February 2015|September 2021|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|89 Years|No|||February 2016|February 29, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202044||39789|
NCT02202564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-02|Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma|||Huazhong University of Science and Technology||Completed|October 2006|August 2013|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|70 Years|No|||July 2014|July 28, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02202564||39749|
NCT02194452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302711|Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors|Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors||University of Iowa|Yes|Suspended|September 2013|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|6 Months|29 Years|No|||April 2015|April 21, 2015|July 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194452||40370|
NCT02194777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.37|Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Volunteers After Inhalative Administration of BIBN 4096 BS (Dosage: 5 - 80 mg)||Boehringer Ingelheim||Completed|June 2001|||August 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|July 17, 2014||||No||https://clinicaltrials.gov/show/NCT02194777||40345|
NCT02202304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLOVADENT|The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient|The Effects of Chlorhexidine/Thymol Varnish on the Abutment Teeth in Partial Denture Wearers.||University of Aberdeen|Yes|Not yet recruiting|October 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 27, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202304||39769|
NCT02191722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0213-14-RMC|"Medikidz Explain JIA Comic Book- Hebrew"|Evaluating the Efficacy of a Comic Book as an Educating Tool for Children With Juvenile Idiopathic Arthritis||Rabin Medical Center|No|Not yet recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|10 Years|18 Years|No|||July 2014|July 15, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02191722||40579|
NCT02191735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP024|RAMP 200 / RAMP Cardiovascular Tests at the Point-of-Care|Performance Evaluation of the RAMP® Cardiac Tests / RAMP® 200 in a Point-Of-Care Setting (C-POC)|C-POC|Response Biomedical Corp.|No|Completed|July 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|719|Samples With DNA|EDTA plamsa specimens|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 600 total subjects, 18 years of age and older will be enrolled into this        study at a minimum of 3 sites in the United States of America (USA).        Each site will screen for a minimum of approximately 200 clinical surplus whole blood        samples derived from subjects presenting with symptoms and signs indicative of        cardiovascular heart disease (i.e. acute myocardial infarction and/or heart failure). It        is expected that the population will be divided approximately equally between males and        females. Clinical site enrollment will be monitored throughout the trial to verify        population distribution.|January 2015|January 7, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191735||40578|
NCT02192034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS255086|Optimizing Navigation to Successful Colorectal Cancer Screening|Optimizing Navigation to Successful Colorectal Cancer Screening||Rush University Medical Center|No|Completed|March 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|156|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02192034||40555|
NCT02188524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM_TCFP|The Effect of Training Older Adults in Tai Chi and Compensatory Stepping on Balance Control|The Effect of Training Older Adults in Tai Chi and Compensatory Stepping on Balance Control||Wilfrid Laurier University|No|Active, not recruiting|April 2014|August 2015|Anticipated|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02188524||40825|
NCT02188810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE1202|Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults|A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults.||Folia Biotech Inc.|Yes|Active, not recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|6||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02188810||40803|
NCT02188823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11813p|Examining the Effects of Diet on Health in Prediabetes With an Online Program|Examining the Effects of Diet on Health in Prediabetes With an Online Program||University of California, San Francisco|No|Recruiting|July 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188823||40802|
NCT02203617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD447749|Using Baby Books to Promote Maternal and Child Health|Using Baby Books to Promote Maternal and Child Health||Vanderbilt University|No|Completed|April 2005|July 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|198|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02203617||39668|
NCT02203981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TopQ_Maestro_OCT2000_001|TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000|TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000||Topcon Medical Systems, Inc.|No|Completed|January 2014|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that have no known ocular pathologies|October 2014|October 21, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203981||39640|
NCT02203942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010349|Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis|Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices.|VAST|University of Pittsburgh|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Enrollments will include patients seeking care at Magee-Womens Hospital.|January 2016|January 26, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02203942||39643|
NCT02192619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAPOLEON-Registry|National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup|National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup||Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|No|Recruiting|June 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly-diagnosed or relapsed APL (de novo or therapy-related) who require a        therapeutic intervention according to their disease state are the study population within        this registry.|April 2015|April 7, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192619|5 Years|40511|
NCT02192632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP-BPO|Dermatologists' Educational Demonstration for Epiduo Application|||Seoul National University Hospital||Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|40 Years|No|||March 2015|March 10, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192632||40510|
NCT02204761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9148|Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy|Definitive Re-irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers||University of Washington|No|Recruiting|September 2014|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||February 2016|February 9, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02204761||39580|
NCT02204774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V 1.1|Is Obstructive Sleep Apnoea a Risk Factor for Thoracic Aortic Aneurysm Expansion? A Prospective Cohort Study.|Is Obstructive Sleep Apnoea a Risk Factor for Thoracic Aortic Aneurysm Expansion? A Prospective Cohort Study.||University of Zurich|No|Recruiting|July 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|18 Years|90 Years|No|Non-Probability Sample|Diagnosis of thoracic aortic aneurysm defined by the following parameters          -  Women: at the level of the sinus of valsalva >39mm, or ascending aorta >42mm.          -  Men: at the level of the sinus of valsalva >44mm, or ascending aorta >46mm.|December 2015|December 7, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204774||39579|
NCT02204735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK_9560 B|Timing of Meals for Weight Loss|Timing of Meals for Weight Loss|TIME|University of Tennessee|Yes|Active, not recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02204735||39582|
NCT02204995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48197.075.14|Surgical Treatment for Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 4|Trapeziectomy With Ligament Reconstruction and Tendon Interposition or Simple Trapeziectomy for Treating Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 4: a Randomized Clinical Trial||Isala|No|Recruiting|September 2014|September 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Female|40 Years|N/A|No|||February 2016|February 25, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204995||39562|
NCT02201056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-935_101|Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects||Takeda|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|48|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02201056||39865|
NCT02201043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLDA-201|Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis||Shanghai Pharmaceuticals Holding Co., Ltd|No|Completed|February 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201043||39866|
NCT02201355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112013-007|Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck|A Phase I Study of Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for T1/2N0-2 Squamous Cell Carcinoma of the Head and Neck||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201355||39842|
NCT02201576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120119|Bortezomib in Rejection of Kidney Transplants|Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation|TRIBUTE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2015|October 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02201576||39825|
NCT02201784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jnmch2012|Spinal Anaesthesia With Levobupivacaine 0.5% and Ropivacaine 0.75% for Lower Limb Orthopaedic Surgery|A Comparative Study Between Levobupivacaine 0.5% and Ropivacaine 0.75% in Patients Undergoing Spinal Anaesthesia for Lower Limb Orthopaedic Surgery.||Aligarh Muslim University|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||January 2015|January 14, 2015|July 24, 2014|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT02201784||39809|Exact baricity was not known as Specific gravity was not measured; Quality of anaesthesia was not assessed
NCT02201797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0060|Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body|Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body||Asan Medical Center|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201797||39808|
NCT02202057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400183|Respiratory Load Magnitude Estimation in PD|Magnitude Estimation of Respiratory Resistive Load in Parkinson's Disease||University of Florida|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|45 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include 2 participant groups: those with Parkinson's disease, and healthy        age- matched control participants. We will recruit 40 healthy older adults and 40        individuals with PD to participate. We will recruit all participants with PD from those        referred for swallowing evaluation by the speech-language pathology service at the        University of Florida (UF) Center for Movement Disorders and Neurorestoration (CMDNR).        Healthy participants will be recruited via the UF Institutional Review Board's (IRBs)        Healthstreet program, and local/campus advertisements.|October 2015|October 14, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202057||39788|
NCT02194790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICC program|Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.|Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.||Bhumirajanagarindra Kidney Institute, Thailand|Yes|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|238|||Both|18 Years|70 Years|No|||July 2014|July 17, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194790||40344|
NCT02194751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X13-21008|Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma|Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma||XEME Biopharma Inc.|No|Not yet recruiting|December 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194751||40347|
NCT02194764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012115600086371|An Adherence Tool to Manage Narcotic -Addicted HIV Patients|A Breath-based Naltrexone Adherence Tool to Manage Narcotic-addicted HIV Patients.||Xhale Assurance|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194764||40346|
NCT02191748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2013003377|Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo|Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo||Rutgers, The State University of New Jersey|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|89 Years|No|||June 2015|June 3, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02191748||40577|
NCT02188511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312014623|Effects of Electronic Cigarettes on Lung Biology|Effects of Electronic Cigarettes on Lung Biology||Weill Medical College of Cornell University|Yes|Recruiting|January 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|50|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02188511||40826|
NCT02188537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 39/13 - FORTUNE|Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma|Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Recruiting|December 2014|December 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02188537||40824|
NCT02188550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CUS242T|Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer|Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)||Sinai Hospital of Baltimore|No|Recruiting|June 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|80 Years|No|||May 2015|May 18, 2015|May 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188550||40823|
NCT02219334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33659|Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study|Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study||Baylor College of Medicine|No|Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|2 Months|2 Years|No|||July 2015|July 16, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219334||38463|
NCT02196415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0459|Three-Dimensional Hindfoot Alignment Measurements Based On Biplanar Radiographs: Prospective Clinical Feasibility Study|Three-Dimensional Hindfoot Alignment Measurements Based On Biplanar Radiographs: Prospective Clinical Feasibility Study||Balgrist University Hospital|No|Recruiting|July 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with clinically suspected hindfoot malalignment|July 2014|July 18, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02196415||40219|
NCT02204254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-AOI-13|RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea|Prospective, Open Label, Randomized Study Comparing Bipolar Radiofrequency Potentiated by Infrared Light to Doxycycline in Patient With Papulopustular Rosacea|Rosac-RF|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||July 2014|July 29, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02204254||39619|
NCT02192372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetS CIN|Metabolic Syndrome and Contrast Induced Nephropathy|Impact of Metabolic Syndrome on Development of Contrast Induced Nephropathy After Elective Percutaneous Coronary Intervention||Ankara University|No|Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|599|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective percutaneous coronary intervention Patients with metabolic        syndrome|July 2014|July 15, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192372||40529|
NCT02192398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-001377|Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)|Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)||Massachusetts General Hospital|Yes|Recruiting|September 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192398||40528|
NCT02192645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAR|The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study|||Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Active, not recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|453|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02192645||40509|
NCT02192879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042166|TEA vs. PVB vs. PCA in Liver Resection Surgery|A Comparison of the Efficacy of Alternative Analgesia Modalities in Complex Hepatic Resection Surgery: Thoracic Epidural Analgesia Versus Continuous Paravertebral Block With Patient-Controlled Analgesia Versus Patient-Controlled Analgesia||Duke University|Yes|Recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||July 2015|August 3, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02192879||40491|
NCT02204748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13002|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty||The University of Tennessee Knoxville|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|5|||Both|30 Years|80 Years|No|Non-Probability Sample|Patients will have been implanted with the DePuy Attune PS FB knee system by Dr. Thomas        Fehring of OrthoCarolina, PA in Charlotte, NC.|January 2016|January 5, 2016|July 28, 2014||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02204748||39581|
NCT02205008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-GC|Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer|Prospective Randomized Multicenter Phase III Trial of Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer|EPIC-GC|Kyungpook National University|No|Recruiting|October 2012|November 2018|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|19 Years|70 Years|No|||July 2014|July 29, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02205008||39561|
NCT02201368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/084|Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects|Study to Evaluate the Effectiveness of Dietary Treatment With Triheptanoin in Patients With Long-chain Fatty Acid Beta-oxidation Defects||Hospital Clinico Universitario de Santiago|No|Withdrawn|November 2009|October 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||July 2014|July 25, 2014|March 22, 2013||No|IMP management difficulties|No||https://clinicaltrials.gov/show/NCT02201368||39841|
NCT02201381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metabolic Cancer 001|Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer|Prospective Observational Study of the Safety, Tolerability and Efficacy of Metabolic Combination of Existing Medicines on Cancer|METRICS|Health Clinics Limited|Yes|Suspended|December 2013|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood Serum Tissue|Both|18 Years|85 Years|No|Probability Sample|All Cancer Patients with metastatic disease|May 2015|May 18, 2015|July 22, 2014||No|Pending discussions with regulatory and ethics bodies|No||https://clinicaltrials.gov/show/NCT02201381|5 Years|39840|
NCT02201589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIDE:Ascending Thoracic Aorta|Feasibility of Endovascular Repair Of Ascending Aortic Pathologies|Proposed Single Center Investigational Device Exemption: Feasibility of Endovascular Repair Of Ascending Aortic Pathologies||Los Angeles Biomedical Research Institute|No|Recruiting|September 2013|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201589||39824|
NCT02201810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140076H|Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)|Enhancing the Efficacy of Smoking Quit Line in the Military|Freedom|University of Tennessee|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201810||39807|
NCT02201823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-C1-2013|Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients|A PHASE I/Ib, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF ABTL0812 IN PATIENTS WITH ADVANCED SOLID TUMOURS||Ability Pharmaceuticals SL|Yes|Completed|February 2014|April 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|May 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02201823||39806|
NCT02195063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAHM 1001|Survey Study for Pain Management, Wound Care, Scar Care or UDT|Survey of Patients Who Have Been Prescribed a Topical Compound for Pain Management, Wound Care or Scar Care or to Patients Who Have Been Requested to do a Urinary Drug Test (UDT) by Their Provider.||Rahm Foundation|No|Recruiting|November 2013|||December 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are given a prescription for topical compound for pain, scar care, or wound        care, and agree to complete the surveys        or        Patients who are given a UDT and agree to complete the surveys.        Patients will be recruited into the study if their providers prescribe a topical cream for        pain, scar care or wound care or if the provider performs a UDT prior to treatment or        surgery. The providers will follow their office procedure for UDT. If they perform a UDT        and the patient agrees to participate in the survey study, they will have the patient        complete the surveys.|January 2015|January 27, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02195063||40323|
NCT02195050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOB2012|Hypertriglyceridaemia - Cause and Effects|Hypertriglyceridaemia: Therapeutic Targets, Genetic Causes, and Associated Neuropathy||Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|January 2014|February 2025|Anticipated|February 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|1396|Samples With DNA|Serum & plasma samples will be stored for further studies.|Both|18 Years|N/A|No|Non-Probability Sample|Patients are recruited from secondary and tertiary care hospital clinics.|January 2016|January 28, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02195050||40324|
NCT02188238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR01/2014|Effect of Oral Health Ingredients on the Acquired Salivary Pellicle|Effect of Active Ingredients in Oral Health Products on the in Vitro Structure of the Acquired Salivary Pellicle.||Institute of Food Research|No|Enrolling by invitation|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Apparently healthy volunteers from the local community able to donate saliva samples|August 2015|August 24, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188238||40847|
NCT02188264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01484|Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer|A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer||National Cancer Institute (NCI)|Yes|Recruiting|August 2014|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|March 14, 2016|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02188264||40845|
NCT02188277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ-R-201212_01001_N_2|Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy|Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin) in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy|XEBEC|Merz Pharmaceuticals GmbH|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|2 Years|12 Years|No|||February 2016|February 23, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188277||40844|
NCT02219061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZCDC001|Early Waning of Maternal Measles and Meningitis C Antibodies|Observation Study on Early Waning of Maternal Measles and Meningitis C Antibodies|EWMM|Guangzhou Center for Disease Control and Prevention|Yes|Recruiting|May 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Children's Serum will be collected for measles and meningitis C antibodies test by ELISA      method.|Both|N/A|7 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants.|August 2014|September 16, 2014|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219061||38484|
NCT02219074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEB-0005|Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris|A Feasibility Study to Evaluate the Safety and Preliminary Efficacy of the Sebacia Acne Treatment System for the Treatment of Acne Vulgaris||Sebacia, Inc.|No|Active, not recruiting|June 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|310|||Both|16 Years|35 Years|No|||July 2015|July 13, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219074||38483|
NCT02219347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH7100|Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)|Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)|BioRRA|Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02219347||38462|
NCT02196168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00759|Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN)||National Cancer Institute (NCI)|Yes|Recruiting|March 2014|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|19 Years|N/A|No|||November 2015|December 11, 2015|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196168||40238|
NCT02192359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14108|Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas||City of Hope Medical Center|Yes|Recruiting|March 2016|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|64 Years|No|||March 2016|March 9, 2016|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192359||40530|
NCT02192658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12302 - HandiVIH|Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa|Disability and HIV: an Appraisal of the Vulnerability of People With Disabilities to HIV Infection in Two Main Cities of Sub-Saharan Africa|HandiVIH|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|November 2014|February 2016|Anticipated|December 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|1610|||Both|15 Years|49 Years|No|Probability Sample|Community sample:        - PWD are identified thanks to the disability screening tool developped by the Washington        Group (WG). This tool is based on the WHO International Classification of Functionning        (ICF).        A stratified cluster sampling in 2 steps is used in Yaounde. The city has been divided in        enumeration areas (EAs). First step : EAs are drawn randomly with probability proportional        to their size in number of households. Second step: in each EA, 30 households are randomly        drawn and each person living in these households is screened for disability with the WG        tool, according to the inclusion and exclusion criteria.        - For each PWD, 1 non-disabled control person is randomly chosen from the census list of        the same enumeration area. Controls are matched on age and sex.|December 2015|December 8, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192658||40508|
NCT02192892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10-28-AmyVisc|Acceptability Among Children and Caregivers of Amylase Porridges|Acceptability of α-amylase Fortified Blended Foods Among Children 12-36 Months Old Children and Caregivers in Burkina Faso|AMY-01|DSM Food Specialties|Yes|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|18||Actual|240|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||August 2014|August 5, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02192892||40490|
NCT02205021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001603|Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome|Compartmental Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome||Massachusetts General Hospital|No|Completed|January 2014|||March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|303|||Both|18 Years|91 Years|Accepts Healthy Volunteers|Non-Probability Sample|Retrospective search of whole-body PET/CT examinations and consecutively selected imaging        studies.|July 2014|July 30, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205021||39560|
NCT02201095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18196|Active Warming During Elective Caesearean Section|Active Warming for Elective Caesarean Section - a RCT||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02201095||39862|
NCT02193360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFP104-001|Pilot Study of FFP104 Dose Escalation in PBC Subjects|A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)||Fast Forward Pharmaceuticals|Yes|Recruiting|May 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02193360||40454|
NCT02201069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087322|My Health Coach Study|My Health Coach Study||University of Michigan|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|75|||Both|21 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201069||39864|
NCT02201082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physionebu|Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|September 2012|July 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|16 Years|50 Years|No|||August 2015|August 24, 2015|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02201082||39863|
NCT02193828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-750|Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules|A Phase 2a, Double-blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of AA4500 in the Treatment of Dupuytren's Disease Nodules||Endo Pharmaceuticals|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 19, 2014|Yes|Yes||No|June 12, 2015|https://clinicaltrials.gov/show/NCT02193828||40418|
NCT02194062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pneubauer|Comparison of Nasal Steroids After FESS in CRSwNP|A Comparison of Budesonide Nasal Irrigation in Different Head Positions and Fluticasone Nasal Spray in Post-operative Functional Endoscopic Sinus Surgery Patients With Chronic Rhinosinusitis With Nasal Polyposis||Yale University|No|Recruiting|January 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02194062||40400|
NCT02194465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15525|A Study of LY2623091 in Participants With High Blood Pressure|A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension||Eli Lilly and Company|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|306|||Both|18 Years|80 Years|No|||May 2015|May 8, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194465||40369|
NCT02194478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S091301|Stress Reduction for Busy Professionals|Pilot Study of a Brief Mind/Body Meditation Intervention for Allina Health Employees||Allina Health System|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194478||40368|
NCT02195076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0695-13-SMC|Non Invasive Detection of Lung and Breast Cancer by Odor Signature|A Clinical Study Design to Evaluate the Specificity and Sensitivity of Our Novel System for Detection of Breast and Lung Cancer by Odor Signature||BioSense Medical LTD||Recruiting|July 2014|||July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|400|Samples Without DNA|urine samples and exhaled breath samples|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breast Cancer patient after diagnosis. Lung Cancer patients after diagnosis. Healthy        controls, matching gender and age.|July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195076|3 Years|40322|
NCT02195310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCI.2013.Prevena.01|The Use of PrevenaTM on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.|The Use of PrevenaTM Incision Management System on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.||KCI Europe Holding B.V.|No|Recruiting|November 2013|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|504|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195310||40304|
NCT02187978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/098/2012/ETEF|Early Total Enteral Feeding Versus Conventional Enteral Feeding in Stable Very Low Birth Weight Infants|Comparison of Early Total Enteral Feeding (ETEF) Versus Conventional Enteral Feeding (CEF) in Stable Very Low Birth Weight (VLBW) Infants - A Randomized Controlled Trial||Lady Hardinge Medical College|Yes|Completed|July 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|180|||Both|N/A|120 Hours|No|||September 2015|September 26, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02187978||40867|
NCT02188251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14AWHG|A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants|A Randomized, Double-blind, Placebo Controlled, Parallel Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants|14AWHG|KGK Synergize Inc.||Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|100|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188251||40846|
NCT02188290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-AIR-006|Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation|An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation||Kiadis Pharma|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|178|||Both|18 Years|65 Years|No|Probability Sample|Patients having received a haploidentical hematopoietic stem cell transplantation (HSCT)        between 1 January 2006 and 30 June 2014, an HSCT from an unrelated donor between 1 January        2010 and 31 December 2012, or a double UCB transplantation between 1 January 2010 and 31        December 2012 will be selected from the centers that enrolled patients in study CR-AIR-004        and/or study CR-AIR-007.|October 2015|October 5, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188290||40843|
NCT02219087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0024|Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery|Local Liposomal Bupivacaine Versus Standard of Care in an Opioid-Sparing Analgesic Approach to Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial||OhioHealth|No|Recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219087||38482|
NCT02219867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheba- Ketamine|Ketamine Infusions for Major Depression Disorder|Evaluation of Safety and Efficacy of Sub-anesthetic Ketamine Infusions as a Treatment for Patients Diagnosed With Resistant Major Depression|Ketamie|Sheba Medical Center|Yes|Not yet recruiting|August 2014|August 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||August 2014|August 28, 2014|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219867||38422|
NCT02192411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JVDL070714|Efficacy of Variable Lidocaine Concentrations in Tumescent Anesthesia for Pain Control During and After Endovenous Laser Procedure; Non-inferiority Trial|Efficacy of Variable Lidocaine Concentrations in Tumescent Anesthesia for Pain Control During and After Endovenous Laser Procedure; a Double Blinded, Randomized, Controlled Non-inferiority Trial||Midwest Vein Center|Yes|Not yet recruiting|July 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|85 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192411||40527|
NCT02196428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ 14809.2|Medical Telemonitoring Plus Individual Teleconsultation in Elderly|Medical Telemonitoring Plus Individual Teleconsultation Based on an Ambient Assisted Living (AAL-) Wizard - an Interdisciplinary, Integrated Innovation.||University of Zurich|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|50 Years|N/A|No|||December 2015|December 3, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196428||40218|
NCT02192918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA161576-01A1|Pilot Investigation of Behavioral Alternatives to Indoor Tanning|Pilot Investigation of Behavioral Alternatives to Indoor Tanning||University of Massachusetts, Worcester|Yes|Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|74|||Female|16 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02192918||40488|
NCT02193126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8977 3|Trauma Focus Model for Reducing Long-Term Foster Care|Permanency Innovations Initiative- Trauma Focus Model for Reducing Long-Term Foster Care Project||Westat|No|Enrolling by invitation|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|N/A|||||||Both|11 Years|16 Years|No|||July 2014|July 17, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02193126||40472|
NCT02193139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH1304|Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis|A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis||Watson Pharmaceuticals||Completed|December 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|195|||Both|18 Years|55 Years|No|||November 2014|July 15, 2015|June 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193139||40471|
NCT02193100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-BMT-13 Leuk Metabolomics|Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center|PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center||James Graham Brown Cancer Center|Yes|Withdrawn|August 2014|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Leukemia Subjects-clinically diagnosed or histologically diagnosed leukemia Healthy        Subjects-no record of diagnosed cancer or hematologic disorders|January 2016|February 29, 2016|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02193100||40474|
NCT02193373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1044|Study of Osteopathic Manipulative Medicine on the Autonomic Nervous System|What is the Best Osteopathic Manipulative Medicine (OMM) Approach to Affect Autonomic Nervous System (ANS) Control of Heart Rate Variability (HRV)?||New York Institute of Technology|No|Recruiting|June 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02193373||40453|
NCT02193594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRADLE|Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma|Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma||Peking University|Yes|Recruiting|January 2014|May 2020|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|80 Years|No|||June 2015|June 4, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193594||40436|
NCT02193841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000042364|Simple Bone Cysts in Kids|Simple Bone Cysts in Kids (SBoCK)|SBoCK|The Hospital for Sick Children|Yes|Recruiting|March 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|2 Years|21 Years|No|||February 2016|February 29, 2016|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02193841||40417|
NCT02194075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013006|Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder|||Guangdong General Hospital|Yes|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|40 Years|No|||December 2013|October 22, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02194075||40399|
NCT02194491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3662-CL-0011|A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662|||Astellas Pharma Inc|No|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02194491||40367|
NCT02194803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE18|Observation of Treatment Patterns With Lucentis in Approved Indications|Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications|OCEAN|Novartis|No|Active, not recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|6072|||Both|18 Years|N/A|No|Probability Sample|Male and female patients suffering from neovascular eye pathology in real life setting for        whom a therapy with Lucentis® is recommended by the treating physician in line with        approved indications. Warnings and contraindications have to be taken into account        according to the summary of product characteristics (SmPC).|October 2015|October 27, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02194803||40343|
NCT02195089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT2013-BLS-ILB-E710c|Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)|A Phase 1/2a Trial to Evaluate the Efficacy and the Safety of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)||BioLeaders Corporation|No|Recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Female|20 Years|50 Years|No|||January 2016|January 11, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02195089||40321|
NCT02195323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Kidney-004|Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)|Administration of Autologous Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)||Royan Institute|Yes|Completed|April 2014|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|25 Years|60 Years|No|||November 2015|January 3, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195323||40303|
NCT02195336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BevMar|dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.|Diffusion MR (dMRT) During First Line Treatment of Non Squamous Lung Cancer With Chemotherapy Combined With Bevacizumab: Time Course and Prognostic and Predictive Impact.|BevMar|Karolinska University Hospital|No|Not yet recruiting|August 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02195336||40302|
NCT02187991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-033|Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer|A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer||US Oncology Research|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|252|||Female|18 Years|N/A|No|||November 2015|November 7, 2015|July 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187991||40866|
NCT02218580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRA (CIORA grant #4)|Massage Therapy in Juvenile Idiopathic Arthritis|Massage Therapy for Children With Juvenile Idiopathic Arthritis Experiencing Pain: a Pilot Randomized Controlled Trial||McGill University Health Center|No|Recruiting|May 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|17 Years|No|||September 2015|September 29, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02218580||38521|
NCT02219633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0083-1085|Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Trial Evaluating the Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)||LEO Pharma|No|Completed|July 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02219633||38440|
NCT02220127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0050|RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases|Optimal Radiation Method for Gamma Knife Radiosurgery of Brain Micrometastases: A Multi-centre Randomised Clinical Trial (RCT) of the 4mm vs. the 8mm Collimator.||University College, London|Yes|Recruiting|September 2014|April 2021|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|298|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220127||38402|
NCT02220140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-res-adhd|Resilience for Young People With ADHD - a Randomized Controlled Trial of a Brief Intervention Program.|Resilience for Young People With Attention Deficit Hyperactivity Disorder (ADHD) - a Randomized Controlled Trial of a Brief Intervention Program.||University of Aarhus|No|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|8000|||Both|18 Years|27 Years|No|||May 2015|June 1, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220140||38401|
NCT02192424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0263-A Main|Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)|A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT)|RESET-IT|Mount Sinai Hospital, Canada|No|Recruiting|July 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|30 Years|80 Years|No|||March 2016|March 15, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02192424||40526|
NCT02192671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRFA-HCC/PHT|HR Versus RFA for HCC in Patients With PHT|Hepatic Resection Versus Radiofrequency Ablation for Patients With Hepatocellular Carcinoma and Portal Hypertension|HR-HCC/PHT|Guangxi Medical University|No|Recruiting|May 2015|December 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02192671||40507|
NCT02202187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114595|A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects||GlaxoSmithKline||Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202187||39778|
NCT02193113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVD001-001|A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME|An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision||KalVista Pharmaceuticals, Ltd.|Yes|Active, not recruiting|July 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|17|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02193113||40473|
NCT02193386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51880|Evidence-based Physical Therapy in Children With Cerebral Palsy|Evidence-based Practice and Its Effectiveness in Physical Therapy Treatment of Children With Bilateral Spastic Cerebral Palsy.||Universitaire Ziekenhuizen Leuven|Yes|Completed|September 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|4 Years|9 Years|No|||September 2010|July 14, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02193386||40452|
NCT02193633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3667|A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.|TAX-TORC: A Phase I Multi-centre Trial of the Combination of AZD2014 (Dual mTORC1 and mTORC2 Inhibitor) and Weekly Paclitaxel in Patients With Solid Tumours.|TAX-TORC|Royal Marsden NHS Foundation Trust|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||March 2015|March 11, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02193633||40433|
NCT02193607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTOS-2014|Outcomes of Pelvic Surgery With and Without Anti-incontinence Procedure in Occult Stress Urinary Incontinence Patients|Improved Reconstruction Pelvic Surgery With and Without Tension-free Vaginal Tape-obturator in Women With Occult Stress Urinary Incontinence(PTOS): a Randomized Controlled Trial|PTOS|Peking Union Medical College Hospital|No|Enrolling by invitation|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|196|||Female|55 Years|N/A|No|||July 2014|July 15, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02193607||40435|
NCT02193620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP025|Study of PHN131 in Patients After Surgery|A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management||PhytoHealth Corporation|No|Active, not recruiting|April 2013|February 2016|Anticipated|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||September 2015|November 3, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02193620||40434|
NCT02194088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001857|Combined Medication for Improved Analgesia in Superficial Pain|Potential for Improved Analgesia From Combined Medication for Superficial Pain||Brigham and Women's Hospital|No|Completed|April 2014|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02194088||40398|
NCT02194504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44614.081.13|The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity|The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity||Wageningen University|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|110|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02194504||40366|
NCT02194816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-13A-1332|Complementary & Alternative Medicine in Parkinson's Disease (CAM Care in PD)|Complementary & Alternative Medicine in Parkinson's Disease||Bastyr University|No|Recruiting|September 2012|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|19 Years|N/A|No|Non-Probability Sample|Any individual with PD is invited to participate.|January 2016|January 12, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02194816||40342|
NCT02204605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000132|Video-based Consensus Opinion for Hand and Upper Extremity Problems|||Massachusetts General Hospital|No|Enrolling by invitation|May 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|2||Anticipated|128|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02204605||39592|
NCT02195349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200630|A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis|A Randomised, Double Blind (Sponsor Unblinded), Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis||GlaxoSmithKline|No|Recruiting|July 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195349||40301|
NCT02195362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2009-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||July 18, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195362||40300|
NCT02222584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0364|The Effects of Physical Activity on Patients With Inflammatory Bowel Disease|||Yonsei University|No|Recruiting|June 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|19 Years|N/A|No|Non-Probability Sample|patients with inflammatory bowel disease who are visiting the out-patient clinic of        severance hospital from July 2014 to Feburary 2015|August 2014|August 20, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222584||38213|
NCT02222597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209046DPB|An Evaluation of Near-Infrared Spectroscopy for Intracranial Hematoma Detection of Head Trauma Patients in the Emergency Department.|An Evaluation of Near-Infrared Spectroscopy for Intracranial Hematoma Detection of Head Trauma Patients in the Emergency Department.||National Taiwan University Hospital|No|Recruiting|April 2014|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|The patients within 12 hours after head injury visit the Emergency Department of the NTUH.|August 2014|August 24, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222597||38212|
NCT02219880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137/14|Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial|Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial|KGAD|University of Melbourne|No|Recruiting|September 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02219880||38421|
NCT02219893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImmunoPeCa Trial|Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial|Phase I/II Trial of MOC31PE Immunotoxin in Peritoneal Carcinomatosis From Colorectal Carcinoma|ImmunoPeCa|Oslo University Hospital|Yes|Recruiting|August 2014|August 2021|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02219893||38420|
NCT02219906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130996|Resveratrol in Metabolic Syndrome|Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation||Vanderbilt University|Yes|Enrolling by invitation|May 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|118|||Both|30 Years|75 Years|No|||December 2015|December 4, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219906||38419|
NCT02220153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0018|A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers|A Subject-Blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of UCB7665 in Healthy Subjects||UCB Pharma|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|41|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220153||38400|
NCT02215733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.599|The Use of Angiotensin Receptor Blockers and the Risk of Cancer|The Use of Angiotensin Receptor Blockers and the Risk of Cancer||Boehringer Ingelheim||Completed|February 2011|||February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1165781|||Both|N/A|N/A|No|Probability Sample|All patients prescribed an antihypertensive agent between January 1, 1995 and December 31,        2008, with follow-up until December 31, 2010 Information extracted from United Kingdom        General Practice Research Database (GPRD)|August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215733||38740|
NCT02215746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.2|Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers|Relative Oral Bioavailability of BI 44370 TA Drinking Solution (100 mg and 200 mg) and BI 44370 TA Tablets (100 mg as Two 50 mg Tablets) With and Without a High Fat Meal in Healthy Male and Female Volunteers: A Single Dose, Open-label, Randomised Six-way Cross-over Trial||Boehringer Ingelheim||Completed|January 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215746||38739|
NCT02213003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140144|Allogeneic Islet Cells Transplanted Into the Omentum|Allogeneic Islet Cells Transplanted Into the Omentum||University of Miami|Yes|Recruiting|September 2014|May 2019|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213003||38948|
NCT02213861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-141-003|Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma|A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma||TetraLogic Pharmaceuticals|No|Active, not recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213861||38883|
NCT02213848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calcium RNMB|Effect of Calcium Chloride on Recovery From Neuromuscular Blockade|Effect of Calcium Chloride on Recovery From Neuromuscular Blockade in Patients Undergoing General Anesthesia||Seoul National University Hospital|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|65 Years|No|||August 2014|June 29, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02213848||38884|
NCT02210429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15849|Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques|Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques||Ann & Robert H Lurie Children's Hospital of Chicago|No|Active, not recruiting|January 2009|November 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|N/A|17 Years|No|||June 2015|July 27, 2015|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02210429||39144|
NCT02210702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-06-FB-0118-HOSP|Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales|Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales||The Jones Institute||Recruiting|July 2014|||January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|33|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02210702||39124|
NCT02210988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGHIRBCT-P-100002|Evaluating the Therapeutic Effect of Acupuncture on Acute Ischemic Stroke Patients|||Cathay General Hospital|Yes|Completed|May 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|38|||Both|40 Years|85 Years|No|||August 2014|August 5, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02210988||39102|
NCT02211287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14/25|Promoting Informed Decision Making Through Advance Care Planning|Promoting Informed Decision Making and Effective Communication Through Advance Care Planning for People With Dementia and Their Family Carers||Queen's University, Belfast|No|Not yet recruiting||August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|420|||Both|18 Years|N/A|No|||April 2014|August 6, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211287||39079|
NCT02211300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002055|MANAGE Automated Glucose Monitoring|MANUAL VS. AUTOMATED MONITORING ACCURACY OF GLUCOSE|MANAGE IDE|OptiScan Biomedical Corporation|Yes|Recruiting|April 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Anticipated|230|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211300||39078|
NCT02211573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/14|Aquatic Aerobic Training, Cardiorespiratory and Metabolic Variables in Coronary Artery Disease|Effects of Aquatic Aerobic Training on Body Composition and Cardiorespiratory and Metabolic Variables in Patients With Coronary Artery Disease||Universidade Metodista de Piracicaba|No|Completed|May 2013|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|50 Years|70 Years|No|||August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211573||39057|
NCT02211313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205184|Evaluation of Ureteral Stents in the Management of Stone Disease|Evaluation of Ureteral Stents in the Management of Stone Disease||Washington University School of Medicine|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211313||39077|
NCT02211586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 433903|Effects and Response of LY2605541 in Patients With Type 1 Diabetes Mellitus (BIDO)|Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus (BIDO)|BIDO|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Completed|June 2014|March 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|62|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211586||39056|
NCT02201706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER201407|Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye|The Explore Study for the Efficacy and Safety of Multi-electrocoagulation Retinectomy in the Treatment of Retinal Re-detachment in Silicone Oil Filled Eye||Sun Yat-sen University|Yes|Recruiting|October 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|5 Years|60 Years|No|||May 2015|May 5, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02201706||39815|
NCT02201940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1138|Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV|ASTRAL-1|Gilead Sciences|Yes|Completed|July 2014|September 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|741|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201940||39797|
NCT02202226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14754A|Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia|Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|January 2013|||February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|60 Years|No|||March 2015|March 4, 2015|July 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02202226||39775|
NCT02202447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1169-01|Phase 1 of EC1169 In Patients With Recurrent MCRPC|A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)||Endocyte|No|Recruiting|May 2014|July 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02202447||39758|
NCT02201927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01243-42/1|Stimulation Galvanique Vestibulaire|Galvanic Vestibular Stimulation : Role in the Improvement of Egocentric Frame in Patient With Right Parietal Lobe Lesions|GVS|Centre d'Investigation Clinique et Technologique 805|Yes|Terminated|April 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 22, 2014||No|lack of performance|No||https://clinicaltrials.gov/show/NCT02201927||39798|
NCT02217072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFI 2691|Educational Support Interventions for Children in Care|A Randomized Controlled Trial of Educational Support Interventions for Children in Care||The Danish National Centre For Social Research|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|190|||Both|6 Years|13 Years|No|||August 2014|August 13, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02217072||38637|
NCT02217332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNS-76704-CS201|Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia|Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)|CS201|Knopp Biosciences|No|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217332||38617|
NCT02212457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_15|Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents|A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents||Novartis||Active, not recruiting|August 2014|February 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|1050|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212457||38989|
NCT02213614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vio829429989|Lithium Water in Gun Violence Prevention|Lithium Water Use in Gun Violence Prevention|LWGVP|American Society Of Thermalism And Climatology Inc|Yes|Active, not recruiting|August 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|14 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213614||38902|
NCT02213016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141-2011|Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients|Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder||Universidad Nacional Autonoma de Mexico|Yes|Recruiting|September 2013|February 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|35 Years|No|||August 2014|August 8, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213016||38947|
NCT02213315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2190C00016|A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, and Safety of Mavrilimumab in Healthy Japanese Subjects||MedImmune LLC|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213315||38924|
NCT02213328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAMPS PrEP|Evaluating the Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents|CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills' A Demonstration Open Label Study to Assess the Acceptability and Use of Truvada Pre-exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents, 15-19 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|April 2015|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213328||38923|
NCT02209909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPCAB_ASA_PLT activation|Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery|Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery||Seoul National University Hospital|Yes|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Anticipated|48|||Both|20 Years|80 Years|No|||August 2014|August 5, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209909||39184|
NCT02210208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MpT Ag 03|An Open, Non Controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.|An Open, Non Controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.|MpT Ag 03|Molnlycke Health Care AB|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Months|65 Years|No|||January 2016|January 22, 2016|August 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210208||39161|
NCT02210221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602150|CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI|Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)|CENTER-TBI|University Hospital, Antwerp|Yes|Recruiting|October 2014|March 2020|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5400|Samples With DNA|whole blood samples|Both|N/A|N/A|No|Non-Probability Sample|Patients presenting with traumatic brain injury.        The data collection will be stratified upon enrolment into 3 clinical groups        differentiated by clinical care path:          -  ER stratum: patients seen and discharged from the ER          -  Admission stratum: patients admitted to hospital but not to the ICU          -  ICU stratum: patients admitted directly to the ICU|March 2016|March 23, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02210221|6 Months|39160|
NCT02210442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0047|Effectiveness of Educational Games to Implementation Clinical Practice Guidelines to Family Medicine Residents in Spain.|Educaguia Project: Clinical Trial, Randomised by Clusters, to Assess the Effectiveness of a Strategy With Educational Games to Implementation pf Clinical Practice Guidelines to Family Medicine Residents in Spain.|EDUCAGUIA|Gerencia de Atención Primaria, Madrid|No|Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|394|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02210442||39143|
NCT02210715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|switchMerck|Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients|Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods||McGill University Health Center|Yes|Enrolling by invitation|March 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|58|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210715||39123|
NCT02211001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1159-8500|Pilates, Postural Global Reeducation and Ball Exercises|Comparative Study of Strenght, Endurance, Flexibility of Muscle Trunk Between the Techniques: Global Postural Reeducation , Pilates and Segmented Dynamic Exercises.||University of Sao Paulo|No|Completed|October 2010|December 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02211001||39101|
NCT02211625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP734-1002|A Safety, Tolerability, PD and PK Study in Healthy Adults|A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacodynamics And Pharmacokinetics of TRV734 in Healthy Adult Male and Female Subjects||Trevena Inc.|Yes|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211625||39053|
NCT02211963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.3|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Oral Doses (50-800 mg b.i.d. or q.d. for 8 Days) of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes||Boehringer Ingelheim||Completed|February 2007|||June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|21 Years|70 Years|No|||August 2014|August 12, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211963||39027|
NCT02211976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122.52|Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness|Comparative Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and the Combination of Both in the Treatment of Constipation and Bloatedness: an Open, Randomised, Parallel Group Trial||Boehringer Ingelheim||Completed|October 2003|||November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211976||39026|
NCT02212236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14069|Psychological Intervention for Distress During HSCT|Development and Evaluation of a Psychological Intervention to Alleviate Distress During Haematopoietic Stem-cell Transplantation||University of Nottingham|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02212236||39006|
NCT02212249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00186-41|Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis|Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis|Sclerocadh1|University Hospital, Grenoble|No|Completed|May 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|85|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02212249||39005|
NCT02201485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2BCS-rencanalization|Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?|Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial||Fourth Military Medical University|No|Recruiting|May 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201485||39832|
NCT02201953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1140|Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Subjects With Chronic Genotype 3 HCV Infection|ASTRAL-3|Gilead Sciences|Yes|Completed|July 2014|December 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|558|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201953||39796|
NCT02202239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140723|Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients|||Zhujiang Hospital|Yes|Not yet recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202239||39774|
NCT02211547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3091|Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients|Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients||University of Colorado, Denver|Yes|Withdrawn|August 2014|October 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 5, 2014||No|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT02211547||39059|
NCT02211560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vayacog_002|Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment|A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)||Enzymotec|No|Recruiting|September 2014|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|360|||Both|65 Years|85 Years|No|||January 2016|January 18, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211560||39058|
NCT02217904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8591-003|A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)|A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8591 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217904||38573|
NCT02217917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5201007|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Rivipansel (pf 06460031) Following Subcutaneous Administration With Rhuph20 (pf 06744547) In Healthy Subjects||Pfizer|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217917||38572|
NCT02212470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPC_3 2014|Drug Eluting Ballon Versus Stenting in the Superficial Femoral Artery|Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery||Instituto Dante Pazzanese de Cardiologia|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212470||38988|
NCT02212756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW1029M-I-4|Pharmacokinetic Profiles of Metformin With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Metformin After Oral Administration in Healthy Male Volunteer|PMD|Dong Wha Pharmaceutical Co. Ltd.|Yes|Completed|August 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212756||38967|
NCT02212769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW1029M-I-5|the Pharmacokinetic Profiles of Losartan With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Losartan After Oral Administration in Healthy Male Volunteer|PLD|Dong Wha Pharmaceutical Co. Ltd.|Yes|Completed|August 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||August 2014|June 25, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212769||38966|
NCT02213627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403-MAD-013-AR|Use of Corifolitropin Alfa in Oocyte Donors|Randomized, Multicentric and Prospective Clinical Trial to Check the Cost-effectiveness of Corifollitropin Alfa vs. Recombinant FSH and/or HP-hMG||IVI Madrid|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213627||38901|
NCT02213341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR9|Impact of Vaccination on Th2 Immunity in Infancy|Impact of Vaccination on Th2 Immunity in Infancy||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Whole blood|Both|5 Months|7 Months|Accepts Healthy Volunteers|Probability Sample|Infants who are scheduled to receive their ~6 month (third dose of primary series)        vaccines including the DTaP vaccine as part of routine care.|December 2015|December 2, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213341||38922|
NCT02213354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0034|H7N9 Mix and Match With MF59 in Healthy Elderly Persons|A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|479|||Both|65 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213354||38921|
NCT02213601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105725|Efficacy of Yoga for Postpartum Depression|Efficacy of Yoga for Depressed Postpartum Women: A Randomized Controlled Trial||University of Iowa|No|Completed|June 2011|||October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Female|18 Years|45 Years|No|||August 2014|August 7, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213601||38903|
NCT02209584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCEDE-2000|Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists|PROCEDE-2000|Myriad Genetic Laboratories, Inc.|No|Active, not recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|||Male|18 Years|N/A|No|Non-Probability Sample|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer.|May 2015|May 4, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02209584|3 Months|39209|
NCT02209558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-305B|The Effect of Visual Sternal Precautions on Behavioral Intentions and Readmissions|The Effect of Visual Sternal Precautions on Behavioral Intentions and Readmissions|Sternal|Northwell Health|Yes|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|19|||Both|N/A|N/A|No|||April 2015|April 13, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02209558||39211|
NCT02209571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0076|Breath Analysis in in Adults With Cystic Fibrosis (CF)|Exhaled Breath Analysis by Secondary Electrospray Ionisation Mass Spectrometry (SESI-MS) in Adults With Cystic Fibrosis: An Exploratory Matched Case-Control Study||University of Zurich|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02209571||39210|
NCT02209948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEINO 14-01|Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.|Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.||Grupo Español de Investigación en Neurooncología|No|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209948||39181|
NCT02209922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS and postural control|The Effects of tDCS Combined With Balance Training on Postural Control in Chronic Stroke Patients|The Effects of tDCS Combined With Balance Training on Postural Control in Chronic Stroke Patients ( A Randomized Controlled Trial)||hahid Beheshti University of Medical Sciences|Yes|Recruiting|December 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02209922||39183|
NCT02210728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-06-002|Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder|Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder||McGill University Health Center|No|Active, not recruiting|April 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02210728||39122|
NCT02211014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-MY-001|An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma|An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma||Acerta Pharma BV|No|Recruiting|February 2015|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211014||39100|
NCT02211326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XY3-WARF1405A01|Genotype-guided Warfarin Individualized Treatment|Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients||The Third Xiangya Hospital of Central South University|Yes|Recruiting|September 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|864|||Both|60 Years|N/A|No|||June 2015|June 9, 2015|August 6, 2014||||No||https://clinicaltrials.gov/show/NCT02211326||39076|
NCT02211612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPOGAIN-2|Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation|Role of Fatty Acids in Skeletal Muscle Hypertrophy and Ectopic Fat Accumulation During Overfeeding (LIPOGAIN-2)|LIPOGAIN-2|Uppsala University|No|Recruiting|September 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211612||39054|
NCT02211937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.2|Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers|Relative Oral Bioavailability of 400 mg BI 44847 as Suspension Compared to 400 mg BI 44847 as Tablet and the Influence of Food (Standardised High Fat Breakfast) on the Tablet in a Single Dose, Open-label, Randomised Three-way Crossover Trial and Relative Oral Bioavailability of 40 mg BI 44847 as Solution Compared to 40 mg BI 44847 as Tablet in Healthy Male Volunteers in a Single Dose, Open-label, Randomised Two-way Crossover Trial||Boehringer Ingelheim||Completed|January 2007|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|25|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211937||39029|
NCT02211950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.22|Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers|Evaluation of Relative Bioavailability of BI 44847 in Different Ethnic Groups (Subjects of White, Asian, and African Origin), and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers. An Open-label, Single-dose, Parallel Group, Phase 1 Study (Group 1 With Additional Crossover Aspects)||Boehringer Ingelheim||Completed|October 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|37|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211950||39028|
NCT02212522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08049|Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications|Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications. French Multicentric Cohort of Diabetic Patients.|ISIS-DIAB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2004|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|20000|Samples With DNA|whole blood|Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients: T1D patients are enrolled into the Isis-Diab cohort, continuously, from 110        clinical diabetes centers distributed over the whole France territory. Inclusion in the        cohort occurs most often soon after the initial diagnosis of T1D. This diagnosis is made        according to classical criteria of autoimmune T1D.        Controls: we will recruit age-matched controls among friend patients' families and among        cases admitted in the participating centers for benign transient intercurrent events.|December 2015|December 21, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212522||38984|
NCT02201719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/637a|Norwegian Adenomyosis Study I|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I|NAPPED I|Oslo University Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|101|||Female|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women referred to our clinic and volunteering to participate and that are registrated in        Norway with a norwegian social security number.|August 2015|August 25, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02201719||39814|
NCT02201966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00229|Regional Interdependence of the Shoulders and Hips in Gymnasts With Low Back Pain|Regional Interdependence of the Shoulders and Hips in Gymnasts With Low Back Pain||Nationwide Children's Hospital|No|Withdrawn|August 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|0|||Female|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Competitive female gymnasts. Females who perform gymnastics at local gymnastics training        centers.|July 2015|July 2, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02201966||39795|
NCT02202252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGC-45|Single Versus Double Drains After Mastectomy|Comparison of Single Versus Double Drains After Modified Radical Mastectomy||Ankara Diskapi Training and Research Hospital|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|80 Years|No|||March 2015|March 25, 2015|July 23, 2014||No||No|March 9, 2015|https://clinicaltrials.gov/show/NCT02202252||39773|
NCT02212795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW224-I-7|Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin|Phase I Study of Pharmacokinetics and Bacteriocidal Activity|Bacteriocide|Dong Wha Pharmaceutical Co. Ltd.|Yes|Completed|May 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|18|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||February 2015|June 25, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02212795||38964|
NCT02212808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052362|Antimicrobial Stewardship in Community Hospitals|A Multicenter, 3-Stage Cluster Randomized Historically-Controlled Crossover Trial to Determine the Feasibility and Outcomes From Two Antimicrobial Stewardship Interventions in Community Hospitals||Duke University|Yes|Completed|May 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3972|||Both|N/A|N/A|No|||March 2016|March 21, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02212808||38963|
NCT02212184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manual Therapy in COPD|Diaphragm Release Manual Technique Efficacy in COPD Patients|Diaphragm Release Manual Technique Efficacy on Diaphragmatic Mobility, Respiratory Muscle Strength and Exercise Performance in COPD Patients: a Randomized Controlled Trial||Universidade Federal de Pernambuco|Yes|Completed|August 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|60 Years|N/A|No|||November 2015|November 30, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02212184||39010|
NCT02213367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCSU|Bilastine Updosing in Chronic Spontaneous Urticaria|Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria.||Charite University, Berlin, Germany|No|Recruiting|July 2014|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213367||38920|
NCT02209961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0054-13|Combined Ex-PRESS Implantation Alone or With Phacoemulsification for Glaucoma Associated With Cataract|To Check the Efficacy and Saftey of Combined Ex-PRESS Implantation Alone or With Phacoemulsification for Glaucoma Associated With Cataract||Hillel Yaffe Medical Center|Yes|Enrolling by invitation|March 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|patient with uncontrolled glaucoma|August 2014|August 5, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02209961||39180|
NCT02213874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dempsey-Trust Pro 12660|The Influence of Trust in the Health Care System on Postpartum Contraceptive Choice|The Influence of Trust in the Health Care System on Postpartum Contraceptive Choice||Medical University of South Carolina|No|Completed|January 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|208|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02213874||38882|
NCT02209597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312021|Bupropion in Depression|Bioequivalence and Clinical Effects of Generic and Brand Bupropion|BALANCE|Washington University School of Medicine|Yes|Recruiting|June 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|75|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209597||39208|
NCT02209935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI APDTO|RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury|RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury||University of Pittsburgh|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|3 Years|17 Years|No|||January 2016|January 15, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209935||39182|
NCT02210481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOL2010-02|The Role of Intravitreal Glucose in Macular Thinning Following Surgery for Retinal Detachment or Epimacular Membrane|Impact of Intravitreal Glucose Rate in Macular Thinning Following Retinal Detachment or Epimacular Membrane Surgery|GLU-MAC|CHU de Reims|No|Recruiting|February 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|cohort composed of patients undergoing vitrectomy for retinal detachment or epimacular        membrane at Reims University Hospital|August 2014|August 6, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210481||39140|
NCT02210234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2010|Wheat Bioactives and Immune Function|Wheat Bioactives and Immune Function||University of Florida|Yes|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210234||39159|
NCT02210455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017014|Parenting Training for Children With FASD|Strongest Families FASD: Parent Training for Challenging Behaviour in Children With Fetal Alcohol Spectrum Disorder (FASD)|SF-FASD|IWK Health Centre|No|Recruiting|July 2014|April 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|4 Years|12 Years|No|||March 2016|March 8, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02210455||39142|
NCT02210468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cyt300-01|APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee|A Phase I/II, Multicenter, Double-Blind, Placebo-controlled Safety and Efficacy Study to Evaluate APIC-CF Therapy for Mild to Moderate Primary Osteoarthritis of the Knee||Cytonics Corporation||Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|21 Years|70 Years|No|||August 2015|August 19, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210468||39141|
NCT02211040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE670201421382|eHealth Intervention to Promote Self-regulation of Physical Activity and Fruit and Vegetable Intake Among Adults Who Visit General Practice|Effect Evaluation of an eHealth Intervention to Promote Self-regulation of Physical Activity and Fruit and Vegetable Intake Among Adults in General Practice||University Ghent|No|Not yet recruiting|October 2014|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02211040||39098|
NCT02211339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL JRO ref: 13/0477|A New Intervention for Social Skills Following Brain Injury (Version1)|An Investigation Into the Effectiveness of a Social Communication Skills Training Programme for Adults Following Severe Traumatic Brain Injury (TBI) Using a Peer-to-peer Learning Model||University College, London|No|Active, not recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||July 2015|July 13, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211339||39075|
NCT02211638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460-017|Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」|Blopress Tablets Special Drug Use Surveillance 「Challenge - Quality Control」||Takeda|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17184|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension|August 2014|August 5, 2014|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02211638||39052|
NCT02211989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 200 mg) of BI 14332 CL as Powder in the Bottle Reconstituted With 0.1% Tartaric Acid Administered to Healthy Male Subjects. A Randomised and Placebo-controlled Trial, Double Blinded Within Dose Groups||Boehringer Ingelheim||Completed|February 2006|||April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211989||39025|
NCT02212002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO-2014-MICROBIOTA|Effect of Intrapartum Antibiotic Prophylaxis (IAP) on the Development of the Neonatal Gut Microbiota.|Effect of Intrapartum Antibiotic Prophylaxis (IAP) on the Development of Neonatal Gut Microbiota|MICROBIOTA-SO|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|May 2013|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|||Both|N/A|6 Days|No|Non-Probability Sample|At least 60 infants (IAP group n=30, control group n=30), born at Sant'Orsola-Malpighi        University Hospital and fulfilling the inclusion criteria will be enrolled.|August 2014|August 7, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212002||39024|
NCT02212015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISG-06|Evaluation of Votrient in Angiosarcoma|Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma|EVA|Heidelberg University|No|Recruiting|July 2014|March 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02212015||39023|
NCT02212262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0498|Role of Osteocytes in Myeloma Bone Disease|Role of Osteocytes in Myeloma Bone Disease||Indiana University|Yes|Recruiting|July 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Oncology Clinics at Indiana University Roudebuch VA Medical Center Community sample|August 2015|August 28, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02212262||39004|
NCT02212548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydrogel|Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose|Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose||Royal North Shore Hospital|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|N/A|N/A|No|||July 2015|July 14, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02212548||38982|
NCT02201732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130920|Effectiveness of Hysteroscopy in the Treatment of Intrauterine Trophoblastic Retentions|Assessment of the Effectiveness of Hysteroscopy in the Treatment of Intrauterine Trophoblastic Retentions|HY-PER|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|October 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|572|||Female|18 Years|44 Years|No|||February 2016|February 23, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02201732||39813|
NCT02201979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swanson 004|Laser Fluorescent Imaging of Nipple and Areola During Breast Lift|Laser Fluorescent Imaging of Nipple and Areola During Breast Lift in Combination With Breast Implants||Swanson Center|No|Completed|July 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult women undergoing cosmetic breast lifts in combination with implants.|November 2014|November 18, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201979||39794|
NCT02202499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17654|Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence|Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence: Intervention Development and Feasibility Trial||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|July 2014|October 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02202499||39754|
NCT02202785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26003|A Study of MLN0264 in Patients With Pancreatic Cancer|A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|July 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202785||39732|
NCT02202798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00741|New Devices to Measure the Intracuff Pressure|||Nationwide Children's Hospital|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|N/A|18 Years|No|Non-Probability Sample|Patients that are being intubated with a cuffed endotracheal tube prior to surgery.|February 2015|February 3, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02202798||39731|
NCT02212496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-136|Identification the Cause of Cerebral Infarction in Patients With Cancer|Identification the Cause of Cerebral Infarction in Patients With Cancer||Samsung Medical Center|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|124|||Both|18 Years|N/A|No|Probability Sample|Tertiary Hospital|October 2014|October 27, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212496||38986|
NCT02212821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erythromycin_v6|Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects|||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|14|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02212821||38962|
NCT02212197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-460|Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer|A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 q1m (Leuprolide Acetate FluidCrystal® Injection Depot Once Monthly) After Repeat Doses of 3.75 mg and 7.5 mg of Leuprolide Acetate vs. Eligard® 7.5 mg in Patients With Prostate Cancer||Camurus AB|No|Active, not recruiting|September 2014|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Male|40 Years|85 Years|No|||December 2015|December 4, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212197||39009|
NCT02213380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAGA-Delirium|Effect of Anesthesia on Post-operative Delirium in Elderly Patients Undergoing Hip Fracture Surgery|Effect of Regional Anaesthesia and General Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery: a Multicenter Randomized Controlled Trial.|RAGADelirium|Wenzhou Medical University|Yes|Recruiting|September 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|65 Years|N/A|No|||December 2015|December 22, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02213380||38919|
NCT02209610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1572-P|Premature Fatigue in Veterans With Heart Failure: Neuronal Influences|Premature Fatigue in Veterans With Heart Failure: Neuronal Influences||VA Office of Research and Development|Yes|Recruiting|July 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy controls will consist of age (within 5 years), gender, activity, and BMI matched        subjects (frequency matched) with no history of cardiovascular related abnormalities        (i.e., shortness of breath, chest discomfort, abnormal rest or exercise ECG), or pulmonary        abnormalities, not morbidly obese (BMI <36) and no or minimal smoking history (<15 pk yr).        Initial personal interviews will facilitate subject screening. Suitable volunteers will        undergo a series of preliminary studies, including, in the presence of a licensed        physician, a conventional maximum VO2 test on a cycle ergometer with EKG monitoring and        forehead pulse oxymetry. Subjects will be sedentary, defined here as no regular physical        activity for at least the prior 6 months and current activity level will be documented by        an activity questionnaire. Human subject safety during these studies will be at the        forefront of all of the investigators' experiments.|March 2016|March 3, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02209610||39207|
NCT02213887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01095|Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications|A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications|PK-PPI|University of British Columbia|No|Enrolling by invitation|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|220|||Both|19 Years|65 Years|No|||November 2015|November 30, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02213887||38881|
NCT02210494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP202|Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)|Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)||Effexus Pharmaceutical|Yes|Recruiting|April 2013|||August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210494||39139|
NCT02210507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL93|Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari|Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil||USDA, Western Human Nutrition Research Center|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02210507||39138|
NCT02210520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|São Lucas College|Effect of Ultrasound and Laser in Chronic Low Back Pain: Randomized Double-blinded Controled Trial|Effect of Laser and Ultrasound in Pain and Disability in Women With Chronic Non-specific Low Back Pain: Randomized Double-blinded Controled Trial||University of Sao Paulo General Hospital|Yes|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|22|||Female|18 Years|40 Years|No|||August 2014|August 4, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02210520||39137|
NCT02210741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312091RINB|Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease|Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease||National Taiwan University Hospital|No|Not yet recruiting|August 2014|February 2024|Anticipated|February 2024|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Patient from our hospital, National Taiwan University Hospital|August 2014|August 5, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210741||39121|
NCT02210754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Galileo|Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes|Characterization of Nicotine Exposure and Urge-to-Smoke Following a Single Controlled Administration and Short-Term Ad Lib Use of Electronic Cigarettes and Conventional Cigarettes in Adult Smokers||Lorillard Tobacco Company|No|Completed|March 2014|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|6||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02210754||39120|
NCT02211027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-160|Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA|Active Immunization of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Using Fibroblasts Transfected With DNA From Autologous Tumor||University of Pittsburgh|Yes|Not yet recruiting|April 2016|December 2028|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211027||39099|
NCT02211352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS302-100|Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension|Randomized Control Clinical Trial for Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension|KRGCBP|Daegu Catholic University Medical Center|Yes|Completed|May 2012|July 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|70 Years|No|||August 2014|August 6, 2014|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02211352||39074|
NCT02211664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-120130|Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results)||BIOLUX 4EVER|Flanders Medical Research Program||Recruiting|June 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211664||39050|
NCT02211651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 499458|Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)|Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)|PlacentA-DM|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|150|Samples With DNA|Blood Adipose tissue Placental tissue Umbilical Cord tissue Umbilical Cord blood|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Vulnerable populations- Pregnant Women, Fetuses and Neonates        Propose to study pregnant women in order to determine the relevant phenotype with        offspring at risk for obesity and T2DM.|May 2015|May 11, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02211651||39051|
NCT02212275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065239|Cortical Metrics in Intervention Trials With Autism Spectrum Disorders|Initial Development of Cortical Metrics, an Objective, Physiologically-Based Outcome Measure, for Intervention Trials in Autism Spectrum Disorders (ASD)||Duke University|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Male|8 Years|12 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212275||39003|
NCT02212288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO14/FM-StressOX-PCU|Antioxidant Signature in Adult Patients With Phenylketonuria|Antioxidant Signature in Adult Patients With Phenylketonuria (PKU) and Healthy Volunteers : Relationship With Metabolic Disturbances|StressOX-PCU|University Hospital, Tours|No|Recruiting|September 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 PKU patients and 10 healthy controls with age and sex match|October 2014|October 13, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02212288||39002|
NCT02212301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5573|Comparison of Two Marketed Lenses in a Controlled Environment|||Johnson & Johnson Vision Care, Inc.|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212301||39001|
NCT02212535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAO13017|Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients|Open Study of Phase I / II Evaluating Tolerance and Efficacy of Mobilization and Collection of Peripheral Hematopoietic Stem Cells Device After a Single Injection of 0.24mg/kg of Plerixafor in Sickle Cell Patients|DrepaMob|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|July 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212535||38983|
NCT02201264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.2|Cardiovascular Patient Outcomes and Research Team Primary PCI Registry|The Atlantic CPORT Primary PCI Registry|CPORT|Johns Hopkins University|No|Recruiting|March 2007|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|6500|||Both|18 Years|N/A|No|Non-Probability Sample|acute myocardial infarction with          1. > 30 mins ongoing ischemic cardiac pain at presentation and > 0.1 mv ST-segment             elevation in 2 or more contiguous ECG leads or          2. new or suspected new LBBB or          3. > 0.1 mv ST-segment depression in V1 and V2 consistent with true posterior infarction             cardiogenic shock - (defined as systolic blood pressure <80 mmHg sustained for more             than 30 minutes despite correction of non-myocardial factors (hypovolemia, acidosis,             arrhythmia, etc) or requirement for pressors and/or IABP to sustain systolic blood             pressure > 80 mmHg)|April 2015|April 10, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201264|5 Days|39849|
NCT02202018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0083_MOD1|A Cluster Randomized Trial to Assess the Impact of Patient and Provider Education on Use of Home Dialysis|Patient and Provider Education for Patients With Severe Chronic Kidney Disease: Assessing the Impact on Barriers and Use of Home Dialysis||University of Calgary|No|Enrolling by invitation|September 2014|September 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|66|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02202018||39791|
NCT02202031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13319|Controlling Urgency Through Relaxation Exercises||CURE|University of California, San Francisco|Yes|Recruiting|September 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202031||39790|
NCT02202512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.43|Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers|Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)||Boehringer Ingelheim||Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|5||Actual|53|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|July 28, 2014||||No||https://clinicaltrials.gov/show/NCT02202512||39753|
NCT02213393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48893.081.14|Cater With Care Effect Study|Effectiveness of Cater With Care Products in Reaching Recommendations for Protein Intake During and After Hospital Stay and in Improving Functional Status After Hospital Stay in Elderly Patients.|CwC|Wageningen University|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|65 Years|N/A|No|||November 2015|November 11, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213393||38918|
NCT02213406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFP|Neuronal and Sensory Perception of Fat|Fat and the Brain-Neuronal and Sensory Fat Perception||University Hospital Tuebingen|No|Recruiting||||April 2016|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Basic Science|2||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02213406||38917|
NCT02213042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117165|Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer|An Open-Label, Phase II, Study to Evaluate Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Receiving Treatment With Trastuzumab in Combination With Lapatinib or Chemotherapy (EGF117165)||Novartis|No|Recruiting|October 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213042||38945|
NCT02213900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFR-398-Khan|Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy|Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients|PE-POD|Indiana University|Yes|Completed|September 2013|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213900||38880|
NCT02209623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISA 2014 Task III|TDAP Safety in Pregnant Women|Clinical Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) Safety in Pregnant Women|Tdap|Vanderbilt University|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|375|Samples Without DNA|Serum Samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|375 healthy pregnant women at ≥ 20 weeks 0 days gestation through ≤ 34 weeks 0 days        gestation and their infants and 225 healthy non-pregnant women, age range 18-45 years|March 2015|March 3, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02209623||39206|
NCT02210247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-113|Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers|An Open-Label Cohort Study to Evaluate the Safety and Pharmacokinetics of Redosing EXPAREL Via Local Subcutaneous Infiltration in Healthy Volunteers||Pacira Pharmaceuticals, Inc|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 27, 2014|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210247||39158|
NCT02210793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANH-1|Dry Eye Evaluation After Transepithelial PRK|Evaluation of Dry Eye Following Transepithelial Photorefractive Keratectomy in Comparison to Conventional LASIK: a Comparative Study||AL-Nour Eye Hospital|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|40|||Both|18 Years|40 Years|No|||August 2014|August 5, 2014|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02210793||39117|
NCT02210806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A006-CL-B3|Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation|Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)|A006-B3|Amphastar Pharmaceuticals, Inc.|No|Completed|July 2014|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|22|||Both|18 Years|55 Years|No|||October 2014|October 20, 2014|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210806||39116|
NCT02210767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE ALA|Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors|||Penn State University|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|50|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02210767||39119|
NCT02210780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1314|Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)|A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab||Regeneron Pharmaceuticals|Yes|Completed|August 2014|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|64 Years|No|||September 2015|September 28, 2015|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210780||39118|
NCT02211053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-987|Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial|Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controlled Trial|ECHOT4|Hopital du Sacre-Coeur de Montreal|No|Recruiting|July 2014|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|16 Years|74 Years|No|||August 2014|August 5, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02211053||39097|
NCT02211365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16/14|Registro Campania Salute Network on Hypertension|Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases|RCSN|Federico II University|Yes|Recruiting|February 2014|April 2024|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|85 Years|No|Probability Sample|Hypertensive patients|February 2016|February 2, 2016|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02211365|10 Years|39073|
NCT02212028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prasugrel-CRUSH|Pharmacological Effects of Crushing Prasugrel in STEMI Patients|Pharmacodynamic and Pharmacokinetic Profiles of Prasugrel in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Standard Versus Crushed Formulation||University of Florida|Yes|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||August 2015|October 1, 2015|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02212028||39022|
NCT02212314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.351|Response Inhibition Training for Children With Williams Syndrome|Developing Treatments to Improve Psychosocial Functioning in Children With Williams Syndrome Part 1: Response Inhibition Training for Children With Williams Syndrome|WSRIT|University of Wisconsin, Milwaukee|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|10 Years|17 Years|No|||May 2015|May 26, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212314||39000|
NCT02212561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELHEM|Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome|A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome||St. Jude Children's Research Hospital|No|Recruiting|August 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|24 Years|No|||November 2015|November 30, 2015|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212561||38981|
NCT02201992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4512|Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)|A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein||Eastern Cooperative Oncology Group|Yes|Recruiting|August 2014|||May 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|378|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02201992||39793|
NCT02202005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEVIR5U14EU|Multiple Dose BE Study With Nevirapine 400mg PR Tablets|A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference Product Viramune® 400 mg Prolonged Release Tablets Under Fasted Conditions in HIV1 Infected Patients||Teva Pharmaceutical Industries|No|Completed|August 2014|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202005||39792|
NCT02202265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48612013|Polymorphisms in CD36 and STAT3 Genes and Different Dietary Interventions Among Patients With Coronary Artery Disease|Effect of Polymorphisms in CD36 and STAT3 Genes on Different Dietary Interventions Among Patients With Coronary Artery Disease: a Randomized Clinical Trial With a Nutrigenetic Approach|GENUTRI|Instituto de Cardiologia do Rio Grande do Sul|No|Recruiting|September 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|40 Years|80 Years|No|||March 2015|March 6, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02202265||39772|
NCT02202525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.362|Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension|Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy||Boehringer Ingelheim||Completed|January 2001|||March 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2148|||Both|N/A|N/A|No|Non-Probability Sample|Patients with essential hypertenstion treated by private or hospital cardiologists|July 2014|July 28, 2014|July 28, 2014||||No||https://clinicaltrials.gov/show/NCT02202525||39752|
NCT02202538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-IND01|Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).|Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).|Indego|Human Motion and Control|Yes|Recruiting|August 2014|||October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||July 2014|June 24, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202538||39751|
NCT02202551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-AMT-PD302|Open-Label Safety Study of ADS-5102 in PD Patients With LID|Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)||Adamas Pharmaceuticals, Inc.|No|Recruiting|July 2014|||August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|30 Years|85 Years|No|||October 2015|October 1, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02202551||39750|
NCT02213653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FERASE|Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency|Phase IV Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency||Centre Francois Baclesse|Yes|Terminated|April 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02213653||38899|
NCT02213055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000685|Pediatric Head Lice Study Product Comparison|Safety and Efficacy of a 100% Dimethicone Pediculocide in School-Age Children||Hackensack University Medical Center|No|Completed|May 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|3 Years|12 Years|No|||August 2014|August 8, 2014|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213055||38944|
NCT02210013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-CI-01-2012-01|Differences in Ovarian Aging Between Caucasian and Indian Women|Ethnicity as a Determinant of Ovarian Aging: Differences Between Caucasian and Indian Women||IVI Madrid|No|Completed|January 2012|January 2013|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Female|18 Years|42 Years|No|Non-Probability Sample|Caucasian infertile women and Indican infertile women age < 42 years old, with both        ovaries present, undergoing an IVF treatment due to male factor, tubal disease or previous        failed IUI.|August 2014|August 5, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02210013|11 Months|39176|
NCT02209974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-COPD-2014|Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD|Inhaled Corticosteroids do Not Modify the Systemic Inflammation Induced by Exercise in Patients With Chronic Obstructive Pulmonary Disease||Hospital Son Llatzer|Yes|Completed|February 2004|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Male|58 Years|72 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02209974||39179|
NCT02209987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-326-1430|Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults|A Phase 1 Study to Evaluate the Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Subjects||Gilead Sciences|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02209987||39178|
NCT02210819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17237|Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy|XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia|XALIA LEA|Bayer|No|Active, not recruiting|June 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|In- and outpatients in sites participating in the study.|January 2016|January 11, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02210819||39115|
NCT02210832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD075669-01|Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women|Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant||University of Vermont|No|Recruiting|January 2014|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|345|||Female|18 Years|N/A|No|||August 2014|August 5, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02210832||39114|
NCT02211066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIGER-BVS|TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization|TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization|TIGER-BVS|Hospital Clinic of Barcelona|No|Recruiting|October 2014|November 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02211066||39096|
NCT02211378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB2012/402/D|Effects of Stress on Observers and Their Subsequent Performance During High Fidelity Simulation-based Training.|Effects of Stress on Observers and Their Subsequent Performance During High Fidelity Simulation-based Training: A Randomized Controlled Trial.||KK Women's and Children's Hospital|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|33|||Both|24 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211378||39072|
NCT02215642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cdk-201001|Nutrition and Lifestyle Study Cohort of Colorectal Cancer in China|Impact of Nutrition, Dietary Pattern, Obesity, Physical Activity, Depression, Diabetes, Aspirin Use and Vitamin Supplement in Colorectal Cancer in China||State Key Laboratory of Cancer Biology|Yes|Recruiting|January 2009|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|19 Years|90 Years|No|Probability Sample|The investigators will recruit about 50,000 patients with colorectal cancer in 12        hospitals of China|October 2014|October 30, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02215642||38747|
NCT02215915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140729|Intravascular Ultrasound Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions|A Prospective, Multi-center, Randomized Trial of Intravascular Ultrasound Guided Compared to Angiography Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2516|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215915||38726|
NCT02216188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFiRiS 008A|Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity|Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008|AFF008A|Affiris AG|Yes|Completed|August 2014|||August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|28|||Both|40 Years|68 Years|No|||August 2015|August 14, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216188||38705|
NCT02216474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WM/0119-NRR1301|Brain Stimulation in Movement Disorders|Brain Stimulation in Movement Disorders||Birmingham and Solihull Mental Health NHS Foundation Trust|Yes|Enrolling by invitation|September 2014|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|240|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216474||38683|
NCT02201758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 14-128|Flaxseed Lignan-Enriched Complex (FLC) for the Treatment of Patients With Ulcerative Colitis (UC): A Pilot Assessment|Flaxseed Lignan-enriched Complex (FLC) for the Treatment of Patients With Mild to Moderately Severe Ulcerative Colitis (UC): A Pilot Assessment.|FLC&UC|University of Saskatchewan||Not yet recruiting|September 2014|||August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02201758||39811|
NCT02203032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104918|A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab|A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab|NAVIGATE|Janssen Research & Development, LLC|Yes|Active, not recruiting|October 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|876|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203032||39713|
NCT02203045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0648|Outcomes Following Tourniquet and Non-Tourniquet Assisted Total Knee Arthroplasty|Outcomes Following Tourniquet and Non-Tourniquet Assisted Total Knee Arthroplasty||University of Colorado, Denver|No|Completed|October 2012|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|N/A|75 Years|No|||October 2014|May 13, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02203045||39712|
NCT02203331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15832|Bay98-7196, Dose Finding / POC Study|A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period||Bayer|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|318|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203331||39690|
NCT02202278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139EK1|Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients|Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status||Karadeniz Technical University|No|Recruiting|June 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples Without DNA|Blood of involved patients in study was drawn for study for ischemia modified albumin (IMA),      malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS)      and oxidative stress capacity (OSI) levels. After the study all blood samples will be      destroyed according to regulations.|Female|20 Years|40 Years|No|Non-Probability Sample|Patients that are administered luteal long protocol for controlled ovarian stimulation|July 2014|July 24, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02202278||39771|
NCT02203929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-Progression|Preoperative Progression of Macular Holes|Preoperative Progression of Macular Holes Using Optical Coherence Tomography||Glostrup University Hospital, Copenhagen|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Both|40 Years|120 Years|No|Non-Probability Sample|Tertiary Ophthalmic University Center|February 2016|February 10, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203929||39644|
NCT02209636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-006-13F|Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease|Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease||VA Office of Research and Development|Yes|Recruiting|September 2014|June 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|79 Years|No|||February 2016|February 3, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02209636||39205|
NCT02209649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173.6|Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects|Bioavailability of Lacidipine 4 mg and Telmisartan 40 mg Administered Orally as Two Experimental Fixed Dose Combination Tablets Relative to Separate Tablets. An Open Randomised Three-way Cross-over Steady State Trial in 6 Female and 6 Male Healthy Subjects||Boehringer Ingelheim||Completed|October 1999|||December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209649||39204|
NCT02213640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-803|Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation|Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation|PRIStiM1|Hospices Civils de Lyon|No|Not yet recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||August 2014|August 8, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213640||38900|
NCT02218073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104998|Pharmacokinetic Study of JNJ-42756493 in Healthy Participants|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Pharmacokinetic Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Following Intake of a Tablet Versus a Solution and to Assess the Absolute Bioavailability of Orally Administered JNJ-42756493 Following Concomitant Administration of an Intravenous Microdose of the Stable Isotope JNJ-61818549 in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218073||38560|
NCT02210260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNE 2190|Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.|Pain Relief After Colorectal Surgery: Single-shot Spinal Combined With Painbuster® vs Painbuster® Alone. A Pilot Randomised Controlled Trial|PROSP|York Teaching Hospitals NHS Foundation Trust|No|Active, not recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02210260||39157|
NCT02210546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2009-1539582|Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk|A Multicenter Randomised Trial of Contrast-enhanced MR Imaging as a Breast Cancer Screening Tool Alternative to Mammography and Ultrasonography in Women at Intermediate Risk. Feasibility, and Short Term Results.|MRIB|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Recruiting|May 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2000|||Female|40 Years|59 Years|No|||August 2014|August 4, 2014|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02210546||39136|
NCT02214719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASI02IDM01|Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care|Edmonton Automated Sugar Intelligence for Intelligent Diabetes Management, (EASI-IDM), a Computer Program to Assist People With Diabetes.|EASI-IDM|University of Alberta|No|Active, not recruiting|August 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214719||38818|
NCT02215408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HL116259|MEDication Focused Outpatient Care for Underutilization of Secondary Prevention|MEDication Focused Outpatient Care for Underutilization of Secondary Prevention|MEDFOCUS|University of Iowa|Yes|Enrolling by invitation|February 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02215408||38765|
NCT02215421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33915|Mommio: Training in Vegetable Parenting|Kiddio Food Fight: Training Parents in Effective Vegetable Parenting||Archimage, Inc.|No|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215421||38764|
NCT02215655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141143|Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence|Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence||Vanderbilt University|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02215655||38746|
NCT02215928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0114|Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors|Tumor Genomic Profiling: A Personalized Medicine Approach||Stanford University|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|liquid biopsy|Both|18 Years|N/A|No|Non-Probability Sample|adult oncology clinic at the Stanford Cancer Institute|October 2015|October 15, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215928||38725|
NCT02216201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impeto-015|Clinical Utility of SUDOSCAN in the Pediatric Population|Clinical Utility of SUDOSCAN in the Pediatric Population||Impeto Medical||Withdrawn|December 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 subjects will be recruited by age group, with approximately 10 subjects representative        of each age between 8 and 17. Both lean and obese subjects will be included from        University of Southern California's Childhood Obesity Research Center (CORC).|November 2014|November 7, 2014|August 7, 2014|Yes|Yes|Sponsor terminated study|No||https://clinicaltrials.gov/show/NCT02216201||38704|
NCT02216214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-MA-1005|Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)|A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)|PILLAR|Astellas Pharma Inc|No|Recruiting|September 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|65 Years|N/A|No|||November 2015|November 18, 2015|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216214||38703|
NCT02216487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO-004|Trial of FOLF(HA)Iri With Cetuximab in mCRC|Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer|Chime|Western General Hospital, Australia|Yes|Recruiting|June 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216487||38682|
NCT02216708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11004|Slow Versus Rapid Rehydration of Severely Malnourished Children|Comparison of Rapid and Slow Rehydration of Severely Malnourished Children Suffering From Dehydrating Diarrhoea and Impact on Renal Function and Subsequent Growth of Children||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|6 Months|36 Months|No|||March 2011|August 20, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216708||38665|
NCT02202590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000863|Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus|Pilot Study to Image the Esophagus Using Spectrally Encoded Confocal Microscopy (SECM)||Massachusetts General Hospital|No|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|36|||Both|14 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02202590||39747|
NCT02202603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-11-HMO-EnteraBio|A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects|A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects||Entera Bio Ltd.|Yes|Completed|July 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|13||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02202603||39746|
NCT02202863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-029|Effects of Wine Grape Pomace Flour Used as a Dietary Supplement on Metabolic Syndrome Components|Study on the Effects of Wine Grape Pomace Flour, Used as a Dietary Supplement to Increase the Intake of Dietary Fiber and Antioxidants in Human, on Components of Metabolic Syndrome, Plasma Antioxidants, Oxidative Stress Markers and Inflammatory Markers||Pontificia Universidad Catolica de Chile|No|Completed|April 2013|September 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Male|30 Years|65 Years|No|||July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202863||39726|
NCT02203591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-013260|In Vivo Patient Preoperative Preps Efficacy Study|||3M||Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1035|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203591||39670|
NCT02203604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091309|High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery|A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma||Rutgers, The State University of New Jersey|Yes|Recruiting|November 2014|||November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02203604||39669|
NCT02203344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2014-05--013|BIS Monitoring to Detect Deep Sedation|Use of Bispectral Index Monitoring as an Alert to Detect Deep Sedation in Mechanical Ventilated Patients: a Prospective Observational Study||Capital Medical University|Yes|Completed|August 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|45|||Both|18 Years|65 Years|No|Probability Sample|Adult patients admitted to a 22-bed general ICU in a University Affiliated Hospital will        be screened daily and enrolled consecutively.|December 2014|December 24, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02203344||39689|
NCT02213939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cytosorb2014|Clinical Impact of Cytokine in Cardiac Surgery|Removal of Cytokine on Cardiopulmonary Bypass With CytoSorb® Compared to on- and Off-pump Myocardial Revascularization||University Hospital of Cologne|Yes|Recruiting|August 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|whole blood, serum|Both|18 Years|N/A|No|Probability Sample|Patients receiving surgical myocardila revascularization|May 2015|May 27, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02213939||38877|
NCT02209662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cyt201-01|Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers|A Multi-Center, Randomized Trial Comparing the Effectiveness of APIC-PRP to Control, When Added to Standard of Care in the Treatment of Non-healing Diabetic Foot Ulcers||Cytonics Corporation|No|Not yet recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|274|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209662||39203|
NCT02213913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1406|Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas|Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas||University of Chicago|Yes|Active, not recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213913||38879|
NCT02210000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201159|A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis|A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis||GlaxoSmithKline|No|Completed|August 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|80 Years|No|||December 2015|February 22, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210000||39177|
NCT02210273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD1001|Solace Stress Urinary inContinence Control Efficacy and Safety Study|Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence|SUCCESS|Solace Therapeutics, Inc.|Yes|Active, not recruiting|August 2014|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|No|||August 2015|August 28, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210273||39156|
NCT02210286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29329|Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia|The Use of Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Mild to Moderate Dementia||Stanford University|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|N/A|No|||May 2015|May 13, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02210286||39155|
NCT02210559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-069|A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer|A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer||FibroGen|No|Recruiting|July 2014|June 2021|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210559||39135|
NCT02215148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3991|Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients|Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients||University of North Carolina, Chapel Hill|Yes|Recruiting|November 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood samples for pharmacokinetic sampling will be collected in serum separator tubes at 0,      0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20, 24, 30 and 36 hours after the dose of study drug is      administered. Serum sodium will be collected at baseline and 2, 4, 6, 8, 12, 24, and 36      hours after study drug administration. Approximately 180 mL of blood will be collected over      36 hours. Urinary output and urine specific gravity will be collected 0-2, 2-4, 3-6, 6-8,      8-12, and 12-24 hours after tolvaptan administration.|Both|18 Years|N/A|No|Non-Probability Sample|The population will be comprised of 30 acute brain injury patients in the ICU.|December 2015|December 1, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215148||38785|
NCT02215161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14552|Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide|Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide||University of California, San Francisco|Yes|Recruiting|September 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215161||38784|
NCT02215135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-101-DR-15|Corifollitropin Alfa Application in PCOS Patients|Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|January 2014|||June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02215135||38786|
NCT02215668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313.907|The Effect of Physical Exercise in Reducing Pain in Women Undergoing Mammography|Impact of Physical Exercise, Aimed at Reducing Pain in Women Who Underwent Mammography.||University of Sao Paulo|Yes|Recruiting|August 2014|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|198|||Female|20 Years|69 Years|No|||August 2014|August 11, 2014|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02215668||38745|
NCT02215941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV45070-PK-10033|Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers|A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study to Characterize the Pharmacokinetics and Safety of 8% TV-45070 Ointment Following 7.5 Days of Twice Daily Topical Application in Healthy Subjects||Teva Pharmaceutical Industries|No|Completed|August 2014|February 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215941||38724|
NCT02215954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000176|A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing|A Phase III, Randomized, Assessor-Blinded, Parallel-Group, Multi-Centre, Clinical Study With FE 999169 for Oral Administration Versus Niflec® for Colon Cleansing: J-CLEAR||Ferring Pharmaceuticals|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|637|||Both|20 Years|80 Years|No|||January 2015|January 16, 2015|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215954||38723|
NCT02216227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-291|Checklist to Prevent MRSA Surgical Site Infections|Checklist to Prevent MRSA Surgical Site Infections||Iowa City Veterans Affairs Medical Center|No|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10748|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02216227||38702|
NCT02216500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173-2006|Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy|Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy||University of Florida|No|Recruiting|September 2006|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|N/A|50 Years|No|||March 2016|March 21, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216500||38681|
NCT02216721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-2014-267|The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism|The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism||University Malaysia Sarawak|Yes|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|35|Samples Without DNA|Blood samples|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective study conducted in out-patient clinics of a tertiary care center.        The study population consists of patients referred to our centres for endocrine        hypertension.|November 2015|November 30, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216721||38664|
NCT02202616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ACA01|Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)|Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)|POWER|Novartis|Yes|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|710|||Both|40 Years|N/A|No|||February 2016|February 5, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02202616||39745|
NCT02202629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1406|Plant Based Extracts and Cognition|The Effects of Different Combinations of Plant Based Extracts on Cognitive Function and Cerebral Blood Flow in Humans|CEOPTB|PepsiCo Global R&D|No|Not yet recruiting|July 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02202629||39744|
NCT02203071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211220|Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee|Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee||University of Missouri-Columbia|Yes|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients recruited from Missouri Orthopaedic Institute's patient population.|November 2015|November 30, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02203071||39710|
NCT02203058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLB2014|Pursed-lips Breathing and Dynamic Hyperinflation|Pursed-lips Breathing Reduces Reduces Dynamic Hyperinflation Induced by Activities of Daily Living Test in Patients With COPD||University of the State of Santa Catarina|No|Completed|March 2012|July 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|25|||Both|40 Years|80 Years|No|||July 2014|July 25, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02203058||39711|
NCT02203643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNITO-MM-01 / FORTE|Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.|A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as Pre Transplant INDUCTION and Post Transplant Consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as Pre Transplant INDUCTION and Post Transplant Consolidation or Continuous Treatment With CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 Cycles) Without Transplant, All Followed by MAINTENANCE With LENALIDOMIDE (R) Versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT|FORTE|University of Turin, Italy|Yes|Recruiting|February 2015|October 2020|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|477|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02203643||39666|
NCT02203955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001220|Study of Sc-FOS for Pouchitis Prevention|Prevention of Pouchitis With Short-Chain Fructooligosaccharide Therapy, A Double-Blind, Placebo-Controlled Trial||Mayo Clinic|No|Recruiting|August 2014|August 2019|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|15|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02203955||39642|
NCT02203968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064-2014|Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)|Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST): a Randomized Feasibility Trial|FiiRST|Sunnybrook Health Sciences Centre|Yes|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|March 6, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02203968||39641|
NCT02217462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN275201300015C|Pregnancy Eating Attributes Study|Diet, Obesity, and Weight Change in Pregnancy|PEAS|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Not yet recruiting|October 2014|||July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Serum Plasma White and red blood cells Urine Stool|Female|18 Years|44 Years|No|Non-Probability Sample|PEAS is a prospective observational study of N=450 women without evidence of psychiatric        or eating disorders, recruited in early pregnancy (≤12 weeks), targeting N=150 in each        weight status group: normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9) and obese        (BMI >=30). Women will be followed through pregnancy and until 1 year postpartum, along        with their infants from birth to 1 year, with collection of blood, stool, and urine        specimens, previous and current medical information, dietary intake and eating behaviors,        anthropometrics, and demographic information.|August 2014|August 13, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217462||38607|
NCT02209675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tissue C4d|Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation|||Ain Shams University|No|Completed|December 2012|October 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|65 Years|No|||October 2014|October 12, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209675||39202|
NCT02209688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1172.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects|Administration of ESR 1150 CL in Ascending Doses of 0.5, 1, 2, 4 and 8 mg in an Open, Group Comparison and Placebo-controlled Design (Placebo Randomised Double Blind in the Dose Groups) for the Assessment of Safety, Tolerability (Maximum Tolerated Dose, MTD), Pharmacokinetics and Pharmacodynamics in 5 Groups of 8 Female and 5 Male Healthy Subjects, and 4 mg Additionally in Fed State, in a Cross Over Design. Safety, Tolerability and Pharmacokinetics of MTD/4, MTD/2 and MTD in 6 Healthy Male Subjects, Identified as CYP2D6 and/or "Spartein" Poor Metabolizers, in a 3-fold Cross Over, Open Study.||Boehringer Ingelheim||Terminated|February 2000|||March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209688||39201|
NCT02214212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46038-K|TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI|TWILIGHT: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI.|TWILIGHT|University of Washington|Yes|Recruiting|December 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||December 2014|December 26, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02214212||38856|
NCT02218320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1647|Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults|A Phase IV, Open-Label Study to Compare Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Men and Women||University of North Carolina, Chapel Hill|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will be recruited from University of North Carolina Infectious Diseases Clinic.|October 2015|December 4, 2015|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02218320||38541|
NCT02214472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)200/2011|Treatment of Rumination by Biofeedback - a Randomized Controlled Trial|Valoración Objetiva y Tratamiento de la rumiación.||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|January 2013|April 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02214472||38837|
NCT02215681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-13-ziv|Acupuncture Effect on Inflammatory Markers in Pediatric Otitis Media With Effusion: A Pilot Study|Acupuncture Effect on Inflammatory Markers in Pediatric Otitis Media With Effusion: A Pilot Study||Ziv Hospital|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|8 Years|No|||July 2014|August 12, 2014|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215681||38744|
NCT02215434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNP/CNPq02|Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women|Phase 2 Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women|TESTOSTERONE|University Potiguar|No|Completed|September 2009|August 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02215434||38763|
NCT02216240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005795QM|Safety and Efficacy of Paramedic Treatment of Regular Supraventricular Tachycardia|Safety and Efficacy of Paramedic Treatment of Regular Supraventricular Tachycardia|Para-SVT|Barts & The London NHS Trust||Recruiting|December 2010|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|16 Years|N/A|No|||February 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02216240||38701|
NCT02216513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001400|Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage|Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage||Brigham and Women's Hospital|No|Terminated|September 2014|July 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|August 6, 2014|Yes|Yes|Principle Investigator is moving to another institution and plans to restart this proctocol in    the new location.|No||https://clinicaltrials.gov/show/NCT02216513||38680|
NCT02216734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC526|Effects of Facility-based Mother Support Groups on Prevention of mother-to Child Transmission Outcomes in Zimbabwe|Effects of Mother Support Groups on Prevention of Mother-To-Child Transmission (PMTCT) Outcomes in Mutare & Makoni Districts, Zimbabwe: A Cluster Randomized Controlled Trial|EPAZ|Family AIDS Caring Trust|No|Recruiting|July 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Female|18 Years|N/A|No|||August 2014|August 13, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216734||38663|
NCT02216981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILSALK1|Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD|A Pilot Randomised Controlled Trial to Assess the Feasibility of Cognitive Behavioural Therapy (CBT) Delivered in Time-Intensive and Weekly Treatment Formats for Treatment Resistant Obsessive Compulsive Disorder (OCD).||University of Bath|No|Recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02216981||38644|
NCT02217267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI140/2014|Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain|Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study||Mahidol University|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217267||38622|
NCT02195024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMUN-DB-001-MRIPM|Cardiac MRI After Pacemaker Replacement|Cardiac MRI After Replacement of Long Term Implanted PACEmakers by a MRI Conditional Pulse Generator (MRI-rePace)|MRI-rePACE|Paracelsus Medical University|No|Recruiting|July 2014|September 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195024||40326|
NCT02195037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-DCC|Changes in Cardiac Output During Delayed Umbilical Cord Clamping|Changes in Cardiac Output During Delayed Umbilical Cord Clamping||Sharp HealthCare|No|Completed|July 2014|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|1 Minute|No|Non-Probability Sample|Healthy full term infants delivered by vaginal birth with an estimated gestational age of        37+1 to 41+6 weeks corrected gestational age|August 2014|May 18, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195037||40325|
NCT02195648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tension type headache|Sub-occipital Muscle Inhibition in Tension Type Headache|Treatment Efficacy of Tension Type Headache After Application of Sub-occipital Muscle Inhibition Technique Associated With Interferential Electrotherapy|TTH|Universidad Católica San Antonio de Murcia|No|Not yet recruiting|September 2014|August 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2014|July 17, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02195648||40278|
NCT02203357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepB-2014|A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults|A Randomized, Opened, Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Young Adults||Peking University||Recruiting|March 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|354|||Both|18 Years|25 Years|No|||July 2014|October 27, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02203357||39688|
NCT02203630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 140141|A Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients|A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients||Vanderbilt University|No|Recruiting|August 2014|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02203630||39667|
NCT02196155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32003B_152671|Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis|Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis: a Randomized Controlled Study||University Hospital Inselspital, Berne|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|60 Years|No|||January 2016|January 6, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196155||40239|
NCT02217475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-2-203|Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis|CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis|CENTAUR|Tobira Therapeutics, Inc.|Yes|Active, not recruiting|September 2014|October 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217475||38606|
NCT02217488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG3173-I-001|Single Ascending Dose Tolerability Study of DG3173|||Aspireo Pharmaceuticals Limited||Completed|May 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217488||38605|
NCT02217774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0210-14-RMB CTIL|MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study|MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study||Rambam Health Care Campus|No|Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217774||38583|
NCT02214225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-QIV-13-01|A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.|A Phase 3, Randomized, Multicenter, Double-blinded Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1), and a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2), in Adults Aged 18 Years and Above.||bioCSL PTY LTD|Yes|Completed|August 2014|April 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3484|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 21, 2016|August 10, 2014|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT02214225||38855|
NCT02214485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101038RC|Integrated Care and Lower Extremity Strength Training Among Community-Dwelling Frail Older Adults in Taiwan|Integrated Care and Lower Extremity Strength Training Among Community-Dwelling Frail Older Adults in Taiwan||National Taiwan University Hospital|No|Completed|March 2011|February 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|98|||Both|65 Years|79 Years|No|||August 2014|August 10, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02214485||38836|
NCT02214732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0860|Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy|A Randomized Controlled Trial of Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy||University of Calgary|No|Recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214732||38817|
NCT02214745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-14-HYMC|Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||4|Anticipated|400|||Both|1 Year|18 Years|No|Probability Sample|Israeli Arab and Israeli Jewsih children suffering from mental retardation or cerebral        palsy who have presented at the Child Development Institute at the Hillel Yaffe Medical        Center.|August 2014|August 11, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214745||38816|
NCT02215694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|probiotics_140801|Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels|Supplementation of Dual Probiotic Strains, Lactobacillus Curvatus HY7601 and Lactobacillus Plantarum KY1032, Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels in Nondiabetic and Hypertriglyceridemic Subjects||Yonsei University|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|128|||Both|24 Years|68 Years|No|||August 2014|August 11, 2014|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02215694||38743|
NCT02215707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR #2080|A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses|A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses||Sanaria Inc.|Yes|Completed|June 2014|June 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|August 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215707||38742|
NCT02215967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140168|Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma|A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|October 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|73 Years|No|||November 2015|December 15, 2015|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215967||38722|
NCT02216253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI 2014|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection.|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection: a Double-blind Randomized Controlled Trial.||IRCCS San Raffaele|Yes|Completed|October 2014|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02216253||38700|
NCT02216526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-SP-A-15|Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents|A Prevalence and Multi-center Randomized Parallel-group Pragmatic Trial to Compare the Effectiveness of Standardized Skin Care Regimens on Skin Health in Nursing Home Residents||Charite University, Berlin, Germany|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|133|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216526||38679|
NCT02216747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC14 6413 CTIL|Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse|Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose|NS|Rabin Medical Center|Yes|Not yet recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|1 Year|18 Years|No|||August 2014|August 13, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216747||38662|
NCT02216994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCD-D-13-00074|A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study|Efficacy and Accuracy of a New Diagnostic Scoring System to Differentiate Hirschsprung Disease From Hirschsprung Disease Allied Disorders in the Patients With Suspected Intestinal Dysganglinosis: a Prospective Study||Tongji Hospital|Yes|Recruiting|January 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|N/A|3 Years|No|||October 2014|October 27, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02216994||38643|
NCT02217280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210810|Dispersal Pattern for Spine Injections (Gadolinium Contrast)|Dispersal Pattern of Injectate After Cervical Epidural Steroid Evaluated With Magnetic Resonance Imaging||University of Missouri-Columbia|No|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217280||38621|
NCT02195687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-113|BOTOX® in the Treatment of Crow's Feet Lines in China|||Allergan|No|Completed|September 2014|June 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|417|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 18, 2014|Yes|Yes||No|February 17, 2016|https://clinicaltrials.gov/show/NCT02195687||40275|
NCT02195908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543201-01|The Different Effectiveness of Single Acupoint（PC6 or CV12) vs Matching Acupoints(PC6 and CV12) in Chemotherapy-induced Nausea and Vomiting|The Comparative Study on the Effectiveness of Single Acupoint and Matching Acupoints.||Tianjin University of Traditional Chinese Medicine|Yes|Recruiting|August 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|80 Years|No|||July 2014|June 14, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195908||40258|
NCT02195921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543201-02|The Different Effectiveness of Single Acupoint（ST36 or CV12) vs Matching Acupoints(ST36 and CV12) in Chemotherapy-induced Nausea and Vomiting|||Tianjin University of Traditional Chinese Medicine|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|80 Years|No|||July 2014|June 14, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02195921||40257|
NCT02218333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/150/REK sør-øst C|Health Effects of Milk Proteins in Elderly Subjects|Effect of Milk Proteins on Body Composition, Muscle Strength, Inflammation and Bone Health in Elderly Subjects||University of Oslo|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02218333||38540|
NCT02218346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG221-C-002|Food Effect Study of AG-221 in Healthy Male Subjects|A Phase 1, Two-Way Crossover Study to Assess the Pharmacokinetics and Safety of a Single Dose of AG-221 in Healthy Male Subjects When Administered Under Fed and Fasted Conditions||Agios Pharmaceuticals, Inc.|No|Completed|August 2014|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|56 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218346||38539|
NCT02213991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-IORT|Intraoperative Radiotherapy for Korean Patients With Breast Cancer|A Phase II Trial Investigating Acute Local Toxicities of Intraoperative Radiotherapy as a Boost Dose in Korean Breast Cancer Patients Undergoing Breast Conserving Surgery||Gangnam Severance Hospital|No|Recruiting|August 2014|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|215|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02213991||38873|
NCT02217592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO1206|Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand|Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast (NE) Thailand||University of Oxford|No|Recruiting|March 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5020|Samples With DNA|Blood. Urine, pus, sputum, throat swab, and stool (if available)|Both|18 Years|N/A|No|Probability Sample|Male and female patients, 18 years old with community-acquired sepsis or severe sepsis in        Northeast Thailand|October 2015|March 10, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02217592||38597|
NCT02217605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A32006_FRU|31P Magnetic Resonance Spectroscopy Fructose Study|Investigating the Effects of an Oral Fructose Challenge on Hepatic ATP Reserves in Healthy Volunteers|31PMRS_FRU|University of Nottingham|Yes|Completed|March 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217605||38596|
NCT02214498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_THYME|Treatment of HYpertension: Morning Versus Evening|Treatment of HYpertension: Morning Versus Evening|THYME|Erasmus Medical Center|No|Not yet recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||August 2014|August 13, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214498||38835|
NCT02214758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECID84/2012|Optimising Nutrition, Oral Health and Medication for Older Home Care Clients (NutOrMed)|Optimising Nutrition, Oral Health and Medication for Older Home Care Clients|NutOrMed|University of Eastern Finland|Yes|Completed|November 2012|June 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|300|||Both|75 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 8, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02214758||38815|
NCT02214771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-FID-NI-001|Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients|Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)|DAFNE|Astellas Pharma Inc|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Adult hospitalized patients diagnosed with clostridium difficile infection|December 2015|December 18, 2015|May 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02214771||38814|
NCT02215447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCC 14.01|A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas|A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas|NABNEC|Barwon Health|Yes|Recruiting|May 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02215447||38762|
NCT02215473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPP|Bacteremia in Periodontal Patients|Influence of Pre-procedural Oral Rinse in the Induced Bacteremia by Periodontal Instrumentation: a Randomized Clinical Trial||University of Taubate||Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|45 Years|No|||August 2014|August 11, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215473||38760|
NCT02215720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-012275-88|Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors|Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors|TORERO|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|April 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215720||38741|
NCT02215980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-0752|STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS|A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS||Fondazione Neoplasie Sangue Onlus|No|Recruiting|July 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|N/A|No|||February 2016|February 5, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02215980||38721|
NCT02215993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51476|Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis|Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis After Loading Dose of Clopidogrel|SAMPA|Federal University of São Paulo|No|Completed|July 2013|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|75 Years|No|||October 2014|October 19, 2014|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02215993||38720|
NCT02218138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4265H|Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls|Depression and Insulin Resistance in Adolescents||Colorado State University|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||July 2015|February 11, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218138||38555|
NCT02214810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5187|A Study of Postsurgical Pain Control for Lower Extremity Fractures|A Randomized, Single-blinded, Prospective Study of Postsurgical Pain Control After Open Reduction and Internal Fixation of Lower Extremity Fractures With Liposomal Marcaine.||Broward Health|Yes|Withdrawn|January 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214810||38811|
NCT02215772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.14|Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers|A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open Label Single Dose of 200 mg [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2008|||October 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215772||38737|
NCT02216019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13015 Influx|Diagnostic Interest of Leukocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry in Heart Surgery|Diagnostic Interest of Leukocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry in Heart Surgery|INFLUX|University Hospital, Limoges|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patient undergoing planned heart surgery with cardiopulmonary bypass|August 2014|August 13, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216019||38718|
NCT02216773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1123|Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)|Liver Regeneration: a Single-centre, Prospective, Randomised Controlled Trial Comparing Radiofrequency Assisted Liver Partition With Portal Vein Ligation (RALPP) With Portal Vein Embolization (PVE) for Preoperative Induction of Liver Hypertrophy in Patients With Insufficient Future Liver Remnant Volume for Major Liver Resection.|REBIRTH|Imperial College London|No|Recruiting|July 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02216773||38660|
NCT02217891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-159|IFACT: Incidental Findings in Advanced Cancer Therapy|IFACT: Incidental Findings in Advanced Cancer Therapy|IFACT|Memorial Sloan Kettering Cancer Center||Enrolling by invitation|August 2014|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|IFACT study participants will be recruited from existing MSK protocol #12-245.|January 2016|January 21, 2016|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217891||38574|
NCT02195700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-18|Aim to Reduce Movements in Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|ARM-TD|Teva Pharmaceutical Industries|Yes|Completed|July 2014|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|75 Years|No|||February 2016|February 8, 2016|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195700||40274|
NCT02195284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200330|To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma|An Open-label Study of Inhaler Device Attributes Investigating Critical and Overall Errors, and Ease of Use and Preference Between a Number of Inhaler Devices (ELLIPTA, DISKUS/ACCUHALER, TURBUHALER, and MDI) in Adult Subjects With Asthma (Study 200330)||GlaxoSmithKline|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|162|||Both|18 Years|N/A|No|||September 2015|November 19, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02195284||40306|
NCT02195297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1513|Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market|Clinical and Instrumental Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market: Comparison Within Subjects (Double Blind Study)||Derming SRL|Yes|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02195297||40305|
NCT02195661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/2014|The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children|The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children||University of Cape Town|Yes|Active, not recruiting|April 2014|||August 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|194|||Both|6 Months|13 Years|No|||July 2014|July 17, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02195661||40277|
NCT02195674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054004|EMBARK Follow-up Project|Exploring Massage Benefits for Arthritis of the Knee (EMBARK): Post-study Massage Questionnaire|EFP|Duke University|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|35 Years|N/A|No|Non-Probability Sample|Participants in the EMBARK parent study.|October 2015|November 12, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02195674||40276|
NCT02192125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-061|REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial|Phase 1 REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial|REWIRE|University of Zurich|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|September 14, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02192125||40548|
NCT02192138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPU-DIMPA-WUM14(1)|Pathophysiological Effects of Intrapleural Pressure Changes During Therapeutic Thoracentesis|Ventilation, Gas Exchange and Cardiac Function in Relation to Intrapleural Pressure Changes in Patients Undergoing Therapeutic Thoracentesis||Medical University of Warsaw|No|Recruiting|April 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|85 Years|No|||June 2014|July 14, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02192138||40547|
NCT02218099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8232-CL-0002|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease|A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled, Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)||Astellas Pharma Inc|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|55|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218099||38558|
NCT02214784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-11-1002|Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence|A Randomised Controlled Double-Blind Clinical Study To Evaluate The Safety And Performance Of Neuromuscular Electrical Stimulation (NMES) With The Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence||Bio-Medical Research, Ltd.|No|Completed|December 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02214784||38813|
NCT02215798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208.31|Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients|Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients||Boehringer Ingelheim||Completed|July 2006|||October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|269|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|August 2014|August 21, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215798||38735|
NCT02215460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSQSPT|Treatment of Periodontitis by Conventional 4 Weekly Sections or Within 24 Hours|Effectiveness of Two Non-surgical Periodontal Treatment Protocols: Randomized Controlled Clinical Trial||University of Taubate||Completed|April 2012|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|130|||Both|18 Years|60 Years|No|||August 2014|August 11, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215460||38761|
NCT02216266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELIcu|Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery|Monocenter, Double Blind, Randomised, Placebo Controlled Study to Evaluate Physostigmine for the Treatment of Delirium in Perioperative Intensive Care Medicine||Johann Wolfgang Goethe University Hospitals|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||August 2014|August 11, 2014|October 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02216266||38699|
NCT02216539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00538-39|Interest of Learning Self-hypnosis for Patients Awaiting Lung Transplantation||AUTOHYPNOSE-TP|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|July 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|78|||Both|15 Years|90 Years|No|||October 2015|October 27, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216539||38678|
NCT02216760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH1922|Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia.|Determining the Pathophysiological Role of Slow Conduction Channels Identified by Ripple Mapping of the Ventricular Scar.|Ripple-VT|Imperial College London|Yes|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|85 Years|No|||February 2016|February 22, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02216760||38661|
NCT02217007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNC-102-211 TS|A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome|A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome||Synchroneuron Inc.|No|Recruiting|April 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|75 Years|No|||September 2015|September 4, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217007||38642|
NCT02214277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-10836|Cerebral Protection in Transcatheter Aortic Valve Replacement|Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL Study||Claret Medical|Yes|Recruiting|September 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|359|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214277||38851|
NCT02214537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADDA12201301|Does DNA Sperm Fragmentation Affects Embryo Morphokinetic?|Embryo Development Measure Depending on the DNA Sperm Fragmentation|MACs-ESD|IVI Madrid|Yes|Active, not recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|36 Years|38 Years|No|||February 2016|February 23, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02214537||38832|
NCT02215486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03391|The Effect of Head Massage Therapy on the Regulation of the Autonomic Nervous System|Head Massage Intervention to Decrease Physiological Signs of Stress as Assessed by Changes in the Autonomic Nervous System Functions in Healthy Volunteers: A Pilot Study||Children's & Women's Health Centre of British Columbia||Completed|April 2014|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02215486||38759|
NCT02215759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.15|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study||Boehringer Ingelheim||Completed|January 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215759||38738|
NCT02216552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01-15-RESV|Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents|Safety and Efficacy of Resveratrol for the Treatment of Non-Alcoholic Fatty Liver Disease and Associated Insulin Resistance in Overweight and Obese Adolescents||University of Manitoba|Yes|Recruiting|August 2014|February 2016|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|13 Years|18 Years|No|||August 2014|October 23, 2014|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216552||38677|
NCT02217306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM2295/14R|Contrast Sensitivity and Diabetic Macular Edema|Contrast Sensitivity and Diabetic Macular Edema||Hospital Juarez de Mexico|No|Completed|January 2014|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|132|||Both|40 Years|70 Years|No|Non-Probability Sample|Diabetic patients attended at Ophthalmology service in a general hospital|August 2014|August 13, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02217306||38619|
NCT02217319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK005|Cardioprotection by Sevoflurane Preconditioning in Noncardiac Thoracic Surgery|Does a Sevoflurane Preconditioning Have Cardioprotective Properties in Noncardiac Thoracic Surgery?||Dr. Horst Schmidt Klinik GmbH|No|Completed|September 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02217319||38618|
NCT02218164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17759|Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell|A Phase 2 Study of Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma||H. Lee Moffitt Cancer Center and Research Institute|No|Suspended|August 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|August 14, 2014||No|pending amendment|No||https://clinicaltrials.gov/show/NCT02218164||38553|
NCT02214043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEINCP|Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population|Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population||Chinese Pulmonary Vascular Disease Research Group|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples Without DNA|BNP，D-dimer|Both|15 Years|85 Years|No|Probability Sample|Acute pulmonary embolism in Chinese population|February 2015|October 27, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02214043|5 Years|38869|
NCT02195713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-JMSRF2014-BCF01|Evaluation of a Novel Electronic Urine Output Monitor (eUOM)|Evaluation of a Novel Electronic Urine Output Monitor (eUOM)||Potrero Medical|Yes|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Probability Sample|ICU patient that needs a Foley catheter|January 2016|January 20, 2016|July 15, 2014||No||No|August 3, 2015|https://clinicaltrials.gov/show/NCT02195713||40273|
NCT02195726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301|Efficacy of RIPC to Reduce AKI for Patients Undergoing PCI|The EUROpean and Asian Cardiac and Renal Remote Ischemic Pre-conditioning Study : A Prospective, Randomized Control Trial|EUROCRIPS|Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Completed|January 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1110|||Both|18 Years|85 Years|No|||July 2014|July 18, 2014|January 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02195726||40272|
NCT02195934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR03/2014|The Orange Juice and Cardiovascular Disease Study|The Orange Juice and Cardiovascular Disease Study|OJ & CVD|Institute of Food Research|No|Enrolling by invitation|July 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|25 Years|84 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02195934||40256|
NCT02196181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01470|Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma||National Cancer Institute (NCI)|No|Suspended|July 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 18, 2014|Yes|Yes|Drug Supply Issues|No||https://clinicaltrials.gov/show/NCT02196181||40237|
NCT02196194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.290|A Prescription-Event Monitoring (PEM) Study of Tiotropium|A Prescription-Event Monitoring (PEM) Study of Tiotropium Based on Prescription Data Collected by the Prescription Pricing Authority (PPA) in England for Tiotropium (Spiriva®)||Boehringer Ingelheim||Completed|September 2002|||August 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13891|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with tiotropium|July 2014|July 18, 2014|July 18, 2014||||No||https://clinicaltrials.gov/show/NCT02196194||40236|
NCT02192151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP019|Study of PHN131 in Healthy Volunteers|The Pharmacokinetic and Bioavailability Studies of PHN131, an Oral Formulation of Nalbuphine Hydrochloride, in Healthy Volunteers||PhytoHealth Corporation|No|Terminated|October 2011|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|16|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|18|July 2014|July 14, 2014|November 24, 2013||No|Not completed its inspection.(CSR completed)|No||https://clinicaltrials.gov/show/NCT02192151||40546|
NCT02192164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801365|Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis|Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis||Pfizer|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|128|||Both|18 Years|99 Years|No|Non-Probability Sample|etanercept treated plaque psoriasis patients|March 2016|March 18, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02192164||40545|
NCT02214511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-31|Biomarkers of Social Sensitivity in Major Depression|Etude de la sensibilité Aux Signaux Sociaux Dans la dépression, Modulateurs Psychologiques, Comportementaux et Inflammatoires.|SENSO|Institut National de la Santé Et de la Recherche Médicale, France|No|Active, not recruiting|July 2014|||October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|Samples With DNA|Blood samples to explore inflammatory cytokines. Dosage of IL-6, IL-10, TNFa, IP-10, MCP-1,      MIP-1b, Rantes, sIL-6Ra, IL1ra, VEGF, Leptin, PECAM1, sTie2, sVEGFR1, sVEGFR2 will be      performed by luminex technique and usCRP, srIL2 ans sCD14 by ELISA technique.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|1. st group : major depression disorder patients          2. nd group : healthy volunteers|June 2014|August 8, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02214511||38834|
NCT02216565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00519-38|Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase|Benefits of the Endovascular Treatment in the Early Management of Proximal Sylvian Artery Thrombosis in Patients Refractory or Ineligible to Intravenous Fibrinolysis : a Multicenter Controled Randomized Trial|EASYTRAL|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|82 Years|No|||October 2015|October 27, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216565||38676|
NCT02216578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1317|Ph II CABOGIST in GIST|Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|May 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02216578||38675|
NCT02214563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKDR-003|Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients|Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial|CHAMBER|Osaka University|No|Active, not recruiting|August 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Both|20 Years|N/A|No|||October 2015|October 13, 2015|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214563||38830|
NCT02214849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010472|LATCH: Lactation Advice Thru Texting Can Help|LATCH: Lactation Advice Thru Texting Can Help||Yale University|No|Active, not recruiting|August 2014|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02214849||38808|
NCT02215174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13695.|Rosuvastatin Interethnic PK Study|Rosuvastatin Pharmacokinetic (PK) Study in Caucasian and Asian Morbid Obese Patients|RST|University of California, San Francisco|No|Recruiting|February 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|April 24, 2015|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215174||38783|
NCT02215187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#000435754|Telehealth-Education-Based Program for Military Caregivers of Injured Service Members With Head Injuries|Cognitive Behavioral Therapy (CBT) for Caregivers of Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Service Members With Combat-Related Traumatic Brain Injuries (TBI)||University of Alabama at Birmingham|Yes|Recruiting|July 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02215187||38782|
NCT02215512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-22-01|Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases|A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)|BRAINSTORM|EpicentRx, Inc.|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215512||38757|
NCT02215525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMMS 2014 1|Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy|Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy||Egyptian Military Medical Services|Yes|Recruiting|April 2014|May 2015|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||July 2014|August 11, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02215525||38756|
NCT02217020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU07|Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer|A Phase II Study of Neoadjuvant FOLFOXIRI Chemotherapy Alone in Treating Patients With Locally Advanced Rectal Cancer|FORTUNE|Sun Yat-sen University|No|Recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|70 Years|No|||August 2014|August 14, 2014|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02217020||38641|
NCT02217293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB: 1-101-05-049|Efficacy of Pulsed Radiofrequency of the Median Nerve Under Ultrasound Guidance in Patients With Carpal Tunnel Syndrome|Efficacy of Pulsed Radiofrequency of the Median Nerve Under Ultrasound Guidance in Patients With Carpal Tunnel Syndrome||Tri-Service General Hospital|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217293||38620|
NCT02217878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUMK202|Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction|A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction.|IMPRESSION|Collegium Medicum w Bydgoszczy|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|August 14, 2014||No||No|February 4, 2016|https://clinicaltrials.gov/show/NCT02217878||38575|
NCT02215213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF8/0911|Assessment of Dose Effectiveness of Vitamin D Supplementation During Pregnancy- a Dose Comparison Trial|Assessment of Dose Effectiveness of Vitamin D Supplementation During Pregnancy||Aga Khan University|No|Active, not recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|315|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02215213||38780|
NCT02216279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulmoBind II safety Trial|Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension|Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension|PB-02|Montreal Heart Institute|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216279||38698|
NCT02217033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R822662|Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo|A Pilot Study Evaluating the Effect of 'R' (Electro-Kinetically Altered Beverage) on Insomnia, Fatigue and Depression in Breast Cancer Patients Receiving Adjuvant Chemotherapy||South Sound Care Foundation|No|Active, not recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|24|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02217033||38640|
NCT02217046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISINFECTION II|Decrease Implantation Site INFECTION : a Randomized Controlled Trial|Phase 1 Study of Prevention of Cardiac Device Replacement Site Infection||Seoul St. Mary's Hospital|Yes|Recruiting|December 2013|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217046||38639|
NCT02210663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-489|A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors|A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors||AbbVie|Yes|Active, not recruiting|July 2014|September 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|20 Years|99 Years|No|||February 2016|February 7, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02210663||39127|
NCT02200900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7022|Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates.|Study of Nasopharyngeal Pressures, Tidal Breathing Indices and Inspired Gas Concentrations During High Flow Nasal Cannula (HFNC) and CPAP Treatment in Neonates||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Not yet recruiting|August 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|45|||Both|N/A|4 Months|No|||July 2014|July 24, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200900||39877|
NCT02195947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72014|Antagonist Protocol in Poor Responders|Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial||Cairo University|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Female|20 Years|45 Years|No|||August 2015|August 8, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02195947||40255|
NCT02195960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuromed-ATH-EU2014|Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer|Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer|ATHENA|Neuromed IRCCS|No|Recruiting|June 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|N/A|No|||April 2015|April 27, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02195960||40254|
NCT02196207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14020038|Hemophilia Inhibitor Prevention (INHIBIT) Trial|Phase II Single-Arm Trial of Preemptive Prophylaxis With Long-Acting Recombinant Factor VIII Fc Fusion Protein, Eloctate, to Prevent Inhibitor Formation in Children With Severe Hemophilia A|INHIBIT|University of Pittsburgh|Yes|Not yet recruiting|March 2017|March 2024|Anticipated|February 2024|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Male|4 Months|6 Years|No|||February 2016|February 21, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02196207||40235|
NCT02192177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M30 Intrahepatic cholestasis|Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.|Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|September 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|None Retained|Maternal venous and umbilical cord blood.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who admitted our clinic without foreknown systemic diseases or multiple        pregnancy.|July 2014|July 14, 2014|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02192177||40544|
NCT02192190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15515|A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain|A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 in Patients With Mild to Moderate Osteoarthritis Pain of the Knee||Eli Lilly and Company|Yes|Terminated|July 2014|June 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|268|||Both|40 Years|75 Years|No|||September 2015|September 3, 2015|July 14, 2014|Yes|Yes|Interim assessment: Lack of efficacy|No||https://clinicaltrials.gov/show/NCT02192190||40543|
NCT02217345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001680|Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease|Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease|NAFLD|Massachusetts General Hospital|Yes|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217345||38616|
NCT02214251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH103-REC2-017|The Electrophysiological Investigation of Higher Level Neural Manifestations of Freezing of Gait in Parkinson's Disease Patient|||China Medical University Hospital||Recruiting|August 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|37|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214251||38853|
NCT02214264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0572|Brief Trainings to Buffer Against Acute Stress Effects|Brief Trainings to Buffer Against Acute Stress Effects||University of Wisconsin, Madison|No|Enrolling by invitation|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02214264||38852|
NCT02214862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/02031|2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism|Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism|[F18]-FDDNP|Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|March 2013|February 2016|Actual|December 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|40 Years|N/A|No|||February 2016|February 3, 2016|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214862||38807|
NCT02214797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTC2013-02|Dispensing Study to Assess Visual Performance of Prototype Contact Lenses|Dispensing Study to Assess Visual Performance of Prototype Contact Lenses||Brien Holden Vision|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214797||38812|
NCT02215200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG-GCSF (IND)|ATG-GCSF in New Onset Type 1 Diabetes|Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes|ATG-GCSF|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|December 2014|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|84|||Both|12 Years|45 Years|No|||February 2016|February 18, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215200||38781|
NCT02213302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000873-38|Premedication by Midazolam for Emergency Surgery|Effects of Premedication by Midazolam on Preoperative Anxiety for Emergency Surgery||University Hospital, Lille|Yes|Completed|July 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|79 Years|No|||February 2016|February 10, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02213302||38925|
NCT02214030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCD-03|Efficacy Study of Assiut Femoral Compression Device Versus Manual Compression in the Achievement of Hemostasis|A Randomized Comparison of Assiut Femoral Compression Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Coronary Intervention||Assiut University|Yes|Recruiting|September 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|85 Years|No|||August 2014|August 14, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02214030||38870|
NCT02213835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD001|Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis|Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis|SCD|Seattle Children's Hospital|No|Active, not recruiting|June 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Years|21 Years|No|||December 2015|December 7, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02213835||38885|
NCT02209532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP LNM 01|A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping|A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping|FILM|Novadaq Technologies Inc.|Yes|Recruiting|December 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209532||39213|
NCT02209883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sevofluorane washout time COPD|The Effect of Sevofluorane on Wash-out Time in COPD|The Effects of Chronic Obstructive Pulmonary Disease on the Washout Time of Sevofluorane Anesthesia|washout|Duzce University|No|Completed|November 2012|August 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|the study was conducted by reserchers among 60 American Society of Anesthesiologists (ASA)        physical status 1 or 2 patients scheduled for orthopedic, urologic and lower limp surgery        which performed under general anesthesia .We investigated patientes who have normal        pulmonary function and who have chronic obstructive pulmonary disease .We divided into two        groups by via questioning and evaluating pulmonary function tests of patients.        The patients were 18-60 years old, with body mass index between 22-29|August 2015|August 5, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02209883|1 Day|39186|
NCT02217566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103352|Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy|Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer, Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy||Janssen Research & Development, LLC|No|Active, not recruiting|September 2014|July 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217566||38599|
NCT02217579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofC Protocol REB13-0169|Effect of Protein and Prebiotic Fiber Intake on Adiposity in Overweight and Obese Adults|Effect of Protein and Prebiotic Fiber Intake on Adiposity in Overweight and Obese Adults||University of Calgary|No|Active, not recruiting|August 2013|February 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217579||38598|
NCT02200913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WYodchaisarn|Effects of Core Stabilization Exercise on Balance|Effects of Core Stabilization Exercise on Balance in Low Back Pain Patients With Clinical Lumbar Instability||Khon Kaen University|Yes|Recruiting|July 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|60 Years|No|||September 2015|September 22, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02200913||39876|
NCT02195973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140214007 (UAB 1357)|Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer|Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer||University of Alabama at Birmingham|Yes|Recruiting|September 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|19 Years|N/A|No|||March 2016|March 9, 2016|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02195973||40253|
NCT02195986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVCR-11196|A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis|Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis||Mylan Inc.|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|366|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02195986||40252|
NCT02201173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|376696|Health Outcomes After Locomotor Training in Spinal Cord Injury|||Stony Brook University|No|Recruiting|July 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||August 2014|August 27, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02201173||39856|
NCT02196220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59910|Ultrasonographic Assessment of Carpal Tunnel Syndrome|Ultrasonographic Assessment of Carpal Tunnel Syndrome in Children With Mucopolysaccharidosis and Comparison to Median Nerve Anatomy in Healthy Children.||University of Utah|No|Enrolling by invitation|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study Size: *150 total which includes the following:        Arm 1: 25 Children with mucopolysaccharidosis        Arm 2: 100 Control Group - Healthy children ages 3-12 with no previous history of upper        extremity trauma or history of mucopolysaccharidosis.|February 2016|February 2, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02196220||40234|
NCT02214004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERAKLES|Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women|A Phase II Trial of Preoperative HER2 Targeting and Endocrine Therapy in Postmenopausal Women With HER2 and HR Positive Breast Cancer|HERAKLES|Gangnam Severance Hospital|Yes|Recruiting|March 2015|September 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02214004||38872|
NCT02214017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telemedicine in type 2 DM|Telemedicine Strategy With Home Treatment Save Resources|Can a Telemedicine Strategy With Home Treatment Save Resources in Acute Medical Conditions While Maintaining Quality of Care?||Kolding Sygehus|No|Completed|October 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|40 Years|85 Years|No|||August 2015|August 31, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214017||38871|
NCT02218177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF wAMD cytokine study|Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD|Neovascular Age-related Macular Degeneration: Intraocular Inflammatory Cytokines in the Non-responder to Ranibizumab Treatment||University Health Network, Toronto|No|Active, not recruiting|August 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|Aqueous Humour from Eye|Both|18 Years|N/A|No|Non-Probability Sample|Study patients in the treatment group will be those greater than 50 years old, with age        related macular degeneration, who are non-responder/ resistance to ranibizumab treatment.        Control group will include patients who are responders to ranibizumab treatment.|January 2016|January 4, 2016|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02218177||38552|
NCT02212717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC-2014.301-T|A Randomized Controlled Trial on EGBD vs PC for Acute Cholecystitis.|Endosonography-guided Gallbladder Drainage (EGBD) Versus Percutaneous Cholecystostomy (PC) in Patients Suffering From Acute Cholecystitis That Are Unsuitable for Surgery. A Randomized Controlled Trial.|DRAC|Chinese University of Hong Kong|No|Recruiting|August 2014|August 2018|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212717||38969|
NCT02212730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-031|A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)|A Clinical Trial to Evaluate the Effect of Neoadjuvant MK-3475 (Pembrolizumab) Therapy on Intratumoral Immune Infiltrates in Renal Cell Cancer (RCC) Patients Undergoing Surgical Resection||Merck Sharp & Dohme Corp.|No|Recruiting|December 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02212730||38968|
NCT02215252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291026|A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)|A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate Pf-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy||Pfizer|No|Completed|November 2014|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|141|||Both|18 Years|80 Years|No|||November 2015|November 10, 2015|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215252||38777|
NCT02216006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012/335|High Fresh Gas Flow After Intubation|High Fresh Gas Flow After Intubation - A Randomized Clinical Trial||Landstinget Västmanland|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|40 Years|75 Years|No|||May 2015|May 12, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02216006||38719|
NCT02213588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABG AOX-2 Efficacy|Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans|Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans||Access Business Group|Yes|Completed|July 2013|August 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213588||38904|
NCT02213575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-00102 Study 3|Study 3: Minocycline Decreases Microglia Activation|Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients||University of Florida|No|Not yet recruiting|May 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|80 Years|No|||October 2015|October 2, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213575||38905|
NCT02209545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00091259|Misoprostol for Reduction of Blood Loss During Fibroid Surgery|Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial||Northwestern University|No|Recruiting|October 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209545||39212|
NCT02209896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04-001|BlueWind Reprieve System for the Treatment of PNP|Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain||Rainbow Medical|No|Recruiting|December 2014|March 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||May 2015|May 18, 2015|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02209896||39185|
NCT02210195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030988-04S1|Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence|Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence||The Scripps Research Institute|No|Recruiting|July 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210195||39162|
NCT02210169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanc_IIV vs CIV|RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates|A Randomised Controlled Trial of Continuous and Intermittent Infusion of Vancomycin in Neonates||Murdoch Childrens Research Institute|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|90 Days|No|||March 2016|March 17, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210169||39164|
NCT02210182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCZ103-300-1401|A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma|A Phase I Clinical Study on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation||Oncozyme Pharma Inc.|Yes|Completed|August 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210182||39163|
NCT02210390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY-BPD-03|Culturally Adapted Psychological Intervention to Reduce Relapse in Bipolar Disorder in Pakistan|Feasibility RCT of the Efficacy of a Culturally Adapted Psychological Intervention to Reduce Relapse in Bipolar Disorder in Pakistan||Pakistan Institute of Learning and Living|Yes|Active, not recruiting|June 2012|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210390||39147|
NCT02210403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54797|The Influence of tDCS on the Arm and Hand Function in Stroke Patients|||Universitaire Ziekenhuizen Leuven||Recruiting|April 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||February 2013|August 4, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02210403||39146|
NCT02210416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-011|Costs of Complications in Inguinal Hernia Repair|||North Karelia Central Hospital|No|Completed|December 2012|June 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|968|||Both|15 Years|N/A|No|Non-Probability Sample|All patients undergoing laparoscopic inguinal hernia repair (TAPP or TEP) during 2002-2011        A sample of 528 patients undergoing open flat mesh repair in 2002-2011.|October 2015|October 11, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210416||39145|
NCT02201693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130302|Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease|Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease|CD-HOPE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2014|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|18 Years|No|||February 2016|February 15, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02201693||39816|
NCT02201472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3065|Magnetic Resonance Elastography in Infants|Magnetic Resonance Elastography in Infants|MRE in Infants|Children's Hospital Medical Center, Cincinnati|No|Terminated|August 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|N/A|6 Months|No|||November 2015|November 3, 2015|July 23, 2014|Yes|Yes|Change of research focus|No||https://clinicaltrials.gov/show/NCT02201472||39833|
NCT02201186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02740|To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis|To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study)||St. Paul's Hospital, Canada|No|Not yet recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|65 Years|No|||July 2014|July 23, 2014|July 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02201186||39855|
NCT02201199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY13928|Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus|A Single-Center, Randomized, Double-Blind, 3-Treatment, 3-Period, 6-Sequence Cross-Over Study To Compare The Pharmacokinetic And Pharmacodynamic Effects of Single Doses of Insulin Glargine Given As U200 And U500 To Lantus® In A Euglycemic Clamp Setting In Subjects With Type 1 Diabetes||Sanofi|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|65 Years|No|||December 2014|December 23, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201199||39854|
NCT02201446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131224|The Role of Circulating Soluble CD74 in Acute Lung Injury|||Changhai Hospital|No|Recruiting|March 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without ALI/ARDS were screened from Changhai Hospital. Patients were        enrolled consecutively over a 2-year time period (2014-2016). All enrolled patients with        ALI met the American-European Consensus Committee criteria.In addition, healthy        individuals were recruited from the general population.|July 2014|July 25, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02201446||39835|
NCT02201433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERAM-QUAL|Study on the Treatment of Children and Their Families in Services Related to Early Childhood|Study on the Treatment of Children and Their Families in Services Related to Early Childhood Morvan Hospital Qualitative Study|PERAM-QUAL|University Hospital, Brest|Yes|Recruiting|July 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Part 1: caregivers and members of associations of preterm parents Part 2: fathers of        preterm newborns, hospitalized in a neonatal intensive care unit Part 3: fathers who have        experienced premature and caregivers of NICU who not participating in the first part|February 2016|February 10, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02201433||39836|
NCT02201680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15112005|Anxiety Level of Child and Parents During Preoperative Anesthesia Evaluation|Anxiety Level of Child and Parents During Preoperative Anesthesia Evaluation||Istanbul University|Yes|Completed|June 2012|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|117|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children planned to undergo surgical procedures or diagnostic procedures under general        anesthesia|July 2014|July 24, 2014|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02201680||39817|
NCT02216292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSDM001|Impact of Preterm Single Donor Milk in Very Low Birth Weight Infants|Impact of Preterm Single Donor Milk on Enteral Feeding in Very Low Birth Weight Infants||Medical University of Vienna|Yes|Completed|June 2012|June 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|||Both|N/A|1 Year|No|Non-Probability Sample|inborn very low birth weight infants with a birthweight <1500g and a gestational age <32        weeks|August 2014|August 11, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216292||38697|
NCT02216305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-RAR Plató 2.0|HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial|Prospective and Randomized Trial Comparing Dopplper-Guided Transanal Hemorrhoid Artery Ligation With Recto-anal Repair (HAL-RAR) Versus Excisional Hemorrhoidectomy for the Treatment of Grade III-IV Hemorrhoids||Hospital Plató|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216305||38696|
NCT02214069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-612|Can Patients With Atrial Fibrillation Read Their Own Rhythm Recording Using a Novel Wireless ECG Recording System? iRead Study||iRead|The Cleveland Clinic||Active, not recruiting|August 2014|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to the hospital for your atrial fibrillation or atrial flutter|August 2014|August 11, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02214069||38867|
NCT02214082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIH-Cardio-001|Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention|Feasibility and Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention (PCI) in a Tertiary Care Hospital in Karachi, Pakistan.||Indus Hospital|No|Recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|21 Years|70 Years|No|||September 2014|April 17, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02214082||38866|
NCT02212782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW1029M-I-6|the Pharmacokinetic Profiles of Linagliptin With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer|PLID|Dong Wha Pharmaceutical Co. Ltd.|Yes|Completed|September 2014|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||February 2015|June 25, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212782||38965|
NCT02213029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116828|A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban|Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin||GlaxoSmithKline|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213029||38946|
NCT02214524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDI0092|Comparison of Active and Passive Perioperative Warming Techniques in Reducing Intraoperative Blood Loss|Comparison of Active Warming System and Conventional Passive Warming Care in Reducing Intraoperative Blood Loss for Patients Undergoing Major Surgery||Peking Union Medical College Hospital|Yes|Not yet recruiting|August 2014|January 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214524||38833|
NCT02206503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRd|Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)|A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA||Fondazione Neoplasie Sangue Onlus|Yes|Recruiting|March 2013|April 2018|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||February 2016|February 5, 2016|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02206503||39446|
NCT02206490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090562|Trial of Naltrexone and Dextromethorphan for Gulf War Illness|Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses|GWI Treatment|East Carolina University|No|Completed|January 2012|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|100 Years|No|||March 2016|March 2, 2016|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206490||39447|
NCT02206750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 13-1644|The Interaction of Social Factors With Air Pollution|The Interaction of Social Factors With Air Pollution|SOZIAL|Environmental Protection Agency (EPA)|No|Recruiting|July 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|33 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206750||39427|
NCT02207010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBTRC 001|A Phase 0 Study of AZD1775 in Recurrent GBM Patients|A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Active, not recruiting|July 2014|September 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207010||39407|
NCT02208115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West-Walker3.1|Post-exercise Appetite Responses in Type 1 Diabetes|A Comparison of the Appetite Responses to High and Low Glycemic Index Post-exercise Meals Under Matched Insulinemia and Fibre in Type 1 Diabetes||Northumbria University|Yes|Completed|November 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|50 Years|No|||August 2014|August 1, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02208115||39322|
NCT02207465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 32213|A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer|A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2014|||July 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207465||39372|
NCT02207777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403065|Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes|Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes|RBD-T2D|Washington University School of Medicine|Yes|Recruiting|August 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|96|||Both|25 Years|65 Years|No|||February 2016|February 4, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207777||39348|
NCT02207790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-006|Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects||Eisai Inc.|No|Completed|July 2014|October 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207790||39347|
NCT02208089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLB1018|Simultaneous TransPRK and Corneal Collagen Cross-Linking|A Prospective Trial of Simultaneous Combined Transepithelial Photorefractive Keratectomy and Corneal Collagen Cross-linking for Keratoconus|TransPRKCXL|Moorfields Eye Hospital NHS Foundation Trust|Yes|Active, not recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|35 Years|No|||March 2016|March 14, 2016|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208089||39324|
NCT02208375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0784|mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer|A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208375||39302|
NCT02208401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17227|Randomised Comparison of 2 Cold Snare Polypectomy Techniques|A Prospective Randomised Comparison of Cold Snare Polypectomy Versus Cold Snare Pseudosuction Technique||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02208401||39300|
NCT02208648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/108|Coronary Assessment for Mortality Prediction|Coronary Assessment for Mortality Prediction|CAMP|Plymouth Hospitals NHS Trust|No|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|180|||Both|18 Years|N/A|No|Probability Sample|Plymouth Hospital NHS Trust patients|October 2015|October 30, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208648||39281|
NCT02205372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-J04|Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy|A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy||Mitsubishi Tanabe Pharma Corporation|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|75 Years|No|||September 2015|September 14, 2015|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02205372||39533|
NCT02212509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203074RIC|Functional Recovery After Cardiac Surgery : Does Delirium and Calorie Intake Matter?|Functional Recovery After Cardiac Surgery : Does Delirium and Calorie Intake Matter?||National Taiwan University Hospital|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|patients on the cardio-surgical wards|August 2014|August 6, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212509||38985|
NCT02212210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goodier_Epidural_Steroids|Maternal Epidural Steroids and Hyperthemia|Maternal Epidural Steroids to Prevent Neonatal Exposure to Hyperthermia and Inflammation||Medical University of South Carolina|Yes|Terminated|February 2012|July 2015|Anticipated|April 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Female|18 Years|N/A|No|||August 2014|April 7, 2015|August 4, 2014|Yes|Yes|PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study    remains open; PI is currently editing the manuscript.|No||https://clinicaltrials.gov/show/NCT02212210||39008|
NCT02211911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122.57|Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females|Investigation of the Pharmacokinetics of 10 mg Bisacodyl (Coated Tablets) or 10 mg Sodium Picosulfate (Drops) Administered Orally in Healthy Lactating Females||Boehringer Ingelheim||Completed|February 2008|||May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211911||39031|
NCT02212483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC12_9713_ECENVIR|Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients|Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients (ECENVIR Study)|ECENVIR|Rennes University Hospital|No|Recruiting|September 2014|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|6 Years|44 Years|No|||December 2015|December 17, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212483||38987|
NCT02205294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB ROMEO # 1017573|Osteopathic Treatment and Deep Vein Thrombosis (DVT)|The Effect of Osteopathic Treatment in Acute Proximal Leg Deep Vein Thrombosis (DVT) to Reduce Pain and Swelling||Nova Scotia Health Authority|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205294||39539|
NCT02205580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZWCMC|Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children|Comparison of Three Different Rates of Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Coblation Tonsillectomy or Adeno-tonsillectomy in Children||Guangzhou Women and Children's Medical Center|Yes|Enrolling by invitation|September 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|5 Years|8 Years|No|||September 2014|September 28, 2014|July 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205580||39517|
NCT02205853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI 2010-4854|Implementation of Physical Cancer Rehabilitation Programmes in a European Healthcare System.|An Evaluation of a Patient-directed Strategy Compared With a Multi-faceted Strategy to Implement Physical Cancer Rehabilitation Programmes; a Controlled Before and After Study.||Radboud University|No|Recruiting||||October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|September 4, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02205853||39496|
NCT02205879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRPI-PGBL-A01|Pregabalin for Alcohol Dependence|Double Blind Placebo Controlled Randomized Clinical Trial of Pregabalin for Alcohol Dependence||St. Petersburg Bekhterev Research Psychoneurological Institute|No|Recruiting|January 2013|December 2015||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|60 Years|No|||May 2015|May 18, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205879||39494|
NCT02205892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-lupeol|Clinical Study for Topical Lupeol in Acne|Clinical Study for the Effectiveness and Safety of Topical Lupeol in Mild to Moderate Acne||Seoul National University Hospital|Yes|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|15 Years|N/A|No|||September 2014|September 25, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205892||39493|
NCT02205905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-004|An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects|An Open-label, Single-dose, Non-randomized Study of the Absorption, Metabolism, and Excretion of Intravenously Administered 14C-labeled PER977 in Healthy Male Subjects||Perosphere, Inc.|Yes|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|15 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205905||39492|
NCT02206776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6952|Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With Obsessive Compulsive Disorder (OCD)|Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With Obsessive Compulsive Disorder (OCD)||New York State Psychiatric Institute|Yes|Active, not recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|No|||May 2015|August 27, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206776||39425|
NCT02207023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-03353|Healthy Lifestyles After Stroke|A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study|Stroke COACH|University of British Columbia|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|50 Years|N/A|No|||July 2015|July 23, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02207023||39406|
NCT02206763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-370-1298|Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)||Gilead Sciences|No|Active, not recruiting|October 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206763||39426|
NCT02207829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201316|A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease|A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1017|||Both|40 Years|N/A|No|||October 2015|January 11, 2016|July 31, 2014|Yes|Yes||No|January 11, 2016|https://clinicaltrials.gov/show/NCT02207829||39344|
NCT02208427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201309055MINC|Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan|Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan||National Taiwan University Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|322|||Both|12 Years|N/A|No|||October 2015|October 25, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02208427||39298|
NCT02207478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201401|ENB-GS-TBLB for the Diagnosis of PPLs|Diagnostic Value of Electromagnetic Navigation Bronchoscopy With a Guide Sheath for Peripheral Pulmonary Lesions : a Randomized Controlled Trial||Shanghai Chest Hospital|Yes|Completed|July 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|August 1, 2014||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02207478||39371|
NCT02207491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS301|Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure|Rocket-1|Aerie Pharmaceuticals|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|411|||Both|N/A|N/A|No|||February 2016|February 11, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207491||39370|
NCT02207803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21TW009746|A Culturally Sensitive Intervention for TBI Caregivers in Latin America|A Culturally Sensitive Intervention for TBI Caregivers in Latin America||Virginia Commonwealth University|Yes|Recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|220|||Both|18 Years|85 Years|No|||December 2015|December 4, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207803||39346|
NCT02207816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200599|An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa|Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa||GlaxoSmithKline||Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|4000|||Both|42 Months|9 Years|Accepts Healthy Volunteers|||June 2015|October 8, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207816||39345|
NCT02208102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_IMPACT II|Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|Association of Cardiac Biomarkers With AF Ablation|IMPACTII|Texas Cardiac Arrhythmia Research Foundation|No|Active, not recruiting|July 2014|May 2016|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|155|Samples Without DNA|Plasma from whole blood|Both|50 Years|75 Years|No|Probability Sample|Patients undergoing catheter ablation for atrial fibrillation|May 2015|May 19, 2015|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02208102||39323|
NCT02208908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBC3|Oral Care and Cancer: Assessing the Contribution of Training Healthcare Teams to Support the Oral Status of Patients Hospitalized in Palliative Situation|Oral Care and Cancer: Assessing the Contribution of Training Healthcare Teams to Support the Oral Status of Patients Hospitalized in Palliative Situation||Centre Francois Baclesse|Yes|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with cancer hospitalize inpalliative situation|August 2015|August 5, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208908||39261|
NCT02209194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLIANT|Post-market Registry in Patients With Iliac Aneurysm Undergoing Endovascular Stenting With the E-liac Stent Graft System|PLIANT - A Post-market Registry in Patients With Iliac Aneurysm Undergoing Endovascular Stenting With a New Generation of Low Profile E-liac Stent Graft System||JOTEC GmbH|No|Recruiting|June 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Patients with uni- or bilateral aortoiliac or common iliac aneurysm|February 2016|February 23, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02209194||39239|
NCT02205385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMR Neuroma|Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation|Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation|TMR|Northwestern University|No|Recruiting|October 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 1, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02205385||39532|
NCT02212847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vest_loss_percept_zurich|Spatial Orientation and Vestibular Function|Spatial Orientation and Vestibular Function in Patients With Acute or Chronic Unilateral Vestibular Deficits and in Patients With Bilateral Vestibular Deficits||University of Zurich|No|Recruiting|July 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02212847||38960|
NCT02213081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00091840|Ulipristal for Endometriosis-related Pelvic Pain|Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain||Northwestern University|No|Recruiting|February 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|50 Years|No|||March 2016|March 11, 2016|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213081||38942|
NCT02211924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.11|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (50 mg to 800 mg) of BI 44847 as Tablet(s) Administered to Healthy Male Subjects. A Randomised, Placebo-controlled (Within Dose Groups) and Double-blinded Trial||Boehringer Ingelheim||Completed|August 2007|||September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211924||39030|
NCT02212223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helsinki U|Marwo-D Research -Need for Vitamin D in Different Population Groups|Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN)|ODIN|Helsinki University|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|147|||Female|21 Years|66 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212223||39007|
NCT02205307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP PLR 03|A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection|A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection|PILLAR III|Novadaq Technologies Inc.|Yes|Recruiting|January 2015|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205307||39538|
NCT02205320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-01-003|A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers|||Dr. Reddy's Laboratories Limited|No|Recruiting|February 2014|September 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|192|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205320||39537|
NCT02205593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haut-Tief|Haut-Tief Patient Education on Psoriasis and Eczema|A Prospective, Randomized, Controlled Study of the Impact of Education and Stress-reduction Techniques on Psoriasis and Eczema.||University of Zurich|No|Active, not recruiting|July 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|75 Years|No|||July 2014|July 30, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02205593||39516|
NCT02205918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH103617|Brain-Behavior Interactions in Tic Suppression|Integrative Examination of Neurobehavioral Mechanisms in Tic Suppression||Rhode Island Hospital|Yes|Recruiting|September 2014|June 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|13 Years|18 Years|No|Non-Probability Sample|Community sample|January 2015|January 12, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205918||39491|
NCT02207556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22850|Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis|A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis||Medical College of Wisconsin|Yes|Recruiting|October 2014|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207556||39365|
NCT02207569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10126779DOC|Medtronic CoreValve Evolut R U.S. Clinical Study|Medtronic CoreValve Evolut R United States IDE Clinical Study||Medtronic Cardiovascular|Yes|Active, not recruiting|August 2014|August 2019|Anticipated|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|240|||Both|N/A|N/A|No|||March 2016|March 14, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207569||39364|
NCT02207504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-230|Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer|A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.||Dana-Farber Cancer Institute|Yes|Recruiting|August 2014|July 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207504||39369|
NCT02207517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salus - HMS1310|Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency|Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART)|CITT-ART|Salus University|Yes|Recruiting|May 2014|April 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|324|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207517||39368|
NCT02208128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-539/2013|Molecular Determinants for Therapy Response on Renal Cell Carcinoma|Molecular Determinants for Therapy Response on Renal Cell Carcinoma|MORE|Heidelberg University|Yes|Recruiting|May 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|80 Years|No|||July 2014|July 31, 2014|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02208128||39321|
NCT02208687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/077|Effectiveness and Cost-effectiveness of the Energetic Program|Energetic, a Self Management Group Program Aimed at Reconditioning and Social Participation in Persons With a Muscle Disease; a Multicentre Randomized Controlled Trial.||Radboud University|No|Recruiting|August 2014|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||August 2014|August 8, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208687||39278|
NCT02208414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111069RID|Randomized Double-Blind Placebo-Controlled Crab or Shrimp Allergy Reduction Study Using Nambudripad Allergy Elimination Techniques|A Randomized Double-Blind Placebo-Controlled Crab Allergy Reduction Study Using Nambudripad Allergy Elimination Techniques in NTU Campus||National Taiwan University Hospital|Yes|Active, not recruiting|June 2012|December 2014|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|N/A|No|||August 2014|August 3, 2014|January 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02208414||39299|
NCT02208661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072780|Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)|Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy|MAPLE|Emory University|Yes|Active, not recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with Morquio A syndrome|March 2016|March 9, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208661||39280|
NCT02209207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walking trial 2014|Continuous Versus Interval Walking Training in Patients With COPD - a Pilot Study|Continuous Versus Interval Walking Training in Patients With Severe Chronic Obstructive Pulmonary Disease - a Pilot Study||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|July 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||February 2016|February 23, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209207||39238|
NCT02209220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAP-21014|Impact of Automatic Positive Airway Pressure on Treatment Compliance in OSA Patients Awaiting Bariatric Surgery|Impact of Automatic Positive Airway Pressure on Treatment Compliance in Obstructive Sleep Apnea Patients Awaiting Bariatric Surgery|APAP-CPAP|Laval University|No|Recruiting|September 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02209220||39237|
NCT02205164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS/PALO/002|Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients|Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy||Associazione Salentina Angela Serra|No|Recruiting|October 2011|October 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|134|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02205164||39549|
NCT02205684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/372/REK sør-øst C|Effects of Physical Activity in Psychosis|Effects of Aerobic High Intensity Training on Symptoms, Cognition, Cortical Structure, Substance Use and Metabolic Indices in Patients With Schizophrenia Spectrum Disorder|EPHAPS|Sykehuset i Vestfold HF|No|Enrolling by invitation|August 2014|December 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|67 Years|No|||May 2015|May 20, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205684||39509|
NCT02212860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGNAL|Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy|A Phase II Trial to Evaluate Single Dose Stereotactic Radiation Therapy (SBRT) Prior to Surgery for Early Stage Breast Carcinoma|SIGNAL|Lawson Health Research Institute|Yes|Recruiting|March 2015|April 2023|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|55 Years|N/A|No|||March 2016|March 2, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212860||38959|
NCT02212834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-6656|Surveillance Imaging Modalities for Breast Cancer Assessment|Comparative Effectiveness of Surveillance Modalities in Breast Cancer Survivors|SIMBA|Group Health Cooperative|No|Active, not recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40000|||Female|18 Years|N/A|No|Probability Sample|Women included in the Breast Cancer Surveillance Consortium who are 18+ years of age at        the the of a Stage 0-III incident breast cancer diagnosis between January 1, 2005 and        December 31, 2012.|August 2015|August 10, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02212834||38961|
NCT02213068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00085274|Belatacept 3 Month Post Transplant Conversion Study|Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA||Northwestern University|No|Recruiting|July 2014|July 2018|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213068||38943|
NCT02205333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4981C00001|A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies|A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas|MEDI6469|MedImmune LLC|No|Active, not recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|58|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|July 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205333||39536|
NCT02205606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROZE-301|Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia|A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia||Hanmi Pharmaceutical Company Limited|No|Completed|June 2014|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|412|||Both|19 Years|N/A|No|||July 2014|September 21, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205606||39515|
NCT02205619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-1233-RV|Amount of Cementum After Scaling, Root Planing and Glycine Air Polishing|Remaining Root Substance Comparing a New Ultrasonic Scaling Device, Hand Instrumentation and Subgingival Air Polishing With Glycine. An in Vivo and in Vitro Study||University of Roma La Sapienza|Yes|Completed|September 2013|July 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02205619||39514|
NCT02206516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0214-14|Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).|Using Combined Neuroimaging Techniques and Clinical Measures to Assess Feasibility of tDCS as an Intervention in Adult ADD.|BMST|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2014|||August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 2, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206516||39445|
NCT02207231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105047|A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis|Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|VOYAGE 1|Janssen Research & Development, LLC|Yes|Active, not recruiting|November 2014|May 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|839|||Both|18 Years|99 Years|No|||February 2016|February 22, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207231||39390|
NCT02207530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4193C00001|Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||AstraZeneca|No|Recruiting|October 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|130 Years|No|||March 2016|March 14, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207530||39367|
NCT02207543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALSATIS|Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care|Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care||Centre Francois Baclesse|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207543||39366|
NCT02207842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00012751|The Determination of the Effect of Volatile Anesthetics on Leukocyte Function ex Vivo|The Determination of the Effect of Volatile Anesthetics on Leukocyte Function ex Vivo||Children's Hospital Boston|No|Recruiting|November 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|12 Months|N/A|No|Non-Probability Sample|Male and female patients greater than or equal to 12 months of age, who present for a        cardiac catheterization, cardiac surgery, or cardiac MRI at Boston Children's Hospital.|July 2015|July 27, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02207842||39343|
NCT02207855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00231|Chloroprocaine for Continuous Epidural Analgesia in Neonates and Infants|||Nationwide Children's Hospital|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|21|||Both|N/A|2 Years|No|Non-Probability Sample|Neonates and infants who have received chloroprocaine for epidural anesthesia.|August 2015|August 5, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207855||39342|
NCT02208440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-CL-02-UK|InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Safety and Efficacy of InSpace™ Device in Comparison to Full Thickness Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.||OrthoSpace Ltd.|No|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|95 Years|No|||October 2015|October 14, 2015|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02208440||39297|
NCT02208154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2012-002604-41|Ecological Effects of Decolonisation Strategies in Intensive Care|RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care|RGNOSIS|UMC Utrecht|Yes|Recruiting|December 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|10800|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02208154||39319|
NCT02208453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-CL-05|InSpace™ System Implantation in a Procedure Under Local Anesthesia|A Single Arm, Open-label, Prospective, Study to Assess the Feasibility, Efficacy and Safety of InSpace™ Device Implantation in a Procedure Under Local Anesthesia for a Treatment of Subjects With Massive, Irreparable Rotator Cuff Tear||OrthoSpace Ltd.|No|Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|50 Years|N/A|No|||October 2015|October 14, 2015|June 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02208453||39296|
NCT02208674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0251|Early Identification and Action in CKD|Early Identification and Action in CKD||Geisinger Clinic|Yes|Active, not recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|93|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208674||39279|
NCT02208921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00050|An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients|An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease in Type 2 Diabetes Patients in India|START-INDIA|AstraZeneca|Yes|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|3000|||Both|N/A|N/A|No|Probability Sample|A total of 3000 T2DM patients of either gender with age of 18 years and more will be        enrolled in the study after the Informed Consent Process.|March 2016|March 24, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208921|1 Day|39260|
NCT02208934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2014-28|Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers|Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208934||39259|
NCT02205177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000288 - PILOT|Youth Mayo Clinic Anxiety Coach Pilot Study|Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - PILOT||Mayo Clinic|No|Enrolling by invitation|January 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|7 Years|17 Years|No|||January 2016|January 5, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205177||39548|
NCT02205398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2104|Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy|A Phase Ib, Open-label, Multicenter, Dose Escalation and Expansion Study, to Evaluate the Safety, Pharmacokinetics and Activity of INC280 in Combination With Cetuximab in c-MET Positive CRC and HNSCC Patients Who Have Progressed After Anti-EGFR Monoclonal Antibody Therapy.||Novartis||Recruiting|July 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205398||39531|
NCT02205411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP00030|Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation|A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the Thoratec HeartMate II® VAD and HeartWare® HVAD for Left Ventricular Support in Patients Awaiting Cardiac Transplantation||ReliantHeart Inc.|Yes|Recruiting|September 2014|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205411||39530|
NCT02205190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FRC-CT-101|to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|81|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|October 13, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205190||39547|
NCT02205424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP-1020526|Cognition And Neocortical Volume After Stroke|Is Stroke Neurodegenerative? A Longitudinal Study of Brain Volume and Cognitive Decline Following Stroke (CANVAS: Cognition And Neocortical Volume After Stroke).|CANVAS|The Florey Institute of Neuroscience and Mental Health|Yes|Active, not recruiting|May 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|175|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ischaemic stroke patients will have been admitted to the Acute Neurology Units of the        Austin Hospital (Heidelberg), Royal Melbourne Hospital (Parkville), and Box Hill Hospital        (Box Hill).|May 2015|May 26, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02205424||39529|
NCT02213133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-006|Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas|A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus|STARRS|Karyopharm Therapeutics, Inc|No|Terminated|July 2014|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 7, 2014|Yes|Yes|Due to enrollment challenges and availability of other options for lung cancer patients. The    termination is not a consequence of any safety concern.|No||https://clinicaltrials.gov/show/NCT02213133||38938|
NCT02213094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2203|Nicotinamide Safety Study|A Dose Escalation Safety Study of Vitamin B3 Amide Supplementation in Women With Hypertensive Complications of Pregnancy||University of North Carolina, Chapel Hill|Yes|Completed|October 2013|December 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Female|18 Years|45 Years|No|||January 2016|January 4, 2016|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213094||38941|
NCT02213107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53018|Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.|A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Vulnerable Patients =/> 65 Years Old With Systemic Prostate Cancer.||University of Rochester|Yes|Recruiting|September 2014|September 2020|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|65 Years|85 Years|No|||December 2015|December 18, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213107||38940|
NCT02213419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-058-001|Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study|EUS-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study||Samsung Medical Center|Yes|Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2014|February 10, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213419||38916|
NCT02205931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0656|Ketogenic Diet in Infants With Epilepsy (KIWE)|A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years|KIWE|University College, London|Yes|Not yet recruiting|December 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|3 Months|2 Years|No|||July 2014|July 31, 2014|December 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205931||39490|
NCT02206217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ZG3B|Myopia Control With the Multi-segment Lens|The Clinical Trial of Myopia Control in Schoolchildren Using the Multi-segment (MS) Lens||The Hong Kong Polytechnic University|Yes|Active, not recruiting|August 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|183|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02206217||39468|
NCT02207036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A119678|Tobacco Status Project: Social Media Intervention for Young Adult Smokers|Social Media Intervention for Young Adult Smokers|TSP|University of California, San Francisco|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02207036||39405|
NCT02207244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105048|A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment|A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment|VOYAGE 2|Janssen Research & Development, LLC|Yes|Active, not recruiting|November 2014|June 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|998|||Both|18 Years|99 Years|No|||March 2016|March 7, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207244||39389|
NCT02207257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-02-001|Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban|Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal||Perosphere, Inc.|Yes|Recruiting|July 2014|September 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|5||Anticipated|69|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207257||39388|
NCT02207868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVA 3D|3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH|3 D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (EVA 3D Pilot Study)|EVA 3D|Elisabethinen Hospital|No|Recruiting|June 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|||Both|18 Years|N/A|No|Probability Sample|patients with pulmonary arterial hypertension associated with WHO group 1 who start with a        parenteral prostanoidtherapy.|August 2014|August 1, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02207868||39341|
NCT02208141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFB ADI K7-10|Leipzig Adipose Tissue Childhood Cohort|Determinants of Adipose Tissue Development and Obesity in Children and Adolescents|LeipAT Child|University of Leipzig|No|Recruiting|October 2010|||October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|-  adipose tissue sample        -  mRNA from adipose tissue samples, adipocytes, stromal vascular fraction        -  protein from whole adipose tissue samples        -  blood samples for DNA analysis, serum samples        -  urine samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|children and adolescents undergoing surgery at the University Hospital Leipzig|July 2014|August 1, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02208141||39320|
NCT02208167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0741|Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy|IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chronic Infection|HXTC|University of North Carolina, Chapel Hill|Yes|Recruiting|January 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|July 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02208167||39318|
NCT02217085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSA-RTSC 2014|Colorectal Polyp Resection Adequacy|Determining True Colorectal Polyp Resection Adequacy: Correlation of Endoscopic Margins With Histopathologic Margins||Rush University Medical Center|No|Recruiting|May 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Polyp margins will be biopsied and retained.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Adults aged 40 to 80 who are undergoing surveillance colonoscopy for colorectal        adenomatous polyps.|October 2015|October 26, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217085||38636|
NCT02208947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120230|Consumer Engagement to Increase Advance Care Planning|Consumer Engagement to Increase Advance Care Planning||University of Pittsburgh|No|Terminated|April 2014|February 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|77|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 19, 2014||No|failure to accure|No||https://clinicaltrials.gov/show/NCT02208947||39258|
NCT02209233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140181|Effects of Massage on Post-operative Pain in Urologic Patients|Effects of Massage on Post-operative Pain in Urologic Patients||Loma Linda University|Yes|Withdrawn|February 2015|||February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02209233||39236|
NCT02209246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001425|The Effect of Feedback Regarding Illness Behavior on Patient Satisfaction in Hand Surgery|The Effect of Feedback Regarding Illness Behavior on Patient Satisfaction in Hand Surgery||Massachusetts General Hospital|No|Completed|July 2013|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|2||Actual|128|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02209246||39235|
NCT02209259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000666|The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness|The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness||Massachusetts General Hospital|No|Enrolling by invitation|May 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02209259||39234|
NCT02209272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002622|Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia|Local Anesthesia for Ultrasound Guided Hip Joint Injections: A Double-Blinded Randomized Controlled Trial of Bacteriostatic Saline Versus Buffered Lidocaine||Mayo Clinic|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209272||39233|
NCT02218190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401126|Alvimopan and Ileus in PSF|A Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion||Washington University School of Medicine|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218190||38551|
NCT02218203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1NS41503-2|Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial|Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial||Brigham and Women's Hospital|Yes|Completed|April 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|26|||Both|18 Years|70 Years|No|||August 2014|August 15, 2014|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218203||38550|
NCT02212873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR1343916563|My Body is Fit and Fabulous at School|School-based Intervention Program - My Body is Fit and Fabulous|MyBFF@school|Ministry of Health, Malaysia|Yes|Completed|February 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|332|||Both|7 Years|16 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212873||38958|
NCT02216682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001139|Assessing the Efficacy of Intravenous Acetaminophen Versus the Oral Formulation for Perioperative Pain Treatment|Assessing the Efficacy of Intravenous Acetaminophen Versus the Oral Formulation for Perioperative Pain Treatment||Massachusetts General Hospital|No|Not yet recruiting|August 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|174|||Both|18 Years|N/A|No|Non-Probability Sample|174 adult patients from the orthopedic surgeons undergoing total knee replacement with        spinal anesthesia will be enrolled. Patients will be enrolled for the study the morning of        their surgery. Subjects will randomly receive one of the three treatments. The study will        be double blind, randomized; placebo controlled comparing PO and IV acetaminophen to each        other and a control (placebo). At the time patients arrive in the PACU, Group 1 will        receive IV 1 gram acetaminophen, and PO placebo; Group 2 will receive PO 1 gram        acetaminophen and IV placebo; Group 3 will receive IV placebo and PO placebo.|August 2014|August 12, 2014|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216682||38667|
NCT02213120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BETA5003|To Study the Characteristics of Different Types of Vertigo in Patients Attending the Ear Nose & Throat (ENT) Clinics.|To Study the Characteristics of Different Types of Vertigo in Patients Attending the ENT Clinics.|VERTIGO|Abbott|No|Completed|August 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic/Private Clinic|May 2015|May 27, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213120||38939|
NCT02213432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407-057-593|Influenza Vaccination in Cancer Patients|Randomized Controlled Trial to Compare Seroprotection Rate According to Timing of Influenza Vaccination in Adult Patients With Non-Hematologic Malignancies Receiving Scheduled Cytotoxic Chemotherapy||Seoul National University Hospital|No|Terminated|September 2014|August 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|97|||Both|20 Years|N/A|No|||February 2016|February 22, 2016|August 7, 2014||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT02213432||38915|
NCT02213666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000387|Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography|Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography for Imaging of the Left Atrial Appendage and Right Atrial Appendage in Patients With Atrial Fibrillation|ICE-TEE|Beth Israel Deaconess Medical Center|No|Completed|January 2012|May 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213666||38898|
NCT02213926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-004|An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma|An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma||Acerta Pharma BV|No|Active, not recruiting|September 2014|January 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|117|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213926||38878|
NCT02206529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211098|Enhancing Family Based Treatment of Childhood Obesity Through Social Networks|Enhancing Family Based Treatment of Childhood Obesity Through Social Networks|CONNECT|Group Health Cooperative|No|Completed|May 2012|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|7 Years|13 Years|No|||July 2014|July 30, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02206529||39444|
NCT02206789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2011011CLI|Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection|Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection||Aravind Eye Care System|No|Recruiting|February 2012|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||October 2011|July 31, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206789||39424|
NCT02207049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9564 B|The Effect of Snack Consumption on Energy Intake in Preschoolers|The Effect of Snack Consumption on Energy Intake in Preschoolers||University of Tennessee|No|Active, not recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|20|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2014|March 23, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02207049||39404|
NCT02207270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-14-1479|Study Of Costs Realized After Percutaneous Coronary intervenTion Employing Same Day Discharge|A Randomized Cost Minimization Analysis Comparing Same Day Discharge With Overnight Hospital Stay Following Elective and Low Risk Urgent Percutaneous Coronary Intervention.|SOCRATES|Saint Joseph Mercy Health System|No|Terminated|August 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|4|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|July 28, 2014||No|Unable to meet projected enrollment|No||https://clinicaltrials.gov/show/NCT02207270||39387|
NCT02207582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tRNS in depression|Prefrontal Transcranial Random Noise Stimulation in Patients With Depression|Prefrontal Transcranial Random Noise Stimulation in Patients With Depression|tRNS-depr|University of Regensburg|No|Recruiting|July 2014|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207582||39363|
NCT02207595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0021|Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects|A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects||UCB Pharma|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207595||39362|
NCT02207881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-RMN3001-01|A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis|A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis||Yung Shin Pharm. Ind. Co., Ltd.|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|75 Years|No|||July 2014|July 31, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207881||39340|
NCT02216799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2121166|Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)|Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)|GLUCOSE-in-PN|King Faisal Specialist Hospital & Research Center|No|Completed|March 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||April 2015|February 24, 2016|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216799||38658|
NCT02208700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1141459|Efficacy of Oxepa Enteral Feeding in LTAC (Long Term Acute Care Hospital) Patients on Chronic Ventilation- a Pilot Study|Efficacy of the Use of Enteral Feeding High in EPA,GLA and Antioxidants in LTAC Patients on Chronic Ventilation- a Pilot Study|ANUS1305|Grace Hospital, Cleveland, Ohio|No|Recruiting|January 2014|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||August 2014|August 1, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208700||39277|
NCT02208960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000044053|Newborn Kit to Save Lives and Brains in Kenya|An Integrated Toolkit to Save Newborn Lives and Brains in Kenya||The Hospital for Sick Children|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|3000|||Female|N/A|N/A|No|||November 2015|November 16, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208960||39257|
NCT02217930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-2349-101|Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers|A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive- Controlled, Crossover Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers||Wockhardt|No|Completed|August 2014|July 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217930||38571|
NCT02217943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-14-002|Prospective Metabolic Surgery in T2DM Chinese Subjects|A Prospective, Multi-Center Study for the Evaluation of Metabolic Surgery in Subjects With Type 2 Diabetes in China||Ethicon Endo-Surgery|No|Recruiting|July 2014|July 2021|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|20 Years|60 Years|No|||December 2015|December 2, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217943||38570|
NCT02217657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MucM001-13|SmartTouch Catheter for Left Anterior Line - SmarT Line Study|"Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter||Klinikum der Universitaet Muenchen|No|Recruiting|August 2013|June 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|80 Years|No|||August 2014|August 14, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217657||38592|
NCT02217670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-GT016|Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet|||Disphar International B.V.||Withdrawn||||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 14, 2014||No|Commercial reasons|No||https://clinicaltrials.gov/show/NCT02217670||38591|
NCT02216968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30554|Increasing Vegetable Intake in Children|Increasing Vegetable Intake in Children||Baylor College of Medicine|Yes|Active, not recruiting|July 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|600|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02216968||38645|
NCT02216695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2|Epidemiology of Acute Kidney Injury in England - 1998 to 2013|Epidemiology of Acute Kidney Injury in England - 1998 to 2013||Derby Hospitals NHS Foundation Trust|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1200000|||Both|N/A|N/A|No|Non-Probability Sample|This is a historical cohort study using already collected data from the Hospital Episode        Statistics (HES), a data warehouse containing details of all admissions, outpatient        appointments and A&E attendances at NHS hospitals in England.|December 2014|December 1, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02216695||38666|
NCT02213458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1C12013003302|Care Ecosystem: Navigating Patients and Families Through Stages of Care|University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem||University of California, San Francisco|Yes|Recruiting|February 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|2100|||Both|45 Years|N/A|No|||May 2015|May 22, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213458||38914|
NCT02213679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|878/13-EUTC:03|Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome|Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome||Center for Health, Exercise and Sport Sciences, Serbia|Yes|Completed|August 2014|July 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02213679||38897|
NCT02206542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311021DINB|Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: Second-year Project-Comparison of Robot and Conventional Physiotherapy (Including Preliminary Test on Healthy Volunteers)|Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: Second-year Project-Comparison of Robot and Conventional Physiotherapy (Including Preliminary Test on Healthy Volunteers)||National Taiwan University Hospital|No|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206542||39443|
NCT02206555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPP 1403|PrEP Demonstration Project (PRELUDE Study)|Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project|PRELUDE|Kirby Institute|Yes|Recruiting|November 2014|||November 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 30, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206555||39442|
NCT02206568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER511|Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus|A Randomised Trial Investigating Pharmacokinetic Properties of Ultra-Rapid-Acting Insulin Lispro (URAL) in Subjects With Type 1 Diabetes Mellitus||Perosphere, Inc.|Yes|Withdrawn|June 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Actual|0|||Male|18 Years|65 Years|No|||May 2015|May 19, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206568||39441|
NCT02206802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-IVD-MINOXIDIL-004|Minoxidil Response Testing in Females With Female Pattern Hair Loss|Minoxidil Response Testing in Females With Female Pattern Hair Loss||Applied Biology, Inc.|No|Active, not recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Plucked hair follicles with visible bulbs|Female|18 Years|N/A|No|Non-Probability Sample|Females with Female Pattern Hair Loss - Androgenetic Alopecia|January 2016|January 29, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206802||39423|
NCT02207075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309014365|Measuring Active Microglia in Progressive Multiple Sclerosis|||Weill Medical College of Cornell University|No|Recruiting|July 2014|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|26|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 36 subjects (with SPMS and controls) including screen failures will be        enrolled regardless of gender|July 2014|July 30, 2014|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207075||39402|
NCT02215811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-ARDS|Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells|Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells||Karolinska University Hospital|No|Recruiting|March 2014|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215811||38734|
NCT02215824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1181.1|Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia|A Randomised, Double-blind, Placebo-controlled, Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of Different Doses (0.2, 0.6, 2.0, 6.0, and 20.0 μg/hr) of BIWH 3 Administered for 6 Hours in Patients With Chronic Critical Limb Ischaemia (CLI, Fontaine Class III or IV). COINART-1 Trial (First COllateral INto ARTery Trial)|COINART-1|Boehringer Ingelheim||Terminated|October 2002|||October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215824||38733|
NCT02216045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mashhad UMS|Effect of Camel Milk on Chronic Hepatitis C|Investigating the Effects of Camel Milk Products on the Laboratory Markers in the Patients With Chronic Hepatitis C, Genotype 2 & 3|HCV|Mashhad University of Medical Sciences|Yes|Recruiting|June 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2014|August 12, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02216045||38716|
NCT02216318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-085|Energy-efficient and Health Promoting Light for Elderly People|A Study of Two Different Light Conditions for Healthy Subjects Above 65 Years|light-age|Glostrup University Hospital, Copenhagen|No|Completed|October 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|29|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216318||38695|
NCT02216331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC207-CL002|PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)|A Phase I Open-label Trial to Investigate the Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects||Global Alliance for TB Drug Development|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216331||38694|
NCT02216604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S105-2011|Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment|Physical Activity Intervention Program for Childhood Cancer Patients Under Chemo- and/or Radiation Therapy|ONKOKIDS-HD|German Cancer Research Center|No|Recruiting|December 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|5 Years|21 Years|No|||March 2016|March 21, 2016|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216604||38673|
NCT02216838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU97514|Treatment of Facial Flushing With Botulinum Toxin A Injections|Treatment of Facial Flushing With Botulinum Toxin A Injections: A Split-Face, Double-blinded, Randomized Control Trial||Northwestern University|Yes|Recruiting|August 2014|July 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216838||38655|
NCT02216591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053630|Improving Memory Performance by Applying Cognitive Training|Impact of Cognitive Training on Medication Adherence in HIV-infected Individuals|IMPACT|Duke University|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216591||38674|
NCT02216851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43CH1310|Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root|A Randomized, Open Label, No-treatment Controlled, Multi-center, Efficacy and Safety Study Using Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root||Q-Med AB|Yes|Active, not recruiting|September 2014|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216851||38654|
NCT02217358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-NBI|Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions|Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions||University Hospital Ostrava|No|Recruiting|February 2012|March 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|30 Years|80 Years|No|||March 2015|March 3, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02217358||38615|
NCT02217618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14580|A Study of LY2409021 in Healthy Participants|A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects||Eli Lilly and Company|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|16|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217618||38595|
NCT02217631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1262.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Trial With Open-label Active Comparator||Boehringer Ingelheim||Completed|October 2009|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|140|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 14, 2014||||No||https://clinicaltrials.gov/show/NCT02217631||38594|
NCT02217644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1262.1|Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 0.1 mg - 1500 mg). A Singleblind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Phase I Study||Boehringer Ingelheim||Completed|November 2008|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|80|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 14, 2014||||No||https://clinicaltrials.gov/show/NCT02217644||38593|
NCT02217371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/06|Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity|Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity|VEILLETDAH|University Hospital, Bordeaux|No|Not yet recruiting|August 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02217371||38614|
NCT02218229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB: 1-102-05-122|The Effect of Extracorporeal Shock Wave Therapy on Carpal Tunnel Syndrome|The Effect of Extracorporeal Shock Wave Therapy on Carpal Tunnel Syndrome||Tri-Service General Hospital|Yes|Recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02218229||38548|
NCT02217540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lirio-001-UAH|Mulligan Concept Mobilisation With Movement for Shoulder Dysfunction in Older Adults|Mulligan Concept Mobilisation With Movement for Shoulder Dysfunction in Older Adults- A Pilot Randomised Clinical Trial||University of Alcala|No|Completed|January 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|65 Years|N/A|No|||August 2014|August 18, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217540||38601|
NCT02217215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-4-CLP_0|Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies|Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies|Spectral|Guided Therapeutics|No|Not yet recruiting|August 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|Samples With DNA|cells from the cervix to collect and test for HPV|Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|General screening population Scheduled for colposcopy|August 2014|August 13, 2014|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217215||38626|
NCT02217800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG3173-II-02|The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics|||Aspireo Pharmaceuticals Limited||Active, not recruiting|January 2014|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217800||38581|
NCT02218086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCP-2014-0107|Effectivity of Slackline-Training in Physiotherapy|Effectivity of Slackline-Training in Physiotherapy - a Randomised Controlled Study||Thim van der Laan University College Physiotherapy|No|Recruiting|August 2014|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02218086||38559|
NCT02206815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0256|Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"|Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial||Southeast University, China|Yes|Recruiting|August 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|75 Years|No|||September 2014|September 24, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206815||39422|
NCT02206607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621015|Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.|A Phase 1, Randomized, Open-label, Cross-over, Single-day Study Of Pf-04937319 To Characterize Relative Bioavailability, Tolerability, And Pharmacodynamics Of Four Oral Formulations In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|39|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|July 30, 2014|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT02206607||39438|
NCT02207062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9107|Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma|A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma||University of Washington|No|Recruiting|October 2014|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207062||39403|
NCT02215538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00012246|OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD|Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality||University of Utah|Yes|Completed|November 2004|June 2006|Actual|February 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||August 2014|August 12, 2014|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215538||38755|
NCT02215837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Gastric Cancer|Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer|Randomized,Controlled,Multicenter Study of Autologous Tumor Lysate-pulsed Dendritic and Cytokine-induced Killer Cells(Ag-D-CIK) Combined With Chemotherapy for Gastric Cancer.||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Active, not recruiting|August 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||November 2015|December 23, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02215837||38732|
NCT02216058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR-CT-001|Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery Disease|A Prospective, Multicenter Trial of NOYA Sirolimus-Eluting Stent With Biodegradable Coating in Patients With Coronary Artery Disease||Medfavour (Beijing) Medical Co., Ltd|Yes|Recruiting|April 2013|June 2020|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|80 Years|No|||August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216058||38715|
NCT02216071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXL CDOS-300 AOE|Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa|A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa||Exela Pharma Sciences, LLC.|No|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|6 Months|N/A|No|||August 2014|August 12, 2014|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216071||38714|
NCT02216084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281101|Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)|BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)||Baxalta US Inc.|Yes|Completed|September 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|12 Years|65 Years|No|||March 2016|March 1, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216084||38713|
NCT02216344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0440|Controlled Acute Hypoxia Study - Abbreviated Sensor Line|Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples Using the Abbreviated Sensor Line in Healthy Subjects With the USB Pulse Oximetry Monitor Interface Cable||Medtronic - MITG|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|13|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Up to 20 subjects recruited from the Clinical Laboratory subject data base.|October 2014|October 8, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216344||38693|
NCT02216357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-IFE-003|Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease||Cumberland Pharmaceuticals|No|Completed|August 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||January 2016|January 18, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216357||38692|
NCT02217137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1108/10/2014|Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients|Analysing Tear Protein, Conjunctival Cells, and Imaging Eyes in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus||Singapore National Eye Centre|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|80|Samples Without DNA|Tear samples will be collected from the schimers strips for protein analysis|Both|21 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rheumatoid Arthriris, Systemic Lupus Erythematosus and healthy normal volunteers will be        recruited.|June 2014|November 16, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02217137||38632|
NCT02217111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14060563|Prospective Study of Voice Therapy in Children: A Pilot Study|||University of Pittsburgh|No|Completed|January 2015|May 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|4 Years|11 Years|No|||January 2016|January 21, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02217111||38634|
NCT02216812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000561|Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?|Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures? A Placebo Randomized Controlled Trial||Massachusetts General Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216812||38657|
NCT02216825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-12LCHMe|Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile|||Micropharma Limited|No|Completed|November 2013|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|10|||Both|20 Years|75 Years||||June 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02216825||38656|
NCT02217098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUSP6808912|The Survival Rate of Glass Ionomer Cement, Glass Carbomer Cement and Compomer in Occlusal and Proximal ART Restorations|The Survival Rate of Glass Ionomer Cement, Glass Carbomer Cement and Compomer in Occlusal and Proximal ART Restorations|ARTUSP|University of Sao Paulo|No|Active, not recruiting|July 2014|September 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|530|||Both|4 Years|8 Years|No|||March 2015|March 26, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02217098||38635|
NCT02217982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-001-TEC|Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation|A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration|IIT9|Rocky Mountain MS Research Group, LLC|No|Terminated|July 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|July 30, 2014|Yes|Yes|Study did not meet required enrollment numbers|No||https://clinicaltrials.gov/show/NCT02217982||38567|
NCT02217995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138-2014|Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients|A Pilot Randomized Trial Testing Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||August 2014|August 14, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217995||38566|
NCT02214134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1335-LCG-PBG|SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access|SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access|SPECTAlung|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|May 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3500|Samples With DNA|FFPE blocks of tumour tissue Blood samples Pleural effusion samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at        any stage.|January 2016|January 18, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214134|5 Years|38862|
NCT02215330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPL|A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy|A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy||Vienna Institute for Research in Ocular Surgery|No|Not yet recruiting|October 2014|September 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215330||38771|
NCT02217553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402001|The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity|The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity||Universitas Padjadjaran|Yes|Completed|December 2013|June 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 15, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217553||38600|
NCT02216955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cdk-201002|Nutrition and Lifestyle Study Cohort of Gastric Cancer in China|Impact of Nutrition, Dietary Pattern, Obesity, Physical Activity, Depression, Diabetes, Aspirin Use and Vitamin Supplement in Colorectal Cancer in China||State Key Laboratory of Cancer Biology|Yes|Recruiting|January 2009|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|90 Years|No|Probability Sample|The investigators will recruit about 50,000 patients with gastric cancer in 12 hospitals        of China|October 2014|October 30, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216955||38646|
NCT02217228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEB-0121|Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris|A Randomized, Prospective, Multicenter, Controlled Study With Blinded Assessment to Determine the Safety and Effectiveness of the Sebacia Acne Treatment System in the Treatment of Inflammatory Acne Vulgaris||Sebacia, Inc.|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|15 Years|35 Years|No|||October 2015|October 1, 2015|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217228||38625|
NCT02217241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101125|Effect of Hand-off Skills Training for Students During the Medicine Clerkship|Effect of Hand-off Skills Training for Students During the Medicine Clerkship: A Randomized Study||George Washington University|No|Completed|January 2012|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|95|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217241||38624|
NCT02217501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122013-065|Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities|Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities|ASPIRE|University of Texas Southwestern Medical Center|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|90 Years|No|||January 2016|January 19, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217501||38604|
NCT02217514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.3|Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers|Effects of 100 mg and 500 mg BI 44370 TA Orally Applied as 50 mg Tablets on the Pharmacokinetics of 2 mg Orally Administered Midazolam Solution. An Open-label, Randomised, Parallel Group, Fixed-sequence Study With Intraindividual Comparison of Midazolam Pharmacokinetics With and Without BI 44370 TA||Boehringer Ingelheim||Completed|February 2008|||March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|48|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 13, 2014||||No||https://clinicaltrials.gov/show/NCT02217514||38603|
NCT02217787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431008|Food Effect Study for PF-06372865|A Phase 1, Cross-over, Randomized, Single-dose Open Label Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered Pf-06372865 In Healthy Adult Subjects||Pfizer|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02217787||38582|
NCT02217813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461044|A Bioequivalence Study Comparing Two Different Tafamidis Formulations|A Phase 1, Open-label, Randomized, Crossover, Single Dose Study To Determine The Bioequivalence Of Pf-06291826 (Tafamidis) 20 Mg Capsule Manufactured By Catalent Versus Capsule Manufactured By Pii In Healthy Subjects Under Fasted Conditions||Pfizer|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217813||38580|
NCT02217826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG3173-I-003|Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173|||Aspireo Pharmaceuticals Limited||Completed||||April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217826||38579|
NCT02217839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG3173-I-002|Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173|||Aspireo Pharmaceuticals Limited|No|Completed|April 2012|||January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217839||38578|
NCT02214875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6-TSA-037|Lafiyan Jikin Mata "Excellent Health for Mothers"|Increasing Retention-in-care of HIV Positive Women in PMTCT Services Through Continuous Quality Improvement -Break Through Series in Primary & Secondary Health Care Facilities in Nigeria: A Cluster Randomized Controlled Trial|LJM|Centre for Integrated Health Programs, Nigeria|Yes|Recruiting|July 2014|March 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|640|||Female|N/A|N/A|No|||August 2014|August 11, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02214875||38806|
NCT02206828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVSYMB0441|The SymCHro - Observational Registry Study for Symbotex™ Composite Mesh in Ventral Hernia Repair|Observational Registry Study for Symbotex™ Composite Mesh in Ventral Hernia Repair|SymCHro|Sofradim Production|Yes|Recruiting|July 2014|||July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients scheduled for primary and incisional abdominal wall hernia surgeries|June 2015|June 25, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02206828|2 Years|39421|
NCT02215551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O0798-R|Predictors of Decompressive Laminectomy Outcomes|Toward Optimizing Decompressive Laminectomy Outcomes: Looking Outside the Spine||VA Office of Research and Development|No|Recruiting|October 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|350 Veterans with degenerative lumbar spinal stenosis (LSS) who are scheduled to undergo        decompressive laminectomy (DL) will be recruited. No one will be excluded on the basis of        age, race, gender or ethnicity. There is no age restriction as investigators are targeting        patients with degenerative lumbar spinal stenosis, most of who are in their 50's and 60's.        Investigators exclude participants with non-degenerative causes of LSS, as noted below.        Investigators anticipate that the demographics of the participants will reflect that of        the three participating VA sites and their affiliated University spine surgery practices.        Our goal is to recruit at least 70% Veteran participants and Investigators have added        three additional VA sites that will help to ensure this.|November 2015|November 25, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02215551||38754|
NCT02216383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3344|Intramuscular Oxytocics: A Comparison Study of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth|Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth|IMox|North Bristol NHS Trust|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|6285|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02216383||38690|
NCT02216097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541013|A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder|A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study To Assess Effects Of Pf 04457845 On Bold Functional Mri In Subjects With Ptsd||Pfizer|No|Terminated|October 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|60 Years|No|||November 2015|November 12, 2015|August 12, 2014|Yes|Yes|The study stopped based on Pfizer portfolio prioritization and not due to safety and/or    efficacy concern or change in benefit:risk assessment of PF-04457845.|No||https://clinicaltrials.gov/show/NCT02216097||38712|
NCT02216370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRRXT0001|Detection of Occult Paroxysmal AF in Cryptogenic Stroke or TIA Patients Using an Implantable Loop Recorder and Correlation With Genetic Markers.|Detection of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Stroke Patients or TIA Using an Implantable Loop Recorder and Correlation With Genetic Markers.||University Hospital, Martin|No|Recruiting|April 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|125|||Both|18 Years|65 Years|No|Probability Sample|Patients with stroke or TIA confirmed by neurologist within 72 hours of onset symptoms|August 2014|August 11, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216370||38691|
NCT02217709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-14-1|Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer|Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer||University of Southern California|Yes|Recruiting|September 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Male|18 Years|N/A|No|||June 2015|June 30, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217709||38588|
NCT02217722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0096-14-WOMC|Use of the Ulcerative Colitis Diet for Induction of Remission|An Open Label Non Randomized Pilot Study: Use of the Ulcerative Colitis Diet for Induction of Remission.||Wolfson Medical Center|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|5 Years|18 Years|No|||December 2015|December 21, 2015|July 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217722||38587|
NCT02217397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402033RINC|Combinations of Oral Appliance and CPAP for Patients With Severe Obstructive Sleep Apnea Untolerate High-pressure CPAP|Combinations of Oral Appliance and CPAP for Patients With Severe Obstructive Sleep Apnea Untolerate High-pressure CPAP||National Taiwan University Hospital|Yes|Not yet recruiting|August 2014|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|90 Years|No|||August 2014|March 16, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02217397||38612|
NCT02217124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S17213|Impact of High Fiber Snacks on Adiposity, Glucose Regulation and Appetite|Impact of High Fiber Snacks on Adiposity, Glucose Regulation and Appetite in Children||San Diego State University|Yes|Recruiting|July 2014|February 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|48|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217124||38633|
NCT02217384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140040|Whole Gut Microbiome Sequencing in Patients With Anorexia Nervosa|Whole Gut Microbiome Sequencing in Patients With Anorexia Nervosa||Odense University Hospital|Yes|Recruiting|September 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Gut microbiome Blood|Female|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients referred to specialist unit.|September 2014|September 23, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02217384||38613|
NCT02217683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BloodiNO|Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion|Pulmonary Hemodynamic Effects of Stored Red Blood Cell Transfusion in Post-Operative Cardiac Surgical Patients: Influence of Breathing Nitric Oxide. A Randomized Controlled Trial in the Cardiac-Intensive Care Unit.||Massachusetts General Hospital|Yes|Withdrawn|March 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 13, 2014|Yes|Yes|This trial never started due to lack of funding.|No||https://clinicaltrials.gov/show/NCT02217683||38590|
NCT02218242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-LUN-95-MCC|Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound|A Single-arm, Phase II Study of Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound at the Time of Definitive Resection||University of Kentucky|Yes|Recruiting|June 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218242||38547|
NCT02215044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.8|Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase I Open-label Dose-finding Study of Intravenous BI 2536 Administered in Repeated 4-week Cycles as Repeated Doses on Day 1 and Day 15 in Combination With Gemcitabine Administered on Day 1, Day 8 and Day 15 in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Boehringer Ingelheim||Terminated|June 2007|||December 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02215044||38793|
NCT02215343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyNewGut, Task 3.3|Effect of Prebiotic and PUFA on the Gut Microbiota and Metabolic Risk Markers|Effect of Prebiotic Fibre and Polyunsaturated Fatty Acid (PUFA) on the Gut Microbiota and Metabolic Risk Markers in a Metabolically Challenged Population|MyNewGut|University of Copenhagen|Yes|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|60 Years|No|||February 2016|February 16, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02215343||38770|
NCT02215616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV5600-CNS-20007|A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod|A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease|LEGATO-HD|Teva Pharmaceutical Industries|No|Recruiting|November 2014|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|400|||Both|21 Years|55 Years|No|||March 2016|March 1, 2016|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215616||38749|
NCT02218151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051024|Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2|Patient-Centered Medical Home Care for Hematopoietic Stem Cell Transplantation: A Randomized Phase 2 Study||Duke University|Yes|Recruiting|October 2014|August 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218151||38554|
NCT02217254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-OF01|The OneFreeze Study|THE ONE FREEZE STUDY: A PROSPECTIVE MULTI-CENTER RANDOMIZED CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY OF ONE VS. TWO CRYOABLATIONS PER PULMONARY VEIN FOR THE TREATMENT OF ATRIAL FIBRILLATION|OneFreeze|University of California, San Francisco|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||October 2014|October 30, 2014|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217254||38623|
NCT02217527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH3-PRO14070319|Test of Novel Drug for Smoking Cessation|Development of a Novel Therapeutic for Smoking Cessation|UH3-P2|University of Pittsburgh|Yes|Recruiting|November 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217527||38602|
NCT02214238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-116|Evaluation of Treatment Efficacy and Comfort of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea.|Evaluation of Treatment Efficacy and Comfort of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea, in Comparison to a Market Released Device.||Fisher and Paykel Healthcare|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214238||38854|
NCT02214888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.18|Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis|A 12 Week Double-blind, Randomized, Placebo-controlled Trial to Investigate Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets at Doses of 50 and 70 mg Administered Twice a Day in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD||Boehringer Ingelheim||Terminated|May 2003|||January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|75 Years|No|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214888||38805|
NCT02214901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219.1|Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses BIBW 2948 BS (0.75 to 150 mg Inhalation Powder, Hard Capsule for HandiHaler®) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|March 2005|||July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|91|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214901||38804|
NCT02214914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 5, 10, 25, 50, 100, 200 and 400 mg BI 11634 Solution Administered to Healthy Male Volunteers. Randomised, Double-blind, Placebo Controlled at Each Dose Level. Intra-individual Comparison of Solution to an Immediate Release Tablet Formulation at One Dose Level (50 mg)||Boehringer Ingelheim||Completed|November 2006|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|56|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214914||38803|
NCT02214927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234.12|Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers|Relative Bioavailability of 10 mg BI 11634 Immediate Release Tablet (IR) Compared to 10 mg of Oral Solution Following Oral Administration in Healthy Male Volunteers (Open-label, Single-dose, Intra-individual Comparison); Determination of Pharmacokinetics of 5 mg, 10 mg and 25 mg IR-tablet Formulation (Open-label, Single Dose)||Boehringer Ingelheim||Completed|May 2007|||July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214927||38802|
NCT02215265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/VCC/0014|Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)|A Phase II/III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer|PATHOS|Velindre NHS Trust|Yes|Not yet recruiting|December 2014|||December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|242|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215265||38776|
NCT02216110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHDDC-2014-01|Endoscopic Submucosal Dissection Versus Gastrectomy|Long-term Outcomes of Endoscopic Submucosal Dissection Versus Gastrectomy for Early Gastric Cancer||Soonchunhyang University Hospital|Yes|Completed|May 2003|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|500|||Both|20 Years|80 Years|No|Non-Probability Sample|All patients with early gastric cancer were treated by surgery or ESD at a single,        tertiary-care, academic medical center.|May 2015|May 19, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02216110||38711|
NCT02216630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-SVF-1002|Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-center Study to Assess the Safety and Effects of Intravenous Implantation of Liposuction Derived Autologous Adipose-derived Stem Cells in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Kimera Society Inc|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|85 Years|No|||February 2016|February 26, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02216630||38671|
NCT02216617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2013-01|Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy|A Phase I Study Evaluating the Combination Afatinib With Docetaxel and Cisplatin (TPA) in Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Upper Aerodigestive Tract|TAPIS|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Recruiting|August 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|70 Years|No|||August 2014|August 13, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02216617||38672|
NCT02216864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU97928|Effect of Multiple Subcisions on Rolling Acne Scars|Pilot Split Face Randomized, Evaluator Blinded Study on the Effect of Multiple Subcisions on Rolling Acne Scars||Northwestern University|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216864||38653|
NCT02218268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400553|Arterial Stiffness in Type I Diabetes Mellitus|Acute Effect of a Mixed Meal With and Without Extra Insulin on Arterial Stiffness, a Prospective Randomized Study.||University of Florida|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02218268||38545|
NCT02218021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-012|A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Abuse Potential and Safety of Orally Administered Samidorphan in Non-Dependent Recreational Opioid Users||Alkermes, Inc.|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02218021||38564|
NCT02218255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-AUX-010|Eeva™ Pregnancy Pilot Study (PPS)|Eeva™ Pregnancy Pilot Study (PPS)|PPS|Progyny, Inc.|No|Recruiting|August 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Female|18 Years|40 Years|No|||October 2015|October 19, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218255||38546|
NCT02217696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEXI SNF32003B_141201/1|Prediction and Intervention in Developmental Dyslexia|Neuronal Markers of Grapheme-phoneme Training Response for Prediction of Successful Reading Acquisition in Children at Familial Risk for Developmental Dyslexia|LEXI|University of Zurich|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|110|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02217696||38589|
NCT02218008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-207|A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study)||Alkermes, Inc.|No|Recruiting|July 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218008||38565|
NCT02214420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJPIIS-01-14|SMV + SOF With/Without RBV for IFN-II Patients With CHC|Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC)||SC Liver Research Consortium, LLC|No|Active, not recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214420||38841|
NCT02215057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1479|Evaluation of Topical Anesthesia Alone Versus Combined With Intracameral LIdocaine 1%|Evaluation of Topical Anesthesia Alone Versus Combined With Intracameral Lidocaine 1% in Patients Undergoing Implantable Collamer Lens (ICL) Procedure||Cairo University|Yes|Recruiting|August 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|20 Years|90 Years|No|||August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215057||38792|
NCT02215629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-4718-102|Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia|A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia||Verastem, Inc.|No|Withdrawn||November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215629||38748|
NCT02216175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SMxxx|Improving the Safety of Oral Immunotherapy in Cow's Milk Allergy|Phase 2/3 Clinical Trial to Assess the Effect of a Sublingual Treatment Phase Prior to Oral Immunotherapy in Children With Cow's Milk Allergy|SOCMA|Imperial College London||Not yet recruiting|June 2016|||May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|53|||Both|6 Years|15 Years|No|||October 2015|October 20, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02216175||38706|
NCT02214056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/DC-02|Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Feasibility|Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Part I Feasibility|DéProPAss|Centre Hospitalier Universitaire de Nīmes|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|50 Years|N/A|No|Non-Probability Sample|The study population consists of patients at least 50 years of age with a chronic disease        (COPD, Type II diabetes, atherosclerosis) recruited by one of the GP investigators.|April 2015|May 5, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214056||38868|
NCT02217852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WestChinaH 20140701|Treatment of Hypertension in Tibetan Adult Population|A Randomized, Open-label, Positive Drug Controlled Clinical Trials to Compare the Efficacy of Nitrendipine and Hydrochlorothiazide , Captopril Plus Hydrochlorothiazide and Beijing Hypotensive No.0 in Tibetan Hypertension||West China Hospital|Yes|Not yet recruiting|August 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Both|18 Years|80 Years|No|||August 2014|August 28, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217852||38577|
NCT02218112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF_ 32003B_149903|Impact of Weight Loss After a Bypass Surgery on Renal Hemodynamic Under Stress Conditions|Effect of Weight Loss Induced by a Bypass Surgery on Renal Salt Excretion, Renal Hemodynamic and on Neurohormonal Responses During an Induced Orthostatic Stress in Obese Patients|OBBYSS|Centre Hospitalier Universitaire Vaudois|No|Recruiting|June 2014|||June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|||Both|18 Years|65 Years|No|Probability Sample|Patient will briefly be informed about the study during their follow-up at the obesity        consultation (Medical Universitary Polyclinic) and the they will be recruited at the        Nephrology center in CHUV (Lausanne).|August 2015|August 8, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218112|1 Year|38557|
NCT02216032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30000000|Thirty Million Words Home Visiting: A Longitudinal RCT|Thirty Million Words Home Visiting: A Longitudinal RCT|TMW HV RCT|University of Chicago|No|Enrolling by invitation|November 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|200|||Both|13 Months|16 Months|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216032||38717|
NCT02215304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LALLEM-001|Safety and Tolerance Study of Three Probiotic Strains in Infants|A Randomized, Double-blind, Placebo-controlled Intervention Study to Assess the Safety and Tolerance Effect of Three Probiotic Strains in Infants|PROBINFANT|ProbiSearch SL|No|Recruiting|June 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|200|||Both|3 Months|12 Months|Accepts Healthy Volunteers|||September 2014|September 10, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215304||38773|
NCT02215564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17545|Bordetella Pertussis Carriage in College-aged Students|Bordetella Pertussis Carriage in College-aged Students||University of Virginia|No|Active, not recruiting|October 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|College-aged students/young adults|May 2015|May 27, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02215564||38753|
NCT02215278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lpa_002|A Multiple Meal Stable Iron Isotope Study in Iron Deficient Rwandese Women to Investigate the Performance of Low Phytic Acid Bean Seeds|||GroundWork|No|Completed|February 2014|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|25|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02215278||38775|
NCT02215291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_02|High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging System Registry|||NinePoint Medical|No|Recruiting|July 2014|||March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Up to 20 sites; each site will have the opportunity to enroll up to 100 patients. There        will be up to 1000 patients enrolled in the registry.|October 2015|October 29, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02215291|12 Months|38774|
NCT02216396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143438|A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes|MARQUE (Managing Agitation and Quality of Life) Stream 2: A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes|MARQUE2|University College, London|Yes|Active, not recruiting|April 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1734|||Both|N/A|N/A|No|Non-Probability Sample|We will recruit care homes from across England. Our sampling frame will encompass all care        homes types where people with dementia reside to ensure external validity and        generalisability. We will recruit homes to ensure a representation of each provider type        (voluntary, state and private) care provision (nursing, residential) and of urban/suburban        and rural locations. There are around 18,000 English care homes and 80% of residents have        dementia (Alzheimer's Society).        We will include all people with dementia diagnosed or screening positive for possible        dementia on the Noticeable Problems checklist, all care home staff who provide care for        this population and family carers who are in regular contact.|May 2015|December 3, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02216396||38689|
NCT02216409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0113|Phase I Trial of Hu5F9-G4|A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies||Stanford University|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216409||38688|
NCT02217423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34609514100005502|Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy|The Relationship Between Abdominal Circumference and Cardiorespiratory Repercussions in Hospitalized Patients Submitted to Physical Therapy|RACCRPPT|Universidade Federal de Sao Carlos|No|Completed|September 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|46|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 6, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217423||38610|
NCT02216877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MgCKDRos|Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease|Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease - A Dose-Finding Trial||Roskilde County Hospital|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216877||38652|
NCT02217150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS|The STAR Prospective Clinical Series|The DFINE STAR™ Tumor Ablation Prospective Clinical Series|PCS|DFINE Inc.|No|Active, not recruiting|June 2013|March 2016|Anticipated|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|100 Years|No|Non-Probability Sample|Subjects with painful spinal metastases following t-RFA with the STAR™ Tumor Ablation        System.|January 2016|January 19, 2016|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217150|3 Months|38631|
NCT02217410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFZ533X2201|CCFZ533X2201 - PoC Study in de Novo Renal Transplantation|A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients||Novartis|Yes|Recruiting|February 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|51|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217410||38611|
NCT02214186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 675.011|Restrictive Fluid Therapy in Severe Preeclampsia|Impact of Restrictive Fluid Therapy on Renal Function in Severe Preeclamptic Women Submitted to Cesarean Section Under Spinal Anesthesia||University of Sao Paulo General Hospital|Yes|Completed|January 2014|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Female|18 Years|N/A|No|||July 2014|September 8, 2015|July 16, 2014||No||No|July 6, 2015|https://clinicaltrials.gov/show/NCT02214186||38858|
NCT02215395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|571|An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women|Phase 1, Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication (Miconazole Nitrate) on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring Releasing a Daily Dose of 150 ug of NES and 15 ug of EE||Population Council|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215395||38766|
NCT02214160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX007-CL202|Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.|An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies||Ultragenyx Pharmaceutical Inc|No|Enrolling by invitation|December 2014|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|6 Months|N/A|No|||February 2016|February 26, 2016|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214160||38860|
NCT02214173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130279|The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV|The Effect of an Enhanced Rice Bran Nutritional Supplement on Metabolic Syndrome Variables in HIV|BRM4|University of Miami|No|Active, not recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02214173||38859|
NCT02214147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14019|Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function|Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function||Millennium Pharmaceuticals, Inc.|No|Recruiting|September 2014|September 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02214147||38861|
NCT02214667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA036791|Treating Jail Inmates|Treating Co-Occurring Substance Use and Mental Disorders Among Jail Inmates||RTI International|No|Not yet recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214667||38822|
NCT02215083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMC 13-32|L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer|L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer||Eastern Regional Medical Center|No|Terminated|August 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|August 11, 2014|Yes|Yes|Insufficient Patient Population|No||https://clinicaltrials.gov/show/NCT02215083||38790|
NCT02215356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV66|Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer|Icotinib With Concurrent Radiotherapy Versus Etoposide/Cisplatin With Concurrent Radiotherapy in Stage III Non-small Cell Lung Cancer With EGFR 19/21 Mutation||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|August 2014|February 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||August 2014|August 11, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215356||38769|
NCT02216448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1236-DP-CTIL|Arthroscopy Simulator Training vs OR Training Knee|The Benefit of Arthroscopic Simulator Training Versus Operating Room Training in Diagnostic Knee Arthroscopy for Residents With Basic Arthroscopic Skills|ASTOR|Sheba Medical Center|No|Not yet recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|17|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02216448||38685|
NCT02208037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1203|Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)|A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203; Progress I)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|August 2014|December 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|270|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208037||39328|
NCT02214550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH13-094|Chronic Pain Risk Associated With Menstrual Period Pain|Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain|CRAMPP|NorthShore University HealthSystem Research Institute|Yes|Recruiting|July 2014|September 2025|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|195|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 29, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214550||38831|
NCT02217865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA13-1002|Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer|Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer||M.D. Anderson Cancer Center|No|Recruiting|July 2014|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of MD Anderson Colorectal Center and their caregivers recruited by study staff.|February 2016|February 18, 2016|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217865||38576|
NCT02218125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100965|A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults|A Phase I Study of Modified Vaccinia Ankara With Mosaic HIV Inserts in Healthy, HIV-Uninfected Adults, Some of Whom Have Previously Received an Adenovirus Type 26 ENVA.01 Vaccine|MENSCH|Crucell Holland BV|Yes|Completed|September 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02218125||38556|
NCT02215226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_28OBTP|GBS Sero-correlate of Protection|Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged <=90 Days|V98_28OBTP|University of Witwatersrand, South Africa|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|35000|Samples Without DNA|Cord blood and maternal blood (serum samples) Vaginal swab samples from mothers Invasive GBS      isolates from cases|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 18 years or older attending for antenatal care or delivery at Chris        Hani Baragwanath Academic hospital, and infants who develop GBS disease at the other 2        hospitals in the Johannesburg area|August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215226|3 Months|38779|
NCT02214602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEl-Sawy172014|Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer|The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial|NMIBCIVT|Mansoura University|Yes|Recruiting|July 2014|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214602||38827|
NCT02214615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW0023|Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations|Pilot Study on the Response of Inherited Erythromelalgia Patients With NaV1.7 Mutations to Carbamazepine: Clinical Imaging Study||VA Connecticut Healthcare System|No|Enrolling by invitation|April 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|80 Years|No|||July 2015|July 13, 2015|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214615||38826|
NCT02215590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-9|Re-Step: Dynamic Balance Treatment of Gait for Acquired Brain Injury (ABI) Victims|Re-Step: a Computerized Dynamic Balance Treatment for Rehabilitation of Unassisted Gait in ABI Victims: a Prospective, Exploratory and Interventional Clinical Trial||Reuth Medical Center|Yes|Active, not recruiting|September 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02215590||38751|
NCT02215577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SweLiv 1-2014|ALPPS Versus PVE/PL|Comparison of Two Different Models of Liver Growth Stimulation in Advanced Colorectal Liver Metastatic Disease, (LIGRO Trial) Enabling Liver Resection|LIGRO|Regionalt Cancercentrum Väst|Yes|Recruiting|June 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215577||38752|
NCT02215850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-055/SLC0111-14-C01|Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours|A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours||Welichem Biotech Inc.|No|Recruiting|October 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215850||38731|
NCT02217163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGHMM1|A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma|A PHASE 2 SINGLE ARM STUDY OF CARFILZOMIB IN TRANSPLANT ELIGIBLE HIGH RISK MULTIPLE MYELOMA||Singapore General Hospital|No|Recruiting|October 2014|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||October 2014|October 8, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02217163||38630|
NCT02217748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096620-S2|Name Generator Order Effects in Social Networks|Understanding Name Generator Order Effects When Eliciting Social Networks in Rural Uganda: A Randomized Controlled Trial||Massachusetts General Hospital|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|6||Anticipated|1557|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 29, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217748||38585|
NCT02217735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM#13659|Expressive Writing for Individuals With Parkinson's Disease and Their Caregivers|Randomized Controlled Expressive Writing Pilot in Individuals With Parkinson's Disease and Their Caregivers|PDEWS|Virginia Commonwealth University|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 17, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217735||38586|
NCT02218034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190168-069|Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris|||Allergan|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|78|||Both|12 Years|N/A|No|||April 2015|April 28, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218034||38563|
NCT02206724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140794|Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer|PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER||Sharp HealthCare|No|Not yet recruiting|August 2016|August 2024|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|18 Years|75 Years|No|||November 2015|November 23, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206724||39429|
NCT02214446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311041RINC|Factors Related to Truth Telling in Primary Caregivers|Explore Factors Related to Truth Telling in Primary Caregivers of Children Newly Diagnosed With Cancer||National Taiwan University Hospital|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|84|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Caregivers of Children Newly Diagnosed with Cancer|August 2014|August 21, 2014|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02214446||38839|
NCT02214693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA1229_RI_I|PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients|A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Tolerability of DA-1229(Evogliptin) Tablet in Renal Impaired Patients||Dong-A ST Co., Ltd.|Yes|Completed|July 2014|||March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214693||38820|
NCT02214433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1450-103|A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects||Debiopharm International SA|Yes|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|11||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|August 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02214433||38840|
NCT02214680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0016-CTIL|The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter|The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter||Carmel Medical Center|No|Not yet recruiting|October 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214680||38821|
NCT02215070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051736|Pasireotide in Prevention of GI Toxicity|Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide||Duke University|Yes|Recruiting|February 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215070||38791|
NCT02215902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEMD - IDE - 2013|Safety Study of the Aethlon Hemopurifier|A Clinical Safety Study of the Aethlon Hemopurifier® in Chronic ESRD Patients With HCV Infection|AEMD-IDE-20|Aethlon Medical Inc.|No|Recruiting|December 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2014|December 9, 2014|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215902||38727|
NCT02207413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201251|A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children|Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children||GlaxoSmithKline||Completed|August 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|1886|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207413||39376|
NCT02208050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVUHneuro002|A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis|A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis||University College Dublin|Yes|Recruiting|March 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||June 2015|June 8, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02208050||39327|
NCT02210962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N402 243435|Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia|Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods.|OFFER|Medical Universtity of Lodz|Yes|Active, not recruiting|September 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|16 Years|35 Years|No|||February 2015|February 16, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210962||39104|
NCT02214290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2013.10514|Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy Males|Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy Males||Florida State University|No|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02214290||38850|
NCT02215239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310041RINA|Development of Workplace Physical Activity Promotion Models in Taiwan|Development of Workplace Physical Activity Promotion Models in Taiwan||National Taiwan University Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|240|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215239||38778|
NCT02214953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234.7|Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers|An Open, Randomised, Single-dose, Four-way Cross-over Formulation Finding Study of the Oral Bioavailability of Four Prototype Extended Release Formulations With 25 mg BI 11634, and Intra-individual Comparison to Immediate-release Tablets (25 mg) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2007|||December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|17|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214953||38800|
NCT02214966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236.3|Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers|Influence of Food on the Bioavailability of 80 mg Telmisartan / 10 mg Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Two-period Crossover Study)||Boehringer Ingelheim||Completed|October 2007|||December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214966||38799|
NCT02214979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236.4|Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers|Bioequivalence of 40 mg Telmisartan / 2.5 mg Ramipril Fixed Dose Combination Compared With the Monocomponents, Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|March 2007|||June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214979||38798|
NCT02216422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-252|A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection|An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turquoise-IV)|Turquoise-IV|AbbVie|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216422||38687|
NCT02216643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22042613.6.1001.5327|EndoVascular Treatment With Solitaire FR® vs. Best Medical Therapy in Acute Ischemic Stroke|Randomization of EndoVascular Treatment With Solitaire FR® vs. Best Medical Therapy in Acute Ischemic Stroke Due to Large VEssel OcclusioN Trial|RESILIENT|Hospital de Clinicas de Porto Alegre|Yes|Not yet recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|690|||Both|18 Years|85 Years|No|||January 2015|January 5, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216643||38670|
NCT02216916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0794|Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy|||Yonsei University|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|August 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02216916||38649|
NCT02216123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116564|Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria||GlaxoSmithKline|Yes|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|16 Years|N/A|No|||January 2016|February 11, 2016|June 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216123||38710|
NCT02216136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404004|Tumor: Breast Ratio Study|A Prospective Trial to AssessTumor:Breast Ratio and Patient Satisfaction in Following Lumpectomy Versus Mastectomy With Reconstruction|T:B|Washington University School of Medicine|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|186|||Female|22 Years|70 Years|No|Non-Probability Sample|Females ages 22 - 70 years of age scheduled to undergo breast conservation therapy (BCT),        mastectomy or mastectomy with immediate reconstruction for ductal carcinoma in situ        (DCIS), lobular carcinoma in situ (LCIS), and early stage breast cancer (Clinical Stages        IA-IIB).|February 2016|February 16, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02216136||38709|
NCT02217436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iPadWilliams|iPad as a Distraction Tool During Facial Laceration Repair|iPad as a Distraction Tool During Facial Laceration Repair||University of California, San Diego|Yes|Recruiting|April 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|2 Years|12 Years|No|||August 2014|August 14, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02217436||38609|
NCT02217449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0010|Virtual Chromoendoscopy for Distal Polyps|||University of Erlangen-Nürnberg Medical School||Recruiting|January 2011|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients undergoing screeining or surveillance colonoscopy|August 2014|August 13, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02217449||38608|
NCT02214459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32775|Dietary Approaches to Stopping Hypertension (DASH) Mobile App Pilot|Dietary Approaches to Stopping Hypertension (DASH) Mobile App Pilot|DASH Mobile|Boston University|No|Recruiting|July 2015|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214459||38838|
NCT02218047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTINUATION-PV|AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.|An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.|CONTI-PV|AOP Orphan Pharmaceuticals AG|Yes|Recruiting|November 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|130|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218047||38562|
NCT02218281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA037886|Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation|Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation||University of Massachusetts, Worcester|Yes|Recruiting|September 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|144|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02218281||38544|
NCT02215096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200331|Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer|A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination With Enzalutamide (Xtandi^TM ) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)||GlaxoSmithKline|No|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Male|18 Years|N/A|No|||December 2015|March 17, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215096||38789|
NCT02215369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-VC300|Prospective Safety and Effectiveness Study: VenaCure Endovenous Laser Treatment (EVLT) 400 µm Fiber Procedure Kit for Treatment of Incompetent Perforator Veins|Prospective Safety and Effectiveness Study: VenaCure Endovenous Laser Treatment (EVLT) 400 µm Fiber Procedure Kit for Treatment of Incompetent Perforator Veins|SeCure|Angiodynamics, Inc.|No|Recruiting|January 2015|October 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Incompetent Perforator Veins (IPV's) and meeting all inclusion        criteria will be eligible for the study. Diagnosis and definition of perforating vein        insufficiancy will be consistent with the SVS/AVF Clinical Practice Guidelines for the        Care of Patients with Vericose Veins and Associated Chronic Venous Disease.|September 2015|September 2, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02215369||38768|
NCT02215382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odu-3|Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade|||T.C. ORDU ÜNİVERSİTESİ||Completed|August 2014|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|36|||Both|18 Years|65 Years|No|||August 2014|April 18, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02215382||38767|
NCT02207725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-503|A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban|A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa||Portola Pharmaceuticals|Yes|Completed|March 2014|September 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207725||39352|
NCT02207738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1062|Comparison of Efficacy Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency for Acne Scar|Comparative Study of Efficacy and Safety Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency Treatment for Acne Scar||Seoul National University Hospital|Yes|Completed|January 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02207738||39351|
NCT02208609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0282|Zinc Bioavailability From Amaranth-enriched Maize Tortillas|Absorption of Zinc (Zn) From Traditional Maize Tortillas and Amaranth-enriched Tortillas by Toddlers in the Indigenous Post-Mayan Population||University of Colorado, Denver|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|20|||Both|18 Months|36 Months|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208609||39284|
NCT02210676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001041|Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger|Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger||Massachusetts General Hospital|No|Enrolling by invitation|June 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|320|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210676||39126|
NCT02210689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1052|A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women|||Actavis Inc.|No|Completed|January 2014|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|604|||Female|18 Years|N/A|No|||March 2015|March 18, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210689||39125|
NCT02214823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12612000528853|eStimCycle: Early Rehabilitation in Critical Care|Functional Electrical Stimulation Assisted Cycling (eStimCycle):A Novel Intervention to Improve Outcomes in the Critically Ill|eStimCycle|University of Melbourne|Yes|Recruiting|July 2012|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214823||38810|
NCT02214836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35261-A|Ultrasound Imaging of Kidney Stones and Lithotripsy|Ultrasound Imaging of Kidney Stones and Lithotripsy||University of Washington|Yes|Recruiting|October 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|21 Years|N/A|No|||March 2015|March 23, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214836||38809|
NCT02215785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R13/055|The Effect of Consumption of Kiwifruit on Constipation in Adults|Improvement of Functional Constipation With Kiwifruit Intake in a Mediterranean Patient Population: Open Non-controlled and Non-randomized Longitudinal Study||Jordi Gol i Gurina Foundation|No|Completed|April 2013|October 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Both|18 Years|65 Years|No|||August 2014|August 12, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02215785||38736|
NCT02215317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSS|Sleep and Stent Study: a Multicentre, Prospective Study|Impact of Obstructive Sleep Apnea on Cardiovascular Outcomes in Patients Treated With Percutaneous Coronary Intervention||National University, Singapore|Yes|Active, not recruiting|December 2011|July 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1815|||Both|18 Years|80 Years|No|Non-Probability Sample|This is a prospective, observational multi-national cohort study of patients undergoing        PCI for coronary artery disease. Adult patients undergoing clinically indicated PCI for        coronary artery disease will be enrolled in the Sleep and Stent Study.|November 2015|November 4, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02215317||38772|
NCT02216929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK2|Assessment of the Patients of Emergency Consultation|The Demographics, Mortality and Clinical Diagnosis of the Patients Who Were Evaluated, Intubated and Interned to ICU by the Anesthesiology in 2010-2011|ICU|Umraniye Education and Research Hospital|Yes|Completed|January 2011|May 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|287|||Both|N/A|N/A|No|Non-Probability Sample|This study aimed to retrospectively evaluate patients throughout the whole hospital who        were intubated and interned to the ICU by anaesthesiology team due to an urgent        consultation call in our hospital during 2010-2011.|January 2011|August 13, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216929||38648|
NCT02216890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN70A-001|Safety Study of SGN-CD70A in Cancer Patients|A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies||Seattle Genetics, Inc.|No|Recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216890||38651|
NCT02216903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0502|Respiratory Motion Related Ablation Gap and Clinical Outcome After Catheter Ablation for Atrial Fibrillation|||Yonsei University|No|Not yet recruiting|August 2014|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|80 Years|No|Non-Probability Sample|Consecutive patients with atrial fibrillation who undergoing catheter ablation in Yonsei        Cardiovascular hospital, Yonsei university health system, Seoul, Korea.|August 2014|August 13, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02216903||38650|
NCT02214199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21/2013|Effectiveness of Cervicothoracic Manipulative Treatment in Unilateral Shoulder Impingement Syndrome: A Randomized Controlled Trial.|||Universidad de Almeria|No|Active, not recruiting|August 2014|December 2015|Anticipated|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|55 Years|No|||May 2015|May 27, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02214199||38857|
NCT02205827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-005|A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements|A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements||Perosphere, Inc.|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|September 25, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02205827||39498|
NCT02205840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614/1131|A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.|A Multicenter, Randomized, Double-masked and Placebo-controlled Study Evaluating the Efficacy and Safety of SI-614 Ophthalmic Solution in Patients With Dry Eye||Seikagaku Corporation|No|Completed|July 2014|||November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205840||39497|
NCT02214706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC14022_POLAR|Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus|Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus in an Open Label Pilot Study (POLAR).||Erasmus Medical Center|No|Active, not recruiting|July 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214706||38819|
NCT02215109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHOPH2014-01|Retinal Vessel Diameter in Branch Retinal Vein Occlusion|Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection||Kyungpook National University|Yes|Recruiting|April 2012|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|40 Years|85 Years|No|Non-Probability Sample|A total of 25 patients will be included. All subjects with branch retinal vein occlusion        scheduled for intravitreal bevacizumab injection.|April 2015|April 1, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215109||38788|
NCT02215122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR001-1008|Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs|A Bioequivalence Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol Administered as a Fixed Dose Combination From Different Dry Powder Inhalers in Healthy Subjects||Mylan Inc.|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|August 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215122||38787|
NCT02207179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM010|Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology|Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology: An Ex-vivo Pilot Study of Real-time Breast Margin Imaging in Women Undergoing Breast Conservation Surgery for Early Stage Breast Cancer||LumaMed|No|Recruiting|January 2014|November 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|70 Years|No|||March 2015|March 30, 2015|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02207179||39394|
NCT02207192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRC obesity|Postural Changes in Lung Volumes in Obesity|Effect of Weight Loss on Postural Changes in Pulmonary Function : a Longitudinal Study in Morbidly Obese to Obese Subjects Following Gastroplasty||Association pour la Formation du Personnel à la Medecine d'Urgence|No|Completed|August 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|12|||Both|N/A|60 Years|No|Probability Sample|Twelve morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric        surgery at the Montpellier university hospital were recruited. They were 3 men and 9        women.|August 2014|August 5, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207192||39393|
NCT02207439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15313|A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx|A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2014|||July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207439||39374|
NCT02206451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914159|Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali|Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Don(SqrRoot)(Copyright)gu(SqrRoot)(Copyright)Bougou Mali||National Institutes of Health Clinical Center (CC)||Completed|July 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|110|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|August 28, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206451||39450|
NCT02206711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-036|Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.|Pharmacokinetics and Metabolism of [14C] BMS-955176 in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|9|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206711||39430|
NCT02206945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0206017435-2|Neurofeedback for Obsessive-Compulsive Disorder (OCD)|Neurofeedback of Activity in the Orbitofrontal Cortex for OCD||Yale University|No|Recruiting|July 2015|July 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206945||39412|
NCT02207166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406066RINB|Identify Possible Errors on Home Use Blood Pressure Monitors by Usability Reasoning|Identify Possible Errors on Home Use Blood Pressure Monitors by Usability Reasoning (IPEOHUBPMBUR)|IPEOHUBPMBUR|National Taiwan University Hospital|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults who are able to operate general healthcare devices (eg thermometer, electronic        blood pressure measures)|March 2015|March 17, 2015|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02207166||39395|
NCT02208336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99210|Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy|Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2010|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|240|||Both|N/A|N/A|No|Non-Probability Sample|Brain Tumor Patients|February 2015|February 12, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208336||39305|
NCT02208622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0398|Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet|Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet||University of Colorado, Denver|No|Active, not recruiting|August 2013|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|50|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208622||39283|
NCT02215499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP386.1001|A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics|A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics||Concert Pharmaceuticals|No|Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|August 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02215499||38758|
NCT02211261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3501001|A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus|A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|9||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211261||39081|
NCT02216786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009175QM|A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer|A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer|MANTA|Queen Mary University of London|Yes|Recruiting|January 2014|April 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Female|18 Years|N/A|No|||January 2015|January 23, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216786||38659|
NCT02217059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEMF0000|Congruence of Emergency Department Attendings' Predictions of Hypertension With Results of Home Blood Pressure Monitoring|||Rhode Island Hospital|No|Not yet recruiting|August 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Emergency Department|August 2014|August 14, 2014|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217059||38638|
NCT02216149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-01/2013|Effects of S-1 and Capecitabine on Coronary Artery Blood Flow|Effects of S-1 and Capecitabine in Combination With Oxaliplatin on the Coronary Artery Blood Flow in Patients Metastatic Gastrointestinal Tract Adenocarcinoma: a Randomized Phase II Study|FluoHeart|Helsinki University Central Hospital|No|Recruiting|January 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||March 2016|March 4, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02216149||38708|
NCT02218060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Force Cardiac|Coronary CT Angiography Using a Novel 3rd Generation Dual-Source CT System|Coronary CT Angiography Using a Novel 3rd Generation Dual-Source CT System: Diagnostic Performance and Potential for Reduction in Radiation Dose and Contrast Material Requirement||Medical University of South Carolina|No|Recruiting|January 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|90 Years|No|||April 2015|April 16, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218060||38561|
NCT02217176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-662|Ultrasonography of the Neck: The Influence of Airway Devices on Vascular Topography in Pediatric Patients|||Ankara University|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|92|||Both|1 Month|16 Years|No|Non-Probability Sample|The pediatric population who were undergone any type of surgery under general anesthesia|August 2014|August 14, 2014|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02217176||38629|
NCT02217189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Babil-3|Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers|Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers in Spermatozoa of Patients With Asthenospermia||Babylon University|No|Completed|July 2011|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Male|26 Years|36 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02217189||38628|
NCT02205567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT14|Bergamot and Cardio-Metabolic Risk Factors|The Effect of Bergamot on Plasma Lipids, Lipoproteins and Carotid Intima-media Thickness||University of Palermo|No|Completed|June 2014|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|160|Samples Without DNA|Serum and plasma samples|Both|35 Years|75 Years|No|Probability Sample|adult subjects with dyslipidemia|August 2015|August 5, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205567||39518|
NCT02206737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW14025|The Effects of Electronic Cigarettes on the Microcirculation of the Hand|The Effects of Electronic Cigarettes on the Microcirculation of the Hand||Chelsea and Westminster NHS Foundation Trust|Yes|Recruiting|July 2014|||September 2014|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206737||39428|
NCT02206152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 22498|A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes|A Randomized Double Blinded Study to Examine the Use of N-Acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes|NAC for HAAF|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|May 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206152||39473|
NCT02206165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144HT13021|A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension|A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension||Chong Kun Dang Pharmaceutical||Recruiting|March 2014|June 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|456|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02206165||39472|
NCT02206464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140160|H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...|VRC 315: A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boost||National Institutes of Health Clinical Center (CC)||Completed|July 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206464||39449|
NCT02207205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-006|Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture|A Study to Determine Variability in the Measurement of Whole Blood Clotting Time (WBCT) Between Blood Drawn From Indwelling Catheters and Direct Venipuncture||Perosphere, Inc.|No|Completed|April 2014|June 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02207205||39392|
NCT02206958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112S07944|Defeating Urinary Incontinence With Exercise Training (DUET) Feasibility Study|Preventing Toileting Disability in Frail Older Women|DUET|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|53|||Female|60 Years|N/A|No|||June 2015|June 11, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206958||39411|
NCT02206971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203M11223|Biomarker Feedback for Smoking Cessation|Biomarker Feedback for Smoking Cessation||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|May 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206971||39410|
NCT02207426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TobrAir - CT0040|Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™|A Phase 1 Study in Healthy Volunteers Investigating the Delivery of Tobramycin Using the TobrAir® 6.0 Device Compared With the Delivery of Marketed Tobramycin Nebuliser Solution (TOBI®) by PARI LC® PLUS and PARI TurboBoy® SX and With Delivery of Tobramycin by the TOBI® Podhaler™ Device, Using Pharmacokinetic and Pharmacoscintigraphic Methods.||Pharmaero ApS|No|Active, not recruiting|July 2014|September 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207426||39375|
NCT02207751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18109|Improving Outcomes in Peritoneal Dialysis|Improving Outcomes in Peritoneal Dialysis: Identification and Characterization of Optimal Clinical Practice to Enhance Peritoneal Dialysis Catheter Functionality, Minimize Access-related Complications and Promote Peritoneal Dialysis as an Initiating Therapeutic Modality for Chronic Kidney Disease.||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Not yet recruiting|September 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3861|||Both|16 Years|N/A|No|Non-Probability Sample|All incident patients requiring peritoneal dialysis for end stage renal disease of all        etiologies.|July 2014|July 31, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02207751||39350|
NCT02208063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112|A Phase 3 Telavancin Staphylococcus Aureus Bacteremia Trial|A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including SA Right-sided Infective Endocarditis||Theravance Biopharma Antibiotics, Inc.|Yes|Recruiting|December 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208063||39326|
NCT02208349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LECOM Research Grant 2013|King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial|King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial||Saint Vincent Hospital, Pennsylvania|Yes|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02208349||39304|
NCT02208362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13384|Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma|Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma||City of Hope Medical Center|Yes|Recruiting|May 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|August 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02208362||39303|
NCT02208635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1126|Absorption of Zinc (Zn) From Zn-biofortified and Zn-fortified Maize in Young Zambian Children Between 24-36 Months|Absorption of Zinc (Zn) From Zn-biofortified and Zn-fortified Maize in Young Zambian Children Between 24-36 Months|HPZM|University of Colorado, Denver|No|Completed|October 2012|December 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|24 Months|36 Months|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208635||39282|
NCT02208882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV004-006|Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120|Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of BMS-986120 in Healthy Subjects and the Effect of BMS-986120 on the Pharmacokinetics of Midazolam in Healthy Subjects||Bristol-Myers Squibb|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02208882||39263|
NCT02211820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140164|PET Imaging in Chronic Traumatic Encephalopathy|PET Imaging in Chronic Traumatic Encephalopathy||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211820||39038|
NCT02211833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.5|Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer|A Phase I Open-label Dose Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer||Boehringer Ingelheim||Completed|October 2006|||February 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211833||39037|
NCT02211846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-202|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder|A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)||Astellas Pharma Inc|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|5 Years|17 Years|No|||October 2015|October 2, 2015|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211846||39036|
NCT02211859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.2|Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|August 2004|||December 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211859||39035|
NCT02211872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.1|BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit|An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|August 2004|||March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211872||39034|
NCT02211534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI.2014.002|Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty|A Randomized, Sham-Controlled Pilot Study of Pulsed Electromagnetic Field Therapy in the Treatment of Persistent Post-Operative Pain Following Total Knee Arthroplasty||Regenesis Biomedical, Inc.|No|Active, not recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211534||39060|
NCT02211794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11009-7|Journey II BCS EU Observational Trial|A Prospective, Non-randomized, Consecutive Series, Multicenter, Observational Trial to Evaluate the Clinical Outcome of Total Knee Arthroplasty Using Journey II BCS Total Knee System||Smith & Nephew, Inc.|No|Enrolling by invitation|January 2014|June 2025|Anticipated|June 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|167|||Both|18 Years|75 Years|No|Non-Probability Sample|a patient population consisting of 150 cases and recruited from 4 different countries,        will be followed up when undergoing TKA as part of their standard care|March 2015|March 27, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02211794||39040|
NCT02211807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-960|Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens|The Risk of Suicidality and Suicide Attempt Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens||Bristol-Myers Squibb|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|11400|||Both|12 Years|N/A|No|Probability Sample|Patients in a commercial insurance database and a Medicaid database|October 2014|October 14, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02211807||39039|
NCT02216656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-005|Phase 2 Study of KHK7580|A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis||Kyowa Hakko Kirin Company, Limited|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|201|||Both|20 Years|74 Years|No|||March 2015|March 3, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02216656||38669|
NCT02216669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2014|Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer|Phase I Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer||Maastricht Radiation Oncology|Yes|Not yet recruiting|May 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02216669||38668|
NCT02218294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4161-103|Study to Determine How BCX4161 is Metabolized and Eliminated by the Body|A Phase 1 Study to Evaluate the Absorption, Metabolism and Excretion of BCX4161 Following Administration of a Single, Oral Dose of [14C]-Radiolabelled BCX4161 to Healthy Male Subjects||BioCryst Pharmaceuticals|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|August 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02218294||38543|
NCT02218307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110846|The Use of Antibiotic Sinonasal Rinse After Sinus Surgery|The Use of Antibiotic Sinonasal Rinse After Sinus Surgery: A Randomized Double-Blind Control Trial||University of Miami|No|Completed|November 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02218307||38542|
NCT02206477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005-13-RMC|DMSO for Prevention of Capsular Contraction in Alloplastic Breast Reconstruction|||Rabin Medical Center|Yes|Not yet recruiting|August 2014|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||July 2014|July 31, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206477||39448|
NCT02206984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILC|Endocrine Response in Women With Invasive Lobular Breast Cancer|A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer||University of Pittsburgh|Yes|Recruiting|August 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|N/A|N/A|No|||September 2015|September 21, 2015|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206984||39409|
NCT02206997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THER-GUIDE-EVA|Evaluation of a Patient Warming Concept Following the German S3 Guideline for Prevention of Intraoperative Hypothermia|Evaluation of a Patient Warming Concept Following the New German Speaking S3 Guideline for Prevention of Intraoperative Hypothermia With Respect to Incidence and Complications of Perioperative Hypothermia||University of Schleswig-Holstein|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|485|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of FEK Hospital Neumünster scheduled for elective surgery under defined        conditions (see below)|December 2015|December 5, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206997||39408|
NCT02207218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-4105|To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan|A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight® (rFVIII) During Long-Term Treatment of Haemophilia A in Japan||Novo Nordisk A/S|No|Recruiting|August 2014|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|N/A|N/A|No|Non-Probability Sample|NovoEight® in prevention, treatment of bleeds and prevention of bleeds during and after        surgery in previously treated patients (PTPs) and previously untreated patients (PUPs)        with haemophilia A in routine clinical setting in Japan.|December 2015|January 22, 2016|August 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207218||39391|
NCT02207452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111175|Helium-3 MRI Imaging Study in COPD|A Randomized, Methodology Study to Investigate the Use of 3He-MRI Lung Ventilation and Proton MRI Perfusion Imaging to Detect Changes in Ventilation Perfusion Relationships in Chronic Obstructive Pulmonary Disease (COPD) Patients; a Proof of Concept Study.||GlaxoSmithKline||Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|11|||Both|50 Years|N/A|No|||September 2014|September 4, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT02207452||39373|
NCT02207764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1358|Reiki as a Complementary Therapy: A Pilot Study|Reiki as a Complementary Therapy: A Pilot Study||Sidney Kimmel Comprehensive Cancer Center|Yes|Withdrawn|September 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||July 2014|December 19, 2014|July 29, 2014||No|competing priorities at the organization|No||https://clinicaltrials.gov/show/NCT02207764||39349|
NCT02208076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-537|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia|Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Columbia|ECOS COL|Merck KGaA|No|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|13|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02208076||39325|
NCT02208388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-06|Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial|Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial: Ischemia-guided Revascularization Using Perfusion Coronary CT vs. Fractional Flow Reserve|PERFUSE RCT|Asan Medical Center|Yes|Recruiting|August 2014|December 2021|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|20 Years|N/A|No|||January 2016|January 4, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02208388||39301|
NCT02208895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3785|Correlation of In-lab Pleural Fluid Glucose Measurements With a Finger Stick Glucometer and Portable Point of Care Testing Device (i-STAT).|Correlation of In-lab Pleural Fluid Glucose Measurements With a Finger Stick Glucometer and Portable Point of Care Testing Device (i-STAT).||University of Oklahoma|Yes|Recruiting|July 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|50|None Retained|Pleural fluid|Both|18 Years|N/A|No|Probability Sample|Pleural effusions|August 2014|August 1, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02208895||39262|
NCT02205151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FAC-CT-101|To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets|An Open-label, Randomized, Single-dose, 2×2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|86|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||July 2014|October 13, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205151||39550|
NCT02211599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC507|Fat Burning After a Meal|Post-Prandial Substrate Utilization in Response to the Inclusion of Sweetened Beverage to Meals With Different Levels of Protein Content||USDA Grand Forks Human Nutrition Research Center|No|Recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211599||39055|
NCT02211885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.6|Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects|A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects||Boehringer Ingelheim||Completed|October 2002|||November 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211885||39033|
NCT02211898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.6|Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux|Clinical Study of BNS003 on Swelling Due to Disorder of Leg Venous Reflux||Boehringer Ingelheim||Completed|July 2004|||January 2005|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|20 Years|N/A|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02211898||39032|
NCT02210975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4834906814|An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy|An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy||Maastricht University Medical Center|Yes|Recruiting|July 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||August 2014|August 6, 2014|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210975||39103|
NCT02211274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1241-W|Improving Veteran Transitions From VA Community Living Centers to the Community|Improving Veteran Transitions From VA Community Living Centers to the Community||VA Office of Research and Development|No|Not yet recruiting|July 2016|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02211274||39080|
NCT02217761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112163RID|Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan|Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan||National Taiwan University Hospital|No|Enrolling by invitation|March 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Whole blood, serum. white cells, saliva|Both|13 Years|N/A|No|Non-Probability Sample|Patients in National Taiwan University receiving posaconazole|August 2014|August 13, 2014|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02217761||38584|
NCT02209090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AMI)182/2012|Modified Intrapartum Sims Position-related Efficiency in Correction of Persistent Foetal OP Positions|Randomised Clinical Trial: Modified Intrapartum Maternal Sims Position-related Efficiency in the Correction of Persistent Foetal Occipito-posterior Position|MSIMSFPOP|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02209090||39247|
NCT02209103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43845.068.13|The Sleep Improving Effects of Orange Phenolics|Determination of the Sleep Improving Effects of Phenolics From an Orange Peel Extract||Maastricht University Medical Center|Yes|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|77|||Both|18 Years|75 Years|No|||August 2014|November 19, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209103||39246|
NCT02209415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-41-5702|EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer|Endoscopic Ultrasound (EUS) and PET-CT Based Follow-up of Patients Radically Resected for Cancer of the Oesophagus, Stomach or Pancreas.|EUFURO|Odense University Hospital|Yes|Active, not recruiting|April 2011|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|182|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT02209415||39222|
NCT02205281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72514|Partners in Health: A Couples-based Approach to Obesity Prevention|Partners in Health: A Couples-based Approach to Obesity Prevention.|PIH|California Polytechnic State University-San Luis Obispo|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205281||39540|
NCT02205866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403-VLC-012-JB|Incidence of Non Receptive Endometrium in Obese Women|Incidence of Not Receptive Endometrium During the Window of Implantation as Body Mass Index by Testing ERA.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Recruiting|August 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|432|||Female|18 Years|45 Years|No|||March 2016|March 7, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02205866||39495|
NCT02206191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00262|The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake|The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake|PCON|Nationwide Children's Hospital|Yes|Active, not recruiting|July 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mothers of 6-11 year olds being seen in primary care offices throughout Columbus, OH.|July 2014|July 31, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02206191||39470|
NCT02206204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065-106|Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects|Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects||Actelion|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|159|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206204||39469|
NCT02206178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0202|Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine|ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE|PANACE|University Hospital, Clermont-Ferrand||Recruiting|September 2013|October 2014|Anticipated|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02206178||39471|
NCT02220075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0550|Fiberoptic Evaluation of the LMA(Laryngel Mask Airway) Position During Anesthesia With Spontaneous Respiration or Controlled Ventilation in Children|||Yonsei University|No|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|1 Month|7 Years|No|Probability Sample|Pediatric patients who are planed to get urologic surgery under general anesthesia using        LMA|August 2014|August 15, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220075||38406|
NCT02220348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-PK-01|A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically|An Open-label, Multiple-dose, Milk-only Lactation Study in Lactating Women Receiving Linaclotide Therapeutically|LIN-PK-01|Forest Laboratories|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Female|18 Years|45 Years|No|||September 2015|September 2, 2015|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220348||38385|
NCT02220361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNi|Dexmedetomidine on Prevention of Side Effects of Hemabate|Phase 4 Study of Effects of Dexmedetomidine on Prevention of Side Effects of Hemabate in Cesarean Section Patients||Guangzhou Women and Children's Medical Center|Yes|Enrolling by invitation|September 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 28, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220361||38384|
NCT02220608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412026|Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma|A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma||Washington University School of Medicine|No|Recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220608||38365|
NCT02190617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1307-05498|Guidelines to Practice: Reducing Asthma Health Disparities Through Guideline Implementation||G2P|Public Health - Seattle and King County|Yes|Enrolling by invitation|December 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|550|||Both|5 Years|75 Years|No|||July 2014|May 8, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190617||40664|
NCT02221440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYH001|Maternal Oxygen Administration for Fetal Distress|Prophylactic Maternal Low Flow Nasal Oxygen Administration During the Second Stage of Labor for Fetal Distress||Navy General Hospital, Beijing|Yes|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|443|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02221440||38301|
NCT02222324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-004|A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects|A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, 4-Treatment Crossover Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects||Eisai Inc.|No|Completed|August 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222324||38233|
NCT02221986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140108|Interdisciplinary Specialised Rehabilitation Among Glioma Patients|The Effect of a Six Weeks Interdisciplinary Rehabilitation in Terms of HRQoL, Physical Performance and Symptom Burden Among Glioma Patients - a Prospective RCT Study.||Odense University Hospital||Recruiting|September 2014|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221986||38259|
NCT02222272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT-42201038|Effect of 2nd Gen TKI in CML|Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia||European Group for Blood and Marrow Transplantation|No|Active, not recruiting|January 2010|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|432|||Both|18 Years|N/A|No|Probability Sample|eligible patients from EBMT centres|August 2014|August 20, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222272||38237|
NCT02222285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS_005|An Exploratory, Double-Blind, Placebo-Controlled Study of PS_005 in Children With Autism Spectrum Disorder (ASD)|An Exploratory, Double-Blind, Placebo-Controlled Study of PS_005 in Children With Autism Spectrum Disorder (ASD)||Enzymotec|No|Recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|51|||Both|6 Years|13 Years|No|||October 2015|October 15, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02222285||38236|
NCT02222610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29236|Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.|A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).|RRR|Greater Houston Retina Research|No|Recruiting|August 2014|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02222610||38211|
NCT02222623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1623|The Inova Type 2 Diabetes Mellitus Study|Insulin Glargine vs NPH as Basal Insulin on Glycemic Values in Hospitalized Patients: The Inova Diabetes Study|InovaDM2|Inova Health Care Services|No|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|75 Years|No|||March 2015|March 25, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222623||38210|
NCT02218593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|579772-2|WREX Outcome Study|WREX Outcome Study||Nemours Children's Clinic|No|Enrolling by invitation|July 2014|July 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|1||Actual|42|||Both|2 Years|21 Years|No|||August 2014|August 14, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02218593||38520|
NCT02218606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-046|Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer|An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|August 2014|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Male|18 Years|N/A|No|||October 2015|October 9, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218606||38519|
NCT02199366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1419-BR02|Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy|Prospective Pilot Study of Early Markers of Radiation-Induced Cardiac Injury in Patients With Left-Sided Breast Cancer Receiving Photon or Proton Therapy||University of Florida|No|Recruiting|September 2014|July 2020|Anticipated|January 2017|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|No|Non-Probability Sample|Radiation oncology clinic|March 2016|March 2, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199366||39993|
NCT02199613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00490|Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy|Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir in Treatment-experienced Patients: Quality Control Monitoring of a Treatment Simplification Strategy|QuaDar|University of British Columbia|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||May 2015|May 27, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199613||39974|
NCT02191150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130300|Study of Haemodialysis Patients Switching From Aranesp to Biosimilar|Retrospective Study of Stable Haemodialysis Patients Switched From Darbepoetin Alfa to Epoetin Alfa Biosimilar|SHADE|Amgen|No|Completed|June 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|272|||Both|18 Years|N/A|No|Probability Sample|The study population comprises prevalent haemodialysis (HD) patients treated at EU and        Australian dialysis clinics after September 2008. Eligible patients will have received        treatment with darbepoetin alfa for at least 26 weeks prior to being converted to an        EMA/TGA-approved epoetin alfa biosimilar. At each participating study site, all        potentially eligible patients are to be considered for enrolment.|February 2016|February 5, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02191150||40623|
NCT02200159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0197|Predictive Factors of Failure or Success of Sedation With Dexmedetomidine in ICU|Predictive Factors of Failure or Success of Sedation With Dexmedetomidine in ICU||University Hospital, Clermont-Ferrand||Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients ventilated requiring sedation in ICU with RASS objective more than -2|November 2014|November 25, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02200159||39933|
NCT02200172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI-MELAT-2013|The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study|The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial||Bruyere Research Institute|Yes|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200172||39932|
NCT02189018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00059151|Activity To Improve Outcomes in Peripheral Arterial Disease|Activity To Improve Outcomes in Peripheral Arterial Disease|ACTION|Baltimore VA Medical Center|Yes|Not yet recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|21 Years|90 Years|No|||July 2014|July 11, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189018||40787|
NCT02189915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53737|Open-Label Creatine Study for Female Meth Users|Open-Label Creatine Monohydrate Supplementation in Depressed Female Methamphetamine Users||University of Utah|No|Terminated|January 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|13 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|July 11, 2014|No|Yes|Received funding for the next phase of the study|No||https://clinicaltrials.gov/show/NCT02189915||40718|
NCT02220374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/YH/1040|A RCT of Supportive Finger Tape for PIPJ Osteoarthritis|Supportive Tape for Arthritis of the Proximal Interphalangeal Joint: A Two Group Parallel Randomised Placebo Controlled Trial||Mid Yorkshire Hospitals NHS Trust|No|Recruiting|November 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02220374||38383|
NCT02220907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-2412-J01|Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes|Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||September 2015|September 15, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02220907||38342|
NCT02220582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAHHM|Canadian Alliance for Healthy Hearts and Minds|A Pan-Canadian, Multi-ethnic Cohort Study in Healthy Participants Aimed to Better Understand the Impact of Individual, Socioeconomic and Other Environmental Factors Leading to Cardiac and Vascular Disease||Montreal Heart Institute|No|Recruiting|November 2013|May 2018|Anticipated|May 2017|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9700|Samples With DNA|The study will precisely phenotype individuals with respect to cardiac, vascular and      cognitive dysfunction and to identify novel targets for indicators of early disease.|Both|35 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants of Canadian Partnership for Tomorrow Project (CPTP) cohorts (BC Generations,        Alberta Tomorrow Project, Ontario Health Study, CARTaGENE, Atlantic PATH) or non--CPTP        cohorts (Montreal Heart Institute Biobank or the Prospective Urban-Rural Epidemiology,        PURE study, or aboriginal cohort participants).        Multi-ethnic participants including reserve-based Aboriginal peoples.|December 2015|December 10, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220582||38367|
NCT02220595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H - 22797|A Comparison of Cognitive Function After Carotid Endarterectomy and Stenting|A Comparison of Cognitive Function After Carotid Endarterectomy and Stenting||Baylor College of Medicine|No|Completed|April 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|90 Years|No|||August 2014|August 18, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02220595||38366|
NCT02221453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PersDMEcytokineTA|Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide|Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study||St. Michael's Hospital, Toronto|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221453||38300|
NCT02221687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505564 - PEC10561|The Combiotic-Study|Evaluation of the Efficacy and Safety of an Infant Formula Containing Synbiotics and Its Effects on the Incidence of Infectious Diseases in the Infant Gut : a Double-blind, Randomized, Controlled Interventional Study|GOLFIII|HiPP GmbH & Co. Vertrieb KG|No|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|560|||Both|N/A|5 Weeks|Accepts Healthy Volunteers|||August 2014|March 2, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221687||38282|
NCT02221700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0250|Massage for Chemotherapy Induced Peripheral Neuropathy (CIPN)|A Pilot Study of Massage for Symptom Reduction in Oxaliplatin Induced Peripheral Neuropathy||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221700||38281|
NCT02222038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KISPI-UZH-LLS-2014|Genetic Variants in Linear Localized Scleroderma|Investigation of the Genetic Architecture of Linear Localized Scleroderma (LLS) (Linear Morphea) by Whole Exome Sequencing. A Tailored Approach to Test the Hypothesis That LLS is a Genetic Mosaic Condition||University Children's Hospital, Zurich|No|Recruiting|August 2014|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|5 Years|N/A|No|||January 2016|February 4, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02222038||38255|
NCT02222298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|framar|Video Assisted Ablation of Pilonidal Sinus Versus Conventional Treatment|Video Assisted Ablation of Pilonidal Sinus Versus Convention Off-midline Bas Com Cleft Lift Procedure||Federico II University||Completed|April 2012|||November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|65 Years|No|||November 2015|November 2, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222298||38235|
NCT02222311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0038-14-HYMC|Influence of Vitamin D Deficiency on the Development of Autism|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|November 2014|April 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Children with autism who have presented to the Child Development Institute at the Hillel        Yaffe Medical Center and from pediatric neurology community clinics. The control groups        include healthy age-matched children and children with Attention Deficit Disorder (ADD)        who have presented to the Child Development Institute at the Hillel Yaffe Medical Center        and from pediatric neurology community clinics.|August 2014|August 20, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02222311||38234|
NCT02218359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-01-103|Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization|A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-positive Bacterial Colonization||Cardeas Pharma|No|Withdrawn|October 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|August 14, 2014|Yes|Yes|No Participants Enrolled|No||https://clinicaltrials.gov/show/NCT02218359||38538|
NCT02218372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-CL-0202|A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects With Clostridium Difficile-associated Diarrhea|SUNSHINE|Astellas Pharma Inc|Yes|Recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|N/A|17 Years|No|||February 2016|February 5, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218372||38537|
NCT02218619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN2402|Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes|Clinical Investigation of Efficacy of Tauroursodeoxycholic Acid (TUDCA) to Enhance Pancreatic Beta Cell Survival In Type 1 Diabetes by Reducing Endoplasmic Reticulum Stress||Columbia University|Yes|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|No|||October 2015|October 2, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218619||38518|
NCT02218866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAR-UofU|The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration|The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration|BAR|University of Utah|No|Recruiting|January 2012|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|205|Samples With DNA|DNA, serum, tissue|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited through bariatric surgery clinics in the local area.|November 2015|November 30, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02218866||38499|
NCT02190630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReDA Ref: 009038|Study to Measure the Effect of Part Time Versus Full Time Orthodontic Appliance Wear|A Prospective Randomised Controlled Trial Investigating the Skeletal and Dental Effects of a Removable Brace That Works on the Upper and Lower Teeth at the Same Time Worn Part Time Versus Full Time||Queen Mary University of London|Yes|Recruiting|December 2013|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|84|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190630||40663|
NCT02191163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.3|Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency|A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency||Boehringer Ingelheim||Completed|April 2002|||August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191163||40622|
NCT02190903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818017|A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia|A Randomized Controlled Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia||University of Pennsylvania|Yes|Completed|October 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02190903||40642|
NCT02191839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR 133-13 ctil|Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery|Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury and Post Operative Bleeding in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Double-blind, Placebo-controlled Pilot Study||Soroka University Medical Center|Yes|Not yet recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|70 Years|No|||July 2014|July 15, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02191839||40570|
NCT02191527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF-004|Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique|Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services and Their Impact on Mother and Child Health Outcomes in Cabo Delgado Province, Mozambique||Elizabeth Glaser Pediatric AIDS Foundation|No|Completed|September 2013|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Female|18 Years|N/A|No|||October 2014|October 15, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02191527||40594|
NCT02191540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-MPE-2010|Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients|A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions||Abnoba Korea|No|Completed|January 2011|May 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|20 Years|80 Years|No|||July 2014|July 21, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191540||40593|
NCT02189031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11061-H39|Sensory Feedback for Touch and Proprioception With Prosthetic Limbs|Sensory Feedback Tactor Systems for Implementation of Physiologically Relevant Cutaneous Touch and Proprioception With Prosthetic Limbs||Louis Stokes VA Medical Center|No|Enrolling by invitation|February 2013|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Amputees who have undergone targeted sensory reinnervation|March 2016|March 17, 2016|July 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189031||40786|
NCT02220101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1A|Temperature Measurement in Surgical and Intensive Care Patients - Comparison of Four Measurement Methods|Temperature Measurement in Surgical and Intensive Care Patients - Comparison of Four Measurement Methods|Temp|Sykehuset i Vestfold HF|No|Recruiting|April 2014|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Laparoscopic surgery and in ICU patients|August 2014|August 18, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02220101||38404|
NCT02220114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGO-VGB-III-01|Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy|Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study|SoluWest|Targeon SAS|Yes|Recruiting|May 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Month|6 Years|No|||August 2015|August 25, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220114||38403|
NCT02219815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREHAB|Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.|Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.|PREHAB|St. Boniface General Hospital Research Centre|Yes|Recruiting|April 2015|May 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|244|||Both|60 Years|N/A|No|||December 2015|December 18, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02219815||38426|
NCT02220621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNL-2011-03|Efficacy and Safety of Crosslinked Hyaluronan Gel for Preventing Intrauterine Adhesion|A Prospective, Multi-center, Randomized, Controlled Clinical Study on Self-crosslinked Sodium Hyaluronate Gel for Prevention of Intrauterine Adhesion||BioRegen Biomedical (CHangzhou) Co., Ltd||Completed|October 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|20 Years|40 Years|No|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220621||38364|
NCT02220920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-11|Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|20 Years|N/A|No|||December 2015|December 20, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02220920||38341|
NCT02220946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVESFDS|Effect of Vaginal Electrical Stimulation on Female Sexual Dysfunction||EVESOFS|Kanuni Sultan Suleyman Training and Research Hospital|No|Active, not recruiting|January 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|80 Years|No|||August 2014|August 19, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02220946||38339|
NCT02221180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104980|Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (150 mg/500 mg) With Respect to the Metformin IR Tablet (Locally Sourced From Canada [Glucophage, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg and 1 x 100 mg) in Healthy Fed and Fasted Subjects||Janssen Research & Development, LLC|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221180||38321|
NCT02222012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sha-04-14|Neuromarkers Identification in Major Depressive Disorder Based on Monitoring Measures|Identification of Neuromarkers in Novel Neuromodulation Treatment in Major Depressive Disorder Based on Integration of Multiple Monitoring Measures||Shalvata Mental Health Center|Yes|Not yet recruiting|August 2014|September 2017|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02222012||38257|
NCT02218411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU UCH|Video-supported Group-based Otago Exercise Programme on Physical Performance in Older Adults.|Effectiveness of a Video-supported Group-based Otago Exercise Programme on Physical Performance in Community-dwelling Older Adults: a Pilot Randomized Controlled Trial||Cardenal Herrera University|Yes|Completed|September 2012|January 2013|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|55|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 14, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218411||38534|
NCT02218697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117276|Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older||GlaxoSmithKline||Completed|October 2014|May 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|357|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 14, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218697||38512|
NCT02218385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCP003|ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid|A Single-arm, Multi-laboratory Clinical Trial of the ForeCYTE Breast Aspirator for Sample Collection, Processing and Cytological Testing of Nipple Aspirate Fluid||Atossa Genetics, Inc.|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|52|||Female|20 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02218385||38536|
NCT02218632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12020|Glycosylation in Patients With Galactosaemia|Galactosaemia, a Modifiable Multi-system Glycosylation Disorder?||Children's University Hospital, Ireland|No|Completed|July 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|5 Years|40 Years|No|||August 2014|August 14, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02218632||38517|
NCT02218645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.508|Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) Taken With Water in Healthy Adult Males|The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis), Both Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)||Boehringer Ingelheim||Completed|August 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|August 15, 2014||||No||https://clinicaltrials.gov/show/NCT02218645||38516|
NCT02218879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013581|Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS|Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis||Yale University|No|Recruiting|August 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with a relapsing form of MS|April 2014|August 14, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02218879||38498|
NCT02219126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILK|Effect of Homogenization and Pasteurization of Milk on the Stomach Problems in Adults|Effect of Homogenization and Pasteurization of Milk on the Stomach Problems in Adults||University of Turku|No|Recruiting|August 2014|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|7|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219126||38479|
NCT02219139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 03/10 ESTA|A Comparative, Randomized, Prospective, Performance Evaluation of Abutments in Single Tooth Gaps|A Comparative, Randomized, Prospective, Clinical Pilot Study to Evaluate the Performance of Modified Study Abutments in Single Tooth Gaps||Institut Straumann AG|No|Withdrawn|December 2012|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|July 17, 2014||No|No patients could be recruited|No||https://clinicaltrials.gov/show/NCT02219139||38478|
NCT02191176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1134.3|Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects|A Phase I Multiple Dose Trial to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of 30 mg q.i.d. and 90 mg q.i.d. Dextromethorphan Hydrobromide Monohydrate (2 mg/mL Syrup) in Healthy Male and Female Subjects for 2 Days Followed by a Morning Dose (Extensive Metabolisers of CYP 2D6) and for 10 Days Followed by a Morning Dose (Poor Metabolisers of CYP 2D6) (Randomised, Double-blind, Placebo-controlled Groups)||Boehringer Ingelheim||Completed|June 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191176||40621|
NCT02191189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1484|Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males|A Single-dose, 2-part, Open-label, Randomised, Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract||Boehringer Ingelheim||Completed|May 2005|||January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|27|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191189||40620|
NCT02191553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/0129|Differential Effect of Four Mindfulness Exercises|Differential Effect of Four Mindfulness Exercises on Mindfulness, Cerebral Cartography and Heart Ratio Variability||Grupo de Investigación en salud mental en Atención Primaria|No|Active, not recruiting|September 2014|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02191553||40592|
NCT02191566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA01 Version 1.0 (KBC14078)|S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy|A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection|SOHUG|Kangbuk Samsung Hospital|No|Recruiting|November 2014|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|No|||February 2016|February 22, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02191566||40591|
NCT02191579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-US-NEU-0206|Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults|||Allergan|No|Recruiting|August 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191579||40590|
NCT02191852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1135.4|Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers|A Pharmacokinetic Study on the Antioxidant Activity of Seresis® in the Skin: an Open, Uncontrolled, Non-randomized Intra-individual Pilot Trial in Healthy, Young Female Volunteers||Boehringer Ingelheim||Completed|June 1999|||October 1999|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191852||40569|
NCT02192112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.NV1301|Advanced XLIF Monitoring Pilot Study|Evaluation of Transcutaneous Stimulation of Lumbosacral Nerve Roots: A Pilot Study||NuVasive|No|Enrolling by invitation|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|At least 20 subjects will be consecutively enrolled in this prospective pilot study from        up to three (3) participating centers. Patients who, in the surgeon investigator's        opinion, require lateral approach spinal fusion surgery at spinal level L4-5 (though may        include any number of levels from L2 through L5), and have consented to XLIF surgery for        their condition will be included. The following eligibility criteria are designed to        identify existing clinic patients for whom study under this protocol is considered        appropriate. All subjects must meet the inclusion/exclusion criteria below in order to be        considered for enrollment.|April 2015|April 29, 2015|July 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02192112||40549|
NCT02191865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.200|Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers|Pharmacokinetics, Safety and Tolerability of Nintedanib Single Oral Dose in Male and Female Patients With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) as Compared With Nintedanib Administration to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)||Boehringer Ingelheim||Completed|July 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|July 14, 2014||||No|December 21, 2015|https://clinicaltrials.gov/show/NCT02191865||40568|
NCT02219594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W201310|The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent|The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent||Xuzhou Central Hospital|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|20 Years|80 Years|No|||August 2014|August 18, 2014|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02219594||38443|
NCT02219607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colorectal 1|Liver Enzymes and Fluid Balance Following Colorectal Surgery|||Attikon Hospital|No|Recruiting|January 2014|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|patients undergoing colorectal surgery|August 2014|August 16, 2014|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219607||38442|
NCT02220660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1256.2|Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|A Single-blind, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|March 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02220660||38361|
NCT02220673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1256.13|Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)|Serial Lung Function Measurements in 12 Healthy and 48 Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT, 0.1% and 0.5%) Administered With the Respimat® B (RMT-B) vs. Corresponding RMT-B and HFA MDI Without BHT; Repeated Increasing Doses With 2, 4, and 6 Actuations of Low Concentration Prior to High Concentration on Separate Days, Double Blind for RMT-B Use, Randomised 4-way Cross-over Design||Boehringer Ingelheim||Completed|November 2009|||May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02220673||38360|
NCT02220088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC201408|The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial|The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial||Sun Yat-sen University|Yes|Recruiting|August 2014|January 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|262|||Both|18 Years|70 Years|No|||August 2014|August 18, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220088||38405|
NCT02220647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.3|Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)||Boehringer Ingelheim||Completed|January 2010|||April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02220647||38362|
NCT02220933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD1003CT2013-02MS-SPI|Effect of MD1003 in Spinal Progressive Multiple Sclerosis|Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study|MS-SPI|Medday SAS|Yes|Active, not recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||August 2014|April 6, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220933||38340|
NCT02221206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF81371167|Volumetric Analysis of Root Resorption With Mini-Screw Implant Anchorage-assisted Retraction of Maxillary Incisors|Clinical Observation for the Root Resorption With Mini-Screw Implant Anchorage-assisted Retraction of Maxillary Incisors||Zhejiang University|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|25 Years|No|||September 2014|September 17, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221206||38319|
NCT02221193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0568677142|Comparing Site Specific Mouth Disinfection With Commercial Oral Mouth Rinse With Traditional Oral Maouth Disinfection|Site-Specific Mouth Rinsing to Improve Oral Odor by Altering Bacterial Counts: Blind Crossover Clinical Study||Al-Baha University|No|Completed|July 2013|September 2013|Actual|August 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|20|||Male|17 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221193||38320|
NCT02222337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-13-5635|Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers|Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers||Georgetown University|Yes|Active, not recruiting|May 2013|October 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|272|||Both|N/A|85 Years|No|||March 2016|March 24, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222337||38232|
NCT02218398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCYRT-002|Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients|Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients, a Randomized Controlled Trial||Beijing Chao Yang Hospital|Yes|Recruiting|May 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|No|||August 2014|August 15, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02218398||38535|
NCT02218658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.507|Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males|The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) Taken Without Water and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis) Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)||Boehringer Ingelheim||Completed|July 2000|||August 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|August 15, 2014||||No||https://clinicaltrials.gov/show/NCT02218658||38515|
NCT02218671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.506|Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers|Clinical Pharmacological Study on Absorption From Mucous Membrane of Oral Cavity of WE 941 OD Tablets||Boehringer Ingelheim||Completed|March 2000|||March 2000|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||10|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 15, 2014|August 15, 2014||||No||https://clinicaltrials.gov/show/NCT02218671||38514|
NCT02218684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173.1|Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects|Tolerability and Pharmacokinetics of 80 mg Telmisartan in Combination With 2, 4, or 6 mg Lacidipine. An Open, Single Rising Dose Group Comparison Trial - Placebo Randomised Double Blind in Each Dose Group - in Male Healthy Subjects||Boehringer Ingelheim||Completed|September 1998|||November 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|27|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|August 15, 2014|August 15, 2014||||No||https://clinicaltrials.gov/show/NCT02218684||38513|
NCT02218892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2089-31/2|Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis|Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis||Folktandvården Stockholms län AB|No|Recruiting|February 2011|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|whole blood, serum,saliva|Both|7 Years|14 Years|No|Non-Probability Sample|One-hundred consecutive patients with active JIA, as diagnosed by the Department of        Pediatric Rheumatology, Astrid Lindgrens Barnsjukhus, Karolinska University Hospital will        be included.|August 2014|August 15, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02218892||38497|
NCT02190929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5534|Educational Needs of Patients With Systemic Vasculitis|Educational Needs of Patients With Systemic Vasculitis- an International Survey||University of South Florida|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|386|||Both|18 Years|N/A|No|Non-Probability Sample|Patients were recruited from within the Vasculitis Clinical Research Consortium (VCRC)        Patient Contact Registry to participate in an online questionnaire. More than 3000        patients, representing all the different types of idiopathic vasculitis, are currently        enrolled into the on-line registry. The different types of vasculitis available for study        include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis,        granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura,        Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.|June 2014|July 11, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02190929|1 Year|40640|
NCT02191202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1461|Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression|Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV||Boehringer Ingelheim||Completed|June 2004|||February 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|283|||Both|N/A|N/A|No|Non-Probability Sample|Hospital physicians, specialized in treatment of patients infected by the HIV|July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191202||40619|
NCT02191215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1457|Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS|Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS||Boehringer Ingelheim||Completed|June 2003|||May 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|442|||Both|N/A|N/A|No|Non-Probability Sample|Mexican patients infected by HIV/AIDS|July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191215||40618|
NCT02191228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.26|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple 5 mg Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group, Phase I Trial||Boehringer Ingelheim||Completed|April 2008|||February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|51|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191228||40617|
NCT02191592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407024|EMA-Defined Tinnitus Subgroups|Identification of Unique Tinnitus Subgroups Using Ecological Momentary Assessment (EMA).||Washington University School of Medicine|No|Completed|July 2014|February 2016|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|21 Years|80 Years|No|Non-Probability Sample|Subjects will be recruited from Otolaryngology Clinics and from Tinnitus Support Groups|March 2016|March 1, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191592|6 Weeks|40589|
NCT02187744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3271004|A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)|A Randomized, Double-Blind Pharmacokinetic Study Of PF-05280014 Plus Taxotere (Registered) And Carboplatin Versus Herceptin (Registered) Plus Taxotere (Registered) And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable HER2-Positive Breast Cancer||Pfizer|Yes|Active, not recruiting|September 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|June 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02187744||40885|
NCT02219620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-953118|Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care|Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care|MiM|George Mason University|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||March 2015|March 9, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02219620||38441|
NCT02220413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00018603|Predictors of Lactogenesis II|Predictors and Moderators of Delayed Lactogenesis II and Duration of Breastfeeding||University of South Florida|No|Recruiting|August 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|186|||Female|18 Years|50 Years|No|Non-Probability Sample|We plan to prospectively enroll 186 pregnant women into a protocol to examine factors        associated with delayed lactogenesis. Ninety-three women will have a BMI of 30 or higher        at the time of delivery and the other 93 women will have a BMI ≤ 29 at the time of        delivery.|July 2015|July 27, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220413||38380|
NCT02220699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEA-RN-2014-1|Screening for Osteoporosis in General Practice|Screening for Osteoporosis in General Practice. Identifying Patients With Osteoporosis in General Practice by Using the Program Data Capture||Aalborg University|No|Enrolling by invitation|January 2014|January 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|367|||Both|25 Years|N/A|No|Non-Probability Sample|Patients at list at the participating general pracitices who are identified to be at an        increased risk of osteoporosis by the data capture program are invited to participate (by        direct contact, mail or e-mail)|August 2014|August 19, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02220699||38358|
NCT02220725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-504|A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban|A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha||Portola Pharmaceuticals|Yes|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|79|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220725||38356|
NCT02220387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01201463369/1|Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures|Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures||Novosibirsk City Hospital #2|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|352|Samples With DNA|whole blood, serum,bronchoalveolar lavage fluid|Male|40 Years|75 Years|No|Probability Sample|Residents of a certain town (Novosibirsk, Russian Federation)|October 2015|October 5, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02220387||38382|
NCT02221219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD070792|Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury|Indomethacin and Delayed Umbilical Cord Clamp for Preterm Infant IVH||University of Kentucky|Yes|Recruiting|August 2014|||December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|400|||Both|24 Weeks|30 Weeks|No|||August 2014|August 19, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221219||38318|
NCT02221479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT13710|Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma|A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Multiple Myeloma||Sanofi|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|75 Years|No|||August 2015|August 3, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221479||38298|
NCT02221492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12781|Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma|A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma||Sanofi|No|Active, not recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|75 Years|No|||March 2016|March 16, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221492||38297|
NCT02221466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOPAT-1-HBO-MH-2014|Measurement of Endothelial Function With Peripheral Arterial Tonometry in Patients Undergoing Hyperbaric Oxygen Therapy|Measurements of Endothelial Function by Means of Peripheral Arterial Tonometry in Diabetic Foot Ulcer Patients Undergoing Hyperbaric Oxygen Therapy.||Rigshospitalet, Denmark|No|Recruiting|February 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|Samples With DNA|Whole blood and serum.|Both|18 Years|N/A|No|Probability Sample|Diabetic and none diabetic patients admitted for HBOT.|July 2015|July 3, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221466||38299|
NCT02221713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS 163084|The Gut Microbiome in Diverticulitis and Diverticulosis|Assessment of the Gut Microbiome in Diverticulitis and Diverticulosis||King's College Hospital NHS Trust|No|Not yet recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||4|Anticipated|100|Samples With DNA|stool samples and rectal swabs of stool|Both|18 Years|90 Years|No|Non-Probability Sample|Groups A and B. Patients with acute diverticulitis will be recruited from A&E at King's        College Hospital. If they agree to participate, we will request either a stool sample to        be produced, or, if that is not feasible, then a member of the study team will procure a        rectal swab.        Those patients with Hinchey III or IV's specimens will be assessed in Group A, while those        patients with Hinchey I or II will be assessed in Group B.        Groups C and D. Patients referred through the Two Week Wait (2ww) Colorectal Cancer        pathway who are both at low risk for colorectal cancer and have low levels of anxiety,        both as assessed by a physician outside the study team will be approached to participate.        These patients will be able to produce the stool sample prior to presenting for flexible        sigmoidoscopy as a part of their workup.|September 2015|September 10, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221713||38280|
NCT02222025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-232|Injury Prevention in Children´s Football|Injury Prevention in Children´s Football (FIFA 11+ Kids): a Cluster-randomized Controlled Trial||University of Basel||Enrolling by invitation|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02222025||38256|
NCT02190708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002308-8302860|Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole|A Phase I, Open Label Study to Assess the Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole in Healthy Male Subjects||Probiodrug AG|No|Completed|June 2014|August 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|October 19, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02190708||40657|
NCT02190721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM02-ONC-201|A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement|A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement||Teva Pharmaceutical Industries|Yes|Recruiting|May 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|1 Month|16 Years|No|||March 2016|March 2, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190721||40656|
NCT02218710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120156|Bone Structure in Patients With Adult Onset Growth Hormone Deficiency Assessed Using High Resolution Peripheral Quantitative Computed Tomography|Bone Geometry, Volumetric Density, Microarchitecture and Estimated Bone Strength Assessed by High Resolution Peripheral Quantitative Computed Tomography in Patients With Adult Onset Growth Hormone Deficiency||Odense University Hospital|No|Not yet recruiting|September 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|45|||Both|18 Years|80 Years|No|Probability Sample|Patients are all seen at the Odense University Hospital at the department of        Endocrinology. All patients at the hypophysis clinic were checked and those receiving        growth hormone replacement therapy were invited to participate.|August 2014|August 14, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02218710||38511|
NCT02218905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/311|Normative Values and Forming Regression Equations for One Minute Sit to Stand Test in Healthy Normal Indian Population|Phase 0 Study of Reference Values for One Minute Sit to Stand Test in Healthy Indian Population - a Cross Sectional Study|1minSTS|PSG Hospitals|Yes|Enrolling by invitation|August 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|196|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218905||38496|
NCT02219165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.841|Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study|Efficacy of IntraVenous ImmunoGlobulins (IVIG) in Toxic Shock Syndromes (Staphylococcal and Streptococcal): a Paediatric Pilot Study.|IVIG|Hospices Civils de Lyon|Yes|Recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|1 Month|17 Years|No|||March 2016|March 15, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02219165||38476|
NCT02219178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 13-17|Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02219178||38475|
NCT02219399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00186H|DHA Supplementation and Pregnancy Outcome|Maternal DHA Supplementation and Pregnancy Outcome||Colorado State University|No|Completed|January 2001|January 2014|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|871|||Female|18 Years|40 Years|No|||August 2014|August 15, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02219399||38458|
NCT02190916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5533|Vasculitis Illness Perception (VIP) Study|Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study)||University of South Florida|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|707|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC)        Patient Contact Registry to participate in an online questionnaire. More than 2000        patients, representing all the different types of idiopathic vasculitis, are currently        enrolled into the on-line registry. The different types of vasculitis available for study        include: granulomatosis with polyangiitis (Wegener's granulomatosis), microscopic        polyangiitis, Churg-Strauss Syndrome, polyarteritis nodosa, giant cell arteritis,        Takayasu's arteritis, Henoch-Schöenlein purpura, Behçets disease, and CNS vasculitis.|June 2014|July 11, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02190916|1 Year|40641|
NCT02190942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5535|VCRC Patient Contact Registry Patient-Reported Data Validation Study|VCRC Validation of Patient-Reported Diagnostic Data||University of South Florida|No|Enrolling by invitation|September 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|140|||Both|N/A|N/A|No|Probability Sample|Consent will be obtained from at least 20 randomly selected patients with each of the        following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's        disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic        Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care        providers to request that the providers complete an online version of this questionnaire        (or print copy, if they prefer), and request specific chart items from their office to        further verify the data. The sensitivity and specificity for various combinations of the        diagnostic questions to predict vasculitis and to confirm type of vasculitis will be        calculated using physician diagnosis / chart review as the gold standard.|June 2014|July 11, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02190942|1 Year|40639|
NCT02191241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.9|Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)|An Open, Uncontrolled Trial in Healthy Volunteers to Explore the Plasma and Urinary Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)||Boehringer Ingelheim||Completed|August 2001|||September 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191241||40616|
NCT02191254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.4|Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency||Boehringer Ingelheim||Completed|April 2004|||October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191254||40615|
NCT02191267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000035|Tau Imaging of Chronic Traumatic Encephalopathy|Tau Imaging of Chronic Traumatic Encephalopathy||Brigham and Women's Hospital|No|Enrolling by invitation|January 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Male|40 Years|69 Years|No|||January 2015|January 26, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191267||40614|
NCT02191280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.2|Antistax® in Patients With Chronic Venous Insufficiency|The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study||Boehringer Ingelheim||Completed|April 1998|||September 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|260|||Both|25 Years|75 Years|No|||July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191280||40613|
NCT02191605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA036788|Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy|Computer-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Marijuana Use in Pregnancy: Planning a Stage II Trial||Wayne State University|Yes|Recruiting|September 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Female|18 Years|40 Years|No|||December 2015|December 7, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191605||40588|
NCT02191878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKM-HCC-001|Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma|Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma||Arbutus Biopharma Corporation|No|Active, not recruiting|June 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|July 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02191878||40567|
NCT02220166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-GA2-2010|Safety of Prolonged Administration of Triticum Monococcum in Celiac Disease|Phase II Study on Safety of 60 Days Administration of Triticum Monococcum in Patients With Celiac Disease on Remission in Gluten Free Diet||Università degli Studi di Brescia|No|Completed|November 2010|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220166||38399|
NCT02220686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14197|Vascular Physician Offer and Report (VAPOR) Trial|Vascular Physician Offer and Report (VAPOR) Trial|VAPOR|Dartmouth-Hitchcock Medical Center|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220686||38359|
NCT02221011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB: 2-102-05-018|The Effect of Extracorporeal Shock Wave Therapy on Spasticity|The Effect of Extracorporeal Shock Wave Therapy on Spasticity||Tri-Service General Hospital|Yes|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221011||38334|
NCT02220400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPPOCD|Ketamine Prevent POCD|Low Dose Ketamine Prevent the Postoperative Cognitive Dysfunction in Aged Patients Underwent Orthopaedic Surgery，a Randomized Control Double Blinded Multicenter Clinical Trail|KPPOCD|RenJi Hospital|Yes|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|484|||Both|60 Years|N/A|No|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220400||38381|
NCT02220634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2820|Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension|Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension|RHINO|National Jewish Health|Yes|Not yet recruiting|August 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||August 2014|August 18, 2014|May 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220634||38363|
NCT02221245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120959|Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During the Staging Ultrasound of Esophageal Cancer Patients|Interrogation of Wnt, Notch and Hedgehog Activity in Chemo-naive Tumors Collected During the Staging Ultrasound of Patients Diagnosed With Esophageal Cancer||University of Miami||Recruiting|April 2013|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Esophageal cancer tumor cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with esophageal cancer|December 2015|December 7, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221245||38316|
NCT02221505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOP628X2101|Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia|A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia||Novartis|No|Terminated|December 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221505||38296|
NCT02221726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105188|Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults|Evaluation of Scoring Methods to Assess Adhesion Quality and Wear of the Placebo JNJ-35685-AAA-G-023 5.5 cm^2 and 44 cm^2 Transdermal Systems||Janssen Research & Development, LLC||Completed|August 2014|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221726||38279|
NCT02222051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5672 Tai Chi Neck Pain|Tai Chi for Chronic Non-specific Neck Pain|Tai Chi for Chronic Non-specific Neck Pain: A Randomized Controlled Trial|TaiChiNe|Universität Duisburg-Essen|No|Completed|August 2014|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222051||38254|
NCT02222064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0190|Pilot of Mindfulness Therapy for Inpatients With Gastro-intestinal Pain|Exploratory Study of Mindfulness for Inpatients With Chronic Gastrointestinal Pain: Does it Reduce Pain Related Distress and Increase Confidence in Pain Self-management?||University College, London|No|Completed|August 2014|September 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|December 3, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02222064||38253|
NCT02222350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8500-A-J201|Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes|A Phase 2, Placebo-controlled, Double-blind Study of DS-8500a in Patients With Type 2 Diabetes||Daiichi Sankyo Inc.|No|Completed|July 2014|January 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|20 Years|69 Years|No|||April 2015|April 20, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222350||38231|
NCT02222363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V13-11045|Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors|A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors||Vivolux AB|No|Recruiting|August 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||August 2014|April 21, 2015|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02222363||38230|
NCT02190994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WestChina-2013137|Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions|Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions||West China Hospital|No|Recruiting|August 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02190994||40635|
NCT02191345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD002265|The Effectiveness of Guided Imagery for a Nonprofit's Employees|A Randomized Controlled Trial Measuring the Effectiveness of Prerecorded Guided Imagery in Reducing Compassion Fatigue, Burnout, Perceived Stress, and State Anxiety of a Mental Health Nonprofit's Employees||FrontLine Service|Yes|Completed|July 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191345||40608|
NCT02191631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiPOCD RCT|Internet-delivered CBT for Adolescents With OCD: A Randomized Controlled Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Obsessive-Compulsive Disorder: A Randomized Controlled Study|BiPOCD|Karolinska Institutet|No|Active, not recruiting|August 2014|June 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|12 Years|17 Years|No|||March 2016|March 7, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02191631||40586|
NCT02190656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009515|Anterior Resection Syndrome Following Sphincter-preserving Surgery|Anterior Resection Syndrome Following Sphincter-preserving Surgery||Queen Mary University of London|No|Recruiting|May 2014|September 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having had an anterior resection for rectal cancer who are more than 12 months        post surgery|July 2014|August 14, 2014|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190656||40661|
NCT02190955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6802|Assessment of the Educational Experiences for Patients Newly Diagnosed With Nephrotic Syndrome|Assessment of the Educational Experience for Patients With Newly Diagnosed Nephrotic Syndrome||University of South Florida|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|186|||Both|18 Years|N/A|No|Non-Probability Sample|Patients and caregivers were recruited from the Nephrotic Syndrome Study Network (NEPTUNE)        Patient Contact Registry. Over 1000 patients and caregivers are members of the registry        and have already provided permission to be contacted for future research studies. The        Contact Registry was created to inform patients and/or parents of patients with Nephrotic        Syndrome of clinical research studies.        Health professionals, including pediatric and internal medicine nephrologists and        nephrology nurses will be recruited from the 18 NEPTUNE study network sites.|June 2014|July 11, 2014|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02190955|1 Year|40638|
NCT02191293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1402|Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®|Long-term Observational Study in Patients Under Anti-retroviral Combination Therapy Who Were Switched From Protease Inhibitors or Other NNRTI to Viramune® Plus Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) for Reasons of Therapy. (Long-Term Switch)||Boehringer Ingelheim||Completed|May 2002|||September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|228|||Both|18 Years|N/A|No|Non-Probability Sample|HIV treatment centres and HIV out-patient facilities|July 2014|July 15, 2014|July 15, 2014||||No||https://clinicaltrials.gov/show/NCT02191293||40612|
NCT02191306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000446|Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy|||Florida State University||Completed|October 2013|||March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|78|||Both|35 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Patients aged 35 to 50 with HIV and on antiretroviral therapy for at least 5 years. These        patients also cannot have any documented history of coronary artery disease or cardiac        interventions.|July 2014|July 14, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191306|1 Week|40611|
NCT02188394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCSC11/263|Anesthetic Blockades and Migraine|Effects of Anesthetic Blockades on Pain Modulation in Migraine||Universidad Rey Juan Carlos|Yes|Completed|July 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|65 Years|No|||January 2016|January 3, 2016|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188394||40835|
NCT02191891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.16|BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)|A Phase Ib Open-label Clinical Trial of Once Daily Oral Treatment of Afatinib Plus Weekly Intravenous Infusion of BI 836845 in Patients With EGFR Mutant Non-small Cell Lung Cancer With Progression Following Prior EGFR Tyrosine Kinase Inhibitor||Boehringer Ingelheim||Recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191891||40566|
NCT02191904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alkin01|Laryngoscope Types and The Cervical Motion|||Trakya University||Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|150|||Both|20 Years|75 Years|No|||July 2014|July 14, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02191904||40565|
NCT02220439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIGHD-CSP2013-001a|Does the Fecal Microbiome Influence Rotarix Immunogenicity|Nested Case-control Analysis of the Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|76|Samples Without DNA|fecal samples|Both|N/A|N/A|No|Non-Probability Sample|The study will be nested within an existing rotavirus immunogenicity study being conducted        in Karachi, Pakistan (clinicaltrials.gov: NCT01199874) . The physical setting is a        peri‐urban slum outside of Karachi, primarily populated by fishermen. Parents and legal        guardians of infants participating in NCT01199874 will provide new informed consent for        inclusion in this study.|August 2014|August 19, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02220439||38378|
NCT02220712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-13-005|A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia|||Otsuka Pharmaceutical Co., Ltd.|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|18 Years|64 Years|No|||October 2015|October 21, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220712||38357|
NCT02220959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14467|Is Preoperative Exercise Test in Morbid Obese Patients a Predictive Test for Extubation?|Is Preoperative Exercise Test in Morbid Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy a Predictive Test for Extubation?||Istanbul University||Completed|May 2014|||September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|60 Years|No|||October 2014|October 9, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220959||38338|
NCT02220972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-408|To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures||Eisai Inc.||Withdrawn|March 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||January 2015|February 9, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220972||38337|
NCT02220985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2684.00|Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD|A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2015|||February 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|14 Years|60 Years|No|||October 2015|October 29, 2015|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220985||38336|
NCT02221518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7000/R01MH104648-01|Control and Reward Circuits in Obsessive Compulsive Disorder|Control & Reward Circuits as Targets for Repetitive Thoughts and Behaviors||New York State Psychiatric Institute|No|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221518||38295|
NCT02190461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-EXA-2013-04|Impact of Early Respiratory Rehabilitation in the Exacerbations of Re-admitted COPD Patients|Impact of Early Respiratory Rehabilitation in the Exacerbations of Re-admitted Patients With Chronic Obstructive Pulmonary Disease (COPD)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|41 Years|N/A|No|||July 2015|September 1, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190461||40676|
NCT02190747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVO-1A-201|An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)||Clementia Pharmaceuticals Inc.|Yes|Active, not recruiting|July 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|6 Years|N/A|No|||February 2016|March 1, 2016|July 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190747||40654|
NCT02190253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914148|Seroprevalence of Hepatitis E in People With an Organ Transplant|Hepatitis E in the Organ Transplant Population||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190253||40692|
NCT02190474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201009502|Mindfulness Interventions and Chronic Widespread Pain in Adolescents|Mindfulness Interventions and Chronic Symptoms||Yale University|Yes|Recruiting|July 2014|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|17 Years|No|||March 2016|March 4, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190474||40675|
NCT02190734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pusher1|Pushing Behaviors in Individuals Post-stroke|Inpatient Rehabilitation Treatments and Effect on Pushing Behaviors in Individuals Post-stroke||Rehabilitation Institute of Chicago|No|Recruiting|May 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|89 Years|No|||September 2015|September 8, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02190734||40655|
NCT02191007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUP2012D001|Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis|Multi-center,Single Blind, Parallel-Controlled Study of the Efficacy and Safety of Calcipotriol Betamethasone Ointment Plus Calcipotriol Ointment in Sequential Therapy to Psoriasis Vulgaris||Xijing Hospital||Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|230|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|December 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191007||40634|
NCT02190669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-67|Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control|Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control||William Sansum Diabetes Center|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|individuals without diabetes and those with type 1 and type 2 diabetes|November 2014|November 12, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190669||40660|
NCT02190695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21357|Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly AML and MDS|Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||Temple University|No|Recruiting|April 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190695||40658|
NCT02187822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17816|Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases|A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2014|||October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02187822||40879|
NCT02187835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS001|Decreased EEG Complexity in Schizophrenia|Decreased EEG Complexity in Chronic Residual Schizophrenia||Uskudar University|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|diagnosed with schizophrenia,|July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187835||40878|
NCT02188108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW QOL|Validation of the Wisconsin Stone-QOL|Validation of the Wisconsin Stone-QOL, a Quality of Life Survey for Kidney Stone Formers||University of Wisconsin, Madison|No|Recruiting|July 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2000|||Both|18 Years|N/A|No|||May 2015|October 1, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02188108||40857|
NCT02199470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGEAH-1|β-cells in Type 1 Diabetes|FUNCTIONING β-CELLS IN TYPE 1 DIABETES MAY NOT BE AS LOW AS IT IS PRESUMED||Istanbul Medeniyet University|No|Recruiting|April 2013|||July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|135|||Both|18 Years|70 Years|No|Probability Sample|Patients with type 1 diabetes|July 2014|July 23, 2014|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199470||39985|
NCT02199483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140154|Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain|Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199483||39984|
NCT02188901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0337|Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study|Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study||Yonsei University|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|450|||Both|20 Years|N/A|No|||December 2015|December 6, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02188901||40796|
NCT02189174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLR457X2101|Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies|A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies||Novartis|No|Terminated|August 2014|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189174||40775|
NCT02188927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAM/2012-9/5|Effect of an Advanced Notification Letter on Screening Colonoscopy Participation|Participation in Screening Colonoscopy in Response to an Advanced Notification Letter Plus Standard Invitation Versus Standard Invitation Only - a Population-based Randomized Controlled Trial||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Not yet recruiting|August 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|6800|||Both|55 Years|64 Years|No|||July 2014|July 11, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02188927||40794|
NCT02188641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed12671300|Effect of Exercise and Diet on Psoriatic Arthritis|EFFECT OF EXERCISE AND DIETARY WEIGHT LOSS ON SYMPTOMS AND SYSTEMIC INFLAMMATION IN OBESE ADULTS WITH PSORIATIC ARTHRITIS: RANDOMIZED CONTROLLED TRIAL||Faculty of Medicine, University of Alexandria|Yes|Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02188641||40816|
NCT02220998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1139|Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection|ASTRAL-2|Gilead Sciences|Yes|Completed|September 2014|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220998||38335|
NCT02221232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131112-103 (ZX-ZP-0035)|Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™|A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™|ZX-ZP-0035|Zurex Pharma, Inc.|No|Terminated|August 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|August 18, 2014|Yes|Yes|To assess product performance (test and reference products), move into further testing.|No||https://clinicaltrials.gov/show/NCT02221232||38317|
NCT02189486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140367H|Prostate Cancer Upgrading Reference Set|Biomarkers and Clinical Parameters Associated With Gleason Score Upgrading||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Blood, voided urine and prostate tissue slides and blocks|Male|35 Years|99 Years|No|Non-Probability Sample|We will recruit a cohort of 600 men with prostate cancer who have elected radical        prostatectomy for treatment of their prostate cancer within two years after prostate        biopsy. This biopsy must show no greater grade than Gleason 3+3 disease as determined on        central pathology review. The patient may have had previous biopsies that showed cancer        but may never have had a tumor grade greater than Gleason 3+3.|November 2015|November 16, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02189486||40751|
NCT02190019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391721|Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study|Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study||Central Arkansas Veterans Healthcare System|No|Active, not recruiting|April 2014|July 2016|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|55 Years|91 Years|No|||February 2016|February 9, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190019||40710|
NCT02190032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-003-004|Modified Angled Tube vs. Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation|Comparison of Individually Modified Angled Tube and Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation: A Randomized Clinical Trial||Samsung Medical Center|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|108|||Both|20 Years|N/A|No|||February 2015|February 22, 2015|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02190032||40709|
NCT02191020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XijingH-PF-20120909|Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis|Multi-center, Randomized, Double Blind, Placebo Parallel-Controlled Study of the Efficacy and Safety of Total Glucosides of Paeony Combined With Acitretin Capsules to Treat Psoriasis Vulgaris||Xijing Hospital||Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|January 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191020||40633|
NCT02191371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaO2 & StO2 in OLV|Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation|Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation||Seoul National University Hospital|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|20 Years|90 Years|No|||August 2014|December 3, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02191371||40606|
NCT02191384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLST-MDD-Ⅱa-1401|Comparison of Orcinoside With Placebo in Treatment of MDD|Proof Of Concept Study of Orcinoside in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial||Shanghai Mental Health Center|Yes|Recruiting|July 2014|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|210|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02191384||40605|
NCT02191657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA26-106|Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects|A Double Blind, Placebo-controlled, Dose-escalating, Multiple Dose Study, Investigating the Safety, Antiretroviral Activity, Tolerability and Pharmacokinetic Profile of Deferiprone When Administered in Healthy Volunteers and Asymptomatic HIV Infected Subjects||ApoPharma|Yes|Completed|November 2006|April 2010|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2007|July 14, 2014|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191657||40584|
NCT02191969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1324|Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer|The Impact of a Physical Activity Intervention in Older Patients Undergoing Adjuvant Chemotherapy for Colorectal Cancer: a Randomized, Controlled Trial||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|60 Years|N/A|No|||October 2015|October 29, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02191969||40560|
NCT02191618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP13-001|The WEB-IT Clinical Study|The WEB® Intrasaccular Therapy Study (WEB-IT)|WEB-IT|Sequent Medical, Inc|Yes|Active, not recruiting|August 2014|March 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191618||40587|
NCT02191917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701-201|A Study of Repiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)|||BioMarin Pharmaceutical|No|Recruiting|September 2014|||September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02191917||40564|
NCT02198651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-500|A Study of Subjects With Rheumatoid Arthritis Who Are in Clinical Remission to Investigate Patient and Disease Characteristics That Could Help Identify Which Subjects Could Reduce Their Adalimumab Dose Without Flaring|A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)|PREDICTRA|AbbVie|No|Recruiting|December 2014|February 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|334|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198651||40048|
NCT02198664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC002|Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study|Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study||Aimmune Therapeutics, Inc.|Yes|Active, not recruiting|August 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|4 Years|26 Years|No|||August 2015|August 31, 2015|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02198664||40047|
NCT02198911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9212-B|The Effects of Chewing Gum on a Computer Task and Liking Ratings of Ice Cream|The Effects of Chewing Gum on a Computer Task and Liking Ratings of Ice Cream||University of Tennessee|Yes|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02198911||40028|
NCT02198924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI1180091|Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients|A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients||Peking Union Medical College Hospital|Yes|Recruiting|December 2013|September 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|90 Years|No|||February 2016|February 2, 2016|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02198924||40027|
NCT02199236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-104|Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management|A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management||Memorial Sloan Kettering Cancer Center||Recruiting|July 2014|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199236||40003|
NCT02199743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC806|Lurasidone Effects on Tissue Glutamate in Schizophrenia|Lurasidone Effects on Tissue Glutamate in Schizophrenia||University of Texas Southwestern Medical Center|No|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|65 Years|No|||July 2014|May 29, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199743||39965|
NCT02200003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 SC MH 109349-01|Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers|Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers|ABMT|Hunter College|Yes|Recruiting|February 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|40 Years|No|||February 2016|February 23, 2016|July 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02200003||39945|
NCT02188719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RTB-002|Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation|Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Liver Transplantation (RTB-002)|deLTa|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|December 2014|January 2022|Anticipated|January 2022|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|21 Years|70 Years|No|||January 2016|January 14, 2016|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02188719||40810|
NCT02188654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed12671416|Metformin in Psoriatic Arthritis|Metformin: A Valid Add-On Drug in the Treatment of Psoriatic Arthritis-Randomized Controlled Trial||Faculty of Medicine, University of Alexandria|Yes|Completed|September 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02188654||40815|
NCT02221258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSB-RA|Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)|Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis|RA|Kang Stem Biotech Co., Ltd.|Yes|Completed|October 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|19 Years|80 Years|No|||March 2015|October 20, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221258||38315|
NCT02189499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0170|Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent|Amaranth Endovascular Study of a Drug-Eluting Bioresorbable Coronary Scaffold|MEND II|Amaranth Medical Inc.|No|Recruiting|September 2014|September 2020|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|84 Years|No|||August 2015|August 7, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189499||40750|
NCT02189512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMO-20140206|Study on the Effect of Surgical Intestinal Manipulation|CD14/CD16 Activation in Brain-death Organ Donors and Effect of Surgical Intestinal Manipulation|IMMO|Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|July 10, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02189512||40749|
NCT02189785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH102264|Endogenous Opioid Mechanisms for Rejection Sensitivity|Endogenous Opioid Mechanisms for Rejection Sensitivity||Stony Brook University|No|Not yet recruiting|February 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|96|Samples With DNA|saliva, whole blood, blood plasma|Both|18 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Controls|December 2015|December 1, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189785||40728|
NCT02189798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0114|Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness|Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness||Advanced Bionics|No|Recruiting|April 2014|October 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189798||40727|
NCT02190487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0076|Incidence and Risk Factors of Acute Kidney Injury After Thoracic Aortic Surgery Due to Dissection|||Yonsei University|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|N/A|N/A|No|Probability Sample|Patients who had thoracic aortic surgery due to dissection|July 2014|July 14, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190487||40674|
NCT02190500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 13-0322|BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit|BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services:The BEST-MSU Study|BEST-MSU|Memorial Hermann Health System|Yes|Recruiting|May 2014|||July 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190500||40673|
NCT02190266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140146|Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis|The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|July 2025|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|60|||Both|2 Years|N/A|No|||June 2015|June 13, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190266||40691|
NCT02190513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ 0211-07|Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease|Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease and Prevalence of Celiac Disease in Children With Eosinophilic Esophagitis in a Tertiary Community Hospital||St. John Health System, Michigan|No|Completed|February 2011|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|56|||Both|2 Years|21 Years|No|Non-Probability Sample|Children seen in the Pediatric Gastroenterology clinic at St. John Hospital & Medical        Center and diagnosed with celiac disease or eosinophilic esophagitis or both based on the        endoscopic and histopathological findings.|July 2014|July 14, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190513||40672|
NCT02190760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-13.7.14|Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.|Comparison Between Perineural and Systemic Effect of Dexamethasone as an Adjuvant for Prolongation of the Interscalene Brachial Plexus Block.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||July 2014|July 13, 2014|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02190760||40653|
NCT02190773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RANKL|Effect of Surgical Therapy on RANKL/OPG (Osteoprotegerin) System|Effect of Surgical Periodontal Therapy on the RANKL/OPG System : Do we Need Osteo-immune Modulation Targeting RANKL?||Hacettepe University||Completed|January 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|65||Gingival Crevicular fluid (GCF) is collected at baseline and 3 months after the surgical      treatment.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individulas that applied to periodontology clinic in faculty of dentistry, Hacettepe        University.|July 2014|July 13, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02190773||40652|
NCT02190786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUX1201|Phase II Exploratory Clinical Study of KUX-1151|||Kissei Pharmaceutical Co., Ltd.||Completed||||March 2015|Actual|Phase 2|Interventional|N/A|3||||||Both|20 Years|64 Years|No|||October 2015|October 16, 2015|July 11, 2014||||No||https://clinicaltrials.gov/show/NCT02190786||40651|
NCT02191033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245677|Text Messaging for Smoking Cessation in College Health Clinics|Text Messaging to Augment Physician Brief Advice for Smoking Cessation in College Health Clinics||Yale University|No|Recruiting|January 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02191033||40632|
NCT02191397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114589|Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder|A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Daily) in Subjects With Major Depressive Disorder||GlaxoSmithKline|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|524|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191397||40604|
NCT02191410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2014045|Nondependent Lung Ventilation and Fluid Responsiveness|Comparative Study of the Non-dependent Continuous Positive Airway Pressure and High-frequency Positive-pressure Ventilation on Fluid Responsiveness During One-lung Ventilation for Thoracoscopic Surgery||Dammam University|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02191410||40603|
NCT02191670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.22|Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation|A Post-registration, Open Label Therapeutic Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation.||Boehringer Ingelheim||Completed|April 2005|||January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|July 2014|July 14, 2014|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191670||40583|
NCT02198144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARBER-1|Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)|Barber-Based Intervention for Hypertension in Black Men: Follow-Up Evaluation||Cedars-Sinai Medical Center|No|Completed|August 2009|July 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||July 2014|July 22, 2014|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02198144||40086|
NCT02198404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-01|Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit|Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit|PROPOPAL1|Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02198404||40067|
NCT02199496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140153|Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency|An Open-Label Phase I Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|April 2020|Anticipated|April 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||July 2015|March 15, 2016|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02199496||39983|
NCT02199262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER:02-190|Quality Improving Program on Agitation in the Surgical Intensive Care Unit|Quality Improving Program on Agitation in the Surgical Intensive Care Unit||University Hospital, Geneva|No|Completed|February 2004|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1107|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02199262||40001|
NCT02199275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2013/174|Effect of General Anesthesia on Enterocyte Damage|Impact of General Anesthesia on Enterocyte Damage|GUT|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|August 2013|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood samples on venous puncture|Both|18 Years|N/A|No|Non-Probability Sample|Adults requiring non-urgent surgery, in whom a protocol of general anesthesia using        propofol and remifentanyl with monitoring of bispectral index is expected.|July 2014|July 23, 2014|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02199275|1 Day|40000|
NCT02200016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000707-28|Displacement of Popliteal Sciatic Nerve Catheters After Major Foot and Ankle Surgery|||Kolding Sygehus|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02200016||39944|
NCT02200029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-168|Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption|Open-Label Study With Ademetionine (Heptral®) in Subjects With Intrahepatic Cholestasis (IHC) Associated With Alcoholic Liver Disease (ALD)||Abbott|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|75 Years|No|||June 2015|June 15, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200029||39943|
NCT02200042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-GI001|Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery|Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma||NRG Oncology|Yes|Recruiting|September 2014|||July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02200042||39942|
NCT02188732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11522753|Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes|Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|September 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188732||40809|
NCT02189200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03131712.3.0000.5265|Nutritional Counseling Associated With the Ingestion of Oat Bran in Hypercholesterolemic Subjects|Effect of Nutritional Counseling Associated With the Ingestion of Oat Bran in Hypercholesterolemic Subjects in Secondary Prevention||Universidade Federal do Rio de Janeiro|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|20 Years|85 Years|No|||July 2014|July 11, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02189200||40773|
NCT02189551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ: 2014-052|Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System||LOKOMAT|Cereneo AG||Recruiting|June 2014|||September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||||||Both|18 Years|N/A|No|||July 2014|July 10, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02189551||40746|
NCT02189564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFSP-SUB1-LU13054|Rewarding Feedback in Motor Learning and Rehabilitation|Die Auswirkung Von Dopaminergen Belohnungsreizen Auf Das Lernen Einer Motorischen Fertikgeit Bei Gesunden Probanden "Effects of Dopaminergic Reward on Motor Skill Learning in Healthy Subjects"|KFSP-REWARD|Cereneo AG|No|Recruiting|January 2014|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|45|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02189564||40745|
NCT02190045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404039|Wii-Fit For Balance And Gait In Elderly Veterans|Wii-Fit For Balance And Gait In Elderly Veterans||Central Arkansas Veterans Healthcare System|No|Active, not recruiting|September 2013|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|60 Years|95 Years|No|||February 2016|February 5, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190045||40708|
NCT02190084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547461|Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia|Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia||Central Arkansas Veterans Healthcare System|No|Recruiting|May 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|91 Years|No|||February 2016|February 9, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190084||40705|
NCT02190279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140140|18F-DCFBC PET/CT in Prostate Cancer|A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|June 2014|July 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|125|||Male|18 Years|99 Years|No|||May 2015|January 7, 2016|July 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190279||40690|
NCT02190292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523-2011-3646_1|PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort|||Karolinska Institutet||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|N/A||3|Anticipated|185|Samples With DNA|blood (whole blood and serum)|Both|N/A|N/A||Probability Sample|Consecutive cases that have been assumed to have PANS and have been assessed with the        Cunningham panel in Scandinavia.|July 2014|July 11, 2014|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02190292||40689|
NCT02190526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8811215278|Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome|Therapeutic Effects of Mesalamine and Amitriptyline in IBS: a Randomized Clinical Trial||Tehran University of Medical Sciences|Yes|Recruiting|September 2014|September 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||November 2014|November 12, 2014|March 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02190526||40671|
NCT02190552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP001|Analysis of Revascularisation in Ischemic Stroke With EmboTrap|A.R.I.S.E. Analysis of Revascularisation in Ischemic Stroke With EmboTrap: Post Marketing Observational Study of CE Marked EmboTrap Mechanical Thrombectomy Device|ARISE|Neuravi Limited|Yes|Enrolling by invitation|November 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Ischemic stroke patients|March 2014|March 9, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190552||40669|
NCT02190799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13-244|Anti-MERS-COV Convalescent Plasma Therapy|Anti-MERS-COV Convalescent Plasma Therapy||King Abdullah International Medical Research Center|Yes|Active, not recruiting|May 2014|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|N/A|No|||July 2014|April 14, 2015|June 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190799||40650|
NCT02191046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ทป 45/2555|Effect of Squeezable Bottle Nasal Irrigation Device in Children With Sinusitis|A Randomized- Controlled Study Comparing the Effect of Squeezable Bottle Nasal Irrigation Device With Syringe in Children With Sinusitis||Thammasat University|No|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|3 Years|15 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|July 13, 2014||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT02191046||40631|
NCT02191059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Icotinib|Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer|Single Arm, Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel as Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR:||Shandong Cancer Hospital and Institute|Yes|Not yet recruiting|July 2014|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||July 2014|July 30, 2014|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02191059||40630|
NCT02191423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-MB-161-CTIL|Oxytocin and Dyadic Psychotherapy in the Treatment of Post Partum Depression|The Effect of Oxytocin on Brain Attachment and Empathy Networks, and the Association Between the Brain Response and Treatment Outcome of Brief Dyadic Psychotherapy - in Women Suffering From Postpartum Depression||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 13, 2014|July 9, 2014||||No||https://clinicaltrials.gov/show/NCT02191423||40602|
NCT02199249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105500|Open Reduction Syndesmosis Tightrope Versus Screw Fixation|A Prospective Randomized Multi Center Study to Compare Open Reduction, TightRope Fixation (OT) Versus Open Reduction Screw Fixation (OS) of the Tibia - Fibular Syndesmosis.||Lawson Health Research Institute|No|Recruiting|April 2015|January 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02199249||40002|
NCT02199288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29314|Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting|A NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFECTIVENESS, SAFETY AND NURSE MANAGEMENT DURING INDUCTION TREATMENT WITH MABTHERA S.C. FOLLOWING A FIRST INITIAL MABTHERA I.V. TREATMENT, IN PATIENTS WITH NON-HODGKINS LYMPHOMA IN A REAL-LIFE SETTING||Hoffmann-La Roche||Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Patients within label indication for MabThera SC and subject for induction therapy with        MabThera SC; patients object for maintenance therapy are excluded|March 2016|March 1, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02199288||39999|
NCT02199717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039947|An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia|An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia|HEPS|The Hospital for Sick Children|No|Active, not recruiting|September 2013|December 2016|Anticipated|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Male|5 Years|17 Years|No|Non-Probability Sample|Patients will be 5 to 18 years of age with a diagnosis of hemophilia with no history of        inhibitors or pre-existing co-morbidity (e.g. cerebral palsy, chronic respiratory        conditions, congenital heart defects) that can affect activity participation.|May 2015|May 27, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199717|7 Days|39966|
NCT02199535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/340|The Analysis of the Risks of the Personnel Working in Anesthesiology Departments in Turkey|The Analysis of the Risks of the Personnel Working in Anesthesiology Departments in Turkey||TC Erciyes University|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|568|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The anesthesia staff doctors nurses and anesthesia personal|November 2014|November 4, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199535||39980|
NCT02199509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140152|Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia|Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia: A Randomized, Double-Blind Placebo-Controlled Cross-Over Study||National Institutes of Health Clinical Center (CC)||Completed|July 2014|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|8|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199509||39982|
NCT02199522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDMZ-1|Clinical Observation of Titration Induction and Convention Induction of Propofol|Clinical Observation of Titration Induction and Convention Induction of Propofol||Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|July 2014|November 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||July 2014|July 27, 2014|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199522||39981|
NCT02188667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300433|Integrating Patient Reported Outcomes (I-PRO) Study for Multidisciplinary Pain Care|An Integrative and Sustainable Approach to Pain Management in Primary Care|I-PRO|University of Florida|No|Enrolling by invitation|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02188667||40814|
NCT02188745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14122|ER Reactivation Therapy for Breast Cancer|Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Advanced Breast Cancer|POLLY|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|August 2015|March 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|59|||Female|18 Years|90 Years|No|||December 2015|December 7, 2015|June 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02188745||40808|
NCT02188914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/13 protocol|Brain Imaging Studies of the Effect of Inhalant Use Disorder|Neurobiología Del Consumo de Substancias Psicoactivas: PET-CT- Inhalables||Instituto para la Atención y Prevención de las Adicciones en la Ciudad de México|Yes|Recruiting|November 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|cDNA obtained from reversal transcription of RNA isolated from periferical blood cells|Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in inhalant use disorder treatment program or Normal Control Subjects        volunteers|March 2016|March 9, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188914||40795|
NCT02189226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0009|Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection|||Yonsei University|No|Recruiting|November 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|20 Years|N/A|No|||July 2014|July 10, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189226||40771|
NCT02189213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6884|Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep|Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep||New York State Psychiatric Institute|Yes|Recruiting|July 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|8 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189213||40772|
NCT02189577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-09|Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients|A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Trigon|Chiesi Farmaceutici S.p.A.|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|80 Years|No|||February 2015|February 12, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02189577||40744|
NCT02189837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130194|Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody|Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics|FLOREY|Amgen|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|89|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189837||40724|
NCT02190097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13770|Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)|PALEOLITHIC VS Healthy ADA DIETS FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS)||University of California, San Francisco|No|Recruiting|January 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|35 Years|No|||January 2015|January 28, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02190097||40704|
NCT02190539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0050-14-MMC|Homeopathic Protocol for Advanced Breast Cancer|The Banerji Protocol for Advanced Breast Cancer- Feasibility Study||Meir Medical Center|Yes|Enrolling by invitation|August 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190539||40670|
NCT02190565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/815-31/4|Safety and Efficacy Study of a Food Supplement for Pregnant and Lactating Women|Supplementation With WellnessPack Mama During Pregnancy and Lactation - a Randomized Double-blind, Placebo-controlled Study||Oriflame Cosmetics AB|No|Not yet recruiting|October 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02190565||40668|
NCT02190812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302026RINB|An Intelligent Evaluation of Wrist Strength for the Elderly People and Its Clinical Application|An Intelligent Evaluation of Wrist Strength for the Elderly People and Its Clinical Application||National Taiwan University Hospital|Yes|Recruiting|April 2013|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 13, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02190812||40649|
NCT02191072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404056MIPC|Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria|Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria||National Taiwan University Hospital|No|Not yet recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|75 Years|No|||July 2014|July 14, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02191072||40629|
NCT02191436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHERENCE|Adherence to Treatment in Hemophilia|Psychosocial Factors and Adherence to Treatment in Patients With Hemophilia. A Multicenter Study|ADHERENCE|Universidad de Murcia|No|Recruiting|May 2015|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Male|6 Years|75 Years|No|Non-Probability Sample|Patients with haemophilia treated at the Hospital Clínico Universitario Virgen de la        Arrixaca de Murcia, and the Hospital Clínico Universitario Carlos Haya (Málaga)|September 2015|October 19, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191436|1 Day|40601|
NCT02198963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP01-117838|21 Day Cumulative Skin Irritation of RUT058-60|Phase 1 21-Day Evaluation of the Cumulative Irritation Potential of RUT058-60 on Abraded and Non-Abraded Skin Sites||Pulmatrix Inc.|Yes|Completed|July 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|July 18, 2014|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT02198963||40024|Results from 36 subjects receiving all applications and completing all visits
NCT02198976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/10/4.1 (3829)|Australian Barrett's Cohort With Dysplasia and Early Cancer Study|Australian Barrett's Cohort With Dysplasia and Early Cancer Study|ABCDE|Western Sydney Local Health District|Yes|Recruiting|April 2014|April 2020|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|99 Years|No|Non-Probability Sample|Patient's presenting to tertiary referral study site with HGD or IMC Barrett's Oesophagus        for removal.|December 2015|December 15, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02198976||40023|
NCT02199301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-210|Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation|Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation||Samsung Medical Center||Recruiting|December 2011|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||September 2012|July 22, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02199301||39998|
NCT02199769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062013-058|Reducing Type 2 Diabetes Diagnostic Delays Using Decision Support|Harnessing the Electronic Medical Record to Reduce Delays in the Diagnosis of Type 2 Diabetes: a Systems-based, Decision Support Approach||University of Texas Southwestern Medical Center|No|Active, not recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199769||39963|
NCT02188680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/011/HP|Irritable Bowel Syndrome and Low FODMAP Diet|Does Irritable Bowel Syndrome Improved by Low FODMAP Diet ?|FructIBS|University Hospital, Rouen|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02188680||40813|
NCT02188693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLLY-01|Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer|Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer||Xijing Hospital|No|Recruiting|July 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|267|Samples With DNA|2 ml blood sample is needed before enrollment.|Female|18 Years|70 Years|No|Non-Probability Sample|Patients with MBC exhibited disease control (complete response + partial response + stable        disease) with first-line PG and were randomly assigned to maintenance chemotherapy or        observation.|July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188693|3 Years|40812|
NCT02188706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0543|A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2014|||July 2026|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188706||40811|
NCT02188979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLOBE|GlideScope With EGRI Assessment in Obese Patients|GlideScope Videolaryngoscopy and Pre-Operative Assessment of El-Ganzouri Risk Index for Tracheal Intubation in Morbidly Obese Patients The Prospective Observational GLOBE Study|GLOBE|Università degli Studi di Brescia|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|195|||Both|18 Years|N/A|No|Probability Sample|Our patients population is the population of morbidly obese patients scheduled for        bariatric surgery or other non-bariatric abdominal surgical interventions and referring to        the University Division of Anaesthesia and Intensive Care at Spedali Civili of Brescia.|July 2014|July 10, 2014|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02188979||40790|
NCT02189525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-001|Evaluation of Mild TBI in Collegiate Athletes|AWARE: Mild Traumatic Brain Injury in Collegiate Athletes - A Prospective Study With Blood-based Biomarkers, Advanced Neuroimaging and the Head Impact Telemetry System (HITS)|AWARE|Banyan Biomarkers, Inc|No|Recruiting|August 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Collegiate atheltes from University of Florida involved in Men's Football, Women's Soccer,        or Women's Lacrosse|October 2014|October 29, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189525||40748|
NCT02189538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidad de la República|Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients|Effect of Omega-3 PUFA From Fish in Major Brun Patients EFECTO DE ÁCIDOS GRASOS POLIINSATURADOS OMEGA 3 DERIVADOS DE ACEITE DE PESCADO, EN QUEMADOS GRAVES|OmegaBurn|Centro Nacional de Quemados, Uruguay|No|Recruiting|January 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|16 Years|80 Years|No|||February 2016|February 7, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02189538||40747|
NCT02189590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-gel versus air-Q|Assessment of the I-gel and Air-Q Supraglottic Airways as Conduits for Tracheal Intubation in Children|A Randomized Comparison of the I-gel and Air-Q as Conduits for Fiberoptic-guided Tracheal Intubation in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|96|||Both|1 Month|6 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189590||40743|
NCT02189811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGS|Polio End-game Strategies - Poliovirus Type 2 Challenge Study|Polio End-game Strategies - Poliovirus Type 2 Challenge Study||Aga Khan University|Yes|Not yet recruiting|August 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|900|||Both|N/A|1 Day|No|||July 2014|July 14, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189811||40726|
NCT02190058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E102|Multiple Dose Study of DS-1971a|A PHASE I, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF DS-1971A IN HEALTHY MALE SUBJECTS||Daiichi Sankyo Inc.|No|Completed|July 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190058||40707|
NCT02190071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-IMGPB-2014-03|Comparison Between Base and Cover Slide From Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer|Comparison of the Diagnostic Accuracy Between Base and Cover Slide Smear After Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer|EUS-FNA|Seoul National University Hospital|Yes|Recruiting|June 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|73|Samples Without DNA|One identical and skilled endoscopist's EUS-FNA sampling with multiple punctures|Both|N/A|N/A|No|Non-Probability Sample|The patients who visited to tertiary medical center(Seoul National University Bundang        Hospital) because of suspicious pancreatic cancer in radiologic study|July 2015|November 30, 2015|July 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02190071||40706|
NCT02190110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Pulmonary Embolism Diagnosis: Ultrasound Wells Score vs Traditional Wells Score|Ultrasound Wells Score vs Traditional Wells Score in the Diagnostic Approach to Pulmonary Embolism||Azienda Ospedaliero-Universitaria Careggi|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|444|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients (more than 18 years old) suspected of PE presenting to ED will be recruited        at the time of the medical evaluation and before a final diagnosis is established.|February 2016|February 6, 2016|July 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02190110||40703|
NCT02190578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP005|Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test|Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test for the Detection of HIV-1 Antibodies in Fingerstick and Venous Whole Blood Samples||MedMira Laboratories Inc.|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1649|||Both|13 Years|N/A|Accepts Healthy Volunteers|||July 2014|April 23, 2015|July 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02190578||40667|
NCT02190305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP002|Rapid Diagnostics for HIV and Hepatitis|Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg||MedMira Laboratories Inc.|No|Recruiting|May 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|4000|||Both|13 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|July 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02190305||40688|
NCT02191475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDH2014|Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock|Tigecycline (Hai Zheng Li Xing®) Combined With Piperacillin/Tazobactam (Tazocin ®) Empirical Treatment of Severe Sepsis and Septic Shock in Patients With Abdominal Infection|Tigecycline|Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||May 2014|July 13, 2014|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191475||40598|
NCT02190825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0040|Safety and Efficacy Study of the NeuGuide Device|||Pop Medical Solutions||Active, not recruiting|November 2014|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|80 Years|No|||October 2015|October 27, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02190825||40648|
NCT02190838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMM-1|Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma|Phase II Multicenter Randomized Study to Compare Dacarbazine With Melatonin or Metformin Versus Dacarbazine in the First Line Therapy of Disseminated Melanoma||Petrov Research Institute of Oncology|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02190838||40647|
NCT02191085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-1280|Evaluation of a "Fast Track" Respiratory Therapy Clinic for Patients With Suspected Severe Sleep-Disordered Breathing|Evaluation of a "Fast Track" Respiratory Therapy Clinic for Patients With Suspected Severe Sleep-Disordered Breathing||University of Calgary|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02191085||40628|
NCT02191449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160068|The Influence of Preoperative Warfarin Medication on Thromboelastography and Blood Transfusion|Influence of Warfarin on Thromboelastography and Transfusion||Konkuk University Medical Center|Yes|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|107|||Both|20 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery with Maze-operation|February 2015|February 23, 2015|June 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02191449||40600|
NCT02191462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14NBHC|A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects|A Randomized, Double-blind, Cross-over Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects|14NBHC|KGK Synergize Inc.||Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|12|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02191462||40599|
NCT02198716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0 20.06.2008|Xience or Vision Stent Management of Angina in the Elderly|Multi-centre, Randomised,Prospective Trial of Xience or Vision Stent, Management of Angina in the Elderly|XIMA|Brighton and Sussex University Hospitals NHS Trust|Yes|Completed|November 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|80 Years|N/A|No|||August 2014|August 13, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02198716||40043|
NCT02198989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD-022|Effects of Peer Support and Yoga Music on T2DM With Depression and Sleep Disorders|Effects of Peer Support and Yoga Music on T2DM With Depression and Sleep Disorders||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|45|||Both|40 Years|84 Years|No|||December 2014|December 2, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02198989||40022|
NCT02199002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55731|Acid Pocket: Position and Aspiration|Acid Pocket: Different Position and Chemical Content Between Healthy Volunteers and GERD Patients||Katholieke Universiteit Leuven|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02199002||40021|
NCT02199561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47055|Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease||University of Alberta|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||May 2015|May 28, 2015|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199561||39978|
NCT02199548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPS14|The Good Patient Study|The Good Patient Study||St. Jude Children's Research Hospital|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|12 Years|19 Years|No|Non-Probability Sample|Participants will be teens who are patients at St. Jude Children's Research Hospital and        meet the criteria for study enrollment.|June 2015|June 3, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199548||39979|
NCT02188446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-22841-01|Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients|Randomised Controlled Multicenter Study.Effect of an Intensive Smoking- and/or Alcohol Cessation Intervention Placed Shortly Before and 5 Weeks After Bladder Cancer Surgery on Postoperative Complications|STOP-OP|Rigshospitalet, Denmark|No|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02188446||40831|
NCT02188459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820364|Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women|Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women|BIBS|University of Pennsylvania|Yes|Recruiting|October 2014|January 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188459||40830|
NCT02189616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjhx-song2|Efficacy of Mobile Phone Short Message Service (SMS) Reminder and Consultation on Asthma Control|Evaluate the Clinical Efficacy of Mobile Phone Short Message Service (SMS) Reminder and Consultation on the Self-management and Outcomes of Poorly-controlled Asthma: a Multicenter Randomized Controlled Trial||Xijing Hospital|Yes|Recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|65 Years|No|||August 2014|August 18, 2014|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02189616||40741|
NCT02188940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETLWOA|Exercise Training to Lose Weight in Obese Asthmatics|Effects of Exercise Training in a Weight-loss Lifestyle Intervention on Clinical Control and Psychosocial Morbidity in Obese Asthmatics: a Randomized and Controlled Trial||University of Sao Paulo General Hospital|Yes|Completed|July 2014|October 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|30 Years|60 Years|No|||July 2014|February 19, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02188940||40793|
NCT02189239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ze 185-4-2014-02|Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress|A Phase IV, Randomised, Placebo Controlled Study to Investigate the Effects of Zeller Entspannung Film Coated Tablets on Cortisol Responses in Healthy Volunteers With Acute Stress||Max Zeller Soehne AG|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189239||40770|
NCT02189252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5880C00003|An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis|A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis|ECLIPSEIV|AstraZeneca|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|June 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189252||40769|
NCT02189876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-13-010|Females of African American Legacy Empowering Self (FemAALES)|Reducing HIV/STD Risk in African American Women With AT-Risk Male Partners|FemAALES|Charles Drew University of Medicine and Science|No|Recruiting|July 2013|November 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|325|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189876||40721|
NCT02189889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APART.V1.2013|Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery|Active Preoperative Anemia Management to Reduce Erythrocyte Transfusion in Patients Undergoing Cardiac Surgery (APART): A Pilot, Feasibility Study|APART|University of Texas Southwestern Medical Center|Yes|Recruiting|April 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 5, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189889||40720|
NCT02189824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCTL141501|Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation|Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation|SCRAMBLE|University of Sydney|No|Recruiting|August 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||October 2015|October 29, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189824||40725|
NCT02189850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI800-501|Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy|||Braintree Laboratories||Completed|June 2014|||January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|12 Years|17 Years|No|||January 2015|January 26, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189850||40723|
NCT02191098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-803|Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People|Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People on Optimized ART With Undetectable Plasma HIV RNA|ALT-803|University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191098||40627|
NCT02191111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047475|A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies|A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies Using the PARiHS Framework||University of Alberta|No|Active, not recruiting|July 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191111||40626|
NCT02191761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM04755-ONC-01|Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer|Phase1, Open-Label, Dose Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer||Samumed LLC|No|Suspended|June 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|June 30, 2014|No|Yes|pending results of a separate study|No||https://clinicaltrials.gov/show/NCT02191761||40576|
NCT02192047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD 174/13|Chronic Effects of Natural and Interesterified Fats Margarine on Insulin Sensitivity and Selected Markers of Cardiovascular Diseases (CVD)|Chronic Effects of Natural Palm-based Margarine and Interesterified Palm- and Soy-based Margarine on Insulin Sensitivity and Selected Markers of Cardiovascular Diseases (CVD)||Malaysia Palm Oil Board|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|85|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02192047||40554|
NCT02187952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PAF07294|Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children|Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children||University of Michigan||Enrolling by invitation|July 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|12 Months|48 Months|No|||July 2014|July 9, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02187952||40869|
NCT02187965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107011060|Impact of Muscle Fat Accumulation on the Genomic Profile of Skeletal Muscle in Older Adults|||Purdue University||Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|11|Samples With DNA|muscle tissue, RNA|Both|60 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|normal weight and obese older adults|August 2011|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02187965||40868|
NCT02199015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Andreani, JCM 1|Lateral Cord Stimulation as a New Treatment for Refractory Spastic Cerebral Palsy|Lateral Cord Electrical Stimulation Can Improve Spasticity in Chronic Spastic Cerebral Palsy|Andreani1|Sociedad Argenttina de Neuromodulación|Yes|Enrolling by invitation|March 2017|May 2019|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|N/A|No|||July 2015|July 29, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199015||40020|
NCT02199314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1065|Anesthesia and Motor Evoked Potential (MEP) Recruitment|The Effect of Anesthesia on the Recruitment of Motor Evoked Potentials Using an Increased Number of Pulses||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|March 2013|September 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|12 Years|17 Years|No|||March 2016|March 10, 2016|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02199314||39997|
NCT02199821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-00000|Inflammatory Response With Different Lipid Emulsions In Parenteral Nutrition In Children After Bone Marrow Transplantation|||Maimónides Biomedical Research Institute of Córdoba||Completed|February 2011|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|N/A|14 Years|No|||May 2014|July 24, 2014|April 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02199821||39959|
NCT02199808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0198|Fatty Acids and Executive Function Development in 7-12 Year Olds|Fatty Acids and Executive Functions: Cortical Activation and Behavioral Performance.||University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|79|||Both|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|All participants will be typically-developing, healthy 7-to-12-year-olds who are fluent in        English. Every effort will be made to recruit roughly equal numbers of boys and girls.        Recruitment will be conducted irrespective of race and ethnicity. An attempt will be made        to match the sample to the race and ethnicity of the region: 80% White, 15%        African-American, and 5% Native American, Asian, and Other descent.|February 2016|February 10, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02199808||39960|
NCT02200094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.361|Micardis®. Observational Study in Patients With Essential Hypertension|Micardis®. Observational Study||Boehringer Ingelheim||Completed|December 1999|||October 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4532|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients over 18 years of age suffering essential hypertension, treated by general        practitioners and/or specialists|July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02200094||39938|
NCT02188472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN1011|Pentriox - Induction of Oxidative Stress|PENTRIOX - a Randomized, Placebo-controlled Clinical Study on the Possible Induction of Oxidative Stress by Phenoxymethylpenicillin and Trimethoprim on Healthy Volunteers|PENTRIOX|Rigshospitalet, Denmark|Yes|Completed|November 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|90|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT02188472||40829|
NCT02189369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311-FIVI-135-CS|Diagnostic Test for Endometrial Receptivity 24 Hours Before Embryo Transfer|Clinical Validation of a Diagnostic Test Which Measures the Endometrial Prostaglandins Liquid 24 Hours Before Embryo Transfer and That is Capable of Predicting a State of Endometrial Receptivity||Igenomix|No|Recruiting|February 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|120|||Female|18 Years|50 Years|No|||January 2016|January 20, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189369||40760|
NCT02189629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18250|CD5789 Long Term Safety Study on Acne Vulgaris|A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS||Galderma R&D|No|Recruiting|February 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|9 Years|N/A|No|||January 2016|January 18, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189629||40740|
NCT02188953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC Protocol No. 2603|Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya|Evaluation of the Effectiveness, Acceptability, and Palatability of Air Classified Calcium Silicate (ACCS100) Clay to Reduce Aflatoxin Exposure in a High-risk Community in Kenya|ACCS100|Kenya Medical Research Institute|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 15, 2014|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02188953||40792|
NCT02189265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRF NR-0166-1.3|Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands|Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands||University of Edinburgh|No|Completed|January 2000|July 2014|Actual|December 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|2069695||None Retained|Both|N/A|1 Week|Accepts Healthy Volunteers|Probability Sample|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for        all outcomes other than stillbirths and congenital anomalies.|July 2014|July 11, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02189265||40768|
NCT02189278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022895|Improving Adherence to Recommended Surveillance in Breast Cancer Survivors|Improving Adherence to Recommended Surveillance in Breast Cancer Survivors||Duke University|Yes|Active, not recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Female|21 Years|N/A|No|||March 2016|March 9, 2016|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189278||40767|
NCT02189863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-009|Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses|Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses||Alcon Research|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|33|||Both|N/A|70 Years|No|||January 2016|January 21, 2016|July 11, 2014|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT02189863||40722|
NCT02190591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14034-14-027|Use of Peanut Labor Ball Following Epidural Anesthesia|Use of Peanut Labor Ball for Pelvic Positioning for Nulliparous Patients Following Epidural||TriHealth Inc.|Yes|Completed|May 2014|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|204|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02190591||40666|
NCT02221167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406730|Rx Milk Study of Donor Milk Supplementation to Improve Breastfeeding Outcomes|Rx Milk: Donor Milk Supplementation to Increase Breastfeeding Duration & Exclusivity, a Randomized Controlled Trial|Rx Milk|University of Iowa|No|Recruiting|July 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|48 Hours|No|||May 2015|May 26, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221167||38322|
NCT02190851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7047 01|Transcutaneous Electrical Nerve Stimulation (TENS) for Lower Urinary Tract Disorders in Parkinson's Syndrome|Evaluation of Treatment by Transcutaneous Electrical Nerve Stimulation (TENS) of the Posterior Tibial Nerve for Lower Urinary Tract Disorders in Parkinson's Syndrome|UROPARKTENS|University Hospital, Toulouse|No|Recruiting|April 2015|December 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|90 Years|No|||September 2015|September 29, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02190851||40646|
NCT02190864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318-13-EP|Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients|Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients||University of Nebraska|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|210|||Both|19 Years|N/A|No|Non-Probability Sample|Newly diagnosed advanced stage non-small cell lung cancer patients with age > 19 years.|November 2015|December 3, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02190864||40645|
NCT02191488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 13066|ALA-induced PpIX Fluorescence During Brain Tumor Resection|Quantification of ALA-induced PpIX Fluorescence During Brain Tumor Resection||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|July 2014|||July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|540|||Both|21 Years|N/A|No|||February 2016|February 24, 2016|July 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02191488||40597|
NCT02191501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feinstein IRB#13-037B|Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity|Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity||Feinstein Institute for Medical Research|Yes|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||June 2015|June 17, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02191501||40596|
NCT02191774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marions 2014 1.2|Medical Abortion up to 10 Weeks Gestation at Home|||Karolinska Institutet||Not yet recruiting|September 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Female|18 Years|N/A|No|Probability Sample|Women with an unwanted pregnancy opting for medical abortion|July 2014|July 15, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02191774||40575|
NCT02192060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVOppermann01|Efficacy of a Triclosan Formulation to Control the Initial Subgingival Biofilm Formation|Efficacy of a Triclosan Formulation to Control the Initial Subgingival Biofilm Formation||Federal University of Rio Grande do Sul|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 14, 2014|November 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02192060||40553|
NCT02199327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2012-785-094|Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia|Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia||Coordinación de Investigación en Salud, Mexico|Yes|Active, not recruiting|May 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|90 Years|No|||January 2015|February 10, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02199327||39996|
NCT02199574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-401|Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy|Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy||Pacira Pharmaceuticals, Inc|No|Completed|August 2014|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 7, 2015|July 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02199574||39977|
NCT02199834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2013.033|Effect of Personalized Feedback Report and Peer Support on Diabetes|A Quality Improvement Project Evaluating the Effect of Regular Personalized Feedback Report and Peer Support for Patients With Diabetes in Hong Kong||Chinese University of Hong Kong|No|Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|1488|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199834||39958|
NCT02199847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1114.11|Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift|An Evaluation of the Effects of Pharmaton® Caplets Film-coated Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shifts: a Double-blind, Placebo Controlled Pilot Trial||Boehringer Ingelheim||Completed|June 2000|||January 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|32|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02199847||39957|
NCT02200120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99904021982|Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury|Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury- Assessment of Dialysis Adequacy and Infection Rates||Brigham and Women's Hospital|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted to the hospital with acute kidney injury requiring renal replacement        therapy|July 2015|July 20, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200120||39936|
NCT02188485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH096936|Social Connections and Late Life Suicide|Social Connections and Late Life Suicide||University of Rochester|Yes|Recruiting|January 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||February 2016|February 21, 2016|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02188485||40828|
NCT02219581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066081|Steroids in Total Knee Arthroplasty|Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty||Emory University|Yes|Recruiting|August 2014|August 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|100 Years|No|||November 2015|November 25, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02219581||38444|
NCT02188966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRAA4|Application of Geographical Information System Data in the Emergency Department, Effect on Trauma Team and Medical Emergency Team Wait|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 4: Application of Geographical Information System Data in the Emergency Department, Effect on Trauma Team and Medical Emergency Team Wait - a Before and After Study||University of Aarhus|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|599|||Both|15 Years|N/A|No|||March 2014|December 8, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02188966||40791|
NCT02189291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00010603|Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy|When to Remove the Indwelling Catheter After Minimally Invasive Sacrocolpopexy?|CARESS|Oregon Health and Science University|Yes|Recruiting|July 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|21 Years|85 Years|No|||April 2015|April 20, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02189291||40766|
NCT02189304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010002-00|Pharmacokinetics and Safety Study of PT010 in Healthy Subjects|A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort® Turbohaler® in Healthy Subjects||Pearl Therapeutics, Inc.|No|Completed|June 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189304||40765|
NCT02190123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CBE-XXX-2014/1|REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.|REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)|REWINDER|AstraZeneca|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|430|||Both|18 Years|130 Years|No|Non-Probability Sample|Male and female patients from Belgium and Luxembourg, aged 18 years or more , discharged        alive from hospital to home following an acute coronary syndrome (ACS) and who were        treated with an oral antiplatelet (OAP) (ticagrelor, prasugrel or clopidogrel) after an        acute coronary syndrome (ACS) event (Unstable Angina (UA), ST-elevation myocardial        infarction (STEMI) or non-STEMI(NSTEMI)).|January 2016|January 7, 2016|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190123||40702|
NCT02190136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga-0610-52|Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity|Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study|PRISE|Skidmore College|No|Completed|December 2006|July 2014|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|39|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02190136||40701|
NCT02190318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-RENAL-IIS-2013-029|Residual Renal Function Preservation in Peritoneal Dialysis Patients|The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients||Second Xiangya Hospital of Central South University||Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|July 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190318||40687|
NCT02190331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFRH/BD/77633/2011|Effects of a Resistance and Stretching Training Program on Forward Head and Protracted Shoulder Posture Adolescents|The Effects of Training and Detraining After an 8 Month Resistance and Stretching Training Program on Forward Head and Protracted Shoulder Postures in Adolescents||Faculdade de Motricidade Humana|Yes|Completed|October 2012|October 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|275|||Both|15 Years|17 Years|No|||July 2014|July 14, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02190331||40686|
NCT02190877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perm-IRB-001|Monitoring Subjects With Fluid-Management Issues In the Home Environment|A Study for Monitoring Subjects With Fluid-Management Issues Using Repeated Measurements In the Home Environment||toSense, Inc.|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|23|||Both|21 Years|90 Years|No|Non-Probability Sample|Subjects will be volunteers from Riverside Meadows Estates. Subjects will be taking one or        more diuretic medication(s) prescribed by a physician|July 2014|July 21, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02190877||40644|
NCT02190890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16/2013|Dry Needling Dosage in the Treatment of Myofascial Neck Pain|||Universidad Rey Juan Carlos||Completed|September 2013|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|150|||Both|18 Years|53 Years|No|||July 2014|July 11, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02190890||40643|
NCT02221661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG/JD/11.830|Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center|Non-interventional Longitudinal Study in Alzheimer Disease Diagnosis in Primary Consultants Patients With Cognitive and / or Memory Complaint Requiring Specialized Exploration Using AclarusDx® Blood Test in Memory Centers|DIALOG|Diaxonhit|Yes|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|606|Samples With DNA|Whole blood samples collected in PAXgene® blood RNA tubes|Both|18 Years|N/A|No|Probability Sample|Patients with cognitive impairment and/or memory complaint justifying a first clinical        investigation for diagnosis|August 2014|August 21, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221661|12 Months|38284|
NCT02221674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503-72|Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old|Open-label Evaluation of the Population Pharmacokinetic Profile, Safety, Tolerability, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children Aged From Birth to Less Than 2 Years||Grünenthal GmbH|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|23 Months|No|||March 2016|March 17, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221674||38283|
NCT02191514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS-2014-SV-01|Prehospital Management of Stroke Patients by Emergency Medical Services|Prehospital Management of Stroke Patients by Emergency Medical Services - an Evaluation of Emergency Medical Dispatch and Ambulance Personnel.||Emergency Medical Services, Capital Region, Denmark||Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2653|||Both|N/A|N/A|No|Probability Sample|The study population consists of patients suffering from a stroke in the Capital Region of        Denmark. The Capital Region of Denmark is home to 1,8 mio. people and covers an area of        2.568 km². The regions has 24-hour fast track stroke service divided at 2 hospitals, with        alternate 24-hour shifts.|January 2016|January 4, 2016|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02191514||40595|
NCT02191787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1135.2|Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers|Pharmacokinetic-pharmacodynamic Assessment of Seresis® o.d.: an Open, Uncontrolled, Non-randomised Intraindividual Pilot-study||Boehringer Ingelheim||Completed|March 1998|||May 1998|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191787||40574|
NCT02191800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Securisyn Medical TP-013|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2014|||||N/A|N/A|N/A||||||||||||||March 5, 2015|July 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191800||40573|
NCT02191813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1135.3|Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers|The Ability of Seresis to Act as a Skin Protection Agent: a Double-blind, Parallel Group, Placebo-controlled Trial in Healthy, Young Female Volunteers||Boehringer Ingelheim||Completed|March 2000|||July 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|July 14, 2014||||No||https://clinicaltrials.gov/show/NCT02191813||40572|
NCT02192073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13081402|Analysis of Suprapectoral and Subpectoral Biceps Tenodesis|Prospective Analysis of Arthroscopic Suprapectoral and Open Subpectoral Biceps Tenodesis: 1 Year Follow-Up||Rush University Medical Center|No|Recruiting|May 2014|November 2020|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02192073||40552|
NCT02199340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11AR14|The iStep Study: Development and Validation of an Incremental Exercise Step Test for Children With Cystic Fibrosis|||Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Active, not recruiting|July 2011|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|6 Years|16 Years|No|||July 2014|July 22, 2014|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02199340||39995|
NCT02199587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc069-14CTIL|The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test|The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or Growth Hormone Provocation Test||Meir Medical Center|No|Recruiting|December 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|4 Years|18 Years|No|||July 2014|March 9, 2015|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02199587||39976|
NCT02199873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1150.1|Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Methacholine Challenge) Study After Inhalational Administration of BIIX 1 XX (Single Doses: 5 - 800 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)||Boehringer Ingelheim||Completed|June 1998|||September 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02199873||39955|
NCT02199886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152.3|Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection|A Phase I Single Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection||Boehringer Ingelheim||Terminated|July 1998|||December 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02199886||39954|
NCT02199899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1157.2|Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Citric Acid Challenge) Study After Oral Administration of BIIF 1149 BS (Drinking Solution, Single Doses: 0.1 - 25 mg; in Addition, at 25 mg Also as a 25 mg Tablet) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled, Parallel Groups)||Boehringer Ingelheim||Completed|March 1999|||July 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|64|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02199899||39953|
NCT02200133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-SCP|Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors|Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors||Center for International Blood and Marrow Transplant Research|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|495|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02200133||39935|
NCT02188758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14136|Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment|Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?||Dartmouth-Hitchcock Medical Center|No|Recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|23|Samples With DNA|Bacterial DNA and RNA will be isolated from sputum samples and stored for future analyses.|Both|18 Years|65 Years|No|Non-Probability Sample|Patients greater than|August 2015|August 14, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02188758||40807|
NCT02219828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40/08/13|AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)|AnakInRa for Treatment of Recurrent Idiopathic Pericarditis|AIR TRIP|Maria Vittoria Hospital|Yes|Completed|June 2014|October 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|5 Years|90 Years|No|||December 2015|December 17, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219828||38425|
NCT02219841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_ISOLATE|Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation|Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation|ISOLATE|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|August 2014|December 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|A total of 50 consecutive AF patients with BMI 26-40, will be enrolled in this pilot study        and randomized to 2 groups in a 1:1 design (25 per group).|January 2015|January 27, 2015|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219841||38424|
NCT02189317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073168|Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction|Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction||Emory University|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||April 2015|April 11, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189317||40764|
NCT02189330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461030|A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples|A Phase 1, Open-Label, Randomized, 2-Cohort, Crossover, Single Dose Study to Estimate the Relative Bioavailability of PF 06291826 (Tafamidis) Following Administration of Two Oral Formulations Versus Commercial Capsule in Healthy Subjects Under Fasted Conditions||Pfizer|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02189330||40763|
NCT02189603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HE-05|Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）|Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine（Hecolin®） in Seniors Aged Over 65 Years||Xiamen University|Yes|Recruiting|June 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|16 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02189603||40742|
NCT02190357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPDLCC-2|Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial|Rifaximin Reduces the Complications of Decompensated Cirrhosis||Shanghai Changzheng Hospital|Yes|Not yet recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||July 2014|July 12, 2014|July 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02190357||40684|
NCT02190344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-2014|Functionality of an 8-Channel Paddle Coil for Use With MRI|Study to Evaluate the Functionality of an Eight-Channel Paddle Coil System Using MRI||Sunnybrook Health Sciences Centre|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02190344||40685|
NCT02190604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBW251X2101|Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients|A Randomized, Double Blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of QBW251 in Healthy Subjects and Multiple Doses in Cystic Fibrosis Patients||Novartis|Yes|Terminated|July 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|July 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02190604||40665|
NCT02220894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-042|Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)|A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)||Merck Sharp & Dohme Corp.|Yes|Recruiting|October 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1240|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220894||38343|
NCT02221999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-BC-002|Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients|Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Hormone Receptor Positive Locally Advanced Breast Cancer Patients|SHPD002|RenJi Hospital|Yes|Recruiting|January 2014|October 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Female|18 Years|70 Years|No|||August 2014|August 20, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221999||38258|
NCT02191124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1051|The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial|Measurement-based Care vs. Standard Care for Major Depressive Disorder: a Randomized Controlled Trial With Masked Raters||Capital Medical University|Yes|Completed|June 2011|May 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|65 Years|No|||July 2014|July 15, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02191124||40625|
NCT02191137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17407|MOTION, Measuring Outcomes in Treatment Naive Patients|A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment||Bayer|No|Active, not recruiting|September 2014|July 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|80 Years|No|||February 2016|February 14, 2016|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02191137||40624|
NCT02221427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPS3293|The Labour Progression Study, a Cluster Randomised Trial on Labour Progression for First Time Mothers|The Labour Progression Study, a Cluster Randomised Trial on Labour Progression for First Time Mothers|LAPS|Ostfold Hospital Trust|Yes|Recruiting|December 2014|December 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|6582|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221427||38302|
NCT02221648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210011010|Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain|Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain||Yale University|No|Terminated|December 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||February 2016|February 9, 2016|April 1, 2014|Yes|Yes|PI retired and moved- funding sponsor contacted and Oked|No|September 7, 2015|https://clinicaltrials.gov/show/NCT02221648||38285|This study was terminated due to relocation of the PI. The initial goal was enrolling 90 patients. The number enrolled at the time of termination was 43, with 33 completed the study. Results may not provide enough statistical power.
NCT02221960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6050C00001|A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors||MedImmune LLC|No|Recruiting|September 2014|October 2019|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|99 Years|No|||February 2016|February 19, 2016|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221960||38261|
NCT02221973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.03.NRC|Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects|Effect of a Low Fat Milk Product on Serum Lipids Profile in Chinese Primary Dyslipidemia Subjects|Lipidown|Nestlé|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|No|||August 2014|November 11, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221973||38260|
NCT02222259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7879-CE|A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients|A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients (A GEM Study for Older Cancer Patients)||University of Toronto|No|Active, not recruiting|September 2014|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|70 Years|N/A|No|||December 2015|December 4, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222259||38238|
NCT02199353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46/2012|Occupational Therapy Programme of Patients With Dementia Performing Activities of Daily Living|Effectiveness of A Therapy Programme Based On The Reestablishment of Cognitive Functions on The Independence of Patients With Dementia Performing Activities of Daily Living - A Pilot Study|OTSALD|University of Extremadura|No|Completed|November 2012|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02199353||39994|
NCT02199600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02.014.01|The Medacta International GMK Sphere Post-Marketing Surveillance Study|||Medacta International SA||Recruiting|October 2012|||October 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02199600||39975|
NCT02199860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149.44|Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled, Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Two Spray-dried Formulations of BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|May 2003|||February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|63|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|July 24, 2014||||No||https://clinicaltrials.gov/show/NCT02199860||39956|
NCT02199912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.752|Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years With Colorectal Surgery|ANC2 Pilot Study Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years With Colorectal Surgery|ANC2|Hospices Civils de Lyon|No|Recruiting|October 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|70 Years|N/A|No|||May 2014|July 21, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02199912||39952|
NCT02200146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HySSAS-FARM639KLZ|Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).|Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.|HySSAS|University of Milano Bicocca|Yes|Completed|March 2009|September 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|70 Years|No|||July 2014|July 24, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02200146||39934|
NCT02189343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-MM-104|Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma|A Phase 1B Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma||Acetylon Pharmaceuticals Incorporated|Yes|Recruiting|August 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02189343||40762|
NCT02189356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-348-11/1539-227|Gulhane Military Medical Academy Ethical Committee Exercise Program for Pregnant Women With Low Back and Pelvic Pain|Evaluation of the Efficacy of an Exercise Program for Pregnant Women With Low Back and Pelvic Pain: A Prospective Randomized Controlled Trial||Gulhane Military Medical Academy|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|96|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||July 2014|July 12, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02189356||40761|
NCT02219854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASS-01|Single-center Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer|||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|19 Years|74 Years|No|||November 2015|November 7, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219854||38423|
NCT02189902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812323|Botswana Vitamin D Supplementation Study in HIV/AIDS|Botswana Vitamin D Supplementation Study in HIV/AIDS||Children's Hospital of Philadelphia|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|51 Years|No|||July 2014|July 14, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02189902||40719|
NCT02190149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061302|Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS|Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS|SPACE|Baxalta US Inc.|No|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|63|||Both|13 Years|65 Years|No|Non-Probability Sample|Hemophilia treatment center (HTCs) in the US will be identified and invited to enroll        eligible patients in this study|December 2015|December 16, 2015|July 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02190149||40700|
NCT02218983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|620651|The Prognostic Value of Limited Transthoracic Echocardiogram (LTTE) During Trauma Resuscitation|The Prognostic Value of Limited Transthoracic Echocardiogram (LTTE) During Trauma Resuscitation||Riverside County Regional Medical Center|No|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|85 Years|No|||May 2015|May 6, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218983||38490|
NCT02219789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1231|Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery|A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer||Mayo Clinic|Yes|Suspended|September 2014|||September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||April 2015|November 16, 2015|August 15, 2014|No|Yes|Per Study Design|No||https://clinicaltrials.gov/show/NCT02219789||38428|
NCT02220049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014354-15|Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors|Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors|VELDAY|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|December 2010|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||March 2016|March 24, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220049||38408|
NCT02213471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX001|Patient Preference for Biopsy Notification|Patient Preference for Biopsy Notification||University of California, San Francisco||Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals at increased risk for melanoma due to past history of melanoma, family history        of melanoma, the presence of many moles, the presence of a genetic mutation known to        increase the risk of melanoma. Individuals were followed in a Pigmented Lesion Clinic.|August 2014|August 8, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213471||38913|
NCT02213159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.CZ.2|Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery|Intraoperative Dexmedetomidine Versus Morphine for Postoperative Analgesia After Laparoscopic Bariatric Surgery||American University of Beirut Medical Center|No|Recruiting|July 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||June 2015|June 23, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213159||38936|
NCT02220881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|silicone HV|Mold Making Silicone Toe Separator on Hallux Valgus|Effectiveness of Mold Making Silicone Toe Separator on Hallux Valgus: A Prospective, Randomized Single-Blinded Controlled Trial||Mahidol University|No|Recruiting|November 2013|May 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2014|August 18, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02220881||38344|
NCT02221154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 096-13|Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)|Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)|FIV-INOPK|Centre Hospitalier Departemental Vendee|Yes|Recruiting|November 2014|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|280|||Female|18 Years|38 Years|No|||January 2016|January 6, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221154||38323|
NCT02221401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.1|Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed-dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 1000 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)||Boehringer Ingelheim||Completed|January 2010|||April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02221401||38304|
NCT02221414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.2|Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)||Boehringer Ingelheim||Completed|January 2010|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02221414||38303|
NCT02221635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yunchun Chen|Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective|A Study to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder||Xijing Hospital|Yes|Recruiting|March 2013|January 2015|Anticipated|December 2014|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|540|||Both|18 Years|65 Years|No|Probability Sample|Ages Eligible for Study: 18 Years to 65 Years Genders Eligible for Study: Both Accepts        Healthy Volunteers: No|August 2014|August 18, 2014|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02221635||38286|
NCT02221947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTRP101-201|Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease||Neurotrope Bioscience, Inc.|No|Terminated|June 2014|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|50 Years|85 Years|No|||April 2015|April 23, 2015|July 2, 2014|Yes|Yes|Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.|No||https://clinicaltrials.gov/show/NCT02221947||38262|
NCT02210585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC13.554|Study of Neuromuscular Electrical Stimulation to Increase Spontaneous Physical Activity in Obesity Patient|Study of Multi-site Neuromuscular Electrical Stimulation to Increase Spontaneous Physical Activity in Obesity Patient Carrying Severe Inactive: Randomized Controlled Trial vs Placebo|STIMOBIII|University Hospital, Grenoble|Yes|Recruiting|May 2014|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|80 Years|No|||August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210585||39133|
NCT02206698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030071|Pediatric Blunt Abdominal Trauma Clinical Prediction Model|Multicenter, Prospective Development of a Clinical Prediction Model to Determine Which Children Can Safely Avoid Abdominal CT Scanning During the Initial Evaluation of Blunt Abdominal Trauma||Medical University of South Carolina|Yes|Recruiting|July 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|15 Years|No|Non-Probability Sample|Children with blunt abdominal trauma|April 2015|May 14, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206698|30 Days|39431|
NCT02206932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC435HPC2008|A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C|An Open Label, Pilot Study to Investigate the Safety and Efficacy of 12 Weeks of Simeprevir and Sofosbuvir, for HIV-infected, HCV Genotype 1 Patients With Advanced Fibrosis||University of California, San Francisco|No|Withdrawn||||November 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206932||39413|
NCT02222519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014071801|Interaction of Statins and Nondepolarizing Muscle Relaxants|Interaction of Statins and Nondepolarizing Muscle Relaxants||First Hospital of China Medical University|Yes|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|40 Years|80 Years|No|Non-Probability Sample|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three        months.        Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least        three months|October 2014|October 22, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02222519||38218|
NCT02222532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GITX-14-60143-0|Oral Triiodothyronine for Infants Less Than 5 Months & Malnourished Children Undergoing Cardiopulmonary Bypass in Indonesia|Tetronine (Sodium Liothyronine) for Infants & Children Undergoing Cardiopulmonary Bypass in a Middle Income Nation (OTICC Study)|I-TRICC|National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Completed|June 2013|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|N/A|36 Months|No|||February 2016|February 16, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222532||38217|
NCT02218528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1716|Effect of a Plant-based Ingredient on Glucose Response|An Exploratory Study of a Plant-based Ingredient for Reducing the Post-prandial Blood Glucose Response in Healthy Indian Adults, When Administered With a Meal||Unilever R&D|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|February 17, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218528||38525|
NCT02218541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2376|Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.|Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.||University of North Carolina, Chapel Hill|No|Active, not recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218541||38524|
NCT02218515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-C-DRP-090909-0288|Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft|Evaluation of Gingival Crevicular Fluid Transforming Growth Factor-β1 Level After Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft||Marmara University|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|32 Years|57 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218515||38526|
NCT02218801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1409-GITCG|A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program|A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program|CLIMB|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|None Retained|whole blood, plasma, serum and left-over tissue samples from either primary tumor or liver      metastasis|Both|18 Years|N/A|No|Non-Probability Sample|Patients with liver metastasis of colorectal adenocarcinoma (unresectable, borderline        resectable or initially unresectable)|January 2016|January 28, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02218801|2 Years|38504|
NCT02218996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID416|Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics|Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)|TADCAROC|Helse Stavanger HF|No|Recruiting|August 2014|December 2027|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|260|||Both|7 Years|17 Years|No|Non-Probability Sample|Children/adolescents from 7-17 years old referred to ordinary outpatient mental health        service.|January 2016|January 4, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02218996||38489|
NCT02219009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316-14-220|Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole|A Multicenter, 8-week, Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adult Subjects With Schizophrenia Who Are Treated With Oral Aripiprazole||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219009||38488|
NCT02219269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140166|A Complex Contraception Registry|A Complex Contraception Registry - UC Family Planning Collaborative Study||University of California, San Diego|Yes|Recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|45 Years|No|Non-Probability Sample|The study population will consist of women 18-45 years old and seeking contraception with        the medical condition listed in inclusion criteria. Participants will be recruited from        obstetrics and gynecology clinic at UCSD, UCLA, UCSF, UC Irvine and UC Davis. 250        participants will be enrolled. Approximately 50 cases will be recruited at each site.|December 2014|December 2, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02219269|6 Months|38468|
NCT02220062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02-088-005|Randomized, Controlled Trial of Endoscopic Ultrasound-Guided Bilateral Celiac Plexus Neurolysis vs Celiac Ganglia Neurolysis to Control Pain in Inoperable Pancreatic Cancer Patients With Inadequate Pain Control by Pain Killer|||Samsung Medical Center||Not yet recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|166|||Both|19 Years|N/A|No|||August 2014|August 18, 2014|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02220062||38407|
NCT02220335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140618|Pulmonary Arterial Denervation in Patients With Pulmonary Arterial Hypertension Associated With the Left Heart Failure|Pulmonary Arterial Denervation in Patients With Pulmonary Arterial Hypertension Associated With the Left Heart Failure: a Randomised Controlled Trial|PADN-5|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|August 2014|December 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02220335||38386|
NCT02213172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PIHL|Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome-Constipation (IBS-C)|Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome-Constipation (IBS-C): an 8-Week, Randomized, Placebo-Controlled Study|14PIHL|KGK Synergize Inc.||Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|285|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213172||38935|
NCT02213692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2014-051|Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method|Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method: A Prospective Randomized Study||Fudan University|Yes|Terminated|May 2014|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|80 Years|No|Probability Sample|Genders Eligible for Study: Both Accepts Healthy Volunteers: No|February 2016|February 2, 2016|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02213692|7 Days|38896|
NCT02213705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC Severe Systemic Sclerosis|Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells|Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells|MSC|Assistance Publique - Hôpitaux de Paris||Recruiting|June 2014|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||September 2015|September 24, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02213705||38895|
NCT02213952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIAPB-PRPULCERAS-2014-02|PRP ULCERAS: Clinical Trial Phase III|Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III|PRPULCERAS|Basque Health Service|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|N/A|No|||August 2015|August 24, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02213952||38876|
NCT02209701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1164.3|Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors|A Phase I Intensive Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors Who Receive Radiation Therapy||Boehringer Ingelheim||Terminated|December 1999|||July 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209701||39200|
NCT02209714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1157.4|Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Citric Acid Challenge) Study After Oral Administration of BIIF 1149 BS (Single Doses as Tablets: 40, 65, 100 mg) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel Groups)||Boehringer Ingelheim||Completed|November 1999|||February 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209714||39199|
NCT02210026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seattle-PAP 001|Seattle-PAP Bubble Nasal CPAP and Work of Breathing|A Study to Evaluate the Efficacy of Seattle-PAP for the Respiratory Support of Premature Infants|Seattle-PAP|Seattle Children's Hospital|Yes|Recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|N/A|72 Hours|No|||August 2014|August 5, 2014|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210026||39175|
NCT02210325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-302|Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea|An Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of Oral Solithromycin Compared to Single-Dose Intramuscular Ceftriaxone Plus Single-Dose Oral Azithromycin in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea With or Without Concomitant Chlamydia|SOLITAIRE-U|Cempra Inc|No|Active, not recruiting|August 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|15 Years|N/A|No|||November 2015|November 10, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210325||39152|
NCT02229032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0294|Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population|Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population||University of Colorado, Denver|No|Recruiting|August 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|saliva for DNA analysis|Both|N/A|50 Years|No|Non-Probability Sample|Patients with Dravet Syndrome, ages 1-50, who are self- seeking therapy with Charlotte's        Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are        still naïve to therapy|March 2016|March 18, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229032||37717|
NCT02232880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121740|Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation|Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation||Vanderbilt University|Yes|Terminated|August 2014|August 2015|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|August 12, 2014|Yes|Yes|failure to recruit|No||https://clinicaltrials.gov/show/NCT02232880||37421|
NCT02218554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-BNJ-001-PR|Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay|Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay.|BRONJ|Micromedic Technologies Ltd|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2014|August 14, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02218554||38523|
NCT02218840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-021CTP|Behavioral Pharmacology Associated With Cigar Smoking|Behavioral Pharmacology Associated With Cigar Smoking||Food and Drug Administration (FDA)|Yes|Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|106|Samples Without DNA|blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|The subjects will be cigar smokers who are not seeking treatment for smoking cessation and        who are not currently using any other type of tobacco, but may be former users.|August 2014|August 14, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02218840||38501|
NCT02218827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dry eye01|Topical Steroid Treatment For Dry Eye|Evaluation of Steroidal Treatment For Dry Eye Disease||Meir Medical Center|Yes|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||August 2014|August 14, 2014|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218827||38502|
NCT02218814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10231969|Study to Evaluate ACB Versus FNB Early Postoperative Period Functional Outcomes After TKA|Prospective, Double-blind, Randomized Study to Evaluate a Single Shot Adductor Canal Nerve Block Versus Femoral Nerve Block Combined With LIA (Local Infiltration Analgesia): Early Postoperative Period Functional Outcomes After Total Knee Replacement|ACB|Presence Saint Joseph Medical Center|Yes|Completed|August 2014|January 2016|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|40 Years|80 Years|No|||January 2016|January 29, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02218814||38503|
NCT02219022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UNIFESP 1826/10|Progressive Resistance Exercise in Rheumatoid Arthritis|Progressive Resistance Exercise in Rheumatoid Arthritis Patients: a Randomized Controlled Trial||Federal University of São Paulo|No|Recruiting|July 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02219022||38487|
NCT02219295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 11005D|SEGATROM: Sensory and Gastrointestinal Impact of Taste Receptor Variants on Human Metabolism and Nutrition|Sensory and Gastrointestinal Impact of Taste Receptor Variants on Human Metabolism and Nutrition|SEGATROM|German Institute of Human Nutrition|No|Completed|December 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|97|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02219295||38466|
NCT02219282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/08-15|Geriatric Patients and Laryngeal Mask Unique|A Comparison of Laryngeal Mask UniqueTM in Denticulate and Edentulate Geriatric Patients||Dokuz Eylul University|No|Completed|August 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|66|||Both|65 Years|N/A|No|||August 2014|August 15, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02219282||38467|
NCT02212886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI GA Depot - 001|Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS|A Prospective 1-year, Open-label, Two Arms, Multicentre, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis(RRMS)||Mapi Pharma Ltd.|No|Recruiting|October 2014|April 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||December 2014|January 28, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212886||38957|
NCT02213146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT010|A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes||Adocia|No|Completed|August 2014|June 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|38|||Male|18 Years|64 Years|No|||June 2015|June 16, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213146||38937|
NCT02213484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0567|Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes|Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes||University of Colorado, Denver|No|Recruiting|August 2014|July 2019|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Fractionated blood samples will be retained at a part of the study including plasma,      platelets and mononuclear cells. At this time genetic testing (genotyping) of individual      biospecimens is not included in the IRB-approved protocol.|Both|N/A|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|All individuals up to 60 years seen in the Children's Hospital of Colorado and University        Hospital Marfan Syndrome Clinics will be eligible for enrollment in this study.        Individuals with a clinical diagnosis of Marfan syndrome with or without genetic        confirmation will be included as will patients with recognized aortopathy syndromes or        family history of aortopathy with evidence of aorta disease. Subjects will be primarily        recruited through the Heart Institute at Children's Hospital Colorado and through the        cardiology team at the University of Colorado Hospital. Pediatric patients with Marfan        syndrome and related aortopathy syndromes are primarily followed in the Principal        Investigator, Dr. Chatfield's, Cardiac Genetics Clinic at Children's Hospital Colorado and        will be recruited from this clinic. Adult patients with aortopathy syndromes are followed        primarily in the Adult Congenital Heart Disease Clinic at University of Colorado Hospital.|January 2016|January 5, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213484||38912|
NCT02213718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140607|The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting|The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting||Huazhong University of Science and Technology|Yes|Recruiting|July 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|40 Years|60 Years|No|||August 2014|August 7, 2014|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213718||38894|
NCT02213731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cryo4 Persistent AF|Cryoballoon Ablation for Early Persistent Atrial Fibrillation (Cryo4 Persistent AF)|Cryoballoon Ablation for Early Persistent Atrial Fibrillation||Medtronic Atrial Fibrillation Solutions|No|Recruiting|December 2014|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02213731||38893|
NCT02213744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-302-02-02-03|MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients|A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer|HERMIONE|Merrimack Pharmaceuticals||Recruiting|July 2014|||February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213744||38892|
NCT02213965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H 1411|Study Comparing the Handling of Two Peripheral IV Catheter Systems|Clinical Investigation Acc. to MPG §23b: Open-label Prospective Study Comparing the Handling of the Handling of Two Peripheral IV Catheter (PIV) Systems (Ported and Non Ported) in Randomized Order||B. Braun Melsungen AG|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2268|||Both|N/A|N/A|No|Probability Sample|Adults and children|January 2016|January 13, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02213965||38875|
NCT02213978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU-VTE-2014|A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients|A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients|VTEH|Beijing Chao Yang Hospital|Yes|Recruiting|November 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|the critical ill patients in ICUs|March 2016|March 23, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213978|2 Weeks|38874|
NCT02209727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152.6|Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|A Phase I Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer||Boehringer Ingelheim||Terminated|December 2000|||June 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209727||39198|
NCT02209740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDFOUT|Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies|A Prospective, Cohort Study of Renal and Bone Outcome After Changing Tenofovir in Patients With Renal Toxicity According to Antiretroviral Strategy|TDFOUT|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients in regular clinical and analytical follow up, receiving a        tenofovir-containing regimen|December 2015|December 28, 2015|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02209740||39197|
NCT02210039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-001213|Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe|Pilot Study to Image the Esophagus Using a SECM Probe||Massachusetts General Hospital|No|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|12|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210039||39174|
NCT02210052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003619|Safety of Spine Radiofrequency Procedures|Safety of Lumbar Spine Radiofrequency Procedures in the Presence of Posterior Pedicle Screws: A Prospective Trial||Mayo Clinic|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|6|||Both|18 Years|100 Years|No|||March 2016|March 14, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210052||39173|
NCT02210078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0657|Third-Party Cytotoxic T-Lymphocytes (CTLs) for Cytomegalovirus (CMV) Infection|Most Closely HLA Matched Allogeneic CMV Specific Cytotoxic T-Lymphocytes (CTL) to Treat CMV Infection After Hemopoietic Stem Cell Transplantation (HSCT)||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 28, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210078||39171|
NCT02210624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYNR_CS_ABI001|Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial|An Open-label, Safety and Efficacy Assessment of Autologous Bone-marrow Derived Mesenchymal Stem Cell Therapy in Anoxic (or Hypoxic) Brain Injury.||Hanyang University Seoul Hospital|Yes|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|75 Years|No|||August 2014|August 6, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02210624||39130|
NCT02232776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Losartan_IgA_2014|Efficacy and Safety of Losartan in Children With Ig A Nephropathy|A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy||Seoul National University Hospital|No|Recruiting|October 2014|November 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|24 Months|18 Years|No|||November 2015|November 16, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232776||37429|
NCT02232789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIMFTCL/MEF/1|Abuse Liability and Human Pharmacology of Mephedrone|Abuse Liability and Human Pharmacology of Mephedrone (4-methylmethcathinone,4-MMC)||Parc de Salut Mar|Yes|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02232789||37428|
NCT02235350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|neuromedbuccino01|Action Observation Treatment (AOT) as a Rehabilitation Tool|Study on the Effectiveness of Action Observation Treatment (AOT) as a Rehabilitation Tool in Acute Stroke Patients and in Chronic Stroke Patients With Apraxia: a Randomized Controlled Trial|AOT|Neuromed IRCCS|Yes|Recruiting|June 2014|June 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|85 Years|No|||September 2014|September 9, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235350||37231|
NCT02210845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOS-23|Lifestyle Strategies for Improving Diabetes Outcomes|Impact of Two Lifestyle Strategies for Improving Diabetes Related Health Outcomes in a Specialty Care Setting: A Randomized Controlled Trial||BCDiabetes.Ca|Yes|Not yet recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210845||39113|
NCT02211079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105152|A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates|An Open-Label, Fixed-Sequence Study in Healthy Male Subjects to Assess the Drug Interaction Potential of Multiple-Doses of JNJ-54861911 With a Drug "Cocktail" Representative for CYP3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates||Janssen Research & Development, LLC|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211079||39095|
NCT02219048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9111007|An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 12 Weeks In Subjects With Persistent Moderate To Severe Asthma Who Remain Uncontrolled Despite Treatment With Inhaled Corticosteroids (Ics) And Long-acting Beta2 Agonists (Laba)||Pfizer|Yes|Terminated|November 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|August 14, 2014|Yes|Yes|The termination was due to business reasons. No safety or efficacy concerns contributed to the    termination of the study|No||https://clinicaltrials.gov/show/NCT02219048||38485|
NCT02219035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0088|A Prospective Investigation of the VWF-ADAMTS 13 Axis in Acute Ischaemic Brain Injury (TIAs and Stroke).|A Prospective Investigation of the VWF-ADAMTS 13 Axis in Acute Ischaemic Brain Injury (TIAs and Stroke).||University College, London|Yes|Not yet recruiting|December 2014|||December 2016|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|all acute admissions presenting with ? stroke|August 2014|August 15, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02219035||38486|
NCT02219308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141025|Pain Control for Intrauterine Device Placement Using Paracervical Block|Pain Control for Intrauterine Device Placement: A Randomized Controlled Trial of Paracervical Block||University of California, San Diego|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02219308||38465|
NCT02219568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si624/2013|Efficacy of Wireless Capsule Endoscopy and CT Enterography in Obscure Gastrointestinal Bleeding|Efficacy of Wireless Capsule Endoscopy and CT Enterography in Obscure Gastrointestinal Bleeding : Prospective Blinded Comparative Study||Mahidol University||Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02219568||38445|
NCT02219542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140804|Cytokines of Patients With Transversus Abdominis Plane Block After Laparoscopic Colonic Surgery|Cytokines of Patients After Laparoscopic Colonic Surgery||China Medical University, China|Yes|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||May 2014|June 30, 2015|August 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219542||38447|
NCT02219555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003444|DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome|DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome|DUCATS|Mayo Clinic|No|Recruiting|September 2014|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|21 Years|80 Years|No|||December 2015|December 30, 2015|August 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219555||38446|
NCT02212587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPBCC002|Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex|Pilot Study of the in Vivo Efficacy of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex||St. Michael's Hospital, Toronto|No|Not yet recruiting|September 2014|||September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|N/A|No|||July 2014|August 6, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212587||38979|
NCT02212600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHF2014|Proximal Humerus Fracture: A Prospective Cohort|Determinants of Functional Outcome and Quality of Life in Patients With a Low Energy, Proximal Humerus Fracture: A Prospective Cohort||St. Michael's Hospital, Toronto|No|Not yet recruiting|June 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|50 Years|N/A|No|Probability Sample|We will include male and female patients who are over 50 years of age and who have an        acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma and        who provide written informed consent.|November 2015|November 16, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212600|2 Years|38978|
NCT02212899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN111|Prospective, Observational Registry of Renaissance-guided Spine Surgeries|Prospective, Observational Registry of Renaissance-guided Spine Surgeries||Mazor Robotics|No|Recruiting|February 2015|February 2025|Anticipated|February 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|6 Years|90 Years|No|Non-Probability Sample|Any pediatric, adolescent or adult patient undergoing open or MIS Renaissance-guided spine        surgery|March 2016|March 20, 2016|May 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02212899|10 Years|38956|
NCT02212951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-152|Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500|A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day||Biodel|No|Completed|May 2014|||July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212951||38952|
NCT02213497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01214|Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer|Phase I Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2014|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02213497||38911|
NCT02213757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-071|Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)|Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH): A Randomized Controlled Trial [EVER Study]|EVER|Medstar Research Institute|No|Recruiting|August 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Female|N/A|N/A|No|||March 2016|March 14, 2016|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213757||38891|
NCT02209441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAY43|Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer|||Chinese Academy of Medical Sciences||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2014|August 4, 2014|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209441||39220|
NCT02209454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 303/25652(DKP-BE-SOL)|Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations|Comparative Study of the Bioavailability of Dexketoprofen Trometamol Following Single Doses of 25mg Enantyum® Oral Solution vs. Keral® Tablets in Healthy Subjects||Menarini Group|No|Completed|April 2014|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|June 16, 2015|August 4, 2014||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT02209454||39219|
NCT02209753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.10|BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis|Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center, Four Week Trial of BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets Versus Placebo Administered BID in Patients With Moderate to Severe Plaque-type Psoriasis||Boehringer Ingelheim||Completed|June 2001|||September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|182|||Both|18 Years|75 Years|No|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209753||39196|
NCT02209766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5881C00005|A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics in Healthy Male Japanese (Single-blind, Randomized, Placebo-controlled) and Caucasian (Open-label) Subjects After Single and Once Daily Multiple Oral Doses of D5884||AstraZeneca|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02209766||39195|
NCT02210065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0620|Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation|The Pre-Emptive Use of Recipient-Derived Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation After Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210065||39172|
NCT02210091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261202|BAX 855 Pediatric Study|A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A||Baxalta US Inc.|Yes|Completed|September 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|11 Years|No|||November 2015|November 6, 2015|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210091||39170|
NCT02210104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0669|Adoptive Therapy Using Antigen-Specific CD4 T-Cells|Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210104||39169|
NCT02209779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.11|Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis|A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD||Boehringer Ingelheim||Completed|May 2001|||June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|167|||Both|18 Years|75 Years|No|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209779||39194|
NCT02209792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.12|Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease|A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.||Boehringer Ingelheim||Terminated|October 2001|||January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|284|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209792||39193|
NCT02210936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14047|SCOSI-M: Preventing Prescription Drug Problems|Preventing Prescription Drug Problems: A Pilot Military Opioid Safety Initiative||Brandeis University||Not yet recruiting|July 2014|||September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|1||||||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02210936||39106|
NCT02235220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canine guidance / Grindcare|Reduction of Masticatory Muscle Activity by Restoring Canine Guidance|Reduction of Masticatory Muscle Activity by Restoring Canine Guidance With Composite Resin Fillings in Patients With Bruxism.||University of Kiel|No|Enrolling by invitation|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02235220||37241|
NCT02225470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-C086-304|Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane||Eisai Inc.||Active, not recruiting|September 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|522|||Female|18 Years|70 Years|No|||June 2015|June 4, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02225470||37991|
NCT02225782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFOC140002|Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function|A Randomized Double-blind Controlled Study to Compare the Effectiveness of 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring||University of Windsor|No|Not yet recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225782||37967|
NCT02211092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-129|Feasibility Study of a Home-based Physical Activity Intervention for Family Caregivers of People With Advanced Cancer|Development and Pilot Testing of a Home-Based Physical Activity Intervention for Family Caregivers of People With Advanced Cancer||Jewish General Hospital|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211092||39094|
NCT02211417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS107G-02|Oral DS107G in Moderate to Severe Atopic Dermatitis|A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis||Dignity Sciences Ltd.|No|Completed|January 2015|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211417||39069|
NCT02211391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 2014.13509|Nighttime Protein Intake on Overnight Lipolysis and Morning Fat Oxidation in Obese Men|The Effect of Nighttime Protein Intake on Overnight Lipolysis and Morning Fat Oxidation in Obese Men.||Florida State University|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02211391||39071|
NCT02211404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00326|Children's Sleep in the ICU|||Nationwide Children's Hospital||Enrolling by invitation|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|18 Years|No|Non-Probability Sample|Children admitted to the Intensive Care Unit|August 2015|August 6, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211404||39070|
NCT02219321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062014-002|Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients|Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2014|May 26, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219321||38464|
NCT02212327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140157|Testing Tissue Sodium Stores in CAPD Patients—Aims 1 & 2|Testing Tissue Sodium Stores in CAPD Patients Receiving Icodextrin or Glucose-Based Dialysate, A Randomized Trial—Aims 1 & 2||Vanderbilt University|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|blood and urine samples|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients on PD and healthy controls|January 2016|January 18, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212327||38999|
NCT02219802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48495.100.14|Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction|Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.|REVELATION|Onze Lieve Vrouwe Gasthuis|Yes|Not yet recruiting|August 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||August 2014|August 15, 2014|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02219802||38427|
NCT02213198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-6506|Improving Transitional Care Experiences in Mental Health|Improving Transitional Care Experiences in Mental Health||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213198||38933|
NCT02213523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABG AOX-1|ABG Oxidative Stress Study Protocol-1|Proof of Concept Study to Evaluate the Effect of Oxidative Stress Response of Plant Concentrate Blends in Healthy Men||Access Business Group|Yes|Completed|September 2012|December 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|60|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213523||38909|
NCT02213211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA475|School-based Programme of Malaria Diagnosis and Treatment in Southern Malawi|Impact of a School-based Programme of Malaria Diagnosis and Treatment on School Attendance in Southern Malawi||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|April 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3480|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||August 2014|October 8, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213211||38932|
NCT02213510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140718|ZIPS Study - Zip Incision aPproximation vs. Suture|A Prospective, Non-blinded, Randomized Controlled Post-market Study Designed to Compare the Use of the Zip Surgical Skin Closure Device Versus Conventional Sutures for Skin Closure in Subjects Who Undergo a CIED Procedure.|ZIPS|University of California, San Diego|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213510||38910|
NCT02213770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/872/REK sør-øst C|Long Term Effect of High-intensity Training After Heart Transplantation|||Oslo University Hospital|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|41|Samples Without DNA|Blodsamples from the patients will be studied:      Standard samples: RBC, WBC, plates, CRP, kreatinin, urea, liver tests, thyorid gland tests,      lipid profile, fasting- glucose og hba1c, Pro BNP, troponin T, uric acid.      Supplement: Inflammation cytokines/chemokines such as TNF alfa, sTNFR2 og IL-6, IL-10, MCP-1      og IL-8. Growth factors and inhibitors for innervation. Markers for endothelial function;      endotelin and von- Willebrand faktor and anti- trombotic factors; fibrinogen, plasminogen      activator inhibitor-1.|Both|18 Years|80 Years|No|Probability Sample|The TEX population.|January 2016|January 22, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213770||38890|
NCT02209467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Researchweb 153691|Balance and Falls in Multiple Sclerosis|Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins||Örebro County Council|No|Completed|August 2014|August 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209467||39218|
NCT02209480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3497|Alexander Technique Neck Pain|Randomized Controlled Trial on the Efficacy of F.M. Alexander Technique in Chronic Neck Pain Patients|ATNeck|Universität Duisburg-Essen|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|50 Years|No|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209480||39217|
NCT02209805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.14|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 30, 60, and 120 mg) to Healthy Human Subjects for 14 Days. A Double-blind, Placebo-controlled, Parallel Group Study.||Boehringer Ingelheim||Completed|January 2001|||March 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209805||39192|
NCT02210117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0715|Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)|A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy||M.D. Anderson Cancer Center|Yes|Recruiting|November 2014|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210117||39168|
NCT02210338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sghan-cb01|A Comparison of the C-mac and Bonfils Intubation Fibrescope|A Comparison of the C-mac and Bonfils Intubation Fibrescope for Tracheal Intubation in Patients With a Simulated Difficult Airway||Singapore General Hospital|No|Recruiting|August 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|21 Years|80 Years|No|||June 2015|June 18, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210338||39151|
NCT02225483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:304|Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function|Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function||CancerCare Manitoba|No|Active, not recruiting|September 2014|July 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|42|||Male|3 Years|20 Years|No|Non-Probability Sample|Boys with severe Hemophilia A, Factor VIII coagulant activity less than or equal to 1%|January 2016|January 27, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02225483||37990|
NCT02225769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZ01Z0_146896|Electronic Algorithms Based on Host Biomarkers Point of Care Tests to Decide on Admission and Antibiotic Prescription in Tanzanian Febrile Children|Electronic Algorithms Based on Host Biomarkers Point of Care Tests to Decide on Admission and Antibiotic Prescription in Tanzanian Febrile Children|e-POCT|Swiss Tropical & Public Health Institute|Yes|Not yet recruiting|September 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|3500|||Both|2 Months|59 Months|No|||August 2014|August 29, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225769||37968|
NCT02230462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02922|Patient Satisfaction After Facial Reconstruction|Effects of Visualization of Pre-operative Defects on Patient Satisfaction After Facial Reconstruction for Skin Cancer Resection.||University of British Columbia|No|Not yet recruiting|October 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|N/A|No|||October 2014|October 2, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02230462||37607|
NCT02211430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-832|Smoking Cessation for Low-Income Pregnant Women|Smoking Cessation for Low-Income Pregnant Women|ACS|Fox Chase Cancer Center|No|Completed|October 2002|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|277|||Female|18 Years|N/A|No|||August 2014|August 6, 2014|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02211430||39068|
NCT02211443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT200mCRCI|Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer|A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody，in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment||Sinocelltech Ltd.|No|Enrolling by invitation|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|70 Years|No|||April 2015|April 8, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211443||39067|
NCT02211703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDI0091|National Epidemiologic Survey on the Incidence of Perioperative Hypothermia|National Epidemiologic Survey on the Incidence of Perioperative Hypothermia in Patients With Elective Surgery Under General Anesthesia in China||Peking Union Medical College Hospital|No|Not yet recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2208|||Both|18 Years|N/A|No|Probability Sample|patients with elective operation under general anesthesia|August 2014|August 6, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211703||39047|
NCT02211716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-131216|Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System|Physician-Initiated PMCF Trial Investigating the BeGraft Peripheral Stent Graft System for the Treatment of Iliac Lesions||Flanders Medical Research Program|Yes|Active, not recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211716||39046|
NCT02211690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0 dated 23 June 2014|The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis|The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis|dPEP|St Vincent's Hospital, Sydney|No|Active, not recruiting|August 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02211690||39048|
NCT02211677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014-002-01|Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma|Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of TNM Staging System in Nasopharyngeal Carcinoma: A Prospective Multi-institutional Observation Study||Sun Yat-sen University|No|Not yet recruiting|August 2014|July 2019|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|75 Years|No|Non-Probability Sample|All the participants involved in our study are patients who are first diagnosed        nasopharyngeal carcinoma pathologically and treated with radical radiotherapy or        chemoradiotherapy in ourhospital from August 1st 2014 to July 31st 2015.|August 2014|August 13, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211677||39049|
NCT02212574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1403|Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma|Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children With Wnt Positive Standard Risk Medulloblastoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|3 Years|18 Years|No|||October 2015|October 13, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212574||38980|
NCT02212340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0104|Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 in Vitrectomy|||Yonsei University|No|Recruiting|July 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|84|||Both|20 Years|80 Years|No|||August 2014|August 7, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212340||38998|
NCT02212639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130944|Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma|Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma|KADIG 01|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|80 Years|No|||September 2015|September 24, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212639||38975|
NCT02212938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233.3|Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers|Influence of a Standardised High Fat Breakfast on the Bioavailability of 10 mg BI 14332 CL Taken as Two Tablets of 5 mg q.d. in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Trial)||Boehringer Ingelheim||Completed|September 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02212938||38953|
NCT02213796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEROICU14|Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units|Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units||Prince of Songkla University|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213796||38888|
NCT02213783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIFN53-068-11-1-1|Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia|Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection.||Prince of Songkla University|No|Completed|February 2011|September 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|90 Years|No|||August 2014|August 8, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213783||38889|
NCT02209493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nopales-2014|Effects of Nopales (Opuntia Spp.) on Lipoprotein Profile and Oxidative Stress in Moderately Hypercholesterolemic Adults|The Efficacy of Nopales (Opuntia Spp.) on Lipoprotein Profile and Oxidative Stress Among Moderately Hypercholesterolemic Adults||Arizona State University|No|Completed|January 2013|March 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209493||39216|
NCT02209818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Perio-06-2014|Effect of Laser Application in Pain Management Following the Use of Orthodontic Elastomeric Separators|Evaluation of Low Level Laser Therapy (LLLT) Effect on Pain Management Caused by Orthodontic Elastomeric Separators||Damascus University|Yes|Completed|August 2014|February 2016|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|16 Years|45 Years|No|||March 2016|March 11, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209818||39191|
NCT02209831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.17|Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers|An Open Label, Randomised, Crossover Study of the Bioavailability of Oral BIRB 796 BS Tablets (30 mg Single Dose) With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers to Assess the Effect of Gastric pH on Absorption of BIRB 796 BS.||Boehringer Ingelheim||Completed|November 2001|||January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209831||39190|
NCT02209844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (2.5 mg to 1200 mg) of BI 44847 as Powder in the Bottle Reconstituted With 0.2% Natrosol Solution Administered to Healthy Male Subjects. A Randomised, Placebo-controlled (Within Dose Groups) and Double-blinded Trial||Boehringer Ingelheim||Completed|August 2006|||January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02209844||39189|
NCT02210130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR_2013-8|The Microvascular Brain Retina And Kidney Study|Measure of Specific Determinants of the Cerebral Small Vessel Disease in HIV+ Patients|MICROBREAK2|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|May 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|HIV patients over 50 years old, infected for at least 5 years, treated with antiretroviral        (ARV) therapy With (patients) or without Cerebral Small Vessels Disease|October 2015|October 27, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210130||39167|
NCT02210351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0829-DS-CTIL|Evaluation of Association Between Apical Dysfunction and Trans Apical Access for TAVR, in Patients With Severe Aortic Stenosis, Undergoing Trans Apical Trans Catheter Aortic Valve Replacement (TAP-TAVR).|Evaluation of Association Between Apical Dysfunction and Trans Apical Access for TAVR, in Patients With Severe Aortic Stenosis, Undergoing Trans Apical Trans Catheter Aortic Valve Replacement (TAP-TAVR).||Sheba Medical Center|No|Not yet recruiting|September 2014|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210351||39150|
NCT02210637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2301|Non Attendance at Scheduled Appointments as a Marker of Mortality and Hospital Admission|Non Attendance at Scheduled Appointments as a Marker of Visits in the Emergency Department, Hospitalization and Mortality||Hospital Italiano de Buenos Aires|No|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|177083|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We included all requested appointments (random consecutive sampling) between 2012 and 2013        (24 month).|December 2015|December 16, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02210637||39129|
NCT02229942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTS-6-2014|B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.|RituxME|Haukeland University Hospital|Yes|Active, not recruiting|September 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229942||37647|
NCT02233140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21660|Effectiveness of Manual Manipulation With EPAT on Ankle Dorsiflexion and Dynamic Plantar Pressure|Do Physical Manipulation Exercises With EPAT Improve Ankle Dorsiflexion and Reduce Dynamic Plantar Forefoot Pressure in Diabetic Subjects With Equinus?: A Pilot RCT||Temple University|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|21 Years|65 Years|No|||August 2015|August 26, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233140||37401|
NCT02230189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14224|Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics|Mechanistic Study of Epithelial miRNAs and T-cell Recruitment Dynamics That Occur After Allergen Challenge in Patients With Asthma.|ACE|University of California, San Francisco|Yes|Recruiting|March 2015|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230189||37628|
NCT02233478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000905|Comparing the Effect of Whey and Soy Protein on the Absorption of Pomegranate Polyphenols in the Human Body|Dietary Protein in Pomegranate Ellagitannin Bioavailability||University of California, Los Angeles|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|18|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02233478||37375|
NCT02237443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40262-D|Mask Ventilation Before and After Neuromuscular Blockade|Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial||University of Washington|No|Completed|August 2014|February 2015|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|90 Years|No|||April 2015|April 7, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02237443||37070|
NCT02210897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 14-2-016|Influence of Renal Function on the Circadian Variation of Cardiac Troponin|Influence of Renal Function on the Circadian Variation of Cardiac Troponin||Maastricht University Medical Center|Yes|Completed|August 2014|February 2016|Actual|January 2016|Actual|N/A|Observational|N/A||1|Actual|20|||Both|18 Years|100 Years|No|Probability Sample|Individuals with chronic kidney disease (CKD) stage 3 and 4|April 2015|February 17, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210897||39109|
NCT02211118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nystrom01|Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD|Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD||Dayton VA Medical Center|No|Recruiting|October 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|45 Years|70 Years|No|||October 2014|October 31, 2014|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211118||39092|
NCT02212080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16924|First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784|One-center, Randomized, Placebo-controlled, Double Blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (5-1000 mg, Solution) of BAY1214784 Including the Relative Bioavailability of BAY1214784 Administered as Solution With Two Different Concentrations in 56 Healthy Postmenopausal Women||Bayer|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|48|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212080||39018|
NCT02212366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131/2013|To Enhance Cognition in Late Life Depression Using Transcranial Direct Current Stimulation|Enhancing Cognition in Patients With Late-Life Depression: A Randomized Controlled Trial of Transcranial Direct Current Stimulation||Centre for Addiction and Mental Health|No|Recruiting|May 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|60 Years|N/A|No|||January 2016|January 28, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212366||38996|
NCT02212613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-13-004|Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability|Protocol 331-13-004: An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC 34712) (2 mg/Day Tablets) as an Adjunctive Treatment||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|September 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|55 Years|No|||January 2016|January 14, 2016|July 23, 2014|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT02212613||38977|
NCT02212041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149240|Electronic Cigarettes in Smokers With Mental Illness|Acceptability, Patterns of Use and Safety of Electronic Cigarette in People With Mental Illness: a Pilot Study|APUS e-Cigs|King's College London|No|Not yet recruiting|August 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|65 Years|No|||August 2014|August 6, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212041||39021|
NCT02212054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|A Trial on Treatments of Hirschsprung Allied Disease|A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Children With Hirschsprung Allied Disease||Tongji Hospital|Yes|Recruiting|August 2013|January 2015|Anticipated|August 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|14 Years|No|||August 2014|August 6, 2014|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212054||39020|
NCT02212067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3635|A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes|A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|August 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|87|||Both|18 Years|64 Years|No|||May 2015|May 12, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02212067||39019|
NCT02212626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-130326|Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion||ROBINSON|Flanders Medical Research Program||Recruiting|August 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212626||38976|
NCT02212353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTC-RP-PG-0311-12004|Care Delivery in Acute Hospital Settings: an Observational Study|Care Delivery in Acute Hospital Settings: an Observational Study. WP1 P3|PERFECTED|University of East Anglia|Yes|Completed|September 2014|||December 2014|Actual|N/A|Observational|Observational Model: Cohort||3|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Secondry Care|August 2014|May 15, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212353||38997|
NCT02212925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (0.5, 2.5, 10 and 20 mg q.d. for 10 Days) of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups), Followed by a 4-week Treatment Part* (Randomised, Double-blind, Placebo-controlled) of Two Doses (Planned 5 and 20 mg) Selected on the Basis of Tolerability and DPP-4 Inhibition in the Multiple Rising Dose Part||Boehringer Ingelheim||Terminated|November 2006|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|38|||Both|21 Years|70 Years|No|||August 2014|August 7, 2014|August 7, 2014||||No||https://clinicaltrials.gov/show/NCT02212925||38954|
NCT02213185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-9-2013|EMLA and Sterile Water Injections|Effect of EMLA® Patches for Reducing Pain Associated With Sterile Water Injections - a Randomized Controlled Trial||University of Skövde|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 27, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213185||38934|
NCT02213224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD20140805|Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease|Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial|NF-NAFLD|Nanfang Hospital of Southern Medical University|Yes|Recruiting|August 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|70 Years|No|||August 2014|August 8, 2014|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213224||38931|
NCT02213237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107031 RC|The Application of SERS and Metabolomics in Sepsis|The Application of SERS and Metabolomics in Sepsis||National Taiwan University Hospital|Yes|Recruiting|July 2011|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|N/A|N/A|No|Probability Sample|hospitalized patient with Septic shock|March 2015|March 18, 2015|October 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02213237||38930|
NCT02213822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2055-13|Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis|MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS||Rhode Island Hospital|No|Recruiting|May 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Tissue, blood, saliva, body fluid|Both|18 Years|N/A|No|Probability Sample|Patients in this study will have either a suspected or confirmed solid tumor or        hematological malignancy|July 2014|August 26, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02213822|5 Years|38886|
NCT02209506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN3126_103|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects||Takeda|No|Terminated|August 2014|February 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|August 4, 2014|No|Yes|Long-term animal toxicology findings (see detailed description).|No||https://clinicaltrials.gov/show/NCT02209506||39215|
NCT02209857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAK-TrA-20121|The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy|The Symphony Triple A Study: Using Symphony as an Adjunct to Histopathologic Parameters When the Doctor is Ambivalent About the Administration and Type of Adjunctive Systemic Therapy|Symphony|Diakonessenhuis, Utrecht|No|Recruiting|January 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|The tissue specimen for MammaPrint® analysis consists of a tumour block or 10 unstained      slides with 5µm section on each slide. The tissue can be shipped as formalin fixed paraffin      embedded (FFPE) tissue. For further information: www.agendia.com or www.symphonytripleA.nl.|Female|18 Years|N/A|No|Non-Probability Sample|The study population is the CBO 2012 guideline defined group of hormone receptor positive,        invasive ductal breast cancer patients when there is doubt about the indication for        adjuvant chemotherapy based on traditional prognostic factors. Patients are included and        MammaPrint® is determined after complete histological assessment following definitive        surgery. The following pathology items have to be recorded: tumour size, grade, ER- and        PR- receptor status, Her-2 neu status, and lymph node status. No difference is made in        ethnical background or past medical history other than cancer.|May 2015|August 24, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02209857||39188|
NCT02210143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDHF-2011-8-6|An Explorative Study To Develop A Predictive Model Based On Avascular Exposed Root Surface Area For Root Coverage|||Cukurova University||Completed|February 2011|||March 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|91|||Both|21 Years|41 Years|No|Probability Sample|Ninety one patients, 41 females and 50 males, aged between 21-41 years, with 91 isolated        single gingival recessions (32 Miller I, 29 Miller II, 30 Miller III defects) located at        upper and lower incisors and canines.|August 2014|August 5, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210143||39166|
NCT02210364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-006-12|Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)||PharmaMar||Active, not recruiting|April 2013|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||September 2015|January 14, 2016|August 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210364||39149|
NCT02210650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01 DK 043881 Project 3|Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney|Randomized Controlled Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney||Indiana Kidney Stone Institute|Yes|Recruiting|November 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|No|||February 2016|February 22, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210650||39128|
NCT02235883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130_2012|High Performance Computing of Personalized Cardio Component Models|High Performance Computing of Personalized Cardio Component Models|HEART|Transilvania University of Brasov||Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects scheduled to undergo clinically-indicated non-emergent invasive coronary        angiography, with suspected coronary artery disease|November 2015|November 13, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02235883||37190|
NCT02233309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00119|A Prospective Observational Study of Epidural Pressures During Caudal Epidural in the Pediatric Population|Epidural Pressure Changes Following Caudal Blockade: A Prospective Observational Study||Nationwide Children's Hospital|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|No|Non-Probability Sample|Patients who will be receiving caudal anesthesia as part of their surgical procedure.|May 2015|May 13, 2015|August 1, 2014||No||No|May 13, 2015|https://clinicaltrials.gov/show/NCT02233309||37388|
NCT02226341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN4752|ACTHar in the Treatment of Lupus Nephritis|Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.|ACTHar|Columbia University|Yes|Recruiting|October 2014|July 2024|Anticipated|January 2024|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|N/A|No|||March 2016|March 17, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226341||37924|
NCT02211482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-18|Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study|Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study|PADDLE|The Huesped Foundation|No|Active, not recruiting|October 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211482||39064|
NCT02211742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUI_001|Dapagliflozin in Type 1 Diabetes|Short-term Effects of Dapagliflozin on Fasting and Postprandial Glucose Homeostasis in Male Type 1 Diabetes Patients.|DapaT1DM|Medical University Innsbruck|Yes|Recruiting|August 2014|November 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|60 Years|No|||April 2015|April 7, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211742||39044|
NCT02211456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOUBLE-CRT_72014|An Assessment of Dual Site Left Ventricular Endocardial Pacing|Dual Site Left Endocardial Pacing for Cardiac Resynchronisation Therapy|DOUBLE-CRT|Oxford University Hospitals NHS Trust|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|60 Years|85 Years|No|||October 2015|October 16, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02211456||39066|
NCT02211469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM001-001|A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects|A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|41|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||April 2015|September 16, 2015|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211469||39065|
NCT02211729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/K007319/1|A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children|A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children|SMCAZ|London School of Hygiene and Tropical Medicine|Yes|Not yet recruiting|August 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|19200|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||August 2014|August 6, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02211729||39045|
NCT02212912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aic2014|Intervention to Bridge the Evidence-based Gap in Stroke Care Quality|Cluster-randomized Trial of a Targeted Multifaceted Intervention to Bridge the Evidence-based Gap in the Management of Acute Ischemic Stroke|GoldenBridge|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4400|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02212912||38955|
NCT02212379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000828-24|Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL|A Non-comparative Phase II Trial Evaluating the Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age With an HIV-RNA Plasma Viremia Below 50 Copies/mL Under a Current Boosted Protease Inhibitor Containing Regimen (ANRS 163 ETRAL)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|45 Years|N/A|No|||July 2015|November 30, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02212379||38995|
NCT02212392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ap3|Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics|COMPARING THE OUTCOME IN PATIENTS OF ACUTE PANCREATITIS, WITH AND WITHOUT PROPHYLACTIC ANTIBIOTICS.||Benazir Bhutto Hospital, Rawalpindi|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|70 Years|No|||August 2014|August 6, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02212392||38994|
NCT02213536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCA|Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.|Investigating the Efficacy of Scalp Sparing Radiotherapy Treatment to the Whole Brain: Examining the Effect of Hair Loss and Re-growth|SPARE|HCA International Limited|No|Recruiting|August 2015|April 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a positive cancer diagnosis requiring whole brain radiotherapy with a life        expectancy greater than 4 months.|February 2016|February 18, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213536||38908|
NCT02213549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-996|Effect of Coadministration of Ume Paste (Prunus Mume) and Ginger Powder|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effect of Ume Paste and Ginger Powder in Prediabetic Subjects.||Hiroshima University|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213549||38907|
NCT02218424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014MagRCT|Magnesium vs Placebo for Tonsillectomy|Systemic Magnesium to Improve Postoperative Pain in Pediatric Patients Undergoing Tonsillectomy: A Randomized, Double Blinded, Placebo Controlled Trial||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|4 Years|10 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02218424||38533|
NCT02209519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Randomized Controlled Trial of Treatment of Male Partners of Women With BV|Randomized Controlled Trial of Treatment of Male Partners of Women With BV||University of Alabama at Birmingham|No|Recruiting|February 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|736|||Both|19 Years|50 Years|No|||February 2016|February 29, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209519||39214|
NCT02209870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106044RC|The Impact of Resuscitation Quality of CPR Team by Implantation of Electronic Checklist and Alarming System Through Video-recording Analyses|The Impact of Resuscitation Quality of CPR Team by Implantation of Electronic Checklist and Alarming System Through Video-recording Analyses||National Taiwan University Hospital|No|Active, not recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department patient Out-of-Hospital cardiac arrest patient receive CPR in NTUH        Emergency Department Age > 18 years old|April 2015|April 1, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02209870||39187|
NCT02210156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omnilife 01|Effects of a Supplement on Acute Respiratory Infections|Effects of a Dietary Supplement on the Incidence of Acute Respiratory Infections in Susceptible Adults||Omnilife Manufactura, SA de CV|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210156||39165|
NCT02219191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSTA20141102|Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases|The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases||Chengdu PLA General Hospital|Yes|Active, not recruiting|August 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219191||38474|
NCT02210377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chang Gung IRB 102-4749A3|A Preliminary Randomized Study of Tianjiu (Auto-moxibustion) Effects in Patients With Intradialytic Hypotension|Department of Traditional Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung||Chang Gung Memorial Hospital|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Both|20 Years|75 Years|No|||January 2016|January 28, 2016|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02210377||39148|
NCT02219685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1445|Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection|A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||August 2015|August 18, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219685||38436|
NCT02225795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCNCPED1477|Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.|A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Children and Young Adults With Refractory Crohn's Disease.||Vanderbilt University|Yes|Active, not recruiting|August 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|10 Years|30 Years|No|||December 2014|December 5, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02225795||37966|
NCT02236091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELMAC|Monitoring Everyday Life Motor Activity in Children|Monitoring Everyday Life Motor Activity in Children|MELMAC|University Children's Hospital, Zurich|Yes|Recruiting|October 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|5 Years|18 Years|No|Non-Probability Sample|Patients will be inpatients from our rehabilitation center and will be recruited directly        by researchers working on this project|January 2016|January 19, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02236091||37174|
NCT02230995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.15|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (25 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric Meal (an Open-label, Randomised, Single Dose, Crossover Trial)||Boehringer Ingelheim||Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|August 29, 2014||||No||https://clinicaltrials.gov/show/NCT02230995||37566|
NCT02231008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-2401|Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS|||Vanda Pharmaceuticals|No|Recruiting|September 2015|||July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|16 Years|65 Years|No|||January 2016|January 8, 2016|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231008||37565|
NCT02211495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SC/0084|ULCERS - Electrical Stimulation in Diabetic Foot Ulceration|Electrical Stimulation in Diabetic Foot Ulceration||Imperial College London|Yes|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|June 1, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211495||39063|
NCT02211755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140161|Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors|Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|110 Years|No|||May 2015|March 2, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211755||39043|
NCT02212106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-USF-10-69|A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years|A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL's Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years of Age.||bioCSL PTY LTD|Yes|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|402|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||September 2015|September 20, 2015|August 6, 2014|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT02212106||39016|
NCT02212405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170/2010|Does the Insula Control Smoking-Induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans.|Does the Insula Control Smoking-Induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans (Part II).||Centre for Addiction and Mental Health|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|8|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02212405||38993|
NCT02212093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2338|5 Years Mortality-rate in Patients Treated for Severe Pneumonia in an ICU - a Retrospective Study|Cause-specific 5 Years Mortality-rate in Patients Treated for Severe Pneumonia in an ICU - a Retrospective Study|pneumonia|University Hospital, Akershus|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|236|Samples Without DNA|Bacteriology tests|Both|18 Years|N/A|No|Non-Probability Sample|The same as the inclusion criteria|July 2015|July 22, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212093||39017|
NCT02212964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO105014|Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*|Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*||Centre for Functional and Metabolic Mapping|No|Recruiting|July 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had treatment for brain neoplasms treated with radiation and/or        chemotherapy who presents with post-treatment imaging changes on the MRI following        treatment.|January 2016|January 26, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212964||38951|
NCT02213562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-997|Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Chrysanthemum Flower Oil and Its Dose-dependency in Subjects With Hyperuricemia||Hiroshima University|No|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|21|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213562||38906|
NCT02213809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/232-31/5|Case Method Education on COPD to General Practitioners|Effect of Case Method Education to General Practitioners on Their Knowledge on COPD and on the Health of Their Patients With COPD||Karolinska Institutet|No|Recruiting|October 2014|December 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Both|N/A|N/A|No|||March 2016|March 18, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02213809||38887|
NCT02218437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-2014-SAA-1|Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）|Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells.|MSC-SAA|Chinese Academy of Medical Sciences|Yes|Recruiting|October 2013|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Month|18 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02218437||38532|
NCT02218450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-2014-22|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||December 9, 2014|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218450||38531|
NCT02218723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200939|Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation|An Open-label, Randomised, Cross-over, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) With Four Different Formulations for the Delivery of Fluticasone Furoate and to Compare the Pharmacokinetic Profile With the Fluticasone Furorate ELLIPTA Presentation||GlaxoSmithKline|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|May 21, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218723||38510|
NCT02218918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSG01Rehab|Comparison of Supervised Ground Walk Training and Treadmill Walk Training in COPD Patients|Phase 0 Study of Comparison Between Ground Walk Training and Treadmill Walk Training in COPD Patients|GWT/TWT|PSG Hospitals|Yes|Active, not recruiting|July 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||August 2014|August 18, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02218918||38495|
NCT02219204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1142/44/2014|Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye|Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye||Singapore National Eye Centre|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219204||38473|
NCT02219425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miacol-2014-2H|Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women|Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women||University of Aarhus|Yes|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|August 15, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02219425||38456|
NCT02219412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0235|Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy|An Open Label, Two Arms, Randomized Controlled Pilot Study Comparing the Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable Coronary Artery Disease Treated With Ticagrelor Monotherapy or Ticagrelor and Asprin||Peking University First Hospital|No|Not yet recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2014|August 15, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02219412||38457|
NCT02219958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1685|Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)|Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)||The University of Hong Kong|No|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2496|||Both|18 Years|N/A|No|Probability Sample|All HT patients aged <80, without prior history of diabetes and existing cardiovascular        diseases, with suboptimal BP control (average systolic blood pressure (SBP) ≥ 140mmHg or        average diastolic blood pressure (DBP) ≥ 90mmHg) who were enrolled into RAMP-HT.|August 2014|August 16, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219958||38415|
NCT02220205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000106|Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions|Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions||Beth Israel Deaconess Medical Center|No|Completed|April 2014|October 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|59|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220205||38396|
NCT02230475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kingston General Hospital|Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes.|Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes Using the Environmental Exposure Unit (EEU). Part 2.|NMR|Queen's University|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|15|Samples With DNA|Urine samples will be retained for analysis via nuclear magnetic resonance. Blood samples      will be retained after separating the mononuclear layer. These samples will be tested for      epigenetic changes. Blood samples will also be retained for IgE testing.|Both|18 Years|55 Years|No|Non-Probability Sample|Healthy males and females 18-55 years old with ragweed induced allergic rhinitis.|April 2015|April 20, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02230475||37606|
NCT02233673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-276|Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women|Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women||University of Vermont|No|Recruiting|March 2014|December 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Female|18 Years|45 Years|No|||December 2015|December 1, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02233673||37360|
NCT02226068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CsAvsECP-AUH|Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis|Ciclosporine and Extracorporal Photopheresis (ECP) Are Equipotent in Treating Severe Atopic Dermatitis (AD): A Randomized Cross-over Study Comparing Two Efficient Treatment Modalities||University of Aarhus|No|Completed|June 2002|January 2004|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|45 Years|No|||August 2014|March 26, 2015|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226068||37945|
NCT02226081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE3|ShearWave™ Elastography of Breast Lesions in Chinese Patients|Assessment of ShearWave™ Elastography in the Ultrasonic Diagnosis of Breast Cancer in Chinese Patients|BE3|SuperSonic Imagine|No|Recruiting|June 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Female|18 Years|N/A|No|Non-Probability Sample|Chinese women (age of majority) who have been referred to a hospital or clinical for a        breast ultrasound evaluation.|May 2015|May 11, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226081||37944|
NCT02234115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP01C-13-001|Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma|An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma||Foresee Pharmaceuticals Co., Ltd.|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Male|18 Years|N/A|No|||December 2015|December 18, 2015|September 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234115||37326|
NCT02234128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXUS-14-001|Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility|A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™||Lung Bioengineering Inc.|No|Suspended|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|161|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 4, 2014|Yes|Yes|Vendor recall on device component|No||https://clinicaltrials.gov/show/NCT02234128||37325|
NCT02211768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140163|Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1|Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|10 Years|99 Years|No|||July 2015|February 17, 2016|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02211768||39042|
NCT02212145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100473|Follow-up of Sollentuna Prevention Program|Long-term Follow-up of an Individual and Population-based Program Aimed at Preventing Cardiovascular Disease in Sollentuna Municipality|SoPP|Karolinska Institutet|No|Active, not recruiting|June 1988|December 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||3|Anticipated|1600000|||Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. The screened group who participated in the cardiovascular prevention program:             (n=5938) and the rest of the population in Sollentuna Municipality.          2. To the screened group matched "controls" will be selected randomly from the             population of Stockholm County minus Sollentuna. The population in Sollentuna will             compared to the population of Stockholm County minus Sollentuna Municipality.          3. Relatives of individuals included in the intervention group and who lived in             Stockholm County at the time of the intervention will be identified by use of             national registers.|January 2015|January 19, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212145||39013|
NCT02212119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-036|Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness|A Randomized, Placebo Controlled Trial of Botulinum Toxin for Paratonic Rigidity in People With Advanced Cognitive Impairment||Assistive Technology Clinic, Canada|Yes|Completed|December 2010|January 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||August 2014|August 7, 2014|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212119||39015|
NCT02212132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METACAN|Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory|Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory||Centre Francois Baclesse|Yes|Completed|April 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Both|18 Years|65 Years|No|Non-Probability Sample|Patient being treated for a solid tumor or hematological|August 2015|August 5, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02212132||39014|
NCT02212418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UValladolid_1|Effect of an Abdominal Hypopressive Technique Program on Pelvic Floor Muscles and Urinary Incontinence in Women|Effect of an Abdominal Hypopressive Technique Program on Pelvic Floor Muscles and Urinary Incontinence in Women: A Randomized Cross-over Trial|UVa_1|University of Valladolid|No|Completed|March 2013|August 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Female|20 Years|65 Years|No|||August 2014|August 6, 2014|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02212418||38992|
NCT02212652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044789|Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes|The Effect of VItamin D Supplementation on Nutritional STatus and Adverse Outcomes in Bariatric Surgery (VISTA)|VISTA|Johns Hopkins University|No|Enrolling by invitation|January 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|64 Years|No|||March 2015|March 30, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212652||38974|
NCT02213250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1821048|An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B|An Open-label, Single Dose Pharmacokinetic Study Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Male Chinese Subjects With Hemophilia B||Pfizer|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|6 Years|N/A|No|||May 2015|May 18, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02213250||38929|
NCT02213263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3281006|A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)|A Phase 3, Randomized, Double-Blind Study Of PF-05280586 Versus Rituximab For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma||Pfizer|Yes|Recruiting|September 2014|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|394|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213263||38928|
NCT02222376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-1031-13/14-1|Effect of Topic Pirfenidone in Diabetic Ulcers|Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.|PirDFI|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|October 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222376||38229|
NCT02219230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40660-A|Use of Passive, Adaptive, and Active Prosthetic Knees in Persons With Unilateral, Transfemoral Amputation|Outcomes Associated With Use of Passive, Adaptive, and Active Prosthetic Knees in Persons With Unilateral, Transfemoral Amputation: a Randomized Crossover Trial|OPK|University of Washington|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|12|||Both|45 Years|75 Years|No|||December 2015|December 23, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02219230||38471|
NCT02218736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052485|Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a|A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response|FASTMAS_Kor2|Duke University|Yes|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|90|||Both|21 Years|65 Years|No|||November 2015|November 29, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218736||38509|
NCT02218931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009337QM|ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pre-eclampsia|Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pre-eclampsia (ESTEEM): A Randomised Trial|ESTEEM|Queen Mary University of London|Yes|Recruiting|July 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3640|||Female|16 Years|N/A|No|||November 2015|November 30, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02218931||38494|
NCT02218944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM14171|Smoking Response Inhibition Training|Response Inhibition Training in Smoking Cessation||North Dakota State University|No|Enrolling by invitation|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218944||38493|
NCT02219217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT061|SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers|Pharmacokinetics of DOLUTEGRAVIR Once Daily and ELVITEGRAVIR/COBICISTAT Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers||St Stephens Aids Trust|No|Recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219217||38472|
NCT02219438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adductor Canal Basal vs Bolus|Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses|Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses||University of California, San Diego|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219438||38455|
NCT02219971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-101|Phase I Study of Kukoamine B Mesilate in Healthy Volunteers|Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance and Pharmacokinetics of a Single Intravenous Injection Kukoamine B Mesilate in Healthy Volunteers||Tianjin Chasesun Pharmaceutical Co., LTD|No|Completed|August 2014|||April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219971||38414|
NCT02219698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-Dnro122-2014|Symptomatic Treatment of Acute Uncomplicated Diverticulitis|Symptomatic Treatment of Acute Uncomplicated Diverticulitis||Helsinki University Central Hospital||Completed|July 2014|||July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|158|||Both|18 Years|90 Years|No|||July 2015|July 30, 2015|August 11, 2014||||No||https://clinicaltrials.gov/show/NCT02219698||38435|
NCT02219945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBDIAGNOSE|ENOSE in Pulmonary Tuberculosis in Yogyakarta|The Accuracy of the eNose in the Diagnostics and Monitoring of Treatment of Treatment-naive TB Patients|YOGYATBNOSE|University Medical Center Groningen|No|Recruiting|December 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 15, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02219945||38416|
NCT02220478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH24|Signature Acetabular Posterior/Lateral Data Collection|A Prospective Controlled Study on Signature Anterior Posterior/Lateral Acetabular Cup Placement System in Total Hip Arthroplasty||Biomet, Inc.|No|Enrolling by invitation|November 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2015|June 25, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220478||38375|
NCT02220803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-BP13|A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction|A Short Term Open, Randomized Cross Over Trial Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension||Göteborg University||Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Male|18 Years|75 Years|No|||August 2015|August 10, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220803||38350|
NCT02233686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEN-D0501-CL-05|A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD|A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Obstructive Pulmonary Disease||Xention Ltd|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|N/A|No|||July 2015|July 14, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233686||37359|
NCT02206009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000767|Use of a Collagen Membrane for Soft Tissue Grafting|PriMatrix Dermal Repair Scaffold Utilization Intraorally||Mayo Clinic|No|Completed|July 2014|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206009||39484|
NCT02230735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SouzaA|Bupivacaine Injections Into Uterosacral Ligaments During Robotic Assisted Total Hysterectomies|Effectiveness of Bupivacaine With Epinephrine Injections Into the Uterosacral Ligaments for Post-operative Pain Control and the Use of Narcotic Pain Medication Following Robotic Assisted Total Hysterectomies||Souza, Amanda, M.D.|No|Not yet recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Female|21 Years|65 Years|No|||August 2014|August 29, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02230735||37586|
NCT02230748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAARGE|Left-Atrium-Appendage Occluder Register - GErmany|Left-Atrium-Appendage Occluder Register - GErmany||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|all patients with an performed or Intention to laa occluder|August 2014|August 29, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230748||37585|
NCT02206620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9437|Effects of Cholinergic Augmentation on Measures of Balance and Gait|Effects of Cholinergic Augmentation on Measures of Balance and Gait||Oregon Health and Science University|No|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|N/A|No|||July 2014|July 31, 2014|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206620||39437|
NCT02211781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914162|Study of Diets and Way of Life of Native Americans and Hispanics in New Mexico During the Time of the Trinity Nuclear Test|A Pilot Study of Dietary and Lifestyle Patterns Among Native Americans and Hispanics/Latinos in New Mexico at the Time of the Trinity Nuclear Test||National Institutes of Health Clinical Center (CC)||Completed|August 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|9|||Both|75 Years|N/A|No|||June 2015|June 27, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211781||39041|
NCT02212158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:206|Diabetes Intervention Program for Adolescents With Persistent High HA1c|Diabetes Intervention Program for Adolescents With Persistent High HA1c||University of Manitoba|No|Not yet recruiting|September 2014|November 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212158||39012|
NCT02212171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAP|TRIAP: Is Triage by Healthcare Mini-teams Effective to Improve Efficiency in Primary Health Care?|TRIAP: Is Triage by Healthcare Mini-teams Effective to Improve Efficiency in Primary Health Care?|TRIAP|Basque Health Service|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212171||39011|
NCT02212431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/001/14|First Study of Oral Cysteamine in Cystic Fibrosis|An Open Label Investigation of the Tolerability and Pharmacokinetics of Oral Cysteamine in Adults With Cystic Fibrosis.||University of Aberdeen|Yes|Completed|August 2014|April 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212431||38991|
NCT02212678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406M51207|Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease|Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212678||38972|
NCT02212665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-079|Life Without Diabetes|Life Without Diabetes||University Hospital, Gentofte, Copenhagen|No|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212665||38973|
NCT02212977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056064|Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions|Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions||Duke University|No|Completed|September 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02212977||38950|
NCT02213276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-e1|The Effect of Glucose on Bone - Direct og Indirect?|The Effect of Glucose on Bone - Direct or Indirect?|GLUBONE|University of Aarhus|No|Active, not recruiting|August 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2014|June 9, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02213276||38927|
NCT02213289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0141|PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression|PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression||University of Chicago|Yes|Recruiting|January 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|104|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02213289||38926|
NCT02222077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Central BP-TOD|Central Blood Pressure in Adolescents and Young Adults|Diurnal Variation of Central Blood Pressure in Adolescents and Young Adults and Association With Indices of Asymptomatic Target-organ Damage||University of Athens|No|Recruiting|July 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|12 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and subjects referred to the Hypertension Clinic for the assessment of        elevated blood pressure|August 2014|August 19, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02222077||38252|
NCT02222389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13210-001|Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse|P20 Research Project 1 Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse||Washington State University||Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02222389||38228|
NCT02219477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-227|A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB)|TURQUOISE-CPB|AbbVie|No|Active, not recruiting|November 2014|February 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219477||38452|
NCT02219724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29313|A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors|A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS||Genentech, Inc.||Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219724||38433|
NCT02219451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sympathetic modulation|Exercise Improve Sympathetic Modulation in Chronic Heart Failure Patients|Exercise Training Improves Oscillatory Pattern and Arterial Baroreflex Control of Sympathetic Nerve Activity in Patients With Chronic Heart Failure||University of Sao Paulo General Hospital|No|Completed|August 2013|July 2014|Actual|April 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|26|||Both|30 Years|70 Years|No|||August 2014|August 18, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02219451||38454|
NCT02219464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130627|Nasopharyngeal Versus Nasal Cannula Oxygen Supplementation in Surgery Patients|Nasopharyngeal Versus Nasal Cannula Oxygen Supplementation in Surgery Patients||Vanderbilt University|Yes|Recruiting|August 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||July 2015|July 24, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02219464||38453|
NCT02219711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|516-001|Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer|A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies||Mirati Therapeutics Inc.|No|Recruiting|August 2014|August 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219711||38434|
NCT02219984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142/2010/O/Oss|START-Register: Survey on Anticoagulated Patients Register|Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment||St. Orsola Hospital|Yes|Recruiting|October 2011|July 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples Without DNA|plasma samples for measurements of anticoagulant drug activity|Both|18 Years|N/A|No|Probability Sample|Are included in the Registry patients who need chronic anticoagulation for atrial        fibrillation, or venous thromboembolism, or heart valve diseases or prosthesis, or other        clinical conditions requiring anticoagulation.        For the sampling method, participants are instructed to choose and declare one modality of        inclusion for VKA treated patients: one week per month, or one day per week (always the        same), etc. For patients treated with DOACs (low number in our country) it is recommended        to include all patients progressively|August 2014|August 16, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02219984|1 Year|38413|
NCT02220218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104979|Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (50 mg/500 mg) With Respect to the Metformin IR Tablet (Locally Sourced From Canada [Glucophage, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg) in Healthy Fed and Fasted Subjects||Janssen Research & Development, LLC|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220218||38395|
NCT02221583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTA-14B02|Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy|A Multicenter Pilot Study to Determine the Pharmacokinetics of Astagraf XL, Prograf and Mycophenolate Mofetil in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy||University of Cincinnati|No|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|26|||Both|19 Years|75 Years|No|||May 2015|May 11, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02221583||38290|
NCT02206022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6932 03|Remifentanil And Local Anesthesia Compared With Local Anesthesia For The Insertion Of Central Venous Catheters|REMIFENTANIL AND LOCAL ANESTHESIA COMPARED WITH LOCAL ANESTHESIA FOR THE INSERTION OF CENTRAL VENOUS CATHETERS IN AWAKE PATIENTS|REMIDOLCATH|University Hospital, Toulouse|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02206022||39483|
NCT02233842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140189|Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors|Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors||National Institutes of Health Clinical Center (CC)||Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Actual|30|||Both|21 Years|N/A|No|||August 2015|August 28, 2015|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02233842||37347|
NCT02233855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140191|People Presenting With Neurocysticercosis in North America|NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|September 24, 2015|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02233855||37346|
NCT02207101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB/141005/OXY-2/CE|Study to Assess the Effect of OXYJUN on Ejection Fraction and Markers of Cardiovascular Injury|The Effect of Investigational Product E-OJ-01 (OXYJUN) on Left Ventricular Ejection Fraction and Markers of Cardiovascular Injury.|Enduoxy|Vedic Lifesciences Pvt. Ltd.|No|Completed|December 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|32|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02207101||39400|
NCT02220738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-334|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors||AbbVie|No|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|90 Years|No|||January 2016|January 12, 2016|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220738||38355|
NCT02220751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/11033-9|Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic|Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic||University of Sao Paulo|Yes|Completed|March 2009|June 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|56|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220751||38354|
NCT02221024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 10/11|Normal Saline Flushes at 12 vs 24 Hours Intervals for Maintaining Peripheral Intravenous Catheters Patency|Randomized Controlled Trial to Evaluate the Efficacy of Normal Saline Flushes at 12 and 24 Hours Intervals in Maintaining Peripheral Intravenous Catheters Patency||IRCCS Burlo Garofolo|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|400|||Both|1 Year|17 Years|No|||August 2014|August 19, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02221024||38333|
NCT02212444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/051|Comparing the Effects of Two Foot and Ankle Splints for Foot Pain|The Effectiveness of a Dynamic Elastomeric Fabric Orthoses (DEFO) in the Management of Plantar Fasciitis: A Feasibility Study||Plymouth Hospitals NHS Trust|Yes|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02212444||38990|
NCT02212691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL117664|Functional Neuroimaging of Pain Using EEG and fMRI|Functional Neuroimaging of Pain in Sickle Cell Disease Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|January 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects Sickle cell patients|January 2016|January 27, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02212691||38971|
NCT02212704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|perception_head_roll_zurich|Verticality Perception - Multisensory Contribution|Verticality Perception - Dissociating Head and Trunk Contributors in Healthy Human Subjects||University of Zurich|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02212704||38970|
NCT02221531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-088|Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN|Double-blind Randomised Non-inferiority Trial to Assess Efficacy and Safety of Carbetocin After Caesarean Section Applied as Iv-bolus as Compared to a Short-infusion|CARBETOCIN|University Hospital, Basel, Switzerland|Yes|Completed|August 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|46 Years|No|||December 2015|December 7, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221531||38294|
NCT02212990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056213|The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine|Clinical Immunization Safety Assessment (CISA): A Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (IIV) Administered to Children 6 Through 47 Months of Age||Duke University|No|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|160|||Both|6 Months|47 Months|Accepts Healthy Volunteers|||July 2015|July 29, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02212990||38949|
NCT02222090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1181-IG-CTIL|Therapy With New Oral Anticoagulants|Therapy With New Oral Anticoagulants in Patients With Atrial Fibrillation and Renal Impairment||Sheba Medical Center|No|Recruiting|July 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|21 Years|N/A|No|Probability Sample|patients prospectively and retropectively with renal impairment who have been prescribed        apixaban for the prevention of stroke in atrial fibrillation, with a comparison to the        characteristics and outcomes associated with warfarin therapy in this population|August 2014|August 20, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02222090||38251|
NCT02218957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExtPouch|Extended Pouch Roux-en-Y Gastric Bypass Study|Restrictive Extended Pouch in Roux-en-Y Gastric Bypass: a Prospective Randomized Control Trial||Rijnstate Hospital|No|Recruiting|August 2014|||August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||August 2014|May 18, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02218957||38492|
NCT02219750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MMHISO71,13MMHISO72|Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients|Comparison of Switching to Premixed Insulin With Add-on Rapid-acting Insulin in Poorly Controlled Type 2 Diabetes Treated With Basal Insulin|COMPAR|Mackay Memorial Hospital|Yes|Recruiting|August 2013|May 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219750||38431|
NCT02219737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00571|Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||National Cancer Institute (NCI)||Recruiting|September 2014|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219737||38432|
NCT02219997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILQ830-P001|Functional Vision With ACRYSOF® IQ IOLs Blue Light Filtration|Functional Benefit With ACRYSOF® Natural Chromophore||Alcon Research|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|90|||Both|65 Years|75 Years|No|||April 2015|April 2, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219997||38412|
NCT02220231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0492|Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation|Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation||Yonsei University|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|20 Years|80 Years|No|||April 2015|April 16, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02220231||38394|
NCT02220491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02032|Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases|A Randomized Phase II Study of 20 Gy in 5 Fractions Whole Brain Radiotherapy Versus 15 Gy in 1 Fraction Volumetric Modulated Arc Therapy for One to Ten Brain Metastases|Amadeus|British Columbia Cancer Agency|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220491||38374|
NCT02221336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-059|Daily Subjective and Objective Smartphone Measures of Illness Activity to Treat Bipolar Disorder- The MONARCA II Trial|Daily Electronic Monitoring of Subjective and Objective Measures of Illness Activity in Bipolar Disorder - The MONARCA II Trial (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes II)|MONARCAII|Psychiatric Centre Rigshospitalet|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02221336||38309|
NCT02206633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HME-02|Hydration Monitor Validation in Elderly|The Validity of Ultrasound Velocity to Assess Hydration Status of Elderly Residing in Assisted Living Facilities||Artann Laboratories|No|Completed|November 2014|June 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|73|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subject pool will be comprised of 100 elderly (over 65 years old), male and female        subjects who are residing in assisted living center|November 2014|June 22, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206633||39436|
NCT02206646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.25|Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction|Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® (Tenecteplase) in Korean Patients With Acute Myocardial Infarction||Boehringer Ingelheim||Completed|February 2003|||February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|987|||Both|N/A|N/A|No|Non-Probability Sample|patients diagnosed with acute myocardial infarction|July 2014|July 31, 2014|July 31, 2014||||No||https://clinicaltrials.gov/show/NCT02206646||39435|
NCT02206321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 100-0038A3|Effects of Computer Navigation Versus Conventional Total Knee Arthroplasty on Endothelial Damage Marker Levels|Comparison of Navigation and Conventional Total Knee Arthroplasties||Chang Gung Memorial Hospital|Yes|Recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Obtain the serum and hemovac drainage from the patients, and analyze the concentrations of      the markers|Both|N/A|N/A|No|Non-Probability Sample|All the patients were recruited from the patient undergoing scheduled total knee        arthroplasty in our hospitals (Chang Gung Memorial Hospital, Kaohsiung medical center).|July 2014|July 30, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02206321||39460|
NCT02206867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ALCL001|Pharmacokinetics and Safety Study of LBAL in Healthy Subjects|A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers||LG Life Sciences||Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|116|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206867||39418|
NCT02221284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-016|Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"|Nesina Tablets Specified Drug-use Survey "Type 2 Diabetes Mellitus: Combination Therapy With Hypoglycemic Drug (Insulin Preparation or Rapid-acting Insulin Secretagogues, Etc)"||Takeda|No|Recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes mellitus|January 2016|January 27, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221284||38313|
NCT02221544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-13-NG-599-CTIL|The Effect of Low-frequency rTMS on Motor Function in PD Patients With Freezing of Gait|The Effect of Low-frequency Repetitive Transcranial Magnetic Stimulation on Motor Function in Patients With Parkinson's Disease (PD) With Freezing of Gait (FOG).||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|89 Years|No|||August 2014|August 19, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221544||38293|
NCT02221791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAVO2|Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function|Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function|FLAVO2|Wageningen University|No|Completed|June 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|20|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||August 2014|October 14, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221791||38274|
NCT02221271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-13/C-01|Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome|||Nihon Pharmaceutical Co., Ltd|No|Recruiting|April 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02221271||38314|
NCT02221752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vifor/PFH supplement trial|Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health|Impact of Iron/Folic Acid Versus Folic Acid Supplements During Pregnancy on Maternal and Children's Health: A Randomized Controlled Trial in China||Peking University First Hospital|Yes|Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2367|||Female|18 Years|N/A|No|||August 2014|August 19, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221752||38277|
NCT02221739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00208|Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)||New York University School of Medicine|Yes|Active, not recruiting|June 2014|December 2018|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|99 Years|No|||December 2015|December 11, 2015|June 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221739||38278|
NCT02218749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148611|Triaging Patients With Musculoskeletal Disorders Directly to Physiotherapists at Primary Health Care Clinics.|The Effects of Triaging Patients With Musculoskeletal Disorders Directly to Physiotherapists at Primary Health Care Clinics: a Pilot Study and Randomized Controlled Trial.||Göteborg University|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|360|||Both|16 Years|67 Years|No|||January 2016|January 11, 2016|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02218749||38508|
NCT02218970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/640|The Effect of Muscular Strength Training in Patients With Drug Addiction|The Effect of Muscular Strength Training in Patients With Drug Addiction||Norwegian University of Science and Technology|No|Completed|September 2012|January 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|No|||April 2015|April 22, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218970||38491|
NCT02219243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWM14.141|Interpretive Biases in Children With Social Anxiety|Modification of Interpretive Biases in Children With Social Anxiety||University of Wisconsin, Milwaukee|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|8 Years|12 Years|No|||November 2015|November 30, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219243||38470|
NCT02220023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140068|Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI|Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI|iNO|Vanderbilt University|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|26|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220023||38410|
NCT02220010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPF and stenting-002|Does Post Operative Pancreatic Fistula, After Left Sided Resections, Heal Faster After the Introduction of a Pancreatic Stent?|Does a Pancreatic Stent Reduce the Healing Time of Post Operative Pancreatic Fistula (POPF) After Distal Pancreatic Resection - an Open Randomized Clinical Multicenter Trial||Karolinska University Hospital|No|Recruiting|June 2014|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220010||38411|
NCT02220244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD1003CT2013-01MS-ON|Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis|Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study|MS-ON|Medday SAS|Yes|Active, not recruiting|October 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|75 Years|No|||January 2015|September 21, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220244||38393|
NCT02220504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADARFEP|3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals|Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-episode Non-affective Psychosis Individuals: A 3-year Follow-up|ADARFEP|Fundación Marques de Valdecilla|No|Completed|July 2004|July 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|15 Years|60 Years|No|||August 2015|August 7, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220504||38373|
NCT02220816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISA-COG-2014/1|Efficacy of an Attentional Process Training Using Competitive Versus Non Competitive Strategies|Efficacy of an Attentional Process Training Using Competitive Versus Non Competitive Strategies||Hospitales Nisa|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220816||38349|
NCT02221076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN_MKT_2014|Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.|Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Examinations (Colposcopy and Hysteroscopy) or Surgical Procedures for Gynecological Cancers (Cervix, Endometrial, Ovarian and Tubal Carcinoma): a Feasibility Study||Mauna Kea Technologies||Recruiting|July 2014|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02221076||38329|
NCT02221323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-14LIPOINJ01|A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1|A Trial to Compare the Pharmacokinetics and Pharmacodynamics of Insulin Lispro Administered s.c. Into Lipohypertrophic or Normal Abdominal Adipose Tissue in Subjects With Diabetes Mellitus Type 1||Profil Institut für Stoffwechselforschung GmbH|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|64 Years|No|||December 2014|December 29, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02221323||38310|
NCT02221609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17660913.0.0000.5137|Movement System Impairment Based Classification Versus General Exercise for Chronic Non-specific Low Back Pain: a Randomised Controlled Trial|Movement System Impairment Based Classification Versus General Exercise for Chronic Non-specific Low Back Pain: a Randomised Controlled Trial||Universidade Cidade de Sao Paulo|No|Recruiting|October 2014|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|65 Years|No|||October 2014|October 17, 2014|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02221609||38288|
NCT02206659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.367|Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension|An Open-label Evaluation of Trough and Peak Effects of 40 mg Telmisartan Tablet by Ambulatory Blood Pressure Monitoring in Chinese Patients With Mild to Moderate Essential Hypertension||Boehringer Ingelheim||Completed|August 2000|||February 2001|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||July 2014|July 31, 2014|July 31, 2014||||No||https://clinicaltrials.gov/show/NCT02206659||39434|
NCT02206893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14-249|Evaluating Consumer m‐Health Services for User Engagement and Health Promotion: An Organizational Field Experiment|||Carnegie Mellon University||Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Actual|425|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206893||39416|
NCT02207335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-TZS-20140421-01|Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer|A Multicenter Randomized Phase Ⅲ Clinical Trial of Gemcitabine in Combination With Capecitabine Versus Gemcitabine Plus Carboplatin as First-line Treatment in Triple-negative Recurrent or Metastatic Breast Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|December 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|70 Years|No|||June 2013|December 21, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02207335||39382|
NCT02206880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELIRIUM CS-Canada|The Delirium-CS Canada Study|Examining DELIRIUM in Postoperative Cardiac Surgery Patient in Canada: Providing a National "Snapshot" of an Increasingly Devastating Complication|DELIRIUM-CS|St. Boniface General Hospital Research Centre|No|Active, not recruiting|November 2014|December 2015|Anticipated|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|234|||Both|N/A|N/A|No|Probability Sample|All patients undergoing cardiac surgery who are admitted to an ICU or CSRU following their        procedure at twelve Canadian tertiary cardiac surgery centers in which patients are        managed post-operatively in an intensive care unit (ICU) or cardiac surgery recovery unit        (CSRU)|July 2015|July 8, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206880||39417|
NCT02221297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2014_035|Lipid-lowering Effect of a Plant Stanol Ester Supplement Product|Lowering Serum LDL-cholesterol With a Plant Stanol Ester Supplement Product||Raisio Group||Completed|May 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221297||38312|
NCT02221557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-7-1-1|Case Series of New Alloplastic Bone Graft Material|Clinical and Histomorphometric Evaluation of Beta-tricalcium Phosphate/Polylactide Bone Substitute for Socket Preservation||Sunstar Americas|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221557||38292|
NCT02221804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LF002B|The Effect of Two Weeks of Voluntary Reduced Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)|The Effect of Two Weeks of Voluntary Reduced Physical Activity in COPD - A Novel Methodology for Anabolic Drug Development||Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|May 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221804||38273|
NCT02222129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403263-1|Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery|A Randomized Controlled Trial for Pain Control in Laparoscopic Urologic Surgery: 0.25% Bupivacaine Versus Long-Acting Liposomal Bupivacaine||Knight, Richard, M.D.|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|August 19, 2014|Yes|Yes||No|April 6, 2015|https://clinicaltrials.gov/show/NCT02222129||38248|
NCT02222142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-09-127|Volatile Versus Propofol Anesthesia in OPCAB|Comparison of Propofol and Isoflurane Anesthesia on Cardioprotection and Clinical Outcomes in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery : A Propensity-score Analysis||Samsung Medical Center|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1080|||Both|20 Years|N/A|No|Non-Probability Sample|patients underwent OPCAB from January, 2010 to December, 2012|August 2014|August 20, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02222142||38247|
NCT02222103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDS-Sleep Apnea|Pilot Study of the MultiSense Patch to Record Cardiopulmonary Data During Sleep and Wake Cycles|Pilot Study of the MultiSense Patch to Record Cardiopulmonary Data During Sleep and Wake Cycles||Scripps Translational Science Institute|No|Enrolling by invitation|August 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be adults men and women suspected of having obstructive sleep apnea and        already scheduled for an in-lab sleep study at the Scripps Clinic Viterbi Family Sleep        Center.|May 2015|May 18, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222103||38250|
NCT02222116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-15|OCT Study of the MGuard Prime Stent in Patients With Heart Attacks|OCT Study of the MGuard Prime Embolic Protection Stent in Patients With Acute ST-segment Elevation Myocardial Infarction|MASTER-OCT|InspireMD|Yes|Withdrawn|October 2015|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 29, 2015|August 19, 2014||No|Market move to DES|No||https://clinicaltrials.gov/show/NCT02222116||38249|
NCT02222402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHR HTA Project Ref 12/23/09|PrEscription of Intra-Dialytic Exercise to Improve quAlity of Life in Patients With Chronic Kidney Disease|Evaluating the Clinical and Cost-effectiveness of Intra-dialytic Exercise for the Improvement of Health-related Quality of Life in People With Stage 5 Chronic Kidney Disease Undergoing Maintenance Haemodialysis Renal Replacement Therapy.|PEDAL|King's College Hospital NHS Trust|Yes|Recruiting|January 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|380|||Both|18 Years|N/A|No|||August 2014|September 1, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222402||38227|
NCT02221765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIM1420/14/01|Safety, Tolerability and Efficacy Study of PP1420 in HV|A Double-Blind, Randomised, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Single and Multiple Doses of PP 1420 in Healthy Subjects.|PP14201b1c|Imperial College London|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|73|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221765||38276|
NCT02221778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-02/2014|SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE|Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Partial Response to Transarterial Chemoembolization||University of Sao Paulo|No|Recruiting|August 2014|July 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||December 2014|December 23, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221778||38275|
NCT02219256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-079_101|A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Intravenous Infusion and Subcutaneous Administration of TAK-079 in Healthy Subjects||Takeda|No|Active, not recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|82|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02219256||38469|
NCT02219490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-423|A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)|TOPAZ-I|AbbVie|No|Recruiting|November 2014|June 2021|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1650|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219490||38451|
NCT02219503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-490|A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis|An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)|TURQUOISE-III|AbbVie|No|Completed|September 2014|September 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|99 Years|No|||October 2015|October 9, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219503||38450|
NCT02220036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198476|Effect of Magnesium Supplementation on Patients With Diabetic Nephropathy|Effect of Magnesium Supplementation on Kidney Function, Insulin Resistance and Metabolic Profile in Patients With Diabetic Nephropathy||Isfahan University of Medical Sciences|Yes|Not yet recruiting|June 2014|October 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Months|12 Months|No|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220036||38409|
NCT02220270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-01 V1.0 17 June 2014|Hyperion™ International Registry Trial|A Prospective, Multi-center Study to Evaluate the Safety and Performance of the Hyperion™ ASD and PDA Closure Systems.|COM-01|European Cardiovascular Research Center|No|Recruiting|May 2015|August 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|1 Year|90 Years|No|Non-Probability Sample|Patient who comes to hospital for ASD or PDA closure|August 2015|August 17, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220270||38391|
NCT02220257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMISSIONDM1|The Influence of Partial Remission Phase of Type 1 Diabetes on Patient Outcome|Influence of Occurrence of Remission and Its Duration on Development of Chronic Complications of Type 1 Diabetes and Patient Outcome|POZREM|Poznan University of Medical Sciences||Active, not recruiting|January 2012|December 2015|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|35 Years|No|Non-Probability Sample|The study included 240 consecutive patients, including 77 women and 143 men hospitalized        at the Department of Internal Medicine and Diabetology of Poznan University of Medical        Sciences between 2004 and 2007 due to newly diagnosed type 1 diabetes.|August 2014|August 18, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220257||38392|
NCT02220517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Randomized Study Comparing MR-guided in Bore Versus MRI/US Fusion-guided Prostate Biopsy|A Prospective Randomized Study Comparing the Diagnostic Efficacy of MR-guided in Bore Prostate Biopsy Versus MRI/US Fusion-guided Prostate Biopsy in Men With at Least One Negative Prostate Biopsy||Heinrich-Heine University, Duesseldorf|No|Completed|November 2011|October 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|480|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02220517||38372|
NCT02220829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS VII|Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy|Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).||Sir Mortimer B. Davis - Jewish General Hospital|No|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|188|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220829||38348|
NCT02221089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-090911|Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans|||Medical University of Vienna||Completed|January 2013|July 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|January 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02221089||38328|
NCT02221908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1401002513|ED Decision Making Among Hypotensive Patients|ED Decision Making Among Hypotensive Patients||Mespere Lifesciences Inc.|No|Enrolling by invitation|August 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients brough to Hahnemann Hospital ED|September 2015|September 25, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221908||38265|
NCT02221921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0000SYV|Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI|Clinical Evaluation of the Safety and Performance of the MicroPort's Transcatheter Aortic Valve and Delivery System for Treatment of Severe Aortic Stenosis||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Not yet recruiting|September 2014|September 2021|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221921||38264|
NCT02207348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-4162|Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors|A Randomised, Open-label, Single-centre, Two-period, Cross-over Trial Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors||Novo Nordisk A/S|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||September 2014|September 30, 2014|August 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207348||39381|
NCT02207114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813623|Using Biomarkers to Optimize Antibiotic Strategies in Sepsis|Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial||University of Pennsylvania|Yes|Recruiting|January 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|N/A|N/A|No|||December 2015|December 1, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02207114||39399|
NCT02221570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|baclofen cramps|Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis|A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis||Tanta University|Yes|Recruiting|June 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||October 2014|October 2, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221570||38291|
NCT02221817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407358564|Comparison of Ultrasound Guided Versus Blind Corticosteroid Injection for Trochanteric Bursitis|Prospective, Randomized Trial of Ultrasound Guided and Blind Corticosteroid Injection for Trochanteric Bursitis||West Virginia University|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02221817||38272|
NCT02222155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL003_168|Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis|A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis||ChemoCentryx|Yes|Active, not recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222155||38246|
NCT02222168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.22|Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers|Open, Randomised, Two-way Crossover Study to Assess the Effect of a High Fat, High Caloric Meal on the Pharmacokinetics of BI 409306, Followed by a Fixed Sequence Period to Investigate the Pharmacokinetics of BI 409306 After a Single Oral Dose Given at Bed Time in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|August 20, 2014||||No||https://clinicaltrials.gov/show/NCT02222168||38245|
NCT02222415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-03-45|Exercise Training in Healthy Young Men|The Impact of Timed Protein Supplementation to Maximize the Skeletal Muscle Adaptive Response to Resistance Type Exercise Training in Healthy Young Men||Maastricht University Medical Center|Yes|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|44|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222415||38226|
NCT02218476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12-01511|Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients||coenzyme Q10|Maimónides Biomedical Research Institute of Córdoba||Recruiting|September 2013|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1|||50|||Both|18 Years|65 Years|No|||August 2014|August 14, 2014|August 8, 2014||||No||https://clinicaltrials.gov/show/NCT02218476||38529|
NCT02218463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH14010039|Treatment of Prepubertal Labial Adhesions|Treatment of Prepubertal Labial Adhesions: A Prospective Comparison of Topical Emollient Versus Topical Estrogen.||Children's Mercy Hospital Kansas City|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|3 Months|12 Years|No|||September 2014|September 11, 2014|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218463||38530|
NCT02219516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-108|Mild, Moderate and Severe Renal Impairment Study|A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment||Ardea Biosciences, Inc.|No|Active, not recruiting|August 2014|January 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Male|18 Years|85 Years|No|||November 2015|November 10, 2015|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02219516||38449|
NCT02219763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001032|The Effects of a Weight Management Program on Body Weight and Quality of Life|A Longitudinal Study to Investigate the Effects of a 14-visit Comprehensive Lifestyle Weight Management Program on Body Weight and Quality of Life||Massachusetts General Hospital|Yes|Recruiting|June 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (over age 18) with a BMI ≥ 25 enrolled in the 12-week Healthy Habits for Life (HHL)        group program from the MGH Weight Center will be recruited. Subjects will be recruited        over a 5-month period.|June 2014|August 15, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02219763||38430|
NCT02220309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27937|Stanford RAD Study (Research on Anxiety and Depression)|Neural Dimensions of Threat Reactivity and Regulation for Understanding Anxiety||Stanford University|Yes|Recruiting|August 2013|||September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|We will collect saliva samples, and in exploratory analysis focus on consideration of genes      associated with neuroimaging-behavior constructs.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We expect to enroll 160 individuals spanning the spectrum of anxiety and associated mood        symptoms. These individuals include patients of the Gronowski Center, a community clinical        psychology center in Palo Alto. We will also recruit from the community through various        advertisements. Further, participants will include healthy people recruited by        advertisement.|June 2015|June 25, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02220309||38388|
NCT02220322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH No 9|Age-related Cognitive Change of Femur|Age-related Cognitive Change of Femur||Tomidahama Hospital|No|Recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Osteoporosis or osteopenia patients|November 2015|November 3, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220322|1 Year|38387|
NCT02220283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405032RINB|Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function|Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function||National Taiwan University Hospital|No|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|20 Years|N/A|No|Non-Probability Sample|Patient underwent endovascular and open repair of aortic aneurysm at NTUH in 2010~2013|August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220283||38390|
NCT02220296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1438-4137|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220296||38389|
NCT02220530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJD-1|Sedation Effect on the Global Quality Colonoscopy|Sedation Effect on the Global Quality Colonoscopy||Hospital San Juan de Dios Tenerife|Yes|Enrolling by invitation|October 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|7000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospective case-control study. The study will include . Patients will be excluded when        they have had previous colonoscopies, have an anesthetic risk above ASA III, allergy to        the drugs used or if they are undergoing antiplatelet or anticoagulant therapy        contraindicated for the procedure|August 2014|August 18, 2014|April 7, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02220530|30 Days|38371|
NCT02220543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3-019|Chronic Low Back Pain Rehabilitation in Primary Care: an RCT|The Effectiveness of a Biopsychosocial Rehabilitation Program in Primary Care (Back on Track) Versus Primary Care as Usual in Patients With Chronic Low Back Pain in Which Psychosocial Factors Minimally Influence Daily Life Functioning: a Randomized Controlled Trial||Maastricht University Medical Center|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220543||38370|
NCT02220842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29383|A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma|A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (MPDL3280A) ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA||Hoffmann-La Roche||Recruiting|December 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220842||38347|
NCT02220855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0478|A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas|A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas||Indiana University|Yes|Recruiting|September 2014|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02220855||38346|
NCT02221102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-Edoxaban|Edoxaban for TIA and Acute Minor Stroke|Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design||Xijing Hospital|Yes|Not yet recruiting|December 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|3700|||Both|18 Years|80 Years|No|||August 2014|August 18, 2014|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221102||38327|
NCT02221115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 14.135|A Survey of Google Glass by Orthopaedic Trauma Patients and Surgeons|A Survey-driven Evaluation of Patients Response to the Introduction of Google Glass in the Orthopaedic Trauma Clinic|Google Glass|McGill University Health Center|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02221115||38326|
NCT02221349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014069|A Clinical Study of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene|A Randomized Clinical Study of the Safety and Effectiveness of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene||Procter and Gamble|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 9, 2015|August 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221349||38308|
NCT02222246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054047|Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease|Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease||Duke University|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|77|||Both|21 Years|N/A|No|||March 2016|March 15, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222246||38239|
NCT02207985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCHSCT|Allogeneic Hematopoietic Stem Cell Transplantation in Pancreatic Adenocarcinoma|Non Myeloablative Allogeneic Stem Cell Transplantation as Adjuvant Treatment in Patients With Pancreatic Adenocarcinoma||Karolinska Institutet|No|Recruiting|January 2007|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||August 2014|August 1, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02207985||39332|
NCT02222181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24947914.5.0000.5426|Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease|Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Recruiting|April 2014|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|160|||Both|60 Years|N/A|No|||August 2014|May 28, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02222181||38244|
NCT02222441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481039|Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)|A Phase 1, Open-label, Fixed-sequence, 2-cohort, 2-period Study To Investigate The Effect Of Modafinil And Pioglitazone Given As Multiple Doses On Single Dose Pharmacokinetics Of Palbociclib (Pd-0332991) In Healthy Volunteers||Pfizer|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02222441||38224|
NCT02222454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1002-P006|Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers||KLOX Technologies Inc.|No|Completed|November 2012|||August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222454||38223|
NCT02218502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44181.068.13|Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses|Regional Study Into the Performance and Cost-effectiveness of Simple Ultrasound-based Rules Compared to the Currently Used Risk of Malignancy Index in the Diagnosis of Ovarian Cancer|SUBSONiC|Maastricht University Medical Center|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|270|||Female|18 Years|N/A|No|||April 2015|April 9, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02218502||38527|
NCT02222428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1256.3|Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|An Open Label, Randomised, Three-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|April 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||36|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02222428||38225|
NCT02218489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPI-121-C-003|Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease|A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease|Maui|Kala Pharmaceuticals, Inc.|No|Active, not recruiting|July 2014|August 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02218489||38528|
NCT02218788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydroxytite p100:2013|Injectable Filler for Facial Soft Tissue Augmentation|An Open-label, Retrospective, Postmarketing Study of Safety and Performance of Hydroxytite, a Calcium Hydroxyapatite Based Filler for Facial Soft Tissue Augmentation.||Panaxia Ltd|No|Enrolling by invitation|December 2013|||November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|218|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients treated with Hydroxytite, above the age of 18|April 2015|April 27, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02218788||38505|
NCT02218762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201461|A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler|A Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the Low Airflow Resistance Fluticasone Propionate/Salmeterol (100/50 mcg) ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler||GlaxoSmithKline|No|Withdrawn|October 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|August 14, 2014||No|It was decided that data from this study are no longer required and therefore it is not    necessary to expose patients to the study medication|No||https://clinicaltrials.gov/show/NCT02218762||38507|
NCT02218775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052483|FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study|A Phase 1 Study of Kappa and Mu Opioid Receptor Occupancy Associated With Repeated Dosing of LY24516302|KOR1|Duke University|Yes|Withdrawn|October 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|August 15, 2014|No|Yes|Funding for the study ended with one subject consented, but not randomized|No||https://clinicaltrials.gov/show/NCT02218775||38506|
NCT02219529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCE-1|Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases|Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial|MCE|Changhai Hospital|Yes|Completed|August 2014|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|350|||Both|18 Years|70 Years|No|||July 2015|July 19, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02219529||38448|
NCT02219776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400113|Decreasing Infection In Arthroscopic Shoulder Surgery|Decreasing Proprionbacterium Acne Skin Colonization Prior to Arthroscopic Shoulder Surgery||McLaren Health Care|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02219776||38429|
NCT02220569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4073|PhysioFlow to Detect Cardiotoxicity in Chemo|PhysioFlow Use in Longterm Screening and Evaluation of Cardiotoxicity in Chemotherapy|PULSE-ECCho|McGill University Health Center|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting to the oncology day clinic at Royal Victoria hospital and        receiving chemotherapy.|September 2015|September 21, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02220569||38368|
NCT02220556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2010-01|Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology|Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology|CTC-CEC-ADN|Institut Curie|No|Recruiting|December 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|360|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02220556||38369|
NCT02220868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-334-1527|Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study|Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study||Saint Michael's Medical Center|No|Recruiting|July 2014|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|August 18, 2014||||No||https://clinicaltrials.gov/show/NCT02220868||38345|
NCT02221128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT1402.001M(06/14)|PerClot to Control Bleeding in Endoscopic Sinus Surgery|A Post Market Surveillance Study Evaluating the Safety and Effectiveness of PerClot to Control Mild Bleeding in Subjects Undergoing Endoscopic Sinus Surgery||CryoLife Europa|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Adults undergoing Endoscopic Sinus Surgery|July 2014|October 2, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02221128||38325|
NCT02221141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry Disease Cardioscreening|Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography|||Centre Hospitalier Universitaire Dinant Godinne - UCL Namur||Recruiting|December 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients with left ventricular hypertrophy|July 2015|July 28, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221141||38324|
NCT02221388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.56|Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers|Relative Bioavailability of Different Salt Forms and Formulations of Single Doses Either 50 or 200 mg BI 671800 in the Fasted or Fed State. An Open-label, Randomised, Phase I Study With a 3-period Crossover Followed by Two Treatment Periods in Fixed Sequence in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|February 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02221388||38305|
NCT02221362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701-901|A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease|A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease||BioMarin Pharmaceutical|No|Recruiting|December 2014|July 2020|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood and urine samples to be collected for exploratory research, Genetic/Genomic testing is      optional requiring specific consent|Both|18 Years|N/A|No|Non-Probability Sample|Late-onset Pompe Disease patients untreated or treated with rhGAA|September 2015|January 22, 2016|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221362||38307|
NCT02221375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1256.1|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of Butylated Hydroxytoluene Via Respimat Soft MistTM Inhaler B (Sub-study 1) and Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of BI 54903 XX Via Respimat Soft MistTM Inhaler B as Randomised, Double-blind, Placebo-controlled Phase I Trial in Healthy Male Volunteers (Main Study) and Comparison of Systemic Exposure Following a Single Dose of BI 54903 XX Via Respimat Soft MistTM Inhaler B and of a Single Dose of Ciclesonide Via MDI (Randomised, Open-label, Two-way Crossover Sub-study 2)||Boehringer Ingelheim||Completed|June 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|9||Actual|56|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|August 19, 2014||||No||https://clinicaltrials.gov/show/NCT02221375||38306|
NCT02221622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlloPhase1|Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD|Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1|Allo|University of Southern California|Yes|Recruiting|August 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|55 Years|N/A|No|||May 2015|May 26, 2015|July 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221622||38287|
NCT02221934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-0001|Electrical Nerve Block for Amputation Pain|High-Frequency Nerve Block for Post-Amputation Pain: A Pivotal Study||Neuros Medical, Inc.|Yes|Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|21 Years|N/A|No|||November 2015|November 12, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221934||38263|
NCT02210299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC13_8917_TEXTO|TEXTO : Total EXposure To Organic Pollutants|TEXTO : Total EXposure To Organic Pollutants|TEXTO|Rennes University Hospital|No|Withdrawn|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||June 2015|June 9, 2015|August 5, 2014||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT02210299||39154|
NCT02206906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INMED|Incentives to Promote Medication Adherence Among HIV-Infected Youth|Investigation of Incentives to Promote Medication Adherence Among HIV-Infected Youth on Antiretroviral Therapy||St. Jude Children's Research Hospital|No|Active, not recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|16 Years|24 Years|No|Non-Probability Sample|Youth with HIV who meet eligibility criteria.|June 2015|June 18, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206906||39415|
NCT02206919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066-2013|Magnetic Resonance Imaging of Vascular Function|Magnetic Resonance Imaging of Vascular Function||Sunnybrook Health Sciences Centre|No|Not yet recruiting|June 2014|||November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Men and women with type 2 diabetes|July 2014|July 31, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206919||39414|
NCT02207140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKID H-1-2014-051|Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly|Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly||University of Copenhagen|No|Recruiting|October 2014|||May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|140|||Both|75 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207140||39397|
NCT02207361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-TZS-20140421-02|Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer|A Randomized Prospective Clinical Trial of Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|December 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||June 2013|December 21, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02207361||39380|
NCT02222194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTER 3|The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer|Assessment of Surgical Mediastinal sTaging in cN1 Lung canceR|ASTER3|University Hospital, Gasthuisberg|No|Not yet recruiting|August 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|90 Years|No|Probability Sample|Patients with operable and resectable cT1-2- selectedT3 cN1 (suspected) NSCLC. (selected        T3 = intraparenchymal tumour >7cm or T3 chest wall or T3 additional nodule, excluding        mediastinal invasion or invasion of the main bronchus < 2cm from the carina)|August 2014|August 19, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222194||38243|
NCT02222467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1002-P008|Safety Evaluation of the KLOX BioPhotonic System in Venous Leg Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Venous Leg Ulcers||KLOX Technologies Inc.|No|Completed|November 2012|November 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222467||38222|
NCT02222480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FHC-CT-201-BZ|A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide|A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in Combination With Hydrochlorothiazide in Patients With Mild to Moderate Hypertension||Boryung Pharmaceutical Co., Ltd|No|Recruiting|September 2014|||March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|5||||||Both|19 Years|70 Years|No|||October 2014|October 15, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222480||38221|
NCT02222493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5371002|A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).|A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate||Pfizer|Yes|Active, not recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222493||38220|
NCT02229786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218.202|Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms|Buscopan® Plus, Buscopan®, Paracetamol and Placebo: Double-blind Randomized Group Comparison to Investigate the Efficacy and Tolerability of the Film-coated Tablets in Patients With Painful Gastric or Intestinal Spasms||Boehringer Ingelheim||Completed|February 1998|||October 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|1637|||Both|18 Years|70 Years|No|||August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229786||37659|
NCT02230345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392/13|Effects of a Probiotics on the Health of Normal Young Males|Study of the Effects of a Probiotic Yoghourt on the Metabolic Health of Normal Male Volunteers|FFF|Centre Hospitalier Universitaire Vaudois|No|Completed|March 2014|July 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02230345||37616|
NCT02231138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-040-01|Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease|Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study||Chinese PLA General Hospital|Yes|Not yet recruiting|September 2014|October 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1600|||Both|N/A|N/A|No|||August 2014|August 30, 2014|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02231138||37555|
NCT02231151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR Point of View|Visual Feedback of CPR: Does Point of View Matter?|Providing Visual Feedback of Quality of CPR During Pediatric Cardiac Arrest: Does Point of View Matter?||Express Collaborative|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|125|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02231151||37554|
NCT02231437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1352|Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease|Post-marketing Surveillance (in Accordance With § 67,6 AMG) of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease||Boehringer Ingelheim||Completed|January 1999|||November 1999|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3488|||Both|6 Years|N/A|No|Non-Probability Sample|general practitioners, pneumologists and internists|September 2014|September 1, 2014|September 1, 2014||||No||https://clinicaltrials.gov/show/NCT02231437||37532|
NCT02231450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15877A|Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects|Interventional, Open-label, Three-group Study to Determine the Pharmacokinetic Properties of Single Oral Dosing of Lu AE58054 in Patients With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects||H. Lundbeck A/S|No|Completed|July 2014|||March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231450||37531|
NCT02231775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0409|Combi-Neo Study for Stage IIIB-C and Oligometastatic Stage IV Melanoma|Neoadjuvant and Adjuvant Dabrafenib and Trametinib Compared to Upfront Surgery in Patients With Clinical Stage IIIB-C or Oligometastatic Stage IV Melanoma (Combi-Neo)||M.D. Anderson Cancer Center|Yes|Recruiting|October 2014|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231775||37506|
NCT02233257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401M47561|Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy|Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy||University of Minnesota - Clinical and Translational Science Institute||Available||||||N/A|Expanded Access|N/A|||||||Male|18 Months|18 Years||||September 2014|September 3, 2014|May 5, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02233257||37392|
NCT02234739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hangzhou Red Cross Hospital|Voriconazole for IPA in Chinese Patients With COPD|Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective，Open Cohort Study (VIA-COPD)|VIA-COPD|Red Cross Hospital, Hangzhou, China|No|Not yet recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|85 Years|No|||September 2014|September 8, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234739||37278|
NCT02236039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00821|COPD Originates in Polluted Air|The Effects of Traffic-Related Air Pollution on Smokers at Risk for Developing COPD|COPA|University of British Columbia|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02236039||37178|
NCT02239458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0388-14-HMO|DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis|||Hadassah Medical Organization||Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2014|April 15, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02239458||36916|
NCT02239523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201497CTIL|Effectiveness of Orthopedic Intervention in Osteoporosis Management|Management Strategies by an Orthopedic Department to Improve the Evaluation and Treatment of Osteoporosis.||Shaare Zedek Medical Center|Yes|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|360|||Both|50 Years|N/A|No|||September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239523||36912|
NCT02225314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADWilliams2012-647173|Computer-based Cognitive Training for Individuals With Parkinson's Disease|Computer-based Cognitive Training for Individuals With Parkinson's Disease||Virginia Commonwealth University|No|Completed|April 2012|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|21 Years|90 Years|No|||January 2016|January 6, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02225314||38003|
NCT02230033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105398|Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927|An Open-Label, Randomized, Parallel-Group Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Itraconazole or Gemfibrozil on the Pharmacokinetics of a Single Dose of JNJ-56021927 in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230033||37640|
NCT02211131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110266|Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma|A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma||Amgen|No|Recruiting|February 2015|February 2022|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211131||39091|
NCT02211144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.21|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 90, 120, 150 or 180 mg) to Healthy Human Subjects for 14 Days. A Placebo-controlled, Dose Escalation Study Double Blinded at Each Dose Level||Boehringer Ingelheim||Completed|March 2002|||November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02211144||39090|
NCT02211157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.3|Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets (20, 30, 150, 300, and 600 mg) Administered Orally to Healthy Human Subjects Once Daily for 7 Days. A Placebo Controlled, Randomised, Double Blinded Study||Boehringer Ingelheim||Completed|March 2000|||July 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02211157||39089|
NCT02236832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-17'|Study of the Neural Basis of Analogical Reasoning|Organisation du Cortex préfrontal ventrolatéral Pour l'Analogie: Approche Bimodale Chez le Sujet Sain et Chez le Patient Ayant un Syndrome Frontal.|ANALOG|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|120|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02236832||37117|
NCT02236845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM002|Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients|Pilot, Randomized, Cross-over Study to Evaluate Safety and Clinical Effect of Lacrima Medical Device in Patients With Chronic Insomnia||Lacrima Medical LTD|No|Recruiting|October 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||March 2016|March 6, 2016|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02236845||37116|
NCT02223377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-482|Satisfactory Analgesia Minimal Emesis in Day Surgeries|Most Effective Opioid Analgesia in Ambulatory Surgeries: a Randomized Control, Investigator Blinded, Parallel Group With Superiority Design Study of Morphine Versus Hydromorphone|SAME-Day|McMaster University|No|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|532|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02223377||38152|
NCT02228408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK100772-01|Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD|A Phase IV Randomized, Double-blind, Active-controlled, Single-center Study of the Safety and Effects on Cardiac Structure and Function of Hydralazine and Isosorbide Dinitrate in Patients With Hemodialysis Dependent ESRD|HIDE|Brigham and Women's Hospital|No|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|85 Years|No|||July 2015|July 20, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228408||37765|
NCT02224222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSZÉK-FRAILTY|Assessment of Frailty as a Risk Factor for Cardiac and Vascular Surgery|Assessment of Frailty as a Risk Factor for Cardiac and Vascular Surgery||Semmelweis University Heart and Vascular Center|No|Recruiting|July 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Consecutive evaluable patients, 18 years old or older, admitted to Semmelweis University,        Heart and Vascular Center for elective cardiac or vascular surgery.|December 2015|December 1, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02224222|2 Years|38087|
NCT02224235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA 2013-02|COBRA SHIELD OCT Study|COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-term Dual Anti-platelet Therapy: OCT (Optical Coherence Tomography) Evaluation in Comparison With DES||CeloNova BioSciences, Inc.|No|Terminated|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|August 19, 2014||No|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT02224235||38086|
NCT02223039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.002.01|A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis|Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)||AbGenomics B.V Taiwan Branch|No|Completed|May 2014|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|75 Years|No|||May 2015|May 8, 2015|May 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223039||38178|
NCT02223325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOnal - 001|Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis|Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis: A Prospective Cohort Study||Gazi University|No|Active, not recruiting|August 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Tertiary care patients|August 2014|November 19, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02223325||38156|
NCT02223585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.28.MET|Gut Microbiota and Proteins Intake|Gut Microbial Response to Well-balanced Diet With Emphasis on Animal or Vegan Protein||Nestlé|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223585||38136|
NCT02223884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0300|A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy|||Yonsei University|No|Completed|July 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|N/A|No|||August 2014|August 27, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02223884||38113|
NCT02232100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABMT2014|Attentional Bias Modification Training for People With Chronic Musculoskeletal Pain|Attentional Bias Modification Training in People With Chronic Musculoskeletal Pain: A Double-Blind Randomised Control Trial and a Qualitative Investigation of Participants' Experience.|ABMT-P|University of Southampton|No|Not yet recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||September 2014|September 1, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02232100||37481|
NCT02237781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV24042014|Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins|Prospective Randomized Trial on the Level of Anti-Mullerian Hormone (AMH) in Women Undergoing Controlled Ovarian Stimulation for IVFwith Gonadotropins.||University of Athens|Yes|Not yet recruiting|October 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237781||37044|
NCT02224716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS-ANT-2014-01|Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia in Hospitals|Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia in Hospitals||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|968|||Both|18 Years|N/A|No|Non-Probability Sample|Pre-intervention period        All patients admitted with a diagnosis of CAP will be included in the participating        centers during the 12 months prior to the intervention. Case detection is done through the        electronic record of the basic minimum data set (MDS) (2, 36). Diagnosed patients will be        selected at discharge: "simple acute bronchitis and pneumonia excluding asthma major        criteria" (by diagnosis related group, DRG 541) and "simple and pleuritis in over 17        Pneumonia" (DRG 089).        Post-intervention period        All patients admitted with a diagnosis of CAP in the participating centers, which measures        the bundle will apply prospectively included. Case detection was performed by daily review        of patients admitted to target units and will be coordinated by the IP address of each        center.|June 2015|June 11, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02224716||38049|
NCT02225041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD074757-01A1|Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood|Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood|RESTORE-cog|University of Pennsylvania|No|Recruiting|August 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|810|||Both|30 Months|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|RESTORE subjects who consented for 6-month follow-up with normal baseline cognitive        function aged 2 weeks to 8 years at PICU admission. In addition, we will study matched,        healthy siblings of these subjects to provide data on an unexposed group with similar        baseline biological characteristics and environment. If more than one sibling meets        enrollment criteria, the one closest in age will be selected.|June 2015|June 9, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02225041||38024|
NCT02229708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22201|Healthy Babies: Targeting Pregnancy-related Weight Gain to Reduce Disparities in Obesity|Targeting Pregnancy-related Weight Gain to Reduce Disparities in Obesity: a Randomized Controlled Trial||Temple University|No|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|262|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229708||37665|
NCT02234453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO14/11295|Home Testing of Blood Counts in Chemotherapy Patients|A Phase 1 Trial Assessing the Safety and Performance of the Minicare H-2000 in Home Testing of Blood Counts in Chemotherapy Patients.||University of Leeds|No|Not yet recruiting|November 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02234453||37300|
NCT02234687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00609|A mGlu2/3 Agonist in the Treatment of PTSD|A mGlu2/3 Agonist in the Treatment of PTSD||New York University School of Medicine|Yes|Completed|September 2014|February 2016|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234687||37282|
NCT02210312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4646|Study of Depressive Symptoms Predicting Postoperative Cognitive Dysfunction|Are Preoperative Depressive Symptoms Predictive for Postoperative Dysfunction in Non-cardiac Surgery?|DeprPOCD|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|May 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female and male patients, aged 60 years and older undergoing elective non-cardiac surgery        and non-neurosurgical procedures in general anaesthesia or combined general/regional        anaesthesia. To correct for practice effects and conduct additional comparisons, 80        healthy controls will be enrolled and assessed at the same time points (neuropsychological        tests and questionnaires).|August 2014|August 4, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02210312||39153|
NCT02210611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0038-14-EMC|36 Versus 42 Hour Time Interval From Ovulation to Intrauterine Insemination|36 Versus 42 Hour Time Interval From Ovulation Induction to Intrauterine Insemination in Stimulated Cycles With GnRH Antagonists||HaEmek Medical Center, Israel|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Female|17 Years|44 Years|No|||February 2016|February 21, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02210611||39131|
NCT02210910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-CL-02-01|InSpace™ System Over Rotator Cuff Repair in Comparison to Repair Alone.|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Efficacy and Safety of InSpace™ Device Implanted Over a Rotator Cuff Repair in Comparison With Rotator Cuff Repair Only in Subjects With a Full-thickness Large to Massive Rotator Cuff Tear.||OrthoSpace Ltd.||Recruiting|June 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|95 Years|No|||October 2015|October 14, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02210910||39108|
NCT02211183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-CL-02-SP|InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Safety and Efficacy of InSpace™ Device in Comparison to Full Thickness Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.||OrthoSpace Ltd.|No|Recruiting|August 2014|December 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|95 Years|No|||October 2015|October 14, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02211183||39087|
NCT02211508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-301|Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301|A Double-Blinded, Randomized, Sham-Controlled, Pivotal Study of the NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia|PERRFECT-301|Cerephex Corporation|No|Terminated|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|22 Years|65 Years|No|||September 2015|September 2, 2015|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211508||39062|
NCT02237053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601205|Effects of Glucagon Administration on Energy Expenditure|A Prospective Randomized, Placebo (Saline)-Controlled, Balanced, 3-treatment Regimen Crossover Study Comparing the Effects of Prolonged (13 h) Hyperglucagonemia With Those of Acute (3 hr) Hyperglucagonemia on Energy Expenditure and Endogenous Glucose Protection (EGP).|GLEE|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Active, not recruiting|September 2014|||June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237053||37100|
NCT02237131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV04042013|Continuous Versus Cyclic Oral Contraceptives for Endometriosis|Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis||University of Athens|Yes|Recruiting|April 2014|December 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Female|18 Years|45 Years|No|||September 2014|September 9, 2014|March 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237131||37094|
NCT02226172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371013|Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib|A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (PF-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib||Pfizer|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226172||37937|
NCT02226406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT-Early Exercise|Effect of Early Physical Exercise on Pulmonary Ventilation and Recruitment|Effect of Early Physical Exercise on Pulmonary Ventilation and Recruitment Evaluated With Electric Impedance Tomography.|EFRA|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|July 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02226406||37919|
NCT02226419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-130|Fat and Sugar Metabolism During Exercise, With and Without L-carnitine in Patients With Carnitine Transporter Deficiency|Fat and Carbohydrate Metabolism During Exercise, With and Without L-carnitine Supplementation in Patients With Carnitine Transporter Deficiency|CTD|Rigshospitalet, Denmark|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|August 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02226419||37918|
NCT02226653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14627|A Study of Evacetrapib in Healthy Japanese Participants|A Bioequivalence and Food Effect Study of Evacetrapib Evaluating a Single Tablet Compared to Two Tablets in Healthy Japanese Subjects||Eli Lilly and Company|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226653||37900|
NCT02228681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-3007|Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer|A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma||Gynecologic Oncology Group|Yes|Recruiting|February 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228681||37744|
NCT02228928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPNP201|Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain|Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial||Samyang Biopharmaceuticals Corporation|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228928||37725|
NCT02229487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-57-16|The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers|The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers|Sleep GLP-1|Ramathibodi Hospital|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 1, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229487||37682|
NCT02227251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-009|Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)|A Phase 2b Open-label, Randomized Two-arm Study Comparing High and Low Doses of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Karyopharm Therapeutics, Inc|Yes|Recruiting|November 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|February 11, 2016|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227251||37854|
NCT02227511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/170-31|Prospective Randomized Trial of Fruits or Nuts Eaten Between Regular Meals in Healthy Subjects|Prospective Randomized Trial of Fruits or Nuts Eaten Between Regular Meals in Healthy Subjects||University Hospital, Linkoeping|No|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|27|||Both|18 Years|76 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227511||37834|
NCT02227524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro201300052|Trekking Poles to Aid Multiple Sclerosis Gait Impairment|Trekking Poles to Aid Multiple Sclerosis Gait Impairment|TRAMS|Rowan University|No|Recruiting|April 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|30|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02227524||37833|
NCT02227784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14502|A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol|The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study|ACCENTUATE|Eli Lilly and Company|No|Terminated|October 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|366|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|August 26, 2014|Yes|Yes|Study termination due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT02227784||37813|
NCT02228044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5970|Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment|Alcohol, Suicide, and HIV Prevention for Teens in Mental Health Treatment||George Mason University|Yes|Completed|September 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|81|||Both|13 Years|18 Years|No|||August 2014|August 26, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228044||37793|
NCT02224157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589SC00003|A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma|A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma|SYGMA2|AstraZeneca|No|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|4114|||Both|12 Years|130 Years|No|||March 2016|March 24, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224157||38092|
NCT02226666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075454|Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration|Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration||University of Michigan|No|Recruiting|August 2013|August 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|One-hundred patients receiving gadoxetic acid for hepatobiliary indications and 100        patients receiving gadobenate dimeglumine for hepatobiliary indications will be studied        prospectively. All patients will be scheduled to undergo MRI for clinical purposes by        their primary care physicians. The patients will not be randomized.|December 2015|December 4, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226666||37899|
NCT02224430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBSERVESCH4001|Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors|Remote Physiological, Behavioral and Symptom Assessment Study to Identify Predictors of Symptom Exacerbation and Relapse in Schizophrenia||University of Alabama at Birmingham|Yes|Recruiting|August 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||1|Anticipated|40|||Both|19 Years|45 Years|No|Non-Probability Sample|schizophrenia/schizoaffective disorder|June 2015|June 19, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02224430||38071|
NCT02224443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ma sedation|Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients|Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study||First Affiliated Hospital Xi'an Jiaotong University|Yes|Not yet recruiting|September 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|65 Years|80 Years|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224443||38070|
NCT02229162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400656-4|Delayed Umbilical Cord Clamping - C-section Pilot|Delayed Umbilical Cord Clamping For Term Infants: A Pilot Safety Trial During Cesarean Deliveries||University of California, Davis|Yes|Completed|October 2013|November 2014|Actual|October 2014|Actual|N/A|Observational|N/A||2|Actual|41|||Female|18 Years|N/A|No|Non-Probability Sample|pregnant women 18 years of age or older that plan on having an elective Cesarean delivery        of a term singleton infant.|February 2016|February 29, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02229162||37707|
NCT02229435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-MD-040|Urologic-nephrological Care of Chronic Kidney Disease in Saxony-Anhalt/Magdeburg.|Laboratory Database-based Analysis of the Interdisciplinary Urologic-nephrological Care of the Chronic Kidney Disease (CKD) With Estimated Glomerular Filtration Rate (eGFR) Under 60 ml/Min of the Population in Saxony-Anhalt / Metropolitan Area Magdeburg.|UroCKDisS|University of Magdeburg|No|Completed|December 2004|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|1031336|||Both|18 Years|N/A|No|Non-Probability Sample|All sampled outpatient patients (blood tests with measurement of serum creatinine)        12/2004-08/2014 of the medical laboratory Prof. Schenk / Dr. Ansorge and Colleagues, GbR,        Am Neustädter Feld 47, 39124 Magdeburg, metroplitan area Magdeburg Saxony-Anhalt, Germany.|August 2014|August 28, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229435|1 Year|37686|
NCT02234245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC-AL 53/2012|Economic Evaluation in Cardiology: Remote Monitoring of Pacemakers|Economic Evaluation in Cardiology: Remote Monitoring of Pacemakers||Universidad de Almeria|Yes|Completed|October 2012|November 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|83|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02234245||37316|
NCT02238223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.290|Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet||Boehringer Ingelheim||Completed|April 2004|||May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2001|||Both|N/A|N/A|No|Non-Probability Sample|Patients without experience treating of epinastine are selected by physicians at medical        institutions|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238223||37010|
NCT02238236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.293|Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Drug Use-Results Survey of Alesion® Dry Syrup-||Boehringer Ingelheim||Completed|May 2005|||April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3793|||Both|N/A|N/A|No|Non-Probability Sample|Paediatric patients without experience in Treatment with epinastine are selected by        physicians at medical institutions|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238236||37009|
NCT02210923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL3770006813|Effect Baroreflex Activation Therapy on the Carotid Body|Carotid Baroreflex Activation and Its Effect on the Chemoreflex Study||Maastricht University Medical Center|Yes|Recruiting|October 2013|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Arterial blood for analysis of PaCO2, PaO2 and pH|Both|21 Years|75 Years|No|Probability Sample|Subjects implanted with a BAT system will be invited to participate in this study. These        are patients who were enrolled in the DEBuT-HET and Rheos Pivotal Trial and have given        their permission to be approached for follow-up studies. Subjects are all >21 years of age        and were all known with a blood pressure ≥160/90 mmHg despite optimal antihypertensive        therapy before receiving BAT. It is essential to have the Rheos® device implanted to        enable participation in this study, as we want to investigate the effect of electrical        carotid sinus activation on the carotid body chemoreflex.|August 2014|August 5, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02210923||39107|
NCT02211170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.4|Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects|The Effect of Single Oral Dose BIRB 796 BS (50 and 600 mg) on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects. A Placebo-controlled, Randomised, Parallel, Double-blinded Study.||Boehringer Ingelheim||Completed|February 2000|||April 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|August 5, 2014||||No||https://clinicaltrials.gov/show/NCT02211170||39088|
NCT02211521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-056|Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint|Randomized, Double Blind, Comparison Clinical Trial to Test the Efficacy and Safety of Intraarticular Injection of Autologous Platelet-rich Plasma (PRP) for the Treatment of Osteoarthritis of the Knee Joint||Samsung Medical Center|Yes|Completed|August 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|40 Years|80 Years|No|||December 2015|December 9, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02211521||39061|
NCT02222792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJI 2|BJI Inoplex 2 : Test for Diagnosis of Prosthetic Infections|Evaluation of the BJI Inoplex 2 Kit for the Multiplex Serological Diagnosis of Bone and Joint Prosthetic Device Infections||Diaxonhit|No|Active, not recruiting|June 2012|July 2016|Anticipated|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|540|Samples Without DNA|Serologic assays of sera collected from septic or non-septic patients will be performed in      series and operators will be blind in terms of clinical and microbiological status in order      to avoid any interpretation bias due to information collected in advance|Both|18 Years|N/A|No|Non-Probability Sample|The septic patient group will be comprised of patients presenting with bone and joint        prosthetic device infection confirmed by intraoperative microbiological culture (at least        2 deep positive samples for the same bacterial strain).        The non-septic patient group will be comprised of prosthetic patients presenting with        symptoms of mechanical loosening, and whose deep intraoperative samples have all proved        negative.|August 2014|August 20, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222792||38197|
NCT02231099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VROUW2|Effectiveness Prolift+M Versus Conventional Vaginal Prolapse Surgery|A Prospective and Comparative Study of the (Cost)Effectiveness Preformance of Tension Free Vaginal Mesh Plus Monocryl (Prolift+M) Versus Conventional Vaginal Prolaps Surgery in Primary Pelvic Organ Prolapse|VROUW2|Radboud University|No|Active, not recruiting|January 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Female|45 Years|N/A|No|||February 2015|February 5, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT02231099||37558|
NCT02236182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2489|Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Placebo Controlled Trial to Assess the Safety of Two-week Administration of 80 mcg q.i.d. and 160 mcg q.i.d. of Ipratropium Bromide, as Delivered by the RESPIMAT® Device, in Patients With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|July 1998|||February 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|57|||Both|40 Years|N/A|No|||September 2014|September 11, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02236182||37167|
NCT02229500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/L004259/1_SUERC_1|Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling|Regulating Appetite by Targeting Nutrient Delivery in the Gut||Scottish Universities Environmental Research Centre|No|Recruiting|August 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229500||37681|
NCT02226887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)288/2013|Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh|"Prospective Randomized Clinical Trial of Ileostomy Closure Site Hernia and it´s Prophylaxis by Placing an Absorbable Mesh "|ILEOCLOSE|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|April 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02226887||37882|
NCT02231697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-MTM-001 RECENSUS|A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)|The RECENSUS Study: A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)||Audentes Therapeutics|No|Recruiting|September 2014|||July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|100|||Male|N/A|N/A|No|Non-Probability Sample|Males with X-linked myotubular myopathy|December 2015|December 28, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02231697||37512|
NCT02231710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-003|Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases|A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases||Bellicum Pharmaceuticals|No|Recruiting|February 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Months|55 Years|No|||February 2015|February 10, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02231710||37511|
NCT02232022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-336|Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke|Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke||Northwell Health|Yes|Recruiting|September 2014|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|41 Years|N/A|No|||October 2015|October 19, 2015|September 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02232022||37487|
NCT02232321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsA-MDA|Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study|Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study||Chinese University of Hong Kong|No|Recruiting|March 2014|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|N/A|No|||July 2015|July 28, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232321||37464|
NCT02228057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12010024|Long Term Patency Following Arterial Repair|Long Term Patency Following Arterial Repair||University of Pittsburgh|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|patients that underwent upper extremity arterial surgery and are at least 6 months out of        surgery.|February 2015|February 11, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228057||37792|
NCT02233114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR2011/248-31/1|Is Patients With Pulmonary Disease Benefit a Program With Yogic Exercises?|Subjective and Objective Effects After Yogic Exercises||Karolinska Institutet|No|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|35 Years|85 Years|No|||September 2015|January 27, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02233114||37403|
NCT02231398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI-nuMoM2b-HHS-001|nuMoM2b Heart Health Study|Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease|nuMoM2b-HHS|RTI International|Yes|Enrolling by invitation|September 2014|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood Samples: A research or clinical staff member collects a fasting blood draw from the      participant: 2 SST (tiger top) 10 mL tubes for serum; 2 EDTA (purple top) 10 mL tubes for      plasma, and 1 (light blue top) 2.7 mL tube for citrated plasma. Less than 3 tablespoons of      blood are collected. A 0.5 mL aliquot of whole blood from the EDTA tube is reserved. The      rest of the blood is processed and as many 0.5 mL aliquots of serum, EDTA plasma, and      citrated plasma as possible are collected. In addition, a 1.5 mL aliquot of buffy coat is      collected from one of the EDTA tubes.      Urine Sample: A research or clinical staff member collects about 20 mL of clean catch urine      from the participant and 2 urine aliquots (1.8 mL each).|Female|18 Years|N/A|No|Non-Probability Sample|Eligible women are recruited from the cohort enrolled to nuMoM2b. For nuMom2b a        convenience sample was recruited through 8 primary clinical sites that NIH selected        because they could each demonstrate access to more than 4,500 deliveries per year. As a        group, sites were geographically dispersed and ethically diverse. All nulliparous women        aged 13 years or greater with a singleton pregnancy less than 13 weeks 6 days gestation        who presented at recruitment clinics or practices and planned to deliver at a study        hospital were potentially eligible for participation. A clinical or research ultrasound,        performed by a study certified sonographer, confirmed viability of a singleton gestation        with no obvious malformations and estimated gestational age less than or equal to 13 weeks        6 days before the woman was allowed enrollment. The first visit was scheduled and        completed within a window of 6 weeks 0 days and 13 weeks 6 days estimated gestational age.|October 2015|October 29, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02231398||37535|
NCT02228629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21391|Utility of CrocsRx Clog as a Diabetic House Shoe: a Pilot Study|Do CrocsRx Clogs Reduce Dynamic Plantar Pressure as Compared to Conventional House Shoes in Subjects With Diabetes?||Temple University|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|21 Years|75 Years|No|||May 2015|May 12, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228629||37748|
NCT02233582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibuprofen and Altitude|Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude|Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude||University of California, San Francisco|No|Not yet recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233582||37367|
NCT02233595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rectal-PETMRI-1|Evaluation of Rectal Cancer Treatment Response Using PET/MRI|Evaluation of Rectal Cancer Treatment Response Using PET/MRI|Rectal PET/MRI|University of California, San Francisco|No|Recruiting|October 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|20 patients with newly diagnosed rectal adenocarcinoma|May 2015|May 26, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02233595||37366|
NCT02233751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QST-14-004|Pharmacokinetic Study of Testosterone|An Open-Label Study to Evaluate the Pharmacokinetics of Testosterone After Single-Dose Injection Via QuickShot® Testosterone in Healthy Male Subjects||Antares Pharma Inc.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|July 20, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233751||37354|
NCT02233959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orbis Palatability|Palatability of a Novel Oral Formulation of Prednsione|Palatability of a Novel Oral Formulation of Prednsione||Arkansas Children's Hospital Research Institute|No|Completed|December 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|Samples With DNA|Whole Blood|Both|18 Years|32 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 24 healthy young adults (12 males and 12 females), ranging in age from 18 to 32        years of age comprised of a convenience sample who meet study eligibility criteria.|February 2016|February 16, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233959||37338|
NCT02233972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-YXPU-ZS-IV5|A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam|A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam.||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Completed|August 2014|||October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|October 16, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233972||37337|
NCT02238106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.12|Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder (12.5 μg, 25 μg and 50 Salmeterol), Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® (50 μg Salmeterol) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|September 2005|||February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|136|||Both|40 Years|N/A|No|||September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238106||37019|
NCT02238119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.3|Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 6-week Treatment Periods of the Free Combination of Tiotropium Inhalation Powder Capsule (18 μg) + Formoterol Inhalation Powder Capsule (12 μg) QD, Tiotropium Inhalation Powder Capsule (18 μg) QD and Formoterol Inhalation Powder Capsule (12 μg) BID in Patients With COPD||Boehringer Ingelheim||Completed|February 2002|||August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|74|||Both|40 Years|N/A|No|||September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238119||37018|
NCT02238132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2491|Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|December 1998|||November 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|374|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at general practitioners,        pneumologists, internists|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238132||37017|
NCT02228070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0481|Strabismus Measurements Using Automated 3D Video Oculography|Strabismus Measurements Using Automated 3D Video Oculography||University of Zurich||Recruiting|July 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|11 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228070||37791|
NCT02228083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InsufCard|Dental Anesthesia in Heart Failure Patients|Occurrence of Heart Arrhythmia During Restorative Dental Procedure Under Local Anesthesia , in Heart Failure Pacients. A Double-blind Study|DAHFP|University of Sao Paulo General Hospital|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228083||37790|
NCT02211196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99413|Evidence-Based Tobacco Cessation Strategies in Patients With Cancer|Implementing Evidence-Based Tobacco Cessation Strategies in Oncology Clinics||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|February 2013|||February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|400|||Both|N/A|N/A|No|||March 2015|March 2, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211196||39086|
NCT02211209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS6|The APPROACH Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)||Ionis Pharmaceuticals, Inc.|Yes|Active, not recruiting|August 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|November 3, 2015|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02211209||39085|
NCT02220452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sofia-Music|The Effect of Intraoperative Music Listening on Sevoflurane Consumption and Recovery Parameters|The Effect of Intraoperative Music Listening on Sevoflurane Consumption and Recovery Parameters||Aretaieion University Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|70 Years|No|||December 2015|December 28, 2015|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02220452||38377|
NCT02230813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/53|Predictors of Oral Antibiotic Treatment Failure in Emergency Department Patients With Cellulitis|Prevalence and Predictors of Initial Oral Antibiotic Treatment Failure in Adult Emergency Department Patients With Cellulitis: a Pilot Study||Royal College of Surgeons, Ireland|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|139|||Both|16 Years|N/A|No|Non-Probability Sample|Adult patients aged >16 years attending the ED with cellulitis as the primary diagnosis        will be consecutively recruited. Only patients who are deemed suitable for an oral        antibiotic will be enrolled. Patients who require IV therapy will not be enrolled.        Cellulitis may arise de novo, or from a recognised cause such as a wound or ulcer. In        order to generate an externally valid clinical prediction rule, we will include all        patients attending the ED with cellulitis, including those who may have already been        commenced on oral antibiotics (for example, by their general practitioner).|November 2015|November 9, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230813||37580|
NCT02230826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302-T-HIPLTO-RM|Observational Study to Evaluate Long-Term Outcome in Hip Arthroplasty|Multinational Observational Study to Evaluate Long-Term Outcome, Performance, and Safety of Tornier's Implantable Devices in Hip Arthroplasty||Tornier, Inc.|No|Recruiting|May 2014|December 2027|Anticipated|May 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort of patients with a partial or total hip replacement (Tornier implants)|January 2016|January 20, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230826||37579|
NCT02236195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-018|Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes|An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma||Mirati Therapeutics Inc.|No|Active, not recruiting|October 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236195||37166|
NCT02223598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-102|A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma|A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma|CLC-102|Cleave Biosciences, Inc.|Yes|Active, not recruiting|September 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223598||38135|
NCT02226900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERGING|Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING for Complex Triple-vessel Disease|Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING for Complex Triple-vessel Disease|MERGING|InCor Heart Institute|No|Recruiting|August 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 25, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02226900||37881|
NCT02238977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203076|Bupropion for Depression in ESRD Patients on Hemodialysis|Bupropion for Depression in ESRD Patients on Hemodialysis||University of Arkansas|No|Recruiting|January 2015|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|65 Years|No|||September 2015|September 16, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238977||36953|
NCT02239029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB-2-103-05-075|Platelet Rich Plasma on Osteoarthritis of Knee|The Effect of Platelet Rich Plasma on Osteoarthritis of Knee||Tri-Service General Hospital|Yes|Recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|75 Years|No|||February 2016|February 1, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239029||36949|
NCT02237664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD-2015-16-P1Anesth|Patient-Controlled Thoracic Paravertebral Block After Video-Assisted Thoracoscopic Surgery|Patient-Controlled Thoracic Paravertebral Block for Postoperative Analgesia After Video-Assisted Thoracoscopic Surgery||Dammam University|Yes|Recruiting|January 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02237664||37053|
NCT02237703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-01521|Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)|Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)||New York University School of Medicine|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are between the age range of 18 to 55, are medically healthy and currently not        taking any medications to treat any medical illness, have a history of post-traumatic        stress disorder, or are a healthy control who has or has not been exposed to trauma.|June 2015|June 25, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237703||37050|
NCT02233244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-4430-DI-001|Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam|A Phase 1, Open-Label, Two-Period, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam in Healthy Adult Subjects||Celtaxsys, Inc.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02233244||37393|
NCT02237729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5381007|A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))|Phase 1, Double Blind, Randomized, Parallel-group, 3-arm, Single-dose, Comparative Pharmacokinetic Study Of Pf-06410293 and Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects|B538-07|Pfizer|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|362|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237729||37048|
NCT02237898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014326|Harnessing the Power of Technology: MOMBA for Postpartum Smoking|SCH: INT: Harnessing the Power of Technology: MOMBA for Postpartum Smoking||Yale University|No|Not yet recruiting|March 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237898||37035|
NCT02233387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-36-14/12|PET CT With HX4 in Cervix Cancer|Non Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET) in Cervix Cancer.|HX4-cervix|Maastricht Radiation Oncology|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02233387||37382|
NCT02237872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1571|Detection of Brown Adipose Tissue by Magnetic Resonance Imaging|Assessment of MRI Accuracy for the Detection of Brown Adipose Tissue Using FDG-PET as a Gold Standard|BAT_PET/MRI|University of North Carolina, Chapel Hill|Yes|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy adult human with a BMI <28|October 2015|November 30, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237872||37037|
NCT02237989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY2001|Effects Of Native Collagen Type 2 Treatment|Effects Of Native Collagen Type 2 Treatment In Knee Osteoarthritis : A Randomized Controlled Trial||Eskisehir Osmangazi University|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|45 Years|70 Years|No|||December 2013|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02237989||37028|
NCT02238002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC2013QQFYJ|Assessment Of Anterior Chamber Configuration Changes After Phacoemulsification|To Investigate Changes in Anterior Chamber Angle Configuration After Phacoemulsification|AOACCCAP|Wenzhou Medical University|No|Recruiting|December 2013|March 2015|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|64|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|patients who underwent phacoemulsification surgery in Eye Hospital of Wenzhou Medical        University|September 2014|September 11, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02238002||37027|
NCT02227797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LS126|MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients|MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients||Masonic Cancer Center, University of Minnesota|No|Recruiting|January 2015|December 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|21 Years|No|||January 2016|January 22, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227797||37812|
NCT02210949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICSCZE14|Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery|Pre-operative Treatment With Erythropoietin and Iron Supplement for Prevention of Perioperative Blood Transfusion in Cardiac Surgery||Catharina Ziekenhuis Eindhoven|No|Not yet recruiting|August 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02210949||39105|
NCT02211222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-398|An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer|An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer||Eisai Inc.||Approved for marketing||June 2015|Anticipated|August 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2016|March 15, 2016|August 5, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02211222||39084|
NCT02211235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0960|Continuous Glucose Monitoring in Controls With and Without Cystic Fibrosis|Characterization of Glucose Variability by Continuous Glucose Monitoring in Non-diabetic Youth With and Without Cystic Fibrosis||University of Colorado, Denver|No|Recruiting|August 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Alternative markers of glycemia, including fructosamine, glycated albumin, and      1,5-anhydroglucitol|Both|10 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and Adolescents ages 10-20, without diabetes, half with cystic fibrosis, half        healthy controls.|October 2015|October 5, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02211235||39083|
NCT02211248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4524/10|Cardiovascular Autonomic Control Evaluation Through Cardiac Frequency Variability in Hypertensive Patients|Cardiovascular Autonomic Control Evaluation Through Cardiac Frequency Variability in Hypertensive Patients Subjected to Distinct Interventions: Clinical Trial||Instituto de Cardiologia do Rio Grande do Sul|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||August 2014|August 6, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02211248||39082|
NCT02221037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116341|Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery|A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients Undergoing Oesophagectomy Surgery||GlaxoSmithKline|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||October 2015|January 21, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221037||38332|
NCT02230540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP250|Intermittent Catheterization in Spinal Cord Injured Men|||Coloplast A/S|No|Terminated|September 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Male|18 Years|N/A|No|||February 2016|February 17, 2016|August 28, 2014||No||No|January 18, 2016|https://clinicaltrials.gov/show/NCT02230540||37601|
NCT02225873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2013/046/20140528|The Effectiveness of Exercises Protocol in Management of Neck Pain|The Effectiveness of Two Training Protocols When Managing Chronic Cervical Pain: Controlled Randomized Clinical Trial.||University of Alcala|Yes|Completed|September 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02225873||37960|
NCT02225886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWGRO 06/2014|Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patiens|Effects of Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patiens With Iron Overload|FeVitC|Anemia Working Group Romania|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||August 2014|August 25, 2014|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225886||37959|
NCT02235974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNRH-2014-065|Critical Periods After Stroke Study (CPASS)|Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation|CPASS|MedStar National Rehabilitation Network|No|Recruiting|July 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|64|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02235974||37183|
NCT02235987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG3173-II-01|Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.|||Aspireo Pharmaceuticals Limited||Completed|October 2012|||December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02235987||37182|
NCT02223611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBMF9990|Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection|Phase ⅡTrial of S1 Capsule Plus Cisplatin Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage Ⅱ-ⅢA Non-small Cell Lung Cancer (NSCLC) After Complete Resection|S1VSNP|Hebei Medical University Fourth Hospital|Yes|Not yet recruiting|December 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2014|August 21, 2014|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223611||38134|
NCT02231385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The "ACE" Study|Acetic Acid Colonoscopy Enhancement Study|Acetic Acid Colonoscopy Enhancement Study||Istituto Clinico Humanitas|No|Not yet recruiting|September 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|40 Years|N/A|No|||September 2014|September 1, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231385||37536|
NCT02224170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0530|Comparison of Effect on Quality of Recovery Outcome Between Systemic Lidocaine and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy|||Yonsei University|No|Not yet recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|65 Years|No|||August 2014|August 21, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224170||38091|
NCT02224456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201213|Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis|A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis||GlaxoSmithKline|No|Recruiting|March 2015|November 2020|Anticipated|November 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|60 Years|No|||December 2015|February 11, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224456||38069|
NCT02225899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073559|BioEnergetics and Metabolomics in Cystic Fibrosis|Integration of Nutritional Metabolomics With Bioenergetics in Cystic Fibrosis|BEAM-CF|Emory University|No|Recruiting|September 2014|December 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|130|Samples Without DNA|We will collect sputum, urine, and blood.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with cystic fibrosis and healthy volunteers from the Atlanta community|December 2015|December 16, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02225899||37958|
NCT02225912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Previn-C|A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers|||BioHealth Technologies Inc.||Completed|February 2005|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||||||Both|18 Years|65 Years||||August 2014|August 25, 2014|August 23, 2014||||No||https://clinicaltrials.gov/show/NCT02225912||37957|
NCT02226185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ2014BH|Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence|Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence:a Prospective, Double Blind, Randomized, Placebo-controlled, Multicenter Clinical Trial||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02226185||37936|
NCT02237742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7871004|A Study To Understand How The Body Reacts To A Low Dose Of PF‑06427878 When Given In A Vein To Healthy, Adult, Males|A Phase 1, Non‑Randomized, Open‑Label, Single‑Dose, Single Period Study With Non‑Pharmacologically Active Dose Of Pf‑06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects||Pfizer|No|Completed|November 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237742||37047|
NCT02226432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Andreani, JCM 2|Combined Antagonistic Muscle Magnetic Stimulation and Selective Periferal Neurotomy to Improve Results on Spasticity|The Use of Antagonistic Muscle Magnetic Stimulation to Avoid Extensive Lesions and Improve Results of Selective Peripheral Neurotomy on Refractory and I POost Stroke Spasticity With Exclusive or Predominant Right Upper Limb Arm|Andreani2|Sociedad Argenttina de Neuromodulación|No|Enrolling by invitation|April 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|25 Years|N/A|No|||July 2015|July 29, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02226432||37917|
NCT02236299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01851|Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting|Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting - DREAM GLP-1|DREAM GLP-1|Papworth Hospital NHS Foundation Trust|Yes|Not yet recruiting|September 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02236299||37158|
NCT02237833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/194 REK|Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study|Cerebral Oxygenation in Septic Patients Using Vasopressors - The Conscious Study|CONSCIOUS|Sykehuset i Vestfold HF|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Patients in the intensive care unit needing vasopressor for septic shock.|May 2015|May 19, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02237833||37040|
NCT02227264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-005374-57|Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?|Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?||Karolinska University Hospital|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|118|||Both|40 Years|N/A|No|||March 2016|March 11, 2016|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02227264||37853|
NCT02227537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG12-04-13|Evaluation of the Providence Nighttime Brace for the Treatment of Adolescence Idiopathic Scoliosis|Evaluation of the Providence Nighttime Brace for the Treatment of Adolescence Idiopathic Scoliosis||OrthoGeorgia|No|Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|10 Years|14 Years|No|Probability Sample|up to 100 adolescent male/female will be enrolled at up to 4 sites in the US. Patients        must be at least 10 years of age. Participants who receive treatment must have been        diagnosed with adolescent idiopathic scoliosis without other significant spinal pathology.        Appropriate participant selection will be accomplished through the integration of clinical        and radiological parameters while ruling out other confounding sources of back pain or        curvature. Subjects will be included who demonstrate a Cobb angle between 25-40 degrees.        Participants must have radiographic evidence of a Risser grade of 0, 1, or 2. All chronic        disease process and other possible sources for spinal curvature will be excluded by        thorough history and physical examination.|April 2015|April 20, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02227537||37832|
NCT02233270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32500|Pilot of AbStats /AEGIS System for Detecting Motility Abnormalities|Validation of the AbStats Belt and Acoustic Esophago-Gastro-Intestinal Surveillance (AEGIS) System for Analyzing Motility Abnormalities|AEGIS|Cedars-Sinai Medical Center|No|Recruiting|July 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to the Cedars-Sinai Motility Program who are already scheduled to        undergo small bowel manometry, SmartPill, or Lactulose Hydrogen Breath Test.|July 2015|July 27, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02233270||37391|
NCT02219932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS305|Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis|A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis|ENHANCE|Biogen|Yes|Active, not recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|647|||Both|18 Years|70 Years|No|||September 2015|September 17, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02219932||38417|
NCT02220192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140613004 (UAB 1425)|An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure|Focal Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia: an Alternative Treatment Approach||University of Alabama at Birmingham|Yes|Recruiting|December 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|21 Years|45 Years|No|||July 2015|July 30, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02220192||38397|
NCT02230553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49551.031.14|Lapatinib Plus Trametinib in KRAS Mutant Malignancies|Phase I/II Study With Lapatinib Plus Trametinib in Patients With Metastatic KRAS Mutant Colorectal, Non-small Cell Lung and Pancreatic Cancer|M14LTK|The Netherlands Cancer Institute|No|Recruiting|October 2014|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230553||37600|
NCT02235792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002360|High Frequency Oscillations in Neurologic Disease|Chronically-recorded Deep Brain Nuclei/Hippocampal High Frequency Oscillations (HFOs) as Biomarkers of Neurologic Disease.||Mayo Clinic|No|Recruiting|July 2014|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|July 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02235792||37197|
NCT02223052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-CAGEN-001|CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies|A Phase 1, Open-label, Multicenter, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects||Celgene Corporation|No|Recruiting|October 2014|February 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223052||38177|
NCT02223065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-364|Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State|A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State||AstraZeneca|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223065||38176|
NCT02229448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgG4-RD diagnosis|Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.|A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy Was Performed for Other Reasons and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation, Taken From All Patients Admitted at Meir Hospital Since January 2000 Until June 2014 .||Meir Medical Center|No|Not yet recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|All patients that where admitted during the period of January 2000 to June 2014 at MEIR        HOSPITAL- KFAR SABA from all ages, from all parts of Israel, all races will be included,        from both genders.|August 2014|August 29, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229448||37685|
NCT02229461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15525|Naproxen Sodium/ASA Platelet Study|A Randomized, Open Label, Parallel Group Study to Investigate the Effects on Serum Thromboxane by the Addition of Naproxen Sodium to Aspirin Therapy Versus Aspirin Therapy Alone|Kontakt|Bayer|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|117|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|February 23, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229461||37684|
NCT02238938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERLA|Piecemeal Versus En Bloc Resection of Large Rectal Adenomas|Piecemeal Versus En Bloc Resection of Large Rectal Adenomas -A Prospective, Randomized Multicenter Study|PERLA|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|April 2014|June 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238938||36956|
NCT02230046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105286|Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Abiraterone Acetate Coated Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Uncoated Tablet Formulation Under Fasted Conditions in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|102|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230046||37639|
NCT02230306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-123|Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases|Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases|CoBRIM-B|University of Pittsburgh|Yes|Recruiting|February 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230306||37619|
NCT02230319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.1|Prevention of Paclitaxel Neuropathy With Cryotherapy|Prevention of Paclitaxel Neuropathy With Cryotherapy||Medical Oncology & Hematology Associates of Northern Virginia|No|Active, not recruiting|October 2014|March 2017|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|39|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02230319||37618|
NCT02230566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX003-CL301|A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7|A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7||Ultragenyx Pharmaceutical Inc|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Both|5 Years|35 Years|No|||February 2016|February 23, 2016|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230566||37599|
NCT02230839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 500423|Muscle Insulin Resistance in Aging (Mirage)|Muscle Insulin Resistance In Aging||Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Recruiting|June 2014|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|200|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02230839||37578|
NCT02226445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD/DO/MA|Treatment Drop-out and Missed Appointments Among Adults With ADHD|Treatment Drop-out and Missed Appointments Among Adults With Attention-Deficit/Hyperactivity Disorder: Associations With Patient- and Disorder-related Factors||University of Aarhus|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|153|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients referred to a tertiary ADHD Clinic at Regional Psychiatric Services West, Central        Denmark Region|August 2014|August 26, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226445||37916|
NCT02231112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-138-001|Whole Breast RT on Prone Position in Korean Women|Feasibility of Prone Position in Postoperative Whole Breast Radiation Therapy in Korean Breast Cancer Patient||Samsung Medical Center|Yes|Recruiting|November 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|20 Years|70 Years|No|||November 2014|November 6, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02231112||37557|
NCT02226913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193396|Effect of Sodium Bicarbonate Buffered Lidocaine on the Success of IAN Block of Teeth With Irreversible Pulpitis|Effect of Sodium Bicarbonate Buffered Lidocaine on the Success of Inferior Alveolar Nerve Block for Teeth With Symptomatic Irreversible Pulpitis: A Prospective, Randomized Double-blind Study||Isfahan University of Medical Sciences|Yes|Completed|February 2013|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|August 25, 2014|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02226913||37880|
NCT02226926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.142|Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers|Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers||Boehringer Ingelheim||Completed|July 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02226926||37879|
NCT02232035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chuaiyunhai-002|Diazepam at the Active Phase of Labor|Intravenous Injection of Diazepam at the Beginning of Active Phase of Labor||Navy General Hospital, Beijing|Yes|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02232035||37486|
NCT02232048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0061-14-HYMC|The Influence of Corticosteroid Treatment on Heart Function|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients being treated with corticosteroids for various clinical indications who have been        hospitalized in the internal medicine department of the Hillel Yaffe Medical Center.|September 2014|September 8, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02232048||37485|
NCT02232334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brown - 1|Effects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis|Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis||Kathleen Brannan Brown, Inc.|No|Recruiting|September 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232334||37463|
NCT02238015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC2013BNZYJ|Tear Film Evaluation After Phacoemulsification|To Investigate Tear Film Change After Phacoemulsification With SS-OCT|TFAP|Wenzhou Medical University|Yes|Recruiting|October 2013|March 2015|Anticipated|May 2014|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|45 Years|75 Years|No|Non-Probability Sample|60 eyes from 30 age-related cataract participants underwent cataract surgery with 3.0 mm        clear corneal incision at 11 o'clock in one eye and the other eye without surgery history|September 2014|September 11, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02238015||37026|
NCT02238145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2492|Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law] of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|January 1999|||November 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|660|||Both|30 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at general practitioners,        pneumologists, internists|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238145||37016|
NCT02238158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2496|Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance (as Per §67(6)AMG [German Drug Law]) of Atrovent® in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|September 1999|||April 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|595|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at general practitioners|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238158||37015|
NCT02226939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605.9|Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C|A Randomised, Double-blind, Placebo Controlled Trial With 200 mg BILN 2061 ZW Given p.o. at Two Consecutive Days Bid to Investigate the Antiviral Efficacy, Pharmacokinetics, Safety in Patients With Cirrhosis and Chronic Hepatitis C||Boehringer Ingelheim||Completed|September 2002|||November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02226939||37878|
NCT02220465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13CRP14560028|Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers|Using Physical Activity to Reduce Smoking Cue Reactivity Among Low-Income Smokers Preparing to Quit Smoking||Temple University|No|Recruiting|April 2013|December 2015|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||January 2014|August 15, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220465||38376|
NCT02220764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-008|Zirconia Based Fixed Dental Prostheses|Prospective Evaluation of Zirconia Based Tooth- and Implant- Supported Fixed Dental Prostheses||Technische Universität Dresden|No|Completed|May 2008|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|July 16, 2014||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT02220764||38353|
NCT02220777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8477-CL-0001|A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of ASP8477 in Healthy Postmenopausal Females and Healthy Young Vasectomized Males, Including a Food Effect Part and a Part to Investigate the Interaction Between ASP8477 and Omeprazole||Astellas Pharma Inc|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02220777||38352|
NCT02235623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00008033|Orchidopexy Randomized Clinical Assessment|Randomized Trial of One Stage vs Two Stage Orchidopexy for Abdominal Undescended Testis|ORCA|Children's Hospital Boston|Yes|Recruiting|August 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Male|4 Months|36 Months|No|||February 2016|February 7, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02235623||37210|
NCT02235779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CryobiopsieTBB|Diagnostic Yield of Transbronchial Cryobiopsy in Diagnosis of Interstitial Lung Diseases|DIagnostic Yield of Transbronchial Cryobiopsies in Subjects With Interstitial Lung Disease||Laval University|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02235779||37198|
NCT02222753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014AA020801|Immunological Markers Screening for Colorectal Cancer|Therapeutic Effect and Prognosis Predication Related Immunocyte Subgroup and Immunologic Factors Screeing for Colorectal Cancer||State Key Laboratory of Cancer Biology|Yes|Recruiting|January 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Tissue and blood specimens|Both|18 Years|90 Years|No|Probability Sample|primary care clinic|August 2014|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222753||38200|
NCT02234466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:004|Preoperative Oral Dexamethasone to Improve Recovery After Surgery|The Use of Preoperative Oral Dexamethasone to Improve Quality of Recovery After Breast Surgery||University of Manitoba|No|Enrolling by invitation|August 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|80 Years|No|||September 2014|September 8, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02234466||37299|
NCT02223897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014006|Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions|Umbilical Cord Mesenchymal Stem Cells Transplantation for Treatment of Patients With Ischemic-type Biliary Lesions After Liver Transplantation||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|60 Years|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223897||38112|
NCT02235636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098-12|A Randomized Cross-over Trial of Comparison Between Robotic and Laparoscopic Suturing for Gastric Defect by Novices|Da Vinci Robot Compared to Laparoscopic Suturing for Closure of Gastric Incision Among Novice: a Randomized Cross Over Trial||Chinese University of Hong Kong|No|Completed|July 2012|December 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|20|||Both|16 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Medical students with no prior experience in surgery|September 2014|September 8, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02235636||37209|
NCT02240459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES-COG 1808|A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment|A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment||University of Alberta|No|Not yet recruiting|March 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|50|||Both|75 Years|N/A|No|||November 2015|November 30, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240459||36841|
NCT02235805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 14-3-021|Magnesium and Vascular Stiffness|The Effects of Magnesium on Vascular Stiffness: A Long-term Study in Healthy Overweight and Slightly Obese Men and Women||Maastricht University Medical Center|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02235805||37196|
NCT02236000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-10|A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer|A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer||NSABP Foundation Inc|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236000||37181|
NCT02236208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-530604-XG1|Effect of Folate Acid on Offspring Obesity|Mechanism of Folate Acid in Influencing Offspring Obesity During Pregnancy||Nanjing Medical University|Yes|Enrolling by invitation|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|Whole blood|Both|18 Years|45 Years|No|Non-Probability Sample|Women with the early, mid and late pregnancy; Chilren|September 2014|September 9, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02236208||37165|
NCT02236221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-530604-XG2|Effect of Vitamin D on Offspring Obesity|Mechanism of Vitamin D in Influencing Offspring Obesity During Pregnancy||Nanjing Medical University|Yes|Enrolling by invitation|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|Whole blood|Both|18 Years|45 Years|No|Probability Sample|Women with the early, mid and late pregnancy; Chilren|September 2014|September 9, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02236221||37164|
NCT02236234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/07076-4|Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil|Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil|HPV|University of Sao Paulo|No|Completed|January 2012|January 2014|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Male|35 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02236234||37163|
NCT02237885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1138|Pain Management Using Mobile Technology in Veterans With PTSD and TBI|Pain Management Using Mobile Technology in Veterans With PTSD and TBI||University of North Carolina, Chapel Hill|Yes|Recruiting|August 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237885||37036|
NCT02225600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0744|The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults|The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults: A Pilot Behavioral Study||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225600||37981|
NCT02225613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00390-47|Spa Rehabilitation After Cruciate Ligament Injury in Sportsmen|Comparison Between Two Rehabilitation Programs (Conventional and Aquatic) After Cruciate Ligament Injury in Sportsmen|Thermasport|Central Hospital, Nancy, France|Yes|Recruiting|October 2014|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|49 Years|No|||March 2016|March 7, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02225613||37980|
NCT02225626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.44|Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects|Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects||Boehringer Ingelheim||Completed|September 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 10, 2015|August 25, 2014||||No||https://clinicaltrials.gov/show/NCT02225626||37979|
NCT02231723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-118|A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer|A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma||Boston Biomedical, Inc||Recruiting|August 2014|||June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231723||37510|
NCT02231736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVIE-549-1|Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)|Incidence of Chromosomal Damage in Type 2 Diabetes Patients|MIKRODIAB|University of Vienna|No|Recruiting|May 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|130|||Female|30 Years|N/A|No|Non-Probability Sample|Type 2 Diabetes patients, female,|September 2014|September 1, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02231736||37509|
NCT02238028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KZGY 001|Intervention Study on the Health Effects of Wearing Particulate Filtering Respirators|The Health Effects of Wearing Particulate Filtering Respirators in Healthy Adults in China-an Intervention Study||Fudan University|Yes|Not yet recruiting|November 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02238028||37025|
NCT02223091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOKON-109863|KOKON Consultation on Complementary Medicine in Oncology - a Pilot Study|Prospective, Multi-center, Cluster-randomized, Pragmatic, Mixed-method Pilot Study Evaluating a Consultation Training Program for Physicians Within the Framework of KOKON (Competence Network Complementary Medicine in Oncology)|KOKON-AS|Charite University, Berlin, Germany|No|Completed|September 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|137|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02223091||38174|
NCT02226952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605.5|Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection|A Randomised, Double-blind, Placebo Controlled Trial With 25 mg, 200 mg and 500 mg BILN 2061 ZW Given p.o. at Two Consecutive Days Bid to Investigate the Antiviral Efficacy, Pharmacokinetics, Safety in Patients With Chronic Hepatitis C Virus Infection||Boehringer Ingelheim||Completed|November 2001|||April 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|51|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02226952||37877|
NCT02226965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNT2258-03-DLBCL|Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL|A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Wolverine|ProNAi Therapeutics, Inc|Yes|Recruiting|December 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226965||37876|
NCT02226978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.104|Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers|An Open-label One-sequence Cross-over Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir 500/200 mg With Single-dose Valaciclovir (500 mg) in Healthy Volunteers||Boehringer Ingelheim||Completed|February 2007|||May 2007|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|20 Years|58 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02226978||37875|
NCT02220790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056090|BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia|Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric|BIOPIC|Duke University|Yes|Recruiting|January 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood samples|Both|120 Days|18 Years|No|Non-Probability Sample|This study will create an international multi-center cohort of children with new clinical        concern for infection while in the ICU. The study will be collected at 23 US sites and 18        International sites; other sites may be added in the future.|November 2015|November 17, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02220790|30 Days|38351|
NCT02221050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/28|Hemodialysis and Wanting for Protein-rich Foods|Influence of Chronic Renal Failure and Hemodialysis on Liking and Wanting for Foods||University of Burgundy|No|Completed|January 2014|July 2014|Actual|May 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|hemodialysis centers of Clinique Drevon, Dijon, France la Breuchillière, Saint        Apollinaire, France University Hospital, Dijon, France Macon Hospital, Macon, France|August 2014|August 19, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02221050|15 Days|38331|
NCT02238405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00037636|A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes|A Randomized Controlled Smoking Cessation Trial and Prospective Cohort Study of TB Treatment Outcomes||Johns Hopkins University|No|Recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02238405||36996|
NCT02238418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-812|Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.|Vitamin D Supplementation in Children and Adolescents Seen in the Paediatric Nephrology Service: Study of the Efficacy of Service Usual Care (Cholecalciferol) and Its Impact on Calciuria.|VITATOL|Hospices Civils de Lyon|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Months|18 Years|No|||March 2016|March 15, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238418||36995|
NCT02233985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2012-1002-43|Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants|A Randomized Trial of Nebulized 3% Hypertonic Saline With Salbutamol in the Treatment of Acute Bronchiolitis in Pediatric Hospital||Coordinación de Investigación en Salud, Mexico|Yes|Recruiting|August 2013|May 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Months|24 Months|No|||December 2012|March 27, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02233985||37336|
NCT02233998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140508133810-OCCT|A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation|21 Day Clinical Efficacy of Essential Oil Containing Mouth Rinses: Effect on Reducing Existing Gingivitis and Plaque||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|158|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|September 4, 2014||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT02233998||37335|
NCT02228889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0041|Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction|||Ohio State University|No|Recruiting|January 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|99 Years|No|||October 2015|October 15, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228889||37728|
NCT02238704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1205003071|Cornell University-Micronutrient Initiative Calcium Supplementation Study|A Cluster-randomized, Non-inferiority Open-label Trial of the Impact of Supplementation Regimen on Consumption of Prenatal Calcium and Iron/Folic Acid Supplements and Adherence to Related Recommendations|MICA|Cornell University|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1032|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02238704||36974|
NCT02229721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001310-34|Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women|Female Sexual Dysfunction in the Menopause: Effect of Intranasal Oxytocin Administration on Sexual Function and Activity||Medical University of Vienna|Yes|Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229721||37664|
NCT02240472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENOMAC|Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.|Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node||Karolinska University Hospital|Yes|Recruiting|January 2015|December 2029|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3500|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240472||36840|
NCT02240485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-10-156-06.13|Integrative Couple Therapy for Pathological Gambling|Integrative Couple Therapy for Pathological Gambling or Individual Treatment: A Comparison of Efficacy|ICT-PG|Université du Québec à Trois-Rivières|Yes|Recruiting|April 2011|July 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02240485||36839|
NCT02240498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00049677|Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities|A Phase 1 Study to Assess Safety and Feasibility of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities||University of Rochester|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240498||36838|
NCT02240511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC003|Resistance Exercise Program and Branched Chain Amino Acid Supplementation in Heart Failure Patients|Changes in Body Composition in Heart Failure Patients After a Resistance Exercise Program and Branched Chain Amino Acid Supplementation||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|August 2011|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240511||36837|
NCT02230332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 009|Alendronate to Prevent Loss of Bronchoprotection in Asthma|Proof of Concept Study of Alendronate for Asthma|ALFA|Milton S. Hershey Medical Center|Yes|Recruiting|January 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230332||37617|
NCT02236377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU1458|Dismantling Exposure, Relaxation, and Rescripting Therapy|Exposure, Relaxation, Rescripting Therapy (ERRT) Dismantling|ERRT|University of Tulsa|No|Recruiting|August 2014|August 2020|Anticipated|July 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236377||37152|
NCT02236390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU1459|Integrating Sleep, Nightmare and PTSD Treatments|Integrating Sleep and PTSD Treatment: Examining the Role of Emotion Regulation|CPTERRT|University of Tulsa|No|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236390||37151|
NCT02237924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201413__19|Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma|Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma.||First Affiliated Hospital of Guangxi Medical University|Yes|Not yet recruiting|September 2014|October 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 14, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237924||37033|
NCT02237937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003190-29|Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene|Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene||HolsboerMaschmeyer NeuroChemie GmbH|No|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|80|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|August 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02237937||37032|
NCT02226679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-11-001|An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001|An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 (Rollover Study for AUGMENT-HF)||LoneStar Heart, Inc.|Yes|Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|79 Years|No|||August 2014|August 25, 2014|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226679||37898|
NCT02226692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQTR-2011-PFAC|Prognostic Factors of Disabling Low Back Pain in Patients With Chronic Low Back Pain|Risk of Poor Prognosis in Patients With Chronic Low Back Pain : Can it be Predicted by Physical Tests and Screening Tools ? - An Observational Study||Université du Québec à Trois-Rivières|No|Completed|October 2011|September 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|60 Years|No|Non-Probability Sample|volunteer with chronic nonspecific low back pain will be recruited among the university's        community, its outpatients' chiropractic clinic and through advertisements in the local        newspaper. They will first be screened by clinicians at the outpatients' chiropractic        clinic in order to assess for the various inclusion and exclusion criteria.|May 2015|May 26, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02226692||37897|
NCT02231411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRIC|Neonatal Resuscitation With Intact Cord|Neonatal Resuscitation With Intact Cord|NRIC|Sharp HealthCare|Yes|Active, not recruiting|August 2014|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|150|||Both|23 Weeks|31 Weeks|No|||November 2015|November 10, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02231411||37534|
NCT02231424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1353|Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|January 1999|||November 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|713|||Both|6 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of chronic obstructive respiratory tract disease|September 2014|September 1, 2014|September 1, 2014||||No||https://clinicaltrials.gov/show/NCT02231424||37533|
NCT02221063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00103|Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia|Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia||University of British Columbia|No|Active, not recruiting|October 2014|October 2015|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|360|||Female|18 Years|45 Years|No|||April 2015|April 14, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221063||38330|
NCT02221310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-515|Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS|A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome||New York Medical College|No|Recruiting|November 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|30 Years|No|||March 2016|March 10, 2016|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221310||38311|
NCT02228642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14030372|Hypoglycemia in Hospitalized Patients|A Prospective Investigation Into the Causes, Symptoms, and Outcomes in Patients With Diabetes Who Experience Hypoglycemia During Their Hospitalization||University of Pittsburgh|No|Active, not recruiting|August 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|55|||Both|18 Years|90 Years|No|Non-Probability Sample|Non-critically ill hospitalized patients with a diagnosis of diabetes at time of admission        using established ADA criteria or prior physician diagnosis who experience a documented        episode of hypoglycemia, defined as a blood glucose < 70 mg/dl.|December 2015|December 12, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228642||37747|
NCT02238509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM12-TYPHER|Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies|A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies||Consorzio Oncotech|Yes|Recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238509||36988|
NCT02238522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEN-ONC3365-101|Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML|Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia||Zenith Epigenetics Corp.|No|Withdrawn|October 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238522||36987|
NCT02228902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ironabsorption|Iron Absorption Trial|||Rijnstate Hospital||Enrolling by invitation|August 2014|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02228902||37727|
NCT02234258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH105178|Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis|Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis||University of Calgary|No|Recruiting|January 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|14 Years|30 Years|No|||June 2015|June 2, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02234258||37315|
NCT02234713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000035924|Adherence in Pediatric Multiple Sclerosis|Treatment Adherence in Pediatric Multiple Sclerosis||The Hospital for Sick Children||Recruiting|January 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|160|||Both|10 Years|18 Years|No|||February 2015|February 5, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234713||37280|
NCT02230059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100943|Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)|Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC): Real Life Analysis In Brazilian Oncology Centers (REALIST-PRO)|REALIST-PRO|Janssen Research & Development, LLC|No|Completed|July 2013|May 2014|Actual|May 2014|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|382|||Male|18 Years|N/A|No|Non-Probability Sample|Male participants with history of prostatic cancer and metastatic castration-resistant        prostate cancer (mCRPC) from Brazil will be assessed.|September 2014|September 24, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230059||37638|
NCT02236013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0103|A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia||Astellas Pharma Inc|No|Recruiting|November 2014|August 2021|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02236013||37180|
NCT02236026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648|A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers|A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers: A Thorough QT/QTc Study||Population Council||Recruiting|September 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|44|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02236026||37179|
NCT02226198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3561C00004|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)|HYDRA|AstraZeneca|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|17 Years|No|||July 2015|July 15, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226198||37935|
NCT02226211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-46-2014|Ambu Aura-i Laryngeal Mask Versus Air-Q Intubating Laryngeal Airway for Tracheal Intubation in Adults|Ambu® Aura-iTM Laryngeal Mask Versus Air-QTM Intubating Laryngeal Airway as Conduits for Tracheal Intubation in Adults. A Randomized Comparative Clinical Trial||Cairo University|No|Recruiting|June 2014|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|60 Years|No|||August 2014|August 26, 2014|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226211||37934|
NCT02222766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190331-41|Parents and Tots Together: A Family-Based Obesity Prevention Intervention|Parents and Tots Together: A Family-Based Intervention to Promote Healthy Eating and Activity Behaviors Among Preschool Children|PTT|University of Guelph|No|Completed|June 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222766||38199|
NCT02223078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC4|Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.|Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Two Centre Study to Determine the Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.|CC4|Cancer Advances Inc.||Completed|July 2000|November 2001|Actual|August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||||||Both|18 Years|90 Years|No|||August 2014|August 20, 2014|July 2, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02223078||38175|
NCT02231125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-039-01|Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy|Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial||Chinese PLA General Hospital|Yes|Recruiting|September 2014|December 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|1600|||Both|18 Years|65 Years|No|||June 2015|June 29, 2015|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02231125||37556|
NCT02240524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014514|Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer|A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy|HIPEC|Affiliated Tumor Hospital of Guangzhou Medical University|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|582|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240524||36836|
NCT02221830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2738|Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)|Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)|PHP3|University of Colorado, Denver|No|Recruiting|February 2015|||August 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Female|13 Years|45 Years|No|||October 2015|October 2, 2015|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02221830||38271|
NCT02221843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK2013-0283_Sunbit|Sunbit UV Measuring Device to Track Sun Behavior|An Observational Single Center Pilot Study Using a Wearable UV Sensor (Sunbit) Measuring UV Exposure of Patients at High Risk for Skin Cancer - SUNBIT Study||University of Zurich|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|50 Years|N/A|No|Non-Probability Sample|Department of Dermatology of the University Hospital Zurich|December 2015|December 9, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02221843||38270|
NCT02221856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Masoud-001|Clinical Trial Comparing the Accuracy of Computer-assisted Orthodontic Treatment Modalities|A Prospective Clinical Trial Comparing Three Computer Aided Design Systems (SureSmile, Insignia, Invisalign) to Conventional Orthodontic Appliances||Harvard School of Dental Medicine|Yes|Recruiting|June 2014|||May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|N/A|50 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02221856||38269|
NCT02233764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1403004556|Effect of Iron/Zinc-biofortified Pearl Millet on Growth, Immunity, and Cognition in Children Aged 12-18 Months in India|Effect of Iron- and Zinc-biofortified Pearl Millet (ICTP8203-Fe) Consumption on Growth, Immune Competence, and Cognitive Function in Children Aged 12-18 Months in India||Cornell University|Yes|Not yet recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|700|||Both|12 Months|18 Months|No|||October 2015|October 19, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233764||37353|
NCT02224183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32948|Yoga vs. Education for Veterans With Chronic Low Back Pain|Veterans Back to Health: A Study Comparing Yoga and Education for Veterans With Chronic Low Back Pain||Boston Medical Center|Yes|Active, not recruiting|March 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224183||38090|
NCT02234271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA_IRB_14-000821|Plan A Birth Control: Randomized Controlled Trial of a Mobile Health Application for Contraception Information|||University of California, Los Angeles||Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02234271||37314|
NCT02238587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020304|The Effect of Ganoderma on Patients With Head-and-neck Cancer|The Effect of Gandoerma Spores Powder Capsules on the Post-treatment Life Quality and Immune Modulation of the Patients With Head-and-neck Cancer||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|June 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|100|||Both|20 Years|80 Years|No|||September 2014|September 9, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02238587||36982|
NCT02224729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.300|Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma||Thomas Jefferson University|Yes|Active, not recruiting|August 2014|||September 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|37|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224729||38048|
NCT02224742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12EN005|LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers|LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers||Nottingham University Hospitals NHS Trust|No|Recruiting|August 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||April 2013|August 22, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02224742||38047|
NCT02240446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406M51762|Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients|Non-Invasive Brain Stimulation for Clinical Intervention for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|45 Years|No|||May 2015|May 26, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02240446||36842|
NCT02225054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-2013|The Effect of Dexmedetomidine on Brachial Plexus Block for Shoulder Surgery|The Analgesic Effect of Dexmedetomidine as an Adjunct to Local Anesthetics in Ultrasound-guided Interscalene Approach to Brachial Plexus Block for Shoulder Surgery: A Randomized Controlled Trial|DEX|Women's College Hospital|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|65 Years|No|||March 2015|March 2, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225054||38023|
NCT02225067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC-14-001|Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring|Unblinded Comparison Study for Relationship and Reproducibility Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring, in Patients With Acid-related Diseases and Healthy Volunteers||Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02225067||38022|
NCT02225080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-DURSEC-001|Duragen® Secure Post Marketing Clinical Follow-up (PMCF)|Duragen® Secure Post Marketing Clinical Follow-up (PMCF)||Integra LifeSciences Corporation|No|Recruiting|October 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Neurgosurgery service in Hospital|January 2016|January 27, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02225080||38021|
NCT02229175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14153|Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema|Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular Edema||University of California, San Francisco|Yes|Not yet recruiting|May 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229175||37706|
NCT02229188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24MH074717|Games to Overcome Late Life Depression|Games to Overcome Late Life Depression|GOLD|University of California, San Francisco|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229188||37705|
NCT02225327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUADPPV23|MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine|Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination||Korea University Guro Hospital|Yes|Completed|October 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|224|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225327||38002|
NCT02225340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-PCSK9|Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia|Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia||Laval University|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|348|Samples Without DNA|Plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|community sample|August 2014|August 22, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225340||38001|
NCT02235818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB103099|Determining the Immediate Effects of Counterforce Bracing Versus Kinesiotaping in Patients With Tennis Elbow|Immediate Effectiveness of Counterforce Bracing Versus Kinesiotaping During Activity: A Randomized Crossover Trial in Patients With Lateral Epicondylosis|LE|Lawson Health Research Institute|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||September 2014|September 8, 2014|July 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02235818||37195|
NCT02235831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLT330-P001|DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance|DAILIES® AquaComfort Plus® MF - Comparative Assessment of Visual Performance Using Objective Measurements||Alcon Research|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|41 Years|65 Years|No|||December 2015|December 14, 2015|September 8, 2014|No|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT02235831||37194|
NCT02236572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405013982|Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score|A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores||Yale University|Yes|Recruiting|November 2014|September 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236572||37137|
NCT02236585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD-2015-16-P2Anesth|Patient-Controlled Epidural Analgesia After Uterine Artery Embolization|Does Patient-Controlled Epidural Bupivacaine-Fentanyl Offer Advantages Over Continuous Epidural Infusion After Uterine Arteries Embolization? A Controlled Prospective Study||Dammam University|Yes|Recruiting|January 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||January 2016|January 20, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236585||37136|
NCT02236598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056374|The Effects of Potassium on Glucose Metabolism in African Americans|The Effects of Potassium on Glucose Metabolism in African Americans||Duke University|No|Active, not recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|61|||Both|30 Years|N/A|No|||February 2016|February 11, 2016|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236598||37135|
NCT02230579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_MMV390048_14_01|Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers|A Single Centre, Two-part, Double-blind, Randomized, Placebo-controlled Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of MMV390048 in Healthy Adult Volunteers||Medicines for Malaria Venture|Yes|Completed|May 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230579||37598|
NCT02226458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI743-14-025|An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder|An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder|Autism|Edison Pharmaceuticals Inc|No|Withdrawn|October 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Years|14 Years|No|||March 2015|March 9, 2015|August 21, 2014|Yes|Yes|This study was halted prior to enrolling.|No||https://clinicaltrials.gov/show/NCT02226458||37915|
NCT02226471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW1000|Serum CTRP3 and RBP4 Levels in Obesity and Hypertension|Serum CTRP3 and RBP4 Levels in Obesity and Hypertension||Third Military Medical University|Yes|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||4|Actual|2000|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|We consecutively selected 2100 Chinese subjects from the general population who had        undergone medical check-ups at the Southwest Hospital Medical Center at the Third Military        Medical University|August 2014|August 25, 2014|August 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226471|3 Years|37914|
NCT02238717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431003|Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebo-controlled, 4 Period Cross-over Study To Examine The Effect Of Pf-06372865 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin As A Positive Control||Pfizer|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238717||36973|
NCT02222779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPUK-14-Metal|Quantification of Transition Metals|Quantification of Transition Metals in Patients at the Cologne University Hospital||University of Cologne||Not yet recruiting|September 2014|||August 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||4|Anticipated|3000|Samples Without DNA|Remaining portions of samples collected for diagnostic or therapeutic reasons (paired CSF      and blood serum samples). No lumbar puncture will be done specifically for this protocol.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|neurodegenerative diseases infections|August 2014|August 20, 2014|August 20, 2014||||No||https://clinicaltrials.gov/show/NCT02222779||38198|
NCT02221596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG046762-01A1|Vitamin D and Muscle Metabolic Function|Vitamin D Contribution to Muscle Metabolic Function in Aged Adults||University of Kentucky|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|56|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02221596||38289|
NCT02221869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-005|A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy|||Jazz Pharmaceuticals|Yes|Recruiting|September 2014|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|17 Years|No|||July 2015|November 12, 2015|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221869||38268|
NCT02221882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15279|A Study of LY3164530 in Participants With Cancer|A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Recruiting|August 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02221882||38267|
NCT02222207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15984|Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration|A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration|DREAM|Bayer|Yes|Completed|October 2014|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|52|||Both|50 Years|N/A|No|||November 2015|November 19, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222207||38242|
NCT02222506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1002-P009|Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Diabetic Foot Ulcers||KLOX Technologies Inc.|No|Active, not recruiting|April 2013|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222506||38219|
NCT02238431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lucrin depot FET cycle|Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers|Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers: Reduces Time to Transfer and Cycle Cancellation||Antalya IVF|No|Active, not recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|42 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02238431||36994|
NCT02223923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4087|Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours|A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours|Patriot|Royal Marsden NHS Foundation Trust|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223923||38110|
NCT02223936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-491|Follow up of Neurologic Development of Children Who Presented at the First Trimester of Pregnancy an Isolated Nuchal Anomaly With Normal Karyotype|Follow up of Neurologic Development of Children Who Presented at the First Trimester of Pregnancy an Isolated Nuchal Anomaly With Normal Karyotype|EDEN|Hospices Civils de Lyon|No|Completed|February 2009|March 2014|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|500|||Both|N/A|26 Months|Accepts Healthy Volunteers|||July 2014|August 21, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02223936||38109|
NCT02228096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTL019B2205J|Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia||Novartis|Yes|Recruiting|August 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|2 Years|21 Years|No|||January 2016|January 29, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228096||37789|
NCT02228109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20067|Multifocal Lens Centration and Its Effect on Visual Performance in a Presbyopic Population||BUICK|University of Waterloo|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|35|||Both|42 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228109||37788|
NCT02228395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701016|Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers|A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 Following Oral Dose Capsules in Healthy Subjects||Pfizer|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|August 27, 2014|No|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT02228395||37766|The participants received PF-04958242 0.35 milligrams (mg), 0.6 mg and 0.8 mg instead of the proposed doses of 0.35 mg, 0.55 mg and 0.75 mg based on the review conducted after each dosing period prior to proceeding to next dosing level.
NCT02228655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX-C-888|An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD|An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5||FerruMax Pharmaceuticals, Inc.|No|Terminated|October 2014|July 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 17, 2014|Yes|Yes|Inability to recruit patients meeting eligibilty criteria.|No||https://clinicaltrials.gov/show/NCT02228655||37746|
NCT02224755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC03062014|MOMENTUM 3 IDE Clinical Study Protocol|Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol|HM3™|Thoratec Corporation|Yes|Recruiting|September 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1028|||Both|18 Years|100 Years|No|||March 2016|March 24, 2016|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224755||38046|
NCT02228668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-AVANT C13-1|Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma|Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Recruiting|March 2015|January 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|3451|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon cancer included in the AVANT trial and who were randomized between the        three arms of treatment:          -  ARM A: (FOLFOX-4): Oxaliplatin, leucovorin (LV) and 5-fluorouracil (5-FU).          -  ARM B: (FOLFOX-4+bev): Bevacizumab, oxaliplatin, leucovorin (LV) and 5-fluorouracil             (5-FU).          -  ARM C: (XELOX+ bev): Bevacizumab, oxaliplatin in combination with capecitabine.|November 2015|December 10, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02228668||37745|
NCT02228915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1780|Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis|Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis|SOD1|University of North Carolina, Chapel Hill|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|A portion of this sample will be stored for future use in study of ALS and how the critical      protien affects the disease progression long term. This sample will be stored de-identified;      therefore will not be linked to any identifying informaton about the subject. Sample will be      stored at the UNC biophysics and Biochemistry lab indefinitely|Both|18 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|SALS patients SOD1 associated FALS patients Healthy control|November 2015|November 30, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228915||37726|
NCT02234284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI AD-1306-03900|Aides in Respiration Health Coaching for COPD|Health Coaching to Reduce Disparities for Patients With Chronic Obstructive Pulmonary Disease (COPD)|AIR|University of California, San Francisco|Yes|Recruiting|November 2014|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|190|||Both|40 Years|95 Years|No|||January 2016|January 19, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02234284||37313|
NCT02234479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058645|MediHoney for Radiation Dermatitis|A Pilot Study: Topical Application of Medihoney for Management of Radiation Dermatitis||University of Maryland|Yes|Completed|June 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||March 2015|March 16, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234479||37298|
NCT02229474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEA_TANZANIA_CST1|IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania|Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial|IDEA|Northumbria Healthcare NHS Foundation Trust|Yes|Enrolling by invitation|September 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|16|||Both|N/A|N/A|No|||August 2014|August 29, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229474||37683|
NCT02236520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141382|Tissue Sodium in Pre-hypertensive Patients|Tissue Sodium in Pre-hypertensive Patients||Vanderbilt University|Yes|Recruiting|September 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236520||37141|
NCT02236247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:09145612.8.0000.0068|Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure|Heart Rate Control as an Additional Therapeutic Strategy in Patients With Decompensated Heart Failure: a Prospective, Randomized, Double-blinded, Placebo-controlled Study.|CONSTATHE|University of Sao Paulo|Yes|Recruiting|May 2013|November 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02236247||37162|
NCT02230852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201319406|Prehospital Stroke Study at the Universitair Ziekenhuis Brussel I (PreSSUB I)|Study of the Safety, Feasibility and Reliability of In-ambulance Telemedicine During Paramedic Intervention Team Transportation of Patients With Suspicion of Acute Stroke.|PreSSUB I|Universitair Ziekenhuis Brussel|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Patients older than 18 years requesting emergency care for suspicion of acute stroke|November 2014|November 3, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230852||37577|
NCT02236819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eureca1-2014|A Multi-centre Survey of Epidemiology, Treatment and Outcome of Patients Suffering an Out-of-hospital Cardiac Arrest|EuReCa ONE : An International, Prospective, Multi-centre, One Month Survey of Epidemiology, Treatment and Outcome of Patients Suffering an Out-of-hospital Cardiac Arrest in Europe|EuReCaONE|German Resuscitation Registry|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|Residents of 27 European countries|March 2015|March 9, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02236819|30 Days|37118|
NCT02227290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS90200_4024_1|Pediatric Subjects With Tinea Corporis|A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis||Merz Pharmaceuticals, LLC|No|Completed|August 2014|December 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|230|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227290||37851|
NCT02221895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|383665-1|The Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 Months|The Effect of Early (2-3 Week Postpartum) Versus Traditional (6-8 Week Postpartum) Follow-Up on Breastfeeding Rates at 6 Months||Madigan Army Medical Center|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|346|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02221895||38266|
NCT02222545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS721-TMA-001|Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies|A Phase 2, Uncontrolled, Two-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies||Omeros Corporation|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|29|||Both|18 Years|N/A|No|||December 2014|May 4, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222545||38216|
NCT02222571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12JL030|Pilot Study of a Family-based Obesity Prevention Intervention in the Canadian Context|Pilot Study of a Family-based Obesity Prevention Intervention in the Canadian Context||University of Guelph|Yes|Recruiting|July 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02222571||38214|
NCT02227810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-1702C|Electrical Stimulation in Patients With Prolonged Mechanical Ventilation|Effects of Muscular Electrical Stimulation on Skeletal and Lung Mechanics in Patients With Prolonged Mechanical Ventilation||Chang Gung Memorial Hospital|Yes|Recruiting|March 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|N/A|No|||March 2014|August 26, 2014|August 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227810||37811|
NCT02233426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKU-001|Effect of Hypertonic Solutions on Allergic Rhinitis Patients|Do Hypertonic Solutions Have an Impact on Nasal Eosinophilia in Allergic Rhinitis Patients?|hypertonic|Namik Kemal University|No|Not yet recruiting|September 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Medical records of patients who admitted to the outpatient clinic of a tertiary referral        center was enrolled.|September 2014|September 3, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233426||37379|
NCT02233439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 54/2013|Double-blind, Placebocontrolled A Randomized Trial on the Efficacy of Herbal Galactogogues|Efficacy of Herbal Galactogogues: a Double-blinded, Placebo-controlled Randomized Trial.||Università degli Studi dell'Insubria|No|Not yet recruiting|September 2014|March 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 5, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233439||37378|
NCT02233621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49RC10_32_01-PHRC2010-02|Assessment of Performance of [18F]-FES for Endometriosis Diagnosis|Evaluation Des Performances de la Tomographie Par Emission de Positons Avec la 16α-[18F]Fluoro-17β-estradiol ([18F]-FES) Pour le Diagnostic de l'Endometriose|ENDOTEP|University Hospital, Angers|No|Recruiting|June 2012|||October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|50 Years|No|||September 2014|September 3, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233621||37364|
NCT02233777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE.293/EQL/2013|Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg|Bioequivalence Study of 150 mg Pregabalin Capsules Produced by PT Dexa Medica in Comparison With the Comparator Product (Lyrica® Capsule 150 mg, Pfizer Manufacturing Deutschland GmbH, Germany)||Dexa Medica Group|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233777||37352|
NCT02239861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35425, TACTASOM|TAA-Specific CTLS for Solid Tumors (TACTASOM)|Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors||Baylor College of Medicine|Yes|Recruiting|April 2015|October 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|2 Years|80 Years|No|||February 2016|February 19, 2016|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239861||36887|
NCT02234011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001140|A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder|A Placebo-Controlled Crossover Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder||Mclean Hospital|Yes|Terminated|September 2014|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|55 Years|No|||January 2016|January 27, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234011||37334|
NCT02234024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC-62314|Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder|Oral Supplementation of Gangliosides - A Potential Treatment for GM3 Synthase Deficiency||DDC Clinic - Center for Special Needs Children|No|Enrolling by invitation|January 2014|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|20 Years|No|||September 2014|September 8, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02234024||37333|
NCT02234037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064866|Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60|A Pilot Study of Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 Who Are Not Candidates for Standard Induction Chemotherapy||Emory University|Yes|Active, not recruiting|November 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|N/A|No|||October 2015|October 6, 2015|February 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234037||37332|
NCT02236312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43QM1313|Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines|A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines||Q-Med AB|Yes|Active, not recruiting|September 2014|||November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|350|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|September 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236312||37157|
NCT02236325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40846-G|Brief Skills Training Intervention for Suicidal Individuals|Brief Skills Training Intervention for Suicidal Individuals||University of Washington|Yes|Completed|January 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02236325||37156|
NCT02236403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|demodex0.1|Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%|Diagnosis of Demodex Blapharitis and Treatment With Ivermectin Gel 0.1%/ Metronidazole 1%||Universidad Nacional de Colombia|Yes|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236403||37150|
NCT02234726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC 0349-03|Improving Early Childhood Development in Zambia|Improving Early Childhood Development in Zambia|IECDZ|Zambia Center for Applied Health Research and Development|No|Completed|August 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|526|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||December 2015|December 11, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02234726||37279|
NCT02231788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330HT13010|The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy|A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy|TENUVA-BP|Chong Kun Dang Pharmaceutical|No|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|19 Years|N/A|No|||August 2015|August 19, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231788||37505|
NCT02232087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDSD-1030-SAFL|Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate|Phase I Single Blind, Randomised, Cross-over Pharmacodynamic Dose Response Study in Healthy Volunteers of Two Pressurized Metered Dose Inhalers (pMDIs) That Deliver Salmeterol and Fluticasone Propionate||3M|Yes|Completed|July 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232087||37482|
NCT02225925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J13164|Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound|Phase II Study of Dynamic Intraoperative Dosimetry for Prostate Brachytherapy Using Registered Fluoroscopy and Ultrasound||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2014|March 2021|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||November 2015|November 17, 2015|April 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225925||37956|
NCT02225938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGS15-0104|ICU Recovery in Australian Patients|ICU Recovery: A Multicentre Cohort Study in Critically Ill Patients to Determine Functional Recovery and Quality of Life|ICU-RECOVERY|Australian and New Zealand Intensive Care Research Centre|No|Enrolling by invitation|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|300 critically ill patients who were mechanically ventilated >24 hours in an intensive        care unit who have survived to hospital discharge.|February 2015|February 1, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02225938||37955|
NCT02236650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLUBM_24272|Primary Care Stepping Stones Triple P for Children With Autism|A Pilot Study of Primary Care Stepping Stones Triple P for Children With Autism||St. Louis University|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236650||37131|
NCT02238613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanliu307|Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer|Intraluminal Implantation of Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer||307 Hospital of PLA|Yes|Recruiting|August 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||September 2014|September 10, 2014|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02238613||36981|
NCT02226705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110151|Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis|Treatment of Rhino-Sinusal Mucormycosis Through Transnasal Endoscopic Surgery Extended to the Skull Base.|MICCA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|January 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226705||37896|
NCT02226991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.102|Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers|A Single-centre, Open-label Study to Assess the Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration When Tipranavir/Ritonavir Are Administered at Doses 500 mg/200 mg BID to Steady-state in Healthy Adult Volunteers||Boehringer Ingelheim||Completed|April 2006|||July 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02226991||37874|
NCT02240329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-2012|Assessment of Dystussia in Traumatic Brain Injury|Assessment of Dystussia in Traumatic Brain Injury||University of Florida|No|Completed|March 2013|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|60 Years|No|||September 2015|September 29, 2015|June 5, 2014|No|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT02240329||36851|
NCT02222220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLAK-14|Metoclopramide as Treatment of Clozapine-induced Hypersalivation|Metoclopramide as Treatment of Clozapine-induced Hypersalivation||Beersheva Mental Health Center|No|Completed|January 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|19 Years|57 Years|No|||January 2012|August 20, 2014|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02222220||38241|
NCT02222233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.60|Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers|Relative Bioavailability of Single Doses of 200 mg BI 671800 HEA Administered Orally as a Delayed Release (Enteric Coated) Tablet; or Via the EnterionTM Capsule as Solution to the Jejunum, Ascending Colon or Descending Colon; or Via the EnterionTM Capsule as Particulate to the Ascending Colon. An Open-label, Five Periods, Fixed Sequence Phase I Study in Healthy Male Volunteers||Boehringer Ingelheim||Completed|January 2010|||March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|10|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 20, 2014||||No||https://clinicaltrials.gov/show/NCT02222233||38240|
NCT02218567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00327-40|Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience||HUNTEXPERT|University Hospital, Angers|No|Recruiting|June 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A||||June 2014|August 14, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02218567||38522|
NCT02232347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCSSA KETABRAIN|Ketamine and Glutamate After Brain Injury : a Microdialysis Study|Effect of Ketamine Versus Sufentanil on Cerebral Glutamate After Traumatic Brain Injury : a Randomized, Double-blinded, Microdialysis Study|KETABRAIN|Direction Centrale du Service de Santé des Armées|Yes|Not yet recruiting|October 2014|May 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232347||37462|
NCT02239770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000873|Pharmacokinetics of Nicotine Film in Smokers|Pharmacokinetics of Nicotine Film in Smokers||Milton S. Hershey Medical Center|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239770||36893|
NCT02224209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTH-STEP|Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis|Comparison of Staged Angioplasty v.s. Routine Single-stage Stenting (CAS) in the Treatment of Patients With Carotid Artery Stenosis at High Risk of Hyperperfusion (STEP）: A Randomized Controlled Trial|STEP|Beijing Tiantan Hospital|Yes|Not yet recruiting|November 2014|September 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|40 Years|80 Years|No|||November 2014|November 14, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02224209||38088|
NCT02239796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA 2013/05|Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence|A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.|TREAT-UI|Glasgow Caledonian University|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02239796||36891|
NCT02239874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000895|VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue|THE EFFECTS OF VITAMIN D ON MAMMOGRAPHIC DENSITY AND BREAST TISSUE|VITAL|Brigham and Women's Hospital|No|Enrolling by invitation|July 2012|May 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|25875|||Female|55 Years|67 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239874||36886|
NCT02239302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1665|Obstructed Defaecation: Proctography Versus Ultrasound in Symptomatic Patients|Obstructed Defaecation: Proctography Versus Ultrasound (TPUS and EVUS) in Symptomatic Patients|OPUS|Croydon University Hospital|Yes|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients with symptomes of obstructed defaecation|July 2015|July 30, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239302||36928|
NCT02225093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0406|A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer|A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates for CYP1A2 and CYP2D6 in Male Subjects With Prostate Cancer||Astellas Pharma Inc|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|August 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02225093||38020|
NCT02225106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140169|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI||National Institutes of Health Clinical Center (CC)||Suspended|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|55 Years|No|||February 2016|March 3, 2016|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225106||38019|
NCT02225353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC12012/10IEI-9339|Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery|Exploratory Efficacy Study of a Cervical Pessary Sustained Release Progesterone for the Prevention of Preterm Delivery|PCP002|Laboratorios Andromaco S.A.|Yes|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|180|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 14, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225353||38000|
NCT02225366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0422|Intratumoral Injections of LL37 for Melanoma|Induction of Antitumor Response in Melanoma Patients Using the Antimicrobial Peptide LL37||M.D. Anderson Cancer Center|Yes|Recruiting|July 2015|||July 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225366||37999|
NCT02236455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S5862|Effects of Complementary Therapies Delivered Via Mobile Technologies|Effects of Complementary Therapies Delivered Via Mobile Technologies on Surgical Patients' Reports of Anxiety, Pain, and Self-Efficacy in Healing: A Pilot Randomized Controlled Trial in Iceland||University of San Francisco|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|105|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02236455||37146|
NCT02232360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAFENO|Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone|The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)||Gachon University Gil Medical Center|Yes|Recruiting|January 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||August 2015|August 10, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232360||37461|
NCT02225951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM.1.C/A|Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.|A Randomised, Controlled, Open-label Trial to Investigate the Effect of a New Nutritional Supplement on Postprandial Glucose Response in Women Diagnosed With Gestational Diabetes Mellitus.|GDM MTT|Danone Asia Pacific Holdings Pte, Ltd.|No|Terminated|July 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3|||Both|18 Years|40 Years|No|||November 2014|November 20, 2014|August 25, 2014||No|Feasibility of the current protocol is not optimal to further conduct the study.|No||https://clinicaltrials.gov/show/NCT02225951||37954|
NCT02226224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1001|Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro|Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro||Beijing Cancer Hospital|No|Recruiting|June 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced upper GI carcinoma receive surgery as first treatment no        previous surgery involved the upper GI tract|August 2014|August 26, 2014|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02226224||37933|
NCT02236728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.648|Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole|Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP)||Boehringer Ingelheim||Completed|February 2008|||November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|497|||Both|N/A|N/A|No|Non-Probability Sample|neurologists' population of patients treated with pramipexole and suffering from        Parkinson's disease (so called 'primary care' population)|September 2014|September 10, 2014|September 10, 2014||||No||https://clinicaltrials.gov/show/NCT02236728||37125|
NCT02236741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.672|The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia|The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia||Boehringer Ingelheim||Completed|November 2009|||December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|26814|||Both|40 Years|89 Years|No|Non-Probability Sample|Users of anti-parkinsonian drugs registered with an up-to-standard practice from the        United Kingdom's General Practice Research Database (GPRD)|September 2014|September 10, 2014|September 10, 2014||||No||https://clinicaltrials.gov/show/NCT02236741||37124|
NCT02239640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-SFR005|Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke (STRATIS) Registry|Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke (STRATIS) Registry||Medtronic - MITG|No|Recruiting|August 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Acute Ischemic Stroke Patients|September 2014|September 11, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02239640|90 Days|36903|
NCT02239653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403027|Reduction of Excessive Calories From Beverages in Children|Randomized Controlled Trial to Reduce Calorie Intake From Sugar-sweetened Beverages by Children 1 - 12 Years of Age|MWP|Washington University School of Medicine|No|Enrolling by invitation|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239653||36902|
NCT02236338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11792|Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein|Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein: A Prospective Randomized Trial||Virginia Commonwealth University|No|Recruiting|September 2008|September 2028|Anticipated|September 2028|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02236338||37155|
NCT02222558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-006|Oral Testosterone for the Treatment of Hypogonadism in Males|A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males||TesoRx Pharma, LLC|No|Completed|September 2014|April 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|70 Years|No|||May 2015|May 21, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222558||38215|
NCT02210858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01606|Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders|Phase I/II Study of Tipifarnib [ZARNESTRATM, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2000|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02210858||39112|
NCT02210871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3651|Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function|A Multi-centre, Open-label, Parallel-group Trial Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function||Novo Nordisk A/S|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02210871||39111|
NCT02239731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDX104-1|Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients|A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab||Foamix Ltd.|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239731||36896|
NCT02239757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LERRASMI|Left vs Right Radial Approach in the Setting of Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction|||Capital Medical University|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|80 Years|No|||September 2014|July 30, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239757||36894|
NCT02236897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00073452|PET Imaging in ALS Patients|Metabotropic Glutamate Receptor 5 (mGluR5) Imaging in Amyotrophic Lateral Sclerosis (ALS) Patients and Healthy Volunteers||Johns Hopkins University|No|Recruiting|August 2013|||August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|38|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236897||37112|
NCT02237144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEARCTR-0000247|Transfer Modality Research Initiative - Bangladesh|Transfer Modality Research Initiative - Bangladesh|TMRI|International Food Policy Research Institute|No|Active, not recruiting|April 2012|December 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|5000|||Female|15 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 26, 2016|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02237144||37093|
NCT02237326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 1825|Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women|Safety and Validity Evaluation for Cervical Cancer Screening and Treatment Techniques Among HIV-infected Women|SAVE|University of California, San Francisco|No|Completed|October 2011|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|654|||Female|23 Years|59 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02237326||37079|
NCT02224794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0014|LIFE Study: Least Invasive Fast-Track EVAR|LIFE Study: Least Invasive Fast-Track EVAR With the Ovation® Abdominal Stent Graft Platform||TriVascular, Inc.|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll male and female subjects 18 years and older that have an AAA and        meet all other inclusion/exclusion criteria.|November 2015|November 24, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224794|1 Month|38043|
NCT02224768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-242|YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey|YERVOY Risk Minimisation Tool Evaluation Survey||Bristol-Myers Squibb|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|158|||Both|18 Years|N/A|No|Probability Sample|HCPs and Patients in EU member states where YERVOY has been marked for atleast six months|December 2015|December 18, 2015|March 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224768||38045|
NCT02224781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01747|Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma|A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma||National Cancer Institute (NCI)|Yes|Suspended|July 2015|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|March 21, 2016|August 22, 2014|Yes|Yes|Drug supply issues|No||https://clinicaltrials.gov/show/NCT02224781||38044|
NCT02229201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCL-NKG-01|Comparison of Two Anaesthetics on Brain During Brain Tumour Surgery|Phase 1 Study of the Impact of Propofol vs. Sevoflurane on Brain Damage and Inflammatory Response During Brain Tumour Surgery||University Medical Centre Ljubljana|Yes|Completed|May 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||August 2014|August 27, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02229201||37704|
NCT02230072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34680|Fetoscopic Meningomyelocele Repair Study|Minimally Invasive Fetal Neural Tube Defect Repair Study|fMMC|Baylor College of Medicine|Yes|Recruiting|July 2014|January 2021|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230072||37637|
NCT02230085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-121|Adherence Risk Indicator Validation Study|A Validation Study of an Adherence Risk Indicator Statistical Prediction Model.|ARI|Fisher and Paykel Healthcare|No|Active, not recruiting|September 2014|November 2015|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient recieving CPAP for OSA.|August 2015|August 19, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02230085||37636|
NCT02225639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-008|PRC-063 in an ADULT Workplace Environment|A Randomized, Double-blind Study of the Time Course of Response of PRC-063 in Adults With ADHD in a Simulated Adult Workplace Environment||Rhodes Pharmaceuticals, L.P.|No|Completed|August 2014|May 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||July 2015|July 7, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225639||37978|
NCT02225652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST174.05|A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.|A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.||Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Completed|September 2010|July 2014|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|70 Years|No|||August 2014|August 25, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02225652||37977|
NCT02233790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0209|Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI|Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT||First Hospital of China Medical University|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233790||37351|
NCT02233634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/14|Impact of Breathing Maneuvers on the Oxygenation Supply of the Heart Assessed With MRI in Patients With Coronary Artery Disease|Impact of Breathing Maneuvers and Oxygen Administration on Myocardial Oxygenation in Patients With Coronary Artery Disease Compared With Healthy Controls - Non-invasive Assessment With Oxygenation-sensitive Cardiovascular Magnetic Resonance Imaging (OS-CMR)|CADOS-CMR|University Hospital Inselspital, Berne|No|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02233634||37363|
NCT02234492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140263-01H|The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients|The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients||Ottawa Heart Institute Research Corporation|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|82|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02234492||37297|
NCT02226484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0557|Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?|Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?||University of North Carolina, Chapel Hill|No|Enrolling by invitation|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|27|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|August 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226484||37913|
NCT02236533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFLAB14|Healthy Effects of an Innovative Probiotic Pasta|Healthy Effects of an Innovative Probiotic Pasta|SFLABPASTA|University of Parma|Yes|Completed|March 2014|March 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02236533||37140|
NCT02210572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)296/2013/A-4/2014|Effect of Prebiotics Versus Low FODMAPs Diet on Intestinal Microbiota and Symptoms|Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|August 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||August 2014|November 27, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02210572||39134|
NCT02211105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA STAR Registry|Registry to Compare Two Surgical Treatments for GERD|Laparoscopic Nissen Fundoplication (LNF) Surgery Versus Transoral Incisionless Fundoplication (TIF): Anti- Reflux Treatment Registry|STAR Registry|American Gastroenterological Association|Yes|Recruiting|July 2014|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults who meet clinical criteria and have decided to treat their GERD through one of two        surgical procedures, (LNF or TIF) and agree to have their standard GI medical data for 3        years.|April 2015|April 30, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02211105|3 Years|39093|
NCT02223949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033-14-HYMC|Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening Methods|Labor Induction and Maternal BMI: Comparison of Different Pre-induction Cervical Ripening Methods: The Cook Double Balloon Catheter vs PGE1 Tablets in Lean, Overweight, and Obese Women. A Prospective Randomized Study.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|624|||Female|18 Years|45 Years|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223949||38108|
NCT02224196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0270|Comparison of Peak Airway Pressure and Gastric Insufflation in Manual Ventilation and Pressure-controlled Ventilation With Facemask During Anesthesia Induction in Children|||Yonsei University|No|Recruiting|August 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|48|||Both|6 Months|7 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224196||38089|
NCT02237248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055257|Function and Scoliosis Surgery|Functional Testing, and Biomechanics Before and After Scoliosis Surgery||Duke University|No|Enrolling by invitation|November 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Female|12 Years|18 Years|No|Non-Probability Sample|Patients that are undergoing spinal fusion surgery to treat idiopathic scoliosis.|August 2015|August 26, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237248||37085|
NCT02224807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA178359-01A1|Effects of Diet and Exercise on Ductal Carcinoma in Situ|Exploring Effects of Weight Loss on Ductal Carcinoma In Situ|DCIS|University of Alabama at Birmingham|Yes|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|19 Years|N/A|No|||November 2015|February 24, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224807||38042|
NCT02223650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXT3|A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia|A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia|IXT3|Jaeb Center for Health Research|Yes|Completed|December 2014|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|3 Years|6 Years|No|||February 2016|February 22, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223650||38131|
NCT02223663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075593|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||October 14, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223663||38130|
NCT02224469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU 12-370|First Study With a Brain Implant to Help Locked-in Patients Communicate at Home|Utrecht Neural Prosthesis (UNP): A Pilot Study on Controllability of Brain Signals and Application in locked-in Patients|UNP|UMC Utrecht|Yes|Recruiting|November 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|5|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224469||38068|
NCT02224482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA158019|Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)|Randomized Clinical Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors|PROGRESS|Fox Chase Cancer Center|Yes|Recruiting|February 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|600|||Male|18 Years|80 Years|No|||September 2015|September 3, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224482||38067|
NCT02224495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET2011|The Effect of Exercise Training on Cardiac Structure and Function|The Effect of Exercise Training on Cardiac Structure and Function||Gaia Hospital|No|Completed|September 2011|May 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224495||38066|
NCT02224508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-1306-02198|Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks|Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks|CARE|Group Health Cooperative|No|Completed|September 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1589|||Both|18 Years|N/A|No|Probability Sample|The study population will be Chronic Opioid Therapy (COT) patients from Group Health        clinics. We will interview and compare 800 COT patients using opioids long-term from        clinics that implemented the risk reduction initiative and 800 COT patients from care        settings that did not.|February 2016|February 3, 2016|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02224508||38065|
NCT02224521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112071|GSK2190915A - Bioavailability Study|An Open-label, Randomised, Single-dose, Multi-cohort, Crossover Bioavailability Study of a Solution Formulation and Three Capsule Formulations of GSK2190915 in Healthy Adult Subjects Followed by a Repeat-dose, Randomized, Parallel Group, Double-blinded Study of One Selected Capsule Formulation and Matched Placebo in Elderly Healthy Subjects||GlaxoSmithKline|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT02224521||38064|
NCT02230592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140016|PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX|PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX||National Institutes of Health Clinical Center (CC)||Recruiting|November 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230592||37597|
NCT02230605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0388|Perioperative Cognitive Protection - Cognitive Exercise and Cognitive Reserve (The Neurobics Trial)|Perioperative Cognitive Protection - Cognitive Exercise and Cognitive Reserve (The Neurobics Trial)||Ohio State University|No|Recruiting|July 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|268|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230605||37596|
NCT02230865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRPEX-3|Prediction of Acute Postoperative Pain and Analgesic Consumption|Prediction of Acute Postoperative Pain and Analgesic Consumption by Preoperative Responses to Experimental Pain in Patients Undergoing Chest Wall Surgery|MIRPEX-3|University of Aarhus|No|Recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|15 Years|N/A|No|Non-Probability Sample|Patients with funnel chest (pectus excavatum) undergoing corrective chest wall surgery at        Aarhus University Hospital|May 2015|May 29, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230865||37576|
NCT02228356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUN143201215117|Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer|Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer||Universitair Ziekenhuis Brussel||Recruiting|June 2012|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic cancer from any primary origin and no more than 5 metastases.|August 2014|August 26, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02228356||37769|
NCT02234050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1320|Trabectedin for Recurrent Grade II/III Meningioma|Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|July 2015|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02234050||37331|
NCT02234297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-002|Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery|A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery||Blaze Bioscience Inc.|Yes|Recruiting|October 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234297||37312|
NCT02236052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-Q13VLP-008|Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population|Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population||Medicago|Yes|Active, not recruiting|August 2014|September 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|450|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236052||37177|
NCT02236260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0060|Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation|Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.|ACUplus|Nantes University Hospital|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|74 Years|No|||September 2015|September 29, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02236260||37161|
NCT02240277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-RBWH-2014-1|Meropenem and Ciprofloxacin Dosing in Septic Shock|Meropenem and Ciprofloxacin Dosing in the Critically Ill Patient With Septic Shock - a Single Center Pharmacokinetic Study||Rigshospitalet, Denmark|Yes|Not yet recruiting|November 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients admitted to ICU with septic shock treated with the study drugs, initiated at the        discretion of the treating doctor.|September 2014|September 11, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02240277||36855|
NCT02240368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01|Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery|Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery. Bispectral VISTA and ENTROPY Monitor for Pediatric Anesthesia.||University of Foggia|Yes|Completed|January 2014|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|||Both|1 Month|12 Years|No|Probability Sample|Pediatric patients with age ≤ 12 years old scheduled to undergo general anesthesia and        mechanical ventilation for elective surgery|June 2015|June 12, 2015|August 31, 2014||No||No|May 24, 2015|https://clinicaltrials.gov/show/NCT02240368||36848|
NCT02225574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0128|An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)|An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225574||37983|
NCT02225587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-029|Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)|Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Subjects 50 Years of Age and Older||Merck Sharp & Dohme Corp.|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|400|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225587||37982|
NCT02210884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE1357|Maternal Vit D Supplements & Infant and Maternal Biomarkers & Outcomes in Southern Ethiopia|Effects of Maternal Vitamin D Supplementation on Markers of Vitamin D Status and Related Infant and Maternal Outcomes in Southern Ethiopia||Oklahoma State University|Yes|Active, not recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|240|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02210884||39110|
NCT02210598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00740|Outpatient Labor Induction With the Transcervical Foley Balloon|Outpatient Labor Induction With the Transcervical Foley Balloon: A Randomized Trial Comparing Outpatient Immediate Removal Foley Versus Standard Inpatient Foley Induction||University of Southern California|Yes|Recruiting|March 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|N/A|No|||August 2014|August 5, 2014|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02210598||39132|
NCT02228122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoM Study REF: 14118|The Effect of Aquacel® Ag+ Extra Dressing on Wound Biofilms|||University of Manchester|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228122||37787|
NCT02223117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1|Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)|Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)||Cellphire, Inc.|Yes|Recruiting|September 2014|||January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223117||38172|
NCT02223676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-379-13|Clinical Pharmacists in the Emergency Department|Is Length of Stay in the Emergency Department Reduced When Clinical Pharmacists Conduct Medication History? - a Cluster Randomized Study||Randers Regional Hospital|No|Active, not recruiting|October 2013|December 2014|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|860|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|January 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02223676||38129|
NCT02223962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55086|Effects of Physical Activity Counseling After an Exacerbation in COPD|The Effects of a Physical Activity Counseling Program Immediately After an Exacerbation in Patients With COPD.||Katholieke Universiteit Leuven|No|Completed|March 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|80 Years|No|||April 2015|April 30, 2015|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02223962||38107|
NCT02228941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81273314|NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE Syndrome|||Shanghai Children's Medical Center||Not yet recruiting|September 2014|||September 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|1 Month|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|We divided the patients with HIES into two groups, namely Autosomal-dominant Hyper-IgE        Syndrome(AD-HIES) group and Autosomal-recessive Hyper-IgE Syndrome(AR-HIES) group.        According to the different group, we need to do a variety of detection index, for example,        gene mutations, B-lymphocyte subsets, protein expression et al.In addition, healthy        control group is needed in the experiment.|August 2014|August 28, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02228941|3 Months|37724|
NCT02223013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528.204|Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects|Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of 50 mg BIBV 308 SE Each, Versus a Solution of 50 mg BIBV 308 SE Administered Orally Twice a Day for 3.5 Days to Healthy Subjects (Cross-over, Open, Randomized)||Boehringer Ingelheim||Completed|April 1999|||May 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223013||38180|
NCT02223026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.4|Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects|Relative Bioavailability of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial||Boehringer Ingelheim||Completed|January 2010|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223026||38179|
NCT02229734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASTR-2|Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2|Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2|FASTR-2|Lawson Health Research Institute|Yes|Recruiting|December 2014|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|70 Years|N/A|No|||March 2016|March 3, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229734||37663|
NCT02229747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.250|Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis|Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg/kg/Day Once a Day, Versus Diclofenac 1 mg/kg/Day Twice a Day or Nimesulide 4 mg/kg/Day Twice a Day, for Five Days in the Treatment of Patients With Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis||Boehringer Ingelheim||Completed|August 2001|||February 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|2 Years|8 Years|No|||July 2014|August 29, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229747||37662|
NCT02229760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.109|Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV|Effect of Steady State TPV/r 500 mg/200 mg on Intracellular Concentrations of Zidovudine Triphosphate and Carbovir Triphosphate||Boehringer Ingelheim||Terminated|August 2006|||September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|60 Years|No|||August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229760||37661|
NCT02229773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1178.2|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 0.25 mg, 0.5 mg and 1 mg o.d. BIBB 1464 (Tablet) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])||Boehringer Ingelheim||Completed|January 2000|||May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|100|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229773||37660|
NCT02222831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skive-2014-BBP|Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.|Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.||Regionshospitalet Viborg, Skive|No|Enrolling by invitation|June 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222831||38194|
NCT02237196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN057AD|Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy|Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2014|February 2018|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237196||37089|
NCT02237911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14080261|Comparison of Treatments Following Total Knee Replacement|A Comparison of Treatment Methods for Patients Following Total Knee Replacement.||University of Pittsburgh|Yes|Recruiting|December 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|60 Years|N/A|No|||December 2015|December 1, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237911||37034|
NCT02237963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/50|Influence of the Surgical Approach on the Development of a Chronic Pain After Thoracic Surgery|Influence of the Surgical Approach on the Development of a Chronic Pain After Thoracic Surgery|IncisionPain|Hopital Foch|No|Recruiting|July 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|306|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing thoracic surgery by posterolateral or axillary thoracotomy, having no        exclusion criteria for the study,|February 2016|February 22, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237963|4 Months|37030|
NCT02224001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tip Plasty|A New Concept in the Tip Plasty of Asian Rhinoplasty|A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage Without Septal Extension Grafts|TP|Winners Clinic|No|Completed|January 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|17 Years|74 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224001||38104|
NCT02224014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.509|Lendormin D® Tablet (Drug Use Result Survey)|Lendormin D® Tablet (Drug Use Result Survey)||Boehringer Ingelheim||Completed|June 2005|||March 2006|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|485|||Both|N/A|N/A|No|Non-Probability Sample|patients with insomnia, receiving Lendormin D tablet under condition of normal clinical        practice|August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02224014||38103|
NCT02224560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1414|A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.||GW Research Ltd|Yes|Active, not recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|2 Years|55 Years|No|||December 2015|December 21, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224560||38061|
NCT02224859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-CS-001|Invictus Medical, Medical Cranial Support Device (CSD) is a Device Safety Study in Infants at Risk of Head Ulcers.|Clinical Safety and Utility of the Invictus Cranial Support Device (CSD)|INV-CS-001|Invictus Medical, Inc.|Yes|Withdrawn|March 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|30 Weeks|36 Weeks|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 28, 2014|Yes|Yes|Organization has withdrawn their 510k submission and stopped the study|No||https://clinicaltrials.gov/show/NCT02224859||38038|
NCT02238080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22556|An Observational Study of Methoxy Polyethylene Glycol-Erythropoietin [MIRCERA] in Chronic Kidney Disease Patients on Dialysis|||Hoffmann-La Roche||Completed|December 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with chronic kidney disease on dialysis therapy, either initiating        erythropoiesis-stimulating agent (ESA) treatment with Mircera or on stable Mircera        maintenance therapy. The study is to be conducted in Israel.|March 2016|March 1, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238080||37021|
NCT02238093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-13-HYMC|Cardiorenal Syndrome in End-Stage Kidney Disease|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|270|||Both|18 Years|N/A|No|Probability Sample|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.|September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238093||37020|
NCT02230657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHOZ01|A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach|A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach||Rothman Institute Orthopaedics||Completed||||August 2015|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230657||37592|
NCT02230280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STPILOT-134162|My Stroke Team (MYST): Stroke App Pilot Study|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention That Includes a Mobile Health Solution||McMaster University|No|Not yet recruiting|May 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|65 Years|N/A|No|||September 2015|September 24, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230280||37621|
NCT02230293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 3927-06|Assistance Multidisciplinary in Hypertensive Patient: Randomized Clinical Trial|Assistance Multidisciplinary in Hypertensive Patient: Randomized Clinical Trial|MULTIHAS|Instituto de Cardiologia do Rio Grande do Sul|No|Completed|March 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|41 Years|67 Years|No|||September 2014|September 2, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02230293||37620|
NCT02236507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Banasiuk2014 A|Normal Values for 3D High Resolution Anorectal Manometry in Children|Evaluation of Anorectal Area in Children Using 3D High Resolution Anorectal Manometry.||Medical University of Warsaw||Completed|April 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|12 Months|18 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02236507||37142|
NCT02236559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-EDPF2014001Dev|High Flow Therapy for the Treatment of Respiratory Failure in the ED|Vapotherm High Flow Therapy for the Treatment of Respiratory Failure in the ED: A Randomized Controlled Trial||Vapotherm, Inc.|Yes|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|204|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236559||37138|
NCT02237807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRI521/PRO-00|Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions|Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions||Pharmaceutical Research Unit, Jordan||Not yet recruiting|September 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237807||37042|
NCT02237846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNEI-2014-TBS-UCMSCOA-001|Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis|Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis||Translational Biosciences|Yes|Active, not recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237846||37039|
NCT02236780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR13130|Influence of Environmental Conditions on In Vitro Fertilization (IVF) Attempts and Induced Pregnancies|Influence of Environmental Conditions on In Vitro Fertilization (IVF) Attempts and Induced Pregnancies|MeteoFIV|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|24000|||Both|18 Years|N/A|No|Non-Probability Sample|The study focuses on intraconjugal IVF attempts (conventional IVF, microinjection        intra-cytoplasmic sperm injection (ICSI) and frozen embryo transfers) realised for MAP        procedures in metropolitan France, in the period of 01/01/2008 to 12/31/2012 (5 years).|February 2016|February 24, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236780||37121|
NCT02236871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-14-03|Family Milk Product Two-year Dose-response Study to Enhance Bone Health|FAMILY (FAmily MILk Product Two-Year) Dose-response Study to Enhance Bone Health|FAMILY|McGill University|No|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|270|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02236871||37114|
NCT02236936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_HNO_PN|Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck|Randomized Phase III Study: Supplemental Parenteral Nutrition for Patients With Locally Advanced Inoperable Tumors of the Head and Neck, Receiving Definitive Radiotherapy With Cetuximab or Cisplatin|AGMT_HNO_PN|Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Not yet recruiting|April 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02236936||37109|
NCT02227615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasAMU-IRB2011-0735F|Absorption of Mango in Healthy Individuals|Profile of Metabolites After the Intake of Mango (Mangifera Indica, l.) Var. Keitt in Humans||Texas A&M University|Yes|Recruiting|March 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227615||37826|
NCT02223403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|383967-4|Effect of Nitrate-rich Beetroot Juice on Exercise Performance in Heart Failure Patients|Single Dose of Nitrate-rich Beetroot Juice Does Not Improve Steady State Oxygen Consumption or Six-minute Walk Distance in Patients With Systolic Heart Failure.||Brooke Army Medical Center|Yes|Completed|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223403||38150|
NCT02223416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGB-10-001|A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo|||Gedeon Richter Plc.||Completed||||January 2015|Actual|Phase 1|Interventional|N/A|2||||||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|March 17, 2015|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223416||38149|
NCT02223143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910021R|A Registration Study for Dyslipidemia|A Registration Study for Primary and Secondary Prevention in Dyslipidemic Taiwanese||National Taiwan University Hospital|Yes|Recruiting|January 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35000|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|All potential patients will be screened for the eligibility in a screening visit. Those        who fill the inclusion criteria at screening will be invited for the registry study into        different groups.|August 2014|August 21, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223143||38170|
NCT02229006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETM/365|Sodium Fluoride Imaging of Abdominal Aortic Aneurysms|SoFIA3: Sodium Fluoride Imaging (18F-NaF PET-CT) in Abdominal Aortic Aneurysms|SoFIA3|University of Edinburgh|No|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with abdominal aortic aneurysm enrolled in the hospital ultrasound surveillance        programme|December 2015|December 3, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02229006||37719|
NCT02223728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A120096|Evaluation of a Telehealth Lifestyle Management Program to Improve Healthy Behaviors Post Head Injury|Evaluation of Telehealth Lifestyle Program for Persons With Traumatic Brain Injury: Objective 2|ProjectLIFT|University of Alabama at Birmingham|Yes|Recruiting|August 2014|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|19 Years|N/A|No|||February 2016|February 17, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02223728||38125|
NCT02229565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053535|Molecular Mechanisms Underlying Prostate Cancer Disparities|Molecular Mechanisms Underlying Prostate Cancer Disparities.||Duke University|No|Recruiting|November 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|198|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|June 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02229565||37676|
NCT02229890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.317|An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke|SITS-NEW Safe Implementation of Thrombolysis in Stroke in the Non EU-World: An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke||Boehringer Ingelheim||Completed|June 2006|||March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|593|||Both|18 Years|80 Years|No|Non-Probability Sample|Acute ischemic stroke within three hours after symptom onset treated at stroke centers|August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229890||37651|
NCT02229903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-OCD-01|An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD|A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects||Brainsway|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|22 Years|68 Years|No|||July 2015|July 23, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229903||37650|
NCT02230137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00915-42|Text Message for Adolescents With Poorly Controlled Type 1 Diabetes|Impact of Mobile Phone Short Text Messages on the Glycaemic Control of Adolescents With Poorly Controlled Type 1 Diabetes.|Diabeto-SMS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|12 Years|20 Years|No|||August 2015|September 24, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02230137||37632|
NCT02239419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:037|Evaluation of Carbothera in the Treatment of Foot Ulcers|Evaluation of the Clinical Utility, Efficacy and Safety of a Novel Medical Device (Carbothera) in the Treatment of Foot Ulcers||University of Manitoba|No|Recruiting|September 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2014|October 29, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239419||36919|
NCT02238197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2500|Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance Study (as Per §67 (6) AMG [German Drug Law]) of Atrovent® 500µg/2ml Inhalation Solution in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|February 2001|||October 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|477|||Both|13 Years|89 Years|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at pneumologists and        internists|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238197||37012|
NCT02238210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2503|Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy|A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy||Boehringer Ingelheim||Completed|December 2002|||May 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|2 Years|5 Years|No|||September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238210||37011|
NCT02238314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.2|Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients|Tipranavir Disodium: An Open-Label ExploratorySstudy of Tipranavir and Ritonavir in Combination With One Nucleoside Reverse Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase Inhibitor in Multiple Protease Inhibitor-Experienced HIV Patients||Boehringer Ingelheim||Completed|January 1999|||August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|13 Years|N/A|No|||September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238314||37003|
NCT02234700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-AA-0071-CTIL|Are Corneal Epithelial Defects Related to Changes in Ocular Bacterial Flora in Patients With ANLDO|To Estimate Whether Corneal Epithelial Defects Occur in Patients With Acquired Nasolacrimal Duct Obstructions is Linked to Changes Occurring Within Ocular Bacterial Flora in These Patients, and What Are the Specific Changes in Their Flora.|ANLDO|Western Galilee Hospital-Nahariya|Yes|Recruiting|August 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|None Retained|Bacterial flora from the eye|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 patients with nasolacrimal duct obstruction and 30 healthy patients|September 2014|September 8, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02234700|6 Months|37281|
NCT02235480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 573 000 1307|Efficacy and Safety of Tazarotene Gel in Nail Psoriasis|A Phase II Trial to Evaluate the Anti-psoriatic Efficacy and Tolerability of Tazarotene in a Gel Formulation in Patients With Mild to Moderate Nail Psoriasis - Parallel Group Comparison||Almirall, S.A.|No|Completed|February 2014|May 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|75 Years|No|||June 2015|June 9, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02235480||37221|
NCT02237716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN2014|Rapid Intravenous Infusion of Mannitol Results in a Dipper-type Change in Stroke Volume Variation in Patients Undergoing Major Neurosurgery|||First Affiliated Hospital, Sun Yat-Sen University||Active, not recruiting|June 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|65 Years|No|Probability Sample|scheduled for elective craniotomy|September 2014|September 10, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02237716||37049|
NCT02237755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25042014|Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.|Prospective Randomized Trial on the Effect of Clomiphene Citrate Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome.||University of Athens|Yes|Not yet recruiting|October 2014|December 2015|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237755||37046|
NCT02237768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRI520/PR-00|Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions|Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions.||Pharmaceutical Research Unit, Jordan||Not yet recruiting|December 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237768||37045|
NCT02226510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013CV08|MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease|MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease|MET-REMODEL|University of Dundee|No|Recruiting|March 2015|October 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02226510||37911|
NCT02226744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131700|Study to Measure Relaxation From Different Types of Focused Breathing Exercises|Focused Breathing Study||Vanderbilt University|No|Active, not recruiting|August 2014|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02226744||37893|
NCT02237950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-017|Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis||Starpharma Pty Ltd|No|Recruiting|September 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|620|||Female|16 Years|45 Years|No|||April 2015|May 18, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237950||37031|
NCT02238041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|GlucoClear ICU Study|An ICU Study of Safety and Accuracy Using the GlucoClear CGM System||Edwards Lifesciences|No|Withdrawn|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with an anticipated surgical lCU or surgical lCU plus intermediate care        unit stay of at least 24 hours.|September 2015|September 29, 2015|September 10, 2014|No|Yes|Discontinued program|No||https://clinicaltrials.gov/show/NCT02238041||37024|
NCT02222818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTee|Evaluate the Amount of Effective Cardiac Resynchronization Therapy (CRT) Pacing During AF|Cardiac Resynchronization Therapy Efficacy Enhancements (CRTee)|CRTee|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|October 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|75|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222818||38195|
NCT02232152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 59314|CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|December 2014|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|September 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02232152||37477|
NCT02232165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-24927|Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury|Mean Arterial Pressure in Spinal Cord Injury (MAPS): Determination of Non-inferiority of a Mean Arterial Pressure Goal of 65 mmHg Compared to a Mean Arterial Pressure Goal of 85 mmHg in Acute Human Traumatic Spinal Cord Injury.|MAPS|University of Calgary|No|Recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|No|||November 2015|November 30, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232165||37476|
NCT02227862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-GAI-3001|Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)|AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS|INSTRIDE 1|Mylan Inc.|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227862||37807|
NCT02228174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL04502|Sonography Guided Transcervical Ablation of Uterine Fibroids|Evaluation of the Gynesonics System for Transcervical Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation Under Integrated Intrauterine Sonography Guidance|SONATA|Gynesonics|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|147|||Female|25 Years|50 Years|No|||February 2016|February 10, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228174||37783|
NCT02237313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/063/HP|Identification of Vulnerability Factors in the Course of Pemphigus Patients|Identification of Vulnerability Factors in the Course of Pemphigus Patients - SHS Pemphigus Clinical Trial|SHS-Pemphigus|University Hospital, Rouen|No|Recruiting|July 2015|November 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02237313||37080|
NCT02229292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005473-52|Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid|Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.|TXA2014-15|Hospital of South West Denmark|Yes|Active, not recruiting|August 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229292||37697|
NCT02237495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140227-5|Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS)|Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery|DOCS|Xijing Hospital|Yes|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237495||37066|
NCT02237508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7200J02|A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers|An Open-Label, Single-dose, Randomized, Five-Period Cross-over to Compare Pharmacokinetics Profiles of Z7200 and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.||Zambon SpA|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02237508||37065|
NCT02237586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACHMI-001|Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge|Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge||Sanaria Inc.|Yes|Completed|July 2014|February 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237586||37059|
NCT02239484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TASU-101|Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin|An Open-label, Randomized, Multiple-dose Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239484||36915|
NCT02238327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14070355|Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes|The Study is a Multicenter, Prospective Observational Study of Pathogenesis of HIV Pulmonary Disease.|LEAP|University of Pittsburgh|No|Recruiting|September 2014|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Whole blood, serum, bronchial wash and cells|Both|18 Years|80 Years|No|Probability Sample|The study population will be HIV positive subjects previously seen for other studies.        There will be three centers enrolling, the University of Pittsburgh, the University of        California San Francisco, and the University of California Los Angeles. Recruitment will        occur from participants in ongoing lung studies at these sites.|December 2015|December 2, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238327||37002|
NCT02225990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400568|Implementation of Comprehensive Stroke Rehabilitation Therapy for Enhanced Quality of Life|Implementation of Gait Coordination, Mobility, and Fitness Training for Enhanced Quality of Life and Participation in Life Roles|QualPro|University of Florida|No|Recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|21 Years|90 Years|No|||October 2015|October 15, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02225990||37951|
NCT02226263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2010-1002-12|Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics|Incidence of Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Lactobacillus Boucardii.|EPP|Coordinación de Investigación en Salud, Mexico|No|Completed|March 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|150|||Both|27 Weeks|34 Weeks|Accepts Healthy Volunteers|||August 2014|August 25, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226263||37930|
NCT02230917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0428|A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma|A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma||Indiana University|Yes|Recruiting|October 2014|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230917||37572|
NCT02237287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-MD-0007|Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers|Combination of Taliderm® and VAC for Treatment of Pressure Ulcers - a Pilot Study||University Hospital, Basel, Switzerland|Yes|Terminated|February 2011|August 2012|Actual|August 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 18, 2014||No|Open label study part reduced from n=10 to n=6 because of insufficient number of patients    under antiaggregation.|No||https://clinicaltrials.gov/show/NCT02237287||37082|
NCT02231203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46230.029.13|Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function|Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer|EMPIRE|Medical Center Alkmaar|Yes|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|60 Years|80 Years|No|||April 2015|April 8, 2015|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231203||37550|
NCT02227043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOWOT|Study Of Weight Development Over Time|Study Of Adipose Tissue Function and Weight Development Over Time|SOWOT|Karolinska Institutet|No|Recruiting|September 2014|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood, serum, plasma, adipose tissue, adipocytes|Both|24 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Observational study All subjects that have been previously investigated at our lab at        least 7 years ago|January 2016|January 12, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02227043||37870|
NCT02227342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47056|Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis||University of Alberta|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||May 2015|May 28, 2015|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227342||37847|
NCT02237820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no specific protocol ID|Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.|Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.||Rabin Medical Center|No|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||November 2015|November 4, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237820||37041|
NCT02232412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-2014|Monitoring the Effect of Red Blood Cell Transfusion on Cerebral Oxygen Saturation With Near Infrared Spectroscopy (NIRS) in Critically Ill Patients|Monitoring the Effect of Red Blood Cell Transfusion on Cerebral Oxygen Saturation With Near Infrared Spectroscopy (NIRS) in Critically Ill Patients||Johann Wolfgang Goethe University Hospitals|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients requiring haemotherapy|March 2015|March 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232412||37457|
NCT02232425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX-0103|IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)|An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation||Ixchelsis Limited|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Male|18 Years|60 Years|No|||October 2015|October 16, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232425||37456|
NCT02239185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT8121948|Laparoscopic Inguinal Hernia Repair in Infancy and Childhood|Laparoscopic Inguinal Hernia Repair in Infancy and Childhood; a Prospective Controlled Randomized Study of Two Different Technique|LIHR-2014|Al-Azhar University|No|Recruiting|May 2012|April 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Male|6 Months|3 Years|No|||September 2014|September 11, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02239185||36937|
NCT02239224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATYR1940-C-002|Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular Dystrophy|A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular Dystrophies||aTyr Pharma, Inc.|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|September 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239224||36934|
NCT02237365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23TB|A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis|A Pilot Phase II Randomized Controlled Double Blind Trial of 81mg Aspirin Daily vs. 1000 mg Aspirin Daily vs. Placebo as Adjunctive Therapy in HIV Negative Adults With Tuberculous Meningitis|AspirinTBM|Oxford University Clinical Research Unit, Vietnam|Yes|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237365||37076|
NCT02237430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOSE-UP III|Randomized Comparison of MynxGrip Vascular Closure Device and Manual Compression for Closure After Femoral Access Angiography. The Closure Devices Used in Every Day Practice Study, CLOSE-UP III Trial|Randomized Comparison of MynxGrip Vascular Closure Device and Manual Compression for Closure After Femoral Access Angiography. The Closure Devices Used in Every Day Practice Study, CLOSE-UP III Trial|CLOSE-UP III|Aarhus University Hospital Skejby|Yes|Recruiting|June 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237430||37071|
NCT02239341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105699|Effects of Two In-hospital Antepartum Interventions on Functional Ability and Quality of Life in Early Postpartum Women.|Effects of Two In-hospital Antepartum Interventions on Functional Ability and Quality of Life in Early Postpartum Women.||University of Western Ontario, Canada|No|Active, not recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02239341||36925|
NCT02239393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140368|Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study|MEsenchymal Stem Cell Therapy for CAnadian MS Patients|MESCAMS|Ottawa Hospital Research Institute|Yes|Recruiting|June 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||January 2016|January 6, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239393||36921|
NCT02226276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14099|Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer|A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine||City of Hope Medical Center|Yes|Recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226276||37929|
NCT02226289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BATTLE|Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment|Phase II Study of Bevacizumab-containing Regimen in Patients With Metastatic Colorectal Cancer Who Failed to Cytotoxic Treatment|BATTLE|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|August 2014|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226289||37928|
NCT02226536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMG-PDCEAV|Vestibular Dysfunction and Glucose Metabolism|Fractionated and Restrictive Glucose Diet in Patients With Vestibular Dysfunction: a Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Completed|December 2005|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02226536||37909|
NCT02228369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6030C00001|Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer|A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)|BLOOM|AstraZeneca|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228369||37768|
NCT02228382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871039|Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors|A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors||Pfizer|No|Recruiting|November 2014|July 2021|Anticipated|July 2021|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228382||37767|
NCT02230410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004771|Cryo Balloon for Residual Barrett's Esophagus|CryoBalloon Focal Ablation System for Residual Barretts Esophagus Post Ablation; a Pilot Study.|Cryoballoon|Mayo Clinic|No|Enrolling by invitation|August 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230410||37611|
NCT02237105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC14276-13CTIL|The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery|The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery||Meir Medical Center|No|Recruiting|September 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|June 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02237105||37096|
NCT02230644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL1415|RELAX Surgical: Effects of Environmental Design on Pre-surgical Relaxation|RELAX Surgical: Effects of Environmental Design on Pre-surgical Relaxation||Royal College of Music|Yes|Completed|November 2014|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230644||37593|
NCT02237300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI2011-28801|Virtual Reality Based Cue-exposure Treatment for Bulimia Nervosa|Tratamiento de la Bulimia Nerviosa Mediante exposición a señales Con Realidad Virtual||University of Barcelona|Yes|Completed|September 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237300||37081|
NCT02237404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008WABELCMW2014A|Economic Evaluation and Communication in Remote Monitoring of People With Pacemakers|Sustainability of Cardiology Services: Economic Evaluation and Communication in Remote Monitoring of People With Pacemakers.||University of Tromso|No|Recruiting|August 2014|October 2016|Anticipated|December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02237404||37073|
NCT02237417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.AOM.2013.002|Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism|A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism||University of Utah|Yes|Recruiting|September 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02237417||37072|
NCT02231489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105269|Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants|A Single-Dose, Open Label, Randomized, Two-Way Crossover Pharmacokinetic Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Following Intake of Tablet Versus Capsule in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231489||37528|
NCT02231827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/058/HP|Balance Control During Gait|A Study of the Balance Control During Gait : Comparison of Data Acquisition Between Force Plate and 3D Optoelectronic Gait Analysis System|FREINAGE3D|University Hospital, Rouen||Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231827||37502|
NCT02231840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140181|Unit and Clinic Evaluation, Screening, Assessment, and Management|Unit and Clinic Evaluation, Screening, Assessment, and Management||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|March 2034|Anticipated|April 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|7500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|July 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02231840||37501|
NCT02222844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4086|Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers|Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers|IMPRESS|Royal Marsden NHS Foundation Trust|Yes|Recruiting|August 2014|January 2021|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|243|||Both|18 Years|N/A|No|||March 2014|August 26, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222844||38193|
NCT02237859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-303|Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection|Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection||Spectrum Health Hospitals|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|140|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02237859||37038|
NCT02239133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProVATE PT 103|R&D Supporting Pilot Study for the Assessment of the Safety and Effectiveness of the ProVATE (ProTIPI) Vaginal Pessary|Pilot Study for the Evaluation of the ProVATE (ProTIPI) Pessary Designs in the Temporary Management of Pelvic Organ Prolapse (POP) in Women||ConTIPI Medical|No|Active, not recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|21 Years|80 Years|No|||December 2015|December 30, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02239133||36941|
NCT02239172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR #2071|A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults|A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults||Fraunhofer, Center for Molecular Biotechnology|No|Active, not recruiting|August 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Anticipated|30|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02239172||36938|
NCT02225171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914166|Physicians' Experiences With and Attitudes Toward Non-Medical Sex Selection Through Preimplantation Genetic Diagnosis|Physicians' Experiences With and Attitudes Toward Non-Medical Sex Selection Through Preimplantation Genetic Diagnosis||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225171||38014|
NCT02225444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP1020|A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®|A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® to Evaluate Long-Term Safety and Efficacy in Patients Requiring 1-2 Level Instrumented PLF||Bioventus LLC|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|21 Years|85 Years|No|Non-Probability Sample|Male and female patients between 21 and 75 years old with degenerative disc disease,        degenerative spondylolisthesis (up to grade 1), and/or mild degenerative scoliosis (up to        25° curvature) that have failed conservative treatment and are now indicated for        instrumented posterolateral spinal fusion at 1 or 2 contiguous levels between L1-S1.|March 2016|March 7, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225444||37993|
NCT02239237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuh-seng1.0|Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study|Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study||China Academy of Chinese Medical Sciences|Yes|Recruiting|September 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples Without DNA|Serum will be retained from the patients who have the anaphylaxis after given the Compound      Kuh-seng Injection and the other 4 matched patients who do not has the anaphylaxis.|Both|N/A|N/A|No|Non-Probability Sample|Patients who use Compound Kushen Injection in the monitoring hospitals|October 2015|October 9, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239237||36933|
NCT02239250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01882777_2|Water Filters and Improved Cookstoves in Western Rwanda|Assessing the Health Impact of Advance Water Filters and Improved Cookstoves in Western Province, Rwanda: A Cluster-randomised Controlled Trial||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|August 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1740|||Both|N/A|5 Years|No|||February 2015|February 13, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02239250||36932|
NCT02225743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thermoregulation Total Joint|Observational Examination of Thermoregulation in Total Joint Arthroplasty|Observational Examination of Thermoregulation in Total Joint Arthroplasty||Medical University of South Carolina|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults 18 years or older that are having a total joint replacement surgery.|June 2015|June 25, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02225743||37970|
NCT02226029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0185|Quantitative MR Methods for Lipid Emulsions|Quantitative Magnetic Resonance (MR) Methods for Non-invasive Imaging of Gastro-intestinal (GI) Processing of Lipid Emulsions in Healthy Subjects.|Q-MRemulsion|University of Zurich|Yes|Completed|August 2014|March 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226029||37948|
NCT02227836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002050|Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis|Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study|EoE|Mayo Clinic|No|Recruiting|August 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|90 Years|No|||December 2015|December 16, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227836||37809|
NCT02228135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00588|The Effect of Dexamethasone Dosing on Post-tonsillectomy Hemorrhage|||Nationwide Children's Hospital|No|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|8700|||Both|N/A|N/A|No|Non-Probability Sample|Children who have had tonsillectomy or adenotonsillectomy|November 2015|November 10, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228135||37786|
NCT02228421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMPC-03|Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients|A Phase IV Multicenter Trial to Evaluate Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients||PeriPharm|No|Recruiting|February 2015|||June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) found        positive for ALK mutation.|October 2015|October 19, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228421||37764|
NCT02233400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2012-102|A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery|IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: A Double-Blind Prospective Randomized Trial in A Single Accredited Bariatric Center||St. Luke's Hospital and Health Network, Pennsylvania|No|Completed|February 2013|July 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|January 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02233400||37381|
NCT02233413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000430|Light Therapy for Moderate Traumatic Brain Injury|Low Level Light Therapy (LLLT) With Near Infrared Light Emitting Diodes in Patients With Moderate Traumatic Brain Injury (TBI)|LLLT for TBI|Massachusetts General Hospital|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|90|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02233413||37380|
NCT02233608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2014-20|Advanced Pelvic Floor Training Program for Prostate Cancer Surgery|A Randomized Pilot Study of Conventional Versus Advanced Pelvic Floor Exercises to Treat Urinary Incontinence After Radical Prostatectomy|AFPX|University of Guelph-Humber|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|88|||Male|40 Years|80 Years|No|||January 2015|January 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02233608||37365|
NCT02237118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPTO 05|Prospective, Randomized, Non-inferiority Investigation to Compare Effects of Mepitel® One and UrgoTul® Dressings in Acute Wound Management (Only)"|Prospective, Randomized, Non-inferiority Investigation to Compare Effects of Mepitel® One and UrgoTul® Dressings in Acute Wound Management (Only)"|Only|Molnlycke Health Care AB|No|Completed|September 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||September 2014|February 23, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02237118||37095|
NCT02238535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ventavis_PRPH|Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension|Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|September 2014|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02238535||36986|
NCT02237209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT 2000|Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|29|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||October 2015|October 7, 2015|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237209||37088|
NCT02237222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaitPerformance_2014|Evaluation of Gait Performance in Children With Neuromuscular Diagnoses|Evaluation of the Gait Performance Measures 'Functional Mobility Scale' and 'Gillette Functional Assessment Questionnaire' in Children With Neuromuscular Diagnoses||University Children's Hospital, Zurich|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|6 Years|18 Years|No|Non-Probability Sample|Children with neuromuscular diagnoses, who are inpatients in the rehabilitation center of        the University Children's Hospital Zurich in Affoltern am Albis.|January 2016|January 18, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02237222||37087|
NCT02238730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPSC IRB10133|Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy|Comparative Efficacy and Cognitive Side-Effects of Ultrabrief Right Unilateral Electroconvulsive Therapy and Brief Pulse Bitemporal Electroconvulsive Therapy||Kaiser Permanente|Yes|Enrolling by invitation|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238730||36972|
NCT02238821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET/colon 06|Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study|Role of the MET Oncogene in Human Colorectal Cancer. Possible Implications in the Activation of an Acquired Pro-thrombotic Condition - A Translational Study|COMET|Fondazione del Piemonte per l'Oncologia|No|Recruiting|October 2007|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|Patients with resectable colorectal tumor with survival prognosis>6 month|November 2015|February 2, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02238821||36965|
NCT02237482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539-06|Investigating Proximal Migration in Trabecular Metal Cups Used In Acetabular Revision Surgery|Is the Trabecular Metal Cup Associated With Lower Risk of Aseptic Loosening in Acetabular Revision Surgery?||Sahlgrenska University Hospital, Sweden|No|Completed|July 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|85 Years|No|||September 2014|September 10, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237482||37067|
NCT02237573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMG003|Impact of Handing to Patients a Copy of the Consultation Report on Their Medicine Consumption|Impact of Handing to Patients With Viral Gastroenteritis or Upper Respiratory Tract Infections a Copy of the Consultation Report on Their Medicine Consumption: a Randomized Controlled Trial||University Paris 7 - Denis Diderot|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02237573||37060|
NCT02228200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYU-HSEARS20120117002|Nurse-led Care Program for Cancer Patients in Chemotherapy Day Center|A Nurse-led Care Program on Quality of Life and Health Care Utilization for Cancer Patients in a Chemotherapy Day Center: A Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Completed|June 2012|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02228200||37781|
NCT02228460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT13739|Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease|A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease||Sanofi|Yes|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Male|18 Years|49 Years|No|||March 2016|March 15, 2016|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228460||37761|
NCT02228473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRBDGlycoAtr|Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort|Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort||Seoul National University Hospital|Yes|Recruiting|September 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|76|||Both|19 Years|80 Years|No|||August 2014|October 27, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228473||37760|
NCT02228746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01610--43|Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo|Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo||Olygose|Yes|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02228746||37739|
NCT02226718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRQOL-COM1|Validation of a Questionnaire for Measuring Quality of Life in Patients With Chronic Inflammation of the Middle Ear|Validation of a Questionnaire for Measuring Health-related Quality of Life in Patients With Chronic Otitis Media||University of Zurich|No|Not yet recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|patients suffering from chronic otitis media, visiting a tertiary referral centre|August 2014|August 25, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02226718||37895|
NCT02231801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1323|Monitoring of Vital Signs During Skin-to-skin Holding by Mothers of Their Preterm Babies|Vital Sign Monitoring of Mother-Infant Dyads During Kangaroo Care in Preterm Infants||Icahn School of Medicine at Mount Sinai|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|30 Weeks|35 Weeks|No|Non-Probability Sample|Infants born at Mt. Sinai Hospital and admitted to the NICU. Preterm infants between 30        0/7 weeks gestational age to 34 6/7 weeks gestation age.|December 2015|December 29, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02231801||37504|
NCT02227004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00051707|Safety of Magnetic Resonance Imaging in Patients With Pacemakers and Defibrillators|Safety of Clinically Indicated Magnetic Resonance Imaging in Patients With Permanent Pacemakers (PPM) and Implanted Cardioverter Defibrillators||Johns Hopkins University|No|Enrolling by invitation|September 2011|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1700|||Both|9 Years|100 Years|No|||December 2015|December 28, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02227004||37873|
NCT02227303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOVE-2014|A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes|A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes||Medidata Solutions|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|60 Years|No|||March 2015|March 19, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227303||37850|
NCT02227316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14000359|Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure|A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure||University of California, Los Angeles|No|Active, not recruiting|August 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|40|||Female|21 Years|60 Years|No|||March 2016|March 17, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227316||37849|
NCT02227576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001751-38|Prevention of Thrombocytopenia in Glioblastoma Patients|Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients|PLATUM|University Hospital, Lille|Yes|Recruiting|April 2014|July 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227576||37829|
NCT02227589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053448|Treatment for Teens With Alcohol Abuse and Depression|Treatment for Teens With Alcohol Abuse and Depression|T-TAAD|Duke University|Yes|Recruiting|January 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|170|||Both|13 Years|239 Months|No|||July 2015|November 30, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227589||37828|
NCT02234310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998HB303|Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B|An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B|PUPs B-LONG|Biogen|Yes|Recruiting|November 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Male|N/A|17 Years|No|||November 2015|November 19, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234310||37311|
NCT02234505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14040403|Physiologic Range of Step-by-step Variations in Lower Limb Prosthesis Forces During Walking|Physiologic Range of Step-by-step Variations in Lower Limb Prosthesis Forces||University of Pittsburgh|No|Completed|September 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02234505||37296|
NCT02237157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR1|A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer|A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas||RenovoRx|Yes|Active, not recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02237157||37092|
NCT02238249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.294|Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Special Drug Use-Results Survey of Alesion® Dry Syrup-||Boehringer Ingelheim||Completed|October 2005|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Both|N/A|N/A|No|Non-Probability Sample|Patients with urticaria and without experience in treatment with epinastine are selected        by physicians at medical institutions|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238249||37008|
NCT02238262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.374|Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals|Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals||Boehringer Ingelheim||Completed|May 2000|||December 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2318|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with essential hypertension being treated in hospitals|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238262||37007|
NCT02238275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.390|Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension|Post-Marketing Surveillance Study Micardis® Plus||Boehringer Ingelheim||Completed|June 2002|||December 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8135|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with hypertension|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238275||37006|
NCT02238340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxycodone|Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery|Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery||Hospital Central Dr. Luis Ortega||Completed|March 2012|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||September 2014|September 11, 2014|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238340||37001|
NCT02226003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-017|Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Diet and Exercise||Merck Sharp & Dohme Corp.|Yes|Completed|September 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|292|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226003||37950|
NCT02226016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVATOR01|Levator Muscle Strength Evaluation|Quantitative Evaluation of Levator Palpebra Muscle Strength||Meir Medical Center|No|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|21 Years|N/A|No|||August 2014|August 23, 2014|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02226016||37949|
NCT02238626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-166-ALS-1201|Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)|IBU-ALS-1201|MediciNova|Yes|Recruiting|September 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238626||36980|
NCT02226757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HER2-targeting in EGFR-mutated|Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients|Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study||VU University Medical Center|No|Not yet recruiting|August 2014|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226757||37892|
NCT02227056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|loe130007ctil|Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population|Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population||Loewenstein Hospital|Yes|Active, not recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|18 Years|No|||July 2014|August 25, 2014|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02227056||37869|
NCT02238860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIMS-hep B-123|A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis|A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis||Asian Institute Of Medical Sciences|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238860||36962|
NCT02238899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT 2000 Interim Register|Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma|Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma||Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|354|Samples With DNA|Tumor material, CSF, and blood|Both|N/A|21 Years|No|Probability Sample|Patients with medulloblastoma, CNS-PNET (incl. pineoblastoma, ependymoblastoma,        CNS-neuroblastoma), or ependymoma (WHO II/ III) and age at diagnosis 0-21 years|May 2015|May 28, 2015|January 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02238899||36959|
NCT02238912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXII(1)/29097/2011|Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai|Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial|KR|National institute of Siddha|Yes|Completed|June 2012|||April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|No|||September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238912||36958|
NCT02234817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1I21RX001574-01A1|Improving Balance and Mobility in Older Veterans|Improving Balance and Mobility in Older Veterans|SPIRE|Baltimore VA Medical Center|Yes|Not yet recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|56|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 8, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234817||37272|
NCT02237235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00098144 - MgT|Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia|Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia|MgT|Northwestern University|No|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||March 2016|March 21, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237235||37086|
NCT02224872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1424|Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2014|||August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|73 Years|No|||February 2015|February 26, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02224872||38037|
NCT02232113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-004IA|Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients|The Response of Continuous Erythropoietic Receptor Activator (CERA) With Different Dose Interval and the Survey for Influence Factors||Taipei Veterans General Hospital, Taiwan|Yes|Completed|February 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|90 Years|No|||September 2014|September 4, 2014|August 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02232113||37480|
NCT02232373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoN14048|Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates|A Pilot Double Blind, Randomised, Placebo Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Symptoms of Post-infective Bowel Dysfunction|CEDRIC|University of Nottingham|No|Recruiting|August 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232373||37460|
NCT02232386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC1114|Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia|A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).||Gruppo Italiano Malattie EMatologiche dell'Adulto||Recruiting|February 2015|May 2021|Anticipated|May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232386||37459|
NCT02233803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201435|A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma|A Randomised, Multi-centre, Open Label, Cross-over Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of Neumoterol 400 and Symbicort Forte in Adults With Asthma||GlaxoSmithKline|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233803||37350|
NCT02234063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1143|Genetic Testing to Understand and Address Renal Disease Disparities|Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care|GUARDD|Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2014|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2050|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234063||37330|
NCT02236988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-CP-027|Study to Evaluate Pharmacokinetics of Apremilast in Heatlhy Male Subjects|A Phase 1, Open-Label, Single Center Study to Evaluate the Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast (CC-10004) in Healthy Male Subjects||Celgene|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment|4||Actual|79|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02236988||37105|
NCT02237066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chocolate OCT|Understanding Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging|Understanding the Mechanism of Peripheral Arterial Balloon Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging||TriReme Medical, LLC|Yes|Withdrawn|September 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 3, 2014||No|Enrollment goals were not able to be met|No||https://clinicaltrials.gov/show/NCT02237066||37099|
NCT02237170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1689|Immune Monitoring on Sipuleucel-T|A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T|PROVENGE|Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples With DNA|whole blood|Male|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from those patients who receive their care at Mount Sinai        Medical Center, or a participating site|March 2016|March 8, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237170||37091|
NCT02223624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR49.2013 FHEC13/260 LaTrobeU|Effect of an Eccentric Exercise Program on Quality of Life and Function in People With Chronic Heart Failure.|Effect of an Eccentrically Biased Aerobic Exercise Program on Quality of Life and Functional Capacity in People With Chronic Heart Failure: A Randomized Controlled Trial.||La Trobe University|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223624||38133|
NCT02223910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 10-075|Neurofeedback Training of Alpha-band Coherence After Stroke|Neurofeedback Training of Alpha-band Coherence After Stroke: a Randomized Controlled Crossover Trial||University Hospital, Geneva|No|Recruiting|February 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|N/A|No|||December 2015|December 2, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223910||38111|
NCT02231216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130516|Quality of Life Study About the Role of Turbinectomy in Rhinoseptoplasty|The Role of Turbinectomy in Rhinoseptoplasty: a Randomized Clinical Trial With Evaluation of Quality of Life|WHOQOL-BREF|Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|March 2014|July 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Months|90 Years|No|||August 2015|August 21, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02231216||37549|
NCT02226523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103002_N_103CT1026|Magnetic Nanoparticles System in Acute Coronary Syndrome|The Development and Clinical Application of Rapid Assays Using Multi-antibody-activated Magnetic Nanoparticles System in Acute Coronary Syndrome||Far Eastern Memorial Hospital|No|Recruiting|February 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|plasma/serum|Both|20 Years|90 Years|No|Probability Sample|Patients with acute chest pain who are sent to the emergency departments will be included|August 2014|August 26, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226523|6 Months|37910|
NCT02231853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140182|Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections|Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections||National Institutes of Health Clinical Center (CC)||Suspended|August 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||June 2015|August 15, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231853||37500|
NCT02232178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-013|Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant|A Randomized, Blinded, Inpatient Study to Investigate the Pharmacokinetics, Relative Bioavailability and Safety of 2 Doses of the XaraColl® Bupivacaine Collagen Implant (200 and 300 mg Bupivacaine Hydrochloride) Compared to Bupivacaine Hydrochloride Infiltration (150 mg) After Open Laparotomy Hernioplasty||Innocoll|No|Completed|September 2014|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|62|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232178||37475|
NCT02227355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0013|Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease|A Multi-center Noninterventional Study to Evaluate the Effectiveness of Neupro® (Rotigotine Transdermal Patch) and Levodopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)|NEUPART|UCB Pharma|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|170|||Both|18 Years|N/A|No|Probability Sample|Patients with idiopathic Parkinson's Disease receiving levodopa as monotherapy or in        combination with a dopamine agonist other than Rotigotine, but either not sufficiently        controlled on or intolerant to current treatment, or other reason; patients are receiving        treatment in general practitioner (GP) offices, private clinics or hospitals (including        university hospitals) according to routine daily practice.|March 2016|March 9, 2016|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227355||37846|
NCT02227628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasAMU-IRB2010-0797F|Absorption and Antioxidant Effects of Polyphenolics From Acai|Absorption and Antioxidant Effects of Polyphenolics From Acai||Texas A&M University|Yes|Active, not recruiting|April 2013|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227628||37825|
NCT02227875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-GAI-3002|Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)|AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS|INSTRIDE 2|Mylan Inc.|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227875||37806|
NCT02239068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0286|CT Residual Gastric Fluid Volume|Residual Gastric Fluid With Administering Clear Liquids Within Two Hours of Anesthesia in Children||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|March 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|1 Month|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the Radiology CT schedule.|February 2016|February 4, 2016|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02239068||36946|
NCT02239094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6954|Biosignatures of Latuda for Bipolar Depression|Identification of Biosignatures for Lurasidone (Latuda) Response in Bipolar Depression||New York State Psychiatric Institute|No|Recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||September 2014|March 23, 2015|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239094||36944|
NCT02224885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-IR-HEGP-2014|Needle-based Confocal Laser Endomicroscopy in Fluoroscopy-guided Procedures for Lung Applications (Biopsies and Ablation) and Liver Procedures in Interventional Radiology: a Feasibility Study|||Mauna Kea Technologies||Recruiting|January 2015|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02224885||38036|
NCT02236754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ5709|Evaluation of 18F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass|Scan Re-Scan Pancreatic Beta Cell Imaging Using PET Imaging and 18F-FP-DTBZ||Columbia University|Yes|Active, not recruiting|July 2013|June 2016|Anticipated|August 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|January 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236754||37123|
NCT02236767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEF003523.4|Transcranial Magnetic Stimulation Treatment of Hoarding Disorder|Transcranial Magnetic Stimulation Treatment of Hoarding Disorder||Hartford Hospital|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||September 2014|April 8, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236767||37122|
NCT02236858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00085617|Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health|Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health||Johns Hopkins University|Yes|Recruiting|March 2014|June 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|120|||Both|40 Years|N/A|No|||April 2015|April 15, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02236858||37115|
NCT02236910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX-LUT-001-London|An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours|An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours||Lawson Health Research Institute|No|Active, not recruiting|July 2014|September 2021|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|90 Years|No|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02236910||37111|
NCT02236923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOR-14-ACS-24|Study of the Influence of the Moon and Seasons On Outcomes Following Surgery To Repair Ascending Aortic Dissection|The Influence of Lunar Cycle On Hospital Outcomes Following Ascending Aortic Dissection Repair|ACS-MOON-1|22EON|No|Completed|January 1998|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2684|||Both|18 Years|N/A|No|Non-Probability Sample|All acute ascending aortic dissection repair procedures recorded in the United Kingdom's        National Adult Cardiac Surgery Audit.|September 2014|September 9, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236923||37110|
NCT02237001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-CP001|Study of Suture Repair of Torn Meniscus in the Knee|A Prospective, Non-randomized, Multi-Center Investigation of All-suture-based Repair of Horizontal Meniscal Tears (STITCH Study)|STITCH|Ceterix Orthopaedics, Inc.|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|September 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237001||37104|
NCT02224248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-15-1-72-13-09|Effect of Including Fitness Testing in Preventive Health Checks on Cardiorespiratory Fitness and Motivation|The Effect of Including Fitness Testing in Preventive Health Checks on Cardiorespiratory Fitness and Motivation to Change Physical Activity Behaviour||University of Aarhus|Yes|Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|30 Years|49 Years|No|||December 2015|December 4, 2015|August 8, 2014||||No||https://clinicaltrials.gov/show/NCT02224248||38085|
NCT02224261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/032|Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery|Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery: a Randomized Controlled Trial|PTaws|University of Alcala|Yes|Active, not recruiting|September 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||August 2014|August 22, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224261||38084|
NCT02224534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00138|Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction|High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial.|HEALING-AMI|Gyeongsang National University Hospital|Yes|Not yet recruiting|September 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|322|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224534||38063|
NCT02223338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140215|Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics|Conjunctival Floral Resistance in a Single Practice Site Comparing Povidone- Iodine Prep With or Without Post-Intravitreal Injection Second Generation Fluoroquinolones.||Loma Linda University|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02223338||38155|
NCT02223351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-EU22|Drug-Drug Interaction Study: ASP2151 and Ritonovir|A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study to Investigate the Effect of a Single Oral Dose of Ritonavir on the Single Dose Pharmacokinetics of ASP2151 in Healthy Men||Maruho Europe Limited|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|December 9, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02223351||38154|
NCT02227550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET 5 AXAFA|Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy|An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation|AXAFA|German Atrial Fibrillation Network|Yes|Recruiting|December 2014|October 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||October 2015|February 17, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02227550||37831|
NCT02232061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2409|Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod|Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod||Novartis|No|Recruiting|September 2014|July 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 17, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232061||37484|
NCT02238457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 103-10|Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients|Effects of Low-Dose vs High-dose Losartan on Sympathetic Hyperactivity in Patients With Congestive Heart Failure||Baker IDI Heart and Diabetes Institute|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|75 Years|No|||September 2014|September 11, 2014|June 4, 2012|Yes|Yes|Difficulty recruiting patients|No||https://clinicaltrials.gov/show/NCT02238457||36992|
NCT02231502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EE/0070|Innovation in Food Production Techniques to Improve Bioactive Content|Optimising Vegetable Based Convenience Food Production to Retain Compounds Found in Vegetables|ENRICH|University of East Anglia||Active, not recruiting|July 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02231502||37527|
NCT02238639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLICE 1|Pulmonary Embolism as a Cause of COPD Exacerbations|Efficacy and Safety of an Active Strategy for the Diagnosis and Treatment of Acute Pulmonary Embolism (PE) in Patients With Unexplained Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): a Randomized Clinical Trial|SLICE|Ministry of Health, Spain|Yes|Recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238639||36979|
NCT02238743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project ADOPT- UM|Assuring and Defining Outcomes Through Procedural Training Using a Proctorship Model That Collects Patient Outcomes A Single-Arm, Case-Series to Determine the Feasibility of Safe Skills Transfer for Laparoscopic Ventral Hernia Repair Utilizing a Hands-On Proctorship Model.|A Single-Arm, Case-Series to Determine the Feasibility of Safe Skills Transfer for Laparoscopic Ventral Hernia Repair Utilizing a Hands-On Proctorship Model.|ADOPT|Medtronic - MITG|No|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Determined by surgeon|July 2015|July 15, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02238743||36971|
NCT02238756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-8102-201|Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults|Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults||CureVac AG|Yes|Active, not recruiting|September 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|72|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238756||36970|
NCT02232438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6797|Psychotherapy for Depressed or Anxious Adolescents With Cancer|Open Trial of Behavioral Activation Therapy for Depressed or Anxious Adolescents With Cancer||New York State Psychiatric Institute|Yes|Withdrawn|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|21 Years|No|||October 2015|October 5, 2015|September 2, 2014||No|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT02232438||37455|
NCT02234557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH104651-01|Tai Chi Training for Children With ADHD|Movement-Based Training for Children With ADHD: A Feasibility Study||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|8 Years|12 Years|No|||February 2016|February 23, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02234557||37292|
NCT02239003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-3642C|NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment|||Chang Gung Memorial Hospital||Recruiting|January 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|90 Years|No|||July 2015|July 27, 2015|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239003||36951|
NCT02224573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1415|An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes|An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Young Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.||GW Research Ltd|Yes|Enrolling by invitation|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|540|||Both|2 Years|N/A|No|||January 2016|January 27, 2016|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224573||38060|
NCT02226237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSTXPTR2010|Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy|URINARY INCONTINENCE AND ERECTIL DYSFUNCTION AFTER RADICAL PROSTATECTOMY: A Randomized Controlled Trial Comparing Pelvic Muscle Exercises With or Without Electrical Stimulation||Barretos Cancer Hospital|No|Completed|September 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|237|||Male|18 Years|75 Years|No|||January 2016|January 13, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226237||37932|
NCT02223130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00002878|Addressing Discrimination and Mistrust Among Black Men: Phase III|Addressing Discrimination and Mistrust Among Black Men: Phase III||Children's Hospital Boston|No|Completed|July 2014|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02223130||38171|
NCT02223390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C147|Improving the Health of South African Women With Traumatic Stress in HIV Care|Improving the Health of South African Women With Traumatic Stress in HIV Care|ImpACT|Duke University|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223390||38151|
NCT02223689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14-008|Evaluation of Skin Affix in the Emergency Room|Evaluation of SkinAffix as a Topical Emergency Room Department Skin Incision Adhesive||Medline Industries|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|5 Years|N/A|No|Non-Probability Sample|Adults and pediatrics (5 years of age and up) who require skin closure of a wound.|February 2016|February 5, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223689||38128|
NCT02223702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOUKAEK5/9|Alternative Antibiotic Regime in the Treatment of GAgP|Clinical Evaluation of Systemic Moxifloxacin Compared to Amoxicillin Plus Metronidazole Adjunct to Non-surgical Treatment in Generalized Aggressive Periodontitis: A Randomized Clinical Trial||Kocaeli University|No|Completed|May 2011|July 2014|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223702||38127|
NCT02223975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/040/GHT|Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Vulval VS|Gloucestershire Hospitals NHS Foundation Trust|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|Samples With DNA|Histological sections of vulval and lymph node tissue.|Female|16 Years|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within        Gloucestershire Hospitals NHS Foundation Trust.|February 2016|February 10, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223975||38106|
NCT02228434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001052-10081|Study on the Tailored Intervention Strategy of Childhood Obesity Based on Monitoring Physical Activities and Dietary Behaviors|Study on the Tailored Intervention Strategy of Childhood Obesity Based on Monitoring Physical Activities and Dietary Behaviors||Peking University||Completed|May 2009|||December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|450|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228434||37763|
NCT02228707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231HV102|Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers||Biogen|No|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228707||37742|
NCT02228720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-0414|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||March 30, 2015|June 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228720||37741|
NCT02228967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-2-0014|Alcohol Screening, Brief Intervention, and Referral to Treatment in a Military Treatment Facility|Feasibility and Pilot Testing of SBI to Reduce Alcohol Misuse Among Active Duty Members in a Military ER Setting||San Diego State University|No|Not yet recruiting|May 2015|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|May 21, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228967||37722|
NCT02227277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES11990|Reducing Proviral HIV DNA With Interferon-a|Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy|BEAT-HIV|The Wistar Institute|Yes|Recruiting|January 2015|January 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227277||37852|
NCT02231749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-214|Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)|A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma||Bristol-Myers Squibb|Yes|Recruiting|October 2014|September 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1070|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|September 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231749||37508|
NCT02232074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32599|Project SUPPORT (Socio-legal Services for Underserved Populations Thru Patient Navigation to Optimize Resources During Treatment)|Project SUPPORT (Socio-legal Services for Underserved Populations Thru Patient Navigation to Optimize Resources During Treatment)||Boston Medical Center|No|Recruiting|February 2014|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|374|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232074||37483|
NCT02223156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 2013/953-31/4|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation-MYPAF|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation-MYPAF, a Randomized Controlled Three Arms Study|MYPAF|Danderyd Hospital|Yes|Recruiting|March 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|132|Samples Without DNA|BNP and CRP|Both|18 Years|N/A|No|Probability Sample|Patients with diagnosis of paroxysmal atrial fibrillation will be identified from the list        of patients scheduled for second visits at the Arrhythmia Polyclinic        ("Arytmimottagningen") at the Cardiology Clinic, Danderyd Hospital. The selection will        also be made from other hospitals in the Stockholm County Council.|August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223156||38169|
NCT02238548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49042.081.14|Effect of Raw Milk on the Immune Response Upon Cholera Vaccination|Effect of Raw Milk on the Immune Response Upon Cholera Vaccination|MOSAIC|NIZO Food Research|No|Active, not recruiting|July 2014|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238548||36985|
NCT02223741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP_conjugated rehabilitation|Observational Study of the Conjugated Rehabilitation on Children With Cerebral Palsy|An Observational Study of the Conventional Rehabilitation and Traditional Korean Medicine Conjugated Rehabilitation on Children With Cerebral Palsy||Korean Medicine Hospital of Pusan National University|No|Recruiting|August 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|6 Months|78 Months|No|Non-Probability Sample|Population will be selected from rehabilitation clinics for children|March 2016|March 18, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223741|12 Months|38124|
NCT02223754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5593|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2014|||||N/A|N/A|N/A||||||||||||||March 20, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223754||38123|
NCT02238964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_11-186|Reinforcement of Closure of Stoma Site|A Randomised Controlled Trial of Reinforcement of Closure of Stoma Site Using a Biological Mesh.|ROCSS|University of Birmingham|Yes|Active, not recruiting|November 2012|May 2018|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|790|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238964||36954|
NCT02238990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-HL-14-099|Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions|Biomarkerscreening Via Transcriptome and Methylosome Analysis in Cervical Cancer and Its Preinvasive Lesions||University of Luebeck|No|Recruiting|September 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|tissue samples of the cervix uteri|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The population is to be recruted from A. patients suffering from cervical cancer B.        patients suffering from preinvasive cervical lesions|September 2014|September 10, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238990||36952|
NCT02239042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132.831|Effect of Low-level Laser Therapy on Palatal Wound Healing|Effect of Gallium-Aluminum-Arsenide Laser - AsGaAl Low-level Laser Therapy on the Healing of Human Palate Mucosa After Connective Tissue Graft Harvesting: Randomized Clinical Trial|LLLT|UPECLIN HC FM Botucatu Unesp|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02239042||36948|
NCT02225964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XuanwuH 2|Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD|||Xuanwu Hospital, Beijing|Yes|Recruiting|January 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|aMCI patients with APOEε4|August 2015|August 20, 2015|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02225964||37953|
NCT02231463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVL-Position-1|Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter|Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter as a Surrogate Parameter in Punctures of Central Veins||Universitätsklinikum Köln|No|Withdrawn|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing a operative procedure which requires a central venous catheter|January 2016|January 25, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02231463|1 Day|37530|
NCT02227329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007793|Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition|Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition: A Prospective Randomized Control Trial.|ELT|Mayo Clinic|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|25|||Both|18 Years|90 Years|No|||October 2015|October 14, 2015|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227329||37848|
NCT02227602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasAMU-IRB2013-0541F|Anti- Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease|The Consumption of Mango Beverage Improves Biomarkers for Inflammation in Inflammatory Bowel Disease Patients||Texas A&M University|Yes|Recruiting|January 2014|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|June 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227602||37827|
NCT02227849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-12|Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||December 2015|December 2, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227849||37808|
NCT02228148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL5332|Comparison of the New Fitting Method Cochlear Nucleus Fitting Software (NFS) With the Established Fitting Method Cochlear Nucleus Custom SoundTM Suite (CSS)|Comparison of Fitting Methods Using Cochlear Clinical Care Innovation||Cochlear|No|Recruiting|November 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228148||37785|
NCT02228161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101107|The Effects of Yoga in Mental Health Professional Helpers|The Effects of Yoga on Work-related Stress and Stress Adaption Among the Professional Helpers of Psychiatry||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|March 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228161||37784|
NCT02234518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.04.NRC|Fibers and Gut Health|Evaluation of Changes in Gut Transit Time and Gastrointestinal Symptoms Following the Consumption of a Fiber Containing Product in Adults With Constipation||Nestlé|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234518||37295|
NCT02234531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocollo 2013.11|Comparison Study of 'Virtual Teacher' Support for Rehabilitation After Stroke.|Assessment of a Virtual Teacher Feedback for the Recovery of Upper Limb After Stroke.|MAVASI|IRCCS San Camillo, Venezia, Italy|Yes|Recruiting|April 2013|December 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02234531||37294|
NCT02234778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGI-002-01-2013|Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia|Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System™ for Autologous Adipose-Derived Stromal Vascular Fraction Cells to Treat Critical Limb Ischemia|CLI-DI|Tissue Genesis, Inc.|No|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||November 2015|November 9, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234778||37275|
NCT02234791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTK-20140828|Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia|||Shanghai Children's Medical Center||Not yet recruiting|September 2014|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|1 Month|18 Years|No|Non-Probability Sample|XLA patients|September 2014|September 4, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02234791|2 Years|37274|
NCT02231762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52030-268|Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET|Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study|SONNET|Ipsen|No|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02231762||37507|
NCT02240589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A70-4-0791023|Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury|Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury||Indiana University|No|Enrolling by invitation|December 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||May 2015|May 29, 2015|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240589||36831|
NCT02227069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US06|Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers|A Phase 1, 21-Day, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Irritation Potential of M518101 in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design||Maruho North America Inc.|No|Completed|September 2014|March 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227069||37868|
NCT02227368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5135L00003|Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR|A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR|TI-PAD EVR|AstraZeneca|No|Active, not recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|50 Years|130 Years|No|||December 2015|December 21, 2015|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227368||37845|
NCT02229513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-035|Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage|Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage: A Randomized Controlled Trial||Baylor Research Institute|No|Completed|July 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 7, 2014||No||No|October 28, 2015|https://clinicaltrials.gov/show/NCT02229513||37680|
NCT02223429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044782|Neurobiological Bases of Paternal Nurturance|Biological Bases of Individual Variation in Paternal Nurturance||Emory University|Yes|Completed|August 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223429||38148|
NCT02227888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N91115-1PK-02|PK Study of N91115 in Cystic Fibrosis Patients|A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of N91115 in Cystic Fibrosis Patients|SNO3|Nivalis Therapeutics, Inc.|No|Active, not recruiting|October 2014|February 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227888||37805|
NCT02224027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj0821|Comparison of Laryngeal Mask and I-gel to Laryngoscope by Novice Operators in Simulated Difficult Airway|Comparison of Proceal Laryngeal Mask Airway and I-gel to Machintoch Laryngoscope by Novice Operators in Simulated Difficult Airway - a Manikin Study.||Yeungnam University College of Medicine|Yes|Recruiting|August 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|109|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224027||38102|
NCT02224040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64/12|Typhoid Fever: Combined vs. Single Antibiotic Therapy|Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal.||Sheba Medical Center|No|Recruiting|August 2013|August 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|2 Years|80 Years|No|||August 2014|August 26, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224040||38101|
NCT02224300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPHOI|Nursing Care With Patients With Venous Leg Ulcers|Nursing Care With Patients With Venous Leg Ulcers - Developing an Internet-based Education Program and Evaluation of Its Effectiveness||University of Turku|Yes|Recruiting|August 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|300|||Both|60 Years|N/A|No|||August 2014|August 22, 2014|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02224300||38081|
NCT02231164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.128|LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research|Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy||Boehringer Ingelheim||Completed|October 2014|December 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231164||37553|
NCT02231177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.3|Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, 3-way Crossover Study to Compare Pharmacokinetics and Safety of 10 μg BI 1744 CL Plus 5 μg Tiotropium Bromide Given as Fixed Dose Combination Via the Respimat® Inhaler With the Pharmacokinetics and the Safety of the Single Agents, i.e. 10 μg BI 1744 CL and 5 μg Tiotropium Bromide, Delivered Via the Respimat® Inhaler Following 21 Day-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|June 2008|||November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|47|||Both|40 Years|N/A|No|||December 2015|December 2, 2015|September 2, 2014||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT02231177||37552|Additional secondary endpoints were listed in the original protocol, but according to internal rules, descriptive statistics would not be calculated unless data from at least 2/3rds of all subjects were available.
NCT02222805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCANEMIA11|Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment|Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment in Late Pre-term and Term Infants; a Facility-based Randomized-controlled Trial in Nepal||Uppsala University|No|Active, not recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|34 Weeks|41 Weeks|Accepts Healthy Volunteers|||June 2015|June 11, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222805||38196|
NCT02232126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-10-00372|Social Work Intervention Focused on Transitions|Social Work Intervention Focused on Transitions Among At-Risk Older Adults|SWIFT|University of Southern California|Yes|Completed|February 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|181|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2014|September 4, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02232126||37479|
NCT02232139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-87/13-1|Measurement of Psychomotor Recovery After Anesthesia Using 4CRT|Measurement of Psychomotor Function Recovery in Patients After General Anesthesia Using 4-Choice Reaction Time Test|4CRT|University Medicine Greifswald|No|Not yet recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|19 Years|50 Years|No|||September 2014|September 4, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02232139||37478|
NCT02232399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiLe-1|Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?|The Prophylactic Effect of Levosimendan in Reducting Acute Kidney Injury Postoperatively in Pediatric Patients Undergoing Corrective Heart Surgery|MiLe-1|Göteborg University|Yes|Recruiting|October 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|70|||Both|1 Month|12 Months|No|||January 2016|January 31, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232399||37458|
NCT02234076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI1-12-S028-1|A Study on the Efficacy of Virtual Reality Exposure Therapy (VRET) for Survivors of Childhood Sexual Abuse and War Related Trauma|A Study on the Efficacy of Virtual Reality Exposure Therapy (VRET) for Survivors of Childhood Sexual Abuse and War Related Trauma||Erasmus Medical Center|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|70 Years|No|||January 2015|January 29, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02234076||37329|
NCT02234323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997HA306|An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A|An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A||Biogen|Yes|Recruiting|February 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Male|N/A|5 Years|No|||December 2015|December 17, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234323||37310|
NCT02225132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140172|Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease|Assessment of Computerized Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in Subjects With Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|15 Years|99 Years|No|||July 2015|January 28, 2016|August 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02225132||38017|
NCT02240537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBMPI03-Hem-01|Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer|Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer|BBMPI03|Benovus Bio, Inc.|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240537||36835|
NCT02240550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0133|A Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair|A Prospective, Randomized, Double-armed, Single-blinded, Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair||Insightra Medical, Inc.|No|Completed|September 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240550||36834|
NCT02223637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_72OB|Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry|Menveo® Pregnancy Registry: an Observational Study on the Safety of Menveo Exposure in Pregnant Women and Their Offspring||Novartis||Recruiting|September 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|The study population will include pregnant women within the United States who were        immunized with the Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine within 28        days prior to conception or at any time during pregnancy.|March 2016|March 5, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223637|10 Months|38132|
NCT02229214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-404|Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects|A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects||VIVUS, Inc.|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 26, 2014|Yes|Yes||No|November 17, 2015|https://clinicaltrials.gov/show/NCT02229214||37703|
NCT02229227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200977|Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus|Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study||GlaxoSmithKline|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|794|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229227||37702|
NCT02229799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.315|Protocol for Post Marketing Surveillance of Actilyse Vial|Protocol for Post Marketing Surveillance of Actilyse Vial||Boehringer Ingelheim||Terminated|February 2003|||December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|265|||Both|19 Years|79 Years|No|Non-Probability Sample|patients with acute ischemic stroke|August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229799||37658|
NCT02229812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.313|Safe Implementation of Thrombolysis in Stroke - Monitoring Study|Safe Implementation of Thrombolysis in Stroke - Monitoring Study (SITS-MOST)||Boehringer Ingelheim||Completed|December 2002|||July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|6475|||Both|18 Years|80 Years|No|Non-Probability Sample|acute stroke patients in the European Union|August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229812||37657|
NCT02227641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT-MULTIVIR-01|Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation|Prospective, Open, Randomized, Two-arm, Controlled, Multicenter Clinical Phase I/IIa Trial to Evaluate the Safety and Efficacy of Adoptive Immunotherapy With Allogeneic CMV/EBV Specific, Peptide Stimulated T-cells (CD3+) for Prevention or Preemptive Therapy of Reactivation of CMV and/or EBV in Patients After Allogeneic, HLA Identical Stem Cell Transplantation||University of Erlangen-Nürnberg Medical School|Yes|Recruiting|October 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227641||37824|
NCT02230358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODUCE|Cardiac Output and Duplex Sonography in Carotid Endarterectomy|Cardiac Output and Cerebral Blood-flow During Carotid Endarterectomy in Regional vs. General Anesthesia. A Prospective Randomized Controlled Single Center Study||Medical University Innsbruck|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02230358||37615|
NCT02225379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029514ctil|Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia|Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense Sensor as a Tool for Detection of Hypoglycemia - Exploratory Study for Prototype Rev 1|Hypo-Sense|Rabin Medical Center|No|Active, not recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 26, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02225379||37998|
NCT02225665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-728mR-1401|Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART|A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning||Sangamo Biosciences|No|Active, not recruiting|August 2014|June 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||May 2015|July 14, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225665||37976|
NCT02225678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001168|Minimally Invasive Biomarker for Asthma Disease Severity|Feasibility of Using an Eosinophil-Specific Biomarker-(Eosinophil Peroxidase) in Clinical Practice||Mayo Clinic|No|Enrolling by invitation|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|sputum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|asthma patients healthy volunteers|February 2015|February 19, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02225678||37975|
NCT02236689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0553|Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement|A Randomized, Double-blind Controlled Trial Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement for the Management of Chronic Lateral Epicondylitis||Ottawa Hospital Research Institute|Yes|Not yet recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||April 2015|April 21, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236689||37128|
NCT02227030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180.1|Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects|Tolerability and Pharmacokinetics of Single Oral Administration of 10, 20, 50, 100, 200 and 300 mg BIIB 722 CL (Calculated as Free Base) as Drinking Solution and of 200, 450, 600 and 750 mg BIIB 722 CL as Filmcoated Tablet in Healthy Subjects. An Open Study With Rising Doses, Partly Uncontrolled Intra-individual Comparison, Placebo Randomised Double Blind at Each Dose Level.||Boehringer Ingelheim||Completed|April 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|71|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02227030||37871|
NCT02237352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-HLV0178-DV|Mechanisms of Diabetic Nephropathy in Ecuador|Physiopathogenic Mechanisms Involved in Diabetic Nephropathy, Looking for Prevention and Treatment Solutions||Universidad Estatal de Milagro|Yes|Enrolling by invitation|January 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|10064|Samples Without DNA|Plasma and urine.|Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample (general healthy population and diabetics subjects), and patients with        and without diabetic nephropathy evaluated at Hospital Luis Vernaza|September 2014|September 10, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02237352|1 Day|37077|
NCT02237391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140575-01H|Evaluation of a Complex Interdisciplinary Pain Assessment Program Among Patients With Chronic Pain and Frequent Emergency Department Visits|Evaluation of a Complex Interdisciplinary Pain Assessment Program Linked to Primary Care to Improve Clinical Outcomes and Reduce Health Care Utilization Among Patients With Chronic Pain and Frequent Emergency Department Visits|CIPAP|Ottawa Hospital Research Institute|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|46|||Both|18 Years|N/A|No|||April 2015|May 21, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237391||37074|
NCT02237469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG 13-184R|Prone Breast Radiotherapy Treatment Planning Observational Study|Retrospective Dosimetric Study of Prone Radiotherapy for Breast Cancer|HUGProne|University Hospital, Geneva|No|Active, not recruiting|September 2010|December 2015|Anticipated|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|280|||Female|18 Years|N/A|No|Non-Probability Sample|Consecutive patients addressed for adjuvant radiation treatment after breast conserving        surgery for breast cancer, in whom simulation was done prone and supine.|September 2014|September 9, 2014|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02237469||37068|
NCT02237560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS13083|The Aerobic & Cognitive Exercise Study|The Cognitive Benefits of Interactive Mental and Physical Exercise for Older Adults at Risk for or With Mild Cognitive Impairment (MCI)|ACES|Union College, New York|Yes|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237560||37061|
NCT02229552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102924-1-61250|Habituation to Food as a Risk Factor for Pediatric Obesity|Habituation to Food as a Risk Factor for Pediatric Obesity||State University of New York at Buffalo||Active, not recruiting|November 2012|||June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|231|||Both|8 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Two hundred and thirty healthy non-overweight children between the ages of 8-12 will be        studied.|November 2015|February 5, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02229552||37677|
NCT02239575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBC PRT0009|Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples|Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples|GBCPRT0009|Global BioClinical|No|Enrolling by invitation|March 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|pre-surgical blood samples and/or surplus surgical oncology tissues|Both|18 Years|N/A|No|Probability Sample|Surplus surgical specimens from subjects diagnosed with cancer|January 2016|January 6, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02239575||36908|
NCT02239588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-SC-7-BRD-002|Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age|Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age||Bright Dairy & Food Co., Ltd|Yes|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|120|||Both|N/A|90 Days|Accepts Healthy Volunteers|||September 2014|September 11, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02239588||36907|
NCT02223104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-1301|Randomized Controlled Multicenter Study to Evaluate the Performance of Flexima® Active vs. Sensura® in Patients With Colostomy|||BBraun Medical SAS|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02223104||38173|
NCT02223364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002083|Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for TKA|Prospective, Randomized, Controlled Trial Comparing Continuous Femoral and Single Injection Sciatic Peripheral Nerve Blocks vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel) on Patients Undergoing Total Knee Arthroplasty||Mayo Clinic|No|Active, not recruiting|July 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223364||38153|
NCT02227823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1376|Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3|Safety and Efficacy Study of Anti-cholinesterase Therapy on the Motor Functions in Patients With Spinal Muscular Atrophy Type 3.|EMOTAS|Centre Hospitalier Régional de la Citadelle|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Years|N/A|No|||August 2014|August 26, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02227823||37810|
NCT02238925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0310-206|An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients|An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients||Celator Pharmaceuticals|No|Completed|July 2014|January 2016|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||July 2015|February 23, 2016|August 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238925||36957|
NCT02238951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551190-3|Cancer Care Coordination for Chemotherapy Patients|Use of mHealth to Support Nurse-directed Care Coordination for Chemotherapy Patients: Improving Health, Healthcare Delivery, and Healthcare Utilization.|4CP|University of California, Davis|No|Not yet recruiting|September 2014|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238951||36955|
NCT02236351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34627|New Pediatric Patching Method to Improve Compliance|||Texas Children's Hospital||Recruiting|June 2014|||February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|156|||Both|N/A|7 Years|No|||September 2014|September 9, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236351||37154|
NCT02229825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208.24|Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression|An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression.||Boehringer Ingelheim||Completed|February 2007|||August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|339|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229825||37656|
NCT02230098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-124-13|Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans|Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans|CONDI-PET|University of Aarhus|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||November 2013|January 15, 2015|June 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02230098||37635|
NCT02236494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3446|Study of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults|Pilot Trial of Emergency Department Intervention and Referral for Alcohol Misuse in Older Adults||University of North Carolina, Chapel Hill|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236494||37143|
NCT02230618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-4149|Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec /Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India||Novo Nordisk A/S|No|Enrolling by invitation|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetes where the treating physician has decided to start Ryzodeg™        according to routine clinical practice will qualify for starting treatment with Ryzodeg™.|December 2015|December 17, 2015|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230618||37595|
NCT02230878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104154|A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants|A Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-42847922 in Healthy Male and Female Subjects||Janssen-Cilag International NV|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02230878||37575|
NCT02230891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-009-13F|Biomarker Guided Therapies in Stage A/B Heart Failure|Biomarker Guided Therapies in Stage A/B Heart Failure||VA Office of Research and Development|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|210|||Both|40 Years|85 Years|No|||January 2016|January 27, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230891||37574|
NCT02240199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAN14001|Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain|Pregabalin and Lidocaine in Breast Cancer Surgery to Alter Neuropathic Pain (PLAN): A Pilot Trial|PLAN|McMaster University|No|Active, not recruiting|November 2014|May 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|100|||Female|18 Years|75 Years|No|||March 2016|March 16, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02240199||36861|
NCT02231814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105-14|Pilot Study of Partial Enteral Nutrition With a Unique Diet for the Treatment of Adults Patients With Crohn's Disease|Dietary Therapy Using Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet (CDED) for Induction and Maintenance of Remission in Mild to Moderate Crohn's Disease in Adults- A Pilot Study|CDED ADULTS|Wolfson Medical Center|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||December 2015|December 6, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02231814||37503|
NCT02223988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/202|Occurrence of Ventilator Associated Pneumonia in Italian ICU Using Cuffed Tracheostomy Tubes With Subglottic Secretion Drainage|Occurrence of Ventilator Associated Pneumonia (VAP) in Italian ICU Using Cuffed Tracheostomy Tubes With Subglottic Secretion Drainage: a Prospective Observational Study.|VICTOR|University of Turin, Italy||Recruiting|July 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223988||38105|
NCT02224274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypothermia: Clopi vs Tica|Antiplatelet Therapy After Cardiac Arrest|Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia||University Medical Centre Ljubljana|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224274||38083|
NCT02224547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung Vero SBRT|Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System|Phase II Protocol for Risk-adapted Stereotactic Body Radio Therapy for Stage T1-T3N0 Non-Small Cell Lung Carcinoma||Universitair Ziekenhuis Brussel|Yes|Recruiting|January 2013|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|90 Years|No|||September 2014|September 8, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02224547||38062|
NCT02224846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15382|A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction|Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction||Eli Lilly and Company|No|Active, not recruiting|October 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Male|22 Years|69 Years|No|||June 2015|June 17, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224846||38039|
NCT02236949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000026324|Sustainability of a Knowledge Translation Intervention to Improve Paediatric Pain|Sustainability of a Multidimensional Knowledge Translation Intervention to Improve Paediatric Pain Practices and Outcomes||The Hospital for Sick Children|Yes|Completed|September 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3907|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02236949||37108|
NCT02225418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-TQL-LC|Transmuscular Quadratus Lumborum Block for Laparoscopic Cholecystectomy|Ultrasoundguided Transmuscular Quadratus Lumborum Block After Elective Laparoscopic Cholecystectomy. A Prospective, Randomized Clinical Trial.|TQL|Bispebjerg Hospital|Yes|Withdrawn|November 2014|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|January 28, 2014||No|Change of jobs|No||https://clinicaltrials.gov/show/NCT02225418||37995|
NCT02225704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 13-21|Radium-223 in Combination With Enzalutamide|A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|June 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Male|18 Years|N/A|No|||October 2015|October 29, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225704||37973|
NCT02227563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco 2013-3|tDCS & Auditory Hallucinations in Schizophrenia|tDCS & Auditory Hallucinations in Schizophrenia (AVH-SZ)||Herzog Hospital|Yes|Recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||August 2015|August 24, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02227563||37830|
NCT02236663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD076881-01A1|Effectiveness of a Safety App to Respond to Dating Violence for College Women and Their Friends|Effectiveness of a Safety App to Respond to Dating Violence for College Women and Their Friends||Johns Hopkins University|Yes|Recruiting|July 2015|May 2019|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|600|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236663||37130|
NCT02236676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-833-14|Sleep Study Among Inpatients With TBI in an Acute Rehabilitation Hospital|Sleep, Procedural Learning & Therapeutic Engagement Among Inpatients With||Kessler Foundation||Recruiting|June 2014|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||September 2014|September 8, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236676||37129|
NCT02237378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140602|A Pilot Study Evaluating Heart and Lung Metabolism in Pulmonary Hypertension Associated With Left Heart Disease|Evaluation of Cardiopulmonary Metabolism and Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Left Heart Disease||Ottawa Heart Institute Research Corporation|No|Recruiting|December 2014|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02237378||37075|
NCT02237456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-59-14|DOCTOR Compare - A Study in the "DOCTOR" Series (Does Optical Coherence Tomography Optimize Revascularization?"|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Metallic Stents and Bioresorbable Vascular Scaffolds - DOCTOR Compare||Aarhus University Hospital Skejby|Yes|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients undergoing percutaneous coronary intervention (PCI) at Department of        Cardiology, Aarhus University Hospital Skejby, will be invited to participate in the        study. 12 patients will be included; 4 with acute ST-elevation myocardial infarct (STEMI)        and 8 stable or stabilized patients.|March 2015|March 12, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02237456|1 Day|37069|
NCT02236364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Irisense|Noninvasive Blood Glucose Monitoring Method Based on Imaging of the Eye|Blood Glucose Monitoring Based on Imaging of the Eye||University of Toledo Health Science Campus|No|Terminated|August 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|25|||Both|18 Years|75 Years|No|||July 2015|September 22, 2015|September 8, 2014||No|No positive results were detected|No||https://clinicaltrials.gov/show/NCT02236364||37153|
NCT02236429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFT-HMO-CTIL|Vaginal Flora for Treatment of Bacterial Vaginosis|Vaginal Flora Transplantation for Recurrent Bacterial Vaginosis|VFT|Hadassah Medical Organization|No|Recruiting|June 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|50 Years|No|||February 2016|February 21, 2016|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02236429||37148|
NCT02237521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-021|The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease|||Rigshospitalet, Denmark|No|Recruiting|September 2014|January 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|24|Samples With DNA|Serum, plasma and urine|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. End-stage renal disease patients receiving chronic hemodialysis treatments          2. Healthy control subjects|May 2015|May 4, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02237521||37064|
NCT02236546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 1372|FDG-PET in Advanced Melanoma|FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|November 2014|September 2020|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|23|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236546||37139|
NCT02236624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avonex|Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?|Can Aerobic Exercise Reduce Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?||University of Aarhus||Active, not recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|December 1, 2015|September 8, 2014||||No||https://clinicaltrials.gov/show/NCT02236624||37133|
NCT02237274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222/13|Cardiopulmonary Adaptation of Short Term Exposure to High Altitude in Fontan Patients: Swiss Fontan & ALtitude COllaboratioN (FALCON) Study|Cardiopulmonary Adaptation of Short Term Exposure to High Altitude in Fontan Patients: Swiss Fontan & ALtitude COllaboratioN (FALCON) Study|FALCON|University Hospital Inselspital, Berne|No|Completed|July 2014|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02237274||37083|
NCT02223715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-12-003|A Prospective Study to Characterize the Management and Outcome of Clostridium Difficile Infection (CDI) in Asian Pacific Countries|||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|March 2014|||January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1300|||Both|18 Years|N/A|No|Probability Sample|Patients with a confirmed diagnosis of CDI(C. difficile infection) who willing to provide        informed consent and/or informed assent or data release, according to local regulation.|April 2015|April 8, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02223715||38126|
NCT02228447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSP_14|Healthy Habits, Healthy Girls Preventing Unhealthy Weight Gain|Healthy Habits, Healthy Girls: a Intervention Program for Adolescent Girls From Disadvantaged Backgrounds||University of Sao Paulo|No|Recruiting|February 2014|February 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|244|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228447||37762|
NCT02228733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBP5074-1-001|Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074|An Open-Label, Parallel-Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 Following Oral Administration and With a Food Effect Panel||KBP Biosciences|Yes|Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228733||37740|
NCT02228980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST01|Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China|Immunogenicity and Safety of a Single Dose (Subjects From 3 Years of Age) or Two Doses Given 28 Days Apart (Children From 6 to 35 Months of Age) of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China||Sanofi|No|Completed|September 2014|October 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|602|||Both|6 Months|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 26, 2014||No||No|November 18, 2015|https://clinicaltrials.gov/show/NCT02228980||37721|
NCT02228993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00096969|Quality of Recovery Awake Versus Asleep Craniotomy|Quality of Recovery Following Awake Craniotomy Versus Craniotomy Performed Under General Anesthesia||Northwestern University|No|Enrolling by invitation|August 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|N/A|No|Non-Probability Sample|Adult non-pregnant patients (age ≥ 18 years) undergoing Awake Craniotomy or General        Anesthesia Craniotomy for elective supratentorial tumor resection.|September 2015|September 18, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228993||37720|
NCT02236793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC1-CT4|A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer|Phase III, Multicentre, Randomized, Parallel Group, Double Blinded and Control Group Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer||Adocia|No|Recruiting|November 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02236793||37120|
NCT02229266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-HINKL1-059|Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML|Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With Haploidentical Natural Killer Cells in High-risk Acute Myeloid Leukemia|HINKL|Technische Universität Dresden|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|60 Years|99 Years|No|||January 2016|January 15, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229266||37699|
NCT02229279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-HAD|Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures|Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures|SSRHAD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229279||37698|
NCT02238301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130924|Evaluation of Fetoplacental Oxygenation With Functional MRI in Pregnant Women|Study of the Fetoplacental BOLD Effect in Pregnant Women Using Functional MRI|BOLD-FP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238301||37004|
NCT02229864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-392 B|Pharmacokinetics of Everolimus in ABSORB BVS in Patients With Coronary Artery Lesions|ABSORB III RCT Pharmacokinetics (PK) Sub-study||Abbott Vascular|Yes|Active, not recruiting|May 2014|September 2019|Anticipated|October 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|June 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229864||37653|
NCT02229877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-011|A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of AF-219|A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219||Afferent Pharmaceuticals, Inc.|No|Completed|October 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|March 9, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229877||37652|
NCT02236416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21933_III/11|Physical Exercise for Prevention of Dementia|Physical Exercise and Prevention of Cognitive Decline in Subjects at Risk of Dementia: a Randomized Controlled Trial|EPD|University of Molise|No|Recruiting|May 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|600|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02236416||37149|
NCT02236468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHANGE BF|Creating Homestead Agriculture for Nutrition and Gender Equity (CHANGE) in Burkina Faso|Creating Homestead Agriculture for Nutrition and Gender Equity in Burkina Faso|CHANGE|International Food Policy Research Institute|No|Active, not recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2400|||Both|N/A|12 Months|Accepts Healthy Volunteers|||March 2015|February 23, 2016|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02236468||37145|
NCT02236481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRACK|Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes|No-profit" Study to Ensure Normal Clinical Practice, to Evaluate the Efficacy of Anakinra in Reducing the Glycated Haemoglobin in Patients Affected by Rheumatoid Arthritis and Diabetes; Randomized, Open Label, Parallel Group,Controlled Clinical Study|TRACK|University of L'Aquila|No|Recruiting|July 2013|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236481||37144|
NCT02238886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-114|Radical Cystectomy, Nutrition and Convalescence|RADICAL CYSTECTOMY, NUTRITION AND CONVALESCENCE: CAN GOAL-DIRECTED POSTOPERATIVE NUTRITIONAL THERAPY REDUCE THE CONVALESCENCE PERIOD FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY (RC)?||Rigshospitalet, Denmark||Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02238886||36960|
NCT02225392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45394.018.13|Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma|Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma|TASMA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 17, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02225392||37997|
NCT02225405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0844|Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)|Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-small Cell Lung Cancers Amenable for Surgical Resection||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||June 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02225405||37996|
NCT02225691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-32|Effect of Paired Testing to Poorly Controlled Chinese Diabetes on Glycemic Control and Self Care|Effect of Introducing Daily Paired Testing to Poorly Controlled Chinese Diabetes Patients on Glycemic Control and Self Care||Shanghai 6th People's Hospital|Yes|Not yet recruiting|December 2014|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|80 Years|No|||November 2014|November 19, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225691||37974|
NCT02237534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKDR-002|Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia|Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia|LAVALIER|Osaka University|No|Enrolling by invitation|September 2014|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||April 2015|April 20, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237534||37063|
NCT02237547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNEI-2014-TBS-UCMSC-SCI001|Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury|Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury||Translational Biosciences|Yes|Active, not recruiting|September 2014|March 2018|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237547||37062|
NCT02240147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2S-ACHD|Start-to-Sport - Home-based Exercise for Adolescents and Adults With Congenital Heart Disease|Start-to-Sport - Feasibility and Efficacy of Individualized, Telemonitored, Home-based Exercise for Adolescents and Adults With Congenital Heart Disease|S2S-ACHD|Katholieke Universiteit Leuven|No|Recruiting|January 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|65 Years|No|||March 2016|March 18, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240147||36865|
NCT02240173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOjo|Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia|Phase 2 Study of the Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia.||Federal Neuro-Psychiatric Hospital, Yaba|No|Not yet recruiting|September 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||September 2014|September 11, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240173||36863|
NCT02226497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9105|Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy|Integrating a Telemonitoring Device Into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study||Fred Hutchinson Cancer Research Center|No|Recruiting|January 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226497||37912|
NCT02226731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130914|Intrauterine Tamponade With a Belfort-Dildy Balloon in the Treatment of Severe Immediate Postpartum Hemorrhage|Assessment of the Efficacy of Intrauterine Tamponade With a Belfort-Dildy Balloon Obstetric Tamponade System in the Treatment of Severe Immediate Postpartum Hemorrhage|TUB|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Female|18 Years|N/A|No|||November 2015|December 21, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02226731||37894|
NCT02227017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.100|Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers|An Open-label, Single-site, One-sequence Cross-over Study to Assess the Relative Bioavailability of TPV/r 500 mg/200 mg at Steady State When TPV and RTV Are Administered as Oral Solutions vs. Capsules in the Fed and Fasted State.||Boehringer Ingelheim||Completed|February 2006|||April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|August 26, 2014||||No||https://clinicaltrials.gov/show/NCT02227017||37872|
NCT02228187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-14-099|Brain-Computer Interface System for Training Memory and Attention in Elderly|Brain-computer Interface System for Training Memory and Attention in Elderly With Subjective Memory Deficits and Age Related Cognitive Decline (ARCD)||Duke-NUS Graduate Medical School|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228187||37782|
NCT02234544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0378|Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels|Estudo clínico Randomizado, Controlado e Duplo-cego do Impacto da inibição de um Transportador de Membrana do Colesterol na absorção da Vitamina D||Federal University of Rio Grande do Sul|Yes|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|52|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02234544||37293|
NCT02234804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-111-13|The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study|The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study|DOCTOR Recross|Aarhus University Hospital Skejby|Yes|Recruiting|July 2013|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234804||37273|
NCT02236806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFE2014|Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab|Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial|SAFE|Azienda Ospedaliero-Universitaria Careggi|No|Recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|480|||Female|18 Years|N/A|No|||July 2015|July 17, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02236806||37119|
NCT02238067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25473|Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis|||Hoffmann-La Roche||Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with CKD not on-dialysis treated with ESAs|March 2016|March 1, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238067||37022|
NCT02236884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU08|The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer|A Pilot Study of the Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer Without Conventional Laparoscopic Assistance||Sun Yat-sen University|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||September 2014|September 9, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02236884||37113|
NCT02225145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140177|Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease|Fertility Preservation in Females Who Will be Undergoing Gonadotoxic Therapy, Hematopoietic Stem Cell Transplantation, and in Females With Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Suspended|August 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|10|||Both|7 Years|45 Years|No|||July 2015|December 30, 2015|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225145||38016|
NCT02225158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140178|Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection|Longitudinal Study of Immune Responses to Mycobacterium Tuberculosis (Mtb) in Subjects With Latent Tuberculosis (TB) Infection(LTBI) With or Without Concomitant Helminth Infection||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|January 2030|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|70 Years|No|||July 2015|January 22, 2016|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225158||38015|
NCT02238353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|azelastine/fluticasone AZE/FLU|AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)|AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02238353||37000|
NCT02238366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52014-213|Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer|A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy|CHRONOS3|Ipsen|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|369|||Male|18 Years|N/A|No|Non-Probability Sample|Men recently diagnosed with locally advanced or metastatic prostate cancer receiving ADT.|February 2016|February 29, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02238366||36999|
NCT02236611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201315|A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1036|||Both|40 Years|N/A|No|||January 2016|February 25, 2016|September 8, 2014|Yes|Yes||No|January 18, 2016|https://clinicaltrials.gov/show/NCT02236611||37134|
NCT02237339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CV15|Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?|Does Allopurinol Regress Left Ventricular Hypertrophy in Patients With Treated Essential Hypertension?|ALLAY|University of Dundee|Yes|Recruiting|September 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|January 6, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02237339||37078|
NCT02225119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140171|The Focal Electro-Oculogram in Macular Disease|The Focal Electro-Oculogram in Macular Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|130|||Both|10 Years|N/A|Accepts Healthy Volunteers|||June 2015|August 5, 2015|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225119||38018|
NCT02229838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1178.1|Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food|Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of 0.25 mg, 0.75 mg, 2 mg, 6 mg, and 10 mg BIBB 1464 MS (Tablet) in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food of the Dose of 0.75 mg or 2 mg or 6 mg (Two-stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Phase and Subsequent Randomised, Open Parallel Group Phase)||Boehringer Ingelheim||Completed|July 1999|||September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|73|||Male|19 Years|54 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02229838||37655|
NCT02230111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-170|Impact of Cognitive Dietary Restraint on Perceived Stress, Appetite Sensations, Food Cravings During Energy Restriction|Impact of Cognitive Dietary Restraint on Perceived Stress, Appetite Sensations and Food Cravings During Energy Restriction in Women With Obesity||Laval University|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|58|||Female|20 Years|50 Years|No|||August 2015|August 31, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230111||37634|
NCT02230371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC3|Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles|The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles||Karolinska Institutet|No|Completed|March 2007|July 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02230371||37614|
NCT02230384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14060338|Novel Smoking Cessation Drug for Schizophrenia|The Development of of A Novel Therapeutic to Aid Tobacco Smoking Cessation in Persons With Schizophrenia or Schizoaffective Disorder|TRENDS|University of Pittsburgh|Yes|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|July 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230384||37613|
NCT02225977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSGilenya|Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.|Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.||University of Southern California|No|Active, not recruiting|July 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|125|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be selected from those seen by physicians at the USC Multiple Sclerosis        Comprehensive Care Center.|November 2015|November 30, 2015|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02225977||37952|
NCT02226250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-031|Absorption and Metabolic Profiles of a Sugar-based Beverage|Absorption Profile of a Sugar-based Beverage on Inflammatory Mechanism by Timing of Beverage Consumption Relative to Meal Intake.|SR|Institute for Food Safety and Health, United States|Yes|Active, not recruiting|August 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226250||37931|
NCT02231190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200884|GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage|A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|August 27, 2015|September 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02231190||37551|
NCT02231476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sev-4-2014-0440|Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients|Phase II Study of Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients With Gastrointestinal Tumors||Severance Hospital|Yes|Recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||May 2015|May 27, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02231476||37529|
NCT02237183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01891|Iloprost in Preventing Lung Cancer in Former Smokers|A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers||National Cancer Institute (NCI)|Yes|Recruiting|November 2015|||April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|85 Years|No|||November 2015|November 11, 2015|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237183||37090|
NCT02234336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004757|Assessment of Wall Thickness in Hypertrophic Cardiomyopathy|Assessment of Wall Thickness in Hypertrophic Cardiomyopathy||Mayo Clinic|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|Adult patients with hypertrophic cardiomyopathy (HCM)|December 2015|December 30, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234336||37309|
NCT02237976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/10|Self-hypnosis in Patients Awaiting Lung Transplantation|Interest of Learning Self-hypnosis in Patients Awaiting Lung Transplantation|SelfHypTp|Hopital Foch|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|15 Years|N/A|No|||February 2016|February 19, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237976||37029|
NCT02238054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14249|French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS|French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS|FRANCE-ABSORB|French Cardiology Society|Yes|Recruiting|September 2014|September 2022|Anticipated|September 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|All the departments of Cardiology, from French health institutions, who are authorized to        implement, may participate in the observatory.        It is estimated that this procedure will be performed by 50 to 60 sites performing the        installation of BVS. The list of centers is scalable, their number can be expected to        increase.|October 2015|October 1, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238054|5 Years|37023|
NCT02238171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2497|Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance Study (as Per §67(6)AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|April 2000|||December 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|346|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at general practitioners,        pneumologists, internists|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238171||37014|
NCT02224287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00003145|Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control|Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control: A Prospective Randomized Trial||Children's Hospital Boston|Yes|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|5 Years|25 Years|No|||January 2016|January 26, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224287||38082|
NCT02238184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2499|Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)|Postmarketing Surveillance Study (as Per §67(6 )AMG [German Drug Law]) of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|January 2001|||September 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited by registered pneumologists|September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02238184||37013|
NCT02238288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEAC2014|Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients|Randomized Clinical Trial to Verify the Effectiveness of Topical Aminocaproic Acid in the Prevention of Post-exodontic Bleeding in Patients on Anticoagulants||Grupo de Estudos Multicentricos em Onco-Hematologia|No|Enrolling by invitation|December 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|154|||Both|N/A|N/A|No|||September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238288||37005|
NCT02230423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_31_01_2014|Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome|Trigeminale Endonasale Perzeption, Ein Prädiktor für Das Outcome Einer Septumplastik - Eine Prospektive Kohortenstudie Mit Klinischen Und Biologischen Untersuchungen||University of Zurich|No|Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|140|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230423||37610|
NCT02225431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0706|Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis|Personalized Versus Standard Hydration for Prevention of Contrast Induced Acute Kidney Injury. A Randomized Trial With Bioimpedance Analysis.||Ospedale Misericordia e Dolce|Yes|Completed|September 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|296|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02225431||37994|
NCT02236962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-12|Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment|Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment||Bayside Health|Yes|Recruiting|April 2012|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|42|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT02236962||37107|
NCT02236975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIONEER|First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis|Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.||Sino Medical Sciences Technology Inc.|Yes|Not yet recruiting|November 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02236975||37106|
NCT02229526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT2006-41-6257|Fish Oil Trials in Pregnancy for the Prevention of Pregnancy Complications ('FOTIP')|Randomised Clinical Trials of Fish Oil Supplementation in High Risk Pregnancies|FOTIP|Centre for Fetal Programming, Denmark|Yes|Completed|January 1990|December 1999|Actual|January 1996|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|1619|||Female|N/A|N/A||||August 2014|August 29, 2014|March 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02229526||37679|
NCT02229539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221304|Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy|A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy||Alliance for Clinical Trials in Oncology|Yes|Recruiting|November 2014|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229539||37678|
NCT02229851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4054|Trial to Compare the Efficacy and Safety of NNC0195-0092 With Placebo and Norditropin® FlexPro® in Adults With Growth Hormone Deficiency|A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period|REAL 1|Novo Nordisk A/S|No|Recruiting|October 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|280|||Both|23 Years|79 Years|No|||March 2016|March 1, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229851||37654|
NCT02236637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100857|A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care|A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer||Janssen Pharmaceutica N.V., Belgium|No|Recruiting|June 2013|December 2018|Anticipated|March 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Male|18 Years|N/A|No|Probability Sample|Approximately 3,000 patients will be enrolled in this registry. Patients eligible for        enrollment will be men aged at least 18 years, with a confirmed diagnosis of        adenocarcinoma of the prostate, with documented metastatic prostate cancer and documented        castration resistance. Patients will be enrolled at the time of initiating a new systemic        anticancer mCRPC treatment or during surveillance; for the purpose of the registry, at        enrollment, initiation of a new systemic mCRPC treatment is considered as ±30 days from a        patient's baseline data collection.|March 2016|March 11, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236637||37132|
NCT02237794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0049-14-HYMC|Effect of Medical Treatment on Longitudinal Function of the Heart|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|Patients hospitalized in an Internal Medicine Department of the Hillel Yaffe Medical        Center having a variety of medical conditions and treated with a variety of medications        including Beta Blockers, Calcium Channel Blockers, Angiotensine Converting Enzyme        Inhibitors and diuretics and do not suffer from overt heart conditions.|September 2014|September 9, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237794||37043|
NCT02236702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00643|Kappa Opioid Receptor Imaging in Depression (KOR Depression)|Kappa Opioid Receptor Imaging in Depression (KOR Depression)||New York University School of Medicine|Yes|Completed|August 2014|February 2016|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are between the ages of 18-55, are medically healthy and not currently taking any        medications to treat any medical illness, have been diagnosed with major depressive        disorder (MDD) or will be as a result of this study, or are healthy control.|March 2016|March 2, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236702||37127|
NCT02236715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2493|Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|September 1999|||February 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1039|||Both|30 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive airways disease recruited at general practitioners,        pneumologists, internists|September 2014|September 10, 2014|September 10, 2014||||No||https://clinicaltrials.gov/show/NCT02236715||37126|
NCT02230631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4142|A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes||Novo Nordisk A/S|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|704|||Both|18 Years|N/A|No|Non-Probability Sample|Twenty-five sites will be selected, distributed in different regions of the country, in        order to be representative of the Brazilian population.|April 2015|April 8, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230631||37594|
NCT02230904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0018|A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease|A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease||UCB Pharma|No|Completed|September 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 29, 2014||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT02230904||37573|
NCT02237079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI190523|Duavee Prevention of Metabolic Dysfunction in Postmenopausal Women|Pilot Study of Duavee in Preventing Metabolic Dysfunction in Postmenopausal Women|DuaveeMetab|Tulane University Health Sciences Center|No|Not yet recruiting|December 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Anticipated|20|||Female|50 Years|60 Years|No|||September 2014|September 9, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02237079||37098|
NCT02237092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-1|Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia|Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia|IAPSB|Tver Regional Perinatal Center|Yes|Completed|June 2011|June 2013|Actual|January 2013|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|196|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 2, 2014||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT02237092||37097|
NCT02208219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUB011995|Music Therapy to Restore Motor Deficits After Stroke|The Application of Music Therapy in the Neurorehabilitation of Motor Deficits After Subacute Stroke|NEUROMUSIC|University of Barcelona|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|75 Years|No|||December 2015|December 9, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02208219||39314|
NCT02209337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-14-005|Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse|Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse||Lyra Medical Ltd.|Yes|Completed|August 2014|February 2016|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|50 Years|75 Years|No|||March 2016|March 2, 2016|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02209337||39228|
NCT02209350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASC C,D|Study of the AFB and Stenting of the Iliac Arteries|Prospective Randomized Clinical Study of the Aorto-femoral Bypass and the Iliac Arteries With Stenting Recanalization Effectiveness in Patients With the Iliac Segment Occlusive Disease||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|August 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|80 Years|No|||March 2016|March 18, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02209350||39227|
NCT02205489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS13650|Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA|Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA|EMERALD|Sanofi|No|Active, not recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205489||39524|
NCT02205749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAS-12-169|Preferred Consent Models for Secondary Uses of Biospecimens Among Diverse Women|Preferred Consent Models for Secondary Uses of Biospecimens Among Diverse Women||Washington University School of Medicine|No|Active, not recruiting|January 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|454|||Female|35 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205749||39504|
NCT02205762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-428|LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis|LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis||Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|July 2023|Anticipated|November 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1100|||Both|N/A|18 Years|No|||August 2015|August 4, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205762||39503|
NCT02206061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51912|School-based Asthma Care for Teens (SB-ACT)|School-based Asthma Care for Teens (SB-ACT)|SB-ACT|University of Rochester|Yes|Recruiting|July 2014|June 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|430|||Both|12 Years|15 Years|No|||September 2015|September 15, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02206061||39480|
NCT02206074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF107|The Effect of Dietary Nitrate Supplementation on Ability of Individuals With Type 2 Diabetes to Perform Exercise|The Effect of Dietary Nitrate Supplementation on Ability of Individuals With Type 2 Diabetes to Perform Exercise|Ex nit as|NIHR Exeter Clinical Research Facility|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|57|||Both|35 Years|75 Years|No|||July 2014|July 30, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02206074||39479|
NCT02206399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLS-1|Non-Invasive Hemoglobin Study|Non-Invasive Hemoglobin Multi-Center Observational Study||Convergence Biometrics||Active, not recruiting|August 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Whole Blood Donation Center Donors sample|January 2016|January 26, 2016|July 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206399||39454|
NCT02206412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0341|Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft|||Yonsei University|No|Recruiting|July 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|530|||Both|20 Years|N/A|No|Probability Sample|Patients over age 20 who are undergoing off-pump coronary artery bypass graft|July 2014|July 31, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206412||39453|
NCT02206685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H32894|A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery|A Randomized Blinded Prospective Trial Comparing Single Intraoperative Dose of Methadone Versus Placebo in Pediatric Patients Undergoing Spine Surgery.||Baylor College of Medicine|Yes|Recruiting|May 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206685||39432|
NCT02206087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-002|Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin|Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin||Perosphere, Inc.|No|Active, not recruiting|June 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|6||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206087||39478|
NCT02228772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-200|Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults|Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults||Massachusetts General Hospital|Yes|Recruiting|December 2014|July 2020|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|51 Years|75 Years|No|||September 2015|September 21, 2015|August 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228772||37737|
NCT02205671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29894|Building Better Caregivers: Development and Evaluation|Building Better Caregivers: Development and Evaluation||Stanford University|No|Active, not recruiting|August 2014|September 2016|Anticipated|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205671||39510|
NCT02205996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/YH/0161|The Effects of Hypoglycaemia in People With Type 2 Diabetes|The Effects of Hypoglycaemia on Platelets Function and Inflammatory Markers in People With Type 2 Diabetes and Normal Controls.||University of Hull|Yes|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|18|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02205996||39485|
NCT02206581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HME-01|Using Hydration Monitor to Detect Changes in the Hydration Status Athletes|The Validity of Ultrasound Velocity to Detect Changes in the Hydration Status of Male and Female Athletes During Acute Dehydration and Rehydration||Artann Laboratories|No|Completed|October 2014|December 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|82|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subject pool will be comprised of 100 young, healthy, physically active male and        female subjects.|January 2016|January 20, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206581||39440|
NCT02206594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW-EI-001|Combined Cataract Surgery and Planned Descemetorhexis|Combined Cataract Surgery and Planned Descemetorhexis||Medical College of Wisconsin|No|Completed|January 2014|||August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2014|August 20, 2015|April 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02206594||39439|
NCT02231281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZX10001002-001|Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults|A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults||Tang-Du Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|65 Years|No|||September 2014|September 1, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02231281||37544|
NCT02231580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-52966-005|Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients|A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease||Ipsen|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Male|20 Years|70 Years|No|||February 2016|February 29, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02231580||37521|
NCT02234609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mARTIV|Effectiveness of Modified Class IV Atraumatic Restorative Treatment|Effectiveness of Modified Class IV Atraumatic Restorative Treatment - Results After 12 Months|modARTIV|University of Witten/Herdecke|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02234609||37288|
NCT02231905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.544|Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease|Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole||Boehringer Ingelheim||Completed|January 2004|||November 2004|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|20 Years|N/A|No|||September 2014|September 3, 2014|September 3, 2014||||No||https://clinicaltrials.gov/show/NCT02231905||37496|
NCT02231918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.600|Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)|An Open-label Clinical Study to Investigate Pharmacokinetics (PK) of Different Doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)||Boehringer Ingelheim||Completed|May 2006|||July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|6 Years|16 Years|No|||September 2015|September 2, 2015|September 3, 2014||||No|July 17, 2015|https://clinicaltrials.gov/show/NCT02231918||37495|
NCT02207920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 105|Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|July 2014|||September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|104|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207920||39337|
NCT02208505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2013-0192`|Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion|Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion During Emergence in Adults After Thyroidectomy: Comparison With High-dose Remifentanil Infusion Alone||Yonsei University||Active, not recruiting|February 2014|December 2015|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|170|||Both|20 Years|65 Years|No|||November 2015|November 2, 2015|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02208505||39292|
NCT02208791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1157-7462|Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant|Evaluation of the Effects of Sirolimus Addition to the Triple Immunosuppression Protocol on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Sensitized Kidney Transplant Recipients - a Pilot Study||University of Sao Paulo General Hospital|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|60 Years|No|||June 2014|December 15, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208791||39270|
NCT02205515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|File#13-907/OZM-057|An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis|An Open Label, Single-Centre, Pilot Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis|EBRT|Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02205515||39522|
NCT02209389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OctavaPink for Dense Breast|OctavaPink for Women With Dense Breast After Negative Mammography|OctavaPink® For Dense Breast After Negative Mammography||Eventus Diagnostics Ltd|No|Not yet recruiting|August 2014|August 2017|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1750|Samples With DNA|Human plasma samples|Female|30 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|The study population for all parts of the protocol includes women above 30, who have had a        mammography in the past 5-18 months, for which the result was negative (BIRADS assessment        category 1 or 2), and on which they were defined as having dense breast tissue (BIRADS        composition/density 3 or 4).|August 2014|August 18, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02209389|2 Years|39224|
NCT02205775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013622-17|Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty|Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty - The REMEDY Study|REMEDY|G. d'Annunzio University|Yes|Terminated|May 2010|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|280|||Both|N/A|N/A|No|||February 2011|July 30, 2014|July 30, 2014||No|difficult recruitment|No||https://clinicaltrials.gov/show/NCT02205775||39502|
NCT02205528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29476|A Study of Once-Daily RO6811135 in Participants With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily RO6811135 in Type 2 Diabetic Patients Inadequately Controlled With Metformin||Hoffmann-La Roche||Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205528||39521|
NCT02205541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7052 01|Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU|Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo|ECULISHU|University Hospital, Toulouse|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|18 Years|No|||August 2015|August 25, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02205541||39520|
NCT02205788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0479|Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas|Feasibility of Biodynamic Imaging for Predicting Effect of Gemcitabine and Nab-paclitaxel on Metastatic Adenocarcinoma of the Pancreas||Indiana University|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|6|Samples With DNA|core needle biopsy of tumor|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic and Cancer Clinic patients|June 2015|June 4, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02205788||39501|
NCT02206100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER977-01-003|PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin|Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin||Perosphere, Inc.|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206100||39477|
NCT02206113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3989-1|Sit to Stand Intervention for Allina Health Employees|A Sit-to-Stand Intervention for Allina Health Employees: A Pilot Study||Allina Health System|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206113||39476|
NCT02232685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAM_PROSTAGE1|Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer|Whole Body Bone Scan vs 18F-Choline PET/CT, Better Detection of Bone Metastases in Prostate Cancer Patients, PROSTAGE I||Odense University Hospital|Yes|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|280|||Male|N/A|N/A|No|||May 2015|May 4, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232685||37436|
NCT02232698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-CI-APO-13019|An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)|Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes|IMPACT|Abbott Diabetes Care|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|328|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232698||37435|
NCT02205983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC13-1027|The Effects of Hydromorphone on Responses to Verbal Tasks|The Effects of Hydromorphone on Responses to Verbal Tasks|HESS|University of Chicago|No|Enrolling by invitation|January 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205983||39486|
NCT02206282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR-LT-001|Prevalence of Asymptomatic Rupture in SILIMED Breast Implants|Prevalence of Asymptomatic Rupture in SILIMED Breast Implants||Silimed Industria de Implantes Ltda|Yes|Completed|August 2006|February 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|390|||Female|N/A|N/A|No|Probability Sample|390 women (780 implants) from Rio de Janeiro and other Brazilian cities will be randomly        selected to undergo MRI detection of asymptomatic rupture using a stratified sampling        design, stratifying on implant age (time since implantation). Sixty-five (65) women will        be selected from each of six implant age groups between 6-18 years.|July 2014|July 30, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206282||39463|
NCT02206295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065-108|Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg|A Single-center, Open-label, Randomized, Two-period, Two-treatment, Crossover Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg (Reference Drug) or as Single Tablet of 1600 μg (Test Drug)||Actelion|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206295||39462|
NCT02206308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT400NHLI|Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.|A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody，in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.||Sinocelltech Ltd.|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||December 2013|July 31, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02206308||39461|
NCT02234388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12065|Undifferentiated Connective Tissue Disease Registry|Undifferentiated Connective Tissue Disease Registry|UCTD Registry|Hospital for Special Surgery, New York|No|Recruiting|March 2012|||January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under the care of any HSS rheumatologist that have been diagnosed with        undifferentiated connective tissue disease.|September 2014|September 4, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02234388|3 Years|37305|
NCT02206841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD_cohort|Establishment of NAFLD Cohort and Development of Fibrosis Markers|Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis|NAFLD|Seoul National University Boramae Hospital|No|Recruiting|June 2014|July 2019|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Obtained blood samples will be stored by serum and plasma for future analysis.|Both|18 Years|N/A|No|Probability Sample|Non-alcoholic fatty liver disease|March 2016|March 15, 2016|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206841|3 Years|39420|
NCT02207088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-226|Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)||AbbVie|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207088||39401|
NCT02234921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-116B|Pilot Study of DRibble Vaccine for Prostate Cancer Patients|A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer|DRibble|UbiVac|No|Recruiting|September 2014|September 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|N/A|N/A|No|||May 2015|May 26, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234921||37264|
NCT02234934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1XCGD|Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease|A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease||University of California, Los Angeles|Yes|Recruiting|January 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|23 Months|N/A|No|||February 2016|February 8, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234934||37263|
NCT02208232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 1267/2012|Observation of Rotation of an Intraocular Lens|Observation of Rotation of the MC 6125 AS Intraocular Lens||Medical University of Vienna||Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|N/A||1|Actual|100|||Both|40 Years|90 Years|No|Non-Probability Sample|Eyes of patients with uni- or bilateral cataract applying for cataract surgery at the        Department of Ophthalmology, Medical University Vienna.|August 2014|August 1, 2014|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02208232||39313|
NCT02208245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infra Study|Prospective Clinical Trial Comparing Infraclavicular Versus Axillary Approach to Brachial Plexus Block|Prospective Randomized Clinical Trial Comparing Infraclavicular Versus Axillary Approach to Brachial Plexus Block.||Federal University of São Paulo|No|Active, not recruiting|February 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||August 2014|August 2, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02208245||39312|
NCT02208752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARM2014|The Effect of a Pre-operative Exercise Program for Patients With Full Thickness Rotator Cuff Tear Waiting for Surgical Repair|The Effect of a Pre-operative Exercise Program on Pain and Function in Patients With Full Thickness Rotator Cuff Tear Waiting for Surgical Repair.||Université de Montréal|No|Recruiting|June 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208752||39273|
NCT02208804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-287/D|Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization|Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial)|SIM|UMC Utrecht|No|Recruiting|November 2014|||November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|January 28, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02208804||39269|
NCT02205242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55829 - PROactive Substudy|BACE Trial Substudy 1 - Physical Activity as a Crucial Patient Reported Outcome in COPD|BACE Trial - PROactive Substudy|PROactive|Katholieke Universiteit Leuven|No|Recruiting|September 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02205242||39543|
NCT02205502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine-01|Lidocaine as Local Anesthetics in Children Under Ketamine Sedation|Efficacy of Lidocaine as Local Anesthetics in Children Under Procedural Sedation and Analgesia Using Ketamine||Seoul National University Hospital|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|12 Months|10 Years|No|||July 2014|July 29, 2014|June 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02205502||39523|
NCT02205268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPADHDNTX|Near Infrared Spectroscopy Neurofeedback Training for ADHD|A Pilot Study of Near Infrared Spectroscopy Neurofeedback Training of Prefrontal Cortex in Attention Deficit Hyperactivity Disorder|ADHDNTx|North Essex Partnership NHS Foundation Trust|Yes|Recruiting|March 2013|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|7 Years|17 Years|No|||October 2015|October 13, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205268||39541|
NCT02205255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55829 - FarmEc Substudy|BACE Trial Substudy 2 - The Pharmaco-economic Impact of the Azithromycin Intervention|BACE Trial - FarmEc Substudy|FarmEc|Katholieke Universiteit Leuven|No|Recruiting|August 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02205255||39542|
NCT02205814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKOS-04|Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee|A Double-blind, Randomised, Placebo-controlled, Four Parallel Arm, Dose-finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-articular Injections of Fasitibant in Patients With Symptomatic Osteoarthritis of the Knee.|ALBATROSS-3|Menarini Group|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|436|||Both|40 Years|80 Years|No|||October 2015|October 2, 2015|July 14, 2014|Yes|Yes||No|July 6, 2015|https://clinicaltrials.gov/show/NCT02205814||39499|
NCT02232477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRC-002 (100)|Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I|An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I||Los Angeles Biomedical Research Institute|Yes|Enrolling by invitation|May 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|6 Years|N/A|No|||March 2016|March 2, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232477||37452|
NCT02206126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINEX05|Weight Loss and Obstructive Sleep Apnea|Effects of Energy Restriction on Sleep Apnea, Sympathetic Activity, Oxidative Stress, Inflammatory Biomarkers, Endothelial Function, Body Adiposity, Metabolic Profile and Blood Pressure in Obese Patients With Obstructive Sleep Apnea||Rio de Janeiro State University|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02206126||39475|
NCT02206139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBO102|Level of Burn Out of Surgical Residents Working in All Hospitals of Lahore|Burn Out Among Surgical Residents Working at All Institutes in Lahore: An Area of Grave Concerns||Services Hospital, Lahore|Yes|Completed|July 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|150|||Both|25 Years|40 Years|No|Non-Probability Sample|General surgical residents of All the Hospitals Of Lahore|March 2016|March 10, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02206139||39474|
NCT02228499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00005030|Academic Achievement in Children With Asthma|Academic Achievement in Children With Asthma||Children's Research Institute|No|Active, not recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|11 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are proposing a cross-sectional case-control observational study of middle school        (grades 6-8) children to compare academic achievement and school attendance between        children with and without asthma. 200 children with asthma (cases) will be recruited from        the IMPACT DC clinic and/or ED and 200 children without asthma (controls) will be        recruited from the ED.|April 2015|April 15, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228499|3 Weeks|37758|
NCT02235103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B670201316616|The Predictive Value of the Sperm Chromatin Dispersion Test, Halosperm®, Before and After Sperm Preparation for Clinical Pregnancy in Cases of Unexplained Infertility Treated With Intra-uterine Insemination (First Cycle) and Ovulation Induction With Clomiphene Citrate.|The Predictive Value of the Sperm Chromatin Dispersion Test, Halosperm®, Before and After Sperm Preparation for Clinical Pregnancy in Cases of Unexplained Infertility Treated With Intra-uterine Insemination (First Cycle) and Ovulation Induction With Clomiphene Citrate.|DNAFRAG|University Hospital, Ghent||Completed|April 2014|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|21|Samples With DNA|Sperm samples|Both|18 Years|40 Years|No|Non-Probability Sample|Patients with unexplained fertility treated with intra-uterine insemination (first cycle)        and ovulation induction with clomiphene citrate.|March 2016|March 11, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235103||37250|
NCT02235116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC001|Predictors of Patient Attitudes and Barriers to Skin Cancer Screening|Predictors of Patient Attitudes and Barriers to Skin Cancer Screening||University of California, Los Angeles|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1040|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|English-speaking patients 18yrs old and older attending the UCLA Dermatology clinics in        Santa Monica, California or Westwood, California from June 14 to July 1, 2011|September 2014|September 8, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235116||37249|
NCT02205697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mdh-32828|Theory of Planned Behavior and Implementation Intentions|Theory of Planned Behavior and Implementation Intentions: Effective for Improving Fruit and Vegetable Intake in Women of Low Socioeconomic Status?|TPBIIFV|Boston University|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Female|18 Years|72 Years|No|||July 2015|January 15, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205697||39508|
NCT02214303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRA-1017/2012|The Role of Th9 Cells and Eosinophils Activity in Allergic Airway Diseases|The Role of Th9 Cells Expression and Eosinophils Activity in the Course of Allergic Airway Diseases|SAIRA|Lithuanian University of Health Sciences|Yes|Recruiting|April 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|Samples Without DNA|Induced sputum and peripheral blood samples|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Allergic asthma|August 2014|August 10, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02214303||38849|
NCT02214316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201408006|IVF in Pediatric Concussion|||Washington University School of Medicine||Not yet recruiting||||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|6 Years|18 Years|No|||August 2014|August 7, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214316||38848|
NCT02214576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_JDR2|High Flow Nasal Canula Oxygen Helps Preoxygenate ARDS Patients|Observational Study of High Flow Nasal Canula Oxygen to Preoxygenate ARDS Patients That Require Intubation|HIGHER|Hôpital Louis Mourier|No|Completed|September 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|acute respiratory distress syndrome patients that require tracheal intubation in the ICU|August 2015|August 13, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02214576||38829|
NCT02214589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5140027|Non-pharmacological Interventions for Procedural Pain in Premature Neonates|Non-pharmacological Interventions for Procedural Pain in Premature Neonates||Loma Linda University|Yes|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|250|||Both|N/A|1 Month|No|||January 2016|January 19, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02214589||38828|
NCT02206854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLIP0112|Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects|Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects||Goethe University|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206854||39419|
NCT02207660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201211032RIC|Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix|Cisplatin Plus One Day 24 Hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix.||National Taiwan University Hospital|Yes|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|30|||Female|20 Years|90 Years|No|Non-Probability Sample|The general principles for patients schedule for P-HDFL regimen treatment were as        followings: patients must have had white cell count > 3000/mm3, platelet count >        100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance        ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[sereum creatinine level        (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase        (≦3X the upper normal limits). Also, patients needed to have measurable disease by        radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical        issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.|February 2015|February 3, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02207660||39357|
NCT02207647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12H-770352|Prevalence of Pathogens in Cerebrospinal Fluid Obtained From Emergency Department Patients|||Olive View-UCLA Education & Research Institute|No|Recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Cerebrospinal fluid and blood serum are being collected.|Both|3 Months|N/A|No|Non-Probability Sample|This study will be conducted by the Emergency ID Net Study group (P.I. David Talan), which        consists of a network of 10 emergency departments in university-affiliated hospitals        throughout the United States.|October 2015|October 13, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207647||39358|
NCT02207933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0270|Effect of Anterioposterior Weight Shifting Training With Visual Biofeedback in Patients With Step Length Asymmetry After Stroke|||Yonsei University|No|Recruiting|June 2013|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|20 Years|80 Years|No|||July 2014|August 1, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207933||39336|
NCT02208518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELASTOSONO-EUS1|Quantitative And Qualitative Eus Elastography|Could Quantitative And Qualitative EUS-Elastography Results Be Affected By The Compression Rate And The Diameter Of The Region Of Interest (ROI)?||Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Completed|October 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|55 Years|No|Non-Probability Sample|primary care clinic: patients with upper gastrointestinal submucosal tumors for evaluation        by endoscopic ultrasound|August 2014|August 4, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208518||39291|
NCT02209363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4120|Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy|Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)|COPE-PAP|McGill University Health Center|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209363||39226|
NCT02209376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 35313|Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma|Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209376||39225|
NCT02209077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2013-1 Study (REPRO)|Spectralis OCT Repeatability and Reproducibility Study|Repeatability and Reproducibility of Optic Nerve Head (ONH), Retinal Nerve Fiber Layer (RNFL), and Macula Parameters With the Heidelberg Spectralis OCT.|S-2013-1|Heidelberg Engineering GmbH|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|August 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02209077||39248|
NCT02232217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400307|Cognitive Behavioral Treatment for Improving Sleep in Overweight and Obese Youth|Cognitive Behavioral Treatment for Improving Sleep in Overweight and Obese Youth||University of Florida|Yes|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|12 Years|No|||November 2015|November 10, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232217||37472|
NCT02205554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syntrix-Omni-Pain-101|Omnitram Pharmacokinetic Study In Healthy Volunteers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects||Syntrix Biosystems, Inc.|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|July 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205554||39519|
NCT02205801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0374|Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy|A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy||University of Chicago|Yes|Enrolling by invitation|July 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02205801||39500|
NCT02232490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immunitor IMM05|Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimu (V5)|Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimu (V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)|IMM05|Lisichansk Regional Tuberculosis Dispensary|Yes|Recruiting|January 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232490||37451|
NCT02234869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105MS403|Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy|Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)|Frequency|Biogen||Withdrawn|October 2014|March 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2014|November 14, 2014|September 5, 2014|Yes|Yes|Due to a change in Biogen Idec's medical research plans.|No||https://clinicaltrials.gov/show/NCT02234869||37268|
NCT02232516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 14H04|Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma|Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL||Northwestern University|Yes|Recruiting|June 2015|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232516||37449|
NCT02232594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1358|Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease||Boehringer Ingelheim||Completed|January 2000|||December 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|834|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive respiratory tract disease recruited at general        physicians and internists|September 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02232594||37443|
NCT02232607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.339|Efficacy and Safety of Lacidipine in Chronic Stable Angina|A Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Lacidipine in Chronic Stable Angina.||Boehringer Ingelheim||Completed|April 1998|||June 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|283|||Both|18 Years|80 Years|No|||September 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02232607||37442|
NCT02232620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-205c|A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors||Boston Biomedical, Inc|No|Not yet recruiting|July 2016|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232620||37441|
NCT02225197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK Perioptic-01|A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors|A Phase II Study of Fractionated CyberKnife Stereotactic Radiosurgery to Perioptic Tumors||Community Cancer Center, Normal, Illinois|No|Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||August 2014|August 25, 2014|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225197||38012|
NCT02225210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shu 2014|Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients|Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients -a Single Center,Randomized and Controlled Trial||Fuling Central Hospital of Chongqing City|No|Not yet recruiting|September 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|80 Years|No|||August 2014|August 24, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225210||38011|
NCT02225223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-14-01|Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)|Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation Prior to or Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s) [The STARRT Study]|STARRT|DFINE Inc.|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225223||38010|
NCT02218216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2014-GES-0046|TBI MR Study 3 Houston Methodist|Advanced MRI Applications for Mild Traumatic Brain Injury - Study 3||GE Healthcare|No|Terminated|September 2014|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|15 Years|50 Years|No|||November 2015|November 30, 2015|August 13, 2014|No|Yes|Sponsor terminated study early to start a larger feasability study|No||https://clinicaltrials.gov/show/NCT02218216||38549|
NCT02214108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protwii2013|Effect of Physical Activity Through Interactive Video Games in Overweight Children|Effect of Physical Activity Trough Interactive Video Games in Overweight, Randomized, Controlled Study.||Centro Pediatrico Albina de Patino|No|Completed|November 2012|December 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|10 Years|No|||March 2014|March 3, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02214108||38864|
NCT02214628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1005|Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD|||Ophthotech Corporation|No|Active, not recruiting|July 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|N/A|No|||July 2015|July 20, 2015|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214628||38825|
NCT02214329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100000467|Sensor-based Balance Training in Diabetes: A Virtual Reality Paradigm|Game-Based Virtual Reality Approach for Improving Balance, Reducing Falls, and Preventing Complications In Diabetes||University of Arizona|No|Recruiting|February 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|50 Years|80 Years|No|||August 2014|August 11, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214329||38847|
NCT02214342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401199972|Virtual Reality Based Balance Training in People With Mild Cognitive Impairment|Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study||University of Arizona|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||December 2014|December 15, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214342||38846|
NCT02207959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0696B|Gastric In Vivo Study|Endoscopic Multispectral Imaging for the Early Detection of Gastric Neoplasia||Icahn School of Medicine at Mount Sinai|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207959||39334|
NCT02207972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #12-172|Does Ultrasound Help With Placement of Labor Analgesia in Pregnant Patients?|Does Ultrasound-guided CSE Technique Improve Midline Placement of Epidural Needle With Positive CSF Flow, Thereby Facilitating Correct Placement of the Catheter Compared to Catheter Placement Using Palpation of Anatomical Landmarks?||St. Luke's-Roosevelt Hospital Center|No|Completed|May 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|48|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||March 2015|May 22, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207972||39333|
NCT02207946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_2094_1|Botulinum Toxin A to Treat Arm Tremor|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb||Merz Pharmaceuticals GmbH|No|Recruiting|September 2014|October 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207946||39335|
NCT02208258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CON/2013/FI003|Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.|||Consure Medical Pvt. Ltd.|No|Withdrawn|September 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 1, 2014|Yes|Yes|Hospital had initiated a conflicting study, hence the study was terminated.|No||https://clinicaltrials.gov/show/NCT02208258||39311|
NCT02208557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)220/2013|Usefulness of a Prothetic Absorbable Mesh in Incisional Hernia Prevention After Midline Laparotomy|PREBIOUS Trial : A Multicenter Randomized Controlled Trial of Preventive Midline Laparotomy Closure With a Bioabsorbable Mesh for the Prevention of Incisional Hernia.|PREBIOUS|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|488|||Both|18 Years|N/A|No|||August 2014|August 3, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02208557||39288|
NCT02208778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13124|Imaging Pain Relief in Osteoarthritis|Functional Brain Imaging to Understand the Mechanisms of Pain Relief in Knee Osteoarthritis||University of Nottingham|No|Recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|93|||Both|35 Years|N/A|No|||January 2015|January 12, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208778||39271|
NCT02231229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120130 AOM12317|Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation|Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial|FAST-TB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|74 Years|No|||August 2015|August 13, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02231229||37548|
NCT02231242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE13-004|Intrathecal Stem Cells for Cerebral Palsy Phase II|Intrathecal Autologous Stem Cells for Children With Cerebral Palsy Phase II|ISCII|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Recruiting|September 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|7 Years|9 Years|No|||September 2014|September 3, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02231242||37547|
NCT02209402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/11/37/257|ENdothelial DysfUnction in Renal Disease and Exercise Training|Effect of a 3-month Aerobic Training Program on Endothelial Function in Mild-to-moderate CKD: a Randomized Controlled Trial|Endure|Universiteit Antwerpen||Completed|April 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02209402||39223|
NCT02234570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0053|Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole|A Randomized, Double-Blind Placebo-Controlled Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|November 2014|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|October 15, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234570||37291|
NCT02234583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-E312|An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia|AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA||Daiichi Sankyo Inc.|Yes|Active, not recruiting|January 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234583||37290|
NCT02232464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312144RINB|Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With ADHD|Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample consists of 50 adults (ages 18-45) with clinical diagnosis of ADHD according to        the DSM-IV criteria and 50 age-, sex-, and IQ-matched healthy controls without lifetime        diagnosis with ADHD.|March 2015|March 16, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02232464||37453|
NCT02224339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000555|New Technologies to Determine Carotid Plaque Vulnerability|New Technologies to Determine Carotid Plaque Vulnerability: A Pilot Study to Assess Contrast-Enhanced Ultrasound (CEUS) and Strain Deformation Imaging in Patients of Known or Suspected Coronary Artery Disease|CEUS|Mayo Clinic|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|216|||Both|18 Years|90 Years|No|Probability Sample|Suspected or known to have CAD and referred to stress echo lab.|January 2016|January 27, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224339|24 Months|38078|
NCT02234895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01313|Shoe Orthotics for Improvement of Biomechanics and Symptoms of Knee Osteoarthritis|Combined Medial and Lateral Orthotics for the Treatment of Knee Osteoarthritis||University of British Columbia|No|Active, not recruiting|August 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|50 Years|80 Years|No|||December 2015|December 2, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234895||37266|
NCT02234947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-2013|Pancreas Volume in Preclinical Type 1 Diabetes|Pancreas Volume in Preclinical Type 1 Diabetes||University of Florida|No|Recruiting|November 2013|October 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|Samples Without DNA|serum, whole blood|Both|8 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The new onset will be people that have been diagnosed with T1D for less than one year. The        anitbody negative or anitbody positive will be people that have been enrolled in the        TrialNet study, Pathway to Prevention. The healthy control will be people from the general        population with no history or family history of T1D.|December 2015|December 1, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234947||37262|
NCT02214095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|randomized clinical trial|Glucosamine Periodontal Adjunctive Therapy|Glucosamine Sulphate as an Adjunctive Therapy to Closed Mechanical Debridement Reduced Gingival Cervicular Fluid IL-1β in Patients With Chronic Periodontitis||Ain Shams University|Yes|Terminated|January 2012|February 2013|Actual|February 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|48 Years|Accepts Healthy Volunteers|||July 2014|August 11, 2014|July 8, 2014|Yes|Yes|had been finished|No||https://clinicaltrials.gov/show/NCT02214095||38865|
NCT02214368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YB20130097|Noninvasive Ventilation Bundle in Postoperative Respiratory Failure|The Efficacy and Safety of Noninvasive Ventilation Bundle in Postoperative Respiratory Failure||West China Hospital|Yes|Completed|January 2013|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|85 Years|No|||August 2015|August 15, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02214368||38845|
NCT02214381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM06 / ADAPT Elderly|A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response|A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.||West German Study Group|Yes|Recruiting|July 2014|July 2021|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|70 Years|N/A|No|||June 2015|June 18, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02214381||38844|
NCT02214641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01DK099202-01A1|Resilient, Empowered, Active Living: REAL Diabetes Study|Diabetes Self-Management Lifestyle Intervention for Urban Minority Young Adults|REAL|University of Southern California|Yes|Active, not recruiting|October 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|30 Years|No|||December 2015|December 18, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02214641||38824|
NCT02214940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234.2|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of 2.5 mg, 5 mg, 7.5 mg, and 10 mg BI 11634 Oral Solution Administered t.i.d. for 5 Days to Healthy Male Volunteers; Randomised, Doubleblind, Placebo-controlled at Each Dose Level||Boehringer Ingelheim||Completed|June 2007|||September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214940||38801|
NCT02215005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236.6|Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers|Steady State Pharmacokinetics of 80 mg Telmisartan (Micardis®), 10 mg Ramipril (Delix®) or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers (an Open-label, Randomised, Multiple-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|June 2007|||September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215005||38796|
NCT02207322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-241|Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield)|Randomized Study of a Targeted Inpatient Supportive Care Intervention in Patients Hospitalized for Hematopoietic Stem Cell Transplantation (HSCT)|SHIELD|Massachusetts General Hospital|Yes|Active, not recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207322||39383|
NCT02207283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27634|PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy|PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy||Cedars-Sinai Medical Center||Active, not recruiting|March 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Male|15 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02207283||39386|
NCT02207296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00330-47|Operative Hemodynamic Optimization Using the Plethysmographic Variability Index During Orthopedic Surgery|Operative Hemodynamic Optimization Using the Plethysmographic Variability Index During Orthopedic Surgery : a Multicentric Prospective Randomized Controlled Study|OPVI|University Hospital, Caen||Recruiting|February 2015|November 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02207296||39385|
NCT02207309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPM001|Pazopanib Maintenance Phase II|A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia||Ludwig-Maximilians - University of Munich||Recruiting|December 2014|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207309||39384|
NCT02208765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC13.723|Prognostic Value of SPECT-imaging Myocardial Perfusion Heterogeneity|Prognostic Value of Myocardial Perfusion Heterogeneity Assessed by Stress Single Photon Emission Computed Tomography|EVAPERF|University Hospital, Grenoble|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1600|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208765||39272|
NCT02207998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morris 201005532|Efficacy of Homoeopathy and Physiotherapy in Chronic Low Back Pain Due to Osteoarthritis|The Efficacy of the Homoeopathic Complex and Physiotherapy in the Treatment of Chronic Low Back Pain Due to Osteoarthritis||University of Johannesburg|Yes|Completed|July 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207998||39331|
NCT02209051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS2014.01.01|Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized, Parallel-group, Standard of Care-controlled Clinical Trial to Evaluate the Use of AMNIOEXCEL® in the Management of Chronic Diabetic Foot Ulcers||Derma Sciences, Inc.|No|Completed|July 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209051||39250|
NCT02209064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002 (rev C)|"EASE" Epicardial Access With the EpiAccess System|EASe 2- an Epicardial Access Study With the EpiAccess System- A Post-market Follow up Study.|EASE2|EpiEP, Inc.|Yes|Completed|December 2013|November 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 29, 2014||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT02209064||39249|
NCT02208570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_PPV_predictability|Predictability of the Pulse Pressure Variation (PPV) During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia|Predictability of the Pulse Pressure Variation During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia||Seoul National University Hospital||Recruiting|July 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|172|||Both|20 Years|80 Years|No|||August 2014|August 4, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02208570||39287|
NCT02208583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2014064|Molecular Phenotype Changes and Personalized Treatment for CRPC|Exploratory Study of Molecular Phenotype Changes and Personalized Treatment for Patients With Castration Resistant Prostate Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|150|||Male|18 Years|N/A|No|||June 2014|August 4, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02208583||39286|
NCT02234089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000156|Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists.||ProComD|Ferring Pharmaceuticals||Recruiting|September 2014|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Male|N/A|N/A|No|Non-Probability Sample|Patients with advanced prostate cancer where a treatment decision on therapy has already        been made according to medical practice.|October 2015|October 19, 2015|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234089||37328|
NCT02222896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-053|Preoperative CHG Cloth|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|August 2014|May 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|347|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 16, 2015|August 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222896||38189|
NCT02231528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230|Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.|Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.|VVC and GPS|University Hospital, Grenoble|Yes|Completed|October 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02231528||37525|
NCT02231541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3295/2014|Very Low Frequency Magnetic Fields in the Treatment of Fibromyalgia|Effectiveness of Very Low Frequency Magnetic Fields in the Treatment of Fibromyalgia||University of Roma La Sapienza|Yes|Completed|September 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Female|18 Years|60 Years|No|||September 2014|June 4, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02231541||37524|
NCT02223455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-289|Building an Optimal Hand Hygiene Bundle|Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach||Iowa City Veterans Affairs Medical Center|No|Recruiting|October 2014|March 2019|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223455||38146|
NCT02234843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14372|EINSTEIN Junior Phase III: Oral Rivaroxaban in Children With Venous Thrombosis|Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism|EINSTEIN Jr|Bayer|Yes|Recruiting|November 2014|August 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Months|17 Years|No|||March 2016|March 7, 2016|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234843||37270|
NCT02234856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30509|Evaluation of Laparoscopic Hysterectomy Simulator|Evaluation of Laparoscopic Hysterectomy Simulator to Improve Cognitive Surgical Knowledge of Obstetrics and Gynecology Trainees||St. Michael's Hospital, Toronto|No|Enrolling by invitation|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||March 2016|March 9, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02234856||37269|
NCT02229344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103116|Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea|Cohort Study of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Tertiary Referral Hospital Setting in Korea|MOSAIK|Janssen Korea, Ltd., Korea|No|Recruiting|August 2014|August 2021|Anticipated|July 2021|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood sample will be collected and stored for genetic and biomarker research from      participants who agree to give additional informed consent form.|Both|7 Years|N/A|No|Non-Probability Sample|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary        referral hospital within 4 weeks before prior to enrollment will be observed.|March 2016|March 11, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229344||37693|
NCT02224599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kirovax 003|Treatment of Patients With Progressive and/or Refractory Solid Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte-Macrophage Colony Stimulating Factor, in Patients With Progressive and/or Refractory Solid Malignancies||Kiromic, LLC|Yes|Not yet recruiting|May 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224599||38058|
NCT02224924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-141|Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures|Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures||Memorial Sloan Kettering Cancer Center||Recruiting|August 2014|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224924||38033|
NCT02217956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024361-51|Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma|Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months|CHIPASTIN|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|June 2011|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|65 Years|No|||January 2016|January 25, 2016|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02217956||38569|
NCT02217969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 24886|Prospective Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome After Surgery|Prospective, Randomized Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome Following Adult Non-Cardiac Surgical Procedures: The SLUScore™ Trial|SLUScore™|St. Louis University|Yes|Not yet recruiting|January 2016|March 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|56248|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02217969||38568|
NCT02214654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0241|A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage|A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage||Tianjin Medical University|Yes|Not yet recruiting|August 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|144|None Retained|We will collect blood samples from the vena mediana cubiti, volume of sample blood will be      5ml.Centrifuge samples at 700gfor 20 min at 4 °C with no brake.Remove gently the upper phase      (plasma) with a 5 ml pipette into a separate tube and store in 0.25 ml aliquots.Distribute      500 μl of samples into one isotype control and three sample tubes and add the special      antibodies.Then account the CECs and sCD40/40L,etc.|Both|18 Years|75 Years|No|Probability Sample|All patients will be enrolled from outpatient and in hospital in Tianjin First Central        Hospital|April 2014|August 11, 2014|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02214654|1 Month|38823|
NCT02214992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236.5|Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers|Bioequivalence of 80 mg Telmisartan / 10 mg Ramipril Fixed Dose Combination Compared With the Monocomponents, Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Study)||Boehringer Ingelheim||Completed|March 2007|||June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02214992||38797|
NCT02215018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.1|Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 5 - 800 mg). A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Study, Including Re-dosing at 100 mg and 500 mg (Solution) and at 200 mg (Four 50 mg Tablets)||Boehringer Ingelheim||Completed|April 2007|||August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|56|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215018||38795|
NCT02215031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.12|Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (10 to 50 mg) of BI 44370 BS Solution in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Phase I)||Boehringer Ingelheim||Completed|September 2008|||November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|23|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02215031||38794|
NCT02208271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK003-14014|A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty|A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|A convenience sample of a total of 100 hip patients will be enrolled at orthopedic        clinics.|March 2016|March 23, 2016|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02208271||39310|
NCT02207374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4091|A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes|Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy|SUSTAIN™|Novo Nordisk A/S|No|Completed|August 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|601|||Both|20 Years|N/A|No|||February 2016|February 25, 2016|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207374||39379|
NCT02207673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44527.041.13|A New Method for Delineation of Epileptic Brian Tissue During Epilepsy Surgery (The HFO Study)|Intra-operative Detection and Localisation of High Frequency Oscillations in the ECoG to Guide Epilepsy Surgery||UMC Utrecht|Yes|Recruiting|November 2014|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|78|||Both|N/A|N/A|No|||July 2015|July 24, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207673||39356|
NCT02208531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13099|Transition to Scale of Nutrition and Psychosocial Stimulation Program for Malnourished Children|Transition to Scale of an Integrated Program of Nutritional Care and Psychosocial Stimulation to Improve Malnourished Children's Development in Bangladesh|TTS Bangladesh|International Centre for Diarrhoeal Disease Research, Bangladesh|No|Recruiting|February 2014|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|6400|||Both|6 Months|24 Months|No|||March 2016|March 24, 2016|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02208531||39290|
NCT02208011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L8608-W13010|A Comparison of Rapid Immunoassays for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassays for the Detection of Ruptured Membranes||Louisiana State University, Baton Rouge||Recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant woman presenting to Woman's Hospital, LSU Baton Rouge Clinic with ruptured        membranes.|September 2014|April 16, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208011||39330|
NCT02208024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCI-GI-002|Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body|Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body||University of Cincinnati|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2016|January 4, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02208024||39329|
NCT02208284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7871001|A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06427878 Co-administered With Meal In Healthy Adult Subjects||Pfizer|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02208284||39309|
NCT02208297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|843|Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|322|||Both|18 Years|N/A|No|||March 2015|August 4, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208297||39308|
NCT02233816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-Q13VLP-007|Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults|Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults||Medicago|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233816||37349|
NCT02227927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-Domperidone|Treatment Use of Domperidone for Gastroparesis|Treatment Use of Domperidone for Gastroparesis||The Cleveland Clinic||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Years|N/A||||August 2015|August 15, 2015|August 25, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02227927||37802|
NCT02234349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.768|Bile Acids and Incretins in Pancreas Kidney Transplant Patients|Impact of Duodena-pancreatic Transplantation on Bile Acids and Incretins Metabolism.|ITABI|Hospices Civils de Lyon|No|Recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|May 6, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234349||37308|
NCT02228785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC1C|A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer|Study of the Safety and Tolerance of Three Doses of G17DT in Patients With Metastatic Colorectal Cancer.|CC1C|Cancer Advances Inc.|Yes|Terminated|May 1994|||October 1994|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Male|18 Years|N/A|No|||August 2014|August 28, 2014|August 27, 2014|No|Yes|Poor local tolerance to injection.|No||https://clinicaltrials.gov/show/NCT02228785||37736|
NCT02224079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180.3|Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers|Safety, Tolerability and Preliminary Pharmacokinetics of Single Rising Doses of 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg, 125 mg and 150 mg BIIB 722 CL (Calculated as 'Free Base') and HPβCD Given as Intravenous Infusion Over 30 Minutes to Young Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.||Boehringer Ingelheim||Completed|April 2002|||June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|100|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02224079||38098|
NCT02232802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA/14/2|Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.|Comparative, Randomized, Single-dose, 2-way Cross Over Bioavailability Study of Enoxaparin Sodium Chemi (80 mg/0.8mL) and Clexane® (80 mg/0.8mL) s.c. in Healthy Adult Subjects Under Fasting Conditions.||Chemi S.p.A.|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|January 14, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232802||37427|
NCT02229617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00862|Subcutaneous Testosterone Project|A Pilot Study of Subcutaneous vs. Intramuscular Testosterone for Gender Affirming Therapy|STP|University of British Columbia|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|19 Years|59 Years|No|||December 2015|December 2, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229617||37672|
NCT02233010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|postOPNGAL01|Usefulness of Neutrophil Gelatinase-associated Lipocalin(NGAL) to Confirm Acute Kidney Function Decrease of the Patients Who Had Non-cardiac Surgery|||Inje University||Completed|February 2014|||August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|43|||Both|18 Years|79 Years|No|Non-Probability Sample|43 patients who had non-cardiac surgery in Seoul Paik Hospital.|September 2014|September 5, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02233010||37411|
NCT02233023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.342|Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease|Matched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease||Boehringer Ingelheim||Completed|June 1998|||June 2000|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|705|||Both|N/A|N/A|No|||September 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02233023||37410|
NCT02235675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0109|Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study|Prospective, Multicenter Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-It Endovascular System™|TOBABTK|Intact Vascular|Yes|Active, not recruiting|December 2013|February 2017|Anticipated|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02235675||37206|
NCT02214121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5136C00007|A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease|Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease|HESTIA 1|AstraZeneca|No|Suspended|September 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|39|||Both|2 Years|18 Years|No|||November 2015|November 12, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214121||38863|
NCT02216162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-777|PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program|PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program Including a Regular Physical Training, a Medical and Nutritional Follow-up, on Adjuvant Hormonal Treatment Compliance in Breast Cancer Patients Over 70 Years.|PROACTIVE|Hospices Civils de Lyon|No|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|87|||Female|70 Years|N/A|No|||August 2014|August 12, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02216162||38707|
NCT02207153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-210|Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients|Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients|RACE|University Hospital, Basel, Switzerland|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|At the beginning and the end of the dialysis session, at the time of the monthly routine      blood tests additional venous blood samples will be collected. All draws will be performed      after a three day interdialytic interval. Until the time of en bloc analysis the aliquots      will be stored at -80°. All study data and blood samples will be stored for 10 years after      study termination, for the future assessment of novel cardiovascular biomarkers. The stored      blood samples will be anonymised and only labelled by a barcode. This barcode be      unambiguously linked to the study ID code for the individual patient. There will be no      direct link between the original participant details and the blood sample bar code.|Both|18 Years|N/A|No|Non-Probability Sample|The data of patients undergoing chronic hemodialysis and peritoneal dialysis will be        analysed overall (RACE-Dial) and separately in the two substudies, RACE-HD and RACE-PD.|March 2016|March 14, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02207153|1 Year|39396|
NCT02208544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUN 2014-6514|FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS)|Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study|EfFECTS|Radboud University|Yes|Recruiting|June 2015|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208544||39289|
NCT02207387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02074|Ambulosono Rasagiline Musical Walking Study|A Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's Disease||University of British Columbia||Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|60|||Both|19 Years|N/A|No|||March 2015|March 31, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02207387||39378|
NCT02207400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202193|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms||GlaxoSmithKline|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02207400||39377|
NCT02207686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-012-A|Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?|Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?||University of Copenhagen|No|Enrolling by invitation|September 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|Samples With DNA|Whole blood Tumor tissue (Paraffin embedded and fresh frozen)|Both|18 Years|N/A|No|Non-Probability Sample|vHL patients over 18 years of age who have had at least one vHL-related tumor removed, and        for whom a reference DNA sample (from blood or normal tissue) and tumor tissue        (paraffin-embedded or fresh frozen) can be obtained.|November 2015|November 12, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02207686||39355|
NCT02207699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3551003|Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers|Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers||Pfizer|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|June 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207699||39354|
NCT02230449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OocyteCompetenceSK001|Identifying Expression Markers of Cumulus Cells to Identify Oocyte Developmental Potential Through a Maturation Analysis|Identifying Markers of Oocyte Competence Through a Maturation Analysis||Memorial Sisli Hospital, Istanbul|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Cumulus cells from each oocyte of every enrolled patient will be collected and mRNA & miRNA      extraction will be performed.|Female|18 Years|39 Years|No|Non-Probability Sample|Infertile couples applying to the clinic for assisted reproductive technologies|September 2015|September 24, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02230449||37608|
NCT02208310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFA-329225|Trial of High Dose Vitamin D in Patient's With Crohn's Disease|A Randomized Controlled Trial of High-Dose Vitamin D in Crohn's Disease|RODIN-CD|University of Michigan|No|Recruiting|April 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208310||39307|
NCT02230696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-14-018|Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis|||Perrigo Company|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1218|||Both|12 Years|65 Years|No|||July 2015|July 1, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230696||37589|
NCT02222636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sedation wei|The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children|The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children : A Single Center ,Randomized ,Double-blinded, Controlled Study.||Xijing Hospital|Yes|Not yet recruiting|September 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|6 Months|7 Years|No|||August 2014|August 19, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02222636||38209|
NCT02222883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-TR 1|Prevalence of BRCA in Patients With Ovarian Cancer|Prevalence of BRCA in Patients With Primary or Platinum Sensitive Recurrent Ovarian Cancer.|BRCA-Screening|AGO Research GmbH|No|Active, not recruiting|March 2015|December 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|530|||Female|18 Years|N/A|No|Probability Sample|500 consecutive patients (up to 250 patients with primary diagnosis and up to 250 patients        with platinum-sensitive recurrence of ovarian cancer.|August 2015|February 16, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02222883||38190|
NCT02232230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21C-2013-02|A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T|A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T||21st Century Oncology|Yes|Recruiting|June 2014|||June 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Male|18 Years|N/A|No|Non-Probability Sample|Men with castrate refractory metastatic prostate cancer (mCRPC).|July 2015|July 15, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02232230||37471|
NCT02232243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-MULTI-14-MCC|HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors|A Pilot Study to Determine the Biological Effects of Hydroxychloroquine on PAR-4 Levels in Patients With Resectable Solid Tumors||University of Kentucky|Yes|Not yet recruiting|September 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||April 2015|June 12, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232243||37470|
NCT02223195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC 2|Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis|Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis||Folktandvården Stockholms län AB|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Saliva sampels|Both|7 Years|14 Years|No|Non-Probability Sample|Group 1: 40 consecutive patients with active JIA, as diagnosed by the Department of        Pediatric Rheumatology, Astrid Lindgrens Barnsjukhus, Karolinska University Hospital will        be included.        Group 2: 40 healthy children, age-and sex-matched.|August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223195||38166|
NCT02232529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN-101C02|Pharmacokinetic Study of MIN-101 in Healthy Subjects|A Two-Part Study Designed to Evaluate the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites Following Single and Multiple Dose Modified Release Prototype Formulation Administration in Healthy Cytochrome P450 2D6 Extensive Metabolizer Male and Female Subjects, and to Evaluate the Relationship Between the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites and Cardiovascular Parameters.||Minerva Neurosciences|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232529||37448|
NCT02232542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208.1|Tolerability and Safety of Duloxetine BID in Healthy Female Subjects|Tolerability and Safety of 40 mg and 100 mg Duloxetine BID Given Over 7 Days in Healthy Female Subjects. A Randomised, Placebo-controlled Double-blind Trial.||Boehringer Ingelheim||Completed|June 2003|||August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|32|||Female|40 Years|N/A|Accepts Healthy Volunteers|||August 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02232542||37447|
NCT02229045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-FU|Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer|Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer||Sun Yat-sen University|No|Recruiting|November 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|No|||August 2014|August 27, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02229045||37716|
NCT02229058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-SG|Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer|Phase II Study of Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer||Sun Yat-sen University|No|Recruiting|November 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||August 2014|August 27, 2014|March 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02229058||37715|
NCT02235246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0601|The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study|||Yonsei University|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|40 Years|80 Years|No|||May 2015|May 8, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235246||37239|
NCT02235363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thread Lift|Thread Lift by Use of Retaining Ligaments|Thread Lift by Use of Retaining Ligaments With V-lock Barbed Sutures|TL|Winners Clinic|No|Enrolling by invitation|January 2012|January 2016|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|29 Years|61 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02235363||37230|
NCT02232893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100P2T3|Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy|A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy|TU100P2T3|Tsumura USA|Yes|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232893||37420|
NCT02235688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P1-MTD-03|Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors|An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors||CytRx|No|Recruiting|August 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|15 Years|80 Years|No|||August 2014|October 31, 2014|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235688||37205|
NCT02235701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P1/2-STS-03|Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma|An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma||CytRx|No|Recruiting|August 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|15 Years|80 Years|No|||July 2014|September 8, 2014|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235701||37204|
NCT02214394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121475-00087006|Detection of Propofol in Exhaled Breath|Propofol in Exhaled Breath: Real-time Detection by Surface Acoustic Wave Sensors.||Xhale Assurance|No|Not yet recruiting|August 2014|||October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02214394||38843|
NCT02214407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-DAC-CMML|Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML|A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)|GFM-DAC-CMML|Groupe Francophone des Myelodysplasies|Yes|Recruiting|October 2014|August 2018|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02214407||38842|
NCT02216942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUSP2408|Endodontic Treatment of Necrotic Primary Teeth With Guedes Pinto Paste: A Randomized Clinical Trial|Endodontic Treatment of Primary Teeth With Guedes Pinto Paste: A Randomized Clinical Trial||University of Sao Paulo||Completed|January 2015|||July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|August 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02216942||38647|
NCT02215863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUPCV13|Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years|Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years||Korea University Guro Hospital|Yes|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1195|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02215863||38730|
NCT02215876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS1405|Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer|A Phase II (Single Center) Study of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2014|March 2020|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|21 Years|N/A|No|||May 2015|May 20, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02215876||38729|
NCT02229604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ0708081|Electroacupuncture for Diminished Ovarian Reserve|Electroacupuncture for Diminished Ovarian Reserve—a Cohort Study||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|40 Years|No|||November 2015|February 10, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229604||37673|
NCT02207712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPX-2014-004|Noctura400 Treatment for Diabetic Retinopathy (CANDLE)|Noctura400 Treatment for Diabetic Retinopathy: Pilot Study to Demonstrate and Evaluate the Care Pathway for NHS Adoption|CANDLE|PolyPhotonix Medical|Yes|Recruiting|November 2014|June 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|99 Years|No|||January 2016|January 21, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02207712||39353|
NCT02233452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Methadone plus ketamine|Methadone and Ketamine for Neuropathic Pain Treatment|Management of Neuropathic Chronic Pain With Methadone Combined With Ketamine: Randomized, Double Blind, Active-controlled Clinical Trial||Universidade Federal de Santa Maria|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|22 Years|77 Years|No|||September 2014|September 5, 2014|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233452||37377|
NCT02233465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-021M|Treating Parastomal Hernia With a Mesh|Mesh-repair With Inraperitoneal On-lay Mesh (IPOM) for Parastomal Hernia||Norrbottens Lans Landsting|No|Completed|January 2008|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02233465||37376|
NCT02230709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/2012|Immediate Effects of Dry Needling and Tens in Chronic Neck Pain|IMMEDIATE EFFECTS OF DRY NEEDLING VERSUS DRY NEEDLING AND TENS ON PAIN IN PATIENTS WITH CHRONIC MIOFASCIAL NECK PAIN||Universidad Rey Juan Carlos|No|Completed|November 2012|||November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|48 Years|No|||August 2014|September 2, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230709||37588|
NCT02230956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-145|BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis|||Allergan|No|Active, not recruiting|October 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|176|||Both|40 Years|75 Years|No|||October 2015|October 1, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230956||37569|
NCT02227394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7200K02|Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients|A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Z7200 and Symbicort® Turbohaler on Functional Respiratory Imaging Parameters in Asthmatic Patients.||Zambon SpA|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227394||37843|
NCT02227680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32796|Massage Therapy Versus Music Therapy Pilot Study|Massage Therapy vs. Music Therapy vs. Usual Care in an Inpatient Setting: A Pilot Study||Boston Medical Center|No|Completed|July 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|90|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02227680||37821|
NCT02234960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29444|Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)|TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)||Hoffmann-La Roche||Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with a diagnosis of moderate to severe RA who are inadequate responders to        DMARDs, or participants who are intolerant to DMARDs, in a routine clinical practice        setting in Poland.|March 2016|March 1, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234960||37261|
NCT02234973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000031372|Transformation of Indigenous Primary Healthcare Delivery|Transformation of Indigenous Primary Healthcare Delivery (FORGE AHEAD): Community-driven Innovations and Strategic Scale-up Toolkits|FORGE AHEAD|Lawson Health Research Institute||Recruiting|September 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|434|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Indigenous community and clinic team members|August 2015|August 31, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02234973|3 Years|37260|
NCT02228252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-Premeal2|The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome.|Whey Protein, Postprandial Lipemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipiemia in Subjects With the Metabolic Syndrome and Type 2 Diabetes||Aarhus University Hospital|Yes|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|16|||Both|18 Years|75 Years|No|||August 2014|May 4, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228252||37777|
NCT02228512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140176|Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas|Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228512||37757|
NCT02228525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005|Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes|A Phase II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes||Memorial Sloan Kettering Cancer Center||Recruiting|August 2014|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228525||37756|
NCT02232633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-205b|A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer||Boston Biomedical, Inc|No|Recruiting|February 2015|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232633||37440|
NCT02232646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-205a|A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies||Boston Biomedical, Inc|No|Not yet recruiting|July 2016|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232646||37439|
NCT02232711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDY-014162|Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting|Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting||BioFire Diagnostics, LLC|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1082|Samples With DNA|Nasopharyngeal swab (NPS) specimens|Both|N/A|N/A|No|Non-Probability Sample|Individuals with signs and/or symptoms of respiratory infections|July 2015|July 23, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02232711||37434|
NCT02224937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003023-10|MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.|MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.||University Hospital Koge|Yes|Completed|December 2013|||February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224937||38032|
NCT02235506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apsj0901|A Comparison of Epidural Block With Adding Sciatic Block to Continuous Femoral Block in Total Knee Arthroplasty|A Comparison of Epidural Analgesia With Adding Sciatic Nerve Block to Continuous Femoral Nerve Block for Post-operative Pain Management Following Total Knee Arthroplasty||Yeungnam University College of Medicine|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|90 Years|No|||July 2015|July 14, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02235506||37219|
NCT02235519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI/12/404B/4/85|Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients|A Randomized, Open Label Study to Evaluate the Pleiotropic Effects of Azilsartan Medoxomil 40 and 80 mg for 12 Weeks Over Metabolic Markers in Patients With Hypertension, Obesity or Type 2 Diabetes Mellitus||Hospital General de México Dr. Eduardo Liceaga|Yes|Recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2014|March 27, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235519||37218|
NCT02225496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0925|Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma|A Phase II Study of Transoral Robotic Surgery With Adjuvant Therapy for Surgically Resectable HPV-positive Oropharyngeal Cancer||M.D. Anderson Cancer Center|No|Recruiting|September 2014|||September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225496||37989|
NCT02225509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00971-46|Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology|Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis|CITHY|Diaxonhit|No|Recruiting|October 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02225509||37988|
NCT02215603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProlongedSitting|Effects of Disrupting Prolonged Sitting With Different Physical Activity Protocols on Metabolic Risk Factors in Sedentary Adults|||Rigshospitalet, Denmark||Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|10|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02215603||38750|
NCT02208596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140729|The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial|||Third Affiliated Hospital of Zhengzhou University|Yes|Not yet recruiting|September 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|35 Years|No|||August 2014|August 3, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208596||39285|
NCT02216435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2965|Using Parkinson's Disease to Study the Role of the Substantia Nigra Pars Reticulata|Using Parkinson's Disease to Study the Role of the Substantia Nigra Pars Reticulata in Movement Initiation and Perception||University of Colorado, Denver|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Parkinson's disease who are candidates for Deep Brain Stimulation surgery.|November 2015|November 25, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02216435||38686|
NCT02229305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEPs Phase III|Maine Implementation Study - Phase III|Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project in Maine - Phase III||Harvard University|Yes|Completed|December 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|235|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229305||37696|
NCT02229318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-FRV-012014-01|A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.|A Taste and Acceptance Study of FruitiVits, for Use in the Dietary Management of Young Children Requiring Very Restrictive Diets Such as the Ketogenic Diet.||Vitaflo International, Ltd|No|Enrolling by invitation|September 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|4 Years|8 Years|No|||August 2014|August 28, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229318||37695|
NCT02229331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3DMKFM_haemo1|Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.|Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.|3DMKFM|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Male|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children with haemophilia|August 2014|August 28, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229331||37694|
NCT02233127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045918|Birth Cohort in Rahimyar Khan, Pakistan|A Longitudinal Birth Cohort Study in Rahimyar Khan, Pakistan||The Hospital for Sick Children|No|Recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|1 Year|No|Probability Sample|This study will be conducted in Rahimyar Khan (RYK) in Punjab Province, Pakistan and        follows a longitudinal birth cohort design that will be conducted alongside a        community-based, cluster randomized intervention trial in RYK (NCT02130856). In the        concurrent intervention trial, approximately 6000 pregnant women and their unborn babies        will be enrolled to participate in either the control or intervention arm of the trial;        approximately half of the women will be enrolled to the control arm and half will be        enrolled to the intervention arm. At the time of enrolment, women in the control arm of        the trial will also be asked to participate in the birth cohort study.|May 2015|May 20, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02233127||37402|
NCT02230163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM-PAP-2014/39|Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins|Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins|CHIKIVIG-01|Centre Hospitalier Universitaire de Pointe-a-Pitre|Yes|Recruiting|September 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|72 Hours|No|||August 2014|October 31, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230163||37630|
NCT02230176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004032-30|Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Carcinoma: First Randomized Phase II|Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Carcinoma: First Randomized Phase II.|OCCLURANDOM|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|February 2015|October 2023|Anticipated|October 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02230176||37629|
NCT02236065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBnG-CSF|Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders|A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders||Bundang CHA Hospital|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|75 Years|No|||September 2014|September 8, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236065||37176|
NCT02236078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-6435|Brief Bactericidal Activity of Anti-Tuberculosis Drugs|Brief Bactericidal Activity of Anti-Tuberculosis Drugs in Drug-Resistant Tuberculosis|BBA|Centers for Disease Control and Prevention|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|150|||Both|8 Years|N/A|No|||July 2015|July 28, 2015|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236078||37175|
NCT02233647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BED (IN) 29|Phendimetrazine and Cocaine|Safety and Tolerability of Cocaine During Phendimetrazine Maintenance||University of Kentucky|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02233647||37362|
NCT02232503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DSK01|Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia|DIARET SK - Prevalence of Diabetic Retinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in Slovakia|DIARET SK|Novartis Slovakia, s.r.o.|No|Not yet recruiting|September 2014|September 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|For the purpose of DNA isolation prior to genetic analysis two samples of peripheral blood      will be taken. Tubes with sampled material will be stored under temperature of 2 - 8°C and      in the least possible time delivered to the laboratory where DNA will be isolated. Of all      the samples delivered to the laboratory, DNA will be extracted using the automated isolation      method. From the second sample related to the genetic analysis also the plasma will be      obtained and stored at -20°C. The DNA sample is then divided into two aliquot parts which      will be stored separately for future analysis in order to decrease the risk of their      impairment. DNA isolated from cells of biological material will be properly stored prior to      further analysis. DNA will be archived by its freezing to -80°C, a temperature in which the      characteristics are maintained for several decades.|Both|18 Years|N/A|No|Probability Sample|Total expected number of patients included in this survey is 5000. With the objective to        guarantee non-biased patient selection sample, each screening day the pre-specified        sequence of patients (5th, 10th, 15th...) will selected. If the pre-selected patient does        not come for visit or does not fulfill the inclusion criteria or does not want to sign the        informed consent the next patient is asked to participate in the research. We plan to        enroll 4500 patients using this non-biased method.        The weakness of the non-biased random selection is that the less frequent groups of        patients will not have enough subjects for the proper statistical analysis. To correct for        this effect pool of 500 patients is reserved for special subgroups. Pre-defined subgroups        are:          1. patients with DM duration more 20 years          2. patients with DM duration less than 5 years already with DR in history All patients             from these subgroups will be asked to participate in this project regardless of the             pre-specified order.|September 2014|September 9, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232503||37450|
NCT02235025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAL-1|Asymptomatic Versus Symptomatic Mild COPD: Comparisons at Rest and at Exercise|Ventilatory Constraints During Exercise in Asymptomatic Versus Symptomatic Patients With Mild COPD||Centre Hospitalier Universitaire de Besancon|Yes|Completed|September 2012|May 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|111|||Both|40 Years|N/A|Accepts Healthy Volunteers|||August 2014|September 5, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02235025||37256|
NCT02235038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00014678|Metabolic Fuels Study|A Mechanistic Examination of Dietary Composition on Metabolic Fuels Availability||Children's Hospital Boston|No|Active, not recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235038||37255|
NCT02235129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6MWTBH|Six Minute Walking Test and Breath-holding|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|September 2014|December 2014|Anticipated|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|50|||Both|30 Years|N/A|No|||September 2014|September 8, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02235129||37248|
NCT02235142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/01|Prostatic Cancer Versus Androgen Deficiency|Localised Cancer of Prostate and Androgen Deficiency.|AndroCan|Hopital Foch||Recruiting||||June 2016|Anticipated|N/A|Interventional|N/A|||||||Male|18 Years|N/A|No|||September 2014|September 5, 2014|September 5, 2014||||No||https://clinicaltrials.gov/show/NCT02235142||37247|
NCT02235233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3362|Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin|Clinical Study to Investigate the Effect of NASH (Non-alcoholic Steatohepatitis) on the Disposition of 99mTechnetium(Tc)-Mebrofenin in Healthy Subjects Compared to Patients With NASH.||University of North Carolina, Chapel Hill|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235233||37240|
NCT02229630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130915|Diffusion-weighted Cerebral MRI and Intra Uterine Growth Restriction.|Prognostic Value of Diffusion-weighted Cerebral MRI in Prenatal Evaluation of Foetuses With Intra Uterine Growth Restriction.|REDIFF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|January 2020|Anticipated|August 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|56|||Female|18 Years|N/A|No|||November 2015|November 19, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02229630||37671|
NCT02225236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP00006613|Improving Self-regulation & School Readiness in Preschoolers|Improving Self-regulation & School Readiness in Preschoolers||Children's Hospital Medical Center, Cincinnati|No|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|144|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225236||38009|
NCT02230202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1209|Endothelial Microparticles: A Novel Marker of Vascular Dysfunction|Endothelial Microparticles: A Novel Marker of Vascular Dysfunction||University of Colorado, Denver|No|Completed|September 2014|March 2016|Actual|March 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|90|Samples Without DNA|plasma and urine biospecimens to be retained.|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|90 volunteers from the Anschutz Medical Campus|March 2016|March 10, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02230202|1 Day|37627|
NCT02215889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID 2014|Partial Liver Segment 2/3 Transplantation Study|A Phase I/II Clinical Trial to Evaluate the Benefit and Efficacy of Liver Resection And Partial Liver Segment 2/3 Transplantation With Delayed Total Hepatectomy as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma||Oslo University Hospital|No|Recruiting|June 2014|June 2026|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02215889||38728|
NCT02216461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219.3|Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses (7.5 to 60 mg Daily for 12 Days) of BIBW 2948 BS Inhalation Powder, Hard Capsule for HandiHaler® in Healthy Male Volunteers (Randomised, Double-blind Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|January 2006|||April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|36|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|August 12, 2014||||No||https://clinicaltrials.gov/show/NCT02216461||38684|
NCT02209116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAHRC-EM 14046|Assessing QbTest Utility in ADHD: A Randomised Controlled Trial|A RCT Comparing the Effects of Providing Clinicians and Patients With the Results of an Objective Measure of Activity and Attention (QbTest) Versus Usual Care on Diagnostic and Treatment Decision Making in Children and Young People With ADHD|AQUA2|University of Nottingham|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|178|||Both|6 Years|17 Years|No|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209116||39245|
NCT02217202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho 1302|Study of AQUACEL™ Ag Surgical Cover Dressing Following Total Knee Replacement|Prospective Cohort Study of the AQUACEL™ Ag SURGICAL Cover Dressing in Total Knee Replacement Surgery||Golden Jubilee National Hospital|No|Withdrawn|April 2014|September 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Total knee replacement or revision knee replacement|August 2014|August 13, 2014|August 12, 2014||No|Funding withdrawn before ethical approval granted|No||https://clinicaltrials.gov/show/NCT02217202||38627|
NCT02208817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14021|The Paediatric Refill Study (PRefill)|Development of a Novel Paediatric Continuous Early Warning Monitor for the Children at Risk of Respiratory and Cardiovascular Collapse - The Paediatric Refill Study (PRefill)|PRefill|University of Nottingham|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|135|||Both|1 Month|15 Years|No|Non-Probability Sample|Children will be recruited in The Queens Medical Centre, Nottingham University Hospitals        NHS Trust, a teaching hospital, which has a paediatric intensive care unit (PICU).|August 2015|August 18, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02208817||39268|
NCT02232997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC20140818|The optImal Hydration With sodiuM chloridE in High Risk Patients Undergoing Coronary Angiography|The optImal Hydration With sodiuM chloridE in High Risk Patients Undergoing Coronary Angiography, REduction of riSk of Contrast-Induced Nephropathy After carDiac Catheterization 2 (TIME RESCIND 2) Study|TIME|Guangdong General Hospital|Yes|Recruiting|April 2015|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1400|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02232997||37412|
NCT02235649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1791|Exploring the Feasibility of Social Skills Training in People With Psychosis|||Institute of Psychiatry, London|Yes|Recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||April 2015|April 8, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02235649||37208|
NCT02235662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-128|Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone|Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone||CONRAD|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02235662||37207|
NCT02233283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43/13|Effect of Modifications of Nutritional Intake Upon Reproductive Hormones in Normal Women|Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers|Polynut|Centre Hospitalier Universitaire Vaudois|No|Completed|January 2014|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|9|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02233283||37390|
NCT02233296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-104|Food-Effect Study in Healthy Subjects|A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects||CoLucid Pharmaceuticals|No|Completed|January 2015|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02233296||37389|
NCT02226809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEO-BNM-2014-01|Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit|Incidence of Residual Neuromuscular Block in Adult Patients in the Postanesthesia Care Unit. An Observational Cross-sectional Study of a Multicenter Cohort. The Residual Curarization in Spain Study (ReCuSS).|ReCuSS|University of Valencia|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|763|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical patients under general anesthesia|August 2014|August 26, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02226809||37888|
NCT02236286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8979|Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact|Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact||Oregon Health and Science University|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|20|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02236286||37159|
NCT02231892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914186|Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study|Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02231892||37497|
NCT02223780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projet 13-102|Early Palliative Care for Patients With Severe and Very Severe COPD: a Randomised Study|Can Early Introduction of Specialized Palliative Care Limit Intensive Care, Emergency and Hospital Admissions in Patients With Severe and Very Severe COPD? A Randomized Study||University Hospital, Geneva|Yes|Recruiting|September 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02223780||38121|
NCT02223793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1660|Vascular Lifestyle-Intervention and Screening in Pharmacy|Effects of Cardiovascular Risk Screening in Pharmacies: A Randomized Study|VISA|University of Oslo|No|Active, not recruiting|September 2014|February 2022|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Actual|583|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223793||38120|
NCT02224092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amway-2010-RU1|Effects of Supplementation in Healthy Russian Population|Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Selected Nutrients Blood Level and Heart Health Risk Factors in Russian Population||Access Business Group|No|Completed|October 2010|September 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02224092||38097|
NCT02224352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF-1417104|VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning|VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning||Edward Hines Jr. VA Hospital|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224352||38077|
NCT02224612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-044|A Comparative Evaluation of the Performance and Fit of Pediatric Face Masks|A Comparative Evaluation of the Performance and Fit of Pediatric Face Masks||Medline Industries|No|Completed|January 2014|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|96|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||January 2014|August 21, 2014|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02224612||38057|
NCT02224625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-051|Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth|Randomized and Observer-blinded Study to Evaluate the Cumulative Irritation and Contact Sensitizing Potential of One Finished Test Product||Medline Industries|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|222|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 16, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224625||38056|
NCT02224638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14-028|Wound Management for Sacral Pressure Ulcers With Necrotic Tissue|Evaluation of Wound Management for Sacral Pressure Ulcers With Necrotic Tissue||Medline Industries|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||August 2015|August 19, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224638||38055|
NCT02233153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047180|Elder-friendly Approaches to the Surgical Environment (EASE) Study|Elder-friendly Approaches to the Surgical Environment - Implementation of an Elder Friendly Surgical Unit|EASE|University of Alberta|No|Enrolling by invitation|April 2014|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|560|||Both|65 Years|N/A|No|Non-Probability Sample|All patients > 65 years old admitted and received acute abdominal surgery|December 2015|December 14, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02233153||37400|
NCT02229955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_TSPR_302|Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease|HL_TSPR_302|Hanlim Pharm. Co., Ltd.|No|Completed|December 2013|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|21 Years|N/A|No|||August 2014|September 2, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02229955||37646|
NCT02233491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBirminghamNHS|Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients|A Prospective, Randomised Controlled Trial Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients|CAVIAR|University Hospital Birmingham NHS Foundation Trust|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02233491||37374|
NCT02233504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 40413|Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)|Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2014|||August 2016|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233504||37373|
NCT02208323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1406M51386|Advancement of Modified Bubble CPAP|Advancement of Modified Bubble CPAP for the Use in Children in Low Resource Settings: A Study of Safety||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|1 Month|5 Years|No|||November 2015|November 30, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208323||39306|
NCT02209129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201421047|Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women|3D Digital Breast Tumorsynthesis Versus 2D Digital Mammography in the Clinical Evaluation of Women at High Risk for Breast Cancer||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|40 Years|90 Years|No|Non-Probability Sample|women with an increased risk for breast cancer > 17% according to the IBIS calculation,        and also defined by the Multidisciplinary Breast centre UZ Leuven, Belgium|August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209129||39244|
NCT02209142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-19|Blood Biomarkers in Major Depression|Blood Biomarkers in Major Depression||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2012|April 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|275|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209142||39243|
NCT02209428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2014-182|A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas|A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas||Huashan Hospital|Yes|Recruiting|June 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||March 2015|March 21, 2015|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02209428||39221|
NCT02235493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-HPP-502s|Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09|A Single-Center, Non-interventional Substudy of ALX-HPP-502 to Assess Functional Natural History Data of Patients With Juvenile Historical Controls in ENB-006-09||Alexion Pharma GmbH|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|6|||Both|5 Years|N/A|No|Non-Probability Sample|Patient has juvenile-onset HPP and was selected as a historical-control for Study        ENB-006-09.|October 2015|October 22, 2015|September 5, 2014||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT02235493||37220|
NCT02226315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-109|Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies|A Retrospective Analysis of Fetal Outcome Compared to Massively Parallel Sequencing Test Results Obtained From Multiple Gestation Pregnancies at Increased Risk for Fetal Chromosomal Aneuploidy||Sequenom, Inc.|No|Terminated|August 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|Samples With DNA|Some subjects will be asked to provide a buccal cell sample for sequencing.|Female|18 Years|N/A|No|Non-Probability Sample|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have        passed their Estimated Date of Delivery (EDD).|September 2015|September 15, 2015|August 20, 2014||No|Slow enrollment of eligible subjects|No||https://clinicaltrials.gov/show/NCT02226315||37926|
NCT02226328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-004358-12|Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl-sedation for Flexible Bronchoscopy: A Randomized, Single Blind, Controlled Study of Satisfaction and Safety.|||Copenhagen University Hospital at Herlev|Yes|Recruiting|November 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02226328||37925|
NCT02235844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 16026 DMD Single Patient|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)|Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)||Allergy and Asthma Consultants, Wichita, Kansas|No|Enrolling by invitation|September 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|28 Years|31 Years|No|||September 2014|September 8, 2014|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235844||37193|
NCT02235857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPA-FSGS-001|Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children|Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System||Kaneka Pharma America LLC|No|Recruiting|March 2015|October 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|21 Years|No|||February 2016|February 24, 2016|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02235857||37192|
NCT02235870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1100-0013|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||December 15, 2015|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235870||37191|
NCT02231554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3297/2014|Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial|Effectiveness of Feldenkrais Method Versus a Back School Program in Patients With Chronic Low Back Pain: A Randomized Controlled Trial||University of Roma La Sapienza|Yes|Completed|September 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|80 Years|No|||September 2014|April 30, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02231554||37523|
NCT02231567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3298/2014|Neurocognitive Rehabilitation After Hip Replacement|Effectiveness of Neurocognitive Rehabilitation in Pain Management and Functional Recovery After Hip Replacement: Randomized Controlled Trial||University of Roma La Sapienza|Yes|Suspended|September 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|50 Years|80 Years|No|||January 2016|January 3, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02231567||37522|
NCT02227095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL087923|Exercise & Overweight Children's Cognition|Exercise & Overweight Children's Cognition|SMART|Georgia Regents University|No|Completed|May 2008|April 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|175|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02227095||37866|
NCT02227108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-CAT-8015-1036|A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma|A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin||MedImmune LLC|Yes|Terminated|August 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|6 Months|18 Years|No|||November 2015|November 18, 2015|August 21, 2014|No|Yes|Study terminated early because the required efficacy for study continuation was not met|No||https://clinicaltrials.gov/show/NCT02227108||37865|
NCT02234908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33047|Rewards for Tuberculosis Contact Screening|Rewards for Tuberculosis Contact Screening|RECON|Boston University|No|Recruiting|October 2014|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|620|||Both|N/A|N/A|No|||July 2015|July 20, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234908||37265|
NCT02228265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9259|Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide|Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer||OHSU Knight Cancer Institute|Yes|Recruiting|March 2013|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|65|Samples With DNA|Genomic DNA from individuals will be extracted from collected blood samples (germ line) and      tumor biopsies; sonicated to approximately 50 - 200 bp fragments; and used to make a library      for paired-end sequencing (Illumina) or for sequencing within the Oregon Health & Science      University (OHSU) CLIA laboratory (Ion Torrent sequencing). using established protocols.      We will use whole genome sequencing or Sanger sequencing of cell-free DNA (cfDNA) from blood      and DNA from the tumor biopsy specimens. This will enable us to identify molecular features      (mutations, including but not limited to the androgen receptor (AR), copy number      alterations, and gene fusions) that may predict resistance or early progression despite      enzalutamide treatment.|Male|N/A|N/A|No|Non-Probability Sample|This is a prospective, single-arm multi-center biomarker study to identify molecular        predictive markers for PSA response (</>=50% decline) at 12 weeks vs. baseline in man with        metastatic CRPC. We expect to enroll 65 patients over the period of three years, with an        approximate of 21 patients per year. All subjects will be treated with MDV3100 and        followed on protocol until disease progression or intolerance.|February 2016|February 11, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228265||37776|
NCT02232724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAM_PROSTAGE2|Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer|Choline PET/CT vs. Dual Time Point FDG PET/CT. Better Detection of Bone and Lymph Node Metastasis in Prostate Cancer Patients, PROSTAGE II||Odense University Hospital|Yes|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|N/A|N/A|No|||May 2015|May 4, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232724||37433|
NCT02228538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003|Total Knee Arthroplasty Functional Outcomes Study Research Design|Total Knee Arthroplasty Functional Outcomes Study Research Design||ConforMIS, Inc.|Yes|Active, not recruiting|October 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Total knee arthroplasty patients|August 2014|April 9, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02228538||37755|
NCT02229071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDH1B|Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma|Donafenib in Advanced Hepatocellular Carcinoma: A Randomized Phase 1B Study of Safety, Efficacy, and Pharmacokinetics||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|No|Completed|April 2014|January 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|70 Years|No|||March 2015|January 3, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229071||37714|
NCT02229357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPO Avian Flu Vaccine-Boost|Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine|Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study||Mahidol University|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229357||37692|
NCT02209285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRCT- 06669|Community Stroke Intervention Study|A Community Navigation and Rehabilitation Intervention for Stroke Survivors With Multiple Chronic Conditions||McMaster University|No|Not yet recruiting|October 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|65 Years|N/A|No|||September 2015|September 9, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02209285||39232|
NCT02233322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRON/ADHR|Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.|Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot||Indiana University|Yes|Recruiting|August 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|25 Months|N/A|No|||February 2016|February 22, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02233322||37387|
NCT02205437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXANT|Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia|Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia: Evidence From Pharmacogenetics in the Light of Personalized Medicine|GEXANT|Fundación Marques de Valdecilla|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Anticipated|200|Samples With DNA|Whole blood, RNA|Both|15 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the        University Hospital Marqués de Valdecilla (Santander - Cantabria).|August 2015|August 7, 2015|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205437||39528|
NCT02205710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16-14-018|Cognitive Training in Aging|||Bruyere Research Institute||Not yet recruiting|July 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|90|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 30, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205710||39507|
NCT02208830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCQPC|Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program|Effects of Pulmonary Rehabilitation Associated With Respiratory Therapy vs Physiotherapy in Physical Capacity, Peripheral Muscle Strength and Quality of Life in Patients With Bronchiectasis: a Randomized Controlled Trial.|PCBCQ|University of Nove de Julho|Yes|Completed|January 2012|January 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT02208830||39267|
NCT02209155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-Verapamil-001|R-Verapamil for the Prophylaxis of Episodic Cluster Headache|A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache||Center Laboratories, Inc.|No|Active, not recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||August 2014|July 31, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209155||39242|
NCT02209168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405-MAD-020-JG|Differences in Ovarian Reserve Markers and Vitamin D Between Infertile Indian, Arabian and Caucasian Population|Differences in Ovarian Reserve Markers, Vitamin D Serum Levels and Reproductive Outcomes Between Infertile Indian, Arabian and Caucasian Population||IVI Madrid|Yes|Recruiting|November 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|600|Samples Without DNA|Vitamine D serum levels.|Female|21 Years|43 Years|Accepts Healthy Volunteers|Probability Sample|WOMEN BETWEEN 21-43 YEARS FIRST OR SECOND IN VITRO FERTILIZATION TREATMENT DUE TO TUBAL,        MASCULINE OR PREVIOUS INTRAUTERINE INSEMINATION FAIL TREATMENT|February 2016|February 23, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02209168||39241|
NCT02205073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29412|A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism|A RANDOMIZED, DOUBLE-BLIND, THREE PERIOD CROSS-OVER, PLACEBO CONTROLLED, PROOF OF MECHANISM STUDY TO INVESTIGATE THE EFFECT OF RG7314 ON VASOPRESSIN (AVP) PATHWAY ACTIVATION IN HEALTHY MALE SUBJECTS||Hoffmann-La Roche||Recruiting|July 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02205073||39556|
NCT02205086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SimulConsult2|Empowering Physicians With Evidence-Based Decision Support for Pediatric Rheumatology|Empowering Physicians With Evidence-Based Decision Support for Pediatric Rheumatology|Rheumatology|SimulConsult, Inc.|No|Not yet recruiting|August 2014|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02205086||39555|
NCT02205099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKL15508C003|A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia|A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia||SK Life Science|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|60 Years|No|||August 2015|August 21, 2015|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02205099||39554|
NCT02226055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoECKDu1|An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka|An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka||University of Edinburgh|No|Not yet recruiting|September 2014|July 2017|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|350|Samples With DNA|Urine samples: up to 30ml Blood samples: up to 40ml - 2 x EDTA blood bottles + 2 x serum gel      Z bottles|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending clinics or admitted to hospital during Aug 2014 to Oct 2014 with CKDu        (Chronic kidney disease of unknown origin).        Subjects must be aged 18 to 85 with evidence of renal dysfunction and no other obvious        cause noted (see inclusion/exclusion criteria above).        Control groups will be sought for the measure of arterial stiffness: Sri Lankan CKD of        known cause, Sri Lankan healthy volunteers. Our controls will be age, sex and blood        pressure matched to the cases.|August 2014|August 26, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226055||37946|
NCT02230969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105MS401|Plegridy Observational Program|Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program|POP|Biogen|No|Recruiting|November 2014|November 2022|Anticipated|November 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in participants with relapsing forms of MS who are initiating        Plegridy as prescribed under routine clinical practice and participants who participated        in Study 105MS302 (NCT01332019) or Study 105MS303 (NCT01939002).|July 2015|September 10, 2015|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230969||37568|
NCT02230982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.192|Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis|Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis||Boehringer Ingelheim||Available||||||N/A|Expanded Access|N/A|||||||Both|40 Years|N/A|No|||January 2016|January 12, 2016|August 29, 2014||||No||https://clinicaltrials.gov/show/NCT02230982||37567|
NCT02226562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202196|Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|August 25, 2014|Yes|Yes||No|July 30, 2015|https://clinicaltrials.gov/show/NCT02226562||37907|
NCT02234362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001812|Vortioxetine for Menopausal Depression|Vortioxetine for Menopausal Depression and Associated Symptoms||Massachusetts General Hospital|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|40 Years|62 Years|No|||March 2016|March 16, 2016|September 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234362||37307|
NCT02234375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002535b|Use of Gadolinium in CT Pulmonary Angiography|Efficacy of Gadolinium Contrast in CT Pulmonary Angiography in Patients With Allergy to Iodine||Massachusetts General Hospital|No|Not yet recruiting|April 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|20 Years|N/A|No|||January 2015|January 28, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234375||37306|
NCT02234596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-094|Nintedanib in Patients With Advanced Esophagogastric Cancer|Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234596||37289|
NCT02234882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-048|Study on Pharmacokinetics|Effect of BMS-663068 on the Pharmacokinetics of Rosuvastatin||Bristol-Myers Squibb|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|September 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234882||37267|
NCT02227940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 248813|Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer|A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors||Roswell Park Cancer Institute|Yes|Recruiting|January 2015|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227940||37801|
NCT02227953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-04-025|A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease|A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 11) After Transcranial Direct Current Stimulation in Mild to Moderate Alzheimer's Disease||Samsung Medical Center|No|Recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|45 Years|80 Years|No|||August 2014|August 31, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227953||37800|
NCT02208180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1500|Heart Healthy Lenoir: Return of Results Study|Heart Healthy Lenoir: Return of Results Study|HHL|University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02208180||39317|
NCT02208193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00139-38|Alzheimer's Disease, Art and Garden|Alzheimer's Disease and Healing Gardens: Study of the Cognitive and Psycho-behavioral Effects of an Artistic Dimension|JAZ ART|Central Hospital, Nancy, France|No|Recruiting|July 2014|September 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02208193||39316|
NCT02208206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroPain CBF_01|Analysis of Markers in the Blood Correlated With Neuropathic Pain|Neuropathic Pain: Association Between Phenotype and Biomarkers||Charite University, Berlin, Germany|No|Recruiting|July 2014|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Whole blood, plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|Hospitals, primary care clinics, resident physicians|January 2016|January 14, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02208206||39315|
NCT02232815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-02|CELTIC Bifurcation Study|||European Cardiovascular Research Center||Recruiting|December 2014|November 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|No|Non-Probability Sample|Patients planed for culotte DES stenting|September 2015|September 15, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02232815||37426|
NCT02208466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001046|Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients|Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients||Spaulding Rehabilitation Hospital|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02208466||39295|
NCT02232906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCM-ND-CKD 2012|Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)|Pilot Open Label Study to Evaluate Intravenous Ferric Carboxymaltose (Ferinject ®) in Patients With CKD (Pre-dialysis) With Anemia Treated With Epo and Oral Iron in Buenos Aires, Argentina||Hospital Aleman|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02232906||37419|
NCT02233036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914088|Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease|Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|60|||Both|18 Years|26 Years|No|||January 2016|January 14, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02233036||37409|
NCT02205723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 140934|Smartphone-facilitated Asthma Control|Smartphone-facilitated Medication Notification for Asthma Control in Pediatric Patients (SNAPP) Pilot Study|SNAPP|Vanderbilt University|No|Not yet recruiting|July 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|4 Years|11 Years|No|||July 2014|July 30, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02205723||39506|
NCT02205203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-000288 - RCT|Youth Mayo Clinic Anxiety Coach Randomized Controlled Trial|Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - RCT||Mayo Clinic|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|70|||Both|7 Years|17 Years|No|||March 2016|March 15, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205203||39546|
NCT02206334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-BR001|Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer|A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases||NRG Oncology|Yes|Recruiting|August 2014|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206334||39459|
NCT02206347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209056RIC|The Effect of Prioritization of Attentional Allocation on Postural-suprapostural Tasking|The Effect of Prioritization of Attentional Allocation on Postural-suprapostural Tasking||National Taiwan University Hospital|No|Recruiting|March 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 31, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206347||39458|
NCT02208843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.217|Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy||Boehringer Ingelheim||Recruiting|October 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 4, 2014||||No||https://clinicaltrials.gov/show/NCT02208843||39266|
NCT02208856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175.1|Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (1, 4, 15, 50, 100, 200, 400, and 600 mg) Oral BIRB 796 BS in Healthy Human Subjects. A Placebo Controlled, Randomised Study, Double Blinded at Each Dose Level||Boehringer Ingelheim||Completed|September 1999|||December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 4, 2014||||No||https://clinicaltrials.gov/show/NCT02208856||39265|
NCT02205138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLOB-IF1|Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion|A Pilot Phase 2a, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Lumbar Spinal Fusion||Bone Therapeutics S.A|No|Recruiting|October 2014|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205138||39551|
NCT02205346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|October 2013|Urinary Leukotriene E4 Levels in Children With Obstructive Sleep Apnea|Urinary Leukotriene E4 Levels in Children With Obstructive Sleep Apnea||Eastern Virginia Medical School|No|Recruiting|February 2014|June 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|urine sample|Both|2 Years|16 Years|No|Probability Sample|Otolaryngology practice|August 2014|August 20, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205346||39535|
NCT02205112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-6|A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP|A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP||TaiGen Biotechnology Co., Ltd.||Active, not recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|603|||Both|18 Years|80 Years|No|||January 2016|January 10, 2016|July 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02205112||39553|
NCT02205125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/8/6.6(3797)|Cold Polypectomy Site Study|Prospective Characterization of the Mucosal Defect After Cold Snare Polypectomy||Western Sydney Local Health District|Yes|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|Samples Without DNA|All polypectomy specimens were submitted for histopathological assessment as per clinical      practice. The biopsy samples from the irregular areas were also submitted in the same      fashion. All specimens are stored as per current clinical practice.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing colonoscopy at a tertiary endoscopy unit.|July 2014|July 29, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02205125||39552|
NCT02230722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11892|Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support|Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support|OPTI|San Francisco Veterans Administration Medical Center|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02230722||37587|
NCT02233829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140187|Dopamine Rhythms in Health and Addiction|Dopamine Rhythms in Health and Addiction||National Institutes of Health Clinical Center (CC)||Suspended|September 2014|March 2020|Anticipated|March 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|112|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 24, 2015|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02233829||37348|
NCT02231255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.517|Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease|Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease||Boehringer Ingelheim||Completed|February 2002|||December 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1216|||Both|N/A|N/A|No|Non-Probability Sample|Idiopathic Parkinson's disease patients recruited at office-based neurologists,        psychiatrist or special neurology clinics|September 2014|September 16, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231255||37546|
NCT02231268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|533.2|Observational Study to Assess a 6-months Treatment With Gladem|Observational Study Via Internet to Assess a 6-months Treatment With GLADEM||Boehringer Ingelheim||Completed|September 2000|||January 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|546|||Both|18 Years|N/A|No||out-patients|August 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231268||37545|
NCT02223208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_PTCL13|Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study|Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study|FIL_PTCL13|Fondazione Italiana Linfomi ONLUS||Recruiting|September 2014|March 2023|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|65 Years|No|||August 2015|August 14, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223208||38165|
NCT02223221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIAI E2014-02|Effects of PGS in Infertile Female Patients With RPL|Effects of Preimplantation Genetic Screening for Aneuploidies in Infertile Female Patients With Recurrent Spontaneous Abortion History||ShangHai Ji Ai Genetics & IVF Institute|Yes|Recruiting|August 2014|April 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|48 Years|No|||March 2016|March 14, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223221||38164|
NCT02223468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microta.LT.14|Human Microbiota and Liver Transplant|Prospective Study To Characterize The Human Microbiota In Liver Transplantation And Its Impact On Early Outcome||Hospital Vall d'Hebron|Yes|Recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Stool samples Portal nodes Periphereal blood|Both|18 Years|68 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult liver transplant patients in Hospital Vall d´Hebron (Barcelona, Spain)|January 2016|January 2, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223468||38145|
NCT02223481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528.19|Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension|A Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension||Boehringer Ingelheim||Completed|May 1998|||September 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223481||38144|
NCT02232659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SynCardia 70cc TAH-t for DT|SynCardia 70cc TAH-t for Destination Therapy (DT)|SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)|RA-540|SynCardia Systems. Inc.|Yes|Recruiting|May 2015|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|19 Years|N/A|No|||January 2016|January 18, 2016|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232659||37438|
NCT02208999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011045|Follow-up of Post-spinal Implantable Neurostimulator PRECISION®|Two-years Follow-up of Post-spinal Implantable Neurostimulator PRECISION®|PRECISION|Cemka-Eval|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All implanted patients (primary implementation and reimplantation) with the        neurostimulator PRECISION ®, during the inclusion period (1 year).|January 2016|January 27, 2016|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208999||39254|
NCT02209012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0108A|Twelve Month Follow-Up of CP0108|Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)||DUSA Pharmaceuticals, Inc.|No|Active, not recruiting|August 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who were enrolled in the DUSA-CP0108 study, completed their assigned treatment        (ALA-PDT or vehicle + blue-light) and Visit 6.|July 2015|July 14, 2015|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209012||39253|
NCT02209025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46131.068.13/METC 13-3-065|Theobromine, Vascular Function and Intestinal apoA-I Production|The Effects of Short-term Theobromine Supplementation on Vascular Function and Intestinal apoA-I Production in Fasting and in the Postprandial State||Maastricht University Medical Center|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||August 2014|September 4, 2015|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02209025||39252|
NCT02208479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-13|Cardiac Surgery and Diaphragm Function|Diaphragmatic Dysfunction in Cardiac Surgery: Observational Study||University Hospital, Grenoble|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Non-Probability Sample|patient admitted in Intensive Care Unit (ICU) after planned cardiac surgery|September 2015|September 22, 2015|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02208479||39294|
NCT02209298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-02|CoreValve VIVA Study Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis.|Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis. A Prospective, Observational Post-market Study.||Medtronic Cardiovascular|Yes|Recruiting|November 2014|March 2019|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be screened from symptomatic high risk adult patients candidates for an        intervention on degenerative surgical aortic bioprosthesis.|February 2016|February 29, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02209298||39231|
NCT02208713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-007|Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)|Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy (FSHD), Phase I Clinical Trial||Royan Institute|Yes|Recruiting|May 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|50 Years|No|||November 2015|December 3, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208713||39276|
NCT02208973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2014-04|Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"|Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 "After Multiple Oral Doses" in Healthy Volunteers.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|May 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208973||39256|
NCT02208986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_01_2014|GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study|GnRHa Trigger in Asian Oocyte Donors Co-treated With a GnRH Antagonist - a Dose Finding Study||Vietnam National University|No|Completed|August 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Female|18 Years|35 Years|No|||May 2015|May 18, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02208986||39255|
NCT02205476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5301012|A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study|A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871||Pfizer|No|Terminated|December 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|57 Years|No|||December 2015|December 21, 2015|July 29, 2014|Yes|Yes|B5301001 study did not meet its predefined efficacy endpoints, the long term follow up study    B5301012 was terminated in 1/6/2015. No safety concerns identified.|No|December 21, 2015|https://clinicaltrials.gov/show/NCT02205476||39525|The study was prematurely terminated at the discretion of sponsor as study B5301001 did not meet its pre-defined efficacy endpoints for the dosing regimens evaluated.
NCT02206035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00023000|Phase II Open Label Trial Of Tacrolimus/Methotrexate And Tocilizumab For The Prevention Of Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Open Label Trial Of Tacrolimus/Methotrexate And Tocilizumab For The Prevention Of Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation||Medical College of Wisconsin||Recruiting|December 2014|September 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|75 Years|No|||August 2015|August 14, 2015|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206035||39482|
NCT02206048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0885|High-Resolution Microendoscopy (HRME) of Cervix|Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|21 Years|64 Years|No|||January 2016|January 12, 2016|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02206048||39481|
NCT02208869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSCRES0179|Russian Familial Hypercholesterolemia Registry|Prospective Russian Study Evaluating the Extent of Underdiagnosed and Undertreated of Familial Hypercholesterolaemia in the Population|RuFH|Russian Cardiology Research and Production Center|Yes|Recruiting|January 2014|December 2026|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|whole blood, serum, white cells, urine|Both|7 Years|80 Years|No|Non-Probability Sample|Russian cohort of individuals who have been tested in the offices of the "INVITRO"        Laboratory on the basis of advertising campaign for the purpose of total cholesterol level        measurement and determination of cardiovascular risk with the use of SCORE chart.|May 2015|May 12, 2015|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02208869|10 Years|39264|
NCT02205944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPCR-ID: 13-6763-AE|Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes|The Impact of Exercise on Vascular Remodeling, Arteriovenous Fistula Creation and Use in Patients With Chronic Kidney Disease: A Randomized Controlled Trial||University Health Network, Toronto|No|Not yet recruiting|September 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02205944||39489|
NCT02205957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mah2014S1|Training Quality in Anaesthesia and Intensive Care: Tunisian Residents Feed Back|Training Quality in Anesthesia and Intensive Care : Tunisians Residents' Feed Back||University Hospital, Mahdia|No|Completed|July 2014|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|160|||Both|30 Years|40 Years|No|Non-Probability Sample|Residents in anesthesiology and intensive care|January 2016|January 13, 2016|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02205957||39488|
NCT02205359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdaptResponse|AdaptResponse Clinical Trial|AdaptResponse Clinical Trial||Medtronic Cardiac Rhythm Disease Management|Yes|Recruiting|July 2014|March 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02205359||39534|
NCT02205632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSII-RMB|Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.|||Poitiers University Hospital||Completed|February 2014|||November 2014|Actual|N/A|Interventional|N/A|2||Anticipated|39|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02205632||39513|
NCT02205645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORX/2014/FM01|Initial Safety Evaluation of FibroFix™ Meniscus|A Prospective Open-Label Study to Evaluate the Safety of the Meniscal Repair Scaffold, FibroFix™ Meniscus, in the Treatment of Meniscal Defects||Orthox Limited|No|Recruiting|April 2015|November 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02205645||39512|
NCT02233660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUFA PI -12/0023|The Role of the Cervical Spine in Carpal Tunnel Syndrome|Changes in Function, Cervical Range of Motion and Pinch Grip Force After Physical Therapy in Carpal Tunnel Syndrome: A Randomized Clinical Trial||Universidad Rey Juan Carlos|Yes|Completed|September 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|65 Years|No|||March 2016|March 14, 2016|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02233660||37361|
NCT02222649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGabriela|Evaluation of the High Dose Vitamin D3 Supplementation Effect and Influence of Polymorphism VDR Gene on Oxidative Stress and Inflammatory Process in Elderly|EVALUATION OF THE HIGH DOSE VITAMIN D3 SUPPLEMENTATION EFFECT AND INFLUENCE OF POLYMORPHISM VDR GENE ON OXIDATIVE STRESS AND INFLAMMATORY PROCESS IN ELDERLY||Federal University of Paraíba|Yes|Recruiting|July 2014|September 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|60 Years|90 Years|Accepts Healthy Volunteers|||August 2014|March 4, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02222649||38208|
NCT02234102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF 34/2014 version 02|Eagle AF (Atrial Fibrillation) - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation|Eagle AF - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation||Märkische Kliniken GmbH|No|Recruiting|August 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||August 2015|August 20, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234102||37327|
NCT02227407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305047RINC|Reciprocating Gait Orthoses for Paraplegia Patients|NSC Assistive Technology Research: Reciprocating Gait Orthoses for Paraplegia Patients|UPGO|National Taiwan University Hospital|Yes|Recruiting|August 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|8|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 26, 2014|April 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02227407||37842|
NCT02227693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-J081-204|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia||Eisai Inc.|No|Completed|July 2014|June 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|39|||Both|20 Years|N/A|No|||June 2015|June 19, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227693||37820|
NCT02227706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-12-006|The Paediatric EVICEL® Soft Tissue Bleeding Study|A Prospective, Randomized, Controlled Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Haemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Paediatric Patients||Ethicon, Inc.|No|Recruiting|August 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|17 Years|No|||August 2015|August 17, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227706||37819|
NCT02232555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208.10|Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain|A Ten-week, Randomized, Double-blind Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain (EU-Pain Enriched Study)||Boehringer Ingelheim||Completed|May 2005|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||327|||Both|18 Years|N/A|No|||August 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02232555||37446|
NCT02207894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZRM_ObsITI_2005|A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI|A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled (High Dose) Immune Tolerance Induction (ITI)||Haemophilia Centre Rhine Main|No|Recruiting|August 2006|December 2027|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood, serum, white cells, plasma.|Male|N/A|N/A|No|Non-Probability Sample|all male patients with haemophilia A and inhibitor|February 2016|February 18, 2016|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02207894||39339|
NCT02207907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202192|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste||GlaxoSmithKline|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207907||39338|
NCT02209311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-CCH-06-01-14|Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs|Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Tissue Engineered Construction Based on a Synthetic Tricalcium Phosphate and Autologous Multipotent Mesenchymal Stromal Cells Obtained From Oral Mucosa||Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati|No|Enrolling by invitation|September 2014|March 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|60 Years|No|||September 2015|September 30, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02209311||39230|
NCT02205216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD226/14|Can tDCS Enhance Efficacy of Rehabilitative Intervention for Freezing of Gait in Parkinson's Disease?|Can Transcranial Direct Stimulation Enhance the Efficacy of a Rehabilitative Intervention for the Treatment of Freezing of Gait in Parkinson's Disease? A Double Blind Randomized Controlled Study||Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|September 2014|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|40|||Both|30 Years|80 Years|No|||July 2015|July 3, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205216||39545|
NCT02205450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT_ENDOPED201401|Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell|Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell||Corporacion Parc Tauli|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|N/A|2 Years|No|Non-Probability Sample|Hospitalary population|July 2014|July 30, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02205450||39527|
NCT02205463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-01171|KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer|A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach||New York University School of Medicine|Yes|Withdrawn|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|July 29, 2014|No|Yes|IND application withdrawn|No||https://clinicaltrials.gov/show/NCT02205463||39526|
NCT02206360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPH 1401|Pancreatic Cancer Early Detection Program|Observational Study to Analyze the Outcomes of Subjects Who - Based Upon Their Sufficiently Elevated Risk for the Development of Pancreatic Adenocarcinoma- Elect to Undergo Early Detection Testing|PCEDP|White Plains Hospital|Yes|Recruiting|April 2014|March 2020|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals aged 18 and older, who carry sufficiently elevated risk for the development of        pancreatic cancer, numerically defined as over (or near) 5 times the general population        risk, as determined by their personal, familial, or genetic history.|July 2014|July 30, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02206360|5 Years|39457|
NCT02205736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-BRE-NOS-HEP-001|Breast Health Education for Underserved Latino Women|A Cross Sectional Study of a Breast Health Education Program for Under-served Latino Women in Union and Mecklenburg County||Carolinas Healthcare System|Yes|Active, not recruiting|July 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205736||39505|
NCT02207127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00101|Magnetic Resonance Imaging in Obstructive Sleep Apnea|Magnetic Resonance Imaging in Obstructive Sleep Apnea|MRI in OSA|University of Southern California|No|Recruiting|July 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|21 Years|N/A|No|Non-Probability Sample|Study participants will be adults with obstructive sleep apnea undergoing surgery. All        participants will undergo magnetic resonance imaging (MRI) and drug-induced sleep        endoscopy (DISE).|November 2015|November 30, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02207127||39398|
NCT02209181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-131230135611-CTPA|A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine|A Randomized, Double-blind, Placebo- and Active-controlled Trial to Investigate the Single-dose Efficacy, Safety, and Pharmacokinetics of 250 and 1000 mg JNJ-10450232 in Postoperative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|269|||Male|18 Years|45 Years|No|||January 2016|January 28, 2016|July 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02209181||39240|
NCT02205970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSaoCarlos0001/14|Application of Electrical Neurostimulation Transcutaneous in Patients With Primary Dysmenorrhea.|Methodological Proposal of Application of Electrical Neurostimulation Transcutaneous (Comparative Study Between Proposed Method of Application Versus Traditional Method in Patients With Primary Dysmenorrhea).||Universidade Federal de Sao Carlos|No|Completed|August 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|124|||Female|18 Years|36 Years|No|||December 2015|December 15, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02205970||39487|
NCT02206256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47021.029.13|Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function|Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function|OLIVIER|Medical Center Alkmaar|Yes|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Female|18 Years|65 Years|No|||September 2015|September 22, 2015|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206256||39465|
NCT02206230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-02-1401|Trial of Hypofractionated Radiation Therapy for Glioblastoma|A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma||AHS Cancer Control Alberta|Yes|Recruiting|August 2014|August 2020|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|70 Years|No|||December 2015|December 31, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02206230||39467|
NCT02237625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049204|Natural History Study of Patients With Hypophosphatasia (HPP)|Natural History Study of Adult and Pediatric Patients With Hypophosphatasia|NatHisHPP|Duke University|Yes|Recruiting|September 2014|September 2026|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Up to 100 minor and 100 adult subjects will be enrolled into this natural history study.|January 2016|January 20, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237625|100 Years|37056|
NCT02226822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692R00001|DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan|J-DISCOVER: DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan|J-DISCOVER|AstraZeneca|No|Active, not recruiting|September 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Non-Probability Sample|Adult patients with documented history of type 2 diabetes mellitus who are initiating        their second line oral or parenteral anti-diabetics medication after first line oral        diabetic therapy|January 2016|January 20, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02226822||37887|
NCT02222909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-12-11-4948|Reverse Innovation and Patient Engagement to Improve Quality of Care and Patient Outcomes|Reverse Innovation and Patient Engagement to Improve Quality of Care and Patient Outcomes|CONNECT|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|April 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|22|||Both|N/A|N/A|No|||August 2014|August 20, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02222909||38188|
NCT02222922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7661001|A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors|A First-In-Human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647020 In Adult Patients With Advanced Solid Tumors||Pfizer|No|Recruiting|October 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02222922||38187|
NCT02232256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALPXT96-01|The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain|A Phase 3 Double Blind, Randomized, Placebo Controlled, Cross-Over Trial to Asses the Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain|CALPXT96|9305-9954 Quebec Inc|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02232256||37469|
NCT02232568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001165|Trial of Feedback on Blood Use|Trial of Feedback on Blood Use|TOFU|Brigham and Women's Hospital|No|Recruiting|September 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|N/A|N/A|No|||July 2015|July 20, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232568||37445|
NCT02232581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211.1|Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure|Randomised, Double Blind, Placebo-controlled Dose Ranging Trial to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure||Boehringer Ingelheim||Completed|April 2004|||December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|N/A|No|||August 2014|September 4, 2014|September 4, 2014||||No||https://clinicaltrials.gov/show/NCT02232581||37444|
NCT02207608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-1|Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects|Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects||University of Rome Tor Vergata|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 31, 2014||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT02207608||39361|
NCT02208492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0365|The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study|||Yonsei University|No|Completed|September 2011|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|4 Years|16 Years|No|||December 2014|December 8, 2014|August 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02208492||39293|
NCT02208726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaronWillson200731900|The Effect of Picricum Acidum and Phosphoricum Acidum Homaccord on Perceived Levels of Anxiety in University Students|The Effect of Picricum Acidum and Phosphoricum Acidum Homaccord on Perceived Levels of Anxiety in University Students||University of Johannesburg|Yes|Completed|September 2013|August 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02208726||39275|
NCT02208739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPPC-C2|Effect of Nonsurgical Periodontal Therapy Verses Oral Hygiene Instructions on Patients With Chronic Periodontitis|Effect of Nonsurgical Periodontal Therapy Verses Oral Hygiene Instructions on Clinical Parameters as Well as Immunological and Microbial Profile of Patients With Chronic Periodontitis||University of Malaya|Yes|Completed|December 2011|December 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|30 Years|70 Years|No|||July 2015|July 13, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02208739||39274|
NCT02209038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820002|Choice Sets for Advance Directives|A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives||University of Pennsylvania|No|Completed|July 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Actual|321|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02209038||39251|
NCT02209324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-J12|Open-label Study of ASP2151 in Herpes Simplex Patients|Open-label Study of ASP2151 in Herpes Simplex Patients||Maruho Co., Ltd.|Yes|Completed|November 2013|||July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|16 Years|79 Years|No|||March 2016|March 15, 2016|July 31, 2014||||No||https://clinicaltrials.gov/show/NCT02209324||39229|
NCT02205229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medimix Pharm-03|Compounded Pain Preparation Absorption Study|Compounded Pain Preparation Absorption Study (ComPPAS)|ComPASS|Medimix Specialty Pharmacy, LLC||Suspended|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|30 Years|65 Years|No|Non-Probability Sample|Patient between the ages of 30 and <65 years old not taking concomitant medications that        may interact with study ingredients.|May 2015|May 15, 2015|July 29, 2014||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT02205229|1 Month|39544|
NCT02206373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301031RINC|How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr)|How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr)||National Taiwan University Hospital|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|2012.01.01~2012.12.31 adult patients with serum creatinine test result in NTUH|August 2015|August 9, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206373||39456|
NCT02206386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH096441|Homecare Agency-Randomized Trial of Web Implementation Strategy for Depression|Homecare Agency-Randomized Trial of Web Implementation Strategy for Depression||Weill Medical College of Cornell University|No|Enrolling by invitation|January 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|7800|||Both|65 Years|N/A|No|||July 2014|July 30, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02206386||39455|
NCT02206672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01014-43|EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS|EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS|FACE|Assistance Publique Hopitaux De Marseille|No|Recruiting|July 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|80 Years|No|||September 2015|November 4, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02206672||39433|
NCT02206425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X16041|Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients|A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib||Oncotherapeutics|Yes|Recruiting|September 2014|August 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02206425||39452|
NCT02206438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0081|The Clinical Efficacy of Supraglottic Airway Device, Self-pressurized Air-Q Intubating Laryngeal Airway (ILA -SP) in Adult Patients: Comparison With Classic-laryngeal Airway (c-LMA)|||Yonsei University|Yes|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|84|||Both|20 Years|75 Years|No|||July 2014|July 30, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02206438||39451|
NCT02205658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027|Sensory Processing Difficulties in Adults and Adolescents|Standardization of the Adult/ Adolescent Sensory History||The Spiral Foundation at OTA Watertown|No|Recruiting|January 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1300|||Both|13 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals will be a nationally representative sample of US residents|July 2014|July 29, 2014|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02205658||39511|
NCT02206269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7100|China Alair System Registry Study-CARE Study|Registry of Bronchial Thermoplasty (BT) Procedures in China|CARE|BSC International Medical Trading (Shanghai) Co., Ltd.|No|Not yet recruiting|December 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|18 Years|N/A|No|Non-Probability Sample|The real world patient polulaiton who undergo BT in China|July 2014|July 30, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02206269|1 Year|39464|
NCT02206243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3952-12/13|Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia|An Observational Study to Evaluate the Safety and Efficacy of Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia|EmboProstate|Jena University Hospital|No|Recruiting|September 2014|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7|||Male|40 Years|N/A|No|Non-Probability Sample|Primary care clinic (within clinical routine)|July 2015|July 17, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02206243||39466|
NCT02226575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMAC-PAFHM11|Management and Coaching in Atrial Fibrillation|Study of Management and Coaching in Atrial Fibrillation|MANCAF|FUTURUM, Academy of Health and Science|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02226575||37906|
NCT02231593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52030-257|SAGIT for Classification of Patients With Acromegaly in Clinical Practice|Testing the Use of SAGIT for Classification of Patients With Acromegaly in Clinical Practice|SAGIT Pilot|Ipsen|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Acromegaly patients registered with endocrinologists (hospital-based or outpatient        clinics)|September 2014|September 30, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02231593||37520|
NCT02227121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD Study|Acute Defibrillation Study|||Medtronic Bakken Research Center|No|Terminated|February 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 22, 2014||No|Sufficient enrollments under current protocol for further development & studies|No||https://clinicaltrials.gov/show/NCT02227121||37864|
NCT02227134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00572|Ultrasound to Predict a Pediatric Difficult Airway and Obstructive Sleep Apnea Syndrome in Children|||Nationwide Children's Hospital|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|1 Month|18 Years|No|||November 2015|November 20, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227134||37863|
NCT02234986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-006|A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma|A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)||CASI Pharmaceuticals, Inc.|No|Recruiting|October 2015|June 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|99 Years|No|||March 2016|March 19, 2016|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234986||37259|
NCT02234999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-CP-003|Radiolabeled Study of CC-122 in Healthy Subjects|A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C]-CC-122 in Healthy Male Subjects||Celgene|Yes|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|September 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02234999||37258|
NCT02207621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS302|Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension|||Aerie Pharmaceuticals|No|Active, not recruiting|July 2014|June 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|690|||Both|N/A|99 Years|No|||January 2016|January 21, 2016|July 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02207621||39360|
NCT02207634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130385|Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects|A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial|EBBINGHAUS|Amgen|Yes|Active, not recruiting|August 2014|February 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|1972|||Both|40 Years|85 Years|No|||November 2015|November 25, 2015|July 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02207634||39359|
NCT02234206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref.No. ExII(1)/29096/2011|A Clinical Trial to Study the Safety and Efficacy of Chandrakanthi Choornam in Patients With Low Sperm Count|Safety and Efficacy of Chandrakanthi Choornam in Oligospermia - A Preclinical and Clinical Study||Tamil Nadu Dr.M.G.R.Medical University|No|Completed|December 2012|August 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|21 Years|45 Years|No|||August 2014|September 4, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02234206||37319|
NCT02234427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARes-III|Pharmacogenomics of Antiplatelet Response|Pharmacogenomics of Antiplatelet Response|PARes-III|Johns Hopkins University|Yes|Completed|June 2014|May 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|45 Years|75 Years|No|||September 2015|September 4, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234427||37302|
NCT02228330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-14-RMC|Prospective Clinical Trial - Obturator Reflex Predictors and Blockage|Prospective Clinical Trial - Obturator Reflex Predictors and Blockage||Rabin Medical Center|Yes|Enrolling by invitation|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02228330||37771|
NCT02228343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM2013.1|A Prospective Trial of Ayurveda for Coronary Artery Disease|A Prospective Trial of Ayurveda for Coronary Artery Disease||University of New Mexico|No|Completed|January 2013|January 2014|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02228343||37770|
NCT02228616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102381|Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation|A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC)||Xian-Janssen Pharmaceutical Ltd.||Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Female|18 Years|65 Years|No|||March 2016|March 14, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228616||37749|
NCT02223572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HipFracture2014|Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture|Secondary Fracture Prevention in Patients Hospitalized for Hip Fracture: Adding the Metabolic Treatment to the Surgical One.||Meir Medical Center|No|Not yet recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223572||38137|
NCT02228863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC-2014-01-005|Upper Extremity Rehabilitation Using Robot and Botulinum Toxin|||National Rehabilitation Center, Seoul, Korea|No|Recruiting|March 2014|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|348|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02228863||37730|
NCT02229149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13011|Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer|Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)||US Oncology Research|Yes|Recruiting|December 2014|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229149||37708|
NCT02229409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WD-PILOT-2014|Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population|Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population||MeYou Health, LLC|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229409||37688|
NCT02229422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140396|A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)|A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients|GA101 & HDMP|University of California, San Diego|Yes|Recruiting|September 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229422||37687|
NCT02229695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0167-14|The Effect of Different Types of Temporary Abdominal Closure on Intra Abdominal Hypertension.|The Effect of Different Types of Temporary Abdominal Closure on Intra Abdominal Hypertension and Abdominal Compartment Syndrome.|TACACS|Soroka University Medical Center|No|Not yet recruiting|October 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients that undergo emergent laparotomy for trauma or non-traumatic surgical emergency        condition, and that according to the surgeon decision get their abdominal wall closed by a        temporary closure technique.|August 2014|August 28, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229695||37666|
NCT02233946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00004862|Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|cASCA|Children's Hospital Boston|Yes|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02233946||37339|
NCT02238808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EER001|A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers|Two Week Estradiol Exposure in Postmenopausal Women With Newly Diagnosed ER Positive Breast Cancer - Prior to Surgery: Window of Opportunity Study||AHS Cancer Control Alberta|No|Recruiting|August 2015|January 2027|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|55 Years|N/A|No|||March 2016|March 2, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238808||36966|
NCT02238834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP02C-14-001|Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers|A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, a Matrix Metalloproteinase-12 (MMP-12) Inhibitor, in Healthy Male Subjects||Foresee Pharmaceuticals Co., Ltd.|No|Not yet recruiting|December 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|September 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02238834||36964|
NCT02363946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCAAT-1001|A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)|A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)||Arrowhead Research Corporation|No|Recruiting|February 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|November 11, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363946||27366|
NCT02226159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9086-14019|Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain|Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain (SPIES): a Randomized, Controlled Trial|SPIES|OrthoCarolina Research Institute, Inc.|Yes|Recruiting|August 2014|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226159||37938|
NCT02237651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH 09/03/2014|Topical Anesthesia / Bronchoscopy|Topical Nasopharyngeal Anesthesia in Outpatient Bronchoscopy|TNA|Hannover Medical School|Yes|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|252|||Both|18 Years|88 Years|No|Non-Probability Sample|Patients after lung transplantation|April 2015|August 19, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237651||37054|
NCT02231086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49960.018.14|Adjuvant HIPEC in High Risk Colon Cancer|Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis|COLOPEC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|March 2015|April 2022|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|176|||Both|18 Years|75 Years|No|||December 2015|December 29, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02231086||37559|
NCT02235610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE14.100|Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation|Clinical Trial of Ex Vivo Lung Perfusion (EVLP) for the Reconditioning of Marginal Donor Lungs for Transplantation.|EVLP-CHUM|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02235610||37211|
NCT02235766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kell-1|Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates|Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates|CORELAB-CRT|Kell s.r.l.|No|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all        patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection        fraction equal or less than 35% will be considered eligible to participate in this        observational study.|March 2016|March 3, 2016|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02235766||37199|
NCT02239965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLT-NM3|Qualitative Analysis of Barriers to Consistent Use of Neuromuscular Monitoring in General Anaesthesia|Qualitative Analysis of Barriers to Consistent Use of Neuromuscular Monitoring in General Anaesthesia||Herlev Hospital||Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Anaesthesiologists and nurse anaesthetists at Danish anaesthesia departments.|March 2015|March 19, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02239965||36879|
NCT02239991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1986-14|Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant|Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant||Hospital Israelita Albert Einstein|No|Recruiting|September 2014|February 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239991||36877|
NCT02240017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 URO 02|A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.|Randomized, Multicenter, Phase II/III Study, Evaluating Fractionated Cisplatin Chemotherapy/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.|VEFORA|Institut Claudius Regaud|No|Recruiting|September 2014|September 2023|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||September 2014|May 26, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02240017||36875|
NCT02240043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/09|Growth Hormone Evaluation in the Elderly People|Growth Hormone Evaluation in the Elderly People||Universidade Federal do Rio de Janeiro|No|Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|65 Years|95 Years|No|||September 2014|September 11, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02240043||36873|
NCT02222714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ-3K3A-201 (NN104)|Safety Evaluation of 3K3A-APC in Ischemic Stroke|A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, a Recombinant Variant of Human APC, in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke|RHAPSODY|ZZ Biotech, LLC|Yes|Recruiting|October 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|90 Years|No|||November 2015|November 11, 2015|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222714||38203|
NCT02233218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH22189-101|The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers|A Phase 1, Open Label, Non-randomized, Two-cohort, Single-sequence, Crossover Study to Investigate the Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers||Yuhan Corporation|No|Completed|July 2014|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 16, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02233218||37395|
NCT02233231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Young smoking asthmatics|Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment|Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment||Bispebjerg Hospital|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|40 Years|No|||September 2014|September 4, 2014|March 18, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02233231||37394|
NCT02228876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403019RINA|A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder|A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder||National Taiwan University Hospital|Yes|Active, not recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|360|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|3 Years|N/A|No|Non-Probability Sample|Based on our preliminary CNV results of 339 probands, approximately 120 probands had been        identified to have CNVs larger than 500kb. In the present project, the parents and        siblings of the probands with CNVs larger than 500kb will be recruited (estimated sample        size, parents = 200, siblings = 40) and reassess the ~120 probands.|August 2014|August 27, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02228876||37729|
NCT02233569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHvsVS|Comparison of Two Mesh/Fixation Concepts for Laparoscopic Ventral and Incisional Hernia Repair|COMPARISON OF TWO DIFFERENT CONCEPTS OF MESH AND FIXATION TECHNIQUE IN THE LAPAROSCOPIC OPERATIONS FOR VENTRAL AND INCISIONAL HERNIA - A RANDOMIZED CONTROLLED MONOCENTER TRIAL.||Polish Hernia Study Group|Yes|Terminated|November 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 5, 2014|August 29, 2014||No|The high recurrence rate and the findings during the reoperations were considered as serious    adverse events and were the reason for study termination.|No||https://clinicaltrials.gov/show/NCT02233569||37368|
NCT02233738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-317|Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services|Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services|GMI in Vets|VA Office of Research and Development|No|Recruiting|May 2015|September 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|75 Years|No|||February 2016|February 12, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02233738||37355|
NCT02234219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anastomosis in Hirschsprung|Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease: A Prospective Multicenter Randomized Controlled Trial|Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease: A Prospective Multicenter Randomized Controlled Trial||Tongji Hospital|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|14 Years|No|||September 2014|September 28, 2014|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234219||37318|
NCT02238496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM3801|Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas|Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas||Columbia University|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238496||36989|
NCT02238574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46343.068.13|Diagnostics for the Treatment of Progressive Mucosal Lesions of the Oral Cavity: a Prospective Study|Chromosomal Instability as an Indicator for the Treatment of Progressive Mucosal Lesions of the Oral Cavity.||Maastricht University Medical Center|Yes|Not yet recruiting||December 2024|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|374|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238574||36983|
NCT02368093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09060-1|Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis|A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis||Taichung Veterans General Hospital|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2015|March 22, 2015|February 4, 2015||No||No|March 22, 2015|https://clinicaltrials.gov/show/NCT02368093||27050|
NCT02230527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-799|Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia|Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia||The Cleveland Clinic||Recruiting|August 2014|||August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230527||37602|
NCT02222662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC24945(2)|Parent-delivered Massage for Children With Autism - Ages 6 to 11|Phase 1 Study of the Parent-delivered Massage Treatment Protocol for Children With Autism Ages 6 to 11||Western Oregon University|No|Active, not recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|6 Years|11 Years|No|||December 2015|December 8, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02222662||38207|
NCT02222675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-001_1.1|Conserving Breast Surgery - Comparison of Conventional With Sonography|Comparison of Sonographically Assisted With Conventionally Breast Surgery - Prospective, Randomised, Multicenter, Parallel Group Study With Two Study Arms|MAC-001|University Women's Hospital Tübingen||Recruiting|April 2009|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|142|||Female|18 Years|70 Years|No|||August 2014|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222675||38206|
NCT02235467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1157-8984|Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism|Multisite Study: Acquisition of Social Skills in Children With Autism Using Video Modeling in Parental Training||Federal University of São Paulo|Yes|Completed|February 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|3 Years|7 Years|No|||March 2015|March 31, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235467||37222|
NCT02222727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0099|Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage|Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage|DASH|St George's, University of London|No|Active, not recruiting|January 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||May 2015|November 19, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222727||38202|
NCT02222740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN154088-203|A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain|A Multiple-Dose, Safety, Tolerability, and Pharmacokinetic Dose-Escalation Study of Hydrocodone Bitartrate Extended Release (HC-ER) in Patients With Chronic, Moderate to Severe Osteoarthritis Pain||Zogenix, Inc.|No|Completed|September 2002|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|July 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222740||38201|
NCT02223000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528.22|Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects|Relative Bioavailability and Tolerability of Various Experimental Formulations of 50 mg BIBV 308 SE Administered Orally Twice a Day Over 3.5 Days to Healthy Subjects (Intraindividual Comparison, Open, Partially Randomised).||Boehringer Ingelheim||Completed|March 1998|||July 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223000||38181|
NCT02235051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14135|Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors|Deciphering the Breast Cancer Exercise Paradox: The Role of DNA Repair and Inflammation||City of Hope Medical Center|Yes|Recruiting|May 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|56 Years|N/A|No|||February 2016|February 11, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235051||37254|
NCT02227485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT93747064|Evaluation of the Effects of Iranian Traditional Mouth Rinse (Golnaar) in Treatment of Gingivitis in Diabetic Patients|Evaluation of the Effects of Punica Granatum Plenifora (Golnaar) in Treatment of Gingivitis in Patients With Diabetes Mellitus||Shiraz University of Medical Sciences|Yes|Completed|July 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|65 Years|No|||December 2014|December 1, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02227485||37836|
NCT02227498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04-01|Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol|Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol||Second Sight Medical Products|Yes|Recruiting|October 2014|March 2018|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|25 Years|85 Years|No|||January 2015|January 16, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227498||37835|
NCT02227758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-11-059-EU-ON|Peripheral Nerve Stimulation Registry for Intractable Migraine Headache|Peripheral Nerve Stimulation Registry for Intractable Migraine Headache|Relief|St. Jude Medical|No|Active, not recruiting|September 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|112|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with intractable chronic migraine and implanted with a St.Jude Medical        conformité européenne approved implantable neurostimulation system|March 2015|November 2, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02227758||37815|
NCT02227771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-03|Consistent CTO Trial|CONventional Antegrade vs Sub-Intimal Synergy sTENTing in Chronic Total Occlusions||European Cardiovascular Research Center||Recruiting|December 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|215|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who come to hospital for CTO and who met all the inclusion/eclusion criteria|September 2015|September 15, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227771||37814|
NCT02228031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00059904|Oxytocin, Emotions and Mirror Neurons|The Influence of Oxytocin on the Mirror Neuron System: Developing Brain Imaging Paradigms for Future Therapeutic Interventions||University of Maryland|Yes|Not yet recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|September 3, 2014|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228031||37794|
NCT02233088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11111701-CA01|A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)|A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome|3ELM|Rush University Medical Center|Yes|Active, not recruiting|July 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|72 Years|No|||November 2014|November 18, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233088||37405|
NCT02233101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUSH2233|Oral vs. Intravenous TXA Study Proposal: TJA|Oral vs. Intravenous TXA Study Proposal: TJA||Rush University Medical Center|No|Recruiting|June 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|65 Years|No|||June 2014|September 3, 2014|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02233101||37404|
NCT02240381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 1426|Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant|Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|March 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240381||36847|
NCT02233361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2/0252|Use of Hearing Aids. Development and Implementation of a Counselling Program for Hearing Aid Users|Use of Hearing Aids. Development and Implementation of a Counselling Program for Hearing Aid Users.||Lovisenberg Diakonale Hospital|No|Recruiting|January 2014|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|280|||Both|65 Years|N/A|No|||September 2014|September 3, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02233361||37384|
NCT02233374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-NSCCRO-P001|Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET|Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET|PRISM|Royal North Shore Hospital|Yes|Recruiting|September 2014|December 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|44|||Both|18 Years|N/A|No|||July 2015|July 12, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02233374||37383|
NCT02240407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400137|Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease|Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)|AAV9-GAA IM|University of Florida|Yes|Not yet recruiting|October 2016|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|9|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240407||36845|
NCT02240420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDA 10.586|Diabetes Prevention Among Post-partum Women With History of Gestational Diabetes|Reaching High Risk Post-partum Women for Nutritional Assessment and Counseling Via a Telephone-based Coaching Program|Star-Mama|University of California, San Francisco|No|Recruiting|December 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Female|18 Years|39 Years|No|||January 2016|January 4, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240420||36844|
NCT02240433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14856|A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)|A Phase 1b Study of LY2157299 in Combination With Sorafenib in Patients With Unresectable Hepatocellular Carcinoma||Eli Lilly and Company|Yes|Recruiting|November 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|N/A|No|||March 2016|March 8, 2016|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240433||36843|
NCT02226588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3004|Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt|Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in El Beheira Governorate, Egypt||Gynuity Health Projects|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2827|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226588||37905|
NCT02227147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF0214|Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 Neurotrophic Keratitis|An 8-week Phase II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 24 or 32 Week Follow-up Period to Evaluate the Efficacy of a Formulation Containing Anti-oxidant of Recombinant Human Nerve Growth Factor (rhNGF) 20 µg/ml, Eye Drops Solution Versus Vehicle Containing Anti-oxidant in Patients With Stage 2 and 3 Neurotrophic Keratitis||Dompé Farmaceutici S.p.A|No|Recruiting|February 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227147||37862|
NCT02227160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073021|Group Interventions for Suicidal African Americans|Group Interventions for Suicidal African Americans||Emory University|Yes|Not yet recruiting|May 2016|||September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|64 Years|No|||November 2015|November 9, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227160||37861|
NCT02227173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-004|A Phase 1 Drug-drug Interaction Study in Healthy Volunteers|Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp|DDI|Bristol-Myers Squibb||Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|November 17, 2014|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227173||37860|
NCT02232191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261729|Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients|Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients||University of California, Davis|No|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232191||37474|
NCT02232204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157-2008|Sleep and Ventricular Arrhythmias Study|Sleep in Cardiac Patients With Implantable Cardioverter Defibrillators (ICD)|SAVE|University of Florida|No|Completed|October 2009|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02232204||37473|
NCT02234661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACF Grant # 90YR0073|Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start|Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start|CAPFAST|Northwestern University|No|Recruiting|June 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|390|||Both|N/A|N/A|No|||January 2016|January 13, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02234661||37284|
NCT02234674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00355-42|Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema|Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema||Stendo|Yes|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||September 2014|May 21, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234674||37283|
NCT02228278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400433|Healthcare Text Messaging to Improve Diet, Physical Activity and Weight Loss in a Pediatric Lipid Clinic|Text 4 Fit Project: Healthcare Text Messaging as an Adjunct to Routine Care for Overweight and Obese Adolescents Enrolled in a Pediatric Lipid Clinic|Text4Fit|University of Florida|No|Active, not recruiting|April 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|13 Years|17 Years|No|||January 2016|January 7, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228278||37775|
NCT02237690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Libaoduo-BE-002|Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer|A Randomized, Open Label, Single-Dose, Two-Cycle Crossover Study to Assess Bioequivalence of Test and Reference Formulations of Doxorubicin Hydrochloride Liposome Injection in Female Patients With Ovarian Cancer||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Active, not recruiting|August 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|75 Years|No|||June 2015|June 16, 2015|August 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237690||37051|
NCT02223234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14AP008|Guelph Family Health Study: Pilot Study|Guelph Family Health Study: Pilot Study||University of Guelph|No|Not yet recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223234||38163|
NCT02223247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3V2640-CLIN-002|A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors|A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors||3V Biosciences, Inc.|Yes|Recruiting|November 2013|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|131|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|August 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223247||38162|
NCT02223260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.105|Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age|Open-label, Single Dose, Tolerability, Pharmacokinetic/Pharmacodynamics and Safety Study of Dabigatran Etexilate Given at the End of Standard Anticoagulant Therapy in Children Aged Less Than 1 Year Old||Boehringer Ingelheim||Completed|September 2014|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|N/A|12 Months|No|||February 2016|February 23, 2016|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223260||38161|
NCT02223494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528.21|Safety of Terbogrel in Patients With Primary Pulmonary Hypertension|An Open-label, Long-term Safety Evaluation of Terbogrel in Patients With Primary Pulmonary Hypertension||Boehringer Ingelheim||Terminated|October 1998|||March 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|N/A|No|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223494||38143|
NCT02223507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600.6|Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers|A Single-blind, Placebo-controlled Single Dose Tolerance Study in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIIR 561 CL as Loading Dose (Dosage: 75 mg/h, Infusion Time 1 Hour) Followed by Maintenance Dose (Dosage: 40 mg/h and 75 mg/h, Infusion Time 5 Hours)||Boehringer Ingelheim||Completed|August 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||13|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02223507||38142|
NCT02232308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004137|Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects|Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects||Mayo Clinic|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|June 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02232308||37465|
NCT02232984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROSS X4|Quadripolar CRT-D On Currently Approved Lead SystemS|Quadripolar CRT-D On Currently Approved Lead SystemS|CROSS X4|Boston Scientific Corporation|No|Recruiting|October 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Subjects will be selected from the center's general population who are indicated for a        CRT-D. All study subjects will be implanted with the BSC DYNAGEN or INOGEN X4 CRT-D (or        any future FDA approved BSC X4 CRT-D). Subjects may have a previously implanted/will be        receiving an approved quadripolar left ventricular lead.|March 2016|March 2, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02232984||37413|
NCT02240303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400471|Pain, Brain and Mobility Study|Central and Peripheral Mechanisms Predicting Clinical Pain and Physical Performance in Older Adults|PBAM|University of Florida|No|Withdrawn|April 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Plasma samples will be stored.|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Older adults|February 2016|February 16, 2016|September 2, 2014||No|Consolidated study with another protocol|No||https://clinicaltrials.gov/show/NCT02240303||36853|
NCT02240316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28886|An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice|||Hoffmann-La Roche||Recruiting|July 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1076|||Both|18 Years|N/A|No|Non-Probability Sample|CD-20 positive, diffuse large cell B-cell non-Hodgkin lymphoma (DLBCL) and CD-20 positive        follicular non-Hodgkin lymphoma (NHL)|September 2014|September 11, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240316||36852|
NCT02240342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOFOL2014|Bone Marrow Transplantation to Promote Follicle Recruitment in Poor Ovarian Reserve|Ovarian Rejuvenation: Regeneration of Ovarian Follicles in Women With Poor Ovarian Reserve by Autologous Transplantation of Bone Marrow Derived Progenitors Cells in Peripheral Blood. Pilot Study.||Hospital Universitario La Fe|No|Recruiting|September 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|40 Years|No|||September 2014|September 12, 2014|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240342||36850|
NCT02240355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29420|A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)|A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).||Hoffmann-La Roche||Suspended|November 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|64|||Both|N/A|55 Years|No|||December 2015|December 31, 2015|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240355||36849|
NCT02235714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-09-031|Exhaled Breath Condensate Biomarkers of Inflammation in Individuals With Chronic Cervical Spinal Cord Injury|Exhaled Breath Condensate Biomarkers of Inflammation in Individuals With Chronic Cervical Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|No|Completed|July 2009|April 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|36|Samples Without DNA|Exhaled Breath Condensate Blood Serum|Both|18 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|1. Chronic stable tetraplegia (duration of injury > 1 year) matched for age, gender, and             BMI with healthy control subjects, and clinically stable mild asthmatic subjects. The             subjects approached will have already consented to, or be actively participating in             "Effects of Nitric Oxide Synthase Inhibitor on Levels of Exhaled NO and Airway Tone             in Subjects with Chronic Cervical Spinal Cord Injury" study.          2. Clinically stable mild asthmatic subjects (as defined by NIH asthma guidelines) [51].          3. Healthy able-bodied individuals.|September 2014|September 8, 2014|December 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02235714||37203|
NCT02240394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai6thPeoplesH|TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure|TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Active, not recruiting|March 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|75 Years|No|Non-Probability Sample|Traumatic brain injury patients has been in patients with invasive intracranial pressure        monitoring|February 2015|February 10, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02240394||36846|
NCT02236104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01042-37|Effect of Mechanical Insufflation-exsufflation on Respiratory Parameters in Two Neuromuscular Populations.|Effect of Mechanical Insufflation-exsufflation on Respiratory Parameters in Two Neuromuscular Populations.|coughassistAFM|Centre d'Investigation Clinique et Technologique 805|No|Completed|November 2010|January 2014|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|No|||March 2015|March 23, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02236104||37173|
NCT02238392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2014|Adenosine vs AF Termination for Paroxysmal AF Ablation|Arrhythmia Inducibility Versus Elimination of Dormant PV Conduction as a Procedural Endpoint of Catheter Ablation for Paroxysmal Atrial Fibrillation: a Prospective Randomized Trial||Johannes Gutenberg University Mainz|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238392||36997|
NCT02238483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2550C00005|A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy|A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy||AstraZeneca|Yes|Active, not recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|40 Years|85 Years|No|||January 2016|January 18, 2016|September 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238483||36990|
NCT02231606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-PRICE|Potentiating Rural Investment in Children's Eyecare (PRICE)|Potentiating Rural Investment in Children's Eyecare (PRICE)|PRICE|Sun Yat-sen University|No|Completed|September 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|10234|||Both|7 Years|12 Years|No|||March 2016|March 7, 2016|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02231606||37519|
NCT02231931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2082|Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin|Relative Bioavailability of a Single Oral Dose of Digoxin, Furosemide, Metformin, and Rosuvastatin Given Alone and All Together as a Cocktail, and Investigation of the Effect of Increased Doses of Metformin or Furosemide on Relative Bioavailability of the Other Cocktail Compounds in Healthy Male Subjects||Boehringer Ingelheim||Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|September 3, 2014||||No||https://clinicaltrials.gov/show/NCT02231931||37494|
NCT02231944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R9VFSE|An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients|An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients.||Bio Products Laboratory||Completed|July 1997|||October 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|12 Years|N/A|No|||August 2014|September 3, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231944||37493|
NCT02239978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1480-M|Effect of Levodopa on Postural Motor Learning in Parkinson Disease|Effect of Levodopa on Postural Motor Learning in Parkinson Disease||VA Office of Research and Development|No|Active, not recruiting|August 2014|September 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|24|None Retained|No Biospecimens will be collected or retained|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Parkinson Disease or age-matched healthy adults in the north west United        States (Oregon and Washington state).|February 2016|February 1, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02239978||36878|
NCT02238873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGFIL|Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma|Pegfilgrastim on Day +3 Compared to Day +1 for Patients With Refractory or Relapsed Aggressive Lymphoma Receiving Salvage Chemotherapy - a Randomized Controlled Trial||Rabin Medical Center|No|Not yet recruiting|October 2014|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|85 Years|No|||October 2014|October 1, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02238873||36961|
NCT02232737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA036114:P1S2|Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders|Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders||Brown University|Yes|Recruiting|October 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|405|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232737||37432|
NCT02222935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSG02|Effectiveness of Balance Training in Chronic Low Back Pain Patients|Effectiveness of Balance Training Over Routine Back Exercise in Improving Functional Outcomes of Chronic Low Back Pain Patients|CLB|PSG Hospitals|Yes|Active, not recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|25 Years|45 Years|No|||August 2014|August 21, 2014|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222935||38186|
NCT02232919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230/2012|Deep Brain Stimulation for Human Morbid Obesity|Hypothalamus Deep Brain Stimulation for Human Morbid Obesity: Feasibility Trial|BLESS|Hospital do Coracao|Yes|Active, not recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02232919||37418|
NCT02228798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-PAUSE-2014|Perioperative Anticoagulant Use for Surgery Evaluation Study|Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).|PAUSE|McMaster University|Yes|Recruiting|July 2014|December 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3291|Samples Without DNA|Blood (platelet deprived plasma) will be collected on day of surgery/procedure and measured      by 'everyday' coagulation tests that are not DOAC-specific (e.g., activated partial      thromboplastin time [aPTT]) and 'specialized' coagulation tests that are DOAC-specific      (dilute thrombin time [TT] - HemoclotTM, and anti-factor Xa assays) to determine the effect      of the pre-operative DOAC interruption protocol on the level of residual anticoagulation.|Both|18 Years|N/A|No|Non-Probability Sample|Those patients who are currently taking dabigatran, rivaroxaban or apixaban for oral        anticoagulation used for stroke prevention in atrial fibrillation, and who require its        temporary interruption for a surgical or other procedure, will be recruited from 15 to 25        participating sites across Canada.        The study plans to screen 4,114 patients over a 3 year period, with 80 per cent expected        enrollment (3,291 patients) from 16 sites across Canada. Equal number of patients, per        oral anticoagulant arm will be enrolled, with approximately 1,000 patients taking each        DOAC.|December 2015|December 22, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02228798||37735|
NCT02235961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9030-4111|Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects|A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects||Novo Nordisk A/S|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|176|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02235961||37184|
NCT02236156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-018|Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis.||Starpharma Pty Ltd|No|Recruiting|September 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|620|||Female|18 Years|45 Years|No|||September 2015|September 1, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02236156||37169|
NCT02236169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2480|Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2000|||April 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|N/A|No|||September 2014|September 9, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02236169||37168|
NCT02235376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0201|Criteria of Extubation Failure of Brain Injured Patients. Elaboration of a Prognostic Score.|Criteria of Extubation Failure of Brain Injured Patients. Elaboration of a Prognostic Score.|GODWEAN|University Hospital, Clermont-Ferrand||Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|140|||Both|15 Years|N/A|No|Non-Probability Sample|brain injured patients|October 2015|October 13, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02235376||37229|
NCT02235389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.301|A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)|A Multicentre, Feasibility Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®). Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)|PHARAOH|Boehringer Ingelheim||Terminated|February 1998|||December 1998|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|59|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with acute myocardial infarction treated by paramedics under the direction of        hospital physicians|September 2014|September 9, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02235389||37228|
NCT02235532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT2014040517053N2|Effects of Aloe Vera Toothpaste on Periodontal Parameters|Effects of Aloe Vera Toothpaste on Periodontal Parameters of Patients With Gingivitis||Islamic Azad University, Tehran|No|Completed|September 2013|June 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|24 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02235532||37217|
NCT02225249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250-14|VASCULUX-examination of the Pulmonary VASCUlar Barrier in Patients During LUng Transplantation|Examination of the Pulmonary Vascular Barrier in Patients During Lung Transplantation|VASCULUX|Ludwig-Maximilians - University of Munich|No|Not yet recruiting|October 2014|July 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood samples will be taken. In summary, 61.2 ml blood will be collected at 7 specific time      points.      Components of the vascular barrier are examined, in detail hyaluronan, syndecan-1, and      angiopoietin-2.|Both|18 Years|65 Years|No|Non-Probability Sample|Eligible for this study are all patients being full of age and younger than 65 years        scheduled for lung transplantation|August 2014|August 22, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02225249||38008|
NCT02225522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD13-010|Genomic Sequencing in Acutely Ill Neonates|Prospective Randomized Trial of the Clinical Utility of Rapid Next Generation Sequencing in Acutely Ill Neonates|NSIGHT|Children's Mercy Hospital Kansas City|Yes|Recruiting|October 2014|October 2021|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|N/A|4 Months|No|||October 2014|October 8, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02225522||37987|
NCT02235896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004122|Reducing CVD Risk in African Americans Faith Communities|Cardiovascular Disease Prevention Among African-Americans by FAITH! (Fostering African-American Improvement in Total Health)|FAITH!|Mayo Clinic|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235896||37189|
NCT02235909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR14.001|An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension|A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension||Arbor Pharmaceuticals, Inc.|Yes|Recruiting|December 2014|August 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|260|||Both|6 Years|18 Years|No|||March 2016|March 18, 2016|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235909||37188|
NCT02226094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWT CIP 002|Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension|A Prospective, Randomized, Controlled Clinical Feasibility Investigation of the Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects||OcuTherix, Inc.|No|Terminated|November 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|August 20, 2014||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT02226094||37943|
NCT02226107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1374|Latino Peers as Patient Navigators for Colon Cancer Screening|Training Latinos as Peer Patient Navigators for Colon Cancer Screening||Icahn School of Medicine at Mount Sinai|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02226107||37942|
NCT02226354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-NHPD-196699|Study of the Safety and Efficacy of Dietary Buglossoides Oil|Study of the Safety and Efficacy of Dietary Buglossoides Oil||Réseau de Santé Vitalité Health Network|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02226354||37923|
NCT02235181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPPIT-2|An Open Randomised Trial of the Arabin Pessary to Prevent Pre-term Birth in Twin Pregnancy|An Open Randomised Trial of the Arabin Pessary to Prevent Pre-term Birth in Twin Pregnancy in Woman With a Short Cervix (STOPPIT-2)|STOPPIT-2|University of Edinburgh|Yes|Recruiting|April 2015|October 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1850|||Female|16 Years|50 Years|No|||May 2015|December 4, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235181||37244|
NCT02365337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC19771981|Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters|Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters in Women Undergoing Controlled Ovarian Hyperstimulation||Bahceci Clinic|Yes|Recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|18 Years|38 Years|No|Probability Sample|participants will be recruited among infertile women who is seeking for IVF treatment and        fullfilling the inclusion criteria.|January 2016|January 27, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02365337||27259|
NCT02227719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00077102|Customized Titanium Membrane for Growing Jaw Bone Horizontally|The Use of Customized Titanium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement||University of Michigan|No|Withdrawn|September 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|August 26, 2014||No|Funding|No||https://clinicaltrials.gov/show/NCT02227719||37818|
NCT02227732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-IS-VH-13-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2014|||||N/A|N/A|N/A||||||||||||||August 10, 2015|July 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227732||37817|
NCT02238795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKSJ0065|Sepsis-Associated Purpura Fulminans International Registry - Europe|Sepsis-Associated Purpura Fulminans International Registry - Europe|SAPFIRE|Jena University Hospital|Yes|Not yet recruiting|April 2016|September 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Blood plasma|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with sepsis-associated Purpura fulminans|February 2016|February 23, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238795|3 Months|36967|
NCT02227966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-04-026|A Pilot Study of tDCS for Mild Cognitive Impairment|A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 13) After Transcranial Direct Current Stimulation in Mild Cognitive Impairment||Samsung Medical Center|No|Not yet recruiting|September 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|65 Years|80 Years|No|||August 2014|August 31, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227966||37799|
NCT02235922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPESI-01|Effects of a Dual Task Protocol on Cognition and Functionality in Non-sedentary Older Adults|||Universidade Federal de Sao Carlos|Yes|Completed|March 2014|||August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||September 2014|September 6, 2014|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02235922||37187|
NCT02224976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL94|Effect of Intense Training on Ovarian Function and Bone Turnover|Impact of Intense Exercise Training on Energy Availability, Ovarian Function and Bone Turnover in Female Athletes||USDA, Western Human Nutrition Research Center|No|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|January 26, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224976||38029|
NCT02228551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55822-S55712|Augmented Renal Clearance in the Adult Non-critically Ill Surgery Patient: a Prospective Point Prevalance Study|Augmented Renal Clearance in the Adult Non-critically Ill Surgery Patient: a Prospective Point Prevalance Study and Identification of Risk Factors|ARCPPS|Universitaire Ziekenhuizen Leuven|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|279|||Both|18 Years|N/A|No|||November 2013|August 26, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02228551||37754|
NCT02228564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-12-001|BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease|A Prospective, Multi-Center, Non-Randomized, Single-Arm Study of the BARD® LIFESTREAM™ Balloon Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease (BOLSTER)|BOLSTER|C. R. Bard|No|Active, not recruiting|September 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|21 Years|N/A|No|||February 2016|February 29, 2016|August 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228564||37753|
NCT02239016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0026|Screening Patients With Sickle Cell Disease for Kidney Damage|Screening Patients With Sickle Cell Disease for Kidney Damage||Children's Hospital Medical Center, Cincinnati|No|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Urine, whole blood and serum|Both|N/A|N/A|No|Non-Probability Sample|Sickle cell clinics at various universities and hospitals.|December 2015|December 18, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02239016||36950|
NCT02228811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCC-2701-01-001|A Study of DCC-2701 in Participants With Advanced Solid Tumors|A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors||Deciphera Pharmaceuticals LLC|No|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228811||37734|
NCT02233049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001929-32|Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication|Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication|BIOMEDE|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|250|||Both|6 Months|25 Years|No|||February 2016|February 5, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233049||37408|
NCT02235155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017|Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Uzbekistan||Gynuity Health Projects|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|January 2016|January 13, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02235155||37246|
NCT02235168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6MWTElderly|Effect of Rollator on Walking Distance in Elderly Patients|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|September 2014|March 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02235168||37245|
NCT02235259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDD-1004-059|Efficacy and Safety of XG-104 for the Treatment of Dry Eye|A Phase II, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of XG-104 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAESM ) Model for the Treatment of Dry Eye||Xigen SA|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|260|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235259||37238|
NCT02235272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDD-1002-064|Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation|A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation||Xigen SA|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|339|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235272||37237|
NCT02224378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0686|Prediction of Fluid Responsiveness in Atrial Fibrillation Patients Who Underwent Valvular Heart Surgery: Peep-induced Increase in Central Venous Pressure vs. Passive Leg Raising|||Yonsei University|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|44|||Both|20 Years|N/A|No|||March 2015|March 31, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224378||38075|
NCT02224651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7921001|Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf 06650833 Delivered In Multiple Formulations In Healthy Subjects Under Fasted And Fed Conditions||Pfizer|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02224651||38054|
NCT02224950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofMLyocell|Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema|Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|3 Months|5 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224950||38031|
NCT02224963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG 032032|Macular Degeneration and Aging Study|Improving Care Planning and Well-being in Older Adults With Macular Degeneration|MADAS|University of Rochester|Yes|Active, not recruiting|May 2009|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|60 Years|N/A|No|||January 2016|January 15, 2016|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02224963||38030|
NCT02230215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105453|Assessment of Conventional and Patient-specific Instrumentation in Total Knee Arthroplasty|Assessment of Conventional and Patient-specific Instrumentation in Total Knee Arthroplasty||Lawson Health Research Institute|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02230215||37626|
NCT02225808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211011144|Neural Mechanisms of CBT for Anxiety in Autism|Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study||Yale University|Yes|Recruiting|August 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Years|14 Years|No|||August 2014|August 22, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02225808||37965|
NCT02225821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB155014|Wound Infections Following Implant Removal|Antibiotic Prophylaxis to Prevent Wound Infections Following Implant Removal|WIFI|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|November 2014|May 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225821||37964|
NCT02231021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-IIT-012|The Practical Evidence of Antidiabetic Combination Therapy in Korea|Multicenter, Randomized, Double Blind, Three-arm Parallel Group Study to Evaluate Efficacy and Safety of Alogliptin and Pioglitazone Combination Therapy on Glucose Control in Type 2 Diabetes Subjects Who Have Inadequate Control With Metformin Monotherapy in Korea|PEAK|The Catholic University of Korea|No|Recruiting|September 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|19 Years|75 Years|No|||May 2015|May 19, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02231021||37564|
NCT02231034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA137|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2014|||||N/A|N/A|N/A||||||||||||||March 10, 2015|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231034||37563|
NCT02231294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.511|The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease|The Effect of SIFROL® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease Patients.||Boehringer Ingelheim||Completed|July 2000|||January 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1464|||Both|N/A|N/A|No|Non-Probability Sample|Ambulatory patients with idiopathic parkinson's disease requiring therapy with Sifrol®|September 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231294||37543|
NCT02231307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB/0042|SUBLIVAC FIX Birch Phase III Short-term Efficacy|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Clinical Efficacy and Safety of SUBLIVAC FIX Birch Immunotherapy in Patients Suffering From Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen.||HAL Allergy|No|Active, not recruiting|September 2014|||July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02231307||37542|
NCT02231320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1367|Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease|Berodual® Respimat® 20/50 Microgram/Dose Solution for Inhalation: Assessment of Handling and Patient Satisfaction||Boehringer Ingelheim||Completed|December 2005|||June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|236|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of chronic obstructive pulmonary disease recruited at        pneumologists in practice|September 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231320||37541|
NCT02223273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIDGE-Stroke|Brazilian Intervention to Increase Evidence Usage in Practice - Stroke ( BRIDGE-Stroke)|A Cluster Randomized Trial to Evaluate the Increase in Usage of Evidence-based Practices for Stroke Treatment Using a Multifaceted Strategy|BRIDGE-Stroke|Hospital do Coracao|No|Not yet recruiting|January 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1140|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02223273||38160|
NCT02223845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMO&G0201|Randomised Controlled Trial of the Effect of Music on Women Undergoing Assisted Reproductive Technology Treatments.|Randomised Controlled Trial of the Effect of Music on Women Undergoing Assisted Reproductive Technology Treatments.||University of Southampton|Yes|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|40 Years|No|||August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223845||38116|
NCT02368756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endurance 2|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)||Palmetto Retina Center, LLC|No|Enrolling by invitation|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02368756||26999|
NCT02368769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-Pathology Frozen Section|Assessment of Tele-expertise for Frozen Section Diagnosis|Multidimensional Assessment of Tele-expertise for Frozen Section Diagnosis|Télé-extempo|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|253|Samples Without DNA|Tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients who need a frozen section diagnosis|December 2015|December 8, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02368769||26998|
NCT02232269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-655|Coffee Interaction With the Antihypertensive Drug Felodipine|Phase 1 Study of the Hemodynamic and Pharmacokinetic Interactions Between Coffee and Felodipine||Lawson Health Research Institute|No|Completed|February 2012|May 2013|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02232269||37468|
NCT02227979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044782A|Effects of PURPLE Cry Intervention|Biological Bases of Individual Variation in Paternal Nurturance||Emory University|Yes|Completed|September 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|42|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227979||37798|
NCT02224989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00052611|Mind-Body Intervention for Veterans With PTSD|A Pilot Feasibility Study of a Novel Mind-body Intervention Program for Veterans With PTSD||University of Utah|Yes|Recruiting|April 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224989||38028|
NCT02229669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1158-9611|Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions|Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions: A Split-mouth RCT||Paulista University|Yes|Completed|March 2011|July 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 28, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02229669||37668|
NCT02232828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARIEX2or1|Selective or Stepwise Removal of Deep Caries|Selective or Stepwise Removal of Deep Caries in Deciduous Molars: A Multi-center Randomized Controlled Trial||Charite University, Berlin, Germany|No|Recruiting|October 2014|June 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|9 Years|No|||July 2015|July 27, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02232828||37425|
NCT02225535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio13-241|Investigation of a Physiotherapist and Nurse Practitioner Intervention for Chronic Low Back Disorders Delivered Through Telehealth|Advancing Interprofessional Primary Health Care Services in Rural Settings for People With Chronic Low Back Disorders: Investigation of a Physiotherapist and Nurse Practitioner Intervention Delivered Through Telehealth||University of Saskatchewan|No|Active, not recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02225535||37986|
NCT02225834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21770|Atorvastatin in Acute Stroke Treatment|Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification||University of Palermo|No|Completed|November 2011|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|March 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02225834||37963|
NCT02233062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140901|Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease|Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease||Jinling Hospital, China|No|Completed|May 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|40 Years|No|||September 2014|September 5, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02233062||37407|
NCT02223806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC-GH 002|Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration|Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration|UTAMP|UMC Utrecht|No|Recruiting|April 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 3, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02223806||38119|
NCT02223819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-063|Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy|Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|August 2014|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223819||38118|
NCT02223832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058-107|Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects|Single-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of 40 mg ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects||Actelion|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02223832||38117|
NCT02224105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1262.9|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg Once Daily (qd) for 3 Days Assessing Pharmacodynamics as Endotoxin-induced Inflammatory Response of a Single Intravenous Bolus Administration of 2 ng/kg Body Weight Lipopolysaccharide (LPS). A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Phase I Trial With Open-label Active Comparator in Healthy Male Subjects||Boehringer Ingelheim||Completed|March 2010|||May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|56|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02224105||38096|
NCT02224365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF02435|The Effects of Apple Consumption on Cardiovascular Health in Prediabetics andType 2 Diabetics|Regular Apple Consumption Improves Cardiovascular Risk Factors and Glycemic Control in Overweight and Obese Prediabetics and Type 2 Diabetics||Florida State University|No|Recruiting|August 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|65 Years|No|||June 2015|June 24, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224365||38076|
NCT02229656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N13ORH|Olaparib and Radiotherapy in Head and Neck Cancer|Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma||The Netherlands Cancer Institute|No|Recruiting|February 2014|February 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|February 4, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229656||37669|
NCT02229968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00004263|Efficacy of Amicar for Children Having Craniofacial Surgery|Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery||Children's Research Institute|Yes|Recruiting|October 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|2 Months|36 Months|No|||August 2015|August 21, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229968||37645|
NCT02229981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-102|An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma|An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma||RedHill Biopharma Limited|No|Recruiting|July 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229981||37644|
NCT02233699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEN-D0501-CL-04|A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough|A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.||Xention Ltd|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02233699||37358|
NCT02233868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140192|Brain Inflammation and Function in Alcoholism|Brain Inflammation and Function in Alcoholism||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|March 2020|Anticipated|March 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|96|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|March 24, 2016|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02233868||37345|
NCT02234141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-357-1394|GS-4997 in Adults With Pulmonary Arterial Hypertension|A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension|ARROW|Gilead Sciences|Yes|Active, not recruiting|November 2014|March 2023|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234141||37324|
NCT02230488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405143|Intensive Case Diabetes Management (ICDM) to Prevent Readmission|Intensive Case Diabetes Management to Prevent Readmission of Previously Identified High Risk Patients||Washington University School of Medicine|No|Terminated|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|August 26, 2014||No|Unable to enroll due to protocol exclusion criteria and participant population pool|No||https://clinicaltrials.gov/show/NCT02230488||37605|
NCT02230761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XOPH5-OINT-2|Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)|A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon||Topokine Therapeutics, Inc.|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|40 Years|70 Years|No|||December 2015|January 9, 2016|August 28, 2014|Yes|Yes||No|November 19, 2015|https://clinicaltrials.gov/show/NCT02230761||37584|
NCT02235012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D512|Cognitive Biases Under Ketamine|Cognitive Biases in Decision Making in a Pharmacological Model of Psychosis : a Study in Healthy Humans Recieving Low Dose Anesthetic, Ketamine Versus Placebo|KETABI|Centre Hospitalier St Anne|Yes|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02235012||37257|
NCT02235064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH IRB#: 14-078|Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression|Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial||The Cooper Health System|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|124|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02235064||37253|
NCT02235077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057090|Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure|Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)|ATHENA-HF|Duke University|Yes|Recruiting|December 2014|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|21 Years|N/A|No|||January 2016|January 19, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235077||37252|
NCT02228577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-14-01|Safety and Performance Study of the CyPass System Applier Model 241|A Study Assessing the Safety and Performance of the Transcend CyPass System Applier Model 241 for Implantation of the CyPass Micro-Stent in Subjects With Open Angle Glaucoma Who Underwent Cataract Surgery|RePASS|Transcend Medical, Inc.|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|172|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with OAG who underwent combination cataract/glaucoma surgery and received the        CyPass Micro-Stent using the CyPass Applier Model 241|May 2015|May 11, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228577||37752|
NCT02228590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTH-105|A Study to Examine APL-130277 in Patients With Parkinson's Disease|A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease||Cynapsus Therapeutics Inc|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228590||37751|
NCT02372058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|Transcutaneous Bilirubinometry in Neonates With Bilicare System|Transcutaneous Bilirubinometry in Neonates With Bilicare System||Gerium Medical|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|103|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|February 22, 2015||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02372058||26748|
NCT02235428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2413|Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children|Double-blind, Controlled Trial to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, for 120 Minutes, in Acute Asthmatic Attacks in Young Children||Boehringer Ingelheim||Terminated|September 1998|||September 1998|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|3|||Both|3 Years|6 Years|No|||September 2014|September 9, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02235428||37225|
NCT02235545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60045220|Optisure Lead Post Approval Study|Optisure Lead Post Approval Study||St. Jude Medical|No|Recruiting|August 2014|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1725|||Both|18 Years|N/A|No|Non-Probability Sample|ICD/CRT-D indicated patients|November 2015|November 17, 2015|September 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235545||37216|
NCT02235558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0975-F1V|Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke|Super-Selective Intra-Arterial Administration of Verapamil for Neuroprotection After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Phase I Study|SAVER-I|University of Kentucky|No|Recruiting|February 2013|March 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|85 Years|No|||March 2015|March 23, 2015|September 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02235558||37215|
NCT02232672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAM_PROSTAGE3|Choline PET/CT vs. MeAIB PET/CT in Prostate Cancer|Choline PET/CT vs. MeAIB PET/CT. Better Detection of Bone and Lymph Node Metastases in Prostate Cancer Patients, PROSTAGE III||Odense University Hospital|Yes|Not yet recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|N/A|N/A|No|||May 2015|May 4, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232672||37437|
NCT02234167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swedish Prison Program|The Swedish Prison Program is an Intervention Prevention Program Targeting Injecting Drug Users Risk Behaviours and Infectious Diseases|Svenska Häktesprogrammet, Prevention, Risk Behaviour and Infectious Diseases Among IDU.|SHP|Karolinska Institutet|Yes|Suspended|April 2002|||December 2013|Actual|N/A|Interventional|Primary Purpose: Prevention|1||||||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|September 8, 2014|April 4, 2014||No|Termination of data collection|No||https://clinicaltrials.gov/show/NCT02234167||37322|
NCT02234180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU021212I|Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy|Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy||Academic and Community Cancer Research United||Recruiting|September 2014|||October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234180||37321|
NCT02234193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000120|Reducing Side-effects of Autologous Skin Tissue Harvesting|A Pilot Clinical Trial to Reduce Side-effects of Autologous Skin Tissue Harvesting||Massachusetts General Hospital|No|Not yet recruiting|September 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02234193||37320|
NCT02236117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP 5231|Aerobic Training on the Autonomic Modulation in Children|The Effects of 10 Weeks of Aerobic Training on the Autonomic Modulation in Prepubertal Children: a Randomized Control Trial||Universidade Estadual de Londrina|No|Enrolling by invitation|March 2016|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02236117||37172|
NCT02230501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVS|Metabolic Activation With Protein-rich Formula Diet|Metabolic Activation With Protein-rich Formula Diet - a Randomized-controlled Trial|AVS|West German Center of Diabetes and Health|No|Recruiting|February 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|25 Years|79 Years|No|||February 2016|February 22, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02230501||37604|
NCT02239055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NS/0063|Staff Nurse Perceptions of MBT Skills Training for Working With BPD in AMH|Staff Nurse Perceptions of the Impact of Mentalization Based Treatment (MBT) Skills Training on Clinical Practice When Working With Borderline Personality Disorder (BPD) in Acute Mental Health Admission Wards: A Qualitative Analysis.||University of Aberdeen|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Staff nurses who had completed the 2 day Mentalization Based Treatment (MBT) skills        training and were still working in acute mental health.|September 2014|September 10, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02239055||36947|
NCT02229084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202556|Vaccination of High Risk Breast Cancer Patients|A Combined Phase I/II Feasibility-and-Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51 VG Combined With Neoadjuvant Chemotherapy||University of Arkansas|Yes|Recruiting|January 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|61|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229084||37713|
NCT02229097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7029 08|Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients|Clinical Efficacy of Coordinated Boluses in Type 1 Diabetic Patients Treated With Insulin Pumps: a Multicentric, Randomised, Cross Over Study|COBOL|University Hospital, Toulouse|No|Recruiting|October 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229097||37712|
NCT02229370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR2014|Carotid Aneurysm Registry|Extracranial Carotid Artery Aneurysm Registry|CAR|UMC Utrecht|No|Recruiting|June 2014|December 2025|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|blood withdrawel|Both|18 Years|120 Years|No|Non-Probability Sample|Participation in the CAR is intended for all subjects diagnosed with an extracranial        carotid artery aneurysm irrespective of chosen treatment.|December 2015|December 10, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02229370|5 Years|37691|
NCT02229643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|658346|Serum Neuroglobin and Nogo-A Concentrations in Acute Traumatic Brain Injury|Neuroglobin and Nogo-A as Biomarkers for the Prognosis of Closed Traumatic Brain Injury||Shanghai 6th People's Hospital|No|Completed|May 2012|June 2014|Actual|June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|34|Samples Without DNA|Serum samples|Both|19 Years|68 Years|No|Probability Sample|The patient group comprised 19 male and 15 female. Their age averaged 40 years and ranged        from 19 to 68 years, with mean age of 45.1 years. The mechanisms of trauma included motor        vehicle collisions, falls, heavy strikes (patients who were hit by heavy objects such as        bricks, sticks, or falling objects) and assaults. Types of lesions, as evidenced by        radiologic and neurologic symptoms or signs, included cerebral contusions/lacerations,        intracranial hematomas, brain stem injury and diffuse axonal injury.|August 2014|August 31, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02229643|6 Months|37670|
NCT02233517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1298-W|CBT for Aggression in Veterans|Group Cognitive Behavioral Therapy for Anger and Aggression in Veterans With PTSD|CBT-A|VA Office of Research and Development|No|Recruiting|February 2015|September 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02233517||37372|
NCT02239211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_13-027|A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis|A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).|BUTEO|University of Birmingham|Yes|Recruiting|March 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239211||36935|
NCT02234154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1513-CL-TP-01 NOT UK|A Study to Evaluate the Safety and Effectiveness of TOPS(TM) System|A Study to Evaluate the Safety and Effectiveness of the Premia Spine TOPS(Total Posterior Spine) System.||Premia Spine|Yes|Recruiting|December 2014|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|85 Years|No|||October 2015|October 19, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02234154||37323|
NCT02234622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1487-R|Comparing Effects of a Holistic Yoga Program and a Wellness Program on PTSD Symptoms|Outcomes of a Holistic Yoga Program Designed to Relieve PTSD (RELIEVE Trial)|RELIEVE|VA Office of Research and Development|No|Recruiting|August 2015|September 2019|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02234622||37287|
NCT02222688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#140141|UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase I Clinical Trial to Determine the Safety and Tolerability of UC-961 (Cirmtuzumab), an Anti-ROR1 Monoclonal Antibody, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Are Ineligible for Chemotherapy||University of California, San Diego|Yes|Recruiting|August 2014|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|August 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02222688||38205|
NCT02227992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-12-004|The EVARREST™ Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study|A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST™ Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Paediatric Patients||Ethicon, Inc.|No|Recruiting|July 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|17 Years|No|||February 2016|February 29, 2016|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227992||37797|
NCT02222948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI13839|Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis|A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)|EMPIRE|Sanofi|Yes|Active, not recruiting|September 2014|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|168|||Both|18 Years|55 Years|No|||December 2015|December 22, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222948||38185|
NCT02228291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3-019|The Effect of Citric Flavonoid on Endothelial Function|The Effect of Citric Flavonoid Administration on Endothelial Function and Gut Barrier Function||Maastricht University Medical Center|Yes|Completed|March 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02228291||37774|
NCT02233075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP 301|REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection|A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection||Replicor Inc.|No|Active, not recruiting|September 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|No|||February 2015|October 21, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02233075||37406|
NCT02224391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0999|Smartphone-Delivered Training for Smokers|Smartphone-Delivered Attentional Bias Modification Training for Quitting Smokers||M.D. Anderson Cancer Center|No|Recruiting|January 2016|||January 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02224391||38074|
NCT02224404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEXU02|Post Market Clinical Follow-up Investigation to Evaluate Performance and Safety on Pressure Ulcers, PU, When Using Exufiber as Intended|Open, Non-comparative, Multi-centre Post Market Clinical Follow-up Investigation to Evaluate Performance and Safety on Pressure Ulcers, PU, When Using Exufiber as Intended||Molnlycke Health Care AB|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2014|September 7, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224404||38073|
NCT02235727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBR 900-101|To Study the Safety and Action of GBR 900 in the Body of Healthy Volunteers|A Phase 1, Double-Blind, Randomised, Placebo-Controlled, Study to Evaluate the Safety and Pharmacokinetics of GBR 900 in Adult Healthy Volunteers||Glenmark Pharmaceuticals Ltd. India|No|Active, not recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 13, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02235727||37202|
NCT02225262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK Prostate-01|A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating Homogenous Dose Distribution||Community Cancer Center, Normal, Illinois|No|Active, not recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|21 Years|N/A|No|||August 2014|August 25, 2014|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225262||38007|
NCT02225275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0115|Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||October 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225275||38006|
NCT02225847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400425|Effect of Gardening on Brain Activity|Effect of Gardening on Brain Activity||University of Florida|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Female|26 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02225847||37962|
NCT02233166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1117|OSA in Children Referred for Adenotonsillectomy|Obstructive Sleep Apnea in Children Referred for Adenotonsillectomy||Lovisenberg Diakonale Hospital|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|115|Samples Without DNA|Blood sample|Both|2 Years|5 Years|No|Probability Sample|Children aged between 2 and 5 years who are referred for adenoidectomy and/or        tonsillectomy.|September 2014|September 5, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02233166||37399|
NCT02233179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0900000701|The Association Between Unprotected Standing, Walking and Wound Healing in Diabetes|Body-worn Sensor Technology for Improving Diabetic Care During Activities of Daily Living||University of Arizona|No|Completed|June 2009|November 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|37 Years|68 Years|No|||September 2014|September 3, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02233179||37398|
NCT02233335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201305026RINC|The Factors Associated With the Recurrence in Patients With Cushing Disease|The Factors Associated With the Recurrence in Patients With Cushing Disease||National Taiwan University Hospital|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|42|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Cushing's disease who presented to the National Taiwan University Hospital        between 1992 and 2011|September 2014|September 2, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02233335||37386|
NCT02226601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CognAp|Aprepitant to Mitigate Opioids' Cognitive Side Effects|Aprepitant to Mitigate Opioids' Cognitive Side Effects||University of Arizona|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226601||37904|
NCT02226614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vs1 25.03.14|Development of a Head Cooling Device|Development of a Head-cooling Device for Brain Injury: Healthy Volunteer Study||University of Edinburgh|No|Enrolling by invitation|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226614||37903|
NCT02239198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutrition Bar Trials|Impact of a Nutritional Supplement on Metabolic Health|Attenuating the Micronutrient Malnutrition of Overnutrition (AMMO)|CHORIBar|Children's Hospital & Research Center Oakland|No|Recruiting|April 2007|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239198||36936|
NCT02231957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM3756|Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions|Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions||Columbia University|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|520|||Both|11 Years|N/A|No|||January 2016|January 26, 2016|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02231957||37492|
NCT02239289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIR UQTR 2013-2014|Use of Biofeedback Training to Correct Abnormal Neuromechanical Pattern in Chronic Low Back Pain Patients|Correction of Abnormal Flexion-relaxation Phenomenon in Chronic Low Back Pain: the Benefit Associated With Biofeedback Training||Université du Québec à Trois-Rivières|No|Completed|March 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||July 2015|July 10, 2015|September 4, 2014||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT02239289||36929|
NCT02228005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-2013-10|The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults|The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults||University Health Network, Toronto|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228005||37796|
NCT02228304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-503-3-AMD-001|Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD||Neurotech Pharmaceuticals|Yes|Recruiting|September 2014|August 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|50 Years|N/A|No|||January 2016|January 7, 2016|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228304||37773|
NCT02232932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120106|Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma|Randomized Prospective Multicentric Study: Radio-chemotherapy and Liver Transplantation Versus Liver Resection to Treat Respectable Hilar Cholangiocarcinoma|TRANSPHIL|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2014|September 2021|Anticipated|September 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|68 Years|No|||December 2015|December 8, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02232932||37417|
NCT02223858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-080|Staying Positive With Arthritis Study|Staying Positive: An Intervention to Reduce Osteoarthritis Pain Disparities|SPA|VA Office of Research and Development|No|Recruiting|July 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|360|||Both|50 Years|N/A|No|||January 2016|January 26, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223858||38115|
NCT02363127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER-PRO-2014-01|Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients|Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone Capsules (Progeffik) for Endometrial Preparation in Fresh Donated Oocytes Recipients: a Randomised, Prospective, Single-blind, Pilot Study||Instituto Bernabeu|Yes|Recruiting|February 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|48 Years|No|||November 2015|November 9, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363127||27428|
NCT02229110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-039/C|Effectiveness of a Computerised Prompt for Primary and Secondary Care Physicians to Refer or Refer Back Type 2 Diabetes Patients|Effectiveness of a Computerised Prompt for Primary and Secondary Care Physicians to Refer or Refer Back Type 2 Diabetes Patients||UMC Utrecht|No|Completed|October 2013|March 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2779|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229110||37711|
NCT02224664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601005|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease|A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations||Pfizer|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|48|||Both|30 Years|80 Years|No|||March 2016|March 23, 2016|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02224664||38053|
NCT02239367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401014663|Depression Decision Aid: Feasibility Pilot|Electronic Depression Decision Aid for Nurses in Primary Care: Development and Implementation in a Diverse Low-Income Population||Weill Medical College of Cornell University|Yes|Enrolling by invitation|August 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|21 Years|N/A|No|||September 2014|September 17, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239367||36923|
NCT02239380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3541002|Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan|A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus||Pfizer|No|Recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|3 Months|N/A|No|||March 2016|March 23, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239380||36922|
NCT02230228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK001-P1001|Phase 1 Safety Study of ALK-001 in Healthy Volunteers|A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers||Alkeus Pharmaceuticals, Inc.|No|Completed|April 2014|February 2015|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 21, 2015|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230228||37625|
NCT02234401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199|Non Invasive Ventilation for Acute Exacerbations in Adult CF|A Mixed Methods Study Comparing the Clinical Efficacy With the Patient Experience of Non-invasive Ventilation During an Acute Exacerbation Complicated by Respiratory Failure in Adult Cystic Fibrosis|NIVinCF|Manchester Metropolitan University|No|Recruiting|August 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02234401||37304|
NCT02234414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGO-SwOF 01|Epidemiology, Identification Rate and Treatment Penetration of Osteoporotic Vertebral Fractures in Switzerland|Pilot Study on the Epidemiology, Identification Rate and Treatment Penetration of Vertebral Fractures Due to Osteoporosis in Switzerland (SwOF)|SwOF|Interessengemeinschaft Osteoporose|No|Completed|February 2009|June 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|303|Samples Without DNA|serum|Female|65 Years|79 Years|No|Probability Sample|The study population will be based on a representative (age categories, urban vs. rural,        plain vs. mountain) stratified random sample taken from the general population of women        living in urban/ suburban and country/ mountain regions (stratified for n = one third        each, based on city code) in the german speaking part of Switzerland.|September 2014|September 8, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT02234414||37303|
NCT02230774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12118|Hydration Amongst Nurses and Doctors Oncall|Hydration Amongst Nurses and Doctors Oncall|HANDsOn|University of Nottingham|No|Completed|March 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|Samples With DNA|Serum and urine sampling|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Nurses and doctors oncall working on acute medical and surgical admissions wards at the        Queens Medical Centre Nottingham|September 2014|September 2, 2014|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02230774||37583|
NCT02239081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP730.1001|A Safety and Tolerability Study of CTP-730 in Healthy Volunteers|A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers||Concert Pharmaceuticals|Yes|Completed|September 2014|May 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02239081||36945|
NCT02239120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.189|Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)|Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)||Boehringer Ingelheim||Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|6000|||Both|18 Years|150 Years|No|||March 2016|March 21, 2016|September 10, 2014||||No||https://clinicaltrials.gov/show/NCT02239120||36942|
NCT02239159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2014-02-21-1|Acupuncture-assisted-anesthesia to Improve Postoperative Outcome After Digestive Surgery in Elderly Patients|Acupuncture-assisted-anesthesia to Improve Complications After Digestive Surgery in Elderly Patients:Multi-center Double-blinded Randomized Controlled Trial|AID|Fourth Military Medical University|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|460|||Both|65 Years|N/A|No|||January 2016|January 13, 2016|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02239159||36939|
NCT02231619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|677/2013|Use of Low Sensitivity Pregnancy Test for Self-assessment of Medical Abortion|The Feasibility of Replacing In-person Follow-up for Early Medical Abortion With a Low Sensitivity Pregnancy Test, Symptom Checklist and Text Messages in the South African Public Sector Setting.|m-Assist+|University of Cape Town|No|Completed|August 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|525|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02231619||37518|
NCT02231632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yangjingsi2014|The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)|Phase 2/3 Clinical Trial to Assess the Safety and Immunogenicity of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)||Chinese Academy of Medical Sciences|Yes|Completed|January 2011|August 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||September 2014|September 1, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231632||37517|
NCT02231970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|657-GHM|Endoscopic Sleeve Gastroplasty for Treatment of Obesity|Endoscopic Sleeve Gastroplasty for Treatment of Obesity||Grupo Hospital de Madrid|No|Recruiting|September 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||September 2014|September 4, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231970||37491|
NCT02226835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140173|Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198|An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|150|||Both|45 Years|N/A|Accepts Healthy Volunteers|||July 2015|November 4, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02226835||37886|
NCT02227186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ-5 R18 HS021163|Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York|Study of Effectiveness of a School-located Influenza Vaccination Program in Raising Influenza Vaccination Rates|SKIPP RCT|University of Rochester|No|Not yet recruiting|August 2014|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|39000|||Both|4 Years|19 Years|No|||August 2014|August 27, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227186||37859|
NCT02227446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-2-0134|Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)|Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)|VANCO|Major Extremity Trauma Research Consortium|Yes|Recruiting|October 2014|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|August 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227446||37839|
NCT02227459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-L02-s0201-002|Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)|A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, A Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects With Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)||Nitto Denko Corporation|Yes|Active, not recruiting|October 2014|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||September 2015|December 10, 2015|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227459||37838|
NCT02232841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4656H|Electrical Impedance Imaging of Patients on Mechanical Ventilation|Pilot Study: Electrical Impedance Imaging of Patients on Mechanical Ventilation With Lung Pathology||Colorado State University|Yes|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|4|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated adult intensive care unit patients at Medical Center of the        Rockies with pulmonary pathology who have received or will be receiving a CT scan as part        of their standard care|August 2015|August 6, 2015|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02232841||37424|
NCT02232854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1130230|Training and Supervision Program for Depression Management|Comprehensive Technology-Assisted Training and Supervision Program to Enhance Depression Management in Primary Care||University of Chile|No|Recruiting|April 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|434|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02232854||37423|
NCT02232945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWBY-001|Banlangen Granules Anti-seasonal Influenza Study|Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study.|BLG|Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited|Yes|Recruiting|April 2012|November 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|177|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|November 18, 2012||No||No||https://clinicaltrials.gov/show/NCT02232945||37416|
NCT02236130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0027|Peripheral Nerve Blocks in Pediatric Orthopedic Patients|Peripheral Nerve Blocks in Pediatric Orthopedic Patients: Are There Any Post Recovery Benefits?||University of Mississippi Medical Center|Yes|Terminated|June 2014|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|52|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|August 25, 2014||No|Poor response rate on follow up of patients|No|December 30, 2015|https://clinicaltrials.gov/show/NCT02236130||37171|
NCT02228317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA5|Emergency Medical Technician Treat-and-leave Patients Receiving Telemedicine Consultation With Emergency Medical Dispatch Physician - a Controlled Before and After Pilot-study|Emergency Medical Technician Treat-and-leave Patients Receiving Telemedicine Consultation With Emergency Medical Dispatch Physician - a Controlled Before and After Pilot-study||University of Aarhus|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|774|||Both|N/A|N/A|No|||July 2014|December 8, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02228317||37772|
NCT02367755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102060-F_102-FTN12|Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest|Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest||Far Eastern Memorial Hospital|No|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||February 2015|February 13, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02367755||27076|
NCT02367768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410060RINA|Long-term Outcome Related Prognostic Factor and Biomarkers of Major Trauma Database Analysis|Long-term Outcome Related Prognostic Factor and Biomarkers of Major Trauma Database Analysis||National Taiwan University Hospital|No|Recruiting|February 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|CRP, IL-6, cortisol / prolactin / growth hormone|Both|20 Years|N/A|No|Non-Probability Sample|All major trauma (ISS>=16 ) patients sent to NTUH and initiated the trauma team, except        children younger than 20 years old, pregnancy woman, breast feeding woman, and those        forbidden legally.|March 2015|March 9, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02367768||27075|
NCT02233712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3|Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.|An Open-label, Dose-finding, Schedule-changing, Multi-center Study to Determine the Antibody Response to G17DT Treatment of Patients With Gastric Cancer.|GC3|Cancer Advances Inc.|Yes|Completed|August 1999|||March 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|August 27, 2014||Yes||||https://clinicaltrials.gov/show/NCT02233712||37357|
NCT02229383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5553C00002|Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin||AstraZeneca|No|Active, not recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|130 Years|No|||December 2015|December 31, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229383||37690|
NCT02225002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 10903|Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|January 2004|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2014|August 22, 2014|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02225002||38027|
NCT02225015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324638|Cancer Prevention in Women With a BRCA Mutation|Cancer Prevention in Women With a BRCA Mutation: A Follow-up Genetic Counselling Intervention||Women's College Hospital|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|500|||Female|35 Years|70 Years|No|||June 2015|June 9, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02225015||38026|
NCT02239406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK025|Acetabular Bone Vascularity in Metal-on-Metal Revisions|Acetabular Bone Vascularity in Metal-on-Metal Revisions||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|A convenience sample of a total of 15 patients will be enrolled at OrthoCarolina.|October 2015|November 11, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239406||36920|
NCT02225288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2022-J081-007|A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males|||Eisai Inc.|No|Completed|September 2014|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|65 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225288||38005|
NCT02239432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-14-MMC|Telomere Biology in Early Adenocarcinoma of the Lung|Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung||Meir Medical Center|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples Without DNA|One peripheral blood sample is taken for lymphocyte culture and subsequently telomere length      and activity analysis (previously described, Laish I, Gene 2013;529:245-9)|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred by a multi-disciplinary team meeting recommendation for surgical lung        biopsy due to suspected adenocarcinoma of the lung.|September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239432||36918|
NCT02239445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZhang|Intranasal Dexmedetomidine VS Oral Chloral Hydrate for Rescue Sedation During Magnetic Resonance Imaging|||Guangzhou Women and Children's Medical Center|Yes|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|3||Actual|158|||Both|1 Month|6 Months|No|||May 2015|May 9, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239445||36917|
NCT02234635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VQIOL-21|Visual Quality Change of Eyes Implanted With Diffractive Multifocal Intraocular Lens After Cataract Surgery|Phase 1 Evaluate the Visual Quality Change of Eyes Implanted With Multifocal Intraocular Lens and Monofocal Lenses; Phase 2 Evaluate the Tear Film Quality Dynamics of Eyes Implanted With Multifocal Intraocular Lens and Monofocal Lenses.||Wenzhou Medical University|Yes|Recruiting|August 2012|February 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|80 Years|No|||September 2014|September 8, 2014|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02234635||37286|
NCT02226120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2317|Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction|A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696||Novartis|No|Recruiting|October 2014|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3714|||Both|N/A|N/A|No|||February 2016|February 29, 2016|August 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226120||37941|
NCT02226367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-2-0094|Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD|Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD||Seattle Institute for Biomedical and Clinical Research|Yes|Recruiting|January 2015|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||November 2015|November 18, 2015|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226367||37922|
NCT02235298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140671|Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes|||University of Miami|No|Recruiting|September 2015|June 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235298||37235|
NCT02235441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055718|Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies|Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies: A Pilot Study||Duke University|No|Active, not recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02235441||37224|
NCT02232282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206129|Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial|Acupuncture for Female Interstitial Cystitis/Painful Bladder Syndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial||Loyola University|No|Recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|21 Years|65 Years|No|||March 2016|March 11, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02232282||37467|
NCT02232750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141524|Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)|Evaluation of CPD (Cell Population Data) MNV (Mean Neutrophil Volume) as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)|Beckman|Ohio State University|Yes|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Emergency Department|September 2014|September 2, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02232750||37431|
NCT02232763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Losartan_tubularPU_2014|Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria|A Prospective, Randomized, Cross-over Study Evaluating the Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria||Seoul National University Hospital|No|Not yet recruiting|September 2014|November 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|24 Months|18 Years|No|||September 2014|September 3, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232763||37430|
NCT02235935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/14|The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy|The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy||Assaf-Harofeh Medical Center|No|Recruiting|September 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Any diabetic patient undergoing hyperbaric chamber treatment due to diabetic ulcers|September 2014|September 8, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02235935||37186|
NCT02232958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2014.011|Effect of HBO on Functional Connectivity of Resting State Networks in Patients With Cerebral Small Vessel Disease|The Effect of Hyperbaric Oxygen on the Functional Connectivity of Resting State Neural Networks in Patients With Cerebral Small Vessel Disease|HBO|St. Luke's Hospital, Chesterfield, Missouri|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|90 Years|No|||December 2015|December 13, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02232958||37415|
NCT02232971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GluST1_2014|Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes|Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus|GluST1|Hvidovre University Hospital|Yes|Active, not recruiting|September 2014|July 2015|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|8|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02232971||37414|
NCT02370134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/58|Development of Parkinson's Glove for Detection and Suppression of Hand Tremor|Development of Parkinson's Glove for Detection and Suppression of Hand Tremor at Rest Among the Tremor-predominant Parkinson's Disease Patients With Medically Intractable Tremor||Chulalongkorn University|Yes|Not yet recruiting|February 2015|May 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2015|February 23, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02370134||26895|
NCT02239354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC01-101|A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus|A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus||ViaCyte||Recruiting|September 2014|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|55 Years|No|||December 2015|December 1, 2015|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239354||36924|
NCT02233881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2501|Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|January 2001|||November 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4222|||Both|40 Years|N/A|No|Non-Probability Sample|Patient with chronic obstructive pulmonary disease recruited at general practitioners,        pneumologists and internists|September 2014|September 8, 2014|September 8, 2014||||No||https://clinicaltrials.gov/show/NCT02233881||37344|
NCT02233894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2502|Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|February 2001|||May 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|526|||Both|40 Years|N/A|No|Non-Probability Sample|Patient with chronic obstructive pulmonary disease recruited at general practitioners|September 2014|September 8, 2014|September 8, 2014||||No||https://clinicaltrials.gov/show/NCT02233894||37343|
NCT02229396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5553C00003|Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo|A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin||AstraZeneca|No|Active, not recruiting|September 2014|December 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|660|||Both|18 Years|130 Years|No|||January 2016|January 11, 2016|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229396||37689|
NCT02225548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sagene 2014|Sagene 2014 - Parkinson's Disease and Erectile Dysfunction|An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.||University of South Florida||Recruiting|September 2014|||January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|40 Years|64 Years|No|||December 2015|December 18, 2015|August 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02225548||37985|
NCT02229682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-NKTRT-01|Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy|Mild-dose Intensity-modulated Radiation Treatment for Stage IE/IIE Extranodal Nasal-type NK/T-cell Lymphoma With Complete Remission Tumor After Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) Chemotherapy:a Phase II Study||Sun Yat-sen University|Yes|Not yet recruiting|October 2014|October 2019|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||September 2014|September 28, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229682||37667|
NCT02225860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11111|Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease|Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD||Tufts Medical Center|No|Active, not recruiting|May 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||May 2015|May 11, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02225860||37961|
NCT02226133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D&D CIP-0030|Video-Assisted Left Atrial Appendage Exclusion Trial|A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")|VALET|LAAx, Inc.|Yes|Withdrawn|April 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|August 23, 2014|No|Yes|stopped for operational reasons|No||https://clinicaltrials.gov/show/NCT02226133||37940|
NCT02239510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14040|Efficacy of Linaclotide to Senna for CIC|A Randomized, Double-Blind, Trial Comparing the Efficacy of Linaclotide to Senna in Relieving Symptoms in Patients With Chronic Idiopathic Constipation (CIC)||TriHealth Inc.|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||October 2015|October 21, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239510||36913|
NCT02231047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2O - BCO1|64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings|64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings||H2O Health and Agriculture LLC|Yes|Not yet recruiting|January 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|1 Day|Accepts Healthy Volunteers|||November 2014|November 15, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02231047||37562|
NCT02231060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_A55|Study for the Improvement of Long-Term Outcome Prediction in Patients in Coma After Cardiac Arrest|Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors|HOPE|Ludwig-Maximilians - University of Munich|Yes|Recruiting|October 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|172|||Both|18 Years|75 Years|No|Probability Sample|Patients with anoxic-ischemic encephalopathy following cardiac arrest.|March 2016|March 2, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02231060|12 Months|37561|
NCT02231333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-NASH-01|The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis|A Randomized Controlled Trial to Study the Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis.||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2014|March 20, 2015|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02231333||37540|
NCT02239705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02|Mathematical Coupling of Data in Transpulmonary Thermodilution|Mathematical Coupling of Data Between Global-End Diastolic Volume Index and Cardiac Index Calculated by Edwards EV1000||University of Foggia|Yes|Not yet recruiting|September 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients|September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239705||36898|
NCT02239718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17100314|Novel Use of 2-unit Cantilever Resin-bonded Bridges for Replacing Missing Molar Teeth - a Randomized Clinical Trial|Novel Use of 2-unit Cantilever Resin-bonded Bridges for Replacing Missing Molar Teeth - a Randomized Clinical Trial||The University of Hong Kong|No|Recruiting|October 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239718||36897|
NCT02222701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUCH2012/10-4|Composite Resins Reconditioned, Behavior and Survival: Clinical Follow-up 10 Years|Composite Resins Reconditioned, Behavior and Survival: Clinical Follow-up 10 Years|reacondcomp|University of Chile|Yes|Completed|May 2003|December 2013|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any person with composite restorations|August 2014|August 20, 2014|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02222701|10 Years|38204|
NCT02235571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076067|iChoose Decision Kidney Aid for End-Stage Renal Disease Patients|iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients||Emory University|Yes|Active, not recruiting|September 2014|September 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02235571||37214|
NCT02235740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200623|A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)|An Open Label, Two-part, Phase I/Randomized Phase II Study in Subjects With Relapsed/Refractory Multiple Myeloma to Determine a Dose of Afuresertib for Administration in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of Afuresertib With Carfilzomib Compared With Carfilzomib Alone (Part 2)||GlaxoSmithKline|No|Recruiting|November 2014|August 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|130|||Both|18 Years|N/A|No|||March 2015|April 9, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235740||37201|
NCT02223520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS022872|Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial|Treating Parents to Reduce Neonatal Intensive Care Unit (NICU) Transmission of Staphylococcus Aureus|TREAT PARENTS|Johns Hopkins University|Yes|Recruiting|November 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223520||38141|
NCT02223533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sork-2011111058|Multimodal Analgesia With Interfascial Continuous Wound Infiltration: A Randomized Clinical Trial|Multimodal Analgesia With Interfascial Continuous Wound Infiltration of a Local Anaesthetic vs Intravenous Opioids After Laparoscopic Colon Surgery: A Randomized Clinical Trial.||Hospital Galdakao-Usansolo|No|Completed|January 2012|January 2014|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02223533||38140|
NCT02223546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVdi|Circadian Macular Volume Changes in the Choroid|Pilotstudy: Diurnal Changes in Choroidal Volume|CVdi|Medical University of Graz|No|Completed|October 2013|February 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Helathy human subjects|August 2014|August 21, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223546||38139|
NCT02240563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 11459|Low Level Laser Therapy for Autoimmune Thyroiditis|Long-term Follow-up After Treatment of Chronic Autoimmune Thyroiditis With Low Level Laser||University of Sao Paulo General Hospital|No|Active, not recruiting|September 2014|||November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|43|||Both|20 Years|60 Years|No|||February 2016|February 20, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02240563||36833|
NCT02240576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nose fracture study|Possible Manifestation of Rhinitis After Nasal Fracture|Possible Manifestation of Rhinitis After Nasal Fracture||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|310|||Both|18 Years|65 Years|No|Non-Probability Sample|patients who suffered a nasal fracture five to ten years ago (time period 2005-2013) with        nose reposition afterwards under general anaesthesia in the chirurgical day care centre        (CDC) of Gasthuisberg.|December 2015|December 2, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02240576||36832|
NCT02373592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21TW009982|Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer|Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer||Universidad Peruana Cayetano Heredia|No|Recruiting|September 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|172|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373592||26630|
NCT02373605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMT0001|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Cervicogenic Headache|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Cervicogenic Headache: a Multi-center Randomized Clinical Trial||Alabama Physical Therapy & Acupuncture|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373605||26629|
NCT02224417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHA-2013-1-005|Trial to Incentivise Adherence for Diabetes|A Randomized Controlled Trial to Improve Diabetes Outcomes Through Financial Incentives|TRIAD|Duke-NUS Graduate Medical School|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|240|||Both|21 Years|70 Years|No|||November 2015|November 26, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02224417||38072|
NCT02224677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR: 13-002-E|Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)|Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)|CLOCK|Seattle Children's Hospital|No|Recruiting|November 2013|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|685|Samples With DNA|Saliva|Both|12 Months|24 Months|No|Non-Probability Sample|Children with and without craniofacial microsomia will be drawn from outpatient clinics,        medical centers, and local pediatric practices near performance sites and local pediatric        practices. Cases will be approached in their first 24 months by either a member of their        craniofacial team, a member of the CLOCK study team, or one of their treating providers.        Cases may find out about the study through ClinicalTrials.gov. Controls will initially be        approached through a treating provider, a member of the CLOCK team, or through an        announcement about the study.|December 2015|December 11, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224677||38052|
NCT02224690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1423|A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.||GW Research Ltd|Yes|Active, not recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|2 Years|55 Years|No|||December 2015|December 21, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224690||38051|
NCT02233543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ANO01|A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)|A Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)||Novartis|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02233543||37370|
NCT02233556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308083MINB|Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects|Effects of Memantine on Event-related Potential in the Comparison of Patients With Early Schizophrenia and Healthy Subjects||National Taiwan University Hospital|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02233556||37369|
NCT02233725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00830|MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance|Pilot-Study - Incorporating Contrast-Enhanced Ultrasound (CEUS) to Real-Tim MRI / Ultrasound Fusion Imaging for Prostate Biopsies||University of British Columbia|No|Active, not recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Male|25 Years|N/A|No|||September 2014|September 2, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02233725||37356|
NCT02226146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immune/BRT/BP-01|Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid|An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid||Immune Pharmaceuticals|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|60 Years|N/A|No|||March 2016|March 2, 2016|July 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226146||37939|
NCT02235090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMA-INPN-1|Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting|Assessment of Feasibility and Statistical Reliability of Functional Outcomes Measurement in Neuromuscular Patients Without Trial Site Visiting by Standard Functional Scales and by Special Autonomic Device in Double-blind, Placebo Controlled Study of Cervical Spinal Cord Transdermal Direct Current Stimulation in Patients With Spinal Muscular Atrophy||Charitable Foundation Children with Spinal Muscular Atrophy|Yes|Not yet recruiting|February 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 5, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02235090||37251|
NCT02235194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWZRP-14-01|Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism|Influence of an Amino Acid and Chromium Containing Table Water on Glucose Response to a Test Meal in Type 2 Diabetes Patients in a Double Blind Cross - Over Design||Stoffwechselzentrum Rhein - Pfalz|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02235194||37243|
NCT02226848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140174|Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury|Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2015|July 8, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226848||37885|
NCT02226861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140180|Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation|Ultra Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|70 Years|No|||July 2015|February 27, 2016|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226861||37884|
NCT02227199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9111|Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)|BV-ICE|University of Washington|Yes|Recruiting|October 2014|||September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227199||37858|
NCT02222961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600.2|Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers|A Single-blind, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIIR 561 CL as Loading Dose (Dosage: 37.5 mg/h - 150 mg/h, Infusion Time 1 Hour) Followed by Maintenance Dose (Dosage: 20 mg/h - 40 to 125 mg/h), Infusion Time 5 Hours||Boehringer Ingelheim||Completed|November 1999|||June 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||60|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02222961||38184|
NCT02223286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX_000016|Understanding Clinician Utilization - Cardiology|Understanding Clinician Utilization of Corus® CAD in Clinical Decision Making|UCU-CARD|CardioDx|No|Completed|March 2013|August 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|552|||Both|21 Years|N/A|No|Non-Probability Sample|The patient population of interest and the main inclusion criterion for inclusion is the        occurrence of chest pain (or anginal equivalent) in a patient without known significant        CAD or a history of prior myocardial infarction, and the utilization of Corus® CAD.        Additionally, subjects with similar chest pain (or angina equivalent) whom did not undergo        Corus CAD will be included as a control group, to understand the diagnostic evaluation and        management of patients prior to Corus CAD use.|August 2014|August 21, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02223286||38159|
NCT02227745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM 2296/14-R|Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema|Efficacy of Dorzolamide as an Adjuvant to Improve Visual Function After Focal Photocoagulation Treatment in Diabetic Patients With Clinically Significant Macular Edema||Hospital Juarez de Mexico|No|Recruiting|January 2014|December 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|40 Years|70 Years|No|Probability Sample|the accessible population are type 2 diabetic patients treated with focal photocoagulation        in Hospital Juarez Mexico|March 2015|March 18, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227745||37816|
NCT02228018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2014-118|The Comparison of Electronic Auscultation Coupled With CALSA and FRI; Repeatability of FRI Biomarkers|The Comparison of Electronic Auscultation Coupled With Computer Aided Lung Sound Analysis (CALSA) and Functional Respiratory Imaging (FRI) and Repeatability of FRI Biomarkers in Healthy Subjects and Asthma Patients||FLUIDDA nv|Yes|Withdrawn|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||January 2016|February 2, 2016|August 25, 2014||No|Other strategies followed|No||https://clinicaltrials.gov/show/NCT02228018||37795|
NCT02225301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-0376|iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers|Early Childhood Practitioner's Knowledge and Attitudes Regarding Reporting Child Abuse/Neglect-iLookOut|iLookOut|Milton S. Hershey Medical Center|No|Recruiting|June 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02225301||38004|
NCT02363140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR11/9770|Magnetic Resonance Imaging to Assess Changes in Meniscus Vascularity||MOVE|The Leeds Teaching Hospitals NHS Trust|No|Active, not recruiting|June 2012|||June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363140||27427|
NCT02228850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NexMed 2014-RPS-001|Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis|A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)||NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)|No|Completed|November 2014|December 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|35|||Both|18 Years|79 Years|No|||March 2016|March 21, 2016|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228850||37731|
NCT02229123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000791-26|Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study|Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study|LEVNEONAT1|University Hospital, Tours|Yes|Not yet recruiting|December 2014|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|37 Weeks|43 Weeks|No|||September 2014|September 18, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229123||37710|
NCT02229136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13026|Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus|Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis||US Oncology Research|Yes|Recruiting|September 2014|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||November 2015|November 7, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229136||37709|
NCT02239783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002I|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems||MicroPort Orthopedics Inc.|No|Enrolling by invitation|November 2014|November 2028|Anticipated|November 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with a primary PROFEMUR® TL Modular Femoral        Stem|October 2015|October 16, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239783||36892|
NCT02233348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403109RINC|Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder|Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder: a Follow-up Study||National Taiwan University Hospital|Yes|Recruiting|January 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|523|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments|Both|10 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|373 ASD, aged 10-25, from the cohort of ASD established by NRPGM, who consented to this        follow-up study at their first assessments in 2007-2011 and 150 age-, and sex-matched TD,        at the ratio of 2:1.|March 2016|March 13, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02233348||37385|
NCT02239822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271/2013|Electrical Stimulation in Patients With Unipolar Major Depression|Double Blinded Randomized Trial of eTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.|TREND2|Hospital do Coracao|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02239822||36889|
NCT02239835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.4|Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients|Tipranavir: An Open-label, Randomized Study Comparing Combination Therapy (Tipranavir and Ritonavir vs. Saquinavir and Ritonavir) Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients||Boehringer Ingelheim||Terminated|December 1999|||November 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02239835||36888|
NCT02239887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP005|Coherex WAVECREST I Left Atrial Appendage Occlusion Study|Coherex WAVECREST I Left Atrial Appendage Occlusion Study||Coherex Medical|No|Completed|October 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|N/A|No|Non-Probability Sample|The target population for this study is the subset of patients who have non-valvular        paroxysmal, persistent, or permanent atrial fibrillation; LAA anatomy amenable to        treatment by percutaneous techniques; and an anticoagulation indication for potential        thrombus formation in the left atrium. Patients with an absolute or relative        contraindication to anticoagulants will also be included.|January 2015|January 13, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239887||36885|
NCT02239900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0882|Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors|Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies||M.D. Anderson Cancer Center|Yes|Recruiting|August 2014|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239900||36884|
NCT02239913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BED IN 27|Topiramate-Phentermine Combinations for Cocaine Dependence|Topiramate-Phentermine Combinations for Cocaine Dependence||University of Kentucky|Yes|Recruiting|September 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|September 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239913||36883|
NCT02239926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000581|Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D|Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)|Ranolazine|Mayo Clinic|No|Terminated|September 2014|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|September 11, 2014|Yes|Yes|Difficulty in enrolling subjects|No|January 5, 2016|https://clinicaltrials.gov/show/NCT02239926||36882|The study was terminated early due to enrollment issues.
NCT02229994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00181-56|Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases|Development of a New Tool for Dyspnea Measurement (DYSLIM for Dyspnea Limitation) in Chronic Respiratory Diseases|DYSLIM|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2010|December 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|Study Population are adults patients with chronic respiratory diseases (Sample1: COPD;        Sample 2: Diffuse interstitial lung diseases; Sample 3: Pulmonary Arterial Hypertension        primary or secondary (post embolic .....); Sample 4: Adult with Cystic fibrosis)|December 2015|December 15, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02229994||37643|
NCT02239562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140114|sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Females With Autoimmune Hepatitis||University of Miami|Yes|Recruiting|August 2014|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|18|||Female|18 Years|70 Years|No|||January 2016|January 28, 2016|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239562||36909|
NCT02239614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-13-10|TDENV PIV and LAV Dengue Prime-boost Strategy|A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region||U.S. Army Medical Research and Materiel Command|No|Recruiting|November 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|September 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239614||36905|
NCT02239627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140735818|Epidural Clonidine Versus Corticosteroid for Low Back Pain|Prospective, Randomized, Double Blinded Comparison of the Analgesic Efficacy of Epidural Clonidine Versus Corticosteroid for Low Back Pain||West Virginia University|No|Terminated|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|September 10, 2014||No|based on interim anaylsis|No||https://clinicaltrials.gov/show/NCT02239627||36904|
NCT02230787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186/13|Gingival Recession Coverage With and Without Emdogain|Effect of Emdogain on Wound Healing After Gingival Recession Coverage Using Connective Tissue Graft: A Pilot Study||University of Bern|No|Recruiting|August 2014|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02230787||37582|
NCT02230800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3894|PPALM-Palm Oil and Pentoxifylline Against Late Morbidity|Randomised Double-blind Placebo Controlled Phase II Trial of Tocovid SupraBio in Combination With Pentoxifylline (PTX) in Patients Suffering Long-term Adverse Effects of Radiotherapy for Pelvic Cancer|PPALM|Royal Marsden NHS Foundation Trust|No|Not yet recruiting|January 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|117|||Both|18 Years|N/A|No|||July 2014|September 2, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230800||37581|
NCT02231346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1366|Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease|Berodual® Respimat® 20/50 Microgram/Dose Solution for Inhalation: Assessment of Handling and Patient Satisfaction in Comparison to a Powder Inhaler||Boehringer Ingelheim||Completed|October 2005|||April 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of chronic obstructive pulmonary disease recruited at        pneumologists in practice|September 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231346||37539|
NCT02231359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1363|Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|January 2004|||September 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2006|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diagnosis chronic obstructive airways disease recruited at general        practitioners, internal specialists and specialists in pneumology in practice|September 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231359||37538|
NCT02227472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMREAD|Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease|Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease: Family and Environmental Factors||St. Jude Children's Research Hospital|No|Recruiting|September 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|99|||Both|48 Months|68 Months|No|Non-Probability Sample|Participants will be between 4 and 5 years of age, have a diagnosis of sickle cell disease        (SCD) and be patients at St. Jude Children's Research Hospital.|March 2016|March 22, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02227472||37837|
NCT02231645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02154724|Subthalamic Deep Brain Stimulation Effects on Decision-making Processing in Patients With Parkinson's Disease|Subthalamic Deep Brain Stimulation Effects on Moral and Economics Decision-making Processing in Patients With Parkinson's Disease||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|May 2013|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|22|||Both|40 Years|N/A|No|||September 2014|September 1, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231645||37516|
NCT02231983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCID-20140901|Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China|Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China||Shanghai Children's Medical Center|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|2 Months|2 Years|No|Non-Probability Sample|SCID patients|September 2014|September 1, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231983|50 Months|37490|
NCT02232295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M44-124|A Clinical Trial to Study the Effect of Imagined Progressive Movements in Patients With Paralysis of One Side of the Body.|To Study the Effect of Graded Motor Imagery on Upper Limb Motor Functions and Quality of Life in Patients With Stroke||Maharishi Markendeswar University|Yes|Completed|April 2013|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|45 Years|65 Years|No|||September 2014|September 4, 2014|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02232295||37466|
NCT02232867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-480-04d|Arm and Leg Cycling Exercise After Stroke|Adjunct Locomotor Training to Improve Walking Ability After Stroke||University of Victoria|No|Recruiting|July 2011|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||September 2014|September 2, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02232867||37422|
NCT02230020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00084508|Efficacy of High Flow Therapy in COPD At Home|Efficacy of High Flow Therapy in COPD At Home|EHFT|Johns Hopkins University|No|Recruiting|August 2013|||September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|CRP Fibrinogen|Both|18 Years|N/A|No|Non-Probability Sample|Chronic Obstructive Pulmonary Disease|August 2014|August 29, 2014|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02230020||37641|
NCT02230254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2323|PE PREMIER CHINA CLINICAL TRIAL|PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)||Boston Scientific Corporation|No|Completed|April 2014|May 2015|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||April 2015|December 11, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02230254||37623|
NCT02367820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-181-08|Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain|A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-cancer Pain|SUMMIT-LTS|Nektar Therapeutics|No|Recruiting|March 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367820||27071|
NCT02367833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000053|Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis|Primary Mechanisms Underlying the Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis and Bone Metabolism in Young Women||Penn State University|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|48|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2015|February 13, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02367833||27070|
NCT02239809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239/2012|Electrical Stimulation in Patients With Unipolar Major Depression|Double Blinded Randomized Trial of sTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.|TREND1|Hospital do Coracao|Yes|Active, not recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02239809||36890|
NCT02226640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 238153|Uncovering the 'ORIGINS' of Diabetes|Uncovering the 'ORIGINS' of Diabetes|ORIGINS|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Completed|November 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|80|Samples With DNA|Blood Urine Fat tissue Muscle Tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|January 2016|January 14, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02226640||37901|
NCT02226874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914170|Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation|A Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|38|||Male|80 Years|90 Years|Accepts Healthy Volunteers|||June 2015|January 12, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02226874||37883|
NCT02227212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14065|Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM|A Multi-Center,Open-Label, Single-Arm, Multiple Dose Study With HOE901-U300 to Assess The Ease of Use And Safety of a New U300 Pen Injector in Insulin-Naïve Patients With T2DM||Sanofi|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227212||37857|
NCT02227225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2014/748|Factors Affecting the Incidence of Postoperative Delirium in Frail Elderly|Factors Affecting the Incidence of Postoperative Delirium in Frail Elderly Undergoing Non-cardiac Surgery: An Observational Study||Singapore General Hospital|No|Recruiting|September 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|65 Years|N/A|No|Non-Probability Sample|Postoperative inpatients|January 2015|January 13, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227225||37856|
NCT02227238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200304|Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment|A Phase 3b, Randomized, Open-label Study of the Antiviral Activity and Safety of Dolutegravir Compared to Lopinavir/Ritonavir Both Administered With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1 Infected Adult Subjects With Treatment Failure on First Line Therapy||ViiV Healthcare|Yes|Recruiting|December 2014|August 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|612|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02227238||37855|
NCT02230007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000065-37|Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly|Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly||Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2013|July 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|65 Years|N/A|No|||December 2013|September 2, 2014|May 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02230007||37642|
NCT02226380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-JZ|FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer|A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer|FOLFOX6|Peking Union Medical College Hospital|No|Recruiting|October 2013|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|75 Years|No|||August 2014|August 26, 2014|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02226380||37921|
NCT02226627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELANS-2014|Latin American Survey of Nutrition and Health / Estudio Latinoamericano de Nutrición y Salud|Latin American Survey of Nutrition and Health / Estudio Latinoamericano de Nutrición y Salud||Hospital Infantil Sabará|Yes|Active, not recruiting|March 2014|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|9000|||Both|15 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The sample will include subjects of both sexes, between 15 and 65 years old, considering        four age ranges (as see below), that belong to high, middle or low socioeconomic levels        (SEL), living in private households in the major cities and other relevant cities in terms        of population weight, according to the regions of each of the countries selected for the        study.|August 2015|August 17, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02226627||37902|
NCT02234648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUKK1|To Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Vascular Function.|Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Vascular Function.||Northumbria University|Yes|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|14|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02234648||37285|
NCT02235207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14030|Effectiveness of Fustra—Exercise Program in Neck and Low Back Pain|Effectiveness of Fustra—Exercise Program on Pain, Physical Fitness and Quality of Life in Female and Male Office Workers Suffering From Recurrent Neck and Low Back Pain — a Randomized Controlled Trial|FUSTRA|UKK Institute|No|Completed|September 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|30 Years|50 Years|No|||March 2016|March 10, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02235207||37242|
NCT02235311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212917|Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed|Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed||University of Missouri-Columbia|Yes|Not yet recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235311||37234|
NCT02231658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-Motil|Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion|Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion||Profil Institut für Stoffwechselforschung GmbH|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02231658||37515|
NCT02235324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-13-7|Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer||University of Southern California|Yes|Withdrawn|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|September 4, 2014|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02235324||37233|
NCT02235584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-070|Insulinotropic Effect of GLP-1 and GIP After Dexamethasone|Loss of Insulinotropic Properties of Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Peptide (GIP) After Glucocorticoid Induced Insulin Resistance||Hvidovre University Hospital|No|Completed|July 2009|||June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|19|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 7, 2014|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02235584||37213|
NCT02235597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-Doebbeling-4198014|Improving Healthcare Systems for Access to Care by Underserved Patients|Improving Healthcare Systems for Access to Care by Underserved Patients|PCORI|Indiana University|No|Enrolling by invitation|January 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|350|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Clinic patient Population|November 2015|November 10, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02235597|2 Years|37212|
NCT02235753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1072011|High-intensity Exercise After Acute Cardiac Event (HITCARE)|High-Intensity Exercise Training in Cardiac Rehabilitation After Acute Coronary Event - Randomized Controlled Trial|HITCARE|Kuopio Research Institute of Exercise Medicine|Yes|Not yet recruiting|December 2014|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|40 Years|80 Years|No|||November 2014|November 19, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02235753||37200|
NCT02235948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y211045|Effects of Folic Acid Supplementation on Arsenic Lowering|Efficacy and Safety of Folic Acid Supplementation Lowering Arsenic in a Chronic, Low-level Exposed Arsenic Population: a Randomized, Double-blind, Placebo Controlled Clinical Trial.||Wenzhou Medical University|Yes|Active, not recruiting|July 2014|December 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|450|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235948||37185|
NCT02236143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212M24883|Ultrahigh Field Body MR Imaging|Ultrahigh Field Body MR Imaging||University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|February 2013|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male or females over the age of 18, recruiting by invitation only.|June 2015|June 17, 2015|March 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02236143||37170|
NCT02234232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0016810|The Feasibility and Safety of an Intradialytic Exercise Program: DIALY-SIZE|Exercise in the Dialysis Unit: a Randomized Factorial Pilot Study on the Feasibility and Safety of Intradialytic Exercise||University of Alberta|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|4||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234232||37317|
NCT02370641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000874|Effects of Pomegranate Extract on Intestinal Flora|Variations in Urolithin Production by the Microbiome After Pomegranate Extract Administration: Understanding Metabolism and Responsiveness to Pomegranate Ellagitannins|PomX|University of California, Los Angeles|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|26|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370641||26856|
NCT02233192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrEPception|PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples|PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples||Boston University|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|Samples Without DNA|To measure levels of PrEP to assess medication adherence, approximately 4ml of blood will be      drawn on female participants (2 tests total for the study period). One dried blood spot will      be collected after steady state tenofovir (approximately one month after beginning PrEP) is      reached and one at the time a pregnancy is confirmed.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will take place in teaching hospitals in four U.S. cities: Boston, Baltimore,        Philadelphia, and San Francisco and will involve couples who have chosen to begin PrEP for        conception as part of their clinical care after receiving preconception counseling and        reviewing their options with their health care provider.|July 2015|July 27, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02233192||37397|
NCT02233205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014YJZ11|Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System|Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma||Beijing Cancer Hospital|Yes|Recruiting|October 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||July 2015|July 23, 2015|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02233205||37396|
NCT02226393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC147804ctil|Evaluating Effectiveness of Dyadic Prolonged Exposure on 2-4 Years Old vs. Toddler-parent Focused Treatment|Evaluating Effectiveness of Dyadic Prolonged Exposure Treatment on 2-4 Years Old vs. Toddler-parent Focused Treatment||Rabin Medical Center|Yes|Not yet recruiting|October 2014|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Months|54 Months|No|||March 2015|April 15, 2015|July 29, 2014||||No||https://clinicaltrials.gov/show/NCT02226393||37920|
NCT02231372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1362|Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease||Boehringer Ingelheim||Completed|March 2004|||December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4602|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diagonsis chronic obstructive airways disease recruited at general        practitioners, internal specialists and specialists in pneumology|September 2014|September 2, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02231372||37537|
NCT02231671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-008176-504|A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176|A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of 14C-ALS-008176 in Healthy Male Subjects||Alios Biopharma Inc.|No|Completed|August 2014|November 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02231671||37514|
NCT02231684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3687|Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide|A Randomised, Single Centre, Two Period, Incomplete Cross Over Trial in Healthy Subjects Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide||Novo Nordisk A/S|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02231684||37513|
NCT02231996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGD-20140829|Chronic Granulomatous Disease Study in China|||Shanghai Children's Medical Center||Not yet recruiting|September 2014|||August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|CGD patients|September 2014|September 3, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02231996|2 Years|37489|
NCT02232009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2013-GES-0011|Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit|Development of MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit|Firefly|GE Healthcare|No|Recruiting|May 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|180|||Both|N/A|2 Years|No|||September 2015|September 23, 2015|August 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02232009||37488|
NCT02233907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54.563|Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|October 1999|||August 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|595|||Both|40 Years|N/A|No|Non-Probability Sample|Patient with chronic obstructive pulmonary disease at general practitioners|September 2014|September 8, 2014|September 8, 2014||||No||https://clinicaltrials.gov/show/NCT02233907||37342|
NCT02233920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54.564|Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis|Postmarketing Surveillance Study (as Per § 67(6) AMG [German Drug Law]) of Ventilat® Metered-dose Inhaler in Chronic Obstructive Bronchitis||Boehringer Ingelheim||Completed|January 2000|||December 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|716|||Both|40 Years|N/A|No|Non-Probability Sample|Patient with chronic obstructive bronchitis disease recruited at pneumologists|September 2014|September 8, 2014|September 8, 2014||||No||https://clinicaltrials.gov/show/NCT02233920||37341|
NCT02233933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RadP|Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation Proctitis|Randomized Trial of Argon Plasma Coagulation Versus Argon Plasma Coagulation and Hemospray in the Therapy of Radiation Proctitis||British Columbia Cancer Agency|Yes|Not yet recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02233933||37340|
NCT02230241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-XXX-2014/1|CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)|CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II|CEPHEUSII|AstraZeneca|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2700|||Both|N/A|N/A|No|Non-Probability Sample|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk,        on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for        a minimum of 8 weeks (56 days). Before starting any study-related activities, the        investigator should obtain written informed consent personally signed and dated by the        subject.|December 2015|December 15, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02230241||37624|
NCT02230514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-PSART-01|Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones|A Phase IIa, Single Center, Prospective, Randomized, Parallel, Two-arms, Single-dose, Open-label With Blinded Assessor Pilot Clinical Trial to Assess ex Vivo Expanded Adult Autologous Mesenchymal Stromal Cells Fixed in Allogeneic Bone Tissue (XCEL-MT-OSTEO-ALPHA) in Non Hypertrophic Pseudoarthrosis of Long Bones||Banc de Sang i Teixits|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|December 10, 2015|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230514||37603|
NCT02222974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600.1|Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL|A Single-blind, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIIR 561 CL (Dosage: 1mg/h - 175 mg/h), Infusion Time 1 Hour||Boehringer Ingelheim||Completed|January 1999|||August 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|84|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02222974||38183|
NCT02222987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528.23|Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects|Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Oral Doses of 100 mg Terbogrel Bid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial.||Boehringer Ingelheim||Completed|February 1999|||March 1999|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02222987||38182|
NCT02223299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553Schanzer0002|Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.|A Randomized Double-Blind Placebo-Controlled Pilot Study of L-tyrosine and L-tryptophan in Depressed Patients Receiving L-methylfolate and and SSRI||John D. Dingell VA Medical Center|No|Not yet recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|24|||Both|18 Years|65 Years|No|||September 2015|September 2, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02223299||38158|
NCT02223312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiroVAX002|Therapy for Progressive and/or Refractory Hematologic Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte- Macrophage Colony Stimulating Factor, in Patients With Progressive and/or Refractory Hematologic Malignancies||Kiromic, LLC|Yes|Not yet recruiting|May 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223312||38157|
NCT02235454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056471|SDOCT-GMPE Software|A Prospective Evaluation of the Novel Glaucoma Premium Edition Software for Spectral Domain Optical Coherence Tomography||Duke University|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02235454||37223|
NCT02223559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-593 ex 12/13|Non-invasive Assessment of Pulmonary Artery Pressure|Non-invasive Assessment of Pulmonary Artery Pressure and Right Ventricular Function in Patients With Pulmonary Hypertension||Medical University of Graz|No|Recruiting|August 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|Serum and plasma samples will be retrained|Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing right heart catheterization due to clinical reasons|February 2016|February 29, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223559||38138|
NCT02223871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-071-102|Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects|A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects||Actelion|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02223871||38114|
NCT02224144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM7850|Bone Mass and Strength After Kidney Transplantation|A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation||Columbia University|Yes|Recruiting|August 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|40 Years|N/A|No|||January 2016|January 26, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02224144||38093|
NCT02224703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1424|A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.||GW Research Ltd|Yes|Recruiting|March 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|2 Years|18 Years|No|||December 2015|December 21, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224703||38050|
NCT02225028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47327-G|Feasibility of Telephone Counseling to Increase Physical Fitness in SCI|Feasibility of Telephone Counseling to Increase Physical Fitness in SCI (Co-Motion Study)||University of Washington|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02225028||38025|
NCT02360072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangzhouIRD-LSUN1|Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma|To Delineate the Characteristics of Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma and Sought to Explore a Possible Predictor in the Progression of Allergic Rhinitis to Asthma||Guangzhou Institute of Respiratory Disease|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|300|Samples Without DNA|serum ,nasal lavage fluid ,induced sputum|Both|6 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Children 6-15 years old with allergic rhinitis and/or asthma diagnosed by specialist        physician were enrolled in the department of paediatrics,respiratory and        otorhinolaryngology in Guangzhou Institue of Respiratory Diseas .In addition, healthy        students in a school were enrolled as normal control group.|February 2015|February 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360072||27663|
NCT02239744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDUEH-1|Intervention Study on the Health Impact of Air Filters in Chinese Adults|Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: a Randomized Double-blind Crossover Trial of Air Purifiers||Fudan University|Yes|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 7, 2014||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT02239744||36895|The study only included 35 participants in 10 rooms, we might therefore have missed some potentially important but modest differences due to the relatively small sample size.
NCT02235337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17406|The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion|The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion||University of Virginia|No|Active, not recruiting|September 2014|||August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|September 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02235337||37232|
NCT02237638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45279.000.13|Phase I Study on VEGF Vaccination in Metastatic Solid Tumors|A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors||VU University Medical Center|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02237638||37055|
NCT02231073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4131|Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism|Peripheral and Central Postural Disorders in the Elderly|EEforPD|Oregon Health and Science University|Yes|Recruiting|August 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|120|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02231073||37560|
NCT02360631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000721|Advancing Tobacco Use Treatment for African American Smokers|Advancing Tobacco Use Treatment for African American Smokers|KIS-IV|University of Kansas Medical Center|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 8, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360631||27620|
NCT02360644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1150|Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease|Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease||University of Colorado, Denver|Yes|Recruiting|October 2014|August 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02360644||27619|
NCT02374372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE10.253|Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit|Prospective Randomized Study Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit|PHARMACO-$|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2013|February 26, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02374372||26570|
NCT02374411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDW091114A|Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients|A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients||Edward Hospital|No|Enrolling by invitation|September 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|HIPEC surgeons based internationally|February 2015|February 23, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02374411||26567|
NCT02360891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-50|Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis|Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis Prognosis and Endophenotype Biomarkers French Database Set up|PULSE|University Hospital, Lille|Yes|Recruiting|January 2015|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|whole blood, serum, white cells, platelets, cerebrospinal fluid,skin, muscle, brains|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Multicentric French cohort of 1000 ALS patients, 100 neurological controls and 200 healthy        controls|January 2016|January 6, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02360891|10 Years|27600|
NCT02374476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1827|Bipolar Ventricular Tachycardia (VT) Study|Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|February 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374476||26562|
NCT02374528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015046|Negative Pressure Wound Therapy for Skin Grafts|Clinical Randomized Controlled Trials on Negative Pressure Wound Therapy for Skin Grafts||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|85 Years|No|||February 2015|February 27, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374528||26558|
NCT02361918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTF-EH0001|Predictive Value of Procalcitonin, CRP, Drain Fluid Culture, Il-6 and Tnf-α in Anastomotic Leakage|Predicting Value of Serum Procalcitonin, C-reactive Protein, and Drain Fluid Culture, Fluid Il-6 and Tnf-α Levels in Anastomotic Leakage Following Rectal Resection||Istanbul University||Completed|March 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|N/A|N/A|No|Probability Sample|patient had colonic resection|February 2015|February 8, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02361918||27521|
NCT02361931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0252-12-RMB|Safety and Efficacy of a Novel Topical Formulation Containing Erythropoietin|SAFETY AND EFFICACY OF A NOVEL TOPICAL FORMULATION CONTAINING ERYTHROPOIETIN FOR THE TREATMENT OF CHRONIC DIABETIC ULCERS. A DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED PILOT STUDY||Remedor Biomed Ltd|No|Not yet recruiting|April 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2015|February 18, 2015|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT02361931||27520|
NCT02366377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-108|The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients|An Efficacy, Safety, and Tolerability Study of SHR3824 in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy||Jiangsu HengRui Medicine Co., Ltd.||Not yet recruiting|February 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|168|||Both|18 Years|75 Years|No|||February 2015|February 18, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366377||27180|
NCT02362165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-MM-308|CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma|A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma||Sun Yat-sen University|No|Not yet recruiting|April 2015|May 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|80 Years|No|||February 2015|February 11, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02362165||27502|
NCT02362178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/10|Thromboelastographic Guide for Blood Products in Cirrhotics|USE OF THROMBOELASTOGRAPHY TO GUIDE BLOOD PRODUCTS REPLACEMENT IN DECOMPENSATED CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES||University of Modena and Reggio Emilia||Completed|February 2011|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||February 2015|February 11, 2015|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02362178||27501|
NCT02371928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140093|A Neuromuscular Exercise Program for Patients With Anterior Shoulder Instability|A Neuromuscular Exercise Program for Patients With Anterior Shoulder Instability: A Randomized Controlled Trial|SINEX|University of Southern Denmark|No|Recruiting|February 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|39 Years|No|||March 2016|March 9, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02371928||26757|
NCT02238847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90905950|Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy|Randomized Controlled Trial Comparing Covered and Uncovered Biliary Self Expanding Metal Stents (SEMS) for Pre-operative Drainage During Neoadjuvant Therapy in Patients With Pancreatic Cancer||Boston Scientific Corporation|No|Recruiting|March 2015|March 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||April 2015|November 20, 2015|May 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02238847||36963|
NCT02372630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514091|The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects|The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects|1971|University at Buffalo|Yes|Recruiting|May 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||December 2015|December 1, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372630||26704|
NCT02372643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-AOUC-2015-01|Ultrasound and Psychobiological Correlates of Female Sexual Function|Pilot Interventional Study on Clitoral Ultrasound Measures and Psychobiological Correlates of Female Sexual Function||University of Florence|No|Active, not recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02372643||26703|
NCT02373241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F141107009|Preventing Sickle Cell Kidney Disease|Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease||University of Alabama at Birmingham|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|25 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373241||26657|
NCT02373306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPS-ICD|NIPS to Identify High-risk Patients With ICD|Non-invasive Programmed Stimulation to Identify High-risk Patients With Implanted Cardioverter-defibrillator|NIPS-ICD|St. Joseph's Centre, Poland||Active, not recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|150|||Both|N/A|N/A|No|||November 2015|November 17, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02373306||26652|
NCT02360150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/205/HP|Evaluation of Myocardial Viability : Dual Energy Cardiac CT vs. Cardiac MRI|Evaluation of Myocardial Viability in Late Presentation Myocardial Infarction: Dual Energy Cardiac CT vs. Cardiac MRI.|InfarctusGSI|University Hospital, Rouen|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02360150||27657|
NCT02362802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-015|Myocardial Minimal Damage After Rapid Ventricular Pacing|Myocardial Minimal Damage After Rapid Ventricular Pacing|MyDate|Deutsches Herzzentrum Muenchen|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02362802||27453|
NCT02363543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14-090|Comparison of Hyalomatrix and Integra Wound Matrix on Burn Wounds||Hyalomatrix|Medline Industries|No|Not yet recruiting|February 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363543||27396|
NCT02364700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409015458|Portable EMG-triggered Hand Robot for Individuals After Stroke|||Rehab-Robotics Company Limited|No|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364700||27308|
NCT02364713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1365|MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer|A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer||Mayo Clinic|Yes|Recruiting|March 2015|||February 2025|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Female|18 Years|N/A|No|||October 2015|January 6, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364713||27307|
NCT02364960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-047|Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)|Implementation of the Target Intraoperative Therapy Registry at Bethesda North TriHealth Hospital (TARGIT)|TARGIT|TriHealth Inc.|No|Terminated|January 2015|January 2016|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Female|45 Years|N/A|No|Non-Probability Sample|Women, aged 45 and greater who have been diagnosed with early stage invasive breast cancer        that is suitable for breast conserving surgery.|August 2015|February 9, 2016|January 26, 2015|Yes|Yes|Study site will join the TARGIT-US trial in lieu of this trial|No||https://clinicaltrials.gov/show/NCT02364960|10 Years|27288|
NCT02365194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-1025|Modifying Risk in Ventral Hernia Patients|Modifying Risk in Ventral Hernia Patients||The University of Texas Health Science Center, Houston|No|Recruiting|May 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|332|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02365194||27270|
NCT02365207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002|Intravesical BCG Administration to Patients With Invasive Bladder Cancer|Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With Invasive Bladder Cancer||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|November 2013|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365207||27269|
NCT02361138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-102|The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following Multiple Dose of SHR3824 in Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|December 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|February 6, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02361138||27581|
NCT02361424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PXT00864-03|Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)|First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients|PLEODIAL-I|Pharnext, SAS|Yes|Completed|February 2013|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|47|||Both|60 Years|N/A|No|||October 2015|February 12, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02361424||27559|
NCT02361437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD-01|Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers|Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers and Improving Insulin Sensitivity: A Pilot Study||Primus Pharmaceuticals|No|Completed|February 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|85 Years|No|||October 2015|October 19, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361437||27558|
NCT02361671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB # 14-8172|Optic Nerve Sheath Diameter in Patients With Intracranial Pathology|Ultrasonographic Assessment of the Optic Nerve Sheath Diameter in Patients With Intracranial Pathology||University Health Network, Toronto|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Intracranial pathology patients scheduled for elective or emergency surgery.|February 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361671||27540|
NCT02366104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gerus|Brasília Study on Healthy Aging|Brasília Study on Healthy Aging|BSHA|University of Campinas, Brazil|No|Active, not recruiting|December 2008|December 2015|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|230|Samples With DNA|Plasma Leukocyte DNA|Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Non-institutionalized outpatients under preventive care were voluntarily enrolled into the        study. Participants were aged of 80 years or over, have never manifested myocardial        infarction, stroke or peripheral arterial disease.|February 2015|February 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02366104||27200|
NCT02371421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408M53223|Genetics of Hyperuricemia Therapy in Hmong|Genomic Guided Assessment of Drug Therapy Effectiveness in Managing Hmong Adults With Hyperuricemia or Gout.|GOUT-H|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371421||26796|
NCT02366624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-126|Effect of Bariatric Surgery on Bile Acid Homeostasis|Effect of Gastric Bypass, Sleeve Gastrectomy and Duodenal-jejunal Bypass on Bile Acid Homeostasis||Pontificia Universidad Catolica de Chile|Yes|Completed|February 2013|March 2015|Actual|March 2014|Actual|Phase 3|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|Samples Without DNA|-  Blood samples (serum and plasma).        -  Stool samples.        -  Liver samples.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese patients that have undergone bariatric surgery or medical treatment to lose weight.|June 2015|June 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366624|1 Year|27161|
NCT02363517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacfarlaneBIMRPH|The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach|The Treatment And Prevention (TAP) Study: Treating People Who Inject Drugs (PWID) in Community-based Settings Using a Social Network Approach|TAP|Macfarlane Burnet Institute for Medical Research and Public Health Ltd|Yes|Recruiting|February 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|420|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02363517||27398|
NCT02238678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOBLAD 1057/2014|Impact of Deep Endometriosis Surgery on Bladder Function|Impact of Deep Endometriosis Surgery on Bladder Function||Medical University of Vienna|No|Active, not recruiting|June 2014|||June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|- Patients with confirmed diagnosis of deep infiltrating endometriosis requiring surgical        treatment|August 2014|September 10, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02238678||36976|
NCT02238691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pelles PEEP-studie|Risk of Gastric Insufflation Related to Facemask Ventilation Technique During Anaesthetic Induction, With or Without PEEP|Risk of Gastric Insufflation Related to Facemask Ventilation Technique During Anaesthetic Induction||Örebro University, Sweden|No|Not yet recruiting|October 2014|March 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02238691||36975|
NCT02372851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LondonSHTM|Assessing the Effectiveness of a Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal|Assessing the Effectiveness of a Point-of-use Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|January 2015|December 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|362|||Female|18 Years|N/A|No|||September 2015|September 8, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372851||26687|
NCT02372864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURSUE2014|Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy|PURSUE - Psychosexual Consequences of Risk-reducing Salpingooophorectomy in BRCA1/2 Mutation Carriers|PURSUE|University Medical Center Groningen|Yes|Active, not recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Female|N/A|N/A|No|||November 2015|November 30, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02372864||26686|
NCT02373618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMT0002|Dry Needling Versus Conventional Physical Therapy in Patients With Plantar Fasciitis|Dry Needling Versus Conventional Physical Therapy in Patients With Plantar Fasciitis: a Multi-center Randomized Clinical Trial||Alabama Physical Therapy & Acupuncture|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373618||26628|
NCT02361190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-0062|Effects of Fast Acting Testosterone Nasal Spray on Anxiety|Effects of Fast Acting Testosterone Nasal Spray on Anxiety||University of Texas at Austin|No|Recruiting|February 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|160|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02361190||27577|
NCT02364050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_Elderly Project|Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM|Prospective Data Collection of Elderly Patients (≥ 65 Years) With Diffuse Large B-cell Lymphoma (DLBCL) Receiving at the Time of Diagnosis Multidimensional Geriatric Assessment (VGM)||Fondazione Italiana Linfomi ONLUS|No|Recruiting|September 2013|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients with large B-cell lymphoma classified FIT or UNFIT or FRAIL by        Multidimensional Geriatric Assessment (MGA)|February 2015|February 26, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364050||27358|
NCT02374216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2014/333|A Prospective Analysis of Failures of Oral Implants|A Prospective Analysis of Failures/Complications With Oral Implants||Malmö University|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02374216||26582|
NCT02374268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.648-T|Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia|Intervention for Sarcopenia Among Older Chinese Adults: A Randomized Controlled Trial Assessing the Role of Exercise Program and Nutrition Supplement||Chinese University of Hong Kong|No|Recruiting|March 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374268||26578|
NCT02369354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052724|Transplant Social Worker Support for Live Kidney Donation in African Americans|Transplant Social Worker Support for Live Kidney Donation in African Americans|TALKS|Duke University|Yes|Recruiting|September 2015|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|570|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|October 13, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369354||26954|
NCT02369601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMC001|PROMComplete for Determination of Rupture of Fetal Membranes|Clinical Evaluation of PRO-MComplete as an Aid in Determination of Rupture of Fetal Membranes|(PROMComplete|Pro-Lab Diagnostics|No|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|18 Years|45 Years|No|Probability Sample|The study population will be women presenting with signs, symptoms or suspicion of        membrane rupture at 20 to 42 weeks gestation.|September 2015|September 1, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369601||26935|
NCT02370745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G12122013 MSGEM|Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle|Characterizing the Incretin Effect of Amino Acids (AA) and Defining the Effect of GLP-1 on Muscle Microvascular Blood Flow and Muscle Protein and Glucose Metabolism in Older Age.|Incretin|University of Nottingham|Yes|Enrolling by invitation|November 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|8||Anticipated|32|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02370745||26848|
NCT02365506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-394-1658|Effect of GS-6615 on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome|A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome||Gilead Sciences|No|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365506||27246|
NCT02365519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LME636-2202|LME636 in the Relief of Persistent Ocular Discomfort in Patients With Severe Dry Eye Disease|A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Patients With Severe Dry Eye Disease||Alcon Research|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|514|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365519||27245|
NCT02365831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM13-AMBRA|Observation of Medical Treatments in MBC HER2-negative Patients|Evaluation of Medical Treatments in MBC HER2 Negative Patients in Italy - Observational Study|AMBRA|Consorzio Oncotech|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|1500|Samples With DNA|Histologic samples for the evaluation of metastatic breast cancer according to biological      subtype definition (Luminal A, Luminal B, HER2 positive, triple-negative).|Female|18 Years|N/A|No|Non-Probability Sample|Female patients from Italy with metastatic breast cancer.|December 2015|January 22, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02365831||27221|
NCT02373774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO3705|Ultrasound vs Palpation for Infant Lumbar Puncture|Sonographic Visualization vs Palpation Technique for Infant Lumbar Puncture||Columbia University|Yes|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|N/A|90 Days|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02373774||26616|
NCT02371655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URomLSDBAL1|Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial|Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial|DIETSAN|University of Roma La Sapienza|No|Recruiting|October 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371655||26778|
NCT02369367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0472 Phase 2|Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II)|Phase II Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Withdrawn|April 2008|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|February 16, 2015|No|Yes|Original study did not progress to Phase 2.|No||https://clinicaltrials.gov/show/NCT02369367||26953|
NCT02369380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29108|Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Metatarsalgia|Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Treatment of Metatarsalgia of Forefeet Further Use of High Heel Shoes|ELFE|Galderma|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|30 Years|N/A|No|||November 2015|November 9, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02369380||26952|
NCT02227420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-175|Effects of IL-1 Beta on the HPA-axis in Obese Persons|Effects of IL-1 Beta on the Hypothalamic-pituitary-adrenal (HPA) Axis in Obese Persons - the CortIL-Study|CortIL|University Hospital, Basel, Switzerland|Yes|Recruiting|October 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|69|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227420||37841|
NCT02227433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL BVHD01|A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.|A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.|FIL BVHD01|Fondazione Italiana Linfomi ONLUS|No|Recruiting|September 2014|April 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|N/A|No|||August 2015|August 19, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02227433||37840|
NCT02373072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601009|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease||Pfizer|No|Recruiting|March 2015|March 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|18|||Both|30 Years|85 Years|No|||March 2016|March 7, 2016|February 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373072||26670|
NCT02373085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTxR-H12O|Prospective Comparative Study About Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients.|Effect of Systematic Search and Antimicrobial Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients in the Incidence of Acute Pyelonephritis: a Pragmatic Prospective Randomized Controlled Study.||López-Medrano, Francisco, M.D.|No|Completed|January 2011|January 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373085||26669|
NCT02363257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1369 BEST-SF|Smoke Free Policy Among BEST Bus Employees and Commuters in Mumbai|Compliance, Perceptions and Attitudes of Bus Employees and Commuters Towards Smoke Free Bus Policy (as Part of Smoke Free Public Places) in Mumbai, India||Tata Memorial Hospital|Yes|Not yet recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1025|||Both|18 Years|90 Years|No|Non-Probability Sample|BEST Employees, Regular BEST commuters, Stakeholders:1.BEST Committee members 2.Important        people in the managerial and administrative cadre in authoritative positions who can        influence tobacco policy 3.Members of Employee Unions within the organization 4.Medical        Unit including - Chief Medical Officers, Junior and Senior Medical Officers, Paramedical        workforce 5.BEST Commuters Forum 6.Personnel in authoritative positions in: G. M. office        7.Welfare Department 8.Personnel Department 9.PRO Department 10.Legal Department 11.BEST        Commuters 12.Any other stakeholders eventually identified|May 2015|May 21, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363257|1 Week|27418|
NCT02363491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-305-106|A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome|A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)||Opsona Therapeutics Ltd.|Yes|Recruiting|January 2015|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363491||27400|
NCT02373683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14-08|Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis|Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis||Case Western Reserve University|Yes|Recruiting|December 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|2 Years|No|||February 2015|February 23, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373683||26623|
NCT02373696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/160/D|Chronic Pain Dynamic Psychophysical Tests and Genetic Screening|Prediction of Chronic Pain in the Asian Population- Comprehensive Programme Encompassing Dynamic Psychophysical Tests and Genetic Screening to Determine and Prevent Persistent Post-caesarean Pain||KK Women's and Children's Hospital|No|Completed|April 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|178|Samples With DNA|Blood sampling|Female|21 Years|50 Years|No|Non-Probability Sample|Women undergoing spinal anaesthesia for Caesarean section|September 2015|September 3, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02373696||26622|
NCT02363504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51297.068.14|The Locus Coeruleus and Memory|Focus on the Locus Coeruleus Network With 7 T MRI: Link to Memory (Dys)Function|LOCUS|Maastricht University Medical Center|Yes|Not yet recruiting|June 2015|||June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|70|Samples Without DNA|Saliva samples|Both|60 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|35 healthy older individuals and 35 patients with prodromal Alzheimer's disease|March 2015|March 23, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02363504|2 Months|27399|
NCT02368717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000101|An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase|A Randomized, Double-blind, Placebo-controlled, Multi-centre, Superiority Study Investigating the Efficacy and Safety of PENTASA Enema Compared With Placebo Enema for 4-Week Treatment in Chinese Patients With Left-sided Active Ulcerative Colitis (UC) Followed by a Maximal 28-Week Open-Label Extension Phase of PENTASA Enema and/or PENTASA Tablets||Ferring Pharmaceuticals|No|Recruiting|March 2015|November 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|249|||Both|18 Years|70 Years|No|||October 2015|October 8, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02368717||27002|
NCT02360384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMC1|Caecal pH as a Biomarker for Irritable Bowel Syndrome|A Randomised Controlled Trial to Validate the Use of Caecal pH Measurement as a Biomarker in Irritable Bowel Syndrome||Wingate Institute of Neurogastroenterology|No|Recruiting|November 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|48|||Both|18 Years|65 Years|No|||November 2015|November 28, 2015|January 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02360384||27639|
NCT02360397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-1341|Ranolazine Mediated PVC Reduction in Ischemic Heart Disease|Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease||Kent Hospital, Rhode Island|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360397||27638|
NCT02364479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013]2-21|Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein|Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu®||Sun Yat-sen University|No|Recruiting|July 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364479||27325|
NCT02364492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.14|A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse|An Open Label First-in-Human Adjuvant Phase I Study of a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri Tn Glycotope (MAG-Tn3) Plus AS15, as a Therapeutic Vaccine Candidate in Patients With Non Metastatic, HER2 Negative Localized Breast Cancer at High-Risk of Relapse|MAGTRIVACSEIN|Institut Pasteur|Yes|Recruiting|February 2015|March 2019|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|70 Years|No|||April 2015|April 14, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364492||27324|
NCT02374905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH 14-158|Testing Interventions to Reduce Alcohol Consumption Among Outpatients in a Dental Setting|Assess and Improve Patient's Self-reported Alcohol Consumption While Attending the Oral Medicine Clinic||King's College Hospital NHS Trust|Yes|Recruiting|October 2014|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02374905||26529|
NCT02374918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404301151|Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury|Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury||University of Arizona|No|Recruiting|April 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|69|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374918||26528|
NCT02375009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411505682|Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty|Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty||West Virginia University|Yes|Active, not recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|30 Years|N/A|No|||January 2016|January 5, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375009||26521|
NCT02375087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|"STAR"|Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?|Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?|STAR|University Hospital, Grenoble|No|Recruiting|May 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from myotonic dystrophy (DM1)|March 2015|March 2, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02375087||26515|
NCT02371044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|.0 259/2013BO1|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1|POCT-DOAC 1|University Hospital Tuebingen|No|Completed|May 2013|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|Samples Without DNA|Whole blood samples and citrated plasma samples|Both|18 Years|N/A|No|Probability Sample|Consecutive stroke patients, who were newly started on oral anticoagulation with        rivaroxaban, apixaban or dabigatran for secondary prevention of thromboembolic events.|February 2015|February 25, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371044||26825|
NCT02371057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED13/10973|Acromegaly & Sleep Apnoea|The Prevalence of Acromegaly in the Sleep Apnoea Clinic||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|16 Years|N/A|No|Probability Sample|All patients attending the sleep apnoea clinic.|February 2015|February 19, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02371057||26824|
NCT02373631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMT0003|Dry Needling Versus Conventional Physical Therapy in Patients With Knee Osteoarthritis|Dry Needling Versus Conventional Physical Therapy in Patients With Knee Osteoarthritis: a Multi-center Randomized Clinical Trial||Alabama Physical Therapy & Acupuncture|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373631||26627|
NCT02371239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2-050|SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2|SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2|SIT LESS 2|Maastricht University Medical Center|Yes|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|40 Years|75 Years|No|||March 2016|March 15, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02371239||26810|
NCT02362984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033-0614|DLBS1033 for the Treatment of Acute Ischemic Stroke|The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: A Randomized Controlled Study||Dexa Medica Group|Yes|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02362984||27439|
NCT02373839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 2013/8820|Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia|Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia, a Randomized Study|MAP|Fetal Medicine Research Center, Spain|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|N/A|No|||January 2014|February 22, 2015|January 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02373839||26611|
NCT02376088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD-003|Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease|Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease||Qilu Hospital|No|Completed|June 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|328|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 283 outpatients, aged 22 to 55 years old(mean age 39±4 years), of whom 41 were        male and 242 were female (M/F=1/5.90), were enrolled for the study from Qilu Hospital of        Shandong University and Shandong Jiaotong Hospital between June, 2011 and June, 2014. An        additional 45 age-matched healthy checkup subjects were included in the normal control        group (NC). Patients with a medical history of diabetes, pancreatitis and other related        conditions and positive family histories as well as medication history of glucocorticoid        and anti-diabetic agents were excluded.|February 2015|February 24, 2015|February 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376088||26438|
NCT02362750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-5255|Evaluating Cancer Survivorship Care Models|Evaluating Cancer Survivorship Care Models||George Washington University|No|Recruiting|July 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1350|||Both|18 Years|N/A|No|Non-Probability Sample|Phase 1 of our study focused on developing instruments to conduct comparative        effectiveness research. The investigators analyzed three large national studies of cancer        survivors; conducted focus groups across the country with adult survivors of breast,        prostate or colorectal cancer; surveyed Commission on Cancer accredited institutions        regarding provision of survivorship care and surveyed a nationally representative sample        of adult cancer survivors. In phase II, the investigators will conduct surveys with        survivorship program leaders at eligible Commission on Cancer accredited institutions;        adult survivors of breast, prostate or colorectal cancer; and the survivorship program        clinicians providing their care.|March 2016|March 2, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02362750||27457|
NCT02374892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The CHAPTER III Study|The CHAPTER III Study of Young Adolescents|The CHAPTER III Study of Young Adolescents: Congenital Heart Adolescents Participating in Transition Evaluation Research||University of Alberta|No|Recruiting|March 2015|January 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|13 Years|14 Years|No|||November 2015|November 30, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374892||26530|
NCT02368392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCAS|National Cardiac Arrest Survey|National Cardiac Arrest Survey of Sri Lanka|NCAS|Ministry of Health, Sri Lanka|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|537|||Both|N/A|N/A|No|Probability Sample|Patients admitting to state hospitals in Sri Lanka|February 2016|February 16, 2016|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02368392||27027|
NCT02368405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-14-06E|Nutrition Education for Cardiovascular Disease Prevention in Spinal Cord Injury|Nutrition Education for Cardiovascular Disease Prevention in Individuals With Spinal Cord Injury||Carolinas Healthcare System|No|Recruiting|February 2015|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02368405||27026|
NCT02363725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9439|Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response|Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response|COLIN|University Hospital, Montpellier|Yes|Active, not recruiting|December 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|90 Years|No|||September 2015|September 3, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02363725||27382|
NCT02374658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123123|The ARTS-REHAB Project Research Study|The Royal Conservatory's ARTS-REHAB Project Research Study|ARTS-REHAB|The Royal Conservatory of Music|No|Recruiting|February 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|188|||Both|18 Years|90 Years|No|||February 2015|February 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374658||26548|
NCT02364258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13020063|Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients|Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition|SD2|Children's Mercy Hospital Kansas City|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364258||27342|
NCT02369107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM201410|The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting|A Multi-center,Randomized Controlled Clinical Trial: the Effect of Acupuncture in Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting on Patients With Malignancy||Beijing Hospital of Traditional Chinese Medicine|No|Not yet recruiting|February 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|75 Years|No|||February 2015|February 17, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02369107||26972|
NCT02361450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01520-45|Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial|Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial|IRRICO|Rennes University Hospital|No|Recruiting|February 2015|March 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|15 Years|N/A|No|||September 2015|September 11, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02361450||27557|
NCT02361684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI07|e-Compared-S: Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial|European Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial|E-COMPARED_S|Universitat Jaume I|Yes|Recruiting|February 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02361684||27539|
NCT02361944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131128|Risk of Oxygen During Cardiac Surgery Trial|Risk of Oxygen During Cardiac Surgery (ROCS) Trial|ROCS|Vanderbilt University|Yes|Not yet recruiting|August 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02361944||27519|
NCT02366637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9111004|An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)||Pfizer|Yes|Terminated|January 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|40 Years|80 Years|No|||January 2016|January 7, 2016|September 2, 2014|Yes|Yes|Study terminated on 7 April 2015 for business reasons. No safety and/or efficacy concerns    contributed to the termination of the study|No||https://clinicaltrials.gov/show/NCT02366637||27160|
NCT02376582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV06|Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS|A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection|EV06|EuroVacc Foundation|Yes|Completed|September 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02376582||26400|
NCT02362451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150075|Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer|A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|December 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Male|18 Years|99 Years|No|||December 2015|January 5, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362451||27480|
NCT02373709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/539/F|Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression|Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression||KK Women's and Children's Hospital|Yes|Recruiting|October 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|750|Samples With DNA|Saliva samples for DNA extraction|Female|21 Years|35 Years|No|Non-Probability Sample|Chinese women attending antenatal and postnatal clinics in KK Women's and Children's        Hospital and National University Hospital, Singapore.|February 2015|February 22, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02373709||26621|
NCT02373722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01714|Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery|Web App Based Patient Education in Mohs Surgery||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|March 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Anticipated|192|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373722||26620|
NCT02368730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000149|Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures|Documentation of the Efficacy of Desmopressin (MINIRIN Parenteral 4 Microgram/ml Solution for Injection) Within the Context of Surgical Procedures|RAPID|Ferring Pharmaceuticals||Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Hospital doctors specialised in anaesthesia|February 2016|February 1, 2016|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368730||27001|
NCT02368938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSS|Prognosis in the Elderly Chinese: the Northern Shanghai Study|Prognosis Factors of Mortality and Cardiovascular Diseases in the Elderly Chinese: the Northern Shanghai Study|NSS|Shanghai 10th People's Hospital|No|Enrolling by invitation|August 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Pasting venous blood sample and urine sample were collected for each participant.|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|5000 subjects aged over 65 years old, living in communities located in the northern        Shanghai, will be invited to participate in the present study, if they are willing to give        their written informed consents.|February 2015|February 20, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368938||26985|
NCT02363270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-08-MMC|Ketamine: Comparison of IV Push vs. IV Drip|Comparison of Intravenous Push Dose of Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study||Maimonides Medical Center|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363270||27417|
NCT02235285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Augmentarion|Asian Outcomes of Primary Breast Augmentation|Asian Outcomes of Primary Breast Augmentation in 162 Consecutive Cases Using Single Antibiotic Breast Irrigation by A Single Surgeon Under Sedative Anesthesia (Propofol Infusion)|BA|Winners Clinic|No|Completed|January 2010|January 2015|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|22 Years|57 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 5, 2014||No||No|June 19, 2015|https://clinicaltrials.gov/show/NCT02235285||37236|
NCT02235402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.336|A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients|A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients||Boehringer Ingelheim||Completed|December 1997|||March 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02235402||37227|
NCT02235415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.340|Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension|Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension, Under Normal Conditions Compared With an Open Clinical Trial||Boehringer Ingelheim||Completed|June 1998|||September 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24526|||Both|18 Years|N/A|No|Probability Sample|Patients with essential Hypertension recruited by General practicioners, cardiologists and        specialists in internal medicine in non-Hospital practice|September 2014|September 9, 2014|September 9, 2014||||No||https://clinicaltrials.gov/show/NCT02235415||37226|
NCT02362971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|External validity|External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture|External Validity of a Randomized Controlled Trial in Patients With a Femoral Neck Fracture|EXVAL|Danderyd Hospital|No|Recruiting|September 2009|October 2027|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|900|||Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A femoral neck fracture in the elderly patient is a common cause of suffering and        premature death in an aging population. Femoral neck fractures are mainly a fragility        (osteoporotic) fracture, predominantly affecting women after menopause. Included in the        study are elderly patients (>80 years) with a displaced femoral neck fracture.|January 2016|January 27, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02362971||27440|
NCT02374541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1728|Screening and Linkage to Services for Autism|Screening and Linkage to Services for Autism|SaLSA|University of Colorado, Denver|No|Recruiting|March 2015|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|982|||Both|16 Months|32 Months|No|||March 2016|March 18, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02374541||26557|
NCT02368522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-259|Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)|Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe||Bristol-Myers Squibb|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients from private practices and outpatients units in hospitals|November 2015|November 19, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02368522||27017|
NCT02368535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFON STUDY|Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit|A Decade of Safon Rounds: Interdisciplinary Daily Rounding as a Method of Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit|SAFON|Brigham and Women's Hospital|Yes|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|234|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Staff working at Brigham and Women's Hospital Labor and Delivery Suite|July 2015|July 20, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02368535||27016|
NCT02360657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106397|Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia|A Double-blind, Placebo-controlled, Randomized, 4-Week, Multiple-dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-beta Processing in Cerebrospinal Fluid (CSF) and Plasma||Janssen Pharmaceutical K.K.|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|65 Years|85 Years|No|||January 2016|January 22, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360657||27618|
NCT02360670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11NE418|Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation|Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation|PRACTISE|NHS Greater Glasgow and Clyde|Yes|Recruiting|February 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02360670||27617|
NCT02368925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1411/274-002|Clinical Trial to Evaluate Safety and Efficacy of Ultherapy™ System for Lifting Skin on the Neck|Clinical Trial to Evaluate Safety and Efficacy of Ultherapy™ System for Lifting Skin||Seoul National University Hospital|No|Completed|March 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368925||26986|
NCT02374788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SophiahemmetU|Sophia Step Study - a Behaviour Change Program on Physical Activity in Persons With Pre- and Type 2 Diabetes|Health Promotion in the Primary Care Setting- an Evaluation of the Sophia Step Study- a Structured Behaviour Change Program Focusing on Physical Activity in Persons With Pre- and Type 2 Diabetes||Sophiahemmet University|No|Recruiting|November 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|310|||Both|40 Years|80 Years|No|||December 2015|December 7, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02374788||26538|
NCT02374801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITSY10|Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D (CAS RESPOND CRT)|Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D||Sorin Group USA, Inc.|Yes|Recruiting|April 2015|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374801||26537|
NCT02366117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2012/CEFCM|Rehabilitation and Quality of Life in Residential Units for People With Longer Term Mental Health Problems|Rehabilitation and Quality of Life in Residential Units for People With Longer Term Mental Health Problems||Universidade Nova de Lisboa|No|Active, not recruiting|April 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02366117||27199|
NCT02366130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0508|Phase II Trial of Ra-223 Dichloride and Hormonal Treatment|Phase II Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||November 2015|November 2, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366130||27198|
NCT02366390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIACOL|Dialogue Aimed at Reducing Anxiety in Patients With Severe COPD|Efficacy of a Minimal Homebased Psychoeducative Intervention Versus Usual Care for the Management of Anxiety and Dyspnea in Patients With Severe Chronic Obstructive Pulmonary Disease|DIACOL|Nordsjaellands Hospital|No|Recruiting|February 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Both|N/A|N/A|No|||October 2015|February 22, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02366390||27179|
NCT02366403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1485-R|Breathing Meditation Intervention for Post Traumatic Stress Disorder|Breathing Meditation Intervention for Post-Traumatic Stress Disorder||VA Office of Research and Development|No|Recruiting|October 2015|April 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366403||27178|
NCT02366650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERO1|Help in the Emergency Room to Detect Organ Dysfunction|Help in the Emergency Room to Detect Organ Dysfunction - The HERO Study|HERO|Region Skane|No|Recruiting|February 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|Samples With DNA|Plasma and blood samples|Both|18 Years|N/A|No|Probability Sample|Subject enrolment will be based on adult patients presenting to the emergency department        at the different sites with suspicion of organ dysfunction or identified at the hospital        wars/units.|October 2015|October 19, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366650||27159|
NCT02362191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0600|Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD|Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD||University of North Carolina, Chapel Hill|No|Enrolling by invitation|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|45 Years|No|||September 2015|September 8, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02362191||27500|
NCT02367157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-009|Effectiveness of Kinesio Tape in Morning Stiffness and Functional Capacity in Patients With Rheumatoid Arthritis.|||CEU San Pablo University|No|Not yet recruiting|March 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|65 Years|No|||July 2015|July 3, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367157||27121|
NCT02362763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESTIB-HMO-CTIL|The Use of Acupuncture for the Treatment of Vulvar Vestibulitis|The Use of Acupuncture for the Treatment of Vulvar Vestibulitis||Hadassah Medical Organization|No|Completed|June 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|40 Years|No|||February 2015|February 9, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02362763||27456|
NCT02362776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/046U|Metabolic Changes as a Diagnostic Indicator for Cancer|Metabolic Changes as a Diagnostic Indicator for Cancer||Hasselt University|No|Completed|October 2009|July 2012|Actual|July 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|426|Samples Without DNA|Metabolic phenotype of cancer|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosis of breast or lung cancer|February 2015|February 9, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02362776|1 Day|27455|
NCT02376608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN00714101|Bioavailability of Omega-3 Food Supplement in Healthy Subjects|Pronovum - An Open-label, Randomized, Single-dose Study to Evaluate the Bioavailability of Omega-3 Food Supplements in Healthy Male and Female Subjects.||Pronova BioPharma|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|February 25, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02376608||26398|
NCT02369120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULleida|Influence of a Biopsychosocial Educational Internet-based Intervention in Chronic Low Back Pain Patients: A Mixed Methods Approach|The Influence of a Biopsychosocial Educational Internet-based Intervention on Pain, Dysfunction, Quality of Life, and Pain Cognition in Chronic Low Back Pain Patients in Primary Care: a Mixed Methods Approach||Universitat de Lleida||Recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02369120||26971|
NCT02224118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016429|Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus|Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus||Janssen Pharmaceutical K.K.|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|64|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224118||38095|
NCT02366845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0064|Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease|Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease||University of Colorado, Denver|Yes|Active, not recruiting|January 2012|January 2017|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||January 2016|January 20, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366845||27144|
NCT02366858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510467|Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures|Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures||Florida Hospital|Yes|Recruiting|October 2013|June 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|89 Years|No|||February 2015|February 12, 2015|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02366858||27143|
NCT02372175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-09|Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain|Phase One, Open Label, Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain||U.S. Army Medical Research and Materiel Command|Yes|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372175||26739|
NCT02367118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRD- CRSsNP-1|Prednisone in Chronic Rhinosinusitis Without Nasal Polyps|Prednisone in Chronic Rhinosinusitis Without Nasal Polyps. A Double-blind, Randomized, Placebo-controlled Trial||University of Chile|No|Recruiting|June 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|February 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367118||27123|
NCT02372565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000485|Facebook to Promote Physical Activity in Black Women African American Women|Using Mass Media to Promote Physical Activity in African American Women||Arizona State University|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|24 Years|49 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02372565||26709|
NCT02372578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3662-CL-0049|Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy|A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy||Astellas Pharma Inc|Yes|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|February 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372578||26708|
NCT02374593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401199401|Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism|Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism||Indiana University|Yes|Active, not recruiting|March 2014|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|2 Weeks|No|||March 2016|March 4, 2016|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374593||26553|
NCT02360163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 2921|The "Peripheral Access Utilizing Sonographic Evaluation" Study|The "Peripheral Access Utilizing Sonographic Evaluation" Study|PAUSE|Hackensack University Medical Center|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|21 Years|N/A|No|||August 2015|August 20, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360163||27656|
NCT02364726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011|Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients|Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients: A Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|21 Years|N/A|No|||March 2016|March 10, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364726||27306|
NCT02374723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNr52120125706|Evaluation of Biosynthetic Constructs to Replace Donor Corneas|Evaluation of Biosynthetic Constructs as Replacement for Donor Corneas as Graft Material for Corneal Transplantation||Region Östergötland|Yes|Not yet recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374723||26543|
NCT02374736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140501|Effect of Privigen Against Graft Loss|A Pilot Study on the Effect of Privigen Against Graft Loss: Interventional Study of Kidney Transplant Recipients at Risk for Graft Loss Through Antibody-mediated Rejection|InAuGuRAL|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02374736||26542|
NCT02361151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038855|The mFIT Study (Motivating Families With Interactive Technology)|Enhancing Parent-Child Communication and Promoting Physical Activity and Healthy Eating Through Mobile Technology: the mFIT Study (Motivating Families With Interactive Technology)|mFIT|University of South Carolina|No|Completed|February 2015|December 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|9 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361151||27580|
NCT02361164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.11.NRC|Birth Cohort Study for Respiratory Infections|Prospective Two-year Observational Study to Evaluate the Effect of Bacterial Colonisation of the Nasopharynx on the Occurence of Acute Respiratory Infections in a Birth Cohort of Children and Their Mothers||Nestlé|No|Active, not recruiting|July 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood samples, clinical samples for bacterial and viral isolates|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|October 2015|October 27, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361164||27579|
NCT02371668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150069|Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02371668||26777|
NCT02371941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02521-FB|Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis|A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis||University of Tennessee|No|Recruiting|December 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|2 Years|18 Years|No|||March 2015|March 11, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371941||26756|
NCT02372201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicrobColonIrrFFG2013|Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome|Effects of Fasting and Hydro Colon Therapy Plus Probiotics on Abundance and Diversity of GI Microbiota in Intolerances and Irritable Bowel Syndrome|MicFFGAH2013|University of Vienna|No|Completed|January 2013|October 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|68|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02372201||26737|
NCT02366871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0187|Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy|The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design||University of Colorado, Denver|Yes|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|89 Years|No|||February 2016|February 19, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366871||27142|
NCT02367131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.98|Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance in Japan on Drug Use of JARDIANCE® Tablets in Elderly Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Active, not recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|||Both|65 Years|N/A|No|Non-Probability Sample|All patients start taking JARDIANCE® Tablets within 3 months after launch will be        included.|March 2016|March 16, 2016|February 13, 2015||||No||https://clinicaltrials.gov/show/NCT02367131||27122|
NCT02375100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IzmirBoyaka|Transversus Abdominis Plane Block Versus Ilioinguinal Nerve Block for Pain Management in Inguinal Herniorraphy|Comparison of Efficacy of Transversus Abdominis Plane Block and Ilioinguinal Nerve Block for Postoperative Pain Management in Patients Undergoing Inguinal Herniorraphy With Spinal Anesthesia||Bozyaka Training and Research Hospital|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02375100||26514|
NCT02372669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGU-LU-123|Chitosan Nerv Tube for Primary Repair of Traumatic Sensory Nerve Lesions of the Hand|Chitosan Nerv Tube for Primary Repair of Traumatic Sensory Nerve Lesions of the Hand - a Clinical Randomized Controlled Multicenter Trial|CNT|BG Unfallklinik|Yes|Recruiting|March 2015|March 2018|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|67 Years|No|||January 2016|January 11, 2016|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02372669||26701|
NCT02368548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PAF-2011-81|Randomized Clinical Trial of a Pharmaceutical Care Program in Chronic Patients Users of an Emergency Department|||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|January 2012|September 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|65 Years|N/A|No|||February 2015|February 16, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02368548||27015|
NCT02376595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003|Pharmacokinetic and Pharmacodynamic of Rocuronium|Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.||Pontificia Universidad Catolica de Chile|Yes|Completed|March 2013|January 2015|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Plasma samples.|Both|18 Years|65 Years|No|Non-Probability Sample|10 ASA I-II patients, aged 18-65 years, scheduled for elective surgery under general        anesthesia, were recruited.|February 2015|February 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02376595||26399|
NCT02372903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PELV_25|Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Endometriosis|Pilot Study About Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Laparoscopic Diagnosis of Endometriosis||University of Cagliari|No|Completed|October 2013|September 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02372903||26683|
NCT02376634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00837|Hypnotherapy in Major Surgical Procedures|The Effectiveness of Clinical Hypnotherapy in Reducing Anxiety and Pain in Major Surgical Procedures (Nuss and Scoliosis Repair)||Nationwide Children's Hospital|No|Not yet recruiting|June 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|21 Years|No|||January 2016|January 11, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376634||26396|
NCT02372968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.03.MET|Use of Metabonomics and Body Imaging for Metabolic Health Assessment|Use of Metabonomics and Body Imaging for Metabolic Health Assessment||Nestlé|No|Completed|April 2008|October 2010|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|225|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Studied population: 100-300 subjects, men and women selected out of Nestlé employees|February 2015|February 20, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02372968||26678|
NCT02228824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3P30CA047904-25S4|Very-Low Nicotine Cigarettes and Non-Daily Smokers|The Effect of Very-Low Nicotine Cigarettes on Smoking in Non-Daily Smokers||University of Pittsburgh|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|455|||Both|21 Years|N/A|No|||July 2015|July 14, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228824||37733|
NCT02372188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-14|Influence of a Bitter Compound and Bittermasking Compound on Gastric pH|Effect of Caffeine With and Without a Bitter Masking Compound on Gastric pH, Taking Into Account the Effect on Satiety Hormones in Blood Plasma and on Food Intake||University of Vienna||Active, not recruiting|September 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|25|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02372188||26738|
NCT02374437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aramchol004|Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers|Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers||Galmed Pharmaceuticals Ltd||Completed|April 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|8||Actual|66|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374437||26565|
NCT02374489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3214|A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma|A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma||National Health Research Institutes, Taiwan|Yes|Recruiting|March 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|20 Years|75 Years|No|||October 2015|October 12, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374489||26561|
NCT02364271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10110121|Early Risk Stratification in ED Chest Pain Patients|Improving Early Risk Stratification in Patients Presenting to Emergency Departments With Undifferentiated Chest Pain||Chinese University of Hong Kong|No|Completed|March 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|604|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who had chest or epigastric pain within 24 hours of emergency department        presentation and suspected with acute coronary syndrome|February 2015|February 10, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02364271||27341|
NCT02360410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6 R40MC26817-01-01|Check Yourself Study|Promoting Adolescent Health Through Personalized Feedback||Seattle Children's Hospital|No|Recruiting|February 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|13 Years|18 Years||||March 2015|March 5, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360410||27637|
NCT02360904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025-14|A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy|A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy: Effects on Quality of Life and Chemotherapy-associated Symptoms||Beth Israel Medical Center|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02360904||27599|
NCT02364973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T31/2014|Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study|Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study||Turku University Hospital|No|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|IBD patients living in the Turku University Hospital referral area|November 2015|November 3, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02364973||27287|
NCT02365558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15373|A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants|Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Pharmacokinetics of Evacetrapib in Healthy Subjects||Eli Lilly and Company|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365558||27242|
NCT02365844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0044|NBI to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer|An Evaluation of Narrow Band Imaging (NBI) to Characterize Patterns of Vascular Supply Within the Lymphoepithelial Mucosa of Patients With Oropharyngeal Carcinoma (OPC)||Stanford University||Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Stanford Cancer Center patients with oropharyngeal carcinoma|February 2015|February 24, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365844||27220|
NCT02362464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150076|Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139|A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|99 Years|No|||December 2015|March 3, 2016|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02362464||27479|
NCT02375022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1501|Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations|A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar®) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations||Zhejiang University|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02375022||26520|
NCT02372734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401054|Long Term Cognitive Impact of Pediatric Acute Renal Injury|Long Term Cognitive Impact of Pediatric Acute Renal Injury||University of Florida|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|250|||Both|2 Years|36 Years|No|Non-Probability Sample|Subjects are former patients admitted for sepsis as a child.|November 2015|November 2, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372734||26696|
NCT02372799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-22|Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)|A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder|VLZ-MD-22|Forest Laboratories|Yes|Recruiting|February 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|7 Years|17 Years|No|||December 2015|December 17, 2015|February 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372799||26691|
NCT02372812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206000541|Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores|Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores: A Double Blinded Randomised Controlled Clinical Trial|DOPP|Makerere University|Yes|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|173|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372812||26690|
NCT02363764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201422976|The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients|The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients||Universitair Ziekenhuis Brussel|Yes|Enrolling by invitation|January 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|165|||Both|N/A|N/A|No|Probability Sample|CF patients|February 2015|February 9, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02363764||27379|
NCT02364076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1315|MK-3475 in Patients With Thymic Carcinoma|A Phase II Study of MK-3475 in Patients With Thymic Carcinoma||Georgetown University|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364076||27356|
NCT02364089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/34|Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas|Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas|CHIRACIC|University Hospital, Bordeaux|Yes|Recruiting|January 2015|September 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||February 2015|February 13, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02364089||27355|
NCT02364284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280R00005|Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP|Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With Complicated Urinary Tract Infection,Complicated Intra-abdominal Infection and Nosocomial Pneumonia Including Ventilator-associated Pneumonia.|RECOMMEND|AstraZeneca|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|1320|||Both|18 Years|N/A|No|Non-Probability Sample|Adult (≥18 years) patients. Hospitalized patients with a diagnosis of at least one of the        following three conditions during the period July 1, 2013 to June 30, 2014 should be        included in this study.        Hospital acquired or healthcare associated cUTI Hospital acquired or healthcare associated        cIAI NP including VAP|February 2016|February 11, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02364284||27340|
NCT02233530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEA_NIGERIA_CST1|IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria|Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial|IDEA|Northumbria Healthcare NHS Foundation Trust|Yes|Enrolling by invitation|September 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|8|||Both|N/A|N/A|No|||September 2014|September 3, 2014|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02233530||37371|
NCT02373943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCEA - PoC2013 - 619161|The MULTINUTRIENT Maize Project: Results of Human Feeding Trial|Bioavailability of Vitamin A From β-carotene-Biofortified Maize Porridge Consumed by Women and Men: Results of a Randomized Crossover Trial|MAIZE|Institut de Recerca Biomèdica de Lleida|No|Completed|September 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02373943||26603|
NCT02373956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/JPL-01|Efficacy and Tolerance of Honey-impregnated Dressings in the Local Management of Pressure Ulcers|Evaluation of the Efficacy and Tolerance of Honey-impregnated Dressings Versus Non-impregnated Dressings in the Local Management of Pressure Ulcers: A Randomized Single-blind Trial|MeliCare|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373956||26602|
NCT02364505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23042013205901|A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers|Improving the Quality of Life of People With Multiple Sclerosis and Their Caregivers With a Telemedicine Mindfulness-Based Intervention||Fondazione Don Carlo Gnocchi Onlus|No|Recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02364505||27323|
NCT02370862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-13-02|Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI|A Novel Application of Iontophoresis in the Transcutaneous Delivery of a Prokinetic Agent for the Promotion of Bowel Evacuation||James J. Peters Veterans Affairs Medical Center|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370862||26839|
NCT02370875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400993|rTMS and Botulinum Toxin in Benign Essential Blepharospasm|Combined Effects of rTMS and Botulinum Toxin in Benign Essential Blepharospasm: A Novel Approach||University of Florida|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|30 Years|75 Years|No|||March 2016|March 17, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370875||26838|
NCT02365220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIBAS-MMH-SMA1|Smartphone Application, Mood and Stress|Smartphone Application, Mood and Stress||University Hospital, Basel, Switzerland|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02365220||27268|
NCT02365532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-372-1666|Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects||Gilead Sciences|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365532||27244|
NCT02365545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE852-E001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||March 23, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365545||27243|
NCT02371447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 06/14|VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer|A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy||Swiss Group for Clinical Cancer Research|Yes|Recruiting|August 2015|October 2023|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|85 Years|No|||August 2015|August 17, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02371447||26794|
NCT02361957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46674.081.13|The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients|The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients|CUPIDO|Wageningen University|No|Suspended|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|January 15, 2015||No|We recruited 25 of the 40 participants from intended study population. Recruitment in new    populations requires an METC amendment.|No||https://clinicaltrials.gov/show/NCT02361957||27518|
NCT02372435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChariteU|Short Interval in Treatment of PJI|Efficacy and Safety of Fast-track Treatment for Prosthetic Joint Infection (PJI)|Fast-track|Charite University, Berlin, Germany|Yes|Not yet recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|418|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02372435||26719|
NCT02372448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-APN-01|Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients|Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients|STALKLUNG01|Centre Hospitalier Universitaire de Nice|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|224|||Both|18 Years|N/A|No|||February 2015|March 5, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02372448||26718|
NCT02366884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI/2015|Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis|Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments||Dr. Frank Arguello Cancer Clinic|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02366884||27141|
NCT02372513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LALD-TR|National Lysosomal Acid Lipase Deficiency Study|The Frequency of Cholesteryl Ester Storage Disease in Children With Unexplained Transaminase Elevation and Chronic Liver Disease|LAL-D|Ankara University|No|Recruiting|January 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1700|Samples Without DNA|whole blood|Both|3 Months|18 Years|No|Non-Probability Sample|Patients of 3 months to 18 years of age at the time of enrolment who have unexplained        transaminase elevation (serum ALT levels > 1.5 times the upper limit of normal) for more        than 3 months and/or unexplained hepatomegaly or hepatosplenomegaly and/or obesity-        unrelated hepatosteatosis and/or biopsy-proven cryptogenic fibrosis and cirrhosis and/or        liver transplantation for cryptogenic cirrhosis|February 2016|February 17, 2016|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02372513||26713|
NCT02372591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093537|Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain|Analgesic Effects and Abuse Liability of Intravenous Hydromorphone and Buprenorphine in Opioid Dependent Participants With Chronic Musculoskeletal Pain|1401|Johns Hopkins University|No|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|55 Years|No|||August 2015|August 11, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372591||26707|
NCT02363283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00159|Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma|A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma||National Cancer Institute (NCI)||Recruiting|September 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363283||27416|
NCT02363530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corneal Protect|Corneal Protect Used During Cataract Surgery|Influence of 2% HPMC Used During Cataract Surgery for Intraoperative Corneal Optical Clarity and Post-operation Xerophthalmia.|CPUDCS|Second Affiliated Hospital, School of Medicine, Zhejiang University|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02363530||27397|
NCT02369393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaimeI06|Efficacy of Two Internet Delivered Intervention Programs for Depression: Behavioral Activation vs Physical Activity|Treatment of Depression: Efficacy and Efficiency of Two Self-administered Online Intervention Protocols Based on Behavioral Activation and Physical Activity|PROMETEOII|Universitat Jaume I|Yes|Not yet recruiting|April 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369393||26951|
NCT02369627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|477192-10|Facilitating HIV Testing Among Young Adult MSM Through Social Networking|Facilitating HIV Testing Among Young Adult MSM Through Social Networking||Rhode Island Hospital||Enrolling by invitation|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|450|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369627||26933|
NCT02369640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2015-FSP|Learning From Errors During Simulation-based Ultrasound Training|Learning From Errors During Simulation-based Ultrasound Training||Rigshospitalet, Denmark||Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369640||26932|
NCT02373865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-2-REDESIGN|Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes|Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy||GWT-TUD GmbH|No|Recruiting|September 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|40 Years|80 Years|No|||December 2015|December 3, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02373865||26609|
NCT02373878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11001395|Telecoaching Plus a Portion Control Device for Weight Management in the Primary Care Setting|Telecoaching Plus a Portion Control Device for Weight Care Management||Mayo Clinic|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373878||26608|
NCT02364063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/766.1|Micturition Reeducation in Children With Cerebral Palsy|Micturition Reeducation in Children With Cerebral Palsy||University Hospital, Ghent|No|Active, not recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|5 Years|12 Years|No|||December 2015|December 1, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02364063||27357|
NCT02369861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-05-14|Study of ACCS Eye Drops in Treating Dry Eye|A Randomized, Masked, Active Placebo-controlled Phase 1 Study of Amnion-derived Cellular Cytokine Solution (ACCS) Eye Drops in the Treatment of Dry Eye||Stemnion, Inc.|No|Recruiting|March 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|March 25, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369861||26915|
NCT02369874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4193C00002|Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||AstraZeneca|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|720|||Both|18 Years|96 Years|No|||February 2016|February 16, 2016|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369874||26914|
NCT02373852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVG-CL003|PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention|Post Marketing Surveillance (PMS) Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention||Gardia Medical|No|Recruiting|October 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing percutaneous intervention (PI) of saphenous vein graft (SVG) stenting|February 2015|February 22, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02373852||26610|
NCT02373891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-002-04|Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers|||Hyundai Pharmaceutical Co., LTD.|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02373891||26607|
NCT02373904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03-PATHOLHUM-01|A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease|A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease||IlluminOss Medical, Inc.||Active, not recruiting|February 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373904||26606|
NCT02373969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEG-099-11|Thromboelastogram During Total Knee Replacement|Thromboelastogram During Surgery for Total Knee Replacement With Tourniquet Application and Single Dose Tranexamic Acid||Rambam Health Care Campus|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|75 Years|No|Non-Probability Sample|As described in eligibility criteria|February 2015|February 22, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02373969||26601|
NCT02373982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAGO-FA|Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation|External Validation of the Left Atrial Sphericity as Predictor of Recurrence After Atrial Fibrillation Ablation: A Multicenter Observational Study.|LAGO-FA|Hospital Clinic of Barcelona|No|Active, not recruiting|January 2013|April 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Multi-center cohort of consecutive patients undergoing first ablation of symptomatic        drug-refractory AF during 2013 in whom 3D-imaging of the left atrium was performed        (Cardiac CT or MRA).|March 2016|March 15, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373982||26600|
NCT02371070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|.1 259/2013BO1|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2|POCT-DOAC 2|University Hospital Tuebingen|No|Active, not recruiting|December 2013|June 2015|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|Samples Without DNA|Whole blood samples and citrated plasma samples|Both|18 Years|N/A|No|Probability Sample|Consecutive stroke patients, who were newly started on oral anticoagulation with        rivaroxaban, apixaban or dabigatran for secondary prevention of thromboembolic events.|February 2015|May 29, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371070||26823|
NCT02371434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONEnTreg13|The ONE Study nTreg Trial (ONEnTreg13)|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - nTregs Trial|ONEnTreg13|Charite University, Berlin, Germany|Yes|Enrolling by invitation|January 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371434||26795|
NCT02366416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-122|Effects of Physical Exercise on Blood Glucose and Pain From the Muskuloskeletal System in Patients With Type 2 Diabetes|Effects of Physical Exercise on Blood Glucose and Pain From the Muskuloskeletal System in Patients With Type 2 Diabetes and Diabetes Related Complications||Nordsjaellands Hospital|No|Recruiting|April 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|February 22, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02366416||27177|
NCT02362204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversityFreiburg|Lung Cancer Nurse Model: a Phase II Study|Development and Feasibility of a Lung Cancer Nurse Model During Early Treatment: a Phase II Study|LCN-II|University of Freiburg|No|Recruiting|January 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|71|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients newly diagnosed receiving systemic therapy|February 2015|February 7, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02362204||27499|
NCT02373657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02169|Water Uptake for Health in Amhara Pilot||WUHA|Francis I. Proctor Foundation|Yes|Active, not recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2800|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373657||26625|
NCT02373670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-470H|Parent Mentors Using Positive Deviance in Childhood Obesity|||The University of Texas Health Science Center at San Antonio|No|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373670||26624|
NCT02362789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457ADE03|Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers|Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase|PSORITUS|Novartis|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362789||27454|
NCT02362997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-566|Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL|A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma||Dana-Farber Cancer Institute|Yes|Recruiting|April 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362997||27438|
NCT02363010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402002613|Project Impact: An Innovative Approach to Weight Loss Maintenance|||Drexel University|No|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|No|||February 2015|February 9, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02363010||27437|
NCT02368951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16897|Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)|Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)||Bayer|No|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368951||26984|
NCT02369133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 13-180|Preemptive Analgesia With Intravenous Paracetamol for Post-cesarean Section Pain Control|Preemptive Analgesia With Intravenous Paracetamol for Post-cesarean Section Pain Control : A Randomized Controlled Trial||Baskent University|Yes|Completed|November 2013|November 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369133||26970|
NCT02369146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBP-A202-HIV|To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults|A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults||United BioPharma|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|20 Years|N/A|No|||February 2015|June 17, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02369146||26969|
NCT02374073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13/082|Functional Massage of Teres Major Muscle|Effectiveness of Functional Massage of the Teres Major Muscle in Patients With Subacromial Impingement Syndrome. A Randomized Controlled Pilot Study||Jordi Gol i Gurina Foundation|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374073||26593|
NCT02374099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-BRSTM-001|Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant|A PHASE 2, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE EPIGENETIC MODIFYING EFFECTS OF CC-486 (ORAL AZACITIDINE) IN COMBINATION WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ER+, HER2- METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON AN AROMATASE INHIBITOR||Celgene|Yes|Recruiting|March 2015|February 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374099||26591|
NCT02360449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31420|Social Motivation Intervention for Children With Autism Spectrum Disorder: Improving Peer Initiation|Social Motivation Intervention for Children With Autism Spectrum Disorder: Improving Peer Initiation||Stanford University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360449||27634|
NCT02239315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|495462|Study of Tumor RNA Disruption Assay™ (RDA)|Study of Tumor RNA Disruption Assay™ (RDA) and Its Association With a Response to Neoadjuvant Chemotherapy in Breast Cancer - A Prospective Mixed-Methods Study|RnaDx|University of Toronto|Yes|Recruiting|December 2015|June 2022|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02239315||36927|
NCT02239328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17525|A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer|A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer||University of Virginia|No|Recruiting|August 2014|March 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer Esophageal cancer|May 2015|May 29, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02239328||36926|
NCT02363738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infliximab-BD|12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression|A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression||University Health Network, Toronto|No|Not yet recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363738||27381|
NCT02363751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0160/1210 GETUG-AFU 24|Study of Gemcitabine+Platinium Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (BEVABEL)|Prospective Phase II Study of Gemcitabine Plus Platinium Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma|BEVABEL|UNICANCER|Yes|Recruiting|December 2014|||July 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363751||27380|
NCT02373748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111CLD|Performance of the BioGaming Device (YuGo) in the Support of Physical Rehabilitation|A Prospective, Single Site, Single-arm Study Designed to Evaluate the Performance of the BioGaming Device (YuGo) in the Support of Physical Rehabilitation||BioGaming Ltd.|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02373748||26618|
NCT02373787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T 186|A 5 Year Clinical Investigation on Creos Xenoprotect|A 5 Year Clinical Investigation on Creos Xenoprotect|CXP|Nobel Biocare|No|Recruiting|July 2013|July 2020|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02373787||26615|
NCT02373800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/VL-02|Elastography for Evaluating Cervical Maturity in Preparation for Labor Induction at 37 to 42 Weeks of Gestation|Elastography for Evaluating Cervical Maturity in Preparation for Labor Induction at 37 to 42 Weeks of Gestation|ElastoDéclench|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Female|18 Years|N/A|No|Non-Probability Sample|The study population is composed of pregnant women with a medical indication for the        induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the        participating center.|November 2015|February 5, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373800||26614|
NCT02360917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT 2014-01|Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment|Emerging From the Haze™-A Multi-center, Randomized Controlled Trial to Measure Impact of a Multi-dimensional Psycho-educational Program on Subjective Cognitive Complaints After Breast Cancer Treatment Using Virtual Technology|Haze|Cedars-Sinai Medical Center|No|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02360917||27598|
NCT02361177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-0033|Role of Oxytocin in Telling and Detecting Lies|Role of Oxytocin in Telling and Detecting Lies||University of Texas at Austin|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361177||27578|
NCT02361463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|2D Versus 3D Laparoscopic Training on a Virtual Reality Simulator|2D Versus 3D Laparoscopic Training on a Virtual Reality Simulator - A Randomised Trial||Rigshospitalet, Denmark|No|Enrolling by invitation|February 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361463||27556|
NCT02374034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X13-0032|Effect of Egoscue Corrective Exercise Prescription on Acute and Short-term Chronic Knee and Hip Pain|Effect of Egoscue Corrective Exercise Prescription on Acute and Short-term Chronic Knee and Hip Pain||Brigham Young University|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|71 Years|No|||February 2015|February 23, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374034||26596|
NCT02374047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2054-101|A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects|||Catabasis Pharmaceuticals|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|12||Actual|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374047||26595|
NCT02372227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-6063-104|A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma|A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma||Verastem, Inc.|No|Active, not recruiting|January 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372227||26735|
NCT02366663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12338|Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma|SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma|SPINOZA|City of Hope Medical Center|Yes|Recruiting|January 2015|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366663||27158|
NCT02373150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXL008-011|Safety, Tolerability and PK of Imeglimin in Japanese Volunteers|A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects||Poxel SA|No|Recruiting|February 2015|||May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02373150||26664|
NCT02367170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400889|Project 4A: Inspiratory Muscle Training and Diaphragm Strength|Study: Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care: Project 4A: Inspiratory Muscle Training and Diaphragm Strength||University of Florida|Yes|Recruiting|March 2015|May 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|January 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367170||27120|
NCT02367183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GED-0301-CD-001|A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease|A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EXPLORE THE EFFECT OF GED-0301 ON ENDOSCOPIC AND CLINICAL OUTCOMES IN SUBJECTS WITH ACTIVE CROHN'S DISEASE||Celgene|Yes|Recruiting|April 2015|March 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367183||27119|
NCT02367196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90002-ST-001|A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers|A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-90002, A MONOCLONAL ANTIBODY DIRECTED AGAINST CD47, IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS||Celgene|Yes|Recruiting|March 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367196||27118|
NCT02368743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000179|QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)|QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)|QUARTZ|Ferring Pharmaceuticals||Recruiting|December 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Gastroenterologists with private and/or hospital practice|January 2016|January 3, 2016|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368743||27000|
NCT02373917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-14|Characterization of Methylation Patterns in Lung Cancer|Characterization of Methylation Patterns in Lung Cancer||Nucleix Ltd.|No|Not yet recruiting|May 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|430|Samples Without DNA|1. Blood samples        2. Sputum samples        3. saliva samples|Both|18 Years|65 Years|No|Probability Sample|Participants who come to the medical center for the diagnosis of lung cancer.|March 2016|March 7, 2016|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02373917||26605|
NCT02373995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Indigo|Role of the Microbiome in Graves' Orbitopathy|Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy|Indigo|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Not yet recruiting|February 2015|December 2016|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2015|February 26, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02373995||26599|
NCT02374008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003343-35|The Analgesic Effect of Combined Nerve Block and Systemic High Dose Glucocorticoid After Total Knee Arthroplasty.|The Effect of Saphenous Nerve and Obturator Nerve Block Combined With Systemic High Dose Glucocorticoid Versus Local Infiltration Analgesia Combined With a Systemic High Dose Glucocorticoid on Opioid Consumption and Pain After Total Knee Arthroplasty|HOBSALIplus|Regionshospitalet Silkeborg|Yes|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|50 Years|100 Years|No|||November 2015|November 25, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02374008||26598|
NCT02374060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006139|PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial|PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial|POINT|JHSPH Center for Clinical Trials|Yes|Recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|267|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374060||26594|
NCT02360189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-12345|Mechanisms of Social Inequalities in Post-hospitalization Rehabilitation in Patients With Acute Coronary Syndrome|Mechanisms of Social Inequalities in Post-hospitalization Rehabilitation in Patients With Acute Coronary Syndrome||Nordsjaellands Hospital|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|267|||Both|N/A|N/A|No|Non-Probability Sample|Patients hospitalized with acute coronary syndrome (ACS) to Nordsjællands Hospital (ICD10:        DI210-DI219, DI200, DI200B, DI200C, DI23, DI24) will be invited to participate in the        survey as an ongoing process during the inclusion period (N=267).|October 2015|October 6, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02360189||27654|
NCT02372253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-SRA-2014-302-M-R|Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes|Repurposing of Verapamil as a Beta Cell Survival Therapy in Type 1 Diabetes||University of Alabama at Birmingham|No|Recruiting|January 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|45 Years|No|||September 2015|September 11, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372253||26733|
NCT02360462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0643|The Effect of tDCS in the Preoperative Period of Hallux Valgus Surgical Treatment|The Effect of tDCS in the Preoperative Period of Hallux Valgus Surgical Treatment||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|December 2014|June 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Female|18 Years|70 Years|No|||February 2016|February 22, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02360462||27633|
NCT02224131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-1401|Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling|Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling|ATIASC|Beijing Tiantan Hospital|Yes|Not yet recruiting|January 2015|December 2020|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1856|||Both|18 Years|80 Years|No|||August 2014|August 22, 2014|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224131||38094|
NCT02369614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2014.0061|Low -vs- High-Frequency Repetitive TMS of the Right Dorsolateral Prefrontal Cortex in PTSD|Low-Frequency Versus High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Posttraumatic Stress Disorder||United States Naval Medical Center, San Diego|No|Enrolling by invitation|August 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|268|||Both|18 Years|65 Years|No|||February 2015|February 17, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02369614||26934|
NCT02360423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE8-China-RCT|Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions|A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions||CID S.p.A.|Yes|Recruiting|November 2014|April 2021|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360423||27636|
NCT02360436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPITRA-14-001|Analysis of the Glutathione Cycle in Children With Rett Syndrome|EPITRA-14-001: Analysis of the Glutathione Cycle in Children With Rett Syndrome||Edison Pharmaceuticals Inc|No|Withdrawn|March 2015|September 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|2 Years|10 Years|No|Non-Probability Sample|Children aged 2-10 with genetically confirmed diagnosis of Rett syndrome with MeCP2        mutation|February 2015|January 19, 2016|February 2, 2015||No|Priorities other studies|No||https://clinicaltrials.gov/show/NCT02360436||27635|
NCT02360683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_41|Predictive Factors and Subthalamic Stimulation in Parkinson's Disease|Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease|PREDI-STIM|University Hospital, Lille|Yes|Recruiting|May 2014|April 2020|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|75 Years|No|Probability Sample|Multicentric French cohort of 1000 Parkinson's disease patients, for obtain 400 patients        in the failure group|November 2015|November 3, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360683||27616|
NCT02365571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15510|A Study of LY3154207 in Healthy Participants|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Cytochrome P450 Interaction Study of LY3154207 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|64|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365571||27241|
NCT02365584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-93-52030-279|Quality of Life in Patients With Inoperable Malignant Bowel Obstruction|A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)|QoL in IMBO|Ipsen|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02365584||27240|
NCT02365857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thecaldex|Intrathecal Dexmedetomidine With Bupivacaine for Spinal Anesthesia in Cesarean Section|Effects of Intrathecal Dexmedetomidine on the Perioperative Clinical Profile of Bupivacaine-induced Spinal Anesthesia for Cesarean Section||Cairo University|No|Completed|December 2014|October 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 30, 2016|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365857||27219|
NCT02361697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-490-f-S|DTI in Children With Multiple Sclerosis|Monitoring of Neurodegenerative Processes in Children With Multiple Sclerosis by Diffusion-weighed Magnetic Resonance Imaging (DTI)||University Hospital Muenster|No|Recruiting|December 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02361697||27538|
NCT02372981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUI|Doppler-guided Haemorrhoidal Artery Ligation With Suture Mucopexy vs. Suture Mucopexy Alone|Doppler-guided Haemorrhoidal Artery Ligation With Suture Mucopexy vs. Suture Mucopexy Alone for the Treatment of Grade III Haemorrhoids: A Prospective-randomised Controlled Trial||Medical University Innsbruck|Yes|Completed|October 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02372981||26677|
NCT02375867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLI-FHF-S-GH-PED|Steroids and/or Growth Hormone in Fulminant Hepatic Failure in the Pediatric Age Group|Safety and Efficacy of Steroids and/or Growth Hormone in the Management of Fulminant Hepatic Failure in the Pediatric Age Group||National Liver Institute, Egypt|Yes|Recruiting|January 2015|June 2018|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Both|N/A|18 Years|No|||March 2016|March 21, 2016|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02375867||26455|
NCT02365246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201421152|Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)|Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis. Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis.|IGEIAAD|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|August 2014|June 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||May 2014|February 17, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02365246||27266|
NCT02373761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-034-CDH|A Prospective Radiostereometric Analysis (RSA) and Clinical Evaluation of the Triathlon Tritanium Total Knee Replacement|A Prospective Radiostereometric Analysis (RSA) and Clinical Evaluation of the Triathlon Tritanium Total Knee Replacement||Central DuPage Hospital|No|Not yet recruiting|February 2015|||February 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|27|||Both|18 Years|80 Years|No|Non-Probability Sample|Community sample of patients undergoing total knee replacement with the Triathlon        Tritanium knee components at Central DuPage Hospital.|February 2015|February 26, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373761|2 Years|26617|
NCT02373813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110186|Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission|A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis||Amgen|No|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|720|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373813||26613|
NCT02373826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-13-HYMC|Novel Method for Real Time Co-Registration of IVUS and Coronary Angiography|||Hillel Yaffe Medical Center|Yes|Recruiting|March 2015|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing routine coronary angioplasty|March 2015|March 9, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373826||26612|
NCT02373371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14034|Actinic Keratoses Treatment With Metvix® in Combination With Light|Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses||University Hospital, Limoges|No|Recruiting|March 2015|December 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373371||26647|
NCT02367313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA798-203|A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection|SPIRITUS|Biota Scientific Management Pty Ltd|No|Recruiting|February 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367313||27109|
NCT02367391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41720|Penn State TXT2Quit Study|Pilot Randomized Trial of an Automated Smoking Cessation Intervention Via Mobile Phone Text Messages as an Adjunct to Varenicline in Primary Care||Milton S. Hershey Medical Center|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|152|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367391||27103|
NCT02373930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201674|Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects|A Phase I, 2-part Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Fasted and Fed Healthy Subjects||ViiV Healthcare|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373930||26604|
NCT02374112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2103C|Creatine Supplementation in Chronic Fatigue Syndrome|The Effects of Medium-term Creatine Supplementation in Adults With Chronic Fatigue Syndrome|CREFAS|Center for Health, Exercise and Sport Sciences, Serbia|No|Enrolling by invitation|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02374112||26590|
NCT02228603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/92|Exercise as a Life-long Medicine in Patients With Coronary Artery Disease|How to Enhance Physical Activity After Cardiac Rehabilitation? A Randomised Controlled Study Comparing Two Follow-up Training Exercise Programs||Norwegian University of Science and Technology|No|Recruiting|August 2014|April 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228603||37750|
NCT02228837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF02456|The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome|The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome||Florida State University|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|65 Years|No|||September 2015|September 14, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02228837||37732|
NCT02373644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMT0004|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Sacroiliac Dysfunction|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Sacroiliac Dysfunction: a Multi-center Randomized Clinical Trial||Alabama Physical Therapy & Acupuncture|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373644||26626|
NCT02373735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-2192|Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes|Effect of Stroke Volume Variation Guided Fluid Therapy on the Blood Loss and Postoperative Outcomes in Radical Cystectomy||Asan Medical Center|No|Completed|March 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|20 Years|80 Years|No|||December 2015|December 28, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02373735||26619|
NCT02364986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-201201-RESI|Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis|Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis|RESI|University Hospital, Bonn|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02364986||27286|
NCT02365233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-021|Fatty Liver Study in Patients With Type II Diabetes|A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes||The University of Texas Medical Branch, Galveston|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|May 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02365233||27267|
NCT02371460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2144, B14-09-2144-21|Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia|Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial)|MOBYDIck|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|May 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Female|16 Years|N/A|No|||November 2015|March 9, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371460||26793|
NCT02371681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915070|NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis|NexGen EBA Radiologic and Immunologic Biomarkers to Enhance Early Bactericidal Activity Measurements of Sterilizing Drug Activity in Tuberculosis||National Institutes of Health Clinical Center (CC)||Not yet recruiting|January 2015|March 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|350|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371681||26776|
NCT02366143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29436|A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]|A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)||Hoffmann-La Roche||Recruiting|March 2015|November 2022|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366143||27197|
NCT02366156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-1403|A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism|A Randomized, Double-Blind, 3-Period Crossover Study to Evaluate the Effects of a Dietary Supplement Containing Botanical Extracts on Fasting and Postprandial Lipid Metabolism in Apparently Healthy, Overweight and Obese Individuals||Access Business Group|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|93|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02366156||27196|
NCT02363296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150066|Influence on Plasticity of Brain Temperature|Influence on Plasticity of Brain Temperature||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|23|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 19, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02363296||27415|
NCT02363309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150080|Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)|Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 19, 2016|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02363309||27414|
NCT02373046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-117-NRM|Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets|A Phase 1, Randomized, Single-center, Open-label, 2-sequence, 2-period, Single-dose Crossover Study to Evaluate Bioequivalence (Pharmacokinetics) and to Compare Total 24-hour Urinary Glucose Excretion (Pharmacodynamics) When 400 mg LX4211 is Administered as a Single 400-mg Tablet and 2 × 200-mg Tablets in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|February 2015|||April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373046||26672|
NCT02373059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009665|Shared Decision Making With Pharmaceutical Care|Examining the Use of a Shared Decision Making Tool With Pharmaceutical Care in Type 2 Diabetes|SDMPC|Mayo Clinic|No|Active, not recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373059||26671|
NCT02365870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AG044441|Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment|Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment|ANXPD|Johns Hopkins University|No|Not yet recruiting|May 2015|March 2019|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|89 Years|No|||February 2015|February 11, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365870||27218|
NCT02373215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR01|Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|A Phase 1, Open-Label, Non-Randomized, Parallel-Group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of Escalating Oral Doses of Nalbuphine Hydrochloride Extended Release Tablets in End-Stage Renal Disease Patients on Hemodialysis and Matched Healthy Control Subjects||Trevi Therapeutics|No|Completed|April 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373215||26659|
NCT02373228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2014-0520|Optimization of Music Compression|Optimization of Music Compression for People With Hearing Impairment|OMC|Phonak AG, Switzerland|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|99 Years|No|||January 2015|October 19, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373228||26658|
NCT02373293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAR-BOR/TAULI-2013|Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)|Epidemiologic , Observational, Prospective Study to Assess the Prognostic Value of the Antithrombin III in the Development of Moderate or Severe Acute Pancreatitis (AT-PROPANC)|AT-PROPANC|Corporacion Parc Tauli|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Adult patients with mild acute pancreatitis|February 2015|February 26, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373293||26653|
NCT02369653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-155|Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase|A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Pegylated L-Asparaginase||Bristol-Myers Squibb|Yes|Recruiting|April 2015|May 2020|Anticipated|May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|1 Year|17 Years|No|||October 2015|March 11, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369653||26931|
NCT02369666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0093|LycoRed 40051 Product as a Countermeasure to Exercise Stress|Effects of 4-weeks Ingestion of LycoRed 40051 Product on Exercise-Induced Inflammation, Muscle Damage, and Oxidative Stress in Endurance Runners||Appalachian State University|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02369666||26930|
NCT02371473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD-93-04|Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption|Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption||hahid Beheshti University of Medical Sciences|No|Recruiting|November 2014|June 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02371473||26792|
NCT02374086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO37771|Benefits of Exercise Training in Women With Ischemic Syndrome|A Pilot Study to Test the Benefits of Exercise Training in Women With Ischemic Syndrome||Cedars-Sinai Medical Center||Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|60 Years|No|||August 2015|August 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374086||26592|
NCT02372474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M Edessy|"It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure|"It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure||Al-Azhar University|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Female|20 Years|40 Years|No|||February 2015|February 25, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02372474||26716|
NCT02240602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxyNorm|Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery|Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery||Seoul National University Hospital|Yes|Withdrawn|July 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|70 Years|No|||September 2014|June 14, 2015|September 11, 2014||No|Lack of internal resources|No||https://clinicaltrials.gov/show/NCT02240602||36830|
NCT02360176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130940|Benefit of Single Port-surgery in Sleeve Gastrectomy|Evaluation of Minimally Invasive Bariatric Surgery Using a Single Laparoscopic Trocar (Single Incision of 2.5 to 3 cm) Versus 4 to 7 Trocars in Sleeve Gastrectomy|MINIOB|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|398|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360176||27655|
NCT02372604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.849|Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria|Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage|LEVURE PLUS|Hospices Civils de Lyon|No|Not yet recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372604||26706|
NCT02372617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AACD 30/2011|Hip Reconstruction in Cerebral Palsy With Pelvic Osteotomy|||Associação de Assistência a Criança Deficiente|No|Recruiting|January 2012|December 2017|Anticipated|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients with cerebral palsy of AACD Cerebral Palsy Clinic, with progressive hip        subluxation.|February 2015|February 25, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02372617||26705|
NCT02372747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-179|Comparison of Delta-Shaped and Billroth II After TLDG|Comparison of Delta-Shaped and Billroth II for Intracorporeal Anastomosis After Totally Laparoscopic Distal Gastrectomy for Gastric Cancer|TLDG|First Hospital of Jilin University|Yes|Completed|October 2012|December 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|78|||Both|N/A|N/A|No|||February 2006|February 21, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372747||26695|
NCT02372825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343/13/03/02/13/2|Role of Free Iliac Crest Flap in Heel and Ankle Reconstruction|Role of Free Iliac Crest Flap in Heel and Ankle Reconstruction||Helsinki University Central Hospital|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|7|||Male|18 Years|N/A|No|Non-Probability Sample|Thirteen men patients with acute defects or sequela in the heel or ankle treated with the        vascularized iliac crest transfer.|May 2015|May 12, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02372825|4 Years|26689|
NCT02372838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343/13/03/02/13/3|Reconstruction of Extensive Upper Extremity Long Bone Defects With a Microvascular Fibula Flap|Reconstruction of Extensive Upper Extremity Long Bone Defects With a Microvascular Fibula Flap: a Cross-sectional Study of Long-term Outcomes||Helsinki University Central Hospital|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|13|||Both|5 Years|N/A|No|Non-Probability Sample|Twenty patients with upper extremity long bone bone defect treated with a microvascular        fibula transfer. Population aged below 90 years.|August 2015|August 17, 2015|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02372838||26688|
NCT02371954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140607|Exercise to Prevent Depression and Anxiety in Older Hispanics|Exercise to Prevent Depression and Anxiety in Older Hispanics||University of Miami||Recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02371954||26755|
NCT02372214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3Daneurysm|Production of a Patient-specific Simulator for Endovascular Aneurysm Repair Training|Impact of a Patient-specific Simulation on the Learning Curve of Infra-renal Aneurysm Endovascular Repair||University of Sao Paulo General Hospital|Yes|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||January 2015|February 25, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02372214||26736|
NCT02364102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-028|Effect of Hypothyroidism on Brown Adipose Tissue|Effect of Restoration of Euthyroidism in Patients With Primary Hypothyroidism on Brown Adipose Tissue Thermogenesis - the ThyroBAT Study||University Hospital, Basel, Switzerland|No|Recruiting|April 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Serum|Both|18 Years|65 Years|No|Non-Probability Sample|currently hypothyroid patients which are started on levothyroxin substitution|October 2015|October 20, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02364102||27354|
NCT02364297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET_GV15|TIPS in Fundal Variceal Bleeding (the TFB Study)|Efficacy of Early-TIPS in the Treatment of Acute Variceal Bleeding From Gastric Fundal Varices: a RCT vs Standard Therapy|TFB|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Yes|Recruiting|September 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364297||27339|
NCT02366429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141959311|ICBT for Antenatal Depression|Psychological Treatment Via the Internet for Antenatal Depression||Karolinska Institutet|No|Active, not recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|55 Years|No|||September 2015|September 1, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366429||27176|
NCT02366676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-170|Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract|Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract: a Multicenter, Prospective Study||Samsung Medical Center|No|Recruiting|January 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|164|||Female|18 Years|80 Years|No|||December 2013|February 18, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366676||27157|
NCT02366169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|Medigus Ultrasonic Surgical Endostapler (MUSE) Registry|A Worldwide Post-Market Surveillance Registry to Assess the Medigus Ultrasonic Surgical Endostapler (MUSE™) System for the Treatment of GERD||MediGus Ltd|No|Recruiting|March 2015|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|70 Years|No|Non-Probability Sample|The registry population will consist of adult subjects diagnosed with GERD who are deemed        suitable for the procedure by the investigator given the information provided in the        instructions for use.|February 2016|February 1, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366169|3 Years|27195|
NCT02368964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1817-YH-CTIL|IVF Treatment in Women With Immature Oocytes in Previous Cycle|Treatment for Final Follicular Maturation Induction in Patients With Previous High Ratio of Immature Oocytes||Sheba Medical Center|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368964||26983|
NCT02371278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEU-MEALS-2015|Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults|Influence of Leucine Co-ingestion With Mixed Meals on Integrative Myofibrillar Protein Synthesis in Older Adults||McMaster University|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02371278||26807|
NCT02371967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29507|An Observational Study of the Effectiveness and Safety of Erivedge® in Patients With Advanced Basal Cell Carcinoma|A Prospective Observational Study Of Erivedge® Treatment, Effectiveness, and Safety Outcomes In Patients With Advanced Basal Cell Carcinoma||Hoffmann-La Roche||Recruiting|April 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include adult patients with advanced BCC, in whom the treating        physician has made the decision to commence Erivedge® treatment (in accordance with the        local label).|March 2016|March 1, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02371967||26754|
NCT02372240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V14-11056|A Study of VLX1570 and Dexamethasone in Myeloma Patients|VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study||Vivolux AB|No|Recruiting|March 2015|December 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372240||26734|
NCT02374125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/033|Teres Major Muscle and Subacromial Impingement Syndrome|Effectiveness of Teres Major Muscle Specific Treatment in Patients Diagnosed With Subacromial Impingement Syndrome||Jordi Gol i Gurina Foundation|No|Recruiting|November 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02374125||26589|
NCT02372760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2014-47|For A More Comfortable Bronchoscopy: Is Spray Catheter The Answer?|For A More Comfortable Bronchoscopy: Is Spray Catheter The Answer?||University of Florida|No|Withdrawn|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 3, 2015|Yes|Yes|The PI has relocated and the study has been closed.|No||https://clinicaltrials.gov/show/NCT02372760||26694|
NCT02225561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130946|SNPeCPR In Cardiac Arrest REsuscitation|SNPeCPR Pour la prIse en Charge Des Arrêts CaRdiaques Extrahospitaliers|SICARE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|75 Years|No|||August 2015|August 7, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02225561||37984|
NCT02364752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-344|A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344)|A Clinical Trial to Evaluate Circulating and Imaging Biomarkers in Heart Failure Patients||Merck Sharp & Dohme Corp.|No|Withdrawn|September 2015|November 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|0|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364752||27304|
NCT02371083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2014-0112|Timing of Pessary Care|Timing of Pessary Care||Hartford Hospital|No|Recruiting|January 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02371083||26822|
NCT02372695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICROBUB-2011-01|Effect of Paricalcitol Over Vessel Wall|Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects|MICROBUB|Effice Servicios Para la Investigacion S.L.|Yes|Terminated|July 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|75 Years|No|||February 2015|February 20, 2015|March 5, 2013||No|Protocol showed to be inappropriate for the evaluation of the selected patients|No||https://clinicaltrials.gov/show/NCT02372695||26699|
NCT02371252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/2557(EC3)|Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment|Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment||Mahidol University|Yes|Recruiting|April 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02371252||26809|
NCT02371265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD074557-01|Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique|Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique||University of Washington|No|Recruiting|April 2012|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Female|14 Years|50 Years|No|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371265||26808|
NCT02373384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEl-Sawy122015|The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation|The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation||Mansoura University|Yes|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02373384||26646|
NCT02372916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8235|Geographic Atrophy and Intravitreal Ranibizumab Injections|Progression of Geographic Atrophy and Intravitreal Injections of Ranibizumab Among Treated for Age-related Macular Degeneration||University Health Network, Toronto||Recruiting|November 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|50 Years|N/A|No|Probability Sample|Patients with both dry and wet-AMD|February 2015|February 25, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372916||26682|
NCT02364765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0267.0.203.000-10|Assessment of Hematologic Parameters Before and After Bimaxillary Orthognathic Surgery|Assessment of Changes of Hematological Parameters and Need for Blood Transfusion in Bimaxillary Orthognathic Surgery||Federal University of Minas Gerais|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 10, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02364765||27303|
NCT02364999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7391003|A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC|A Phase 3 Randomized, Double-Blind Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-Line Treatment Of Patients With Advanced Non-squamous Non-Small Cell Lung Cancer||Pfizer|Yes|Recruiting|January 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|710|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364999||27285|
NCT02374424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_GA101_DHAP|Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT (GIOTTO)|Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT). (GIOTTO)|GIOTTO|Fondazione Italiana Linfomi ONLUS|No|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02374424||26566|
NCT02366897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SensorPen.v.1.0|Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics|Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics||University of Edinburgh|No|Not yet recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|50 Years|No|||February 2015|February 11, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02366897||27140|
NCT02369406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AI114235|Early Infant HIV Treatment in Botswana|BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana|EIT|Harvard School of Public Health|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|N/A|56 Days|No|||March 2016|March 7, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02369406||26950|
NCT02371694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CorkUH|What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM?|What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With Type 1 Diabetes Mellitus?|REQINSOIL|Cork University Hospital|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|30|||Both|8 Years|18 Years|No|||February 2016|February 2, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371694||26775|
NCT02371707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16052A|Bioequivalence Study of Idalopirdine Tablets 60 mg|Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)||H. Lundbeck A/S|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02371707||26774|
NCT02374021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002747|Treatments Against RA and Effect on FDG-PET/CT|Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)|TARGET|Brigham and Women's Hospital|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|N/A|No|||January 2016|January 12, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374021||26597|
NCT02374710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17922|Tibial Tunnel Placement for ACL Reconstruction|Tibial Tunnel Placement for ACL Reconstruction: A Prospective, Randomized Clinical Trial||University of Virginia|No|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|16 Years|50 Years|No|||April 2015|April 16, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374710||26544|
NCT02374775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT164523564|Exploring the Mechanism of the Plaque Rupture in Acute Myocardial Infarction|Exploring the Mechanism of the Plaque Rupture in Acute Myocardial Infarction Using Coronary CT Angiography and Computational Fluid Dynamics (EMERALD)|EMERALD|Seoul National University Hospital|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients who experienced acute myocardial infarction from 2010-2014 whose diagnosis have        confirmed by invasive coronary angiography with or without IVUS or OCT evaluation, and who        underwent coronary CT angiography from 1 month to 2 year prior to the acute myocardial        infarction event. Acute coronary syndrome without cardiac enzyme elevation (unstable        angina) will be excluded. The time limit of the coronary CT angiography prior to the event        is from 1 month to 2 year. Participating center will perform abovementioned search        process.|February 2015|February 23, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02374775||26539|
NCT02374879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3128466|User Performance and System Accuracy Evaluations Using Glucose Adjustment|User Performance and System Accuracy Evaluations Using Glucose Adjustment||LifeScan|No|Completed|February 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|45 Years|No|||April 2015|April 9, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374879||26531|
NCT02230267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTR-IN UNLVPT 2014.01|High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease|High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease||University of Nevada, Las Vegas|No|Recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|85 Years|No|||May 2015|May 26, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02230267||37622|
NCT02371096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGB-03-104|Comparative Pharmacokinetic Trial of RGB-03 and MabThera|||Gedeon Richter Plc.|No|Not yet recruiting||||June 2016|Anticipated|Phase 1|Interventional|N/A|2||||||Both|18 Years|75 Years||||February 2015|February 19, 2015|February 5, 2015||||No||https://clinicaltrials.gov/show/NCT02371096||26821|
NCT02372526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZJ-MA-14|The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation|The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation||Hvidovre University Hospital|No|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|Samples Without DNA|Plasma and serum.|Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|RYGB Patients who have underwent RYGB surgery more than 18 months earlier, weight stabile        (+/- 5 kg during 1 month). Healthy control subjects who have not underwent bariatric        surgery.|February 2015|February 20, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372526||26712|
NCT02372929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356407|Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer|Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer|ESOCA|Florida Hospital|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred for EUS for esophageal cancer staging will be eligible for        participation in this study.|February 2015|February 20, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02372929||26681|
NCT02372682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25138|Shear Wave Sonoelastography in Pediatric Liver Fibrosis|Shear Wave Sonoelastography for the Noninvasive Evaluation of Hepatic Fibrosis in the Pediatric Population||St. Louis University|No|Recruiting|May 2015|January 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The test population is pediatric patient (0-18 years of age) with known liver disease with        plans to undergo a liver biopsy within 1 month of ultrasound exam. Underlying diagnoses        include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille        syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive        familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia,        Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD),        mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH).        The control population is any pediatric patient (0-18 years of age) undergoing an        abdominal ultrasound for reasons other than liver disease and in whom the US shows a        normal liver, gallbladder, pancreas, spleen, and biliary tree.|December 2015|December 9, 2015|February 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372682||26700|
NCT02361710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC24120209|Serum Vitamin D Levels and Pregnancy Rates in Women Undergoing Elective Frozen Embryo Transfer (eFET)|Comparing the Serum Vitamin D Levels and Pregnancy Rates in Women Undergoing Elective Frozen Embryo Transfer (eFET)||Bahceci Clinic|Yes|Recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|35 Years|No|Probability Sample|Infertile women undergoing a frozen ET with 1 Day 5 (blastocyst stage) embryo|January 2016|January 27, 2016|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02361710||27537|
NCT02361723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-290-AU-002|Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Solid Tumors|A Phase IA, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety and Pharmacokinetics of the PARP Inhibitor BGB-290 in Subjects With Solid Tumors||BeiGene|No|Recruiting|July 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02361723||27536|
NCT02373449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8706-AE|Ketamine and fMRI for Neuropathic Pain|Functional Magnetic Resonance Imaging to Predict and Correlate Clinical Outcomes of Ketamine Infusions for Refractory Neuropathic Pain||University Health Network, Toronto|No|Recruiting|February 2015|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|80 Years|No|||November 2015|February 1, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02373449||26641|
NCT02362217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACHI-04|A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination|A Phase I Study to Evaluate the Safety and Immunogenicity of Simultaneous Prime-Boost Immunisations With Candidate HCV and HIV-1 Vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in Healthy Volunteers||University of Oxford|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02362217||27498|
NCT02374307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2051|Falls-prevention in Older People Receiving Home-help Services|Effect of a Falls-prevention Program on Quality of Life in Older People Receiving Home-help Services. A Randomized Controlled Clinical Trial||Oslo and Akershus University College of Applied Sciences|No|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|180|||Both|67 Years|N/A|No|||February 2016|February 5, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02374307||26575|
NCT02365597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105065|An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer|A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations||Janssen Research & Development, LLC|Yes|Recruiting|April 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365597||27239|
NCT02365610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1330 Part B|A Study of GWP42006 in People With Focal Seizures - Part B|A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.||GW Research Ltd|Yes|Not yet recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2015|February 13, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02365610||27238|
NCT02369159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-305|Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza|A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza||BioCryst Pharmaceuticals|Yes|Recruiting|February 2015|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|17 Years|No|||March 2016|March 23, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369159||26968|
NCT02369172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-EU25|Drug-Drug Interaction Study: ASP2151 and Bupropion|A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Bupropion||Maruho Europe Limited|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369172||26967|
NCT02369198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/13/CRGH/199|MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC|MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy||University of Sydney|Yes|Recruiting|September 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369198||26966|
NCT02369900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000415|Esmolol to Treat the Hemodynamic Effects of Septic Shock|Esmolol to Treat the Hemodynamic Effects of Septic Shock||Beth Israel Deaconess Medical Center|Yes|Recruiting|March 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02369900||26912|
NCT02374580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHT_041406|Can Uganda's Village Health Teams be Sustained and Expanded Without Materials Support?|Can Uganda's Village Health Teams be Sustained and Expanded Without Materials Support?||George Washington University|Yes|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|143|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of at least 200 individual working VHT members, and at        least 10 stakeholders, that is, program managers, administrators, district health        officers, and policymakers. Almost all study subjects will be of Ugandan nationality. Some        stakeholders may be expatriates.|August 2015|August 11, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02374580||26554|
NCT02374645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5080C00001|A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC|A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa®) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment||Hutchison Medipharma Limited|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374645||26549|
NCT02362438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150073|Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy|A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|April 2030|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|99 Years|No|||October 2015|November 3, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02362438||27481|
NCT02234440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-NASH-Cirrhosis-01|Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance|Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance: a Prospective Randomized, Open Labeled, Clinical Trial"||Institute of Liver and Biliary Sciences, India|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02234440||37301|
NCT02360930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLA CCI-14-00092|Vincristine PK and PD in the AYA Population Compared to Younger Children|The Pharmacokinetics and Pharmacodynamics of Vincristine in the Adolescent and Young Adult Population Compared to Younger Children||Children's Hospital Los Angeles|No|Active, not recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|1 Year|24 Years|No|Non-Probability Sample|30 patients with ALL. Our study will enroll patients ages 1-24 years with ALL at start of        Induction or in Maintenance therapy. Patients will be classified into Tanner stage ≤ 2 or        ≥ 4. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥        4. Each patient will receive vincristine weekly x 4 (Induction) or monthly (Maintenance),        at a standard dose specified by the treatment protocol.        The study will be conducted at Children's Hospital Los Angeles.        Tanner staging will take place after the patient is consented to the study using standard        Tanner stage diagrams.|June 2015|June 18, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02360930|4 Weeks|27597|
NCT02373163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERVENCION Trial|INTERVENCION Trial|Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level|INTERVENCION|Prevencion|No|Recruiting|September 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|50 Years|80 Years|No|||October 2015|October 19, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373163||26663|
NCT02372994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410001734|My Team of Care: a Pilot Randomized Controlled Trial of an Online Communication Tool for Collaborative Care|My Team of Care (MyTOC) Trial: a Pilot Randomized Controlled Trial of an Online Communication Tool (Loop) for Collaborative Care in Complex Patients|Loop|Mount Sinai Hospital, Canada|No|Recruiting|January 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02372994||26676|
NCT02362477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-1-1037|Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD|Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD||VA Pacific Islands Health Care System|No|Completed|September 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Female|18 Years|N/A|No|||February 2015|February 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02362477||27478|
NCT02361970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sepsis-kyan0127|Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism|||West China Hospital|No|Recruiting|May 2014|||May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|84|Samples Without DNA|Peripheral blood sample was collected to examine extra-cell expression of gamma delta T      cells and their intracellular cytokines with or without immuno-stimulants using flow      cytometry.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted in ICUs of West China Hospital|February 2015|February 6, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02361970||27517|
NCT02363023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP protocol|Study of Different Etiologic Diagnostic Methods in Ventilator Associated Pneumonia (VAP)|Prospective Comparative Study of Different Etiologic Diagnostic Methods in Ventilator Associated Pneumonia (VAP)||Federal University of Uberlandia|No|Not yet recruiting|February 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|Samples Without DNA|All positive cultures.|Both|18 Years|80 Years|No|Non-Probability Sample|All patients older than 18 years admitted to the ICU of Hospital de Clínicas de Uberlândia        with suspected VAP will be included in the project. from february 2015 to complete the        total of 72 patients required, since provided that agree with the terms of informed        consent.|February 2015|February 12, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02363023||27436|
NCT02363036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0004-15-HYMC|The Shift From Monocytes to Neutrophils in Blood Samples of Women in Labor|The Shift From Monocytes to Neutrophils in Blood Samples of Women in Labor||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood samples|Female|18 Years|N/A|No|Non-Probability Sample|Healthy women without any complications in the current pregnancy.|January 2015|February 9, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363036||27435|
NCT02363049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00685-40|Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer|Randomized Phase III Study Assessing the Interest of Primary Tumor Resection in Patients With Asymptomatic Colon Cancer and Unresectable Synchronous Liver Metastases.|CLIMAT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|278|||Both|18 Years|75 Years|No|||September 2015|September 4, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363049||27434|
NCT02376413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sysubcr001|Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients|Prospective Non-randomized Evaluation of Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Withdrawn|March 2015|December 2022|Anticipated|March 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|65 Years|No|Non-Probability Sample|Non-metastatic breast cancer patients received surgical treatment in Sun Yat-sen Memorial        Hospital, Sun Yat-sen University. Informed consent must be obtained for all of the        included patients.|December 2015|December 2, 2015|February 17, 2015||No|Unavailable to recruit patients.|No||https://clinicaltrials.gov/show/NCT02376413||26413|
NCT02365324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIllinoisUC|Peer Education About Weight Steadiness|PAWS CLUB: Peer Education About Weight Steadiness|PAWS|University of Illinois at Urbana-Champaign|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02365324||27260|
NCT02365675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-106-2014|Wound Dressings for Pemphigus and Pemphigoid|An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid||Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|N/A|No|||September 2014|February 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365675||27233|
NCT02376439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087494-1-54072|Discordance of Obesity in Adolescent Sibilngs|Non-shared Environments and Discordance of Obesity in Adolescent Sibilngs||State University of New York at Buffalo|Yes|Completed|April 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|176|||Both|13 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty-eight sibling pairs (24 pairs of boys and 24 pairs of girls, 96 total adolescents)        age 13 to 17 years who are discordant for overweight/obesity will be studied to assess        potentially modifiable non-shared experiences within and outside the family environment        that alter energy balance behaviors and contribute to adolescent overweight. We will also        measure the height and weight of up to 3 of their best friends.|February 2015|February 24, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02376439||26411|
NCT02375711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVVI P/2013/173|Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient|Evaluation of Immunosenescence as a Predictive Biomarker of HBV Vaccine Efficacy in Chronic Renal Disease Patient|IVVI|Centre Hospitalier Universitaire de Besancon|No|Recruiting|March 2014|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|85 Years|No|||February 2016|February 4, 2016|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02375711||26467|
NCT02367547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JointAPHSHC|Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL|Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate||Joint Authority for Päijät-Häme Social and Health Care|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02367547||27091|
NCT02360475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510|Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women|An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women||GlaxoSmithKline||Active, not recruiting|March 2015|June 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|507|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360475||27632|
NCT02360709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE8-China-SA|Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions|A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions||CID S.p.A.|Yes|Recruiting|November 2014|April 2021|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|75 Years|No|Non-Probability Sample|This trial plans to enroll 800 subjects with de novo coronary artery lesions. Patients        with reference diameter between 2.25mm and 4.5 mm (by visual estimation) and lesion length        not more than 60mm (by visual estimation) will be enrolled.|March 2015|March 23, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360709|5 Years|27614|
NCT02360722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL26|Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly|Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly||Abbott Nutrition|No|Not yet recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|666|||Both|60 Years|80 Years|No|||August 2015|August 12, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02360722||27613|
NCT02367664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT015|A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants|A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety||Jiangsu Province Centers for Disease Control and Prevention|No|Active, not recruiting|October 2014|August 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|900|||Both|6 Months|11 Months|Accepts Healthy Volunteers|||August 2015|August 31, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02367664||27083|
NCT02367690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-501|Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients|Phase 1/2, Multi-Dose, Evaluator-Blinded, Randomized, Vehicle & Standard Of Care-Controlled Dose-Escalation Study To Assess Safety, Tolerability, Pharmacokinetics Of Topical Selinexor In Patients With Diabetic Foot Ulcers||Karyopharm Therapeutics, Inc|No|Withdrawn|January 2015|September 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|February 9, 2015|Yes|Yes|Due to enrollment challenges & improved SOC during run-in phase; no patients received KPT-330.    Withdrawal is not a consequence of any safety concern.|No||https://clinicaltrials.gov/show/NCT02367690||27081|
NCT02367703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0223|Feasibility and Benefit of Laparoscopic Hysterectomy With Less Than 3 Millimeter Diameter's Instruments in Current Practice|Assessment of Feasibility and Benefit of the Use of Less Than 3 Millimeter Diameter's Instruments Compared to Standard Size Instruments in Laparoscopic Hysterectomy: a Randomized Single-center Comparative Study||University Hospital, Clermont-Ferrand||Recruiting|March 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|80 Years|No|||September 2015|September 18, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02367703||27080|
NCT02374749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140401|COMorbidities and EDucation in SPondyloArthritis Study|COmorbidities and EDucation in SpondyloArthritis Study (COMEDSPA) Evaluation of Standardized Follow-up in Axial Spondyloarthritis|COMEDSPA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02374749||26541|
NCT02361515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-846|Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid|Moderate Hypofractionated Radiotherapy (62 Gy in 20 Fractions of 3.1 Gy) Versus Stereotactic Radiotherapy (37.5 Gy in 5 Fractions of 7.5 Gy) With Hyaluronic Acid Injection Between the Prostate and the Rectum for Prostate Cancer of Low- to Intermediate Risk; RPAH2|RPAH2|Hospices Civils de Lyon|Yes|Not yet recruiting|March 2015|||March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Male|18 Years|80 Years|No|||February 2015|February 6, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361515||27552|
NCT02366468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DDE26|Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema|A 12-months, Randomized, VA-assessor Blinded, Multicenter, Controlled Phase IV Trial to Investigate Noninferiority of Two Treatment Algorithms (Discretion of the Investigator vs. Pro re Nata) of 0.5 mg Ranibizumab in Patients With Visual Impairment Due to Diabetic Macula Edema|DIVERSE|Novartis|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366468||27173|
NCT02374619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTH2010|Iron Supplementation and Eccentric Exercise|The Effect of Eccentric Exercise and Iron Supplementation on Blood Redox Status and Muscle Performance in Different Age Groups||University of Thessaly|No|Completed|December 2011|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|28|||Male|10 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 12, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02374619||26551|
NCT02366715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0586-14-RMC|Treatment Of Bronchiolitis With Heated Humidified High Flow Nasal Cannula - Prospective And Retrospective Research|IMLEMENTATION OF High Flow Nasal Cannulae Therapy FOR THE TREATMENT OF BRONCHIOLITIS IN A GENERAL PEDIATRIC WARD - A RETROSPECTIVE AND PROSPECTIVE CLINICAL TRIAL||Rabin Medical Center|No|Recruiting|September 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|N/A|2 Years|No|||October 2015|November 23, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02366715||27154|
NCT02374697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLM-Pathology Expertise|Assessment of Tele-expertise for Second Medical Opinion on Pathological Diagnosis|Assessment of Tele-expertise for Second Medical Opinion on Pathological Diagnosis||Assistance Publique - Hôpitaux de Paris|No|Completed|September 2013|October 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|470|Samples Without DNA|Fixed tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients in need for a second medical opinion on a pathological sample|June 2015|December 8, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02374697||26545|
NCT02367456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371012|A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients|A Randomized, Double Blind Phase 1b/2 Study Of PF 04449913 In Combination With Azacitidine In Patients With Previously Untreated Intermediate 2 Or High Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi Lineage Dysplasia, Or Chronic Myelomonocytic Leukemia||Pfizer|Yes|Recruiting|April 2015|March 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367456||27098|
NCT02367534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Umbilical-vein|Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein|Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein||Fuzhou General Hospital|Yes|Completed|June 2008|December 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||February 2015|February 12, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02367534||27092|
NCT02367599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 595 Vitamin D Sub-Study|Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM|Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595|CCTG595VitD|California Collaborative Treatment Group|No|Active, not recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367599||27088|
NCT02375217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.MA.14|"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"|"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"||American University of Beirut Medical Center|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02375217||26505|
NCT02375607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26/07/2011-195|Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?|Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?||Tokat Gaziosmanpasa University|Yes|Recruiting|February 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02375607||26475|
NCT02375620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci 031 CT|Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature|||GeneScience Pharmaceuticals Co., Ltd.|No|Recruiting|October 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|3 Years|7 Years|No|||January 2015|February 24, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02375620||26474|
NCT02367482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novocure rGBM AMT-PET|Tryptophan Metabolism in Human Brain Tumors|Tryptophan Metabolism in Human Brain Tumors: For Patients Whose Clinical Treatment Includes NovoTTF||Wayne State University|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|we will collect and analyze the tumor specimens obtained prior to NovoTTF therapy (as well      as any tissue specimens available if a patient undergoes surgical resection after initiating      NovoTTF therapy) for various histopathologic features (e.g., proliferative activity, vessel      density, expression of L-type amino acid transporter), and correlate with neuroimaging      findings and clinical response to NovoTTF. This may provide additional useful information on      potential mechanisms of treatment failure.|Both|22 Years|N/A|No|Non-Probability Sample|Patients eligible and agreeable to undergo NovoTTF treatment at KCC/WSU due to recurrent        glioblastoma (initial or subsequent tumor recurrence) will be recruited by the        multidisciplinary neuro-oncology team to undergo the two AMT-PET studies.|December 2015|December 10, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367482||27096|
NCT02367378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0161|Minimally Invasive Surgery (MIS) for Spine Metastases|Minimally Invasive Surgery for Spine Metastases - A Prospective Study||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Chart review of patients having undergone minimally invasive surgery of spine metastases,        18 years and older.|December 2015|December 22, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367378||27104|
NCT02367469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI Tryptophan|Tryptophan Metabolism in Human Brain Tumors|Tryptophan Metabolism in Human Brain Tumors||Wayne State University|No|Recruiting|February 2014|December 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|105|Samples Without DNA|We will collect and analyze tumor specimens obtained after AMT-PET during tumor resection      (if not used for routine histopathology). Various histopathologic features will be studied,      e.g., tumor proliferative activity, expression of amino acid transporter as well as enzymes      and metabolites of the kynurenine pathway, and these will also be correlated with      neuroimaging findings.|Both|13 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed or recurrent brain tumors will be studied.|December 2015|December 10, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367469||27097|
NCT02360488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01NS091951-01A1|Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke|Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke An Assessor-blind, Randomized, Non-inferiority Trial||University of California, Irvine|No|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360488||27631|
NCT02371486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1399-RM-CTIL|Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?|Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?||Sheba Medical Center|No|Not yet recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|35 Years|No|||February 2015|February 19, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02371486||26791|
NCT02360943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208182|Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE|Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE|PEAGE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|July 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|75 Years|N/A|No|Non-Probability Sample|patients older than 75 years receiving an anticoagulant treatment (unfractionnated and low        molecular weight heparins, fondaparinux, vitamin K antagonists and direct oral        anticoagulants) for a symptomatic and confirmed pulmonary embolism|March 2016|March 9, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02360943||27596|
NCT02361203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12-0037|Exercise and Virtual Reality Exposure Therapy for Acrophobia|Exercise and Virtual Reality Exposure Therapy for Acrophobia||University of Texas at Austin|No|Completed|February 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02361203||27576|
NCT02361216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0105-1032|Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest|Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest||LEO Pharma|No|Recruiting|April 2015|February 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361216||27575|
NCT02365259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15178|Phototherapy in Persons With Multiple Sclerosis|Effect of UVB Phototherapy on Serum Vitamin D in Persons With Multiple Sclerosis; a Placebo Controlled Study||University of Illinois at Urbana-Champaign|No|Active, not recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|64 Years|No|||February 2015|February 10, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02365259||27265|
NCT02365272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Hospitals Leuven|Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department|Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED)||Universitaire Ziekenhuizen Leuven||Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02365272||27264|
NCT02361255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01481|Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism|Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism||Philadelphia Veterans Affairs Medical Center||Recruiting|February 2015|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|40 Years|89 Years|No|Non-Probability Sample|antipsychotic treated patients with or without parkinsonism|August 2015|August 25, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361255||27572|
NCT02366208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-20046-2|Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B|Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial|PEG-Tα1|Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Completed|May 2011|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|65 Years|No|||January 2015|February 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366208||27192|
NCT02374632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBM-R2-14|Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass|||Hvidovre University Hospital|Yes|Recruiting|October 2014|June 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|50|||Both|20 Years|75 Years|No|||February 2015|February 24, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02374632||26550|
NCT02374762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-051|Hemodialysis Vascular Access Imaging Study|Contact-Free Video Imaging of Arteriovenous Fistulas In Chronic Hemodialysis Patients||Renal Research Institute|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|90 Years|No|Non-Probability Sample|The investigators would like to study patients with chronic kidney disease, currently        undergoing hemodialysis via AVF at Renal Research Institute dialysis clinics.|February 2016|February 22, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02374762||26540|
NCT02363868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-568|Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population|Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population||Bristol-Myers Squibb|No|Completed|February 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|186|||Both|18 Years|N/A|No|Non-Probability Sample|Others: Retrospecitve database analysis of patients in a health plan|July 2015|July 3, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363868||27371|
NCT02364141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/61199-5|Trunk Restraint Therapy in Post-stroke Patients.|Trunk Restraint Therapy: the Continuous Use of the Harness Could Promote Feedback Dependence in Post-stroke Patients. A Randomized Trial.||University of Campinas, Brazil|Yes|Completed|August 2004|July 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 13, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364141||27351|
NCT02364349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2015-01|A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture|A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture||Jaseng Hospital of Korean Medicine|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|20|||Both|20 Years|39 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02364349||27335|
NCT02364362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-FMTN- Ⅱ-NSCLC-COM|A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|November 2014|December 2016|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|70 Years|No|||February 2015|February 10, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02364362||27334|
NCT02364375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA220115|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||February 17, 2015|February 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364375||27333|
NCT02364583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAC10.14|Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection|Safety, Tolerability and Pilot Efficacy of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection||Papua New Guinea Institute of Medical Research|No|Recruiting|June 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|5 Years|10 Years|No|||October 2015|October 12, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02364583||27317|
NCT02363556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-110|Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol|A Factorial-Design Randomized Controlled Trial Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol for Same-Day Cervical Preparation Prior to Dilation & Evacuation||Medstar Research Institute|No|Recruiting|January 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 19, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02363556||27395|
NCT02376426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106458|A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults||Crucell Holland BV|Yes|Active, not recruiting|March 2015|July 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376426||26412|
NCT02360202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/110/HP|Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid|Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid|RECOPB|University Hospital, Rouen|No|Recruiting|April 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02360202||27653|
NCT02371499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBE-IBS/14|Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study|Effect of Lactobacillus Casei dg (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: Multicenter, Randomized, Double-blind, Cross-over, Placebo Controlled, Pilot Study||SOFAR S.p.A.|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02371499||26790|
NCT02364531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105924|A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting|A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry|COSMiC|Janssen Inc.|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|N/A|No|Non-Probability Sample|Chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who        were prescribed Abiraterone Acetate (ZYTIGA) will be enrolled.|March 2016|March 15, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364531||27321|
NCT02364544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRC|Improving Care and Reducing Cost Study|The Improving Care and Reducing Cost (ICRC) Program|ICRC|Northwell Health|Yes|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|461|||Both|18 Years|60 Years|No|||September 2015|September 2, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02364544||27320|
NCT02364778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1777|Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease|ORBID Trial: Three-Dimensional (3D) Optical Coherence Tomography Guided Assessment of Side Branch Vessel After Provisional Main Vessel Stenting in Coronary Artery Stenting||Icahn School of Medicine at Mount Sinai|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with stable coronary artery disease with angiographic main vessel lesion not        involving side branch (SB) in whom provisional stenting strategy is planned|May 2015|May 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364778|1 Year|27302|
NCT02365012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01482|Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine|Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine||Philadelphia Veterans Affairs Medical Center|No|Recruiting|April 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|22 Years|89 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365012||27284|
NCT02365025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0075-10-EMC|The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents|The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents||HaEmek Medical Center, Israel|Yes|Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|70|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02365025||27283|
NCT02268851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-396|A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies||Dana-Farber Cancer Institute|Yes|Recruiting|November 2014|October 2020|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02268851||34662|
NCT02365922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTFL8101|Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)|Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2|ARTFL|University of California, San Francisco|No|Recruiting|September 2014|February 2021|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1560|Samples With DNA|Plasma, serum, cell lines and cerebrospinal fluid will be retained by study investigators      and stored at NIH-funded repositories.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a diagnosis of a frontotemporal lobar degeneration (FTLD) syndrome,        including progressive supranuclear palsy (PSP), semantic variant primary progressive        aphasia (svPPA), and frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS).        Family members of patients with FTLD syndromes.|February 2016|February 5, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365922||27214|
NCT02374567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAP-2014|Pharmacovigilance in Gerontopsychiatric Patients|Pharmacovigilance in Gerontopsychiatric Patients|GAP|Hannover Medical School|No|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|65 Years|N/A|No|||March 2015|March 24, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02374567||26555|
NCT02375802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002855|Adipose-Derived Stromal Cells (ASC's) and Pressure Ulcers|A PILOT STUDY: EVALUATING THE SAFETY AND FEASIBILITY OF USING AUTOLOGOUS ADIPOSE-DERIVED STROMAL CELLS (ASCs) ON ADULTS WITH STAGE III OR IV PRESSURE ULCERS||Mayo Clinic|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375802||26460|
NCT02367365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055232|Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD|Neovascular Morphology and Persistent Disease Activity Among Patients With Neovascular Age-Related Macular Degeneration||Duke University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with treatment naive NVAMD or newly reactivated NVAMD|December 2015|December 9, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367365||27105|
NCT02374970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/084|Transversus Abdominis Muscular Training and Chronic Low Back Pain|Effectiveness of Transversus Abdominis Muscular Training in Patients With Chronic Low Back Pain||Jordi Gol i Gurina Foundation|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02374970||26524|
NCT02375061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaime011|A Positive Psychology Intervention for Fibromyalgia Patients Using ICT´s|A Positive Psychology Intervention for Fibromyalgia Patients to Promote Physical and Psychological Wellbeing Using Information and Communication Technologies|BPS_FM|Universitat Jaume I|Yes|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02375061||26517|
NCT02375139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-1229_01|A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers|A Randomized, Open-label, Crossover, Single Dose Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 (Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg After Single Oral Administration in Healthy Male Volunteers||Dong-A ST Co., Ltd.|Yes|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375139||26511|
NCT02369211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002749|Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)|Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV) in Patients Undergoing Robotic-assisted Laparoscopic Prostatectomy||Brigham and Women's Hospital|No|Recruiting|September 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369211||26965|
NCT02369419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNI2013-02-Dr KUBALA|Frailty Score Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy|Frailty Score Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy|FRAILTY|Centre Hospitalier Universitaire, Amiens|No|Active, not recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|70 Years|N/A|No|Probability Sample|Patients of > 70 years age, selected for CRT according to the ESC 2013 guidelines|February 2016|February 19, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369419||26949|
NCT02367404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-01-2014|Prospective RCT on Post Prostatectomy Urine Leak|A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy||Institut Mutualiste Montsouris|No|Recruiting|May 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Male|N/A|N/A|No|||February 2016|February 10, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367404||27102|
NCT02367417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0751 RP|Prospective Clinical 5-year Follow-up of the LINK® MEGASYSTEM-C®|Prospective Clinical 5-year Follow-up of the LINK® MEGASYSTEM-C®||Waldemar Link GmbH & Co. KG||Not yet recruiting|March 2015|January 2022|Anticipated|October 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|80 Years|No|Non-Probability Sample|All subjects enrolled in the PMCF in compliance with the inclusion/exclusion criteria who        signed the Informed Consent Form and received the MEGASYSTEM-C® prosthesis, will be        included in the primary and secondary endpoint analysis.|February 2015|February 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367417||27101|
NCT02363777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203M11482|Paravertebral Catheters for Pancreatic Surgery|Ultrasound Guided Bilateral Paravertebral Catheters Versus Thoracic Epidural Analgesia for Post- Operative Pain Control in Open Pancreatic Surgery: A Prospective Outcomes Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|August 2012|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||January 2016|January 25, 2016|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02363777||27378|
NCT02363790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0170|Primary Fascial Closure With Laparoscopic Ventral Hernia Repair: A Randomized Controlled Trial|Primary Fascial Closure With Laparoscopic Ventral Hernia Repair: A Randomized Controlled Trial||The University of Texas Health Science Center, Houston|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02363790||27377|
NCT02364310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00632-45|Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN|Evaluation médico-économique de la Stimulation unilatérale du Sinus Carotidien Dans le Traitement de l'Hypertension artérielle résistante: Essai Multicentrique contrôlé, randomisé, Ouvert Avec évaluation d'efficacité Tensionnelle et de sécurité|ESTIM-rHTN|Central Hospital, Nancy, France|Yes|Recruiting|March 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|75 Years|No|||August 2015|August 31, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02364310||27338|
NCT02373397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/465-31|Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy|Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy of the Anterior Cornea: A Randomized Double-Blinded Placebo-Controlled Study|CACICOL-PTK|Region Östergötland|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373397||26645|
NCT02371720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074105|Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease|Patient Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy With Hydroxyurea in Patients With Sickle Cell Disease|SCD Mobile Dot|Emory University|No|Recruiting|June 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|160|||Both|2 Years|65 Years|No|||October 2015|October 1, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371720||26773|
NCT02371980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_402|Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder||Takeda|No|Recruiting|February 2015|August 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|228|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371980||26753|
NCT02372266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGO 96-042|Safety and Cost-Effectiveness of Early Maternal Newborn Infant Discharge|A Randomized Controlled Trial to Assess the Safety and Cost-Effectiveness of Early Maternal Newborn Infant Discharge||Wilford Hall Medical Center|No|Completed|April 1997|August 2001|Actual|January 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2223|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 19, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02372266||26732|
NCT02271100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000267|Assessment of the Use of Ultrasound for Epidural Catheter Placement and Comparison With Palpation Technique|Assessment of the Use of Ultrasound for Epidural Catheter Placement and Comparison With Palpation Technique||Beth Israel Deaconess Medical Center|No|Recruiting|October 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02271100||34489|
NCT02373566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESG-NVM-II-2014|A Study to Evaluate the Efficacy of an Acellular Dermal Template for the Treatment of Full Thickness Skin Defects|A Phase 2, Intra-patient Randomised Controlled Multicentre International Study to Evaluate the Efficacy of an Acellular Dermal Template Novomaix for the Treatment of Full Thickness Skin Defects||Association of Dutch Burn Centres|No|Recruiting|February 2015|September 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373566||26632|
NCT02363361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no 2014-002170-36|Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study|Treatment of Acute Cervical Spinal Cord Injury With Imatinib (Glivec®) - a Safety and Feasibility Study (EudraCT no 2014-002170-36)||Karolinska University Hospital|No|Not yet recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||February 2015|February 9, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02363361||27410|
NCT02363608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-010|Animal Assisted Activity Program on Patients and Staff on an Inpatient Surgical Oncology Unit|Caring Canines: Outcomes From an Animal Assisted Activity Program on Patients and Staff on an Inpatient Surgical Oncology Unit||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|146|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Staff and inpatients on the 15th floor.|January 2016|January 13, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02363608||27391|
NCT02363855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17719|Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects|An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer||Bayer|No|Active, not recruiting|February 2015|April 2018|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|20 Years|N/A|No|||January 2016|January 11, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363855||27372|
NCT02376335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5997|B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis|B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis|RITPBC|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Active, not recruiting|October 2012|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376335||26419|
NCT02376361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140235|Hemodialysis Access Surveillance Evaluation Study|Hemodialysis Access Surveillance Evaluation Study|HASE|University of Miami|No|Recruiting|March 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|886|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|February 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376361||26417|
NCT02376400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106459|A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults||Crucell Holland BV||Active, not recruiting|April 2015|July 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|78|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376400||26414|
NCT02373098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DTR04|Fingolimod Effect on Cytokine and Chemokine Levels|Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients||Novartis|No|Recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02373098||26668|
NCT02369432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API/2012/32|Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis|Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis|MicroIskin|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|February 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369432||26948|
NCT02369679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/5584/I|Effectiveness of Two Compression Methods in the Treatment of Upper Limb Lymphedema|Comparison of the Effectiveness of a Precast Adjustable Compression Wrap With the Multilayer Compression Bandage in Upper Limb Lymphedema||Parc de Salut Mar|No|Active, not recruiting|February 2015|June 2017|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|47|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02369679||26929|
NCT02369913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401007|A Metabolomic Approach to Probing Myocardial Fuel Shifts in Human Heart Failure|A Metabolomic Approach to Probing Myocardial Fuel Shifts in Human Heart Failure||University of Florida|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing cardiac resynchronization therapy or receiving a catheter ablation        procedure.|October 2015|October 1, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369913||26911|
NCT02360215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-CC001|Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases|A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases||NRG Oncology|Yes|Recruiting|July 2015|||November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|510|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360215||27652|
NCT02360228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3285|STimulation to Improve Auditory haLLucinations|Targeting Auditory Hallucinations With Alternating Current Stimulation|STILL 2|University of North Carolina, Chapel Hill|Yes|Recruiting|May 2015|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360228||27651|
NCT02373462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0888|Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)|||Yonsei University|No|Recruiting|February 2015|February 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|20 Years|85 Years|No|||February 2015|February 22, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02373462||26640|
NCT02373540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLPR 0236|Algovita Post-Market Clinical Study: Spinal Cord Stimulation to Treat Chronic Pain|Real-world Evaluation of Outcome Data Under a Prospective, Observational, Post-Market Clinical Study, Using the Algovita SCS System to Treat Patients With Chronic Pain of the Trunk and/or Limbs Per the Applicable Indications for Use||Greatbatch, Inc|No|Recruiting|June 2015|September 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic, intractable pain of the trunk and/or limbs who are appropriate to        receive SCS therapy and successfully complete a stimulation trial.|December 2015|December 2, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373540||26634|
NCT02375230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054147|MRSOPA-Drills to Improve Mask Ventilation in the Delivery Room|MRSOPA-Drills to Improve Mask Ventilation in the Delivery Room|MRSOPA|University of Alberta|No|Recruiting|May 2015|October 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|56|||Both|N/A|10 Minutes|No|||December 2015|December 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375230||26504|
NCT02367300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-Ahead|Validation Of TBI Detection System For Head Injured Patients|Validation Of Point-Of-Care TBI Detection System For Head Injured Patients|B-AHEAD III|BrainScope Company, Inc.|No|Active, not recruiting|February 2015|January 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects who are suspected of a traumatic, closed head injury within 72 hours will be        recruited from patients who enter the Emergency Department at hospitals that are        participating as clinical sites for this study.|December 2015|December 28, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367300||27110|
NCT02362854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IstanbulU|Efficacy of Diode Laser in Peri-implantitis|A Randomized Clinical Trial of an Adjunct Diode Laser Application in the Treatment of Peri-implantitis.||Istanbul University|No|Completed|February 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02362854||27449|
NCT02375776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-560.|Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention|Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal mHealth Intervention|CORA|Massachusetts General Hospital|No|Recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|104|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02375776||26462|
NCT02363114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141-2014|DOC Utility: Screening of Depression, Obstructive Sleep Apnea and Cognitive Impairment|DOC Utility: Simple Screening of Depression, Obstructive Sleep Apnea and Cognitive Impairment to Identify Stroke Clinic Patients at Risk of Adverse Outcomes||Sunnybrook Health Sciences Centre|No|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8000|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients attending outpatient Stroke Prevention and TIA Clinics.|November 2015|November 23, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363114|1 Year|27429|
NCT02373579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams University 1351|Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia|Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia||Ain Shams University|Yes|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|2 Years|16 Years|No|||February 2015|February 23, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373579||26631|
NCT02376270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143055|Pectin, Aging and Intestinal Barrier Function|The Effects of Pectin on Aging-related Changes in Intestinal Barrier Function, Immune Function and Microbial Composition||Maastricht University Medical Center||Recruiting|March 2015|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|96|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02376270||26424|
NCT02374853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWI-01-14|Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)|Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)|SWI|University of Alberta|Yes|Enrolling by invitation|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1552|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374853||26533|
NCT02376283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004-04-02-CARD|P3AMI Antiplatelet Trial|Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study||The Royal Wolverhampton Hospitals NHS Trust|No|Recruiting|March 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02376283||26423|
NCT02376296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBI-DTX-004|Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients|Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay||Saladax Biomedical, Inc.|No|Recruiting|February 2015|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Plasma|Male|18 Years|N/A|No|Probability Sample|Metastatic prostate cancer patients, either newly diagnosed or castrate resistant, who are        about to start treatment with a 3-weekly docetaxel treatment regimen (starting dose of 75        mg/m2) within the University of Pittsburgh Medical Center (UPMC) Cancer Center network.|December 2015|December 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02376296||26422|
NCT02376322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMPA01|Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients With KPS|A Phase II Trial of Hypofractionated Radiotherapy (16 Gy in 2 Fractions With an Interval of One Week) for the Palliation of Complicated Bone Metastases in Patients With Poor Performance Status||Santa Casa de Porto Alegre|No|Recruiting|July 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 31, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02376322||26420|
NCT02375178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCAS antisseptico oral|Antimicrobial Activity of Two Mouthwashes|Antimicrobial Activity of Two Mouthwashes||Universidade do Vale do Sapucai|Yes|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375178||26508|
NCT02375191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0921|A Comparative Study of the Effect of Epidural Dexmedetomidine Versus Fentanyl Added to Ropivacaine in Pediatric Orthopedic Surgery|||Yonsei University|No|Recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|3 Years|12 Years|No|||April 2015|April 15, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375191||26507|
NCT02375204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031102|Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors|A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Alliance for Clinical Trials in Oncology|Yes|Recruiting|March 2015|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Male|14 Years|N/A|No|||December 2015|December 8, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375204||26506|
NCT02363075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110501|Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia|A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial|DXA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||September 2015|November 11, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363075||27432|
NCT02373176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN401614102|[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study|[14C] PRC-4016 (Icosabutate) - A Phase I, Open-label Study of the Absorption, Metabolism and Excretion Following Oral Dosing to Healthy Male Subjects.||Pronova BioPharma|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|35 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373176||26662|
NCT02373254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|656916|NSAIDS Versus Opioids in Acute SER II Ankle Fractures|Pain Management With NSAIDS in Acute Ankle Fractures Type Supination, External Rotation (SER) II: A Prospective Randomized, Single Blinded Controlled Study||University of California, Davis|Yes|Recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|No|||February 2015|February 20, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02373254||26656|
NCT02373319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5815/I|Self-screening of Cardiovascular Risk|Validity and Effectiveness of a Method for Self-screening of Cardiovascular Risk|ACRISC|Parc de Salut Mar|No|Recruiting|March 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|900|||Both|35 Years|74 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373319||26651|
NCT02360501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCX in NPC|Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma|Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma: a Prospective, Phase 2 Study||Sun Yat-sen University|No|Recruiting|January 2008|October 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360501||27630|
NCT02360735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLD-2014|Manual Lymph Drainage|Manual Lymph Drainage for Patients With Acute Total Knee Replacement|MLD|Anne Arundel Health System Research Institute|No|Active, not recruiting|January 2015|December 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|45 Years|90 Years|No|||November 2015|November 4, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02360735||27612|
NCT02360956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-119-01|Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)|Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA)||Chinese PLA General Hospital|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||February 2015|February 6, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02360956||27595|
NCT02364518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TranQuill™ Sling Snoreplasty|TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea:|TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea: A Single-arm, Pilot Study for Safety and Effectiveness||Medical University of South Carolina|No|Completed|February 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|22 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 10, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02364518||27322|
NCT02364739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUESE2|Evaluate Educational Interventions for Increasing Fertility Knowledge and Awareness|A Randomized Controlled Trial to Evaluate Two Educational Interventions for Increasing Fertility Knowledge and Awareness in Oocyte Donors|QUESE2|Fundació Privada Eugin|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|201|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|December 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02364739||27305|
NCT02372305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203456|Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery|Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery||University of Arkansas|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372305||26729|
NCT02373358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700871-1|Evaluation of Effectiveness of a Group Yoga Intervention as Trauma Therapy for Adolescent Girls|A Mixed Methods Evaluation of Effectiveness of a Group Yoga Intervention as an Adjunctive Trauma Therapy for Adolescent Girls||Hamilton Health Sciences Corporation|Yes|Completed|May 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|11 Years|18 Years|No|||October 2015|October 13, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02373358||26648|
NCT02360787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-030|The Effects of Including Almonds in a Weight Loss Trial|The Effects of Including Almonds in an Energy-restricted Diet on Weight, Abdominal Fat Loss, Blood Pressure, and Cognitive Function||Purdue University|Yes|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02360787||27608|
NCT02360800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Cardiac Surgery|Multicenter Randomized Prospective Comparison of Tisseel Or Control to Diminish Blood Loss After Ascending Aorta Surgery: the MARTOC Study|MARTOC|Cardiochirurgia E.H.|No|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||September 2015|September 4, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02360800||27607|
NCT02360995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2014-06-PLAGIN-CT-YPZ|The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US|The Clinical Investigation of Colgate Total Toothpaste as Compared to Crest Pro-Health Toothpaste and Crest Pro-Health Mouthwash, and Crest Cavity Protection Toothpaste and Crest Fluoride Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US||Colgate Palmolive|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|February 6, 2015|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360995||27592|
NCT02362815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/27|Ultrasound Assessment of Clear Liquid Intake During Labour|Fluid Intake During Labour, Ultrasound Evaluation|EGTO|Hopital Foch|Yes|Recruiting|February 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|40 Years|No|||March 2015|March 25, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02362815||27452|
NCT02363062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00157-40|Identification of New FTLD Genes|Identification of New Genes Causing Frontotemporal Lobar Degeneration by Whole Exome Sequencing and Characterization of the Associated Phenotypes|FTLD-Exome|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|440|Samples With DNA|Blood samples will be collected by a nurse, during a single consultation or hospitalization|Both|18 Years|N/A|No|Non-Probability Sample|Patients affected by FTLD±ALS according to the international diagnosis criteria and their        relatives|September 2015|September 4, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363062||27433|
NCT02367326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208169|Identification of Scores Associated With a Favorable Clinical Response With Thiopurines in IBD Patients|Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial|SCORE1|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|70 Years|No|Probability Sample|patients with Crohn's Disease or Ulcerative Colitis and on thiopurines at stable doses for        at least 3 months, monotherapy or combined with corticotherapy|March 2016|March 9, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367326||27108|
NCT02367339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0224|Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff|Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff|REASSE|University Hospital, Clermont-Ferrand||Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ICU staff|February 2015|February 19, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367339||27107|
NCT02367430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6681|Critical Time Intervention for Individuals With Hoarding Disorder|Critical Time Intervention for Individuals With Hoarding Disorder|CTI-HD|New York State Psychiatric Institute|Yes|Completed|January 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367430||27100|
NCT02367495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No.S03814|Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES|Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue Drug-eluting Coronary Stents|ISAR-DESIRE 3A|Deutsches Herzzentrum Muenchen|No|Recruiting|January 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367495||27095|
NCT02367560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-336-10202014|Calcific Tendinitis: Comparing Minimally Invasive Modalities|Calcific Tendinitis: Comparing Minimally Invasive Modalities||Lakehead University|No|Recruiting|July 2015|August 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02367560||27090|
NCT02364115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49316.041.14|Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Spinal Metastases - VERTICAL Study|Randomized Controlled Trial Comparing Conventional Radiotherapy With Stereotactic Body Radiotherapy in Patients With Spinal Metastases - VERTICAL Study|VERTICAL|UMC Utrecht|No|Recruiting|January 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02364115||27353|
NCT02364323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM Study|Genetic Testing and Counseling to Reduce Diabetic Complications|A Randomized Clinical Trial to Compare a Strategy Utilizing Genetic Testing and Personalized Risk Counseling With Standard Care on Patient Empowerment, Risk Factors Control and the Risk of Diabetic Complications||Chinese University of Hong Kong|No|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|40 Years|75 Years|No|||January 2016|January 26, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364323||27337|
NCT02364557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-BR002|Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer|A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer||NRG Oncology||Recruiting|December 2014|||December 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|402|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364557||27319|
NCT02364791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemopatch|A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures|A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL).|Hemopatch|National Cancer Institute, Naples|No|Recruiting|February 2015|July 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364791||27301|
NCT02369887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Test and Treat PrEP|Evaluation of a Facility-based Test, Treat, and Prevent HIV Program Among Men Who Have Sex With Men and Transgender Women in Thailand|Bureau AIDS, TB, and STI, Thailand Ministry of Public Health|PrEP|Thai Red Cross AIDS Research Centre|Yes|Recruiting|September 2014|||August 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Thai nationals not known to be HIV-infected aged ≥18 years old who are men or transgender        women who report unprotected anal sex with a man in the past 6 months and are eligible for        the study.|November 2015|November 2, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02369887|12 Months|26913|
NCT02376218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105807|Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.|Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.|PLUG|Lawson Health Research Institute||Completed|April 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02376218||26428|
NCT02376244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP 006 - HIIT|The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation|A Randomised Controlled Trial on the Efficacy of High Intensity Interval Training Compared With Moderate Intensity Interval Training for Patients Undergoing Cardiac Rehabilitation||Liverpool Heart and Chest Hospital NHS Foundation Trust|No|Recruiting|September 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|N/A|N/A|No|||March 2016|March 4, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02376244||26426|
NCT02361983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AirwaysThor|Airway Management in Thoracic Anesthesia in Italy|Airway Management in Thoracic Surgery and Incidence Rate of Dislocation and Related Intraoperative Hypoxemia: State of the Art in Italy|AIRTHOR|Azienda Ospedaliera S. Maria della Misericordia|Yes|Completed|July 2012|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2129|||Both|18 Years|90 Years|No|Non-Probability Sample|patients undergoing thoracic surgery|February 2015|February 7, 2015|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02361983||27516|
NCT02362230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-006|Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy|Sun Yat-sen University Cancer Center||Sun Yat-sen University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Female|18 Years|65 Years|No|||February 2015|February 8, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02362230||27497|
NCT02362243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMW-2013-FP-00723|Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters|Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters||University of South Florida|No|Enrolling by invitation|March 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|345|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02362243||27496|
NCT02373501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0494-EC-CTIL|Extra - Abdominal Versus Intra - Abdominal Repair of the Uterine Incision at Cesarean Section|Extra - Abdominal Versus Intra - Abdominal Repair of the Uterine Incision at Cesarean Section|EKAM|Sheba Medical Center|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||March 2015|March 1, 2015|July 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02373501||26637|
NCT02373514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57051259-020/70177|IV Paracetamol Versus IV Dexketoprofen in Dysmenorrhea|Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department||Akdeniz University|No|Recruiting|January 2015|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||February 2015|February 26, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373514||26636|
NCT02373527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411-60|Strict Versus No Fasting Prior to Cardiac Catheterization: A Prospective Evaluation of Safety and Clinical Outcomes|Strict Versus No Fasting Prior to Cardiac Catheterization: A Prospective Evaluation of Safety and Clinical Outcomes||The Guthrie Clinic|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373527||26635|
NCT02372942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Padua|Lactoferrin or Progesterone for Prevention of Preterm Delivery|Lactoferrin or Progesterone for Prevention of Preterm Delivery||University of Padua|Yes|Recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1030|||Female|18 Years|43 Years|No|||February 2015|February 25, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02372942||26680|
NCT02367209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-COPD-2015-002|Assessment of Lung Perfusion in Patients With Chronic Obstructive Pulmonary Disease Using FD MRI|Non-contrast-enhanced Perfusion Imaging of the Lung Using Fourier Decomposition Magnetic Resonance Imaging (FD MRI): Assessment of Feasibility in Patients With COPD in Correlation With Perfusion Scintigraphy, SPECT/CT and DCE MRI|FD-COPD|University Hospital, Basel, Switzerland|No|Recruiting|February 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|The study participants will be recruited by the department of thoracic surgery at the        University Hospital Basel among all patients who undergo Perfusion scintigraphy and        SPECT/CT of the lung with 99mTc-MAA for one of the following clinical indications (of        note: this selection of patients does per se exclude pregnant women):          1. Preoperative assessment of regional lung perfusion before video-assisted lung volume             resection (VATS-LVRS) in patients with COPD.          2. Preoperative assessment of regional lung perfusion before segmentectomy, lobectomy or             pneumonectomy procedures with curative intention in NSCLC patients with concomitant             COPD and reduced pulmonary function parameters (FEV1 < 80%).|March 2015|March 9, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367209||27117|
NCT02367222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200405 (H2014:019)|A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada|An Observational Retrospective Database Analysis to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada|H1N1-014VS|University of Manitoba|Yes|Active, not recruiting|August 2014|December 2015|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children above 6 months of age (at the time of vaccination) who normally reside        in Manitoba, Canada and who had been registered with MH during the study period.        To ensure sufficient historical data, all participants will be required to have at least        one year of insurance coverage before the study period (15 September 2009 to 15 March        2010).|November 2015|November 12, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02367222||27116|
NCT02363569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc 180-12|The Prognosis of Early Pregnancy With Post Coital Bleeding|The Prognosis of Early Pregnancy With Post Coital Bleeding Compared to Early Pregnancy With Spontaneous Bleeding||Meir Medical Center|Yes|Not yet recruiting|February 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|40 Years|No|Non-Probability Sample|Women with early pregnancy (4-23 weeks) with singletons or twins that address to the        "Women E.R." due to vaginal bleeding.|December 2014|February 13, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02363569|2 Years|27394|
NCT02363803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412073|Lidocaine for Diabetic Peripheral Neuropathy|Predicting Individual Response to Analgesic Treatment in Painful Diabetic Neuropathy||Washington University School of Medicine|No|Recruiting|February 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02363803||27376|
NCT02363816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSGAWSU|Beta-carotene and Oxidative Stress in Pediatric Second Generation Antipsychotic Use|||Wayne State University|No|Not yet recruiting|January 2016|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|10 Years|17 Years|No|Non-Probability Sample|pediatric population treated with second generation antipsychotics|February 2015|February 9, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02363816||27375|
NCT02363829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 32814|A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)|A Phase I Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|6|||Female|18 Years|N/A|No|||December 2015|December 15, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363829||27374|
NCT02369926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLS-002|Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis|Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS), Stage 1||Transparency Life Sciences|No|Recruiting|November 2014|||November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|64 Years|No|||May 2015|May 11, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02369926||26910|
NCT02369939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYCAN|Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy|Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy|HYCAN|University of Erlangen-Nürnberg Medical School|No|Recruiting|December 2014|April 2021|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02369939||26909|
NCT02371733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gazi University2|Aerobic Exercise Training in Pulmonary Arterial Hypertension|Effects of Upper Extremity Aerobic Exercise Training on Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension||Gazi University|No|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02371733||26772|
NCT02371746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENV515-01|A Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 Travoprost Extended-Release (XR) in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma|A Multi-Center, Open-Label, Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 Travoprost Extended-Release (XR) in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma||Envisia Therapeutics|No|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|85 Years|No|||February 2015|February 20, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371746||26771|
NCT02371993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R15-3427B|Asthma in the Elderly: A Study of Choline Supplementation|Asthma in the Elderly: A Study of Choline Supplementation||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|No|||October 2015|October 28, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02371993||26752|
NCT02372006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.120|Phase I Trial of Afatinib in Pediatric Tumours|Phase I Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours With ErbB Pathway Deregulation||Boehringer Ingelheim||Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|17 Years|No|||March 2016|March 21, 2016|February 24, 2015||||No||https://clinicaltrials.gov/show/NCT02372006||26751|
NCT02372279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InstitutoBernabeu|Prospective Randomized Study to Evaluate the Effect of Embryonic Observation on the Gestation (PROdE)|Prospective Randomized Study to Evaluate the Effect of Embryonic Observation on the Implantation Rates and Ongoing Gestation|PROdE|Instituto Bernabeu|Yes|Recruiting|February 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|130|||Female|18 Years|50 Years|No|||February 2016|February 29, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372279||26731|
NCT02372721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400925|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis|IMPRESS|University of Florida|No|Withdrawn|March 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|0|Samples Without DNA|serum and urine|Both|5 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|We intend to contact and enroll patients with severe sepsis related AKI patients without        sepsis related AKI and a sample of age and sex-matched healthy controls|October 2015|October 29, 2015|February 20, 2015||No|The IRB required this protocol to be split into two different protocols|No||https://clinicaltrials.gov/show/NCT02372721||26697|
NCT02372461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/L004283/1|Randomized Trial of Amoxicillin Versus Placebo for (Fast Breathing) Pneumonia|A Double Blind Community-based Randomized Trial of Amoxicillin Versus Placebo for Fast Breathing Pneumonia in Children Aged 2-59 Months in Karachi, Pakistan|RETAPP|Aga Khan University|Yes|Recruiting|November 2014|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2500|||Both|2 Months|59 Months|No|||April 2015|September 10, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02372461||26717|
NCT02360267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0673|Pediatric Bipolar Registry|Pediatric Bipolar Registry|PBR|The University of Texas Health Science Center, Houston|No|Enrolling by invitation|May 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based||1|Anticipated|500|||Both|6 Years|17 Years|No|Non-Probability Sample|Children ages 6-17 who may suffer from Bipolar Disorder (BP I, BP II, or BP-NOS) or whose        parents suffer from Bipolar Disorder (BP I or BP II).|December 2015|December 19, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360267|2 Years|27648|
NCT02360540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC2014_02|PERCEPIC: PERC Rule Combined With Implicit Low Clinical Probability|Performance of the Pulmonary Embolism Rule-out Criteria (the PERC Rule) Combined With Implicit Low Clinical Probability (Gestalt) to Rule-out PE Without Further Exams|PERCEPIC|University Hospital, Angers||Recruiting|May 2015|||July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the emergency department for dyspnea or thoracic pain without        another obvious cause or suspected PE|September 2015|September 22, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360540|3 Months|27627|
NCT02366442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WashingtonVAMC|Exploring Relationships Among Balance Performance, Cognitive Dysfunction, Affective Dysregulation, and Community Integration in Veterans With Traumatic Brain Injury (TBI)|Exploring Relationships Among Balance Performance, Cognitive Dysfunction, Affective Dysregulation, and Community Integration in Veterans With Traumatic Brain Injury (TBI)||Washington D.C. Veterans Affairs Medical Center|Yes|Not yet recruiting|February 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|65 Years|No|Probability Sample|Veterans with the diagnosis of TBI|February 2015|February 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02366442||27175|
NCT02366689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2014-05-PG-6MCTCPG-ED|Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)|Clinical Efficacy in Reducing Established Dental Plaque and Gingivitis of a Toothpaste Containing 0.3% Triclosan, 2% Copolymer / Sodium Fluoride and a Manual Toothbrush as Compared to an Oral Hygiene Multi-component Regimen Encompassing the Use of a Manual Toothbrush, a Toothpaste Containing Stannous Fluoride / Sodium Hexametaphosphate and a Mouthwash Containing 0.07% Cetylpyridinium Chloride||Colgate Palmolive|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|179|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366689||27156|
NCT02362490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY004|Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues|HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues||Beijing Ditan Hospital|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||January 2015|March 1, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362490||27477|
NCT02374502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC2015/01/02|Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial|Increasing Physical Activity in Ankylosing Spondylitis (INPACT-AS): a Randomised Controlled Trial|INPACT-AS|University of Dublin, Trinity College|No|Completed|March 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|64 Years|No|||March 2016|March 8, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374502||26560|
NCT02373007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTN U1111-1166-7218|Evaluation of Two Surgical Scopinaro Techniques in the Treatment of Obesity|Evaluation of Safety and Effectiveness Modified Scopinaro Technique in the Surgical Treatment of Obesity Compared to Classical Scopinaro Technique||Instituto Paulo Reis|No|Active, not recruiting|July 2014|April 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02373007||26675|
NCT02363322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150083|Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection|A Multicenter Randomized Phase 1/2 Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|333|||Both|N/A|N/A|No|||December 2015|January 22, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363322||27413|
NCT02363335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915074|The Role of Phosphodiesterase Inhibitors in Incretin Secretion|The Role of Phosphodiesterase Inhibitors in Incretin Secretion||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|100|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02363335||27412|
NCT02369445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R40 MC27705-01-00|Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention|Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention||University of Rochester|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369445||26947|
NCT02369458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503060|Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane|Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane||Washington University School of Medicine|No|Recruiting|April 2015|February 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369458||26946|
NCT02369692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP 021 Embolization|Embolization Procedures in the Peripheral Vasculature Using the Magellan™ Robotic System|Embolization Procedures in the Peripheral Vasculature Using the Magellan™ Robotic System||Hansen Medical|No|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|A subject must be a candidate for an embolization procedure or other endovascular        procedure in the peripheral vasculature, meet all inclusion and no exclusion criteria, and        be willing to comply with all protocol testing and follow-up.|September 2015|September 10, 2015|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02369692|30 Days|26928|
NCT02374398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1-M-194|Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)|A Randomized, Controlled Clinical Trial Comparing the Use of Intravenous Tranexamic Acid With Aquamantys Bipolar Sealer for Blood Loss Reduction in Primary Total Knee Arthroplasty||Eastern Maine Medical Center|No|Completed|March 2011|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02374398||26568|
NCT02374463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1574-P|Improving Balance and Mobility|Improving Balance and Mobility in Older Veterans|MMBI|VA Office of Research and Development|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|56|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374463||26563|
NCT02374515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230/14|Safety and Efficacy of Endocuff-assisted Colonoscopy for Adenoma Detection.|Endocuff-assisted Colonoscopy: a Randomized Back-to-back Colonoscopy Study of Adenoma Detection.||University of Naples|Yes|Recruiting|February 2015|December 2015|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|274|||Both|18 Years|80 Years|No|||March 2015|March 5, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374515||26559|
NCT02374554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-T3D-001|Thora-3Di™ Respiratory Rate Validation|Thora-3Di™ Respiratory Rate Validation||Pneumacare Ltd|No|Recruiting|February 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|43|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374554||26556|
NCT02374606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038868|Accurate Test of Limb Isometric Strength (ATLIS) in ALS|Accurate Test of Limb Isometric Strength (ATLIS) in ALS||Cedars-Sinai Medical Center|No|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Adults with ALS|February 2016|February 1, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374606||26552|
NCT02374671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIS-2014|A Clinical Trial of The VisAbility Implant System Presbyopic Patients|A Prospective, Multicenter Clinical Trial Of The VisAbility Implant System For Improvement Of Near Visual Acuity In Presbyopic Patients||Refocus Group, Inc.|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374671||26547|
NCT02374684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HubeiBMITI- CM2010-01-I|Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects|A Within-group Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics and Food Effect of Methosulide After Oral Administration In Healthy Adult Subjects.||Hubei Biological Medicine Industrial Technology Institute Co., Ltd.|Yes|Completed|February 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|February 17, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02374684||26546|
NCT02360696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13100348|Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children|Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia||Children's Mercy Hospital Kansas City|No|Recruiting|August 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Samples retained, with potential for extraction of DNA from at least one of the types of      samples retained.|Both|8 Years|17 Years|No|Non-Probability Sample|Up to 50 subjects (allowance of 20 additional subjects for screen fails and those who will        not complete Phase 3 of the study) will be recruited from a cohort of patients referred to        the Abdominal Pain Clinic at Children's Mercy Hospitals and Clinics and enrolled prior to        routine initial endoscopy.|February 2015|February 5, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02360696||27615|
NCT02361476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H - 2 - 2014 - 072|Does Intraoperative Clonidine Reduce Post Operative Agitation in Children?|Does Intraoperative Clonidine Reduce Post Operative Agitation in Children Anaesthetised With Sevoflurane? A RCT Including Pharmacokinetic Investigation.||Rigshospitalet, Denmark|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|379|||Both|1 Year|5 Years|No|||December 2015|December 29, 2015|February 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361476||27555|
NCT02361749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIUNIPEDSURG-CR2|Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation|Comparative Study Between Botulinum Toxin Injection and Myectomy in Treatment of Idiopathic Constipation in Children||Cairo University|Yes|Active, not recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|12 Years|No|||January 2016|January 27, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02361749||27534|
NCT02372708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML125396|Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy|Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy||Chinese PLA General Hospital|No|Completed|August 2008|May 2014|Actual|May 2012|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|72|||Both|18 Years|70 Years|No|Non-Probability Sample|patients with stage III (b or c) or stage IV skin (which could not be excised by        operations) malignant melanoma|February 2015|February 25, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02372708||26698|
NCT02372773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007532|Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects|Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects|LEFFTDS|Mayo Clinic|Yes|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||4|Anticipated|300|Samples With DNA|Blood - DNA, Plasma, Peripheral blood mononuclear cells, RNA, Cerebrospinal Fluid|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Have a mutation, or be a relative of an individual with a mutation, in one of the three        most common genes associated with Frontotemporal Dementia - microtubule associated protein        tau (MAPT), progranulin (PGRN; also known as granulin or GRN), or chromosome 9 open        reading frame 72 (C9ORF72).|December 2015|December 9, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372773||26693|
NCT02366910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-45|Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses||Coopervision, Inc.|No|Completed|March 2015|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|17 Years|N/A|No|||July 2015|July 15, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366910||27139|
NCT02363088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14IC2120|Can Text Reminders Improve Uptake of Cervical Screening?|Can Text Reminders Improve Uptake of Cervical Screening? A RCT.||Imperial College Healthcare NHS Trust|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|9||Actual|14597|||Female|24 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363088||27431|
NCT02366923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-56|Dehydration of Stenfilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Dehydration of Stenfilcon A Contact Lenses Versus Delefilcon A Contact Lenses||Coopervision, Inc.|No|Completed|April 2015|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|17 Years|N/A|No|||July 2015|July 16, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366923||27138|
NCT02367235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1834|Analysis of Procedural Times Using Colpassist for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial|Analysis of Robotic Procedural Times Using the Colpassist Vaginal Positioning Device for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial|ACRAS|University of North Carolina, Chapel Hill|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|99 Years|No|||October 2015|October 6, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02367235||27115|
NCT02367248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHe|Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage|Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage||Capital Medical University|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|80 Years|No|||May 2015|May 14, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367248||27114|
NCT02373553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Impact of Physical Therapy Program in Mouthbreathing Children After Adenotonsillectomy|Impact of Physical Therapy Program in Mouthbreathing Children After Adenotonsillectomy: Randomized Clinical Trial.||Federal University of Minas Gerais|No|Enrolling by invitation|October 2014|February 2016|Anticipated|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|45|||Both|4 Years|10 Years|No|||March 2015|March 2, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373553||26633|
NCT02367508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312088151|Mindfully Optimizing Delivery of End-of-Life Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care): Feasibility of a Synergistic Intervention for Patients, Family Caregivers, and Providers|MODEL Care|Indiana University|Yes|Enrolling by invitation|February 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02367508||27094|
NCT02374346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/11/2004|Postoperative Headache in Elective Surgery Patients|Factors Associated With the Presence of Postoperative Headache in Elective Surgery Patients: a Prospective Single Center Cohort Study||Attikon Hospital|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|494|||Both|18 Years|N/A|No|Non-Probability Sample|all adult patients admitted in our hospital for elective general, orthopaedic,        gynaecologic, ENT(ear nose and throat) and vascular procedures|November 2015|November 29, 2015|February 24, 2015||No||No|June 28, 2015|https://clinicaltrials.gov/show/NCT02374346||26572|
NCT02367625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH2CA189923-01|Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia|Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia||Jhpiego|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|30 Years|49 Years|No|||October 2015|October 19, 2015|December 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02367625||27086|
NCT02367638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1111_P1|Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults|A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults||Green Cross Corporation|Yes|Completed|March 2015|||July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|39|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367638||27085|
NCT02360241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 14-36|Light Needle Positioning Robot Under MRI Guidance|LPRobacus: Light Needle Positioning Robot Under MRI Guidance|LPRobacus|University Hospital, Grenoble|No|Completed|February 2015|October 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 27, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02360241||27650|
NCT02360514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTV_P3|Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS|Non-comparable and Open Clinical Research to Evaluate Long-term Immunity by Neutralizing Antibody Test of Adults in High Risk Population of HFRS (Hemorrhagic Fever With Renal Syndrome) After Vaccination and Booster Vaccination of Hantavax||Green Cross Corporation|No|Completed|December 2007|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|226|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360514||27629|
NCT02360748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011136|A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients|A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients|LOPSIE|Ochsner Health System|No|Recruiting|October 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|90 Years|No|||October 2015|October 14, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360748||27611|
NCT02360969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908125|Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child|Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child|STRABO|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|3 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients for whom surgery under general anesthesia with administration of curare is        planned|February 2016|February 19, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02360969||27594|
NCT02372539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1764|Glucose Variability in Cancer Patients Receiving Dexamethasone|Pilot Project to Evaluate Hyperglycemia and Glucose Variability in Cancer Patients Receiving Dexamethasone||University of Colorado, Denver|Yes|Recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Cancer patients with and without diabetes who are receiving intermittent high dose        dexamethasone for prevention of chemotherapy-induced nausea and vomiting|March 2016|March 18, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372539||26711|
NCT02361489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-029|Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices|Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE)|TITRATE|Valeritas, Inc.|No|Recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|80 Years|No|||February 2015|February 6, 2015|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361489||27554|
NCT02361736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2014-102-01|Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery|Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients||Tianjin Medical University General Hospital|Yes|Completed|March 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|120|||Both|65 Years|90 Years|No|||February 2016|February 23, 2016|February 2, 2015|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT02361736||27535|We may have to prolong the follow-up visit for patients.
NCT02366182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ch09101401|Does Neck Circumference Help to Predict Difficult Airway in Obstetric Patients?|Does Neck Circumference Help to Predict Difficult Airway in Obstetric Patients?||Corniche Hospital|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Female|18 Years|45 Years|No|Non-Probability Sample|patients scheduled for cesarean section under general anesthesia|July 2015|July 2, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02366182||27194|
NCT02374320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.155.C|Exparel as a Nerve Block for Severe Hand Pain|Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine||Ochsner Health System|Yes|Terminated|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2015|March 21, 2016|February 23, 2015|Yes|Yes|PI leaving institution|No||https://clinicaltrials.gov/show/NCT02374320||26574|
NCT02374333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BT022|Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy|Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy||University of Pennsylvania|Yes|Recruiting|March 2014|November 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|24 Years|No|||February 2016|February 23, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374333||26573|
NCT02374385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI1401|Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine|A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects|VSVΔG-ZEBOV|Dalhousie University|Yes|Completed|November 2014|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02374385||26569|
NCT02372877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIC-003-CMD|Evaluation of the AMICUS RBCx System in Sickle Cell Patients|Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients||Fenwal, Inc.|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372877||26685|
NCT02366702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01329|Kinematic, Kinetic, and Metabolic Comparison of Bilateral Transfemoral Ambulation With Passive Versus Powered Prosthetic Devices|Kinematic, Kinetic, and Metabolic Comparison of Bilateral Transfemoral Ambulation With Passive Versus Powered Prosthetic Devices||Southern California Institute for Research and Education|No|Recruiting|February 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|3|||Both|18 Years|45 Years|No|Non-Probability Sample|Individuals with bilateral transfemoral amputation who are community level ambulators.        Individuals are ambulatory with non-powered prosthetic devices.|November 2015|November 16, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366702||27155|
NCT02373410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-2014-6010|Effect of the Height of the Operating Table During Spinal Anesthesia|Effect of the Height of the Operating Table During Spinal Anesthesia||Seoul National University Hospital|No|Recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|4||Anticipated|60|||Both|18 Years|75 Years|No|||September 2014|February 26, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02373410||26644|
NCT02373423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN_HT1|A Trial to Determine the Effects of a Behavioural Communication Strategy on Salt Levels in Foods|Protocol for a Cluster-randomized Trial to Determine the Effects of a Behavioural Communication Strategy on the Salt Levels of Processed Foods||The George Institute|No|Active, not recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|45|||Both|N/A|N/A|No|||March 2016|March 9, 2016|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02373423||26643|
NCT02373475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0955|Effect of Perioperative Lung Protective Strategies on the Occurrence of Postoperative Pulmonary Complications in Patients Undergoing Lumbar Spinal Surgery in the Prone Position|||Yonsei University|No|Not yet recruiting|February 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|78|||Both|20 Years|N/A|No|||February 2015|February 22, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02373475||26639|
NCT02367521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11222005|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)|rTMS TBI|Johns Hopkins University|Yes|Recruiting|March 2015|August 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02367521||27093|
NCT02367573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCH-328-150128|3D vs 2D HD Laparoscopy in Inguinal Hernia Repair|3D Versus 2D HD Laparoscopy in Inguinal Hernia Repair: a Prospective, Single Blinded, Randomized, Controlled Trial||Helsinki University Central Hospital||Recruiting|January 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|274|||Both|N/A|N/A|No|||February 2015|February 12, 2015|February 9, 2015||||No||https://clinicaltrials.gov/show/NCT02367573||27089|
NCT02364336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150082|Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B|Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|October 28, 2015|February 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364336||27336|
NCT02364570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0307|Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults|Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults||Ohio State University|No|Active, not recruiting|January 2015|January 2017|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02364570||27318|
NCT02364804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-20|A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer|A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer||Shiga University|No|Active, not recruiting|April 2012|September 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|10|||Both|20 Years|79 Years|No|Non-Probability Sample|Non-small cell lung cancer patients who receive the combination chemotherapy of nedaplatin        and docetaxel|September 2015|September 21, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02364804||27300|
NCT02365051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-014-3|Translation of COPE for Publicly-Funded Home Care Clients and Their Families|Translation of COPE for Publicly-Funded Home Care Clients and Their Families|COPECT|University of Connecticut Health Center|No|Recruiting|May 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|580|||Both|65 Years|N/A|No|||July 2015|July 27, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02365051||27281|
NCT02365298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5695|Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365298||27262|
NCT02365311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0486|Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function During One-lung Ventilation|||Yonsei University|No|Completed|September 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|20 Years|80 Years|No|||April 2015|April 15, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02365311||27261|
NCT02365662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-429|A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor|A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor||AbbVie|No|Recruiting|January 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365662||27234|
NCT02365623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105158|An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)|An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)||Janssen Pharmaceutical K.K.|No|Recruiting|February 2015|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||March 2016|March 22, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02365623||27237|
NCT02365636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-45070-CNS-20013|A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia|(PHN)|Teva Pharmaceutical Industries|No|Recruiting|February 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365636||27236|
NCT02365883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0044|Transrectal Photoacoustic Imaging of the Prostate|Transrectal Photoacoustic Imaging of the Prostate||Stanford University||Recruiting|September 2011|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Male|18 Years|80 Years|No|Non-Probability Sample|English speaking men at the Palo Alto Veterans Hospital between the ages of 18 and 80        years with clinically localized prostate cancer who desire prostatectomy|March 2015|March 12, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365883||27217|
NCT02365896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLDG vs. LADG|Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer|||Fujian Cancer Hospital||Not yet recruiting|June 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|176|||Both|18 Years|75 Years|No|||January 2015|April 24, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02365896||27216|
NCT02372552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML/014/001|Microwave Coagulation Using CROMA Electrosurgical System|Clinical Evaluation of the Safety and Performance of Microwave Coagulation by the CROMA Electrosurgical System During Resection of Complex Colorectal Polyps||Creo Medical Limited|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02372552||26710|
NCT02372656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/10C/2013-14|Simvastatin and Metformin in Chronic Periodontitis|Comparison Of Efficacy Of Locally Delivered 1.2% Simvastatin And 1% Metformin Gel In Chronic Periodontitis: A Randomized Placebo Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|December 2013|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|98|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02372656||26702|
NCT02362256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158200-01-443-124|The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism|The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism With Naltrexone and Sedation||Vilnius University|No|Completed|May 2014|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02362256||27495|
NCT02362503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-047|Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients|A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1||Bristol-Myers Squibb|No|Recruiting|February 2015|May 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|410|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362503||27476|
NCT02374450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115055|A Surveillance Study of Diseases Specified as Adverse Events of Specific Interest (AESI) and Serious Adverse Events (SAEs) in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine|A Cohort Event Monitoring Study to Define the Incidence of Diseases Specified as Protocol-defined Potential Adverse Events of Specific Interest (AESI) and Serious Adverse Events (SAE) in Infants and Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine.||GlaxoSmithKline||Recruiting|January 2015|February 2021|Anticipated|February 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40000|||Both|N/A|35 Months|Accepts Healthy Volunteers|||March 2016|March 17, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374450||26564|
NCT02373332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Michigan-114405A|Fatty Acid Regulation of Platelet Function in Diabetes|Fatty Acid Regulation of Platelet Function in Diabetes||University of Michigan|No|Recruiting|August 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Platelets, plasma, and whole blood will be assessed for platelet reactivity and thrombosis      and stored for later analysis of protein expression. DNA will be stored for assessment of      levels of gene products throught to play a role in platelet reactivity.|Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Adults ages 21-70. Both female and male and no preference for race or ethnicity. Subjects        will abstain from anti-platelet therapy for 10 days. Health status will be confirmed by        oral questioning and written questionnaire and confirmed following blood draw prior to        evaluation of platelets with fatty acid or oxylipins.|December 2015|December 2, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373332||26650|
NCT02367352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14022|Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors|A Phase 1b Study of Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Recruiting|March 2015|February 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|February 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367352||27106|
NCT02367443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentralHMIA|Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC|Hypofractionated Accelerated Radiotherapy With Concomitant Full Dose Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Phase I/II Study||Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367443||27099|
NCT02363842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIQ2014-01|Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)|A Randomized, Controlled Trial Assessing Use of Skin IQ™ MCM Compared to Current Standard of Care for the Management of Moisture and Temperature at the Patient/Surface Interface for Prevention of Pressure Ulcer Development||Arjohuntleigh|Yes|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363842||27373|
NCT02364128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00083670|Improving Patient Decisions About Bariatric Surgery|Patient-Centered Outcomes Research Institute (PCORI)- Improving Patient Decisions About Bariatric Surgery|PCORI|University of Michigan|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02364128||27352|
NCT02373202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13618|A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)|A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis||Sanofi|No|Active, not recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Both|20 Years|N/A|No|||November 2015|November 4, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373202||26660|
NCT02373280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1407/259-005|The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection|A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori||Seoul National University Bundang Hospital|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02373280||26654|
NCT02373345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQTR-IRSST-2013-2016|Clinical and Neuromechanical Predictors for the Evolution of Chronic Non-specific Low Back Pain|Clinical and Neuromechanical Predictors for the Evolution of Chronic Non-specific Low Back Pain||Université du Québec à Trois-Rivières|No|Recruiting|February 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|60 Years|No|Non-Probability Sample|Individuals with a history of nonspecific low back pain|February 2015|February 26, 2015|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02373345||26649|
NCT02373436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSaoCarlos|Effects of Constraint-induced Therapy for the Scapular Kinematics in Patients With Severe Chronic Hemiparesis|Effects of Constraint-induced Therapy for the Scapular Kinematics and Related to the Quality of Movement in Patients With Severe Chronic Hemiparesis||Universidade Federal de Sao Carlos|Yes|Recruiting|January 2015|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|65 Years|No|||May 2015|May 27, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02373436||26642|
NCT02373488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 14/480|The Effects of Connective Tissue Manipulation and Abdominal Massage in Patients With Chronic Constipation|||Hacettepe University|No|Recruiting|November 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||February 2015|February 26, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02373488||26638|
NCT02372487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ob/gyn 3|Sildenafil Citrate Therapy for Oligohydramnios|Sildenafil Citrate Therapy for Oligohydramnios||Al Hayat National Hospital|Yes|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02372487||26715|
NCT02372500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surg050/14|Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery|Randomised Controlled Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery||Countess of Chester NHS Foundation Trust|No|Not yet recruiting|March 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02372500||26714|
NCT02374229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAPA 1|Ablation of the Pulmonary Artery With High Pulmonary Hypertension During Mitral Valve Surgery|Surgical Ablation of Ganglion Plexuses of the Pulmonary Artery in Patients With Valvular Heart Disease, Complicated by High Pulmonary Hypertension May Reduce Its Degree.||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02374229||26581|
NCT02374242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209‐170|Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases|A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases|ABC|Melanoma Institute Australia|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374242||26580|
NCT02374281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308143|Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking|Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking : A Controlled Randomized Single-center Study.|BBSUCROSE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|180|||Both|N/A|8 Days|Accepts Healthy Volunteers|||May 2015|May 6, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02374281||26577|
NCT02365909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203684|Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)|A Prospective Randomized Double-Blind Placebo Controlled Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)|PDPH|University of Arkansas|Yes|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365909||27215|
NCT02366195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120325|Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma|Phase 2, Open-Label, Single-arm Trial to Evaluate the Correlation Between ORR and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma With Talimogene Laherparepvec|TVEC-325|Amgen|No|Recruiting|April 2015|November 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366195||27193|
NCT02373189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13082603|Bright Light Treatment At Home To Manage Chronic Pain In U.S. Veterans|||Rush University Medical Center|No|Recruiting|August 2014|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|46|||Both|18 Years|70 Years|No|||February 2016|February 10, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373189||26661|
NCT02362828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPiMAP Obstetrics|EPiMAP Obstetrics: European Practices in the Management of Accidental Dural Puncture in Obstetrics|EPiMAP Obstetrics: European Practices in the Management of Accidental Dural Puncture in Obstetrics: European Prospective Multicentre Observational Audit to MAP Out Current Practices in the Management of Patients Who Had Accidental Dural Puncture During EPIdural Insertion|EPiMAP|European Society of Anaesthesiology|No|Recruiting|January 2016|November 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Female|18 Years|N/A|No|Probability Sample|All women ≥ 18 years old, who develop classical symptoms of post-dural puncture headache        after epidural anaesthesia for labour or for caesarean section.|March 2016|March 15, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362828||27451|
NCT02363348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSJ1054-11|Efficacy and Safety of L Arginine to Prevent Preeclampsia|Efficacy and Safety of L Arginine to Prevent Preeclampsia in High Risk Pregnancies||Hospital Civil Juan I. Menchaca|Yes|Completed|August 2010|March 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|96|||Female|18 Years|40 Years|No|||March 2016|March 3, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02363348||27411|
NCT02369965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB-ABWT-Ⅲ-301|Test Albuvirtide in Experienced Patients|Efficacy and Safety of Albuvirtide Plus Lopinavir-ritonavir in HIV-1-infected Adults Failed Standard First-line ART Regimen|TALENT|Frontier Biotechnologies Co., Ltd.|Yes|Recruiting|January 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|16 Years|60 Years|No|||February 2015|February 18, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02369965||26908|
NCT02363582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMCIRB-K2013005|The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants|The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|No|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|5 Weeks|7 Weeks|No|||February 2015|February 9, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02363582||27393|
NCT02363595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-277|Genomic Predictors of Papillary Microcarcinoma Disease Progression|Genomic Predictors of Papillary Microcarcinoma Disease Progression||Memorial Sloan Kettering Cancer Center||Recruiting|December 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|325|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|All papillary thyroid cancer patients evaluated at MSKCC clinic.|December 2015|December 10, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02363595||27392|
NCT02373033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Formas Sida Dn 222-2009-1975|Folate-Rich Foods Improve Folate Status|The Effects of a 3-months Dietary Intervention With Folate Enhanced Foods on Folate Status in Healthy Egyptian Women|Folatefood|Mansoura University|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|57|||Female|19 Years|32 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02373033||26673|
NCT02373137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010818|Descemets Endothelial Thickness Comparison Trial||DETECT|Oregon Health and Science University|Yes|Enrolling by invitation|January 2015|||January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02373137||26665|
NCT02375503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-07-HC|Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture|Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture in Response to Army Basic Combat Training||United States Army Research Institute of Environmental Medicine|No|Not yet recruiting|April 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|175|||Both|17 Years|42 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375503||26483|
NCT02375529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/19|A Trial of Single Incision Versus Four Ports Laparoscopic Cholecystectomy|Estudio Prospectivo Aleatorizado de la colecistectomía laparoscópica Por Puerto único vs colecistectomía laparoscópica Por Cuatro Puertos en Pacientes Con Colelitiasis sintomática y régimen de cirugía Sin Ingreso.||Consorci Sanitari Integral|No|Completed|May 2011|July 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|80 Years|No|||February 2015|February 24, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02375529||26481|
NCT02375542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO1301.001M|Characterization of Aortic Tissue at Reoperation|Clinical Observation and Pathological Characterization of Aortic Tissue at Reoperation||CryoLife Europa|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Samples of aortic tissue which are removed as standard practice during surgery|Both|N/A|N/A|No|Non-Probability Sample|Prospective, Single center, single arm study.|February 2015|February 24, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02375542||26480|
NCT02375594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSIE-LAPP-2014|Exercise Park Equipment for Improving Physical Function and Physical Activity Levels in the Elderly|Sustained Effect of a 12 Week Guided Exercise Program Conducted in an Exercise Park Equipment in the Physical Function and Physical Activity Levels of Physically Inactive Elderly: Randomized Clinical Trial||Fundacio Salut i Envelliment UAB|No|Recruiting|December 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02375594||26476|
NCT02375646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0446-14-HMO|Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients|Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients: a Prospective Single-blinded Multicenter Study Comparing Warfarin vs. Low Molecular Weight Heparin Based Bridging Anticoagulation||Hadassah Medical Organization|No|Not yet recruiting|May 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|286|||Both|40 Years|75 Years|No|||February 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375646||26472|
NCT02375685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-78989-019|Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)|A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study|EYEGUARD-X|Servier|No|Terminated|August 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02375685||26469|
NCT02375698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-037-456|A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB|A Phase I, Double-blind, Randomized, Placebo-controlled, Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV Negative Adults Successfully Treated for Drug-susceptible Pulmonary Tuberculosis|C-037-456|Aeras|Yes|Active, not recruiting|November 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02375698||26468|
NCT02375243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|942LB|Use of Dexmedetomidine in Children Undergoing Cardiac Surgery|Use of Dexmedetomidine in Children Undergoing Cardiac Surgery||Bambino Gesù Hospital and Research Institute|No|Recruiting|February 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Month|2 Years|No|||February 2015|February 24, 2015|October 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375243||26503|
NCT02361229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0276|Skin Cancer in Swiss Transplant Cohort Study|Skin Cancer in Swiss Transplant Cohort Study|SCSTCS|University of Zurich|No|Recruiting|January 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|Solid organ transplant recipients within the STCS.|December 2015|December 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02361229|10 Years|27574|
NCT02361502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRACLE|MIrabegron With oveRACtive bLadder Symptoms in mEn|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men||Seoul National University Hospital||Recruiting|February 2015|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|462|||Male|20 Years|N/A|No|||February 2015|February 6, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02361502||27553|
NCT02361996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENE271242|Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients|Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Before and After Coronary-bypass-surgery, Before and After Dilating/Stenting and Before and After Aortic-valve-replacement.|CCT/MPERF|Bakulev Scientific Center of Cardiovascular Surgery|Yes|Not yet recruiting|February 2015|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|690|||Both|18 Years|N/A|No|Non-Probability Sample|All patients above 18 years of age, who are reffered with suspected or known coronary        artery disease or aortic valve stenosis either to the Bakoulev Scientific Centre for        Cardiovascular Surgery, Moscow / Russia or to the Republican Special Centre of Surgery,        Tashkent / Uzbekistan and fulfill the eligibility criteria.|February 2015|February 7, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02361996||27515|
NCT02373111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1412-144-637|Effects of Isoflavone Combined With Astaxanthin on Skin Aging|Effects of Isoflavone Combined With Astaxanthin on Skin Aging||Seoul National University Hospital|No|Not yet recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|45 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 28, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02373111||26667|
NCT02373124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7051|Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial|||New York State Psychiatric Institute|Yes|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|8|||Both|21 Years|55 Years|No|||January 2015|February 20, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02373124||26666|
NCT02375113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRSGP 2012|Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women|Soy as an Innovative Dietary Component in Abdominal Obesity Management||The University of Texas at San Antonio|No|Completed|September 2012|December 2014|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||January 2013|February 27, 2015|February 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02375113||26513|
NCT02366455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-ATB2014|New Measures for Tracheobronchial Anatomy|Knowing the Right Upper Lobe Anatomy Allows for the Efficient Use of the Right-sided Double Lumen Endobronchial Tube|ATB|Laval University|No|Active, not recruiting|August 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|106|||Both|35 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Evaluation of radiological consecutives thoracic CT-Scan reconstruction in a tertiary        university hearth and lung institute. Patients had CT- scan for diagnosis or follow-up        purposes|October 2015|October 7, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366455||27174|
NCT02375321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rubrica n. SPE 14.015|Quality of Life in Patients With Obstructive Sleep Apnea: The Role of CPAP Associated to Psychological Support|Quality of Life in Patients With Obstructive Sleep Apnea: The Role of CPAP Associated to Psychological Support|QUOLOSA|Careggi Hospital|No|Enrolling by invitation|May 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|70 Years|No|||June 2015|June 23, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02375321||26497|
NCT02375334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU # 99115|Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy|Comparative Development of Data Driven Systems for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|February 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients who receive concurrent temozolomide and radiation therapy for newly diagnosed        malignant gliomas|September 2015|September 22, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02375334||26496|
NCT02372019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-0009|Augmentation Study of A Computerized Treatment for Social Anxiety Disorder|Augmenting Interpretative Cognitive Bias Modification Using Memory Reconsolidation Updating||University of Texas at Austin|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|122|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02372019||26750|
NCT02375126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024985|Normal Quantitative EEG (qEEG) Dataset|Normal Quantitative EEG (qEEG) Dataset for the Use in Comparison With Patients Suffering Carbon Monoxide (CO) Poisoning|NormalEEG|Intermountain Health Care, Inc.|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal, healthy volunteers (adult men and women, ages 18-55) will be selected from a        carefully screened convenience sample.|September 2015|September 15, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02375126||26512|
NCT02372032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZDSYLL134|A Trial of Percutaneous Lumbar Discectomy Combined With Ozone for Treatment of LDH|Percutaneous Lumbar Discectomy (PLD) Combined With Ozone Versus Percutaneous Lumbar Discectomy (PLD) for Treatment of Lumbar Disc Herniation:A Single-Blind Prospective Randomized Controlled Trial||Zhongda Hospital|No|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02372032||26749|
NCT02372292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankararenal|Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure|Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure||Ankara University|No|Completed|February 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02372292||26730|
NCT02375425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14090571|Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception|Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception||University of Pittsburgh|No|Recruiting|June 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|360|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|non-pregnant, HIV negative, healthy 18-45 year old women|January 2016|January 26, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375425||26489|
NCT02375464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0587|Gallium-68 DOTATOC for Management of Neuroendocrine Tumors|Gallium-68 DOTATOC for Management of Neuroendocrine Tumors||Northwell Health||Available|April 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Expanded Access|N/A|||||||Both|N/A|N/A|No|||March 2016|March 6, 2016|February 24, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02375464||26486|
NCT02375477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1815|Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods|Improved Adherence to C. Difficile Isolation Protocols Though Improved Inter-disciplinary Educational Methods||Case Comprehensive Cancer Center|No|Not yet recruiting|May 2016|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|600|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375477||26485|
NCT02360774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000335|Mechanisms of Weight Loss With SGLT2 Inhibition|Mechanisms of Weight Loss With SGLT2 Inhibition||Beth Israel Deaconess Medical Center|No|Recruiting|February 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|75 Years|No|||August 2015|August 26, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360774||27609|
NCT02361268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141325|End-Stage Renal Disease Intra-dialysis Lifestyle Education Study|End-Stage Renal Disease Intra-dialysis Lifestyle Education Study|END-IDLE|Vanderbilt University|Yes|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02361268||27571|
NCT02361528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.856|GM-CSF to Decrease ICU Acquired Infections|A Double-Blind, Randomized, Placebo-controlled Multicenter Trial of GRanulocyte-Macrophage Colony-stimulating Factor Administration to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression|GRID|Hospices Civils de Lyon|Yes|Recruiting|September 2015|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|488|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361528||27551|
NCT02362035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-005|ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies|A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Hematologic Malignancies|KEYNOTE145|Acerta Pharma BV|No|Recruiting|February 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|324|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|February 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02362035||27512|
NCT02362282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7675-R|Combined Cognitive and Gait Training|Combined Cognitive and Gait Training|CogGait|VA Office of Research and Development|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02362282||27493|
NCT02362529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB056/2014|Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder|Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder||Centre for Addiction and Mental Health|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|115|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02362529||27474|
NCT02361242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PXT00864-04|24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion|24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion|PLEODIAL-II|Pharnext, SAS|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|60 Years|N/A|No|||December 2014|February 12, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361242||27573|
NCT02365285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141552|Racial Differences in Vagal Control of Glucose Homeostasis|Racial Differences in Vagal Control of Glucose Homeostasis|RDVCGH|Vanderbilt University|No|Recruiting|March 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02365285||27263|
NCT02365649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-740|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy (Celest Study)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Anti-TNF Therapy||AbbVie|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Anticipated|210|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365649||27235|
NCT02375035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO93224|Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer|Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer|CAMPROBE|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|January 2015|September 2019|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Male|18 Years|85 Years|No|Probability Sample|Subjects who have had a standard biopsy and now require a transrectal biopsy as part of        their management|February 2015|February 24, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02375035||26519|
NCT02362269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0047|Personalized Vitamin D Supplementation in European and African Americans|Personalized Vitamin D Supplementation in European and African Americans||University of Wisconsin, Madison|Yes|Recruiting|October 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|334|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02362269||27494|
NCT02373267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41-14|Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)|Screening of TMA Patients for ADAMTS13 Activity and the Description of Systematic Organ Damage and/or Organ Failure in Different Entities of Thrombotic Microangiopathies (TMA)|Adamscreen|University of Cologne|Yes|Not yet recruiting|March 2015|February 2019|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|-  2x 5 ml citrate blood        -  2x 3 ml EDTA blood        -  1x 5 ml lithium heparin blood        -  1x 5 ml serum blood        -  1x 3 ml stool        -  1x 9 ml urine        -  1x blood smear|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with a constellation of thrombocytopenia, Coombs negative hemolytic anaemia        and clinical signs of ischaemic end organ damage or abdominal symptoms.|February 2015|February 20, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02373267||26655|
NCT02362841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEGP-SAR-001|Assessment of the Evolutions of Transcutaneous CO2 With the Modification of Blood Flow During On-pump Cardiac Surgery|Assessment of the Evolutions of Transcutaneous CO2 With the Modification of Blood Flow During On-pump Cardiac Surgery||European Georges Pompidou Hospital|No|Completed|January 2012|||September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for cardiac surgery under cardiac arrest and cardiopulmonary bypass        were prospectively included in the present observational study conducted at a French        teaching hospital.|February 2015|February 9, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362841||27450|
NCT02363101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA012015|Health Outcomes and Costs (HOC) in Lung Cancer (LC)|Health Outcomes and Costs (HOC) in Brazilian Public Health Care System - The HOC Study in Lung Cancer|HOC-LC|Instituto Nacional de Cancer, Brazil|No|Not yet recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients from Instituto Nacional de Câncer during one year.|March 2015|March 3, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363101||27430|
NCT02367651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201187|Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma|A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)||GlaxoSmithKline|No|Not yet recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367651||27084|
NCT02367677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1905, C14-06-1905|Comparison Between Clinical Measurements and Computer-based Measurements on Digital Photographs to Evaluate Blepharoptosis|Comparison Between Clinical Measurements and Computer-based Measurements on Digital Photographs to Evaluate Blepharoptosis||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|November 2013|June 2017|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with ptosis of all causes|December 2014|February 13, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02367677||27082|
NCT02375399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-553/2012|New Echocardiographic Parameters for Prediction of Response to Cardiac Resynchronization Therapy|New Approaches to Echocardiography Assessment of Cardiac Dyssynchrony: Relevance Concerning Response Rate to Cardiac Resynchronization Therapy|NEW-CRT|Heidelberg University|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients referred to the University Hospital of Heidelberg with congestive        heart failure to undergo the implantation of CRT device|September 2015|September 30, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375399||26491|
NCT02360527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(IR)15/2014|Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease|Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease|DIALRET|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|September 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|140|Samples With DNA|Biochemical evaluation including Hba1c, lipidic profile, renal and hepatic function. We will      also determine the APOE genotype and plasmatic beta-amyloidal fractions (Aβ1-40 and Aβ1-42)      as previously described (Hixson JE and Vernier DT. Restriction isotyping of human      apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.)|Both|65 Years|N/A|No|Non-Probability Sample|We will include the following groups: 1) Type 2 diabetic patients with AD; B) Type 2        diabetic patients with MCI; 3) Type 2 diabetic patients with normal cognitive status; 4)        Non-diabetic patients with AD. The groups will be matched by age (± 5 years), gender, risk        factors related to AD (APOE genotype and family history of dementia), diabetes duration        and Hba1c (±1%)- the last two criteria apply for the three groups of diabetic patients.|July 2015|July 16, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360527|12 Months|27628|
NCT02360761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1504|Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy|Surgical Treatment of Elderly Patients With Early Stage Non-small Cell Lung Cancer (STEPS): Comparison Between Sublobar Resection and Lobectomy - an Open, Multicenter, Randomized Phase III Clinical Trial|STEPS|Peking University People's Hospital|No|Not yet recruiting|March 2015|March 2021|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|339|||Both|70 Years|N/A|No|||July 2015|July 4, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02360761||27610|
NCT02360982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cukurova university|The Comparison of Incidence and Risk Factors of Postoperative Delirium in Elderly Patients After Lower Extremity Surgery|Cukurova University Faculty of Medicine||Cukurova University|No|Completed|March 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|65 Years|N/A|No|Probability Sample|American Society of Anesthesiologists physical status I-III, 120 patients aged ≥65 years        scheduled for total hip or knee arthroplasty and femur fracture surgery were enrolled into        the study.|February 2015|February 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02360982||27593|
NCT02366221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999P008705|Upper-Extremity Bone or Joint Surgery: Long Term Outcome|Upper-Extremity Bone or Joint Surgery: Long Term Outcome||Massachusetts General Hospital|No|Enrolling by invitation|January 1998|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with a history of complex arm or leg trauma who have completed their normal care        in the Orthopaedic Hand and Upper Extremity Service|August 2015|August 28, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02366221||27191|
NCT02366481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|620511|Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)|Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes||Georgia Regents University|Yes|Recruiting|February 2015|February 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366481||27172|
NCT02366728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054740|DC Migration Study for Newly-Diagnosed GBM|Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma|ELEVATE|Duke University|Yes|Recruiting|September 2015|June 2020|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|116|||Both|18 Years|80 Years|No|||October 2015|October 2, 2015|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366728||27153|
NCT02366741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-1476-14|Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study|Neurocognitive Function Changes in Patients With LD Small Cell Lung Cancer Undergoing Prophylactic Whole Brain Radiotherapy With Hippocampal Sparing - a Pilot Study||Sheba Medical Center|No|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02366741||27152|
NCT02366975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003494-26|TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST|Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST|PROTEST|University of Florence|No|Recruiting|November 2012|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Male|18 Years|N/A|No|||December 2015|December 4, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366975||27134|
NCT02367274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-Ahead|Point-Of-Care TBI Detection System For Head Injured Patients In The Emergency Department|Use Of A Point-Of-Care TBI Detection System For Identification Of Head Injured Patients Who Present To The Emergency Department|READ-TBI|BrainScope Company, Inc.|No|Active, not recruiting|January 2015|May 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects who are suspected of a traumatic, closed head injury within 24 hours will be        recruited from patients who enter the Emergency Department at hospitals that are        participating as clinical sites for this study.|December 2015|December 28, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367274||27112|
NCT02369978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124156935014|CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)|Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)|CHICAMOCHA-3|Universidad Autónoma de Bucaramanga|No|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|20 Years|55 Years|No|||November 2015|November 25, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369978||26907|
NCT02365038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART2pilot|ART-2 Pilot - Driving Pressure Limited Ventilation for Patients With ARDS|ART-2 Pilot: A Controlled, Randomized Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs. Standard Strategy (ARDSNet) in Patients With ARDS|ART2pilot|Hospital do Coracao|No|Not yet recruiting|February 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02365038||27282|
NCT02372890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277/2014|Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer|Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer||University Hospital Inselspital, Berne|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with head and neck squamous cell carcinoma undergoing routine PET/CT staging or        restaging and sheduled for neck dissection according to the decision of the        interdisziplinary tumor board.|July 2015|July 13, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02372890||26684|
NCT02374814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|568085|Immunogenicity of Rabies Vaccine for Pre Exposure|Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination|RABVAX|State University of New York - Upstate Medical University|No|Active, not recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374814||26536|
NCT02372955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10022/D1690L00020|Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes|Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes||Gulf Regional Research & Educational Services, LLC|No|Recruiting|February 2015|December 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|21|||Both|21 Years|N/A|No|||February 2015|February 20, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372955||26679|
NCT02373020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e coli|Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis?|ROLE OF E COLI IN Colorectal Tumourigenesis|EPEC|Mansoura University||Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients who were diagnosed to have colorectal cancer (Group 1) and healthy controls who        had colonoscopy for colorectal symptoms in the same study period (Group 2|February 2015|April 7, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02373020|6 Months|26674|
NCT02366936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060408|Effectiveness of Tortle Midliner Positioning System on the Prevention and Treatment of Cranial Molding Deformities in Preterm Infants|Effectiveness of Tortle Midliner Positioning System on the Prevention and Treatment of Cranial Molding Deformities in Preterm Infants||Duke University|Yes|Recruiting|June 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|23 Weeks|30 Weeks|No|||March 2016|March 16, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366936||27137|
NCT02366949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17350|Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel|An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies||Bayer|No|Recruiting|February 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366949||27136|
NCT02366962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7374-CL-0107|A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older|Phase III Study of ASP7374－Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older||Astellas Pharma Inc|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366962||27135|
NCT02362516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346.3|Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809|Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers||Boehringer Ingelheim||Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|February 9, 2015||||No||https://clinicaltrials.gov/show/NCT02362516||27475|
NCT02367261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-001|A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of SPI Implant|An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol.|SPI|Alpha - Bio Tec Ltd.|Yes|Active, not recruiting|November 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2015|December 31, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367261||27113|
NCT02369705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP200/U-Cardio-001|Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects|Diagnosis of Sleep-related Respiratory Disorders in Patients With Cardiac Disorders Such as Atrial Fibrillation, Heart Failure and Other Comorbidities||Itamar-Medical, Israel|No|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|12 Years|90 Years|No|Non-Probability Sample|Adults with cardiac disorder, referred to the sleep lab for a night study, who consent to        undergo an overnight sleep study in the clinical sleep laboratory.|December 2015|December 29, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02369705||26927|
NCT02364817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_09|ADHD: Gaps Between Patients With Alcohol-dependence and Impact on Relapse|Impact of Attention Deficit/Hyperactivity Disorder on the Post-detoxification Alcohol Relapse Rate|AGADIR|University Hospital, Lille|No|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with alcohol-dependence who undergo a residential alcohol detoxification program|February 2016|February 4, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364817||27299|
NCT02360254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3324/Ao/14|Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes|Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetic Patients. An Observational Study.|Basal21|University of Padova|No|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|26|||Both|18 Years|65 Years|No|Non-Probability Sample|Type 1 diabetic patients|February 2015|February 4, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02360254||27649|
NCT02365688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0436|Hemodynamic Response During Goal Directed Fluid Therapy in the OR|Correlation of Multiple Invasive and Non-Invasive Hemodynamic Monitored Modalities to Support Goal Directed Fluid Therapy During Open Abdominal Surgery||Medtronic - MITG|No|Terminated|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||July 2015|February 15, 2016|September 9, 2014||No|Lack of consistent reference devices|No||https://clinicaltrials.gov/show/NCT02365688||27232|
NCT02375659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSLP100114|Black Patients' Lived Experiences and Perceptions of Skin of Color Clinics|Black Patients' Lived Experiences and Perceptions of Skin of Color Clinics||Northwestern University|Yes|Recruiting|February 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|N/A|No|Non-Probability Sample|African American patients evaluated at the Northwestern Center for Ethnic Skin|February 2015|February 24, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375659||26471|
NCT02365935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC/47 cbm|4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery|Phase II Randomized Controlled Trial on the Safety and Efficacy of 4 Versus 6 Courses of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Previously Treated With Neoadjuvant Chemotherapy Plus Radical Surgery||Campus Bio-Medico University|No|Completed|February 2007|September 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Female|18 Years|75 Years|No|||February 2015|February 18, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02365935||27213|
NCT02375880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEK-DKK1-P103|Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder|A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder||Leap Therapeutics, Inc.|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|30 Years|N/A|No|||December 2015|December 10, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375880||26454|
NCT02375906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepNet-HDIN|The Hepatitis Delta International Network|Hepatitis Delta Registry and Research Network- Observational Study|HDIN|HepNet Study House, German Liverfoundation|No|Recruiting|November 2013|November 2023|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic hepatitis delta will be screened regardless of HDV or HBV genotype|August 2015|August 26, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02375906|10 Years|26452|
NCT02367612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210/12ES1|Fermented Milk on the Appearance of Common Winter Infectious Diseases|Fermented Milk on the Appearance of Common Winter Infectious Diseases||Federico II University|No|Completed|December 2014|June 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|140|||Both|12 Months|48 Months|No|||June 2015|June 24, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367612||27087|
NCT02375932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1579|Pre-Visit Prioritization for Complex Patients With Diabetes|Pre-Visit Prioritization for Complex Primary Care Patients With Diabetes|PVP|Kaiser Permanente|No|Active, not recruiting|March 2015|July 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|95|||Both|21 Years|85 Years|No|||September 2015|September 17, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375932||26450|
NCT02375971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002H2301|RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|RAINBOW|Novartis|Yes|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|N/A|N/A|No|||November 2015|November 16, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375971||26447|
NCT02375984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIL-TREATMENT-0614|A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas|A Phase II Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) Plus IL-2 Followed by Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanomas|TIL|John Wayne Cancer Institute|Yes|Recruiting|February 2015|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375984||26446|
NCT02376179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00613|Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Tonsillectomy and/or Adenoidectomy|||Nationwide Children's Hospital|No|Enrolling by invitation|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Non-Probability Sample|Less than 18 years of age, undergoing otolaryngological surgery with endotracheal        intubation.|January 2016|January 27, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376179||26431|
NCT02376192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK1010276|Maternal Microcirculation & SDF Imaging|Maternal Microcirculation & SDF Imaging: A Novel Assessment of the Microcirculation During Cesarean Delivery With Spinal Anesthesia and the Impact of Phenylephrine Prophylaxis to Prevent Spinal Anesthesia-induced Hypotension.||IWK Health Centre|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|45 Years|No|||February 2015|February 25, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02376192||26430|
NCT02372786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2014-517_OPTICA|7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream|A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal|OPTICA|Erasmus Medical Center|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02372786||26692|
NCT02374827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140630003 (ST)|Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)|Complete Salpingectomy Versus Standard Postpartum Tubal Ligation at the Time of Cesarean Delivery- a Randomized Controlled Study|SCORE|University of Alabama at Birmingham|Yes|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|25 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374827||26535|
NCT02374931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SAR 1458|18F-FES PET/CT in Imaging Patients With Desmoid Tumors|Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374931||26527|
NCT02374944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0625|Fixation Insitu Versus Removal for Midfoot Lisfranc Injuries|A Randomized Clinical Trial Evaluating Fixation Insitu Versus Removal for Midfoot Lisfranc Injuries|FIRM|University of Calgary|No|Active, not recruiting|November 2015|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02374944||26526|
NCT02361762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00014188|Gaming for Autism to Mold Executive Skills Project|Electrophysiological Response to Executive Control Training|GAMES|Children's Hospital Boston|No|Recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|7 Years|11 Years|No|||February 2016|February 29, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02361762||27533|
NCT02362009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-099|South Miami Hospital Fibroid Registry|South Miami Hospital Fibroid Registry||Baptist Health South Florida|Yes|Terminated|February 2015|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Female|18 Years|89 Years|No|Probability Sample|Outpatients seen for fibroid treatment services.|November 2015|March 4, 2016|January 20, 2015||No|A policy has been approved which describes all procedures outlined as standard of care|No||https://clinicaltrials.gov/show/NCT02362009|12 Months|27514|
NCT02362022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.09.2007/88-4|The Effects of Morphine on Desflurane Consumption and Recovery Time|Comparison of Two Different Doses of Intravenous Morphine on Desflurane Consumption and Recovery Time in Patients Undergoing Total Abdominal Hysterectomy||Baskent University|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|90|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||June 2015|December 2, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02362022||27513|
NCT02374840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2014-102|Pharmacogenomics Registry to Assess Clinical Utility|Pharmacogenomics Registry to Assess Clinical Utility|PREACT|Companion Dx Reference Lab, LLC|No|Not yet recruiting||||February 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|340778|||Both|2 Years|N/A|No|Non-Probability Sample|Male and female subjects aged 2 years and above, currently receiving or under        consideration to receive at least one medication known to be metabolized through relevant        genetically-modified pathways.|July 2015|July 20, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02374840|90 Days|26534|
NCT02374957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00030275|Cilostazol After Lower Extremity Arterial Revascularization Trial|Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR)|CLEAR|Wake Forest School of Medicine|Yes|Recruiting|February 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|N/A|No|||December 2015|December 16, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02374957||26525|
NCT02375048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288|Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI|Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI)||Istituto Clinico Humanitas|Yes|Recruiting|January 2015|January 2025|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Female|55 Years|70 Years|No|||September 2014|February 27, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02375048||26518|
NCT02375555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-453|Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM|An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Recruiting|May 2015|June 2022|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375555||26479|
NCT02375568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405EMO|Large-scale Expansion and Characterization of Mesenchymal Stem Cells for Clinical Application|Large-scale ex Vivo Expansion and Characterization of Synovial Membrane Mesenchymal Stem Cells (SM-MSC) and Infrapatellar Fat Pad Mesenchymal Stem Cells (IF-MSC) for Clinical Application||Far Eastern Memorial Hospital|No|Recruiting|May 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|N/A|N/A|No|Probability Sample|Patient who have an total knee replacement surgery|February 2015|February 24, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02375568||26478|
NCT02361593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-VARICE|Transparent Cap-assisted Endoscopic Sclerotherapy|Transparent Cap-assisted Endoscopic Sclerotherapy(Lauromacrogol Injection) in Esophageal Varices: a Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Not yet recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|76 Years|No|||February 2015|February 6, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02361593||27546|
NCT02374866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13031 SUIVI OBESITE|Monitoring Obese Patients : Impact on the Frequency of Monitoring Weight|Monitoring Obese Patients: Impact on the Frequency of Monitoring Weight, Quality of Life, Dietary Behavior, Physical Ability and Comorbidities|SUIVIOBESITE|University Hospital, Limoges|No|Active, not recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02374866||26532|
NCT02374983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0188|Gamma Knife Dosimetric Differences, TMR 10 Versus Convolution Algorithm|Evaluation of Dosimetric Differences Between the TMR 10 and Convolution Algorithm for Gamma Knife Radiosurgery Planning||University College, London|No|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The population of the study is all adult patients receiving treatment at the Gamma Knife        Centre at Queen Square Radiosurgery Centre (QSRC). The sample will consist of the first        100 patients (200 observations) receiving Gamma Knife treatment in QSRC who accomplish all        the inclusion and exclusion criteria and consent to participate in the study. This study        does not involve group allocation or randomization of patients.|February 2015|February 27, 2015|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374983||26523|
NCT02374996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPBIOPWSU|Pharmacoepigenetics of Bipolar Disorder Treatment|Pharmacoepigenetics of Second Generation Antipsychotic-Induced Insulin Resistance in Bipolar Disorder||Wayne State University||Recruiting|November 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|105|||Both|18 Years|65 Years|No|Non-Probability Sample|Bipolar patients treated with Lithium or an antipsychotic|March 2016|March 5, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02374996||26522|
NCT02362334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChuncheonSHH|IOL Power Calculation Using Dual Schiempflug Analyzer|Precision of Optical Biometry and Intraocular Lens Power Calculation Using Dual Schiempflug Analyzer||Chuncheon Sacred Heart Hospital|No|Recruiting|October 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|140|||Both|20 Years|N/A|No|Non-Probability Sample|140 eyes of patients who scheduled for cataract surgery|October 2014|February 15, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362334||27489|
NCT02362347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CON001|Investigating Novel Treatments for Concussion: Impact of Compression Vest on Rehabilitation Outcomes|Investigating Novel Treatments for Concussion: Impact of Compression Vest on Rehabilitation Outcomes||Western University, Canada|No|Recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02362347||27488|
NCT02375152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-14|Safety and Effectiveness of Capsulotomy in Refractory OCD|Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder||Ruijin Hospital|Yes|Recruiting|April 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||April 2015|April 25, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375152||26510|
NCT02375256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-021-402|A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402|A Phase I, Double-Blind, Randomized, Placebo-controlled Leukapheresis Study to Obtain Lymphocytes for the Study of Immune Responses in Healthy Adult Volunteers in the U.S. Who Receive BCG Vaccination Followed by Boosting With AERAS-402|C-021-402|Aeras|No|Completed|October 2009|December 2013|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02375256||26502|
NCT02363153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400844|Diet and Exercise in Pompe Disease|A Pilot Study of Diet and Exercise Therapy in Pompe Disease||University of Florida|No|Not yet recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|40 Years|No|||September 2015|September 15, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363153||27426|
NCT02363413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNI_001|Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome|Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome: Randomized Controlled Non-inferiority Study|OVNI-Dom|IP Santé Domicile|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2015|August 5, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02363413||27406|
NCT02367989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333|Effects of Barley on Glucose Control|A Dose-response, Double-blind, Randomized, Controlled, Cross-over Trial Examining the Effect of Barley Beta-glucan on Post-prandial Glucose Response in Healthy Adults||St. Boniface General Hospital Research Centre|No|Not yet recruiting|February 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02367989||27058|
NCT02368002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA188892-01|BestFIT: a Personalized Weight Loss Program|Evaluating Options for Non-Responders: A SMART Approach to Enhancing Weight Loss||HealthPartners Institute|Yes|Recruiting|May 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02368002||27057|
NCT02225730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28213|Imaging Collaterals in Acute Stroke (iCAS)|Imaging Collaterals in Acute Stroke|iCAS|Stanford University|No|Recruiting|September 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the hospital with diagnosis of acute ischemic stroke who are        scheduled to undergo (or have undergone) acute IA stroke therapy will be screened for        study enrollment.|April 2015|April 20, 2015|August 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02225730||37971|
NCT02360306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00081049|The Analysis of the EBUS Scope as a Hybrid Bronchoscope|The Analysis of the EBUS Scope as a Hybrid Bronchoscope||Johns Hopkins University|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|62|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02360306||27645|
NCT02364180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bhatt Pyriodostigmine|Electromyography in Patients on Chronic Pyridostigmine Therapy|Electromyography With Repetitive Nerve Stimulation in Patients on Chronic Pyridostigmine Therapy||University of Toledo Health Science Campus|No|Recruiting|December 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|12 Years|80 Years|No|Non-Probability Sample|Subjects who have been taking pyridostigmine for the treatment of any condition.|February 2016|February 2, 2016|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02364180||27348|
NCT02367976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012L01494|Efficacy and Safety on Prouk for STEMI Patients in China|A Phase III Study to Research the Efficacy and Safety on Prouk for ST Elevated Mycadial Infarction Patients in China||Suzhou RxD Biopharmaceutical Co., Ltd|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02367976||27059|
NCT02368171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-PH-001|Role of Heme-oxygenase (HO) and Nitric Oxide (NO) Pathway in Patients With Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension (PH)|||Southern California Institute for Research and Education||Not yet recruiting|March 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with newly diagnosed and untreated OSA with total apnea-hypopnea index (AHI)        >5/h, and control (AHI<5/h) will be recruited from the Long Beach VA sleep center.        Controls are subjects without OSA or other sleep disorders and no sign of pulmonary        hypertension based on echo. We also measure pulmonary artery pressure by 2D Echo and        exclude patient with any sign of left heart dysfunction. PH will be defined as RVSP > 35        mmHg or mean PA pressure>25 mmHg. We will recruit subjects with and without PH and OSA in        three separate groups:          1. group one : OSA+ PH,          2. group two: normal individual with no OSA and no PH,          3. group three: OSA with no PH Pulmonary function test will be done to exclude patients             with underlying lung disease.|February 2015|February 12, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02368171||27044|
NCT02371824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_47|Study of Normal Hip and Lumbar Bone Marrow With Dynamic Contrast Enhancement Magnetic Resonance Imaging|Study of Normal Hip and Lumbar Bone Marrow With Dynamic Contrast Enhancement Magnetic Resonance Imaging|PERFOS|University Hospital, Lille|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|60 Years|No|Non-Probability Sample|Adult patients referred to the musculoskeletal imaging department for a MRI examination of        the hip or sacro-iliac joints with normal appearing bones on MR images.|February 2015|February 19, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02371824||26765|
NCT02361333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010730|Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators|Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators||Yale University||Enrolling by invitation|October 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|86|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02361333||27566|
NCT02361346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3724_NHL_001|PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia|MT-3724NHL001|Molecular Templates, Inc.|Yes|Recruiting|February 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361346||27565|
NCT02365753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delivery2|Effect of Pulsed Electromagnetic Field Therapy on Pain After Cesarean Delivery|Effect of Pulsed Electromagnetic Field Therapy on Pain After Cesarean Delivery||New York City Health and Hospitals Corporation|No|Enrolling by invitation|February 2015|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365753||27227|
NCT02365766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU14-188|Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects|Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188||Hoosier Cancer Research Network|Yes|Active, not recruiting|May 2015|March 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365766||27226|
NCT02361840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFAA 003/12|Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock|Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock||Hospital Civil de Guadalajara|Yes|Recruiting|October 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|65|||Both|1 Month|14 Years|No|Non-Probability Sample|The sample size Calculated sample size for study of prospective cohort with a confidence        interval (CI) of 95%, 80% power. Exposed non-exposed 2:1 relation. Probability of        occurring event in the cohort exposed 72% and 32% in the unexposed.        We calculated that 41 patients of unexposed cohort and 21 of the exposed are required to        observed differences. Total number of 62 patients (n=62).        The sample size was calculated through the Epi Info version 7 of the Centers for Disease        Control and Prevention (CDC), Atlanta.        Population Population was taken from the room of emergency Pediatrics of the Hospital        Civil Fray Antonio Alcalde (HCFAA).|February 2015|February 11, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02361840||27527|
NCT02362100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150458-01H|Proximal Humerus Fractures Randomized Control Trial|Proximal Humerus Fractures Randomized Control Trial||Ottawa Hospital Research Institute|Yes|Recruiting|September 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|155|||Both|60 Years|N/A|No|||October 2015|October 21, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02362100||27507|
NCT02366546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301-01|Investigator Initiated Phase 1 Study of TBI-1301|Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors||Mie University|Yes|Recruiting|March 2015|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366546||27167|
NCT02366559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU105340|Electrocautery vs Q-switch for Seborrheic Keratosis|Comparing the Efficacy and Risk of Adverse Events of Electrocautery Versus 532 nm Qswitched Neodymium-doped Yttrium Aluminium Garnet Laser for the Treatment of Flat Seborrheic Keratoses: A Randomized Control Trial||Northwestern University|Yes|Withdrawn|August 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366559||27166|
NCT02362633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-018|Effect of Long-term Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Effect of Long-term Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions||Chungbuk National University||Completed|February 2015|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02362633||27466|
NCT02362646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-0008|Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients|Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362646||27465|
NCT02362906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307007|Effectiveness Study of Integrative Treatment for Pediatric Community Acquired Pneumonia|Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by the Special Scientific Research Fund of Public Welfare Profession of China||Liaoning University of Traditional Chinese Medicine|Yes|Recruiting|April 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1500|||Both|1 Year|14 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02362906||27445|
NCT02367859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0043|Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma|A Pilot Study of Dabrafenib for Patients With BRAF Mutated Ameloblastoma||Stanford University|Yes|Not yet recruiting|March 2015|February 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367859||27068|
NCT02367924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-D-023-13|Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma|Non-interventional Study to Investigate Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma|YonSar|PharmaMar, Spain|No|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|100 patients (≥ 18 years) with advanced sarcoma after failure of anthracyclines and        ifosfamide or patients unsuited to receive these drugs|March 2016|March 24, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02367924||27063|
NCT02231866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140183|Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults|VRC 207: A Phase I/1b, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccines, VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ), in Healthy Adults||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02231866||37499|
NCT02231879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140185|Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome|A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.||National Institutes of Health Clinical Center (CC)||Recruiting|August 2014|February 2020|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|75 Years|No|||August 2015|August 28, 2015|September 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02231879||37498|
NCT02230930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46934|Treatment of Apomorphine-induced Skin Reactions: a Pilot Study|Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions||University Medical Center Groningen|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|30 Years|N/A|No|||March 2016|March 2, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230930||37571|
NCT02368184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6537|Pilot Study of the CoVa™ Monitoring of Patients With Congestive Heart Failure|Pilot Study of the CoVa™ Monitoring of Patients With Congestive Heart Failure|CoVa|Scripps Translational Science Institute|No|Active, not recruiting|February 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|19 Years|N/A|No|Non-Probability Sample|The study population will be made up of adult men and women admitted to the hospital with        a primary clinical diagnosis of acute decompensated heart failure. A convenience sample of        25 individuals meeting the following Inclusion criteria and have no Exclusion criteria        will be enrolled.|February 2015|April 21, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368184||27043|
NCT02371161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_RecAnz|A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients With Relapsed Aggressive Non-Hodgkin Lymphoma (NHL) or Resistant to First Line Therapy|A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (≥65 and ≤ 75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy||Fondazione Italiana Linfomi ONLUS|No|Recruiting|February 2014|February 2023|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|65 Years|75 Years|No|||February 2015|March 1, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02371161||26816|
NCT02360566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8211|Participatory Video as a Recovery-Oriented Intervention in Early Psychosis|The Novel Use of Participatory Video as a Recovery-Oriented Intervention in Early Psychosis: A Pilot Study||Lawson Health Research Institute|No|Active, not recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|16 Years|25 Years|No|||March 2016|March 2, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360566||27625|
NCT02360579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-144-01|Study Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 Metastatic Melanoma|A Phase 2, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma|LN-144|Lion Biotechnologies|No|Recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||February 2016|February 8, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360579||27624|
NCT02371551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84/14|Evaluation of Complex Renal Cyst With CEUS/Functional MRI Versus CT|Evaluation of Complex Renal Cystic Lesions With Contrast Enhanced Ultrasound (CEUS) and Functional MRI Versus the Gold Standard: Computer Tomography (CT)||University Hospital Inselspital, Berne|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who were referred to the outpatient clinic of the Department of Nephrology or to        the Department of Urology, Bern University Hospital for the clarification of a complex        renal cyst/lesion and already underwent or will undergo a standard CT examination or        patient who where accidentally diagnosed with a complicated renal cyst/lesion from the        Department of Nephrology, Urology or Radiology (with CT imaging)|September 2015|September 30, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371551||26786|
NCT02371811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m2491|Use of v Care in Abdominal Hysterectomy|||Ain Shams Maternity Hospital|Yes|Active, not recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 7, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02371811||26766|
NCT02361047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-175|Let's Play! Healthy Kids After Cancer|Healthy Kids After Cancer: A Physical Activity and Nutrition Intervention||HealthPartners Institute|Yes|Enrolling by invitation|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|4 Years|10 Years|No|||April 2015|April 9, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02361047||27588|
NCT02365402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY006|Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment|Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment||Beijing Ditan Hospital|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|No|||February 2015|February 15, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02365402||27254|
NCT02365415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00005257|Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement|Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement||Children's Hospital Boston|Yes|Recruiting|February 2015|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Months|N/A|No|||March 2016|March 9, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365415||27253|
NCT02228759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105097|Ambulatory Continuous Adductor Canal Block to Facilitate Same Day Discharge Following Total Knee Arthroplasty: A Pilot Study|||Lawson Health Research Institute|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|40 Years|70 Years|No|||August 2015|August 31, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02228759||37738|
NCT02229019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED1203|The Southampton Mealtime Assistance Roll-out Trial|The Southampton Mealtime Assistance Roll-out Trial|SMART|University Hospital Southampton NHS Foundation Trust.|No|Recruiting|August 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|250|||Both|70 Years|N/A|No|||May 2015|May 21, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02229019||37718|
NCT02366000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-J86|An Intervention Study: Shaping a Healthier Child|A Randomized Controlled Trial of a Brief Intervention by Parents to Prevent Their Children From Experimenting With Health Risk Behavior: a Pilot Study||The Hong Kong Polytechnic University|Yes|Completed|September 2010|February 2015|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|88|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02366000||27208|
NCT02366286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001670|Identification of Chronic Hepatitis B Infections Among Somali Immigrants in Minnesota Through Community-wide Screening|Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in Somali Immigrants: Role of Viral Genetics and the Immune Response||Mayo Clinic|No|Recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|A blood draw of 45 ml. will be taken for serum, plasma and buffy coat|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Somali immigrants and refugees in Minnesota|November 2015|November 5, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02366286||27187|
NCT02230150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADhesion-HF|ADHESION TO THERAPEUTIC STRATEGIES FOR OUTPATIENTS WITH HEART FAILURE - ADhesion-HF|ADHESION TO THERAPEUTIC STRATEGIES FOR OUTPATIENTS WITH HEART FAILURE - ADhesion-HF|ADhesion-HF|Federal University of Bahia|No|Completed|December 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|80 Years|No|||August 2014|August 29, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02230150||37631|
NCT02366793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAlcala|Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.|Accessory Joint and Neural Mobilizations in Shoulder Range of Motion Restriction After Breast Cancer Surgery. A Pilot Randomized Clinical Trial.||University of Alcala|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|January 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02366793||27148|
NCT02367040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17067|Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)|A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3|CHRONOS-3|Bayer|Yes|Recruiting|June 2015|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|567|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367040||27129|
NCT02367846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000464|Assessing the Impact of Contraceptives on Bone Health Using 41Ca|The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology||Penn State University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|6|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||January 2015|February 13, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02367846||27069|
NCT02230943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISE|Rheumatology Informatics System for Effectiveness|American College of Rheumatology's Rheumatology Informatics System for Effectiveness|RISE|American College of Rheumatology|No|Recruiting|April 2014|||December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|August 2014|August 29, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02230943|1 Year|37570|
NCT02231515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219|Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG|A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma||University Hospital, Geneva|No|Recruiting|April 2014|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02231515||37526|
NCT02239939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00028928|Arthritis Pilot for Preserving Muscle While Losing Weight|Weighted Vest Use to Preserve Muscle and Bone During Obesity Treatment for Osteoarthritis|APPLE|Wake Forest School of Medicine|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02239939||36881|
NCT02239952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.465|HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)|Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma||VU University Medical Center|Yes|Recruiting|November 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239952||36880|
NCT02238379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309012677-Pilot|Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception|Oxytocin Pilot: Oxytocin and Face Perception||Yale University||Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|26|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238379||36998|
NCT02232451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|loop20216|Comparison of Loop-tip Cook Medical® Wire Versus Traditional Endoscopic Technique|Comparison of Loop-tip Cook Medical® Wire vs Traditional Endoscopic Technique Cannulation in the Prevention of Post-ercp Pancreatitis and Biliary Tree Access in High-risk Patients|loop|Azienda Ospedaliera San Paolo|No|Completed|November 2010|August 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|320|||Both|18 Years|90 Years|No|||September 2014|September 23, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT02232451||37454|
NCT02364414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rdb394 v6.1|The Accuracy of Direct Digital Intra-oral Scanning Measurements Compared to Measurements on Study Models|The Accuracy of Direct Digital Intra-oral Scanning Measurements Compared to Measurements on Study Models||Kettering General Hospital NHS Foundation Trust|No|Completed|December 2014|August 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|22|||Both|11 Years|18 Years|No|||September 2015|September 23, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02364414||27330|
NCT02364622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20130194|The Effects of Flexible Intubating Stylet in the Accurate Placement of Double-lumen Endobronchial Tube|The Effects of Flexible Trachway(R) Intubating Stylet in the Accurate Placement of Left-sided Double-lumen Endobronchial Tube||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|February 17, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364622||27314|
NCT02360839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 1092-11|The Use of FNA and FNB in the Optimization of EUS-assisted Tissue Sampling|The Use of FNA and FNB in the Optimization of EUS-assisted Tissue Sampling||Sahlgrenska University Hospital, Sweden|No|Recruiting|July 2009|July 2019|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|1000|Samples With DNA|Cytology and histology tissue samples harvested by an endoscopic ultrasound guided puncture      needle. Samples are aimed for clinical use only (cytologist and pathologist assessment).|Both|18 Years|N/A|No|Non-Probability Sample|All patients referred to the Sahlgrenska University hospital for a diagnostic EUS due to        clinical reasons are candidates for enrollment.|December 2015|December 8, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02360839||27604|
NCT02364869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTI/CNPQ: 449614/2014-0|Prebiotic in Chronic Kidney Disease Patients|Effect of Prebiotic (Fructooligosaccharide) on Uremic Toxins and Cardiovascular Markers of Chronic Kidney Disease Patients||Federal University of São Paulo|Yes|Recruiting|May 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02364869||27295|
NCT02365116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH103447-01|Peer Mentorship to Reduce Suicide Risk Following Psychiatric Hospitalization|Peer Mentorship to Reduce Suicide Risk Following Psychiatric Hospitalization||University of Michigan|No|Recruiting|August 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02365116||27276|
NCT02228486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aCR|Relapse Prevention in Alcohol Dependency by Transcranial Direct Current Stimulation Supported Cue Exposure Therapy|Alcohol Cue-Reactivity in Patients With Alcohol Dependency and Effects of Transcranial Direct Current Stimulation (tDCS) on Cue-exposure Therapy||University Hospital Tuebingen|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02228486||37759|
NCT02238769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FECH-PET-2014|18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma|Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma||Peking Union Medical College Hospital|No|Recruiting|July 2014|October 2017|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The studied population is consisted of the patients with a suspicion of HCC treated in our        hospital from September 2014 to August 2015.|September 2014|September 10, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02238769||36969|
NCT02238782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00080|A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.|A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers||AstraZeneca|No|Completed|October 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|August 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02238782||36968|
NCT02229578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400019|Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.|Lidocaine In The Treatment of Post-operative Pain Management From a Donor Site After Split Thickness Skin Graft Harvesting Following Thermal Injury|LidocaineBurn|University of Florida|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229578||37675|
NCT02229591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17082014|Expiratory Flow Limitation and Postoperative Complications|||Università degli Studi di Ferrara|Yes|Recruiting|January 2013|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|330|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing abdominal, thyroid or vascular surgery in Sant'Anna Hospital|February 2016|February 2, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02229591||37674|
NCT02229916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG359/13|Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS|Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS|SAG TCCS|Cantonal Hospital of St. Gallen|Yes|Recruiting|December 2013|January 2021|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6900|||Male|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with testicular cancer of any type and any stage and any age        (incident cases).        Testicular cancers are generally classified as seminomatous (seminoma) and nonseminomatous        germ cell tumours (nonseminoma) of the testis. Mixed germ cell tumours belong to the group        of non-seminomas. The stage of disease and the choice of treatment (active surveillance        vs. chemotherapy vs. radiotherapy) define the risk of relapse, the pattern of relapse and        the long-term toxicities. Staging in testicular cancer is performed according to the        American Joint Committee on Cancer (AJCC) TNM staging system for testis cancer [46].        Metastatic testicular cancers are classified according to the International Germ Cell        Cancer Collaborative Group (IGCCCG) risk groups [47].|July 2015|July 28, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02229916|8 Years|37649|
NCT02229929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845-CLIN2005|Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus||Cara Therapeutics, Inc.|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|89|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02229929||37648|
NCT02239276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-047|Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies|Expanded Access Use of Stiripentol in Participants With Dravet Syndrome or Epileptic Encephalopathies Associated With Sodium Channel Mutations||Cook Children's Health Care System||Available||||||N/A|Expanded Access|N/A|||||||Both|6 Months|18 Years||||July 2015|July 27, 2015|September 10, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02239276||36930|
NCT02230436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-GS02|Early Versus Late Drain Removal After Pancreatectomy: A Randomized Prospective Trial|The Impact of Early Versus Late Drain Removal on Postoperative Morbidity After Pancreatectomy: A Randomized Prospective Trial||Peking Union Medical College Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||September 2014|September 16, 2014|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02230436||37609|
NCT02230670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-10|A Study of IDN-6556 in Subjects With Liver Cirrhosis|A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis|LC|Conatus Pharmaceuticals Inc.|Yes|Completed|August 2014|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230670||37591|
NCT02230683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-11|A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension|An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension|PH|Conatus Pharmaceuticals Inc.|Yes|Completed|August 2014|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||May 2015|July 28, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02230683||37590|
NCT02239601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:281|Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?|Pre-existing Nerve Entrapment as a Risk Factor for Chemotherapy - Induced Peripheral Neuropathy (CIPN). Could There be a Role for Physical Therapy Treatment?||CancerCare Manitoba|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239601||36906|
NCT02239666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120363|Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis|A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics||Amgen|No|Active, not recruiting|March 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|899|||Both|18 Years|100 Years|No|Non-Probability Sample|Adults greater than or equal to 18 years of age who have been diagnosed with moderate to        severe plaque psoriasis based on treating physician's judgment|February 2016|February 23, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02239666||36901|
NCT02239679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0109|Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy|A Phase 2 Study Comparing the Occurrence of Actinic Keratoses on the Face in High-Risk Individuals After Cryotherapy + Photodynamic Therapy With Levulan Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light||DUSA Pharmaceuticals, Inc.|No|Active, not recruiting|September 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239679||36900|
NCT02239692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000121|A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy|A Randomised, Assessor-blinded, Multi-centre Trial Comparing the Efficacy, Safety and Tolerability of the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy|OPTIMA|Ferring Pharmaceuticals|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|204|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239692||36899|
NCT02223442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|opioids for chronic pain|Central Analgesic Drugs for the Treatment of Chronic Pain|Cognitive Study on the Use of Central Analgesic Drugs in the Management of Chronic Pain||University of Parma|No|Not yet recruiting|September 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with persistent pain syndromes (chronic pain) followed on an outpatient / DH at        some Italian centers of Pain Therapy|November 2012|August 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223442||38147|
NCT02222857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406118RIND|Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis|Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis||National Taiwan University Hospital|No|Not yet recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients with acute retinal necrosis|August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02222857||38192|
NCT02240030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-004|Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD ™)|SPAN-PD ™|Acorda Therapeutics|Yes|Recruiting|November 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|345|||Both|30 Years|85 Years|No|||November 2015|November 12, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240030||36874|
NCT02224066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIX-VALV-002|Platelet Reactivity After TAVI: A Multicenter Pilot Study|Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation|REAC-TAVI|Hospital de Meixoeiro|Yes|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224066||38099|
NCT02368288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY005|Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment|Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a||Beijing Ditan Hospital|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||February 2015|February 14, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02368288||27035|
NCT02368301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-143|Expanded Access Treatment Protocol CA204-143|An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Bristol-Myers Squibb||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2015|September 11, 2015|February 6, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02368301||27034|
NCT02368457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORN-2014-16|Management of Mandibular ORN: PENTO as Medical Treatment|Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment|PENTO|Hospital Vall d'Hebron|Yes|Recruiting|February 2015|April 2017|Anticipated|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|90 Years|No|||February 2015|February 20, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02368457||27022|
NCT02364882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-6006-008-01|A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women|A Phase 1, Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Vulvar-Vaginal Safety and Pharmacokinetic Profile of SST-6006, a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women||Strategic Science & Technologies, LLC|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|21|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364882||27294|
NCT02228213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS416-202|Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis|A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis||Innate Immunotherapeutics|Yes|Recruiting|October 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02228213||37780|
NCT02228226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJKK-MIT-002|Follow-up Study After Bankart Repair Using MG-1|Follow-up Study After Arthroscopic Bankart Repair Using MG-1 for Dislocation of Shoulder||Johnson & Johnson K.K. Medical Company|No|Completed|August 2014|April 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|16 Years|N/A|No|Non-Probability Sample|Patients those who underwent arthroscopic Bankart repair for glenohumeral instability        using MG-1|April 2015|April 15, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02228226||37779|
NCT02238652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222113|Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy|Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy (The KOSMOS Study)|KOSMOS|University of Bergen|No|Enrolling by invitation|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|310|||Both|65 Years|N/A|No|||September 2014|September 11, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02238652||36978|
NCT02238665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0005|CLE for Differential Diagnosis of IBD|||University of Erlangen-Nürnberg Medical School||Completed|October 2009|September 2014|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with well-established diagnosis of Crohn's disease and ulcerative        colitis.|September 2014|September 11, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238665|1 Day|36977|
NCT02240186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002930|Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees|Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees for Patients With Transtibial Amputations|MPK-AOPA|Mayo Clinic|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|55 Years|N/A|No|||December 2015|December 31, 2015|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240186||36862|
NCT02240212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201050|Study of Afuresertib Combined With Paclitaxel in Gastric Cancer|Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer||Novartis|No|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240212||36860|
NCT02239107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n-acetyl cysteine PCOS|N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome|N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome||Assiut University|Yes|Completed|January 2012|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|39 Years|No|||September 2014|September 11, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02239107||36943|
NCT02239146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13CARD-1660|Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass||Novo Nordisk A/S|Yes|Completed|October 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|35 Years|75 Years|No|||September 2014|September 10, 2014|September 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02239146||36940|
NCT02239263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM5555|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||May 15, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02239263||36931|
NCT02240251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU STU 00058721|Excimer Laser Assisted IVC Filter Retrieval|A Prospective Review of Excimer Laser Assisted Inferior Vena Cava (IVC) Filter Retrieval||Northwestern University|Yes|Recruiting|January 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|100 Years|No|Non-Probability Sample|Anyone ages 18-100 years old that will undergo laser assisted IVC filter removal at        Northwestern Memorial Hospital in Chicago IL USA|October 2015|October 5, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240251|2 Weeks|36857|
NCT02239497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Femoral Block|Femoral Preincisional Block in Acute Postoperative Pain Management of Surgery Orthopaedic Lower Limb|||Hospital Central Dr. Luis Ortega||Completed|March 2013|||September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02239497||36914|
NCT02239536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-0039|Hot Snare Versus Hot Snare Polypectomy With Saline Injection for Colorectal Polyps|Hot Snare Polypectomy Vs. Hot Snare Polypectomy After Saline Injection for the Complete Resection of Neoplastic Colorectal Polyps: Prospective, Randomized Controlled Trial|HSP vs HSPASI|Seoul St. Mary's Hospital|Yes|Enrolling by invitation|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|30 Years|85 Years|No|||September 2014|September 10, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239536||36911|
NCT02239549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H130473|Biopsy Forceps Versus Cold Snare for the Resection of Small Colonic Polyps|A Prospective Randomized Study Comparing Jumbo Cold Biopsy Forceps Versus Cold Snare for the Resection of Small Colonic Polyps||San Diego Veterans Healthcare System|Yes|Completed|April 2009|March 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|419|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02239549||36910|
NCT02222870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC56|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine (2014-2015 Formulation)||Sanofi|No|Completed|August 2014|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|August 20, 2014|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT02222870||38191|
NCT02223169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECFP7-312090|Human Intervention Study of Egg Protein Derivative on Cardiovascular Risk|Dietary Intervention Study to Assess the Effects of Albumin-Derived Peptides on Cardio-Metabolic Risk Factors in Adults|CardiProtein|University College Cork|Yes|Completed|April 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223169||38168|
NCT02223182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILES|Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy|A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow's Milk Allergy in Children|MILES|DBV Technologies|Yes|Recruiting|November 2014|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|194|||Both|2 Years|17 Years|No|||February 2016|March 11, 2016|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02223182||38167|
NCT02228694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004749|The IMPROVE Study-IMPact of a Regulated ADC System|IMPact of a Regulated ADC System On Medication Distribution and Administration VariablEs|IMPROVE|Hackensack University Medical Center|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|120|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Number of Participants by Group          -  Children (Minor Subjects): 0          -  Cognitively Impaired Participants:0          -  Employees and Students: 120          -  Patients: 25238          -  Prisoners: 0          -  Normal Healthy Volunteers: 0          -  Pregnant Women-Human Fetuses: 0          -  Wards: 0|March 2015|March 16, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02228694||37743|
NCT02226770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252/12|Heart-focused Anxiety in Patients With Heart Failure and ICD|Heart-focused Anxiety in Patients With Implantable Cardioverter Defibrillator (ICD) and/or Mechanical Cardiovascular Assist Device (AD) (Anxiety-CHF)|Anxiety-CHF|University Hospital, Saarland||Recruiting|July 2010|October 2016|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|N/A|N/A|No|||August 2014|August 26, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02226770||37891|
NCT02226783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00003|D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects|Phase I Study in Healthy Subjects to Evaluate the Pharmacodynamics (PD) of AZD1722 Given With and Without Food (Part A) and a 2-way Crossover to Evaluate the PD of AZD1722 Given as a Free-base Tablet With and Without Omeprazole (Part B)||Ardelyx|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02226783||37890|
NCT02224313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-VgCy|Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women|Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women||Eastern Virginia Medical School|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02224313||38080|
NCT02365948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0045|A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects|A Randomized, Double-blind, Placebo-controlled, Single Escalating Dose Study of Subcutaneous Certolizumab Pegol (CZP) to Evaluate the Pharmacokinetics and Safety of CZP in Healthy Chinese Subjects||UCB Pharma|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|February 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365948||27212|
NCT02234830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-68-12|Randomized Comparison of ExoSeal® and Angio-Seal Vascular Closure Devices: The CLOSE-UP II Trial|Randomized Comparison of ExoSeal® and Angio-Seal Vascular Closure Devices: The CLOSE-UP II Trial|CLOSE-UP II|Aarhus University Hospital Skejby|Yes|Recruiting|December 2012|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02234830||37271|
NCT02237599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104826|Somatosensory Evoked Potential Algorithm for Detection of Intraoperative Positional Neuropraxia|A Feasibility Study of Integrated SSEP and Detection Algorithm for Detection of Intraoperative Positional Neuropraxia|EPAD|Lawson Health Research Institute|No|Active, not recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|95 Years|No|Non-Probability Sample|Intraoperative adult patients undergoing surgical procedure|September 2014|September 10, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02237599||37058|
NCT02237612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-08-4|Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer|Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study||University of Southern California|No|Completed|January 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Male|18 Years|N/A|No|||September 2014|September 9, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02237612||37057|
NCT02368600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.373-T|Lifestyle Intervention and Prevention of Gestational Diabetes Mellitus|A Randomized Controlled Trial Examining the Effectiveness of a Lifestyle Intervention in Reducing Gestational Diabetes Mellitus in High Risk Chinese Pregnant Women in Hong Kong||Chinese University of Hong Kong|Yes|Recruiting|April 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368600||27011|
NCT02238561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/123|The Cost in Oxygen of Surgical Trauma|The Cost in Oxygen of Surgical Trauma (CO2ST) - a Feasibility Study of the Non-invasive Measurement of Oxygen Delivery and Consumption After Major Abdominal Surgery||Plymouth Hospitals NHS Trust|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth        Hospitals NHS Trust (PHNT)|February 2015|October 29, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02238561||36984|
NCT02240160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP10116|A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects|A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects||GW Pharmaceuticals Ltd.|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02240160||36864|
NCT02226042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCTMechanisms|Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)|Investigating the Neuropsychological Mechanisms Underlying Mindfulness-based Cognitive Therapy||University of Manchester|No|Recruiting|October 2014|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|108|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02226042||37947|
NCT02240225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZIRD-20140910|Validation of Chinese SRI Questionnaire|Validation of Chinese Severe Respiratory Insufficiency （SRI）Questionnaire for COPD Patients With Chronic Hypercapnic Respiratory Failure|VCSRI|Guangzhou Institute of Respiratory Disease|No|Recruiting|January 2014|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult COPD patients with chronic hypercapnic respiratory failure receiving home        noninvasive ventilation|September 2014|September 11, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240225|2 Weeks|36859|
NCT02240238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-6004-004A|Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer|A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer||Nanocarrier Co., Ltd.|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240238||36858|
NCT02226796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCSandaphasia|Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia|Effects of a Combination of Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Non-fluent Aphasia||University of Minnesota - Clinical and Translational Science Institute||Not yet recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|4|||Both|20 Years|85 Years|No|||June 2015|June 1, 2015|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02226796||37889|
NCT02227082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N13ORB|Olaparib and Radiotherapy in Inoperable Breast Cancer|Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast and Regional Lymph Nodes in Patients With Inoperable, Metastatic or Inflammatory Breast Cancer||The Netherlands Cancer Institute|No|Recruiting|October 2013|August 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||October 2015|February 4, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227082||37867|
NCT02240264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Food2Learn|Effect of Omega-3 LCPUFA Intervention on Learning, Cognition, Behaviour and Visual Processing.|Food2Learn: Effect of Omega-3 LCPUFA Intervention on Learning, Cognition, Behaviour and Visual Processing.||Open University|Yes|Active, not recruiting|January 2014|December 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|350|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02240264||36856|
NCT02240290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0026|Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant|A Single-Center, Open-Label Study of Excretion Balance, Pharmacokinetics, and Metabolism of 14C-Labeled Tozadenant After 240 mg Single Oral Dose Administration in Healthy Male Subjects||Biotie Therapies Inc.|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|January 13, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02240290||36854|
NCT02227901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01809|Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|September 2002|April 2014|Actual|June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||September 2014|December 19, 2014|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02227901||37804|
NCT02227914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPZ011|Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma||Onyx Pharmaceuticals|Yes|Withdrawn|December 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|August 26, 2014|Yes|Yes|Study stopped due to administrative reasons|No||https://clinicaltrials.gov/show/NCT02227914||37803|
NCT02228239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104764|Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants|A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects|DRiVESaFe|Janssen Research & Development, LLC|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|26|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02228239||37778|
NCT02234752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHS IRB # 604148-4|Galantamine and Memantine for Cognitive Impairments in Schizophrenia|A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?||Sheppard Pratt Health System|Yes|Recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|55 Years|No|||March 2016|March 17, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02234752||37277|
NCT02234765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/02004|Management of Patients With Suspected of Sleep Apnea-hypopnea Syndrome From Primary Care|Management of Patients With Suspected Sleep Apnea Syndrome From Primary Care: Territorial Assistance Network.|GESAP|Sociedad Española de Neumología y Cirugía Torácica||Recruiting|May 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|280|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02234765||37276|
NCT02228954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-RCC study|IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)|Watchful Waiting in Patients With Good and Intermediate Risk Metastatic Renal Cell Carcinoma; an Imaging Guided Observational Approach. Part of: Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging. IMPACT Study: Imaging Patients for Cancer Drug Selection|IMPACT-RCC|Radboud University||Recruiting|December 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with good or intermediate prognosis mccRCC according to the Heng criteria, ≥18        years, without contra-indications for a watchful waiting period, able to provide informed        consent|November 2015|November 27, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02228954||37723|
NCT02365961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038232|Hip Scope Fascia-iliaca (FI) Block Study|Reduction of Hip Arthroscopy Post-operative Pain Using Ultrasound-guided Fascia-iliaca Block||The Hawkins Foundation|No|Not yet recruiting|April 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|65 Years|No|||February 2015|February 11, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02365961||27211|
NCT02240056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAKINSULA|Brain fMRT In Takotsubo Cardiomyopathy|Pilot Study: Central Nervous System and Hormonal Changes In Takotsubo Cardiomyopathy|TAKINSULA|Medical University Innsbruck|No|Recruiting|October 2014|December 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Female|N/A|90 Years|No|Probability Sample|Postmenopausal women with TTC or STEMI aged below 90 years|March 2016|March 18, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240056||36872|
NCT02240069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 218-12|Wood Smoke Interventions in Native American Populations|Residential Wood Smoke Interventions Improving Health in Native American Populations|EldersAIR|University of Montana|No|Recruiting|November 2014|June 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|188|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240069||36871|
NCT02240082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL114185|COPing With Shift Work - Web Based Program for Police Officers|COPing With Shift Work||ISA Associates, Inc.|No|Enrolling by invitation|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240082||36870|
NCT02240095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRN86465-B|Increasing Medical and Nursing Students Searching of Current Best Evidence to Answer Clinical Questions|Multifaceted Online Interventions to Increase Medical and Nursing Students Searching of Current Best Evidence to Answer Clinical Questions (MPFS-2)|MPFS-2|McMaster University|No|Active, not recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|8||Anticipated|800|||Both|N/A|N/A|No|||April 2015|April 7, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240095||36869|
NCT02238470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ACO-2010-10|Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance|Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance|HERO|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Active, not recruiting|April 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|65 Years|N/A|No|Probability Sample|Patients admitted to tertiaty hospital for cardioembolic ischemic stroke|September 2015|September 21, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02238470|2 Years|36991|
NCT02240121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECD3125|One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease|A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease||Valeant Pharmaceuticals International, Inc.|No|Recruiting|July 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||July 2014|June 11, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240121||36867|
NCT02240134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 276-13|Wood Stove Interventions and Child Respiratory Health|Wood Stove Interventions and Child Respiratory Infections in Rural Communities|KidsAIR|University of Montana|No|Recruiting|November 2014|April 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|486|||Both|N/A|5 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240134||36866|
NCT02225756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110119|Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms|Brief Administration of Cyclosporine A to Induce the Stabilisation of the Diameter of Small Diameter Abdominal Aortic Aneurysms.|ACA4|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|December 2013|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|50 Years|85 Years|No|||May 2015|June 1, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02225756||37969|
NCT02367287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691654|USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study|Assessing the Impact of Diet on Inflammation in Healthy and Obese Adults in a Cross-Sectional Phenotyping Study||USDA, Western Human Nutrition Research Center|No|Recruiting|May 2015|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|436|Samples With DNA|Whole blood, stool|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy people in the general population|November 2015|November 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367287||27111|
NCT02226302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FETCH|Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer|Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer|FETCH|Queensland Centre for Gynaecological Cancer|No|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|16|Samples With DNA|Omental fat samples will be stored for one year for study purposes. They will not be stored      for future research|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|12 female patients undergoing surgery for pre-existent conditions will be recruited for        this study. The groups will include 6 patients with a BMI < 30 kg/m2 and 6 patients with a        BMI ≥ 35 kg/m2. In addition 4 males patients will be recruited to assess responses from        patients with low levels of serum estradiol.|April 2015|April 20, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02226302||37927|
NCT02226549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1512|Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis|A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis||Gilead Sciences|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 25, 2014|Yes|Yes||No|February 5, 2016|https://clinicaltrials.gov/show/NCT02226549||37908|There were no limitations affecting the analysis or results.
NCT02367872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-272/CPH-012|Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Patients With Renal or Hepatic Impairment|Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment||Takeda|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|48|||Both|20 Years|85 Years|No|||January 2016|January 6, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367872||27067|
NCT02367885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-850/CCT-101|Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants|An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects||Takeda|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|99|||Both|6 Months|19 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367885||27066|
NCT02227381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1003/98|Action Medical Research|Using New Genetic Technology to Diagnose Neurodevelopmental Disorders||Central Manchester University Hospitals NHS Foundation Trust|No|Completed|February 2011|June 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|119|Samples With DNA|DNA extracted from whole blood, saliva or skin biopsy|Both|N/A|N/A|No|Non-Probability Sample|We will approach a cohort of patients with severe LD/seizures/behaviour problems who have        presented to us in our genetic clinic for diagnosis over the past few years, but where the        cause of their problems remains unknown. This will be our study population. In virtually        all cases we will have performed routine diagnostic testing and will have stored DNA.|July 2015|July 31, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02227381||37844|
NCT02367950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.RCHT.62|Exercise as an Intervention in Endometrial Cancer Survivors|Feasibility and Acceptability of Exercise as a Lifestyle Intervention in Endometrial Cancer Survivors.||Royal Cornwall Hospitals Trust|No|Recruiting|January 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||February 2015|February 13, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02367950||27061|
NCT02227654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-GYN-200|Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors|Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors||University of Kentucky|Yes|Suspended|February 2015|August 2022|Anticipated|August 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3290|||Female|25 Years|N/A|No|||January 2016|January 8, 2016|August 26, 2014||No|Revision Due.|No||https://clinicaltrials.gov/show/NCT02227654||37823|
NCT02227667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-109|Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer|Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02227667||37822|
NCT02368418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU00001052|China Rural Health Initiative Follow up Study|China Rural Health Initiative Follow up Study|CRHIFU|The George Institute for Global Health, China|Yes|Enrolling by invitation|September 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|9164|||Both|50 Years|N/A|No|Probability Sample|The baseline cohort of 5050 and post-intervention cohort of 4887 CRHI participants who        were randomly selected from the 120 villages from 5 northern provinces (Liaoning, Hebei,        Shanxi, Shaanxi and Ningxia) of rural China will be recruited for the follow up study.|February 2015|February 20, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02368418||27025|
NCT02371304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50364.029|Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers||TESAR|VU University Medical Center|Yes|Not yet recruiting|August 2015|January 2022|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|302|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371304||26805|
NCT02368561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC140082CTIL|Treatment of Insertional Achilles Tendinopathy by Hyaluronic Acid Injection|A Pilot Study of the Effects of 3 Retro-calcaneal Hyalin G-F 20 Injection on the Clinical and Radiological Changes in 20 Adult Patients With Changes in Insertional Achilles Tendinopathy.||Meir Medical Center|No|Not yet recruiting|March 2015|July 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2014|February 16, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02368561||27014|
NCT02237261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV|Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma|Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).|BPV|University Hospital Heidelberg|Yes|Recruiting|November 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02237261||37084|
NCT02224820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-HMedIdeS-02|Phase II Study to Evaluate Safety and Efficacy of Intravenous Immunoglobulin G Degrading Enzyme of Streptococcus Pyogenes (IdeS) in Chronic Kidney Disease|A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous IdeS After Administration of Ascending Doses in Chronic Kidney Disease Patients||Hansa Medical AB|Yes|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02224820||38041|
NCT02236273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM3960|Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents|Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents||Columbia University||Recruiting|December 2014|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|956|||Both|N/A|N/A|No|||January 2016|January 26, 2016|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02236273||37160|
NCT02369224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRB2014A|Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|EMST-LE|Brown, Theodore R., M.D., MPH|No|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|27|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who may qualify for this study will be identified in the context of clinical care        at the participating sites. They may also be contacted through approved research flyers.        Eligible patients may receive a copy of the informed consent form at the time of their        clinic visit. Recruitment will also occur through local promotional opportunities        (doctor's programs, patient education programs).|January 2016|January 11, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369224||26964|
NCT02224326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vogel-1|Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia|Prospective Study to Evaluate the Predictive Value of Vagus Somatosensory Evoked Potentials (VSEP) and Near-infrared Spectroscopy (NIRS) in the Early Diagnosis of Alzheimer´s Disease|Vogel|University of Wuerzburg|No|Active, not recruiting|June 2011|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|604|Samples With DNA|whole blood, serum|Both|70 Years|78 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inhabitants of Wuerzburg, the 130 000 inhabitants capital of the german district Lower        Franconia who are born between 1.4.1936 and 31.3.1941|December 2015|December 19, 2015|September 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02224326||38079|
NCT02224586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNU_AH_jaundice fMRI|Resting State Functional Magnetic Resonance Imaging Study of Jaundice Infants Before and After Light Treatment.|Resting State Functional Magnetic Resonance Imaging Study of Jaundice Infants Before and After Light Treatment.||Hangzhou Normal University|Yes|Recruiting|August 2014|July 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|28 Days|No|Non-Probability Sample|municipal hospitals|August 2014|August 21, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224586||38059|
NCT02224898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-30976|Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis|Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis||Stanford University|Yes|Completed|August 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit a minimum of 10 and maximum of 40 subjects diagnosed with chronic        pancreatitis and 5 healthy control subjects with no past or present chronic        gastrointestinal symptoms lasting greater than 8 weeks, no chronic medical conditions and        no organic gastrointestinal disease. All patients with suspected/definite chronic        pancreatitis will be associated with Stanford Hospital and Clinics and the 5 healthy        controls may or may not be associated with Stanford.|November 2015|November 16, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02224898||38035|
NCT02224911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITT Treatment|Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer|Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study|LITT|Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|August 2016|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Male|40 Years|85 Years|No|Non-Probability Sample|Men, 40 to 85 years of age, recently diagnosed with prostate cancer using the MRI fusion        technology.|August 2015|August 27, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02224911||38034|
NCT02240108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECD3126|One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease|A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease||Valeant Pharmaceuticals International, Inc.|No|Recruiting|August 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||September 2014|June 11, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240108||36868|
NCT02225457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391/13|Study of the Mechanisms of Metabolic Adaptations to Overfeeding|Study of the Determinants and Mechanisms of Adaptation of Metabolic Responses to Controlled Overfeeding in Female and Male Healthy Volunteers|Polynut|Centre Hospitalier Universitaire Vaudois|No|Recruiting|December 2013|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|52|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 5, 2016|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02225457||37992|
NCT02370121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-271281-YZ|Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin|Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion||University of Guadalajara|Yes|Completed|February 2013|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|60 Years|No|||February 2015|February 23, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370121||26896|
NCT02367716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM- CIP-CRD 733|Post-market Study of Multi-Vector LV Lead Performance in Chinese Patients With Chronic Heart Failure|Post-market Study of Multi-Vector LV Lead Performance in Chinese Patients With Chronic Heart Failure|MVLV|St. Jude Medical|No|Recruiting|December 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|A patient meets the current ESC or ACCF/AHA/HRS Class I or Class IIa indications for CRT        implant|February 2015|February 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367716||27079|
NCT02367742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRIEPATT|Effect of Physical Activity on NAFLD|Effect of Two Different Programs of Physical Activity on the Grade of Severity of NAFLD||Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|Yes|Completed|January 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2015|March 23, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367742||27077|
NCT02367794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29437|A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]|A Phase III, Open-label, Multicenter, Randomzed Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination With Carboplatin + Paclitaxel or MPDL3208A in Combination With Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|June 2015|February 2023|Anticipated|February 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367794||27073|
NCT02370615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-272/CPH-011|A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin and Midazolam|An Open-label, Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin and Midazolam in the Healthy Adult Subjects||Takeda|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370615||26858|
NCT02370758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-CMV-001|Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients|Cell Mediated Immunity as a Guide for Secondary Prophylaxis in SOT Patients With CMV Infection|Q-CMV|University Health Network, Toronto|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|N/A|No|||October 2015|October 14, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370758||26847|
NCT02368145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012001658|Inflammation and Post-Stroke Depression|Inflammation and Post-Stroke Depression||Rutgers, The State University of New Jersey|No|Active, not recruiting|July 2013|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|Samples Without DNA|whole blood serum|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with acute iechemic stroke|November 2015|November 2, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02368145||27046|
NCT02368249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0581|Does Terlipressin Improve Renal Outcome After Liver Surgery|Does Terlipressin Improve Renal Outcome After Liver Surgery - A Double-Blinded Randomized Control Trial (TIROL-Trial)|TIROL|University of Zurich|Yes|Recruiting|February 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368249||27038|
NCT02371122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1673|Spinal Cord Stimulation (SCS) Therapy Study|Spinal Cord Stimulation (SCS) Therapy Study||MedtronicNeuro|No|Withdrawn|June 2015|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|0|||Both|22 Years|N/A|No|||July 2015|July 9, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371122||26819|
NCT02371759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBelgrade 534/2|Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2|Efficacy and Safety of Intraoral Local Anesthesia by Lidocaine + Clonidine in Patients With Diabetes Mellitus Type 2|LCIOADMT2|University of Belgrade|No|Completed|June 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|8||Actual|256|||Both|18 Years|65 Years|No|||March 2016|March 13, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02371759||26770|
NCT02362594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-054|Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)|Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group||Merck Sharp & Dohme Corp.|No|Recruiting|July 2015|September 2023|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362594||27469|
NCT02371772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBergen|Self-management of Anticoagulation Treatment|Comparison Between Conventional Anticoagulation Treatment and Self-management of Anticoagulation Treatment||University of Bergen|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|70 Years|No|||February 2015|February 19, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02371772||26769|
NCT02224833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHARM-PC|Inappropriate Prescription in Elderly and Polypharmacy Patients in Primary Care. PHARM-PC Trial|PHARMACIST-LED INTERVENTION TO REDUCE POTENTIALLY INAPPROPRIATE PRESCRIPTION IN ELDERLY AND POLYPHARMACY PATIENTS AT PRIMARY CARE SETTING (PHARM-PC) CLUSTER RANDOMIZED TRIAL.|PHARM-PC|Hospital Comarcal de Inca|No|Active, not recruiting|January 2015|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|65 Years|N/A|No|||July 2015|July 17, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02224833||38040|
NCT02229240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111892|Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus|Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Withdrawn|August 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 28, 2014|Yes|Yes|Study was cancelled prior to enrolling any patients|No||https://clinicaltrials.gov/show/NCT02229240||37701|
NCT02240004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRB2014|Hemo Filtration Reinfusion (HFR) Clearance Efficiency Towards P-bound Toxins and Effects on Inflammatory and Endothelial Damage Markers|Removal of Uremic Toxins and Improvement of Chronic Inflammation With HFR in Comparison With "On-Line" Hemodiafiltration and High Flux Hemodialysis.|SUPREMO|Hospital Universitario Reina Sofia|No|Completed|May 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing dialysis three times week|March 2015|March 27, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240004||36876|
NCT02366234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002670|Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid|Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid||Massachusetts General Hospital|No|Enrolling by invitation|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|82|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with distal tubercle fracture of the scaphoid|February 2015|February 11, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02366234||27190|
NCT02366494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23842|Micro RNAs to Predict Response to Androgen Deprivation Therapy|Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients||Medical College of Wisconsin|No|Recruiting|March 2015|December 2020|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Whole blood collection at pre treatment (at enrollment), 3 months post treatment, and at the      time of disease progression (or at 2 years post treatment).|Male|21 Years|85 Years|No|Probability Sample|Men with systemic disease ( with biochemical relpase or metastaic disease)|March 2016|March 4, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366494||27171|
NCT02225184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999914167|Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans|The Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|August 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|N/A|||Anticipated|135|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 19, 2016|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02225184||38013|
NCT02366988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_43|The PASTEC Study: Endoscopic Stenting Versus Surgery for the Treatment of Bile Duct Stricture in Chronic Pancreatitis|Phase 3 Prospective, Multicentric Randomized Study of Endoscopic Versus Surgical Treatment of Bile Duct Stricture in Chronic Pancreatitis|PASTEC|University Hospital, Lille|No|Recruiting|February 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02366988||27133|
NCT02360813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Central Mental Hospital|Cognitive Remediation Therapy Within a Secure Forensic Setting|Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients||Central Mental Hospital|No|Enrolling by invitation|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|May 1, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02360813||27606|
NCT02361008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCQ-2012-80-SXHZJH-1|A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect|TEE-guided Perventricular Device Closure Through Minithoracotomy vs Traditional Surgery Repair Via CBP in Treatment of Infundibular Ventricular Septal Defect：A Two-center Clinical Randomized Controlled Trial||The First Affiliated Hospital of Nanchang University|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|20121212|||Both|N/A|70 Years|No|||February 2015|February 6, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02361008||27591|
NCT02370186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2014-193|The Role of Dysfunctional HDL in Severe Sepsis|The Role of Dysfunctional HDL in Severe Sepsis||University of Florida|No|Enrolling by invitation|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|145|Samples With DNA|Serum Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Adults who present to one Emergency Department and who meet criteria for severe sepsis or        septic shock.|March 2015|March 10, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370186||26891|
NCT02370329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC138F|P1101 in Treating Patients With Early Myelofibrosis|Phase II Study of P1101 in Early Myelofibrosis||Mayo Clinic|Yes|Recruiting|August 2015|||March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370329||26880|
NCT02370420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR15-002|Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application|Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|January 2015|February 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370420||26873|
NCT02361801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|877619|Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery|Liberal Versus Restrictive Dobutamine in Cardiac Surgery (DOBUTACS): a Prospective Randomized Non-inferiority Clinical Trial|DOBUTACS|University of Sao Paulo|Yes|Active, not recruiting|February 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02361801||27530|
NCT02370888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB20151509|Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease|A Phase I Clinical Trial to Evaluate the Maximally Tolerated Dose (MTD), Dose Limiting Toxicities (DLTs) and Safety Profiles of Increasing Doses of Lenalidomide After Allo-HCT in AML and MDS Subjects With Minimal Residual Disease (MRD) Detected by the CD34+ Mixed Chimerism Analysis|UF-BMT-MRD-101|University of Florida|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370888||26837|
NCT02371109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU12/10329|SYSTEMATIC: NAATS of Pooled Selftaken Versus Clinicantaken Swabs 1|||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|February 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2350|||Both|16 Years|N/A|No|Probability Sample|The study population is all patients who attend the Leeds Centre for Sexual Health for an        appointment where diagnostic tests for gonorrhoea and chlamydia. All will be given the        opportunity to take part in the research project.|February 2015|February 19, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02371109||26820|
NCT02371291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mrccbu|Memory Flexibility Training for Depression|A Randomized Controlled Trial Comparing Memory Flexibility Training to Psychoeducation in the Treatment of Major Depressive Disorder||Medical Research Council Cognition and Brain Sciences Unit|No|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02371291||26806|
NCT02362880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBB-FAD-2014|Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study|Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362880||27447|
NCT02367729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KovacicK|Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain|Efficacy of Auricular Neurostimulation for Adolescents With Pain-Associated Functional Gastrointestinal Disorders||Medical College of Wisconsin|No|Recruiting|September 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|12 Years|18 Years|No|||September 2015|September 28, 2015|February 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367729||27078|
NCT02229253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000171|Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer|||Ferring Pharmaceuticals||Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|N/A|N/A|No|Non-Probability Sample|Patients will be selected from prostate cancer patients in a hospital setting, meeting the        inclusion criteria.|October 2015|October 22, 2015|August 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02229253||37700|
NCT02223767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wuerzburg177/12|TMS Augmented Exposure Therapy|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Height Phobics|BEAT|Wuerzburg University Hospital|No|Completed|August 2014|October 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02223767||38122|
NCT02224053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00010|Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers|A Phase I, Fixed Sequence, Open-label, Study to Assess the Pharmacokinetics of AZD9291 in Healthy Male Volunteers When a Single Oral Dose of AZD9291 80 mg is Administered Alone and in Combination With Omeprazole||AstraZeneca|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|August 20, 2014|No|Yes||No|November 26, 2015|https://clinicaltrials.gov/show/NCT02224053||38100|
NCT02372318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37|Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity|Nalmefene Challenge to Modulate Neural Reactivity to Alcohol-related and Emotional Cues in Non-treatment Seeking Alcohol Dependent Participants|NALCUE|Central Institute of Mental Health, Mannheim|No|Recruiting|April 2015|||April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|25|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02372318||26728|
NCT02372331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERAS|The Effect of ERAS on Pancreaticoduodenectomy|The Effect of ERAS (Enhanced Recovery After Surgery) on Pancreaticoduodenectomy|ERAS|Asan Medical Center|No|Recruiting|March 2015|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02372331||26727|
NCT02369471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1330 Part A|A Study of GWP42006 in People With Focal Seizures - Part A|A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.||GW Research Ltd|Yes|Recruiting|March 2015|July 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|30|||Both|18 Years|65 Years|No|||March 2015|March 31, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02369471||26945|
NCT02369718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.873|Cochlear Implants : Influence of Microphone Aging and Dirtying|Consequences of Aging and Dirtying of Microphones on the Performances of Cochlear Implants. Influence of Signal Coding||Hospices Civils de Lyon|No|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|February 17, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02369718||26926|
NCT02369991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343/13/03/02/2013/4|Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique|Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique: a Cross-sectional Study of Long-term Outcomes||Helsinki University Central Hospital|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|9|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with acute compound tibial fracture or sequela treated with free latissimus dorsi        flap and bone transport|May 2015|May 12, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02369991|5 Years|26906|
NCT02370004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014p000994|Flexibility and Strength Training in Asthma|FASTA: Flexibility and Strength Training in Asthma|FASTA|Brigham and Women's Hospital|No|Active, not recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02370004||26905|
NCT02366754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDMRP-PT130274|rTMS: A Treatment to Restore Function After Severe TBI|rTMS: A Treatment to Restore Function After Severe TBI||Edward Hines Jr. VA Hospital|Yes|Recruiting|February 2016|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366754||27151|
NCT02370017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC-ANKL-002|Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment|Combined Effect of Autologous Ex-vivo Expanded Activated NK Cell-lymphocytes (ANKL) and Doublet Chemotherapy in Patients With Advanced NSCLC as the 1st Line Treatment; Phase II|ANKL-2|The Catholic University of Korea|Yes|Not yet recruiting|February 2015|February 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|20 Years|75 Years|No|||February 2015|February 23, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02370017||26904|
NCT02370056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFJJN4|Evaluation of 3D Visualization for Total Colectomy|Comparative Assessment of Three-dimensional vs. Conventional Laparoscopy in a Total Colectomy Model for Ulcerative Colitis|3Dvs2DforUC|The Cleveland Clinic|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02370056||26901|
NCT02370069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-232-08262014|The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13|The Effect of Previous Pneumococcal Immunization on the Immune Response of Adult Patients With Severe Chronic Kidney Disease to Prevnar 13||Lakehead University|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370069||26900|
NCT02365064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682031-1_MA20150206|CPAP vs ASV for Insomnia|PAP to PAP: CPAP vs ASV for Insomnia|P2P|ResMed|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02365064||27280|
NCT02361021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0222|Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound|Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound|IWEAN|University Hospital, Clermont-Ferrand||Recruiting|July 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adult ICU patients|July 2015|July 23, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02361021||27590|
NCT02365363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-6|PERFECT Project - Part 2 - Study 3|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 3||University of Manitoba||Not yet recruiting|February 2015|July 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|February 10, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02365363||27257|
NCT02361294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TechnischeUM 1|Immature Plateletes in the Etiopathology of Deep Venous Thrombosis|Prospective Study to Generate Hypotheses About the Role of Platelets and Immature Platelets in the Pathogenesis of Idiopathic Venous Thromboses and Pulmonary Embolisms|iPLATELET|Technische Universität München|No|Recruiting|December 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|thrombophilia screening|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|all-comers|February 2015|February 10, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361294||27569|
NCT02361307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC2480/2557|The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients|The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients||Mahidol University|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|36|||Both|18 Years|75 Years|No|||April 2015|April 11, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02361307||27568|
NCT02361567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103278|Comparison of Tramacet Versus Percocet in Post Surgical Patients|Comparison of Tramacet Versus Percocet in Post Surgical Patients||Lawson Health Research Institute|No|Not yet recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361567||27548|
NCT02366247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-20046-3|Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B|Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase Ⅲ Trial|PEG-Tα1|Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|August 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|65 Years|No|||January 2015|February 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366247||27189|
NCT02362074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-455|Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis|Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis.|P @ Work|AbbVie|No|Recruiting|January 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|760|||Both|18 Years|99 Years|No|Probability Sample|This is a Multi-Center Canadian Observational Study that will enroll rheumatoid arthristis        (RA) subjects for whom the treating physician has decided to treat with adalimumab.|January 2016|January 20, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362074||27509|
NCT02362308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141553|Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas|Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas||Vanderbilt University|Yes|Recruiting|January 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|70 Years|No|||February 2015|February 11, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362308||27491|
NCT02362568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2013/181|Study of Interest on Cervical Ultrasound Exploration for Association With Difficult Intubation|Human Study of Interest on Cervical Ultrasound Exploration for Association With Criteria of Difficult Intubation in General Surgery|TUBECHO|Centre Hospitalier Universitaire de Besancon|Yes|Completed|October 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|462|||Both|18 Years|N/A|No|||February 2015|May 15, 2015|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02362568||27471|
NCT02362581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3125055|Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A|Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A||Chulalongkorn University|No|Completed|December 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Months|18 Years|No|||February 2015|February 9, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02362581||27470|
NCT02367001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA-P3644-KH-GPs|Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations|Randomized Trial Evaluating the Effectiveness of a "Targeted Communication" With the General Practitioner Involvement in Cancer Screening Invitation Letters|GPs|University Hospital, Tours|No|Completed|February 2014|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Actual|53978|||Both|25 Years|74 Years|No|||February 2015|September 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02367001||27132|
NCT02367014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIMM-201|A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy|A Phase 1/2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study Investigating the Safety, Tolerability, and Efficacy of Intravenous MTP-131 for the Treatment of Mitochondrial Myopathy in Subjects With Genetically Confirmed Mitochondrial Disease|MMPOWER|Stealth BioTherapeutics Inc.|Yes|Recruiting|February 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|36|||Both|16 Years|65 Years|No|||December 2015|December 17, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367014||27131|
NCT02370082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019820|SAVI SCOUT Clinical Evaluation Study|A Prospective, Single-Arm, Multi-Site, Clinical Evaluation of the SAVI SCOUT® Surgical Guidance System for the Location of Non-Palpable Breast Lesions During Excision||Cianna Medical, Inc.|No|Enrolling by invitation|February 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|90 Years|No|||February 2015|March 5, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370082||26899|
NCT02236442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00973-44|Protocol to Ease Acute Cephalalgia in Emergency-department|Therapeutic Management of Acute Cephalalgia Before and After Use of a Therapeutic Protocol in Emergency Department|PEACE|University Hospital, Grenoble|No|Not yet recruiting|October 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|55 Years|No|||August 2014|September 8, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02236442||37147|
NCT02365350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-244|Randomized Clinical Trial on Follicular Flushing in IVF|A Randomized, Controlled, Open Trial Comparing a 17 G Single Lumen Aspiration Needle With a Modified Double Lumen Needle System (STEINER-TAN Needle®) for Follicular Flushing During Oocyte Pick-up in IVF Patients With Poor Ovarian Response||University of Luebeck|No|Recruiting|January 2015|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||February 2015|February 10, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02365350||27258|
NCT02365701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moti_FD_II|Study of Motilitone to Treat Functional Dyspepsia|Double-blind, Placebo-controlled, Randomized, 4-week, Phase II Clinical Trial for Assessment of Efficacy and Safety of Motilitone in Patients With Functional Dyspepsia||Dong-A ST Co., Ltd.|No|Not yet recruiting|March 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||February 2015|February 11, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365701||27231|
NCT02365714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC012015-02|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)|A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With DCIS or Early Stage Breast Cancer|CK-SAPBI|Georgetown University|Yes|Recruiting|February 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|50 Years|N/A|No|||August 2015|August 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365714||27230|
NCT02363894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1009|DEFINITIVE AR Two Year Follow-up Extension Study|Directional AthErectomy Followed by a PaclItaxel-Coated BalloN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment - Two Year Follow-up Extension Study||Medtronic Endovascular|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who participated in DEFINITIVE AR I and completed the 12 month follow-up        assessment in DEFINITIVE AR.|January 2016|February 1, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363894||27370|
NCT02363907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900982|Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics|Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4||DexCom, Inc.|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|2 Years|17 Years|No|Non-Probability Sample|Children and adolescents with diabetes mellitus (Type 1 or Type 2)|February 2015|February 10, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363907||27369|
NCT02372370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-132|Pretreatments of the Skin Prior to PDT|Pretreatments of the Skin to Enhance MAL-induced Protoporphyrin IX (PpIX) Accumulation Prior to Photodynamic Therapy (PDT)||Bispebjerg Hospital|No|Completed|December 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02372370||26724|
NCT02372422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20020099H|Transvaginal Ultrasound Cervical Length Measurements in Twin Gestations|Use of Transvaginal Ultrasound Cervical Length Measurements in Twin Gestations||Wilford Hall Medical Center|No|Completed|October 2002|July 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02372422||26720|
NCT02360033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPHO-PT-2014|Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders|Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders With Adults: Manual Development and Randomized-Controled Feasibility Study||Heidelberg University|No|Recruiting|January 2015|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||February 2015|February 4, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02360033||27666|
NCT02360280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-018-14S|Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression|Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression||VA Office of Research and Development|Yes|Recruiting|April 2015|March 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02360280||27647|
NCT02360553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|azmawati|The Effect of ObeseGO! Towards Adolescent Obesity|The Effect of Internet Based Intervention (OBESEGO!) Towards Obesity Among Adolescents||Universiti Kebangsaan Malaysia Medical Centre|Yes|Completed|July 2013|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|47|||Both|16 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360553||27626|
NCT02365077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUP2015D001|GWAS Identified Susceptibility Loci for Glucocorticoid-induced FHN in the Chinese Population|Genome-wide Association Study Identified Susceptibility Loci for Glucocorticoid-induced Femur Head Necrosis in the Chinese Population||Xijing Hospital|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2500|Samples With DNA|We will collect 4ml whole blood samples under the consent of patient and extract the genome      from the samples. During the process the blood samples will be collected strickly according      the international guide clinical blood specimen collection.|Both|18 Years|60 Years|No|Probability Sample|patients coming from the Department of Dermatology Xijing Hospital, Fourth Military        Medical University Xi'an, China|February 2015|February 10, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02365077|1 Year|27279|
NCT02365376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMN 000-901|Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions|Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions||BioMarin Pharmaceutical|No|Recruiting|June 2013|||||N/A|Observational|Observational Model: Case-Only||1|||||Both|N/A|N/A|No|Non-Probability Sample|Individuals diagnosed with rare genetic diseases or medical conditions actively being        investigated by BioMarin.|February 2015|February 11, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365376||27256|
NCT02365727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034356|Exparel vs Exparel Plus ACB in TKAs|Two-arm, Double-blind Randomized Study Comparing Exparel and Exparel Plus an Adductor Canal Block in Total Knee Arthroplasty||The Hawkins Foundation|No|Withdrawn|April 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|February 11, 2015|Yes|Yes|Protocol not feasible as written|No||https://clinicaltrials.gov/show/NCT02365727||27229|
NCT02365974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-07606212500005415|Transcutaneous Electrical Nerve Stimulation (TENS) on Arterial Stiffness and Blood Pressure|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Arterial Stiffness and Blood Pressure in Resistant Hypertensive Individuals|TENS|Hospital de Base|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|40 Years|70 Years|No|||August 2015|August 17, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02365974||27210|
NCT02369237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeSSIAM_03|Non-invasive Determination of Anemia in Children With Renal Failure|A Non-invasive Device to Determine Iron Deficiency Anemia in Children of Different Age Groups With Renal Failure||Center for Studies of Sensory Impairment, Aging and Metabolism||Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|54|||Both|N/A|N/A|No|Non-Probability Sample|The subjects (n ≈ 80) will be enrolled in the Fundación del Niño Enfermo Renal (FUNDANIER)        in Guatemala-City. Approximately 50% of the patients in this institution are on        hemodialysis and 50% are on peritoneal dialysis.|February 2012|February 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369237||26963|
NCT02366507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD-02|Systolic Blood Pressure Measurement in Critically-ill Patients|Systolic Blood Pressure Measurement in Critically-ill Patients||Carolinas Healthcare System|No|Completed|July 2014|||September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients that present to the Emergency Department with hypotension or suspected        shock.|February 2016|February 4, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02366507||27170|
NCT02366767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140095|Assessment of an Automatic Closed-loop Insulin Delivery System|Assessment of an Automatic Closed-loop Insulin Delivery System||Stanford University|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|14 Years|40 Years|No|||February 2015|February 11, 2015|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366767||27150|
NCT02370030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2014-785-082|Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.|Controlled Randomized Multi-centric Clinical Trial on the Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.|CITRUSEP|Instituto Mexicano del Seguro Social|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370030||26903|
NCT02370043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KQ-791-01|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791|Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of KQ-791 in Healthy Subjects||Kaneq Bioscience Limited|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|February 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370043||26902|
NCT02372383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1043|Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis|Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls||University of Colorado, Denver|Yes|Recruiting|October 2014|October 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372383||26723|
NCT02237677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02787|CB1 Receptor PET Imaging Reveals Gender Differences in PTSD|Cannabinoid-1 (CB1) Receptor Positron Emission Tomography (PET) Imaging Reveals Gender Differences in Posttraumatic Stress Disorder (PTSD)||New York University School of Medicine|Yes|Completed|June 2012|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are between the age range of 18 to 55, are medically healthy and currently not        taking any medications to treat any medical illness, history of post-traumatic stress        disorder (PTSD) or healthy control.|March 2016|March 3, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02237677||37052|
NCT02368977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avantis TEP 13-01|Third Eye Panoramic Device Feasibility Evaluation|Third Eye Panoramic Device Feasibility Evaluation||Avantis Medical Systems|No|Enrolling by invitation|November 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|75 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368977||26982|
NCT02367963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHE-001-FM|Peer-group-based Intervention Program|Evaluation of Comprehensive Lifestyle Peer-group-based Intervention on Cardiovascular Risk Factor, a Randomized Controlled Trial: Fifty-Fifty Program|Fifty-Fifty|Foundation for Science, Health and Education, Spain|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|543|||Both|25 Years|50 Years|No|||February 2016|February 2, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02367963||27060|
NCT02364154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/070U|Colorectal Cancer Detected by 1H-NMR Spectroscopy|Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy: a New Tool to Detect Colorectal Cancer?|BIOCOR|Hasselt University|No|Recruiting|December 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|-  blood plasma for NMR spectroscopy        -  blood sample for free circulating miRNA|Both|40 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Colorectal cancer patients and control subjects who undergo a coloscopy without diabetes        and/or a history of cancer during the past 5 years, of an age between 40 and 90 years and        willing to provide written informed consent.|February 2015|February 16, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364154|3 Weeks|27350|
NCT02364388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAESTRO-01|IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)|IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)|MAESTRO|Seno Medical Instruments Inc.|No|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|A total of approximately 200 subjects, with a BI-RADS 4a or 4b classification and        scheduled to undergo gold standard histologic assessment via an un ultrasound-guided large        (14 gauge or larger) core needle biopsy, ultrasound-guided vacuum assisted needle biopsy,        or excisional biopsy will be recruited.|November 2015|January 20, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364388||27332|
NCT02364596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3451015|Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years|A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years||Pfizer|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364596||27316|
NCT02364830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E.C. Anise-oil on IBS|Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel Syndrome|Randomised Clinical Trial: Enteric-coated Anise-oil Capsules vs. Placebo & Active Controlled in Irritable Bowel Syndrome - A 4 Week Double-blind Study With 2 Weeks Follow-up|IBS-Anise|Shiraz University of Medical Sciences|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364830||27298|
NCT02368262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/766.2|Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy|Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy||University Hospital, Ghent|No|Active, not recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|80|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with CP: Cerebral palsy Reference Centre (Ghent university hospital) Incontinent        children with normal development: Urology department (Ghent university hospital) continent        children with normal development: community sample|December 2015|December 1, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368262||27037|
NCT02368431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-003-14S|Effectiveness of Zonisamide in Alcohol Dependent Veterans|Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans||VA Office of Research and Development|Yes|Recruiting|March 2015|April 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|21 Years|70 Years|No|||March 2016|March 22, 2016|February 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368431||27024|
NCT02368574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG-001|Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer|Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer||Chinese Gynecological Oncology Group|Yes|Not yet recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Female|20 Years|55 Years|No|||February 2015|February 15, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02368574||27013|
NCT02368782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30112011|Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children|Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children With Normal Hearing Tests Undergoing Adenoidectomy and Tonsillectomy|OAE|Istanbul University|Yes|Completed|December 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|4 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|children ages 4-15 years ASA I-II Tonsillectomy and/or adenoidectomy Normal ear hearing        tests|February 2015|February 15, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02368782||26997|
NCT02368795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642416|Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis|Non-inferiority Trial Comparing Pharmacological Prevention Alone Versus Pancreatic Stents Plus Pharmacological Prevention to Prevent Post-ERCP Pancreatitis||Tehran University of Medical Sciences|No|Recruiting|February 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|15 Years|N/A|No|||November 2015|November 5, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02368795||26996|
NCT02368990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160R00001|T790M Mutation Positive 2nd Line STandard of cAre Registry|T-STAR - T790M Mutation Positive 2nd Line STandard of cAre Registry|T-STAR|AstraZeneca|No|Withdrawn|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed EGFRm+, T790M mutation positive, locally advanced or metastatic        NSCLC who have been prescribed pemetrexed + cisplatin/carboplatin in accordance with        clinical practice after 1st line treatment with approved EGFR-targeted TKI will be        selected from approximately 100 sites across 17 countries worldwide.|July 2015|July 6, 2015|January 29, 2015||No|Since the conception of the study, the competitive environment has developed and as a result    this study is no longer able to generate the necessary information.|No||https://clinicaltrials.gov/show/NCT02368990||26981|
NCT02369484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP 7-14|Afatinib in NSCLC With HER2 Mutation|Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations|NICHE|European Thoracic Oncology Platform|Yes|Recruiting|June 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369484||26944|
NCT02369731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-025o-DMD|Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy|Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care||PTC Therapeutics|No|Recruiting|April 2015|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|The target study population will include patients for whom the decision to prescribe        Translarna (outside of a clinical trial) has already been made, including patients in        named patient early access programs. Patients within each prescriber's practice who are or        will be receiving treatment with Translarna, and who meet the eligibility criteria and        provide informed consent (either by the patient or through authorisation by a legal        guardian), will be invited to enroll into the study and will be followed according to the        protocol.|February 2016|February 4, 2016|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02369731|5 Years|26925|
NCT02372344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5884C00004|A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects|A Phase I, Single Centre, Randomized, Open-Label, Three-Period Crossover Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA With a Single 4 g Dose of AZD0585 in Healthy Male Japanese Subjects||AstraZeneca|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|72|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02372344||26726|
NCT02372357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2841/20 Feb 2012|A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area|A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area||Universitaire Ziekenhuizen Leuven|No|Completed|February 2012|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|2 Years|13 Years|No|||March 2015|March 2, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02372357||26725|
NCT02362893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/159|Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control|Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control|DRIVE|Oslo University Hospital|No|Recruiting|April 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362893||27446|
NCT02225717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140502|Identification of Spontaneous Delivery Markers|Markers of Fetal Membranes Remodelling in Cervicovaginal Fluid and Delivery|TrophY2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|260|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02225717||37972|
NCT02363621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29634|Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema|Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema||Sierra Eye Associates||Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 1, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363621||27390|
NCT02368158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 13-095|Reha Drive: Predictors of Fitness to Drive a Car for Cardiologic Patients and Determination of Vital Signs|Reha Drive: Predictors of Fitness to Drive a Car for Cardiologic Patients in Rehabilitation and Acute Clinic and Contactless Determination of Vital Signs Via Camera|RehaDrive|RWTH Aachen University|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368158||27045|
NCT02370771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/059/HP|Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis|Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis|PASEO|University Hospital, Rouen|Yes|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|70 Years|No|||September 2015|September 14, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370771||26846|
NCT02370901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plagiocephaly|Cranial Orthotic Device Versus Repositioning Techniques for the Management of Plagiocephaly: the CRANIO Randomized Trial|Cranial Orthotic Device Versus Repositioning Techniques for the Management of Plagiocephaly: the CRANIO Randomized Trial|CRANIO|University of South Florida|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|4 Months|7 Months|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370901||26836|
NCT02370914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21114|Concussion Testing: A Novel Non-invasive Concussion Detection Device|Concussion Testing: A Novel Non-invasive Concussion Detection Device||Jan Medical, Inc.|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|84|||Male|14 Years|18 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02370914||26835|
NCT02371135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-016|Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes|Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes||Memorial Sloan Kettering Cancer Center||Recruiting|February 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|tissue stool|Both|18 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified prospectively within the clinics of the        Clinical Genetics and Gastroenterology Services, of MSKCC.|January 2016|January 19, 2016|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371135||26818|
NCT02371148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_BRB|Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's|Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse|FIL_BRB|Fondazione Italiana Linfomi ONLUS|No|Recruiting|June 2014|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|January 4, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02371148||26817|
NCT02371317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KentSU|Stress Management for High Blood Pressure|||Kent State University|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02371317||26804|
NCT02361580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002781|Impact of Keeping a Personal Recovery Diary on Upper Extremity Disability|Impact of Keeping a Personal Recovery Diary on Upper Extremity Disability||Massachusetts General Hospital|No|Enrolling by invitation|January 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361580||27547|
NCT02361814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15002|The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair|The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair: a Pilot Study||University of Tampere|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361814||27529|
NCT02371512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATTERHORN|A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN|A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN|MATTERHORN|Universitätsklinikum Köln|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2015|March 19, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371512||26789|
NCT02371525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH095628|Enhancing PrEP in Community Settings (EPIC)|Enhancing PrEP in Community Settings (EPIC)||University of California, San Francisco||Recruiting|March 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371525||26788|
NCT02371538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3363|Human Breastmilk in Young Children With Norovirus Infection of the Gut|A Pilot Study of Enteral Donor Human Milk in Young Children With Norovirus Infection of the Gut||Children's Hospital Medical Center, Cincinnati|No|Recruiting|October 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|N/A|N/A|No|||November 2015|November 10, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371538||26787|
NCT02371785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002|Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease|Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease|RAPID|Corindus Inc.|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371785||26768|
NCT02371798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077659|Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?|Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration||Emory University|No|Enrolling by invitation|February 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|5|||Both|18 Years|90 Years|No|||March 2016|March 16, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371798||26767|
NCT02372071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Transcutaneous Bilirubinometry in Neonates With the BiliCare System Compared to the Invasive TSB Test|Transcutaneous Bilirubinometry in Neonates With the BiliCare System Compared to the Invasive TSB Test||Gerium Medical|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|111|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|February 22, 2015||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02372071||26747|
NCT02362607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-006|Integrated Diabetes Management Protocol Using Smartphone|Integrated Diabetes Management Protocol Using Smartphone||Chungbuk National University||Completed|February 2015|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|80 Years|No|||February 2016|February 3, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02362607||27468|
NCT02362620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI-DOC-2014-02|PROSTAC: Multicentre Biomarker Study in CRPC Treated With Chemotherapy|Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With doceTaxel or Cabazitaxel|PROSTAC|Centro Nacional de Investigaciones Oncologicas CARLOS III|No|Recruiting|May 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|402|Samples With DNA|Paxgene and tempus tubes on baeline, pre-cycle 3 and progression Tumor paraffine sample at      baseline|Male|18 Years|N/A|No|Non-Probability Sample|Patient with Castrationresistant Prostate Cancer|October 2015|October 8, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362620||27467|
NCT02367781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29537|A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]|A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|April 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367781||27074|
NCT02230124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 20618|Magnetic Resonance Elastography in Hydrocephalus|Magnetic Resonance Elastography in Hydrocephalus||Dartmouth-Hitchcock Medical Center|No|Recruiting|December 2004|||July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|45 Years|95 Years|Accepts Healthy Volunteers|||August 2014|September 2, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02230124||37633|
NCT02230397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2713|Efficacy and Tolerance Evaluation of a Topical "Revitalizing" Face Day Cream|Efficacy and Tolerance Evaluation of a Topical "Revitalizing" Face Day Cream: Comparison Within Subjects Versus Placebo||Derming SRL|Yes|Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||July 2014|September 2, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02230397||37612|
NCT02367807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-276-1295|PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color|Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men||Philadelphia Fight|No|Active, not recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|49|Samples Without DNA|urine and plasma samples for measurement of tenofovir concentration, blood samples for      measurement of safety labs, and urine/plasma samples and rectal/pharyngeal swabs for      sexually transmitted infection screening|Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 biological males from urban Philadelphia who identify as men who have sex with men        (MSM) ages 18-30 at risk of HIV acquisition|February 2016|February 1, 2016|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367807||27072|
NCT02367898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLI-001|Enhancing Cognitive Abilities With Comprehensive Training|Enhancing Cognitive Abilities With Comprehensive Training: A Large, Online, Randomized, Active-Controlled Trial||Lumos Labs, Inc.|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|11470|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367898||27065|
NCT02374138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5819|Breathe With Ease: A Unique Approach to Managing Stress (BEAMS)|Improving Asthma Outcomes Through Stress Management||Children's Research Institute|Yes|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|4 Years|12 Years|No|||August 2015|August 21, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02374138||26588|
NCT02374151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1980- 15-SMC|Accuracy of Electrohysterography in Assessing Intrauterine Pressure|Accuracy of Electrohysterography in Assessing Intrauterine Pressure Compared to Invasive Intrauterine Pressure Catheter|EHG|Sheba Medical Center|No|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women at term in second or third phase of labor who are indicated to have an IUPC during        active labor|March 2015|March 1, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02374151||26587|
NCT02370264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-12-4|Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer|Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer||University of Southern California|No|Recruiting|October 2012|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Female|18 Years|N/A|No|||October 2015|October 24, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370264||26885|
NCT02370342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4K-14-3|Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery|Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) for Thermal Ablative Therapy of Small Renal Mass: Corroborating With Robot-Assisted Laparoscopic Partial Nephrectomy Specimens||University of Southern California|Yes|Not yet recruiting|August 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370342||26879|
NCT02368041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400800|Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure|Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure||University of Florida|No|Recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|N/A|25 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368041||27054|
NCT02368054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49024|Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization|Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study|HSBAPCB|Helse Fonna|Yes|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|50 Years|No|||July 2015|July 22, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02368054||27053|
NCT02368067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERMC- Endometrial Carcinoma|Improved Method of Detecting Cancer Metastases|Study of Instillation Technique Using The Modified Intra- Uterine Manipulator Catheter With Methylene Blue, Isosulfan Blue or Indocyanine Green Dyes, Compared to Cervical Injection, For Sentinel Lymph Node Detection in Endometrial Carcinoma|SITs|Southeastern Regional Medical Center|No|Enrolling by invitation|June 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368067||27052|
NCT02370628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE14.334|Vertebroplasty In The Treatment Of Acute Fracture Trial - The VITTA Trial|Vertebroplasty In The Treatment Of Acute Fracture Trial (The VITTA Trial)|VITTA|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|495|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02370628||26857|
NCT02360293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-305|Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans|Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans||VA Office of Research and Development|No|Not yet recruiting|April 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|455|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02360293||27646|
NCT02360826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13CRP1711002|Statin Distribution|Pharmacokinetics of Pravastatin and Simvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition||Children's Mercy Hospital Kansas City|Yes|Recruiting|July 2013|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02360826||27605|
NCT02361034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 27864-102|To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects|A Two-Part, Phase I Study of Orally Administered GRC 27864, a Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses in Healthy Subjects (Part 1), and of Multiple Doses in Elderly Subjects (Part 2)||Glenmark Pharmaceuticals S.A.|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361034||27589|
NCT02361320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0319|Imaging Biomarkers in Pancreatic Cancer|Imaging Biomarkers in Pancreatic Cancer||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|259|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361320||27567|
NCT02365740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248/13|Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options|Postprandial Blood Glucose Control and Gastric Emptying in Patients With Type 1 Diabetes: Pathogenetic Factors, Clinical Relevance and Possible Therapeutic Options||Federico II University||Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|February 18, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02365740||27228|
NCT02361827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCZZU-Vitamin D|The Effect of Vitamin D on in Vitro Fertilization Outcome|The Effect of Vitamin D on in Vitro Fertilization Outcome, a Prospective Observational Study||The First Affiliated Hospital of Zhengzhou University|Yes|Recruiting|January 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|800|Samples With DNA|Serum|Female|21 Years|40 Years|No|Probability Sample|Patients whose IVF cycles were cancelled due to ovarian hyperstimulation syndrome were        also excluded);.|February 2015|February 11, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02361827||27528|
NCT02365987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDM/14/15-26|The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety|The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety: a Randomised Controlled Trial. The INTER-FAT Study|INTERFAT|King's College London|No|Active, not recruiting|February 2015|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365987||27209|
NCT02362087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150011-01H|Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer|A Multi-Centre Study to Investigate the Natural History of Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer|TAPS OTT 14-06|Ottawa Hospital Research Institute|No|Recruiting|March 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|141|Samples With DNA|Serum, plasma and buffy coat will be collected and archived tissure.|Both|18 Years|N/A|No|Probability Sample|Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer|January 2016|January 27, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02362087||27508|
NCT02362321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-370|Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma|Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma: a Double-blind Randomized Controlled Pilot Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Terminated|January 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 9, 2015|Yes|Yes|Due to serious adverse events|No|February 12, 2015|https://clinicaltrials.gov/show/NCT02362321||27490|
NCT02367027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17769|Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions|Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare a Dry Powder Oral Suspension (10 mg and 20 mg Dose of Rivaroxaban) With an Oral Suspension (10 mg of Rivaroxaban) and 10 mg of an Immediate Release Tablet Under Fasting Conditions (10 mg Doses) and Under Fed Conditions (20 mg Dose) in Healthy Male Subjects||Bayer|No|Completed|February 2015|June 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02367027||27130|
NCT02370459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3599|AFIX to Improve HPV Vaccination|Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices|AFIX|University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|225|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02370459||26870|
NCT02237014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11062012-11219|Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease|Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease||Stanford University|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|Samples Without DNA|whole blood|Both|N/A|10 Years|No|Non-Probability Sample|Children with cyanotic heart disease undergoing cardiac catheterization or heart surgery        in Stanford University Medical Center(SUMC) or Lucile Packard Children's Hospital(LPCH)        respectively with peripheral arterial saturation less than 90% at time of enrollment.|September 2014|February 4, 2016|November 9, 2012||No||No||https://clinicaltrials.gov/show/NCT02237014||37103|
NCT02370199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22652|Peripheral Blood Flow Responses to Electromagnetic Energy|Peripheral Blood Flow Responses to Electromagnetic Energy||Medical College of Wisconsin|No|Recruiting|November 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370199||26890|
NCT02374164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Febuxostat-XR-1009|Food Effect Study of Febuxostat XR in Healthy Participants|A Phase 1, Open-Label, Single-Center, Randomized, 3-Way Crossover Study to Assess the Effect of Food on the Bioavailability of a Single Oral Dose of 80 mg Febuxostat Extended-Release Formulation and the Pharmacokinetics of a Single Oral Dose of 40 mg and 80 mg Febuxostat Extended-Release Formulation in Healthy Subjects||Takeda|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02374164||26586|
NCT02374177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160073|The Effects of Anaesthetic Agents on Postoperative Delirium|The Effects of Anaesthetic Agents on Postoperative Delirium in the Patients Undergoing Off-pump Coronary Artery Bypass Grafting Surgery||Konkuk University Medical Center|No|Completed|November 2014|February 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|292|||Both|N/A|N/A|No|Non-Probability Sample|The medical records of the patients undergoing off-pump CABG in Konkuk University Medical        Centre from Jan 2010 to Aug 2014 were retrospectively reviewed.|February 2015|February 23, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02374177||26585|
NCT02370433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-12-035|Use of Prokinetics During Inpatient Bowel Care for SCI Patients|||James J. Peters Veterans Affairs Medical Center||Recruiting|December 2012|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|75 Years|No|||August 2015|August 31, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370433||26872|
NCT02370446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008|Testing a Personalize Medication Log for Patients With Lymphoma (Restarted From NUR13-009)|Testing a Personalize Medication Log for Patients With Lymphoma (Restarted From NUR13-009)||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified by a member of the patient's treatment team, the protocol        investigator, or research team at Memorial Sloan-Kettering Cancer Center (MSKCC).|February 2016|February 4, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370446||26871|
NCT02360046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211/14|The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism|The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids (Intrahepatocellular IHCL and Intramyocellular IMCL) in Patients With Corticotropic Hypopituitarism, a Randomised Placebo-controlled Double-blind Trial|Hydrocort|University Hospital Inselspital, Berne|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02360046||27665|
NCT02360059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0438|Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer|Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study||M.D. Anderson Cancer Center|Yes|Recruiting|October 2015|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|74 Years|No|||December 2015|December 18, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360059||27664|
NCT02364609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#250|Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib|A Phase I/Ib Trial of MK-3475 (Pembrolizumab) and Afatinib in EGFR-Mutant Non-small Cell Lung Cancer With Resistance to Erlotinib||University of California, Davis|Yes|Recruiting|September 2015|December 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364609||27315|
NCT02364843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048977|A Physiological Study to Determine the Enteral Threonine Requirements in Infants Aged 1 to 6 Months|A Physiological Study to Determine the Enteral Threonine Requirements in Infants Aged 1 to 6 Months|INFORALTHR|The Hospital for Sick Children|No|Enrolling by invitation|February 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|1 Month|6 Months|No|||February 2016|February 3, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02364843||27297|
NCT02364856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_22|Pain Assessment in Children With Cerebral Palsy Through Parasympathetic Tone Analysis.|Assessment of Pain Through Parasympathetic Tone Analysis : Applicability in Children With Cerebral Palsy.||University Hospital, Lille|No|Recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|6 Years|18 Years|No|Non-Probability Sample|Our population will be 40 CP children (6-18y) receiving rehabilitation therapy in        specialized centres.|February 2016|February 10, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364856||27296|
NCT02365090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Binocular iPad Sub-Study|Binocular iPad Sub-Study|Binocular iPad Sub-Study; Suppression in Amblyopia||Retina Foundation of the Southwest|No|Recruiting|February 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|4 Years|10 Years|No|||December 2015|December 11, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02365090||27278|
NCT02365103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NW/0310 S-LS17042014|Tea Consumption and Iron Bioavailability in Women Using a Stable Isotope|Investigation Into the Inhibitory Effects of Tea Consumption on Iron Bioavailability in a Cohort of Healthy UK Women, Using a Stable Iron Isotope||University of Chester|No|Active, not recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Anticipated|12|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02365103||27277|
NCT02365389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vaginal gell|Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis|Assiut University Hospital - Women Health Hospital|MNZ|Assiut University||Completed|May 2014|December 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Female|20 Years|40 Years|No|||February 2015|February 17, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02365389||27255|
NCT02369497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-HRA-001|Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study|Ascension® Humeral Resurfacing Arthroplasty HRA Follow-Up Study|HRA|Integra LifeSciences Corporation|No|Terminated|December 2007|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with arthritis requiring humeral resurfacing arthroplasty|February 2015|February 17, 2015|November 4, 2014||No|PI left institution and site did not have resources to continue study|No||https://clinicaltrials.gov/show/NCT02369497||26943|
NCT02366273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-20140023881|Diabetes and Psoriasis|Diabetes and Psoriasis: Study on Prevalence, Role of Inflammation and Insulin-resistance||University of Pavia|No|Recruiting|February 2015|||February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Patients with psoriasis|February 2015|February 11, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02366273||27188|
NCT02369744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4441|Silodosin Versus Tamsulosin for Treatment of Ureteral Stones|Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy||Albert Einstein Healthcare Network|No|Terminated|March 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|70 Years|No|||February 2015|February 23, 2015|June 19, 2014||No|due to lack of suitable patient population|No||https://clinicaltrials.gov/show/NCT02369744||26924|
NCT02366520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-14-37|Handheld Mirror to Improve Child's Behavior During Dental Treatment|Using a Handheld Mirror to Improve Child's Behavior During Dental Treatment||Case Western Reserve University|No|Recruiting|May 2015|June 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02366520||27169|
NCT02366533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 093|CDC-ATN Linkage Evaluation|CDC-ATN/NICHD Testing and Linkage to Care Project|SMILES and LTC|Westat|Yes|Completed|May 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2133|||Both|N/A|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Research will be performed on 15 AMTU sites' ability to implement the CDC/NICHD linkage to        care project. The "study population" is the 15 AMTU research sites. The 15 AMTUs are        located in 12 U.S. cities (there are 2 sites located in New York City and 2 sites in        Chicago) and 1 in San Juan, Puerto Rico.|March 2016|March 3, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366533||27168|
NCT02366780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-0662-11-TLV|Breast Milk Content Expressed Manually Compared to Electric Pump|Breast Milk Content Expressed Manually Compared to Electric Pump||Tel-Aviv Sourasky Medical Center|No|Completed|November 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|50|||Female|18 Years|60 Years|No|||September 2015|September 2, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02366780||27149|
NCT02370147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaPLAGHW|Very Brief Smoking Reduction Intervention|The Effect of Very Brief Smoking Reduction Intervention in Smokers Who Having no Intention to Quit: Study Protocol for a Randomized Controlled Trial||Chinese PLA General Hospital|No|Not yet recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02370147||26894|
NCT02370355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-14-6|Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer|Assessment of Novel Biomarkers in Patients With Metastatic Castration Resistant Prostate Cancer||University of Southern California|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|100|Samples With DNA|Blood, plasma, and tissue (optional)|Male|19 Years|N/A|No|Non-Probability Sample|Patients with metastatic and/or hormone-resistant prostate cancer consented under        University of Southern California (USC) protocols IRB numbers 10-00006 and 11-004500 or        treated at the USC/Westside Cancer Center, USC/Norris Comprehensive Cancer Center, or LAC        + USC Medical Center.|October 2015|October 24, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370355||26878|
NCT02375295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02514|Struvite Stones Antibiotic Study|A Prospective Randomized Trial of 2 Weeks vs 3 Months of Antibiotics Post Percutaneous Nephrolithotomy for the Prevention of Infection-Related Kidney Stones||University of British Columbia|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28|||Both|19 Years|N/A|No|||December 2015|December 17, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375295||26499|
NCT02237027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1098973|Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin|Demonstration Project of Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin|TasP/PrEP|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|361|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02237027||37102|
NCT02237040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-Clinical Treatment|A New Treatment Protocol for Paediatric Mandibular Condylar Fractures|Management of Paediatric Mandibular Condylar Fractures Simply With a Mandibular Manipulation Technique and Mouth Opening Training||Sun Yat-sen University|Yes|Recruiting|March 2010|March 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|12 Years|No|||May 2015|May 19, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02237040||37101|
NCT02367911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-0551-305|A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis||Therapeutics, Inc.|No|Active, not recruiting|January 2015|January 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367911||27064|
NCT02363400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1313|A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA|Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|November 2014|December 2022|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|147|||Both|20 Years|N/A|No|||November 2014|February 9, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02363400||27407|
NCT02363920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402015|Short Term Physiological Effects of Nasal High Flow Oxygen on Respiratory Mechanics|Short Term Physiological Effects of Nasal High Oxygen Flow vs Low Oxygen Flow and Noninvasive Ventilation (NIV) on Respiratory Mechanics||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|15|||Both|18 Years|85 Years|No|||December 2015|December 28, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02363920||27368|
NCT02363933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055609|Perampanel in Seizure Patients With Primary Glial Brain Tumors|Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors||Duke University|No|Recruiting|February 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363933||27367|
NCT02374190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEHE40914022015|Examining How Chronic Health States and Acute Treatment Contribute to Variations in AMI Mortality Across the English NHS|Examining How Chronic Health States and Acute Treatment Contribute to Variations in Acute Myocardial Infarction (AMI) Mortality Across the English National Health Service (NHS): An Observational Study Using the Myocardial Ischaemia National Audit Project||London School of Economics and Political Science||Active, not recruiting|February 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|600000|||Both|18 Years|N/A|No|Probability Sample|Population of patients admitted to hospital (acute care trust) for myocardial infarction        between 2005-2014.|February 2015|February 26, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02374190||26584|
NCT02364401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMCEP_PHS_001|Impedance vs. Contact Force Guided Atrial Fibrillation Ablation Using Automated Annotation System|Comparison of Efficacy Between Impedance Guided and Contact Force Guided Atrial Fibrillation Ablation Using Automated Annotation System||Keimyung University Dongsan Medical Center|Yes|Recruiting|February 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||August 2015|August 31, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02364401||27331|
NCT02368444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITRP-01|A Cognitive Behavioral Therapy and Yoga Program for Trauma Symptoms|A Cognitive Behavioral Therapy and Yoga Program for Trauma Symptoms||Georgetown University|No|Completed|May 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02368444||27023|
NCT02368587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NavyGHB|Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy|Randomised, Double-blind, Placebo-controlled, Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy|WJ-ICMP Tria|Navy General Hospital, Beijing|Yes|Not yet recruiting|March 2015|October 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|17 Years|90 Years|No|||January 2015|February 20, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368587||27012|
NCT02368808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-674-A-12-00002-CWL|Family Bereavement Initiative in the Free State, South Africa|Coping With Loss: A Family Bereavement Initiative for Adolescent Girls in the Free State, South Africa||Tulane University School of Social Work|No|Enrolling by invitation|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1008|||Female|13 Years|18 Years|No|||February 2015|February 16, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02368808||26995|
NCT02369003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0729-F6A|Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS|Continuation of a Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts in Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment|APNG2|University of Kentucky|No|Enrolling by invitation|February 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|40 Years|75 Years|No|||March 2016|March 8, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02369003||26980|
NCT02375074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|227002/H20|Supported Employment and Preventing Early Disability|Supported Employment and Preventing Early Disability (SEED)|SEED|Uni Research|Yes|Recruiting|May 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|210|||Both|18 Years|30 Years|No|||June 2015|June 25, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02375074||26516|
NCT02369757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-04|Patients Navigator for Organized Colorectal Cancer Screening|Patients Navigator for Organized Colorectal Cancer Screening in Underserved Population|COLONAV|Institut de Cancérologie de la Loire|No|Completed|October 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40774|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||November 2014|February 26, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02369757||26923|
NCT02370095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0490|Treprostinil Sodium Inhalation for Patients At High Risk for ARDS|Treprostinil Sodium Inhalation for Patients At High Risk for ARDS: Effect on Oxygenation and Disease-related Biomarkers||University of North Carolina, Chapel Hill|Yes|Recruiting|February 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|75 Years|No|||July 2015|July 1, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370095||26898|
NCT02370108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483/57|The Study of Rest Tremor Suppression by Using Electrical Muscle Stimulation|The Study of Rest Tremor Suppression by Using Electrical Muscle Stimulation||Chulalongkorn University|Yes|Not yet recruiting|February 2015|May 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2015|February 23, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02370108||26897|
NCT02375269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0458|Effect of Remote Ischemic Preconditioning on Postoperative Complications in Visceral Surgery|A Randomized, Double- Blind Multicentric Study of the Effect of Remote Ischemic Preconditioning on Postoperative Complications in Patients Undergoing Major Minimal and Open Visceral Surgery|RIPC|University of Zurich|Yes|Not yet recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|526|||Both|18 Years|N/A|No|||January 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375269||26501|
NCT02375282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-14-169|Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study|Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study||Baystate Medical Center|No|Active, not recruiting|March 2015|August 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02375282||26500|
NCT02363660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINI Study|Gardasil Immunogenicity With Needle-Free Injection|A Randomized, Parallel Design Study to Compare the Safety and Effectiveness of Gardasil When Delivered Per Standard Practice (Full Dose, Intramuscular (IM) Delivery Using a Needle and Syringe) vs. Full Dose, IM Delivery Via Needle-free Jet Injection or Reduced Dose, Intradermal Delivery Via Needle-free Jet Injection|GINI|Thai Red Cross AIDS Research Centre|Yes|Recruiting|January 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|150|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02363660||27387|
NCT02238444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YZUC-001|Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy|Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy|ESWA|Yangzhou University|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02238444||36993|
NCT02370927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-4|PERFECT Project - Part 2 - Study 2|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 2||University of Manitoba||Recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02370927||26834|
NCT02363634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDP-Mg-2012|Clinical Trial to Evaluate Magtein in Older Adults|A Randomized Double Blind Parallel Group Placebo Controlled Clinical Trial Evaluating the Effects of Magtein on Anxiety, Mood and Sleep Quality in Older Adults||Miami Research Associates|No|Completed|August 2012|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 13, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02363634||27389|
NCT02363647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO#1: 15-0146|Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer|Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer||Icahn School of Medicine at Mount Sinai|Yes|Enrolling by invitation|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02363647||27388|
NCT02368080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLuc MBWN2 01|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults: a Comparison of Two Commercially Available Devices||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|April 2013|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|95|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|CF : primary care clinic HC : community sample|July 2015|July 29, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02368080||27051|
NCT02371330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRF-1516|The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study|The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study - Neo-HAT Study|Neo-HAT|Karolinska Institutet||Recruiting|April 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|||Both|N/A|N/A|No|Probability Sample|Patients admitted to the Neonatal Intensive Care Unit who are <32 weeks gestation or with        a birth weight <1500 grams.|February 2016|February 24, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02371330||26803|
NCT02364167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC SC BB 04/15|Acupuncture for Pain Control After Elective Caesarean Section|Acupuncture vs. Placebo Acupuncture and vs. Standard Therapy for Pain Control After Elective Caesarean Section - a Randomized Controlled Trial|ACUSEC|University Medicine Greifswald|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Female|19 Years|45 Years|No|||February 2015|February 13, 2015|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364167||27349|
NCT02368275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Predictive cohort|Genetic, Neurophysiological and Psychological Risk Factors for Neuropathic Pain|Role of Genetic, Neurophysiological and Psychological Factors in the Development of Postsurgical Neuropathic Pain After Breast Surgery for Cancer||Hospital Ambroise Paré Paris|No|Not yet recruiting|March 2016|December 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|The samples will use GWAS to detect potential genetic risk factors for neuropathic pain.      These data will be analysed in Oxford laboratory (McCarthy).|Female|18 Years|N/A|No|Non-Probability Sample|The first group of patients consists of patients are women recruited from René Huguenin        Hospital (Saint Cloud, Ile de France) for mastectomy or lumpectomy to treat breast cancer,        with axillary lymph node dissection in all cases.        The second cohort will consist of women already operared of breast surgery in the last 2        years.|December 2015|December 4, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368275||27036|
NCT02372084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C2103|A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function|A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of Osilodrostat (LCI699) in Subjects With Impaired Hepatic Function Compared to Subjects With Normal Hepatic Function||Novartis|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 20, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372084||26746|
NCT02372097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472-1005|A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets|A Randomized, Open-label, Crossover Phase 1 Study to Evaluate the Bioequivalence Following a Single Oral Dose Administration of SYR-472 25mg and 50mg Tablets in Healthy Adult Male Subjects||Takeda|No|Not yet recruiting|February 2015|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372097||26745|
NCT02372396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H130565|Compassion Meditation for PTSD|A Proof of Concept and Feasibility Trial of Compassion Meditation for PTSD||Veterans Medical Research Foundation|Yes|Recruiting|February 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02372396||26722|
NCT02372409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502062|Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors|A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors||Washington University School of Medicine|No|Recruiting|August 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|3 Years|21 Years|No|||February 2016|February 29, 2016|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372409||26721|
NCT02372136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102014-056|Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants|Individualizing and Optimizing Nutrition to Prevent Metabolic Syndrome and To Improve Neurodevelopment in Preterm and Small for Gestational Age Infants||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2016|July 2021|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|7 Days|No|||March 2016|March 1, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02372136||26742|
NCT02372149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8297-B|IVIg for Demyelination in Diabetes Mellitus|Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study|IDIDM|University of Toronto|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372149||26741|
NCT02365493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC1078930|Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection|CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial|CAMERA2|Menzies School of Health Research|Yes|Recruiting|August 2015|March 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365493||27247|
NCT02361099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-A-2014-03|SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse|Phase 3 Multicentric Randomized Study Assessing Self-reported Symptoms Transmitted Via an Internet Web-application " Sentinel " Versus Conventional Follow-up in Patients With High Risk Lung Cancer (SENTINEL)|SENTINEL|Institut Cancerologie de l'Ouest|No|Terminated|June 2014|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|133|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361099||27584|
NCT02361112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLTN-Ic|Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer|A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer|BLTN-Ic|Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|August 2014|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|70 Years|No|||February 2015|February 6, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02361112||27583|
NCT02361125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-166|Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate|Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue||M.D. Anderson Cancer Center|No|Recruiting|August 2002|||August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361125||27582|
NCT02361411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH-2014191|Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy|A Research of the Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy||Peking University Third Hospital|Yes|Not yet recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|blood brain tissure|Both|N/A|N/A|No|Non-Probability Sample|We recruited consecutive patients with intracerebral hemorrhage.|February 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361411||27560|
NCT02366091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047206|Inflammation and Coronary Endothelial Function|Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease||Johns Hopkins University|Yes|Recruiting|January 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|120|||Both|21 Years|N/A|No|||November 2015|November 11, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366091||27201|
NCT02363959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055849|Hyperbaric Oxygen Therapy for Lung Transplantation|Hyperbaric Oxygen Therapy for Lung Transplantation-Associated Pseudomembranes and Central Airway Stenosis||Duke University|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||January 2016|January 20, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363959||27365|
NCT02363972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0014-01|Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD|Ellipsys Vascular Access Catheter System Clinical Trial||Avenu Medical|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363972||27364|
NCT02363985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPHI_IAEA_P6047|Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection|Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection in Ethiopia||Ethiopian Public Health Institute|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|110|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||February 2015|February 14, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02363985||27363|
NCT02375737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054572|Evaluating CVD Medication Adherence Program in Low SES|Evaluating CVD Medication Adherence Program in Low SES|CVDMAT|Duke University|No|Active, not recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|21 Years|85 Years|No|||January 2016|February 24, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02375737||26465|
NCT02370368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP213-13-14|Comparison of a Videogame Based Dance Training Intervention With Agility Ladder Drills on Agility of Club Volleyball Players at UWI|A Comparison of a Dance Programme Delivered With the XBOX Kinect With Traditional Agility Ladder Drills on Agility Scores of Club Level Volleyball Players of the University of the West Indies, Mona||The University of The West Indies|Yes|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|40 Years|No|||February 2015|February 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370368||26877|
NCT02276014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-18-BETASNP2|Effect of SNPs in the BCMO1 Enzyme|Effect of SNPs in the Beta-carotene 15, 15'-Monooxygenase (BCMO1) Enzyme on Retinol Formation and Beta-carotene Plasma Responses|BETASNP2|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|April 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|85|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276014||34111|
NCT02276040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-14-13E-9084|Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty|Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty||OrthoCarolina Research Institute, Inc.|No|Active, not recruiting|October 2014|June 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting for total knee replacement|October 2015|November 11, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276040||34109|
NCT02262026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZD0530|The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism|A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism||Yale University|Yes|Recruiting|November 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262026||35186|
NCT02262247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLX-ENT-PMK-OUS-001|A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures|A Multicenter OUS Post-Market Clinical Follow-Up of the Medrobotics Flex® Robotic System Used for Accessing and Visualizing the Oropharynx, Hypopharynx, and Larynx During Transoral Procedures||Medrobotics Corporation|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects ≥ 22 years of age requiring transoral procedures|March 2016|March 14, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02262247||35169|
NCT02364921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/01975|Effectiveness of Double-layer Compression Therapy in the Healing of Chronic Venous Ulcers in Primary Health Care|Effectiveness of Double-layer Compression Therapy in the Healing of Chronic Venous Ulcers in Primary Health Care. Randomized Clinical Trial||Gerencia de Atención Primaria, Madrid|No|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364921||27291|
NCT02366598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:115|A FINEH Protein Trial - Part 1|Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 1 - Acute Effects of Hemp Protein on Blood Glucose, Appetite, Blood Pressure and Food Intake.||University of Manitoba|No|Active, not recruiting|May 2015|May 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|January 26, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02366598||27163|
NCT02366832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078008|Cryoablation for Phantom Limb Pain|Percutaneous Image Guided Cryoablation for the Treatment of Refractory Phantom Limb Pain||Emory University|No|Active, not recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|March 14, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02366832||27145|
NCT02376127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-203|Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion|Evaluation of Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion||Memorial Sloan Kettering Cancer Center||Recruiting|February 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Research subjects will be identified by a member of the patient's treatment team, the        protocol investigator, or research team at Memorial Sloan-Kettering Cancer Center (MSKCC).|February 2016|February 8, 2016|February 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376127||26435|
NCT02362685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RANNOU|Metabolic Exercise Testing|Exercise Testing in Metabolic Myopathies|RANNOU|University Hospital, Brest|No|Recruiting|September 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood sample Urine sample Muscle tissue DNA|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects referred to perform a metabolic exercise testing.|October 2015|October 1, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02362685||27462|
NCT02368132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-080|Delivery Models of Caregiver Support and Education|Comparative Effectiveness of Delivery Methods for Caregiver Support and Education||VA Office of Research and Development|No|Active, not recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|405|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02368132||27047|
NCT02376153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS004-H-35894|Air Barrier System for the Prevention of Prosthesis-related Infections|Air Barrier System for the Prevention of Prosthesis-related Infections||Nimbic Systems, LLC|Yes|Recruiting|April 2015|June 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|816|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376153||26433|
NCT02376166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0472|Metformin for Rising PSA Remote Trial|M-RePoRT: Metformin - Rising PSA Remote Trial|M-RePoRT|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Male|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|February 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376166||26432|
NCT02368353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14-P008|"Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial"|Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial|START|Centre Hospitalier St Anne|No|Recruiting|February 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|25 Years|No|||September 2015|September 2, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02368353||27030|
NCT02364947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339-14-001|A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)|||Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|December 2014|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|660|||Both|20 Years|N/A|No|||October 2015|October 16, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364947||27289|
NCT02365168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/757(REK)|Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish|Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish|TRO-FAST|University Hospital of North Norway|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|44|||Both|5 Years|20 Years|No|||December 2015|December 14, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02365168||27272|
NCT02360358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIS2012|Autologous Skin Substitute for Chronic Leg/Foot Ulcers.|A Phase II Randomized Multicenter Study on Efficacy and Safety of Cultured Autologous Skin (Tiscover®) and Acellular Dermal Matrix (AS210) in Chronic (Arterio-)Venous Ulcers||VU University Medical Center|No|Terminated|August 2012|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 29, 2015||No|slow inclusion|No||https://clinicaltrials.gov/show/NCT02360358||27641|
NCT02360371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA035246-01A1|Individual Differences in Drug Response|Individual Differences in Drug Response||Johns Hopkins University|Yes|Recruiting|April 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02360371||27640|
NCT02370732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA022336|Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery|Alcohol Related Impairment and Reinforcement After Gastric Bypass Surgery||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Recruiting|February 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02370732||26849|
NCT02365818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOND 2 version 3.5|Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure|AN OPEN LABEL, SINGLE ARM, PHASE III, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CARCINOMA WHO HAVE FAILED BCG THERAPY AND REFUSED CYSTECTOMY|BOND2|Cold Genesys, Inc.|Yes|Recruiting|May 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365818||27222|
NCT02366078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005976|Stress Management Training for School Staff|The Efficacy of Using Blended Learning With the Stress Management and Resilience Training (SMART) Program to Decrease Stress and Enhance Resilience in Public School Staff||Mayo Clinic|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02366078||27202|
NCT02366364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX1074-C-102|Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Multiple Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers|NRX-1074|Naurex, Inc|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02366364||27181|
NCT02371018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14385|Acute Effects of Nutrition Supplementation on Treatment Efficiency and Hemodynamics During Dialysis|Acute Effects of Nutrition Supplementation on Treatment Efficiency and Hemodynamics During Dialysis||University of Illinois at Urbana-Champaign|No|Recruiting|February 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|20|||Both|18 Years|90 Years|No|||December 2015|December 1, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02371018||26827|
NCT02370212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15--00205|Interval Training Plus Creatine Effects on Performance and Glucose Tolerance|Interval Training Plus Creatine Effects on Performance and Glucose Tolerance|Cr + HIIT|University of British Columbia||Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02370212||26889|
NCT02370225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRPPG 3363/2012|Aerobic Exercise in Primary Sjögren's Syndrome|Effects of Aerobic Exercise on Fatigue in Women With Primary Sjögren's Syndrome: Randomized Controlled Trial|AEPSS|Federal University of Espirito Santo|No|Active, not recruiting|March 2015|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|65 Years|No|||February 2016|February 1, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02370225||26888|
NCT02368470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-07-146-001|Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection|Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection||Samsung Medical Center|No|Recruiting|February 2015|October 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|19 Years|70 Years|No|||February 2015|February 22, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368470||27021|
NCT02364193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50327.060.14|Thoracic Fluid Assessment by Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance|Thoracic Fluid Assessment by Dynamic Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance Spectroscopy: An Explorative Study in Healthy Subjects||Catharina Ziekenhuis Eindhoven|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02364193||27347|
NCT02276027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2205|A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer|A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||Novartis|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|85|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02276027||34110|
NCT02266381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(29)2014|A Prospective Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy|A Prospective and Randomized Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy||The First Affiliated Hospital of Guangzhou Medical University|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|70 Years|No|||July 2015|July 25, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266381||34852|
NCT02368860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-13-01|OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma|Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma|OXIRI|National Cancer Centre, Singapore|No|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|21 Years|75 Years|No|||March 2016|March 21, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02368860||26991|
NCT02368873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/2009|the Use of a IPOM Mesh for Prevention of Parastomal Hernia|Prospective, Randomized Study on the Use of a Intraperitoneal Onlay Mesh for Prevention of Parastomal Hernia of Permanent Colostomy||Oulu University Hospital|No|Completed|January 2010|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02368873||26990|
NCT02370992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11/9837|I125 Brachytherapy After TURP|Prospective Multi-centre Study of Low-dose Rate Iodine125 (I-125) Prostate Brachytherapy Performed After Transurethral Resection||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|July 2011|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|40 Years|90 Years|No|Non-Probability Sample|Patients taking part will do so having chosen I125 brachytherapy as their chosen treatment        for prostate cancer and will have previously undergone TURP|February 2015|February 19, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02370992||26829|
NCT02362698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07LQ04|Clinical Research of Electro-acupuncture Combined Psychological Intervention on Internet Addiction Disorder|Clinical Research of Electro-acupuncture Combined Psychological Intervention on Internet Addiction Disorder||Chengdu University of Traditional Chinese Medicine|No|Completed|January 2010|October 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02362698||27461|
NCT02362711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-16-2|Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea|Phase3, Placebo Controlled, Randomized, Double-blinded, Long-Term, NSAID-Add-on, Clinical Trial of NPC-16 for Treatment of Dysmenorrhea||Nobelpharma|No|Not yet recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Female|16 Years|N/A|No|||February 2015|February 12, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362711||27460|
NCT02367079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StudiFM|Diathermy Compared With Sham Diathermy in Doms Management|Diathermy Compared With Sham Diathermy in Doms Management||Studi Fisioterapici di Montagna|Yes|Terminated|April 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|January 21, 2015||No|1 day data collection|No||https://clinicaltrials.gov/show/NCT02367079||27126|
NCT02371382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.H41|Multicentre Prospective Study to Evaluate Long-term Clinical Outcomes of the Sirius Cemented Femoral Stem|Multicentre Prospective Study to Evaluate Long-term Clinical Outcomes of the Sirius Cemented Femoral Stem|Sirius|Biomet, Inc.|No|Recruiting|March 2013|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|minimum age: 18 maximum age: gender: both|September 2015|September 28, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371382||26799|
NCT02363192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH10/9328|Effectiveness of Pharmacist Interventions in Difficult Asthma|The Effectiveness of Pharmacist Interventions in Improving Asthma Control and Quality of Life in Patients With Difficult Asthma||The Leeds Teaching Hospitals NHS Trust|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|65 Years|No|||February 2015|February 12, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363192||27423|
NCT02363205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/427-31|Internet-Delivered Cognitive Behaviour Therapy for Adolescent Depression|Guided Internet-Delivered and Tailored Cognitive Behaviour Therapy for Adolescents With Depression: a Randomized Controlled Trial||Linkoeping University|No|Active, not recruiting|February 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|15 Years|19 Years|No|||March 2016|March 1, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363205||27422|
NCT02363218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ping Wang|Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife|An Open-Label, Multi-Center, Single-Arm Study on Effectiveness and Safety of Stereotactic Body Radiotherapy (SBRT) Treating Hepatocellular Carcinoma Patients With CyberKnife||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|May 2014|December 2016||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|117|||Both|18 Years|N/A|No|||February 2015|December 21, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363218||27421|
NCT02371902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|ESWT vs Cryo-US Therapy in the Treatment of Chronic Lateral Epicondylitis: One Year Follow up Study|Extracorporeal Shock Wave Therapy vs Cryoultrasound Therapy in the Treatment of Chronic Lateral Epicondylitis: One Year Follow up Study||University of Roma La Sapienza|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02371902||26759|
NCT02369848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0232|Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)|Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)||Shockwave Medical, Inc.|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02369848||26916|
NCT02370589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBOV-H-101|Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects|A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M™ Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age||Novavax|No|Active, not recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|13||Actual|230|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370589||26860|
NCT02365181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR092014|A Trial Between the Intra-articular Local Anesthetic Infiltration With Catheter and Interscalene Block With Catheter in Postoperative Analgesia After Shoulder Prosthesis|A Randomized Controlled Non-inferiority Trial Between the Intra-articular Local Anesthetic Infiltration With Catheter and Interscalene Block With Catheter in Postoperative Analgesia After Shoulder Prosthesis|LIA|Hospital Ambroise Paré Paris|No|Recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365181||27271|
NCT02370602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-063_103|An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063|An Open-Label [^11C]T-773 Positron Emission Tomography Study to Determine Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human Volunteers||Takeda|No|Completed|October 2013|March 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|February 18, 2015|No|Yes||No|March 11, 2015|https://clinicaltrials.gov/show/NCT02370602||26859|
NCT02369770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00097289|Sensory-Motor Rehabilitation Post Stroke|Sensory-Motor Rehabilitation Post Stroke||Rehabilitation Institute of Chicago|No|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||February 2015|February 17, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02369770||26922|
NCT02369783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05|Screening for Social Weaknesses and Coordination Course of Cancer Patients|Screening for Social Weaknesses and Coordination Course of Cancer Patients: A New Approach by an Expert System IT|DEFCOCANCERO|Institut de Cancérologie de la Loire|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|71|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02369783||26921|
NCT02370849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150207|Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma|Cisplatin and S-1 With or Without Nimotuzumab for Patients With Previously Untreated Advanced Gastric Adenocarcinoma: a Single-center, Randomised, Open-label, Parallel-group, Controlled Phase 2 Clinical Trial||Chinese Academy of Medical Sciences||Completed|October 2009|February 2015|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02370849||26840|
NCT02371005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6026|Oral Manifestations of Systemic Sclerosis|Oral Manifestations of Systemic Sclerosis: Toward the Identification of New Prognostic Markers||University Hospital, Strasbourg, France|No|Not yet recruiting|June 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02371005||26828|
NCT02371031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502019|FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas|FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas||Washington University School of Medicine|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371031||26826|
NCT02375633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-330SR2_301|Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients|A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients||Daewon Pharmaceutical Co., Ltd.||Completed|April 2014|||November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375633||26473|
NCT02368613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-3102_201|A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients|||Daewon Pharmaceutical Co., Ltd.||Not yet recruiting|October 2015|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|64|||Both|19 Years|N/A|No|||February 2015|February 20, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368613||27010|
NCT02368626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-FR-01|Safety and Efficacy of the EndyMed Pro System Using RF Micro-needles Fractional Skin Remodeling|Evaluation of the Safety and Efficacy of the EndyMed Pro™ System Using Radiofrequency (RF) Micro-needles Fractional Skin Remodeling Handpiece (Intensif) for Wrinkle Reduction and Lifting - a Post Marketing Study||EndyMed|Yes|Not yet recruiting|March 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368626||27009|
NCT02274272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P201404-31|Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients|||GenMont Biotech Incorporation||Recruiting|October 2014|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|25 Years|70 Years|No|||August 2015|August 10, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02274272||34245|
NCT02376101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00521|Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure|Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure||Nationwide Children's Hospital|No|Enrolling by invitation|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|4 Years|8 Years|No|||March 2016|March 11, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376101||26437|
NCT02362152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PICATO-1116|The Real Life Topical Field Treatment of Actinic Keratosis Study|The Real Life Topical Field Treatment of Actinic Keratosis Study. An Observational Study Focusing on Patient Reported Outcomes|RAPID-ACT|LEO Pharma|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1168|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with actinic keratosis planned to receive treatment with ingenol        mebutate, 5-fluorouracil, imiquimod or diclofenac at the discretion of the dermatologist        (and patient).|August 2015|February 23, 2016|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02362152||27503|
NCT02375360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/14|OIT Effect on FAQLQ|Quality of Life in Food Allergic Patients Before, During and After Oral Immunotherapy||Assaf-Harofeh Medical Center||Recruiting|July 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||7|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Children, teenagers and their parents and adults with food allergy|February 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375360||26494|
NCT02367092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14783|Exercise Intervention in Liver Transplant Patients|Exercise Intervention in Liver Transplant Patients||University of California, San Francisco|Yes|Not yet recruiting|February 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02367092||27125|
NCT02374203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MMHIS229|Nutritional Intervention Study in the Critically Ill Ventilated Patient|Clinical Dietitian, Dietetic Service, Mackay Memorial Hospital||Mackay Memorial Hospital|Yes|Enrolling by invitation|December 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|20 Years|N/A|No|||February 2015|February 26, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02374203||26583|
NCT02374255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0082|Improving Goals of Care Discussion in Advanced Cancer Patients|Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|280|||Both|21 Years|N/A|No|||December 2015|December 23, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02374255||26579|
NCT02368223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YouGrabber_Feasibility_2014|Feasibility of the Portable YouGrabber System|Feasibility of a Home-based Interactive System for Upper Limb Therapy (YouGrabber)|YouGrabber|University Children's Hospital, Zurich|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|5 Years|18 Years|No|||July 2015|July 23, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368223||27040|
NCT02374359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTCAR-EP201501|Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke|Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke||Corporacion Parc Tauli|Yes|Active, not recruiting|January 2015|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|210|||Both|N/A|N/A|No|Non-Probability Sample|We review all consecutive patients that were hospitalized from stroke in our hospital        (Neurology department) between January 2010 and September 2013, and who had the diagnosis        of cryptogenic stroke at discharge|February 2015|February 26, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02374359||26571|
NCT02369510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2058|Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?|Does the Addition of Epinephrine Increase the Duration of Intrathecal Hyperbaric Bupivacaine for Repeat Cesarean Section?||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 26, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369510||26942|
NCT02375490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6282-15-2010/3381056-RSFS|Healthy Start to Increase Physical Activity and Improve Healthy Eating in Early Childcare Centres|A Multilevel Intervention to Increase Physical Activity and Improve Healthy Eating Among Young Children (Ages 3-5) Attending Early Childcare Centres: the Healthy Start Study||Université de Sherbrooke|No|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|735|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375490||26484|
NCT02370160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LS093|HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma|HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|12 Years|N/A|No|||January 2016|January 22, 2016|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370160||26893|
NCT02370173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407389306A003|A Method for Enhancing Sleep in PTSD|A Non-Pharmacologic Method for Enhancing Sleep in PTSD||University of Arizona|No|Recruiting|September 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|45 Years|No|||January 2016|January 29, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370173||26892|
NCT02375581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZFH CA15-01|Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer||First People's Hospital of Hangzhou|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|70 Years|85 Years|No|||March 2016|March 18, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375581||26477|
NCT02363673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGoodwin201006636|The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children|The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children||University of Johannesburg|No|Recruiting|February 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363673||27386|
NCT02371343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SamiUlusCH|Fish Oil Supplementation in Women With Gestational Diabetes|Effect of Fish Oil Supplementation in Women With Gestational Diabetes on Insulin Like Growth Factor-1 DNA Methylation in Newborns||Dr. Sami Ulus Children's Hospital|No|Not yet recruiting|March 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371343||26802|
NCT02371356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1650-H|Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health|Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health|PCORIPTD|Kaiser Permanente|No|Enrolling by invitation|May 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|88000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Stage One: Pregnant KPNC members who have been screened as part of KPNC's peripartum        depression screening program        Stage Two: 4 comparison cohorts within each depression type (with or without comorbidity)        and one control cohort (a total of nine cohorts).|March 2016|March 4, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02371356||26801|
NCT02371577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141671|Evaluation of the Immune Restoration Potential Of Lenalidomide|A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency|Revlimid|University of California, San Diego|Yes|Not yet recruiting|February 2016|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371577||26784|
NCT02371590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150342|Lenalidomide and Obinutuzumab for Previously Untreated CLL|A Phase 1/2 Clinical Trial To Evaluate Lenalidomide And Obinutuzumab For The Treatment Of Patients With Not Previously Treated Chronic Lymphocytic Leukemia||University of California, San Diego|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371590||26783|
NCT02261727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGI-Resp-01|Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study|Low Dose Corticosteroids and Theophylline in the Treatment of Chronic Obstructive Pulmonary Disease - the TASCS Study|TASCS|The George Institute|Yes|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2400|||Both|40 Years|80 Years|No|||April 2014|May 14, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261727||35209|
NCT02261740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13946|Program to Overcome Pelvic Pain With Yoga|Program to Overcome Pelvic Pain With Yoga (POPPY) (a.k.a., Development of a Therapeutic Yoga Program for Female Genito-Pelvic Pain)|POPPY|University of California, San Francisco|No|Active, not recruiting|October 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261740||35208|
NCT02262013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20003076|Evaluation of a Family-based Pediatric Obesity Program: TEENS+|Evaluation of a Family-based Pediatric Obesity Program: TEENS+||Virginia Commonwealth University|Yes|Active, not recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262013||35187|
NCT02262039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yale HIC1405013985|Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System|Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System: A Randomized Control Trial||Yale University|No|Completed|August 2014|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|42|||Both|N/A|N/A|No|||March 2016|March 14, 2016|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02262039||35185|
NCT02366351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-107|The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Clinical Trial to Evaluate the Pharmacokinetics/Pharmacodynamics, Efficacy and Safety of SHR3824 as Monotherapy in Chinese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Jiangsu HengRui Medicine Co., Ltd.||Recruiting|February 2015|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|168|||Both|18 Years|75 Years|No|||February 2015|February 18, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02366351||27182|
NCT02363478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laikon 181/21-02-2014|Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)|Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)||Laikon General District Hospital, Athens|Yes|Recruiting|December 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||February 2015|February 13, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02363478||27401|
NCT02371226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT-181-102|Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I|A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)||ArmaGen, Inc|Yes|Recruiting|July 2015|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371226||26811|
NCT02364037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402021|Innovative Model of Patient-Centered ConTraception|Implementation of Patient-Centered Contraception Provision in Community Settings|IMPACCT|Washington University School of Medicine|No|Recruiting|August 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|960|||Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of reproductive age who are at risk for unintended pregnancy.|June 2015|June 24, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02364037||27359|
NCT02371629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2320|A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD|A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease||Novartis|No|Not yet recruiting|June 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|752|||Both|40 Years|N/A|No|||June 2015|June 5, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371629||26780|
NCT02364687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SS/0152|Optimisation and Quantification of Contrast Enhanced Computed Tomography Myocardial Fibrosis Imaging|Optimisation and Quantification of Contrast Enhanced Computed Tomography||University of Edinburgh|No|Active, not recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|40 Years|N/A|No|Non-Probability Sample|Patients who have previously undergone magnetic resonance imaging which showed myocardial        late enhancement.|February 2015|February 10, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364687||27309|
NCT02369588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PortionSize102|Effects of Portion Size of Multiple Items at a Meal on Food Intake of Adults|||Penn State University|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|51|||Female|20 Years|45 Years|No|||February 2015|February 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369588||26936|
NCT02369250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/12/2013-14|Rosuvastatin Gel With 1:1 Mixture of Platelet-rich Fibrin and Bone Graft in Mandibular Degree II Furcation Defects|Rosuvastatin 1.2mg in Situ Gel Combined With 1:1 Mixture of Autologous Platelet-rich Fibrin and Porus- Hydroxyappatite Bone Graft in Surgical Treatment of Mandibular Degree II Furcation Defects: A Randomized Clinical Control Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|November 2013|September 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|26 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02369250||26962|
NCT02369263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMP2013-01|DVT Ultrasound in the Emergency Department|An Observational Study of Emergency Medicine Resident Performed Ultrasonography for DVT.||Emergency Medicine Physicians, Nevada|No|Completed|May 2013|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|288|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients presenting to the Emergency Departmetn suspicious of DVT|February 2015|February 17, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02369263||26961|
NCT02375438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242/14|Nutritional Assessment in Mitochondrial Cytopathy|Nutritional Assessment in Patients Affected by Mitochondrial Cytopathy|NAMITO|University Hospital Inselspital, Berne|Yes|Enrolling by invitation|December 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Whole blood, urine. All samples collected in this study (blood and urinary) will be sent to      a central biobank for long term storage.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patients affected by mitochondrial cytopathy from the outpatient's clinic of the        Department of Neurology of the University Hospital of Bern who fulfill the inclusion        criteria will be asked to participate in the study. All potential participants will be        provided with a patient information sheet and will be given adequate time to consider        participation in the study. Those who will participate will be asked to provide written        informed consent.|February 2015|February 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375438||26488|
NCT02362919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100359|Influenza Vaccination Among the Elderly Individuals|Determinants of Vaccine Response to Influenza Vaccination Among Individuals Over 65 Years of Age - a Population-based Study||Helmholtz Centre for Infection Research|No|Not yet recruiting|February 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Anticipated|50|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362919||27444|
NCT02375516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK6105|Preventing Drug Abuse Among Hispanic Adolescents|Drug Abuse Prevention Programming for Hispanic Adolescents||Columbia University|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|700|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02375516||26482|
NCT02363426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-006|Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation|Randomized Controlled Open-Label Non-Inferiority Trial Comparing Day 5 Embryos Derived From Intravaginal Culture Using the Medical Device INVOcell to Traditional In Vitro Fertilization||Invaron Pharmaceuticals Inc.|No|Completed|January 2013|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02363426||27405|
NCT02368314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-080-2|A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries|International Multicenter Randomized Double-blind Comparative Clinical Trial of Safety and Efficacy of BCD-080 (CJSC BIOCAD, Russia) and Clexan® (Sanofi Aventis France, France) for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries||Biocad|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|116|||Both|18 Years|80 Years|No|||January 2015|February 16, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02368314||27033|
NCT02368327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC305E|Gene Expression Profiles in Muscle After Immunisation|Clinical Study to Generate Exploratory Training Set of Data on the Time Course of Gene Expression Profile at Site of Antigen Deposition Compared With Whole Blood Following IM Injection With Alum or MF59-adjuvanted Protein Subunit Vaccines||University of Surrey||Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|45|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|August 7, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368327||27032|
NCT02360098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 14-8212 BE|Emergence From Anesthesia in Anterior Temporal Lobectomy and Amygdalohippocampectomy Patients|Determinants of the Pattern of Emergence From Anesthesia in Patients Undergoing Anterior Temporal Lobectomy and Amygdalohippocampectomy||University Health Network, Toronto|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Emergence from anesthesia in anterior temporal lobectomy and amygdalohippocampectomy        PATIENTS|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360098||27661|
NCT02364206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-005442-11|Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma|Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma|GLYRad|Centre Jean Perrin|Yes|Active, not recruiting|February 2015|February 2019|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||February 2015|February 10, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02364206||27346|
NCT02266134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH103310-01A1|Standardized Versus Tailored Implementation of Measurement Based Care for Depression|Standardized Versus Tailored Implementation of Measurement Based Care for Depression|iMBC|Indiana University|Yes|Recruiting|June 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|812|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02266134||34871|
NCT02266147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV3-LYM-01|Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma|A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma||Dynavax Technologies Corporation|No|Recruiting|October 2014|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266147||34870|
NCT02366052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUCES_NASH-JGU|Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study|Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)|NucesNASH|Johannes Gutenberg University Mainz|Yes|Recruiting|January 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02366052||27204|
NCT02366065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR00006973|Does Oral Acetaminophen Lower Intraocular Pressure?|Does Oral Acetaminophen Lower Intraocular Pressure?||Johns Hopkins University|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 6, 2015|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02366065||27203|
NCT02370836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIB14142|Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Cancer Patients|Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Patients Who Have Received and Completed Chemotherapy Treatment With Curative Intent. A Pilot Study.||Sidney Kimmel Comprehensive Cancer Center|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|28|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02370836||26841|
NCT02368912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-CL-0001|A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects|A Double Blind, Randomized, Placebo-controlled, Ascending Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1707 in Healthy Young and Elderly Male Subjects and in Healthy Pre-menopausal Female Subjects Including an Open-label Comparison of Pharmacokinetics Under Fasted and Fed Conditions in Healthy Young Male Subjects||Astellas Pharma Inc|No|Completed|June 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|10||Actual|176|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02368912||26987|
NCT02375373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400716 Long Term|Effects of Adding Chickpeas to the American Diet (Long Term Study)|Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation||University of Florida|No|Completed|April 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Fecal|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals directly associated with the University of Florida (faculty, staff, students)        or through the University of Florida's Health Street program.|January 2016|January 22, 2016|February 24, 2015||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02375373||26493|
NCT02369328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01532-45|Multimodal MRI Study of Ischemic Stroke|Multimodal MRI Study of Ischemic Stroke||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2015|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369328||26956|
NCT02374294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPF-614|TCOT Effectiveness in Preventing Wound Infections in Perineal Resections|A Prospective, Randomized, Parallel Study Comparing Transdermal, Continuous Oxygen Therapy (TCOT) to Standard of Care to Assess Postoperative Wound Infection Rate in Perineal Resections||Ogenix Corporation|Yes|Withdrawn|September 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|February 11, 2015|No|Yes|could not come to budget agreement|No||https://clinicaltrials.gov/show/NCT02374294||26576|
NCT02364245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D0941|Evaluation the Feasibility and Effects of Kinect-based Computer Games as UE Training Tool in Cerebral Palsy Children|Design and Evaluation the Feasibility, Effects of Kinect-based Computer Games as Upper Extremity Training Tool in Children With Cerebral Palsy||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||November 2014|February 25, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02364245||27343|
NCT02371837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJA2015|Effects of Pilates in Risk Fall in Older Population|Effects of 6 Week of Pilates in Fall Prevention||University of Jaén|No|Completed|February 2015|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|103|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02371837||26764|
NCT02371850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transdermal Patch CVD 1000|Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers|Determination of Plasma Nicotine Levels After Using Reference and Generic Transdermal Nicotine Patches With and Without Standardized Heat Application in Adult Smokers||University of Maryland|No|Completed|October 2014|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02371850||26763|
NCT02372110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015010023|Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response|Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response||University of Texas at Austin|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02372110||26744|
NCT02362659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1543-00002|Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry|Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI||Icahn School of Medicine at Mount Sinai|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|2500 patients with non-valvular AF undergoing all-comer PCI with stenting at up to 50        Northern American and European hospital centers.|December 2015|December 23, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362659|12 Months|27464|
NCT02368015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49426.091.14|Penetration of Cefazolin Into Hepatic Cysts|An Explorative Study Determining the Hepatic Cyst Penetration of Cefazolin and Factors Affecting Penetration.|PENTAC|Radboud University|No|Completed|December 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02368015||27056|
NCT02363166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400426|Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy|Molecular Epidemiology and Phylodynamic and Phylogeographic Analysis of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Transmission: An Emergency Department Population Sampling Strategy||University of Florida|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|575|Samples With DNA|Genomic DNA (gDNA) will be isolated from pelleted bacteria using the Roche High Pure PCR kit      following the standard protocol for isolation of nucleic acids from bacteria. The quality of      the extracted gDNA will be determined through gel electrophoresis and the quantity through      Nanodrop2000.|Both|1 Month|N/A|No|Non-Probability Sample|Adult and pediatric patients presenting to the UFHealth Shands Emergency Department with        evidence of an acute abscess, or skin/soft tissue infection (SSTI), which can be sampled        for culture and sensitivity testing|March 2016|March 24, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363166||27425|
NCT02368197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB.cr.il|Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas|Prospective Randomized Trial Comparing Drug Eluting Balloon Versus Conventional Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas.||Shaare Zedek Medical Center|No|Recruiting|July 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||July 2015|July 26, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02368197||27042|
NCT02360111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-273|GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant|A Pilot Trial of GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant||Memorial Sloan Kettering Cancer Center||Recruiting|February 2015|||February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02360111||27660|
NCT02363998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-3003-2|Open-Label, Safety Study of Lofexidine|A Phase 3, Open-Label, Safety Study of Lofexidine|NU LEAF|US WorldMeds LLC|Yes|Completed|February 2015|September 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|286|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363998||27362|
NCT02368340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150104|A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis|A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis||Vanderbilt University|Yes|Recruiting|March 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|Samples With DNA|blood, urine, lymphocytes|Both|12 Years|90 Years|No|Non-Probability Sample|Individuals with diagnosis of Hermansky-Pudlak Syndrome|December 2015|December 7, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368340||27031|
NCT02360319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.AOM.2013.005|Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics|A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia|PRELAPSE|Vanguard Research Group|Yes|Recruiting|December 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|35 Years|No|||December 2015|December 7, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360319||27644|
NCT02360332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDDRDRRP09-13|A Collaborative Public/Private Employment Training and Placement Model ASD Transition Age Youth With Autism Spectrum Disorder (ASD)|A Collaborative Public/Private Employment Training and Placement Model for Transition Age Youth With Autism Spectrum Disorder (ASD)|ProjSEARCH1|Virginia Commonwealth University|No|Completed|October 2009|January 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|21 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02360332||27643|
NCT02272049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-5279|Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults|Use of Hyperpolarized 129 Xe MR Lung Imaging in Children and Adults|HPXeMR|Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02272049||34416|
NCT02370706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPIM447X2104C|Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis||Novartis|No|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|92|||Both|18 Years|N/A|No|||December 2015|December 26, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02370706||26851|
NCT02370719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BantII|Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes|Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes Mellitus||University Health Network, Toronto|No|Recruiting|June 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||December 2015|December 21, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370719||26850|
NCT02375347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400716|Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation|Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation||University of Florida|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Fecal|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals directly associated with the University of Florida (faculty, staff, students)        or through the University of Florida's Health Street program.|August 2015|August 19, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375347||26495|
NCT02375451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00012399|Effect of Childhood Radioiodine Therapy on Salivary Function|Effect of Childhood Radioiodine Therapy on Salivary Function||Children's Hospital Boston|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|3 Years|55 Years|No|Non-Probability Sample|Patients who have receive I-131 therapy in childhood for thyroid disease, compared to a        control group of patients who have never receive I-131 therapy|February 2015|February 24, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02375451||26487|
NCT02363712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475_BIOTOK|APOS Therapy for Osteoarthritis of the Knee: a Randomized Controlled Trial BIOTOK|Biomechanical Therapy for Osteoarthritis of the Knee: a Randomized Controlled Trial(BIOTOK)|BIOTOK|University Hospital Inselspital, Berne|No|Recruiting|May 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|N/A|No|||June 2015|June 15, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02363712||27383|
NCT02369081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCRN 4500|Optimum Treatment for Drug-Resistant Hypertension|Optimum Treatment for Drug-Resistant Hypertension|PATHWAY2|University of Cambridge|No|Active, not recruiting|May 2009|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|348|||Both|18 Years|79 Years|No|||July 2015|July 1, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02369081||26974|
NCT02368821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202-14-MMC|From Cytotrophoblast to Syncytiotrophoblast|From Cytotrophoblast to Syncytiotrophoblast - Telomere Length, Aggregate Formation and Senescence in Placenta From Complicated Pregnancies Compare to Placenta From Normal Pregnancies.||Meir Medical Center|Yes|Not yet recruiting|March 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|300|Samples Without DNA|paraffin blocks placenta cell cultures|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|placentas from normal and complicated pregnancy|January 2015|February 22, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368821||26994|
NCT02369016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17322|Phase III Copanlisib in Rituximab-refractory iNHL|A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2|CHRONOS-2|Bayer|Yes|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|189|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369016||26979|
NCT02364466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Giraffe-T|Cohort of Peripheral T Cell Lymphoma|Multicenter Prospective Cohort Study of Peripheral T Cell Lymphoma||Korea Cancer Center Hospital|No|Recruiting|January 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|19 Years|N/A|No|Non-Probability Sample|Peripheral T-cell lymphoma as followings:        Anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma Peripheral T cell        lymphoma-NOS Enteropathy-associated T cell lymphoma Hepatosplenic T-cell lymphoma        Subcutaneous panniculitis-like T-cell lymphoma Primary cutaneous gamma-delta T-cell        lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma|February 2015|February 10, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02364466|2019 Years|27326|
NCT02369341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201959|Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above|A Phase III Study for the Evaluation of the Immunogenicity and Reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above||GlaxoSmithKline||Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|January 21, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369341||26955|
NCT02362113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1364|Glycemic Index/ Load and Mental Disorders|Glycemic Index, Glycemic Load and Common Psychological Disorders||Isfahan University of Medical Sciences|No|Active, not recruiting|December 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|18 Years|75 Years|No|Probability Sample|non-academic staff of Isfahan University of Medical Sciences (IUMS), Isfahan, Iran, who        were working in hospitals, university campus and health centers affiliated with IUMS|February 2015|February 7, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02362113||27506|
NCT02362360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP255|Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy|Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy||Coloplast A/S|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362360||27487|
NCT02362373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0750|Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users|Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users|WESAIL|Columbia University|No|Completed|August 2011|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|18 Years|45 Years|No|||December 2015|December 14, 2015|February 9, 2015|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT02362373||27486|
NCT02367053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP4207-14013|Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator|A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator||Zealand Pharma|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02367053||27128|
NCT02367937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN401614103|PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study|A Phase I, Open-Label Study to Assess the Effects of PRC-4016 (Icosabutate) on the Pharmacokinetics of Midazolam, Omeprazole, Flurbiprofen and Simvastatin in Healthy Male/Female Subjects||Pronova BioPharma|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 13, 2015|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02367937||27062|
NCT02370810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARU-0115|A CBT-based Internet Intervention for Adults With Tinnitus in the United Kingdom|Study Protocol for a CBT-based Internet Intervention for Adults With Tinnitus in the United Kingdom: A Randomise Controlled Trial||Anglia Ruskin University|Yes|Active, not recruiting|October 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02370810||26843|
NCT02368106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00060494|Prospective Patient Registry for Radiation Oncology Techniques and Quality|Patient Registry for Prospective Research on Evolving Radiation Oncology Techniques and Quality||University of Maryland|Yes|Not yet recruiting|February 2016|December 2025|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2016|February 1, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02368106|5 Years|27049|
NCT02371200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-1.5-09.2015|Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients|A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System (System Version 1.5) in Epilepsy Patients||Brain Sentinel|No|Recruiting|April 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|72|||Both|2 Years|N/A|No|||September 2015|September 18, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371200||26813|
NCT02364011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75446|Outcomes Following Total Knee Arthroplasty|Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty||University of Utah|Yes|Enrolling by invitation|November 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|40 Years|N/A|No|Non-Probability Sample|Patients who present to the University of Utah for TKA surgical procedure|February 2016|February 18, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02364011||27361|
NCT02371889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821035|A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers|A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers|TOPG|University of Pennsylvania|Yes|Recruiting|January 2015|January 2020|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||March 2016|March 24, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371889||26760|
NCT02360618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS_1|Metformin and Simvastatin Use in Bladder Cancer|A Window of Opportunity Study to Evaluate the Role of the Combination of Metformin and Simvastatin as a Neoadjuvant Therapy in Invasive Bladder Cancer||London Health Sciences Centre|Yes|Not yet recruiting|June 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|85 Years|No|||March 2015|March 12, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02360618||27621|
NCT02364440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1405/250-001|Safety and Efficacy Evaluation of Ultherapy™ System in Aging Hand|Safety and Efficacy Evaluation of Ultherapy™ System in Aging Hand||Seoul National University Hospital|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|7|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2015|May 7, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364440||27328|
NCT02272387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0223|Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?|Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?||St. Luke's-Roosevelt Hospital Center|No|Recruiting|October 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02272387||34390|
NCT02375308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTubingen|Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression|Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression||University Hospital Tuebingen|Yes|Recruiting|April 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||May 2015|May 7, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375308||26498|
NCT02363231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01157-38|Maximal Inspiratory Pressure at Extubation: Relationship With Mortality|||University Hospital, Rouen|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patient under invasive mechanical ventilation|January 2016|January 8, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363231||27420|
NCT02363244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1413 Pap HPV Project|Pap and HPVDNA Before and After Acetic Acid|A Pilot Study on Comparative Evaluation of Results of Pap Smears and HPV Hybrid Capture 2 Performed on Cervical Samples Before and After Application of Acetic Acid||Tata Memorial Hospital|Yes|Not yet recruiting|March 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|HPV DNA TEST will be collected in stored as per protocol of storage and will be analysed by      hybridisation method in microbiologt Dept of Tata Memorial hospital.|Female|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Married women attending the Preventive Oncology screening clinic in the age group        30 to 60 years for cervical cancer screening.|February 2015|February 9, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363244||27419|
NCT02369094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC1215|A Study on Effects of Acupressure Among the Frail Elderly in the Community Dwellings|A Study on Effects of Acupressure Among the Frail Elderly in the Social Centers for the Elderly and Neighbourhood Elderly Centers of Yan Chai Hospital, Social Services Department (YCHSS)||The University of Hong Kong|Yes|Completed|December 2014|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|65 Years|N/A|No|||December 2015|December 29, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02369094||26973|
NCT02375165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17690|Biomarkers for the Detection of Lymphatic Insufficiency|Biomarkers for the Detection of Lymphatic Insufficiency|Biomarkers|Stanford University|No|Enrolling by invitation|September 2009|December 2025|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|600|Samples With DNA|Serum, plasma, tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who receive their care within Dr. Rockson's clinic in the Stanford Center for        Lymphatic and Venous Disorders may be spoken to about voluntary participation in this        study.|December 2015|December 16, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375165||26509|
NCT02371187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-5529H|Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?|Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?||Colorado State University|No|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371187||26814|
NCT02369575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0367|Identification of Novel Markers of Human Lung Disease|Identification of Novel Markers of Human Lung Disease||Ohio State University|No|Recruiting|February 2015|February 2030|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|lung cells|Both|18 Years|N/A|No|Non-Probability Sample|patients on lung transplant waiting list|February 2015|February 23, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369575||26937|
NCT02369029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17437|BAY1238097, First in Man|An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies||Bayer|No|Terminated|March 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02369029||26978|
NCT02366806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRO035|Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer|Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer||University of California, Davis|No|Recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|100 Years|No|Probability Sample|This study is for women with breast cancer. All patients will be staged according to the        American Joint Committee on Cancer Seventh edition. Primary disease treatment information        including surgical approach and utilization of adjuvant chemotherapy will be evaluated.|November 2015|November 30, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02366806||27147|
NCT02370485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15778|A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children|Relative Bioavailability and the Effect of Food on the Bioavailability of LY2801653 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370485||26868|
NCT02370498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-061|A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)|A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine||Merck Sharp & Dohme Corp.|Yes|Recruiting|May 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370498||26867|
NCT02370667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiomechanicalExerciseProgram|A Biomechanical Exercise Program for Knee OA|Clinical and Tissue Outcomes of a Biomechanical Exercise Program for Knee Osteoarthritis||McMaster University|Yes|Active, not recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|60|||Female|50 Years|N/A|No|||August 2015|August 24, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02370667||26854|
NCT02376010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21429|Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium|Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium||Los Angeles Biomedical Research Institute|No|Recruiting|February 2015|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|84 Years|No|||February 2015|March 2, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376010||26444|
NCT02376023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC Med UC 14-213|Messages For Your Health: A Cancer Screening Prevention Study|Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.||Pontificia Universidad Catolica de Chile|No|Recruiting|December 2015|June 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|25 Years|64 Years|No|||February 2016|February 23, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02376023||26443|
NCT02370953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51895.068.14|VERION Versus Conventional, Manual Ink-marking in Toric IOL Implantation|VERION Versus Conventional, Manual Ink-marking in Toric IOL Implantation||Maastricht University Medical Center|Yes|Completed|May 2015|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||November 2015|March 15, 2016|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370953||26832|
NCT02376062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHCMEnyaya|Improving Knowledge, Awareness, and Practices of Primary Care Providers in Rural Nepal About Mental Illness.|Assessing Impact of Online Educational Modules to Improve Knowledge, Awareness, and Practices of Primary Care Providers in Rural Nepal About Mental Illness||Possible|No|Not yet recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|45|||Both|15 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02376062||26440|
NCT02376075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ikfe-Lina-003|Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria|Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Comparison to Placebo in Patients With Hypertension and Albuminuria||ikfe-CRO GmbH|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|43|||Both|45 Years|80 Years|No|||February 2015|February 25, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376075||26439|
NCT02368210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-0551-306|A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)||Therapeutics, Inc.|No|Active, not recruiting|January 2015|January 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368210||27041|
NCT02365454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP004.00|NEXUS™ Aortic Arch Stent Graft System First In Man Study|Feasibility Clinical Study to Evaluate the Safety and Performance of the NEXUS™ Aortic Arch Stent Graft System||Endospan Ltd.|No|Recruiting|August 2014|August 2021|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|95 Years|No|||February 2015|February 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365454||27250|
NCT02365467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10151194DOC|Valiant Mona LSA Feasibility Study|Valiant Mona LSA Thoracic Stent Graft System Feasibility Study||Medtronic Endovascular|Yes|Recruiting|April 2015|February 2021|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365467||27249|
NCT02365480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00173|Berberine Chloride in Treating Patients With Ulcerative Colitis in Remission|Phase I Trial of Berberine in Subjects With Ulcerative Colitis||National Cancer Institute (NCI)|Yes|Not yet recruiting|March 2016|||May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02365480||27248|
NCT02368483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAI conservative treatment 1|Conservative Treatment in Patients With Symptomatic Femoroacetabular Impingement|The Effectiveness of Neuromuscular Training of the Lower Limb Muscles in Reducing the Hip Symptoms in Patients With Symptomatic Femoroacetabular Impingement: a Prospective Intervention Study||Schulthess Klinik||Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|35 Years|No|||February 2015|February 14, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02368483||27020|
NCT02261753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0688|Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy|A Randomised Controlled Trial to Compare Seizure Remission Outcome Following Resective Surgery With or Without Prior Treatment With Ketogenic Diet in Children With Epilepsy the Result of Focal Cortical Dysplasia Type II|EDIBLE|University College, London|Yes|Not yet recruiting|October 2014|September 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|5 Years|15 Years|No|||October 2014|October 13, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02261753||35207|
NCT02362724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC131202|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||December 3, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362724||27459|
NCT02362737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1403-11098|Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men|||Gramercy Research Group||Recruiting|January 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|440|||Male|30 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02362737||27458|
NCT02362958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-005|A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer|Sun Yat-sen University Cancer Center||Sun Yat-sen University|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|159|||Female|18 Years|65 Years|No|||February 2015|February 12, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02362958||27441|
NCT02368704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUCOSTRESS P 08 11 22|Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes|Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes|GLUCOSTRESS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|blood samples. These samples will be anonymized, frozen and stored in the INSERM UMR-S 872      in the Cordeliers Research Center (Madame Fabienne Foufelle) under the responsibility of      Professor Jean-François Gautier for a maximum period of 15 years, beyond which they will be      destroyed. These samples will be destroyed at any time at the request of the patient. This      DNA storage will be used to study genes related to the secretion of insulin and to identify      other genes involved in the onset of diabetes.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 2 diabetes Healthy volunteers Adults|September 2015|September 24, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02368704||27003|
NCT02370784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010170|Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma|The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis|TAMER|University of Pittsburgh|Yes|Recruiting|February 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370784||26845|
NCT02370797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI-1450-IOERTSFX|Node Negative, Invasive Breast Cancer Single Fraction IOERT|Lumpectomy Followed by Intraoperative Electron Radiation Therapy (IOERT) as a Single Full Dose Partial Breast Irradiation for Early Stage, Node Negative, Invasive Breast Cancer||Avera McKennan Hospital & University Health Center|Yes|Recruiting|February 2015|May 2029|Anticipated|February 2029|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|60 Years|N/A|No|||June 2015|June 17, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370797||26844|
NCT02370940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPAAD Study|Regular Consumption of High Phytate Reduces Inhibitory Effect of Phytate on Iron Absorption|Regular Consumption of High Phytate Diet Reduces Inhibitory Effect of Phytate on Nonheme Iron Absorption in Female Subjects||Iowa State University|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02370940||26833|
NCT02371174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL02T|Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.|An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.||Eisai Inc.|No|Recruiting|September 2014|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|590|||Female|N/A|N/A|No|Non-Probability Sample|HER2-negative subjects who are treated with HALAVEN for the first time.|November 2015|November 5, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02371174||26815|
NCT02361606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009108|An Internet Cognitive-Behavioral Intervention for Youth With Type 1 Diabetes - Participation and Efficacy|An Internet Cognitive-Behavioral Intervention for Youth With Type 1 Diabetes - Participation and Efficacy||Sheba Medical Center|No|Completed|March 2009|January 2013|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|89|||Both|13 Years|20 Years|No|||February 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361606||27545|
NCT02366299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-P-SIRS-220115|Comparison of Dexmedetomidine and Propofol on the Delirium and Neuroinflammation in Patients With SIRS.|Comparison of Sedative Effects of Sevoflurane and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Patients With SIRS.||Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy|No|Not yet recruiting|February 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2015|February 11, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02366299||27186|
NCT02371564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P 2013-25|High Flow Oxygen Therapy in Patients Suffering From Chronic Obstructive Pulmonary Disease Exacerbation: Effects and Mechanisms of Action|High Flow Oxygen Therapy in Patients Suffering From Chronic Obstructive Pulmonary Disease Exacerbation: Effects and Mechanisms of Action|Oh BPCO|University Hospital, Angers||Recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371564||26785|
NCT02370381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_16_02_2015|Hemoglobin and INR Out of Nose Blood|Vergleich Zwischen Hb Und INR Aus Nsaenblut Und venösem Blut||University of Zurich|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Nose blood|Both|18 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|Potential candidates with active epistaxis are recruited consecutively at the Polyclinic.|December 2015|December 1, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370381||26876|
NCT02375945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS7NL|Comparison Between a Non-elastic Falcro Device and Current Method After Total Knee Arthroplasty|Prospective, Randomized Controlled Trial Comparing the Effect of a Non-elastic Compression Device Juxta Reduction Kit (Medi ®)" Versus Elastic Class 1 Stockings (BSN Medical® in Patients Undergoing Total Knee Arthroplasty||Nij Smellinghe Hosptial|No|Recruiting|March 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02375945||26449|
NCT02375958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCA062X2101|PCA062 in pCAD-positive Tumors|A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors||Novartis|No|Recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02375958||26448|
NCT02375997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC-UPGI|Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer|Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer||Peking University|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|592|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02375997||26445|
NCT02363179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500083|Music in the Emergency Department (ED): Phase II|Music in Urgent and Emergent Settings (MUES) Trial: Phase Two|MUES|University of Florida|No|Active, not recruiting|May 2015|March 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1107|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02363179||27424|
NCT02376036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGD010-01|Phase 1 Study of MGD010 in Healthy Subjects|A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART®) Bi-specific Antibody-Based Molecule, in Healthy Subjects||MacroGenics|Yes|Recruiting|February 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376036||26442|
NCT02376049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1184|A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis||LEO Pharma|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376049||26441|
NCT02363686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0184|Aspiration in Acute Respiratory Failure Survivors|Aspiration in Acute Respiratory Failure Survivors||University of Colorado, Denver|No|Recruiting|February 2012|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02363686||27385|
NCT02371603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200229|Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers|An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers||GlaxoSmithKline|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|October 22, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02371603||26782|
NCT02371616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202199|Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity|A Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity||GlaxoSmithKline|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371616||26781|
NCT02370407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohnsHopkinsU|Assessment of the Transferability of Skills From Robotic to Laparoscopic Simulation Platforms|Assessment of the Transferability of Skills From Robotic to Laparoscopic Simulation Platforms in Surgical Skill Naive Participants||Johns Hopkins University|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02370407||26874|
NCT02370550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-M03|Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome|Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial|CTRIPS|Peking University People's Hospital|Yes|Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||February 2015|February 18, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370550||26863|
NCT02376621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN00714102|Bioavailability of Omega-3 Food Supplements in Healthy Subjects|Nutrition Products - An Open-Label, Randomised, Single-Dose Study to Evaluate the Bioavailability of Omega-3 Based Dietary Supplements Under Fasting Conditions in Healthy Male and Female Subjects||Pronova BioPharma|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|24|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02376621||26397|
NCT02266693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057/2012|Transdiagnostic iCBT for Depression and Anxiety|Efficacy of Transdiagnostic Internet-based CBT for Early Illness Unipolar Depression and Anxiety||Centre for Addiction and Mental Health|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|29 Years|No|||December 2015|December 21, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02266693||34828|
NCT02272062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055866|Patient-Reported Preferences Affecting Revascularization Decisions|Patient-Reported Preferences Affecting Revascularization Decisions|PREPARED|Duke University|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272062||34415|
NCT02368509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.871|Sensory Approach of Food Modifications Led by Chemotherapy|Sensory Approach of Food Modifications Led by Chemotherapy||Hospices Civils de Lyon|No|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02368509||27018|
NCT02368691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200901|Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)|A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)||GTx|Yes|Recruiting|June 2015|November 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368691||27004|
NCT02375412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KARIM-2|Preoperative Measurement of Heart Rate Variability as a Predictor of Postoperative Outcome|Preoperative Evaluation of Autonomic Nervous System by Heart Rate Variability as a Predictor of Postoperative Outcome in the Patient Undergoing Major Elective Abdominal Surgery||University Hospital Ostrava|No|Recruiting|February 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|21 Years|90 Years|No|Non-Probability Sample|Patients undergoing elective major abdominal surgery.|December 2015|December 3, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375412||26490|
NCT02361060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIN-SUGAR-2014|Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery|Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial||Hospital Universitario de la Princesa|No|Recruiting|February 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02361060||27587|
NCT02361073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-PC-0813|The Role of Emotional Stress in Patients With Stress-induced Cardiomyopathy|Event-related Potentials in Patients With Takotsubo Cardiomyopathy||University of Magdeburg|Yes|Recruiting|June 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Takotsubo Cardiomyopathy compared with healthy subjects and patients with        ACS.|February 2015|February 10, 2015|January 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02361073|6 Months|27586|
NCT02361359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR012014|Preoperative Catastrophizing Predicts Pain Outcome After Shoulder, Knee and Hip Arthroplasty|Preoperative Catastrophizing Predicts Pain Outcome After Shoulder, Knee and Hip Arthroplasty||Hospital Ambroise Paré Paris|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo joint arthroplasty (shoulder, hip ou knee) for osteoarthritis|November 2015|November 30, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361359||27564|
NCT02361372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC-99-2324-B-005-017-CC1|Kefir on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients|Short-term Effect of Kefir-fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients||Ministry of Science and Technology, Taiwan|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 30, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02361372||27563|
NCT02366312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00254|A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors|A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors|KCOT|The Bluestone Center for Clinical Research|Yes|Recruiting|January 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366312||27185|
NCT02366325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-EPOP2a|Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis|A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||June 2014|February 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366325||27184|
NCT02361853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0086-14-HYMC|The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor|The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Blood sample.|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women from: 34 weeks to 42 weeks|January 2015|February 11, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02361853||27526|
NCT02361866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1107_AD_P3|To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults|Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults||Green Cross Corporation|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|376|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|April 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02361866||27525|
NCT02375919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB 2015-A00215-44|PERC Rule to Exclude Pulmonary Embolism in the Emergency Deparment|The Pulmonary Embolism Rule Out Criteria (PERC) Rule to Exclude the Diagnosis of Pulmonary Embolism in Emergency Low Risk Patients: a Non-inferiority Randomized Controlled Trial|PROPER|Assistance Publique - Hôpitaux de Paris|No|Recruiting|August 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1920|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375919||26451|
NCT02362672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-181-07|Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain|A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain|SUMMIT-07|Nektar Therapeutics|No|Recruiting|February 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|75 Years|No|||September 2015|September 10, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362672||27463|
NCT02362932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8345|The Effect of an Urban Sanitation Intervention on Child Health|A Controlled Before and After Study to Measure the Effect of an Urban Sanitation Intervention on Child Health, in Low-income Neighborhoods of Maputo, Mozambique|MapSan|London School of Hygiene and Tropical Medicine|No|Recruiting|February 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|N/A|48 Months|No|||October 2015|October 12, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02362932||27443|
NCT02367066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6420C00001|A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)|A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX After Administration of Repeated Doses for 3 Days in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02367066||27127|
NCT02363439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8400-404|Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401|An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401||Idera Pharmaceuticals, Inc.|No|Enrolling by invitation|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363439||27404|
NCT02363452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140203|Reverse Transcriptase Inhibitors in AGS|A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)|RTIs in AGS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2015|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Month|17 Years|No|||October 2015|October 5, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02363452||27403|
NCT02368119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062458|Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)|A PHASE IB, DOUBLE-BLIND, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF TWO DIFFERENT DOSAGE LEVELS OF EBOLA CHIMPANZEE ADENOVIRUS VECTOR VACCINE "VRC-EBOADC069-00-VP (cAd3-EBO)" AND THE HETEROLOGOUS PRIME-BOOST CANDIDATE VACCINE REGIMEN OF cAD3-EBO FOLLOWED BY MVA-VECTORED VACCINE IN HEALTHY ADULTS, 18-65 YEARS OF AGE, IN BAMAKO, MALI||University of Maryland|Yes|Active, not recruiting|March 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02368119||27048|
NCT02360345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3941|Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly|A Phase I Trial of ONX-0801 (a Novel α-folate Receptor-mediated Thymidylate Synthase Inhibitor) Exploring Once Weekly and Alternate Week Dosing Regimens in Patients With Solid Tumours|ONX-0801|Royal Marsden NHS Foundation Trust|No|Recruiting|September 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360345||27642|
NCT02376556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1496-GBS-CTIL|The Effect of Eyelid Surgery on Dry Eye - a Prospective Study|The Prevalence of Dry Eye Syndrome Among Patients Who Underwent Upper Eyelids Blepharoplasty With and Without Muller Muscle Resection||Sheba Medical Center|No|Not yet recruiting|March 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are referred for blepharoplasty with or without muller muscle resection in        the oculoplastic clinic in our institution|June 2015|June 14, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376556||26402|
NCT02360878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJBS meal test|The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones|The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|Samples With DNA|whole blood feces|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Obese subjects with or without type 2 diabetes treated with the DJBS will be suitable for        participating in the trial|November 2015|November 12, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02360878||27601|
NCT02272075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scripps-Mobile OCT 1|SmartScope vs Standard Colposcope for the Evaluation of Cervical Dysplasia|Image Comparison of a Mobile Colposcope (SmartScope) vs. a Standard Colposcope for Directing Cervical Biopsies in Women With Abnormal Pap Smears: A Non-inferiority Trial.||Scripps Health|No|Not yet recruiting|November 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|80 Years|No|||October 2014|October 21, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272075||34414|
NCT02272803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-116|Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan|A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan||Bristol-Myers Squibb|No|Recruiting|January 2015|September 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||March 2016|March 18, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272803||34358|
NCT02375386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300827|Feasibility Assessment of Neurophysiological Measurement in Veterans With LBP|CENTRAL MECHANISMS OF BODY BASED INTERVENTION FOR MUSCULOSKELETAL LOW BACK PAIN: Feasibility Assessment of Neurophysiological Measurement in Veterans With Low Back Pain||University of Florida|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|40 Years|No|||March 2016|March 15, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375386||26492|
NCT02360592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endeavor study, a pilot study|Combination Therapy of Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients|Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)||Tongji Hospital|Yes|Recruiting|April 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|No|||February 2015|February 5, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360592||27623|
NCT02360852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4250 PBC Pruritus|IBAT Inhibitor A4250 for Cholestatic Pruritus|An Exploratory, Phase IIa Study to Demonstrate the Safety and Efficacy of A4250 in Patients With Primary Biliary Cirrhosis and Cholestatic Pruritus||Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02360852||27603|
NCT02365129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/01393|Activating Brown Adipose Tissue Through Exercise|Activating Brown Adipose Tissue Through Exercise: Randomized Controlled Trial|ACTIBATE|Universidad de Granada|No|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02365129||27275|
NCT02366013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rcAd001/IAVI R001|Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine|A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults||International AIDS Vaccine Initiative|Yes|Active, not recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366013||27207|
NCT02366026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR103-007|REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study|REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study|RAISE|Immune Response BioPharma, Inc.|Yes|Not yet recruiting|June 2017|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|16 Years|N/A|No|||February 2016|February 22, 2016|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366026||27206|
NCT02370238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0114|A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer|A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)|FRIDA|Dompé Farmaceutici S.p.A|Yes|Recruiting|June 2015|February 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370238||26887|
NCT02370251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5451|Compassionate Use of Omegaven in Children|Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants||University of Oklahoma|Yes|Recruiting|June 2015|April 2021|Anticipated|April 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|18 Years|No|||November 2015|November 17, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370251||26886|
NCT02366572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-3|PERFECT Project - Part 1 - Study 2|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 2||University of Manitoba|No|Active, not recruiting|April 2015|July 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02366572||27165|
NCT02370303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003962|A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System|A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System||Mayo Clinic|No|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Preoperative blood sample, tumor tissue from lung resection, postoperative blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a stage IB or above non-small cell lung cancer or metastatic cancer        undergoing lung surgery at the Mayo Clinic in Rochester, MN.|January 2016|January 8, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370303||26882|
NCT02362386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The FAST Study|Feasibility of Obtaining ADRCs From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System|Feasibility of Obtaining Adipose Derived Regenerative Cells (ADRCs) From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System for Autologous Treatment of Thermal Burn Injury (The FAST Trial)||Cytori Therapeutics|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|Adipose tissue and adipose derived regenerative cells (ADRCs) will be obtained for      microbiological testing and for non-DNA-based cell characterization.|Both|N/A|80 Years|No|Probability Sample|Target population includes patients with a burn injury that requires surgery in which fat        excision of approximately 100 g (or more) is anticipated|March 2016|March 15, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362386||27485|
NCT02366585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERIOC_CTP001|The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets|The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets||PerioC Limited|No|Recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|N/A|No|||October 2015|October 26, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02366585||27164|
NCT02366819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0594|Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer|A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma||University of Chicago|No|Recruiting|December 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02366819||27146|
NCT02370823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSI2014-LAB01|A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment|A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment||Regenerative Sciences, LLC|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Synovial Fluid an QC bone marrow sample may be retained.|Both|35 Years|85 Years|No|Non-Probability Sample|Subjects will have unilateral knee OA as evidenced with physical examination and MRI.        Subjects will be recruited from the physician practice and will be males and females age        35-85.|August 2015|August 14, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02370823||26842|
NCT02370966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KristianstadU|Berry Intake - Effects on Systemic and Oral Inflammation|Berry Intake - Effects on Systemic and Oral Inflammation||Kristianstad University|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02370966||26831|
NCT02368028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272-2012|Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)|Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)||University of Florida|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|131|Samples With DNA|Saliva and Dental Plaque|Both|2 Years|5 Years|No|Probability Sample|The study population will consist of unrelated children aged between 2 and 5 years with        different levels of caries experience.|September 2015|September 14, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02368028||27055|
NCT02371369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-10|PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)|A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath|ENLIVEN|Daiichi Sankyo Inc.|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371369||26800|
NCT02365805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005843-28|Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer|Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuvant Chemotherapy Scheme Customized by Levels of BRCA1 in Women With Primary HER2 Negative Breast Cancer (The BERNAQ Clinical Trial)|BERNAQ|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Active, not recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02365805||27223|
NCT02262611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.428|Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)|Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)||Boehringer Ingelheim||Completed|January 2003|||December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|266|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hypertension recruited at hospitals in Germany specialized in cardiology,        nephrology, diabetology and pneumology|October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262611||35141|
NCT02262897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK1401|The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy||Tongji University|Yes|Recruiting|September 2013|May 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||October 2014|October 7, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02262897||35119|
NCT02370472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38067|Evaluation of a New Training Model for Ultrasound Guided Regional Anesthesia - A Feasibility Study|Evaluation of a New Training Model for Ultrasound Guided Regional Anesthesia - A Feasibility Study||Milton S. Hershey Medical Center|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02370472||26869|
NCT02370654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCCOPD CER21009|Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease|Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease||Laval University|No|Recruiting|March 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Both|N/A|N/A|No|||March 2016|March 24, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02370654||26855|
NCT02364895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375-2013|ColonCancerCheck Mailed Invitations: An Evaluation|ColonCancerCheck Mailed Invitations: An Evaluation||Sunnybrook Health Sciences Centre|No|Completed|November 2013|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|75317|||Both|55 Years|74 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02364895||27293|
NCT02364908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_65|Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus|Prospective Evaluation of Adherence to Antimalarials in Patients With Systemic Lupus and Role of Therapeutic Education|ESSTIM|University Hospital, Lille|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364908||27292|
NCT02369523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74975|Multimodal Pain Management Following Primary TKA|Periarticular Infusion With Liposomal Bupivacaine or a Ropivacaine Cocktail Versus Continuous Femoral Nerve Catheters for Multimodal Pain Management Following Primary TKA: A Randomized Controlled Trial||University of Utah|Yes|Enrolling by invitation|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|375|||Both|40 Years|N/A|No|||February 2016|February 16, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02369523||26941|
NCT02375815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006048|Statin Choice Decision Aid Implementation First Phase|The Statin Choice Implementation Project: Phase 1|SCIP1|Mayo Clinic|No|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|7500|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02375815||26459|
NCT02369796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-448-2001|A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism|An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism||Takeda|Yes|Active, not recruiting|February 2015|February 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|48|||Male|18 Years|60 Years|No|||November 2015|November 9, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369796||26920|
NCT02375854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2900|Outcomes of Neonatal Acute Kidney Injury In Premature Infants|Outcomes of Neonatal Acute Kidney Injury and Prematurity: An Observational Study and Einstein-Montefiore Neonatal Acute Kidney Injury Clinical Registry and Biorepository||Montefiore Medical Center|No|Recruiting|November 2014|December 2022|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood and urine samples|Both|N/A|5 Years|Accepts Healthy Volunteers|Probability Sample|Preterm infants less than 32 weeks' gestational age|September 2015|September 21, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02375854|5 Years|26456|
NCT02375893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01643-44|Bile Acids and Gut Microbiota as Potent Coronary Atheroma Risk Factors: a Prospective Study in Human|The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)|MABAC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|79 Years|No|Non-Probability Sample|Tertiary care center: cardiology unit.|December 2015|December 15, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375893||26453|
NCT02366338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPER|PRescriptiOn PattERns Of Oral Anticoagulants|PRescriptiOn PattERns Of Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Single Center Experience From Turkey (PROPER)|PROPER|Muğla Sıtkı Koçman University|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Non-valvular AF patients|April 2015|April 30, 2015|February 8, 2015||No||No|April 30, 2015|https://clinicaltrials.gov/show/NCT02366338|1 Day|27183|
NCT02370394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0056|Intervention for IPV Perinatal Women|Computer-Based Intervention for Victimized Perinatal Women With Mental Illness (Phase 1)||Women and Infants Hospital of Rhode Island|Yes|Recruiting|March 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370394||26875|
NCT02370537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5881C00006|A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI|A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI|PRECISE|AstraZeneca|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|491|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02370537||26864|
NCT02370680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHP-ASP-102|Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease|Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover|DURATION|New Haven Pharmaceuticals, Inc.|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|February 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370680||26853|
NCT02370693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34|Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis|Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Grant Number: R34HL122558||Northwestern University|Yes|Recruiting|March 2016|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370693||26852|
NCT02376348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH 005-000513|Male Circumcision Against HIV Hukomboa|Increasing Uptake of Voluntary Medical Male Circumcision Among Men Aged 20-34 Years in Njombe & Tabora Regions, Tanzania: A Cluster Randomised Controlled Trial||National Institute for Medical Research, Tanzania|Yes|Recruiting|February 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|10000|||Male|10 Years|50 Years|Accepts Healthy Volunteers|||February 2015|March 2, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376348||26418|
NCT02370979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5973|Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients|Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients|DRONE|University Hospital, Strasbourg, France|No|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|202|||Both|18 Years|80 Years|No|||August 2015|August 6, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02370979||26830|
NCT02371213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISONET-1|Social Networking on Mobile Phone to Improve Maternal and Neonatal Outcomes|Antenatal Care Health Education Intervened by Social Networking on Mobile Phone Compared With Usual Care to Improve Maternal and Neonatal Outcomes: Randomized Controlled Trial|HISONET|Nopparatrajathanee Hospital|No|Enrolling by invitation|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1160|||Female|18 Years|N/A|No|||June 2015|June 7, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371213||26812|
NCT02360124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW11-120|Preventing and Arresting Dental Root Surface Caries in Community-dwelling Older Adults|Randomized Clinical Trial on Preventing and Arresting Dental Root Surface Caries Using Silver Diamine Fluoride Solution in Community-dwelling Older Adults||The University of Hong Kong|No|Recruiting|January 2012|April 2015|Anticipated|April 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|323|||Both|56 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02360124||27659|
NCT02369549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPAC-CKD|Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease|Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease|MPAC-CKD|Lawson Health Research Institute|Yes|Recruiting|September 2015|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|750|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02369549||26939|
NCT02365142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM-PRGF/ART|Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma|Phase I/II. Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma(PRGF)|CMM-PRGF/ART|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|38|||Both|40 Years|80 Years|No|||July 2014|February 17, 2015|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02365142||27274|
NCT02365155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRibera|Training Intervention in Heart Failure and Frail Elderly Population|Effectiveness of an Interdisciplinary Intervention on Frailty Geriatric Patients With Heart Failure.|TIHFEP|Hospital de la Ribera|No|Active, not recruiting|October 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|70 Years|N/A|No|||March 2016|March 7, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02365155||27273|
NCT02361892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPA and ovarian reserve|The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve|The Effect of UPA on Women Ovarian Reserve|UPA_ovAge|University Magna Graecia|Yes|Recruiting|February 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361892||27523|
NCT02361905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPA hypoecoic myomas|Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas|Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas||University Magna Graecia|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361905||27522|
NCT02370563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSPG010114|PET Imaging of Intracranial Cancers With 18F-FSPG|An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers||Piramal Imaging SA|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|February 18, 2016|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370563||26862|
NCT02370576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rambam001|The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology|The Effect of Traumatic Childbirth on the Incidence of Postpartum PTSD, MDD and Anxiety Disorders||Rambam Health Care Campus|Yes|Not yet recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Either healthy women without previous psychiatric background,1-2 days after an        uncomplicated planned Cesarean birth, or healthy women without previous psychiatric        background, 1-2 days after an emergency Cesarean birth.|February 2015|February 24, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02370576|1 Month|26861|
NCT02266992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18166|Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study|Exploring Novel Mechanisms of Vaccine Failure and Induction of Pulmonary Immunity Following Live Attenuated Influenza Vaccination in HIV-infected Individuals: a Pilot Study.|LAIV|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|49 Years|No|||March 2016|March 18, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02266992||34805|
NCT02267252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab.Reprod.Biol.- Odense.01|Effects of Male-specific Antibodies on Sex Ratio|||Odense University Hospital|No|Recruiting|September 2014|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood and ejaculates|Male|25 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Vasectomized men|October 2014|October 14, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02267252||34785|
NCT02360085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB # 14-8164|Does Heart Rate Variablity (HRV) Predict Hypotension in Patients Undergoing Cervical Myelopathy Surgery ?|Does Heart Rate Variablity (HRV) Predict Hypotension on Induction in Patients Undergoing Surgery for Cervical Myelopathy ?||University Health Network, Toronto|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cervical myelopathy presenting for cervical spine surgery at Toronto Western        Hospital.|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360085||27662|
NCT02369276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D1201|Safety Study of Musculoskeletal Ultrasonographic to Assess Disabilities Arm of Head and Neck Cancer Patient|Musculoskeletal Ultrasonographic Assessment for the Soft Tissue Injury of Ipsilateral Shoulder of Head and Neck Cancer Patient Following Selective Neck Dissection||Chang Gung Memorial Hospital|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|head and neck cancer by Never-Sparing Selective Neck dissection, SND, the skin condition        is stable, there is no wound, infection or inflammation metastasis. Exclusion criteria:        (1) in head and neck cancer before surgery and there had been other nerves, bones,        muscles, tendons, resulting in lesions of the shoulder pain disorders or a history of        activity. (2) severe cognitive function can not meet the examiner. (3) age less than 20        years of age or over 65 years of age.|February 2016|February 1, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369276||26960|
NCT02375828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003436-39|Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels|Tolerance and Acceptability of Glibentek in Patients With Neonatale Diabetes Secondary to Mutations in K+-ATP Channels|NEOGLI|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|1 Month|18 Years|No|||November 2015|November 11, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02375828||26458|
NCT02375841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-034|Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers|Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers||Memorial Sloan Kettering Cancer Center||Recruiting|February 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with GBM will be screened in the outpatient clinic at MSKCC.|December 2015|December 9, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02375841||26457|
NCT02361879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPA and hysteroscopy|Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma|Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma||University Magna Graecia|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361879||27524|
NCT02362126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WALL-RESECT|Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"|Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"- A Prospective Multicenter Trial|WALL-RESECT|Kliniken Ludwigsburg-Bietigheim gGmbH|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colorectal lesions which are difficult or impossible to resect with        conventional endoscopic methods|February 2015|February 11, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02362126||27505|
NCT02362139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0463-13-RMC|The Impact of Papaverine on First Stage of Labor|The Impact of Papaverine on First Stage of Labor||Rabin Medical Center|Yes|Not yet recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02362139||27504|
NCT02370511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH15-136|Mitral Implantation of TRAnscatheter vaLves|Mitral Implantation of TRAnscatheter vaLves in Native Mitral Stenosis. The Safety and Feasibility of the SAPIEN XT™ and SAPIEN 3™ Transcatheter Valves in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery|MITRAL|NorthShore University HealthSystem|Yes|Recruiting|February 2015|September 2021|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|22 Years|N/A|No|||December 2015|December 10, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02370511||26866|
NCT02370524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[18F]T807|Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease|Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease||Molecular NeuroImaging|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02370524||26865|
NCT02376231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJEOCRSCH|To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study|A Pilot Single Blinded Randomized Controlled Trial to Evaluate the Utility and Efficacy of Neutral Argon Plasma as a New Technology in Achieving Complete Cytoreduction of Advanced Epithelial Ovarian Carcinoma- Initial Feasibility Study|PJEOC|Royal Surrey County Hospital NHS Foundation Trust|Yes|Recruiting|March 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||February 2015|February 24, 2015|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02376231||26427|
NCT02376257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH102646|Improving Therapeutic Learning in Depression: Proof of Concept|Improving Therapeutic Learning in Depression: Proof of Concept||Boston University|Yes|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|85|||Both|18 Years|65 Years|No|||February 2016|February 27, 2016|July 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376257||26425|
NCT02376309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50679|The Effect of Nandrolone Decanoate and Leucine on Muscle Loss|The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss|Le-Na|Maastricht University Medical Center|Yes|Recruiting|August 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376309||26421|
NCT02364453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-103|The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients|The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients||Danish Headache Center|Yes|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|18|||Both|20 Years|50 Years|No|||February 2015|February 10, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02364453||27327|
NCT02376374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31546|OPV Transmissibility in Communities After Cessation of Routine OPV Immunization|OPV Transmissibility in Communities After Cessation of Routine OPV Immunization||Stanford University|No|Enrolling by invitation|February 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|450|||Both|N/A|59 Months|No|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02376374||26416|
NCT02376387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 41169|Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation|Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation|DHS|Stanford University|No|Enrolling by invitation|March 2015|October 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|65 Years|No|Non-Probability Sample|Brain dead donors for heart transplant|February 2015|February 24, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02376387|5 Years|26415|
NCT02369562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2014/598|A Retrospective Analysis of Failures of Oral Implants|A Retrospective Analysis of Failures/Complications With Oral Implants||Malmö University|No|Enrolling by invitation|September 2014|September 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The population rehabilitated with dental implants at/or referred to prosthetic        rehabilitation at the Avdelning för Oral Protetik at the Folktandvården Specialistklinik        in Malmö.|February 2016|February 29, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02369562||26938|
NCT02376517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200215|Helping All Children be Safe Outdoors With Sun Protection|Helping All Children be Safe Outdoors With Sun Protection||Northwestern University|No|Completed|May 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02376517||26405|
NCT02369835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0042|Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy|A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer||Stanford University|Yes|Recruiting|May 2015|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369835||26917|
NCT02368236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112010-132|Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS)|||University of Texas Southwestern Medical Center|No|Completed|December 2008|||February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|3||Actual|1012|||Both|25 Years|75 Years|No|||January 2015|February 13, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02368236||27039|
NCT02376569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1418|An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle|An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle||PepsiCo Global R&D||Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population >=18 years old|February 2015|February 25, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02376569||26401|
NCT02362412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6949-CL-0023|Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes|Study of FK949E - An Open-label, Two-way Crossover Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes||Astellas Pharma Inc|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|64 Years|No|||February 2016|February 22, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02362412||27483|
NCT02272413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302.5|Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer|A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer||Boehringer Ingelheim||Recruiting|July 2015|March 2019|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 21, 2014||||No||https://clinicaltrials.gov/show/NCT02272413||34388|
NCT02364635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN401614104|Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects||Pronova BioPharma|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02364635||27313|
NCT02375789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3414|Intranasal Cooling for Symptomatic Relief of Migraine|Intranasal Evaporative COOLing for the Symptomatic Relief of Migraine HEADache - A Randomized, Double Blind, Placebo Controlled Study"|COOLHEAD2|Cumbria Partnership NHS Foundation Trust|Yes|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2015|October 8, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02375789||26461|
NCT02361385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11132|PBR28 PET and Inflammatory Arthritis|Pilot Study to Evaluate the Feasibility of [11C]PBR28 PET-CT to Image Inflammation in the Joints of Arthritis Patients||University of Oxford|Yes|Recruiting|April 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|12|Samples With DNA|A single blood sample will be taken for a genotyping test, to ascertain whether or not      individuals are suitable to undergo PET-CT with the PBR28 PET tracer. Further, blood samples      will be taken for serum and RNA, and synovial biopsy will be done.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with known rheumatoid arthritis or psoriatic arthritis, with at least one swollen        joint, with evidence of joint inflammation in the feet and/or ankles (on clinical        examination and/or ultrasound)|December 2015|December 4, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361385||27562|
NCT02361619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T162/2014|Dabigatran in an Interaction Probe Drug Cocktail|An Open-label Crossover Trial Assessing the Value of Dabigatran in a Drug Interaction Cocktail in Healthy Young Volunteers|D-cocktail|Turku University Hospital|No|Recruiting|February 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02361619||27544|
NCT02361632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK|Does Adding Milk to Coffee Change Gastric Volume?|Does Adding Milk to Coffee Change Gastric Volume?||University of Aarhus|No|Completed|August 2013|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|February 16, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02361632||27543|
NCT02366039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006665|Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia|Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia|VLE EMR|Mayo Clinic|No|Enrolling by invitation|September 2014|August 2020|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|subjects undergoing clinically-indicated EMR for BE dysplasia will be invited to        participate|January 2016|January 4, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02366039||27205|
NCT02363699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIDOCAINE X CYTOCINES|Endovenous Lidocaine and Serum Cytokines Concentration|Effect of Endovenous Lidocaine on Analgesia and Serum Cytokines Concentration: Randomized and Double-blind Trial||Universidade Federal de Santa Maria|No|Completed|July 2013|January 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02363699||27384|
NCT02364024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETACC8-BIO1|Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas|Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)|CD3-OncoQuant|Federation Francophone de Cancerologie Digestive|No|Completed|November 2005|||May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|856|Samples With DNA|Tissues: colorectal carcinoma and adjacent non-tumor tissues are collected in formalin fixed      paraffin embedded blocks.|Both|18 Years|74 Years|No|Probability Sample|Adult patient of both gender who have underwent surgical resection of stage III colorectal        carcinoma|March 2015|March 26, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364024||27360|
NCT02364219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/348/14|Impact of Prewarming on Perioperative Body Core Temperature and the Outcomes of Cytoreductive- and Major Open Abdominal Surgery: A Randomised Trial|Impact of Prewarming on Perioperative Body Core Temperature and the Outcomes of Cytoreductive- and Major Open Abdominal Surgery: A Randomised Trial (PREWARM)|PREWARM|Charite University, Berlin, Germany|No|Recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Female|18 Years|N/A|No|||February 2015|February 19, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02364219||27345|
NCT02364232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-3962A3|Effects of Home-based vs. Clinic-based Rehabilitation on Sensorimotor, Cognition, Daily Function, and Participation|Effects of Home-based vs. Clinic-based Rehabilitation on Sensorimotor, Cognition, Daily Function, and Participation: Bilateral Training With and Without Mirror Feedback Program||Chang Gung Memorial Hospital|No|Recruiting|September 2014|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||December 2015|January 31, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02364232||27344|
NCT02368886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU021407I|Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer|Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)||Academic and Community Cancer Research United|Yes|Recruiting|March 2015|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02368886||26989|
NCT02369068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-008|Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain|A Double-Blind, Randomized Study to Compare Onabotulinumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain||William Beaumont Hospitals|No|Recruiting|August 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02369068||26975|
NCT02364674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2014-103_USA|Transplant Optimization Using Functional Imaging|Transplant Optimization Using Functional Imaging|TROFI|FLUIDDA nv|No|Active, not recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364674||27310|
NCT02364934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB014-090-01|Pharmacokinetics and Pharmacodynamics of Rocuronium in Closed－Loop Infusion System|Effect of Different Anesthetics on Pharmacokinetics and Pharmacodynamics of Rocuronium in Closed－Loop Muscle Relaxant Infusion System||Tianjin Medical University General Hospital|No|Not yet recruiting|March 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|240|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|ASA physical status group I and II undergoing elective surgical procedures were studied.        Pateients with neuromuscular and metabolic diseases, morbid obesity or receiving        medication known to influence neuromuscular transmission were excluded from the study.|February 2015|February 24, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02364934||27290|
NCT02376530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101757-1-60725|Price Changes and Nutrient Profiling Among Adult Grocery Shoppers|Price Changes and Nutrient Profiling Among Adult Grocery Shoppers||State University of New York at Buffalo|No|Completed|September 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|788|||Female|19 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Primary household grocery shoppers with at least one child between the ages of 2 and 18.|February 2015|January 14, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02376530||26404|
NCT02361658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB # 14-8014|Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion|Ultrasonographic Assessment of the Optic Nerve Sheath Diameter During Variations in PetCO2 and Controlled Internal Jugular Venous Occlusion: A Volunteer Study||University Health Network, Toronto|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult healthy volunteers|February 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02361658||27541|
NCT02376543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC14-1020 Pancreatic Fiducial|Comparison Study in Pancreatic Fiducial Placement|Comparison Study in Pancreatic Fiducial Placement||Parkview Health|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376543||26403|
NCT02367105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-034-12F|Lifestyle Intervention and Testosterone Replacement in Obese Seniors|Testosterone Replacement to Augment Lifestyle Therapy in Obese Older Veterans|LITROS|VA Office of Research and Development|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Male|65 Years|85 Years|No|||January 2016|January 21, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02367105||27124|
NCT02371915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-176|Interprofessional Care Models Using Videoconferencing for Patients With Inflammatory Arthritis|Addressing Rural and Remote Access Disparities for Patients With Inflammatory Arthritis Through Telehealth/Videoconferencing and Innovative Inter-professional Care Models||University of Saskatchewan|No|Recruiting|June 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02371915||26758|
NCT02362425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150072|Antioxidant Therapy in RYR1-Related Congenital Myopathy|Antioxidant Therapy in RYR1-Related Congenital Myopathy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|N/A|No|||September 2015|September 18, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362425||27482|
NCT02264262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00036916|Noninvasive Measurement of Sympathetic Nerve Activity in Healthy Volunteers|Noninvasive Measurement of Sympathetic Nerve Activity in Healthy Volunteers||Cedars-Sinai Medical Center|No|Recruiting|October 2014|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02264262||35014|
NCT02369042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChristH|KYMA Device: External Measure of Thoracic Fluid and Vital Signs|KYMA Device: External Measure of Thoracic Fluid and Vital Signs|Ease|The Christ Hospital|Yes|Enrolling by invitation|October 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|January 27, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02369042||26977|
NCT02361086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-VT-464-CL-004|A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients With Castration-Resistant Prostate Cancer||Innocrin Pharmaceutical|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|54|||Male|18 Years|N/A|No|||October 2015|October 16, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361086||27585|
NCT02369055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP1174-14|Quality of Life and Rehabilitation Pathway in Northern Norway and Denmark.|Relationship Between Quality of Life and Rehabilitation Pathway One Year Post Stroke in Northern Norway and Denmark. A Mixed Method Study.||University Hospital of North Norway|No|Recruiting|March 2014|August 2018|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with stroke|January 2016|January 8, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02369055|12 Months|26976|
NCT02369536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuromed-Nutrafast-PON2015|Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Clinical Trial on the Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|NUTRAFAST|Neuromed IRCCS|No|Not yet recruiting|May 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369536||26940|
NCT02365779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.875|Optical Biopsy and Fallopian Tube|Dynamic Real-time in Vivo Confocal Laser Endomicroscopy Cellvizio® of the Fallopian Tube During Laparoscopy|FALLOPTIC|Hospices Civils de Lyon|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|40|||Female|18 Years|N/A|No|||September 2015|September 4, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02365779||27225|
NCT02365792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProDEmsTrial|Professional Development in Emergency Medical Services|Efficacy of a Clinical Decision Support System in Prehospital Care: Single Blind, Randomized Clinical Trial.|ProDEms|Katholieke Universiteit Leuven|No|Not yet recruiting|May 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02365792||27224|
NCT02370316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2011-02351347|Biomarkers of Change in BPD After Metacognitive Interpersonal Therapy-standard Approach|Neuroimaging and Clinical Markers of Change in Borderline Personality Disorder After Metacognitive Interpersonal Therapy - Standard Approach|CLIMAMITHE|IRCCS Centro San Giovanni di Dio Fatebenefratelli|No|Not yet recruiting|March 2015|November 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02370316||26881|
NCT02368496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.825|APOSTrophe Study (Parenteral Nutrition and Bone Trophicity) Impact of a Long-term Parenteral Nutrition on Bone Metabolism Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-pQCT) in Children and Young Adults|Parenteral Nutrition and Bone Trophicity||Hospices Civils de Lyon|No|Recruiting|March 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|9 Years|30 Years|No|||October 2015|October 8, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02368496||27019|
NCT02368678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K4gnj9dd|"Study of Halitosis in Patients With Advanced Chronic Periodontitis"|Effect Off Full Mouth Disinfection And Scaling Root Planing Per Quadrant In Halitosis in Patients With Advanced Chronic Periodontitis: Randomized Controlled Clinical Trial|HACP|Federal University of Minas Gerais|No|Completed|April 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|60 Years|No|||February 2015|February 20, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02368678||27005|
NCT02368899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCA-AA020451-R42|Computerized Alcohol Misuse Intervention System for Health Care|Micro-targeted Computerized Alcohol Misuse Intervention System for Health Care|CAMI|Research Circle Associates, LLC|No|Not yet recruiting|April 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02368899||26988|
NCT02376478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK208/2009|On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection|On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection||Medical University of Vienna|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|222|Samples With DNA|Swab samples to detect mucosal HPV DNA using a FDA-approved Assay (Digene Hybrid Capture 2      kit).      Cervical PAP smears were collected by cytobrush. Whole blood to obtain peripheral blood      mononuclear cells and serum|Both|18 Years|80 Years|No|Non-Probability Sample|patients with psoriasis or inflammatory bowel diseases|February 2015|February 25, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376478||26408|
NCT02369315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB-2014-VE-1|Randomized Trial of the Effects of Musical Training on Child Development in the Venezuela Orchestra Program (El Sistema)|Design of a Multi-site Cluster Randomized Trial to Study the Effects of Musical Training on Child Development in the National System of Child and Youth Orchestras in Venezuela (El Sistema)||Inter-American Development Bank|No|Active, not recruiting|February 2012|October 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2914|||Both|6 Years|14 Years|No|||February 2015|February 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369315||26957|
NCT02366611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U036889|Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer|Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Locally Advanced Head and Neck Cancer||University of Michigan|No|Enrolling by invitation|November 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02366611||27162|
NCT02371642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unsponsored|Strain Echo in Acute Heart Failure|The Utility of Strain Echocardiography in the Management of Acute Heart Failure|Strain Echo|Wayne State University||Recruiting|January 2015|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible subjects will be recruited in the emergency department (ED) of Detroit Receiving        Hospital (DRH). The DRH ED has research team coverage 24 hours a day, 7 days a week and        existing research personnel will be specifically trained to assist with subject        identification for this protocol. We will also utilize resident physicians who are on ED        based ultrasound and critical care rotations to help identify potential subjects and        ensure that participants are captured early in their course and prior to initial treatment        for acute HF. The ED will have 2 emergency ultrasound fellows beginning in July 2014 who        will also assist with patient recruitment and performance of bedside echocardiograms for        purposes of the study.|February 2015|February 26, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371642||26779|
NCT02368366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1306-02435|Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI|Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|November 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|14 Years|19 Years|No|||February 2015|February 16, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02368366||27029|
NCT02368379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293113|Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome|Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome||Nationwide Children's Hospital|No|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|2 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 16, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02368379||27028|
NCT02265042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-13|Effect of Electrostimulation on Denervated Muscles in Individuals With Spinal Cord Injury|||Swiss Paraplegic Centre Nottwil|No|Recruiting|January 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265042||34954|
NCT02265926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/00226|Respiratory Consequences of N95-type Mask Usage in Pregnant Healthcare Workers - A Controlled Clinical Study|Respiratory Consequences of N95-type Mask Usage in Pregnant Healthcare Workers - A Controlled Clinical Study||National University Health System, Singapore|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|21 Years|40 Years|No|||October 2014|October 15, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02265926||34887|
NCT02372123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO15/98|The Effect of Connective Tissue Massage in Women With Primary Dysmenorrhoea|||Hacettepe University|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02372123||26743|
NCT02376114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ginkgo and blood flow|Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma|The Effect of Ginkgo Biloba on Ocular Blood Flow in Primary Open-Angle Glaucoma Patients: A Double-Blind Randomized Crossover Trial||Maisonneuve-Rosemont Hospital|No|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|80 Years|No|||February 2015|March 2, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02376114||26436|
NCT02365428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307009388|Evidence-based Websites to Increase Physical Activity for Pregnant Women|Pregnancy and Physical Activity: Text-message Referral to Evidence-based Websites||Arizona State University|No|Active, not recruiting|July 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Actual|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 11, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02365428||27252|
NCT02365441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1013GST|A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)|A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)|ALT GIST|Australasian Gastro-Intestinal Trials Group|Yes|Recruiting|February 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02365441||27251|
NCT02376140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HarvestPlus Agreement #8908|Food Consumption and Iron Status Survey in Two Provinces of Rural Burkina Faso|Food Consumption and Iron Status Survey in Two Provinces of Rural Burkina Faso||Institut de Recherche pour le Developpement|No|Completed|June 2010|February 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|480|Samples Without DNA|Serum|Both|36 Months|59 Months|Accepts Healthy Volunteers|Probability Sample|Children 36-59 months old and their mothers|February 2015|February 25, 2015|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02376140||26434|
NCT02369809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG-03|Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia|Non-Interventional Post Marketing Surveillance Study to Evaluate Safety and Efficacy of Neovasculgen® in Patients With Stage IIA-III Chronic Lower Limb Ischemia (According to Pokrovsky-Fontaine Classification)|NVG-LIGHT|Human Stem Cell Institute, Russia|No|Active, not recruiting|September 2012|July 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|40 Years|N/A|No|Non-Probability Sample|Subjects with diagnosed lower limb ischemia (Fontaine-Pokrovsky Stages IIa-III of chronic        limb ischemia)|February 2015|February 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369809||26919|
NCT02369822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin C, Children, Epilepsy|Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy|Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy||Ain Shams University|Yes|Active, not recruiting|February 2015|March 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|16 Years|No|||February 2015|February 23, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02369822||26918|
NCT02376205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPNI-4|Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery|The Effectiveness of Postoperative Local Retropharyngeal Space Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery||Justin Parker Neurological Institute|No|Active, not recruiting|February 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02376205||26429|
NCT02363465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300201523257|Echographic Measurement of Skin Thickness|Echographic Measurement of Skin Thickness at the Deltoid and Proximal Forearm in Adults||Novosanis NV|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be recruited in the vicinity of the university and its university        hospital of Antwerp, in the period of January 2015 until April 2015.|October 2015|October 5, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02363465||27402|
NCT02360137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-29410A|Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque in Carotids and a Risk of Stroke|Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque and a Risk of Stroke in Patients With the carotId Bifurcation Plaque Study|ANTIQUE|University Hospital Ostrava|No|Recruiting|April 2015|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|413|Samples Without DNA|atherosclerotic plaque|Both|30 Years|90 Years|No|Probability Sample|The project period will take 54 months. Total of 413 patients with atherosclerotic plaques        in the carotid bifurcation and internal carotid artery causing arterial stenosis ≥ 30%        detected by duplex sonography will be included to the study - 152 patients indicated for        carotid endarterectomy according to the currently valid guidelines (American Heart        Association/American Stroke Association [AHA], European Stroke Organisation [ESO]) and 261        patients indicated for conservative treatment. Patients will be screened and enrolled in        sonographic laboratories of the Military University Hospital in Prague and University        Hospital Ostrava.|December 2015|December 3, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02360137||27658|
NCT02376452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALIRI|Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients|Phase II Study of 2-weekly Raltitrexed Plus Irinotecan Regimen (RAILIRI) Versus Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) as Second-line Treatment in Advanced Colorectal Cancer Patients||Fudan University|No|Recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2015|March 2, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02376452||26410|
NCT02376465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI4600-201|A Pilot Evaluation of an Experimental BLI4600 Formulation for Bowel Preparation in Adult Patients Undergoing Colonoscopy|||Braintree Laboratories|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376465||26409|
NCT02376491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0375|Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study|Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study|THETA-DEP|Nantes University Hospital|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02376491||26407|
NCT02376504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21OH010564-01|Modifying the Workplace to Decrease Sedentary Behavior and Improve Health|Modifying the Workplace to Decrease Sedentary Behavior and Improve Health||Northeastern University|No|Recruiting|April 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02376504||26406|
NCT02371395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6619|Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil|Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil||Centers for Disease Control and Prevention|No|Not yet recruiting|February 2015|March 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|7 Years|N/A|No|Non-Probability Sample|Patients with fever who present for malaria diagnosis and regular health posts.|February 2015|February 24, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02371395||26798|
NCT02371408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-202|A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4|A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4||Pharco Pharmaceuticals|No|Active, not recruiting|January 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|300|||Both|18 Years|65 Years|No|||October 2015|December 22, 2015|February 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371408||26797|
NCT02375672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GI14-186|Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer|A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186||Hoosier Cancer Research Network|Yes|Recruiting|April 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375672||26470|
NCT02375724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6560C00001|BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH|A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL STUDY TO ASSESS THE BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH WHEN ADMINISTERED TO PATIENTS WITH COPD|M-34273-46|AstraZeneca|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|301|||Both|40 Years|110 Years|No|||December 2015|December 9, 2015|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375724||26466|
NCT02370277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-14-6|Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer|Changes in Intestinal Microbiota in Association With Chemotherapy Treatment||University of Southern California|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples With DNA|Stool, blood, and urine|Female|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed breast cancer will be recruited from the Norris        Comprehensive Cancer Center and the Los Angeles County + University of Southern California        Medical Center.|July 2015|July 7, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370277||26884|
NCT02370290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4K-13-2|Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer|CT Metrology: Quantitative Imaging Metrics With Advanced Visualization Tools for Cancer Imaging||University of Southern California|Yes|Completed|April 2014|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|No|Non-Probability Sample|Patients' clinical and imaging data from the University of Southern California/Norris        Comprehensive Cancer Center and Keck Hospital.|March 2016|March 1, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02370290||26883|
NCT02372162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e:Med Tuebingen, Protocol #1|Fingerprint Characterization of Advanced HCC|Fingerprint Characterization of Advanced HCC to Optimize Treatment Decisions and Enable an Early Prediction of Therapy Resistance (HCC Multiscale Trial-1)|e:Med-HCC-1|University Hospital Tuebingen|No|Recruiting|July 2015|October 2019|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Biospecimens that will be investigated are tumor tissue and blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients aged ≥ 18, of both genders, with advanced stage hepatocellular carcinoma, for        Group A BCLC class B (intermediate stage, performance status-ECOG 0, multinodular HCC),        for Group B BCLC class B or C (advanced stage, performance status-ECOG 1-2, invasive tumor        pattern (vascular invasion/extra hepatic spread)).        Number: Up to 20 patients to receive therapy with TACE (Group A) and up to 20 patients to        receive Sorafenib as first-line systemic therapy (Group B).|July 2015|July 27, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02372162||26740|
NCT02270541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003463-38|Prehospital Study at the Universitair Ziekenhuis Brussel II|Single-center Clinical Trial Evaluating the Efficacy, Safety, Feasibility, Reliability, and Cost-effectiveness of In-ambulance Telemedicine for Patients With Suspicion of Acute Stroke|PreSSUB II|Universitair Ziekenhuis Brussel|Yes|Active, not recruiting|November 2014|February 2017|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270541||34532|
NCT02270814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410073|Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma|Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)||Washington University School of Medicine|No|Recruiting|February 2015|June 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270814||34511|
NCT02360865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-150 - project 2|Mechanisms of Exercise Intolerance in Chronic Obstructive Pulmonary Disease|Mechanisms of Exercise Intolerance in Chronic Obstructive Pulmonary Disease|COPD|Rigshospitalet, Denmark|No|Recruiting|February 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360865||27602|
NCT02362399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|menoufia ob/gyn 1|Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses|Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses||Al Hayat National Hospital|Yes|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Female|18 Years|45 Years|No|||February 2016|February 2, 2016|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362399||27484|
NCT02369289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-15-TLV|Bone Mineral Density in Israeli Female Vegans and Omnivores|Bone Mineral Density in Israeli Female Vegans and Omnivores||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|240|||Female|30 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|generaly healthy vegan and omnivore females, age 30-45|February 2015|February 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02369289||26959|
NCT02369302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1367001|Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Drug Interaction Between DWC20141 and DWC20142 in Healthy Adult Subjects||Daewoong Pharmaceutical Co. LTD.|No|Completed|January 2015|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02369302||26958|
NCT02362945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0656-14|Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic|Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic||Rabin Medical Center|Yes|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|18 Years|50 Years|No|||September 2015|September 7, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02362945||27442|
NCT02268578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03395|Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy|Efficacy of Transcranial Direct Current Stimulation for Treating Working Memory Dysfunction and Depression For Patients With Temporal Lobe Epilepsy||New York University School of Medicine|Yes|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2015|October 12, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02268578||34683|
NCT02264743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013MM002B|Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy|Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease|OPTIMISE|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|November 2013|November 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02264743||34977|
NCT02265016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBC in CAD|Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease|Regulation and Signaling of RBC-eNOS in Patients With Stable and Unstable Coronary Artery Disease||Heinrich-Heine University, Duesseldorf|No|Recruiting|January 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|300|Samples Without DNA|blood samples|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|3 groups:          -  ACS group (100 Patients)          -  stable CAD group (100 Patients)          -  healthy control group (100 Healthy Volunteers)|October 2015|February 11, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265016||34956|
NCT02270151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-163/C|Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick|Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick|IDEAL-MD|UMC Utrecht|No|Not yet recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|16000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 16, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02270151||34562|
NCT02272608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ordu University|Evaluation of Sleep Apnea Related Inflammation With CRP, ESR and Neutrophil toLymphocyte Ratio|||T.C. ORDU ÜNİVERSİTESİ||Completed|November 2012|August 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|279|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients suffering from sleep apnea and were referred to perform polysomnoraphy        constituted the study groups. There were grouped into 4 according to apnea- hypopnea        scores: control, mild apnea, moderate apnea and severe apnea.|October 2014|October 21, 2014|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02272608||34373|
NCT02272660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-503|Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty|Perioperative Parecoxib Administration for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty-A Randomized, Placebo-controlled Trial||Peking Union Medical College Hospital|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02272660||34369|
NCT02266706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-010|Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)|A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis||Cubist Pharmaceuticals LLC|No|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Both|N/A|17 Years|No|||March 2016|March 18, 2016|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02266706||34827|
NCT02272556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408014461|Investigating the Role of the Polyol Pathway in the Central Nervous System|Investigating the Role of Polyol Pathway in the Central Nervous System||Yale University|No|Recruiting|February 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272556||34377|
NCT02272569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISM01|STARflo European Safety and Efficacy Study|A Prospective, Non-comparative, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the STARflo Glaucoma Implant in Patients With Open Angle Glaucoma||iSTAR Medical||Recruiting|September 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272569||34376|
NCT02286076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040/30|Influence of Laparoscopic Endometrioma Stripping Surgery on Serum Anti-mullerian Hormone Levels|Impact of Laparoscopic Endometrioma Stripping Surgery on Fertility: Pre- Operative and Post- Operative Changes of Serum Anti-mullerian Hormone Levels||Clinical Centre of Serbia|Yes|Recruiting|May 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|The endometrioma specimens that will be obtained from operation will be submitted for      pathology examination|Female|18 Years|42 Years|No|Probability Sample|study group: patients with diagnosed endometrioma(s) in one ovary or in both ovaries, in        reproductive years, otherwise healthy|November 2014|November 6, 2014|November 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02286076||33338|
NCT02272491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0191|Monolithic Zirconia Crowns for Single Implants in the Molar Region: a Multicenter Clinical Trial|Monolithic Zirconia Crowns for Single Implants in the Molar Region: a Multicenter Randomized Controlled Clinical Trial|MonoZrO2crown|University of Zurich|No|Recruiting|October 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02272491||34382|
NCT02258750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULKLSA002|Assessing a Polydextrose Containing Soup on Food Intake, Appetite and Biomarkers of Satiation and Satiety|Experimental Study to Investigate the Effect of a High Fibre, Polydextrose-enriched Tomato Soup on Food Intake, the Experience of Appetite and Biomarkers of Satiation and Satiety||University of Liverpool|No|Terminated|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|42|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|September 25, 2014||No|End of EU funding for the work package under investigation|No||https://clinicaltrials.gov/show/NCT02258750||35438|
NCT02276105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eq5d_val_cts|Investigation of Psychometric Properties of the EuroQoL EQ-5D-5L in Patients With Carpal Tunnel Syndrome|Investigation of Psychometric Properties of the EuroQoL EQ-5D-5L in Patients With Carpal Tunnel Syndrome||Schulthess Klinik|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the Schulthess Klinik (Zurich, Switzerland) with will be asked to        participate on the study.|May 2015|May 20, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02276105||34104|
NCT02259296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZHKI-HDVA-001|Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure|Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure|TACTIC|Shanghai Changzheng Hospital|Yes|Not yet recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2200|||Both|18 Years|65 Years|No|||October 2014|October 7, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02259296||35396|
NCT02259829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.3|Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers|Bioequivalence of 40 mg Telmisartan/5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two-period Crossover Study||Boehringer Ingelheim||Completed|September 2007|||November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259829||35355|
NCT02259842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1258.1|Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 5 - 500 mg). A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Study, Including Re-dosing at 50 mg and 150 mg (Food Effect) and at 100 mg (Two 50 mg Tablets)||Boehringer Ingelheim||Completed|March 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|63|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259842||35354|
NCT02269761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47935A|Chest Ultrasound of ER Patients With Cough or SOB|Prospective Evaluation With Ultrasound of Emergency Department Patients Presenting With Cough or Dyspnea||University of Washington|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269761||34592|
NCT02269930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105HV105|Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers|An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers||Biogen|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269930||34579|
NCT02269943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-NPC-001|Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma|A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent Cc-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma||Celgene Corporation|No|Active, not recruiting|February 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269943||34578|
NCT02272504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WLS 13-6926|A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers|A Randomized Controlled Trial to Determine the Role of Biomarkers in Surveillance for Hepatocellular Carcinoma (HCC)||Wako Life Sciences|No|Recruiting|August 2014|February 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2500|Samples Without DNA|Frozen Serum samples will be retained|Both|18 Years|N/A|No|Probability Sample|Patients who are at risk for the development of HCC as identified by the prior presence of        chronic liver disease and cirrhosis.|June 2015|June 1, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272504||34381|
NCT02272517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15907A|Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study on the Efficacy of Vortioxetine Versus Escitalopram on Cognitive Dysfunction in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder||H. Lundbeck A/S|No|Completed|December 2014|||March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272517||34380|
NCT02261779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM_04_12_TCP_ATRA_AML|Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible|Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible|TCP-AML|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02261779||35205|
NCT02261792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111118|Spontaneous Intracranial Hypotension Treatment "SIHT"|Parallel Randomised Open Blind Evaluation Study of the Efficacy of 20° Trendelenburg Position During 24 Hours After Epidural Blood Patch in the Treatment of Spontaneous Intracranial Hypotension|SIHT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2014|November 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02261792||35204|
NCT02272218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s12-03313|Bariatric Lap Band Surgery as a Treatment for Knee Osteoarthritis|Bariatric Lap Band Surgery as a Treatment for Knee Osteoarthritis||New York University School of Medicine|No|Recruiting|October 2012|September 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|25 Years|N/A|No|||October 2015|October 19, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02272218||34403|
NCT02266394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002799|Hypoxia and Inflammatory Injury in Human Renovascular Hypertension|Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy||Mayo Clinic|Yes|Recruiting|October 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|40 Years|80 Years|No|||October 2015|October 8, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266394||34851|
NCT02272296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPD_INSJ_4|Reliability of Insulin by Jet Injection|Reproducibility of Insulin Action When Administered by Needle-free Jet Injection||Radboud University|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272296||34397|
NCT02272348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9372|Self-management of Type 1 Diabetes Under Functional Insulin Therapy|Evaluation of Self-management of Patients With Type 1 Diabetes After Education to Functional Insulin Therapy|EVAUTODIAB|University Hospital, Montpellier|No|Not yet recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|170|||Both|18 Years|70 Years|No|||October 2014|October 20, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272348||34393|
NCT02259075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTACM2014|Botox Injection in Treatment of Chronic Migraine|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues.||Norwegian University of Science and Technology|Yes|Completed|February 2015|March 2016|Actual|March 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259075||35413|
NCT02272634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YPL-001_YJP-130403|A Phase 2a Study to Assess Safety, Daily Symptoms, Pharmacokinetics (PK), and Biomarkers of YPL-001 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease||Yungjin Pharm. Co., Ltd.||Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|69|||Both|40 Years|80 Years|No|||July 2015|July 14, 2015|October 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272634||34371|
NCT02272426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140203|The Safety and Tolerability of an Aerobic and Resistance Exercise Program With or Without Cognitive Training Post-stroke|The Safety and Tolerability of an Aerobic and Resistance Exercise Program With or Without Cognitive Training Post-stroke||University of Miami|No|Recruiting|November 2014|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02272426||34387|
NCT02272439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDC-ARB-002|Endocrine Disrupting Chemicals: Potential Effects on Male and Female Reproductive Health in Saskatchewan|Endocrine Disrupting Chemicals: Potential Effects on Male and Female Reproductive Health in Saskatchewan.||University of Saskatchewan|No|Completed|March 2012|January 2015|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|118|Samples With DNA|Blood, Follicular Fluid and Seminal Plasma Samples|Both|18 Years|43 Years|Accepts Healthy Volunteers|Probability Sample|Infertile couples with unexplained infertility, male factor infertility and PCOS Healthy        volunteers with history of fertility|December 2015|December 18, 2015|April 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02272439|3 Weeks|34386|
NCT02262520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-028|Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects|Effect of Apixaban on the Pharmacokinetics of Digoxin in Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262520||35148|
NCT02262533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-033|Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects|Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects||Bristol-Myers Squibb|No|Completed|June 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262533||35147|
NCT02262546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.545|Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers|A Double-blind, Randomised, Placebo Controlled Study With Two Sequential Two-way Cross-over Parts to Demonstrate That the Influence of Pramipexole up to 4.5 mg Daily on the QT Interval of the ECG in Healthy Male and Female Volunteers is Comparable With Placebo, With a Positive Control (Two-way Cross-over Moxifloxacin Versus Placebo)||Boehringer Ingelheim||Completed|May 2007|||October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|60|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02262546||35146|
NCT02262559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.414|Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers|Bioequivalence Study of BIBR 277 Tablet (Erythritol Based) Compared With Its Capsule Formation in Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 2002|||August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02262559||35145|
NCT02276066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400795|Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle. Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS||University of Florida|Yes|Recruiting|February 2015|May 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|230|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276066||34107|
NCT02272582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-03|A Study to Evaluate the Use of SOMVC001 (GALA) Vascular Conduit Preservation Solution in Patients Undergoing CABG (STEPS)|A Study to Evaluate the Use of SOMVC001 (GALA) Vascular Conduit Preservation Solution in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|GALA|Montreal Heart Institute|No|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02272582||34375|
NCT02263092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise_tdcs_metaplasticity|Effects of Transcranial Direct Current Stimulation Associated With Physical Exercise: a Metaplasticity Study|Effects of Transcranial Direct Current Stimulation Associated With Physical Exercise: a Metaplasticity Study||Universidade Federal de Pernambuco|Yes|Active, not recruiting|February 2014|July 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|10||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|February 25, 2015|August 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02263092||35104|
NCT02259023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFS2014|Discretionary Food Sources and Stress Perception|Discretionary Food Sources and Stress Perception||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02259023||35417|
NCT02263625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK_03|Regional Differences In Indication for Ventral Hernia Repair|Regional Differences In Indication for Ventral Hernia Repair||University Hospital Koge|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred to Køge Hospital Surg. Department with ventral hernia in December 2014|August 2015|August 13, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02263625||35063|
NCT02263859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT 2014-01|Targeted Hypoglossal Neurostimulation Study #3|ImThera Medical Targeted Hypoglossal Neurostimulation Study #3|THN3|ImThera Medical, Inc.|No|Recruiting|November 2014|May 2021|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|141|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263859||35045|
NCT02264223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLBIO 07-10-14|The Bioavailability of Red Clover Isoflavones|The Effects of Processing and Matrices on Bioavailability of Red Clover Isoflavones in Healthy Women|KLBIO|University of Aarhus|Yes|Active, not recruiting|October 2014|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|16|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264223||35017|
NCT02272192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCaliforniaDavis|Intervention Effects of Intensity and Delivery Style for Toddlers With Autism|Intervention Effects of Intensity and Delivery Style for Toddlers With Autism|TADPOLE|University of California, Davis|Yes|Recruiting|March 2013|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|15 Months|30 Months|No|||December 2015|December 2, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272192||34405|
NCT02272283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110030|Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation|Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non ST Segment Elevation Myocardial Infarction|OCTACS|Odense University Hospital|No|Completed|August 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||October 2014|October 20, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02272283||34398|
NCT02272335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081005|Facilitating Adjustment in Low Income Black Women With Breast Cancer|Facilitating Adjustment in Low Income Black Women With Breast Cancer||University of Miami|No|Completed|December 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|114|||Female|21 Years|N/A|No|||October 2015|October 26, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02272335||34394|
NCT02272400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S07-582|Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation|Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation (PBI)|PBI|New York University School of Medicine|Yes|Active, not recruiting|September 2007|September 2019|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Female|18 Years|65 Years|No|||October 2015|October 5, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272400||34389|
NCT02261506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187-2014|Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT|Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT|BALANCE|Sunnybrook Health Sciences Centre|No|Recruiting|October 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261506||35226|
NCT02261766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHOT001|Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients|Detection of Atrial Fibrillation, -Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients|EHOT|Herlev Hospital|Yes|Completed|August 2012|June 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|65 Years|N/A|No|||June 2015|June 23, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261766||35206|
NCT02272231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F131127001|Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women|Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women||University of Alabama at Birmingham|No|Enrolling by invitation|September 2014|May 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Self-collected vaginal swabs from women participating in this study will be stored for      future research purposes related to the study of the vaginal microbiome.|Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sexually active African American women who have sex with women with normal vaginal flora        at baseline (determined based on 0/4 Amsel criteria and a normal Nugent score of 0-3 with        no Gardnerella vaginalis morphotypes noted on vaginal Gram stain) will be followed        prospectively over a 90 day time period for the development of incident BV.|October 2015|October 2, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272231||34402|
NCT02263118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/FM UFM 0062-13|A Mobile-health Pilot Experiment Targeting Mothers With Newborns in Rural Areas of San Juan Sacatepequez, Guatemala|A Mobile-health Pilot Experiment Targeting Mothers With Newborns in Rural Areas of San Juan Sacatepequez, Guatemala, in the Context of Exclusive Breastfeeding Practices||Universidad Francisco Marroquín||Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|4||Actual|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|October 2, 2014||No||No|May 31, 2015|https://clinicaltrials.gov/show/NCT02263118||35102|Future work could consider a wider time span and inspect complementary instruments to ensure consistency between answers to interviews and behaviour. SMSs in virtual communities could be further analyzed to locate longitudinal changes in knowledge.
NCT02263651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRCK13 - LO / QUISERMAS|Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage|Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage in Prevention of Seroma Formation After Mastectomy for Breast Cancer : a Randomized Controlled Trial|QUISERMAS|University Hospital, Tours|No|Recruiting|October 2014|July 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Female|18 Years|85 Years|No|||January 2016|January 5, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02263651||35061|
NCT02263885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD002|ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease|A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System||InSightec|Yes|Recruiting|April 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|N/A|No|||June 2015|June 24, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263885||35043|
NCT02263898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000616|Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations|Biomarkers of Durable Response With Intermittent Therapy With LGX818 and MEK162 Combined Therapy in Patients With BRAF Mutant Metastatic Melanoma||Jonsson Comprehensive Cancer Center|Yes|Not yet recruiting|January 2016|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263898||35042|
NCT02263911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14612|A Study of Baricitinib in Healthy Japanese Participants|Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects||Eli Lilly and Company|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|16|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02263911||35041|
NCT02259348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFNK1|Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation|CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation||St. Jude Children's Research Hospital|No|Active, not recruiting|October 2014|March 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||October 2015|October 29, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259348||35392|
NCT02262273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816R00004|OSCA - Olaparib Standard of CAre Study|Real-World Treatment Patterns, BRCA Testing Practices, Outcomes, and Health Care Utilization in Platinum-Sensitive Recurrent Serous Ovarian Cancer: A Multi-Country Retrospective Study|OSCA|AstraZeneca|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Female|18 Years|N/A|No|Probability Sample|platinum-sensitive recurrent serous ovarian cancer patients|March 2016|March 24, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02262273||35167|
NCT02262286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9GP-02-10DELK14|MIND (Management of Traumatic Brain Injury Diagnosis)|Study to Procure Human Specimens for Use in the Diagnosis and Management of Traumatic Brain Injury and Other Related Conditions|MIND|Abbott Diagnostics Division|No|Recruiting|September 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|Samples Without DNA|Plasma and serum samples stored at -70C or colder|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals presenting to the ED within 6 hours of experiencing a head trauma, or bone        fractions only.|December 2015|December 29, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02262286||35166|
NCT02267486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAD1402|Exploratory Study for the Validity of QuQu Scale|Exploratory Study for the Validity of a Novel Dementia Rating Scale (QUick QUestion Scale) for Alzheimer's Disease Dementia|QuQu|Translational Research Informatics Center, Kobe, Hyogo, Japan||Recruiting|October 2014|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Alzheimer Dementia (AD), non-dementia|May 2015|May 15, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267486||34767|
NCT02272595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA12-0381|Rational Therapeutics Based on Matched Tumor and Normal Tissue|A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood (about 2 teaspoons) drawn initially and again about 2-3 weeks after chosen treatment      begins.|Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients from University of Texas MD Anderson Cancer Center in Houston, Texas,        Cancer Institute Gustave Roussy in Villejuif, France, Vall D'Hebron University Hospital in        Barcelona, Spain, and Chaim Sheba Medical Center at Tel Hasomer in Ramat Gan, Israel|November 2015|November 3, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272595||34374|
NCT02263339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10599|Exercise & Brain Health in MS|Aerobic Exercise to Improve Brain Metabolism in MS||Oregon Health and Science University|Yes|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|14|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02263339||35085|
NCT02263612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK_02|Late Mesh Complications After 3258 Incisional Hernia Operations|Late Mesh Complications After 3258 Incisional Hernia Operations||University Hospital Koge|No|Recruiting|January 2007|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3258|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All incisional hernia repairs registered in tha Danish National Hernia Database from        January 1st 2007 to December 31st 2010|October 2014|October 8, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02263612||35064|
NCT02268331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surveillance|Comparison of Active vs. Passive Surveillance to Collect Adverse Events|Comparison of Active vs. Passive Surveillance to Collect Adverse Events After Chiropractic Manual Therapy in the Children||University of Alberta|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268331||34702|
NCT02272205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-14|Evaluation of Conventional Antibiotic Prophylaxis During a Change of Hip or Knee Infected at a Time|Evaluation of the Effect of a Conventional Antibiotic Prophylaxis on the Positivity of Intraoperative Bacteriological Samples During a Change of Hip or Knee Infected at a Time||University Hospital, Strasbourg, France|No|Not yet recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|80 patients operated in service between January 2012 and July 2013 for treatment of an        infection of total hip or knee.|October 2014|October 20, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272205||34404|
NCT02260635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14503|A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia|A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia||Eli Lilly and Company|No|Active, not recruiting|November 2014|April 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|20 Years|N/A|No|||September 2015|September 3, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260635||35293|
NCT02260895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MH-14-0667|Almond Effects on Glucose Intolerance Study|Almond Effects on Glucose Intolerance Study (AEGIS)|AEGIS|Memorial Hermann Health System|No|Enrolling by invitation|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260895||35273|
NCT02261220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00010|A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors|A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors||MedImmune LLC|No|Recruiting|October 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|393|||Both|18 Years|99 Years|No|||March 2016|March 4, 2016|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02261220||35248|
NCT02261233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM U19 AT006057 Project 1|Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach|Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach||Michigan State University|Yes|Recruiting|April 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|72|||Both|21 Years|65 Years|No|||March 2016|March 1, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02261233||35247|
NCT02266186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2012/375-31|Treatment of Severe Fear of Childbirth With CBT, Comparison of ICBT With Traditional Live Therapy|Treatment of Severe Fear of Childbirth With CBT, Comparison of ICBT With Traditional Live Therapy (Victoria)|(Victoria)|Linkoeping University|No|Recruiting|October 2013|March 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Female|18 Years|50 Years|No|||March 2016|March 1, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02266186||34867|
NCT02262312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-402|Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome|Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome||Roskilde County Hospital||Completed|September 2014|||June 2015|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with myelodysplastic syndrome among these include also patients with chronic        myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia        progressed from myelodysplastic syndrome and patients with        myelodysplastic/myeloproliferative neoplasm, unclassifiable.|June 2015|June 8, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02262312||35164|
NCT02262624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.438|Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers|Bioequivalence of 80 mg Telmisartan/12.5 mg HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|February 2005|||February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262624||35140|
NCT02264769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03|Carbetocin at Elective Cesarean Delivery Part 4|Carbetocin at Elective Cesarean Deliveries: A Non-inferiority Study Between 20 and 100 Micrograms - Part 4||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264769||34975|
NCT02258802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102014-CIE|Pilot Psychoeducational Intervention Model to Improve Nutritional Status in Low Resource Settings|A Psychoeducational Intervention Model in Nutrition to Improve Nutritional Status in a Pilot Low Resource Population in the City of Saltillo, Coahuila Mexico.||Universidad de Monterrey|Yes|Active, not recruiting|June 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Female|18 Years|60 Years|No|||October 2014|October 2, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02258802||35434|
NCT02268357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42210.018.13|The Effects of Propranolol on Fear of Tooth or Molar Extraction|Effects of Propranolol on Fear of Dental Extraction: Study Protocol for a Randomized Placebo-controlled Trial.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|October 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02268357||34700|
NCT02268617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0385|Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease|Immediate Effects of Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease||Ohio State University|No|Recruiting|February 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||April 2015|April 20, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268617||34680|
NCT02264275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSBG-UniBasel-Ex-CED-2014-220|Influence of Aerobic Exercise Training (AET) on Inflammatory Bowel Disease (IBD) in Children and Adolescents|The Influence of Aerobic Exercise Training on Disease Symptoms, Cardiovascular Fitness, Depression, Sleep and Quality of Life in Children and Adolescents Suffering From Inflammatory Bowel Disease in Switzerland|Ex-CED|University of Basel|Yes|Recruiting|October 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|7 Years|20 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264275||35013|
NCT02267239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|immersion vs. mouthwash|Methodology Antiseptic Application, Influence on Oral Biofilm.|Methodology of Application and Immediate Effect of the Essential Oils and 0.2% Chlorhexidine on Oral Biofilm: Immersion Versus Mouthwash.||University of Santiago de Compostela|No|Recruiting|October 2014|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|15|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02267239||34786|
NCT02275208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVSIPS0447|A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure|A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure||Medtronic - MITG|No|Active, not recruiting|November 2014|January 2017|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|65 Years|No|Non-Probability Sample|This is a prospective, multi-center, single-arm study. Patients who have elected to        undergo bariatric surgery using the SIPS procedure (according to patient and investigator        assessment and standard of care) will be evaluated for eligibility.|January 2016|January 12, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275208||34173|
NCT02262884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT DD112313|SurgiQuest AirSeal in Robotic Partial Nephrectomy - (TARPAN Study)|A Physician Preference Study of the Use of SurgiQuest AirSeal vs. Conventional Insufflation Systems for the Management of Pneumoperitoneum in Robotic Partial Nephrectomy .|TARPAN|SurgiQuest, Inc.|No|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|189|||Both|18 Years|80 Years|No|||October 2014|May 24, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262884||35120|
NCT02267785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00422|Exercise Targeting Cognitive Impairment in Parkinson's Disease|Exercise Targeting Cognitive Impairment in Parkinson's Disease||University of Southern California|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|30 Years|85 Years|No|||February 2016|February 16, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267785||34744|
NCT02275884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK366112012|Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease|Evaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease|Choc-PD|Technische Universität Dresden|No|Recruiting|June 2013|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|40 Years|N/A|No|||October 2014|October 23, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275884||34121|
NCT02268058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-Petrelli|Use of Ibuprofen and Acetaminophen for Treatment of Acute Headache Post Concussion in Children|The Use of Ibuprofen and Acetaminophen for Acute Headache in the Post Concussive Youth: A Pilot Study.||McMaster Children's Hospital|No|Completed|October 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|80|||Both|8 Years|18 Years|No|||October 2014|October 15, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02268058||34723|
NCT02272153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310M44503|Satiety Effects of the Combination of Egg and Whole Grains|The Effects of the Combination of Egg and Whole Grains on Appetite, Blood Glucose Response and Food Intake||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Actual|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272153||34408|
NCT02260336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNP01RP001|The Effect of Panax Notoginseng Powders on Rheumatic Pain|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02260336||35316|
NCT02260609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osiris Protocol 310|GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds|A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE® for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and/or Bone||Osiris Therapeutics|No|Completed|October 2014|||October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260609||35295|
NCT02260622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130484-01H|Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia|A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia|RIFLE|Ottawa Hospital Research Institute|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260622||35294|
NCT02260648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14501|A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia|A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia||Eli Lilly and Company|No|Active, not recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|147|||Both|20 Years|N/A|No|||September 2015|September 25, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260648||35292|
NCT02265549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiomics SRT 09-2014|Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases|Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases||Maastricht Radiation Oncology|Yes|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with 1 upto 4 brain metastases treated with SRT|February 2016|February 9, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02265549||34915|
NCT02265562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10102014|Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy|Evaluation of the Effect of Rectal Misoprostol on Blood Loss During Abdominal Hysterectomy: A Double Blind Randomized Controlled Trial.||Cairo University|Yes|Recruiting|October 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265562||34914|
NCT02265887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241/2011|The Pan African Pulmonary Hypertension Cohort Study|The Pan African Pulmonary Hypertension Cohort Study|PAPUCO|University of Cape Town|No|Completed|June 2012|June 2015|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|254|||Both|1 Year|N/A|No|Probability Sample|250 patients with pulmonary hypertension (PHT) who reside in sub-Saharan Africa will be        enrolled in the registry|August 2015|August 6, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02265887|6 Months|34890|
NCT02265900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02200|Parkinson's Disease Exercise TMS PET Study|Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits||Pacific Parkinson's Research Centre|No|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||November 2015|November 14, 2015|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02265900||34889|
NCT02265913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-14-008|Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis|||Perrigo Company|No|Recruiting|October 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|2667|||Both|12 Years|N/A|No|||July 2015|July 31, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265913||34888|
NCT02272166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/088/HP|Effects of Propofol on Early Recovery of Hunger After Surgery|Effects of Propofol on Early Recovery of Hunger After Ambulatory Surgery Compared With Sevoflurane|Propo-Faim|University Hospital, Rouen|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|116|||Female|18 Years|45 Years|No|||January 2016|January 22, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02272166||34407|
NCT02262910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401|Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer||Emergent Product Development Seattle LLC|No|Recruiting|January 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Male|N/A|N/A|No|||May 2015|May 11, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262910||35118|
NCT02263378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OASIT-K|A New Supplement in the Prevention of Cervical Carcinoma|Ellagic Acid and Annona Muricata May Prevent Cervical Cancer Through the Activation of Tumor Suppressor Proteins. A Randomized, Controlled Trial.||University of Messina||Not yet recruiting|December 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Female|24 Years|48 Years|No|||October 2014|October 7, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02263378||35082|
NCT02263664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17551|Observational Study of Sublingual Microcirculatory Blood Flow Characteristics in Patients Undergoing Transthoracic Esophagectomy|Observational Study of Sublingual Microcirculatory Blood Flow Characteristics in Patients Undergoing Transthoracic Esophagectomy||University of Virginia|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|75 Years|No|Non-Probability Sample|Race: ANY|June 2015|June 21, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263664||35060|
NCT02259569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0594|Comparison of Peak Airway Pressure and Gastric Insufflation in Pressure-Controlled Ventilation or Volume-Controlled Ventilation With I-Gel in Pediatric Patient|||Yonsei University|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|34|||Both|6 Months|7 Years|No|||April 2015|April 23, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02259569||35375|
NCT02259582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-007|A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer|A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer|DENALI|OncoMed Pharmaceuticals, Inc.|Yes|Recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|201|||Both|21 Years|N/A|No|||February 2016|February 25, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259582||35374|
NCT02266979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEFIIRPDstaff2014|Study to Determine Appropriate Nurse: Patient Ratios in Peritoneal Dialysis Programs|Study to Determine Appropriate Nurse: Patient Ratios in Peritoneal Dialysis Programs||Pontificia Universidade Católica do Rio Grande do Sul|No|Active, not recruiting|June 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Renal nurses, master and PhD nurse experts in peritoneal dialysis to develop a list of        activities to be timed|April 2015|April 27, 2015|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02266979||34806|
NCT02275156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140213|Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab|Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving Hemodialysis||Amgen|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|July 15, 2014|No|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT02275156||34177|
NCT02275169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLBari|FSH Treatment for Non-obstructive Azoospermic Patients|Follicle-stimulating Hormone Treatment for Infertile Male Patients With Non-obstructive Azoospermia: a Multicenter Randomized Clinical Trial||Azienda Sanitaria Locale Bari|Yes|Not yet recruiting|February 2015|November 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|60 Years|No|||January 2015|January 30, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275169||34176|
NCT02258763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP026-14HTM|Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia|Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life||University of Malaya|No|Recruiting|November 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Months|59 Months|No|||December 2015|December 20, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02258763||35437|
NCT02275273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adnexal masses|Adnexal Masses : Correlation Between MRI (Magnetic Resonance Imagery) and Anatomopathology|Adnexal Masses : Correlation Between MRI (Magnetic Resonance Imagery) and Anatomopathology||Brugmann University Hospital|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Female|18 Years|N/A|No|Probability Sample|Women with adnexal masses, with a planned pelvic magnetic resonance imagery and a planned        adnexectomy within the institution, having signed the informed consent form.|May 2015|May 15, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02275273||34168|
NCT02275806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 2014-01|Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC|A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer||Leo W. Jenkins Cancer Center|Yes|Recruiting|October 2014|October 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02275806||34127|
NCT02267798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regionale WP1|Repetitive Arm Training Combined With Functional Electrical Stimulation on Upper Extremity Motor Recovery in Sub-acute Stroke Survivors|The Effects of Repetitive Arm Training Combined With Functional Electrical Stimulation on Upper Extremity Motor Recovery in Sub-acute Stroke Survivors||University Hospital of Ferrara|Yes|Recruiting|September 2013|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|79 Years|No|||February 2016|February 2, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02267798||34743|
NCT02259530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01DG13020_a|Case Series for Traumatized Refugees With Khat Dependence|Sustainable and Adapted Treatment Strategies to Restore Psychological Functioning and Mental Health Among Displaced Somalis: Preparation of a Multicenter Treatment Study (P114/02/2014): Pilot Study 3.||University of Konstanz|No|Active, not recruiting|January 2015|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||November 2015|November 24, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02259530||35378|
NCT02259868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.5|Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects|Randomized Single Dose Multiple Crossover Relative Bioavailability Trial of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects||Boehringer Ingelheim||Completed|June 2005|||September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|88|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259868||35352|
NCT02259881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1192.11|Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers|Investigation of the Effect of 0.9, 2.25 or 4.5 mg of BIBT 986 Over 1 Hour, Followed by 0.2, 0.5 or 1.0 mg/Hour of BIBT 986 for 7 Hours Given as IV Infusion on Tissue Factor Triggered Coagulation in a Randomised, Placebo Controlled, Dose Escalation Design in Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2002|||May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|64|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259881||35351|
NCT02259894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.1|Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers|Safety, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BIRT 2584 XX (5, 30, 100, 200, 350, 500, and 700 mg) as a Solution in PEG 400 Administered to Healthy Male Volunteers. Placebo Controlled and Blinded at Each Dose Level.||Boehringer Ingelheim||Completed|March 2004|||June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|55|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259894||35350|
NCT02259907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.1|Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 to 400 mg) of KUC-7483 Tablets in Healthy Male Volunteers (Double-blind at Each Dose Level, Randomised, Placebo Controlled Study) as Well as Food Effects at 80 mg (Intraindividual Testing in the Same Volunteers)||Boehringer Ingelheim||Completed|May 2003|||February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|50|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259907||35349|
NCT02265029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC/13/68|Evaluation of Spa Therapy in the Treatment of Fibromyalgia|Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study|THERMALGI|Association Francaise pour la Recherche Thermale|Yes|Recruiting|September 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265029||34955|
NCT02265302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.1|Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS (Dose Range: 0.025 mg - 75 mg PSE Solution, 25 mg, 75 mg, 250 mg and 750 mg WIF Tablets) in Healthy Male Volunteers as Well as Food Effects at 75 mg (WIF Tablet)||Boehringer Ingelheim||Completed|June 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|95|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02265302||34934|
NCT02274532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008649|Myoelectric SoftHand Pro to Improve Prosthetic Function for People With Below-elbow Amputations: A Feasibility Study|Myoelectric SoftHand Pro to Improve Prosthetic Function for People With Below-elbow Amputations: A Feasibility Study|SoftHand|Mayo Clinic|No|Enrolling by invitation|March 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274532||34225|
NCT02274571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-039|Raising Insulin Sensitivity in Post Menopause|Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women|RISE|Pennington Biomedical Research Center|No|Recruiting|September 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|8|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274571||34222|
NCT02261519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNR-04|Study to Evaluate Safety & Efficacy of NaBen as Add-on Treatment for Negative Symptoms of Schizophrenia in Adults|Phase IIB/III, Multi-center, Prospective, Randomized, Placebo-controlled, Sequential Parallel Comparison Design Study of the Safety and Efficacy of NaBen (DAAO Inhibitor) as Add-on Treatment for Negative Symptoms of Schizophrenia in Adults||SyneuRx International (Taiwan) Corp|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|55 Years|No|||November 2015|November 16, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261519||35225|
NCT02263365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Loperamide Dehydration|Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies|Prospective Randomized Control Study on Effect of Post Operative Loperamide in Decreasing Readmission for Dehydration in Colorectal Patients After Diverting Ileostomies||Cedars-Sinai Medical Center|No|Recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263365||35083|
NCT02270320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212161RIND|Cognitive Effects of Tai Chi Chuan in Healthy Older Adults and Older Adults|Study of School and Graduate Institute of Physical Therapy College of Medicine in Taiwan||National Taiwan University Hospital|Yes|Completed|January 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|65|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02270320||34549|
NCT02268097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJK-003|Comparison of Two Methods of Patellar Resurfacing in Total Knee Arthroplasty|Comparison of Two Methods of Patellar Resurfacing in Total Knee Arthroplasty.A Prospective, Randomized, Double-blind Study||Peking University Third Hospital|Yes|Recruiting|January 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||March 2015|March 7, 2015|October 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268097||34720|
NCT02264795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-04|Does Intraperitoneal Instillation of Lidocaine at Cesarean Delivery Improve Postoperative Analgesia?|Does Intraperitoneal Instillation of Lidocaine at Cesarean Delivery Improve Postoperative Analgesia? A Randomized, Double-blind, Placebo-controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264795||34973|
NCT02275104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/35|Multimodal Image Processing Software to Guide Cardiac Ablation Therapy||MIGAT|University Hospital, Bordeaux|No|Not yet recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ventricular arrhythmias or persistent atrial fibrillation|October 2014|October 22, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02275104||34181|
NCT02272985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR 48969|Cerebral Blood Flow During Hemodialysis|A [15O]H2O PET-CT Pilot Study Comparing Cerebral Blood Flow Before, During and After Hemodialysis||University Medical Center Groningen|No|Completed|April 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|65 Years|N/A|No|||November 2015|November 30, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02272985||34344|
NCT02263638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000609-10|Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study|Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study|THERA|Rennes University Hospital|No|Recruiting|February 2015|January 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02263638||35062|
NCT02259036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH102666|Using Smartphones to Enhance the Treatment of Childhood Anxiety|Using Smartphones to Enhance the Treatment of Childhood Anxiety|Smart-CAT|University of Pittsburgh|No|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|9 Years|14 Years|No|||January 2016|January 5, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02259036||35416|
NCT02275858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB#105974|Enteroscopy Stiffening Device for Retrograde Balloon Assisted Enteroscopy|A Double Blind, Placebo Controlled, Randomized Cross Over Study of an Enteroscope Stiffening Device to Increase Terminal Ileum Intubation Rate During Retrograde Balloon Assisted Enteroscopy||Lawson Health Research Institute|No|Terminated|March 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|7|||Both|14 Years|N/A|No|||March 2016|March 17, 2016|October 23, 2014||No|The study was stopped due to carry over effect in the cross over study design.|No||https://clinicaltrials.gov/show/NCT02275858||34123|
NCT02264483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-EPO-2013-152|Low-dose CT for Diagnosis of Pneumonia in COPD Exacerbations and Comparison of the Inflammatory Profile.|Assessment of the Degree of Pneumonia Underdiagnosis in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Using Chest Low-dose Computed Tomography (CT) and Comparison of Inflammatory Profile Between the Two Entities||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|September 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Blood samples and sputum (supernatant)|Both|18 Years|85 Years|No|Probability Sample|COPD patients with an exacerbation of their disease and symptoms of respiratory infection,        wich come to visit at outpatient pneumologic clinic.|August 2015|August 28, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02264483||34997|
NCT02264756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPASP2013|Improving Antibiotic Use in Hospitalized Patients With Pneumonia|Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Length of Stay of Immune-competent Adult Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia|CAPASP|Royal Victoria Hospital, Canada|No|Completed|April 2013|April 2015|Actual|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|763|||Both|18 Years|N/A|No|Non-Probability Sample|Adult immune-competent hospital inpatients admitted to a ward at the Royal Victoria        Regional Health Centre, Barrie, Ontario, Canada|August 2015|August 17, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02264756|4 Weeks|34976|
NCT02270879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHBaixoVouga|Multi-formula Optimization of Second Eye Refinement According to Direction of the Prediction Error of the First Eye|Multi-formula Optimization of Second Eye Refinement According to Direction of the Prediction Error of the First Eye||Centro Hospitalar do Baixo Vouga|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|156|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal)        admitted for bilateral consecutive cataract surgery|October 2014|October 18, 2014|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02270879||34506|
NCT02274493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0232|Robotic Harvest of the Latissimus Dorsi (LD) Muscles|Pilot Study of Robotic-Assisted Harvest of the Latissimus Dorsi Muscles||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274493||34228|
NCT02259335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110/2014|Weaning Form Mechanical Ventilation Using Extracorporeal CO2 Removal|A Pilot Study on the Use of Extracorporeal CO2 Removal During the Weaning Process From Mechanical Ventilation|WeanPRO|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|October 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||August 2015|August 19, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02259335||35393|
NCT02260349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308190|Interest of Indocyanine Green in Neoplastic Prostatic Tissue|Interest of Indocyanine Green in the Neoplastic Prostatic Tissue Characterization and the Peroperative Surgical Margins Detection During a Radical Prostatectomy.||Centre Hospitalier Universitaire de Saint Etienne|No|Withdrawn|April 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|18 Years|N/A|No|||March 2016|March 9, 2016|September 25, 2014||No|Scientific coordinator left the hospital|No||https://clinicaltrials.gov/show/NCT02260349||35315|
NCT02262078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005091|Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction|Acute Effects of Inhaled Sodium Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction||Mayo Clinic|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262078||35182|
NCT02262637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.441|Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)|Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)||Boehringer Ingelheim||Completed|September 2003|||March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|4814|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with hypertension recruited at Cardiologists, Nephrologists, Diabetologists|October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262637||35139|
NCT02274337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avitinib-phaseI|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Advanced Non Small Cell Lung Cancer|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent||Sun Yat-sen University|Yes|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 26, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02274337||34240|
NCT02275988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-104|Drug-Drug Interaction Study in Healthy Adult Volunteers|||Kowa Research Institute, Inc.||Completed|June 2014|||August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275988||34113|
NCT02276001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-103|Drug-Drug Interaction Study in Healthy Adult Volunteers|||Kowa Research Institute, Inc.||Completed|June 2014|||July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276001||34112|
NCT02273648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1401 French Satellite|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite|||Biotronik France|No|Not yet recruiting|November 2014|August 2020|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)|October 2014|October 22, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273648||34293|
NCT02270658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230/08/146|Morbidity in Patients With Hypertension and Obstructive Sleep Apnea|Morbidity in Patients With Hypertension and Obstructive Sleep Apnea|MORPHEOS|University of Sao Paulo General Hospital|Yes|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|64 Years|No|||May 2015|May 27, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270658||34523|
NCT02270671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-49-Fitzgerald|Attention Bias Modification Training for Young People|Attention Bias Modification Training for Socially Anxious Adolescents: A Randomized Control Trial||University College Dublin|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|130|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02270671||34522|
NCT02272855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T14-10682|A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma|A Phase II Study of Combination Treatment With HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients With Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma||Takara Bio Inc.|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272855||34354|
NCT02272868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15262|Fecal Microbial Transplant in Pediatric Crohn's Disease|Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study|FMTCD|Seattle Children's Hospital|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|12 Years|21 Years|No|||November 2015|November 16, 2015|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272868||34353|
NCT02263352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/98/12|A Clinical Trial to Study the Effect of Lycopene in Patients With Gum Disease and type2 Diabetes Mellitus|Systemic Lycopene as an Adjunct to Scaling and Rootplaning in Chronic Periodontitis Patients With Type 2 Diabetes Mellitus|"SLSRPD"|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Completed|January 2013|August 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|50 Years|No|||October 2014|October 8, 2014|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263352||35084|
NCT02268591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00539|Transcranial Stimulation During Sleep to Improve Cognition in Epilepsy|Transcranial Stimulation During Sleep to Improve Cognition in Epilepsy||New York University School of Medicine|Yes|Suspended|October 2014|||October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02268591||34682|
NCT02263872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINDEP001|Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial|Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial||Pakistan Institute of Learning and Living|Yes|Recruiting|October 2014|February 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263872||35044|
NCT02259309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140667|Immune Modulation by Misoprostol|Immune Modulation by Misoprostol||Vanderbilt University|No|Completed|November 2014|November 2015|Actual|July 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259309||35395|
NCT02259322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK098492|Loss of Control Eating Following Weight Loss Surgery|Treatment of Loss of Control Eating Following Bariatric Surgery||Yale University||Recruiting|September 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02259322||35394|
NCT02270359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL124204-01|Research on Infarction With Open Arteries Using OCT and CMR|Research on Infarction With Open Arteries Using OCT and CMR (RIO)|RIO|New York University School of Medicine|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|21 Years|99 Years|No|||December 2015|December 31, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02270359||34546|
NCT02270580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120059H|Komen Breast Cancer Survivor Health Screening Promotion Project: Staying Healthy|Patient Navigation to Improve Quality of Life and Screening Practices Among Latino Breast Cancer Survivors||The University of Texas Health Science Center at San Antonio|Yes|Completed|June 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270580||34529|
NCT02273219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN4901|Trial of AEB071 in Combination With BYL719 in Patients With Melanoma|Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma||Columbia University|Yes|Recruiting|November 2014|December 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273219||34326|
NCT02275728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02605013.9.0000.5327|Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence|Evaluating the Effectiveness of Pelvic Floor Muscle Training With and Without EMG Biofeedback and Quality of Life in Peri and Postmenopausal Women With Stress Urinary Incontinence.||Federal University of Rio Grande do Sul|No|Active, not recruiting|May 2014|November 2014|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|45|||Female|50 Years|65 Years|No|||October 2014|October 24, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275728||34133|
NCT02259920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.2|Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers|Open Label, Randomized, Single-dose, Five-way Crossover Study to Investigate the Regional Drug Absorption of 80 mg KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers.||Boehringer Ingelheim||Completed|December 2003|||May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259920||35348|
NCT02259933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.3|Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of KUC 7483 CL Tablets (Dosage: 40, 120, 180 mg b.i.d.) Over 7 Days in Healthy Male Volunteers||Boehringer Ingelheim||Completed|February 2004|||May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|35|||Male|21 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259933||35347|
NCT02259946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.1|Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (2.5 μg, 5 μg, 10 μg, 20 μg and 40 μg) of BI 1744 CL (Administered With the Respimat®) in Free Dose Combination With Tiotropium Bromide 5 μg ( for Doses up to and Including 20 μg BI 1744 CL), 10 μg (for Doses of 20 μg and 40 μg BI 1744 CL) (Administered With the Respimat®) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259946||35346|
NCT02259959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2 μg/5 μg, 10 μg/5 μg, and 40 μg/10 μg) of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide for 14 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)||Boehringer Ingelheim||Completed|April 2007|||September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|36|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259959||35345|
NCT02260921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0946|Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain|A Muti-Center, Prospective, Double-Blind, Randomized Controlled Study to Evaluate the Effectiveness and Safety of the Iovera° Device for the Temporary Relief of Pain Associated With Knee Osteoarthritis||MyoScience, Inc|No|Recruiting|October 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2015|October 19, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02260921||35271|
NCT02261246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM U19 AT006057 Project 2|Trunk Motor Control Performance Before and After Spinal Manipulation Treatment|Trunk Motor Control Performance Before and After Spinal Manipulation Treatment|TMCSMT|Michigan State University|Yes|Recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|108|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02261246||35246|
NCT02261259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM U19 AT006057 Project 3|Effects of Osteopathic Manipulative Treatment on Neuromuscular Control of the Head-neck System|Effects of Osteopathic Manipulative Treatment on Neuromuscular Control of the Head-neck System||Michigan State University|Yes|Recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|108|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02261259||35245|
NCT02262650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.457|Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects|Relative Bioavailability of Telmisartan and SR26334, the Main Metabolite of Clopidogrel, After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After p.o. Administration of 80 mg Telmisartan and 75 mg Clopidogrel Alone. A Four-way, Single Dose, Open, Randomised Crossover Study in 24 Healthy Male and Female Subjects||Boehringer Ingelheim||Completed|April 2004|||May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|40 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262650||35138|
NCT02265861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingUSMwy|Response of VEGF and AT-II to HCG in PCOS|The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women With Polycystic Ovary Syndrome||Nanjing University School of Medicine|No|Completed|January 2010|December 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|60|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02265861||34892|
NCT02259361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0380-AA-CTIL|Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS|Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study||Sheba Medical Center|No|Not yet recruiting|November 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2014|October 5, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02259361||35391|
NCT02274714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDQ|Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis|Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis||University of Wisconsin, Madison|No|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|249|||Female|18 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Women aged 18-48 years with regular menstrual cycles AND with an established        diagnosis of CD or UC involving the small bowel, colon or both will be eligible for the        study.        Controls: Women aged 18-48 years with regular menstrual cycles and without a diagnosis of        CD will qualify for the study|October 2014|May 26, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02274714||34211|
NCT02274740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIXISL07016|Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients|Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients||Sanofi|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|70 Years|No|||August 2015|August 26, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274740||34209|
NCT02263105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT001|Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas|Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas: A Single-arm Prospective Phase II Clinical Study||Huashan Hospital||Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02263105||35103|
NCT02267811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX8|OrthoPulse™ Product Evaluation and Assessing Clinical Effectiveness|OrthoPulse™ Product Evaluation and Assessing Clinical Effectiveness||Biolux Research Ltd.|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|70 Years|No|||February 2016|February 15, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267811||34742|
NCT02267824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP2|The Effects of Extraoral Photobiomodulation on the Rate of Orthodontic Alignment|The Effects of Extraoral Photobiomodulation on the Rate of Orthodontic Alignment||Biolux Research Ltd.|No|Completed|December 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|11 Years|40 Years|No|||February 2016|February 15, 2016|October 10, 2014|Yes|Yes||No|February 15, 2016|https://clinicaltrials.gov/show/NCT02267824||34741|
NCT02267005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000041466|The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis|The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis||The Hospital for Sick Children|Yes|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|12|||Both|7 Years|18 Years|No|||October 2015|October 20, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02267005||34804|
NCT02269956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055958|Mealtime Symptoms in Dementia|Mealtime Symptoms in Dementia: Adaptive Leadership Approaches||Duke University|Yes|Enrolling by invitation|October 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|132|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02269956||34577|
NCT02267512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-ATG-KTx-12-1|Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients|Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in de Novo Kidney Transplant Patients - a Multicenter, Randomized, Parallel Group Study||Astellas Pharma Inc|No|Completed|July 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|280|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267512||34765|
NCT02264236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203199|Vaccination of Stage IV NSCLC Patients With a Carbohydrate Mimotope Vaccine|Vaccination of Stage IV NSCLC Patients With a Carbohydrate Mimotope Vaccine||University of Arkansas|Yes|Recruiting|October 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264236||35016|
NCT02264249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 14-086|Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation|Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation: A Prospective Observational Study||Cleveland Clinic Florida|No|Active, not recruiting|September 2014|February 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult patients (ages 18 and over) scheduled for elective non-emergency outpatient combined        Esophagogastroduodenoscopy and colonoscopy procedures at Cleveland Clinic Florida.|January 2016|January 26, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02264249||35015|
NCT02272881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-42r|A Randomized, Prospective Clinical Trial of Immediate Flap Closure Versus Wound Care for Management of Late-stage Pressure Ulcers|The Santa Barbara Pressure Ulcer Study Comparison of Immediate Flap Closure Versus Wound Care for Management of Late-stage Pressure Ulcers: a Randomized, Prospective Clinical Trial||Santa Barbara Cottage Hospital|No|Not yet recruiting|November 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02272881||34352|
NCT02272998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14078|Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations|Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2015|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272998||34343|
NCT02275702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV-100|Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients|Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients|APV|Laval University|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275702||34135|
NCT02259049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1056|The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease|The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease||New York Institute of Technology|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|40 Years|84 Years|No|||September 2014|January 19, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259049||35415|
NCT02259062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN13CP462|Listening for Leisure After Stroke|Measuring the Effects of Listening for Leisure on Outcome After Stroke (MELLO)|MELLO|NHS Greater Glasgow and Clyde|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|80 Years|No|||January 2015|January 22, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259062||35414|
NCT02260661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6140C00001|Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multicentre, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|November 2014|May 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|130 Years|No|||March 2016|March 18, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260661||35291|
NCT02260908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT1-22-06-10|OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study|OPTTICH Pilot Study - OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage|OPTTICH|McMaster University|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|16 Years|N/A|No|||April 2015|April 8, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260908||35272|
NCT02261805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1195|A Phase I/II Study of Ganetespib in Combination With Doxorubicin|A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)||Georgetown University|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261805||35203|
NCT02262065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230-12|Risk Factors for Enhanced Inflammation to Arthroplasty Wear Particles: Analysis of Cytokine Production and Polymorphisms|Individual Risk Factors for Enhanced Inflammation to Arthroplasty Wear Particles: Analysis of Cytokine Polymorphisms and in Vitro Cytokine Production to Wear Particles (Ceramic, Metal, XPE)||Ludwig-Maximilians - University of Munich|No|Recruiting|July 2012|July 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|Samples With DNA|blood samples of 20 patients (subgroup analysis)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with arthroplasty:        A) without symptoms B) with aseptic complications|October 2014|October 7, 2014|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02262065||35183|
NCT02270125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-Nanoparticles|Nanoparticles in Nasal Mucosa|The Role of Nanoparticles in Inflammatory Changes of the Nasal Mucosa||University Hospital Ostrava|No|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|35|Samples Without DNA|nasal mucosa of the inferior nasal turbinate obtained by mucotomy in adult pacients nasal      mucosa of the inferior nasal turbinate obtained by mucotomy in stillborn children|Both|19 Years|64 Years|No|Probability Sample|Adult patients with chronic hypertrophic rhinosinusitis, with or without polyposis        Stillborn children|December 2015|December 3, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02270125||34564|
NCT02261181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 52/14|Preemptive Treatment With XONRID to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients|Preemptive Treatment With XONRID a Medical Device to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients Receiving Curative Treatment||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261181||35251|
NCT02261194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Réseau Vision Freeman|Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration|Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration||Maisonneuve-Rosemont Hospital|No|Completed|October 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|N/A|No|||March 2016|March 24, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02261194||35250|
NCT02271867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 9/25/113|Thermal QST for Interscale Block Evaluation|Thermal Quantitative Sensory Testing as a Method to Semi-quantitatively Assess the Neurosensory Effects of 3 Local Anesthetic Solutions in an Interscalene Block||University Hospital, Antwerp|No|Completed|July 2009|||August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|45|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02271867||34430|
NCT02264522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-14-39|Pilot Study Using a Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Hemodialysis Ultrafiltration|Use of Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Ultrafiltration in Hemodialysis Patients to Achieve Euvolemia While Minimizing Intra-dialytic Hypotension||Intelomed, Inc.|No|Active, not recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02264522||34994|
NCT02260700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR102380|A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants|A Randomized, Open-Label, 3-Way Crossover Study in Healthy Older Male Subjects to Evaluate the Bioavailability, Food Effect, Safety and Tolerability of A Solid Dosage Formulation of JNJ-54861911||Janssen Research & Development, LLC|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Male|55 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260700||35288|
NCT02267499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84171|Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project|The Effects of Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The Long Lasting Memories Project (LLM)|LLM|Aristotle University Of Thessaloniki|No|Completed|November 2010|April 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|322|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267499||34766|
NCT02265575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001390|Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration|Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration|HARK|Massachusetts General Hospital|No|Enrolling by invitation|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|1 Month|N/A|No|||September 2015|September 21, 2015|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265575||34913|
NCT02267265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMW-NI|Pilot Study of Novel Postpartum Educational Video Intervention|A Randomized Controlled Trial Pilot Study of the Thirty Million Words® Newborn Initiative Intervention, a Novel Postpartum Educational Video|TMW-NI|University of Chicago|No|Not yet recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|1000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02267265||34784|
NCT02267278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0445|Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)|Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis||M.D. Anderson Cancer Center|No|Recruiting|January 2015|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267278||34783|
NCT02267525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099|The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis||Theravance Biopharma R & D, Inc.|No|Recruiting|December 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267525||34764|
NCT02272530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proteome|Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells|Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells||Heinrich-Heine University, Duesseldorf|No|Recruiting|July 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood sample|Both|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|100 healthy volunteers and 100 patient with stable coronary artery disease|February 2016|February 22, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272530||34379|
NCT02272543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14047|Acceptability and Efficacy of 'Fish Surimi Peptide' in Under Five Children Suffering From Moderate Acute Malnutrition|||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||June 2015|July 26, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272543||34378|
NCT02270164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0167|The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study|The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study||University of Mississippi Medical Center|No|Recruiting|October 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02270164||34561|
NCT02273128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D129206005|A Study to Assess the Disturbances in Calcitonin Gene in Patients With Gum Disease and Osteoporosis|Calcitonin Receptor Gene Polymorphisms in Patients With Osteoporosis and Chronic Periodontitis-An Observational Study|CTROP|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Completed|June 2014|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|50|Samples With DNA|2ml of blood sample from each subject was collected in EDTA containing vials and kept at -20      degrees until DNA extraction. The genomic DNA was isolated and C/T polymorphism in CTR gene      was identified by PCR followed by restriction digestion pattern by Alu 1 restriction enzyme.|Both|35 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Patients both male and female aged between 35-60 Years with Osteoporosis and Chronic        Periodontitis.|April 2015|April 18, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273128||34333|
NCT02273141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1006-03/2014 (DAYB)|Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using a Day Before-Only Dosing Regimen in Adults.|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus a Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using a Day Before-Only Dosing Regimen in Adults.||Norgine|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|515|||Both|18 Years|85 Years|No|||June 2015|January 18, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273141||34332|
NCT02258776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PomSkin 14-001011|The Effect of Pomegranate on Aging and Inflammation of the Skin|Clinical Trial to Determine the Efficacy of Pomegranate for Skin Inflammation and Aging|PomSkin|University of California, Los Angeles|No|Recruiting|October 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|15|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258776||35436|
NCT02258789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmeaU ClinNeuro HF Neglect|Assessment and Training Visio Spatial Neglect in a Virtual Reality Environment|Assessment and Training Visio Spatial Neglect in a Virtual Reality Environment|RehAtt|Umeå University|Yes|Completed|September 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|60 Years|85 Years|No|||October 2014|October 2, 2014|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02258789||35435|
NCT02259543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018/2010|Root Biomodification With Citric Acid and Tetracycline Improves the Outcomes of Root Coverage|Conditioning of Root Surfaces With Citric Acid and Tetracycline for Different Application Times Improves the Outcomes of Root Coverage by Subepithelial Connective Tissue Graft: a Randomized Clinical Trial.||University of Sao Paulo|Yes|Completed|August 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 5, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02259543||35377|
NCT02269722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10796|Postcath Radial Arterial Clamp Time In the CAth Lab|A Comparison of Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via a Percutaneous Transradial Approach|PRACTICAL|Lawson Health Research Institute|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|564|||Both|N/A|N/A|No|||November 2015|November 25, 2015|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02269722||34595|
NCT02269735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2640-001|A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)|A Three-part Study Parts I, II and III: Rising Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Subjects (Part I) and Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Subjects With Type 1 Diabetes Mellitus (Part II and Part III).||Merck Sharp & Dohme Corp.|No|Recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269735||34594|
NCT02269878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Master (No14)|Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma|The Effect of FAS and FAS Ligand Genetic Polymorphisms on the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Platinum-Based Regimens||Ain Shams University|No|Active, not recruiting|April 2014|December 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|patients with malignant pleural mesothelioma (MPM)|March 2016|March 6, 2016|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02269878||34583|
NCT02269891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14NMHB|A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women|A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women|14NMHB|KGK Synergize Inc.||Recruiting|October 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|100|||Female|40 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269891||34582|
NCT02274259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690110|Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen|Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm||St. Erik Eye Hospital|No|Recruiting|June 2014|December 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02274259||34246|
NCT02265497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Relinfo|Brazilian Network for Lymphoma Registry|Brazilian Network for Lymphoma Registry|Relinfo|Instituto Nacional de Cancer, Brazil|No|Recruiting|March 2014|December 2020|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|N/A|N/A|No|Non-Probability Sample|All patients with diagnosis of Hodgkin's or non-Hodgkin lymphoma with available with        available clinical, histopathology and treatment data.|October 2014|October 15, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02265497|24 Months|34919|
NCT02272322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCR-11-01|Transvaginal Treatment of Symptomatic Cystocele Grade II-III|Transvaginal Treatment of Symptomatic Cystocele Grade II-III Using Cousin Biomesh Soft Prolaps or Allium Medical Endofast Reliant|BCR|Regionaal Ziekenhuis Heilig Hart Tienen|No|Recruiting|June 2014|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|40 Years|90 Years|No|Non-Probability Sample|Patients with symptomatic anterior prolapse|October 2014|October 20, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02272322||34395|
NCT02268630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOVE1213|Long Term Outcomes of Venous Thromboembolism|Long Term Outcomes of Venous Thromboembolism -the LOVE Study-|LOVE|Ostfold Hospital Trust|Yes|Recruiting|January 2014|October 2023|Anticipated|October 2023|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|460|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with VTE in Østfold who fulfil study criteria will be invited to        participate.|November 2015|November 11, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02268630||34679|
NCT02265081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1162-7720|A Prospective Study on USS Assessment of Pelvic Structures in 3rd Trimester of Pregnancy Versus Delivery Outcome|A Prospective Study on USS Assessment of Pelvic Structures in 3rd Trimester of Pregnancy Versus Delivery Outcome.|PLUSSMODEL|Birmingham Women's NHS Foundation Trust|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|135|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 26, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265081||34951|
NCT02265094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014- A00481-46|Associative Memory in Autism Spectrum Disorder|Associative Memory in ASD Without Mental Retardation : Study in EEG and Neuropsychology|MEM-TA|University Hospital, Caen|No|Not yet recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265094||34950|
NCT02264496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/YH/0322 V3|Prospective Randomised Trial of Exercise and / or Antioxidants in COlorectal Cancer Patients Undergoing Surgery.|The Effects of Exercise on Outcomes in Patients Undergoing Surgery for Colorectal Cancer: a Pilot Prospective Randomised Trial.|PEACOCS|Hull and East Yorkshire Hospitals NHS Trust|No|Completed|March 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02264496||34996|
NCT02267837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS1.5|OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study|OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study.||Biolux Research Ltd.|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|11 Years|40 Years|No|||August 2015|August 12, 2015|October 10, 2014|Yes|Yes||No|August 12, 2015|https://clinicaltrials.gov/show/NCT02267837||34740|
NCT02267850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS2|Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time|Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time: A Randomized Control Trial||Biolux Research Ltd.|No|Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|40 Years|No|||July 2015|August 12, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267850||34739|
NCT02272452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExtempoRMN - RNI|Assistance in Neurosurgery (ExtempoRMN)|Assistance in Neurosurgery by Extemporaneous Analysis of Magnetic Resonance of the Metabolic Content in Excised Tissues (ExtempoRMN)|ExtempoRMN|University Hospital, Strasbourg, France||Not yet recruiting|October 2014|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Under the " ExtempoRMN "project, we propose to focus on primary brain tumors mainly        gliomas that include: Glioblastomas, the low-grade oligodendrogliomas (WHO grade II) and        high grade (WHO grade III), Astrocytomas. Normality will be obtained by analysis of        control brain tissues from epilepsy surgery. Study population for this project is all the        patients of department of neurosurgery of Strasbourg University Hospitals and Colmar        Hospital center, for whom a neurosurgical operation is programmed before inclusion in this        study, and who meets inclusion criteria.|October 2014|October 22, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02272452||34385|
NCT02272738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TatsuyaIoka2013|A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer|A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma||Osaka Medical Center for Cancer and Cardiovascular Diseases|Yes|Recruiting|August 2013|April 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|20 Years|75 Years|No|||April 2015|April 20, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02272738||34363|
NCT02272621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMILE-C|Surgical Trauma After Partial Upper Hemisternotomy Versus Full Sternotomy Aortic Valve Replacement|||Karolinska University Hospital|No|Recruiting|April 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272621||34372|
NCT02272686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0096|Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma|Targeting BTK With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma||M.D. Anderson Cancer Center|No|Not yet recruiting|January 2016|||January 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272686||34367|
NCT02272920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538-13|PCI and Renal Denervation in Hypertensive Patients With Acute Coronary Syndromes|Combined Treatment With Percutaneous Coronary Intervention and Renal Denervation in Hypertensive Patients With Acute Coronary Syndromes.|COMBI-RDN|Sahlgrenska University Hospital, Sweden|Yes|Not yet recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2014|October 23, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02272920||34349|
NCT02272933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14-125|Operability and Implementation of a Patient Motion Monitoring System Using Wireless Body Worn Sensors|Operability and Implementation of a Patient Motion Monitoring System Using Wireless Body Worn Sensors|GFD1|Texas Tech University Health Sciences Center|No|Recruiting|August 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272933||34348|
NCT02275676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDERN1|Resting Energy Expenditure and Nutritional Status in IBD|Influence of Disease Activity of Inflammatory Bowel Disease on Resting Energy Expenditure and Nutritional Status|CEDERN-1|University Hospital Muenster|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with active or inactive inflammatory bowel disease at our medical tertiary        referral center, Muenster Germany|October 2014|October 22, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02275676||34137|
NCT02269410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN6105|Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss|Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)|MIPS|Columbia University|No|Active, not recruiting|November 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|65 Years|No|||March 2016|March 21, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02269410||34619|
NCT02269553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMJ-1001|TMJ-1001 Bruxism Run-In/Pivotal Trial|A Pivotal Study of the TMJ NextGeneration(TradeMark) Compared to Occlusal Splint Treatment for Reduction in Nocturnal Bruxism Episodes and Monthly Migraine Episodes in Subjects Diagnosed With Sleep Bruxism||Cardiox Corporation|No|Withdrawn|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|October 7, 2014|Yes|Yes|Study redesigned into three separate trials.|No||https://clinicaltrials.gov/show/NCT02269553||34608|
NCT02274025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TISS001|NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients|Collection of Lung Malignant Tissue for the Validation of a Novel Technology to Identify Oncogenic Mutations and Personalized Medicine||NovellusDx|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Biopsy material of patient or pleural fluids.|Both|18 Years|85 Years|No|Probability Sample|Patients that are suspected to have lung cancer and are eligible for biopsy, surgical        intervention or pleural fluid suction.|October 2015|October 6, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02274025|2 Years|34264|
NCT02274038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC130313|Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer|Serial [18F]Fluorothymidine (FLT)PET/CT as a Biomarker of Therapeutic Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer||University of Pennsylvania||Recruiting|March 2015|November 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|October 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274038||34263|
NCT02274103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6000|Skype for Youth With Poorly Controlled Diabetes|Improving Health Through SkypeTM: Family-Based Intervention for Teens With Poorly Controlled Diabetes|SKYPE|Oregon Health and Science University|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|12 Years|18 Years|No|||October 2014|October 23, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02274103||34258|
NCT02274181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-112|An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration|An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration||Repros Therapeutics Inc.|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|19 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274181||34252|
NCT02265250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037025|Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment|Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment Pilot Study||Cedars-Sinai Medical Center|Yes|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|20|Samples Without DNA|We will obtain fasting lipid and inflammatory biomarkers (LDL-C, HDL-C, lipoprotein(a),      ApoB/ApoA-1 ratio, hemoglobin A1c, plasma adiponectin, hsCRP).|Both|18 Years|N/A|No|Non-Probability Sample|20 subjects with known coronary atherosclerosis but varying degrees of CVD risk|August 2015|August 21, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02265250||34938|
NCT02265263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioCog|Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)|Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)|BioCog|Charite University, Berlin, Germany|No|Recruiting|October 2014|January 2020|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|-  Whole blood-/plasma (RNA-/DNA-Analysis) (N = 1200)        -  Cerebrospinal fluid (sequencing of candidate nicotinic receptor genes and genes for           acetylcholine synthesis/-catabolism: CHRNA3, CHRNA4, CHRNA5, CHRNA7, CHRNB2, CHRNB4,           ACHE, CHAT) (N = 200, only in Berlin).|Both|65 Years|N/A|No|Non-Probability Sample|1200 surgical patients (400 in Utrecht, 800 in Berlin), 65 years or above        At the maximum 300 ASA (ASA Physical Status Classification System) II/III-patients (100 in        Utrecht, 200 in Berlin), 65 years or above|February 2016|February 15, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02265263||34937|
NCT02270840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Budapest Upgrade CRT 009-4.1|Budapest Upgrade CRT Study (Version 009-4.1)|Effect of Biventricular Upgrade on Left Ventricular Reverse Remodeling and Clinical Outcomes in Patient With Left Ventricular Dysfunction and Intermittent or Permanent Apical/Septal Right Ventricular Pacing (Budapest CRT Upgrade Study)||Semmelweis University Heart and Vascular Center|Yes|Enrolling by invitation|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|360|||Both|18 Years|N/A|No|Non-Probability Sample|Altogether 360 subjects will be enrolled at the European and Israeli study sites,        randomized in the rate of 3:2 (CRT-D:ICD groups).|February 2016|February 18, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270840||34509|
NCT02270853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-136|SAS in Patients With Bronchial Carcinoma|Incidence of Sleep Apnea Syndrome (SAS) in Patients With Bronchial Carcinoma|SAS CA|RWTH Aachen University|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270853||34508|
NCT02274675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTM-CR2-001|A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training|A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training||Universiti Teknologi Malaysia|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|90 Years|No|||July 2015|July 3, 2015|October 21, 2014|No|Yes||No|May 2, 2015|https://clinicaltrials.gov/show/NCT02274675||34214|The limitations of this study include the relatively small number of subjects in each group, the variation in severity level across subjects and also the lack of comparison groups to differentiate the improvement benefit from robot therapy.
NCT02274688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-6319|A Comparative Effectiveness Trial of Optimal Patient-Centered Care|A Comparative Effectiveness Trial of Optimal Patient-Centered Care for US Trauma Care Systems|TSOS 5|University of Washington|Yes|Recruiting|March 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|14 Years|N/A|No|||October 2014|October 21, 2014|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02274688||34213|
NCT02265315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03265-FB UM|Voice Therapy in Parkinson Disease|Augmenting Treatment Effects of Voice Therapy in Parkinson Disease||Le Bonheur Children's Hospital|Yes|Recruiting|October 2014|March 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|70|||Both|45 Years|80 Years|No|||September 2015|September 2, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265315||34933|
NCT02266719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140108|Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex Abdominal Aortic Aneurysms Using CMDs|Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex Abdominal Aortic Aneurysms Using Custom-Made Devices (CMD)||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2014|July 2025|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|90 Years|No|||November 2015|November 25, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266719||34826|
NCT02266732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN11/9771|Ultrasound Vs Nerve Stimulation - Why is a PNS so Effective?|Ultrasound Vs Nerve Stimulation - Why is a PNS so Effective?||The Leeds Teaching Hospitals NHS Trust||Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||February 2015|February 19, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02266732||34825|
NCT02272465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-14-0735|Prehospital Resuscitation On Helicopter Study|Prehospital Resuscitation On Helicopter Study|PROHS|The University of Texas Health Science Center, Houston|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1049|||Both|15 Years|N/A|No|Non-Probability Sample|The target population for this study is trauma patients who are transported to one of the        participating Level I trauma centers via air ambulance, directly from the scene, and meet        the eligibility criteria.|December 2015|December 7, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02272465||34384|
NCT02267772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0763|IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women|A Randomized, Controlled Trial of IV Acetaminophen Versus IV Morphine to Manage Pain in Pregnancy: Can Opioid Use be Reduced in Pregnant Women?||The University of Texas Health Science Center, Houston|No|Recruiting|January 2014|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|330|||Female|18 Years|60 Years|No|||February 2016|February 29, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267772||34745|
NCT02272816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007065|A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT|A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT|Car-PET|Barts & The London NHS Trust|No|Recruiting|February 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|75 Years|No|||October 2013|October 21, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02272816||34357|
NCT02268045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTXM83-AC-01-11|Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma|A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line||mAbxience S.A|Yes|Recruiting|May 2013|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||February 2015|February 10, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02268045||34724|
NCT02273050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00009|Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control|A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control||AstraZeneca|No|Active, not recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|639|||Both|18 Years|100 Years|No|||March 2016|March 2, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273050||34339|
NCT02268552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMI070X2201|An Open Label Study of LMI070 in Type 1 Spinal Muscular Atrophy (SMA)|An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy||Novartis|Yes|Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|N/A|N/A|No|||March 2016|March 2, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02268552||34685|
NCT02273882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4800L00009|An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants|The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations Among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis|SENTINEL1|AstraZeneca|No|Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|12 Months|No|Non-Probability Sample|Infants born at 29 to 35 wGA not receiving RSV prophylaxis hospitalized for RSV at less        than 12 months of age|March 2016|March 1, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02273882||34275|
NCT02259790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.17|Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers|Relative Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Telmisartan 40 mg Tablet and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|July 2007|||August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years||||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259790||35358|
NCT02259803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.18|Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers|Relative Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Two Telmisartan 40 mg Tablets and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|October 2007|||November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259803||35357|
NCT02273947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-049|Food Effect Study With BMS-955176|An Open-Label, Randomized, Crossover Adaptive Design Study to Assess the Effect of Food on the Pharmacokinetics of BMS-955176 Administered as a Micronized Crystalline Tablet in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|12||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 10, 2016|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273947||34270|
NCT02273960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM140-103|Study to Evaluate Safety and Efficacy in Adult Subjects With ITP|Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)|ITP|Bristol-Myers Squibb|Yes|Recruiting|November 2014|May 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273960||34269|
NCT02260583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176/2013|Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients|EFFECT OF EXTRACORPOREAL CO2 REMOVAL IN STABLE COPD PATIENTS WITH CHRONIC HYPERCAPNIC RESPIRATORY FAILURE:A PILOT STUDY||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 28, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260583||35297|
NCT02260869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-2014-GNK|Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain|A Prospective Double Blind, Randomized Control Trial to Compare the Efficacy of Cool Radiofrequency Ablation vs. Conventional Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain||Millennium Pain Center|No|Recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260869||35275|
NCT02270554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-Study 1401|A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy|A Prospective, Multi-center Investigation of Impact of the Endo GIA Reinforced Reload With Tri-Staple Technology During Distal Pancreatectomy||Wakayama Medical University|Yes|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||August 2015|August 11, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02270554||34531|
NCT02272244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1306-01882|Increasing Colorectal Cancer (CRC) Screening Among Hispanic Primary Care Patients|||Thomas Jefferson University|No|Recruiting|April 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272244||34401|
NCT02272257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22290|Temple University Employees With Musculoskeletal Conditions Receive Physical Therapy to Treat Limitations Early|Direct Access Physical Therapy Compared With Physician Portal of Entry for Temple University Employees With Recent Onset Musculoskeletal Conditions: A Randomized Controlled Trial.|TEMPLE|Temple University|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272257||34400|
NCT02272270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI75289|Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)|Phase 1 Trial in Newly Diagnosed High Grade Glioma With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide. (D-TERMINED)|D-TERMINED|University of Utah|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02272270||34399|
NCT02261480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSCREEN|A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease|Investigation in Sickle Cell Disease of a New Reagent Assay Examining Natural Parvovirus B19 Infection||St. Jude Children's Research Hospital|No|Recruiting|October 2014|May 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|89|Samples Without DNA|Blood and/or nasopharyngeal wash samples will be taken and retained. If participants agree,      leftover samples will be saved for potential health research in the future.|Both|1 Year|N/A|No|Non-Probability Sample|Sickle cell disease patients being seen at St. Jude Children's Research Hospital.|October 2015|October 28, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02261480||35228|
NCT02261493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-143|A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides|||Allergan|No|Active, not recruiting|October 2014|April 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|787|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261493||35227|
NCT02260388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001500|Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations|Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)|PAIN-CONTRoLS|University of Kansas Medical Center|Yes|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|30 Years|N/A|No|||March 2016|March 16, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260388||35312|
NCT02274220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046036|Feeding Study - Effects Post-cardiac Surgery|Randomized Study of Early Nutritional Delivery on Glucose Control, Insulin Resistance and Systemic Inflammation Following Pediatric Cardiac Surgery||The Hospital for Sick Children|Yes|Recruiting|October 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|6 Months|No|||May 2015|May 19, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02274220||34249|
NCT02274233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-420-702|Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia|Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia||Sideris Pharmaceuticals|No|Terminated|October 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|October 21, 2014|No|Yes|Changes in renal function parameters.|No||https://clinicaltrials.gov/show/NCT02274233||34248|
NCT02266199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNQI-2012|Validation of a New Questionnaire Regarding Pain Management|Validation of a New Questionnaire Regarding Pain Management in Hospitals Using a Qualitative Verification||Ruhr University of Bochum|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|350|||Both|18 Years|N/A|No|Non-Probability Sample|Included are all conservative and postoperative patients who are inpatients on pneumology,        cardiology, neurology, gastroenterology, endocrinology, Traumatology, Plastic Surgery,        Cardiothoracic Surgery, Gynecology, Abdominal Surgery|October 2014|October 12, 2014|August 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02266199||34866|
NCT02271672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP1000RF|XP1000 RF Therapy on Waist Circumference Reduction|Effect of the XP1000 RF Therapy on Waist Circumference Reduction||BTL Industries Ltd.|No|Completed|August 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271672||34445|
NCT02272699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC002|Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma|Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma||Peking University|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|195|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02272699||34366|
NCT02272036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102014|Short Message Service in Colonoscopy Preparation (PERICLES-II-SMS)|Improvement of Colonoscopy Preparation by New Media (SMS) (PERICLES-II-Study)|PERICLES-II|Technische Universität München|No|Recruiting|September 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272036||34417|
NCT02268279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-120|Pharmacokinetics and Safety of Solithromycin in Adolescents and Children|A Phase 1, Open-label, Multi-center Study to Determine the Pharmacokinetics and Safety of Solithromycin as Add-on Therapy in Adolescents and Children With Suspected or Confirmed Bacterial Infection||Cempra Inc|Yes|Recruiting|January 2015|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|N/A|17 Years|No|||January 2016|January 26, 2016|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02268279||34706|
NCT02268292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG12147|Home Bicycle Exercise and Aerobic Capacity|The Effects of Home Bicycle Exercise Program on Hyperlipidemia, Hypertension, Blood Sugar Control, Muscle Strength and Aerobic Capacity||Taichung Veterans General Hospital|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|20 Years|85 Years|No|||October 2014|October 15, 2014|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02268292||34705|
NCT02273726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-064|Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects|A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis||FibroGen|Yes|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273726||34287|
NCT02273791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA1|HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients|Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Polycystic Ovarian Syndrome Patients||Mansoura University|No|Recruiting|May 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|20 Years|38 Years|No|||March 2016|March 4, 2016|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02273791||34282|
NCT02259816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.2|Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers|Pharmacokinetics of Repeated Oral Doses of 80 mg Telmisartan (Micardis®) at Steady State Alone and in Combination With Repeated Oral Doses of Amlodipine 10 mg (Norvasc®) at Steady State. A Two-way Crossover, Open, Randomised Design Study||Boehringer Ingelheim||Completed|May 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259816||35356|
NCT02264210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1003|Icotinib for Completed Resected IB NSCLC With EGFR Mutation|A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation|CORIN|Sun Yat-sen University|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264210||35018|
NCT02260297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD-023|A Study of Wrist Actigraphy in Overweight and Obese Adults With Sleep Disorders|A Study of Wrist Actigraphy in Overweight and Obese Adults With Sleep Disorders||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|18 Years|N/A|No|Non-Probability Sample|Overweight and obese adults with sleep disorders|December 2014|December 2, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260297||35319|
NCT02264717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dan-NICAD|Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease|Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease||University of Aarhus|Yes|Recruiting|September 2014|January 2026|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|2000|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02264717||34979|
NCT02264730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-030H2|ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered|Phase 1 Single-Arm Study Evaluating ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery in Which Liver Bleeding is Encountered||Biomedica Management Corporation|Yes|Recruiting|July 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264730||34978|
NCT02265003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anaemie|Red Blood Cells as a Reflection of Endothelial Function in Old Age|Red Blood Cells as a Reflection of Endothelial Function in Old Age||Heinrich-Heine University, Duesseldorf|No|Recruiting|July 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|140|Samples Without DNA|blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|4 groups:          -  healthy young aged 18-35 years (30 subjects)          -  healthy middel aged 35-45 years (30 subjects)          -  healthy old aged > 70 years (30 subjects)          -  patients (50 subjects)|October 2015|February 11, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265003||34957|
NCT02272140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.NV1401|Advanced XLIF Monitoring Multicenter Study|A Prospective, Non-randomized, Multicenter Evaluation of the Utility of Transcutaneous Stimulation of the Lumbosacral Nerve Roots During XLIF® and Its Relationship to Postoperative Nerve Health||NuVasive|No|Enrolling by invitation|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|316|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 316 subjects will be enrolled in this study from multiple centers. Patients        who, in the investigator's opinion, require lateral approach spinal fusion surgery at        spinal level L4-5 (though may include any number of levels from L2 through L5), and have        consented to XLIF surgery for their condition will be included. All subjects must meet the        inclusion/exclusion criteria below in order to be considered for enrollment.|February 2016|February 11, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02272140||34409|
NCT02265874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0291|Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study|Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study||Ohio State University|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265874||34891|
NCT02266160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0055-14|Treating Tinnitus Using Eutectic Mixture of Local Anesthetics (EMLA) 5% Cream|EMLA 5% as a Treatment for Tinnitus and Its Accompanied Symptoms||HaEmek Medical Center, Israel|Yes|Not yet recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266160||34869|
NCT02266173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29299|Observational Study of Perjeta Safety in Breast Cancer|POST-MARKETING SURVEILLANCE OF PERJETA IN BREAST CANCER||Hoffmann-La Roche||Recruiting|February 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with breast cancer who are to be administered Perjeta according to the        medical opinions of the doctor in charge of surveillance and in line with the current        summary of product characteristics (SmPC)/local labeling. Patients are to have been        diagnosed with metastatic or locally unresectable recurrent breast cancer and have never        received chemotherapy or anti-HER2 therapy for metastatic disease with HER2 positivity.|March 2016|March 1, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02266173||34868|
NCT02264808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400699|Developmental Outcomes|Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE).||University of Florida|No|Enrolling by invitation|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|Samples Without DNA|Biomarkers will be compared to developmental outcomes, however these blood samples were      already obtained through IRB#504-2011|Both|18 Months|20 Months|No|Non-Probability Sample|Children 18-20 months of age born with Hypoxic Ischemic Encephalopathy (HIE)|October 2015|October 14, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02264808||34972|
NCT02264821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apcisaal 01|Wound Infusion vs Spinal Morphine for Post-caesarean Analgesia|Is Continuous Wound Infusion With Ropivacaine Better Than Intrathecal Morphine for Post-caesarean Analgesia? A Prospective, Randomized, Controlled, Double Blinded Study|Apcisaal|Brugmann University Hospital|No|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|192|||Female|18 Years|N/A|No|||May 2015|May 21, 2015|August 25, 2014||No||No|April 22, 2015|https://clinicaltrials.gov/show/NCT02264821||34971|
NCT02266407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-07711|Surgical / Economic Effect of the Aquamantys System in Blood Management for Aseptic and Septic Revision TKA|The Surgical and Economic Effect of the Aquamantys System in Blood Management During and Following Aseptic and Septic Revision TKA||Medtronic Surgical Technologies|Yes|Recruiting|September 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|March 13, 2015|October 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02266407||34850|
NCT02272127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-2014-069|Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer|Intercalated Combination of Chemotherapy Plus Icotinib for Patients Undergoing Resection of EGRF Mutation-positive Non-small-cell Lung Cancer||Nanfang Hospital of Southern Medical University|No|Recruiting|July 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02272127||34410|
NCT02271841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLouvain|How Are Changing the Practices After the Introduction of the Pleth Variability Index? A Before/After Survey.|How Are Changing the Practices After the Introduction of the Pleth Variability Index? A Before/After Survey.||Université Catholique de Louvain|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|The plan will seek to recruit a minimum of 3 centers in Belgium and/or France who have        little to no prior PVI experience, each institution requiring about a minimum of 10        participating anesthesiologists for that institution. As it may be difficult to locate a        center without Masimo technology, the goal is to locate a center not actively in use with        PVI technology for managing fluid responsiveness, and the clinicians are not actively        consulting with Masimo|May 2015|May 26, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02271841||34432|
NCT02271854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-P-323|A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness|A Randomized, Double-blind, Placebo-controlled, Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs||Novartis|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|35 Years|No|||January 2015|January 29, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271854||34431|
NCT02258724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 180/13|Swiss National Registry of Grown up Congenital Heart Disease Patients|Swiss National Registry of Grown up Congenital Heart Disease (GUCH) Patients|GUCH|University Hospital, Basel, Switzerland|No|Recruiting|September 2013|December 2033|Anticipated|December 2033|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|GUCH patient treated in one of the Swiss centre with specialized organisation GUCH        (University Hospital Basel, University Hospital Zurich, University Hospital Lausanne,        University Hospital Geneva, Canton Hospital StGallen).|October 2015|October 5, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02258724|20 Years|35440|
NCT02258737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT|Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge|Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge: a Randomized Trial||University of Lausanne Hospitals|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|65 Years|No|||October 2014|October 2, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02258737||35439|
NCT02273674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-14-1006|TMS in Borderline Personality Disorder Patients|Repetitive Transcranial Magnetic Stimulation in Borderline Personality Disorder Patients. Effects in Clinical Measurements, Inhibition, Cognitive Flexibility, and Social Cognition Process||Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|Yes|Completed|January 2014|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||February 2016|February 22, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02273674||34291|
NCT02273739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG221-C-003|Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation|||Agios Pharmaceuticals, Inc.|No|Active, not recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273739||34286|
NCT02259283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POEM-ICH|Prospective Study on the Feasibility and Results of POEM in Idiopathic Achalasia|Prospective Study on the Feasibility and Results of the Treatment of Idiopathic Achalasia With the POEM (Per Oral Endoscopic Myotomy) Technique|POEM|Istituto Clinico Humanitas|Yes|Completed|December 2012|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||October 2014|October 3, 2014|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259283||35397|
NCT02259504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00035000|COAST: Coiling of Aneurysms Smaller Than 5mm With Hypersoft®|COAST: Coiling of Aneurysms Smaller Than 5mm With Hypersoft®|COAST|Medical University of South Carolina|No|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|80 Years|No|||November 2015|December 14, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02259504||35380|
NCT02259764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.6|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400, 440 and 480 mg) of KUC 7483 CL Tablets in Healthy Male Volunteers. A Double-blind at Each Dose Level, Randomised, Placebo Controlled Study||Boehringer Ingelheim||Completed|August 2004|||September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259764||35360|
NCT02259777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.12|Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers|Influence of Food on the Bioavailability of 80 mg Telmisartan/10 mg Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Period, Crossover Study||Boehringer Ingelheim||Completed|September 2007|||November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259777||35359|
NCT02269748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2566P|Morbidity and Coverage Outcome With Connective Tissue Graft Used With Coronally Advanced Flap and Tunneling Technique|Patient Morbidity and Root Coverage Outcome After Subepithelial Connective Tissue Graft Used in Combination With Coronally Advanced Flap and Tunneling Technique: a Comparative Randomized Controlled Clinical Trial.||University of Padova, School of Dental Medicine|Yes|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02269748||34593|
NCT02264457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISR-2014-003|A Intra-patient Comparison of Closed Loop and Plate Haptic Toric Intraocular Lenses|A Randomised Intra-patient Comparison of Closed Loop and Plate Haptic Toric, Aspheric, Aberration Neutral, Hydrophilic Acrylic Intraocular Lenses in Patients With Bilateral Astigmatism||University of Plymouth||Not yet recruiting|November 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264457||34999|
NCT02270138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05062014|An Experimental Study on Music and Sedentariness Among Mothers and Children|Movement-to-music Video Program in Decreasing Sedentary Time in Mothers and Children: a Randomized Controlled Trial|MovingSound|UKK Institute|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|N/A|N/A|No|||December 2015|December 4, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02270138||34563|
NCT02270333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaziU|Inspiratory Muscle Training in Sarcoidosis|Effects of Inspiratory Muscle Training in Patients With Sarcoidosis||Gazi University|No|Completed|April 2012|April 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|20 Years|75 Years|No|||October 2014|October 18, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02270333||34548|
NCT02274948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-13-143|Use of Metformin in Treatment of Childhood Obesity|Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A Randomized Clinical Trial||University of Colombo|No|Recruiting|July 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|16 Years|No|||January 2015|January 3, 2015|October 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274948||34193|
NCT02261207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFT-AX2014|Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor|Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Not yet recruiting|November 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261207||35249|
NCT02270567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WREN_REGISTER_01|RegisterNET - A Registry for Neuroendocrine Tumors in the USA|A Registry for Neuroendocrine Tumors in the USA|RegisterNET|Wren Laboratories LLC|Yes|Recruiting|February 2015|March 2020|Anticipated|September 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood collection (EDTA tube) used for neuroendocrine tumor biomarker measurements|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a histologically confirmed diagnosis of a neuroendocrine tumour|December 2015|December 7, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02270567|5 Years|34530|
NCT02270866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-APH-01|Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia|Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia||Scion NeuroStim|No|Active, not recruiting|October 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||February 2016|February 7, 2016|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270866||34507|
NCT02260713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIC-BMC|Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.|Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study||Indian Spinal Injuries Centre|Yes|Active, not recruiting|February 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|50 Years|No|||February 2016|February 23, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02260713||35287|
NCT02275598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV-ABVD|Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma|A Pilot Phase II Study To Assess The Efficacy Of Brentuximab Vedotin Administered Sequentially With ABVD Chemotherapy In Patients With Untreated Hodgkin Lymphoma.||University of Modena and Reggio Emilia|No|Active, not recruiting|April 2013|March 2015|Anticipated|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|8 Years|70 Years|No|||October 2014|October 22, 2014|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275598||34143|
NCT02275611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1862|Oxytocin Treatment of Alcohol Dependence|Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial|OT-ETOH2|University of North Carolina, Chapel Hill|Yes|Completed|January 2013|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|February 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275611||34142|
NCT02275624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2014-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||May 11, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275624||34141|
NCT02275637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140002277 del 27/05/2014|Arrhythmias Detection in a Real World Population|Arrhythmias Detection in a Real World Population: the RHYTHM DETECT Registry|RHYTHM DETECT|IRCCS Policlinico S. Matteo|No|Recruiting|September 2014|September 2022|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4800|||Both|18 Years|N/A|No|Non-Probability Sample|This study requires patients implanted with a defibrillator that meet all        inclusion/exclusion criteria.|October 2014|October 23, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02275637||34140|
NCT02270827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013AT001B|A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics|A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics|SARAH|Royal Brompton & Harefield NHS Foundation Trust|No|Terminated|June 2014|February 2015|Actual|February 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|65 Years|No|Non-Probability Sample|Severe Asthmatic Adults|October 2015|October 26, 2015|October 6, 2014||No|Study was set up by an MSc student who left her post.|No||https://clinicaltrials.gov/show/NCT02270827||34510|
NCT02262507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-5717|Concussion Device Audiological Measures|Concussion Device Audiological Measures||Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|410|||Both|8 Years|50 Years|Accepts Healthy Volunteers|||October 2014|April 1, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02262507||35149|
NCT02272179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH100451|Brief Intervention for Suicide Risk Reduction in High Risk Adolescents|Brief Intervention for Suicide Risk Reduction in High Risk Adolescents|ASAP|University of Pittsburgh|Yes|Recruiting|February 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|12 Years|17 Years|No|||January 2016|January 5, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272179||34406|
NCT02263066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17653|Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis|Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis|ReCARE|Bayer|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|181|||Male|2 Years|18 Years|No|Non-Probability Sample|About 300 at most hemophilia boys (2-<18 years) in the representative hemophilia treatment        centers (HTCs) with available medical data record, having received rFVIII contained        regular prophylaxis between Nov. 1st 2007 and May 31st 2013 will be enrolled from about 15        centers.|July 2015|July 16, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263066||35106|
NCT02263079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25361|An Open-label Study of Pegasys in Combination With Lamivudine in Children With HBeAg-positive Chronic Hepatitis B in the Immune-Tolerant Phase|||Hoffmann-La Roche||Recruiting|December 2014|April 2024|Anticipated|April 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|3 Years|17 Years|No|||March 2016|March 1, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263079||35105|
NCT02267226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMA-02|Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery|Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency||Octapharma||Recruiting|September 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|N/A|No|||October 2015|October 23, 2015|August 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267226||34787|
NCT02259010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14020|A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma|A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259010||35418|
NCT02263586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ironman|Influence of Triathlon on the Electrolyte Balance|Acid-base and Electrolyte Balance Among Triathletes in the Ironman European Championship|Ironman|University Hospital of Cologne|No|Completed|August 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1089|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Participants of a long-distance triathlon|May 2015|May 2, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02263586||35066|
NCT02263599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK_01|Conservative Treatment For Ventral Hernia|Conservative Treatment For Ventral Hernia||University Hospital Koge|No|Enrolling by invitation|September 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2089|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred to the Surgical Department of Køge University Hospital in the        timeperiod from 2009 - 2014 with the diagnosis ventral hernia|September 2014|October 8, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02263599||35065|
NCT02263846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCSG008|Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer|Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer||Affiliated Hospital to Academy of Military Medical Sciences|No|Completed|November 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1183|||Female|20 Years|N/A|No|Non-Probability Sample|Chinese women with invasive breast cancer.|April 2015|April 9, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263846||35046|
NCT02275390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012100368|Nurse-led Psycho-education Program for People With First-onset Mental Illness|Effects of a Nurse-led Psycho-education Program for People With First-onset Mental Illness in Psychiatric Outpatient Clinic: A Randomized Controlled Trial|APN-PEP|The Hong Kong Polytechnic University|Yes|Active, not recruiting|May 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|180|||Both|18 Years|64 Years|No|||February 2016|February 17, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275390||34159|
NCT02269904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinofuan01|Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.|Fluorouracil Implants（SinoFuan®）Used for Intraperitoneal Chemotherapy During Operation for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer, Randomized, Controlled, Multicentres Open Study.||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|April 2014|June 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269904||34581|
NCT02269917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105736|Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants|A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects||Janssen R&D Ireland|Yes|Recruiting|March 2015|March 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269917||34580|
NCT02274935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15002|Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis|Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis|DUETS|University of Illinois at Urbana-Champaign|No|Recruiting|October 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|64 Years|No|||August 2015|August 25, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274935||34194|
NCT02260882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-902|Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)|A Study Evaluating the Safety and Immunogenicity of Revaccination With 23-Valent Pneumococcal Polysaccharide Vaccine in Older Japanese Adults||Merck Sharp & Dohme Corp.|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|243|||Both|70 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|October 6, 2014|No|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT02260882||35274|
NCT02265510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 52793-101|An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies|A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies||Incyte Corporation|No|Recruiting|August 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|235|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265510||34918|
NCT02265523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAMA - Sanzo2014|Exercise and Cycle Ergometry Post TKA - A Randomized Controlled Trial|The Effects of Exercise and Cycle Ergometry in Post-Operative Total Knee Patients-A Randomized Controlled Trial||Lakehead University|No|Not yet recruiting|August 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|80 Years|No|||October 2015|October 20, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265523||34917|
NCT02265536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15441|A Study of LY3022855 In Participants With Breast or Prostate Cancer|Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer||Eli Lilly and Company|No|Recruiting|May 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|September 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265536||34916|
NCT02272673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2011|The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia|The Effect of Honey on Episodes of Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia: A Randomized Crossover Open- Labeled Pilot Study||Ain Shams University|Yes|Completed|March 2011|September 2014|Actual|August 2013|Actual|Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|40|||Both|2 Years|12 Years|No|Non-Probability Sample|All patients > 2 years of age with acute lymphoblastic leukemia (ALL), treated according        to the Modified CCG 1991 protocol for standard- risk ALL and on maintenance therapy|October 2014|October 23, 2014|October 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272673||34368|
NCT02272725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31907|Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances|Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances|NAKED|Stanford University|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|November 12, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272725||34364|
NCT02272790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6010C00004|AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.|A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||AstraZeneca|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|130 Years|No|||March 2016|March 24, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272790||34359|
NCT02282631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-00759|Development and Feasibility of an Incentive Scheme to Promote Walking/Cycling to School|The RIGHT TRACKS Study - Development and Feasibility of an Incentive Scheme to Promote Active School Travel in Year 5 Children|RIGHT_TRACKS|Newcastle University|Yes|Completed|June 2014|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|29|||Both|9 Years|10 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02282631||33603|
NCT02282644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.824|Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry|Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry|PROMET II|Hospices Civils de Lyon|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|18 Years|N/A|No|||October 2014|November 3, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282644||33602|
NCT02260999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHL-2113|Experimental Study of Detection an Intentional Performance Degradation in Grip Strength|||Ruhr University of Bochum|No|Completed|May 2012|March 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|136|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|chronic pain patients patients with injury at the upper extremity healthy subjects|October 2014|October 6, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260999||35265|
NCT02261012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPS2014|Examination of the Pathophysiologic Mechanisms of CRPS by Using QST, CPM, RIC, and Heart Rate Variability QST|Examination of the Pathological Mechanism of the Complex Regional Pain Syndrome of the Upper Limb in Comparison to Patients With Painful Carpal Tunnel Syndrome and Healthy Subjects - an Explorative Clinical Study||Ruhr University of Bochum|No|Completed|April 2014|August 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects, CRPS-patients, CTS-patients|February 2016|February 7, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02261012||35264|
NCT02276053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0045|Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors|A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy|VIBES|UCB Pharma|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|16 Years|N/A|No|Non-Probability Sample|Patients ≥ 16 years of age with brain tumor related epilepsy secondary to low grade tumor        starting with lacosamide as add-on to one or two baseline anti-epileptic drugs.|March 2016|March 15, 2016|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276053||34108|
NCT02262871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-338|HFN Versus NIV in Cystic Fibrosis. The HIFEN Study|Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study||St. Michael's Hospital, Toronto|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262871||35121|
NCT02267473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-008|Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function|A Multicenter, Prospective, Observational Study of Patients With Chronic Hepatitis B Under Various Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function|BONIKA|Johann Wolfgang Goethe University Hospitals|No|Recruiting|October 2014|December 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|spontaneous urine sample to test for proximal tubular function|Both|18 Years|89 Years|No|Probability Sample|Patients with chronic Hepatitis B under oral antiviral treatment with an approved        Nucleos(t)ice for a minimal duration of 6 months at study inclusion|October 2014|October 14, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267473||34768|
NCT02263326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPIRE|Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure|Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study|ASPIRE|Northwestern University|Yes|Recruiting|December 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263326||35086|
NCT02268565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N222 2014P-000269|Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms|Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms||Beth Israel Deaconess Medical Center|No|Active, not recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02268565||34684|
NCT02269566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140101480|Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|A Double-blinded Placebo-controlled Randomized Clinical Trial Evaluating the Efficacy and Adverse Effect of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|ILIT|Gachon University Gil Medical Center|Yes|Recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|19 Years|N/A|No|||October 2014|October 20, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269566||34607|
NCT02269579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0314-208|Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment|An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment||Celator Pharmaceuticals|No|Recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269579||34606|
NCT02259855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.59|Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment|Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment||Boehringer Ingelheim||Completed|January 2006|||October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|September 24, 2014||||No||https://clinicaltrials.gov/show/NCT02259855||35353|
NCT02260310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL40GB30|The Effect of Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points in Treating Ankylosing Spondylitis|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02260310||35318|
NCT02275429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/CHU/03|Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal|Etude Des Troubles métaboliques Induits Par Une Course à Pied très Longue Distance, " La Diagonale Des Fous " de La Réunion / Metabolic Disorders in Ultramarathon Runners of the Madmen's Diagonal Race on Reunion Island|METARUN|Centre Hospitalier Universitaire de la Réunion|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|106|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02275429||34156|
NCT02260323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT20141003|Compliance of Traditional Chinese Medicine in Young Patients With Rheumatic Diseases|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|35 Years|No|||August 2015|August 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02260323||35317|
NCT02260596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056727|Respiratory Viral Infections in Pediatric Transplantation|A Multicenter Consortium to Define the Epidemiology and Outcomes of Respiratory Viral Infections in Pediatric Transplant Recipients||Duke University|Yes|Completed|September 2014|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2669|||Both|N/A|18 Years|No|Non-Probability Sample|The study cohort will consist of any SOT or HSCT recipient ≤18 years of age that received        their transplant between January 1st, 2010 and June 30th, 2013. Participants will have        information collected from 30 days prior to transplant until the first of the following:        365 days post receipt of transplant, death, or loss to follow-up. If a patient has more        than one viral respiratory infection of the same pathogen during the study period, then        only the first infection will be considered unless isolated at least one month after the        first positive test and only if after at least two negative tests for that same virus. A        patient can contribute more than one viral respiratory infection if they are caused by        different viral pathogens.|July 2015|December 14, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02260596||35296|
NCT02265276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO/2014/4|A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease|A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (GLAZED Trial)|GLAZED|Command Hospital, India|No|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2014|October 14, 2014|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265276||34936|
NCT02265289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|509.302|Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects|Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Fradafiban After Oral Doses of 30 mg Lefradafiban Tid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial.||Boehringer Ingelheim||Completed|January 1999|||February 1999|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02265289||34935|
NCT02270346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaziUniversity|Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients|Effects of Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients||Gazi University|No|Completed|March 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|65 Years|No|||October 2014|October 18, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270346||34547|
NCT02262052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeidenU|Advanced Diagnostic Management of Suspected Recurrent Ipsilateral DVT With MRDTI|Advanced Diagnostic Management of Suspected Recurrent Ipsilateral Deep Vein Thrombosis of the Leg With Magnetic Resonance Direct Thrombus Imaging|Theia|Leiden University Medical Center|No|Recruiting|March 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|305|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02262052||35184|
NCT02262299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-HJE-2014-09|European Trial of Pirfenidone in BOS, A European Multi-center Study|A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-2 in Lung Transplant Recipients|EPOS|Rigshospitalet, Denmark|Yes|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02262299||35165|
NCT02262572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.415|Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects|Relative Bioavailability of Telmisartan and HCTZ p.o. (80 mg Telmisartan/12.5 mg HCTZ) in Two Experimental Formulations (Given t.i.d. for One Day Each) Compared to the Standard Formulation 80 mg Telmisartan/12.5 mg HCTZ (MicardisPlus®), Given t.i.d. for One Day in Healthy Female and Male Subjects. A Three-way Crossover, Open, Randomised Study||Boehringer Ingelheim||Completed|April 2003|||August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02262572||35144|
NCT02262585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.417|Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers|Bioequivalence Study of BIBR 277 Tablet (Mannitol Based) Compared With Its Capsule Formation in Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 2002|||August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02262585||35143|
NCT02262598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.437|Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers|Bioequivalence of 40 mg Telmisartan / 12.5 mg HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|September 2004|||October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02262598||35142|
NCT02285998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC12|Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age|Comparison of the Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age||Protein Sciences Corporation|No|Active, not recruiting|October 2014|December 2015|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|9000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285998||33344|
NCT02282891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014189|Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia|A Randomized-Controlled Trial to Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia||Yale University|No|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282891||33583|
NCT02282904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150007|Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide|Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Post-Transplant Cyclophosphamide||National Institutes of Health Clinical Center (CC)||Recruiting|October 2014|January 2034|Anticipated|January 2024|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||September 2015|March 23, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02282904||33582|
NCT02262260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DTR01|Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME|A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.|SALUTE-D|Novartis|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262260||35168|
NCT02274350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEH-2014-091|The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects|The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects||Herlev Hospital|Yes|Completed|May 2015|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|515|||Male|N/A|N/A|No|Non-Probability Sample|All patients have received either external beam radiation therapy or brachie therapy as        definitive treatment for localized prostate cancer between at Herlev hospital, Copenhagen,        Denmark between 3 months and 5 years prior to being invited to participate in the study.|February 2016|February 17, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02274350||34239|
NCT02266667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140303|Surgical Treatment of Progressive Scoliosis With "NEMOST" Growing Rod|Evaluation of the Efficiency of Nemost Growing Spine Device Associated With Physiotherapy in the Surgical Treatment of Progressive Scoliosis of the Child|NEMOST|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|5 Years|15 Years|No|||January 2016|January 14, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02266667||34830|
NCT02266680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/2011|Breathing Focused Yoga in Social Anxiety Disorder|A Randomized Controlled Trial of the Effectiveness of Breathing Focused Yoga (BFY) in Improving Symptoms of Social Anxiety Disorder||Centre for Addiction and Mental Health|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02266680||34829|
NCT02266953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/726|The Use of Communication Tool About Diet|The Use of Communication Tool About Diet in Public Health Nurse Consultations at the Child Health Centre When the Child is Aged 10 Months to 2 Years||Oslo and Akershus University College of Applied Sciences|No|Recruiting|January 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|6 Months|3 Years|No|||February 2016|February 1, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02266953||34808|
NCT02266966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F02695LP105|Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging|||Pierre Fabre Medicament|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|October 13, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02266966||34807|
NCT02276079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400882|The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury|The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury||University of Florida|Yes|Recruiting|February 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02276079||34106|
NCT02268305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140075H|The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain|The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain.||Mike O'Callaghan Federal Hospital|No|Recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268305||34704|
NCT02268318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU359|"A Clinical Study for Evaluating the Effect of a Plant Sterol-enriched Fermented Dairy Product on Blood Lipoprotein Profile in Japanese Adults"|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFECT OF A 12-WEEK CONSUMPTION PERIOD OF SINGLE DOSE A DAY OF A PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT ON BLOOD LIPOPROTEIN PROFILE IN JAPANESE ADULTS WITH HIGH LDL-C||Danone Research|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|154|||Both|20 Years|75 Years|No|||October 2014|October 16, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268318||34703|
NCT02275325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01189-38|Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery|Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery|ReveSTAN|Central Hospital, Nancy, France|Yes|Recruiting|January 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||March 2015|March 3, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275325||34164|
NCT02275364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202178|Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Congestion|A Magnetic Resonance Imaging Study of Nasal Strips in Subjects With Nasal Congestion||GlaxoSmithKline|No|Completed|August 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 22, 2014||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT02275364||34161|
NCT02259517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6961|An fMRI Study of Non-Stimulant Treatment of ADHD|Imaging Non-Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD)||New York State Psychiatric Institute|Yes|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259517||35379|
NCT02264470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUPersson|Fall Study in Gothenburg (FallsGOT)|Identification of Fall Risk in Patients With Stroke During Inpatient Rehabilitation on a Stroke Unit|FallsGOT|Göteborg University|Yes|Recruiting|October 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|The group will consist of consecutively included patients with clinical stroke at the        stroke unit at Sahlgrenska University Hospital/Östra, Gothenburg.|August 2015|August 11, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02264470||34998|
NCT02274285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J2I02 (EFC13640)|DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants|Immunogenicity and Safety of the DTaP-IPV/Hib Vaccine SP0204) Given as Three-dose Primary and One-dose Booster Vaccinations Versus Co-administration of DTaP-IPV Vaccine (DD-687) and Hib Vaccine (DF-098) in Infants in Japan||Sanofi|No|Active, not recruiting|October 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|414|||Both|2 Months|68 Months|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274285||34244|
NCT02274363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100727|A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis|Assessment of Psoriasis Severity in Brazilians Patients With Chronic Plaque-type Psoriasis Attending Outpatient Clinics: a Multicenter, Observational, and Cross-sectional Study (APPISOT)||Janssen Pharmaceutica|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1131|||Both|18 Years|N/A|No|Non-Probability Sample|Participants at least 18 years of age with chronic plaque psoriasis under outpatient        follow-up will be included irrespective of disease severity.|April 2015|April 13, 2015|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274363||34238|
NCT02263391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3878|HIV Risk and Prevention in Women|Collaborative Biosocial Research on HIV Risk and Prevention in Women||University of Oklahoma|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|44 Years|No|||May 2015|June 2, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02263391||35081|
NCT02263677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERCK-9938|Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI||University of Missouri-Columbia|No|Recruiting|March 2014|||December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||October 2014|October 8, 2014|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263677||35059|
NCT02264288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA-002-DFU-002|Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease|A Phase 2 Multicenter, Randomized, Doubleblind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease||Celgene|Yes|Recruiting|October 2014|July 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|133|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264288||35012|
NCT02268110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-566-13|The Effect of Conservative Interventions on the Signs and Symptoms of Diastasis Recti|The Effect of Exercise Therapy and/or Abdominal Binding on Inter-rectus Distance, Abdominal Muscle Strength, Lumbopelvic and Urogynecological Complaints, Perceived Function, and Body Image in Post-partum Women With Diastasis Recti||Queen's University|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|108|||Female|18 Years|35 Years|No|||August 2015|August 28, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268110||34719|
NCT02274610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOPNP201|Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer|Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor|DOPNP201|Samyang Biopharmaceuticals Corporation|No|Not yet recruiting|November 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02274610||34219|
NCT02274623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-1017|Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid|Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid||OPKO Health, Inc.|No|Recruiting|December 2014|February 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274623||34218|
NCT02291146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R21 DK094066-02|LA Sprouts: The Impact of Gardening and Nutrition Education on Childhood Obesity in Latino Youth|LA Sprouts: The Impact of Gardening and Nutrition Education on Childhood Obesity in Latino Youth|LA Sprouts|University of Southern California|No|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|421|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02291146||32949|
NCT02280811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150005|T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers|A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers||National Institutes of Health Clinical Center (CC)||Recruiting|October 2014|May 2020|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|70 Years|No|||January 2016|February 20, 2016|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280811||33742|
NCT02281071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU2|Microsurgical Instruments and Magnification May Enhance Treatment Outcomes Of Laterally Moved, Coronally Advanced Flap in Miller Class III Isolated Recession Defects|Microsurgical Instruments and Magnification May Enhance Treatment Outcomes Of Laterally Moved, Coronally Advanced Flap in Miller Class III Isolated Recession Defects||Cukurova University||Completed|January 2012|October 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|22 Years|39 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281071||33722|
NCT02286167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1444 NA_00093542|Glioma Modified Atkins-based Diet in Patients With Glioblastoma|The Feasibility and Biologic Effect of a Modified Atkins-based Intermittent Fasting Diet in Patients With Glioblastoma (GBM)|GLAD|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286167||33331|
NCT02259985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208.629|Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects|Investigation of the Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose of 1 mg in Healthy Male Subjects (3-way Cross-over)||Boehringer Ingelheim||Completed|March 1998|||May 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259985||35343|
NCT02259998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21.449|Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers|An Open-labelled, Randomised, 2-way Crossover Study to Compare the Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets 75 mg p.o. (Present and Proposed Formulation in France) q.i.d. for Three Days in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2001|||December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259998||35342|
NCT02260011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2498|Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease|A Single-Dose, Double Blind, Crossover Trial to Determinate the Comparability of Ipratropium Bromide HFA-134a Inhalation Aerosol to the Market Standard, Atrovent® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2000|||February 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|41|||Both|40 Years|N/A|No|||October 2014|October 7, 2014|September 11, 2014||||No||https://clinicaltrials.gov/show/NCT02260011||35341|
NCT02260362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14126|Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease|Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease|ItinerAir|French Cardiology Society|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|1 Month|N/A|No|Non-Probability Sample|All patients with Pulmonary Arterial Hypertension of Congenital Heart Disease supported by        one of the 20 centers participating in the observatory during the period incusion and        respecting al the selection criteria|February 2015|February 12, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260362||35314|
NCT02273011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEvsSSSA|Combined Spinal-epidural Versus Spinal Analgesia for Elective Caesarean Section in the Postoperative Period|Combined Spinal-epidural Versus Spinal Analgesia for Elective Caesarean Section in the Postoperative Period||Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Female|18 Years|50 Years|No|Probability Sample|healthy parturients scheduled for elective caesarean section|October 2014|October 21, 2014|January 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02273011||34342|
NCT02265939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-13|Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy|||Nihon Pharmaceutical Co., Ltd|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|132|||Both|20 Years|N/A|No|||April 2015|April 13, 2015|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02265939||34886|
NCT02266212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS101-016|A Study on Analgesia and Related Outcomes for Patients With Tabacco Smoking|||Kaohsiung Veterans General Hospital.||Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 12, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266212||34865|
NCT02262689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402|To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions|A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions||GlaxoSmithKline|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262689||35135|
NCT02262702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202175|Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study|Panadol Osteo PBS Claims Cohort Study||GlaxoSmithKline|No|Withdrawn|January 2013|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|0|||Both|50 Years|85 Years|No|Probability Sample|Cohort of Australian concessional patients with osteoarthritis|January 2016|January 21, 2016|May 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02262702||35134|
NCT02263144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDEFINE|Resect and Discard Extension to FICE of NIcE Classification|Resect and Discard Extension to Fuji Intelligent Color Enhancement (FICE) of Narrow Band Imaging International Colorectal Endoscopic (NicE) Classification|FICE;NICE|Istituto Clinico Humanitas|No|Recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|Samples Without DNA|colonic polyps|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive adult patients who were referred for elective outpatient colonoscopy|October 2014|October 8, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02263144||35100|
NCT02267577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-082F-A|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers||William Marsh Rice University|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 90 men and women adults (at least 18 years of age) willing and able to provide        consent.|May 2015|October 26, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02267577||34760|
NCT02274129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C51|Clinical Survey of Oticon Medical Healing Cap|C51 - Clinical Survey of Oticon Medical Healing Cap||Oticon Medical|No|Active, not recruiting|July 2014|August 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|February 11, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02274129||34256|
NCT02267889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRBH01|Ganglionated Plexus Ablation For Treatment of Atrial Fibrillation|A Pilot Study on the Role pf Ganglionated Plexus Ablation for Catheter Ablation of Atrial Fibrillation.||Spectrum Dynamics|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|80 Years|No|||February 2015|February 20, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267889||34736|
NCT02274584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30273-4SCAR|CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas||Peking University|Yes|Recruiting|March 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274584||34221|
NCT02260063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.252|Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers|A Trial in Healthy Volunteers of the Relative Bioavailability of Epinastine Syrup, a New Galenic Form, Compared to the Reference Product Tablets||Boehringer Ingelheim||Completed|November 1998|||January 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|October 8, 2014||||No||https://clinicaltrials.gov/show/NCT02260063||35337|
NCT02260076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2030|Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects|Safety of Total Daily Doses of 5, 10, 15 and 20 mL PEG 400 Administered Orally to Healthy Male Human Subjects Once (QD) or Twice (BID) for 14 Days. A Single Center, Multiple Rising Dose Study, Placebo Controlled, Double-blinded at Each Dose Level||Boehringer Ingelheim||Completed|September 2001|||March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|October 8, 2014||||No||https://clinicaltrials.gov/show/NCT02260076||35336|
NCT02285894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/375 (REK)|Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients?|Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients? A Pilot Study.||Oslo University Hospital|No|Recruiting|November 2014|August 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285894||33352|
NCT02285959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlobalNI|Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme|Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme||Global Neurosciences Institute|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|November 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285959||33347|
NCT02272751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0108|Relaxation and Exercise In Lymphoma Patients|A Comparison of Exercise Training With Relaxation Intervention in Lymphoma Patients Post-chemotherapy.|REIL|St George's, University of London|Yes|Recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02272751||34362|
NCT02264782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03142|PreView: The Preventive Video Education in Waiting Rooms Program|PreView: The Preventive Video Education in Waiting Rooms Program|PreView|University of California, San Francisco|No|Recruiting|July 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|572|||Both|50 Years|70 Years|No|||October 2015|October 30, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02264782||34974|
NCT02265055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|u12345|Early Embryo Cleavage And Multiple Pregnancies After ICSI|Early Embryo Cleavage And Multiple Pregnancies After ICSI||Al-Azhar University||Completed|December 2010|December 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|193|||Female|N/A|35 Years|No|||October 2014|October 9, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265055||34953|
NCT02260674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105240|A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease||Janssen Research & Development, LLC|Yes|Active, not recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|114|||Both|50 Years|85 Years|No|||February 2016|February 15, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260674||35290|
NCT02272712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140224-01H|The Effectiveness of Online Treatment for Insomnia in Cancer Survivors|The Effectiveness of Online Treatment for Insomnia in Cancer Survivors: A Randomized Controlled Trial||Ottawa Hospital Research Institute|No|Not yet recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02272712||34365|
NCT02272764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-214|A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study of the Effects of Itraconazole on the Pharmacokinetics of ALKS 5461 in Healthy Volunteers||Alkermes, Inc.|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02272764||34361|
NCT02272777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ECN02E1|A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase|An Open-label Multi-center Study of Imatinib and Nilotinib in CAMN107ECN02 On-treatment Patients With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase After the End of CAMN107ECN02 Core Study||Novartis|No|Active, not recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272777||34360|
NCT02272842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808734|Vitamin B12, Neurodevelopment and Growth in Nepal|The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development|BeLive|Centre For International Health|No|Recruiting|April 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|6 Months|11 Months|No|||April 2015|April 21, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272842||34355|
NCT02267304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-02|Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)|Etude Comparative Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, de l'Action de la Morphine et de la Naloxone Dans un modèle Cognitif de Gestion Des Efforts Physiques|MBBAnalgesic|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|October 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02267304||34781|
NCT02267564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014099|MPFL Reconstruction With or Without Tibial Tubercle Transfer|Medial Patellofemoral Ligament (MPFL) Reconstruction With or Without Tibial Tubercle Transfer for Recurrent Patellar Instability||Peking University Third Hospital|Yes|Recruiting|September 2014|December 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|40 Years|No|||October 2014|October 16, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02267564||34761|
NCT02274142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTCARDEC|Cost-effectiveness of ART Using Encapsulated or Powder-liquid Glass Ionomer Cement: Clinical Trial|Randomized Clinical Trial, Double-blinded on ART Restorations||University of Sao Paulo|No|Recruiting|October 2014|October 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02274142||34255|
NCT02274298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074-2013-2|Improving Care for Patients With Chronic Kidney Disease Using EMRALD|Improving Care for Patients With Chronic Kidney Disease Using Electronic Medical Record Interventions: A Pragmatic Cluster Randomized Trial||Sunnybrook Health Sciences Centre|No|Enrolling by invitation|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|221|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 24, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02274298||34243|
NCT02274376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21556|Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer|NIS Xeloda in Gastric Cancer||Hoffmann-La Roche||Completed|August 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|223|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced gastric cancer eligible for Xeloda (capecitabine)|March 2016|March 1, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02274376||34237|
NCT02259595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-07-PK-101|Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC|Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects||Otologic Pharmaceutics, Inc.|Yes|Completed|October 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259595||35373|
NCT02264535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-YXPU-ZS-IV4|A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.|A Pilot Study for Ginkgolides Meglumine Injection Skin Testing||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Completed|June 2014|||November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|149|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|November 26, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02264535||34993|
NCT02264548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Ablation|A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy|A Phase I Study Evaluating the Integration of Hypofractionated Renal Ablative Radiotherapy in the Setting of Metastatic Renal Cell Carcinoma||Lawson Health Research Institute|Yes|Recruiting|July 2009|July 2019|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02264548||34992|
NCT02264561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.12.NRC|Caffeine's Effect on Attention|The Effect of Caffeine on Attention||Nestlé|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|71|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02264561||34991|
NCT02280486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSSAXA0014|Safety and Efficacy of Saxagliptin vs.Glimepiride as Add-on Therapy in T2DM Patients With Metformin Monotherapytients|A 48-week, Multi-center, Randomized, Open Label, Parallel Group Comparison of the Comprehensive Glycemic Control of Saxagliptin and Glimepiride in Patients Inadequately Controlled With Metformin Monotherapytients With Type 2 Diabetes||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|25 Years|75 Years|No|||February 2016|February 16, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02280486||33767|
NCT02280499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8240-1|Multicenter Clinical Observation PROMOS®|Multicenter Clinical Observation PROMOS®||Smith & Nephew, Inc.||Completed|November 2003|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2016|February 23, 2016|October 29, 2014||No||No|January 25, 2016|https://clinicaltrials.gov/show/NCT02280499||33766|One limitation of the study relates to the small number of subjects available at the 10 year interval for final analysis due to the early termination of 2 sites.
NCT02288429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2597|Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium|Evaluation of Steady-state Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium in Cystic Fibrosis and Critically Ill Patients||University of Colorado, Denver|No|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Plasma|Both|18 Years|89 Years|No|Non-Probability Sample|Inpatients at the University of Colorado Hospital|January 2016|January 13, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02288429||33157|
NCT02288442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEMadrid|Whole Muscle Exercise Training (WHOLEi+12) in Pulmonary Hypertension|Exercise Training (WHOLEi+12) in Pulmonary Hypertension|WHOLEi+12|Universidad Europea de Madrid|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2015|July 6, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288442||33156|
NCT02288611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJWA STUDY|The Impact of Palm Date Intake on Colon Health Biomarkers|A Randomised, Controlled Intervention Trial to Assess the Impact of Palm Date Intake on Markers of Large Intestinal Health|AJWA|University of Reading|No|Completed|May 2012|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|N/A|55 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02288611||33143|
NCT02259556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-BT-011|CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|CART30|Chinese PLA General Hospital|Yes|Recruiting|October 2014|October 2029|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|80 Years|No|||January 2016|January 26, 2016|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02259556||35376|
NCT02270905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRG-D02-01|Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus|An Open Non-comparative Clinical Investigation of a Novel Decellularised Porcine Xenograft (dCELL® Meniscus) for Partial Replacement of the Meniscus||Tissue Regenix Ltd|No|Recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|50 Years|No|||June 2015|June 17, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270905||34504|
NCT02272647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002829|Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women|Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women||Mayo Clinic|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|65|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272647||34370|
NCT02265328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBS-2014|Efficacy of Combination Therapy of Glucocorticoids and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis.|Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study.|COBS|Dayanand Medical College and Hospital|Yes|Completed|September 2014|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02265328||34932|
NCT02273973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28888|A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)|A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer||Genentech, Inc.||Recruiting|November 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Female|18 Years|N/A|No|||September 2015|September 9, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273973||34268|
NCT02274051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0762|The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia|The Safety and Tolerability of Kinetin, a Nutritional Supplement That Corrects the Splicing Defect, in Patients With Familial Dysautonomia||New York University School of Medicine|No|Recruiting|November 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|16 Years|N/A|No|||October 2015|October 26, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02274051||34262|
NCT02274116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044670|Acute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury|Repetitive Exposure of Intermittent Hypoxia to Enhance Walking Recovery in Persons With Chronic Spinal Cord Injury||Emory University|No|Recruiting|October 2014|August 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|77 Years|No|||November 2015|November 18, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02274116||34257|
NCT02274194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 102/13|Type of Breathing and CPAP on Patients With Obstructive Sleep Apnea|Nasal, Oral, Oronasal Breathing and CPAP on Nasal Mucociliary Clearance, Mucus Properties, Cytokines in Nasal Lavage and Exhaled Breath Condensate pH of Patients With Obstructive Sleep Apnea||University of Sao Paulo|Yes|Recruiting|April 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02274194||34251|
NCT02274207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-14-NPWT|Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound|Phase IV Study of Antibacterial Effect on Silver Dressing of NPWT|NPWT-silver|Severance Hospital|No|Recruiting|December 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|20 Years|N/A|No|||November 2015|November 22, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02274207||34250|
NCT02273999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2976P|Pulsed Electromagnetic Fields for Postoperative Pain: a Linical Trial in Humans|Pulsed Electromagnetic Fields for Postoperative Pain: a Randomized Controlled Clinical Trial in Patients Undergoing Mandibular Third Molar Extraction||University of Padova, School of Dental Medicine|Yes|Completed|September 2012|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|14 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273999||34266|
NCT02274064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R56HL119180|Motivating Type O- Blood Donors to Return|Motivating Type O- Blood Donors to Return||Ohio University|No|Active, not recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|598|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02274064||34261|
NCT02259101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065796|RCT of CBT for Insomnia With PLWHA|A Randomized Controlled Trial of Cognitive Behavior Therapy for Insomnia With Persons Living With HIV/AIDS||Emory University|No|Recruiting|November 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02259101||35411|
NCT02259374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/729/D|Use of Tap Block in Patients After Hysterectomy|Use of Tap Block in Patients After Hysterectomy||Singapore General Hospital|Yes|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Female|21 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 5, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02259374||35390|
NCT02264314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UChile|Tele-educative Program to Improve Adherence to the Use of Hearing Aids in Patients With Hearing Loss|Tele-educative Program to Improve Adherence to the Use of Hearing Aids in Patients With Hearing Loss: a Randomized Clinical Trial||University of Chile|No|Active, not recruiting|July 2012|December 2014|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|65 Years|N/A|No|||October 2014|October 14, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264314||35010|
NCT02274155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-042A|Anti-OX40 Antibody in Head and Neck Cancer Patients|Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma||Providence Health & Services|No|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274155||34254|
NCT02275572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/12|Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients|Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients|REMEI|Consorci Sanitari del Maresme||Completed|March 2012|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|503|||Both|70 Years|N/A|No|||October 2014|October 23, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275572||34145|
NCT02285569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16496|The Pleth Variability Index and Hypotension at Caesarean Under Spinal.|Can Changes in the Pleth Variability Index be Used to Predict Significant Hypotension During Spinal Anaesthesia for Caesarean Section?||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|17|||Female|18 Years|55 Years|No|Non-Probability Sample|Patients with a singleton uncomplicated pregnancy presenting for elective caesarean        section under spinal anaesthesia where surgery and anaesthesia are anticipated to be        uncomplicated.|May 2015|May 26, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285569||33377|
NCT02277236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB01671|Screening for Age-Related Skeletal Muscle Dysfunction|Creating a Model of Proactive Geriatric Care Within VISN 5: Screening for Age-Related Skeletal Muscle Dysfunction at the Washington DC VA Medical Center|ARMS|Washington D.C. Veterans Affairs Medical Center|No|Active, not recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|Blood samples will be collected for determination of lipid profiles, HbAC1, selected      cytokines (IL-6, IL-10, TNF-α), macrophages, unoxidized long-chain fatty acyl CoAs      (LCFA-CoAs), acylcarnitine conjugates, and the HOMA-IR.|Male|45 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veteran men (45-85 years of age; n = 30) consecutively recruited from outpatients at the        DC VAMC and assigned to a "younger" or "young old" group (i.e., 45-64.9, and 65-84.9 years        of age).|January 2016|January 3, 2016|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02277236||34017|
NCT02264509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InstitutoNCMNSZ-CIIBH693|Peripheral Arterial Insufficiency Associated With HIV/AIDS|Prevalence and Risk Factors of Arterial Insufficiency in Patients With HIV / AIDS|AIHIV|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|September 2014|December 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|18 Years|89 Years|No|Probability Sample|The 206 patients will be randomly selected from the cohort HIV / AIDS INCMNSZ, which have        confirmed diagnosis of the disease and wish to participate in the study, without a disease        that put life in imminent danger.|January 2016|January 28, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02264509|1 Day|34995|
NCT02270632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F8IL10-03/13|A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.||Philogen S.p.A.|No|Recruiting|October 2014|June 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|87|||Both|18 Years|75 Years|No|||October 2014|October 17, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270632||34525|
NCT02273895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-CT-001|The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study|Development of a Diagnostic Tool for Alzheimer's Disease||Mentis Cura|No|Completed|April 2004|January 2010|Actual|October 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|29|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273895||34274|
NCT02273986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-106|Drug-Drug Interaction Study in Health Adult Volunteers|||Kowa Research Institute, Inc.||Completed|August 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273986||34267|
NCT02261298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-14|ONO-4538 Phase I Study in Patients With Solid Tumor|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid Tumor||Ono Pharmaceutical Co. Ltd|No|Active, not recruiting|October 2014|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|N/A|No|||September 2014|January 16, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261298||35242|
NCT02261545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25367|The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient|The Effect of n-3 Fatty Acid Supplementation on the Expression of Sirt-1, Adiponectin Receptor 1 (AdipoR1) & Adiponectin Receptor 2 (AdipoR2) Genes of PBMC and Circulatory Levels of Resistin,Monocyte Chemotactic Protein (MCP-1) and Adiponectin of type2 Diabetes Patient||Tehran University of Medical Sciences|Yes|Enrolling by invitation|September 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|30 Years|65 Years|No|||November 2015|November 17, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261545||35223|
NCT02261831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6936 03|Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood|Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood.|MICIMAB|University Hospital, Toulouse|No|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|120|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02261831||35201|
NCT02262104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2012-1150|Effects of an Exercise Program for Nursing Home Patients With Dementia|Effects of an Exercise Program for Nursing Home Patients With Dementia - a Six Months Assessor Blind Randomized Controlled Trial|EXDEM|Oslo and Akershus University College of Applied Sciences|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|55 Years|N/A|No|||December 2014|December 2, 2014|November 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02262104||35180|
NCT02262338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT-182-101|Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome|A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)||ArmaGen, Inc|Yes|Recruiting|March 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262338||35162|
NCT02275117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD403-CLIN-005|A Multicenter Assessment of ALD403 in Chronic Migraine|A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine||Alder Biopharmaceuticals, Inc.|No|Active, not recruiting|October 2014|November 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|617|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275117||34180|
NCT02258841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 105436|Effectiveness of an Online Safety Tool for Canadian Women Experiencing Intimate Partner Violence|Testing an Internet-based Safety Decision Aid for Women Experiencing Intimate Partner Violence||Western University, Canada|Yes|Active, not recruiting|October 2014|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|462|||Female|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258841||35431|
NCT02263690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RetinaC|Comparison of Three Different Anesthetic Approaches for Intravitreal Injections|Comparison of Three Different Anesthetic Approaches for Intravitreal Injections: A Prospective Randomized Trial||Retina Clinic, Sao Paulo, Brazil|Yes|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|92|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02263690||35058|
NCT02268383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A536-05|ACE-536 Extension Study - Myelodysplastic Syndromes|An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03||Acceleron Pharma, Inc.|No|Recruiting|October 2014|November 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268383||34698|
NCT02263937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0538|Deep Brain Stimulation for Patients With Dementia With Lewy Bodies|Double Blind, Randomised, Dual Centre, Crossover, Pilot Trial of Bilateral Nucleus Basalis of Meynert Deep Brain Stimulation to Improve Cognitive Deficits in Patients With Dementia With Lewy Bodies.||University College, London|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|50 Years|80 Years|No|||June 2015|June 3, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02263937||35039|
NCT02270931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-69|A Prospective Longitudinal Breast Cancer Study|A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients With Breast Cancer||Fujirebio Diagnostics, Inc.|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples Without DNA|Serum and Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 130 subjects will be enrolled in this study. Women and men greater than or        equal to 18 years of age with a histologically/pathologically confirmed diagnosis of        breast cancer and a minimum of three serial blood draws collected at disease evaluation        time points, as determined by the treating physician's standard of care, will be eligible.|November 2015|November 20, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02270931||34502|
NCT02260401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39023|Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis|Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis|LESSER|University of Washington|No|Completed|October 2013|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|165|||Both|50 Years|N/A|No|||December 2015|December 3, 2015|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260401||35311|
NCT02288299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01005-42|Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease|Long-Term Effect of LIAM (Lung Insufflation Assist Maneuver) on Respiratory Performance in Non-invasive Ventilated Patients Suffering From Neuromuscular Disease|LIAM|Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|October 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288299||33167|
NCT02276963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBX-001|Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses|Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)||Johns Hopkins University|Yes|Recruiting|September 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276963||34038|
NCT02276976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BCB022|MRI,Gene And Cognitive Performance Study of Patients With Cerebral White Matter Lesions(WMLs)|MRI,Gene And Cognitive Performance Study of Patients With Cerebral White Matter Lesions||Huazhong University of Science and Technology|Yes|Recruiting|March 2014|September 2019|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|DNA extracted from whole blood sample|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with cerebral white matter lesions|December 2015|December 11, 2015|October 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02276976||34037|
NCT02270385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20140223001|The Effectiveness of a Pressure Ulcer Prevention Programme for Older People in For-profit Private Nursing Homes|The Effectiveness of a Pressure Ulcer (PU) Prevention Programme for Older People in For-profit Private Nursing Homes (NHs): a Cluster Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Not yet recruiting|January 2015|December 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1126|||Both|18 Years|N/A|No|||October 2014|October 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270385||34544|
NCT02270645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120815|Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser|Randomized Pilot Study of Treatment for Basal Cell Carcinoma Using the Multiplex 595/1064 nm Laser|BCC|University of Miami|Yes|Recruiting|October 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270645||34524|
NCT02260375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC liver transplant tolerance|MSC Therapy in Liver Transplantation|THIRD-PARTY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVER TRANSPLANT RECIPIENTS||A.O. Ospedale Papa Giovanni XXIII|No|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260375||35313|
NCT02273804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091122|Topiramate and Severe Obesity|Topiramate and Severe Obesity in Children and Adolescents|TOBI|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|June 2015|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|9 Years|17 Years|No|||October 2014|October 22, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273804||34281|
NCT02273817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICE-NASU-05SB03-CE|A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Bioquivalence of Ciclesonide Nasal Spray(Apotex Inc.) to That of Omnaris ™Nasal Spray (Sepracor, Inc.) in the Treatment of Seasonal Allergic Rhinitis||Apotex Inc.|Yes|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|580|||Both|18 Years|65 Years|No|||February 2012|October 23, 2014|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273817||34280|
NCT02273830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131001|Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation During Exercise.|Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation on Exercise But Without Conventional Criteria for Domiciliary Oxygen Therapy.||Hospital de Granollers|No|Not yet recruiting|September 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273830||34279|
NCT02260947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5261005|Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebocontrolled, 5 Period Cross-over Study To Examine The Effect of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls||Pfizer|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260947||35269|
NCT02260960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 20142|The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease|The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease.||Physician Recommended Nutriceuticals||Completed|March 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|122|||Both|18 Years|90 Years|No|||June 2015|June 5, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260960||35268|
NCT02261311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130232-01H|An Innovation During the Surgical Wait; Evaluation of the Opportunity for Intervention|An Innovation During the Surgical Wait; Evaluation of the Opportunity for Intervention|RADS II|Ottawa Hospital Research Institute|No|Not yet recruiting|November 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Additional tissue samples will be collected at the time of initial biopsy. The samples will      be stored for neoadjuvant studies that the patient may choose to participate in during the      wait time between diaganosis and surgery.|Female|19 Years|N/A|No|Probability Sample|Women with BIRADS 4/5 on initial mammogram.|November 2015|November 23, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02261311||35241|
NCT02266433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00878|Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders|A Double-blinded, Prospective, Randomized, Controlled Trial Comparing Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders||New York University School of Medicine|Yes|Recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|780|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266433||34848|
NCT02273271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1217|Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo|Evaluation of 3'-Deoxy-3'-[18F]Fluorothymidine -PET and Diffusion Weighted Imaging -MRI in Patients With Early Stage Non-small Cell Lung Cancer Treated With a Platinum-based Doublet as Preoperative Chemotherapy|EVIDENCE|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|31|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02273271||34322|
NCT02266771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2169|Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice|Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice||LifeBridge Health|No|Recruiting|September 2014|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02266771||34822|
NCT02267031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-2012|The Role of Perioperative Ventilation (Gas Exchange) During Intrabdominal Surgery on Cognitive Function|The Role of Perioperative Ventilation (Gas Exchange) During Intrabdominal Surgery on Cognitive Function: a Randomized Clinical Study|ACDYS|Northern State Medical University|No|Recruiting|October 2012|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02267031||34802|
NCT02263404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-004|PINS Stimulator System to Treat Severe Anorexia Nervosa|PINS Stimulator System to Treat Severe Anorexia Nervosa||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|20 Years|60 Years|No|||March 2015|October 12, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02263404||35080|
NCT02268396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003016-00|Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD|An Open-Label, Multi-Center, Dose Indicator Study of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) in Adult Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)||Pearl Therapeutics, Inc.|No|Completed|November 2014|May 2015|Actual|January 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|40 Years|80 Years|No|||July 2015|July 7, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268396||34697|
NCT02275468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-2009-Ⅲ-01|Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4|Fu-zheng-qu-zhuo Oral Liquid Combined With Integrated Therapy Improves Renal Function in Patients of Chronic Kidney Disease Stage 3 and 4，a Randomized Placebo-Control Clinical Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|June 2010|October 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||October 2014|October 23, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275468||34153|
NCT02268643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-breast-screening 2|Ultrasound-based Breast Cancer Screening in Chinese Women|Ultrasound-based Breast Cancer Screening in Chinese Women||Peking Union Medical College Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Female|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy women without breast-related symptoms|October 2014|October 15, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02268643||34678|
NCT02268656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCIRB2014-153|Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction With a Single-dose Dexmedetomidine|Preducted Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction|D-pofol|Gachon University Gil Medical Center|Yes|Completed|October 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|2||Actual|40|||Both|20 Years|60 Years|No|||April 2015|April 20, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02268656||34677|
NCT02275533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02167|Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy|Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy||National Cancer Institute (NCI)|No|Recruiting|May 2015|||June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|March 8, 2016|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275533||34148|
NCT02282384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVT-2014|An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.|A Randomized Controlled Trial of Oseltamivir in Outpatients With Chronic Pulmonary Disease: a Pilot Study|AVT|McMaster University|Yes|Not yet recruiting|October 2014|September 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|90 Years|No|||October 2014|October 31, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02282384||33622|
NCT02285972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odu-5|Efficacy of Intravenous Dexketoprofen and Tenoxicam on Propofol Associated Injection Pain|||T.C. ORDU ÜNİVERSİTESİ||Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|118|||Both|18 Years|65 Years|No|||November 2014|April 18, 2015|November 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02285972||33346|
NCT02285985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032|Effects of Saxagliptin on Adipose Tissue Inflammation in Humans|Effects of Saxagliptin on Adipose Tissue Inflammation in Humans||Phoenix VA Health Care System|No|Recruiting|February 2013|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|70 Years|No|||March 2015|March 25, 2015|June 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285985||33345|
NCT02265341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1345|Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions|Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions||Mayo Clinic|Yes|Recruiting|December 2014|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|March 8, 2016|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265341||34931|
NCT02260687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17416|Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization|Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization||Bayer|No|Recruiting|December 2014|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients with mCNV(myopic choroidal neovascularization) diagnosis will be        enrolled after the investigators have taken the decision for the treatment with EYLEA.        Those patients who have had EYLEA prescribed previously will not be included in this        study. Physicians should consult the full prescribing information for EYLEA before        enrolling patients and be familiarized with the safety information in the product package        label.|March 2016|March 7, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260687||35289|
NCT02265952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1500-CL-1331|Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)|An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia||Regeneron Pharmaceuticals|No|Recruiting|October 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265952||34885|
NCT02266225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19377|Measuring the Implementation of the LiFE Program in Primary Care for Older Adults Aged 75 Years or Older|Measuring the Implementation of a Group-based Lifestyle-integrated Functional Exercise (Mi-LiFE) Intervention Delivered in Primary Care for Older Adults Aged 75 Years or Older: A Pilot Feasibility Study|Mi-LIFE|University of Waterloo|Yes|Active, not recruiting|June 2014|January 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|75 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266225||34864|
NCT02275026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0359|Trajectory of Recovery in the Elderly|Trajectory of Recovery in the Elderly|TORIE|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2015|March 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|76|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275026||34187|
NCT02273843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS 306|A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis|Effect of Different Dosages Oral Vitamin D on Serum Interleukin-6 in Preterm Infants With Late-onset Sepsis||Mansoura University Children Hospital|Yes|Completed|September 2013|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|28 Days|No|||September 2015|September 29, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02273843||34278|
NCT02273908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081333|PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin|Patient-reported-outcomes in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings||Medical Affairs, Pfizer Japan|No|Completed|July 2014|March 2015|Actual|February 2015|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|331|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic low-back pain patients with neuropathic component will be treated with pregabalin        or other analgesics|April 2015|April 7, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02273908||34273|
NCT02262936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0188-A|Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older|A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial|DEFEND|Mount Sinai Hospital, Canada|No|Not yet recruiting|December 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Female|65 Years|N/A|No|||October 2014|October 8, 2014|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262936||35116|
NCT02262949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-13-002|A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System|A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System (REALITY2)|REALITY2|C. R. Bard|No|Active, not recruiting|September 2014|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|21 Years|N/A|No|||August 2015|August 10, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02262949||35115|
NCT02263157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSI-PLT|Evaluate the Association Between Infection and Thrombocytopenia|Evaluate the Association Between Blood Stream Infection (BSI) and Thrombocytopenia (Surgical Intensive Care Unit)SICU Patients||Jinling Hospital, China||Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|390|||Both|18 Years|85 Years|No|Non-Probability Sample|Sequential consenting adult patients of either sex were prospectively enrolled into the        study.|October 2014|October 8, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02263157||35099|
NCT02267902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA1229_BAMB_I|Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229|A Phase I, Open-Label, 2-Part Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism and Excretion of DA-1229 in Healthy Male Subjects||Dong-A ST Co., Ltd.||Enrolling by invitation|September 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02267902||34735|
NCT02268123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2014-05|Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation|Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|October 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|An aliquot semen (0.5 - 1mL) will be collected and cryopreserved for analysis for DNA      Fragmentation. Two tubes of serum (approximately 20 mL) will be collected from male partner      via venipuncture.|Both|35 Years|40 Years|No|Non-Probability Sample|Couples completing their first IVF/ICSI cycle at Reproductive Medicine Associates of New        Jersey utilizing CCS (Comprehensive Chromosome Screening).|November 2015|November 16, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268123||34718|
NCT02268136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599.1|Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL|A Single-blind, Placebo-controlled, Parallel Group, Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIII 890 CL (Dosage: 0.5 mg/h - 80 mg/h), Infusion Time 1 Hour.||Boehringer Ingelheim||Terminated|April 1999|||December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|76|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02268136||34717|
NCT02259114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-003|A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)|A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors||Oncoethix GmbH|No|Active, not recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259114||35410|
NCT02259127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODYSSEY (PENTA 20)|A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART|||PENTA Foundation|Yes|Not yet recruiting|May 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|6 Years|18 Years|No|||January 2016|January 26, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259127||35409|
NCT02275494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sarwar-2|The Influence of Leg Length Discrepancy After Total Hip Arthroplasty on Function and Quality of Life|The Influence of Leg Length Discrepancy After Total Hip Arthroplasty on Function and Quality of Life|BioHipLLD|Sundsvall Hospital|No|Completed|September 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|174|||Both|N/A|N/A|No|Non-Probability Sample|All patients with unilateral primary osteoarthritis (OA) treated with THA at the        orthopaedic department in Sundsvall, Sweden were considered for inclusion.|October 2015|October 28, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275494||34151|
NCT02260089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.363|Telmisartan in Mild to Moderate Hypertensive Patients|A Multicenter Open-label Study of the Efficacy and Safety of Telmisartan in Mild to Moderate Hypertensive Patients||Boehringer Ingelheim||Completed|March 2000|||July 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|October 8, 2014||||No||https://clinicaltrials.gov/show/NCT02260089||35335|
NCT02282137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ga PSMA124388|68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer|68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer|PSMA|Radio Isotope Therapy of America|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|208|||Male|18 Years|N/A|No|||April 2015|April 13, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282137||33641|
NCT02285907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMissouri|Protein Quality on Appetite Control, Reward-driven Eating, & Subsequent Food Intake|The Effects of Consuming Beef vs. Soy-rich Lunch Meals, Matched for Macronutrient Content or Serving Size, on Markers of Appetite Control and Satiety||University of Missouri-Columbia|No|Completed|May 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02285907||33351|
NCT02288312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-117|Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate|Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Market Formulation in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|May 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|November 7, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02288312||33166|
NCT02288325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-15|A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder||Forest Laboratories|No|Active, not recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|70 Years|No|||December 2015|December 23, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288325||33165|
NCT02281929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_05|Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone|Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis|AntibioCor|University Hospital, Lille|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02281929||33657|
NCT02281942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA035877-01A1|Behavioral Interventions to Target Self-Control|Behavioral Interventions to Target Self-Control in Abstinent Nicotine Dependent Smokers||Oregon Health and Science University|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281942||33656|
NCT02273687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/20143/XBAC-01|Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department|Analysis of Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department: Predicting Respiratory Prognosis|EDDRAPro|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|104|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273687||34290|
NCT02273700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/GL-01|Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention|Evaluation of Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention in Patients With Atrial Fibrillation|Naco_Nîmes|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients in the cardiology department at the Nîmes        University Hospital with non-valvular atrial fibrillation and who are candidates for        treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be        selected according to criteria designed to result in a homogeneous population (associated        anticoagulants, etc., see below). For this study, patients must not have had a direct oral        anti-Xa (activated Factor 10) in the 6 months preceding enrollment.|December 2015|December 3, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273700||34289|
NCT02273765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12300 REFLATE TB2|Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis|Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis|REFLATE TB2|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02273765||34284|
NCT02272972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI program II|Performance Improvement Program on Imaging II|Performance Improvement Program on Imaging II||AO Clinical Investigation and Documentation|No|Recruiting|October 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are eligible if they are at least 18 years old, have an AO 31-A1, A2 or A3        fracture and were treated with either a Proximal Femoral nail Antirotation (PFNA), a PFNA-        II, a Dynamic Hip Screw (DHS) or a Titanium Trochanteric Fixation Nail System (TFN).|March 2016|March 16, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02272972||34345|
NCT02265601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGHP-08-005-01-CPHPS|End-of-Life Health Care Decisions by Patients With Advanced Cancer|End-of-Life Health Care Decisions by Patients With Advanced Cancer||Milton S. Hershey Medical Center|No|Active, not recruiting|March 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|200|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02265601||34911|
NCT02273102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140328|Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS|An Open-Label, Dose Escalation, Phase 1 Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)|TCP-ATRA|University of Miami|Yes|Recruiting|February 2015|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273102||34335|
NCT02273193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20130041H|Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes|Utility Of Hemoglobin A1C (HbA1C) For The Diagnosis Of Gestational Diabetes Mellitus (GDM).|A1cGDM|Mike O'Callaghan Federal Hospital|No|Recruiting|April 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|750|||Female|8 Years|N/A|No|Non-Probability Sample|Active duty or DoD beneficiaries of childbearing age 18 years or older with a positive        pregnancy test|February 2016|February 1, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02273193||34328|
NCT02262351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIAAF-FP|Program for the Identification of "Actionable" Atrial Fibrillation in the Family Practice Setting|Program for the Identification of "Actionable" Atrial Fibrillation in the Family Practice Setting|PIAAF-FP|Population Health Research Institute|No|Recruiting|April 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2950|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02262351||35161|
NCT02262364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSS-22-01|Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)|A Pilot Study of a Single Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis||Biomet, Inc.|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|75 Years|No|||October 2015|November 25, 2015|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262364||35160|
NCT02275052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201317|A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD||GlaxoSmithKline|No|Active, not recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|194|||Both|40 Years|N/A|No|||November 2015|March 17, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275052||34185|
NCT02275078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-053-BMD|Innovations in Treating COPD Exacerbations: Pilot Project on Action Plans Using New Technology.|Pilot Study Evaluating the Feasibility and Potential Benefits of a Novel Approach of COPD Self-management That Includes a Phone Assessment/Reporting System (Tele-system)||McGill University Health Center|Yes|Recruiting|October 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|40 Years|N/A|No|||April 2015|April 7, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275078||34183|
NCT02275234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B709|Care After Resuscitation|A Feasibility Study of Implementing a Simple Psychological Intervention in Survivors of Cardiac Arrest and Their Family Members/Friend to Assess the Impact on Their Quality of Life and Cognitive Function|CARE|Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Retrospective and prospective cohort of patients following cardiac arrest|December 2015|December 14, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275234||34171|
NCT02275247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXKJGG2014|Perioperative Neuroprotection of Stellate Ganglion Block|Effect of Stellate Ganglion Block on the Cerebral Oxygen Metabolism and Cognitive Recovery During Intracranial Aneurysm Surgery||General Hospital of Ningxia Medical University|Yes|Enrolling by invitation|August 2014|October 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|20 Years|60 Years|No|||November 2015|November 10, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02275247||34170|
NCT02275286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS 37|Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients|Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients|TRASTS|Grupo Espanol de Investigacion en Sarcomas|No|Recruiting|November 2014|March 2017|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|February 18, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275286||34167|
NCT02275299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tranmod|Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis||Jiangsu Simcere Pharmaceutical Co., Ltd.||Recruiting|September 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||October 2014|October 23, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275299||34166|
NCT02264327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH092951-02A1|Phase II Motivational Interviewing: An Experiential Online Training Tool - Small Business Innovation Research (SBIR) - Clinical Trial|Phase II Motivational Interviewing: An Experiential Online Training Tool - SBIR - Clinical Trial||Center for Social Innovation, Massachusetts|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|3780|||Both|21 Years|70 Years|No|||July 2015|July 28, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02264327||35009|
NCT02264574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1130-CA|A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL|A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Pharmacyclics|Yes|Active, not recruiting|October 2014|January 2020|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264574||34990|
NCT02259608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45427.091.13|γ-irradiated BCG to Train Innate Immunity|Training of Innate Immunity by Vaccination With γ-irradiated BCG||Radboud University|No|Completed|November 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259608||35372|
NCT02285855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0255|Metformin in Non Small Cell Lung Cancer (NSCLC)|Tumor Mutation Status Will Predict Metabolic Response to Metformin in Non Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285855||33355|
NCT02272478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML18|Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations|A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome|AML18|Cardiff University|Yes|Not yet recruiting|October 2014|October 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1600|||Both|60 Years|N/A|No|||October 2014|October 22, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02272478||34383|
NCT02288169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USflorida|Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial|||University of South Florida|Yes|Recruiting|September 2013|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|450|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288169||33177|
NCT02288247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-MA-1001|A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone|A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone|PRESIDE|Astellas Pharma Inc|Yes|Recruiting|November 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288247||33171|
NCT02288455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP13-101|Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II)|A Prospective, Non-Randomized, Multi-Center Clinical Investigation of the Safety and PeRformancE of GT UroLogIcal, LLC's ArtiFicial Urinary Sphincter (RELIEF II)|RELIEFII|GT Urological, LLC|Yes|Recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Male|21 Years|N/A|No|||August 2015|August 10, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288455||33155|
NCT02288468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000568|One Pass thalamIc aNd subthalamIc stimulatiON|One Pass thalamIc aNd subthalamIc stimulatiON|OPINION|University Hospital Freiburg|No|Recruiting|July 2015|August 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|35 Years|75 Years|No|||July 2015|July 30, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02288468||33154|
NCT02288481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBA-354-CL-001|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects||Global Alliance for TB Drug Development|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|48|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02288481||33153|
NCT02260024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.560|In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers|A Single Dose Five-way Cross-over Study to Establish an in Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets With 0.375 mg Pramipexole in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2005|||December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02260024||35340|
NCT02260037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.261|Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal|A Double-blind, Randomised, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal (Dosage: 0.035 mg (0.025 % Solution) - 0.42 mg (0.3 % Solution))||Boehringer Ingelheim||Completed|August 2001|||September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02260037||35339|
NCT02260050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262.284|Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers|Bioequivalence of 20 mg of the New Formulation of WAL 801 CL Dry Syrup Compared to 20 mg of the Conventional Formulation of WAL 801 CL Dry Syrup Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, 2x2 Crossover Study)||Boehringer Ingelheim||Completed|June 2004|||July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02260050||35338|
NCT02274805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMD FH 644456|Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures|Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures|Human BAT|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Active, not recruiting|November 2014|||September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|Samples With DNA|Muscle and adipose tissue from the neck region, and blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a protocol for the collection of muscle and adipose tissues from patients of Dr.        Alric Simmonds undergoing surgery in the neck region as part of their clinical care. In        addition to the tissues collected at the time of the procedure, these patients will also        be asked to provide additional blood samples before their procedure either at their        pre-operative visit or on the morning of the surgery.|January 2016|January 14, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02274805||34204|
NCT02274844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-R-AD-1306-03565|Improving Medication Adherence in the Alabama Black Belt|Improving Medication Adherence in the Alabama Black Belt||Weill Medical College of Cornell University|No|Not yet recruiting|March 2016|April 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|19 Years|N/A|No|||March 2016|March 9, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02274844||34201|
NCT02273037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031587|Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda|The Fetal Heart Monitor Project - Human Energy to Save Lives: Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda||The Hospital for Sick Children|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|1987|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 22, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02273037||34340|
NCT02274896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAYPDC-14-01|Bayston Multicenter Antimicrobial PD Catheter Safety Study|A Prospective Multicenter Investigation to Evaluate the Safety of the Bayston Antimicrobial Peritoneal Dialysis Catheter in ESRD Patients|Bayston|Medical Components, Inc dba MedComp|Yes|Not yet recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02274896||34197|
NCT02274974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|local infilteration of C.S|Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine|Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine;Randomized Controlled Trial.||Ain Shams Maternity Hospital|Yes|Completed|August 2014|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|160|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274974||34191|
NCT02274987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNOC 003|Molecular Profiling for Individualized Treatment Plan for DIPG|A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Children and Young Adults With Newly Diagnosed DIPG||University of California, San Francisco|Yes|Recruiting|September 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|25 Years|No|||June 2015|June 2, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02274987||34190|
NCT02266784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055228|Contingency Management, Quitting Smoking, and ADHD|Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)|ADQUIT|Duke University|No|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02266784||34821|
NCT02262715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105145|A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir|A Phase 1, Randomized, 3-way Crossover, Open-label Study to Assess the Drug-drug Interaction Between VX-787 and Tamiflu®, Followed by a Double-blind, Randomized, Placebo-controlled Study to Collect Safety, Tolerability and Pharmacokinetics of VX-787, in Healthy Subjects||Janssen Infectious Diseases BVBA|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|August 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262715||35133|
NCT02267317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140498H|The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects|Phase 2 Study of The Role of Pharmacologic Inhibition of TLR4 With E5564 on Glucose Metabolism in Insulin Resistant Subjects.|Eritoran2|The University of Texas Health Science Center at San Antonio|No|Recruiting|January 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267317||34780|
NCT02267330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53129|Gonadal Radiation Exposure and Risk Secondary to Fluoroscopic Imaging During Trauma Surgery|A Descriptive Cohort Analysis of Gonadal Radiation Exposure and Risk Secondary to Fluoroscopic Imaging During Trauma Surgery About the Pelvis and Femur||University of Utah|No|Completed|February 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified for inclusion in the study through routine trauma workup        performed at the University of Utah. Patients will be managed through standard of care        treatment as dictated by their injuries. If standard of care treatment dictates that a        patient requires operative intervention for their injuries and injury pattern is found to        meet inclusion criteria, an orthopaedics attending or resident physician will determine        the patient's ability to enter the study.|May 2015|May 28, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02267330||34779|
NCT02275819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1423-P|Exercise Training in Heart Failure: Changes in Cardiac Structure and Function|Exercise Training in Heart Failure: Structural and Functional Cardiac Remodeling||VA Office of Research and Development|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|None Retained|none retained|Both|50 Years|N/A|No|Non-Probability Sample|75 male and female HFrEF patients with mild-moderate symptoms while on optimal medical        therapy will be enrolled. The data collected from this pilot study will be used for        building future research. HF diagnosis will be contingent on a previous hospitalization        for HF or physician assessment of HF associated with systolic dysfunction (left        ventricular ejection fraction [LVEF] =40%).|January 2016|January 28, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02275819||34126|
NCT02258854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052132|An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data|An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US)|EYEGUARD™-E|XOMA (US) LLC|No|Terminated|March 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258854||35430|
NCT02258867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052133|Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis|A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis|EYEGUARD™-US|XOMA (US) LLC|No|Terminated|November 2014|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258867||35429|
NCT02285764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL10|Nutritional Intervention During Gestation and Offspring Health|NIGO Health- Nutritional Intervention During Gestation and Offspring Health||Abbott Nutrition|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|324|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 5, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285764||33362|
NCT02281877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0905|Alterations in Muscle After Total Knee Arthroplasty|Alterations in Skeletal Muscle Gene Expression Following Total Knee Arthroplasty||University of Colorado, Denver||Recruiting|October 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|75 Years|No|||December 2015|December 3, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02281877||33661|
NCT02281890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INIS-01|Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database|Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database||University of Edinburgh|No|Completed|October 2001|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3493|||Both|N/A|2 Years|No|Non-Probability Sample|The study population consists of all babies included in the INIS trial. The INIS trial was        an RCT of intravenous immunoglobulin (two infusions of 500 mg/kg body weight polyvalent        IgG) versus placebo in the treatment of suspected or proven neonatal sepsis.[5] 3493        infants were included from 113 hospitals in nine countries.[6]|October 2014|October 30, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02281890||33660|
NCT02272361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_03|Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair.|Randomized Controlled Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair: Functional and Anatomical Results at Four Years Follow-up|PROSPERE4|University Hospital, Lille|Yes|Recruiting|October 2014|December 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|262|||Female|45 Years|75 Years|No|||October 2015|October 13, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272361||34392|
NCT02272374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZHKI-HDVA-004|Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China|Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China :a Multicenter Prospective Cohort Study|ACCESS-China|Shanghai Changzheng Hospital|Yes|Not yet recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|500|||Both|65 Years|N/A|No|||October 2014|October 20, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02272374||34391|
NCT02273752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072091|Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer|Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma||Emory University|Yes|Terminated|November 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 22, 2014|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT02273752||34285|
NCT02279641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-107|RDEA3170 and Allopurinol Combination Study in Gout Subjects|A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout||Ardea Biosciences, Inc.|No|Completed|November 2014|September 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|75 Years|No|||September 2015|September 11, 2015|October 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279641||33832|
NCT02288377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE31|A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)|A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT|REMINET|Federation Francophone de Cancerologie Digestive|Yes|Recruiting|September 2014|January 2024|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||September 2014|November 10, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02288377||33161|
NCT02288390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of Medicine 10.07.2007|Oral Care as a Preventive Measure of VAP; Miswak Versus Chlorhexidine and Toothbrush.|Oral Care as a Preventive Measure of VAP; Miswak Versus Chlorhexidine and Toothbrush, a Prospective, Randomized Controlled Study||Faculty of Medicine, University of Alexandria|No|Completed|July 2007|September 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|2 Years|70 Years|No|||November 2014|November 10, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02288390||33160|
NCT02265068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Real-TICA|Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes|Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes. Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS.|Real-TICA|IHF GmbH - Institut für Herzinfarktforschung|No|Recruiting|August 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|All patients from the ALKK-PCI registry discharged alive after PCI for ACS (STEMI and        NSTE-ACS) and treated with ticagrelor during the acute phase.|February 2016|February 23, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265068||34952|
NCT02270918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14P.366|Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra|A Phase I Placebo-Controlled, Open-Label, Crossover Study to Assess the Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra in Healthy Volunteers|4PAR|Thomas Jefferson University|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270918||34503|
NCT02261324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LF001H|Is the 4MGS a Useful Outcome Measure Post-PPCI|Is the Four Metre Gait Speed a Useful Outcome Measure in Patients With Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention?||Royal Brompton & Harefield NHS Foundation Trust||Recruiting|December 2013|April 2020|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|560|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient hospitalised for primary percutaneous coronary intervention for acute        myocardial infarction. The cohort will be recruited from Harefield hospital|May 2015|May 12, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261324||35240|
NCT02261337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LF003H|Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?|Do Gait Speed and Markers of Sarcopenia Predict Prognosis in Patients With Chronic Respiratory Disease?||Royal Brompton & Harefield NHS Foundation Trust||Recruiting|December 2013|April 2021|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|520|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient with chronic respiratory disease. The cohort will be recruited from Harefield        hospital.|May 2015|May 12, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261337||35239|
NCT02274857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REAFFIRM|Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures|Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures (REAFFIRM)|REAFFIRM|Topera, Inc.|Yes|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 2, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274857||34200|
NCT02261844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ResveraCA|Resveratrol and Human Hepatocyte Function in Cancer|Resveratrol and Human Hepatocyte Function in Cancer||University of Louisville|No|Not yet recruiting|December 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Both|21 Years|80 Years|No|||January 2016|January 4, 2016|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02261844||35200|
NCT02262117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130929|Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates|A Prospective, Randomized, Controlled, Two-arm Study to Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates Through a Care Personalization in Reproductive Medicine Before IVF|PRECONCEPTIO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|38 Years|No|||October 2015|October 6, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262117||35179|
NCT02274909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESPI-8|Pilates and PNF Methods Induces Similar Strength Gains|PILATES AND PNF METHODS INDUCES SIMILAR STRENGTH GAINS, BUT DIFFERENT NEUROMUSCULAR ADAPTATIONS IN ELDERLY WOMEN||Universidade Estadual do PiauÍ|Yes|Completed|May 2014|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274909||34196|
NCT02267044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14061|Effective Pain Management of Interscalene Blocks During Shoulder Surgery|Effective Pain Management of Continuous Versus Single Shot Injection Interscalene Block During Shoulder Replacement Surgery||TriHealth Inc.|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|N/A|N/A|No|||October 2015|October 20, 2015|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02267044||34801|
NCT02267057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR project nr 221951|Efficacy of Pain Treatment on Depression in Patients With Dementia|Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.|DEP-PAIN-DEM|University of Bergen|Yes|Recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|266|||Both|60 Years|N/A|No|||September 2014|October 16, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267057||34800|
NCT02275182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401|Impact of Dexmedetomidine on the Post-Operative Cognition Dysfunction(POCD) in Geriatric Patients|Impact of Dexmedetomidine Sedation on the Post-Operative Cognition Dysfunction——a Multiple Center,Randomized, Controlled,Double Blinded Clinical Trial.||The First Affiliated Hospital of Anhui Medical University|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|65 Years|90 Years|No|||February 2016|February 3, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275182||34175|
NCT02263417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-005|A Randomized Controlled Trail Comparing Subthalamic and Pallidal Deep Brain Stimulation for Dystonia|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Dystonia||Beijing Pins Medical Co., Ltd|Yes|Recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02263417||35079|
NCT02263430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-007|PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease|PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|N/A|No|||March 2015|October 12, 2015|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02263430||35078|
NCT02263950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LON002-002|A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours|A Phase 1/2a Study of LON002 (Sublingual Artemether Spray) in Subjects With Advanced Solid Tumours.|LON002-002|LondonPharma Ltd.|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263950||35038|
NCT02263963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-066.|The Transversus Abdominis Plane Block: A Prospective Randomized Clinical Trial Using EXPAREL.|The Transversus Abdominis Plane Block: A Prospective Randomized Clinical Trial Using EXPAREL.||Spectrum Health Hospitals|Yes|Completed|July 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02263963||35037|
NCT02270892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-142|Ultherapy for Buttock Lift|Evaluation of the Ulthera® System for Lifting of the Buttock||Ulthera, Inc|No|Active, not recruiting|September 2014|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270892||34505|
NCT02273531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.149|Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers|Bioequivalence of a New Asasantin Capsule Formulation (Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Compared to the Commercially Available Asasantin Capsule Formulation (Aggrenox®; Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Following Multiple Oral Administration at Steady State After a run-in Phase (Persantine ER BID for 2 Days Each: 25 mg, 50 mg, 100 mg, 150 mg [Persantine®]; 200 mg Dipyridamole/25 mg ASA [Asasantin ER])- an Open Label, Randomized, Multiple-dose, Two-way Crossover, Change-over Study in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|January 2004|||March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273531||34302|
NCT02285777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_16E1|Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents|A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.||Novartis|No|Completed|December 2014|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|189|||Both|10 Years|19 Years|No|||June 2015|June 29, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285777||33361|
NCT02285803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 14/40/406|The Effect of Transcranial Direct Current Stimulation (tDCS) in Addition to Tinnitus Retraining Therapy (TRT) for Treatment of Chronic Tinnitus Patients|The Effect of Transcranial Direct Current Stimulation (tDCS) in Addition to Tinnitus Retraining Therapy (TRT) for Treatment of Chronic Tinnitus Patients||University Hospital, Antwerp|No|Recruiting|November 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||November 2014|November 4, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285803||33359|
NCT02273635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PIE-26946CORFO|Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS|Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis||Innobioscience SpA|Yes|Recruiting|September 2014|April 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|70 Years|No|||October 2014|October 24, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02273635||34294|
NCT02279342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1407027|the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia|the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia||Yokohama City University Medical Center|No|Not yet recruiting|October 2014|||September 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||October 2014|October 30, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02279342||33855|
NCT02284529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF12099|Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer|Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer|Oxaliplatin|Sinphar Pharmaceutical Co., Ltd|No|Completed|October 2012|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|75 Years|No|||October 2014|November 3, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02284529||33457|
NCT02279914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso|Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial|Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial||Planned Parenthood of New York City, Inc.|No|Recruiting|November 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|118|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 24, 2015|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279914||33811|
NCT02279927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0063-CTIL|Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy|Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During||Carmel Medical Center|No|Recruiting|October 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279927||33810|
NCT02274753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI13017|Personalizing Colorectal Cancer Medicine (ImmuCol2)|Personalizing Colorectal Cancer Medicine: an Integrative Approach for the Identification of Prognostic Parameter Combinations at the Time of Surgery and During the Follow-up|ImmuCol2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|The pathologist of each center will choose a tumor block containing the core of the tumor      and the invasive margin. Seven tissues sections (five of 4 microns and two of 20 microns) of      this tumor bmock will be cut and deposited on glass slides for the immunohistochemical and      tumor genetic analysis. If biopsies for diagnostic purpose are available in the laboratory      of pathology for the same patient, two tissue sections of 4 microns of each biopsy will be      cut and deposited on a glass slide. Two tubes of blood (5 ml tube without anticoagulant) and      a 10 ml tube with EDTA will be taken in consultation or hospitalization before the first      chemotherapy and at 1 year, 2 years and 3 years. These samples will be used for gene      expression analysis and in the search for biological signs of autoimmunity.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patient with newly diagnosed colon cancer.|January 2016|January 22, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02274753||34208|
NCT02274792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101177|Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis|A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis||Amgen|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|125 Years|No|||February 2016|February 8, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274792||34205|
NCT02265614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVFResearch|PGS Using Microarray in IVF Patients With Repeated Implantation Failure|Preimplantation Genetic Screening (PGS) Using Microarray Technique: Method to Select the Embryo With the Greatest Chance for Successful Implantation During in Vitro Fertilization in Couples With a History of Unsuccessful IVF Attempts||IVF Research Sweden|Yes|Recruiting|August 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|25 Years|39 Years|No|||October 2014|October 17, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02265614||34910|
NCT02265627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.26|Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers|Pharmacokinetics, Safety and Tolerability of Single Dose BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Subjects (An Open Label, Matched Pair, Two Center Study)||Boehringer Ingelheim||Completed|March 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|24 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 15, 2014||||No||https://clinicaltrials.gov/show/NCT02265627||34909|
NCT02261558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-090|Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy|Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy||Beth Israel Medical Center|No|Recruiting|June 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02261558||35222|
NCT02266238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZHKI-HDVA-003|Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial|Randomized Controlled Trial to Compare Therapeutic Effect of Digital Subtraction Angiography(DSA)，Ultrasound Guided Balloon Dilatation and Surgical Reconstruction in Arteria-venous Fistula(AVF) Stenosis in Maintenance Hemodialysis Patients|SAVEIT|Shanghai Changzheng Hospital|Yes|Not yet recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|80 Years|No|||October 2014|October 12, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02266238||34863|
NCT02266446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308000908|Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders|Phase 1 Open Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care|AIM-PC|Brown University|Yes|Active, not recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02266446||34847|
NCT02275754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110094H|Redes III Patient Navigator Qol Study|Improving Quality of Life Among Hispanic/Latino Breast, Colorectal & Prostate Cancer Survivors: A Randomized Control Trial of Patient Navigators Using the LIVESTRONG Cancer Navigation Services Program||The University of Texas Health Science Center at San Antonio|Yes|Completed|November 2010|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02275754||34131|
NCT02275130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-Radiesse Voice|Functional Effect of Treatment of Glottic Insufficiency With Calcium Hydroxyapatite|Assessment of the Functional Effect of Treatment of Glottic Insufficiency With Injection Technique With the Use of Calcium Hydroxyapatite||University Hospital Ostrava|No|Recruiting|April 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02275130||34179|
NCT02275780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-018|Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)|A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2014|August 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|680|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275780||34129|
NCT02285283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0165|RCT of Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps|Randomized Double-Blinded Controlled Trial of Oral Antifungal for the Treatment of Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps||The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|75 Years|No|||November 2014|November 5, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285283||33399|
NCT02285530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOSCAN2014|GDF15 Based TPF Induction Chemotherapy for OSCC Patients|GDF15(Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN0 (Clinical Node Negative) Stage: a Phase II Randomized Controlled Trial||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|December 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|75 Years|No|||November 2014|November 4, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02285530||33380|
NCT02285751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTPR-ICU|High "on Treatment" Platelet Reactivity in the Intensive Care Unit|High "on Treatment" Platelet Reactivity in the Intensive Care Unit||Medical University of Vienna|Yes|Recruiting|November 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 25, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT02285751||33363|
NCT02273544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.158|Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects|Bioavailability of Dipyridamole After Asasantin (Extended Release 200mg Dipyridamole/25mg ASA) in 3 Experimental Formulations (Given b.i.d. Over 3 or 5 Days, Respectively) Relative to the Standard Formulation in 16 Healthy Female and Male Subjects. Intraindividual Comparison, Randomised, Open||Boehringer Ingelheim||Terminated|September 2002|||October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273544||34301|
NCT02273557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.163|Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects|Bioavailability of Dipyridamole of Asasantin p.o. (Extended Release 200 mg Dipyridamole/25 mg ASA) in Three Experimental Formulations (Given BID Over 3 Days Each) Relative to the Standard Formulation After a run-in Phase (Persantine ER BID for 2 Days Each: 25 mg, 50 mg, 100 mg; 150 mg [Persantine®]; 200 mg Persantine/25 mg ASA [Asasantin ER] in Healthy Male Subjects. Four-way, Change-over, Randomised, Open||Boehringer Ingelheim||Completed|January 2003|||February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|19|||Male|50 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273557||34300|
NCT02262663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15818|Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan|A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety After Daily Oral Administration of 4 Different Doses of Vilaprisan (BAY1002670) in Healthy Women of Reproductive Age||Bayer|No|Completed|October 2014|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|70|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02262663||35137|
NCT02272309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0518|Neurophysiological Assessment of Healthy and Impaired Human Lower Urinary Tract Function|||University of Zurich|No|Recruiting|May 2014|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|150|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272309||34396|
NCT02263131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_CH_301|Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children|Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.||Il-Yang Pharm. Co., Ltd.|No|Completed|October 2013|June 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|416|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|September 23, 2014||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT02263131||35101|
NCT02284295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01201463369/2|Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2|Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures 2.||Novosibirsk City Hospital #2|No|Completed|November 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|352|Samples With DNA|whole blood, serum,bronchoalveolar lavage fluid|Male|40 Years|75 Years|No|Probability Sample|Residents of a certain town (Novosibirsk, Russian Federation)|April 2015|April 13, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284295||33475|
NCT02287012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mozo Time and Motion|Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection -The European Perspective|Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection - The European Perspective||Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|No|Active, not recruiting|October 2013|October 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The study will consist of two parts:        I. Retrospective study:        A medical record review will be conducted covering 200 patients file undergoing peripheral        blood stem cell mobilization in different European centers. Patients will be selected from        each of centers, evenly divided between two eras: 1) prior to approval of plerixafor=        Pre-P era (July 2009); and 2) after approval of plerixafor= P era .        II. Prospective study :Time/Motion evaluation of actual apheresis - 20 events each center|November 2014|May 6, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287012||33266|
NCT02284789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17819|Colorado Adult Joint Assessment Scale (CAJAS) Validation|Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis|CAJAS|Bayer|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Male|18 Years|50 Years|No|||December 2015|December 2, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284789||33437|
NCT02284802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP354/13|Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy|Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy||Instituto do Cancer do Estado de São Paulo|No|Recruiting|September 2014|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|November 26, 2015|November 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284802||33436|
NCT02260973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 20145|The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity|The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity Outcomes In Cases Undergoing Cataract Surgery: A Pilot Study.||Physician Recommended Nutriceuticals||Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|30 Years|90 Years|No|||January 2016|January 5, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260973||35267|
NCT02260986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1224|Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Active, not recruiting|September 2014|November 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|739|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260986||35266|
NCT02274389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104620|A Prospective Patient Registry of Patients Exposed to Bedaquiline|Bedaquiline Patient Registry: Prospective Patient Registry of Patients Exposed to Bedaquiline In the United States||Janssen Research & Development, LLC|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Study population will be drawn from the population of all partIcipants treated with        bedaquiline (BDQ) in the United States. All participants meeting registry inclusion        criteria will be eligible for inclusion in the BDQ patient registry provided they submit        the necessary informed consent for participation.|March 2016|March 22, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274389||34236|
NCT02265965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-OB-NTG|Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension|Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension||University of California, San Francisco|Yes|Recruiting|October 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265965||34884|
NCT02265978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOIPG/2013/450|CopeSmart: Using Mobile Technology to Promote Positive Mental Health in Young People|CopeSmart: Using Mobile Technology to Promote Positive Mental Health in Young People||University College Dublin|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|387|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265978||34883|
NCT02274818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051227|Individualized Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education.|Individualized Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education (iCOMPARE).|iCOMPARE|Johns Hopkins University|Yes|Active, not recruiting|July 2015|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3500|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02274818||34203|
NCT02274870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB: 14-237B|Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery|Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia||Northwell Health|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|74 Years|No|||August 2015|November 10, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274870||34199|
NCT02262728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105028|An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease|A Phase 2 Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of 12 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir, Followed by a 5-Year Post-treatment Long-term Follow-up, in Treatment-naïve and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2014|January 2020|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262728||35132|
NCT02275767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2014-454H|Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft|Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|October 2014|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275767||34130|
NCT02263170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-BE: 048/2014|Assessment of Anatomic, Physiologic and Biomechanical Characteristics of the Anal Canal and Pelvic Floor. An Observational Pilot Study|Assessment of Anatomic, Physiologic and Biomechanical Characteristics of the Anal Canal and Pelvic Floor. An Observational Pilot Study||University Hospital Inselspital, Berne|Yes|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited by flyers and advertisement in internet.|November 2015|November 23, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02263170||35098|
NCT02270372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-10-104|Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer|A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer||Oncothyreon Inc.|Yes|Active, not recruiting|November 2014|May 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270372||34545|
NCT02270593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prospective study-2|ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).|ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta)||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|August 2013|October 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|None Retained|serum and fetal membranes (placenta) and maternal myometrial sample|Female|25 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|tertiary health institutions|October 2014|October 16, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02270593|2 Years|34528|
NCT02270606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10491|Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouricil for Rectal Cancer|Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer||Virginia Commonwealth University|Yes|Enrolling by invitation|December 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270606||34527|
NCT02270619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AG049085|Sleep Health, Inflammation, and Emotion Study|Sleep Loss as a Vulnerability Factor for Inflammation Induced Depressive Symptoms in Older Women|SHINE|University of California, Los Angeles||Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|80|||Female|60 Years|69 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270619||34526|
NCT02262676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17671|Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain|Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)|HEROIC|Bayer|No|Completed|October 2014|May 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2251|||Both|18 Years|N/A|No|Non-Probability Sample|Patients taking rivaroxaban for stroke prevention in atrial fibrillation attending        consults of hematology, cardiology and internal medicine|June 2015|June 4, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02262676||35136|
NCT02273596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTX101-201|Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients|A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months||Wilson Therapeutics AB|Yes|Recruiting|November 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273596||34297|
NCT02267863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253-HEM1-01|A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Dose Escalation With Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients With Relapsed or Refractory Hematologic Malignancies||Aptose Biosciences Inc.|No|Suspended|October 2014|January 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 3, 2014|No|Yes|Drug manufacturing process and procedure review|No||https://clinicaltrials.gov/show/NCT02267863||34738|
NCT02267876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDS-USLHPV|Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens|Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens||Becton, Dickinson and Company|No|Enrolling by invitation|October 2014|February 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|8000|||Female|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267876||34737|
NCT02286817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFC1-2014|Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder|Phase I Single Dose, Open-label, Pharmacokinetic Study Followed by Single-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Plasma Concentration Profiles, and Targeted Efficacy of NFC-1 in Adolescents (12-17 Years of Age) With Attention-Deficit Hyperactivity Disorder and Genetic Disruption Impacting Metabotropic Glutamate Receptor Genes (NFC1-GREAT)|NFC1-GREAT|NeuroFix Therapeutics LLC|Yes|Active, not recruiting|January 2015|June 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|17 Years|No|||June 2015|June 15, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286817||33281|
NCT02290119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|PILOT STUDY: Gait and Functional Improvement in Total Knee Arthroplasty With the Use of Verasense for Soft Tissue Balancing: A Randomized, Double-Blind, Controlled Trial|||Orthosensor, Inc.|No|Recruiting|May 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290119||33027|
NCT02290132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013（56）|ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors|Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China|HSCT|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|August 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|63|||Both|18 Years|60 Years|No|Probability Sample|According to the World Health Organization (WHO) classification,study population is        diagnosis of T cell tumor of lymphatic system sources (including peripheral T-cell        lymphoma and T lymphoblastoid cell lymphoma/leukemia) confirmed by pathological        examination, morphology, cytochemistry, immunophenotyping and chromosome examination,        molecular biology including complete remission, partial remission, relapse after remission        or refractory recurrent invasive patients|November 2014|November 8, 2014|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290132|4 Years|33026|
NCT02287207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57231|Effects of Transcranial Direct Current Stimulation on Fine Motor Skills in Parkinson's Disease: a Pilot Study|||Katholieke Universiteit Leuven||Recruiting|October 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287207||33251|
NCT02265354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K07CA172677-02|Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System|Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System|S4S|University of Massachusetts, Worcester|No|Not yet recruiting|June 2016|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265354||34930|
NCT02275663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFMC-AML01|Azacytidine Plus FLAG for Relapsed or Refractory AML|Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML||King Fahad Medical City|Yes|Recruiting|December 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|16 Years|60 Years|No|||January 2015|January 4, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02275663||34138|
NCT02274766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-AMT-PD304|Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia|ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)|EASE LID 3|Adamas Pharmaceuticals, Inc.|No|Active, not recruiting|October 2014|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|30 Years|85 Years|No|||December 2015|December 21, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274766||34207|
NCT02275715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400831|Treatment of Feeding Problems in Children With Autism|Treatment of Feeding Problems in Children With Autism|PT-F|University of Florida|Yes|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|7 Years|No|||November 2015|November 10, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02275715||34134|
NCT02275741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMR-MS2012|Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis|Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis||University of Rostock|No|Recruiting|October 2009|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Serum sample|Both|18 Years|70 Years|No|Non-Probability Sample|relapsing remitting multiple sclerosis|October 2014|October 22, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02275741||34132|
NCT02284516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP606-304|A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye|A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use|OPUS-3|Shire||Completed|November 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284516||33458|
NCT02262962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R40MC21516|Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families|Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families||University of California, Los Angeles|No|Completed|June 2005|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|249|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02262962||35114|
NCT02285062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-DLC-002|Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma|Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma|ROBUST|Celgene|Yes|Recruiting|January 2015|September 2022|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285062||33416|
NCT02273336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCMI-003|Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer|Genomics of Young Lung Cancer Study||University of Southern California|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood and tissue|Both|N/A|39 Years|No|Non-Probability Sample|Subjects will be recruited at Dana Farber Institute and USC Norris Cancer Center.|October 2015|October 24, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273336||34317|
NCT02273427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.5|Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers|Randomised 3-way Cross-over Phase I Study to Investigate the Effect of Different Food Compositions (Low Fat and High Fat Meal) on Bioavailability of BIIL 284 BS 75 mg Tablet in Healthy Male Volunteers||Boehringer Ingelheim||Completed|February 2000|||March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273427||34310|
NCT02273440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.7|Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers|The Effects of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Theophylline in Healthy Male Volunteers (a Randomized, Double-blind, Placebo-controlled, Two-period, Two-way Crossover Study)||Boehringer Ingelheim||Completed|May 2000|||July 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273440||34309|
NCT02273453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|582.2|Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets|A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)||Boehringer Ingelheim||Completed|February 2003|||June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|54|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273453||34308|
NCT02273466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599.11|Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects|Pharmacokinetics of 50 mg Desipramine Daily, Given Orally Over 7 Days With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomized, Placebo Controlled, Single Blind (for Crobenetine), Two-way Cross Over Trial in Healthy Male Subjects||Boehringer Ingelheim||Completed|February 2002|||April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273466||34307|
NCT02273518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.144|Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers|A Double-blind, Randomised, 3-way Cross-over Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin ER Extended Release (ER) 200 mg Dipyridamole/25 mg ASA Formulations in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|April 2001|||May 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|18|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273518||34303|
NCT02267291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104/14|Impact of Non-invasive Positive Pressure Ventilation on Cardiac Function and Echocardiographic Parameters|Impact of Non-invasive Positive Pressure Ventilation on Cardiac Function and Echocardiographic Parameters||University Hospital Inselspital, Berne|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|75 Years|No|||July 2015|July 16, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02267291||34782|
NCT02262923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0209-A|Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial|Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial||Mount Sinai Hospital, Canada|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262923||35117|
NCT02273245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/155|Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?|Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?||Plymouth Hospitals NHS Trust|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult        (age>18) patients presenting with symptoms of AAS.|November 2015|November 4, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273245||34324|
NCT02273258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY12704|A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes|A Randomized, Double-Blind, Controlled, Single-Dose, 3-Treatment, 3-Period, 6-Sequence Crossover Study to Compare Exposure and Activity of SAR342434 to Humalog® Using the Euglycemic Clamp Technique, in Subjects With Type 1 Diabetes Mellitus||Sanofi|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||October 2014|October 21, 2014|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273258||34323|
NCT02288871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1790/2013-1|Pilot Trial: Comparison of Flow Patterns|Pilot Trial: Comparison of Flow Patterns. Is There a Difference Between sewed-in and "Sutureless" Bioprosthetic Aortic Heart Valves?||Medical University of Vienna||Recruiting|October 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02288871||33123|
NCT02279654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-010|Registry Study for Individuals With Del 5q Low or Intermediate-1 Risk MDS|A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.|PASS MDS del5q|Celgene|No|Recruiting|December 2014|December 2019|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1800|||Both|18 Years|N/A|No|Non-Probability Sample|The MDS registry will aim to recruit prevalent patients if diagnosed on 15th June 2007 or        later, along with newly diagnosed patients, transfusion-dependent or have a history of        transfusion dependence, International prognostic scoring system (IPSS) low or        intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q) according to the        inclusion criteria and independently from the treatment prescribed.|December 2015|December 8, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279654|3 Years|33831|
NCT02279940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0|Rivaroxaban Acute Stroke Safety Study|Rivaroxaban Acute Stroke Safety Study|RASS|University of Alberta|No|Active, not recruiting|March 2014|||January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients with atrial fibrillation (new onset or previous history) with acute        ischemic stroke or TIA will be screened from Emergency Department or stroke unit. A total        of 50 male and female patients will be recruited within 24 hours of symptom onset.        Informed consent will be obtained from the patient or substitute decision maker, in all        cases prior to enrolment.|December 2015|December 1, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279940|90 Days|33809|
NCT02279953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15905A|Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder||H. Lundbeck A/S|No|Active, not recruiting|October 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279953||33808|
NCT02274311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClomipheneAcro|Clomiphene Citrate for Treatment of Acromegaly|Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies||University of Sao Paulo General Hospital|No|Completed|January 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|80 Years|No|||October 2014|October 23, 2014|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274311||34242|
NCT02261571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMI-14-01-08|Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer|A Pilot Study to Estimate the Efficacy of Moxibustion Stimulation at Abdominal Acupoints on Quality of Life in Cancer Patients Under Chemotherapy||The Comprehensive and Integrative Medicine Institute of South Korea|No|Not yet recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|20 Years|70 Years|No|||October 2014|October 9, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02261571||35221|
NCT02261584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microwave vs PSE|Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism|Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism||Tanta University|Yes|Recruiting|August 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||October 2014|October 9, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02261584||35220|
NCT02275689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1133|Radiofrequency Microtenotomy for Treatment of Rotator Cuff Tendinopathy|Alternative Treatment of Rotator Cuff Tendinopathy||University Hospital of North Norway|No|Recruiting|March 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|65 Years|No|||October 2015|November 9, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02275689||34136|
NCT02262130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2013/209|Omalizumab in Severe and Refractory Solar Urticaria|Phase 2 Multicentric Study Evaluating the Efficacy of Omalizumab in Idiopathic Severe and Refractory Solar Urticaria|XOLUS|Centre Hospitalier Universitaire de Besancon|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262130||35178|
NCT02262377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33096|Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression|Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression in a Disparate Urban Population|IMGV|Boston Medical Center|Yes|Recruiting|April 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02262377||35159|
NCT02284269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMDA-A2602|Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus|Meta-analysis in Post-Marketing Surveillances for Long-Term Drug Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus||Pharmaceuticals and Medical Devices Agency, Japan|No|Active, not recruiting|October 2014|||May 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|18000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Type 2 diabetes mellitus starting medication of SGLT2 inhibitors|November 2014|November 3, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284269||33477|
NCT02284776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00226-43|Preliminary Evaluation Study of Therapeutic Education on Overweight People in Addition to a Hydrotherapeutic Cure|Preliminary Evaluation Study of Therapeutic Education on Overweight People in Addition to a Hydrotherapeutic Cure at the Thermal Baths of Brides-les-Bains|Educatherm|Institut Pasteur de Lille|Yes|Active, not recruiting|July 2013|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02284776||33438|
NCT02270177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1430 REK sør-øst|Telemedicine Versus Traditional Specialist Consultation for Headache: a Non-inferiority Trial|Patients` Satisfaction With Telemedicine Versus Traditional Specialist Consultation for Headache. An Open-labeled Randomized Non-inferiority Study Among Patients With Headache Referred to a Neurologic Outpatient Clinic|VHS|University Hospital of North Norway|No|Active, not recruiting|September 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|402|||Both|16 Years|65 Years|No|||June 2015|June 1, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02270177||34560|
NCT02270190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18418|PTNS as a Treatment for Tenesmus|Evaluating the Effectivenemss of Percutaneous Tibial Nerve Stimulation as a Treatment for Tenesmus in Patients With Pelvic Floor Disorders||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|August 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270190||34559|
NCT02262091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.22.NRC|Immune Benefits of WGP in Elderly|Strengthening Immunity of Prefrail and Frail Elderly by WGP||Nestlé|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|150|||Both|70 Years|N/A||||September 2014|April 9, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02262091||35181|
NCT02262325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14091|Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery|A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for Surgery||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2014|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262325||35163|
NCT02273089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLC.CI.105.2014|CPAP to Reduce Arterial Stiffness in Non Sleepy, Moderate to Severe Obstructive Sleep Apnea (STIFFSLEEP)|Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP)|STIFFSLEEP|Centro Hospitalar de Lisboa Central|No|Enrolling by invitation|October 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Male|30 Years|65 Years|No|Non-Probability Sample|Men with moderate to severe obstructive sleep apnea, with or without excessive daytime        sleepiness|December 2015|December 22, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02273089||34336|
NCT02267538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUFH|Dexmedetomidine and Delirium in Patients After Cardiac Surgery|Impact of Dexmedetomidine on the Incidence of Postoperative Delirium in Patients After Cardiac Surgery: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial||Peking University First Hospital|Yes|Completed|November 2014|November 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|285|||Both|60 Years|N/A|No|||December 2015|December 28, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267538||34763|
NCT02267551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574541-1|Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery|Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery||Atlantic Health System|No|Recruiting|April 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|2||||||Both|N/A|N/A|No|||October 2014|October 16, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267551||34762|
NCT02259088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002D2305|A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients|A 12-month, Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Dosed PRN in Subjects With Visual Impairment Due to Diabetic Macular Edema in Chinese Patients||Novartis|No|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259088||35412|
NCT02279355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0323|Peri-operative Risk Factors for Postoperative Pressure Ulcer in Surgical Patients|||Yonsei University|No|Not yet recruiting|October 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|126|||Both|30 Years|90 Years|No|Non-Probability Sample|Total about 130 adult surgical patients underwent surgical procedures and admitted in        intensive care unit (ICU) using electronic documentation applications from Jan 2012        through Dec 2013.|October 2014|October 27, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02279355||33854|
NCT02279368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adwin006|Nursing Led Interdisciplinary Intervention in Prevention of Girl Child Mortality and Maltreatment|Nursing Led Interdisciplinary Intervention in Prevention of Girl Child Mortality and Maltreatment: Randomized Controlled Trial||Adwin Life Care|Yes|Completed|September 2013|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|134|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279368||33853|
NCT02283996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001688|Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment|Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment||Brigham and Women's Hospital||Recruiting|November 2014|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283996||33498|
NCT02284308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELDAPT|Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy|ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy|ELDAPT|Maastricht Radiation Oncology|Yes|Not yet recruiting|January 2016|January 2022|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|75 Years|N/A|No|||November 2015|November 30, 2015|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284308||33474|
NCT02284321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-188|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2014|||||N/A|N/A|N/A||||||||||||||November 3, 2014|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284321||33473|
NCT02275650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maintenance_uv|The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter|The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter||Joint Authority for Päijät-Häme Social and Health Care|Yes|Completed|September 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02275650||34139|
NCT02283411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-US-VAL-14135|Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems|Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring System - Personal and Abbott Sensor Based Glucose Monitoring System - Professional||Abbott Diabetes Care|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with type 1 or type 2 diabetes who require multiple daily insulin injections        (MDI) or continuous subcutaneous insulin infusion (CSII) or non-intensive insulin therapy.        The study will aim to recruit a representative population. The study subjects should be        approximately 50% male and no more than 75% white. The age range should have a mean of        around 45 years, and a range of approximately 20-70 years. It is anticipated that BMI will        range from approximately 20-45 with a mean of around 27.|March 2015|March 23, 2015|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283411||33543|
NCT02261857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00078727|3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea|Personalized Three-Dimensionally Printed CPAP Masks for Obstructive Sleep Apnea Therapy in Children With Craniofacial Anomalies||University of Michigan|No|Recruiting|September 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|1 Year|18 Years|No|||July 2015|July 24, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02261857||35199|
NCT02283970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K11|Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)|Investigation of Patients With BAV Requiring Valve and/or Aortic Repair. Correlation of Surgical and ECO Distinctive Features With Histologic and Genetic Findings in Phenotypically Homogeneous Outlier Cases (GISSI VAR)|VAR|Gruppo di Ricerca GISSI|No|Active, not recruiting|December 2012|July 2017|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|62|Samples With DNA|Serum samples and tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|BAV patients eligible for cardiac surgery due to each of these conditions: BAV        Regurgitation isolated, ascending aorta aneurysm in normal BAV or both AR and ascending        aorta aneurysm, BAV stenosis isolated in over 60 year-old patients.|October 2014|November 3, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02283970||33500|
NCT02284282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43488.101.13|Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery|Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery|Salmon|Maasstad Hospital|No|Recruiting|August 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02284282||33476|
NCT02273063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404-005|rTMS for PTSD Comorbid With Major Depressive Disorder|5Hz Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder Comorbid With Major Depressive Disorder||Butler Hospital|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273063||34338|
NCT02268344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pro00046671|Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection|Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection (ESSAN): a Double-blinded, Randomized Control Trial|ESSAN|University of Alberta|Yes|Recruiting|July 2014|July 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|55 Years|No|||June 2015|June 17, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268344||34701|
NCT02273154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUS-IV-01|Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder|||Peking University|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273154||34331|
NCT02268604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180.2|Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers|Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.||Boehringer Ingelheim||Terminated|October 2010|||October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02268604||34681|
NCT02275221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B664|Immune Response in Patients With Hepatitis B and C Infection|Investigation and Elucidation of Host Immune Responses in Patients With Hepatitic B and C Virus Infection||Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|No|Non-Probability Sample|Hepatitis B and C|January 2016|January 18, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02275221||34172|
NCT02266745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-112-101|A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors||Phosplatin Therapeutics|Yes|Recruiting|July 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02266745||34824|
NCT02266758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD074794|Randomizing Two Gestational Diabetes Screening Methods in a Diverse HMO|Comparing Two Gestational Diabetes Screening Methods: A Pragmatic Outpatient RCT||Kaiser Permanente|No|Enrolling by invitation|May 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|17626|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02266758||34823|
NCT02267018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2014|Diaphragm Electrical Activity of Preterm Infants on nCPAP Versus NIHFV|Effect of Nasal Continuous Positive Airway Pressure (nCPAP) Versus Non-Invasive High Frequency Ventilation (NIHFV) on the Diaphragm Electrical Activity in Very Low Birth Weight Preterm Infants||Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|60 Days|No|||December 2015|December 23, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267018||34803|
NCT02274441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI12027|Activity and Quality of Care Indicators' for a Sentinel Network Creation|Gynaecological Emergencies: Validation of Indicators of Activity and Quality of Care for Creation of a Network Sentinel|URGO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Female|N/A|N/A|No|Probability Sample|Number of centers :        22 French-speaking gynaecological emergencies departments leaned with a public maternity        Number of subjects expected:        2000 consultations for acute pelvic pain, 200 patients hospitalized for data-gathering        stage; 408 records for checking data stage|January 2016|January 29, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02274441||34232|
NCT02273180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12619|Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine|Six-Month, Randomized, Open-Label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period|SORELLA 1|Sanofi|No|Active, not recruiting|October 2014|June 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273180||34329|
NCT02264301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QKL20140588|Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis|The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis||Chengdu PLA General Hospital|Yes|Enrolling by invitation|August 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02264301||35011|
NCT02283697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20142641|Dietary Counseling to Reduce Salt Intake in Patients With High Blood Pressure|Assessment of Effectiveness of Counseling by a Registered Dietician on Low Salt Diet in Patients With Hypertension: A Pragmatic Clinical Trial.||Ottawa Hospital Research Institute|No|Recruiting|September 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02283697||33521|
NCT02287467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSIGHT 006: FLU-IVIG|Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza|Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287467||33231|
NCT02287701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00072|Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization|Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization||New York University School of Medicine|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287701||33213|
NCT02261350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LF004H|Post-hospitalisation Nutritional Support and Gait Speed in COPD|The Effect of Nutritional Support on Gait Speed Following Hospitalisation for Acute Exacerbation of COPD||Royal Brompton & Harefield NHS Foundation Trust|No|Terminated|January 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|22|||Both|40 Years|N/A|No|||October 2015|October 30, 2015|May 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02261350||35238|
NCT02286271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP version 5.1|Preliminary Testing of a Novel Device to Detect Epileptic Seizures|Preliminary Testing of a Novel Device to Detect Epileptic Seizures|PTEpD|University of Edinburgh|No|Recruiting|November 2014|March 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|126|||Both|3 Months|N/A|No|Non-Probability Sample|Patients who are being admitted for electroencephalographic videotelemetry as part of        their clinical management of their epilepsy will be invited to participate in the study.|November 2015|March 21, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286271||33323|
NCT02283671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TolDec-EM-NMO|Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B|||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02283671||33523|
NCT02273076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2014-1299|Predicting Breast Flap Necrosis by Spatial Frequency Domain Imaging|Predicting Breast Flap Necrosis by Spatial Frequency Domain Imaging||University of California, Irvine|No|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Study Population will be recruited from UCI Anesthetic and Plastic Surgery Institute        clinics, seen by the Plastic Surgery Service. Subjects requiring breast reconstructive        surgery using either implant based or autologous reconstruction will be identified.|February 2016|February 5, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273076||34337|
NCT02260934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN055AI|Rituximab and Belimumab for Lupus Nephritis|Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2014|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260934||35270|
NCT02273167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1006-02/2014 (MORA)|Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using a 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimens in Adults.|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus MOVIPREP® Using a 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimens in Adults.||Norgine|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|849|||Both|18 Years|85 Years|No|||June 2015|January 18, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273167||34330|
NCT02261272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHUTiNorse|Internet-based Treatment for Insomnia|Internet-based Treatment for Insomnia in Norway.|SHUTiNorse|Norwegian Institute of Public Health||Active, not recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02261272||35244|
NCT02273232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A 1154|Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial|Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial||National University of Ireland, Galway, Ireland|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02273232||34325|
NCT02261818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23_MH100705|Using Peer Mentors to Deliver Depression Care|Phase 1 Study of Using Peers to Deliver Depression Care to Older Adults||Johns Hopkins University|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|50 Years|N/A|No|||October 2014|October 9, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261818||35202|
NCT02272959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|loe140498ctil|Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth Who do Not Respond to CBT|Attention Bias Modification Treatment for Children With Anxiety Disorders Who do Not Respond to Cognitive Behavioral Therapy: A Randomized Controlled Trial||Tel Aviv University|No|Recruiting|January 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|No|||January 2016|January 25, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272959||34346|
NCT02273024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7699|Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation|Exercise Therapy for Patients Awaiting Allogeneic Hematological Stem Cell Transplantation||University Health Network, Toronto|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|17 Years|N/A|No|||March 2016|March 4, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02273024||34341|
NCT02274506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0235|Infusion of Allogeneic, 3rd Party CD19-specific T Cells|Infusion of Allogeneic, 3rd Party CD19-specific T Cells for Patients With Refractory CD19+ B-Lineage Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Withdrawn|July 2014|||July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||October 2014|October 22, 2014|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274506||34227|
NCT02274519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007210|Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma|Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma||Mayo Clinic|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274519||34226|
NCT02258815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT:2009-015936-14|CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma|Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma||University Children’s Hospital Tuebingen|Yes|Recruiting|August 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|1 Year|21 Years|No|||October 2014|October 2, 2014|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02258815||35433|
NCT02258828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00255|An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder|An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder||VA Nebraska Western Iowa Health Care System|No|Completed|July 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|19 Years|65 Years|No|||October 2014|October 7, 2014|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258828||35432|
NCT02263924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-CRC-001-03|Stroke and Tocotrienol: Unique Role in Neuroprotection|Phase III, Single Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Oral Vitamin E (Mixed Tocotrienol) for 6 Months in Patients With Moderate Acute Ischemic Stroke|SATURN|Seberang Jaya Clinical Research Centre|No|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|35 Years|N/A|No|||December 2015|December 9, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02263924||35040|
NCT02268370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS CA180-543|Treatment-free Remission Accomplished With Dasatinib in Patients With CML|Treatment-free Remission Accomplished With Dasatinib in Patients With CML|TRAD|University Health Network, Toronto|No|Recruiting|October 2014|October 2021|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|135|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02268370||34699|
NCT02287025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17347|A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?|Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer|SMART|Bayer|No|Active, not recruiting|November 2014|March 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287025||33265|
NCT02276170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29957|Pharmacology of Aminophylline for Acute Kidney Injury in Neonates||PAANS|Stanford University|No|Enrolling by invitation|October 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|3 Months|No|Non-Probability Sample|Neonates with AKI admitted in the NICU who receive aminophylline.|October 2014|October 23, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276170||34099|
NCT02276456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00046405|The Impact of Early Follow-up on Readmission Rates in AMI Patients|The Impact of Early Versus Standard Post-Discharge Follow-up on Readmission Rates in Patients Admitted With Myocardial Infarction||Duke University|Yes|Recruiting|March 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 5, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02276456||34077|
NCT02283164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01OH010582-01|Drug Exposure Feedback and Education for Nurses' Safety|Randomized Controlled Trial to Improve Oncology Nurses' Protective Equipment Use|DEFENS|University of Michigan|Yes|Active, not recruiting|March 2015|July 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|380|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283164||33562|
NCT02283177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-006|A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations|A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations||Arog Pharmaceuticals, Inc.||Recruiting|January 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|December 11, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283177||33561|
NCT02272829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA038203|Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain|Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain|CHOACOT|Butler Hospital|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||November 2015|November 10, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02272829||34356|
NCT02259972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272.1|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers|Investigation of Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 5 to 800 mg BI 113823 Powder in Bottle (PiB) and Tablet Administered to Healthy Male Volunteers in a Partially Randomised and Double Blinded, Placebo Controlled Phase I Trial. Including Intra-individual Open Comparisons of PiB and Tablet (Fasted and Fed).||Boehringer Ingelheim||Completed|January 2010|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|63|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|October 7, 2014||||No||https://clinicaltrials.gov/show/NCT02259972||35344|
NCT02272894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E201419A|A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer|Randomized Controlled Trial to Evaluate Mesenteric Vein (14V) Lymphadenectomy for Gastric Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|July 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|510|||Both|18 Years|70 Years|No|Probability Sample|Distal Advanced Gastric Cancer|July 2014|December 8, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02272894|3 Years|34351|
NCT02268071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001773-14|Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)|Arrêt du Traitement Antihypertenseur Chez Les Patients Hypertendus Suivis en Médecine Générale / Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care: The STOP-Trial||Central Hospital, Nancy, France|No|Not yet recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02268071||34722|
NCT02268084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRT-002|Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD|A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Treatment Efficacy of EEG/ECD-Guided Magnetic Resonant Therapy in Combat Veterans With Post-Traumatic Stress Disorder (PTSD).||Newport Brain Research Laboratory|Yes|Recruiting|October 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|No|||January 2015|January 15, 2015|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02268084||34721|
NCT02272946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canakinumab|Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk|Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk||University of California, San Francisco|Yes|Recruiting|September 2015|June 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|110|||Both|40 Years|N/A|No|||February 2016|February 12, 2016|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272946||34347|
NCT02265588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49147.078.14|Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).|Reducing Symptoms of Depression and Anxiety in Adolescents With Inflammatory Bowel Disease in Order to Improve Quality of Life and the Clinical Course of Disease.|HAPPY-IBD|Erasmus Medical Center|No|Recruiting|September 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|20 Years|No|||September 2015|September 4, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02265588||34912|
NCT02261285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-13|ONO-4538 Phase I Study in Patients With Solid Tumor|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor||Ono Pharmaceutical Co. Ltd|No|Completed|October 2014|||February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|20 Years|N/A|No|||September 2014|May 10, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261285||35243|
NCT02261532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10040100|A Phase I Study of TAS-102 in Solid Tumors|A Phase 1, OPEN-Label, Non-randomized, Pharmacokinetic Study of TAS-102 in Chinese Patients With Solid Tumors||Taiho Pharmaceutical Co., Ltd.|No|Active, not recruiting|September 2014|February 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261532||35224|
NCT02266420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 SEIN 09|Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm|Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm.|COCABIO000|Institut Claudius Regaud|No|Recruiting|October 2014|October 2022|Anticipated|October 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|18 Years|N/A|No|||November 2014|May 26, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266420||34849|
NCT02272907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-27r|Leak Pressure After Reinforcement in Gastric Specimens|Comparison of Leak Pressure in the Resected Gastric Specimen From Sleeve Gastrectomy With Different Reinforcement Techniques||Santa Barbara Cottage Hospital|No|Enrolling by invitation|November 2014|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|48|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02272907||34350|
NCT02272088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-NEBIN|Effect of Different Intensities of Exercise on Daily Energy Expenditure With Physical Activity in Overweight Boys||PAPPAS2|Rio de Janeiro State University|Yes|Not yet recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Male|11 Years|14 Years|No|||October 2014|October 20, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272088||34413|
NCT02272101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R14-3326B|Rhinitis in the Elderly: The Role of Vitamin D|"Rhinitis in the Elderly: A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study of the Effect of Vitamin D Supplementation on Nasal Symptoms and Rhinitis Related Quality of Life"||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|65 Years|N/A|No|||October 2014|October 21, 2014|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02272101||34412|
NCT02272114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA148|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||February 2, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02272114||34411|
NCT02263183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD164/12|Red Palm Olein and Cardiovascular Health|Red Palm Olein and Cardiovascular Health||Malaysia Palm Oil Board|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 12, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02263183||35097|
NCT02258893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308012531|Indoor Air Pollution and Children With Asthma: An Intervention Trial|Indoor Nitrogen Dioxide Exposure and Children With Asthma: An Intervention Trial|CAPS|Yale University|Yes|Not yet recruiting|January 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|600|||Both|5 Years|11 Years|No|||December 2015|December 2, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258893||35427|
NCT02259140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-199|A Randomized Control Trial of Hip Dislocation Techniques for Pediatric Patients With Cerebral Palsy|Proximal Femoral Resection-Interposition Arthroplasty Versus Resection at the Femoral Neck With Subtrochanteric Valgus Osteotomy for Hip Dislocation in Patients With Cerebral Palsy: A Randomized Control Trial||Hospital for Special Surgery, New York|Yes|Not yet recruiting|October 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|7 Years|21 Years|No|||September 2015|September 28, 2015|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02259140||35408|
NCT02263703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/028|Immunogenicity of HPV Vaccine in Immunosuppressed Children|Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine||The University of New South Wales|No|Active, not recruiting|May 2007|August 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|N/A|18 Years|No|||November 2015|November 30, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02263703||35057|
NCT02263716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141504|Actigraphy to MEasuRe Intensive Care Unit Activity|Actigraphy to MEasuRe Intensive Care Unit Activity (AMERICA)|AMERICA|Vanderbilt University|No|Recruiting|July 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|A diverse population of adult patients with medical or surgical critical illness in the        ICU.|July 2015|July 24, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02263716||35056|
NCT02259387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3128|Adolescents With Migraine: What's Stress Got To Do With It?|Adolescents With Migraine: What's Stress Got To Do With It?|Adostress|University of Colorado, Denver|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Hair samples for cortisol.|Both|13 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|The population to be sampled is adolescents (13-17 years old) with migraines, both male        and female. Migraines are common in the pediatric population with a prevalence as high as        10% in children 5-14 years old,1 and 28% in adolescents 15-19 years old (Split W, 1999).|June 2015|June 9, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259387||35389|
NCT02263976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.1|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Rising Inhaled BEA 2180 BR Doses (2.5 μg to 1600 μg Cation Administered With the Respimat®) in Healthy Male Subjects, Alone and Followed by Methacholine Challenge. A Randomised, Double-blind Within Dose Group, Placebo-controlled Study, With a 36 μg Tiotropium Bromide Single Dose Sub-study (Open, Two-fold Crossover).||Boehringer Ingelheim||Completed|August 2003|||June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|101|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02263976||35036|
NCT02264340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F(EFP)-003/2010|Effects of Exercise and Relaxation Techniques on Tension Headache Pain Parameters of University Students|EFFECTS OF EXERCISE AND RELAXATION TECHNIQUES ON TENSION-TYPE HEADACHE PAIN PARAMETERS OF UNIVERSITY STUDENTS; A RANDOMIZED AND CONTROLLED CLINICAL TRIAL|ERTTHU|Universidad Complutense de Madrid|No|Completed|September 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|25 Years|No|||October 2014|October 14, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264340||35008|
NCT02268721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-O-FNG-2014-1|Food'to'Go - a Feasibility Study of Post-discharge Meals for Older Patients by the Use of ICT-technology|Food'to'Go - a Feasibility Study of Post-discharge Delivery of Protein- and Energy-enforced Meals for Older Patients by the Use of ICT-technology||Herlev Hospital|No|Completed|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02268721||34672|
NCT02268747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACOMINT14|Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer|Efficacy and Safety of Single Agent Pan-HER Inhibitor Dacomitinib in the Treatment of Locally Advanced Unresectable or Metastatic Squamous Cell Cancer of the Skin or With Clinical Contraindication to Surgery||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|August 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02268747||34670|
NCT02364648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|680076-2|Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease|Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease||University of Delaware|No|Recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02364648||27312|
NCT02364661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601-14-RMC|The Influence of Short-term Starvation on Hepatitis B Virus Load|The Influence of Short-term Starvation on Disease Severity and Viral Replication Among Hepatitis B Virus Patients||Rabin Medical Center|No|Not yet recruiting|March 2015|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|75 Years|No|||February 2015|February 10, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02364661||27311|
NCT02262806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150002|Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy|Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|6 Months|N/A|No|||August 2015|August 28, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262806||35126|
NCT02265991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKEppendorfMKG|Prospective Biomechanical Analysis of Donor-site Morbidity Following Microvascular Fibula Transplantation|Prospective Biomechanical Analysis of Donor-site Morbidity Following Microvascular Fibula Transplantation in 27 Consecutive Cases: a Clinical Cohort Study.||Universitätsklinikum Hamburg-Eppendorf|No|Completed|September 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult patients with informed consent and that will undergo mandible resection and        reconstruction via free fibula flap at the Department of Oral and Maxillofacial Surgery,        University Medical Center Hamburg Eppendorf, Germany.|October 2014|October 10, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265991||34882|
NCT02269007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT019|A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China|A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|May 2015|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02269007||34650|
NCT02266459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF04|Study to Evaluate Performance, Usability, Safety of Microwave Technology When Collecting Data From Patients With Stroke|A Prospective, Open, Multicenter Study to Evaluate the Performance, Safety and Usability of the Microwave Technology Developed by Medfield Diagnostics When Collecting Measurement Data From Patients With Clinical Signs of Stroke.||Medfield Diagnostics|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266459||34846|
NCT02361281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC/1408-389|Validation of a Non-invasive Diagnostic Method for Sarcoidosis Using Exhaled Breath|Validation of a Previously Performed Study on Non-invasive Diagnostic Method for Sarcoidosis Using Exhaled Breath||Maastricht University|No|Enrolling by invitation|December 2014|July 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|sarcoidosis patients with confirmed disease, with a range of disease stages. Average age        for all study subjects: +- 50 y/o male/female ratio: approx 15 men vs. 10 women in each        group.|February 2015|February 6, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02361281||27570|
NCT02361541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-Epi|Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia|Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia|HCV-Epi|Institute of Tropical Medicine, Belgium|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2700|Samples Without DNA|Left over biological samples (whole blood plasma and serum)|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients in a cohort of HIV-positive patients in Cambodia|December 2015|December 8, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02361541||27550|
NCT02269423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V920-001|Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)|A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects||Merck Sharp & Dohme Corp.|Yes|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|39|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269423||34618|
NCT02262741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00011|A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer|A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||MedImmune LLC|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|99 Years|No|||November 2015|November 6, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262741||35131|
NCT02262754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431006|PF-06372865 In Subjects With Chronic Low Back Pain|A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of Pf-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control||Pfizer|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|223|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262754||35130|
NCT02262975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-M082-602|A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)||ADOS|Eisai Inc.||Active, not recruiting|July 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|536|||Both|50 Years|89 Years|No|Probability Sample|Alzheimer's disease patients who have been recently prescribed with donepezil (Aricept) as        monotherapy for the first time|March 2016|March 8, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02262975||35113|
NCT02267356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMT-VT-1161-CL-005|A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail||Viamet|No|Active, not recruiting|December 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|70 Years|No|||June 2015|August 3, 2015|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02267356||34777|
NCT02263443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBG-2557-02203|Appropriated Bowel Preparation Before Exploratory Laparotomy in Gynecologic Surgery|Appropriated Bowel Preparation Before Exploratory Laparotomy in Gynecologic Surgery||Chiang Mai University|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Anticipated|330|||Female|N/A|80 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263443||35077|
NCT02267928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14-574|Information Presentation Formats|Information Presentation Formats and Pursuit of Diagnostic Information||Carnegie Mellon University|No|Recruiting|October 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|4||Anticipated|280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267928||34733|
NCT02268175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-283|Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate|A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy||Dana-Farber Cancer Institute|Yes|Recruiting|October 2014|February 2022|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Male|18 Years|N/A|No|||February 2016|February 25, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268175||34714|
NCT02268435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1401|Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors|A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib||Asan Medical Center|No|Withdrawn|March 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|N/A|No|||August 2015|August 1, 2015|October 7, 2014||No|Dovitinib Production stopped|No||https://clinicaltrials.gov/show/NCT02268435||34694|
NCT02263989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.520|Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers|Bioequivalence of the 40 mg Telmisartan Film-coated Tablet Compared With the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|January 2007|||April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02263989||35035|
NCT02264002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503.203|Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers|Pharmacodynamic Effects, Safety and Tolerability of 0.25 mg, 0.5 mg, 1 mg and 2 mg Cilobradine, Compared to 190 mg Metoprolol Succinate and Placebo, Administered p.o. Once Daily Over 14 Days to Healthy Volunteers in a Randomised, Placebo-controlled, Partly Double Blind Study, With a 4 mg/14 mg and 10 mg/20 mg Cilobradine Single Dose Versus Placebo Substudy (Double Blind, Three-fold Cross-over)||Boehringer Ingelheim||Completed|February 2003|||November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|119|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264002||35034|
NCT02264015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503.204|Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers|Pharmacodynamic Effects, Safety and Tolerability of 2 mg and 5 mg Cilobradine, Administered p.o. Once Daily Over 14 Days to Healthy Male and Female Volunteers in a Randomised, Placebo-controlled, Double Blind Study, With an Open-label Uncontrolled Intra-individual Comparison to 400 mg Moxifloxacin Single Dose in a Subset of Volunteers.||Boehringer Ingelheim||Completed|January 2004|||May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|125|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264015||35033|
NCT02271048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03|The Feasibility and Effectiveness Study for Tele-ultrasonography|The Feasibility and Effectiveness Study for Clinical Application of Realtime Tele-ultrasonography Using the Smartphone||Hanyang University|Yes|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|12|||Male|33 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271048||34493|
NCT02271113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1271-102|Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects|A Randomized, Placebo Controlled, Phase1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects||GlycoMimetics Incorporated|No|Recruiting|October 2014|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271113||34488|
NCT02368639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-156|Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing|Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing||Fisher and Paykel Healthcare|No|Recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02368639||27008|
NCT02368652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CCA_301A|A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy|A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy||CJ HealthCare Corporation|No|Recruiting|October 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|19 Years|75 Years|No|||October 2014|February 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02368652||27007|
NCT02368665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_CCA_301B|A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy|A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy||CJ HealthCare Corporation|No|Recruiting|October 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|158|||Both|19 Years|75 Years|No|||October 2014|February 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02368665||27006|
NCT02265640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.28|Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers|Randomised 4-way Cross-over Phase I Study to Investigate the Relative Bioavailability of BIIL 284 BS 75 mg Boli in Comparison to Tablet C in Fasted Condition and After Ingestion of a Standardised Meal in Healthy Volunteers||Boehringer Ingelheim||Completed|October 2000|||December 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 15, 2014||||No||https://clinicaltrials.gov/show/NCT02265640||34908|
NCT02265653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.3|Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers|Randomised 3-way Cross-over Phase I Study to Investigate the Relative Bioavailability of BIIL 284 BS 75 mg Tablet C and Tablet D in Comparison to WIF Tablet in Healthy Volunteers||Boehringer Ingelheim||Completed|November 1999|||December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 15, 2014||||No||https://clinicaltrials.gov/show/NCT02265653||34907|
NCT02269124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006H|Use of Amplification in Children With Unilateral Hearing Loss|Use of Amplification in Children With Unilateral Hearing Loss||Massachusetts Eye and Ear Infirmary|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02269124||34641|
NCT02271399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKRPROVTE|Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty|Randomized Controlled Study on the Prophylaxis of Venous Thromboembolic Events in Patients Undergoing Total Knee Arthroplasty: Comparison of Aspirin and Rivaroxaban||Hanyang University Seoul Hospital|Yes|Completed|October 2014|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|156|||Both|N/A|N/A|No|||February 2016|February 17, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271399||34466|
NCT02266797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00108|Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery|Effect of Intravenous Corticosteroid Injections on Dysphagia After Anterior Cervical Spine Surgery: a Randomized, Double-blind, Placebo-controlled Study||New York University School of Medicine|No|Terminated|November 2013|||September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|21 Years|65 Years|No|||February 2016|February 16, 2016|October 2, 2014|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT02266797||34820|
NCT02266810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-0514|Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus|The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study|PROGRESS|Intersect ENT|No|Recruiting|September 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266810||34819|
NCT02271685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14-553|Sound Estimation and Accuracy Task|Estimation and Accuracy in Sound Task Perceived to be Medically Diagnostic||Carnegie Mellon University|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|4||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271685||34444|
NCT02266823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-00563|Diabetes CKD Lifestyle Technology Study|Program to Improve Care in Complex Chronic Disease||New York University School of Medicine|No|Recruiting|October 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|N/A|No|||October 2015|October 26, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02266823||34818|
NCT02267083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPX-150-002|Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma|Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma||Gem Pharmaceuticals|No|Active, not recruiting|January 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267083||34798|
NCT02269982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056936|Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)|Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)||Duke University|No|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|All 120 subjects will have blood collected at 3 time points for CTC-based AR-v7 analysis.      Biopsy samples will be collected from up to 20 consenting subjects who are already      undergoing a standard of care metastatic biopsy or from a research only biopsy.|Male|18 Years|N/A|No|Non-Probability Sample|The study population includes men with progressive metastatic castration resistant        prostate cancer (mCRPC).|January 2016|February 15, 2016|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269982||34575|
NCT02269995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCB01S|Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma|||Eisai Inc.|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Hepatocellular carcinoma|November 2015|November 5, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02269995||34574|
NCT02267616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108136|Effectiveness of Prolonged Use of IUD/Implant for Contraception|Effectiveness of Prolonged Use of IUD/Implant for Contraception|EPIC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|December 2011|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1350|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267616||34757|
NCT02270411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6036|Inflammatory Cells From Various Pathologies|Development of a Method to Isolate Inflammatory Cells From Skin Biopsies of Patients With Various Pathologies for Quantitative Flow Cytometry Analysis||Innovaderm Research Inc.|No|Recruiting|May 2014|August 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Invitation to volunteer|February 2016|February 23, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270411||34542|
NCT02270697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ER-101-336|Evaluation of an Oligonucleotide Array for Rapid Identification of Dermatophytes in Clinical Specimens|Evaluation of an Oligonucleotide Array for Rapid Identification of Dermatophytes in Clinical Specimens||National Cheng-Kung University Hospital|No|Completed|March 2012|March 2014|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|32|Samples With DNA|-  Nail Samples        -  Scrap Samples|Both|N/A|N/A|No|Probability Sample|The subject were suspect onychomycosis and treatment at National Cheng Kung University        Hospital.|October 2014|October 17, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270697||34520|
NCT02268448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610M95566|Atopic Dermatitis Itch|Treatment of Chronic Itch in Atopic Dermatitis With Oral Clonidine and Oral Naltrexone||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268448||34693|
NCT02268708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCHIN2014BPCO|Evaluation of Post-operative Respiratory Complications After Thoracic Surgery in Patients With COPD|Evaluation of Post-operative Respiratory Complications After Thoracic Surgery in Patients With COPD||Hôpital Cochin|No|Completed|July 2014|February 2016|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|40 Years|N/A|No|Non-Probability Sample|male or female aged more than 40 years, permanent airflow obstruction as defined by an        FEV/FVC ratio < 70% after bronchodilator. Collected data will be: COPD symptoms (dyspnea        score, exacerbations) by a questionnaire given to the patient during the anesthesia        consultation, COPD severity scores, comorbidities, per operative data, postoperative        complications, hospitalization and intra-hospital mortality.|February 2016|February 17, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02268708||34673|
NCT02260739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00208-37|Sequential Analysis in Patients With an Hemopathy|Sequential Analysis in Patients With an Hemopathy|S-HEMO|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|January 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|246|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02260739||35285|
NCT02261038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rad-2CT-3CT_001_MH|Comparison of the Femoral Prothesis-rotation in Conventional X-ray, in Axial CT Slices and 3D-reconstructed CT|Comparative Study pf the Femoral Prothesis-rotation in Conventional X-Ray, in Axial CT Slices and 3D-reconstructed CT||Kantonsspital Baselland Bruderholz|Yes|Recruiting|November 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|55 Years|95 Years|No|||September 2015|September 1, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02261038||35262|
NCT02376647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-3pilot|ART-3 Pilot - Driving Pressure Limited Ventilation for Patients Without ARDS (ART3pilot)|ART-3 Pilot: A Randomized Controlled Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs.Standard Strategy in Patients Without ARDS|ART-3pilot|Hospital do Coracao|No|Not yet recruiting|March 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|March 3, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02376647||26395|
NCT02271178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Multi-cap for Increase Adherence After Acute Myocardial Infarction|Multi-cap for Increase Adherence After Acute Myocardial Infarction||Hospital El Cruce|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||October 2014|October 23, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02271178||34483|
NCT02268903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 130519|Diuretic Versus Placebo in Pulmonary Embolism|Diuretic Versus Placebo in Pulmonary Embolism With Right Ventricular Enlargement: a Double-blind Randomized Controlled Study|DiPER|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268903||34658|
NCT02268916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1190-W|Physical Activity and Participation|Veterans With Diabetes Mellitus: Improving Physical Activity and Participation||VA Office of Research and Development|No|Active, not recruiting|June 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|60 Years|N/A|No|||February 2016|February 25, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268916||34657|
NCT02271256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRF2015|Functional Intimate Apparel for Adolescents With Early Scoliosis|Safety and Efficacy of Functional Intimate Apparel for Adolescents With Early Scoliosis||The Hong Kong Polytechnic University|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|10 Years|13 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271256||34477|
NCT02271269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRNIG12nov007|Study on Incentives for Glaucoma Medications Adherence|A Randomized Controlled Trial to Increase Glaucoma Medication Adherence Using Value Pricing|SIGMA|Duke-NUS Graduate Medical School|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|21 Years|85 Years|No|||November 2015|November 26, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02271269||34476|
NCT02271412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY03005 MAD|Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005||Luye Pharma Group Ltd.|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271412||34465|
NCT02271425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14622|A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants|An Absolute Bioavailability Study of Evacetrapib in Healthy Subjects Using the Intravenous Tracer Method||Eli Lilly and Company|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271425||34464|
NCT02269306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Menoufia OGG-1|Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome|Visceral Fat Area and Other Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome||Menoufia Obstetrics and Gynecology Group|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|150|||Female|18 Years|40 Years|No|||October 2014|October 16, 2014|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269306||34627|
NCT02262390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST/0109/14|Syphilis Treatment of Partners Trial|Comparison of Different Partner Notification Strategies After Antenatal Syphilis Screening|STOP|Makerere University|No|Not yet recruiting|November 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|1752|||Both|14 Years|N/A|No|||October 2014|October 10, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02262390||35158|
NCT02269605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRYOLAT|Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment|Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial|BRYOLAT|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Yes|Completed|September 2014|December 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|50 Years|No|||December 2015|December 17, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02269605||34604|
NCT02258607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-370-1297|Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase|A Phase 1b With Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase||Gilead Sciences|No|Recruiting|March 2015|March 2018|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|111|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258607||35449|
NCT02269800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LST-001|An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD|An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD||Lustre Pharmaceutical Lab Co., Ltd|No|Not yet recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269800||34589|
NCT02259153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEICA;PI13-00106|Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis|A Randomized Study to Assess the Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis||Instituto Aragones de Ciencias de la Salud||Completed|March 2014|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02259153||35407|
NCT02259166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHFP+ TZ|Enhanced Homestead Food Production Plus+ Program in the Lake Zone, Tanzania|Impact of the Evaluation of the Enhanced Homestead Food Production Program in Sengerema, and Ukerewe in the Lake Zone,Tanzania||International Food Policy Research Institute|No|Active, not recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2400|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||September 2015|September 8, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02259166||35406|
NCT02270216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KhonKaenU|Cardiovascular Responses to Static and Dynamic Exercise in Elderly With Isolated Systolic Hypertension|Study of Cardiovascular Responses to Static and Dynamic Exercise in Isolated Systolic Hypertension||Khon Kaen University||Enrolling by invitation|May 2014|||October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270216||34557|
NCT02270229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rev5162014|Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.|Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.||La Isla Foundation||Not yet recruiting|November 2014|||May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|This study will be performed in a public hospital in northwest Nicaragua.        There will be four groups of participants:          1. Healthcare professionals, including physicians, nurses, technicians, and             administrators          2. PD patients          3. Primary caregivers of the PD patients          4. Laboratory personnel|October 2014|October 17, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02270229||34556|
NCT02259634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1304-6854|Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients|Impact of Patient Navigators on Health Education and Quality of Life in Formerly Incarcerated Patients||St. Luke's-Roosevelt Hospital Center|Yes|Terminated|June 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 15, 2014||No|Target sample size not reached for enrollment.|No||https://clinicaltrials.gov/show/NCT02259634||35370|
NCT02260115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-01EU-2013|A Randomized Multi-centre Study to Assess the Safety and Manageability of a Laparoscopic Adhesion Barrier in Women Undergoing Gynecologic Laparoscopic Surgery Followed by Second Look Laparoscopy|A Randomized, Controlled, Subject and Reviewer-Blinded, Multi-Centre Study To Assess The Safety and Manageability Of LABS™ In Women Undergoing Gynaecologic Laparoscopic Surgery Followed By Second Look Laparoscopy|LABS-1|Actamax Surgical Materials LLC|Yes|Active, not recruiting|November 2013|July 2015|Anticipated|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Female|18 Years|46 Years|Accepts Healthy Volunteers|||August 2014|October 8, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02260115||35333|
NCT02260128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tyggegummi|Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery|Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery||Odense University Hospital|No|Not yet recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 8, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260128||35332|
NCT02260427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0157|A Comparison of the I-gel and Self-pressurised Air-Q Intubating Laryngeal Airway (Air-Q sp) in the Elderly Patients|||Yonsei University|No|Recruiting|October 2014|May 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|100|||Both|65 Years|90 Years|No|||October 2014|October 27, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260427||35309|
NCT02270983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-40|Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain||Forest Laboratories|No|Completed|October 2014|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|254|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270983||34498|
NCT02271009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN008T|Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC|A Double-Blind, Placebo-Controlled, Randomized Trial to Compare the Efficacy and Tolerability of Three Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in Environmental Exposure Chamber||Anergis|Yes|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|213|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271009||34496|
NCT02265744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM128-027|Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus||Bristol-Myers Squibb|Yes|Recruiting|November 2014|February 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|350|||Both|18 Years|70 Years|No|||December 2015|March 11, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265744||34901|
NCT02266030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1010/114-005|Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM|Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With Type 2 Diabetes Mellitus|ESCAPE|Seoul National University Bundang Hospital|Yes|Recruiting|February 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|80 Years|No|||October 2015|October 23, 2015|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02266030||34879|
NCT02266277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9713747|System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts|System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts.||University of Massachusetts, Worcester|No|Enrolling by invitation|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|30000|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266277||34860|
NCT02361398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-ARDS-EIT|Lung Alveolar Recruitment and Individualized PEEP Setting in Patients With ARDS|Lung Alveolar Recruitment and Individualized Positive End Expiratory Pressure(PEEP) Setting in Patients With Acute Respiratory Distress Syndrome(ARDS)||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||February 2015|February 6, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02361398||27561|
NCT02361645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitreo001|NSAIDs and PGE2 Levels in Vitrectomy Patients|Vitreous Nonsteroidal Antiinflammatory Drus Concentrations And Prostaglandin E2 Levels in Vitrectomy Patients Treated With Indomethacin 0.5%, Bromfenac 0.09%, and Nepafenac 0.1%||Università degli Studi di Brescia|No|Completed|March 2014|January 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|70|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02361645||27542|
NCT02260726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140318-01H|Evaluation of Ultrasound for Detecting Hip Impingement|Diagnosing Deformities of the Hip Associated With Arthritis: MRI vs Ultrasound||Ottawa Hospital Research Institute|No|Active, not recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260726||35286|
NCT02261025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120308|The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis|The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis||Shanghai Jiao Tong University School of Medicine|Yes|Completed|January 2008|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|410|||Both|18 Years|85 Years|No|||October 2014|October 22, 2014|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261025||35263|
NCT02261363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00008526|The Moment Study: Mixed Method Ecigarette Study|A Mixed Method EMA Assessment of Cognition and Behavior Among New ENDS Users: An Observational Cohort Study|Moment|Truth Initiative|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In total, our goal is to enroll 150 individuals, with 120 participants completing the        protocol. For the main arm of the study, we will recruit a racially and ethnically diverse        sample of 140 daily smokers (or 100 study completers), with the goal of recruiting at        least 50% non-Hispanic black participants. For the second study arm, we will enroll an        additional 30 participants, with the goal of 20 individuals completing the protocol. There        are no race/ethnicity recruitment goals associated with the second arm. In total, the main        study arm will consist of 100 daily smokers who do not intend to quit smoking in the next        30 days, while the second arm will include 20 daily smokers who do intend to quit smoking        in the next 30 days.|November 2015|November 30, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02261363||35237|
NCT02261376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E103|Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a|||Daiichi Sankyo Inc.|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261376||35236|
NCT02261597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #: 2014P-000297|Challenging the Inflammatory Response System in Insomnia Disorder|Challenging the Inflammatory Response System: Are Individuals With Insomnia More Reactive?||Beth Israel Deaconess Medical Center|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|44|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261597||35219|
NCT02261870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00848-39|Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2|"Detection of Acute Rejection in Heart Transplant Patients by Mean of T2 Quantification With MRI" Open Transversal Clinical Trial With Repeated Measures|DRAGET|Central Hospital, Nancy, France|No|Recruiting|December 2014|July 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|190|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02261870||35198|
NCT02261883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PN-201|Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn|Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study||United Therapeutics|Yes|Recruiting|May 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|14 Days|No|||September 2015|September 3, 2015|October 30, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261883||35197|
NCT02271555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inonu 3|The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy|Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya||Inonu University|No|Not yet recruiting|October 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|60 Years|No|||October 2014|October 20, 2014|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271555||34454|
NCT02262143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-ROFE-301|Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia|Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients||IlDong Pharmaceutical Co Ltd|No|Not yet recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|19 Years|80 Years|No|||October 2014|October 7, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262143||35177|
NCT02266472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.28|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (10 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric Meal (an Open-label, Randomised, Single Dose, Crossover Trial)||Boehringer Ingelheim||Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266472||34845|
NCT02266485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525.3|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 2.5 mg o.d. BIBB 515 BS (Capsule) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])||Boehringer Ingelheim||Completed|July 1998|||September 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266485||34844|
NCT02258906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0633|Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy|Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy||Yonsei University|Yes|Recruiting|October 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|79 Years|No|||June 2015|June 23, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258906||35426|
NCT02263469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R9VF03|A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years|An Open Multi-centre Phase III Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients Under the Age of 6 Years||Bio Products Laboratory||Completed|August 2005|||July 2006|Actual|Phase 3|Interventional|N/A|1||||||Both|N/A|6 Years|No|||August 2014|October 9, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02263469||35075|
NCT02258919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163/14|Decompressive Hemicraniectomy in Intracerebral Hemorrhage|Swiss Trial of Decompressive Craniectomy Versus Best Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): a Randomized Controlled Trial|SWITCH|University Hospital Inselspital, Berne|Yes|Recruiting|October 2014|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02258919||35425|
NCT02264041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503.213|Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine|The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|January 2004|||April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|25|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264041||35031|
NCT02268825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI76239|Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers|A Phase I/IIA Study of MK-3475 in Combination With Chemotherapy and Supplemental Celecoxib in Patients With Advanced GI Cancers (Colorectal/Appendiceal Adenocarcinoma, Gastroesophageal, Pancreatic and Biliary)|MK-3475 GI|University of Utah|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268825||34664|
NCT02259400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV/RDS-01|NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome)|Noninvasive Ventilation Strategies for Early Treatment of RDS in Preterm Infants: An RCT|NIV|Azienda Ospedaliera Universitaria Policlinico "G. Martino"||Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|N/A|2 Hours|No|||January 2015|January 30, 2015|October 2, 2014||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT02259400||35388|
NCT02264613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALRN-6924-1-01|Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein||Aileron Therapeutics|No|Recruiting|October 2014|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264613||34987|
NCT02265133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102011-033|Corneal Sensitivity in Patients With Sleep Apnea Syndrome|Corneal Sensitivity and Nerve Fiber Morphology in Patients With Sleep Apnea Syndrome||University of Texas Southwestern Medical Center|No|Recruiting|December 2011|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sleep Apnea and normal controls|October 2014|October 9, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT02265133||34947|
NCT02260440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-118|A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer|A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer||University of Pittsburgh|Yes|Recruiting|January 2015|November 2020|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02260440||35308|
NCT02265393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-201403|A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom|A 6-Month, Prospective, Randomized, Multicenter, Placebo-Controlled Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Followed by a 6-Month Open-Label Extension||Otonomy, Inc.|Yes|Active, not recruiting|October 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|80 Years|No|||April 2015|April 20, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265393||34927|
NCT02269449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI20140920|Radial Artery Patency and Bleeding, Efficacy, Adverse evenT Trial|RAP and BEAT Clinical Trial (Radial Artery Patency and Bleeding, Effectiveness, Adverse evenT Trial)|RAPandBEAT|NPO International TRI Network|Yes|Not yet recruiting|October 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|1900|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02269449||34616|
NCT02269618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N.160|Telehealth Program in Chronic Patients|Innovative Multidisciplinary Telehealth Program in COPD and CHF Patients: a Randomized Control Trial.||Fondazione Salvatore Maugeri|No|Completed|June 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|113|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269618||34603|
NCT02269813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-PRIMe|PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)|PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)|PRIMe|West German Study Group|No|Recruiting|April 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|450|||Female|18 Years|N/A|No|Probability Sample|The study population will comprise patients for whom the investigator will advise either        endocrine therapy or chemotherapy + endocrine therapy. Patients confirmed to be low/high        risk by the gene signature will receive the respective treatment. Patients with discordant        results will be investigated for investigator's chemotherapy intention after MammaPrint        results are available.|June 2015|June 18, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02269813||34588|
NCT02260414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408049|Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer|Effects of Injection Tinzaparin Prophylactic Dose (4,500 IU Anti-Xa) on Thrombin Generation in Patients With Multiple Myeloma, Lymphoma Patients and Patients Hospitalized for an Acute Medical Condition.|METRO B|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|April 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02260414||35310|
NCT02265120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-14-00447|Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening|Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening||University of Southern California|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1000|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02265120||34948|
NCT02265380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMT-CT-002-PED|A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population|A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population||Optomeditech Oy|No|Not yet recruiting|October 2014|February 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|N/A|12 Years|No|||October 2014|October 14, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265380||34928|
NCT02265666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.31|Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS|Randomised, Open-label, Two-way Crossover Study in Male Healthy Volunteers to Investigate the Relative Bioavailability of BIIL 284 BS 5 mg Tablet FF in Comparison to Tablet C After Ingestion of a Standardised Meal||Boehringer Ingelheim||Completed|October 2001|||November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|October 15, 2014||||No||https://clinicaltrials.gov/show/NCT02265666||34906|
NCT02265679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.36|Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients||Boehringer Ingelheim||Completed|October 2001|||July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|45|||Both|6 Years|N/A|No|||October 2014|October 15, 2014|October 15, 2014||||No||https://clinicaltrials.gov/show/NCT02265679||34905|
NCT02265705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14875|A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy||Eli Lilly and Company|No|Recruiting|October 2014|May 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265705||34904|
NCT02265718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001489|A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers|A Randomized, Double Blind, Placebo Controlled Trial To Study Difference In Cognitive Learning Associated With Repeated Self-administration Of Remote Computer Tablet-based Application Assessing Dual-task Performance Based On Amyloid Status In Healthy Elderly Volunteers||Pfizer|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|70 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265718||34903|
NCT02266004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140127|Transcranial Direct Current Stimulation for Freezing of Gait|Transcranial Direct Current Stimulation for Freezing of Gait in Patients With Parkinson's Disease|TDCS-FOG|University of Miami|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2015|October 27, 2015|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266004||34881|
NCT02266017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054792|Mobile Pain Coping Skills Training for Cancer Pain|An Accessible Mobile Health Behavioral Intervention For Cancer Pain||Duke University|No|Recruiting|October 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02266017||34880|
NCT02266264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-R2R-200|Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock|Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial||Srinakharinwirot University|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266264||34861|
NCT02269319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-I-03|MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection|A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection|ABSSSI|MicuRx|No|Active, not recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|October 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269319||34626|
NCT02269436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0029-004|A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS|A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis||Newron Sweden AB|Yes|Terminated|January 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|October 8, 2014||No|Issues with development and supply of infusion system for delivery of IMP. Lack of favorable    benefit risk ratio in sNN0029-003 study (review of interim data).|No||https://clinicaltrials.gov/show/NCT02269436||34617|
NCT02263729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14050083|Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains|Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains||University of Pittsburgh|No|Not yet recruiting|March 2016|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|35 Years|No|||January 2016|January 4, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02263729||35055|
NCT02263742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-1304-7294|Project Wellness Enhancement: Increasing Health Care Choice and Outcomes for People With Mental Illness|Increasing Health Care Choices and Improving Health Outcomes Among Persons With Serious Mental Illness|WE|Yale University|No|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 7, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02263742||35054|
NCT02264028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503.209|Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL After Administration of Single Doses of 5 mg [14C]-DK-AH 269 CL Intravenously and 10 mg [14C]-DK-AH 269 CL as Oral Solution in a Parallel-group Design in 12 Healthy Male Volunteers||Boehringer Ingelheim||Completed|March 2004|||April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264028||35032|
NCT02268877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1444|A Randomized Prospective Analysis of Time to Diagnosis and Length of Stay of Emergency Department Pelvic Ultrasonography|A Randomized Prospective Analysis of Time to Diagnosis and Length of Stay of Emergency Department Pelvic Ultrasonography||Denver Health and Hospital Authority|No|Enrolling by invitation|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|330|||Female|18 Years|55 Years|No|||April 2015|April 17, 2015|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02268877||34660|
NCT02264353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD141272|The Impact of Arousal Threshold in Obstructive Sleep Apnea|The Impact of Arousal Threshold in Obstructive Sleep Apnea: Donepezil's Effects on the Arousal Threshold and on the Apnea Hypopnea Index||University of California, San Diego|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02264353||35007|
NCT02269033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20080535H|Redes II National Patient Navigator Intervention Study|Redes en Acción: National Patient Navigator Intervention Study||The University of Texas Health Science Center at San Antonio|Yes|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|480|||Female|18 Years|N/A|No|||October 2014|October 20, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02269033||34648|
NCT02269046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LML|Acupuncture and Moxibustion for Hyperlipemia|A Multi-center, Randomized, Stratified, Active-controlled Trial to Evaluate the Effects of Acupuncture and Moxibustion for Hyperlipidemias|AMH-RCT|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Yes|Not yet recruiting|December 2014|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|20 Years|75 Years|No|||August 2014|October 16, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02269046||34647|
NCT02269163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004C009G|A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG|A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children With PID|IGIV|ProMetic BioTherapeutics, Inc|Yes|Recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|2 Years|80 Years|No|||February 2016|February 12, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269163||34638|
NCT02269176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.365|Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension|12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients||Boehringer Ingelheim||Completed|July 2000|||January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|330|||Both|N/A|N/A|No|||October 2014|October 20, 2014|October 20, 2014||||No||https://clinicaltrials.gov/show/NCT02269176||34637|
NCT02269189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.37|Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses (15-day Dosing) of BIIL 284 BS in Adult (300 mg) and Pediatric (150 mg) Cystic Fibrosis Patients||Boehringer Ingelheim||Completed|April 2002|||November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|36|||Both|6 Years|N/A|No|||October 2014|October 20, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02269189||34636|
NCT02269202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599.12|Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects|Pharmacokinetics of 7.5 mg Midazolam, Given Orally With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomised, Single Blind, Two-way Crossover Trial in Healthy Male Subjects||Boehringer Ingelheim||Completed|February 2002|||April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|20|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02269202||34635|
NCT02265731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-834|Study Evaluating Venetoclax in Subjects With Hematological Malignancies|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Japanese Subjects With Hematological Malignancies||AbbVie|Yes|Recruiting|October 2014|November 2018|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|99 Years|No|||March 2016|March 8, 2016|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265731||34902|
NCT02269332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140085H|Vitamin D and Screening Colonoscopy or Polyp Surveillance|Association of 25-OH Vitamin D Status With Findings on Screening Colonoscopy.|VitDColon|Mike O'Callaghan Federal Hospital|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|298|||Both|18 Years|N/A|No|Non-Probability Sample|DoD beneficiaries age 18 or older will be recruited from the clinics at the Mike        O'Callaghan Federal Medical Center (MOFMC). Subjects meeting the inclusion/exclusion        criteria will be offered an opportunity to participate.|February 2016|February 1, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02269332||34625|
NCT02274168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDEG-VTA|Utility of ICD Electrograms During Ventricular Tachycardia Ablation|Aid of Recording ICD Electrograms During Monomorphic Ventricular Tachycardia Ablation Procedures||Fundación Hospital de Madrid|Yes|Recruiting|April 2011|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02274168||34253|
NCT02274246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTORE-HV|Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)|GIMIAS® Tool Validation for the Detection of Left Atrium Fibrosis Through Late Enhancement Magnetic Resonance Image Processing. Pattern Determination in a Cohort of Healthy Volunteers|RESTORE-HV|Fundacion Clinic per a la Recerca Biomédica|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02274246||34247|
NCT02264860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062730A|Researching Alveolar Macrophage Improvements With Supplements in HIV|Cohort 2: Researching Alveolar Macrophage Improvements With Supplements in HIV|RAISe|Emory University|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|21 Years|N/A|No|||October 2015|October 1, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264860||34968|
NCT02268864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105490|A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants|A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects|COMMIT|Janssen-Cilag International NV|No|Active, not recruiting|January 2015|April 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268864||34661|
NCT02268929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001231|A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.|Integrated Personalized Diabetes Management (Integrated PDM):Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in General Medical Practices in Germany (GP).||Hoffmann-La Roche||Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|474|||Both|18 Years|N/A||||October 2014|July 1, 2015|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268929||34656|
NCT02269020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/BL-01|Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx: the First Three Patients|RoboCurage ORL|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|February 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|89 Years|No|||October 2015|October 21, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02269020||34649|
NCT02269137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-49|Assessment of Severity and Prognosis for Patients With Status Epileptics(SE)|Assessment of Severity and Prognosis for Patients With Status Epileptics||Xijing Hospital|Yes|Recruiting|March 2008|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Patients with status epilepticus|December 2015|December 31, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02269137|3 Months|34640|
NCT02269150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-025|Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation|A Randomized Controlled Trial of Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269150||34639|
NCT02273115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC-34107|Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor|Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor (NOFOX): a Randomized Control Trial|NOFOX|Christiana Care Health Services|No|Recruiting|October 2014|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273115||34334|
NCT02273206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-4522|Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)|Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project|PCM3|Clinical Directors Network|No|Recruiting|January 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|756|||Female|50 Years|64 Years|No|||October 2014|October 22, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02273206||34327|
NCT02273284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no number yet|Pain Perception of Children and Youth Receiving Non-sedated Botulinum Toxin-A Injections Using the Buzzy®|Pain Perception of Children and Youth Receiving Non-sedated Botulinum Toxin-A Injections Using the Buzzy®||Hamilton Health Sciences Corporation|No|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|2 Years|18 Years|No|||August 2015|August 17, 2015|October 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273284||34321|
NCT02268461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS-SP-2014|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268461||34692|
NCT02268760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605.1|Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1500 mg, 2000 mg and 2400 mg BILN 2061 ZW (PEG 400: Ethanol Solution) in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect of the Dose of 200 mg (Two-Stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Part and Subsequent Open Intraindividual Comparison Part)||Boehringer Ingelheim||Completed|June 2001|||September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|103|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 17, 2014||||No||https://clinicaltrials.gov/show/NCT02268760||34669|
NCT02268773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.130|Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers|A Randomised, Two-period, Cross-over Trial to Compare the Effects of Acetylsalicylic Acid (75 mg/Day) With the Combination of Acetylsalicylic Acid (25 mg) + Modified-release Dipyridamole (200 mg) (bd) on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers||Boehringer Ingelheim||Completed|January 2000|||May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 17, 2014||||No||https://clinicaltrials.gov/show/NCT02268773||34668|
NCT02268786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-001|Single Embryo TrAnsfeR of Euploid Embryo|Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment|STAR|Illumina, Inc.|No|Active, not recruiting|September 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|600|||Female|25 Years|40 Years|No|||February 2016|February 4, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268786||34667|
NCT02268942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW006 Thoracotomy|A Prospective, Single Arm, Multi-Center Clinical Study in Collaboration With the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS®) to Evaluate the Thoracotomy Implant Technique of the HeartWare HVAD® System in Patients With Advanced Heart Failure|A Prospective, Single Arm, Multi-Center Clinical Study in Collaboration With the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS®) to Evaluate the Thoracotomy Implant Technique of the HeartWare HVAD® System in Patients With Advanced Heart Failure (HVAD LATERAL)|HVAD LATERAL|HeartWare, Inc.|Yes|Recruiting|November 2014|December 2019|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|19 Years|N/A|No|||March 2016|March 22, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268942||34655|
NCT02271724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDP CD163|sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN|sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid||University of Aarhus|Yes|Recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|N/A||4|Anticipated|85|Samples Without DNA|Spinal fluid and blood sample for identification of different factors|Both|18 Years|100 Years|No|Non-Probability Sample|-  Patients with CIDP and MMN in maintenance treatment with SCIG or IVIG          -  Patients with newly diagnosed CIDP and MMN (drug-naïve)          -  Patients with other causes of peripheral neuropathies          -  Symptomatic controls|September 2015|October 21, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02271724||34441|
NCT02271932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00651|Multi-institutional Trial of Non-operative Management of Appendicitis|Multi-institutional Trial of Non-operative Management of Uncomplicated Pediatric Appendicitis||Nationwide Children's Hospital|Yes|Recruiting|October 2014|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|||Male|8 Years|17 Years|No|Probability Sample|Children with uncomplicated appendicitis|August 2015|August 14, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271932||34425|
NCT02271945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2852C00004|Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas|A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas||MedImmune LLC|No|Active, not recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|99 Years|No|||March 2016|March 1, 2016|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271945||34424|
NCT02274077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00042032|Transverse Abdominal Plane Anesthesia for Abdominal Wall Reconstruction|Abdominal Wall Reconstruction: Postoperative Outcomes Using Transverse Abdominal Plane Anesthesia||University of Rochester|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274077||34260|
NCT02262416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01102014|GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles|A Prospective Randomised Controlled Trial of GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles|GALA|Queensland Fertility Group|Yes|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262416||35156|
NCT02262793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.458|Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects|Relative Bioavailability of Telmisartan in Micardis® and of Dipyridamole in Aggrenox® After Co-administration Compared to the Bioavailability of Telmisartan Respectively of Dipyridamole After Oral Administration of 80 mg Telmisartan Respectively of 25 mg ASA/200 mg Extended-release Dipyridamole Alone. An Open-label, Randomised, Single-dose, Four-way Crossover Study in 24 Healthy Female and Male Subjects||Boehringer Ingelheim||Completed|May 2004|||July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262793||35127|
NCT02267382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMT-VT-1161-CL-006|A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis||Viamet|No|Active, not recruiting|February 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|200|||Female|18 Years|65 Years|No|||December 2015|December 2, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267382||34775|
NCT02267655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-7002-COPD-006|Exploratory, 2-Part Study to Assess Pulsed Inhaled Nitric Oxide on Functional Pulmonary Imaging Parameters in Subjects With WHO Grp 3 Pulmonary Hypertension Associated With COPD on LTOT|An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT)||Bellerophon|No|Not yet recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|10|||Both|40 Years|80 Years|No|||September 2015|September 16, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267655||34754|
NCT02268812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-111-E044-401|Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.|Patient Registry of Intrathecal Pain Management in Europe: An Open-label, Long-term, Multi-centre, Multi-national Post-marketing Observational Study of the Use of Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.|PRIME|Eisai Inc.||Completed|April 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|N/A||1|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have a diagnosis of severe, chronic pain for which intrathecal infusion is        indicated|October 2014|October 16, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268812||34665|
NCT02271438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103807|A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271438||34463|
NCT02271568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYUH 2013-07-024-001|Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome|Change in Glomerular Filtration Rate and 24 Hours Ambulatory Blood Pressure After Gastric Bypass Surgery Versus Conventional Weight Loss in Morbid Obesity.||Hanyang University|Yes|Enrolling by invitation|March 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|60 Years|No|Non-Probability Sample|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or        hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery. 15        matched controls.|February 2016|February 18, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02271568||34453|
NCT02271698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055895|Dexamethasone and Pain Following Total Knee Arthroplasty|Perioperative Dexamethasone to Promote Systemic Pro-Resolution Phenotype for Prevention of Acute and Chronic Pain Post-Total Knee Arthroplasty.||Duke University|No|Enrolling by invitation|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|55 Years|N/A|No|||January 2016|January 11, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271698||34443|
NCT02271711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0765|Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors|Phase I Study of Fourth Ventricle Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System NOAH's (New Opportunity, Advancing Hope) Protocol||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|21 Years|No|||February 2016|February 10, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271711||34442|
NCT02271906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0305|The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting|The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271906||34427|
NCT02271919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0213|Varenicline and Combined Nicotine Replacement Therapy (NRT) for Smoking Cessation|Varenicline and Combined Nicotine Replacement Therapy (NRT) for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial||M.D. Anderson Cancer Center|Yes|Recruiting|May 2015|||May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|310|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271919||34426|
NCT02262767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601007|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Pf 06649751 Co-administered With Trimethobenzamide Hydrochloride In Healthy Volunteers||Pfizer|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262767||35129|
NCT02262780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.453|Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 mg Telmisartan / 12.5 mg HCTZ to 80 mg Telmisartan / 12.5 mg HCTZ) and Multiple Oral Doses (80 mg Telmisartan / 12.5 mg HCTZ) of Drug in Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2003|||February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262780||35128|
NCT02263196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921839|The Efficacy of Alcohol After Betadine and Combination of Alcohol and Betadine on Inflammation Vascular Access|Mashhad University of Medical Sciences||Mashhad University of Medical Sciences|Yes|Recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|96|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263196||35096|
NCT02263456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP9VFPK|A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B|An Open Study to Compare the Pharmacokinetics and Safety of Replenine®-VF and Replenine® or Any Other High Purity Factor IX Concentrate, in Severe Haemophilia B Patients.||Bio Products Laboratory||Completed|July 1997|||September 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||||||Both|12 Years|N/A|No|||August 2014|October 9, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02263456||35076|
NCT02271204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21741|Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis|Post Authorization Safety Study of iv Ibandronate (Bonviva) in Postmenopausal Osteoporosis, Observational, Non-interventional Open Label Trial||Clinic of Endocrinology and Metabolic Disorders, Macedonia|No|Completed|March 2009|April 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|||Female|18 Years|N/A|No|Probability Sample|Women with postmenopausal osteoporosis in everyday routine practice from selected centers        in R. Macedonia|October 2014|October 20, 2014|October 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271204||34481|
NCT02271217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALF-PS-1016|A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke|This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine-ER Tablets for Treatment of Stable Walking Deficits in Subjects With Post-ischemic Stroke.|MILESTONE℠|Acorda Therapeutics|Yes|Recruiting|December 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|540|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271217||34480|
NCT02260752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057883|Patient Centered Results for Uterine Fibroids|Comparing Options for Management: Patient Centered Results for Uterine Fibroids|COMPARE-UF|Duke University|No|Enrolling by invitation|November 2015|September 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|Samples Without DNA|blood assay|Female|18 Years|54 Years|No|Non-Probability Sample|10,000 patients diagnosed with UF between the ages of 18 and 54. Patients must have had a        menstrual period within the last 12 months. Source documentation of UF must include either        imaging or a pathology report.|February 2016|March 16, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02260752|3 Years|35284|
NCT02271282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004704|Estradiol-Receptor Blockade in Older Men and Women|Pilot Study of Estradiol-Receptor Blockade in Older Men and Women||Mayo Clinic|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271282||34475|
NCT02271451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-5009|Q-collar and Brain Injury Biomarkers|Q-collar and Brain Injury Biomarkers||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|October 2014|October 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02271451||34462|
NCT02271464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMA261111|Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer|Phase II Randomized Study of Maintenance Treatment With Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy After First-line Induction FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients|MOMA|Azienda Ospedaliero, Universitaria Pisana|Yes|Recruiting|March 2012|March 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271464||34461|
NCT02271581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSYNC|Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer|INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer||Leo W. Jenkins Cancer Center|No|Recruiting|October 2014|July 2020|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Retain serum samples draw at baseline, 4 months, 10 months for storage and analysis by      Biodesix Laboratories.|Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with metastatic (stage IV) non-small cell lung cancer|October 2014|October 20, 2014|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02271581||34452|
NCT02261623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90921899|Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry|Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry||Boston Scientific Corporation|No|Recruiting|March 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with a blockage of the bile duct which may be caused by a        benign or malignant biliary stricture.|July 2015|July 20, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261623|2 Years|35217|
NCT02261636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000157|Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment||IMPACT|Ferring Pharmaceuticals||Recruiting|January 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|70 Years|No|Non-Probability Sample|Out-patient clinics in the Netherlands|October 2015|October 16, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261636||35216|
NCT02261909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|New Prognostic Kidney Function Markers in Emergency Patients New Markers of Kidney Function in ED Patients|New Prognostic Kidney Function Markers in Emergency Patients||Krankenhaus Barmherzige Brüder, Regensburg|No|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Serum, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients in the in emergency department who have the indication for contrast enhanced CT        and a predicted hospital admission time of 48 hours or longer.|August 2015|August 14, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02261909||35195|
NCT02262169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS2411-0313|DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers|DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers||Dexa Medica Group|No|Recruiting|October 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262169||35175|
NCT02267122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital General Elche|Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection|Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection||Hospital General Universitario Elche||Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|147|||Both|N/A|N/A|No|||October 2014|October 16, 2014|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267122||34795|
NCT02267135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AUS01|Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis|SCALP|Novartis|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02267135||34794|
NCT02270723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL18|The Effect of Human Albumin on Coagulation Competence and Hemorrhage|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery||Rigshospitalet, Denmark|Yes|Enrolling by invitation|August 2014|November 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|September 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270723||34518|
NCT02270736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3091_1|Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Children and Adolescents (2-17 Years) With Chronic Troublesome Sialorrhea Associated With Neurological Disorders, and/or Intellectual Disability|SIPEXI|Merz Pharmaceuticals GmbH|Yes|Recruiting|December 2014|June 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|249|||Both|2 Years|17 Years|No|||March 2016|March 22, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270736||34517|
NCT02271191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-2011-0205|Effect of Nicardipine on Renal Function in Deliberate Hypotension|Effect of Nicardipine on Renal Function in Deliberate Hypotension||Yonsei University|Yes|Completed|May 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|20 Years|N/A|No|||October 2014|October 21, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02271191||34482|
NCT02261610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0203|Pulmonary Embolism and PCT. PE-PCT Study|Interest of PCT in the Management of Antibiotic for the Patient With a Febrile Pulmonary Embolism.||University Hospital, Clermont-Ferrand||Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|62|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02261610||35218|
NCT02261896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CIP-2013-166|Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions|Multicenter, Randomized and Double-blinded Clinical Trial on the Use of Antibiotic Prophylaxis for EUS Guided FNA of Pancreatic Cystic Lesions||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|218|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261896||35196|
NCT02262156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49/06|CBT Versus Selective Serotonin Reuptake Inhibitor For Treatment Of Depression In Temporal Lobe Epilepsy Patients|Treatment Of Depression In Patients With Temporal Lobe Epilepsy: Comparative Study Of Cognitive Behavioral Therapy Vs. Selective Serotonin Reuptake Inhibitors|CBTvsSSRI|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|No|Completed|August 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||October 2014|March 27, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262156||35176|
NCT02262403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-HIRP-01|Hookworm Immune Regulation Project|Study of Immuno-regulatory Mechanisms Induced by Hookworm Infection|HIRP-01|Brugmann University Hospital|No|Recruiting|August 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02262403||35157|
NCT02267629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6986|Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder|Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder||New York State Psychiatric Institute|Yes|Completed|October 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|No|||August 2015|February 9, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267629||34756|
NCT02267941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHBeijing-20140702|Risk Factors for Aortic Dissection in the Chinese Patients|Food and Drug Administration in China||General Hospital of Beijing PLA Military Region|Yes|Completed|January 2011|December 2013|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|3045|||Both|18 Years|80 Years|No|Probability Sample|Between January, 2011 and December, 2012, we collected 3045 patients with AAD (1668 with        type A and 1377 with type B) from 15 major centers in China as the case group. As the        control group, 2760 patients without AD were obtained from the hospitalized patients in        the same period.|December 2013|October 15, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02267941||34732|
NCT02268188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14013|Harvesting Health Program in Improving Diet and Physical Activity Level in Cancer Survivors|Harvesting Health for Cancer Survivors: A Pilot Project||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268188||34713|
NCT02260453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University "La Sapienza" Rome|Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease|Randomized Controlled Trial Analyzing the Role of Systematic Preoperative Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease|CACEA|University of Roma La Sapienza|No|Completed|January 2005|June 2012|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260453||35307|
NCT02260466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02|Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.|AMYLO-CARTESIAN Study :Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.|AMYLOCARTESIAN|French Cardiology Society||Recruiting|October 2014|July 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|180|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260466||35306|
NCT02265146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112013-073|ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study|Association of Lipid Core Plaque With Subsequent Clinical Outcomes: a Collaborative Near-infrared Spectroscopy Study|ORACLE-NIRS|University of Texas Southwestern Medical Center|No|Enrolling by invitation|September 2014|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|Patients undergoing clinically-indicated Near Infrared Spectroscopy (NIRS) among various        participating centers.|April 2015|April 24, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02265146|15 Years|34946|
NCT02265159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0415|Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer|Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer||University of Zurich|No|Recruiting|May 2014|May 2020|Anticipated|May 2020|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|40 Years|99 Years|No|||December 2015|December 14, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02265159||34945|
NCT02269228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.131|Tolerability of Asasantin in Healthy Female and Male Subjects|Tolerability of a Two Week Treatment With Asasantin Extended Release 200/25 mg Capsules b.i.d., Compared to Reduced Dose During the First Week of Treatment in a Double-blind, Randomised, Placebo Controlled Parallel Group Comparison Trial in Healthy Female and Male Subjects||Boehringer Ingelheim||Completed|February 2000|||April 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|October 20, 2014||||No||https://clinicaltrials.gov/show/NCT02269228||34633|
NCT02261051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-48|Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm|Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm|LCCM-Control|Lancaster General Hospital|No|Recruiting|October 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|288|||Both|18 Years|N/A|No|Non-Probability Sample|Our study population includes patients newly diagnosed with a solid tumor-type cancer that        is considered either advanced and unresectable or metastatic. Patients also will be at        least 18 years of age and English-speaking.|October 2014|October 13, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02261051||35261|
NCT02261064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.27|Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers|Influence of Food on the Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination and of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination in Healthy Japanese Male Volunteers (a Phase I, Open-label, Randomised, Single-dose, Two-way Crossover Trial)||Boehringer Ingelheim||Completed|December 2008|||February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261064||35260|
NCT02261077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.833|Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Single Rising Oral Doses (20 mg, 60 mg, 100 mg, 200 mg and 400 mg) and Multiple Rising Oral Doses (3 x 20 mg, 3 x 60 mg and 3 x 100 mg Per Day) of Buscopan® in Healthy Male Volunteers||Boehringer Ingelheim||Completed|May 2007|||July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|60|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261077||35259|
NCT02261402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apokus-001|Effectiveness of "Medisinstart"|Effectiveness of "Medisinstart" - an Open Randomized Controlled Trial of a Newly Developed Pharmacy Service||Apokus AS|No|Active, not recruiting|October 2014|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1500|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261402||35234|
NCT02266043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACE-Subproject SP5-Tuebingen|Early Treatment Outcomes in Pierre-Robin-Like Phenotype|Cohort Study on Prevalence and Early Treatment Outcomes in Pierre-Robin-Like Phenotype||University Hospital Tuebingen|No|Recruiting|January 2013|August 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|12 Months|No|Non-Probability Sample|Infants <1 year admitted with Pierre-Robin-like phenotype to participating centres|September 2014|October 10, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02266043||34878|
NCT02266056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0559|The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery|||Yonsei University|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|72|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02266056||34877|
NCT02266290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC_21_2012|Effect of Kinesio® Taping in Chronic Ankle Instability|Effect of Kinesio® Taping on Measurements of Balance in Subjects With Chronic Ankle Instability: a Randomized Clinical Trial||Universidad Rey Juan Carlos|No|Completed|January 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|28 Years|No|||October 2014|October 16, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266290||34859|
NCT02266550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.16|Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers|Investigation of Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS After Administration of a Single Oral Dose of 25 mg [14C]-BIIL 284 BS in 6 Healthy Volunteers||Boehringer Ingelheim||Completed|October 1999|||October 1999|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266550||34839|
NCT02266563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0732|Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury|Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury||Icahn School of Medicine at Mount Sinai|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|50|||Male|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited through the Mount Sinai's Alzheimer's Disease Research Center        (ADRC), the Memory and Aging Center (MAC), Center for Cognitive Health (CCH), and the NFL        Neurological Program at the Icahn School of Medicine at Mount Sinai.|February 2016|February 16, 2016|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02266563||34838|
NCT02266849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20140081|Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study|Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study||Odense University Hospital|Yes|Recruiting|October 2014|August 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02266849||34816|
NCT02270437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBX 726|Safety and Efficacy of Cocktail Periarticular Injection in Simultaneous Total Knee Arthroplasty|Safety and Efficacy of Cocktail Periarticular Injection for Pain Management in Simultaneous Bilateral Total Knee Arthroplasty- A Prospective, Randomized Trial||Peking Union Medical College Hospital|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|N/A|80 Years|No|||August 2015|August 27, 2015|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02270437||34540|
NCT02270450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1316|S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction|S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction||Southwest Oncology Group|Yes|Recruiting|March 2015|May 2020|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02270450||34539|
NCT02274883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6027|The Effect of Feeding Infant Formula With Enriched Protein Fractions|The Effect of Feeding Infant Formula With Enriched Protein Fractions||Mead Johnson Nutrition|No|Recruiting|November 2014|June 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|450|||Both|N/A|14 Days|Accepts Healthy Volunteers|||August 2015|September 24, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02274883||34198|
NCT02262429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA13|Quality Improvement Program (QIP) to Reduce 30-Day Readmission in Malnourished Hospitalized Patients|Does a Rapid, Comprehensive Oral Nutritional Supplementation Quality Improvement Program (QIP) Reduce 30-Day Readmission in Malnourished Hospitalized Patients?||Abbott Nutrition|No|Terminated|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2386|||Both|18 Years|N/A|No|Non-Probability Sample|Newly admitted patients to four hospitals within the Advocate Health Care System that have        been identifed to be at risk for malnutrition.|October 2015|October 5, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02262429||35155|
NCT02261389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRONOS|Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET|Three-monthly Dynamic Evaluation of CEA and CA 15.3 vs Usual Practice in the Follow-up of Early Breast Cancer Patients: a Randomized Study||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|September 2014|September 2022|Anticipated|September 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Female|18 Years|N/A|No|||October 2014|October 11, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261389||35235|
NCT02266498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525.4|Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects|Single-dose Pharmacokinetics of 2.5 mg BIBB 515 BS and Effect of Food After Oral Administration of Capsules to Healthy Subjects (Randomized, 2-way-cross-over, Open Study)||Boehringer Ingelheim||Completed|June 1998|||July 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266498||34843|
NCT02266836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-ST-2001|MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke|Clinical Feasibility and Usability of MyndMove Therapy for FES Facilitated Treatment of Subacute and Chronic Severe Hemiparesis of the Upper Limb Following Stroke||MyndTec Inc.|No|Recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02266836||34817|
NCT02267096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-541|Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening|Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening||Georgetown University|No|Active, not recruiting|January 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267096||34797|
NCT02267109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00061513|Phase 1 Trial of Ebola Vaccine in Mali|A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.||University of Maryland|Yes|Active, not recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|91|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02267109||34796|
NCT02267369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819455|The Causal Impact of Online Social Media on Physical Activity: A Randomized Controlled Trial|The Causal Impact of Online Social Media on Physical Activity: A Randomized Controlled Trial||University of Pennsylvania|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|217|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267369||34776|
NCT02267642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.009.01|A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis|Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.||AbGenomics B.V Taiwan Branch|No|Completed|January 2015|January 2016|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||October 2015|February 17, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267642||34755|
NCT02271061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MURA2014/415|Effects of Elastic Therapeutic Tape on Biomechanical Changes of Knee Joint During Drop Vertical Jump in ACL Injuries|Effects of Elastic Therapeutic Tape on Biomechanical Changes of Knee Joint During Drop Vertical Jump in ACL Injuries||Mahidol University|Yes|Completed|March 2015|December 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|8|||Male|18 Years|40 Years|No|||January 2016|January 7, 2016|October 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271061||34492|
NCT02271126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|932/2014|TEG Anticoagulation Monitoring During ECMO|Prospective Randomized Study Of Anticoagulation Monitoring With Thromboelastography Versus aPTT During Extracorporeal Membrane Oxygenation In Adults||Policlinico Hospital|No|Recruiting|September 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 3, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02271126||34487|
NCT02271139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29453|Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy|An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy||Genentech, Inc.||Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 17, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02271139||34486|
NCT02271958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endomife 2,5/5/10/placebo|Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis|Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis||Mediterranea Medica S. L.|Yes|Completed|November 2010|December 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|360|||Female|18 Years|45 Years|No|||October 2014|October 20, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02271958||34423|
NCT02265406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001668-36|PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone|PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone|PROPHY-VAP|Poitiers University Hospital||Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265406||34926|
NCT02265757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000885|Behavioral Interventions to Prevent or Delay Dementia|Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)||Mayo Clinic|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|600|||Both|50 Years|N/A|No|||March 2016|March 17, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02265757||34900|
NCT02265770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOP Ependymoma II (ET-13-002)|An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma|An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma|SIOP-EP-II|Centre Leon Berard|Yes|Recruiting|April 2015|August 2026|Anticipated|June 2023|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|480|||Both|N/A|22 Years|No|||February 2016|February 19, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02265770||34899|
NCT02269631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075830|Legume Diet Satiety Pilot Study|Legume Diet Satiety and Weight Loss Pilot Study||Emory University|No|Recruiting|December 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269631||34602|
NCT02270021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12257|Decreasing Over Screening and Treatment of Cervical Precancers in Young Women|Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women||University of California, San Francisco|No|Active, not recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|10500|||Female|21 Years|29 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270021||34572|
NCT02270034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEINO 1402|Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma|Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma||Grupo Español de Investigación en Neurooncología|No|Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||August 2015|August 25, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270034||34571|
NCT02270255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4242|Superior Hypogastric Nerve Block for Pain Control Post-UFE|Prospective Blinded Study Looking at PO/IV Analgesia Alone Versus PO/IV Analgesia With Superior Hypogastric Nerve Block for Uterine Artery Embolization Pain Management||McGill University Health Center|No|Recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270255||34554|
NCT02274831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StJosephMHS|EMail Reminder to Follow up With Primary Physician|You Have Got Got Mail....and Need Follow Up||Saint Joseph Mercy Health System|No|Completed|August 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|577|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02274831||34202|
NCT02265107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC-FMD-2014|Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft|Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft||Universidade Federal do Rio Grande (FURG)|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265107||34949|
NCT02265367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRD14.42:|Novel Medication as a Potential Smoking Cessation Aid|Novel Medication as a Potential Smoking Cessation Aid||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Both|25 Years|55 Years|No|||June 2015|June 17, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265367||34929|
NCT02266511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.22|Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects|A Single-dose, Randomized, Two-treatment, Two-period, Open-label, Crossover Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride 0.4-mg Capsules in Healthy Male Subjects||Boehringer Ingelheim||Completed|August 1999|||September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266511||34842|
NCT02266524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.49|Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders|Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders||Boehringer Ingelheim||Completed|January 2005|||April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|5 Years|15 Years|No|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266524||34841|
NCT02266537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.70|Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers|A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers||Boehringer Ingelheim||Completed|November 2005|||February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|97|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02266537||34840|
NCT02270008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065572|Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study|Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study||Emory University|Yes|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270008||34573|
NCT02270242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1383|Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention|Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention|TWILIGHT|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|9000|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270242||34555|
NCT02270424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM for severe COPD|Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD|A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Effectiveness of on Severe / Very Severe COPD Patients||Henan University of Traditional Chinese Medicine|Yes|Not yet recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|564|||Both|40 Years|80 Years|No|||October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270424||34541|
NCT02270710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311014560|Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease|Immune Deregulation in Patients With SLE|SLE|Weill Medical College of Cornell University|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|20|Samples With DNA|Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Subjects|December 2015|December 9, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270710||34519|
NCT02271022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-BRIL-UPSTREAM|Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry|Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry||AstraZeneca|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP        agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the        timeframe that emergency physicians consider to be "upstream"-within the first 72 hours of        care and at least 4 hours before diagnostic angiography. In addition, only those patients        who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be        eligible for UPSTREAM.|March 2016|March 24, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02271022|40 Days|34495|
NCT02259647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HCC-02|Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma|Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02259647||35369|
NCT02260141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN- ALZ001|Treating Alzheimer's and Dementia With D-ribose|||Practitioners Alliance Network|Yes|Recruiting|September 2014|||September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||October 2014|October 10, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260141||35331|
NCT02260154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEBE5002|Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm|Effectiveness of Duspatalin® (Mebeverine Hydrochloride) 200 mg b.i.d. in Patients With Post-cholecystectomy Gastrointestinal Spasm: a Post Marketing Observational Program in the Russian Federation|ODYSSEY|Abbott|No|Recruiting|July 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Both|18 Years|65 Years|No|Probability Sample|Primary care clinic|January 2016|January 29, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02260154||35330|
NCT02264873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400612|Phase I, Dose Escalation Study of Decitabine|Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant||University of Florida|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|1 Year|30 Years|No|||November 2015|November 20, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264873||34967|
NCT02264886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410002|Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies|Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies||Washington University School of Medicine|No|Recruiting|January 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02264886||34966|
NCT02260479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OpPm2013|Preheated Skin Disinfection vs Room-temperature on Bacterial Colonization During Pace Device Implantation|The Effect of Preheated Skin Disinfection in Relation to Room-temperature Skin Disinfection on Bacterial Colonization During Pace Device Implantation: a Randomized Controlled Non-inferiority Trial.||Örebro University, Sweden|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260479||35305|
NCT02260492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT329/305|Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma|Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma||Oriel Therapeutics|No|Completed|September 2014|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|879|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260492||35304|
NCT02260505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMADGIST|Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)|A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)|ImadGist|Centre Leon Berard|Yes|Recruiting|December 2014|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|256|||Both|18 Years|N/A|No|||February 2015|June 8, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02260505||35303|
NCT02269345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140088H|Auricular Acupuncture in Ureteral Stent Pain|Auricular Acupuncture: A Novel Application in Ureteral Stent Pain.|AAstent|Mike O'Callaghan Federal Hospital|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02269345||34624|
NCT02269462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC60000|A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation|Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation||Obafemi Awolowo University|No|Completed|December 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|460|||Female|18 Years|N/A|No|Non-Probability Sample|HIV positive pregnant women and nursing mothers taking efavirenz or nevirapine as part of        HAART to prevent mother-to-child transmission of HIV and/or for their own health and their        breastfed infants.|July 2015|July 7, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02269462||34615|
NCT02274701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WS/0126|Holistic Needs Assessment in Outpatient Cancer Care|Evaluating the Impact of Holistic Needs Assessment in Outpatient Cancer Care||University of the West of Scotland|No|Not yet recruiting|October 2014|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|156|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02274701||34212|
NCT02274727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001|Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study|Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study||University of Zurich|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|The BIOSIGNAL study will be a prospective observational multicenter cohort study to        evaluate selected CE and LAA blood biomarkers in patients with incident ischemic stroke.        We will consecutively recruit at least 300 patients per center (i.e. 10 centers, thus        totally 3000 patients) over a time period of two years. All participants will be followed        for 1 year.|July 2015|July 24, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02274727||34210|
NCT02274779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-N-2014-02|Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer|Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS / GETUG P07)|OLIGOPELVIS|Institut Cancerologie de l'Ouest|Yes|Recruiting|September 2014|September 2026|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|18 Years|N/A|No|||October 2015|October 5, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02274779||34206|
NCT02262182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0033|Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® After Cardiac Surgery in the Management of Postoperative Atelectasis|Evaluation of the Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® Device Associated With Respiratory Physiotherapy in the Treatment of Postoperative Pulmonary Atelectasis in Patients After Cardiac Surgery|PEPKIN|Nantes University Hospital|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262182||35174|
NCT02264834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDB001|Deambulatory Epidural During the Labour|Comparison of Two Different Peridural During the Labor and Effect of Deambulation||Brugmann University Hospital|No|Active, not recruiting|July 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|August 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02264834||34970|
NCT02268799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL002|High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter|High Sensitivity Troponin T Levels Following Elective External Direct Current Cardioversion for Atrial Fibrillation / Atrial Flutter||University of Limerick|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|101|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with atrial fibrillation/flutter who attend the Coronary Care Unit of the        University Hospital Limerick for a pre-organised appointment for direct current external        cardioversion will be requested to participate in the study|August 2015|August 12, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268799||34666|
NCT02274324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310-14-SMC|Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s Disease|Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's Disease||Sheba Medical Center|No|Not yet recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||October 2014|October 23, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274324||34241|
NCT02274402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00926-41|Pharmacokinetics of Prednisone in Adults|Study of Pharmacokinetic and Pharmacodynamic Variability of Prednisone, in Adults|Glucomad|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|April 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Biospecimen Description :        -  Standard blood test as planned in the routine care follow up of corticotherapy.           Especially, numeration blood formula, renal function estimated by MDRD formula, liver           function (transminases, γGT, alkaline phosphatase, bilirubinemia, prothrombin).        -  Albuminemia, transcortin, HbA1c, 8am cortisol.        -  4 ml of blood in an dry tube for pharmacokinetic studies at each blood sample,           precising the delay between the last dose of treatment and th sampling.        -  Buccal cell collection swab|Both|N/A|N/A|No|Non-Probability Sample|Adults receiving glucocorticoids (Prednisone) are recruited in Service de medicine        interne, Hôpital Cochin, Paris|August 2015|August 28, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02274402||34235|
NCT02258620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-SAR|Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.|Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.||Brugmann University Hospital|Yes|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|442|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02258620||35448|
NCT02259179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-240|Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers|A Phase 1 Bioequivalence Study of Naltrexone SR/Bupropion SR Combination Trilayer Tablets From Two Manufacturers in Healthy Subjects||Orexigen Therapeutics, Inc|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02259179||35405|
NCT02259192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI for SSD adults|Cochlear Implants for Adults With Single-sided Deafness|Cochlear Implantation for Single-Sided Deafness|SSD|University of Southern California|No|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259192||35404|
NCT02259413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:088|Effect of an Exercise Rehabilitation Program in Patients Starting Hemodialysis|Effect of an Exercise Rehabilitation Program on Physical Function in Incident Hemodialysis Patients: A Randomized Controlled Pilot Study||University of Manitoba|No|Recruiting|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|October 1, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259413||35387|
NCT02259426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPPI-1|Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission|A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission.|DAPPI|London School of Hygiene and Tropical Medicine|Yes|Completed|October 2014|December 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|5 Years|15 Years|No|||January 2016|January 13, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02259426||35386|
NCT02264626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116/2014O|Sedation During Noninvasive Ventilation (NIV)|Effects of Remifentanil Based Sedation on Patient-ventilator Interaction, in Patients Undergoing Noninvasive Ventilation (NIV)|REMI|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 28, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02264626||34986|
NCT02264639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-CP0514|A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH|An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).||Apellis Pharmaceuticals, Inc.|Yes|Recruiting|October 2014|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|8|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02264639||34985|
NCT02268955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-067|Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic|Assessment of the Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic||Maricopa Integrated Health System|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|55 Years|No|||November 2015|November 4, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268955||34654|
NCT02269059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7680-003|Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-7680 in Patients With Hepatitis C Infection||Merck Sharp & Dohme Corp.|No|Completed|December 2014|April 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||July 2015|July 24, 2015|October 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269059||34646|
NCT02269215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599.2|Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers|A Single Blind, Placebo-controlled, Parallel-group, Single Increasing Dose Tolerance Study in Healthy Young Male Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 12.5, 25, 50 mg/h, Infusion Time 1 hr; 50 mg/h, Infusion Time 2 Hrs) Followed by Maintenance Dose (Dosage: 6.25, 12.5, 25 mg/h, Infusion Time 5 Hrs; 30 mg/h, Infusion Time 4 Hrs) and in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 50 mg/h, Infusion Time 1 hr) Followed by Maintenance Dose (Dosage: 25 mg/h, Infusion Time 5 Hrs)||Boehringer Ingelheim||Completed|January 2000|||September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|73|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 20, 2014|October 20, 2014||||No||https://clinicaltrials.gov/show/NCT02269215||34634|
NCT02362048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-003|ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer|A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer|KEYNOTE144|Acerta Pharma BV|No|Active, not recruiting|April 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02362048||27511|
NCT02362061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128|3D Ultrasound Measurement of Junctional Zone Thickness and Its Relation to Implantation Success|Thickness of the Junctional Zone Measured by 3D Ultrasound and Its Relation to the Success/Failure Implantation Rates in Assisted Reproduction Techniques||Cairo University|No|Recruiting|February 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|21 Years|40 Years|No|Non-Probability Sample|100 patients aged 21-40 years old, diagnosed as primary or secondary infertility due to        the following causes of infertility; ( Pelvic Inflammatory disease, dysovulation , tubal        infertility, unexplained infertility, combined infertility or due to male factor ).|February 2015|February 11, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02362061||27510|
NCT02274636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401|Study of a Dietary Supplement for Reflux During Sleep|Study of a Dietary Supplement for Reflux During Sleep|SXDSFRS|Oral Care Research Associates, Seattle|No|Not yet recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274636||34217|
NCT02274649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|581327-1|Clinical Trial to Evaluate One-to-one Peer Mentoring|A Patient Centered Approach to Successful Community Transition After Catastrophic Injury: Clinical Trial to Evaluate One-to-one Peer Mentoring||Shepherd Center, Atlanta GA|No|Enrolling by invitation|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|N/A|N/A|No|||December 2015|December 2, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274649||34216|
NCT02261090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.529|Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers|A Multiple Dose Seven-way Cross-over Formulation-finding Study Comparing the Oral Bioavailability of Seven Prototype Slow-release Formulations With 0.75 mg Pramipexole (Four Days Each) to Immediate-release Tablets at Steady State in Healthy Male Volunteers||Boehringer Ingelheim||Completed|June 2004|||September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|14|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261090||35258|
NCT02261103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.530|Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers|A Multiple Dose Study With Increasing Pramipexole Doses (0.375 mg to 4.5 mg q.d.) of Oral Extended Release (ER) Tablets With a Three-way Cross Comparison of 4.5 mg Pramipexole ER q.d. Fasted Versus 4.5 mg Pramipexole ER q.d. Fed Versus 1.5 mg Pramipexole Immediate Release Tablets t.i.d. Fasted in Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|39|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261103||35257|
NCT02261415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244-2014|The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial|The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial|HeLiX|Sunnybrook Health Sciences Centre|No|Recruiting|November 2014|January 2022|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261415||35233|
NCT02261649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-104|Impact of Cerebellar Mass Resection on Pain Processing|The Impact of Cerebellar Mass Resection on Pain Processing||Dana-Farber Cancer Institute|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|6 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with cerebellar resection and healthy volunteers.|February 2016|February 22, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02261649||35215|
NCT02261662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin HCV mucocutaneous|Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection|Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection||Tanta University|Yes|Recruiting|June 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||October 2014|October 6, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02261662||35214|
NCT02261922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM240|Ticagrelor and Endothelial Function|A Prospective Randomized Double Blind Study to Evaluate the Effect of Ticagrelor on Endothelial Function||Hotel Dieu de France Hospital|No|Recruiting|October 2014|November 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|75 Years|No|||October 2014|October 9, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261922||35194|
NCT02261935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVN-core2013-01 CCSRI-702597|Supporting Family Caregivers of Palliative Patients at Home: the Carer Support Needs Assessment Intervention|Clustered, Randomized, Controlled Trial of the Home Care Nurse Carer Support Needs Assessment Practice Tool With Family Caregivers of Palliative Patients at Home|CSNAT|University of Victoria|Yes|Recruiting|September 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|476|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02261935||35193|
NCT02264847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5102014|Human Chorionic Gonadotrophin & Trigger|Trigger or Not to Trigger? : An Answer for an Old Question||Cairo University|Yes|Recruiting|October 2014|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264847||34969|
NCT02263482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 232/12|Inspiratory Muscle and Peripheral Muscle Training in Chronic Heart Failure|Inspiratory Muscle and Peripheral Muscle Combined Training Effects on the Respiratory and Functional Capacity and Quality of Life in Chronic Heart Failure||University of Sao Paulo|No|Completed|October 2012|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02263482||35074|
NCT02263495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0857|Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer|A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy|EG_PG|Asan Medical Center|No|Active, not recruiting|November 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|19 Years|N/A|No|||March 2016|March 22, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02263495||35073|
NCT02263755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0582|Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B|||Yonsei University|No|Not yet recruiting|October 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|500|||Both|20 Years|N/A|No|Non-Probability Sample|outpatient clinic in tertiary hospital|October 2014|October 7, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02263755|10 Years|35053|
NCT02264054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.109|Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects|Investigation of Metabolism and Pharmacokinetics of Talsaclidine After Administration of Single Oral and Single Intravenous Dose of 20 mg of [14C]-Labelled Talsaclidine to 6 Healthy Subjects||Boehringer Ingelheim||Completed|February 1999|||March 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264054||35030|
NCT02268474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-14-EV04|Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea|Prospective, Randomized, Controlled Split-Face Study of the Excel V 532nm KTP Laser for the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea||Cutera Inc.|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|20 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268474||34691|
NCT02264366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCELERATION|Activity ,Smoking Cessation, Healthy Eating and Alcohol Intervention Program:(ACCELERATION)|ACCELERATION: An Activity,Smoking Cessation, Healthy Eating and Alcohol Intervention Program With Motivational Supports Aimed at Chronic Disease Prevention||University Health Network, Toronto|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264366||35006|
NCT02268890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104583|A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma|Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study||Johnson & Johnson Taiwan Ltd|No|Recruiting|December 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||July 2015|July 31, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268890||34659|
NCT02271594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-14LIPOINJ02|Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care|Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care: A Randomized, Prospective, Controlled Study in Ealing, United Kingdom||Becton, Dickinson and Company|Yes|Recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|75 Years|No|||July 2015|August 11, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271594||34451|
NCT02271737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15|Newborn Infection Control and Care Initiative for Health Facilities to Accelerate Reduction of Newborn Mortality|Newborn Infection Control and Care Initiative for Health Facilities to Accelerate Reduction of Newborn Mortality|NICCI|National Institute of Public Health, Cambodia|No|Enrolling by invitation|February 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1938|||Female|18 Years|N/A|No|||June 2015|June 10, 2015|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02271737||34440|
NCT02271750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dementia IGF|IGF and Other Neurotrophic Factors in Patients With Dementia|A Study of Insulin-like Growth Factors and Other Neurotrophic Factors in the Cerebrospinal Fluid From Patients With Dementia||University of Aarhus|Yes|Completed|October 2014|||November 2015|Actual|N/A|Observational|N/A||2|Actual|120|Samples Without DNA|spinal fluid and blood sample for identification of different factors|Both|18 Years|100 Years|No|Non-Probability Sample|dementia|October 2014|December 7, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02271750||34439|
NCT02267590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4187|Tissue Collection for Biomarkers Determining Resistance to Ibrutinib|Clinical Validation of Biomarkers Determining Resistance to BTK Inhibition With Ibrutinib in Mantle Cell Lymphoma & Chronic Lymphocytic Leukaemia - Stage 1|CLARITY|Royal Marsden NHS Foundation Trust|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|20mls of PB in EDTA; 5ml of BM in EDTA and/or tissue biopsy (fresh/frozen/FFPE) and/or      pleural/ascitic fluid containing tumour cells.|Both|N/A|N/A|No|Non-Probability Sample|The Ibrutinib named patient supply (NPS) was introduced across the NHS for relapsed/        refractory CLL in April this year. Patients with relapsed/ refractory MCL were allowed to        enter this programme in September. The NPS for CLL is likely to be open until the 30th of        September this year while MCL patients can access Ibrutinib until the end of November.        Strict inclusion and exclusion criteria have been set out for the NPS and patients are        required to be screened through an online portal prior to entry on to the programme. The        NPS provides an excellent window of opportunity to collect patient samples for this study.|October 2014|October 14, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02267590||34759|
NCT02260765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCP-Post Marketing-Brainsway|Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual|Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual||Brainsway|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|70 Years|No|||October 2014|October 8, 2014|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02260765||35283|
NCT02260778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000664|Treat-to-target in RA: Collaboration To Improve adOption and adhereNce|Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)|TRACTION|Brigham and Women's Hospital|No|Active, not recruiting|September 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|11|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260778||35282|
NCT02261116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.402|Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers|Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues||Boehringer Ingelheim||Completed|April 2002|||August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261116||35256|
NCT02261129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.557|Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers|Bioequivalence of the 80 mg Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|September 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||||No||https://clinicaltrials.gov/show/NCT02261129||35255|
NCT02362542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02-014|Effect of Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Effect of Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions||Chungbuk National University||Completed|February 2015|||October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02362542||27473|
NCT02362867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-0017|Balanced Knee System Clinical Protocol for IRB Approval|Balanced Knee System Clinical Protocol for IRB Approval||Ortho Development Corporation|No|Active, not recruiting|January 2003|March 2015|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|No|||February 2015|February 9, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02362867||27448|
NCT02363374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUniversity|Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer|Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group|CAOAROAIO-12|Goethe University|Yes|Recruiting|February 2015|May 2022|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02363374||27409|
NCT02363387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044740|Suppression of HIV 1 RNA in People Living With HIV|Suppression of HIV 1 RNA in People Living With HIV||Johns Hopkins University|No|Not yet recruiting|April 2015|December 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02363387||27408|
NCT02264587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-IIS-2013-03|Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis|Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis|MDGP|Qingdao University|No|Not yet recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2014|October 14, 2014|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02264587||34989|
NCT02268734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/13|Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib|Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|April 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|25|Samples With DNA|primary tumor and metastases tissue samples and other biological materials, including blood      are collected|Both|18 Years|N/A|No|Non-Probability Sample|Petient with a diagnosis of sporadic locally relapsed and or metastatic medullary thyroid        cancer surgically treated (total thyroidectomy) who adheres to a voluntary program of        donation of own biological materials to a biorepository|October 2014|October 16, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02268734||34671|
NCT02375750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS13530231|Treatment of Peri-implantitis Lesions by Using Biomaterial|Surgical Treatment of Peri-implantitis Lesions, With or Without the Placement of a Bone Substitute and a Collagen Membrane. A Randomized Clinical Trial||Geistlich Pharma AG|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2014|March 2, 2015|July 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02375750||26464|
NCT02375763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-2908|Dietary Analysis for Caries Prevention in Children Using a Computer Software|Dietary Analysis for Caries Prevention in Children Using a Computer Software||Marquette University||Recruiting|February 2015|June 2018|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|250|||Both|3 Years|13 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02375763||26463|
NCT02364427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH heart-AKI|Arterial Stiffness and AKI Post-CABG|Arterial Stiffness and Acute Kidney Injury Post-Coronary Artery Bypass Graft Surgery|Heart-AKI|King's College Hospital NHS Trust|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|September 11, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02364427||27329|
NCT02262988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOG-TOH150|Adipose-Derived Regenerative Cells in Total Knee Arthroplasty|Intra-articular Injection of Autologous Adipose-Derived Regenerative Cells (ADRCs) as Adjuvant Therapy for Total Knee Arthroplasty||Fondren Orthopedic Group L.L.P.|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 11, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262988||35112|
NCT02263209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU77|Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty|Prospective Clinical Investigation to Determine the Safety of Taperloc Stems With BioGuard Coating and Exceed ABT Taperfit Acetabular Cups With BioGuard Coating When Used in Cementless Total Hip Arthroplasty||Biomet, Inc.|No|Active, not recruiting|June 2013|June 2023|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|40 Years|80 Years|No|||April 2013|June 5, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263209||35095|
NCT02263222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-02|A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty|A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty||Medtronic Spinal and Biologics|Yes|Recruiting|February 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263222||35094|
NCT02267954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14-582|Fast Food Photo Study|What's Wrong With This Photo? Fast Food Literacy Study||Carnegie Mellon University|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|309|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267954||34731|
NCT02267967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-012-00CH1|Phase Ib Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors|A Multicenter, Open-label, Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Sulfatinib in Treating Advanced Neuroendocrine Tumors||Hutchison Medipharma Limited|Yes|Recruiting|October 2014|December 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02267967||34730|
NCT02268201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNKTxCon|A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule|Efficacy and Safety of Switch From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule in Maintenance Kidney Transplant Recipients: a Randomized, Controlled, Open-label, Multi-centers Clinical Trial||Astellas Pharma Inc|No|Terminated|March 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||November 2015|November 25, 2015|October 15, 2014|No|Yes|Due to difficulty enrolling patients|No||https://clinicaltrials.gov/show/NCT02268201||34712|
NCT02268487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|795996|Integral Assessment in Unipolar Depression|THE AIUNI - Integral Assessment in Unipolar Depression|AIUNI|University of Sao Paulo|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02268487||34690|
NCT02268838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6007-J081-002|Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects|A Phase 1 Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects||Eisai Inc.|No|Completed|October 2014|November 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||December 2015|January 19, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268838||34663|
NCT02271477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERU-1402|Can Vena Cava Ultrasound Guided Volume Repletion Prevent Spinal Induced Significant Hypotension in Elective Patients?|Can Vena Cava Ultrasound Guided Volume Repletion Prevent Spinal Induced Significant Hypotension in Elective Surgical Patients? A Randomized, Case Control, Prospective Trial.||Ente Ospedaliero Cantonale, Bellinzona|Yes|Completed|May 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|October 10, 2014||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT02271477||34460|It cannot be performed blindly. Ultrasound is an operator-dependent technique.
NCT02259660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400642|Airway Muscle Training for Obstructive Sleep Apnea|Upper Airway Muscle Training for Obstructive Sleep Apnea|OSA|University of Florida|No|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259660||35368|
NCT02260167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-ALZ002|Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol|Effective Treatment of Alzheimer's and Dementia With the MIND Protocol|MIND|Practitioners Alliance Network|Yes|Recruiting|September 2014|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|N/A|N/A|No|||October 2014|October 10, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260167||35329|
NCT02260180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-203|Study of A-101 for the Treatment of Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face||Aclaris Therapeutics, Inc.|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|116|||Both|18 Years|75 Years|No|||March 2015|March 12, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260180||35328|
NCT02267603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00848|Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer|A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)||National Cancer Institute (NCI)|No|Recruiting|November 2014|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267603||34758|
NCT02362295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00791-40|Prospective National Survey of the Palliative Situation Among Inmates in French Prisons|Prospective National Survey of the Palliative Situation Among Inmates in French Prisons|PARME|Centre Hospitalier Universitaire de Besancon|Yes|Completed|May 2011|December 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Every prisonners with terminal illness|February 2015|February 23, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02362295||27492|
NCT02362555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-140305|The Effect of Nuchal Ligament Calcification on Cervical Function in Patients With Neck Pain|The Effect of Nuchal Ligament Calcification on Cervical Function in Patients With Neck Pain||Changhua Christian Hospital|Yes|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|68|||Both|20 Years|80 Years|No|Probability Sample|patient with chronic neck pain|November 2015|November 10, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02362555||27472|
NCT02268149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.24|Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects|The Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Male Subjects (A Randomized, Double-blind, Placebo-controlled, Two Period, Two-way Cross-over Study)||Boehringer Ingelheim||Completed|April 2000|||July 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|October 16, 2014||||No||https://clinicaltrials.gov/show/NCT02268149||34716|
NCT02268409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A536-06|ACE-536 Extension Study - Beta Thalassemia|An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04||Acceleron Pharma, Inc.|No|Active, not recruiting|October 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268409||34696|
NCT02268422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1507|Bioequivalence and Adhesion Comparison of Buprenorphine Patches|A Two-period, Randomised, Open-label, Crossover, Pharmacokinetic Study to Assess the Bioequivalence and Adhesion of Buprenorphine Transdermal System Second Generation Patch Compared With First Generation Patch, in Healthy Volunteers||Mundipharma Research Limited|No|Completed|October 2014|October 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02268422||34695|
NCT02268669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRACIA4|Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI|A Randomized Clinical Trial Comparing Primary PCI and Post-thrombolysis PCI as Reperfusion Strategies in Patients With ST Segment Elevation Acute Myocardial Infarction|GRACIA4|GRACIA Group|Yes|Active, not recruiting|May 2010|March 2016|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1444|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02268669||34676|
NCT02268682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R39OT26843|Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge|Improving Low-Income End Stage Renal Disease Patients' Transplant Knowledge: A Case Management Trial||University of California, Los Angeles|Yes|Active, not recruiting|July 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|558|||Both|18 Years|74 Years|No|||December 2015|December 8, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268682||34675|
NCT02268695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2014-01|Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC|TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck|TPExtreme|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|71 Years|No|||March 2015|March 23, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02268695||34674|
NCT02271035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rabin Medical Center|A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children|A Prospective Study Comparing the Success Rate of Injection of Dextranomer /Hyaluronic Acid (DefluxR) Versus Polyacrylate Polyalcohol (VantrisR) for Treatment of Bilateral Similar Grade Vesicoureteral Reflux in Children||Rabin Medical Center|No|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|18 Years|No|||June 2014|October 21, 2014|August 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02271035||34494|
NCT02368834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-4024-04-01|Psychoeducation for the Parents of Attention Deficit Hyperactivity Disorder (ADHD) Children|Evaluation of a Psychoeducation Program for the Parents of Attention Deficit Hyperactivity Disorder||Peking University|Yes|Completed|August 2014|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|89|||Both|6 Years|16 Years|No|||April 2015|April 27, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02368834||26993|
NCT02368847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI_UCP|Urinary Tract Infections in Older Persons Admitted to a Psychogeriatric Ward|Optimizing and Validating the Clinical Algorithm for Diagnosing Urinary Tract Infections in Older Persons Admitted to a Psychogeriatric Ward|UTI_UCP|Katholieke Universiteit Leuven|No|Not yet recruiting|March 2015|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02368847||26992|
NCT02267668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-13-04|Subsymptom Threshold Exercise Protocol Following Mild TBI|Subsymptom Threshold Exercise Protocol (STEP) to Recovery Following Mild Traumatic Brain Injury: A Pilot Randomized Controlled Clinical Trial|STEP|University Hospital Case Medical Center|Yes|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Years|22 Years|No|||November 2015|November 30, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267668||34753|
NCT02271152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-121|FAST Mapping During Atrial Fibrillation|Focal Electrical Source and Trigger Mapping During Atrial Fibrillation||University Health Network, Toronto|No|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02271152||34485|
NCT02271230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001206|Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure|||Brigham and Women's Hospital||Active, not recruiting|August 2014|December 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|No|||March 2016|March 16, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02271230||34479|
NCT02259439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16022012|Assessment of Updated Evaluation Scores in Critically ILL COPD Patients Admitted to Assiut University Hospital|||Assiut University|No|Recruiting|September 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|20 Years|N/A|No|Probability Sample|We include for study all patients critically ill hospitalized for COPD exacerbation during        the study period.|October 2014|March 30, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02259439||35385|
NCT02267343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-12|Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer|ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer||Ono Pharmaceutical Co. Ltd|Yes|Recruiting|October 2014|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|20 Years|N/A|No|||October 2015|October 14, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02267343||34778|
NCT02269969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183-2014|Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study|Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study||Sunnybrook Health Sciences Centre||Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02269969||34576|
NCT02267915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-MAN2|Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT|An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT|MAN2|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Recruiting|November 2014|November 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02267915||34734|
NCT02268162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lungcancer diagnosis|Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy Combination|Prospective Multicenter Randomized Control Study on Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy Combination||Tang-Du Hospital|Yes|Recruiting|April 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|3228|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268162||34715|
NCT02270944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_21|Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine|A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years.||Novartis|No|Completed|November 2014|September 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1053|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270944||34501|
NCT02270957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF 13-38|Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches|Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)|ABC|Oklahoma Medical Research Foundation|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270957||34500|
NCT02270970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF 14-18|Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy|Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy|BLAST|Oklahoma Medical Research Foundation|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|70 Years|No|||October 2015|October 13, 2015|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270970||34499|
NCT02270996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH PedSurg ACS 002|Antimicrobial Stewardship in Pediatric Surgery|An Antimicrobial Stewardship Intervention Program in Pediatric Surgery|AbxPS|Alberta Children's Hospital|No|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|18 Years|Accepts Healthy Volunteers|Probability Sample|The study population is the pediatric surgeons at our institution who will have their        antibiotic prescribing audited.|October 2014|October 21, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02270996||34497|
NCT02260102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|temocillin-pediatrics|Temocillin Pharmacokinetics in Paediatrics|Temocillin Pharmacokinetics in Paediatrics|TEMOPEDI|Université Catholique de Louvain|No|Not yet recruiting|October 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|45|||Both|6 Months|3 Years|No|||October 2014|October 7, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02260102||35334|
NCT02371863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39865.041.14|Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic MR|SEP-study; The Assessment of Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic Mitral Valve Regurgitation|SEP|UMC Utrecht|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|25 Asymptomatic patients (≥18 years) at least 6 months after successful MV repair.        Patients will have a LVEF ≥45%, and were initially operated based on organic MV        regurgitation.|December 2015|December 27, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02371863||26762|
NCT02371876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2014-005-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||May 1, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02371876||26761|
NCT02271074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUR5-9-119|Thol'Impilo: Bringing People Into Care|An Evaluation of Strategies to Accelerate Entry-into-care Following HIV Diagnosis Among Adults in Gauteng and Limpopo Provinces, South Africa||The Aurum Institute NPC|Yes|Active, not recruiting|June 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|2500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02271074||34491|
NCT02271087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA210314|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2016|||||N/A|N/A|N/A||||||||||||||March 6, 2016|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271087||34490|
NCT02258633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00026025|The Seatbelt Intervention Study|A Brief Tailored Family-centered Seatbelt Intervention for Hospitalized Trauma||University of Michigan|No|Completed|March 2009|||February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258633||35447|
NCT02258646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228919/DHE|Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Trial|Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial|iTrain|University Hospital of North Norway||Recruiting|October 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|40 Years|80 Years|No|||November 2015|January 8, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258646||35446|
NCT02263508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110265|Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma|A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)||Amgen|Yes|Recruiting|December 2014|May 2022|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|660|||Both|18 Years|95 Years|No|||March 2016|March 1, 2016|September 26, 2014|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT02263508||35072|
NCT02258932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NW/0122-1|CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study|Eating Behaviours, Quality of Life and Cardiometabolic Risks in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy - A Longitudinal Study||Liverpool John Moores University|No|Completed|December 2013|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples Without DNA|Plasma will be retained for use by the research team during the study. After the study      remaining samples will be destroyed in accordance with the Human Tissue Authority Code of      Practice.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from the Diabetes Centre from the Royal Liverpool and Broadgreen        Hospital.|July 2015|February 18, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258932|12 Months|35424|
NCT02258945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NW/0122-2|CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study|Eating Behaviours, Quality of Life and Cardiometabolic Risks in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy - A Cross-Sectional Study||Liverpool John Moores University|No|Completed|April 2014|August 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|Samples Without DNA|Plasma will be retained for use by the research team during the study. After the study      remaining samples will be destroyed in accordance with the Human Tissue Authority Code of      Practice.|Both|18 Years|N/A|No|Probability Sample|Patients will be selected from the Diabetes Centre from the Royal Liverpool and Broadgreen        Hospital.|April 2015|February 18, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258945|1 Year|35423|
NCT02271295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130926|Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study|Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study|Childbenox|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271295||34474|
NCT02361554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHM IRB NA_00042065|Deep Brain Stimulation in Treatment Resistant Schizophrenia|Deep Brain Stimulation in Treatment Resistant Schizophrenia||Johns Hopkins University|Yes|Recruiting|June 2012|||June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|22 Years|N/A|No|||August 2015|August 31, 2015|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02361554||27549|
NCT02269592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-174|Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome|Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome||Dana-Farber Cancer Institute|Yes|Recruiting|August 2014|September 2043|Anticipated|December 2039|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood, buccal swabs or mouthwashes, and urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Known or Suspected Precursor Hematological Cancer|January 2016|January 22, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02269592||34605|
NCT02361775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201M09227|Paravertebral Catheters for VATS Procedures|Ultrasound Guided Paravertebral Catheter Versus Patient Controlled Analgesia for Postoperative Pain Control in Video Assisted Thoracoscopic Surgery: A Prospective Outcomes Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||February 2015|February 11, 2015|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02361775||27532|
NCT02361788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU 1307|Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study)|A Prospective Cohort Study on the Etiology of Neonatal Hyperbilirubinemia in a Migrant and Refugee Population on the Thai-Myanmar Border||University of Oxford|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1887|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Over the course of a one year period, the mothers of neonates (estimated gestation ≥ 28        weeks) who meet the inclusion criteria and none of the exclusion criteria will be asked to        participate in this study.        Based on previous experience, assuming that most mothers will agree to participate in the        study and 15% of the included neonates will be lost before completion of the study, we        will include approximately 1887 neonates. With an estimated proportion of neonatal        hyperbilirubinemia of 18%, 340 of 1887 neonates will develop neonatal hyperbilirubinemia.        Other prospective studies had numbers of neonates with neonatal hyperbilirubinemia ranging        from 21 to 624.|February 2015|March 2, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02361788||27531|
NCT02258594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001966|Promoting Respect and Ongoing Safety Through Patient-centeredness, Engagement, Communication and Technology|Transforming the Acute Care Environment: BWH PROSPECT Framework|PROSPECT|Brigham and Women's Hospital|No|Recruiting|March 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|4368|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02258594||35450|
NCT02270203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300244|LOIS: Long-Term Follow-Up in INSITE/SIFI|LOIS: Long-Term Follow-Up in INSITE/SIFI|LOIS|SI-BONE, Inc.|No|Recruiting|October 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|21 Years|70 Years|No|Non-Probability Sample|Subjects with degenerative sacroiliitis or sacroiliac joint disruption who underwent iFuse        placement.|June 2015|June 5, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270203||34558|
NCT02258880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 802|Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke|A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke||Daiichi Sankyo Inc.|Yes|Withdrawn|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||October 2015|October 19, 2015|September 29, 2014|Yes|Yes|study was stopped for business/administrative reasons and not for patient safety concerns|No||https://clinicaltrials.gov/show/NCT02258880||35428|
NCT02270398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20140714003-01|Dual-task Training in Chronic Stroke|Training Dual-task Balance and Walking in Community-dwelling Older Adults With Chronic Stroke: a Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|50 Years|N/A|No|||November 2014|November 9, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270398||34543|
NCT02270684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP00002312|StepRite Evaluation|Comparative Effectiveness of an Activity-Specific Monitoring Device (StepRite) on Short Term Outcomes in Adults After Total Knee Arthroplasty||University of Southern California|No|Not yet recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|75 Years|No|||October 2014|October 17, 2014|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270684||34521|
NCT02259621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1414|Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC|Neoadjuvant Anti-Programmed Death-1 Antibody, Nivolumab, in Resectable Non-Small-Cell Lung Cancer.|NA_00092076|Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|September 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|95 Years|No|||October 2015|October 13, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259621||35371|
NCT02264600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWED-31014|Apelin in Willis Ekbom Disease|Oxidative Stress and Apelin Level in Willis Ekbom Disease||Acibadem University|No|Not yet recruiting|November 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples Without DNA|Plasma|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are administered to Kayseri Acibadem Hospital Sleep Medicine Unit, outpatient        clinic.|October 2014|October 10, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02264600|2 Days|34988|
NCT02360605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSG-13-021-01 - CPPB|Health Literacy Interventions to Overcome Disparities in CRC Screening|Health Literacy Interventions to Overcome Disparities in CRC Screening||Louisiana State University Health Sciences Center Shreveport|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02360605||27622|
NCT02274922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/05|Evaluation of Immunochromatographic Tests for Campylobacter Detection in Stools|Evaluation of Immunochromatographic Tests for Campylobacter Detection in Stools|CAMPYTEST|University Hospital, Bordeaux|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Serology control|Both|N/A|N/A|No|Probability Sample|All of the patients coming to an emergency care unit and for whom a stool culture is        prescribed will be included, corresponding to an estimate number of 1,000 patients for two        years.|October 2014|October 31, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274922||34195|
NCT02263235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8652|In Vivo Alzheimer Proteomics|Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease|PROMARA|University Hospital, Montpellier|No|Recruiting|October 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|110|||Both|55 Years|85 Years|No|||October 2014|October 7, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02263235||35093|
NCT02263248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035/2014|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|(IRLGREY-B)|Centre for Addiction and Mental Health|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|50 Years|N/A|No|||September 2015|September 11, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263248||35092|
NCT02266251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052757|Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease|Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease|PCORI-AVR|Duke University|No|Enrolling by invitation|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|6484|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To compare health outcomes among patients with a similar baseline health status who are        eligible for surgical and transcather AVR procedures, we will include 1)'operable'        transcatheter AVR patients enrolled in the TVT Registry (Nov 2011 -Dec 2013), and 2)        surgical AVR patients with a STS perioperative risk of mortality (PROM) ≥4% whose index        procedure is included in the STS ACSD (Jan 2011 - Dec 2013).|November 2015|November 12, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266251||34862|
NCT02263768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7709191|Impact of Two Recall Intervals on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children|Impact of Two Recall Intervals Associated to Oral Health Counseling on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children With Low and Moderate Caries Risk: Randomized Clinical Trial||University of Sao Paulo|Yes|Active, not recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|224|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||August 2015|October 30, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02263768||35052|
NCT02259205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SYN-2-652|Cardio Protective Properties of a Yogurt Enriched With Bioactive Lipids of Olive Oil Products|Cardio Protective Properties of a Yogurt Enriched With Bioactive Lipids of Olive Oil Products||Harokopio University|No|Recruiting|September 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02259205||35403|
NCT02267070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH102529-01|Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode|Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode|CT&E|University of California, Los Angeles|Yes|Recruiting|November 2013|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|November 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02267070||34799|
NCT02271880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH097819|Improving Medication Adherence in ADHD Adolescents|Improving Medication Adherence in ADHD Adolescents||Florida International University|No|Recruiting|September 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|16 Years|No|||February 2016|February 8, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02271880||34429|
NCT02271893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0214|Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management|Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management|CHEMODEX|University Hospital, Clermont-Ferrand||Recruiting|November 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271893||34428|
NCT02269774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0203|Origin of Premature Atrial Beats Induced by Simulated Obstructive Sleep Apnea|Electroanatomic Origin of Premature Atrial Beats in Patients With Paroxysmal Atrial Fibrillation Induced by Intra-thoracic Pressure Swings Simulating Obstructive Sleep Apnea||University of Zurich|No|Terminated|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|2|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|October 14, 2014||No|Due to the strict in- and exclusion criteria only few patients could be enrolled into the    study.|No||https://clinicaltrials.gov/show/NCT02269774||34591|
NCT02269787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-010|TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification|TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification||VA Office of Research and Development|Yes|Recruiting|October 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|256|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02269787||34590|
NCT02266069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA C130298|PROject - Supportive and Palliative Care and INnOvation - Antwerp (Pro-Spinoza)|Implementation of the Care Pathway for Primary Palliative Care in Five Research Clusters in Belgium|pro-Spinoza|Universiteit Antwerpen|No|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Anticipated|200|||Both|45 Years|N/A|No|||February 2015|February 3, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266069||34876|
NCT02270463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-401-0214|SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission|A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR||Stemline Therapeutics, Inc.|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270463||34538|
NCT02270476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKH-TRACK-1|Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening|Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening|TRACK-CF|Heidelberg University|No|Recruiting|December 2011|December 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients with CF diagnosed in the first 4 months of life (corrected age of 4 months in        preterms) not before January 1st, 2006 build up the early diagnosed (ED) group. Early        identification can be achieved by newborn screening, clinical diagnosis (e.g. patients        with meconium ileus), due to positive family history or prenatal diagnosis. Patients with        CF diagnosed after the first 4 months of life and after January 1st, 2006, are included as        a comparison group with clinically diagnosed patients (late diagnosed, LD). Both groups        (ED and LD) are investigated after the same investigational plan with all investigations        that are part of the annual check-up and additional, study-related monthly telephone        interviews on bronchopulmonary symptoms, quarterly assessment of QoL and voluntarily        yearly bronchoscopy with broncho-alveolar lavage.|December 2015|December 1, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270476||34537|
NCT02259452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0808|Radiation Induced Cardiopulmonary Injury in Humans|Radiation Induced Cardiopulmonary Injury in Humans||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2008|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are to receive 3D-planned RT for lung cancer (conformal or IMRT) or other        tumors in/around the thorax.|October 2015|October 9, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259452||35384|
NCT02264665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181214|Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years|Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (Pnet): A Study Of Morbidity And Mortality At 2 Years|OPALINE|Pfizer|No|Recruiting|May 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|150|||Both|18 Years|99 Years|No|Non-Probability Sample|patients with progressive and metastatic pancreatic neuroendocrin tumors|March 2016|March 7, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02264665||34983|
NCT02264925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/15|Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives|Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives|VIM-CLT|University Hospital, Bordeaux|No|Recruiting|September 2014|October 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||October 2014|October 22, 2014|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02264925||34963|
NCT02265185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409-091|Measuring the Weight Status, Primary Care Usage and Dietary Intake in the Pediatric Emergency Department|Measuring the Weight Status, Primary Care Usage and Dietary Intake in the Pediatric Emergency Department||Children's Hospitals and Clinics of Minnesota|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|484|||Both|2 Years|10 Years|No|Probability Sample|Patients (aged 2-10) visiting the Children's EDs, who are triaged level 3-5, when a study        RA is on duty will be eligible for the study. We have selected the 2-10 year old patient        population for this study as the early grade school years are a critical time to intervene        before unhealthy lifestyle habits are established, and this age group provides a unique        window of opportunity in which to utilize parent and child interaction.|November 2015|November 17, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265185||34943|
NCT02283307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47637K|Dual Energy CT Urography With Reduced Iodinated Contrast|Dual Energy CT Urography Using 50% Reduction in Iodinated Contrast: Feasibility, Image Quality, and Radiation Dose Reduction With Virtual Unenhanced Images.||University of Washington|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|50 Years|N/A|No|||May 2015|May 26, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02283307||33551|
NCT02283541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 105915|Gait, Depression, and Mind-body Therapy in Seniors|Investigating the Relationship Between Gait, Depression, and Mind-body Therapy in Seniors||Lawson Health Research Institute|No|Recruiting|June 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|51|||Both|65 Years|85 Years|No|||June 2015|June 4, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02283541||33533|
NCT02278458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV70|Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer|Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|October 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||May 2015|May 21, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278458||33923|
NCT02293005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0497|Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma|Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293005||32806|
NCT02289534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2013-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||February 12, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289534||33072|
NCT02275000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0573|Feasibility Study of Physiotherapy for Functional Motor Symptoms|Randomised Feasibility Study of a Physiotherapy Programme for Patients With Functional Motor Symptoms (FMS).||University College, London|No|Active, not recruiting|September 2014|March 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|October 15, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02275000||34189|
NCT02275013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ea1-044-13b|Levosimendan Administration and Outcome in Cardiac Surgery|||Charite University, Berlin, Germany||Completed|January 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|159|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac surgery patients|October 2014|October 23, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275013||34188|
NCT02264067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.111|Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers|Phase I Clinical Study of WAL2014 (Talsaclidine) Capsule: A Single Oral Dose Study||Boehringer Ingelheim||Completed|July 1998|||November 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264067||35029|
NCT02263053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFCeara|Immediate Effects of Posterior Mobilization Versus Caudal Mobilization in Patients With Temporomandibular Disorders|Immediate Effects of Posterior Mobilization Versus Caudal Mobilization in Patients With Temporomandibular Disorders: A Randomized Clinical Trial|TMD|Universidade Federal do Ceara|Yes|Recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02263053||35107|
NCT02263300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00098465|Spatial Orientation and Fiberoptic Intubation Skills in the Novice: A Randomized Controlled Trial|Does Spatial Orientation Affect the Rate of Learning Fiberoptic Intubation Skills in the Novice: A Randomized Controlled Trial||Northwestern University|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||4|Actual|51|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|First year medical students.|October 2015|October 29, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02263300||35088|
NCT02263261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTF 13-03|Evaluation of a Human Acellular Dermal Matrix in Post Mastectomy Reconstruction|Reconstructive, Aesthetic and Patient Reported Outcomes Associated With the Use of Flex HD Pliable, Perforated Human Acellular Dermal Matrix in Implant-Based Breast Reconstruction: A Pilot Study||Musculoskeletal Transplant Foundation|No|Recruiting|March 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||March 2015|April 14, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02263261||35091|
NCT02265419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2014-0064|Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of SIRS in Heart Surgery Patients|Case-observation and Compassionate Use: Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery With the Use of a Heart-lung-machine|CASHSP|University of Rostock|Yes|Recruiting|October 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265419||34925|
NCT02259218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11108|Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy|Biomarker Discovery for Toxicity and Survival in Radiation Oncology: An Integrative Molecular-Clinical Approach||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|October 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|360|Samples With DNA|Blood, urine, tissue|Both|19 Years|N/A|No|Non-Probability Sample|Patients diagnosed with lung, brain, prostate or cervical cancer that are being treated        with radiation therapy.|September 2015|September 4, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259218||35402|
NCT02264392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMASSEDUS4|US Guided Versus BlindI&D for Treatment of Soft Tissue Abscesses in the ED|Ultrasound Guided Versus Blind Incision and Drainage for the Treatment of Soft Tissue Abscesses in the Emergency Department||University of Massachusetts, Worcester|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|274|||Both|1 Month|65 Years|No|||December 2015|December 7, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264392||35004|
NCT02268981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12hOXY-ILD2014|Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)|Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|30 Years|80 Years|No|||September 2015|September 2, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02268981||34652|
NCT02268994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-306|KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD|A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects With Non-Dialysis Dependent Chronic Kidney Disease||Keryx Biopharmaceuticals|No|Completed|September 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268994||34651|
NCT02269098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-010|The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes|The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes: STEP-Diabetes.|STEP-DM|Medstar Research Institute|No|Completed|February 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|101|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02269098||34643|
NCT02288988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Collis-Nissen Surgery|Minimally Invasive Collis-Nissen for the Treatment of Short Esophagus|Results of the Minimally Invasive Collis-Nissen Technique for the Treatment of True Short Esophagus|COLLIS-NIS|University of Bologna|Yes|Completed|January 1995|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02288988||33114|
NCT02291107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK.S P07|Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods|Robot-assisted Gait Training in Patients Affected by Multiple Sclerosis: Rehabilitative Efficacy Evaluation and Comparison With Traditional Methods||Habilita, Ospedale di Sarnico|Yes|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|17|||Both|N/A|N/A|No|||August 2015|August 20, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291107||32952|
NCT02283866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWJung_BA|Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil|Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil||Seoul National University Hospital||Completed|June 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|20 Years|90 Years|No|||July 2015|July 13, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283866||33508|
NCT02284126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN3703|Topical Vancomycin for Neurosurgery Wound Prophylaxis|Topical Vancomycin for the Reduction of Surgical Site Infections in Neurosurgery|Vanco|Columbia University|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3600|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284126||33488|
NCT02276300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATZ-1068-KRA-20I|HER2-Peptide Vaccination of Patients With Solid Tumors|A Phase 1 Study of Peptide Vaccination for the Treatment of Patients With Solid Tumors Moderately Expressing HER2/Neu|HER2|Technische Universität München|No|Recruiting|December 2014|April 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02276300||34089|
NCT02280317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL201-001|Dose Finding Safety Study of VAL201 in Cancer Patients|A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours|VAL201-001|ValiRx Plc|Yes|Enrolling by invitation|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||July 2015|December 9, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02280317||33780|
NCT02262195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP2338|Dysfunctional Hemoglobin|Dysfunctional Hemoglobin Pulse Co-ox||Nonin Medical, Inc|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|62|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Adult volunteers|October 2014|April 20, 2015|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262195||35173|
NCT02269358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0143-14-WOMC|Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation|Phase 4, Open Lable Non Randomized un Controlled Study. Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation||Wolfson Medical Center|Yes|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|8 Years|18 Years|No|||December 2015|December 6, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269358||34623|
NCT02264379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR - Oli-P - 2014|Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma|Effectiveness and Toxicity of a Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma|Oli-P|Technische Universität Dresden|No|Recruiting|December 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|71|Samples With DNA|Blood before therapy, at the end of radiotherapy, three months after the end of radiotherapy      and at progress before starting further treatment|Both|18 Years|N/A|No|Non-Probability Sample|Patients with oligometastases (1-5) and state after local therapy of prostate cancer|February 2016|February 24, 2016|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02264379||35005|
NCT02263001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2011.0119|Acupuncture Therapy for Treatment of Musculoskeletal Pain|Auricular Acupuncture Therapy for Treatment of Musculoskeletal Pain in the Setting of Military Personnel: A Randomized Trial||University of California, San Diego|Yes|Recruiting|April 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02263001||35111|
NCT02267408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fearon pilot RCT, version 03|Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin|A Single-site, Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Patients With Unstable Warfarin Effect.||McMaster University|Yes|Recruiting|November 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267408||34773|
NCT02269826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB-04/2007|Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness|Medical Device Study to Investigate the Efficacy and Tolerability of Vagisan® Moisturising Cream vs. Gynomunal® Vaginal Gel in a 2-period Changeover Design in n=120 Patients With Vaginal Dryness Who Cannot or do Not Wish to Use Oestrogens||Dr. August Wolff GmbH & Co. KG Arzneimittel|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Female|18 Years|N/A|No|||February 2008|October 17, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02269826||34587|
NCT02270047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B315|SATIN The Acute Effect of Orange Nectar With NAXUS Fibre Made by Novel Processing on Satiety and Satiation|SATIN The Acute Effect of Orange Nectar With NAXUS Fibre Made by Novel Processing on Satiety and Satiation|SATIN|University of Copenhagen|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02270047||34570|
NCT02270060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-14-11|Music Therapy in Sickle Cell Pain Mixed Methods Study|The Effects of a Single Music Therapy Session on the Pain of Adult Patients With Sickle Cell Disease: A Mixed Methods Study||University Hospital Case Medical Center|Yes|Recruiting|September 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02270060||34569|
NCT02270268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NLY073|Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome|Therapeutic Effects of Pectin Supplementation in Patients With Diarrhea-predominant Irritable Bowel Syndrome||Nanjing PLA General Hospital|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02270268||34553|
NCT02264080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.112|Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers|Phase I Clinical Study of WAL2014 (Talsaclidine) Capsule: A Multiple Oral Dose Study||Boehringer Ingelheim||Completed|March 1999|||March 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264080||35028|
NCT02264093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.114|Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers|Effects on the Airway Lumen of Single Oral Doses of Talsaclidine (12, 24, 48 and 60 mg) in Combination With a Single Oral Doses of 160 mg Propranolol in Comparison to the Effects of the Monosubstances (60 mg Talsaclidine and 160 mg Propranolol) in Healthy Elderly Male Volunteers (Partially Randomised, Open Label, Intraindividual Comparison)||Boehringer Ingelheim||Completed|November 1999|||February 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264093||35027|
NCT02276118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1406/254-001|Outcome Comparison of Two Total Knee Arthroplasty Systems: e.Motion-Pro Versus Genesis II|Comparisons of Prosthesis Fitness, Early Recovery Patterns, Functional Outcomes and Patient Satisfaction Between E.Motion-Pro, a New Mobile Bearing System and Genesis II, an Established Successful System||Seoul National University Hospital|No|Recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|79 Years|No|||July 2014|October 23, 2014|October 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276118||34103|
NCT02276131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VG1HFHUS1|Human Factors and Home Use Study of the Vigilant Diabetes Management Application|Human Factors and Home Use Study of the Vigilant Diabetes Management Application||InSpark Technologies, Inc.|No|Completed|January 2015|December 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|13 Years|N/A|No|||February 2016|February 23, 2016|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276131||34102|
NCT02268500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0656|VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)|VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study|VACC-HeFT|University of Wisconsin, Madison|Yes|Recruiting|September 2014|May 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268500||34689|
NCT02268513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00083722|Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study|Social and Cultural Influences on Cardiovascular Disease Risk in South Asians||Northwestern University|No|Recruiting|September 2014|February 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|40 Years|N/A|No|Non-Probability Sample|Volunteer participants from the the Mediators of Atherosclerosis in South Asians Living in        America (MASALA) study cohort.|July 2015|July 7, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02268513||34688|
NCT02275377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0405|Effects of Inspiratory Muscle Training on Blood Pressure Levels in Hypertensive Individuals|Effects of Inspiratory Muscle Training on Blood Pressure Levels in Hypertensive Individuals: a Randomized Clinical Trial.||Hospital de Clinicas de Porto Alegre|No|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02275377||34160|
NCT02275403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_DOG06_165|Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma|Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN)|ACUFOCIN|Christie Hospital NHS Foundation Trust|Yes|Recruiting|March 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02275403||34158|
NCT02275416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UV1/hTERT-MM|Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma|Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma||Ultimovacs AS|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02275416||34157|
NCT02289248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015171|Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine|Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine||Yale University|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|November 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289248||33094|
NCT02289261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDICP01|A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain|A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain||Cukurova University|No|Recruiting|November 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||November 2014|November 10, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289261||33093|
NCT02289313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004474|Development of a Youth Healthy Living Program With Underserved Adolescents at Rochester Alternative Learning Center|Development of a Youth Healthy Living Program at the Rochester Alternative Learning Center||Mayo Clinic|No|Active, not recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|224|||Both|12 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289313||33089|
NCT02289417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-UC-001|Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis|A Phase 2, Randomized, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety, of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis|UC|Celgene|Yes|Recruiting|December 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289417||33081|
NCT02291185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0698|Prediction of Fluid Responsiveness Using Dynamic Preload Indices During Arthroscopic Shoulder Surgery in the Beach Chair Position|||Yonsei University|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|20 Years|75 Years|No|Non-Probability Sample|patients undergoing shoulder arthroscopic surgery in the beach chair position|August 2015|August 30, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02291185||32946|
NCT02289430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-1205-02|to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers|A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers|NVP-1205|Navipharm Corporation|Yes|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289430||33080|
NCT02280330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCP-RPU-2014-0001|Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months|Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months|MNP-CAR|Nutrition Center of the Philippines|Yes|Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|396|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02280330||33779|
NCT02266589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NLY031|Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Research of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock||Nanjing PLA General Hospital|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|80 Years|No|||October 2014|October 16, 2014|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02266589||34836|
NCT02266602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11143|Intraoperative Radiation Therapy in Early Stage Breast Cancer|Intra-Operative Radiotherapy After Breast Conserving Therapy in the Treatment of in Situ and Early Stage Breast Cancer|IORT Breast|Benaroya Research Institute|Yes|Recruiting|February 2012|February 2022|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Female|45 Years|N/A|No|||January 2016|January 11, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266602||34835|
NCT02275039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13373|p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer|A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer||City of Hope Medical Center|Yes|Recruiting|January 2015|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275039||34186|
NCT02269475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2560C00006|A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years|A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years||AstraZeneca|Yes|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1314|||Both|7 Years|18 Years|No|||January 2016|January 5, 2016|October 13, 2014||No||No|October 29, 2015|https://clinicaltrials.gov/show/NCT02269475||34614|
NCT02269488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2560C00007|A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years|A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years||AstraZeneca|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|2 Years|6 Years|No|||August 2015|August 31, 2015|October 13, 2014||No||No|July 30, 2015|https://clinicaltrials.gov/show/NCT02269488||34613|
NCT02271503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX203-B14-02|A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease|A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease||IMPAX Laboratories, Inc.|No|Recruiting|November 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|40 Years|N/A|No|||February 2016|February 26, 2016|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02271503||34458|
NCT02275260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP025|Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study|Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study (REDUCE-TE Pilot)||Biotronik SE & Co. KG|No|Recruiting|December 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|125|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275260||34169|
NCT02275312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52120-192|ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity|ETREAT Study: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.|ETREAT|Ipsen|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|304|||Both|18 Years|80 Years|No|Non-Probability Sample|Post-stroke spasticity|September 2015|December 21, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275312||34165|
NCT02258659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0639|Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer|An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial|OPTIMA|University of Chicago|Yes|Recruiting|September 2014|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|61|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258659||35445|
NCT02268240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS_CARE4PCS|Care for Post-Concussive Symptoms|Care for Post-Concussive Symptoms|CARE4PCS|Seattle Children's Hospital|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|11 Years|18 Years|No|||January 2016|January 13, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02268240||34709|
NCT02260219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-12-01|Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma|Comparative Study of the Safety and Efficacy of the Ahmed Glaucoma Valve Drainage Device, Model M4 (High Density Porous Polyethylene) and the Model S2 (Polypropylene) in Patients With Neovascular Glaucoma||Asociación para Evitar la Ceguera en México|No|Active, not recruiting|January 2012|||February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2014|October 6, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02260219||35325|
NCT02260232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEM_ASISA_1|Worksite Exercise Intervention Effects on Cardiovascular Disease Risk Factors and Physical Activity Levels Among Healthy Employees|||Universidad Europea de Madrid|No|Completed|June 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|295|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260232||35324|
NCT02275338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-48-52030-269|Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction|An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction|IMIO|Ipsen|No|Recruiting|October 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275338||34163|
NCT02275351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM04554-AGA-02|A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)|A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)||Samumed LLC|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|310|||Male|18 Years|55 Years|No|||November 2015|November 24, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275351||34162|
NCT02261155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU 137/06|Changes in Sensory Perception During Hypnotic Relaxation|Veränderungen Der Sensibilität Durch Medizinische Hypnose||Ludwig-Maximilians - University of Munich|No|Completed|September 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02261155||35253|
NCT02261441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBERICAN|Cardiovascular and Renal Risk in Spain|Identificación de la poBlación Española de RIesgo CArdiovascular y reNal|IBERICAN|La Sociedad Española de Médicos de Atención Primaria||Recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout        Spain|October 2014|May 18, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02261441||35231|
NCT02279498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-EPI3331|SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis|A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency||Anthera Pharmaceuticals|Yes|Recruiting|June 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|7 Years|N/A|No|||March 2016|March 23, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279498||33843|
NCT02279511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECA4A|ATP in Alzheimer Disease|Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|20|||Both|55 Years|85 Years|No|||August 2015|August 17, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02279511||33842|
NCT02279771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siccr/2014|Transanal Reinforcement of Low Rectal Anastomosis in Rectal Cancer Surgery|Multicenter Randomized Controlled Trial of Transanal Reinforcement of Low Rectal Anastomosis Versus Protective Ileostomy in the Prevention of Anastomotic Leak After Rectal Cancer Surgery|LessStoReS|Societa Italiana di Chirurgia ColoRettale|No|Not yet recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|30 Years|80 Years|No|||October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279771||33822|
NCT02289443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09-E71-12B|a 10-year Follow-up Study of a Randomized Clinical Trial|Comparison of Two Different Procedures Fabrication of Conventional Complete Dentures: a 10-year Follow-up Study of a Randomized Clinical Trial||Nihon University|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|104|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who participated and completed 6-month follow-ups in the RCT (T group: 50, and S        group: 54; total 104 subjects) will be contacted by telephone.|November 2014|November 15, 2014|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289443||33079|
NCT02289521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF325130_156937|Effect of Stimulation of Dorsolateral Prefrontal Cortex on Language Control|Role of Executive Function on Language: an Experimental and Clinical Approach With Application to Mother Language and Second Language||University of Fribourg|No|Active, not recruiting|August 2014|September 2017|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02289521||33073|
NCT02284152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809649|Responsive Feeding Study|Responsive Feeding Study|RFS|Drexel University|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|N/A|6 Months|Accepts Healthy Volunteers|||November 2014|November 3, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284152||33486|
NCT02292121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130402|Intestinal Permeability in Obesity|Intestinal Permeability in Obesity of Intercellular Tight Junctions to Metabolic Complications|LEAKY GUT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2014|January 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|110|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292121||32874|
NCT02270281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZDSYLL093.0|The Effect of Dexmedetomidine on Microcirculation in Septic Shock|The Effect of Dexmedetomidine on Microcirculation in Septic Shock||Southeast University, China|Yes|Recruiting|October 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 17, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270281||34552|
NCT02262442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-074|Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer During the Bronchoscopy|Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer on Usage of Anaesthetics and Sedatives During the Bronchoscopy|EnkAtomizerII|RWTH Aachen University|No|Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|85 Years|No|||February 2016|February 17, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262442||35154|
NCT02275065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-141-1219|Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects|A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects||Gilead Sciences|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|65 Years|No|||February 2015|February 6, 2015|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275065||34184|
NCT02275091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0755|Children With Diabetes at Risk for Heart Disease.|Identifying Children With Diabetes Type 1 at High Risk for Cardiovascular Disease.||Georgetown University|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children with diabetes type 1 and healthy children|December 2015|December 4, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275091||34182|
NCT02267148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1392|Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression|Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression||UNC Nutrition Research Institute|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|53|Samples With DNA|Whole blood will be collected and used for DNA extraction. Plasma and serum will also be      collected and banked.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of the greater Charlotte, NC metropolitan area|January 2015|January 15, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02267148||34793|
NCT02267161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-RCB: 2014-A00625-42|Infants With Agenesis of the Corpus Callosum|Outcome of Infants With Prenatal Corpus Callosum Agenesis|Dacci|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|December 2021|Anticipated|July 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02267161||34792|
NCT02263521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAHSA0901|Understanding Physician Work Motivation|Physician Work Motivation: A Measure Validation Study||American Medical Association|No|Enrolling by invitation|October 2014|September 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|4500|||Both|21 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Population #1 includes practicing physicians in all medical specialties. Population #2        includes resident physicians in all medical specialties. Population #3 includes fourth        year medical students in all US allopathic medical schools.|January 2015|January 12, 2015|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02263521||35071|
NCT02263781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57206|PREPL in Health and Disease|PREPL in Health and Disease|PHD|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|125|||Both|N/A|40 Years|Accepts Healthy Volunteers|||September 2014|October 13, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02263781||35051|
NCT02263794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0039|Hyperpolarized Magnetic Resonance Imaging in Asthma Pre- and Post-Bronchial Thermoplasty|Hyperpolarized Magnetic Resonance Imaging in Asthma Pre- and Post-Bronchial Thermoplasty||Western University, Canada|No|Enrolling by invitation|October 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02263794||35050|
NCT02276092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASP2013|Impact of a Regional Antimicrobial Stewardship on the Length of Stay of Patients Admitted to Hospital With Pneumonia|Effectiveness of a Regional Antimicrobial Stewardship Program to Reduce the Length of Stay of Patients Admitted to Hospital With Community-acquired Pneumonia: a Pragmatic Multi-centre Clinical Study|RASPCAP|Royal Victoria Hospital, Canada|Yes|Enrolling by invitation|April 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients over the age of 18 years admitted to a hospital ward with a diagnosis of        community-acquired pneumonia as determined by the most responsible physician|October 2015|October 14, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276092|60 Days|34105|
NCT02264938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-11-112|Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation|Drusen Morphology Changes in Nonexudative Age-related Degeneration Using Spectral Domain Optical Coherence Tomography After Oral Antioxidants Supplementation: One-year Results.||Germans Trias i Pujol Hospital|No|Completed|January 2013|October 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|50 Years|N/A|No|||October 2014|October 9, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264938||34962|
NCT02264951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFAS|Fat-induced Release of GLP-1 in Humans|Short Fatty Acids-induced Release of GLP-1 in Humans||Glostrup University Hospital, Copenhagen|No|Completed|October 2013|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264951||34961|
NCT02260817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZM-CCH-40-PTL0114|Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer|Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities||Global Isotopes, LLC d/b/a Zevacor Molecular|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|August 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260817||35279|
NCT02260830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15911A|Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167|Interventional, Open-label, Part Fixed Sequence, Part-randomised Study Investigating the Pharmacokinetic Properties of up to 6 Prototype Modified Release Tablet Formulations of Lu AF11167 in Healthy Young Subjects||H. Lundbeck A/S|No|Completed|August 2014|||March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02260830||35278|
NCT02265445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130949|Deescalating Carbapenems in Hospital Setting|Deescalating Carbapenems in Hospital Setting: a Multicentre Randomized Controlled Study Comparing Carbapenem Continuation and Switch to Another Beta-lactam for the Treatment of Infections Due to ESBL-producing Enterobacteriaceae|CARBEPARGNE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|April 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|578|||Both|18 Years|N/A|No|||October 2014|March 11, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02265445||34923|
NCT02265809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILfrequency|Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes|Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency)|DILfrequency|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|36|||Both|18 Years|70 Years|No|||January 2016|January 10, 2016|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02265809||34896|
NCT02283320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIND-014-007|A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer||BIND Therapeutics|Yes|Active, not recruiting|September 2014|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283320||33550|
NCT02283554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014B|Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony Defects|Platelet Rich Fibrin With 1% Metformin for the Treatment of Intrabony Defects in Chronic Periodontitis : A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore||Completed|November 2013|||July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02283554||33532|
NCT02280083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HengLi002|A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection in Chinese Subjects With Post-stroke Upper Limb Spasticity||Lanzhou Institute of Biological Products Co., Ltd|Yes|Enrolling by invitation|July 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||July 2014|December 24, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280083||33798|
NCT02261948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFM 199/312|Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)|Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)||Centro Cardiologico Monzino|No|Completed|September 2012|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|90 Years|No|||October 2015|October 7, 2015|July 22, 2014||No||No|August 4, 2015|https://clinicaltrials.gov/show/NCT02261948||35192|
NCT02261961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1203-R|Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults|Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults|TDAP2|VA Office of Research and Development|No|Recruiting|July 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02261961||35191|
NCT02275546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8342A-063|Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)|A Multicenter, Open Label, Randomized, Two-period Crossover Study on the Insertion of MK-8342A (NuvaRing®) Placebo With and Without the Use of NuvaRing Applicator in Healthy Female Subjects||Merck Sharp & Dohme Corp.|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275546||34147|
NCT02275559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT008393|Asthma Symptom Management Through Mindfulness Training|Asthma Symptom Management Through Mindfulness Training||University of Massachusetts, Worcester|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|254|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02275559||34146|
NCT02266875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0050|Nebulized Hypertonic Saline for Inpatient Use in COPD|Nebulized Hypertonic Saline for Inpatient Use in Chronic Obstructive Pulmonary Disease||OhioHealth|No|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|N/A|No|||October 2014|April 20, 2015|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266875||34814|
NCT02270762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Early passive verticalization|Early Passive Verticalization in Critically Ill Patients|Effect of Early Passive Verticalization in Pulmonary Recruitment Evaluated With Electric Impedance Tomography|TILT|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Active, not recruiting|August 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270762||34515|
NCT02270775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI-French|Traduction and Validation of the Central Sentitization Inventory Into French|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Not yet recruiting|October 2014|||June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|3 groups:        Fibromyalgia Patients (group 1) Acute or subacute Ankle Sprain (Group 2) Healthy        Volunteers (Group 3)|October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270775||34514|
NCT02271347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-205|An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease|An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease|CMX|Chimerix|No|Withdrawn|October 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Months|75 Years|No|||October 2014|January 30, 2015|October 7, 2014||No|Suspended Development Program|No||https://clinicaltrials.gov/show/NCT02271347||34470|
NCT02271360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-ahmed 7|Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome||Benha University|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|220|||Female|22 Years|44 Years|No|||January 2016|January 14, 2016|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02271360||34469|
NCT02258958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_VTEincidence|Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against DVT and PE in Patients Undergoing Major Lung Resection|Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection||McMaster University|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|All adults of at least 18 years of age who are to undergo sub-lobar resection, lobectomy,        bilobectomy or pneumonectomy for lung cancer or metastatic lung disease will be offered        the opportunity to participate in the study. The inclusion criteria are intentionally        broad to increase the generalizability of the study. Eligibility criteria will be        considered for enrollment in the study and are listed in the methodology section. The        study population for both phases one and two of the study will have the same inclusion and        exclusion criteria but will not include the same participants.|December 2014|December 16, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258958||35422|
NCT02258971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.8|Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of 1200 μg (Free Cation) [14C] BEA 2180 BR Administered Orally Compared to 500 μg (Free Cation) [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design||Boehringer Ingelheim||Completed|March 2007|||May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||September 2014|October 1, 2014|October 1, 2014||||No||https://clinicaltrials.gov/show/NCT02258971||35421|
NCT02267707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-004|Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia|A Phase 1, Multicenter, Open-label, Dose-escalation Study to Investigate the Safety and Pharmacokinetics of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Secondary to Bile Duct Obstruction||Celgene|Yes|Terminated|May 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 1, 2014|No|Yes|Study population more infrequent than estimated. No study-related safety issues and no safety    concerns were identified for the study.|No||https://clinicaltrials.gov/show/NCT02267707||34750|
NCT02267720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPARTOP2014|Occlusal-proximal ART Restorations in Primary Molars Using 2 Different Kinds of GIC|Survival Rate and Cost Effectiveness From Two Different Materials of GIC Using in Occlusol-proximal ART Restorations in Primary Molars||University of Sao Paulo|Yes|Active, not recruiting|November 2014|March 2017|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267720||34749|
NCT02267993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHBDH-IIT2014010|Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients|A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia||Institute of Hematology & Blood Diseases Hospital|No|Recruiting|October 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|55 Years|No|||August 2015|August 20, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02267993||34728|
NCT02259699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI CE-12-11-4755|Ovarian Cancer Patient-Centered Decision Aid|Ovarian Cancer Patient-Centered Decision Aid|PCOA|University of California, Irvine|No|Recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|229|||Female|21 Years|N/A|No|||December 2014|December 1, 2014|May 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02259699||35365|
NCT02269514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSD1303|Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum|A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Electronic Cigarettes||R.J. Reynolds Vapor Company|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|45|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02269514||34611|
NCT02269527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08810|Effects of an Live Music on the Perception of Noise in the SICU: A Patient, Caregiver, and Medical Staff Environmental Study|Effects of an Integrative Music Therapy Program on the Perception of Noise in the SICU: A Patient, Caregiver, and Physician/Nursing Environmental Study||Beth Israel Medical Center|No|Active, not recruiting|June 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|318|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02269527||34610|
NCT02265198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG03-018|Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome|Relationship of Pulmonary Contusion Morphology to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome||Wake Forest School of Medicine|No|Recruiting|September 2014|March 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples With DNA|Bronchial Alveolar Lavage - Supernatant Blood-Serum|Both|16 Years|N/A|No|Non-Probability Sample|The study will be conducted at Wake Forest University Baptist Medical Center and will        enroll 40 patients in the PC study group, 20 patients in each control group, and 20 MICU        patients. Eligible subjects for study group will be patients with PC on admission CT;        eligible subjects for control group #1 (CG1) are normal patients without PC undergoing a        standard general surgical procedure; eligible subjects for control group #2 (CG2) are        non-chest, non-PC trauma patients who are admitted intubated to the trauma ICU; eligible        MICU subjects are patients on mechanical ventilation admitted to the Medical ICU with        acute respiratory failure.|December 2015|December 21, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265198||34942|
NCT02275949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUSAH20141059|Acupuncture for Cerebral Vasospasm After Subarachnoid Hemorrhage|The Efficacy and Safety of Acupuncture for Cerebral Vasospasm After Subarachnoid Hemorrhage||Kyung Hee University Hospital at Gangdong|Yes|Recruiting|September 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275949||34116|
NCT02287818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-201-GOU-002|A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout|||TWi Biotechnology, Inc.|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|65 Years|No|||November 2015|November 2, 2015|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287818||33204|
NCT02289001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBAR-1|Simulation Training in Undergraduate Nursing Education as a Means to Improve Awareness of Team Member Roles|Study to Evaluate the Use of the SBAR (Situation-Background-Assessment-Recommendation) Checklist as a Means to Help Undergraduate Nursing Students Understand Team Member Roles and Improve Healthcare Team Communication|SBAR|University of Girona|No|Completed|February 2015|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|93|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02289001||33113|
NCT02291978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29163|MR Guided High Intensity Focused Ultrasound for Lumbar Back Pain|A Feasibility Study to Evaluate the Safety and Initial Effectiveness of MR Guided High Intensity Focused Ultrasound (MRgHIFU) in the Treatment of Facetogenic Lumbar Back Pain||Stanford University|Yes|Recruiting|October 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||November 2015|November 18, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291978||32885|
NCT02283879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Cerebral hemorrhage|Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela|Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Cerebral Hemorrhage||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Active, not recruiting|March 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|80 Years|No|||July 2015|December 23, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283879||33507|
NCT02291991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-E2-P1|Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects|A Randomized, Double-blind Placebo Controlled, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 After Single Intravenous Administration in Healthy Subjects|GX-E2-P1|Genexine, Inc.|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02291991||32884|
NCT02292004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00012985|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||January 22, 2016|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292004||32883|
NCT02266316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WARM/COPD/1112|Use of an Air Warming Mask for Exercise in Patients With COPD V1.0|A Randomised Controlled Trial of an Air Warming Mask to Increase Exercise Tolerance in Patients With Stable and Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD).||University of Worcester|No|Recruiting|March 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|40 Years|80 Years|No|||October 2014|October 10, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266316||34857|
NCT02267421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKPTMHLivCirHomeTraining|Effects of Home Based Exercise Therapy in Early Cirrhosis|An 8 Week Randomized Controlled Trial Assessing Home Exercise Therapy in Early Cirrhosis||University of Alberta|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2014|October 14, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267421||34772|
NCT02267434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFiRiS 011|Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease|A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease|AFF011|Affiris AG|Yes|Active, not recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Both|45 Years|70 Years|No|||March 2016|March 2, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02267434||34771|
NCT02270489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFiRiS 009|Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA|A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy|AFF009|Affiris AG|Yes|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|30 Years|75 Years|No|||November 2015|November 30, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02270489||34536|
NCT02258672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQTR-CSSSTR 2014|Preoperative Rehabilitation for Patients Undergoing Surgery for Lumbar Spinal Stenosis|Effects of a Preoperative Rehabilitation Program on the Recovery of Patients Undergoing Surgery for Lumbar Spinal Stenosis: a Feasibility Study.||Université du Québec à Trois-Rivières|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258672||35444|
NCT02263274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-01171|Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS|Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS||New York University School of Medicine|Yes|Recruiting|November 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263274||35090|
NCT02263534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMS001|Retropubic Single Incision Minisling Versus Tension Free Vaginal Tape for Management of Stress Urinary Incontinence|Retropubic Single Incision Minisling Versus Tension Free Vaginal Tape for Management of Stress Urinary Incontinence||Ain Shams University|No|Active, not recruiting|November 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Female|N/A|N/A|No|||April 2015|April 27, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263534||35070|
NCT02263547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ-2013-11023|Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride|Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride|TERCOL|University of South Florida|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263547||35069|
NCT02271620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759/25569(EC3)|The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis|The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis||Mahidol University|Yes|Recruiting|January 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|53|||Both|8 Years|18 Years|No|||April 2015|April 15, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02271620||34449|
NCT02271789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2014-1390|Low-cost, Noninvasive Method to Assess Pulpal Vitality|Low-cost, Noninvasive Method to Assess Pulpal Vitality||University of California, Irvine|No|Recruiting|November 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from affiliated researcher at Dentists clinic in Orange        Country and will be referred to investigator at University of California Irvine|February 2016|February 5, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02271789||34436|
NCT02271802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 08-2-006|Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids|Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids||Maastricht University Medical Center|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271802||34435|
NCT02271997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ironsuppletion|Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass||Ironsuppletion|Rijnstate Hospital||Enrolling by invitation|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|65 Years|No|||October 2014|October 20, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271997||34420|
NCT02264405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT-8410015|Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study|Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT|NISSC|European Group for Blood and Marrow Transplantation|No|Recruiting|December 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients treated with autologous HSCT for severe systemic sclerosis|September 2014|October 17, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02264405||35003|
NCT02264418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3113001|Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours|Safety and Tolerability of Single and Repeated Doses of ODM-203: An Open-label, Non-randomised, Uncontrolled, Dose Escalation, Multicentre, First-in-Human Study in Subjects With Advanced Solid Tumours|KIDES-203|Orion Corporation, Orion Pharma|Yes|Recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|42|||Both|18 Years|N/A|No|||March 2015|October 2, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264418||35002|
NCT02275897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-13-608-16854 (IIR)|Effect of Different Injection Speeds for Spinal Anaesthesia in Caesarean Section|Injection Speed of Spinal Anaesthesia for Asian Women Undergoing Lower Segmental Caesarean Section and the Incidence of Hypotension and/or Use of Vasopressors||Ministry of Health, Malaysia|No|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02275897||34120|
NCT02275910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7090-J081-101|Phase 1 Study of E7090 in Subjects With Solid Tumor|A Phase 1 Study of E7090 in Subjects With Solid Tumor||Eisai Inc.|Yes|Recruiting|November 2014|May 2019|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||December 2015|January 19, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02275910||34119|
NCT02269696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101090|The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients|The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients||Kuopio University Hospital|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|65 Years|No|||June 2015|June 12, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02269696||34597|
NCT02261168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC143027|Day-Night Rhythm in Human Skeletal Muscle|Day-night Rhythm in Human Skeletal Muscle Metabolism||Maastricht University Medical Center|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02261168||35252|
NCT02269839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15971|A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus|A Feasibility Study to Assess the Effectiveness of Different Modalities of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|September 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||June 2015|November 21, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02269839||34586|
NCT02269852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-INF-4013|The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine|A Single-centered, Open-labeled, Phase 4 Study of a Northern Hemisphere 2013-2014 Seasonal Trivalent Influenza Inactivated Vaccine, Anflu®||Sinovac Biotech Co., Ltd|No|Completed|December 2013|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|182|||Both|6 Months|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02269852||34585|
NCT02289755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000396|Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria|A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria||Allena Pharmaceuticals|No|Completed|September 2014|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|N/A|N/A|No|||March 2015|March 4, 2015|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289755||33055|
NCT02289885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST/2014/02|FAST Examination During Emergency Practice|Knowledge, Attitude and Practice About Focused Assessment With Sonography in Trauma Among Paramedics. Randomized Crossover Manikin Trial|FAST|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02289885||33045|
NCT02289898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-006|Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma|A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma|YOSEMITE|OncoMed Pharmaceuticals, Inc.|Yes|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|201|||Both|21 Years|N/A|No|||February 2016|February 25, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289898||33044|
NCT02289911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST/2014/03|FAST Learning Methods|Comparison of Two Learning Methods in Focused Assessment With Sonography for Trauma (FAST) Training Among Paramedics|FAST|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02289911||33043|
NCT02292082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-018|The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)|The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)|ACB PAI|Hospital for Special Surgery, New York||Recruiting|November 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|80 Years|No|||November 2015|November 4, 2015|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292082||32877|
NCT02290002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahmed-khalid 8|Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome|Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome||Benha University|No|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|210|||Female|23 Years|45 Years|No|||January 2016|January 14, 2016|November 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02290002||33036|
NCT02270073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA6526/2-1(DFG)|The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study|Mindfulness Interventions in Outpatient Cognitive Behavior Therapy in Trainee Therapists: The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study|PrOMET|Heidelberg University|Yes|Recruiting|October 2014|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02270073||34568|
NCT02270086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1038|Evaluating Bacterial Response in Sarcoma Management Using Fluorescence Imaging|Evaluating Bacterial Response Throughout Sarcoma Management Using An Optically Tracked, Hand-Held Fluorescent Imaging Device||University Health Network, Toronto|No|Active, not recruiting|August 2011|January 2016|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study is conducted at the Princess Margaret Cancer Centre in Toronto. Patients present        with soft tissue sarcoma and receive pre-operative radiation therapy.|December 2015|December 9, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02270086||34567|
NCT02271373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013001|Effect of Increasing Time Spent Outdoors on Myopia Prevention in School-Aged Children in Northeast China|Development and Application of Appropriate Technology for Myopia Prevention and Control||Anhui Medical University|Yes|Completed|November 2012|February 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3521|||Both|6 Years|14 Years|No|||October 2014|October 22, 2014|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02271373||34468|
NCT02271386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011189|Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD|Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD||Children's Hospital of Philadelphia|No|Recruiting|November 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7750|||Both|5 Years|12 Years|No|||October 2015|October 23, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02271386||34467|
NCT02275585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT2013628|Portal Vein Thrombosis in Cirrhosis|Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy||Corporacion Parc Tauli|No|Not yet recruiting|October 2014|October 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|78|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital care clinic|October 2014|October 24, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02275585||34144|
NCT02263014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0752|Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)|Treatment Decisions and Breast Cancer: Psychosocial Outcomes||M.D. Anderson Cancer Center|No|Recruiting|February 2014|||February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|345|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients seen at University of Texas MD Anderson Cancer Center and at Kelsey        Seybold Clinic.|November 2015|November 19, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263014||35110|
NCT02268253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-401-0314|SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)|SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)||Stemline Therapeutics, Inc.|Yes|Recruiting|December 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268253||34708|
NCT02268526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSJ148X2201|Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients|A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients||Novartis|No|Recruiting|June 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|86|||Both|N/A|N/A|No|||December 2015|December 9, 2015|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268526||34687|
NCT02259231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1401|RTA 408 Capsules in Patients With Melanoma - REVEAL|An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma||Reata Pharmaceuticals, Inc.|No|Recruiting|October 2014|April 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259231||35401|
NCT02259244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-0000000-3521|Effect of Mediterranean and Hypolipemic Reduction Diet in Obese Patients|Effect of the Mediterranean Diet and Hypolipemic Reduction Diet in Combination With Exercise in Obese Croatian Population- 1-year Randomized Controlled Trial||University of Zagreb|No|Completed|October 2008|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|124|||Both|18 Years|69 Years|No|||October 2014|October 3, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02259244||35400|
NCT02259465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoM A14082014 FOG|The Effect of the Low FODMAP Diet and Dietary Oligofructose on Gastrointestinal Form, Function and Microbiota|A Randomised Controlled Trial of the Effect of the Low FODMAP Diet and Dietary Oligofructose on Gastrointestinal Form, Function and Microbiota in Healthy Volunteers|FOG|University of Nottingham|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02259465||35383|
NCT02264132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.607|Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers|A Multiple Dose Study of Pramipexole With Increasing Doses (0.375 mg to 1.5 mg q.d.) of Oral Extended Release (ER) Tablet in Two-way Cross-over Comparison of 0.375 mg ER Tablet q.d. Versus 0.125 mg Immediate Release (IR) Tablet t.i.d. and 1.5 mg ER Tablet q.d. Versus 0.5 mg IR Tablet t.i.d. in Japanese Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264132||35024|
NCT02269384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MountSMCLA|The Effects of Pain and the Memory of Pain on Autonomic and Neuromuscular Function|The Effects of Pain and the Memory of Pain on Autonomic and Neuromuscular Function||Mount St. Mary's College, Los Angeles, CA|No|Enrolling by invitation|May 2014|October 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02269384||34621|
NCT02275923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REEF|Reveal LINQ™ Evaluation of Fluid|Reveal LINQ™ Evaluation of Fluid|REEF|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|October 2014|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|21 Years|N/A|No|||December 2014|December 18, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275923||34118|
NCT02275936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N91115-1CF-03|Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation|SNO4|Nivalis Therapeutics, Inc.|Yes|Active, not recruiting|February 2015|February 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275936||34117|
NCT02265458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P131201|Musical Intervention in Non-invasive Ventilation|Musical Intervention in the ICU: Effect on Tolerance and Acceptance of Non-invasive Ventilation|Mus-IRA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02265458||34922|
NCT02265471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRQ1277|Knowledge and Perception of Resistance to Antimicrobials Among Healthcare Workers in France|Knowledge and Perception of Resistance to Antimicrobials in French Healthcare Facilities|PerceptR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|July 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||6|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|health care workers (medical or not)|April 2014|October 10, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02265471||34921|
NCT02275962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-107|Drug-Drug Interaction Study in Healthy Adult Volunteers|||Kowa Research Institute, Inc.||Completed|September 2014|May 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275962||34115|
NCT02275975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-105|Drug-Drug Interaction Study in Healthy Adult Volunteers|||Kowa Research Institute, Inc.||Completed|July 2014|||August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02275975||34114|
NCT02279797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone_marrow2014|Bone Marrow Donation|Knowledge, Attitudes and Practices About Bone Marrow Donation Among Medical Students and Medical Staff|KAPsurvey|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff: medical doctors, nurses, paramedics Medical students: PhD students,        medicine students, nursing and paramedics studies|October 2014|October 29, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02279797||33820|
NCT02280343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UERJ|Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis|OSCILLATION MECHANICS OF THE RESPIRATORY SYSTEM ASBESTOS EXPOSED : Early Diagnosis||Rio de Janeiro State University|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|2|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|exposed to asbesto|June 2015|June 30, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02280343||33778|
NCT02284984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4813605814|Synergetic B-cell Immodulation in SLE|Synergetic B-cell Immodulation in SLE|SYNBIoSe|Leiden University Medical Center|No|Recruiting|March 2014|March 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|64 Years|No|||November 2014|November 13, 2014|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284984||33422|
NCT02280668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4177|Investigating Muscle Repair in Response to Icing Therapy Post Eccentric Muscle Damage Exercise|||Wilfrid Laurier University|No|Recruiting|October 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280668||33753|
NCT02275507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|613231|Non-Invasive Hemoglobin Monitoring of Women Undergoing Cesarean Delivery|Non-Invasive Hemoglobin Monitoring of Women Undergoing Cesarean Delivery||Stony Brook University|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|women who are scheduled for an elective repeat or primary cesarean delivery. We will        exclude women at high-risk for hemorrhage, thalassemia major, sickle cell disease, or        women with hypertensive disorders|October 2014|October 24, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275507||34150|
NCT02275520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IO2014|Intraosseous Access|Comparison of NIO, BIG, EZ-IO, Jamshidi and Cook Intraosseous Devices in Adult Patients Under Resuscitation by Paramedics: a Randomized Crossover Manikin Trial.|NIO|International Institute of Rescue Research and Education|Yes|Completed|December 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02275520||34149|
NCT02268006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41/12/13|IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment|Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER|BISER|Institute of Oncology Ljubljana||Recruiting|January 2014|December 2020|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|No|||September 2014|October 15, 2014|February 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02268006||34727|
NCT02268019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUMS2014|Hemostasis During Hypospadias Surgery|A Comparison Between Tourniquet Application and Epinephrine Injection for Hemostasis During Hypospadias Surgery: the Effect on Bleeding and Post-operative Outcome||Isfahan University of Medical Sciences|Yes|Recruiting|January 2013|March 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|N/A|15 Years|No|||October 2014|October 15, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02268019||34726|
NCT02271815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2013-9778|A Clinical and Imaging Study to Evaluate a Novel Dentifrice|A Clinical and Imaging Study to Evaluate a Novel Dentifrice||University of California, Irvine|No|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will be selected from University of California Irvine staffs and students|February 2016|February 5, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02271815||34434|
NCT02272010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanley-13T-013|Dietary Intervention for Bipolar Disorder|Targeted Alterations in n-3 and n‐6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder||Milton S. Hershey Medical Center|No|Recruiting|October 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|100 Years|No|||October 2015|October 2, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02272010||34419|
NCT02263807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2148|Knee Function in Patients With Two or More Episodes of Patella Dislocations|RCT Study:Knee Function in Patients With Two or More Episodes of Patella Dislocations|MPFL|University Hospital, Akershus|Yes|Recruiting|February 2011|December 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT02263807||35049|
NCT02264106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|509.118|Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects|Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 30 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial||Boehringer Ingelheim||Completed|April 1998|||June 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264106||35026|
NCT02264119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|509.119|Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects|Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 20 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial.||Boehringer Ingelheim||Completed|April 1998|||July 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||||No||https://clinicaltrials.gov/show/NCT02264119||35025|
NCT02264145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260.3171|The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers|The Effect of Alcoholic-carrier Solutions Within-devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers||Boehringer Ingelheim||Completed|November 1998|||December 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264145||35023|
NCT02275871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-225|Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer|Dual-energy Contrast-enhanced Digital Subtraction Mammography (CESM) as a Tool to Screen High Risk Women for Breast Cancer: a Comparison to Screening Breast MRI||Dana-Farber Cancer Institute|Yes|Recruiting|November 2014|January 2021|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|220|||Female|30 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275871||34122|
NCT02260544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|591-13|Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection|A Multicenter, Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Cross-over Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 20mg/10mL of Dr. Reddy's Laboratories Ltd, India, With That of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL , Manufactured by: Sun Pharmaceutical Ind. Ltd, India; in Ovarian Cancer Patients Whose Disease Has Progressed or Recurred After Platinum Based Chemotherapy and Who Are Already Receiving or Scheduled to Start Therapy With the Reference Listed Drug Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Recruiting|July 2014|May 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|60 Years|No|||February 2015|February 4, 2015|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02260544||35300|
NCT02260557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065C202|Raynaud's Phenomenon Secondary to Systemic Sclerosis|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis||Actelion|No|Completed|October 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260557||35299|
NCT02260843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaiChi and Insonmia|Efficacy of Tai Chi Training on Insomnia in Older Adults|Efficacy of Tai Chi Training to Alleviate Insomnia in Older Adults: A Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Recruiting|June 2014|December 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|600|||Both|60 Years|N/A|No|||October 2014|October 6, 2014|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02260843||35277|
NCT02265211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4207|Mindfulness and Acceptance-Based Treatments for Social Anxiety: Defusion App|Mindfulness and Acceptance-Based Treatments for Social Anxiety: Defusion App||Wilfrid Laurier University||Completed|October 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 15, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02265211||34941|
NCT02269865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28486|Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy|Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy|CHRI|Stanford University|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Blood Samples and Cerebrospinal Fluid (CSF) samples|Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 subjects with Myotonic Dystrophy type 1 aged 8 to 17 years and 20 controls who are        healthy volunteers or siblings of affected subjects.|October 2014|October 16, 2014|December 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02269865||34584|
NCT02261454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH PedSurg ACS 001|RCT Gum Chewing on Bowel Function After Abdominal Surgery in Children|The Effect of Gum Chewing on Return of Bowel Function After Abdominal Surgery in Children Over the Age of 4 Years|GUM_RCT|Alberta Children's Hospital|Yes|Not yet recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02261454||35230|
NCT02284711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0166|Impact of Salpingectomy on Ovarian Reserve|Impact of Salpingectomy on Ovarian Reserve, With Comparison Between Two Coagulation Techniques|SALPOVA|Hospices Civils de Lyon|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|N/A|No|||November 2015|November 13, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284711||33443|
NCT02284971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17456|Pilot Study of SBRT and CDX-1127 in Prostate Cancer|A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer|Prostate-04|University of Virginia|Yes|Recruiting|November 2014|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284971||33423|
NCT02285218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0073|Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD|||Yonsei University|No|Recruiting|April 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|Samples Without DNA|plasma (blood)|Both|20 Years|80 Years|No|Non-Probability Sample|Subjects are recruited from either patients who visit out-patient clinics (Diabetes center        in Severance hospital) or healthy volunteers.|November 2014|November 12, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285218||33404|
NCT02285439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrenHLA|Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors|Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors||Children's Hospital Los Angeles|Yes|Not yet recruiting|January 2016|June 2020|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|1 Year|18 Years|No|||November 2015|November 9, 2015|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285439||33387|
NCT02262455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM-434-001|Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors|An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors||Santa Maria Biotherapeutics|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262455||35153|
NCT02262468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2012012|Warwick Metal On Metal Study|Review of 750 36mm MOM Hip Replacements ( Pinnacle/Corail) With up to 6 Year Follow up||South Warwickshire NHS Foundation Trust|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|750|||Both|N/A|N/A|No|Non-Probability Sample|All patients with 36mm metal on metal hips|October 2014|October 10, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262468||35152|
NCT02274467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-05|Response Patterns to the Electric Stimulation of Epidural Catheters in Term Pregnant Women|Response Patterns to the Electric Stimulation of Epidural Catheters in Term Pregnant Women: A Randomized Controlled Trial of Uniport Versus Multiport Catheters.||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02274467||34230|
NCT02274480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-191|Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity|Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who meet the selection criteria will be recruited from the breast medical        oncology clinics at MSKCC.|March 2016|March 9, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274480||34229|
NCT02262819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140199|Human Immunity Against Staphylococcus Aureus Skin Infection|Human Immunity Against Staphylococcus Aureus Skin Infection||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|January 2025|Anticipated|January 2025|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||August 2015|September 18, 2015|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02262819||35125|
NCT02262832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150003|Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy|Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|6 Months|N/A|No|||August 2015|March 11, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02262832||35124|
NCT02271633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC14-3-020|Nitrate Supplementation; Source|The Effect of Nitrate Supplementation: Source of Supplementation|NO-what|Maastricht University Medical Center|Yes|Completed|September 2014|March 2016|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|March 15, 2016|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02271633||34448|
NCT02271646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/2557(EC2)|Ultrasound Guided Thoracic Paravertebral Block for Hepatic Tumors Ablation|Ultrasound Guided Thoracic Paravertebral Blocks: An Effective Pain Control in Percutaneous Radiofrequency Ablation of Hepatic Tumors||Mahidol University|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02271646||34447|
NCT02258685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1595|Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.|Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.||University of Colorado, Denver|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|93|Samples Without DNA|Blood and rectosigmoid biopsy tissue will be collected.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive and HIV negative subjects (with and without lipodystrophy) between 18 and 65        years old.|December 2015|December 30, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02258685||35443|
NCT02258984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407013246|Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial|Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial||Mespere Lifesciences Inc.|No|Enrolling by invitation|October 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258984||35420|
NCT02264171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.78|Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers|An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers)||Boehringer Ingelheim||Completed|April 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264171||35021|
NCT02269111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC NEU1424|Quantitative MRI in Assessing Disease in Patients With Brain Metastases|Quantitative High-Field Magnetic Resonance Imaging (MRI) for Assessing Brain Metastases||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269111||34642|
NCT02269267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00023447|The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)|The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)||Medical College of Wisconsin|Yes|Recruiting|December 2014|December 2021|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|173|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02269267||34630|
NCT02264964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZHKI-HDVA-002|Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis|Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis : a Multicenter Prospective Cohort Study|DACAPO|Shanghai Changzheng Hospital|Yes|Not yet recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1400|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02264964||34960|
NCT02264977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSB 11-03|Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (Branched TAG® Device) in the Treatment of Aortic Arch Aneurysms||W.L.Gore & Associates|Yes|Recruiting|April 2015|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264977||34959|
NCT02265224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7169J02|Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)|Comparative Bioavailability Study of N-acetyl-cysteine (NAC) 600 mg Uncoated Tablets vs. NAC 600 mg Film-coated Tablets in Healthy Male and Female Volunteers||Zambon SpA|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02265224||34940|
NCT02265822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|797/2012|Melatonin Premedication in Children Undergoing Surgery|Assessment of the Effects of Melatonin on Preoperative Anxiety and Postoperative Analgesia in Children Undergoing Surgery: a Prospective, Randomized Clinical Trial||Azienda Ospedaliera Universitaria Policlinico "G. Martino"|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|5 Years|14 Years|No|||October 2014|October 15, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265822||34895|
NCT02265835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML6736|Anastomotic Airway Complications After Lung Transplantation|Anastomotic Airway Complications After Lung Transplantation : Risk Factors, Treatment Modalities and Outcome : a Single Center Experience.||Katholieke Universiteit Leuven||Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|432|||Both|N/A|N/A|No|Non-Probability Sample|Lung transplant recipients between 1/2005 en 12/2012|October 2014|October 13, 2014|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02265835||34894|
NCT02289287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM - 0018-14-CTIL|Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.|Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.||Clalit Health Services|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|50 Years|75 Years|No|||February 2016|February 7, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289287||33091|
NCT02289352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71304906|Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea||Actavis Inc.|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|462|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02289352||33086|
NCT02289365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBM-001|Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients|Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients||Joben Bio-Medical Co., Ltd.|Yes|Enrolling by invitation|November 2014|November 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|20 Years|N/A|No|||November 2014|November 16, 2014|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289365||33085|
NCT02289378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaeMon Plus|Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|DaeMon-Plus|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|November 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2014|November 13, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02289378||33084|
NCT02289482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912|A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With and Without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects||GlaxoSmithKline|No|Terminated|November 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|November 10, 2014|No|Yes|Study prematurely terminated due to safety concerns leading to clinical hold|No||https://clinicaltrials.gov/show/NCT02289482||33076|
NCT02289560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET002CA|Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors|A Continued Access Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects||InSightec|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|22 Years|N/A|No|||January 2016|January 7, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289560||33070|
NCT02266888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-08|B Cell Induction in Pediatric Lung Transplantation|B Cell Targeted Induction to Improve Outcomes in Pediatric Lung Transplantation (CTOTC-08)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|21 Years|No|||September 2015|September 21, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266888||34813|
NCT02267174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWD-10044739|Handoffs and Transitions in Critical Care|Handoffs and Transitions in Critical Care (HATRICC): Optimizing Operating Room to Intensive Care Unit Handoffs|HATRICC|University of Pennsylvania|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267174||34791|
NCT02273297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0563|Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth|Exploring the Fuel-mediated Programming of Neonatal Growth||University of Colorado, Denver||Active, not recruiting|July 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2821|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants were recruited from prenatal obstetrics clinics at the University of Colorado        Hospital outpatient pavilion.|October 2015|October 22, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273297||34320|
NCT02267733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014244|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING Trial)|SHIVERING|Yale University|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|N/A|No|||October 2014|July 14, 2015|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02267733||34748|
NCT02267746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAT 14-1096|A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris||Actavis Inc.|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|894|||Both|12 Years|40 Years|No|||October 2014|October 16, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267746||34747|
NCT02273362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02170|Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery|Pilot Study of EGFR Inhibition With Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma||National Cancer Institute (NCI)|Yes|Recruiting|November 2014|||January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273362||34315|
NCT02263820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSDX-1502|Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography|Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography (NORDICA Study)|NORDICA|HealthSpan Dx|No|Recruiting|January 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Urine, plasma, buffy coat|Both|18 Years|N/A|No|Non-Probability Sample|Adults undergoing cardiac catheterization with or without percutaneous coronary        intervention (PCI)|March 2016|March 6, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263820||35048|
NCT02264158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.378|Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers|A Double-blind, Randomised, Placebo Controlled, 6 Parallel Groups Study to Assess the Influence of Telmisartan (40 mg or 160 mg), Lacidipine (4 mg or 6 mg) and Their Combination (Telmisartan 40 mg and Lacidipine 4 mg) p.o. Once Daily for Seven Days on the QT Interval of the ECG in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|September 2001|||March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|149|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264158||35022|
NCT02264184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.79|Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers|An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers)||Boehringer Ingelheim||Completed|September 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264184||35020|
NCT02275793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVR|The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure|The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure|PVR|University of Toledo Health Science Campus|No|Recruiting|September 2011|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|Samples With DNA|DNA storage for future exploratory research into genes/genetic variations which may indicate      the presence or absence of pulmonary hypertension and congestive heart failure either as an      extension of this research protocol or future protocols developed in the study of pulmonary      hypertension/chf|Both|18 Years|N/A|No|Non-Probability Sample|We will study a cohort of patients that will be recruited from the cath lab during        diagnositic heart catheterization|July 2015|July 7, 2015|December 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02275793||34128|
NCT02275832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-57077|Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement|Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement : A Randomized, Double-blind, Placebo-controlled Study||Mae Fah Luang University Hospital|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275832||34125|
NCT02275845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48005.101.15|Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus|Metformin vs Control to Prevent Gestational Diabetes Mellitus (GDM) in Women With a High Risk for GDM, an Open Label Randomized Controlled Trial, The Medico-GDM Trial|Medico-GDM|Maasstad Hospital|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275845||34124|
NCT02260245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000045|Stepping Up for Safety: Improving Teamwork at the Planned Parenthood Affiliates Through the TeamSTEPPS Model|Stepping Up for Safety: Improving Teamwork at the Planned Parenthood Affiliates Through the TeamSTEPPS Model||Beth Israel Deaconess Medical Center|No|Enrolling by invitation|February 2014|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02260245||35323|
NCT02264678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5330C00004|Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents|A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.||AstraZeneca|No|Recruiting|October 2014|September 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|114|||Both|18 Years|130 Years|No|||March 2016|March 22, 2016|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264678||34982|
NCT02264691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-128|UTMB Research on Severe Asthma (UROSA) Study|UTMB Research on Severe Asthma (UROSA) Study|UROSA|The University of Texas Medical Branch, Galveston|No|Recruiting|March 2009|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal volunteers; Mild asthmatics not taking inhaled corticosteroids; Mild to moderate        asthmatics requiring and using inhaled corticosteroids and Severe asthmatics|June 2015|August 24, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264691||34981|
NCT02269540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137/2013|A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)|A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A)||Centre for Addiction and Mental Health|No|Recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|49 Years|No|||January 2016|January 28, 2016|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02269540||34609|
NCT02273570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSantAnna|Optimal Anemia Treatment in End Stage Renal Disease (ERSD)|Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism|OPTIMAL|Azienda Ospedaliera Sant'Anna|No|Recruiting|March 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|June 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273570||34299|
NCT02269709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00090329|Stage 3 Fontan Operation Liver Ultrasound Study|Noninvasive Detection of Liver Injury Immediately Following the Fontan Operation: the Role of Ultrasound-Based Elastography||University of Michigan|Yes|Recruiting|November 2014|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|N/A|17 Years|No|||December 2015|December 7, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269709||34596|
NCT02273609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAY-AVK-2013-01|INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)|English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.|PAULA|Hospital Universitario Ramon y Cajal|Yes|Completed|February 2014|October 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1524|||Both|18 Years|N/A|No|Probability Sample|Patients aged ≥18 years old, with nonvalvular AF, treated with VKAs for at least one year        in primary care setting were included in the study.|October 2014|October 28, 2014|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02273609||34296|
NCT02273622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD PI011|Human Study of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects|Nutritional Intervention Study to Evaluate the Effect of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects||IMDEA Food|No|Completed|October 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2014|March 23, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02273622||34295|
NCT02273661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEBULAMB|Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).||NEBULAMB|Poitiers University Hospital||Recruiting|November 2014|||June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|145|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02273661||34292|
NCT02270112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ:2014-080|Enhanced Diagnostics for Early Detection of Atrial Fibrillation|Enhanced Diagnostics for Early Detection of Atrial Fibrillation - DETECT AF Trial|DETECT-AF|University Hospital, Basel, Switzerland|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|287|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All inhospital and outpatient patients of our Institution with known paroxysmal AF are        screened for eligebility. Control Group is equally recruted from patients of our        intitution matching the studygroup.|October 2015|October 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02270112|1 Day|34565|
NCT02270515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-5420|Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease|Bringing Care to Patients: A Patient-Centered Medical Home for Kidney Disease|PCMH-KD|University of Illinois at Chicago|Yes|Recruiting|November 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|350|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02270515||34534|
NCT02276326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL-Dett 2014|Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients|Title Effect of Microbial Translocation and Supplementation With the Probiotic VSL#3 on Neuro-cognitive Functions of HIV Positive Patients Receiving HAART||Azienda Policlinico Umberto I|No|Recruiting|July 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02276326||34087|
NCT02290418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RYGBvsOLGB|Roux-en-Y Gastric Bypass (RYGB) Versus Omega-Loop Gastric Bypass (OLGB) Safety and Efficacy Short-term Study|Prospective Randomized Controlled Clinical Study Comparing Two Bariatric Bypass Procedures, Roux-en-Y Gastric Bypass (RYGB) and Omega-Loop Gastric Bypass (OLGB), in Patients With Severe Obesity and Metabolic Disease|ROSESS|Nemocnice Břeclav, p.o.|No|Active, not recruiting|January 2012|December 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||November 2014|November 10, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290418||33004|
NCT02270788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELHEM2|Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies|A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)||St. Jude Children's Research Hospital|No|Recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Year|39 Years|No|||March 2016|March 9, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02270788||34513|
NCT02263027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0808|Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?|Do Some Healthy Adults Consistently Have Systemic Reactions to Trivalent Inactivated Split Virus Influenza Vaccines?||Mount Sinai Hospital, Canada|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||September 2015|January 13, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263027||35109|
NCT02271516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCR12009|to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage|A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.||Institute of Nuclear Energy Research, Taiwan|No|Not yet recruiting|October 2014|December 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|80 Years|No|||October 2014|October 20, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02271516||34457|
NCT02271529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-14|Zilver PTX Delivery System|Zilver Paclitaxel(PTX) Thumbwheel Delivery System||Cook|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|October 17, 2014|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT02271529||34456|
NCT02263560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFribourg|Supraspinal Contributions to the Control of Human Locomotion: Clinical and Fundamental Aspects|Supraspinal Contributions to the Control of Human Locomotion: Clinical and Fundamental Aspects|SUPLOCO|University of Fribourg||Suspended|March 2014|March 2017|Anticipated|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|32|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The selected patients will be described by following parameters:          -  Parameters in relation to the person: age, gender.          -  Parameters in relation to the pathology: NIHSS, exact localisation, time since start             of the symptoms, FIM (functional independence measure) visual field (ophthalmological             examen), visual acuity (ophtalmological examen), visual neglect (Bells Cancellation             Task), visuo-spatial short term working memory (Corsi span), visual motor integration             (3-D cub subtest MoCA)          -  Parameters in relation to hospital stay: length of stay.|May 2015|May 26, 2015|October 6, 2014||No|A first group of patients (N=10) has been tested. Additional patients may be tested but this    is not fixed yet.|No||https://clinicaltrials.gov/show/NCT02263560|1 Year|35068|
NCT02267759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DE1-14-312|McGrath Videolaryngoscopy for Nasotracheal Intubation|A Comparison of McGrath Videolaryngoscopy and Macintosh Laryngoscopy for Routine Nasotracheal Intubation||Ajou University School of Medicine|Yes|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|70|||Both|20 Years|60 Years|No|||June 2015|June 17, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02267759||34746|
NCT02268032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVR+T001|Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve|Assess the Effect of DHEA or Other Androgenic Agents on Ovarian Reserve Markers in Women With Diminished Ovarian Reserve.||Laboratorios Andromaco S.A.|No|Recruiting|May 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Female|38 Years|45 Years|Accepts Healthy Volunteers|||August 2015|September 14, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02268032||34725|
NCT02268266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERIGO LIFE StV 22_2009|ERIGO® Life- Control of Cardiovascular Parameters Via Verticalization and Simultaneous Mobilization|ERIGO® Life - Study of Cardiovascular Parameters and Other Physiologic Parameters Under Verticalization and Simultaneous Mobilization of the Leg on Neurological Patients and Healthy Subjects|ERIGO®LIFE|Swiss Federal Institute of Technology|No|Completed|April 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02268266||34707|
NCT02259712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OE 20/2013|Effectiveness of Hipopressive Exercises Versus Classical Perineal Physiotherapy|Randomized Clinical Trial on the Effectiveness of Hipopressive Exercises Versus Classical Perineal Physiotherapy in Women With Pelvic Floor Dysfunction|HEPFD|University of Alcala|Yes|Recruiting|October 2013|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|78|||Female|18 Years|85 Years|No|||October 2014|October 7, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02259712||35364|
NCT02259725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-14-3|Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors|Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors||University of Southern California|Yes|Not yet recruiting|October 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259725||35363|
NCT02260258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000204|Neuromuscular Blockade for Post-Cardiac Arrest Care|Neuromuscular Blockade for Post-Cardiac Arrest Care|NMB in CA|Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02260258||35322|
NCT02269280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0112|Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)|Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Dependent Versus Best Supportive Care (BSC) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Independent||M.D. Anderson Cancer Center|Yes|Recruiting|October 2014|||October 2026|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269280||34629|
NCT02269397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817914|Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures|Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures||Cognizance Biomarkers, LLC|No|Active, not recruiting|July 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples Without DNA|Subjects will be asked to give blood for evaluation of a diagnostic blood test for epilepsy|Both|12 Years|N/A|No|Non-Probability Sample|Subjects aged 12 years and older who are attending their first visit to the University of        Pennsylvania's Epilepsy Center for diagnostic purposes|August 2015|August 27, 2015|July 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02269397||34620|
NCT02273583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLATO 2006|Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity|||Grupo de Apoio ao Adolescente e a Crianca com Cancer|Yes|Recruiting|May 2006|||June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|738|||Both|N/A|30 Years|No|||February 2016|February 10, 2016|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02273583||34298|
NCT02260271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504-2010|Florida Neonatal Neurologic Network|Florida Neonatal Neurologic Network|FN3|University of Florida|No|Enrolling by invitation|September 2011|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|blood, urine and buccal samples|Both|N/A|3 Weeks|No|Non-Probability Sample|Infants diagnosed with hypoxic-ischemic encepholopathy (HIE) at birth|October 2015|October 14, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260271||35321|
NCT02260570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0825-I|Remediation of Impaired Self-Regulation in Patients With Mild TBI|Remediation of Impaired Self-Regulation in Patients With Mild TBI||VA Office of Research and Development|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260570||35298|
NCT02260856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13215|A Randomized Controlled Trial of Leg Length Discrepancy Techniques|Percutaneous Screw Versus Percutaneous Drill Epiphysiodesis for Leg Length Discrepancy: A Randomized Controlled Trial||Hospital for Special Surgery, New York|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|7 Years|18 Years|No|||July 2015|July 2, 2015|June 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260856||35276|
NCT02273713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 49837.018.14|The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)|The ACTION Trial: a Phase Ib/II Study on the Addition of Nab-paclitaxel (Abraxane) to Capecitabine and Oxaliplatin in the First-line Treatment of Metastasized Oesophagogastric Carcinoma.|ACTION|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|154|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02273713||34288|
NCT02280096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-785-091|Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis|Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.||Coordinación de Investigación en Salud, Mexico|Yes|Active, not recruiting|October 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||November 2015|December 15, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02280096||33797|
NCT02280109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS-ES #12015|Comparison of Tenofovir Vaginal Gel and Film Formulations|Comparison of the Pharmacokinetics and Pharmacodynamics of Single Dose Tenofovir Vaginal Gel and Film Formulation|FAME-05|CONRAD|No|Completed|November 2014|||December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280109||33796|
NCT02292667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API/2014/52|Efficacy of the Ultrasound-guided Transversus Abdominis Plane Block in Open Aortic Abdominal Aneurysm Repair Surgery|Efficacy of the Ultrasound-guidedTransversus Abdominis Plane (TAP) Block on Postoperative Pain Control in Open Aortic Abdominal Aneurysm Repair Surgery|ETAP|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02292667||32832|
NCT02292680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1403|Childhood Measures of NICU-based Chemical Exposure|Novel Biomarkers for Exposures in the Neonatal Intensive Care Unit||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|65|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children who were cared for as neonates in the Mount Sinai NICU|October 2015|October 27, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292680||32831|
NCT02277145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA001-SH/IGDB|A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells|Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells||Chinese Academy of Sciences|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|70 Years|No|||October 2014|January 20, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02277145||34024|
NCT02277392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02814|A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|September 2014|||June 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|15|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277392||34005|
NCT02262481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA57/104|Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor|A Randomized, Double Blinded, Placebo Controlled Trial of Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor||Chulalongkorn University|Yes|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02262481||35151|
NCT02266901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bariatric endoscopic drainage|Transluminal or Percutaneous Endoscopic Drainage and Debridement of Abcesses After Bariatric Surgery|Transluminal or Percutaneous Endoscopic Drainage and Debridement of Abcesses After Bariatric Surgery||Erasme University Hospital|No|Completed|October 2007|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|9|||Both|18 Years|60 Years|No|Non-Probability Sample|All the patient treated in an academic tertiary center (Erasme Hospital) who underwent        endoscopic drainage and debridement of abdominal abscesses secondary to postbariatric        surgery leaks from october 2007 to April 2011. All other necrosectomies performed for        pancreatic disorders were excluded from the study|October 2014|October 16, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02266901||34812|
NCT02267187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14040197|Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material|Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material|BTI++|University of Pittsburgh|Yes|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267187||34790|
NCT02273310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HL070585|Families Taking Control (FTC): Family-based Problem-solving Intervention for Children With Sickle Cell Disease|Families Taking Control (FTC): Family-based Problem-solving Intervention for School-age Children With Sickle Cell Disease|FTC|University of Pennsylvania|No|Completed|July 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|83|||Both|6 Years|12 Years|No|||December 2015|December 1, 2015|October 21, 2014||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT02273310||34319|
NCT02273349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL001-AATD|Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency|Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema in Alpha-1 Antitrypsin Deficient Patients|LuReCAA|University Hospital, Saarland|No|Recruiting|October 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02273349||34316|
NCT02274558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1304|A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia|KINECT 3|Neurocrine Biosciences|No|Active, not recruiting|October 2014|July 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274558||34223|
NCT02274597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scs-2014|Does Environmental Factors Affect Accuracy in Pre-hospital Non-invasive Temperature Measurement?|Does Environmental Factors Affect Accuracy in Pre-hospital Non-invasive Temperature Measurement?||Oslo University Hospital|No|Completed|March 2014|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|October 2014|April 24, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274597||34220|
NCT02274662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051692|Expanded Access Protocol Thymus Transplantation|Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function||Duke University||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||August 2015|August 3, 2015|October 22, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02274662||34215|
NCT02264431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1327|Severe Obesity Outcome Network Cohort|Déterminants Des Troubles Respiratoires Nocturnes Des Patients obèses référés Dans un Centre spécialisé.|cohorte SOON|University Hospital, Grenoble|No|Recruiting|January 2014|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Serum bank, gene bank, tissue bank (subcutaneous fat, visceral fat)|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with class II or class III obesity (Body mass index >=35)|December 2015|December 2, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264431|5 Years|35001|
NCT02269293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-110|Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers|A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269293||34628|
NCT02273388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.1|BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours|An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Active, not recruiting|November 2005|August 2017|Anticipated|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273388||34313|
NCT02273401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1250.1|Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat®) of BI 11054 CL in Healthy Male Volunteers||Boehringer Ingelheim||Completed|January 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|96|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273401||34312|
NCT02273414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.4|Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Repeated Oral Doses (9 Days Dosing) of BIIL 284 BS (Doses: 25 mg, 150 mg, 250 mg as WIF Tablets) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 1999|||September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|35|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273414||34311|
NCT02273479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.127|Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers|Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) 200/25 mg Capsules b.i.d. in Randomised, Double-blind, Placebo-controlled Study in Japanese Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 1999|||September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|32|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273479||34306|
NCT02273492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.136|Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects|Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin Extended Release (ER) 200/25 mg Capsules b.i.d. in a Randomized, Open, 2-way Cross-over Study in Healthy Subjects||Boehringer Ingelheim||Completed|August 1999|||October 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273492||34305|
NCT02273505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.138|Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects|Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) 200/25 mg Capsules Bid and in a Combination of Persantin Immediate Release Tablets (100 mg Qid) and ASA Tablets (25 mg Bid) in an Open, Randomized, 2-way Crossover Study in Healthy Subjects||Boehringer Ingelheim||Completed|April 2000|||May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2014||||No||https://clinicaltrials.gov/show/NCT02273505||34304|
NCT02260284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LBP01|The Effect of Acupotome in Treating Ankylosing Spondylitis|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|50 Years|No|||August 2015|August 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02260284||35320|
NCT02264990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-359|Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers|A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers||AbbVie|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|525|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02264990||34958|
NCT02265237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-665|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)||AbbVie|Yes|Active, not recruiting|October 2014|April 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|190|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265237||34939|
NCT02265484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-bromocriptine-01|To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism|A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism||Institute of Liver and Biliary Sciences, India|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||April 2013|September 7, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02265484||34920|
NCT02261467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-142|A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides|||Allergan|No|Active, not recruiting|October 2014|April 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261467||35229|
NCT02290249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2014/145|Intubation of a Pediatric Manikin in Difficult Airway by Novice Personnel: A Comparison of Glidescope and Airtraq|Face-to-face Intubation With Glidescope or Airtraq||Kocaeli University|No|Completed|November 2014|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|36|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290249||33017|
NCT02292134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081115|Improving Sleep Quality in ICU Patients|Benefit of an Individual Protection Against Noise and Light on Sleep Quality in ICU Patients|EARS|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2013|November 14, 2014|November 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02292134||32873|
NCT02290665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-29620|Localized Therapeutics for the Treatment of Gastrointestinal Disorders|Localized Therapeutics for the Treatment of Gastrointestinal Disorders||Stanford University||Recruiting|September 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02290665||32986|
NCT02290678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adventure_PILOT|Pushing Limits - Adventure: Pilot Study|Examining the Feasibility and Efficacy of Adventure Based Therapy as a Treatment Intevention for Depression and Anxiety.||St. Joseph's Healthcare Hamilton|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|16 Years|N/A|No|||February 2015|February 18, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02290678||32985|
NCT02271659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-704|Medical and Economic Evaluation for Intermediate-risk Prostate Cancer|Medical and Economic Evaluation of an External Beam Radiotherapy Combined With a Brachytherapy Boost Compared With an Exclusive External Beam Radiotherapy for Intermediate-risk Prostate Cancer|GETUGP05|Hospices Civils de Lyon|Yes|Recruiting|June 2013|June 2021|Anticipated|June 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|298|||Male|18 Years|80 Years|No|||August 2015|September 16, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02271659||34446|
NCT02271828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOG 2013-08|Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy|Clinically Node Negative Breast Cancer Patients Undergoing Breast Conserving Therapy: Sentinel Lymph Node Procedure Versus Follow-Up.||Maastricht University Medical Center|Yes|Recruiting|April 2015|April 2027|Anticipated|April 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1644|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271828||34433|
NCT02263287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0007|LESCOD: "Lewy Body Screening in Cognitive Disorders"|LESCOD: "A Single Center, Prospective Study Aimed at Validating a Clinical Scale, Screening for Symptoms of Lewy Body Disease in Patients Incipient Dementia of the Alzheimer's and/or Lewy Body Type"|LESCOD|Nantes University Hospital|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|180|||Both|60 Years|90 Years|No|||December 2015|December 23, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02263287||35089|
NCT02258997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2811|Hepcidin Levels in Sickle Cell Disease (SCD)|Hepcidin Levels in Sickle Cell Disease (SCD)||University of North Carolina, Chapel Hill|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|42|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects will be recruited from the population followed in the Adult Sickle Cell Clinic        with either HbSS or HbS-βthalassemia who meet the eligibility criteria for the study.|October 2014|October 7, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02258997||35419|
NCT02263573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5830|Effect of PEP'C-R on Endurance Parameters and Maximal Cardio-respiratory Function Among Sedentary Older Seniors Over 70|Effect of a New Training Protocol: the PEP'C With Constant Load and Intermittent Recovery (PEP'C-R), on Endurance Parameters and Maximal Cardio-respiratory Function Among Sedentary Older Seniors Over 70.|PEP'C-R|University Hospital, Strasbourg, France|No|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02263573||35067|
NCT02259257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-14 RMB CTIL|3D/4D Ultrasound Contrast Enhanced Imaging (CEUS) for Carotid Plaque Vulnerability|3D/4D Ultrasound Contrast Enhanced Imaging (CEUS) for Carotid Plaque Vulnerability|CEUS carotid|Rambam Health Care Campus|No|Not yet recruiting|November 2014|November 2017|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Tissue: Carotid plaque histological specimen|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for endarterectomy due to carotid stenosis demonstrated on a previous        imaging examination (exhibiting >50% intra-luminal narrowing or a maximum IMT measurement        of > 1.5mm) or have experienced a CVA event (TIA/CVA) .|October 2014|October 5, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02259257||35399|
NCT02268539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B703|Efficacy, Safety and Efficiency of the nMARQ Pulmonary Vein Isolation System in Paroxysmal Atrial Fibrillation|Efficacy, Safety and Efficiency of the nMARQ Pulmonary Vein Isolation System in the Treatment of Paroxysmal Atrial Fibrillation - A Pilot Study||Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Active, not recruiting|February 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Both|18 Years|80 Years|No|||September 2015|December 14, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02268539||34686|
NCT02259738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hanying1|Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase|||Xuanwu Hospital, Beijing|Yes|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|70 Years|No|||October 2014|October 4, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02259738||35362|
NCT02259751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.4|Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Determine Pharmacodynamic Effects and Pharmacokinetics of a Single Oral Dose of 320 mg KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity||Boehringer Ingelheim||Completed|February 2004|||February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|70 Years|No|||October 2014|October 6, 2014|October 6, 2014||||No||https://clinicaltrials.gov/show/NCT02259751||35361|
NCT02266576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-30015|A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians|A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians||Stanford University|Yes|Recruiting|June 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|204|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266576||34837|
NCT02266862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2330|Changes in Renal Artery Movement Due to Respiration Before and After Fenestrated Endovascular Repair|Changes in Renal Artery Movement Due to Respiration Before and After Fenestrated Endovascular Repair||University of North Carolina, Chapel Hill|No|Withdrawn||||August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with fenestrated endovascular aortic repair (FEVAR) will be included in this        study.|September 2015|September 3, 2015|October 13, 2014||No|No funding|No||https://clinicaltrials.gov/show/NCT02266862||34815|
NCT02267395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Scapular and Cervical Neuromuscular Control Deficits in Musicians With and Without Playing Injuries.|Scapular and Cervical Neuromuscular Deficits in Musicians With and Without Playing Related Musculoskeletal Disorders: A Case Control Study.||Vanderbilt University|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Musicians with and without playing related musculo-skeletal Injuries.|November 2015|November 30, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02267395||34774|
NCT02265848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR-2014-01|High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System|Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief|HFSCS|The Center for Clinical Research, Winston-Salem, NC|Yes|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|September 30, 2014||No||No|October 12, 2015|https://clinicaltrials.gov/show/NCT02265848||34893|This study was limited by the sampling size, and by device type. Study was open to subjects who were implanted with Boston Scientific's Precision Plus device only
NCT02290366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14020322|Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer|Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer||University of Pittsburgh|No|Recruiting|November 2014|August 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|N/A|N/A|No|||November 2014|September 3, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02290366||33008|
NCT02290392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915011|Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0|The Minority Health Genomics and Translational Research BIo-Repository Database (MH-GRID)-2.0||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2014|July 2030|Anticipated|July 2030|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1692|||Both|30 Years|55 Years|No|||September 2015|October 6, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02290392||33006|
NCT02280356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-193|Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer|Ultra-hypofractionated, Image-guided, Intensity-modulated Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280356||33777|
NCT02280369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140749|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2014|||||N/A|N/A|N/A||||||||||||||December 8, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280369||33776|
NCT02274012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM5905|Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment|Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer||Columbia University|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274012||34265|
NCT02274090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/10B/2013-14|1% Metformin in Moderate and Severe Periodontitis|Local Drug Delivery of 1% Metformin Gel in Moderate and Severe Periodontitis Subjects: a Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02274090||34259|
NCT02267447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR FRN - 133550|Cardiovascular Disease Population Risk Tool|Risk of Cardiovascular Disease in Canada and Burden of Health Behaviours: Development of Population-based Risk Algorithms|CVDPoRT|Ottawa Hospital Research Institute|No|Active, not recruiting|September 2000|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130000|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The derivation cohort will be eligible respondents to the combined 2001, 2003 and 2005        Canadian Community Health Surveys, conducted by Statistics Canada. The validation cohort        will consist of respondents to the 2007 and 2009 surveys.|April 2015|April 20, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02267447||34770|
NCT02263313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 14-456 (IRB HKU)|EGO-COMBO Clinical End-point Extension Study Beyond 36 Months|Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent 36-months Clinical End-point Extension Study (EGO-COMBO Clinical End-point Extension Study Beyond 36 Months)||The University of Hong Kong|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|This is a single centre observational study to assess the safety and effectiveness        clinical endpoints of COMBO TM stent beyond 36 months. Clinical notes for all subjects        that previously participated in EGO-COMBO Pilot Study (UW 10-342) will be reviewed for        clinical end points according to the definition of Academic Research Consortium and angina        symptoms will be classified with Canadian Cardiovascular Society Angina Classification.|October 2014|October 7, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02263313||35087|
NCT02264652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00622|High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy|High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy|HD-TDCS|New York University School of Medicine|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|9 Years|65 Years|No|||August 2015|August 3, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02264652||34984|
NCT02264899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/32|MEMENTO-VAScular COmponents of Dementia|MEMENTO-VAScular COmponents of Dementia|VASCOD|University Hospital, Bordeaux|No|Recruiting|November 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|800|||Both|50 Years|N/A|No|||February 2016|March 10, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02264899||34965|
NCT02264912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2008|The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry|The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry|LAPCOR|Faculty Hospital Kralovske Vinohrady|No|Recruiting|July 2008|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients were included in the registry after having signed an informed consent for        participation. No exclusion criterion has been applied for the registry participation.|October 2014|October 14, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02264912|12 Months|34964|
NCT02259270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55785|Acid Suppressive Therapy - Review of Appropriateness|Acid Suppressive Therapy - Review of Appropriateness|ASTRA|Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|August 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|Part 1: All adult patients discharged from the participating hospitals in the period July        2012 - July 2013.        Part 2: Subset of Part 1 - random selection of 600 patients with startup of AST in the        hospital and AST on date of discharge.|August 2014|June 29, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02259270||35398|
NCT02273323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF-BEV-1376|Flow Mediated Dilation in Response to Black Tea|Flow Mediated Dilation in Response to Consumption of Black Tea Versus Artificial Tea, in Non-tea Drinking Hypertensive Subjects.|T|Unilever R&D|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02273323||34318|
NCT02273375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR31|Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC|A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Recruiting|October 2014|||January 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273375||34314|
NCT02259478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8191-CE|Isoagglutinins in the Development of IVIG-associated Hemolysis|Elucidation of the Mechanism of IVIG-Associated Hemolysis||Toronto Transfusion Medicine Collaborative|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood samples will be collected immediately prior and following a course of IVIG      therapy, and then again 5-10 days later|Both|3 Months|N/A|No|Non-Probability Sample|All orders for IVIG received by the UHN Blood Transfusion Service will be reviewed by the        study coordinator to identify potential study participants|November 2015|November 2, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02259478||35382|
NCT02259491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1507|Manuka Honey for Wound Care|Honey Dressings for Local Wound Care of Split Thickness Skin Graft and Free Tissue Transfer Donor Sites: A Prospective, Randomized, Controlled Trial.||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259491||35381|
NCT02264704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Exercise Intensity and Immune Function in Multiple Sclerosis|Exercise Intensity and Immune Function in Multiple Sclerosis||University of the West of Scotland|Yes|Not yet recruiting|November 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|63|||Both|18 Years|60 Years|No|||October 2014|October 8, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02264704||34980|
NCT02271165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13P.192|Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study|||Thomas Jefferson University||Recruiting|November 2014|||October 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271165||34484|
NCT02271243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00012105|Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections|Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections||Children's Hospital Boston|No|Recruiting|November 2014|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Bacteria growing from swab of oral cavity, sputum, skin, stool, and blood; stool and plasma      samples.|Both|N/A|N/A|No|Non-Probability Sample|Children with CLABSI|December 2015|December 14, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02271243||34478|
NCT02271308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030109|The Effects of Low Resistance Training on the Residents in Nursing Homes|The Effects of Low Resistance Training Using Elastic Band on Muscle Strength, Flexibility, Quality of Life and Ease of Care in Nursing Home Residents: A Pilot Study||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|March 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 21, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02271308||34473|
NCT02271321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1021001|The Effects of White Noise on Agitated Behaviors and Cortisol Level in Saliva Among the Patients With Dementia|The Effects of White Noise on Agitated Behaviors and Cortisol in Saliva Among the Patients With Dementia||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|November 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|84|||Both|65 Years|N/A|No|||October 2014|October 21, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02271321||34472|
NCT02271334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A006-CL-D|Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers|Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults)|A006-D|Amphastar Pharmaceuticals, Inc.|Yes|Completed|August 2014|March 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02271334||34471|
NCT02267681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ufuk University|Opioid Effects on Cognitive Function Following Colonoscopy|The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy||Ufuk University|No|Recruiting|October 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02267681||34752|
NCT02267694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRB113728|Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis|A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis|BRB|University of Connecticut Health Center|Yes|Recruiting|August 2013|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||October 2014|October 14, 2014|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267694||34751|
NCT02290470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gineolanzapina|Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel|Olanzapine for the Prevention of Delayed Nausea and Vomiting in Patients With Gynecologic Cancers Receiving Carboplatin and Paclitaxel-based Chemotherapy and Guideline-directed Prophylactic Anti-emetics||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|April 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|81|||Female|18 Years|N/A|No|||November 2014|November 11, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02290470||33000|
NCT02290535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-076|Electrical Impedance Tomography of Lung in Child and Young Age|Electrical Impedance Tomography of Lung in Child and Young Age|EIT-Lunge|RWTH Aachen University|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|192|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients, who come to the consultation to the Department of Pediatric Pneumology, Children        and Adolescent Medicine, University Hospital Aachen, will be recruited and divided into        groups by age and diagnosis. Recriutment will be performed in accordance to the inclusion        and exclusion criteria.|July 2015|July 15, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02290535||32996|
NCT02278692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001961|Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy|Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy|VitK-CUA|Massachusetts General Hospital|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278692||33905|
NCT02267213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC388.4|Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma|An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma||Taiwan Liposome Company|Yes|Recruiting|March 2014|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|20 Years|N/A|No|||September 2014|October 13, 2014|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02267213||34788|
NCT02267460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-807|An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease|A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Active, not recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||October 2015|October 22, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02267460||34769|
NCT02272023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA022857|Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women|Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women||Public Health Institute, California|No|Recruiting|February 2015|August 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02272023||34418|
NCT02274545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 14-004|Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in 50 to 70 Year Olds in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|October 2014|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|March 15, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02274545||34224|
NCT02269644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-305|A P3 Comparator Trial in Community Acquired Bacterial Pneumonia|A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia||Durata Therapeutics Inc., an affiliate of Allergan plc|Yes|Withdrawn|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|No|||January 2016|January 21, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269644||34601|
NCT02269657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011016|AIS Patient Positioning in EOS System®|Patients' Arm Positioning in the EOS® Stereoradiography System: Study the Sagittal Spinal Parameters and Postural Balance in EOS® Full Spine X-rays in Scoliosis||Children's Hospital of Philadelphia|No|Enrolling by invitation|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|10 Years|18 Years|No|||November 2015|November 30, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02269657||34600|
NCT02275195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B663|Immune Cell Dysfunction in Severe Alcoholic Hepatitis|Immune Cell Dysfunction in Severe Alcoholic Hepatitis||Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|November 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood|Both|18 Years|65 Years|No|Non-Probability Sample|Patients attending / being treated at the Basildon Hospital for acute severe alcoholic        hepatitis will be identified as potential participants in these studies|January 2016|January 18, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02275195||34174|
NCT02263833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22560|An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice|Post Marketing Surveillance of Mircera®||Hoffmann-La Roche||Completed|September 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|748|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic renal anemia regardless of pre-dialysis / dialysis in Korea.        Patients who were prescribed Mircera by their physician according to the local Korean        Mircera label, for the treatment of anemia associated with chronic kidney disease who        require erythropoietin-stimulating agent (ESA) therapy could be included in the study.|March 2016|March 1, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02263833||35047|
NCT02265172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN GBG 328-09|Physiotherapy Assessment of Patients Referred to Orthopaedic Surgeon|Does Orthopaedic Manual Therapy Assessment of Patients Referred to Orthopaedic Surgeon Bring Any Changes to Referral Routines, Patient Satisfaction and Health-related Variables?||Vastra Gotaland Region|No|Completed|August 2009|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|208|||Both|18 Years|67 Years|No|||September 2014|October 24, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02265172||34944|
NCT02264197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|537.7|Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects|Single-dose Pharmacokinetics of 160 mg BIBX 245 CL and Effect of Food After Oral Administration of Tablets to Healthy Subjects (Randomized, 2-way-cross-over, Open Study)||Boehringer Ingelheim||Completed|May 1998|||June 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02264197||35019|
NCT02264444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461326|Establishing Visualization Grading Scale on LESS Cholecystectomy|A Grading System for Laparoscopic Visualization and Predicting Factors That Affect Visualization Level During Laparoscopic Cholecystectomies: A Prospective, Single Group, Open Label Study||Florida Hospital Tampa Bay Division|No|Recruiting|September 2013|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02264444||35000|
NCT02265783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0461|Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable|Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable||Medtronic - MITG|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the available Covidien Boulder Clinical Lab subject data        base.        Adults 18 and over will be recruited for testing of any of the devices described within        this protocol. The goal is to have an equitable distribution of female and male subjects        to eliminate the possibility of gender bias and ensure a broad range of finger sizes.        Subjects of all racial and ethnic backgrounds may be included in the studies.|November 2014|November 13, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02265783||34898|
NCT02266303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWestIndies|The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation|The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation: a Randomized Controlled Trial||The University of The West Indies|No|Recruiting|July 2014|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2014|October 16, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266303||34858|
NCT02270749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAALII|Vitamin Deficiencies and Suppletion in Morbid Obesity|Vitamin Deficiencies and Suppletion in Morbid Obesity||Rijnstate Hospital|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Months|65 Years|No|||May 2015|May 6, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02270749||34516|
NCT02259673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920788|Effects of Fun Physical Activity on the Interest to Daily Physical Activity and Sarcopenia of Elderly People|Mashhad University Medical of Sciences||Mashhad University of Medical Sciences|Yes|Recruiting|September 2014|June 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|63|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02259673||35367|
NCT02259686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apelin2014|Cardiovascular Effects of Apelin In Healthy Volunteers|Cardiovascular Effects of Apelin In Healthy Volunteers||University of Edinburgh|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|14|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02259686||35366|
NCT02260193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0011|16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Subjects With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis|Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.||Akebia Therapeutics|No|Completed|September 2014|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|79 Years|No|||November 2015|November 17, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260193||35327|
NCT02260206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colchicine|Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion|Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation||Seoul St. Mary's Hospital|Yes|Recruiting|July 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|N/A|N/A|No|||October 2014|October 8, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02260206||35326|
NCT02260518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD078407|Promoting Health in Pregnancy and Postpartum|Promoting Health in Pregnancy and Postpartum Among Overweight/Obese Women|HIPP|University of South Carolina|No|Recruiting|January 2015|January 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02260518||35302|
NCT02260531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-359|Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases|A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases||Dana-Farber Cancer Institute|Yes|Recruiting|October 2014|February 2022|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260531||35301|
NCT02271490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01376-35|Acrosome Reaction Induction Prior to ICSI|Improvement of the Post ICSI Pregnancy Outcome by Induction of the Acrosome Reaction Prior to ICSI|RA-ICSI|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2014|October 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|620|||Both|18 Years|43 Years|No|||October 2015|October 15, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02271490||34459|
NCT02278146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP-01-2014|Feasibility Study Evaluating the ParaPatch System|A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder||ParaPatch, Inc|No|Active, not recruiting|November 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02278146||33947|
NCT02290600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF KK1413|Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias|Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias||William Sansum Diabetes Center|No|Not yet recruiting|December 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 diabetes|August 2014|November 10, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02290600||32991|
NCT02290613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05ED|Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)|Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA|EDITA|Heidelberg University|No|Recruiting|December 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290613||32990|
NCT02284139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUH-14-211|Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects|Pilot Trial of Epidermal Growth Factor (EGF) Ointment for the Patients With Epidermal Growth Factor Receptor (EGFR) Inhibitor Related Skin Side Effects||Dong-A University Hospital|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|N/A|No|||August 2015|August 4, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284139||33487|
NCT02284425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1193-DM-1402|Study of REGN1193 in Patients With Type 2 Diabetes Mellitus|||Regeneron Pharmaceuticals|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|25 Years|70 Years|No|||January 2016|January 8, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284425||33465|
NCT02269241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF111/303|Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles|A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles||Chemo|No|Recruiting|October 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|995|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 9, 2016|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269241||34632|
NCT02262845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90987979|Short Term Pancreatic Stenting Registry|A Prospective Multi-Center Registry Using Plastic Pancreatic Stents for Short Term Drainage of the Pancreatic Duct||Boston Scientific Corporation|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|This study will examine how well the Advanix Pancreatic stent helps drainage of the        pancreas when used per standard-of-practice in many different situations.|November 2015|November 25, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02262845|6 Weeks|35123|
NCT02262858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.495|Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II|Bioequivalence of 80 mg Telmisartan/12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|August 2005|||October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|October 10, 2014||||No||https://clinicaltrials.gov/show/NCT02262858||35122|
NCT02263040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0909|A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV|A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose Trivalent Inactivated Influenza Vaccine for Healthcare Workers||Mount Sinai Hospital, Canada|No|Active, not recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|170|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|January 13, 2016|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02263040||35108|
NCT02258698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56/13|Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery|Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery||University Hospital, Basel, Switzerland|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|325|Samples Without DNA|blood samples (Serum)|Both|18 Years|N/A|No|Non-Probability Sample|A total of 325 patients admitted to the surgical intensive care unit after elective        on-pump cardiac surgery (Table 1) will be consecutively enrolled. This study population        has been chosen not only because of the clinically relevant stress response to cardiac        surgery but also because of the opportunity to differentiate between the different impacts        of the cardiovascular system and the metabolic state on insulin resistance.|January 2016|January 28, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02258698||35442|
NCT02258711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPPFR02062014|Self-Monitoring and Psychoeducation in Bipolar Patients With a Smart-phone Application|SIgns and Symptoms Self-Monitoring and Psychoeducation in bipoLar Patients With a Smart-phonE Application (SIMPLE)|SIMPLE|Hospital Clinic of Barcelona|Yes|Active, not recruiting|October 2014|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258711||35441|
NCT02275143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/152|Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis|Feasibility of Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis (CT TAP)||Plymouth Hospitals NHS Trust|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|40 Years|N/A|No|Non-Probability Sample|Patients having routine follow up cancer CT TAP scan|October 2015|October 29, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02275143||34178|
NCT02278497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006|Assessment of Coronary Flow Reserve by PET-H215O and FFR. Comparison With Dynamic Acquisition Using CZT Camera|Assessment of Coronary Flow Reserve by PET-H215O and FFR in Patients Suspected of Coroanry Artery Disease. a Comparative Study With Dynamic Acquisition Using CZT Camera and 99mcTc-mibi.|WATERDAY|University Hospital, Caen|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|80 Years|No|||July 2015|July 30, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278497||33920|
NCT02278718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW2012-01-01|A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care|A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment||MediWound Ltd|Yes|Recruiting|November 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|17 Years|No|||January 2016|January 21, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278718||33903|
NCT02289339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MucS001-14|Everyday Practice With Transcatheter Aortic Valve Implantation|Experience With Percutaneous Transcatheter Aortic Valve Implantation in Patients With Symptomatic Aortic Valve Disease in Two German Centers|EVERY-TAVI|Klinikum der Universitaet Muenchen|No|Recruiting|November 2007|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1200|||Both|N/A|N/A|No|Non-Probability Sample|patients with aortic valve stenosis suitable for transfemoral transcatheter aortic valve        implanation|March 2016|March 16, 2016|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02289339||33087|
NCT02289456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-NSCL-004|Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2|A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)|AboundPS2|Celgene Corporation|Yes|Recruiting|April 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289456||33078|
NCT02289469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44MD004048-04|PictureRx: Improving Medication Safety in Health Disparity Populations|PictureRx: Improving Medication Safety in Health Disparity Populations||PictureRx, LLC|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289469||33077|
NCT02287155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZHAW-F&E-Ergo|Occupation Based Health-Promotion Program for People Aged Over 60: "Bliib Gsund"|Occupation Based Health-Promotion Program for People Aged Over 60: "Bliib Gsund"|bg60|Zurich University of Applied Sciences|No|Not yet recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|16|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 5, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02287155||33255|
NCT02289612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14AP003|Glycemic and Satiety Response Study of Fibre-Enriched Pudding Products|The Pudding Study: The Effect of Effect of Fibre-enriched Pudding Products on Glycemic and Satiety Response in Adults at Risk for Type 2 Diabetes|Pudding|University of Guelph|No|Recruiting|November 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|10||Anticipated|15|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02289612||33066|
NCT02279524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aramchol005|A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH|A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study|Aramchol_005|Galmed Pharmaceuticals Ltd|Yes|Recruiting|January 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|No|||October 2015|November 1, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279524||33841|
NCT02279784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo013|Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix|||Ospedale San Donato|No|Recruiting|October 2014|October 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279784||33821|
NCT02291666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 14.066|Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects|Effects of Type 2 Diabetes on CYP450s Activities; Intersubject Variability in Drug Metabolism.||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|November 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|126|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|November 11, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02291666||32909|
NCT02283398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE-TAVI|Cardioprotective Effect of RIPC in Patients Undergoing TAVI|The CARE-TAVI Study: Cardioprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation|CARE-TAVI|Institut für Pharmakologie und Präventive Medizin|No|Withdrawn|November 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|0|||Both|N/A|N/A|No|||September 2015|September 24, 2015|November 3, 2014||No|administrative issues|No||https://clinicaltrials.gov/show/NCT02283398||33544|
NCT02291757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESM-CLN#2013T01 REV00|Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Knee Osteoarthiritis With Joint Pain and Stiffness|Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Knee Osteo Arthiritis With Joint Pain and Stiffness. A Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study||Generica Pharmaceuticals|Yes|Recruiting|October 2013|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|40 Years|N/A|No|||November 2014|November 11, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02291757||32902|
NCT02291770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.GRDEC 2014210H|Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells|Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China.|MSC-cGvHD|Guangdong General Hospital|Yes|Recruiting|October 2014|December 2019|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|14 Years|65 Years|No|||November 2014|November 11, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02291770||32901|
NCT02335853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/11/02|Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder|Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder|NGF|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|90|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|women with overactive bladder|January 2015|January 9, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02335853||29518|
NCT02293018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL14001|Pharmacokinetic Study of MTC896 Gel in Subjects With Acne|A Randomized, Single-Blind, Phase 2 Study to Determine the Safety, Tolerability, and Systemic Exposure of 3 Dose Regimens of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris||Mimetica Pty Limited|Yes|Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|32|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293018||32805|
NCT02293031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-NextGen-20-01-2013|Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery|Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration||NextGen Company Limited|No|Enrolling by invitation|November 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|No|||March 2016|March 21, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02293031||32804|
NCT02276807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-047|Improving Mood in Veterans in Primary Care|RCT of Behavioral Activation for Depression and Suicidality in Primary Care||VA Office of Research and Development|Yes|Recruiting|March 2015|October 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02276807||34050|
NCT02277067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 7|Carbetocin Versus Misoprostol in High Risk Patients for Postpartum Hemorrhage After C.S.|Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S.|PPH|Beni-Suef University|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|25 Years|40 Years|No|||December 2015|December 26, 2015|October 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277067||34030|
NCT02284958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-218|Walking Away From Back Pain, One Step at a Time|A Single-centre, Randomized Controlled Trial Investigating Clinical Utility and Cost-effectiveness of an Individualized Pedometer Driven Walking Programme for People With Chronic Low Back Pain||University of Saskatchewan|No|Recruiting|April 2015|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02284958||33424|
NCT02292849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307014080|Peer to Peer Delivery of Behavioral Activation|Peer to Peer Delivery of Behavioral Activation||Weill Medical College of Cornell University|Yes|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292849||32818|
NCT02285426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL5012109114|HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study|A Multicenter Study Evaluating the Diagnostic Value for Vascular Abnormalities of High Definition Bronchoscopy When Combined With I-scan Imaging Technology Compared to High Defintion Bronchoscopy Alone|i-scan|Radboud University|No|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|biopsy of sites with abnormal or suspicious vascular patterns|Both|18 Years|90 Years|No|Probability Sample|Patients with suspected or proven lung cancer are eligible if there is an indication for        bronchoscopy. Eligible are patients with ASA physical status 1-3 and aged 18 years or        older.|February 2016|February 22, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285426||33388|
NCT02285673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD-UC-MSC-1|Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy|Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy: Phase 1/2 Study||Acibadem University|No|Recruiting|November 2013|November 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|7 Years|20 Years|No|||November 2014|November 6, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285673||33369|
NCT02286765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-126|Ulthera® System for Treating Axillary Hyperhidrosis|Optimization of the Ulthera® System for Treating Axillary Hyperhidrosis||Ulthera, Inc|No|Recruiting|October 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286765||33285|
NCT02286778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN9892131B|Eradication of Malignant Carcinoma in the Breast Tissue|The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor||Optimal Health Research|Yes|Enrolling by invitation|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|35 Years|75 Years|No|||February 2016|February 22, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286778||33284|
NCT02283060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H027|Sleep and Cognition After Atripla to Stribild Switch|Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild.||University of Hawaii|No|Recruiting|September 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02283060||33570|
NCT02283567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0152-14-MMC|The Difference Between Elasticity of the Uterine Cervix in Singleton and Twin Pregnancies|The Difference Between Elasticity of the Uterine Cervix in Singleton and Twin Pregnancies|DEU|Meir Medical Center|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|20 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|20-44 years old pregnant patients|September 2015|September 22, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283567||33531|
NCT02278731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1162-4778|Exercise Protocols in Postural Balance Of Elderly Women|EFFECTS OF TWO EXERCISE PROTOCOLS IN POSTURAL BALANCE OF ELDERLY WOMEN||Universidade Estadual do PiauÍ|Yes|Completed|May 2014|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02278731||33902|
NCT02278744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-054|Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery|A Phase I Dose Escalation Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278744||33901|
NCT02289547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCGA1 Trial|Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer|Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma||The Catholic University of Korea|No|Recruiting|May 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02289547||33071|
NCT02279264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM-2014-001|Product Validation Study of RightSpot Infant pH Indicator for Rapid Bedside Verification of Proper Nasogastric (NG) Tube Placement in Newborn Intensive Care (NICU) Patients|Product Validation Study of RightSpot Infant pH Indicator for Rapid Bedside Verification of Proper Nasogastric (NG) Tube Placement in Newborn Intensive Care (NICU) Patients||RightBio Metrics|Yes|Recruiting|September 2014|||November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|24 Weeks|40 Weeks|No|Probability Sample|Infants in the Newborn Intensive Care Unit with an NG Tube|October 2014|October 28, 2014|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279264||33861|
NCT02284451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR014782-01A1|Facilitating HIV/AIDS and HIV Testing Literacy for Emergency Department Patients|Facilitating HIV/AIDS and HIV Testing Literacy for Emergency Department Patients||Rhode Island Hospital|Yes|Enrolling by invitation|February 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|1200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2014|June 9, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02284451||33463|
NCT02292797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29104|Assessment of the Rosacea Prevalence in the General Population|Assessment of the Prevalence of Rosacea in the General Population|RISE|Galderma|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6000|||Both|18 Years|65 Years|No|Probability Sample|Part I:        Subjects will be screened from the general population by questionnaires mainly focusing on        detection of signs and symptoms of rosacea.        Subjects' answers will be submitted to a pre-defined algorithm to identify the potential        subjects with rosacea (screened positive for rosacea, Screened R+).        Part II:        A subgroup of subjects (100 maximum per country) will be randomly selected among those who        screened positive for rosacea and will be referred to the closest investigational site        (dermatologist practice).|November 2014|November 14, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02292797||32822|
NCT02291705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USG12|Ultrasound-guided Rectus Sheath Block In Children|||Cukurova University|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|2 Years|7 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291705||32906|
NCT02291718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048275|Thoracoabdominal Arortic CTA Study|Comparison of High Iodine Concentration Contrast Material (Isovue 370) vs Standard Protocol (Isovue 300) in Thoracoabdominal Aortic Computed Tomographic Angiography (CTA) for Radiation Dose Reduction||Duke University|No|Completed|January 2014|||September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291718||32905|
NCT02276677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPID 1127|Oxytocin Effects on Food Motivation Pathways|Oxytocin Effects on Food Motivation Pathways||Massachusetts General Hospital|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276677||34060|
NCT02338258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141107002514086|The Study of the Nonunion of Long Tubular Bone|The Prospective、Randomized、Comparative Clinical Study About the Two Operation Methods Between Anti-rotational Plate Group and Exchanged Intramedullary Nailgroup to Treat the Nonunion of Long Tubular Bone After Intramedullary Nail Fixation||Beijing Jishuitan Hospital|Yes|Recruiting|June 2014|June 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 11, 2015|December 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338258||29333|
NCT02338271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMSC-DD-Han|Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration|Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration||Bundang CHA Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2015|January 13, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338271||29332|
NCT02276560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1407|Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC|Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)|LCCC1407|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|January 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276560||34069|
NCT02284698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aravind-RES2013064CLI|Corneal Ulcer Prevention Through Health Education|Corneal Ulcer Prevention Through Health Education|CUP|Aravind Eye Care System|No|Not yet recruiting|December 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|98207|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|42 villages eligible for the study will comprise a total population of 98,207|November 2014|November 5, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284698||33444|
NCT02292823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-13|MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction|e-MASTER Registry: MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction|e-MASTER|InspireMD|Yes|Terminated|April 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing primary revascularization for STEMI and who are intended to undergo        primary PCI with the MGuard™ Prime Embolic Protection Stent System.|August 2015|August 31, 2015|November 13, 2014||No|Enrolment rate|No||https://clinicaltrials.gov/show/NCT02292823|12 Months|32820|
NCT02277353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05-090-003|Evaluation of SVV From NICOM as a Predictor of Fluid Responsiveness in Prone Position During Spine Surgery|Evaluation of Stroke Volume Variation Derived From NICOM as a Predictor of Fluid Responsiveness in Prone Position During Spine Surgery||Samsung Medical Center|Yes|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|20 Years|80 Years|No|Probability Sample|Patients undergoing spine surgery under general anesthesia in prone position|July 2015|July 20, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02277353||34008|
NCT02277366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lungcancer screening|Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population|A Multi-center Randomized Control Study of Bronchoscopy in Early Lung Cancer Screening of High Risk Population||Tang-Du Hospital|Yes|Terminated|May 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|75 Years|No|Non-Probability Sample|All the patients recruited in the study should meet one item as follows.          -  Patient is over 40 years in age and is a heavy cigarette smoker.(smoking index is             over 400.)          -  Patient has been coughing irritably for 2-3 weeks with a failed treatment and without             obvious causes.          -  The nature of cough changes in a patient who has chronic respiratory disease.          -  Patient has blood-stained sputum persistently or repeatedly without obvious causes.|November 2015|November 13, 2015|October 21, 2014|Yes|Yes|We have recruited some patients, but we haven't found any significant result by bronchoscopy    in the high risk population.|No||https://clinicaltrials.gov/show/NCT02277366||34007|
NCT02289079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305m34041|TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy|Ultrasound Guided Subcostal Transversus Abdominis Plane (TAP) Block With Liposomal Bupivacaine vs Bupivacaine in Robotic Hysterectomy Patients: A Prospective Randomized Study.||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 30, 2014|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT02289079||33107|
NCT02289092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05142014.022|The Positive Family Support Project - Partnering With Families for a Successful Transition to School|Testing the Efficacy of an Ecological Approach to Family Intervention and Treatment During Early Elementary School to Prevent Problem Behavior and Improve Academic Outcomes||University of Oregon|No|Recruiting|September 2014|January 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2100|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02289092||33106|
NCT02289131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 00016479|Frequency of Oral Care Intervention Study|Oral Care Intervention In Mechanically Ventilated Adults: Renewal|FOCIS|University of South Florida|No|Recruiting|December 2014|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|345|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02289131||33103|
NCT02289183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Prospective Study on Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery for Distal Gastric Cancer|Prospective Randomized Controlled Trial on Clinical Application Value of Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery and Billroth-I Anastomosis in Laparoscopy-assisted Surgery for Distal Gastric Cancer|MDSG|Fujian Medical University|Yes|Active, not recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02289183||33099|
NCT02290145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDSCAN2014|Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage|Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|December 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||November 2014|November 8, 2014|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02290145||33025|
NCT02283580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLHR-COPD-2014|Low Load, High-repetitive Elastic Band Resistance Training in COPD|Intramuscular and Functional Effects and Mechanism of Partitioning the Exercising Muscle Mass in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Laval University|No|Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|43|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283580||33530|
NCT02278978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201306022MIPB|BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma|A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-based Chemotherapy||National Taiwan University Hospital|Yes|Active, not recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|129|||Both|20 Years|N/A|No|||May 2015|May 10, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278978||33883|
NCT02278991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0022-01|Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries|A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries||C. R. Bard|No|Recruiting|October 2014|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|149|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital Patients|November 2015|November 23, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278991||33882|
NCT02284165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044034|Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke|Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke||Duke University|No|Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|275711|||Both|N/A|N/A|No|Non-Probability Sample|Patients hospitalized for acute ischemic stroke in 2006-2008, and successfully linked to        Medicare claims available through 2009|September 2015|September 8, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284165||33485|
NCT02289209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1456GCC, HP-00061458|Reirradiation With MK-3475 (Pembrolizumab) in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck|A Phase II Trial of Reirradiation Combined With Open Label MK-3475 in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)||University of Maryland|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289209||33097|
NCT02279901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaiserPermanente|Impact of Automated Education and Follow-up Mechanisms on Patient Engagement|Impact of Interactive Web-Based Education and Interactive Voice Response (Automated Follow-up) Programs on CPAP Adherence for the Treatment of Obstructive Sleep Apnea|EmmiUSleep|Kaiser Permanente|No|Active, not recruiting|November 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1000|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279901||33812|
NCT02276417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400611|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care|PICS|University of Florida|Yes|Recruiting|January 2015|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02276417||34080|
NCT02280447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPV-04|3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as a Booster Vaccination to Adolescents|Safety and Immunogenicity of 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, Given as a Booster Vaccination to Adolescents With a History of IPV Vaccination at 3, 5, 12 Months and 5 Years of Age||Statens Serum Institut|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|240|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280447||33770|
NCT02280655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015316A|Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)|Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis|INOBA|Emory University|Yes|Completed|April 2009|October 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||November 2014|November 26, 2014|October 29, 2014|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT02280655||33754|Only patients receiving routine transfusions were included in the study, thus excluding critically ill/actively bleeding patients requiring emergent transfusions.
NCT02292784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200722|Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies|Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies|ARIOS|GlaxoSmithKline|Yes|Recruiting|June 2015|March 2024|Anticipated|March 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|2100|||Both|10 Weeks|20 Weeks|No|||March 2016|March 17, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292784||32823|
NCT02277106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-ETD-201|Evaluate SAGE-547 in Patients With Essential Tremor|A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor||Sage Therapeutics|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|35 Years|75 Years|No|||January 2016|January 21, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277106||34027|
NCT02277119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maestro2|Clinical Study of the Optic Disc Parameters|Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue||Topcon Medical Systems, Inc.|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02277119||34026|
NCT02282033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-01|Safety and Performance Study of the Moderato System|Clinical Evaluation of Safety and Performance of the BackBeat Moderato System||BackBeat Medical Inc|Yes|Active, not recruiting|April 2013|May 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02282033||33649|
NCT02282046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE023518|Diabetes Effects on Long-Term Implant Survival and Success|Diabetes Effects on Long-Term Implant Survival and Success||The University of Texas Health Science Center at San Antonio|No|Recruiting|May 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will include those edentulous patients benefiting from mandibular implant        overdenture support. It may include those already being followed in a similar study or        patients newly receiving dental implants. It will also include type 2 diabetes patients        who received dental implant therapy as part of a previous study on the impact of glycemic        control.|December 2015|December 2, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02282046||33648|
NCT02277665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028307|Clinical Trial Tobacco Marijuana|Randomized Trial Evaluating Treatment for Cannabis Use Disorders Among Those Who Use Tobacco|RCTTM|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|December 2014|November 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277665||33984|
NCT02277912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH2013311|Efficacy of Transcranial Magnetic Stimulation (TMS) in Central Post Stroke Pain ( CPSP)|Efficacy of Navigated Repetitive Transcranial Magnetic Stimulation in Treatment of Central Post Stroke Pain||Helsinki University Central Hospital|No|Enrolling by invitation|June 2013|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277912||33965|
NCT02278172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC14.0087|The Effects of Vitamin D Supplementation on Aerobic Fitness in Athletes|The Effects of Vitamin D Supplementation on VO2max in Athletes: a Randomised, Double-blind, Placebo-controlled Trial|VDAF|University of Ulster||Active, not recruiting|October 2014|||April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278172||33945|
NCT02278484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2827-001|Sinus Balloon Dilation in Pediatric Patients|XprESS Device and PathAssist Confirmation Tools in Pediatric Patients-Expanded Indication Study||Entellus Medical, Inc.|No|Active, not recruiting|September 2014|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|21 Years|No|||July 2015|July 28, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278484||33921|
NCT02279004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-147|A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care|A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care||Dana-Farber Cancer Institute|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|540|Samples With DNA|Cell-free plasma DNA (cfDNA) derived from tumor cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients with NSCLC and advanced melanoma that are either newly diagnosed, have acquired        resistance to kinase inhibitor therapy or have a known targetable mutation and are        beginning a new line of therapy.|January 2016|January 19, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279004||33881|
NCT02279017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057562|mHealth Messages to Sustain Recent Weight Loss - Phase 2|Mobile Health Messages to Sustain Recent Weight Loss - Phase 2||Duke University|No|Active, not recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|100 Years|No|||March 2016|March 16, 2016|October 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279017||33880|
NCT02283892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0198|Respiratory Complaints Checklist Trial|Randomized Clinical Trial of the Impact of a Respiratory Complaints Assessment Checklist on Resources Utilization and Clinical Outcomes in an Acute Evaluation Outpatient Clinic|RCC|Hospital de Clinicas de Porto Alegre|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283892||33506|
NCT02289144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082014-029|Ceritinib (LDK378) in Mutation,Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer|Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|October 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289144||33102|
NCT02289196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vx-006-101|Safety Study of Vx006 Vaccine in Solid Tumor Patients|A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg and 5mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours||Vaxon Biotech|No|Active, not recruiting|March 2014|December 2014|Anticipated|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||November 2014|December 15, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02289196||33098|
NCT02335047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5898|Investigation of the Putative Correlation Between Involuntary Psoas Activity During Passive Flexion of the Trunk at the Hips|The Putative Correlation Between Impaired Hip Flexor Passivity and Common Lower Back Pain: a Pilot Study.||University Hospital, Strasbourg, France|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|90|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02335047||29579|
NCT02335060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402013406|N-acetylcysteine Effects on Tetrahydrocannabinol|Effect of N-acetylcysteine on the Acute Cognitive Effects of Delta-9-Tetrahydrocannabinol||Yale University|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335060||29578|
NCT02280174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS000586|Effect of Linagliptin on TRL Metabolism|Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients||Ministry of Public Health, Argentina|Yes|Recruiting|September 2014|October 2016|Anticipated|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|40 Years|60 Years|No|||November 2014|November 3, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02280174||33791|
NCT02335593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHCL394|Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients|Evaluation of the Effect of Zinc Supplementation on the Health Status of Hemodialysis Patients||Ain Shams University|No|Recruiting|December 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2015|January 9, 2015|December 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335593||29538|
NCT02338219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1159-6256|Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women|Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women||Al-Azhar University|Yes|Completed|May 2013|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|120|||Female|N/A|N/A|No|||January 2015|January 11, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02338219||29336|
NCT02328391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGC-ERL-2012-01|STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE|MULTICENTER, PROSPECTIVE, OBSERVATIONAL OF ERLOTINIB AS SECOND-LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL (NSCLC) LUNG CANCER WITH PREDOMINANTLY SQUAMOUS HISTOLOGY AND CARRIERS OF THE GENE (EGFR) EPIDERMAL GROWTH FACTOR RECEPTOR NATIVE|GGCP 055/12|Grupo Gallego de Cancer de Pulmon|Yes|Recruiting|September 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|51|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with diagnosis of NSCLC with predominantly squamous histology. The subject        shall be considered included in the study when, fulfilling the criteria of selection,        accept their participation therein by the signing of informed consent.|September 2014|December 30, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02328391|8 Months|30090|
NCT02284438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMI-ETT|Biofilm Formation on Different Endotracheal Tube Materials|Innovation Against Infection - Device Related Infections - Part ETT||Region Skane|No|Recruiting|April 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02284438||33464|
NCT02276820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H35136 Viralym-A|Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)|A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)||ViraCyte|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||February 2016|February 5, 2016|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276820||34049|
NCT02277093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412087|Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer|Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer||Washington University School of Medicine|No|Active, not recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277093||34028|
NCT02281799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thiopurine_Pancreatitis|Thiopurine Induced Pancreatitis in IBD Patients|Thiopurine Induced Pancreatitis in IBD Patients||Shaare Zedek Medical Center|No|Recruiting|March 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|60 Years|No|||October 2014|June 9, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02281799||33667|
NCT02287610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-PRE-NIS02|A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis|A Non-Interventional Study to Evaluate the Effectiveness of Delayed-Release Prednisone (RAYOS) on Clinical Assessments and Serologic Disease Activity in Patients With Active Rheumatoid Arthritis in the Clinical Practice Setting|SUNRAY|Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|Adult males and females with moderately to severely active disease who have previously        received immediate-release prednisone (conventional) therapy, and prior to enrolling the        SUNRAY Study, have made the joint decision (with their physicians) to convert to        delayed-release prednisone (RAYOS).|March 2016|March 18, 2016|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287610||33220|
NCT02282293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMOTE-BC2|Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)|Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)||University of California, San Francisco|Yes|Active, not recruiting|December 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|16 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282293||33629|
NCT02282553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18317|Gastric Capsule Examination for Iron Deficiency Anaemia|Diagnosis of Upper Gastrointestinal Pathology in Patients With Recurrent/Refractory Iron Deficiency Anaemia: Magnetically Steerable Gastric Capsule Endoscopy Versus Conventional Gastroscopy.||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|20 Years|N/A|No|||January 2016|January 29, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02282553||33609|
NCT02282813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-3003|Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002|A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)||OPKO Health, Inc.|No|Completed|April 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|298|||Both|18 Years|N/A|No|||April 2015|October 9, 2015|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282813||33589|
NCT02282826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU13475|A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis||Sanofi|No|Active, not recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|44|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282826||33588|
NCT02289157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042014-047|Negative Pressure Wound Therapy in Cesarean Section|Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean|NPWTCS|University of Texas Southwestern Medical Center|No|Recruiting|January 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|440|||Female|10 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289157||33101|
NCT02289222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC1454|Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma|Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma||University of Maryland|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289222||33096|
NCT02289040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE0463|Acute Kidney Injury Following Paediatric Cardiac Surgery|A Feasibility Study to Consider the Role of Microvesicles (MV) and MV Derived microRNA (miRNA) in Acute Kidney Injury (AKI) Following Paediatric Cardiac Surgery: p-MiVAKI Study|p-MiVAKI|University of Leicester|Yes|Active, not recruiting|October 2014|September 2015|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|24|Samples With DNA|-  serum        -  EDTA plasma        -  citrated blood        -  hirudin blood        -  urine|Both|N/A|17 Years|No|Probability Sample|Children undergoing cardiac surgery in a tertiary academic cardiac surgery unit|November 2014|June 3, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02289040||33110|
NCT02289105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818456|Impact of Active Choice on Advance Directive Completion Rates|The Impact of Active Choice on Completion Rates of Advanced Directives in New Employees of an Academic University Hospital||University of Pennsylvania|No|Completed|November 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1279|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02289105||33105|
NCT02279810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAPtransplant2014|Attitudes About Organ Transplantation|Knowledge, Attitude and Practice About Organ Transplantation Among Medical Students and Medical Staff|KAPsurvey|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff: medical doctors, nurses, paramedics Medical students: PhD students,        medicine students, nursing and paramedics studies|October 2014|October 29, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02279810||33819|
NCT02279823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171-7152-201|A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia|A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)||Intrepid Therapeutics, Inc.|No|Active, not recruiting|October 2014|April 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Male|18 Years|50 Years|No|||March 2016|March 10, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279823||33818|
NCT02292641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4115|The Role of MRI in Improving Surgical Technique and Outcomes in Exenterative Pelvic Surgery for Locally Extensive Primary or Recurrent Rectal Cancer|The Role of MRI in Improving Surgical Technique and Outcomes in Exenterative Pelvic Surgery for Locally Extensive Primary or Recurrent Rectal Cancer.|Beyond TME|Royal Marsden NHS Foundation Trust|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||May 2014|November 12, 2014|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02292641||32834|
NCT02292654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI13803|Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency|A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency|ASCEND-Peds|Sanofi|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|17 Years|No|||February 2016|February 23, 2016|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292654||32833|
NCT02337478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22214|Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|May 2015|||May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337478||29393|
NCT02337699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-SMI-2014|Dorsal Root Ganglion Stimulation as Treatment for Post-surgical Groin Pain|DORSAL ROOT GANGLION STIMULATION AS TREATMENT FOR POSTSURGICAL GROIN PAIN (GASPA Study)|GASPA|St. Jude Medical|No|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Male|18 Years|18 Years|No|Non-Probability Sample|Chronic Post Surgical Groin Pain Patients|December 2015|December 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337699||29376|
NCT02335333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSDX-1501|Biomarkers of Aging as Predictors of Kidney Transplant Function|Clinical Utility of Biomarkers of Aging as Predictors of Kidney Graft Function in Extended Criteria Organ Recipients||HealthSpan Dx|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|T lymphocytes, plasma and white blood cells isolated from peripheral blood sample will be      stored.|Both|18 Years|N/A|No|Non-Probability Sample|Renal Transplant Recipients at UNC Hospitals who received a single organ from a deceased        donor (ECD, DCD, or SCD).|March 2016|March 6, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335333||29557|
NCT02338232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro5465|Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation|Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation||Hackensack University Medical Center|Yes|Not yet recruiting|August 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02338232||29335|
NCT02292199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPERTENSIONTENS|Transcutaneous Electrical Nerve Stimulation on Nervous System in Patients With Hypertension.|Effects of Transcutaneous Electrical Nerve Stimulation on Sympathetic and Parasympathetic Nervous System in Patients With Hypertension: a Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Recruiting|August 2014|August 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292199||32868|
NCT02292212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVID|Clinical Study of Asahi ViE Dialyzer in Canada|Clinical Study of Asahi ViE Dialyzer in Canada (AVID)|AVID|Asahi Kasei Medical Co., Ltd.|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02292212||32867|
NCT02276573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-02|Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus|Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus|LICHENVIR|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2015|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|October 23, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02276573||34068|
NCT02281513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 69201|Activity and Nutrition Trial in Lupus to Energize and Renew|Activity and Nutrition Trial in Lupus to Energize and Renew|ANTLER|Northwestern University|No|Active, not recruiting|October 2014|December 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02281513||33688|
NCT02281526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-111|An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093|An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Moderate Hepatic Impairment.||Bial - Portela C S.A.|No|Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|October 30, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02281526||33687|
NCT02287363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTian|Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis|Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis:an Observational Study of Sichuan Individuals in China.||West China Hospital|Yes|Active, not recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|We intend to draw a 3-5mL whole blood from each participant and extract their genome DNA for      genetic analysis.|Male|20 Years|60 Years|No|Non-Probability Sample|Chinese han population within Sichuan province who is diagnosed with TPP.|November 2014|November 7, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02287363||33239|
NCT02287376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0076|Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)||Depomed||Completed|January 2015|||February 2016|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|17 Years|No|||March 2016|March 9, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287376||33238|
NCT02287831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13ZCZDSY02200|Umbilical Cord Mesenchymal Stem Cells Injection for Diabetes Secondary Peripheral Arterial Disease|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Diabetes Secondary Peripheral Arterial Disease||Institute of Hematology & Blood Diseases Hospital|No|Enrolling by invitation|February 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02287831||33203|
NCT02291380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HengLi003|A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine|A Multi-center, Randomized, Double-blind, Placebo Parallel-Controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection (HengLi ®) for Prophylactic Treatment of Chronic Migraine in Adults||Lanzhou Institute of Biological Products Co., Ltd|Yes|Enrolling by invitation|September 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|65 Years|No|||November 2014|December 24, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291380||32931|
NCT02291419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAZ-2014|Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery|An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events|INTREPID|The Cleveland Clinic|Yes|Recruiting|July 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291419||32928|
NCT02289391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexmedetomidine-14115|Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia|Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia-single Center,Randomized,Double-blind，Controlled Trial||Second Affiliated Hospital of Xi'an Jiaotong University|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|65 Years|No|||November 2014|November 10, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289391||33083|
NCT02289404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-1203-FE|Evaluate the Food Effect on the Pharmacokinetics of NVP-1203|Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 in Healthy Male Volunteers|NVP-1203|Navipharm Corporation|Yes|Suspended|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 9, 2014||No|Due to operational reasons|No||https://clinicaltrials.gov/show/NCT02289404||33082|
NCT02290223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-14-1928-H|Patient Activation to Address Chronic Pain and Opioid Management in Primary Care|Patient Activation to Address Chronic Pain and Opioid Management in Primary Care||Kaiser Permanente|Yes|Recruiting|June 2015|October 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|432|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02290223||33019|
NCT02290236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Post ICU Sat|Monitored Saturation Post-ICU|Monitored Saturation Post-ICU; Correlation to Charted Saturation, Pre-intensive Care Unit Obstructive Sleep Apnea and Outcome||Karolinska University Hospital|No|Enrolling by invitation|September 2014|June 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are discharged from the intensive care unit|December 2015|December 15, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02290236||33018|
NCT02292615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402075MIND|Application of Integrated MR-PET in Patients With Gynecologic Cancers|||National Taiwan University Hospital||Recruiting|April 2014|||April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|220|||Female|20 Years|90 Years|No|Non-Probability Sample|patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and        ovarian cancers) and patients with suspicious recurrent gynecologic cancers will be        enrolled. The study period is two years and the estimated patient number is about 220.|November 2014|November 12, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292615||32836|
NCT02292628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMAd/InFe/2011|Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence|Study Phase I/II, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Active, not recruiting|October 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02292628||32835|
NCT02289950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-011|A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer||Morphotek|Yes|Recruiting|March 2015|August 2019|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289950||33040|
NCT02290080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETO2X-biomarkers 2012/287-12|Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers|Determination of the Role of Oxygen on Mechanisms Involved in Ischemia-reperfusion Injury in Suspected Acute Myocardial Infarction by Biomarkers. A Sub Study to the DETO2X-AMI Trial.|DETO2X-bio|Karolinska Institutet|No|Active, not recruiting|October 2014|September 2017|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|30 Years|N/A|No|||January 2016|January 25, 2016|November 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290080||33030|
NCT02290158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACAZA1|Effects of a Finishing Protocol Implementation in Orthodontic Patients|Effects of a Finishing Protocol Implementation on the American Board of Orthodontics - Objective Grading System Score in Patients of Orthodontic Postgraduate Program: A Quasiexperimental Clinical Trial||Universidad de Antioquia|No|Completed|June 2013|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||November 2014|December 7, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02290158||33024|
NCT02327923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IERB/284/014|Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy|Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy: a Randomized Clinical Trial||B.P. Koirala Institute of Health Sciences|Yes|Completed|July 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|60 Years|No|||February 2016|February 24, 2016|October 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327923||30126|
NCT02327936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOXY2014|Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children|Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.|FOXY|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Enrolling by invitation|December 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|5 Years|14 Years|No|||January 2016|January 27, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02327936||30125|
NCT02337959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6K9740|Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors|Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors||Carestream Health, Inc.|No|Active, not recruiting|January 2015|March 2015|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will consist of pediatric and adult cadaver, and adult live human subject        double-exposed images. These captures will be used to confirm diagnostic image quality as        compared to the cleared predicate device.|January 2015|March 3, 2015|January 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337959||29356|
NCT02338206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP112015|Long Protocol in Poor Responders|Can the Addition of Growth Hormone to the Long Down Regulation Protocol Improve the Outcome of In Vitro Fertilization Cycles in Poor Responders?||Woman's Health University Hospital, Egypt|Yes|Recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|20 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 30, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02338206||29337|
NCT02332317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pal-Rehab|Early, Integrated, Specialized Palliative Rehabilitation|A Randomized, Controlled Phase III Study of Integrated, Specialized Palliative Rehabilitation for Patients With Newly Diagnosed Non-resectable Cancer.||Vejle Hospital|Yes|Recruiting|November 2014|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332317||29789|
NCT02276313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1211|BIOLUX P-III All-Comers Passeo-18 Lux Registry|BIOTRONIK - A Prospective, International, Mulit-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries - III||Biotronik AG|No|Recruiting|October 2014|October 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects from an all-comers patient population with all subjects requiring infrainguinal        revascularization with the Passeo-18 Lux DRB.|January 2016|January 26, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276313||34088|
NCT02281188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registry UTUC|Registry for Treatment of Upper Urinary Tract Tumours|Registry for Treatment of Upper Urinary Tract Tumours; A Multi-Center, International Registry to Evaluate the Treatment of Upper Tract Urothelial Cancer: Incidence, Indications, Treatment Types and Outcomes.||Clinical Research Office of the Endourological Society|No|Recruiting|November 2014|December 2024|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|100 Years|No|Probability Sample|The study population comprises those patients presenting with (a) (suspected) primary UUT        tumour(s) and are planned to undergo either nephroureterectomy, ureteroscopic diagnostics        and/or ureteroscopic treatment, percutaneous treatment or adjuvant treatment in the        participating centers.|October 2015|October 19, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02281188|10 Years|33713|
NCT02281201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_3004|Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects|An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure||CSL Behring||Active, not recruiting|October 2014|March 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|N/A|No|||February 2016|February 19, 2016|October 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02281201||33712|
NCT02287168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GastCancPerLav2014|Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients|Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients||Bezmialem Vakif University|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||December 2014|December 26, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02287168||33254|
NCT02289768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98605101-1401|Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses|Multicentre, Randomized, Parallel, Double-Blind, Vehicle Controlled Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In The Field-Directed Treatment Of Actinic Keratoses Grade I To II (Field Cancerization)||Almirall, S.A.|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|85 Years|No|||October 2015|October 1, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289768||33054|
NCT02277379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCZG8.1-14/62-2|Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery|Prediction of Bleeding Outcomes / Transfusion Requirements and Assessment of Perioperative Changes in Platelet Reactivity Using Point-of-care Platelet Function Testing in Patients Undergoing Cardiac Surgery||University of Zagreb|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing elective cardiac surgery procedures will be consecutively        enrolled.|January 2015|January 8, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277379||34006|
NCT02289807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSYCC-2014-11|Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy|Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era||Sun Yat-sen University|Yes|Not yet recruiting|March 2015|March 2020|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|65 Years|No|||November 2014|November 10, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289807||33051|
NCT02289820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4420C00004|A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults|A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults||MedImmune LLC|Yes|Active, not recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|264|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289820||33050|
NCT02289924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17634|Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy|PERSEUS-IT. A Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept (Eylea®) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy|PERSEUS-IT|Bayer|No|Recruiting|January 2015|April 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|wet AMD (wet age-related macular degeneration) patients|March 2016|March 7, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289924||33042|
NCT02289937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2013|Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery|Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery: a Clinical Randomized Trial||Naestved Hospital|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289937||33041|
NCT02290015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP-2010/14804-6|Acupuncture as a Treatment for Tinnitus|Effectiveness of Acupuncture as a Treatment for Tinnitus: a Randomized Controlled Trial Using 99mTc-ECD SPECT||Federal University of São Paulo|Yes|Completed|August 2010|March 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 8, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02290015||33035|
NCT02290067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-V-1203|System Accuracy and User Performance of Blood Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus|EVALUATING SYSTEM ACCURACY AND USER PERFORMANCE OF BLOOD GLUCOSE MONITORING SYSTEMS FOR SELF-TESTING IN MANAGING DIABETES MELLITUS||B. Braun Melsungen AG|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02290067||33031|
NCT02289586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|szkcw-2014-322|Interventional Bronchoscopy Under Noninvasive Ventilation|Interventional Bronchoscopy Under Noninvasive Ventilation for Central Airway Stenosis||Futian People's Hospital|Yes|Recruiting|July 2014|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||August 2014|November 12, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02289586||33068|
NCT02289638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/13|Effectiveness of Child Intubation|First Comparison of the /Intubrite VideoLaryngoscope System Versus the Miller Laryngoscope for Intubations by Non-anaesthetists: a Manikin Study.||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289638||33064|
NCT02279277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Austin2014|Physical Therapy Prior to Total Knee Replacement|Effect of Physical Therapy on Grade 3 or 4 Knee Osteoarthritis||Rothman Institute Orthopaedics|No|Not yet recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02279277||33860|
NCT02279537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17374|Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD|A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept|RAINBOW|Bayer|No|Active, not recruiting|October 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Naïve treatment patients with wet AMD who started a treatment with Anti VEGF (Vascular        Endothelial Growth Factor) may be included in the study|March 2016|March 21, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279537||33840|
NCT02290327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV-06MAR14|Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU||REVISE|McMaster University|No|Completed|May 2015|||January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290327||33011|
NCT02284737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstNanjingMU|Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension|Comparison of Pulmonary Artery Denervation and Medications for Treatment of Pulmonary Arterial Hypertension: a Multicenter, Randomized, Prospective PADN-PAH Trial|PADN-PAH|The First Affiliated Hospital with Nanjing Medical University|Yes|Active, not recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|N/A|No|||July 2015|July 2, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02284737||33441|
NCT02328170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054/2557(EC2)|Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Measured by EUROIMMUN Allergy and ImmunoCap|Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Among Thai Children Measured by EUROIMMUN Allergy and ImmunoCap||Mahidol University|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|235|Samples Without DNA|Clotted blood 3 mL|Both|N/A|15 Years|No|Non-Probability Sample|Patients who was diagnosed as having asthma and/or allergic rhinitis and/or atopic        dermatitis and/or food allergy, were enrolled.|August 2015|August 19, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02328170||30107|
NCT02332070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-096|Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)|Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)|MARCE|Baylor Research Institute|No|Recruiting|January 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1750|||Both|N/A|N/A|No|Non-Probability Sample|Using the Texas Quality Initiative cardiothoracic surgery database, patients who have        recorded one preoperative and at least one baseline and postoperative serum creatinine        (mg/dl).|July 2015|July 27, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332070||29808|
NCT02285712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01143-44|Ultrasound-Guided Peripheral Intravenous Access by Critical Nurses.|Contribution of Ultrasound for Peripheral Intravenous Catheter Placement by Intensive Care Nurses|IDECHO|Central Hospital, Nancy, France|Yes|Recruiting|March 2015|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|114|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285712||33366|
NCT02280928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The graduate school, CMU|Development and Evaluation of a Home-Based Dual-Task Training Program to Improve Balance Performance for Older Adults|Development and Evaluation of a Home-Based Dual-Task Training Program to Improve Balance Performance for Older Adults||Chiang Mai University|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 21, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02280928||33733|
NCT02286986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 70871|Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy|A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With||University of Utah|Yes|Active, not recruiting|September 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|25 Years|No|||January 2016|January 7, 2016|May 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286986||33268|
NCT02277132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-83600-98-20081|The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)|The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)|STRIDER|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|354|||Female|18 Years|50 Years|No|||January 2016|January 7, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02277132||34025|
NCT02282839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCVGH-1047004C|Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation|The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial||Taichung Veterans General Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|20 Years|N/A|No|||November 2015|November 2, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282839||33587|
NCT02277678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/321/D|Comparison of Epidural Oxycodone and Epidural Morphine|Comparison of Epidural Oxycodone and Epidural Morphine for Post Caesarean Section Analgesia: a Randomised Controlled Trial||KK Women's and Children's Hospital|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|21 Years|50 Years|No|||September 2015|September 3, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277678||33983|
NCT02277925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2402|Permanent Versus Absorbable Colpopexy Trial|Permanent Versus Delayed-absorbable Monofilament Suture for Vaginal Graft Attachment During Minimally-invasive Total Hysterectomy and Sacrocolpopexy: A Randomized Clinical Trial|PACT|University of North Carolina, Chapel Hill|Yes|Recruiting|December 2014|December 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277925||33964|
NCT02278185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0909.cc|Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer|An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer||University of Colorado, Denver|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|56|||Male|19 Years|N/A|No|||March 2016|March 1, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278185||33944|
NCT02278198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0300|Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123|Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123||University of Colorado, Denver|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|21 Years|N/A|No|||November 2015|November 11, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278198||33943|
NCT02278510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFT1314|Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma|A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy||Case Comprehensive Cancer Center|Yes|Active, not recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|October 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278510||33919|
NCT02278757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-6707|Effect of Two Diets With Different Content of Protein on Weight Loss in Adults With Metabolic Syndrome|Effect of Enriched Meal Replacements Protein on Weight Loss in Adults With Metabolic Syndrome|DPMS|Mexican National Institute of Public Health|Yes|Completed|January 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|118|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278757||33900|
NCT02277054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/2013|Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty|A Clinical Trial to Evaluate the Safety and Effectiveness of the Collagen-phosphorylcholine Corneal Substitutes in Patients Requiring Lamellar Keratoplasty||The Filatov Institute of Eye Diseases and Tissue Therapy|Yes|Recruiting|March 2013|January 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||August 2015|August 10, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277054||34031|
NCT02289495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200207|A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects|A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 With and Without Ritonavir for 8-11 Days in Healthy Subjects||GlaxoSmithKline|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289495||33075|
NCT02289508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.464|Role of USCOM in Adult Patients With Heart Failure|Diagnostic and Prognostic Role of USCOM in Adult Patients With Heart Failure-A Prospective Observational Study||Chinese University of Hong Kong|No|Recruiting|November 2014|September 2017|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|280|Samples With DNA|10ml venous blood will be collected through venipuncture. Blood will be centrifuged, plasma      decanted, and stored pending B-type Natriuretic Peptide (BNP) measurements.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be screened and recruited from adult patients either scheduled for elective        2D-echo at a cardiology clinic at the Prince of Wales Hospital, or attending the emergency        department at the Prince of Wales Hospital.|July 2015|July 23, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02289508||33074|
NCT02289833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29389|A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A PHASE 2, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN||Hoffmann-La Roche||Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289833||33049|
NCT02289846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-112-202|Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis||Ironwood Pharmaceuticals, Inc.||Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289846||33048|
NCT02277886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALG-NR-14|Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances|Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD||Chang Gung Memorial Hospital|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|20 Years|80 Years|No|||November 2014|November 18, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02277886||33967|
NCT02290171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02247219|Promoting Health in Healthy Living Centres - a Clinical Study Among Children|Promoting Health in Healthy Living Centres - a Clinical Study Among Famililies With Overweight Children||University of Bergen|No|Recruiting|August 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||November 2014|November 8, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02290171||33023|
NCT02331784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-PACR-AD-01|Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease|Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease|PACR-AD|Posit Science Corporation|Yes|Not yet recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||January 2015|January 2, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02331784||29830|
NCT02331797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 57-0123-13-1|Endoscopic Transcanal Lateral Graft Tympanoplasty|Endoscopic Transcanal Lateral Graft Tympanoplasty: a Minimally Invasive Otologic Surgery||Prince of Songkla University|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|12 Years|70 Years|No|||January 2015|January 2, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02331797||29829|
NCT02281240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soochowhy 2014|Hemostatic Complications in Hematopoietic Stem Cell Transplantation|Pathogenesis, Diagnosis, Management and Outcome of Hemostatic Complications in Hematopoietic Stem Cell Transplantation: A Prospective Study|HCIHSCT|The First Affiliated Hospital of Soochow University|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|60 Years|No|Non-Probability Sample|The incidence and severity of hemostatic complications in patients following HSCT.|October 2015|October 7, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281240||33709|
NCT02281253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-CAR-2010-01|Effects of a Bakery Product Enriched With Fibre and L-carnitine on Insulin Resistance in Patients With Metabolic Syndrome|Evaluation of a Bakery Product Enriched With Fibre and L-carnitine on Cardiovascular Risk Parameters in Patients With Metabolic Syndrome: a Randomized, Double-blind, Placebo-controlled Study||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Completed|April 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|25 Years|70 Years|No|||October 2014|October 30, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02281253||33708|
NCT02290496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH104647|CBT Insomnia Teens: Augmenting SSRIs to Improve Youth Depression|CBT Insomnia Teens: Augmenting Usual Care SSRIs to Improve Youth Depression Outcomes|SleepWell|Kaiser Permanente|Yes|Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|12 Years|19 Years|No|||December 2015|December 23, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02290496||32999|
NCT02285686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-674|Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study|Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study|PRO-TROPICS|McMaster University|No|Not yet recruiting|November 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples Without DNA|2 cryovials|Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients|November 2014|November 6, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285686||33368|
NCT02289625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0833/10|Effects of Exercise Training on Cognitive Performance, Cerebral Metabolism and Sympathetic Activity in Obstructive Sleep Apnea|Effects of Exercise Training on Structure and Cerebral Metabolism, Cognition and Neurovascular Control in Individuals With Obstructive Sleep Apnea||University of Sao Paulo General Hospital|Yes|Recruiting|October 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02289625||33065|
NCT02281214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01163-44|NGS Genome Analysis in Personalisation of Lung Cancer Treatment|Genome Analysis by Next Generation Sequencing in Personalisation of Lung Cancer Treatment|ALCAPONE|Centre Georges Francois Leclerc|Yes|Recruiting|November 2014|||November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02281214||33711|
NCT02281227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0721|Determination of a Proper Needle Entry Point; Effects of Skin Compression With an Indicator on Radiation Exposure Time of Fluoroscopically Guided Transforaminal Epidural Block in Obese Patients|||Yonsei University|Yes|Recruiting|October 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|64|||Both|20 Years|80 Years|No|||October 2014|October 29, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02281227||33710|
NCT02283606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0154-14-MMC|Sonoelastography of the Uterine Cervix Before Induction of Labor|Sonoelastography of the Uterine Cervix Before Induction of Labor|SUCI|Meir Medical Center|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|20 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|20-44 years old pregnant patients|September 2015|September 22, 2015|October 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283606||33528|
NCT02284178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR014508-01A1|Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE|Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE|NO-ASPIRATE|University of Central Florida|Yes|Recruiting|August 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|560|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02284178||33484|
NCT02284191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID-CTCA-2014|Rapid Assessment of Potential Ischaemic Heart Disease With CTCA|The Role of Early CT Coronary Angiography in the Evaluation, Intervention and Outcome of Patients Presenting to the Emergency Department With Suspected or Confirmed Acute Coronary Syndrome.|RAPID-CTCA|University of Edinburgh|Yes|Recruiting|January 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|2500|||Both|18 Years|N/A|No|||May 2015|January 19, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02284191||33483|
NCT02285231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406-BR-171-04|Anti-hyperglycemic Effect of Short-term Arginyl-fructose Supplementation in Subjects With Pre-diabetes and Newly Diagnosed Type 2 Diabetes: Randomized, Double-blinded, Placebo-controlled Trial.|||Yonsei University|Yes|Completed|November 2013|May 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|70 Years|No|||November 2014|November 5, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285231||33403|
NCT02287181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uhongkong|A Phase IV Study Investigating the Effects of Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes|A Phase IV Study to Investigate the Effects of Varied Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes||The University of Hong Kong||Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2016|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02287181||33253|
NCT02287389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAO-NO.201402024-benign|Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture|Prospective, Randomized, Open, Controlled, Multicenter Stucy of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture||Tang-Du Hospital|Yes|Not yet recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|70 Years|No|||November 2014|November 7, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02287389||33237|
NCT02281773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.6|A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.|A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment||Boehringer Ingelheim||Active, not recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|516|||Both|18 Years|55 Years|No|||February 2016|February 23, 2016|October 31, 2014||||No||https://clinicaltrials.gov/show/NCT02281773||33669|
NCT02282007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2013/1913|Norwegian Psychomotor Physiotherapy - The Effect on Quality of Life|Norwegian Psychomotor Physiotherapy - The Effect on Quality of Life, The Feeling of Pain, Coping, Physical, Psychological and Social Functioning After the Treatment||Oslo and Akershus University College of Applied Sciences|No|Recruiting|February 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02282007||33651|
NCT02289651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/12|Effectiveness of Pediatric Intubation|Comparison of the Venner(TM) A.P. Advance(TM) With the Macintosh Laryngoscope for Emergency Intubation in a Standardized Airway Manikin With and Without Chest Compressions by Nurses. A Randomized, Controlled Crossover Trial.|PETI|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289651||33063|
NCT02289664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/11|Videolaryngoscopy During Child Intubation|A Comparison of Coopdech, Intubrite, and CoPilot Video-laryngoscopes With Macintosh Laryngoscope for Tracheal Intubation in Pediatric Patients During Resuscitation. Randomized Crossover Manikin Trial||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289664||33062|
NCT02290028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016|Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads|Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads|QP ExCELs|Biotronik SE & Co. KG|Yes|Recruiting|January 2015|May 2023|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1754|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290028||33034|
NCT02283034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR/2014/06|Effectiveness of Pediatric Resuscitation|Quality of Chest Compressions During 8 Min of Single-rescuer Pediatric Cardiopulmonary Resuscitation With Five Different CPR Feedback Devices. Randomised Crossover Manikin Trial|EPR|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 2, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02283034||33572|
NCT02276885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01306|Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial|Prone Partial Breast Irradiation (PBI): A Prospective Randomized Trial Comparing Five Versus Three Fractions||New York University School of Medicine|Yes|Recruiting|August 2014|September 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|284|||Female|50 Years|90 Years|No|||December 2015|December 28, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02276885||34044|
NCT02280954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818012|Indocyanine Green for Solid Tumors|A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green|818012|University of Pennsylvania|Yes|Recruiting|November 2013|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280954||33731|
NCT02285244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14026|Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation|A Phase 2 Feasibility Study of Sotrastaurin for Relapsed and Refractory CLL/SLL/PLL/RT||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn||||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|November 4, 2014|Yes|Yes|Decision made by the Principal Investigator|No||https://clinicaltrials.gov/show/NCT02285244||33402|
NCT02277704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-P201|Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions|A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken at Bedtime in Subjects With Military-Related PTSD and Related Conditions (Protocol No. TNX-CY-P201) -"AtEase STUDY"|AtEase|Tonix Pharmaceuticals, Inc.|No|Active, not recruiting|October 2014|July 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|247|||Both|18 Years|65 Years|No|||March 2016|March 24, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277704||33981|
NCT02289573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZDSYLL086.0|Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space|Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space||Southeast University, China|No|Not yet recruiting|November 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|75 Years|No|||October 2014|November 12, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02289573||33069|
NCT02276833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-001|Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee|Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee||Renew Center, San Antonio, Texas|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276833||34048|
NCT02276846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondJilinU|Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT|Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT|PEBCBLO|Second Hospital of Jilin University|Yes|Recruiting|October 2014|December 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Probability Sample|This study is designed for 25 subsequent patients with coronary heart disease to complete        the study per protocol. Eligible patients shall exhibit a bifurcational lesion in the        native left coronary artery (reference diameter LAD or LCx: 2.5 mm -4.0 mm, length of        stenosis: ≤30 mm, reference diameter D1/D2 or OMS1/OMS2: 2.0 mm-3.5 mm, length of        stenosis: ≤ 30 mm) in need of percutaneous coronary intervention. Eligible patients may        have single or multivessel coronary artery disease.|October 2014|October 27, 2014|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02276846|9 Months|34047|
NCT02282566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1331|Effect of Protein-nutrition Beverages on Muscle Protein Synthesis in Women|A Pilot Trial to Assess the Effect of a Protein-Nutrition Beverage on Skeletal Muscle Protein Synthesis in Women||PepsiCo Global R&D|No|Recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Anticipated|48|||Female|65 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282566||33608|
NCT02283333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-001-14S|Treatment of Prolonged Grief Disorder in Combat Veterans|Treatment of Prolonged Grief Disorder in Combat Veterans|PGD|VA Office of Research and Development|No|Recruiting|December 2014|September 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|21 Years|N/A|No|||January 2016|January 8, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02283333||33549|
NCT02283593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/686-31/5|Self-help Internet-based Relapse Prevention for Problematic Alcohol Use|Self-help Internet-based Relapse Prevention for Problematic Alcohol Use: A Naturalistic Study Among Internet Help-seekers|eChangeNAT|Karolinska Institutet|No|Completed|March 2013|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|4165|||Both|15 Years|N/A|No|Non-Probability Sample|Internet help-seekers with problematic alcohol use.|August 2015|August 31, 2015|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02283593||33529|
NCT02284997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20246|The Effect of an Eyelid Warming Device for the Management of Meibomian Gland Dysfunction||Hummingbird|University of Waterloo|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|17 Years|N/A|No|||May 2015|May 28, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284997||33421|
NCT02285010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si594/2014|Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine|Effects of Pre-operative Oral Pregabalin on Post Operative Morphine Consumption After Abdominal Hysterectomy With/Without Salpingo-oophorectomy Under Spinal Anesthesia With Intrathecal Morphine||Mahidol University|No|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285010||33420|
NCT02285699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-722|The Gut Microbiota in Obsessive-Compulsive Disorder|A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment||McMaster University|No|Recruiting|November 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|December 12, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285699||33367|
NCT02287844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00273-50|Prebiotics Change Microflora and Decrease LPS|Xylo-oligosaccharide (XOS) in Combination With Inulin Modulates Both the Intestinal Environment and Immune Status in Healthy Subjects, While XOS Alone Only Shows Prebiotic Properties|PIB|Institut Pasteur de Lille|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02287844||33202|
NCT02287337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLV-1212-4327|Validation of CPR for Manipulation for Neck Pain|Validation of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Cervical Spine Manipulation: A Randomized Clinical Trial||University of Nevada, Las Vegas|No|Recruiting|September 2013|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287337||33241|
NCT02277639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008330|Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases|Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|MiniClini|Children's Hospital of Philadelphia|Yes|Recruiting|November 2011|June 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|22 Years|No|||October 2015|October 19, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277639||33986|
NCT02281565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blood_donation2014|Attitudes About Blood Donation|Knowledge, Attitude and Practice About Blood Donation Among Medical Students and Medical Staff|KAPsurvey|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff: medical doctors, nurses, paramedics Medical students: PhD students,        medicine students, nursing and paramedics studies|October 2014|October 30, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02281565||33684|
NCT02281578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH104044|Community-based Combination HIV Prevention in Tanzanian Women|Community-based Combination HIV Prevention in Tanzanian Women at Heightened Risk||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281578||33683|
NCT02285023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thai-version of CU-Q2oL|The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire|Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)|CU-Q2oL|Mahidol University|No|Active, not recruiting|November 2014|October 2015|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|166|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who were diagnosed as chronic urticaria.|February 2015|February 24, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02285023||33419|
NCT02290431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589D1201|Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma|A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma||Novartis|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02290431||33003|
NCT02290444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465028|Effects of Acthar on Recovery From Cognitive Relapses in MS|Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis||State University of New York at Buffalo|Yes|Enrolling by invitation|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290444||33002|
NCT02282332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ_ISSBRIL0304|NIRS Ticagrelor Evaluation|The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy||Medstar Research Institute|No|Active, not recruiting|June 2014|November 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282332||33626|
NCT02282345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0045|Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation|A Pilot Study of BMN673 as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282345||33625|
NCT02276586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2737P|Prospective Clinical Evaluation of Periodontal Response to Different Prosthetic Margin Design|Prospective Clinical Evaluation of Periodontal Response to Different Prosthetic Margin Design||University of Padova, School of Dental Medicine|Yes|Completed|January 2013|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|No|||October 2014|October 23, 2014|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276586||34067|
NCT02276859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protein Food Insulin Bolus|Normal Versus Dual Wave Insulin Bolus for High-protein Food|The Optimal Type of Bolus Following a High-protein Meal in Type 1 Diabetic Children Treated With Insulin Pumps||Medical University of Warsaw|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|10 Years|18 Years|No|||September 2014|September 29, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02276859||34046|
NCT02276872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-206|Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years|A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil Extended Release Tablets Following Transition From Remodulin or Inhaled Prostacyclin Therapy or as Add-on to Current PAH Therapy in De Novo Prostacyclin Pediatric Subjects Aged 7 to 17 Years With Pulmonary Arterial Hypertension||United Therapeutics|Yes|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|7 Years|17 Years|No|||September 2015|September 21, 2015|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276872||34045|
NCT02283073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDx001|Study for the Early Diagnosis of Parkinson's Disease|PDx Biomarker Assay Study for the Diagnosis of Parkinson's Disease||Bio Shai Ltd.|No|Recruiting|November 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|446|Samples Without DNA|The mRNA in blood samples will be transcribed to cDNA.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Movement disorder clinics|September 2015|September 22, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02283073||33569|
NCT02289014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFS-3260-08-2013|Web-based Stress Management for Newly Diagnosed Cancer Patients (STREAM-1)|Web-based Stress Management for Newly Diagnosed Cancer Patients (STREAM-1): A Randomized, Wait-list Controlled Intervention Study|STREAM|University Hospital, Basel, Switzerland|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289014||33112|
NCT02283905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:032|Amphotericin-B and Voriconazole for Pulmonary Blastomycosis|Case Series of Continuously-infused Amphotericin-B and Follow-up Voriconazole Therapy for Severe Blastomycosis Pulmonary Infections|BLASTO|University of Manitoba|No|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||November 2014|June 23, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283905||33505|
NCT02285452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWI_02|Psychophysiological Effects of Thorax Wraps With Ginger and Mustard Flour|Psychophysiological Efficacy of Thorax Wraps With Ginger or Mustard Flour in Comparison to Wraps With Warm Water in Healthy Subjects - a Randomized, Placebo-controlled, Three-armed Study With Cross-over Design|SWI_02|ARCIM Institute Academic Research in Complementary and Integrative Medicine||Enrolling by invitation|November 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285452||33386|
NCT02285465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3700-CL-0002|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3700 in Healthy Subjects||Astellas Pharma Inc|No|Withdrawn|November 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|November 5, 2014||No|Study terminated due to sponsor decision|No||https://clinicaltrials.gov/show/NCT02285465||33385|
NCT02287623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301M27261|Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study|Subcostal TAP Block With Liposomal Bupivacaine vs Bupivacaine in Donor Nephrectomy Patients: A Prospective Randomized Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2013|October 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 30, 2014|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT02287623||33219|
NCT02289235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P-9364-6254|The Effects of Ginger on Nonalcoholic Fatty Liver Disease|The Effects of Ginger on Biochemical Markers and Imaging Studies of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|GinLiv|Shiraz University of Medical Sciences|Yes|Active, not recruiting|November 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|65 Years|No|||February 2016|February 22, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02289235||33095|
NCT02289300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO1202-LF1201|A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients|A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies||A2 Healthcare Taiwan Corporation|Yes|Suspended|December 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|188|||Both|20 Years|65 Years|No|||December 2015|December 28, 2015|November 7, 2014|Yes|Yes|On hold by FDA|No||https://clinicaltrials.gov/show/NCT02289300||33090|
NCT02289027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cAd3-EBOZ Lau|A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland|A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland||Centre Hospitalier Universitaire Vaudois|Yes|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02289027||33111|
NCT02289716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100070|Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|January 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289716||33058|
NCT02289729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-335|Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease|Study on Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease|ADEQUA|AbbVie|No|Recruiting|October 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|99 Years|No|Non-Probability Sample|Advanced Parkinson's Disease patients|January 2016|January 12, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289729||33057|
NCT02282774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-13-968|Subtenon Block Combined With General Anesthesia for Vitreoretinal Surgery|||King Saud University|No|Completed|December 2013|||June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|80|||Both|40 Years|90 Years|No|||October 2014|November 3, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282774||33592|
NCT02282787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-1291|Dexmedetomidine Adjuvant in Retinal Surgery|DEXMEDETOMIDINE ADJUVANT TO LOCAL ANAESTHESIA FOR PERIBULBAR BLOCKS IN RETINAL SURGERY||King Saud University|No|Active, not recruiting|January 2014|May 2015|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|90|||Both|40 Years|90 Years|No|||March 2015|March 30, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282787||33591|
NCT02287792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM13549|18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis|Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study|TEPvENDO|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02287792||33206|
NCT02287805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC 1073|Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their Care|Craniosynostosis: How to Improve the Diagnosis and Assist Patients and Their Families?|AmAc|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2014|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|624|||Both|N/A|N/A|No|Non-Probability Sample|children with craniosynostosis who are followed by the Reference Center "Dysostoses        craniofaciales" and their parents.|November 2015|November 25, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02287805||33205|
NCT02290262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SheppHeartCABG RCT|SheppHeartCABG - Phase One Rehabilitation After Coronary Artery Bypass Grafting|SheppheartCABG. A Randomised Clinical Trial of a Comprehensive Physical and Psycho-educative Rehabilitation Programme Plus Usual Care Versus Usual Care in Phase 1 Rehabilitation After Coronary Artery Bypass Grafting|SheppHeart|Rigshospitalet, Denmark|Yes|Recruiting|November 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|326|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290262||33016|
NCT02277418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/05|Venner a.p. Advance Video Laryngoscope|Intubation of Child and Infant Manikins During Resuscitation. Does the Venner™ A.P. Advance™ Video Laryngoscope Improve Nurses' Performance?|VAVL|International Institute of Rescue Research and Education|Yes|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|112|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277418||34003|
NCT02277431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00007145|Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms|A Randomized Controlled Trial of a Commercially-Available Probiotic Supplement (Trenev Trio®/Healthy Trinity®) and the Promotion of Normal Gastrointestinal Function Among Adults With Recurrent Gastrointestinal Symptoms||University of Maryland|No|Completed|December 2014|October 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02277431||34002|
NCT02287870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NLY-004|Epidural Anesthesia With Chloroprocaine Versus Lidocaine|Low Epidural Anesthesia With Chloroprocaine Versus Lidocaine: a Prospective, Randomized, Double-blinded Multi-centre Clinical Trial in China||Jinling Hospital, China|Yes|Completed|January 2008|June 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|120|||Both|18 Years|60 Years|No|||November 2014|November 10, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02287870||33200|
NCT02291653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/17|Pediatric Endotracheal Intubation|Comparing the Novel McGrath MAC EMS Videolaryngoscope With Conventional Direct Laryngoscopy During Child Resuscitation: a Randomized Crossover Mannequin Study of Paramedic Students|EMS|International Institute of Rescue Research and Education|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291653||32910|
NCT02276339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS-13-50-OShea-McCarthy|Muscle Activation in Chronic Ankle Instability and the Effect of an Exercise Programme|The Role of the Peroneus Brevis and Peroneus Longus in Patients With Chronic Ankle Instability and the Effect of an Exercise Intervention||University College Dublin|No|Completed|October 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02276339||34086|
NCT02276352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.226|Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers|An Open, Randomized, Three-way Cross-over Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Meloxicam After Single p.o. Administration of 2 x 7.5 mg Meloxicam Tablets Compared to 15 mg Meloxicam Tablet, and Dose-proportionality Over a Dosage Range of 7.5 mg and 15 mg.||Boehringer Ingelheim||Completed|June 1999|||August 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|October 27, 2014|October 27, 2014||||No||https://clinicaltrials.gov/show/NCT02276352||34085|
NCT02280941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140589|Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)|Comparison of Myocardial Blood Flow Measurements With Dedicated Solid State SPECT Camera Imaging and 99mTc-Tetrofosmin Versus PET Imaging and Rubidium-82|SPECT MBF|Ottawa Heart Institute Research Corporation|No|Recruiting|October 2014|August 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02280941||33732|
NCT02279758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 515/2014|A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors|A PHASE II PILOT STUDY OF METFORMIN TREATMENT IN PATIENTS WITH WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS|MetNet|Instituto do Cancer do Estado de São Paulo||Recruiting|March 2014|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||October 2014|October 30, 2014|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02279758||33823|
NCT02280070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCC1301|RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).|Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301).||Clinical Research Support Center Kyush|Yes|Recruiting|September 2013|August 2020|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|N/A|No|||October 2014|October 29, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02280070||33799|
NCT02280304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1608-P|Meditation in Veterans With PTSD and Mild TBI|Neuroimaging Meditation Therapy in Veterans With Co-Morbid TBI and PTSD||VA Office of Research and Development|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|49 Years|No|||November 2015|November 4, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02280304||33781|
NCT02284464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVITAESTEROIDE-12|Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients|Steroid Withdrawal and Novo Donor-specific Anti-HLA Antibodies in Renal Transplant Patients: a Prospective, Randomized and Controlled Study in Parallel Groups||Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02284464||33462|
NCT02284724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202-4059|Dry Needling to the Multifidus Muscle in Subjects With Low Back Pain|The Effect of Trigger Point Dry Needling to the Multifidus Muscle on Resting and Contracted Thickness of Transversus Abdominis in Subjects With Low Back Pain||University of Nevada, Las Vegas|No|Recruiting|November 2014|May 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284724||33442|
NCT02276274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-MET/CPH-002|Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects|A Randomized, Open-label, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects||Takeda|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 26, 2014||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT02276274||34091|
NCT02276287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMilan|HIV Patients Illness Perception and Adherence|HIV Positive Patient's Cognitive and Emotional Illness Perception: a Possible Tool for Understanding Adherence?||University of Milan|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|187|||Both|18 Years|N/A|No|Probability Sample|HIV positive patients recruited at the outpatients clinic of Infectious Disease, S.Paolo        University Hospital, Milan, Italy during their check up visit or blood test|October 2014|October 27, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02276287||34090|
NCT02276547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|047-CPT-001|Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System|Early Feasibility Study of the Neovasc Tiara™ Mitral Transcatheter Heart Valve With the Tiara™ Transapical Delivery System|TIARA-I|Neovasc Inc.|Yes|Recruiting|December 2014|August 2021|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276547||34070|
NCT02276794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19051513.5.0000.5345|Thrust Versus Non-thrust Manipulation in Chronic Low Back Pain|The Effects of Thrust Versus Non-thrust Manipulation on Pain, Trunk Proprioception and Postural Stability in Subjects With Chronic Low Back Pain||Federal University of Health Science of Porto Alegre|No|Recruiting|October 2014|March 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276794||34051|
NCT02278705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HL118152-01A1 Aim 1|Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status|Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status||University of Texas Southwestern Medical Center|No|Completed|January 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|4000|||Both|6 Years|12 Years|No|Probability Sample|Overweight 6-12 year-old children followed by pediatricians at community-based and        academic primary-care clinics. A random sample of controls will be matched to cases by        age, gender, race/ethnicity, BMI-percentile category, and clinic site.|July 2015|July 2, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02278705||33904|
NCT02277314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404277367|Manual Small Incision Cataract Surgery Outcomes in an Educational Setting|Manual Small Incision Cataract Surgery Outcomes in an Educational Setting|MSICS|University of Arizona|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|No|||January 2016|January 11, 2016|October 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277314||34011|
NCT02289118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820665|Tau Imaging in Young Onset Dementia|[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia||University of Pennsylvania|No|Active, not recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|45 Years|70 Years|No|||January 2016|January 11, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289118||33104|
NCT02289170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCH-S100-2014|Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)|A Randomized, Double-blind, Multicenter, Parallel Designed Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) in Patients With Chronic Low Back Pain||DongGuk University|Yes|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|No|||November 2014|November 9, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02289170||33100|
NCT02285478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 13.03|Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children|Once Daily Darunavir/Ritonavir in HIV-infected Children 6-12 Years Old: a Pharmacokinetic Validation of Model Based Dosing Recommendations|DAPHNE|Radboud University|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|Samples Without DNA|Plasma samples|Both|6 Years|12 Years|No|Non-Probability Sample|HIV-infected children (6-12 years) using once daily darunavir/ritonavir.|January 2016|January 25, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02285478||33384|
NCT02285491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|els7680|Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision|Efficacy of Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision for Postoperative Cesarean Delivery Analgesia.||Ain Shams Maternity Hospital||Completed|November 2014|November 2015|Actual|November 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 7, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285491||33383|
NCT02285504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-PPD-201|Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression|An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression||Sage Therapeutics|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|45 Years|No|||August 2015|August 11, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285504||33382|
NCT02277158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP03182014|Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.|A Phase I Study of Concurrent Radiotherapy and Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|No|Recruiting|November 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||November 2014|November 30, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02277158||34023|
NCT02282098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-14350|Colchicine in Atrial Fibrillation to Prevent Stroke|Targeting Inflammation in Atrial Fibrillation to Prevent Ischemic Stroke: A Feasibility Study Evaluating the Effect of Colchicine on D-dimer and Hs-CRP in Anticoagulated Patients With Atrial Fibrillation|CIAFS-1|Population Health Research Institute|Yes|Not yet recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02282098||33644|
NCT02291692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVB|Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Nephrolithotomy Operations in Children|Ultrasound Guided Thoracic Paravertebral Block||Cukurova University|No|Completed|June 2013|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|1 Year|5 Years|No|||November 2014|November 14, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291692||32907|
NCT02276599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00332|A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children|A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children||Nationwide Children's Hospital|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|1 Year|12 Years|No|Non-Probability Sample|Children undergoing cardiac catheterization for atrial septal defect.|August 2015|August 14, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02276599||34066|
NCT02276612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1515|Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents|A Phase 2/3 Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents||Gilead Sciences|Yes|Active, not recruiting|December 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|12 Years|17 Years|No|||December 2015|December 18, 2015|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276612||34065|
NCT02282059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181215|The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors|A Multi-Center, Prospective, Non-Interventional (NI) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors||Pfizer|No|Recruiting|December 2014|November 2022|Anticipated|November 2022|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The Chinese adult with progressive advanced or metastatic well-differentiated unresectable        pancreatic neuroendocrine tumors is the target population.|March 2016|March 7, 2016|October 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282059||33647|
NCT02285192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-222|Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer|Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|November 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285192||33406|
NCT02285413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32381.000.10|Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients|Immunochemotherapy: Do Platin-based Chemotherapeutics Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients?||Radboud University|No|Active, not recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|70 Years|No|||November 2014|November 4, 2014|May 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02285413||33389|
NCT02289053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24-DK|Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer|Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer||University of Michigan|No|Active, not recruiting|April 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1623|||Both|40 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants are recruited from the endoscopy units of the participating study sites prior        to their colonoscopy procedure.|December 2015|December 3, 2015|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02289053||33109|
NCT02286570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2014/255|Face-to-face Tracheal Intubation: a Comparison of Airtraq, Glidescope and Fastrach|Face-to-face Tracheal Intubation With Fastrach or Videolaryngoscopes||Kocaeli University|No|Completed|October 2014|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|120|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02286570||33300|
NCT02281461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-06|Feasibility Study of PrePex Device When Performed on Early Infants & Children Male Population by Physicians|A Feasibility Study of PrePex Device for Infants and for Children, When Performed on Early Infants and Children Male Population by Physicians|RMC-06|Ministry of Health, Rwanda|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Male|N/A|10 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02281461||33692|
NCT02281760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150006|Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease|A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease||National Institutes of Health Clinical Center (CC)||Recruiting|October 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|80 Years|No|||September 2015|December 19, 2015|November 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02281760||33670|
NCT02282501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odu-4|Leptin and Ghrelin in ICU|||T.C. ORDU ÜNİVERSİTESİ||Completed|August 2014|||October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|85 Years|No|||October 2015|November 11, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282501||33613|
NCT02282514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD.SPS.2014|Stem Cell Transplantation for Stiff Person Syndrome (SPS)|Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia|SPS|Northwestern University|Yes|Recruiting|October 2014|October 2021|Anticipated|October 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||March 2016|March 21, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282514||33612|
NCT02279251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229020|Low-intensity Versus Standard CBT for Anxious Youth|Low-intensity Versus Standard CBT for Anxious Youth. A Multi-site Randomized Controlled Trial.|LIST|Uni Research|No|Recruiting|October 2013|December 2023|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|393|||Both|12 Years|16 Years|No|||December 2015|December 4, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02279251||33862|
NCT02291497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPP-Study|Burden of Disease in Hypophosphatasia (HPP)|Non-interventional, Prospective, Single-center Investigation With Exploratory Data Analysis to Delineate the Variability and Frequency of Symptoms and Disease Manifestations in Adult HPP Patients||Wuerzburg University Hospital|No|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|112|||Both|18 Years|N/A|No|Non-Probability Sample|see "Eligibility Criteria"|March 2016|March 9, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291497||32922|
NCT02281838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0|The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II|The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II|ICH-ADAPT II|University of Alberta|Yes|Recruiting|November 2012|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281838||33664|
NCT02287662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|The Multidisciplinary, Multimodality, But Minimalist Approach to Transfemoral Transcatheter Aortic Valve Replacement|The Multidisciplinary, Multimodality, But Minimalist (3M) Approach to Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Trial|3MTAVR|BC Centre for Improved Cardiovascular Health|Yes|Recruiting|January 2015|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|N/A|N/A|No|||February 2016|February 22, 2016|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287662||33216|
NCT02279615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRTAM-2014OB|Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.|EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA.||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|June 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Male|50 Years|90 Years|No|||March 2015|March 17, 2015|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279615||33834|
NCT02280681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57341|MAR With Artificial Gametes: Treatment Characteristics and Their Trade-offs Determining Treatment Preference|Medical Assisted Reproduction With Artificial Gametes in Women With Ovarian Failure: Treatment Characteristics and Their Trade-offs Determining Treatment Preference of Patients and Clinicians||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|400|||Both|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Heterosexual couples confronted with infertility due to ovarian failure between the             age of 18 and 44 years old treated in the K.U.Leuven and          2. clinicians who indicated an interest in reproductive medicine in their membership of             the Belgian Society for Reproductive Medicine (BSRM).|October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280681|1 Day|33752|
NCT02280694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-14-EMC|Metronomic Poly-chemotherapy for Metastatic CRC|Metronomic Poly-chemotherapy for Metastatic Colorectal Cancer at Progression Following Established Treatments: Clinical and Laboratory Research|LDMtreatmCRC|HaEmek Medical Center, Israel|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||July 2015|July 6, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280694||33751|
NCT02292992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MMHIS167|Lung Volume Change Between Noninvasive Positive Pressure Ventilation by Nasal Pillow and High Flow Nasal Cannula|The Difference of Lung Volume Change Detected by Electrical Impedance Tomography (EIT) Between Noninvasive Positive-pressure Ventilation (NIPPV) Support by Nasal Pillow and High Flow Nasal Cannula in Post-extubation Patients||Mackay Memorial Hospital|Yes|Recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|20 Years|N/A|No|||December 2014|December 11, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02292992||32807|
NCT02292277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1174-31/1|Ticagrelor Pharmacokinetics in NSTEMI|Evaluation of Ticagrelor Pharmacokinetics in Patients With Non-ST Elevation Myocardial Infarction After a 180 mg Ticagrelor Loading Dose||Karolinska University Hospital|No|Recruiting|November 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|Samples Without DNA|Samples of venous blood will be collected into lithium-heparin tubes, centrifuged at 1500 g      at 4ºC for 10 min within 30 min of blood sampling at the following time points: pre-dose, 1,      2, 3, 4, 5, and 6 hours post-dose, as shown in the table below. For P2Y12-antagonist naïve      patients and controls, sampling of venous blood into Hirudin tubes for pharmacodynamics      evaluation will be performed for analysis using an ADP-induced platelet aggregation assay.      The resulting plasma samples will then be stored below minus 20ºC until analyzed. Plasma      concentrations of ticagrelor and its active metabolite AR-C124910XX will be determined by      validated methods (high-performance liquid chromatography and tandem mass spectrometry      detection; LC-MS/MS) at a certified laboratory.|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting at emergency department and angiography laboratory|November 2014|November 12, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02292277||32862|
NCT02292303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS812/14|Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations|Randomized, Monocentric, Double-blind, 3-way-cross-over Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations||Lesaffre International|No|Active, not recruiting|October 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|26|||Both|20 Years|50 Years|No|||November 2014|November 12, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02292303||32860|
NCT02280642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014388_1|Alternate Dosing Schedules Study for HPV Vaccine (ADS)|Alternate Dosing Schedules Study for HPV Vaccine|ADS|Duke University|No|Completed|March 2009|September 2012|Actual|September 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||4|Actual|331|Samples Without DNA|Serum|Female|9 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent females attending primary care clinics in central North Carolina|October 2014|October 29, 2014|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280642||33755|
NCT02281162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|632260-2|The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain|The Role of Vitamin D and Quetiapine-induced Weight Gain||Creighton University|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|20|Samples Without DNA|40 ml venous blood will be collected in three separate tubes. One tube of 10 ml will be sent      to the Clinical Pathology Labs for the measurement of complete blood count, complete      metabolic panel, fasting lipid profile for the measurement of triglycerides, high density      lipoproteins, low density lipoproteins, very low-density lipoproteins. The complete blood      count and complete metabolic panel will be done to rule out infection or any other      co-morbidity. Another 10 ml tube will be sent to Clinical Pathology lab for the measurement      of serum 25-hydroxy D levels. The third tube with 20 ml blood will be used to measure      protein and mRNA expression of vitamin D receptor (VDR), CYP24A1 and CYP27B1, and to measure      leptin and adiponectin levels.|Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|approximately 40 subjects with schizophrenia, bipolar disorder, and schizoaffective        disorder, both male and female, 21-65 years, of all ethnicities will be recruited.|January 2016|January 7, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02281162||33715|
NCT02287129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-0000-SIV-0028-I|Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction|Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction|MEMORI|Technische Universität München|No|Recruiting|November 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02287129||33257|
NCT02282254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-09|Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia|An Open-label, Randomized, Cross-over Study to Assess the Efficacy of Single-hormone and Dual-hormone Closed-loop Strategy in Regulating Overnight Glucose Levels in Type 1 diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia||Institut de Recherches Cliniques de Montreal|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02282254||33632|
NCT02282267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCHDTC002|Blood Detection of EGFR Mutation For Iressa Treatment|||Beijing Cancer Hospital|Yes|Not yet recruiting|October 2014|February 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|177|||Both|18 Years|75 Years|No|||October 2014|October 31, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282267||33631|
NCT02282280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SET-STUDY|Clinical Use of Prilocaine Chlorhydrate Among a General Surgical Population|Clinical Use of Prilocaine Chlorhydrate Among a General Surgical Population||Astes|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|380|||Both|18 Years|N/A|No|Non-Probability Sample|500 consecutive patients with a spinal anesthesia with prilocaine at Clinique Saint-Luc de        Bouge|December 2015|December 29, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282280||33630|
NCT02282527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1402|A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency|||Grifols Therapeutics Inc.|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282527||33611|
NCT02287571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.4.İSM.4.06.68.49/|Skin Traction Versus Position Splint in Patients With Hip Fracture|The Effects of Preoperative Skin Traction and Position Splint on Pain, Comfort and Satisfaction in Patients With Hip Fracture||Gulhane Military Medical Academy|Yes|Completed|March 2013|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Both|50 Years|N/A|No|||November 2014|November 6, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287571||33223|
NCT02287584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4904020|Confirmatory Study of DSP-5423P in Patients With Schizophrenia|Confirmatory Study of DSP-5423P in Patients With Schizophrenia||Sumitomo Dainippon Pharma Co., Ltd.|No|Recruiting|November 2014|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287584||33222|
NCT02278939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13100|Fit and Trim for Diabetes Prevention|Filipinos Fit and Trim Weight Loss for Diabetes Prevention Program||University of California, San Francisco|No|Active, not recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|65|||Both|24 Years|80 Years|Accepts Healthy Volunteers|||July 2015|February 24, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278939||33886|
NCT02278952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Astellas ISR000990|Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.|Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.|TANGELA|University of California, San Francisco|No|Enrolling by invitation|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Lung transplant recipients|May 2015|May 26, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278952||33885|
NCT02278965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAL2650|Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer|Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer||Columbia University|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|21 Years|75 Years|No|||January 2016|January 15, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278965||33884|
NCT02283047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHU14/08|Effects of Different Aerobic Exercise Programs With Nutritional Interventions in Hypertensive and Overweight People|Effects on Blood Pressure, Cardiorespiratory Condition and Cardiovascular Risk of Different Aerobic Exercise Programs With Nutritional Interventions in Hypertensive and Overweight People.|EXERDIET-HTA|Basque Country University|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|176|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02283047||33571|
NCT02278796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2014-.003629-16|A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)|A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)|BEB|University Hospital Inselspital, Berne|No|Recruiting|April 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02278796||33897|
NCT02285725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMPRP1001|Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid|||Bone and Joint Clinic of Baton Rouge|No|Active, not recruiting|March 2011|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|64 Years|No|||March 2016|March 15, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285725||33365|
NCT02287649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100119|Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)|Fc Gamma RIIIA V/F158 Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) and Correlations With Treatment|Poly-ITP|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|September 2012|January 2016|Anticipated|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287649||33217|
NCT02291562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGIN_EpMem|Effects of THC and CBD on Human Episodic Memory Function|Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function||Central Institute of Mental Health, Mannheim|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|January 15, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291562||32917|
NCT02291575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHCPWestBengal|Improving the Quality of Private Sector Health Care in West Bengal|Improving the Quality of Private Sector Health Care in West Bengal||Abdul Latif Jameel Poverty Action Lab|No|Completed|October 2012|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|304|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02291575||32916|
NCT02283957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-MN-202|A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)||Centrexion Therapeutics||Active, not recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283957||33501|
NCT02284230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1149-7801|The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure|Glycaemic and Cardiovascular Efficacy of Liraglutide in Prediabetic Patients With End-stage Renal Disease|LiRA2|Rigshospitalet, Denmark|Yes|Withdrawn|December 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||August 2015|August 21, 2015|November 3, 2014|Yes|Yes|Inability to recruit participants|No||https://clinicaltrials.gov/show/NCT02284230||33480|
NCT02284243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-14-013|Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy||Recro Pharma, Inc.|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|70 Years|No|||July 2015|July 27, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284243||33479|
NCT02281812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC133/12|Radiofrequency Ablation in Breast Cancer|Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors||Hospital Universitari de Bellvitge|No|Recruiting|September 2013|January 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|74|||Female|40 Years|N/A|No|||August 2015|August 20, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281812||33666|
NCT02279472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondXHCSU|Optical Coherence Tomography Quantitative Analysis of Changes in Anterior Chamber After Laser Peripheral Lridotomy|||Second Xiangya Hospital of Central South University|No|Recruiting|October 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|80 Years|No|||October 2014|October 28, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02279472||33845|
NCT02279485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-048|A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects|A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects||Eisai Inc.|No|Completed|September 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279485||33844|
NCT02277080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-063|The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids|The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids: Effects on Cognition, Pain and Quality of Life||Rigshospitalet, Denmark|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|41|Samples With DNA|whole blood/serum|Both|18 Years|65 Years|No|Probability Sample|Pain patients at Multidisciplinary Pain Centre at Rigshospitalet, Denmark|February 2016|February 8, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02277080||34029|
NCT02277327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLAMedHomeRCT|Trial to Reduce Hospitalizations in Children With Medical Complexity|Randomized Controlled Trial to Decrease Admission Rates in Medically Complex Children in a Medical Home Program||University of California, Los Angeles|No|Active, not recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|1 Month|17 Years|No|||February 2016|February 8, 2016|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02277327||34010|
NCT02277340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRKAP-001|Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol|Endoscopic Treatment of Pilonidal Sinus May Decrease the Recurrence After Crystallized Phenol Application|EPSITCRYSP|Ankara University|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|16 Years|60 Years|No|||October 2014|October 26, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02277340||34009|
NCT02285660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD11/9711|Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition|Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition for Patients With Lung, Lower Oesophageal and Pancreatic Carcinomas.||The Leeds Teaching Hospitals NHS Trust||Recruiting|June 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|90 Years||||November 2014|November 6, 2014|October 21, 2014||||No||https://clinicaltrials.gov/show/NCT02285660||33370|
NCT02292316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2011A00556-35|Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility|Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility|CFC|University Hospital, Caen|No|Recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02292316||32859|
NCT02292329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF1UReading|Cardiovascular Benefits of Acai Polyphenols in Volunteers at Risk of Metabolic Syndrome|Cardiovascular Benefits of Acai in Volunteers at Risk of Metabolic Syndrome.|AF1|University of Reading|No|Recruiting|September 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02292329||32858|
NCT02286752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Odu-6|Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.|||T.C. ORDU ÜNİVERSİTESİ||Completed|June 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|98|||Both|18 Years|65 Years|No|||January 2015|January 11, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286752||33286|
NCT02291809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR-HIV-007|REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study|REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study||Immune Response BioPharma, Inc.|Yes|Not yet recruiting|November 2017|November 2019|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|3 Months|16 Years|No|||February 2016|February 22, 2016|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291809||32898|
NCT02289066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54GM104944|Impact of Periodontal Disease on Outcomes in Diabetes|Impact of Periodontal Disease on Outcomes in Diabetes||University of Nevada, Reno|Yes|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|University of Nevada School of Medicine (Las Vegas) Internal medicine and endocrinology        clinics|November 2015|November 30, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02289066||33108|
NCT02282800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PanineeyaMVIDS|Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients|Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients|IVDAP|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|No|Completed|November 2010|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|61|||Both|24 Years|32 Years|No|Non-Probability Sample|The study population was divided in to two groups i.e test and control group|October 2014|October 31, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282800||33590|
NCT02287597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29055|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice|||Hoffmann-La Roche||Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cancer eligible for second-line chemotherapy and        Avastin in Croatia.|March 2015|March 9, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287597||33221|
NCT02283151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant No.81300689|The Effects of a Very Low Carbohydrate Diet Intervention on Weight Control in Overweight/Obese Patients in China|The Effects of a Very Low Carbohydrate Diet Intervention on Weight Control in Overweight/Obese Patients in China||Southern Medical University, China|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|68 Years|No|||October 2014|November 2, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02283151||33563|
NCT02291536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB_THC_CBD|Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)|Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)|AB_THC_CBD|Central Institute of Mental Health, Mannheim|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|January 15, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291536||32919|
NCT02279316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000580|Move for Your Mind|Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia|MFYM|University of Zurich|Yes|Active, not recruiting|October 2014|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|19|||Both|65 Years|N/A|No|||December 2015|December 2, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02279316||33857|
NCT02292043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wei liu|Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction|Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction||Harbin Medical University|No|Recruiting|May 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Both|20 Years|80 Years|No|Probability Sample|heart failure.|November 2014|November 12, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02292043||32880|
NCT02292095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYMZ-002|Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair|Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|January 2016|August 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|80 Years|No|||November 2015|November 5, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02292095||32876|
NCT02279238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/208|The Comparison of the 3 Minutes Ramp Walk Test With 6 Minutes Walk Test in Stable Patients After Valve Replacement|The Comparison of the 3 Minutes Ramp Walk Test With 6 Minutes Walk Test in Stable Patients After Valve Replacement||PSG Institute of Medical Science and Research|No|Recruiting|November 2013|October 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|45|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|To find a smallest difference of 70% and a minimal correlation of 40%(r=0.4)between two        test , walk distance , vital responses at level of significance of 95% and power of the        study 90%, we needed at least 45 patients.to allow for drop outs and missing values,50        patients will be included|October 2014|October 28, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02279238||33863|
NCT02284945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE11/9972|Randomized Controlled Trial of Open Stabilisation Versus TPS|A Randomized Controlled Trial Comparing Open Spinal Stabilisation and Percutaneous Solution (TPS) Surgery in Patients With Metastatic Spinal Disease.||The Leeds Teaching Hospitals NHS Trust||Completed|August 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||November 2014|November 4, 2014|October 28, 2014||||No||https://clinicaltrials.gov/show/NCT02284945||33425|
NCT02281175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIUGM-003|How to Ease the Withdrawal of Tranquilizers Among Older Consumers?|The Effectiveness of a Novel Psychosocial Intervention "Programme d'Aide au Succès du Sevrage " (PASSE-65+) Designed to Help Older Benzodiazepine Users to Gradually Wean Their Medication||Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Yes|Recruiting|August 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|65 Years|N/A|No|||April 2015|April 1, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02281175||33714|
NCT02277652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/03|Endotracheal Intubation Devices|Comparison of Four Different Endotracheal Intubation Devices Performed by Emergency Medical Professionals: a Manikin Study With 6 Airway Scenarios|ETID|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 11, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277652||33985|
NCT02281474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-2014-001|Nilotinib in Cognitively Impaired Parkinson Disease Patients 001|Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein||Georgetown University|Yes|Completed|November 2014|||May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281474||33691|
NCT02281487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYSTUB|Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy|Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy|HYSTUB|Gynaecologisch Oncologisch Centrum Zuid|No|Recruiting|July 2012|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|36 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02281487||33690|
NCT02277899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HL118152-01A1 Aim 2|Primary Care, Communication, and Improving Children's Health|Primary Care, Communication, and Improving Children's Health||University of Texas Southwestern Medical Center|No|Recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|85|||Both|6 Years|12 Years|No|Non-Probability Sample|We will recruit pediatricians (from academic, community, and private practices), children,        and a consenting parent. Pediatricians and children will be selected to reflect the        proportions of minority pediatricians and children in the practices. Pediatricians at the        community and private practices will be eligible to participate if they provide outpatient        pediatric care ≥20 hours/week. At the academic clinic, only second and third-year        residents will be eligible. Eighty-five children and a consenting parent will be        recruited.|July 2015|July 2, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277899||33966|
NCT02291796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2010-3604-17|Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction|Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction|BEZAFIBRAMI|Instituto Mexicano del Seguro Social|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291796||32899|
NCT02278471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141583|The SCCS Polypill Pilot Trial|The SCCS Polypill Pilot Trial||Vanderbilt University|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|45 Years|75 Years|No|||February 2016|February 2, 2016|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278471||33922|
NCT02286960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00096|Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes|Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes|AAO|New York University School of Medicine|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286960||33270|
NCT02286973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1407/257-005|Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty|Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty: Is it the Most Effective Regime? A Randomized Controlled Trial.||Seoul National University Hospital||Not yet recruiting|November 2014|June 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|264|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286973||33269|
NCT02282540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET31068|Novel Imaging of the Eustachian Tube; Patient Study|Novel Imaging of the Eustachian Tube; Patient Study|CT-ET|Oslo University Hospital|No|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02282540||33610|
NCT02287142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14013|Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery|Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery||Benaroya Research Institute|Yes|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02287142||33256|
NCT02287350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0074|Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Diclofenac Potassium Oral Solution in Pediatric Subjects (Ages 2-12 Years) With Mild to Moderate Acute Pain||Depomed||Completed|September 2014|||January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|2 Years|12 Years|No|||March 2016|March 9, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287350||33240|
NCT02289703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105711|A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis|An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis||Janssen Research & Development, LLC|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289703||33059|
NCT02279069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-4roll-53/2014|4-point vs 4-roll Canne as Walking Aids After Stroke|Comparison Between Classical 4-point Canne and 4-roll Canne on Gait Parameters (Gait Speed and Energy Cost) as Walking Aids After Stroke. A Multicentric Randomized Controled Cross-over Study|4roll|University Hospital of Mont-Godinne|No|Recruiting|October 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||October 2014|October 28, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279069||33876|
NCT02279082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFN-02-CD-010|DFN-02 Open Label Safety Study in Patients With Acute Migraine|||Dr. Reddy's Laboratories Limited|No|Active, not recruiting|September 2014|March 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279082||33875|
NCT02283658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1464|Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase 2 Pilot Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas||Mayo Clinic|Yes|Active, not recruiting|November 2014|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283658||33524|
NCT02283944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15102014|TMS Electrochemotherapy for Glioblastoma Multiforme|TMS Electrochemotherapy for Glioblastoma Multiforme||University of Aarhus|Yes|Not yet recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|November 4, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283944||33502|
NCT02280772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2014|Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children|Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children: A Randomized Controlled Trial||Medical University of Warsaw|No|Recruiting|April 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|6 Years|17 Years|No|||April 2015|April 7, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280772||33745|
NCT02284672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-296|The Effect of Dexmedetomidine on Propofol Requirement for Insertion of Laryngeal Mask Airway|The Effect of Dexmedetomidine on Propofol Requirement for Insertion of Laryngeal Mask Airway||Ajou University School of Medicine|Yes|Completed|November 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|39|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284672||33446|
NCT02284685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F037058|A Novel Intervention Promoting Eating Disorder Treatment Among College Students|A Novel Intervention Promoting Eating Disorder Treatment Among College Students||University of Michigan|Yes|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|8||Actual|1149|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284685||33445|
NCT02293057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA035231-01A1|Gender-Responsive Drug Use Treatment for Juvenile Justice Girls|Gender-Responsive Drug Use Treatment for Juvenile Justice Girls||Rhode Island Hospital|Yes|Recruiting|September 2014|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02293057||32802|
NCT02293070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-104|One More Magnetic Resonance Imaging|One More Magnetic Resonance Imaging|OMM|Saint Luke's Health System|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293070||32801|
NCT02280902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/25|Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases|Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases|INFIM|University Hospital, Bordeaux|No|Recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|217|Samples With DNA|- Blood sampling|Both|18 Years|N/A|No|Non-Probability Sample|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for        immunologic and inflammatory diseases|March 2016|March 10, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02280902||33735|
NCT02280915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-SAV-1615|Bioavailability of Iron From Savoury Food Product|Assessment of the Bioavailability of Iron in Iron Fortified Savoury Food Product in Healthy Women||Unilever R&D|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|24|||Female|18 Years|40 Years|No|||April 2015|April 30, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02280915||33734|
NCT02285205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0778|A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD|||Yonsei University|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|20 Years|N/A|No|||January 2016|January 31, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285205||33405|
NCT02281500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0902|Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenaemia|Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenaemia|IG0902|Grifols Biologicals Inc.|Yes|Not yet recruiting|March 2016|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|N/A|70 Years|No|||February 2016|February 9, 2016|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281500||33689|
NCT02281786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29462|A Study of RO6926496 in Healthy Volunteers|A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT BLIND, SINGLE ASCENDING DOSE, PLACEBO CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO6926496 FOLLOWING INTRAVENOUS INFUSION IN HEALTHY SUBJECTS||Hoffmann-La Roche||Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281786||33668|
NCT02278159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZ41367|Evaluation of the Integrated Home Dialysis Model|||Princess Alexandra Hospital, Brisbane, Australia|No|Completed|January 2000|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|11600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with home dialysis as the first renal replacement therapy [RRT] modality (defined        by the dialysis modality at 90 days) in Australia and New Zealand as reported in Australia        and New Zealand Dialysis and Transplant Registry [ANZDATA]|October 2014|October 27, 2014|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02278159||33946|
NCT02282020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00010|Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments|A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations|SOLO3|AstraZeneca|Yes|Recruiting|February 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|411|||Female|18 Years|96 Years|No|||March 2016|March 22, 2016|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282020||33650|
NCT02289274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-1203-BE|Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203|Partial Replicated Crossover Clinical Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203 Treatment to Those of Co-administration of Eperisone Hydrochloride Slow Release and Aceclofenac in Volunteers|NVP-1203|Navipharm Corporation|No|Suspended|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 9, 2014||No|Due to operational reasons|No||https://clinicaltrials.gov/show/NCT02289274||33092|
NCT02289326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scripps IRB 14-6419|Biomarker Monitoring in TP53 Mutation Carriers|Biomarker Monitoring for a Young Individual Carrying a TP53 Gene Mutation in a Familial High-Cancer Predisposition Setting||Scripps Health|Yes|Active, not recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|-  DNA and RNA from blood        -  Stool samples for microbiome analysis        -  Urine samples for microbiome and general biomarker analysis        -  Saliva samples for microbiome and general biomarker analysis        -  Blood for general biomarker and metabolite profiling|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with functionally significant germline TP53 gene mutations who are susceptible        to Li-Fraumeni Syndrome.|April 2015|April 26, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289326||33088|
NCT02336659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSV-14|Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery|Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery||Hvidovre University Hospital|Yes|Recruiting|April 2014|October 2016|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|12|||Both|18 Years|60 Years|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336659||29456|
NCT02336672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTP/2014|EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)|EUS-Guided Cryothermal Ablation in Patients With Stage III (Locally Advanced and Borderline Resectable) Pancreatic Adenocarcinoma||IRCCS San Raffaele|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|75 Years|No|||August 2015|August 28, 2015|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02336672||29455|
NCT02336789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0088-14-KMC|Proposal to Examine the Effect of Fecal Transplantation on Obesity|Proposal to Examine the Effect of Fecal Transplantation on Obesity.||Kaplan Medical Center|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336789||29446|
NCT02331251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PembroPlus|Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)|A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)||Western Regional Medical Center|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|February 19, 2016|January 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331251||29871|
NCT02331524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-180-H|Interventions to Improve Daily Activity in Heart Failure|Exercise and Psychosocial-Based Interventions to Improve Daily Activity in Heart Failure||Grand Valley State University|No|Recruiting|October 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|33|||Both|40 Years|N/A|No|||January 2015|January 2, 2015|December 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02331524||29850|
NCT02327481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02|Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer|Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer||Fujian Medical University|Yes|Active, not recruiting|January 2015|June 2019|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|19 Years|74 Years|No|||March 2015|March 5, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327481||30160|
NCT02338284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2141 103|Optic Nerve Sheath Diameter as a Screening Test for Increased Intracranial Pressure|Optic Nerve Sheath Diameter Measured by Bedside Ultrasound May be a Simple Screening Test for Increased Intracranial Pressure in the Comatose Critically Ill Patient||King Faisal Specialist Hospital & Research Center|No|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|14 Years|N/A|No|Non-Probability Sample|Consecutive, adult patients already admitted to the critical care service with unexplained        coma|June 2015|June 14, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02338284||29331|
NCT02338336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nowarta111545|A Phase I/II Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts|A Phase I/II, Two- Staged Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts and Clinical Recovery||Nowarta Biopharma Inc|Yes|Not yet recruiting|February 2015|March 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338336||29327|
NCT02338414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-I001|An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP|An Observational Study to Evaluate the Efficacy of Romiplostim Administered at Every Other Week in Adult Patients With Chronic Immune Thrombocytopenia (ITP) Who Attained Platelet Counts ≥ 50 x 109/L After Weekly Doses of Romiplostim||Samsung Medical Center|No|Not yet recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02338414||29321|
NCT02328404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD31.0|The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome|The Effect of Vitamin D Supplementation on Chromium Serum Levels and Insulin Resistance Among Overweight Jordanian Women With Polycystic Ovary Syndrome in Irbid||Hayat Pharmaceutical Co. PLC|Yes|Completed|February 2014|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|April 14, 2015|December 14, 2014|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT02328404||30089|The study was conducted only in the north of JordanBody composition was measured by bioelectrical impedanceInsulin resistance was assessed using the indirect method of assessment (HOMA)The study was done exclusively on overweight women
NCT02292147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111012|Functional Outcome After Cardiac Arrest|Functional Outcome After Cardiac Arrest; Prediction and Prognosis Factors for Patients Awake Within the First 15 Days|HANOX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients presenting an Out of hospital cardiac arrest|December 2015|December 15, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292147||32872|
NCT02292160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/186/HP|Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?|Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance? Pilot Study to Guide Probabilistic Antibiotic Regimens of Community-acquired Urinary Tract Infections||University Hospital, Rouen|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1128|||Both|15 Years|N/A|No|Probability Sample|Patient with an community-acquired urinary tract infection|September 2015|September 21, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02292160||32871|
NCT02284763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0688|Modeling the Effect of EtCO2 on Cerebral Oxygenation|Pharmacodynamic Modeling of the Effect of End-tidal Carbon Dioxide on Cerebral Oxygen Saturation in Beach Chair Position Under General Anesthesia||Severance Hospital|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|19 Years|N/A|No|||February 2015|February 10, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02284763||33439|
NCT02292225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-18|Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)|A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)||Infinity Pharmaceuticals, Inc.|No|Recruiting|February 2015|November 2021|Anticipated|November 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292225||32866|
NCT02292238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-451|Benfotiamine in Alzheimer's Disease: A Pilot Study|Benfotiamine in Alzheimer's Disease: A Pilot Study|Benfotiamine|Burke Medical Research Institute|Yes|Recruiting|November 2014|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|65 Years|95 Years|No|||January 2016|January 19, 2016|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292238||32865|
NCT02277457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.117|Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations|Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations||University of Michigan Cancer Center|No|Recruiting|September 2015|||June 2021|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277457||34000|
NCT02336282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLSTIM|Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia|Feasibility and Efficacy of Transcranial Direct Current Stimulation (tDCS) and Cognitive Training for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336282||29485|
NCT02332304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2014-02|Amniotic Fluid Optical Density Determination as a Test for Assessment of Fetal Lung Maturity.|Amniotic Fluid Optical Density Determination Between 28 and 36 6/7 Weeks of Pregnancy and Its Relationship With the Diagnosis of Neonatal Respiratory Distress Syndrome.||Saint Thomas Hospital, Panama|No|Completed|May 2014|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Female|N/A|N/A|No|||January 2015|January 4, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332304||29790|
NCT02332564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000001138|Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses|Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses|CIMA|University Hospital Inselspital, Berne|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients electively referred for coronary angiography|September 2015|September 23, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332564||29770|
NCT02336360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A15|Augmenting 18F-AV-1451 Dosimetry Estimates|A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451||Avid Radiopharmaceuticals|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336360||29479|
NCT02336438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1036|The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery|The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With RNY Gastric Bypass Surgery||Bassett Healthcare|No|Completed|May 2013|||November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|January 8, 2015|Yes|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT02336438||29473|
NCT02330432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pulm/Mw/002|Mycobacterium w in Patients With Severe Sepsis|Phase IIb Randomized, Double Blind, Two Arm, Controlled Clinical Trial of Mycobacterium W in Combination With Standard Therapy Versus Standard Therapy Alone in Sepsis|MISS|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||July 2015|July 24, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02330432||29934|
NCT02339285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1622|Transcranial alternatinG Current stimuLation for mAjor Depressive Disorder|Pilot Clinical Trial for the Evaluation of Feedback Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder|GLAD|University of North Carolina, Chapel Hill|Yes|Recruiting|April 2015|May 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339285||29255|
NCT02330679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 14-0194|Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis|Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis||University of Calgary|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|61|||Both|20 Years|55 Years|No|||December 2014|January 2, 2015|December 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330679||29915|
NCT02326987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA5PR-103|A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open, Single-dose, 3-treatment, 3-period, 6-sequence Crossover Study in Healthy Male Subjects to Evaluate the Pharmacokinetics of GLA5PR GLARS-NF1 Tablet 150mg and LYRICA® Capsule 75mg||GL Pharm Tech Corporation|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02326987||30198|
NCT02280122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/13|Activated MMP-8 as Diagnostic Test for Periodontitis|Activated Matrix Metalloproteinase 8 (aMMP-8) in Saliva as Diagnostic Test for Periodontal Disease? A Case-control Study|MMP-8|Goethe University|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Periodontally healthy individuals and patients with untreated generalized moderate and        generalized severe ChP from a German dental Office in Frankfurt/Main|July 2015|July 8, 2015|October 29, 2014||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT02280122||33795|The aMMP-8 test is sensitive to distinguish untreated periodontally diseased from healthy individuals. However, this study does not provide information how clearly the test may distinguish between gingivitis and untreated chronic periodontitis.
NCT02280135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC/RP|Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa|Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa|TC/RP|Red de Terapia Celular|Yes|Recruiting|November 2014|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|No|||September 2015|September 30, 2015|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280135||33794|
NCT02280382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.RCHT.76|An Intervention to Improve Prolapse Using Femmeze® (v1)|An Intervention to Improve the Management of Posterior Vaginal Compartment Prolapse Using Femmeze®: a Feasibility Study|Femmeze®|Royal Cornwall Hospitals Trust|No|Recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02280382||33775|
NCT02331810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14076|Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients|A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient||Sanofi|Yes|Not yet recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|75 Years|No|||June 2015|June 18, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331810||29828|
NCT02327702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-02-pregnant CHB patients|Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients|Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients||Asian-Pacific Alliance of Liver Disease, Beijing|Yes|Not yet recruiting|January 2015|July 2017|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327702||30143|
NCT02327949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZY-0001|W-Shaped Acetabular Angular Plate (WAAP) Versus Reconstruction Plate|Prospective Comparison Between W-Shaped Acetabular Angular Plate (WAAP) and Reconstruction Plate for the Treatment of Posterior Acetabular Wall Fracture||Hebei Medical University Third Hospital|No|Active, not recruiting|December 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|December 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327949||30124|
NCT02328183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|568/2557(EC4)|Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria|Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria|XDR|Mahidol University|Yes|Recruiting|December 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 31, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328183||30106|
NCT02332850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139511|SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma|A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma||University of California, San Francisco|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|18 Years|No|||June 2015|June 30, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332850||29748|
NCT02333084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 20141|The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee|The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee||Physician Recommended Nutriceuticals||Recruiting|July 2014|||July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|90 Years|No|||January 2016|January 5, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02333084||29730|
NCT02292394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI2012-37396|Brief Telephone Psychological Intervention for Depressive Symptoms in Caregivers|A Study of Randomized Controlled Dismantling of a Brief Telephone Psychological Intervention Applied to Informal Caregivers With Depressive Symptoms|RCDS|University of Santiago de Compostela|Yes|Active, not recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02292394||32853|
NCT02281617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139664|Smart-device Apps as Memory Aids|Smart-device Apps as Memory Aids||King's College London|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|95 Years|No|Non-Probability Sample|Adults attending an NHS memory clinic with fluent English and in possession of a        smart-phone or tablet|October 2014|October 30, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02281617||33680|
NCT02281630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1204|Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||October 2015|Anticipated|Phase 2|Interventional|N/A|3||||||Both|20 Years|N/A||||November 2014|November 4, 2014|October 22, 2014||||No||https://clinicaltrials.gov/show/NCT02281630||33679|
NCT02338583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-14-003|Powered Surgical Stapler in VATS Lung Resection Procedures in China|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in China||Ethicon Endo-Surgery|No|Completed|December 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals scheduled for VATS lobectomy or diagnostic VATS wedge resection in accordance        with their institution's SOC|January 2015|May 21, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338583||29308|
NCT02338687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528759|Low Dose Calcium to Prevent Preeclampsia|Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study|AMCAL|Federal University of São Paulo|No|Recruiting|October 2014|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1040|||Female|10 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338687||29300|
NCT02338804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|breast cancer MV|Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Breast Carcinoma Patient||Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2015|September 8, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338804||29291|
NCT02279290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH103394|Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology|Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology||Rush University Medical Center|No|Recruiting|July 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|March 23, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02279290||33859|
NCT02330692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0479|Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome|||Yonsei University|No|Recruiting|September 2013|September 2023|Anticipated|July 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Acquisition and storage of blood and bone marrow samples at diagnosis, at response      evaluation and at times of relapse or refractory period.|Both|16 Years|N/A|No|Non-Probability Sample|Patients who are diagnosed with MDS in Severance Hospital. All patients are eligible for        study occuring from the starting day of the study. Patients are enrolled if the written        consent are acquired. Considering the annual incidence rate of the disease, target patient        population is 1,000 people during the study period.|December 2014|December 31, 2014|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02330692|10 Years|29914|
NCT02279550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1950|Institutional Registry of Hip Fracture in the Elderly|Institutional Registry of Hip Fracture in the Elderly||Hospital Italiano de Buenos Aires|No|Recruiting|September 2014|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|65 Years|N/A|No|Non-Probability Sample|aged >65 hip fracture|December 2015|December 16, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02279550|20 Years|33839|
NCT02330978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP 14151/2010|Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.|Intravitreal Autologous Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Patients With Advanced Glaucoma. Phase I: Safety Study.||University of Sao Paulo|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|90 Years|No|||December 2014|December 31, 2014|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330978||29892|
NCT02330991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014062501|A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse|||Beijing Sanbo Brain Hospital||Not yet recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|75 Years|No|||January 2015|January 1, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330991||29891|
NCT02331238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14020618|Trial of a Middle School Coach Gender Violence Prevention Program|Cluster-Randomized Trial of a Middle School Coach Gender Violence Prevention Program||University of Pittsburgh|Yes|Recruiting|March 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2408|||Both|11 Years|N/A|No|||November 2015|November 30, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02331238||29872|
NCT02283918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999MS005|Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery|Study to Establish Patient-Matched Population Norms for the MS-COG||Biogen|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|467|||Both|25 Years|58 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a multinational, multicenter study that will be conducted in healthy adult        volunteers to establish normative values for the MS-COG. A total of 150 to 200        participants in each of the 3 countries will be enrolled. The study sample will include        healthy participants who are matched in age and level of education to the general MS        patient population for the respective country and/or region.|October 2015|October 1, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283918||33504|
NCT02284204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKSevadversos|Use of Sevoflurane, Midazolam and Ketamine in Children for Sedation Dental Treatment: Occurrence of Adverse Events|||Universidade Federal de Goias|No|Active, not recruiting|January 2012|||November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|27|||Both|2 Years|6 Years|No|||November 2014|November 6, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02284204||33482|
NCT02336217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574049|Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations|Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations|GEMApp|Marshall University|No|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||July 2015|July 31, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336217||29490|
NCT02332083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSc-study (Horgen)|Innovative Training Program for Elderly in Need of Care|Skilling-up Exercise for Elderly in Need of Care||Bern University of Applied Sciences|No|Completed|August 2014|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332083||29807|
NCT02332330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0104|CD0104 VEST II Post Marketing Surveillance Study|A Post-market Prospective Study of the VGS VEST (Venous External Support), Supporting Saphenous Vein Grafts for Coronary Bypass Graft Surgery in Patients With Severe Coronary Heart Disease|VEST II|Vascular Graft Solutions Ltd.|No|Active, not recruiting|January 2015|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 15, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332330||29788|
NCT02332603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_08_2014c|Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Glucose Homeostasis in Patients Scheduled for Total Hip- and Knee-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|122|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332603||29767|
NCT02336464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K120103|Impact of Dyspnea on Patients in the Intensive Care Unit|Impact of DYSpnea on the ouTcome of Patients Admitted for an Acute RESpiratory Failure in the intenSive Care Unit|DYSTRESS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|622|||Both|18 Years|N/A|No|Non-Probability Sample|The aims of the present multicentre study are 1) to quantify the prevalence of dyspnea in        a large population of ICU mechanically ventilated patients, 2) to examine the link between        the level of dyspnea and the occurrence of adverse events in the ICU, 3) to determine        whether dyspnea in intensive care unit patients is associated with a higher length of stay        in the ICU and a higher incidence of post traumatic stress disorder associated symptoms.|January 2016|February 5, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336464||29471|
NCT02276898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000024909|A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index|A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.||The Hospital for Sick Children|No|Completed|November 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|18 Years|No|||May 2015|May 20, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276898||34043|
NCT02276911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BN033|Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery|Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery||St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276911||34042|
NCT02277197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-059|Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives||University of Pittsburgh|Yes|Recruiting|August 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277197||34020|
NCT02336178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1821052|Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China|An Open-label, Single-arm, Post-authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Subjects With Hemophilia B In Usual Care Settings In China||Pfizer|Yes|Recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|N/A|N/A|No|||March 2016|March 10, 2016|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02336178||29493|
NCT02336230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-GVHD001|A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|||Mesoblast, Ltd.|Yes|Recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Months|17 Years|No|||January 2015|January 7, 2015|December 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336230||29489|
NCT02329418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00758-39|Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit|Impact of a Written Document on Post Traumatic Stress Disorder (PTSD) Diagnosed in Family Members After Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit|LATA|University Hospital, Grenoble|No|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329418||30011|
NCT02329431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2106|Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children|Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children||University of North Carolina, Chapel Hill|No|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|270|||Both|N/A|N/A|No|||December 2015|December 11, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329431||30010|
NCT02329665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-CL-001P-IL|Data Collection in Patients Undergoing CT-Guided Needle Interventions for NeedleWays System Development|A Prospective Data Collection, Single-Center, Open Label Study in Patients Undergoing CT-Guided Needle Interventions for the Development of the NeedleWays System||NeedleWays|Yes|Not yet recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02329665||29992|
NCT02329964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS-sugammadex study KoreaUH|Effectiveness of Sugammadex in LMS Surgery|Comparison of the Effectiveness of Rocuronium - Sugammadex With Succinylcholine-Cisatracurium-Neostigmine in Patients Undergoing Laser Microlaryngeal Surgery||Korea University Anam Hospital|Yes|Active, not recruiting|February 2015|September 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|December 27, 2014|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT02329964||29969|The surgical rating score was assessed on the basis of the degree of laryngx exposure. This was influenced not only by neuromuscular relaxation but also by anatomical factors.
NCT02330198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T181/2014|Validation of the Foot and Ankle Ability Measure Tool in Finnish|Evidence for Validity and Reliability of the Finnish Version of the Foot and Ankle Ability Measure|FAAM-Fi|Turku University Hospital|Yes|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|No|Non-Probability Sample|40 patients who will receive operative treatment at the Turku University Hospital Foot and        ankle unit, At the outpatient clinics of Turku University Hospital and Physiotherapy        Consults Helsinki 40 foot and ankle patients who will get physiotherapy|November 2015|November 4, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330198|3 Months|29951|
NCT02279030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062156|Use of MIBG Scan Images in PVC Ablations|Three Dimensional Neuro-cardiac Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Premature Ventricular Contractions Ablations|PVC-MIBG|University of Maryland|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients requiring PVC ablation|October 2014|October 28, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02279030||33879|
NCT02283086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P001587|Effects of Performance Feedback on Imaging Use in the Emergency Department|||Brigham and Women's Hospital|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|43|||Both|15 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 4, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02283086||33568|
NCT02283099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE-DZIF2-VSV{Delta}G/ZEBOVGP|Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)|An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001)||Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|November 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283099||33567|
NCT02279563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZFL-NASU-05RB02-CE|A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled,Parallel-group Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc. )in the Treatment of Seasonal Allergic Rhinitis||Apotex Inc.|Yes|Enrolling by invitation|December 2013|||February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|595|||Both|18 Years|65 Years|No|||October 2014|October 30, 2014|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279563||33838|
NCT02279576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOG-CPE-2014-03|Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)|Phase II Study With Pazopanib and Weekly Paclitaxel in Metastatic or Locally Advanced Squamous Penile Carcinoma Patients Previously Treated With Cisplatin Based Chemotherapy|PAZOPEN-SOGUG|Spanish Oncology Genito-Urinary Group|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02279576||33837|
NCT02279836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Invendo s14-01040|Single Arm Post-marketing Study of SC20 Colonoscope|Open Label, Multi-center, Single Arm Post-marketing Study of SC20 Colonoscope and Colonoscopy System for Colonoscopy in Male and Female Patients >18 Years Old|SC20 Scope|Invendo Medical GmbH|Yes|Terminated|October 2014|January 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|October 28, 2014|Yes|Yes|Study was stopped due to the expected introduction of a next product generation.|No||https://clinicaltrials.gov/show/NCT02279836||33817|
NCT02290041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMAd-VIH-2014|Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response|Clinical Trial Phase I/II, of Test of Concept, Blind Double, Randomized, Controlled With Placebo, to Assess the Safety and Efficiency of the Treatment With Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue Expanded, in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Not yet recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||November 2014|June 12, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290041||33033|
NCT02290093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4LPEG-2LPEGA-Elderly-2014|Bowel Preparation for Colonoscopy in the Elderly|Bowel Preparation With Standard 4 Liters of PEG vs. Split-dose of 4 Liters PEG vs. Split-dose of 2 Liters PEG Containing Ascorbic Acid Solutions for Outpatient Elective Colonoscopy in the Elderly: A Randomized, Colonoscopist-blinded Study||Kyunghee University Medical Center|Yes|Completed|November 2014|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|230|||Both|65 Years|N/A|No|||February 2016|February 22, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02290093||33029|
NCT02276638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEM-530-US-0002|Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality|Comparative Study of the Specular Microscopes for Center Point Method and Corner Point Method for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area and % Hexagonality.||Nidek Co. LTD.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|79|||Both|18 Years|80 Years|No|Non-Probability Sample|Ophthalmology Practice|March 2016|March 22, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02276638||34063|
NCT02338427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 063-14|Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis|Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis. Multicenter Prospective|IPA|Centre Hospitalier Departemental Vendee|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338427||29320|
NCT02336256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB-1|Plasma Total Antioxidant Status and Thiobarbituric Acid-reacting Substances in Patients With Inguinal Hernia|Plasma Total Antioxidant Status and Thiobarbituric Acid-reacting Substances in Patients With Inguinal Hernia Operated by Totally Extraperitoneal (TEP) or Single Incision Laparoscopic Surgery (SILS)||Poznan University of Medical Sciences|No|Completed|January 2013|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||January 2015|January 7, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02336256||29487|
NCT02336308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1671|A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients|A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients||University of Colorado, Denver|No|Withdrawn|January 2015|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|No|||November 2015|November 24, 2015|January 6, 2015|Yes|Yes|Standard of care for dressing changes at the institution now includes treatment intervention|No||https://clinicaltrials.gov/show/NCT02336308||29483|
NCT02336386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-MM|CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma|Study of Cyclophosphamide，Liposome Doxorubicin Dexamethasone（CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients||Beijing Chao Yang Hospital|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336386||29477|
NCT02338830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR1|Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix|Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix||Mansoura University|No|Completed|June 2012|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|182|||Female|20 Years|35 Years|No|||January 2015|January 13, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02338830||29289|
NCT02280993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transplant BRaVE|Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients|Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|May 2014|May 2020|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02280993||33728|
NCT02281006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-09-985|Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity|Randomized Controlled Trial to Test the Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer|STS001|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281006||33727|
NCT02281305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22977 / 29-08-2014|Post-MI PET Scan Imaging of Inflammation|Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine||G.Gennimatas General Hospital|Yes|Recruiting|October 2014|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||October 2014|October 31, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281305||33704|
NCT02336139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1309|A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use|A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use|SIMPLIFY|Kirby Institute|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02336139||29496|
NCT02338466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EC/02|Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion|Randomized Therapeutic Study Assessing the Superiority of a Sequential Intravenous Thrombolysis Treatment (Rt-PA + Tenecteplase) in Comparison With Rt-PA Standard Treatment in Proximal Middle Cerebral Artery Occlusion (DIVA).|DIVA|Centre Hospitalier Universitaire de Fort-de-France|No|Not yet recruiting|April 2015|July 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||January 2015|January 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338466||29317|
NCT02329119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07|Psychiatric Disorders and Electrophysiological Markers|Psychiatric Disorders and Electrophysiological Markers|ERPs-PSY|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|September 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2015|August 20, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329119||30034|
NCT02278523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangzhouIRD|The Respiratory Physiology Variation of COPD Patients in Inspiratory Muscle Training|The Respiratory Physiology Variation of COPD Patients in Inspiratory Muscle Training||Guangzhou Institute of Respiratory Disease|Yes|Completed|June 2014|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02278523||33918|
NCT02278770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0405/80|DD Obesity MRI Study|Pilot Study: MRI Study of Diverticular Disease Symptoms and Its Relationship to Visceral Adipose Tissue|DDOMRI|University of Nottingham|No|Active, not recruiting|December 2011|December 2015|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Serum and stool|Both|18 Years|85 Years|No|Non-Probability Sample|Participants will include:          1. Participants with symptomatic DD stratified by patient heath questionnaire 12 somatic             symptom scale          2. Participants with asymptomatic DD|May 2015|May 27, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278770||33899|
NCT02279043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-9716|Online Peer Influence on IUD Behaviors and Attitudes|Peer Influence on Intrauterine Contraceptive Behavior and Attitudes in an Online Social Community||University of California, San Francisco|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|540|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02279043||33878|
NCT02283346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-P01|Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial|Single Fraction High Dose Rate (HDR) Brachytherapy Plus Hypofractionated External Beam Radiotherapy (EBRT) for Low-risk Prostate Cancer: Phase II Trial|AC-P01|AC Camargo Cancer Center|Yes|Not yet recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|90 Years|No|||November 2014|November 4, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283346||33548|
NCT02283359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17919|Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus|An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|December 2014|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 3, 2014|No|Yes|Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT02283359||33547|
NCT02283619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051429|Left Bundle Branch Block ECG Characteristics in the Evaluation of Acute Coronary Syndrome|Correlation of Clinical Outcomes With ECG Findings in Patients With Left Bundle Branch Block Being Evaluated for Acute Coronary Syndrome - a Prospective Cohort Study||Duke University||Terminated|November 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Probability Sample|Selection of Subjects: The population will be patients age 18 or older who present to the        ED with LBBB and suspected ACS. The investigators expect the mean age of the population to        be approximately 60 years old, with most patients between 40 and 90. They anticipate that        these patients will on average have multiple medical comorbidities given that those with        LBBB and ACS are reported to be a sicker, older population with more cardiac risk factors        than the usual ACS patient without LBBB. Patients under age 18 will be excluded because        they extremely rarely have ACS and/or LBBB.|August 2015|September 24, 2015|October 31, 2014||No|Study was found to be non-feasible. Not enough patients to perform an adequate study in the    allocated time period.|No||https://clinicaltrials.gov/show/NCT02283619||33527|
NCT02276378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.569|Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers|Influence of Food on the Bioavailability of Telmisartan 40 mg/HCTZ 12.5 mg Fixed-dose Combination and of Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination in Japanese Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|July 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 27, 2014||||No||https://clinicaltrials.gov/show/NCT02276378||34083|
NCT02276391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.571|Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers|Bioequivalence of Telmisartan Administrated in Two Different Ways: Either in Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|July 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 27, 2014||||No||https://clinicaltrials.gov/show/NCT02276391||34082|
NCT02276625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R5|One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding|One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults.||Leiden University Medical Center|No|Recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02276625||34064|
NCT02281279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1288|Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma|A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma||Mayo Clinic|Yes|Not yet recruiting|June 2016|||October 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281279||33706|
NCT02328417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-RAC|Enhanced Recovery After Radical Cystectomy Study|Enhanced Recovery After Radical Cystectomy Study||Hospital Universitario Fundación Alcorcón|No|Recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|188|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive male and female patients older than 18 years submitted to radical        cystectomy due to bladder cancer in the 13 participating hospitals.|February 2016|February 18, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328417||30088|
NCT02338505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21264/14|Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX||OB-ALFX|Catholic University of the Sacred Heart|Yes|Not yet recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|90 Years|No|||January 2015|January 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338505||29314|
NCT02338518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140621|Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients|Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients|SVOSA|Jinling Hospital, China|No|Recruiting|January 2015|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|30 Years|70 Years|No|||January 2016|January 26, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02338518||29313|
NCT02338531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB-TNBC-1-RHEA|Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer|Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer|RHEA|Jules Bordet Institute|No|Withdrawn|June 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|January 5, 2015||No|Due to the discontinuation of the development of the Notch inhibitor PF-03084014-04|No||https://clinicaltrials.gov/show/NCT02338531||29312|
NCT02338609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001M2305|Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301|Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301|EXIST-LT|Novartis|No|Active, not recruiting|December 2014|June 2026|Anticipated|June 2026|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|15|||Both|N/A|17 Years|No|||September 2015|September 21, 2015|December 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338609||29306|
NCT02338713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calcichew-1001|Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption|A Single-Sequence, 2-Period, Open-Label Study of a Novel Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet Dosed for 3 Days to Investigate the Effect on Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men||Takeda|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|27|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02338713||29298|
NCT02338726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T268/2014|Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study|Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study||Turku University Hospital|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Female|64 Years|66 Years|Accepts Healthy Volunteers|Probability Sample|100-130 women aged 64-66 years in one single municipality|November 2015|November 3, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338726||29297|
NCT02332590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC14092|Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)|A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis||Sanofi|Yes|Active, not recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332590||29768|
NCT02336113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/704|Effect of Pharmacist Intervention on Hospital Readmissions|Effect of Pharmacist Intervention on Hospital Readmissions|OPERA|Oslo University Hospital|No|Recruiting|August 2014|December 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|N/A|N/A|No|||January 2015|January 7, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02336113||29498|
NCT02336126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOPSYCH|Biopsychological Intervention in Chronic Fatigue Syndrome - a Pilot Study|||Oslo University Hospital|No|Recruiting|October 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|12 Years|18 Years|No|||January 2015|January 7, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02336126||29497|
NCT02336152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varmedrakt.OUS.15.1|Use of Onepiece Suit or Forced Warm Air for Perioperative Temperature Conservation.|Use of Onepiece Suit or Forced Warm Air for Perioperative Temperature Conservation.||Oslo University Hospital|No|Not yet recruiting|January 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2015|January 7, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02336152||29495|
NCT02338388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(EA1/149/11)|Cesarean-scar Thickness and Closure Technique|Longitudinal Transvaginal Ultrasound Evaluation of Cesarean-scar Thickness in the First Two Years After Single- or Double-layer Uterotomy Closure: a Prospective Randomized Study||Charite University, Berlin, Germany|Yes|Completed|January 2012|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|435|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338388||29323|
NCT02329132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26-000|Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema|Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema||Kagawa University|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Aqueous humor is obtained at the initial injection of Lucentis.|Both|N/A|N/A|No|Probability Sample|Diabetic macular edema involving the foveal center, who are planned to be treated with        intravitreal injections of ranibizumab.|November 2015|November 1, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329132||30033|
NCT02282579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOG-SPA-2014-02|Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy|Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy, in Patients With Metastatic Renal Cell Carcinoma in Daily Clinical Practice|SPAZO|Spanish Oncology Genito-Urinary Group|Yes|Completed|October 2014|April 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|This study is aimed at patients who received pazopanib in first-line metastatic cell renal        cancer, so care (clinical trial patients are excluded) in the period from April 2011 (date        of approval of pazopanib in Spain) to 30 June 2014, ie, before the presentation of CEICs        in each hospital. In all cases, any decision to administer pazopanib therapy in first line        will be taken according to local clinical practice and prior to the inclusion of patients        in this retrospective study.|February 2015|May 7, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02282579||33607|
NCT02282852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17268|Can Steerable Capsule Endoscopy Enhance Gastric Emptying?|Randomised Comparison of a Standard Protocol Using Metoclopramide Versus a Hand Held Magnet to Enhance Gastric Emptying of the Small Bowel Capsule.||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|24|||Both|20 Years|N/A|No|||October 2014|March 20, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282852||33586|
NCT02289781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200002|Wear of Enamel Against Polished Zirconia Crowns|Wear of Enamel Antagonists by Polished Ceramic Surfaces||University of Florida|No|Recruiting|April 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02289781||33053|
NCT02289794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVXN EC-4V|Vaccine Against Escherichia Coli Infection|Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection||GlycoVaxyn AG|Yes|Completed|January 2014|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|194|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02289794||33052|
NCT02289859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|613430|Undermining During Cutaneous Wound Closure|Undermining During Cutaneous Wound Closure: a Randomized Split Wound Comparative Effectiveness Trial||University of California, Davis|No|Active, not recruiting|July 2014|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289859||33047|
NCT02289872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TruView/01|Pediatric Intubation|Comparison of the TruView PCD Video Laryngoscope and Macintosh Laryngoscope for Pediatric Tracheal Intubation by Novice Paramedics: A Randomized Crossover Simulation Trial.|ETICPR|International Institute of Rescue Research and Education|Yes|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02289872||33046|
NCT02289963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC14074|Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan||Sanofi|Yes|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289963||33039|
NCT02280967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFR-387561|Prevention of HPV in the School Health Service|Prevention of Human Papillomavirus (HPV) Associated Cancer by Intervention Studies in Teenagers Attending School Health||Uppsala University|No|Active, not recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1050|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02280967||33730|
NCT02281266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZDX-2014-05|Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection|Investigator Initiated Study of Thymosin in HBV-related HCC||Fudan University|Yes|Not yet recruiting|January 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|70 Years|No|||November 2014|November 20, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02281266||33707|
NCT02291432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-11|Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery|Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells||Cook||Recruiting|December 2014|April 2019|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||June 2015|November 17, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291432||32927|
NCT02332616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_08_2014b|Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|58|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332616||29766|
NCT02328638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073170|Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity|Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity||Emory University|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|3 Years|10 Years|No|||January 2016|January 19, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328638||30071|
NCT02328898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-244/M|Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent|A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8||UMC Utrecht|Yes|Recruiting|November 2014|January 2020|Anticipated|November 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1532|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02328898||30051|
NCT02329158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105755|Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery|Clinical Impact of Disinvestment in Hydroxyl-ethyl Starches (HES) for Patients Undergoing Cardiac Surgery||Lawson Health Research Institute|No|Not yet recruiting|May 2015|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|The proposed study population includes adult patients (age >/= 18) who underwent coronary        artery bypass surgery (CABG) with or without valve surgery at the London Health Sciences        Centre.|December 2014|December 30, 2014|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02329158||30031|
NCT02329171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-2-031|Imiquimod Treatment of CIN Lesions|TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial.|TOPIC|Maastricht University Medical Center|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329171||30030|
NCT02338323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB2015|Compare the Renal Protective Effects of Febuxostat and Benzbromarone|Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min||Shanghai 10th People's Hospital|Yes|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2015|January 14, 2015|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02338323||29328|
NCT02338401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Guelph|Effect of Fish Oil Supplementation on Resting Energy Expenditure, Skeletal Muscle Membrane Composition and Metabolism in Elderly Subjects.|Effect of Fish Oil Supplementation on Resting Energy Expenditure, Skeletal Muscle Membrane Composition and Metabolism in Elderly Subjects.||University of Guelph|No|Not yet recruiting|May 2015|May 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 10, 2015|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02338401||29322|
NCT02278211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREFFIR|Prediction of Recurrent Events With 18F-Fluoride|Prediction of Recurrent Events With 18F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients With Myocardial Infarction|PREFFIR|University of Edinburgh|No|Recruiting|October 2015|June 2024|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with recent (<21 days) type 1 myocardial infarction and multi-vessel coronary        artery disease|December 2015|December 1, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02278211||33942|
NCT02282306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2591|Phone Interview to Prevent Recurring Opioid Overdoses|Pilot Evaluation of the "Tailored Telephone Intervention Delivered by Peers to Prevent Recurring Opioid-Overdoses"|TTIP-PRO|University of Cincinnati|Yes|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282306||33628|
NCT02282319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/35/334|Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery|Influence of Spinal or Intravenous Dexmedetomidine on Spinal Anesthesia With Chloroprocaine and Bladder Function in Day-case Surgery. A Double Blind Randomized Study.||University Hospital, Antwerp|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|3||Anticipated|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282319||33627|
NCT02289742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-14-010|Tear Film Evaluation of Dailies® AquaComfort Plus® Multifocal and Toric|Characterization of Pre-Lens Tear Film Stability of Daily Disposable Multifocal and Toric Contact Lenses Using Ring Mire Projection||Alcon Research|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2015|May 12, 2015|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289742||33056|
NCT02291120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-ODP-4|MEDCEM PC and MTA in Pulpotomies of Primary Molars|||Universitat Internacional de Catalunya||Recruiting|March 2014|December 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|June 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291120||32951|
NCT02279849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH110547|Multi-level Communications and Access Strategies to Improve the Food Environment|Multi-level Communications and Access Strategies to Improve the Food Environment:B'More Healthy: Retailer Rewards (BHRR)|BHRR|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|444|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 30, 2014|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02279849||33816|
NCT02291198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG-001|Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy|Open Label, Prospective, Cross-Sectional Clinical Performance Study of the in Vitro Diagnostic Device NK Vue Kit: Measurement of Natural Killer Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy||ATGen Canada Inc|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1046|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02291198||32945|
NCT02291302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AI110397|School Inner-City Asthma Intervention Study (SICAS-2)|School Inner-City Asthma Intervention Study|SICAS-2|Children's Hospital Boston|Yes|Recruiting|January 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Both|4 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291302||32937|
NCT02291328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR04/2014|Effects of Brassica on Human Gut Lactobacilli|A Human Intervention Trial Investigating the Effects of Brassica on Gut Lactobacilli|EBL|Institute of Food Research|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291328||32935|
NCT02291341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859089-01|Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition|Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2008|November 13, 2014|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291341||32934|
NCT02291393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD12/10936|The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)|The Role of High Density Surface Cardiac Electrographic Mapping in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy :A Pilot Study||The Leeds Teaching Hospitals NHS Trust||Completed|August 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291393||32930|
NCT02276365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.17|Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 50 mg and Pioglitazone 45 mg After Co-administration Compared to BI 10773 and Pioglitazone Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|June 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|October 27, 2014|October 27, 2014||||No||https://clinicaltrials.gov/show/NCT02276365||34084|
NCT02285257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICU2014-1|Epidemiology of Sepsis at Yuetan Subdistrict in Beijing|Epidemiology of Sepsis at Yuetan Subdistrict in Beijing||Peking Union Medical College Hospital|Yes|Recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Questionnaires were used to collect the characteristic information of people living in        Yuetan subdistrict in Beijing for more than 1 years people who had been hospitalized        because of any reasons between July 2012 and June 2014 were selected.Patients were        included in the study cohort when having, in association with a documented or strongly        suspected infection and fullfil the diagnostic criteria of sepsis according to the        "Surviving Sepsis Campaign:International guidelines for management of severe sepsis and        septic shock:2012".|October 2014|November 5, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285257|1 Year|33401|
NCT02278549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT001GC|Comparison of Spinal Kinematics Between Asymptomatic Subjects and Patients With Low Back Pain|Comparison of Spinal Kinematics Between Asymptomatic Subjects and Patients With Low Back Pain Using a Multi-segment Model||Haute Ecole Cantonale Vaudoise de Santé|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|22|||Both|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with recurrent low back pain (more than months in duration) recruited through        physiotherapy practices and medical consultations in the area of Lausanne, Switzerland.|October 2015|October 26, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278549||33916|
NCT02336321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288551-2|Daily-life Brain Control Of A Hand Exoskeleton After Cervical Spinal Cord Injury|Restoration of Daily-life Hand Function Using a Brain/Neural-Computer Interaction (BNCI) System in Paralysis After Cervical Spinal Cord Injury||University Hospital Tuebingen|Yes|Completed|April 2014|May 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Both|15 Years|65 Years|No|||March 2014|May 13, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02336321||29482|
NCT02332863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1711|Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer.|Comparison of Traditional Back-loaded Fiducial Needles With Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement for Image-guided Radiation Therapy in Patients With Pancreatic Cancer: A Multicenter Randomized Controlled Trial.||University of Colorado, Denver|No|Not yet recruiting|April 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02332863||29747|
NCT02333110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-161|GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors|Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors||Sir Mortimer B. Davis - Jewish General Hospital|No|Recruiting|January 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02333110||29728|
NCT02333370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2115C|Phase Ib Dose-escalation, Phase II Study of LEE011 and Letrozole for Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer|A Phase Ib Dose-escalation Followed by a Phase II Single Arm Study of the Combination of LEE011 With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer||Novartis|No|Recruiting|February 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333370||29708|
NCT02281539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLP-004664|Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain|Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain||Integrum|No|Active, not recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02281539||33686|
NCT02328612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx611-0102|Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers|Phase I, Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers|CELLULA|Cellerix|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02328612||30073|
NCT02328859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1598-P|Virtual Reality Rehabilitation for Individuals With Lower Limb Amputation|Virtual Reality for Rehabilitation for Individuals With Lower Limb Amputation||VA Office of Research and Development|No|Active, not recruiting|March 2016|November 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02328859||30054|
NCT02289599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2307-J081-001|A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects|A Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects||Eisai Inc.|No|Completed|November 2014|July 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|24|||Male|20 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289599||33067|
NCT02289677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/10|Pediatric Intubation During CPR|Comparison of the Atmos Scope, the Coopdech and the AirTraq in Pediatric Patients During Resuscitation. Randomized Crossover Manikin Trial|ETICPR|International Institute of Rescue Research and Education|Yes|Enrolling by invitation|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02289677||33061|
NCT02289690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-361|Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer|A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer||AbbVie|No|Recruiting|October 2014|March 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|99 Years|No|||January 2016|January 7, 2016|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02289690||33060|
NCT02290873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS7056-006|A Phase III of Remimazolam in Patients Undergoing Colonoscopy|A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS7056) Compared to Placebo and Midazolam in Patients Undergoing Colonoscopy||Paion UK Ltd.|No|Recruiting|March 2015|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|460|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290873||32970|
NCT02291016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3798|COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers|A Randomized, Double-Dummy, Crossover, Single-Center Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers in the Treatment of Patients Recovering From Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)||University of Tennessee Graduate School of Medicine|No|Recruiting|February 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|N/A|No|||February 2015|February 6, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291016||32959|
NCT02279862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-437|Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive|A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic||Bristol-Myers Squibb|No|Active, not recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||February 2016|March 11, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279862||33815|
NCT02280148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJFH-EC/2013-073|Accessing the Driving Skills After the Endoscopy of Intravenous Anesthesia by Driving Simulator|Accessing the Driving Skills After the Endoscopy of Intravenous Anesthesia by Driving Simulator||Beijing Friendship Hospital|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02280148||33793|
NCT02280395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02-117838|A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60|A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics||Pulmatrix Inc.|Yes|Terminated|October 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|75 Years|No|||August 2015|August 5, 2015|October 26, 2014|Yes|Yes|Company merger resulted in business decision to terminate the study.|No||https://clinicaltrials.gov/show/NCT02280395||33774|
NCT02280408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V920-002|Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)|A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults||Merck Sharp & Dohme Corp.|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280408||33773|
NCT02280733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWR 001|A Real World, Observational Registry of Chronic Wounds and Ulcers|A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data|USWR|U.S. Wound Registry|Yes|Recruiting|January 2005|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|175000|||Both|N/A|N/A|No|Non-Probability Sample|All wounds in all patients at participating centers|October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280733|3 Months|33748|
NCT02291211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCCC006|S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis|Phase Ⅱ Study of S-1 Combined Cisplatin Hyperthermic Intraperitoneal Chemotherapy for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis||Tang-Du Hospital|Yes|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||September 2014|November 13, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291211||32944|
NCT02291224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-6588|Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens|Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens|2Gether|Centers for Disease Control and Prevention|Yes|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|710|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02291224||32943|
NCT02282878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406014201|The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis|The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis||Yale University|No|Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282878||33584|
NCT02339116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBE2|Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC|FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC COLORECTAL CANCER.|TRIBE2|Gruppo Oncologico del Nord-Ovest|No|Recruiting|January 2015|February 2021|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|654|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339116||29267|
NCT02339129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST0225-US-111-001A|Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Dosing Interval, Efficacy, and Safety of SST-0225, a Topical Ibuprofen Cream, in the Treatment of Delayed Onset Muscle Soreness (DOMS)|DIS DOMS|Strategic Science & Technologies, LLC|No|Completed|November 2014|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339129||29266|
NCT02336399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY002|Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment|Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment||Beijing Ditan Hospital|No|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|the study population in this study were composed of patients who had chronic hepatitis B        and achieved HBsAg loss by interferon treatment, and serum HBsAg and HBV DNA would be        tested every 3 months for 96 weeks after finished treatment.the sustained HBsAg response        defined serum HBsAg mantaining below the low limited value would be evalued during the        observation periad.|January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336399||29476|
NCT02336477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091101|Mexiletine and Non Dystrophic Myotonias|Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias|MYOMEX|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336477||29470|
NCT02336581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411-001|Researching the Effectiveness of Acceptance-Based Coping During Hospitalization|Effectiveness of Psychosocial Treatment for Inpatients With Psychosis|REACH|Butler Hospital|No|Recruiting|March 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336581||29462|
NCT02336828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1155044283|Validation of Modified Early Warning Score (MEWS) in Predicting Outcomes in Clinical Oncology Ward Adult Patients|Validation of Modified Early Warning Score (MEWS) in Predicting Outcomes in Clinical Oncology Ward Adult Patients|MEWS|Chinese University of Hong Kong|No|Recruiting|January 2015|March 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|171|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical oncology ward adult patients|January 2015|January 23, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336828||29443|
NCT02281552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921215|A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate||Pfizer|Yes|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281552||33685|
NCT02277405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/04|Pediatric Intubation During Resuscitation|A Comparison of Endotracheal Intubation Using the Shikani Optical Stylet or the Endoeye Flexible Intubation During Pediatric Resuscitation|PIDR|International Institute of Rescue Research and Education|Yes|Recruiting|October 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277405||34004|
NCT02277691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536TCH/OCT-001|A Phase III Long-term Study of TAK-536TCH in Patients With Essential Hypertension|A Phase III, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Long-term Administration of TAK-536, Amlodipine (AML), and Hydrochlorothiazide (HCTZ) in Patients With Essential Hypertension||Takeda|No|Active, not recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|20 Years|N/A|No|||January 2016|January 28, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277691||33982|
NCT02277938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:063|Acetylamantadine Excretion by Cancer Patients|Urinary Excretion of Acetylamantadine by Cancer Patients||University of Manitoba|No|Recruiting|August 2013|October 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|80 Years|No|||October 2014|October 27, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277938||33963|
NCT02282085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.AOM.2013.004|Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia|A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2014|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||June 2015|June 3, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282085||33645|
NCT02290795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPI study|Vitreopapillary Interface and Optic Disc Morphology|Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population consists of patients visiting either the glaucoma consultation or the        vitreo-retinal disease consultation (depending on study group recruitment). Healthy        controls will be recruited from subjects accompanying these patients.|October 2014|January 20, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02290795||32976|
NCT02290808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133614|First-time Parents Physical Activity Intervention|First-time Parents Physical Activity Intervention||University of Victoria|No|Recruiting|March 2014|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|40 Years|No|||December 2015|December 1, 2015|April 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02290808||32975|
NCT02290938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA022066|Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)|Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)|MICUNAY|RAND|Yes|Recruiting|July 2014|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290938||32965|
NCT02279589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130903|Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers|Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers|HYPOPNEUMO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2014|May 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02279589||33836|
NCT02279602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX4219s|Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study|Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers||OXiGENE|Yes|Enrolling by invitation|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02279602||33835|
NCT02284217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-009|An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an External Ventricular Drainage (EVD) Device|A Prospective, Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Intracranial Pressure (ICP) Monitor, in Patients Undergoing Invasive ICP Monitoring Procedure for Various Clinical Conditions||HeadSense Medical|Yes|Not yet recruiting|December 2014|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284217||33481|
NCT02284490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI003|High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases|High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases||Shandong Cancer Hospital and Institute|Yes|Not yet recruiting|November 2014|November 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|95 Years|No|||November 2014|November 3, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02284490||33460|
NCT02284750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH20141029|Two-stent vs Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions|A Prospective, Multi-center, Randomized Trial Comparing Two-stent With Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions|DEFINITION-2|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|December 2015|December 2021|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02284750||33440|
NCT02285036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walvax-01|Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children|A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children||Walvax Biotechnology Co., Ltd.|Yes|Completed|September 2012|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|1660|||Both|2 Years|N/A|No|||November 2014|November 5, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02285036||33418|
NCT02278237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-1844|Pre/Post Pilot Test of Video Module Education|Pre/Post Pilot Test of VME for the Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN Study|Pilot VME|University of Chicago|No|Not yet recruiting|November 2014|||March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|90|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02278237||33940|
NCT02278250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-803-001|An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma|An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma||Vertex Pharmaceuticals Incorporated|No|Recruiting|January 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|18 Years|N/A|No|||November 2015|March 23, 2016|October 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278250||33939|
NCT02292745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014- 00235039|Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.|Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.|LAPC-1|Foundation for Liver Research|No|Recruiting|November 2014|November 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02292745||32826|
NCT02292758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU021302I|Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer|A Randomized, Double-blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer||Academic and Community Cancer Research United||Recruiting|March 2015|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|December 24, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292758||32825|
NCT02328651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEJB_Ver1.0|Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease|Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients||Children's Hospital of Fudan University||Recruiting|October 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|398|||Both|1 Year|5 Years|No|||February 2016|February 4, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328651||30070|
NCT02328664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAPURA-Study|SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality|The Sensitivity of Scar-biopsies for Residual Colorectal Adenocarcinoma After Endoscopic Resection With Uncertain Radicality|SCAPURA|Deventer Ziekenhuis|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1356|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02328664||30069|
NCT02341677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0044|SmartTarget: BIOPSY|SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Biopsy||University College, London|No|Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Male|N/A|N/A|No|||January 2015|January 14, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02341677||29071|
NCT02341716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUH|Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication|Hospital- or Home-based Supervised Exercise Therapy or Unsupervised Walk Advice for Patients With Intermittent Claudication|SUNFIT|Sahlgrenska University Hospital, Sweden|No|Recruiting|September 2014|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|N/A|N/A|No|||November 2015|November 23, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02341716||29068|
NCT02341742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_69|Physical Activity and Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel Disease|Relationship Between Physical Activity and Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel Disease|PHYSICOSMICI|University Hospital, Lille|No|Recruiting|October 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|6 Years|18 Years|No|Non-Probability Sample|Children and Adolescents With Inflammatory Bowel Disease: Crohn´s disease and Ulcerative        colitis|January 2016|January 18, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02341742||29066|
NCT02287402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO-128/OCT-910|Postmarketing Clinical Study on AO-128|Postmarketing Clinical Study on AO-128||Takeda|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|197|||Both|20 Years|N/A|No|||April 2015|April 8, 2015|October 22, 2014|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT02287402||33236|
NCT02281825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sha-0001-14|Correlating Real and Virtual World Behavioral Fluctuations in Adolescence|Correlating Real and Virtual World Behavioral Fluctuations in Adolescence||Shalvata Mental Health Center|No|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|||Male|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male adolescents, 13-18, with and without psychopathology, evaluated and diagnosed by        psychiatrists. Adolescents will be recruited from Shalvata MHC children and adolescents        outpatient clinic and from convinience sample in the community.|May 2015|May 19, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281825||33665|
NCT02282072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-003|PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction|PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction||Beijing Pins Medical Co., Ltd|Yes|Recruiting|October 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|October 12, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02282072||33646|
NCT02287857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTQ-TDF-V3.0|Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B|||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|September 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|65 Years|No|||October 2014|November 6, 2014|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287857||33201|
NCT02290691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJ-501-14|Inactivated Influenza Via Jet Injection|Inactivated Influenza Via Jet Injection|IIJI|PharmaJet, Inc.|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|985|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2014|April 28, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290691||32984|
NCT02279056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00834886|Randomized Controlled Trial of a Self-help Book for Insomnia in Patients With Co-morbid OSA and Insomnia|A Randomized Controlled Trial (RCT) of a Self-help Book for Insomnia in Patients With Co-morbid Obstructive Sleep Apnea (OSA) and Insomnia||University of Bergen|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02279056||33877|
NCT02279303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140150H|Rx for Better Breast Health|Prescription for Better Breast Health||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|April 2013|March 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02279303||33858|
NCT02283632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-14-001|A Trial of the Jejunal Diversion Procedure|A Trial of the Jejunal Diversion Procedure (Side-to-side Jejuno-jejunostomy) (Europe)||Ethicon Endo-Surgery|No|Active, not recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|60 Years|No|||December 2015|December 1, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283632||33526|
NCT02283931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002175|Assessement of Hemodynamic Changes Associated With Uterine Displacement Using Noninvasive Cardiac Output Monitoring and Transthoracic Echocardiography:|Assessement of Hemodynamic Changes Associated With Uterine Displacement Using Noninvasive Cardiac Output Monitoring and Transthoracic Echocardiography:|LUDCO|Brigham and Women's Hospital|Yes|Recruiting|January 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|25|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283931||33503|
NCT02290821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-P-322|Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Blunt Soft Tissue Injuries/Contusions of the Limbs||Novartis|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|215|||Both|16 Years|N/A|No|||November 2015|November 23, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290821||32974|
NCT02290834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-217|Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer|Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer||Massachusetts General Hospital|Yes|Not yet recruiting|November 2014|September 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|200|||Female|60 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 11, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02290834||32973|
NCT02290951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1979-HM-1333|A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies|An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy||Regeneron Pharmaceuticals|No|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02290951||32964|
NCT02291029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFZ533X2203|Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome||Novartis|No|Recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|42|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291029||32958|
NCT02291042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05|Effect of an Anti-spasmodic Suppository to Improve Comfort After Urologic Surgery|Pre-operative Administration of a Muscarinic Antagonist for Elective Cystoscopy Patients|SPASMS|Southern New Hampshire Medical Center|Yes|Not yet recruiting|November 2014|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|October 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291042||32957|
NCT02291133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21K/02/14|Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)|Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)|ECT-HCC|University Medical Centre Ljubljana|Yes|Recruiting|June 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02291133||32950|
NCT02282618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|doctorliuwei|Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure|Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure, a 2-year, Prospective, Randomized Cohort Study||Harbin Medical University|No|Recruiting|May 2013|||May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|||Both|17 Years|80 Years|No|Probability Sample|heart failure|October 2014|November 3, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282618||33604|
NCT02279628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004498-14|Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section|Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section. Controlled Comparative Study.||Central Hospital, Nancy, France|No|Recruiting|July 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|55 Years|No|||October 2014|October 28, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02279628||33833|
NCT02332876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K07CA181323-01A1|Physical Activity and Neuropsychological Outcomes in a Cancer Population|||University of California, San Diego|No|Recruiting|August 2014|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|80|||Female|21 Years|85 Years||||November 2015|November 30, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02332876||29746|
NCT02328911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110921|Laser Therapy for Diabetic Peripheral Neuropathic Pain|Laser Therapy Treatment of Peripheral Neuropathic Pain in Individuals With Diabetes||University of Miami|No|Withdrawn|January 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|November 16, 2014|Yes|Yes|Difficulty recruiting qualified subjects.|No||https://clinicaltrials.gov/show/NCT02328911||30050|
NCT02329184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYK-461-001|Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461|Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy||MyoKardia, Inc.|Yes|Active, not recruiting|December 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|December 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02329184||30029|
NCT02329197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H005|Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure|||Mansoura University|Yes|Recruiting|October 2014|March 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Female|19 Years|40 Years|No|||December 2014|December 30, 2014|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329197||30028|
NCT02329470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr: 2010-329-31M|Obstructive Sleep Apnea and Arterial Stiffness|Cardiovascular Effects of CPAP Treatment for Obstructive Sleep Apnea||Umeå University|No|Recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02329470||30007|
NCT02290548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MMHIS164|Effect of High-flow Nasal Oxygen on Extubation Outcome|Effect of High-flow Nasal Oxygen vs Standard Oxygen Therapy on Extubation Outcome With High Risk of Extubation Failure in Medical ICU Patients||Mackay Memorial Hospital|Yes|Recruiting|December 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|95 Years|No|||December 2014|December 11, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02290548||32995|
NCT02287636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Z13|PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer|Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients||Case Comprehensive Cancer Center|No|Active, not recruiting|April 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|N/A|17 Years|No|||January 2016|January 14, 2016|April 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287636||33218|
NCT02290743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT-QF|Effect of Kinesio Taping on Muscle Strength in Quadriceps Femoris|The Effect of One Application of Kinesio Tape on Muscle Strength in Quadriceps Femoris on Patients With Knee Problems or Pain and Weak Quadriceps Femoris - a Randomized Controlled Trial||Norwegian School of Sport Sciences|Yes|Completed|November 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|67 Years|No|||January 2015|January 30, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02290743||32980|
NCT02278536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-016-NPT|Multiple Gestation Study|Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated From Maternal Blood||Natera, Inc.|No|Recruiting|March 2013|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Maternal and Paternal blood samples      CVS or Amniocentesis sample (optional)      Child saliva sample (optional)      *Biospecimen retention is optional portion of consent form|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|October 2015|October 15, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278536||33917|
NCT02283385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306014011|Mental Health Intervention for Elderly Abuse Victims|Mental Health Intervention for Elderly Abuse Victims: Providing Options to Elderly Clients Together (PROTECT)|PROTECT|Weill Medical College of Cornell University|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|350|||Both|60 Years|N/A|No|||October 2014|November 4, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02283385||33545|
NCT02283645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-57080|Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement|Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement : A Randomized, Double-blind, Placebo-controlled Study||Mae Fah Luang University Hospital|No|Not yet recruiting|January 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 29, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02283645||33525|
NCT02290704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013MEKY039|Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People|Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People||Sun Yat-sen University|Yes|Recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Controls- normal people; GO patients- patients with Graves' ophthalmopathy|November 2014|November 13, 2014|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290704||32983|
NCT02290756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:301|A Community Based Implementation of a Toolkit and Parenting Program for Improving Brain Development in Newborns|A Community Based Implementation of a Low Cost Evidence-based Toolkit and Parenting Program for Improving Brain Development in Newborns||University of Manitoba|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1080|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02290756||32979|
NCT02276651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Observational Trial of a Therapeutic Platelet Transfusion Regimen|A Prospective Multicenter Observational Trial of a Therapeutic Platelet Transfusion Regimen for Patients With Acute Myeloid Leukemia in Consolidation Chemotherapy||Klinikum Nürnberg|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with acute myeloid leukemia in complete remission receiving postremission        chemotherapy|September 2015|September 4, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276651||34062|
NCT02276664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17952|Capitalizing on a Teachable Moment to Promote Smoking Cessation|Capitalizing on a Teachable Moment to Promote Smoking Cessation||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276664||34061|
NCT02277171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOX PHASE I_1.1|Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters|Prospective, Phase I, Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters in Patients Undergoing Radical Prostatectomy||Enox Israel Ltd|No|Completed|December 2014|September 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02277171||34022|
NCT02277184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-060|Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma|A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives||University of Pittsburgh|Yes|Suspended|September 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277184||34021|
NCT02277444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105178|A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy|A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy|GO-VIVA|Janssen Research & Development, LLC|Yes|Recruiting|December 2014|October 2022|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|2 Years|18 Years|No|||March 2016|March 1, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277444||34001|
NCT02277964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2324|Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod|An Observational Study to Evaluate Disease Control, Safety and Immunological Changes in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Transferred From Previous Treatment With Natalizumab to Fingolimod.||University Hospital, Basel, Switzerland|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|-  assess alterations of the composition of myeloid cells and lymphocyte subpopulations           (i.e. naïve, central memory and effector memory and regulatory T cells, B cells) and           adhesion molecule expression in peripheral blood        -  measure autoantigen specific T cell proliferation and IFNγ production        -  characterize transcriptomic alterations (including mRNA and small non-coding RNA           expression) in lymphocytes of MS-patients        -  assess changes in plasma cytokine, chemokine, and Matrix metallo-proteinase levels        -  assess the migratory capacity of PBMCs|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with relapsing remitting multiple sclerosis, who are planned to change treatment        from natalizumab to fingolimod|November 2015|November 23, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277964||33961|
NCT02282358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-106|Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma|An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282358||33624|
NCT02291588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060203|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus||Amgen|No|Completed|December 2007|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||November 2014|November 11, 2014|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291588||32915|
NCT02291601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-052|Preoperative CHG Cloth (2)|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|879|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 5, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291601||32914|
NCT02334826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Poznan01/2015|Revascularization With BVS or CABG in Patients With Advanced CAD|Revascularization With the Use of Biodegradable Scaffolds Compared to CABG in Patients With Advanced Stable Ischemic Heart Disease|RELEASE-BVS|Poznan University of Medical Sciences|Yes|Not yet recruiting|February 2015|August 2022|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334826||29596|
NCT02333123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0096|Aspirin for Venous Ulcers: Randomised Trial (AVURT)|Aspirin for Venous Ulcers: Randomised Trial (AVURT)|AVURT|St George's, University of London|Yes|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02333123||29727|
NCT02333383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-238|Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients|A Prospective, Mono-Country, Multi-Center Study to Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis Patients on Adalimumab Therapy|AS PMOS|AbbVie|No|Recruiting|December 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|19 Years|100 Years|No|Probability Sample|General Hospital|January 2016|January 27, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333383||29707|
NCT02333617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00621|Manual Therapy to Treat Gluteus Medius Trigger Points|Manual Therapy to Treat Gluteus Medius Trigger Points to Improve Hip Abduction Strength in Patients With Anterior Knee Pain.||Nationwide Children's Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|13 Years|N/A|No|||November 2015|November 18, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02333617||29689|
NCT02333864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-000321|POGO® Automatic Blood Glucose Monitoring System Clinical Study|||Intuity Medical, Inc|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|287|||Both|18 Years|N/A|No|Non-Probability Sample|People who are 18 years of age or older and have been diagnosed with diabetes|May 2015|May 26, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02333864||29670|
NCT02333877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skinlink_SHH|Comparison of Skinlink With Suture for ED Patients|Comparison of Skinlink With Suture for ED Patients: a Randomized Controlled Trial|Skinlink|Hallym University Kangnam Sacred Heart Hospital||Completed|January 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02333877||29669|
NCT02277951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InternationalIRRE|Intubation During Resuscitation|Comparison of Four Types of Laryngoscope for Tracheal Intubation During Chest Compressions|IDR|International Institute of Rescue Research and Education|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|141|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Personnel of emergency medical services and hospital emergency units|October 2014|October 27, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02277951||33962|
NCT02290626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED vs. Semi-solid|Elemental Diets vs. Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation|Randomized Comparison of Elemental Diets and Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation in Bedridden Gastrostomy-fed Patients||Showa Inan General Hospital|No|Withdrawn|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|90 Years|No|||October 2015|October 30, 2015|November 2, 2014||No|Study protocol was changed.|No||https://clinicaltrials.gov/show/NCT02290626||32989|
NCT02278783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI77685|Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer|Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer||University of Utah|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278783||33898|
NCT02283138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lab7680|Prediction of Neonatal Respiratory Distress Syndrome in Preterm Fetuses by Assessment of Fetal Lung Volume by Vocal and Pulmonary Artery Resistance Index a Pilot Study|||Ain Shams University||Recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women at 28 to 34 weeks gestation|March 2016|March 7, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283138||33564|
NCT02283372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412038|Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer|Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer||Washington University School of Medicine|No|Recruiting|January 2015|July 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283372||33546|
NCT02290275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2014:117|Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis|Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis||University of Manitoba|No|Recruiting|January 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|45 Years|65 Years|No|||November 2015|November 30, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290275||33015|
NCT02292017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNVI 001|Prospective Packing Density With Target Coils I|A Prospective Single Center Trial Investigating the Effects of Prospectively Measuring Packing Density Prior to Choosing Target Coils for the Treatment of Intracranial Saccular Aneurysms.|PropackI|Tennessee Neurovascular Institute, LLC|No|Recruiting|October 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||November 2014|November 14, 2014|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292017||32882|
NCT02292030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dong hao|Cardioversion of Atrial Fibrillation Accompanied by Chronic Heart Faliure|Cardioversion of Atrial Fibrillation Accompanied by Chronic Heart Faliure With or Without HTEA||Harbin Medical University|No|Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|20 Years|70 Years|No|Probability Sample|congestive heart failure.|November 2014|November 12, 2014|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02292030||32881|
NCT02276404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-5778-BO|Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer Patients|Entspannung Und Akupunktur Zur Reduktion Perioperativer Symptome Bei Brustkrebspatientinnen- Eine Randomisiert-kontrollierte Interventionsstudie im Kontext Einer Integrativ Onkologischen Versorgung (EARpeS)||Universität Duisburg-Essen|No|Recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|75 Years|No|||December 2015|December 3, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276404||34081|
NCT02281591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-115|Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine|Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Following Oral Administration in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|October 30, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02281591||33682|
NCT02281604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|In-line Filter 13/14|In-line Filters on ICU|||Johann Wolfgang Goethe University Hospitals|No|Enrolling by invitation|January 2013|December 2017|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients, which will be treated on the anaesthesiological/surgical ICU of the        University Hospital Frankfurt between 2013 - 2014|April 2015|February 22, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281604||33681|
NCT02281851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125663|Examining Endogenous Antioxidant Levels in Well Trained Cyclists|The Effects of Habitual Antioxidant Supplementation on Endogenous Antioxidants and Oxidative Damage in Well Trained Cyclists||University of Birmingham|No|Recruiting|July 2013|||May 2015|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|50|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cyclist from the local West Midlands (United Kingdom) area will be invited to take part in        the study.|October 2014|October 30, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02281851||33663|
NCT02282111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00028905|EUS-CNB Versus EUS-SINK for Diagnosis of UGI Subepithelial Tumors|EUS-guided Core Needle Biopsy (EUS-CNB) Versus EUS-guided Single-incision With Needle Knife (SINK) for the Diagnosis of Upper Gastrointestinal Subepithelial Lesions - a Multicenter Randomized Controlled Trial||Johns Hopkins University|Yes|Recruiting|July 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02282111||33643|
NCT02282124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZK-Nr. 2011-0411|Effectiveness of an APN-led Self-management Program in Patients in the First Year After Renal Transplantation|Effectiveness of an Advanced Practice Nurse-led Self-management Program on Prevention of Weight Gain, Physical Activity and Medication Adherence in Patients in the First Year After Renal Transplantation|SMP-NEP|University of Zurich|No|Recruiting|May 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|122|||Both|18 Years|N/A|No|||May 2015|June 2, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02282124||33642|
NCT02282371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-116|Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)|A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282371||33623|
NCT02282605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XF-73B03|Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects|A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.||Destiny Pharma Ltd|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 16, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02282605||33605|
NCT02291237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-361-1157|Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy|Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy|LIBERTY-HCM|Gilead Sciences|Yes|Recruiting|February 2015|June 2019|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291237||32942|
NCT02292719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-567|A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis||AbbVie|No|Recruiting|December 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|70|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292719||32828|
NCT02292732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113707|A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors|A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics and Safety of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) and to Characterize the Pharmacokinetics of Trametinib's Metabolite M5 in Female Subjects With Solid Tumors||GlaxoSmithKline|No|Withdrawn|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|58 Years|No|||January 2016|January 25, 2016|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292732||32827|
NCT02337270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M002|Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol|Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol||McMaster University|Yes|Not yet recruiting|April 2015|||April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337270||29409|
NCT02337283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346.2|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets Given Orally Once Daily for 12 Days to Young and Elderly Healthy Male and Female Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Study)(Part 1) and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 After Oral Administration in the Morning Versus Oral Administration in the Evening in Young Healthy Male and Female Volunteers (Randomised, Two-sequence, Open, Two Period, Two-way Cross Over) (Part 2)||Boehringer Ingelheim||Completed|January 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|96|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|January 9, 2015||||No||https://clinicaltrials.gov/show/NCT02337283||29408|
NCT02336698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100069|Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|February 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336698||29453|
NCT02336711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/13MAR/117|Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx|Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced Squamous Cell Carcinoma of the Oropharynx: a Phase-I Study.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|November 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336711||29452|
NCT02336724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-II-GIST|A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor|A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor||Jiangsu HengRui Medicine Co., Ltd.|No|Active, not recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|75 Years|No|||January 2016|January 31, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336724||29451|
NCT02336841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159490|Self-Help And Recovery Guide in Eating Disorders|A Study of the Feasibility and Effectiveness of the Addition of Self Help And Recovery Guide for Eating Disorders (SHARED) to Treatment as Usual for Anorexia Nervosa|SHARED|King's College London|No|Not yet recruiting|January 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|N/A|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336841||29442|
NCT02336997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2014]47|Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration|||Shanghai Jiao Tong University School of Medicine||Recruiting|January 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||January 2015|January 20, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02336997||29430|
NCT02337153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9367|Ankylosed Teeth Treatment by Bone Orthodontic Treatment|Study of Validation of Measurements of the Movement of Stiff Treated Teeth and Orthodontic Corticotomy|OBS|University Hospital, Montpellier|No|Recruiting|April 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|13 Years|25 Years|No|Probability Sample|Patient in need of orthodontic treatment and presenting one or more teeth stiff|November 2015|November 19, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02337153||29418|
NCT02342171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM0614|Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea|Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea|Ebola-Tx|Institute of Tropical Medicine, Belgium|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|N/A|N/A|No|||January 2016|January 15, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02342171||29033|
NCT02282592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481.165|Metabolic Syndrome and Female Breast Cancer|Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil||Catholic University of Pelotas||Completed|November 2013|October 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|164|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Between December 2013 and August 2014, newly diagnosed (within 6 months) BC female        patients referred to the oncology sector of the Teaching Hospital of the Federal        University of Pelotas and to the Radiotherapy and Oncology Center of Santa Casa de        Misericordia of Pelotas were invited to the study, before starting any adjuvant or        neoadjuvant treatment. Women with a recidivated tumor, HIV infection, renal, heart or        liver disease, hypothyroidism or hyperthyroidism, mobility or neurological limitations,        chronicle use of corticosteroids, pacemakers or identified with severe edema were        excluded. For each cancer case, one female control should be matched for age (± 5 years)        and menopausal status (pre and post-menopausal). Apart from being free from all the        exclusion criteria used for BC cases, controls should also have no signs of malignant        disease. These women were invited to participate in the study while frequenting the        Gynecologic Ambulatory of the same institutions, in the same period.|October 2014|October 31, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02282592||33606|
NCT02278224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RuCoD-CPH|Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression|Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression and Relapse Prevention -a Pragmatic RCT Study in a Danish Psychiatric Outpatient Service|RuCoD|University of Copenhagen|Yes|Completed|November 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02278224||33941|
NCT02290106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014p-002117|Effects of Pitavastatin on Insulin Sensitivity and Liver Fat|Effects of Pitavastatin on Insulin Sensitivity and Liver Fat||Massachusetts General Hospital|No|Recruiting|February 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|40 Years|65 Years|No|||March 2016|March 14, 2016|November 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290106||33028|
NCT02291913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 212|Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer|Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer||SCRI Development Innovations, LLC|No|Active, not recruiting|November 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291913||32890|
NCT02291939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT-IT-01|Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery|Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery||Domain Surgical, Inc.|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an indication for surgical intervention for a parotidectomy.|January 2016|January 23, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291939||32888|
NCT02280980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLC.CI.HCC7.2014|Effect of Oculomotor and Gaze Stability Exercises on the Improvement of Balance After Stroke|Effectiveness of Oculomotor and Gaze Stability Exercises on the Improvement of Balance After Brain Stroke in Patients Older Than 60 Years Old||Centro Hospitalar de Lisboa Central|No|Enrolling by invitation|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|60 Years|N/A|No|||February 2016|February 23, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02280980||33729|
NCT02281292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LKA651X-2101|A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema|A Randomized, Sham Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Diabetic Macular Edema||Alcon Research|Yes|Withdrawn|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|No|||December 2015|December 9, 2015|October 30, 2014||No|Management Decision|No||https://clinicaltrials.gov/show/NCT02281292||33705|
NCT02287883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS-1310-06821|Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs|The Comparative Impact of Patient Activation and Engagement on Improving Patient-Centered Outcomes of Care in Accountable Care Organizations|ACTIVATE|University of California, Berkeley|No|Enrolling by invitation|April 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4368|||Both|18 Years|82 Years|No|Probability Sample|4368 patients with diabetes or cardiovascular disease receiving care from selected clinics        at two Accountable Care Organizations in Los Angeles, CA and Chicago, IL.|June 2015|June 1, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287883||33199|
NCT02287896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADNC-1301|Pharmacokinetics and Safety of Roledumab, in RhD-negative Pregnant Women Carrying an RhD-positive Foetus|Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study||Laboratoire français de Fractionnement et de Biotechnologies|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02287896||33198|
NCT02290964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-201409.01|Effect of Acute Normovolemic Haemodilution on Allogenic Transfusion Needs In Laparotomy|Effect of Acute Normovolemic Haemodilution on Allogenic Transfusion Needs in Patients Undergoing Laparotomy Surgery|ANH|Universitas Padjadjaran|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|79 Years|No|||November 2014|November 13, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02290964||32963|
NCT02291055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADXS001-04|Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer|Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer||Advaxis, Inc.|No|Active, not recruiting|April 2015|December 2019|Anticipated|July 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291055||32956|
NCT02291068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TelAvivSMO|Psychological Flexibility and Effectiveness of Psychotherapy|Psychological Flexibility and Effectiveness of Psychotherapy Treatment in Patients With Adjustment Disorder||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|65 Years|No|||November 2014|November 11, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02291068||32955|
NCT02292706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1431|A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection|A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection||Gilead Sciences|Yes|Enrolling by invitation|December 2014|March 2021|Anticipated|March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Participants with cirrhosis who have achieved an SVR after receiving a SOF-based regimen        without IFN while participating in a Gilead-sponsored HCV study. In addition, participants        with cirrhosis who have achieved SVR after an all-oral SOF-based regimen outside a        clinical study may be eligible to enroll in this registry at sites preselected by Gilead.|March 2016|March 22, 2016|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292706|5 Years|32829|
NCT02279329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0018|Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging|Longitudinal Study of 3He and 129Xe Magnetic Resonance Imaging in Chronic Obstructive Pulmonary Disease||Western University, Canada|No|Recruiting|May 2009|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|50 Years|85 Years|No|||March 2016|March 23, 2016|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02279329||33856|
NCT02327689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-01-cirrhosis patients|Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients|Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients||Asian-Pacific Alliance of Liver Disease, Beijing|Yes|Not yet recruiting|January 2015|July 2017|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327689||30144|
NCT02342041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP13031H3|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects||Suven Life Sciences Limited|Yes|Completed|September 2014|August 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|January 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342041||29043|
NCT02342067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-1-122|Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination|A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ||Tobira Therapeutics, Inc.|No|Completed|December 2014|April 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342067||29041|
NCT02342093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-DRSP|Contraceptives Containing Drospirenone and Blood Pressure|Effects of Two Contraceptives Containing Drospirenone on Blood Pressure in Normotensive Women: a Randomized Controlled Trial||University of Sao Paulo|No|Completed|January 2011|September 2014|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|44|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342093||29039|
NCT02342158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERMED01-IPC 2014-003|Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors|Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003|PERMED01|Institut Paoli-Calmettes|No|Recruiting|November 2014|November 2020|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|460|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02342158||29034|
NCT02330250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADELES/002|Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment|Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment in Rio de Janeiro: a Randomized Clinical Trial|ADELES|Oswaldo Cruz Foundation|Yes|Active, not recruiting|July 2014|March 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||October 2015|October 22, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330250||29947|
NCT02289976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGU-01/14|Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression|Talar Avascular Necrosis: Surgical Angiogenesis Compared to Core Decompression With Osseous Autografting|TalarAVN|BG Trauma Center Ludwigshafen|No|Recruiting|February 2014|November 2016|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289976||33038|
NCT02289989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2012002449|Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis|Investigator-Initiated, Randomized, Investigator-Blind, Half-Side Comparison of Topical Oregano Extract Ointment vs .Hydrocortisone 1% for the Treatment of Atopic Dermatitis in Pediatric Patients||Rutgers, The State University of New Jersey|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|17 Years|No|||December 2015|December 17, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02289989||33037|
NCT02282865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0599|The Relationship Between the Surgery-related Anxiety and HRV: Prediction for Aggressive Emergence Behavior|||Yonsei University|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|140|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|20-60 years old male, ASA 1-2, scheduled for elective closed reduction for nasal bone        fracture.|July 2015|July 6, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282865||33585|
NCT02283112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLUH 4520|Validation of Drug Assays in Various Biological Matrices|Validation of Drug Assays in Various Biological Matrices||University of Liverpool|No|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers receiving specific medication or healthy volunteers taking no        medication.|January 2016|January 8, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02283112||33566|
NCT02283125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||February 15, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283125||33565|
NCT02291874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0132|Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)|An Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With GLP-1 Receptor Agonists||Astellas Pharma Inc|No|Active, not recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02291874||32893|
NCT02291900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGU - 01/14|Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression|Talar Avascular Necrosis: Surgical Angiogenesis Compared to Core Decompression With Osseous Auto Grafting|TalarAVN|BG Trauma Center Ludwigshafen|No|Recruiting|February 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2014|November 15, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02291900||32891|
NCT02280759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB56/2014|Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children.|Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children: A Double Blind Randomized, Placebo- Controlled Trial .||Medical University of Warsaw|Yes|Recruiting|November 2014|November 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|158|||Both|N/A|5 Years|No|||July 2015|September 29, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280759||33746|
NCT02285517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShahrakiB|Comparing Modified Meek and Mesh Techniques|Comparing Mesh and Modified Meek Skin Grafting Techniques in Third Degree Burned Patients Referred to Burn Ward of Khatam-al-anbia Hospital, Irtan||Shahraki, Babak N., M.D.|Yes|Completed|April 2013|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||November 2014|November 7, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285517||33381|
NCT02285738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8Y14|Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis|Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis: A Pilot Study||Case Comprehensive Cancer Center|Yes|Recruiting|December 2014|||August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285738||33364|
NCT02292576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.21.NRC|Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits|Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits||Nestlé|No|Completed|June 2012|August 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292576||32839|
NCT02292589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAHC-001|Brain Stimulation for Mild Traumatic Brain Injury|tDCS in Patients With Mild Traumatic Brain Injury and Persistent Post Concussion Syndrome: Randomized Crossover Trial|tDCS/PPCS|University of Sao Paulo General Hospital|Yes|Recruiting|October 2014|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|3||Anticipated|20|||Both|18 Years|60 Years|No|||November 2014|September 10, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292589||32838|
NCT02292602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD078890-01|Developing a Preschool Obesity Intervention for Families Enrolled in WIC|Developing a Preschool Obesity Intervention for Families Enrolled in WIC||Wayne State University|No|Recruiting|February 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|24 Months|55 Months|No|||June 2015|June 2, 2015|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02292602||32837|
NCT02292693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/18|Direct Laryngoscopy During Cervical Trauma|Comparison Three Different Laryngoscope Blades for Endotracheal Intubation in Pediatric Patients With Cervical Spine Immobilization.||International Institute of Rescue Research and Education|Yes|Enrolling by invitation|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292693||32830|
NCT02279095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVO-1A-202|An Open-Label Extension Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects|A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)||Clementia Pharmaceuticals Inc.|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|65 Years|No|||January 2016|January 7, 2016|October 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279095||33874|
NCT02334579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 5642|Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer|Function-Preserving Stereotactic Body Radiotherapy for Clinical State I-III Prostate Cancer||Swedish Medical Center|No|Recruiting|December 2014|December 2024|Anticipated|December 2023|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|146|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334579||29615|
NCT02280707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19475-105|Intervention to Promote Water Consumption in School Lunchrooms|Grab a Cup, Fill it up! An Intervention to Promote Convenience of Drinking Water and Increase Student Water Consumption During School Lunch.||Harvard School of Public Health|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280707||33750|
NCT02280720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-006|Vascular Healing After Deployment of Titanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Everolimus-Eluting Stent|A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 2 Months After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Drug-Eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve|TIDES-OCT|The Hospital District of Satakunta|Yes|Completed|January 2013|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280720||33749|
NCT02329483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BagcilarTRH|Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders|Early Follicular Phase Androstenedione Monitoring During Low-dose Step-up Induction of Ovulation in High Responders||Bagcilar Training and Research Hospital|No|Recruiting|December 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary/Secondary Infertile patients (couples); ovarian high response to ovulation        induction anticipated; with mild male factor or without any male factor.        Hysterosalpingography reveals patent uterine tubes and normal uterine cavity.|April 2015|April 4, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329483||30006|
NCT02329743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR-45-1401|Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery|A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery||A.T. Resolve SARL|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|256|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329743||29986|
NCT02329756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor College of Medicine|Tranexamic Acid in Adherent Placenta (TAP)|TRANEXAMIC ACID IN ADHERENT PLACENTA (TAP) , A RANDOMIZED CLINICAL TRIAL||Baylor College of Medicine|Yes|Active, not recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329756||29985|
NCT02330029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D00320141210|Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)|A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome||Macrohard Institute of Health|Yes|Active, not recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|800|||Both|18 Years|70 Years|No|||December 2014|December 30, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330029||29964|
NCT02334683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1113|Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia|Comparison of Electrophysiologic And Ultrasound Guidance For Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia And Spasticity||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02334683||29607|
NCT02291744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guoweijian-2014-XELOX|A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients|A Randomized Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients With Unresectable Metastatic Lesions||Fudan University|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02291744||32903|
NCT02290054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/41|Auriculotherapy for Prevention of Postoperative Urinary Retention|Auriculotherapy for Prevention of Postoperative Urinary Retention in Men Receiving Postoperative Epidural Analgesia After Thoracic Surgery|RUPO|Hopital Foch|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Male|18 Years|85 Years|No|||March 2015|March 25, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02290054||33032|
NCT02291835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrockU|Dietary Intakes and Periodontal Outcomes After Sanative Therapy|Dietary Intakes and Periodontal Outcomes After Sanative Therapy||Brock University|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|Samples Without DNA|Serum|Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing sanative therapy for the treatment of chronic generalized        periodontitis.|November 2014|November 14, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02291835||32896|
NCT02280434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBP-307AU001|Phase 1 Study Accessing the Safety and Tolerability of CBP-307|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-307 Following Oral Single and Multiple Escalating Dose Administration||Suzhou Connect Biopharmaceuticals, Ltd.|No|Active, not recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02280434||33771|
NCT02280746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 8/2013|Gluten for Autism Spectrum Disorders|Gluten Dietary Intervention for Autistic Symptoms in Children With Autism Spectrum Disorders - Randomized Open Trial||Medical University of Warsaw|Yes|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280746||33747|
NCT02285270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819607|Circadian Brown Adipose Tissue Metabolism|A Pilot Study to Investigate Circadian Variations in Brown Adipose Tissue Metabolism in Healthy Volunteers.||University of Pennsylvania|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285270||33400|
NCT02292511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-SSE-123|Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints|Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints||Lawson Health Research Institute|No|Active, not recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|50 Years|N/A|No|||March 2016|March 22, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292511||32844|
NCT02292537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS4|A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Patients With Later-onset Spinal Muscular Atrophy|A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy||Ionis Pharmaceuticals, Inc.|Yes|Active, not recruiting|November 2014|June 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|117|||Both|2 Years|12 Years|No|||March 2016|March 15, 2016|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292537||32842|
NCT02292550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2110C|Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.|A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer||Novartis|No|Recruiting|May 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|170|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292550||32841|
NCT02292563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBYY2014001|The Impact of Experienced Endoscopy Nurse Participation on Polyp and Adenoma Detection During Colonoscopy|Can Experienced Endoscopy Nurse Participation During Screening Colonoscopy Increase Polyp and Adenoma Detection Rate?:A Prospective Randomized Trial||Ningbo No. 1 Hospital|No|Recruiting|June 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292563||32840|
NCT02277977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUPIDDCH|Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound|Messung Von Mikrozirkulationsstörungen im Septischen Schock Mit Kontrastmittel- verstärkter Sonographie Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound||University Hospital Freiburg|No|Not yet recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|N/A|N/A|No|||October 2014|October 27, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277977||33960|
NCT02278263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRACKS Study|Tranexamic Acid in Knee Joint Surgery|Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial|TRACKS|University of Auckland, New Zealand|No|Recruiting|December 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02278263||33938|
NCT02278276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sulfagenix-SG1002-002|Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients|A Randomised, Double-blinded, Placebo-controlled Study to Assess the Safety and Bioactivity of Sodium Polysulthionate (SG1002) in Heart Failure Patients||Sulfagenix Australia Pty Ltd.|No|Not yet recruiting|April 2016|July 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|85 Years|No|||November 2015|November 25, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02278276||33937|
NCT02278562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPH-011-11S|Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2|Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease|INSPIRED|VA Office of Research and Development|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|N/A|No|||February 2016|February 8, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278562||33915|
NCT02333318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-VVZ149-02|A Single Ascending Dose Escalation to Investigate Safety and PK of VVZ-149 Injection in Healthy Older Male Volunteers|A Single Ascending Dose Escalation Clinical Trial to Investigate Safety and Pharmacokinetics of VVZ-149 Injection in Healthy Older Male Volunteers||Vivozon, Inc.|No|Completed|July 2014|October 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|24|||Male|50 Years|85 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02333318||29712|
NCT02278809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B670201214212|Promoting Healthy Lifestyle Behaviors in Schoolchildren: an Online Video Intervention for Parents|Promoting Healthy Lifestyle Behaviors in Primary Schoolchildren: Evaluation and Implementation of an Online Video Intervention for Parents|Movie Models|University Ghent|No|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|207|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278809||33896|
NCT02333565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09|Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas|Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.|CEVOREM|Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2015|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02333565||29693|
NCT02334046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-383|Remifentanil for Smooth Emergence in Elderly Patients|Effect-site Concentration of Remifentanil for Preventing Cough During Emergence in Elderly Patients||Ajou University School of Medicine|Yes|Completed|February 2015|December 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|47|||Both|20 Years|80 Years|No|||December 2015|December 16, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334046||29656|
NCT02336945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-US-RES-14137|Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional|Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional||Abbott Diabetes Care|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|146|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with type 2 diabetes who meet one of the therapy groups|August 2015|August 4, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336945||29434|
NCT02337101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18122014|Early Intervention Programme for Young Patients (Aged 15 - 30 Years) With Symptoms Following Concussion.|Early Intervention Programme for Impairing Post-concussional Symptoms in Adolescents and Young Adults: Randomised Trial||University of Aarhus|No|Recruiting|March 2015|March 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|30 Years|No|||October 2015|October 23, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02337101||29422|
NCT02284477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2075|Associations of Exposure to Phthalates With Insulin Resistance and Epigenetic Change|Associations of Exposure to Phthalates With Insulin Resistance and Epigenetic Change||Seoul National University Hospital|Yes|Recruiting|January 2015|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||October 2014|January 27, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02284477||33461|
NCT02333890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT 14-02|A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer|A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer|CUBiC|Ottawa Hospital Research Institute|Yes|Recruiting|July 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333890||29668|
NCT02334124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC34254C|Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital|CHOICE Trial: Cellulitis at Home Or Inpatient in Children From ED|CHOICE|Murdoch Childrens Research Institute|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|January 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334124||29650|
NCT02334371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50080.068.14|MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study|MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study||Maastricht University Medical Center|Yes|Completed|April 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02334371||29631|
NCT02336191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MansouraU_LDLT_TEG|Monitoring Living Donor Liver Functions by Thromboelastometry|Monitoring Post-transplant Living Donor Liver Functions by Thromboelastometry. A Prospective Observational Study.|TGF|Mansoura University|No|Completed|June 2014|August 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|60 Years|No|Non-Probability Sample|Living donor liver transplant recipients operated upon in mansoura university liver        transplantion project|August 2015|August 13, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02336191||29492|
NCT02336243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-217|A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders|Docosahexaenoic Acid (DHA) Supplementation During Pregnancy to Prevent Deep Placentation Disorders: A Randomized Clinical Trial and a Study of the Molecular Pathways of Abnormal Placentation Prevention||Pontificia Universidad Catolica de Chile|Yes|Recruiting|May 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02336243||29488|
NCT02279875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-CL001|A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients|A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.||Global Alliance for TB Drug Development|Yes|Recruiting|November 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|83|||Both|18 Years|75 Years|No|||July 2014|January 6, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279875||33814|
NCT02279888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-10035|CardioMEMS HF System Post Approval Study|CardioMEMS HF System Post Approval Study||St. Jude Medical|Yes|Recruiting|January 2015|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|patients with NYHA class III heart failure|February 2016|February 20, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279888||33813|
NCT02291848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35626, TACTAM|TUMOR-ASSOCIATED ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR MULTIPLE MYELOMA|ADMINISTRATION OF TUMOR-ASSOCIATED ANTIGEN (TAA)-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH ACTIVE MYELOMA (TACTAM)|TACTAM|Baylor College of Medicine|Yes|Recruiting|April 2015|April 2021|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291848||32895|
NCT02285049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urticaria Control Test|Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test|Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test (UCT)||Mahidol University|No|Completed|November 2014|January 2016|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|169|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who were diagnosed as chronic urticaria|February 2016|February 28, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02285049||33417|
NCT02292472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_PRT_BMH01|Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy|A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine Safety and Efficacy of Medytoxin® in Subjects in Benign Masseteric Hypertrophy||Medy-Tox|No|Recruiting|August 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|19 Years|N/A|No|||May 2015|May 26, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292472||32847|
NCT02277990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAP-IT|World-wide Randomized Antibiotic Envelope Infection Prevention Trial|Cardiovascular Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial|WRAP-IT|Medtronic Cardiac Rhythm Disease Management|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|7764|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02277990||33959|
NCT02332577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRISTL06562|Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia|A Multi-centre, Non-inferiority, Randomized, Double-blind, Phase IV Study Comparing Pristinamycin (2g x 2 Per Day for 2 Days Then 1g x 3 Per Day for 5 to 7 Days) to Amoxicillin (1g x 3 Per Day) for 7 to 9 Days in Adults With Acute Community Acquired Pneumonia With a PORT Score of II or III||Sanofi|Yes|Recruiting|April 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332577||29769|
NCT02333058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.17/M|Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies|Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies||medac GmbH|Yes|Recruiting|July 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|17 Years|No|||September 2015|September 22, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02333058||29732|
NCT02333331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338E2202|Dose Range Finding Study in Sarcopenia|A 28 Week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia||Novartis||Recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|70 Years|N/A|No|||March 2016|March 24, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333331||29711|
NCT02333799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NiX-TB-(B-L-Pa)|A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis|A Phase 3 Open-label Trial Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB) or Treatment Intolerant / Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB).||Global Alliance for TB Drug Development|Yes|Recruiting|March 2015|October 2021|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|14 Years|N/A|No|||December 2015|January 12, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02333799||29675|
NCT02334033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnkaraUHyper|Cystatin C and Uncontrolled Hypertension|Cystatin C and Uncontrolled Hypertension||Ankara University||Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|903|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults residing in both rural and urban communities|January 2015|January 24, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02334033||29657|
NCT02327221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXC-CD-002-2011|Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease|A Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Active Refractory Crohn's Disease|CATS29|TxCell|Yes|Suspended|July 2015|August 2019|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|70 Years|No|||December 2014|January 7, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327221||30180|
NCT02327455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140601409|Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography|Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography||Yale University|No|Not yet recruiting|January 2016|||July 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|90 Years|No|||December 2014|December 22, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02327455||30162|
NCT02327468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22913|Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers|A Study of hTERT Immunotherapy Alone or in Combination With IL12 DNA Followed by Electroporation in Adults With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327468||30161|
NCT02338245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN001-003|Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab|Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy||Aslan Pharmaceuticals|No|Recruiting|December 2014|March 2019|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||October 2015|November 20, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02338245||29334|
NCT02335866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/10|Platelet-Rich Fibrin in the Treatment of Multiple Gingival Recessions|Platelet Rich Fibrin Against Connective Tissue Graft in Treatment of Gingival Recessions||Necmettin Erbakan University|Yes|Completed|January 2014|August 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|December 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335866||29517|
NCT02335879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci 008 CT|Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation|||GeneScience Pharmaceuticals Co., Ltd.||Completed|May 2008|||August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|534|||Female|21 Years|38 Years|No|||January 2015|January 9, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02335879||29516|
NCT02336165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2013-006|Phase 2 Study of MEDI4736 in Patients With Glioblastoma|Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)||Ludwig Institute for Cancer Research|No|Recruiting|February 2015|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|108|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336165||29494|
NCT02336204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24447/14|Alcohol Consumption Relation With Nutritional Knowledge and Body Weight|Effect of Alcohol Consumption and Nutritional Knowledge on Body Weight and Composition in a Group of Piacenza Students||Catholic University of the Sacred Heart||Completed|September 2011|September 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|104 healthy subjects (56 males and 54 females)|January 2015|January 7, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02336204||29491|
NCT02338479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-TLEC|Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies|Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies||Center for International Blood and Marrow Transplant Research|Yes|Recruiting|March 2015|||February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|N/A|22 Years|No|Non-Probability Sample|This study will enroll is a nonrandomized prospective cohort undergoing HCT for treatment        of childhood leukemia and myelodysplasia.|March 2016|March 4, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338479||29316|
NCT02338492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03-PATHOLHUM-02|Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease|A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease||IlluminOss Medical, Inc.||Recruiting|March 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338492||29315|
NCT02284256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-005|A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery|A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical FibrocapsTM (RaplixaTM) and Tachosil® in Surgical Hemostasis During Hepatic Resection||ProFibrix, Inc.|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284256||33478|
NCT02284503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSCRES0169|Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)|A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS||Shanghai Zhongshan Hospital|No|Not yet recruiting|November 2014|June 2016|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1350|||Both|18 Years|80 Years|No|||November 2014|November 3, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02284503||33459|
NCT02280161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001115|Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer|An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology, and Response to Treatment||Jonsson Comprehensive Cancer Center|No|Recruiting|September 2014|November 2025|Anticipated|November 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|A blood sample of 30mL or a saliva collection (obtained by spitting into a special      collection cup) will be obtained from each patient.|Both|18 Years|N/A|No|Probability Sample|Adults with a confirmed diagnosis of cancer.|March 2016|March 4, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280161||33792|
NCT02280421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-EU21|Drug-Drug Interaction Study: ASP2151 and Ciclosporin|A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean||Maruho Europe Limited|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 16, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280421||33772|
NCT02292420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-743|The Normal Reference Values of Pulse Oximetry Plethymographic Waveform Parameters|The Normal Reference Values of Pulse Oximetry Plethymographic Waveform Parameters||Peking Union Medical College Hospital|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1019|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|April 2015|April 27, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292420||32851|
NCT02292433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621018|A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy|A Phase 1, Randomized, Double-blind, Placebo-controlled, 3- Period, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Two Dose Levels of Pf-04937319 In Japanese Subjects With Type 2 Diabetes Mellitus as Monotherapy||Pfizer|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|20 Years|64 Years|No|||February 2016|February 16, 2016|November 12, 2014||No||No|February 16, 2016|https://clinicaltrials.gov/show/NCT02292433||32850|
NCT02281864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0105|Interventions to Help Smoking Parents of Inpatients Reduce Exposure (INSPIRE)|Interventions to Help Smoking Parents of Inpatients Reduce Exposure (INSPIRE)|INSPIRE|University of Colorado, Denver|Yes|Recruiting|December 2014|February 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Both|N/A|80 Years|No|||November 2015|November 24, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02281864||33662|
NCT02277717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYD985.001|First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients|A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors||Synthon Biopharmaceuticals BV|Yes|Recruiting|October 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277717||33980|
NCT02277730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHF/CTG047/2012|A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability|A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability to Improve Perioperative Outcome During Spinal Anaesthesia for Caesarean Section|DIVA|KK Women's and Children's Hospital|No|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|286|||Female|21 Years|45 Years|No|||September 2015|September 3, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277730||33979|
NCT02332824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-272/CCT-101|A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria|A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria||Takeda|No|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|408|||Both|20 Years|74 Years|No|||January 2016|January 28, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02332824||29750|
NCT02338947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPauloGH1000|Off Pump Versus On Pump Coronary Artery Bypass Grafting in Frailty Patients (FRAGILE)|Off Pump Versus On Pump Coronary Artery Bypass Grafting in Frailty Patients: A National, Multicenter, Prospective, Randomized Clinical Trial|FRAGILE|University of Sao Paulo General Hospital|Yes|Not yet recruiting|March 2016|February 2021|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|March 21, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02338947||29280|
NCT02339077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_27OBTP|Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting|Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting|Stillborn|University of Witwatersrand, South Africa|No|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Cord blood Placenta skin swab from fetus Gastric/ tracheal aspirate|Both|N/A|1 Day|No|Non-Probability Sample|Stillborn infants (gestational age >= 28 weeks gestation) born at CHBAH|January 2015|January 9, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02339077|1 Day|29270|
NCT02336646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-070B|Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease|Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease||Taiwan Bio Therapeutics Co., Ltd.|Yes|Recruiting|July 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|80 Years|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336646||29457|
NCT02279394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-338|Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma|Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Recruiting|December 2014|October 2023|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279394||33851|
NCT02279407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5883C00004|A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients|A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II|EFFECTII|AstraZeneca|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|223|||Both|40 Years|75 Years|No|||January 2016|January 14, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279407||33850|
NCT02291783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9936-101|Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment|A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects||Heptares Therapeutics Limited|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 11, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291783||32900|
NCT02280512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407114RIND|Intra-op Monitoring With NIRS and NICOM, and Surgical Outcome in Elderly Patients With Fractures of Lower Limbs|Intraoperative Monitoring With Noninvasive Near-infrared Spectroscopy and Noninvasive Cardiac Output Measurement, and Postoperative Outcome in Elderly Patients With Fractures of Lower Extremities||National Taiwan University Hospital|No|Active, not recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|65 Years|N/A|No|Non-Probability Sample|patient older than 65 years old with fractures of lower limbs|May 2015|May 12, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02280512||33765|
NCT02281084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-MDS-006|Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes|A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine||Celgene|Yes|Recruiting|July 2015|January 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281084||33721|
NCT02281097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANDERBILT_IRB_121816|Transdermal Vagal Stimulation for POTS|Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|June 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02281097||33720|
NCT02288130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.421|Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy|Ulipristal Versus Gonadotropin-releasing Hormone Agonists Prior to Laparoscopic Myomectomy: a Double Blind Randomized Controlled Trial|MYOMEX|VU University Medical Center|No|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288130||33180|
NCT02288143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 37537014.6.0000.5440|COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation|Evaluation of a Simplified Low-cost and Friendly Controlled Ovarian Stimulation Combining Oral Letrozole and Clomiphene Citrate: a Pilot Study|COOL-COS|University of Sao Paulo|Yes|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|40 Years|No|||December 2015|December 1, 2015|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02288143||33179|
NCT02288221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-04|Safe & Easy Environment at Home for Patients Presenting a Frail Syndrome|SafEE : Safe & Easy Environment at Home for Patients Presenting a Frail Syndrome|SafEE|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|January 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|60 Years|N/A|No|||June 2014|November 7, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02288221||33173|
NCT02262000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU010513|Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer|A Phase II Clinical Trial of Image Guided Stereotactic Ablative Radiotherapy (SABR) for T2 and Microscopic T3 (PL3), N0,M0 Non-small Cell Lung Cancer (NSCLC)|SABR|West Virginia University|Yes|Active, not recruiting|September 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02262000||35188|
NCT02266368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antimicrobeal ureteral stents|Comparison of Antimicrobial Coated Ureteral Stents With Non-coated Stents|A Randomized Controlled Trial Comparing Antimicrobial Coated (Silver Sulfadiazine) Ureteral Stents With Non-coated Stents||Mansoura University|No|Recruiting|October 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02266368||34853|
NCT02266914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0318|Magnetic Resonance Elastography of Cardiac Transplant Rejection|Magnetic Resonance Elastography of Cardiac Transplant Rejection||Ohio State University|No|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266914||34811|
NCT02262494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/XB-01|Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography|Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography: a Diagnostic Study|EchoComp TVP|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|236|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02262494||35150|
NCT02288078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCC1402/HGCSG1402|Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)|A Study of Prophylactic Oral Steroids for Fatigue and Malaise Due to Regorafenib Treatment for Unresectable Metastatic Colorectal Cancer: a Randomized, Placebo-controlled, Double-blind Phase 2 Clinical Study (KSCC1402/HGCSG1402)||Clinical Research Support Center Kyush|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|20 Years|N/A|No|||November 2014|November 11, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02288078||33184|
NCT02288091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701|A Pilot Study of Inosine in ALS|A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)||Massachusetts General Hospital|No|Active, not recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288091||33183|
NCT02276716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S11-02100|The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia|The Nutritional Supplement Phosphatidylserine in Patients With Familial||New York University School of Medicine|Yes|Recruiting|November 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|12 Years|N/A|No|||October 2015|October 20, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02276716||34057|
NCT02288897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-MM-31|PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma|PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Without Distant Metastases||Provectus Pharmaceuticals|Yes|Recruiting|April 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288897||33121|
NCT02282176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-75|TINN2: Treat Infection in NeoNates 2|A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants|TINN2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Withdrawn|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|23 Weeks|28 Weeks|No|||February 2016|February 24, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02282176||33638|
NCT02282423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006411|PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes|PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes|PGC-1|Mayo Clinic|Yes|Recruiting|May 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|96|||Both|30 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282423||33619|
NCT02278354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A11|Tau Imaging in Professional Fighters|18F-AV-1451 PET Imaging in Professional Fighters||Avid Radiopharmaceuticals|No|Recruiting|December 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Male|18 Years|N/A|No|||January 2015|January 7, 2015|October 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278354||33931|
NCT02286622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-024|A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics|A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics||Marathon Pharmaceuticals, LLC|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|January 6, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286622||33296|
NCT02286635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-025|Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort|A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects||Marathon Pharmaceuticals, LLC|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|January 6, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286635||33295|
NCT02286843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-156|Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?|Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286843||33279|
NCT02286856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39724.091.1|DINAMITE Study Nutritional State and Effect Diet in Mitochondrial Disease|DINAMITE Study: An Explorative Study of the Effect of Dietary Intervention on Body Function and Quality of Life in Adults With Mitochondrial Disease Caused by the m.3243A>G Mutation.|DINAMITE|Radboud University|No|Enrolling by invitation|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02286856||33278|
NCT02279147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-WGu-001|Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.|The Prevention and Treatment of SIRS in Patients With Cholestatic Jaundice After Operation.||Chinese PLA General Hospital|Yes|Recruiting|August 2014|September 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||October 2014|October 28, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02279147||33870|
NCT02287038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1725-P|Atomoxetine in Comorbid ADHD/PTSD|Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study||VA Office of Research and Development|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover||1|Anticipated|40|None Retained|Urine and blood samples will be obtained and handled by the Ralph H. Johnson VA Medical      Center. All laboratory procedures will be completed by hospital personnel who are trained in      to use all appropriate forms of PPE.|Both|20 Years|60 Years|No|Probability Sample|Subjects will be recruited from Charleston VAMC OIF/OEF Screening Clinic. Additionally,        Veterans with or without PTSD may be recruited through Savannah CBOC referrals if        Charleston VAMC does not have a sufficient number of participants. The study will be open        to all Veterans from Iraq Freedom Operation and Afghanistan who meet eligibility criteria        regardless of ethnicity, gender or socioeconomic status.|February 2016|February 12, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287038||33264|
NCT02284581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM14-BIOMETA|Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments|Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metastatic Breast Cancer Patients According to Biologic Subtype and Line of Treatment|BIO-META|Consorzio Oncotech|Yes|Not yet recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|2000|Samples With DNA|Evaluation of duration of metastatic breast cancer treatments and numer of lines according      to biological subtype (Luminal A, Luminal B, HER2 positive, triple-negative)|Both|18 Years|N/A|No|Non-Probability Sample|Italian patient with metastatic breast cancer|May 2015|May 5, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02284581||33453|
NCT02280525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0297|Cord Blood Natural Killer (NK) Cells in Chronic Lymphocytic Leukemia (CLL)|A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280525||33764|
NCT02285114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-311-1269|Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen|A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen||Gilead Sciences|Yes|Recruiting|January 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|100|||Both|6 Years|17 Years|No|||February 2016|February 9, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285114||33412|
NCT02285127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002490|Short Versus Long Cephalomedullary Nailing of Pertrochanteric Hip Fractures: A Randomized Prospective Study|Short Versus Long Cephalomedullary Nailing of Pertrochanteric Hip Fractures: A Randomized Prospective Study||Mayo Clinic|No|Enrolling by invitation|November 2014|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285127||33411|
NCT02288039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1132|Quality of Life in Pulmonary Rehabilitation: A Social Identity Based Intervention|A Pilot Study to Assess the Feasibility and Efficacy of a Social Identity Theory Based Intervention to Improve the Quality of Life of Patients Attending Pulmonary Rehabilitation.||Liverpool Heart and Chest Hospital NHS Foundation Trust|No|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|84|||Both|18 Years|75 Years|No|||February 2016|March 14, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02288039||33187|
NCT02288156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBM|Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis|Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis||Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2015|December 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288156||33178|
NCT02266121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B039201421534|Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis|Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques|MScog-tDCS|University Hospital of Mont-Godinne||Recruiting|October 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|December 2, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266121||34872|
NCT02267980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inonu 2|Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy|Turgut Ozal Medical Center Department of Anesthesiology and Reanimation||Inonu University|Yes|Recruiting|July 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||October 2014|October 15, 2014|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02267980||34729|
NCT02268968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS 012|Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal CPAP Continuous Positive Airway Pressure|Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal Contiuous Positive Airway Pressure||Mansoura University Children Hospital|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|N/A|28 Days|No|||April 2015|April 12, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02268968||34653|
NCT02266927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-FLU-1102|A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)|An Open-Label, 2-Part, Randomized, Crossover Study to Compare the Bioavailability of Intranasal Administration of 200 and 400 µg of OPTINOSE™ FLUTICASONE With 400 µg of Flonase® (Fluticasone Propionate) Nasal Spray (Part 1), and Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) (Current Investigation is Part 2 Only)||Optinose US Inc.||Completed|September 2014|April 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|No|||February 2016|February 2, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266927||34810|
NCT02266940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E104|Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets|A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation||Daiichi Sankyo Inc.|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02266940||34809|
NCT02267200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMCIRB-K2014004|The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD|The Screening and Analysis of Plasma Biomarkers in Irreversible Pulmonary Arterial Hypertension Associated With Congenital Heart Disease||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|1 Month|18 Years|No|Probability Sample|those patients with systolic PAP (sPAP) >65mmHg before surgery were included.|November 2015|November 22, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02267200||34789|
NCT02281357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2210C00013|Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)|TROPOS|AstraZeneca|Yes|Recruiting|February 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|75 Years|No|||March 2016|March 17, 2016|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02281357||33700|
NCT02277821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00804-43|Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients|Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Central Blood Pressure in Essential Hypertension Patients Treated But Not Stabilized||Stendo|Yes|Recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|40 Years|70 Years|No|||October 2014|May 21, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02277821||33972|
NCT02286206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01644|Study of the Effect of Dosing on Clozapine Levels|A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine|PK-CLZ|University of British Columbia|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|19 Years|65 Years|No|||December 2015|December 10, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286206||33328|
NCT02283229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:27/2011|Newborn Head Molding and Later Asymmetries|Newborn Head Molding and Later Asymmetries in Follow up (3D Head Shape Modelling)||University of Oulu|No|Recruiting|February 2012|February 2024|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|110|||Both|N/A|6 Days|Accepts Healthy Volunteers|||June 2015|June 8, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02283229||33557|
NCT02291523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328-14|The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis|The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis||MemorialCare Health System|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|7 Years|21 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291523||32920|
NCT02291549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-1113|RESOLVE II Clinical Evaluation of Safety and Efficacy of S8 Sinus Implant in Chronic Sinusitis Patients|RESOLVE II: A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Sinus Obstruction||Intersect ENT|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291549||32918|
NCT02291614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130354|A Phase 1 Study of AMG 211 in Subjects With Advanced Gastrointestinal Cancer|A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Gastrointestinal Adenocarcinoma||Amgen|No|Recruiting|December 2014|December 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02291614||32913|
NCT02284022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14055|Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders.|Protocole de Validation Clinique du Logiciel d'Interface Cerveau-Ordinateur RoBIK Pour la Communication Des Patients Atteints de Maladie Neuromusculaires (MNM)|PVCAFM|Centre d'Investigation Clinique et Technologique 805|No|Active, not recruiting|October 2014|July 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|neuromuscular disease patients|February 2016|February 12, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284022||33496|
NCT02287051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/14|Bowel Prep Acceptance in Clinical Practice|Acceptance and Compliance of Split-dose Bowel Preparation for Colonoscopy in Clinical Practice||Valduce Hospital|No|Completed|March 2014|October 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|18 Years|80 Years|No|Non-Probability Sample|population undergoing colonoscopy|November 2014|November 5, 2014|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02287051||33263|
NCT02287064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA IVIG 2014|An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias|An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias||University of South Florida||Recruiting|April 2015|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2015|December 18, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287064||33262|
NCT02287246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399635|Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery|Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Pain Management Following Urogynecologic Surgery: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial||Walter Reed National Military Medical Center|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02287246||33248|
NCT02284867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK Cells & Pretem labor|Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ?|Comparison Between Uterine Natural Killer Cells In Preterm Labor And Term Labor||Ain Shams University|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|Samples With DNA|a placental sample will be taken either the patient delivered preterm or at term (term      patients will be either control term group or patients with successful treatment of preterm      labor). The placental sample taken should have part of the decidua and then the sample will      be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in      paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane      -coated slides. Serial sections will be immunostained for CD 16 and CD56 .      Immunohisto-chemistery study will be done at Ain Shams Maternity Hospital Histopathology      department.|Female|18 Years|35 Years|No|Probability Sample|The patients will be recruited from women attending casualty at Ain Shams University        Maternity Hospital.|January 2016|January 5, 2016|November 2, 2014||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT02284867|4 Weeks|33431|
NCT02287727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 246813|Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment|(Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment||Roswell Park Cancer Institute|Yes|Recruiting|March 2015|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287727||33211|
NCT02287961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP57 APACHES|Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men|Natural History of Anal Human Papillomavirus Infection and Associated Disease in HIV-infected Men Who Have Sex With Men: Towards an Evidence Base for the Prevention of Anal Cancer.|APACHES|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|December 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Male|35 Years|80 Years|No|||June 2015|June 30, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02287961||33193|
NCT02287974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMMoTa/ICPDI/2010|Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin|Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs: Study of the Needs of Insulin||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|85 Years|No|||November 2014|June 12, 2015|February 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02287974||33192|
NCT02287987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOCKBS 1.1|CLamp vs Off Clamp Kidney During Partial Nephrectomy|Prospective Randomized Trial Comparing Clamp Versus Clampless Robot Assisted Partial Nephrectomy|CLOCK|Azienda Ospedaliera Spedali Civili di Brescia|No|Enrolling by invitation|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2016|January 3, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02287987||33191|
NCT02279108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408153|Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer|Comparative, Prospective, Randomized Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer|FLUOTECH|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02279108||33873|
NCT02268214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-229|Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus|DEPICT 1|Bristol-Myers Squibb|Yes|Recruiting|November 2014|August 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|768|||Both|18 Years|75 Years|No|||January 2016|February 25, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268214||34711|
NCT02268227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-L24-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||October 17, 2014|October 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02268227||34710|
NCT02271763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01177|Comparing a Horizontal Ultrasound Technique With a Palpation Technique for Localising the Cricothyroid Membrane|A Descriptive Study Comparing a Horizontal Ultrasound Technique With a Palpation Technique for Localising the Cricothyroid Membrane in an Obstetric Population.|CTM|University of British Columbia|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Actual|37|||Female|19 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02271763||34438|
NCT02271971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-412|Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis|Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Moderate to Severe Psoriasis||Pontificia Universidad Catolica de Chile|No|Completed|October 2014|October 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02271971||34422|
NCT02271984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200661-001|Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers|A Phase I, Open-label, Randomized, Single Dose, Five-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of the 150 mg ODT Formulation of L-PZQ (MSC2499550A) vs the Current 500 mg PZQ Commercial Racemate Tablet Formulation in Healthy Male Volunteers||Merck KGaA|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|73|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271984||34421|
NCT02269072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P00|Testosterone Regulation of the Natriuretic Peptide System|Testosterone Regulation of the Natriuretic Peptide System||Massachusetts General Hospital|Yes|Withdrawn|February 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|October 15, 2014|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02269072||34645|
NCT02269085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0677|A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma|A Phase I Trial of Ibrutinib (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269085||34644|
NCT02288741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WiSP_AM71|Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy|Phase III-study for Evaluation of Induction Therapy Before Stem Cell Mobilization and Tandem High-dose Melphalan in Multiple Myeloma Patients 60 to 70 Years of Age|DSMM-II|WiSP Wissenschaftlicher Service Pharma GmbH|No|Completed|August 2001|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|549|||Both|60 Years|70 Years|No|||November 2014|November 6, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02288741||33133|
NCT02282696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPSA-PK|Validation Study CARES|Research on Psychosocial Aspects in the Care for Patients With Cancer: Validation Study CARES.|OPSA-PK|Hasselt University|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|25 Years|60 Years|No|||October 2014|October 31, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02282696||33598|
NCT02286219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA014-001|Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)|Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors||Bristol-Myers Squibb|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286219||33327|
NCT02278068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-2014-ANZ-001|COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy|A First in Human (FIH) Clinical Study to Assess Safety and Performance of Hepatic Sympathetic Denervation for Treatment of Inadequately Controlled Type 2 Diabetic Subjects on Oral Antihyperglycemic Agents.||Metavention|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2014|December 3, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02278068||33953|
NCT02278341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0613|Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis|A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis|Pyrenees|Astellas Pharma Inc|Yes|Recruiting|November 2014|July 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278341||33932|
NCT02286492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS-102-401|Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer|An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy||Taiho Oncology, Inc.||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||June 2015|June 18, 2015|November 5, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02286492||33306|
NCT02278627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11002|Impact of a Technique of Massage During the First Week of Hospitalization on the Recycling of the Mobility of the Knee Further to the Installation of Knee Replacement|Impact of a Technique of Massage During the First Week of Hospitalization on the Recycling of the Mobility of the Knee Further to the Installation of Knee Replacement|PTGMass|University Hospital, Limoges|No|Recruiting|September 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|98|||Both|18 Years|N/A|No|Probability Sample|Patients with knee replacement|October 2014|October 28, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02278627||33910|
NCT02278874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-016B-NPT|High Risk Multiple Gestation Study|Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated From Maternal Blood||Natera, Inc.|No|Recruiting|August 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Maternal and Paternal blood samples      CVS or Amniocentesis sample (optional)      Child saliva sample (optional)      *Biospecimen retention is optional portion of consent form|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|October 2015|October 15, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278874||33891|
NCT02287428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-362|Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma|A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Among MGMT Unmethylated, Newly Diagnosed Glioblastoma Patients||Dana-Farber Cancer Institute|Yes|Recruiting|November 2014|September 2020|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287428||33234|
NCT02287441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2014-090|Feasibility Study to Increase Vegetable Consumption|Feasibility Study Comparing Dietary Methods to Increase Vegetable Consumption|VEG1|Institute for Food Safety and Health, United States|No|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287441||33233|
NCT02287675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNIC-P14-N001|Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer|A Randomized, Double-Blinded Trial Comparing Lymphoseek and 99mTc-Sulfur Colloid With Regard to Pre-op Imaging and Imaging Drug Kinetics and Intra-op Lymphatic Mapping and Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer|Lymphoseek|Kettering Health Network|No|Recruiting|October 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287675||33215|
NCT02287909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2014-153|Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease|Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease|SWAP-4|University of Florida|Yes|Recruiting|December 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|80 Years|No|||January 2016|January 15, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287909||33197|
NCT02287493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4244|Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)|Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)|PhA-SLED|Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|July 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Adult ICU patients at University Medical Center Hamburg-Eppendorf receiving SLED and        either meropenem or ceftazidim.|May 2015|May 4, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02287493||33229|
NCT02287506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF166|StartRIGHT:the Right Diabetes Diagnosis and Treatment (Pilot Study)|The StartRIGHT Study; Getting the Right Diagnosis and the Right Treatment From the Start in Young Adult Diabetes- a Pilot Study|StartRIGHT|NIHR Exeter Clinical Research Facility|No|Not yet recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287506||33228|
NCT02278575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2012-005770-57|Atenativ Effect on Uterine Blood Flow and Preeclampsia|Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia||Vastra Gotaland Region|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|6|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278575||33914|
NCT02278588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[616856-4]|Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.|Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.||University at Buffalo|No|Enrolling by invitation|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|57|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Idiopathic Parkinson's disease (IPD) and Healthy Controls (HC)|November 2015|November 30, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278588||33913|
NCT02278822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000405|Oral Liposomal Glutathione Supplementation in Healthy Subjects|Pilot Study of Oral Liposomal Glutathione Supplementation on Levels of Glutathione in Blood and Biomarkers of Oxidative Stress and Immune Function in Healthy Adults||Milton S. Hershey Medical Center|Yes|Recruiting|October 2014|November 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02278822||33895|
NCT02271607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405|The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients|A Pilot Study About The Effects of Indirect-Moxibustion on Bladder- Functional Improvement and Symptoms Management in Patients With Overactive Bladder: A Randomized Controlled Trial||Korean Medicine Hospital of Pusan National University|Yes|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|75 Years|No|||March 2016|March 11, 2016|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02271607||34450|
NCT02271776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 143026|GOS and Insulin Sensitivity|The Effects of Galactooligosaccharide (GOS) on Peripheral Insulin Sensitivity and Body Weight Control in Obese Adults With Impaired Glucose Homeostasis||Maastricht University Medical Center|Yes|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|46|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02271776||34437|
NCT02261428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AttikonH|Nasotracheal Suction With Tiemann Catheter Compared to the Classic Technique With the Suction Catheter|Randomized Controlled Study of Nasotracheal Suction With Tiemann Catheter Compared to the Classic Technique With the Standard One.||Attikon Hospital|Yes|Completed|May 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|45 Years|85 Years|No|||March 2015|March 15, 2015|September 30, 2014||No||No|October 13, 2014|https://clinicaltrials.gov/show/NCT02261428||35232|
NCT02261675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Macbar DEX|Reduction in MACbar of Sevoflurane by Dexmedetomidine in Children|Dexmedetomidine Augments Block of Sympathetic Responses to Skin Incision During Sevoflurane Anesthesia in Children||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2013|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Actual|63|||Both|2 Years|6 Years|No|||October 2014|October 7, 2014|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02261675||35213|
NCT02274961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTP10_KR_1301|S-pantoprazole 10mg Phase III Clinical Study|||Ahn-Gook Pharmaceuticals Co.,Ltd|No|Recruiting|October 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|174|||Both|19 Years|75 Years|No|||October 2014|October 24, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02274961||34192|
NCT02277548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 43313|A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.|A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277548||33993|
NCT02286349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD_ brain stimulation_adults|Non Invasive Brain Stimulation Effects on Attentional Performance in ADHD Adults|Effects of Noninvasive Brain Stimulation on Attentional Performance of Adults With Symptomatology of Attention Deficit Hyperactivity Disorder (ADHD)||Universidade Federal de Pernambuco|Yes|Active, not recruiting|September 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|April 10, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286349||33317|
NCT02282969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0072|PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing|Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development||M.D. Anderson Cancer Center|No|Recruiting|July 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|55 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants recruited from Houston and Galveston areas.|October 2015|October 30, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282969||33577|
NCT02286362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28983|An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer|||Hoffmann-La Roche||Active, not recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|511|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with HER2-positive early breast cancer scheduled to initiate a treatment with        Herceptin SC.|March 2016|March 1, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02286362||33316|
NCT02286791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-14-110|Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial|Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial|MAPRCT|National University, Singapore|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|60 Years|85 Years|No|||August 2015|August 16, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286791||33283|
NCT02283476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-ED-1302|The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.|The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Not yet recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2014|November 5, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283476||33538|
NCT02283723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-726|A Randomized Controlled Trial Using the TAPESTRY Approach to Care for Older Adults|Teams Advancing Patient Experience: Strengthening Quality (TAPESTRY): A Randomized Controlled Trial Using the TAPESTRY Approach to Care for Older Adults|TAPESTRY|McMaster University|No|Not yet recruiting|December 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|316|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 3, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283723||33519|
NCT02283736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDECYT 1130570|Efficacy of Oral Probiotic Administration in Patients With Chronic Periodontitis|Efficacy of Oral Probiotic Administration in Clinical, Immunological and Microbiological Parameters of Patients With Chronic Periodontitis Treated With Non Surgical Periodontal Treatment.|probiotic|University of Chile|Yes|Recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|35 Years|N/A|No|||June 2015|June 15, 2015|November 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02283736||33518|
NCT02277470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48785.018.14|Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis|Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis|GO-KINETIC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Stool samples and blood samples.|Both|18 Years|N/A|No|Probability Sample|Patients eligible for inclusion are patients (either outpatient or hospitalized) with        moderate to severe UC refractory to corticosteroids and immunomodulators.|July 2015|July 2, 2015|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277470||33999|
NCT02277483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-CT4-14-159|Efficacy and Safety of LAIS® Mites Sublingual Tablets|Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma|korLAIS|Ajou University School of Medicine|Yes|Recruiting|October 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|60 Years|N/A|No|||June 2015|June 21, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02277483||33998|
NCT02277743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1334|Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|SOLO 1|Regeneron Pharmaceuticals|Yes|Active, not recruiting|October 2014|February 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|674|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277743||33978|
NCT02277756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOUPA (RB 14.035)|Pain in Adults With Autism Spectrum Disorder|Pain Neuromodulation in Adults With Autism Spectrum Disorder|DOUPA|University Hospital, Brest|No|Recruiting|May 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02277756||33977|
NCT02278003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-006|A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients|A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2012|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|69|||Both|4 Years|14 Years|No|||March 2016|March 1, 2016|October 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278003||33958|
NCT02278016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-120|Biological Markers for the Diagnosis of Central Nervous System Infective Diseases|Diagnosis Value of Procalcitonin, Interleukin-6, AgiotensininⅡin the Cerebrospinal Fluid of Patients With Central Nervous System Infective Diseases||Xijing Hospital|Yes|Recruiting|August 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|procalcitonin,interleukin-6,agiotensininⅡ|Both|13 Years|N/A|Accepts Healthy Volunteers|Probability Sample|More than 12 years old; meet the clinical diagnostic criteria for the central nervous        system infection disease|December 2015|December 31, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278016|1 Year|33957|
NCT02287922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0061-C202|A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis|A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate||Ablynx|Yes|Active, not recruiting|February 2015|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|228|||Both|18 Years|74 Years|No|||March 2016|March 15, 2016|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287922||33196|
NCT02283684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mans-2014-03|GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT|Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Plasma Kinetic Vaporization (PKVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Controlled Study||Mansoura University|No|Active, not recruiting|September 2014|November 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Male|50 Years|N/A|No|||January 2016|January 3, 2016|November 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283684||33522|
NCT02283983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 097-13|Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose|Evaluation of Cryoprotection of Nail Toxicity Induced by Docetaxel Low Cumulative Dose. Controlled, Randomized, Open, Multicentre Prospective.|BANQUISE|Centre Hospitalier Departemental Vendee|No|Recruiting|December 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|302|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283983||33499|
NCT02260791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKB327-002|A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients|A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate|ARABESC|Fujifilm Kyowa Kirin Biologics Co., Ltd.|No|Active, not recruiting|December 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|729|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|July 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260791||35281|
NCT02260804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 3.4|To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma|A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma||Celltrion|Yes|Not yet recruiting|October 2015|August 2020|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|October 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02260804||35280|
NCT02261142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIU-ED2013|Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS|Evaluation of Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal Transcutaneous Electrical Stimulation, Through a Garment With built-in Electrodes in Combination With Training.||Linkoeping University|No|Completed|September 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02261142||35254|
NCT02266082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400616|Persistent Post-Surgical Pain in Women With BrCA|Biobehavioral Predictors of Persistent Post-Surgical Pain in Women Undergoing Breast Cancer Treatment||University of Florida|Yes|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|A stool sample for microbiota analysis will be collected by participants at home using a      standard test kit, and returned via mail. Fecal microbial DNA will be extracted from between      50-200 mg of fecal material. The 16S ribosomal gene (V4 region) of each sample will be      amplified using a barcoding system to allow multiplexing with the Illumina MiSeq system.      Blood samples will be collected to measure C-reactive protein (CRP) (at each visit) and      telomerase/telomere and 25(OH)D level at baseline and the 6-month visit. Venous blood      samples will be collected by trained staff.|Female|40 Years|75 Years|No|Non-Probability Sample|Women diagnosed with early stage breast cancer, who plan to have breast surgery at UF        Health/Shands Hospital in Gainesville, Florida|November 2015|November 30, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266082||34875|
NCT02282189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0036|Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD|Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD||Western University, Canada|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|50 Years|85 Years|No|||October 2014|December 9, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02282189||33637|
NCT02282436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXA-COPD-20765|Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Muscle Atrophy in Patients With Chronic Obstructive Pulmonary DIsease : Substudy With Patients Who Experienced an Acute Exacerbation|EXA|Laval University|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood sample and muscle biopsy of vastus lateralis (quadriceps)|Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female who are experiencing an acute exacerbation of their COPD.|October 2014|October 31, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02282436|1 Day|33618|
NCT02286427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130907 - 2014-001805-42|A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane|A Comparative Study of the Healing of Chronic Skin Ulcers of Recessive Dystrophic Epidermolysis Bullosa : Standard Dressing Versus Amniotic Membrane.|MABUL|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|January 2019|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|2 Years|60 Years|No|||November 2014|June 10, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286427||33311|
NCT02286583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LabdomSuisseRD|Medical Radiometer - RTM - 01 - RES and Its Use in Detecting Hotspots in Female Breast|Early Detection of Breast Disease Using Medical Radiometer - RTM - 01 - RES|RTM|Labdom Suisse|Yes|Recruiting|February 2015|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2000|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2014|March 31, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02286583||33299|
NCT02276690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9190|Hepcidine and Iron Deficiency in Critically Ill Patients|Medical Economic Analysis of the Interest of Hepcidin Quantitation by Quantitative Mass Spectrometry for the Diagnosis of Iron Deficiency in Anemic Critically Ill Patients|HEPCIDANE|University Hospital, Montpellier|No|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02276690||34059|
NCT02281318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200862|Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control||GlaxoSmithKline|No|Active, not recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|544|||Both|12 Years|N/A|No|||March 2016|March 10, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281318||33703|
NCT02286648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921762|Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars|||Mashhad University of Medical Sciences|No|Recruiting|February 2014|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02286648||33294|
NCT02286661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1631|Short-Arm Casting Effective in Type A2 Fractures in the Distal Radius|Outcome Assessment in the Treatment of Type A2 Fractures of the Distal Radius by Short Arm Cast Versus Long Arm Cast||Mashhad University of Medical Sciences|Yes|Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286661||33293|
NCT02286869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaVeCo|Cardioventilatory Coupling in Critically Ill Patients|||Ospedale L. Sacco – Polo Universitario|No|Active, not recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|22|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286869||33277|
NCT02282657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPERNOVA|Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS|Pilot Feasibility and Safety Study on Low-flow Extracorporeal CO2 Removal in Patients With Moderate ARDS to Enhance Lung Protective Ventilation|SUPERNOVA|European Society of Intensive Care Medicine|No|Recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282657||33601|
NCT02282917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-078H|Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma|Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma||Massachusetts Eye and Ear Infirmary|Yes|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282917||33581|
NCT02282930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006965|Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression|An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression||Mayo Clinic|Yes|Recruiting|March 2015|||June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02282930||33580|
NCT02283190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1336GCC, HP-00056335|1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)|1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations||University of Maryland|Yes|Recruiting|April 2014|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283190||33560|
NCT02278289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuddhistTCGHTaipei|Comparative Effectiveness of Ultrasound and Paraffin Therapy in Patients With Carpal Tunnel Syndrome: A Randomized Trial|Comparative Effectiveness of Ultrasound and Paraffin Therapy in Patients With Carpal Tunnel Syndrome: A Randomized Trial||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02278289||33936|
NCT02278302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.135|Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers|Placebo-controlled, Randomized, Double-blind Study Comparing the Effect of a Combination of 200 mg Dipyridamole With Sustained Release and 25 mg Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Volunteers and 10 Days of Treatment Alone and in Combination With Alcohol (Study no. 591002)||Boehringer Ingelheim||Completed|August 1999|||March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|56|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 28, 2014||||No||https://clinicaltrials.gov/show/NCT02278302||33935|
NCT02286440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005547|A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression|A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression (Abbreviation Assurex AMOD)|AMOD|Mayo Clinic|No|Recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|276|||Both|13 Years|18 Years|No|||August 2015|August 6, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286440||33310|
NCT02286596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APHERESE|Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia|Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia|APHERESE|Laval University|No|Completed|April 2013|December 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Actual|9|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with homozygous familial hypercholesterolemia already treated with LDL apheresis        using both systems being compared (HELP vs Dextran)|March 2016|March 7, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286596||33298|
NCT02286804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-301|Ultherapy for the Treatment of Spider Veins on the Legs|Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Leg Telangiectasia||Ulthera, Inc|No|Completed|October 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286804||33282|
NCT02265432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R -608-000-071-112|Using Mobile Technology to Promote Physical Activity|iFit-Study: Using Mobile Technology to Promote Physical Activity||National University, Singapore||Recruiting|October 2014|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02265432||34924|
NCT02265796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-2013|Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients|Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients|IMWELL|North Florida Foundation for Research and Education|No|Recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02265796||34897|
NCT02269670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071229|Phase II Study of Everolimus Beyond Progression|Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer||Emory University|Yes|Recruiting|November 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|19 Years|N/A|No|||March 2016|March 22, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02269670||34599|
NCT02269683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-02|Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer|Randomized Controlled Trial of Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer - The DAVID-study|DAVID|Technische Universität Dresden|No|Not yet recruiting|October 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02269683||34598|
NCT02286128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiangMaiU|Effect of NF-кB Dependent Proinflammation on Osteogenic Differentiation of the Mesenchymal Stem Cells in Type 2 Diabetes|The Effect of NF-кB Dependent Proinflammation on the Overexpression of Receptor of Advanced Glycation End Products (RAGE) and the Osteogenic Differentiation Defect in the Mesenchymal Stem Cell-isolated From Patients With Type 2 Diabetes||Chiang Mai University|No|Not yet recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|90|Samples Without DNA|Serum and RNA (from peripheral blood-derived mesenchymal stem cells)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include 30 non-diabetic control subjects, and 60 type 2 diabetic patients        who has HbA1c higher than 7% with metformin monotherapy.|November 2014|November 5, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02286128||33334|
NCT02276144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fatty liver in pregnancy|Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy|Investigation on the Frequency and Obstetric Significance of Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy||Seoul National University Hospital|No|Recruiting|November 2014|November 2019|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|Samples With DNA|serum for lab tests|Female|N/A|N/A|No|Probability Sample|1st trimester pregnancy women with singleton|October 2014|November 20, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02276144||34101|
NCT02281643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ:JA 1479/5-1|Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana|Comparison of Early and Late Administration of Doxycycline in Their Efficacy Against Mansonella Perstans and in Development of Immunity Against Mycobacterial Infections|Map2Co|Kwame Nkrumah University of Science and Technology|Yes|Recruiting|October 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|9 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 2, 2015|October 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281643||33678|
NCT02286999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-1224|Probiotic Supplementation in Breastfed Newborn Infants|A Parallel-group, Randomized, Placebo-controlled Ascending Dose Phase I Study Protocol for Dietary Supplementation With Bifidobacterium Longum Subsp. Infantis (B. Infantis) in Healthy Breastfed Infants||University of California, Davis|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|N/A|7 Days|Accepts Healthy Volunteers|||November 2014|November 7, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286999||33267|
NCT02287194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7101|SpyGlass Direct Visualization System Clinical Registry in China|Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System Throughout China|SpyChina|Boston Scientific Corporation|No|Not yet recruiting|September 2014|May 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|85 Years|No|Probability Sample|All consecutive patients seen at an investigational site during the enrollment period          -  Presenting with an indication for cholangioscopy, or          -  Presenting with a possible indication for cholangioscopy to be determined during the             ERCP procedure immediately preceding the SpyGlass procedure.|September 2014|November 6, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02287194|6 Months|33252|
NCT02287415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-108|The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin|The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|May 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|November 6, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02287415||33235|
NCT02286011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCIM/ELA|Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis|Phase I Clinical Trial on Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.|TCIM/ELA|Red de Terapia Celular|Yes|Recruiting|November 2014|January 2018|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||September 2015|September 30, 2015|October 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286011||33343|
NCT02286089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN_CT02|Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration|Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)||Cell Cure Neurosciences Ltd.|Yes|Recruiting|April 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|55 Years|N/A|No|||February 2016|February 8, 2016|November 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286089||33337|
NCT02286180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF14045|Subjective Feelings of Job Stress and Frontal Activity During Verbal Fluency Test: A Near-infrared Spectroscopy Study|Job Stress and Frontal Activity During Verbal Fluency Test: A Near-infrared Spectroscopy Study||Taichung Veterans General Hospital|No|Enrolling by invitation|April 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical Intern Doctors in a medical center|November 2014|November 10, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286180|1 Day|33330|
NCT02283424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLATS1401|Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation|A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation||Chinese PLA General Hospital|Yes|Active, not recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|No|||November 2014|November 4, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02283424||33542|
NCT02278835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0011/09|The Effectiveness of Respiratory Physiotherapy in Mitral Valve Surgery|To Analyze the Effectiveness of Respiratory Physiotherapy Techniques in the Post Operative Mitral Valve||University of Sao Paulo General Hospital|No|Completed|March 2009|September 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|60 Years|No|||October 2014|October 29, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02278835||33894|
NCT02278848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 2013- KM / Multimod'HCA|Multimodal Investigation in the Diagnosis and Treatment of Chronic Adult Hydrocephalus|Multimodal Investigation in the Diagnosis and Treatment of Chronic Adult Hydrocephalus|Multimod'HCA|University Hospital, Tours|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|65 Years|N/A|No|||October 2014|October 27, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02278848||33893|
NCT02269254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13.277|Persona Versus NexGen|||Leiden University Medical Center|No|Enrolling by invitation|September 2014|February 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|90 Years|No|||March 2016|March 4, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02269254||34631|
NCT02269371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20140089H|Auricular Acupuncture in the Treatment of Obesity|Auricular Acupuncture in the Treatment of Obesity: a Randomized, Placebo-controlled, Trial|AcupObesity|Mike O'Callaghan Federal Hospital|No|Recruiting|February 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02269371||34622|
NCT02269501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-090|Exercise in Migraine and Co-existing Tension-type Headache and Neck Pain|The Effect of a Specific Exercise Program on Patients Suffering From Migraine and Co-existing Tension-type Headache and Neck Pain||Danish Headache Center|Yes|Recruiting|November 2012|November 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|65 Years|No|||October 2014|October 20, 2014|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02269501||34612|
NCT02275481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP091-402|A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects|A Comparative Effectiveness and Safety Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects||Sunovion|No|Recruiting|November 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|55 Years|N/A|No|||March 2016|March 3, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02275481||34152|
NCT02286037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1-2013-045|Delineating Areas of Secondary Hyperalgesia: Influence of the Assessment Method|Delineating Areas of Secondary Hyperalgesia: Influence of the Assessment Method||Rigshospitalet, Denmark|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|N/A||1|Actual|23|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy participants|November 2014|November 6, 2014|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02286037||33341|
NCT02286050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000179|Effect of a Nursing Program for Patients With Cystic Fibrosis on Disease Management|Auswirkung Eines CF Nursing-Programms Auf Das Krankheitsmanagement Und Die Erfahrungen Der Behandlung Von Patientinnen Und Patienten||University of Zurich||Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|18 Years|N/A|No|||May 2015|June 2, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02286050||33340|
NCT02288754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tumor DNA|Detection of Tumor DNA in Blood Samples From Cancer Patients|||Impact Genomics, Inc.|Yes|Not yet recruiting|December 2014|November 2020|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood Tumor from formalin-fixed, paraffin embedded tissue blocks|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are (i) commencing (ii) currently undergoing, and /or (iii) have undergone        cytotoxic chemotherapy or targeted drug therapies for diagnosed metastatic disease whose        primary lesion is one of the following solid tumor types: lung, breast, prostate, bladder,        ovarian, skin and colon. Patients who are commencing or currently undergoing may be        screened several time during the course of their therapy.|November 2014|November 7, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288754||33132|
NCT02288767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0730|The Effect of Fluid Management by SVV of FloTrac/ Vigileo™ Monitoring on Postoperative Recovery in Bowel Resection Laparotomy|||Yonsei University|No|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|74|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02288767||33131|
NCT02288832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001559-22|Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy|Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy|AuTop|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|March 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|6800|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02288832||33126|
NCT02288845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-008|Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia|An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients||Intra-Cellular Therapies, Inc.|No|Completed|October 2014|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|60 Years|No|||November 2015|November 5, 2015|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288845||33125|
NCT02288858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2G-Stephens-Viviscal|To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair|A Multi-site, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair||Irish Response t/a Lifes2good|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|96|||Both|24 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288858||33124|
NCT02281019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90947376|SpyGlass AMEA Registry|Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System (DVS) Throughout the AMEA (Asia, Middle-East, Africa) Region||Boston Scientific Corporation|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|Tissue acquisition in the bile ducts|Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients seen at an investigational site during the enrollment period          -  Presenting with an indication for cholangioscopy, or          -  Presenting with a possible indication for cholangioscopy to be determined during the             ERCP procedure immediately preceding the SpyGlass procedure.|January 2016|January 6, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02281019|6 Months|33726|
NCT02281032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBO-IWT 100036|Informed Palliative Care in Nursing Homes Through the interRAI Palliative Care Instrument|Informed Palliative Care in Nursing Homes Through the interRAI Palliative Care Instrument: A Study Protocol Based on the Medical Research Council Framework|interRAI PC|Katholieke Universiteit Leuven|Yes|Enrolling by invitation|November 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|172|||Both|65 Years|N/A|No|||October 2014|October 31, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281032||33725|
NCT02285816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I214|MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours|A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours|I214|Canadian Cancer Trials Group|No|Recruiting|November 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|79|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285816||33358|
NCT02285829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01568|Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery|Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery||New York University School of Medicine|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects undergoing elective lumbar spine fusion surgery|October 2015|October 5, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285829||33357|
NCT02276924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0026|Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors|Diagnostic Relevance of Laser Confocal Microscopy During Reno-ureteroscopy in the Context of the Screening and Follow-up of Upper Urinary Tract Tumors|UROVISIO|Lille Catholic University|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02276924||34041|
NCT02276937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTR-001|Randomized Phase IIb Trial of DVC1-0101|DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: a Randomized Phase IIb Trial||Kyushu University|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|79 Years|No|||September 2015|September 1, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02276937||34040|
NCT02277210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14-428|Follicular Flushing in Patients With Suboptimal Responses|Effect of Follicular Flushing on the Ongoing Pregnancy Rate in Patients Who Developed Four or Fewer Follicles of 14mm Following Standard Ovarian Stimulation for In-vitro Fertilization Treatment - A Randomized Controlled Trial.||The University of Hong Kong|No|Active, not recruiting|October 2014|September 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Female|N/A|42 Years|No|||December 2015|December 4, 2015|October 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02277210||34019|
NCT02288182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR03/13|Randomized, Controlled Study to Compare Straumann® VivOss™ to Geistlich Bio-Oss® in Sinus Floor Augmentation.|A Randomized Controlled Clinical Trial to Investigate the Capability of Straumann® VivOss™ Compared to Geistlich Bio-Oss® in Sinus Floor Augmentation||Institut Straumann AG|No|Recruiting|October 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02288182||33176|
NCT02277769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1416|Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|SOLO 2|Regeneron Pharmaceuticals|Yes|Completed|November 2014|January 2016|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|708|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277769||33976|
NCT02288260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00242|RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy|RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy (STREAM)|STREAM|AstraZeneca|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|Study includes patients, in a real-life setting, who are hospitalized for acute coronary        syndrome (ACS) within 24 hours of symptom onset and who have a final diagnosis of Unstable        Angina (UA), Myocardial Infarction (MI) and were discharged. Including transferred to        another medical institution after 24 hours from the moment of hospitalization; transferred        from other medical institutions within 24 hours from the moment of initial hospitalization        to hospital.        Principal of choice in the Single-cohort study: only patients with ticagrelor at        discharged.        Patients received the standard medical care as determined by the treating cardiologist.|March 2016|March 24, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288260|2 Years|33170|
NCT02288403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIIT-1-UdeA|Interval Versus Continuous Training in Healthy Adults|Effects of a High-intensity Interval Training Program Compared to a Moderate Intensity Program in Adults 18-44 Years||Universidad de Antioquia|No|Recruiting|April 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Male|18 Years|44 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02288403||33159|
NCT02286284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130928/ N°IDRCB2014-A01044-43|Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia|Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation|ADENA|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|March 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|45 Years|No|||June 2015|December 21, 2015|November 3, 2014||No|Safety of patients : CSI recommandation and promotor decision|No||https://clinicaltrials.gov/show/NCT02286284||33322|
NCT02283203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOTEL-02|A New Formulation of Intravenous Paracetamol for Fever Management|A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin||Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|No|Completed|February 2015|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283203||33559|
NCT02288702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000604|Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome|Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome||Milton S. Hershey Medical Center|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|2 Years|17 Years|No|Non-Probability Sample|Patients aged 2-17 years (inclusive) scheduled for tympanostomy on the 24-hr and 48-hr        operating room (OR) schedules|September 2015|September 21, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288702||33136|
NCT02288715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPPV-KYan1205|Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy|Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy||West China Hospital|No|Recruiting|March 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|109|||Both|18 Years|N/A|No|Probability Sample|all patients admit to the general ICU of an academic teaching hospital|November 2014|November 6, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02288715||33135|
NCT02275442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0212|Effect of Precariousness in RUral Areas During preGNANCY||PRUGNANCY|University Hospital, Clermont-Ferrand||Active, not recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|190|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|rural parturient women|October 2014|October 23, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02275442||34155|
NCT02275455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0213|Design Of WELL Being Monitoring Systems, Application in Autism|Design Of WELL Being Monitoring Systems, Application in Autism|Do Well B|University Hospital, Clermont-Ferrand|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|12 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02275455||34154|
NCT02262208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120148|Exercise as a Tool for Studying the Mechanisms and Applicability of Glycemic Variability|Exercise as a Tool for Studying the Mechanisms and Applicability of Glycemic Variability in Individuals With and Without Type 2 Diabetes Mellitus|ETSMAGV|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|January 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|69|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02262208||35172|
NCT02266615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-14-4-077|Biobank Clinical Genetics Maastricht (KG01)|Biobank Clinical Genetics Maastricht|KG01|Maastricht University Medical Center|Yes|Recruiting|September 2014|||September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3600|Samples With DNA|DNA retrieved out of blood or tissue|Both|N/A|N/A|No|Non-Probability Sample|New patients visiting the out patient clinic of the department of Clinical Genetics of the        Maastricht University Medical Hospital and who get blood or tissue sampled for DNA        diagnostics.|September 2015|September 22, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02266615||34834|
NCT02288624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOR-0002|The Effects of Whole Versus Processed Orange Consumption on Satiety|A Randomized, Double Blind and Crossover Study Investigating the Effect of Whole Versus Processed Orange Consumption on Satiety in Healthy Volunteers||University of Reading|Yes|Completed|April 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02288624||33142|
NCT02280460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-194|ECMO: Optimization of Its Use|Extracorporeal Membrane Oxygenation(ECMO): Optimization of Its Use||Spectrum Health Hospitals|No|Recruiting|September 2014|September 2025|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||3|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Spectrum Health requiring ECMO therarpy. For the control, patients in        the Intensive Care Unit at Spectrum Health will be considered.|October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280460|1 Year|33769|
NCT02280473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11193X-001|A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease|||Allergan|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280473||33768|
NCT02280785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-04-059|To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma|A Phase II Study of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma|BRAN|Samsung Medical Center|Yes|Not yet recruiting|November 2014|December 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|75 Years|No|||November 2014|November 1, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02280785||33744|
NCT02285790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-OSS 2014_244|One-stop-shop Study for Treatment of Basal Cell Carcinoma Using Reflectance Confocal Microscopy|Treatment of Basal Cell Carcinoma Using a One-stop-shop With Reflectance Confocal Microscopy: a Randomized Controlled Multicenter Trial|B-OSS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|January 2015|February 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|November 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02285790||33360|
NCT02281903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR/2014/05|Pediatric Resuscitation With Feedback CPR Devices|Is Chest Compressions Using the TrueCPRTM Feedback Device More Effective Than Manual Compressions During Pediatric Resuscitation? A Manikin Study|PRFD|International Institute of Rescue Research and Education|Yes|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 15, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281903||33659|
NCT02282397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-901148|Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes|Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes|DIaMonD|DexCom, Inc.|No|Active, not recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|316|||Both|25 Years|N/A|No|||March 2016|March 14, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282397||33621|
NCT02277782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002384|Intrathecal Hydromorphone for Labor Analgesia|Intrathecal Hydromorphone for Labor Analgesia|LITH|Brigham and Women's Hospital|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|45 Years|No|||October 2015|October 30, 2015|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277782||33975|
NCT02278029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1611|Driving Performance of Teenage Patients With mTBI: a Longitudinal Assessment|Driving Performance of Teenage Patients With mTBI: a Longitudinal Assessment||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|16 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Enrollment of patients with mTBI will take place through our institution's previously        established network of outpatient sports medicine clinics. Patients will be defined as        those who have suffered closed head trauma diagnosed as mTBI or concussion. We aim to        enroll 100 total subjects (50 patients with concussion, 50 control subjects)|August 2015|August 6, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02278029||33956|
NCT02278315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-14-002|Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma|Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma||Cellectar Biosciences, Inc.|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278315||33934|
NCT02288585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-SCC-1552|The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus|The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes||Unilever R&D|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|214|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02288585||33145|
NCT02286609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-023|A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics|A Single Dose Evaluation of the Effects of Moderate (Child-Pugh Grade B) Hepatic Impairment on Deflazacort Pharmacokinetics||Marathon Pharmaceuticals, LLC|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|January 6, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286609||33297|
NCT02279121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMetzThionville|ATAPAC Study (TauroLock Activity in Adult Cancer Patients)|Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non-hematological Cancer Treated With Intravenous Anti-tumor Therapy|ATAPAC|Centre Hospitalier Régional Metz-Thionville|No|Active, not recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|162|||Both|18 Years|N/A|No|||May 2015|February 19, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02279121||33872|
NCT02261688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002358|Salt and TH-17 in Healthy Human Subjects|Evaluation of the Influence of Salt Intake on TH17 Interleukin(IL)-17 Producing CD4+ Helper T Cells in Human Subjects||Brigham and Women's Hospital|Yes|Active, not recruiting|March 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261688||35212|
NCT02261974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(OUS) V-013|VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness|VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness|VIVEVE I|Viveve Inc.|No|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|113|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02261974||35190|
NCT02266628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-E-201|Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults|A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients||Novavax|No|Active, not recruiting|October 2014|February 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1599|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266628||34833|
NCT02266641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401034RINB|Parental One-carbon Folate and Choline Nutrition Modulates Risk of Off-spring Cancer Development: Human Cohort Study|Parental One-carbon Folate and Choline Nutrition Modulates Risk of Off-spring Cancer Development: Human Cohort Study||National Taiwan University Hospital|No|Not yet recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|500|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02266641||34832|
NCT02288546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKuopio|Vegans Health Status and Exposure to Pesticides and Nitrate|Vegans Exposure to Pesticides and Nitrate||University of Eastern Finland|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|41|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Vegans and non-vegans|August 2011|November 6, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02288546||33148|
NCT02288559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29455|A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy|||Genentech, Inc.||Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|90|||Both|60 Years|N/A|No|||March 2016|March 1, 2016|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288559||33147|
NCT02288572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGPS001|Probiotic Bacteria in Prevention of the Metabolic Syndrome|Mechanisms of Action of Probiotic and Protective Bacteria PCS 20, PCS 26, and LGG in Prevention of the Metabolic Syndrome||University Maribor|No|Completed|May 2013|May 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|21 Years|85 Years|No|||November 2014|November 6, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02288572||33146|
NCT02285296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_40|The Needs and Burden of Family Caregivers of Older Adults With Cancer|The Needs and Burden of Family Caregivers of Older Adults With Cancer and Their Social Determinants||University Hospital, Lille|Yes|Recruiting|December 2014|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|236|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285296||33398|
NCT02285543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPIC2014|a Trial of TPF(Docetaxel, Cisplatin and 5-fluorouracil ) Induction Chemotherapy in OSCC at cN2 Stage|A Randomized Phase II Trial of TPF Induction Chemotherapy in Patients With Oral Squamous Cell Carcinoma at cN2 (Clinical Node 2) Stage||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|December 2014|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|101|||Both|18 Years|75 Years|No|||November 2014|November 4, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02285543||33379|
NCT02281331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 14-677|Optimal Exercise Training and Nutrition Supplementation in Older Men|Evaluation of the Effects of a Combined Resistance and High-intensity Interval Exercise Training Program, Along With Nutritional Supplementation, on Strength and Physical Function in Older Men||McMaster University|No|Active, not recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Male|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02281331||33702|
NCT02281344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP14C11|MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants|A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.||Medicines for Malaria Venture|Yes|Recruiting|October 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281344||33701|
NCT02287948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WII Balance Board_MS|Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects|Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects||University Hospital of Ferrara|Yes|Completed|September 2014|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Will be recruited 20 healthy subjects and 20 subject with a diagnosis of multiple        sclerosis and mild to moderate disability ambulatory identified with a value not higher        than 5.5 EDSS score. The subjects of both groups will be age-matched to exclude        differences caused by age posturographic. All individuals carry out the task of torque        balance both on the platform and on the Wii Fit Balance Board on the same day.|February 2016|February 2, 2016|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287948||33194|
NCT02285868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI EGIS01012015|ATI Evidence-based Guide Investigating Clinical Services|ATI Evidence-based Guide Investigating Clinical Services: Rehabilitation and Physical Therapy Patient Outcomes Registry|AEGIS|ATI Holdings, LLC|Yes|Recruiting|November 2014|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community||6|Anticipated|100000|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients presenting ith orthopedic rehabilitation needs|December 2015|December 28, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285868|2 Months|33354|
NCT02285920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821193|Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial|Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial|SPin-D|University of Pennsylvania|Yes|Recruiting|November 2014|September 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|125|||Both|18 Years|85 Years|No|||August 2015|October 2, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02285920||33350|
NCT02285933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-14-0005830|Virtual Reality Exercise for Stroke Rehabilitation in Inpatients Who Are Unable to Stand|Does the Addition of Virtual Reality Training to a Standard Program of Inpatient Rehabilitation Improve Sitting Balance Ability and Function After Stroke? A Blinded Randomized Controlled Trial.||Bruyere Research Institute|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02285933||33349|
NCT02282410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-053-01|Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A|Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|18 Years|No|||October 2014|October 31, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02282410||33620|
NCT02282670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA5204_GR_III|A Study to Evaluate the Efficacy and Safety of DA-5204|A Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5204 and to Demonstrate the Non-inferiority of DA-5204 Compared With Stillen Tab. in Patients With Acute or Chronic Gastritis||Dong-A ST Co., Ltd.|No|Active, not recruiting|April 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|434|||Both|20 Years|75 Years|No|||October 2014|October 31, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02282670||33600|
NCT02286310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO14-189|Effect of Exercise Programs on 3-dimensional Scapular Kinematics, Disability and Pain|Effect of Exercise Programs on 3-dimensional Scapular Kinematics, Disability and Pain in Subjects With Shoulder Impingement||Hacettepe University|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|45 Years|No|||November 2014|November 6, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02286310||33320|
NCT02278601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTGL13feb013|Comparison of Regimens VAMB, CIPCEA, PCEA|Comparison of Variable-frequency Automated Mandatory Bolus (VAMB), Computer-integrated Patient Controlled Epidural Analgesia (CIPCEA) and Conventional Patient Controlled Epidural Analgesia (PCEA) During Labour|COLEUS|KK Women's and Children's Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|3412|||Female|21 Years|50 Years|No|||September 2015|September 3, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02278601||33912|
NCT02291081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4970-BO A|A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected Patients|A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk, New Cardiovascular Events and the Cardiovascular Diseases in HIV-infected Patients: 10 Year Follow-up|HIV-HEART10|University Hospital, Essen|No|Recruiting|October 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Stored blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Participiants were included in several cities of the Ruhrarea. Locations were Essen,        Bochum, Dortmund and Duisburg The study population included outpatients who were at least        18 years of age, had a known HIV-infection and exhibited a stable disease status within 4        weeks before inclusion of the trial. Written informed consent was obtained from all        participants.|November 2014|November 11, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02291081||32954|
NCT02283437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS2014218003|A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia|A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Schizophrenia Spectrum Disorders|PSBBP|The Hong Kong Polytechnic University|Yes|Recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|129|||Both|18 Years|60 Years|No|||February 2016|February 17, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283437||33541|
NCT02266095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2013-136|Oval-8 Splinting Versus Standardized Treatment With Tee Pee or Forearm Based Thumb Spica Splinting|Pilot Study of a Novel Splint Treatment for Thumb CMC Joint Arthritis: a Comparison of Oval-8 Splinting Versus Standardized Treatment With Tee Pee or Forearm Based Thumb Spica Splinting|Oval-8|University of Florida|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02266095||34874|
NCT02266329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1136-W|Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin|Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin||VA Office of Research and Development|No|Recruiting|January 2016|December 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266329||34856|
NCT02266342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPR12-03|GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry|Evaluation on the Treatment of Diseases of the Thoracic Aorta With the Thoracic Endoprosthesis GORE® TAG®||W.L.Gore & Associates|No|Recruiting|October 2014|January 2022|Anticipated|November 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with a disease of the descending thoracic aorta, requiring treatment        with a thoracic endoprosthesis.|December 2015|December 8, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02266342|5 Years|34855|
NCT02270502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000249|Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit|Ultrasound Assessment of Muscle to Quantify Frailty.||Massachusetts General Hospital|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the surgical intensive care unit (SICU)|March 2016|March 16, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270502||34535|
NCT02280187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.05.8005|InductOs® in Real World Spine Surgery; A Retrospective, French, Multi-centric, Study|InductOs® in Real World Spine Surgery; A Retrospective, French, Multi-centric, Study|InductOR|Medtronic Spinal and Biologics|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|The retrospective review of records will focus on patients who have undergone a spinal        fusion surgery. Patient should be considered for enrollment if he/she has been treated        with InductOs between January 1, 2011 and 31st December 2012.|January 2016|January 26, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280187||33790|
NCT02287688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_74OB|Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study|Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo®) in Children 2 Months Through 23 Months of Age.||Novartis|No|Recruiting|December 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|2 Months|23 Months|No|Non-Probability Sample|Children 2-23 months of age who receive at least one dose of MenACWY-CRM vaccine at a        Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan        member.|March 2016|March 4, 2016|October 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287688||33214|
NCT02287935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdanaNTRH|Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease|Effectiveness of Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease||Adana Numune Training and Research Hospital|No|Completed|January 2009|September 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02287935||33195|
NCT02285309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLondon|Perioperative Measurements of Diastolic Function in Cardiac Surgery|The Utility of Novel Measurements of Diastolic Function Involving Transoesophageal and Transthoracic Echocardiography in the Peri-operative Period in Patients Undergoing Cardiac Surgery -an Exploratory Trial||University College, London|Yes|Not yet recruiting|November 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Any cardiac surgery|November 2014|November 4, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285309||33397|
NCT02288000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_55|Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases|Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers|WP3_P002|University Hospital, Lille|Yes|Not yet recruiting|January 2016|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288000||33190|
NCT02288052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G.0906.11|Consolidation of Motor Learning of Writing Skills and Its Related Brain Activity Changes in Parkinson's Disease|Consolidation of Motor Learning of Writing Skills and Its Related Brain Activity Changes in Parkinson's Disease||Katholieke Universiteit Leuven|No|Completed|January 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|N/A|N/A|No|||January 2016|January 27, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02288052||33186|
NCT02288065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S561430|Predictive Factors and Outcome in Medical Thoracoscopy|Predictive Factors and Outcome in Medical Thoracoscopy||Katholieke Universiteit Leuven|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|pulmonary or extrathoracic malignancy|October 2015|October 12, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02288065||33185|
NCT02282150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLEN-EMA-hypo|Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism|Effect of Modified-release Compared to Conventional Hydrocortisone on Fatigue, Measured by Ecological Momentary Assessments; a Pilot Study.|PlenadrEMA|Rigshospitalet, Denmark|No|Enrolling by invitation|October 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|November 3, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02282150||33640|
NCT02282163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-140|Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography|A Multicenter Clinical Evaluation of Safety and Efficacy of Lumason as a Contrast Agent in Pediatric Echocardiography||Bracco Diagnostics, Inc|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|92|||Both|9 Years|17 Years|No|||January 2016|January 20, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282163||33639|
NCT02286193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011 Hsu PCORI Cycle 1|Creating a Clinic-Community Liaison Role in Primary Care: Engaging Patients and Community in Health Care Innovation|Creating a Clinic-Community Liaison Role in Primary Care: Engaging Patients and Community in Health Care Innovation|LINCC|Group Health Cooperative|No|Enrolling by invitation|March 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group Health primary care patients at one of two pilot clinics who are aged 18 and older        and are referred or self-refer to work with a Community liaison|November 2014|November 5, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286193||33329|
NCT02286297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/08|Pediatric Endotracheal Intubation During Resuscitation|Comparison of Intubation Through the McGrath® MAC, GlideScope®, AirTraq® and Miller Laryngoscope by Paramedics During Pediatric Cardiopulmonary Resuscitation: a Randomized Crossover Manikin Trial.|PETI|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286297||33321|
NCT02286323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/07|Endotracheal Intubation During Resuscitation|Can the Bonfils Intubation Fiberscope Rival the Macintosh Laryngoscope During Resuscitation With Uninterrupted Chest Compression?|EIDR|International Institute of Rescue Research and Education|Yes|Enrolling by invitation|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286323||33319|
NCT02282943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC71/02|Carbon Dioxide-laser Versus Harmonic Scalpel in the Treatment of Pelvic Pain Due to Endometriosis|Carbon Dioxide-laser Versus Harmonic Scalpel in the Treatment of Pelvic Pain Due to Endometriosis||Royal Surrey County Hospital|Yes|Completed|October 2002|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 1, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282943||33579|
NCT02286453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-ES-6-152/56|Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac|Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac (Clinical Trial Phase II)||Thammasat University|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|45 Years|80 Years|No|||September 2015|September 26, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286453||33309|
NCT02280239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01160|Safety and Efficacy of Acetaminophen in the Intensive Care Unit.|Safety and Antipyretic Efficacy of Acetaminophen in the Febrile Intensive Care Unit Patient.|SEA-ICU|University of British Columbia|No|Enrolling by invitation|May 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280239||33786|
NCT02286830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG 22/14|Prolonged Protection From Bone Disease in Multiple Myeloma|Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial|Magnolia|Odense University Hospital|Yes|Recruiting|January 2015|March 2021|Anticipated|January 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|March 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286830||33280|
NCT02270099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10921-HSVPS-CSP-01|Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects|Clinical Evaluation of the Aptima® Herpes Simplex Viruses 1 & 2 Assay on the Panther® System in Swab Specimens From Symptomatic Subjects Presenting With a Suspected Herpes Lesion(s)||Hologic, Inc.|No|Recruiting|December 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1900|Samples With DNA|lesion swab|Both|N/A|N/A|No|Non-Probability Sample|Male and female subjects attending participating US collection sites and presenting with        suspected HSV lesion(s) will be eligible for the study. Sites may include family planning,        general practice, dermatology, research, sexually transmitted infection, adolescent, and        public health clinics. There are no age restrictions for this study.|December 2015|December 28, 2015|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02270099||34566|
NCT02270294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPSC-3|Acute Effects of Thai Traditional Massage on Cerebrovascular Reactivity in Ischemic Stroke Patients|Acute Effects of Thai Traditional Massage on Cerebrovascular Reactivity in Ischemic Stroke Patients||Chulalongkorn University||Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|50 Years|80 Years|No|||August 2015|August 1, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02270294||34551|
NCT02270307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-CY-Russia|MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis|Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis|MSC-CY|National Research Center for Hematology, Russia|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|65 Years|No|||October 2014|October 17, 2014|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02270307||34550|
NCT02285075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVDC Temocillin 1|Temocillin Pharmacokinetic in Hemodialysis|A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis?||AZ Sint-Jan AV|Yes|Completed|June 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02285075||33415|
NCT02287454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSMC-002-UD|Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis|Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis: a Randomized Clinical Trial||University of Deusto|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|20 Years|60 Years|No|||November 2014|November 5, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02287454||33232|
NCT02290288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-28601|Prospective Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of Two Surgical Methods|Prospective Randomized Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of a Vaginal and Laparoscopic Method With Validation of Translated Questionnaire for Symptoms and Quality of Life by Vaginal Prolapse.||Sahlgrenska University Hospital, Sweden|No|Completed|October 2005|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Female|40 Years|N/A|No|||May 2015|May 18, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02290288||33014|
NCT02276157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-026|Direct Peroral Cholangioscopy by Using an Ultra-slim Upper Endoscope|Direct Peroral Cholangioscopy by Using an Ultra-slim Upper Endoscope||Soonchunhyang University Hospital|Yes|Recruiting|August 2006|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Refered or inpatients of tertiary medical center|June 2015|June 1, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276157||34100|
NCT02281045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55895|CITrate and Evodial for Effective Dialysis (CITED) Study||CITED|Universitaire Ziekenhuizen Leuven||Recruiting|October 2014|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02281045||33724|
NCT02288273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5551L00006|Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes|A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes||AstraZeneca|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288273||33169|
NCT02288286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCP-11|Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans|Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans From 10-60 Years Old||Beijing Center for Disease Control and Prevention|Yes|Completed|November 2014|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|1200|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||November 2014|January 19, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288286||33168|
NCT02276430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWF2011-5209|TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects|A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors|TACkLE|University Medical Center Groningen|No|Recruiting|July 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|900|Samples With DNA|Blood samples: analysis of cardiovascular risk factors (lipid profile, glucose metabolism,      hormonal status), platinum levels and several biomarkers.      Urine samples: microalbuminuria, platinum levels. DNA: polymorphisms in candidate genes for      development of cardiovascular damage, leukocyte telomere length|Male|18 Years|75 Years|No|Probability Sample|Testicular cancer survivors|October 2015|October 1, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02276430||34079|
NCT02276443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0185|Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy|Improving Outcomes in Triple-Negative Breast Cancer Using Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy||M.D. Anderson Cancer Center|Yes|Recruiting|November 2015|||November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276443||34078|
NCT02276703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000725|Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU|Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU||Milton S. Hershey Medical Center|No|Recruiting|October 2014|||October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|89 Years|No|Non-Probability Sample|Adult Intensive Care Unit (ICU) patients between the ages of 18-89 years (inclusive), that        are scheduled to receive a painful procedure. We are requesting a total population of 120        to allow for withdrawals|July 2015|July 13, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02276703||34058|
NCT02276950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARTROCS|HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery|HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery (HARTROCS)|HARTROCS|Karolinska University Hospital|No|Active, not recruiting|January 2011|March 2020|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150000|||Both|18 Years|N/A|No|Probability Sample|All adult patients who underwent cardiac surgery in Sweden during the study period|February 2016|February 22, 2016|October 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02276950||34039|
NCT02277496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2056|Wellness Program Implementation: School & Student Toolkits|Wellness Program Implementation: School & Student Toolkits||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|July 2013|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|14520|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02277496||33997|
NCT02277509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3252|Chinese Diabetes Prevention Program (Chinese DPP)|Chinese Diabetes Prevention Program: An Implementation and Dissemination Study||Albert Einstein College of Medicine of Yeshiva University|Yes|Suspended|April 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|435|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 27, 2014|October 15, 2014||No|Completed pilot and larger scale trial requires additional funding.|No||https://clinicaltrials.gov/show/NCT02277509||33996|
NCT02286102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11005|A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains|A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains for Adults Undergoing Multilevel Spine Surgery for Deformity||Hospital for Special Surgery, New York|No|Recruiting|January 2011|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|March 17, 2015|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286102||33336|
NCT02279381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106-Ped-ERC-14|Neonatal Package Study in Rural District of Pakistan|A Randomized Controlled Trial to Evaluate the Acceptability, Feasibility and Efficacy of the Use of a Neonatal Package to Reduce Neonatal Infection in a Rural District of Pakistan||Aga Khan University|Yes|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1350|||Both|N/A|28 Days|Accepts Healthy Volunteers|||November 2015|November 11, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279381||33852|
NCT02290886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMAd/ELA/2011|Clinical Trial Phase Multicentric I/II to Evaluate Safety in Patients With Amyotrophic Sclerosis Lateral|Clinical Trial Phase I/II, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|July 2014|September 2019|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02290886||32969|
NCT02286466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-533|Mobile App of CBT for Anxiety and Cancer|Mobile Application of Cognitive-Behavioral Therapy (CBT) for Anxiety and Cancer||Massachusetts General Hospital|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286466||33308|
NCT02290977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-009|Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)|Scheduled Interval Trans-catheter Arterial Chemo-embolization and Radiation Therapy for Hepatocellular Carcinoma Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial||Samsung Medical Center|Yes|Recruiting|November 2014|April 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|70 Years|No|||December 2014|December 3, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02290977||32962|
NCT02285101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT-100-005|Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors|Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD||Bio-Cancer Treatment International Limited|No|Recruiting|November 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285101||33413|
NCT02285322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10_164R|Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study|Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study||University College, London|Yes|Active, not recruiting|January 2014|April 2015|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the CALIBER database who had high blood pressure (the Clinical Practice        Research Datalink [CPRD]) and consenting to data linkage. High blood pressure was defined        as the record of ≥3 systolic or diastolic high blood pressure readings within a one year        period, or ≥2 systolic or diastolic high blood pressure readings within a 6 month period        in CPRD. High blood pressure measurements were defined as in the eighth Joint National        Committee (2014 JNC8) guidelines for patient management, that is ≥140/90mmHg for        individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years.|November 2014|November 4, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285322||33396|
NCT02274415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10028|Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease|Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti-pneumococcal and Polysaccharide Anti-pneumococcal Vaccine Compared to Polysaccharide Anti -Pneumococcal Vaccine Alone in Patients With Sickle Cells Disease|DREVAC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2013|March 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02274415||34234|
NCT02274428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-103|Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage|Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage||Samsung Medical Center|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|23 Weeks|34 Weeks|No|||December 2014|December 28, 2014|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02274428||34233|
NCT02261987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR_FQ- 013|Resistive Inspiratory Manoeuvre as Airway Clearance Technique in Cystic Fibrosis|Role of Resistive Inspiratory Manoeuvres During Bronchial Drainage Session in Cystic Fibrosis: a Randomized Crossover Trial||Universidad San Jorge|Yes|Active, not recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|16 Years|N/A|No|||November 2015|November 9, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02261987||35189|
NCT02274454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02|Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro|Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|41|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02274454||34231|
NCT02280798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407-MAD-056-MC|Endometrial Gene Expression in Different Protocols of Endometrial Preparation for Embryo Transfer'|Endometrial Gene Expression in Different Protocols of Endometrial Preparation|ERA|IVI Madrid|Yes|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5|Samples With DNA|endometrial biopsies for ADN analysis|Female|18 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 5 volunteers from our egg donation program were included in the study from        Setember 2014 to jnuary 2015|February 2016|February 22, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02280798||33743|
NCT02281058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000699|Open-label Pilot Study of Abatacept for the Treatment of Vitiligo|Open-label Pilot Study of Abatacept for the Treatment of Vitiligo||Brigham and Women's Hospital||Recruiting|January 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281058||33723|
NCT02277535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001702|An Email Intervention to Prevent Iatrogenic Malnutrition in the ICU|An Email Intervention to Prevent Iatrogenic Malnutrition in the ICU||Massachusetts General Hospital|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|197|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277535||33994|
NCT02277795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000774/BWH|Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya|Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya||Brigham and Women's Hospital|Yes|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|600|||Male|N/A|60 Days|Accepts Healthy Volunteers|||July 2015|July 20, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02277795||33974|
NCT02281656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7126|Prospective Evaluation of Reverse End to Side Anterior Interosseous Nerve to Ulnar Nerve Transfer for Severe Compressive Ulnar Neuropathy at the Elbow|Prospective Evaluation of Reverse End to Side Anterior Interosseous Nerve to Ulnar Nerve Transfer for Severe Compressive Ulnar Neuropathy at the Elbow||Lawson Health Research Institute|No|Not yet recruiting|January 2015|October 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||January 2015|January 8, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02281656||33677|
NCT02281916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_02|Safety Study of P28GST Treatment in Crohn's Disease Patients|Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial|ACROHNEM|University Hospital, Lille|Yes|Recruiting|March 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|64 Years|No|||October 2015|October 13, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02281916||33658|
NCT02285946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-14|Comparison of Supine to Prone Position During Major Spinal Surgery|Alveolar Recruitment Maneuvers: Comparison of Supine to Prone Position During Major Spinal Surgery|MRA-RACHIS|University Hospital, Strasbourg, France|No|Not yet recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patient operated major spine surgery, including:          -  The transpedicular osteotomies          -  Tumor spinal surgery (sarcoma, osteosarcoma) or metastatic          -  Degenerative spinal surgery on multiple vertebral levels and degraded land          -  Surgery of scoliosis          -  Recovery of spinal surgery on several levels          -  Sepsis spinal presumed origin|November 2014|November 4, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02285946||33348|
NCT02288884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RQhealth|The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section|The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section||Regina Qu'Appelle Health Region|No|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288884||33122|
NCT02284009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110933|Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus|Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus||GlaxoSmithKline|No|Recruiting|October 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|30 Years|No|||February 2016|March 3, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02284009||33497|
NCT02290899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4067-14|Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder|Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder||Rhode Island Hospital||Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|30|||Both|13 Years|17 Years|No|Non-Probability Sample|Patients with ADHD|October 2015|October 22, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02290899||32968|
NCT02290990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMMI SI|Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS|A Randomized Controlled Trial on Integrated Imaginative Distention in MS Ans Insomnia: a Self Managed Tool to Cope With Fatigue, Stress and Insomnia|DIMMISI|Niguarda Hospital|Yes|Active, not recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|144|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290990||32961|
NCT02279966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15906A|Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|October 2014|||February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279966||33807|
NCT02279979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thoratec HeartMate PHP™ CS|Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial|Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial||Thoratec Corporation|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||March 2016|March 24, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279979||33806|
NCT02288117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202 HP|Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem|Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem||Waldemar Link GmbH & Co. KG||Recruiting|July 2015|December 2021|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with mobility-limiting disease, fracture or defect of the hip joint requiring        primary THA with SP-CL® (i.e. primary or secondary coxarthrosis, osteoarthritis, femoral        neck fracture, necrosis of the femoral head)        ·|July 2015|July 15, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02288117||33181|
NCT02288208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-POC-0095-PTL|Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B||TetraLogic Pharmaceuticals|No|Terminated|November 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 3, 2014||No|Due to cranial nerve palsies observed|No||https://clinicaltrials.gov/show/NCT02288208||33174|
NCT02261701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTV-426521|Rehabilitation After Rotator Cuff Repair|Rehabilitation After Rotator Cuff Repair a Randomised Controlled Study||Uppsala University|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02261701||35211|
NCT02261714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG01-01|Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer|A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas||Targovax AS|No|Recruiting|December 2012|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|99 Years|No|||December 2015|December 9, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02261714||35210|
NCT02266355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408014510|Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction|A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)||Yale University|Yes|Recruiting|November 2014|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|October 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02266355||34854|
NCT02262221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 48/14|Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer|Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer|HETeCo|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|330|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02262221||35171|
NCT02290184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14158|PilAm Go4Health Weight Loss Program|Pilipino Americans Go4Health Weight Loss Program to Prevent Heart Disease||University of California, San Francisco|No|Active, not recruiting|November 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|February 24, 2016|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02290184||33022|
NCT02290197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0886-09|Knee Dislocation - Clinical Evaluation of the Use of Hinged External Fixator After Ligament Reconstruction|Knee Dislocation - Clinical Evaluation of the Use of Hinged External Fixator After Ligament Reconstruction. Randomized Prospective Study.||University of Sao Paulo General Hospital|No|Active, not recruiting|August 2010|March 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 8, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02290197||33021|
NCT02284815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRECT-2011-119|Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?|Diet Intervention in Newly Diagnosed Children With Type 1 Diabetes. How to Prolong Remission Using a Non-medical Approach?||Herlev Hospital|Yes|Active, not recruiting|March 2012|August 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Years|18 Years|No|||November 2014|November 4, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02284815||33435|
NCT02284828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-123|Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function|Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function: Single-blind, Single-centre, Single and Multiple Dose, Fixed-order, Placebocontrolled Trial in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 4, 2014||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT02284828||33434|
NCT02285088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBT440-001|A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease|A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease||Global Blood Therapeutics||Recruiting|December 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|November 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285088||33414|
NCT02282683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hebmu 201312|Long-term Prednisone Use for End-stage Heart Failure|Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia||Hebei Medical University|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||October 2014|October 31, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02282683||33599|
NCT02285556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZhao-003|The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus|The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus||Shanghai Mental Health Center|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|560|||Both|18 Years|49 Years|No|||November 2015|November 16, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02285556||33378|
NCT02285842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002F|Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components|Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components||MicroPort Orthopedics Inc.|No|Enrolling by invitation|December 2014|December 2028|Anticipated|December 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with CONSERVE® Press-Fit Femoral Components|October 2015|October 16, 2015|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285842||33356|
NCT02285881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39039.041.11|Shared Decision Making Between Patients and GPs in the Treatment of Type 2 Diabetes in Primary Care.|Shared Decision Making in Type 2 Diabetes With a Support Decision Tool That Takes Into Account Patient Preferences, Clinical Factors and the Intensity of Treatment: Design of a Cluster Randomised Trial||UMC Utrecht|No|Active, not recruiting|March 2012|February 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Both|60 Years|80 Years|No|||December 2015|December 4, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285881||33353|
NCT02288728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH-GC-01|Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy|Remnant Stomach-jejunum Double Tract Anastomosis vs. Gastric Tube Anastomosis to Proximal Gastrectomy of Early Gastric Cancer- a Randomized Controlled Trial|DTA&GTA|West China Hospital|Yes|Not yet recruiting|December 2014|October 2019|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|75 Years|No|||November 2014|November 6, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02288728||33134|
NCT02278614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2347-PIII-12/13|Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients|Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients.||Laboratoires Thea|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||February 2016|March 16, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02278614||33911|
NCT02279134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-090/880|Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma|A Phase II/III Study of Adjuvant Chemoradiotherapy, Radiotherapy After Surgery Versus Surgery Alone in Patients With Stage ⅡB-Ⅲ Esophageal Carcinoma||Chinese Academy of Medical Sciences|Yes|Recruiting|October 2014|October 2022|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|68 Years|No|||October 2015|October 11, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02279134||33871|
NCT02287480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCER 14-221|VSV-ZEBOV Geneva Vaccine Trial|A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.|VSV-ZEBOV|University Hospital, Geneva|Yes|Completed|November 2014|January 2016|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|115|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02287480||33230|
NCT02279667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-109|Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093|Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|October 29, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02279667||33830|
NCT02279680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-AO1800-45|Associative Memory in Adults With an Autism Spectrum Disorder|The Associative Memory in Autism Spectrum Disorders Without Intellectual Disability|MEM-T2A|University Hospital, Caen|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02279680||33829|
NCT02284568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV5600-CNS-20006|A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo|A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) Phase 2||Teva Pharmaceutical Industries|Yes|Recruiting|January 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|25 Years|55 Years|No|||March 2016|March 2, 2016|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284568||33454|
NCT02284841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Effect of Hilotherm Therapy on Post-operative Pain and Swelling Following Surgical Wisdom Tooth Removal|Effect of Hilotherm Therapy on Post-operative Pain and Swelling Following Surgical Lower Third Molar Removal||King's College Hospital NHS Trust|No|Recruiting|August 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||August 2015|September 2, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02284841||33433|
NCT02284854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-129|Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine|Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine in Healthy Subject||Bial - Portela C S.A.|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|November 4, 2014||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT02284854||33432|
NCT02276469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC 0748/006|Peer Support for Severe Mental Disorders|Randomized Controlled Trial of Peer to Peer Support for People With Severe Mental Disorders: Schizophrenia, Affective Disorders and Personality Disorders in Comparison to Standard Care|PEER|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|July 2011|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|17 Years|N/A|No|||January 2015|January 1, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02276469||34076|
NCT02276482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1986-012|Study of Tedizolid Phosphate (TZD) in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)|Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to < 18 Years With cSSTI.||Cubist Pharmaceuticals LLC|Yes|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|12 Years|18 Years|No|||March 2016|March 18, 2016|October 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276482||34075|
NCT02276729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165094|Mirror Box Therapy for Upper Limb Function With Stroke|A Pilot Randomized Controlled Trial (RCT) of Mirror Box Therapy in Upper Limb Rehabilitation With Sub-acute Stroke Patients||University of Ulster|No|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02276729||34056|
NCT02266108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140523|Economic and Social Empowerment To Increase Upwards Mobility Among Women|ESTIMA: Economic and Social Empowerment To Increase Upwards Mobility Among Women|ESTIMA|University of California, San Diego|Yes|Enrolling by invitation|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02266108||34873|
NCT02270801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhTPO-ITP-Pregnancy|Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy|Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial||Shandong University|Yes|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|50 Years|No|||October 2014|October 17, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02270801||34512|
NCT02266654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-2014|Early Goal Directed Therapy in Sepsis by Emergency Medical Services|Early Goal Directed Therapy in Sepsis by EMS||Massachusetts General Hospital|No|Recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|17 Years|N/A|No|||June 2015|June 24, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02266654||34831|
NCT02290210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC102KR|Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients|A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients||JW Pharmaceutical||Recruiting|April 2014|||March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Male|20 Years|70 Years|No|||November 2014|November 10, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02290210||33020|
NCT02280200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mays-2|Ankle-foot Orthoses for Peripheral Artery Disease|Efficacy of Ankle-Foot Orthoses on Walking Ability in Peripheral Artery Disease: The AFO for PAD Trial I||International Heart Institute of Montana Foundation|No|Active, not recruiting|November 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02280200||33789|
NCT02280213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/06|Comparison Four Intubation Devices|Comparison of Tracheal Intubation Using the Miller, Macintosh, Phillips and Wis-Hipple Blades During Infant Resuscitation: A Randomized Crossover Simulation Trial||International Institute of Rescue Research and Education|Yes|Completed|November 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 31, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02280213||33788|
NCT02288104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-IR-NHC-2014|Needle-based Confocal Laser Endomicroscopy in CT-guided Procedures in Interventional Radiology With Applications in Liver and Kidneys: a Feasibility Study|||Mauna Kea Technologies||Recruiting|January 2015|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02288104||33182|
NCT02281669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1571-ES-CTIL|Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients|Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients||Sheba Medical Center|No|Not yet recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients arriving to the Geographic clinic or to the Skin clinic, diagnosed with Cutaneous        leishmaniasis, and the treatment which is choosen by their physican is Pentostam        injections.|October 2014|October 30, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281669||33676|
NCT02288195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT201401|Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients|Phase III Study of Neoadjuvant Chemotherapy With Capecitabine and Oxaliplatin Versus Chemoradiation for Locally Advanced Rectal Cancer Patients||Sun Yat-sen University|No|Recruiting|August 2014|June 2024|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|648|||Both|18 Years|75 Years|No|||November 2014|November 6, 2014|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02288195||33175|
NCT02286336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-64|The Minimum Effective Concentration of Ropivacaine in Ultrasound-guided Supraclavicular Block|The Minimum Effective Concentration of Ropivacaine in Ultrasound-guided Supraclavicular Block||Huazhong University of Science and Technology|No|Completed|October 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|65 Years|No|||July 2015|July 25, 2015|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02286336||33318|
NCT02286479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2014/259|Comparison of Loop and Primary Incision&Drainage Techniques in the Emergency Department|Comparison of Loop Drainage and Primary Incision and Drainage Techniques in Patients With Cutaneous Abscess in the Emergency Department||Kocaeli University|No|Recruiting|October 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286479||33307|
NCT02288416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14169|Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening|Pilot Study of a Video-Based Intervention to Reduce Psychological Harm Associated With Lung Cancer Screening||City of Hope Medical Center|Yes|Recruiting|December 2014|||June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288416||33158|
NCT02288598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-IDREC-C2-2014-013|Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering|Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering||University of Oxford|No|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|50 Years|No|||January 2016|January 7, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02288598||33144|
NCT02278055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-098|Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer|Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Male|18 Years|N/A|No|||September 2015|September 17, 2015|October 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278055||33954|
NCT02278861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFG 133/11|Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis|Low Dose Oral Isotretinoin Versus Topical Tretinoin for Prevention of Actinic Keratosis in Immunocompetent Patients: a Randomized, Comparative Trial|ARISOAK|Universidade Federal de Goias|Yes|Completed|November 2011|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|50 Years|75 Years|No|||October 2014|October 29, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278861||33892|
NCT02283710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9011160012|The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease|The Effect of Pentoxifylline on Liver Function Tests in Non-alcoholic Fatty Liver Disease Patients Refereed to Sina Hospital Gastroenterology Clinic||Tehran University of Medical Sciences|No|Completed|May 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|November 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02283710||33520|
NCT02291731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRP37103N|Autologous Serum Eye Drops With Contact Lenses for Corneal Epithelial Defects|Topical Autologous Serum Eye Drops Combined With Silicone Hydrogen Lenses for theTreatment of Corneal Epithelial Defects||E-DA Hospital|Yes|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||September 2015|September 16, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291731||32904|
NCT02284334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011156|Glycemic Index in Mitochondrial Disease|Acute Effects of Dietary Glycemic Index on Lactate and Glucose Homeostasis in Individuals With Primary Mitochondrial Disease||University of Pennsylvania|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|12|Samples Without DNA|Blood samples obtained during MMTT.|Both|7 Years|65 Years|No|Non-Probability Sample|patients with mitochondrial diseases, from existing observational cohort study and/or CHOP        Genetics/Metabolism clinic|December 2015|December 1, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02284334||33472|
NCT02284347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-09330|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||December 10, 2015|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284347||33471|
NCT02288026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14110700020000|Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer|||Capital Medical University|Yes|Recruiting|September 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|630|||Both|60 Years|80 Years|No|Non-Probability Sample|Patients are stratified according to age and lesion type (GGO component ratio) two        matching factor of 1: 2 to the lobectomy and sub-lobectomy surgery groups.|November 2014|November 7, 2014|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02288026||33188|
NCT02281370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201583|Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects|A Phase I, Open-label, Randomized, Three-period Cross-over Study Evaluating the Effect of Cyclosporine on the Pharmacokinetics of Eltrombopag in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|39|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2015|March 19, 2015|October 30, 2014||Yes||No||https://clinicaltrials.gov/show/NCT02281370||33699|
NCT02281682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50621.068.14|IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis|Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study|Akti|Maastricht University Medical Center|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|624|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281682||33675|
NCT02270528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUKHS111213|Acute Effects of High Intensity Interval Exercise on Executive Function|Acute Effects of High Intensity Interval Exercise on Executive Function||Virginia Commonwealth University|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02270528||34533|
NCT02273856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-MA-1002|Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)|Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic Lymphocytic Leukaemia Or Indolent Non Hodgkin's Lymphoma|NADIR|Astellas Pharma Inc|No|Suspended|January 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are from the MENA region, and will be selected from sites that are considered        clinical centres of excellence in the region.|November 2015|November 23, 2015|September 2, 2014||No|Operational difficulty in recruiting the required number of patients in the approved sites|No||https://clinicaltrials.gov/show/NCT02273856||34277|
NCT02273869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-011413-CTIL|Assessment of Ovarian Reserve in Women With Rheumatologic Diseases|The Influence of Rheumatologic Diseases on Fertility and Ovarian Reserve||Meir Medical Center|Yes|Not yet recruiting|December 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|serum blood test|Female|12 Years|45 Years|No|Non-Probability Sample|Women in reproductive age with rheumatoligic disease|September 2014|October 22, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02273869||34276|
NCT02271542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/215|Identification of Polymorphisms Involved in the Metabolism of Propofol|Identification of Polymorphisms Involved in the Metabolism of Propofol||TC Erciyes University|No|Recruiting|November 2014|April 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|300|||Both|1 Year|85 Years|No|||November 2014|November 19, 2014|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02271542||34455|
NCT02280226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBonn-MRI-heart-14|Evaluating the Influence of Apnea on Cardiac Function Using Cardiac Magnetic Resonance Imaging.|Evaluating the Influence of Apnea on Heart Function With Strain Analysis and Measurement of Fibrosis Derived From T1-mapping Using Cardiac Magnetic Resonance Imaging (MRI).||University Hospital, Bonn||Active, not recruiting|April 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|16 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280226||33787|
NCT02284542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-81|NAPS: Non-awake Versus Awake Placement of Spinal Cord Stimulators|NAPS (Non-awake Versus Awake Placement of Spinal Cord Stimulators) Study for the Evaluation of Awake and Non-awake Methods of SCS Paddle Lead Placement|NAPS|St. Luke's Hospital, Pennsylvania|Yes|Recruiting|November 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients who have had a successful SCS trial and are indicated for permanent implantation        will be approached to participate in this study prior to permanent implantation. Patients        will be recruited and enrolled by physicians at any one of the involved sites. Each        Investigator will only use one method (awake or non-awake) according to his/her typical        practice. Patients will receive treatment from their enrolling physician.|November 2015|November 19, 2015|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284542||33456|
NCT02277808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nebulizers for pentamidine|Which Apparatus for Inhaled Pentamidine?|Which Apparatus for Inhaled Pentamidine? A Comparison of Drug Delivery to the Lung Between Two Nebulizers: The Respirgard II and the Isoneb.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|December 2013|||October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277808||33973|
NCT02278042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131024|A Comparison of the Neurocognitive and Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Ages 20-60 Years Old|||Rippe Lifestyle Institute|No|Completed|June 2013|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|225|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278042||33955|
NCT02278328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010857|MEG Study of STX209|Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder||Children's Hospital of Philadelphia|Yes|Recruiting|February 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Male|14 Years|17 Years|No|||March 2016|March 3, 2016|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278328||33933|
NCT02283450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013|Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy Patients|Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy patients--a Randomized Double Blind Clinical Trial||Harbin Medical University||Completed|May 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|70 Years|No|Probability Sample|congestive heart failure.|November 2014|November 4, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02283450||33540|
NCT02283463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB001|Novel Cervical Retraction Device|Patient Discomfort With a Novel Suction Based Cervical Retractor Compared to the Traditional Cervical Tenaculum||Bioceptive||Recruiting|September 2014|||February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283463||33539|
NCT02287220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17492|Non Contact Measurement of Vital Signs|Non Contact Measurement of Vital Signs||University of Virginia|No|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|12 Months|No|Non-Probability Sample|Newborn infants that are prone to desaturation events|November 2014|November 7, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02287220||33250|
NCT02279693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00122-45|Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer||PROSTRACK|Centre Georges Francois Leclerc|No|Recruiting|December 2014|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Male|18 Years|N/A|No|||June 2015|June 23, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279693||33828|
NCT02287714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0043|Instep Plantar Fasciotomy With and Without Gastrocnemius Recession|Surgical Treatment of Plantar Fasciitis: Instep Plantar Fasciotomy With and Without Gastrocnemius Recession||OhioHealth|No|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||June 2015|October 6, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02287714||33212|
NCT02276183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.25 NRC|Move Study in Healthy Aging People|Effects of a Test Formula Milk Powder Combined With a Physical Activity Program on Mobility in Healthy Aging Subjects With Joint Discomfort||Nestlé|No|Recruiting|April 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|55|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|January 11, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276183||34098|
NCT02285335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0708|Effects of GINST on Human Semen|||Yonsei University|No|Not yet recruiting|November 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Male|19 Years|N/A|No|||November 2014|November 6, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02285335||33395|
NCT02285582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045224|International Rare Histiocytic Disorders Registry (IRHDR)|International Rare Histiocytic Disorders Registry (IRHDR)|IRHDR|The Hospital for Sick Children|No|Recruiting|October 2014|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Patient with rare histiocytic disorder.        Rare histiocytic disorders include:          1. Cutaneous non-LCH: such as the Juvenile Xanthogranuloma (JXG) family and             reticulohistiocytoma (epithelioid histiocytoma).          2. Cutaneous with a major systemic component               -  Xanthoma disseminatum (XD)               -  Multicentric reticulohistiocytosis (MRH)          3. Systemic non-LCH               -  Systemic juvenile xanthogranuloma               -  Erdheim-Chester disease (ECD)               -  Multi-system Rosai-Dorfman disease (RDD).          4. Malignant Histiocytoses               -  Histiocytic sarcoma               -  Langerhans cell sarcoma               -  Interdigitating dendritic cell sarcoma               -  Follicular dendritic cell sarcoma               -  Indeterminate dendritic cell tumour               -  Fibroblastic reticular cell tumour|May 2015|May 26, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02285582|10 Years|33376|
NCT02273778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO10/9645|MRI and PET-CT for Radiotherapy Planning for Head and Neck Cancer|A Pilot Study Investigating the Use of Co-registered 18FDG-PET-CT and MRI for Radiotherapy Planning in Locally Advanced Head and Neck Squamous Cell Carcinoma||The Leeds Teaching Hospitals NHS Trust||Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||October 2014|October 21, 2014|October 14, 2014||||No||https://clinicaltrials.gov/show/NCT02273778||34283|
NCT02262234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-815-14|Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study|Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study||Kessler Foundation|No|Recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02262234||35170|
NCT02273921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-CT-002|EEG Classification System for Dementia|EEG Classification System for Dementia||Mentis Cura|No|Enrolling by invitation|March 2005|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02273921||34272|
NCT02273934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EL-123-REHAB|The Effectiveness of Reablement in Home Dwelling Adults|The Effectiveness of Reablement in Home Dwelling Adults. A Quasi Experimental Trial||Bergen University College|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|November 17, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02273934||34271|
NCT02284555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XF-MupC01|Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)|A Single Centre, Open, Non-controlled Study in Healthy Subjects to Assess the Eradication of Nasal Carriage of Staphylococcus Aureus (SA) Following a Five Day Course of Mupirocin (Bactroban 2% Nasal Ointment) Using a Broth Enriched Culture Microbiological Assessment.||Destiny Pharma Ltd|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 21, 2014||No||No|February 2, 2016|https://clinicaltrials.gov/show/NCT02284555||33455|
NCT02288013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS 13-207|Uterine Closure at C-section by Stratafix Tissue Control Device: Randomized Case-Control Study|||Cairo University|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|N/A|N/A|No|||January 2016|January 26, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288013||33189|
NCT02286024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01733-42|Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder|Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder.|LONGIDEP|Rennes University Hospital|No|Recruiting|November 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with a diagnosis (according to DSM IV criteria measured at MINI) for Major        Depressive Episode, and / or recurrent depressive disorder unipolar or bipolar , or        chronic and resistant depression (according to the criteria of Thase and Rush)|December 2015|December 17, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286024||33342|
NCT02286115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC.2014-151|Life-Stress Interview for Women With Chronic Urogenital Pain Conditions|||William Beaumont Hospitals|No|Recruiting|September 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|80 Years|No|||September 2014|November 5, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286115||33335|
NCT02277223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCC 1|Curcumin in Pediatric Ulcerative Colitis|Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis||Schneider Children's Medical Center, Israel|Yes|Not yet recruiting|July 2015|April 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|18 Years|No|||May 2015|May 18, 2015|October 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02277223||34018|
NCT02277522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04414|CD19 Redirected Autologous T Cells for Hodgkin Lymphoma|Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2014|||October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|N/A|No|||December 2015|February 5, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277522||33995|
NCT02291458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2014-001733-86|L-arginine and Brown Adipose Tissue|The Effect of L-arginine on Brown Adipose Tissue Metabolism in South Asian and White Caucasian Subjects|ArgMB|Maastricht University Medical Center|Yes|Recruiting|November 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Male|35 Months|50 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291458||32925|
NCT02291471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T0001-P1.0|Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers|An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291471||32924|
NCT02291510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCRM103|Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects|A Randomized, Crossover Study Assessing the Pharmacokinetics of EFB0027 Versus ETB0015 and ETB0014 in Healthy Subjects||Elcelyx Therapeutics, Inc.|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|20|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|November 11, 2014|No|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT02291510||32921|
NCT02282956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 13/126|Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery|Monocentric, Non-blinded, Prospective Randomized Parallel Group Phase IV Clinical Study to Evaluate the Efficacy of Ultrasound Guided Single Shot Block of Nervus Tibialis Posterior for Postoperative Pain Relief After Hallux Valgus Surgery.|Hallux|Spitalregion Rheintal, Werdenberg, Sarganserland|No|Recruiting|October 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 6, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02282956||33578|
NCT02283216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409M53708|Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus|Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|June 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|October 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283216||33558|
NCT02291627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/15|Pediatric Intubation With Difficult Airway|Comparison of the Macintosh, Coopdech and AirTraq Laryngoscopes Using a Rigid Neck Collar in Pediatric Patients With Simulated Difficult Laryngoscopy.||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291627||32912|
NCT02291640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/16|Pediatric Intubation Among Nursing|Coparison of Miller and CoPilot Laryngoscopes for Intubation by Nurses During Child Chest Compression. A Manikin Study||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291640||32911|
NCT02287233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-387|A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)|A Phase 1/2 Study of ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy||AbbVie|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|65 Years|99 Years|No|||February 2016|February 4, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287233||33249|
NCT02291679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-309|Trial of Linaclotide in Patients With Chronic Idiopathic Constipation|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation||Ironwood Pharmaceuticals, Inc.|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1223|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291679||32908|
NCT02291445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50941|Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study|A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Healthy Volunteers||Maastricht University Medical Center|No|Completed|March 2015|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|September 21, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291445||32926|
NCT02281994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1402ODFX|Odontoid Fracture Study Treated With Pulsed Electromagnetic Fields|Safety and Efficacy of Pulsed Electromagnetic Fields (Cervical-Stim®) as an Adjunct to Enhance Union in Conservatively Treated Type II Fractures of the Odontoid Process||Orthofix Inc.|No|Enrolling by invitation|September 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|50 Years|N/A|No|||November 2014|November 10, 2014|October 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281994||33652|
NCT02282241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02843|Melatonin for Delirium Prophylaxis|A Randomized Double-Blind Placebo-Controlled Study on the Use of Melatonin for the Prevention of Delirium||University of British Columbia|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|65 Years|N/A|No|||July 2015|July 30, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282241||33633|
NCT02291159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USJ_DNHS_UL_01|Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke|Effectiveness of Dry Needling (DNHS Technique) in the Treatment of Upper Limb Spasticity and Function in Stroke Patients: a Randomized Clinical Trial||Universidad San Jorge|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|40 Years|85 Years|No|||December 2014|December 30, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02291159||32948|
NCT02291172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141453|Comprehensive Communication Intervention for Minimally Verbal Children With Autism|Comprehensive Communication Intervention for Minimally Verbal Children With Autism||Vanderbilt University|No|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|97|||Both|36 Months|54 Months|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02291172||32947|
NCT02340728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-260|Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies|A Randomized Trial of Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340728||29144|
NCT02340780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I216|Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia|A Phase II Study of Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia||Canadian Cancer Trials Group|Yes|Recruiting|January 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02340780||29140|
NCT02339610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13005|Evaluation of Post-Operative Recovery in ATTUNE® Total Knee Arthroplasty|Multi-Center Evaluation of Post-Operative Recovery in ATTUNE Primary, Cemented Total Knee Arthroplasty||DePuy Orthopaedics|No|Recruiting|January 2015|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|22 Years|80 Years|No|||August 2015|August 3, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02339610||29230|
NCT02339662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbvsam001-HMO-CTIL|Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain|Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain||Hadassah Medical Organization|No|Recruiting|February 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 18, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02339662||29226|
NCT02327364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMDC7408|Natural History of Pearson Syndrome|Rare Disease Clinical Research Network Natural History of Pearson Syndrome North American Mitochondrial Disease Consortium (NAMDC)||The Cleveland Clinic|No|Enrolling by invitation|March 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Blood samples will be obtained for analyses of mtDNA deletions and hematologic parameters|Both|N/A|N/A|No|Non-Probability Sample|Patients with confirmed Pearson Syndrome|January 2016|January 26, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02327364|3 Years|30169|
NCT02279745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD811-007|Long Term Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension|An Open-Label Extension Study of APD811-003 in Patients With Pulmonary Arterial Hypertension||Arena Pharmaceuticals|Yes|Recruiting|July 2015|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||July 2015|July 9, 2015|October 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279745||33824|
NCT02283840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-122|Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation|Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate 400mg, 600mg and 800mg Tablets Clinical Trial Formulation (CTF) Versus the To-be-marketed Formulation (TBM) in Healthy Male and Female||Bial - Portela C S.A.|No|Completed|May 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 3, 2014||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT02283840||33510|
NCT02290717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45970.018.13|Fractional Laser in Combination With UVB Therapy in Vitiligo Patients|Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study.||Netherlands Institute for Pigment Disorders||Recruiting|May 2015|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290717||32982|
NCT02290574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-019|Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial|Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial|NEO TREAT|Samsung Medical Center|Yes|Recruiting|November 2014|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|20 Years|N/A|No|||November 2014|November 10, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02290574||32993|
NCT02290587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/01|Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients|Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients|SOCOG-MS|University Hospital, Bordeaux|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|35|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02290587||32992|
NCT02284659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUHSPortoAlegre|Effect of Functional Electrical Stimulation on Erectile Dysfunction|Effect of Functional Electrical Stimulation on Erectile Dysfunction||Federal University of Health Science of Porto Alegre|Yes|Completed|November 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Male|40 Years|70 Years|No|||March 2015|March 5, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02284659||33447|
NCT02276261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111401|The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy|||Bridgeport Hospital|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02276261||34092|
NCT02276534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110082|SENSE Theatre Intervention for Children With Autism Spectrum Disorder (ASD)|SENSE Theatre Research Program||Vanderbilt University|No|Active, not recruiting|August 2014|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|8 Years|16 Years|No|||May 2015|May 18, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02276534||34071|
NCT02291406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-431061|Importance of Surgical Approach for Gynecological Surgery on Metabolic Effects and Subsequent Recovery|Importance of Surgical Approach for Hysterectomies on Metabolic Effects Regarding Development of Insulin Resistance and Subsequent Recovery. A Randomized Controlled Study.||University Hospital Orebro|Yes|Recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|N/A|No|||October 2014|November 13, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291406||32929|
NCT02276781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL089619|BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients|BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients|BRAVO|Northwestern University|No|Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|595|Samples With DNA|Blood: EDTA plasma, Citrate plasma, serum, whole blood (DNA)* and RNA*. Lower extremity      muscle biopsies*      *genetic factors and muscle biopsies are optional study elements|Both|N/A|N/A|No|Non-Probability Sample|PAD participants from among consecutive patients with PAD identified from Chicago area        non-invasive vascular laboratories and vascular surgery, cardiology, general internal        medicine, geriatric, and endocrinology clinics.|May 2015|May 4, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02276781||34052|
NCT02277041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 8|Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.|Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Cases With Placenta Previa After C.S.|PPH|Beni-Suef University|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|25 Years|40 Years|No|||December 2015|December 26, 2015|October 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277041||34032|
NCT02286557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP2280|Testing the Effects of Methylphenidate on Multiple Sclerosis|Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial||Kessler Foundation|Yes|Not yet recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|October 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286557||33301|
NCT02286739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102|Prospective Clinical Study Evaluating Tibiofemoral Rotational Alignment Using Intraoperative Sensing During TKA|Prospective Clinical Study Evaluating Tibiofemoral Rotational Alignment Using Intraoperative Sensing During Total Knee Arthroplasty||Orthosensor, Inc.|No|Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02286739||33287|
NCT02276495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES06|Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?|Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?||University of California, Irvine|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02276495||34074|
NCT02330081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-0081|Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood|Mirasol System for Whole Blood: Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood in Healthy Volunteers|Medic|Terumo BCTbio|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330081||29960|
NCT02330094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005288|Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage|Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage||Mayo Clinic|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|December 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330094||29959|
NCT02340845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116911|Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans|The Methods and Compositions for Treating / Preventing Various Types of Cancer Which Comprise Administered an Effective Amount of Glyco-Polypeptides, Such as Comosain, Bromelainases, Ananase, and a Mixture Thereof. By Way of (a) MMAPKinase (Major Mitogen Activiting Protein Kinase), (b) TPKinase (Tryosine Phosphorylation Kinase) Inhibitors Which Induce Cascade Production of Interleukin II B, 6, 8 & TNFs Through TCRs/ CD-2, TCRs/ CD-3 of WBC||Oeyama-Moto Cancer Research Foundation|Yes|Recruiting|May 2014|February 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||January 2015|January 13, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340845||29135|
NCT02340858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF-20150112(3)|Percutaneous Irreversible Electroportion for Unresectable Breast Cancer|Safety and Efficacy of Irreversible Electroporation (IRE) for Breast Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||January 2015|January 16, 2015|January 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340858||29134|
NCT02340871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0643-13|Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases|Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases|NGS|Rabin Medical Center|Yes|Not yet recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Samples with DNA|Both|N/A|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a constellation of neurological findings that seem to be a new syndrome or        disease are enrolled to the study to decipher the genetic basis of their disease with next        generation techniques.|December 2014|January 13, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02340871||29133|
NCT02330575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA-CC-14-0153|Alberta Cancer Exercise Pilot Randomized Trial|Alberta Cancer Exercise Community-based Program: A Pilot Randomized Controlled Trial|ACE|University of Alberta|No|Recruiting|April 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330575||29923|
NCT02330588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPPLE-0613|The Resource Information Program for Parents on Lifestyle and Education|Working With Parents to Prevent Childhood Obesity: A Primary Care-based Study|RIPPLE|University of Alberta|No|Completed|October 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|225|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 19, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02330588||29922|
NCT02330861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFujii-000000|Relationship Between Pressure and Flow Velocity on Coronary Physiology|Relationship Between Pressure and Flow Velocity on Coronary Physiology||Hyogo College of Medicine||Recruiting|December 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330861||29901|
NCT02331121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR82RR-II|Multimedia First Aid Program for Families|Multimedia First Aid Program for Families|FirstAid_2|Oregon Center for Applied Science, Inc.|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|182|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|January 5, 2015|June 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02331121||29881|
NCT02283853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS306|Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis|CONNECT|Biogen|Yes|Recruiting|August 2014|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|10 Years|17 Years|No|||July 2015|July 10, 2015|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283853||33509|
NCT02284087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-38|Paired Associative Stimulation in Post-stroke Hand Motor Deficits|Assessment of Paired Associative Stimulation Protocols Using Cerebellar or Visual Afferences in Post-stroke Hand Motor Deficits|PAS-stroke|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|November 2014|January 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Stroke patients|September 2015|September 7, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02284087||33491|
NCT02280044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR296|Efficacy of Rifaximin in Preventing Campylobacteriosis|Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni||Johns Hopkins Bloomberg School of Public Health|Yes|Active, not recruiting|October 2014|October 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|January 7, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280044||33801|
NCT02280057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2166-00|Trial With Metformin in Women With Polycystic Ovary Syndrome|Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome||Herning Hospital|Yes|Completed|September 2001|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|45 Years|No|||June 2015|June 30, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02280057||33800|
NCT02291887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCMichigan|Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept|Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept||Associated Retinal Consultants, Michigan|No|Not yet recruiting|November 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|17|Samples With DNA|Blood from each patient will be drawn for genetic analysis.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|17 subjects from approximately 1 site in the United States will be enrolled. Eligible        subjects will be administered and provided with a copy of informed consent.|November 2014|November 12, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02291887||32892|
NCT02290652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0296|Sexual Function Questionnaire Total Hip Replacement|Development and Validation of a Sexual Function Questionnaire for Female Patients Undergoing Total Hip Replacement||University Hospital Southampton NHS Foundation Trust.|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02290652||32987|
NCT02280889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0242|Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision|Quality of Life and Experience of Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision: a Prospective Study||University Children's Hospital, Zurich|No|Recruiting|October 2013|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|9 Months|16 Years|No|Non-Probability Sample|All patients with CMN of at least 2 square centimeter (projected adult size) that are        scheduled for surgical removal of the CMN at our tertiary center for pediatric surgery.|February 2016|February 4, 2016|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02280889||33736|
NCT02285179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14POS|Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen|Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.|Poseidon|The Netherlands Cancer Institute|Yes|Recruiting|November 2014|July 2019|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285179||33407|
NCT02281747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915010|Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries|Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries||National Institutes of Health Clinical Center (CC)||Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|500050|||Both|20 Years|100 Years|No|||September 2015|October 1, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02281747||33671|
NCT02291003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00096215|Identification of Novel Circadian Biomarkers|Identification of Novel Circadian Biomarkers||Northwestern University|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|30|Samples With DNA|Blood, saliva and skin samples|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls, age 18-60 with habitual sleep|October 2015|October 5, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02291003||32960|
NCT02291094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lido01|Effect of Intravenous Infusion of Lidocaine and Remifentanil Perioperatively in Patients Undergoing Mastectomy|Effect of Intravenous Infusion of Lidocaine and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized, Double-blind Study||Hospital de Base|No|Completed|August 2013|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|75 Years|No|||November 2014|November 23, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291094||32953|
NCT02276196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2014ELIX001|Effect of LIXIsenatide on the Renal System|A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus|ELIXIRS|VU University Medical Center|No|Recruiting|September 2014|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|75 Years|No|||February 2016|February 8, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02276196||34097|
NCT02334189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014055|Targeted Letters to Reduce Avoidable Emergency Department Attendances|Targeted Letters to Reduce Avoidable Emergency Department Attendances||The Behavioural Insights Team|No|Not yet recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|25000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334189||29645|
NCT02334202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F172NC-S2|Preventing Obesity in Military Communities, Adolescents|Preventing Obesity in Military Communities, Adolescents (POMC-Adolescents)|POMC-A|Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Active, not recruiting|November 2011|September 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Female|12 Years|17 Years|No|||August 2015|August 17, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02334202||29644|
NCT02335216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-SMI-2013|A Post Market Study on Dorsal Root Ganglion (DRG) Stimulation in Failed Back Surgery Syndrome (FBSS)|A Post Market ObServational StudY on the Effect of DRG StiMulation in PATients witH Chronic Pain Following Surgical Lumbar DiscectomY (Failed Back Surgery Syndrome): SYMPATHY|SYMPATHY|St. Jude Medical|No|Recruiting|January 2014|November 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from chronic pain post discectomy surgery|December 2015|December 15, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335216||29566|
NCT02335229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-SMI-2013|A Post Market Study to Assess the Spinal Modulation Dorsal Root Ganglion Stimulator System in Chronic Post Surgical Pain|A Post Market Observational Cohort Study to Assess the Performance of the Spinal Modulation Dorsal Root Ganglion Stimulator System for the Management of Chronic Post Surgical Pain||St. Jude Medical|No|Active, not recruiting|June 2013|June 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patient suffering from chronic post surgical pain|December 2015|December 15, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335229||29565|
NCT02335489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-SMI-2013|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg||St. Jude Medical|No|Suspended|March 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Neuropathic Pain of the Foot and/or Lower Leg|February 2016|February 25, 2016|January 7, 2015||No|A significant local issue has to led to the suspension of recruitment, this study will be    terminated in the coming months|No||https://clinicaltrials.gov/show/NCT02335489||29545|
NCT02335502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-SMI-2012|A Post Market Study to Assess the Spinal Modulation Neurostimulator System for Chronic Intractable Pain|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Intractable Pain||St. Jude Medical|No|Active, not recruiting|April 2012|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Pain Patients|December 2015|December 15, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335502||29544|
NCT02335762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24475/14|Dietary Conjugated Linoleic Acid (CLA) Intake Among Students in Italy|Dietary Intake of Conjugated Linoleic Acid in a Cohort of Healthy Students in Italy||Catholic University of the Sacred Heart||Completed|January 2012|October 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|19 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 healthy students|January 2015|January 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02335762||29525|
NCT02288975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CytoSorb-2014|Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study|The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock||Szeged University|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|ICU patients with septic shock of medical origin|November 2015|November 22, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288975||33115|
NCT02284100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130005132|Animal-assisted Therapy in Pediatric Surgery: Post-operative Benefits|Animal-assisted Therapy in Pediatric Surgery: Cardiovascular, Neurological and Endocrinological Responses to Stress and Pain in the Immediate Post-operative Period||IRCCS Policlinico S. Matteo|Yes|Completed|September 2013|September 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|3 Years|17 Years|No|||November 2014|November 5, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02284100||33490|
NCT02284113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-1070|A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty|A Post-Market, Multi-Center, Prospective, Double-Blind, Randomized, Controlled Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty||MyoScience, Inc|No|Recruiting|December 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|22 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284113||33489|
NCT02278640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG-14-002|Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy|Prospective, Multicenter, Study Evaluating Vessel Sealing Utilizing the Harmonic ACE®+7 Shears During Total Laparoscopic Hysterectomy||Ethicon Endo-Surgery|No|Completed|October 2014|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|40 Years|N/A|No|||August 2015|August 3, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02278640||33909|
NCT02291926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Articular Cartilage Defect|Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect|Phase I Study of Human Umbilical Cord Mesenchymal Stem Cell Implantation in the Treatment of Articular Cartilage Defect of Knee||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||July 2015|December 23, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291926||32889|
NCT02284932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-20739|Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease|Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease||Laval University|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|Samples With DNA|Blood sample and muscle biopsy of vastus lateralis (quadriceps)|Male|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with COPD|November 2014|November 5, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02284932|6 Weeks|33426|
NCT02290782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGIT C|TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer|TARGIT-C(Consolidation) Prospective Phase IV Study of Intraoperative Radiotherapy (IORT) in Patients With Small Breast Cancer|TARGIT-C|Universitätsmedizin Mannheim|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|387|||Female|50 Years|N/A|No|||January 2016|January 7, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02290782||32977|
NCT02281435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-05 (Phase I)|Follow Up Study to Evaluate a Non-Surgical Device for Adult Male Circumcision for Screen Failure Subjects|One-arm, Open Label, Phase I (Out of 3 Phases), Pilot Study to Verify the Safety of PrePex™ Device for Screen Failure Subjects (Men With Narrow Foreskin and Phimosis) for Adult Male Circumcision, Performed by Physicians, in a Male Population That is Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV.|RMC-05|Ministry of Health, Rwanda|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Male|21 Years|49 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02281435||33694|
NCT02281448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-114|Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.|Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Volunteers||Bial - Portela C S.A.|No|Completed|March 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|October 30, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02281448||33693|
NCT02285647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11-5016-C|An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant|An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant||Tesaro, Inc.|No|Completed|September 2014|May 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|138|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|September 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02285647||33371|
NCT02286414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM13472|Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over|Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study|PRESAGE-ACO|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2193|||Both|80 Years|N/A|No|Non-Probability Sample|Consecutive patients aged 80 years or more, newly treated with oral anticoagulants for nv        AF or for flutter, living in community or in nursing home|October 2014|February 15, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286414||33312|
NCT02292251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSMF220020220|Study to Enhance Motor Acute Recovery With Intensive Training After Stroke|Study to Enhance Motor Acute Recovery With Intensive Training After Stroke|SMARTS2|Johns Hopkins University|No|Recruiting|May 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|21 Years|N/A|No|||February 2016|February 23, 2016|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02292251||32864|
NCT02292264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS_01|Risk Factors and Complications of Ventral Hernia Repair|Risk Factors and Complications of Ventral Hernia Repair||University Hospital Koge|No|Recruiting|September 2014|||November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who underwent ventral hernia repair at the Surgical Department of Køge        University Hospital in the timeperiod from 2009 - 2014.|November 2014|November 12, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292264||32863|
NCT02276209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-301|Dasotraline Adult ADHD Study|A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Sunovion|Yes|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|55 Years|No|||January 2016|January 12, 2016|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276209||34096|
NCT02284594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK5058_3|Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts|Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts||Columbia University|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4026|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284594||33452|
NCT02284607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29609|A Study of High Dose MHAA4549A in Healthy Volunteers|A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HIGH DOSE MHAA4549A IN HEALTHY VOLUNTEERS||Genentech, Inc.||Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02284607||33451|
NCT02280252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S06-209|Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response|Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation||New York University School of Medicine|Yes|Active, not recruiting|March 2005|December 2020|Anticipated|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280252||33785|
NCT02333955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS-100-CS-4004|A Phase 2 Extension of Study GCS-100-CS-4003|A Phase 2 Extension of Study GCS-100-CS-4003||La Jolla Pharmaceutical Company|No|Withdrawn|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||January 2015|January 13, 2015|December 15, 2014|Yes|Yes|Corporate decision|No||https://clinicaltrials.gov/show/NCT02333955||29663|
NCT02342899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139750|Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure|Medium Cost Effectiveness of Automated Non-Invasive Ventilation Outpatient Set Up vs Standard Fixed Level Non-Invasive Ventilation Inpatient Set Up In Obese Patients With Chronic Respiratory Failure|OPIP|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||January 2015|October 22, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02342899||28977|
NCT02339506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002423|Stress and the Nervous System|Stress and the Nervous System||Brigham and Women's Hospital|No|Recruiting|January 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 10, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339506||29238|
NCT02339558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02673|Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer|Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)|No|Recruiting|July 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|March 21, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339558||29234|
NCT02339337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980019|A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection|A Randomized-Controlled, Comparative Study, To Evaluate the Efficacy of Tailored Regimen of Peginterferon Alfa Plus Ribavirin According to Rapid Virological Response and Baseline Viral Loads in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection: A Pilot Study (Pioneer)||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|June 2010|||June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339337||29251|
NCT02339428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHRijeka-diclo-colono|Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy|Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy: a Randomized Controlled Study||University Hospital Rijeka|No|Recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02339428||29244|
NCT02339480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141021|Research on Mechanism of Massage Therapy on Energy Metabolism Disorder of Simple Obesity|||Guiyang College of Traditional Chinese Medicine||Recruiting|July 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|August 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339480||29240|
NCT02291822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-150|Retrospective Study of MRI in Pediatric Patients|The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age||Bracco Diagnostics, Inc|No|Enrolling by invitation|November 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|82|||Both|N/A|2 Years|No|Non-Probability Sample|Pediatric patients less than 2 years of age who have previously undergone a MRI of the        brain or spine with MultiHance|May 2015|May 18, 2015|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02291822||32897|
NCT02290522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300530|Copenhagen Prospective Personalized Oncology (CoPPO)|A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment|CoPPO|Rigshospitalet, Denmark|No|Recruiting|May 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02290522||32997|
NCT02282982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-579|Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis|Prospective, Multi-Center, Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Prescribed for Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation|SUNRISE|AbbVie|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|359|||Both|N/A|2 Years|No|Probability Sample|Infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness (infants born ≤        35 weeks of gestation and infants ≤24 months with Bronchopulmonary Dysplasia (BPD) or        Congenital Heart Disease (CHD) who received immunoprophylaxis during the RSV season        defined as October 2014 through April 2015 in routine clinical settings in the Russian        Federation.|June 2015|June 4, 2015|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02282982||33576|
NCT02278887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14TIL|Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma|Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma|TIL|The Netherlands Cancer Institute|Yes|Recruiting|September 2014|September 2020|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02278887||33890|
NCT02279160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD811-003|Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension|A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension||Arena Pharmaceuticals|Yes|Recruiting|December 2014|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|October 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279160||33869|
NCT02290730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT-LT|Effect of Kinesio Taping on Muscle Strength in Lower Trapezius|The Effect of One Application of Kinesio Tape on Muscle Strength in Lower Trapezius on Patients With Shoulder Problems and Weak Lower Trapezius - a Randomized Controlled Trial||Norwegian School of Sport Sciences|Yes|Completed|November 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|67 Years|No|||January 2015|January 30, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02290730||32981|
NCT02292056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131088|Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions|Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions|MSRP|University of California, San Diego|No|Recruiting|September 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Female|18 Years|50 Years|No|||November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292056||32879|
NCT02292069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-VIN-107|Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fed Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2011|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|November 12, 2014|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292069||32878|
NCT02285400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY20140927|Effects of CPAP Level on Respiratory Mechanics and Central Drive in Patients With COPD|Effects of Continuous Positive Airway Pressure (CPAP) Level on Respiratory Mechanics and Central Drive in Patients With Chronic Obstructive Pulmonary Disease||Zhujiang Hospital|Yes|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|70 Years|No|||July 2015|December 29, 2015|October 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285400||33390|
NCT02290925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAJ-001|The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose Levels in Patients With Diabetes|The Effect of a Biscuit Containing the Extract of Salacia Reticulata on Glycaemia in Patients With Type II Diabetes Mellitus A Two Center Randomized Double Blind Placebo Controlled Two Period Two Sequence Crossover Clinical Trial||Rajarata University, Sri Lanka|Yes|Recruiting|May 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|30 Years|65 Years|No|||July 2015|July 7, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290925||32966|
NCT02288338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152DDI14016|CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers|CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration||Chong Kun Dang Pharmaceutical|Yes|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||November 2014|March 9, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02288338||33164|
NCT02342847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-CPM-2014-01|Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer|Observational Cohort Study of Health-related Quality of Life in Patients Initiating Treatment With Chemotherapy for Metastatic Pancreatic Cancer|aLIVE|Celgene|No|Recruiting|December 2014|November 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Patients who will be treated with any of the first line chemotherapy treatments at the        participating site approved for the treatment of Metastasic Pancreatic Cancer (MPC) will        be included consecutively according to the criteria set.        Therefore, the choice of therapeutic strategy will be made according to usual clinical        practice and independently by the doctor before assessing the possible involvement of the        patients in the study and their corresponding inclusion in it.        The patients selected for the study must meet all inclusion criteria and none of the        exclusion.|January 2016|January 25, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02342847||28981|
NCT02330315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002496|Effects of tDCS and tUS on Pain Perception in OA of the Knee|Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) on the Perception of Pain and Functional Limitations Due to Osteoarthritis of the Knee.||Spaulding Rehabilitation Hospital|No|Recruiting|March 2015|||March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|85 Years|No|||April 2015|April 10, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02330315||29942|
NCT02327611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURITIBA/9/OSR|CUstodiol Versus RInger: whaT Is the Best Agent?|CUstodiol Versus RInger: whaT Is the Best Agent? A Randomized Double Blind Trial.||Scientific Institute San Raffaele||Recruiting|February 2015|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2|||90|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02327611||30150|
NCT02327858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054068|Supportive Text Messages to Reduce Mood Symptoms and Problem Drinking- Randomised Controlled Pilot Trials|Supportive Text Messages to Reduce Mood Symptoms and Problem Drinking in Patients With Primary Depression or Alcohol Use Disorder - Randomised Controlled Pilot Trials||University of Alberta|Yes|Active, not recruiting|July 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|131|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327858||30131|
NCT02277834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1361|Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice|Characterizing the Pancreatic Adenocarcinoma Proteome From Pancreatic Juice||University of Alabama at Birmingham|No|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|samples will be in 3 differant cohorts;        1. Subject with biopsy-proven Pancreatic Adenocarcinoma of the pancreas        2. Subjects witha diagnosis of Pancreatitis        3. Subject with NO pancreatic abnormality|Both|19 Years|90 Years|No|Non-Probability Sample|Group A: Participants with a confirmed diagnosis of a pancreatic adenocarcinoma will be        enrolled in this study. Potential participants will be identified from the Surgical        Oncology and Gastroenterology outpatient settings.        Group B: Participants with a confirmed diagnosis of chronic pancreatitis will be enrolled        in this study. Participants will be derived from the Gastroenterology and Gastrointestinal        Surgery outpatient setting.        Group C: Participants undergoing endoscopy for non-pancreatic, non-neoplastic indications.        The typical patient population we anticipate recruiting to this group with be those with        non-malignant, non-pancreatitis biliary calculous disease. Participants will be derived        from the Gastroenterology outpatient setting.|February 2016|February 29, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02277834||33971|
NCT02278081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4225|The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate|The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial|Pale Turbinate|McGill University Health Center|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|7 Years|18 Years|No|||October 2014|October 27, 2014|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278081||33952|
NCT02291861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-23|Addressing Involuntary Movements in Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|AIM-TD|Teva Pharmaceutical Industries|Yes|Recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|288|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291861||32894|
NCT02286505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101353|Automated Brain Morphometry for Dementia Diagnosis|Automated Brain Morphometry for Dementia Diagnosis|BrainMeasure|King's College London|No|Not yet recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|51 Years|N/A|No|||November 2014|November 5, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286505||33305|
NCT02283242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:27386114.9.0000.0068|Galantamine Effects in Patients With Metabolic Syndrome|Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial|GALANTA-MS|University of Sao Paulo|Yes|Active, not recruiting|March 2014|February 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|59 Years|No|||January 2016|January 27, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283242||33556|
NCT02291952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL118601|Development of Countermeasures Against Adverse Metabolic Effects of Shift Work|Development of Countermeasures Against Adverse Metabolic Effects of Shift Work||Brigham and Women's Hospital|No|Recruiting|November 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02291952||32887|
NCT02291965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9117|Blood Samples to Identify Biomarkers of Busulfan|Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics||Fred Hutchinson Cancer Research Center|No|Recruiting|November 2014|||June 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Plasma samples from metabolomic and/or pharmacokinetic analysis.|Both|N/A|N/A|No|Non-Probability Sample|Patients receiving targeted IV busulfan as part of conditioning for a hematopoietic stem        cell transplant|November 2015|November 19, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02291965||32886|
NCT02279420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR 50402|ESSENTIAL Trial™ Sham Cross-over|A Supplemental Open Label Multicenter Sham Cross-over Clinical Trial Using an Endoscopic Suturing Device (g-Cath EZ™ Suture Anchor Delivery Catheter) For Primary Weight Loss Essential Study (IDE G130163) Crossover Study||USGI Medical|No|Active, not recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|111|||Both|23 Years|61 Years|No|||January 2015|January 19, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279420||33849|
NCT02283762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16277|Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)||Bayer|Yes|Recruiting|January 2015|June 2022|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283762||33516|
NCT02290860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-161|Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus|Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus - Stage 2, a Multicentre Trial.|SoL|Université de Sherbrooke|No|Recruiting|December 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|301|||Female|18 Years|45 Years|No|||January 2016|January 4, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290860||32971|
NCT02292173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17932|Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer|A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|December 2014|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292173||32870|
NCT02292186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTRSC-003|A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis|A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC||Alnylam Pharmaceuticals|No|Active, not recruiting|October 2014|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|90 Years|No|||June 2015|June 29, 2015|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292186||32869|
NCT02279992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC IIT: Levitra Carboplatin|Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases|CSMC IIT: Pilot Study of Phosphodiesterase-V Inhibition to Increase Intratumoral Concentration of Carboplatin in Patients With Recurrent High Grade Gliomas and Brain Metastases|LevitraCarbo|Cedars-Sinai Medical Center|No|Recruiting|May 2011|December 2018|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02279992||33805|
NCT02280005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAK Seattle|24 Hour Use of the Wearable Artificial Kidney|First 24 Hour Human Trial of the Wearable Artificial Kidney|WAK US 1|Blood Purification Technologies, Inc.|Yes|Active, not recruiting|September 2014|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||July 2015|July 13, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280005||33804|
NCT02276222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN101-303|A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD|A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|GOLDEN-5|Sunovion Respiratory Development Inc.|No|Completed|October 2014|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1087|||Both|40 Years|N/A|No|||March 2016|March 18, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276222||34095|
NCT02331407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3437|Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke|Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke||Columbia University|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|21 Years|N/A|No|||January 2015|January 2, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02331407||29859|
NCT02331706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09414|IFN-DLI for Relapsed Acute Leukemia After Allo-SCT|A Pilot Study to Determine the Feasibility of Conventional Induction Chemotherapy Followed by G-CSF Mobilized Donor Leukocyte Infusion (DLI) and IFN-α (IFN-DLI) for Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation.||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02331706||29836|
NCT02327130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canary01|Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients|Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients||Isomark, LLC|Yes|Recruiting|April 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327130||30187|
NCT02327143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15533|A Study of LY2835219 in Healthy Participants|An Absolute Bioavailability Study of LY2835219 in Healthy Subjects Using the Intravenous Tracer Method||Eli Lilly and Company|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02327143||30186|
NCT02334969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14401970300|Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM|A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM||ShuGuang Hospital|Yes|Not yet recruiting|January 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2015|January 11, 2015|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334969||29585|
NCT02332200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00848|Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis|Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis.||Nationwide Children's Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a confirmed diagnosis of spondylolysis and spondylolisthesis who have been        treated by Nationwide Children's Hospital Sports Medicine physicians and physical        therapists from 12/2009-12/2013.|November 2015|November 18, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332200||29798|
NCT02332486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLP-Metabonomics-2014|Based on Metabonomics Dryness Pathogen Type of OLP: a Dynamic Study|Based on Metabonomics Dryness Pathogen Type of Oral Lichen Planus of Dynamic|OLP|Heilongjiang University of Chinese Medicine||Not yet recruiting|January 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 3, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332486||29776|
NCT02281955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1413|De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study|De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|August 2014|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02281955||33655|
NCT02282202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0038|Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD|Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD||Western University, Canada|No|Completed|September 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|40 Years|85 Years|No|||October 2014|December 9, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02282202||33636|
NCT02278367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A14|Clinical Evaluation of 18F-AV-1451|Clinical Evaluation of 18F-AV-1451||Avid Radiopharmaceuticals|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278367||33930|
NCT02278900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1759(REK)|Supporting Doctor-patient Communication in Oncology|Supporting Doctor-patient Communication in Oncology. A Randomized Controlled Trial (RCT) of Question Prompt List and Audio Recording as Communication Aids in Oncology Consultation||University Hospital of North Norway|No|Active, not recruiting|April 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|180|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|March 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278900||33889|
NCT02286674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400076|Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety|Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety: A Randomized Control Trial.||McLaren Health Care|No|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|2 Years|12 Years|No|||September 2015|September 30, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02286674||33292|
NCT02286687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0961|Phase II Study of BMN 673|Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2014|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|270|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286687||33291|
NCT02279173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101221|Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.|A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)||Amgen|No|Recruiting|December 2014|March 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|1 Year|18 Years|No|||February 2016|February 17, 2016|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279173||33868|
NCT02284035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALAM|Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine|Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.|RALAM|Hospital Clinic of Barcelona|No|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02284035||33495|
NCT02292108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P131202|Hypnosis, Self-hypnosis and Weight Loss in Obese Patients|Study of the Influence of Erickson's Hypnosis and Self-hypnosis Practice on Food Impulsivity and Weight Loss in Obese Patients: a Pilot Project|HYPNODIET|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2014|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|69 Years|No|||June 2015|June 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292108||32875|
NCT02287740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG045094-01A1|Prevention of Falls Among Older Adults in Community Settings|Cost-Effectiveness of A Fall Prevention Program: Tai Ji Quan: Moving for Better Balance||Oregon Research Institute|No|Recruiting|November 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|700|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02287740||33210|
NCT02335515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY1049#10600-1-001|The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast|Gastric Retention Time of Floating Gastro-Retentive Capsules in Male Healthy Subjects After Breakfast as Measured by Magnetic Resonance Imaging (MRI)||SkyePharma AG|No|Active, not recruiting|September 2014|March 2015|Anticipated|October 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335515||29543|
NCT02331719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-39E|Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation|Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation|MiSPACE|Aurora Health Care|No|Recruiting|August 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients treated for subcortical intracerebral hemorrhage (ICH) using a systems approach        which integrates five separate core competencies for safe and consistent parafascicular        minimally invasive subcortical (MIS) access|December 2015|December 30, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02331719|90 Days|29835|
NCT02342938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.698|Simultaneous MEG or fMRI And INtracranial EEG||SEMAINE|Hospices Civils de Lyon|No|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02342938||28974|
NCT02339779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC142059|Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy|the Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy Trial|BREAST|Maastricht University Medical Center|No|Not yet recruiting|March 2015|March 2022|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Female|18 Years|N/A|No|||January 2015|January 12, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02339779||29217|
NCT02286141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI NA|Matching Appropriate Treatments to Consumers' Healthcare Needs, MATCH|Evaluation of a Patient-Centered Risk Stratification Method for Improving Primary Care for Back Pain|MATCH|Group Health Cooperative|No|Enrolling by invitation|March 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1760|||Both|18 Years|N/A|No|Non-Probability Sample|Group Health enrollees aged 18 and older who make a visit to one of the six primary care        clinics participating in this study that results in a diagnosis of non-specific back pain.|December 2014|December 22, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286141||33333|
NCT02286232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0610.01|Chronic Low Back Pain Randomized Controlled Trial|A Randomized Trial Comparing a Stretching/Exercise Program and Learning About Self-care Practices From a Self-care Book for Chronic Low Back Pain||Stamford Hospital|No|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286232||33326|
NCT02282449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-42|Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy|Assessment of a Power Injectable vs. a Non-Power Injectable, Upper Arm, Totally Implanted Venous Access Devices for Chemotherapy||University of Saskatchewan|No|Recruiting|September 2013|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||August 2015|August 11, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282449||33617|
NCT02286375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPP-01|Effects of Health-social Partnership Programme|Health-social Partnership Intervention Programme for Community-dwelling Older Adults: a Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Not yet recruiting|March 2016|January 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|480|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02286375||33315|
NCT02283489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChengduShiEn_RMZ_001|Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors|Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial||Chengdu Shi Endor Biological Engineering Technology Co., Ltd|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|70 Years|No|||November 2014|November 3, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02283489||33537|
NCT02283749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 301|BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases|BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases||Brown University|Yes|Recruiting|September 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283749||33517|
NCT02287077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.522|Umbilical Cord Milking for Neonates With Hypoxic Ischemic Encephalopathy|A Randomized Controlled Trial of Umbilical Cord Milking for Neonates With Hypoxic Ischemic Encephalopathy||Thomas Jefferson University|No|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|1 Minute|No|||July 2015|July 9, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02287077||33261|
NCT02287259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChibaU|Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)|A Randomized, Open Label Trial of Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified.||Chiba University||Not yet recruiting|November 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|65 Years|No|||November 2014|November 7, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02287259||33247|
NCT02279706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-OBS-14-158|Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test|Linguistic Adaptation of Rhinitis Control Assessment Test (RCAT) in Korean and Responsiveness to Disease Severity, Quality of Life, and Treatment in Adult Rhinitis Patients: A Multicenter Prospective Study|R-CAT|Ajou University School of Medicine|Yes|Recruiting|October 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|19 Years|N/A|No|Probability Sample|rhinitis within 12 months from the time of study enrollment.|June 2015|June 21, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02279706||33827|
NCT02284048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0217|Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina|Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina||Second Xiangya Hospital of Central South University|Yes|Not yet recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||November 2014|November 5, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02284048||33494|
NCT02292485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0824|PCORI-CER-1306-03385 Lung Cancer Screening Readiness Study|Promoting Informed Decisions About Lung Cancer Screening: Lung Cancer Screening Readiness Study||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and        in Dallas, Texas, November 7-9, 2014.|January 2016|January 25, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292485||32846|
NCT02292498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001327|Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections|Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections||Massachusetts General Hospital|No|Enrolling by invitation|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292498||32845|
NCT02284360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MarsyasI|A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds|A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds||Medical University of Vienna|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02284360||33470|
NCT02284373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01568|Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema|Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema||New York University School of Medicine|No|Completed|May 2011|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|N/A|N/A|No|||January 2016|January 21, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02284373||33469|
NCT02280538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA-FCM-Rheuma-2|Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of Hyaluronic Acid in Primary Knee OA|A Randomized Placebo Controlled Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Repeated Intra-articular Injections of Hyaluronic Acid in Primary Knee Osteoarthritis|ViscOA|Universidade Nova de Lisboa|No|Recruiting|April 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|50 Years|N/A|No|||October 2014|October 31, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280538||33763|
NCT02280551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP:1096668|The Australian Parental Supply of Alcohol Longitudinal Study (APSALS)|The Australian Parental Supply of Alcohol Longitudinal Study (APSALS)|APSALS|The University of New South Wales|No|Active, not recruiting|March 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1927|||Both|11 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cohort includes 1927 Australian adolescents born from 1996-1999 (mean age at baseline:        12.9 years), and a parent or guardian (typically the mother (in 86.3% of dyads; mean age        at baseline: 43.9 years)).|October 2014|October 30, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280551||33762|
NCT02280850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL-CTP-Z20020055|Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina|Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial||Shaanxi Buchang Pharmaceutical Co., Ltd|No|Not yet recruiting|October 2014|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||October 2014|October 29, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02280850||33739|
NCT02339584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-13-013|Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)|Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|376|||Both|18 Years|95 Years|No|||February 2016|February 23, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339584||29232|
NCT02339636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306PLA-002|A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis|A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis||The 306 Hospital of People's Liberation Army|Yes|Not yet recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Both patients with psoriasis and patients with other skin diseases|August 2013|January 14, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339636||29228|
NCT02335775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008993|Lymph Node Counts in Endometrial Cancer Staging|A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging||Duke University||Completed|July 2008|September 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Female|N/A|N/A|No|Non-Probability Sample|Woman over the age of 18 diagnosed with grade 3, clear cell, serous or sarcoma types of        endometrial cancer|January 2016|January 20, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02335775||29524|
NCT02327377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140559|Web-based Management of Pediatric Functional Abdominal Pain|Predicting Treatment Outcomes in Pediatric Functional Abdominal Pain||Vanderbilt University|Yes|Recruiting|April 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|11 Years|17 Years|No|||December 2015|December 9, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02327377||30168|
NCT02331979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000932|Improving Bladder Function in SCI by Neuromodulation|Improving Bladder Function in SCI by Neuromodulation||University of California, Los Angeles|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Male|18 Years|45 Years|No|||January 2016|January 26, 2016|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331979||29815|
NCT02337231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils|Role of Fatty Acid Desaturase(s) (FADS) Polymorphisms in Determining the In Vivo Metabolism of Polyunsaturated Fatty Acids (PUFAs) in Botanical Oils in Humans.||Wake Forest Baptist Health|Yes|Active, not recruiting|June 2014|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|66|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02337231||29412|
NCT02337244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSE2013-07K|Zimmer POLAR Persona - TKA (EMEA Study)|Persona Outcomes Led Assessment Research in Total Knee Arthroplasty (POLAR - TKA)||Zimmer, Inc.|No|Recruiting|November 2013|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee        System.|February 2016|March 11, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02337244||29411|
NCT02337257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001693|Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease|Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans|GumD|Georgia Regents University|No|Recruiting|April 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337257||29410|
NCT02293083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003046001|Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome|Effect of Hyaluronidase Addition to Lidocaine for Trigger Point Injection in Myofascial Pain Syndrome||Samsung Medical Center|No|Completed|April 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|25 Years|75 Years|No|||November 2014|November 13, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02293083||32800|
NCT02292290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOLDR0001N|Trial for People With Established Type 2 Diabetes During Ramadan|A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea|T4R|University of Leicester|Yes|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|75 Years|No|||August 2012|November 14, 2014|January 16, 2011||No||No||https://clinicaltrials.gov/show/NCT02292290||32861|
NCT02292342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpicatechinStudy|An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men|An Acute, Double-blind, Randomised, Placebo-controlled, Crossover Intervention Trial Investigating the Dose-dependent Vascular Effects of Pure (-)-Epicatechin (≤1 mg/kg BW) in Healthy Men.||University of Reading|No|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|21|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02292342||32857|
NCT02282709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foundation_LiverR|Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients|Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients|ImmunoDual|Foundation for Liver Research|Yes|Completed|February 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|70 Years|No|||October 2015|October 16, 2015|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282709||33597|
NCT02282722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-143|Improving Informed Consent for Palliative Chemotherapy|Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers||Dana-Farber Cancer Institute|No|Recruiting|December 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|21 Years|N/A|No|||December 2015|December 2, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02282722||33596|
NCT02292355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URioGrande|Effect of the Method Pilates in Women With Temporomandibular Disorders|Effect of the Method Pilates in Women With Temporomandibular Disorders - Clinical Trial||Federal University of Rio Grande do Sul|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|35 Years|No|||May 2015|May 29, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02292355||32856|
NCT02292368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0769|Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia|Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2014|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02292368||32855|
NCT02286882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7881001|A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects||Pfizer|No|Terminated|November 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|9||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|November 6, 2014||No|The trial was terminated prematurely on June 19, 2015 for business reasons. There were no    safety concerns in the study which led to the decision.|No||https://clinicaltrials.gov/show/NCT02286882||33276|
NCT02286895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH-RVI-PRV-01|Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali|An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali||PATH|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Both|9 Months|11 Months|Accepts Healthy Volunteers|||September 2014|August 18, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02286895||33275|
NCT02292407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12PRE|Prospective Pilot Study ANDPrecise|AND Precise! : Axillary Lymph Node Dissection and No Drain With the PRECISE Instrument|ANDPrecise|The Netherlands Cancer Institute|No|Recruiting|June 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2014|November 12, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02292407||32852|
NCT02287272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-12|Drug-drug Interaction Study of CHF5993 With Cimetidine|Open-label, Randomized, Single Dose, 2-sequence, 2-period Cross-over Study to Investigate the Effect of Inhibition of the Organic Cation Transport in the Kidneys by Cimetidine on the Pharmacokinetics of the CHF5993 in Healthy Volunteers||Chiesi Farmaceutici S.p.A.|No|Completed|May 2014|September 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02287272||33246|
NCT02287519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-368|Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention|Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention|START-OC|Dana-Farber Cancer Institute|Yes|Recruiting|November 2014|October 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|75|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02287519||33227|
NCT02280265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prophylaxis201407008-1|Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A|Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A.||Nanjing Medical University|Yes|Not yet recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|18 Years|No|||October 2014|October 29, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02280265||33784|
NCT02288234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120|Telavancin Observational Use Registry (TOUR)|Telavancin Observational Use Registry (TOUR)|TOUR|Theravance Biopharma Antibiotics, Inc.|No|Recruiting|November 2014|September 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|The study will aim to enroll approximately 1,000 patients from 50-60 hospital sites or        outpatient infusion centers.|January 2016|January 5, 2016|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02288234||33172|
NCT02285361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.235|GIOTRIF rPMS in Korean Patients With NSCLC|A Regulatory Requirement Post-marketing Surveillance Study to Monitor the Safety and Efficacy of GIOTRIF®(Afatinib Dimaleate, 20mg, 30mg, 40mg, q.d) in Korean Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutation(s)||Boehringer Ingelheim||Recruiting|October 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|110 Years|No|Probability Sample|NSCLC in Korea|January 2016|January 21, 2016|October 20, 2014||||No||https://clinicaltrials.gov/show/NCT02285361||33393|
NCT02285374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 056|Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity|A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir||St Stephens Aids Trust|No|Not yet recruiting|November 2014|December 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|November 6, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02285374||33392|
NCT02328313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1410|Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older|LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|65 Years|N/A|No|||October 2015|October 29, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02328313||30096|
NCT02328326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-074|Caring Others Increasing EngageMent in PACT|Engaging Veterans and Family Supporters in PACT to Improve Diabetes Management|CO-IMPACT|VA Office of Research and Development|No|Not yet recruiting|March 2016|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|30 Years|70 Years|No|||December 2015|December 24, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02328326||30095|
NCT02339688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML10457- S56574|Psychometric Properties Mobility Measures MS|Psychometric Properties of Mobility, Beyond Walking Speed, in Multiple Sclerosis: a Multi-center Study.|MCS-III-MOB|Hasselt University|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02339688||29224|
NCT02336035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014 3830 RCT radius 65|Distal Radius Fractures in Patients Over 65 Years, Operation or Cast?|Unstable Distal Radius Fractures in Patients Over 65 Years. Conservative Treatment With Cast Immobilization Versus Volar Locking Plate. A Prospective Randomized Controlled Trial.|DROC|Oslo University Hospital|No|Recruiting|January 2015|July 2023|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||October 2015|October 15, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02336035||29504|
NCT02328768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-2014-BJ|Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children|Compassionate Use of an Intravenous Fish Oil Lipid Emulsion (Omegaven®) for the Treatment of Intestinal Failure Associated Liver Disease in Children||University of Nebraska|Yes|Enrolling by invitation|April 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|18 Years|No|||April 2015|April 28, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328768||30061|
NCT02328781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTH-PESS|Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System|Prospective Multi-center Single-arm Target Value Clinical Trial for Evaluating Clinical Use Safety and Efficacy of the Firehorus Vertebral Artery Rapamycin-target-eluting Stent System|PESS|Beijing Tiantan Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|December 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328781||30060|
NCT02329041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK201412002|Comparison of McGrath Series 5 and Airtraq Videolaryngoscope for Double-lumen Tube (DLT) Intubation|A Randomised Controlled Trial Comparing of McGrath Series 5 and Airtraq Videolaryngoscope for Double-lumen Tube Intubation in Patients With Low Airway Risk Index Score||Huazhong University of Science and Technology|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02329041||30040|
NCT02339831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFCAMCPM1|Active Versus Passive Motion Device Following Knee Replacement Surgery|A Prospective, Randomized, Controlled, Single Center Study Evaluating the Clinical Performance of CAMOPED Following Knee Replacement||Brigham and Women's Hospital|No|Completed|March 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02339831||29213|
NCT02278094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|--/A-ER-103-168|The Influences of Intervention With Home-based Recovery Activity in Obstructive Sleep Apnea Syndrome|A Randomized Controlled Study to Examine the Effect of Home-based Recovery Activity in Moderate to Severe Obstructive Sleep Apnea Syndrome Patients|OSAS|National Cheng-Kung University Hospital|No|Recruiting|September 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|N/A|No|||October 2014|October 27, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278094||33951|
NCT02278107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JM-001-2014|Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease|Evaluation of a Lightweight Nasal Interface and Ventilator for Use by Patients With Respiratory Disease||New Aera, Inc|No|Enrolling by invitation|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278107||33950|
NCT02278380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM.1.C/D|Different Glycemic Index (GI) Values in 7 Food Products|In-Vivo Glycemic Index (GI) and Insulinemic Index (II) Testing of 7 Test Foods in Total (5 Milk-based Beverage and 2 Standard Breakfast Items)||Danone Asia Pacific Holdings Pte, Ltd.|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02278380||33929|
NCT02278393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU360|A Clinical Study for Evaluating the Safety of a Plant Sterol-enriched Fermented Dairy Product in Japanese Healthy Adults|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY OF EXCESSIVE CONSUMPTION OF PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT OVER A 4-WEEK PERIOD IN JAPANESE HEALTHY ADULTS||Danone Research|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|84|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 29, 2014|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02278393||33928|
NCT02278653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49171.068.14|Functional Outcome of Organ Preservation After Neo-adjuvant Chemo Radiation for Rectal Cancer|Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer||Maastricht University Medical Center|No|Recruiting|September 2014|September 2022|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The population will consist of patients, aged 18 years or older, with locally advanced        rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very        good response (ycT1-2N0). Patients will be recruited from the outpatient clinic, by        researchers or research nurses at Maastricht University Medical Center.|March 2016|March 15, 2016|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02278653|5 Years|33908|
NCT02287532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCOMPL06211|Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen|Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen|TELESAGE|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|696|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287532||33226|
NCT02279186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|septemper 2014|Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section|Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section ,A Randomized Clinical Trial .||Ain Shams Maternity Hospital|Yes|Recruiting|September 2014|September 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 1, 2014|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279186||33867|
NCT02279199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Motor Proficiency & Hemophilia|Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)|Assessment of Motor Proficiency in People With Bleeding Disorders Using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2™)||Oregon Health and Science University|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Male|4 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and young adults with hemophilia A or hemophilia B, between the ages of 4 years,        0 months to 21 years, 11 months.|April 2015|April 20, 2015|February 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02279199|5 Years|33866|
NCT02292381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-250313|Blood Flow Regulation in Glaucoma|||Medical University of Vienna||Recruiting|April 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|60 open angle glaucoma patients 60 healthy age- and sex matched controls|September 2015|September 4, 2015|October 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02292381||32854|
NCT02279719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIHCC-103|A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma|A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma||Boston Biomedical, Inc|No|Recruiting|December 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279719||33826|
NCT02284061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-25|Physical Activity Program in Children and Adolescents With Cancer : Assessment of Benefits on Physical, Psychological and Social Health.|||Assistance Publique Hopitaux De Marseille||Recruiting|November 2014|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|5 Years|19 Years|No|||November 2015|November 16, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02284061||33493|
NCT02292446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424B2001X|Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.|An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.||Novartis|No|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02292446||32849|
NCT02292459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18128|Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)|A Multicenter, Open Label, Non-controlled Phase 3 Clinical Trial of the Efficacy and the Safety for the Relief of Constipation of Polyethylene Glycol 3350||Bayer|No|Withdrawn|December 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02292459||32848|
NCT02284906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-4833/TOMM40_303|AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease|A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease||Takeda|Yes|Recruiting|February 2015|April 2021|Anticipated|April 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|149|||Both|65 Years|N/A|No|||March 2016|March 22, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284906||33428|
NCT02292524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0137|Prostate Biomarkers in Men Consuming Tomato Products|Prostate Biomarkers in Men Consuming Tomato Products||Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2002|October 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|33|||Male|18 Years|N/A|No|||November 2014|November 12, 2014|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292524||32843|
NCT02292810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0194|Acute Effects of Inspiratory Muscle Exercise on Glucose Level and Glucose Variability in Patients With Type 2 Diabetes.|Acute Effects of Inspiratory Muscle Exercise on Glucose Level and Glucose Variability in Patients With Type 2 Diabetes.||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|November 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|14|||Both|30 Years|N/A|No|||November 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02292810||32821|
NCT02332499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-07-IIB|Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)|Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)|ALTER0703|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02332499||29775|
NCT02332512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-APTN-Ⅲ-NSCLC-02|Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)|A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)|ANSWER|Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|January 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|417|||Both|18 Years|70 Years|No|||January 2015|June 10, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332512||29774|
NCT02328547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-FMT-IBSD|Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome|Multicenter, Randomized, Double-blinded, Placebo-controlled Trial of Fecal Microbiota Transplantation (FMT) for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)||Montefiore Medical Center|Yes|Recruiting|May 2015|February 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|19 Years|65 Years|No|||November 2015|November 23, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328547||30078|
NCT02339740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML1331|Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia|A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid||Children's Oncology Group|Yes|Recruiting|June 2015|||April 2023|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|158|||Both|1 Year|21 Years|No|||December 2015|December 30, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339740||29220|
NCT02333266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57146|Bio-assay Development and Implementation for Fungal Infection Detection|Bio-assay Development and Implementation for Fungal Infection Detection||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|February 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|Whole blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients laying in the hospital that suffer from a candidemia.|December 2014|January 5, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02333266||29716|
NCT02329327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-505|A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants|Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding||Portola Pharmaceuticals|Yes|Recruiting|January 2015|||November 2022|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|270|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329327||30018|
NCT02329340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR76R-2|Safety Skills Training: Parents of School-Aged Children|Safety Skills Training: Parents of School-Aged Children|SAS_2|Oregon Center for Applied Science, Inc.|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|175|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329340||30017|
NCT02282215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLT008-03|Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia|An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia||Cellerant Therapeutics|Yes|Recruiting|December 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|146|||Both|55 Years|N/A|No|||February 2016|February 22, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282215||33635|
NCT02282462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study of Postoperative Chest Tube Management|A Randomized Comparison of Active Suction vs. Passive Chest Tube Drainage and Regulated and Unregulated Pleural Pressure After Anatomic Lung Resection||Yale University|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|600|||Both|18 Years|90 Years|No|||October 2014|November 6, 2014|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282462||33616|
NCT02287285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1360|Determinants of Diabetes Remission After Gastric Bypass Surgery|Long Term Change of GLP-1 Insulinotropic Effect After GBP Surgery||Columbia University|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287285||33245|
NCT02291354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGS-Pectin-STC-2015|Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation|A Randomized, Controlled Study of Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation||Jinling Hospital, China|Yes|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|February 3, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291354||32933|
NCT02291367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA085908801|Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition|Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2008|November 13, 2014|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291367||32932|
NCT02283502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-CTC-067|Clinical Test of the MRgHIFU System on Uterine Fibroids|For Research Purpose the Clinical Test of the Magnetic Resonance Imaging Guided Focused Ultrasound Ablation System on Uterine Fibroids|MRgHIFU|Chang Gung Memorial Hospital|Yes|Recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|35 Years|45 Years|No|||October 2014|November 2, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02283502||33536|
NCT02287753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1309-095-522|Relationship Between Parameters of VOT Using NIRS and Clinical Outcomes in Pediatric Cardiac Surgery|Relationship Between Parameters of Vascular Occlusion Test Using Near Infrared Spectroscopy and Clinical Parameters & Outcomes in Pediatric Cardiac Surgery||Seoul National University Hospital|Yes|Recruiting|November 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|N/A|8 Years|No|||February 2016|February 22, 2016|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02287753||33209|
NCT02279433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS6051-A-U101|A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b|A Phase 1, Two-Part, Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Recruiting|September 2014|December 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279433||33848|
NCT02284386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-405|Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty|Evaluation of the Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Subjects Undergoing for Unilateral Total Knee Arthroplasty||Pacira Pharmaceuticals, Inc|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284386||33468|
NCT02280018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105925|A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants|A Double Blind, Placebo-Controlled, Randomized Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Subjects||Janssen Research & Development, LLC||Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280018||33803|
NCT02288949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPVM-2014|Stratification of the Acute Respiratory Distress Syndrome|STratification AND Outcome of Patients With the Acute Respiratory Distress Syndrome|STANDARDS|Dr. Negrin University Hospital|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive ARDS patients|August 2015|August 10, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288949||33117|
NCT02285153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA-MORT|Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit|Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit||Medical University of Vienna|Yes|Recruiting|November 2012|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||October 2015|October 25, 2015|October 24, 2012||No||No||https://clinicaltrials.gov/show/NCT02285153||33409|
NCT02277275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRG041|Comparison of Different Weight Loss Diets With Different Protein Content|Effects of a BCAA-supplemented Hypocaloric Diet Versus a Standard Hypocaloric Diet on Weight Loss, Lean Mass Preservation and Improvement of Insulin Sensitivityand Its Benefits Over a High-protein Hypo-caloric Diet.||National University, Singapore|No|Recruiting|August 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|120|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02277275||34014|
NCT02277288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026292|Does Bladder Instillation Reduce Time to Discharge After Sling Surgery|Does Intraoperative Bladder Instillation Decrease Outpatient Recovery Time After Mid-Urethral Sling||Cedars-Sinai Medical Center|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|250|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02277288||34013|
NCT02332759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H- 31936|A Pilot Study To Evaluate The Preliminary Safety And Feasibility Of The Materna Medical Device|A PILOT STUDY TO EVALUATE THE PRELIMINARY SAFETY AND FEASIBILITY OF THE MATERNA MEDICAL DEVICE FOR THE PREVENTION OF PERINEAL LACERATIONS AND OCCULT DISRUPTION OF THE PELVIC FLOOR AND ASSOCIATED SEQUELA DURING VAGINAL DELIVERY.||Baylor College of Medicine|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02332759||29755|
NCT02332993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141371|Nutritional Regulation of Wound Inflammation: Part III|Nutritional Regulation of Wound Inflammation: Part III|FPP3|Ohio State University|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Blood|Both|30 Years|30 Years|No|Probability Sample|Type 2 Diabetic patients that are recieving negative pressure therapy for a wound.|September 2015|September 8, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02332993||29737|
NCT02339454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-RCT-UP|Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris|Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris - A Randomized, Double Blind, Placebo Controlled, Multicenter Study||Moscow State University of Medicine and Dentistry|No|Recruiting|May 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339454||29242|
NCT02333500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-06|Oxytocin and Incitement to Use Olfactory Stimuli in Restrictive Anorexia Nervosa|Pilot Study: a Comparative Study Between Serum Levels of Oxytocin and Incitement to Use Olfactory Stimuli in Restrictive Anorexia Nervosa in Adolescents||Fondation Lenval|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|60|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02333500||29698|
NCT02286908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/573/REK sør-øst|Global Strain and Mechanical Dispersion May Predict Death and Ventricular Arrhythmias Better Than Ejection Fraction|Improved Prediction of Clinical Outcome With the Use of Global Strain and Mechanical Dispersion in Patients With Myocardial Infarction and Heart Failure||Oslo University Hospital|No|Recruiting|June 2014|June 2017|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with myocardial infarction, heart failure and patients planned for primary        prophylactic ICD. Echocardiography is performed at inclusion. Comparism of the ability of        left ventricular ejection fraction, global strain and mechanical dispersion to predict        clinical outcome in patients with these conditions.|November 2014|November 5, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02286908||33274|
NCT02286921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14146|Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance|A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer|Transformer|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Male|18 Years|80 Years|No|||December 2015|December 21, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286921||33273|
NCT02287090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140857|Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears|Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears|ROW|Vanderbilt University|No|Enrolling by invitation|March 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|45 Years|N/A|No|Non-Probability Sample|Patients presenting to the clinic with rotator cuff tears.|November 2014|November 5, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02287090||33260|
NCT02291315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: MU 2007-145|Calcium Absorption in Postmenopausal Thai Women|Calcium Bioavailability of Cassia Leaves in Post-Menopausal Women||Cornell University|No|Completed|July 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|22|||Female|53 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Post-menopausal Thai women|November 2014|November 12, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02291315||32936|
NCT02279732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-153|Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin|A Randomized, Multicenter, Double-Blind, Multinational, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) With Squamous Histology||Bristol-Myers Squibb|Yes|Active, not recruiting|October 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|867|||Both|18 Years|N/A|No|||July 2015|March 11, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279732||33825|
NCT02287766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-009|Metabolic Syndrome Feasibility Study|Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView|EPIC-009|Epic Research & Diagnostics, Inc.|Yes|Completed|November 2014|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|193|||Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women ages 21-85 who present to the investigators clinical office and meet all of        the inclusion criteria while having none of the exclusion criteria will be approached for        consent to participate in the study.|August 2015|August 3, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02287766||33208|
NCT02283775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD14079|SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients|A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma|PomdeSAR|Sanofi|No|Recruiting|May 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283775||33515|
NCT02288520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATEGE|Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis|Therapeutic Strategy in Rheumatology When Faced With a Patient Treated With Methotrexate (MTX) for Rheumatoid Arthritis (RA).|STRATEGE|Nordic Pharma SAS|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid arthritis (RA) patients with clinical, functional, structural and/or        therapeutic disease progression, for whom the rheumatologist intends to change the        therapeutic treatment of the RA will be asked to participate from RA treatment change        (inclusion visit) up to 6 months after inclusion.|October 2015|October 22, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288520||33150|
NCT02284620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZ-001|Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Total Knee Arthroplasty --- A Randomized Controlled Trial|Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Unilateral Total Knee Arthroplasty --- A Randomized Controlled Trial||First Affiliated Hospital of Chongqing Medical University|No|Recruiting|January 2015|June 2017|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|75 Years|No|||July 2015|July 25, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284620||33450|
NCT02284633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-83-14|Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer|Use of a New Blood Test to Identify Response to Targeted Treatment in Patients With EGFR Mutated Lung Cancer. Evaluation in a Multicenter Study||Aarhus University Hospital|Yes|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Liquid biopsies: Bloodsamples investigating circulating tumor DNA|Both|18 Years|N/A|No|Probability Sample|Patients with metastatic EGFR mutated lung cancer|August 2015|August 13, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02284633||33449|
NCT02276768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIC1.14.1.02|Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method|A Phase 1b Clinical Study on the Analgesic Effect of GIC-1001 and GIC-1002 on Visceral Pain Under Rectal Distension and Rectal Sensory Threshold Using the Barostat Method in Male and Female Healthy Volunteers.||gicare Pharma Inc.|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276768||34053|
NCT02292771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200721|A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor||GlaxoSmithKline|Yes|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Female|12 Years|45 Years|No|||February 2016|March 17, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292771||32824|
NCT02281981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curcumin|The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery|The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery|Cur|University of Prince Edward Island|No|Active, not recruiting|November 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281981||33653|
NCT02342223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergan-97727|Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy|Voluma Treatment of HIV Facial Lipoatrophy||VA Northern California Health Care System|No|Active, not recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342223||29029|
NCT02342236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06101968-3|Cerebral Regional Oxygen Saturation and Markers of Brain Damage During Primary Hip Arthroplasty|The Regional Cerebral Oxygen Saturation and Both S100B and GFAP Proteins Serum Concentration in Patients Undergoing Primary Hip Arthroplasty.||Military Institute of Medicine, Poland|No|Recruiting|January 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02342236||29028|
NCT02342249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-787-103|Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects|A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|500|||Both|18 Years|64 Years|No|||June 2015|July 28, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342249||29027|
NCT02337647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|625-14|Evaluation of the Distortion Correction Data Collection (DCDC) App Software|Evaluation of the Distortion Correction Data Collection (DCDC) App Software to Repair Visual Distortions for Low Vision Age-related Macular Degeneration, and the Correlation of the Distortions With Clinical Examination||University of Nebraska|No|Not yet recruiting|January 2015|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Both|55 Years|N/A|No|||January 2015|January 12, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02337647||29380|
NCT02338141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055627|Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women|Evaluating the Accuracy of Portable Colposcopy and Prevalent HPV Genotypes Among HIV Positive Women in Haiti||Duke University|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|500|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338141||29342|
NCT02340494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WomensCHCanada|An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer|An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer||Women's College Hospital|No|Not yet recruiting|April 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|40 Years|No|||January 2015|January 13, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340494||29162|
NCT02340546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1368/2014|Trajectory Changes of Coronary Sinus Lead Tip and Cardiac Resynchronization Therapy Outcome|Trajectory Changes of Coronary Sinus Lead Tip and Cardiac Resynchronization Therapy Outcome|TRAJECTORIES|Ospedale Santa Maria delle Croci|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients with chronic systolic heart failure who are submitted to a cardiac        resynchronization therapy device implant, with either pacemaker or implantable        cardioverter-defibrillator capabilities, as a first implant or as an upgrade from a        previously implanted cardiac electric device, who exhibit a normofrequent regular        ventricular rhythm.|October 2015|October 13, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340546||29158|
NCT02340624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WayneSU|Optimizing Technology-Delivered Interventions for Smoking in Pregnancy: The Mommy Check-Up Study.|Optimizing Technology-Delivered Interventions for Smoking in Pregnancy: The Mommy Check-Up Study.||Wayne State University|No|Not yet recruiting|January 2015|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|8||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340624||29152|
NCT02339545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-0006-P|Coronary Flow Reserve Following Orbital Atherectomy|Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions||Cardiovascular Systems Inc|No|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02339545||29235|
NCT02340637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228846/H10|Coping Kids: Early Intervention for Anxiety and Depression|Coping Kids: A Randomized Controlled Study of a New Indicated Preventive Intervention for Children With Symptoms of Anxiety and Depression|TIM|Regionsenter for barn og unges psykiske helse|Yes|Recruiting|January 2014|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|560|||Both|8 Years|13 Years|No|||January 2015|January 15, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02340637||29151|
NCT02291276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GynRight|Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right) - Pilot Study|Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (GynRight) - Pilot Study||Charite University, Berlin, Germany|No|Recruiting|November 2014|April 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|Female cancer patients being observed in the Department of Anesthesiology and Intensive        Care Medicine CVK and CCM in cooperation with the Department of Gynecology and Obstetrics        CVK at the Campus Virchow - Klinikum, Charité - Universitaetsmedizin Berlin|May 2015|May 28, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02291276||32939|
NCT02291289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29112|A Multi-Center Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer|A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL)||Hoffmann-La Roche||Recruiting|April 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|610|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02291289||32938|
NCT02279446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263/13-10-2014|Development of a Validated Chart for Intermediate Vision Assessment|Development of a Validated Chart for Intermediate Vision Assessment||Democritus University of Thrace|No|Recruiting|October 2014|April 2015|Anticipated|October 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Random|October 2014|October 29, 2014|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02279446||33847|
NCT02284074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRRU/2010/001|Nasal LPS Challenge in Healthy Volunteers|Nasal Lipopolysaccharide (LPS) Challenge in Healthy Volunteers (HVs): Investigation of Tolerability, Dose Response and the Expression Profile of Intercellular Adhesion Molecule-1 (ICAM-1)||Imperial College London|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|November 3, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02284074||33492|
NCT02290301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPOS001|An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin|An Observational Study to Evaluate Cardiovascular Outcomes of Patients With Type 2 Diabetes Mellitus Treated With Gemigliptin||LG Life Sciences||Active, not recruiting|June 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5180|||Both|19 Years|N/A|No|Probability Sample|Approximately 5,000 Korean patients whose diabetic condition requires gemigliptin in        monotherapy or in combination with other antidiabetic treatment, according to the        physician's judgment, will be enrolled.|January 2016|January 27, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290301||33013|
NCT02288351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054934|Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass|Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass||Duke University|Yes|Withdrawn|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288351||33163|
NCT02288364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056728|Reducing Pain of Lidocaine Injection|Does Sodium Bicarbonate Reduce the Pain of Lidocaine for Local Anesthesia in Percutaneous Breast Biopsies?||Duke University|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|88|||Both|21 Years|89 Years|No|||February 2016|February 16, 2016|October 13, 2014|Yes|Yes||No|February 16, 2016|https://clinicaltrials.gov/show/NCT02288364||33162|
NCT02276235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101XDAA00024|The Therapeutic Effect of Catgut Embedding in Obesity|The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial||Taipei City Hospital|Yes|Enrolling by invitation|January 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02276235||34094|
NCT02288650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5547|Incidence of Post-operative Vomitings (POV) After Early Refeeding in Pediatric Day Case Surgery.|||University Hospital, Strasbourg, France||Recruiting|July 2013|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|808|||Both|3 Months|4 Years|No|||November 2014|November 6, 2014|July 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02288650||33140|
NCT02281149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMO-1307|Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy:|Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy: Evaluation of the Toxicity and Quality of Life|TOMO|Centre Oscar Lambret|No|Recruiting|November 2014|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|prospective study of routine care done on women with breast cancer treated by adjuvant        radiotherapy with intensity modulated|December 2014|January 16, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02281149|36 Months|33716|
NCT02277028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOTFIRG13STOYKOV|Bilateral Priming for Upper Extremity Hemiparesis in Older Adults|A Comparison of Two Types of Priming for Upper Extremity Hemiparesis||Rush University Medical Center|No|Recruiting|April 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|55 Years|N/A|No|||October 2015|October 26, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02277028||34033|
NCT02286401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00091805|Functional Assessment of Coronary Artery Disease by CTA Flow Encoding|Functional Assessment of Coronary Artery Disease by CTA Flow Encoding||Johns Hopkins University|No|Recruiting|October 2014|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with symptoms suspicious for obstructive coronary artery disease who will undergo        cardiac catheterization.|February 2016|February 16, 2016|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02286401||33313|
NCT02290353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00220|Functional Engagement in Assisted Therapy Through Exercise Robotics|Functional Engagement in Assisted Therapy Through Exercise Robotics|FEATHERS|University of British Columbia|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|13 Years|N/A|No|||November 2015|November 23, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02290353||33009|
NCT02329353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAN_PERIO-SOM_01|Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers|Clinical And Microbiological Analysis Of Orally Administered Lactobacillus Probiotic Lozenges In Chronic Periodontitis Patients Among Smokers And Non-smokers And Its Correlation With Clinical Parameters - A Clinico-Microbiological Study||Next Gen Pharma India Pvt. Ltd.|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|55 Years|No|||July 2015|July 31, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329353||30016|
NCT02337660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRG-1|Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia|Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02337660||29379|
NCT02340468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2014-1505|Breast Tumor Oxygenation During Exercise|Breast Tumor Oxygenation During Exercise||University of California, Irvine|No|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Female|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Study population will be recruited from an outpatient at UC Irvine Health|February 2016|February 5, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340468||29164|
NCT02341053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411M55281|Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy|Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy||Gillette Children's Specialty Healthcare|Yes|Recruiting|September 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|3 Years|14 Years|No|||February 2016|February 15, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02341053||29119|
NCT02341209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53677|Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma|Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma|CTCL|Rochester General Hospital||Not yet recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341209||29107|
NCT02341222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM108/2008-B|BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B|"BP as a Super-light Mesh and as a New Fixing Device for General, Emergency and Prosthetic Surgery. The BP Implantation Effects on Immunity System, on the Metabolism and on Sealing. Preliminary Experimentation of Small Feasibility Study"|DM108/2008-B|University of Roma La Sapienza|Yes|Active, not recruiting|January 2008|December 2015|Anticipated|August 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|2 Months|4 Months|No|||July 2014|January 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02341222||29106|
NCT02341235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0376|Self-monitoring Activity: a Randomized Trial of Game-oriented Applications|Self-monitoring Activity: a Randomized Trial of Game-oriented Applications (SMARTGOAL)|SMARTGOAL|The University of Texas Medical Branch, Galveston|No|Recruiting|February 2015|December 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02341235||29105|
NCT02291250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rowett 905|Effect of Soft Fruit on Postprandial Blood Glucose|Effect of Soft Fruit on Postprandial Blood Glucose||University of Aberdeen|Yes|Recruiting|November 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|16|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291250||32941|
NCT02291263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB-RRC-PR-13097|Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine|Assessing the Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine Against Type 2 With Bivalent Oral Poliovirus Vaccine in Routine Immunization||Centers for Disease Control and Prevention|Yes|Completed|October 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|738|||Both|6 Weeks|7 Weeks|Accepts Healthy Volunteers|||August 2015|August 26, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02291263||32940|
NCT02279212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07505b (REK)|Neuropathic Pain and Quality of Life in ICU Survivors|Neuropathic Pain and Quality of Life in ICU Survivors|NEUPAQ|Oslo University Hospital|No|Active, not recruiting|May 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients in a Norwegian ICU. Medical and surgical patients, no thorasic surgery or        trauma.|October 2014|October 30, 2014|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT02279212||33865|
NCT02283788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-116|Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization|A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women||Bial - Portela C S.A.|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|October 31, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02283788||33514|
NCT02283801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-119|Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.|A Phase 1, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Lamotrigine 150mg Following Multiple Doses Administrations in Healthy Male Volunteers||Bial - Portela C S.A.|No|Completed|November 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283801||33513|
NCT02283814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-120|A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate|A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male||Bial - Portela C S.A.|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|November 3, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02283814||33512|
NCT02280031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1817|Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.|Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|November 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280031||33802|
NCT02290340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5290C00002|A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants|A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants|MEDI8897 1b|MedImmune LLC|No|Active, not recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|N/A|12 Months|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02290340||33010|
NCT02280564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0240|Study of A Cell-Phone System to Improve Health of Youth With Diabetes|Pilot Study of A Cell-Phone System to Improve Health of Youth With Diabetes|FL3X|University of North Carolina, Chapel Hill|No|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|12 Years|16 Years|No|||October 2014|October 29, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280564||33761|
NCT02280577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL901200|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||June 22, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280577||33760|
NCT02280590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNT_HLP_IV|Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia|||Dong-A ST Co., Ltd.||Completed|September 2014|||June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|223|||Both|20 Years|N/A|No|||July 2015|July 2, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280590||33759|
NCT02276521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.5.FNRERC.5.SU|Evaluation of Long Term Immunity Following HPV Vaccination|Evaluation of Long-term Immunological Responses Following Reduced Dose Quadrivalent Human Papillomavirus (HPV) Vaccine Schedules: A Phase II/III Clinical Trial||Murdoch Childrens Research Institute|Yes|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|200|Samples With DNA|We will be collecting blood from the participants, which include the plasma and peripheral      blood mononuclear cells.|Female|15 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|In 2008/9, the MoH in Fiji accepted a one-off donation of 110,000 doses of Gardasil®        vaccine, which was enough to vaccinate four birth cohorts of girls (30,338 girls aged 9-12        years) with a three-dose schedule via a school-based program. However, not all the girls        received the full-recommended three-dose schedule, mainly due to absence from school on        the day the school health team were visiting. The coverage following the initial and the        subsequent mop-up campaign was: 62%, 56%, and 55% for doses one, two, and three        respectively. The girls that received different doses of Gardasil® vaccine in Suva area        who are potentially contactable in this study are 676 (three doses), 204 (two doses) and        116 (one dose), demonstrating feasibility of recruitment.|September 2015|September 22, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02276521||34072|
NCT02285634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006312|The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.|The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.||Mayo Clinic|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285634||33372|
NCT02281721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4029|Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection|Prospective, Observational, Multi-Center, Single-Arm, Consecutive Enrollment, Post-Marketing, International Registry of the Surpass™ Flow Diverter in Intracranial Arteries||Stryker Neurovascular|Yes|Recruiting|March 2015|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Probability Sample|For the primary endpoint, the evaluable patient population will consist of all individuals        treated with the Surpass Flow Diverter(s) who have provided consent, and who have        completed their 12 month follow-up assessment.|November 2015|January 19, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281721|5 Years|33672|
NCT02286258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100151|Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)|MultiGFR: Equivalency Study of Different Methods of Measuring Glomerular Filtration Rate|MultiGFR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|350|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02286258||33324|
NCT02278133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWNT974X2102C|Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations|A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations||Array BioPharma|No|Recruiting|December 2014|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02278133||33948|
NCT02278432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28217914.6.0000.5426|Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense|Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|June 2014|October 2015|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|427|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized patients will be separated into three groups: those who make indicated and        approved prophylactic use of omeprazole (exposed group 1), those who make not indicated        and not approved prophylactic use (exposed group 2), and those who do not use the        omeprazole (non-exposed group). Patients who do not make prophylactic use of omeprazole        will be excluded. Patients will have their pharmacotherapy monitored and data will be        collected daily using an investigation guide of the first day of admission and will be        included in group 1 or 2, from the first use of omeprazole to discontinuation (washout        period of seven half-lives or higher).|October 2015|October 18, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278432||33925|
NCT02340065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOCUFF-001|Endocuff-assisted vs. Standard Colonoscopy|Endocuff-assisted vs. Standard Colonoscopy: a Randomized, Back-to-Back Study||Attikon Hospital|No|Recruiting|January 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340065||29195|
NCT02340078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL011|A Clinical Study to Evaluate the Efficacy and Safety of HA IDF II Plus Versus HA IDF II in Nasolabial Fold Injection|||LG Life Sciences||Active, not recruiting|November 2013|||February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|30 Years|60 Years|No|||January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340078||29194|
NCT02340390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH42|G7 Acetabular System vs. Exceed ABT Acetabular System in THA|A PROSPECTIVE MULTI CENTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE G7 Acetabular System With CoC ARTICULATION COMPARED TO EXCEED ABT Acetabular System With CoC ARTICULATION IN TOTAL HIP ARTHROPLASTY|G7|Biomet, Inc.|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|No|||February 2016|February 18, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02340390||29170|
NCT02340156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT53-02-2|Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma|Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma||SynerGene Therapeutics, Inc.|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340156||29188|
NCT02340559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01347|Effectiveness of Meta-Cognitive Training (EMC) in People With Psychosis of Brief Evolution.|Effectiveness of Meta-Cognitive Training (EMC) on Symptmos, Metacognition, Social and Neuropsychological Functioning in People With Psychosis of Brief Evolution||Fundació Sant Joan de Déu|No|Completed|August 2012|December 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|45 Years|No|||January 2015|January 20, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340559||29157|
NCT02341131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 11/01958|Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels|BDNF as a Potential Biomarker for Cognitive Remediation Therapy in Schizophrenia||Hospital Clinic of Barcelona|No|Active, not recruiting|January 2012|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|February 19, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02341131||29113|
NCT02330133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR64R-2|Mid-life Women: Preventing Unintended Pregnancy and STIs|Mid-life Women: Preventing Unintended Pregnancy and STIs|FemRepro_2|Oregon Center for Applied Science, Inc.|No|Completed|May 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|333|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT02330133||29956|
NCT02278913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 08/09|Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay|Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay||Universidad Nacional de Asunción|No|Completed|April 2009|March 2011|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02278913||33888|
NCT02290769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382 - 072014|Time of Cannulation During Primary ERCP With Short Guide Wire Rapid Exchange or With Long Guide Wire|Evaluation of the Cannulation Time During Primary ERCP With Short Guide Wire Rapid Exchange or With Long Guide Wire. Multicentre Prospective Randomized Trial|RELG|Niguarda Hospital|No|Not yet recruiting|November 2014|October 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02290769||32978|
NCT02290847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140055H|Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD|Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|September 2012|April 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02290847||32972|
NCT02288806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-D|Melatonin and Vitamin D in Breast Cancer|Anti-proliferative Effects of Melatonin and Vitamin D in Breast Cancer|MELO-D|Hamilton Health Sciences Corporation|No|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Female|18 Years|N/A|No|||November 2014|November 7, 2014|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288806||33128|
NCT02290912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5606|Gray Matters Alzheimer's Disease Prevention Intervention|Gray Matters: Multi-domain Lifestyle Behavioral Alzheimer's Disease Prevention Randomized Controlled Trial||Utah State University|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|146|||Both|40 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02290912||32967|
NCT02284399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0032|National Prevalence and Impact of Noninvasive Prenatal Testing|National Prevalence and Impact of Noninvasive Prenatal Testing||Mednax Center for Research, Education and Quality|No|Active, not recruiting|January 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|4276|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women at participating Obstetrix Outpatient centers who are undergoing IDTFK        between January 2012 and June 2014.|March 2016|March 11, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02284399||33467|
NCT02280278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010010|Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy|The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy||Sun Yat-sen University|Yes|Recruiting|October 2014|||October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|70 Years|No|||November 2014|November 3, 2014|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280278||33783|
NCT02284919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820737|[18F]ISO-1 PET/CT in Breast Cancer|Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer||University of Pennsylvania|Yes|Recruiting|November 2014|||November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284919||33427|
NCT02280876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaCRU-02/PCNS.EM/12|Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)|Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).|PCNS-EM|Universidad Austral de Chile|Yes|Completed|January 2012|May 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||January 2016|January 22, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02280876||33737|
NCT02291484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC2013022|Comprehensive Cardiac CT Versus Exercise Testing in Suspected Coronary Artery Disease (2)|Comprehensive Cardiac CT Versus Exercise Testing in Suspected Coronary Artery Disease (2)|CRESCENT2|Erasmus Medical Center|Yes|Recruiting|August 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02291484||32923|
NCT02290314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105951|Midline Lumbar Fusion Versus Posterior Lumbar Interbody Fusion|Minimal Access Midline Lumbar Fusion Versus Traditional Open Posterior Lumbar Interbody Fusion for Degenerative Lumbar Spondylolisthesis||The London Spine Centre|Yes|Recruiting|December 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290314||33012|
NCT02282488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.14.INF|Effect of the Level of Dietary Protein on the Infant Hormonal Profile and Body Composition|Effect of the Level of Dietary Protein on the Infant Hormonal Profile and Body Composition||Nestlé|No|Completed|April 2006|December 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|238|||Both|N/A|7 Days|Accepts Healthy Volunteers|||October 2014|October 31, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02282488||33614|
NCT02340338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioMed0713|rTSST-1 Variant Vaccine Phase 1|Phase 1 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults|rTSST-1|Biomedizinische Forschungs gmbH|Yes|Completed|July 2014|July 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|46|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02340338||29174|
NCT02340169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS-1303|Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort® (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.||Taro Pharmaceuticals USA|No|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|2 Years|17 Years|No|||November 2015|November 1, 2015|December 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340169||29187|
NCT02341313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0443|Point of Care Ketone Measurement in the Newborn|Feasibility of the Use of Point of Care Technology to Measure Ketone and Lactate Levels in the Newborn at Risk From Hypoglycaemia Due to Impaired Perinatal Counter Regulation|POCKET|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|March 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|1 Month|No|Non-Probability Sample|Newborn infants at risk of hypoglycaemia|January 2015|January 16, 2015|March 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02341313||29099|
NCT02340923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-003-2014|A Device for Rapid, Painless, Bedside Muscle Evaluation of Children|A Device for Rapid, Painless, Bedside Muscle Evaluation of Children||Skulpt, Inc.|Yes|Active, not recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|256|||Male|N/A|18 Years|Accepts Healthy Volunteers|Probability Sample|Duchenne Muscular Dystrophy Subjects|March 2016|March 7, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340923|12 Months|29129|
NCT02329886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141218|The Qingdao Port Health Study|The Qingdao Port Health Study||China National Center for Cardiovascular Diseases|Yes|Active, not recruiting|March 2013|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25000|Samples With DNA|In 2013, whole blood samples were collected for future genetic studies. And saliva and urine      samples were also collected for future analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Employees and retirees in Qingdao Port Group, Shandong province, China|December 2014|December 30, 2014|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02329886||29975|
NCT02331173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XLRS-001|Clinical Evaluation of Patients With X-linked Retinoschisis|Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS)||Applied Genetic Technologies Corp|No|Active, not recruiting|March 2012|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|55|||Male|7 Years|N/A|No|Probability Sample|Potential subjects will be identified from the Oregon Retinal Degeneration Center (ORDC)        database and the Retina and Ophthalmic practices at Oregon Health and Science University        Casey Eye Institute, Retina Foundation of the Southwest and Kellogg Eye Center.|August 2015|August 11, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02331173||29877|
NCT02331186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/11/01|Effects of Bariatric Surgery on Pelvic Floor Fonctions in Obese Women|Effects of Bariatric Surgery on Pelvic Floor in Obese Women||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|50 Years|No|Non-Probability Sample|women who underwent bariatric surgery Body mass index ≥ 40 kg/m2 >18 years old|January 2015|January 2, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02331186||29876|
NCT02288533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regionale WP2|Transcranial Direct Current Stimulation Effects in Patients With Chronic Consciousness Disorders|Transcranial Direct Current Stimulation (tDCS) Effects in Patients With Chronic Consciousness Disorders||University Hospital of Ferrara|Yes|Recruiting|September 2014|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|10|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02288533||33149|
NCT02283255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 3765/12/021|Cardiovascular, Pulmonary and Skeletal Muscle Evaluation in Late Postoperative Period of the Fontan Surgery|Cardiovascular, Pulmonary and Skeletal Muscle Evaluation in Patients With Univentricular Physiology in the Late Postoperative Period of the Fontan Surgery: Effects of Exercise Training||University of Sao Paulo|No|Recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|12 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02283255||33555|
NCT02283268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071101|Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery|A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease||Baxalta US Inc.|Yes|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283268||33554|
NCT02280291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03598|Single Shot Versus OnQ Pump in Extremity Fractures|Study: Comparison Between Single Shot Peripheral Nerve Block and Continuous Infusion Via a On-Q Pump in Extremity Fracture Operations: a Randomized Prospective Control Trial||New York University School of Medicine|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||March 2016|March 8, 2016|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280291||33782|
NCT02276248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GREEN|Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma|Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Patients With Unfavorable Prognostic Factors: an Open-label, Single-arm, Phase II Clinical Trial||Chinese Academy of Medical Sciences|Yes|Recruiting|June 2010|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02276248||34093|
NCT02280603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA4001_AGAP_POC|Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application|A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia||Dong-A ST Co., Ltd.|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|49 Years|No|||June 2015|June 22, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280603||33758|
NCT02288962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/677|Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial|The Efficacy of Cabergoline on Tumour Volume in Previously Untreated Macroadenomas or Residual Adenomas After Pituitary Surgery or Irradiation: a Randomized Controlled Trial||St. Olavs Hospital|No|Recruiting|November 2014|May 2025|Anticipated|May 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288962||33116|
NCT02284646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7027 08|Physical Training Program in Ankylosing Spondylitis|Assessment of the Efficacy of a Physical Training Program in Patients With Ankylosing Spondylitis|PEPS|University Hospital, Toulouse|No|Recruiting|November 2014|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|60 Years|No|||June 2015|June 10, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02284646||33448|
NCT02285166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142-012|Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3|Specified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)||Takeda|No|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|14000|||Both|50 Years|N/A|No|Non-Probability Sample|Hyperlipidemia|December 2015|December 16, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285166||33408|
NCT02285387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0728|Rhythm Control of AF in Patients With Acute Stroke|||Yonsei University|No|Not yet recruiting|November 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|19 Years|N/A|No|||November 2014|November 3, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02285387||33391|
NCT02277301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/033/14|Mellow Babies - a Pilot Waiting List Trial|Mellow Babies - a Pilot Waiting List Trial||University of Aberdeen|Yes|Recruiting|August 2014|July 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Female|16 Years|50 Years|No|||October 2014|October 24, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02277301||34012|
NCT02277626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24248|Electro Flo 5000 and Vest Therapy|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and Vest Therapy in|EF/Vest|Stanford University|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|12 Years|N/A|No|||December 2015|December 7, 2015|October 27, 2014|No|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02277626||33987|
NCT02277873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGM-CRP1|Models for Evaluate the Proximity of the Moon on the Frequency of Births|Two Models for Evaluate the Effect of the Proximity of the Moon on the Frequency of Births. Study on Mexican Population||Hospital General de Mexico|No|Completed|January 2009|March 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|25152|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women from urban and rural regions from north part of Mexico city county area|October 2014|October 28, 2014|July 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02277873||33968|
NCT02286947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4658-204|Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy|An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy||Sarepta Therapeutics|No|Active, not recruiting|November 2014|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|7 Years|21 Years|No|||March 2016|March 4, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286947||33271|
NCT02340650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC_MS_14_0144|High Resolution Imaging for Early and Better Detection of Bladder Cancer|High Resolution Imaging for Early and Better Detection of Bladder Cancer|HRME_Bladder|The University of Texas Health Science Center, Houston|Yes|Recruiting|April 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|100 Years|No|||January 2016|January 13, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340650||29150|
NCT02340507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00266|The Impact of the Glycaemic Index (GI) on Daily Blood Glucose Profiles and Food Intake in Young Chinese Adult Males|||Clinical Nutrition Research Centre, Singapore|No|Completed|May 2013|January 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02340507||29161|
NCT02340936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR-ESHAP|Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma|National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Active, not recruiting|January 2011|May 2019|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|53|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340936||29128|
NCT02329600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|polyphenol_TOC_OLP|Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus|Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus||Cairo University|No|Completed|June 2013|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|30 Years|68 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329600||29997|
NCT02330627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5UL1TR000100|Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes|Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes||University of California, San Diego|No|Active, not recruiting|April 2014|December 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330627||29919|
NCT02330913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-001|Novel Esophago-Jejunal Anastomosis Method During Totally Laparoscopic Total Gastrectomy|Novel Esophago-Jejunal Anastomosis Method During Totally Laparoscopic Total Gastrectomy: π-shape Esophagojejunostomy, Three-in-one Technique||Keimyung University Dongsan Medical Center|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|80 Years|No|||December 2015|December 24, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02330913||29897|
NCT02343133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003|Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome|A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects||Neumedicines Inc.|Yes|Active, not recruiting|January 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343133||28959|
NCT02290639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130057H|Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings|Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings: A Randomized Controlled Trial||The University of Texas Health Science Center at San Antonio|Yes|Completed|December 2012|November 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02290639||32988|
NCT02288663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5744|Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement|Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement|FREAGE|University Hospital, Strasbourg, France|No|Not yet recruiting|November 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|220|||Both|75 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 6, 2014|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02288663||33139|
NCT02284412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGC02|Functional Respiratory Imaging After Neostigmine or Sugammadex|Visualization of Regional Lung Ventilation During Neostigmine or Sugammadex Enhanced Recovery From Moderate Residual Neuromuscular Blockade in the Anaesthetized Rat Using Functional Respiratory Imaging|FRINeoS|Onze Lieve Vrouw Hospital|Yes|Completed|December 2014|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Male|3 Months|6 Months|No|||April 2015|April 20, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02284412||33466|
NCT02280616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUU-2/EEA|Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis|Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis||Dr. Falk Pharma GmbH|Yes|Completed|June 2011|May 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280616||33757|
NCT02280629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCG-4/UCR|Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)|Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis|PROTECT-2|Dr. Falk Pharma GmbH|Yes|Recruiting|October 2014|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02280629||33756|
NCT02339441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10H101429|Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis|Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis|ESOS|University of Manchester|No|Active, not recruiting|June 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|320|||Both|18 Years|N/A|No|Non-Probability Sample|Eligibility:        Age > 18 Skin thickening < 3 years Immunosuppressant use < 4 months Proximal skin        involvement to face/neck, elbow or knee|January 2015|January 15, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02339441||29243|
NCT02335242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23400|Sildenafil for the Treatment of Lymphatic Malformations|Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations||Stanford University|Yes|Recruiting|January 2015|December 2021|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|6 Months|10 Years|No|||August 2015|August 7, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335242||29564|
NCT02351375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50518.081.14|MICRO-study: The IntelliCap® System as a Gastrointestinal Fluid Sampling Tool|MICRO-study: The IntelliCap® System as a Gastrointestinal Fluid Sampling Tool|MICRO|NIZO Food Research|No|Completed|November 2014|June 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351375||28329|
NCT02351609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125785-RSG-14-034-01CPPB|Patient Navigation and Financial Incentives to Promote Smoking Cessation|Patient Navigation and Financial Incentives to Promote Smoking Cessation||Boston Medical Center|No|Recruiting|July 2014|June 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|352|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351609||28311|
NCT02351830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Birch Validation Study|Clinical Validation of Birch Pollen in the EEU|Controlled Birch Pollen Challenge in the Environmental Exposure Unit (EEU); Clinical Validation and Biomarker Exploration||Queen's University|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|N/A|||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351830||28294|
NCT02352350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201300816|Lactate in Cardiac Arrest|The Predictive Value of Prehospital Blood Lactate Measurement Following Out of Hospital Cardiac Arrest (OHCA) and Return of Spontaneous Circulation (ROSC).||University of Florida|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|365|||Both|18 Years|N/A|No|Probability Sample|All primary cardiac arrest patients in Alachua County with prehospital return of        spontaneous circulation (ROSC) in Alachua County, FL.|September 2015|September 17, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02352350||28254|
NCT02354261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP2001|Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)|Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)||HedgePath Pharmaceuticals, Inc.|Yes|Recruiting|August 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354261||28108|
NCT02343848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1197-14-SMC|Physical Activity and Gestational Complications|Physical Activity and Gestational Complications|PEDPTB|Sheba Medical Center|No|Not yet recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 24, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343848||28904|
NCT02344173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_723|ABLATOR Ablation Observational Registry|ABLATOR Ablation Observational Registry|ABLATOR|St. Jude Medical|No|Enrolling by invitation|November 2014|May 2018|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are indicated for an atrial fibrillation ablation procedure.|January 2016|January 21, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344173|12 Months|28881|
NCT02349165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL29961|Standard Versus Transepithelial Corneal Crosslinking|Standard Versus Transepithelial Corneal Crosslinking for Treatment of Progressive Keratoconus||UMC Utrecht|No|Completed|May 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02349165||28498|
NCT02327585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-4024-04|Behavioral Intervention for Children With Attention Deficit Hyperactivity Disorder(ADHD)|Study on the Psychological Behavior Intervention Technology of Attention Deficit Hyperactivity Disorder||Peking University|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|80|||Both|6 Years|12 Years|No|||December 2014|December 30, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02327585||30152|
NCT02327598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sure Press 1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||December 5, 2015|December 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327598||30151|
NCT02327845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54NS092091|Phenotype, Genotype & Biomarkers in ALS and Related Disorders|Phenotype, Genotype & Biomarkers in ALS and Related Disorders||University of Miami|No|Recruiting|April 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|DNA, serum, urine and CSF|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ALS or a related neurodegenerative disorder, including FTD, HSP, PLS, PMA        and MSP. Select family members of affected participants.|December 2015|December 10, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327845||30132|
NCT02331680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-13-003|A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|A Phase 2, Multicenter, Placebo-controlled, Double-blind, Randomized, Parallel-group Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration||Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|80 Years|No|||February 2016|February 25, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02331680||29838|
NCT02328053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2013019CLI|Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis|Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis||Aravind Eye Care System|No|Recruiting|February 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||December 2014|December 26, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02328053||30116|
NCT02332187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 12-0807-F6A|Effect of All-Stim 2 Quadriceps Treatments on Limb Muscle Strength In Mechanically Ventilated Patients|Effect of All-Stim 2 Quadriceps Treatments on Limb Muscle Strength In Mechanically Ventilated Patients.||University of Kentucky|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332187||29799|
NCT02337894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203454|Effects of Amino Acid Supplementation on Liver Lipid Content and Protein Metabolism in Obese Children|Effects of Nutritional Supplementation With Amino Acids on Liver Lipid Content, Whole-body Protein Turnover, and Body Composition in Obese Pre-pubertal Children||Arkansas Children's Hospital Research Institute|Yes|Not yet recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|32|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02337894||29361|
NCT02342769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202033|Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany|Prospective Non-Interventional Observational Study of Use of Triumeq® and Corresponding Monitoring Measures in Clinical Practice in Germany|TRIUMPH|ViiV Healthcare|No|Recruiting|February 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Approx. 40 HIV treatment sites in Germany are planned to be involved in the documentation.        The recruitment target is to include a total of 400 patients in the study across Germany.        In order to allow for adequately answering in particular the problems regarding HLA-B*5701        testing, at least half of the recruited population should not have received abacavir (ABC)        in their prior therapy. Each site will be allowed to recruit a maximum of 5 patients per        month and a maximum of 20 patients in total. If the monthly quota of 5 patients is not        utilized, the difference may be transferred to the subsequent months.|October 2015|December 3, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342769||28987|
NCT02339818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-365|Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries|Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries||Bristol-Myers Squibb|No|Recruiting|August 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|192|||Both|18 Years|N/A|No|Non-Probability Sample|HCPs will be considered for participation in the study if they prescribe/use Eliquis for        any approved indications, including the following subgroups as appropriate for each        country:          -  Cardiologists (including allied specialties, e.g. angiologists, electrophysiologists)          -  Non-cardiology specialists (e.g. internal medicine/hospital general medicine             physicians, geriatricians/care of the elderly physicians, neurologists,             hematologists, orthopedic surgeons)          -  General practitioners/internal medicine          -  Other HCPs (e.g. nurses, pharmacists)          -  Patients taking Eliquis for all three currently approved indications|December 2015|December 8, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339818||29214|
NCT02327390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3612|Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma|Phase I Study Using Autologous Ex Vivo-Activated (X-ACT) Lymph Node Lymphocytes as Adoptive Immunotherapy in Advanced Malignant Melanoma Patients||Case Comprehensive Cancer Center|Yes|Recruiting|March 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02327390||30167|
NCT02334761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOPSy|Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.|Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.||University Health Network, Toronto|No|Recruiting|January 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|The patient must be 18 years or older with a life expectancy of greater than 3 months. The        patient must be undergoing a biopsy for research or diagnostic purposes with a diagnosis        of malignancy or an assumed diagnosis of malignancy. The patient must be able to complete        the questionnaires independently.|March 2016|March 4, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334761||29601|
NCT02339532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP13|Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status|Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer|NeoTOP|UNICANCER|Yes|Recruiting|January 2015|June 2023|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02339532||29236|
NCT02353702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/176/HP|Efficacy of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery|Efficacy of Parietal Continuous Infiltration of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery Through a Subcostal Incision|CATPAR|University Hospital, Rouen|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|80 Years|No|||September 2015|September 14, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02353702||28151|
NCT02353858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT01|Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer|Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial|HT01|University Hospital Tuebingen|No|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|80 Years|No|||December 2015|December 4, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02353858||28139|
NCT02353871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-189|Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve the Appearance of Moderate to Severe Glabellar Lines|A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines|BTX-A-HAC NG|Ipsen|No|Completed|January 2015|September 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|65 Years|No|||November 2015|November 10, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353871||28138|
NCT02354053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN286|Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations|A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone|TRIIADD|McGill University Health Center|Yes|Recruiting|November 2015|January 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02354053||28124|
NCT02354248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-TST01|Application of the Triple Stimulation Technique to Patients With CNS Disorders Including Stroke|Application of the Triple Stimulation Technique to Patients With CNS Disorders Including Stroke||Brugmann University Hospital|No|Active, not recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02354248||28109|
NCT02343510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lab7682|Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study|Detection of Chlamydia DNA by Polymerase Chain Reaction ( PCR ) in Tumours Tissue of Primary Tubal and Ovarian Cancers : a Pilot Study||Ain Shams University|Yes|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Anticipated|70|Samples With DNA|Archival Paraffin blocks for cases of primary tubal cancers , high grade serous ovarian      cancers , low grade serous ovarian cancers and normal Fallopian tubes removed during      Hysterectomy operations for benign Gynecological indications|Female|40 Years|80 Years|No|Probability Sample|Pathology blocks of patients with primary tubal cancer and with high grade serous ovarian        cancer and normal tubes.|October 2015|October 28, 2015|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02343510||28930|
NCT02343835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF-20150113(4)|Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer|IRE: Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2015|January 16, 2015|January 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343835||28905|
NCT02348918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DME 202B|A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema|A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema||Allegro Ophthalmics, LLC|Yes|Recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|150|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348918||28517|
NCT02348931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT_12_05_2013|Clinical Effect of a Nasal Former in Nasal Deformities|Investigation of the Effect of a Customized Nasal Brace on Nasal Deformities With or Without Prior Surgery||University of Zurich|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02348931||28516|
NCT02353195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/2013|Effects of Radio-frequency in Patients With Myofascial Chronic Neck Pain|"Analgesic Effects of Capacitive Resistive Monopolar Radio-frequency (448 kHz) in Patients With Myofascial Chronic Neck Pain: A Pilot Randomized Controlled Trial."||Universidad Rey Juan Carlos|Yes|Completed|October 2013|November 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||January 2015|January 27, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02353195||28190|
NCT02331394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-14-150|A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced NSCLC|A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced Non-small-cell- Lung Cancer|CH|Lady Davis Institute|No|Not yet recruiting|September 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331394||29860|
NCT02331693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-20141110|CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR|Genetically Modified T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR||RenJi Hospital||Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2015|January 5, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331693||29837|
NCT02331966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51741|Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia|Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors||AHEPA University Hospital|Yes|Recruiting|September 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|RNA extraction from bone marrow and tissue samples from patients with tumor -induced      osteomalacia|Both|18 Years|80 Years|No|Probability Sample|Patients with tumor induced osteomalacia|January 2015|January 5, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02331966||29816|
NCT02337634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0480|Milk Thistle in Pathological Gambling|Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study||University of Chicago|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337634||29381|
NCT02339727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ayham alshweki|Omega-6/Omega-3 Ratio and Neural Development in Preterm Infants.|Clinical Trial of the Relation Between Omega-6/Omega-3 Ratio in Formula of Preterm Infants Less Than 1500 Grams and/or Less Than 32 Weeks Gestational Ages and Brunet Lezine Score at 2 Years of Live. Anuvis Study||Health Research Institute of Santiago|No|Completed|July 2010|September 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|40|||Both|N/A|2 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339727||29221|
NCT02331147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20142081|Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Allogenic Dermis Graft in the Management of Diabetic Foot Ulcers||Professional Education and Research Institute|No|Recruiting|December 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02331147||29879|
NCT02331160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-101|Rebozo and External Cephalic Version in Breech Presentation.|Rebozo Som Vendingsmetode Ved sædepræsentation (in Danish)|RECeiVe|Hvidovre University Hospital|No|Recruiting|March 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|378|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02331160||29878|
NCT02330328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00091964|Evaluation of the Utility of Telemetry in Patients Admitted for Chest Pain Who Are at Low Risk for Acute Coronary Syndrome|||Carilion Clinic|Yes|Not yet recruiting|April 2015|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|49 Years|No|||February 2015|February 4, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330328||29941|
NCT02331732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405*|Virtually Observed Treatment (VOT) for Tuberculosis Patients in Moldova|||The Behavioural Insights Team|No|Not yet recruiting|October 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02331732||29834|
NCT02339493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002317|Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter|Randomized Controlled Trial of Electronic Alerts to Increase Anticoagulation Prescription for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter||Brigham and Women's Hospital|No|Not yet recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|21 Years|N/A|No|||July 2015|July 20, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02339493||29239|
NCT02328079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antiviral in facial palsy|Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy|Antiviral Treatment in Facial Palsy. Randomized Control Trial||Assiut University|Yes|Completed|April 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|15 Years|60 Years|No|||December 2014|December 26, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02328079||30114|
NCT02355873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013QX-FZC-001|Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients|Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients||Peking University First Hospital|No|Recruiting|February 2015|||July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02355873||27984|
NCT02347722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014869-01H|Biomarkers to Classify Heart Failure|Evaluation of Existing Biomarker Candidates to Accurately Classify the Etiology of Heart Failure||Ottawa Heart Institute Research Corporation|No|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|825|Samples Without DNA|Serum and plasma for biomarkers|Both|18 Years|N/A|No|Probability Sample|The retrospective cohort consists of stored blood samples from various biobanks.        The prospective cohort consists of patients admitted to academic hospitals or outpatient        clinics with symptomatic heart failure diagnosed within 2 years.        The acute cohort consists of newly diagnosed patients admitted with acute heart failure.|March 2016|March 4, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347722||28608|
NCT02356042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-42|Effects of Geriatric Inclusive Art Activity in Nursing Home Residents (GIA)|Effects of Geriatric Inclusive Art Activity in Nursing Home Residents (GIA)||University Hospital, Angers||Completed|February 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|65 Years|N/A|No|Non-Probability Sample|Patients were recruited in nursing home.|January 2015|February 4, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02356042||27971|
NCT02356055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4648|Mass Practice of Activities of Daily Living in Dementia (STOMP)|High-dose Mass Practice Intervention to Reduce ADL Disability in Dementia|STOMP|University of Oklahoma|Yes|Recruiting|October 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|50 Years|90 Years|No|||February 2016|February 18, 2016|October 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02356055||27970|
NCT02343211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120101|Immunotherapy and Paraneoplastic Neurological Syndromes|Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes|IaSON|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343211||28953|
NCT02343224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074563|Phase II Pegylated Interferon|A Phase II Study Of Pegylated Interferon ALFA-2b in Children With Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas|Peg Interferon|Emory University|Yes|Recruiting|November 2014|December 2021|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|18 Years|No|||February 2016|February 22, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343224||28952|
NCT02348658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536TCH/CPH-004|A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet|A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose Administration of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects||Takeda|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02348658||28537|
NCT02348671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-2|Evaluation of Wound Dressings in the Reduction of Shear- Force|Evaluation of Wound Dressings to Reduce the Harmful Effects of Shear- Force at the Skin||Maastricht University Medical Center|Yes|Completed|March 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Ten healthy volunteers|January 2015|September 22, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02348671||28536|
NCT02353117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1116131|Preventing Congenital Syphilis|Preventing Congenital Syphilis|PCS|Tulane University School of Public Health and Tropical Medicine|Yes|Not yet recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Female|13 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02353117||28196|
NCT02341495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204961|Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65|A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients|EXJADE|Loyola University|Yes|Recruiting|February 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|65 Years|89 Years|No|||March 2015|March 30, 2015|September 26, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341495||29085|
NCT02336022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015003|The Evaluation of a Noninvasive Respiratory Monitor in Pediatric Patients Undergoing General Anesthesia|The Evaluation of a Noninvasive Respiratory Monitor in Pediatric Patients Undergoing General Anesthesia||Children's Hospital Boston||Recruiting|March 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|1 Year|17 Years|No|Non-Probability Sample|Patients undergoing general anesthesia for surgical procedures at Boston Children's        Hospital.|December 2015|December 1, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02336022||29505|
NCT02337088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0546|Delayed Cord Clamping in Very Low Birth Weight Infants|Delayed Cord Clamping at 30 vs. 60 Seconds for Very Low Birth Weight Infants: A Randomized Controlled Trial|DCC|University of Chicago|No|Not yet recruiting|January 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|No|||January 2015|January 12, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02337088||29423|
NCT02337439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1CDA2013-24|Perceptual Deficits in Schizophrenia|Cognitive Remediation for Perceptual Deficits in Schizophrenia||VA Connecticut Healthcare System|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 2, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02337439||29396|
NCT02339675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML10456-S56575|Psychometric Properties Upper Limb Function Measures Multiple Sclerosis|Psychometric Properties of Outcome Measures for Upper Limb Function, in Multiple Sclerosis: a Multi-center Study|MCS-III-UL|Hasselt University|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02339675||29225|
NCT02329561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-20|PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects|Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers||Université de Montréal|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02329561||30000|
NCT02329860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTN-III-HCC|Study of Apatinib After Systemic Therapy（Chemotherapy and/or Targeted Therapy） in Patients With Hepatocellular Carcinoma|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|January 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02329860||29977|
NCT02335528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-504 W74V8H-06-C-0002|SimCoach Evaluation: A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression|SimCoach Evaluation: A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression||RAND|Yes|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|333|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335528||29542|
NCT02340221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29058|SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy|A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY||Hoffmann-La Roche||Recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340221||29183|
NCT02327624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18423|STEEL Percutaneous Coronary Intervention|Study of Two Regimens of TicagrElor Compared to Clopidogrel in Patients Undergoing ELective Percutaneous Coronary Intervention|STEEL-PCI|Sheffield Teaching Hospitals NHS Foundation Trust|No|Not yet recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||December 2014|December 24, 2014|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327624||30149|
NCT02332213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914|Volatile Markers in Digestive Cancer|Volatile Marker Testing for Digestive Cancer and Precancerous Lesion Detection, Evaluation of Confounding Factors|VOLGACORE|University of Latvia|No|Recruiting|January 2014|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|2000|Samples With DNA|Exhaled air samples being stored in specific adsorbent media Plasma/serum samples for group      stratification Faecal samples for occult blood testing and microbiota analysis Biopsy      samples from stomach and colon|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cancer patients (Group 1 and 5) will be predominantly enrolled at the time scheduled for        surgery, however also patients undergoing diagnostic procedures (endoscopy) will be        eligible        Patients without malignant disease but defined colorectal (Groups 2-4) status will be        predominantly enrolled prior colonoscopy in out-patient settings. Sampling starting from 1        week after colonoscopy will be allowed if the lesions will not get removed during the        index endoscopy        Patients without malignant disease but defined gastric mucosal status (Groups 6-8) status        will be predominantly enrolled prior upper endoscopy in out-patient settings. Sampling        starting from 2 days after upper endoscopy will be allowed if the lesions will not get        removed during the index endoscopy        Average cancer risk subjects (Group 9) will get enrolled by inviting individuals        predominantly selected from the lists of general practitioners.|January 2015|January 2, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332213||29797|
NCT02347735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC142073|Predictive Factors for Anastomotic Leakage After Colorectal Surgery|Predictive Factors for Anastomotic Leakage After Colorectal Surgery: The REVEAL Study|REVEAL|Maastricht University Medical Center|Yes|Not yet recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|628|Samples With DNA|Buccal swab|Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with colorectal cancer|February 2015|February 19, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347735||28607|
NCT02348008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCRC GU14-003|Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:|Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003||Big Ten Cancer Research Consortium|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|61|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348008||28587|
NCT02348021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14J01|Leaders Free Japan|BF-14J01 Drug Coated Stent (DCS) Clinical Trial||Biosensors Europe SA|No|Active, not recruiting|July 2014|July 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|139|||Both|N/A|N/A|No|||September 2015|September 28, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02348021||28586|
NCT02348034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-259|A Randomized Controlled Trial Exploring the Ability of Negative Pressure Wound Therapy (NPWT) to Reduce Colorectal Surgical Site Infections (SSI)|A Randomized Controlled Trial Exploring the Ability of Negative Pressure Wound Therapy (NPWT) to Reduce Colorectal Surgical Site Infections (SSI)||University of Saskatchewan|Yes|Recruiting|November 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|398|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348034||28585|
NCT02348307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-001|Single Dose Phase I Study of FYU-981|Single Dose Clinical Pharmacological Study of FYU-981 Administered to Healthy Male Adults (Phase I Study).||Fuji Yakuhin Co., Ltd.|No|Completed|March 2013|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|54|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02348307||28564|
NCT02348320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505074|Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy||Washington University School of Medicine|No|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||November 2015|November 20, 2015|January 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348320||28563|
NCT02348333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-002|Repeated Dose Phase I Study of FYU-981|Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Healthy Male Adults (Phase I Study).||Fuji Yakuhin Co., Ltd.|No|Completed|September 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02348333||28562|
NCT02353026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro028|Phase I Study of Intravenous Artesunate for Solid Tumors|A Phase I Study of Intravenous Artesunate in Patients With Solid Tumors||Georgetown University|Yes|Active, not recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353026||28203|
NCT02355587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPAND_1_Protocol- Amendment 1|Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes|An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes|EXPAND|Castle Biosciences Incorporated|No|Active, not recruiting|March 2014|February 2024|Anticipated|February 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with cutaneous melanoma for whom DecisionDx-Melanoma testing is to be clinically        performed.|January 2016|January 27, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02355587|10 Years|28006|
NCT02330640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zzheng|A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting|A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting|ATCCC|Chinese Academy of Medical Sciences, Fuwai Hospital|No|Not yet recruiting|March 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|140|||Both|18 Years|80 Years|No|||December 2014|January 2, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330640||29918|
NCT02339519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK4|A Comparison of Supraglottic Airway Devices|A Comparison of Supraglottic Airway Devices; Lma Classic, Lma Fastrach and Lma Supreme; a Prospective, Randomized, Clinical Trial of Efficacy, Safety and Complications||Umraniye Education and Research Hospital|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02339519||29237|
NCT02339571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02674|Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|September 2015|||June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|March 14, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339571||29233|
NCT02339623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 021|Fetal Adrenal Gland Volume Estimation in Prediction of Preterm Birth|Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth||Ain Shams Maternity Hospital|Yes|Recruiting|August 2014|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|78|||Female|18 Years|40 Years|No|Probability Sample|Women who are diagnosed as having threatened preterm labour based on the American college        of obstetricians and gynaecologists guidelines (ACOG,2003) :          -  Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )          -  Cervical dilataion >1cm, &/or          -  Cervical effacement ≥ 80%|January 2015|January 13, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339623||29229|
NCT02329314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-365-61-01|The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）|The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）||ShuGuang Hospital|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Probability Sample|This experiment will screen and collect qualified casefrom medical records in Shuguang        Hospital.to collect the patients with liver injury in clinic, including (1) conforms to        ALT>1.5 times the normal value or >70IU/L, age 18 to 70 years of age, sex is not limited;        (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease,        or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear        leading to abnormal liver function ; (3) except for tumor patients.|December 2014|December 30, 2014|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329314||30019|
NCT02334215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3U01DA013636|A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail|A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail|SOMATICS FRI|Friends Research Institute, Inc.|Yes|Recruiting|December 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02334215||29643|
NCT02334982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-137_101|Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects||Takeda|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 6, 2015|No|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT02334982||29584|
NCT02334995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRUS-BF|The Biofeedback Therapy in Solitery Rectal Ulser Patients BIOFEEDBACK THERAPY|The Biofeedback Therapy in Solitery Rectal Ulser Patients||Ege University|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Probability Sample|Patients with solitary rectal ulser|January 2016|January 24, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02334995||29583|
NCT02334462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150044|Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali|Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2014|December 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334462||29624|
NCT02334475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9154/PG-2Trg/2012/20886|Steroid Versus Platelet Rich Plasma Injection for Chronic Low Back Pain|Steroid Versus Platelet Rich Plasma in Ultrasound Guided Sacroiliac Joint Injection for Chronic Low Back Pain||Postgraduate Institute of Medical Education and Research|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||January 2015|January 7, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02334475||29623|
NCT02334488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMéTé|Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function|Prospective Multicenter Randomized Openlabel Study to Evaluate the Benefit on Renal Function at 12months Post-transplantation of Immunosuppressive Treatment With Withdrawal of Calcineurin Inhibitor at 3months and Combining Mycophenolate Sodium-Everolimus Versus Tacrolimus-Everolimus, in Patients With de Novo Kidney Transplant||Poitiers University Hospital|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02334488||29622|
NCT02340234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS29250|A Study of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis|A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH PERSISTENT MODERATE TO SEVERE ATOPIC DERMATITIS THAT IS INADEQUATELY CONTROLLED BY TOPICAL CORTICOSTEROIDS||Hoffmann-La Roche||Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340234||29182|
NCT02328339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF-BEV-1797|Tea and Forearm Blood Flow|Forearm Blood Flow Response to Acute Consumption of Black Tea||Unilever R&D|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02328339||30094|
NCT02331992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-146|Positive Airway Pressure Program|Positive Airway Pressure Program||Fisher and Paykel Healthcare|No|Active, not recruiting|February 2015|September 2015|Anticipated|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02331992||29814|
NCT02336048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29448|A Study Evaluating the Safety of Tocilizumab Plus Standard of Care Premedication Given Before Obinutuzumab+Chlorambucil Administration in Patients With Untreated B-Cell Chronic Lymphocytic Leukemia Who Have Comorbidities|||Hoffmann-La Roche||Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336048||29503|
NCT02337465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6Y14|KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer|Integrated 3D X-ray and Ultrasound Guided Radiation Therapy of Soft Tissue Targets||Case Comprehensive Cancer Center|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|19 Years|N/A|No|||March 2016|March 11, 2016|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337465||29394|
NCT02352896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI743-13-023|Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome|EPI743-13-023: Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome||Edison Pharmaceuticals Inc|No|Enrolling by invitation|January 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|1 Year|18 Years|No|||September 2015|September 14, 2015|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352896||28213|
NCT02352922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloridaH|Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy|A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy||Florida Hospital|No|Recruiting|July 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02352922||28211|
NCT02355184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140_CD 01-Extension|An Extension of Protocol PRO 140_CD01 TS Study|Extension of Protocol PRO140_CD01 to Evaluate Long-term Suppression of HIV-1 Replication Following Substitution of Stable Combination ART With PRO 140 (Monoclonal CCR5 Antibody) Monotherapy for Additional 108 Weeks in Adult Subjects w/ HIV-1||CytoDyn, Inc.|Yes|Recruiting|November 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02355184||28037|
NCT02352961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUR2-4-121|An Implementation Science Study Investigating Profiles of Men Interested in MMC|An Implementation Science Study Investigating Profiles of Men Interested in Medical Male Circumcision (MMC), Barriers and Methods to Increase the Uptake of MMC Among Older Men in South Africa|Imbizo|The Aurum Institute NPC|No|Completed|April 2014|December 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|2817|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males 18 and above accessing medical male circumcision services in Ekurhuleni North, South        Africa        Females 18 and above who live in the vicinity of Ekurhuleni North, South Africa|January 2016|January 27, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352961||28208|
NCT02352974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAGNODE-1|GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)|Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd®) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen|DIAGNODE|Linkoeping University|No|Recruiting|January 2015|July 2018|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|30 Years|No|||March 2015|March 13, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02352974||28207|
NCT02355457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4306|Biomarkers in Acute Cardiac Care|Biomarkers in Acute Cardiac Care|BACC|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|July 2013|December 2017|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|blood samples, white blood cells.|Both|18 Years|N/A|No|Probability Sample|All patients presenting with acute chest pain in the chest pain unit of the University        Hospital Hamburg-Eppendorf.|November 2015|November 13, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355457|4 Years|28016|
NCT02341430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|689069|A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh|A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh||Anne Arundel Health System Research Institute|No|Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341430||29090|
NCT02328066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC14/47|Diagnostic Accuracy of NICE Classification to Predict Deep Submucosal Invasion|Diagnostic Accuracy of NICE Classification to Predict Deep Submucosal Invasion in Colon Lesions. Prospective Multicenter Study in Routine Clinical Practice|NICE|Asociación Española de Gastroenterología|No|Recruiting|July 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1921|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02328066||30115|
NCT02328300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1327|FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions|FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|UNC Hospitals|October 2015|October 13, 2015|August 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02328300||30097|
NCT02328534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlBarakaSD1|Semen Processing for ICSI Using Swim-down and Density Gradient Methods|Novel Approach of Semen Preparation to Improve ICSI Outcome.||Al Baraka Fertility Hospital|No|Completed|March 2007|January 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|890|Samples With DNA|Semen samples Embryos processed after ICSI and IVF cycles.|Both|20 Years|38 Years|No|Probability Sample|Cases collected were submitted for ART treatment using ICSI/IVF procedures. In two        different IVF clinics at Manama-Bahrain and Sohag-Egypt. The groups of about 890 couple        prepared for treatment.|December 2014|December 30, 2014|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02328534||30079|
NCT02329028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/13/03/02/2013|Feasibility of Mini-EEG in the Prehospital Setting|Feasibility of Mini-EEG in the Prehospital Setting||Helsinki University Central Hospital|Yes|Recruiting|January 2015|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Unconscious patients in the prehospital field|August 2015|August 19, 2015|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02329028|4 Weeks|30041|
NCT02333968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM 2011-5079|Self-management Support in Cancer Pain|Effects of a Multifaceted Teleguided Pain Care Program in Patients With Cancer Pain||Maastricht University Medical Center|No|Recruiting|February 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|174|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02333968||29662|
NCT02339350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO_HRALL|Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children|Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children||The Korean Society of Pediatric Hematology Oncology|Yes|Recruiting|January 2015|April 2023|Anticipated|April 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|1 Year|21 Years|No|||January 2015|January 15, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339350||29250|
NCT02342717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346.10|Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects|Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)||Boehringer Ingelheim||Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 15, 2015||||No||https://clinicaltrials.gov/show/NCT02342717||28991|
NCT02339948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21C-2006-01|Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Intensity Modulated Radiation Therapy (IMRT) in the Treatment of Patients With Clinically Confined Prostate Adenocarcinoma||21st Century Oncology|No|Recruiting|June 2006|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339948||29204|
NCT02339714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMH001|Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis|Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial||China Academy of Chinese Medical Sciences|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339714||29222|
NCT02335788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-EPE-0028|EMBA Peripheral Embolization Device ("EPED") Study|EMBA Peripheral Embolization Device ("EPED") Study|EPED|EMBA Medical, Inc.|Yes|Recruiting|February 2015|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|February 9, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02335788||29523|
NCT02329054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-63|Efficacy of Favipiravir Against Ebola (JIKI)|Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea|JIKI|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|December 2014|September 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|1 Year|N/A|No|||March 2015|December 18, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02329054||30039|
NCT02355093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACB vs FNB|Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically|Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Enrolling by invitation|July 2014|October 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02355093||28044|
NCT02355106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-001|Prospective, Multicenter, Investigation of the Adagio System in Subjects With Atrial Flutter|||Adagio Medical|No|Recruiting|January 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||January 2015|January 30, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02355106||28043|
NCT02355197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124|Antioxidants in Gestational Diabetes|Physiological Effects of Gestational Diabetes on the Placenta and Neonatal Outcome; Role of Antioxidant Administration||Cairo University|Yes|Recruiting|January 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|20 Years|40 Years|No|||January 2015|February 3, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02355197||28036|
NCT02355275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR05|Thera-Band® HEP for LBP Secondary Prevention|Thera-Band® Based Home Exercise Program for Low Back Pain Secondary Prevention|TBKT_HEP|Sport and Spine Rehab Clinical Research Foundation|No|Terminated|January 2015|||January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|January 30, 2015||No|large non-response rate|No|January 11, 2016|https://clinicaltrials.gov/show/NCT02355275||28030|
NCT02355288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130910|Left Internal Thoracic Artery Bypass Versus Percutaneous Revascularization in Diabetics|Left Internal Thoracic Artery Bypass Versus Percutaneous Revascularization in Diabetics:Is Minimally Invasive Left Internal Thoracic Artery Bypass Superior to Percutaneous Revascularization in Diabetic Patients With Isolated LAD Stenosis?|LIBERTI|Ottawa Heart Institute Research Corporation|Yes|Not yet recruiting|May 2016|October 2019|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02355288||28029|
NCT02330146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-01-001-2014|Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|ReaCT|RepliCel Life Sciences, Inc.|Yes|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|January 5, 2016|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02330146||29955|
NCT02330367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC201410AVTN02(v1.0)|Safety, Pharmacokinetic and Preliminary Efficacy Study of Avitinib in Patients With Definitely EGFR T790M State NSCLC|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent||Hangzhou ACEA Pharmaceutical Research Co.,Ltd.|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|172|||Both|18 Years|75 Years|No|||October 2015|November 4, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330367||29938|
NCT02332746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308009564|Exploring Temporal Relationships Between Self-worth and Physical Activity Middle-aged Women|Novel Exploration of Temporal Relationships Between Self-worth and Physical Activity in Middle-aged Women||Arizona State University|No|Completed|September 2013|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Female|35 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nationally recruited sample of active and inactive middle-aged women (35-64 years-old)|January 2015|January 5, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02332746||29756|
NCT02332980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1485|Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas|A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)||Mayo Clinic|Yes|Recruiting|February 2015|||January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332980||29738|
NCT02333253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase|Delayed Start vs Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase.||Cairo University|Yes|Completed|January 2015|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|35 Years|44 Years|No|||January 2016|January 26, 2016|January 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333253||29717|
NCT02333474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FudaCH|Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient|Safety Issue and Efficacy of Combining Mix Vaccine and Standard Therapy in the Treatment of Lung Carcinoma Patient||Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2015|September 8, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02333474||29700|
NCT02333487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15859A|Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700|Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|December 2014|||February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|60 Years|No|||February 2016|February 12, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333487||29699|
NCT02333708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00273-44|Study of Circulating Microparticles in Giant Cell Arteritis|Study of Circulating Microparticles in Giant Cell Arteritis|MicroGiant|University Hospital, Caen||Not yet recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary and secondary care hospital|January 2015|January 6, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333708||29682|
NCT02341612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/FS-UnB 234/13|Cold Therapy in the Treatment of Exercise-induced Muscle Damage|Effects of Different Cold Therapy Modalities on Muscular Recovery and Inflammatory Responses Following Exercise-induced Muscle Damage in Healthy Men||University of Brasilia|Yes|Completed|December 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|65|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02341612||29076|
NCT02342743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50207|Open-trial on the Prevention of Chronic Migraines With the CEFALY Device|Open-trial on the Prevention of Chronic Migraines With the CEFALY Device||Cefaly Technology|No|Recruiting|February 2015|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342743||28989|
NCT02339389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P00152|Does Maternal Fever During Labor Analgesia Has Any Relationship With Maternal Ventilation?|Does Maternal Fever During Labor Analgesia Has Any Relationship With Maternal Ventilation?|matvent|Brigham and Women's Hospital|No|Recruiting|December 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|40 Years|No|Non-Probability Sample|Informed consent will be obtained by one of the licensed physician investigators at the        earliest opportunity when the subject arrives on the labor suite and following contact        with their provider. While the timing between subject arrival and request for neuraxial        analgesia can be variable, in subjects who present in early labor at less than 5 cm        cervial dilation, there is often several hours available for a subject to consider 1)        whether they desire a central neuraxial technique during labor, and 2) whether they would        be willing to participate in this study.|January 2015|January 14, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02339389||29247|
NCT02327156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC-IRB-2014-1|Dexmedetomidine as an Adjuvant for Sub-Tenon's Anesthesia|The Effect of a Low-dose Dexmedetomidine as an Adjuvant to Levobupivacaine in Patients Undergoing Vitreoretinal Surgery Under Sub-Tenon's Anesthesia|Precedex|Magrabi Eye & Ear Hospital|Yes|Completed|January 2014|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327156||30185|
NCT02340325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00143|FS2 Safety and Tolerability Study in Healthy Volunteers|The Safety of Topically Delivered FS2 in Humans. Phase 1 Clinical Trial||British Columbia Professional Firefighters' Burn and Wound Healing Laboratory|No|Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02340325||29175|
NCT02339961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP22_4|Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)||Echosense Ltd.|No|Withdrawn|February 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|November 29, 2015|January 13, 2015||No|No patients|No||https://clinicaltrials.gov/show/NCT02339961||29203|
NCT02339974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140131|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation|HOVER|Temple University|Yes|Recruiting|January 2015|January 2021|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|22 Years|N/A|No|||November 2015|November 2, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339974||29202|
NCT02344888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA1|Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS|Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome||Mansoura University|No|Recruiting|February 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|35 Years|No|||March 2016|March 4, 2016|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02344888||28826|
NCT02345135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFECTION_AT2012|Susceptibility to Infections in Ataxia Telangiectasia|Susceptibility to Infections in Patients With Ataxia Telangiectasia : A Prospective Follow-up Study||Johann Wolfgang Goethe University Hospitals|No|Enrolling by invitation|September 2012|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Both|2 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345135||28807|
NCT02345148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106172|Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (>= 75 Years of Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive)||Janssen Research & Development, LLC|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345148||28806|
NCT02334527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1406|Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy|Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|March 2015|January 2025|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334527||29619|
NCT02334540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412M57002|Satiety Effects of Pulses Compared to Matched Protein Smoothie|Satiety Effects of Pulses Compared to Matched Protein Smoothie||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334540||29618|
NCT02334553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMi-02-1-02|Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma|Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma.|S-1226(8%)|SolAeroMed Inc.|Yes|Recruiting|January 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|40 Years|No|||November 2015|November 6, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02334553||29617|
NCT02334800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481013|A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib|A Phase 1, Open-Label, Single Dose, Parallel-Cohort Study To Evaluate The Pharmacokinetics Of Palbociclib (PD-0332991) In Subjects With Impaired Hepatic Function||Pfizer|No|Recruiting|March 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|28|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334800||29598|
NCT02337452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0715|The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families|The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2015|||April 2048|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with genetic abnormalities and their families at MD Anderson Cancer Center in        Houston, Texas|February 2016|February 9, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337452|40 Years|29395|
NCT02337907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.7|BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.|A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease||Boehringer Ingelheim||Recruiting|January 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Anticipated|293|||Both|55 Years|N/A|No|||March 2016|March 21, 2016|December 23, 2014||||No||https://clinicaltrials.gov/show/NCT02337907||29360|
NCT02337920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA-NIRS|Prediction of Femoral Revascularization Quality Using the Somatic NIRS Signal|Prediction of Femoral Revascularization Quality Using the Somatic NIRS Signal|TEA-NIRS|University Hospital, Caen|No|Recruiting|April 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing unilateral femoral endarteriectomy|July 2015|July 30, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02337920||29359|
NCT02338128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPD2015|The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients|The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study||Shanghai 10th People's Hospital|Yes|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Peritoneal dialysis patients with hyperuricemia|January 2015|January 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338128||29343|
NCT02341547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT14-HPP-003|Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'|A Prospective, Observational, Non-inferiority Study to Assess the Effectiveness of a Biosimilar Epoetin Alfa in Maintaining Haemoglobin Levels in Stable 'End Stage Renal Failure' Patients on Haemodialysis||Penang Hospital, Malaysia|No|Not yet recruiting|February 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|44|||Both|12 Years|N/A|No|Non-Probability Sample|End Stage Renal Failure (ESRF) patients stable on Eprex who are switched over to Binocrit|January 2015|January 18, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02341547||29081|
NCT02341573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 12401905500|Experienced Chinese Herbal Formulas on Pediatric Asthma|Effect of Experienced Chinese Herbal Formulas Based on Different Stages and Different Symptoms on Pediatric Asthma: a Single-blinded Randomized Controlled Trial||Children's Hospital of Fudan University|Yes|Completed|March 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|182|||Both|3 Years|12 Years|No|||August 2015|August 10, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02341573||29079|
NCT02340312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|490390|Functional Dyspepsia Microbiome Study|Evaluation of the Duodenal Microbiome in Pediatric Functional Dyspepsia||Children's Mercy Hospital Kansas City|No|Recruiting|January 2015|||January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Collection of .5 aggregate of doudenal tissue. Collection of stool samples.|Both|8 Years|17 Years|No|Non-Probability Sample|Children and adolecents ages 8 to 17 inclusive that have been diagonsed with functional        dyspepsia and are scheduled to have a EGD with biopsy.|January 2015|January 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02340312||29176|
NCT02342704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS408|Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants|A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects|REVEAL|Biogen||Terminated|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 15, 2015|Yes|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT02342704||28992|
NCT02330887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GroupANCnyaya|Group Antenatal Care: The Power of Peers for Increasing Skilled Birth Attendance in Achham, Nepal|Group Antenatal Care: The Power of Peers for Increasing Skilled Birth Attendance in Achham, Nepal||Possible|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1800|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330887||29899|
NCT02330900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-245|Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators|Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators||University Hospital, Geneva|No|Recruiting|November 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02330900||29898|
NCT02327871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB 2014: AO-1145-42|Esophageal Temperature Management After Cardiac Arrest|Targeted Temperature Management With Therapeutic Hypothermia Using Esophageal COOLing After Cardiac Arrest: THE COOL STUDY|THE-COOL|IST cardiology|No|Recruiting|December 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327871||30130|
NCT02331420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4569/14|Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients|Prospective Randomized Controlled Trial on the Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Progression of Atherosclerosis in Obese, Type II Diabetic Patients|BASTA|Catholic University of the Sacred Heart||Not yet recruiting|February 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|58|||Both|40 Years|70 Years|No|||January 2015|January 5, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331420||29858|
NCT02335255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFTC 1409|Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis|A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis.||Taro Pharmaceuticals USA|No|Completed|June 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|690|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335255||29563|
NCT02339753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH_carboplatinPK|Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation|Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation||The Korean Society of Pediatric Hematology Oncology|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|19 Years|No|||January 2015|January 15, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02339753||29219|
NCT02339805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB13.03|Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS|Assessment of the Minimal Residual Disease in Diffuse Large B-Cell Lymphomas (DLBCL) From Cell-free Circulating DNA by Next Generation Sequencing (NGS)|LymphoSeq|Centre Henri Becquerel|No|Active, not recruiting|November 2014|July 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339805||29215|
NCT02328794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820451|Randomized Clinical Trial to Reduce Harm From Tobacco|Randomized Clinical Trial to Reduce Harm From Tobacco||University of Pennsylvania|No|Not yet recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|6000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02328794||30059|
NCT02333526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syndecan-NOM|Syndecan 1 as Biomarker for Inflammation|Soluble Syndecan 1 as Biomarker for Acute and Chronic Bowel Inflammation||Helios Albert-Schweitzer-Klinik Northeim|No|Not yet recruiting|February 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|44|Samples Without DNA|blood serum for soluble Syndecan 1 and CRP Leucocyte cound Blood panel Stool analysis for      calprotectin|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with inflammatoy bowel disease, infectious colitis and healthy volunteers|February 2016|February 17, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333526|2 Days|29696|
NCT02333539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK091558|Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents With Type 1 Diabetes|Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents|Pump It Up!|Florida State University|Yes|Recruiting|September 2012|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|10 Years|17 Years|No|||February 2016|February 1, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333539||29695|
NCT02340286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202870|Pilot Study for Determination of Total Energy Expenditure and Fat Oxidation in Children|Pilot Study for Determination of Total Energy Expenditure and Fat Oxidation in Children.||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|September 2014|December 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|2 Years|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 toddlers born from mothers of the Glowing study (NCT01131117)|September 2015|September 9, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02340286||29178|
NCT02344407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915071|Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)|Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|28170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|November 21, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344407||28863|
NCT02344654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-HVH-LLS-01|Fluorescence Cholangiography During Cholecystectomy - a RCT|Fluorescence Cholangiography Versus X-ray Cholangiography During Laparoscopic Cholecystectomy for Complicated Gallstone Disease||Hvidovre University Hospital|Yes|Enrolling by invitation|May 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02344654||28844|
NCT02329613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/BH-01|Introduction of an Enriched Evening Meal on the Feeding Behavior of Institutionalized Residents|Impact of the Introduction of a New Qualitative Composition of the Evening Meal on the Feeding Behavior of Institutionalized Residents of a Long-term Care Unit: a Randomized, Single Center Study|IRCAR|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|75 Years|N/A|No|||November 2015|November 6, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329613||29996|
NCT02329899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-246|Standardisation of Investigations of Mild Bleeding Disorders|Standardisation of Investigations of Mild Bleeding Disorders|MBD|University Hospital, Geneva|No|Active, not recruiting|July 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|2 aliquots of plasma from 2x 6 ml EDTA blood 2 aliquots of plasma from 2 x 2.7 ml citrate      blood 2 aliquots of plasma from 1 x 4 ml heparin blood Storage at -80°C|Both|2 Years|N/A|No|Non-Probability Sample|Patients (children or adults) referred to a tertiary care center (haemostasis unit) for        investigation of mild bleeding symptoms (with suspicion of mild bleeding disorder)|December 2015|December 22, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329899||29974|
NCT02341066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H89D14000850003|Endothelial Dysfunction Evaluation for Coronary Heart Disease Risk Estimation in Rheumatoid Arthritis (EDRA Study)|Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.|EDRA|Azienda Ospedaliero Universitaria di Sassari|No|Recruiting|July 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|45 Years|84 Years|No|Non-Probability Sample|Three thousand consecutive RA patients free of overt cardiovascular disease|February 2016|February 25, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341066||29118|
NCT02341144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41103|Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair|Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair: A Prospective, Randomized Study||All Children’s Hospital Johns Hopkins Medicine|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|58|||Both|3 Years|18 Years|No|||December 2015|December 28, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02341144||29112|
NCT02339935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141265|Improving Hospitalizations for Children With ASD|Improving Hospitalizations for Children With ASD: Testing the Cost and Clinical Efficacy of Integrated Behavioral Intervention||Vanderbilt University|No|Enrolling by invitation|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|6 Years|18 Years|No|||September 2015|September 22, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02339935||29205|
NCT02340026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011172|Cerebral Palsy Early Mobility Training|Dynamic Supported Mobility for Infants and Toddlers With Cerebral Palsy|iMOVE|Children's Hospital of Philadelphia|No|Recruiting|December 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|12 Months|36 Months|No|||October 2015|October 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02340026||29198|
NCT02340039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF2015|Effects of Fruit Extracts on Glycaemia: The GLU-FRU Study|The Acute Effects of Blackcurrant and Apple Extracts on Postprandial Glycaemia: a Randomised Controlled Trial. The GLU-FRU Study|GLU-FRU|King's College London|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|34|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 23, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340039||29197|
NCT02340117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT53-02-1|Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer|Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer||SynerGene Therapeutics, Inc.|No|Recruiting|January 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340117||29191|
NCT02340208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDOS002|A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47|A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients||Helix BioPharma Corporation|Yes|Recruiting|May 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340208||29184|
NCT02330614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-18|Personality Bleaching|Is the Personality Relevant in the Choice of Bleaching ?|NEOFFI|University of Chile|Yes|Completed|July 2013|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|128 patients between 18 and 76 years who attended the Operative Dentistry Clinic at Dental        School, Universidad de Chile, were included in the study|December 2014|December 31, 2014|December 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02330614||29920|
NCT02335801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSCA0001|The TOSCA Registry: Hormonal and Metabolic Deficiencies in Chronic Heart Failure|The TOSCA Registry: Epidemiology, Clinical and Prognostic Value of Hormonal and Metabolic Deficiencies in Chronic Heart Failure|TOSCA|Federico II University|Yes|Recruiting|April 2013|January 2018|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|650|Samples Without DNA|serum for determination of hormonal levels|Both|18 Years|N/A|No|Non-Probability Sample|patients with stable chronic heart failure with reduced ejection fraction|December 2014|January 9, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02335801|30 Months|29522|
NCT02335814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLX925-01|First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia||FLX Bio, Inc.|No|Recruiting|January 2015|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|123|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335814||29521|
NCT02335268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440/47 EUROPE|VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA|PROSPECTIVE VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME (MDS) AND THROMBOCYTOPENIA - THE EUROPE-TRIAL|EUROPE|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Yes|Recruiting|June 2015|September 2020|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335268||29562|
NCT02340052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-AG-2014|Pain Map DK: a Prospective Cohort Study of Pain Treatment in 500 Hip Arthroplasty Patients at Different Danish Hospitals|||Koege Sygehus|Yes|Recruiting|April 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Total hip arthroplasty patients|January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340052||29196|
NCT02339896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5704|Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children|Observation an Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) With or Without Rabies Immunoglobulin in Children||Queen Saovabha Memorial Institute|No|Enrolling by invitation|February 2014|January 2016|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|45|Samples Without DNA|Rabies Neutralizing antibody|Both|1 Year|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|recruit the patients from Rabies clinic of Queen Saovabha Memorial Institute, Thammasat        Hospital, Charoen Krung Pracha Rak Hospital and HRM Princess Maha Chakri Sirindhorn        Medical Center and all had experienced WHO category II or III exposure to suspected rabid        animal. In patients with WHO category III have to receive a heterologous biological (ERIG        or HRIG)|January 2015|January 15, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339896|365 Days|29208|
NCT02341911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2015-16|Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)|A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|TNBC|Fudan University|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|70 Years|No|||December 2015|December 24, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02341911||29053|
NCT02341924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:113|Validating the "Foods for Health" Portfolio of Functional Food Products|Validating the "Foods for Health" Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy||University of Manitoba||Recruiting|September 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02341924||29052|
NCT02329925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01333|The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea|The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea||University of British Columbia|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02329925||29972|
NCT02329366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14328|Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers|||Winthrop University Hospital|No|Recruiting|December 2014|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|In this study, diabetic patients undergoing Diabetic Foot Ulcer debridement under the      standard of care will be asked for their permission to collect the debrided tissue for use      in scientific research.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Both male and female patients at Winthrop University Hospital over the age of 18 with Type        2 Diabetes and a Diabetic Foot Ulcer are eligible for enrollment.|December 2015|December 7, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329366||30015|
NCT02334007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHHVTE_Pilot|Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis--Pilot Trial|Extended Low-Molecular Weight Heparin VTE Prophylaxis in the Thoracic Surgery Population--a Randomized Controlled Pilot Study||McMaster University|Yes|Recruiting|September 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334007||29659|
NCT02334254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anzhen2013009|Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention|Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention||Beijing Anzhen Hospital|Yes|Recruiting|August 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|80 Years|No|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334254||29640|
NCT02342080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0718.0.015.000-11|Effects of System Suspended Robotic Lokomat Gait in Patients With Incomplete Spinal Cord Injury|Effects of System Suspended Robotic Lokomat Gait in Patients With Incomplete Spinal Cord Injury||University of Sao Paulo General Hospital|Yes|Completed|March 2013|February 2015|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|60 Years|No|||May 2015|May 8, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342080||29040|
NCT02342119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13100511|Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation|Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation||University of Pittsburgh|No|Recruiting|May 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1289|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02342119||29037|
NCT02342132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00473|Methods to Improve Expiratory Cough Flow and Lung Volume in Children With NMDs|A Comparison of Three Methods for Improving Expiratory Cough Flow and Lung Volume in Children With Neuromuscular Diseases||University of British Columbia|No|Completed|August 2014|February 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|5 Years|N/A|No|||March 2015|March 5, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02342132||29036|
NCT02329574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002202|Prediction of Persistent Post-Mastectomy Pain|Prediction of Persistent Post-Mastectomy Pain||Brigham and Women's Hospital|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|saliva|Female|18 Years|80 Years|No|Probability Sample|Women undergoing partial or total mastectomy|July 2015|July 28, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329574||29999|
NCT02329587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405-003|Transcranial Direct Current Stimulation Augmented Exposure and Response Prevention for Obsessive-Compulsive Disorder|tDCS for Inhibitory Control Deficits: A Test in OCD||Butler Hospital|Yes|Recruiting|January 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||July 2015|July 28, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329587||29998|
NCT02329873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER-100-202|Respiratory Rehabilitation Exercises in Older Adults With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Efficacy of the Respiratory Rehabilitation Exercise Training Package in Hospitalized Elderly Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Randomized Control Trial||Chest Hospital, Ministry of Health and Welfare, Taiwan|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|61|||Both|65 Years|N/A|No|||December 2014|December 30, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02329873||29976|
NCT02330120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intensive care|Effects of Dexmedetomidine and Propofol on Pulmonary Mechanics|||Cukurova University|No|Completed|January 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|90 Years|No|||December 2015|December 9, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02330120||29957|
NCT02330341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-ESTRAGON|Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion|Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion||University of Guadalajara|Yes|Completed|December 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|60 Years|No|||November 2015|November 30, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330341||29940|
NCT02334774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411079RIND|Effects of An Oral Swallowing Care Program on Swallowing and Oral Intake Status in Patients Following Prolonged Endotracheal Intubation|Effects of An Oral Swallowing Care Program on Swallowing and Oral Intake Status in Patients Following Prolonged Endotracheal Intubation||National Taiwan University Hospital|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|50 Years|N/A|No|||August 2015|August 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334774||29600|
NCT02339883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150057|Physiological and Psychosomatic Effects of Exposure to MRI Scanning Environment|Physiological and Psychosomatic Effects of Exposure to MRI Scanning Environment||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|50|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02339883||29209|
NCT02334787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-14-001|A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects|A Single-center, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Assess the Safety and Pharmacokinetics of OPA-15406 Ointment in Healthy Adult Male Subjects (Phase 1 Trial)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02334787||29599|
NCT02337673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannesGU-EIT-01|Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography|Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography in Intensive Care Patients Undergoing Epigastric Surgery||Johannes Gutenberg University Mainz|No|Completed|May 2014|March 2016|Actual|March 2016|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Probability Sample|Patients of a primary care clinic (university hospital) undergoing elective epigastric        surgery by laparotomy in general anesthesia with elective postoperative intensive care        surveillance.|March 2016|March 22, 2016|May 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02337673|7 Days|29378|
NCT02337686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0820|Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma|Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337686||29377|
NCT02340130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301-PG-PSC-203|Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma|A Multicentre, Open Label, Phase IIb Clinical Trial to Evaluate Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites Mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides Pteronyssinus / Lepidoglyphus Destructor and DP/MG/14-2 Dermatophagoides Pteronyssinus /Blomia Tropicalis) in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma||Laboratorios Leti, S.L.|Yes|Recruiting|September 2014|March 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|70 Years|No|||July 2015|July 29, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340130||29190|
NCT02340143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6025|Assessing Early Behavioral Indicators of Formula Tolerance|Assessing Early Behavioral Indicators of Formula Tolerance||Mead Johnson Nutrition|No|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|92|||Both|N/A|28 Days|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02340143||29189|
NCT02339844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-149|Pan European Collaboration on Antipsychotic Naïve Schizophrenia II|Pan European Collaboration on Antipsychotic Naïve Schizophrenia II|PECANS II|University of Copenhagen|Yes|Recruiting|January 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02339844||29212|
NCT02339857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102881|The Long-term Results of the No-touch Vein Graft to the Left Anterior Descending Artery.|The Long-term Results of Coronary Artery Bypass Surgery When the No-touch Vein Graft is Anastomised to the Left Anterior Descending Artery.||Örebro County Council|No|Completed|November 2011|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|N/A|N/A|No|Non-Probability Sample|All patients that performed coronary artery bypass surgery between 2003-2008 and received        a no-touch saphenous vein graft to the left anterior descending artery were included        consecutively.|January 2015|January 15, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339857||29211|
NCT02340247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-GALDE-14|Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on GLP-1 Secretion After Roux-en-Y Gastric Bypass||Hvidovre University Hospital|Yes|Recruiting|November 2014|||April 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Both|N/A|N/A|No|||January 2015|January 13, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340247||29181|
NCT02340260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/801|Time Efficient Exercise in Type 2 Diabetes|Effects of Time Efficient Low-volume Interval Exercise on Cardiometabolic Risk Factors in Individuals With Type 2 Diabetes||Norwegian University of Science and Technology|No|Completed|August 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|20 Years|65 Years|No|||January 2015|January 12, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02340260||29180|
NCT02329938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM200956|Desarda Repair for Inguinal Hernia|Desarda Versus Lichtenstein's Repair for Inguinal Hernia: a Comparative Study||Mansoura University||Completed|December 2010|December 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02329938||29971|
NCT02333747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2014-12-003|Can Transcutaneous Electrical Acupoint Stimulation Improve the Quality of Recovery After Thyroidectomy?|The Effects of Transcutaneous Electrical Acupoint Stimulation on the Quality of Recovery After Thyroidectomy Surgery||Fujian Provincial Hospital|Yes|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|84|||Female|18 Years|60 Years|No|||July 2015|February 21, 2016|January 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333747||29679|
NCT02333760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNT-WAS-03|Gene Therapy for WAS Follow-up|Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).|WAS FUP|Genethon|No|Recruiting|September 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Male|N/A|N/A|No|||February 2016|February 15, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02333760||29678|
NCT02340884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-N114|A Pilot RCT of the PRISM Intervention for AYAs With Cancer|A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults With Cancer||Seattle Children's Hospital|Yes|Recruiting|January 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|13 Years|25 Years|No|||November 2015|November 16, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02340884||29132|
NCT02340949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-1402|Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer|Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II Randomized, Multicenter, Open Label Trial|RIA|Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Recruiting|January 2015|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|69 Years|No|||February 2015|February 10, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02340949||29127|
NCT02340962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-2349-03|A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection|A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.||TaiGen Biotechnology Co., Ltd.|Yes|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340962||29126|
NCT02330952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM13195|Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD|Efficacy and Safety of Oral Corticosteroids for the Treatment of Acute Exacerbations of COPD in General Practice|BECOMEG|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1014|||Both|40 Years|N/A|No|||July 2015|July 27, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02330952||29894|
NCT02331212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU # 74A14|Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer|Role of Hyaluronic Acid in Cancer Stem Cell Niche||Comprehensive Cancer Center of Wake Forest University|No|Suspended|March 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Female|20 Years|60 Years|No|Non-Probability Sample|Patients with newly diagnosed, histologically confirmed primary and/or metastatic breast        cancer|November 2015|November 5, 2015|December 23, 2014||No|Working out logistical issues|No||https://clinicaltrials.gov/show/NCT02331212||29874|
NCT02333721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03|Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer|Study on Long-term Outcome of Laparoscopic Spleen-Preserving D2 Lymphadenectomy With and Without No. 10 Lymph Node Dissection for Advanced Gastric Cancer|LSPLN|Fujian Medical University|Yes|Active, not recruiting|January 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|536|||Both|10 Years|75 Years|No|||March 2015|March 5, 2015|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02333721||29681|
NCT02333981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1234|Efficacy of Passive Oral Motor Therapy on Drooling in Children With Multiple Disabilities|Efficacy of Passive Oral Motor Therapy on Drooling in Children With Multiple Disabilities||Maharishi Markendeswar University||Completed|August 2012|May 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|7 Years|19 Years|No|||January 2015|January 7, 2015|January 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02333981||29661|
NCT02334228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Concord InSHAPE|Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness|Promoting Health and Functioning in Persons With SMI||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|133|||Both|21 Years|N/A|No|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334228||29642|
NCT02334501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA-NER-0101|Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects|An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Effect of Lansoprazole on the Pharmacokinetics of Neratinib in Healthy Subjects||Puma Biotechnology, Inc.|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|January 7, 2015|October 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02334501||29621|
NCT02339792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM87SA2B|E-learning to Improve the Quality of Drug Prescribing in Hospitalized Elderly Patients|Effect of an Integrated E-learning Intervention, Focused on Comprehensive Geriatric Assessment to Improve the Quality of Drug Prescribing in Hospitalized Elderly Patients||Mario Negri Institute for Pharmacological Research|Yes|Completed|November 2012|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|697|||Both|75 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02339792||29216|
NCT02327637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140455|A Comparison of Bed Rest Versus Moderate Activity in Preterm Premature Rupture of Membranes (PPROM)|A Comparison of Bed Rest Versus Moderate Activity Among Inpatient Antepartum Patients With Preterm Premature Rupture of Membranes (PPROM): A Randomized Controlled Trial|PACT|University of California, San Diego|Yes|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02327637||30148|
NCT02335281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU-DP-GI-FMT-001|Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease|Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel Disease|SFMT-IBD|Third Military Medical University|Yes|Recruiting|January 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|70 Years|No|||January 2015|January 8, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335281||29561|
NCT02328092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rSMS in nocturnal enuresis|A Double-blind Randomized Clinical Trial on the Efficacy of Magnetic Sacral Roots Stimulation for the Treatment of Nocturnal Enuresis|Therapeutic Effect of Sacral Root Stimulation on Nocturnal Enuresis||Assiut University|No|Completed|May 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|7 Years|20 Years|No|||December 2014|December 26, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328092||30113|
NCT02328105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-LUN-ABR-001|LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer|LCI-LUN-ABR-001: A Pilot Study of Carboplatin With Nab-Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer of Squamous Histology||Carolinas Healthcare System|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328105||30112|
NCT02339402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48304/METC azM/UM 14-02-012|Non Invasive Prenatal Testing (NIPT) of Single-gene Disorders|NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD||Maastricht University Medical Center|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Foetal DNA is isolated from the blood of pregnant women|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women and their partner (≥18y) that undergo an invasive procedure for prenatal        genetic diagnosis in the MUMC+ of RUMC for one of the following indications:          -  fetus at high risk of having inherited a dominant or recessive disorder of his/her             affected parent(s) or          -  fetus at risk of having a de novo disorder on the basis of ultrasonography findings.|January 2015|January 14, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339402||29246|
NCT02339415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-008|Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease|Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease|TACTICAL-HIV|Minneapolis Medical Research Foundation|Yes|Recruiting|April 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339415||29245|
NCT02339467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:391|Getting Older Adults OUT-of -Doors|Getting Older Adults OUT-of-doors (GO-OUT): A Randomized Controlled Trial of a Community-based Outdoor Walking Program|GO-OUT|University of Manitoba|Yes|Active, not recruiting|February 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2015|October 1, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02339467||29241|
NCT02334020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHFA Evaluation|Investigating the Impact of the Mental Health First-Aid Training Course in Danish Employees|Effectiveness of Mental Health First-Aid Training in Denmark. A Randomized Controlled Trial With a Six-Month Follow-Up Supplemented With a Qualitative Study||Mental Health Services in the Capital Region, Denmark|No|Active, not recruiting|September 2013|June 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|538|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 25, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02334020||29658|
NCT02340351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE-Psych-Aku-08-14|Auricular Acupuncture vs. Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.|Auricular Acupuncture Versus Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.||Universitätsklinikum Hamburg-Eppendorf|No|Completed|July 2007|August 2013|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|N/A|N/A|No|||January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340351||29173|
NCT02342028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-005AC|The Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea|Impact of Intermittent Hypoxia on the Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|the whole blood of enrollees|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|OSA patients free of other specific conditions affecting immunity are enrolled in this        study.|January 2015|January 23, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02342028||29044|
NCT02342054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINFRA_PROST|Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer|Prospective Phase II Trial of Single Fraction Real-time High-Dose-Rate (19-HDR) Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer|SINFRA_PROST|Hospital de Cruces|Yes|Recruiting|October 2014|December 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Male|18 Years|N/A|No|||January 2015|January 16, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02342054||29042|
NCT02335580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVT-LC Prognosis|Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis|Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Cohort Study||General Hospital of Shenyang Military Region|No|Recruiting|January 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Study population should be the patients with a diagnosis with liver cirrhosis who were        admitted to the Department of Gastroenterology of General Hospital of Shenyang Military        Area.|August 2015|August 11, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335580||29539|
NCT02335840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21/2011|Doses of Coffee and Blood Pressure Response Post-exercise|Influence of Different Doses of Coffee in the Blood Pressure Response Post-exercise||Federal University of Paraíba|Yes|Completed|March 2011|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|12|||Both|40 Years|55 Years|No|||January 2015|January 7, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335840||29519|
NCT02342535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00101433|Community-Clinic Partnership to Promote Physical Activity in South Asian Women|Community-Clinic Partnership to Promote Physical Activity in South Asian Women||Northwestern University|No|Completed|September 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|71|||Female|N/A|N/A|No|||October 2015|October 5, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342535||29005|
NCT02339597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/306/13|Therapy Adherence of APAP Therapy Initiation in Sleep-lab Versus at Home|Therapy Adherence in Different Settings of Automatic Positive Airway Pressure (APAP) Therapy Initiation in Patients With Obstructive Sleep Apnea (OSA): Comparison Between in Sleep-lab vs. at Home Environment.||Charite University, Berlin, Germany|No|Recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|224|||Both|18 Years|80 Years|No|||January 2015|January 12, 2015|January 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02339597||29231|
NCT02339649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN005|Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors|Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors|BonSEP|German Center for Neurodegenerative Diseases (DZNE)|Yes|Recruiting|September 2013|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|308|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT02339649||29227|
NCT02339701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PST005|Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer|A Randomized, Open Label, Phase II Study: Stereotactic Body Radiotherapy (SBRT) vs Conventional Intensity-modulated Radiotherapy (IMRT) for Low or Intermediate Risk Prostate Cancer in Asia Population||Chinese University of Hong Kong|No|Recruiting|January 2015|June 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|64|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339701||29223|
NCT02327403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7-1|Belatacept Conversion in Proteinuric Kidney Transplant Recipients|The B7-1 Study": Belatacept Conversion in Proteinuric Renal Transplant Recipients and B7-1 Positivity Status on Biopsy: an Interventional Multi-Center Trial||Brigham and Women's Hospital|No|Recruiting|August 2015|July 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327403||30166|
NCT02333994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3456|Efficacy of Education With Balance Exercise in Improving Balance and Reducing the Fear of Falls in Elderly|Efficacy of Education With Balance Exercise in Improving Balance and Reducing the Fear of Falls in Elderly||Maharishi Markendeswar University|No|Completed|March 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|80 Years|No|||January 2015|January 7, 2015|January 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333994||29660|
NCT02336061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-QUI-2014-01|Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer|Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer.|IMPULSO|Asociación para la Investigación del Cáncer de Pulmón en Mujeres|Yes|Recruiting|February 2015|March 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1250|||Both|18 Years|N/A|No|Probability Sample|Approximately 1250 patients over 18 years of age (approximately 50% men/women), with        metastatic NSCLC, who are going to commence first-line treatment and who have a life        expectancy of over three months will be included. They will be distributed into two        cohorts (men and women) at 50% and will be distributed by age group and smoking status to        facilitate the homogeneity between the two cohorts.|December 2015|December 28, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02336061||29502|
NCT02336074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-NAPN-24772|Research In Viral Eradication of HIV Reservoirs|Research In Viral Eradication of HIV Reservoirs|RIVER|Imperial College London|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|60 Years|No|||December 2015|January 27, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02336074||29501|
NCT02337933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-MS|Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome|Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome||University of Guadalajara|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|60 Years|No|||November 2015|November 2, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337933||29358|
NCT02339311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-249|Zuni Health Initiative - Chronic Disease Education|A Home-based Educational Intervention Improves Patient Activation Measures and Diabetes Health Indicators Among Zuni Indians|ZHI-CDE|University of New Mexico|No|Completed|June 2012|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|21 Years|75 Years|No|Non-Probability Sample|Study population is Zuni diabetics with HbA1c level of 6.6% and above in the age range of        21 yrs to 75 yrs old lining in Zuni Pueblo.|January 2015|January 14, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339311||29253|
NCT02338154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-13|EDWARDS INTUITY Valve System FOUNDATION Study|Assessing Standard oF Care and Clinical Outcomes UsiNg the EDWARDS INTUITY VAlve SysTem in a European multI-center, Active, pOst-market surveillaNce Study.|FOUNDATION|Edwards Lifesciences|Yes|Active, not recruiting|July 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects, age 18 or older, that have been diagnosed with aortic stenosis or        stenosis-based insufficiency and are scheduled to undergo surgical aortic valve        replacement are eligible for participation in this study. Study subjects shall be drawn        from the general patient populations served by each investigational center. Candidates for        this study must meet all of the following inclusion criteria and none of the exclusion        criteria.|February 2016|February 2, 2016|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338154||29341|
NCT02329548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00528|Qualitative Sweat Distribution During Tilt Table Procedure|Qualitative Sweat Distribution Among Youth With Postural Tachycardia Syndrome (POTS), Syncope, or Anxiety||Nationwide Children's Hospital|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|12 Years|25 Years|No|||December 2014|December 30, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02329548||30001|
NCT02329847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106681|A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies|A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies||Janssen Research & Development, LLC|No|Recruiting|March 2015|May 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|158|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329847||29978|
NCT02342145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gxmuh-2014-14|Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major|Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study||First Affiliated Hospital of Guangxi Medical University|Yes|Recruiting|June 2014|December 2018|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|2 Years|18 Years|No|||January 2015|January 16, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342145||29035|
NCT02342002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1015|Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial|Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial||Gynuity Health Projects|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|416|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342002||29046|
NCT02330380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-13-21|Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation|Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation||University Hospital Case Medical Center|No|Active, not recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|26|Samples With DNA|Skin biopsies and blood samples will be collected|Both|18 Years|65 Years|No|Non-Probability Sample|Psoriasis patients|December 2015|December 2, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330380||29937|
NCT02330653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00014876|Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis|A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis||Children's Hospital Boston|Yes|Not yet recruiting|March 2016|November 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|30 Years|No|||January 2016|January 8, 2016|December 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330653||29917|
NCT02342509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUB 4780-13|Automated Control of End-tidal Volatile Anesthetic Concentration|Automated Control of End-tidal Volatile Anesthetic Concentration Using the MIRUS System: A Comparison of Isoflurane, Sevoflurane and Desflurane in Anesthesia.|MIRCONTROL|Ruhr University of Bochum|Yes|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|63|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342509||29007|
NCT02342561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140060|Iodine Impregnated Incision Drapes and Bacterial Recolonization in Simulated Knee Surgery. A Controlled Randomized Experimental Trial.|Iodine Impregnated Incision Drapes and Bacterial Recolonization in Simulated Total Knee Arthroplasty. A Controlled Randomized Experimental Trial.||Odense University Hospital|No|Completed|September 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|50 Years|N/A|No|||November 2015|November 8, 2015|January 14, 2015||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT02342561||29003|
NCT02340715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advanced MRI|Advanced MRI Sequences for Radiation Therapy Treatment Planning|Investigation on the Utility of Advanced MRI Imaging Methods for Radiation Therapy Treatment Planning||Medical College of Wisconsin|No|Completed|February 2009|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|158|||Both|18 Years|89 Years|No|Probability Sample|Subjects who are planning to have radiation therapy for their cancer.|June 2015|June 11, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02340715||29145|
NCT02340767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003-E|Decision Aids for the Management of Suspicious Occlusal Caries Lesions|Decision Aids for the Management of Suspicious Occlusal Caries Lesions|SOCL|The National Dental Practice-Based Research Network|Yes|Recruiting|December 2014|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|108|||Both|6 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 22, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02340767||29141|
NCT02327169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C28002|A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies|A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|February 2015|March 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02327169||30184|
NCT02333279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUP062|Cancer Development In Organ Transplant Recipients|Cancer Development In Organ Transplant Recipients||University of Zurich|Yes|Recruiting|May 2008|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|No|Probability Sample|All solid organ transplant recipients in Switzerland since 2008 who have given their        consent to be included in the study.|January 2015|January 5, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02333279|5 Years|29715|
NCT02334514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0472-14-RMB paul CTIL|The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection|The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection Among Adults - a Prospective, Cohort Study.||Rambam Health Care Campus|Yes|Recruiting|November 2014|September 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Nasopharyngeal swabs taken after start of oseltamivir treatment in patients diagnosed with      influenza|Both|18 Years|N/A|No|Non-Probability Sample|Adults hospitalized and diagnosed with influenza|September 2015|September 24, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02334514||29620|
NCT02341976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405M50481|Whole Body Vibration Training for Pelvic Floor Muscle|Study of Pelvic Floor Muscle and Urinary Sphincter Activity by Electromyography During Whole Body Vibration Training||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|18|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|May 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341976||29048|
NCT02339324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 14-102|Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b|Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b in Patients With Locally/Regionally Advanced/Recurrent Melanoma: Safety, Efficacy and Biomarker Study||University of Pittsburgh|Yes|Recruiting|June 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02339324||29252|
NCT02339376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000216|Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation|Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation||Beth Israel Deaconess Medical Center||Recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|64 Years|No|||February 2016|February 24, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339376||29248|
NCT02333448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charles MSD 2014|Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.|Diagnostic Value of PCR Genetic Amplification and Mannan Antigenemia Coupled With Antimannan Antibodies in Intensive Care Patients With Suspected Invasive Candidiasis|EMPIRICAND|Centre Hospitalier Universitaire Dijon||Recruiting|October 2014|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|patients in a medical Intensive Care Patients with suspected invasive candidiasis|October 2014|January 5, 2015|December 5, 2014||||No||https://clinicaltrials.gov/show/NCT02333448||29702|
NCT02333461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURN CURB POM-1|Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism|Study to Evaluate Botanicals for Mechanisms Related to Appetite and Fat Metabolism in Healthy, Overweight and Obese Individuals||Access Business Group|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333461||29701|
NCT02333695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gavionerrvemag|Medical Device for Magnetic Therapy for Spinal Cord Injuries (SCI)|Medical Device for Magnetic Therapy for Spinal Cord Injuries (SCIMAG)|SCIMAG|American Society Of Thermalism And Climatology Inc|Yes|Recruiting|January 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||January 2015|January 6, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333695||29683|
NCT02330159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACellCSA01|Feasibility of a Novel Technique for Pilonidal Wound Healing|A Feasibility Study of a Novel Technique for Pilonidal Wound Healing on Patient, Financial, and Quality of Life Outcomes||Southeast Clinical Research Associates, Houston, Texas|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is patients with Pilonidal Disease undergoing surgical management.        Patients will be recruited, evaluated in clinic preoperatively to assure they meet        eligibility, then managed via a standard of care surgical procedure, with our protocol        used for post-operative wound healing|November 2015|November 17, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330159||29954|
NCT02334566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06705|Lending a Hand to Our Future: PTSD in Refugee Children and Youth|Lending a Hand to Our Future: Documenting, Assessing and Treating Posttraumatic Stress Disorder in Refugee Children and Youth|LHOF|St. Michael's Hospital, Toronto|No|Not yet recruiting|August 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|7 Years|18 Years|No|||July 2015|July 30, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02334566||29616|
NCT02334813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIS2002|Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia|A Randomized Trial of Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia|EIS2002|University Hospital, Essen|No|Completed|July 2002|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334813||29597|
NCT02335034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq nº 898.174|Project Arthritis Recovering Quality of Life by Means Education II (PARQVE II)|Project Osteoarthritis: Recovering Quality of Life by Means Education II (PARQVE II) - A Prospective Randomized Study Comparing the Multidisciplinary Care Associated With Education to Multidisciplinary Treatment Without Education.||University of Sao Paulo General Hospital|No|Active, not recruiting|December 2014|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|40 Years|N/A|No|||March 2015|March 16, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02335034||29580|
NCT02335320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC POC|Qualification of Point-of-Care Assays for Management of HCV Patients|Qualification of Point-of-Care Assays for Management of HCV Patients|ANRS HC POC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|HCV chronic patients (all viral genotypes)|March 2015|March 20, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02335320||29558|
NCT02327676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-01-child patients|Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients|Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients||Asian-Pacific Alliance of Liver Disease, Beijing|Yes|Not yet recruiting|January 2015|July 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327676||30145|
NCT02327910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingMSTC|The Clinical Value of Applying TOF and TcPO2 to Guide Elderly Patients Extubation|The Clinical Value of Applying Qualitative TOF Monitoring and Transcutaneous Partial Pressure of Carbon Dioxide to Guide Elderly Patients Extubation||Beijing Municipal Science & Technology Commission|Yes|Enrolling by invitation|October 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Both|65 Years|N/A|No|||December 2015|March 22, 2016|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02327910||30127|
NCT02332278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2014-08|Early Oral Feeding Versus Traditional Postoperative Care After Cesarean Section.|Early Oral Feeding Versus Traditional Postoperative Care After Uncomplicated Cesarean Section. A Randomized Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|June 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|444|||Female|N/A|N/A|No|||January 2015|January 4, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332278||29792|
NCT02330354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2379|Our Year of Healthy Living (Formative Research & Intervention)|Our Year of Healthy Living: A Social Marketing Intervention for Child Care & Home||University of North Carolina, Chapel Hill|Yes|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2160|||Both|3 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02330354||29939|
NCT02331745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z131107002213157|RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure|Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study||Beijing 302 Hospital|No|Recruiting|October 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|17 Years|70 Years|No|||January 2015|January 5, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02331745||29833|
NCT02332525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1407-260-006|The Influence of Oral Vibrational Stimulation on Cognitive Function of Elderly Individuals|The Influence of Oral Vibrational Stimulation on Brain Activity and Cognitive Function of Elderly Individuals With Mild Cognitive Impairment|OVSCF|Seoul National University Bundang Hospital|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 3, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02332525||29773|
NCT02333734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2D-training|Investigation of the Effect of 8-week Controlled High Intense Interval Training in Type 2 Diabetic Patients|Investigation of the Effect of 8-week Controlled High Intense Interval Training in Type 2 Diabetic Patients|DIATRAIN|Aarhus University Hospital|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02333734||29680|
NCT02335008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405026766-1|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot Study|AFS_pilot|Yale University|Yes|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02335008||29582|
NCT02332733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 2041|Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand|Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of Two Doses of the LID/NIAID Live-Attenuated Tetravalent Dengue Vaccine, TV003, Administered Six Months Apart, to Healthy Adults, Adolescents, and Children in Thailand||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|November 2014|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|266|||Both|12 Months|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332733||29757|
NCT02329015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SONIMA001|Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools|Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools||Long Island University|No|Active, not recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329015||30042|
NCT02329301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH-WIRB-20140824|Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia|Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia||PATH|Yes|Recruiting|December 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|5640|||Both|3 Months|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02329301||30020|
NCT02342184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B211-13|Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome|Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome||Japan Blood Products Organization|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|16 Years|N/A|No|||December 2015|February 3, 2016|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02342184||29032|
NCT02342288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409441146|Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients|Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients|IOP|West Virginia University|No|Completed|July 2008|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|79|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 8, 2015||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT02342288||29024|The main limitation of our trial is that these were not consecutive cases, due to availability of the technician and a limited number of anesthesiologists on the protocol.
NCT02342808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055703|Lifestyle Interventions in Treatment-Resistant Hypertension|Treating Resistant Hypertension Using Lifestyle Modification to Promote Health|TRIUMPH|Duke University|Yes|Recruiting|June 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|150|||Both|35 Years|N/A|No|||March 2016|March 7, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342808||28984|
NCT02334267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABChD|Acid-Base Composition With Use of Hemodialysates|Acid-Base Composition With Use of Hemodialysates|ABChD|Fresenius Medical Care North America|No|Active, not recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|April 24, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334267||29639|
NCT02342197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|610012011|Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation|Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation for Poor Responders in ICSI Cycles||Kasr El Aini Hospital|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|35 Years|42 Years|No|||January 2015|January 19, 2015|December 28, 2014||No||No|January 19, 2015|https://clinicaltrials.gov/show/NCT02342197||29031|
NCT02342262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46401.081.13|The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability|The Effects of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability. A Placebo-controlled Trial|Promi2|Wageningen University|No|Enrolling by invitation|August 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02342262||29026|
NCT02342301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6005871|Cardiometabolic Response to Sit-stand Workstations.|Cardiometabolic Response to Sit-stand Workstations.||University of Prince Edward Island|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342301||29023|
NCT02342314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15503|A Study of LY3143753 and LY3185643 in Healthy Participants|A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects||Eli Lilly and Company|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342314||29022|
NCT02332044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1340001|Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers|A Randomized, Open-label, Single Dose, Three-treatment, Three-period, Six-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Erdosteine and Bepotastine Besilate After Oral Administration in Healthy Volunteers||Daewoong Pharmaceutical Co. LTD.|No|Completed|April 2014|January 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 4, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332044||29810|
NCT02332057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diclofenac/lidocaine/IUD|Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device Insertion(IUD).|Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device (IUD) Insertion. A Randomized Double Blinded Placebo-controlled Study||Cairo University|Yes|Recruiting|February 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|50 Years|No|||September 2015|September 19, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332057||29809|
NCT02332291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141137|Connectivity Affecting the Antidepressant REsponse Study|Connectivity Affecting the Antidepressant REsponse (The CAARE Study)|CAARE|Vanderbilt University|No|Recruiting|April 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|130|||Both|60 Years|N/A|No|||September 2015|September 11, 2015|December 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332291||29791|
NCT02331433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APN1125-001|Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects|A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects||CoMentis|No|Active, not recruiting|December 2014|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02331433||29857|
NCT02331446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27371214.4.0000.5313|The Effect of Different Volumes of Physical Exercise on the Immune System|Dose-response Effects of Different Volumes of Structured Exercise in the Inflammatory and Oxidative Stress Parameters in Postmenopausal Women: a Randomized Clinical Trial|ProAFIM|Federal University of Pelotas|Yes|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|27|||Female|N/A|N/A|No|||January 2015|January 2, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02331446||29856|
NCT02332226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR2013-0086|The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology|The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology - A Randomized Controlled Trial Based Upon a Conceptual Framework for Patient Education|PIFBO|Umeå University|No|Enrolling by invitation|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|130|||Both|N/A|N/A|No|||January 2015|January 2, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02332226||29796|
NCT02333006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00110-47|Anosognosia Evaluation After Cranocerebral Trauma Moderate to Severe|Anosognosia Evaluation After Cranocerebral Trauma Moderate to Severe|ANOSOGNOSIA|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02333006||29736|
NCT02334241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INR 2014-001|The Sorbact® Antimicrobial Dressing in the Holistic Wound Management Of Diabetic Foot ulCers (Phase III Study)|The Sorbact® Antimicrobial Dressing in the Holistic Wound Management Of Diabetic Foot ulCers (Phase III Study)|ADHOC|INRESA Pharma|No|Recruiting|October 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02334241||29641|
NCT02341963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA#: 14071504|A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery|A Prospective, Open-Label Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery||Rush University Medical Center|Yes|Recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||June 2015|June 19, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341963||29049|
NCT02338115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.002|Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients|Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients||University of Michigan Cancer Center|Yes|Recruiting|May 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Serum at end of first infusion and 24 hours after Whole blood prior to infusion, at end of      infusion and 24 hours after, and every 3-4 weeks|Female|19 Years|N/A|No|Non-Probability Sample|Breast cancer patients receiving weekly 1-hour paclitaxel infusions for curative treatment|January 2015|January 13, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338115||29344|
NCT02328742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/VL-03|Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.|Pathophysiology of Intrauterine Synechia - Exploratory Study. Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.|PréSynUT-1|Centre Hospitalier Universitaire de Nīmes|No|Suspended|November 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Endometrial biopsies.|Female|18 Years|44 Years|No|Probability Sample|The study population consists of women of childbearing age (≥18 years and <45 years)        requiring a hysteroscopy motivated by an infertility evaluation, failure of embryo        implantation after invitro fertilization, repeated miscarriages|November 2015|November 4, 2015|December 26, 2014||No|Feasibility issues require solutions.|No||https://clinicaltrials.gov/show/NCT02328742||30063|
NCT02328755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.107|Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia|Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia||University of Michigan Cancer Center|Yes|Recruiting|January 2015|January 2019|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328755||30062|
NCT02329002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rb-SPT-SCR|SPT Screening in Irradiated Hereditary Retinoblastoma Survivors|Multicenter Implementation of MR Imaging Studies in Irradiated Hereditary Retinoblastoma Survivors for Assessment of the Value of Craniofacial MRI Screening for Early Detection of Second Craniofacial Primary Tumors and to Enhance Survival||VU University Medical Center|No|Recruiting|October 2014|October 2023|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|8 Years|18 Years|No|Non-Probability Sample|The potential study population will be irradiated hereditary retinoblastoma survivors in        the Netherlands and joining centers from other countries. Currently, there is no screening        program for these high-risk patients. The age of patients at highest risk of developing        craniofacial SPTs is 8-18 years.|December 2014|December 29, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02329002||30043|
NCT02333240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10959|Self-management of Postnatal Anti-hypertensive Treatment: a Trial Development Pilot Study|Self-management of Postnatal Anti-hypertensive Treatment: a Trial Development Pilot Study|SNAP-HT|University of Oxford|Yes|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02333240||29718|
NCT02342106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0054-14-HYMC|Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization|Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization (IVF)||Hillel Yaffe Medical Center|No|Not yet recruiting|January 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Follicular fluid|Female|18 Years|45 Years|No|Non-Probability Sample|Women undergoing IVF treatment.|January 2015|January 14, 2015|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02342106||29038|
NCT02339909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 14/LO/1779|Incentives in Diabetic Eye Assessment by Screening|Incentives in Diabetic Eye Assessment by Screening (IDEAS) Trial|IDEAS|Imperial College London|No|Enrolling by invitation|March 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|1000|||Both|16 Years|N/A|No|||March 2015|March 17, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02339909||29207|
NCT02339922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9571|Ixazomib Citrate in Treating Patients With Untreated B-cell Non-Hodgkin Lymphoma|A Pilot Window Study of Ixazomib in Untreated B-NHL||University of Washington|No|Not yet recruiting|April 2016|||December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02339922||29206|
NCT02340013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Endometrial Shedding Prior to Ovulation Induction Pilot Study|The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|July 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02340013||29199|
NCT02342821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-174-1254|Empowering Immigrants in the Greater Boston Area to Connect to HBV Care|Empowering Immigrants in the Greater Boston Area to Connect to HBV Care||Massachusetts General Hospital|No|Not yet recruiting|February 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|immigrants and other persons at HBV risk in Greater Boston area|January 2015|January 20, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02342821||28983|
NCT02342860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076404|The Impact of Improved WASH in Schools on Absence, Diarrhea and Helminth Infection in Lao PDR|Measuring the Impact of WASH in Schools in the Lao People's Democratic Republic||Emory University|No|Enrolling by invitation|September 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8160|||Both|N/A|N/A|No|||February 2016|February 18, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02342860||28980|
NCT02327208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-33HC|Lean Body Mass Response to Higher-protein Diets During Winter Military Training|Effects of Carbohydrate and Protein Supplementation on Whole-body Protein Balance and Skeletal Muscle Mass During Winter Military Training: a Randomized Controlled Trial||United States Army Research Institute of Environmental Medicine|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02327208||30181|
NCT02327442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY20140522-6|68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients|Prospective Imaging Study of 68Ga-NOTA-NFB in Tumors|GNNGB|Xijing Hospital|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|46|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|6 healthy volunteers. 10 patients with glioma before surgery. 30 patients with breast        cancer before and after neoadjuvant chemotherapy.|December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327442||30163|
NCT02331498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/49|Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT|PAZOGLIO|Centre Antoine Lacassagne|Yes|Recruiting|June 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02331498||29852|
NCT02352363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-005|Randomized Safety Study of CVT-301 Compared to an Observational Control Group|A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control||Acorda Therapeutics|Yes|Recruiting|March 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|365|||Both|30 Years|85 Years|No|||November 2015|November 17, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352363||28253|
NCT02352610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-239|A Prospective Randomized Trial Comparing Standard Ligament Reconstruction Tendon Interposition (LRTI) VS Ligament Reconstruction Tendon Interposition (LRTI) With an Interference Screw for Thumb Carpometacarpal Arthritis - Pilot Study|A Prospective Randomized Trial Comparing Standard Ligament Reconstruction Tendon Interposition (LRTI) VS Ligament Reconstruction Tendon Interposition (LRTI) With an Interference Screw for Thumb Carpometacarpal Arthritis - Pilot Study||Nova Scotia Health Authority|No|Active, not recruiting|March 2015|February 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02352610||28235|
NCT02332005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-ARI-231|12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study|Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study|DE-DPN|NeuromaxBionevia|No|Recruiting|November 2014|November 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02332005||29813|
NCT02332772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0866|Prospective Study of Colonoscopic Resection of Large Polyps and Flat Lesions|Prospective Study of Colonoscopic Resection of Large Polyps and Flat Lesions||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing endoscopy at MD Anderson Cancer Center in Houston, Texas|October 2015|October 22, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02332772||29754|
NCT02333513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YDCR-2014-006|A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation|A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation||Hebei Yanda Hospital|Yes|Not yet recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||April 2015|April 8, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333513||29697|
NCT02342444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8080|Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)|A Prospective Randomized Trial Comparing Two Standard Doses of Enoxaparin for the Prevention of Thromboembolism in Surgical Patients||Oregon Health and Science University|No|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|15 Years|N/A|No|||January 2015|January 14, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02342444||29012|
NCT02328521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-099-03|Efficacy Study of Nicorandil on Neointima|Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus||Chinese PLA General Hospital|Yes|Recruiting|December 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||January 2015|January 17, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02328521||30080|
NCT02339766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106224|Quadratus Lumborum Block for Post-Cesarean Analgesia|Comparison of Intrathecal Morphine With Quadratus Lumborum Block for Post-Cesarean Delivery Analgesia:||Lawson Health Research Institute|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Female|18 Years|45 Years|No|||February 2016|February 4, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02339766||29218|
NCT02332967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.16.INF|Safety and Efficacy of Addition of Structured Lipids in Starter Formulas|Safety and Efficacy of Addition of Structured Lipids in Starter Formulas||Nestlé|Yes|Completed|July 2007|September 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|488|||Both|N/A|4 Months|Accepts Healthy Volunteers|||November 2014|January 12, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332967||29739|
NCT02339870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9216|Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer|Caring for Caregivers: Increasing Cancer Caregiver Wellbeing and Comforting Sensitivity||University of Washington||Completed|April 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02339870||29210|
NCT02330874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/2014|Validation of the SD-ICU. A Risk Assessment Tool of Unplanned ICU Readmission|Assessment of the Risk of Unplanned Readmission to the Intensive Care Unit Using the Safe Discharge From ICU (SD-ICU) Score: A Validation Study.||Hospital Sao Domingos|Yes|Active, not recruiting|April 2014|September 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|All adult patients discharged alive from a general ICU|December 2014|January 2, 2015|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02330874||29900|
NCT02331134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0842.cc|Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer|Pilot Study of Tissue and Hematopoietic Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer||University of Colorado, Denver|Yes|Recruiting|March 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02331134||29880|
NCT02330666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-352|Parent-child Communication and Health-risk Behavior|Parent-child Communication and Health-risk Behavior|MP|University of Wisconsin, Madison|Yes|Completed|August 2004|December 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|604|||Both|10 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330666||29916|
NCT02330965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AMS04|Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis|Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples With DNA|Blood & Cerebrospinal Fluid Samples|Both|18 Years|60 Years|No|Non-Probability Sample|Ambulatory participants with Secondary Progressive Multiple Sclerosis (SPMS) enrolled in        the EXPAND trial (BAF312 treated and placebo [control] participants) may be enrolled in        this study after the EXPAND baseline visit has occurred provided that the subject has not        passed the Month 12 time point.        -Refer to ClinicalTrials.gov record NCT01665144.|February 2016|February 21, 2016|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330965||29893|
NCT02331225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8772|Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension|Endothelial Mircroparticles as a Biomarker of Pulmonary Hypertension in Systemic Sclerosis||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|December 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|30|Samples Without DNA|Blood will be retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There will be 3 groups: systemic sclerosis subjects with pulmonary hypertension, systemic        sclerosis subjects without pulmonary hypertension, and healthy age- and sex-matched        controls.|March 2016|March 1, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02331225||29873|
NCT02331511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRC100|Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator|Effect of Aspirin and Clopidogrel in Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator||hahid Beheshti University of Medical Sciences|Yes|Recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331511||29851|
NCT02352090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYLVI030785|Synthetic vs Natural Estrogen in Combined Oral Contraception|Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.|SYLVI|Helsinki University Central Hospital|Yes|Recruiting|February 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352090||28274|
NCT02354495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00004109|Individualized Metabolic Assessment and Nutritional Optimization in Children With Chronic Respiratory Insufficiency|Individualized Metabolic Assessment and Nutritional Optimization in Children With Chronic Respiratory Insufficiency on Ventilatory Support at Home|NutriCAPE|Children's Hospital Boston|No|Completed|August 2013|June 2015|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|1 Month|18 Years|No|||January 2016|January 26, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354495||28090|
NCT02344641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSEXEN0054|Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients|Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344641||28845|
NCT02343146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5649|Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D|Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D||Children's Research Institute|Yes|Enrolling by invitation|October 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|99 Years|No|||October 2015|October 8, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02343146||28958|
NCT02343172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDM201X2103C|Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma|A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma||Novartis|No|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343172||28956|
NCT02343185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-UCH-125|Effects of Diaphragmatic Manual Therapy in Chronic Low Back Pain|Effects of Diaphragmatic Manual Therapy in Chronic Low Back Pain||Cardenal Herrera University|Yes|Active, not recruiting|January 2014|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|60 Years|No|||January 2015|January 20, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02343185||28955|
NCT02342392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study|Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study||University of Science Malaysia|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|No|||January 2015|January 14, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342392||29016|
NCT02342418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-019|Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults|Single Dose Pharmacokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults||Albany College of Pharmacy and Health Sciences|No|Completed|March 2015|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|February 1, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342418||29014|
NCT02328287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLOB-RIF1|Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion|A Pilot Phase 2a, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion||Bone Therapeutics S.A|No|Recruiting|November 2014|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328287||30098|
NCT02332460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1368|Infusion Related Reactions in Patients Receiving Infliximab|Incidence, Risk Factors and Immunologic Mechanisms of Infusion Related Reactions in Patients With Chronic Inflammatory Disease Receiving Infliximab||Haukeland University Hospital|No|Recruiting|February 2015|January 2025|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|immunological and biochemical biomarkers, autoimmune antibodies, antibodies to infliximab,      allergy analysis, concentrations of drugs (Infliximab, Metothrexat, and Imurel), HLA type|Both|N/A|N/A|No|Probability Sample|The study will be a prospective, longitudinal study where all departments with patients        starting infliximab or switching infliximab from one supplier to another in the Western        Norway Regional Health Authority (Helse Vest RHF) are invited to participate.|January 2016|January 28, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02332460||29778|
NCT02332473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1405IFN|A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B|A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.||Xiamen Amoytop Biotech Co., Ltd.|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332473||29777|
NCT02330107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-ZVD4|Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men|Effectiveness of Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men: A Randomized Controlled Feasibility Study.||The Hong Kong Polytechnic University|No|Recruiting|September 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Male|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 25, 2015|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02330107||29958|
NCT02339272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070-C-027-CR|Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility|Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility||Igenomix|No|Completed|January 2008|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Fixed slides with paraformaldehide, and metanol-acetic acid|Male|N/A|N/A|No|Non-Probability Sample|Testicular biopsies from NOA patients and a control group from post-vasectomized (OA)        patients.|January 2015|January 14, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339272||29256|
NCT02330601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140424-6|Effect of Endoscopic Papillary Large Balloon Dilation on Recurrent Rate of Patients With Recurrentstones in Bile Duct|||Fourth Military Medical University|Yes|Recruiting|August 2014|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|80 Years|No|||November 2015|November 15, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330601||29921|
NCT02328560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANNONCEP|Impact of the Paramedic Announced Consultation on the Use of Patient Care With Cancer and Treated With Chemotherapy|Impact of the Paramedic Announced Consultation on the Use of Patient Care With Cancer and Treated With Chemotherapy|ANNONCEP|Centre Francois Baclesse|Yes|Recruiting|January 2016|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|192|||Both|18 Years|75 Years|No|Probability Sample|Patients undergoing treatment with first-line IV chemotherapy|February 2016|February 10, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02328560||30077|
NCT02333019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR79RR-IIRR|A Parent Child Program to Prevent Adolescent Pregnancy|A Parent Child Program to Prevent Adolescent Pregnancy|PPP_2|Oregon Center for Applied Science, Inc.|No|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|395|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02333019||29735|
NCT02333032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01500-47|Effects of a Positive Slope Treadmill Training in Individuals After Stroke. (Hemislope)|Evaluation of Biomechanical and Functional Effects of a Positive Slope Treadmill Training in Individuals After Stroke.|Hemislope|Centre d'Investigation Clinique et Technologique 805|No|Completed|February 2015|July 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02333032||29734|
NCT02344901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMSES|ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)|ReAl-life Multicentre Survey Evaluating the Status of Stroke Prevention Strategies in Patients With Non-Valvular Atrial Fibrillation in TurKey (RAMSES)|RAMSES|Muğla Sıtkı Koçman University|No|Completed|February 2015|May 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|6273|||Both|18 Years|N/A|No|Non-Probability Sample|Non-valvular atrial fibrillaiton patients|September 2015|September 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02344901|1 Day|28825|
NCT02355366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404-2014|Family Focused Therapy for Teens at Risk for Bipolar Disorder|Family Focused Therapy (FFT) for Adolescents at Familial Risk for Bipolar||Sunnybrook Health Sciences Centre|Yes|Recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355366||28023|
NCT02355379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE34-ADAGE|Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over|Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi|ADAGE|Federation Francophone de Cancerologie Digestive|Yes|Recruiting|January 2015|August 2025|Anticipated|August 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|774|||Both|75 Years|N/A|No|||January 2015|February 3, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02355379||28022|
NCT02355392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110011|Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements|Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements||Regional Hospital Holstebro|No|Completed|February 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3159|||Both|55 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|A population study in the municipality of Holstebro, which has 57.000 inhabitants. Using        the Civil Registration System, we invite all citizens aged 55-64 years.|January 2015|January 30, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355392||28021|
NCT02349464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#27878|Promoting Lactation Education, Access, and Support Efforts for Preterm Infants|Promoting Lactation Education, Access, and Support Efforts for Preterm Infants|PLEASE|Medical University of South Carolina|Yes|Enrolling by invitation|December 2014|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|N/A|No|||January 2015|January 23, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02349464||28475|
NCT02349711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400894|Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies|Probiotics (Lactobacillus Gasseri KS-13, Bifidobacterium Bifidum G9-1, Bifidobacterium Longum MM-2) and Health-related Quality of Life in Individuals With Seasonal Allergies|JEN|University of Florida|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|224|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349711||28456|
NCT02349958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPEC|Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy|Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Using Cisplatin, Mitomycin, and Adriamycin in Peritoneal Surface Malignancies Also Known as Hyperthermic Intraperitoneal Chemotherapy.|HIPEC/IPHC|Bay Area Gynecology Oncology|Yes|Recruiting|September 2006|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||January 2015|January 26, 2015|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02349958||28437|
NCT02345954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lapSKPvslapHP|Laparoscopic Supracervical Hysterectomy and Sacropexy Versus Hysteropexy Study|Laparoscopic Supracervical Hysterectomy and Sacropexy Compared to Uterus Conserving Hysteropexy: a Randomized Clinical Trial|HysPex|Kantonsspital Aarau|No|Recruiting|January 2015|September 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02345954||28744|
NCT02355912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00101767|Adaptive Recalibration of Prosthetic Leg Neural Control System|Adaptive Recalibration of Prosthetic Leg Neural Control System||Rehabilitation Institute of Chicago|No|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02355912||27981|
NCT02350543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-13-0666|Peri-operative Aspirin Continuation Versus Discontinuation|Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.||Rabin Medical Center|No|Enrolling by invitation|February 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||February 2015|February 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350543||28393|
NCT02350556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00097-40|Interest of Evaluating the Movement of the Center of Mass in a Dynamic Avoidance Task as the Endpoint of the Dynamic Equilibrium of Hemiplegic Patients|Interest of Evaluating the Movement of the Center of Mass in a Dynamic Avoidance Task as the Endpoint of the Dynamic Equilibrium of Hemiplegic Patients|EQHEM|Rennes University Hospital||Recruiting|March 2015|September 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350556||28392|
NCT02353325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omnisalt|Iron Bioavailability From Encapsulated Ferrous Sulphate|Iron Bioavailability From Salt Fortified With Ferrous Sulphate, Zinc Sulphate and Ascorbic Acid Encapsulated in a Polymer Jacket||Swiss Federal Institute of Technology|No|Not yet recruiting|March 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Anticipated|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|November 27, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353325||28180|
NCT02349932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400446|The Influence of Histo-blood Group Antigen Polymorphism on the Composition of the Microbiota|The Influence of Histo-blood Group Antigen Polymorphism on the Composition of the Microbiota||University of Florida|No|Not yet recruiting|March 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Blood, saliva, and fecal material will be collected from subjects. The blood and saliva will      be used for typing sugar expression. DNA will be extracted from stool samples and used for      characterization of the gut flora.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|January 2016|January 11, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349932||28439|
NCT02357121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA of Prostate Tissue|Focal Laser Ablation of Prostate Tissue|Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance|FLA|Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|40 Years|85 Years|No|||November 2015|January 6, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02357121||27888|
NCT02327182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P211-05|Safety Study of MT-4666 in Subjects With Alzheimer's Disease|A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)||Mitsubishi Tanabe Pharma Corporation|No|Terminated|December 2014|October 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|55 Years|85 Years|No|||November 2015|November 12, 2015|December 23, 2014||No|This study was terminated due to the benefit-risk balance of MT-4666.|No||https://clinicaltrials.gov/show/NCT02327182||30183|
NCT02327650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA RA Bone Study|To Examine Whether or Not the Primary Causes of OA or RA Might be Bone Alterations|The Examinations Whether or Not the Primary Causes of Osteoarthritis or Rheumatoid Arthritis in Joints Might be Bone Alterations||Shinshu University|No|Recruiting|November 2015|||February 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The patients who have OA with accompaying joint pain or the patients who have RA with        accompaying joint pain|February 2016|February 9, 2016|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327650||30147|
NCT02331758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014180|The Influence Factors of Ovarian Response in PCOS Patients With IVF-ET Treatment|The Influence Factors of Ovarian Response in Polycystic Ovary Syndrome Patients(PCOS) With In Vitro Fertilization and Embryo Transfer (IVF-ET) Treatment||Peking University Third Hospital|No|Not yet recruiting|January 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Female|N/A|N/A|No|||December 2014|January 2, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331758||29832|
NCT02327884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150051|Characterization of Diseases With Salivary Gland Involvement|Characterization of Diseases With Salivary Gland Involvement||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1020|||Both|4 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02327884||30129|
NCT02341729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO/2013/011|Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome|Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest.|ticagrelor|University Hospital, Ghent|No|Not yet recruiting|January 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02341729||29067|
NCT02332538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mans-2014-05|HoLEP vs. Greenlight 532nm-laser PVEP vs. Bipolar TURP in Management of Moderate/ Large BPH|Randomized Trial Comparing Holmium Laser Enucleation of the Prostate vs. Greenlight 532nm-laser Vapo-Enucleation of the Prostate vs. Bipolar Transurethral Resection of the Prostate in Management of Moderate/Large Benign Prostate Hyperplasia||Mansoura University|Yes|Recruiting|September 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Male|50 Years|N/A|No|||March 2016|March 2, 2016|December 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02332538||29772|
NCT02332785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0879|Prospective Study of Colon Serrated Polyps|Prospective Study of Colon Serrated Polyps||M.D. Anderson Cancer Center|No|Recruiting|November 2014|||November 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|Participants undergoing colonoscopy at MD Anderson Cancer Center in Houston, Texas.|January 2016|January 14, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02332785||29753|
NCT02340091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL012|A Clinical Study to Evaluate the Efficacy and Safety of HA IDF Plus Versus HA IDF in Nasolabial Fold Injection|||LG Life Sciences||Completed|February 2014|||June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|30 Years|60 Years|No|||January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340091||29193|
NCT02340104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14610|A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants|An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method||Eli Lilly and Company|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 1, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340104||29192|
NCT02340273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZetrOZ-20140923|Long Duration Therapeutic Ultrasound on Tendon Injuries|Long Duration Therapeutic Ultrasound on Tendon Injuries||ZetrOZ, Inc.|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340273||29179|
NCT02348957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC 2014-I|Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib|Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction|DasPAQT|Onco Medical Consult GmbH|Yes|Recruiting|October 2014|April 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Non-Probability Sample|This non-interventional study will document around 300 adult patients with newly-diagnosed        CP-CML and CML patients in chronic phase resistant or intolerant to prior therapies,        including Imatinib and Nilotinib.|January 2015|January 22, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02348957||28514|
NCT02345161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116853|A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (With an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler With Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily Via a Reservoir Inhaler in Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1800|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345161||28805|
NCT02345174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200980|Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors|An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors||GlaxoSmithKline|No|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345174||28804|
NCT02345187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202191|fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.|Impact of a Multiple Micronutrient (MMN) Fortified Powder Supplemented With Bacopa Monnieri Extract (EBM) on Hemodynamic Responses as Measured by Functional Magnetic Resonance Imaging (fMRI) in Indian School Children (11-12 Yrs; Inclusive) After Approximately 4 Months of Intervention: an Exploratory, Randomized, Double-blind, Controlled Trial||GlaxoSmithKline|Yes|Completed|October 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345187||28803|
NCT02353221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRO|CPMC Early Undifferentiated Arthritis Registry|California Pacific Medical Center Early Undifferentiated Arthritis Registry|CEUAR|California Pacific Medical Center Research Institute|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Blood samples: Our objective is to create a repository that includes PBMCs and serum samples      suitable for functional assays as well as nucleic acid analysis. These efforts will make our      cohort a unique source to measure PBMC antigen-specific proliferation, cytokine and      chemokine secretion, and activation markers expression among others. Blood will be      fractionated for serum analysis and cell analysis. PBMCs will be sorted into neutrophils, B      cells, T cells, and monocytes. Cells will be used for RNA and DNA extraction and analysis,      for functional assays involving cytokine and chemokine production, cell proliferation, and      expression of surface markers of activation.|Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants: Any patient undergoing evaluation for arthritis will be considered eligible.        The pool of potential subjects will include any patient presenting to the office of        participating physicians for evaluation of arthritis.|January 2016|January 26, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353221|12 Months|28188|
NCT02349971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU OO|Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children|Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children||Children's Research Institute|Yes|Recruiting|January 2015|||December 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|25 Years|No|||October 2015|October 2, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349971||28436|
NCT02353351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS130046|ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study|Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study|ASO 522|St. Jude Medical|Yes|Recruiting|June 2014|March 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8000|||Both|N/A|N/A|No|Probability Sample|Patients indicated for ASD closure have echocardiographic evidence of ostium secundum        atrial septal defect and clinical evidence of right ventricular volume overload (such as,        1.5:1 degree of left-to-right shunt or RV enlargement).        The subject population includes vulnerable patients.|February 2016|February 11, 2016|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02353351||28178|
NCT02346201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMET2|Apathy in Dementia Methylphenidate Trial 2|Apathy in Dementia Methylphenidate Trial 2|ADMET2|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|January 2016|August 2020|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||August 2015|January 28, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346201||28725|
NCT02353572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0817.cc|Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma||University of Colorado, Denver|Yes|Terminated|November 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||January 2015|February 23, 2015|January 28, 2015|Yes|Yes|Principle investigator left the institution|No|February 23, 2015|https://clinicaltrials.gov/show/NCT02353572||28161|This study was terminated due to the investigator's departure from the institution.
NCT02353442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860.648|Changes in Subjects With Posterior Capsule Tightness|Biomechanical and Neurophysiological Changes in Subjects With Posterior Capsule Tightness - Evaluation and Treatment||Universidade Federal de Sao Carlos|No|Enrolling by invitation|March 2015|January 2018|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||December 2015|December 8, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02353442||28171|
NCT02327416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anchor study|A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)|A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)||Tongji Hospital|Yes|Recruiting|October 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||January 2015|January 4, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327416||30165|
NCT02335827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRE-001|Irreversible Electroporation(IRE) For Unresectable Renal Tumors|Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|80 Years|No|||January 2015|January 7, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02335827||29520|
NCT02332018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.: 2014-0405|Measurements Of Lower Limbs And Spine Based On Biplanar Radiographs: Microdose Compared To Standard Dose Protocol|Two-dimensional And Three-dimensional Measurements Of Torsion And Length Of Lower Limbs And Spine Based On Biplanar Radiographs: Microdose Imaging Protocol Compared To Standard Dose Imaging Protocol||Balgrist University Hospital|Yes|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients referred for assessment of spine or lower limb with biplanar x-ray-scanner|January 2015|January 7, 2015|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02332018||29812|
NCT02332239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH095866|Text-Message-Based Depression Prevention for High-Risk Youth in the ED|Text-Message-Based Depression Prevention for High-Risk Youth in the ED|iDOVE|Rhode Island Hospital|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|13 Years|17 Years|No|||October 2015|October 26, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02332239||29795|
NCT02328573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-14|The Impact of Group Singing on Patients With Stroke and Their Personal Caregivers|The Impact of Group Singing on Patients With Stroke and Their Personal Caregivers||Beth Israel Medical Center|No|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328573||30076|
NCT02328586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070-14|Group Acupuncture for Pain|Group Acupuncture for Pain|GAP|Beth Israel Medical Center|No|Recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02328586||30075|
NCT02338167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEN-01/14|Praegnant Breast Cancer|Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic Setting: Health Care Research, Pharmacogenomics, Biomarkers, Health Economics|PRAEGNANT|University Hospital Tuebingen|Yes|Recruiting|June 2014|||June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|3500|Samples With DNA|Blood samples|Both|18 Years|99 Years|No|Non-Probability Sample|3500 patients with locally advanced/metastatic breast cancer in any line of treatment        (e.g. 1st, 2nd, 3rd, or ≥ 4th line). A patient can only participate after providing        informed consent.|November 2015|December 9, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338167|36 Months|29340|
NCT02339987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIL-PROCURE-0614|Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration|Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration||John Wayne Cancer Institute|No|Recruiting|November 2014|||January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Tissue from resection of a metastatic melanoma lesion|Both|15 Years|N/A|No|Non-Probability Sample|cancer clinic|March 2016|March 14, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02339987||29201|
NCT02340000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3968|Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate|Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate||Albany Medical College|No|Recruiting|November 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|November 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340000||29200|
NCT02341846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/069/14|Exploring New Technologies to Manage Cancer Pain in the Community|Exploring the Desirability, Feasibility and Practicalities of Using Information and Communication Technology (ICT) to Improve Cancer Pain Management in the Community||University of Aberdeen|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|N/A||3|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cancer pain, their caregivers, and health care professionals.|November 2015|January 20, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341846||29058|
NCT02341859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-MKTG-201501|Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®|Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®||Coopervision, Inc.|No|Completed|January 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|19|||Both|18 Years|40 Years|No|||September 2015|September 18, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341859||29057|
NCT02341872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thesis|Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions|Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions||Ege University|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|48|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341872||29056|
NCT02353052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiZhongshan|Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST|Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of Primary Gastrointestinal Stromal Tumor||Shanghai Zhongshan Hospital|Yes|Recruiting|July 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|900|Samples Without DNA|GIST paraffin specimens|Both|18 Years|80 Years|No|Non-Probability Sample|patients diagnosed with GIST by pathology|January 2015|January 28, 2015|January 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02353052||28201|
NCT02355743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120030|rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome|Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome||University of Pittsburgh|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|6 Months|18 Years|No|||December 2015|December 18, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355743||27994|
NCT02349191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cottam - 1|Omental Transposition Surgery for Mild Alzheimer's Disease|A Prospective, Single Site, Single Arm, Non-randomized, Interventional Study to Evaluate the Safety and Effectiveness of Omental Transposition Surgery for Patients With Alzheimer's Disease.||Bariatric Medicine Institute, Salt Lake City, UT|Yes|Not yet recruiting|March 2016|May 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|65 Years|85 Years|No|||March 2016|March 21, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02349191||28496|
NCT02349204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1938|The Effect of Music on Surgical Skill in the Setting of Simulated Intraocular Surgery|The Effect of Music on Surgical Skill in the Setting of Simulated Intraocular Surgery||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02349204||28495|
NCT02353130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1996|Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment|Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders||University of North Carolina, Chapel Hill|No|Withdrawn|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|8 Years|12 Years|No|Probability Sample|15 boys with ASD (8-12 years old) will receive Memantine XR®.|October 2015|October 23, 2015|January 27, 2015|Yes|Yes|Protocol did not continue once Investigator relocated to another institution|No||https://clinicaltrials.gov/show/NCT02353130||28195|
NCT02353143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMY-1|Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia|First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.|ARMY|Menarini Group|No|Active, not recruiting|December 2014|June 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02353143||28194|
NCT02358616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-003D|An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial (MTN-003)|An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial||Microbicide Trials Network|Yes|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|219|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Former VOICE (MTN-003) participants|February 2015|August 31, 2015|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02358616||27775|
NCT02353364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-001|Blastocyst Euploidy Assessment and Conditioned embryO traNsfer|Prospective Randomised Control Trial of Blastocyst Euploidy Assessment and Conditioned Embryo Transfer for Infertility Patients of Advanced Maternal Age|BEACON|Chinese PLA General Hospital|Yes|Recruiting|November 2014|October 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|1000|||Female|35 Years|N/A|No|||January 2015|January 28, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353364||28177|
NCT02350270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-17|Gait, cOgnitiOn & Decline (GOOD)|Gait, cOgnitiOn & Decline (GOOD)||University Hospital, Angers||Recruiting|January 2015|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|2800|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients were recruited in each memory clinic by a physician|February 2014|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350270||28414|
NCT02350283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAE08B02|Endovascular Therapy for Acute Ischemic Stroke Trial|A Multicenter, Prospective, Non-randomized Pilot Control Study to Evaluate of Thrombectomy With Solitaire in Patients With Acute Ischemic Stroke|EAST|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|January 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||July 2015|November 1, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02350283||28413|
NCT02355717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|616274|Role of Cardiometabolic Risk Factors in Childhood Bone Development|Role of Cardiometabolic Risk Factors in Childhood Bone Development (Healthy Heart 'N' Bones Study)||Georgia Regents University|Yes|Recruiting|December 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|9 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|400 children and adolescents aged 9 to 15 years|August 2015|August 10, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355717||27996|
NCT02355886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9274|Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy|Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy||University of Washington|Yes|Recruiting|April 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|44|||Both|18 Years|85 Years|No|||November 2015|November 3, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355886||27983|
NCT02355899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM 01|Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.|Evaluation of the Suitability of PD P 506 A in the Photodynamic Therapy of Distal Subungual Onychomycosis (DSO) of the Great Toenail.||photonamic GmbH & Co. KG|No|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355899||27982|
NCT02331459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULR-EMTIFE-2013-1|Training Intervention in a Controlled Population of Frail Elderly|Effect of a Multicomponent Training Intervention on Cognition, Mood, and Function in a Controlled Population of Community-dwelling Frail Elderly Patients.|EMTIFE|Hospital de la Ribera|No|Completed|December 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|70 Years|N/A|No|||January 2015|January 31, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331459||29855|
NCT02336087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14122|Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer|Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Metastatic Pancreatic Cancer||City of Hope Medical Center|Yes|Recruiting|January 2016|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336087||29500|
NCT02333045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074767|Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women|Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women|MIP|Emory University|No|Recruiting|January 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333045||29733|
NCT02341755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47/12|Dual Energy Computerized Tomography (DE-CT) in Patients With Crohn's Disease|Dual Energy Computerized Tomography (DE-CT) for Evaluation of Obstructive Intestinallesions in Patients With Crohn's Disease||Shaare Zedek Medical Center|No|Terminated|May 2012|November 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known Crohn's disease undergoing abdominal CT for possible obstructive        presentation|January 2015|January 16, 2015|January 11, 2015||No|Interim analysis was sufficient to demonstrate accuracy of the evaluated test|No||https://clinicaltrials.gov/show/NCT02341755||29065|
NCT02341794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2900|Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography|Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography||Tokyo Medical University|No|Recruiting|January 2015|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|30 Years|80 Years|No|||January 2015|January 17, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341794||29062|
NCT02329379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-103-05-081|The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance|Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter|TGAUS|National Defense Medical Center, Taiwan|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|1200|||Both|20 Years|70 Years|No|||April 2015|April 13, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329379||30014|
NCT02329912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI-201202|Postoperative Ileus: Duration and Severity Assessment With the SmartPill®|The SmartPill® as an Objective Parameter to Evaluate Severity and Duration of Postoperative Ileus|PIDuSA|University Hospital, Bonn|No|Recruiting|December 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02329912||29973|
NCT02355756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCP14-3301-PAC1|Biomarker Development for Future PAC1 Antagonists With Maxadilan|Development of a Target Engagement Biomarker for Future PAC1 Antagonists With the Use of Intradermal Injected Maxadilan Induced Dermal Blood Flow Changes, Assessed by Laser Doppler Imaging||Universitaire Ziekenhuizen Leuven||Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|July 9, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02355756||27993|
NCT02345200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA_AT2014|Body Composition and Hormonal Status in Ataxia Telangiectasia|Body Composition, Muscle Strength and Hormonal Status in Patients With Ataxia Telangiectasia Compared to Healthy Controls||Johann Wolfgang Goethe University Hospitals|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|2 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345200||28802|
NCT02355925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Emb-020|Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Cycle Outcomes|Evaluation the Effect of Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Implantation, Clinical Pregnancy and Miscarriage Rates: Double Blind Randomized Clinical Trial ,Phase 3||Royan Institute|Yes|Recruiting|October 2014|January 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|40 Years|No|||April 2014|February 3, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02355925||27980|
NCT02358577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-530|Early In-bed Cycling in Critically Ill Children|Early Exercise in Critically Ill Youth and Children, a preLiminary Evaluation.|wEECycle|McMaster University|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|17 Years|No|||March 2016|March 3, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02358577||27778|
NCT02346214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1119360|Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age|Smartphone Ophthalmoscope Image Analysis of Lens Capsule Vascularity to Estimate Preterm Gestational Age||RTI International|No|Not yet recruiting|March 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|165|||Both|N/A|24 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Singleton live births between 26 and 36 weeks' gestation (determined by first or        early-second trimester ultrasound dating)|February 2016|February 3, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346214||28724|
NCT02358642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEI-RCT|Drug to Prevent Pneumonia in the Tube Fed|A Randomized Placebo Controlled Trial of Low Dose Angiotensin Converting Enzyme Inhibitor to Prevent Pneumonia in Older People Who Require Tube Feeding Because of Neurological Dysphagia||Chinese University of Hong Kong||Terminated|September 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|93|||Both|60 Years|N/A|No|||January 2015|February 6, 2015|February 28, 2013||No|The interim analysis suggested that low dose lisinopril given to be tube fed older patients    with neuroligical dysphagia had increased mortality.|No||https://clinicaltrials.gov/show/NCT02358642||27773|
NCT02353468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0816.cc|Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant|Phase II Study: Therapy With Bortezomib + Lenalidomide + Dexamethasone With Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients With Symptomatic Multiple Myeloma Following Autologous Transplantation||University of Colorado, Denver|Yes|Terminated|December 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|N/A|No|||January 2015|February 23, 2015|January 28, 2015|Yes|Yes|Principle investigator left the institution|No|February 23, 2015|https://clinicaltrials.gov/show/NCT02353468||28169|This study was terminated due to the investigator's departure from the institution.
NCT02358694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBI-IBS-D|Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS|Safety and Tolerability of Serum-Derived Bovine Immunoglobulin in Children With Diarrhea-Predominant Irritable Bowel Syndrome||Connecticut Children's Medical Center|No|Recruiting|February 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|8 Years|18 Years|No|||March 2016|March 11, 2016|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02358694||27769|
NCT02358707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP|Is Phonophoresis Treatment Effective?|Is Phonophoresis Treatment Effective? Determination of Ibuprofen Levels by Microextraction and HPLC (High Liquid Pressure Chromatography) Method in the Tissues of the Patients With Knee Osteoarthritis?||Cukurova University||Recruiting|May 2014|May 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||February 2015|February 6, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02358707||27768|
NCT02358720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART|Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases|Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases|SMART|Heidelberg University|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2015|February 6, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02358720||27767|
NCT02341521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/018/14|Evaluation of Metabolic Profile of OC000459|An Evaluation of the Plasma and Urine Pharmacokinetics of Parent Compound and a Metabolite of OC000459 in Healthy Male and Female Subjects||Atopix Therapeutics, Ltd.|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|May 22, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341521||29083|
NCT02341560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK207|Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)||Quark Pharmaceuticals|Yes|Recruiting|October 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|530|||Both|50 Years|80 Years|No|||March 2016|March 9, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341560||29080|
NCT02341651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/L004224/1|Control of Blood Pressure and Risk Attenuation-rural Bangladesh, Pakistan, Sri Lanka, Feasibility Study|Feasibility Study for a Cluster Randomized Trial on Integrated Primary Care Strategies to Reduce High Blood Pressure (Control of Blood Pressure and Risk Attenuation-rural Bangladesh, Pakistan, Sri Lanka, Feasibility Study)|COBRA-BPS|Duke-NUS Graduate Medical School|Yes|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|453|||Both|40 Years|N/A|No|||November 2015|November 19, 2015|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02341651||29073|
NCT02341664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058405|Patient and Provider Assessment of Lipid Management Registry|Patient and Provider Assessment of Lipid Management Registry|PALM|Duke University|No|Completed|May 2015|February 2016|Actual|February 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7658|||Both|18 Years|N/A|No|Non-Probability Sample|This registry will recruit approximately 175 sites to enroll ~7,500 patients with        cardiovascular risk factors warranting consideration of lipid-lowering therapies as well        as those already on statin therapy. Patients will be recruited from outpatient clinics        including primary care, internal medicine, family medicine, cardiology, and endocrinology.        Patients will be recruited across all regions of the U.S., including rural and urban        areas, as well as from minority populations.|January 2016|February 15, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02341664|1 Day|29072|
NCT02341703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Hospital|Ovulation Induction in Clomiphene Citrate Resistant PCO Women|Letrozole-metformin Versus Letrozole-metformin-pioglitazone in PCO Clomiphene Citrate Resistant Women||Cairo University|Yes|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|40 Years|No|||July 2015|July 27, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341703||29069|
NCT02328820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0442|Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses|DEFINE-FLOW (Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect - Combined Pressure and Doppler FLOW Velocity Measurements)|DEFINE-FLOW|The University of Texas Health Science Center, Houston|Yes|Enrolling by invitation|October 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328820||30057|
NCT02328833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-CSPT-DP2014-01|Controlled Study About Implementation of a Computerized Depression Guideline in Primary Care|Controlled Study About Implementation of a Computerized Depression Guideline in Primary Care|GPC-DEPc|Corporacion Parc Tauli|No|Not yet recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02328833||30056|
NCT02329080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG42|A Trial on a New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement|An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)||International Extranodal Lymphoma Study Group (IELSG)|No|Recruiting|December 2014|December 2023|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329080||30037|
NCT02329093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip OA Pro-Study 2015|Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA|||Shinshu University||Recruiting|November 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329093||30036|
NCT02333773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhangZhikai-IRE-01|Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli|Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333773||29677|
NCT02333786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1409-095-610|Ultrasound-guided Arterial Catheterization in Pediatric Patients|Comparison of Long-axis/In-plane and Short-axis/Out-of-plane Methods During the Ultrasound-guided Arterial Cannulation in Pediatric Patients||Seoul National University Hospital|Yes|Completed|January 2015|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|108|||Both|N/A|5 Years|No|||October 2015|October 6, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333786||29676|
NCT02350569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1428|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting||Gilead Sciences|Yes|Active, not recruiting|May 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350569||28391|
NCT02345486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141349|Isotonic Solution Administration Logistical Testing|Isotonic Solution Administration Logistical Testing: Pilot Study for the Isotonic Solutions and Major Adverse Renal Events Trial|SALT|Vanderbilt University|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345486||28780|
NCT02345746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-19|Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis|Phase 2 Study of Hepatic Arterial Infusion With Oxaliplatin, Folinic Acid and 5 Fluorouracil Alone or in Combination With Intravenous Chemotherapy in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Colorectal Cancer||Western Regional Medical Center|No|Withdrawn|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|June 12, 2013|Yes|Yes|patient population|No||https://clinicaltrials.gov/show/NCT02345746||28760|
NCT02345967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR13-004|Function of Implanted Glucose Sensor 2|Function of Implanted Glucose Sensor 2|FIGS-2|GlySens Incorporated||Recruiting|January 2015|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345967||28743|
NCT02345980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil and USS|Is There a Role of Phosphodiesterase 5 Inhibitor (Sildenafil) in Relieving Ureteral Stent Related Symptoms, RCT|Is There a Role of Phosphodiesterase 5 Inhibitor (Sildenafil) in Relieving Ureteral Stent Related Symptoms: A Randomized Controlled Trial||Mansoura University|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02345980||28742|
NCT02351427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1223|Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation|Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney||Asan Medical Center|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|N/A|No|||February 2015|February 3, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351427||28325|
NCT02351440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00096889|Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery|Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery||Northwestern University|No|Not yet recruiting|August 2015|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|65 Years|No|||August 2015|August 11, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351440||28324|
NCT02346500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052503|Ultrasound-Guided Photoselective Vaporization of the Prostate|Ultrasound-Guided Photoselective Vaporization of the Prostate||Johns Hopkins University|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|40 Years|85 Years|No|||January 2015|January 20, 2015|October 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02346500||28702|
NCT02346734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040344|Physical Telerehabilitation in Veterans With Multiple Sclerosis|Physical Telerehabilitation in Veterans With Multiple Sclerosis||University of Maryland|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|170|||Both|18 Years|65 Years|No|||January 2015|January 20, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02346734||28684|
NCT02335021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405026766-2|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults|AFS-adult|Yale University|Yes|Recruiting|January 2015|February 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|120|||Both|23 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02335021||29581|
NCT02330926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENAC-2013-05|Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy|A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy|MENAC|Norwegian University of Science and Technology|Yes|Recruiting|April 2015|August 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330926||29896|
NCT02330939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980/14|Fats And Carbohydrates Quality on Postprandial glycemIc Response in Type 1 Diabetes|Impact of Fats And Carbohydrates Quality on Postprandial glycemIc Response in People With Type 1 diabEtes on Insulin Pump (FACILE Study)|FACILE|Federico II University||Active, not recruiting|June 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|14|||Both|18 Years|70 Years|No|||January 2015|January 2, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02330939||29895|
NCT02331199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|preterm 1|Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity|Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity||Cairo University|Yes|Recruiting|December 2014|||August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|20 Years|40 Years|No|||September 2015|September 24, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331199||29875|
NCT02335554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81RR-2R|Internet Program for Workers With Subthreshold Depression|Multimedia Internet-Based Program for Workers With Subthreshold Depression|WorkDep|Oregon Center for Applied Science, Inc.|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|300|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335554||29541|
NCT02335567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE sequence|Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms|Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms|3TMR|Michigan State University|No|Recruiting|June 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|180|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with 50% asymptomatic stenosis of the carotid artery that are safe to undergo 3        tesla MRI imaging.|April 2015|April 6, 2015|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335567||29540|
NCT02328144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-1301-71|Effectiveness of Metronidazole in Pain Control Posthemorrhoidectomy|Effectiveness of Metronidazole Versus Homologated Placebo in Pain Control Posthemorrhoidectomy||Instituto Mexicano del Seguro Social|Yes|Completed|July 2013|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02328144||30109|
NCT02328378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ch27021403|Postoperative Pain Relief After Cesarean Section: Is There a Role for the Quadratus Lumborum Block?|Postoperative Pain Relief After Cesarean Section: Is There a Role for the Quadratus Lumborum Block?||Corniche Hospital|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|45 Years|No|||March 2015|March 9, 2015|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02328378||30091|
NCT02341443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP_DMFx_V1.0|A Multicenter RCT to Investigate the Treatment of Double (Bilateral) Mandibular Fractures|A Multicenter Randomized Controlled Clinical Investigation to Investigate the Treatment of Double (Bilateral) Mandibular Fractures|DMFx|AO Clinical Investigation and Documentation|No|Recruiting|April 2015|May 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02341443||29089|
NCT02342756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8253|Esophageal Pressure-Guided Optimal PEEP/mPaw in CMV and HFOV: The EPOCH Study|Esophageal Pressure-Guided Optimal PEEP/mPaw in CMV and HFOV: The EPOCH Study|EPOCH|University of Toronto|No|Active, not recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|N/A|No|||January 2015|January 29, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342756||28988|
NCT02333305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081107|Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10|Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10|AOA1|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2014|January 6, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02333305||29713|
NCT02333552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INA-FRAGILE00|Frailty Status and Quality of Life in Elderly|A Cohort Study of Frailty Status Transition and Its Impact to Quality of Life in Outpatient Elderly||Indonesia University|No|Completed|March 2013|December 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|269|||Both|60 Years|N/A|No|Non-Probability Sample|Fit or pre-frail elderly aged >= 60 years old who came to Comprehensive Geriatric Clinics,        Cipto Mangunkusumo General Hospital, Jakarta, during March 2013-April 2014.|January 2015|January 6, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02333552||29694|
NCT02341885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACE|PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy|PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment|PEACE|European Society of Intensive Care Medicine|No|Completed|March 2015|November 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive Care Unit patients diagnosed with acute kidney injury and chronic end stage        kidney disease.|January 2016|January 21, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02341885||29055|
NCT02341937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version n. 1, 10 June 2014|D-dimer and Pre-test Clinical Probability Score in Cancer Patients With Suspected Deep Vein Thrombosis of the Legs|D-dimer and Pre-test Clinical Probability Score in Cancer Patients With Suspected Deep Vein Thrombosis of the Legs||G. d'Annunzio University|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|420|||Both|N/A|N/A|No|Probability Sample|All patients with cancer and clinically suspected DVT of the lower limbs|January 2015|January 19, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341937||29051|
NCT02354105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS0002|A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life|A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice|CIMAX|UCB Pharma|No|Recruiting|January 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|678|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with axial spondyloarthritis (axSpA) (including both ankylosing spondylitis (AS)        and nonradiographic axial spondyloarthritis (nr-axSpA)) who have been newly prescribed        Certolizumab Pegol (CZP) by the treating physician in regular course of practice.|March 2016|March 9, 2016|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354105||28120|
NCT02350907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/2013|Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea|Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea: RaDAR-Go|RaDAR-Go|University of Bern|No|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|Swabs from the urethra, rectum, oropharynx, vagina and endocervix|Both|18 Years|N/A|No|Non-Probability Sample|Adult male and females at risk of gonorrhoea infection.|March 2016|March 1, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350907||28365|
NCT02351180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUIBCARV1|Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients|A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients||Washington University School of Medicine|No|Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02351180||28344|
NCT02355249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412|Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer|Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer: a Multi-center, Randomized, and Open-label Trial||Chinese Academy of Medical Sciences|Yes|Recruiting|September 2014|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|648|||Both|18 Years|75 Years|No|||January 2015|February 3, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02355249||28032|
NCT02351661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTF Prevalence 2010-2013|The Nutrition Care in Canadian Hospitals Study; 2010-2013.|The Nutrition Care In Canadian Hospitals Study: 2010-2013|CMTF|Canadian Malnutrition Task Force|No|Completed|August 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1022|||Both|18 Years|N/A|No|Non-Probability Sample|medical or surgical patients; large hospitals (>250 beds) recruited 60 patients and small        hospitals recruited 40 patients over the age of 18 years; all provided informed consent or        proxy provided informed consent|January 2015|January 27, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351661||28307|
NCT02351895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-08-FB-0171|Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use|Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use in a Single Intensive Care Unit||Eastern Virginia Medical School|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1302|||Both|18 Years|90 Years|No|Probability Sample|All patients >18 years and <90 years who were admitted to the GICU during the study period|August 2015|August 4, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351895||28289|
NCT02352142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN6850|Family Nurture Intervention in the CHoNJ NICU|Randomized Control Trial of Family Nurture Intervention in the Children's Hospital of New Jersey Neonatal Intensive Care Unit||Columbia University|No|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|145|||Both|26 Weeks|42 Weeks|No|||August 2015|August 19, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02352142||28270|
NCT02352155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLOGD|Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes|Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes||Chinese University of Hong Kong|Yes|Recruiting|February 2015|September 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|99 Years|No|||January 2016|January 28, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02352155||28269|
NCT02341248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14KH275|Bacteria & Inflammation in the Gut (BIG) Study|Gut Microbial Taxonomy and Metabolism in Paediatric Crohn's Disease During Exclusive and Supplementary Enteral Nutrition Using -Omics Technologies|BIG|NHS Greater Glasgow and Clyde|No|Recruiting|August 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|Blood, faecal, urine and mucosal samples retained.|Both|3 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with suspected or diagnosed Crohn's Disease attending a tertiary paediatric        centre for treatment with exclusive enteral nutrition|January 2015|January 14, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341248||29104|
NCT02335294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-2002|A Study of TRV130 for the Treatment of Pain After Abdominoplasty|A Phase 2, Randomized, Double-Blind, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain Following Abdominoplasty||Trevena Inc.|No|Completed|December 2014|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|65 Years|No|||September 2015|September 2, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335294||29560|
NCT02335307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400501|Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics|Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics||University of Florida|No|Recruiting|June 2015|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|340|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335307||29559|
NCT02341625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA008-002|A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors|A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors||Bristol-Myers Squibb|No|Recruiting|June 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341625||29075|
NCT02341638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV006-003|Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects|Randomized, Double-Blinded, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|17||Actual|149|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|January 26, 2016|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341638||29074|
NCT02327897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150058|NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)|Natural History of Asthma With Longitudinal Environmental Sampling||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|January 2030|Anticipated|December 2029|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|60 Years|No|||September 2015|February 12, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02327897||30128|
NCT02332551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF-20141229|Pilot Study of Percutaneous Irreversible Electroporation to Treat Unresectable Hepatic Carcinoma Close to the Gallbladder|A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2015|January 6, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332551||29771|
NCT02332798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701017|Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia|A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia|MAD|Pfizer|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|39|||Both|18 Years|55 Years|No|||April 2015|April 27, 2015|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02332798||29752|
NCT02332811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB10012|An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients|An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic Chronic Kidney Disease Patients|TOSCANA|Sanofi|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02332811||29751|
NCT02341768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTSY03|Clinical and Device Functional Assessment of Real World ICD Patients|Clinical and Device Functional Assessment of Real World ICD Patients|CARAT|LivaNova|No|Not yet recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2058|||Both|18 Years|N/A|No|Non-Probability Sample|The aim of this study is to include all patients from a global "real world" (standard of        care) population at participating centers and will reference the indication and the        contra-indications specified in the guidelines and IFUs.|January 2015|January 14, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02341768||29064|
NCT02341807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV2-hCHM-101|Safety and Dose Escalation Study of AAV2-hCHM in Subjects With CHM (Choroideremia) Gene Mutations|A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina||Spark Therapeutics|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Male|18 Years|N/A|No|||December 2015|December 6, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341807||29061|
NCT02342795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 DA036105 7693|Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation|Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation||Virginia Commonwealth University|Yes|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Anticipated|520|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02342795||28985|
NCT02330406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE_2014_01R|Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial|Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial|REASON|Institute for Clinical Effectiveness, Japan|Yes|Recruiting|January 2015|March 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||December 2015|December 25, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330406||29936|
NCT02330419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1DP5OD019809|Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM|Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM|Say When|University of California, San Francisco|Yes|Recruiting|April 2015|February 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330419||29935|
NCT02359266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaarlandU|Vitamin D Improves Depression in Liver Patients|Clinical Trial Investigating the Role of Vitamin D in the Treatment of Depression in Patients With Chronic Liver Disease|CLDVitD|Saarland University|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359266||27725|
NCT02347267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clic 002|Reduction in Consumption of Sweetened Beverages on Weight, Body Composition and Blood Pressure in Young Adults|The Impact of Reduction in Consumption of Caloric and no Caloric Sweetened Beverages on Weight, Body Composition and Blood Pressure in Young Adults.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|May 2012|February 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347267||28643|
NCT02354573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/SC/0009|The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)|A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)||University of Oxford|Yes|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|121|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2013|February 3, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354573||28084|
NCT02354781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00630|Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy|Phase I/II Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy||Nationwide Children's Hospital|Yes|Enrolling by invitation|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|7 Years|N/A|No|||March 2015|March 4, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354781||28068|
NCT02355236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Naxozol_P4_1|Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis|A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis||Severance Hospital|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|50 Years|N/A|No|||March 2015|March 20, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355236||28033|
NCT02343913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6005a|Simplifying Menstrual Regulation (MR): Post Abortion Care in Pakistan|Simplifying Menstrual Regulation (MR): Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service Provision in Pakistan: Post Abortion Care (PAC)||Gynuity Health Projects|No|Completed|June 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|329|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 2, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343913||28900|
NCT02343926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMIGL07185|Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin|A Multicentre, National, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin||Sanofi|No|Active, not recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343926||28899|
NCT02355509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF.1467|Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients|Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|January 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355509||28012|
NCT02355626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PANICU|Prognosis of Anxiety in Intensive Care Unit|Prognosis of Anxiety in Intensive Care Unit|PAN-ICU|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|ICU patients, not comatose and not confused|February 2016|February 17, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02355626||28003|
NCT02327195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0296|General Anesthesia Emergence Induced by Methylphenidate|Active Emergence of From Isoflurane General Anesthesia Induced by Methylphenidate|MPOrtho|Ohio State University|Yes|Recruiting|March 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02327195||30182|
NCT02341326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311014509|Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD|Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD||Weill Medical College of Cornell University|No|Active, not recruiting|July 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|Samples With DNA|Biospecimens, in particular SAE BC and stem/progenitor cell will be obtained from      bronchoscopic brushings. In vitro assays will be performed to assess SAE BC stem/progenitor      capacities relevant to the maintenance of small airway architecture.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|April 2015|December 9, 2015|July 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02341326||29098|
NCT02327663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-01|Emtricitabine for Naive Chinese Chronic Hepatitis B Patients|Emtricitabine for Naive Chinese Chronic Hepatitis B Patients||Asian-Pacific Alliance of Liver Disease, Beijing|Yes|Not yet recruiting|December 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327663||30146|
NCT02332265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144-PRJ51ZT|Evaluation of the Effects of a Structural Economic and Food Security Intervention on HIV Vulnerability in Rural Malawi|Pathways Linking Poverty, Food Insecurity, and HIV in Rural Malawi|SAGE4Health|University of Wisconsin, Milwaukee|No|Completed|February 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|N/A||3|Actual|1901|||Both|N/A|N/A|No|Non-Probability Sample|[Study 1] Random selection of households chosen by CARE-Malawi to participate in SAFE        intervention residing in Mwase, Kaomba, or Njombwa Traditional Authorities in Malawi.        These households are compared to household not receiving the CARE-Malawi SAFE intervention        residing in Lukwa, Kawamba, or Chaima.        [Study 2] Random selection of households in program TAs (Mwase, Kaomba, or Njombwa)        including households not receiving intervention. This sample is compared to a random        selection of households residing in non-intervention areas TAs (Lukwa, Kawamba, or        Chaima).        [Study 3] Random selection of individuals participating in SAFE intervention within        intervention TAs.|January 2015|January 2, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02332265||29793|
NCT02341339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WeillMC|Utility of Fallopian Tube Cocultures in Assisted Reproductive Technology|Utility of Fallopian Tube Cocultures in Assisted Reproductive Technology||Weill Medical College of Cornell University|No|Withdrawn||||August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|25 Years|40 Years|No|||August 2015|August 10, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02341339||29097|
NCT02342678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14732|Lessening Incontinence Through Low-impact Activity|Lessening Incontinence Through Low-impact Activity, a.k.a. Yoga to Enhance Behavioral Self-Management of Urinary Incontinence in Women|LILA|University of California, San Francisco|Yes|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342678||28994|
NCT02342730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE13813|Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia|Referral of Obese Endometrial Cancer Survivors to a Bariatric Specialist and a Healthier Survivorship: A Prospective Intervention Cohort Study||Case Comprehensive Cancer Center|No|Active, not recruiting|December 2014|April 2016|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|127|||Female|18 Years|65 Years|No|||October 2015|October 12, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342730||28990|
NCT02329626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/ETIC-01|Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder|Evaluation Via PET Scan of Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder|HYCORE|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|January 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood samples will be taken at baseline, 3 months and 6 months.|Both|18 Years|65 Years|No|Probability Sample|The study population consists of patients with paralysis, motor weakness or abnormal        movements meeting DSM-IV criteria for motor conversion disorder consulting via the        Emergency or Neurology department of participating centers.|February 2016|February 3, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329626||29995|
NCT02329639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Pisa - Az. USL 5|Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy|Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS)|BEVAPROS|University of Pisa|No|Recruiting|April 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|189|Samples With DNA|whole blood|Female|18 Years|N/A|No|Non-Probability Sample|MBC patients treated with a first-line chemotherapy including paclitaxel with or without        bevacizumab|December 2015|December 1, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329639||29994|
NCT02329652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetroHealthMC|Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury|Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury|NNP-UE+T|MetroHealth Medical Center|No|Recruiting|December 2014|December 2027|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|17 Years|N/A|No|||September 2015|September 22, 2015|December 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02329652||29993|
NCT02342782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14349|Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma|Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen||City of Hope Medical Center|Yes|Recruiting|June 2015|||June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|January 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342782||28986|
NCT02330172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1312230009|Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery.|Comparison Sugammadex With Neostigmine in Laryngeal Microsurgery.||Seoul National University Hospital|No|Recruiting|May 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|19 Years|74 Years|No|||July 2015|November 17, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02330172||29953|
NCT02330185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALANDMARKUSG|Comparison of Two Anatomic Landmarks With Ultrasonography in Spinal Anesthesia|Phase IV Study of Landmarks for Spinal Anesthesia||Diskapi Yildirim Beyazit Education and Research Hospital|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Actual|80|||Both|18 Years|50 Years|No|||August 2015|August 4, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02330185||29952|
NCT02351128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC14.040|Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues|Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II.|PHRC-Merkel|University Hospital, Grenoble|No|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02351128||28348|
NCT02347280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McGill-A08-M59-14B|Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis|Less May be More: Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis A Prospective National Multi-Center Cohort Study||Jewish General Hospital|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|110 Years|No|||September 2015|September 25, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02347280||28642|
NCT02343302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00080937|Prospective Trial Evaluating the Effect of Closed Suction Drainage Versus Straight Drainage After Distal Pancreatectomy|Prospective Trial Evaluating the Effect of Closed Suction Drainage Versus Straight Drainage After Distal Pancreatectomy||Johns Hopkins University|Yes|Recruiting|February 2013|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343302||28946|
NCT02343575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28330|Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU|Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU||Stanford University|Yes|Recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343575||28925|
NCT02344225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349622|The Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)|The Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP STUDY)|SPIPROP|State University of New York - Downstate Medical Center|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|N/A|28 Weeks|No|||January 2015|January 21, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344225||28877|
NCT02344446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalshU|Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion|Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion||Walsh University|No|Completed|November 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|10 Years|23 Years|No|||February 2016|February 24, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344446||28860|
NCT02331472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1220|The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)|||Asan Medical Center|Yes|Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|75|Samples With DNA|RNA in urine specimen|Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Interstitial cystitis|December 2015|December 29, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02331472|1 Month|29854|
NCT02331485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPWT Ireland|Randomised Control Study to Asses the Role of Negative Pressure Wound Therapy (NPWT) in the Management of Wound in Surgical Patient|RANDOMISED CONTROL STUDY TO ASSES THE ROLE OF NEGATIVE PRESSURE WOUND THERAPY (NPWT) IN THE MANAGEMENT OF WOUND IN SURGICAL PATIENT||St James Connolly Memorial Hospital|No|Recruiting|August 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2015|January 3, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02331485||29853|
NCT02327429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053775|Pilot Test of a Chinese Menu Plan for Type 2 Diabetes|||University of Alberta|No|Not yet recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|35 Years|N/A|No|||December 2014|December 23, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02327429||30164|
NCT02332031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17436|Sorafenib Drug Drug Interaction Study in Healthy Male Subjects|An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib||Bayer|No|Completed|February 2015|September 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332031||29811|
NCT02341261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2RO1DK064814|Activity for Diabetic Polyneuropathy|Activity for Diabetic Polyneuropathy: the ADAPT Study|ADAPT|University of Utah||Recruiting|November 2015|||April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|30 Years|70 Years|No|||November 2015|November 30, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02341261||29103|
NCT02342691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-020-E|Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis|A Phase 1 / 2 Clinical Trial to Assess the Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis|BLXA4|The Forsyth Institute|Yes|Recruiting|April 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|125|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342691||28993|
NCT02329392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0070|Assessment of Skin Perfusion Pressure as an Indicator of Tissue Oxygenation in Cardiac Surgery Patients Undergoing Cardiopulmonary Bypass|||Yonsei University|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|||Both|20 Years|N/A|No|Probability Sample|Patinets > 20 years old who are scheduled for elective on-pump cardiac surgery|August 2015|August 20, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329392||30013|
NCT02350231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progesterone vaginal pessary|Progesterone Vaginal Pessary for Prevention of Preterm Twin Birth||PPPTP|Assiut University|Yes|Completed|January 2014|January 2015|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|20 Years|40 Years|No|||January 2015|January 25, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02350231||28417|
NCT02329951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050132|Predictive Factors for LBP Interventional Treatment Outcomes|Prospective, Observational Study Evaluating the Ability of Clinical Factors to Predict Interventional Treatment Outcomes for Low Back Pain (LBP)||Johns Hopkins University|No|Recruiting|December 2014|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|346|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with low back pain scheduled for an injection|February 2016|February 23, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02329951||29970|
NCT02350842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSY02|Triple-site Biventricular Stimulation in the Optimization of CRT|Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)|TRIUMPH-CRT|LivaNova|No|Recruiting|July 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350842||28370|
NCT02353533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiRE|Endoscopic Full-thickness REsection of Residual Colorectal Lesions - The FiRE Study||FiRE|Technische Universität München|No|Recruiting|January 2015|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02353533||28164|
NCT02351908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 066|Renal Integrase Study|A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretroviral naïve Patients||St Stephens Aids Trust|No|Recruiting|March 2015|February 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|60|||Both|18 Years|64 Years|No|||September 2015|September 16, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351908||28288|
NCT02347553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152813|Effect of Hypoglycaemia on Social Cognition and Cardiac Conduction|The Effect of Hypoglycaemia on Social Cognition and Cardiac Conduction in Adults With Type 1 Diabetes||University of Edinburgh|No|Recruiting|August 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|40 Years|No|Non-Probability Sample|People with type 1 diabetes (i.e. insulin treated diabetes from the outset) will be        recruited for this study.|October 2014|January 21, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02347553||28621|
NCT02352441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11215006|Cognitive Rehabilitation:ACTION Training for Soldiers With Executive Dysfunction|Cognitive Rehabilitation:ACTION Training for Soldiers With Executive Dysfunction|ACTION|Allina Health System|No|Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02352441||28248|
NCT02355782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMA-100|OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy|Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use||Medical Universtity of Lodz||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2015|April 14, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02355782||27991|
NCT02347787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821368|A Multi-center Trial of IMPaCT CHW Support for Chronically-ill Patients|A Multi-center Trial of Clinician Versus Community Health Worker Support to Help Low Socioeconomic, Chronically-ill Patients Achieve Health Goals|IMPaCT|University of Pennsylvania|Yes|Active, not recruiting|January 2015|February 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|444|||Both|18 Years|N/A|No|||January 2015|March 24, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347787||28603|
NCT02348437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQ Project|Repair vs Non-repair of the Pronator Quadratus Muscle in Distal Radius Fractures. RCT.|Clinical Outcome After Repair of the Pronator Quadratus Muscle in Volar Locked Plating of the Distal Radius. A Randomised Clinical Trial.||Nordsjaellands Hospital|No|Recruiting|February 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348437||28554|
NCT02348736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannesGUM|Comparison of SensaScope Intuboscope and McGrath Series 5 for Endotracheal Intubation|Comparative Study Between SensaScope Intuboscope and McGrath Series 5 Videolaryngoscope to Tracheal Intubation: a Prospective Randomised Study|SensaScope|Johannes Gutenberg University Mainz|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||April 2015|November 16, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02348736||28531|
NCT02336100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP010|Diagnostic Value of Flexible Spectral Imaging Color Enhancement (FICE) Plus Probe-based Confocal Laser Endomicroscopy (pCLE) for Minimal Change Esophageal Reflux Disease (MERD) Diagnosis|Diagnostic Value of Flexible Spectral Imaging Color Enhancement (FICE) Plus Probe-based Confocal Laser Endomicroscopy (pCLE) for Minimal Change Esophageal Reflux Disease (MERD) Diagnosis||King Chulalongkorn Memorial Hospital|Yes|Completed|June 2011|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02336100||29499|
NCT02342574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F901318-01-02-14|F901318 Multiple Ascending Dose Study|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects||F2G Ltd.|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|18||Anticipated|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 19, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342574||29002|
NCT02331771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PorterAH|Donepezil Memory Preservation Post ECT|Can Donepezil Preserve Autobiographical Memory Post Electroconvulsive Therapy? A Randomized, Placebo-Controlled Trial||Porter Adventist Hospital|No|Recruiting|June 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|162|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 28, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331771||29831|
NCT02341157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 002-00|ICE COPD PikoLogic® Cohort Study.Implementation, Compliance, and Effectiveness of Integrating the PikoLogic®|Implementation, Compliance, and Effectiveness of Integrating the PikoLogic® Into Disease Management Discharge Care for Patients With COPD Exacerbation: A Prospective Cohort Study.|ICE|University of Louisville|No|Not yet recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|40 Years|N/A|No|Non-Probability Sample|Have a diagnosis of COPD at or prior to hospitalization.|January 2015|January 13, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02341157||29111|
NCT02342652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN003-002|A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects|A Phase 1, Randomised, Single Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects||Aslan Pharmaceuticals|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|7|||Both|55 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 22, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342652||28996|
NCT02342665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17792|Japanese Phase Ib Copanlisib in Relapsed, Indolent B-cell NHL|Open-label, Uncontrolled, Single-arm, Phase Ib Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy||Bayer|No|Recruiting|April 2015|March 2019|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|20 Years|N/A|No|||March 2016|March 16, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342665||28995|
NCT02329405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifa-Stea|The Effects of PXR Activation on Hepatic Fat Content|PXR-aktivaation Vaikutus Maksan Rasvoittumiseen||University of Oulu|No|Recruiting|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329405||30012|
NCT02349906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.16/NM|Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases|Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases||medac GmbH|Yes|Recruiting|April 2015|March 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|17 Years|No|||September 2015|September 23, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349906||28441|
NCT02349919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-TOI-2014-01|Effect of Oral Procaterol on Postinfectious Persistent Cough|Effect of Oral Procaterol on Chronic Persistent Cough Following Upper Respiratory Tract Infection: Double-Blind Randomized Placebo-Controlled Trial||Mahidol University|Yes|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|15 Years|N/A|No|||February 2016|February 8, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349919||28440|
NCT02353091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0333|FM Systems on Children With Auditory Processing Disorders|Effects of Frequency Modulation (FM) Assistive Listening Device Systems on Listening and Related Skills in Children With Auditory Processing Disorders (APD)||University College, London|No|Enrolling by invitation|February 2015|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|32|||Both|8 Years|11 Years|No|||February 2015|February 3, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353091||28198|
NCT02353182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35014|The T REX Pilot Study: a Study to Investigate the Use of an Alternative Anaesthetic in Infants.|An Open Label Pilot Study of Feasibility of a Dexmedetomidine-Remifentanil-Caudal Anaesthetic for Infant Lower Abdominal/Lower Extremity Surgery: The TREX Pilot Study||Murdoch Childrens Research Institute|Yes|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Month|12 Months|No|||March 2016|March 16, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353182||28191|
NCT02350478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2012-01|Effects of Linagliptin on Endothelial Function|Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes||Medical University of Graz|Yes|Recruiting|July 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||October 2015|October 2, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350478||28398|
NCT02350491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5860|Study During Pregnancy of Expression of miRNAs in RA or SLE|Study During Pregnancy of miRNAs in Rheumatoid Arthritis or Systemic Lupus Erythematosus|SPIRALE|University Hospital, Strasbourg, France|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|40|Samples With DNA|The samples that will be analyzed in the present application are serum, urine, placenta,      blood monocytes.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women suffering from RA or SLE compared wiht pregnant woman in good health|January 2015|January 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350491||28397|
NCT02353429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 112/11|Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets|Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|November 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353429||28172|
NCT02355574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTEGRATE_1_Protocol|5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results|An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics|INTEGRATE|Castle Biosciences Incorporated|No|Active, not recruiting|March 2014|June 2024|Anticipated|February 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1672|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with cutaneous melanoma for whom DecisionDx-Melanoma testing is to be clinically        performed.|January 2016|January 27, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02355574|10 Years|28007|
NCT02352168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangzhouIRD-LSUN|Airway Inflammation in Children With Allergic Rhinitis and Intervention|To Evaluate Airway Inflammation in Children With Allergic Rhinitis and To Examine the Effects of Nasal Corticosteroids Therapy on Lower Airway Inflammation of Rhinitis.||Guangzhou Institute of Respiratory Disease|No|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||December 2014|January 30, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02352168||28268|
NCT02355795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUOLI201501|A Multi-centre Controlled-feeding Study of Dietary Fat Intake and Metabolic Syndrome Risk Factors in China|||Zhejiang University||Completed|November 2014|||December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|300|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02355795||27990|
NCT02344953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0669|Prospective and Retrospective Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia (Acute Leukemia HSCT Cohort)|||Yonsei University|No|Recruiting|January 2011|January 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|||Both|16 Years|N/A|No|Non-Probability Sample|Sampling is performed in patients diagnosed with acute leukemia who underwent allo-HSCT in        Severance Hospital.        Every eligible patients in peroid of study are enrolled. Patients must have the ability        and willingness to sign a written informed consent document. Planned number of patients is        1000 considering annual incidence rate.|January 2011|January 18, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02344953||28821|
NCT02345239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-329-BMB|Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes|Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes||McGill University|No|Not yet recruiting|February 2015|||June 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345239||28799|
NCT02348112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU020|Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence|A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence||Coloplast A/S|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|356|||Female|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from urology or urogynecology specialties.|March 2016|March 11, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348112||28579|
NCT02353169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03274|The Effects of Dexmedetomidine on the Heart Beat During Elective Surgery in Children|The Effects of Dexmedetomidine on Myocardial Repolarization in Children|DexmedQT|University of British Columbia|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|60|||Both|3 Years|10 Years|No|||August 2015|August 31, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353169||28192|
NCT02353260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-A|Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer|A Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ultrasound Hyperthermia in Combination With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer||Shanghai 9th People's Hospital|Yes|Recruiting|December 2014|September 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353260||28185|
NCT02342600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC029|SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)|SARC029: Phase II Pilot Study of Trametinib in Combination With Pazopanib in Patients With Metastatic or Local-regionally Recurrent GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib||Sarcoma Alliance for Research through Collaboration|No|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342600||29000|
NCT02328157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26-061|Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.|Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.||Kagawa University|No|Recruiting|January 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||September 2015|September 1, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02328157||30108|
NCT02338180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project DIPUV 30/2007|Preventive and Therapeutic Proximal Sealants|A Randomized Clinical Trial on Preventive and Therapeutic Proximal Sealants|PTPS|Universidad de Valparaiso|Yes|Completed|March 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|390|||Both|8 Years|10 Years|No|||January 2015|January 13, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338180||29339|
NCT02338193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-14-012|Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women|A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities|DAPA-GDM|Woman's|No|Recruiting|August 2015|March 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|72|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338193||29338|
NCT02342639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001638|Rifaximin Therapy in Chronic Kidney Disease|Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease||University of Kansas Medical Center|No|Recruiting|May 2015|July 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342639||28997|
NCT02328846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17872|Transcutaneous-Arterial Carbon Dioxide and Microcirculatory Dysfunction|Transcutaneous-Arterial Carbon Dioxide Gradient Predicts Microcirculatory Dysfunction And The Development of Organ Failure After Cardiac Surgery||University of Virginia|No|Not yet recruiting|January 2016|February 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing cardiac surgery with cardiopulmonary bypass|November 2015|November 30, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328846||30055|
NCT02329106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF-20141225|Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome|Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|December 2014|January 2020|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2014|December 30, 2014|December 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329106||30035|
NCT02353013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4885|Effect of Protein Intake on Preterm Infant Body Composition|Effect of Protein Intake on Preterm Infant Body Composition||University of Oklahoma|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|36|||Both|N/A|1 Year|No|||December 2015|December 1, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353013||28204|
NCT02353104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORN1000|The Effects of the Onion-Pumpkin Extract on Blood Pressure|The Effects of the Onion-Pumpkin Extract on Blood Pressure: An Open-label, Adaptive-design, Pilot Study||Medicus Research, LLC|No|Completed|November 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02353104||28197|
NCT02346448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELIOS 4/8/14|Endoscopic Sphincterotomy vs. Balloon Dilation for Assessment of Pancreatitis|Endoscopic Sphincterotomy vs. Balloon Dilation for Assessment of Pancreatitis: A Prospective Randomized Multicenter Trial||Helios Albert-Schweitzer-Klinik Northeim|Yes|Recruiting|February 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346448||28706|
NCT02355145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00243|Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin|REALITY: A Non-inteRvEntional Study to Observe the rAtionaLe of selectIng add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin in Real-life Practice at 1 Year Distance|REALITY|AstraZeneca|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Type 2 diabetes patients, inadequately controlled with metformin, with a current treatment        based on any add-on (non-insulin) diabetes therapy.|February 2016|February 3, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02355145||28040|
NCT02353312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-051|Rhode Island Diastolic Dysfunction - Heart Failure|Rhode Island Diastolic Dysfunction - Heart Failure|RIDD-HF|Providence VA Medical Center|No|Recruiting|March 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02353312||28181|
NCT02355444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardio-rubus 13F539|Effects of Blackberry-derived Polyphenols on Cardiovascular Risk in Adults|Dietary Intervention to Investigate the Effects of Blackberry-derived Polyphenols on Cardio-metabolic Risk Factors in Adults|Cardio-Rubus|University College Cork|Yes|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355444||28017|
NCT02347488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001836|Endotracheal Tube Holder and Bite Guard Research|Testing a Novel Combined Endotracheal Tube Holder and Bite Guard in Neurosurgical Patients, Thoracic Surgery Patients, and Orthopedic and Neurosurgical Spine Surgery Patients.||University of California, Los Angeles|No|Completed|February 2015|January 2016|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347488||28626|
NCT02347501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPIP-2012-02|Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)|Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial|DINUP|University College Dublin|Yes|Recruiting|November 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02347501||28625|
NCT02355418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not yet available|The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation|A Prospective Observational Study Examining the Role of Myocardial Fibrosis in Outcome Following Mitral Valve Repair in Degenerative Mitral Regurgitation.||University Hospital Birmingham NHS Foundation Trust|No|Recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|115|Samples Without DNA|Blood samples will be taken from all patients as part of their routine care, including      measurements for full blood count, urea and electrolytes, liver function test, and markers      of cardiac fibrosis.      In patients who chooses to undergo surgical repair of mitral regurgitation, myocardial      biopsies will be taken to look for the degree of diffuse myocardial fibrosis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with asymptomatic chronic, severe primary degenerative mitral regurgitation (MR)        under clinical follow-up or on the surgical waiting list at Queen Elizabeth Hospital        Birmingham (QEHB). Aetiology and severity of MR will be based on the findings of        echocardiography.|November 2015|November 30, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355418||28019|
NCT02355522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-294|Trial of Local Lidocaine Gel and Intrauterine Lidocaine Infusion for Pain Relief During Saline Infusion Sonohysterography|Randomized Controlled Trial of Local Lidocaine Gel and Intrauterine Lidocaine Infusion for Pain Relief During Saline Infusion Sonohysterography||The University of Hong Kong|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02355522||28011|
NCT02355535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0057|Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies|(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies||Vanquish Oncology, Inc.|Yes|Recruiting|February 2015|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|85 Years|No|||September 2015|September 22, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355535||28010|
NCT02355639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1090|A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin|A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin||LEO Pharma|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|16|||Male|25 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02355639||28002|
NCT02355652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.883|Cemented Versus Uncemented Total Knee Arthroplasty : a Prospective Randomized Study|Comparison of Two Surgical Strategies of Total Knee Arthroplasty : Cemented Versus Uncemented HLS Knee-Tec Prosthesis System. A Prospective Randomized Study.|HLS|Hospices Civils de Lyon|No|Active, not recruiting|January 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|50 Years|80 Years|No|||February 2016|March 24, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02355652||28001|
NCT02349243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJETKP01|Effect of Entacapone on Bodyweight Loss in Obese Population|Effect of Entacapone on Bodyweight Loss in Obese Population: A Randomized, Double-blind, Placebo-controlled, Pilot Trial||Fourth Military Medical University|Yes|Recruiting|January 2015|November 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349243||28492|
NCT02349503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-77860-1401|Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia|A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia||Neurocrine Biosciences|Yes|Withdrawn|February 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|12 Years|18 Years|No|||June 2015|June 9, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349503||28472|
NCT02352688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2014.550-T|RCT on Elderly Patients Undergoing Colorectal Cancer Surgery With Enhanced Geriatric Care|A Randomised Controlled Trial on Preoperative Elderly Patients Undergoing Colorectal Cancer Surgery With Enhanced Geriatric Input||Chinese University of Hong Kong|Yes|Not yet recruiting|February 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|78|||Both|70 Years|N/A|No|||January 2016|January 27, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02352688||28229|
NCT02359981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302003617|MyBehavior: Persuasion by Adapting to User Behavior and User Preference|MyBehavior: Persuasion by Adapting to User Behavior and User Preference||Cornell University|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359981||27670|
NCT02360020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTCM03|The XLIMUS-DES in Very Complex Lesions|Performance of the XLIMUS Sirolimus-eluting Coronary Stent In Very Complex Lesions||Clinica Mediterranea|Yes|Active, not recruiting|August 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Consecutive patients scheduled for elective PCI in native coronary arteries will be        considered for eligility. Study participants must suffer for ischemic heart disease due to        critical (>70%) lesion in native coronary arteries. Inclusion criteria are chronic total        occlusion (CTO), severe target vessel calcification and severe target vessel tortuosity.        CTO is defined as the presence of TIMI 0 flow within the occluded segment and high        likelihood of an occlusion duration of ≥3 months. Calcification is defined severe when        larger than 3x vessel diameter and comprising the vessel wall totally in 2 perpendicular        views. Tortuosity is defined severe when it satisfies the following criteria: one or more        bends >= 90°, or 3 or more bends of 45-90° proximal to the diseased segment.|February 2015|February 5, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02360020|12 Months|27667|
NCT02359305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00149|Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy|||Nationwide Children's Hospital|Yes|Enrolling by invitation|June 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients who presented for pyloromyotomy|March 2016|March 8, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02359305||27722|
NCT02348905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCMAJCUT2014|ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial|ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial||Albany Medical College|No|Not yet recruiting|March 2015|January 2016|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|June 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02348905||28518|
NCT02342626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCS14115|Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low Grade Prostate Cancer|CDC SIP: Rochester Prevention Research Center: Development and Evaluation of an Active Surveillance Decision Aid for Men With Low Grade Prostate Cancer||University of Rochester|No|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Male|40 Years|85 Years|No|||September 2015|September 17, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342626||28998|
NCT02349399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17660|Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases|Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases||Bayer|No|Completed|May 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|26065|||Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are new users of CPA/EE in 2011/2012 and in 2014|March 2016|March 8, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349399||28480|
NCT02349672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400671|Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)|Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE) Control Levels||University of Florida|No|Recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|blood samples|Both|N/A|3 Days|Accepts Healthy Volunteers|Probability Sample|neonates|March 2016|March 18, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349672||28459|
NCT02355080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN5869|A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results|A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results|iKnow2 Project|Columbia University|No|Not yet recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|239|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355080||28045|
NCT02346461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150068|An Open Label Phase 2 Study of DEX-M74 in Subjects With GNE Myopathy|An Open-Label Phase 2 Study of DEX-M74 in Subjects With GNE Myopathy||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|60 Years|No|||November 2015|November 17, 2015|January 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346461||28705|
NCT02351388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2014-086|Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research|Ameliorating Depression in Alzheimer's Disease Patients by Transcranial Direct Current Stimulation (ADAPT) - Preliminary Research|ADAPT - prelim|National Center of Neurology and Psychiatry, Japan|Yes|Recruiting|December 2014|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|65 Years|90 Years|No|||February 2015|February 1, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351388||28328|
NCT02355158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-311|A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy|A Multicenter, Open-label, Single-arm Study to Evaluate the Long-term Use of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy||BioDelivery Sciences International|No|Completed|June 2014|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|197|||Both|18 Years|85 Years|No|||December 2015|December 4, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02355158||28039|
NCT02355171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMT|Personalize my Treatment|A Large-scale Longitudinal Oncology Platform||Exactis Innovation||Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|Samples With DNA|Tissue (from surgical resection or biopsy) and blood|Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients|January 2016|January 18, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355171||28038|
NCT02355262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9862|CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers|Community-Based HIT Tools for Cancer Screening and Health Insurance Promotion (CATCH-UP)|CATCH-UP|OHSU Knight Cancer Institute|No|Recruiting|July 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Patients with at least one encounter at a community health centers in the OCHIN network        since January 1, 2013|October 2015|October 14, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02355262||28031|
NCT02355353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1423|Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer|Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer Treated With Fluoropyrimidine-based Chemotherapy as Preoperative Treatment||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|February 2015|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|31|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02355353||28024|
NCT02347150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVFX01|International Multicenter Study of In-hospital Outcome of Patients After ICU Discharge|International Multicenter Study of In-hospital Outcome of Patients After ICU Discharge||Hospital Vila Franca de Xira|No|Recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients discharge from the ICU with a ICU LOS>24h|August 2015|August 17, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347150|6 Months|28652|
NCT02347163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-BRC-6591|Pre-operative Zoledronate in Triple Negative Breast Cancer|A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level||Mario Negri Institute for Pharmacological Research|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347163||28651|
NCT02352636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-YBBR|Auriculotherapy for Osteoarthritis Knee|The Experiences for Receiving Auriculotherapy for Osteoarthritis Knee: A Randomised Controlled Feasibility Study.||The Hong Kong Polytechnic University|Yes|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|96|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02352636||28233|
NCT02344459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36685-D|Comparing 30mL Single Versus 80mL Double Balloon Catheters for Pre-induction Cervical Ripening|Randomized Controlled Trial: Comparing 30mL Single Versus 80mL Double Balloon Catheters for Pre-induction Cervical Ripening||University of Washington|No|Completed|January 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 16, 2015|December 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02344459||28859|
NCT02344719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020880-19|Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis|The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced||Medical University of Vienna|No|Completed|October 2010|June 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02344719||28839|
NCT02344940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1401|Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer|Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study|TTOS|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|December 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|N/A|No|||December 2015|December 29, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02344940||28822|
NCT02355951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1050.01|Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection|||Transgene|No|Completed|December 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Primary Purpose: Screening|||Actual|166|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02355951||27978|
NCT02345252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-366-1216|Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)|A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)||Gilead Sciences|Yes|Active, not recruiting|January 2015|June 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|632|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345252||28798|
NCT02345512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlasgowCULycraTrial01|Investigating the Clinical and Cost Effectiveness of Lycra Splinting|Investigation of Lycra Splinting Garments for Falls and Intellectual Disabilities||Glasgow Caledonian University|No|Active, not recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02345512||28778|
NCT02345772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20140462|Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer|Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)|Neohttp|Western Regional Medical Center||Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345772||28758|
NCT02345720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5632|Effects of Multifocal Contact Lens on Ocular Tissue|Effects on Ocular Tissues of Vistakon® Investigational Multifocal Contact Lenses - Asian Population Study||Johnson & Johnson Vision Care, Inc.|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345720||28762|
NCT02352857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00785-40|Glycaemic and Insulinaemic Responses After Consumption of FOS.|Postprandial Glycaemic and Insulinaemic Responses After Consumption of Minicakes Containing FOS in Adults|GLYCOFOS-cake|Institut Pasteur de Lille|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02352857||28216|
NCT02328599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV EES-14606|Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes|A Prospective Consortium Evaluating the Long-term Follow-up of Patients With Type 2 Diabetes Enrolled In a Randomized Controlled Trial Comparing Bariatric Surgery Versus Medical Management|ARMMS-T2D|The Cleveland Clinic|Yes|Enrolling by invitation|February 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|302|Samples Without DNA|Study specific blood and urine specimens will be analyzed at a central laboratory.      Participation in the research repository is optional. Blood will be drawn and stored at each      site for later analysis.|Both|20 Years|65 Years|No|Probability Sample|Subjects who were previously enrolled in a Randomized Control Trial (RCT) at one of the        four participating sites who initiated one of the intervention procedures - bariatric        surgery or medical/lifestyle therapy.|January 2016|January 5, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328599||30074|
NCT02352909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15-1 (OPPQ-REPAR)|A Controlled Trial on Recreational Runners With Patellofemoral Pain|A Randomised Controlled Trial on Recreational Runners With Patellofemoral Pain: Effects of Rehabilitation Approaches Based on Specific Underlying Mechanisms||Laval University|Yes|Recruiting|July 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|45 Years|No|||September 2015|September 2, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02352909||28212|
NCT02352948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4191C00004|A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).|ARCTIC|AstraZeneca|Yes|Recruiting|January 2015|November 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|730|||Both|18 Years|130 Years|No|||January 2016|January 11, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352948||28209|
NCT02346175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-103|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|June 2014|December 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||January 2015|February 1, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346175||28727|
NCT02354274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARLAL 2|Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®|Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®||Odense University Hospital|No|Recruiting|January 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02354274||28107|
NCT02354287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166725|Effectiveness of Cold Biopsy Forceps With Pre-lift for Complete Resection of Colonic Polyps ≤7mm in Size|Effectiveness of Cold Biopsy Forceps With Pre-lift for Complete Resection of Colonic Polyps ≤7mm in Size.||Gloucestershire Hospitals NHS Foundation Trust|Yes|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents from within Gloucestershire, United Kingdom whom have been referred for a        Colonoscopy through either.          1. Bowel cancer screening program or outpatient referral          2. Outpatient clinics          3. Inpatient referral|August 2015|August 19, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02354287||28106|
NCT02346695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/19-6-12|Association Between Left Ventricular Deformation and Aerobic Exercise Capacity in Untreated Arterial Hypertension|Vascular and Biochemical Determinants of Left Ventricular Deformation and Twisting-untwisting and Their Interrelation With Aerobic Exercise Capacity in Untreated Arterial Hypertension||University of Athens|No|Recruiting|June 2012|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|480|Samples Without DNA|Plasma in serum for fibrosis and inflammatory markers|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|320 ntreated consecutive patients with newly diagnosed essential hypertension and 160        normotensive individuals|January 2015|January 20, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02346695||28687|
NCT02346903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029|Chest Pain Perception and Capsaicin Sensitivity|Chest Pain Perception and Capsaicin Sensitivity||Bassett Healthcare|No|Active, not recruiting|April 2013|||August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346903||28671|
NCT02352103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9220|Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery|The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial||Henry Ford Health System|No|Recruiting|January 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|102|||Male|40 Years|95 Years|No|||February 2016|February 17, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352103||28273|
NCT02352623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-127|Quality of Life and Surgical Late Effects of Melanoma Treatment|Quality of Life and Surgical Late Effects of Melanoma Treatment||Herlev Hospital|Yes|Recruiting|February 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|435|||Both|18 Years|75 Years|No|Probability Sample|Patients treated for cutaneous melanoma (AJCC stage IB-III) with wide local excision (WLE)        and sentinel lymph node biopsy (SNB) and/ or complete lymph node dissection in the axilla        and/or groin will be included in the study.|August 2015|August 18, 2015|January 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02352623||28234|
NCT02355041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1212|Meal Replacement Study|Pilot Meal Replacement-Based Diet Effectiveness Study||Icahn School of Medicine at Mount Sinai|No|Withdrawn|February 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 30, 2015||No|The PI changed institutions|No||https://clinicaltrials.gov/show/NCT02355041||28048|
NCT02355054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411142|Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study|Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study||Washington University School of Medicine||Available||||||N/A|Expanded Access|N/A|||||||Male|18 Years|N/A||||August 2015|August 17, 2015|January 29, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02355054||28047|
NCT02348749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-138|18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies|A Pilot Study of 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|5 Years|N/A|No|||February 2016|February 11, 2016|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348749||28530|
NCT02349425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-010|A Dose Escalation Study of AF-219 in Refractory Chronic Cough|A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough||Afferent Pharmaceuticals, Inc.|No|Recruiting|March 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 19, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349425||28478|
NCT02348996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEFDRYWEIGHT|Study Comparing Dryweight Determination in Hemodialysis Patients With Two Methods|Randomized Study Comparing Analysis With Bioeletric Impedance and Clinical Evaluation to Determine Dry Weight in Hemodialyis Patients||Pontificia Universidade Católica do Rio Grande do Sul|No|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02348996||28511|
NCT02349009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-C82T-3101|Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial|A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial||Prism Pharma Co., Ltd.|Yes|Recruiting|June 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349009||28510|
NCT02349685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1412/280-119|The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori|The Efficacy of the Culture Based Tailored Therapy for Helicobacter Pylori Eradication Comparing With the Traditional 2nd Line Rescue Therapy in Korean||Seoul National University Bundang Hospital|No|Completed|January 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|370|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02349685||28458|
NCT02349698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU-BTC-001|A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma||Southwest Hospital, China|No|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|70 Years|No|||June 2015|November 8, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02349698||28457|
NCT02345265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00051|Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer||National Cancer Institute (NCI)|Yes|Recruiting|December 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|N/A|No|||December 2015|March 21, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345265||28797|
NCT02349750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|Endometrial Scratch Injury in Women With Unexplained Infertility Undergoing IUI|Endometrial Scratch Injury Induced Higher Pregnancy Rate for Women With Unexplained Infertility Undergoing IUI With Ovarian Stimulation||Cairo University|No|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Female|20 Years|40 Years|No|||January 2015|January 28, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02349750||28453|
NCT02345941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD069221-01A1|Safety in Seconds 2.0: An App to Increase Car Seat Use|Evaluating a Web-based Child Passenger Safety Program: Safety in Seconds 2.0||Johns Hopkins Bloomberg School of Public Health|No|Enrolling by invitation|July 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1250|||Both|N/A|N/A|No|||March 2016|March 8, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02345941||28745|
NCT02354716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819014|EndoFLIP Use in Upper GI Tract Stenosis|Expanding the Clinical Applications of Functional Luminal Imaging (EndoFLIP) in Esophageal Stenoses|EndoFLIP|University of Pennsylvania|No|Recruiting|December 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients with benign refractory esophageal strictures referred for placement of an        esophageal stent are eligible for this study.|December 2015|December 1, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354716||28073|
NCT02349152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110258|Remifentanil and Glycemic Response in Cardiac Surgery|The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Prospective, Randomized, Open Label Clinical Trial||University of Pittsburgh|Yes|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349152||28499|
NCT02355002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002560|Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers|Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers|TMSOCD|Massachusetts General Hospital|Yes|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|65 Years|No|||May 2015|May 4, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355002||28051|
NCT02355028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHA510-2201|LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration|A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)||Alcon Research|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|50 Years|90 Years|No|||January 2016|January 25, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355028||28049|
NCT02350855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_13_11|Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients|To Study the Impact of Nutritional Intervention in Delaying the Progression of Cachexia to Refractory Cachexia in Female Cancer Patients: A Study Based in India||University of Westminster|Yes|Completed|December 2013|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Female|18 Years|N/A|No|||January 2015|January 29, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350855||28369|
NCT02350868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPT0E028-101|Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment|A Phase 1, First-In-Human, Dose-Seeking Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment||Taipei Medical University||Recruiting|January 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||November 2015|November 3, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02350868||28368|
NCT02343237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130605|Osteopathic Medicine in Fibromyalgia Syndrome|A Multicenter, Randomized Study, Against Credible Factitious Intervention That Evaluates the Interest of Osteopathic Medicine in the Management of Fibromyalgia Syndrome|FIBROPATHIC|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|November 2015|April 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343237||28951|
NCT02351622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Caffeic acid|Caffeic Acid Tablets as a Second-line Therapy for ITP|A Multicentre Randomized Double-blind Placebo-controlled Study of Caffeic Acid Tablets as a Second-line Therapy for the Treatment of Newly Diagnosed Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|December 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2015|March 3, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351622||28310|
NCT02351843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058639|Efficacy and Safety of Low Amplitude Electroconvulsive Therapy|Efficacy and Safety of Low Amplitude Electroconvulsive Therapy||Duke University|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|No|||August 2015|December 29, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351843||28293|
NCT02351856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-001|A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy|||Array BioPharma|No|Recruiting|February 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351856||28292|
NCT02355015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/205/F|A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections|A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections||Singapore General Hospital|No|Recruiting|March 2014|||December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|21 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients diagnosed with NTM infection in the institution|October 2015|October 19, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02355015|5 Years|28050|
NCT02329067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WALNUT-2|The Metabolic Effect of Walnuts in Healthy Subjects|The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women Substituting Walnuts for Different Food Components|WALDI|Ludwig-Maximilians - University of Munich|No|Active, not recruiting|December 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|180|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329067||30038|
NCT02349438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5685|Assessment of Contact Lens Wettability Using Wavefront Aberrometry|||Johnson & Johnson Vision Care, Inc.|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349438||28477|
NCT02349451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-197|A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate|A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate||AbbVie|No|Active, not recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|220|||Both|18 Years|99 Years|No|||February 2016|February 17, 2016|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02349451||28476|
NCT02353039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC6101A_P2|Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis|Double Blind, Multicenter, Randomized, Placebo-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis||Green Cross Corporation|No|Recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|19 Years|N/A|No|||July 2015|July 1, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02353039||28202|
NCT02353208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03443|The Effect of Sham Feeding on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy|The Effect of Sham Feeding on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: a Prospective Randomized Trial||University of British Columbia|No|Enrolling by invitation|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|122|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02353208||28189|
NCT02349945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-020240-35|FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy|Significance of the FSH Receptor Polymorphism p.N680S for the Efficacy of FSH Therapy of Idiopathic Male Infertility: a Pharmacogenetic Approach||Azienda USL Modena|Yes|Active, not recruiting|January 2011|||December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|88|||Male|20 Years|50 Years|No|||January 2015|January 26, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02349945||28438|
NCT02345447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTV.PRE.01.A3|Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence|Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group Comparison for Superiority|OTV_PRE_01|University Hospital Tuebingen|No|Active, not recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|296|||Both|12 Months|59 Months|No|||July 2015|July 22, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345447||28783|
NCT02345460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4214|Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study|Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study||Case Comprehensive Cancer Center|No|Active, not recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345460||28782|
NCT02345707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201741|Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir|A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects||ViiV Healthcare|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|July 9, 2015|January 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345707||28763|
NCT02350517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-17|Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer|A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer||Sun Yat-sen University|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|75 Years|No|||October 2015|October 28, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02350517||28395|
NCT02350530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU09|FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type|A Phase II Study to Evaluate the Surgical Conversion Rate in Patients With RAS Mutation-type Receiving FOLFOXIRI +/- Bevacizumab for Unresectable Colorectal Liver-Limited Metastases|FORBES|Sun Yat-sen University|No|Recruiting|January 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|70 Years|No|||September 2015|October 1, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02350530||28394|
NCT02354729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn|Encouraging Allergic Young Adults to Carry Epinephrine|Using Text Messaging and Financial Incentives to Encourage Allergic Young Adults to Carry Epinephrine||University of Pennsylvania|No|Completed|October 2013|October 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02354729||28072|
NCT02352870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAHTMZA WPAH 68913|Intervention for Improving Psychological Distress in Dialysis|Intervention for Improving Psychological Distress in Dialysis (iDiD) Feasibility Two Arm Randomised Controlled Trial: Online Cognitive Behavioural Therapy (CBT) Intervention With Therapist Support vs Online CBT Intervention Alone (no Therapist Support)|iDiD|King's College London|No|Not yet recruiting|February 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02352870||28215|
NCT02352883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4112|MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ|Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)||Eastern Cooperative Oncology Group||Recruiting|March 2015|||November 2027|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|350|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02352883||28214|
NCT02345694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01523-44|Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome (CIH-Gait)|Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome : a Randomised Controlled Trial of Continuous Positive Airway Pressure Effectiveness (CIH - Gait)|CIH-Gait|University Hospital, Grenoble|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02345694||28764|
NCT02345928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105130|A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Ascending Dose Study of CNTO 7160 in Subjects With Asthma and Subjects With Atopic Dermatitis||Janssen Research & Development, LLC|No|Recruiting|August 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|13||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02345928||28746|
NCT02354066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602006052013|The Effect of Foot Orthoses on the Braking Response Time|The Effect of Different Foot Orthoses (Hallux Valgus Shoe; Forefoot Relief Shoe) on the Brake Response Time After Hallux Valgus and/or Additional Forefoot Surgery||Medical University Innsbruck|No|Completed|June 2013|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|42|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02354066||28123|
NCT02328118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDR-RAN-LSY|25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China|25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients|RaTAPDR|The First People's Hospital of Xuzhou|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02328118||30111|
NCT02328131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hp-EuReg|European Registry on the Management of Helicobacter Pylori Infection|European Registry on the Management of Helicobacter Pylori Infection||Hospital Universitario de la Princesa|No|Recruiting|June 2013|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Infected adult patients by Helicobacter pylori|February 2016|February 10, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02328131||30110|
NCT02328352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM SALUTE 159/2010 20/09/2010|"BP as a New Device for Surgery and Solid Cancer and Hematopoietic System Tumors Treatment. Effects of BP Implantation"|The Buckypaper as a New Device in the Treatment of Some Solid Cancer and Hematopoietic System Tumors and as a New Fixing Device for Prosthetic Surgery. In Vivo Study on Effects of BP Implantation, Preliminary to Human Surgical Applications|DM159|University of Roma La Sapienza|Yes|Active, not recruiting|October 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Female|3 Months|6 Months|Accepts Healthy Volunteers|||December 2014|December 30, 2014|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02328352||30093|
NCT02354508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C2413|Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues|A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues||Novartis|No|Recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354508||28089|
NCT02354521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-10 11 0569|Nutrition Support During Pediatric Critical Illness - 2nd Multicenter, International Cohort Study|NUTRITION SUPPORT DURING PEDIATRIC CRITICAL ILLNESS - 2ND MULTICENTER, INTERNATIONAL COHORT STUDY OF BARRIERS AND OUTCOMES|PINS2|Children's Hospital Boston|No|Completed|August 2011|July 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|||Both|1 Month|18 Years|No|Probability Sample|Children (age 1 month to 18 yrs) admitted to the PICU with anticipated stay longer than 48        hours, and who require mechanical ventilatory support.|January 2015|February 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354521||28088|
NCT02354742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024925|Echo vs. EGDT in Severe Sepsis and Septic Shock|Echocardiography-Guided Resuscitation in Severe Sepsis and Septic Shock Vs. Early Goal-Directed Therapy: Pilot Study|ECHO RCT|Intermountain Health Care, Inc.||Recruiting|December 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02354742||28071|
NCT02344186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21440|Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes|Effects of Liraglutide on Endoplasmic (ER) Stress in Obese Patients With Type 2 Diabetes||Temple University|No|Active, not recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|12|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02344186||28880|
NCT02333292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEHEP-MONO|Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions|Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort|FPSMON201401|Valme University Hospital|No|Recruiting|December 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|whole blood samples|Both|18 Years|N/A|No|Probability Sample|HCV-infected patients who initiated treatment against HCV including a direct-acting        antiviral|November 2015|November 10, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02333292||29714|
NCT02352987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-008-CT|Effect of Neem Extract, Propylene Glycol and Salicylic Acid Combination in the Treatment of Arsenical Palmar Keratosis|Randomized, Single Blind, Placebo Controlled Clinical Trial to See the Effect of Combination of Neem, Propylene Glycol and Salicylic Acid in the Treatment of Arsenical Palmar Keratosis||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 11, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352987||28206|
NCT02355470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14110392|College Health Center-based Alcohol and Sexual Violence Intervention|GIFTSS (Giving Information for Trauma Support and Safety): A College Health Center-based Alcohol and Sexual Violence Intervention|GIFTSS|University of Pittsburgh|Yes|Recruiting|August 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2200|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355470||28015|
NCT02355483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8741|Impact of Unenhanced Computed Tomography (CT) in Elderly Patients Admitted to the Emergency Department With Acute Abdominal Pain|Accuracy of Unenhanced CT in Elderly Patients Admitted to the Emergency Department With Acute Abdominal Symptoms||University Hospital, Montpellier|No|Completed|May 2012|August 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|423|||Both|75 Years|N/A|No|||January 2015|January 30, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355483||28014|
NCT02355600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/0642|Oocyte Recovery During Tamoxifen Adjuvant Therapy|Tamoxifen as Adjuvant Treatment in Breast Cancer and Its Impact on Ovarian Function|TAMOXIFERT|Instituto de Investigacion Sanitaria La Fe|No|Recruiting|November 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|35 Years|No|Non-Probability Sample|Young breast cancer patients (with positive estrogen receptors) using tamoxifen as        adjuvant treatment|January 2015|February 3, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355600|6 Years|28005|
NCT02353338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0025250|Distal Radial Fractures in the Late Middle Aged|Distal Radial Fractures in the Late Middle Aged: Surgical or Conservative Treatment - A Randomized Control Trial|RIST|Shoulder & Upper Extremity Research Group of Edmonton|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353338||28179|
NCT02350257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPSY RCT|Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings|Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings||Karolinska Institutet|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|8 Years|12 Years|No|||September 2015|September 18, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350257||28415|
NCT02353559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6631|Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute Leukemia|Emotion And Symptom-focused Engagement (EASE): A Randomized Pilot Trial of an Intervention for Individuals With Acute Leukemia|EASE|University Health Network, Toronto|Yes|Recruiting|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353559||28162|
NCT02344862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-003|Study of FYU-981 in Hyperuricemia With or Without Gout|Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)||Fuji Yakuhin Co., Ltd.|No|Completed|January 2014|September 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|20 Years|64 Years|No|||January 2015|January 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02344862||28828|
NCT02344875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-004|Clinical Pharmacology of FYU-981 (Elder Subjects)|Clinical Pharmacological Study of FYU-981 Administered to Male and Female Elder or Non-elder Subjects||Fuji Yakuhin Co., Ltd.|No|Completed|May 2014|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02344875||28827|
NCT02354989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPONSIBLE|Rate RESPONSIVe Pacing in Patients With Permanent AF Underwent AV Node ABLation and bivEntricular Pacing (RESPONSIBLE)|Effect on Exercise Capacity of Fixed Rate Vs Rate RESPONSIve Pacing in Patients With Permanent AF and Left Ventricular Dysfunction Underwent Radiofrequency Atrioventricular Junction aBLation and bivEntricular Pacing (RESPONSIBLE Study)|RESPONSIBLE|Azienda Ospedaliera Cardinale G. Panico|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02354989||28052|
NCT02350244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0219|Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work|Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work|I-Preventive|University Hospital, Clermont-Ferrand||Completed|June 2014|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02350244||28416|
NCT02350504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR033614CTIL|Impact of Childrens Preparation Before MRI on Anxiety and Need for Anesthesia: a Prospective Randomized Clinical Trial|IMPACT OF CHILDREN&Apos;S PREPARATION BEFORE MRI ON ANXIETY AND NEED FOR ANESTHESIA: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL.||Soroka University Medical Center|Yes|Completed|December 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|131|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02350504||28396|
NCT02357186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0038|Broad Validation Study of a Management Algorithm Mild Head Injury in Children|Multicenter Prospective Broad Validation of a Management Algorithm Mild Head Injury in Children|EVEACE|Nantes University Hospital|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10300|||Both|N/A|16 Years|No|Non-Probability Sample|Will be included in the study all children under 16 years of age admitted to the emergency        room with mild head trauma with a Glasgow score greater than or equal to 14, occurred in        the previous 24 hours. The mild head injury is usually defined by a GCS ≥ 13, but the        study of the Pediatric Emergency Care Applied Research Network was interested in the        population of children with TBI Glasgow score was greater than or equal to 14. Indeed the        care of children with head trauma with a Glasgow score below 14 is not controversial. The        risk of traumatic brain injury is at least 20%, achieving a brain scan is routinely        recommended for these children. The investigators will resume the same characteristics for        the study population as the study of the Pediatric Emergency Care Applied Research        Network.|December 2015|December 17, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02357186||27883|
NCT02332252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2014-10|Electrocautery Versus Scalpel for Surgical Skin Incisions in Cesarean Section.|Electrocautery Versus Scalpel for Surgical Skin Incisions in Cesarean Section. A Randomized Controlled Trial.||Saint Thomas Hospital, Panama|No|Not yet recruiting|February 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|N/A|N/A|No|||January 2015|January 5, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332252||29794|
NCT02343523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-6510|Pilot Study of the QI Device for Monitoring of Patients With Congestive Heart Failure|Pilot Study of the Quanttus Device for Monitoring of Patients With Congestive Heart Failure||Scripps Translational Science Institute|No|Completed|January 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|N/A||1|Actual|13|||Both|19 Years|N/A|No|Non-Probability Sample|The study population in both phases of the study will be made up of adult men and women        admitted to the hospital with a clinical diagnosis of acute decompensated heart failure.        Phase 1 and Phase 2 will include up to 10 individuals each that meet the following        Inclusion criteria and have no Exclusion criteria.|November 2015|November 5, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343523||28929|
NCT02343861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2014-154|The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis|The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis: A Pilot Study||Seoul National University Hospital|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343861||28903|
NCT02328807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17753|Focal Prostate Radio-Frequency Ablation|Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Recruiting|December 2014|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||November 2015|November 9, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02328807||30058|
NCT02352935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF-20150127（5）|Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function|Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2015|January 30, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02352935||28210|
NCT02345473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4186|Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy|Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy|CirCanCell|Azienda Ospedaliero-Universitaria Consorziale|Yes|Completed|January 2005|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|59|Samples With DNA|Peripheral blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing radical cystectomy for bladder cancer and healthy volunteers|January 2015|January 19, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02345473||28781|
NCT02345733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009-15-WOMC|Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis|Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study||Wolfson Medical Center|No|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|19 Years|No|||December 2015|December 21, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345733||28761|
NCT02355730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDE03|Blood Donation From Warfarin Users for the Development of POC INR Monitor|Blood Donation for the Development and Optimisation of the Second Generation Microvisk International Normalized Ratio (INR) Testing System for the Measurement of Prothrombin Time (PT)/INR in Patients on Warfarin Therapy.||Microvisk Technologies Ltd|No|Recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|1560|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02355730||27995|
NCT02353455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-13|Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity|Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity||Ludwig-Maximilians - University of Munich|No|Recruiting|March 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|Samples Without DNA|PBMC samples, monocyte derived cells|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The groups or cohorts will be selected from patients treated at the LMU University        Hospital.        Sampling Method is non-probability sample: patients are invited to volunteer to        participate.|September 2015|September 8, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353455||28170|
NCT02357966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-PT029|A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus|A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus||XBiotech, Inc.|No|Recruiting|May 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||July 2015|July 26, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357966||27825|
NCT02358057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL - DexAlf - 1|Can we Get Conscious Sedation by Combining Dexmedetomidine With Alfentanil?|Can we Get Conscious Sedation in Optimal Safety Conditions in an Emergency Department, by Combining Dexmedetomidine With Alfentanil?||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Active, not recruiting|February 2015|||August 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02358057||27818|
NCT02349412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221303|Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers|Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies||Alliance for Clinical Trials in Oncology|Yes|Recruiting|April 2015|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349412||28479|
NCT02345122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054/2014|CAMH PARTNERs Integrated Care Study|CAMH PARTNERs: Integrated Care for Better Outcomes|PARTNERs|Centre for Addiction and Mental Health|No|Enrolling by invitation|November 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345122||28808|
NCT02353546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 09-0855-C|CALM Phase 2b Pilot|Managing Cancer and Living Meaningfully (CALM): Phase 2b Pilot Randomized Psychotherapy Trial in Patients With Advanced Cancer|CALM|University Health Network, Toronto|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353546||28163|
NCT02353715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058229|Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing|PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing|PEAX|Duke University|No|Recruiting|May 2015|||December 2018|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|67|||Male|18 Years|N/A|No|Probability Sample|Duke clinics patients|February 2016|February 2, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353715||28150|
NCT02353884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hanying3|Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion|||Xuanwu Hospital, Beijing|Yes|Completed|January 2010|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|150|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The cognition of MCI is between healthy control and AD, which is thought the transitional        stage of AD. Patients with MCI have heavy risk to convert to AD.|January 2015|January 28, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02353884||28137|
NCT02357199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2084/14-3000|Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease|Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease||University of Copenhagen|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|93|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02357199||27882|
NCT02337946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panitumumab-2003|Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma|SAPPHIRE Study - A Phase II Randomized Study Comparing the Efficacy and Safety of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in the Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-type After 6 Cycles of Combination Therapy With mFOLFOX6 +|SAPPHIRE|Takeda|No|Recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|N/A|No|||January 2015|January 13, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02337946||29357|
NCT02328365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Comorbidity|Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer|Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer||Vejle Hospital|No|Recruiting|March 2014|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02328365||30092|
NCT02331550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2014-01|Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions.|Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions. Retrospective Paired Cohort Study.||Saint Thomas Hospital, Panama|No|Completed|January 2014|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|250|||Female|N/A|N/A|No|Non-Probability Sample|Patients referred to the Colposcopic Unit of Saint Thomas Hospital for the diagnosis of        Low-Grade Squamous Intraepithelial Lesions, between January 2010 and December 2013.|January 2015|January 5, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331550||29848|
NCT02331563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20.10.2014/24/07|Adjuvant Effect of Dexmedetomidine in Ultrasound (USG) Guided Transvers Abdominis Plane Block|Adjuvant Effect of Dexmedetomidine for the Ultrasound Guided Transversus Abdominis Plane Block in Patients Undergoing Laparascopic Cholecystectomy: a Randomized Controlled Clinical Trial.|USG|Kırıkkale University|No|Withdrawn|October 2014|November 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|September 3, 2015|January 1, 2015|Yes|Yes|patients should have assurance to attend this study, money is the main problem|No||https://clinicaltrials.gov/show/NCT02331563||29847|
NCT02335632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAH|Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis|Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis||Chuncheon Sacred Heart Hospital|Yes|Active, not recruiting|December 2012|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||January 2015|January 26, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02335632||29535|
NCT02338843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ501-CRH01|A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension|A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)|ATHOS-3|La Jolla Pharmaceutical Company|Yes|Recruiting|March 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|315|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338843||29288|
NCT02338856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB12066_003|Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers|A Phase I Clinical Trial to Evaluate the Pharmacokinetics and Safety of MB12066 in Healthy Male Volunteers||KT&G Life Sciences Corp|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|11|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338856||29287|
NCT02338986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150056|Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|December 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|5|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|February 24, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02338986||29277|
NCT02286531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 111 01|Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma|Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine (or FET), a New Tracer PET (Positron Emission Tomography) , in the Diagnosis of Low Grade Glioma|PET-FETII|University Hospital, Toulouse|No|Completed|June 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|93|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286531||33303|
NCT02286544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR-2014/252-31|Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers|Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Single Center, Randomized, Controlled Pilot Study in Healthy Volunteers||Karolinska Institutet|No|Active, not recruiting|October 2014|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286544||33302|
NCT02282475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK098707-01A1|Role of Liver and Visceral Fat in Glucose and Lipid Metabolism During Pregnancy|Role of Liver and Visceral Fat in Glucose and Lipid Metabolism During Pregnancy||Kaiser Permanente|Yes|Enrolling by invitation|November 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|75|||Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant women ages 18-40 years and actively enrolled in Kaiser Permanente Northwest        (KPNW).|February 2016|February 9, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02282475||33615|
NCT02286713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0628|PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening|Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|55 Years|77 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02286713||33289|
NCT02286934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP-CVDL-01|Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol|A Clinical Trial to Investigate the Influence of Cytochrome P450 2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamics Characteristics of Carvedilol in Healthy Korean Volunteers||Seoul National University Hospital|No|Completed|September 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286934||33272|
NCT02287103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0160-14-WOMC|Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D|Effect of Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Subsequent Isocaloric Lunch and Dinner in Type 2 Diabetic Patients|SkippB-T2D|Tel Aviv University|No|Recruiting|April 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|70 Years|No|||June 2015|June 2, 2015|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02287103||33259|
NCT02290509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC16|Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age|Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age||Protein Sciences Corporation|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1350|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02290509||32998|
NCT02336568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370-14CTIL|The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)|The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail||Rambam Health Care Campus|No|Not yet recruiting|March 2015|March 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336568||29463|
NCT02339103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31036|Study of Heat and Intravenous Fluids for Exogenous Rewarming|Study of Heat and Intravenous Fluids for Exogenous Rewarming (SHIVER)|SHIVER|Stanford University|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 22, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339103||29268|
NCT02341079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2014.0101|Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty|Prospective Randomized Trial Comparing Intraoperative Liposomal Bupivacaine Injection With Indwelling Femoral Nerve Blockade in Early Postoperative Pain Control for Primary Total Knee Arthroplasty||United States Naval Medical Center, San Diego|Yes|Not yet recruiting|March 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341079||29117|
NCT02336971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RyersonU|Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder|Individual Prolonged Exposure (PE) Versus Couples' Cognitive-Behavioral Therapy for Combat-Related Posttraumatic Stress Disorder (PTSD)||Ryerson University|Yes|Active, not recruiting|November 2011|October 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02336971||29432|
NCT02334618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73982|Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures|Clinical Trial of an Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures||University of Utah|No|Enrolling by invitation|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who present to the University of Utah emergency department with ankle fractures.|January 2016|January 4, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334618||29612|
NCT02334865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 247913|SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy|A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy||Roswell Park Cancer Institute|No|Recruiting|March 2016|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334865||29593|
NCT02335099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17224|Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis|Randomized, Placebo-controlled, Single Blind, Trial to Determine the Safety and Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis||University of Virginia|No|Recruiting|December 2014|March 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|85 Years|No|||August 2015|August 26, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335099||29575|
NCT02335385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM200912|Single Incision Laparoscopic Varicocelectomy|Single Incision Transumbilical Laparoscopic Varicocelectomy: Comparison With the Conventional Laparoscopic Approach.||Mansoura University|No|Completed|June 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|90|||Male|18 Years|N/A|No|||January 2015|January 7, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335385||29553|
NCT02338544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMP-it|Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne|Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne|PUMP-it|Galderma Laboratorium GmbH|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1388|||Both|9 Years|N/A|No|Probability Sample|About 2000 patients aged ≥9 years with moderate to severe inflammatory acne|February 2016|February 15, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338544||29311|
NCT02338622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4058|Trial of Olaparib in Combination With AZD5363 (ComPAKT)|A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours|ComPAKT|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02338622||29305|
NCT02338739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH104123-01|An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R) in Nyanza, Kenya|An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R)|AdaPT-R|University of California, San Francisco|No|Recruiting|March 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|15||Anticipated|2500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02338739||29296|
NCT02328430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3480|Feasibility and Validity of Remote Lung Function Assessment|Comparison of Remote Camera Measures of Lung Function Compared to Standard Spirometry||North Bristol NHS Trust|No|Not yet recruiting|January 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending UK secondary care outpatient department in respiratory medicine and how        are scheduled to undergo spirometry|December 2014|December 30, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02328430||30087|
NCT02290379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-IS-T101|Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers|A Single-Center, Randomized, Double-blind, Placebo-controlled, Phase 1, Single Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of TNX-201 Capsules in Healthy Volunteers.||Tonix Pharmaceuticals, Inc.|No|Active, not recruiting|November 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|April 8, 2015|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02290379||33007|
NCT02286726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0548|Phase II CPX-351 in Acute Myeloid Leukemia (AML)|Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality||M.D. Anderson Cancer Center|Yes|Recruiting|May 2015|||May 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02286726||33288|
NCT02290405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2786|Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers|Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers||National Jewish Health|No|Recruiting|October 2014|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|164|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|This study will use a matched-groups cross-sectional experimental design. Age and gender        matched groups of hyperaroused PI sufferers and non-complaining normal sleepers (NS) will        be recruited and enrolled. A comprehensive screening process that includes structured        sleep and psychiatric interviews, screening questionnaires, medical exam, and diagnostic        PSG will be used to determine eligible subjects.|October 2014|November 10, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02290405||33005|
NCT02290457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPotsdam|Core Strength Training in Youth|Effects of Core Strength Training Using Unstable Surfaces on Physical Fitness in Adolescents||University of Potsdam|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290457||33001|
NCT02279225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|y4tma2ef|Protocol Phototherapy Treatment for Fibromyalgia and Temporomandibular Joint Dysfunction|RANDOMIZED DOUBLE-BLIND CONTROLLED THE USE OF PHOTOTHERAPY IN FIBROMIÁLGICOS WITH TEMPOROMANDIBULAR JOINT DYSFUNCTION|FM and DTM|University of Nove de Julho|No|Recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|61|||Female|35 Years|58 Years|No|||October 2015|December 13, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02279225||33864|
NCT02288676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A08-M79-13B|DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries|DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries|DOvEEgene|McGill University|No|Recruiting|January 2014|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|280|||Female|18 Years|N/A|No|Non-Probability Sample|The participating hospitals run multiple weekly routine gynecology and gynecologic        oncology clinics. The Cases include women scheduled to undergo surgery for tumor removal,        for either proven or suspected upper genital tract cancer. The Controls include women        scheduled to have a hysterectomy, bilateral salpingectomy (removal of the fallopian tubes)        with/without bilateral oophorectomy (removal of the ovaries) to treat benign conditions.|February 2016|February 8, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02288676||33138|
NCT02283515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/10/2013-14A|Efficacy of Locally Delivred 1.2% Rosuvastatin Gel in Chronic Periodontitis|Efficacy of Locally Delivered 1.2% Rosuvastatin Gel in Non Surgical Treatment of Chronic Periodontitis Patients: A Randomised Clinical Control Trial.||Government Dental College and Research Institute, Bangalore|Yes|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|22 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02283515||33535|
NCT02283528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076048|A Comparison of Stryker Hybrid Arch Bars|A Comparison of Stryker Hybrid Arch Bars Versus Erich Arch Bars for Maxillomandibular Fixation of Mandibular Fractures: A Prospective Randomized Study|Hybrid|Emory University|Yes|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|October 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283528||33534|
NCT02283827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-121|Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.|Phase I, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Phenytoin 300 mg Following Multiple Dose Administrations in Healthy Male Volunteers||Bial - Portela C S.A.|No|Completed|January 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|November 3, 2014||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT02283827||33511|
NCT02338973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150052|Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)|Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|12 Years|N/A|No|||May 2015|January 14, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338973||29278|
NCT02329990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUT:00.11|Effect of Phosphorus Supplementation on Body Weight|Premeal Phosphorus Supplementation for Reducing Energy Intake and Body Weight||American University of Beirut Medical Center|Yes|Completed|June 2013|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|71|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02329990||29967|
NCT02336685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100068|Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336685||29454|
NCT02336815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-012|Phase 2b Open-Label Single-Arm Study of Selinexor & Dexamethasone in Patients Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide|A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Dexamethasone in Patients With Multiple Myeloma Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide and Refractory to an IMiD and a Proteasome Inhibitor|STORM|Karyopharm Therapeutics, Inc|Yes|Recruiting|May 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336815||29444|
NCT02341170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPPO-S|HS-PCI in Locally Advanced Adenocarcinoma of the Lung|A Phase III Trial of Hippocampal-sparing Prophylactic Cranial Irradiation (HS-PCI) in Locally Advanced (Stage IIIA/IIIB) Adenocarcinoma of the Lung|HIPPO-S|Universitätsmedizin Mannheim|No|Not yet recruiting|January 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02341170||29110|
NCT02337127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20110187|Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents|A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|June 2011|May 2016|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02337127||29420|
NCT02341274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409250015|Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers|Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteers|ASDBioequiv|Indiana University|Yes|Not yet recruiting|May 2016|October 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341274||29102|
NCT02338362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6069-A|Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma|The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.||University Health Network, Toronto|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|22|||Both|18 Years|85 Years|No|||March 2015|March 9, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338362||29325|
NCT02338375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-078|Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product|Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients|Cartistem|Samsung Medical Center|No|Enrolling by invitation|December 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|70 Years|No|||January 2015|January 11, 2015|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02338375||29324|
NCT02338440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-HSCT-lipoPGE1|Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT|Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT||Seoul National University Hospital|Yes|Recruiting|January 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||November 2015|November 17, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02338440||29319|
NCT02327975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I+D|Prescription of Physical Exercise Through Mobile Application in Elderly|Effects of a Training Program of Physical Exercise Administered Through Mobile Application in Elderly|PEME|University of the Balearic Islands|No|Completed|November 2012|||September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|48|||Both|53 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 27, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02327975||30122|
NCT02332109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODM5FDE-PMCF-DE-2015-01|ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy|ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy||TRB Chemedica AG|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a Fuchs endothelial dystrophy-induced corneal edema and an ODM 5 therapy        recommendation.|December 2015|December 4, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02332109||29805|
NCT02332356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC study|Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease|Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease||Tokyo Medical and Dental University||Recruiting|September 2014|||March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|16 Years|65 Years|No|||January 2015|January 4, 2015|January 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02332356||29786|
NCT02328196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetropolitanUC|Validation of a Revised Version of the Danish McGill Ingestive Skills Assessment|Validation of a Revised Version of the Danish McGill Ingestive Skills Assessment for Measuring Dysphagic Clients' Performance During Meals||Metropolitan University College|No|Completed|August 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|328|||Both|18 Years|N/A|No|Non-Probability Sample|Clients +18 years referred to occupational therapy for swallowing evaluation because of        known or suspected dysphagia|March 2016|March 15, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02328196||30105|
NCT02328209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000014056|Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration|Evaluation of the Efficacy and Continuance Rate of Treatment in Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration||Mie University|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|N/A|No|||December 2014|December 26, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02328209||30104|
NCT02332369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EyeKon CTR|EyeKon Medical Inc. CTR Study|EyeKon Medical, Inc. Capsular Tension Ring Clinical Study|CTR|EyeKon Medical, Inc.||Active, not recruiting|February 2005|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332369||29785|
NCT02332629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_08_2014a|Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Endothelial Function in Patients Scheduled for Total Knee-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|58|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332629||29765|
NCT02278445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP22_3|Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)||Echosense Ltd.|No|Withdrawn|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||August 2014|November 29, 2015|October 27, 2014||No|No patients|No||https://clinicaltrials.gov/show/NCT02278445||33924|
NCT02282748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP 000000612|Swiss Longitudinal Cohort|Swiss Longitudinal Cohort||Hypertension Excellence Centre Lucerne|No|Recruiting|October 2014|||September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population of four Swiss municipalities|August 2015|August 18, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02282748||33594|
NCT02278679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17658|Digital Rectal Exam Proficiency Tool|Validation of the DiRECT Proficiency Tool|DiRECT|University of Virginia|Yes|Recruiting|October 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|410|||Male|30 Years|90 Years|No|Probability Sample|Subjects with Benign Prostate Hypertrophy, Prostate Cancer or routine digital exam being        seen by Urology Attendings, residents or medical students.|December 2015|December 2, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278679||33906|
NCT02278926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|442-092014|Lypo-hypertrofia Characterization in Diabetes|Ultrasound Characterization of Lipo-hypertrophy in Type 1 Diabetes Mellitus||Niguarda Hospital|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 diabetes patients with visible lypo-hypertrphy that attend consecutively in our        outpatient clinic|October 2014|October 31, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278926||33887|
NCT02288689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0180-14-MMC|Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term|Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term|EUC|Meir Medical Center|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|20 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant patients 20-44 years old at term|September 2015|September 22, 2015|October 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288689||33137|
NCT02288819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOL-DIPSTICK|Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure|Diuretic Efficiency in Patients With Stable Heart Failure: Ion Excretion Capacity of the Kidneys (DIPSTICK) Study|DIPSTICK|Hasselt University|Yes|Recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02288819||33127|
NCT02329691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Team and safety|Team, Competence and Safety Climate in the Operating Room|Team, Competence and Safety Climate in the Operating Room||Sahlgrenska University Hospital, Sweden|No|Enrolling by invitation|December 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|125|||Both|N/A|N/A|No|Non-Probability Sample|All health care personnel working in the OR at the general surgery department, Sahlgrenska        University Hospital|December 2014|December 27, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02329691||29990|
NCT02333851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOHUCA1|Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)|Comparison of Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)|PININ|Hospital Universitario Central de Asturias|No|Terminated|June 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|December 20, 2014||No|Safety reasons|No||https://clinicaltrials.gov/show/NCT02333851||29671|
NCT02341092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/34|Analysis and Valuation of the Expertise of Use of the Close Friends of People Victims of Traumatic Brain Injury|AVEC-TC : Post-traumatic Behavioral Disorders : Analysis and Valuation of the Expertise of Use of the Close Relations of People Victims of Traumatic Brain Injury|AVEC-TC|University Hospital, Angers|No|Recruiting|February 2013|June 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|65 Years|No|Probability Sample|Victim of a grave or moderate traumatic brain injury and existence of at least a referent        close friend (relation): parent (relative), child, spouse, professionnal, other.|January 2015|January 13, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02341092||29116|
NCT02330458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027597|The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients|The Role of Small Bowel Ultrasound After Ileocolic Resection or When Starting Infliximab in Crohn's Disease Patients||Cedars-Sinai Medical Center|No|Recruiting|January 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|6 Years|23 Years|No|Non-Probability Sample|Patients with Crohn's disease involving the small bowel, initiating Infliximab treatment.|January 2015|January 6, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330458||29932|
NCT02330731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|482|N-butyl-2-cyanoacrylate, Iso-amyl-2-cyanoacrylate and Hypertonic Glucose With 72% Chromated Glycerin in Gastric Varices|N-butyl-2-cyanoacrylate, Iso-amyl-2-cyanoacrylate and Hypertonic Glucose With 72% Chromated Glycerin in Gastric Varices||Ain Shams University|Yes|Completed|January 2012|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|25 Years|60 Years|No|||January 2015|January 2, 2015|January 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330731||29911|
NCT02341352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-8|Three Measures for the Prevention of Carious Lesions in Preschool Children|Study on Children's Dental Caries Prevention and Mechanism||Zhejiang University|Yes|Active, not recruiting|April 2013|June 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|500|||Both|24 Months|54 Months|Accepts Healthy Volunteers|||January 2015|January 13, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02341352||29096|
NCT02330744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21695|The Neurobiology of Approach Avoidance Training in Depression|The Neurobiology of Approach Avoidance Training in Depression|ACTIV8|University of California, San Diego|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330744||29910|
NCT02327507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advantage001|Everybody Brush: A Community-wide Toothpaste Distribution Campaign|Bending the Oregon Health Plan (OHP) Dentistry Cost Curve in Central Oregon by Reducing the Burden of Oral Disease||Advantage Dental Services, LLC|No|Active, not recruiting|June 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|21731|||Both|6 Months|20 Years|No|Non-Probability Sample|Children and adolescents enrolled in Medcaid OHP and assigned to Advantage Dental Services        in Oregon in Crook, Deschutes, or Jefferson counties|December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327507||30158|
NCT02331303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17399|A Drug Utilization Study of Radium-223 in Sweden|A Drug Utilization Study of Xofigo Use in Sweden||Bayer|No|Active, not recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|This study will include patients receiving treatment of Xofigo at certified nuclear        medicine centers across Sweden during a two year period. It will consist of mCRPC patients        and potentially some other patient groups in whom Xofigo may be used off-label including        women, children, cancer patients having bone metastasis with a diagnosis other than CRPC,        and patients with repeated courses of treatment or in excess of those recommended in the        label. This study will be based on data extracted from two pre-established data sources:        15 nuclear medicine centers across Sweden and the Swedish National Cancer Registry.|March 2016|March 14, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331303||29867|
NCT02327728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC00173|Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm|Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm||Sun Yat-sen University|Yes|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2014|December 24, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02327728||30141|
NCT02331836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-CUFF-2015|Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy|Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy for Adenoma Detection: A Randomized Controlled European Multicenter Study|EC-Cap-SC|Helios Albert-Schweitzer-Klinik Northeim|No|Recruiting|February 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|561|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331836||29826|
NCT02331849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIMEOS-2013|Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.|Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry - Effect on Esophageal Motility of Standard Therapy.|HIMEOS|Technische Universität München|No|Recruiting|October 2013|||February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|90 Years|No|||January 2015|January 2, 2015|December 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02331849||29825|
NCT02336490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BostonMC|Randomized Pilot Trial of the Impact of Bedside Delivery of Discharge Medications to Pediatric Patients With Asthma|Randomized Pilot Trial of the Impact of Bedside Delivery of Discharge Medications||Boston Medical Center|No|Completed|January 2015|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|23|||Both|2 Years|17 Years|No|||October 2015|October 28, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336490||29469|
NCT02336594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-110|RDEA3170 Bioavailability Study|A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Two RDEA3170 Tablets||Ardea Biosciences, Inc.|No|Completed|November 2014|March 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|15|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02336594||29461|
NCT02342015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio clinico n° 14/AULSS 9|Effect of Atorvastatin on Bone-vascular Axis|||University of Padova|No|Completed|September 2009|March 2013|Actual|November 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Female|N/A|N/A|No|||January 2015|January 14, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02342015||29045|
NCT02282761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-301|A Trial to Assess the Antipsychotic Efficacy of ITI-007|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia||Intra-Cellular Therapies, Inc.|No|Completed|November 2014|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|60 Years|No|||November 2015|November 5, 2015|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02282761||33593|
NCT02283021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALCIUM-HMO-CTIL|Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)|Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)||Hadassah Medical Organization|Yes|Enrolling by invitation|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Lung specimen biospsies are routinely taken from NSCLC patients and sent to pathological      evaluation. We will obtain small samples from these biopsies from the pathologist, which are      normally discarded. mRNA will be extracted from these samples.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed with NSCLC and patients not diagnosed with NSCLC|August 2015|August 19, 2015|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02283021||33573|
NCT02283281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cannapremed-HMO-CTIL|Anesthetic Premedication With a Cannabis Extract (Cannapremed)|Effects of a Cannabis Extract as Anaesthetic Premedication on Postoperative Pain, Nausea-vomiting and Perioperative Anxiety|Cannapremed|Hadassah Medical Organization|Yes|Recruiting|May 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|60 Years|No|||March 2016|March 23, 2016|November 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02283281||33553|
NCT02283294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00019754|Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation|Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation|AREST|University of South Florida|Yes|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|October 2, 2015|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02283294||33552|
NCT02292966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1304|Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism|Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and Beclabuvir for Patients With HCV Genotype 1 Infection|HEPCOG-II|Kirby Institute|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02292966||32809|
NCT02292979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREACH|Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.|Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study|BREACH|The Lymphoma Academic Research Organisation|Yes|Recruiting|March 2015|August 2022|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|60 Years|No|||October 2015|October 16, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02292979||32808|
NCT02288910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14030305|Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver|Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver||Rush University Medical Center|No|Recruiting|November 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with non-diffuse hepatocellular carcinoma or metastatic liver disease|August 2015|August 21, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02288910||33120|
NCT02337335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCSRR01|Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients|Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients||NephroCare Spain|No|Recruiting|November 2014|April 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|268|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on hemodialysis|January 2015|January 8, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02337335||29404|
NCT02330224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/663/E|Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health|Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health - A Cluster Randomized Pilot Trial in SingHealth Polyclinics, Singapore||Duke-NUS Graduate Medical School|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|40 Years|N/A|No|||December 2014|December 31, 2014|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02330224||29949|
NCT02334332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14286|Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for Recovery After Surgery|Pilot Study of an Educational Brochure to Prepare Patients and Informal Caregivers for Recovery Following Gastrectomy||City of Hope Medical Center|Yes|Withdrawn|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|January 6, 2015||No|No accrual|No||https://clinicaltrials.gov/show/NCT02334332||29634|
NCT02334644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-049|Probiotic Treatment in Adult Obsessive-Compulsive Disorder|A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder||McMaster University|No|Recruiting|April 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|65 Years|No|||May 2015|May 19, 2015|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334644||29610|
NCT02334657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/13|Prospective Study of Long-term Outcome After Non-aneurysmal Subarachnoid Hemorrhage|Prospective Study of Long-term Outcome After Non-aneurysmal Subarachnoid Hemorrhage||University Clinic Frankfurt|No|Completed|November 2013|January 2015|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|173|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a spontaneous, non-traumatic SAH, in whom no bleeding source was identified        by repetitive angiography including 3D digital subtraction angiography|November 2015|November 30, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334657|15 Years|29609|
NCT02337998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1593-14-SMC|The Effect of Load Carriage on Upper Limb Performance|||Sheba Medical Center|No|Active, not recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02337998||29353|
NCT02331576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHH-2014-141|Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics in Femoral Nerve Block|Femoral Nerve Block in Patient With Total Knee Arthroplasty; Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics||Chonnam National University Hospital|Yes|Recruiting|January 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|90 Years|No|||January 2016|January 30, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02331576||29846|
NCT02331589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFEKRG|Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis|Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis||Chuncheon Sacred Heart Hospital|Yes|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|80 Years|No|||December 2014|February 8, 2015|December 31, 2014||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT02331589||29845|
NCT02336334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PosturingSensor|Evaluation of Posturing-Adherence in Patients After Intraocular Surgery|Measurement and Logging of Posturing Adherence of Patients After Intraocular Surgery With Gasendotamponades Using a Sensorsystem With Different Feedback-Methods||University Hospital Tuebingen|No|Recruiting|October 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02336334||29481|
NCT02336347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AVP-786-102|A Phase 1 Study Comparing AVP-786 With AVP-923|A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786 With AVP-923||Avanir Pharmaceuticals|No|Completed|May 2014|March 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|62|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336347||29480|
NCT02338999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150060|Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)|The Role of PPAR-Gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|January 2020|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|99 Years|No|||October 2015|February 11, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338999||29276|
NCT02341989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2012|Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer|A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer|SWENOTECA-ABC|St. Olavs Hospital|No|Recruiting|April 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|348|||Male|18 Years|60 Years|No|||October 2015|October 13, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341989||29047|
NCT02329210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAW10113|Clinical Registry Investigating Bardet-Biedl Syndrome|Clinical Registry Investigating Bardet-Biedl Syndrome|CRIBBS|Marshfield Clinic Research Foundation|No|Recruiting|June 2014|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Individuals meeting the diagnostic criteria of Bardet-Biedl syndrome and/or with genetic        confirmation of the condition are eligible for participation in CRIBBS. Deceased        individuals meeting diagnostic and/or genetic criteria may also be enrolled by their next        of kin.|December 2014|December 26, 2014|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329210|10 Years|30027|
NCT02287116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRBILYA|Continuous Positive Airway Pressure Via Binasal Prong vs Nasal Mask: a Randomised Controlled Trial|Continuous Positive Airway Pressure Via Binasal Prong vs Nasal Mask: a Randomised Controlled Trial|MASK|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|May 2014|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|150|||Both|N/A|1 Year|Accepts Healthy Volunteers|||November 2014|November 5, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02287116||33258|
NCT02287324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLV-1303-4418|Effects of Cervical Spine Manipulation on Gait|Immediate Effects of Cervical Spine Manipulation on Gait Parameters in Individuals With and Without Mechanical Neck Pain||University of Nevada, Las Vegas|Yes|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02287324||33242|
NCT02287558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Z14|Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study|A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia||The Cleveland Clinic|Yes|Not yet recruiting|November 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287558||33224|
NCT02277574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-110-02|Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis|A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis||Amplimmune|No|Recruiting|June 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|75 Years|No|||October 2014|October 27, 2014|July 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277574||33991|
NCT02281695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHO 001|PEEP Influence on Gas Exchange During Early Weaning|The Influence of Different PEEP Values on Gas Exchange in Spontaneously Breathing Patients During Early Weaning|MHOPEEP|Marienhospital Osnabrück|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281695||33674|
NCT02329457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU 11-174|VZV Vaccine for Hematopoietic Stem Cell Transplantation|Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial|VZIDST|The University of Hong Kong|Yes|Recruiting|December 2014|August 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|120|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329457||30008|
NCT02333591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ02|Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults|Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults||Bispebjerg Hospital|Yes|Not yet recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|20|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333591||29691|
NCT02333604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01295658|Cancer Experience Registry|Cancer Experience Registry|CER|Cancer Support Community, Research and Training Institute, Philadelphia||Recruiting|January 2013|||January 2035|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any individual who has received a cancer diagnosis or is caring for someone with cancer.|January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02333604|10 Years|29690|
NCT02333838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130916|Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies|Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies|TBF-Cord|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|57|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02333838||29672|
NCT02341898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPRINT|Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents (IMPRINT)|Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents: a Cluster-randomized Controlled Trial|IMPRINT|University of Luebeck|Yes|Recruiting|March 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|10800|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02341898||29054|
NCT02334098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRF-11402514|Omega-3 Supplementation and Behavior Problems|Omega-3 Supplementation and Behavior Problems in Children and Adolescents||City University of Hong Kong|Yes|Recruiting|February 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|300|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|December 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334098||29652|
NCT02337751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/OCT-001|A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants|A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa||Takeda|No|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|182|||Both|30 Years|79 Years|No|||March 2016|March 7, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337751||29372|
NCT02337764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/OCT-002|A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants|A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients||Takeda|No|Active, not recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|215|||Both|30 Years|79 Years|No|||January 2016|January 7, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337764||29371|
NCT02338011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiChest Hospital|Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)|Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial|EGFR|Shanghai Chest Hospital|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 23, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338011||29352|
NCT02327286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|563942/2010-0|Randomized Clinical Trial of Lifestyle Interventions to Prevent Diabetes in Women With Previous Gestational Diabetes|Prevenção do Diabetes em Mulheres Com Diabetes Gestacional prévio: Estudo multicêntrico de mudanças Intensivas de Estilo de Vida: LINDA-Brasil|LINDA-Brasil|Federal University of Rio Grande do Sul|No|Not yet recruiting|January 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|740|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327286||30175|
NCT02335645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00823|AlterG ACL Return to Running Case Series|AlterG ACL Return to Running Case Series||Nationwide Children's Hospital|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5|||Both|N/A|N/A|No|Non-Probability Sample|Study population will include post operative ACL patients who meet the eligibility        criteria who are being treated at Nationwide Children's Westerville Physical Therapy        location.|November 2015|November 18, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335645||29534|
NCT02335931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-055|Characterization of the Charcot Foot|Follow-up on Cross-sectional Study of Known Population With Charcot Osteoarthropathy - Metabolic, Physiologic and Pathologic Changes||Bispebjerg Hospital|No|Enrolling by invitation|September 2014|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|49|Samples Without DNA|Frozen full blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Follow-up study, population of patients referred with charcot foot 8 years ago. Control        population without Charcot foot, taken from the outpatient clinic.|January 2016|January 11, 2016|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02335931||29512|
NCT02335944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2105C|Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.|A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.||Novartis|No|Recruiting|January 2015|November 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02335944||29511|
NCT02338869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2047|Psycho-Social Well Being Following Stroke|Psycho-Social Well Being Following Stroke - A Randomized Controlled Trial|PsychoStroke|University of Oslo|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02338869||29286|
NCT02338882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC001|Clinical Investigation of the Bi Flex M Multifocal IOL|Randomised Clinical Investigation of the Bi Flex M Multifocal Intraocular Lens||University of Plymouth|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338882||29285|
NCT02328677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6407|ColoCare Study - Colorectal Cancer Cohort|ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis||Fred Hutchinson Cancer Research Center|No|Recruiting|March 2007|October 2030|Anticipated|October 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|5000|Samples With DNA|blood, urine, feces, saliva, FFPE and fresh frozen tissue (multiple sources/locations), DNA,      RNA, miRNA|Both|18 Years|89 Years|No|Non-Probability Sample|ColoCare is an international prospective cohort study of stage I-IV colorectal cancer        patients (ICD-10 C18-C20). The ColoCare Consortium is a multicenter initiative of        interdisciplinary research on CRC outcome and prognosis, and comprises patient recruitment        at 4 sites. Patients are recruited at baseline (time of first diagnosis, time prior to        surgery or during treatment (FHCRC and HCI)) and followed for up to 10 years at regular        timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive        collection of biospecimens and data.|January 2016|January 14, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02328677||30068|
NCT02328924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uospmacg|There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols?|There is a Cut Off Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome? A Randomized Controlled Trial in Fixed Versus Flexible Gonadotropin-releasing Hormone Antagonist Protocols.||U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti|Yes|Completed|May 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|213|||Female|35 Years|39 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02328924||30049|
NCT02328937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5550|Central Corneal Swelling With Silicone Hydrogel Materials|Daily Wear Central Corneal Swelling With Etafilcon A and 2 Silicone Hydrogel Materials||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328937||30048|
NCT02333396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Navigate Study|Improving Communication in the PICU: The Navigate Study|Improving Communication in the Pediatric Intensive Care Unit for Patients Facing Life-Changing Decisions: The Navigate Study||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Enrolling by invitation|April 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|506|||Both|N/A|N/A|No|||June 2015|June 25, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02333396||29706|
NCT02292927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1368|Trimodal Prehabilitation for Aneurysm Surgery Study|Maximising Recovery to Health Through Trimodal (Bio Psycho Social) Prehabilitation for Aneurysm Surgery Study|T-PASS|Imperial College London|No|Active, not recruiting|November 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|40 Years|95 Years|No|Non-Probability Sample|Patients from Imperial College Healthcare NHS Trust Vascular Unit undergoing aortic        aneurysm repair will be recruited. The unit performs in the region of 100 abdominal aortic        repairs annually with a further 100 thoracic aneurysms.|November 2014|June 29, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02292927||32812|
NCT02292940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1567-H|Consumer Health IT Tools: Impact on Experience, Access, and Outcomes for Patients With Complex Chronic Conditions|Consumer Health IT Tools: Impact on Patient Experience, Access, and Health Outcomes for Patients With Complex Chronic Conditions||Kaiser Permanente|No|Active, not recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a chronic disease|October 2015|October 1, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02292940||32811|
NCT02292953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13952014|Variation in Serum Prolactin Levels During IntraCytoplasmic Sperm Injection|Variation in Serum Prolactin Levels in Response to Ovum Pickup for Patients Undergoing ICSI & it's Effect on Pregnancy Rate||Kasr El Aini Hospital|No|Recruiting|November 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|||Female|20 Years|43 Years|Accepts Healthy Volunteers|Probability Sample|Ninety normo-prolactinemic patients attending the Assisted reproduction unit in the        Obstetrics and Gynecology Department-Faculty of Medicine -Cairo University, Scheduled for        ICSI treatment cycle .Each participant will be subjected to infertility work up        investigation in the form of semen analysis, hormonal profile (FSH, LH, TSH and        prolactin).|November 2014|November 17, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02292953||32810|
NCT02286063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013OE005B|Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)|Randomized, Controlled Crossover Trial to Evaluate the Effects of Ambulatory Oxygen on Health Status in Patients With Fibrotic Lung Disease (FLD).|AmbOx|Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02286063||33339|
NCT02336984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03114|A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS|A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|June 2014|||June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336984||29431|
NCT02337140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9357|Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation|Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation : Contribution of Electrophysioly Study|TAVISTIM|University Hospital, Montpellier|No|Recruiting|August 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|50 Years|N/A|No|||January 2015|January 8, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02337140||29419|
NCT02330237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGCPP|Natural Gels for Treatment of Plaque Psoriasis|Safety and Efficacy of Natural Gel Combination and Hair Mask of Plant Origin in Patients With Psoriasis: A Randomized, Double-Blind, Placebo (Vehicle) Controlled||Secret of Youth|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 31, 2014|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330237||29948|
NCT02337517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02672|Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease|Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)||National Cancer Institute (NCI)|Yes|Recruiting|September 2015|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337517||29390|
NCT02337530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I219|Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|March 22, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337530||29389|
NCT02327039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3302/AO/14|The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients|The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients. A 12 Weeks Randomized Placebo-controlled Phase IV Study|DAPA-HDL|University of Padova|No|Recruiting|March 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02327039||30194|
NCT02331030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2047|A Randomised Trial Comparing Supraclavicular Block vs Supraclavicular and Pecs II Block in Arteriovenous Grafting|A Randomised Controlled Trial Comparing Ultrasound-guided Supraclavicular Brachial Plexus Block With Combined Supraclavicular and Pecs II Block in Patients Undergoing Arteriovenous Grafting Surgery||Changi General Hospital|No|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|90 Years|No|||July 2015|July 29, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331030||29888|
NCT02338635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URSA-1|Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis|Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis||Ewha Womans University|No|Not yet recruiting|July 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|55|||Both|15 Years|80 Years|No|||May 2015|May 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338635||29304|
NCT02327754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY1004|Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout|Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).|UPWARD|Sanwa Kagaku Kenkyusho Co., Ltd.|No|Active, not recruiting||December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||November 2015|November 16, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327754||30139|
NCT02338752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pancreatic cancer MV|Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Pancreatic Carcinoma Patient||Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|18 Years|No|||January 2015|September 8, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338752||29295|
NCT02328443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP3A_weak|Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of Drug-drug Interaction|Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of Drug-drug Interaction in Korean Healthy Subjects|CYP3A_weak|Seoul National University Hospital|No|Not yet recruiting|December 2014|||July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|16|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328443||30086|
NCT02332902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0758|Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T|Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T|DCLNF1|The University of Texas Health Science Center, Houston|No|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02332902||29744|
NCT02333136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327074-1|In Vivo Raman Spectroscopy of Human Capillary Beds|In Vivo Raman Spectroscopy (IVRS) of Human Fingertip Capillary Beds|IVRS|State University of New York - Upstate Medical University|No|Active, not recruiting|August 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|N/A|No|Non-Probability Sample|stabel dialysis patients|November 2015|December 30, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02333136||29726|
NCT02333149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022025|Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population|Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population|MYNAP|University of Alberta|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|6 Years|17 Years|No|||December 2015|December 10, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02333149||29725|
NCT02335073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFT4-LC|Effect of 4 Liver Fibrosis Tests (PIIINP, CIV, LN, and HA) on the Prognosis of Liver Cirrhosis|Effect of 4 Liver Fibrosis Tests (PIIINP, CIV, LN, and HA) on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Observational Study||General Hospital of Shenyang Military Region|No|Active, not recruiting|January 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100||Venous blood|Both|N/A|N/A|No|Probability Sample|Study population should be patients with a diagnosis of liver cirrhosis who were admitted        to the Department of Gastroenterology of the General Hospital of Shenyang Military Area.|February 2016|February 9, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335073||29577|
NCT02335359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tranex-AAA/34/OSR|Tranexamic Acid in Major Vascular Surgery|Tranexamic Acid in Major Vascular Surgery. A Randomized Placebo-controlled Trial.||IRCCS San Raffaele||Recruiting|March 2015|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|50 Years|N/A|No|||March 2015|March 4, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335359||29555|
NCT02335606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-440|Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan|Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Multi-center Observational Study in Taiwan||Bristol-Myers Squibb|No|Recruiting|October 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|318|||Both|20 Years|N/A|No|Non-Probability Sample|Hospital : Research based hospital centers, Teaching hospitals affiliated with medical        schools, National/Regional medical centers and/or in which thought leaders are employed|March 2016|March 7, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335606|2 Years|29537|
NCT02276742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-01469|Lifestyle Management of CKD in Obese Diabetic Patients|Lifestyle Management of CKD in Obese Diabetic Patients||New York University School of Medicine|Yes|Recruiting|October 2014|October 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|300|||Both|40 Years|N/A|No|||December 2015|December 4, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02276742||34055|
NCT02276989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0751|Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain|Evaluation of a Compliance Marker A Supplement to: U01DA029580-02 Opioid-Induced Hyperalgesia In Prescription Opioid Abusers: Effects of Pregabalin||Georgetown University|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|50 Years|No|||October 2015|October 3, 2015|October 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02276989||34036|
NCT02277249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#12-001241|Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion|Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion: a Pilot Study of Patient Preference||University of California, Los Angeles|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 25, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02277249||34016|
NCT02277561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-01-047|Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery|Prediction of Response of Brain Metastases to Brain Irradiation Using Voxel Based Diffusion Tensor Imaging||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|April 2013|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|44|||Both|19 Years|N/A|No|||October 2014|October 27, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277561||33992|
NCT02293044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014115|A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity|A Pilot Clinical Study to Evaluate the Safety and Efficacy of a Self-Applied Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity||Procter and Gamble||Completed|November 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293044||32803|
NCT02341781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MCL-004|Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment|A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.|MCL-004|Celgene|No|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Mantle Cell Lymphoma (MCL) subjects who received lenalidomide, either as monotherapy or as        combination treatment, after having relapsed or progressed on ibrutinib treatment or were        refractory or intolerant to ibrutinib treatment.        Lenalidomide does not need to be the next subsequent treatment after ibrutinib.|January 2016|January 28, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02341781||29063|
NCT02329704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlBarakaSD2|Evaluation Study Between Density Gradient and Swimming Down for Semen Processing|Evaluation Study Between Density Gradient and Swimming Down for Semen Processing||Al Baraka Fertility Hospital|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|Samples With DNA|Semen samples|Male|18 Years|60 Years|No|Non-Probability Sample|Cases arranged for study were submitted for routine semen analysis. Patient agreements        collected as consent form signed during sample submission.|December 2014|December 30, 2014|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02329704||29989|
NCT02329717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4350|Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma|A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma||Phoenix Biotechnology, Inc|Yes|Recruiting|April 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329717||29988|
NCT02341820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8713|PICTURE Breast L: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Longitudinal|PICTURE Breast L: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Longitudinal|PICTURE L|University College, London|No|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|N/A|No|Non-Probability Sample|Women who are scheduled to undergo breast conserving surgery for early breast cancer.|October 2015|October 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02341820||29060|
NCT02341833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-26-06|Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts|||University Hospital of Liege||Not yet recruiting|January 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|N/A|N/A|No|||January 2015|January 20, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02341833||29059|
NCT02334670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01GH000758|Vietnam Cryptococcal Retention in Care Study|Evaluation of a Public Health Strategy to Improve Survival of HIV Infected Patients|CRICS|National Hospital for Tropical Diseases, Hanoi, Vietnam|No|Not yet recruiting|May 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2612|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02334670||29608|
NCT02341950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-RERC-82972|Clinical Trial of a Serious Game for Individuals With SCI/D|Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction||University of Michigan|No|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|13 Years|29 Years|No|||December 2015|January 8, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02341950||29050|
NCT02330757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA2|HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients|Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients||Mansoura University|No|Recruiting|January 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|20 Years|38 Years|No|||January 2016|January 29, 2016|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02330757||29909|
NCT02335398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289/2554(EC4)|Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management|Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management||Mahidol University|Yes|Completed|July 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335398||29552|
NCT02327988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387.826|Cryotherapy and Laser Therapy on Muscle Damage|Cryotherapy and Laser Therapy do Not Interfere in the Response to Eccentric Exercise-induced Muscle Damage: a Randomized Clinical Trial.|CLMD|Universidade Federal do Rio Grande do Norte|Yes|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02327988||30121|
NCT02328222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWKT|ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION|PHASE 4, STUDY OF THE EFFECT OF EARLY STEROID WITHDRAWAL IN RENAL TRANSPLANT RECEPIENTS OF A LIVING-RELATED DONOR|ESWMEX001|Unidad de Investigacion Medica en Enfermedades Renales|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|60 Years|No|||December 2014|December 26, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02328222||30103|
NCT02332655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00029264|Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome|Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Month|45 Years|No|||January 2016|January 8, 2016|January 5, 2015|No|Yes||Yes||https://clinicaltrials.gov/show/NCT02332655||29763|
NCT02332889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0855|Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs|A Phase I/Pilot II Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed or Refractory Pediatric High Grade Gliomas, Medulloblastomas, and CNS PNETs||University of Louisville|Yes|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|25 Years|No|||November 2015|November 30, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332889||29745|
NCT02334839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0206-14|The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction|The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction||Rabin Medical Center|Yes|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|A prospective cohort study of approximately 150 gravidas who are hospitalized in        maternal-fetal medicine (MFM) ward in Rabin Medical Center in Israel.|January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334839||29595|
NCT02335346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15611|An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)|An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain||Eli Lilly and Company|No|Active, not recruiting|January 2015|March 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|40 Years|79 Years|No|||October 2015|October 7, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335346||29556|
NCT02337972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheba_Medical_Center|Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients|Conjunctival Flora Patterns After Serial Intravitreal Injections Without Postinjection Topical Antibiotics in Diabetic Patients||Sheba Medical Center|No|Recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02337972||29355|
NCT02281110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-CV-001|The REAL Registry for Utilization of iFR in Assessing Coronary Stenoses|A Prospective, Observational, Non-randomized European, Multi-center Registry Collecting Real Life Information for the Utilization of Instantaneous Wave Free Ratio in Assessing Coronary Stenosis Relevance in the Multi-vessel Disease Patients Population.|DEFINE REAL|Volcano Corporation|No|Recruiting|July 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Eligibility includes adults undergoing coronary angiography and/or PCI|December 2015|December 8, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02281110|1 Day|33719|
NCT02281383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-174|Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer|Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281383||33698|
NCT02281396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCP-10|The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans|A Safety Study of Freeze-dried Rabies Vaccine(MRC-5 Cell)in Chinese Humans From 10-60 Years Old||Beijing Center for Disease Control and Prevention|No|Completed|November 2014|May 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|40|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||October 2014|January 19, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281396||33697|
NCT02277847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDREC.[2010]017|Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia|A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia||Guangdong General Hospital|Yes|Enrolling by invitation|March 2010|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|14 Years|60 Years|No|||October 2014|October 27, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02277847||33970|
NCT02329730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTao-EC IIa|Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Antigen ESAT6-CFP10||Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|No|Completed|February 2014|August 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|144|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|December 23, 2014||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT02329730||29987|
NCT02330003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_102|Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer|A Randomized, Active-Comparator, Open-Label, Phase 1 Clinical Trial to Assess the Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' and Fluarix Prefilled Syringe in Healthy Korean Male Volunteer||Il-Yang Pharm. Co., Ltd.|No|Completed|May 2013|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330003||29966|
NCT02330016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VolumaChin-001|Juvederm Voluma® XC for the Treatment of Hypoplastic Chin|Juvederm Voluma® XC for the Treatment of Hypoplastic Chin|VolumaChin|Beer, Kenneth R., M.D., PA|No|Recruiting|December 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|22 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02330016||29965|
NCT02337790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERM-IRB-001-ICC|Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals|Necklace-Shaped Sensor for Non-Invasive Monitoring of Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate in Patients With a Pacemaker, Implanted Cardioverter-Defibrillator, or Ventricular Assist Device||toSense, Inc.|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|109|||Both|18 Years|90 Years|No|Non-Probability Sample|Subjects will be from the Imperial Cardiac Clinic|December 2015|December 28, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337790||29369|
NCT02330471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONE-1|Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial|Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial|CONE-1|Ruhr University of Bochum|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|80 Years|No|||April 2015|April 16, 2015|December 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02330471||29931|
NCT02335112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhangZhikai-IRE-02|Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms|Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335112||29574|
NCT02335125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH2MH106338|A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot||TSOS 6|University of Washington|Yes|Active, not recruiting|February 2015|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02335125||29573|
NCT02338557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D789|Effect of Motor Relearning Programme and Mirror Therapy Along for Improving Hand Function In Patients With Stroke.|Effectiveness of Motor Relearning Programme and Mirror Therapy Along With Conventional Physiotherapy Treatment for Improving Hand Function In Patients With Stroke.||Maharishi Markendeswar University||Completed|January 2010|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|45 Years|65 Years|No|||January 2015|January 9, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338557||29310|
NCT02332122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57222|Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis|Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs COPD Patients Without Bronchiectasis||Katholieke Universiteit Leuven|No|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Sputum sample obtained through induction|Both|18 Years|N/A|No|Non-Probability Sample|Patients who present in the emergency department with an acute COPD exacerbation (as        defined by GOLD executive summary) requiring hospitalization are eligible for this study.        Patients should have an established diagnosis of COPD (based on clinical history or        pulmonary function test). They will be recruited during their hospital stay in the        University Hospital of Leuven.        Additionally, we will include 20 patients with COPD (10 with bronchiectasis versus 10        without) in stable state during their outpatient visits.|August 2015|August 21, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332122||29804|
NCT02332382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1424-14-SMC|The Influence of Mother Nutrition on Breast Milk Microbiome|The Influence of Mother Nutrition on the Composition of Fatty Acid, Oligosacharides and Its Effect on Breast Milk Microbiome|Breast Milk|Sheba Medical Center||Not yet recruiting|February 2015|||April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy lactating women|January 2015|January 4, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332382|3 Months|29784|
NCT02332642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-624N-MA|Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy|Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy|ImmunoPAX|Universitätsmedizin Mannheim|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|12|||Both|18 Years|80 Years|No|Non-Probability Sample|Metastatic melanoma patients (AJCC stage IV)|August 2015|August 24, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332642||29764|
NCT02334592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDS-1234|Vitamin D Production Levels Achieved by Sunbed Tanning|The Impact of Health Canada's Sunbed Exposure Time Guidelines on Serum 25(OH)D Concentrations||Vitamin D Society|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|87|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334592||29614|
NCT02334605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAvsDiscsvsCap|Comparison of Cold Dry Air Exposure, Discs and Capsaicin|Comparison of Cold Dry Air Exposure, Hyperosmolar Sponge and Capsaicin Nasal Spray for Objective Evaluation of Nasal Hyperreactivity||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334605||29613|
NCT02337491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-477|Pembrolizumab +/- Bevacizumab for Recurrent GBM|Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2015|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337491||29392|
NCT02337712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-FXY-037|Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer|Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy Compared With Twice-daily Radiotherapy in Limited Small-cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide||Sun Yat-sen University|No|Recruiting|January 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337712||29375|
NCT02284880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-130|Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate|Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate in Healthy Subjects||Bial - Portela C S.A.|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|November 4, 2014||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT02284880||33430|
NCT02284893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-363|Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone||Bristol-Myers Squibb|No|Active, not recruiting|December 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||September 2015|February 25, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02284893||33429|
NCT02280824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915009|Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access|Transcaval Access for Transcatheter Aortic Valve Replacement in Patients With No Good Options for Aortic Access||National Institutes of Health Clinical Center (CC)||Recruiting|October 2014|December 2018|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|21 Years|99 Years|No|||August 2015|November 24, 2015|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02280824||33741|
NCT02280837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-83|Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?|An Observational Study to Examine the Relationship Between GLP-1 Insufficiency and Severity of Coronary Artery Disease in Patients Enrolled in BOREAS Registry, a Prospective Registry of Cardiovascular and Renal Diseases. : Is GLP-1 Insufficiency a Residual Risk in Coronary Artery Disease?||Sapporo Medical University|No|Recruiting|March 2015|September 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|220|||Both|35 Years|80 Years|No|Probability Sample|Non-diabetic patients with suspected or diagnosed CAD who are hospitalized for coronary        angiogram will be enrolled in this study. The patients are expected to be similar to those        who have visited our institute recently; approximately 28% of patients with CAD are        diabetics, and one third of them are medically untreated at the time of their first visit.        In recent years, 500-600 patients have undergone coronary angiography per year in this        institute, and approximately 50% of them were without history of percutaneous coronary        interventions (PCI) or coronary bypass surgery. Hence, approximately 180-210 patients per        year will be candidates for the present project.|May 2015|May 21, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02280837||33740|
NCT02285348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA-AT.CSF.2012|Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T|Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of Patients With Ataxia Telangiectasia||Johann Wolfgang Goethe University Hospitals|No|Recruiting|April 2013|||May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|2 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02285348||33394|
NCT02285595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-06|Sonendo GentleWave™ System for Treatment in Molar Teeth Requiring Root Canal Therapy|A Prospective, Multicenter Study Comparing Healing After Treatment With the Sonendo GentleWave™ System as Compared to a Traditional Root Canal Therapy Literature Control|SUPREME|Sonendo, Inc.|No|Recruiting|July 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|75 Years|No|||June 2015|June 17, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02285595||33375|
NCT02285608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIMM MDP|Partnership in Medication Management (PIMM) in Patients With Mood Disorders|Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders|PIMM|St. Joseph's Healthcare Hamilton|No|Recruiting|January 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|166|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02285608||33374|
NCT02281968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-391A|NSAIDs for Pain After Ankle Fracture Surgery|An NSAID Pain Protocol Provides Adequate Pain Relief in Ankle Fractures Treated Operatively||Northwell Health|Yes|Withdrawn|December 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02281968||33654|
NCT02334111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS-2012-ACF-ACYF-CB-0286|RESPECT PLUS Services for Infants With Prenatal Opiate Exposure|Project RESPECT-Plus: Recovery, Empowerment, Social Services, Prenatal Care, Education and Community Treatment-Plus.|RESPECT-Plus|Boston Medical Center|No|Recruiting|July 2013|August 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|21 Days|No|||July 2015|July 27, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02334111||29651|
NCT02334345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13026|Skin Protection During Radiotherapy in Patients With Breast Cancer|Skin Protection During Radiotherapy in Patients With Breast Cancer: A Comparative Study of Evoskin® Verus Trixéra®|EVOSKIN|University Hospital, Limoges|No|Recruiting|January 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|25|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02334345||29633|
NCT02334358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HAOS004|Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s|A Multi-center, Prospective and Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s Injected Into the Nasolabial Folds||LG Life Sciences|No|Active, not recruiting|September 2014|August 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subject who receive hyaluronic acid filler into the nasolabial folds|September 2015|September 9, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02334358||29632|
NCT02327052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL01-04|Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease|Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects With Chagas Disease||Hospital Sao Rafael|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|58|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult subjects in the Chagas disease outpatient clinics at our institution from January        2011 to December 2013 were invited to participate in this study.|December 2014|December 29, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02327052||30193|
NCT02327065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014tj1212|Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion|Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB（Endoscopic Ultrasonography-Fine Needle Biopsy ） and EUS-FNA（Endoscopic Ultrasonography-Fine Needle Aspiration ） on Solid Occupying Lesion||Huazhong University of Science and Technology|Yes|Recruiting|December 2014|May 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|408|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02327065||30192|
NCT02334878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMASU 3098/2014|Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence|Autologous Bone Marrow-derived Mesenchymal Stem Cells Versus Tension-free Vaginal Tape for Treatment of Female Stress Urinary Incontinence: An Open-label Clinical Trial||Ain Shams Maternity Hospital|No|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02334878||29592|
NCT02338453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TauGeha-001-15|Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) in Social Anxiety Disorder|Examining the Effects of a Combined Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) for Social Anxiety Disorder|ABMT+CBGT|Tel Aviv University|No|Enrolling by invitation|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||January 2015|January 11, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338453||29318|
NCT02327741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-2348|Efficacy of Long Term Plavix Therapy Post Angioplasty|Evaluation of Safety, Benefits and Complications of Long-term Dual Antiplatelet Therapy in Patients With Angioplasty||Shiraz University of Medical Sciences|No|Completed|October 2012|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1010|||Both|50 Years|70 Years|No|||December 2014|December 29, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02327741||30140|
NCT02336958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2013-0075|Ultrasound Guided Intermediate Cervical Plexus Block and Additional Perivascular Local Anesthetic Infiltration|Ultrasound Guided Intermediate Cervical Plexus Block -Randomized Evaluation Concerning the Significance of Additional Perivascular Local Anesthetic Infiltration||Helios Research Center|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|January 2, 2015||No||No|March 12, 2015|https://clinicaltrials.gov/show/NCT02336958||29433|
NCT02337309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANT 2014-01|SF1126 for Patients With Relapsed or Refractory Neuroblastoma|Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma||New Approaches to Neuroblastoma Therapy Consortium|Yes|Active, not recruiting|July 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|1 Year|30 Years|No|||December 2015|December 18, 2015|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02337309||29406|
NCT02327234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio REB 14-283|Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma|Assessment of Repeated Allergen Challenge and the Effects of Ibuprofen on the Inflammatory Process||University of Saskatchewan|No|Active, not recruiting|December 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02327234||30179|
NCT02327247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243_FELOD_08|Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With PLENDIL® Extended Release Tablet (Containing Felodipine 10 mg) Manufactured by Merck & Co. Inc. for AstraZeneca in Healthy, Adult, Male, Human Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|September 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02327247||30178|
NCT02288494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0204|Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach|Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach|STEWALB|University Hospital, Clermont-Ferrand||Active, not recruiting|October 2013|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients with severe hypoalbuminemia|November 2014|November 7, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02288494||33152|
NCT02288507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acoba 2014 -1|Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer|Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer||University of Hawaii|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02288507||33151|
NCT02285140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICS|Prevention of Infections in Cardiac Surgery|Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial|PICS|Hamilton Health Sciences Corporation|No|Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|3000|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02285140||33410|
NCT02288780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0734|Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients|||Yonsei University|No|Not yet recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Male|65 Years|85 Years|No|Non-Probability Sample|BPH patients with/without preoperative diastolic dysfunction|October 2014|November 10, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02288780||33130|
NCT02288793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST/2014/01|Focused Assessment With Sonography in Trauma|Prepared for Focused Assessment With Sonography in Trauma Examination?|FAST|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff: medical doctors, nurses, paramedics Medical students: PhD students,        medicine students, nursing and paramedics studies|November 2014|November 7, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02288793||33129|
NCT02288923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SW/0016|Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement.|A Randomised, Observer Blinded, Controlled Trial Of Femoral Nerve Block Versus Local Infiltration Analgesia for Post Operative Analgesia Following Total Knee Arthroplasty|LIFT|Royal Devon and Exeter NHS Foundation Trust|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|19 Years|N/A|No|||October 2015|October 26, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02288923||33119|
NCT02288936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOG-MIE-2014-04|Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer|Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy|PREMIERE-SOGUG|Spanish Oncology Genito-Urinary Group|No|Active, not recruiting|February 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02288936||33118|
NCT02286700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-ECD108|Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis|A Randomized, Double-Blind, Active Control, 5 Week Study to Evaluate the Safety and Skin Effects of A New, Twice-daily, Topically Applied Amino Acid Moisturizing Cream vs. Desonide Cream in Adult Atopic Dermatitis||NeoStrata Company, Inc.|No|Recruiting|November 2014|March 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02286700||33290|
NCT02337348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1653/REK|Prospective Randomized Optical Coherence Tomography Oslo tRial|Optical Coherence Tomography (OCT) Guided Compared to Conventional Angiography Guided Coronary Intervention in Stentfailure|PROCTOR|Oslo University Hospital|Yes|Recruiting|August 2014|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337348||29403|
NCT02337543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO6860-1301|NEO6860, a TRPV1 Antagonist, First in Human Study|NEO6860: A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects||Neomed Institute|Yes|Completed|January 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|March 9, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337543||29388|
NCT02337777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S097|The Study of Functional Magnetic Resonance Imaging in Abdominal and Pelvic Diseases|The Study of Functional Magnetic Resonance Imaging in Abdominal and Pelvic Diseases||Tongji Hospital||Recruiting|July 2014|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients with abdominal or pelvic diseases who provide informed consent Healthy        Volunteers|January 2015|January 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337777||29370|
NCT02331043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL 2012_034|Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester|Serum Cholesterol Reduction Efficacy of Biscuit With Added Plant Stanol Ester||Raisio Group||Completed|March 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331043||29887|
NCT02331056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-053-002|Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?|Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?||Samsung Medical Center|Yes|Recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|20 Years|75 Years|No|Non-Probability Sample|The patients scheduled for pulmonary lobectomy with one lung ventilation by lung cancer,        nodule, or pulmonary tuberculosis under thoracoscopy or thoracotomy in our hospital were        included.|January 2015|January 1, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02331056|1 Week|29886|
NCT02338024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3 U01 GH000752-01|Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine|Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine|MARTAS|Ukrainian Institute on Public Health Policy|No|Recruiting|October 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|276|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338024||29351|
NCT02327520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP009|Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study|The Burden of Clostridium Difficile Infection in Thai Population: the First Report in Southeast Asia by 2010 Nationwide Study||King Chulalongkorn Memorial Hospital|Yes|Completed|January 2010|December 2014|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|204666|||Both|18 Years|N/A|No|Non-Probability Sample|The patients with the diagnosis of Clostridium difficile (ICD10-A07) with age of more than        18 years were included.|December 2014|December 24, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02327520||30157|
NCT02331602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kimura5656|Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran|Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study-|RIVAL-AF|Yokohama City University Medical Center|Yes|Recruiting|July 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|90 Years|No|||August 2015|August 4, 2015|January 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02331602||29844|
NCT02331862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-BR-103-050|To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection|To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection||National Cheng-Kung University Hospital|Yes|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|16 Years|No|||January 2015|January 4, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331862||29824|
NCT02331875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2201-201|Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity|Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity||Innate Pharma||Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331875||29823|
NCT02334280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InSHAPE Implementation Study|Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI|Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|120|||Both|21 Years|N/A|No|||January 2015|January 7, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334280||29638|
NCT02334293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13055|Omegaven® as Parenteral Nutrition|Omegaven® as Parenteral Nutrition||Carle Foundation Hospital|No|Recruiting|October 2013|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|4 Months|No|||January 2015|January 7, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334293||29637|
NCT02334306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5181C00001|A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome|A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome||MedImmune LLC|No|Recruiting|June 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||November 2015|November 13, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334306||29636|
NCT02327000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA5PR-104|A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers||GL Pharm Tech Corporation|No|Completed|October 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02327000||30197|
NCT02327013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15996A|Investigating the Effect of Vortioxetine in Adult ADHD Patients|Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||H. Lundbeck A/S|No|Recruiting|December 2014|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|55 Years|No|||October 2015|October 19, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327013||30196|
NCT02331264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157144|Cardiac Assessment of Patients With Hip Implants|Cardiac Assessment of Patients With Hip Implants||Royal National Orthopaedic Hospital NHS Trust|No|Recruiting|November 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with hip replacements. Groups 1 and 2 include patients with Metal on Metal hip        replacements. Group 3 includes patients with non Metal bearing hip replacements including        Ceramic on Ceramic Hip replacements.        All three groups will be matched for Age, Sex, Time since hip Implantation, and diabetes        status.|January 2015|January 2, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331264||29870|
NCT02331537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1944-31-5|Internet-based Exposure Therapy for Excessive Worry|Internet-based Exposure Therapy for Excessive Worry: A Randomized Trial||Karolinska Institutet|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02331537||29849|
NCT02276508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00586|Open Label Trial of Nissle 1917|Phase 1 Open Label Trial of Nissle 1917 to Assess Safety and Tolerance in Healthy Adult Volunteers||Nationwide Children's Hospital|Yes|Completed|October 2014|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 16, 2015|October 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02276508||34073|
NCT02288637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCZC58|Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product|Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product, Separately and Together, Against Malaria Transmitted by Pyrethroid Resistant Mosquitoes.||London School of Hygiene and Tropical Medicine|Yes|Recruiting|September 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|3840|||Both|6 Months|14 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|October 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02288637||33141|
NCT02277015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/02|Intubation During Pediatric Resuscitation|Pediatric Tracheal Intubation Using Four Video-laryngoscopes and the Miller Laryngoscope With and Without Chest Compressions||International Institute of Rescue Research and Education|Yes|Enrolling by invitation|October 2014|November 2014|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|November 11, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02277015||34034|
NCT02277262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-14|PROPHYlactic Implantation of BIOlogic Mesh in Peritonitis (PROPHYBIOM)||PROPHYBIOM|A.O. Ospedale Papa Giovanni XXIII||Recruiting|October 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2014|October 25, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02277262||34015|
NCT02277587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyposurrenalism_1|Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)|A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.|DREAM|University of Roma La Sapienza|No|Recruiting|March 2014|June 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277587||33990|
NCT02278666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO21|Minimally Invasive Versus Conventional Aortic Valve Replacement: a Long Term Registry|Minimally Invasive Aortic Valve Replacement Versus Conventional Aortic Valve Replacement: a Long Term Registry on Potential Benefits of the Different Surgical Techniques|SATURNO|Maria Cecilia Hospital|No|Recruiting|October 2014|December 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing isolated aortic valve surgery|November 2014|November 3, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02278666||33907|
NCT02342210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106127|Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study|Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study||Lawson Health Research Institute|No|Active, not recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|30 Years|No|||September 2015|September 3, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02342210||29030|
NCT02342275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-229|Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma|Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma||West China Hospital|Yes|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|5 Weeks|24 Weeks|Accepts Healthy Volunteers|||October 2015|February 25, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02342275||29025|
NCT02342327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-2014-0009|Smoking Cessation in Menthol Flavored Cigarette Smokers|||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|October 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|64 Years|No|||September 2015|September 25, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342327||29021|
NCT02333344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HCN13|The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA|The Efficacy Study of Aclasta (Zoledronic Acid 5mg) on Prosthetic Fixation in Postmenopausal Women After Cementless Total Hip Arthroplasty (THA): a 24 Months, Single Center, Open- Label, Randomized, Parallel Controlled Study||Novartis|No|Recruiting|July 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Female|55 Years|80 Years|No|||March 2016|March 3, 2016|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02333344||29710|
NCT02327299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-SAV-1615|Iron Bioavailability From Cubes|Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Women|Fe Bouillon|Swiss Federal Institute of Technology|Yes|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|24|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327299||30174|
NCT02331615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-11-LOE|Application of Trans Cranial Direct Current Stimulation for Executive Dysfunction After Traumatic Brain Injury|Feasibility of the Use of Electrical Stimulation Using tDCS to Influence Executive Abilities After Traumatic Brain Injury Patients||Loewenstein Hospital|Yes|Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331615||29843|
NCT02334059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001623|Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery|Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery||Milton S. Hershey Medical Center|No|Not yet recruiting|August 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|80 Years|No|||January 2015|January 7, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02334059||29655|
NCT02340182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42072.018.12|The Role of the Microbiota in the Systemic Immune Response|The Role of the Microbiota in the Systemic Immune Response|MISSION-1|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|July 8, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340182||29186|
NCT02340195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14916A|Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function|Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects||H. Lundbeck A/S|No|Completed|January 2015|||September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340195||29185|
NCT02337114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/WS/1152|Recovery Enhancement From Traumatic Brain Injury Using Acceptance and Commitment Therapy - a Pilot Study.|REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study.|REACT|University of Glasgow|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02337114||29421|
NCT02337296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC103421|An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE|An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE||Michigan State University|No|Completed|January 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|59|||Both|21 Years|N/A|No|||March 2016|March 14, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02337296||29407|
NCT02331004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fine motor skills|Effectiveness of an Intervention Program for Fine Motor Skills|Effectiveness of an Intervention Program for Fine Motor Skills in Institutionalized Elderly Residents: a Randomized Clinical Trial||Universidad de Granada|Yes|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|No|||May 2015|May 28, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331004||29890|
NCT02335619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02082|Early Integrated Supportive Care Study for Gastrointestinal Cancer Patients|Early Integrated Supportive Care Study for Gastrointestinal Cancer Patients||British Columbia Cancer Agency|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|152|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335619||29536|
NCT02335892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DGB04|PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod|Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)|PROFILE|Novartis|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|55 Years|No|Non-Probability Sample|Patients with relapsing remitting multiple sclerosis starting treatment with fingolimod|October 2015|October 21, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02335892||29515|
NCT02335905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35130|Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children|Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children||Baylor College of Medicine|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|17 Years|No|||January 2016|January 27, 2016|December 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335905||29514|
NCT02280863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE: G140086|Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller|Hybrid Closed-Loop Studies With Medtronic PID Controller- Hotel HCL Study||Stanford University|Yes|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|July 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02280863||33738|
NCT02285621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR_259812|Validation of a New Generation of Optimized Orthoses for Personalized Treatment of Adolescent Idiopathic Scoliosis|||St. Justine's Hospital|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|14 Years|No|||November 2015|November 17, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02285621||33373|
NCT02276755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140513|Vitamin D Suplementation in TB Prevention|Vitamin D in TB Prevention in School Age Children||Harvard School of Public Health|Yes|Recruiting|September 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|8020|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02276755||34054|
NCT02277002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2014-0006|Commuter Air Pollution Intervention Study|Reducing Commuter Air Pollutant Exposure by Cabin Air Filtration|CAPI|Health Canada||Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02277002||34035|
NCT02281409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-135|Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors|A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281409||33696|
NCT02281422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-112|An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093|An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Various Degrees of Renal Impairment||Bial - Portela C S.A.|No|Completed|March 2005|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|October 30, 2014||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT02281422||33695|
NCT02281708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO|Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma|A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma||Seoul National University Hospital|Yes|Recruiting|October 2014|September 2020|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1012|||Both|18 Years|80 Years|No|||October 2014|October 31, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02281708||33673|
NCT02330484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD-026|Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes|Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes||Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|March 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|400|||Both|40 Years|74 Years|No|||December 2014|December 31, 2014|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330484||29930|
NCT02330770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA5|Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration|Dual Trigger Versus Gonadotropin Releasing Hormone Agonist Trigger Combined With Luteal Human Chorionic Gonadotropin Administration||Mansoura University|No|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|225|||Female|20 Years|35 Years|No|||January 2016|January 29, 2016|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02330770||29908|
NCT02331316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThinkWell PLOT-02|Drinking Water to Reach or Maintain a Healthier Weight|Drinking Water To Prevent or Reduce Weight Gain - An Online Randomized Controlled Trial With Adult Participants||ThinkWell|Yes|Not yet recruiting|January 2016|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|9600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 5, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02331316||29866|
NCT02331329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOM|Evaluation of NICOM (Bioreactance) for the Non-invasive Determination of Cardiac Output|||Universitätsmedizin Mannheim|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|hemodynamically and respiratory stable patients undergoing cardiac magnetic resonance        imaging with a clinical indication|January 2015|January 5, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331329||29865|
NCT02333812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0318-14-HMO-CTIL|Prevalence of Malignant and Premalignant Lesions in the Head & Neck in Patients With Chronic Obstructive Pulmonary Disease|||Hadassah Medical Organization|No|Not yet recruiting|January 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|250|||Both|18 Years|85 Years|No|Non-Probability Sample|The study group of adult COPD patients will be recruited from the Institute of Pulmonary        medicine patient pool and referred for further evaluation in the Voice and Swallowing        disorders outpatient Clinic in Hadassah University Medical Center.The study group will be        compared to two control group:        2. Adult patients with smoking history and no clinical manifestation of COPD who will be        recruited form the institute of pulmonary medicine and the otolaryngology outpatient        clinic.        3. Adult patients with lung disease unrelated to smoking, i.e. bronchial asthma who will        be recruited from the institute of pulmonary medicine|September 2014|January 5, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02333812||29674|
NCT02336802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bramvervliet|Threat-Avoidance Learning in Anxiety Patients|The Experimental Study of Threat-Avoidance in Anxiety Patients: Behavioral, Emotional, and Neural Correlates|AVOID|Katholieke Universiteit Leuven|No|Not yet recruiting|January 2016|December 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Controls, Panic Disorder, Phobic Disorders, Post-Traumatic Stress Disorder|January 2015|February 5, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336802||29445|
NCT02330445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100-105|6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection|Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers|SPARTA-II|Protalex, Inc.|Yes|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330445||29933|
NCT02340299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/011/12|Nasal High Frequency Oscillation Ventilation Versus Nasal Continuous Positive Airway Pressure to Reduce Post-extubation pCO2|Nasal High Frequency Oscillation Ventilation Versus Nasal Continuous Positive Airway Pressure to Reduce Post-extubation pCO2 in Very Low Birth Weight Infants: a Randomized Controlled Trial||Charite University, Berlin, Germany|Yes|Recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|N/A|28 Days|No|||January 2015|January 20, 2015|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02340299||29177|
NCT02335372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0396|Cervical Cancer Screening Study in Brazil|A Pilot Study of a Low-Cost Optical Imaging Tool for Cervical Cancer Screening in Brazil||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2013|||June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|357|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335372||29554|
NCT02338297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC001|Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC|A Randomized Controlled Trial of Ethanol-gelfoam Mixture(EGM) Versus Gelfoam for the Treatment of Arterioportal Shunts (APS) in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolization (TACE)||Nanjing Medical University|Yes|Not yet recruiting|February 2015|December 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02338297||29330|
NCT02338310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2007/10015|Trial of Perioperative Endocrine Therapy - Individualising Care||POETIC|Institute of Cancer Research, United Kingdom|Yes|Active, not recruiting|September 2008|||April 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4486|||Female|50 Years|N/A|No|||January 2015|January 9, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02338310||29329|
NCT02338349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD1901-005|A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer|A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer||Radius Health, Inc.|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|December 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338349||29326|
NCT02286154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN_TREAT_001|Therapeutic Response Evaluation and Adherence Trial (TREAT)|Therapeutic Response Evaluation and Adherence Trial (TREAT): A Prospective Study of Hydroxyurea for Children With Sickle Cell Anemia|TREAT|Children's Hospital Medical Center, Cincinnati|No|Recruiting|October 2014|October 2024|Anticipated|October 2024|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|6 Months|21 Years|No|||February 2016|February 11, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02286154||33332|
NCT02292836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29105|Rosacea Prevalence in General Population - Pilot Study|Rosacea Prevalence in General Population - Pilot Study||Galderma|No|Completed|August 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|120|||Both|18 Years|65 Years|No|Non-Probability Sample|Rosacea and non-rosacea patients|November 2014|November 13, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02292836||32819|
NCT02281123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/B/03|Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya|Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya|EchoCHIK|Centre Hospitalier Universitaire de Fort-de-France|No|Active, not recruiting|July 2014|January 2016|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|45 Years|N/A|No|Non-Probability Sample|Recruitment will be done among the patients from the Fort-de-France hospital and came for        a suspected infection by the chikungunya virus|July 2015|July 27, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02281123||33718|
NCT02281136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0110|MUSE Study of Levulan Kerastick|A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions||DUSA Pharmaceuticals, Inc.|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02281136||33717|
NCT02286388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-854|Multicenter Trial Comparing One-step Partial Caries Removal to Complete Caries Removal for the Treatment of Deep Carious Lesions in Permanent Teeth. (DECAT : DEep CAries Treatment).|Multicenter Randomized Controlled Trial Comparing One-step Partial Caries Removal to Complete Caries Removal for the Treatment of Deep Carious Lesions in Permanent Teeth DECAT DEep CAries Treatment|DECAT|Hospices Civils de Lyon|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|464|||Both|8 Years|80 Years|No|||April 2015|September 29, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02286388||33314|
NCT02286518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-114/CPH-001|TAK-114 Single- and Multiple-Dose Phase 1 Study|A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male Subjects||Takeda|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|13||Actual|94|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02286518||33304|
NCT02282995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDFDR|Effect of Genetic Association With Functional Dyspepsia and Mood Disorders|Effect of Genetic Association With Functional Dyspepsia and Mood Disorders|FDFDR|Chinese University of Hong Kong||Recruiting|August 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|1200|Samples With DNA|Nine ml of blood will be used for the detection of biomarkers for functional dyspepsia      through single nucleotide polymorphism (SNPs). The genotyping DNA will be isolated from      whole blood samples by (FlexGene DNA kit, Qiagen). High-throughput genotyping will be      performed on the serotonin 3A receptor polymorphism (rs1062613) and ghrelin CLOCK 3111C      polymorphism (rs1801260). It will be analyzed by Applied Biosystems (ABI) 3730xl DNA      Analyzer.      Six ml of blood will be used for detection of plasma ghrelin and serotonin expression for      development of diagnostic test in classification of functional dyspepsia by ELISA.      Blood sampling stored for future use The remaining blood samples for each patient will be      stored in the Laboratory of Institute of Digestive Diseases (Room 701, 7/F, Li Ka Shing      Medical Sciences Building, Prince of Wales Hospital) for tests stated in the Aim section.      Remaining blood samples will be stored for future studies for emerging diseases related to      FGID.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred for oesophagogastroduodenoscopy (OGD) in Endoscopy Center, Prince of        Wales Hospital, with symptoms suggestive of FGID or who participated in PI's previous        clinical trials will be invited to participate in this study as FD patients.        Patients meeting the inclusion criteria will be identified by medical staff in LKS Medical        Gastroenterology or Ulcer clinics, Prince of Wales Hospital and be invited to participate.        Patients not suffering from FGID will be identified from the gastrointestinal specialty        clinic or Endoscopy Center, Prince of Wales Hospital as healthy volunteers. These patients        may include those referred for GI malignancy screening.        Study advertisement will be posted in public area of Prince of Wales Hospital, and on the        educational website (www.digestion.hk) which is maintained by PI. Controls who are        self-referred to this study will be recruited.|August 2015|August 11, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02282995||33575|
NCT02283008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS Project ID: 153018|Inhaler Technique Training|Evaluating the Efficacy of 2 Different Educational Strategies for Improving and Maintaining Inhaler Technique||Northampton General Hospital NHS Trust|No|Not yet recruiting|December 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|35 Years|90 Years|Accepts Healthy Volunteers|||October 2014|November 4, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02283008||33574|
NCT02332837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThinkWell PLOT-03|Interactive Tool for Informed Consent|Interactive Tool for Informed Consent: A Randomized Controlled Trial|I-TIC|ThinkWell|Yes|Not yet recruiting|January 2017|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|9600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|November 2, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332837||29749|
NCT02333071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT-301|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension|Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)||Palatin Technologies|Yes|Active, not recruiting|December 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|723|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|December 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333071||29731|
NCT02336373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35010 SCYTHE|Treatment of Hemoglobin SC Disease|SC Youth Treatment With Hydroxyurea Effects|SCYTHE|Baylor College of Medicine|Yes|Recruiting|December 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|5 Years|21 Years|No|||January 2016|January 11, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336373||29478|
NCT02336451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2205|A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges|A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges|Ascend-7|Novartis|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336451||29472|
NCT02333578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVD001|Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment|A Phase I/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for Treatment of EVD|EVD001|Clinical Research Management, Inc.|No|Recruiting|November 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02333578||29692|
NCT02330211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00014880|Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis|A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's Colitis||Children's Hospital Boston|Yes|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|30 Years|No|||January 2016|January 26, 2016|December 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330211||29950|
NCT02334852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARMEN|Registry of Atrial Fibrillation and Embolic Risk in Mexico|Registry of Atrial Fibrillation and Embolic Risk in Mexico|CARMEN-AF|Registro de Fibrilación Auricular y Riesgo Embólico en México|No|Enrolling by invitation|December 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|Patients with documented diagnosis of AF in the last six months|January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334852|2 Years|29594|
NCT02330705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIE3|Timing of HCG Administration in IUI Cycles|Timing of Human Chorionic Gonadotropin Administration in Intrauterine Insemination Cycles||Mansoura University|No|Recruiting|January 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|225|||Female|20 Years|35 Years|No|||January 2016|January 29, 2016|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330705||29913|
NCT02330718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0236|Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia|||Yonsei University|No|Recruiting|May 2014|January 2020|Anticipated|April 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1500|Samples Without DNA|peripheral blood and bone marrow aspirates have been collected and stored for the study|Both|19 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed or relapsed malignant hematologic disorders except acute        leukemia|December 2014|December 31, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330718|5 Years|29912|
NCT02337985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14004|Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma|Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs||City of Hope Medical Center|Yes|Recruiting|August 2015|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02337985||29354|
NCT02327715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-02-prevention|Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients|Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients||Asian-Pacific Alliance of Liver Disease, Beijing|Yes|Not yet recruiting|January 2015|July 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327715||30142|
NCT02327962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG2014|Comparing an Automatic PWV Analyser to Pulse Pressure in Hemodialysis|A Prospective Observational Study Comparing a Non-operator Dependent Automatic PWV Analyser to Pulse Pressure, in Assessing Arterial Stiffness in Hemodialysis||Ospedale Regionale di Locarno|No|Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|143|||Both|18 Years|N/A|No|Probability Sample|Hemodialysis patients were recruited from 4 dialysis units located in the Italian-speaking        part of Switzerland (Ospedale la Carità, Locarno; Ospedale San Giovanni, Bellinzona;        Ospedale Civico, Lugano; Ospedale Beata Vergine, Mendrisio), starting from January 2011.        Subjects of the control group were recruited among patients hospitalized at Ospedale la        Carità, Locarno, for minor surgery and waiting for transfer or discharge.|December 2014|December 25, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02327962||30123|
NCT02292862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trial 1650 12|Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation|Search for Maternal Microchimerism in Swollen Portal Lymph Nodes of Infants With Biliary Atresia.|K-LNMC|Medizinische Hochschule Brandenburg Theodor Fontane|No|Completed|November 2012|November 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|7|Samples With DNA|Lymph nodes from children Whole Blood from mother and infant|Both|N/A|5 Months|No|Probability Sample|Children with newly and preoperatively diagnosed infantile Biliary Atresia of the        non-syndromatic form|November 2014|November 14, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02292862||32817|
NCT02277600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-044|A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers|Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects|DDI|Bristol-Myers Squibb|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|October 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02277600||33989|
NCT02286245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K120104|The Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Patients Calling for Primary Care|Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Primary Care: the Formalised Telephone Medical Advice Study, a Cluster Randomised Control Trial.|CMTp|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2880|||Both|1 Year|N/A|No|||October 2015|October 13, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02286245||33325|
NCT02292888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FortisH|Can Changes in Velocity Time Integral Serve as a Sensitive Indicator for Monitoring Changes in Stroke Volume ?|Can Changes in LVOT VTI Before and After Passive Leg Raising (PLR) Test Serve as a Sensitive Indicator for Changes in SV and CO and Hence Volume Responsiveness ?||Fortis Hospital, India|No|Not yet recruiting|December 2014|||December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02292888||32815|
NCT02292901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/42|McGrath Mac VideoLaryngoscope vs the Macintosh Laryngoscope|Randomised Controlled Trial of Intubation With the McGrath Mac VideoLaryngoscope vs the Macintosh Laryngoscope|MGM-Eval|Hopital Foch|No|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02292901||32814|
NCT02292914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP433/13|Prospective Analysis of Robot-Assisted Surgery|Prospective Analysis of Robot-Assisted Surgery||Instituto do Cancer do Estado de São Paulo|Yes|Recruiting|March 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1120|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|September 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02292914||32813|
NCT02278406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P_000117|Non-invasive Measurement of Brain Oxygen Levels in People With Subthalamic Deep Brain Stimulators|Employing Near Infrared Spectroscopy to Non-invasively Assess Changes in Cerebral Perfusion in Response to Subthalamic Deep Brain Stimulation||Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|75 Years|No|||October 2014|October 29, 2014|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278406||33927|
NCT02287545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK399122012|Biomechanical Changes After Trabeculectomy|Corneal Biomechanical Changes Following Trabeculectomy|TE-biomech|Technische Universität Dresden|No|Completed|February 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Primary open-angle glaucoma patients assigened for a trabeculectomy.|August 2015|August 20, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02287545||33225|
NCT02287779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP626-101|Safety and Tolerability Study of SHP626 in Overweight and Obese Adults|A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects||Shire||Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02287779||33207|
NCT02336295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0469-14-TLV|Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel|Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel||Tel-Aviv Sourasky Medical Center||Not yet recruiting|February 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02336295||29484|
NCT02338596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shortstem005|Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old|Comparison of the Outcomes of Ultra-Short Anatomic and Conventional Cementless Stems in Patients Younger Than Fifty-Five Years Old||Ewha Womans University|Yes|Completed|June 2001|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|111|||Both|19 Years|50 Years|No|||January 2015|January 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02338596||29307|
NCT02338700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prostate cancer MV|Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient||Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2015|September 8, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338700||29299|
NCT02338817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400105|Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population|Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population||University of Florida|No|Recruiting|December 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|70 Years|No|||January 2016|January 21, 2016|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338817||29290|
NCT02338960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT-302|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension|Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)||Palatin Technologies|Yes|Active, not recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|713|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338960||29279|
NCT02336542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTao-IIb-patient|Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase IIb Clinical Research||Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|199|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02336542||29465|
NCT02336555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8291-012|The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)|A Randomized Clinical Trial to Study the Efficacy, Safety, and Tolerability of MK-8291 in Subjects With Post-Herpetic Neuralgia With Allodynia||Merck Sharp & Dohme Corp.|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336555||29464|
NCT02334631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7339|High Volume Simethicone VCE Pilot Study|The Use of High Volume Simethicone to Improve Visualization Quality During Small Bowel Video Capsule Endoscopy: A Pilot Study||Lawson Health Research Institute|No|Active, not recruiting|June 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334631||29611|
NCT02337322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advanz-4|Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir|Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).||Hospital Clinic of Barcelona|Yes|Recruiting|April 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337322||29405|
NCT02337504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH000765|Developing and Assessing a Community Based Model of Antiretroviral Care|Developing and Assessing a Community Based Model of Antiretroviral Care|ARTCo-ops|Moi University|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|360|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337504||29391|
NCT02335086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0238|DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease|DNA Damage and Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease|DECODE|University of Surrey|No|Recruiting|September 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Whole blood, plasma, serum, white blood cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with stable angina (n=75) or NSTEMI (n=75) undergoing percutaneous        revascularization at Ashford and St. Peter's Hospitals Foundation Trust will be        prospectively enrolled. Data regarding demographic, clinical, and procedural        characteristics of patients will be collected by the Ashford and St. Peter's Hospitals        Foundation Trust research personnel and entered into a secure, dedicated database.|March 2016|March 1, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02335086||29576|
NCT02337725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/CCT-001|A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa||Takeda|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|30 Years|80 Years|No|||March 2016|March 7, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337725||29374|
NCT02327494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR254/14|Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery|Prospective Study to Evaluate the Central Venous Oxygen Saturation and the Regional Cerebral Oxygen Saturation Monitoring at Different Stages of Neuromuscular Blockade in High-risk Patients Scheduled for Colorectal Surgery|OXYMUBLOC|Hospital Universitari de Bellvitge|Yes|Not yet recruiting|January 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Candidates are all adult patients (over 18 y.o) on the waiting list for elective oncologic        colorectal surgical resection procedure.|January 2015|January 6, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02327494|90 Days|30159|
NCT02332096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P-000038|Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation|Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation||Beth Israel Deaconess Medical Center|No|Recruiting|June 2015|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a        known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All        enrolled subjects will undergo pre-procedure screening sleep study using the Berlin        questionnaire and home sleep study using an FDA approved home sleep testing device (HST).|January 2016|January 13, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332096||29806|
NCT02332343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173/14|Sparing of the Fovea in Geographic Atrophy Progression|Sparing of the Fovea in Geographic Atrophy Progression|SIGHT|University Hospital, Bonn|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|55 Years|N/A|No|Non-Probability Sample|Patients suitable for the study will be recruited at the University of Bonn, Department of        Ophthalmology|December 2015|December 7, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332343||29787|
NCT02277613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02-02|A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction|A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction|MI-NSTEMI|Athersys, Inc|Yes|Recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||January 2016|February 4, 2016|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02277613||33988|
NCT02292875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG002B|ToleroMune Grass Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit.||Circassia Limited|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|65 Years|No|Non-Probability Sample|Subject previously randomised in study TG002 and completed all dosing visits and the PTC|November 2014|November 14, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02292875||32816|
NCT02278120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011E2301|Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer|A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer|MONALEESA-7|Novartis|Yes|Recruiting|November 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|660|||Female|18 Years|59 Years|No|||February 2016|February 19, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02278120||33949|
NCT02278419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104970|An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection||Janssen-Cilag International NV||Completed|December 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02278419||33926|
NCT02290561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0389|SmartTarget THERAPY|SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Therapy||University College, London|No|Not yet recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Male|N/A|N/A|No|||November 2014|November 13, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02290561||32994|
NCT02328625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR Registry|Scleroderma Treatment With Celution Processed ADRCs Registry|Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (ADRCs) Registry|STAR|Cytori Therapeutics|No|Withdrawn|April 2015|June 2017|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are scheduled to receive or have received ADRCs prepared by Celution to treat        hand scleroderma.|March 2016|March 15, 2016|December 23, 2014||No|Corporate decision|No||https://clinicaltrials.gov/show/NCT02328625|1 Year|30072|
NCT02328872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exec-PP-12|Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia|Compass - Randomized Controlled Trial of 5-yearly Cervical Screening With Primary HPV Testing Versus Cervical Screening With 2.5-yearly Liquid Based Cytology Testing, in HPV-Unvaccinated and HPV-Vaccinated Women in Australia|Compass|Victorian Cytology Service|Yes|Recruiting|January 2015|December 2023|Anticipated|December 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|121000|||Female|25 Years|69 Years|No|||December 2015|December 7, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328872||30053|
NCT02328885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I.2013.004|Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation|Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation||Banc de Sang i Teixits|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|60 Years|No|||July 2015|July 16, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02328885||30052|
NCT02329145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204069|Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy|Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy||Jagiellonian University|No|Recruiting|July 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02329145||30032|
NCT02329444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-08-074|The Effect of Remote Ischemic Preconditioning on Elective Percutaneous Coronary Intervention in Diabetic Nephropathy|Remote Ischemic Preconditioning for the Prevention of Contrast-induced Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention||Ulsan University Hospital|Yes|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||April 2015|April 19, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329444||30009|
NCT02329678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pgimsrohtak|Efficacy of Guided Tissue Regeneration Membrane in the Healing of Apicomarginal Defects|Efficacy of Guided Tissue Regeneration Membrane in the Healing of Apicomarginal Defects - A Prospective, Controlled Clinical Trial.||Postgraduate Institute of Dental Sciences Rohtak|Yes|Completed|January 2012|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|16 Years|47 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02329678||29991|
NCT02339090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14VR4|Comparison of Long-acting Growth Hormone Somavaratan (VRS-317) to Daily Growth Hormone in Pediatric GHD Patients|Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.|VELOCITY|Versartis Inc.|Yes|Recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|3 Years|11 Years|No|||January 2016|January 14, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339090||29269|
NCT02341365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406-MAD-035-JG|Vitamin D Influence on Oocyte Donation|Impact of Vitamin D Levels on Ovarian Reserve and Ovarian Response to Controlled Stimulation in Egg Donors||IVI Madrid|No|Completed|June 2013|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|269|||Female|18 Years|34 Years|No|Non-Probability Sample|oocytes' donors who underwent ovarian stimulation cycles in our clinic from June 2013 to        April 2014|January 2015|January 16, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02341365||29095|
NCT02327026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130932|Tracheal Intubation vs. Bag-valve-mask Ventilation in Patients With Out-of-Hospital Cardiac Arrest _ CAAM STUDY|Initial Airway Management in Patients With Out-of-Hospital Cardiac Arrest: Tracheal Intubation vs. Bag-valve-mask Ventilation - CAAM STUDY|CAAM|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327026||30195|
NCT02331277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293.9|Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of BI 655064 in Healthy Chinese Male Volunteers (Randomised, Double-blind, Placebo-controlled, Clinical Phase I Study)||Boehringer Ingelheim||Active, not recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|12|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 5, 2015||||No||https://clinicaltrials.gov/show/NCT02331277||29869|
NCT02337738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/CCT-002|A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off||Takeda|No|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|30 Years|79 Years|No|||March 2016|March 7, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337738||29373|
NCT02331823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10003009|Research on New Regimens for Retreatment Pulmonary Tuberculosis|New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis||Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|864|||Both|18 Years|65 Years|No|||January 2015|January 2, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02331823||29827|
NCT02335918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1127-02|A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors|A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors||Celldex Therapeutics|No|Recruiting|January 2015|January 2020|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335918||29513|
NCT02336269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDI-PGX-80801.01|Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics|Protocol For The Evaluation of Primex's PGX Assay||Primex Clinical Laboratories, Inc.|Yes|Recruiting|October 2013|October 2019|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100000|Samples With DNA|Buccal swab|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A minimum of 10,000 buccal swab samples will be identified for inclusion in the study as        follows:          -  A minimum of 8700 specimens from subjects who are on multiple medications of which at             least 2 are affected by the pathways tested and the physician made changed to their             drug regimen based on the assay interpretations          -  A minimum of 5200 specimens from subjects who are on multiple medications of which at             least 2 are affected by the pathways tested and the physician made no changes based             on the assay interpretations          -  A minimum of 1100 apparently healthy subjects.        Study subjects may be enrolled prospectively, from collection sites.|January 2015|January 7, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02336269||29486|
NCT02282228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSH 01|Detecting Chronic Subdural Hematoma With Microwave Technology|Detecting Chronic Subdural Hematoma With Microwave Technology - An Open Study Evaluating the Sensitivity and Specificity of a Microwave-based Device, Medfield Strokefinder MD100, to Detect Chronic Subdural Hematoma||Sahlgrenska University Hospital, Sweden|No|Completed|November 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02282228||33634|
NCT02277860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F120307002|Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis|Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis||University of Alabama at Birmingham|No|Recruiting|May 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|19 Years|N/A|No|||December 2015|December 7, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02277860||33969|
NCT02282735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-083|Parental Decision-Making for Children With Relapsed Neuroblastoma|Parental Decision-Making for Children With Relapsed Neuroblastoma||Dana-Farber Cancer Institute|Yes|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|Parents of children with relapsed or refractory neuroblastoma.|December 2015|December 7, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02282735||33595|
NCT02287298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-07-0540|Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment|Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment||The Retina Center of St. Louis County, PC|No|Active, not recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|||Both|50 Years|N/A|No|Non-Probability Sample|PATIENTS MUST HAVE A DIAGNOSIS CODE OF AGE RELATED MACULAR DEGENERATION AND MUST BE 50        YEARS OR OLDER AND HAVE EXUDATIVE AMD IN ATLEAST ONE EYE|November 2015|November 3, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02287298||33244|
NCT02287311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35253 MABEL|Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)|ADMINISTRATION OF MOST CLOSELY MATCHED THIRD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH EBV-POSITIVE LYMPHOMA|MABEL|Baylor College of Medicine|Yes|Recruiting|February 2015|March 2023|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|N/A|N/A|No|||November 2015|November 1, 2015|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02287311||33243|
NCT02279459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140728-01H|Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas|Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas: Assessing Tumor Perfusion and Prediction of Treatment Outcomes||Ottawa Hospital Research Institute|No|Not yet recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, aged 18 years and older with untreated, histologically confirmed head and neck        squamous cell carcinoma|October 2014|October 31, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02279459||33846|
NCT02333097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01528-39|Non Syndromic Congenital Heart Defect and Array-CGH in Prenatal Diagnosis|Prospective Study for Diagnosis Utility of Array-CGH Screening in Case of Non Syndromic Congenital Heart Defect in Prenatal Diagnosis (CAPA)|CAPA|Rennes University Hospital||Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant woman whose a fetal isolated congenital heart defect is identified|January 2016|January 25, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02333097||29729|
NCT02333357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905|Multimedia Toolkits to Implement 12-Step Recovery Concepts in Group Counseling|Multimedia Toolkits to Implement 12-Step Recovery Concepts in Group Counseling||Treatment Research Institute|No|Completed|March 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3483|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02333357||29709|
NCT02333825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-087|Pediatric and Adolescent Patellar Instability|Pediatric and Adolescent Patellar Instability|PAPI|Hospital for Special Surgery, New York|Yes|Not yet recruiting|January 2015|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|240|||Both|8 Years|20 Years|No|||January 2015|January 5, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02333825||29673|
NCT02334072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adiyaman/LMA-MEP|The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients|The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients||Adiyaman University Research Hospital|No|Recruiting|January 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|100|||Both|N/A|18 Years|No|||June 2015|June 22, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334072||29654|
NCT02334085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091527|The Health of Women Study|The Health of Women (HOW) Study|HOW|Dr. Susan Love Research Foundation|No|Recruiting|August 2009|August 2031|Anticipated|August 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women and men aged 18 and older, with or without breast cancer, and of all nationalities        and ethnicities, from the United States and beyond, are encouraged to participate in the        study.|January 2015|January 6, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02334085||29653|
NCT02329977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130508-2|Rate of Duodenal-biliary Reflux Increases in Patients With Recurrent Common Bile Duct Stones|Rate of Duodenal-biliary Reflux Increases in Patients With Recurrent Common Bile Duct Stones: Direct Evidence From Barium Meal Examination||Fourth Military Medical University|Yes|Completed|June 2013|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|64|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with history of recurrent common bile duct stone (recurrent group) and        non-recurrent common bile duct stone (control group) in Xijing Hospital of Digestive        Diseases were invited to participate the study. All the patients underwent successful        stone removal by ERCP previously. Patients in the control group were matched with the        recurrence group by age and gender at 1:1 ratio.|December 2015|December 1, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02329977||29968|
NCT02334319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070264|Ganetespib Window of Opportunity Study in Head and Neck Cancers|A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Emory University|Yes|Active, not recruiting|December 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|79 Years|No|||March 2016|March 2, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334319||29635|
NCT02331017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZ0084|Assessment of Bimodal Contribution in Adult Cochlear Implant Users|Assessment of the Contribution of the Combined Acoustic Hearing Via a Hearing Aid and Electric Hearing Via a Cochlear Implant in Adult Bimodal Users With Moderate to Severe Residual Hearing in the Implanted and Non Implanted Ear.||Bnai Zion Medical Center|No|Recruiting|December 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|December 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331017||29889|
NCT02331290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRIC 2014-047|Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen|Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen||University of Manitoba|No|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood (2 x 10 ml) at 2 and 4 hours after amantadine ingestion. Saliva (2 x 5ml) immediately      after the blood samples. Urine specimen between the time of the 2 blood samples.      The sampling protocol will be repeated 3 weeks later with the second cycle of chemotherapy.|Both|19 Years|N/A|No|Non-Probability Sample|20 patients: 10 patients with biopsy proven newly diagnosed Stage III or IV adenocarcinoma        of the lung and 10 patients with Stage III or IV small-cell histology will be included.|October 2014|January 5, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02331290||29868|
NCT02327260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-521|Increasing Adherence to Treatment Recommendations Following a Cardiac Event|Increasing Adherence to Treatment Recommendations Following a Cardiac Event||University of Missouri, Kansas City|No|Recruiting|February 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327260||30177|
NCT02327273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB006-002|Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects|Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|December 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02327273||30176|
NCT02331914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19082014|GIST: Assessment of Tumor Mutations and TKI Plasma Exposure|Gastrointestinal Stromal Tumors: Assessment of Mutations in Tumors and in Circulating Tumor DNA and Measurement of TKI Plasma Exposure to Optimize Treatment||University Medical Center Groningen|No|Recruiting|November 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Tumor biopsy after disease progression|Both|18 Years|90 Years|No|Probability Sample|Patients with locally advanced or metastatic gastrointestinal stromal tumors treated with        tyrosine kinase inhibitors.|October 2015|October 1, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02331914||29820|
NCT02331927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERMAD|PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer|Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial|PERMAD|University of Ulm|Yes|Recruiting|March 2015|March 2021|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02331927||29819|
NCT02327338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2014|Use of ThermaCare Heat Wraps and Ibuprofen as an Adjunct to Physical Therapy for Neck Pain|Use of ThermaCare Heat Wraps and Ibuprofen as an Adjunct to Physical Therapy for Neck Pain||Future Sciene Technology|No|Recruiting|November 2014|March 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|90|||Both|18 Years|80 Years|No|||December 2014|December 29, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02327338||30171|
NCT02305641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29629|An Observational Study of Kadcyla Safety in Breast Cancer|POST-MARKETING SURVEILLANCE OF KADCYLA IN BREAST CANCER||Hoffmann-La Roche||Recruiting|May 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Korean patients with HER2-positive, unresectable locally advanced or metastatic breast        cancer, who have received prior treatment with trastuzumab and a taxane and administered        Kadcyla infusion at physician's discretion|March 2016|March 1, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305641||31835|
NCT02295020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8627|Bioskin Cytokine Study|Bioskin Cytokine Study|Bioskin|Cropper Medical|No|Active, not recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295020||32651|
NCT02356068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|there is no sponsor|Predictions of Bleeding During Liver Transplantation With Thromboelastometry|Thromboelastometry as a Tool to Predict Bleeding and Transfusion Requirement During Liver Transplantation||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|70 Years|No|Non-Probability Sample|every patient who had a liver transplantation|January 2015|February 12, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02356068|1 Week|27969|
NCT02346305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014 - NIV - 14734|Cohort of Respiratory Failure Patients Treated for the First Time With Non-Invasive Ventilation at Home|Multicenter Prospective and Observational Cohort of Respiratory Failure Patients Treated for the First Time With Non-invasive Ventilation (NIV) at Home||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||Recruiting|January 2015|||April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with respiratoy insufficiency|July 2015|July 2, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02346305|2 Years|28717|
NCT02352558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-103HEME|A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies|A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies||Boston Biomedical, Inc||Recruiting|May 2015|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352558||28239|
NCT02293681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104999|An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement|A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement|RECOVERY|Janssen Research & Development, LLC|No|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|Samples Without DNA|Blood samples will be retained for the assessment of laboratory parameters: CRP = C-reactive      protein; ESR = erythrocyte sedimentation rate.|Both|16 Years|40 Years|No|Non-Probability Sample|Participants suffering from ankylosing spondylitis with hip involvement.|March 2016|March 21, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293681|52 Weeks|32754|
NCT02350972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-1300774|Inducing Systemic Immunity and Regressions in Metastatic Melanoma|Inducing Systemic Immunity and Regressions in Metastatic Melanoma||New York University School of Medicine|No|Completed|July 1978|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|88|||Both|21 Years|80 Years|No|||January 2015|January 26, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02350972||28360|
NCT02350985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HasekiTRH|Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine|Effectivity of Propranolol and Venlafaxine in Treatment of Vestibular Migraine: A Randomized Controlled Clinical Trial||Haseki Training and Research Hospital|No|Completed|January 2014|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|60 Years|No|||January 2015|January 29, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02350985||28359|
NCT02357680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45129|Diaries for Critically Ill Patients Written by Relatives|Dagbøger Til Kritisk Syge Patienter Skrevet af pårørende: Betydning for Patient og pårørende Samt Effekt i Forhold Til Udvikling af Symptomer på Posttraumatisk Stress||Hospitalsenheden Vest|No|Recruiting|March 2015|December 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357680||27846|
NCT02357693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 280/12|Neurokinin Receptor Antagonist Associated to Ondansetron in PONV|Effect of the Association of Neurokinin-1 Receptor Antagonist Aprepitant to Dexamethasone/Ondansetron in the Incidence of Postoperative Nausea and Vomiting in High Risk Apfel Score Patients|PONV|Instituto do Cancer do Estado de São Paulo|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02357693||27845|
NCT02333929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSP P391-US|Validation of Rivaroxaban Assay for US Registration|Validation of Rivaroxaban Assay for US Registration||Diagnostica Stago|No|Recruiting|March 2015|September 2016|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Plasma samples|Both|18 Years|N/A|No|Probability Sample|Patients receiving rivaroxaban treatment for one of the 3 drug indications cleared in the        US|January 2015|January 21, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333929||29665|
NCT02331940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPDTIOT100|Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients|Tiotropium Respimat Soft Mist Inhaler Versus HandiHaler to Improve Sleeping Oxygen Saturation and Sleep Quality in COPD.||University of Crete|No|Completed|March 2010|September 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|40 Years|65 Years|No|||January 2015|January 6, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02331940||29818|
NCT02331953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0606|Predictors of Postoperative Delirium in Elder Patients After Spine Surgery: Regional Cerebral Oxygen Saturation|||Yonsei University|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|109|||Both|60 Years|90 Years|No|Non-Probability Sample|patients undergoing spine surgery|March 2016|March 9, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02331953||29817|
NCT02327572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56278 UGasthuisberg|Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer|Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer|IMAGE|Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2014|July 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood samples (two 10-mL EDTA tubes) will be collected from each patient immediately prior      to surgery for assessing ageing/immunosenescence biomarkers|Female|35 Years|N/A|No|Probability Sample|-  Patients newly diagnosed with breast cancer who will undergo surgery and gave written             informed consent          -  Group 1 : 30 patients aged 70+ Group 2 : 15 patients aged 55-65 (post-menopausal)             Group 3 : 15 patients aged 35-45 (pre-menopausal)          -  Tumor selection : grade II/III invasive tumor, any histological type, ER-positive,             HER2-negative          -  Tumor size ≥1.5 cm (clinical assessment: mammoechography and/or clinical examination)          -  Routine geriatric assessment performed prior to surgery in group 1.|December 2014|December 29, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02327572||30153|
NCT02331095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0262|Statin Use in Patients With Acute VTE|A Pilot Study of Using Statins in Patients With Acute Venous Thromboembolism (VTE)||Ohio State University|No|Recruiting|January 2015|October 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02331095||29883|
NCT02335190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8368-US|Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study|Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study||Western University, Canada|No|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335190||29568|
NCT02341105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmioCaAF1|AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation|AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase|AmioCAAF|Hamilton Health Sciences Corporation|No|Not yet recruiting|March 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|80 Years|No|||January 2015|January 13, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02341105||29115|
NCT02335710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R011373506|Optimized Loading Response by JOURNEY II BCS Knee Increases Daily Physical Activity and Functions|In Vivo Comparison of Knee Kinematics for Subjects Implanted With a Smith & Nephew Journey PS TKA and Subjects Having a Normal Knee||The University of Tennessee Knoxville|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|50|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients implanted with a Smith & Nephew Journey II BCS implanted by Dr. Harold E. Cates        or subjects with a healthy knee|January 2016|January 5, 2016|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335710||29529|
NCT02335723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-CI-01|ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber|Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber|ASSET|Alteco Medical AB|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335723||29528|
NCT02332161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1375|Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer|Does Harvesting an Anterolateral Thigh (ALT) Flap Impact Lower Extremity Function and Activities of Daily Living (ADL) in Patients Undergoing Reconstructive Surgery for Head and Neck Cancer||University of Chicago|No|Recruiting|January 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient over age 18 undergoing anterolateral thigh free tissue transfer for head and        neck cancer reconstruction at the University of Chicago|January 2015|January 2, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02332161||29801|
NCT02295280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15742|A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.|Metoclopramide and Diphenhydramine (MAD): A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective (MAD Headache Study)|MAD|St. Louis University|Yes|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Female|14 Years|50 Years|No|||November 2014|November 17, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02295280||32631|
NCT02346318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014EC085-01|The Randomized Controlled Clinical Trial of Kushen Injection|The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer||Beijing Zheng Ju Medical Technology Co., Ltd.|No|Recruiting|November 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|75 Years|No|||October 2014|January 26, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02346318||28716|
NCT02350673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29435|A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors|A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v), THAT TARGETS CARCINOEMBRYONIC ANTIGEN (CEA), AND MPDL3280A, AN ANTIBODY THAT TARGETS PROGRAMMED DEATH-LIGAND 1 (PD-L1), ADMINISTERED IN COMBINATION INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS.||Hoffmann-La Roche||Recruiting|June 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350673||28383|
NCT02356874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97026: The ESpA study|The Effect of Exercise on Disease Activity and Cardiovascular Risk for Patients With Axial SpondyloArthritis|Exercise for SpondyloArthritis (SpA) - the ESpA Study The Effect of a Supervised Exercise Intervention on Disease Activity and Cardiovascular Risk in Patients With SpA - A Multicenter Randomized Controlled Trial|ESpA|Diakonhjemmet Hospital||Recruiting|August 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 4, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02356874||27907|
NCT02356887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB # 14-8319|Internal Jugular Vein Flow in the Sitting Position|Measurement of Flow in Internal Jugular Vein in the Sitting Position: an Ultrasound Study on Healthy Volunteers||University Health Network, Toronto|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356887||27906|
NCT02297841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-7554|Repeated Insult Patch Test of Personal Lubricants|||Church & Dwight Company, Inc.||Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|4||Actual|201|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297841||32435|
NCT02297854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|569-10|Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|July 2011|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|November 19, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297854||32434|
NCT02304276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147780|18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome|18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome|18F-FAABULOUS|University of Edinburgh|No|Enrolling by invitation|January 2015|January 2021|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|180|||Both|40 Years|N/A|No|||March 2015|March 17, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02304276||31940|
NCT02304289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO/2014/003|Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma|Phase I Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Oral Artesunate (ART) in Patients With Advanced Hepatocellular Carcinoma (HCC).|DESPARTH|University Hospital, Ghent|No|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02304289||31939|
NCT02358161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCMEDONC 2013-215|Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer|Phase I/II Study of LDE225 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Locally Advanced or Metastasized Pancreatic Cancer|MATRIX|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|April 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358161||27810|
NCT02344823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT: 2010-023420-25|Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis|Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis||Medical University of Vienna|Yes|Recruiting|June 2012|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|30|||Male|18 Years|N/A|No|||September 2015|September 24, 2015|January 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02344823||28831|
NCT02333656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229079|Management of Hip and Knee Osteoarthritis in Primary Health Care|Improved Management of Patients With Hip and Knee Osteoarthritis in Primary Health Care||Diakonhjemmet Hospital|No|Recruiting|January 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|388|||Both|45 Years|N/A|No|||February 2016|February 25, 2016|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02333656||29686|
NCT02333669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DapingH023|Association of SCNN1A Single Nucleotide Polymorphisms With Neonatal Respiratory Distress Syndrome|Association of SCNN1A Single Nucleotide Polymorphisms With Neonatal Respiratory Distress Syndrome||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Completed|January 2012|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|249|||Both|N/A|28 Days|Accepts Healthy Volunteers|Probability Sample|Newborns with RDS are consecutively recruited for this study from the neonatal intensive        care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China,        a tertiary care facility. The control blood samples, which are collected from healthy        neonatal umbilical cord blood, are obtained from the maternity ward of 80 hospitals in        Chongqing and nearby areas.|January 2015|January 6, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02333669||29685|
NCT02340611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e-Volve|A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib|A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer||University Health Network, Toronto|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340611||29153|
NCT02337075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02526|PAthway To Health (PATH): Fostering Culturally Appropriate Physical Activities in Indigenous Communities|PAthway To Health (PATH): Fostering Culturally Appropriate Physical Activities Using Digital Technology in Indigenous Communities|PATH|University of British Columbia|No|Active, not recruiting|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02337075||29424|
NCT02332174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJXH－Rufi|Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects|Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects||Wuhan Union Hospital, China|Yes|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 3, 2015|January 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02332174||29800|
NCT02334722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400876|1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients|A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial||University of Florida|No|Recruiting|August 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334722||29604|
NCT02340910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBV-612299|Dose-Response Effects of Whole Body Vibration on Spasticity and Walking in SCI||WBV|Shepherd Center, Atlanta GA|No|Recruiting|January 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|16 Years|65 Years|No|||December 2015|December 2, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02340910||29130|
NCT02331654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2786/13|Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis|Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment and Evaluation of Endocannabinoid System Activity||IRCCS National Neurological Institute "C. Mondino" Foundation|No|Recruiting|November 2013|February 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02331654||29840|
NCT02341118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRCA Screening|Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.|Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.||University Health Network, Toronto|Yes|Recruiting|May 2014|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with high grade serous carcinoma originating from the ovaries, fallopian tube or        peritoneal cavity; subtype of high grade endometrioid and clear cell ovarian cancer could        be eligible in the exploratory cohort|March 2016|March 4, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02341118||29114|
NCT02335996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-23|Hypercortisolism and Epicardial Adipose Tissue|Impact Hypercortisolism on Adipose Epicardial and on Myocardial Function|Hyper-Cor|Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02335996||29507|
NCT02341183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057004|Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects|Novel Therapies for Muco-Obstructive Lung Diseases: A Study of Tolerability and MCC Effect of Hypertonic Saline Delivered Via the tPAD in Patients With Chronic Bronchitis|tPAD|University of North Carolina, Chapel Hill|No|Not yet recruiting|September 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|40 Years|80 Years|No|||September 2015|September 7, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02341183||29109|
NCT02300337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannesGU|Comparison of Reduced Cuff-pressure of the Laryngeal Tube Under General Anesthesia|Comparative Study of the Tightness of the Laryngeal Tube Under Mechanical Ventilation Before and After Reduction of Cuff Pressure on 60cmH₂O, 50cmH₂O, 40cmH₂O or 30cmH₂O|LTS|Johannes Gutenberg University Mainz|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300337||32243|
NCT02350686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-020|XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy|Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy||Samsung Medical Center|No|Not yet recruiting|January 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02350686||28382|
NCT02344082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1819|Pharmacists Provide Telemedicine in Addition to Clinic Visits to Improve Diabetes Management|||Johns Hopkins University||Enrolling by invitation|January 2015|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02344082||28887|
NCT02348593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002|"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"|A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy||Jazz Pharmaceuticals|No|Recruiting|May 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|75 Years|No|||August 2015|March 8, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348593||28542|
NCT02302144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-SAR-BAL|A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease|A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease||Boston University|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302144||32104|
NCT02309502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03019|Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy|Pascal Pan Retinal Photo-Stimulation in Pre-Proliferative Diabetic Retinopathy: a Safety and Efficacy Study|PRPhS|Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|October 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02309502||31540|
NCT02309541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFRA-A01/CEL5584|Evaluation of New Feedback Canceller for Carina™ Implant|Evaluation of a New Feedback Canceller Algorithm for Patient With Moderate to Severe Hearing Loss Implanted With a Fully Implantable Carina™ Medical Device||Cochlear|No|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|N/A|No|||November 2015|November 2, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02309541||31537|
NCT02356328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-003|NovaTears® Eye Drops Observational Study NT-003|NovaTears® Observational Study NT-003||Novaliq GmbH|No|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dry eye disease due to chronic ocular GvHD|March 2016|March 8, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02356328||27949|
NCT02356341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-002|NovaTears® Eye Drops Observational Study NT-002|NovaTears® Observational Study NT-002||Novaliq GmbH|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dry eye disease due to meibomian gland dysfunction|March 2016|March 8, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02356341||27948|
NCT02349126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2005|Study of ARC-520 in Patient With Chronic Hepatitis B Virus|||Arrowhead Research Corporation|No|Withdrawn|February 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||August 2015|August 12, 2015|January 20, 2015|Yes|Yes|Company decision to pursue alternative clinical trial|No||https://clinicaltrials.gov/show/NCT02349126||28501|
NCT02339233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0066 Epi Stim|Epi Stim to Facilitate Standing and Stepping|Spinal Epidural Electrode Array to Facilitate Standing and Stepping After Spinal Cord Injury||University of Louisville|Yes|Recruiting|January 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|75 Years|No|||January 2015|July 30, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339233||29259|
NCT02340598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/432-31|Pilot Study of Effects of Cold Vests on Cardiovascular Risk Markers|Prospective Randomized Pilot Study of the Effects of Cold Vests on Cardiovascular Risk Markers and Basal Metabolic Rate||University Hospital, Linkoeping|No|Active, not recruiting|January 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340598||29154|
NCT02339363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quach-1-2013|Effects of Sitting Meditation and Hatha Yoga in Adolescents|Differential Effects of Sitting Meditation and Hatha Yoga on Working Memory, Stress, and Mindfulness Among Adolescents in a School Setting||Alliant International University|No|Completed|March 2013|July 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|198|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02339363||29249|
NCT02328235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-367|Effect of High Fat Diet on Muscle Metabolism|Effect of High Fat Diet on Muscle Metabolism||Virginia Polytechnic Institute and State University|Yes|Active, not recruiting|January 2013|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02328235||30102|
NCT02337218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062012-035|Electrical Stimulation for Improving Balance in Diabetes|Electrical Stimulation for Improving Balance in Diabetes||University of Texas Southwestern Medical Center|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|89 Years|No|||December 2015|December 11, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02337218||29413|
NCT02340819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-C14-004|Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome|A 3-Stage Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome||Shire|No|Active, not recruiting|December 2014|June 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|N/A|No|||January 2016|January 29, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340819||29137|
NCT02340832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETE002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2014|||||N/A|N/A|N/A||||||||||||||January 20, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340832||29136|
NCT02328040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-330-000|Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop|Double-blinded, Randomized, Controlled Paired Trial Comparing Sitagliptin to Placebo in Closed Loop.||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|September 2014|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|14 Years|30 Years|No|||January 2016|January 12, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328040||30117|
NCT02335463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402039RINB|3D Single Cell Analysis Using Cell Morphology and Organelle Scattering Texture|3D Single Cell Analysis Using Cell Morphology and Organelle Scattering Texture||National Taiwan University Hospital|No|Recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Participants are those who received skin or colon surgery, with their surgical specimens        preserved and stored at Department of Pathology, National Taiwan University Hospital.|August 2015|August 9, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335463||29547|
NCT02341014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-179|Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas|Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341014||29122|
NCT02328508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0876B, 101-0507C|Hyperbaric Oxygen Therapy in Diabetics With Chronic Foot Ulcers and Improvement of Quality of Life|Hyperbaric Oxygen Therapy in Diabetics With Chronic Foot Ulcers and Improvement of Quality of Life||Chang Gung Memorial Hospital|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|N/A|No|||December 2014|December 30, 2014|December 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328508||30081|
NCT02341196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR01|Randomized Clinical Trial of Polyester vs. Polyurethane Patch for Carotid Endarterectomy|Randomized Clinical Trial of Polyester vs. Polyurethane Patch for Carotid Endarterectomy. Long-term Results||University of Poitiers|Yes|Completed|January 1995|December 2014|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|25 Years|90 Years|No|||January 2015|January 13, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02341196||29108|
NCT02309463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-506|Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension|A Prospective Multicenter Study to Assess the Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance and 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension Newly Initiating Endothelin Receptor Antagonist Therapy|LONGACT|Actelion|No|Withdrawn|January 2015|February 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with PAH, and not receiving ERA therapy in the 30 days prior to the        enrolment visit, are eligible for inclusion in this study. Patients in need of ERA therapy        will receive ERA treatment according to the physician's decision|March 2016|March 17, 2016|October 22, 2014||No|EC did not accept measurement of patient's activity for the primary end-point with a    non-validated activity tracking device|No||https://clinicaltrials.gov/show/NCT02309463||31543|
NCT02309489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA649|Involving Men in Maternity Care in Burkina Faso|Involving Men in Maternity Care in Burkina Faso||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1115|||Female|16 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309489||31541|
NCT02356016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMOsA P2 TP3|Effects of Whole-body Electromyostimulation and Dietary Supplements on "Sarcopenic Obesity"|Effects of Whole-body Electromyostimulation and Dietary Supplements on "Sarcopenic Obesity" in Elderly Females Living in the Community||University of Erlangen-Nürnberg Medical School|No|Active, not recruiting|January 2015|August 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Female|70 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02356016||27973|
NCT02348606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003|"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)|OSA|Jazz Pharmaceuticals|No|Recruiting|May 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|440|||Both|18 Years|75 Years|No|||August 2015|March 8, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348606||28541|
NCT02307175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMS-2014-01|A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication|A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication||Centre Hospitalier Universitaire de Sherbrooke|No|Recruiting|September 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients between 18 and 80 years of age with thyroid scan indication|December 2014|December 1, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02307175||31718|
NCT02346825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD074574-01A1|The Baby CHAMP Study (Children With Hemiparesis Arm and Movement Project)|Multisite RCT of 3 Neurorehabilitation Therapies for Infants With Asymmetrical Cerebral Palsy|The Baby CHAMP|Virginia Polytechnic Institute and State University|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Both|6 Months|24 Months|No|||December 2015|December 8, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02346825||28677|
NCT02356926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14017|Cross Checking to Reduce Adverse Events in the Emergency Department|Cross Checking to Reduce Adverse Events Resulting From Medical Errors in the Emergency Department|Charmed|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|1680|||Both|18 Years|N/A|No|Probability Sample|Emergency patients|February 2016|February 24, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356926||27903|
NCT02356939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 130919|Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation|Efficacy Of A Removable Intraductal Stent In Duct-To-Duct Biliary Reconstruction To Prevent Biliary Complications In Liver Transplantation: A Randomized Controlled Trial|BILIDRAINT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|268|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356939||27902|
NCT02339298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Music study StV 10/09|Intraoperative Music Application and Postoperative Behaviour in Children and Adolescents.|Impact of Intraoperative Music Application on Postoperative Behaviour in Children and Adolescents.||University Children's Hospital, Zurich|No|Completed|July 2009|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|140|||Both|4 Years|16 Years|No|||November 2015|November 9, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02339298||29254|
NCT02331667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1396|The Effect of Diet on Learning Abilities for Children in Kindergarden|The Effect of Diet on Learning Abilities for Children in Kindergarden||National Institute of Nutrition and Seafood Research, Norway|Yes|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|233|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02331667||29839|
NCT02332915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1782-R|Treatment Intensity - Apraxia of Speech|Effect of Intensity of Treatment on Rehabilitation of Acquired Apraxia of Speech||VA Office of Research and Development|No|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|40 Years|80 Years|No|||December 2015|December 9, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02332915||29743|
NCT02327832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHINAI-BMSC1|Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs|Safety Study of a Less Invasive Liver Regeneration Therapy Using Cultured Autologous Bone Marrow-derived Mesenchymal Stem Cells for Compensated Liver Cirrhotic Patient||Yamaguchi University Hospital|No|Recruiting|December 2014|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|75 Years|No|||December 2014|December 29, 2014|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327832||30133|
NCT02332954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15913A|Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine|Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD)|AtWoRC|Lundbeck Canada Inc.|No|Recruiting|February 2015|June 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332954||29740|
NCT02333214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 31998714.4.0000.0064|Effectiveness of a Program Using Video Games Associated With Conventional Physiotherapy in Physical Functioning in Frail Elderly Compared to Conventional Physiotherapy|The Effectiveness of an Exercise Program Using Video Games Associated With Conventional Physiotherapy in Physical Functioning in Frail Elderly Compared to Conventional Physiotherapy: Randomized Clinical Trial||Universidade Cidade de Sao Paulo|Yes|Recruiting|October 2014|December 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|60 Years|N/A|No|||January 2015|January 5, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02333214||29720|
NCT02341027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP2016|Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial|Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial||University of California, San Francisco|No|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|202|||Female|18 Years|50 Years|No|||July 2015|July 26, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341027||29121|
NCT02341040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1416|Evaluation of Potential Allergenicity of New Wheat Varieties|Evaluation of Potential Allergenicity of New Wheat Varieties||University of Colorado, Denver|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Subjects may opt to have extra blood drawn. This sample will be de-identified and sent to      the sponsor, Monsanto, for future study that is yet to be determined.|Both|1 Year|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric and adult subjects between the ages of 1 (inclusive) to 21 years (inclusive)        that have sensitivity to wheat|January 2016|January 13, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02341040||29120|
NCT02333682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-04-17-HDPK|Pharmacokinetics of Calcifediol and Cholecalciferol|The Response of Serum 25-hydroxyvitamin D to Different Doses of Calcifediol Hy.D Compared to Vitamin D3 Supplementation: A Randomized, Controlled, Double Blind, Long Term Pharmacokinetic Study||DSM Nutritional Products, Inc.|Yes|Active, not recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|September 1, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02333682||29684|
NCT02336854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111HPS14027|Tacrobell tab_Phase1_PK|||Chong Kun Dang Pharmaceutical||Not yet recruiting|February 2015|||May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336854||29441|
NCT02328989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7048 01|Pessary to Prevent Prematurity in Twins in Case of Short Cervix|Pessary to Prevent Prematurity in Twins in Case of Short Cervix|PESSAR'ONE|University Hospital, Toulouse|No|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Female|18 Years|60 Years|No|||December 2015|December 22, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02328989||30044|
NCT02301949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhnj3015|Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment|Retreatment and Its Clinical Efficiency of Thalidomide for Gastrointestinal Vascular Malformation Patients With Failure of First Course Treatment——a Randomized, Double Blind, Placebo Controlled Study||Shanghai Jiao Tong University School of Medicine|No|Not yet recruiting|December 2014|November 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|85 Years|No|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02301949||32119|
NCT02301962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200092|Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer|An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer||GlaxoSmithKline|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||August 2015|October 1, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02301962||32118|
NCT02356198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003143|Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery|Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial||Mayo Clinic|No|Recruiting|March 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356198||27959|
NCT02352571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1118_P1|Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer|A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers||Green Cross Corporation|Yes|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|19 Years|N/A|No|||February 2016|March 7, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02352571||28238|
NCT02296840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070851|Post-operative Pain Control After Pediatric Adenotonsillectomy|Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy||Emory University|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|17 Years|No|||January 2016|January 20, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296840||32512|
NCT02297659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397284-1|Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure|Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure||San Antonio Military Medical Center|Yes|Recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|312|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|August 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297659||32449|
NCT02297672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02175|Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant|Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant|PBSI|British Columbia Cancer Agency|Yes|Recruiting|February 2015|January 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|55 Years|80 Years|No|||August 2015|August 6, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297672||32448|
NCT02351999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-14-01|Clinical Study of the TSP Crosser System for Transseptal Access and Left Atrial Catheter Navigation|Clinical Study of the TSP Crosser System For Transseptal Access and Left Atrial Catheter Navigation in Patients Undergoing Atrial Fibrillation Ablation||Transseptal Solutions Ltd.|No|Not yet recruiting|February 2015|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|80 Years|No|||January 2015|January 30, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02351999||28281|
NCT02335476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402036RINA|Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography|Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography||National Taiwan University Hospital|No|Recruiting|March 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Participants are patients at out-patient clinics or ward of Department of Dermatology,        National Taiwan University Hospital.|August 2015|August 9, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335476||29546|
NCT02335736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA2015|Antagonist Protocol in IVF|Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?||Woman's Health University Hospital, Egypt|Yes|Recruiting|January 2015|April 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Female|20 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335736||29527|
NCT02331381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311081|Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device|A Pilot Study of Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device||Washington University School of Medicine|No|Active, not recruiting|December 2013|February 2016|Anticipated|December 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|January 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02331381||29861|
NCT02335749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA14-004|Distal Thigh Study|CoolSculpting the Distal Thigh|DST|Zeltiq Aesthetics|No|Active, not recruiting|January 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||January 2015|September 2, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335749||29526|
NCT02336932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITD201501|Vitamin D and the Free Hormone Hypothesis|Vitamin D and the Free Hormone Hypothesis: Lessons From Surgical Stress||Rigshospitalet, Denmark|Yes|Active, not recruiting|February 2015|September 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|serum|Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|20 otherwise healthy patients (10 males and 10 females) age 50-75 years undergoing        elective total knee arthroplasty in Department of Orthopaedic Surgery, Hvidovre Hospital.        All patients undergo standard anaesthesia and analgesic treatment in a fast-track set-up        with discharge not earlier than 48-hours postoperatively.|February 2016|February 3, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02336932||29435|
NCT02337179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0863|Male Circumcision Services for HIV Prevention in the Dominican Republic|A Pilot Study to Introduce Male Circumcision (MC) Services to Prevent HIV Infection in Two High Prevalence Areas of the Dominican Republic (DR)||University of Illinois at Chicago|No|Active, not recruiting|February 2011|||June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|539|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02337179||29416|
NCT02337387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15728|A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women|A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women||Eli Lilly and Company|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|53|||Female|45 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337387||29400|
NCT02336412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14NE625|Short Message Service (SMS) Reminders for Stroke Secondary Preventative Medications|The Use of Short Message Service (SMS) as a Reminder for Continuation of Treatment With Secondary Preventative Medications After Stroke or TIA||NHS Greater Glasgow and Clyde|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336412||29475|
NCT02336425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031B2204|Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma|A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 s.c. in Asthma Patients Not Adequately Controlled by Medium- or High-dose ICS Plus LABA With or Without OCS||Novartis|Yes|Recruiting|September 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|440|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336425||29474|
NCT02336503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-4000-CL-201|A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis|A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis||Brickell Biotech, Inc.|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|189|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336503||29468|
NCT02332447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-853|Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy|Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy|ENALEPSY|Hospices Civils de Lyon|Yes|Recruiting|January 2015|July 2017|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2015|September 24, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332447||29779|
NCT02332720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682-012|Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT3, GT4, GT5, and GT6 Infection||Merck Sharp & Dohme Corp.|No|Recruiting|January 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|22||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02332720||29758|
NCT02337621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14-124|Pain, Exercise and Psychological Well-being in Pectus Excavatum|Evaluating Outcomes for Pectus Excavatum: Pain, Exercise, and Psychological Well-being|PEP|Phoenix Children's Hospital|No|Recruiting|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|12 Years|17 Years|No|Non-Probability Sample|Children who are scheduled to undergo surgical correction for pectus excavatum (Nuss        procedure)|June 2015|June 25, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02337621||29382|
NCT02328274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103138-E|A Modified Technique for Laparoscopic Subtotal Hysterectomy|||Far Eastern Memorial Hospital|No|Completed|August 2014|November 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients aged 20 years old and above with symtomatic uterine myomas or adenomyosis|December 2014|December 25, 2014|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02328274||30099|
NCT02336867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-2018|Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial|Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial|FISCLOSE|University Hospital, Clermont-Ferrand||Recruiting|January 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|80 Years|No|||September 2015|September 18, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336867||29440|
NCT02333942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082189|Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia|A Non-Blinded, Non-Significant Risk Study With a Non-Invasive, Passive Pressure Wave Method of Diagnosing Brain Pathologies to Develop a Diagnostic Algorithm for Alzheimer Disease and Other Dementias.||Jan Medical, Inc.|No|Active, not recruiting|May 2014|March 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Alzheimer's Disease, Frontotemporal Lobar Degeneration, Mild Cognitive        Impairment, and Age-Matched Controls.|June 2015|June 2, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02333942||29664|
NCT02305979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98414|Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies|Evaluation of Loratadine for Granulocyte-Colony Stimulating Factor Induced Bone Pain in Patients With Hematologic Malignancies||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|December 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Wake Forest Baptist Health Hematology and Oncology Clinic|July 2015|July 27, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02305979||31809|
NCT02346591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2R|Mobile-Web Emotion Self-management Tool|Emotion Management Training: An Innovative Stress Reduction Program|Emotions|Oregon Center for Applied Science, Inc.|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|298|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02346591||28695|
NCT02357602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2797|Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women|Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7340 in Women||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|March 2015|March 2017|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|24|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02357602||27852|
NCT02357615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-004PIV -2|Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure|||Shanghai Shyndec Pharmaceutical Co.,Ltd.||Recruiting|December 2014|September 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|70 Years|No|||December 2014|February 3, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02357615||27851|
NCT02301637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-AUX-012|Eeva System Imaging Study|Prospective Observational Study Utilizing the Eeva™ System 2.2.1 for Ongoing Collection of Development and Validation Data|PROSPECT|Progyny, Inc.|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing in vitro fertilization treatment who fulfill all eligibility criteria.|July 2015|July 9, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301637||32143|
NCT02309788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAOBAI|Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis||RHCC|Guangxi Medical University||Recruiting|January 2016|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed with HCC at the Affiliated Tumor Hospital of Guangxi Medical University        Science were considered for enrollment in the study. The diagnostic criteria for HCC used        in the study were in accordance with the American Association for the Study of Liver        Diseases' 2005 guidelines. All patients had preoperative serum a-fetoprotein (AFP) levels        >200 ng/mL or a typical enhancement pattern (arterial enhancement and portal/delayed        washed out) on dynamic imaging of hepatic mass(es)>2 cm, or cytologic/histologic evidence        of HCC|January 2016|January 23, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02309788||31518|
NCT02359760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMontreal|Assessment of Piezoelectric Periodontal Surgery Effects on Orthodontic Treatment: a Prospective Pilot Study|Assessment of Piezoelectric Periodontal Surgery Effects on Orthodontic Treatment: a Prospective Pilot Study||Université de Montréal|Yes|Not yet recruiting|February 2015|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359760||27687|
NCT02335411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-059|A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)|A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)||Merck Sharp & Dohme Corp.|Yes|Recruiting|February 2015|October 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|253|||Both|18 Years|N/A|No|||February 2016|March 1, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335411||29551|
NCT02335424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-052|Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)|A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer||Merck Sharp & Dohme Corp.|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02335424||29550|
NCT02336009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orebro Lans landsting 01-14|Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant|Clinical, Radiological and Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant||Örebro University, Sweden|No|Recruiting|October 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|100 Years|No|||September 2015|September 26, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02336009||29506|
NCT02335957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIC-RAD-2014-02|OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)|OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)|OPTIMAL|Grupo de Investigación Clínica en Oncología Radioterapia|Yes|Recruiting|April 2015|April 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1422|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02335957||29510|
NCT02337426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13-09950|Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Trial of Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Glioblastoma Multiforme||Virginia Commonwealth University|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337426||29397|
NCT02336620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF_58015|Balanced Salt Solution VS. Normal Saline Solution in Septic Shock|Balanced Salt Solution Versus Normal Saline Solution During Initial Resuscitation in Severe Sepsis or Septic Shock Children: A Randomized Controlled Trial||Ramathibodi Hospital|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Month|18 Years|No|||October 2015|October 22, 2015|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336620||29459|
NCT02333227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHSRC # 1030|Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi|Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi (Prevention of Prematurity and Xylitol)|PPaX|Baylor College of Medicine|No|Recruiting|May 2015|January 2020|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|9365|||Female|14 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02333227||29719|
NCT02333435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-10-1012|Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life|Étude randomisée, contrôlée, de Phase II, Effets d'un Supplement d'oméga-3 (EPA) Sur l'Inflammation, la prolifération Cellulaire et la qualité de Vie Chez Des Patients Avec Cancer de la Prostate traités Par Prostatectomie Radicale|RCT-EPA|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|January 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Male|18 Years|N/A|No|||February 2016|February 3, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333435||29703|
NCT02293772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284438/WP5|Planetary Habitat Simulation: Nutrition Studies|Planetary Habitat Simulation: An Investigation Into the Effects of Hypoxia and / or Bedrest on Fuel Metabolism and Appetite (WP5)|PlanHab|University of Nottingham|Yes|Completed|March 2012|October 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293772||32747|
NCT02294058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-301|Phase 3 Study of RPC1063 in Relapsing MS|A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients||Celgene|Yes|Active, not recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1200|||Both|18 Years|55 Years|No|||February 2016|February 4, 2016|August 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294058||32725|
NCT02351739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-005|Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer|Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)|KEYNOTE143|Acerta Pharma BV|Yes|Active, not recruiting|April 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351739||28301|
NCT02305056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBONOMIC|Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)||CARBONOMIC|University Hospital, Grenoble|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|18 Years|90 Years|No|||August 2015|August 27, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02305056||31880|
NCT02350023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9121/PG-2Trg/12/8073|Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata|A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata|COLA|Postgraduate Institute of Medical Education and Research|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|99 Years|No|||November 2015|November 29, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350023||28433|
NCT02343393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHE|Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study|Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study|NICHE|National University Hospital, Singapore|Yes|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|No|||January 2015|January 15, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343393||28939|
NCT02343406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-483|ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma|ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG)|INTELLANCE 2|AbbVie|Yes|Recruiting|February 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|99 Years|No|||January 2016|January 7, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343406||28938|
NCT02338661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8319|Clinical Observation Study With the SBG Stem|Clinical Observation Study With the SBG Stem||Smith & Nephew, Inc.||Active, not recruiting|January 2004|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2016|January 22, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02338661||29302|
NCT02338765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A123858|MoTHER Buddy Program|With Help From Buddies: The Impact of Social Support Using Mobile Technology on Physical Activity Among Women With Young Children||University of California, San Francisco|No|Recruiting|January 2015|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|46|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338765||29294|
NCT02335658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4904040|Long-term Study of DSP-5423P in Patients With Schizophrenia|Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>||Sumitomo Dainippon Pharma Co., Ltd.|No|Recruiting|February 2015|||February 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2015|March 22, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335658||29533|
NCT02335671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-476|Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy|Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy||Dana-Farber Cancer Institute|Yes|Recruiting|February 2015|December 2021|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|43|||Female|18 Years|75 Years|No|||October 2015|October 19, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335671||29532|
NCT02339012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150063|Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)|The Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|December 2036|Anticipated|November 2036|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|20 Years|N/A|No|||October 2015|October 30, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02339012||29275|
NCT02341456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6011C00003|Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours|A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy and in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|100 Years|No|||March 2016|March 18, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341456||29088|
NCT02341469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRZC78|A Trial of an Integrated E-diagnosis Assessment to Improve the Management of Childhood Illnesses in Burkina Faso|Integrated eDiagnosis Assessment (IeDA) for Children Under Five Years Old: a Stepped-wedge Randomized Cluster Trial of a Quality Improvement of the Management of Children Illnesses in Burkina Faso at the Primary Health Care Level|IeDA|London School of Hygiene and Tropical Medicine|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|7200|||Both|N/A|5 Years|No|||December 2014|January 13, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02341469||29087|
NCT02339142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03166|Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease|Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease|CRISEPTED|University of British Columbia|No|Not yet recruiting|January 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|35 Years|N/A|No|||January 2015|January 14, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339142||29265|
NCT02339155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201436|Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed|A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)||GlaxoSmithKline|No|Recruiting|February 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339155||29264|
NCT02336516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130910 / AOM13540|Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome|Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome|ZITHROSHU|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|6 Months|18 Years|No|||February 2016|February 24, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336516||29467|
NCT02336607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4385L00001|The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.|A Randomized, Open-label Study to Evaluate the Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release, Alone and in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide, in Chinese Patients With Mild to Moderate Essential Hypertension.||AstraZeneca||Completed|December 2005|August 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|529|||Both|35 Years|79 Years|No|||March 2015|March 13, 2015|November 25, 2014||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT02336607||29460|
NCT02343198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB_NMES_PC|The Use of NMES as a Home-based Therapy Following Total Knee Arthroplasty|The Use of NMES as a Home-based Therapy Following Total Knee Arthroplasty||National University of Ireland, Galway, Ireland|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|55 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02343198||28954|
NCT02337881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ob/gyn 2|Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate|Combined Nifedipine and Sildenafil Citrate Versus Nifedipine Alone in Acute Tocolysis of Preterm Labor: A Randomized Clinical Trial||Al Hayat National Hospital|Yes|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|227|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02337881||29362|
NCT02342340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:122|Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.|A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.|BBB-2014|University of Manitoba|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|6||Anticipated|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342340||29020|
NCT02342353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503052|Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)|A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI||Washington University School of Medicine|No|Active, not recruiting|December 2015|March 2023|Anticipated|March 2023|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342353||29019|
NCT02342366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUK-GHB01|Characterization of the Prosocial and Prosexual Effects of GHB|Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms||University of Zurich|No|Completed|February 2012|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342366||29018|
NCT02342379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 12-0105|TH-302 in Combination With Bevacizumab for Glioblastoma|A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342379||29017|
NCT02338089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-06|Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro|Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338089||29346|
NCT02338102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000087|Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer|Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer: A Pilot Study||University of Kansas Medical Center|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338102||29345|
NCT02353780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10100422|Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept|Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept|MAZERATI|University of Pittsburgh|No|Recruiting|March 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|64 Years|No|||January 2016|January 14, 2016|June 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02353780||28145|
NCT02359721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADHIKA DISSERTATION|Clarithromycin is an Adjunct to Scaling and Root Planing|Efficacy of Clarithromycin is an Adjunct to Scaling and Root Planing .A Clinical Microbiological and Immunological Study.|CASRCMI|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Completed|January 2012|December 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||January 2015|February 4, 2015|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359721||27690|
NCT02344589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-UG-14|The Effect of Local Anesthetic Volume Within the Adductor Canal on Quadriceps Function Evaluated by Electromyography|The Effect of Local Anesthetic Volume Within the Adductor Canal on Quadriceps Function Evaluated by Electromyography: A Randomized, Observer-Masked, Placebo-Controlled Study in Volunteers.||University Hospital, Gentofte, Copenhagen|Yes|Completed|January 2015|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344589||28849|
NCT02344602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5427-A|The Effect of Uric Acid Lowering in Type 1 Diabetes|A Deep Phenotyping Approach to Assess the Effect of Uric Acid Lowering in Patients With Uncomplicated Type 1 Diabetes Mellitus||University Health Network, Toronto|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344602||28848|
NCT02293421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA STOP-BANG|Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic|Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic||Karolinska University Hospital|No|Recruiting|November 2014|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293421||32774|
NCT02293434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9251|Nutritional Status on Admission to Pediatric Intensive Care|Nutritional Status on Admission to Pediatric Intensive Care: A French Multicentric Study|NUTRI-REAPED|University Hospital, Montpellier|Yes|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|1 Month|18 Years|No|Non-Probability Sample|All children (1 month to 18 years) admitted to all PICUs in France|November 2014|November 19, 2015|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02293434||32773|
NCT02353962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-2014-0543|Evaluating the Feasibility and Usability of Exergames in Stroke Patients With Visuo-spatial Neglect|Evaluating the Feasibility and Usability of Exergames on Exploring the Hemineglected Space in Stroke Patients With Visuo-spatial Neglect||University of Zurich|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02353962||28131|
NCT02353975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-104|Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects|An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR3824 and Mass Balance Study in Healthy Volunteers||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|May 2014|September 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|February 2, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02353975||28130|
NCT02347917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8807005|A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma|A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma||Sumitomo Dainippon Pharma Co., Ltd.||Recruiting|February 2015|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|20 Years|N/A|No|||February 2015|February 15, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347917||28594|
NCT02327533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK2013/15|Gene Expression Profiles in Generalized Aggressive Periodontitis: A Gene Network-based Microarray Analysis|Gene Expression Profiles in Generalized Aggressive Periodontitis: A Gene Network-based Microarray Analysis||Kocaeli University|No|Completed|February 2013|December 2014|Actual|September 2014|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|Samples With DNA|Biospecimens were kept for analysis|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Aggressive periodontitis patients: The periodontal diagnosis of subjects with GAgP was        established on the basis of clinical and radiographic criteria and was defined by the 1999        International World Workshop for a Classification of Periodontal Diseases and        Conditions.(Lang et al., 1999) Patients were included if they were between 18 and 35 years        of age and otherwise healthy. The bone loss estimation was radiographically performed in        each patient for the assessment of the extent and severity of alveolar bone loss.|December 2014|December 24, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02327533||30156|
NCT02338895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC # 2141039|Algorithm for Oliguria in Septic Shock|An Ultrasound- Guided Algorithm for the Management of Oliguria in Septic Shock|AMOSS|King Faisal Specialist Hospital & Research Center|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|14 Years|N/A|No|Non-Probability Sample|Critically ill patients with septic shock presenting with acute oliguria|January 2015|January 22, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338895||29284|
NCT02328001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4667|Cost-Minimization Analysis After a Targeted Intervention for EGD and Colonoscopy|Cost-Minimization Analysis and Its Impact on Resource Utilization After a Targeted Intervention for EGD and Colonoscopy||University of Oklahoma|Yes|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|1200|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02328001||30120|
NCT02329236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|meir medical center|Prevalence of Attention Deficit Disorder Among Patients With Constitutional Growth Delay|||Meir Medical Center|Yes|Not yet recruiting|January 2015|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|4 Years|18 Years|No|Probability Sample|children with short stature due to constitutional growth delay or familial short stature        followed at the endocrine unit.|December 2014|December 30, 2014|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02329236||30025|
NCT02329249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR37R-2|Pharmacological Aids for Interactive Smoking Cessation|Pharmacological Aids for Interactive Smoking Cessation|NRT_2|Oregon Center for Applied Science, Inc.|No|Completed|February 2001|January 2006|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 31, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329249||30024|
NCT02328456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-CREST-COMPLIANCE-GLAUCOMA|Effect of SMS Reminder and Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China|A Randomized Controlled Trail to Determine the Impact of a SMS Reminder Associated With Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China||Sun Yat-sen University|Yes|Recruiting|November 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|174|||Both|N/A|N/A|No|||December 2014|December 30, 2014|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02328456||30085|
NCT02328469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mgt-0614|Aseptic Meningoencephalitis in Slovenia|Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia||University Medical Centre Ljubljana|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|800|Samples With DNA|Samples of full blood, serum and plasma will be collected and retained in deep freezer for      further analyses.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adult patients with acute aseptic meningitis/meningoencephalitis|December 2014|December 30, 2014|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02328469||30084|
NCT02343159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS413|Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.|A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.||Biogen|Yes|Terminated|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|84|||Both|18 Years|65 Years|No|||November 2015|December 10, 2015|January 9, 2015|No|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT02343159||28957|
NCT02328950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA5Bucy-SCT-01|A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome|A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome||Fujian Medical University|No|Recruiting|December 2014|December 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Year|65 Years|No|Non-Probability Sample|Patients with high-risk, recurrent or refractory acute leukemia and advanced        myelodysplastic syndrome|February 2016|February 16, 2016|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02328950||30047|
NCT02336737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-001|SentiMag® Intraoperative Comparison in Breast Cancer|A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure|SentiMagIC|Endomagnetics Inc|No|Active, not recruiting|January 2015|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|160|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02336737||29450|
NCT02329769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO044-CLIN-02|Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy||BioMarin Pharmaceutical|Yes|Enrolling by invitation|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Male|9 Years|20 Years|No|||April 2015|April 30, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329769||29984|
NCT02337010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeVOX-study|Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management|Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management During Major Abdominal Surgery||Szeged University|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|79|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02337010||29429|
NCT02359825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131329|Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function|Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function||Vanderbilt University|No|Recruiting|September 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|18|||Both|18 Years|64 Years|No|||December 2015|December 28, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359825||27682|
NCT02356965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET005|Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of A Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction||iX Biopharma Ltd.|Yes|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356965||27900|
NCT02348866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro#00041187|Bacterial Contamination on Obstetric Resident Surgical Scrubs|Bacterial Contamination on Obstetric Resident Surgical Scrubs: a Randomized Trial||Greenville Health System|No|Completed|January 2015|January 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|4||Actual|18|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02348866||28521|
NCT02297880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CreaBIO1|Effects of Low Calorie Sweeteners on Dietary Intakes, Hunger, Appetite and Satiety|Effects of Beverages Containing Low Calorie Sweeteners (LCS) on Energy and Macronutrient Intakes and on Hunger, Appetite and Satiety Sensations||The Coca-Cola Company|No|Recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|170|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02297880||32432|
NCT02359838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-515|Patient-Centered Care for the Older Adult With Hematologic Malignancy|Patient-Centered Care for the Older Adult With Hematologic Malignancy||Dana-Farber Cancer Institute|Yes|Recruiting|February 2015|January 2020|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|162|||Both|75 Years|N/A|No|||December 2015|December 28, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359838||27681|
NCT02344966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0732|Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia|||Yonsei University|No|Recruiting|February 2011|February 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1100|||Both|16 Years|N/A|No|Non-Probability Sample|Sampling is performed in patients diagnosed with acute leukemia in Severance Hospital.        Every eligible patients in peroid of study are enrolled. Patients must have the ability        and willingness to sign a written informed consent document. Planned number of patients is        1100 considering annual incidence rate.|February 2011|January 18, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02344966||28820|
NCT02352012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tdhx007|Interventional Treatment of Refractory Pneumothorax by Bronchoscope|A Multi-site Randomized Controlled Study of Interventional Treatment of Refractory Pneumothorax by Bronchoscope||Tang-Du Hospital|Yes|Recruiting|February 2015|June 2017|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|269|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352012||28280|
NCT02332135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJFH-EC/2014-101|The Efficacy and Safety of Microwave Ablation in Hemodialysis Patients With Secondary Hyperparathyroidism in Early Stage|The Efficacy and Safety of Microwave Ablation in Hemodialysis Patients With Secondary Hyperparathyroidism in Early Stage||Beijing Friendship Hospital|Yes|Not yet recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 13, 2015|January 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332135||29803|
NCT02336750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2014-15 CBCSG019|Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis|A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement||Fudan University|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|212|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02336750||29449|
NCT02327767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314-153-a|Use of a Mechanically Passive Rehabilitation Device in Vietnam: Impact on Upper Extremity Hemiparesis After Stroke|Use of a Mechanically Passive Rehabilitation Device as a Training Tool in Vietnam: Impact on Upper Extremity Hemiparesis After Stroke||California State University, Northridge|No|Not yet recruiting|January 2015|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327767||30138|
NCT02332668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-051|A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)|A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)||Merck Sharp & Dohme Corp.|No|Recruiting|March 2015|January 2019|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|310|||Both|6 Months|17 Years|No|||March 2016|March 23, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332668||29762|
NCT02332681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38151514.8.0000.5404|Osteoporosis and Knee Insufficiency Fracture|Osteoporosis and Knee Insufficiency Fracture||University of Sao Paulo General Hospital|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|45 Years|N/A|No|Non-Probability Sample|patients older than 45 years, with sudden joint line knee pain without high trauma        history, with or without a history of osteoarthritis and / or osteoporosis.|December 2014|January 5, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332681||29761|
NCT02333162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0709|Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant|A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies||University of Chicago|Yes|Recruiting|December 2014|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02333162||29724|
NCT02333175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0040|Care for Late Stage Parkinsonism|Care for Late Stage Parkinsonism|CLaSP|University College, London|No|Recruiting|September 2014|April 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|1 Year|N/A|No|||February 2015|February 2, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02333175||29723|
NCT02328690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361395|The Sound Mind Warrior Study|Binaural Beat Technology: A Complementary Path to Post Deployment Wellness (The Sound Mind Warrior Study)||Fort Belvoir Community Hospital|No|Active, not recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328690||30067|
NCT02337842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0033|Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)|Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 2015|January 2016||January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|February 4, 2016|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337842||29365|
NCT02329223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025E2306|Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy||Novartis|No|Active, not recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|218|||Both|12 Years|75 Years|No|||August 2015|August 10, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02329223||30026|
NCT02329496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2332|REPRISE Next Generation Delivery System|REPRISE NGDS: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With the Next Generation Delivery System|NGDS|Boston Scientific Corporation|No|Recruiting|December 2014|November 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|70 Years|N/A|No|||January 2016|January 11, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02329496||30005|
NCT02334384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-ATG-001|Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess|Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess||Eastern Virginia Medical School|No|Not yet recruiting|April 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2015|January 7, 2015|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02334384||29630|
NCT02342405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-409|High Inspiratory Oxygen Fraction on Endothelial Function in Healthy Volunteers|Effect of High Inspiratory Oxygen Fraction on Endothelial Function in Healthy Volunteers: a Randomized Controlled Cross-over Trial||University Hospital Koge|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342405||29015|
NCT02344732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-13-449-15617|Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy|Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy||University of Science Malaysia|No|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02344732||28838|
NCT02354963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/0004|Follicular Activation in Poor Responders|Follicle Activation in Patients With Poor Ovarian Response Through Fragmentation of the Ovarian Tissue.|FAPPOR|Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|40 Years|No|||July 2015|July 22, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02354963||28054|
NCT02302430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15259|Intranasal Oxytocin and Enhancement of Team Cohesion|Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.|ECHO|University of California, San Francisco|No|Recruiting|October 2015|||July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|360|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302430||32082|
NCT02345278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM/0044|SUBLIVAC FIX Mite Mixture Dose Tolerability Study|A Randomized, Double-blind, Placebo-controlled Study to Determine Tolerability and Safety of Different Dosages of SUBLIVAC FIX Mite Mixture in Patients With Allergic Rhinitis / Rhinoconjunctivitis Caused by House Dust Mites|DTS|HAL Allergy|Yes|Completed|May 2015|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|81|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345278||28796|
NCT02356380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChathamU|The Effects of Thoracic Spine Mobilizations in Individuals With Neck Pain.|The Effects of Thoracic Spine Mobilizations in Individuals With Neck Pain.|THSPMOBS|Chatham University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356380||27945|
NCT02336880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-CBT in NCCP|Internet-delivered CBT for NCCP-patients - a Pilot Trial|Short-term Internet-delivered Cognitive Behavioural Therapy for Treatment of Cardiac Anxiety and Fear of Body Sensations in Patients With Non-cardiac Chest Pain - a Pilot Randomized Controlled Study||Linkoeping University|No|Active, not recruiting|January 2015|March 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336880||29439|
NCT02342990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1/13-15_1.4|Telerehabilitation of Working Memory in Children With Periventricular Leukomalacia and Bilateral Cerebral Palsy|Telerehabilitation of Working Memory in Children With Periventricular Leukomalacia and Bilateral Cerebral Palsy, a Neuropsychological and Electrophysiological (High-density EEG) Study||IRCCS Fondazione Stella Maris|No|Completed|March 2014|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|14 Years|No|||February 2016|February 23, 2016|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02342990||28970|
NCT02332395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-KAEK-226|The Evaluation of Postoperative Pain After Caesarean Section|The Evaluation of Postoperative Pain After Emergency and Elective Caesarean Section Operations||Tokat Gaziosmanpasa University|No|Enrolling by invitation|December 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Female|18 Years|45 Years|No|Probability Sample|individuals whose underwent caesarean section operation in terms of surgical priority        whether emergency or elective|February 2016|February 10, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332395||29783|
NCT02337023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101002|Brain Scintigraphy in Normal Versus Kleine-Levin Syndrome Subjects|Brain Scintigraphy in Normal Versus Kleine-Levin Syndrome Subjects|SCINTIK|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects|July 2015|July 20, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02337023||29428|
NCT02333409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA_CA pancreas|Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer|Electroacupuncture Analgesia in Patients With Inoperable Pancreatic Cancer: A Randomized, Sham-controlled Study||Chinese University of Hong Kong|No|Not yet recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||January 2015|January 5, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333409||29705|
NCT02337855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0009|A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults|A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|February 2015|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 19, 2015|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337855||29364|
NCT02338063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0079-10|Eliciting Affect in Teens in a Virtual World (Project AVATAR)|Eliciting Affect in Teens in a Virtual World (Project AVATAR)||Rhode Island Hospital|No|Active, not recruiting|May 2010|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||January 2015|October 26, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338063||29348|
NCT02337582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAC110001|Colombian Screening Mammography Project|Pilot Study for Implementing Breast Cancer Early Detection Programs in Colombia||Fred Hutchinson Cancer Research Center|No|Completed|January 2007|August 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|15855|||Female|50 Years|69 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337582||29385|
NCT02337816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOMETAB01|Role of Metabolomics in the Diagnosis of Endometriosis|Role of Metabolomics in the Diagnosis of Endometriosis||University of Cagliari||Active, not recruiting|December 2014|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337816||29367|
NCT02337829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-H-0016|ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL|A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL.||Acerta Pharma BV|No|Recruiting|December 2014|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02337829||29366|
NCT02341508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT3114-NPP-001|A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers|A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers||Lpath, Inc.|Yes|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341508||29084|
NCT02333630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00678|Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management|Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management|AsthmaCare|Nationwide Children's Hospital|Yes|Enrolling by invitation|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|6 Months|21 Years|No|||January 2016|January 27, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02333630||29688|
NCT02333643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS003-CO-PR-002|A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Cutaneous Warts||Cutanea Life Sciences, Inc.|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02333643||29687|
NCT02333903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0030|Adapted Physical Activity Program After Sleeve Gastrectomy|Effects of an Adapted Physical Activity Program on Health and Physical Condition After Sleeve Gastrectomy|PEEPSO|Lille Catholic University|Yes|Withdrawn|January 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|25 Years|45 Years|No|||January 2015|July 27, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02333903||29667|
NCT02334137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes Ed at Lions Eye|A Pilot Project to Assess the Impact of Diabetes Education During Ophthalmology Visits|Providing Diabetes Services in the Lions Eye Clinic: a Pilot Project to Assess the Impact of Diabetes Education During Ophthalmology Visits|LionsDMed|California Pacific Medical Center Research Institute|No|Enrolling by invitation|November 2014|December 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|The proposed subjects are diabetic patients already approved to be seen in the Lions Eye        Clinic, specifically for dilated eye exam by a retinal specialist. This is a high-risk        population with advanced disease and often with limited preexisting knowledge about        diabetes, thus providing the motivation for these educational interventions.|December 2014|January 13, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02334137||29649|
NCT02338778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liver cancer MV|Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Hepatocyte Carcinoma Patient||Fuda Cancer Hospital, Guangzhou|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|September 8, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338778||29293|
NCT02297633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCYYT-12345|Evaluation of Reactive Oxygen Metabolites in the Value of COPD|System Evaluation of Reactive Oxygen Metabolites in the Value of Chronic Obstructive Pulmonary Disease||Beijing Chao Yang Hospital|No|Recruiting|October 2014|July 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|320|Samples Without DNA|Serum|Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chaoyang hospital clinic|November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297633||32451|
NCT02349516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ohr-005|Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)|A Randomized, Controlled Study of the Safety and Efficacy of Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema||NJ Retina|No|Withdrawn|February 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|June 2, 2014|Yes|Yes|Study stopped/cancelled due to changing priorities as of 9/12/15. 0 subjects enrolled.|No||https://clinicaltrials.gov/show/NCT02349516||28471|
NCT02347644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D43TW009310|Prevention of Substance Use in Youth in Ukraine|Pilot Study of Prevention of Alcohol and Other Drug Use Using Motivational Interviewing Among Youth in Ukraine|PSUUKR|University of Michigan|No|Completed|January 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347644||28614|
NCT02347904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49889.018.14|Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer|Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer|SOX|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02347904||28595|
NCT02345668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI09|Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders|Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders vs Treatment as Usual in Specialized Care: a Randomized Controlled Trial||Universitat Jaume I|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||July 2015|October 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02345668||28766|
NCT02305264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091001|Imaging of Intracerebral Inflammation in MS|Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis|INFLASEP|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2012|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|March 20, 2015|January 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02305264||31864|
NCT02349763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pHSR01|Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction|Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial|DEPARO|Rajavithi Hospital|Yes|Not yet recruiting|February 2015|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|260|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02349763||28452|
NCT02343419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFT-DIMPA-WUM1|Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Methacholine Challenge Test|Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Evaluation of Bronchial Hyperreactivity by Methacholine Challenge Testing||Medical University of Warsaw|No|Recruiting|November 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02343419||28937|
NCT02343003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-14-0001|Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain|A Prospective, Multi-Center, RCT Evaluating the Safety and Effectiveness of Coolief™ Cooled Radiofrequency Probe to Create Lesions of the Genicular Nerves and Comparing Corticosteroid Injection in the Management of Knee Pain||Halyard Health|No|Active, not recruiting|January 2015|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|21 Years|N/A|No|||January 2016|March 23, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343003||28969|
NCT02336893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI-I-0734-13|A Semi-structured Interview PACIENTE Improves Communication With Family Members at the Intensive Care Unit|Result of an Intervention for the Group of Physicians Responsible for Providing Information on the Satisfaction of the Relatives of Patients Hospitalized in an Intensive Care Unit|PACIENTE|Fundación Universitaria de Ciencias de la Salud|Yes|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|245|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336893||29438|
NCT02343016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|781_OPBG_2014|NIRS as a Continuous Noninvasive Monitoring System of Liver/Kidney Graft Perfusion|Evaluation of NIRS as a Continuous Noninvasive Monitoring System of Liver/Kidney Graft Perfusion in the Early Postoperative Period in Pediatric Patients. Pilot Study|NIRS|Bambino Gesù Hospital and Research Institute|No|Not yet recruiting|February 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|Samples Without DNA|-  Blood count        -  Coagulation: INR, PT,PTT, ATIII, fibrinogen        -  Electrolytes        -  Albumine, proteins        -  Liver function specific markers: GOT/GPT, total and direct bilirubin, urea nitrogen,           lactic acid        -  Renal function specific markers: NGAL, creatinine, urea nitrogen|Both|N/A|17 Years|No|Probability Sample|All pediatric patients admitted to our ICU for postoperative care after liver/kidney        transplantation.|November 2014|January 15, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02343016||28968|
NCT02328963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2012/29|Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A|A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).|EVERCMV|University Hospital, Bordeaux|Yes|Recruiting|May 2014|||May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02328963||30046|
NCT02338076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGU-811|A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin|A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin||Rockefeller University|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02338076||29347|
NCT02341482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701021|A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects|A Phase 1, Open-label, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Pharmacokinetics Of Pf 04958242 In Healthy Adult Subjects||Pfizer|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02341482||29086|
NCT02329782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH104086|Supporting Treatment Adherence Readiness Through Training (START)|Controlled Evaluation of the Adherence Readiness Program for ART Adherence|START|RAND|Yes|Recruiting|February 2015|November 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329782||29983|
NCT02329795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192/13|Image-derived Prediction of Response to Chemo-radiation in Glioblastoma|Image-derived Prediction of Response to Chemo-radiation in Patients With Glioblastoma|IDEPREG|Rigshospitalet, Denmark|Yes|Recruiting|October 2014|September 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary glioblastoma, eligible for chemoradiotherapy.|November 2015|November 2, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02329795||29982|
NCT02338050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-MOXE|Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation||Center for International Blood and Marrow Transplant Research|Yes|Terminated|May 2015|||May 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|6 Months|24 Years|No|||September 2015|September 15, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338050||29349|
NCT02338674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTIT-HBV|Telbivudine and Tenofovir in Women of Childbearing Age With Immune-tolerant Chronic Hepatitis B|Telbivudine and Tenofovir Double Therapy in Women of Childbearing Age With Immune-tolerant Chronic Hepatitis B||Fuzhou General Hospital|Yes|Active, not recruiting|October 2014|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|45 Years|No|||June 2015|June 10, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338674||29301|
NCT02302170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMUHP03|A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children|A Phase Ⅲ Clinical Trial for Efficacy, Immunogenicity, Safety and Immune Persistence of Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Aged From 6-15 Years Old.||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|December 2004|September 2008|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|4464|||Both|6 Years|15 Years|No|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302170||32102|
NCT02354625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140846|The Safety of ahSC in Chronic SCI With Rehabilitation|The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation||University of Miami|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354625||28080|
NCT02351752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014【851】|Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study|Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease||Peking University First Hospital|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351752||28300|
NCT02356289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYK-461-002|Single Ascending Dose Study of MYK-461 in Healthy Volunteers|Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Healthy Volunteers||MyoKardia, Inc.|Yes|Completed|January 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02356289||27952|
NCT02350829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039963|T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease|Quantification of Diffuse Myocardial Fibrosis in Children With Cardiomyopathy or Congenital Heart Disease by T1 Mapping Cardiac Magnetic Resonance||The Hospital for Sick Children|No|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|200|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350829||28371|
NCT02294253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6999|Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone|Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone: An Outpatient Detoxification for Opioid Dependence.||New York State Psychiatric Institute|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294253||32710|
NCT02298738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnkaraU|Effect of Vit D on New-onset AF in Hypertension|Relation of Low Vitamin D Levels and New-onset AF Among Hypertensive Patients||Ankara University|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|227|||Both|18 Years|N/A|No|Non-Probability Sample|Hypertensive patients with new-onset AF. New onset AF was defined as AF identified for the        first time by an electrocardiogram or ambulatory holter monitoring. Hypertension was        defined as blood pressure ≥ 140/90 mmHg or a history of antihypertensive drug use.|November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298738||32366|
NCT02354820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA-GI Constipation|Child Health Improvement Through Computer Automation of Constipation Management in Primary Care|Child Health Improvement Through Computer Automation of Constipation Management in Primary Care|CHICA-GI|Indiana University|No|Not yet recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|1 Year|12 Years|No|||March 2015|March 25, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02354820||28065|
NCT02357836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122014-038|Neoadjuvant Itraconazole in Non-small Cell Lung Cancer|Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357836||27834|
NCT02347930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014DFT30090|Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury|Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury||RenJi Hospital|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|only plasma and urine|Both|18 Years|80 Years|No|Probability Sample|Confirmed acute kidney injury|October 2015|October 31, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02347930||28593|
NCT02328482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-OPMD-301|Continuation Protocol to Protocol BBCO-001|A Pivotal, Multicenter, Open-label, Randomized Withdrawal, Non-Treatment Concurrent Control Study to Assess the Safety, Tolerability, and Efficacy of Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients Who Participated in Study BBCO-001|HOPEMD|Bioblast Pharma Ltd.|Yes|Enrolling by invitation|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|80 Years|No|||July 2015|July 23, 2015|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02328482||30083|
NCT02328703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375746|Reiki for the Management of Neuropathic Pain|Reiki for the Management of Neuropathic Pain in Service Members With Extremity Trauma|Reiki4Pain|Fort Belvoir Community Hospital|No|Terminated|May 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 18, 2014||No|Study closed due to substantial decrease in the desired patient population.|No||https://clinicaltrials.gov/show/NCT02328703||30066|
NCT02337595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD45RA_NEG_DLI_2014FRCPHOI|Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation|Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation|45RA_NEG_DLI|Federal Research Institute of Pediatric Hematology, Oncology and Immunology|No|Recruiting|August 2014|January 2016|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|N/A|25 Years|No|||January 2015|January 12, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337595||29384|
NCT02329509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1158-3755|Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients|Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients. A Prospective Randomized Trial||Professor Fernando Figueira Integral Medicine Institute|Yes|Active, not recruiting|January 2010|October 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|64|||Both|N/A|6 Months|No|||December 2014|December 30, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02329509||30004|
NCT02334150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanningMCH|Epidural Analgesia on Electrophysiological Function|Effects of Combined Spinal-epidural Analgesia During Labor on Postpartum Electrophysiological Function of Maternal Pelvic Floor Muscle: a Randomized Controlled Trial||Nanjing Maternity and Child Health Care Hospital|No|Completed|June 2013|September 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|308|||Female|22 Years|30 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02334150||29648|
NCT02341534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS058|BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction|BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction|BIO/GUARD-MI|Biotronik SE & Co. KG|Yes|Recruiting|June 2015|April 2021|Anticipated|April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2900|||Both|18 Years|99 Years|No|||October 2015|October 16, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02341534||29082|
NCT02330276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08847|Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin|(+)-Epicatechin: Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin|Epicatechin|Veterans Medical Research Foundation|Yes|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330276||29945|
NCT02340364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X130515002|Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Failure|Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Failure|NAVI-HF|University of Alabama at Birmingham|No|Recruiting|March 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|416|||Male|40 Years|N/A|No|||February 2016|February 15, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340364||29172|
NCT02340403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0217|Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin|Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin|INSULOX|University Hospital, Clermont-Ferrand||Recruiting|September 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|46|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02340403||29169|
NCT02305173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexamethasone-2014-4|Dexamethasone and Respiratory Function After Mastectomy|Effect of the Preoperative Administration of Dexamethasone in the Respiratory Function and Postoperative Symptoms in Women Undergoing Mastectomy for Cancer. Results of a Randomized Clinical Trial.|Dexa-mama|Instituto Mexicano del Seguro Social|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Female|20 Years|79 Years|No|||November 2014|December 1, 2014|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02305173||31871|
NCT02294019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491013|Actual Use Trial of Ibuprofen 400 mg|A Multicenter Actual Use And Compliance Study Of Ibuprofen 400 Mg In A Simulated Over-the-counter Environment||Pfizer|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|738|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294019||32728|
NCT02357784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00098840|Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment|Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment|SaNDI|Northwestern University|No|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02357784||27838|
NCT02356302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-027|Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048|Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|48|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02356302||27951|
NCT02358811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308014|Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age|Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age|VOILAGE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|106|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects without SAOS and Patients with SAOS|January 2016|January 6, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358811||27760|
NCT02298751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cue Exposure Study, RESCueH|Exposure Therapy as Aftercare for Alcohol Use Disorder|Alcohol Cue Exposure: An Investigator-blinded, Randomized, Controlled Study of Exposure-based Aftercare in Alcohol Use Disorder Individuals||University of Southern Denmark|Yes|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|60 Years|No|||June 2015|June 8, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02298751||32365|
NCT02302456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2013-01|Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery|Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial|TRAAP|University Hospital, Angers|Yes|Recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4000|||Female|18 Years|N/A|No|||August 2015|August 6, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02302456||32080|
NCT02351271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL5940-0996|Cataract Surgery: Femto LDV Z8 Versus Conventional|A Single Centre Randomized Eye Study to Compare the Performance and Safety of Femtosecond Laser-assisted Cataract Procedures With Conventional Ultrasound-assisted Cataract Surgery|COMFORT|Ziemer Ophthalmic Systems AG|Yes|Enrolling by invitation|February 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|50 Years|N/A|No|||January 2016|January 7, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02351271||28337|
NCT02352792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0|Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer|Randomized Phase II Study for Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated With Radiochemotherapy||University Hospital Tuebingen|No|Recruiting|December 2008|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352792||28221|
NCT02354222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-2412-J02|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin in Patients With Inadequate Glycemic Control on Canagliflozin)||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|75 Years|No|||March 2016|March 2, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354222||28111|
NCT02332694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #14-1261-1804|Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia|Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia|Fibro and WBH|University of Arizona|No|Withdrawn|February 2015|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|January 5, 2015||No|Investigator transferred to the University of Wisconsin - Madison|No||https://clinicaltrials.gov/show/NCT02332694||29760|
NCT02333188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0595|Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients With Advanced Gastrointestinal Cancer|A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies||University of Chicago|No|Recruiting|December 2014|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02333188||29722|
NCT02330536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMao|Cardiopulmonary Effects of Intrathoracic Pressure Overshoot During Carbon Dioxide Insufflation in Thoracoscopic Surgery|Cardiopulmonary Effects of Intrathoracic Pressure Overshoot During Carbon Dioxide Insufflation in Thoracoscopic Surgery||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Active, not recruiting|December 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|20 Years|70 Years|No|||December 2014|January 2, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02330536||29926|
NCT02330549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-2-204|ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD|ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)||Tobira Therapeutics, Inc.|No|Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330549||29925|
NCT02340793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14RA448|BEYOND Weight Loss Study|Body Composition and Energy Expenditure With Total Diet Replacement During Weight Loss and Maintenance|BEYOND|NHS Greater Glasgow and Clyde|No|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02340793||29139|
NCT02340806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00100819|Association Between Bolus Rate and Duration of Adequate Labor Analgesia|Association Between Bolus Rate and the Adequacy of Labor Analgesia Using Timed-intermittent Boluses for Maintenance of Labor Analgesia||Northwestern University|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 9, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02340806||29138|
NCT02333916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47945.068.14|Effect of Exercise and Training on Fat Oxidation During Overfeeding - the FeedEX Study|Effects of Short-term Overfeeding With or Without Exercise on 24-hour Fat Oxidation and Fat Balance Before and After 10 Weeks of Training - The FeedEX Study|FeedEX|Maastricht University Medical Center|Yes|Terminated|June 2014|||April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|September 22, 2015|December 30, 2014||No|Recruitment target could not be met|No||https://clinicaltrials.gov/show/NCT02333916||29666|
NCT02338921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triple_3|Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy|Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.||Seoul National University Bundang Hospital|Yes|Recruiting|January 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|78|||Both|20 Years|80 Years|No|||October 2015|October 23, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338921||29282|
NCT02330055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001326B|Determination of the Predictors of Nocturnal Desaturation in Postpartum Women|Determination of the Predictors of Nocturnal Desaturation in Postpartum Women||Massachusetts General Hospital||Recruiting|May 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|55 Years|No|||September 2015|September 21, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02330055||29962|
NCT02334709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/1087|Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.|Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.||University Hospital, Ghent||Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334709||29605|
NCT02330523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13530232|An RCT Comparing Xenograft and Allograft for Ridge Preservation|A Prospective, Randomized, Controlled, Multi-center Study With Direct Measure and Histological Evaluation Comparing Xenograft and Allograft for Posterior Buccal Dehiscence Extraction Site Ridge Preservation||McGuire Institute|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||December 2015|January 21, 2016|December 31, 2014||No||No|December 10, 2015|https://clinicaltrials.gov/show/NCT02330523||29927|
NCT02294240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED 3009|Effect of Energy Dense Biscuits in Undernourished Women on Birth Weight of Their Neonates|Effect of Energy Dense Biscuits in Under Nourished Pregnant Women on Birth Weight of Their Newborns in a Low Income Peri-urban Setting of Karachi; a Community Based Randomized Interventional Study||Aga Khan University|No|Active, not recruiting|September 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Female|N/A|N/A|No|||January 2016|January 7, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02294240||32711|
NCT02346786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRRhumatologique|Epidemiology of Incidents and Accidents in Sport. Influence of Moisture.|Epidemiology of Incidents and Accidents in Sport. Influence of Moisture.||Centre de Recherche Rhumatologique et Thermal|No|Not yet recruiting|April 2015|May 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|10 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02346786||28680|
NCT02346799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821291|Creating Exercise Habits Through Incentives for Routines|Creating Exercise Habits Through Incentives for Routines|Routines|University of Pennsylvania|No|Not yet recruiting|January 2015|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02346799||28679|
NCT02359682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409057RIN|Population Research of Sublingual Microcirculation Data of Healthy Volunteers|Population Research of Sublingual Microcirculation Data of Healthy Volunteers||National Taiwan University Hospital|No|Completed|October 2014|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|90|||Both|20 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|August 2015|August 11, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02359682||27693|
NCT02305784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kin_YKL-40_CF|Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients|Chitinase and Cystic Fibrosis Disease Evolution|Kin_YKL_CF|Institut de Recherches Cliniques de Montreal|No|Recruiting|May 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|We will take a blood and sputum samples at each regular clinic visit (3-4/year-no evidence      of exacerbation in the past two weeks) as well as at the beginning and the end of an      exacerbation treated with IV antibiotics.|Both|18 Years|N/A|No|Non-Probability Sample|We will follow the patients (<18-year-old) for a period of 24 months. In parallel to the        measurement of YKL-40 in blood and airway secretions we will monitor other biological        parameters (see list below) as well as the BMI, lung function (FEV1/FVC), oxygen        saturation and heart rate. We will monitor the glucose metabolism status of the patient        (IGT, CFRD) and the number of exacerbations per year as well any significant changes in        the microbiology status of the patients. A pulmonary exacerbation will be defined as an        acute exacerbation of pulmonary symptoms that in the opinion of the CF physician is severe        enough to require intravenous antibiotics.|July 2015|July 28, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02305784||31824|
NCT02355704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1301-78|Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney|Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney Transplantation in Vivo||Instituto Mexicano del Seguro Social|Yes|Completed|January 2012|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355704||27997|
NCT02356991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-FMTN- Ⅱ-NSCLC-MON|A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|October 2014|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02356991||27898|
NCT02357004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A000502641|Mechanisms of Refractory Hypertension (Carvedilol)|||University of Alabama at Birmingham|No|Recruiting|February 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|70 Years|No|||February 2016|February 20, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02357004||27897|
NCT02337192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orto14|Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients.|Oral Decontamination Using Antimicrobial Photodynamic Therapy Applied in Orthodontic Patients.||University of Sao Paulo|Yes|Completed|January 2014|December 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02337192||29415|
NCT02337400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eval_Smoke_less_LMU|Evaluation of a Cognitive Behavioral Smoking Reduction Program|Das Verhaltenstherapeutische Therapiemanual "Smoke_less" Zur Reduktion Des Tabakkonsums: Eine Evaluationsstudie Mit Ambulanten Patienten||Ludwig-Maximilians - University of Munich|No|Active, not recruiting|January 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337400||29399|
NCT02334163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHCL400|The Effects of Nitazoxanide in Hepatic Encephalopathy|The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study||Ain Shams University|No|Recruiting|December 2014|April 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|65 Years|No|||January 2015|January 7, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334163||29647|
NCT02330822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OMFS-01-2015|Role of Hyaluronic Acid in Bone Healing After Dental Extraction|A Clinical and Experimental Study to Evaluate the Efficacy of Locally Applied Hyaluronic Acid in Bone Healing Following Dental Extraction||Damascus University|Yes|Completed|December 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 26, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02330822||29904|
NCT02338791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1211|Rehabilitative Ultrasound Imaging: Measurements of Articular Movement of the Shoulder|Rehabilitative Ultrasound Imaging: Measurements of Articular Movement of the Shoulder||University of Cincinnati|No|Recruiting|April 2012|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02338791||29292|
NCT02340975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00021|A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma|A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma||MedImmune LLC|No|Recruiting|March 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|236|||Both|18 Years|99 Years|No|||January 2016|January 12, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340975||29125|
NCT02340988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-14-02|Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects|An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.||The Medicines Company|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340988||29124|
NCT02341001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOBSRCT01|Does Text Message Support After Discharge Improve Outcomes Following Bariatric Surgery? A Randomised Trial.|Does Text Message Support After Discharge Improve Outcomes Following Bariatric Surgery? A Randomised Trial and Sub-study of the BOBS Study (Better Outcomes Following Bariatric Surgery)||University of Auckland, New Zealand|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02341001||29123|
NCT02334397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00095770|Bump on the Ball: Impact of a Prenatal Exercise & Education Program on Birth Outcomes & Maternal Quality of Life|Bump on the Ball: Impact of a Prenatal Exercise & Education Program on Birth Outcomes & Maternal Quality of Life||Northwestern University|No|Recruiting|February 2016|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02334397||29629|
NCT02339194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136958818|Application of a Simplified Method of Complete Denture Fabrication for Severely Resorbed Mandibular Ridges|Application of a Simplified Method of Complete Denture Fabrication for Severely Resorbed Mandibular Ridges||Universidade Federal do Ceara|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|72|||Both|45 Years|N/A|No|||December 2015|December 3, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339194||29262|
NCT02339207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-335-601|First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-335 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection||Alios Biopharma Inc.||Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02339207||29261|
NCT02334917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02604|Comparison of Fast-Absorbing Sutures for Mohs Surgery|Comparison of Fast-Absorbing Sutures for Mohs Surgery Repair on the Face (ComFAS): a Randomized Controlled Split-scar Study||University of British Columbia|Yes|Not yet recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 6, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02334917||29589|
NCT02334930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/34|Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors|Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors|PEC-Hem|University Hospital, Bordeaux|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|N/A|N/A|No|Probability Sample|Patients who will have biopsy or surgery for PEComa or vascular pediatric tumor (RICH,        NICH, hemangioma or pyogenic granuloma)|July 2015|July 22, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02334930||29588|
NCT02298166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 19-13/ARO-007|Study of Crenolanib in Combination Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations||University of Ulm|Yes|Not yet recruiting|April 2015|October 2023|Anticipated|April 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298166||32410|
NCT02350959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-022|Adverse Plaque Characteristics in CCTA and TVC Imaging|Evaluation of Adverse Plaque Characteristics in Coronary Computed Tomography Angiography Using Combined Near Infrared Spectroscopy With Intravascular Ultrasound [CITRUS Study]|CITRUS|National Health Insurance Service Ilsan Hospital|No|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||October 2015|October 5, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02350959||28361|
NCT02359643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kawasaki Disease|Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease|Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|May 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|January 31, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02359643||27696|
NCT02346682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zjsltdyy2014009|Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder|Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder|NMNTDM|Zhejiang Provincial Tongde Hospital|Yes|Recruiting|February 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346682||28688|
NCT02295488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/069/HP|Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy|Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy|MAISAVEN|University Hospital, Rouen|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02295488||32615|
NCT02356081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC331|eSMART Trial to Evaluate ASyMS|eSMART: Randomised Controlled Trial to Evaluate Electronic Symptom Management Using the Advanced Symptom Management System (ASyMS) Remote Technology for Patients With Cancers||University of Surrey|Yes|Recruiting|February 2015|||February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1108|||Both|18 Years|N/A|No|||January 2015|March 16, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02356081||27968|
NCT02344329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCC-104|A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.|A Comparison of Total Contact Casting (TCC-EZ) Using Human Amnion Allograft (AmnioExcel) Versus Total Contact Casting (TCC-EZ) and Standard Wound Care in Treating Diabetic Foot Ulcers (TAD)|TAD|University of North Dakota|No|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344329||28869|
NCT02340663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00085489|Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV|Preliminary Phase IV Trial Comparing the SOVA Night Guard With the Clinical Standard Acrylic Orthotic|SISU-SOVA|University of Michigan|No|Recruiting|November 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|58|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340663||29149|
NCT02340676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-479|A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease||Dana-Farber Cancer Institute|Yes|Recruiting|February 2015|April 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340676||29148|
NCT02340741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-54-22|Insufflation of Carbon Dioxide During Cardiac Surgery as Prevention Neurologic Complications|Assessing of Carbon Dioxide Insufflation on the Neurological Complications During Open Heart Operations||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|334|||Both|18 Years|70 Years|No|||March 2016|March 19, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02340741||29143|
NCT02340689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006384|Primary Hyperoxaluria Mutation Genotyping/Phenotyping|Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria||Mayo Clinic|Yes|Recruiting|October 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1250|||Both|N/A|N/A|No|||November 2015|December 17, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02340689||29147|
NCT02340702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006196|Chronic Obstructive Pulmonary Disease (COPD) in Patients Hospitalized for Acute Decompensated Heart Failure.|COPD in Patients Hospitalized for Acute Decompensated Heart Failure.|COPD|Mayo Clinic|No|Active, not recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105388|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized for acute decompensated heart Failure|January 2015|January 13, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02340702|5 Weeks|29146|
NCT02334410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEC14/57|Early Intervention to Reduce Bone Loss After Spinal Cord Injury|||University of Strathclyde|No|Not yet recruiting|February 2015|February 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334410||29628|
NCT02340897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1043|Diagnostic Accuracy of Nontuberculous Mycobacterial Lung Disease Based on Chest CT|Diagnostic Accuracy and Inter-rater Agreement of Chest Computed Tomography in the Diagnosis of Nontuberculous Mycobacterial Lung Disease||Seoul National University Hospital|No|Active, not recruiting|December 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|124|||Both|N/A|N/A|No|Non-Probability Sample|Patients with nontuberculous mycobacterial lung diseases, pulmonary tuberculosis,        bronchiectasis|January 2015|January 13, 2015|December 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02340897||29131|
NCT02331368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.134|Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma|Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma||University of Michigan Cancer Center|Yes|Recruiting|June 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|January 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331368||29862|
NCT02339038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915064|Study to Assess Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia|A Phase IV Pilot Study to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 2015|August 2025|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|99 Years|No|||November 2015|March 11, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339038||29273|
NCT02327104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCESSO FAPESP 2013/02316-5|Effectiveness of Mindfulness Based Relapse Prevention for Tobacco Dependents|Evaluation of the Effectiveness of the Program of Mindfulness - Based Relapse Prevention (MBRP) as an Assistant Strategy to the Treatment of Tobacco Dependence||Federal University of São Paulo|No|Recruiting|October 2012|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02327104||30189|
NCT02341586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02551|Lucky Iron Fish Home Fortification of Iron|A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia||University of British Columbia|No|Active, not recruiting|April 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|330|||Female|18 Years|49 Years|No|||July 2015|July 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02341586||29078|
NCT02341599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618-REN-14-02|Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects|A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects||Cubist Pharmaceuticals LLC||Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|December 12, 2014||||||https://clinicaltrials.gov/show/NCT02341599||29077|
NCT02302183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infant-FreeO2|Automatic Oxygen Administration During the Respiratory Distress in Infants and Children (Infant-FreeO2)|Automatic Oxygen Administration in Spontaneous Ventilation During the Hypoxemic Acute Respiratory Distress in Infants and Children|Infant-Free02|University Hospital, Brest|Yes|Recruiting|December 2014|August 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Month|15 Years|No|||January 2016|January 13, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302183||32101|
NCT02302443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-INS115-101|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Administration of HM12470 in Subjects With Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM)||Hanmi Pharmaceutical Company Limited|No|Not yet recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|100|||Both|18 Years|70 Years|No|||November 2014|November 27, 2014|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302443||32081|
NCT02354833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406316590|Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery|Phenylephrine vs. Norepinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Delivery||West Virginia University|No|Recruiting|August 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354833||28064|
NCT02359916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13012802|Delays to Influence Snack Choice|Time Over Money? A Novel System to Influence Snack Machine Choices|DISC|Rush University Medical Center|No|Not yet recruiting|February 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||7|Anticipated|4900|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is an environmental intervention. No subjects will be recruited or enrolled.|August 2015|August 20, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359916||27675|
NCT02347657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-106|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|490|||Both|12 Years|N/A|No|||March 2016|March 23, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347657||28613|
NCT02300246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFederalFluminense|Clinical, Histological and Micro-computed Tomographic Evaluation of Neoformed Tissue in Post-extraction Sockets Covered With Platelet-rich Fibrin (PRF) Membrane: a Randomized Controlled Trial|Clinical, Histological and Micro-computed Tomographic Evaluation of Neoformed Tissue in Post-extraction Sockets Covered With Platelet-rich Fibrin (PRF) Membrane: a Randomized Controlled Trial||Universidade Federal Fluminense|Yes|Recruiting|July 2014|||December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300246||32250|
NCT02300545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501057|Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy|A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy||Washington University School of Medicine|No|Recruiting|April 2015|March 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300545||32227|
NCT02300597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBSC-2|Internet-based Support for Young People With ADHD and Autism - a Controlled Study|Internet-based Support and Coaching for Adolescents and Young Adults With ADHD and Autism Spectrum Disorders - a Controlled Study||Göteborg University|No|Recruiting|September 2010|June 2017|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|15 Years|30 Years|No|||November 2014|November 24, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02300597||32223|
NCT02346578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUU-CRPC|Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.|Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide.||Osaka City University||Recruiting||||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|20 Years|N/A||||June 2015|June 1, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02346578||28696|
NCT02352805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSIMA|Coagulopathy and SIRS During ECC in Intensive Care|A Comparative Clinical Study to Understand the Coagulopathy and Systemic Inflammation Associated With the Use of Extracorporeal Circulation in Intensive Care Patients||University Hospital Tuebingen|No|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||8|Anticipated|80|Samples With DNA|human whole blood and blood plasma|Both|18 Years|85 Years|No|Non-Probability Sample|-  Patients undergoing implantation of extracorporeal circulation or mechanical             circulatory support systems (ECLS / ECMO / LVAD / dialysis) due to cardiac failure,             or lung failure, or renal failure, or a combination of these diseases.          -  Patients undergoing cardiac surgery with extracorporeal circulation (ECC).|December 2015|December 2, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352805||28220|
NCT02330068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002154|Microbiome of Depression & Treatment Response to Citalopram|Microbiome of Depression &Amp; Treatment Response to Citalopram: A Feasibility Study||Mayo Clinic|No|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Blood, saliva and stool samples will be collected at three time points.|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators will enroll 80 participants, both male and female with the goal of        having 20 paired data of responders and 20 non-responders each. Forty age-matched healthy        controls will also be recruited. The investigators will recruit 100 subjects anticipating        drop outs or inability to participate fully with microbiome sample collection and /or at        least paired biological specimens before and after treatment. The Mayo Clinic Jacksonville        patients (n=10) will be matched with Mayo Clinic Jacksonville controls (n=10) and the Mayo        Clinic Rochester patients (n=30) will be matched with the Mayo Clinic Rochester controls        (n=30).|September 2015|January 22, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02330068||29961|
NCT02330289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820924|Effect of Norms on Laboratory and Imaging Testing (ENLITen)|The Effect of Norms on Laboratory and Imaging Testing (ENLITen): a Pragmatic Randomized Controlled Trial|ENLITen|University of Pennsylvania|No|Enrolling by invitation|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|N/A|N/A|No|||September 2015|September 18, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330289||29944|
NCT02327117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392114|Low Dose Peri- Operative Intra Venous Teranexamic Acid Reduces Blood Loss After Total Knee Arthroplasty: A Double Blind Randomized Placebo Controlled Clinical Trial|||Isfahan University of Medical Sciences||Recruiting|January 2013|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||December 2014|December 23, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327117||30188|
NCT02327351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCRabPID-2012|TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID|Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases||Federal Research Institute of Pediatric Hematology, Oncology and Immunology|Yes|Recruiting|July 2012|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|1 Month|18 Years|No|||December 2014|December 24, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02327351||30170|
NCT02340754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR-MS-001|Mindfulness-based Stress Reduction for Multiple Sclerosis|||National College of Natural Medicine|Yes|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02340754||29142|
NCT02357108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0113|Message: Study of Patients' Perception of Physician's Compassion|A Trial on Patient's Evaluation of a Physician Conveying Two Different Messages||M.D. Anderson Cancer Center|No|Completed|May 2013|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|103|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357108||27889|
NCT02297620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL001|The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients|Specified Drug Use resulTs survEy of IpragLifLozin treAtment in ELDERly type2 Diabetes Patients (STELLA-ELDER)|STELLA-ELDER|Astellas Pharma Inc|No|Completed|April 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8687|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients with type 2 diabetes who used Suglat Tablets within 3 months from its        launch|October 2015|October 14, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02297620||32452|
NCT02298504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058711|Vital Pulp Treatment in Primary Teeth|Evaluation of MTA Pulpotomy, Biodentine Pulpotomy, and Glass Ionomer Indirect Pulp Treatment in Primary Teeth||University of Maryland Baltimore Dental School|Yes|Recruiting|November 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298504||32384|
NCT02347345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA-0874|Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs|The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.||Rockefeller University|No|Recruiting|January 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|No|||August 2015|August 10, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347345||28637|
NCT02349360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400370|Safety, Tolerability and Host Response to Lactobacillus Johnsonii|Safety, Tolerability and Host Response to Lactobacillus Johnsonii|LJ|University of Florida|Yes|Active, not recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|July 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349360||28483|
NCT02297867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28113265|Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis|Food and Drug Administration, Ministry of Health and Welfare||Gwo Xi Stem Cell Applied Technology Co., Ltd.|No|Recruiting|July 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|80 Years|No|||February 2016|February 15, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297867||32433|
NCT02303249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-337|Interventional Study of Videoconferences Between Hospital and Municipality - a Randomized Controlled Trial|Interventional Study of Videoconferences Between Hospital and Municipality After Discharge From Roskilde and Køge Hospitals - a Randomized Controlled Trial|Tele-hjem|Roskilde County Hospital|No|Completed|July 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1387|||Both|55 Years|N/A|No|||January 2015|January 9, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02303249||32019|
NCT02353845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hanying2|Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology|||Xuanwu Hospital, Beijing|Yes|Recruiting|November 2013|December 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|aMCI is a group of patients whose memory are impaired to a greater degree than expected        given the individual's age, sex, and educational background, while the individual's        ability to perform the activities of daily living is preserved and the criteria for        dementia are not met.|December 2015|December 29, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02353845||28140|
NCT02350192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10110301|Effectiveness of an E-health Educational Intervention for Cardiovascular Disease Adults in Improving Total Exercise and Outcomes|A Randomized Controlled Trial of the Effectiveness of a Home-based Interactive E-health Educational Intervention for Middle-aged Cardiovascular Disease Adults in Improving Total Exercise, Adherence Rate, Exercise Efficacy and Outcomes||Chinese University of Hong Kong|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|438|||Both|30 Years|65 Years|No|||August 2015|August 2, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02350192||28420|
NCT02350205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOEX 014|SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma|SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma.||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|January 2015|||January 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|17|||Both|N/A|N/A|No|||January 2016|January 27, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02350205||28419|
NCT02297919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80558721/244|Evaluation of the Effectiveness of Internet Based Nutrition and Physical Activity Education Programme in Adolescents|Eskisehir Osmangazi University- Scientific Research Projects||Eskisehir Osmangazi University|No|Active, not recruiting|January 2014|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02297919||32429|
NCT02297932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|843-14|Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes|Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes|PHYSACTINMS|Kessler Foundation|No|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|64 Years|No|||November 2014|November 20, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02297932||32428|
NCT02351284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/15|Impact of Hypovitaminosis D on Bone Disease in HIV Infected Patients|Impact of Hypovitaminosis D in Metabolic Disturbances and Bone Metabolism, and Changes in Patients Receiving Vitamin D Supplementation|PuraVIHta|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Active, not recruiting|January 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients in follow up|January 2015|January 27, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02351284|18 Months|28336|
NCT02357758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-12-387|Effects of Antibiotic Prophylaxis on Recurrent UTI in Children|Recurrent Urinary Tract Infections in Children: Bacterial Identification, Antibiotic Susceptibility Profiling and Cytokine Levels Associated With Antibiotic Prophylaxis||Lawson Health Research Institute|No|Recruiting|September 2012|||October 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|3 Years|15 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357758||27840|
NCT02302157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-OPC1-01|Dose Escalation Study of AST-OPC1 in Spinal Cord Injury|A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Cervical Sensorimotor Complete Spinal Cord Injury||Asterias Biotherapeutics, Inc.|Yes|Recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302157||32103|
NCT02309866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83-13|Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases|||Hillel Yaffe Medical Center||Not yet recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|genomic DNA|Both|N/A|N/A|No|Non-Probability Sample|The study will be composed of Israeli individuals who have been clinically diagnosed with        RP but do not have a confirmed diagnosis by genetic testing.|November 2014|December 3, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02309866||31512|
NCT02309879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LidovsMgvsRemi|Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy|Effect of Intravenous Infusion of Lidocaine, Magnesium Sulphate and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized and Double-blind Study||Hospital de Base|No|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Female|18 Years|75 Years|No|||August 2015|August 17, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02309879||31511|
NCT02344056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIChildNutrition|Cognition Intervention Study Dortmund- Continued (Coco)||Coco|Research Institute of Child Nutrition, Dortmund||Active, not recruiting|October 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|200|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02344056||28889|
NCT02358889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-002|Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|EMERGE|Iconic Therapeutics, Inc.||Recruiting|February 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|50 Years|N/A|No|||February 2016|February 26, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358889||27754|
NCT02358915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00672|A Two-step Training Paradigm for Voluntary Control of the Peri-auricular Muscles|A Two-step Training Paradigm for Voluntary Control of the Peri-auricular Muscles||University of Southern California|No|Recruiting|February 2015|||July 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02358915||27752|
NCT02302417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201703|Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)|The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD||GlaxoSmithKline|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1215|||Both|18 Years|N/A|No|||September 2015|October 22, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02302417||32083|
NCT02303145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00010885|Breast Cancer Survivorship & Work-Related Cognitive Limitation|The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.|BCSurvivorship|Palo Alto University|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|187|||Female|18 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|The study population description is that we are aiming to find women between the ages of        18 to 69 who are currently employed (i.e. part-time or full-time) with and without history        of breast cancer. For the breast cancer survivor group, we are aiming to recruit women who        have received a stage I-III breast cancer in the past and completed primary treatment and        finished with treatment for at least 6 months.|April 2015|April 30, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303145||32027|
NCT02351726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT001|Mitroflow DL Post Approval Study- North America|Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment Post Approval Study||Sorin Group USA, Inc.|Yes|Recruiting|March 2015|December 2024|Anticipated|October 2024|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|185|||Both|N/A|N/A|No|||May 2015|May 19, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351726||28302|
NCT02354703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP00061575|Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder||University of Maryland|Yes|Recruiting|July 2015|December 2021|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354703||28074|
NCT02302729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00061322|Early Child Development and Nutrition in Guatemala|Professor, Department of Pediatrics, University of Maryland School of Medicine||University of Maryland|Yes|Not yet recruiting|December 2014|October 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|3000|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02302729||32059|
NCT02309931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR-HCUVA-2014-01|ISOperistaltic Versus ANTIperistaltic Anastomosis After Laparoscopic Right Colectomy for Cancer|Randomized Clinical Trial Comparing Isoperistaltic Versus Antiperistaltic Side to Side Anastomosis After Right Laparoscopic Hemicolectomy for Cancer.|ISOVANTI|Hospital Universitario Virgen de la Arrixaca|Yes|Recruiting|June 2014|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02309931||31507|
NCT02356211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840|Longitudinal Outcome in a Veterans Geriatric Multifactorial Falls Assessment Clinic|Longitudinal Outcome in a Veterans Geriatric Multifactorial Falls Assessment Clinic: A Prospective Controlled Study||Powers, James S., M.D.|No|Recruiting|August 2008|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|65 Years|N/A|No|||January 2015|February 4, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02356211||27958|
NCT02357771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHO_PERIO-ODB_01|Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients|Topical Application of Probiotic Lozenge to Reduce Streptococcus Mutans in Plaque Around Orthodontic Brackets||Next Gen Pharma India Pvt. Ltd.|No|Completed|April 2015|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|No|||September 2015|September 22, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357771||27839|
NCT02303964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14813|Pre-Hospital Use of Plasma for Traumatic Hemorrhage|Pre-Hospital Use of Plasma for Traumatic Hemorrhage|PUPTH|Virginia Commonwealth University|Yes|Withdrawn|November 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 6, 2014|Yes|Yes|Low patient enrollment is the primary reason|No||https://clinicaltrials.gov/show/NCT02303964||31964|
NCT02303977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 21514|Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy|Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|November 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303977||31963|
NCT02303990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 40914|RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers|RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2015|||February 2017|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02303990||31962|
NCT02358278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI-PAED|Evaluation and Implementation of the "Paediatric Anesthesia Emergence Delirium Scale" (PAED) in the PACU in Children Under 14 Years of Age|Evaluation and Implementation of the "Paediatric Anesthesia Emergence Delirium Scale" (PAED) in the PACU in Children Under 14 Years of Age||Charite University, Berlin, Germany|No|Completed|March 2013|January 2015|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|821|||Both|N/A|13 Years|No|Probability Sample|All children (age 0-13) receiving anesthetic care for operative procedures and are cared        for in the post-anesthesia care unit are monitored for emergence delirium and therapeutic        measures.|February 2015|February 3, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02358278||27801|
NCT02345083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INA-FRAGILE01|Indonesia Frailty, Aging, and Longitudinal Study|Indonesia Frailty, Aging, and Longitudinal Study|INA-FRAGILE|Indonesia University|Yes|Recruiting|June 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|60 Years|N/A|No|Non-Probability Sample|Fit or pre-frail elderly aged >= 60 years old who came to Comprehensive Geriatric Clinics,        Cipto Mangunkusumo General Hospital, Jakarta, during March 2015-March 2016.|August 2015|August 24, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345083|1 Year|28811|
NCT02305160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012005B|A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants|Phase 3 Multicenter, Randomized, Open Label Trial of a New Low Cost Animal Extracted Surfactant to Treat Respiratory Distress Syndrome in Preterm Infants||University of Sao Paulo|Yes|Completed|April 2005|July 2007|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|327|||Both|N/A|24 Hours|No|||November 2014|November 26, 2014|February 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02305160||31872|
NCT02350608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14013|Pulse Waveform and ECG Analysis in Postoperative Cardiac Surgical Patients|Pulse Waveform and ECG Analysis in Postoperative Cardiac Surgical Patients||Tampere University Hospital|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Postoperative cardiac surgery patients|November 2015|November 3, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350608||28388|
NCT02350933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endostudy|Endoscopic Evaluation of the Paediatric Airway After Prior Prolonged (>24 h) Tracheal Intubation|Endoscopic Evaluation of the Paediatric Airway After Prior Prolonged (>24 h) Tracheal Intubation||University Children's Hospital, Zurich|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|1 Month|16 Years|No|||February 2016|February 4, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02350933||28363|
NCT02348554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1070|A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities for Overweight and Obese People|A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities in Free-living Conditions for Overweight and Obese People (eMouve3)|eMouve3|Institut National de la Recherche Agronomique|Yes|Completed|October 2013|August 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02348554||28545|
NCT02346409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-44|Cerebello-thalamo-cortical Coupling in Essential Tremor|Cerebello-thalamo-cortical Coupling in Essential Tremor: Effects of High Frequency tACS of the Cerebellum|CERESTIM|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|75 Years|No|||August 2015|August 27, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02346409||28709|
NCT02346422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELL-009|A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR® at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled||Celladon Corporation|Yes|Terminated|April 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|80 Years|No|||July 2015|July 6, 2015|January 15, 2015|Yes|Yes|Sponsor has suspended clinical development of MYDICAR for heart failure.|No||https://clinicaltrials.gov/show/NCT02346422||28708|
NCT02305251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202031|Patient Preferences of a Resect and Discard Paradigm|Patient Preferences of a Resect and Discard Paradigm||Washington University School of Medicine|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients reporting in for colonoscopies either for screening or for polyp surveillance.|November 2014|November 26, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02305251||31865|
NCT02309905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Teledermatology for Inmates|Evaluation of Tele-expertise for Inmates With a Dermatological Lesion|Evaluation of Tele-expertise for Inmates With a Dermatological Lesion|TLM-Inmates|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2014|December 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Inmates|December 2015|January 14, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02309905||31509|
NCT02309918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepNet-aHCV-IV|HepNet Acute HCV IV - LDV/SOF FDC in Akute Genotype 1 Hepatitis C Virus Infection|Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study||HepNet Study House, German Liverfoundation|No|Recruiting|November 2014|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|April 2, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02309918||31508|
NCT02357862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVR_TV|Changes in the Tricuspid Valve Complex Induced by Mitral Valve Annuloplasty|Impact of Isolated Mitral Valve Annuloplasty on the Geometry and the Function of the Tricuspid Valve Complex||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing minimally invasive, isolated mitral valve annuloplasty in the        University Hospitals Leuven|July 2015|July 22, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02357862||27832|
NCT02357940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140908134135-SBCT|Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema|Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis||Johnson & Johnson Consumer and Personal Products Worldwide|Yes|Completed|January 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|6 Months|N/A|Accepts Healthy Volunteers|||October 2015|February 3, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357940||27827|
NCT02305368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09019 Oncogramme colon|Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4|Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4: a Pilot Study|Oncogramme|University Hospital, Limoges|No|Completed|March 2011|March 2013|Actual|March 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|tumor fragment|Both|18 Years|N/A|No|Probability Sample|patient with adenocarcinoma of the colon diagnosed at stage 4 receiving standard therapy|November 2014|November 26, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02305368|1 Year|31856|
NCT02351466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|588973|Type 1 Diabetes and the Brain in Children|Type 1 Diabetes and the Brain in Children: Metabolic Interventions. Protocol #1: Longitudinal Assessment||Nemours Children's Clinic|Yes|Enrolling by invitation|March 2015|||June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|||Both|7 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with Type 1 Diabetes or Healthy non-diabetic controls|June 2015|June 5, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351466||28322|
NCT02344550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2013-0720|Study of GnRH Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer|Ovarian Suppression Plus Letrozole Plus Everolimus for Hormone Receptor-Positive, Tamoxifen and Ovarian Suppression Pretreated, Premenopausal Women With Recurrent or Metastatic Breast Cancer[LEO]|LEO|Asan Medical Center|No|Recruiting|February 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|137|||Female|20 Years|N/A|No|||January 2015|January 17, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02344550||28852|
NCT02344563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-RBH3012-03|Bioequivalence of Two Formulations of Meropenem Intravenous Injection|A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Meropenem In Healthy Volunteers(Meropenem Intravenous Injection) After Intravenous Infusion||Yung Shin Pharm. Ind. Co., Ltd.||Completed|September 2014|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02344563||28851|
NCT02358980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73/2014|Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy|KIDNEY THERAPY FOR FREE LIGHT CHAIN REMOVAL IN PATIENTS WITH MULTIPLE MYELOMA & CAST NEPHROPATHY|KEEPER|Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|July 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cast nephropathy, dialysis dependent renal failure and de novo multiple        myeloma|February 2015|February 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358980||27747|
NCT02307253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7427/13|EUS GUIDED Transduodenal Biopsy Using the 19G Flex|EUS-guided Fine Needle Tissue Acquisition Using a Newly Developed Nitinol Ultra Flex 19 Gauge Needle for Transduodenal Lesions: a Multicenter Prospective Feasibility Study|NIFLEX|Catholic University of the Sacred Heart|No|Recruiting|June 2013|August 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|90 Years|No|||November 2014|December 1, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02307253||31712|
NCT02302196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPNW Fat Grafting 001|Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects|Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects||Kaiser Permanente|No|Not yet recruiting|August 2015|January 2022|Anticipated|January 2022|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302196||32100|
NCT02302209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04286|Dyad Oxytocin Study (DOS)|Effects of Oxytocin on Familial Interactions|DOS|University of California, San Francisco||Recruiting|April 2011|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302209||32099|
NCT02302222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS.2012.Customizable.01|The Management of Closed Surgical Incisions Resulting From Incisional Hernia Repair and/or Functional Panniculectomy Using the Prevena™ Customizable™ Dressing|The Management of Closed Surgical Incisions Resulting From Incisional Hernia Repair and/or Functional Panniculectomy Using the Prevena™ Customizable™ Dressing||KCI USA, Inc.|No|Recruiting|May 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302222||32098|
NCT02356406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1630-DH-CTIL|Celiac Plexus Radiosurgery for Pain Management|Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial||Sheba Medical Center|No|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02356406||27943|
NCT02349373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20140069|Focus of a Running Schedule and Risk of Running Injuries|The Focus of a Running Schedule and Its Association With the Risk of Running Injuries? A Randomized Controlled Trial.||Northern Orthopaedic Division, Denmark|No|Recruiting|April 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|4366|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349373||28482|
NCT02294006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ist Nazionale Tumori Milano|Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs|Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study|MetNET1|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02294006||32729|
NCT02354365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00370|Measuring Lung Pressures in Critically Ill Children Who Are on Mechanical Ventilation|Transpulmonary Pressure and Pressure Rate Product as a Guide to Ventilator Management and Extubation Readiness||Children's Hospital Los Angeles|Yes|Recruiting|February 2014|February 2016|Anticipated|April 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|N/A|18 Years|No|Non-Probability Sample|Any patient weighing >2 kg between the ages of > 37 weeks corrected gestational age and        <18 years who is intubated and mechanically ventilated in the pediatric intensive care        unit at Children's Hospital Los Angeles will be eligible for the study.|January 2015|February 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354365|1 Week|28100|
NCT02352545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cough|Montelukast for Postinfectious Cough|Montelukast for Postinfectious Cough in Adults||Beijing Chao Yang Hospital|Yes|Recruiting|August 2014|October 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02352545||28240|
NCT02351596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPSP1415|Do Core Stability Exercise Classes Help Children With Cerebral Palsy Improve Their Balance|The Effect of a 'Core Stability' Physiotherapy Group Intervention Programme on Balance in Ambulant Children With Cerebral Palsy: A Randomised Control Trial||Royal College of Surgeons, Ireland|No|Recruiting|August 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02351596||28312|
NCT02294227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2336|16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)|FUTURE 4|Novartis|Yes|Active, not recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|341|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294227||32712|
NCT02351219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAP study|FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer|Phase II Study of FOLFOXIRI as Primary Treatment for Stage III Unresectable Locally Advanced Pancreatic Cancer|FLAP|Azienda Ospedaliero, Universitaria Pisana|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||January 2015|January 27, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351219||28341|
NCT02351232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT2015|The Lira Pump Trial|The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial||Hvidovre University Hospital|Yes|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351232||28340|
NCT02359929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076372|BMT Auto MSCs GvHD Ph 1|A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft Versus Host Disease||Emory University|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|12 Years|N/A|No|||February 2016|February 23, 2016|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359929||27674|
NCT02359942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1412/279-004|The Diagnostic Validity of the Urea Breath Test|The Effect of Citric Acid as the Test Meal on the Diagnostic Accuracy of the 13C-Urea Breath Test in Korean, Randomized Controlled, Open Label Prospective Study||Seoul National University Bundang Hospital|No|Not yet recruiting|March 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02359942||27673|
NCT02345655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7049 01|On-site Evaluation of Substances Consumption on Opiate Maintenance|Impact of On-site Evaluation of Substances Consumption on Opiate Maintenance in the Context of Family Practice|ESUB-MG|University Hospital, Toulouse|No|Not yet recruiting|January 2016|January 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02345655||28767|
NCT02294474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13403|Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine|Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine|SORELLA 2|Sanofi|No|Completed|January 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|505|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294474||32693|
NCT02358408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1416-BL|System Accuracy Evaluation of Karajishi Contour and Karajishi TS Blood Glucose Monitoring Systems Following ISO 15197:2013|System Accuracy Evaluation of Karajishi Contour and Karajishi TS Blood Glucose Monitoring Systems Following ISO 15197:2013||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|January 2015|April 2015|Actual|February 2015|Actual|N/A|Interventional|N/A|||Actual|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02358408||27791|
NCT02346877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130340|Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Subjects With Rheumatoid Arthritis|A Multicenter, Historical Control Study to Evaluate the Effects of Personalized Patient Counselling on Persistence to Enbrel® Therapy in Subjects With Rheumatoid Arthritis (PerSuit)||Amgen|No|Terminated|April 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Both|18 Years|100 Years|No|||November 2015|November 30, 2015|January 7, 2015||No|Business Decision|No||https://clinicaltrials.gov/show/NCT02346877||28673|
NCT02297113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK Zurich 2014-0356|Rapid Sequence Intubation at the Emergency Department|The C-MAC Videolaryngoscope Compared With Conventional Laryngoscopy for Rapid Sequence Intubation at the Emergency Department||University of Zurich|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02297113||32491|
NCT02309840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21198-103|The Modifying Eating and Lifestyles at School Study|The Modifying Eating and Lifestyles at School (MEALS) Study|MEALS|Harvard School of Public Health|Yes|Completed|September 2011|June 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|6873|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 3, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02309840||31514|
NCT02347020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1801|Impact of Sleep and Meal Timing on Food Intake Regulation|Impact of Sleep and Meal Timing on Food Intake Regulation||Columbia University|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|6|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347020||28662|
NCT02347358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013CB733805|Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke|Mechanical Opening Device Implantation Following Intravenous r-tPA and Recanalization Outcome Evaluation in Stroke Disease (MODIFIED) Trial||The Second Artillery General Hospital|Yes|Not yet recruiting|February 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2015|January 26, 2015|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02347358||28636|
NCT02357030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-PAX-002-2|Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness|Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of KPAX 002 (Methylphenidate Hydrochloride + K-PAX Synergy) as a Treatment for Gulf War Illness in Patients Meeting the Kansas Case Definition||K-PAX Pharmaceuticals, Inc.|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|64 Years|No|||October 2015|October 13, 2015|January 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357030||27895|
NCT02357043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0002|User Performance Evaluation for DARIO™ BGMS|User Performance Evaluation for DARIO™ Blood Glucose Monitoring System (BGMS)||LabStyle Innovations Ltd.|No|Recruiting|December 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|350|||Both|N/A|N/A|No|||February 2015|February 2, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357043||27894|
NCT02356562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-224|A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Sofosbuvir and RBV in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection|An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Active, not recruiting|February 2015|July 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|99 Years|No|||March 2016|March 21, 2016|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02356562||27931|
NCT02356575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 30914|Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy|Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356575||27930|
NCT02359188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-207|Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility|Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility|EpimiRNA_D|Philipps University Marburg Medical Center|No|Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359188||27731|
NCT02359240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH1502|HO-1 and Muscle Mitochondrial Dysfunction in Sepsis|Skeletal Muscle Wasting in Patients With Sepsis||Changhai Hospital|Yes|Active, not recruiting|December 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|skeletal muscle|Both|18 Years|90 Years|No|Probability Sample|septic patients; non septic patients with a femoral fracture,who need an fixation surgery|February 2015|February 4, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02359240||27727|
NCT02298478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI05|Efficacy of a Computer-aided Self-help Treatment for Flying Phobia: NO-FEAR Airlines|Efficacy of a Computer-aided Self-help Treatment for Flying Phobia: A Randomized Controlled Trial||Universitat Jaume I|No|Recruiting|May 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02298478||32386|
NCT02354612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105CON101|An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy|An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy||Tracon Pharmaceuticals Inc.|No|Enrolling by invitation|May 2011|December 2020|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354612||28081|
NCT02358356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC0120 / AG0114NET|Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study|Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study|CONTROL NETS|Australasian Gastro-Intestinal Trials Group|Yes|Not yet recruiting|July 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358356||27795|
NCT02356536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013000952|The Effect of a Wearable Cueing Device on Freezing of Gait in Parkinson's Disease|The Effect of a Wearable Cueing Device on Freezing of Gait in Parkinson's Disease|CuePed|The University of Queensland|No|Recruiting|October 2013|December 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|90 Years|No|||February 2015|February 4, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02356536||27933|
NCT02343380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIT-01|Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern|Is the Timing of Caloric Intake Associated With Variation in Diet-induced Thermogenesis and Hormonal Pattern?||University of Turin, Italy|No|Completed|May 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|January 12, 2015||No||No|August 20, 2015|https://clinicaltrials.gov/show/NCT02343380||28940|
NCT02349880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDM-training|A Shared Decision-making Training for Inpatients With Schizophrenia|A Shared Decision-making Training for Inpatients With Schizophrenia||Technische Universität München|No|Active, not recruiting|October 2011|March 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|240|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349880||28443|
NCT02349893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study|Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study||Olympus Surgical Technologies Europe|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|22 Years|N/A|No|||November 2015|November 24, 2015|January 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349893||28442|
NCT02298725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648620|Individual Metabolism and Physiology Signature Study|Individual Metabolism and Physiology Signature Study|iMAPS|USDA, Western Human Nutrition Research Center|No|Recruiting|December 2014|September 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02298725||32367|
NCT02346552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-65-004|Usability and Performance Evaluation of the AutoLap System - a Feasibility Study|Usability and Performance Evaluation of the AutoLap System - a Feasibility Study||M.S.T. Medical Surgery Technology LTD.|No|Recruiting|January 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02346552||28698|
NCT02351245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH201412|Clinical Characteristics of Lip Hemangiomas|Clinical Characteristics and Complications of Infantile Hemangiomas Located in Lips||Zhujiang Hospital|No|Active, not recruiting|December 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|39|||Both|N/A|2 Years|No|Non-Probability Sample|All the patients of lip hemangiomas after Dr. Zhang in Dermatology Clinic of Zhujiang        Hospital.|January 2015|January 26, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02351245||28339|
NCT02348801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34800|Lifestyle Intervention for Senior Diabetics|Lifestyle Intervention Strategy to Treat Diabetes in Older Adults|LISD|Baylor College of Medicine|Yes|Recruiting|January 2015|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|85 Years|No|||February 2016|February 4, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02348801||28526|
NCT02348814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1TR000124-2016|Development of a Novel Biomarker for Liver Fibrosis|Development of a Novel Biomarker for Liver Fibrosis||University of California, Los Angeles|No|Recruiting|May 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|125|Samples Without DNA|Biospecimens include inflammatory markers (cytokines) and markers of metabolic dysfunction      (adipokines):      leptin, adiponectin, TNF-alpha, PAI-1, IL-6, MCP-1, and retinoids|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects 18 years and older with at least one liver function test abnormality and        body mass index > 20.|December 2015|December 2, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02348814||28525|
NCT02301871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N44-449|The Effect of Soft Tissue Mobilization in Myofascial Neck Pain|Efficacy of Muscle Energy Technique and Deep Neck Flexors Training in Mechanical Neck Pain- A Randomized Clinical Trial||Maharishi Markendeswar University|Yes|Completed|July 2013|May 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|45 Years|No|||November 2014|November 25, 2014|November 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301871||32125|
NCT02350335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2561b|Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage|Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage|NRT-SAH|Oslo University Hospital|No|Recruiting|January 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 25, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02350335||28409|
NCT02350595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISK2|A Study on the Possible Health Effects of Lean Fish and Fatty Fish Intake in Overweight or Obese Adults|Fiskespisestudiene 2011-2014. Spiseforsøk Med Fisk. Delstudie 2: Studie av Mulige Effekter av Fet og Mager Fisk på Glukosemetabolismen og inflammasjonsmarkører i Overvektige Voksne.|FISK2|University of Bergen|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350595||28389|
NCT02352246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0220|HIIE and Abdominal Fat Mass in DT2 Postmenopausal Women|Effect of High-Intensity Intermittent Exercise on Abdominal Fat Mass in Type 2 Diabetes Postmenopausal Women.||University Hospital, Clermont-Ferrand||Not yet recruiting|February 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Female|55 Years|82 Years|No|||January 2015|January 30, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02352246||28262|
NCT02358785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-14-005|Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy|Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy||Ethicon Endo-Surgery|No|Completed|January 2015|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals scheduled for laparoscopic sleeve gastrectomy|November 2015|November 16, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358785||27762|
NCT02358798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9393|Respiratory Function at Preschool Age of Children Detected of Cystic Fibrosis in Neonatal Period||REVOLMUCO|University Hospital, Montpellier|No|Recruiting|August 2014|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|N/A|N/A|No|||September 2015|September 3, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02358798||27761|
NCT02298140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3245|Providers' Compliance to Malaria Treatment|Responding to Efficacy Decay Analysis of Artemisinin Based Combination Therapy (ACTs) in Rural Tanzania: Intervening on Provider Compliance and Patient Adherence to Correct Malaria Treatment|(PCMT)|Ifakara Health Institute|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|712|||Both|N/A|N/A|No|||July 2015|July 31, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02298140||32412|
NCT02298153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-110|A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer||Incyte Corporation|No|Recruiting|November 2014|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298153||32411|
NCT02358330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1041 EHR|Project 1: Evaluating EHR-Based Health System Modifications for the Chronic Care of Smoking|Project 1: Evaluating EHR-Based Health System Modifications for the Chronic Care of Smoking|EHR Project|University of Wisconsin, Madison|Yes|Recruiting|February 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|28|||Both|N/A|N/A|No|Non-Probability Sample|This is a multiple baseline design with the unit of analysis as the clinic. 20-28 clinics        will be recruited.|October 2015|October 5, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358330||27797|
NCT02358343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48647-B|A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}|ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression|ASCEND|University of Washington|Yes|Recruiting|February 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|800|||Both|21 Years|N/A|No|||May 2015|May 30, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358343||27796|
NCT02344069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRooF-iTH|Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage|Effect of Immediate, Pre-emptive Fibrinogen Concentrate in Patients With Trauma Haemorrhage Needing Haemostatic Resuscitation - a Randomized, Controlled, Double-blinded Investigator-initiated Pilot Trial||Rigshospitalet, Denmark|No|Recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02344069||28888|
NCT02344316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14251|Bringing Relief to Adolescents Naturally Using Melatonin for Migraine|Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: "The BRAiN-M Study"|BRAiN-M|University of California, San Francisco|Yes|Active, not recruiting|May 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|17 Years|No|||March 2016|March 16, 2016|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344316||28870|
NCT02343484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/8-2-13|Intradiscal Gelified Ethanol and Pulsed Radiofrequency Versus Gelified Ethanol Injection for Discogenic Low Back Pain|Intradiscal Combination of Gelified Ethanol and Pulsed Radiofrequency Versus Gelified Ethanol Injection for the Treatment of Chronic Discogenic Low Back Pain. A Randomized Controlled Trial.||Attikon Hospital|No|Recruiting|March 2013|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02343484||28932|
NCT02343497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00198-39|Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia|Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia|LLAX|Ajinomoto Foods Europe SAS|No|Active, not recruiting|August 2014|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|68|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02343497||28931|
NCT02302963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17725|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Hypoglycemia Reduction in Type 1 Diabetes|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Hypoglycemia Reduction in Type 1 Diabetes||University of Virginia|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|15 Years|65 Years|No|||July 2015|July 3, 2015|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302963||32041|
NCT02302976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014655|GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration|||Yale University|Yes|Recruiting|November 2014|||November 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|24|||Both|18 Years|50 Years|No|||December 2015|December 28, 2015|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302976||32040|
NCT02358369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-004|Dose-Ranging Study of the Bimatoprost Ocular Insert|A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.||ForSight Vision5, Inc.|No|Completed|January 2015|November 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358369||27794|
NCT02346266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176|SMART (School-aged Children Making Healthy Choices And Recognizing sTroke)|SMART (School-aged Children Making Healthy Choices And Recognizing sTroke): A Pilot Trial of a Stroke Awareness Program|SMART|Los Amigos Research and Education Institute|No|Enrolling by invitation|November 2014|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346266||28720|
NCT02347878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLPH|Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)|Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)||Sun Yat-sen University|No|Not yet recruiting|April 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|85|||Both|16 Years|80 Years|No|||January 2015|January 26, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347878||28597|
NCT02347891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-621|Belimumab in Myositis|Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis|BIM|Northwell Health|Yes|Recruiting|January 2015|||December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347891||28596|
NCT02357264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-25|Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia|Thoracic Ultrasonography for the Assessment of Pulmonary Edema in Patients With Pre-Eclampsia||Maimonides Medical Center|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Females|February 2016|February 15, 2016|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02357264||27877|
NCT02358928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 082013 020|Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome|Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome|NAFLD|University of Texas Southwestern Medical Center|Yes|Recruiting|July 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|11 Years|17 Years|No|||February 2015|February 3, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02358928||27751|
NCT02303080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.19.MET|Whey Protein Micelles and Thermogenesis in Overweight Subjects|Whey Protein Micelles and Thermogenesis In Overweight Subjects|Thermowhey|Nestlé|No|Completed|November 2010|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|17|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02303080||32032|
NCT02351258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS022870|Community Central Line Infection Prevention Trial|Community Central Line Infection Prevention Trial|CCLIP|Johns Hopkins University|No|Active, not recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|N/A|35 Years|No|||November 2015|November 20, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351258||28338|
NCT02358499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1490413|Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children|Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children||Children's Mercy Hospital Kansas City|Yes|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|2 Years|17 Years|No|||January 2016|January 26, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02358499||27784|
NCT02358538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-900|A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy|A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy||Marinus Pharmaceuticals|No|Recruiting|March 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|2 Years|18 Years|No|||January 2016|January 13, 2016|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358538||27781|
NCT02354040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3165- MED-ERC_14|Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence|Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence in a Pakistani Population With Vascular Disease|TalkingRx|Aga Khan University|No|Recruiting|March 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354040||28125|
NCT02358681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1302|Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children|Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children: A Randomized Non-inferiority Clinical Trial||Columbia University|Yes|Recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|8 Years|17 Years|No|||November 2015|November 11, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358681||27770|
NCT02358733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRH-BROIMSI-2014|Use of IMSI in Poor Responders to IVF|Use of Intra-Cytoplasmic Morphologically Selected Sperm Injection (IMSI) in Poor Responders to In Vitro Fertilization (IVF): a Prospective, Double-blind, Randomized, Controlled Trial||Centro de Infertilidad y Reproducción Humana|No|Recruiting|February 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Female|37 Years|N/A|No|||January 2016|January 26, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358733||27766|
NCT02305108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot. gen. 0018810|Fascial Manipulation in Patients With Hip Osteoarthritis|Evaluation of the Efficacy of Treatment of the Soft Tissues With Fascial Manipulation for Patients That Are Waiting for Total Hip Arthroplasty in Osteoarthritis|manifahip|Istituto Ortopedico Rizzoli|No|Completed|June 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|No|||August 2015|November 18, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02305108||31876|
NCT02293707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-GX301-02|A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer|A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy||Laboratoires Leurquin Mediolanum|No|Recruiting|November 2014|November 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Male|18 Years|N/A|No|||February 2016|February 23, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293707||32752|
NCT02354131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENGOT-OV24-NSGO/AVANOVA|Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer|AVANOVA1 - Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer.|AVANOVA|Nordic Society for Gynaecologic Oncology|Yes|Recruiting|February 2015|December 2019|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|147|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02354131||28118|
NCT02359786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAHM 1002 v.6|RAHM Foundation Retrospective Study of Various Diseases|Retrospective Registry To Enhance the Understanding of the Variability, Progression and Treatment of Various Disorders||Rahm Foundation|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||6|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with various disorders|January 2015|February 4, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02359786||27685|
NCT02346149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNSF132913|Effect of Acute Hyperglycemia on Renal Tissue Oxygenation|Effect of Acute Hyperglycemia on Renal Tissue Oxygenation as Measured By BOLD-MRI in Individuals With Impaired Glucose Tolerance and Controls|Glucox|Centre Hospitalier Universitaire Vaudois|No|Recruiting|June 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346149||28729|
NCT02302898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409107|Roux-en-Y Gastric Bypass and Weight Regain|Characteristics Associated With Weight Regain After Roux-en-Y Gastric Bypass||Washington University School of Medicine|No|Not yet recruiting|November 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|21 Years|60 Years|No|Non-Probability Sample|The study population will consist of 20 patients who had laparoscopic RYGB surgery >2        years before screening and have regained >20% weight from their maximum weight lost after        surgery and 20 patients who had laparoscopic RYGB surgery >2 years before screening and        have maintained at least 90% weight loss from the maximum weight loss after surgery. These        patients will be identified from the bariatric surgical population at Washington        University School of Medicine.|November 2014|November 26, 2014|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302898||32046|
NCT02345785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0891|Evaluation of the Change of Penile Corpus Cavernosum After Caudal Block Using Ultrasonography in Children|||Yonsei University|No|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|2 Years|7 Years|No|Probability Sample|pediatric patients who need urologic surgery and caudal block|January 2015|January 23, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02345785||28757|
NCT02346045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XC13EIMV0110D|Effect of Renal Denervation in End Staged Renal Disease With Resistant Hypertension|Effects of Catheter Based Renal Sympathetic Denervation on Resistant Hypertension in End Stage Renal Disease in Korea||Seoul St. Mary's Hospital|Yes|Recruiting|September 2014|October 2018|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||January 2015|January 19, 2015|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02346045||28737|
NCT02348567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Unannounced Periodic Surveys on Public Hospitals|Unannounced or Announced Periodic Hospital Surveys: A Study Protocol for a Nationwide Cluster-randomised, Controlled Trial||Danish Center for Healthcare Improvement|No|Active, not recruiting|August 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02348567||28544|
NCT02348580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOUN-2013-Rwanda-AMIR01|Effectiveness Study of Teacher Training and Social and Financial Education in Rwanda's Primary and Secondary Schools|Active Learning Methods for Social and Financial Education in Rwanda's Primary and Secondary Schools: A Cluster Randomized Controlled Trial||Stichting Child Savings International|No|Completed|September 2013|March 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1750|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02348580||28543|
NCT02347475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0312|SMA Flow Patterns in Neonatal Transfusion|Impact of Red Cell Transfusion on Superior Mesenteric Artery Flow Patterns and Intestinal Oxygenation in Fed Preterm Neonates (SPARTAN: Sma PAttern Related to TrAnsfusion in Neonates)|SPARTAN|University of Calgary|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|N/A|6 Months|No|Non-Probability Sample|Prematurity (<34 completed weeks of gestation at birth) Need for PRBC transfusion|December 2015|December 3, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347475||28627|
NCT02305615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29425|An Observational Study of Continued Avastin Plus Chemotherapy Until First Progression in Patients With Metastatic Colorectal Cancer|||Hoffmann-La Roche||Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with metastatic colorectal cancer in first-line setting in Hungary|March 2016|March 1, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305615||31837|
NCT02305628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29625|An Observational Study of Herceptin SC Safety in Breast Cancer|POST-MARKETING SURVEILLANCE OF HERCEPTIN SUBCUTANEOUS IN BREAST CANCER||Hoffmann-La Roche||Recruiting|March 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment for breast cancer with Herceptin SC under observation        according to standard of care and in line with the current local labeling in Korea.|March 2016|March 1, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305628||31836|
NCT02346279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Responsivität und MCID MSQPT|Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists|Study to Evaluate the Responsiveness and Minimal Clinical Important Difference (MCID) of the 'Multiple Sclerosis Questionnaire for Physiotherapists' (MSQPT)||Institut fuer Physiotherapieforschung|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Non-Probability Sample|Persons suffering from Multiple Sclerosis that are in physical therapy treatment because        of the multiple sclerosis and are treated in private practice or in ambulant department of        hospitals in the German part of Switzerland|January 2015|January 24, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346279||28719|
NCT02350634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A13|18F-AV-1451 High Resolution Autopsy Study|A High Resolution Autopsy Study Evaluating the Relationship of 18F-AV-1451 PET Imaging and Tau Pathology||Avid Radiopharmaceuticals|No|Recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|60 Years|85 Years|No|||June 2015|June 10, 2015|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02350634||28386|
NCT02352766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14040164|Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules|Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules||University of Pittsburgh|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients that undergo a routine diagnostic thyroid FNA that consent in participating in        the research study whose samples have indeterminate cytologic diagnosis (Bethesda III, VI,        or V) and surgical outcome are submitted for molecular testing. (Sample will be given a        code that de-identifies the sample before it is sent to the testing laboratory. The lab        that will analyze specimens is a CLIA certified Pitt lab.)|November 2015|November 17, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352766||28223|
NCT02358941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF: 320030_149411/1|Neurofeedback and Computerized Cognitive Training in Different Settings for Children and Adolescents With ADHD|Neurofeedback and Computerized Cognitive Training in Different Settings for Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)||University of Zurich|No|Recruiting|December 2013|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|8 Years|16 Years|No|||February 2015|February 3, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02358941||27750|
NCT02346669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-NM-447-CTIL|Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|February 2015|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02346669||28689|
NCT02305771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01461-46|Contributions From the Analysis of Graphs for Identification of Neural Cliques|Contributions From the Analysis of Graphs for Identification of Neural Cliques|BRAINGRAPH|Rennes University Hospital|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305771||31825|
NCT02343354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT 2014-35|The MoMMii Study. Diabetes Prevention Intervention on Families With Past Gestational Diabetes|The MoMMii Study: Effects of a Multimodal Diabetes Prevention Intervention on Families With a History of Gestational Diabetes|MoMMii|McGill University Health Center|No|Recruiting|November 2014|May 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|132|||Both|18 Years|60 Years|No|||October 2015|October 23, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343354||28942|
NCT02356679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUPASIDIN-S_P4|Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients|A Phase 4, Multicenter, Randomized, Open, Active Drug Comparative Trial to Evaluated the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients||Chong Kun Dang Pharmaceutical|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|19 Years|N/A|No|||August 2015|August 21, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02356679||27922|
NCT02356692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-38|Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses|Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses||Coopervision, Inc.|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356692||27921|
NCT02345902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InstitutoNCMNSZ|Treatment of Hypoactive Delirium and Outcome Measures|Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium|THDOM|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Recruiting|January 2016|October 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|70 Years|N/A|No|||January 2016|January 28, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02345902||28748|
NCT02293720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1E|An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System|An Open-Label Extension to Protocol 09-1, Multi-Center, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects|OLE|GI Dynamics|Yes|Withdrawn|April 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|65 Years|No|||November 2014|July 31, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293720||32751|
NCT02293993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343-14-001|Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia|Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|14|||Both|20 Years|N/A|No|||February 2016|February 9, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293993||32730|
NCT02345525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio CIMT|Constraint-Induced Movement Therapy in Chronic Stroke Patients|The Feasibility of a Home-based Constraint-Induced Movement Therapy Program in Chronic Stroke Survivors.||University Hospital of Ferrara|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||July 2015|August 3, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345525||28777|
NCT02343718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I218|Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours|A Study of Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours||Canadian Cancer Trials Group|Yes|Recruiting|May 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|18 Years|No|||April 2015|March 22, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02343718||28914|
NCT02343731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending NCT02343731|Dogs as Probiotics|Dogs as Probiotics to Enhance the Health and Emotional Well-Being of Elderly Adults||University of Arizona|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02343731||28913|
NCT02343744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104128|An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis|A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis||Janssen Pharmaceutical K.K.|Yes|Recruiting|January 2015|September 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343744||28912|
NCT02351349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-275-GEN|Frail Elderlies With CKD|MULTIDISCIPLINARY INTERVENTION FOR FRAIL ELDERLY PATIENTS WITH STAGE 4 or 5 Chronic Kidney Disease (Not on Dialysis)|FRED-CKD|McGill University Health Center|No|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|65 Years|N/A|No|||January 2015|January 29, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351349||28331|
NCT02351362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33546|A Pilot Voucher Incentive for Improving Retention in Postpartum HIV Care in South Africa|A Pilot Study of a Voucher Incentive System for Improving Retention in Postpartum HIV Care in South Africa||Boston University|No|Not yet recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Female|19 Years|N/A|No|||January 2015|January 27, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02351362||28330|
NCT02305459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRSECIRT|CIRSE Registry for SIR-Spheres Therapy|CIRSE Registry for SIR-Spheres Therapy|CIRT|Cardiovascular and Interventional Radiological Society of Europe|Yes|Recruiting|November 2014|November 2020|Anticipated|November 2019|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres        as part of the treatment determined by the treating clinician.|November 2014|November 27, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02305459|12 Months|31849|
NCT02350348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NECTARINE|NEonate-Children sTudy of Anaesthesia pRactice IN Europe Epidemiology of Morbidity and Mortality in Neonatal Anaesthesia|NECTARINE: NEonate-Children sTudy of Anaesthesia pRactice IN Europe Epidemiology of Morbidity and Mortality in Neonatal Anaesthesia: A European Prospective Multicentre Observational Study|NECTARINE|European Society of Anaesthesiology|No|Recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|60 Weeks|No|Non-Probability Sample|Neonates and infants from birth to 60 weeks of post-menstrual age|March 2016|March 15, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02350348||28408|
NCT02350621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1150-31/2|Cervical Foraminal Stenosis and Radiculopathy - ACDF Versus Minimal Invasive Posterior Cervical Foraminotomy.|Cervical Foraminal Stenosis and Radiculopathy - Anterior Cervical Discectomy and Fusion (ACDF) Versus Minimal Invasive Posterior Cervical Foraminotomy miPCF).||Stockholm Spine Center AB|No|Not yet recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|70 Years|No|||January 2015|January 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350621||28387|
NCT02354690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM1414|Vemurafenib and TIL Therapy for Metastatic Melanoma|T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma||Herlev Hospital|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02354690||28075|
NCT02301351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819610|Effects of Implicit Messaging by Cigarette Pack Color on Smoking Behaviors|Effects of Implicit Messaging by Cigarette Pack Color on Smoking Behaviors||University of Pennsylvania|No|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|360|||Both|21 Years|60 Years|No|||November 2015|November 6, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301351||32165|
NCT02301364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-177|Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)|A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301364||32164|
NCT02295007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5253|Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging|Pilot Study to Assess Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging (2014-2015 Season)||Columbia University|No|Recruiting|December 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|275|||Both|2 Years|11 Years|No|||December 2015|December 22, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295007||32652|
NCT02350946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK163/13|Effects of Oxytocin on Emotion Recognition and Response Inhibition|Effects of Oxytocin on Emotion Recognition and Response Inhibition||RWTH Aachen University|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350946||28362|
NCT02356172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915077|Psychological Outcomes in Isolated GnRH Deficiency|Psychological Outcomes in Isolated GNRH Deficiency||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 2, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02356172||27961|
NCT02351804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-PJ-14|Does Perineural Dexamethasone Prolong Duration of a Nerve Block?|Does Perineural Dexamethasone Prolong Duration of an Adductor Canal Block When Controlling for a Systemic Effect? A Paired, Randomized, Blinded, Study in Healthy Volunteers||Rigshospitalet, Denmark|Yes|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351804||28296|
NCT02351817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP256|An Explorative Randomized Controlled Investigation Evaluating Newly Developed Ostomy Products|||Coloplast A/S|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 27, 2015||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT02351817||28295|
NCT02295267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0519|Molecular Analysis of IgE Antibodies in Walnut Allergic Patients|Molecular Analysis of IgE Antibodies in Walnut Allergic Patients||University of Zurich|No|Recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|120|||Both|1 Year|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02295267||32632|
NCT02347839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1004|NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.|A Multicenter Phase II Trial of Neoadjuvant Gefitinib Followed by Surgery, Followed by Adjuvant Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.|NEGOTIATE|Sun Yat-sen University|Yes|Active, not recruiting|January 2015|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|No|||April 2015|April 14, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347839||28600|
NCT02345031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUT022063|Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss|A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]|CLARITY-1|Autifony Therapeutics Limited|No|Recruiting|January 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|89 Years|No|||November 2015|November 19, 2015|January 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345031||28815|
NCT02345044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS3150-A-J203|A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension||Daiichi Sankyo Inc.|No|Completed|January 2015|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|426|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345044||28814|
NCT02351102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655-14|Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy|Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy||Rabin Medical Center|No|Recruiting|November 2015|March 2021|Anticipated|April 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 15, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02351102||28350|
NCT02351115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-002-202|Staccato® Alprazolam and EEG Photoparoxysmal Response|Assessment of Staccato® Alprazolam on the EEG Photoparoxysmal Response in Patients With Epilepsy||Alexza Pharmaceuticals, Inc.||Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|6|||Both|18 Years|60 Years|No|||August 2015|August 12, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351115||28349|
NCT02302794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC-14004877|A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery|Prospective Randomized Controlled Multicenter Clinical Trial for Comparison of Long-term Outcomes Between Laparoscopy-assisted and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer||Huazhong University of Science and Technology|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1056|||Both|18 Years|75 Years|No|||July 2014|November 25, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302794||32054|
NCT02350036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125|Placental Protein 13 and Uterine Doppler Indeces as Predictors of Pre-eclampsia|Maternal Serum Placental Protein 13 and Uterine Doppler Indeces as Predictors of Pre-eclampsia||Cairo University|No|Recruiting|January 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women at 11 to 14 weeks of gestation|January 2015|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350036|9 Months|28432|
NCT02350049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GK10|Cementless Oxford Partial Knee Controlled Observational Study|Cementless Oxford Partial Knee Retrospective and Prospective Controlled Multi-center Observational Study|GK10|Biomet, Inc.|No|Active, not recruiting|November 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|362|||Both|21 Years|N/A|No|Probability Sample|A total of 362 cases (121 investigational cases and 241 control cases) for primary        efficacy and safety assessment (Primary Comparative Analysis Group); and exploratory        assessment from one center in England.        A total of approximately 1,000 investigational cases for "survivorship only" assessment        from three centers.|February 2016|February 10, 2016|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02350049||28431|
NCT02348190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4148|Fat Induced Insulin Resistance and Atherosclerosis|Fat Induced Insulin Resistance and Atherosclerosis||Temple University|No|Completed|June 2003|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|86|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348190||28573|
NCT02359123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNBX-001|Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients|Cannabics Capsules as Treatment to Improve Cancer Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients- Pilot Study||Cannabics Pharmaceuticals Inc.|No|Recruiting|March 2016|August 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02359123||27736|
NCT02294760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44418|Long-term Sacral Nerve Stimulation for Irritable Bowel Syndrome.|Long-term Efficacy of Sacral Nerve Stimulation for Irritable Bowel Syndrome. A Randomised Controlled Crossover Study||University of Aarhus|Yes|Enrolling by invitation|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|60 Years|No|||November 2014|November 14, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02294760||32671|
NCT02355691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1920|Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty|Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty||University of North Carolina, Chapel Hill|No|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355691||27998|
NCT02355834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD14/042|Faecal Incontinence iNtervention Study|Improving Continence in People With Inflammatory Bowel Disease: Active Case Finding and a Randomised Controlled Trial|FINS|London North West Healthcare NHS Trust|No|Recruiting|May 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|186|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02355834||27987|
NCT02357160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000378|The Value of Integrating Visual Arts: Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing|The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing|VIVA|Milton S. Hershey Medical Center|No|Recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|400|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357160||27885|
NCT02304965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-B03|Activity at Pulse Pressure Above an Individual Threshold in Patients With LVAD|Daily Physical Activity at Pulse Pressure Above an Individual Threshold in Patients With Continuous Flow Left Ventricular Assist Devices - a Feasibility Study||Hannover Medical School|No|Completed|November 2014|September 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|45 Years|65 Years|No|||June 2015|September 2, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02304965||31887|
NCT02355977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-25|The Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis|The Response of Periodontal Pathogens to the Respective or Combined Treatment of Scaling and Root Planning and Locally Delivered Minocycline in Patients With Chronic Periodontitis- a Short-term Randomized Clinical Trial||Zhejiang University|No|Completed|June 2013|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|N/A|N/A|No|||October 2015|October 29, 2015|January 31, 2015||No||No|September 26, 2015|https://clinicaltrials.gov/show/NCT02355977||27976|
NCT02355990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN-FIM-1|Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study|Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study||Sanoculis Ltd|No|Not yet recruiting|February 2015|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2015|February 3, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02355990||27975|
NCT02344290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5332|Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults|Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE|REPRIEVE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|March 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6500|||Both|40 Years|75 Years|No|||March 2016|March 21, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344290||28872|
NCT02344303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-1008|Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals|A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects||Trevena Inc.|No|Completed|December 2014|October 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344303||28871|
NCT02359253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00103492|Robot Aided Rehabilitation - Intervention|Robot Aided Diagnosis, Passive-Active Arm Motor and Sensory Rehabilitation Post Stroke - Intervention|RAR2|Rehabilitation Institute of Chicago|No|Not yet recruiting|February 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|85 Years|No|||February 2015|February 4, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359253||27726|
NCT02359409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IndianaU|Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy|Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy||Indiana University|No|Active, not recruiting|July 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359409||27714|
NCT02299492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCP-13-9762|Person-Centered Care Planning and Service Engagement|Person-Centered Care Planning and Service Engagement|PCCP|New York University|No|Recruiting|September 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|476|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02299492||32308|
NCT02351960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-P4-001|Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease|A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole||Takeda|No|Recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||August 2015|August 11, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351960||28284|
NCT02351973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCRN 4501|Comparison of Single and Combination Diuretics in Low-Renin Hypertension|Comparison of Single and Combination Diuretics in Low-Renin Hypertension|PATHWAY3|University of Cambridge|Yes|Active, not recruiting|November 2009|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|423|||Both|18 Years|80 Years|No|||July 2015|July 1, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351973||28283|
NCT02349347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL-CAP|A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)|A Single Arm Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)|MEL-CAP|Queen Mary University of London|No|Recruiting|December 2012|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Male|18 Years|N/A|No|||January 2015|January 27, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349347||28484|
NCT02359084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH104355-01|Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children|Early Identification and Service Linkage for Urban Children With Autism||Boston University|Yes|Recruiting|February 2015|June 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|15 Months|27 Months|No|||July 2015|July 28, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02359084||27739|
NCT02305381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3627|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes|SUSTAIN™ 5|Novo Nordisk A/S|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|397|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305381||31855|
NCT02294487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMvax-pilot|Study of the Immune Response After Vaccination in Multiple Myeloma Patients|The Immune Response Following Vaccination in Multiple Myeloma Patients: A Prospective Pilot Study||Aurora Health Care|No|Recruiting|December 2014|November 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Multiple myeloma patients and age and sex matched control subjects over 50 who are already        planning to have the flu and/or pneumonia vaccine as part of normal care. The control        group is important for comparison of age-adjusted changes in immune responses to        vaccination.|December 2015|December 30, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02294487||32692|
NCT02355561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106621|A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants|An Open-Label, Randomized, Three-Period Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect of JNJ-54861911 Tablet (1x25mg) After Single Dose Administration in Healthy Elderly Subjects||Janssen Research & Development, LLC|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02355561||28008|
NCT02352259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-Z/KESOPKR-28|Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II|Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II||Institute of Oncology Ljubljana|Yes|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02352259||28261|
NCT02359734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000709|A National Study of Intravenous Medication Errors|A National Study of Intravenous Medication Errors: Understanding How to Improve Intravenous Safety With Smart Pumps||Brigham and Women's Hospital|No|Recruiting|April 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|10||Anticipated|15000|||Both|21 Years|N/A|No|||February 2015|February 9, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02359734||27689|
NCT02302989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29346|Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration|Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)|PROTECT|NJ Retina (Retina Associates of New Jersey)|No|Recruiting|May 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|88|||Both|50 Years|N/A|No|||October 2015|October 26, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302989||32039|
NCT02303002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT002-CL002|Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines|||Revance Therapeutics, Inc.|No|Completed|December 2014|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|268|||Both|30 Years|65 Years|No|||March 2016|March 8, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303002||32038|
NCT02347332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 309 F0|Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer|Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy||Pierre Fabre Medicament|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|80 Years|No|||January 2015|January 21, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02347332||28638|
NCT02299206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP05012014|CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants|Randomized, Double-Blind, Parallel Group, Non-Inferiority Clinical Trial of CeraVe Baby Diaper Rash Cream Compared to Desitin Maximum Strength Original Paste for Management of Diaper Dermatitis in Infants||Northwestern University|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Months|18 Months|No|||December 2015|December 25, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299206||32330|
NCT02303093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM 10-06|Non-Interventional Octagam® 10% - GAM10-06 "GammaTrack"|Non-Interventional Study on the Tolerability and Efficacy of Octagam® 10% - GAM10-06 "GammaTrack"|GAM 10-06|Octapharma|No|Not yet recruiting|September 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Any patient who needs to be treated with a product of this class because of his/her        medical condition and whom the treating physician decides to prescribe Octagam regularly,        may be included.|June 2015|June 5, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303093||32031|
NCT02352779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC13091|Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors|Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue||University of Rochester|Yes|Active, not recruiting|February 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|75|||Female|18 Years|120 Years|No|||February 2016|February 17, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352779||28222|
NCT02343822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-14-2117-B|Multiple Platelet-Rich Plasma Lateral Epidondylitis Injections Versus a Single Platelet-Rich Plasma Injection|Multiple Platelet-Rich Plasma Lateral Epidondylitis Injections Versus a Single Platelet-Rich Plasma Injection in a Double-Blinded Randomized Controlled Study (PRPLE)|PRPLE|Kaiser Permanente|Yes|Recruiting|March 2015|March 2023|Anticipated|March 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|532|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343822||28906|
NCT02303223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/MD/1008/13592-93|Propofol Pharmacokinetics in Children After Single Bolus Dose|Propofol Pharmacokinetics in Children After Single Bolus Dose||Postgraduate Institute of Medical Education and Research|Yes|Completed|January 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02303223||32021|
NCT02357654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO20140001128|GnRH for Luteal Support in IVF/ICSI/FET Cycles|GnRH for Luteal Support in IVF/ICSI/FET Cycles||University Reproductive Associates|No|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|40 Years|No|||November 2015|November 30, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02357654||27848|
NCT02356250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC 14-0117-CTIL|A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive Cirrhotic Patients|A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive||Carmel Medical Center|Yes|Not yet recruiting|February 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Probability Sample|A maximum of 30 patients with cirrhosis Ages between 18 to 75|February 2015|February 18, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02356250||27955|
NCT02359695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRH-BROHC-2013|Low-dose GH Supplementation Increases Clinical Pregnancy Rate|Low-dose Growth Hormone Supplementation Increases Clinical Pregnancy Rate in Poor Responders Undergoing in Vitro Fertilisation.||Centro de Infertilidad y Reproducción Humana|No|Recruiting|October 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|50 Years|No|||January 2016|January 26, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02359695||27692|
NCT02298985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLJB-14|Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients|Curcumin as add-on to Antipsychotic Treatment in Chronic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-controlled Study||Beersheva Mental Health Center|Yes|Recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298985||32347|
NCT02357901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-13-0001|Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine|Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Efficacy of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP 6000) Over 24 Weeks in Treatment-Seeking Participants With Opioid Use Disorder||Indivior Inc.|Yes|Active, not recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|505|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357901||27830|
NCT02356497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49273.041.14|Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort|Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort|PRESENT|UMC Utrecht|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1470|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with bone metastases undergoing radiotherapy will be asked to participate in        this cohort study.|February 2015|February 1, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356497|3 Years|27936|
NCT02347137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-267|Influence of Reduced Daily Step Count and Anabolic Interventions on Muscle Protein Metabolism in Older Persons|Efficacy of Isolated Whey and Micellar Whey Protein (+/-Citrulline) to Stimulate Protein Synthesis in 'Healthy' and 'Anabolically Resistant' Elderly Muscle||McMaster University|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|30|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02347137||28653|
NCT02308813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503/2014BO2|Predictability of the Ability to Perform an Emergency Stop With Disorders of the Hip|Predictability of Braking Performance in Patients With Degenerative Disease of the Hip Joint or With Total Hip Arthroplasty||University Hospital Tuebingen|No|Completed|October 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2014|February 1, 2016|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02308813||31592|
NCT02356003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-1839|Transcranial Magnetic Stimulation for Children With Tourette's Syndrome|TICS: Transcranial Magnetic Stimulation for Children With Tourette's Syndrome|TICS|University of Calgary|No|Recruiting|May 2015|April 2020|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Male|7 Years|12 Years|No|||January 2016|January 11, 2016|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02356003||27974|
NCT02344797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBpixie|Prevention of Myocardial Injury in Non-cardiac Surgery|Prevention of Myocardial Injury by Remote Ischemic Preconditioning in Emergent or Urgent Non-cardiac Surgery: a Randomized Clinical Trial|PIXIE|University Hospital Koge|No|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|45 Years|N/A|No|||February 2016|February 4, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344797||28833|
NCT02344810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2132|C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer|A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma||Eastern Cooperative Oncology Group|Yes|Not yet recruiting|January 2015|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344810||28832|
NCT02294448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PopPK profile of Qishe Pill|PopPK Profile of Qishe Pill: Study Protocol for a Phase I Clinical Trial|Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|November 2014|July 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 15, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02294448||32695|
NCT02294682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116576|A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae|A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae||GlaxoSmithKline|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|February 11, 2016|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294682||32677|
NCT02303106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-386|Interaction Between Paracetamol and Lamotrigine: A Clinical Interaction Study|Interaction Between Paracetamol and Lamotrigine: A Clinical Interaction Study.||Odense University Hospital|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303106||32030|
NCT02308852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B039201317382|Improving Bi-manual Activities in Stroke Patients With Application of Neuro-stimulation|||University Hospital of Mont-Godinne|No|Recruiting|October 2014|December 2030|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308852||31589|
NCT02357979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaserFissure-1st|Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser|Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser - A Randomized, Single Blind, Prospective, Split Mouth Controlled, Clinical Trial|LaserFissure|University of California, San Francisco|No|Not yet recruiting|February 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|6 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357979||27824|
NCT02356627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKT|The Cancer Home Life Intervention Study. A Randomised, Controlled Multicentre Trial and a Health Economic Evaluation|The Cancer Home Life Intervention Study Protocol: Effectiveness on Everyday Activities and Quality of Life in People With Advanced Cancer Living at Home. A Randomised, Controlled Multicentre Trial and a Health Economic Evaluation||University of Southern Denmark|No|Recruiting|February 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|272|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02356627||27926|
NCT02347709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14024|Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds|Differential Clinical, Molecular, and Pathological Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds-a Pilot Study||Winthrop University Hospital|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Tissue samples will be obtained via 3mm punch biopsy during standard of care wound      debridement.|Both|18 Years|N/A|No|Non-Probability Sample|The study population will include eligible patients from three Winthrop outpatient        services, separated into three study groups. Based on demographic data from this        institution, we expect our population sample to be representative of all major races and        ethnic groups.|December 2015|January 5, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02347709||28609|
NCT02308904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS46T|Reproductive Capacity and Iron Burden in Thalassemia|Reproductive Capacity and Association to Iron Burden and Chelation Patterns in Thalassemia Major Patients|Fertility thal|Children's Hospital & Research Center Oakland|No|Recruiting|June 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|12 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02308904||31585|
NCT02308930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TY0131002|Effect of DHA Supplementation on Cognitive Performance and Growth in Chinese Children|Effect of Dietary DHA Supplementation on Cognitive Performance and Growth in Chinese School Children: A Randomized Controlled Study||Sun Yat-sen University||Active, not recruiting|July 2014|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|106|||Both|6 Years|12 Years|No|||December 2014|December 4, 2014|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02308930||31583|
NCT02344017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3116001|Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer|Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC): Open, Non-Randomised, Uncontrolled, Multicentre, Dose Escalation, First-in-man Study With a Dose Expansion|DUALIDES|Orion Corporation, Orion Pharma|Yes|Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|December 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02344017||28892|
NCT02359175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.034|Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study|Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study|SEAVATS|Odense University Hospital|Yes|Recruiting|February 2015|February 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359175||27732|
NCT02346890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00006|A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722|A Phase 1, Single-center, Randomized, 2-way Crossover, Open Label Study to Evaluate the Effect of Renvela on the Pharmacodynamics of AZD1722 in Healthy Volunteeers||Ardelyx|No|Completed|April 2013|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|September 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02346890||28672|
NCT02300792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/013|The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A|The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A||Ain Shams University|Yes|Completed|November 2013|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|18 Years|No|||November 2014|November 24, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02300792||32208|
NCT02302911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEIPA|Swiss Early Intervention Project in Autism: An Evaluation of Early Intervention Outcome|Swiss Early Intervention Project in Autism: An Evaluation of Early Intervention Outcome|SwissEIPA|University of Zurich|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|no biospecimens are being retained|Both|N/A|5 Years|No|Non-Probability Sample|Experimental Groups: Child with Autism Spectrum Disorder diagnosis referred to one of the        EIBI or EIEI Service Provider receiving Treatment as of January 2013.        Control Group: Child with Autism Spectrum Disorder diagnosis receiving Treatment as usual        and willing to participate|November 2014|November 24, 2014|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02302911||32045|
NCT02343757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-12-13|Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid|Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid||University Hospital Case Medical Center|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|21 Years|N/A|No|||January 2015|January 21, 2015|May 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02343757||28911|
NCT02301091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-FXY-036|Combine TACE and RFA Versus TACE Alone for HCC With PVTT|Combine Transcatheter Arterial Embolization and Radiofrequency Ablation Versus Transcatheter Arterial Embolization Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus|CORTT|Sun Yat-sen University|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||November 2014|November 26, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02301091||32185|
NCT02296021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY20140916-2|Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy|Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail||Xijing Hospital of Digestive Diseases|Yes|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|612|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02296021||32574|
NCT02343367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD075936|Health4Kids Intervention Trial for Hispanic Families|Pediatric Obesity Management Intervention Trial for Hispanic Families|H4K|The University of Texas Health Science Center at San Antonio|No|Recruiting|January 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|6 Years|11 Years|No|||January 2016|January 11, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02343367||28941|
NCT02349113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001935|Effects of Acute Estrogen Therapy on Bone Formation|Effects of Acute Estrogen Therapy on Bone Formation||Mayo Clinic|No|Completed|February 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Female|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 13, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349113||28502|
NCT02298699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSL 06-2014|Biomarker for Sly Disease|Biomarker for Sly Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioSly|University of Rostock|Yes|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with Sly disease or patients with high-grade suspicion for Sly disease should be        included into the study.|October 2015|October 6, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298699||32369|
NCT02308891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-011|A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis|Multicenter Prospective Randomized Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis||Dankook University|Yes|Recruiting|November 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|510|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02308891||31586|
NCT02347605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2385492|Medicinal Nicotine for Preventing Cue Induced Craving|||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|56|||Both|18 Years|64 Years|No|||September 2015|September 25, 2015|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02347605||28617|
NCT02347618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGUP14107|Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer|Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer||University of Rochester|Yes|Recruiting|December 2014|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02347618||28616|
NCT02344576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2102|PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device|A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for End-Stage Heart Failure|DECIDE-LVAD|University of Colorado, Denver|Yes|Recruiting|May 2015|November 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344576||28850|
NCT02301611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB Protocol: 20141932|Phase IIB TL + YCWP + DC in Melanoma|A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.||Cancer Insight, LLC|Yes|Recruiting|January 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|99 Years|No|||December 2015|December 8, 2015|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301611||32145|
NCT02305004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT001|Blood Serum Concentrations of Routine Drugs in Patients Treated in the Intensive Care Unit.|INTOx A Prospective Measurement of Serum Concentrations of Routine Drugs in Patients Treated in the Intensive Care Unit-A Quality Measurement/Improvement for Clinical Treatment and Forensic Assessment|INTOx|Uppsala University|No|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|7 Years|N/A|No|Probability Sample|All patients except children under the age of 7 admitted in the ICU at Uppsala University        hospital within the time period of 2 years. Estimated number of patients is approximately        1000-1500 patients. The inclusion of patients undergoing autopsy will be after consent        from family is obtained according to local routines. Patients undergoing forensic autopsy        will also be included in compliance with current regulations. The number of patients in        the autopsy group is estimated to be around 100 patients.|December 2015|December 3, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305004||31884|
NCT02296554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401M47421|Superior Labral Tear From Anterior to Posterior (SLAP) Repair Versus Biceps Tenodesis for SLAP Tears in the Shoulder|SLAP Repair Versus Biceps Tenodesis for SLAP Tears in the Shoulder: A Randomized Outcomes Study|SLAP|HealthPartners Institute|No|Recruiting|June 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|November 25, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02296554||32533|
NCT02296892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS7056-008|A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy|A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in Patients Undergoing Bronchoscopy||Paion UK Ltd.|No|Recruiting|April 2015|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|460|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296892||32508|
NCT02347631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robertson_SCLProject|DAILIES TOTAL1 Versus ACUVUE TruEye|A Comparison of the Effects of Alcon DAILIES TOTAL1 and a Control High Oxygen Permeable Silicone Hydrogel Daily Disposable Contact Lens, the ACUVUE TruEye, on the Biology of the Ocular Surface and Lid Margin|TruEyeTotal1|University of Texas Southwestern Medical Center|No|Not yet recruiting|March 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|94|||Both|21 Years|38 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347631||28615|
NCT02345369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095|Locked Versus Unlocked Set Screws in Intramedullary Fixation of Intertrochanteric Fractures|Does Static Locking of Set Screws in Intramedullary Fixation of Intertrochanteric Fractures Prevent Shortening of Intertrochanteric Hip Fractures?||Bassett Healthcare|No|Recruiting|January 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345369||28789|
NCT02345382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16520|Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia||Bayer|No|Recruiting|February 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345382||28788|
NCT02300805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lab7681|Accuracy of Endometrial Volume Measured by VOCAL Versus Office Hysteroscopy for Diagnosis of Endometrial Polyps|Accuracy of Endometrial Volume Measured by Virtual Organ Computer-aided AnaLysis (VOCAL)Versus Office Hysteroscopy for Diagnosis of Endometrial Polyps|VOCAL|Ain Shams University|No|Completed|November 2014|December 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|117|||Female|20 Years|50 Years|No|Probability Sample|Premenopausal women complaining of irregular vaginal bleeding|January 2016|January 9, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300805||32207|
NCT02305927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD083113|Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health|Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health|ToV5|Harvard School of Public Health|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2300|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02305927||31813|
NCT02305940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14IC2030|Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients|A Phase III Double-blind, Randomised, Placebo Controlled Trial of Long Term Therapy on Exacerbation Rate in Patients With Stable COPD Using Doxycycline||Imperial College London|Yes|Recruiting|July 2014|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|222|||Both|45 Years|N/A|No|||February 2016|February 15, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02305940||31812|
NCT02346981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIUEL2008|Resistance Training and Post-exercise Blood Pressure in Normotensive Older Women|Chronic Resistance Training and Post-exercise Blood Pressure in Normotensive Older Women||Universidade Estadual de Londrina|No|Completed|February 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346981||28665|
NCT02346994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN3253|Development of Melt Organic Baking Fat for Reducing Child Obesity|Development and Expansion of Melt Organic Baking Fat for Oxidative Stability and Reducing Child Obesity||Columbia University|Yes|Recruiting|January 2013|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02346994||28664|
NCT02348203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00061|Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers|Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers||National Cancer Institute (NCI)|Yes|Recruiting|January 2016|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02348203||28572|
NCT02348216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTE-C19-101|A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)|ZUMA-1|Kite Pharma, Inc.|Yes|Recruiting|January 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|N/A|No|||February 2016|March 22, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348216||28571|
NCT02304679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2013/SD-01|Low Energy Shockwave Therapy for Improving Erectile Dysfunction|The Effectiveness of Low Energy Shockwave Therapy for Improving Erectile Dysfunction in Men: a Double Blind Randomized Controlled Trial|Shock-ED|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|September 2015|December 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|154|||Male|18 Years|79 Years|No|||January 2016|January 18, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02304679||31909|
NCT02298439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6128-AE|Fatty Liver Patient Registry|Non-Alcoholic Fatty Liver Disease Patient Registry||University Health Network, Toronto|No|Recruiting|October 2013|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Non-Alcoholic Fatty Liver Disease (NAFLD )which includes simple steatosis        (SS) and non-alcoholic steatohepatitis (NASH) that being treated|November 2014|November 19, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02298439|5 Years|32389|
NCT02301156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTX-IB-301|Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)||TG Therapeutics, Inc.|Yes|Recruiting|January 2015|August 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301156||32180|
NCT02301169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1001-01|A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain|A Study to Investigate the Effects of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain||Tools4Patient|No|Completed|March 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02301169||32179|
NCT02301429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV DDD|Model 20105 Lead Study|Model 20105 Lead Study||Medtronic BRC|No|Recruiting|November 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02301429||32159|
NCT02347007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN4353|Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults|Impact of Almond Supplementation, Relative to a Low-fat, High Carbohydrate Control, on Body Composition in Overweight and Obese Black and Hispanic Adults||Columbia University|Yes|Active, not recruiting|October 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02347007||28663|
NCT02296294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM Volunteer Study|Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy|Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy|BCM_Volunteer|Medical University of Vienna|No|Recruiting|October 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296294||32553|
NCT02349100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093|PET-CT After Nellix Implantation|Clinical Relevance of Positron Emission Tomography (PET) Imaging Following Endovascular Aneurysm Repair Using the Nellix Endoprosthesis||Rijnstate Hospital|No|Recruiting|January 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients with abdominal aortic aneurysms eligible for EVAS with Nellix endoprosthesis.|May 2015|May 6, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02349100||28503|
NCT02305017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-125|Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers|Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|November 28, 2014||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02305017||31883|
NCT02294695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EProK study|Early Procalcitonin Kinetics During Empirical Antibiotic Therapy in Critically Ill Patients|Early Procalcitonin Kinetics May Indicate Effectiveness of the Empirical Antibiotic Therapy in Sepsis Within Hours||Szeged University|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over 18 years with suspected infection on admission or during their stay on        the intensive care unit were screened for eligibility. Patients were enrolled, when the        attending intensive care specialist had a suspicion of infection and decided to start        empirical antibiotic therapy.|November 2014|November 14, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02294695||32676|
NCT02301676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPOCD60|Long Term Postoperative Cognitive Dysfunction in the Elderly Patients|Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients||Pusan National University Yangsan Hospital|No|Not yet recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|190|||Both|60 Years|N/A|No|||November 2014|December 1, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02301676||32140|
NCT02351986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1162-2746|Effects of Cryotherapy on Joint Function and Pressure Pain Threshold in Patients With Subacromial Impingement Syndrome.|Effects of Cryotherapy on Inflammatory Mediators, Joint Function and Pressure Pain Threshold in Patients With Subacromial Impingement Syndrome.||Universidade Federal de Sao Carlos||Completed|June 2014|December 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351986||28282|
NCT02349607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291010|Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-05089771 Alone And In Combination With Pregabalin On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls||Pfizer|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349607||28464|
NCT02304406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081046|Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa|Retrospective Epidemiology Study Of EML4-ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa|ALK NSCLC MENA|Pfizer||Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|700|Samples With DNA|The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular      diagnostic units & pathology departments in these study centers. The histological diagnosis      will be confirmed by the pathologists. The retained samples will then be tested by      performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by      the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue      samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics      GmbH) in the selected study centers.|Both|18 Years|N/A|No|Non-Probability Sample|Since this is a retrospective epidemiology study, no patients will be enrolled. Tissue        samples of non-squamous NSCLC cases less than 5 years old from each of the centers will be        selected.|March 2016|March 7, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02304406||31930|
NCT02304419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15189|A Study of Galunisertib on the Immune System in Participants With Cancer|Phase 1 Study to Determine the Immunomodulatory Activity of LY2157299 Monohydrate in Patients With Solid Tumors||Eli Lilly and Company|No|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304419||31929|
NCT02295735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PU-A-16|Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention|A Randomized Controlled Parallel-group Trial to Investigate the Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention Compared to no Dressings||Charite University, Berlin, Germany|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|464|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02295735||32596|
NCT02351492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221/13|Radiological Investigation of Bile Duct Obstruction|Diagnostic Pathway for Surgical Patients With Suspected Bile Duct Obstruction|RIBO|University Hospital, Basel, Switzerland|No|Recruiting|May 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02351492||28320|
NCT02354235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-2412-J03|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin)||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|75 Years|No|||January 2016|January 24, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354235||28110|
NCT02298452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 2013-0144|Performance of a Hearing Aid Platform Including Different Styles of Hearing Aids|Structured Post Market Clinical Follow-up (PMCF) to Evaluate the Quality of a New Hearing Aid Product Generation.||Phonak AG, Switzerland|No|Recruiting|May 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|382|||Both|18 Years|90 Years|No|||February 2015|February 26, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298452||32388|
NCT02304744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/183|Utrecht Coronary Biobank (UCORBIO)|Utrecht Coronary Biobank (UCORBIO)|UCORBIO|UMC Utrecht|No|Active, not recruiting|October 2011|December 2019|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Whole blood and EDTA plasma.|Both|18 Years|N/A|No|Non-Probability Sample|All adult (>18 years) patients who undergo coronary angiography.|March 2015|March 5, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304744||31904|
NCT02304757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SanghaiXinhua|99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density|Randomized Trial of 99Tc-MDP and Alendronate Sodium in Postmenopausal Women With Differentiated Thyroid Cancer and Decrease in Bone Mineral Density Treated With Supraphysiological Doses of Thyroid Hormone||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|206|||Female|N/A|N/A|No|||November 2015|November 16, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304757||31903|
NCT02351505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14136|Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer|An Investigator-Sponsored Phase 2 Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|May 2015|||May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351505||28319|
NCT02354469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00016469|The Effects of Head Trauma on Collegiate Athletes|The Effects of Head Trauma on Biological Markers and Neurologic Function in Collegiate Athletes: a Prospective Investigation||Children's Hospital Boston|No|Recruiting|August 2015|August 2020|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|250|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be comprised of active members of various varsity teams at Harvard        University.|January 2016|January 26, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354469||28092|
NCT02354482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3048112229|Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence|Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence|ACHIEVE|University of Kentucky|No|Enrolling by invitation|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|19000|||Both|18 Years|N/A|No|Probability Sample|Project ACHIEVE will focus on Medicare fee-for-services beneficiaries and study diverse        high risk patient populations, including those with: 1) multiple chronic conditions; 2)        mental health issues; 3) rural area domicile; 4) limited English proficiency or low health        literacy; 5) low socioeconomic status; 6) Medicare and Medicaid dual eligible; 7) disabled        and younger than 65.|July 2015|July 31, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354482||28091|
NCT02302703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fodmap1-HMO-CTIL|Low FODMAP (Fermentable Oligo-,di-,Mono-saccharides and Polyols) Versus Gluten-free Diet in Pediatric IBS Patients; a Cross-over Randomized Trial.|Low FODMAP (Fermentable Oligo-,di-,Mono-saccharides and Polyols) Versus Gluten-free Diet in Pediatric IBS Patients; a Cross-over Randomized Trial.||Hadassah Medical Organization|Yes|Recruiting|May 2015|January 2017||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|18 Years|No|||November 2014|March 2, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302703||32061|
NCT02302716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15615|A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus|A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study|ELEMENT 5|Eli Lilly and Company|No|Active, not recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|492|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302716||32060|
NCT02301442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULimerick|Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis|A Randomised Controlled Trial of an Exercise Plus Behaviour Change Intervention in People With MS: the "Step it Up" Study Protocol||University of Limerick|No|Recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02301442||32158|
NCT02351700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14BN090|Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors|Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|February 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|79 Years|No|||March 2016|March 4, 2016|January 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351700||28304|
NCT02351713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternSCU|Comparison of Exercise Intensity Prescription|Is a Threshold-Based Model a Superior Method to the Relative Percent Concept for Establishing Individual Exercise Intensity? A Randomized Controlled Trial||Western State Colorado University|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02351713||28303|
NCT02354898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA101003|A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma|A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma||Sumitomo Dainippon Pharma Co., Ltd.||Recruiting|March 2015|||March 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|N/A|No|||May 2015|September 3, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02354898||28059|
NCT02354911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV-0100-101|Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes||DiaVacs, Inc.|Yes|Not yet recruiting|October 2015|January 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|12 Years|35 Years|No|||January 2015|February 2, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354911||28058|
NCT02354924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000601M|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2013|||||N/A|N/A|N/A||||||||||||||January 30, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354924||28057|
NCT02298946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150021|AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer|A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|99 Years|No|||October 2015|December 5, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02298946||32350|
NCT02305498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-059|Yoga Practice for Breast or Ovarian Cancer Patients|Yoga Practice for Breast or Ovarian Cancer Patients: A Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02305498||31846|
NCT02359955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201395|Comparison of Masticatory Efficiency Between Complete Denture With Zero-degree Teeth and Anatomic Teeth in Patients With Severely Resorbed Ridge|Comparison of Masticatory Efficiency and EMG Activity Between Complete Denture With Zero-degree Teeth and Anatomic Teeth in Patients With Severely Resorbed Ridge||Shanghai 9th People's Hospital||Active, not recruiting|June 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||May 2015|May 1, 2015|January 23, 2015||No||No|March 7, 2015|https://clinicaltrials.gov/show/NCT02359955||27672|
NCT02359968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTECT-1402|PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer|PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial|PROTECT|Centre Oscar Lambret|Yes|Recruiting|January 2015|October 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02359968||27671|
NCT02354937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201480|Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment|A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Severe Renal Impairment and Healthy Matched Control Subjects||ViiV Healthcare|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|70 Years|No|||October 2015|October 1, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354937||28056|
NCT02354950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201479|A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers|A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects||ViiV Healthcare|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354950||28055|
NCT02293967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E11|Mass Balance Study of MT-1303|An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.||Mitsubishi Tanabe Pharma Corporation||Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293967||32732|
NCT02300896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/2014|Functional and Cognitive Impairment Prevention for Elderly Hospitalized Patients|Functional and Cognitive Impairment Prevention Through Early Physical Activity for Elderly Hospitalized Patients: a Randomized Clinical Trial||Fundacion Miguel Servet|No|Recruiting|March 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|370|||Both|74 Years|N/A|No|||March 2015|March 5, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02300896||32200|
NCT02355847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029701|Cultural Competency, Risk Management, and Patient Safety Internet-Based Curriculum for OB/GYN Resident Physicians|Cultural Competency, Risk Management, and Patient Safety Internet-Based Curriculum for OB/GYN Resident Physicians and Adverse Patient Events|PROM|Ohio State University|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 30, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02355847||27986|
NCT02357069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ECCL002|A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate Similarity of Efficacy and Safety of LBEC0101 50mg Subcutaneous Weekly Injection to Enbrel® 50mg Subcutaneous Weekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX||LG Life Sciences||Active, not recruiting|February 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|372|||Both|20 Years|75 Years|No|||January 2016|January 5, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357069||27892|
NCT02357147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-009-201|Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma.|ARTEMIS|Morphotek|Yes|Recruiting|November 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357147||27886|
NCT02304237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICTORIA|Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women|A Multicenter, Randomized, Open-label, Investigator Initiated Trial of Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women||Ewha Womans University Mokdong Hospital|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Female|20 Years|N/A|No|||November 2014|November 26, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304237||31943|
NCT02304432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH105732|Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine|Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine|DCS|Mclean Hospital|Yes|Enrolling by invitation|January 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|33 Years|62 Years|No|||November 2015|November 9, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304432||31928|
NCT02293759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mans-2014-04|Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency|Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency||Mansoura University|No|Recruiting|October 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|50 Years|N/A|No|||September 2015|September 25, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293759||32748|
NCT02356471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 02114|Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery|Pilot Study of a Consumer-Based Activity Monitor (Fitbit Zip) in Evaluating Perioperative Activity of Older Adults Undergoing Major Oncologic Surgery||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|March 2015|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|38|||Both|60 Years|90 Years|No|||September 2015|September 22, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02356471||27938|
NCT02357810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 14S03|Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas|A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas||Northwestern University|Yes|Recruiting|February 2015|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|136|||Both|18 Years|N/A|No|||October 2015|February 26, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357810||27836|
NCT02304445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ2014022|Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer|Trans-Arterial Chemo-Embolization (TACE) Vs. TACE Plus Stereotactic Body Radiosurgery (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)|TACE-SBRT|Midwestern Regional Medical Center|No|Withdrawn|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||November 2015|November 25, 2015|November 26, 2014||No|Necessary equipment could not be obtained.|No||https://clinicaltrials.gov/show/NCT02304445||31927|
NCT02304458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01222|Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas|A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab||National Cancer Institute (NCI)|Yes|Recruiting|February 2015|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|242|||Both|12 Months|30 Years|No|||February 2016|March 21, 2016|November 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02304458||31926|
NCT02304692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C49|Clinical Survey of Different Abutment Topologies|C49:Clinical Survey of Different Abutment Topologies Installed With a Minimally Invasive Surgery for Bone Anchored Hearing Systems||Oticon Medical|No|Active, not recruiting|October 2014|October 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02304692||31908|
NCT02305303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K131202|Diary for Severe Trauma|Impact of an Intensive Care Unit Diary on Long-term Quality of Life After Severe Trauma|Qualitrau|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|January 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|226|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02305303||31861|
NCT02357576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00075458|Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD|Phase 3 Study of Standard Lipid Therapy Versus Intravenous Fat Emulsion Minimization for the Prevention of Parenteral Nutrition-Associated Liver Disease||University of Michigan|Yes|Recruiting|November 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|1 Year|No|||November 2015|November 23, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357576||27854|
NCT02357225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200154|A Pilot Study of Pyridostigmine in Pompe Disease|Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease||University of Florida|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|8 Years|60 Years|No|||September 2015|September 15, 2015|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02357225||27880|
NCT02357238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-087|Genetics of Uveitis|Genetics of Uveitis||The Cleveland Clinic|No|Recruiting|January 2011|||January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Whole blood serum will be collected|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Any patient able to sign an informed consent or child of age 6 with parental /guardian        consent with the diagnosis of uveitis or infectious uveitis.|March 2016|March 14, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357238|10 Years|27879|
NCT02302768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELENIO 2012|Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT|Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.||University of Siena|No|Active, not recruiting|December 2012|January 2015|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02302768||32056|
NCT02302846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0379|Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission|Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302846||32050|
NCT02294279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR01013|The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms|The Evaluation of FeNO for Predicting Response to an Inhaled Corticosteroid in Subjects With Non-specific Respiratory Symptoms|NSRS|Research in Real-Life Ltd|No|Not yet recruiting|December 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|80 Years|No|||November 2014|November 18, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294279||32708|
NCT02343692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0427|A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas|A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas (RADIOCYST01)|RADIOCYST01|University College, London|No|Not yet recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02343692||28916|
NCT02343705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-0001|Evaluation of the Latella Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-2 Study)|Evaluation of the Latella Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-2 Study)||Cotera, Inc.|No|Enrolling by invitation|January 2015|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|30 Years|70 Years|No|||September 2015|December 30, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343705||28915|
NCT02358005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0925|Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity|||Yonsei University|No|Not yet recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|N/A|No|||February 2015|February 2, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02358005||27822|
NCT02358018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-226|68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial|68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial||Memorial Sloan Kettering Cancer Center||Available||||||N/A|Expanded Access|N/A|||||||Both|5 Years|N/A||||January 2016|January 7, 2016|February 3, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02358018||27821|
NCT02298127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AASC101114|Auricular Acupressure for Smoking Cessation|Acceptability and Potential Efficacy of a Randomised, Double-blinded, Sham-controlled Trial of Auricular Acupressure for Smoking Cessation: A Pilot Study||The Hong Kong Polytechnic University|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02298127||32413|
NCT02304510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEKU-BJ-2014|Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing|Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing||Peking University|No|Recruiting|November 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2800|||Female|18 Years|50 Years|No|Probability Sample|residents of Beijing|December 2014|December 2, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304510||31922|
NCT02304523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-BCS-CDFR0612/0613_3|Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy|A Prospective, Randomized, Single-blinded (Evaluator), 3-treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of CDFR0612 and CDFR0613||CTC Bio, Inc.|No|Completed|January 2015|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|310|||Both|19 Years|N/A|No|||September 2015|September 10, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304523||31921|
NCT02356146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB225/56|First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction|First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction||Chulalongkorn University|No|Recruiting|January 2012|June 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Blood level for tacrolimus was took 12 hours after first dose.|Both|15 Years|N/A|No|Non-Probability Sample|All KT recipient who transplanted and will be transplanted in King Chulalongkorn Memorial        Hospital from 2012-2015|February 2015|February 1, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356146||27963|
NCT02293109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#246|Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma|Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma||University of California, Davis|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|64 Years|No|||January 2016|January 22, 2016|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293109||32798|
NCT02298205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO201410095|Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children|Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children|ASIST|Washington University School of Medicine|Yes|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|6 Years|17 Years|No|||December 2015|December 7, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298205||32407|
NCT02347371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSZR - 001|Heart Transplant Registry of Városmajor|Follow-up Registry of Heart Transplant Recipients, to Determine Long Term Outcome and Need for Further Interventional and Non-interventional Procedures||Semmelweis University Heart and Vascular Center|No|Recruiting|January 2015|December 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood samples|Both|18 Years|80 Years|No|Non-Probability Sample|Heart transplant recipient, cared for by the Semmelweis University Heart and Vascular        Center|July 2015|July 28, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347371|5 Years|28635|
NCT02352532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10586012|Using Structural Health Monitoring to Improve Diagnosis and Treatment of Low Back Injury in U.S. Service Members- Phase 2|Using Structural Health Monitoring to Improve Diagnosis and Treatment of Low Back Injury in U.S. Service Members- Phase 2|SWE/DN|Baylor University|No|Recruiting|January 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352532||28241|
NCT02345395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSPALPEBRAL USP|Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms|Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms|MININCRUSP|University of Sao Paulo General Hospital|No|Recruiting|September 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||January 2014|January 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345395||28787|
NCT02345408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL002_872|Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma|An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma||ChemoCentryx|No|Recruiting|February 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02345408||28786|
NCT02293408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGLU-NH02|Natural History Study to Characterise the Course of Disease Progression in Patients With Mucopolysaccharidosis Type IIIB|A Prospective Cross-Sectional and Longitudinal Study With Additional Retrospective Chart Review to Evaluate Clinical and Biochemical Characteristics and Disease Progression in Patients With Mucopolysaccharidosis Type IIIB||Alexion Pharmaceuticals|No|Active, not recruiting|September 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Clinical laboratory tests, including heparan sulfate and exploratory disease biomarkers from      serum and urine.|Both|1 Year|N/A|No|Non-Probability Sample|30 patients with MPS IIIB.        Component 1 - 30 patients - The patient has a definitive diagnosis of MPS IIIB.        Component 2 - 15 patients from Component 1, considered to be at risk of rapid disease        progression.|October 2015|October 3, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02293408||32775|
NCT02294045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120242|Analysis of Joint Sounds in the Diagnosis of Knee Disorders|Analysis of Joint Sounds in the Diagnosis of Knee Disorders|Joint Sounds|Loma Linda University|Yes|Not yet recruiting|July 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Male or female english-speaking from the ages of 18 thru 70|July 2015|July 22, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02294045||32726|
NCT02343666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2673.00|HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection|A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|March 2016|||August 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|66 Years|No|||December 2015|December 1, 2015|December 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02343666||28918|
NCT02343679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056623|Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies|A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies||Duke University|No|Recruiting|May 2015|October 2022|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343679||28917|
NCT02345057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS3150-B-J204|A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria||Daiichi Sankyo Inc.|Yes|Active, not recruiting|January 2015|March 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|325|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345057||28813|
NCT02345070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI11772|Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis|Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study|ESTAIR|Sanofi|Yes|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|40 Years|N/A|No|||March 2016|March 15, 2016|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345070||28812|
NCT02293694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631917-1|Sayana® Press Self-injection Study in Malawi|A 12-month Open-label Randomized Controlled Trial to Evaluate Sayana® Press Suitability for at Home Subcutaneous Self-injection Procedures in Adult Women||FHI 360|No|Recruiting|June 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|734|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293694||32753|
NCT02298777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5723|Metabolomic Analysis of Systemic Sclerosis|Metabolomic Analysis of Systemic Sclerosis|SCLEROMICS|University Hospital, Strasbourg, France|No|Active, not recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with systemic sclerosis (SSc),|November 2014|November 19, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02298777||32363|
NCT02348177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiHIVPed001|Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB|A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.||Drugs for Neglected Diseases|Yes|Recruiting|January 2013|May 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|N/A|No|||January 2015|January 22, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02348177||28574|
NCT02345889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412036333|A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy|A 4-arm Randomized Controlled Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy||Indiana University|No|Enrolling by invitation|February 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|4||Anticipated|1600|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345889||28749|
NCT02302404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200975|A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects|A Single-centre, Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects||GlaxoSmithKline|No|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|76|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02302404||32084|
NCT02302690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIG-COL-01|Immunity Against AAV in Crigler Najjar Patient|Study of the Prevalence of Pre-existing Immunity Against the Adeno-associated Virus (AAV) in Patients With Crigler-Najjar Syndrome||Genethon|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Crigler Najjar syndrome|February 2016|February 15, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302690||32062|
NCT02293174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCON-003-2014|Retinal Fundus Camera Evaluation|TRC-NW400 Retinal Fundus Camera Image Evaluation and Instrument Comparison Protocol||Topcon Medical Systems, Inc.|No|Completed|September 2014|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Normal subjects will be recruited from Topcon Medical Systems.|November 2015|November 30, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02293174||32793|
NCT02293187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2710|Impact of Vitamin D on 25-hydroxyvitamin D Levels and Physical Function|The Impact of Supplemental Vitamin D on Serum 25-hydroxyvitamin D Levels and Short Term Indicators of Physical Function||Tufts University|No|Recruiting|January 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02293187||32792|
NCT02346812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS49|Brassica Intake and Isothiocyanate Absorption|Brassica Intake and Isothiocyanate Absorption: Intake Patterns May Have Implications for Cancer Prevention by Dietary Brassica Vegetables||USDA Beltsville Human Nutrition Research Center|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|18|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||January 2015|April 29, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02346812||28678|
NCT02348827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-044|Family Psychoeducation to Reduce the Risk of New Depressive Episodes|Family Psychoeducation to Reduce the Risk of New Depressive Episodes - A Randomized Controlled Trial||Mental Health Services in the Capital Region, Denmark|No|Recruiting|January 2015|September 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|April 9, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02348827||28524|
NCT02348840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076231|Perinatal mHealth Intervention in Guatemala|Mobile Health Intervention to Improve Perinatal Continuum of Care in Guatemala||Emory University|No|Recruiting|January 2015|December 2020|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|1050|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02348840||28523|
NCT02348853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13035001|Healthy Families Healthy Forces Study|Intervention for Sustainable Weight Loss in Military Families|HF2|Tufts University|Yes|Recruiting|January 2015|April 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|580|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|March 11, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02348853||28522|
NCT02297347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015326|PKU Kuvan Imaging Study|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria||Children's Hospital Boston|No|Recruiting|April 2015|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with PKU on Kuvan treatment for at least one month prior to enrolling in the study.|February 2016|February 2, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297347||32473|
NCT02302482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.868|Predictive Factors and Autonomy Level Change|Predictive Factors of the Autonomy Level Change Related to Memory Disorders|MEMORA|Hospices Civils de Lyon|No|Recruiting|November 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2200|||Both|65 Years|N/A|No|||October 2015|October 2, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02302482||32078|
NCT02302495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_32|Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma|A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma|IFM2012-03|University Hospital, Lille|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|65 Years|N/A|No|||December 2015|December 3, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02302495||32077|
NCT02356107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5HTP/Creatine|5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females|5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females||University of Utah|No|Recruiting|April 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356107||27966|
NCT02349620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Effect of Platelet-rich Factor on Implant Stability and Bone Resorption in the Lower Posterior Mandible|Platelet-rich Factot in Implant Dentistry||Shiraz University of Medical Sciences|Yes|Recruiting|September 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|October 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349620||28463|
NCT02349633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7971001|Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)|Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 or L858R ± t790M) Non‑Small Cell Lung Cancer||Pfizer|No|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349633||28462|
NCT02352597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222|Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS|Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome|PCOS|Cairo University|Yes|Completed|January 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Female|20 Years|37 Years|No|||January 2015|January 30, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02352597||28236|
NCT02352831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503074|Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma|Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma||Washington University School of Medicine|No|Recruiting|August 2015|April 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352831||28218|
NCT02295254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1543-ES-CTIL|Microbiome Changes in Travelers to Tropical Destinations|Microbiome Changes in Travelers to Tropical Destinations||Sheba Medical Center|No|Recruiting|September 2014|January 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Travelers who intended to travel to tropical areas.|November 2014|November 17, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02295254||32633|
NCT02299752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gloves/2014/01|Unnoticed Gloves Perforation|Double Gloves: A Randomized Trial to Evaluate a Simple Strategy to Reduce Contamination During Resuscitation||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02299752||32288|
NCT02352454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM003 Gold|Effectiveness of Aurix Therapy in Venous Leg Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Venous Leg Ulcers||Nuo Therapeutics|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352454||28247|
NCT02345330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS-I130|Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)|A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck||OncoSec Medical Incorporated|No|Active, not recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345330||28792|
NCT02359513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408170|Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.|Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359513||27706|
NCT02300584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074715|Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program|Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program||Emory University|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|21 Years|N/A|No|||October 2015|October 18, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300584||32224|
NCT02300870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWHMG370000|Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection|Myocardial Perfusion Echocardiography to Detect Human Heart Transplant||Brigham and Women's Hospital|Yes|Not yet recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Heart Transplant patients|November 2014|November 21, 2014|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300870||32202|
NCT02357342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKM008|Sirolimus Versus AntiVEGF for Wet AMD|Sirolimus Versus AntiVEGF for Wet AMD||Maturi, Raj K., M.D., P.C.|No|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357342||27871|
NCT02356978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140202|New Phototherapy Device to Treat Patients With Crigler-Najjar Disease|Trial of a New Phototherapy Device for Treating Hyperbilirubinemia in Crigler-Najjar Patients : a New Concept|DRAP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|6 Years|No|||December 2014|February 5, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356978||27899|
NCT02354976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5881C00007|A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.|A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I||AstraZeneca|No|Active, not recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|40 Years|70 Years|No|||February 2016|February 29, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02354976||28053|
NCT02302781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47393.075.14|Why Subfertile Couples Drop Out|Why Subfertile Couples Drop Out|DOT|Isala|No|Recruiting|April 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Couples referred to one of the four participating hospitals with any type of subfertility        for work up and/ or treatment will be screened for inclusion. Couples have not visited any        other clinic yet.|February 2016|February 26, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302781|3 Years|32055|
NCT02309944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013NTLS073|Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients|Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients: A Randomized Controlled Trial||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309944||31506|
NCT02344784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaEmekMC|The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder|The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.|PPI|HaEmek Medical Center, Israel|No|Enrolling by invitation|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|7 Years|18 Years|No|Non-Probability Sample|Children and adolescents (age 7 to 17.11 years) who are diagnosed with attention deficit        hyperactivity disorder and are under the Medical surveillance of the mental health clinic        for children and adolescents at the HaEmek Medical Center- Afula.        Patients who meet the criteria for inclusion and exclusion will be offered to participate        in the study|January 2015|January 22, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344784||28834|
NCT02347124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-047-E|Oral Health Randomized Trial|Promoting Oral Health Among Tobacco Quitline Callers||Group Health Cooperative|Yes|Enrolling by invitation|February 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|712|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02347124||28654|
NCT02308553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nipawilma_2013|Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma|Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma|NIPAWILMA|University Hospital, Essen|No|Recruiting|January 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308553||31612|
NCT02358590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-026|The Effect of Theory Menu-Based Intervention on Vitamin D Adherence in People With Osteoporosis-Pilot Study|The Effect of Health Action Process Approach Menu-Based Intervention on Vitamin D Adherence in Older Adult With Osteoporosis-Pilot Study||McMaster University|Yes|Enrolling by invitation|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|50 Years|N/A|No|||September 2015|September 22, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02358590||27777|
NCT02343991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBB001|Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound|A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin||InSightec|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||March 2015|March 6, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02343991||28894|
NCT02349334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34825|UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence|CONtrol of Faecal Incontinence Using Distal NeuromodulaTion (CONFIDeNT)|CONFIDeNT|Queen Mary University of London|Yes|Completed|January 2012|September 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349334||28485|
NCT02359487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6031|Behavioral Counseling Intervention Trial to Reduce Alcohol-related Sexual Risk Behavior Among HIV-negative Men in Namibia|Behavioral Counseling Intervention Trial to Reduce Alcohol-related Sexual Risk Behavior Among HIV-negative Men in Namibia||Centers for Disease Control and Prevention|No|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|550|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 6, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02359487||27708|
NCT02355548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018558|Outpatient Treatment of Low-risk Pulmonary Embolism|Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism|Low Risk PE|Intermountain Health Care, Inc.|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The subject population is drawn from patients arriving in the Emergency Department who are        then diagnosed with a lower risk pulmonary embolism (PESI score <86).|August 2015|August 24, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02355548||28009|
NCT02349581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-036|Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery|Ultrasound Guided Pectoral Nerves (Pecs) Blockade in Persistent Pain After Breast Cancer Surgery|PPBCS|Rigshospitalet, Denmark|Yes|Recruiting|November 2014|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|6|||Female|18 Years|N/A|No|||January 2015|January 23, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349581||28466|
NCT02348892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0343|Evaluation Program of the Benefit of the Coordination of the Course of the Elderly Patient in Health Establishment - Pilot Study.|Evaluation Program of the Benefit of the Coordination of the Course of the Elderly Patient in Health Establishment - Pilot Study.|PROCOPES|Nantes University Hospital|No|Recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|70 Years|N/A|No|Probability Sample|The eligible patients for the study will be the patients of 70 and more years old        hospitalized in the Nantes UH in the acute care medical department internal medical        departement medical urgency, rehabilitation unit, neurology, gastro-enterology of the CHU        of Nantes and which are in complex medical and social situation, whoever is their motive        for hospitalization.|January 2015|January 22, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02348892||28519|
NCT02304029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-27|Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy|Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy|EPISODIUM|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|March 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02304029||31959|
NCT02309203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 14.295|Canadian Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms|Canadian Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms - The CanFRED Trial|CanFRED|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Withdrawn||September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|December 3, 2014||No|Study not initiated at our site.|No||https://clinicaltrials.gov/show/NCT02309203||31563|
NCT02344979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShenyangSunshine|The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC|The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy||Shenyang Sunshine Pharmaceutical Co., LTD.|No|Active, not recruiting|May 2009|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120||Randomized, open label, controlled, parallel, multi-center Study|Both|18 Years|N/A|No|Probability Sample|Patients with NSCLC for whom treatment with gemcitabine and cisplatin or carboplatin,and        Platele counts ≤ 50×109/L during Screening chemo cycle|January 2015|January 22, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02344979||28819|
NCT02346110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtokolSB1|Protracted Effect of the Ultrasound-guided Saphenous Block|Comparison of the Effect of a Single Shot Saphenous Block With Plain Bupivacaine vs. Protracted Bupivacaine Mixture as a Supplement to Continuous Sciatic Catheter After Major Ankle and Foot Surgery|PEUSB|University of Aarhus|Yes|Completed|April 2015|February 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|80 Years|No|||October 2015|February 11, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346110||28732|
NCT02359552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-519|Rasagiline Rescue in Alzheimer's Disease Clinical Trial|A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Effect of Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease|R2|The Cleveland Clinic|No|Recruiting|May 2015|March 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|90 Years|No|||October 2015|October 22, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359552||27703|
NCT02305446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_74|Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.|Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis||Novartis|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 20, 2014||No||No|October 1, 2015|https://clinicaltrials.gov/show/NCT02305446||31850|
NCT02294734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116678|An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Active, not recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||March 2016|March 17, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294734||32673|
NCT02351687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFU2014|Package of Interventions After Recovering From Moderate Acute Malnutrition|Randomized Controlled Trial of the Impact of Offering a Nutrition and Health Intervention to Children Recovered From Moderate Acute Malnutrition||Washington University School of Medicine|No|Active, not recruiting|April 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1499|||Both|6 Months|59 Months|No|||December 2015|December 17, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351687||28305|
NCT02351921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23423432|Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study|Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study||McMaster University|No|Not yet recruiting|February 2015|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02351921||28287|
NCT02351934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008292|Early Diuresis Following Colorectal Surgery|A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery||Mayo Clinic|No|Recruiting|January 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|286|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351934||28286|
NCT02349087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH507T010|EEG in Resuscitated In-hospital Patients|Integrating EEG Into Acute Medicine: EEG in Resuscitated In-hospital Patients||Kuopio University Hospital||Recruiting|December 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|In- hospital resuscitated patients, who are going to be treated in ICU after ROSC.        Patients with Do Not Attempt to Resuscitate -decision will not be included.|May 2015|August 31, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349087||28504|
NCT02349321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECO22-9|Skhokho Supporting Success: A Cluster RCT of a Multi-faceted, School-based IPV Prevention Intervention in South Africa|Skhokho Supporting Success: A Cluster Randomised Controlled Trial of a Multi-faceted, School-based Intimate Partner Violence Primary Prevention Intervention in Gauteng, South Africa||Medical Research Council, South Africa|No|Active, not recruiting|February 2013|May 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3192|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 23, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02349321||28486|
NCT02352337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE35|Cancer pancréatique métastatique 1ière Ligne : FOLFIRINOX +/- LV5FU2 en Entretien et le Firgem|Phase II randomisée Dans le Cancer pancréatique métastatique évaluant le FOLFIRINOX +/- LV5FU2 en Entretien et le Firgem en 1ière Ligne|PANOPTIMOX|Federation Francophone de Cancerologie Digestive|Yes|Recruiting|January 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|276|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02352337||28255|
NCT02295722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pending|Gem-HDM HDT and ASCT for Relapsed/Refractory Lymphoma|Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma|HDMgem|AHS Cancer Control Alberta|No|Not yet recruiting|November 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02295722||32597|
NCT02344004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-212|Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone|A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment|CONVERT|Insmed Incorporated|Yes|Recruiting|January 2015|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344004||28893|
NCT02354456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DicleU|Atrial Fibrillation in Turkey: Epidemiologic Registry-2|An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey|AFTER-2|Dicle University|No|Recruiting|January 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4100|||Both|18 Years|95 Years|No|Non-Probability Sample|nonvalvular atrial fibrillation|January 2016|January 20, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02354456|1 Year|28093|
NCT02344628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM-8832|Comparison of Two Different Doses of Azithromycin for Treatment of Yaws|Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin||London School of Hygiene and Tropical Medicine||Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Male|6 Years|16 Years|No|||March 2016|March 15, 2016|January 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344628||28846|
NCT02303314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P-9362-6352|Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease|||Shiraz University of Medical Sciences|Yes|Recruiting|November 2014|December 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303314||32014|
NCT02303327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS VI|Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients|Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)||Sir Mortimer B. Davis - Jewish General Hospital|No|Recruiting|January 2015|January 2029|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02303327||32013|
NCT02347592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHUmea01|Peritoneal Dialysis Catheter Function|Comparison of Self-locating Catheter Versus a Straight Catheter for Outflow Problems.||University Hospital, Umeå|No|Completed|November 2007|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02347592||28618|
NCT02354677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9244|Repair, Remodeling and Regeneration of the Bronchial Epithelium of COPD Patients||RRR|University Hospital, Montpellier|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 27, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02354677||28076|
NCT02302651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OO-MC-MRGFUS-002|Non-invasive Focal Therapy for Osteoid Osteoma|Treatment of Osteoid Osteoma With MR Guided High Intensity Focused Ultrasound||University of Roma La Sapienza|Yes|Recruiting|June 2010|December 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|80 Years|No|||November 2014|November 24, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02302651||32065|
NCT02302664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SC/1333|PATH-2: Platelet Rich Plasma in Achilles Tendon Healing|A Pragmatic Multi-centre Blinded Randomised Placebo-controlled Trial Comparing Platelet Rich Plasma Injection (PRP) to Placebo (Imitation) Injection in Adults With Achilles Tendon Rupture|PATH-2|University of Oxford|Yes|Not yet recruiting|April 2015|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|214|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02302664||32064|
NCT02293148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113635|Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers|A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|April 23, 2015|November 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293148||32795|
NCT02293161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902|Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers|A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02293161||32794|
NCT02349048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105963|Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection|A Phase 2, Randomized, Open-label Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 6 or 8 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|ACCORDION-1|Janssen Research & Development, LLC|Yes|Recruiting|January 2015|May 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 11, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349048||28507|
NCT02350413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOCA1415|Multicenter Italian Validation of EHP-30|Multicenter Italian Validation of EHP-30 at Centres Located in the Territory||University of Cagliari|No|Recruiting|May 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women referred to five Obstetrics and Gynecological Department for the treatment of        endometriosis.|November 2015|November 22, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02350413|3 Months|28403|
NCT02350426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201659|A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques|An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques||GlaxoSmithKline|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|30 Years|85 Years|No|||August 2015|August 20, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02350426||28402|
NCT02294747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/475/REK SO B|Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA|Trochanteric Hip Fractures (AO A2) Treated With Sliding Hip Screw With or Without Trochanteric Stabilizing Plate - a Randomized Controlled Trial Using Radiostereometry.||Oslo University Hospital|No|Recruiting|November 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||October 2015|October 14, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294747||32672|
NCT02354209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 057|Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy|Targeted Clinical Strategies and Low Abundance HIV Viraemia in Boosted-PI Therapy: an Observational Study||St Stephens Aids Trust|No|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|Plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|Current HIV clinic attendee at the Chelsea and Westminster Hospital, St Mary's Hospital,        and Guy's and St Thomas' Hospital [defined as at least 1 attended clinic visit since        January 2010] receiving a boosted protease inhibitor-containing antiretroviral regimen        (bPI ARV)|October 2015|October 9, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354209||28112|
NCT02359448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0382|Melatonin for Nocturia in Parkinson's Disease|Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease||University College, London|Yes|Not yet recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359448||27711|
NCT02303639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7U/2014|Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias|Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study.|MANTRA-VT|Central Finland Hospital District|Yes|Not yet recruiting|December 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2014|November 28, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303639||31989|
NCT02348502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY003|Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment|Sustained Viral Response and HBsAg Level Changes in Chronic Hepatitis B Patients Who Achieved HBsAg Level≤100 IU/ml After Completed Interferon Therapy||Beijing Ditan Hospital|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|N/A|N/A|No|Non-Probability Sample|the study population in this study were composed of patients who had chronic hepatitis B        and achieved HBsAg level≤100 IU/ml with undetectable HBV DNA level after interferon        treatment, and serum HBsAg and HBV DNA would be tested every 3 months for 96 weeks after        finished treatment. Sustained viral response defined as serum HBV DNA maintaining        undetectable during the observation period. HBsAg loss is defined as HBsAg level reached        the value lower than the low limited value.|January 2015|January 27, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348502||28549|
NCT02356809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAT|Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon|Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma||Human Stem Cell Institute, Russia||Not yet recruiting|March 2015|August 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2015|February 2, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02356809||27912|
NCT02348645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6927-B|Decompression vs. Fusion for Stable Degenerative Spondylolisthesis|Decompression Alone vs. Decompression and Instrumented Fusion for the Management of Lumbar Spinal Stenosis Associated With Stable Degenerative Spondylolisthesis: A Pragmatic Randomized Clinical Pilot Trial||University Health Network, Toronto|No|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|50 Years|N/A|No|||February 2016|February 9, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02348645||28538|
NCT02308592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Patient Decision Aid for Antidepressant Use in Pregnancy|Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy||Women's College Hospital|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308592||31609|
NCT02352467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM004 Gold|Effectiveness of Aurix Therapy in Pressure Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers||Nuo Therapeutics|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352467||28246|
NCT02352480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM002 Gold|Effectiveness of Aurix Therapy in Diabetic Foot Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers||Nuo Therapeutics|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|760|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352480||28245|
NCT02356861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1768-P|LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans|LED Light Therapy to Improve Cognitive/Psychosocial Function in TBI-PTSD Veterans||VA Office of Research and Development|No|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|No|||January 2016|January 20, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356861||27908|
NCT02305316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-120|Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone|Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|November 28, 2014||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02305316||31860|
NCT02305329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-121|Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation|Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation in Healthy Subjects||Bial - Portela C S.A.|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|November 28, 2014||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02305329||31859|
NCT02298179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V122_01|To Evaluate the Safety and Ability of the Medicine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults|A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults||Novartis|Yes|Recruiting|December 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|12||Anticipated|288|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298179||32409|
NCT02298192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4056|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms|DUAL™ VI|Novo Nordisk A/S|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298192||32408|
NCT02353520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELIBILITY OF MOTRICITY INDEX|"Reliability of Motricity Index Strength Assessments for Upper Extremity in Post Stroke Hemiparesis- a Correlation Study''|"Reliability of Motricity Index Strength Assessments for Upper Extremity in Post Stroke Hemiparesis- a Correlation Study''||Maharishi Markendeswar University|No|Completed|June 2013|July 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Both|37 Years|76 Years|No|Probability Sample|stroke patients of both sex|January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353520||28165|
NCT02357927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StAMedSchoolSEC|A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients|A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients (The Mini AFTERc): A Controlled Trial|Mini-AFTER|University of St Andrews|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Female|18 Years|80 Years|No|||January 2016|January 19, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357927||27828|
NCT02356432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14R-155|Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)|Cerebral Microbleeds as Predictor of Future Intra-Cerebral Hemorrhage During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)|CMB-NOW|Tokai University|Yes|Recruiting|March 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients with NVAF, who had at least one CMB at the time of entry into this study, and        were prescribed a NOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) or warfarin for        secondary prevention of cerebral infarction or transient ischemic attack within 2 weeks        after the onset. This study is an observational study, and the numbers of patients in the        NOACs and warfarin groups were not predetermined, though the total number of patients for        the study was limited to 200 for practical reasons.|March 2016|March 8, 2016|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356432|1 Year|27941|
NCT02344836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034960|The Social Pounds Off Digitally (Social POD) Study|Refining and Pilot Testing Social Networks for Encouraging Healthy Behaviors: The Social Pounds Off Digitally (Social POD) Study|SocialPOD|University of South Carolina|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344836||28830|
NCT02344849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellgram-ED|Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction|An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.||Pharmicell Co., Ltd.|No|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|20 Years|N/A|No|||August 2015|August 6, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344849||28829|
NCT02298972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201422086|Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer|Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02298972||32348|
NCT02299466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0845-AE|Registry for Patients Receiving Intravenous Nutrition at Home|Home Total Parenteral Nutrition (HTPN) in Canada: A New Website Based Patient Registry|HTPN|University Health Network, Toronto|No|Recruiting|December 2003|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving home total parenteral nutrition (HTPN)|November 2014|November 19, 2014|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02299466|10 Years|32310|
NCT02354794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRMA13-1|Effect of Arginine Supplementation in the Metabolic Syndrome|Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.||Institut National de la Recherche Agronomique|No|Completed|February 2014|September 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02354794||28067|
NCT02354807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU_OVPR1|Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults|Efficacy of Pharmacological Stimulation of Brown and White Fat in Lean and Obese Young Adults|MiraBAT|Wayne State University|Yes|Not yet recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354807||28066|
NCT02356744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126|Maternal and Neonatal Outcome in Pregnant Women Before and After 1 Year Since Bariatric Operation|Comparison of Maternal and Neonatal Outcome Before and After 1 Year of Bariatric Surgery||Cairo University|Yes|Not yet recruiting|February 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|18 Years|39 Years|No|Non-Probability Sample|Pregnant women in third trimester after laparoscopic adjustable gastric banding done        within last 1 year or earlier|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356744||27917|
NCT02356757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-009|Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy|Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy|PATRIOT|VA Office of Research and Development|No|Recruiting|August 2015|January 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|404|||Both|21 Years|N/A|No|||January 2016|January 21, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356757||27916|
NCT02344394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRHACA Study|Prospective, Randomized Comparison of Hybrid Ablation vs. Catheter Ablation (PRHACA)|Prospective, Randomized Comparison of Hybrid Ablation vs. Catheter Ablation (PRHACA)|PRHACA|Aurora Health Care|No|Recruiting|September 2014|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|264|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344394||28864|
NCT02309034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140485|Aquatic and Land Physical Training Effects on Cardiometabolic Risk Factors in Adolescents With Overweight and Obesity|Aquatic and Land Physical Training Effects on Cardiometabolic Risk Factors in Adolescents With Overweight and Obesity: a Randomized Controlled Clinical Trial.||Hospital de Clinicas de Porto Alegre|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309034||31576|
NCT02309073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-109|PC Protocol: Preconceptional Screening|PC Protocol: Preconceptional Screening Part 2|PC|UMC Utrecht|No|Recruiting|November 2013|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood will be drawn for later determination of various parameters. DNA will also be      extracted.|Female|18 Years|45 Years|No|Probability Sample|In the present proposal we are aiming to include all normo-ovulatory women with a regular        indication for ART.|June 2015|June 3, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02309073|3 Years|31573|
NCT02309086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-AdNS3|Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C|Phase I-II Vaccination Clinical Trial in Patients With Chronic Hepatitis C by Administration of Autologous Dendritic Cells Transduced With an Adenoviral Vector Encoding NS3 Protein||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|May 2011|May 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||May 2015|July 16, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02309086||31572|
NCT02352493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-CC5-001|A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH|A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria||Alnylam Pharmaceuticals|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02352493||28244|
NCT02352506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1680/2014|Serum MIF in Acute Kidney Injury|Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury||Medical University of Vienna||Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Non-Probability Sample|Critical care patients|September 2015|September 28, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352506||28243|
NCT02345616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0221|Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility|Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility|NOCaPH|University Hospital, Clermont-Ferrand||Recruiting|February 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02345616||28770|
NCT02345629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0833|Cordotomy for Refractory Cancer Pain|Minimally Invasive Cordotomy for Refractory Cancer Pain||M.D. Anderson Cancer Center|Yes|Recruiting|March 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02345629||28769|
NCT02302391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4546|Pharmacokinetic Analysis of Midazolam and Fentanyl in Pediatric Patients With Long-term Analgosedation|Pharmacokinetic Analysis of Midazolam and Fentanyl in Pediatric Patients With Long-term Analgosedation.|Morpheus|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|October 2014|December 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|17 Years|No|Probability Sample|Pediatric patients with long-term analgosedation at the Pediatric Intensive Care Unit of        the University Medical Center Hamburg-Eppendorf.|December 2015|December 4, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302391||32085|
NCT02302638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sage vs CSCM|Embryo Development Using Two Commercial Single-step Media|Embryo Development and Utilization Using Two Commercial Single-step Media||Eugonia|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302638||32066|
NCT02296008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Banasiuk2014 B|3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders|3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders||Medical University of Warsaw|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|40|||Both|12 Months|18 Years|No|||July 2015|July 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02296008||32575|
NCT02357290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002011|Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders|Open-Label Study of N-Acetylcysteine in Children and Adolescents Ages 5-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Recruiting|January 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|5 Years|17 Years|No|||February 2016|February 12, 2016|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02357290||27875|
NCT02345863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2-BIG|Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients|A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of B Followed by GA101 and I Followed by I and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia [CLL]||German CLL Study Group|No|Active, not recruiting|January 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2015|December 23, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02345863||28751|
NCT02295683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T124E2|Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry|Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - IBERIS - HTN Registry|Iberis|Terumo Europe N.V.|No|Recruiting|November 2014|December 2020|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with uncontrolled hypertension entitled to receive renal sympathetic denervation        treatment per routine hospital practice and according to relevant international, or        country specific guidelines|September 2015|September 2, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295683|5 Years|32600|
NCT02303132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48505.068.14|Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis|Ex Vivo Experiments to Evaluate the Role of Medication on the Colon Permeability in Microscopic Colitis||Maastricht University Medical Center|Yes|Recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303132||32028|
NCT02303236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-092-B|Biological Markers Predicting Exercise Capacity in CF-LVAD Patients.|Biological Markers Predicting Exercise Capacity in Heart Failure Patients Supported With a Continuous-flow Left Ventricular Assist Device.||Rigshospitalet, Denmark|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Blood samples in biological bank.|Both|18 Years|90 Years|No|Non-Probability Sample|Stable CF-LVAD patients.|October 2015|October 26, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303236||32020|
NCT02357992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0870|Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy|STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy||M.D. Anderson Cancer Center|No|Recruiting|April 2010|||April 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357992||27823|
NCT02356445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCincinnati|Use of Immunosuppressive Therapy for Sarcoidosis|Outcome of Use of Cytotoxic Drugs for Inflammatory Lung Diseases||University of Cincinnati|No|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|Samples Without DNA|serum in some cases|Both|15 Years|90 Years|No|Non-Probability Sample|All patients with sarcoidosis treated|December 2015|December 4, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02356445||27940|
NCT02356458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 36/13|Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma|Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.||Swiss Group for Clinical Cancer Research|No|Recruiting|August 2015|March 2021|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356458||27939|
NCT02357433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2015_R|Mortality Reduction in Septic Shock by Plasma Adsorption|Reduccion de la Mortalidad Mediante Plasma-Adsorción en Shock séptico (ROMPA)|ROMPA|Hospital Universitario San Juan de Alicante||Recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|190|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02357433||27864|
NCT02352064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00724-43|Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)|EVALUATION OF THE DIAGNOSTIC VALUE OF PET (18F-FDG) IN CHRONIC GRAFT VERSUS HOST DISEASE (cGVH)|TEP-GVH|University Hospital, Caen|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02352064||28276|
NCT02352077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-SCI/IGDB|NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair|Safety and Efficacy of NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair||Chinese Academy of Sciences|No|Active, not recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||January 2015|January 19, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02352077||28275|
NCT02303210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012FrL2612901|Evaluation of Frequency Lowering Technique|Evaluation of Frequency Lowering Technique||Phonak AG, Switzerland|No|Recruiting|May 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303210||32022|
NCT02346773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNottingham|Effects of Omega-3 Fatty Acids Supplementation on Brain and Behaviour in Healthy Children.|Effects of Omega-3 Fatty Acids Supplementation on Brain and Behaviour in Healthy Children.||University of Nottingham|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|40|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02346773||28681|
NCT02345343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-399|Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico|Early Post-Marketing Study of Eliquis (Apixaban), in Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE in Adults||Bristol-Myers Squibb|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The sentinel site for the CNFV in Mexico|January 2016|January 6, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02345343||28791|
NCT02345356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1HL123911|Pharmacogenetics of Warfarin in Caribbean Hispanics|A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics||University of Puerto Rico|No|Recruiting|December 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Buccal swabs|Both|21 Years|89 Years|No|Non-Probability Sample|Caribbean Hispanics (e.g., Puerto Ricans, Dominicans, Cubans), whose parents are Caribbean        Hispanics as well.|January 2016|January 16, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345356||28790|
NCT02348281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2015-17|Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients|A Prospective, Single Center, Phase II Study of Bicalutamide as A Treatment in Androgen Receptor (AR)-Positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients||Fudan University|Yes|Recruiting|January 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|18 Years|70 Years|No|||December 2015|December 24, 2015|January 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348281||28566|
NCT02348294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50794.068.14|The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus|Measurement of Cytokines, Bloodflow and Erythema Index After Pressure and Shear- Force Loading in Patients With Diabetes Mellitus Type 2||Maastricht University Medical Center|Yes|Not yet recruiting|February 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348294||28565|
NCT02297386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-185|[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer|Phase I Trial Of [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Male|21 Years|79 Years|No|||September 2015|September 28, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297386||32470|
NCT02297399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4790-I|Improvement of Tolerance of Bowel Cleansing Before Colonoscopy in Diabetic Patients|Improvement of Tolerability for Bowel Preparation for Colonoscopy in Diabetic Patients. A Randomized Controlled Trial of Two Bowel Preparation Protocols Including 4 Liters PEG vs. 2 Liters PEG Plus Ascorbic Acid. iDIMEPREP Study.|iDIMEPREP|Parc de Salut Mar|No|Recruiting|December 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02297399||32469|
NCT02357797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-465|Adjunctive Vortioxetine in Schizophrenia|Adjunctive Vortioxetine in Schizophrenia|AVIS|Northwell Health|Yes|Recruiting|February 2016|January 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357797||27837|
NCT02349841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASK-001|Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis|A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis.||Task Foundation NPC|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|65 Years|No|||January 2015|January 28, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349841||28446|
NCT02305199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YeungnamU|Hartmann's Solution and Normal Saline in Type II Diabetes Patients|Comparison of Hartmann's Solution and Normal Saline on Postoperative Blood Glucose and Insulin Levels in Type II Diabetic Patients||Yeungnam University College of Medicine|Yes|Recruiting|January 2015|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|20 Years|75 Years|No|||December 2015|December 28, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02305199||31869|
NCT02305212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|786-13 Cog|Cogmed for Working Memory After TBI|Applying Cogmed to Improve Working Memory Abilities After Traumatic Brain Injury|Cogmed|Kessler Foundation|No|Recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|9 Years|59 Years|No|||April 2015|April 1, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02305212||31868|
NCT02344745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00444|Lavender Aromatherapy for Anxiety During Urodynamics|The Use of Lavender Aromatherapy to Decrease Women's Anxiety and Perception of Pain During Multi-channel Urodynamics Procedure||University of Southern California|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02344745||28837|
NCT02350166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sLRC-201312|Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis|Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis||West China Hospital|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||November 2015|November 15, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350166||28422|
NCT02299999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1304|SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer|PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer|SAFIR02_Breast|UNICANCER|Yes|Recruiting|April 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|460|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02299999||32269|
NCT02300012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120614Mullineaux|A Pilot Study to Investigate Biomarkers in Anterior Cruciate Ligament (ACL) Patients and Healthy Controls|A Pilot Study to Investigate Biomarkers in ACL Patients and Healthy Controls||United Lincolnshire Hospitals NHS Trust|No|Recruiting|February 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02300012||32268|
NCT02310139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2014/9/4.7(4082)|Failed/Difficult Colonoscopy Outcomes|Outcomes of Patients With Failed or Difficult Colonoscopy at a Tertiary Referral Centre|FoDCO|Western Sydney Local Health District|Yes|Recruiting|May 2015|May 2021|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|99 Years|No|Non-Probability Sample|For a small proportion of patients a complete colonoscopy is unsuccessful due to technical        and physical reasons. This will be the study population which will be invited to        participate in this study.|December 2015|December 15, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310139||31491|
NCT02310152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311013020|Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)|Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)|SPACE|Yale University|No|Recruiting|November 2014|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|7 Years|14 Years|No|||July 2015|July 14, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310152||31490|
NCT02357459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2014-008|Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|486|||Both|40 Years|N/A|No|||March 2016|March 22, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357459||27863|
NCT02346383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7175|Optimal Stimulation Programming for Spinal Peripheral Neuromodulation|Optimal Stimulation Programming for Spinal Peripheral Neuromodulation||Carolinas Center for Advanced Management of Pain|No|Recruiting|September 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|22 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|October 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02346383||28711|
NCT02359422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iRT-2R44HD061193-02-RCT|Evaluation of a Middle School Comprehensive Sexual Health Media Literacy Education Program|Randomized Control Trial Efficacy Study of a Comprehensive Sexual Health Media Literacy Education Program for Middle School Students|MASH|Innovation Research & Training|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1017|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02359422||27713|
NCT02344134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP607_FluA_III_2013|Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of NBP607 (Trivalent Inactivated Cell Culture-derived Influenza Vaccine) in Healthy Adults and Elderly Subjects||SK Chemicals Co.,Ltd.|Yes|Completed|September 2013|May 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1155|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 16, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02344134||28883|
NCT02305914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstNanchangU|Follow-up Study of Complications of Acute Pancreatitis|A Large Sample Follow-up Study of Long-term Complications of Acute Pancreatitis|FSCAP|The First Affiliated Hospital of Nanchang University|No|Recruiting|November 2014|May 2016|Anticipated|January 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1300|Samples With DNA|Blood sample faeces sample|Both|N/A|N/A|No|Non-Probability Sample|Clinical diagnosis of acute pancreatitis from the First Affiliated Hospital of Nanchang        University from 2005 and 2014,with a follow-up interval of at least 1 year.|November 2014|May 21, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02305914||31814|
NCT02351479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bantum-2013-2|Hula, a Physical Activity Intervention for Female-Cancer Survivors|Hula, a Physical Activity Intervention for Female-Cancer Survivors||University of Hawaii|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Female|21 Years|N/A|No|||March 2016|March 1, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351479||28321|
NCT02351947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6636W|Structural and Functional Brain Changes in Response to Post-Stroke Rehabilitation|Structural and Functional Brain Changes in Response to Post-Stroke Rehabilitation||Louis Stokes VA Medical Center|No|Active, not recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02351947||28285|
NCT02349594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW/MB/42964|Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease|Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study||Radboud University|No|Completed|January 2014|September 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|70 Years|No|||November 2015|November 9, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349594||28465|
NCT02302118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG-II-esophagogastrectomy|Esophagogastrectomy Versus Extended Gastrectomy in AEG II|Survival Benefit by Esophagogastrectomy Versus Extended Gastrectomy of Patients With Carcinoma of the Esophagogastric Junction|AEG-II-EG|Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2013|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|128|||Both|18 Years|N/A|No|Probability Sample|Patients with carcinomas of the esophagogastric junction|December 2015|December 2, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302118||32106|
NCT02302131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Pulmonic XT|Pulmonic SAPIEN XT THV|Pulmonic SAPIEN XT™ THV A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up|Pulmonic XT|Institut für Pharmakologie und Präventive Medizin|No|Active, not recruiting|November 2014|April 2017|Anticipated|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Actual|49|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT        Transcatheter Heart Valve in the pulmonic position at the time of data collection|December 2015|December 3, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302131|24 Months|32105|
NCT02302469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_15/0837|Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia|A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia|RV-WM-0426|University Hospital, Lille|Yes|Active, not recruiting|March 2009|April 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302469||32079|
NCT02303015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaTeCa01|Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors|Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors||Rigshospitalet, Denmark|No|Recruiting|August 2014|January 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|4000|Samples With DNA|Blood samples and /or saliva.|Male|15 Years|N/A|No|Non-Probability Sample|Danish patients with germ cell cancer diagnosed 1984-2007.|November 2014|November 26, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303015||32037|
NCT02356393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1545-MS-CTIL|Serum Magnesium Levels in Desalination Tap Water and Outcomes in Acute Myocardial Infarction Patients|The Effect of Magnesium Serum Levels on Clinical Outcomes in Patients With Acute Myocardial Infarction by Considering Desalination Drinking Water Levels Patients Fed From.||Sheba Medical Center|No|Not yet recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|450|||Both|35 Years|75 Years|No|Probability Sample|All Subjects 35-75 years of age with the first AMI will be prospectively recruited during        1 year from 2 regions; the Departments of Cardiology at the Sheba Medical center (300        patients, predominantly served by DSW) and the Nahariya Medical Center (150 patients,        served by non-DSW).|February 2015|February 1, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02356393||27944|
NCT02295436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHXH-MINO|Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics|Pharmacokinetics and Tolerability of Minodronic Acid Tablets in Healthy Chinese Subjects and Food and Age Effects on the Pharmacokinetics||Wuhan Union Hospital, China|Yes|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|48|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02295436||32619|
NCT02300038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UppsalaU|Lidocaine and Neuroma Pain Related Modalities|Differential Analgesic Effects of Subanesthetic Concentrations of Lidocaine on Spontaneous and Evoked Pain in Human Painful Neuroma||Uppsala University|No|Completed|April 2010|September 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02300038||32266|
NCT02300311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69.53|Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain|A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain||Boehringer Ingelheim||Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||June 2015|June 25, 2015|November 24, 2014||||No||https://clinicaltrials.gov/show/NCT02300311||32245|
NCT02348775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-GSH|Glutathione and Function in HIV Patients|Glutathione and Function in HIV Patients||Baylor College of Medicine|No|Recruiting|November 2014|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|50 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02348775||28528|
NCT02357381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpringTMSUSPMOS 2014-01|eNeura SpringTMS Post-Market Observational US Study of Migraine|eNeura SpringTMS Post-Market Observational U.S. Study of Migraine|ESPOUSE|eNeura, Inc.|No|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|65 Years|No|Non-Probability Sample|4-25 headache days per month (confirmed by 1-month baseline diary, minimum of 5 complete        headache-free days/month)|April 2015|October 9, 2015|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357381||27868|
NCT02357394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUOBGYN001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||January 6, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357394||27867|
NCT02357420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-009|A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis||Rhythm Pharmaceuticals, Inc.|No|Active, not recruiting|January 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|395|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357420||27865|
NCT02303054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00903|MRI-Targed Focal Ablation of the Prostate in Men With Prostate Cancer|MR-US Fusion Biopsy-Guided Focal Bipolar Radio-Frequency Ablation of the Prostate in Men With Localized Prostate Cancer (FUSAblate Trial)|FUSAblate|New York University School of Medicine|Yes|Active, not recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Male|40 Years|80 Years|No|||December 2015|December 1, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02303054||32034|
NCT02295501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00113|A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease|A Prospective, Open Label Observational, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease||Cerus Corporation|No|Enrolling by invitation|December 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||January 2016|January 5, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295501||32614|
NCT02344485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1065|Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease|Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease||New York Institute of Technology|No|Recruiting|January 2015|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||July 2015|July 21, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344485||28857|
NCT02344498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1146|Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa|Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa||Oslo University Hospital|No|Active, not recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1350|||Both|18 Years|N/A|No|Non-Probability Sample|All adults with a positive HBsAg rapid test are eligible for inclusion.|December 2015|December 30, 2015|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02344498||28856|
NCT02346630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-002440|Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation|The Effect of Combining Robotic-Assisted Therapy With Levodopa/Carbidopa in Chronic Post-Stroke Upper-Limb Hemiparesis||Spaulding Rehabilitation Hospital|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||February 2016|February 22, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02346630||28692|
NCT02344160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4538-02|REDAPT Revision System Study to Assess 5 Year Revision Rate & up to 10 Year Revision Rate and Safety and Effectiveness|A Prospective, Multi-center Consecutive Series Study of Subjects Treated With the REDAPT™ Revision Femoral System||Smith & Nephew, Inc.|No|Withdrawn|December 2014|December 2028|Anticipated|December 2028|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|340 subjects|June 2015|June 4, 2015|January 14, 2015||No|Unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT02344160||28882|
NCT02344381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NorthumbriaU|The Impact of Sucrose Ingestion Post-Exercise on Liver and Muscle Glycogen Repletion.|||Northumbria University|Yes|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344381||28865|
NCT02295475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-357|Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome|Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome|ASTRO-APS|Intermountain Health Care, Inc.|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295475||32616|
NCT02358551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJFH-2014-086|Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation|Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation||China-Japan Friendship Hospital|Yes|Recruiting|June 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02358551||27780|
NCT02343640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1415-093|Ultrasound Study of Season-Long Joint Changes to College Baseball Players|Ultrasound Study of Season-Long Joint Changes to College Baseball Players||California State University, Northridge|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Male|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Members of the CSU Northridge baseball team|August 2015|August 4, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02343640|1 Year|28920|
NCT02356315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00067625|Brain, Brainstem, and Spinal Cord fMRI|Investigating Pain Processing in the Brain, Brainstem, and Spinal Cord With fMRI||Northwestern University|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|13|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects and chronic neck pain patients recruited from the community|December 2015|December 18, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356315||27950|
NCT02305134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G26023|Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial|Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial||Chiba University|Yes|Recruiting|January 2015|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|17 Years|No|||January 2016|January 26, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305134||31874|
NCT02305797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDG004-003|EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)|||Edgemont Pharmaceuticals, LLC|No|Recruiting|January 2015|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|474|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305797||31823|
NCT02305953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6037|Cytokines and Vascular Inflammation in Psoriasis|Correlation Between Serum Levels of Cytokines and a Chemokine and Vascular Inflammation in Patients With Moderate to Severe Psoriasis||Innovaderm Research Inc.|No|Completed|October 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|96|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects previously enrolled in the Inno-6025 Trial (ClinicalTrials.gov Identifier        NCT01722214)|November 2014|November 28, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02305953||31811|
NCT02344251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00033472|Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence|A Phase II Randomized Trial to Assess the Effectiveness and Safety of the ID-Cap System for Medication Ingestion Monitoring and Enhancing Adherence||Medical University of South Carolina|Yes|Not yet recruiting|May 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344251||28875|
NCT02344264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOKOL - 001-2014 - KHTY|Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty|Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty||Naestved Hospital|Yes|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|85 Years|No|||September 2015|September 24, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344264||28874|
NCT02357355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307807|Driving Ability in Patients With CMT 1A|Driving Ability in Patients With CMT 1A||University of Iowa|No|Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|16 Years|N/A|No|||February 2015|February 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02357355||27870|
NCT02299726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HL118350-01A1|Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study|Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study||Indiana University|Yes|Withdrawn|May 2015|November 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|22 Years|N/A|No|||October 2015|October 22, 2015|November 17, 2014|Yes|Yes|Study was not funded|No||https://clinicaltrials.gov/show/NCT02299726||32290|
NCT02300324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EE/1121|The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)|An Intervention Study to Assess the Bioavailability of Sulforaphane Delivered by Glucoraphanin-enriched Broccoli Soups in Healthy Subjects|BOBS|Institute of Food Research|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300324||32244|
NCT02352727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153/57|The Measurement of Nocturnal Hypokinesia in Parkinson's Disease (PD) Patient Compared With Spouse by Wearable Sensors||PD|Chulalongkorn University||Enrolling by invitation|May 2014|||January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|28|||Both|N/A|N/A|No|Non-Probability Sample|we study the Parkinson's disease patients and their spouses who received the treatment at        King Chulalongkorn Memorial Hospital.|January 2015|January 28, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02352727||28226|
NCT02346123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-41-11|Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy|Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy||Hospital Sao Rafael|No|Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|55|Samples With DNA|Plasma, Serum, Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Tertiary Hospital|October 2015|October 9, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346123||28731|
NCT02305147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-74|Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease|Etude Des Facteurs prédictifs de l'Apparition et de l'évolution de la Maladie de Parkinson|ICEBERG|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|November 2014|November 2021|Anticipated|November 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|330|Samples With DNA|Sampling at baseline|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with recent onset of Parkinson Disease (less than 3 years since diagnosis)        compared to subjects at risk to develop Parkinson Disease and healthy controls|February 2016|February 24, 2016|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02305147||31873|
NCT02299804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVO-PCIV-2001|A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo|A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction||Sihuan Pharmaceutical Holdings Group Ltd.|Yes|Recruiting|January 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|75 Years|No|||October 2014|November 20, 2014|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02299804||32284|
NCT02299817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No: 2013-004940-48|Denosumab for Treating Periprosthetic Osteolysis.|Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography||Danderyd Hospital|No|Recruiting|August 2015|February 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|110|||Both|40 Years|85 Years|No|||January 2016|January 27, 2016|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02299817||32283|
NCT02348788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR91391379918375 ￼|Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia|Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia|PRIMAL|Menzies School of Health Research|No|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|1 Year|N/A|No|||February 2016|February 2, 2016|January 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348788||28527|
NCT02350790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43830|Robotic Surgical Management of Endometriosis: Excision Versus Ablation|Robotic Surgical Management of Endometriosis: Excision Versus Ablation With Argon Beam Coagulator (ABC)||Milton S. Hershey Medical Center|No|Active, not recruiting|December 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02350790||28374|
NCT02347995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1461-R|Resistive Training Combined With Nutritional Therapy After Stroke|Resistive Training Combined With Nutritional Therapy After Stroke|REPS|VA Office of Research and Development|Yes|Recruiting|August 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|85 Years|No|||February 2016|February 2, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02347995||28588|
NCT02299765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIRES0109|Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC|A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive||Sichuan University|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|75 Years|No|||January 2015|January 26, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299765||32287|
NCT02343653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Training/Cirrhosis|The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis|The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis||University of Aarhus|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02343653||28919|
NCT02348151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPOCPC|Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With COPD|Analysis of Metabolic and Ventilatory Demands During the Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With Chronic Obstructive Pulmonary Disease (COPD)|(SWTiCOPD)|University of Nove de Julho|Yes|Recruiting|January 2014|June 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|47|||Both|18 Years|85 Years|No|||March 2015|March 9, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348151||28576|
NCT02357303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PortugueseOIC 001|Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial|Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial||Portuguese Oncology Institute, Coimbra|No|Completed|April 2015|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|3||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357303||27874|
NCT02294786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117314|Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer|A Randomised, Multicentre, Open Label, Phase II Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer||GlaxoSmithKline|No|Not yet recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||November 2014|November 20, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294786||32669|
NCT02348164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL62 Citrus Study|Human Lycopene and Beta-cryptoxanthin Absorption From Citrus Fruit|Human Lycopene and Beta-cryptoxanthin Absorption From Citrus Fruit||USDA, Western Human Nutrition Research Center|No|Completed|December 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02348164||28575|
NCT02352519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H28183|A Comparison of UGBRS Block and Local Infiltration|A Randomized Comparison of Ultrasound Guided Bilateral Rectus Sheath Block and Local Anesthetic Infiltration for Postoperative Pain Control in Children With Acute Appendicitis||Baylor College of Medicine|Yes|Completed|April 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02352519||28242|
NCT02345876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-799|Maturation of Auditory Processing in Children With Dyslexia Compared to Average-reading Children|Asymmetry, Auditory Processing and Reading Skills in Phonological Dyslexic Children Compared to Average-reading Children|ASTRAUCOLE|Hospices Civils de Lyon|No|Recruiting|December 2013|May 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|6 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|For the dyslexic children: primary care clinic and speech therapists For the normal        reading children : elementary schools of Lyon and Clermond-Ferrand and their suburbs|November 2014|January 19, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02345876||28750|
NCT02303834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 14/092|CPAP in Preeclampsia|Single Blinded Randomised Control Trial of Treatment of Sleep Disordered Breathing in Preeclampsia With Nasal CPAP||University of Sydney|Yes|Recruiting|February 2015|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02303834||31974|
NCT02357849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-199|Fluoxetine vs Aripiprazole Comparative Trial (FACT)|The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT)|FACT|Northwell Health|Yes|Recruiting|July 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|48|||Both|12 Years|25 Years|No|||February 2016|February 16, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02357849||27833|
NCT02357914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUS_81377|Freehand Ultrasound to Evaluate Scapular Kinematics in People With Paraplegia|Freehand Ultrasound to Evaluate Scapular Kinematics in People With Paraplegia|FUS|Rehabilitation Institute of Chicago|No|Recruiting|April 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|individuals with spinal cord injury and the lesion level below T1|September 2015|September 25, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357914||27829|
NCT02350439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY 19|Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).|Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).||University of Patras|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350439||28401|
NCT02294461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0232|An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Patients|Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy||Astellas Pharma Inc|Yes|Active, not recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Male|18 Years|N/A|No|||November 2015|November 25, 2015|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294461||32694|
NCT02304302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121971|Down Syndrome Memantine Follow-up Study|Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome||University Hospital Case Medical Center|Yes|Recruiting|October 2014|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|32 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02304302||31938|
NCT02304536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub5|Comparison Between Laparoscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.|Comparison Between Laproscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial|FSH|Cairo University|Yes|Recruiting|November 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|210|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02304536||31920|
NCT02353832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092013-013|Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer|Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Male|18 Years|N/A|No|||August 2015|September 12, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353832||28141|
NCT02356835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APT-14-002|APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults|A Pivotal Study of the Use of Nitric Oxide / Plasma Therapy as Produced by the APT001 Plasma / Nitric Oxide Generator in Adult Subjects With a Diabetic Foot Ulcer|APT-14-002|Advanced Plasma Therapies Inc|No|Completed|February 2015|March 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|19 Years|80 Years|No|||March 2016|March 15, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356835||27910|
NCT02301832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075483|Reliability of Sensor Spacing for NIRS in Traumatic Tibia Fractures|Reliability of Sensor Spacing for Near Infrared Spectroscopy in Traumatic Tibia Fractures: An Observational Study||Emory University|No|Enrolling by invitation|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will be recruited from the trauma bay, surgical wards and ICU of Grady Memorial        Hospital.|January 2016|January 13, 2016|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02301832||32128|
NCT02303496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-CREAM-1|Autologous Platelet-Rich Plasma Cream for Photoaging and Chronological Skin Aging|The Effects of Autologous Platelet-Rich Plasma Cream on Photoaging and Chronological Skin Aging||Acibadem University|Yes|Not yet recruiting|December 2014|May 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02303496||32000|
NCT02352220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13-02225|Determinants of Onset and Progression of COPD in Young Adults|Early COPD: Determinants of Onset and Progression of COPD in Young Adults|EARLY COPD|Hospital Son Espases||Recruiting|January 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|1100|||Both|35 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Smokers from 35 to 50 years who ever performed a spirometry in the selected primary care        centers. Selected subjects will not have exacerbation symptoms (fever, new onset or        increased cough, increase sputum volume and/or purulence, acute rhinitis) within 8 weeks        prior to the recruitment (from beginning of the symptoms).|February 2016|February 17, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02352220||28264|
NCT02345642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14064|A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices|A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices||Hospital for Special Surgery, New York|Yes|Not yet recruiting|February 2015|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345642||28768|
NCT02349854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31892|Neurobiology of the Scalp in Seborrheic Dermatitis|Neurobiology of the Scalp in Seborrheic Dermatitis||Boston University|No|Recruiting|February 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|24|Samples Without DNA|Scalp biopsy|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Dermatology clinic patients|January 2015|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349854||28445|
NCT02294968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIV1|The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program|The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program|FIV|University of Aarhus|Yes|Recruiting|November 2014|February 2024|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2800|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294968||32655|
NCT02295228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1025|Hip Arthroplasty and Vitamin D Status|Hip Arthroplasty and Vitamin D Status||University of Wisconsin, Madison|No|Active, not recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood and urine samples will be collected at all time points. Blood and urine aliquots will      also be banked from each visit.|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults age 50+ undergoing elective total hip arthroplasty for osteoarthritis will be        included. We will exclude individuals having these procedures for other conditions, e.g.,        rheumatoid arthritis, avascular necrosis and those undergoing reoperation of a previous        hip arthroplasty.|June 2015|June 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02295228||32635|
NCT02299232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295/25.02.2014|Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation|Comparison of Two Different Intranasal Doses of Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation|DEX|Sisli Etfal Training & Research Hospital|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|60|||Both|1 Year|10 Years|No|||November 2014|November 19, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02299232||32328|
NCT02352740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRMA12-1|Characterization of the Metabolic Fate of an Oral Arginine Form|Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.||Institut National de la Recherche Agronomique|No|Completed|March 2013|||May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02352740||28225|
NCT02350179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU1115|Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section|Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section||Ain Shams University|No|Recruiting|June 2014|May 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 7, 2015|January 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02350179||28421|
NCT02302924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-081|Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III|Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III|FluPRO3|Uniformed Services University of the Health Sciences|No|Completed|September 2014|May 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|535|Samples Without DNA|After obtaining informed consent, an oral/nasal swab or wash to confirm or rule out an      influenza etiology will be collected at baseline if the participant does not already have      documented laboratory confirmation of influenza.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The targeted sample population will be recruited from the United States. Participants at        the IDCRP sites will be both male and female military health care beneficiaries age 18        years and older presenting with the diagnosis of influenza or with influenza-like symptoms        suggestive of infection.|June 2015|June 11, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302924||32044|
NCT02302937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/00092|SIngle Port vs Standard TEP for Primary Inguinal Hernia Repair|A Prospective, Randomized, Controlled Trial to Compare Single Port Laparoscopic TEP Inguinal Hernia Repair Versus Standard Laparoscopic (3 Port) TEP Inguinal Hernia Mesh Repair|LESSTEP|National University Hospital, Singapore|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Male|21 Years|80 Years|No|||November 2014|November 24, 2014|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02302937||32043|
NCT02309138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14070556|Gestational Diabetes Diagnostic Methods|Gestational Diabetes Diagnostic Methods (GDM2) Study: Comparison of Two Screening Strategies for Gestational Diabetes|GDM2|University of Pittsburgh|Yes|Recruiting|June 2015|July 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|920|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02309138||31568|
NCT02309190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0444|Transpulmonary Pressures in Mechanical Ventilated Patients With Morbid Obesity|Transpulmonary Pressures in Mechanical Ventilated Patients With Morbid Obesity||The University of Texas Health Science Center, Houston|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults mechanically ventilated with morbid obesity|June 2015|June 13, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02309190||31564|
NCT02348515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201300122|Cardiovascular Disease Protection Tissue|Effects of ACE2/Ang-(1-7) on Cardiac Progenitor Cells From Heart Failure Patients and Explant Control||University of Florida|No|Recruiting|June 2013|October 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|180|Samples With DNA|Blood samples and discarded heart tissue.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing orthotopic heart transplant, left ventricular assist device        implantation, right heart biopsy, and any other heart surgery (atrial fibrillation and        right atria cannulation).|March 2016|March 21, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348515||28548|
NCT02356718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0422014|Cognitive Training in Inpatient Treatment for Substance Use Disorders|Cognitive Training in Inpatient Treatment for Substance Use Disorders||Centre for Addiction and Mental Health|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356718||27919|
NCT02356783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2014-135|Implementation of Pedometer for Monitoring Step Count Pre and Post Lumbar ESI for Radicular Pain|Implementation of Wireless Pedometer for Monitoring Step Count Before and After Lumbar Epidural Steroid Injection for Radicular Pain.||Hospital for Special Surgery, New York|No|Recruiting|February 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02356783||27914|
NCT02299193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073066|Online CBT-I for High Blood Pressure|Online CBT-I for High Blood Pressure||Emory University|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02299193||32331|
NCT02308371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2019|PPV to Guide Fluid Management in the PICU|Automated Pulse Pressure Variation Guided Fluid Management in the Pediatric Intensive Care Setting|PPV|University of North Carolina, Chapel Hill|No|Enrolling by invitation|December 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|N/A|17 Years|No|||November 2015|November 30, 2015|October 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308371||31626|
NCT02344771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBpoetry|Perioperative Endothelial Dysfunction|Perioperative Endothelial Dysfunction in Patients Undergoing Non-cardiac Surgery||University Hospital Koge|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|A population of patients with colon cancer undergoing elective cancer surgery.|June 2015|June 24, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344771||28835|
NCT02358382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13CC21|The Management of Systemic-Pulmonary Collateral Blood Flow in Cyanotic Children During Cardiopulmonary Bypass - Pilot Study|The Management of Systemic-Pulmonary Collateral Blood Flow in Cyanotic Children During Cardiopulmonary Bypass - Pilot Study||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Not yet recruiting|October 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|5 Years|No|||August 2015|August 17, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02358382||27793|
NCT02358395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8808001|A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma|A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma||Sumitomo Dainippon Pharma Co., Ltd.||Recruiting|February 2015|||May 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||January 2016|January 5, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02358395||27792|
NCT02305069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS33323|Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle|The Effect of Obesity-induced Cytokine Elevation on the Molecular Regulation of Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle||University of Nottingham|No|Completed|October 2009|September 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|26|||Male|55 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02305069||31879|
NCT02308969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-344|Neuronal Correlates of Altered States of Consciousness|Neuronal Correlates of Altered States of Consciousness|5HT2A-fMRI|University Hospital, Basel, Switzerland|Yes|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|24|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02308969||31581|
NCT02357719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308191|Effectiveness of VistaO2 FLUX Device in Screening of Sleep Apnea/Hypopnea Syndrome|Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|VISTAO2 FLUX|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|182|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357719||27843|
NCT02349867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12-07328|Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients|A Phase 1 Study of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer||Virginia Commonwealth University|Yes|Suspended|January 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 26, 2015|No|Yes|Pending protocol version 6|No||https://clinicaltrials.gov/show/NCT02349867||28444|
NCT02299401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6006|Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of SQPT for At-Home Follow-Up|Assessing the Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of a Semi-Quantitative Pregnancy Test for At-Home Follow-Up||Gynuity Health Projects|No|Recruiting|December 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|382|||Female|N/A|N/A|No|||December 2015|December 7, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02299401||32315|
NCT02299414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL119242-01|Chronic Hypertension and Pregnancy (CHAP) Project|A Pragmatic Multicenter RCT of Antihypertensive Therapy for Mild Chronic Hypertension During Pregnancy: Chronic Hypertension and Pregnancy (CHAP) Project|CHAP|University of Alabama at Birmingham|Yes|Recruiting|August 2015|May 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4700|||Female|12 Years|N/A|No|||October 2015|November 5, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02299414||32314|
NCT02299427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD075960|A Website to Teach Children Safety With Dogs|A Website to Teach Children Safety With Dogs||University of Alabama at Birmingham|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|69|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299427||32313|
NCT02303873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 2007-03-12|Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta|Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study||Peking Union Medical College Hospital||Completed|March 2007|August 2014|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|N/A|18 Years|No|||November 2014|December 9, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303873||31971|
NCT02359279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R42DE023003-02|Radiographic Contrast To Differentiate Cavitated From Non-cavitated Tooth Decay|Radiographic Contrast To Differentiate Cavitated From Non-cavitated Tooth Decay||Creighton University|Yes|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|96|||Both|19 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359279||27724|
NCT02359292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AB2-01|Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers|Cross-over Clinical Pharmacology Study, to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination Across Two Different Dose Strengths, Administered With and Without Activated Charcoal, in Healthy Volunteers||Chiesi Farmaceutici S.p.A.|No|Completed|February 2015|July 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02359292||27723|
NCT02356653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010286|Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC|Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|ExpMACs|Children's Hospital of Philadelphia|Yes|Recruiting|December 2013|January 2020|Anticipated|January 2020|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|30 Years|No|||October 2015|October 19, 2015|October 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02356653||27924|
NCT02305095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3648634|Genomic Response Analysis of Heart Failure Therapy in African Americans|Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans|GRAHF-2|University of Pittsburgh|Yes|Recruiting|May 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Serum and DNA banked at baseline.|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with systolic heart failure who are self designation as African Americans        are potentially eligible for the study.|January 2016|January 14, 2016|September 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02305095||31877|
NCT02297906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN5404|Pharmacokinetics of Intranasal Ketorolac in Children|Pharmacokinetics of Intranasal Ketorolac in Children||Columbia University|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297906||32430|
NCT02352753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130173|Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI|Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta|OI|Amgen|Yes|Recruiting|June 2015|June 2021|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|2 Years|17 Years|No|||March 2016|March 16, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352753||28224|
NCT02353689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-1040709-AB-N-01-201310-BR-03|The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement|Identification of the Effect of Fermentable Oligo-, di-, and Mono- Saccharides and Poorly Absorbed Short-chain Carbohydrate (FODMAP) Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement||Dong-A University|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|84|||Both|20 Years|90 Years|No|||February 2015|February 4, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353689||28152|
NCT02358291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WANG-8808-KUN|Microendoscopic Discectomy Vs Transforaminal Endoscopic Lumbar Discectomy Vs Open Discectomy|Microendoscopic Discectomy Vs Transforaminal Endoscopic Lumbar Discectomy Vs Open Discectomy for the Treatment of Lumbar Disc Herniation||Southeast University, China|Yes|Not yet recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|No|||February 2015|February 6, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02358291||27800|
NCT02303197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TianjinCIH|Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis|A Randomized,Controlled Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis.||Tianjin Medical University Cancer Institute and Hospital|Yes|Completed|May 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|December 20, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303197||32023|
NCT02352701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-LDS-ILA01|Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori|Efficacy and Safety of Basic Triple Therapy Including Ilaprazole, Levofloxacin on the First Line Eradication Treatment of H.Pylori||Il-Yang Pharm. Co., Ltd.|Yes|Completed|December 2012|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|320|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients who visited the hospital|August 2015|August 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02352701||28228|
NCT02349568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-55-066-21-1-2|The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones|The Cost Effectiveness Between EUS-based Strategy Versus Endoscopic Retrograde Cholangiopancreatography ( ERCP )-Based Strategy in Diagnosis of Common Bile Duct Stones in Patients With Intermediate Risk: a Study in Developing Country.||Prince of Songkla University|Yes|Completed|May 2012|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|141|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with suspected CBD stones based on clinical, biochemical and imaging by        trans-abdominal ultrasonography or computed tomography..|January 2015|January 23, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02349568||28467|
NCT02349802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5554C00001|Autoinjector Device Assessment Study|Evaluation of the Single-Use Pre-Filled Autoinjector|BCB119|AstraZeneca|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|3052|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349802||28449|
NCT02346864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNF201221|Effect of Three-Stair-Position on Improvement of Apnea of Prematurity|Effect of Three-Stair-Position on Improvement of Apnea of Prematurity and Feeding Performance in Prematurity: A Randomized Control Trial||Children's Hospital of Fudan University|Yes|Completed|December 2013|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|144|||Both|N/A|3 Days|No|||January 2015|January 20, 2015|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02346864||28674|
NCT02299180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCPC IN14-0001|Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure|Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure: A Randomized Controlled Trial||Duke-NUS Graduate Medical School|No|Recruiting|February 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|254|||Both|21 Years|N/A|No|||July 2015|July 26, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299180||32332|
NCT02296905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-604|Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function|Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function||AbbVie|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296905||32507|
NCT02296918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-003|ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL|||Acerta Pharma BV||Active, not recruiting|November 2014|||November 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296918||32506|
NCT02297165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0028|Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia|Efficacy Study of an Olfactory Stimulation Program in Relaxing Environment for the Recuperation of Autobiographical Memories in Anorexic Patients|OLFANOR|Lille Catholic University|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|13 Years|24 Years|No|||November 2015|November 9, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02297165||32487|
NCT02347852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17816|Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer|Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer|REGO-ACT|Bayer|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Participants of NIS CORRELATE (NCT02042144, Safety and Effectiveness of Regorafenib in        Routine Clinical Practice Settings) in Austria|March 2016|March 10, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02347852||28599|
NCT02347865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130240|Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France|Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France and Its Use in Routine Clinical Practice|PILOTE|Amgen|No|Recruiting|June 2015|September 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|750|||Female|40 Years|95 Years|No|Probability Sample|post menopausal women with osteoporosis, treated with Prolia|February 2016|February 11, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02347865||28598|
NCT02356601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/03/20 chairman's action|Lumbar Neuraxial Ultrasound Corrrelation With MRI|Lumbar Neuraxial Ultrasound Corrrelation With MRI||The Adelaide and Meath Hospital|No|Completed|April 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients having MRI lumbar spine done|February 2015|February 2, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356601||27928|
NCT02305043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARIANZ|Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer|Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Adenocarcinoma of the Stomach or Gastroesophageal Junction. A Non-interventional Study|VARIANZ|University of Leipzig|No|Recruiting|March 2014|||February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|patients suffer from histologically proven adenocarcinoma of the stomach or        gastroesophageal junction|November 2014|November 27, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02305043|24 Months|31881|
NCT02305082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fast-track-hernia-bbh|Fast-track Giant Ventral Hernia Repair|Fast-track Giant Ventral Hernia Repair||Bispebjerg Hospital|Yes|Completed|December 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are scheduled to undergo elective incisional hernia repair.|September 2015|September 3, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02305082||31878|
NCT02309957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE EU Post Market Study|EAGLE European Post Market Study|Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions ("EAGLE") European Post Market Study|EAGLE|Kensey Nash Corporation|No|Recruiting|May 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02309957||31505|
NCT02344277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0238|Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients|Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients|S-ICD Brugada|Nantes University Hospital|No|Recruiting|April 2015|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects selected for participation will be symptomatic or asymptomatic Brugada        patients and, implanted or not with any ICD. Site investigators are responsible for        screening. Subjects must meet all inclusion criteria. Subjects with any exclusion criteria        will be excluded. The recruitment of the patients will be performed in a selected number        of centers specifically involved in the management of patients affected by the Brugada        syndrome in Europe and in which databases of patients are available.|December 2015|December 17, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344277||28873|
NCT02358174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER.ALL.2013.27.A|Hemorrhoids and Metalloproteinases, Observational Study|Hemorrhoids and Metalloproteinases, Observational Study|HeMe|University of Cantanzaro|Yes|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|187|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02358174||27809|
NCT02303028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046233|Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours|A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours Including CNS Tumours|TOPAZ|The Hospital for Sick Children|Yes|Recruiting|March 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|2 Years|21 Years|No|||March 2015|March 18, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303028||32036|
NCT02303119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLIRT|Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)|A Randomized Phase III Trial Evaluating Two Strategies of Rituximab Administration for the Treatment of First Line/Low Tumor Burden Follicular Lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)|FLIRT|The Lymphoma Academic Research Organisation|No|Recruiting|February 2015|January 2021|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303119||32029|
NCT02305966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7519|Evaluation of Implant Fixation in Reverse Total Shoulder Arthroplasty|Evaluation of Implant Fixation in Reverse Total Shoulder Arthroplasty||Lawson Health Research Institute|No|Not yet recruiting|December 2014|November 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|40|||Both|50 Years|85 Years|No|||November 2014|December 2, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02305966||31810|
NCT02359318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIDeBond|De-bonding Following Infiltration|Enamel Damages Following De-bracketing of Demineralised Teeth With or Without Prior Infiltration Compared to Sound Enamel: A Single-center, Randomized, Single Blinded, Split-mouth Controlled Clinical Trial||DMG Dental Material Gesellschaft mbH|No|Recruiting|May 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|30|||Both|12 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02359318||27721|
NCT02346643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-SMI-2013|A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region|BINGO: A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region|BINGO|St. Jude Medical|No|Terminated|April 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Pain Patients|December 2015|December 15, 2015|January 7, 2015||No|Budget Allocation Decision by Sponsor|No||https://clinicaltrials.gov/show/NCT02346643||28691|
NCT02346656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-SMI-2013|a BavaRiAn eValuatiOn of Dorsal Root Ganglion (DRG) Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin|BRAVO: a BavaRiAn eValuatiOn of DRG Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin|BRAVO|St. Jude Medical|No|Terminated|May 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Post Surgical Groin Pain Patients|December 2015|December 15, 2015|January 9, 2015||No|Inadequate Enrolment|No||https://clinicaltrials.gov/show/NCT02346656||28690|
NCT02305901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.20|The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers|The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion Following Oral Administration in Healthy Male Subjects (an Open-label, One-sequence Trial)||Boehringer Ingelheim||Completed|December 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 10, 2015|December 1, 2014||||No||https://clinicaltrials.gov/show/NCT02305901||31815|
NCT02355665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140121222102-SCCT|Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Using a Naturalistic Clinical Model to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers Motivated to Quit||Johnson & Johnson Consumer and Personal Products Worldwide|No|Active, not recruiting|January 2015|March 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355665||28000|
NCT02355678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212|Dexamethasone Versus Local Infiltration Technique for Tonsillectomy in Children|The Effect of Dexamethasone Versus Local Infiltration Technique on Postoperative Nausea and Vomiting After Tonsillectomy in Children: A Randomized Double-blind Clinical Trial||Makassed General Hospital|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|2 Years|13 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02355678||27999|
NCT02354664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400763|Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease|Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease|DRMF|University of Florida|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|14|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with late-onset Pompe disease, age 20-60 years, and age and gender-matched        unaffected control subjects|October 2015|October 13, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02354664||28077|
NCT02351336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTB 012|Fetal Adrenal Gland Volume Estimation Compared to Cervical Length Assessment in Prediction of Preterm Birth|Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth||Ain Shams Maternity Hospital|Yes|Recruiting|August 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|78|||Female|18 Years|40 Years|No|Probability Sample|Women who are diagnosed as having threatened preterm labour based on the American college        of obstetricians and gynaecologists guidelines (ACOG,2003) :          -  Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )          -  Cervical dilataion >1cm, &/or          -  Cervical effacement ≥ 80%|February 2015|February 15, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02351336||28332|
NCT02358031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-048|A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)|A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma||Merck Sharp & Dohme Corp.|Yes|Recruiting|March 2015|September 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|780|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358031||27820|
NCT02302859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0509|Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study|Mobile Smoking Cessation Treatment for Underserved Smokers: A Pilot and Feasibility Study||M.D. Anderson Cancer Center|No|Completed|January 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02302859||32049|
NCT02302872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU010513|Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation|Mitral Valve Repair Clinical Trial (MAVERIC Trial)|MAVERIC|Mvrx, Inc.|Yes|Recruiting|October 2013|June 2019|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|85 Years|No|||September 2015|September 21, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02302872||32048|
NCT02301923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDF575|Continuous Positive Airway Pressure (CPAP) Compliance in Obstructive Sleep Apnea|Predictive Factors Determining Continuous Positive Airway Pressure (CPAP) Compliance in Obstructive Sleep Apnea|CPAPcompl|Saint-Joseph University|Yes|Not yet recruiting|November 2014|March 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|All patients diagnosed with OSA in the sleep center of Hotel Dieu de France (HDF)        hospital, treated for at least one day by CPAP, from the period of June 2008 to June 2013.|November 2014|November 25, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02301923||32121|
NCT02301936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1405|Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease|An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease||Gilead Sciences|No|Active, not recruiting|March 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301936||32120|
NCT02352233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IECED 01-14-2014|Retroview Colonoscope for the Evaluation of Colon Mucosa Study|Pentax Retroview Colonoscope for the Evaluation of Colon Mucosa in Forward and Retro Viewing: a Safety and Feasibility Pilot Study|REVCOR|Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Completed|January 2014|April 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|Samples Without DNA|biopsies, tissue from colonic mucosa: inflammatory, polyps|Both|18 Years|85 Years|No|Non-Probability Sample|consecutive patients undergoing for colonoscopy at the Instituto Ecuatoriano de        Enfermedades Digestivas|September 2014|January 27, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02352233||28263|
NCT02358109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAMENCO|The Flamenco (Fitness League Against MENopause COsts) Project|Cost-Effectiveness of an Exercise Program in Midlife Women|FLAMENCO|Universidad de Granada|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|160|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02358109||27814|
NCT02298712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUR 02-2014|Biomarker for Patients With Hurler Disease or High-grade Suspicion for Hurler Disease|Biomarker for Hurler Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioHurler|University of Rostock|Yes|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|All patients with MPS1 disease or patients with high-grade suspicion for MPS1 disease        should be included into the study|January 2016|January 13, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298712||32368|
NCT02302885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 42914|Healthy Human Control Blood Collection for Validation of Biomarker Assay|Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|About 20 mL blood will be collected from volunteers up to 20 different timepoints.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|cancer-free 18-60 year old men and women|November 2014|November 26, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02302885||32047|
NCT02352181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-870|Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.|Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.||Hospices Civils de Lyon|No|Recruiting|December 2014|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|January 27, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02352181||28267|
NCT02349074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHV P13/30|Digestive ENdoscopy afTeR Out-of-hospitAl Cardiac arresT|Digestive ENdoscopy afTeR Out-of-hospitAl Cardiac arresT|ENTRACT|Central Hospital, Versailles|No|Recruiting|November 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|270|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02349074||28505|
NCT02346396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.869|CORTICAL STIMULATION BY DIRECT CURRENT FOR THE TREATMENT OF CHRONIC PAIN : PILOT-STUDY OF A STIMULATION DEVICE AT HOME|Non-invasive Analgesic Stimulation of the Motor Cortex at Home|STIMATHOME|Hospices Civils de Lyon|No|Recruiting|January 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|80 Years|No|||January 2015|January 28, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02346396||28710|
NCT02294214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-M-TZ|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania|SR-M-Tz|University of Notre Dame|Yes|Not yet recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2800|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294214||32713|
NCT02295293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P-92-5581|The Effects of Rhus Coriaria L. (Sumac) on Serum Lipid Levels of Patients With Hyperlipidemia|The Effects of Rhus Coriaria L. (Sumac) on Serum Lipid Levels of Patients With Hyperlipidemia||Shiraz University of Medical Sciences|Yes|Completed|December 2014|May 2015|Actual|April 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|20 Years|65 Years|No|||May 2015|May 11, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02295293||32630|
NCT02344511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-304|Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis|A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms|AHOM|Durata Therapeutics Inc., an affiliate of Allergan plc|Yes|Not yet recruiting|March 2016|April 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|285|||Both|2 Years|16 Years|No|||February 2016|February 26, 2016|January 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02344511||28855|
NCT02344524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI/2014/07/004795|Drainage of Traumatic Hemothorax and Pneumothorax: Small Bore Versus Large Bore Chest Drain|Drainage of Traumatic Hemothorax and Pneumothorax: Small Bore Versus Large Bore Chest Drain- a Randomized Controlled Trial||Delhi University|No|Completed|November 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|80 Years|No|||January 2015|January 17, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02344524||28854|
NCT02344537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6927|Meditation and Stretching for Post Treatment Lyme Disease Syndrome|Meditation and Stretching for Post Treatment Lyme Disease Syndrome|LMS|Research Foundation for Mental Hygiene, Inc.|No|Not yet recruiting|January 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344537||28853|
NCT02351076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVO-FNOs/2014|Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient.|Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient. Pilot Study.||University Hospital Ostrava|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|55 Years|No|Probability Sample|Patient after ischemic stroke including TIA, age 18-55 year|December 2015|December 22, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02351076||28352|
NCT02351089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProRad|Probiotics in Radiation-treated Gynecologic Cancer|Probiotics in Radiation-treated Gynecologic Cancer|ProRad|Probi AB|Yes|Recruiting|February 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|200|||Female|18 Years|N/A|No|||February 2015|February 25, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351089||28351|
NCT02295462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPCentCare|Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial|Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial|EPCentCare|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|December 2014|March 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|2340|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02295462||32617|
NCT02356419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSS06|rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics|rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics for Healthy Subjects in the Phase Ⅰ Clinical Study||Shenyang Sunshine Pharmaceutical Co., LTD.|Yes|Recruiting|September 2014|March 2015|Anticipated|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 1, 2015|January 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356419||27942|
NCT02356484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471/14|Surgical Stress Markers for Postoperative Complications: a Prospective Study|Predictive Value of Surgical Stress Markers for Postoperative Complications: a Prospective Study||University of Lausanne Hospitals|Yes|Completed|February 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing major surgery (esophagus, gastric, liver, pancreas, endocrine,        retroperitoneal, or colorectal surgery)|December 2015|December 29, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356484||27937|
NCT02358187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO1310086|A Vaccine Trial for Low Grade Gliomas|A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas (LGG)||University of Pittsburgh|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|12 Months|21 Years|No|||January 2016|January 22, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358187||27808|
NCT02305654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR CTSU/2014/10048|International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)|International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)|InPACT|Institute of Cancer Research, United Kingdom|No|Not yet recruiting|April 2015|||July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|400|||Male|N/A|N/A|No|||November 2014|November 27, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02305654||31834|
NCT02359994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT1101.011-C(02/15)|Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System|Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System|CLOT|CryoLife, Inc.|Yes|Suspended|April 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|324|||Both|22 Years|N/A|No|||February 2016|February 23, 2016|February 3, 2015|Yes|Yes|Voluntary enrollment hold|No||https://clinicaltrials.gov/show/NCT02359994||27669|
NCT02360007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 14-063|Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access||IBT|University of Vermont Medical Center|No|Recruiting|January 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02360007||27668|
NCT02346136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AG025037-09A1|Health Outcomes of Tai Chi in Subsidized Senior Housing|Health Outcomes of Tai Chi in Subsidized Senior Housing|Mi-WISH|Hebrew Rehabilitation Center, Boston|Yes|Recruiting|July 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|320|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346136||28730|
NCT02302950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0559|A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas|A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas||The University of Texas Health Science Center, Houston|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|256|||Female|18 Years|N/A|No|Non-Probability Sample|HIV infected minority women at Thomas Street Health Center that picked up raltegravir in        2013|July 2015|July 24, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02302950||32042|
NCT02305589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160075|The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium|The Comparison of Sugammadex and Conventional Cholinesterase Inhibitor on the Aspect of Postoperative Delirium in the Elderly Patients Undergoing Hip Surgery||Konkuk University Medical Center|No|Recruiting|September 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|60 Years|N/A|No|Non-Probability Sample|patients undergoing hip surgery under general anaesthesia with neuromuscular blocking        agents|December 2015|December 14, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02305589||31839|
NCT02355431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-205|INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations|A Randomized, Double-blind Phase 2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations||Incyte Corporation|Yes|Withdrawn|December 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 30, 2015|Yes|Yes|Study withdrawn before enrolling first patient|No||https://clinicaltrials.gov/show/NCT02355431||28018|
NCT02354196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Big PICTURE 2|Physicians International CT Utilization Registry 2|Big PICTURE 2: Physicians International CT Utilization Registry 2|Big PICTURE 2|MDDX LLC|No|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1000 subjects, 18 or older, no previous CAD|September 2015|September 21, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354196|24 Months|28113|
NCT02350803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUDO-1394|Does Use of Rigid Fixation After Removing Distraction Osteogenesis Device Reduce the Relapse?|Dose Use of Rigid Fixation After Removing the Distraction Device Reduce the Anterior-posterior Relapse or Not?||Shiraz University of Medical Sciences|Yes|Completed|February 2011|December 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02350803||28373|
NCT02350816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP610-201|Safety and Efficacy Study for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093|An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease||Shire|Yes|Enrolling by invitation|April 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|18|||Both|12 Months|48 Months|No|||November 2015|November 19, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350816||28372|
NCT02298959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01984|Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors|A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)|No|Recruiting|March 2015|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02298959||32349|
NCT02299518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 14089|Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|May 2015|||April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299518||32306|
NCT02299531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildFood201|Effects of Portion Size and Energy Density of a Single Meal in Preschool Children|||Penn State University|No|Completed|May 2013|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|131|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02299531||32305|
NCT02299544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-03-001|BlueWind Medical System for the Treatment of Patients With OAB|Safety and Performance of the BlueWind System for the Treatment of Patients With Overactive Bladder (OAB)|OAB|Rainbow Medical|No|Active, not recruiting|February 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299544||32304|
NCT02349308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013224|Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter|Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter for Dialysis|MCENPS|Merit Medical Systems, Inc.|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients who are initiating or continuing in-center intermittent hemodialysis who        are scheduled to receive a tunneled dialysis catheter in the right or left internal        jugular vein. The patients may have had a prior tunneled catheter for dialysis in the        right IJ site.Patients will be expected to need use of the catheter for more than 45 days|January 2015|September 2, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02349308||28487|
NCT02357953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00003-40|Transpulmonary Thermodilution Using an Implented Central Venous Access Port|Measurement of Cardiac Index by Transpulmonary Thermodilution Using an Implanted Central Venous Access Port: a Prospective Study in Patients Scheduled for Oncologic High-risk Surgery|ThermoD-PAC|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for onoclogic hish-risk surgery|February 2016|February 9, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357953||27826|
NCT02300285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00014699|Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia|Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia||Children's Hospital Boston|No|Recruiting|February 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|N/A|60 Days|No|||November 2015|November 2, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300285||32247|
NCT02300298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.90|Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy|An Open Label Phase I Safety run-in Trial of Oral Nintedanib Plus Docetaxel Therapy in Japanese Patients With Locally Advanced or Metastatic Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of Platinum-based First Line Chemotherapy||Boehringer Ingelheim||Active, not recruiting|December 2014|March 2017|Anticipated|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||March 2016|March 21, 2016|November 24, 2014||||No||https://clinicaltrials.gov/show/NCT02300298||32246|
NCT02357277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5309|The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton|The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton||Columbia University|No|Withdrawn|March 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|0|||Female|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|February 3, 2015|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT02357277||27876|
NCT02357316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-039|Heritability and Genetics of Fat Taste|Heritability and Genetics of Fat Taste||Purdue University|No|Active, not recruiting|November 2013|||July 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|2500|Samples With DNA|Buccal cells|Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals ages 8 and older|October 2015|October 14, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02357316||27873|
NCT02345603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/45-31|Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy|Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy During Open Surgery for Aortic Aneurysm|PRASDEN|University Hospital, Linkoeping|No|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|N/A|No|||December 2015|December 2, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02345603||28771|
NCT02304978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09/0908|Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults|Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults|TF|University Hospital, Lille|No|Recruiting|June 2009|June 2020|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 3, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304978||31886|
NCT02304991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0648|FARE Peanut SLIT and Early Tolerance Induction|Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children|FARE/SLIT|University of North Carolina, Chapel Hill|Yes|Recruiting|December 2014|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Months|48 Months|No|||October 2015|October 8, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02304991||31885|
NCT02305030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-127|Effect of Opicapone at Steady State on Warfarin Pharmacokinetics|Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305030||31882|
NCT02294526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBERDEM-PILCHARDUS|A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients|PILCHARDUS STUDY: A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients|PILCHARDUS|Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders|Yes|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|40 Years|85 Years|No|||November 2014|January 28, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02294526||32689|
NCT02294539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSH_AMST|Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients|Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controlled, Phase 4 Randomized Trial||Kyung Hee University Hospital at Gangdong|No|Recruiting|August 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|238|||Both|19 Years|80 Years|No|||September 2015|September 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294539||32688|
NCT02344030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannesGUKV|Comparsion of King Vision® Standard Blade and King Vision® Channeled Blade in Patients Scheduled for Tracheal Intubation|Comparative Study of King Vision® Standard Blade and King Vision® Channeled for Tracheal Intubation: a Prospective Randomised Study|KingVision|Johannes Gutenberg University Mainz|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344030||28891|
NCT02344043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1662-13|Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness|Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness|CONFOCAL|Queen's University|No|Recruiting|March 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|This study is recruiting critically ill patients admitted to the 33-bed medical/surgical        intensive care unit at an academic medical centre.|August 2015|August 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02344043||28890|
NCT02350452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOLASER01|Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Endometriomas|The Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Inner Lining of Ovarian Endometriomas After Laparoscopic Cystectomy: a Randomized Clinical Trial.||University of Cagliari|No|Recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350452||28400|
NCT02305602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-201|A Study of VentriGel in Early and Late Post-myocardial Infarction Patients|A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction||Ventrix, Inc.|Yes|Enrolling by invitation|September 2015|July 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|30 Years|75 Years|No|||September 2015|September 10, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02305602||31838|
NCT02356263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3235-CHS-ERC-14|Adaptation and Validation of Recent Life Changes Questionnaire for Measuring Stress Among Adults in Karachi, Pakistan|Adaptation and Validation of Recent Life Changes Questionnaire (RLCQ) to Measure Stress Among Adult Population of Karachi, Pakistan.||Aga Khan University|No|Recruiting|March 2015|September 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|The target population for the study includes all adults aged 18 years or above living in        Karachi, Pakistan. The source population is that of all adults aged 18 years or above        living in Gulshan-e-Iqbal town Karachi from where we will draw our sample population        comprising of those adults 18 years or more who fulfil the eligibility criteria and        consent to participate in the study.|May 2015|May 5, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02356263||27954|
NCT02357888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00018 PC 2 06|Assessment of V0018 2.5 mg Effect on Craving|Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 2.5 mg Nicotine Lozenge on Smoking Craving||Pierre Fabre Medicament||Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357888||27831|
NCT02303067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150026|Prospective International Study of Coronary Subtraction Using 320 Detector Row CT (CorSub)|Prospective International Study of Coronary Subtraction Using 320 Row-Detector CT||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|55 Years|99 Years|No|||October 2015|November 3, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303067||32033|
NCT02304068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP12/10204|The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity|The Accuracy of Home Monitoring for Disease Activity During Maintenance Therapy for Neovascular Age-related Macular Degeneration||The Leeds Teaching Hospitals NHS Trust||Completed|April 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|N/A|1||||||Both|60 Years|N/A||||November 2014|November 25, 2014|November 4, 2014||||No||https://clinicaltrials.gov/show/NCT02304068||31956|
NCT02354430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-12-1088|The Effect Water-exercise on Low Back Pain and Sick Leave, Among Healthy Pregnant Women|AquaMama - Testing the Effect of a Public Water-exercise Program on Low Back Pain and Sick Leave Among Healthy Pregnant Women|WAPW|Rigshospitalet, Denmark|No|Completed|December 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|516|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02354430||28095|
NCT02354443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT1050-05|A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders|A Phase 1 Trial of a Single ProHema® CB Product as Part of Single Cord Blood Unit Transplant After Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients With Inherited Metabolic Disorders|PROVIDE|Fate Therapeutics|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|1 Year|18 Years|No|||October 2015|October 23, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354443||28094|
NCT02347696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRIATT|Diet and Physical Activity on NAFLD and Erytrocyte Membrane Lipid Profile.|Effect of Two Programs of Physical Activity of Different Intensity, Mediterranean Diet and the Combination of Both on NAFLD and Erytrocyte Membrane Lipid Profile.||Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|Yes|Not yet recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|240|||Both|30 Years|60 Years|No|||February 2015|February 6, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347696||28610|
NCT02303470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14816|Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study|||University of California, San Francisco|Yes|Recruiting|March 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303470||32002|
NCT02303483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44081|The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men|The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial||Aarhus University Hospital|No|Recruiting|November 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303483||32001|
NCT02347826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aqde|Evaluation of Satisfaction in Patients Undergoing Non Surgical Lifting by Means of Coned Wires.|Evaluation of Aesthetic Satisfaction in Patients Undergoing Non Surgical Face and Neck Lift by Means of Coned Wires.|SCW|AQ-DE|No|Completed|January 2014|December 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|243|||Both|19 Years|76 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing non surgical facial and carvical lift from 2013 to 2014|January 2015|January 27, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347826||28601|
NCT02349828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-SIUSM-15-001|Antiviral Prophylaxis in a Burn Population|A Prospective, Randomized Trial of Antiviral Prophylaxis in a Population of Burn Patients||Southern Illinois University|Yes|Not yet recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|24 Months|N/A|No|||August 2015|August 27, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349828||28447|
NCT02343471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-Premeal3|The Effect of Whey Protein Consumed as a Pre-meal on Postprandial Lipemia in Healthy and Subjects With Type 2 Diabetes|Whey Protein, Postprandial Lipemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipiemia in Subjects With the Metabolic Syndrome and Type 2 Diabetes|PREMEAL 3|Aarhus University Hospital|Yes|Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|May 4, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343471||28933|
NCT02347982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELDER-TURK|Epidemiology of Cardiovascular Disease in Elderly Turkish Population|Epidemiology of Cardiovascular Disease in Elderly Turkish Population|ELDER-TURK|Turkish Society of Cardiology|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2500|||Both|65 Years|N/A|No|Non-Probability Sample|Patients ≥65 years followed-up at cardiology clinics|June 2015|June 1, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02347982|1 Day|28589|
NCT02293980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT2385-101|A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma|A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2Α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma||Peloton Therapeutics, Inc.|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293980||32731|
NCT02299024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0017808|Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter|Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter||Northwestern University|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|278|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299024||32344|
NCT02348528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-024|Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year|A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.||Celgene|No|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348528||28547|
NCT02348541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CG-001|CollaGUARD Adhesion Barrier|A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier Following Hysteroscopic Adhesiolysis||Innocoll|No|Recruiting|November 2014|August 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Female|18 Years|45 Years|No|||January 2015|January 27, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02348541||28546|
NCT02357823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV13HIV-BOOST-2013|Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults|Long Term Serological Response and Memory Cells Role After Different Pneumococcal Vaccine Strategies in HIV Adults||University of Siena|No|Active, not recruiting|January 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|250|Samples Without DNA|Microbes isolated from nasopharingeal swab; blood for analysis of immune response|Both|18 Years|65 Years|No|Non-Probability Sample|HIV-positive adults that undergo the International and Italian Ministry of Health        indications for administration of pneumococcal vaccines.|February 2015|February 2, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02357823||27835|
NCT02294994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondJilinU-1|Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease|Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease||Second Hospital of Jilin University|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|18 Years|80 Years|No|||November 2014|November 29, 2014|November 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294994||32653|
NCT02358421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Highresponse_ART|Prediction of High Ovarian Response After Assisted Reproductive Techniques|High Response Predictive Parameters After Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Techniques|HighART|Instituto de Investigacion Sanitaria La Fe|No|Recruiting|October 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|39 Years|No|Non-Probability Sample|Patients with primary infertility at risk of developing ovarian hyperstimulation syndrome        during controlled ovarian hyperstimulation. This population was defined according to the        presence of at least one Rotterdam criterion or the presence of an abnromal luteal phase,        invesion of the FSH/LH ratio or an increased AMH level (see inclusion and exclusion        criteria below)|January 2015|February 3, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02358421|30 Months|27790|
NCT02347319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2010-PN004|To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease|A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease||PharmaKing|No|Completed|April 2012|June 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|262|||Both|20 Years|70 Years|No|||January 2015|January 26, 2015|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02347319||28639|
NCT02356276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150129|Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer|A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2|HIPEC-01|Affiliated Tumor Hospital of Guangzhou Medical University|Yes|Recruiting|February 2015|January 2022|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|584|||Both|18 Years|70 Years|No|||March 2015|March 19, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02356276||27953|
NCT02359071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atıf-001|Shift Characteristics Affect Handover Duration and Rates.|Which Shift Characteristics Affect Handover Duration and Rates? A Prospective Multicentric Study|Handover|Ataturk University|No|Completed|September 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|267|||Both|16 Years|N/A|No|Probability Sample|we obtained data streams from seven centers, and 267 completed records from different        centre were included.|February 2015|November 19, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359071||27740|
NCT02305758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-217|Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer|Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer||AbbVie|No|Active, not recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305758||31826|
NCT02309970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR 05 - 14|Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke|||Rabin Medical Center|No|Not yet recruiting|December 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|85 Years|No|Non-Probability Sample|men and women admittedto the emergency room at Rabin Medical Center, Beilinson Campus and        hospitalized at the neurology department.|December 2014|December 4, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309970||31504|
NCT02308358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210204|Long Term Outcomes of Osteochondral Allografts for Osteochondral Defects of the Knee|Long Term Outcomes of Osteochondral Allografts for Osteochondral Defects of the Knee.|LongTermOC|University of Missouri-Columbia|No|Withdrawn|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of orthopaedic surgeons in Columbia, Missouri at the University of        Missouri-Columbia Hospital and Clinics.|November 2015|November 23, 2015|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308358||31627|
NCT02356354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 14.190 NERVAL|Study of the Cutaneous Reinnervation After Burn|Study of the Cutaneous Reinnervation After Burn With the Aim of a Better Care of Neuropathic Pain and Pruritus After Healing|NERVAL|University Hospital, Brest|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02356354||27947|
NCT02356367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Face Pilot Study|French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10CS): Predictive Factors of Poor Compliance (FACE)|French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10 CS): Predictive Factors of Poor Compliance|FACE|ResMed|No|Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Failure patient eligible for adaptative servo-ventilation|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356367||27946|
NCT02352844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502067|Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations|Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations||Washington University School of Medicine|No|Recruiting|October 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352844||28217|
NCT02308618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS - 2007882|Rehabilitation Programs After Achilles Tendon Rupture|Achilles Tendon Rupture: Comparative Study Between Two Rehabilitation Programs.||Federal University of Rio Grande do Sul|Yes|Completed|March 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308618||31607|
NCT02352714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011286|Study of Pain Control With Hormonal IUS Insertion|Study of Pain Control With Hormonal IUS Insertion (SOPHI Study)|SOPHI|Children's Hospital of Philadelphia|Yes|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|92|||Female|14 Years|22 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352714||28227|
NCT02354885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0069|TXA in the EMS on the Helicopter and the Ambulance|Administration of Tranexamic Acid in the Preclinical Setting and Its Effect on Coagulation Parameters and Outcome in Multiple Trauma Patients and Isolated TBI in EMS (Schutz Und Rettung Zürich) and Helicopter Rescue(REGA).|TXASRZREGA|University of Zurich|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02354885||28060|
NCT02348268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FREMAP|Myofascial Release Therapy and Mechanical Neck Pain|Myofascial Release Therapy in the Treatment of Occupational Mechanical Neck Pain: a Randomized Parallel Group Study.||FREMAP Mutual Insurance Company for Occupational Accidents and Diseases|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02348268||28567|
NCT02298465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueenMaryH|ESWL for Distal Ureteric Stone: Supine Versus Prone|Randomized Controlled Study on Extracorporeal Shockwave Lithotripsy for Distal Ureteric Stone: Transgluteal Versus Traditional Prone Approach||Queen Mary Hospital, Hong Kong|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02298465||32387|
NCT02303366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 3475-077|Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475|A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.|BOSTON II|Peter MacCallum Cancer Centre, Australia|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|November 4, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303366||32010|
NCT02303860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098013|Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)|Pharmacokinetic Study of ORM-12741 After Multiple Oral Doses||Orion Corporation, Orion Pharma|Yes|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303860||31972|
NCT02354027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-105|The Drug-drug Interaction of SHR3824 and Metformin|Drug Interaction Study of Henagliflozin and Metformin in Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|September 2014|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|July 14, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354027||28126|
NCT02359006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412015119|The Effects of Minocycline in Opioid-maintained Patients|The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients||Yale University|Yes|Recruiting|March 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|55 Years|No|||January 2016|January 8, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359006||27745|
NCT02299479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00014511|Adjusting Insulin Delivery to Activity|Adjusting Insulin Delivery to Activity (AIDA)|AIDA|Children's Hospital Boston|No|Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|1 Year|17 Years|No|||August 2015|August 5, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299479||32309|
NCT02352194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-REHABSEP|Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis|Observational Study of the Physical Capacity of Patients With Multiple Sclerosis and Evaluation of the Effects of Usual Rehabilitation in the Day Hospital|REHABSEP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2014|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|60|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients diagnosed with MS since at least 3 months|May 2014|January 27, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02352194||28266|
NCT02352207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI13005|Risk Factors of Neonatal Respiratory Distress for Newborns With Prenatally Diagnosed Congenital Lung Malformations|Prospective Identification of Predictors of Neonatal Respiratory Distress for Newborns With Prenatally Diagnosed Congenital Lung Malformations : A Population-based, Nationally Representative Study|MALFPULM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|January 2021|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|A portion of tissue malformation|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women referred to a Center of Prenatal Diagnosis, because of the identification        of a pulmonary malformation in the fetus|November 2015|November 30, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02352207||28265|
NCT02345018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1079-101114|Primary Insufficiency of the GSV With a Diameter >/= 12 mm, Antero-lateral Branches, or GSV Insufficiency Below the Knee|Registry of the Treatment of Primary Insufficiency of the Great Saphenous Vein With a Diameter >/= 12 mm, Antero-lateral Branches, or Great Saphenous Vein Insufficiency Below the Knee With Mechano-chemical Endovenous Ablation (MOCA)|MOCA-XL|Rijnstate Hospital|No|Active, not recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|79 Years|No|Non-Probability Sample|Patients with primary insufficiency of the GSV with diameters >/=12 m m, insufficient        antero-lateral branches or below-knee GSV insufficiency|January 2015|January 19, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345018|1 Year|28816|
NCT02347462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02397|Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations|A Prospective Open Randomized Clinical Trial Comparing Bilevel Positive Airway Pressure (BiPAP) Therapy Against Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma Unresponsive to Inhaled Bronchodilators.||University of British Columbia|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|18 Years|No|||August 2015|August 27, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02347462||28628|
NCT02344680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2752|Liver Fibrosis in Zambian HIV-HBV Co-infected Patients|Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study||University of North Carolina, Chapel Hill|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|400 HIV-HBV patients|June 2015|June 19, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02344680||28842|
NCT02355613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268|Comparative Evaluation of Two Different Radiosurgery|Comparative Evaluation of Two Different Radiosurgery Modalities in Brain Metastatic Patients From Several Solid Tumors||Istituto Clinico Humanitas|No|Recruiting|July 2014|July 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|85 Years|No|||January 2015|January 30, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02355613||28004|
NCT02335177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00579-38|Technology and Human Help at Home After Hospitalisation|Technology and Human Help at Home After Hospitalisation (T4H): a Randomized Clustered Controlled Trial|T4H|Ages et Vies Association|No|Terminated|February 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|70 Years|N/A|No|||December 2015|December 28, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335177||29569|
NCT02341690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERWALK|Intervention Study - Effectiveness of Smartphone Delivered Interval Walking Training to Patients With Type 2 Diabetes|The Effectiveness of Smartphone Delivered Interval Walking Training on Physical Activity and Glycemic Control in Patients With Type 2 Diabetes: a Pragmatic Randomized Controlled Trial - Part of The InterWalk Study||University of Copenhagen|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|513|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02341690||29070|
NCT02340377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-11566-046|Pill Study Hyperthermia Device (Heckel HT 3000): Monitoring Core Body Temperature Using Wireless Technology|Core Body Temperature During Hyperthermia in a Whole Body Hyperthermia Device (Heckel HT 3000): Monitoring Core Body Temperature Using Wireless Technology||University of Arizona|No|Terminated|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|For the purposes of this study we will enroll subjects 18-50 years of age to undergo a        Hyperthermia session in an open fashion. We expect approximately 20 - 30 subjects to        undergo this open hyperthermia treatment. Subjects must be medically healthy enough to be        able to undergo the Hyperthermia session, all exclusion criteria listed below address what        is deemed "medically healthy", per self-report by potential subjects. There will be no        inclusion of children, pregnant women, mentally impaired individuals, or prisoners in this        study.|August 2015|August 6, 2015|January 13, 2015||No|investigator transferred institutions|No||https://clinicaltrials.gov/show/NCT02340377||29171|
NCT02340429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV 0094-14|Using a Video Otoscope in Pediatric Ear Examination: A Prospective Randomized Controlled Study:|The Impact of Using a Video Otoscope on Parents' Satisfaction in Pediatric Ear Examination: A Prospective Randomized Controlled Study:||Ziv Hospital|Yes|Completed|January 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|N/A|N/A|No|||January 2015|July 13, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340429||29167|
NCT02328261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV21|A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma|Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study||Betta Pharmaceuticals Co.,Ltd.|No|Active, not recruiting|November 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|75 Years|No|||November 2014|December 26, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02328261||30100|
NCT02328495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Misoprostol /bladder/hystero|Misoprostol Versus Uterine Striating by Bladder Filling for Pain Relief During Office Hysteroscopy|Misoprostol Versus Uterine Striating by Bladder Filling for Pain Relief During Office Hysteroscopy. A Randomized Controlled Trial||Cairo University|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Female|40 Years|75 Years|No|||September 2015|September 19, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02328495||30082|
NCT02328716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-GC/AD-01/11|Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma|Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial.|CARCINOHIPEC|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Active, not recruiting|February 2012|June 2015|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|32|||Female|18 Years|75 Years|No|||March 2015|March 11, 2015|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02328716||30065|
NCT02328729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9995-12|Incident and Extent of Pulse Alteration During Local Anesthesia in Children|Incident and Extent of Pulse Alteration During Administration of Various Modes of Local Anesthesia in Children During Routine Dental Treatment||Tel Aviv University|Yes|Not yet recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||6|Anticipated|300|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children undergo routine dental treatment that require local anesthetic.|December 2014|December 25, 2014|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02328729||30064|
NCT02333201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dynamics|DYsphAgia In Mechanically Ventilated ICU patientS|DYsphAgia In Mechanically Ventilated ICU patientS (DYnAMICS) - a Prospective Multicentre Observational Analysis|DYnAMICS|University Hospital Inselspital, Berne||Completed|April 2015|December 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Probability Sample|Mixed Population of adult ICU patients (aged 18+) post invasive mechanical ventilation|March 2016|March 7, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02333201||29721|
NCT02329522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.640|USCOM For Assessing Patients With COPD|Non-Invasive Doppler Ultrasound For Assessing Patients With Chronic Obstructive Pulmonary Disease: A Prospective Observational Study||Chinese University of Hong Kong|No|Active, not recruiting|February 2014|September 2020|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a de novo diagnosis of COPD or a known history of COPD who attend a        respiratory clinic or the emergency department in the Prince of Wales Hospital (Shatin,        Hong Kong) will be recruited.|November 2015|November 30, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02329522||30003|
NCT02329808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 14.02|Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics|Clinical Validation of a Dried Blood Spot (DBS) Method for the Analysis of Immunosuppressive and Antifungal Drugs in Pediatric Patients (Part of the PROTECT Study).|PROTECT|Radboud University|Yes|Recruiting|June 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|126|Samples With DNA|Plasma without DNA, blood with DNA and dried blood spot (with DNA)|Both|2 Years|18 Years|No|Probability Sample|Pediatric hemato-oncology and primariy immunodeficient patients and pediatric renal        transplantation patients.|August 2015|August 13, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02329808||29981|
NCT02329821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-159|Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection|Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection||Samsung Medical Center|Yes|Completed|November 2014|June 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|||Both|20 Years|65 Years|No|Non-Probability Sample|patients with hepatocelluar carcinoma|July 2015|July 9, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02329821||29980|
NCT02351167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA038076-01A1|Genetically Informed Smoking Cessation Trial|Genetically Informed Smoking Cessation Trial|GISC|Washington University School of Medicine|Yes|Recruiting|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|720|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351167||28345|
NCT02346929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000173|Hematoma Block for Distal Radius Fracture|Comparison of Ultrasound-guided Hematoma Block and "Blind" Hematoma Block for Analgesia in Distal Radius Fractures|Hematoma Block|Beth Israel Deaconess Medical Center|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02346929||28669|
NCT02347215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL119153-01A1|Changes in Ischemia and Angina Over 1 Year Among ISCHEMIA Trial Screen Failures With no Obstructive CAD on Coronary CT Angiography|Changes in Ischemia and Angina Over One Year Among ISCHEMIA Trial Screen Failures|CIAO|New York University School of Medicine|Yes|Recruiting|August 2014|May 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|21 Years|100 Years|No|||October 2015|October 6, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02347215||28647|
NCT02347228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB318CLCT01|Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies||Oneness Biotech Co., Ltd.|Yes|Not yet recruiting|July 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||November 2015|November 23, 2015|December 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347228||28646|
NCT02351882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318-2013|Safety and Efficacy of Nabilone in Alzheimer's Disease|Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study||Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|55 Years|N/A|No|||November 2015|November 26, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02351882||28290|
NCT02347774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN101-302|Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer|GOLDEN-4|Sunovion Respiratory Development Inc.|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|641|||Both|40 Years|N/A|No|||December 2015|December 22, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347774||28604|
NCT02348073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-747|Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy|Efficacy of Phosphatidylserine Enriched With Polyunsaturated n-3 Fatty Acid Supplementation on Attention Deficit Disorders in Children With Epilepsy. A Randomized Double-blind Placebo-controlled Trial|AGPIn3|Hospices Civils de Lyon|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|272|||Both|6 Years|16 Years|No|||September 2015|September 21, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348073||28582|
NCT02348086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF01RA|Outcomes Data of Adipose Stem Cells to Treat Rheumatoid Arthritis|Autologous Adipose Stromal Vascular Fraction Outcomes in Rheumatoid Arthritis Research Study||StemGenex|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|January 2015|June 17, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348086||28581|
NCT02348372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115385|Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), Fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects||GlaxoSmithKline||Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|5||Actual|34|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT02348372||28559|
NCT02349997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-SR-168|Fluid Shift on Obstructive and Central Sleep Apnea|The First Affiliated Hospital of Nanjing Medical University||Nanjing Medical University|No|Enrolling by invitation|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|70 Years|No|Probability Sample|patients with chronic heart failure caused by rheumatic heart disease, cardiomyopathy and        coronary heart disease.|March 2016|March 21, 2016|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02349997||28435|
NCT02344914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0523-14-RMC|Dental Support and the Second Stage of Labor Among Multiparous Women|Dental Support and the Second Stage of Labor Among Multiparous Women||Rabin Medical Center|Yes|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|May 17, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02344914||28824|
NCT02327559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEARLSMZHF|Prenatal Education About Reducing Labor Stress (PEARLS)|Randomized Controlled Trial of a Mindfulness Intervention for Labor-Related Pain and Fear|PEARLS|University of California, San Francisco|No|Active, not recruiting|October 2011|April 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02327559||30154|
NCT02327806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-14-TLV|The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance|The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||December 2014|December 24, 2014|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327806||30135|
NCT02327819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0440-14-TLV|The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2014|December 24, 2014|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327819||30134|
NCT02328027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)|A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis||Advanced Accelerator Applications|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|January 26, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02328027||30118|
NCT02337062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10017|Phase IIIb Study of APD421 in Combination as PONV Prophylaxis|Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients||Acacia Pharma Ltd|Yes|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1204|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02337062||29425|
NCT02337205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KX01-AK-01-US|Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis|A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis||Kinex Pharmaceuticals Inc|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337205||29414|
NCT02337868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0020|Phase 1 Trial of Inactivated West Nile Virus Vaccine|A Double Blind, Randomized, Placebo-Controlled, Phase I Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|March 2015|||December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|51|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|March 17, 2016|January 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337868||29363|
NCT02333422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0061|NIRS Neurofeedback as a Treatment for Attention Deficit Hyperactivity Disorder|Clinical Trial Using NIRS Neurofeedback on Children With Attention Deficit Hyperactivity Disorder (ADHD)||Hospital de Clinicas de Porto Alegre|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|7 Years|12 Years|No|||January 2015|January 6, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02333422||29704|
NCT02339051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 563-14|The Effect of Mechanical Loading on Bone Material Strength and Microarchitecture in Postmenopausal Women|||Sahlgrenska University Hospital, Sweden||Not yet recruiting|January 2015|June 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02339051||29272|
NCT02339220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT130232|The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment|Harnessing Neuroplasticity to Promote Rehabilitation: Constraint-Induced (CI) Therapy for Traumatic Brain Injury (TBI)|TBI|University of Alabama at Birmingham|Yes|Recruiting|January 2015|January 2021|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|90 Years|No|||February 2016|February 24, 2016|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02339220||29260|
NCT02346474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915054|Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI|Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI.||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|January 12, 2016|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02346474||28704|
NCT02346487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiHIVPed002|Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)|Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally|LIVING|Drugs for Neglected Diseases|Yes|Not yet recruiting|January 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3000|||Both|N/A|N/A|No|||December 2014|January 26, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02346487||28703|
NCT02354092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141593|Paracervical Block for Pain Control With Osmotic Dilator Placement|Paracervical Block for Pain Control During Osmotic Dilator Placement: a Randomized Controlled Trial||University of California, San Diego|No|Not yet recruiting|February 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354092||28121|
NCT02351414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-LJK-001|Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts|Post Market Clinical Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts||MicroPort Orthopedics Inc.|No|Recruiting|June 2015|December 2028|Anticipated|June 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with the EVOLUTION® TKA System with cruciate        sacrificing (CS) inserts|October 2015|October 19, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351414||28326|
NCT02351648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/848/E|A Randomised Control Trial of a Transitional Care Model in Singapore General Hospital|A Randomised Control Trial of a Transitional Care Model in Singapore General Hospital||Singapore General Hospital|No|Completed|October 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|840|||Both|21 Years|N/A|No|||January 2015|January 29, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351648||28308|
NCT02354768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5971|Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study|Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study|ILEHOS|University Hospital, Strasbourg, France|No|Recruiting|October 2015|January 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02354768||28069|
NCT02352129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00887-34|Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy|Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy||Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2011|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|330|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02352129||28271|
NCT02352389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUMUT|A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents|A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents||St. Jude Children's Research Hospital|No|Recruiting|February 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|21 Years|No|Non-Probability Sample|Children and young adults identified as having influenza infections by the St. Jude        Children's Research Hospital diagnostic microbiology will be approached to participate in        the study.|September 2015|September 21, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02352389||28251|
NCT02350296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSL0114|Two-way Crossover, Single Dose Randomized, Two-stage Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Granules Oral Solution|Two-way Crossover, Randomised, Single Dose and Two-stage Bioequivalence Phase I Study of Ketoprofen Lysine Salt as Immediate Release Tablets Formulation (40 mg) Versus Ketoprofen Lysine Salt as Granules for Oral Solution (80 mg Bipartite Sachet, Half Sachet) After Oral Administration to Healthy Volunteers of Both Sexes||Dompé Farmaceutici S.p.A|No|Completed|November 2014|April 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02350296||28412|
NCT02350309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-107|Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder||Eisai Inc.|No|Completed|January 2015|May 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|123|||Both|18 Years|99 Years|No|||November 2015|November 2, 2015|January 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350309||28411|
NCT02332421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OMFS-02-2015|The Use of a Modified Dentoalveolar Distractor to Retract Maxillary Canines|A Comparison Of The Short-Term Therapeutic Effects Between Two Distractors Used For The Retraction Of Maxillary Canines By Dentoalveolar Distraction Osteogenesis||Damascus University|Yes|Completed|June 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|25 Years|No|||January 2015|September 26, 2015|January 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02332421||29781|
NCT02332434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15|Effects of Various Bariatric Surgical Procedures on Intestinal TRL Metabolism in Obese Type 2 Diabetic Patients|Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Type 2 Diabetic Patients|MISTRAL|Assistance Publique Hopitaux De Marseille|No|Recruiting|March 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02332434||29780|
NCT02332707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682-011|Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection||Merck Sharp & Dohme Corp.|No|Active, not recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Anticipated|465|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02332707||29759|
NCT02343029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART|Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial|Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial|SMART|Goethe University|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02343029||28967|
NCT02343042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-017|Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Relapsed/Refractory Multiple Myeloma|A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma|STOMP|Karyopharm Therapeutics, Inc|No|Recruiting|October 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|201|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343042||28966|
NCT02332928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12-08248|Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy|Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy: A Double Blind Placebo-Controlled Trial||Virginia Commonwealth University|Yes|Recruiting|March 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|112|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332928||29742|
NCT02332941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406106|Treatment -Resistant Neovascular Age-Related Macular Degeneration|Intravitreal Rituximab|Rituximab|Washington University School of Medicine|Yes|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|41 Years|N/A|No|||June 2015|June 1, 2015|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332941||29741|
NCT02343081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFF -0208|Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System|A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions||Monte Verde SA|No|Completed|January 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|No|||March 2015|March 20, 2015|January 7, 2015||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT02343081||28963|
NCT02338934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT14-HPP-004|Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients|An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients||Penang Hospital, Malaysia|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338934||29281|
NCT02343107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K120901|E-coaching for Type 2 Diabetes|E-coaching for Patients With Abdominal Obesity and Type 2 Diabetes : the A.N.O.D.E. Study|ANODE|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||July 2015|July 2, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343107||28961|
NCT02343120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-3111-AU-003|Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies|A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies||BeiGene|Yes|Recruiting|August 2014|February 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343120||28960|
NCT02350894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-139-14|Microstructural Changes in the Brain During Recovery After Mild Traumatic Brain Injury|Microstructural Changes in the Brain During Recovery After Mild Traumatic Brain Injury||University of Aarhus|Yes|Recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|30 Years|No|Non-Probability Sample|Mild traumatic brain injury subjects with ongoing symptoms 3-4 months after trauma|December 2015|December 4, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350894||28366|
NCT02358824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130BE15002|CKD-828 (80/5mg) Pharmacokinetic Study|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of CKD-828(Telmisartan 80mg/S-amlodipine 5mg Combination Tablet) to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers|CKD-828|Chong Kun Dang Pharmaceutical|No|Completed|February 2015|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|19 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358824||27759|
NCT02354326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Y14|Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer|Evaluation of Bone Metastases With Dual Energy Computed Tomography (CT)||Case Comprehensive Cancer Center|No|Recruiting|November 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354326||28103|
NCT02354560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0377-14-TLV|Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version|Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|10 Years|17 Years|No|||January 2015|January 29, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02354560||28085|
NCT02343887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-49|CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy|CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy|CogStim|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|November 2014|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|18 Years|55 Years|No|||October 2015|October 22, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02343887||28901|
NCT02355223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002396|Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission|Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission||Brigham and Women's Hospital|No|Not yet recruiting|January 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|6607|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02355223||28034|
NCT02355314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208184|Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients|Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients|R2D2|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355314||28027|
NCT02353741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XQonc-001|Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC|Concurrent EGFR-TKIs and Thoracic Radiation Therapy in EGFR Active Mutation for the First Line Treatment of Non-Small Cell Lung Cancer at Stage IV: A Single-arm, Open-label, Single Center, Phase II Trial.|CERTAIN|Xinqiao Hospital of Chongqing|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|75 Years|No|||January 2016|January 2, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02353741||28148|
NCT02353754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-402|Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section|A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) After Bupivacaine Spinal Anesthesia in Subjects Undergoing Elective Cesarean Section||Pacira Pharmaceuticals, Inc|No|Terminated|May 2015|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|January 28, 2015|Yes|Yes|Slow enrollment. None of the subjects received EXPAREL.|No||https://clinicaltrials.gov/show/NCT02353754||28147|
NCT02353923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OcuStem-001|OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy|OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy||Aidan Products LLC|No|Active, not recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02353923||28134|
NCT02336776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FESCKD|Functional Electrical Stimulation in Chronic Kidney Disease|Effects of Functional Electrical Stimulation on Muscle Architecture of Patients With Chronic Kidney Disease: Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Active, not recruiting|May 2014|March 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|80 Years|No|||January 2015|January 8, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02336776||29447|
NCT02336919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02385|The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients|The Use of Text Messaging to Improve the Hospital-community Transition and Prevent Readmission in Patients With Cardiovascular Disease (Txt2Prevent)|Txt2Prevent|Simon Fraser University|No|Not yet recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|75|||Both|19 Years|N/A|No|||May 2015|May 18, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336919||29436|
NCT02337049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26702017|Preeclampsia Subtypes and Surrogate Markers of CVD Risk|||University of Aarhus|Yes|Recruiting|September 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|120|Samples With DNA|Blood serum. Blood plasma. Urine.|Female|N/A|N/A|No|Probability Sample|Eligible participants delivered at the Department of Obstetrics at Randers Regional        Hospital 1998-2008. Early-onset preeclampsia is defined as preeclampsia that develops        before 34 weeks of gestation, whereas late-onset preeclampsia develops at or after 34        weeks of gestation.|January 2015|January 8, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02337049||29426|
NCT02329834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scP-01-002|Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure|Open-label, Single-dose, Randomized, Two-way (Two-period) Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80mg) Administered Intravenously in Subjects With Chronic Heart Failure||scPharmaceuticals, Inc.|No|Completed|April 2015|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02329834||29979|
NCT02334735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0780|A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence|A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2015|June 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334735||29603|
NCT02337413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc130342ctil|Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis|A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Moderate-severe Monosymptomatic Nocturnal Enuresis (MNE) Not Meeting ROME-III Constipation Criteria||Rabin Medical Center|No|Not yet recruiting|January 2016|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|5 Years|17 Years|No|||October 2015|October 26, 2015|January 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02337413||29398|
NCT02337608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1205-CL-211|Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis|Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate to Severe Ulcerative Colitis|ORIGIN|Galapagos NV|Yes|Completed|December 2014|November 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337608||29383|
NCT02330562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ-108|Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma|A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma||Triphase Research and Development I Corporation|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330562||29924|
NCT02343094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003924-35|Phenylbutyrate in Proteinuric Nephropathies|Phenylbutyrate Effect on Lcn2 Urianry Expression in Proteinuric Patients|PIRATE|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2015|March 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343094||28962|
NCT02331108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4613|A Comparison of Inhalation vs. Intravenous Induction|A Comparison of the Effect on Temperature Between Patients Induced With Intravenous Propofol vs Inhalation Induction With Sevoflurane|INHvsIV|Albert Einstein Healthcare Network|No|Active, not recruiting|August 2014|December 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02331108||29882|
NCT02353910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|VTE Incidence in Severe Sepsis and Septic Shock|VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock||University of Utah||Completed|July 2009|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|13 Years|N/A|No|Probability Sample|We prospectively studied 113 consecutively enrolled ICU patients with severe sepsis and        septic shock admitted at three hospitals. All patients provided informed consent and this        study was IRB approved. VTE thromboprophylaxis was recorded for all patients. Patients        underwent bilateral lower (and upper, if a central venous catheter [CVC] was present)        comprehensive compression ultrasonography (CUS) and were followed for symptomatic deep        vein thrombosis (DVT) and pulmonary embolism (PE) prior to discharge. We performed        multivariate regression analyses to identify predictors of VTE|January 2015|February 2, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02353910||28135|
NCT02358759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlBarakaSD3|Management of Abnormally Fertilized Zygotes? InVitro Correction of 3PN|Treatment of Abnormally Multinucleated Zygotes Before Before Division Starting.||Al Baraka Fertility Hospital|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|45 Years|No|||January 2016|January 11, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02358759||27764|
NCT02348099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02461|Ultrasound Detection and Characterization of Subclinical Hypertrophy in Diabetes|Ultrasound Guided Detection and Characterization of Subclinical Lipohypertrophy in Type 1 and Type 2 Diabetes Mellitus||University of British Columbia|No|Recruiting|March 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People age 19 and over with type 1 or type 2 diabetes who take insulin to manage their        diabetes.|December 2015|December 2, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02348099||28580|
NCT02348398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0625|Phase II Study of Pazopanib and Topotecan in Cervical Cancer|A Phase II Study of Pazopanib and Oral Topotecan in Women With Recurrent Cervical Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|February 2016|||February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348398||28557|
NCT02343276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSC-2015|Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs|Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs.||Instituto de Cardiologia de Santa Catarina|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|328|||Both|18 Years|N/A|No|||September 2015|February 22, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343276||28948|
NCT02343289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106240|A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants|An Open-Label Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343289||28947|
NCT02343549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-NEU-NOV-001|A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)|A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)||Carolinas Healthcare System|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|22 Years|N/A|No|||January 2016|January 27, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343549||28927|
NCT02343562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIUNIPEDSURG-CR1|Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis|Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis||Cairo University|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|6 Months|12 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02343562||28926|
NCT02348970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONI-003|Efficacy and Compliance of the Mandibular Advancement Devices ONIRIS® vs. Custom Made Devices|Multicenters, Randomised Clinical Trial, to Evaluate Efficacy and Compliance of Mandibular Advancement Devices ONIRIS® vs. Laboratory Devices TALI in Patients With Syndrome of Obstructive Sleep Apnea and Hypopneas|IRIS|ONIRIS|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||September 2015|October 13, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02348970||28513|
NCT02349217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0233|Mindfulness Based Couples Therapy|Mindfulness Based Couples Therapy for Breast Cancer Survivors: A Pilot Study||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349217||28494|
NCT02344212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080107001|Weight Loss and Prevention in Latina Immigrants: Advancing Methods of Community-Based Intervention Delivery|Weight Loss and Prevention in Latina Immigrants: Advancing Methods of Community-Based Intervention Delivery||University of Alabama at Birmingham|No|Completed|February 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Female|19 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344212||28878|
NCT02344433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-R01|Using Virtual Counselors to Overcome Genetic Literacy Barriers: Project VICKY|Using Virtual Counselors to Overcome Genetic Literacy Barriers: Project VICKY|VICKY|Boston University|No|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|500|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 16, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02344433||28861|
NCT02359136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1999|Effect of Local Infiltration Anesthesia With Ropivacaine on Pain After Primary Total Hip Arthroplasty|Effect of Local Infiltration Anesthesia With Ropivacaine on Pain After Primary Total Hip Arthroplasty||St. Olavs Hospital|No|Completed|March 2013|January 2015|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|116|||Both|N/A|N/A|No|||February 2015|February 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359136||27735|
NCT02359149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1719|Intravitreal Injections by Nurses and Physicians Compared|Intravitreal Injections by Nurses or Physicians: a Randomized Controlled Trial Comparing Efficacy, Patient Satisfaction and Health Economy||St. Olavs Hospital|No|Recruiting|March 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|N/A|N/A|No|||November 2015|November 16, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359149||27734|
NCT02359201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00018 PC 2 07|Assessment of V0018 1.5 mg Effect on Craving|Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 1.5 mg Nicotine Lozenge on Smoking Craving||Pierre Fabre Medicament||Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359201||27730|
NCT02341287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301013445|Temperature Manipulating Gloves for the Treatment of Insomnia|Temperature Manipulating Gloves for the Treatment of Insomnia||Weill Medical College of Cornell University|No|Recruiting|May 2015|November 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02341287||29101|
NCT02341378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCG-K1-02|Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Multicenter, Single-blind, Phase 2A Clinical Trial to Evaluate the Efficacy and Safety of TissueGene-C, a Cell-mediated Gene Therapy, in Degenerative Arthritis Patients||Kolon Life Science|Yes|Completed|August 2009|October 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|45 Years|N/A|No|||January 2015|January 21, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02341378||29094|
NCT02341391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC-KI-01|Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis|A Dose-escalating, Single-center, Phase I Clinical Trial to Investigate the Safety and Biological Efficacy of TissueGene-C in Degenerative Arthritis Patients.||Kolon Life Science|Yes|Completed|February 2007|September 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|12|||Both|45 Years|N/A|No|||January 2015|January 21, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02341391||29093|
NCT02334748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885GFR01|a Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis Who Participated in the Study CACZ885G2301E1|A French Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Who Participated in the International Phase III Study CACZ885G2301E1||Novartis|No|Active, not recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|No|||March 2016|March 3, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02334748||29602|
NCT02343055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000941|COPE With COPD Trial|Collaborative Self-Management Patient Education Will Improve Health Outcomes in COPD||Lawson Health Research Institute|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|40 Years|N/A|No|||April 2015|April 30, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02343055||28965|
NCT02343068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-UPM22-1311|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2014|||||N/A|N/A|N/A||||||||||||||November 29, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343068||28964|
NCT02330835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR55-2|Multimedia Program to Promote Positive Bus Behavior|Multimedia Program to Promote Positive Bus Behavior|BUS_2|Oregon Center for Applied Science, Inc.|No|Completed|January 2007|July 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|710|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||December 2014|January 2, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330835||29903|
NCT02330848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2011/16|Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures|Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures|Walnut3|Griffin Hospital|No|Completed|February 2012|April 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|112|||Both|25 Years|75 Years|No|||December 2014|January 2, 2015|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02330848||29902|
NCT02346942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-474|Factors Associated With Biologic DMARD Switching|Factors Associated With Biologic Disease Modifying Antirheumatic Drugs Switching and Impact of Healthcare Resource Utilization in a Managed Care Setting||Bristol-Myers Squibb|No|Completed|June 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4099|||Both|18 Years|N/A|No|Non-Probability Sample|Individual patients with RA will be identified using electronic medical records from        01/01/2007 to 10/31/2012. The medical file contains data on diagnostic and therapeutic        services rendered in both inpatient and outpatient settings. The diagnoses and procedures        for these services are coded using ICD-9-CM, Current Procedural Terminology (CPT), and        Diagnosis-Related Group (DRG) codes with service dates.|February 2016|February 3, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02346942||28668|
NCT02347241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/12769|Infant Special Program for In Hospital Resuscitation Education in the Delivery Room|Infant Special Program for In Hospital Resuscitation Education in the Delivery Room - INSPIRE-D|INSPIRE-D|Oslo University Hospital|Yes|Active, not recruiting|January 2014|May 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|260|||Both|N/A|N/A|No|||October 2015|November 2, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02347241||28645|
NCT02358772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMO_Outcome Analysis|Comparison of Pre-hospital and In-hospital Iv-tPA Stroke Treatment|||Charite University, Berlin, Germany|No|Active, not recruiting|February 2011|March 2016|Anticipated|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|acute ischemic stroke patients with thrombolytic treatment|February 2016|February 24, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358772|3 Months|27763|
NCT02347254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD004|ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease|Feasibility Trial Evaluating the Safety and Efficacy of ExAblate Transcranial Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for Unilateral Pallidotomy for the Treatment of L-Dopa Induced Dyskinesia (LID) of Parkinson's Disease.||InSightec|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02347254||28644|
NCT02347540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 14-02-013|Heart Failure and Related Risk-factors After Preeclampsia|Queen of Hearts Research Program|QoH|Maastricht University Medical Center|Yes|Recruiting|December 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|2580|Samples With DNA|The investigators will perform an unbiased screen for the human genome content of      circulating microRNAs. Standard HF biomarkers will be included so that the added value of      these novel HFpEF miRNAs can be directly compared to established HF biomarkers. In this      cohort of women who experienced pre-eclampsia and matched controls the investigators will      profile miRNAs on a genome wide scale using total RNA from plasma. Differentially expressed      miRNAs will be further investigated in relation to the pathogenesis of micro- and      macrovascular disease. Selected miRNAs will be placed on a custom megaplex array and used to      screen a cohort of patients with HFpEF. In patients with HFpEF the investigators will relate      miRNA expression level to the circulating levels of angiopoietin-2/ang-1ratio's and      micro-albuminuria. Part of the obtained blood and urine will be stored at the Biobank in      Maastricht for future studies.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cases: women with a history of PE. Control group: women with uncomplicated pregnancies in        the history H1: PP interval ½ -2 years: n = 2x 425 H2: PP interval 5-10 years: n = 2x 350        H3: PP interval 10-15 years: n = 2x 282 H4: PP interval 15-30 years: n = 2x 233|January 2015|January 21, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02347540||28622|
NCT02353065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141/13|Sonographic Assessment of Reduction in Colles' Fracture|Sonographic Assessment of Reduction in Colles' Fracture|SONAR|Teesside University|Yes|Recruiting|January 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|N/A|No|||January 2015|January 28, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02353065||28200|
NCT02353078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008661|The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis|The Effect of Sucralfate Slurry on Dilated Intercellular Spaces, Tight Junctions, Mucosal Impedance and Mucosal Activity in Patients With Eosinophilic Esophagitis|EoE|Mayo Clinic|No|Active, not recruiting|January 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|January 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02353078||28199|
NCT02348411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0073|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Bilateral Anterior Capsulotomy in the Treatment of Medication-Refractory MDD|||Yonsei University|No|Recruiting|December 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|65 Years|No|||January 2015|January 27, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02348411||28556|
NCT02348424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0069|Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin|Phase 1 Open Label Trial of the Safety, Tolerability, and Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|May 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|November 5, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348424||28555|
NCT02348710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059469|Exercise Intervention for Cancer Survivors|Exercise Outcome Expectations Among Breast Cancer Survivors||Duke University|Yes|Active, not recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|68|||Female|19 Years|90 Years|No|||June 2015|January 19, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02348710||28533|
NCT02348723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.204|Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)|Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)||Boehringer Ingelheim||Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|724|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 27, 2015||||No||https://clinicaltrials.gov/show/NCT02348723||28532|
NCT02353481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOR-Heart Failure|1 Year Post Discharge Prognostic Model From the National Heart Failure Audit (NHFA)|||University College, London|No|Active, not recruiting|April 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|63320|||Both|18 Years|N/A|No|Non-Probability Sample|Unscheduled heart failure admissions in England and Wales are recorded in the National        Heart Failure Audit. Therefore, patients with data in the audit will be eligible for        inclusion if they meet the inclusion criteria listed below.|February 2015|February 2, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353481||28168|
NCT02349477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032587|Gabapentin for Alcohol Relapse Prevention|Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects||Medical University of South Carolina|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349477||28474|
NCT02349724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU-BTC-002|A Clinical Research of CAR T Cells Targeting CEA Positive Cancer|A Clinical Research of Chimeric Antigen Receptor(CAR) T Cells Targeting CEA Positive Cancer||Southwest Hospital, China|No|Recruiting|December 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|75|||Both|18 Years|80 Years|No|||March 2016|March 13, 2016|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02349724||28455|
NCT02346747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL-119|Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects With Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy|VITAL|Gradalis, Inc.|Yes|Recruiting|February 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|574|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346747||28683|
NCT02346955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6018-001|Phase 1 Study of CM-24 (MK-6018) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)|A Phase 1, Open-Label, Multicenter, Multi-dose Escalation Study of CM-24 (MK-6018) in Subjects With Selected Advanced or Recurrent Malignancies||Merck Sharp & Dohme Corp.|Yes|Recruiting|February 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|62|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02346955||28667|
NCT02329275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab.Reprod.Biol.- Odense.02|HPV as a Possible Cause of Azoospermia|||Odense University Hospital|Yes|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|140|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group 1: Unselected azoospermic men referred to the fertility clinic Group 2: Proven        fertile men referred for vasectomy|December 2014|December 30, 2014|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329275||30022|
NCT02329288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondMMU2014|Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION|Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy||Second Military Medical University|No|Not yet recruiting|May 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|March 27, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02329288||30021|
NCT02329535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-005413-CTIL|Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix|Comparing a Double Dose of Vaginal Progesterone to no Treatment for the Prevention of Preterm Birth in Twins Pregnancy and Short Cervix||HaEmek Medical Center, Israel|Yes|Recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|214|||Female|18 Years|45 Years|No|||August 2015|August 20, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02329535||30002|
NCT02341300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310014372|Use of Cast Iron Pots to Improve Maternal Anemia|Use of Cast Iron Pots to Improve Maternal Anemia||Weill Medical College of Cornell University|Yes|Not yet recruiting|August 2014|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02341300||29100|
NCT02330302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/453/D|Single Shot Fascia Iliaca Block vs Femoral Nerve Block for Analgesia for Surgical Fixation of Hip Fractures|A Randomized Controlled Trial Comparing Single Shot Fascia Iliaca Block With Femoral Nerve Block for Analgesia Following Surgical Fixation of Hip Fractures||Changi General Hospital|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||July 2015|July 27, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02330302||29943|
NCT02341404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPC-003|A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer|An Open, Single Dose, Antitumour Effect Study of 2-hydroxy-flutamide as a Controlled Release Product (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer||Lidds AB|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|50 Years|75 Years|No|||March 2016|March 10, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02341404||29092|
NCT02334943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9187|Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment|Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment: Etiologic Factors, Forms and Potential Association With Chronic Comorbidities Unrelated to Immune Deficiency.|ACTIVIH|University Hospital, Montpellier|Yes|Completed|March 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|140|||Both|45 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02334943||29587|
NCT02334956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/19|Linking fMRI to Mobile Technologies in Addiction Research: Pathophysiology of Executive Deficits, Craving and Substance Use|Linking fMRI to Mobile Technologies in Addiction Research: Pathophysiology of Executive Deficits, Craving and Substance Use|MobiCogIm|University Hospital, Bordeaux|No|Recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334956||29586|
NCT02335203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0099|The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy|The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy||Women and Infants Hospital of Rhode Island|No|Active, not recruiting|February 2015|June 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335203||29567|
NCT02352402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPCABG|The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)|POPular CABG|St. Antonius Hospital|Yes|Recruiting|March 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|22 Years|N/A|No|||September 2015|September 8, 2015|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02352402||28250|
NCT02352428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO-SCSES_1013|Skin Cancer Screening Education Study|Skin Cancer Screening Education Study|SCSES|Association of Dermatological Prevention, Germany|No|Recruiting|February 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2015|June 5, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02352428||28249|
NCT02352675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00016186|Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis|Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.||Children's Hospital Boston|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|The doctor will obtain one 13.6 mL blood sample from the arterial catheter or intravenous      catheter at the beginning of the procedure after the patient has been anesthetized.|Both|2 Months|12 Months|No|Non-Probability Sample|This is a prospective in vitro study being performed on whole blood obtained from two        groups of infants. The first group will include infants with congenital heart disease        (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at        Boston Children's Hospital. The second group will include infants who do not have        congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such        as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at        Boston Children's Hospital.|April 2015|April 8, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02352675||28230|
NCT02358863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0973|Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach|A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma|mEGA|Georgetown University|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02358863||27756|
NCT02358876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44NS065554|BradyXplore Phase II: Bradykinesia Feature Extraction System|BradyXplore Phase II: Bradykinesia Feature Extraction System||Great Lakes NeuroTechnologies Inc.|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with implanted deep brain stimulation systems for treating Parkinson's disease|August 2015|August 10, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02358876||27755|
NCT02353156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3144|Posthemorrhoidectomy Pain Management With Electronic Bidet or Sitz Bath|Single Blind, Randomized Controlled, Multicenter Study to Evaluate the Efficacy and Convenience of Electronic Bidet With Very Low Force Flow Fountain System for Pain Control and Wound Healing After Operation for Anal Disease, Compared to Conventional Sitz Bath||Seoul National University Hospital|Yes|Enrolling by invitation|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|20 Years|65 Years|No|||November 2015|November 17, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353156||28193|
NCT02353234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDR-001|Bioavailability of Phenolic Compounds in Bread|Bioavailability of Phenolic Compounds in Wholegrain Bread Compared With White Bread Enriched With Aleurone Fraction||University of Parma|No|Completed|December 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02353234||28187|
NCT02353247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-N0278|Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant|Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant||Norton Healthcare|No|Not yet recruiting|February 2015|||September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|N/A|N/A|No|||January 2015|January 28, 2015|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353247||28186|
NCT02353377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-ODH-86|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||March 2, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353377||28176|
NCT02358993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820117|Short-course Methenamine Hippurate for Prevention of Post-operative UTI|The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection|NO-UTI|University of Pennsylvania|No|Recruiting|December 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|190|||Female|18 Years|N/A|No|||January 2015|February 6, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358993||27746|
NCT02353585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ: 2014-027|Novel Oral Anticoagulants in Stroke Patients|A Registry of Novel Oral AntiCoagulants and Vitamin K-antagonists In Stroke Patients - a Multi-center Audit Addressing a) Intracerebral Haemorrhage and b) Acute Ischemic Stroke in Patients Treated With Oral Anticoagulants|NOACISP|University Hospital, Basel, Switzerland|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to the Stroke Unit at the University Hospital Basel (leading and        coordinating center).|October 2015|October 5, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353585|3 Months|28160|
NCT02353598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN29632|A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease|A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease||Genentech, Inc.||Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|72|||Both|50 Years|90 Years|No|||January 2016|January 7, 2016|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02353598||28159|
NCT02359097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9846|Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma|High Resolution Steady State Blood Volume Maps in Glioblastoma Using MRI - A Multicenter Study||OHSU Knight Cancer Institute|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359097||27738|
NCT02351453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/24|Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)|Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)||University Hospital, Angers|No|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|||Both|65 Years|N/A|No|Non-Probability Sample|AD patients and their spouses were recruited in each memory clinic by a physician during        the annual follow-up consultation of AD patient based on eligibility criteria.|November 2011|January 29, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02351453||28323|
NCT02351674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10413|Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI|A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI||Chinese PLA General Hospital|No|Not yet recruiting|January 2015|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|The study requires those data including subjects aged from 20 to 80 year-old, diagnosed as        coronary heart disease with records on mean clinical heart rate during PCI from 2009.1 to        2014.5 in the database from the department of cardiology, Chinese PLA General Hospital,        Beijing.|January 2015|January 27, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351674||28306|
NCT02334176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2014/01|US Guided Axillary Block With Only One Injection|A Prospective, Randomized Comparison Between Single and Double Injection Ultrasound-Guided Axillary Brachial Plexus Block||Institut Kassab d'Orthopédie|Yes|Not yet recruiting|January 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|75 Years|No|||January 2015|January 7, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02334176||29646|
NCT02334423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-001|A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001|A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines||Evolus, Inc.|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334423||29627|
NCT02334436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-002|A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002|A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines|EV-002|Evolus, Inc.|No|Completed|January 2015|December 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|December 17, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02334436||29626|
NCT02334449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLML134X2101|First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers|LML134|Novartis|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02334449||29625|
NCT02337556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.23.CLI|The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU|The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU||Nestlé|No|Recruiting|November 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|208|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337556||29387|
NCT02337569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-02-4|A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency|A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency||Nobelpharma||Recruiting|January 2015|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||January 2015|January 12, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337569||29386|
NCT02341417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140159|Single-arm Extension Study on the Safety of Cinacalcet Treatment in SHPT in Pediatric Subjects With CKD on Dialysis|A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis||Amgen|No|Recruiting|June 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|6 Years|18 Years|No|||February 2016|February 4, 2016|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02341417||29091|
NCT02337803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1056|Band Together: Randomized Control Trial|Band Together: Randomized Control Trial||Milton S. Hershey Medical Center|No|Withdrawn||||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|January 8, 2015||No|A similar study was funded by PCORI so PI decided to not begin this study.|No||https://clinicaltrials.gov/show/NCT02337803||29368|
NCT02334891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2311|Kyoto Congestive Heart Failure Study|Kyoto Congestive Heart Failure Study|KCHF|Kyoto University, Graduate School of Medicine|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who admitted to the participating centers due to acutly decompensated CHF        defined by modified Framingham criteria|December 2015|December 9, 2015|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02334891|1 Year|29591|
NCT02335138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072655|Providing Online Counseling for Home-Based HIV Testing With MSM Couples|Providing Online Counseling for Home-Based HIV Testing With MSM Couples||University of Michigan|Yes|Not yet recruiting|January 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|600|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335138||29572|
NCT02335151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0014|Circulating Tumor Cells and Pancreatic Cancer Surgery|Pancreatic Cancer Surgery and the Role of the Choice of the General Anesthetic. A Randomized Controlled Trial|CTC_Pancreas|University of Zurich|Yes|Not yet recruiting|April 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||December 2015|February 5, 2016|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02335151||29571|
NCT02355769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIM-0000000213|Complex Pathophysiological Background of Heart Failure Deterioration|Multiparametric Assessment of Complex Pathophysiological Background of Heart Failure Deterioration - Relation to Treatment Effects and Prognosis||Military Institute of Medicine, Poland|No|Recruiting|December 2014|June 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with heart failure admitted to the Department of Internal Diseases and Cardiology        urgently because of symptomatic heart failure deterioration|October 2015|October 1, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02355769|24 Months|27992|
NCT02355938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000116|Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury|Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection||Baylor College of Medicine|No|Recruiting|February 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02355938||27979|
NCT02345213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-419|A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)|A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)||Eisai Inc.|Yes|Recruiting|March 2015|May 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|50 Years|99 Years|No|||December 2015|January 19, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345213||28801|
NCT02345226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-366-1160|Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults|A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects||Gilead Sciences|Yes|Active, not recruiting|January 2015|November 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|877|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345226||28800|
NCT02358902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08603612.0.0000.5511|Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia|Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia||University of Sao Paulo General Hospital|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|February 3, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02358902||27753|
NCT02358954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPI01|Vestibular Pain Interactions|Modulation of Pain Responses by Vestibular Stimulation. A Contact Heat Evoked Potential Study.|VPI|University of Zurich|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 11, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02358954||27749|
NCT02358967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123314MP4F|Palm Tocotrienols in Chronic Hemodialysis (USA)|Palm Tocotrienols in Chronic Hemodialysis (PATCH Study)|PATCH|Wayne State University|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|400|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02358967||27748|
NCT02345993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C40-14|Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis|Extra-fine Formoterol/Beclomethasone in the Treatment of Asthmatic Crisis||National Institute of Respiratory Diseases, Mexico|No|Active, not recruiting|January 2015|August 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345993||28741|
NCT02346006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CES 001|CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity|CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity.||Odense University Hospital|Yes|Enrolling by invitation|February 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|December 1, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02346006||28740|
NCT02359019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-111|Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy|Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359019||27744|
NCT02359032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6858-CL-0001|A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects|A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6858 in Healthy Subjects||Astellas Pharma Inc|No|Recruiting|January 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359032||27743|
NCT02346513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD13036|Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty|Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty|CoM|Korea University Guro Hospital|No|Recruiting|February 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|228|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient population is being drawn for patients seen in the orthopedics department from        (April. 2009 -December 2012) patients are selected based on implant type then further        selection is based on inclusion and exclusion criteria. Exclusion criteria are        specifically selected to exclude any pathologies, or environmental factors that would        confound the study population. Once patients are initially selected they are contacted for        participation and brought in for screening. Enrollment proceeds until enough patients have        been recruited to meet statistical criteria and provide sufficient study power.|January 2015|January 20, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02346513|3 Months|28701|
NCT02343939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-1559|Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)|A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Subjects With Acute Myeloid Leukemia (AML)||Gilead Sciences|No|Recruiting|July 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343939||28898|
NCT02343952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN LUN14-179|Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC|A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179||Hoosier Cancer Research Network|Yes|Recruiting|March 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343952||28897|
NCT02339064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-AP2-3000|Infusion of Apomorphine: Long-term Safety Study|A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available|INFUS-ON|US WorldMeds LLC|No|Recruiting|February 2015|November 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|30 Years|80 Years|No|||March 2016|March 3, 2016|March 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02339064||29271|
NCT02339246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Envarsus 3006|Pharmacokinetic Comparison Of All FK-506 Formulations|A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations|ASTCOFF|Veloxis Pharmaceuticals|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|N/A|No|||November 2015|December 11, 2015|December 19, 2014|Yes|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT02339246||29258|
NCT02339259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1408|Causes of Fever in Bangladeshi Patients|Rickettsial Disease in Febrile Hospitalised Patients in a Tertiary Referral Hospital in Bangladesh||University of Oxford|No|Recruiting|October 2014|||October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|330|Samples With DNA|Blood, swab and crust specimen.|Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population of this study is consenting adult patients who have had malaria and        typhus rapid tests meeting the eligibility criteria admitted in CMCH. All study patients        must meet the applicable inclusion and exclusion criteria.        In addition, 30 healthy subjects with no recent history of fever will be recruited to        provide control samples for the blood and plasma assays.        The total sample size is therefore estimated to be 330 (300 patients with paired serology        and 30 healthy subjects).|January 2015|January 14, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02339259||29257|
NCT02342548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241022|Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021|An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021||Pfizer|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|30 Years|66 Years|No|||March 2016|March 22, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342548||29004|
NCT02342587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-028|Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer|Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer: A Phase II Single Arm Prospective Study||Samsung Medical Center||Recruiting|December 2014|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02342587||29001|
NCT02338037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14312|Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Brain Metastases From Breast, Bladder, or Non-small Cell Lung Cancer|An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Metastases From Breast, Bladder, or Non-small Cell Lung Cancer||City of Hope Medical Center|Yes|Recruiting|May 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02338037||29350|
NCT02338570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRFMN-RCC-6691|Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)|Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor|ORCHIDEE|Mario Negri Institute for Pharmacological Research|No|Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02338570||29309|
NCT02338648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-131-02|Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN 131 Transdermal System (TDS) as Compared to Placebo TDS in Adult Patients With a Chalazion||Senju USA, Inc.|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02338648||29303|
NCT02344693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/4 03.12.2012|Electroencephalography in Patients Resuscitated From Cardiac Arrest|Electroencephalography in Patients Resuscitated From Cardiac Arrest||Helsinki University Central Hospital|Yes|Not yet recruiting|November 2015|||March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients resuscitated from a non-traumatic cardiac arrest in a urban setting in southern        Finland|August 2015|August 19, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344693|1 Month|28841|
NCT02344706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/3 03.12.2012|Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus|Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus||Helsinki University Central Hospital|Yes|Not yet recruiting|December 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients unconscious due to seizures in the prehospital field|August 2015|August 19, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344706||28840|
NCT02344927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 340|CRT Hydration in the Last Days of Life (Feasibility Study)|A Cluster Randomised Trial of Alternative Forms of Hydration in Cancer Patients in the Last Days of Life (Feasibility Study)||University of Surrey|Yes|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02344927||28823|
NCT02349490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seraseal1|Seraseal for Endoscopic Hemostasis|A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding||Medical University of Vienna|No|Completed|November 2011|January 2015|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02349490||28473|
NCT02345499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4201|Open Versus Laparoscopic Radical Cystectomy|Open Versus Laparoscopic Radical Cystectomy for Invasive Bladder Cancer in the Elderly Patient. A Multicenter Randomized Clinical Trial.|OvsL|Azienda Ospedaliero-Universitaria Consorziale|Yes|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Male|70 Years|N/A|No|||January 2015|January 19, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02345499||28779|
NCT02345759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWG 5/2014|Psychological Aspects and Patients Compliance to Restricted-protein Regimens in Chronic Kidney Disease|Psychological Aspects Related to Compliance of Patients on Restricted-protein Regimens in Chronic Kidney Disease|KetoPsy|Anemia Working Group Romania|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|85 Years|No|Probability Sample|All consecutive adult patients, with stage 4-5ND CKD (estimated glomerular filtration by        MDRD formula of less than 30 mL/min per year) included in the dietary intervention program        of "Dr Carol Davila" Teaching Hospital of Nephrology coming for the scheduled visits        between January the 1st and June the 30th, 2014 will be considered eligible.        Those who will sign the informed consent will be included in the study; the        specially-designed questionnaire will be administered. Simultaneously, their routine        assesment, including the dietary compliance, manifestations of CKD and the nutritional        status will be performed, as recommended by the Romanian Best Practice Guidelines for CKD        [28].|January 2015|January 23, 2015|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02345759||28759|
NCT02350582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS-0457-2010|e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer|e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer Patients|e-CUIDACHEMO|Universidad de Granada|No|Recruiting|April 2012|June 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|25 Years|80 Years|No|||January 2015|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02350582||28390|
NCT02346227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-IHU- 2012-01|Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix|Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo|KINVAV|Universiteit Antwerpen|Yes|Not yet recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|25 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 23, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02346227||28723|
NCT02351206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2014-05|Lumbar Disc Space Height in Young Disc Herniation and Degeneration Patients|Lumbar Intervertebral Disc Space Height in Disc Herniation and Degeneration Patients in Their Early 20s||Jaseng Hospital of Korean Medicine|No|Completed|January 2010|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|389|||Both|20 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Patients visiting Jaseng hospital of Korean Medicine, a spine specializing Korean medicine        hospital designated by the Korean ministry of health and welfare, from January, 2010 to        October 2014|January 2015|January 29, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351206||28342|
NCT02355327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SREC 14-15 02 D 02 12 2014|Vibrating Vaginal Balls After Childbirth|Feasibility Trial on the Effectiveness of Vibrating Vaginal Balls to Improve Pelvic Floor Muscle Performance in Women After Childbirth||City University, London|No|Active, not recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|56|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02355327||28026|
NCT02355340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-411|Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture|Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture||Dana-Farber Cancer Institute|No|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|8 Years|20 Years|No|||January 2016|January 19, 2016|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02355340||28025|
NCT02348463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV and pregnancy|Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg and the Effect on Spontaneous Preterm Delivery|Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg County in Sweden and the Effect on Spontaneous Preterm Delivery||Skaraborg Hospital|No|Completed|January 2007|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|540|||Female|18 Years|52 Years|No|Probability Sample|Pregnant women with bacterial vaginosis in early pregnancy|January 2015|January 27, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348463||28552|
NCT02337166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-HUAM/CCM 21/03|Regeneration of Human Intrabony Defects With rhFGF-2/HA|Regeneration of Human Intrabony Defects With Recombinant Human Fibroblast Growth Factor 2 in a Hyaluronic Acid Gel Carrier - a Longitudinal, Prospective, Randomized Controlled Clinical Trial||Universidade Federal Fluminense|Yes|Completed|December 2002|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02337166||29417|
NCT02337361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AA022697|Computerized Tool for Preventing Prenatal Drinking|Preparing a Computerized Tool for Preventing Prenatal Drinking for a Larger Trial||Public Health Institute, California|Yes|Not yet recruiting|September 2015|August 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02337361||29402|
NCT02337374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSRTH2010-06|Predictive Role of Urodynamics on Mid-urethral Sling Failure|Do Urodynamics Superior to 25 Years of Clinical Expertise Predict Mid-Urethral Sling Failure?|UPMUSF|Kanuni Sultan Suleyman Training and Research Hospital|No|Completed|June 2010|||February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|242|||Female|18 Years|80 Years|No|Probability Sample|Women with stress urinary incontinence and who desired surgical correction of their        incontinence|January 2015|January 9, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02337374||29401|
NCT02330783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-RCC-141201|Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients|A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma||Beijing Cancer Hospital|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|75 Years|No|||February 2016|February 27, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330783||29907|
NCT02330796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV-201|Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout|A RANDOMIZED, MULTICENTRE PHASE IIa OPEN-LABEL, ACTIVE-COMPARATOR TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWO REGIMENS OF BUCILLAMINE 100 MG TABLETS AS COMPARED TO COLCHICINE 0.6 MG TABLETS FOR THE TREATMENT OF AN ACUTE GOUT FLARE IN SUBJECTS WITH MODERATE TO SEVERE GOUT.||Revive Therapeutics, Ltd.|Yes|Recruiting|April 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|December 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330796||29906|
NCT02331069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAI Protocol number 01006|Delto-Tricipital Compression Syndrome: Treated With Injection of Dextrose|Delto-Tricipital Compression Syndrome: A Randomized Treatment Comparison Trial of Dextrose Injection Versus Physical Therapy.||Universidad Abierta Interamericana|No|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|80 Years|No|||March 2015|March 13, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02331069||29885|
NCT02342613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1484|Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation|Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes Derived From Patients With Bone Marrow Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis.||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|January 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342613||28999|
NCT02327078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-204|A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers|A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers||Incyte Corporation|Yes|Recruiting|November 2014|October 2019|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|291|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327078||30191|
NCT02327312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-004|Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty|||Glaukos Corporation|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|35 Years|N/A|No|||June 2015|June 16, 2015|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327312||30173|
NCT02348983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP-ERC 5T42OH009229-06 Pilot|Weight Loss Intervention in Long-Haul Truck Drivers: A Pilot Study|Weight Loss Intervention in Long-Haul Truck Drivers: A Pilot Study|WHEEL-Pilot|University of Utah|No|Completed|January 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02348983||28512|
NCT02349230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10Astym|The Effect of Astym Treatment on Muscle Performance|The Effect of Astym Treatment on Acute Changes in Muscle Performance|Astym|Duquesne University|No|Completed|June 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02349230||28493|
NCT02353936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0432|A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus|||Yonsei University|No|Recruiting|January 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|N/A|No|||February 2015|February 22, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02353936||28133|
NCT02353949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flutemetamol 1|Investigating the Clinical Consequences of Flutemetamol-PET-scanning|Investigating the Clinical Consequences of Flutemetamol-PET-scanning||University of Zurich|No|Recruiting|May 2015|||February 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 24, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02353949||28132|
NCT02349737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quality control study|Evaluation of Interference Between Bioelectrical Impedance Analysis and Implantable Cardioverter Defibrillators|Use of Bioelectrical Impedance Analysis in the Nutritional Assessment of Patients With CHF Equipped With Implantable Cardioverter Defibrillators||University Hospital, Geneva|No|Recruiting|October 2014|||January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ICD.|January 2015|January 28, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02349737||28454|
NCT02350010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D141100000114003|Etiology and Prognostic Risk Factors of Intracerebral Hemorrhage in Beijing|The Research of Etiology and Risk Factors Related to Prognosis of Intracerebral Hemorrhage in Beijing||Beijing Neurosurgical Institute|Yes|Not yet recruiting|January 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted with CT-demonstrated Intracerebral Hemorrhage (ICH) within 72 hours        after symptom onset.|January 2015|January 26, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02350010||28434|
NCT02350322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHF 900842 WP6|Diet and Learning Abilities in Norwegian Youths|Diet and Learning Abilities in Norwegian Youths||National Institute of Nutrition and Seafood Research, Norway|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|478|||Both|14 Years|15 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350322||28410|
NCT02350920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDublin|Acceptance and Commitment Therapy (ACT) in Inflammatory Bowel Disease|A Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) in Inflammatory Bowel Disease||University College Dublin|Yes|Recruiting|February 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350920||28364|
NCT02351193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26012015|a Predictive Scheme for Poor Responders in IVF Cycles|A Predictive Scheme to Assess the Outcome of IVF/ICSI Cycles in Poor Responders. an Observational Study in Egypt||Woman's Health University Hospital, Egypt|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|928|||Female|20 Years|45 Years|No|Non-Probability Sample|Poor responder females|January 2015|January 30, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02351193||28343|
NCT02343315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUSMS107/14|Are Supervised Exercises and TENS Necessary Along With Prescribed Home Exercises for Chronic Low Back Pain?|Effectiveness of TENS and Supervised Motor Control Exercises Compared To Unsupervised Exercises in Subjects With Chronic Low Back Pain: A Randomized Clinical Trial||Kathmandu University School of Medical Sciences|Yes|Not yet recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343315||28945|
NCT02343588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202010|A National School-based Health Lifestyles Interventions Among Chinese Children and Adolescents Against Obesity|Development and Application of Appropriate Technology for Obesity Prevention and Control in Seven Centers in China||Sun Yat-sen University|Yes|Completed|September 2013|January 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70000|||Both|7 Years|18 Years|No|||January 2015|January 22, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02343588||28924|
NCT02343601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00870-47|Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery|Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery : A Randomized Controlled Study|PANEX3|University Hospital, Caen|Yes|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|160|||Both|18 Years|95 Years|No|||December 2015|December 3, 2015|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02343601||28923|
NCT02348944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVAR|Biological Variability in Cartilage Specific Biomarkers in Healthy Volunteers.|Evaluation of Biological Variability in Cartilage Specific Biomarkers (Coll2-1, Coll2-1NO2, FIB3-1 and FIB 3-2) in Healthy Volunteers.|COVAR|Artialis|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|15|Samples With DNA|Serum and urine samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or female above 18 years|January 2015|January 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02348944||28515|
NCT02349178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bridging|Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT|Bridging Study: A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia and Minimal Residual Disease||Medical College of Wisconsin|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|39 Years|No|||January 2016|January 7, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349178||28497|
NCT02342483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BERG1200|MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge|The Efficacy of the MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge A Randomized, Double-blind, Adaptive-design Study||Medicus Research, LLC|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02342483||29009|
NCT02342496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/3|Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly|Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly.||Probi AB||Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|75 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02342496||29008|
NCT02342522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/14/3/31002|Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI|Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention (ERIC-PPCI): A Multicentre Randomised Controlled Clinical Trial|ERIC-PPCI|University College, London|Yes|Not yet recruiting|September 2015|December 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|October 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02342522||29006|
NCT02335437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBA|Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents|Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents|CEBA|University Hospital, Akershus|No|Recruiting|March 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|270|||Both|12 Years|20 Years|Accepts Healthy Volunteers|Probability Sample|Microbiological laboratories serving the population of Oslo and neighbour conties.|December 2015|December 29, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335437||29549|
NCT02335684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-103|Effects of Increased CF-LVAD Pump Speed During Sustained Submaximal Exercise|Improving Functional Capacity in Heart Failure Patients Supported With Continuous-flow Left Ventricular Assist Devices. -Effects of Increased Pump Speed During Sustained Submaximal Exercise||Rigshospitalet, Denmark|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|31|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02335684||29531|
NCT02342873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inter2|Nerve Stimulator Versus Ultrasound-guided Interscalene Block for Shoulder Surgery|A Randomized Comparison of Nerve Stimulator-guided and Ultrasound-guided Interscalene Block for Shoulder Surgery||Cheju Halla General Hospital|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|80 Years|No|||July 2015|July 12, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342873||28979|
NCT02331342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOM IGR|Comparison of NICOM and Innocor for Non-Invasive Determination of Cardiac Output|||Universitätsmedizin Mannheim|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|inpatients and outpatients|January 2015|January 5, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331342||29864|
NCT02331628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-13|ESWT as a Treatment for Chronic NHO in TBI Patients|Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured Patients||Loewenstein Hospital|Yes|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02331628||29842|
NCT02331888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0131-14-RMC|To Compare the Efficacy Between 3 Fetal Monitoring Methods|A Prospective, Blinded Clinical Study to Compare the Efficacy Between Three Fetal Monitoring Methods: Electro Uterine Monitor (EUM), Fetal Doppler and Scalp Electrode.|EUM|Rabin Medical Center|Yes|Recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02331888||29822|
NCT02353611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-ODO 15/001|Safety and Efficacy of a 6% Hydrogen Peroxide Tooth Bleaching Agent|Safety and Efficacy of a Light-activated 6% Hydrogen Peroxide With Nitrogen-doped Titanium Dioxide Tooth Bleaching Agent||University of Chile|Yes|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|February 2, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353611||28158|
NCT02353624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nordkapp cycling study|Physiological Responses to a Prolonged Cycling Expedition in Older Men|Physiological Responses to a Prolonged Cycling Expedition in Older Men||University of Copenhagen|Yes|Completed|May 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Urine samples, muscle and subcutaneous adipose tissue biopsies and venous blood samples.|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Older male cyclits particpating in the cycling event|January 2015|February 2, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02353624||28157|
NCT02353767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 42|Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome||METAFIB|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|478|Samples Without DNA|plasma, serum|Both|18 Years|90 Years|No|Non-Probability Sample|Eligible patients followed in the Infectious Diseases department of Saint-Antoine        hospital.|January 2015|February 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353767||28146|
NCT02359396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKBU/FRG2/13-14/025|A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics|Effects of Oral Administration of a Chinese Proprietary Medicine, MZRW on Tolerability, Exposure and Pharmacokinetics in Healthy Subjects||Hong Kong Baptist University|Yes|Completed|November 2014|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|August 19, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02359396||27715|
NCT02354118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12135-12-079|Maintaining Patency in Implanted Port Catheters|Maintaining Patency in Implanted Port Catheters With Saline Only Flushes||TriHealth Inc.|No|Recruiting|January 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|396|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354118||28119|
NCT02359461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0216|Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2|Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2|STENDO3|University Hospital, Clermont-Ferrand||Recruiting|November 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02359461||27710|
NCT02359474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyperTET|Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin|Trabectedin Combined With Regional Hyperthermia as Second Line Treatment for Adult Patients With Advanced Soft-tissue Sarcoma|HyperTET|Ludwig-Maximilians - University of Munich||Recruiting|January 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02359474||27709|
NCT02354339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-IGABONENSIS|Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity|Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity||University of Guadalajara|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|60 Years|No|||November 2015|November 30, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354339||28102|
NCT02354352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0387|Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy|Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy||Ohio State University|Yes|Recruiting|January 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Male|10 Years|N/A|No|||October 2015|October 1, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354352||28101|
NCT02354586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-30-5020-C|A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens|A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at Least Three Previous Chemotherapy Regimens||Tesaro, Inc.||Recruiting|March 2015|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|January 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354586||28083|
NCT02354599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT203/CPH-001|A Phase 1 MT203 Single-dose Study to Evaluate Safety, PK and PD|A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Male Participants||Takeda|No|Recruiting|November 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02354599||28082|
NCT02347813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URochester RSRB 00052209|Preventing Squamous Cell Skin Cancer|Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients||University of Rochester|Yes|Enrolling by invitation|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347813||28602|
NCT02348450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1404|Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer|Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study||Guangdong Association of Clinical Trials|No|Recruiting|December 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|70 Years|No|||January 2015|January 22, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02348450||28553|
NCT02348684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiac MRI post RT Breast Ca|Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation|Pilot Study to Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation in Women Treated for Node Positive Breast Cancer With Three- Dimensional Conformal Radiation Therapy (3DCRT)||Medical College of Wisconsin|No|Withdrawn|March 2012|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|95 Years|No|Probability Sample|Women Treated for Node Positive Breast Cancer with Three-Dimensional Conformal Radiation        Therapy (3DCRT)|February 2016|February 9, 2016|August 22, 2014||No|no enrollment|No||https://clinicaltrials.gov/show/NCT02348684||28535|
NCT02352649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurotmesis|Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury|1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber||Human Stem Cell Institute, Russia|No|Not yet recruiting|April 2015|September 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||January 2015|January 28, 2015|January 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02352649||28232|
NCT02330263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0908|Effect of Preoperative Oral Carbohydrates on Postoperative Insulin Resistance in Patients Undergoing OPCAB(Off- Pump Coronary Artery Bypass Surgery)|||Yonsei University|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|79 Years|No|||July 2015|July 1, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02330263||29946|
NCT02330497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFAP|Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor|Efficacy and Safety of Radiofrequency Ablation Under Endoscopic Ultrasonography Guidance in Pancreatic Neuroendocrine and Cystic Tumor||Société Française d'Endoscopie Digestive|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||November 2015|November 23, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02330497||29929|
NCT02330510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ml1-112246|Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease|Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease|MITNEC C6|Sunnybrook Health Sciences Centre|Yes|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Whole blood will be collected to better understand the possible contribution of genetics to      white matter disease. DNA will be extracted from blood samples to assess the Apolipoprotein      (ApoE) gene type, as ApoE e4 genotype may influence the rate of disease progression.|Both|60 Years|N/A|No|Probability Sample|Two groups of patients will participate in this study:          1. Patients with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild             Cognitive Impairment who have extensive pvWMH; recruited from memory clinics (n= 75)          2. Patients who have had a stroke or a Transient Ischemic Attack (TIA) with extensive             pvWMH; recruited from stroke prevention clinics (n= 75)|September 2015|September 23, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02330510||29928|
NCT02342834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LISBONA|Effects of a Small Protein and Lipid Preload on Glucose Tolerance in Subjects With Impaired Glucose Homeostasis|Mechanisms Through Which a Small Protein and Lipid Preload Improves Glucose Tolerance in Subjects With Impaired Glucose Homeostasis||Azienda Ospedaliero, Universitaria Pisana|No|Enrolling by invitation|January 2015|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02342834||28982|
NCT02342886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-006-(M-PA-Z)|Shortening Treatment by Advancing Novel Drugs|A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.|STAND|Global Alliance for TB Drug Development|Yes|Suspended|February 2015|May 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1500|||Both|18 Years|N/A|No|||November 2015|January 12, 2016|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02342886||28978|
NCT02342912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK100916|Social Media Obesity Treatment for College Students|Translation of Social Media Obesity Treatment Into Two College Campus Communities||George Washington University|Yes|Recruiting|February 2015|April 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02342912||28976|
NCT02335970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoU in Sweden 13891|Effects of a Training Intervention After Thoracoabdominal Oesophagus Surgery|Effects of a Training Intervention After Thoracoabdominal Oesophagus Surgery -a Randomized Controlled Trial||Göteborg University|No|Completed|September 2005|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02335970||29509|
NCT02336529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-172|Nerveblocks for Persistent Pain After Breast Cancer Surgery|Tenderpoint and Ultrasound Guided Nerveblocks for Persistent Pain After Breast Cancer Surgery||Rigshospitalet, Denmark|No|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|48|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336529||29466|
NCT02336633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130918|Resveratrol and Huntington Disease|Metabolic Intervention Using Resveratrol in Patients With Huntington Disease|REVHD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2015|June 17, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02336633||29458|
NCT02359357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDL169-2014-01|FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers|A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers||Flatley Discovery Lab LLC|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|22||Anticipated|176|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02359357||27718|
NCT02359383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20133001|Impact of Respiratory Physiotherapy in the Management of Infectious Pleural Effusion|Impact of Respiratory Physiotherapy in the Management of Infectious Pleural Effusion|FISIOPLEURA|Hospital de Granollers|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|85 Years|No|||September 2015|September 15, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02359383||27716|
NCT02346526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-375|A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer|A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer||Massachusetts General Hospital|Yes|Recruiting|May 2015|July 2021|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346526||28700|
NCT02346539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002495-01|Effect of Nicotine on Brain Reward Pathways|Effect of Nicotine on Brain Reward Pathways||Mclean Hospital|No|Recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346539||28699|
NCT02359435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaohsiungVGH|Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection|Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection — a Randomized Controlled Trial (REHYTRI Study)|REHYTRI|Kaohsiung Veterans General Hospital.|Yes|Completed|October 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|20 Years|N/A|No|||September 2015|January 11, 2016|January 25, 2015||No||No|January 11, 2016|https://clinicaltrials.gov/show/NCT02359435||27712|The trial was performed in a single country
NCT02346968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/14|Evaluation of CAF22 After Renal Transplantation|Evaluation of Serum and Urinary C-terminal Agrin Fragment-22 (CAF22) as Novel Renal Function Marker in Kidney Transplant Recipients - A Prospective Observational Study||University Hospital Inselspital, Berne|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Serum, urine|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with end stage renal disease (ESRD) planned to undergo kindey transplantation in        Bern University Hospital will be screened consecutively, informed and asked for written        inform consent.|September 2015|September 30, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346968||28666|
NCT02347293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2013/241b|Over-night Effect of Dietary Fiber on Glucose Metabolism and Satiety|Indigestible Carbohydrates in an Over-night Design as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety||Lund University|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|21|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347293||28641|
NCT02359500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2008|68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)|Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359500||27707|
NCT02359526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2014-06|A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients|A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND)|RESPOND|Association for Innovation and Biomedical Research on Light and Image|No|Active, not recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02359526||27705|
NCT02359539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams University|Marginal Periosteal Pedicle Flap - Platelet Rich Fibrin Barriers in Treating Periodontal Intrabony Defects|Marginal Periosteal Pedicle Flap and Platelet Rich Fibrin Barriers for the Treatment of Periodontal Intrabony Defects -Randomized Clinical Trial||Al-Azhar University|Yes|Completed|August 2009|May 2013|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|50 Years|No|||November 2014|February 9, 2015|November 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359539||27704|
NCT02348359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X82-OPH-201|X-82 to Treat Age-related Macular Degeneration|A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD||Tyrogenex|Yes|Recruiting|March 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|50 Years|N/A|No|||March 2016|March 22, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348359||28560|
NCT02342431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|momo_bh_1|Comparison of a Patient Warming System Using a Forced-air, Non-compressible Under-body Mattress Versus a Regular Forced-air Underbody Mattress System During Pediatric Cardiac Catheterization|Comparison of a Patient Warming System Using a Forced-air, Non-compressible Under-body Mattress Versus a Regular Forced-air Underbody Mattress System During Pediatric Cardiac Catheterization||Medical University of Vienna|No|Withdrawn|October 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|1 Year|No|||January 2015|January 14, 2015|November 13, 2012||No|Cardiac Catheterization no longer part of the anesthesia department A (no belonging to cardiac    anesthesia, which is a different department)|No||https://clinicaltrials.gov/show/NCT02342431||29013|
NCT02342457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0274-13-RMC|Electrophysiological Activity of the Anorectum in Children Suspected of Hirschsprung Disease|The Elactrophysiological Response of the Colon, in Normal Bowel, and Large Bowel Lacking Ganglia in Children With Suspected Hirschsprungs Disease.||Rabin Medical Center|No|Not yet recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|3 Months|18 Years|No|||January 2015|January 20, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02342457||29011|
NCT02342470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-S005_Phase II|Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users|A Multiple-center, Randomized, Double-blind, Parallel, Placebo-controlled, Dose-selection Phase II Study to Evaluate the Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users||PharmaKing|No|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|160|||Both|19 Years|N/A|No|||January 2015|January 14, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02342470||29010|
NCT02334904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01075|Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI|Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI|CARB|University of British Columbia|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Participants will be offered the option of taking part in an optional biobanking component      of the main study. Eight milliliters of whole blood samples will be collected and stored at      -80 degrees Celsius for genotyping to determine if certain genetic polymorphisms predispose      individuals to brain changes while taking antipsychotic medications.|Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted to Vancouver.Richmond EPI program who have been on at least 3 months of        continuous antipsychotic drug treatment with either aripiprazole or risperidone for        first-episode psychosis or bipolar disorder, and healthy controls.|November 2015|November 30, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02334904||29590|
NCT02335164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU003|A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults|A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults|FLU003|Vaxine Pty Ltd|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02335164||29570|
NCT02327546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0012|Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548|An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.||Akebia Therapeutics|No|Completed|December 2014|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02327546||30155|
NCT02327780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407-14-TLV|The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome|The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|77 Years|No|||December 2014|December 29, 2014|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327780||30137|
NCT02327793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATIS Version 1.0|Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke|Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke|PATIS|University of Alberta|No|Active, not recruiting|June 2009|August 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02327793||30136|
NCT02342925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29394|A Study of the Effect of RG1662 on Metformin in Healthy Volunteers|||Hoffmann-La Roche||Completed|February 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02342925||28975|
NCT02342951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB-2013-A01175-40|Evaluation of the Lung Clearance Index|Evaluation of Lung Clearance Index for Early Detection of Lung Disease in Young Children With Cystic Fibrosis|LCI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2014|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|3 Years|6 Years|No|||November 2015|November 11, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02342951||28973|
NCT02342964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB-2013-A01579-36|Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis|Comparative Study of Different Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis|MUCO-FIBRO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|6 Years|18 Years|No|||November 2015|November 11, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02342964||28972|
NCT02342977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408905316|Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:|Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.||Indiana University|Yes|Recruiting|November 2014|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 16, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02342977||28971|
NCT02346019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00090292|Thigh Reduction Surgery of Above Knee Amputee Residual Limbs to Improve Prosthesis Fit and Patient Outcomes|Thighplasty of Transfemoral Amputee Residual Limbs to Improve Prosthesis Fit and Patient Functional Outcomes||Rehabilitation Institute of Chicago|No|Active, not recruiting|August 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|3|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02346019||28739|
NCT02346032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-148|Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma|Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma||Samsung Medical Center|No|Not yet recruiting|January 2015|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|20 Years|N/A|No|||January 2015|January 19, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02346032||28738|
NCT02346240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0003|Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)|A Phase 3, Multicenter, Randomized, Double Blind, Parallel Group, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|CIMPACT|UCB Pharma|No|Active, not recruiting|February 2015|January 2019|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|559|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346240||28722|
NCT02346253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0065|High-Dose Brachytherapy in Treating Patients With Prostate Cancer|A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer||Stanford University|Yes|Recruiting|January 2015|||January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|163|||Male|N/A|N/A|No|||April 2015|April 29, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346253||28721|
NCT02346916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1054|Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia|Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia||Bassett Healthcare|No|Active, not recruiting|October 2013|||August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346916||28670|
NCT02347176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2213C00001|Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis|A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis|D2213C00001|MedImmune LLC|No|Completed|January 2015|February 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|306|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347176||28650|
NCT02346760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A101-HSV|Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers|A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Subcutaneous Dose of UB-621 in Healthy Volunteers||United BioPharma|Yes|Recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02346760||28682|
NCT02347514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0973|Implementing Diabetes Group Visits in Community Health Centers|Implementing Diabetes Group Visits in Community Health Centers||University of Chicago|No|Recruiting|November 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|343|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347514||28624|
NCT02347748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046792|Comfort Talk for Pediatric Cardiac Catheterization|The Impact of Comfort Talk on Anxiety Levels and Procedural Experience in a Pediatric Population Undergoing Cardiac Catheterization: A Prospective Randomized Controlled Trial||The Hospital for Sick Children|Yes|Recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|160|||Both|7 Years|18 Years|No|||January 2015|January 21, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347748||28606|
NCT02347306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01987 Protocol 1.0 September|Prospective Identification of High-risk Coronary Plaques Through Non-invasive Imaging|Prospective Identification of High-risk Coronary Plaques Through Non-invasive Imaging||Papworth Hospital NHS Foundation Trust|No|Enrolling by invitation|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|This study will be an observational, retrospective, single center cohort study based at        Papworth Hospital NHS Trust, including up to a maximum of 100 patients. The patients have        already been identified through their participation in a previous research study, as        stated above. Additional inclusion criteria are; age >18 years and the ability to provide        informed consent. The only exclusion criterion is the inability of the participant to        provide informed consent.|January 2015|January 26, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02347306||28640|
NCT02347566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/0380|Physical Activity Enhancing Programme in COPD|The Efficacy of a Physical Activity Enhancing Programme Using Activity Monitors With Set Targets and Feedback for Enhancing Physical Activity Levels in Patients With COPD Attending Pulmonary Rehabilitation.|PAEP|University of Edinburgh|Yes|Recruiting|February 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|30 Years|95 Years|No|||July 2015|July 29, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347566||28620|
NCT02347579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35546.068.11|Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain||BrainEXPain|Maastricht University Medical Center|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|People diagnosed with CRPS, type I, and people with chronic low back pain (CLBP) are        target population for this study. A group of healthy controls matched for age, gender and        handedness will also take part in the study.|September 2015|September 24, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02347579||28619|
NCT02355210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA-NIFA-AFRI-003397|Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults|Application of a Novel Synbiotic to Modulate the Human Gut Microbiota and Improve Health||Rush University Medical Center|No|Active, not recruiting|June 2013|January 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 8, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355210||28035|
NCT02352376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11104413.6.0000.5152|Noninvasive Ventilation After Coronary Bypass Grafting|Effects of Non Invasive Ventilation on Heart Rate Variability After Coronary Bypass Grafting: Comparison Between Different Ventilator|Physiotherapy|Federal University of Uberlandia|Yes|Completed|March 2013|November 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02352376||28252|
NCT02355301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD26012015|Improve the Quality of Care in Patients With Orthopaedic Disorders|How to Improve the Quality of Care in Patients With Orthopaedic Disorders? - by Using the ICF in All Patients After Conservative or Surgical Treatment. - Through the Creation of an International Norm to Improve the Surgical Precision|QualOrtho|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Active, not recruiting|April 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|||Both|1 Year|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with orthopedic disorders usually followed in the Department of Orthopedics        clinics (St Luc Hospital - Brussels - Belgium)|October 2015|October 12, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355301|12 Months|28028|
NCT02330042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#00010949|OCT Biomarkers for Diabetic Retinopathy|Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy||Oregon Health and Science University||Active, not recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|215|||Both|18 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Participants with Type 1 diabetes of greater than 5 years duration OR Type 2 diabetes of        any duration. Healthy controls are also being enrolled in this study.|December 2014|December 30, 2014|December 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02330042||29963|
NCT02339025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915062|DoD-NCI TRICARE Feasibility Study|The NCI-DoD TriCare Feasibility Study||National Institutes of Health Clinical Center (CC)||Not yet recruiting|January 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Both|35 Years|74 Years|No|||November 2015|December 15, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02339025||29274|
NCT02339168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#243|Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer|Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer||University of California, Davis|Yes|Not yet recruiting|October 2015|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||September 2015|September 14, 2015|January 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02339168||29263|
NCT02331641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MajorVsMinorHepatectomy|Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.|Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases. A Propensity Score-matched Dual-institution Analysis.||University of Milan|No|Completed|January 2005|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|554|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colorectal liver metastases (CLM) that underwent hepatectomy.|January 2015|January 5, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02331641||29841|
NCT02331901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mtbi-1|Cerebral Microstructural Changes Following Mild Traumatic Brain Injury|Cerebral Microstructural Changes Following Mild Traumatic Brain Injury||University of Aarhus|Yes|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mild traumatic brain injury subjects with and without symptoms 3-4 months after trauma|December 2015|December 3, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02331901||29821|
NCT02328014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-001|ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies|A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies||Acerta Pharma BV|No|Recruiting|December 2014|November 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02328014||30119|
NCT02328248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-001|Usage of Biological Patch Versus Plastic in the Laparoscopic Repair of Hiatal Hernias|Randomized Control Trial (RCT) That the Usage With Biological Patch Versus Plastic in the Laparoscopic Repair||Xijing Hospital of Digestive Diseases|No|Active, not recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||December 2014|December 26, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02328248||30101|
NCT02346188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.00.07.06B|Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead|Effects of Iron and Zinc Supplementation on Neuropsychological and Educational Achievement in Lead-exposed School Children||Johns Hopkins Bloomberg School of Public Health|No|Completed|January 2000|December 2001|Actual|December 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|602|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346188||28726|
NCT02346708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2724|Cognitive Dysfunction in Parkinson's Disease|Cortical Physiology as a Therapeutic Target in Parkinson's Disease Related Dementia and Cognitive Dysfunction||University of Colorado, Denver|No|Recruiting|January 2014|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|N/A|No|||March 2016|March 18, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346708||28686|
NCT02347189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10154745DOC|Melody(TM) TPV PB1016 Surveillance Study|Melody(TM) Transcatheter Pulmonary Valve PB1016 Surveillance Study Implantation of the Medtronic Melody Transcatheter Pulmonary Valve PB1016 Using the Ensemble(TM) Transcatheter Delivery System in Patients With Dysfunctional RVOT Conduits|Melody PB1016|Medtronic Cardiovascular|No|Recruiting|November 2014|January 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 23, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347189||28649|
NCT02347202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01185|Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention|Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention||New York University School of Medicine||Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|21 Years|125 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02347202||28648|
NCT02351635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALP Cal01|BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS|Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome||Bühlmann Laboratories AG|No|Recruiting|January 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|390|Samples With DNA|Stool samples collected before start of specific medication|Both|22 Years|N/A|Accepts Healthy Volunteers|Probability Sample|100 adult subjects with Inflammatory Bowel Disease or Irritable Bowel Syndrome each have        provided a stool sample. In addition, 50 pediatric subjects, age 2 years to 21 years, 25        subjects in each diagnostic group (IBD, IBS) will be enrolled. Recruitment of 120 normal        subjects who will provide samples.|January 2016|January 26, 2016|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351635||28309|
NCT02347761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN101-301|Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|GOLDEN-3|Sunovion Respiratory Development Inc.|No|Completed|February 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|653|||Both|40 Years|N/A|No|||November 2015|November 17, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347761||28605|
NCT02348047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-CH-01|(S5-SAMU) Randomized Study Comparing the ASV (Adaptative Support Ventilation) to Conventional Ventilation|Randomized Study Comparing the ASV to Conventional Ventilation for Intubated Patients During Inter-hospital Transfers. Controlled Randomized Monocentric Prospective Study Comparing ASV Versus Conventional Ventilation Modes|S5-SAMU|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|No|Not yet recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02348047||28584|
NCT02348060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF01COPD|Outcomes Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease|Autologous Adipose Stromal Vascular Fraction Outcomes in Chronic Obstructive Pulmonary Disease Research Study||StemGenex|No|Recruiting|November 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|November 2015|November 30, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348060||28583|
NCT02348346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVX 1.0|Effect of MVX (Titanium Dioxide) on the Microbial Colonization of Surfaces in an Intensive Care Unit|Effect of MVX (Titanium Dioxide) on the Microbial Colonization of Surfaces in an Intensive Care Unit|TITANIC|Gelderse Vallei Hospital|No|Recruiting|March 2015|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Intensive Care Unit|March 2015|March 12, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02348346||28561|
NCT02344420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOTRONIK-CR017|Clinical Investigation on Differences in the Magnitude of CRT Response in WOmen Versus MEN|Study to Compare the Cardiac Resynchronization Therapy (CRT) Response Rate in a Heart Failure (HF) Population With an Equal Distribution of Men and Women.|BIOWOMEN|Biotronik SE & Co. KG|Yes|Recruiting|June 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|494|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02344420||28862|
NCT02344667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-157|Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT|Randomized Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. Volume Modulated Arc Therapy||Juravinski Cancer Center|Yes|Not yet recruiting|March 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 18, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02344667||28843|
NCT02334696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK5258|Improving Outcomes in Vascular Access|Improving Outcomes in Vascular Access|IMPROVA|University Hospital Birmingham|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with end stage renal disease referred for assessment in vascular access        clinic.|January 2015|January 6, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02334696||29606|
NCT02327091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269/PT02.FK|The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial|Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength||Indonesia University|Yes|Completed|April 2012|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Female|60 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 29, 2014|January 28, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02327091||30190|
NCT02327325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1569-P|Physical Activity for Older Adults Chronic Low Back Pain|Physical Activity for Older Adults With Chronic Low Back Pain: PACe-LBP|PACe-LBP|VA Office of Research and Development|No|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|65 Years|N/A|No|||October 2015|October 28, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02327325||30172|
NCT02335983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ013|Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma|Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma||Onyx Pharmaceuticals|No|Recruiting|December 2014|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|84|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|December 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02335983||29508|
NCT02336763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000903|Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases|Prophylactic Hepatic Irradiation for Uveal Melanoma||Jonsson Comprehensive Cancer Center|Yes|Terminated|October 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|January 8, 2015|Yes|Yes|Closed due to lack of accrual|No|February 12, 2016|https://clinicaltrials.gov/show/NCT02336763||29448|
NCT02332148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3VM0115|Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.|A Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Proof of Concept Study||CDA Research Group, Inc.|No|Not yet recruiting|February 2015|March 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||August 2015|August 19, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02332148||29802|
NCT02332408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRVH-COI-03|CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas|CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial.|CKHRTVH|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|September 2014|September 2021|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|85 Years|No|||January 2015|January 4, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02332408||29782|
NCT02350881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202-T-FGTI-M|A Post-Marketing Observational Study to Evaluate Primus™ FGT Implant at a Minimum of 5 Years Follow-up|A Post-Marketing Observational Study to Evaluate Safety and Performance of Primus™ FGT Implant at a Minimum of 5 Years Follow-up||Tornier, Inc.|No|Completed|May 2013|November 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|This study has included all patients who had had a Primus™ FGT implantation.|January 2015|January 26, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350881||28367|
NCT02353897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-201|Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®|An Assessment of Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®.|APPEAL|Ipsen|No|Active, not recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Private practices and clinics|November 2015|November 30, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353897||28136|
NCT02351141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0037|Structure and Function MRI of Asthma|Structure and Function MRI of Asthma||Western University, Canada|No|Recruiting|January 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02351141||28347|
NCT02351154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IECED 01-08-2014|Grading Atrophic Gastritis by Confocal Laser Endomicroscopy Probe (p-CLE)|Grading Atrophic Gastritis by a New Quantitative Method Using Confocal Laser Endomicroscopy Probe (p-CLE): First Results of a Prospective Cohort Study||Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Completed|September 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351154||28346|
NCT02351401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/01611|Rheumatoid Arthritis Through Education and US Study (RAEUS)|Improvement in Patient Awareness and Ability to Assess Disease in Rheumatoid Arthritis: Rheumatoid Arthritis Through Education and US Study (RAEUS)|RAEUS|National University Hospital, Singapore|No|Completed|November 2011|October 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|101|||Both|21 Years|80 Years|No|||January 2015|January 27, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02351401||28327|
NCT02354534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1498|Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)|A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354534||28087|
NCT02354547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT53-01-2|A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors|A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors||SynerGene Therapeutics, Inc.|Yes|Recruiting|December 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|12 Months|21 Years|No|||November 2015|November 17, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354547||28086|
NCT02351869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|435-2013|Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder|Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder||Sunnybrook Health Sciences Centre|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|60 Years|No|||August 2015|August 25, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02351869||28291|
NCT02352116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5954|Evaluation of Post-PACU Pain Management in Pediatric Surgery|Evaluation of Post-PACU Pain Management Experiences in Pediatric Ambulatory Surgery Patients||Columbia University|No|Recruiting|June 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|900|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02352116||28272|
NCT02348385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106008678|Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers|Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers||Yale University|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Samples will be obtained for hormones and amphetamine drug levels|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Smokers and non smokers|July 2015|July 14, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02348385||28558|
NCT02348697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1418|Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects|Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects|NISANIK|Tetec AG|No|Recruiting|June 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|14 Years|50 Years|No|Non-Probability Sample|specialist clinical centre|October 2015|October 30, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02348697||28534|
NCT02338908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 31/2140|Dry Needling and Exercises in Shoulder Pain|Effectiveness of Dry Needling and Eccentric Exercises in Unspecific Shoulder Pain||Universidad Rey Juan Carlos|Yes|Completed|January 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02338908||29283|
NCT02340416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1633/2013|Tissue Oxygen Index and Pulsatility Index in Orthopedic Surgery: a NIRS and TCD Pilot Trial|Tissue Oxygen Index and Pulsatility Index in Orthopedic Surgery: a NIRS and TCD Pilot Trial||Medical University of Vienna||Completed|August 2014|January 2016|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|50 Years|90 Years|No|Non-Probability Sample|orthopedic patients|March 2016|March 24, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340416||29168|
NCT02331082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hssnyaya|Integrating Pediatric Care Delivery in Rural Healthcare Systems|Integrating Pediatric Care Delivery in Rural Healthcare Systems||Possible|No|Recruiting|November 2014|January 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|7000|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|August 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02331082||29884|
NCT02331355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00078607|Hand Transplantation: Functional and Quality of Life Outcomes|VCA (Hand Transplantation): Functional and Quality of Life Outcomes||University of Michigan|No|Not yet recruiting|February 2015|January 2025|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients who have had traumatic hand transplantation below the elbow.|January 2015|January 5, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02331355||29863|
NCT02340442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-060513|DVA Risk Pregnancy|Retinal Vessel Analysis in Low Risk and High Risk Pregnant Women||Medical University of Vienna||Recruiting|October 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited form the gynecology department and the department of clinical        pharmacology|August 2015|August 31, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340442||29166|
NCT02340481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103534|Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence|A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Loperamide Hydrochloride/Simethicone Chewable Tablet in the Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence||Xian-Janssen Pharmaceutical Ltd.|No|Completed|July 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340481||29163|
NCT02336906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc130348ctil|Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction|A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Lower Urinary Tract Dysfunction (LUTD) Not Meeting ROME-III Constipation Criteria||Rabin Medical Center|No|Not yet recruiting|January 2015|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|5 Years|17 Years|No|||January 2015|January 8, 2015|January 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02336906||29437|
NCT02337036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120904|Pharmacokinetic of Tacrolimus in Paediatric Liver Transplant Patients|Building a Population Pharmacokinetic Model of Tacrolimus in Paediatric Liver Transplant Patients|TACTHEP|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|December 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|6 Months|12 Years|No|||December 2015|December 8, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02337036||29427|
NCT02353728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014950|Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy|Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib|CAMN107AUS42T|Weill Medical College of Cornell University|No|Not yet recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353728||28149|
NCT02358135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00417|Collaborative Connected Health (CCH) for PCORI|Collaborative Connected Health (CCH): A Pragmatic Trial Evaluating Effectiveness of CCH in Psoriasis Management Compared to In-person Visits.|PCORI|University of Southern California|No|Recruiting|February 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 2, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02358135||27812|
NCT02354079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0400|HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism|HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism|HYPOCHOL|Nantes University Hospital|No|Recruiting|February 2016|December 2028|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|N/A|N/A|No|||February 2016|February 5, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02354079||28122|
NCT02358213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 14.133 ETREINTE|Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease|Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease : Etude ETREINTE.|ETREINTE|University Hospital, Brest|Yes|Completed|March 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|21|||Both|18 Years|80 Years|No|||March 2015|December 15, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02358213||27806|
NCT02354300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400923|Transcranial Doppler Ultrasound Monitoring During Flow-Diverter Embolization|A Prospective Study of the Treatment of Intracranial Aneurysms Using Pipeline Flow-Diverter Embolization in Conjunction With Transcranial Dopplers (TCD)||University of Florida|No|Completed|April 2015|May 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354300||28105|
NCT02354313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-MCL0208|STUDY WITH LENALIDOMIDE (Revlimid®) MAINTENANCE VS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MANTLE CELL LYMPHOMA|A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid®) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MANTLE CELL LYMPHOMA.|MCL-0208|Fondazione Italiana Linfomi ONLUS|No|Recruiting|May 2010|January 2019|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||June 2014|February 2, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT02354313||28104|
NCT02343536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-DLBCL-001|A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma|A PHASE 1, OPEN-LABEL, MULTICENTER TRIAL OF ORAL AZACITIDINE (CC-486) PLUS R-CHOP IN SUBJECTS WITH IPI 2 OR MORE PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, GRADE 3B FOLLICULAR LYMPHOMA, OR TRANSFORMED LYMPHOMA||Celgene|Yes|Recruiting|April 2015|June 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343536||28928|
NCT02354755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00858|The Effect of Temperature on Anesthesia and Surgical Resident's Ability to Perform Clinical and Cognitive Tasks|||Nationwide Children's Hospital|No|Enrolling by invitation|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|24|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians in training (Anesthesiology/surgery residents, fellows and certified registered        nurse anesthetists.|January 2016|January 7, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354755||28070|
NCT02355067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-011491|Social Media Intervention for Postpartum Depression|Social Media Intervention to Teach Parenting for Women With Postpartum Depression||Children's Hospital of Philadelphia|No|Active, not recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|15 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355067||28046|
NCT02355119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP-2|Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer|Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer|GIP-2|Azienda Ospedaliero, Universitaria Pisana|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|75 Years|No|||January 2015|February 3, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02355119||28042|
NCT02355132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007327|Assessing a Medicaid Randomized Insurance Experiment Within Community Clinics|Assessing a Medicaid Randomized Insurance Experiment Within Community Clinics|AMRIC|Oregon Health and Science University|No|Active, not recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|34849|||Both|19 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult individuals on the Oregon Experiment 'reservation list' (applied for the Oregon        Experiment) linked to individual patients in an Oregon safety net clinic that is part of        the OCHIN, Inc network using Link Plus software and demographic variables common to both        datasets.|October 2015|October 13, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355132||28041|
NCT02352662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00016002|Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery|Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery||Children's Hospital Boston|No|Not yet recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Collect bloods samples at three different time points intraoperatively to look at      coagulation factors|Both|N/A|12 Months|No|Non-Probability Sample|Neonates and infants undergoing cardiac surgery with cardiopulmonary bypass|January 2015|January 28, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02352662||28231|
NCT02353000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2015|Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (RS) for 4 Upto 10 Brain Metastases|Whole Brain Radiotherapy Versus Stereotactic Radiosurgery for Patients With 4 up to 10 Brain Metastases: a Seamless Phase II/III Trial|WBRTvsRS|Maastricht Radiation Oncology|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02353000||28205|
NCT02355496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821783|The Impact of Charge Displays on Inpatient Laboratory Test Ordering|The Impact of Charge Displays on Inpatient Laboratory Test Ordering||University of Pennsylvania|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|769|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355496||28013|
NCT02330809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThinkWell-PLOT-01|Drinking Extra Water for to Prevent or Decrease Headaches|Drinking Extra Water To Prevent or Decrease Headaches - A Feasibility Online Randomized Controlled Trial With Adult Participants||ThinkWell|Yes|Not yet recruiting|February 2018|November 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|9600|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02330809||29905|
NCT02335450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|619511-2|Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series|Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series||Oakland University|No|Active, not recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|19 Years|N/A|No|||November 2015|November 12, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335450||29548|
NCT02335697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Forte 2013-2095|A Community-based Participatory Intervention to Change Attitudes Towards Female Circumcision Among Somali Immigrants in Sweden|A Community-based Participatory Intervention to Change Attitudes Towards Female Circumcision Among Somali Immigrants in Sweden: a Cluster Randomized Controlled Trial||Uppsala University|Yes|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|195|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02335697||29530|
NCT02340455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0907|Effect of Oral Pregabalin on Hyperalgesia and Post-operative Pain in Patients Undergoing Nephrectomy Surgery: Sex Differential Study|||Yonsei University|No|Recruiting|December 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|252|||Both|19 Years|50 Years|No|||July 2015|July 6, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02340455||29165|
NCT02328976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 197 02|Hypothalamus Connectivity in Chronic and Episodic Migraine|Hypothalamus Connectivity in Chronic and Episodic Migraine in Headache-free Period: A Resting State Functional Magnetic Resonance Imaging Study|HYPOTHAMIG|University Hospital, Toulouse|No|Recruiting|May 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|56|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02328976||30045|
NCT02329262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014B0094|A Skills-based RCT for Physical Activity Using Peer Mentors|A Skills-based RCT for Physical Activity Using Peer Mentors||Ohio State University|No|Recruiting|September 2015|October 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1720|||Both|14 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02329262||30023|
NCT02340520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-032-3|Enhancement of Corticosteroid Efficacy in COPD|Enhancement of Corticosteroid Efficacy in COPD||University of Connecticut Health Center|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|45 Years|N/A|No|||January 2015|January 15, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340520||29160|
NCT02340533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD0152015|Histopathological Diagnosis of Adenomyosis|The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis||Woman's Health University Hospital, Egypt|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|200|||Female|38 Years|52 Years|Accepts Healthy Volunteers|||July 2015|July 26, 2015|January 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02340533||29159|
NCT02340572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS_01_12|First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080|A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Establish Safety, Lack of Immunogenicity, Tolerability, Pharmacokinetic Parameters, Target Engagement and Pharmacodynamic Effects||Pieris AG|Yes|Completed|November 2014|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02340572||29156|
NCT02340585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLAS Study|Neuroform ATLAS IDE Study|Safety and Effectiveness of the Treatment of Wide Neck, Intracranial, Saccular Aneurysms With the Next Generation Neuroform Stent System||Stryker Neurovascular|Yes|Recruiting|June 2015|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|80 Years|No|||December 2015|December 9, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02340585||29155|
NCT02358070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0049|Epidemiologic Study of Hepatocellular Carcinoma in the US|Epidemiologic Study of Hepatocellular Carcinoma in the US||Stanford University||Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|3000|Samples With DNA|saliva samples|Both|35 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients with Hepatocellular Carcinoma in New Jersey and Connecticut as well as        selected patients in New York, Hawaii and northern California.        Healthy volunteers will comprise a random sample of New Jersey and Connecticut residents        as controls.|July 2015|July 7, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02358070||27817|
NCT02346721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1446|Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection|An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection||Gilead Sciences|No|Active, not recruiting|February 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346721||28685|
NCT02358226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA038675|HIV & Drug Abuse Prevention for South African Men|HIV & Drug Abuse Prevention for South African Men||University of California, Los Angeles|No|Recruiting|July 2015|June 2021|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1200|||Male|18 Years|29 Years|No|||February 2016|February 4, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02358226||27805|
NCT02343250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-IDCV-103|A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers|IDCV|IlDong Pharmaceutical Co Ltd|No|Completed|March 2015|||March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343250||28950|
NCT02343263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501306006|Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage|Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage: a Clinical Trial.||Indiana University|No|Enrolling by invitation|March 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|January 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343263||28949|
NCT02347527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1786|Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals|Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals||University of Colorado, Denver|No|Recruiting|May 2013|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347527||28623|
NCT02343874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/8739|Impact of Alcohol Consumption on Use of Health Care Resources|Impact of Alcohol Consumption of the General Population Who Visited Primary Health Care Centers on the Use of Health Care Resources in Catalonia.||Hospital Clinic of Barcelona|No|Completed|December 2012|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1911771|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients over 17 years old attended in the primary health care setting that have their        alcohol consumption registered in the medical record.|January 2015|January 16, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02343874||28902|
NCT02344199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-PLR-EL-55|Eplerenone in Heart Failure Treatment|A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.|INOSET|Elpen Pharmaceutical Co. Inc.|No|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Heart Failure|August 2015|August 17, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344199||28879|
NCT02355405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XY3-LUS-8711|Diagnostic Values of Lung Ultrasound for Perioperative Atelectasis|Diagnostic Performance of Lung Ultrasound for Perioperative Atelectasis in Adult Patients Undergoing General Anesthesia||The Third Xiangya Hospital of Central South University|Yes|Completed|January 2015|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing selective neurosurgical operation in Xiangya Hospital or The Third        Xiangya Hospital of Central South University|April 2015|April 17, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355405||28020|
NCT02301390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14-02-34-05|INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events|INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events|INTERVENE|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|85 Years|No|||September 2015|September 15, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301390||32162|
NCT02248337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOVOL-IBD|Low Volume Colon Preparation for IBD|Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil||Luigi Sacco University Hospital|No|Completed|March 2013|March 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|85 Years|No|||September 2014|September 23, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02248337||36235|
NCT02245100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.172|Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer|A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers||Thomas Jefferson University|Yes|Recruiting|July 2014|||July 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood, saliva, and tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with advanced head and neck carcinoma or NSCLC enrolled at Thomas        Jefferson University|August 2015|August 10, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02245100||36484|
NCT02245347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.LO.1694|Genome Sequencing of Multidrug Resistant Tuberculosis (MDR TB) in Sputum|Genome Sequencing of MDR TB in Sputum|MDRTB01|St George's Healthcare NHS Trust|No|Recruiting|April 2013|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Sputum samples|Both|18 Years|N/A|No|Non-Probability Sample|Smear positive patients with confirmed or suspected TB|September 2014|September 17, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02245347||36465|
NCT02501148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-1001|Clinical Performance and Safety Assessment of the Paladin®|Multi-Center Study to Evaluate Acute Safety and Clinical Performance of Paladin® Carotid Post-Dilation Balloon With Integrated Embolic Protection||Contego Medical, LLC|No|Recruiting|July 2015|||July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adults; either gender; requiring percutaneous intervention of an asymptomatic (> 70%) or        symptomatic (>50%) internal carotid artery stenosis.|February 2016|February 3, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501148|30 Days|16835|
NCT02501161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4228|A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus|A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus|DUAL™ VIII|Novo Nordisk A/S|No|Recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501161||16834|
NCT02245035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12884|Dairy Intake and Brain Health in Aging|Dairy Intake and Brain Health in Aging||University of Kansas Medical Center|Yes|Active, not recruiting|October 2011|||November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|60|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy elderly individuals with an age range of 60-85 years.|September 2015|September 25, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02245035||36489|
NCT02250040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/0417|Effect of a Physiotherapy Protocol for Gait and Functional Recovery After Stroke|Development and Assessment of a New Physiotherapy Protocol for Gait Recovery After Stroke Based on Clinical and Functional Criteria||University of Valencia|No|Completed|March 2011|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|55 Years|N/A|No|||September 2014|September 25, 2014|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02250040||36104|
NCT02504411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0587|Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy|Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy Versus Standard Colonoscopy||The University of Texas Health Science Center, Houston||Not yet recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|640|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504411||16584|
NCT02508532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLU-285-1101|Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors|A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors||Blueprint Medicines Corporation|No|Recruiting|August 2015|May 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508532||16268|
NCT02296931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-081F|Laboratory and Pilot Clinical Assessment of the Accuracy, Usability, and Function of a Low-cost, Low-power Syringe Pump in Administering Magnesium Sulfate to Pre-eclamptic Women in a Low-resource Hospital|Laboratory and Pilot Clinical Assessment of the Accuracy, Usability, and Function of a Low-cost, Low-power Syringe Pump in Administering Magnesium Sulfate to Pre-eclamptic Women in a Low-resource Hospital||William Marsh Rice University|No|Recruiting|March 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Phase 1 will be an initial validation of the clinical performance of the device delivering        only standard IV saline to 10 stable women.        In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of        pre-eclampsia.|May 2015|May 11, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296931||32505|
NCT02300922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0003|Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer|Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer : A Multicentric Phase I/II Study of Fractionated TF2 Plus 90Y-IMP288 (RITCOLON)|RITCOLON|Nantes University Hospital|No|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300922||32198|
NCT02359162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-NK-308|Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage|Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study||Sun Yat-sen University|Yes|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359162||27733|
NCT02358629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-CPEX-01|A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO).|||Nitiloop Ltd.|No|Recruiting|February 2015|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|25 Years|80 Years|No|||October 2015|October 6, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02358629||27774|
NCT02308345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00090259|MiVideo - Video Visit Summary for Cancer Patients|MiVideo - Video Visit Summary for Cancer Patients||University of Michigan|Yes|Completed|December 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|58|||Both|18 Years|80 Years|No|||December 2014|May 29, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02308345||31628|
NCT02305810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S543/310|A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus|An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus||European Institute of Oncology|No|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|47|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02305810||31822|
NCT02355860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.84|Female Sexual Function and Socioeconomic Status|Female Sexual Function and Socioeconomic Status||Ohio State University|Yes|Completed|May 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|268|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|238 sexually-active, non-pregnant women reporting to two urban gynecology clinics,        representing patients with publicly funded (n=70) or privately funded health insurance        (n=168).|January 2015|January 30, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02355860||27985|
NCT02352818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57285|Chronic Total Occlusion Registry|||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2015|January 2025|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|All patients undergoing percutaneous attempt at revascularisation of a chronic total        coronary occlusion|January 2015|January 28, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02352818|1 Year|28219|
NCT02304705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0628-F3R|Sildenafil in Heart Failure With Reactive Pulmonary Hypertension|Sildenafil in Heart Failure With Reactive Pulmonary Hypertension|Sildenafil-HF|University of Kentucky|No|Enrolling by invitation|January 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304705||31907|
NCT02252744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternU-12irb027|Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis|Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis||Western University of Health Sciences|No|Completed|November 2012|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|286|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of rheumatoid arthritis|February 2016|February 2, 2016|September 18, 2014||No||No|September 22, 2015|https://clinicaltrials.gov/show/NCT02252744||35896|
NCT02258490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051037|Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation|Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation to Recipients With Limited Donor Engraftment||Emory University||Available||||||N/A|Expanded Access|N/A|||||||Both|17 Years|75 Years||||November 2015|November 2, 2015|September 16, 2014|No|Yes||||https://clinicaltrials.gov/show/NCT02258490||35458|
NCT02249793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817759|Exploratory Study of Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics|Exploratory Study in Healthy Volunteers to Define Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics||University of Pennsylvania|No|Active, not recruiting|September 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|Samples With DNA|Whole blood, serum, plasma, urine, stool, and mucosal swabs from nose, mouth and rectum|Both|25 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|January 2016|January 28, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02249793||36123|
NCT02501213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIASC-1507|Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)|A Randomized Cross-over Trial Evaluating the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Palliative Stage of Cancer||Centre Oscar Lambret|Yes|Recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02501213||16830|
NCT02501486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51711.091.14|Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients|Inhalation or Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal Axis Suppression in HIV-infected Patients|Incorporate|Radboud University|Yes|Recruiting|July 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02501486||16809|
NCT02249143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB00010607|Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants|Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants||Oregon Health and Science University|No|Recruiting|September 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|1 Year|No|||August 2014|September 22, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02249143||36173|
NCT02249156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG043850-01|The Effect of Financial Incentives on Utilization of Low-cost Providers|The Effect of Financial Incentives on Utilization of Low-cost Providers||Harvard Medical School|No|Active, not recruiting|August 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|1 Year|N/A|No|Non-Probability Sample|The study population is composed of employees of both the intervention and control        employers. We will use medical health plan claims from 2012 to 2014 for laboratory and        imaging services across the study population. Health plan claims data will be provided by        Castlight Health. The approximate number of providers of laboratory and radiology services        who will provide care to this population will be 475,000.|March 2015|March 29, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02249156||36172|
NCT02255708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1161-5560|Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation.|Electromyography Evaluation of the Stabilizing Muscles of the Scapula and Tibial Anterior Muscle, After an Intervention Program by Proprioceptive Neuromuscular Facilitation in Muscle Force Irradiation.||University of Sao Paulo|No|Recruiting|July 2014|||August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02255708||35668|
NCT02508545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002|Influence of Gravity on the Perception of Egocentric Distance (Blindpulling)||Blindpulling|University Hospital, Caen|No|Recruiting|February 2014|||October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508545||16267|
NCT02498353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZNHCR|Comparing Preoperative Short-course Radiotherapy With or Without Local Boost for Rectal Cancer|Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer||Zhongnan Hospital|No|Not yet recruiting|July 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||July 2015|July 10, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02498353||17050|
NCT02510846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140701|Impact of an Intensive Multimodal Educative Program on Behavioral Disorders of Patients With Profound Multiple Disabilities and on the Quality of Life and Feelings of Caregivers|Impact of an Intensive Multimodal Educative Program on Behavioral Disorders of Patients With Profound Multiple Disabilities and on the Quality of Life and Feelings of Caregivers|TDCHandi|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|3 Years|25 Years|No|||February 2016|February 23, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02510846||16090|
NCT02510859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-101|Nutrition and Life QUality Patients With Head and Neck Cancers||NUQUE2|University Hospital, Caen|No|Completed|December 2010|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|117|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510859||16089|
NCT02510885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063777|SD-OCT Angiography|Spectral Domain-Optical Coherence Tomography Angiography of Retinal Diseases||Duke University|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510885||16087|
NCT02301455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00091668|REACH OUT: to Reduce High Blood Pressure in the Emergency Department|||University of Michigan|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||October 2015|January 14, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301455||32157|
NCT02356796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1398 (REK)|Chronic Pelvic Pain in Women - Conservative Group Treatment Compared to Standard Conservative Treatment.|Chronic Pelvic Pain in Women - Conservative Multidisciplinary Group Treatment Compared to Standard Conservative Treatment. A Randomised Controlled Trial.|CPP|University Hospital of North Norway|No|Recruiting|February 2015|March 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|65 Years|No|||January 2016|January 8, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356796||27913|
NCT02345096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP090414.LES|Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis||Lesaffre International|Yes|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345096||28810|
NCT02349659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-SMI-2014|A Multi-Centre RCT of the Axium® Neurostimulator for the Treatment of Chronic Inguinal Pain Following Surgery|A Randomised Controlled Trial to Evaluate the Efficacy of the Spinal Modulation Axium® NeuroStimulator THerapy as a Treatment for Persistent INGuinal Pain Following Surgical Intervention: SMASHING|SMASHING|St. Jude Medical|No|Recruiting|December 2014|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02349659||28460|
NCT02297360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHOTC 0413|Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair|A 3-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Ability Of Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Self-Perceived Thinning Hair||Ablon Skin Institute Research Center|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02297360||32472|
NCT02356159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150067|Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation|A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation||National Institutes of Health Clinical Center (CC)||Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||December 2015|February 13, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356159||27962|
NCT02358655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-CUSP ED|Canadian Community Utilization of Stroke Prevention Study - Emergency Department|Canadian Community Utilization of Stroke Prevention Study - Emergency Department|C-CUSP ED|Population Health Research Institute|No|Recruiting|June 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|360|||Both|N/A|N/A|No|||December 2015|December 10, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02358655||27772|
NCT02293122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602-a01|To Investigate Agreement Between the EM-3000 and the Predicate Device Noncon Robo Pachy (F&A) (CellChek XL)|To Investigate Agreement Between the EM-3000 and the Predicate Device NonCon Robo Pachy (F&A) (CellChek XL).||Tomey Corporation|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study plan calls for 75 subjects divided into three sub-groups, young healthy (18-50        yrs), older healthy (51-80 yrs), and pathologic adults (29-80 years).|July 2015|July 14, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293122||32797|
NCT02254083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1192.2|Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects|Tolerability and Pharmacokinetics/-Dynamics of 0.5 mg and 1.0 mg (Actual 0.8 mg) of BIBT 986 BS Per Hour Given as IV Infusion Over 32 Hours in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level||Boehringer Ingelheim||Completed|February 2003|||May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254083||35793|
NCT02244840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620113700|Anal Resting Pressure After Bidet, Compared to Sitz Bath|The Effects of Electronic Bidet on Anal Resting Pressure, Compared to Conventional Sitz Bath in Normal Healthy Volunteers|Bidet(2)|Seoul National University Hospital|Yes|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|September 16, 2014||No||No|September 20, 2014|https://clinicaltrials.gov/show/NCT02244840||36504|
NCT02255656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS13649|Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409|A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)|TOPAZ|Sanofi|No|Enrolling by invitation|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|812|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255656||35672|
NCT02504255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.630|Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease|Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease : A Multicenter Cohort||Hospices Civils de Lyon|Yes|Completed|April 2011|April 2014|Actual|April 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Crohn Disease|July 2015|July 23, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504255||16596|
NCT02504268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-550|Effects of Abatacept in Patients With Early Rheumatoid Arthritis|A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive|AVERT-2|Bristol-Myers Squibb|No|Recruiting|February 2015|August 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504268||16595|
NCT02504320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Febuxostat XR-1011|Phase 1, Febuxostat XR Bioavailability Study|A Phase 1, Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Assess the Relative Bioavailability of Four 80 mg Febuxostat XR Formulations||Takeda|No|Recruiting|July 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504320||16591|
NCT02505295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1421|Selenium and Ischemic Stroke Outcome|Evaluation of Selenium Supplementation in Ischemic Stroke Outcome||Mazandaran University of Medical Sciences|Yes|Not yet recruiting|July 2015|July 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505295||16516|
NCT02258503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0211|Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More|Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More|DOLEVA75|University Hospital, Clermont-Ferrand||Recruiting|January 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|75 Years|N/A|No|Non-Probability Sample|elderly patients|October 2014|October 6, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258503||35457|
NCT02258516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019792|A Randomized Study of the Efficacy of a New Intervention for Medication Adherence in Chronic Illness: Medications, Meaning and Me (The 3-M Study)|A Randomized Study of the Efficacy of a New Intervention for Medication Adherence in Chronic Illness: Medications, Meaning and Me (The 3-M Study)||Duke University|No|Completed|September 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|87|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258516||35456|
NCT02241356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0002308|The Effect of Bifocals in Children With Down Syndrome|The Effect of Bifocals in Children With Down Syndrome||Radboud University|Yes|Recruiting|June 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|2 Years|14 Years|No|||October 2015|October 28, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02241356||36772|
NCT02498600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02424|Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer||National Cancer Institute (NCI)|No|Suspended|June 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|N/A|No|||February 2016|March 14, 2016|July 14, 2015|Yes|Yes|Temporarily Closed to Accrual|No||https://clinicaltrials.gov/show/NCT02498600||17031|
NCT02498925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-D000149|Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents|Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents||Mclean Hospital|Yes|Recruiting|December 2015|January 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02498925||17006|
NCT02305667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-2014-11-27|Videolaryngoscopes for Double Lumen Tube Intubations|A Comparison of Three Videolaryngoscopes for Double-Lumen Tubes Intubation in Humans. A Randomized Controlled Study||Dammam University|Yes|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|140|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305667||31833|
NCT02347384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-4560-02|Project JAY THA Registration Study|A Prospective, Randomized, Multicenter Clinical Study in Chinese Subjects to Compare the Safety and Efficacy of the Delta PLUS Femoral Head and SL-TWIN Stem With BIOLOX Forte Ball Head and SL-PLUS Stem in Total Hip Arthroplasty||Smith & Nephew Orthopaedics (Beijing) Limited|No|Active, not recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|50 Years|75 Years|No|||November 2015|November 30, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02347384||28634|
NCT02347397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-4561-01|Project JAY HAP Registration Study|A Prospective, Randomized, Multicenter Clinical Study in Elderly Chinese Subjects to Compare the Safety and Efficacy of the SS Bipolar Head and SL-TWIN Stem With Bipolar Head and SL-PLUS Stem in Hemiarthroplasty of the Hip||Smith & Nephew Orthopaedics (Beijing) Limited|No|Recruiting|April 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|65 Years|90 Years|No|||November 2015|November 30, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02347397||28633|
NCT02350218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSI-2014-0624|Safety and Efficacy Study of Eglandin in Living Donor Liver Transplant Patient|Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient|PROVISION|Asan Medical Center|Yes|Active, not recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|19 Years|65 Years|No|||March 2015|March 9, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350218||28418|
NCT02301650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141107002514131|The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children|The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children||Beijing Ditan Hospital|No|Enrolling by invitation|October 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|400|||Both|1 Year|3 Years|No|Non-Probability Sample|The one year old children born in BeiJing DiTan Hospital and whose mothers had taken        Lamivudine, Telbivudine or Tenofovir and untreated in late pregnancy with HBV DNA level        over 6.0 log10 IU/ml|November 2014|November 22, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02301650||32142|
NCT02293512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1578-P|A Comparison of Three Psychoeducational Group Interventions for Veterans With Tinnitus|A Comparison of CBT and CET Interventions for Veterans With Tinnitus||VA Office of Research and Development|No|Recruiting|September 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02293512||32767|
NCT02346344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Cell - Protocol 1e|Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus||Foundation for the National Institutes of Health|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|20|||Both|30 Years|65 Years|No|Probability Sample|obese individuals with type 2 diabetes mellitus|January 2015|January 20, 2015|April 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02346344||28714|
NCT02351518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062723|Cerebral Autoregulation and Vasospasm in Patients With TBI|Cerebral Autoregulation and Vasospasm in Patients With Traumatic Brain Injury||University of Maryland|No|Recruiting|November 2015|August 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients aged 15 years and older, presenting with a motor score of <6 and thought to        have TBI due to a mechanism of injury, will undergo screening with head computed        tomography (CT). Admission CT will be interpreted by an attending radiologist to determine        Head Abbreviated Injury Score (AIS) score. If the AIS score by CT is > 2, the patient will        be eligible for the study. Patients determined by neurosurgery to have a non-survivable        TBI on admission will be excluded given the poor likelihood of completion of the study        protocol.|November 2015|November 30, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02351518||28318|
NCT02345421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CSS01|A Study to Identify and Characterize LAL-D Patients in High-risk Populations|A Study to Identify the Frequency of Lysosomal Acid Lipase Deficiency in At-Risk Patient Populations||Alexion Pharmaceuticals|No|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|10000|||Both|2 Years|N/A|No|Non-Probability Sample|Patients >2 years of age who are at risk for a diagnosis of LAL D|May 2015|May 1, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345421||28785|
NCT02497664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2015-04|Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas|Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas|ABC|University Medical Center Groningen|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02497664||17103|
NCT02248818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5800C00001|AZD8108 SAD/MAD in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD8108 in Healthy Volunteers|AZD8108|AstraZeneca|Yes|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|258|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02248818||36198|
NCT02241070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH 110606|The Potential for Mindfulness-Based Intervention in Workplace Mental Health Promotion|The Potential for Mindfulness-Based Intervention in Workplace Mental Health Promotion: Results of a Randomized Controlled Trial||Chung Shan Medical University|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|September 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02241070||36794|
NCT02508506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALKS5461-A108|Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function|A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment||Alkermes, Inc.|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508506||16270|
NCT02508519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no grant number|Study of Zonal and Balance Acupuncture Pain Relief Effect|Study of Zonal and Balance Acupuncture Pain Relief Effect||Bogomolets National Medical University|No|Enrolling by invitation|July 2015|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|N/A|N/A|No|||August 2015|August 14, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508519||16269|
NCT02498691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140304|Perinatal Consequences of Endometriosis|Perinatal Consequences of Endometriosis: Multicenter Prospective Comparative Study|ENDOBST|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|October 2015|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1800|||Female|18 Years|N/A|No|||July 2015|July 20, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498691||17024|
NCT02245646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-RG_03_06_2014|Distortion Product After Stapedotomy Surgery|Subjektiv Verzerrter Höreindruck Nach Stapedotomie||University of Zurich|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Control group: Healthy volunteers are recruited by flyers that are displayed in the        waiting zones of the ENT clinic.        Subjects with stapedotomy: Patients are being asked by the examining MD as soon as the        indication for stapedotomy is proven.|February 2016|February 8, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02245646||36442|
NCT02245984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|922488|Effect of Applying Paper- Based Versus Electronic Nursing Process on Clinical Competence of Nursing Student|Comparison Effect of Applying Paper- Based Versus Electronic Nursing Process on Clinical Competence of Undergraduate Nursing Students' of Mashhad Nursing and Midwifery School|NP|Mashhad University of Medical Sciences|Yes|Recruiting|July 2014|October 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||September 2014|September 20, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02245984||36416|
NCT02245997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-186|Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma|Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Months|18 Years|No|||February 2016|February 9, 2016|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245997||36415|
NCT02504918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915163|Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children|Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||June 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504918||16545|
NCT02502955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-4 Cardio|Virtual Autopsy in Cardiology, Cardio- and Vascular-Surgery|Virtual Autopsy in Cardiology, Cardio- and Vascular-Surgery||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients dying after a cardiological intervention or a cardio-/vascular surgery.|July 2015|July 17, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502955||16696|
NCT02502968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKH062014|BL-8040 Addition to Consolidation Therapy in AML Patients|A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients|BLAST|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|September 2015|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02502968||16695|
NCT02351310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0031|Effectiveness of ACS in Extreme Preemies|Effects of Antenatal Corticosteroids in Patients With Early (22 - 23w6d) Threatened Preterm Birth||Mednax Center for Research, Education and Quality|Yes|Withdrawn|November 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|January 27, 2015|Yes|Yes|Company decided not to pursue this study.|No||https://clinicaltrials.gov/show/NCT02351310||28334|
NCT02358668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG01|BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes|A Study to Evaluate the Effect of BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in High Risk Chinese Subjects With Pre-Diabetes||Chinese University of Hong Kong|No|Active, not recruiting|March 2015|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358668||27771|
NCT02305121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR TFNA|Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™)|A Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™) - TFNA System in Patients With Proximal Inter-, Per- or Subtrochanteric Fractures|FR TFNA|AO Clinical Investigation and Documentation|Yes|Recruiting|March 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with per- or intertrochanteric fractures of the femur, fracture of the        trochanteric area with diaphyseal extension or combined fractures of the trochanteric area        and the femoral shaft.|January 2016|January 5, 2016|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02305121||31875|
NCT02353637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2014-140|The Peds Obesity Study|Partial Meal Replacements Providing High Protein, Restricted Carbohydrates in the Treatment of Adolescents With Severe Obesity: A Randomized Controlled Trial||University of Florida|No|Recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|45|||Both|12 Years|17 Years|No|||November 2015|November 5, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02353637||28156|
NCT02351531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-2013-02|Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy|Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy|COMETE|United Pharmaceuticals|No|Completed|November 2013|||December 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|1 Month|12 Months|No|||January 2015|January 27, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351531||28317|
NCT02350465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB01714|Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans|Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans|ARMS-II|Washington D.C. Veterans Affairs Medical Center|Yes|Recruiting|March 2015|March 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350465||28399|
NCT02505087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100152|Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM)|Pharmacological Treatment of a Rare Genetic Disease: Pilot Trial Phase II-III With N-acetylcysteine in Myopathy Associated SEPN1-RM (Selenoprotein N-related Myopathy)|SelNac|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02505087||16532|
NCT02505100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP 1439287N|Impact of Complementary Medicine Techniques (Therapeutic Touch and Hypno Analgesia) on the Term of Delivery of Patients Hospitalized for Preterm Labor (Hypnorelax)|Impact of Complementary Medicine Techniques (Therapeutic Touch and Hypno Analgesia) on the Term of Delivery of Patients Hospitalized for Preterm Labor (Hypnorelax)|Hypnorelax|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2015|January 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Female|18 Years|60 Years|No|||June 2015|October 27, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02505100||16531|
NCT02505113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPVDORNO3HSYSU|Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis|||Sun Yat-sen University||Recruiting|October 2010|||December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|1 Year|80 Years|No|Probability Sample|Patients with CTPV|October 2015|October 28, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505113||16530|
NCT02256488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_23|Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects|A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects||Novartis||Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|1561|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|September 26, 2014|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT02256488||35609|
NCT02245737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16023|An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease|A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)|AMARANTH|Eli Lilly and Company|Yes|Recruiting|September 2014|August 2021|Anticipated|August 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|2202|||Both|55 Years|85 Years|No|||March 2016|March 18, 2016|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245737||36435|
NCT02245750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Routine Hysterscopy|Value of Routine Hysteroscopy Prior to IVF/ICSI Cycles|||Ain Shams Maternity Hospital|Yes|Recruiting|August 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|20 Years|40 Years|No|||September 2014|September 19, 2014|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02245750||36434|
NCT02498093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3373|Maximal Strength Training in Patients Undergoing Total Hip Arthroplasty|Maximal Strength Training in Patients Undergoing Total Hip Arthroplasty: Implementing Evidence Based Rehabilitation Into Clinical Practice, and the Influence of Supervised Training||Norwegian University of Science and Technology|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 13, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02498093||17070|
NCT02498106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.332|Diet an Aggression: Reducing Aggression Among Chronic Psychiatric Inpatients Through Dietary Supplementation|Diet an Aggression: Reducing Aggression Among Chronic Psychiatric Inpatients Through Supplementation of Multivitamins, Minerals and n-3 Fatty Acids||Leiden University Medical Center|No|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02498106||17069|
NCT02249806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0214_ZH PH Cohort|Zürich Pulmonary Hypertension Outcome Assessment Cohort|Zürich Pulmonary Hypertension Outcome Assessment Cohort|ZHPHCohort|University of Zurich|No|Recruiting|September 2014|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Venous blood will be collected for serum markers and micro-RNA|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with precapillary pulmonary hypertension classified according to WHO|October 2015|October 2, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02249806|10 Years|36122|
NCT02509676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-KAEK-097 (Ethics Committee)|Dynamic Stretching Training and Muscle Tendon Unit|Effects of Dynamic Stretching Exercise Training on Muscle Tendon Unit||Tokat Gaziosmanpasa University|No|Recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509676||16180|
NCT02498379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409006V|PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)|PET-Magnetic Resonance (MR) Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb (Volunteer - BioDistribution and Safety Study)||Washington University School of Medicine|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498379||17048|
NCT02304250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-50|Dexamethasone and Wound Healing After Thyroid Surgery|The Effect of Dexamethasone on Safety of Thyroid Surgery||Shanghai 6th People's Hospital|Yes|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|18 Years|65 Years|No|||November 2015|November 25, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02304250||31942|
NCT02353494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Indonesia DHP 2013|Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria|Efficacy and Safety of Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum and Plasmodium Vivax Malaria in Timika, Indonesia||Menzies School of Health Research|No|Recruiting|March 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Samples for genotyping of Plasmodium vivax and Plasmodium falciparum.|Both|12 Months|65 Years|No|Non-Probability Sample|Patients suffering from uncomplicated Plasmodium falciparum / Plasmodium vivax infections        attending the study hospital during the study period.|September 2015|September 22, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353494||28167|
NCT02356185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIST-HIV|Substance Use Disorders in HIV People of Cameroon|Prevalence, Socio-demographic Correlates of Substance Use Disorders Among HIV-infected Adults in Cameroon, and Their Influence on Adherence to Antiretroviral Therapy and Immunological Feature: Study Protocol for a Retrospective Cohort Study||Goulfey Health District Unit|No|Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|HIV infected people|February 2015|February 15, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02356185||27960|
NCT02359656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1127/2009|Recent and Non United Odontoid Fractures|Recent and Non United Odontoid Fractures: Clinical and Biomechanical Aspects||Medical University of Vienna|No|Completed|January 2006|January 2015|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|65 Years|N/A|No|||February 2015|February 4, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02359656||27695|
NCT02293733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 04-2013|Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)|Retrospective Multicenter Observational Study in NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutation Treated First Line by Tyrosine Kinase Inhibitor (TKI)|EGFR-RETRO|Groupe Francais De Pneumo-Cancerologie|Yes|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|144|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with NSCLC with activating mutations of EGFR and who began a treatment by TKI in        first line from 1st January 2010 to 1st June 2012.|November 2014|November 17, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02293733||32750|
NCT02359812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200077|Robot Aided Rehabilitation - Multi-point Evaluations|Robot Aided Diagnosis, Passive-Active Arm Motor and Sensory Rehabilitation Post Stroke - Multi-point Evaluations|RAR1|Rehabilitation Institute of Chicago|No|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|85 Years|No|Non-Probability Sample|patients at a rehabilitation hospital, patients at an acute care hospital, patients from        outpatient clinics, patients from day rehabilitation programs.|February 2015|February 4, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02359812||27683|
NCT02359214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|855/13/AT/CSN|Effect of Vitamin D3 Supplementation on Cardiometabolic Risk|Effect of Vitamin D3 Supplementation on Cardiometabolic Risk Factors in a Cohort of Overweight and Obese Adults in the UK||University of Chester|No|Recruiting|April 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|74|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359214||27729|
NCT02359227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDNP-578-01|Safety Study of Cenderitide in Stable Chronic Heart Failure|A Study Assessing the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous, Stepwise, Dose Increasing, Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Subjects With Stable, Chronic Heart Failure||Capricor Inc.|No|Active, not recruiting|January 2015|||July 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359227||27728|
NCT02358746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48168.078.14|Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach|Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach a Randomized Controlled Trial|EPILOGUE|Erasmus Medical Center|Yes|Not yet recruiting|May 2015|December 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358746||27765|
NCT02510820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-54|The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems|The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems||Coopervision, Inc.|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|46|||Both|N/A|N/A|No|||October 2015|October 12, 2015|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510820||16092|
NCT02510833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE- 38511314000005208|Effects of Home Therapeutic Exercises Oriented for Patients With Parkinson's Disease|Home Therapeutic Exercises Oriented for People With Parkinson's Disease: Impact on the Disease and Quality of Life|HTE|Universidade Federal de Pernambuco|Yes|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|80 Years|No|||January 2016|January 16, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510833||16091|
NCT02240771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC-HCC|Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma|Randomized Control Trial of Transarterial Chemotherapy (TAC) Versus Oral Thalidomide and Capecitabine in the Treatment of Unresectable Hepatocellular Carcinoma||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|January 2006|March 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|12 Years|80 Years|No|||September 2014|September 12, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02240771||36817|
NCT02249572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/314|Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.|Vestibular Schwannoma - Radiosurgery or Expectation|V-REX|Haukeland University Hospital|Yes|Recruiting|October 2014|December 2021|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249572||36140|
NCT02249585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405-010-576|Effects of Neuromuscular Blockade Level and Intra-abdominal Pressure on Surgical Conditions and Cardiopulmonary Responses During Laparoscopic Colon Surgery With the Trendelenburg Position|||Seoul National University Hospital||Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|20 Years|90 Years|No|||September 2014|September 22, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02249585||36139|
NCT02502253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062802|BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes|BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes|BDPP|Johns Hopkins University||Recruiting|June 2015|||June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|48|||Both|55 Years|85 Years|No|||March 2016|March 7, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502253||16750|
NCT02502266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00651|Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)|COCOS|National Cancer Institute (NCI)|Yes|Recruiting|February 2016|||June 2023|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|680|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502266||16749|
NCT02502799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA034731|Intervention for Teens With ADHD and Substance Use|Intervention for Teens With ADHD and Substance Use||Florida International University|No|Recruiting|July 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|12 Years|16 Years|No|||February 2016|February 8, 2016|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502799||16708|
NCT02502812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200096|Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects|An Open-label, Randomised, Single-dose, Three-way Cross Over, Six Sequence Study to Determine the Relative Bioavailability of Clopidogrel 75mg From Two Tablet Formulations of SB224326 Relative to One 75mg Reference Tablet of Clopidogrel in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|September 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02502812||16707|
NCT02250209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG20130101005|T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy|Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy：Prospective Observational Study.||Chinese PLA General Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||September 2014|September 24, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250209||36091|
NCT02250222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L6972-02|Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|L6972-02|Ligand Pharmaceuticals|Yes|Completed|October 2014|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|48|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250222||36090|
NCT02254395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-010|PINS Stimulator System for Deep Brain Stimulation to Treat Obesity|PINS Stimulator System for Deep Brain Stimulation to Treat Obesity||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|October 12, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254395||35769|
NCT02256410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeMaLBP|Pain Detecting and Analgesic Stimulating Device on Low Back Pain|The Effects of a Pain Detecting and Analgesic Stimulating Device on Low Back Pain Patients' Clinical Outcomes||Vrije Universiteit Brussel|No|Completed|December 2013|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|December 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02256410||35615|
NCT02256423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 680/25772|A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects|A Single-dose, Randomised, Crossover Study to Compare the Pharmacokinetics of Three Formulations of Ibuprofen in Healthy Fasting Male and Female Subjects||Simbec Research|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02256423||35614|
NCT02498626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087110|Mixed Venous Oxygen Saturation From Central Venous Line, Venous Side of Heart Lung Machine and the Pulmonary Artery|Are Venous Saturations From the Central Venous Line, Venous Side of the Heart Lung Machine Interchangeable or Not With Mixed Venous Saturation From the Pulmonary Artery in Children Undergoing Open Heart Surgery?||Assiut University|Yes|Completed|December 2014|January 2016|Actual|January 2016|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|1 Year|15 Years|No|Probability Sample|cardiac surgery for children with congenital heart defects|February 2016|February 1, 2016|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498626||17029|
NCT02502422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA60|Relationship Between Optimal Laryngeal Mask Airway Cuff Volume and Physical Examination of Head and Neck|Prediction of Optimal Laryngeal Mask Airway Cuff Volume From Parameters of Physical Examination of Head and Neck|RCVPE|Korea University Anam Hospital|Yes|Completed|August 2015|December 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|170|||Both|19 Years|65 Years|No|||February 2016|February 14, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502422||16737|
NCT02308254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130419|Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People|Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.|Lixi|Royal Adelaide Hospital|No|Recruiting|November 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02308254||31635|
NCT02308267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Forton2015|Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis|Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis: Contribution to Lung Pathology and Impaired Defence Against Bacterial Infection|Forton2015|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|1. Lung explants from end-stage CF and control patients, which were obtained for a reason           independent from the study.        2. Sputum, nasal (fluid) and serum samples from CF patients and controls patients (COPD           patients and healthy subjects) will be collected for S-IgA and microbiological assays.           Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal           lavage.        3. Endobronchial biopsies and broncho-alveolar lavage will be sampled in some CF patients           who must have a general anaesthesia for a reason independent from the study. If           possible, nasal and rectal biopsies will also be performed. Control subjects will be           patients without evidence of lung disease and who are undergoing narcosis for an           independent reason.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|CF patients followed in a CF center (UCL, KUL, Hôpital Cochin, Torino university) Controls        patients (healthy volunteers for sputum or patients undergoing lung surgery for another        reason).|February 2016|February 24, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308267||31634|
NCT02359799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00038755|Robotic Rehabilitation of Cerebral Palsy|Home- and Lab-Based Passive and Active Movement Rehabilitation of Ankle Impairments in Children With Cerebral Palsy - A Randomized Controlled Trial||Rehabilitation Institute of Chicago|Yes|Recruiting|January 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02359799||27684|
NCT02349035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00101444|Application of Targeted Reinnervation for People With Transradial Amputation|Application of Targeted Reinnervation for People With Transradial Amputation||Rehabilitation Institute of Chicago|No|Recruiting|December 2014|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|95 Years|No|||November 2015|November 9, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02349035||28508|
NCT02359630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10|Multicenter Study of EasyTube® Compared to Endotracheal Tube in General Anesthesia|The EasyTube® in General Anesthesia: A Multicenter Study Comparing EasyTube and Endotracheal Tube|EasyTube|Medical University of Vienna|No|Completed|January 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|January 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359630||27697|
NCT02347046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-005|Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)|Clinical Pharmacology Study of FYU-981 for Subjects With Renal Insufficiency.||Fuji Yakuhin Co., Ltd.||Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Male|20 Years|N/A|Accepts Healthy Volunteers|||January 2015|March 5, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347046||28660|
NCT02346162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK099882|PREPARE: A Randomized Trial of a Pre-pregnancy Weight Loss Intervention|PREPARE: A Randomized Trial of a Pre-pregnancy Weight Loss Intervention||Kaiser Permanente|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02346162||28728|
NCT02297646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saarland University - CHO|Influencing Factors on Training Efficacy in Healthy Adults|The Influence of Carbohydrates on Training Efficacy and Health Status in Healthy Adults|CHO|Saarland University|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|23|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|September 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02297646||32450|
NCT02297893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luzerner Kantonsspital|Improving Dexterous Skills in Parkinson's Disease|Improving Dexterous Skills in Parkinson's Disease: A Randomized Controlled Trial||Luzerner Kantonsspital|Yes|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297893||32431|
NCT02356848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1858-R|STEP UP to Avert Amputation in Diabetes|STEP UP to Avert Amputation in Diabetes|STEP UP|VA Office of Research and Development|No|Recruiting|September 2015|January 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|238|||Both|21 Years|N/A|No|||January 2016|January 22, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356848||27909|
NCT02356952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medidiet|Effect of a Low Glycemic Index on Metabolic Syndrome|A Low Glycemic Index Mediterranean Diet in the Treatment of Metabolic Syndrome. A Randomized Controlled Trial.||Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|Yes|Recruiting|September 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|163|||Both|30 Years|89 Years|No|||February 2015|February 2, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02356952||27901|
NCT02359669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.11NRC|Effect of a Nutritional Approach in Combination With Cognitive Stimulation on Child Cognitive Abilities|Effect of a Nutritional Approach in Combination With Cognitive Stimulation on Child Cognitive Abilities|Stimulearn|Nestlé|No|Active, not recruiting|January 2015|April 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|200|||Both|36 Months|59 Months|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02359669||27694|
NCT02498431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRICARDIO|Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention|Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention|IRICARDIO|424 General Military Hospital|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|116|||Both|30 Years|80 Years|No|||December 2015|December 29, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02498431||17044|
NCT02245308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1301-R|Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers|Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers||VA Office of Research and Development|No|Recruiting|October 2014|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|70 Years|No|||January 2016|January 21, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02245308||36468|
NCT02245633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081-14-MMC|Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients|||Meir Medical Center||Recruiting|September 2014|September 2015|Anticipated|February 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|70|Samples With DNA|miRNA will be extract from patient'w plasma|Both|18 Years|N/A|No|Non-Probability Sample|Hemodialysis patients with diabetes at Meir Medical Center|September 2014|September 18, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02245633|5 Years|36443|
NCT02256319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXPROPAR|Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators|Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators|DEXPROPAR|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|12|||Both|18 Years|N/A|No|||February 2015|December 17, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256319||35622|
NCT02504801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSPULR0007|Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD|Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD||Xuanwu Hospital, Beijing|Yes|Not yet recruiting|July 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|73|||Both|40 Years|80 Years|No|||July 2015|July 20, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02504801||16554|
NCT02504814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|414-14-06102014|Physiological and Clinical Changes in NHF Therapy|Physiological and Clinical Changes in NHF Therapy|ATMOFLOW|University of Leipzig|No|Recruiting|April 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02504814||16553|
NCT02502565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB #01580|Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia|Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia: Redefining Early Urate Disease||Washington D.C. Veterans Affairs Medical Center|No|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02502565||16726|
NCT02502825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRD201533|Comparison of Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers|Comparison of 2-min Tidal Breathing Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|July 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|July 17, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02502825||16706|
NCT02254408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-0108|Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract||Gilead Sciences|Yes|Recruiting|January 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254408||35768|
NCT02241369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-006|Immunotherapy in Subjects With HPV6 (Human Papillomavirus) Associated Aerodigestive Malignancies|Pilot Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Malignancies||Inovio Pharmaceuticals|Yes|Recruiting|May 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241369||36771|
NCT02505412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLV-0212-15|Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients|Prevalence of Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients: is Cardiac Screening Needed?||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive asymptomatic NF1 patients, aged 0-17y and 11 month, who will visit the        investigators' Neurofibromatosis tertiary outpatients clinics|July 2015|July 21, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505412||16507|
NCT02297126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401206188|A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program|A Prospective Randomized Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program at Eskenazi Hospital|INGenious|Indiana University|No|Recruiting|January 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|6000|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02297126||32490|
NCT02354144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-M98-14B|Lubricant Investigation in Men to Inhibit Transmission of HPV Infection|A Randomized Controlled Trial of a Carrageenan-Containing Lubricant to Reduce Transmission of Human Papillomavirus Infection Among Men Who Have Sex With Men|LIMIT-HPV|McGill University|No|Not yet recruiting|October 2015|December 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|380|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354144||28117|
NCT02347059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8303|L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease|A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease||University of Toronto|No|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||January 2015|January 26, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02347059||28659|
NCT02347072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003011-00|24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo|A Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo||Pearl Therapeutics, Inc.|No|Completed|February 2015|March 2016|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|40 Years|80 Years|No|||March 2016|March 16, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347072||28658|
NCT02299713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-001|Electro-Acupuncture Treatment in Patients With Osteoarthritis Of The Knee (EATOAK)|Randomized, Double-Blind, Placebo-Controlled Trial, Parallel Design Used To Evaluate Pain, Endocrinologic Variations, Life Quality And Medication Use, After Electro-Acupuncture Treatment In Patients With Osteoarthritis Of The Knee|EATOAK|Hospital Son Llatzer|No|Recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 23, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02299713||32291|
NCT02344238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00030913|Smart Capsule for Automatic Adherence Monitoring|Smart Capsule for Automatic Adherence Monitoring||Medical University of South Carolina|Yes|Recruiting|July 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344238||28876|
NCT02344472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-V|Detect V / CHEVENDO (Chemo vs. Endo)|DETECT V / CHEVENDO CHemo- Versus ENDOcrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer||University of Ulm|Yes|Recruiting|September 2015|September 2021|Anticipated|September 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|270|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02344472||28858|
NCT02351544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0024|Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches|||Ohio State University|No|Recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02351544||28316|
NCT02346435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00016036|The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry|The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry|DISSRM|Johns Hopkins University|Yes|Recruiting|January 2009|||January 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||3|Anticipated|600|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult patients (18-100) presenting with a clinically localized, solid renal mass        (cT1a, <=4cm).|March 2016|March 14, 2016|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02346435|5 Years|28707|
NCT02510976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53094|Prucalopride Versus Placebo in Gastroparesis|Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2011|||September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|December 14, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510976||16080|
NCT02510989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI130008|Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME)|Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing|OBEXOME|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|40|Samples With DNA|Tubes of blood for genetic analysis (20 ml of blood/subject)|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|10 unrelated subjects sharing phenotypic features will be selected as their two parents        and one unaffected sibling corresponding to a total of 40 subjects.|February 2016|February 24, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02510989||16079|
NCT02254304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200136-583|Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)|Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™|PROCEED|Merck KGaA|No|Active, not recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254304||35776|
NCT02241096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3194|PK Intravenous Lidocaine Infusion|Pharmacokinetics of Intravenous Lidocaine Infusion in Children||Children's Hospital Medical Center, Cincinnati|Yes|Enrolling by invitation|January 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|3 Years|15 Years|No|||February 2016|February 4, 2016|September 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241096||36792|
NCT02509663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6190|Treatment of Chronic Frontal Sinusitis by a Simple Technique Using Dilation Balloons|Medico-economic Evaluation of the Balloon Sinuplasty as Mini-invasive Treatment of Frontal Sinusitis by a Randomized Multicenter Prospective Trial|SIBA|University Hospital, Strasbourg, France|No|Not yet recruiting|December 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|140|||Both|18 Years|N/A|No|||July 2015|November 25, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02509663||16181|
NCT02502981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/12/8/29620|Comparing the Effects of Spironolactone With Chlortalidone on LV Mass and Arterial Stiffness in Patients With CKD|A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease (SPIRO-CKD)|SPIRO-CKD|University Hospital Birmingham|Yes|Recruiting|June 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02502981||16694|
NCT02242149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30194914.3.0000.5257|Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects|Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects|DGCLFT2DM|Universidade Federal do Rio de Janeiro|No|Recruiting|September 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|75 Years|No|||December 2015|December 1, 2015|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242149||36711|
NCT02246010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.MN.09|Lactose-free Milk in Infants With Acute Diarrhea in a Developing Country|Does Intake of Lactose-free Milk in Infants With Acute Gastroenteritis in a Developing Country Shorten the Duration of Diarrhea? A Randomized Clinical Trial.||American University of Beirut Medical Center|No|Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Months|12 Months|No|||June 2015|June 22, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246010||36414|
NCT02494505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110148|Interest of Mycophenolate for CIDP Weaning|Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP)|MYCOPID|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2013|November 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02494505||17345|
NCT02301403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1041 Cessation|A Comparative Effectiveness RCT of Optimized Cessation Treatments|A Comparative Effectiveness RCT of Optimized Cessation Treatments||University of Wisconsin, Madison||Active, not recruiting|January 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301403||32161|
NCT02357628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078-14-HYMC|Effect of Regulated Oxygen-Enriched Negative Pressure Therapy (RO-NPT) On Soft Tissue Wound Repair|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|All patients presenting at the Hillel Yaffe Medical Center for treatment of hard-to-heal        wounds that have been selected for RO-NPT.|February 2015|February 5, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357628||27850|
NCT02357641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 13-089|Acute Coronary Disease (ACS)- Strain|Analysis of Myocardial Deformation in Patients With Acute Coronary Disease|ACS-Strain|RWTH Aachen University|No|Completed|November 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|300 patients with vague thoracal disorder -cardiac or non cardiac- are enrolled        prospectively to undergo routinely echography as well as routine examinations such as        anamnetic, hemodynamic examinations and laboratory. The distinction between non cardiac        disorder or acute coronary disease (ACS) is offen difficult so that time- consuming and        expensive ischemic diagnostics or coronary artery angiography will follow. To prevent        these time consuming or expensive diagnostics retrospectively a cut off value will be        determined of systolic, diastolic and additionally of circumferential and radial        echographic strain data analysis corresponding to acute coronary disease.|February 2015|February 3, 2015|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357641||27849|
NCT02352025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS 14-2018|S-equol in Women With Triple Negative Breast Cancer|A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||November 2015|November 3, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352025||28279|
NCT02303730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10096|Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes|Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes||Fudan University|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|70 Years|No|||November 2015|February 6, 2016|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02303730||31982|
NCT02301884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBIRB2013-35|Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis|Open-labeled Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|pILIT|Gachon University Gil Medical Center|Yes|Completed|November 2013|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|19 Years|N/A|No|||March 2015|March 10, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02301884||32124|
NCT02301897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-203|A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301897||32123|
NCT02301910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fortelyzin-1|Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI|Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients|FORMAT-1|Supergene, LLC|No|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|392|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02301910||32122|
NCT02349256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123389|Somatoform Disorder in British South Asians|Somatoform Disorder in British South Asians - What Are the Patients' Views?||Global Health Primary Care Research and Innovation and Network|No|Recruiting|December 2014|||May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Men and women self ascribed British South Asian Origin .|January 2015|January 22, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02349256||28491|
NCT02356224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-101|The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following Single Dose of SHR3824 in Healthy Subjects|SHR3824|Jiangsu HengRui Medicine Co., Ltd.||Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|84|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|February 4, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02356224||27957|
NCT02356237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125-14BNZ|The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)|The Effect of Episiotomy on Advanced Perineal Tears and Other Maternal and Fetal Outcomes - Randomized Controlled Multicentric Trial (EPITRIAL)||Carmel Medical Center|No|Recruiting|June 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|14842|||Female|18 Years|50 Years|No|||July 2015|July 27, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356237||27956|
NCT02299986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 13/12/131|An InnovaTive Approach to Ventilator-Induced Diaphragmatic Dysfunction|An InnovaTive Approach to Ventilator-Induced Diaphragmatic Dysfunction|ITAVIDD|University Hospital, Antwerp|No|Completed|April 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|All patients that are admitted in ICU and who require mechanical ventilation will be        screened for inclusion, and participants will be enrolled after informed consent. The        study population will be a mixed medical/surgical cohort, selected with non-probability        sampling because of the different eligibility criteria.|June 2015|June 23, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02299986||32270|
NCT02494843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14025|Dynamic Effects of Online HDF on Cardiac Function and Myocardial Perfusion Utilising Cardiac MRI (CAMRID)|Dynamic Effects of Online HDF on Cardiac Function and Myocardial Perfusion Utilising Cardiac MRI (CAMRID)|CAMRID|University of Nottingham|No|Completed|November 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Both|18 Years|75 Years|No|||July 2015|July 7, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02494843||17319|
NCT02241863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353|The Effect of a Theory Based Educational Intervention on Medication Adherence to and Removes of Related Barriers in Patients With Bipolar Disorder|||Qazvin University Of Medical Sciences|Yes|Completed|September 2014|||September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||October 2015|January 4, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02241863||36733|
NCT02245763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-2|STS/ACC TVT Registry Mitral Module|The Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapies Registry Mitral Module|TMVR|American College of Cardiology|Yes|Recruiting|November 2013|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|1 Year|N/A|Accepts Healthy Volunteers|Probability Sample|Transcatheter Mitral Valve Repair and Replacement must be furnished in a hospital with the        appropriate infrastructre that includes, but is not limited to On site heart valve surgery        program Cardiac catheterization lab or hybrid operating room with a fixed radiographic        imaging system with flat panel fluoroscopy, offering quality imaging Non-invasive imaging        such as echocardiography, vascular ultrasound, computed tomography and magnetic resonance        Sufficient space, in a sterile environment, to accommodate necessary equipment for cases        with and without complications Post-procedure intensive care facility with personnel        experienced in managing patients who have undergone open-heart valve procedures        Appropriate volume requirements|September 2014|September 19, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02245763||36433|
NCT02245776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-16|Stem Cell Therapy in Incurable Neurological Disorders|Autologous Bone Marrow Mononuclear Cell Therapy for Incurable Neurological Disorders||Neurogen Brain and Spine Institute|Yes|Recruiting|December 2008|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|6 Months|80 Years|No|||September 2014|September 17, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245776||36432|
NCT02498119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG291-14AFR|The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome|The Role of Arachidonic Acid Metabolites, in the Lipid Droplets of Macrophages From Patients With Metabolic Syndrome||University of Malaya|No|Recruiting|November 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||2|Anticipated|8|Samples With DNA|Whole blood is collected and blood component separated for the future use. Whole blood, red      blood cells, plasma and buffy coat are was separated and kept in -80 degree Celsius.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study subjects are recruited from Primary Care Clinic of University Malaya Medical        Center|July 2015|July 10, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02498119|12 Months|17068|
NCT02498366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2388-15-SMC|Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty|Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty||Sheba Medical Center|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498366||17049|
NCT02503371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0332-11-RMC|The Effect of In Vitro Fertilization on Coagulation Parameters as Measured by Thromboelastogram|||Rabin Medical Center|No|Completed|December 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Female|18 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parturients undergoing in-vitro fertilization treatment|July 2015|July 17, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02503371||16664|
NCT02246985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/HSMC/2010|Bioavailability of Carotenoids Added Into Processed Foods|Bioavailability of Carotenoids Incorporated Into Processed Foods: Bread and Mayonnaise|CAROTFoods|University of Aberdeen|No|Active, not recruiting|July 2014|December 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246985||36339|
NCT02250599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29153|Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma|Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|August 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02250599||36061|
NCT02498639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE41/2015/O/Sper|The Pacing vs No Pacing Study - PNP Study|Comparison of Safety and Efficacy of Percutaneous Balloon Aortic Valvuloplasty Performed With or Without Rapid Ventricular Pacing - The Pacing vs No Pacing Study (PNP Study)|PNP|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|April 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|70 Years|N/A|No|||July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02498639||17028|
NCT02498652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-206|Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects|A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Allopurinol Compared With Allopurinol Administered Alone in Adult Subjects With Gout||Ardea Biosciences, Inc.|Yes|Active, not recruiting|July 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498652||17027|
NCT02304484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140128|Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab|A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab||Amgen|Yes|Enrolling by invitation|November 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|642|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02304484||31924|
NCT02304718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400010558|Exercise Intervention to Prevent Gestational Diabetes|Cycle Study:an Exercise Intervention to Prevent Gestational Diabetes in Overweight and Obese Chinese Pregnant Women||Peking University First Hospital|No|Recruiting|December 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|45 Years|No|||October 2015|October 21, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304718||31906|
NCT02346292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRU-XXX-2014/1|Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement|Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement|CLOUD|AstraZeneca|No|Active, not recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1250|||Both|40 Years|N/A|No|Non-Probability Sample|Patients of both genders aged 40 years and older, smokers, with smoking history more than        10 pack-years, with severe and very severe COPD who were hospitalized with COPD        exacerbation|January 2016|January 18, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02346292||28718|
NCT02356770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10860|A Clinical Study to Investigate Collagen Matrix 10808 for Soft Tissue Volume Augmentation Around Single Implants|Randomized Controlled Clinical Study to Investigate Effectiveness and Safety of a Collagen Matrix 10808 for Soft Tissue Volume Augmentation After Implant Placement in Single Tooth Gaps||Geistlich Pharma AG|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2015|February 2, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02356770||27915|
NCT02293096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3174|Pharmacogenetic Prediction of Metoprolol Effectiveness|Pharmacogenetic Prediction of Metoprolol Effectiveness||University of Colorado, Denver|Yes|Recruiting|September 2014|||September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|500|||Both|30 Years|80 Years|No|||December 2015|December 10, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293096||32799|
NCT02305472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-201403|NeoVas Bioresorbable Coronary Scaffold Registry Study|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study||Lepu Medical Technology (Beijing) Co.,Ltd|Yes|Recruiting|November 2014|September 2020|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|825|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305472||31848|
NCT02305485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-201402|NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial||Lepu Medical Technology (Beijing) Co.,Ltd|Yes|Active, not recruiting|November 2014|June 2020|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|75 Years|No|||December 2015|December 23, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305485||31847|
NCT02354378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00004739|A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients|A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients||Children's Hospital Boston|No|Completed|August 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|64|||Both|4 Years|14 Years|No|Probability Sample|Children between the ages of 4 and 14 years old either requiring sedation or attempting        without sedation for MRI imaging will be offered inclusion in the study. Sedation will be        administered per established and approved BCH sedation guidelines: over 10 minutes, a        bolus of 2 mcg/kg of dexmedetomidine will be administered intravenously. The sedation        process will not change for this study. During the bolus, pictures will be shown to the        child who will be encouraged to name the item in the picture.|February 2016|February 1, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354378||28099|
NCT02357706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA240115|Comparison of Auto-Adjusting Positive Airway Pressure Devices|Comparison of Auto-Adjusting Positive Airway Pressure Devices||ResMed|No|Completed|January 2015|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02357706||27844|
NCT02347410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62-180|Spineology Clinical Outcomes Trial: An IDE Investigation|Spineology Clinical Outcomes Trial: An Investigation Device Exempt (IDE) Performance Goal Clinical Investigation|SCOUT|Spineology, Inc|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|21 Years|80 Years|No|||June 2015|June 30, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347410||28632|
NCT02304211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056933|Intra-Arterial Microdosing: Proof-of-Concept in Humans|Intra-Arterial Microdosing: Proof-of-Concept in Humans|IAM-POC|Duke University|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304211||31945|
NCT02304224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040114002|the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit|the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit||Shanghai 10th People's Hospital|Yes|Not yet recruiting|December 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304224||31944|
NCT02501512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015136|Maturational Changes in Newborn Infants|Maturational Changes in Coordination of Breathing, Heart Rate and Swallowing in Newborn Infants - a Single-centre Pilot Study||University Hospital, Basel, Switzerland|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|N/A|10 Days|No|Probability Sample|15 infants hospitalized in the NICU of the University Children's Hospital Basel who were        born between 32 and 42 weeks gestational age in the course of their first two weeks of        life.|March 2016|March 9, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501512||16807|
NCT02246686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17155|Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients|A Randomised, Double-blind, Placebo-controlled Multi-centre Study to Investigate the Effectiveness and Safety of STW5-II as add-on Treatment for Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis||Bayer|No|Terminated|November 2014|December 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02246686||36362|
NCT02251899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-AHS-HS-2|A Disease Management Study Targeted to Reduce Health Care Utilization for Patients With Congestive Heart Failure|A Disease Management Study Targeted to Reduce Health Care Utilization for Patients With Congestive Heart Failure||Health Navigator|No|Recruiting|January 2010|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|10000|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251899||35961|
NCT02250300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00022660|MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation|MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation||Medical College of Wisconsin|Yes|Recruiting|November 2014|September 2022|Anticipated|September 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|57|||Both|18 Years|N/A|No|||January 2016|February 24, 2016|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250300||36084|
NCT02257983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI743-14-026|Protective Effects of EPI-743 on Noise-Induced Hearing Loss|A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (VincerinoneTM) on Noise-Induced Hearing Loss||Edison Pharmaceuticals Inc|No|Completed|October 2014|February 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|77|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257983||35497|
NCT02502344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12015C1023|Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance|The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance|MIIIROPOAGT|Beijing Tsinghua Chang Gung Hospital|Yes|Not yet recruiting|August 2015|||August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|20 Years|35 Years|No|||July 2015|July 16, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502344||16743|
NCT02505243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF-15.03|Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens|Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens|RIBACOP|Radboud University|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|chronicHCV infected patients treated with direct acting antivirals (daclatasvir,        simeprevir, sofosbuvir, paritaprevir, ombitasvir, dasabuvir, ledipasvir) and ribavirin.|February 2016|February 22, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505243||16520|
NCT02504879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150165|Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease|Study of the Natural History, Pathogenesis and Outcome of Melorheostosis - a Rare Osteosclerotic Disease||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|August 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504879||16548|
NCT02252120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_4|Laryngeal Mask Airway Supreme Versus Laryngeal Tube|Laryngeal Mask Airway Supreme Versus Laryngeal Tube in Non-paralysed, Anesthetized Children. A Randomized, Crossover Study Assessing Oropharyngeal Leak Pressure and Fiberoptic Position Using the Size 2||Schulthess Klinik|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Months|9 Years|No|||September 2014|September 26, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02252120||35944|
NCT02258022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0294|Changes in 13CO2/12CO2 Delta Value in Exhaled Breath as an Early Indicator of Infection in Adult Trauma Subjects|Changes in 13CO2/12CO2 Delta Value in Exhaled Breath as an Early Indicator of Infection in Adult Trauma Subjects||University of Wisconsin, Madison|Yes|Recruiting|October 2014|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|110|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02258022||35494|
NCT02502929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-164S-3|Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians||DREAM|University of Connecticut Health Center|No|Not yet recruiting|November 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|210|||Both|35 Years|65 Years|No|||July 2015|July 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502929||16698|
NCT02293447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8053|Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization|Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study||University Health Network, Toronto|No|Recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Female|18 Years|N/A|No|||June 2015|June 11, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293447||32772|
NCT02293460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10E-1302|Efficacy and Safety Study of I10E in Treatment of Patients With CIDP|An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.|PRISM|Laboratoire français de Fractionnement et de Biotechnologies|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293460||32771|
NCT02350361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-LL01|Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.|A Study of Endostar Combination With Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Rechallenging Treatment After Resistance of EGFR-TKI and Tumor Progression||Peking University Third Hospital|No|Recruiting|January 2014|March 2016|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2015|January 25, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02350361||28407|
NCT02343432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2008/23|Is the Efficacy of Epidural Steroid Injections Related to the Different Volume Injections?|Is the Efficacy of Epidural Steroid Injections Related to the Different Volume Injections? :A Randomised, Clinical Trial||Yeditepe University Hospital|No|Completed|March 2008|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|75|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02343432||28936|
NCT02343445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-G201|Clearing Lungs With ENAC Inhibition in Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)|CLEAN-CF|Vertex Pharmaceuticals Incorporated|No|Active, not recruiting|April 2015|June 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|12 Years|80 Years|No|||March 2016|March 1, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343445||28935|
NCT02297334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-UKE-PV 4420|Removal of Cytokines During Extracorporeal Circulation in Cardiac Surgery|Reduction of Inflammation Reaction to Extracorporeal Circulation in Cardiac Surgery by Interleukin Dialysis||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|September 2013|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02297334||32474|
NCT02294773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-MIDW-101|Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit|Randomized Controlled Trial Evaluating the Timing of Intrauterine Insemination in Relation to the LH Surge||Midwest Fertility Specialists|No|Completed|October 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13|||Female|21 Years|39 Years|No|||November 2015|November 4, 2015|October 1, 2014||No||No|September 27, 2015|https://clinicaltrials.gov/show/NCT02294773||32670|
NCT02346565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD14/86|Stress Echocardiography Versus Exercise ECG in Women With Chest Pain|The Role of Contemporary Stress Echocardiography Techniques in the Initial Assessment of Women With No Previous History of Coronary Artery Disease Who Present With Chest Pain of Recent Onset. Stress Echocardiography vs Exercise ECG as First Line Investigation in This Population. Potential for Higher Diagnostic Accuracy Cost Saving.||London North West Healthcare NHS Trust|No|Recruiting|January 2015|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|450|||Both|30 Years|N/A|No|||October 2015|October 9, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02346565||28697|
NCT02352272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14ca703op1|Benefits of Sleep Extension on Performances During Total Sleep Deprivation (BankingSleep)|Benefits of Sleep Extension on Cognitive and Physical Performances During Baseline, Total Sleep Deprivation and Recovery (BankingSleep)|BankingSleep|Institut de Recherche Biomedicale des Armees|Yes|Completed|January 2014|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02352272||28260|
NCT02352285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-KOB-1201i|Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure|Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia|AQUATIC|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|December 2012|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||January 2016|January 27, 2016|December 20, 2012||No||No||https://clinicaltrials.gov/show/NCT02352285||28259|
NCT02293395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106261|A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome|A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome|GEMINI ACS 1|Janssen Research & Development, LLC|Yes|Recruiting|April 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|3000|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293395||32776|
NCT02502669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EL-1006-01-01|Finasteride Treatment of Severe Nodulocystic Acne|A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne||Elorac, Inc.|No|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|February 3, 2016|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502669||16718|
NCT02251912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1862b|Oxytocin Treatment of Alcohol Dependence|Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial|OTS ETOH-3|University of North Carolina, Chapel Hill|No|Not yet recruiting|July 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251912||35960|
NCT02254941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD 1401|Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer|Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer||Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Recruiting|August 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1950|Samples With DNA|Colon biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Metastatic colorectal cancer. Adenocarcinoma. First line treatment|September 2014|September 29, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02254941||35727|
NCT02257996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBPP-1|Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy for Neurotic Disorders: Randomized Controlled Trial|The Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy Via HIPAA Complaint Web Conferencing on Adults With Neurotic Disorders: a Randomized Controlled Trial||University of Sao Paulo|Yes|Not yet recruiting|August 2015|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|22 Years|65 Years|No|||January 2015|January 14, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02257996||35496|
NCT02505256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST P-01|Study Into Treatment of Hyperplasia of Mammary Glands|Study Into Treatment of Hyperplasia of Mammary Glands||Shandong University|No|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|None Retained|breast tissues|Female|25 Years|70 Years|No|Non-Probability Sample|Females who reported breast pain of breast lumps.|July 2015|July 21, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02505256||16519|
NCT02509845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3J15-202-00|Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel Doses to Adolescent and Adult Dental Subjects||C3 Jian, Inc.|No|Active, not recruiting|July 2015|April 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|64|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|July 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509845||16167|
NCT02255019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-149|MRI in Patients With Inflammatory Bowel Disease|MRI in Patients With Inflammatory Bowel Disease||Copenhagen University Hospital at Herlev|No|Completed|May 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|125|Samples Without DNA|Patients will receive a faeces sample kit the first day they meet to MRI. The sample should      be taken two days after the MRI scan and sent through the mail. The sample should contain      about 5-10 g of faeces and it will be analyzed by ELISA method for calprotectin.      Calprotectin is a good marker for the degree of inflammation in the intestines.|Both|18 Years|N/A|No|Non-Probability Sample|Minimum 77 subjects in study I-V and minimum 15 subjects in the pilot study are included.        All patients should eighter have a known IBD diagnose or suspect IBD. There will not be        considered healthy subjects. Participants must be over 18 years old.|September 2014|October 1, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255019||35721|
NCT02242227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.10|Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder (25 μg Salmeterol), Administered as the Xinafoate Salt From a Hard Polyethylene Capsule Via the HandiHaler® 2, and Serevent® Diskus® (50 μg Salmeterol) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|September 2005|||February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|111|||Both|40 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242227||36705|
NCT02242240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.2|Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Lung Function Changes Following the Addition of Formoterol Inhalation Capsules (12 µ Once or Twice Daily) to Pharmacodynamic Steady State of Once Daily Tiotropium (18 µg) Inhalation Capsule in Patients With COPD||Boehringer Ingelheim||Completed|March 2001|||December 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Both|40 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242240||36704|
NCT02242253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.7|Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 6-week Treatment Periods of the Free Combinations of Tiotropium Inhalation Powder Capsule (18 μg) QD + Salmeterol Metered Dose Inhaler (2 Puffs of 25 μg) QD or BID, Tiotropium Inhalation Powder Capsule (18 μg) QD and Salmeterol Metered Dose Inhaler (2 Puffs of 25 μg) BID in Patients With (COPD)||Boehringer Ingelheim||Completed|September 2003|||July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|97|||Both|40 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242253||36703|
NCT02505425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X140813007|ENABLE CHF-PC (Comprehensive Heartcare For Patients and Caregivers)|Randomized Trial of ENABLE CHF-PC for Heart Failure Patients and Caregivers. (Comprehensive Heartcare For Patients and Caregivers)|ENABLE CHF PC|University of Alabama at Birmingham|Yes|Enrolling by invitation|October 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|462|||Both|50 Years|N/A|No|||January 2016|January 8, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02505425||16506|
NCT02297373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140622-01H|Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis|Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis||Ottawa Hospital Research Institute|No|Recruiting|November 2014|February 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|745|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients presenting with suspected acute recurrent VTE.|March 2016|March 8, 2016|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02297373||32471|
NCT02354391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1969699|Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis|Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis.||Pacific Dermaesthetics|No|Active, not recruiting|January 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02354391||28098|
NCT02347943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005044|Global Sinus Surgery Registry|OASIS Global Sinus Surgery Registry|OASIS|Acclarent|No|Terminated|January 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|269|||Both|18 Years|N/A|No|Non-Probability Sample|Adults diagnosed by an ENT surgeon with chronic rhinosinusitis (CRS) or recurrent acute        rhinosinusitis (RARS) undergoing a primary transnasal endoscopic sinus surgery.|December 2015|December 11, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347943||28592|
NCT02301624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-MG-302|ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis|ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)||Alexion Pharmaceuticals|No|Enrolling by invitation|November 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301624||32144|
NCT02299778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000026022|Bacterially-synthesized Folate Absorption Across the Large Intestine|Is Bacterially-Synthesized Folate Absorbed Across the Colon of Humans?||The Hospital for Sick Children|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02299778||32286|
NCT02299791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HL095481-01A1|Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics|Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics|ALL|Kaiser Permanente|No|Completed|September 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|11|||Both|18 Years|75 Years|No|||November 2014|November 20, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02299791||32285|
NCT02350647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031426|Suture Anchor Comparison in Rotator Cuff Repairs|TWO-ARM, SINGLE BLIND, RANDOMIZED POST-MARKET STUDY ON THE USE OF HEALICOIL™ REGENESORB SUTURE ANCHOR IN THE REPAIR OF TEARS OF THE ROTATOR CUFF||The Hawkins Foundation|No|Recruiting|May 2014|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|35 Years|75 Years|No|||September 2014|January 29, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350647||28385|
NCT02350660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15098|Oral Immunotherapy for Peanut and Mammalian Meat Allergies|Oral Immunotherapy for Peanut and Mammalian Meat Allergies||University of Virginia|No|Completed|March 2012|June 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|4 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02350660||28384|
NCT02356822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HEOR_01|Sarah Cannon Outcomes Registry|Sarah Cannon Outcomes Registry||SCRI Development Innovations, LLC||Recruiting|December 2014|December 2024|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Patients 18yrs or older, that have been diagnosed with/ or are thought to have any form of        cancer at any stage in the continuum of their care from screening through survivorship.        Patient must have the ability to understand the nature of the trial and give written        informed consent.|September 2015|September 30, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02356822|10 Years|27911|
NCT02343770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9355|Biomarkers in Idiopathic Juvenile Arthritis|Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive.||University Hospital, Montpellier|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02343770||28910|
NCT02297607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00091994|Routine Post-Operative Supplemental Nutrition|Routine Post-Operative Supplemental Nutrition: A Randomized Controlled Trial||University of Michigan|No|Recruiting|November 2014|April 2020|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02297607||32453|
NCT02301845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creatures|Validation of Aspiration Markers|Validation of a Marker for Aspiration and Endotracheal Tube Cuff Leak.||Massachusetts General Hospital|No|Withdrawn|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 23, 2014|Yes|Yes|IRB disapproval|No||https://clinicaltrials.gov/show/NCT02301845||32127|
NCT02503202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V920-012|Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)|A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults||Merck Sharp & Dohme Corp.|No|Active, not recruiting|August 2015|September 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|1198|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503202||16677|
NCT02254954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-118|Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma|A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma||Actelion|No|Active, not recruiting|October 2014|July 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254954||35726|
NCT02242747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11334|Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis|Evaluation of the Tolerability and Safety of 0.015% Ingenol Mebutate Gel Compared to 5% 5-fluorouracil Cream for the Treatment of Facial Actinic Keratosis: a Prospective Randomized Trial||University of Sao Paulo|Yes|Completed|May 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242747||36665|
NCT02241967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-005-13F|Dose Dependent Effects of tDCS on Post-Operative Pain|Dose Dependent Effects of tDCS on Post-Operative Pain|tDCS-TKA|VA Office of Research and Development|No|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|19 Years|90 Years|No|||February 2016|February 5, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02241967||36725|
NCT02510183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GulhaneMMA|P6 Acupressure Before Laparoscopic Cholecystectomy|Evaluation of the Effects of P6 Acupressure Application on Postoperative Nausea and Vomiting Before Laparoscopic Cholecystectomy||Gulhane Military Medical Academy|No|Active, not recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|111|||Female|18 Years|N/A|No|||June 2015|July 26, 2015|June 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510183||16141|
NCT02510196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-13-HMO|Assessment of Skill Retention in Clinical Practice|||Hadassah Medical Organization|No|Active, not recruiting|April 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|July 26, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02510196||16140|
NCT02505503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOR - A02382|York Study of Unloading Shoes for Vascular Intermittent Claudication|Randomised Crossover Study With Nested Qualitative Component Investigating the Clinical Efficacy and Acceptability of Unloading Shoes in Patients With Intermittent Claudication Due to Peripheral Arterial Disease|YORVIC|York Teaching Hospitals NHS Foundation Trust|No|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|N/A|No|||January 2016|January 26, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505503||16500|
NCT02243072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DK102091-01|Home-Based Interventions for Adolescents With Type 1 Diabetes|Translating Home-Based Interventions for Adolescents With Poorly Controlled TID|R34|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|December 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|17 Years|No|||December 2015|December 14, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02243072||36640|
NCT02500381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4045-301|Study of SRP-4045 and SRP-4053 in DMD Patients|A 48-Week, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy|ESSENCE|Sarepta Therapeutics|No|Not yet recruiting|June 2016|May 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Male|7 Years|16 Years|No|||February 2016|February 26, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500381||16894|
NCT02510534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVFFL001v2|Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI|A Prospective Randomized Trial to Study the Effect of Luteal Progesterone Support on Pregnancy Rates in Combined Clomiphene Citrate and Gonadotropin Ovulation Induction Protocol With Intrauterine Insemination.||Northwest Center for Infertility and Reproductive Endocrinology|Yes|Recruiting|July 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510534||16114|
NCT02305394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZ-006|Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy|Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|January 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|65 Years|No|||November 2014|December 1, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02305394||31854|
NCT02359890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-SF|SMART-SF Radiofrequency Ablation Safety Study|Prospective Safety Assessment of the THERMOCOOL® SMARTTOUCH® SF Family of Contact Force Sensing Catheters for the Radiofrequency Ablation Treatment of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation||Biosense Webster, Inc.|Yes|Active, not recruiting|March 2015|December 2016|Anticipated|September 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359890||27677|
NCT02345824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13223|Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma|Early-Phase Study to Assess Tumor Pharmacokinetics and Efficacy of the CDK4/6 Inhibitor Ribociclib (LEE011) in Patients With Recurrent Glioblastoma or Anaplastic Glioma||University of Virginia|Yes|Recruiting|March 2016|January 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||March 2016|March 22, 2016|January 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345824||28754|
NCT02350088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tongji Fast-track surgery|Fast-track Surgery in the Treatment of Hirschsprung's Disease|Fast-track Surgery in the Treatment of Hirschsprung's Disease|Fast-track|Tongji Hospital|Yes|Recruiting|January 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|18 Years|No|||January 2015|January 24, 2015|January 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350088||28428|
NCT02352038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRF01121056|Randomized Controlled Trial of a Novel Laser-aided Orthodontic-periodontal Treatment Strategy|||The University of Hong Kong||Recruiting||||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 27, 2015||||No||https://clinicaltrials.gov/show/NCT02352038||28278|
NCT02304042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH 2|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial|PPH|Cairo University|Yes|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|40 Years|No|||July 2015|July 1, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304042||31958|
NCT02304055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH 3|Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial||Cairo University|Yes|Completed|May 2013|||December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304055||31957|
NCT02354638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMHPOCAB2015|Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai|Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai, India||Tata Memorial Hospital|Yes|Recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|400|||Male|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02354638||28079|
NCT02348229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-212|Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins|Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins in Patients With Advanced Gastric Cancer|ERASAG|First Hospital of Jilin University|No|Completed|September 2013|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|75 Years|No|||January 2015|January 27, 2015|January 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02348229||28570|
NCT02348242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01197-40|Ocular Surface Disorders in Patients in Intensive Care Units, a Comparative Study of Three Preventive Approaches|Ocular Surface Disorders in Patients in Intensive Care Units, a Comparative Study|OCUREA2|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|December 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02348242||28569|
NCT02301858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIV 9743|Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases|Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases||Sykehuset i Vestfold HF|No|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|90 Years|No|||December 2015|December 6, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02301858||32126|
NCT02504047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26110|Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units|Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units||University of Calgary|Yes|Recruiting|February 2014|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||July 2015|July 20, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02504047||16612|
NCT02242760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC202|P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled Study Comparing the Efficacy, Tolerability, and Safety of SB204 Gel and Vehicle Gel Once or Twice Daily in the Treatment of Acne Vulgaris||Novan, Inc.|No|Completed|November 2014|August 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|200|||Both|12 Years|40 Years|No|||August 2015|August 19, 2015|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242760||36664|
NCT02248090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6090C00001|AZD9496 First Time in Patients Ascending Dose Study|Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer||AstraZeneca|No|Recruiting|October 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02248090||36254|
NCT02500108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q13-02|Domperidone and Risk of Sudden Cardiac Death|Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|May 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|214962|||Both|50 Years|N/A|No|Probability Sample|The study population will consist of all subjects with a diagnosis of Parkinson's disease        or a prescription for an antiparkinsonian drug who were registered for provincial medical        services coverage or registered in a clinical practice (CPRD) at any time between January        1, 1990 (or 1 year after site-specific data is available, whichever is later) and June 30,        2012.|July 2015|July 14, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02500108||16915|
NCT02498392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107733|An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress||Janssen Research & Development, LLC|No|Suspended|October 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|64 Years|No|||January 2016|January 22, 2016|July 13, 2015|Yes|Yes|On-hold as serious adverse events reported in another company's Phase1 safety study with    experimental drug in this class|No||https://clinicaltrials.gov/show/NCT02498392||17047|
NCT02244177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS-103-080|Relationship of Essential Hypertension and Its Treatments on the Postoperative Pain Management: a Prospective, Observational, Cross-sectional Study|||Kaohsiung Veterans General Hospital.||Recruiting|November 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those patients enrolled will be divided into three groups as follows As the treatment and        choice of drugs for hypertension is complex but internation guideline-oriented. We would        like to enroll enough sample size in the hypertensive groups and subgroups.          1. Normaltension group (control group)          2. Hypertension without treatment          3. Hypertension with treatment as follows (according to subject's daily routine Tx, the             PI not involved into the choice and further manitence of drugs) I. Hypertension with             treatment with ACEI II. Hypertension with treatment with β blocker III. Hypertension             with treatment with Ca channel blocker IV. Hypertension with treatment with diuretics|March 2015|March 30, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02244177||36555|
NCT02248389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0474|Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses|Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses|HIFU-KIDNEY|Indiana University|Yes|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02248389||36231|
NCT02248623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConsCIOUS|Intraoperative Anaesthesia Awareness Following Induction of Anaesthesia|An International Multi-Centre Cohort Study of the Incidence of Anaesthesia Awareness Following Laryngoscopy and Intubation: The CONSciousness, Connectedness and IntraOperative Unresponsiveness Study (ConsCIOUS)|ConsCIOUS|University of Wisconsin, Madison|Yes|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing anaesthesia requiring intubation and layngoscopy|October 2015|October 9, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02248623||36213|
NCT02503709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01098|Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor AT13387 (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Not yet recruiting|March 2016|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503709||16638|
NCT02294513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPHST101659-03HIAD|Hearing Instruments in Alzheimer's Disease|Hearing Intervention for Patients With Early-Stage Alzheimer's Disease: Determining the Benefits for Patients and Family Caregivers|HIAD|Phonak AG, Switzerland||Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02294513||32690|
NCT02350101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2010-0234/4|Massive Transfusion Protocol With Coagulation Algorithm|Introduction of a Massive Transfusion Protocol - Evaluation Over Three Years||University of Zurich|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|243|||Both|18 Years|N/A|No|Non-Probability Sample|All patients needing massive transfusion (more than 10 RBCs)|January 2015|January 23, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02350101||28427|
NCT02354846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0928|An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)|||Yonsei University|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|||Both|19 Years|N/A|No|Non-Probability Sample|Previously untreated Diffuse Large B-cell Lymphoma (DLBCL) with HBsAg (+) who are suitable        for receiving R-CHOP chemotherapy|October 2015|October 22, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02354846||28063|
NCT02357251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE 17814|Enhanced Recovery After Surgery: A RCT of Perioperative Management of Gynecologic Patients|Enhanced Recovery After Surgery: A Randomized Control Trial of Perioperative Management of Gynecologic Patients||Case Comprehensive Cancer Center|No|Recruiting|February 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357251||27878|
NCT02357472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIAIE2014-03|The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders|The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders|DHEA|ShangHai Ji Ai Genetics & IVF Institute|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|22 Years|45 Years|No|||November 2015|November 16, 2015|January 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357472||27862|
NCT02303600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAC2014|Fractional Concentration of Exhaled NO(FENO) to Direct Montelukast Treatment of Sub-acute Cough|Fractional Concentration of Exhaled NO(FENO) to Direct Montelukast Treatment of Sub-acute Cough:A Prospective, Open Label, Randomized and Placebo-Controlled Trial||Beijing Chao Yang Hospital|Yes|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02303600||31992|
NCT02305888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1148|Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively|Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively||LEO Pharma|No|Completed|March 2015|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|188|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305888||31816|
NCT02309437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAIN-1|Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients|Influences on the Nutrition Statuses and Clinical Outcomes of Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients||Affiliated Tumor Hospital of Guangzhou Medical University|No|Not yet recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|174|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|November 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309437||31545|
NCT02359903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-055-1/ASART-1|Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis|International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis||Biocad|No|Active, not recruiting|February 2015|December 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02359903||27676|
NCT02352298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0003|Protocol for the Evaluation of Dario™ BGMS Performance at Elevated Altitude|Protocol for the Evaluation of Dario™ Blood Glucose Monitor (BGMS) Performance at Elevated Altitude||LabStyle Innovations Ltd.|No|Completed|February 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02352298||28258|
NCT02352311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-DT-002|Safety and Pharmacokinetic Characteristics of DKF-313|A Randomized, Open-label, Single-dose, 2-treatment, 2-way, 2-period Crossover Study to Evaluate the Safety and the Pharmacokinetic Characteristics of DKF-313 in Healthy Male Volunteers||Dongkook Pharmaceutical Co., Ltd.|No|Recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|54|||Male|19 Years|29 Years|Accepts Healthy Volunteers|||February 2015|February 1, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02352311||28257|
NCT02303743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI071114|Improving Bowel Cleansing With a Smart Phone Application|Improving the Quality of Colonoscopy Bowel Preparation Using a Smart Phone Application||Germans Trias i Pujol Hospital|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|260|||Both|18 Years|90 Years|No|||January 2015|January 12, 2015|November 24, 2014|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT02303743||31981|
NCT02303756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140141|Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's A Pilot Study|Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's||Odense University Hospital|Yes|Recruiting|November 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02303756||31980|
NCT02505477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOS53929|Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine|Mechanisms of Improving Cognition and Negative Symptoms in Schizophrenia With N-Acetylcysteine: a Magnetic Resonance Spectroscopy Study of Glutamate and Glutathione|NAC2|University of California, Los Angeles|No|Not yet recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505477||16502|
NCT02505490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK IRB-15-02352-XP|The Effect of Television Watching on Liking of Food|The Effect of Television Watching on Liking of Food in Normal Weight Adults 18-35||University of Tennessee|No|Active, not recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02505490||16501|
NCT02248103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPP graft_GTR|Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects|Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects: A Randomized Controlled Clinical Trial.||Cairo University|No|Completed|March 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|September 20, 2014|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT02248103||36253|
NCT02503462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRVCOBI|Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals|Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals||University Hospital, Basel, Switzerland|No|Recruiting|July 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02503462||16657|
NCT02502773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0242|Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch (FLASH Study)|Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch: A Double-blinded Multicenter Prospective Randomized Trial (FLASH Study)|FLASH|University Hospital, Clermont-Ferrand||Not yet recruiting|July 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|826|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502773||16710|
NCT02502786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-096|Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma|A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|13 Months|40 Years|No|||January 2016|January 19, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502786||16709|
NCT02248558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1865|Spurring Innovation to Promote HIV Testing: An RCT Evaluating Crowdsourcing|Crowdsourcing Versus Conventional HIV Testing Promotion: A Noninferiority Randomized Controlled Trial to Evaluate Promoting First-Time HIV Testing Among MSM and Transgender Individuals in China||University of North Carolina, Chapel Hill|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|721|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02248558||36218|
NCT02248571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOM-12293|Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab|An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer|IMPROVE|iOMEDICO AG|No|Recruiting|August 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|192|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02248571||36217|
NCT02254889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0007|Pain After Endoscopic Submucosal Dissection|Pain After Endoscopic Submucosal Dissection||Gangnam Severance Hospital|Yes|Completed|April 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|156|||Both|20 Years|75 Years|No|||February 2016|February 11, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02254889||35731|
NCT02506569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA109|ProMRI 3T ENHANCED Master Study|ProMRI 3T ENHANCED Master Study||Biotronik SE & Co. KG|No|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|129|||Both|18 Years|N/A|No|Probability Sample|The patients selected for participation should be from the investigator's general patient        population according to the inclusion and exclusion criteria.|November 2015|November 19, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02506569||16418|
NCT02497872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP001|Early Precut Versus Pancreatic Stent for Post-ERCP Pancreatitis|Early Precut Versus Pancreatic Duct Stent in Preventing Post-ERCP Pancreatitis in High-risk Subjects||Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||July 2015|July 12, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02497872||17087|
NCT02498145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014335|Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults|Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults||Yale University|No|Recruiting|October 2014|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498145||17066|
NCT02299505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2112|Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)|A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)||Novartis|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299505||32307|
NCT02354859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44947-D|A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)|A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)||University of Washington|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354859||28062|
NCT02356094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHBaixoVouga2|Posterior Cornea in Primary Open Angle Glaucoma|Posterior Cornea in Primary Open Angle Glaucoma||Centro Hospitalar do Baixo Vouga|No|Recruiting|January 2015|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases from the Glaucoma Outpatient Clinic and controls from the General Ophthalmology        Outpatient Clinic from a single ophthalmological center.|February 2015|February 1, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356094||27967|
NCT02344342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00091053|University of Michigan Advanced Heart Failure Tele-Monitoring and Flexible Diuretic Project|Michigan Advanced Heart Failure TelemoNItoring and FLexible Diuretic Trial - MANIFOLD-HF|Manifold-HF|University of Michigan|Yes|Recruiting|February 2015|December 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344342||28868|
NCT02296255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F11J09000350002|Effect of HPV Vaccination on Women Aged 25 Years|Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany||Cancer Prevention and Research Institute, Italy|Yes|Completed|April 2010|July 2013|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|832|||Female|25 Years|25 Years|No|||November 2014|November 19, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02296255||32556|
NCT02296502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSM5 and ASD|Comparison of DSM-IV-TR and DSM-5 for ASD|Comparison of DSM-IV-TR and DSM-5 Diagnostic Criteria for Autism Spectrum Disorder||University of Pittsburgh|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|2 Years|17 Years|No|Non-Probability Sample|All children ages 2-17 who are being evaluated for a possible diagnosis of autism spectrum        disorder|January 2016|January 7, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296502||32537|
NCT02297412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU221408I|Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial|Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial||Academic and Community Cancer Research United||Active, not recruiting|November 2014|||November 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02297412||32468|
NCT02346071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURKHK1|Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes|Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes: Randomized Trial||University of Aarhus|No|Recruiting|January 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|19 Years|No|||January 2015|March 18, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02346071||28735|
NCT02357524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-14-01|Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers|A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers||The Medicines Company|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357524||27858|
NCT02357537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLS-UC-003|Decentralized Dietary UC Pilot Trial|A Pilot Study Investigating a Decentralized Approach to Studying Dietary Intervention in Patients With Ulcerative Colitis||Transparency Life Sciences|No|Recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|51|||Both|18 Years|80 Years|No|||November 2015|November 5, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357537||27857|
NCT02307097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-OxCADAT-2014|RCT of Bibliotherapy for Social Anxiety Disorder as a Prelude to CBT in IAPT|Randomised Controlled Trial of Cognitive-Behavioural Bibliotherapy (CBB) for Social Anxiety Disorder as a Prelude to High-Intensity Cognitive-Behavioural Therapy (CBT) in a Local IAPT Service.|RCT of CBB/CBT|Solent NHS Trust|Yes|Not yet recruiting|January 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|80 Years|No|||December 2014|December 12, 2014|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02307097||31724|
NCT02509780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Vichy|The Mineral Water of Vichy and the Urinary Alkalization: A Study of the Dose - Effect of Bicarbonate Salt Water on the Urinary pH in Healthy Volunteers|The Mineral Water of Vichy and the Urinary Alkalization: A Study of the Dose - Effect of Bicarbonate Salt Water on the Urinary pH in Healthy Volunteers||Brugmann University Hospital|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509780||16172|
NCT02509832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDC-2420|COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|COOL-AMI EU PILOT TRIAL: A Multicenter, Prospective, Randomized Controlled Trial To Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With ACUTE MYOCARDIAL INFARCTION||ZOLL Circulation, Inc., USA|No|Recruiting|July 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509832||16168|
NCT02254824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2011-4003-04|Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients|Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients (EMINENT Study)||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02254824||35736|
NCT02254837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005-PTX|Zilver PTX Post-Market Study in Japan|Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan||Cook||Active, not recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|909|||Both|N/A|N/A|No|||October 2015|October 6, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02254837||35735|
NCT02506283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2015-0113|The Effect of Thermotherapy on Recovery and Performance|The Effect of Cryotherapy on Recovery and Performance: A Randomized Controlled Double Blind Trial|Cryotherapy|University of Applied Sciences and Arts of Southern Switzerland|Yes|Recruiting|May 2015|December 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02506283||16440|
NCT02505269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-196|Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma|Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma||Massachusetts General Hospital|Yes|Recruiting|July 2015|December 2022|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505269||16518|
NCT02505282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CV14|Vitamin K Status and Markers of Vascular Function in Patients With and Without Postural Hypotension|Vitamin K Status and Markers of Vascular Function in Patients With and Without Postural Hypotension|VITKOH|University of Dundee|No|Completed|April 2012|August 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|49|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Aged 65 years or older, not on warfarin, able to stand unaided, able to give informed        consent.|July 2015|July 23, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505282||16517|
NCT02253576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuz-7HS|Inhaled Hypertonic Saline for Bronchiolitis|7% Hypertonic Saline to Treat Bronchiolitis in the Emergency Department|7HSinED|Queen's University|No|Withdrawn|June 2014|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|24 Months|No|||November 2015|November 12, 2015|September 29, 2014||No|Study not funded - never initiated|No||https://clinicaltrials.gov/show/NCT02253576||35832|
NCT02240823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-Afd-L|Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy|Phase 1 Study. Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy||Odense University Hospital|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|June 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240823||36813|
NCT02497599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13071988|Intraoperative Dual-modality Imaging in Renal Cell Carcinoma|A Phase 1 Study to Evaluate the Safety and Feasibility of Intraoperative Detection of Clear Cell Renal Cell Carcinoma Using Indium-111-DOTA-girentuximab-IRDye800CW||Radboud University|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02497599||17108|
NCT02502370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 33 - BALLAD|Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma|PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma|BALLAD|Centre Hospitalier Universitaire Dijon||Not yet recruiting||||September 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502370||16741|
NCT02303847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141809|Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting|Ultra-low Dose Oral Ketamine for Treatment of Chronic Non-cancer Pain in the Primary Care Setting|Ketamine|University of Washington|No|Active, not recruiting|November 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 24, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303847||31973|
NCT02346084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11991|Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults|CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults||International Partnership for Microbicides, Inc.|Yes|Recruiting|January 2015|March 2016|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|19|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02346084||28734|
NCT02346331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056846|Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya|Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya||Duke University|Yes|Recruiting|January 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||September 2015|November 17, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02346331||28715|
NCT02348255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#249|NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse|A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse||University of California, Davis|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|22 Years|N/A|No|||January 2016|January 20, 2016|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348255||28568|
NCT02301117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS-102-107|A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment||Taiho Oncology, Inc.|No|Recruiting|January 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02301117||32183|
NCT02301468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/903|Ischemic Compression Compared With Dry Needling|Ischemic Compression Compared With Dry Needling as a Treatment of Myofascial Trigger Points in the Neck Region in Office Workers.||University Ghent|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|65 Years|No|||December 2015|December 17, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02301468||32156|
NCT02301689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA120814|SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register|SchlaHF-XF- Register. Sleep Disordered Breathing in Heart Failure Register||ResMed|No|Recruiting|May 2014|December 2020|Anticipated|September 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|The study population is patients with Heart failure (HF). HF is defined as a symptom        complex of shortness of breath and rapid fatigability on the basis of cardiac disease        (World Health Organisation).|January 2015|January 20, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02301689|5 Years|32139|
NCT02350374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-HPNCL-05|Carbohydrate Counting in Children and Adolescents With Type 1 Diabetes|Analysis of the Individual Variation of the Carbohydrate Amount at Each Meal in Children and Adolescents With Type 1 Diabetes Using the Carbohydrate Counting Method||Fondation Lenval|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|87|||Both|1 Year|18 Years|No|||July 2015|July 20, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02350374||28406|
NCT02348619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004|"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"|A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)|OSA|Jazz Pharmaceuticals|No|Recruiting|May 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||August 2015|February 24, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348619||28540|
NCT02296515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSI_TD_001|Intrathecal Pump Refill Undergoing Regular Intrathecal Pump Refill|Intrathecal Pump Refill: Reservoir Fill Port Identification by Palpation Versus Ultrasound,a Mono-centre Prospective Comparison Study in Patients Undergoing Regular Intrathecal Pump Refill||Ospedale Regionale di Lugano|No|Recruiting|November 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|patients with an intrathecal pump for the treatment of chronic non-malignant pain or        spasticity, undergoing regular refills of their intrathecal pumps at our Centro Terapia        del Dolore at the Ospedale Italiano a Viganello(EOC, Switzerland).|November 2014|November 17, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02296515||32536|
NCT02508818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-010|Cardiovascular Response to Orthostatic Fractional Gravity||ORB|University Hospital, Caen|No|Recruiting|June 2011|||November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508818||16246|
NCT02255890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registry IRE Nanoknife®|Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device|Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device; A Multi-Center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety.||Clinical Research Office of the Endourological Society|No|Recruiting|November 2014|December 2024|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|N/A|N/A|No|Probability Sample|The study population comprises those patients diagnosed with histologically confirmed        prostate cancer and are scheduled for treatment with IRE Nanoknife®.|October 2015|October 19, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255890|5 Years|35654|
NCT02497313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15007280|Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes|||University Hospital, Gentofte, Copenhagen|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|15|||Both|40 Years|75 Years|No|||November 2015|November 20, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02497313||17129|
NCT02510521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-063|Effects of Neuro-myo-electrical Stimulation on Insulin Sensitivity in Patients With Type 2 Diabetes||ELECTRODIAB|University Hospital, Caen|No|Completed|February 2012|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|75 Years|No|||November 2015|November 2, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02510521||16115|
NCT02254096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1195.1|Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BIRT 1696 BS as a Solution (10, 100, 400, 1000, 2000, 3000 mg) in 15 ml PEG 400 to Healthy Human Subjects. A Three Part Study: Part 1 Placebo-controlled, Randomised, Dose Escalating Double Blinded Within Each Dose Level; Part 2 Open Label Grapefruit Juice Effect in 100 mg Dose Level Group; Part 3 Open Label Food Effect in 400 mg Dose Level Group||Boehringer Ingelheim||Completed|May 2002|||July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|46|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254096||35792|
NCT02254109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.18|Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254109||35791|
NCT02254122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (20 µg, 50 µg, 100 µg, 200 µg and 400 µg) of BEA 2180 BR for 21 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)||Boehringer Ingelheim||Completed|May 2004|||February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|59|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254122||35790|
NCT02245360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAS3001|Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis|A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis||Abbott|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|September 17, 2014||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT02245360||36464|
NCT02245711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-12|Cell Therapy in Limb Girdle Muscular Dystrophy|Intrathecal Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy||Neurogen Brain and Spine Institute|Yes|Recruiting|December 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|15 Years|60 Years|No|||September 2014|September 17, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245711||36437|
NCT02501421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPT-I-01/2013|Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine|||Research Institute for Biological Safety Problems|Yes|Completed|October 2013|February 2015|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501421||16814|
NCT02501434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0662|Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin|A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden|ASTROH|University of Louisville|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501434||16813|
NCT02504333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-14-05|Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma|A Phase I/II Study of Nab-paclitaxel (Abraxane) and Gemcitabine Followed by Modified FOLFOX (AG-mFOLFOX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|SEQUENCE|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Recruiting|July 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504333||16590|
NCT02505438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMTD2O13|Application of Deuterated Water (D2O) to Define the Etiology of Musculoskeletal Decline in Ageing and the Efficacy of Nutritional Supplementation|||University of Nottingham|No|Recruiting|April 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02505438||16505|
NCT02309385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSPV-201|Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis|A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis||Aciont Inc|No|Recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309385||31549|
NCT02309398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC-AF-2014|CCC Project - Atrial Fibrillation|Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation||Beijing Institute of Heart, Lung and Blood Vessel Diseases||Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|42000|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized patients of atrial fibrillation|January 2016|January 5, 2016|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02309398||31548|
NCT02350998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201404|Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement||Otonomy, Inc.|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|6 Months|17 Years|No|||March 2015|March 9, 2015|January 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02350998||28358|
NCT02351297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01730-45|Effects of High Protein Diet on the Large Intestine in Overweight Humans|Effects of High Protein Diet on the Large Intestine in Overweight Humans||Hospital Avicenne|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351297||28335|
NCT02352584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3110A_AD_P3|A Multicenter, Double-blind, Parallel Phase III Study|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)||Green Cross Corporation|Yes|Completed|October 2014|July 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|1299|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 18, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02352584||28237|
NCT02304471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409019RINB|Circulating lncRNA and CV Morbidities in CKD and ESRD|Circulating Long Non-coding RNAs and Cardiovascular Morbidities in Chronic Kidney Disease and End-Stage Renal Disease||National Taiwan University Hospital|Yes|Recruiting|November 2014|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|360|Samples With DNA|blood|Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|CKD, ESRD, Healthy controls|November 2014|December 1, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304471||31925|
NCT02503358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011462|Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Nab-paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)||OHSU Knight Cancer Institute|Yes|Not yet recruiting|February 2016|September 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503358||16665|
NCT02241525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063432|CT for Pulmonary Thromboembolic Disease|Individually Optimized Uniform Contrast Enhancement in CT Angiography for the Diagnosis of Pulmonary Thromboembolic Disease|CT for PE|University of Maryland|Yes|Recruiting|February 2016|December 2021|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Obese patients for a diagnosis of PE|February 2016|February 24, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02241525||36759|
NCT02241538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29303014.7.0000.0064|Effectiveness of Different Weekly Frequency of Modified Pilates Method Exercises in the Treatment of Chronic Nonspecific Low Back Pain|Cost Effectiveness and Effectiveness of the Addition of Different Weekly Frequency of Modified Pilates Method Exercises to a Minimal Intervention in the Treatment of Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial||Universidade Cidade de Sao Paulo|Yes|Active, not recruiting|September 2014|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|296|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241538||36758|
NCT02241551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 13-143|Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer||University of Pittsburgh|Yes|Recruiting|December 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02241551||36757|
NCT02246725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS01|Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.|Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.|ALLAN|Lund University Hospital|No|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|108|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with tumor in esophagus, stomach, pancreas liver-biliary passage receiving first        line palliative chemotherapy, or patients with colorectal cancer receiving second line        palliative chemotherapy.|February 2016|February 16, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02246725||36359|
NCT02246738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07814|Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts|Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2014|||August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|66|Samples With DNA|Blood Collection|Both|18 Years|N/A|No|Probability Sample|Urothelial Carcinoma of the Bladder|January 2016|January 21, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246738||36358|
NCT02505607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0109|Overactive Bladder Education|Overactive Bladder Education||Hartford Hospital|No|Terminated|July 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|22|||Female|18 Years|89 Years|No|||December 2015|December 29, 2015|July 20, 2015||No|feasibility issues|No||https://clinicaltrials.gov/show/NCT02505607||16492|
NCT02505828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93612|ARTEMIS Synovial Markers in Arthritis Childhood|ARTEMIS Synovial Markers in Arthritis Childhood|ARTEMIS|University Hospital, Montpellier|No|Active, not recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|6 Months|18 Years|No|||June 2015|July 20, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02505828||16475|
NCT02503553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028774|Decision Aids in Cerebral Aneurysm Treatment|Decision Aids in Cerebral Aneurysm Treatment||Dartmouth-Hitchcock Medical Center|No|Withdrawn||||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503553||16650|
NCT02503566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKIKEM|Assessment of Cardiac Allograft Vasculopathy by Optical Coherence Tomography|Assessment of Cardiac Allograft Vasculopathy (CAV) by Optical Coherence Tomography (OCT)|EARLY-OCT|Institute for Clinical and Experimental Medicine|No|Recruiting|September 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02503566||16649|
NCT02241837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1051.B.3|PARACHUTE III Pressure Volume Loop Sub-Study|PARACHUTE III: A Multinational Trial to Evaluate the Longterm Safety of the Parachute System|PIII PV Loop|CardioKinetix, Inc|No|Active, not recruiting|November 2013|June 2019|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|11|||Both|18 Years|79 Years|No|Non-Probability Sample|The study population will be open to all individuals who meet the inclusion/exclusion        criteria. This is a prospective, multi-center, non-randomized trial.|August 2015|August 6, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241837||36735|
NCT02241850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-HIT01|Genetic Polymorphisms Affecting Effect of High Intensity Training|Assessment of Genetic Polymorphisms Affecting Effect of High Intensity Training in Korean Healthy Volunteers||Kyunghee University Medical Center|Yes|Completed|August 2013|August 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|110|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 14, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02241850||36734|
NCT02252835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB102-21426|Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout|A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout||CymaBay Therapeutics, Inc.||Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|September 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252835||35889|
NCT02505841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9488|Transversus Abdominis Plane Block for Laparoscopic Appendicectomy in Children|Transversus Abdominis Plane (TAP) Block for Laparoscopic Appendicectomy in Children: Opioid Saving and Alternative in the Curarization||University Hospital, Montpellier|No|Active, not recruiting|May 2015|June 2017|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|240|||Both|1 Year|12 Years|No|||May 2015|July 20, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02505841||16474|
NCT02495545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX 14BN084|Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury|A Multi-Center, Randomized, Controlled, Trial of Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|October 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 2, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495545||17265|
NCT02511028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150156|In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging|In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02511028||16076|
NCT02245295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBUSEDA1|The Role of Sedation Technique in EBUS-TBNA|Impact of Sedation Technique on the Diagnostic Accuracy of Endobronchial Ultrasound-guided Needle Aspiration (EBUS-TBNA)||University of Zurich|Yes|Completed|January 2014|June 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|232|||Both|18 Years|N/A|No|Probability Sample|Patients with enlarged or suspicious mediastinal and/or hilar lymph nodes, in whom        EBUS-TBNA is indicated|September 2014|September 16, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02245295||36469|
NCT02250274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01IP000471-04|Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents|Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents||Marshfield Clinic Research Foundation|No|Completed|September 2014|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|131|||Both|5 Years|17 Years|No|||January 2016|January 29, 2016|September 17, 2014||No||No|September 22, 2015|https://clinicaltrials.gov/show/NCT02250274||36086|
NCT02502331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVI-CHOVI-EUVICHOL|Safety and Immunogenicity of a New Formulation of Euvichol®|A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol® (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologics Co. Ltd.) in Healthy Individuals||International Vaccine Institute|No|Not yet recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|442|||Both|1 Year|40 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02502331||16744|
NCT02505139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCCCTC|The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients|Using Circulating Tumor Cells to Diagnose and Predict Prognosis in Metastatic Nasopharyngeal Carcinoma Patients||Sun Yat-sen University|Yes|Active, not recruiting|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|166|Samples Without DNA|The blood after separation and purification along with or without CTC.|Both|18 Years|65 Years|No|Probability Sample|NPC patients with distant metastasis|July 2015|July 21, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505139||16528|
NCT02505152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTIPSDORNO3HSYSU|Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy|||Sun Yat-sen University||Recruiting|October 2010|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 10, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505152||16527|
NCT02251691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401105MIPA|Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant|The Influence of Once-daily Versus Twice-daily Immunosuppressive Regimen on Drug Compliance in Patients After Renal Transplantation||National Taiwan University Hospital|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|65 Years|No|||April 2015|April 6, 2015|June 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02251691||35977|
NCT02254590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kasr Einy|Irrigation Endoscopic Decompression|Irrigation Endoscopic Decompressive Laminotomy. A New Endoscopic Approach for Spinal Stenosis Decompression||Cairo University|No|Completed|September 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|25 Years|75 Years|No|||September 2014|October 1, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02254590||35754|
NCT02241941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dapto-ICU-09|Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury|Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury||University of Zurich|Yes|Recruiting|September 2014|||September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241941||36727|
NCT02241954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091371|Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome||VEPTR|Vanderbilt University|No|Enrolling by invitation|January 2010|||January 2024|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|17 Years|No|||December 2015|December 7, 2015|September 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241954||36726|
NCT02502409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-Natural|Natural History Study of Factor IX Treatment and Complications|Natural History Study of Factor IX Treatment and Complications|B-Natural|Skane University Hospital|No|Recruiting|July 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|550|Samples With DNA|Serum, plasma, DNA|Both|N/A|N/A|No|Non-Probability Sample|The population includes groups of two or more affected brothers, with or without a history        of inhibitors, who share(d) one or both biological parents; and individuals with a history        of an inhibitor. Most affected brother pairs will be concordant for no inhibitor and will        serve as a control group for those with inhibitors. The study is open to subjects with        mild (0.05-0.40 IU/mL), moderate (0.01-<0.05 IU/mL), or severe (<0.01 IU/mL) FIX        deficiency. Females meeting the eligibility criteria may participate. There are no lower        or upper age limits. Type of treatment, regimen, dosing and product(s) used are at the        discretion of the investigator.|March 2016|March 16, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502409||16738|
NCT02246413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-05-323|Research Aimed at Improving Both Mood and Weight|RCT on Co-management of Obesity, Depression, and Elevated CVD Risk in Primary Care|RAINBOW|Palo Alto Medical Foundation|No|Recruiting|September 2014|March 2019|Anticipated|March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|404|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246413||36383|
NCT02246426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-1004-14|Treatment of Social Cognition in Schizophrenia Trial|TRuSST: Treatment of Social Cognition in Schizophrenia Trial|TRuSST|Posit Science Corporation|Yes|Recruiting|March 2015|August 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246426||36382|
NCT02250560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R9VFCIMS|A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.|An Open Study to Investigate the Safety and Efficacy of Replenine®-VF by Continuous Infusion in Haemophilia B Patients Undergoing Major Surgery.||Bio Products Laboratory||Completed|April 2000|||November 2003|Actual|Phase 3|Interventional|N/A|1||||||Both|16 Years|N/A|No|||August 2014|September 24, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02250560||36064|
NCT02250573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R9VFSUR|An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery|An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery.||Bio Products Laboratory||Completed|December 2005|||April 2006|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||August 2014|September 24, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02250573||36063|
NCT02250586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-CSO-Gambling|Internet Based Cognitive Behavior Therapy for Concerned Significant Others of Problem Gamblers|Internet Based Cognitive-behavioral Therapy for Concerned Significant Others of Problem Gamblers: a Randomized Wait-list Controlled Trial||Stockholm University|No|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250586||36062|
NCT02495298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fascial Manipulation on CTS|Fascial Manipulation on the Treatment of Carpal Tunnel Syndrome|Evaluation of Fascial Manipulation for the Conservative Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial, Phase II||University of Sao Paulo|Yes|Completed|August 2013|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||July 2015|July 8, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495298||17284|
NCT02506387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEL 0|Belgian Mitraclip Registry|||Universiteit Antwerpen|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|serum sample|Both|25 Years|90 Years|No|Non-Probability Sample|Patient with symptomatic severe mitral regurgitation at too high risk voor cardiac surgery        and with suitable anatomy for mitraclip implantation|July 2015|July 21, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02506387|2 Years|16432|
NCT02506400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Icare-0022|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||July 22, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506400||16431|
NCT02506413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRT #39|Replicating MamaToto in Rural Tanzania|Replicating MamaToto in Rural Tanzania||University of Calgary|No|Not yet recruiting|January 2016|December 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|5000|||Both|15 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02506413||16430|
NCT02246673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-204|RDEA3170 and Febuxostat Combination Study in Gout Subjects|A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout||Ardea Biosciences, Inc.|No|Active, not recruiting|October 2014|December 2015|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246673||36363|
NCT02256904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR 01|RSA and Clinical Comparison of Anatomical and Mechanical Alignment in Total Knee Replacement|Biomechanical and Radiostereometric Analysis of the GMK Sphere Primary Total Knee Replacement. A Randomized, Double Blind Comparison of Anatomical Versus Mechanical Alignment in Total Knee Replacement.||Maisonneuve-Rosemont Hospital|No|Recruiting|January 2015|January 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256904||35577|
NCT02499653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG_PSYNIV_COPD01|A Psychological Intervention to Promote Acceptance and Adherence to NIV in People With COPD|A Psychological Intervention to Promote Acceptance and Adherence to Non-Invasive Ventilation (NIV) in People With Chronic Obstructive Pulmonary Disease (COPD)||Fondazione Don Carlo Gnocchi Onlus||Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02499653||16950|
NCT02499666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9608|Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI|Evaluation of Exercise Capacity as Measured by Peak Oxygen Uptake, Before and After Percutaneous Revascularization of Chronic Total Occlusion|EXERTION|Henry Ford Health System|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|46|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|All patients who present for evalaution of CTO-PCI (male and female, age >18 years old)        will be asked to participate in the study. Patients unable to exercise for any reason will        be excluded.|July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02499666||16949|
NCT02503085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL1304|Ibuprofen Suspension Bioequivalence Study|A Randomised, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic Study Comparing a 2% (w/v) Suspension of Ibuprofen (400 mg/20 ml) With a Reference 2% (w/v) Suspension of Ibuprofen (400 mg/20 ml) in the Fed and Fasted States||Reckitt Benckiser Healthcare (UK) Limited|No|Active, not recruiting|June 2015|February 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02503085||16686|
NCT02508753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-QT-10-02|Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects|A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in Healthy Subjects||Cubist Pharmaceuticals LLC|Yes|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508753||16251|
NCT02508766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID010|Immediate Effect of Stimulating Plant on the Balance in Young Healthy|Immediate Effect of Stimulating Plant on the Balance in Young Healthy. A Randomized Controlled Trial.|Effplant|University of Valencia|No|Completed|July 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508766||16250|
NCT02258529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-313-1414|Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma|A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma||Gilead Sciences|Yes|Active, not recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258529||35455|
NCT02255786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001563|"ACT" for Parents of Children With Autism Spectrum Disorder|Taking ACTion: Acceptance and Commitment Therapy for Parents of Children With Autism Spectrum Disorder||Massachusetts General Hospital|No|Enrolling by invitation|October 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02255786||35662|
NCT02505230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK IRB-15-02349-XP|Meal Presentation and Liking|Meal Presentation and Liking||University of Tennessee|No|Recruiting|July 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|4||Anticipated|45|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505230||16521|
NCT02505932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR012012|Latarjet Procedure: Comparative Outcomes Study of Arthroscopic Versus Mini-open Approach With Minimum 2-year Follow-up|Latarjet Procedure: Comparative Outcomes Study of Arthroscopic Versus Mini-open Approach With Minimum 2-year Follow-up|Latarjet|Hospital Ambroise Paré Paris|No|Completed|January 2012|December 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a chronic anterior instability requiring bone grafting (Instability        Severity Index Score>3)|July 2015|July 20, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505932||16467|
NCT02242721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABx-CVVHDF|Drugmonitoring of Antiinfective Drugs in Patients Receiving Continous Veno-venous Hemodiafiltration (ABx-CVVHDF)|Drugmonitoring of Antiinfective Drugs in Patients Receiving Continous Veno-venous Hemodiafiltration||Charite University, Berlin, Germany|No|Withdrawn|October 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood samples and Dialysate|Both|18 Years|N/A|No|Non-Probability Sample|Critical ill patients|July 2015|July 30, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02242721||36667|
NCT02242734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX002-1001|Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment|Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20mg Capsules||Zogenix, Inc.|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|August 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242734||36666|
NCT02246491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1491|Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia|Induced Pluripotent Stem (iPS) Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|3 Years|100 Years|No|||March 2016|March 23, 2016|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246491||36377|
NCT02505399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7445 03|TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study|TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial|TIRATROP|University Hospital, Toulouse|No|Not yet recruiting|November 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02505399||16508|
NCT02511015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150155|Hereditary Parkinson s Disease Natural History Protocol|Hereditary Parkinson Disease Natural History Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|February 2025|Anticipated|February 2025|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|July 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511015||16077|
NCT02251886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moxibustion and breech|Moxibustion in a Randomized Trial for Version of Breech Position From Week 32|Moxibustion for Version of Singleton Breech Position Before Term||Herning Hospital|No|Completed|January 2003|September 2014|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|206|||Female|18 Years|N/A|No|||September 2014|September 26, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251886||35962|
NCT02256852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QBKPN-01|Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer|Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC||Qu Biologics Inc.|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256852||35581|
NCT02242201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004183|THA Lumbar Plexus Verses Periarticular|Prospective, Randomized Controlled Trial Comparing Continuous Posterior Lumbar Plexus Nerve Block vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel&#174;) on Patients Undergoing Total Hip Arthroplasty||Mayo Clinic|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|September 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242201||36707|
NCT02499419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0294-14-CTIL|Exercise Capacity Evaluation in Patients With Non-rheumatic Mitral Valve Prolapse (MVP)|Exercise Capacity Evaluation in Patients With Non-rheumatic Mitral Valve Prolapse (MVP)||Rambam Health Care Campus||Not yet recruiting|September 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|||Both|6 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People diagnosed with MVP and no other cardiac problems.|July 2015|July 13, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02499419||16968|
NCT02508714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-19|Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents|Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial With Stent Evaluation in All-comers IV (TWENTE IV)|BIONYX|Thorax Centrum Twente|Yes|Not yet recruiting|September 2015|March 2019|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2470|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508714||16254|
NCT02252107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLMA34|10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1|10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1||Radboud University|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02252107||35945|
NCT02252315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01647|Written Versus Verbal Education for Mild Traumatic Brain Injury|Written Versus Verbal Education for Mild Traumatic Brain Injury||University of British Columbia||Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2015|March 31, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02252315||35929|
NCT02242539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2948|Tools to Improve Parental Recognition of Developmental Deficits in Children|Tools to Improve Parental Recognition of Developmental Deficits in Children||Boston University|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|547|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||January 2016|January 11, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02242539||36681|
NCT02242812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.393|Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension|Telmisartan Effectiveness on Left Ventricular MAss Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension - a Prospective, Randomised, Double-blind Comparison of Telmisartan 80 mg Oral, Once Daily, to Metoprolol Succinate 95 mg Oral, Once Daily, Over a Period of 6 Months||Boehringer Ingelheim||Terminated|September 2003|||October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242812||36660|
NCT02503098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRR-023|Optimizing a Smartphone Application for Individuals With Eating Disorders|Optimizing a Smartphone Application for Individuals With Eating Disorders||Recovery Record Research|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12000|||Both|16 Years|N/A|No|||July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02503098||16685|
NCT02509078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETAL01ROSE|Reevaluation Of Systemic Early Neuromuscular Blockade|Reevaluation Of Systemic Early Neuromuscular Blockade|ROSE|Massachusetts General Hospital|Yes|Recruiting|December 2015|October 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1408|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509078||16226|
NCT02246218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-009|A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders (UCDs)|An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Recruiting|December 2014|June 2018|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|2 Years|No|||December 2015|December 16, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246218||36398|
NCT02494479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIX-PRU-004|Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis|A Randomized, Double Blind, Parallel Group, Placebo Controlled Clinical Study of the Efficacy and Safety of Three Different Daily Dosages of Prurisol Administered Orally to Subjects With Active Mild to Moderate Chronic Plaque Psoriasis||Cellceutix Corporation|No|Active, not recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494479||17347|
NCT02494492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081250|Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose|Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose|UVEREG|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||June 2015|July 9, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02494492||17346|
NCT02508610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17142|DNA Sequencing of MDR TB in Eastern Siberia|DNA Sequencing of MDR TB in Eastern Siberia||University of Virginia|No|Recruiting|November 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|630|Samples With DNA|We will collect and use plasma and sputum specimens. For a minority of subjects,      leftover/discarded specimen may be used.      Specimens will be stored under appropriate refrigeration (-80) at the Irkutsk Oblast      Tuberculosis Dispensary and at UVa, MR6 Building Room 1701A, IBC# 327-05.      Further HPLC analysis of the plasma will be conducted by Charles Peloquin, Pharm.D., FCCP      (University of Florida).|Both|15 Years|N/A|No|Non-Probability Sample|Subjects will be enrolled from patients attending either Irkutsk Dispensary or the        affiliate referral clinic (Irkutsk AIDS Center).|July 2015|July 24, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02508610||16262|
NCT02247544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISG-STS-TRAB-2012|Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma|A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma|TRAVELL|Italian Sarcoma Group|No|Recruiting|March 2014|October 2020|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02247544||36296|
NCT02256254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-647|SIMOX - Induction of Oxidative Stress|SIMOX - A Randomized, Double-blinded, Placebo Controlled Study of Simvastatins Possible Effect on Oxidative Stress on Healthy Volunteers|SIMOX|Rigshospitalet, Denmark|Yes|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02256254||35627|
NCT02258074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK099877-C|The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE|The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE|COMBINE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|March 2015|June 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|200|||Both|18 Years|85 Years|No|||March 2015|March 30, 2015|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02258074||35490|
NCT02495051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/cic|Esophageal Atresia: Metaplasia, Barrett|Prevalence of Barrett's Esophagus in Adolescents and Young Adults With Esophageal Atresia|Oesophagix|University Hospital, Lille|No|Completed|February 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|15 Years|19 Years|No|Non-Probability Sample|All esophageal atresia patients treated in 20 centers that participated in the        French-speaking Group of Gastroenterology, Hepatology, and Nutrition and/or were members        of the esophageal atresia national registry|July 2015|July 10, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02495051||17303|
NCT02505321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF 180|for Adipose Tissue DIabetes VAriants (fATDIVA)|Defining Adipose Tissue Lipid Deposition in Normal Weight Individuals With a Genetic Predisposition to Insulin Resistance|fATDIVA|NIHR Exeter Clinical Research Facility|No|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02505321||16514|
NCT02254655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-2012-063|The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis|The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis, a Controlled and Randomized Trial||Chengdu PLA General Hospital|Yes|Completed|November 2013|August 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|119|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|November 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02254655||35749|
NCT02254707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201.14|Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection|A Multinational Randomised, Double-blind, Placebo Controlled Study to Evaluate the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW Oral Solution Administered Q8H for Five Days to Patients With Chronic Hepatitis C Genotype 1 Virus Infection||Boehringer Ingelheim||Completed|July 2004|||April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|96|||Male|18 Years|65 Years|No|||September 2014|October 1, 2014|October 1, 2014||||No||https://clinicaltrials.gov/show/NCT02254707||35745|
NCT02242214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000188|REgistry of MisOprostol 200 µg Vaginal dElivery System||REMOVE|Ferring Pharmaceuticals||Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Female|N/A|N/A|No|Probability Sample|Academic and peripheral hospitals in the Netherlands|September 2015|September 15, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02242214|3 Days|36706|
NCT02246751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP_TT_2014|Case Series_Targeted Training for Trunk Control Cerebral Palsy|Effect of Targeted Training on Sensorimotor Control of Trunk Posture|CP_TT_UHart|University of Hartford|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|2 Years|12 Years|No|||September 2014|September 18, 2014|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246751||36357|
NCT02502760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-131-MUHC|Using Multimodal Prehabilitation to Improve Outcomes for Frail Patients Undergoing Resection of Colorectal Cancer|||McGill University Health Center|No|Enrolling by invitation|August 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|N/A|No|||July 2015|July 29, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502760||16711|
NCT02502916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBILAC/12O_2|Enteral Feeding and Early Gut Colonization of Preterm Infants|Potential Role of the Enteral Feeding Systems on Early Bacterial Gut Colonization of Preterm Infants|PRECOL|Universidad Complutense de Madrid|No|Completed|October 2009|July 2012|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples With DNA|meconium, fecal samples mother's milk donor's milk|Both|N/A|8 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Preterm infants born from October 2009 to June 2010 at the Hospital 12 de Octubre with a        gestational age of less than 32 weeks or with birth weight of less than 1,200 g|July 2015|July 16, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02502916||16699|
NCT02505685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0618-14-RMC|Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer|Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer||Rabin Medical Center|No|Recruiting|June 2015|July 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|95 Years|No|Non-Probability Sample|Advanced lung cancer patients (Stage 4)|March 2016|March 22, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02505685||16486|
NCT02254720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.5|Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (2.5 μg, 7.5 μg, 25 μg, 50 μg, 100 μg, 200 μg, 350 μg, 500 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers With an Additional Arm by Inhalation in One Dose Group (1600 μg)||Boehringer Ingelheim||Completed|September 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|71|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|October 1, 2014|October 1, 2014||||No||https://clinicaltrials.gov/show/NCT02254720||35744|
NCT02254772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0119|TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma|A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas||Stanford University|Yes|Recruiting|September 2014|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02254772||35740|
NCT02247037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0686|Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer|Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|Core Biopsy Specimen, Surgical Specimen|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Triple Negative Breast Cancer that are eligible for neoadjuvant chemotherapy        will be pursued for this protocol.|December 2015|December 23, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247037||36335|
NCT02247050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087820|Primary Care Clinician Commitments to Choosing Wisely®|Primary Care Clinician Commitments to Choosing Wisely®||University of Michigan|No|Active, not recruiting|September 2014|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|60|||Both|21 Years|N/A|No|||March 2015|March 16, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247050||36334|
NCT02506322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EE1404C|Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 30 yr.) of Bipolar Disorder|Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 30 yr.) of Bipolar Disorder|A2BipoLife|University Hospital Tuebingen|Yes|Recruiting|August 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|30 Years|No|||August 2015|August 5, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02506322||16437|
NCT02509143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2015-010|Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery|High-dose Acupuncture for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Colorectal Surgery: A Randomized Controlled Pilot Study|AcuPONV|Pusan National University Yangsan Hospital|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02509143||16221|
NCT02241005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWIPES|Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci|A Randomized Controlled Trial of the Safety and Efficacy of Theraworx Bath Wipes in the Reduction of Skin Colonization With Vancomycin-Resistant Enterococci Compared to Standard Bath Wipes in Children Undergoing Hematopoietic Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Recruiting|October 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|280|||Both|N/A|21 Years|No|||January 2016|January 27, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241005||36799|
NCT02250053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 10214|Exercise and Colon Cancer|The COURAGE Trial: Colon Recurrence and Aerobic Exercise: A Feasibility Study.||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250053||36103|
NCT02498873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVERSO-01|Linear Running Periodization x Nonlinear|Linear Running Periodization x Nonlinear: a Cross Effect of Five Months Controlled Running on VO2Max and Critical Power Performance|Running|Universidade Federal do Rio de Janeiro|Yes|Completed|August 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02498873||17010|
NCT02509091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150616|Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis|Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study||Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509091||16225|
NCT02255162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-265|Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML|Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)||Massachusetts General Hospital|Yes|Recruiting|January 2015|January 2022|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255162||35710|
NCT02255175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3572|Perimenopausal Effects of Estradiol on Reward Responsiveness|Effects of Estradiol on Neural Reward System and Depression in the Perimenopause|PEERS|University of North Carolina, Chapel Hill|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Female|44 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255175||35709|
NCT02258087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMOBRA-2013|HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.|Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer.|PROMOBRA|National Institute of Oncology, Hungary|No|Recruiting|September 2014|September 2019|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|40 Years|75 Years|No|||October 2014|October 2, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02258087||35489|
NCT02499159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1656|Pain Management in Response to Exparel vs. Standard Bupivicaine|A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy|VATS Exparel|Inova Health Care Services|No|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499159||16988|
NCT02506179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-325|Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis|A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)|UCanADA|AbbVie|No|Enrolling by invitation|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Non-Probability Sample|Adult males and females with moderate to severe UC patients from Canada who meet the        inclusion criteria and who do not meet any of the exclusion criteria will be eligible for        enrollment into the study.|January 2016|January 27, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02506179||16448|
NCT02243059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142030|Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer|Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study.|MILO|Maastricht University Medical Center|Yes|Withdrawn|September 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||September 2014|September 24, 2015|September 16, 2014|No|Yes|Problems with availability of study medicine in clinical center|No||https://clinicaltrials.gov/show/NCT02243059||36641|
NCT02246764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS303|Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Aerie Pharmaceuticals|No|Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|19 Years|99 Years|No|||January 2016|January 20, 2016|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02246764||36356|
NCT02256332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1633|Plant-based Ingredient on Post Prandial Glucose in Type II Diabetes|Effect of Plant-based Ingredient on Post Prandial Glucose in Untreated Type II Diabetes Patients||Unilever R&D|No|Completed|January 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|20 Years|65 Years|No|||September 2015|September 21, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256332||35621|
NCT02506088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CE002531|Preventing Sexual Aggression Among High School Boys|Preventing Sexual Aggression Among High School Boys||Lifespan|Yes|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|9000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506088||16455|
NCT02505945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4959|The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease|The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease|CALIBER|Torax Medical Incorporated|No|Recruiting|June 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|N/A|No|||March 2016|March 14, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505945||16466|
NCT02243358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS 13-03|Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer|A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer||Henry Ford Health System|No|Recruiting|February 2014|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243358||36618|
NCT02243371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14113|GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab|A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|December 2014|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243371||36617|
NCT02256540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0532|The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women|The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women||University of Colorado, Denver|No|Recruiting|August 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|15|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256540||35605|
NCT02495311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103129-F|The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms|The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms and Gastrointestinal Symptoms||Far Eastern Memorial Hospital|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with uterine myoma or adenomyosis|February 2016|February 22, 2016|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02495311||17283|
NCT02245906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRASIL-MET|Effect of Brazilian Fruits Peel on Metabolic Regulation and Appetite in Healthy Subjects|Investigation on Effect of Brazilian Fruits on Glucose and Insulin Responses, Anti-inflammatory Properties, Antioxidative Capacity and Satiety in Healthy Subjects|BRASIL-MET|Lund University|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|August 17, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245906||36422|
NCT02256514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMV5|Open Label Trial of Immunotherapy for Advanced Liver Cancer|Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC|HCC|Immunitor LLC|Yes|Enrolling by invitation|September 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02256514||35607|
NCT02256527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS Premier TLX|REWARDS Premier Taxus-Liberte vs Xience V|REWARDS-Premier TLX (Registry Experience at the WAshington Hospital CenteR, DeS - Premier Taxus-Liberte vs Xience V)||Medstar Research Institute|No|Recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients male or female, 18 years or older who have undergone percutaneous coronary        intervention with Promus Premier (alone) drug eluting stent|April 2015|April 30, 2015|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256527||35606|
NCT02256774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.9|Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects|Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir||Boehringer Ingelheim||Completed|October 2004|||May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256774||35587|
NCT02502513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480/2012|Prevention of Intrusive Memories and Posttraumatic Stress Symptoms After Emergency Cesarean Section|Can Playing Tetris Prevent the Development of Traumatic Intrusions in Mothers Following an Emergency Cesarean Section? A Pilot Study||Centre Hospitalier Universitaire Vaudois|No|Completed|June 2013|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502513||16730|
NCT02509156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-15-0443|Stem Cell Injection in Cancer Survivors|A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy|SENECA|The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|June 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|79 Years|No|||January 2016|January 21, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509156||16220|
NCT02243683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX-024-1.01|Safety Study of Immune System Modulator for Autoimmune Diseases|A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects||Artax Biopharma Inc||Completed|September 2014|March 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243683||36593|
NCT02243969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 13-3-064|Alpha-linolenic Acid and Blood Pressure|Effects of Alpha-linolenic Acid on 24h-ambulatory Mean Arterial Pressure in Untreated High-normal and Stage I Hypertensive Subjects|VASALA|Maastricht University Medical Center|Yes|Completed|May 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2015|March 21, 2016|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02243969||36571|
NCT02243982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI1080236|Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease|Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in Cerebrospinal Fluid and Positron Emission Tomography in the Dementia of Parkinson's Disease||Fundacion Clinic per a la Recerca Biomédica|No|Completed|March 2010|December 2012|Actual|June 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2009|September 16, 2014|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02243982||36570|
NCT02242851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.450|Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients|Pharmaco-epidemiological Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients||Boehringer Ingelheim||Completed|September 2004|||May 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5018|||Both|21 Years|94 Years|No|Non-Probability Sample|Hypertensive patients treated with Telmisartan for at least one month recruited by ceneral        practitioners and cardiologists|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242851||36657|
NCT02242864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.506|Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure|Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II||Boehringer Ingelheim||Completed|January 2006|||October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1527|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with hypertension and diabetes mellitus|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242864||36656|
NCT02502617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESAN|Re-nutrition in Severe Anorexia Nervosa|Effect of Intensive Re-nutrition on Eating Disorder Psychopathology, Cognitive Functions, Anxiety, Depression, and Cortisol Level in Severe Anorexia Nervosa|RESAN|Odense University Hospital|No|Not yet recruiting|November 2015|January 2021|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Urine.|Both|15 Years|N/A|No|Probability Sample|Patients with severe AN referred to a specialized unit.|July 2015|July 17, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02502617||16722|
NCT02508649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000133|Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial|A Double-blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients With Vasopressor-dependent Septic Shock|SEPSIS-ACT|Ferring Pharmaceuticals|Yes|Recruiting|July 2015|November 2018|Anticipated|June 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|1800|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508649||16259|
NCT02247817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2013/387|A Combined Transvenous and Epicardial Lead Placement Procedure for Implantation of Cardiac Resynchronization Devices: a Feasibility Study.|||University Medical Center Groningen|Yes|Not yet recruiting|October 2014|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2014|September 20, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02247817||36275|
NCT02256436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-045|A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)|A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|October 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|470|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256436||35613|
NCT02495064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MianyangCH|Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients|Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy||Mianyang Central Hospital|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|12 Years|N/A|No|||March 2016|March 8, 2016|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02495064||17302|
NCT02495077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-19|Effects of Inhibiting Early Inflammation in Kidney Transplant Patients|Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495077||17301|
NCT02506192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4554-A|Gulf War Illness Inflammation Reduction Trial|Gulf War Illness Inflammation Reduction Trial|GWIIRT|Minneapolis Veterans Affairs Medical Center|Yes|Recruiting|July 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 8, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506192||16447|
NCT02248064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14IC1995|Auto-titrating Oxygen in Chronic Respiratory Failure|The Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)|ASI1|Imperial College London|No|Completed|July 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|26|||Both|18 Years|N/A|No|||September 2014|February 15, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02248064||36256|
NCT02248077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-567|A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers|A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers||Cytomedix|No|Not yet recruiting|October 2014|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4140|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248077||36255|
NCT02258113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T109/2014|Measuring of Neuro-visual Functionality With Ocusweep|Measuring of Neuro-visual Functionality With New Human Visual System Device Ocusweep||Ocuspecto Oy||Recruiting|November 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Anticipated|400|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02258113||35487|
NCT02258152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN120-CL03|SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)|SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)|SYNAPSE|Biotie Therapies Inc.|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|No|||February 2016|February 2, 2016|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258152||35484|
NCT02499679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-905-001|Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care|Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE (ADVANCE)|ADVANCE|HeartFlow, Inc.|Yes|Enrolling by invitation|July 2015|February 2021|Anticipated|July 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|All clinically stable, symptomatic patients diagnosed with CAD by cCTA, that meet        eligibility criteria, and are able and willing to participate are candidates for the        ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign        the EC/IRB approved informed consent will be enrolled in the registry. FFRCT shall be used        in accordance with the current Instructions for Use document.|August 2015|January 7, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02499679|3 Years|16948|
NCT02511002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150154|Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge|Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2015|May 2019|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|52 Years|Accepts Healthy Volunteers|||May 2015|July 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511002||16078|
NCT02502994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN0101-JM002|Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC|Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients With Recurrence of Castration Resistant Prostate Cancer||Osaka University|Yes|Recruiting|May 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|20 Years|85 Years|No|||July 2015|July 16, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02502994||16693|
NCT02250495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS1402|The Sympara VIBE Study for Hypertension|VIBE: A Clinical Study to Evaluate the Sympara Therapeutic System for the Treatment of Hypertension|VIBE|Sympara Medical, Inc.|Yes|Terminated|October 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||September 2015|September 11, 2015|September 20, 2014||No|Company closed|No||https://clinicaltrials.gov/show/NCT02250495||36069|
NCT02250508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF04|A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.|A Randomised, Comparative, Single Dose, Open Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Different Types of Von Willebrand Disease.||Bio Products Laboratory||Completed|December 2004|||June 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|12 Years|N/A|No|||August 2014|September 24, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02250508||36068|
NCT02241629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOJI-1423Q|Levo Phencynonate Hydrochloride for the Prevention of Seasickness|Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study||Sihuan Pharmaceutical Holdings Group Ltd.|No|Completed|August 2014|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|180|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|May 6, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241629||36751|
NCT02505620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Neurocognitive Function After Therapy of OSAS|Neurocognitive Function After Surgical and Conservative Therapy in OSAS Patients: a Randomized Control Trial|203_14_B|University of Erlangen-Nürnberg Medical School|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|30 Years|70 Years|No|Probability Sample|Patients recruted at the University Hospital Erlangen prior surgery or conventional        treatment.|July 2015|July 20, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02505620||16491|
NCT02509260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-709|Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery|A Randomized Controlled Trial of Prevena™ Incisional Negative Pressure Wound Therapy to Reduce Surgical Site Infection in Re-operative Colorectal Surgery||The Cleveland Clinic|No|Recruiting|July 2015|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|298|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509260||16212|
NCT02509273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON01|Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients|A Double Blind, Randomised, Multicentre, Active Controlled, Parallel-group, Phase III Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Clonidine (Hydrochloride) Compared to Midazolam for Sedation in Children From Birth to Less Than 18 Years of Age|CloSed1|University of Erlangen-Nürnberg Medical School|Yes|Not yet recruiting|September 2015|November 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|18 Years|No|||September 2015|September 15, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02509273||16211|
NCT02249780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-160|Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy|The Use of Indocyanine Green Fluorescence to Assses the Vascularisation of the Parathyroid Glands During Thyroid Surgery||University Hospital, Geneva|Yes|Recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|138|||Both|18 Years|80 Years|No|||September 2014|September 22, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02249780||36124|
NCT02500888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0341|Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder|Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder||Hospital de Clinicas de Porto Alegre|No|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|55 Years|No|||July 2015|July 16, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02500888||16855|
NCT02501135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-00396|A Retrospective Investigation of Local Anesthetic Concentrations in Femoral Nerve Block|A Retrospective Investigation of Safety and Efficacy From Increasing Concentrations of Local Anesthetic in Pediatric Femoral Nerve Blocks||Nationwide Children's Hospital|No|Enrolling by invitation|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|Patients who have undergone anesthesia and received a femoral nerve block at Nationwide        Children'ts Hospital from 2010-2015 utilizing our EMR - PICIS.|May 2015|July 16, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02501135||16836|
NCT02505854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 104-14|Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women|Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women||Universidade Federal do Rio de Janeiro|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|25 Years|45 Years|No|||July 2015|July 21, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505854||16473|
NCT02505867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0228|The Role of Sleep Disordered Breathing in Heart Failure Admissions|The Role of Sleep Disordered Breathing in Heart Failure Admissions||Ohio State University|Yes|Active, not recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||July 2015|July 21, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505867||16472|
NCT02509325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.01.8006|Parkinson's KinetiGraph as Tool for DBS Eligibility Assessment|Evaluation of the Parkinson's KinetiGraph Data Logger (PKG) as a Tool to Measure Motor Fluctuations and Support the DBS Eligibility Assessment of Parkinson's Disease Patients.|KITE|Medtronic Bakken Research Center|No|Recruiting|July 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Probability Sample|The study population is represented by Parkinson's Disease (PD) patients who are referred        to the DBS surgical center (clinical site) as potential surgical candidate for DBS or to        optimize their PD treatment.|August 2015|August 5, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509325||16207|
NCT02258100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH14-325|Anesthesia Information System vs Paper Anesthesia Records for Care Congruency|Retrospective Review of an Anesthesia Information System and Paper Anesthesia Records for Care Congruency in a Single Surgical Population.||NorthShore University HealthSystem|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|189|||Both|N/A|N/A|No|Non-Probability Sample|Patients who underwent esophageal surgery with one surgeon from 2009-2014|April 2015|April 22, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02258100||35488|
NCT02499432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1061|Improving Implementation of Evidence Based PTSD Psychotherapy for Veterans in the Community|Improving Implementation of Evidence Based PTSD Psychotherapy for Veterans in the Community||Veterans Medical Research Foundation|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|54|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02499432||16967|
NCT02256683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-008|Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF|Effects of Dabigatran in Patients With AF - A Prospective, Randomized, Open-label, Explorative, Blinded-endpoint Trial to Compare the Efficacy of Dabigatran With Phenprocoumon for the Resolution of LAA Thrombus in Patients With AF|RE-LATED_AF|Johannes Gutenberg University Mainz|Yes|Recruiting|July 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02256683||35594|
NCT02243462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIH-Anesth-001|Preoperative Warming and Perioperative Shivering|Effectiveness of Pre-operative Warming in Prevention of Peri-operative Shivering|PWPS|Indus Hospital|No|Recruiting|August 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|15 Years|70 Years|No|||April 2015|April 14, 2015|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02243462||36610|
NCT02503514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0167|Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort||APRIL|University of North Carolina, Chapel Hill|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Subjects will have blood drawn (10 mL EDTA tube, 10mL Serum Separator, and a 6 mL EDTA      tube)at their baseline visit. If a subject experiences a paradoxical reaction they will a      repeat of the blood draw done at their baseline visit.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults with confirmed IBD on a biologic agent or with plans to initiate this within 1        month.|March 2016|March 9, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503514|1 Year|16653|
NCT02503579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0520|The Role of Brain-derived Neurotropic Factor in the Relationship Between Executive Function and Physical Training|What's the Role of Brain-derived Neurotrophic Factor in the Relationship Between Executive Function and Physical Fitness/Training in Typically Developing Children? A Randomized Controlled Study||University Ghent|Yes|Not yet recruiting|August 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02503579||16648|
NCT02503592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060216|Vestibular Function After Cochlear Implantation Using Soft Surgery Techniques|Vestibular Function After Cochlear Implantation Using Soft Surgery Techniques||Duke University|No|Recruiting|April 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503592||16647|
NCT02254499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-090|Prediction of Pain After Total Knee Arthroplasty|Prospective Descriptive Study of Nociceptive and Psychological Prediction of Pain After Total Knee Arthroplasty (TKA)||Rigshospitalet, Denmark|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|50 Years|80 Years|No|Probability Sample|Patients with knee osteoarthritis referred for total knee arthroplasty.|September 2015|September 22, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254499||35761|
NCT02254512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090-13|METformin With a Cargohydrate Restricted Diet in Combination With Platinum Based Chemotherapy in Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer|METformin With a Carbohydrate Restricted Diet in Combination With Platinum Based Chemotherapy in Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) - METRO Study||Beth Israel Medical Center|No|Recruiting|September 2013|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254512||35760|
NCT02246231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01623|Effect of Implant Position on Magnetic Resonance Image Distortion|The Effect of Changes in Head Position on Magnetic Resonance Image Distortion in Patients With Auditory Implants||Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|November 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246231||36397|
NCT02498886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1422|IHAT Absorption Kinetics|An Exploratory Study to Determine Bioavailability and Transferrin Saturation Following a Single Dose of a Novel Iron Supplement (IHAT) in Gambian Women.||Medical Research Council|No|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498886||17009|
NCT02244814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1358|Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring|Randomized Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring|CHOICE|University of Colorado, Denver|No|Recruiting|April 2015|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|N/A|36 Years|No|||October 2015|October 29, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244814||36506|
NCT02255032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS1001-201|Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis|A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis|DOGWOOD|Clearside Biomedical, Inc.|No|Completed|October 2014|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255032||35720|
NCT02241317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-831R-MA|Diabetes Mellitus at the University Medical Center of Mannheim|Effects of Training of Medical Staff on the Outcome of In-Patients With Diabetes Mellitus on Regular Wards|DmUMM|Universitätsmedizin Mannheim|No|Active, not recruiting|June 2014|April 2015|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|In-Patients with Diabetes mellitus|September 2014|September 15, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241317|1 Year|36775|
NCT02504216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17454|Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities|An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures|VOYAGER PAD|Bayer|Yes|Recruiting|August 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6500|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504216||16599|
NCT02509416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0604-2|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study Two|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study Two: A Prospective Multicenter Study Evaluating Competence in Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatogram Among Advanced Endoscopy Trainees|RATES 2|University of Colorado, Denver|No|Enrolling by invitation|July 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|43|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Program directors and AETs at all advanced endoscopy programs registered with the ASGE        will be invited to participate in this study and will be considered as study participants.|July 2015|July 24, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02509416||16200|
NCT02252770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33236|Nitric Oxide Supplementation in Argininosuccinic Aciduria|Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinic Aciduria||Baylor College of Medicine|No|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|8 Years|64 Years|No|||July 2015|July 20, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252770||35894|
NCT02252783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFPET P-02|BFPET for Regional Myocardial Perfusion Imaging|A Phase II Open-Labeled Study to Evaluate BFPET as a Myocardial Perfusion Imaging Agent for the Evaluation of Coronary Artery Disease||Fluoropharma, Inc.|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|21 Years|85 Years|No|||November 2015|November 25, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252783||35893|
NCT02256657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS QUIK|Study of a Quality Improvement Toolkit in Kerala, India, Among Hospitals Treating Acute Coronary Syndrome Patients|Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK) Cluster Randomized, Stepped Wedge Multi-center Implementation of a Locally-Developed Quality Improvement Toolkit|ACS QUIK|Northwestern University|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Anticipated|15750|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256657||35596|
NCT02243150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1T28-1-01|Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1|First-In-Human Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects||G1 Therapeutics, Inc.|No|Completed|September 2014|||February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|7||Actual|53|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02243150||36634|
NCT02508948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002328|Endotracheal Intubation Among the Critically Ill: HEMAIR Pilot Study|Current State of Endotracheal Intubation Among the Critically Ill and Exploring Risk Factors for Immediate Complications of Endotracheal Intubation: a Prospective, Observational Multi-center Study (HEMAIR)|HEMAIR|Mayo Clinic|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to 10-25 participating medical/surgical/mixed ICUs who underwent        endotracheal intubation.|January 2016|January 13, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508948|28 Days|16236|
NCT02509000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHuang14|Beijing Indoor Air Purifier Intervention Study|Beijing Indoor Air Purifier Intervention Study|BIAPSY|Peking University||Completed|December 2013|November 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|35|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||July 2015|October 20, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02509000||16232|
NCT02244879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2313155|Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients|Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients. A Double-blind Randomized Controlled Trial||University of Turin, Italy|No|Completed|October 2013|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|192|||Both|35 Years|85 Years|No|||March 2016|March 6, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244879||36501|
NCT02501655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luciana doutorado 01|Analysis of Deposition With Nebulizers Membrane|ANALYSIS OF DEPOSITION RADIOAEROSOL NEBULIZERS MEMBRANE IN HEALTHY SUBJECTS||Universidade Federal de Pernambuco|Yes|Recruiting|July 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501655||16796|
NCT02506335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00100794|Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease|Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Passive Hepatic Congestion Secondary to Congenital Heart Disease (CHD) or Cardiomyopathy||Northwestern University|No|Enrolling by invitation|June 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|70 Years|No|||July 2015|July 21, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506335||16436|
NCT02506348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011-15|Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort|||Wolfson Medical Center|No|Recruiting|July 2015|||January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02506348||16435|
NCT02504983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-1686A3|Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma|Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma||Chang Gung Memorial Hospital|No|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|20 Years|90 Years|No|||July 2015|September 14, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02504983||16540|
NCT02242487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-004E|Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes|A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)||Acorda Therapeutics|Yes|Recruiting|March 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|30 Years|80 Years|No|||December 2015|December 21, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242487||36685|
NCT02252848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00072308|Phase I Clinical Trial to Determine the Safety of Clonidine in Infants With HIE During Therapeutic Hypothermia.|Phase I Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia.||Gauda, Estelle B., M.D.|No|Recruiting|March 2014|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|N/A|36 Hours|No|||September 2015|September 4, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252848||35888|
NCT02503111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-SAVE|The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men|A Randomized Controlled, Open-label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-grade Anal Dysplasia Versus Observation Alone in HIV-positive Men Who Have Sex With Men (MSM)|HPV-SAVE|University Health Network, Toronto|Yes|Enrolling by invitation|November 2015|December 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|3000|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503111||16684|
NCT02503124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB001|Effect of a Single Nights' Wake Followed by Bright Light Therapy for Severe Depression|Wake and Bright Light Therapy for Depression Among Admitted Patients||Sahlgrenska University Hospital, Sweden|No|Recruiting|July 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||July 2015|July 28, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02503124||16683|
NCT02249117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1181.2|Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers|Pharmacokinetics and Pharmacodynamics of BIWH 3: a Randomised, Placebo-controlled, Double Blind Dose Escalation Study (0.02, 0.06, 0.2, 0.6, and 2.0 μg/kg Intravenous Over One Hour) in Healthy Duffy Positive vs. Duffy Negative Male Volunteers||Boehringer Ingelheim||Completed|June 2003|||August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|September 23, 2014|August 21, 2014||||No||https://clinicaltrials.gov/show/NCT02249117||36175|
NCT02249130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.3|Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir|Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir||Boehringer Ingelheim||Completed|March 1999|||April 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|13 Years|N/A|No|||September 2014|September 23, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249130||36174|
NCT02255825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140456|Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis|Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis.||University of California, San Diego|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02255825||35659|
NCT02241330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2013-N-52|Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status|Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status: a Randomized Controlled Trial||Swiss Federal Institute of Technology|No|Not yet recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|270|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02241330||36774|
NCT02241343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICREC 13 6 5|Venous Occlusion and Limb Swelling|Venous Occlusion and Limb Swelling||Imperial College London|No|Completed|May 2014|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|November 13, 2014|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02241343||36773|
NCT02506608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-602547-6|Use of Hand Prosthesis With Direct Nerve Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|EPIONE|Catholic University of the Sacred Heart|No|Recruiting|June 2015|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506608||16415|
NCT02506621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMAP-AF version 1.0|ELR Monitoring Against Permanent Pacemaker in Atrial Fibrillation|Randomised ELR Monitoring Against Permanent Pacemaker in Atrial Fibrillation|REMAP-AF|Eastbourne General Hospital|No|Not yet recruiting|September 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|N/A|No|||July 2015|July 21, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02506621||16414|
NCT02494791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8533CE|Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer|Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer|LS2|University Health Network, Toronto|No|Recruiting|July 2015|July 2025|Anticipated|July 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|915|Samples With DNA|Blood Tumour Tissue (fixed/paraffin embedded)|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|This study will recruit women aged 18-70 years with endometrial and/or non-serous,        non-mucinous ovarian cancer diagnosed within the preceding 6 months and seen at an        institution where the study is being conducted. Potential participants must have a tumour        tissue specimen available for MMR IHC. Patients who are found to have Lynch Syndrome may        invite family members to participate in the study. These will be first-degree relatives        (parents, full siblings, children), 18 years of age and older who reside in Canada.|March 2016|March 3, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02494791||17323|
NCT02494804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLICIK001|Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas|A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas||The First People's Hospital of Changzhou|Yes|Not yet recruiting|July 2015|July 2030|Anticipated|July 2028|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|80 Years|No|||July 2015|July 8, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494804||17322|
NCT02511041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150159|Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation|Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|January 2030|Anticipated|January 2030|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|N/A|No|||May 2015|September 24, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511041||16075|
NCT02511054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150169|Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...|Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stages of Plasmodium Falciparumc||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|February 3, 2016|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02511054||16074|
NCT02255240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0240|LEVEL UP: Video Games for Activity in Breast Cancer Survivors|LEVEL UP: Leveraging Electronic Videogames for Exercise and Leisure: Understanding Preferences of Breast Cancer Survivors|LEVEL UP|The University of Texas Medical Branch, Galveston|No|Withdrawn|September 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|0|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||September 2014|May 26, 2015|September 29, 2014||No|Relinquished grant funding due to receipt of another incompatible grant|No||https://clinicaltrials.gov/show/NCT02255240||35704|
NCT02255253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BAI05B02|Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population|Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial||The George Institute for Global Health, China|Yes|Completed|October 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1410|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02255253||35703|
NCT02255266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4118|Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice|Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice||Novo Nordisk A/S|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1788|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive subjects initiating liraglutide in 2011 according to Victoza® SmPC meeting        the inclusion criteria will be enrolled.|November 2015|November 18, 2015|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255266||35702|
NCT02501395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15006316|MRI in Patients With Kennedy Disease|MRI in Patients With Kennedy Disease||Rigshospitalet, Denmark||Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Persons in Denmark diagnosed with Kennedy disease is invited to the study.        Gender and age matched controls will be recruited to a control group.|September 2015|September 1, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501395||16816|
NCT02501408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00374-43|Comparing New Prothesis PROPRIO-FOOT® Versus Usual Prothesis Tasks Tibial Amputees|Comparaison du Pied Bionique Proprio-Foot® Versus le Pied Habituel Chez Les amputés Tibiaux|PROPRIO-FOOT|University Hospital, Angers|No|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02501408||16815|
NCT02503319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AzUSL1 di Massa e Carrara|Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH (TRANOXY2015)|Clinical Study,Longitudinal,Controlled, Randomized, Open-label, Phase III,to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the Post Partum Hemorrhage (PHH) in Patients at the End of Pregnancy (37-42 w) at Low Risk of PPH|TRANOXY2015|Azienda U.S.L. 1 di Massa e Carrara|Yes|Not yet recruiting|October 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|486|||Female|18 Years|50 Years|No|||July 2015|July 17, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02503319||16668|
NCT02503332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POT-CP121614|Study of of APL-2 Therapy in Patients Geographic Atrophy|A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)|FILLY|Apellis Pharmaceuticals, Inc.|Yes|Recruiting|September 2015|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|240|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503332||16667|
NCT02245282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R44CA180425|Contrast Enhanced MRI of the Prostate|Contrast Enhanced MRI of the Prostate||OHSU Knight Cancer Institute|Yes|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|75 Years|No|Non-Probability Sample|A total of 20 subjects will be studied under this protocol. Subjects will be selected from        patients scheduled for prostate biopsies with known/suspicious prostate lesions. Subjects        will also be recruited from prostate cancer patients who choose radical prostatectomy as        disease management plan. The research project will first be introduced to a potential        subject by a urologist at OHSU. If interested, the subject will then be contacted through        phone to participate in the study by an investigator or a research assistant on the        research team.|February 2016|February 12, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245282||36470|
NCT02250248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.AX1401|AttraX® Putty vs. Autograft in XLIF®|AttraX® Putty vs. Autograft in eXtreme Lateral Interbody Fusion (XLIF®): A Prospective Randomized Single-Center Evaluation of Radiographic and Clinical Outcomes||NuVasive|No|Enrolling by invitation|December 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||April 2015|April 29, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250248||36088|
NCT02250261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179|Social Ecological Intervention to Promote Active Commuting to Work||KÄPY|UKK Institute|No|Recruiting|August 2014|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250261||36087|
NCT02494752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229/RC/KEMU|Role of Mesenchymal Stem Cells in Fat Grafting|Potential of Mesenchymal Stem Cell Enriched Adipose Tissue Grafting for Contour Deformities of Face||King Edward Medical University|Yes|Not yet recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|60 Years|No|||July 2015|July 9, 2015|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494752||17326|
NCT02495324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FVO-CT-401|Fimasartan Achieving SBP Target (FAST) Study|A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension|FAST|Boryung Pharmaceutical Co., Ltd|No|Enrolling by invitation|June 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|19 Years|70 Years|No|||March 2016|March 3, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02495324||17282|
NCT02247232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z100-01|Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer|Randomized, Double-blind, Placebo-controlled Trial of Z-100 Plus Radiation Therapy in Patients With Locally Advanced Cervical Cancer — A Phase III Trial||Zeria Pharmaceutical|Yes|Recruiting|December 2014|December 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Female|21 Years|79 Years|No|||December 2015|January 4, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247232||36320|
NCT02247245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGHT-TREPPE-1|The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.|The Influence of Iatrogenic Chronotropic Incompetence on Exercise Tolerance in Pacemaker Patients With Chronic Heart Failure.|TREPPE|University of Leeds|No|Recruiting|September 2014|July 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|90 Years|No|||September 2014|September 29, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247245||36319|
NCT02258061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-034|Optimal Cardiac Resynchronization Therapy Pacing Rate|Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-ischemic Heart Failure Patients: a Randomized Crossover Pilot Trial.||Rigshospitalet, Denmark|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02258061||35491|
NCT02505633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBIRB2015-44|Comparison 1 Plane-1 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block|A Randomized Comparison Between 1 Plane - 1 Injection (Cluster Approach) and 2 Plane - 2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCBPB) in Upper Extremity Surgery|US-SCBPB|Gachon University Gil Medical Center|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02505633||16490|
NCT02255877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|ZIPS Study - Zip Incision Approximation vs. STAPLE|A Prospective, Non Blinded, Randomized Controlled Post Market Study Designed to Compare the Use of the Zip Surgical Skin Closure Device vs. Conventional Steel Staples for Skin Closure in Subjects Who Undergo a bi Lateral Knee Arthroplasty|ZIPS|ZipLine Medical Inc.|No|Active, not recruiting|September 2014|October 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||September 2014|June 1, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255877||35655|
NCT02246205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAUDA|RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE MORBIDITY ON RECONSTRUCTION AFTER PANCREATICODUODENECTOMY(PAUDA)|RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE MORBIDITY ON RECONSTRUCTION AFTER PANCREATICODUODENECTOMY BETWEEN TWO RECONSTRUCTION TECHNIQUES (PAUDA)|PAUDA|Hospital Universitari de Bellvitge|Yes|Recruiting|February 2013|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246205||36399|
NCT02499172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006369|Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi|Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|3600|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02499172||16987|
NCT02499185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVELBIO|Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients|A PILOT Study Evaluating Novel Biomarkers of AKI in Post-operative Patients Undergoing Major Intra-Abdominal Surgery||Universitair Ziekenhuis Brussel|No|Recruiting|April 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|July 13, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499185||16986|
NCT02507999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDT|Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients|Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients - A Prospective, Blinded Randomized Controlled Trial||Lawson Health Research Institute|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507999||16308|
NCT02244307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.28|Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade|Evolution of Patients Suffering From Benign Prostatic Hyperplasia (BPH) Treated With Alpha-adrenergic Blockade (JOSEPHINE)||Boehringer Ingelheim||Completed|January 2000|||June 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4561|||Male|N/A|N/A|No|Non-Probability Sample|Patients with BPH for whom alpha-blockade treatement is indicated recruited at general        practitioners|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244307||36545|
NCT02244320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.38|Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)|Observational Study in Patients With Functional BPH (Benign Prostatic Hyperplasia) Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)||Boehringer Ingelheim||Completed|September 2002|||May 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4150|||Male|N/A|N/A|No|Non-Probability Sample|Patients with functional BPH symptoms recruited at urologist offices|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244320||36544|
NCT02504229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-A-004|DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment|||Beijing Biohealthcare Biotechnology Co.,Ltd||Recruiting|November 2014|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504229||16598|
NCT02506101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052103|Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo|Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo||Johns Hopkins University|No|Recruiting|July 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506101||16454|
NCT02506114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14559|Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer|An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy||University of California, San Francisco|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506114||16453|
NCT02506127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000701|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||July 28, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506127||16452|
NCT02255188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16.01.2014 № 2|Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning|Evaluate Hemocompatibility Vascular Prosthesis to Prevent Its Thrombosis||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|October 2014|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|volunteers, donors|July 2015|July 6, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02255188||35708|
NCT02255201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPN-2014|Pre-Workout on Exercise Performance and Cognition|A Randomized, Double-Blind, Crossover Clinical Trial Comparing the Effects of Four Pre-Workout Beverages on Muscular Strength and Endurance and Cognitive Performance in Healthy Adult Males||Miami Research Associates||Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255201||35707|
NCT02255279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_50|Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.|A Phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.||Novartis|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|287|||Both|6 Months|71 Months|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 30, 2014||No||No|January 4, 2016|https://clinicaltrials.gov/show/NCT02255279||35701|
NCT02498340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diet challenge in G6PD|Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation|||Ain Shams University||Not yet recruiting|December 2015|||July 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||July 2015|July 14, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02498340||17051|
NCT02499198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502M63481|Labeled Nornicotine in Smokeless Tobacco|Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499198||16985|
NCT02499211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820635|Healthy In-Store Marketing|The Impact of Healthy Food Marketing Strategies in Supermarkets||University of Pennsylvania|Yes|Recruiting|September 2014|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02499211||16984|
NCT02505659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0240|Efficacy of Preoperative Re-education on Patients With an Anterior Cruciate Ligament Rupture|Efficacy of Preoperative Re-education on Patients With an Anterior Cruciate Ligament Rupture: a Randomized Controlled Trial|PRELIG|University Hospital, Clermont-Ferrand||Recruiting|February 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|No|||September 2015|September 18, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02505659||16488|
NCT02505672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0361-14-RMC|Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma|Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma||Rabin Medical Center|No|Not yet recruiting|August 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with biopsy-proven nasopharyngeal carcinoma who are planned to undergo        chemoradiotherapy.|July 2015|July 20, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02505672||16487|
NCT02252341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-007|Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder|Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder|NACBD|Universidade Estadual de Maringá|Yes|Enrolling by invitation|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02252341||35927|
NCT02252354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385-1009|TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study|An Open-Label, Single-Centre,Two Part Phase I Mass Balance Study to Assess the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of Orally Administered [14C]-TAK-385 in Healthy Male Subjects||Takeda|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|September 26, 2014||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT02252354||35926|
NCT02242552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triceps|Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood|Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood(TRICEPS Study)||St. Justine's Hospital|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood, saliva, tumor sample (bone marrow or solid tumors)|Both|1 Month|21 Years|No|Non-Probability Sample|Children and adolescents with Relapse or refractory leukemia and solid tumor|August 2014|September 15, 2014|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242552||36680|
NCT02500654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFUG 476871|Regenerative Surgical Treatment of Peri-implantitis|Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study.||Region Gävleborg|No|Completed|December 2008|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500654||16873|
NCT02494518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-402|Forced Aerobic Exercise for Stroke Rehabilitation|Forced Aerobic Exercise for Stroke Rehabilitation||The Cleveland Clinic|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|85 Years|No|||January 2016|January 27, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02494518||17344|
NCT02494531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120134|Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging|Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging|AVILL|Assistance Publique - Hôpitaux de Paris||Not yet recruiting|May 2015|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|July 9, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494531||17343|
NCT02240758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-820|Confocal Laser Endomicroscopy for Brain Tumors|INTRA-OPERATIVE CONFOCAL LASER ENDOMICROSCOPY FOR BRAIN TUMORS: A FEASIBILITY STUDY IN HUMAN|GLIOFOCAL|Hospices Civils de Lyon|No|Terminated|September 2014|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02240758||36818|
NCT02250547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSY01 OSCAR|Optimization With SonR Method in the ClinicAl pRactice|Optimization With SonR Method in the ClinicAl pRactice|OSCAR|LivaNova|No|Recruiting|July 2012|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|278|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac resyncronisation therapy - defibrillator (CRT-D) patients|October 2014|October 7, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02250547||36065|
NCT02497820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0246-14-TLV|Aspirin as a Cancer Preventive in Carriers of a Germline Pathological Mismatch Repair Gene Defect, Lynch Syndrome|A Randomised Double Blind Dose Non-inferiority Trial of a Daily Dose of 600mg Versus 300mg Versus 100mg of Enteric Coated Aspirin as a Cancer Preventive in Carriers of a Germline Pathological Mismatch Repair Gene Defect, Lynch Syndrome||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|August 2015|September 2027|Anticipated|September 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|1800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497820||17091|
NCT02505880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9518|Hypnosis Versus General Anesthesia in Pediatric Surgery: Clinical and Medico-economic Interests|Evaluation of Perioperative Use of Hypnosis in Pediatric Surgery: Clinical and Medico-economic Interests||University Hospital, Montpellier|No|Active, not recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|7 Years|16 Years|No|||July 2015|July 21, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505880||16471|
NCT02245022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK12|Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study|Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study|DolPHIN1|University of Liverpool|Yes|Not yet recruiting|January 2016|November 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245022||36490|
NCT02250014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0071.cc|The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer|The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer||University of Colorado, Denver|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|85 Years|No|||October 2015|December 14, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250014||36106|
NCT02250027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_HL301_201|A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)||HL301|Hanlim Pharm. Co., Ltd.|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|156|||Both|19 Years|80 Years|No|||September 2014|September 25, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02250027||36105|
NCT02506660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-379|Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy|Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy|Dex ISB|Hospital for Special Surgery, New York||Recruiting|August 2015|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506660||16411|
NCT02495090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9477|Hypospadias and Exome: Identification of New Genes for Familial Hypospadias|Hypospadias and Exome: Identification of New Genes for Familial Hypospadias||University Hospital, Montpellier|Yes|Enrolling by invitation|November 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|N/A|No|||June 2015|July 10, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02495090||17300|
NCT02498899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0279|Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion|Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498899||17008|
NCT02249702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAUL|Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma|A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy|TAUL|Mario Negri Institute for Pharmacological Research|No|Recruiting|April 2010|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||September 2014|April 21, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249702||36130|
NCT02249715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-1293-14-OC-CTIL|Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease|Pilot Study for Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease||Sheba Medical Center|No|Not yet recruiting|November 2014|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||September 2014|September 23, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249715||36129|
NCT02242175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0046|Efficacy of Hydrogen Breath Test in the Patients With Irritable Bowel Syndrome|||Yonsei University|No|Not yet recruiting|September 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|147|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2014|September 14, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242175||36709|
NCT02502942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD130780|Effects of Upper Airway Muscle Training on OSA|Effects of Upper Airway Muscle Training on Obstructive Sleep Apnea (OSA)||University of California, San Diego|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|79 Years|No|||August 2015|August 17, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02502942||16697|
NCT02509507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140318|Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors|A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors||Amgen|No|Recruiting|February 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509507||16193|
NCT02508571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401139552|Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants|The Effects of Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants||Seoul National University Hospital|Yes|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|189|||Both|24 Weeks|32 Weeks|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508571||16265|
NCT02255071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH103-REC2-058|The Efficacy of Neiguan (P6 Point) Acupressure in Patients With Gastroesophageal Reflux Disease (GERD)|The Efficacy of Neiguan (P6 Point) Acupressure in Patients With Gastroesophageal Reflux Disease (GERD)||China Medical University Hospital|No|Active, not recruiting|June 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|64|||Both|20 Years|60 Years|No|||June 2015|June 8, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255071||35717|
NCT02500667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N91115-1H-04 (SNO-5)|A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects|A Phase 1, Open-label, Drug-Drug Interaction Study to Assess the Steady State Pharmacokinetics of N91115 Alone and in the Presence of Multiple Dose Administration of Rifampin in Healthy Adult Subjects (SNO-5)||Nivalis Therapeutics, Inc.|Yes|Active, not recruiting|July 2015|February 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500667||16872|
NCT02498405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040562|Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction|Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction (ST LEUIS Study)|ST LEUIS|Intermountain Health Care, Inc.|No|Recruiting|December 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients, >18 years old, who are seen for chest pain, and/or patients for        whom the STEMI protocol has been activated, will be screened for this study.|December 2015|December 10, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498405||17046|
NCT02498418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTA/RIFX/2015|Study Comparing Rifaximin With Xifaxan 200mg in Traveler's Diarrhea|A Randomized, Double-Blind, Parallel, Multicenter, Bioequivalence Study Comparing Rifaximin 200-mg Tablets With Xifaxan® 200-mg Tablets and With Placebo in the Treatment of Traveler's Diarrhea||Actavis Inc.|No|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02498418||17045|
NCT02245607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH105247|Compensatory Cognitive Training in Clinical High Risk Latino Youth|Compensatory Cognitive Training in Clinical High Risk Latino Youth||University of California, San Diego|Yes|Recruiting|October 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|30 Years|No|||November 2015|November 30, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245607||36445|
NCT02245620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPITM-201|A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia™) on Skeletal Muscle Function in the Elderly|SPITM-201|Stealth BioTherapeutics Inc.|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|85 Years|No|||July 2015|July 30, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245620||36444|
NCT02255851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP10879|Sentinel(TM) Post-Market Registry|Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement||Claret Medical|No|Enrolling by invitation|March 2014|||December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples With DNA|Capture and histopathology analysis of embolic debris. (Thrombus, valve tissue, amorphous      calcium, etc.)|Both|18 Years|N/A|No|Non-Probability Sample|The registry population comprises subjects with severe symptomatic calcified native aortic        valve stenosis who are selected for TAVR by heart team consensus and treated with        CE-Marked TAVR devices.|September 2014|October 2, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02255851|1 Day|35657|
NCT02497833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXYZM-2|Retinoic Acid Supplementation and Subjects With Hypercholesterolemia|Effect of Retinoic Acid Supplementation on the HDL-Associated Paraoxonase 1 Activity in Subjects With Hypercholesterolemia: A Randomized, Double-Blinded, Placebo-Controlled Trial||Sun Yat-sen University|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|25 Years|65 Years|No|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497833||17090|
NCT02494817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140561|HIV Prevention Toolkit for HIV-negative Male Couples|Development of a HIV Prevention Toolkit for At-risk HIV-negative Male Couples|MCAP|University of Miami|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02494817||17321|
NCT02255968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP788-002|Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers||Enanta Pharmaceuticals|Yes|Terminated|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255968||35648|
NCT02255084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA13-KH / APACHE-3|Vaginal Self-sampling and Human Papillomavirus Testing in Unscreened Women|Attitude of Unscreened Women Face to Different Strategies to Participate in Cervical Cancer Screening by Vaginal Self-sampling : Home-mailed or Invitation to Remove to Their General Practitioner|APACHE-3|University Hospital, Tours|No|Active, not recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|3612|||Female|30 Years|65 Years|No|||April 2015|April 15, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02255084||35716|
NCT02255097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-055|Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)|A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab||Merck Sharp & Dohme Corp.|No|Active, not recruiting|October 2014|October 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255097||35715|
NCT02255110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200592-008|A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|A Phase II, Single-arm, Japanese Multicenter Trial of TH-302 in Combination With Doxorubicin in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma||Merck KGaA|No|Recruiting|December 2014|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|15 Years|N/A|No|||October 2015|October 19, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255110||35714|
NCT02498067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0379|rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities|rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities||University of Chicago|No|Not yet recruiting|July 2015|September 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|15 Years|24 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02498067||17072|
NCT02498080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pmp01|Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia|Drug Eluting Balloons Versus Standard Percutaneous Transluminal Angioplasty in Infra-popliteal Arteries in Patients With Critical Limb Ischemia: a Randomized Clinical Trial||Neuromed IRCCS|No|Not yet recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02498080||17071|
NCT02498912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-014|Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02498912||17007|
NCT02256020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030104|Improvement and Mechanism of Wheel-chair Music Aerobic Exercise on Depression and Insomnia Among the Elderly in Long-term Care Facilities|Improvement and Mechanism of Wheel-chair Music Aerobic Exercise on Depression and Insomnia Among the Elderly in Long-term Care Facilities||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|February 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|170|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 1, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02256020||35644|
NCT02256033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-016|Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline|Effect of Mild Hepatic Impairment (Child-Pugh Class A) on the Single-dose Pharmacokinetics of Istradefylline||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|August 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02256033||35643|
NCT02246712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIABETRA|Influence of Diabetes on Tramadol Pharmacokinetics|Influence of Uncontrolled Diabetes on the Kinetic Disposition, Metabolism and Pharmacokinetics-pharmacodynamics of Tramadol Enantiomers in Patients With Neuropathic Pain||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|June 2008|December 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|59 Years|No|||September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246712||36360|
NCT02502227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT008493-01A1|Mechanisms of Mindfulness Training and Stress Reduction|Mechanisms of Mindfulness Training and Stress Reduction||Carnegie Mellon University|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|135|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02502227||16752|
NCT02502240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK-CLICaP|ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)|Frequency of ALK Rearrangements in Non Small-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).||Instituto Nacional de Cancerologia de Mexico|No|Recruiting|July 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|7000|||Both|18 Years|90 Years|No|Probability Sample|Both: both female and male participants are being studied Analysis of the ALK        translocation was done either by FISH, IHC, or both, with an adequate amount of cancer        cells. Demographic, clinical and pathological data was obtained from patients.|February 2016|February 22, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502240|1 Year|16751|
NCT02511145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40221E|Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration|Exploratory Study to Compare Mechanical Penetration Enhancers on Metvixia Skin Penetration||Galderma R&D|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|9||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511145||16067|
NCT02508844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-076|Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn|The POP-study: Effect of Probiotics on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn - a Randomized, Double-blind Placebo Controlled Trial With Vivomixx®|POP|Hvidovre University Hospital|No|Recruiting|April 2015|October 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 7, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02508844||16244|
NCT02244502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-22|Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma|An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) Concomitant With Weekly Paclitaxel for Recurrent Ovarian Carcinoma|INNOVATE|NovoCure Ltd.|No|Recruiting|September 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244502||36530|
NCT02243384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chenjian-01|Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma|A Randomized Controlled Trial of Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma||Southwest Hospital, China|Yes|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|70 Years|No|||May 2015|May 21, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243384||36616|
NCT02243397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0040|Molecular and Cellular Analysis of Breast Cancer|Molecular and Cellular Analysis of Breast Cancer||Stanford University|No|Recruiting|September 2014|||September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|blood, cerebrospinal fluid, abdominal fluid, chest fluid|Female|N/A|N/A|No|Non-Probability Sample|breast cancer patients at Stanford Cancer Center|July 2015|July 27, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02243397||36615|
NCT02243670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIC-HHSN271201300036C-01|Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy|Feasibility and Validity of Using a Novel Artificial Intelligence Platform to Monitor and Optimize Medication Adherence in Patients Receiving Opioid Replacement Therapy||AiCure|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243670||36594|
NCT02503930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-NG-261-CTIL|The Effect of tDCS on a Motor-cognitive Dual-task Performance of Parkinson's Patients|The Effect of Transcranial Direct Cortical Stimulation (tDCS) on a Motor-cognitive Dual-task Performance of Parkinson's Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2015|October 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 19, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02503930||16621|
NCT02502448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160030|Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery|Impact of Acute Normovolemic Hemodilution on Whole Blood Coagulation Profile During Post-cardiopulmonary Bypass in Cardiac Surgery: Rotational Thromboelastometry Study||Konkuk University Medical Center|Yes|Recruiting|December 2011|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|19 Years|65 Years|No|||July 2015|July 17, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02502448||16735|
NCT02502188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90005-CP-001|Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis|A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis||Celgene|No|Terminated|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|July 16, 2015|No|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT02502188||16755|
NCT02498665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-DSP7888-101|A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies|A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies||Boston Biomedical, Inc||Recruiting|November 2015|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498665||17026|
NCT02498678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22225014.7.0000.0068|Effect of Tetanus on Neuromuscular Junction Monitor Performance in Pediatric Patients|Effect of Tetanus on Neuromuscular Junction Monitor Performance in Pediatric Patients Undergoing Abdominal and / or Perineal Surgical Procedures With Using of Rocuronium||University of Sao Paulo General Hospital|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|February 11, 2015||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT02498678||17025|
NCT02241265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3790|Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma|Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma||University of Oklahoma|No|Recruiting|February 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|May 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241265||36779|
NCT02241889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP3-2014|Three-way, Cross-over Closed-loop Exercise Study|A Randomized, Three-way, Cross-over Study to Assess the Efficacy of a Bi-hormonal Closed-loop System With vs Without Exercise Announcement vs Open-loop Therapy in Reducing Exercise-related Hypoglycemia||Oregon Health and Science University|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2015|November 17, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241889||36731|
NCT02241902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCho1|Impact of Postoperative Pyuria on Treatment Outcomes After PVP|Does Postoperative Pyuria Influence Treatment Outcomes After Photoselective Vaporization of the Prostate (PVP)?: A Short-term Serial Follow-up Study||DongGuk University|No|Recruiting|August 2014|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Male|40 Years|90 Years|No|Non-Probability Sample|men who underwent photoselective vaporization (PVP) using 80 watt        potassium-titanyl-phosphate (KTP) laser or 120 watt high-power-system (HPS) laser for        benign prostatic hyperplasia refractory to medical treatment|September 2014|September 15, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241902||36730|
NCT02504788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4151B|A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline|||Chang Gung Memorial Hospital||Recruiting|March 2014|||April 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|84 Years|No|||January 2016|January 27, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02504788||16555|
NCT02504905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150167|Propensity to Develop Plasticity in the Parieto- and Cerebello-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing|Propensity to Develop Plasticity in the Parieto- & Cerebello-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|September 12, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504905||16546|
NCT02502643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504066RINA|The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak|The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak||National Taiwan University Hospital|No|Not yet recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|70 Years|No|||July 2015|July 17, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502643||16720|
NCT02241512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 082014-033|IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis|IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|18 Years|No|||May 2015|May 26, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241512||36760|
NCT02252588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4526|The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease|The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive|CLIMB|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|September 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||February 2016|February 24, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252588||35908|
NCT02505022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201133|Role Functioning Changes NOS|Role Functioning Changes in New Onset Symptoms||Northwestern University|No|Recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|26 Years|No|Probability Sample|Young adults with emerging psychopathology. Therefore, all subjects we recruit will be in        the age range spanning adolescence and young adulthood, who come to a clinic seeking        psychiatric care.|March 2016|March 21, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505022||16537|
NCT02495831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7219J01|Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers|Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers||Zambon SpA|No|Completed|May 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|22 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02495831||17243|
NCT02495844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0069|A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy|Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.||UCB Pharma|No|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02495844||17242|
NCT02244515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED cerebral palsy|Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy|Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy||Guangzhou Women and Children's Medical Center||Enrolling by invitation|June 2014|||September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|2 Years|12 Years|No|||September 2014|September 18, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244515||36529|
NCT02244528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14172MFDS178-1|PK Study of Sildenafil in Neonate|Pharmacokinetic Study of Sildenafil in Neonates and Preterm Infants||Seoul National University Hospital|Yes|Recruiting|October 2014|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|1 Month|No|||November 2015|November 18, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02244528||36528|
NCT02249533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD080377|Evaluation of Spot Light: A Concussion Injury Management App for Youth Sports|Evaluation of Spot Light: A Concussion Injury Management App for Youth Sports|SpotLight|Nationwide Children's Hospital|Yes|Active, not recruiting|December 2013|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|175|||Both|10 Years|19 Years|No|||January 2016|January 26, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02249533||36143|
NCT02506582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS_DM|The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control|The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control||Yonsei University|Yes|Completed|June 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02506582||16417|
NCT02505646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT/ANSM 2015-A00388-41|Fluid Responsiveness Evaluation by AbdomiNal Compression in Kids Based on the STARLING Concept|Fluid Responsiveness Evaluation by AbdomiNal Compression in Kids Based on the STARLING Concept|FRANCK|Hopital Louis Pradel|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|38|||Both|N/A|8 Years|No|Non-Probability Sample|Patient hospitalized in the intensive care unit of the hospital " feme mère enfant " or        the cardiologic hospital of BRON who suffer from circulatory failure and for whom the        attending physiscian has decided to administer a 10 ml/kg cristalloïd infusion.|February 2016|February 26, 2016|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505646||16489|
NCT02505893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI-MITO 1/2014|Minimal Islet Transplant at Diabetes Onset|A Monocentric, Open-label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients With New-onset Type 1 Diabetes|MITO|Ospedale San Raffaele||Recruiting|April 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|45 Years|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505893||16470|
NCT02249481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/132|A Comparison of Anaesthetic Methods for Total Knee Replacement Surgery|A Comparison of Continuous Adductor Canal Catheter Infusion vs Continuous Femoral Nerve Catheter Infusion for Total Knee Replacement Surgery||Plymouth Hospitals NHS Trust|No|Recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02249481||36147|
NCT02249494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0258|Mobile Application to Improve Nutritional Counseling Provided by Primary Care Physicians for Hypertension.|Nutritional Recommendations for Hypertension: Development of Mobile Application for Improve Knowledge in Lifestyle Modification for Primary Care Physicians||Hospital de Clinicas de Porto Alegre|No|Completed|October 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|N/A|N/A|No|||March 2015|March 18, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249494||36146|
NCT02249728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT2-102|Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2|A Phase I , Open-Label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]-PBT2 and to Estimate the Absolute Bioavailability of PBT2 in Healthy Male Subjects||Prana Biotechnology Limited|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|July 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249728||36128|
NCT02241603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-004-13F|Insulin Resistance and Reward|Insulin Resistance and Reward Signaling in Obesity|IRRSO|VA Office of Research and Development|Yes|Recruiting|November 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|25 Years|55 Years|No|||December 2015|December 21, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241603||36753|
NCT02241616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGHLC20140818002|Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV|A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV||ShuGuang Hospital|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241616||36752|
NCT02504632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7078 03|Study of Platelet Activation by Severe Aortic Stenosis and Its Correction by Transcatheter Aortic Valve Implantation|Study of Platelet Activation by Severe Aortic Stenosis and Its Correction by Transcatheter Aortic Valve Implantation (TAVI) Platelet Activation in TAVI|TAVI|University Hospital, Toulouse|No|Recruiting|May 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|45|||Both|50 Years|N/A|No|||July 2015|July 20, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02504632||16567|
NCT02504645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPP-201101/005|A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|LUPUZOR|ImmuPharma|No|Recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504645||16566|
NCT02504775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204779|Bioequivalence Study for Mejoral 500 Product|Single Blinded, Two-period, Two-treatment, Crossover, Randomized, Single Dose Bioequivalence Study of Two Oral Formulations With 500 mg of Paracetamol (Mejoral® 500 Tablets, Glaxosmithkline méxico s.a. De c.v. Vs. Tylenol® Caplets, Janssen Cilag de méxico, s. De r.l. De c.v.) in Healthy Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504775||16556|
NCT02502539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0234|Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases|Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases|AJI-APA|University Hospital, Clermont-Ferrand||Recruiting|July 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|8 Years|12 Years|No|||September 2015|September 18, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02502539||16728|
NCT02506140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D151100002015001|Platelet Reactivity in Acute Non-disabling Cerebrovascular Events|A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.|PRINCE|Ministry of Science and Technology of the People´s Republic of China|Yes|Not yet recruiting|July 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|952|||Both|40 Years|80 Years|No|||July 2015|July 22, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02506140||16451|
NCT02245893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103747|A Prospective Randomized Pilot Study to Compare Open Versus Percutaneous Syndesmosis Repair of Unstable Ankle Fractures|A Prospective Randomized Pilot Study to Compare Open Versus Percutaneous Syndesmosis Repair of Unstable Ankle Fractures|ART|Lawson Health Research Institute|No|Recruiting|August 2013|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245893||36423|
NCT02246465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1402|A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars|An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults||RXi Pharmaceuticals, Corp.|Yes|Recruiting|July 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246465||36379|
NCT02252380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD003|ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders|A Feasibility Clinical Trial of the Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for the Management of Treatment-Refractory Movement Disorders||InSightec|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||September 2015|September 10, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252380||35924|
NCT02494765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-1154|Spatial Relationship of I-gelTM and Ambu® AuraOnceTM on Paediatric Airway: A Comparison on Three Dimensional MRI|Spatial Relationship of I-gelTM and Ambu® AuraOnceTM on Paediatric Airway: A Comparison on Three Dimensional MRI||King Saud University|Yes|Recruiting|July 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|N/A|12 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02494765||17325|
NCT02494778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV7820-CNS-20016|A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease|A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease||Teva Pharmaceutical Industries|Yes|Enrolling by invitation|August 2015|May 2021|Anticipated|April 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|21 Years|N/A|No|||March 2016|March 2, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494778||17324|
NCT02511119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRR-MEL-2015|Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma|||Maimónides Biomedical Research Institute of Córdoba|No|Not yet recruiting|July 2015|||July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The patients were followed up in the Pigmented Lesions Unit at Reina Sofia University        Hospital. In a subgroup of 200 patients, the investigators will analyze the dermoscopic        imagines of melanocytic nevus, atypical nevus and melanomas to seek common patterns using        artificial intelligence methods. With the patterns obtained, the investigators will build        a robust model to classify population with the risk of developing melanoma. In this model        the sociodemographic, clinical and genetic data will be used to increase the accuracy of        the obtained model. In a second phase, in a subgroup of 100 different patients, the degree        of accuracy of the predictive model will be evaluated.|July 2015|July 29, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511119||16069|
NCT02246153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-2014-067|Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients|Morbidity and Mortality of Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients: A Randomized Controlled Trial||Nanfang Hospital of Southern Medical University|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|65 Years|N/A|No|||September 2014|September 18, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02246153||36403|
NCT02255981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neijing Ophthalmology|Efficacy of Acupuncture in Macular Diseases|¿Es Util la Acupuntura en la Degeneracion Macular? Prospective Study of Efficacy of Acupuncture in Macular Diseases||Escuela Neijing|Yes|Active, not recruiting|March 2013|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|N/A|No|||September 2014|October 2, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02255981||35647|
NCT02256046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|esophageal ulcers|Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices|Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices; Multicenter Study||Tanta University|Yes|Recruiting|August 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|224|||Both|18 Years|70 Years|No|||October 2014|October 2, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02256046||35642|
NCT02495038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|combination P-1|Optimal Dose of Combination of Rocuronium and Cisatracurium|Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial|CRC|Yonsei University|Yes|Completed|March 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02495038||17304|
NCT02499965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404187-2|Skin Refrigerant to Reduce the Pain Associated With IV Insertion|The Use of a Topical Anesthetic Skin Refrigerant to Reduce the Pain Associated With Intravenous Catheter Insertion, A Double Blinded, Patient/Placebo Controlled, Study||Brooke Army Medical Center|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499965||16926|
NCT02248805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGD007-01|Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma|A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma||MacroGenics|No|Recruiting|September 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|158|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02248805||36199|
NCT02249104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10302|Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris|||Galderma Laboratories, L.P.||Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|12 Years|N/A|No|||March 2015|March 10, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249104||36176|
NCT02254967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-MA-1002|A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population|A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population|EXTEND|Astellas Pharma Inc|Yes|Active, not recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|364|||Both|60 Years|N/A|No|||March 2016|March 23, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02254967||35725|
NCT02502110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSCRES0175|Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation|The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation||The Third Xiangya Hospital of Central South University|Yes|Not yet recruiting|August 2015|June 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Both|18 Years|75 Years|No|||July 2015|July 20, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502110||16761|
NCT02494544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005|A Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System Versus Off-the-Shelf Replacement|A Prospective, Randomized, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System Versus Off-the-Shelf Replacement||ConforMIS, Inc.|Yes|Recruiting|July 2015|August 2025|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|800|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02494544||17342|
NCT02494830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketamine_03_2014|Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects|Comparative Bioavailability Study of Ketamine and Norketamine After Single Dose Administration of Ketamine 10, 20, 40 and 80 mg Prolonged Release Tablets in Fasting State and 5 mg Ketamine Solution for Infusion in 15 Healthy Subjects in Serum, Urine and Feces||University Medicine Greifswald|Yes|Completed|August 2014|October 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494830||17320|
NCT02258568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN-II-RU-TE-2012-3-0209|Postnatal Smoking Relapse, Its Associated Risk Factors, and a Proactive Sustainable Preventive Intervention|Postnatal Smoking Relapse, Its Associated Risk Factors, and a Proactive Sustainable Preventive Intervention|PRISM|Babes-Bolyai University|No|Recruiting|December 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|425|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02258568||35452|
NCT02257775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4203|Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer|Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer|EVOLUTION|Institute of Cancer Research, United Kingdom|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Patients requiring systemic therapy for metastatic breast cancer|May 2015|August 24, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257775||35512|
NCT02246478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho10053030|A Study of TAS-205 for Duchenne Muscular Dystrophy|A Phase I Study of Single and Multiple Doses of TAS-205 in Patients With Duchenne Muscular Dystrophy||Taiho Pharmaceutical Co., Ltd.|No|Completed|September 2014|September 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|21|||Male|5 Years|15 Years|No|||September 2015|September 24, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02246478||36378|
NCT02506153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02676|High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery|A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|October 2015|||June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1378|||Both|18 Years|N/A|No|||December 2015|March 24, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506153||16450|
NCT02249962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1366|Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART|Option B+: ART Safety and Durability During First and Subsequent Pregnancies|S4|University of North Carolina, Chapel Hill|Yes|Recruiting|May 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|8600|Samples With DNA|Blood serum samples for:        -  HIV genotyping        -  micronutrient status        -  pharmacokinetics: efavirenz and progesterone levels for women using the contraceptive           implant only|Female|16 Years|50 Years|No|Non-Probability Sample|HIV+ pregnant women and their infants recruited from three clinic sites in Lilongwe,        Malawi.|February 2016|February 9, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02249962||36110|
NCT02250469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-SMI-2014|A Randomised Pilot Study to Assess Differences in Stimulation Induced Paresthesia Between 2 Spinal Cord Stimulation Systems|A Randomised Pilot Study to Assess differenCes in tHe Subjects' Experience of stimulAtion-Induced paRaesthesiA Between Two Different Spinal Cord sTimulation dEvices: the Axium® DoRsal Root Ganglion Stimulation System Versus the Prime Advanced Dorsal Column Stimulation System|CHARACTER SCS|St. Jude Medical|No|Recruiting|September 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02250469||36071|
NCT02255903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-khaled|Middle Cerebral To Umbilical Artery Doppler Ratio And Amniotic Fluid Volume Measurement In Post-date Pregnancies|Middle Cerebral To Umbilical Artery Doppler Ratio And Amniotic Fluid Volume Measurement In Post-date Pregnancies||Benha University|No|Completed|November 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Female|19 Years|44 Years|No|Non-Probability Sample|ome hundred pregnant women will be recruited from antenatal clinic. Starting from November        2013. An informed consent will be obtained from the patients . The patients will be        subdivided into two groups: Group 1(Control Group):consist of 50 pregnant females with        gestational age 37-40 weeks.        Group 2 (post date Group):consist of 50 pregnant females with gestational age 41 weeks or        more.|July 2015|July 19, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255903||35653|
NCT02499406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACHS HSS 01883|Dialectical Behavior Therapy Skills Group Pilot Evaluation|Dialectical Behavior Therapy Skills Group Pilot Evaluation||VA Connecticut Healthcare System|No|Recruiting|December 2014|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499406||16969|
NCT02495337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8514|Tissue Collection Protocol|Tissue Collection for Gastro-esophageal Cancer Primary Cell Line Establishment||University Health Network, Toronto|No|Recruiting|May 2015|||May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Biopsy Samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected or confirmed esophageal cancer|January 2016|January 22, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02495337||17281|
NCT02495584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NI/0091|D-Light Intervention|D-Light Intervention: A Randomised Controlled Human Intervention Study to Assess the Impact of Vitamin D From Milk and Supplements on Functional Health Outcomes and Future Vitamin D Synthesis From UV Exposure|D-Light|University of Ulster|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|52|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02495584||17262|
NCT02250482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF02|An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.|An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.||Bio Products Laboratory||Completed|November 2001|||August 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|12 Years|N/A|No|||August 2014|September 24, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02250482||36070|
NCT02251509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|624918|Rate Control in Atrial Fibrillation|Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate||Creighton University|No|Not yet recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|No|||November 2015|November 27, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251509||35991|
NCT02242188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fe in BF|Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants.|Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial.||Medical University of Warsaw|No|Recruiting|September 2015|June 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|220|||Both|16 Weeks|18 Weeks|Accepts Healthy Volunteers|||January 2016|January 15, 2016|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242188||36708|
NCT02499640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51903/2012|The Effects of Cold Water Immersion With Different Dosages (Duration and Temperature Variations) on Heart Rate Variability Post-exercise Recovery|The Effects of Cold Water Immersion With Different Dosages (Duration and Temperature Variations) on Heart Rate Variability Post-exercise Recovery||Paulista University|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|100|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499640||16951|
NCT02503800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC150100-15CTIL|The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy|The Significance of Blood-tryptase Levels and c-Kit Mutation in the Evaluation of Prognosis and Adverse Reactions in Subjects Undergoing Venom Immunotherapy for Insect Allergy||Meir Medical Center|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Biospecimen will include 5 ml of venous whole blood drawn for measurement of serum tryptase      and leukocyte c-Kit mutation.|Both|4 Years|75 Years|No|Non-Probability Sample|The population will include all the subjects undergoing venom immunotherapy at the Clinic        of Allergy and Clinical Immunology, Meir Medical Center.|July 2015|July 20, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503800||16631|
NCT02504034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORNO3HSYSU|Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein|Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein||Sun Yat-sen University||Recruiting|October 2010|||December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|1 Year|80 Years|No|||July 2015|July 20, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02504034||16613|
NCT02253966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-089|Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty|||Rigshospitalet, Denmark|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|50 Years|80 Years|No|||March 2016|March 8, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253966||35802|
NCT02255760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5470C00002|Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults|A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI3902 in Healthy Adults||MedImmune LLC|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255760||35664|
NCT02241044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS98-CT8-13|Argon Plasma Coagulation for Bleeding Peptic Ulcers|Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan||Kaohsiung Veterans General Hospital.|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|20 Years|N/A|No|||September 2014|September 13, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241044||36796|
NCT02241057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014011|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|A Randomized, Open-Label Study to Evaluate the Temperature Profile and Adhesion of an Air-Activated Adhesive-Backed Heat Patch in Healthy Volunteers||Chattem, Inc.|Yes|Terminated|September 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241057||36795|
NCT02504489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-2358-103|Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion|Randomized Phase 3 Assessment of Second Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel Alone in Patients With Advanced Non-Small Cell Lung Cancer With at Least 1 Large Lung Lesion||BeyondSpring Pharmaceuticals Inc.|Yes|Recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504489||16578|
NCT02504502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0594|Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients|Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients||Geisinger Clinic|No|Enrolling by invitation|August 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|N/A|21 Years|No|||July 2015|July 20, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02504502||16577|
NCT02499224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV110501-101|Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy|A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy||National OncoVenture|Yes|Recruiting|June 2015|September 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|19 Years|N/A|No|||March 2016|March 21, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499224||16983|
NCT02503163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1303|A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||April 2018|Anticipated|Phase 3|Interventional|N/A|1||||||Both|20 Years|N/A||||July 2015|July 17, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503163||16680|
NCT02503176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1302|An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||April 2018|Anticipated|Phase 3|Interventional|N/A|1||||||Both|20 Years|N/A||||July 2015|July 17, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503176||16679|
NCT02241278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK334037|Preoperative Ketamine Has no Preemptive Analgesic Effect in Patients Undergoing Colon Surgery.|Preoperative Low-dose Ketamine Has no Preemptive Analgesic Effect in Opioid-naïve Patients Undergoing Colon Surgery When Nitrous Oxide is Used||Hospital Arquitecto Marcide|No|Completed|September 2001|June 2002|Actual|June 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|75 Years|No|||September 2014|September 15, 2014|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241278||36778|
NCT02250287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000866|New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease|Pilot and Feasibility Study: Evaluation of New Quantitative Magnetic Resonance Imaging Parameters in Assessing the Kidneys of Autosomal Dominant Polycystic Kidney Disease|MRI Pilot|Mayo Clinic|No|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ten known ADPKD patients between the ages of 18-30, and 10 normal non-ADPKD volunteers        between the ages of 18-30, who are MRI compatible will be studied. Study participants will        be selected from a list queried from the Polycystic Kidney Disease database.|November 2015|November 5, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250287||36085|
NCT02494453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.151|Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy|Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy||University of Michigan Cancer Center|Yes|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However,      the investigators have identified potential candidates based on other processes affecting      heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis      and left ventricular dysfunction, these include galectin-3 and N- terminal-Pro brain      natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative      stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15.      Additional blood will be collected and stored for future assessment of other candidate      biomarkers.|Both|18 Years|N/A|No|Probability Sample|Patients receiving radiotherapy for treatment of left-sided breast cancer.|July 2015|July 9, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02494453||17349|
NCT02494466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK6|Preoperative Use of Montelukast Sodium|The Effects on Airway Reactivity of the Use of Preoperative Montelukast Sodium||Umraniye Education and Research Hospital|No|Completed|May 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|30|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02494466||17348|
NCT02495103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150157|Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma|Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|May 2022|Anticipated|May 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|73|||Both|18 Years|100 Years|No|||June 2015|January 8, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495103||17299|
NCT02495116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCS-101-NSTR|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||December 1, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495116||17298|
NCT02257788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210001606|PRO 140 for Human Immunodeficiency Virus Infection|PRO 140 2103: A Phase 2a, Randomized Study of PRO 140 by Subcutaneous Injection in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection||Drexel University|Yes|Withdrawn|September 2014|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|October 2, 2014|Yes|Yes|Unlikely to achieve targeted accrual|No||https://clinicaltrials.gov/show/NCT02257788||35511|
NCT02257827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMEMA-0913|Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule|Randomized Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule.||Marilia Medicine School|Yes|Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Male|18 Years|75 Years|No|||October 2014|October 3, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02257827||35508|
NCT02241915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00471|Use of a Microbial Sealant to Reduce Surgical Site Infections.|Microbial Sealants Do Not Decrease Surgical Site Infection for Clean Contaminated Colorectal Procedures.|Integuseal|University of Southern California|No|Completed|January 2011|||May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 13, 2014|September 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241915||36729|
NCT02241928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-14|Stem Cell Therapy in Muscular Dystrophy|Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy||Neurogen Brain and Spine Institute|Yes|Recruiting|January 2009|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|6 Months|60 Years|No|||September 2014|September 15, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241928||36728|
NCT02502500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0019|Effect of AKB-6548 on the Pharmacokinetics of Celecoxib|An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib||Akebia Therapeutics|No|Completed|July 2015|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502500||16731|
NCT02499705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100FRI_AFS_pediatric|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents||Yale University|Yes|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|45|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02499705||16946|
NCT02257892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140206|Novel Genetic Disorders of the Immune System|Novel Genetic Disorders of the Immune System||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|August 2025|Anticipated|August 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02257892||35504|
NCT02247024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1226|Pupil Response in Patients on Opioids.|Dynamic Assessment of Pupillary Reflex in Patients on High-dose Opioids|Pupillometry|Oslo University Hospital|No|Not yet recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Cancer pain on high-dose opioids; i.e. more than 60 morphine equivalents pr day|September 2014|September 19, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247024||36336|
NCT02502604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0416|Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder|Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|September 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|60 Years|No|||July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502604||16723|
NCT02254200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C301|Exercise Training and Fitness in Severe Obesity|Effect of Short-term High-intensity Interval and Fatmax Training on Aerobic and Metabolic Fitness in Obese Subjects|INTFMOBE|Istituto Auxologico Italiano|Yes|Completed|January 2013|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254200||35784|
NCT02254213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-CT-003|Intra-individual Stability in Electroencephalography (EEG) Parameters|Intra-individual Stability in EEG Parameters||Mentis Cura|No|Completed|June 2005|August 2007|Actual|August 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|15 individuals in the age range of 50 - 90 years.|September 2014|September 29, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254213||35783|
NCT02254226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.8|Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers|A Randomised, Open-label Four-way Crossover Study to Evaluate Pharmacokinetics of Salmeterol (Serevent®) After Inhalation of a 25 μg and 50 μg Single Dose (Metered Dose Inhaler) and a 50 μg and 100 μg Single Dose (Diskus®) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|November 2004|||January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 29, 2014||||No||https://clinicaltrials.gov/show/NCT02254226||35782|
NCT02245724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-15|Stem Cell Therapy in Mental Retardation|||Neurogen Brain and Spine Institute|Yes|Recruiting|September 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|6 Months|40 Years|No|||September 2014|September 17, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245724||36436|
NCT02245971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0380|A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum|||Yonsei University|No|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|19 Years|N/A|No|||July 2014|September 19, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02245971||36417|
NCT02498613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01097|Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors||National Cancer Institute (NCI)||Not yet recruiting|January 2016|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|121|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498613||17030|
NCT02503189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1301|A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||June 2017|Anticipated|Phase 3|Interventional|N/A|2||||||Both|20 Years|N/A||||July 2015|July 17, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503189||16678|
NCT02503813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504-15|Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?|Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?||MemorialCare Health System|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|N/A|No|||July 2015|July 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503813||16630|
NCT02246166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202271|The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.|A Double-Blind, Randomised, Placebo-Controlled, Parallelgroup, Single-Dose Study to Evaluate Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza Over a 4 Hour Period||GlaxoSmithKline|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246166||36402|
NCT02256787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201.1|Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 120 mg, 200 mg, 300 mg, 600 mg, 1000 mg, 1500 mg, 2000 mg, 2400 mg, and 3000 mg BILB 1941 ZW (PEG 400/TRIS Solution) in Healthy Male Subjects, in a Randomised Double Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Three-Way Crossover Bioavailability Comparison of 600 mg BILB 1941 ZW in a PEG 400/TRIS Solution and 600 mg BILB 1941 ZW Tablet and 600 mg BILB 1941 ZW Tablet Administered With Food||Boehringer Ingelheim||Completed|January 2004|||September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|56|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256787||35586|
NCT02256800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-20130020|Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting|||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|June 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|320|||Both|20 Years|80 Years|No|||May 2013|October 3, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02256800||35585|
NCT02498860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHH-2015-7|Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung|Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase Ⅱ Trial|APICAL|Chonnam National University Hospital|No|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|20 Years|N/A|No|||July 2015|July 19, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498860||17011|
NCT02499146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481019|Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer|A Phase 1 Open-Label Pharmacokinetics Study Of Palbociclib, A Cyclin-dependent Kinase 4 And 6 (CDK4/6) Inhibitor, In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer||Pfizer|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Female|18 Years|65 Years|No|||March 2016|March 3, 2016|July 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499146||16989|
NCT02499458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105484|Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer|Prospective Validation of Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) as Prognostic Biomarkers in Clear Cell Renal Cancer||Lawson Health Research Institute|Yes|Recruiting|November 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Oncology care centre|July 2015|March 1, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02499458||16965|
NCT02497911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002109|A Trial Comparing Adductor Canal Catheter and Intraarticular Catheter Following Primary Total Knee Arthroplasty|A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty||Thomas Jefferson University|Yes|Enrolling by invitation|January 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|40 Years|85 Years|No|||October 2015|October 22, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497911||17084|
NCT02248597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97214|Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases|Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02248597||36215|
NCT02248610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST registry|Follow-up in Rivaroxaban Patients in Setting of Thromboembolism|Follow-up in Rivaroxaban Patients in Setting of Thromboembolism|FIRST|King's College Hospital NHS Trust|Yes|Recruiting|November 2014|November 2019|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients aged 18-99 years with acute DVT or PE treated with rivaroxaban, patients will        have not recieved bridging anticoagulation|August 2015|September 3, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02248610|5 Years|36214|
NCT02243735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50013.018.14|Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia|Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients|FIT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243735||36589|
NCT02503982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-14-RMC|Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients|Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study||Rabin Medical Center|No|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|N/A|20 Years|No|||June 2015|July 20, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02503982||16617|
NCT02504372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-091|Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)|A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)|PEARLS|Merck Sharp & Dohme Corp.|Yes|Recruiting|November 2015|April 2024|Anticipated|April 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1380|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504372||16587|
NCT02499250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZKY-PJ-2014-1-A|Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients|Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients and the Mechanism|D-RIC-RAP|Navy General Hospital, Beijing|No|Recruiting|January 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02499250||16981|
NCT02257671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020824-23|Oral Contraceptives and Economic Behaviour|The Influence of Oral Contraceptives on Mood, Sexuality and Economic Behavior|P-piller101|Karolinska University Hospital|No|Recruiting|February 2012|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|September 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257671||35520|
NCT02257684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-011|A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)|A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)||Jazz Pharmaceuticals||Terminated|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|1 Year|21 Years|No|||February 2015|January 6, 2016|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257684||35519|
NCT02257697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-69-C-Ne-302|A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome|A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome||Asahi Kasei Pharma Corporation|No|Recruiting|November 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257697||35518|
NCT02499393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolishMMHRI|Hypothermia Enhanced by Magnesium Sulphate|Comparison of Two Method of Therapeutic Hypothermia Enhanced by Magnesium Sulphate in Neonatal Encephalopathy|Hemen|Polish Mother Memorial Hospital Research Institute|No|Completed|April 2010|December 2014|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|6 Hours|No|||July 2015|July 15, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499393||16970|
NCT02499614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoRT 01/2014|Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)|Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)|METROS|Fondazione Ricerca Traslazionale|Yes|Recruiting|December 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02499614||16953|
NCT02500199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHRUS 1001|Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy|A Two-part Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients Whose Disease Progressed on Prior HER2 Targeted Therapy||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500199||16908|
NCT02246387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/2093/REK|Follow-up Study After Manchester Operation for Pelvic Organ Prolapse|Does the Manchester Operation for Pelvic Organ Prolapse Give Sufficient Apical Fixation?|MAP-POP|Oslo University Hospital|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Female|18 Years|N/A|No|Non-Probability Sample|Women referred to out outpatient clinic for surgery for pelvic organ prolapse.|September 2014|April 24, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02246387||36385|
NCT02246647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002382|Biomarkers for Intestinal Permeability in Patients With Constipation|Biomarkers for Intestinal Permeability in Patients With Functional Lower Gastrointestinal Disorders Associated With Constipation.||Mayo Clinic|No|Recruiting|September 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|36|Samples With DNA|Colonic Biopsies Duodenal Biopsies Duodenal Aspirate Blood Urine Fecal|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|IBS-Constipation cases and healthy volunteers|January 2016|January 12, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246647||36365|
NCT02252328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0172|Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients|Can Simvastatin Significantly Reduce the Amount of Immunosuppressive Medication Required by Patients With Sight Threatening Uveitis? A Phase 2b, Single Site, Randomized, Placebo Controlled, Double Blinded Trial.||University College, London|Yes|Recruiting|September 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252328||35928|
NCT02254785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-054|Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer|A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer||British Columbia Cancer Agency|No|Recruiting|October 2014|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|No|||November 2015|February 25, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02254785||35739|
NCT02256930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US07|Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers|A Phase 1, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Sensitizing Potential of M518101 in Healthy Volunteers Using a Repeat Insult Patch Test Design||Maruho North America Inc.|No|Completed|September 2014|August 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02256930||35575|
NCT02506075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-03-2015-005|A Study of tDCS for Unilateral Neglect in Stroke Patients|Effectiveness of Transcranial Direct Current Stimulation for Unilateral Neglect After Stroke||Pusan National University School of Medicine|No|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|80 Years|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506075||16456|
NCT02495142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK084979-06|Psychosocial Issues and Bariatric Surgery|Psychosocial Issues and Bariatric Surgery|LABS3|Neuropsychiatric Research Institute, Fargo, North Dakota|Yes|Active, not recruiting|July 2010|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|202|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be approached for inclusion into LABS1 and LABS2 at the Sanford Surgery        Department, Fargo ND, at the University of Pittsburgh Medical Center and at        Cornell/Columbia Medical Center in New York. LABS3 Psychosocial participants will be        selected from those individuals participating in LABS1 and LABS2.|July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02495142||17296|
NCT02254863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050198|UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells|Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells|DUOC-01|Duke University|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|22 Years|No|||February 2016|February 4, 2016|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02254863||35733|
NCT02244047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-BIF|Cytokine Profile in Children With Celiac Disease|Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease||University Clinical Centre, Maribor|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|66|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02244047||36565|
NCT02495792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404239-2|Using Real Time Biofeedback to Alter Running Mechanics|Using Real Time Biofeedback to Alter Running Biomechanics||Keller Army Community Hospital|No|Active, not recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|192|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02495792||17246|
NCT02495805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhu62015|Ultrasound-guided Continuous Proximal Adductor Canal vs Continuous Femoral Nerve Block for Postoperative Pain Control and Rehabilitation Following Total Knee Arthroplasty|Ultrasound-guided Continuous Proximal Adductor Canal Versus Continuous Femoral Nerve Block for Postoperative Pain Control and Rehabilitation Following Total Knee Arthroplasty||Yale University|Yes|Not yet recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 8, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02495805||17245|
NCT02498197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA11|Participatory Intervention Among Construction Workers (IRMA11)|Deltagerinvolverende Intervention Mod Fysiske Risikofaktorer for Muskel- og skeletbesvær i Byggebranchen|IRMA11|National Research Centre for the Working Environment, Denmark|No|Recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02498197||17062|
NCT02498210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1604-EM-CTIL|IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle?|IVM Treatment in Patients With Low Ovarian Response. Does it Improve IVF Outcome or May it Cause Activation of Ovarian Follicles and Increase the Chances of Success in the Following IVF Cycle?||Sheba Medical Center|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02498210||17061|
NCT02254265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-101-2014-001|Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca||Ocular Technologies SARL|No|Active, not recruiting|September 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|420|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254265||35779|
NCT02254317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-074|Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance|Dose-dependent Effect of Grape Seed Extract (GSE) on Glucose Control in People With Impaired Glucose Tolerance|GSE3|Institute for Food Safety and Health, United States|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|20|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254317||35775|
NCT02247895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062014|Treatment of Muscle Weakness in Critically Ill Patients|Effect of Treatment With the Niveus Medical Muscle Stimulation System 110 on Quadriceps Strength In Mechanically Ventilated Patients||University of Kentucky|Yes|Recruiting|May 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02247895||36269|
NCT02509923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-215-02|To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects|A Randomized, Open-label, Crossover, Pharmacokinetic and Pharmacodynamic Study of Z-215 Compared With Rabeprazole Sodium in Healthy Male Subjects||Zeria Pharmaceutical|No|Recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02509923||16161|
NCT02499497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-120|A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer|A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|July 2015|November 2022|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|350|||Male|19 Years|N/A|No|||July 2015|July 15, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499497||16962|
NCT02243410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBK01|Visual Analogue Scale - a Quality Assurance Study|Visual Analogue Scale (VAS) - a Quality Assurance Research Study to Assess the Quality of the VAS as a Means for Measuring Postoperative Pain.||Herlev Hospital|No|Completed|March 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All participants will be postoperative patients of Department of Surgery, Department of        Gynecology and Department of Orthopaedic Surgery, all based at Herlev Hospital.|September 2014|September 15, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02243410||36614|
NCT02248116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.208|Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type|An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type||Boehringer Ingelheim||Terminated|May 1999|||September 2000|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|198|||Both|N/A|N/A|No|||September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248116||36252|
NCT02502721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWJ1373001|A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152|A Randomized, Open-labeled, Oral Dose, Crossover Design Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152 in Healthy Male Subjects||Daewoong Pharmaceutical Co. LTD.|No|Completed|June 2015|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02502721||16714|
NCT02502890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-29|Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy|Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 1 (ICAC-29)|MUPPITS|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood, Nasal Samples.|Both|6 Years|17 Years|No|Probability Sample|The MUPPITS study will enroll inner-city children 6-17 years of age with        difficult-to-control, exacerbation-prone asthma. Approximately 150 children will be        enrolled and followed prospectively.|January 2016|January 19, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502890||16701|
NCT02503787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1675|OPTIONS Spinal Cord Stimulation Programming Parameters|A Prospective, Multi-center, Open-label Study of Programming Options in Spinal Cord Stimulation.||MedtronicNeuro|No|Active, not recruiting|July 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02503787||16632|
NCT02251496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-141316051|COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.|Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks, Weight Changes and Functional Capacity in Chronic Obstructive Pulmonary Disease; Randomized Controlled Dietary Intervention|COPD|University of Iceland|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251496||35992|
NCT02243657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0002|A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3652 in Healthy Young and Elderly Male and Female Subjects||Astellas Pharma Inc|No|Completed|May 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 16, 2014|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02243657||36595|
NCT02242825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.505|Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus|Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II||Boehringer Ingelheim||Completed|January 2006|||October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8148|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hypertension and diabetes mellitus recruited by cardiologists, nephrologists        or diabetologists|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242825||36659|
NCT02242838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.500|Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension|Post-Marketing Surveillance of Micardis® (Telmisartan) Special Drug Use-results Survey on Long-term Treatment||Boehringer Ingelheim||Completed|September 2003|||September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6336|||Both|N/A|N/A|No|Non-Probability Sample|Hypertension patients without telmisartan treatment are selected at medical institutions|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242838||36658|
NCT02499913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-177-1|Contingency Management to Reduce Alcohol Use in a Soup Kitchen Sample||SK|University of Connecticut Health Center|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499913||16930|
NCT02495363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-15|Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients|||Rabin Medical Center|No|Not yet recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|No|||June 2015|July 8, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02495363||17279|
NCT02243943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34186.058.10|Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile|Effect of Neuromuscular Blockade Reversal With Sugammadex on Oxygenation, Pain and Arousal States in the Post Anesthesia Care Unit|Neuropa|Leiden University Medical Center|No|Recruiting|September 2014|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02243943||36573|
NCT02243956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-2013/619|Effects on Cognitive Functions and Mood of Food Products Rich in Polyphenols|Food Design for Improved Cognitive Performance/Effects on Cognitive Functions and Mood of Food Products Rich in Polyphenols||Lund University|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02243956||36572|
NCT02502123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-CAN-NEU-0336|Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®||PREDICT|Allergan|No|Recruiting|July 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic migraine treated with BOTOX® as standard of care.|January 2016|January 27, 2016|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02502123||16760|
NCT02502136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-4160A3|Efficacy and Safety of Carbon Dioxide Insufflation During Endoscopy|The Assessment of Differences in Clinical Safety and Efficacy of Carbon Dioxide Insufflation During Sedated and Conventional Endoscopy||Chang Gung Memorial Hospital|Yes|Completed|April 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|8||Actual|640|||Both|20 Years|80 Years|No|||April 2015|July 16, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02502136||16759|
NCT02500186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kanden-hsp-0001|The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor|The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor||Kansai Electric Power Hospital|No|Active, not recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|20 Years|64 Years|No|||June 2015|July 17, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02500186||16909|
NCT02500446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIORR_20150306|Dolutegravir Impact on Residual Replication|Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study|DIORR|University of Melbourne|No|Recruiting|August 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02500446||16889|
NCT02498444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33852|Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation|Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation||Stanford University|Yes|Not yet recruiting|September 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|1 Year|18 Years|No|||July 2015|July 14, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498444||17043|
NCT02258126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/01335|Effect of Exercise on Hepatic Fat in Overweight Children|The Effect of Exercise on Hepatic Fat in Overweight Children; the EFIGRO Study|EFIGRO|Basque Country University|No|Recruiting|November 2014|June 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|9 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258126||35486|
NCT02258139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||October 17, 2014|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258139||35485|
NCT02257125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-LU 13079|ArmeoSenso - Reward|ArmeoSenso - Rewarding vs. Non-rewarding Therapy of Patients With Arm Impairments Based on Wearable Movement Sensors||Cereneo AG|No|Recruiting|December 2014|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02257125||35561|
NCT02496065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-005|Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery|A Phase 1 Exploratory Study of the Safety and ex Vivo Fluorescence of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Solid Tumors Undergoing Surgery||Blaze Bioscience Inc.|Yes|Recruiting|July 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496065||17225|
NCT02499744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangdongWCHHI|Humidified High Flow Nasal Cannula Versus Nasal Intermittent Positive Ventilation in Neonates|Humidified High Flow Nasal Cannula Versus Nasal Intermittent Positive Ventilation in Neonates as Primary Respiratory Support:a Randomized Controlled Trial||Guangdong Women and Children's Hospital and Health Institute|Yes|Active, not recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|28 Days|No|||February 2016|February 22, 2016|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02499744||16943|
NCT02248129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.508|Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide|Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated in General Practice With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide, the Level of Blood Pressure Control and the Modalities of Arterial Hypertension Management||Boehringer Ingelheim||Completed|April 2006|||December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4255|||Both|N/A|N/A|No|Non-Probability Sample|Hypertensive patients treated in general practice|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248129||36251|
NCT02248142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.623|Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)|Sifrol® (Pramipexole) Impact on RLS: A 12-weeks Observational Study in Patients With Primary RLS||Boehringer Ingelheim||Completed|February 2006|||January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1029|||Both|N/A|N/A||Non-Probability Sample|Patients suffering from moderate to severe RLS recruited at office-based neurologists|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248142||36250|
NCT02505815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Neurocognitive Function After Regional and General Anesthesia (245_14 B)|Neurocognitive Function After Regional and General Anesthesia: a Randomized Control Trial|245_14_B|University of Erlangen-Nürnberg Medical School|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients recruted at the University Hospital Erlangen prior surgery. Anesthesia procedure        eigther in regional or general manner.|July 2015|July 20, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02505815||16476|
NCT02510612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150618|Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism|Perioperative Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism|dadpgm|Shaanxi Provincial People's Hospital|No|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|60 Years|No|||July 2015|July 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02510612||16108|
NCT02510625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-035|The Arthroscopic Treatment of Recurrent Anterior Shoulder Instability|The Arthroscopic Treatment of Recurrent Anterior Shoulder Instability: A Randomized Controlled Trial|ATRASI|Nova Scotia Health Authority|Yes|Not yet recruiting|September 2015|September 2022|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510625||16107|
NCT02243033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMI-LITT-001|Laser Interstitial Thermal Therapy of Prostate Cancer|A Pilot Study to Evaluate Magnetic Resonance Thermal Image-guided Laser-Induced Interstitial Thermal Therapy for Focal Ablation of Prostate Cancer||Desert Medical Imaging|No|Recruiting|December 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|45 Years|90 Years|No|Non-Probability Sample|Men with prostate cancer|August 2015|August 14, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02243033||36643|
NCT02248376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 130911|Hyaluronic Acid and Uterine Synechiae|Non-stick Gel Applicated After Scraping Surgery for Natural Miscarriage and Uterine Synechiae Prevention|HYFACO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|May 2018|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|N/A|No|||November 2015|November 19, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248376||36232|
NCT02256735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.22|Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers|A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|August 2005|||December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|39|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256735||35590|
NCT02247310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17591|BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon|BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®||Bayer|No|Active, not recruiting|October 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|N/A|N/A|No|Probability Sample|The study population will consist of patients with relapsing remitting multiple sclerosis        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with        Betaferon or will be treated with Betaferon® according to the attending physician's        decision and for whom the patient and the physician have agreed to use the BETACONNECT        device.        The study will be conducted in neurological centers and neurology departments specialized        in the treatment of Multiple Sclerosis patients.|January 2016|January 25, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247310||36314|
NCT02503501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-INSUL-MCI-AD|Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease|A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease||HealthPartners Institute|Yes|Recruiting|August 2015|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|50 Years|90 Years|No|||November 2015|November 30, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503501||16654|
NCT02495610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0423|Novel Parameters for the Prediction of Ventriculoperitoneal Shunting Efficacy in Patients With iNPH|A Prospective Single-centre Trial Investigating Novel Parameters for the Prediction of Ventriculoperitoneal Shunting Efficacy in Patients With Idiopathic Normal Pressure Hydrocephalus|iNPH|University of Zurich|No|Recruiting|June 2015|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|50 Years|85 Years|No|||July 2015|July 21, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02495610||17260|
NCT02254174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.11|Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers|A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler®2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®], a Single Dose of 50μg Salmeterol (Serevent® Diskus®) and a Single Dose of 18 μg Tiotropium (Spiriva® HandiHaler®) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|March 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 29, 2014||||No||https://clinicaltrials.gov/show/NCT02254174||35786|
NCT02254187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.17|Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers|A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE Capsule for HandiHaler®2) and a 50 μg Single Dose (Serevent® Diskus®) in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2005|||October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 29, 2014||||No||https://clinicaltrials.gov/show/NCT02254187||35785|
NCT02504398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31803|Speed of Injection and Pain During Routine Infant Vaccinations|A Randomized Controlled Trial of Injection Technique for Infant Vaccination||University of Toronto|No|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Months|7 Months|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504398||16585|
NCT02503995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WA/0081|Exercise in Pregnancy Evaluative Controlled Study|Influence of Regular Antenatal Physical Exercise on Cardiovascular, Haemodynamic and Autonomic Nervous System (CHANS) Function During and After Pregnancy|EXPECT|Swansea University|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|90|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02503995||16616|
NCT02498457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1stChongqingMU snkxia1|The Effects and Safety of Low Calcium Dialysis on Coronary Artery Calcification in Maintenance Hemodialysis Patients|The First Affiliated Hospital of Chongqing Medical University||First Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|September 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498457||17042|
NCT02246140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5715|Intracranial Arterial Stenosis and Resin of Cannabis Use|Prevalence of Intracranial Arterial Stenosis in Regular Resin of Cannabis Users Compared to Control Subjects: a Preliminary Study of Feasibility||University Hospital, Strasbourg, France|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246140||36404|
NCT02500940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF15113A|Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma|||Taichung Veterans General Hospital||Recruiting|May 2015|May 2021|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|20 Years|N/A|No|||July 2015|July 14, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500940||16851|
NCT02251353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMET|Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients|Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients: Prospective, Observational, Multi-institutional Registration Study - IMET|IMET|Federation of Breast Diseases Societies|Yes|Recruiting|June 2014|June 2022|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Probability Sample|Breast cancer patients: 1) who present primary tumor with lung and/or hepatic metastases;        2) those with residual lung and/or hepatic metastases after systemic therapy; and 3) those        with relapsed lung and/or hepatic metastases after curative locoregional therapy.|September 2014|March 5, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251353|5 Years|36003|
NCT02251366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00088759|NVAMD Satellite Study|A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy||Johns Hopkins University|Yes|Recruiting|October 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|September 7, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02251366||36002|
NCT02254902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-MRSG-13-069|Physical Activity and Education Program for Somali Women|Physical Activity and Education to Reduce Cancer Risk Among Somali Women (Ladnaan Project)||University of California, San Diego|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254902||35730|
NCT02496273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZYY-CTL-001|Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer|Phase 1 Study of CEA Specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer||The First People's Hospital of Changzhou|No|Active, not recruiting|January 2016|December 2030|Anticipated|December 2026|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496273||17209|
NCT02496858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-CV-2015|Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults|Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults|GRAND|Shanghai Zhongshan Hospital|Yes|Not yet recruiting|August 2015|August 2019|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples With DNA|2 samples of EDTA blood (2ml glass) and 1 sample of serum (2ml glass) will be retained in a      biobank.|Both|18 Years|44 Years|No|Probability Sample|Patients aged < 45 years diagnosed with CAD by coronary angiography will be collected from        multiple institutions.|July 2015|July 9, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496858||17164|
NCT02256748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.9|Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers|A Study to Evaluate the Effect of Multiple Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers||Boehringer Ingelheim||Completed|June 2005|||August 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256748||35589|
NCT02256761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.2|Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers|Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses of 100 mg to 750 mg qd for 14 or 28 Days (Randomised, Double-blind Placebo Controlled Design), and Safety and Pharmacokinetics of 500 mg of BIRT 2584 XX Administered With and Without Food as Single Dose (Open, Intra-individual Comparison) to Healthy Male Volunteers||Boehringer Ingelheim||Completed|January 2005|||July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|74|||Male|18 Years|63 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256761||35588|
NCT02256969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-059H|Intraductal Meibomian Gland Probing Trial|Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction|MGP|Massachusetts Eye and Ear Infirmary|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|89 Years|No|||October 2014|November 3, 2015|August 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256969||35572|
NCT02509806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-G309|Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer|||Hebei Medical University|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||January 2016|February 2, 2016|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02509806||16170|
NCT02509819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2015.017d|The Influence of Heel Wedge Properties on Roll-over of the Intrepid Dynamic Exoskeletal Orthosis (IDEO)|The Influence of Heel Wedge Properties on Roll-over of the Intrepid Dynamic Exoskeletal Orthosis (IDEO)||Brooke Army Medical Center|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02509819||16169|
NCT02495883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131202|Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response|Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response||University of California, San Diego|No|Active, not recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|64|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02495883||17239|
NCT02255435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1402|RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe|A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)||Reata Pharmaceuticals, Inc.|Yes|Recruiting|January 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|56|||Both|16 Years|40 Years|No|||March 2016|March 22, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255435||35689|
NCT02495272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kanuni-Bagcilar|Postpartum Uterotonic Administration|The Effect of the Timing of Uterotonic Administration in the Third Stage of Labour on Postpartum Hemorrhage||Bagcilar Training and Research Hospital|No|Recruiting|June 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|330|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02495272||17286|
NCT02510235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUB0114MD|Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye|A Multicenter, Randomized, Double-masked, Controlled, Non-inferiority Study to Evaluate Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops Administered Four Times a Day for 4 Weeks and 1 Week Follow-up in Subjects With Moderate Dry Eye||Dompé Farmaceutici S.p.A|No|Completed|March 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510235||16137|
NCT02510248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-704-701|First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-part Study of Orally Administered JNJ-54257099 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1) and Food-effect (Part 2) in Healthy Subjects, and Multiple Doses in Subjects With Chronic Hepatitis C Infection (Part 3)||Alios Biopharma Inc.|No|Terminated|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02510248||16136|
NCT02510261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-006|The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)|A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study||Alnylam Pharmaceuticals|No|Enrolling by invitation|July 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|228|||Both|18 Years|85 Years|No|||March 2016|March 23, 2016|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510261||16135|
NCT02250443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2205E1|Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|BYM338|Novartis||Active, not recruiting|March 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|40 Years|75 Years|No|||February 2016|February 3, 2016|March 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250443||36073|
NCT02250456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5545|AVAST Anomalies Vasculaires Associées au Syndrome de Turner (Vascular Abnormalities Associated With Turner Syndrome)|Detect, Monitor and Prevent Vascular Abnormalities Associated With Turner Syndrome|AVAST|University Hospital, Strasbourg, France|No|Recruiting|July 2013|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|Samples Without DNA|Blood|Female|18 Years|N/A|No|Non-Probability Sample|All patient with Turner Syndrome.|November 2015|November 6, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250456||36072|
NCT02245321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL10580901|Strategies to Reduce Iron Deficiency|Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors|STRIDE|Westat|Yes|Completed|June 2011|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|702|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02245321||36467|
NCT02245334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1403/243-004|A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy|A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy||Seoul National University Hospital|No|Not yet recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1578|||Male|18 Years|N/A|No|||September 2014|September 18, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02245334||36466|
NCT02258204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETA|Ketamine for Thrombolysis in Acute Ischemic Stroke|Effets de la kétamine en Association Avec le Rt-PA au Cours de l'Infarctus cérébral Aigu: étude Pilote contrôlée randomisée en Double Aveugle Avec critère de Jugement Radiologique|KETA|University Hospital, Caen|Yes|Recruiting|March 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||February 2016|February 23, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258204||35480|
NCT02244385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NW/0426|Manchester Antenatal Vascular Service|Manchester Antenatal Vascular Service|MAViS|Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples Without DNA|Whole blood sample Urine sample|Female|N/A|N/A|No|Non-Probability Sample|Women will be approached about the study in a dedicated clinic run within the Maternal &        Fetal Health Research Centre.|February 2016|February 13, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244385||36539|
NCT02504463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-B107|A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers|A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of Single Doses of [14c]-Samidorphan in Healthy Male Subjects||Alkermes, Inc.|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504463||16580|
NCT02256358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-127|Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation|Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation : a Randomized Controlled Trial||Inje University|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|68|||Both|2 Years|6 Years|No|||October 2014|October 9, 2014|October 1, 2014||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT02256358||35619|We did not include a placebo group.
NCT02242695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flu-380112|Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis|Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis||Medinova AG|No|Recruiting|November 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|45 Years|No|||July 2015|July 6, 2015|October 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02242695||36669|
NCT02243423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1851|Neonatal Acid-Base Status After C Section With Maternal Tilt vs. Supine|Neonatal Acid-base Status After Elective Cesarean Delivery Under Spinal Anesthesia - a Comparison of Maternal Supine Horizontal Position Versus Left Lateral Table Tilt||Columbia University|Yes|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02243423||36613|
NCT02243436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRESHAP-GELTAMO.LH-2013|Evaluation Study of Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory HL|Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Recruiting|November 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02243436||36612|
NCT02500693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-08|Circulating Tumor Cells in Lung Cancer Screening|Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease|AIR|Centre Hospitalier Universitaire de Nice|Yes|Recruiting|November 2015|December 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|55 Years|N/A|No|||March 2016|March 3, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500693||16870|
NCT02500966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BarretosCH - DUDA|How to Avoid Cervical Stenosis After LEEP in High Grade Cervical Dysplasia?|A Randomized Study to Evaluate the Safety, Efficacy and Quality of Life of a New Device to Prevent Cervical Stenosis After LEEP in High Grade Cervical Dysplasia|DUDA|Barretos Cancer Hospital|Yes|Recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|265|||Female|18 Years|65 Years|No|||August 2015|August 21, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500966||16849|
NCT02509247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T200/2013|Telemonitoring in CPAP Treatment|Telemonitoring in CPAP Treatment|TeleCPAP|Turku University Hospital|No|Completed|August 2012|March 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|90 Years|No|||July 2015|July 23, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02509247||16213|
NCT02258178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_36OB|Flucelvax Pregnancy Registry|Flucelvax Pregnancy Registry: an Observational Study on the Safety of Flucelvax Exposure in Pregnant Women and Their Offspring||Novartis||Recruiting|September 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 18 years or older within the US who were immunized with the Flucelvax        vaccine at any time during pregnancy.The registry will allow eligible pregnant women to        selfenroll and also allow HCPs to report de-identified data on pregnancy exposures and        outcomes|October 2015|October 23, 2015|September 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258178||35482|
NCT02495558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRGCA|Cough Assessment in Patients With Severe Acquired Brain Injury|Pilot Study of the Cough Reflex Assessment in Patients With Tracheostomy Cannula Following Severe Acquired Brain Injury||IRCCS San Camillo, Venezia, Italy|Yes|Recruiting|October 2015|July 2016|Anticipated|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|90 Years|No|||October 2015|October 13, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02495558||17264|
NCT02496117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9209|Renal Nerves Stimulation Study|Feasibility of Electrical Mapping and Stimulation of Renal Arteries in Patients Undergoing Renal Denervation|RNS|Diagram B.V.|No|Recruiting|May 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496117||17221|
NCT02252133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALJ-V2014-1|DAILIES TOTAL1® Lens Centration in a Japanese Population|Pilot Evaluation of DAILIES TOTAL1® Lens Centration in a Japanese Population||Alcon Research|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|53|||Both|20 Years|N/A|No|||November 2015|December 24, 2015|September 26, 2014|No|Yes||No|November 19, 2015|https://clinicaltrials.gov/show/NCT02252133||35943|
NCT02498847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00067979|Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis|Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis: A Pilot Study|ENGAGE|University of Michigan|No|Completed|March 2013|January 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498847||17012|
NCT02499107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRE_29695|The Effects of Carbohydrate Source on Food Intake, Blood Glucose and Gut Hormone Response in Healthy Children|The Effects of Potatoes and Other Carbohydrate Side Dishes Consumed With Meat on Food Intake, Glycaemia and Satiety Response in Children||University of Toronto|No|Recruiting|April 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|35|||Both|11 Years|13 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02499107||16992|
NCT02495818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Suprascapular Nerve Block|Suprascapular Nerve Block Guided by Ultrasound|Suprascapular Nerve Block Guided by Ultrasound in the Rehabilitation of the Supraspinatus Tendonitis - A Randomized Double Blind Controlled Trial||University of Sao Paulo|Yes|Recruiting|June 2013|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|30 Years|60 Years|No|||July 2015|July 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02495818||17244|
NCT02256280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-91/14|A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia|Decurarization After Thoracic Anesthesia - A Prospective Multicenter Double-blind Randomized Trial Comparing Sugammadex vs Neostigmine Reversal After Thoracic Anesthesia|DATA|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|January 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|266|||Both|18 Years|70 Years|No|||February 2016|February 24, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02256280||35625|
NCT02252367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-AOUC-2014-01|Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms Secondary to Prostatic Hyperplasia|Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil.||University of Florence|No|Recruiting|November 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Male|18 Years|N/A|No|||December 2015|December 1, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252367||35925|
NCT02502175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00220|Comparing Opium Tincture (OT) With Methadone for Substitution Treatment of Opioid Dependence|Comparison of Opium Tincture (OT) and Methadone for Maintenance Treatment of Opioid Dependence: A Randomized Double-blind Controlled Clinical Trial|OT-RCT|University of British Columbia|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|N/A|N/A|No|||July 2015|July 16, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502175||16756|
NCT02510300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1113|A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials|A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials||Gilead Sciences|No|Enrolling by invitation|October 2015|April 2023|Anticipated|April 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood samples|Both|3 Years|N/A|No|Non-Probability Sample|Individuals who participated in a Gilead-sponsored chronic hepatitis C study as an        adolescent or pediatric participant and received at least one Gilead HCV direct acting        antiviral (DAA)|March 2016|March 21, 2016|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510300|5 Years|16132|
NCT02252094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/TA/0015/2013|Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS|Ultra-protective Pulmonary Ventilation Supported by Low Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) and Prone Positioning for ARDS; a Pilot Study.|U-Protect|National University Health System, Singapore|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|90 Years|No|||August 2015|August 13, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02252094||35946|
NCT02247869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL - DDABVD|Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma|Dose-dense ABVD as First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma: a Phase II, Prospective, Multi-center Study||Fondazione Italiana Linfomi ONLUS|No|Recruiting|July 2011|April 2017|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|70 Years|No|||July 2013|September 19, 2014|March 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02247869||36271|
NCT02247882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTOA14|Effectiveness of Aquatic Physical Therapy for Knee Osteoarthritis Patients|Effectiveness of Health Education Compared to Aquatic Physical Therapy for Patients With Knee Osteoarthritis: a Randomized Clinical Trial|RCT-OA|Universidade Estadual de Londrina|Yes|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|85 Years|No|||May 2015|May 11, 2015|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02247882||36270|
NCT02503293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAN-06|A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push|A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push||Octapharma|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02503293||16670|
NCT02503306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVANAL07163|Efficacy and Tolerability Study of Avanafil in Russia|Clinical Trial on Efficacy and Tolerability of Two Different Single Doses of Avanafil in Russia|CEDAR|Sanofi|No|Completed|July 2015|March 2016|Actual|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|189|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503306||16669|
NCT02505308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF 172|Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes|Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes (DIabetes VAriants)|DIVA-Exeter|NIHR Exeter Clinical Research Facility|No|Recruiting|March 2015|January 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02505308||16515|
NCT02507986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOBILE-AF|Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation|Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation|MOBILE-AF|Leiden University Medical Center|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507986||16309|
NCT02255331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR064840|Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty|Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty||Hospital for Special Surgery, New York|No|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|Samples Without DNA|1. A small sample of soft tissues surrounding a total hip replacement will be retained for      histological evaluation|Both|21 Years|95 Years|No|Non-Probability Sample|Individuals who will be having revision surgery of a total hip replacement, or individuals        who currently have their first (primary) total hip replacement|March 2016|March 1, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02255331||35697|
NCT02255344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2014-785-051|Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events|Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events Based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS). Stage 1|RENASCA-IMSS|Instituto Mexicano del Seguro Social|No|Active, not recruiting|August 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2434|||Both|18 Years|90 Years|No|Non-Probability Sample|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Acute        Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic        criteria - ACC / AHA / ESC), attended in representative hospitals of tertiary care in the        IMSS will be studied.|September 2014|September 30, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02255344|1 Year|35696|
NCT02255422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 408-C-1403|RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR|A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)||Reata Pharmaceuticals, Inc.|Yes|Recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|56|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255422||35690|
NCT02243748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14206|Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers|Translation of a Lung Cancer Palliative Care Intervention for Clinical Practice||City of Hope Medical Center|Yes|Recruiting|February 2015|||February 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|385|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243748||36588|
NCT02499926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01151|Lysine Oxidation in Response to Arginine Supplementation|Determination of Lysine Oxidation in Response to Arginine Supplementation in Adult Men Using in Vivo Stable Isotope Techniques||University of British Columbia|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|2|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499926||16929|
NCT02500173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2015-0221|Analysis of Effects and Side Effects in Patients Undergoing Radiation Therapy|Analysis of Effects and Side Effects in Patients Undergoing Radiation Therapy - Quality Control Using Clinical Database||Kantonsspital Graubuenden|No|Recruiting|June 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|20 Years|105 Years|No|Non-Probability Sample|Patients undergoing radiotherapy at the Kantonsspital Graubuenden|October 2015|October 4, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02500173||16910|
NCT02496624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7395|Cone-beam CT Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS)|Cone-beam Computed Tomography (CT) Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS)||University Health Network, Toronto|No|Recruiting|June 2015|||May 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496624||17182|
NCT02255357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6933|Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.|Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients||New York State Psychiatric Institute|Yes|Recruiting|March 2015|October 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255357||35695|
NCT02502487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WestChinaHAesthesia-1|Dorsal Penile Nerve Block for Rigid Cystoscopy in Men|Dorsal Penile Nerve Block for Rigid Cystoscopy in Men: a Single-center, Randomized, Double-blind and Placebo-controlled Study||West China Hospital|No|Recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Male|20 Years|75 Years|No|||January 2016|January 1, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02502487||16732|
NCT02499692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2342|SYNERGY China: Assess SYNERGY Stent in China|SYNERGY China: A Prospective, Multicenter Trial to Assess the SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)||Boston Scientific Corporation|No|Active, not recruiting|May 2015|November 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|75 Years|No|||April 2015|December 11, 2015|April 30, 2015||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT02499692||16947|
NCT02242461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS11144|Rhodiola Crenulata as an Adjunctive Therapy in COPD|Rhodiola Crenulata as an Adjunctive Therapy in Patients With Chronic Obstructive Pulmonary Disease|COPD|Chung Shan Medical University|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|40 Years|85 Years|No|||September 2014|September 16, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02242461||36687|
NCT02242682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527345|Video Education: Capitalizing on Caregiver Time Spent in the Pediatric Emergency Department Waiting Room|||Medical College of Wisconsin|No|Completed|May 2014|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|220|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02242682||36670|
NCT02255448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/YH/1182|Evaluation of the esCCO Non-invasive Cardiac Output Measurement Device in Pregnancy|Evaluation of the esCCO Non-invasive Cardiac Output Measurement Device in Pregnancy|esCCO|King's College Hospital NHS Trust|No|Not yet recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Anticipated|100|||Female|18 Years|45 Years|No|||September 2014|October 2, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255448||35688|
NCT02504476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130259|Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective|A Phase I, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective Disorder on Antipsychotic Medication|MAD|Amgen|No|Completed|August 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02504476||16579|
NCT02496078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-114|A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection|A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection||Bristol-Myers Squibb|No|Active, not recruiting|August 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|March 11, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496078||17224|
NCT02254239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1387|Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma||Mayo Clinic|Yes|Recruiting|February 2016|||September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02254239||35781|
NCT02255383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2014-02K|Persona Total Knee Arthroplasty Outcomes Study|Persona The Personalized Knee System TKA Outcomes Study: Prospective Multicenter Study of the Persona Knee System||Zimmer, Inc.|No|Recruiting|July 2014|December 2027|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary care clinic patients that are in need of a total knee arthroplasty|February 2016|February 19, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02255383||35693|
NCT02257112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL001|Measurement of Low-energy Stimulation in Patients With Atrial Fibrillation|Measurement of Low-energy Stimulation in Patients With Atrial Fibrillation||Cardialen, Inc.|No|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02257112||35562|
NCT02506634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10521|The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department|The Primary Symptoms of GERD in Chinese Outpatients in Gastroenterology Department: A Cross-sectional Investigation||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|65 Years|No|Non-Probability Sample|The study will be done in the outpatient clinic, department of Gastroenterology, first        affiliated hospital, sun yet-sen university. Consecutive patients who met the inclusion        criteria in the Gastroenterology clinic in the first affiliated hospital will be enrolled        in the study. There will not be any randomization in the study.|February 2016|February 10, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506634||16413|
NCT02509741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPF2012014|Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China|Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China||Chinese PLA General Hospital|Yes|Recruiting|December 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02509741||16175|
NCT02508038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW13090|TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate|TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors||University of Wisconsin, Madison|Yes|Recruiting|January 2016|November 2020|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|7 Months|21 Years|No|||February 2016|February 5, 2016|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508038||16305|
NCT02508051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506016077|Make a Journal Feel as if it Was Mailed Back From the Future|Make a Journal Feel as if it Was Mailed Back From the Future Rather Than the Past so the Reader Will be More Likely to Read and Retain Journal Content||Yale University|No|Suspended|October 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|July 23, 2015||No|Looking for Funding|No||https://clinicaltrials.gov/show/NCT02508051||16304|
NCT02494570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEC001|A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa|A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-rapamycin) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)||Aadi, LLC|Yes|Recruiting|October 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494570||17340|
NCT02245087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECAD001|Eliminate Coronary Artery Disease|Eliminate Coronary Artery Disease|ECAD|University Health Network, Toronto|Yes|Recruiting|August 2014|||December 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|35 Years|59 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245087||36485|
NCT02502084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3NT-IL1|Safety and Effectiveness Evaluation of the Sinusway Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses|Safety and Effectiveness Evaluation of the Sinusway Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses||3NT Medical Ltd.|No|Not yet recruiting|August 2015|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|July 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02502084||16763|
NCT02502097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-016|A Study of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough|A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough||Afferent Pharmaceuticals, Inc.|No|Recruiting|August 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||December 2015|December 28, 2015|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502097||16762|
NCT02503761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67890|Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis|Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis: A Randomized Control Trial|BVPIMNBLOS|Mansoura University|Yes|Completed|August 2013|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|4 Weeks|No|||July 2015|July 17, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02503761||16634|
NCT02245880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOÜ KAEK 2013/33|Tracheal Intubation With Collar Immobilisation : a Comparison of Glidescope and Fastrach|A Comparison of Glidescope and ILMA in Simulated Sercial Spine Injury||Kocaeli University|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|94|||Both|18 Years|65 Years|No|||March 2015|March 31, 2015|April 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245880||36424|
NCT02246127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE1206|Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET|Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)|SEQTOR|Grupo Espanol de Tumores Neuroendocrinos|No|Recruiting|October 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|94 Years|No|||November 2015|November 3, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02246127||36405|
NCT02242773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140372|The Miami MAST Trial|MRI-Guided Biopsy Selection of Prostate Cancer Patients for Active Surveillance Versus Treatment: The Miami MAST Trial|MAST|University of Miami|Yes|Recruiting|October 2014|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Male|35 Years|80 Years|No|||November 2015|November 6, 2015|September 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242773||36663|
NCT02505386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/12|Pharmacokinetics of Ertapenem in Patients Aged Over 75|Pharmacokinetics of Ertapenem Following Subcutaneous or Intravenous Infusion in Patients Aged Over 75 (PHACINERTA)|PHACINERTA|University Hospital, Bordeaux|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|75 Years|N/A|No|||May 2015|July 21, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02505386||16509|
NCT02503345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000649|Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones|A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria||Allena Pharmaceuticals|No|Recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503345||16666|
NCT02503527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBHP-001-CEN|Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy|Effects of a Diabetes-specific Tube Feed on Glycemic Variability in Critically Ill Patients During Insulin Blood Glucose Management||Fresenius Kabi|No|Recruiting|September 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02503527||16652|
NCT02246959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL118195-01A1|Process Versus Outcomes Incentives for Lipid Management|Comparative Effectiveness of Process and Outcomes Incentives for Lipid Management||University of Pennsylvania|Yes|Enrolling by invitation|February 2015|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|624|||Both|18 Years|85 Years|No|||November 2015|November 17, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246959||36341|
NCT02251860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29087|An Observational Study to Evaluate the Long-Term Effectiveness and Tolerability of RoActemra®/Actemra® Administered Subcutaneously in Patients With Rheumatoid Arthritis in Everyday Clinical Practice|||Hoffmann-La Roche||Recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with active rheumatoid arthritis who are prescribed RoActemra/Actemra        (tocilizumab) s.c. by their physician prior to and independent of the inclusion of the        patient into the study. Patients can be enrolled into the study at maximum 1 month after        first administration if baseline and disease characteristics data are available.|March 2016|March 1, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251860||35964|
NCT02243085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCho2|Predictors of de Novo Urge Urinary Incontinence After Photoselective Vaporization of the Prostate|||DongGuk University|No|Recruiting|August 2014|||October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|126|||Male|40 Years|90 Years|No|Non-Probability Sample|men who underwent photoselective vaporization of the prostate using 80 watt        potassium-titanyl-phosphate (KTP) laser or 120 watt high-power-system (HPS) laser for        benign prostatic hyperplasia refractory to medical treatment|September 2014|September 15, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02243085||36639|
NCT02243098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3818|Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects|An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects||Novo Nordisk A/S|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|September 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243098||36638|
NCT02247843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lenti/βAS3-FB|Stem Cell Gene Therapy for Sickle Cell Disease|Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified With the Lenti/βAS3-FB Lentiviral Vector||University of California, Los Angeles|Yes|Recruiting|July 2014|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247843||36273|
NCT02495519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0074|A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)|A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)||Yonsei University|No|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|10 Years|N/A|No|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495519||17267|
NCT02499120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481044|Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer|A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negative, Cetuximab-Naïve Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After Failure Of One Prior Platinum-Containing Chemotherapy Regimen||Pfizer|Yes|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499120||16991|
NCT02499939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA-CC-15-0107|Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN)|Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN) in Colon and Colorectal Cancer Patients: A Randomized Controlled Pilot Trial|ULTRA|University of Alberta|No|Not yet recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499939||16928|
NCT02499952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU14-206|Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors|A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206||Hoosier Cancer Research Network|Yes|Recruiting|January 2016|January 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499952||16927|
NCT02243046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2014-11-PG-ZNPTCN-ED|The Clinical Investigation of a Zinc Based Toothpaste in Reducing Plaque and Gingivitis|The Clinical Investigation of a Zinc Based Toothpaste as Compared to a Triclosan Based Toothpaste and Colgate Fluoride Toothpaste in Reducing Established Plaque and Gingivitis - a Six-month Study.||Colgate Palmolive|No|Not yet recruiting|November 2014|July 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243046||36642|
NCT02257164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408021|Anesthesic Techniques for Surgery of the Anterior Cruciate Ligament of the Knee in Ambulatory Surgery. Randomized Pilot Monocentric Trial|Anesthesic Techniques for Surgery of the Anterior Cruciate Ligament of the Knee in Ambulatory Surgery. Randomized Pilot Monocentric Trial|CLICA|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||January 2015|June 30, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02257164||35558|
NCT02506647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-GLA-001|PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes|A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus||Gan and Lee Pharmaceuticals|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506647||16412|
NCT02509221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|714457|Effect of Duration of Exposure of Anesthesia With Sevoflurane on Emergence Delirium|||State University of New York - Upstate Medical University||Recruiting|July 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|114|||Both|1 Year|6 Years|No|Non-Probability Sample|Pediatric patients between 1-6 years old receiving anesthesia for non-surgical reasons|July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509221||16215|
NCT02499991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2015:243|Memory Intervention for Older Adults - (Social)|Memory Intervention for Older Adults - A Pilot Study|Social|University of Manitoba|No|Not yet recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02499991||16924|
NCT02494856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 30317314.4.0000.5417|Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal|Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in the Control of Pain, Swelling and Trismus in Lower Third Molar Removal||University of Sao Paulo|Yes|Active, not recruiting|October 2014|March 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494856||17318|
NCT02250534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA036114:P1S2|Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women|Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women||University of Vermont|Yes|Not yet recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|405|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2014|September 23, 2014|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250534||36066|
NCT02510209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP1AH000078|Evaluation of the Teen Outreach Program in Hennepin County, Minnesota|Evaluation of the Teen Outreach Program in Hennepin County, Minnesota: Findings From the Replication of an Evidence-Based Teen Pregnancy Prevention Program||Abt Associates|No|Completed|July 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1644|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510209||16139|
NCT02250196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korea University Prep|A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods|A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy||Korea University Anam Hospital|Yes|Completed|March 2013|November 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|80 Years|No|||September 2014|September 24, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02250196||36092|
NCT02247284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glaucoma-Premium-OCT|Reproducibility of RNFL and ONH Measurements in OAG With Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition|Study to Investigate Reproducibility of the New Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition (Software Version 6.0) in Comparison to Reproducibility of RNFL Scans.||University of Zurich|No|Recruiting|March 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02247284||36316|
NCT02495532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39919814.7.0000.5330|Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer|Randomized Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer||Hospital Moinhos de Vento|No|Recruiting|March 2015|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|126|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02495532||17266|
NCT02510573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2015119|Low Serum Ficolin-3 Levels on Admission Are Associated With Poor Outcomes After Severe Traumatic Brain Injury|Prognostic Value of Serum Ficolin-3 Levels After Severe Traumatic Brain Injury：A Pilot Study||Sanmen People's Hospital|Yes|Completed|April 2011|February 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|Samples Without DNA|All blood samples from the patients at admission were collected in the tubes and centrifuged      within 30 minutes at 1,000*g for 15 minutes. The serum was removed and frozen at -70°C until      measurement.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The patients with isolated head trauma and postresuscitation Glasgow Coma Scale score of 8        or less.|July 2015|July 26, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02510573||16111|
NCT02251873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.42|Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers|An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers||Boehringer Ingelheim||Completed|September 2001|||March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251873||35963|
NCT02254135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.20|Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Peroral Doses (400, 800, 1200 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2006|||January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254135||35789|
NCT02247856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valdecir_COPD|COPD AND ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION|IN VIVO ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION IN STABLE COPD: A RANDOMIZED CROSSOVER CLINICAL TRIAL||Universidade Federal de Pernambuco|Yes|Completed|January 2013|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|60 Years|No|||September 2014|September 23, 2014|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02247856||36272|
NCT02499133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1031-HW-CTIL|Identification and Comprehension of Focused Stress in a Sentence Among Adults Who Suffered Traumatic Brain Injury|Identification and Comprehension of Focused Stress in a Sentence Among Adults Who Suffered Traumatic Brain Injury||Sheba Medical Center|No|Recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|December 21, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02499133||16990|
NCT02502591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510152|Pudendal Nerve Block for Postoperative Posterior Repair Pain Relief|Pudendal Nerve Block for Postoperative Pain Relief in Women Undergoing Posterior Vaginal Repairs: a Pilot Study|PPPR|Royal Devon and Exeter NHS Foundation Trust|No|Not yet recruiting|August 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|80 Years|No|||July 2015|July 17, 2015|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02502591||16724|
NCT02503540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-442|Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO|Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study|PERMEATE|The Cleveland Clinic|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503540||16651|
NCT02503774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6070C00001|MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors||MedImmune LLC|No|Recruiting|July 2015|January 2021|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|101 Years|No|||December 2015|December 22, 2015|July 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503774||16633|
NCT02247804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-091|Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension|||Allergan|No|Recruiting|October 2014|August 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247804||36276|
NCT02248051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-10-002|Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury|An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury||Complexa, Inc.|No|Recruiting|September 2014|June 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||September 2014|February 2, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248051||36257|
NCT02244021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_BRidge|A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment|A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment||Fondazione Italiana Linfomi ONLUS|No|Recruiting|December 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02244021||36567|
NCT02244034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI002|Incidence and Risk Factors of Postoperative Hypothermia in Cardiac Surgery|Incidence and Risk Factors of Postoperative Hypothermia in Patients With Cardiopulmonary Bypass.||Mahidol University|No|Recruiting|May 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|780|||Both|18 Years|N/A|No|Non-Probability Sample|patients who had been underwent cardiac surgery with CPB during 2012-2013|April 2015|April 11, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244034||36566|
NCT02248181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.539|Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease|Post Marketing Surveillance Study of Sifrol® - Monotherapy in Patients With Idiopathic Parkinson's Disease||Boehringer Ingelheim||Completed|February 2004|||December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|442|||Both|N/A|N/A|No|Non-Probability Sample|Idiopathic PD patients recruited at office-based neurologists, psychiatrists or physicians        in special neurological clinics|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248181||36247|
NCT02496299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS 022015|Effect of Dexamethasone Added To Bupivacaine During Caudal Block|Comparison Of The Effect Of Dexamethasone Added To Bupivacaine With Plain Bupivacaine For Caudal Block In Patients For Herniotomy.||Lagos State University|No|Not yet recruiting|September 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|96|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496299||17207|
NCT02496533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRMC14-14|Patient Anxiety During Radiological Examination|The Prevalence of Anxiety in Patients Undergoing Radiologic Exam||Midwestern Regional Medical Center|No|Completed|February 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|217|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496533||17189|
NCT02245594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MbCrohnRemission+Symp|GI Symptoms and Sleep Disturbances in Patients With Quiescent Crohns Disease|Gastrointestinal Motility and Sleep Disturbances in Patients With Quiescent Crohn's Disease||University of Aarhus|Yes|Not yet recruiting|October 2014|October 2015|Anticipated|May 2015|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|A single blood sample (TNF-α, IL-1, IL-6) will be taken at the laboratory.|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with quiescent Crohn's disease who still have gastrointestinal complaints.Found        in the out-patient clinic at Department V (Gastroenterology and Hepatology).|September 2014|September 17, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02245594||36446|
NCT02255292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD- HMO-CTIL|A Study: Pure CBD as Single-agent for Solid Tumor.|||Hadassah Medical Organization|No|Not yet recruiting|November 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|October 1, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02255292||35700|
NCT02504281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIAI E2015-02|Study on the Association Between SXCI and RM and the Possible Genetic Mechanism|Study on the Association Between Skewed X Chromosome Inactivation(SXCI) and Recurrent Miscarriage(RM) and the Possible Genetic Mechanism||ShangHai Ji Ai Genetics & IVF Institute|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood samples from the females|Female|18 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women visiting our centre for IVF/ICSI during 2015.01.01-2016.01.01 will enter RM group or        control group according to their pregnant history or infertility factor.        RM group: Women with a history of recurrent spontaneous abortion (miscarriage occurred        earlier than 22 weeks of gestation for equal or greater than 2 times).        Control group:Infertility women because of only male factor. Both groups meet the same        elgibility criteria|May 2015|July 19, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02504281||16594|
NCT02504294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIN-EPO-1503|A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis|THE PIEDA STUDY: A Phase 3b Investigation of Erythropoietin Drugs Using a Specified Dosing Algorithm: A Randomized Open Label Dosing Study in Adult Chronic Kidney Disease Subject on Hemodialysis||Hospira, Inc.|No|Recruiting|June 2015|April 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|900|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504294||16593|
NCT02504307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laranjeiras|OCT Evaluation 3 Months After Sirolimus Eluting Stent Implantation|Randomized Evaluation of Vascular Healing After Implantation of Sirolimus Eluting Stent Inspiron™ Versus Its Own Bare Metal Version- An OCT Evaluation After 3 Months Follow-up|Laranjeiras|Scitech Produtos Medicos Ltda|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504307||16592|
NCT02495571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRSLA|Assessment of Voluntary and Reflex Cough in Patients With ALS|Pilot Observational Study, Assessing PCEF of the Voluntary and Reflex Cough in Patients With ALS||IRCCS San Camillo, Venezia, Italy|Yes|Recruiting|October 2015|June 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02495571||17263|
NCT02256202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDCINPT|Quality Assurance of Electronic Data Capturing (EDC) in Pain Treatment|Pilot Study of Quality Assurance in Interventional Pain Therapy in the Lumbal Spinal Column. Non-randomised, Evaluative, Multicentral Study Concerning the Applicability of a Tablet-PC.||Qualitouch-HC Foundation|No|Completed|August 2014|October 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Back pain patients|October 2015|October 22, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02256202||35631|
NCT02256215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLSD-1234|Vitamin D in the Treatment of Primary Restless Legs Syndrome|Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial||King Abdulaziz University||Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|75 Years|No|||April 2015|April 3, 2015|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256215||35630|
NCT02254759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29393|A Phase 1 Study in Healthy Volunteers to Investigate Possible Interactions Between RG1662 and Midazolam|||Hoffmann-La Roche||Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02254759||35741|
NCT02500147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4452|Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)|Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion||Columbia University|No|Recruiting|July 2013|June 2020|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Female|13 Years|25 Years|No|||July 2015|July 16, 2015|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500147||16912|
NCT02500407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29781|A Safety and Pharmacokinetic Study of BTCT4465A in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)|An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia||Genentech, Inc.||Recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500407||16892|
NCT02496338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92/11|Menopausal Health Training for Husbands on Women's Quality of Life and Marital Satisfaction|Effect of Menopausal Health Training for Husbands on Women's Quality of Life and Marital Satisfaction During Transitional Period||Gonabad University of Medical Sciences|Yes|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496338||17204|
NCT02496585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-167|Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis|Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496585||17185|
NCT02500472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015NTLS038|Investigation of Kava Effects on NNK Metabolism|Investigation of Kava Effects on the Metabolism of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Humans||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500472||16887|
NCT02254148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.19|The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)|The Effect of Multiple Doses of BI 187004 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P-glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Subjects||Boehringer Ingelheim||Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254148||35788|
NCT02254850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mesoglicano 29/13|Mesoglycan, Vascular Reactivity and Metabolic Syndrome|The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome||Federico II University|No|Completed|May 2013|June 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|30|||Both|18 Years|65 Years|No|||September 2014|September 30, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02254850||35734|
NCT02502708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2105|Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors|A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors||NewLink Genetics Corporation|No|Recruiting|October 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|3 Years|21 Years|No|||October 2015|October 28, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502708||16715|
NCT02510586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sevo_postconditioning|Sevoflurane and Hyperperfusion Syndrome|Effect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya Disease||Seoul National University Hospital|Yes|Not yet recruiting|August 2015|September 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|152|||Both|18 Years|N/A|No|||July 2015|July 26, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510586||16110|
NCT02510599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-205|Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis|An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis||Cempra Inc|Yes|Recruiting|August 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510599||16109|
NCT02257450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyEndo - PA|Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study|Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study|MyEndo-PA|International Islamic University Malaysia|Yes|Enrolling by invitation|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|2500|Samples Without DNA|Serum, plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Malaysian adult population|March 2016|March 10, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257450||35536|
NCT02257463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD/4|Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease||Mansoura University|Yes|Completed|October 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Male|45 Years|65 Years|No|||October 2014|April 7, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02257463||35535|
NCT02248194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tactile ablation|Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding|Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding|TEA|Assiut University|Yes|Completed|April 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|108|||Female|40 Years|50 Years|No|||December 2015|December 30, 2015|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248194||36246|
NCT02257177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-HV-01|RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients|A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)||Galecto Biotech AB|Yes|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257177||35557|
NCT02500706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-4131|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes|onset®8|Novo Nordisk A/S|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1130|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500706||16869|
NCT02500238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500475|Comparison of Smoking and Vaping in Families|Comparison of Smoking and Vaping in Families||University of Florida|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Anticipated|30|Samples Without DNA|Saliva, urine, and toenail clippings|Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|In order to be included in the study, parents must: 1) be a legal guardian of a child        between the ages of 6-17 (if caregiver has more > 1 child between 6-17 years; 2) be aged        18-65 years; and 3) be fluent in English. Additionally, the child must reside in the same        home as the caregiver.|December 2015|December 1, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02500238||16905|
NCT02500251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Belimumab|Belimumab Impacting Transplant Eligibility|Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility||University of Cincinnati|No|Recruiting|June 2015|December 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500251||16904|
NCT02500264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0293-15-RMC|The Effect of Non Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD) Symptoms - Proof of Concept Study|The Effect of Non Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD) Symptoms - Proof of Concept Study||Rabin Medical Center||Not yet recruiting|August 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|75 Years|No|||July 2015|July 15, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02500264||16903|
NCT02249949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091202|Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma|A Phase II Randomized, Double-Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma||Alliance for Clinical Trials in Oncology|Yes|Recruiting|October 2014|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249949||36111|
NCT02242513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB-2-102-05-95|Ultrasound-guided Pulsed Radiofrequency for Plantar Fasciitis|Ultrasound-guided Pulsed Radiofrequency Stimulation of the Tibial Nerve for Plantar Fasciitis||Tri-Service General Hospital|Yes|Recruiting|April 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||February 2016|February 1, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02242513||36683|
NCT02495025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000509|Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening|Developing and Testing a New Model for Telephone-based Early Childhood Developmental Screening and Care Coordination in Vulnerable Populations||University of California, Los Angeles|No|Recruiting|February 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Months|3 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495025||17305|
NCT02499445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160004|Myocardial Injury in Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimens in OPCAB Surgery|Comparisons of Myocardial Injury After Using Different Anesthetics Regimens for Off-pump Coronary Artery Bypass Surgery: Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimen||Konkuk University Medical Center|Yes|Completed|November 2007|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|19 Years|72 Years|No|||July 2015|July 15, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02499445||16966|
NCT02503137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM04554-AGA-04|A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing|A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing||Samumed LLC|No|Active, not recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Male|18 Years|65 Years|No|||January 2016|January 12, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503137||16682|
NCT02242123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM05|Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-Transglutaminase: Duodenal Anti-Endomysium Assay.|Antiendomysium Antibodies Assay in the Culture Medium of Intestinal Mucosa: an Accurate Method for Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-transglutaminase Antibodies.||University of Palermo|No|Recruiting|January 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Duodenal biopsy specimens|Both|18 Years|70 Years|No|Probability Sample|The study will include consecutive patients, referred to two centers in Palermo and        Sciacca, at the Internal Medicine Department of the University Hospital of Palermo, and at        the Internal Medicine Department of the Hospital of Sciacca (Agrigento), between January        2014 and June 2016.|November 2015|November 30, 2015|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242123||36713|
NCT02256228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPLA-CRS|Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery|Peroperative Analgesia Following Cytoreductive Surgery. A Randomized, Double-blind, Comparison Between Intra-peritoneal Local Anesthesia and Placebo - Multicenter Study|IPLA|Göteborg University|No|Recruiting|October 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|74 Years|No|||November 2015|November 2, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256228||35629|
NCT02502903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT009-01|Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders|Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study|TNT009-01|True North Therapeutics|Yes|Recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02502903||16700|
NCT02500485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3824-106|The Drug-drug Interaction of SHR3824 and SP2086|Drug Interaction Study of Henagliflozin and Retagliptin in Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|May 2015|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|November 23, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02500485||16886|
NCT02242708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010807|The Effectiveness of Autonomic Nervous System, Sleep Quality, and Immune Regulation for Shift Nurses Practicing Alternative Nostril Breathing|The Effectiveness of Autonomic Nervous System, Sleep Quality, and Immune Regulation for Shift Nurses Practicing Alternative Nostril Breathing||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|October 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|20 Years|65 Years|No|||September 2014|September 15, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242708||36668|
NCT02256293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040489|Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management|Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management||Duke University|No|Withdrawn|January 2015|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|June 11, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256293||35624|
NCT02256306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30350|The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study|The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease|PLASMA|Stanford University|No|Recruiting|September 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|50 Years|90 Years|No|||March 2016|March 23, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256306||35623|
NCT02505594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD150468|Potential Mechanism of Exercise Impairment in OSA|Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea||University of California, San Diego|No|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Investigators will enroll 30 subjects with OSA (OSA group) and 30 subjects without OSA        (control group). The detailed inclusion and exclusion criteria for subjects are listed        below. Female subjects will be offered a urinary pregnancy test and only those documented        to be non-pregnant will be studied.|July 2015|July 20, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02505594||16493|
NCT02496598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFFR-IVA-2015|In Vitro Follicle Activation|In Vitro Activation of Primordial Follicles as a Method to Treat Infertility Caused by Primary Ovarian Insufficiency|IVA|National Foundation for Fertility Research|No|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|45 Years|No|||July 2015|July 9, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496598||17184|
NCT02496845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL#FIA3-30 #002|Safety and Clinical Efficacy of Local Topical Treatment for Erectile Dysfunction|An Open Label Randomized Study to Examine the Safety and Clinical Efficacy of Local Topical Dual Active Preparation for Erectile Dysfunction||VasoLead (2012) Ltd.|Yes|Not yet recruiting|August 2015|January 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Male|25 Years|75 Years|No|||July 2015|July 13, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02496845||17165|
NCT02255006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI13C0580-2|Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury|Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury Via Adenosine Triphosphate-sensitive Potassium Channels or Prostaglandin Pathway|AURORAS|Kyunghee University Medical Center|Yes|Recruiting|May 2014|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|36|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||May 2014|September 29, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02255006||35722|
NCT02257502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.839|Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Iodiopathic Choroidal Neovascularization in Young Patients|INTUITION|Hospices Civils de Lyon|No|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|No|||October 2015|October 29, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257502||35532|
NCT02504385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM 0024-14|The Effect of Virtual Reality on Motor Functioning and Participation Abilities Among Children With DCD|The Effect of Timocco's Virtual Reality Environment on the Motor Functioning and Participation Abilities Among Children With DCD||Clalit Health Services|No|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|4 Years|6 Years|No|||July 2015|July 20, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02504385||16586|
NCT02500511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-NM-002E1|Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study|Duration of Protection Based on Persistent Antibody Titers 12-24 Months After Vaccination: Follow Up to Phase 2 Study of Meningococcal Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT)||JN-International Medical Corporation|No|Enrolling by invitation|June 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|60|Samples Without DNA|Serum samples used for antibody assays.|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who seroconverted for serogroups A and C after vaccination with        NmVac4-A/C/Y/W-135-DT in study JN-NM-001|July 2015|July 15, 2015|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500511||16884|
NCT02256098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.142|RSA RCT: ATTUNE™ TKA Versus PFC Sigma TKA|A Clinical Randomized Controlled RSA Trial Comparing the Cemented ATTUNE™ Fixed Bearing Cruciate Retaining Knee System With the Cemented PFC Sigma Fixed Bearing Cruciate Retaining Knee System|APKnee|Leiden University Medical Center|No|Active, not recruiting|September 2014|February 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|21 Years|90 Years|No|||March 2016|March 4, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02256098||35638|
NCT02256111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053924|EXTEND Exercise Trial|EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer||Duke University|No|Recruiting|April 2015|March 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|August 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256111||35637|
NCT02247011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XWB-MISP-PKVF|A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women|A 5-Year Long-term Follow-up Study of a Cross-Sectional Cohort Study (PK-VF) For the Examination of the Association of Vitamin D/Bone Turnover/Bone Mineral Density With an Incident Fracture in Chinese Postmenopausal Women|PK-VF|Peking Union Medical College Hospital|Yes|Recruiting|March 2013|December 2015|Anticipated|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1242|Samples With DNA|Fasting whole blood of each participants was retained to measure some biochemical markers,      bone turnover markers,and 25(OH)D. DNA may be extracted from these whole blood samples.|Female|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Peking Vertebral Fracture (PK-VF) study was conducted in 2008, when 2070 proven        postmenopausal women aged over 50 were randomly selected from 7 Peking regions and thus        included for cross-sectional analyses. In 2013, 5 years after PK-VF, the same 2070        subjects were contacted by the original sites. Among them 1242 subjects were able to come        for the follow-up assessment.|September 2014|September 23, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247011|5 Years|36337|
NCT02498587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/SW0002|Short Period Incidence Study of Severe Acute Respiratory Illness|Short Period Incidence Study of Severe Acute Respiratory Illness|SPRINT-SARI|Australian and New Zealand Intensive Care Research Centre|Yes|Not yet recruiting|November 2015|December 2020|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients newly admitted to participating hospitals, of any age, presenting with SARI        during the study period. Patients will be eligible for the study if the patient meets the        case definition for SARI.        A suspected or proven acute respiratory infection requiring new inpatient admission with        onset within the past 14 days. With one or more of the inclusion criteria.|July 2015|July 13, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02498587||17032|
NCT02503150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMU, Shanghai|Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer|Phase III Trial of Antigen Pulsed Dendritic Cells (APDC) Combined With Chemotherapy in Metastatic Colorectal Cancer||Second Military Medical University|Yes|Not yet recruiting|July 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503150||16681|
NCT02246660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG047510-01|RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)|RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)|RESTORE|Northwestern University|Yes|Recruiting|January 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|66|||Both|65 Years|N/A|No|||November 2015|November 18, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246660||36364|
NCT02242786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-174-003|Diffusion-Weighted Magnetic Resonance Imaging|Response Assessment for External Beam Radiation Therapy in Spinal Metastasis of Hepatocellular Carcinoma (HCC): Usefulness of Diffusion-Weighted Magnetic Resonance (MR) Imaging as A Functional Imaging||Samsung Medical Center|Yes|Recruiting|August 2014|||July 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|17|||Both|20 Years|N/A|No|||November 2014|November 6, 2014|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02242786||36662|
NCT02242799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK13|Dolutegravir Interactions With Artemisinin-based Combination Therapies|Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate|DolACT|University of Liverpool|Yes|Recruiting|June 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242799||36661|
NCT02506309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrnoUH|Trans-obturator Mid-urethral Sling and the Single-incision Sling in Women With Stress Urinary Incontinence|Prospective Randomized Comparison of the Trans-obturator Mid-urethral Sling and the Single-incision Sling in Women With Stress Urinary Incontinence||Brno University Hospital|No|Active, not recruiting|January 2012|December 2018|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|35 Years|N/A|No|||February 2016|February 22, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506309||16438|
NCT02504866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150164|Effect of Exercise Training on Physical, Cognitive, and Behavioral Function in People With TBI|Effect of Exercise Training on Physical, Cognitive and Behavioral Function in Patients With Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|79 Years|No|||June 2015|July 28, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504866||16549|
NCT02247531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29185|A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)|||Hoffmann-La Roche||Recruiting|October 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|936|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247531||36297|
NCT02247791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHANCE|Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty|Study of Prosthesis Choice in Older Patients With a Dislocated Femoral Neck Fracture of the Hip|CHANCE|Danderyd Hospital|No|Active, not recruiting|September 2009|September 2024|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|65 Years|79 Years|No|||January 2016|January 27, 2016|October 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02247791||36277|
NCT02243111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP22_1|Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)||Echosense Ltd.|No|Terminated|September 2014|December 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||June 2014|January 20, 2016|September 8, 2014|Yes|Yes|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT02243111||36637|
NCT02243124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS ELP9001|A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)|A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome||Eleos, Inc.|No|Enrolling by invitation|September 2014|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|95 Years|No|||August 2015|August 3, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243124||36636|
NCT02496039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVR-404|Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)|A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients||Avanir Pharmaceuticals|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|125|||Both|18 Years|90 Years|No|||December 2015|December 18, 2015|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02496039||17227|
NCT02500745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAA velocity & LA volume|Left Atrial Volume Index and Left Atrial Appendage Flow Velocities|Left Atrial Volume Index and Left Atrial Appendage Flow Velocities||University of Cincinnati|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|18 Years|80 Years|No|Probability Sample|Patients referred for transesophageal echocardiography|July 2015|July 14, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02500745||16866|
NCT02244580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MammaTyper-FinHer|Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"|Evaluation of the MammaTyperTM Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patients With Breast Cancer: Re-Examination of Tumor Material and Re-Evaluation of Patient Data of the FinHer-Study||Biontech Diagnostics GmbH|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1010|||Female|18 Years|65 Years|No|||September 2014|September 17, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02244580||36524|
NCT02258217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0156|Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)|Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)||Ohio State University|No|Recruiting|June 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 6, 2014|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258217||35479|
NCT02509975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCL503-P2-PAE-01|Safety and Efficacy of OCL 503 in Prostate Artery Embolization|An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in Prostate Artery Embolization for the Treatment of Men With Benign Prostatic Hypertrophy||IMBiotechnologies Ltd.|No|Recruiting|September 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|51 Years|N/A|No|||September 2015|September 18, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509975||16157|
NCT02500771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMOTIVE-1|Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1|Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1||Experiad LLC|Yes|Not yet recruiting|June 2017|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|4 Years|N/A|No|||July 2015|July 14, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02500771||16864|
NCT02241824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB# 1273|Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention|Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention||Aspen Medical Products|Yes|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Male|20 Years|72 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02241824||36736|
NCT02252809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FXT-01|Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects|An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses||Brugmann University Hospital|Yes|Completed|November 2008|July 2009|Actual|April 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|51|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252809||35891|
NCT02252822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59093006|Improving Treatment Engagement for Adolescents With Bulimia Nervosa|Does Offering Adolescents Anonymous Access to Online CBT Self-Help for Bulimia Nervosa Improve Engagement in Treatment-Pilot Study||Nova Scotia Health Authority|No|Completed|September 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|16 Years|18 Years|No|||December 2015|December 7, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252822||35890|
NCT02502396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-1027|Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center|Retrospective Study: Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|375|||Both|18 Years|N/A|No|Probability Sample|Cancer patients with venous-thromboembolism (VTE) or non-valvular atrial fibrillation        (NVAF) The University of Texas MD Anderson Cancer Center in Houston, Texas|December 2015|December 1, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02502396||16739|
NCT02510560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIT-EU-04|A Study to Assess the Efficacy and Safety of NTRA-2112 in Preterm Infants|A Multi-center, Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption Due to GI Immaturity in Preterm Infants||Nutrinia|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|5 Days|No|||July 2015|July 26, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510560||16112|
NCT02251678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EL-1005-01-01|Evaluate the Effect of Elimune Capsules|Open-Label Study to Evaluate the Effect of Elimune Capsules on Biomarkers in Patients With Plaque Psoriasis||Elorac, Inc.|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|N/A|No|||February 2015|December 7, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251678||35978|
NCT02251847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-ROEZ-301|The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients|||IlDong Pharmaceutical Co Ltd||Recruiting|July 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|400|||Both|19 Years|80 Years|No|||September 2014|September 25, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251847||35965|
NCT02255227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308162|Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD|Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease|PneumoMICI|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|April 2015|December 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255227||35705|
NCT02509702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Connected to Care|Connected to Care: Use of Mobile Short Message Services to Improve HPV Care|Connected to Care: Use of Mobile Short Message Services to Improve HPV Care - A Randomised Control Trial Among HPV-positive Tanzanian Women||Odense University Hospital|No|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|950|||Female|15 Years|N/A|No|||September 2015|September 12, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02509702||16178|
NCT02253992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-107|Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma|A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma||Bristol-Myers Squibb|No|Recruiting|September 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253992||35800|
NCT02254005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191.1|Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer|An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Female Patients With CD44v6 Positive Metastatic Breast Cancer With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|October 2002|||December 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254005||35799|
NCT02254018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191.2|Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck|An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|September 2002|||February 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254018||35798|
NCT02500420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9517|Study of Hypertrophic Cardiomyopathy Under Stress Conditions. Concordance Between Two Complementary Tests: Stress MRI and Exercice Stress Echocardiography||CMHStress|University Hospital, Montpellier|No|Active, not recruiting|December 2014|August 2017|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02500420||16891|
NCT02504970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnesthesiaQI|Anesthesia Quality Institute National Anesthesia Clinical Outcomes Registry|Anesthesia Quality Institute National Anesthesia Clinical Outcomes Registry Ongoing|AQINACOR|Anesthesia Quality Institute|No|Recruiting|October 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing an anesthetic.|July 2015|July 21, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02504970|10 Years|16541|
NCT02505126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00576-43|A Clinical Trial on the Efficacy of tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients (REDSTIM)|A Randomized Double-blind Clinical Trial on the Efficacy of Transcranial Direct Current Stimulation (tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder|REDSTIM|Centre Hospitalier Universitaire Dijon||Recruiting|September 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||June 2015|February 2, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505126||16529|
NCT02248857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00097744|Promoting the Universal Medication Schedule Via Mobile and EHR Technologies|Promoting the Universal Medication Schedule Via Mobile and EHR Technologies: A Physician-randomized Control Trial||Northwestern University|No|Recruiting|December 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|600|||Both|30 Years|N/A|No|||March 2016|March 23, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248857||36195|
NCT02244645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010803|Effects of Yoga Versus Passive Modality on Pain, Disability, Salivary Cortisol Concentrations, Brain- Derived Neurotropic Factor, Heart Rate Variability and Immune Functions Among Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Effects of Yoga Versus Passive Modality on Pain, Disability, Salivary Cortisol Concentrations, Brain- Derived Neurotropic Factor, Heart Rate Variability and Immune Functions Among Patients With Chronic Low Back Pain: A Randomized Controlled Trial||Chang Bing Show Chwan Memorial Hospital|Yes|Recruiting|December 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|86|||Both|20 Years|65 Years|No|||September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02244645||36519|
NCT02496312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-14|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated in Healthy Subjects and Patients With Frontotemporal Dementia. Pilot Phase.|ECOCAPTURE|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02496312||17206|
NCT02500992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoBakt transrectal|Bacterial Contamination in Transrectal Hybrid NOTES Sigmoidectomy|Bacterial Contamination in Transrectal Hybrid Natural Orifice Translumenal Endoscopic Surgery Sigmoidectomy for Diverticular Disease||Cantonal Hosptal, Baselland|No|Recruiting|July 2015|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Microbacteriological swabs|Both|18 Years|N/A|No|Probability Sample|Patients with an indication for elective sigmoidectomy for diverticular disease. Status        post several episodes of diverticulitis, status post contained diverticulitis.|July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500992||16847|
NCT02501005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP028|Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction|Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction|BERLIN VT|Biotronik SE & Co. KG|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|80 Years|No|||October 2015|October 22, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02501005||16846|
NCT02246400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 14-01-290|CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact|CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact|eCMP|Palo Alto Medical Foundation|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|74|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246400||36384|
NCT02256124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2013-460|Effect of Lamotrigine on Cognition in NF1|The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL)|NF1-EXCEL|Erasmus Medical Center|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|18 Years|No|||December 2015|December 8, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02256124||35636|
NCT02505217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIVAROXDVT400|Novel Biomarkers of Thrombotic Risk|||University of Vermont|No|Recruiting|July 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood for measuring clot generation, coagulation factors, and platelet measures|Both|N/A|N/A|No|Probability Sample|acute myocardial infarction|July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505217||16522|
NCT02496091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-AA-14-003|Multicenter Retrospective Study Evaluating ATLANTIS™ Abutment Teeth Connected to Implants|A Retrospective Multicenter Study Evaluating ATLANTIS™ Abutments on Implants From Four Manufacturers||Dentsply Implants||Recruiting|September 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|180|||Both|18 Years|N/A|No|Probability Sample|The study population is individuals who received ATLANTIS abutments, between 2010 and        2013, connected to implants from BIOMET 3i, Straumann, Nobel Biocare or DENTSPLY Implants        (only ASTRA TECH Implant System) replacing one or more teeth, in any position in the        mouth, as part of a permanent prosthetic restoration. The partially dentate individuals        have received either single-unit crowns or fixed partial or full dentures. The abutments        need to be titanium or gold-shaded titanium.|March 2016|March 15, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02496091||17223|
NCT02500212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-06235AA1-02|Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients|OPEN-LABEL, MULTICENTRE, RANDOMIZED CLINICAL TRIAL TO COMPARE THE PHARMACOKINETICS OF ENVARSUS® TABLETS AND ADVAGRAF® CAPSULES ADMINISTERED ONCE DAILY IN ADULT DE-NOVO KIDNEY TRANSPLANT PATIENTS||Chiesi Farmaceutici S.p.A.|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02500212||16907|
NCT02257242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHRI-14-AO-001|Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma|A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma|BRiM|Memorial Hospital of Rhode Island|No|Not yet recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257242||35552|
NCT02256956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/12_2|Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II|Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics||University Hospital Inselspital, Berne|Yes|Recruiting|November 2014|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02256956||35573|
NCT02495766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-MS-02|Autologous Mesenchymal Stromal Cells for Multiple Sclerosis|Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis|EMMES|Banc de Sang i Teixits|No|Recruiting|May 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|60 Years|No|||November 2015|November 13, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02495766||17248|
NCT02495779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060504|Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV|Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV||University of Pittsburgh|No|Not yet recruiting|July 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02495779||17247|
NCT02496364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-2015|Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease|Topical and Intravenous Use of Tranexamic Acid in Posterior Lumbar Interbody Fusion - A Prospective, Double-blind, Randomized Study||Instituto Nacional de Traumatologia e Ortopedia|Yes|Enrolling by invitation|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|40 Years|85 Years|No|||October 2015|October 5, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02496364||17202|
NCT02254915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-002-00|SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I|A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)|SHTC-EUROPE-1|Medical Enterprises Europe B.V.|Yes|Withdrawn||||January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|September 30, 2014||No|Shortages of the active comparator drug (BCG) on the market worldwide and a growing    uncertainty as to its future supply.|No||https://clinicaltrials.gov/show/NCT02254915||35729|
NCT02254928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANCOR|Corifollitropin Alfa Versus Daily rFSH in the Controlled Ovarian Stimulation of Poor Responders|Comparative Study Between the Use of Corifollitropin Alfa and Daily Recombinant FSH in the Controlled Ovarian Stimulation of Poor Responders|MANCOR|IVI Sevilla||Terminated|September 2014|November 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|September 25, 2014||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT02254928||35728|
NCT02247570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-CBC-03|Vestibular Rehabilitation Strategies in PTSD Effectiveness of Carrick Brain Centers Strategies Vestibular Rehabilitation Treatment in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries|A Randomized Controlled Trial Comparison of the Effectiveness of Carrick Brain Centers Strategies Vestibular Rehabilitation Treatment in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries.||Carrick Institute for Graduate Studies|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247570||36294|
NCT02247583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF/2010/03|Investigating Patient Satisfaction With Oral Anti-Cancer Treatment|Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.|IPSOC|Katholieke Universiteit Leuven|No|Completed|February 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|mRCC patients starting with an oral anti-cancer treatment|September 2014|September 19, 2014|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02247583||36293|
NCT02503072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH096609-01A1|Rewarding Adherence Program - an Intervention Using Small Prizes Allocated by a Prize Drawing to Increase ARV Adherence|Variable Rewards Incentives for ART Adherence in Uganda|RAP|RAND|No|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|157|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02503072||16687|
NCT02509728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Choline and DHA for Preemies 2|Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants|Nahrungsergänzung Mit Cholin- Und Docosahexaensäure Bei Sehr Unreifen Frühgeborenen||University Hospital Tuebingen|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|40|||Both|N/A|2 Months|No|||July 2015|July 27, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509728||16176|
NCT02254330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVISE Spain|ADenoVirus Initiative Study in Epidemiology in Spain|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis||NicOx|No|Recruiting|June 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|1 Year|N/A|No|Non-Probability Sample|Any female and male patients from one year of age with signs and symptoms of acute        conjunctivitis either seen during ophthalmology consultations or who are in the emergency        room or hospitalized, can be enrolled in the study|November 2013|February 9, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254330||35774|
NCT02254421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-1502|Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract||Gilead Sciences|Yes|Recruiting|January 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254421||35767|
NCT02502318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BERNARD PRME 2014|Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer|Medicoeconomic Analysis of Lobectomy Using Thoracoscopy vs Thoracotomy for Lung Cancer: a Multicentric Randomized Controlled Trial.|LungSco01|Centre Hospitalier Universitaire Dijon||Recruiting|July 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|600|||Both|18 Years|80 Years|No|||September 2015|September 9, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502318||16745|
NCT02501473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMDZ-G142|Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma|Phase 1/2 Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma||Immune Design|Yes|Recruiting|June 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501473||16810|
NCT02501265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063898|The Translational Smoking Cessation Program Study|The Translational Smoking Cessation Program (TSCP) Study|TSCP-P50|Duke University|No|Not yet recruiting|January 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1500|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02501265||16826|
NCT02251522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|A Single Time-Point Study to Evaluate the ConforMIS iTotal® (CR) Knee Versus Off-the-Shelf|A Single Time-Point Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System Versus Off-the-Shelf Replacement|STEPS|ConforMIS, Inc.|No|Enrolling by invitation|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|The study will include a 1:1 ratio of patients enrolled into both the iTotal arm and the        off-the-shelf total knee arm.|June 2015|June 18, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02251522||35990|
NCT02257203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-Based Beverage|Primary Care Beverage Study|Evaluation of a Primary Care-Based Intervention to Reduce Consumption of Sugar-sweetened Beverages and 100% Fruit Juice Among Latino Children||University of California, San Francisco|No|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02257203||35555|
NCT02242526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-568818|Biologic Versus Synthetic Mesh for Treatment of Paraesophageal Hernia|Biologic Versus Synthetic Mesh for Treatment of Paraesophageal Hernia||Stony Brook University|No|Recruiting|September 2014|August 2020|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|312|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02242526||36682|
NCT02495285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H-1406|Gelatines in Pediatric PatientS|Infusion of Gelatine Solutions in Pediatric Patients Aged up to 12 Years|GPS|B. Braun Melsungen AG|No|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|N/A|12 Years|No|Non-Probability Sample|children|January 2016|January 13, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02495285||17285|
NCT02500225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ulku 1|Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy|Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation||Inonu University|No|Active, not recruiting|July 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500225||16906|
NCT02242474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-levallee|Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis|Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis.||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|July 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242474||36686|
NCT02243137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-ECCLIPSE-01|Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate|Effects of Combinated Administration of Lysine Acetylsalicylate Versus Prasugrel and Aspirin on Platelet Aggregation in Healthy Volunteers|ECCLIPSE|Fundacion Investigacion Interhospitalaria Cardiovascular|No|Completed|May 2013|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|June 24, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243137||36635|
NCT02243449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENIOR0000001|Screening Elderly Patients for Weaning|Screening Elderly PatieNts For InclusiOn in a Weaning Trial: The SENIOR Trial||St. Michael's Hospital, Toronto|No|Active, not recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|65 Years|N/A|No|||March 2016|March 9, 2016|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02243449||36611|
NCT02500160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC 2011-058|Comparative Study of Total Knee Arthroplasty Using a Customized-patient Specific Instrument System.|||Kyung Hee University Hospital at Gangdong||Active, not recruiting|February 2011|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02500160||16911|
NCT02496884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-U307|Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease|A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease||Daiichi Sankyo Inc.|Yes|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496884||17162|
NCT02496897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP02.2_CS_01|Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B|A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.||Altimmune, Inc.|Yes|Recruiting|July 2015|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|72|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496897||17161|
NCT02244268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.20|Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia|Effect of ALNA® (Tamsulosin) on the Primary Symptoms of BPH (Benign Prostatic Hyperplasia) Syndrome||Boehringer Ingelheim||Completed|October 2000|||December 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3629|||Male|N/A|N/A|No|Non-Probability Sample|Patients suffering from symptomatic benign prostatic hyperplasia (BPH) syndrome recruited        in urological practices|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244268||36548|
NCT02244281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.25|Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms|An Eight-week, Double-blind, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Daily Versus Placebo, in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms||Boehringer Ingelheim||Completed|May 2001|||November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|74|||Female|18 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244281||36547|
NCT02244294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.26|FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)|A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia||Boehringer Ingelheim||Completed|March 2001|||June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|176|||Male|45 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244294||36546|
NCT02255318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-792|Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition|Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition||Hospices Civils de Lyon|No|Not yet recruiting|October 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255318||35698|
NCT02496052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO.1-20140601|The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions|The Efficacy and Safety of the Dried Biological Amnion Graft Following Hysteroscopic Lysis for the Prevention of Postoperative Adhesions in Patients With Intrauterine Adhesions||Beijing Obstetrics and Gynecology Hospital|No|Recruiting|January 2013|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496052||17226|
NCT02496286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP2014013|Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites|Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites||Eastern Regional Medical Center|No|Terminated|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|July 1, 2015|||Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT02496286||17208|
NCT02498717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539147|Preliminary Review of Cold and Active Compression Therapy for Traumatic Calcaneus or Ankle Fractures|Preliminary Efficacy and Cost-effectiveness Analysis of a Cold and Active Intermittent Compression Therapy Technique for Traumatic Calcaneus or Ankle Fractures||Florida Hospital|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||July 2015|July 13, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498717||17022|
NCT02258165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAGE|Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer|Impact of Gated PET/CT on the Diagnosis of Distant Metastases of Advanced Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|IMAGE|Queensland Centre for Gynaecological Cancer|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|84|||Female|18 Years|N/A|No|Non-Probability Sample|Women with advanced ovarian cancer|April 2015|April 20, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02258165||35483|
NCT02504619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P#01.01.030|Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies|Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies||Gamida Cell ltd|Yes|Recruiting|May 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|25 Years|No|||February 2016|February 15, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504619||16568|
NCT02504567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laser|Laser Ablation Study for trEatment of atRial Fibrillation (LASER)|Laser Ablation Study for trEatment of atRial Fibrillation (LASER)|LASER|Hospital Clinic of Barcelona|No|Recruiting|July 2015|July 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|99 Years|No|||January 2016|January 28, 2016|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02504567||16572|
NCT02504580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTX-011-C2015-202|A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011 Administered Via Injection or Topical Application Following Unilateral Open Inguinal Herniorrhaphy|||Heron Therapeutics||Recruiting|July 2015|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504580||16571|
NCT02495129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736X2103|Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome|A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT||Novartis||Withdrawn|December 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||February 2016|February 2, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495129||17297|
NCT02257216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vayarin®_006|Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized, Sequential Parallel, Double-Blind, Placebo- Controlled Medical Food Study for the Safety and Efficacy of Vayarin® in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Enzymotec|No|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|171|||Both|18 Years|60 Years|No|||January 2016|February 24, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257216||35554|
NCT02257229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032011-131|Prospective Evaluation of Treatment for Clubfoot|Prospective Evaluation of Treatment for Clubfoot||Texas Scottish Rite Hospital for Children|Yes|Recruiting|August 2005|September 2029|Anticipated|September 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|||Both|N/A|18 Years|No|Non-Probability Sample|Primary care clinic|October 2014|October 1, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02257229||35553|
NCT02242136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKULBU2014|Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants|Formation, Orientation and Rehabilitation by Means of Narrative Exposure Therapy (FORNET) for Returning Soldiers of the African Union Mission to Somalia, Male and Female Ex-combatants in Burundi||University of Konstanz|Yes|Enrolling by invitation|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|60 Years|No|||September 2014|September 15, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242136||36712|
NCT02247297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0046|Pancreatic Stone Protein (PSP) in Pregnant Women|Analysis of Serum Pancreatic Stone Protein (PSP) in Healthy Pregnant Women and Its Value in Predicting Inflammatory Complications During Pregnancy||University of Zurich|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|486|Samples Without DNA|Serum|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women (healthy or with preeclampsia, HELLP syndrome, amniotic infection syndrome,        or PPROM)|September 2014|September 18, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247297||36315|
NCT02499887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|754754|Repeat Emergency Department Visits Among Patients With Asthma and COPD|Repeat Emergency Department Visits Among Patients With Asthma and COPD||State University of New York at Buffalo|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499887||16932|
NCT02499900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV44400-CNS-40083|Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®|A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily||Teva Pharmaceutical Industries|No|Recruiting|August 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|840|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499900||16931|
NCT02504736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS ACT-24-FEB-2015|Colesevelam, Lipids And Sugars, South Asian Canadian Trial|24 Week Open Label, Single Arm Study of Colesevelam in High Risk South Asians With Suboptimal LDL-c Levels Despite Maximally Tolerated Statin Therapy|CLASS-ACT|Canadian Cardiovascular Research Network|No|Recruiting|June 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Individuals of South Asian ethnicity; self-declared, at least 3 of 4 grandparents born in        a South Asian country (i.e. India, Pakistan, Bangladesh, Sri Lanka, Nepal and Bhutan)|January 2016|January 26, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02504736||16559|
NCT02247219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228454/DHE|Promoting Health in Healthy Living Centres - a Clinical Study Among Adults|Promoting Health in Healthy Living Centres - Does it Work, How Does it Work and Why?||University of Bergen|No|Recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 31, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247219||36321|
NCT02247518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150DDI14012|CKD-397 Drug-drug Interaction Study (A)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tamsulosin on Tadalafil in Healthy Male Volunteers|CKD-397DDI(A)|Chong Kun Dang Pharmaceutical|No|Completed|September 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247518||36298|
NCT02247596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/00454|Effects of High-Dose Resveratrol in Non-Diabetic Obese Males|Effects of High-Dose Resveratrol on Resting Energy Expenditure and HOMA in Non-Diabetic Obese Males||Khoo Teck Puat Hospital|Yes|Completed|July 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247596||36292|
NCT02257034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC20140601|The Effect of Tai Chi in Treating Fibromyalgia|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|40 Years|N/A|No|||August 2015|August 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257034||35567|
NCT02503748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZH 2015-132|Prostate Cancer E-Health-Tutorial|Prostate Cancer E-Health-Tutorial (PROCET): Multicenter, One-armed Intervention Study to Evaluate an Online Tutorial for Patients With Localized Prostate Cancer|PROCET|Zurich University of Applied Sciences|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|100|||Male|N/A|75 Years|No|||February 2016|February 25, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503748||16635|
NCT02497131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_PTCL_BV|Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients|Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients||Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|July 2015|July 2020|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||July 2015|July 13, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497131||17143|
NCT02497443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minsk-MH001|Safety of Autologous MSC Infusion to Treat Epilepsy|Phase 1 Study of Autologous Mesenchymal Stem Cell Application for Therapy of Drug-Resistant Symptomatic Epilepsy|AMSCDRSE|Ministry of Public Health, Republic of Belarus|No|Active, not recruiting|April 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||April 2015|July 10, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497443||17119|
NCT02256995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATBANG2014|uChek Pilot Study for Urinalysis in the Antenatal Care Setting|A Prospective Observational Pilot Study to Test the Feasibility of Smartphone Enabled uChek Urinalysis Device in Bangladesh|uChekBangla|Maternova Research|Yes|Not yet recruiting|November 2014|June 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|375|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There are two unique subject populations in this study. One group consists of pregnant        women whose urine will be analyzed- hereafter referred to as the Patient Participants. The        second group is a cohort of medical professionals who will answer a questionnaire about        the usability of the device, relating to the second objective, hereafter referred to as        the Medical Staff Participants. The following parameters have been answered in reference        to the Patient Participants.|October 2014|October 1, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02256995||35570|
NCT02257008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.6|Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers|An Open Study to Investigate the Effect of Different Boosting Agents on Pharmacokinetics of Single Doses of BILR 355 BS (Dose Steps: 5 and 12.5 mg) Dissolved in 5 mL PEG 400 After Oral Administration in Healthy Male Volunteers||Boehringer Ingelheim||Completed|March 2003|||December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02257008||35569|
NCT02257021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.7|Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers|Study of Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir||Boehringer Ingelheim||Completed|February 2005|||May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|19 Years|59 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02257021||35568|
NCT02500433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR CHILDREN 2015|Virtual Reality in Children With Cerebral Palsy|Use of a Low Cost Videogame Console in Children With Cerebral Palsy in a School Environment||Universidad Rey Juan Carlos|No|Completed|January 2013|January 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|4 Years|11 Years|No|||July 2015|July 15, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02500433||16890|
NCT02498951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11601|Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response|Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders||OHSU Knight Cancer Institute|Yes|Recruiting|June 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498951||17004|
NCT02245685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC 07/7-M|Longitudinal Followup of Patients Under Substitution Therapy From the Moment They Enter a Specialized Care Center for Addicts to the Period They Are Monitored by a General Practitioner Outside the Specialized Care Center|Longitudinal Followup of Patients Under Substitution Therapy From the Moment They Enter a Specialized Care Center for Addicts to the Period They Are Monitored by a General Practitioner Outside the Specialized Care Center||Nantes University Hospital|No|Completed|January 2008|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|N/A|N/A|No|Non-Probability Sample|Patients under substitution therapy monitored in a specialized care center for addicts|November 2014|November 5, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02245685||36439|
NCT02245698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-11|Autologous Stem Cell Therapy in Stroke|Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Stroke||Neurogen Brain and Spine Institute|Yes|Recruiting|December 2008|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|80 Years|No|||September 2014|September 17, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245698||36438|
NCT02495753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505127|Vaginal Cleansing Before Cesarean Delivery to Reduce Infection|Vaginal Cleansing Before Cesarean Delivery to Reduce Infection: A Randomized Trial||Washington University School of Medicine|Yes|Recruiting|August 2015|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|608|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 8, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02495753||17249|
NCT02510313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15440|Family Strengthening Intervention: Early Childhood Development (Rwanda)|Effectiveness Trial of a Family Home Visiting Intervention to Promote Early Child Development Among Families Served by the Social Protection System in Rwanda|FSI/ECD|Harvard School of Public Health||Not yet recruiting|August 2015|July 2020|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|1040|||Both|N/A|5 Years|No|||July 2015|July 27, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510313||16131|
NCT02496325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9397|Ultrasound-guided Pudendal Nerve Block in Children: A Descriptive Study of Feasibility|Ultrasound-guided Pudendal Nerve Block in Children: A Descriptive Study of Feasibility||University Hospital, Montpellier|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|196|||Both|N/A|15 Years|No|||June 2015|July 13, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02496325||17205|
NCT02246972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072196|BraveMind: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy|BRAVEMIND: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy System for MST||Emory University|No|Recruiting|May 2015|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02246972||36340|
NCT02255136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|793/MBHMCH/CH/Adm/01/2011|Efficacy Study of Homeopathic Medicines in Treatment of Allergic Rhinitis and/or Induced Bronchial Asthma|An Evidence-based Single-blind Randomized Controlled Trial Searching for the Efficacy of Homoeopathic Medicines in Reducing Serum Levels of Cytokines (IL - 10, 13) and Immunoglobulin E in Allergic Rhinitis and/or Induced Bronchial Asthma|SBRCTHILARBA|Mahesh Bhattacharyya Homoeopathic Medical College and Hospital|Yes|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|65 Years|No|||March 2016|March 19, 2016|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT02255136||35712|
NCT02502734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107112|Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma|A Randomised, Double-blind, Two-way Crossover Study to Investigate the Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma||GlaxoSmithKline|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|11 Years|No|||January 2016|January 7, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502734||16713|
NCT02502747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGENERA 2.0|RIGENERA 2.0 Trial|RIGENERA 2.0 (Recupero Dall'Infarto Miocardico Con G-CSF E Nuovi Esempi di Rigenerazione Avanzata) Project: "The Combined Effect of Subcutaneous Granulocyte - Colony Stimulating Factor and Myocardial Contrast Echocardiography With Intravenous Infusion of Sulphur Hexafluoride on Post-infarction Left Ventricular Function"|RIGENERA|Catholic University of the Sacred Heart|Yes|Recruiting|January 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02502747||16712|
NCT02509689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W91YTZ-13-P-0703|Neurofeedback Technology (GZNT) for Persistent Post-Concussive Symptoms in Soldiers|Feasibility Study of a Novel Neurofeedback Technology (GZNT) for Persistent Post-Concussive Symptoms in Soldiers|GZNT|The Defense and Veterans Brain Injury Center|No|Recruiting|December 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|50 Years|No|||August 2015|August 5, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02509689||16179|
NCT02494583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-062|Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)|A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma||Merck Sharp & Dohme Corp.|Yes|Recruiting|July 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494583||17339|
NCT02252549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50451.018.14|An International Randomized Study to Compare SPIES Versus WLI|The SPIES Non-Muscle-Invasive Bladder Cancer Study - A Multicenter Randomized Controlled Study; A Multicenter International Randomized Controlled Study to Compare the Outcome Using the Storz Professional Image Enhancement System (SPIES) Versus White Light Imaging (WLI) During TURB of Non-Muscle-Invasive Bladder Cancer (NMIBC).||Clinical Research Office of the Endourological Society|Yes|Enrolling by invitation|April 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|1928|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252549||35911|
NCT02257047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RYR20140104|Red Yeast Rice and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257047||35566|
NCT02257060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINEAR II|LINEAR II - LME-159 Evaluation of a Multi-Electrode Linear Type Ablation Catheter|Evaluation of a Multi-Electrode Linear Type Ablation Catheter for Endocardial Ablation of Patients With Right Atrial Flutter||Biosense Webster, Inc.||Completed|September 2014|May 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257060||35565|
NCT02509884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166/13|Long-term Results of Comprehensive AE Management|Comprehensive Diagnosis and Treatment of Alveolar Echinococcosis : A Single-center, Longterm Observational Study of 312 Patients in Germany||University of Ulm|No|Completed|January 1992|December 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|312|||Both|N/A|N/A|No|Non-Probability Sample|All patients with AE seen at the specialized treatment unit in Ulm between January 1992        and December 2011 were included in the database. Follow-up ended on 31.12.2012. Cases were        defined according to the likelihood of diagnosis as a "possible", "probable", or        "confirmed case"|July 2015|July 27, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02509884||16164|
NCT02509897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpoxiMet|Normobaric Hypoxic Training and Multiple Sclerosis|Cardiorespiratory, Metabolic and Immunoregulatory Response to Hypoxia in Multiple Sclerosis Patients: A Pilot Study|MS_EPOXI|Charite University, Berlin, Germany|No|Recruiting|July 2015|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|48|||Both|20 Years|60 Years|No|||January 2016|January 27, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509897||16163|
NCT02497703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.037T (Knee)|Interactive Exoskeleton Robot for Walking - Knee Joint|Interactive Exoskeleton Robot for Walking - Knee Joint||Chinese University of Hong Kong|No|Recruiting|May 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02497703||17100|
NCT02296879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-077|A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types|A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types||Samsung Medical Center|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296879||32509|
NCT02345798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14302|Video-Assisted Intervention in Improving Recovery in Patients With Cancer Undergoing Lung Surgery and Caregivers|Preparing Patients and Informal Caregivers for Lung Surgery: Pilot Study of a Video-Assisted Intervention to Enhance Post-Operative Recovery||City of Hope Medical Center|Yes|Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02345798||28756|
NCT02345811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||March 30, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345811||28755|
NCT02356640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUSCGN-02|EUS-guided CGN for Inoperable Cancer|A Randomized Controlled Trial on Endoscopic Ultrasound-guided Celiac Ganglion Neurolysis Versus Percutaneous Celiac Plexus Neurolysis in Patients With Inoperable Cancer||Chinese University of Hong Kong|No|Recruiting|August 2014|||August 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|August 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356640||27925|
NCT02303041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0020|Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma|An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas||Stanford University||Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|November 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02303041||32035|
NCT02303288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-03-01|Post-Market Study of the Argus® II Retinal Prosthesis System - France|Post-Market Study of the Argus® II Retinal Prosthesis System - France||Second Sight Medical Products|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Both|25 Years|N/A|No|Non-Probability Sample|Patients with retinitis pigmentosa who have bare light perception or worse in both eyes|May 2015|May 28, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02303288||32016|
NCT02294500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-1|Cohort Study to Evaluate Ovarian Function|Multicenter Cohort Study to Evaluate and to Protect Ovarian Function and Reproductive Function||Huazhong University of Science and Technology|Yes|Recruiting|July 2011|July 2021|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|Our biospecimen included blood, serum, plasma and other body fluid and tissues|Female|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|women with normal ovarian function or decreased ovarian function|March 2016|March 15, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02294500|10 Years|32691|
NCT02359877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-054-1|Open Label Study of Tolerability, PK and PD of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers|||Biocad|No|Completed|July 2014|December 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02359877||27678|
NCT02345577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176/14|Whole-body Vibration Physiotherapy in Kidney Transplantation|Effects of Stochastic Whole-body Vibration Physiotherapy-WBV (Stochastic Resonance Physiotherapy-SRT) on Muscle Strength in Patients After Kidney Transplantation: a Pilot Study||University Hospital Inselspital, Berne|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|80 Years|No|||July 2015|July 29, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345577||28773|
NCT02357745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|suma thesis|Evaluation of Neopterin Levels in Pre and Post-menopausal Women With Periodontitis Following Non Surgical Therapy|Biochemical Evaluation of Plasma,Urine and Salivary Neopterin Levels in Pre and Post-menopausal Women With Periodontitis Following Non-surgical Therapy|ENLPPMNS|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Not yet recruiting|February 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|30|||Female|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|15 pre-menopausal women with periodontitis 15 post-menopausal women with periodontitis|January 2015|February 5, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02357745||27841|
NCT02301377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00080071|Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis|Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis||University of Michigan|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5|||Both|10 Years|21 Years|No|||June 2015|June 22, 2015|November 21, 2014||No||No|June 3, 2015|https://clinicaltrials.gov/show/NCT02301377||32163|
NCT02300883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2011|Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients|Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma||Istituto Clinico Humanitas|No|Active, not recruiting|April 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|pleural effusion|Both|N/A|N/A|No|Probability Sample|Malignant pleural mesothelioma patients|April 2015|April 13, 2015|May 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02300883||32201|
NCT02344758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELIFLUID1|Gluten-free Diet Monitoring in Urine|Non-invasive Gluten-free Diet Adherence Monitoring in Celiac Patients: Detection of Gluten Immunogenic Peptides in Urine||University of Seville|Yes|Completed|April 2013|December 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|4||Actual|134|||Both|3 Years|N/A|No|||January 2015|January 22, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02344758||28836|
NCT02357498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14BN151|Transsphenoidal Extent of Resection Study|Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas|TRANSSPHER|St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|February 2015|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02357498||27860|
NCT02357511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDIETA2015|Validation of Pulse Waveform Analysis-based Continuous Noninvasive Blood Pressure Measurement Sensor|Validation of Pulse Waveform Analysis-based Continuous Noninvasive Blood Pressure Measurement Sensor||Tampere University Hospital|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02357511||27859|
NCT02300558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-372-1234|Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3|A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3||Gilead Sciences|Yes|Recruiting|December 2014|August 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300558||32226|
NCT02304731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSao Paulo|Physical Exercise and Pollution: Cardiorrespiratory, Cerebral and Molecular Aspects|Physical Exercise and Pollution: Cardiorrespiratory, Cerebral and Molecular Aspects.||Federal University of São Paulo|No|Completed|February 2013|July 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 27, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304731||31905|
NCT02353507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14-054|Comparison of Chitosan and Carboxymethylcellulose Silver Dressings on Burn Wounds in Pediatric and Adult Subjects|A Multi-Center, Randomized, Comparison Study of a Chitosan (Opticell Ag+) Silver Dressing and a Sodium Carboxymethylcellulose (Aquacel® Ag+) Silver Dressing on Burn Wounds in Pediatrics and Adults Subjects||Medline Industries|No|Not yet recruiting|February 2015|August 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|N/A|No|||February 2015|February 9, 2015|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353507||28166|
NCT02353650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/27/286|The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients: a Double-blinded Randomized Trial.|||University Hospital, Antwerp||Recruiting|November 2014|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2015|February 2, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02353650||28155|
NCT02358473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-011|Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer|Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Subjects With Non-small Cell Lung Cancer (NSCLC)||Kyowa Hakko Kirin Pharma, Inc.|Yes|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358473||27786|
NCT02358486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMCOH 2014-08-002|The Effect and Mechanism of Acupuncture on Functional Dyspepsia|Effect and Mechanism of Acupuncture on Patients With Functional Dyspepsia: a Protocol for a Randomized, Assessor-blind, Sham-controlled Trial||Kyunghee University Medical Center|Yes|Recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|49 Years|No|||February 2016|February 26, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02358486||27785|
NCT02298933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150015|Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia|Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||September 2015|February 6, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02298933||32351|
NCT02302807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29294|A Study of Atezolizumab Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]|A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY [IMvigor211]||Hoffmann-La Roche||Active, not recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|930|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302807||32053|
NCT02301416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027047|Qsymia as an Adjunct to Surgical Therapy in the Superobese|Qsymia as an Adjunct to Surgical Therapy in the Superobese||Wake Forest School of Medicine|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||June 2015|June 22, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02301416||32160|
NCT02349776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS12/10259|Experiencing Transplant With Stories From Survivors|How do Stories of Survival Help Patients Going Through Bone Marrow Transplant?||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349776||28451|
NCT02350062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-183|Comparison of Two Neuromuscular Monitors|Comparison of Two Neuromuscular Monitors|NMT-STIMPOD|University Hospital, Caen|No|Completed|January 2014|November 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing vascular surgery under general anesthesia and requiring neuromuscular        blockade for intubation or surgery|January 2015|January 28, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02350062||28430|
NCT02357667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821592|The Study of Cardiovascular Outcomes in Women With Preeclampsia Using Echocardiography: The SCOPE Study|The Study of Cardiovascular Outcomes in Women With Preeclampsia Using Echocardiography: The SCOPE Study|SCOPE|University of Pennsylvania|No|Recruiting|March 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Evaluation of angiogenic factors, markers of heart failure, and evaluation of extracellular      RNAs will specifically be used for discovery. The investigators will not be evaluating DNA.|Female|18 Years|45 Years|No|Non-Probability Sample|This study will take place on the obstetrical unit at the Hospital of the University of        Pennsylvania (HUP) as well as in the outpatient setting. The patient population is primary        from the surrounding urban region. The majority receive prenatal care at our institution.        Based on fiscal year 2010 at HUP, the mean age was 24 years old and 85% were African        American.|October 2015|October 16, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02357667||27847|
NCT02305875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-04115B|The Musculocutaneous Nerve in a High Resolution MRI|The Musculocutaneous Nerve (Mcn) in a High Resolution MRI||Diakonhjemmet Hospital|No|Completed|October 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02305875||31817|
NCT02299219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045896|Teens Taking Charge: Managing Cancer Online|Teens Taking Charge: A Pilot Randomized Controlled Trial of an Online Self-Management and Transitional Care Program for Youth With Cancer||The Hospital for Sick Children|No|Not yet recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|12 Years|18 Years|No|||November 2015|November 16, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299219||32329|
NCT02349789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052263|The Role of Cerebellar Hyperactivity in Parkinson's Disease|Stimulating the Little Brain to Make Big Steps: Improving Gait in Parkinson's Disease Patients by Non-invasive Electrical Stimulation of the Cerebellum.||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|People with Parkinson's disease|January 2016|January 14, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349789||28450|
NCT02347670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#14-380|Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population|Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population||Wills Eye|No|Enrolling by invitation|August 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|250|||Both|50 Years|N/A|No|||January 2015|January 21, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02347670||28612|
NCT02305745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140799-01H|Determining the Risk Elevation After Maternity|Determining the Risk Elevation After Maternity|DREAM|Ottawa Hospital Research Institute|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We plan to enroll 40 participants in the study: 30 women who have been diagnosed with        preeclampsia and 10 women who have had a normal pregnancy.|January 2015|January 5, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305745||31827|
NCT02304497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-62550515-01|PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis|Evaluation of Platelet Rich Fibrin Growth Factors (PRF) in Type 2 Diabetic Patients With Chronic Periodontitis||Bulent Ecevit University|No|Completed|March 2013|November 2014|Actual|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|80|||Both|40 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The patients participating the study were recruited from indivuduals referred to        Department of Periodontology, Faculty of Dentistry, University of Bülent Ecevit University        for either dental treatment or dental check-ups.|December 2014|December 1, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02304497|1 Day|31923|
NCT02349061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106661|A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus||Janssen Research & Development, LLC|Yes|Recruiting|October 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349061||28506|
NCT02346851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0602|The Effects of Accelerometer Triggered Functional Electrical Stimulation on Post-Stroke Hemiplegic Shoulder Subluxation|||Yonsei University|No|Recruiting|October 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|N/A|No|||January 2015|January 20, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02346851||28675|
NCT02347085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003012|24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI|A Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003 and Placebo MDI||Pearl Therapeutics, Inc.|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|40 Years|80 Years|No|||March 2016|March 16, 2016|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347085||28657|
NCT02293746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002|Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study|Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study: CE Certificate Number 562872||Inspire Medical Systems, Inc.|No|Active, not recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02293746||32749|
NCT02357407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004193-4|Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model|Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model|FLUO-POP|Rennes University Hospital|No|Recruiting|June 2015|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02357407||27866|
NCT02357134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0971|High-Flow Oxygen for Exertional Dyspnea|High-Flow Oxygen for Exertional Dyspnea in Cancer Patients||M.D. Anderson Cancer Center|Yes|Recruiting|March 2015|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357134||27887|
NCT02302820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006947|Nurse-led Patient-centered Advance Care Planning: A Pilot Study|Nurse-led Patient-centered Advance Care Planning: A Pilot Study|ACP|Mayo Clinic|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|78|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02302820||32052|
NCT02302833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0081|Cabozantinib for Malignant Pheochromocytoma|A Pilot Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302833||32051|
NCT02305186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17801|Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer|A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic Cancer|UVA-PC-PD101|University of Virginia|Yes|Recruiting|March 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305186||31870|
NCT02354001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94/06|Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia|Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia||The Alfred|No|Recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||January 2016|January 21, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354001||28128|
NCT02347436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1117|Does Benign Prostatic Obstruction Cause Hypertension?|Effect of Transurethral Prostate Resection on 24 Hour Blood Pressure Measurement||St. Olavs Hospital|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Male|N/A|65 Years|No|Non-Probability Sample|Patients on the waiting list for inguinal hernia repair, hydrocele operation, or        transurethral resection of the prostate, at St Olavs University Hospital, Department of        Surgery, Trondheim, Norway|November 2015|November 27, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347436||28630|
NCT02296801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-11|A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer|A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer|PALLET|NSABP Foundation Inc|Yes|Recruiting|January 2015|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|306|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296801||32514|
NCT02296814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDE-1|Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis|Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase IV Study (Sinusitis Study)|CESAR|Hevert-Arzneimittel GmbH & Co. KG|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|75 Years|No|||July 2015|July 16, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02296814||32513|
NCT02303652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACFA1|Biatrial Contractility Recovery After Maze|Surgical Treatment of Concomitant Atrial Fibrillation: a Comprehensive Insight Into Biatrial Contractility Recovery.||Centro Cardiologico Monzino||Completed|January 2005|||November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Both|N/A|N/A|No|Probability Sample|Patients affected by atrial fibrillation undergoing mitral valve surgery|November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02303652||31988|
NCT02354651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-2013|Response to Diaphragmatic Pacing in Subjects With Pompe Disease|Response to Diaphragmatic Pacing in Subjects With Pompe Disease||University of Florida|No|Recruiting|May 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|2 Years|65 Years|No|Non-Probability Sample|Subjects with Pompe disease who are eligible for NeuRx DPS implantation|October 2015|October 14, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354651||28078|
NCT02351778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D43TW008660-04|Quality of Life of Stable Stroke Survivors in Pakistan|Quality of Life of Stable Stroke Survivors and Their Caregivers in an Low and Middle Income Country||Aga Khan University|No|Completed|January 2014|June 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|350|||Both|18 Years|N/A|No|Non-Probability Sample|All men and women greater than 18 years, with a chronic stable stroke, medically confirmed        supported by medical reports or radiological and neurological diagnosis and with an        identified primary care giver.|January 2015|January 29, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02351778||28298|
NCT02295982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-416|Laparoscopic Versus Hand Assisted Laparoscopic Trans-peritoneal Laparoscopic Nephrectomy as One Day Surgery (i.e.: Are There Differences in Postoperative Outcome / Convalescence)|||University Hospital Roskilde|Yes|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|75 Years|No|||November 2015|November 15, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295982||32577|
NCT02296242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVD-523-02|Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes|Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes||BioMed Valley Discoveries, Inc||Recruiting|November 2014|January 2018|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|100 Years|No|||October 2015|October 20, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296242||32557|
NCT02293473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOMM|Surgical Outcome and Multimodal Monitoring - SOMM|The Impact of Multimodal Monitoring During Major Surgery on the Morbidity, Mortality and Duration of Hospital Stay in UMC Ljubljana|SOMM|University Medical Centre Ljubljana|No|Suspended|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|126|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|June 10, 2014||No|Funding attempts failed.|No||https://clinicaltrials.gov/show/NCT02293473||32770|
NCT02293486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRA 01|Study of Pomegranate Juice in the Modulation of Oxidative Stress Markers in Endurance-based Athletes|||Universidad Miguel Hernandez de Elche|Yes|Completed|August 2012|February 2013|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293486||32769|
NCT02293499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00053987|Peer Led Asthma Self Management for Adolescents: PLASMA|Peer Led Asthma Self Management for Adolescents: PLASMA|PLASMA|University of Rochester|Yes|Recruiting|November 2014|November 2019|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02293499||32768|
NCT02354014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106371|Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB|A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB||Janssen Research & Development, LLC|Yes|Not yet recruiting|March 2016|December 2022|Anticipated|March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|18 Years|No|||March 2016|March 15, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354014||28127|
NCT02351050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13595|Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting|Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring||University Hospital Ostrava|Yes|Recruiting|April 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|35 Years|90 Years|No|||December 2015|December 22, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02351050||28354|
NCT02351063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0144|HF Assessment With BNP in the Home: Part II|HF Assessment With BNP in the Home: Part II|HABIT-II|Alere San Diego|Yes|Terminated|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|January 12, 2015||No|Sponsor's discretion to terminate study prematurely for further evaluation.|No||https://clinicaltrials.gov/show/NCT02351063||28353|
NCT02303158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISPV-LIDEAL-HTVC|Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression|Study of the Relationship Between Protein Biomarkers in Cerebrospinal Fluid and the Risk of Progression to Alzheimer&Apos;s Disease in a Cohort of Patients With Depression|LIDEAL|Institut Investigacio Sanitaria Pere Virgili|Yes|Recruiting|January 2014|February 2018|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|cerebrospinal fluid (CSF), blood serum, blood plasma and whole blood|Both|18 Years|60 Years|No|Probability Sample|Consecutive patients referred from Primary Care and Psychiatry, Neurology with        consultations for specialist for cognitive impairment and / or depression who met the        inclusion criteria of the study assessment.|November 2015|November 23, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02303158||32026|
NCT02303171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIE1|Use of Warfarin After the First Trimester in Pregnant Women With APS|Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome||Mansoura University|No|Recruiting|January 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|38 Years|No|||March 2016|March 4, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303171||32025|
NCT02303184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS1003-201|Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO|TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion|TANZANITE|Clearside Biomedical, Inc.|No|Completed|January 2015|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303184||32024|
NCT02345551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03408|A Physical Activity Intervention for Female Shift Workers|The Feasibility of a Telephone and Web-based Physical Activity Intervention for Female Shift Workers.|SWPA|University of British Columbia|No|Completed|February 2015|October 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02345551||28775|
NCT02346617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2010-08-129-008|Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection|Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients||Samsung Medical Center|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|65 Years|No|||November 2015|November 17, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02346617||28693|
NCT02305732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00108|A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components|A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components|TRUE|Cerus Corporation||Recruiting|March 2015|August 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Patients requiring a platelet transfusion.|August 2015|August 24, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305732||31828|
NCT02294032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140147|The Role of B Cells in Kidney Allograft Dysfunction|The Role of B Cells in Kidney Allograft Dysfunction||Loma Linda University|Yes|Recruiting|June 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Whole blood, and plasma or serum|Both|2 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric and Adult patients who are on the waitlist for a kidney or liver, or are about        to undergo kidney or liver transplantation.|January 2016|January 28, 2016|May 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02294032|5 Years|32727|
NCT02358239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120403|Efficacy and Safety of Acupuncture for Dizziness and Vertigo in Emergency Department: a Clinical Control Trial|||Changhua Christian Hospital||Completed|February 2013|February 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Both|20 Years|90 Years|No|||February 2015|February 3, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02358239||27804|
NCT02358252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-140103|Heart Rate Variability and Orthostatic Hypotension in Stroke Patients Evaluated by Intelligent Biosensor System|Changhua Christian Hospital||Changhua Christian Hospital|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|45 Years|75 Years|No|Probability Sample|stroke patients|November 2015|November 10, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02358252||27803|
NCT02358265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU-LATER|Chronic Urticaria - Long Term Assessment of Effects of Rupatadine|A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine.||Charite University, Berlin, Germany|No|Recruiting|December 2014|April 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|192|||Both|18 Years|75 Years|No|||August 2015|August 26, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02358265||27802|
NCT02301104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS-102-106|A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment|A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment.||Taiho Oncology, Inc.|No|Recruiting|January 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02301104||32184|
NCT02309372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL126557|Depression Therapy to Improve Cardiovascular Risk in HIV|A Randomized, Controlled Pilot Trial Assessing the Utility of Cognitive Behavioral Therapy to Improve Endothelial Function and Reduce Inflammation in Depressed, Virologically-Suppressed, Antiretroviral-Treated, HIV-infected Adults||Indiana University|Yes|Recruiting|April 2015|August 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309372||31550|
NCT02358850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|658-14|Post-tonsillectomy Pain Control in Adults|Post-tonsillectomy Pain Control in Adults: a Randomized Prospective Study||University of Nebraska|No|Not yet recruiting|January 2016|||June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 13, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358850||27757|
NCT02357173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035634|A Trial of E-cigarettes in Current Cigarette Smokers|A Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use||Medical University of South Carolina|Yes|Active, not recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|68|||Both|18 Years|N/A|No|||September 2015|February 12, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02357173||27884|
NCT02300831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532R00004|LUMINIST: LUng Cancer Molecular Insights Non Interventional Study|LUMINIST: LUng Cancer Molecular Insights Non Interventional Study|LUMINIST|AstraZeneca|No|Enrolling by invitation|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1065|None Retained|All samples used in the study are collected under the auspices of the SELECT 1 study      screening. Luminist provides the clinical data to correlate the with sample results.|Both|N/A|N/A|No|Non-Probability Sample|Advanced 2nd line NSCLC patients who are screened for two randomised clinical trials        (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet        eligibility criteria for those trials.|March 2016|March 2, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300831||32205|
NCT02310178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8855|Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery|Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery|BAREVAL|University Hospital, Montpellier|No|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|750|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02310178||31488|
NCT02356900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060147|Hyperbaric VO2max Study|Effects of High Intensity Interval Training in a Hyperoxic-hyperbaric Environment on Exercise Performance at Altitude||Duke University|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356900||27905|
NCT02356913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-IN112|Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum|A Pilot, Open Label, Randomised, Single Dose, Four-Period, Four-Treatment, Four-Sequence, Four Way Crossover Comparative Pharmacokinetic Study of Three Different 4 mg Nicotine Chewing Gum Test Formulations of Fertin Pharma A/S, Denmark With Nicorette Freshmint 4 mg Medicated Chewing Gum of McNeil Denmark ApS as Reference Formulation in Healthy, Adult, Human Smokers Under Fasting Conditions||Fertin Pharma A/S||Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356913||27904|
NCT02305342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOX5001|Sensitivity of Antibiotics for Urinary Tract Infections Patients Attending Family Physicians|Antibiotic Susceptibility of Bacterial Uro-Pathogens In Patients Attending Family Physicians" (In Vitro Study)||Abbott|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|350|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinics|March 2015|March 5, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02305342||31858|
NCT02305355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-OM-9412|Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia|Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia||Kuhnil Pharmaceutical Co., Ltd.|No|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|80 Years|No|||November 2014|December 1, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02305355||31857|
NCT02298491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062490|CNS Sarcoidosis and Acthar Gel|Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel||University of Maryland|Yes|Not yet recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||November 2014|November 19, 2014|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298491||32385|
NCT02298764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT2014PTSD|Back Pain and PostTraumaticStressDisorder. A Randomized Clinical Trial|Somatic Experiencing for Patients With Comorbid Posttraumatic Stress and Back Pain - A Randomized Controlled Trial.||University of Southern Denmark|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02298764||32364|
NCT02349529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12KH157|An Exploratory RCT of a Psychosocial Group Intervention for Epilepsy|An Exploratory Randomised Controlled Trial of a Manualised Psychosocial Group Intervention for Young People With Epilepsy (PIE)|PIE|NHS Greater Glasgow and Clyde|No|Not yet recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|12 Years|17 Years|No|||January 2015|January 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02349529||28470|
NCT02351024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXP005-001|Phase I Study PK Study With OXP005 and Naprosyn|Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn® Tablets (Reference) in Normal, Healthy, Adult Subjects||Oxford Pharmascience Ltd|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|N/A|2||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02351024||28356|
NCT02351037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1131-CA|A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia|A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia||Pharmacyclics|No|Recruiting|January 2015|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|101|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02351037||28355|
NCT02296489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D007773|An Association Between Asthma Severity and Capnography Parameters|An Association Between Asthma Severity and Capnography Parameters||Oridion|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|73|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sixty subjects, both men and women, who will be invited to participate in the methacholine        challenge in the Institute of Pulmonary Medicine at Rabin Medical Center, regardless to        the study, will be recruitment to the study.|August 2015|August 26, 2015|November 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296489||32538|
NCT02298998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130177H|Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study|Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|March 2013|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|After participant signs the consent form, research staff may ask participant to provide a      urine sample at each study visit for research purposes.|Both|18 Years|N/A|No|Probability Sample|Patients with a history of low or low-intermediate risk non-muscle invasive bladder        cancer. They are being followed with periodic examinations of their bladder as a means for        cancer surveillance.|December 2015|December 1, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02298998|2 Years|32346|
NCT02299011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1403-244-002|Comparison of Biomatrix and Orsiro Drug Eluting Stent|Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients With All-comer Patients With Coronary Artery Disease : A Multicenter, Randomized, Open Label Study (BIODEGRADE Study)|BIODEGRADE|Seoul National University Bundang Hospital|Yes|Recruiting|February 2014|October 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3850|||Both|18 Years|85 Years|No|||June 2015|June 11, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299011||32345|
NCT02345304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344.3|Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin|A Study to Investigate the Effects of BI 1181181 on the Pharmacokinetics of Midazolam, Warfarin, Omeprazole and Digoxin in Healthy Male Subjects||Boehringer Ingelheim||Withdrawn|March 2015|May 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 8, 2015|January 20, 2015||||No||https://clinicaltrials.gov/show/NCT02345304||28794|
NCT02345564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBEMaRe 001|Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery|Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery||Barmherzige Brüder Eisenstadt|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|16 Years|65 Years|No|||July 2015|July 21, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02345564||28774|
NCT02351323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27812 (K23DK082732)|Novel Type 2 Diabetes Mellitus Preventive Therapies|Novel Type 2 Diabetes Mellitus Preventive Therapies||Boston Medical Center|Yes|Completed|May 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|12 Years|19 Years|No|||January 2015|January 27, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02351323||28333|
NCT02351570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSPH GP´s Prevention Programme|Health Prevention Programmes to Patients Through Their General Practitioners|Offer and Mediation of §20 SGB V Health Prevention Programmes to Patients Through Their Treating General Practitioner - a Mixed Methods Study||Berlin School of Public Health|No|Completed|November 2010|March 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|474|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In this study all general practitioners of Berlin (n=1300) will be mailed. Participants        for the focus groups are invited from the pool of teaching doctors of the Institute for        General Medicine at the Charite (see characteristics below) which are also part of the        mail survey.|January 2015|January 29, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351570||28314|
NCT02303431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-A-U157|Phase 1 Pediatric PK/PD Study|A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients||Daiichi Sankyo Inc.|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|8||Anticipated|48|||Both|N/A|18 Years|No|||July 2015|July 23, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303431||32005|
NCT02296567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29189|Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients|Comparison of Pharmacokinetics of and Effect on Systemic Vascular Endothelial Growth Factor (VEGF) Levels Over Time of Intravitreal Ranibizumab and Bevacizumab and Aflibercept in Age Related Macular Degeneration Patients||East Florida Eye Institute|No|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|10||Anticipated|80|||Both|50 Years|N/A|No|||August 2015|August 7, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296567||32532|
NCT02345837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|menoufia ob/gyn|Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles|Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles||Al Hayat National Hospital|Yes|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345837||28753|
NCT02344095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG3030|A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer|A Randomized Phase 1 Trial Evaluating the Safety of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|POPOPO|Seoul National University Hospital|Yes|Recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Female|N/A|N/A|No|||January 2015|January 22, 2015|November 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344095||28886|
NCT02298686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSF01-2014|Biomarker for Sanfilippo Disease|Biomarker for Sanfilippo Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioSanfilippo|University of Rostock|Yes|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with Sanfilippo Type A-B-C-D disease or patients with high-grade suspicion for        Sanfilippo Type A-B-C-D disease submitted to the participating centers should be included        into the study.|October 2015|October 6, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298686||32370|
NCT02302677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|695-14-WBS#noneMHX#pending|The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids|The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids|BAS|University of Nebraska|No|Not yet recruiting|January 2015|December 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|Samples Without DNA|Serum Urine|Both|19 Years|70 Years|No|Non-Probability Sample|Morbidly obese patients who are being treated in the Bariatric Clinic at the University of        Nebraska Medical Center|November 2014|November 26, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02302677||32063|
NCT02295748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-022OLE|An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort|An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Orally Administrated Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy||Marathon Pharmaceuticals, LLC|No|Active, not recruiting|December 2014|April 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|4 Years|N/A|No|||January 2016|January 14, 2016|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02295748||32595|
NCT02359331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1408/285-005|The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection|A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.||Seoul National University Bundang Hospital|Yes|Recruiting|August 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359331||27720|
NCT02359344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1014802/101|PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers|A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects||Convergence Pharmaceuticals|No|Recruiting|February 2015|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359344||27719|
NCT02358447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPECT/CT-TKR_001_MH|SPECT-CT for Assessment of Total Knee Arthroplasty in Navigated and Non-navigated Total Knee Arthroplasty|SPECT-CT for Assessment of Patients Before and After Navigated and Conventional Total Knee Arthroplasty.||Kantonsspital Baselland Bruderholz|Yes|Recruiting|April 2010|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|210|||Both|18 Years|N/A|No|Probability Sample|Paitents before and after total knee replacement surgery|February 2016|February 23, 2016|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02358447||27788|
NCT02358460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0808/147-3|Pressure-limited Ventilation Versus Volume-targeted Ventilation in Term Newborns|Randomised Controlled Trial Comparing Volume-targeted to Pressure-limited Ventilation in Infants Born at or Near Term||King's College London|No|Completed|May 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|4 Weeks|No|||February 2015|February 3, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02358460||27787|
NCT02294981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15201|Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis|A Randomized Clinical Trial to Determine Whether a Novel Plaque-based Dosimetry Strategy Can Improve the Speed of Response to Treatment in Patients With Plaque Psoriasis (Photos)|Photos|University of California, San Francisco|No|Not yet recruiting|January 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294981||32654|
NCT02353806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042014-059|Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation|Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation||University of Texas Southwestern Medical Center|No|Recruiting|January 2015|September 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|50 Years|No|||January 2015|February 2, 2015|January 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02353806||28143|
NCT02353819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062014-027|Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer|Phase I Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets for Patients With High Risk Prostate Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|99 Years|No|||February 2016|February 12, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353819||28142|
NCT02356588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP301|A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery||AcelRx Pharmaceuticals, Inc.|No|Completed|February 2015|July 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356588||27929|
NCT02300818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141110|Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion.|Magneto Therapy in the Therapy of Glaucoma|GME|American Society Of Thermalism And Climatology Inc|Yes|Recruiting|November 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300818||32206|
NCT02303509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0001|Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject|A Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study Evaluating The Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of UCB5857 in Healthy and Mild-to-Moderate Psoriatic Subjects||UCB Pharma|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|57|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303509||31999|
NCT02303522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120299|Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)|A Retrospective Pooled Analysis of Complete Remission Among Pediatric Patients With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL)||Amgen|No|Completed|December 2014|May 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|207|||Both|N/A|17 Years|No|Non-Probability Sample|Children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)|September 2015|September 22, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02303522||31998|
NCT02349542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-14-10B|Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty|The Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty||OrthoCarolina Research Institute, Inc.|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349542||28469|
NCT02349555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PHX-0001|Nutritional Supplement Impact on Metabolic Parameters|An Open-Label Single-Center Study to Determine Safety and Effects of Novel Nutritional Blend on Inflammatory Balance Markers and Metabolic Parameters||Pharmanex|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02349555||28468|
NCT02357082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001925|Mayo Clinic Cardiac Implantable Electronic Device MRI Registry|Mayo Clinic Cardiac Implantable Electronic Device (CIED) Magnetic Resonance Imaging (MRI) Registry; Determining the Risks of of MRI in the Presence of Cardiac Implantable Electronic Devices||Mayo Clinic|No|Not yet recruiting|May 2016|December 2021|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at Mayo Clinic who have a previously implanted CIED and are scheduled for a        clinically-indicated MRI will be included in the registry.|January 2016|January 12, 2016|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02357082|6 Months|27891|
NCT02357095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT|UACE Followed by Uterine Suction Curettage for the Treatment of Caesarean Scar Pregnancy|Evaluation of the Efficacy and Complications of UACE Combined With Suction Curettage Under Different Kind of Monitoring Methods for the Treatment of Caesarean Scar Pregnancy|UACECSP|Maternal and Child Health Hospital of Hubei Province|Yes|Completed|June 2010|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Female|22 Years|45 Years|No|||February 2015|February 2, 2015|December 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02357095||27890|
NCT02305563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA212-016|Phase 1 Study of BMS-936564|A Phase 1, Open-label Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Acute Myeloid Leukemia||Bristol-Myers Squibb|No|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|N/A|No|||January 2016|March 11, 2016|November 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02305563||31841|
NCT02305576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-181|Effect of Perioperative Factors on the Analgesia Nociception Index|Effect of Perioperative Factors on the Analgesia Nociception Index|ANIFACT|University Hospital, Caen|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patietns undergoing planned surgery under general anesthesia|July 2015|July 30, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305576||31840|
NCT02300610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17924|Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer|A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300610||32222|
NCT02300909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLUD001|dHACM in Lumbar Decompression and Microdiscectomy Surgery|A Randomized, Single Blind, Controlled Trial of Clinical Outcomes of Dehydrated Human Amnion/Chorion Membrane (dHACM) in Lumbar Decompression and Microdiscectomy Surgery||MiMedx Group, Inc.|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|224|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300909||32199|
NCT02350699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Normal-001|Control Study of Nautilus BrainPulse for the Detection of Concussion|Non Blinded Control Study of High School Athletes in Non Contact Sports||Jan Medical, Inc.|No|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|14 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who are healthy controls and participate in a non-contact sport at the high        school level.|February 2016|February 22, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350699||28381|
NCT02350712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31287-A-U106|A Study Using Patritumab in Combination With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer|An Open Label, Phase 1B Safety Evaluation of Patritumab (U31287) in Combination With Cetuximab Plus Platinum Containing Therapy In Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Daiichi Sankyo Inc.|No|Active, not recruiting|December 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350712||28380|
NCT02347956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0864|The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer|||Yonsei University|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|70 Years|No|||November 2015|November 12, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02347956||28591|
NCT02347969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-87|Evaluation of the Effect of the Dietary Supplement X34 on Skin Radiance of Healthy Volunteers With Dull Complexion|Evaluation of the Effect of the Dietary Supplement X34 on Skin Radiance of Healthy Volunteers With Dull Complexion||Nutratech Conseils|No|Enrolling by invitation|October 2014|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347969||28590|
NCT02305420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8114|EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage|EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage|BlastGen|FertilitySA|Yes|Recruiting|November 2014|February 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|25 Years|41 Years|No|||November 2014|November 27, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305420||31852|
NCT02304549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU 14.012|A Prospective Investigation Using the Expired Breath Ethanol Test|Is Absorption of Irrigation Fluid a Problem in Thulium Laser Vaporization of the Prostate? A Prospective Investigation Using the Expired Breath Ethanol Test.||Cantonal Hospital of St. Gallen|No|Completed|April 2014|February 2016|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Male|40 Years|N/A|No|Non-Probability Sample|patients with benign prostatic hyperplasia undergoing TUV-P|February 2016|February 1, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02304549||31919|
NCT02304770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDZJALA-201409|Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia|A Pilot Study of Aminolaevulinic Acid (ALA) Photodynamic Therapy (PDT) in Patients With Cervical Persistent High Risk HPV Infection or Cervical Intraepithelial Neoplasia||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Active, not recruiting|December 2014|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|73|||Female|25 Years|50 Years|No|||December 2015|December 9, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02304770||31902|
NCT02345005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1060-011014|Iliac Branch Excluder ReGistry (IceBERG)|Multi-centre, Observational, Post-market, Real World Registry to Assess Outcomes of Patients Treated With the Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis|IceBERG|Rijnstate Hospital|No|Recruiting|November 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients in whom a Gore IBE was or will be implanted.|October 2015|October 6, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345005|5 Years|28817|
NCT02349815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16903|BAY86-5028 (LCS - ULD LNG Contracept. Syst., Jaydess), NIS|Pharmacoepidemiological Study (Drug Utilization Study) of JAYDESS Use in Routine Clinical Practice in Sweden||Bayer|No|Not yet recruiting|July 2016|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Female|N/A|99 Years|No|Non-Probability Sample|Women in Sweden|March 2016|March 18, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02349815||28448|
NCT02347111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR9644|Pilot Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation|A Pilot and Feasibility Study to Determine If a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs||Vanderbilt University|No|Not yet recruiting|February 2015|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02347111||28655|
NCT02299739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2013-02|Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine|Liver Enzyme Abnormalities and Its Risk Factors in Taking Traditional Herbal Medicine in Korea||Jaseng Hospital of Korean Medicine|No|Completed|December 2005|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|6894|||Both|N/A|N/A|No|Non-Probability Sample|Musculoskeletal patients admitted to an integrated hospital that offers both complementary        and alternative medicine (CAM) and conventional medicine treatment.|November 2014|November 20, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299739||32289|
NCT02303340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor 0130-13-ctil|Diagnosis of Decreased Bone Density by Dental Cone Beam Computed Tomography|Diagnosis of Decreased Bone Density by Dental Cone Beam Computed Tomography||Soroka University Medical Center|No|Recruiting|February 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women above the age of 60 years, eligible for Bone Density Testing in accordance        with their health insurance, who underwent a Dental CBCT recommended by their Dental        Practitioner.|March 2016|March 15, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303340||32012|
NCT02303353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGONKO-01|Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy|Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy||SPGO Research Mannheim GmbH|No|Recruiting|October 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from carcinoma which are treated in practices (ambulant therapy)|February 2016|February 19, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02303353||32011|
NCT02358148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|521-0|Validation of Simple Acute Coronary Syndrome (SACS) Score|Validation of the Simple Acute Coronary Syndrome (SACS) Score and Head-to-Head Comparison of the SACS vs. Modified TIMI vs. HEART ACS Scores|SACS|Bayfront Health St Petersburg|Yes|Enrolling by invitation|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|All patients selected in this study will be patients who are having URGENT (Group 1) or        NON-URGENT (Group 2) cardiac catheterization performed:        Group 1: All (100%) of STEMI / Non-STEMI patients presenting for cardiac catheterization        during the study period, with a minumum number of 25 STEMI and 25 NSTEMI patients to be        included.        Group 2: Non-urgent cardiac catheterization patients will be randomly selected, with        consents obtained, PRIOR TO elective cardiac catheterization.|February 2015|February 9, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358148||27811|
NCT02357589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCH-328-150127|3D vs 2D HD Laparoscopy in Cholecystectomy|3 Versus 2 Dimensional HD Laparoscopy in Cholecystectomy: a Prospective, Single Blinded, Randomized, Controlled Trial||Helsinki University Central Hospital||Recruiting|January 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|208|||Both|N/A|N/A|No|||February 2015|February 9, 2015|February 3, 2015||||No||https://clinicaltrials.gov/show/NCT02357589||27853|
NCT02347098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-09S-1|Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II|Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II|PREMIER|VA Office of Research and Development|Yes|Recruiting|March 2015|March 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|31 Years|N/A|No|||December 2015|December 2, 2015|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02347098||28656|
NCT02303301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProOro|Changes of Oropharyngeal Flora|Changes in the Oropharyngeal Flora in Hospitalised Patients||Region Skane|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303301||32015|
NCT02309268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARIAT|Atrial Appendage Closure Prospective Observational Study|LARIAT: Atrial Appendage Closure Prospective Observational Study|LARIAT|Virginia Commonwealth University|No|Withdrawn|June 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|Patients being asked to take part in this study have a heart disorder known as atrial        fibrillation (AF) and are poor candidates to take blood thinning drug known as warfarin        (Coumadin), and have elected to undergo LARIAT procedure.|June 2015|June 11, 2015|August 1, 2014||No|The principal linvestigator decided not to continue the registry. No patient were enrolled.    CLosure to the registry was done October 2014|No||https://clinicaltrials.gov/show/NCT02309268||31558|
NCT02309281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eylea1|Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab|Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab||Vista Klinik|No|Completed|May 2013|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02309281||31557|
NCT02309294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-7553|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||February 4, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309294||31556|
NCT02309307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-STR-01|Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)|A Prospective, Open Label, Single Arm, Multi-center Study to Assess the Safety and Performance of a Soft Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)|CP-STR-01|Collplant|No|Recruiting|December 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|October 22, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309307||31555|
NCT02354404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 422|Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda|Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|January 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02354404||28097|
NCT02354417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT1050-04|A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies|A Phase 1 Trial of a Single ProHema® CB Product (Ex Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients With Hematologic Malignancies||Fate Therapeutics|Yes|Recruiting|December 2014|November 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|18 Years|No|||October 2015|October 23, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354417||28096|
NCT02343796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-9.1/4|Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint by Using Fibre-reinforced Composite|Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint Applications by Using Fibre-reinforced Composite.||Ege University|No|Active, not recruiting|June 2003|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02343796||28908|
NCT02347683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|594-14-FB|Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy|Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy||University of Nebraska|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All adults age 19 and above already planning to undergo near total /total thyroidectomy        for reasons unrelated to the study.|December 2015|December 1, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02347683||28611|
NCT02295696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|grhu|EMMA: Empowerment, Motivation and Medical Adherence|EMMA: Empowerment, Motivation and Medical Adherence|EMMA|Steno Diabetes Center|No|Recruiting|November 2014|November 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|270|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02295696||32599|
NCT02359110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1183|Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy|Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy: A Prospective Double-blinded, Placebo Controlled Randomized Study|Gabapentin|Milton S. Hershey Medical Center|Yes|Not yet recruiting|March 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02359110||27737|
NCT02352324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|esCCO-vs-TPTD|Cardiac Output Monitoring With Estimated Continuous Cardiac Output (esCCO) vs. Transpulmonary Thermodilution (TPTD)|Continuous Cardiac Output Monitoring Using esCCO: a Validation vs. Transpulmonary Thermodilution in Off-pump Coronary Artery Bypass Grafting||Northern State Medical University|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|80 Years|No|||January 2015|January 27, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02352324||28256|
NCT02295956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0702|Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer|Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295956||32579|
NCT02295969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL74.14|Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis|An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis||Stallergenes|No|Recruiting|December 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|5 Years|9 Years|No|Non-Probability Sample|Outpatients, children 5 to 9 years of age prescribed ORALAIR for the treatment of        grass-pollen-induced allergic rhinitis with or without conjunctivitis.|October 2015|October 16, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02295969||32578|
NCT02308397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rowett 904|Bakery Products for Non-Coeliac Gluten Sensitive Consumers|Bakery Products for Non-Coeliac Gluten Sensitive Consumers||University of Aberdeen|Yes|Recruiting|November 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02308397||31624|
NCT02350114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-AHF-FC01|An Observational Study of the Functional Capacity of Heart Failure|An Observational Study of the Functional Capacity of Heart Failure Patients With Reduced Ejection Fraction Admitted With Acute Heart Failure||Cardioxyl Pharmaceuticals, Inc|No|Completed|November 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02350114||28426|
NCT02351583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17837|Microcirculatory and Tissue and Cerebral Oxygenation in Preeclampsia and Normal Pregnancy: An Observation Study|Microcirculatory and Tissue and Cerebral Oxygenation Differences Between Preeclampsia and Normal Pregnancy: An Observation Study||University of Virginia|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Age 18 years and older females (10 with diagnosis of preeclampsia and 10 with normal        pregnancy), planned to deliver at UVA|January 2015|January 29, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351583||28313|
NCT02303613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC-001|A Validation of Current Hospital Triage Performance System Versus RETTS|A Validation of Current Hospital Triage Performance System Versus RETTS and Identify Trauma Patient Outcome at Moi Teaching and Referral Hospital, Kenya.|HTPS|University Hospital, Linkoeping|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|628|||Both|14 Years|N/A|No|Probability Sample|Close to 600 trauma patients of ages 14 and above seen at the ED will be captured. All        patients presenting through the ED will be identified and those who meet the inclusion        criteria will be recruited into the study on a daily basis until close to the 600 patient        records is achieved. Patients will be followed through the ED to the receiving facilities        (wards, ICU, HDU, theatre etc)|September 2015|September 27, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303613|30 Days|31991|
NCT02309242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57349|Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study|Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|60|||Both|7 Years|25 Years|No|||August 2015|August 20, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02309242||31560|
NCT02344992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT011|Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal|Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal||Adocia|No|Completed|January 2015|||June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|64 Years|No|||June 2015|June 16, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02344992||28818|
NCT02347423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPV-05|Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age|Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age||Statens Serum Institut|Yes|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|824|||Both|42 Days|49 Days|Accepts Healthy Volunteers|||October 2015|October 6, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02347423||28631|
NCT02305433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236/00.01.05.01.00/2013|Effects of Long-term Intensive Home-based Physiotherapy on Older People With an Operated Hip Fracture or Frailty (RCT).|Effects of Long-term Intensive Home-based Physiotherapy on Older People With an Operated Hip Fracture or Frailty (RCT).||South Karelia, Social and Health Care District|No|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|600|||Both|65 Years|N/A|No|||March 2016|March 8, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305433||31851|
NCT02296307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-276061|DOvEE - Diagnosing Ovarian & Endometrial Cancer Early|Diagnosing Ovarian & Endometrial Cancer Early (DOvEE) by Targeting Symptomatic Women|DOvEE|McGill University|No|Recruiting|January 2012|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|13600|||Female|50 Years|N/A|No|Non-Probability Sample|Women who are 50+ years of age, living in greater Montreal. Women may self-identify and        contact the DOvE Study directly, or be referred from primary care physicians.|February 2016|February 8, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02296307||32552|
NCT02300350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-114-NRM|DDI Study With Multiple-dose LX4211 and Single Dose Digoxin|A Phase 1, Single-center, Open-label, Two-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Digoxin (Lanoxin®), a Sensitive P-glycoprotein (P-gp) Substrate, in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300350||32242|
NCT02358837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204.08.2011|Improving Breast Cancer Diagnostic by Novel sonographicTechniques Study|Improving Breast Cancer Diagnostics by Novel Sonographic Techniques|RadioUS|University Hospital, Basel, Switzerland|Yes|Completed|August 2011|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|236|||Female|18 Years|N/A|No|Non-Probability Sample|The recruitment of ductosonography will target all women attending the outpatient breast        clinic of the department og gynecology and Obstretic, University of Basel, Switzerland.|February 2015|February 3, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02358837|7 Days|27758|
NCT02352051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/580|Effects of Atx and Oros-mph on Executive Functions|Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder||TC Erciyes University|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|7 Years|12 Years|No|||January 2015|January 30, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02352051||28277|
NCT02300272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400910|Health Behaviors and Time-of-Day: Older Adult Cognitive Function|Modifiable Health Behaviors Associated With Time-of-Day Differences in Older Adults' Practice-Related Learning|OA-TIME|University of Florida|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|94|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Typically, healthy older adults|January 2016|January 19, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300272||32248|
NCT02305407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCI2014|Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery|Neurocognitive and Radiological Assessments in Adult Patients With Moyamoya Disease Undergoing Surgical Revascularization|NRAAMUS|Huashan Hospital|No|Recruiting|March 2016|May 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02305407||31853|
NCT02305511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IO/2014/01|Intraosseous Access During Pediatric Resuscitation|A Comparison of Four Intraosseous Access Devices With Standard Venous Catheterization During Child Cardiopulmonary Resuscitation Simulation: a Randomized Crossover Trial.|IOCPR|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305511||31845|
NCT02305524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/44|Intubation During Adult Intubation|Evaluation of Chest Compression Effect on Airway Management With he Visualized Tracheoscopic Ventilation Tube and the Macintosh Laryngoscopy by Novice Paramedics: a Randomized Crossover Simulation Study.|SLETI|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02305524||31844|
NCT02356731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-LVT-EL-54|LevetIracetam in Patients Being Treated for Epilepsy|The Diagnosis and Management of Patients With Epilepsy: Nationwide, Multicenter Study of Recordings for the Diagnosis and Management of Patients With Epilepsy and Treatment With Levetiracetam in Daily Clinical Practice in Greece|LIBERTY|Elpen Pharmaceutical Co. Inc.|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|450|||Both|6 Years|80 Years|No|Non-Probability Sample|The study will recruit outpatients who are new epilepsy diagnoses or diagnosed prior to        enrollment in the study and treated with levetiracetam for the management of their        disease. All patients will be included from 15 research centers nationwide. Each center        will include ≥30 patients to be monitored (1: 1 newly diagnosed / older diagnoses).|January 2016|January 20, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02356731||27918|
NCT02358603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI in Heart Failure Study|Chronotropic Incompetence Diagnostic Algorithm in Heart Failure Patients|Investigation of the Chronotropic Incompetence Diagnostic Algorithm in Heart Failure Patients||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with heart failure.|February 2015|February 3, 2015|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02358603||27776|
NCT02300259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15523|A Study of LY2623091 in Healthy Participants|A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects||Eli Lilly and Company|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300259||32249|
NCT02305225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0496|Cortical Excitability and Decision Making After Total Sleep Deprivation and Sleep Restriction|||University of Zurich||Recruiting|May 2013|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|14|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02305225||31867|
NCT02353273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON101CLPK01|The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers|The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers||Oneness Biotech Co., Ltd.|Yes|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||November 2015|November 23, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02353273||28184|
NCT02353286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biodegradable Biliary stent|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2014|||||N/A|N/A|N/A||||||||||||||March 9, 2016|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353286||28183|
NCT02353299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-D1402|Assess the Effect of a Single Dose of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognitive Performance in Healthy Volunteers|Phase IV 4 Way Crossover Study to Assess and Compare the Effect of a Single Nighttime Administration of Zolpidem, Silenor and Placebo on Arousability, Ataxia/Balance and Cognitive Performance in Healthy Volunteers.||Pernix Theraputics LLC|No|Not yet recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Anticipated|52|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02353299||28182|
NCT02354872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1041Motivation|Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit|Optimized Chronic Care for Smokers: A Comparative Effectiveness Approach; Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit||University of Wisconsin, Madison|Yes|Recruiting|January 2015|May 2019|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Anticipated|512|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02354872||28061|
NCT02358304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567|Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma|Treatment of Aggressive Central Giant Cell Granuloma||Shiraz University of Medical Sciences|Yes|Completed|September 2007|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|15 Years|30 Years|No|||May 2015|May 20, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02358304||27799|
NCT02296034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 1409014604|Blood Glucose Variability in Obese Youth Participating in a Lifestyle Modification Program|Blood Glucose Variability in Obese Youth Participating in a Lifestyle Modification Program||Yale University|No|Not yet recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|7 Years|16 Years|No|Non-Probability Sample|Obese children participating in the Bright Bodies lifestyle intervention program|July 2015|July 7, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296034||32573|
NCT02349295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14310|A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis|SPIRIT-P2|Eli Lilly and Company|Yes|Recruiting|December 2014|June 2019|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349295||28488|
NCT02357017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B000502641|Mechanisms of Refractory Hypertension (High and Low Salt Diet)|Mechanisms of Refractory Hypertension (High and Low Salt Diet)||University of Alabama at Birmingham|No|Recruiting|February 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Male|19 Years|80 Years|No|||February 2016|February 20, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02357017||27896|
NCT02295241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1109|Improving Muscle Assessment in Older Adults - The "Can We Build a Better Mouse Trap?" Study|Improving Muscle Assessment in Older Adults - The "Can We Build a Better Mouse Trap?" Study||University of Wisconsin, Madison|No|Recruiting|February 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|112|Samples Without DNA|Blood will be drawn to obtain a serum chemistry panel to document health status of the study      participants. For subjects who agree to optional banking, serum aliquots will be obtained      and banked for future study of markers relevant to musculoskeletal health.|Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will evaluate community dwelling women and men ≥ 70 years recruited from the        Madison, Wisconsin area.|June 2015|June 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02295241||32634|
NCT02295449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.800|Quantitative Prostate Cancer Contrast-enhanced Ultrasound||SONOCAP|Hospices Civils de Lyon|No|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Male|N/A|N/A|No|||November 2014|November 17, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295449||32618|
NCT02300363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-115-NRM|DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin|A Phase 1, Single-center, Open-label, 2-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Rosuvastatin (Crestor®), a Sensitive Breast Cancer Resistance Protein (BCRP) Substrate, in Healthy Male and Female Subjects||Lexicon Pharmaceuticals|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300363||32241|
NCT02345590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/15|Eplerenone in the Management of Abdominal Aortic Aneurysms|Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial||Bayside Health|No|Recruiting|May 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Both|60 Years|90 Years|No|||January 2016|January 13, 2016|January 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345590||28772|
NCT02358564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000837|Gut Permeability, Sensitivity and Symptomatology|Gut Permeability, Sensitivity and Symptomatology: Is There a Link and Explanation for Exacerbation of Symptoms Post Meals|GPSS|Mayo Clinic|No|Recruiting|February 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|39|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02358564||27779|
NCT02304003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BergenUC|The Effect of an Evidence-based Physiotherapy Regimen for Patients With Rotator Cuff Tendinopathy|The Effect of an Evidence-based Physiotherapy Regimen for Patients on Need for Subacromial Decompression Surgery Due to Rotator Cuff Tendinopathy : a Randomized Controlled Trial.||Bergen University College|Yes|Recruiting|April 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||November 2014|November 26, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304003||31961|
NCT02293200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR/2014/03|CPR Feedback Devices|TWO METHODS OF TRAINING TO IMPROVE CHEST COMPRESSION EFFECITVENESS BY MEDICAL STUDENTS AND BYSTANDERS: A Randomized Trial||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293200||32791|
NCT02293213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130695|EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT|Utilizing Electronic Medical Record Referrals for Teratogen and Contraceptive Counseling for Women Taking Category D or X Medications: A Randomized Controlled Trial||University of California, San Diego|No|Recruiting|September 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|45 Years|No|||November 2014|November 20, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293213||32790|
NCT02347033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0249|Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety|RCT of Sertraline Versus Cognitive Behavioural Therapy for Anxiety Symptoms in People With Generalised Anxiety Disorder Who Have Failed to Respond to Low Intensity Psychological Interventions as Defined by the NICE GAD Guidelines|ToSCA|University College, London|Yes|Recruiting|February 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02347033||28661|
NCT02344615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICB1|Nerve Stimulator Versus Ultrasound-guided Infraclavicular Block|A Randomized Comparison of Nerve Stimulator and Ultrasound-guided Infraclavicular Block for Upper Extremity Surgery||Cheju Halla General Hospital|No|Completed|May 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02344615||28847|
NCT02305238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17668|Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration|A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration|ALTAIR|Bayer|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|50 Years|N/A|No|||January 2016|January 18, 2016|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305238||31866|
NCT02294708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-RD-2014|The Influence of Postoperative Postures on Persistent Sub-foveal Fluid After Scleral Buckle Surgery|The Influence of Postoperative Postures on the Incidence and Duration of Persistent Sub-foveal Fluid After Scleral Buckle for Macula-off Retinal Detachment||Peking University Third Hospital|Yes|Recruiting|January 2014|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||November 2014|November 16, 2014|October 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02294708||32675|
NCT02355808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/13-144|Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?|Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?|SUPFASTEHEALTH|University of Plymouth|No|Active, not recruiting|October 2012|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Actual|1044|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02355808||27989|
NCT02355821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOXOC001|Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women|Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)|COMPASS|National Research Center for Preventive Medicine|No|Recruiting|April 2015|March 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|114|||Female|N/A|N/A|No|||April 2015|April 7, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02355821||27988|
NCT02356549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10762|African American Cancer Clinical Trial Decisions: Testing Tailored Messages|African American Cancer Clinical Trial Decisions: Testing Tailored Messages||Virginia Commonwealth University|Yes|Recruiting|May 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|357|||Both|21 Years|N/A|No|||November 2015|November 3, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02356549||27932|
NCT02343809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/032|Diacutaneous Fibrolysis on Lateral Epicondylitis|Effectiveness of Diacutaneous Fibrolysis on Chronic Lateral Epicondylitis. A Randomized Controlled Trial.||Jordi Gol i Gurina Foundation|No|Recruiting|October 2014|January 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343809||28907|
NCT02307916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|625136-3|Open-label, Dose Response Study to Evaluate the Safety and Optimal Biologic Dose of FGF-1 in Subjects With Chronic Non-Healing Tympanic Membrane Perforations (TMPs)|Open-label, Dose Response Study to Evaluate the Safety and Optimal Biologic Dose of FGF-1 in Subjects With Chronic Non-Healing Tympanic Membrane Perforations||Massachusetts Eye and Ear Infirmary|Yes|Not yet recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307916||31661|
NCT02307929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1189|Evaluation of Quality of Care - Nurse Allied Health Clinic Programme, HA|Evaluation of Quality of Care - Nurse Allied Health Clinic Programme, HA|QoC NAHC|The University of Hong Kong|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2496|||Both|18 Years|N/A|No|Probability Sample|Patients enrolled in any of the programmes (fall prevention, continence care, mental        wellness, wound care, respiratory disease management and medication management and        compliance clinics) in Hong Kong Primary care.|December 2014|December 4, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02307929||31660|
NCT02307942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7051 01|Improvement in Physical Performance and Obesity Surgery in Patients Older Than 60 Years|Does Intense Weight Loss Improve Physical Performance in Obese Patients Older Than 60 Yrs Undergoing Exercise Training? Comparison Between Surgery and Standard of Care.|ELDSURG|University Hospital, Toulouse|Yes|Recruiting|February 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|60 Years|75 Years|No|||September 2015|September 29, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02307942||31659|
NCT02354183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/2013|Commitment and Motivation in a Brief DBT Intervention for Self Harm|Commitment and Motivation in a Brief DBT Intervention for Self Harm||Centre for Addiction and Mental Health|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02354183||28114|
NCT02343458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003014|Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD|A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo (PINNACLE 4)||Pearl Therapeutics, Inc.|Yes|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1614|||Both|40 Years|80 Years|No|||April 2015|September 28, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343458||28934|
NCT02343783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106398|A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants|A Phase 0 Study Exploring the Use of Induced Skin Blisters in Adult Subjects With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Subjects.||Janssen Research & Development, LLC|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02343783||28909|
NCT02300025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29342|A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage|||Genentech, Inc.||Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|November 20, 2014|Yes|Yes||No|January 21, 2016|https://clinicaltrials.gov/show/NCT02300025||32267|
NCT02307318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H-002|Heart and Hands Study II: A Retrospective Data Collection & Analysis Project|Heart and Hands Study II: A Retrospective Data Collection & Analysis Project||HealthEast Care System|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307318||31707|
NCT02350387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-010|Efficacy of Eccentric Resistance Training in Persons With Knee Osteoarthritis|Efficacy of Eccentric Resistance Training in Persons With Knee Osteoarthritis||Regis University|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|55 Years|N/A|No|||February 2016|February 25, 2016|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02350387||28405|
NCT02359045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5884C00003|Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions|A Randomized, Open-label, Single-center, Cross-over Study in Healthy Subjects to Assess the Relative Bioavailability of EPA and DHA Delivered by Three New Capsule Formulation Prototypes in Relation to the Current Epanova® Capsule Under Fasting (Part 1) and Fed (Part 2) Conditions||AstraZeneca|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|137|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359045||27742|
NCT02344355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCGBMII|A Phase II Trial of High-Dose Ascorbate in Glioblastoma Multiforme|Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase II Trial||University of Iowa|Yes|Not yet recruiting|July 2015|December 2021|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344355||28867|
NCT02344368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2089|The Effect of Sucrose on Pain Relief During Venous Blood Sampling in Preterm Infants|The Effect of Sucrose on Pain Relief During Venous Blood Sampling in Preterm Infants: a Comparison of Two Different Doses||Norwegian University of Science and Technology|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|8 Weeks|No|||July 2015|July 27, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02344368||28866|
NCT02308137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Domperidone_MS01|Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)|Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)||University of Calgary|Yes|Recruiting|February 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|60 Years|No|||March 2015|March 19, 2015|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308137||31644|
NCT02359773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QI CIP 001 Rev 001|Magnetocardiography as a Tool for Patients Presenting With Chest Pain - Pilot Study|Two Cohort, Pilot Study, to Identify Magnetocardiogram Characteristics That Can be Used to Classify Non Ischemic Chest Pain Patients and Myocardial Infarction Patients.||Quantum Imaging Limited|Yes|Completed|February 2015|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting in Accident and Emergency Department with chest pain of presumed        ischemic origin|February 2015|August 3, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02359773||27686|
NCT02343978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1205|Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||October 2015|Anticipated|Phase 2|Interventional|N/A|2||||||Both|20 Years|N/A||||January 2015|January 21, 2015|January 16, 2015||||No||https://clinicaltrials.gov/show/NCT02343978||28895|
NCT02351011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-001|Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA|Human Autologous Mesenchymal Stromal Cells for the Treatment of Mid to Late Stage Knee Osteoarthritis||University Health Network, Toronto|Yes|Recruiting|February 2015|February 2021|Anticipated|February 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|12|||Both|40 Years|65 Years|No|||February 2015|February 12, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02351011||28357|
NCT02349386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHR-200-201|Maintaining Suppression of Testosterone With Transdermal Estradiol Gel|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer|MASTERS|BHR Pharma, LLC|No|Recruiting|July 2015|October 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Male|18 Years|N/A|No|||March 2016|March 17, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349386||28481|
NCT02349646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-SMI-2012|A Post Market Cohort With the Spinal Modulation Neurostimulator System in Peripheral Neuropathy|A Post Market Cohort With the Commercially Available Spinal Modulation Neurostimulator System for the Management of Peripheral Neuropathy||St. Jude Medical|No|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Peripheral Neuropathy Patients|December 2015|December 15, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02349646||28461|
NCT02294721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR/2014/10|Pediatric Resuscitation With Feedback Devices|Quality of Pediatric Chest Compression: Comparing Four CPR Feedback Devices With Standard BLS by a Single Rescuer: A Randomised Controlled Manikin Trial|CPR_NURSE|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 16, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02294721||32674|
NCT02299440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2013/MA-01|Effects of Ketamine in the Acute Phase of Suicidal Ideation|Evaluation of the Effects of Ketamine in the Acute Phase of Suicidal Ideation: a Multicenter Randomized Double-blind Trial|KETIS|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299440||32312|
NCT02357329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-0390|Food Composition and Palatability|Food Composition and Palatability|FCandP|Purdue University||Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|52|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|unselected convenience sample|December 2014|February 2, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02357329||27872|
NCT02343328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002706|Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum|Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum||Massachusetts General Hospital||Recruiting|January 2015|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343328||28944|
NCT02345850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1301|Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)|A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|August 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|345|||Both|1 Year|65 Years|No|||March 2016|March 7, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345850||28752|
NCT02350140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41186-EJ|Texting to Improve Testing (TextIT):|Texting to Improve Testing (TextIT): A Cluster Randomized Stepped Wedge Trial of Text Messaging to Improve Postpartum Retention in Care and Early Infant Diagnosis of HIV|TextIT|University of Washington|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2508|||Female|14 Years|N/A|No|||July 2015|July 21, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350140||28424|
NCT02348632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005|"An Open-label Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA|A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea||Jazz Pharmaceuticals|No|Enrolling by invitation|May 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|18 Years|75 Years|No|||August 2015|March 8, 2016|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348632||28539|
NCT02295995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1316-W|Exercise and PTSD in Older Veterans|Exercise as an Adjuvant Therapy for Veterans With PTSD||VA Office of Research and Development|No|Recruiting|December 2015|September 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|60 Years|89 Years|No|||December 2015|December 28, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02295995||32576|
NCT02300051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSB-2|Intervention Study for Individuals With Compulsive Sexual Behavior|Sexual Risk Behavior, Clinical and Psychopathological Aspects of Individuals With Compulsive Sexual Behavior of the Institute of Psychiatry of the General Hospital of the University of São Paulo Medical School, an Intervention Study.||University of Sao Paulo General Hospital|Yes|Completed|February 2011|July 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|135|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300051||32265|
NCT02300064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32404|Exercise in Health and Chronic Obstructive Pulmonary Disease|Mechanisms of Adaptation to Exercise in Health and Chronic Obstructive Pulmonary Disease (COPD); Oxidative Stress Links Aging, Activity and Mobility||University of Utah|Yes|Recruiting|January 2009|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 23, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02300064||32264|
NCT02300077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUSTL IRB#201408002|Methadone in Ambulatory Surgery|Methadone in Ambulatory Surgery||Washington University School of Medicine|No|Recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2015|December 9, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300077||32263|
NCT02359370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LidovsMgOTI|The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation|The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation: Single Center, Prospective, Double-Blind and Randomized Study||Hospital de Base|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|January 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359370||27717|
NCT02347449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231-2014|The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population|The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population of Patients With Estrogen Receptor- Positive Early Breast Cancer With 1-3 Positive Lymph Nodes||Sunnybrook Health Sciences Centre|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02347449||28629|
NCT02303769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL2702-301|Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS|A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS|GL2702|GL Pharm Tech Corporation|No|Completed|March 2014|October 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|309|||Male|50 Years|N/A|No|||February 2016|February 24, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02303769||31979|
NCT02303782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-004|A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)|A Phase Ib/II Study Assessing the BET-bromodomain (BRD) Inhibitor OTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)||Oncoethix GmbH|Yes|Withdrawn|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|November 24, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02303782||31978|
NCT02303795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIVER01|RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial|A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER||Hospital do Coracao|Yes|Not yet recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||November 2014|November 25, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02303795||31977|
NCT02359058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15532|A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer|Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma||Eli Lilly and Company|No|Active, not recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|N/A|No|||November 2015|November 2, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02359058||27741|
NCT02356666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1817118|Prevalence of Nocturnal Hypoventilation in Neuromuscular Diseases According to Different Definitions|Prevalence of Nocturnal Hypoventilation in Neuromuscular Diseases According to Different Definitions|TcCO2|Centre d'Investigation Clinique et Technologique 805|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|232|||Both|18 Years|N/A|No|Non-Probability Sample|Neuromuscular disease|February 2016|February 25, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02356666||27923|
NCT02349139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASN001-101|Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer|A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer||Asana BioSciences|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Male|18 Years|N/A|No|||July 2015|November 18, 2015|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349139||28500|
NCT02296866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01257-38|Assessment of Prokinetic Effects of Erythromycin in Emergency Patients With a Full Stomach|||Hôpital Edouard Herriot||Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Probability Sample|all trauma patients with a full stomach, undegoing emergency surgery|December 2014|December 26, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296866||32510|
NCT02301130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-012|Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors|Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors||Kyowa Hakko Kirin Pharma, Inc.|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||December 2015|February 5, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301130||32182|
NCT02348762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glutathione and Aging|Energetics and Function in Older Humans|Energetics and Function in Older Humans||Baylor College of Medicine|No|Recruiting|November 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02348762||28529|
NCT02349022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2M-03.00|Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy|A Phase 2 Study - Comparison Of Positron Emission Tomography (PET/CT) With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-prostatectomy||ImaginAb, Inc.|No|Recruiting|January 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02349022||28509|
NCT02356120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412015010|Inter-Observer Reliability and Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected PE in the ED|The Inter-observer Reliability and Diagnostic Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected Pulmonary Embolus in the Emergency Department||Yale University|No|Not yet recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The subject population will consist of a convenience sample, taken when study        investigators are available, of all those patients for whom suspicion of PE is high enough        that their attending physician has ordered a CTPA in the ED|January 2015|February 4, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02356120||27965|
NCT02356133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810-758|The Relationship Among rSO2, MAP, et al by Near-Infrared Spectroscopy in Endovascular Neurosurgery|The Relationship Among rSO2, MAP,CAM Value, Vital Organ Disfunction and the Outcome of Patients After Operation by Near-Infrared Spectroscopy in Endovascular Neurosurgery||China International Neuroscience Institution||Not yet recruiting|March 2015|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Scheduled to undergoing Endovascular Neurosurgery|August 2014|February 1, 2015|January 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02356133||27964|
NCT02358317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1499|Motor Learning and Brain Changes in Autism|The Effects of Video Game Learning on the Brain in Adolescents With Autism: A Pilot Study||University of Wisconsin, Madison|No|Active, not recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|14 Years|17 Years|No|||October 2015|October 9, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358317||27798|
NCT02299453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10374|Tele-IPT for HIV-Infected Rural Persons|Telephone IPT Intervention for HIV-Infected Rural Persons||University of Georgia|Yes|Active, not recruiting|December 2011|November 2014|Anticipated|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02299453||32311|
NCT02303444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17852|An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors|RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors|RIFTOS MKI|Bayer|No|Recruiting|April 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|||Both|18 Years|N/A|No|Probability Sample|Any setting that provides treatment for progressive asymptomatic RAI refractory DTC|March 2016|March 1, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303444||32004|
NCT02353416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutri_AGEs|Effect of Low-Glycemic Index Mediterranean Diet on AGEs|Effect of a Low Glycemic Index Mediterranean Diet on AGEs. A Randomized Clinical Trial|Nutri_AGEs|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|Yes|Completed|February 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353416||28173|
NCT02350153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSSCDIO|Cushing´s Disease Epidemiology in Sweden|National Swedish Study in Cushing´s Disease Incidence and Outcomes||Vastra Gotaland Region|No|Active, not recruiting|September 2013|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients with confirmed CD diagnosis in Sweden|January 2016|January 4, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02350153||28423|
NCT02358044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-077|Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection|A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 or 6 Infection||Merck Sharp & Dohme Corp.|No|Completed|February 2015|February 2016|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358044||27819|
NCT02304783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral NSAI versus Placebo in RC|Oral NSAI Versus Placebo as a Second Line Treatment for Renal Colics|The Investigation of the Efficacity and Safety of Oral Anti Inflammatory Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Departement for Renal Colics.|ONSAIP in RC|University of Monastir|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|500|||Both|16 Years|N/A|No|||November 2014|December 1, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304783||31901|
NCT02345317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AltenAugenklinik|Reticular Pseudodrusen Progression Study|Reticular Pseudodrusen Progression Study||University Hospital Muenster|Yes|Recruiting|December 2014|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|60 Years|N/A|No|Non-Probability Sample|Patients suitable for the study will be recruited at the University of Muenster,        Department of Ophthalmology|January 2015|January 19, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345317||28793|
NCT02351791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP254|An Exploratory Study Investigating Human Skin Reaction to Output|An Exploratory Study Investigating Human Skin Reaction to Output||Coloplast A/S||Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351791||28297|
NCT02308072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0696|Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer|A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)|ORCA-2|University College, London|Yes|Recruiting|September 2015|June 2022|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308072||31649|
NCT02296528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|619595|Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients|Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients With Life-threatening Aspiration Secondary to Feeding Tube Dependent Oropharyngeal Dysphagia: A Single-site, Open-label, Phase 1 Human Trial||University of California, Davis|No|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296528||32535|
NCT02353390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060114|Oral Water Hydration to Prevent Post-Vaccination Presyncope|Feasibility and Impact of Implementing an Oral Water Hydration Strategy to Prevent Post-Vaccination Presyncope and Syncope in Adolescents and Young Adults||Duke University|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Both|11 Years|21 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353390||28175|
NCT02353403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00786-39|Glycaemic and Insulinaemic Responses After Consumption of FOS.|Postprandial Glycaemic and Insulinaemic Responses After Consumption of Dairy Desserts Containing Fructo-oligosaccharides in Adults.|GLYCOFOS-cream|Institut Pasteur de Lille|No|Completed|January 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353403||28174|
NCT02346604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1458-12|Pulmonary Gas Exchange Abnormalities in Patients With Mild COPD|Pulmonary Gas Exchange Abnormalities in Patients With Mild COPD||Queen's University|No|Completed|July 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients fitting GOLD grade 1B criteria for mild COPD|November 2015|November 19, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02346604||28694|
NCT02304263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1297|Tenofovir Pharmacology in Older HIV Infected Individuals|Assessing Tenofovir Pharmacology in Older HIV Infected Individuals Receiving Tenofovir-based Antiretroviral Therapy||University of Colorado, Denver|No|Active, not recruiting|February 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|Group 1 participants will include 22 adults between the ages of 18-30 years and Group 2        will include 22 individuals >60 years old. Both age groups will be balanced with respect        to the third active ARV (protease inhibitor versus non-protease inhibitor) and will have        representation from women and the major races/ethnicities (25% women, and 33% Hispanic,        33% African-American) to represent the local demographics of the HIV epidemic.|October 2015|October 2, 2015|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304263||31941|
NCT02353793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReadyHeat|Trauma Patients and Hypothermia in the Emergency Room: ReadyHeat® Versus Cotton Wool Blanket|Trauma Patients and Hypothermia in the Emergency Room: a Trial Between Self-warming ReadyHeat® Blanket and Traditional Cotton Wool Blanket||University of Schleswig-Holstein|No|Recruiting|April 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02353793||28144|
NCT02353988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JinlingH-001|AR-inhibitor Bicalutamide in Treating Patients With TNBC|Bicalutamide in Treating Patients With AR-positive Metastatic Triple Negative Breast Cancer|Arbre|Jinling Hospital, China|Yes|Not yet recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||January 2015|February 2, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02353988||28129|
NCT02359604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUG-KCH-1|The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study|The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study||Medical University of Graz|Yes|Recruiting|October 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|3 Months|1 Year|No|||October 2015|October 7, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02359604||27699|
NCT02359617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Single-Port@Home-01|Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration|Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration: Evaluation of a Novel Single-Port Treatment Approach in Type 1 Diabetic Patients During a 1-Day Stay in a Clinical Research Center and a 6-Day Period at Home||Medical University of Graz|Yes|Completed|February 2013|March 2015|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|No|||April 2015|April 24, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02359617||27698|
NCT02303457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014012|CO2 Laser and Open Surgery for T1N0 Glottic SCC With Anterior Commissure Involved|Multicenter, Prospective, Randomized and Controlled Clinical Study 0f CO2 Laser and Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved||Sun Yat-sen University|Yes|Recruiting|July 2014|July 2024|Anticipated|July 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|402|||Both|20 Years|70 Years|No|||January 2016|January 27, 2016|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02303457||32003|
NCT02295709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-46|Cervical Transforaminal Injection of Steroids Guided by Ultrasound|Cervical Transforaminal Injection of Steroids Guided by Ultrasound||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Active, not recruiting|January 2014|March 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||November 2014|November 19, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02295709||32598|
NCT02357368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072549|Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk|Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk||Emory University|No|Recruiting|February 2015|||February 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|90|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02357368||27869|
NCT02358434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTUNE-2015|ATTUNE TM Video-fluoroscopy Study|Kinematics Analysis: Cruciate Retaining, Fixed Bearing Primary Total Knee Arthroplasty With the ATTUNE TM Knee System||Institute for Biomechanics, ETH Zürich|No|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prof. Dr. med. Carsten Perka will do the recruitment, since he is the surgeon that worked        the most with this implant and therefore also has the biggest population of possibly        eligible patients. Furthermore the patients already know and trust him, which could lead        to a greater success in the recruitment as well. For these reasons the financial source        DePuy Synthes, Johnson and Johnson, requires that the clinical collaborator Prof. Dr. med.        Carsten Perka will do the recruitment. He works in the Charité in Berlin, Germany, where        he does the recruitment.|November 2015|November 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02358434||27789|
NCT02359565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00130|Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas|A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children With Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs||National Cancer Institute (NCI)|No|Suspended|May 2015|||April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|1 Year|21 Years|No|||February 2016|February 22, 2016|February 9, 2015|No|Yes|FDA hold due to AE|No||https://clinicaltrials.gov/show/NCT02359565||27702|
NCT02300571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDCTX 2013|Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant|An Observational Retrospective/Prospective Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant Using Peripheral Blood Stem Cells (PBSC) From Unrelated or Related, HLA-identical or Partially Mismatched Donors||Fondazione del Piemonte per l'Oncologia|No|Recruiting|September 2013|September 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|60|Samples With DNA|PBMC|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with Hematological Malignancies Eligible to Allogeneic Hematopoietic Stem Cell        Transplant using Peripheral Blood Stem Cells (PBSC) from unrelated or related,        HLA-identical or partially mismatched donors|August 2015|August 27, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300571||32225|
NCT02308423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204-14-MMC|Clinical and Radiologic Follow up of Subchondral Fractures of the Glenoid|Clinical and Radiologic Follow up of Subchondral Fractures of the Glenoid||Meir Medical Center|No|Enrolling by invitation|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|12|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients 18-80 yo who had subchondral fractures of the glenoid|November 2014|December 10, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02308423||31622|
NCT02307266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.102710|Patient Education in Adherence on Acne (PEAce)|Effect of Patient Education on Treatment Adherence and Satisfaction Among Acne Patients Receiving Once-daily Epiduo Gel Treatment in Primary Care Clinics||Galderma|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|97|||Both|12 Years|N/A|No|||October 2015|October 19, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307266||31711|
NCT02307279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-04|Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes||Gelesis, Inc.|Yes|Active, not recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|22 Years|65 Years|No|||March 2016|March 7, 2016|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307279||31710|
NCT02350127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1507-I|Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia|Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia|PLIE-VA|VA Office of Research and Development|Yes|Recruiting|May 2015|January 2019|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|N/A|No|||January 2016|January 8, 2016|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02350127||28425|
NCT02358525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J3256|Effects of a Rehabilitation Program on Immune Activation and Mood in Heart Failure Patients|Effects of a Multi-Modality Rehabilitation Program on Immune Activation, Depressive Symptoms and Quality of Life in Heart Failure Patients. A Pilot Study||Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation|No|Completed|January 2015|February 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|16|Samples Without DNA|serum|Both|18 Years|85 Years|No|Non-Probability Sample|Heart failure patients, EF ≤ 45%, NYHA I - III; ACC/AHA stage C|March 2016|March 1, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02358525||27782|
NCT02296853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-320-1615|Pharmacokinetics of Tenofovir Alafenamide in Adults With Normal Hepatic Function and Severe Hepatic Impairment|A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment||Gilead Sciences|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296853||32511|
NCT02359747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGD on culture media is easy|Analysis of Human Genomic DNA in Embryo's Culture Media Targeting on a Single Gene Disease and Point Mutations|||Cervesi Hospital, Cattolica, Italy||Recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|45 Years|No|Non-Probability Sample|all the mediun descarted after embryos culture in vitro|February 2016|March 21, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02359747||27688|
NCT02343627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVXT 1405|Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail|A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail||Taro Pharmaceuticals USA|No|Active, not recruiting|December 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||November 2015|November 1, 2015|December 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02343627||28921|
NCT02350738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUBH|Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia|Effects of Multimodal Cognitive Enhancement Therapy (MCET) for People With Mild Cognitive Impairment and Early Stage Dementia: a Randomized, Controlled, Double-blind, Cross-over Trial||Seoul National University Bundang Hospital|Yes|Completed|February 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|55 Years|90 Years|No|||July 2015|July 24, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02350738||28378|
NCT02358122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-062|Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh|Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh|RIGHT|University of Copenhagen|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|75|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02358122||27813|
NCT02358200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14955|Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer|Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer||University of California, San Francisco|Yes|Active, not recruiting|February 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02358200||27807|
NCT02293135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00961-46|Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients|Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Endothelial Function in Diabetic Patients Without Complication|Diabete_1|Stendo|Yes|Recruiting|November 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|75 Years|No|||November 2014|May 21, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02293135||32796|
NCT02357550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-1-10-72-106-14|Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study|Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study||University of Aarhus|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|9|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02357550||27856|
NCT02357563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPA myometrial|Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation|Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2||University Magna Graecia|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02357563||27855|
NCT02345915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEA-JA-IPC 2014-005|Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia|Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia-LEA-JA-IPC 2014-005|LEA-JA|Institut Paoli-Calmettes|No|Recruiting|November 2014|||November 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|30 Years|No|||November 2015|November 30, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02345915||28747|
NCT02303626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4161-301|12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks|OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema|OPuS-2|BioCryst Pharmaceuticals|Yes|Completed|November 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|110|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303626||31990|
NCT02345291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRD135S.E1-201|Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients|A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus||Novaremed Ltd.|No|Recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|99 Years|No|||October 2015|January 25, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02345291||28795|
NCT02345538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053004|Use of a Perineometer to Assess Pelvic Muscle Tone|Use of a Perineometer to Assess Resting Pelvic Muscle Tone in Patients With Pelvic Pain||Duke University|No|Not yet recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A group of adult women, seen in an outpatient urogynecology or minimally invasive        gynecology clinic, including women with and without pelvic pain.|August 2015|August 3, 2015|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02345538||28776|
NCT02357056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LawsonHRI|Randomized Controlled Evaluation of Robotic Cardiac Surgery Training Modalities|Randomized Controlled Evaluation of Robotic Cardiac Surgery Training Modalities||Lawson Health Research Institute|No|Not yet recruiting|February 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02357056||27893|
NCT02345109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15001_Analyzer|Clinical Trial of Transtek Body Fat Analyzer (GBF-835-N2 & Other 7 Models)|Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, 8 Models|15001Analy|BTS International|No|Completed|December 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|60|||Both|10 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|January 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02345109||28809|
NCT02303808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FQ_INH_PEP_01|Positive Expiratory Pressure During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis|Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.||Universidad San Jorge|Yes|Completed|December 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|N/A|No|||December 2015|December 1, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303808||31976|
NCT02303821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ008|Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase 1b/2 Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia||Onyx Pharmaceuticals|Yes|Recruiting|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|39|||Both|N/A|18 Years|No|||August 2015|August 5, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303821||31975|
NCT02355964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFORT Asthma|EFFORT Asthma: Effects of Diet and Exercise in Asthma|EFFORT Asthma: Effects of a High Protein/Low Glycemic Index Diet and Physical Exercise in Sedentary Non-obese Asthmatics.|EFFORT|University of Copenhagen|No|Recruiting|January 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02355964||27977|
NCT02359708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|glovecuff2014|Recolonisation of Bacteria in Hands and Possible Bacterial Leakage From Glove Cuff in Cardiac Surgery|Recolonisation of Bacteria in Hands and Possible Bacterial Leakage From Glove Cuff in Cardiac Surgery. Differences in Microbial Flora and Recolonisation Between Hospital and Non-hospital Persons. A Controlled Clinical Trial.||Örebro University, Sweden|No|Recruiting|February 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02359708||27691|
NCT02356029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B670201422126|Perception of Inappropriate CPR: a Multicenter International Cross-sectional Survey|The REAppropriate Study: Perception of Inappropriate CPR: a Multicenter International Cross-sectional Survey|REAppropriate|University Hospital, Ghent|No|Recruiting|January 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The survey will focus on Healthcare Providers (HCPs) directly involved in treatment of        cardiac arrest patients (out-of-hospital or in the Emergency Department (ED)): nurses,        doctors, ED Technicians/Nurse Assistants and Emergency Medical Technicians(EMT)/Paramedics        working in EDs and prehospital Ambulance Services active in the Emergency Medical Services        system of the country. Hospitals in countries without established EDs but with a group of        HCPs working inside the hospital and having as their daily duty the first care and        stabilisation of patients arriving unplanned in the hospital are also eligible for        participation in the study. The Local Investigator will clearly delineate this functional        unit within the hospital thus determining the number of eligible HCPs within the center.|January 2015|January 30, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02356029||27972|
NCT02344108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-146H|A Pilot Study to Evaluate the Safety and Efficacy of the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea|A Pilot Study to Evaluate the Safety and Efficacy of the Hypoglossal Nerve Stimulator in Adolescents and Young Adults With Down Syndrome and Obstructive Sleep Apnea||Massachusetts Eye and Ear Infirmary|No|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|10 Years|21 Years|No|||September 2015|February 22, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02344108||28885|
NCT02344121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22316|Intra- and Inter-fraction Changes in Radiation Therapy|Intra- and Inter-fraction Changes in Radiation Therapy||Medical College of Wisconsin|No|Recruiting|January 2015|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Cancer patients who have completed treatment.|March 2016|March 7, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02344121||28884|
NCT02300844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9838-3993|Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects||Novo Nordisk A/S|No|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Male|22 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300844||32204|
NCT02300857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001880|Effects of Macronutrient Diet on Brain Activity|Effects of Macronutrient Diet Composition on Brain Reward Activity||Brigham and Women's Hospital|No|Enrolling by invitation|November 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|75|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300857||32203|
NCT02343965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0202|The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study|The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study|TANDHEMS|Nantes University Hospital|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Both|18 Years|65 Years|No|||January 2015|January 20, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02343965||28896|
NCT02348476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-SIM-14-024|A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Open-Angle Glaucoma or Ocular Hypertension treated in clinical practice.|September 2015|September 17, 2015|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02348476||28551|
NCT02358512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14\LO\1792|Intermittent Versus Continuous Feeding in ICU Patients|A Phase 2 Pilot Physiological Randomised Clinical Trial to Investigate the Effect of Intermittent Versus Continuous Enteral Nutrition on Muscle Wasting in Critical Illness||Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|February 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02358512||27783|
NCT02359591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangGungMH|The Development of Child Development Checklist Multimedia System and Its Clinical Evaluation|The Development of Child Development Checklist Multimedia System and Its Clinical Evaluation||Chang Gung Memorial Hospital||Recruiting|March 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|20 Months|65 Years|Accepts Healthy Volunteers|Probability Sample|guardians whose child is between 3 months and 7 years old|October 2015|October 11, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02359591||27700|
NCT02297139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-597|Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib|Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib||Bristol-Myers Squibb|No|Recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297139||32489|
NCT02297152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InstitutoSM|A New Treatment for Premature Ejaculation?|A New Treatment for Premature Ejaculation? Case Series for a Desensitizing Masturbation Aid||Instituto Sexológico Murciano|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02297152||32488|
NCT02346058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF13136A|Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins|Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient||Ten Sun Pharma Company Limited|No|Completed|October 2013|October 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|20 Years|N/A|No|||June 2013|January 19, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02346058||28736|
NCT02346838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prebiotics-Prediabetes|Prebiotics, Gut Microbiota, and Cardiometabolic Health|The Effect of Prebiotics on Insulin Sensitivity, Metabolic Flexibility, and Cardiovascular Health in Prediabetic Adults.||Virginia Polytechnic Institute and State University|Yes|Recruiting|January 2014|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|40 Years|70 Years|No|||December 2015|December 16, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02346838||28676|
NCT02299375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201496|Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)|201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|N/A|No|||February 2016|March 17, 2016|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299375||32317|
NCT02299388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523963-1|To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study|To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study||Tulane University Health Sciences Center|Yes|Recruiting|October 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|May 25, 2015|February 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299388||32316|
NCT02308657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB48991|Multicenter Observational Study of Myotonic Dystrophy Type 1|A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1|MOS-DM1|University of Rochester|No|Recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples will be used for routine laboratory testing, such as tests of blood cells,      chemistry, and ability to form blood clots. Blood samples will be used for genetic testing      (DNA testing) and to identify biomarkers. Needle muscle biopsies will be obtained from the      tibialis anterior, a muscle in the front of the leg, next to the shin.|Both|18 Years|70 Years|No|Non-Probability Sample|Approximately 100 adult patients (18 to 70 years old, inclusive) with DM1 will be enrolled        at 6 centers.|September 2015|September 15, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308657||31604|
NCT02349269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|samuelm1|Postoperative Atrial Fibrillation and Long-term Survival|Postoperative Atrial Fibrillation After Cardiac Surgery is Not an Independent Risk Factor for Long-term Cardiovascular Morbidity and Mortality in Anticoagulated Patients|POAF|Kuopio University Hospital|No|Completed|January 2012|September 2014|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|N/A||1|Actual|519|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients without preoperative history of atrial fibrillation, participated in three        different randomized controlled trials previously|November 2014|January 23, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02349269|105 Months|28490|
NCT02349282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48127.081.148|The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population|The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population: a Randomized, Double-blind, Placebo-controlled Trial.|D-Fit|Wageningen University|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02349282||28489|
NCT02346370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-107-201|A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.|PRIMAL STUDY: A Phase 1b/2, Randomized, Multicenter, Multinational Study of Pegylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) Compared With Docetaxel (Doc) Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|PRIMAL|Halozyme Therapeutics|Yes|Recruiting|December 2014|February 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|N/A|No|||August 2015|October 26, 2015|January 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02346370||28712|
NCT02302742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMC 12614|Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry|PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations|PROGECT|University of Kansas Medical Center|No|Recruiting|March 2011|March 2022|Anticipated|March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|750|Samples With DNA|A baseline blood draw is collected as a part of this registry. If a study participant has a      personal history of cancer and a tumor sample is available, the participant may give consent      for the tissue to be used as a part of the study. Additional optional specimen collection      sub-studies may also be offered to participants.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Academic Center & Community Clinics|July 2015|July 23, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02302742|10 Years|32058|
NCT02302755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIowa|TP10 Use in Patients With C3 Glomerulopathy (C3G)|A Pilot, Open-Label Single Center Trial of TP10 in Pediatric and Adult Patients With C3 Glomerulopathy (C3G)||University of Iowa|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|4 Years|N/A|No|||June 2015|June 4, 2015|November 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302755||32057|
NCT02308722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_054|SBRT Pre-operatively for Borderline Resectable Pancreatic Cancer|A Phase I Trial of Pre-operative, Margin Intensive, Stereotactic Body Radiation Therapy for Previously Untreated Borderline Resectable Pancreatic Cancer|SPARC|University of Oxford|No|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|16 Years|N/A|No|||March 2016|March 16, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308722||31599|
NCT02343341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0256|Family-based Approach to Promotion of Health|Family-based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health (FAMILIA)|FAMILIA|Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|3 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02343341||28943|
NCT02343614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2401|Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer|Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer||Azienda Ospedaliero-Universitaria Consorziale|Yes|Completed|March 2003|January 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02343614||28922|
NCT02356614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apollo-001|A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study|A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study||Apollo Endosurgery, Inc.|No|Recruiting|March 2015|May 2027|Anticipated|March 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|325|||Both|18 Years|N/A|No|Non-Probability Sample|Obese adult patients with a BMI ≥ 30 kg/m2 and < 40 kg/m2 with one or more comorbid        conditions that have had a LAP-BAND® System implanted.|January 2016|January 4, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356614||27927|
NCT02348879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040195|A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject|A Placebo Controlled, Randomized, Double-blind, Sequential, Rising, Single Dose Study to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous AMG 403 in Healthy Young and Older Adult Subjects||Amgen|No|Completed|January 2005|March 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02348879||28520|
NCT02304016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000141|Evaluation of the Effect of Pelvic Floor Physical Therapy on Patients With 3rd and 4th Degree Obstetrical Lacerations|Evaluation of the Effect of Pelvic Floor Physical Therapy on Patients With 3rd and 4th Degree Obstetrical Lacerations||Boston Urogynecology Associates|No|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304016||31960|
NCT02348489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-110-04|SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction|A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy||Astex Pharmaceuticals|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348489||28550|
NCT02353663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1927-CIEI_USMP-CCM|Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren|Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren||University Hospital Inselspital, Berne|No|Active, not recruiting|April 2014|December 2017|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1023|||Both|5 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Schoolchildren aged 5 to 16 years from Arequipa,Peru. Among 457 schools we randomly        selected 40 classes from 20 schools using a mutlistage sampling strategy.|February 2015|February 2, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02353663||28154|
NCT02357212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-2008|Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome|Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome|Lady Gator|University of Florida|No|Completed|April 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||February 2015|February 12, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02357212||27881|
NCT02345681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0268|Impact of Rational Control of Fluid Balance in the Intensive Care Unit|Impact of Rational Control of Fluid Balance in the Intensive Care Unit.IRIHS-REA|IRIHS-REA|Nantes University Hospital||Recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02345681||28765|
NCT02301663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diastolic stress testing|Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease|DEVELOPMENT OF A NOVEL STRESS TESTING PROTOCOL TO DEFINE THE RELATIONSHIP BETWEEN CORONARY MICROVASCULAR DYSFUNCTION AND DIASTOLOGY IN WOMEN WITH ANGINA BUT NO EVIDENCE OF OBSTRUCTIVE CORONARY ARTERY DISEASE||Cedars-Sinai Medical Center|No|Recruiting|November 2014|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02301663||32141|
NCT02305277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-119|Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers|Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|March 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|85|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 28, 2014||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02305277||31863|
NCT02350075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB933600|Clinical Success of Short Dental Implants Alone and Standard Dental Implants Combined With Osteotome Sinus Floor Elevation in Posterior Maxillae|||Shanghai 9th People's Hospital|Yes|Recruiting|March 2015|May 2020|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02350075||28429|
NCT02354157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHRC-Insight: 435-2014-1964|The Nutritional Effect of Parental Use of Food as a Reward|Field Observation of Adverse Nutritional Effect of Parental Use of Food as a Reinforcer for Non-food Related Behavior||McGill University|No|Completed|March 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|207|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|The parents or guardians of 207 children (97 boys and 110 girls) aged from 6 to 12        (M=8.98, SD=1.67) completed the study. Participants were recruited from metropolitan        Montreal, Canada.|January 2015|January 29, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02354157||28116|
NCT02351765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTSp096|ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers|A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers|ABC-08|Christie Hospital NHS Foundation Trust|Yes|Recruiting|January 2016|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02351765||28299|
NCT02303418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH1|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial||Cairo University|Yes|Recruiting|November 2014|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303418||32006|
NCT02306083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92182|Effect of Glucosamine on Intraocular Pressure|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|July 2014|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|41|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2014|May 7, 2015|September 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306083||31801|
NCT02353676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSMOZONE|Bupivacaine Supplementation For Postoperative Pain Control In Surgical Removal Of Mandibular Third Molars|Bupivacaine For Postoperative Pain Control||Cosmozone Dental Clinic|No|Not yet recruiting|January 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02353676||28153|
NCT02350751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6000C00001|Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults|A Phase 1 Double-blind, Single-dose, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Healthy Adults|MEDI8852|MedImmune LLC|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|December 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02350751||28377|
NCT02350764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-137|Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs|An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350764||28376|
NCT02350777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-228|T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Trial of T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|N/A|N/A|No|||December 2015|December 10, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02350777||28375|
NCT02305550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eNO for inhalation|A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation|A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation||Massachusetts General Hospital|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02305550||31842|
NCT02296541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 106|Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|December 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|105|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296541||32534|
NCT02346097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Electro-1-CRT|Electrophysiological Optimization of Left Ventricular Lead Placement in CRT|ElectroCRT - Left Ventricular Lead Implant and Optimization Guided by Electrocardiography in Cardiac Resynchronization Therapy|ElectroCRT|University of Aarhus|Yes|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|40 Years|N/A|No|||December 2015|December 4, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02346097||28733|
NCT02346357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14003|Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy|Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy: A Prospective, Randomized Controlled Trial||Benaroya Research Institute|Yes|Recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02346357||28713|
NCT02359578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY-OCCL-PRESSURE-1|Determining Occlusion Pressure in Lymphatic Vessels|The Occlusion Pressure of Superficial Lymphatics in the Upper Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach|Occlusion|Centre Hospitalier Universitaire Saint Pierre|No|Completed|August 2014|January 2015|Actual|November 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02359578||27701|
NCT02308761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-010-004|A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome||Tensha Therapeutics|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308761||31596|
NCT02357485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAKnee01|ADSC Injections for Pain Management of Osteoarthritis in the Human Knee Joint|Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint||Fodor, Peter B, M.D.|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|January 31, 2015|No|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT02357485||27861|
NCT02351557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9151/PG-2Trg/2012|Pharmacokinetic Study of Effect of Cardiac Output on the Uptake of Isoflurane|Effect of Cardiac Output on Uptake of Isoflurane||Postgraduate Institute of Medical Education and Research|Yes|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients undergoing elective, open cardiac procedures under general endotracheal        anesthesia with cardiopulmonary bypass|February 2015|February 1, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02351557||28315|
NCT02299167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE-2014-1-23|Minimal Effective Dose of Hyperbaric Spinal Bupivacaine for Saddle Block|The Minimal Effective Dose of Hyperbaric Spinal Bupivacaine for Successful Reliable Saddle Block for Minor Perianal Surgeries||Dammam University|Yes|Completed|January 2014|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|55 Years|No|||November 2014|November 20, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02299167||32333|
NCT02305290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2014/7/4.6 (4031)|Upper GI Outcomes Following EMR|Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract|UGI-EMR|Western Sydney Local Health District|No|Recruiting|August 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have Upper Gastrointestinal Tract adenomas which are amendable to Endoscopic        Mucosal Resection|December 2015|December 15, 2015|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02305290||31862|
NCT02294266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIMFTCL/MEF/2|Mephedrone and Alcohol Interactions in Humans|Mephedrone and Alcohol Interactions After Single-dose Administration in Humans||Parc de Salut Mar|Yes|Completed|December 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294266||32709|
NCT02354170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOMP-CSC|Short-Term Oral Mifepristone for Central Serous Chorioretinopathy|Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)|STOMP-CSC|Bay Area Retina Associates|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02354170||28115|
NCT02359851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL1486|Pembrolizumab in Treating Patients With Advanced Uveal Melanoma|A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|May 2015|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359851||27680|
NCT02359864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140132/A001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||February 9, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02359864||27679|
NCT02356705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1098|Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2|Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2||Bassett Healthcare|No|Recruiting|January 2015|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Months|7 Years|No|||March 2016|March 24, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02356705||27920|
NCT02357732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-115|Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib|A Phase I Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma||University of Pittsburgh|Yes|Withdrawn|August 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 27, 2015|No|Yes|PI decided not to proceed|No||https://clinicaltrials.gov/show/NCT02357732||27842|
NCT02297100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026734|Intravesicular Onabotulinumtoxin A in Interstitial Cystitis|The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4||Wake Forest School of Medicine|No|Recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|80 Years|No|||December 2015|December 10, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297100||32492|
NCT02296268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS 2015-223|Stepping up Aerobic Exercise to Improve Health Outcomes After Stroke|Stepping up Aerobic Exercise to Improve Health Outcomes After Stroke: Translating Research Into Clinical Care|STROKE-TRIC|Nova Scotia Health Authority|No|Not yet recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|62|||Both|18 Years|N/A|No|Non-Probability Sample|Patients post-stroke|November 2014|November 18, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02296268||32555|
NCT02296281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNI-F647-1401|Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury|||Beijing Continent Pharmaceutical Co, Ltd.||Not yet recruiting|January 2015|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|70 Years|No|||November 2014|November 19, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296281||32554|
NCT02358083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8645194|Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents|Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents||Indiana University|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|12||Actual|1165|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358083||27816|
NCT02358096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8232-CL-0004|A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease|A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease|ALBUM|Astellas Pharma Inc|No|Recruiting|February 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|85 Years|No|||March 2016|March 24, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02358096||27815|
NCT02356510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SamsunERH|Which One Should be Treated in the Setting of Acute ST Elevation Myocardial Infarction - Culprit Lesion or Culprit Vessel?|||Samsun Education and Research Hospital||Completed|June 2014|||February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|637|||Both|30 Years|80 Years|No|Non-Probability Sample|This multi-centre retrospective study included patients from 3 high-volume primary PCI        centres in Turkey. A total number of 5512 patients underwent emergent PCI for acute STEMI        between January 2011 and December 2013. From this patient population, patients were looked        for the presence of an additional lesion to the culprit lesion (CL). Additional lesion was        defined as the presence of an angiographically severe (≥70%) lesion other than the CL        either proximal or distal to it in the same coronary artery after the distal flow was        observed most commonly as a result of guide-wire passage or PTCA of the total occlusion.|February 2015|February 4, 2015|February 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02356510||27935|
NCT02356523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo014|Incidence and Prognostic Value of Delirium in Cardiac Intensive Care Unit Patients|||Ospedale San Donato|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|65 Years|N/A|No|Probability Sample|Patients admitted in Cardiac Intensive Care Unit for any condition|February 2015|February 4, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02356523|12 Months|27934|
NCT02296229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-001427|Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer|Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer||Jonsson Comprehensive Cancer Center|No|Recruiting|January 2014|November 2019|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02296229||32558|
NCT02301143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-007|Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)|NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE II STUDY (LAPACT)|LAPACT|Celgene|No|Recruiting|April 2015|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301143||32181|
NCT02348125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DrexelMitoApp|Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?|Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?|MitoASD|Drexel University|No|Not yet recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|12 Years|No|||August 2015|August 4, 2015|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02348125||28578|
NCT02348138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOPRESS|Effect of Isometric Handgrip Training on Cardiovascular Risk in Hypertensives|Effect of Isometric Handgrip Training on Cardiovascular Risk in Hypertensives||University of Pernambuco|Yes|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02348138||28577|
NCT02350400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBIRI_TKH_01_2012|Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).|Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI) in the Treatment of Hepatic Colorectal Metastases||Singapore General Hospital|Yes|Recruiting|June 2014|December 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|21 Years|N/A|No|||January 2015|January 25, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02350400||28404|
NCT02350725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-01-001|Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration|A Single Center, Randomized, Open-label, Cross-over Exploratory Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response to a Subcutaneous Administration or Oral Administration of Furosemide in Subjects With Heart Failure Presenting With Chronic Fluid Overload|FUROPHARM-HF|scPharmaceuticals, Inc.|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2014|June 30, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02350725||28379|
NCT02345434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPAL-LETTERS-SII|The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances|The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances||Abdul Latif Jameel Poverty Action Lab|No|Completed|August 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1525|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02345434||28784|
NCT02316743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thyroid-001|Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism|Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism||Université de Sherbrooke|No|Recruiting|December 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|May 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02316743||30984|
NCT02324933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1064|Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care|Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care||Bassett Healthcare|No|Withdrawn|August 2014|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 19, 2014|Yes|Yes|insufficient population, unable to recruit|No||https://clinicaltrials.gov/show/NCT02324933||30355|
NCT02251405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-DT103004|Behaviour Intervention to Decrease Melamine Exposure||Bidme|Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|October 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|August 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02251405||35999|
NCT02256592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12675|Fecal Microbiota Transplantation in HIV|Reconstitution of the Gut Microbiome to Reduce HIV-Associated Inflammation|FMT-HIV|University of California, San Francisco|No|Recruiting|October 2014|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||October 2014|October 2, 2014|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256592||35601|
NCT02323529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.NTBC-003|Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1|Open-label, Multicentre, Multiple-dose Trial to Evaluate Pharmacokinetics, Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Orfadin in Patients Diagnosed With Hereditary Tyrosinemia Type 1|HT-1|Swedish Orphan Biovitrum|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|N/A|No|||November 2015|November 10, 2015|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323529||30463|
NCT02323542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBE032|Plasma Glucose Kinetics and Cereal Product Content in Slowly Digestible Starch (SDS) in Healthy Volunteers|Plasma Glucose Kinetics Following Ingestion of Two Cereal Products With a Different Content in Slowly Digestible Starch (SDS) in Healthy Males and Females||Mondelēz International, Inc.|No|Recruiting|April 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323542||30462|
NCT02326298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0005|An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)|A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|CIMPASI-1|UCB Pharma|No|Active, not recruiting|December 2014|November 2018|Anticipated|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|234|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326298||30250|
NCT02245516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPI-121-C-004|Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema|An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema|Molokini|Kala Pharmaceuticals, Inc.|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245516||36452|
NCT02320630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201305|Combination Therapy Prevents the Relapse of RA|Rheumatology and Immunology Department，Peking University First Hospital，China||Peking University First Hospital|Yes|Recruiting|October 2014|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320630||30686|
NCT02320643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP-SERATOM PA|A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed|A Prospective Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh(Seratom PA®) in Patients With Pelvic Organ Prolapsed||Samyang Biopharmaceuticals Corporation|No|Not yet recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|41 Years|N/A|No|||December 2014|December 15, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02320643||30685|
NCT02255370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0207|Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease|Controlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn Disease|POPCUR|University Hospital, Clermont-Ferrand||Recruiting|December 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02255370||35694|
NCT02497625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44720315.5.0000.5372|Effectiveness of Therapeutic Alliance and Minimal Intervention for Chronic Low Back Pain|Effectiveness of the Addition of Therapeutic Alliance to Minimal Intervention Treatment for Chronic Low Back Pain With Low Risk of Psychosocial Factors: a Randomized Controlled Trial|TalkBack|Universidade Cidade de Sao Paulo|Yes|Recruiting|September 2015|December 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|222|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497625||17106|
NCT02510781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ307-Neo02|A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs|A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis Detecting Circulating Tumor Cells||Hospital Affiliated to Military Medical Science, Beijing|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|69 Years|No|||July 2015|July 27, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510781||16095|
NCT02510794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX28228|Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)|A Phase II Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of The Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration||Genentech, Inc.||Recruiting|September 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|220|||Both|50 Years|N/A|No|||March 2016|March 18, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510794||16094|
NCT02244541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAVEX2-73-002|Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease|Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period|ANAVEX|Anavex Life Sciences Corp.|Yes|Active, not recruiting|December 2014|October 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|55 Years|85 Years|No|||February 2016|February 3, 2016|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02244541||36527|
NCT02244554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-14-TPS05|Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal|Prospective, Open-Label Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal||Cutera Inc.|No|Active, not recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02244554||36526|
NCT02244827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-2349-102|Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment|A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment||Wockhardt|No|Completed|September 2014|June 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02244827||36505|
NCT02244892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 04-14-30|Correlation of Scheimpflug Densitometry Measurements of Corneal Haze With Disability Glare|||University Hospital Case Medical Center||Recruiting|September 2014|||September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|This will be a prospective study in which all eligible and willing patients will undergo        the same workup. The expected duration is 1 year, and the trial will be stopped once the        needed number of subjects has been enrolled. Testing will be performed on the day of the        routine clinical visit and will only extend the appointment by less than 30 minutes.        All patients receiving ophthalmological care at University Hospitals (both at the main        Case Medical Center site and the satellite offices at Westlake and Landerbrook) who meet        the inclusion and exclusion criteria would be eligible for this study. Subjects will be        identified who have an isolated corneal scar in one eye and otherwise healthy eyes with no        clinical evidence of lens or retinal pathology. Patients will be enrolled between        September 6, 2014 and September 5, 2015, with the goal of recruiting at least 80-100        subjects.|September 2014|September 17, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244892||36500|
NCT02497027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHG-1440-PGxUPA|Pharmacogenetic Testing in an Outpatient Population of Patients With Depression|Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified|PGx-UPA|Avera McKennan Hospital & University Health Center|Yes|Recruiting|February 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02497027||17151|
NCT02252029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2014/04|Rotavirus Vaccine in Premature Babies|RotaNeo: Evaluation of Rotavirus Vaccine Administration in Premature Babies in the Neonatal Unit|RotaNeo|University of Oxford|No|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Stool, serum|Both|8 Weeks|15 Weeks|No|Non-Probability Sample|Premature babies receiving their first dose of rotavirus vaccine while an inpatient on the        neonatal unit at the John Radcliffe Hospital, Oxford University Hospitals NHS Trust|November 2015|November 6, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252029||35951|
NCT02322762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00002|DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings|DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings|DISCOVER|AstraZeneca|No|Recruiting|December 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|13350|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy        after first line anti-diabetic therapy. Participating investigators will belong to        primary, secondary or tertiary care clinics or hospitals in proportions trying to resemble        the reality of management of this type of patients in each country.|February 2016|February 24, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322762||30522|
NCT02310438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/EE/0400|Music Therapy for The Rehabilitation of Upper Limb With Stroke Patients|An Investigation Into Music Therapy for Upper Limb Rehabilitation in Stroke Patients|TIMPStro|Anglia Ruskin University|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02310438||31468|
NCT02310672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-403|REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension|A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging|REPAIR|Actelion|No|Recruiting|June 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|64 Years|No|||November 2015|November 25, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310672||31450|
NCT02253771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orth-001|Shockwave Therapy for Acute Low Back Pain|Shockwave Therapy for Acute Low Back Pain: a Randomized Placebo-controlled Clinical Trial||University Hospital Muenster|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02253771||35817|
NCT02253784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-XX-HYMC|Comparison Between Perineural and Systemic Effect of Dexamethasone as an Adjuvant for Prolongation of Four Nerve Blocks With Bupivacaine in Total Knee Arthroplasty|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253784||35816|
NCT02243605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01927|Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma|A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas||National Cancer Institute (NCI)|Yes|Recruiting|December 2014|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|12 Years|N/A|No|||October 2015|October 29, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243605||36599|
NCT02325336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K121202|Detection Medication Administration Errors Using Bar-code and RFID Technology (DREAM)|Effect of Bar-code-assisted Medication Administration on Medication Error Rates: a Controlled Randomized Multicentre Trial|DREAM|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6000|||Both|18 Years|60 Years|No|||October 2015|November 3, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325336||30324|
NCT02310698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-240|Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening|Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening||Memorial Sloan Kettering Cancer Center||Recruiting|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Female|30 Years|N/A|No|Non-Probability Sample|MSKCC clinic|February 2016|February 15, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02310698||31448|
NCT02250807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105429|Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection||Janssen R&D Ireland|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250807||36045|
NCT02324244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO.HGUGM.2014-006|CMV Intensive Care Units|A Prospective Monitoring Study of Cytomegalovirus Infection in Immunocompetent Critical Heart Surgery Patients||Hospital General Universitario Gregorio Marañon|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|immunocompetent adults admitted to a major heart surgery intensive care unit|December 2014|December 23, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02324244||30408|
NCT02324257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29541|A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors|AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION PHASE I STUDY, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY (TCB) TARGETING THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS||Hoffmann-La Roche||Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324257||30407|
NCT02313506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02631|Feasibility and Preliminary Efficacy of an Activity Tracker-driven Intervention for Promoting Physical Activity in People Living With Osteoarthritis of the Knee|Feasibility and Preliminary Efficacy of an Activity Tracker-driven Intervention for Promoting Physical Activity in People Living With Osteoarthritis of the Knee|TRACK-OA|University of British Columbia||Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|34|||Both|N/A|N/A|No|||August 2015|August 20, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313506||31232|
NCT02313519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACT002|Probiotics in the Prevention of Complications After Colorectal Surgery|A Randomized Clinical Study of the Efficacy of a Formulation of Four Probiotics for the Prevention of Post-operative Complications in Patients Undergoing Colorectal Surgery||University of Athens|Yes|Completed|April 2013|August 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|164|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313519||31231|
NCT02313740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-04-IB|Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly|Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan´s Fragmented, Inactivated Trivalent Influenza Vaccine in Healthy Adults and Elderly||Butantan Institute|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health adults with age between 18 and 59 years, as well as elderly over 60 years of age        may participate in the study. To be included in the study, participants need to meet all        inclusion criteria, and not fulfill any exclusion criteria.|July 2015|July 20, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02313740||31214|
NCT02256670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014658|Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial|Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial: Efficacy of a Text-messaging Application in Increasing Adherence With Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer||Yale University|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256670||35595|
NCT02498158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2380-15-SMC|Functional Neural Connectivity at Rest as a Diagnostic Tool for Intolerance to Heat|Functional Neural Connectivity at Rest, as a Diagnostic Tool for Intolerance to Heat and Return to Duty After Exertional Heat Stroke|fMRI|Sheba Medical Center|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|population of soldiers from the israeli defence forces (IDF), healthy in general, who had        gone through heat injury (heat fatigue or hyperthermia) in the two month prior to their        recruitment.|July 2015|July 19, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02498158||17065|
NCT02502656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASANC|RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer|RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer: Concordance With the "Standard" Testing Method From Tumor Tissue and Review of Associated Timelines and Costs|RASANC|Association des Gastroentérologues Oncologues|No|Recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|405|Samples With DNA|Blood collection will be performed on the day of the first oncological consultation|Both|18 Years|N/A|No|Non-Probability Sample|All treatment naive patients seen in consultation for metastatic colorectal cancer in the        participating centers|December 2015|December 15, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502656||16719|
NCT02248584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Betania|VITAMIN E, C and ZINC IN PATIENTS WITH SKIN CANCER: INFLUENCE ON OXIDATIVE STRESS AND INFLAMMATORY STATE|SUPPLEMENTATION OF VITAMIN E, C and ZINC IN PATIENTS WITH NON-MELANOMA SKIN CANCER: INFLUENCE ON OXIDATIVE STRESS AND INFLAMMATORY STATE||University of Campinas, Brazil||Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|90 Years|No|||September 2014|September 24, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248584||36216|
NCT02249546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406074MINC|Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection|Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial||National Taiwan University Hospital|No|Recruiting|September 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|654|||Both|20 Years|N/A|No|||September 2014|September 23, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02249546||36142|
NCT02500901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU14-202|Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)|Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202||Hoosier Cancer Research Network|Yes|Recruiting|March 2016|June 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||March 2016|March 2, 2016|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500901||16854|
NCT02256579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCGM-G-001074-01|Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients|Vietnam-Japan Cooperative Research on Prognosis of HIV-1-infection -Clinical Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction Caused by Use of Tenofovir in Vietnamese HIV-Infected Patients-||National Center for Global Health and Medicine, Japan|No|Enrolling by invitation|October 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|Samples Without DNA|Complete blood cell count, CD4+ cell count, AST, ALT, Serum-creatinine, HIV-1 plasma viral      loads, HBs antigen, anti-HBc antibody, anti-HBs antibody, anti-HCV antibody, Urine-protein,      Urine-creatinine and urine beta2microglobulin.|Both|20 Years|N/A|No|Non-Probability Sample|Vietnamese HIV-infected patients who are registered in the NHTD (National Hospital of        Tropical Diseases) -ACC (AIDS Clinical Center, NCGM) cohort.|April 2014|October 1, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256579||35602|
NCT02323464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012-375-31M|Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer|Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer||Umeå University|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for surgery of colorectal cancer|December 2014|December 22, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323464||30468|
NCT02314637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A8|Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients|Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|20 Years|75 Years|No|||July 2015|July 29, 2015|December 8, 2014||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT02314637||31146|
NCT02314650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2014-6-25-01|TEAS to Reduce Propofol Consumption During General Anesthesia|Effect of Transcutaneous Electrical Acupoint Stimulation on Propofol Consumption During General Anesthesia|TOP|Fourth Military Medical University|Yes|Completed|April 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02314650||31145|
NCT02243514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-RNRE|Intravascular Ultrasound Evaluation of Renal Nerves in Different Diseases|Intravascular Ultrasound Evaluation of the Renal Nerves Remodeling in Different Diseases||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|October 2014|May 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|60|Samples With DNA|whole blood, urine, stool|Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients who are going to take a vascular interventional examination.|October 2014|October 22, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243514||36606|
NCT02243527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00067|Respiratory Muscles and Inspiratory Muscle Training|Effects of Inspiratory Muscle Training on Respiratory Muscle Mechanics and Haemodynamics in Healthy Adults|IMT|University of British Columbia|No|Recruiting|September 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|22|||Male|19 Years|39 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243527||36605|
NCT02252263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA223-028|A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma|A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma||Bristol-Myers Squibb|No|Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02252263||35933|
NCT02252276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2013/031/20131120|Effects of Manual Therapy and Exercise in the Treatment of Ankle Sprains|Effects of Manual Therapy and Exercise in the Treatment of Recurrent Ankle Sprains: Randomised Trial||University of Alcala|Yes|Completed|January 2014|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252276||35932|
NCT02326454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR901-2501|A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)||Light Sciences Oncology|No|Recruiting|November 2014|February 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|192|||Male|40 Years|N/A|No|||March 2016|March 17, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326454||30238|
NCT02326480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0036|Genetic Analysis of Childhood Obesity|Genetic Analysis of Childhood Obesity|OSV|Lille Catholic University|No|Recruiting|January 2015|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Blood|Both|6 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three categories of obese children with their biological parents will be included        (syndromic, familial, isolated obesity).|May 2015|May 29, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02326480||30236|
NCT02246517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-SB-0318-CTIL|The Effect of N2O on Chronic Neuropathic Pain Patients|The Effect of N2O on Chronic Neuropathic Pain|N2O|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2014|||December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||September 2014|September 18, 2014|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02246517||36375|
NCT02253810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS-14028|Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy|The Effect of Intravenous Tranexamic Acid on Blood Loss and Transfusion After Periacetabular Osteotomy: a Prospective, Double-blinded, Randomized Controlled Trial||Hospital for Special Surgery, New York|Yes|Enrolling by invitation|October 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|45 Years|No|||February 2016|February 19, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253810||35814|
NCT02312167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2013-PERSEE-01|Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)|Essai de faisabilité Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d&Apos;ExérèsE|PERSEE|Institut Mutualiste Montsouris|Yes|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|February 10, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02312167||31335|
NCT02312180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002C005G|A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency|A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children With Hypoplasminogenemia||ProMetic BioTherapeutics, Inc|Yes|Completed|December 2014|February 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|12 Years|80 Years|No|||December 2015|February 11, 2016|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02312180||31334|
NCT02245113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R002302000|Effects of High Oleic Palm Olein, Virgin Olive Oil and Coconut Oil Diets on Markers Selected in Malaysian|Effects of High Oleic Palm Olein (HOPO), Virgin Olive Oil (OO) and Refined Bleached and Deodorized (RBD) Coconut Oil (CO) Diets on Lipid Profile, Markers of Insulin Resistance, Inflammatory and Obesity in Overweight Subject.||Malaysia Palm Oil Board|Yes|Completed|December 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|32|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245113||36483|
NCT02245126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC REF 2014-050|The Use of Lignocaine and Bupivacaine Mix in Adult Safe Male Circumcision|The Use of Lignocaine and Bupivacaine Mix in Adult Safe Male Circumcision; Less is More||International Hospital Kampala|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02245126||36482|
NCT02502149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997HA309|Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale|A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A|Elevate|Biogen|No|Recruiting|August 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Male|12 Years|N/A|No|||January 2016|January 14, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502149||16758|
NCT02502162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33607|Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome|Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome|LDN-CRPS|Stanford University|No|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502162||16757|
NCT02504528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRD201534|Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou|Bronchial Provocation Tests With House Dust Mite in Allergic Asthma in Guangzhou||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02504528||16575|
NCT02253979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0334-12-RMB_CTIL|Comparison of VivaSightTM Double Lumen Tube With a Conventional Double Lumen Tube|Comparison of VivaSightTM Double Lumen Tube With a Conventional Double Lumen Tube in Adult Patients Undergoing Video Assisted Thoracoscopic Surgery||Rambam Health Care Campus|Yes|Completed|January 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02253979||35801|
NCT02256475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1403|Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome|A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome|T-FORCE|Neurocrine Biosciences|No|Completed|September 2014|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|36|||Both|6 Years|18 Years|No|||January 2016|January 5, 2016|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02256475||35610|
NCT02255461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-042|Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors|Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors||Pediatric Brain Tumor Consortium||Recruiting|October 2014|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|4 Years|21 Years|No|||October 2015|October 19, 2015|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255461||35687|
NCT02243293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-868|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)||AbbVie|No|Recruiting|September 2014|January 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|19||Anticipated|725|||Both|18 Years|100 Years|No|||February 2016|February 4, 2016|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243293||36623|
NCT02313259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1593, DR-002-1370|The Impact of Ocular Diseases on Driving: a Prospective Study|The Impact of Ocular Diseases on Driving: a Prospective Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Active, not recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients (with glaucoma or AMD) were recruited from the Centre Universitaire        d'Ophtalmologie (CUO), Saint-Sacrement Hospital in Quebec City.        Participants in control groups are residents of Quebec City.|September 2015|September 11, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02313259||31251|
NCT02318615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AxLD|Immediate Axillary Plasty With a Pedicled Muscle Flap for Breast Cancer Related Lymphedema Prevention|The Efficacy and Safety of Immediate Axillary Plasty With Pedicled Partial Latissimus Dorsi Muscle Flap for Lymphedema Prevention in Breast Cancer Patients Who Undergoing Axillary Dissection: a Prospective, Corhort Study||Peking University People's Hospital|No|Not yet recruiting|December 2015|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|450|||Female|18 Years|70 Years|No|||November 2015|November 19, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02318615||30840|
NCT02318849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R39OT26993|Online Intervention for ANHPI College Students|Social and Behavioral Interventions to Increase Solid Organ Donation|iDecide|University of Hawaii|No|Recruiting|November 2014|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|4500|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318849||30822|
NCT02248272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8062|Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes|The Effects of Meal Frequency on Glucose, Insulin, and Insulin Sensitivity in Women With Polycystic Ovary Syndrome (PCOS), People at High Risk for Developing Type 2 Diabetes and People With Type 2 Diabetes||Harokopio University|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248272||36240|
NCT02255942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tba|The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate|The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate|Rice_FeZn|Swiss Federal Institute of Technology|No|Completed|April 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02255942||35650|
NCT02255955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pstoperative pain|Postoperative Analgesia in Laminectomy|The Effect of Naproxen Sodium + Codeine, and Paracetamol+ Codeine on Postoperative Laminectomy Pain|(PAL)|Diskapi Yildirim Beyazit Education and Research Hospital|Yes|Not yet recruiting|October 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|16 Years|85 Years|No|||December 2014|December 25, 2014|September 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255955||35649|
NCT02314078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1043/D|Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section|Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section|Crash|KK Women's and Children's Hospital|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|390|||Female|21 Years|50 Years|No|Non-Probability Sample|Women who underwent category one Caesarean section between 2010 to 2013 at KK Women's and        Children's Hospital, Singapore.|December 2014|December 8, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314078||31189|
NCT02314091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KonyaTRH|Long Term Results of Randomized Prospective Comparison of Onlay and Sublay Mesh Repair Techniques for Incisional Hernia|Long Term Results of Randomized Prospective Comparison of Onlay and Sublay Mesh Repair Techniques for Incisional Hernia|IH01|Konya Training and Research Hospital|No|Completed|January 2011|December 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314091||31188|
NCT02314104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02|Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication|Analgesic Efficacy of Transversus Abdominis Plane Block Versus Local Injection in Postoperative Pain Management Following Minimally Invasive Gynecological Surgery||Liberman, Eric, D.O.|No|Completed|May 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|December 8, 2014|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT02314104||31187|
NCT02250820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-5961|A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)|A Qualitative Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|280|||Both|3 Months|24 Months|No|||January 2016|January 26, 2016|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250820||36044|
NCT02253030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#000010535|OCT Angiography in Wet AMD|Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration||Oregon Health and Science University||Recruiting|September 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|145|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Both female and male participants over the age of 50 are being studied.|April 2015|April 21, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253030||35874|
NCT02317003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P 2014-04|Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Trial|Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Randomised Controlled Trial|PEPPER|University Hospital, Angers|No|Recruiting|March 2015|January 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|35 Years|74 Years|No|||February 2016|February 11, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317003||30964|
NCT02317016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00019|Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI||AstraZeneca|No|Active, not recruiting|March 2015|July 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|99 Years|No|||February 2016|February 24, 2016|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317016||30963|
NCT02248922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100CDE02|Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa|An 8 Week Open-label Interventional Multicenter Study to Evaluate the Lung Clearance Index as Endpoint for Clinical Trials in Cystic Fibrosis Patients ≥ 6 Years of Age, Chronically Infected With Pseudomonas Aeruginosa|ELIXIR|Novartis|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|6 Years|N/A|No|||March 2016|March 3, 2016|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248922||36190|
NCT02504658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BodiMojo-R43DK085748|Mobile Motivation for Health Promotion Among Adolescents|Mobile Motivation for Health Promotion Among Adolescents|BodiMojo|BodiMojo, Inc.|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|16 Years|22 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT02504658||16565|
NCT02506361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2014168|Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer|Evaluation of the Relationship of TOP2α Expression and Effect of Anthracyclines Followed Taxanes or Contains no Taxanes Non Dose-dense Chemotherapy for Breast Cancer: a Prospective, Non-interventional, Multicentre Trail||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|May 2015|October 2025|Anticipated|May 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|800|||Female|18 Years|70 Years|No|Probability Sample|800 breast cancer patients who have already received chemotherapy prior to this study will        be enrolled in the group, including 400 patients who have received the anthracyclines        followed taxanes chemotherapy, and the other 400 patients have received regiments        containing no taxanes.|May 2015|July 21, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02506361||16434|
NCT02506374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412015088|Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads|Project BEST-Sleep: A Pilot Study to Develop a Biobehavioral Self-Management Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads|BEST-Sleep|Yale University|No|Withdrawn|November 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Caregivers of home-based PAD/CG dyads (person with Alzheimer's disease/caregiver dyads)        will be recruited from the community|January 2016|January 11, 2016|July 16, 2015||No|Never able to get any subjects enrolled|No||https://clinicaltrials.gov/show/NCT02506374||16433|
NCT02254694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000049|The Influence of High Heeled Shoes on the Sagittal Balance of the Spine and Whole Body|The Influence of High Heeled Shoes on the Sagittal Balance of the Spine and Whole Body||University of Zurich|No|Completed|September 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|23|||Female|20 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02254694||35746|
NCT02240836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/945-1|Energy Balance and Breast Cancer Aspects-II|Energy Balance and Breast Cancer Aspects-II Study|EBBA-II|Oslo University Hospital|Yes|Recruiting|September 2014|June 2026|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|75 Years|No|||September 2014|September 23, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02240836||36812|
NCT02508480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-22|Testing Effectiveness of a Peer-Led Intervention to Enhance Community Integration|Testing Effectiveness of a Peer-Led Intervention to Enhance Community Integration|Photovoice|Boston University|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|192|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508480||16272|
NCT02508493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCDF-THINC.it|Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder|Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder||Brain and Cognition Discovery Foundation|No|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients will be enrolled at a single site, located in Toronto, Ontario, Canada. The        total planned number of participants is:          -  100 individuals with DSM-5-defined MDD, aged 18-65          -  100 healthy controls matched on age, sex and years of education An equal allocation             of subjects with MDD between the ages of 18-44 and 45-65 will be enrolled.        Healthy controls will be consecutively recruited via media announcements.|November 2015|November 2, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508493||16271|
NCT02247739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 3201|A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)||Pharming Technologies B.V.|No|Active, not recruiting|December 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|32|||Both|13 Years|N/A|No|||February 2016|February 15, 2016|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02247739||36281|
NCT02316756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7991001|A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled First-in-human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06648671 After Administration Of Single Ascending Doses To Fasted And Fed Healthy Subjects||Pfizer|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316756||30983|
NCT02326272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0002|A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)|A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|CIMPASI-2|UCB Pharma|No|Active, not recruiting|December 2014|September 2018|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326272||30252|
NCT02251587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001503|The $Ensible Weight Program: An Intervention Tailored for Low Income Women|The $Ensible Weight Program: An Intervention Tailored for Low Income Women||University of Kansas Medical Center|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|21 Months|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251587||35985|
NCT02251600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-005|A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy|A Multi-center Study to Evaluate the Pharmacokinetics of 21-Desacetyldeflazacort and the Safety of Deflazacort After Oral Administration of Deflazacort Tablets to Children and Adolescent Subjects With Duchenne Muscular Dystrophy||Marathon Pharmaceuticals, LLC|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Male|4 Years|16 Years|No|||September 2015|October 20, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251600||35984|
NCT02320435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29406|A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial|A SINGLE-ARM OPEN-LABEL MULTI-CENTRE EXTENSION STUDY OF PERTUZUMAB ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A HOFFMANN-LA ROCHE-SPONSORED PERTUZUMAB STUDY||Hoffmann-La Roche||Recruiting|February 2015|February 2025|Anticipated|February 2025|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320435||30701|
NCT02323659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLRG-14|Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas|Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas||Polish Lymphoma Research Group|Yes|Recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02323659||30453|
NCT02243163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020106|Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy|Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|May 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|40|||Female|20 Years|65 Years|No|||September 2014|September 16, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243163||36633|
NCT02243176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00018|24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy|SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With Type 2 Diabetes Mellitus (T2D) Inadequately Controlled With Metformin Monotherapy|SMART|AstraZeneca|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|689|||Both|18 Years|150 Years|No|||January 2016|January 11, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243176||36632|
NCT02241707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYCSA-2014-01|Does Minimal Post-operative Compression Affect the Outcome for Endovenous Ablation in Treating Varicose Vein Patients?|Does Minimal Post-operative Compression Affect the Outcome for Endovenous Ablation in Treating Varicose Vein Patients?||NYC Surgical Associates|No|Withdrawn|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|All adults, both male/female, with varicose vein who are here in our clinic to seek for        endovenous ablation treatments will be invited to participate in this study.|April 2015|April 27, 2015|September 11, 2014||No|Since reorganization of the institute, this study is aborted. No patient was recruited.|No||https://clinicaltrials.gov/show/NCT02241707|12 Months|36745|
NCT02241720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI68135|Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers|Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach||University of Utah|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|November 21, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241720||36744|
NCT02242058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QST-Pupillo3614|QST-Pupillometry in Sickle Cell Disease Patients|Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.|QST|Children's Research Institute|Yes|Recruiting|August 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|160|Samples With DNA|Collection of blood samples at baseline to be stored in the Pain Neurobiology laboratory for      future biochemical studies.|Both|13 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|SCD patients referred to the Pain Medicine clinic, either outpatient or inpatient.|February 2016|February 3, 2016|September 13, 2013||No||No||https://clinicaltrials.gov/show/NCT02242058||36718|
NCT02316483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00031 [JIRB]|Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes|Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes||Weill Medical College of Cornell University|Yes|Recruiting|December 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Blood Urine|Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited for the study at Hamad Medical Corporation. Most of the        subjects will belong to the oupatient clinics.|December 2014|December 9, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316483||31004|
NCT02316496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGAIN C13-2|Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study|A Phase II Study of Cetuximab Rechallenge in Combination With Irinotecan in Advanced Metastatic Colorectal Cancer Without KRAS or NRAS or BRAF Mutation (All Wild Type) for Patients Pretreated With FOLFIRI and Cetuximab in First Line With Stopping Cetuximab for Progressive Disease After a Previous Response (Partial Response or Complete Response) and After Treatment With a Fluoropyrimidine, Oxaliplatin Plus Bevacizumab Regimen|REGAIN|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Recruiting|January 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|December 10, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316496||31003|
NCT02316509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29656|Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|An Open-Label, Phase I Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer||Genentech, Inc.||Recruiting|March 2015|December 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316509||31002|
NCT02241291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137/14|CARDIOBASE Bern PCI Registry|CARDIOBASE Bern PCI Registry||University Hospital Inselspital, Berne|No|Recruiting|March 2009|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Prospective, single-center observational, web-based registry of all patients undergoing        percutaneous coronary intervention (PCI) at Bern University Hospital, Switzerland|July 2015|July 15, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241291||36777|
NCT02256137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAILTY|A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer|A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer||St. Jude Children's Research Hospital|No|Recruiting|October 2014|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1493|||Both|18 Years|45 Years|No|Non-Probability Sample|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who        have completed a baseline functional assessment six or less years ago when 18-45 years of        age.|November 2015|November 16, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256137||35635|
NCT02256150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-69-C-Lu-301|A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis|A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Lupus Nephritis||Asahi Kasei Pharma Corporation|No|Recruiting|November 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256150||35634|
NCT02509494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107372|Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2|A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola|EBOVAC-Salone|Crucell Holland BV|Yes|Recruiting|September 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|728|||Both|1 Year|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509494||16194|
NCT02497638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGAND|LIpitor and biGuanide to Androgen Delay Trial|A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial|LIGAND|University Health Network, Toronto|Yes|Not yet recruiting|March 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Male|18 Years|80 Years|No|||March 2016|March 4, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02497638||17105|
NCT02494557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD-risk/2014|Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients|Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients|CAD-risk|Acarix|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|108|Samples With DNA|Blood samples for biobank to be used in potential new studies.|Both|40 Years|80 Years|No|Non-Probability Sample|Diabetic type 2 patient|February 2016|February 5, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494557||17341|
NCT02245048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008535|CIMT and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification|Carotid Intima-Media Thickness and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification||Mayo Clinic|No|Enrolling by invitation|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be undergoing standard of care stress echocardiography|September 2015|September 23, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245048||36488|
NCT02245373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infap|Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.|Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care. INFAP Study.||Fundació Sant Joan de Déu||Active, not recruiting|June 2013|July 2015|Anticipated|July 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|263|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care patients who suffer from major depression.|September 2014|September 17, 2014|September 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245373|12 Months|36463|
NCT02497846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEO-R1-1404|TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles|Feasibility and Acceptability of a TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles||Teoxane SA|No|Active, not recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||May 2015|July 10, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02497846||17089|
NCT02252042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-040|Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)|A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer||Merck Sharp & Dohme Corp.|Yes|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|466|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252042||35950|
NCT02252055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0441|The ONE Study ATDC Trial|A Phase I/II Monocentric Trial of Cellular Immunotherapy Based on Autologous Tolerogenic Dendritic Cells (ATDCs) Administration in Patients With Renal Insufficiency Receiving as First Transplantation a Kidney Transplant From a Living-donor.|ONEatDC|Nantes University Hospital|Yes|Recruiting|March 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252055||35949|
NCT02325297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Famirea22|"Impacts of the Letter of Condolence to the Bereaved Families Experience After a Death in ICU " - Study Famirea 22|"Impacts of the Letter of Condolence to the Bereaved Families Experience After a Death in ICU " - Study Famirea 22|Famirea 22|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2014|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|18 Years|N/A|No|||June 2015|November 30, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325297||30327|
NCT02325310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001538-28|Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR|Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine|BREMEAVAC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|36 Years|No|||December 2015|December 15, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325310||30326|
NCT02310451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-10|Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes|Pilot Study of Exosomes Before and After BRAF Inhibitor Therapy in Patients With Advanced Unresectable or Metastatic BRAF Mutation-positive Melanoma|EXOSOMES|Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02310451||31467|
NCT02256943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/12|Genetic Determinants of Amitriptyline Efficiency for Pain Treatment|Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics||University Hospital Inselspital, Berne|Yes|Recruiting|November 2014|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02256943||35574|
NCT02324569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472/CCT-101|A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy||Takeda|No|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|20 Years|N/A|No|||January 2016|January 28, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324569||30383|
NCT02247336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-378|Impact of Family History and Decision Support on High-risk Cancer Screening|Impact of Family History and Decision Support on High-risk Cancer Screening||VA Office of Research and Development|No|Not yet recruiting|March 2016|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Both|40 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247336||36312|
NCT02246088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDUART13|Neuroscience Education on Osteoarthritis|Effect of Neuroscience Education on Subjects With Chronic Knee Pain Related to Osteoarthritis : a Randomized Controlled Trial||University of Valencia|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|53|||Both|N/A|N/A|No|||September 2014|September 19, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02246088||36408|
NCT02321254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot.2013.16|Myoelectric Robot-assisted Rehabilitation for the Upper Limb After Stroke|A Pilot Study of Active, Robot-assisted Therapy for Shoulder Rehabilitation After Stroke, Using Myoelectric Signals|MyoReArm|IRCCS San Camillo, Venezia, Italy||Recruiting|May 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321254||30638|
NCT02246179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48655.018.14|Fractional Laser Assisted Delivery of Anesthetics|Fractional Carbon Dioxide Laser Assisted Delivery of Topical Anesthetics: a Randomized Controlled Pilot Study||Netherlands Institute for Pigment Disorders|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02246179||36401|
NCT02257476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071307|Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors|A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Malignancies||Emory University|Yes|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257476||35534|
NCT02257489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A083-01|Phase 1 Study of ACE-083 in Healthy Subjects|A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women||Acceleron Pharma, Inc.|No|Recruiting|September 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|58|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257489||35533|
NCT02502279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718/ refer.34|Lung Recruitment and Postoperative CPAP|Lung Recruitment and Postoperative CPAP in Pediatric Laparoscopic Surgery|LRvsCPAP|Assiut University|No|Completed|July 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Male|6 Months|6 Years|No|||February 2016|February 21, 2016|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502279||16748|
NCT02502292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7/2007‐2013|Innovative Policies for Healthy Aging|Sustainable Health Systems Through Health Literacy for Healthy Aging|IROHLA|Jacobs University Bremen gGmbH|No|Recruiting|July 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02502292||16747|
NCT02249975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0004.A|Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium||C2 Therapeutics, Inc.|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||December 2015|February 25, 2016|September 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249975||36109|
NCT02249234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-BTX-RCT|Randomized Control Trial of the Use of Botox to Treat Chronic Scrotal Pain|Randomized Control Trial of the Use of Botox to Treat Chronic Scrotal Pain|ROBOT|Mount Sinai Hospital, Canada|No|Enrolling by invitation|August 2014|August 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|65 Years|No|||August 2014|September 23, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02249234||36166|
NCT02249247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.17|Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease|Effect of 12-week Treatment of 5, 25 or 75 mg BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (Double-blind, Double Dummy, Placebo-controlled, Randomized, Parallel Group, Dose Ranging Study)||Boehringer Ingelheim||Completed|April 2001|||August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|577|||Both|40 Years|N/A|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249247||36165|
NCT02249559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00902|Pilot Study Evaluating Safety of Unilateral Gamma Knife Subthalamotomy for Parkinson's Disease|Pilot Study Evaluating Safety of Unilateral Gamma Knife Subthalamotomy for Parkinson's Disease|GKSTN|New York University School of Medicine|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|74 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2016|February 25, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02249559||36141|
NCT02502201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500220|Environment Effect on Six-Minute Walk Test Performance|Effect of the Environment on Six-minute Walk Test Performance in Individuals With Alpha-1 Antitrypsin Deficiency-Related Chronic Obstructive Pulmonary Disease|6MWTAATD|University of Florida|Yes|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02502201||16754|
NCT02255864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0174|Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent|Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial|RENASCENT|Amaranth Medical Inc.|Yes|Recruiting|February 2015|September 2020|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|84 Years|No|||August 2015|August 12, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02255864||35656|
NCT02323919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL084767|Long-term Exercise in Older Cardiac Patients|Improving Long Term Exercise in Older Cardiac Patients||Case Western Reserve University|Yes|Completed|April 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|379|||Both|55 Years|N/A|No|||January 2016|January 26, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02323919||30433|
NCT02326441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KX02-01-13|Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies|A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies||Kinex Pharmaceuticals Inc|No|Recruiting|December 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326441||30239|
NCT02315417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052172|An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum||XOMA (US) LLC|Yes|Recruiting|November 2014|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315417||31086|
NCT02315638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2801002|Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.|Follow-up to Study Protocol B2801001, A Phase I/II, Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 in Patients With Chronic Hepatitis C [CHC] Infection||Tacere Therapeutics, Inc.|No|Enrolling by invitation|November 2014|November 2022|Anticipated|November 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|14|Samples Without DNA|Blood samples will be collected and archived for further testing, should future data suggest      that it is clinically or scientifically indicated.|Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of subjects that were enrolled in Study B2801001 and who        received a dose of TT-034.|December 2014|December 11, 2014|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315638||31069|
NCT02245191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASPRES-3|Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation|Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean||University of Sao Paulo General Hospital|Yes|Active, not recruiting|July 2014|||July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|60|||Female|18 Years|N/A|No|||May 2014|September 16, 2014|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02245191||36477|
NCT02324205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124.03-2014-GES-0010_2|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy|ADAPT|GE Healthcare|No|Recruiting|March 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Female|30 Years|N/A|No|||December 2015|December 1, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324205||30411|
NCT02324218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201335|This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age|Incidence of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age, in the United Kingdom Clinical Practice Research Datalink (CPRD)||GlaxoSmithKline||Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|161429|||Both|N/A|80 Years|No|Non-Probability Sample|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD        database of UK, from the Year 2000 to 2012.|February 2016|February 25, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02324218||30410|
NCT02314377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNA1052|Bevacizumab Therapy for Brain Arteriovenous Malformation|Bevacizumab Therapy for Brain Arteriovenous Malformation||University of California, San Francisco|Yes|Not yet recruiting|December 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|64 Years|No|||December 2015|December 15, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314377||31166|
NCT02250768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGRH-Embryogen|Effects of Embryogen in RIF Patients|Effects of Granulocyte - Macrophage Colony - Stimulating Factor (GM-CSF) Supplementation in Embryo Culture in Patients With Repeated Implantation Failure|RIF|Vietnam National University|No|Completed|July 2013|August 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250768||36048|
NCT02250144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5832|Foot Orthoses in Patellofemoral Pain Syndrome: a Prospective Randomized Study of Morpho-specific Versus Placebo Orthoses|Foot Orthoses in Patellofemoral Pain Syndrome: a Prospective Randomized Study of Morpho-specific Versus Placebo Orthoses||University Hospital, Strasbourg, France|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|12 Years|40 Years|No|||August 2015|August 6, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02250144||36096|
NCT02250235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111154_14238|Piloting an Intervention for Improving Treatment Adherence|Piloting a Novel Behaviour Change Intervention for Improving Treatment Adherence in Haemodialysis Patients||University of Hertfordshire|Yes|Completed|November 2012|February 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250235||36089|
NCT02245139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRHH12014|Surveillance Study of Acute Gastroenteritis in Hospitalized Children|Surveillance Study of Acute Gastroenteritis Etiologies in Hospitalized Children|SAGE|Shaikh Ragheb Harb Hospital|No|Active, not recruiting|July 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|1 Month|13 Years|No|Non-Probability Sample|male and female patient from 1 month to 13 YO admitted to pediatric floor with acute        gastroenteritis|September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245139|7 Days|36481|
NCT02245386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1781956|Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women|Effects of Pregnancy and Parturition on Pelvic Floor Morphology and Sexual Function in Egyptian Women.||Al-Azhar University|Yes|Completed|May 2013|April 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|120|||Female|N/A|N/A|No|Non-Probability Sample|primiparae in early postpartum period (48 hours to72 hours). written consent was taken.        easy communicable, reachable women for further requirements.|September 2014|September 17, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245386||36462|
NCT02508896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFiRiS 012|Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects|A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects|AFF012|Affiris AG|Yes|Active, not recruiting|July 2015|November 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02508896||16240|
NCT02508909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDEO SIIO trial, 2011/41|Videoscopic Ilioinguinal Lymphadenectomy for Melanoma|Videoscopic Ilioinguinal Lymphadenectomy for Groin Lymph Node Metastases From Melanoma||Istituto Oncologico Veneto IRCCS|No|Completed|September 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02508909||16239|
NCT02254252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12604|Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow|Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon Visited in Imam Reza Hospital, Mashhad, Iran||Mashhad University of Medical Sciences|No|Completed|March 2012|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|N/A|N/A|No|||March 2015|March 28, 2015|September 29, 2014||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT02254252||35780|
NCT02254291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4092|A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes|Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes|SUSTAIN™|Novo Nordisk A/S|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|308|||Both|20 Years|N/A|No|||November 2015|November 12, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254291||35777|
NCT02256241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0180-14-RMB|The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin|The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin|RING UB LIGASE|Rambam Health Care Campus|No|Recruiting|October 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|90|Samples Without DNA|1. Bone marrow will be collected from othewise healthy patients undergoing orthopedic           surgery - arthroplasty for the treatment of degenerative joint disease or traumatised           patients. The bone marrow will be collected from disposable tissue that is removed           during the normal sequence of the surgery.        2. Collection of connective tissue from patients with malignancies of musculoskeletal           origin. The tissue that will be used is part of the resected tumor specimens. The           tissue will be used for:|Both|18 Years|N/A|No|Non-Probability Sample|1. Healthy patients undergoing orthopedic surgery - arthroplasty for the treatment of             degenerative joint disease or traumatised patients.          2. Patients with malignancies of musculoskeletal origin.|February 2015|February 22, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02256241||35628|
NCT02504671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201755|Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis|A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate||GlaxoSmithKline|No|Recruiting|July 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|January 14, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504671||16564|
NCT02509650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6024|Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing|Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing|DERMA-SEQ|University Hospital, Strasbourg, France|No|Recruiting|September 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Whole blood|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Familial lipomatosis|March 2016|March 23, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02509650||16182|
NCT02243891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAPITUP3|AF Ablation With or Without ROX Coupler Study|Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study|LAAPITUP3|Eastbourne General Hospital|No|Not yet recruiting|May 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||March 2015|March 8, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243891||36577|
NCT02313766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-39|Preoxygenation With Positive Inspiratory Pressure During Induction of Anesthesia|Randomized Controlled Trial on Preoxygenation Through Spontaneous Breathing or Non Invasive Positive Pressure Ventilation With and Without Positive End Expiratory Pressure|PREOX|University Hospital, Caen|Yes|Completed|October 2006|January 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|December 1, 2014||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT02313766||31212|
NCT02313779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2428|Meditation and Decision Making Study III|Nonconscious Affective and Physiological Mediators of Behavioral Decision Making Study 3|MDMS3|University of North Carolina, Chapel Hill|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|240|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313779||31211|
NCT02250755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_27|MRI Perfusion on T1 and T2 Brain Lesion(s)|Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia|METAPERF|University Hospital, Lille|No|Completed|June 2013|November 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02250755||36049|
NCT02250365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-012|Electrical Stimulation of the Paretic Upper Limb in the Early Stroke Phase|Electrical Somatosensory Stimulation of the Paretic Upper Limb in Acute Stroke Patients - a Randomized Controlled Study||University of Copenhagen|No|Recruiting|October 2014|October 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250365||36079|
NCT02311829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01580-43|Evaluation of a Telephone Follow-up Procedure on the Quality of Life in Psychogenic Non-epileptic Seizures|Evaluation d'un Dispositif de Suivi téléphonique Sur la Qualité de Vie Dans Les Crises Psychogènes Non Epileptiques.|EDUQ-CPNE|Central Hospital, Nancy, France|No|Recruiting|January 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|136|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02311829||31361|
NCT02317809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200061-006|Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects|An Open-label, Randomized, Two-period, Two-sequence Crossover Trial to Assess the Bioequivalence of the Liquid Formulation Versus the Freeze-dried Formulation of 900 IU r-hFSH and 450 IU r-hLH in Pergoveris®, Administered Subcutaneously in Pituitary Suppressed Healthy Premenopausal Female Subjects||Merck KGaA|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317809||30902|
NCT02253355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-006|PINS Stimulator System for Patients With Treatment Resistant Depression|PINS Stimulator System for Patients With Treatment Resistant Depression||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|70 Years|No|||April 2015|October 12, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02253355||35849|
NCT02243774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-001821|Mail Outreach To Increase Vaccination Acceptance Through Engagement|Mail Outreach To Increase Vaccination Acceptance Through Engagement|MOTIVATE|Brigham and Women's Hospital||Completed|September 2014|September 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|228000|||Both|66 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243774||36586|
NCT02253823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.41|Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers|A Single Center, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effect of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Administered Daily on 3 Non-Consecutive Days and Twice Daily for 7 Days, on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) 600 mg a Day in Healthy Adult Volunteers||Boehringer Ingelheim||Completed|December 2001|||March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|68|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02253823||35813|
NCT02253836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.61|Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir|A Single-Centre Open-Label Study in Healthy Adult Volunteers to Assess the Pharmacokinetic Interactions Between Steady-State TPV (500 mg) and Single-Dose and Steady-State Atazanavir (300 mg QD) in the Presence of Ritonavir (100 mg)||Boehringer Ingelheim||Completed|January 2005|||July 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253836||35812|
NCT02253849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.80|Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers|A Single Centre, Open-label Study With Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r 500/200 mg on the Steady-state Pharmacokinetics of Carbamazepine (200 mg Twice Daily)||Boehringer Ingelheim||Completed|November 2005|||June 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|58 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253849||35811|
NCT02253862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.83|Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers|Assessment of Single-dose Oral Tadalafil Pharmacokinetic Characteristics When Simultaneously Co-administered With Single-dose and Steady-state Tipranavir/Ritonavir 500 mg/200 mg to Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2005|||March 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253862||35810|
NCT02326818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150035|Comparison of Electrophysiologic and Ultrasound Guidance for Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia and Spasticity|Comparison of Electrophysiologic and Ultrasound Guidance for Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia and Spasticity||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|100 Years|No|||August 2015|January 12, 2016|December 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326818||30210|
NCT02326844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150050|BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment|A Phase 2 Pilot Study of BMN 673 (Talazoparib), an Oral PARP Inhibitor, in Patients With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|99 Years|No|||November 2015|March 18, 2016|December 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326844||30209|
NCT02254811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48233|FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff|A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI)||University of Alberta|Yes|Active, not recruiting|September 2014|||August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||September 2014|October 1, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254811||35737|
NCT02249819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-416|Evaluating Anodal tDCS Preceding Aphasia Therapy|Evaluating Anodal tDCS Preceding Aphasia Therapy||Northwell Health|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249819||36121|
NCT02505035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822134|Randomized Evaluation of Default Access to Palliative Services|Default Palliative Care Consultation for Seriously Ill Hospitalized Patients|REDAPS|University of Pennsylvania|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|20000|||Both|45 Years|N/A|No|||October 2015|October 28, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505035||16536|
NCT02505048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1501|A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature|A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature|RUBY|UNICANCER|No|Not yet recruiting|March 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Female|18 Years|99 Years|No|||February 2016|February 15, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02505048||16535|
NCT02505061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC102-2314-B-182-002|The Use of Modified ride-on Cars to Advance Mobility and Socialization in Young Children With Disabilities|||Chang Gung Memorial Hospital|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|12 Months|36 Months|No|||June 2015|July 20, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02505061||16534|
NCT02496351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161976BBM|TENS for Phantom Limb Pain Prevention Following Major Amputation|Transcutaneous Electrical Nerve Stimulation (TENS) for Phantom Limb Pain Prevention Following Arteriopathic Major Amputation: Clinical Trial||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Recruiting|May 2015|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|July 14, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496351||17203|
NCT02241564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALTX-001|Malignancies in Transplanted Patients|Follow-up of Malignancies in Transplanted Patients|MALTX|Uppsala University|No|Recruiting|November 2007|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney, pancreas or liver transplanted patients in the Uppsala/Örebro region with a        diagnosed malignancy pre or post transplantation|September 2014|December 1, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241564||36756|
NCT02241577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGSimplant2014|Surgical and Non-surgical Treatment of Peri-implantitis|Surgical and Non-surgical Treatment of Peri-implantitis: Randomised Controlled Trial of 12-months Follow-up|Perio-implants|Federal University of Rio Grande do Sul|No|Recruiting|June 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|N/A|N/A|No|||September 2014|September 15, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241577||36755|
NCT02240849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2014-03|Effectiveness of Functional Pillow on Neck Pain, Disability, Quality of Sleep and Life|Effectiveness of Functionally Customized Pillow on Neck Pain, Disability, Quality of Sleep and Life: Randomized Controlled Trial|EPNS|Jaseng Hospital of Korean Medicine|No|Completed|June 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|69 Years|No|||September 2014|September 24, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02240849||36811|
NCT02241083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05114|The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements|||Tampere University Hospital||Completed|June 2006|||May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|N/A|N/A|No|||September 2014|September 15, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241083||36793|
NCT02497859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505159|Breakfast Intake and Satiety Hormones|Does Higher Protein Quality Breakfast Reduce Energy Intake When Following a Weight Loss Diet Plan?||Texas Tech University|No|Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|44 Years|No|||January 2016|January 20, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497859||17088|
NCT02311556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302018|Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging|Assessment of Early Treatment Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging||Washington University School of Medicine|No|Recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311556||31382|
NCT02318810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2014 1212|Influence of the Neuromuscular Blockade on Mask Ventilation|The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)||University of Rostock|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|80 Years|No|||October 2015|October 21, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318810||30825|
NCT02252952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1136635|The Effect of Sugar Sweetened and Diet Beverages Consumed as Part of a Weight-Maintenance Diet on Fat Storage|A Comparison of the Effects of Sugar Sweetened Beverages (SSBs), Diet Beverages and Water on Weight, Body Composition, Liver and Muscle Fat Infiltration, Visceral Fat, Neurocognitive Function, Blood Lipids, Insulin Resistance and Hydration Status in Healthy Weight and Overweight, Premenopausal Females Aged 20-50||Rippe Lifestyle Institute|No|Active, not recruiting|February 2013|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|99|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252952||35880|
NCT02252965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200084-513|Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes (CONSENT)|CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study|CONSENT|Merck KGaA|Yes|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|518|||Both|18 Years|79 Years|No|||April 2015|April 29, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252965||35879|
NCT02253641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2107|The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits|The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits||University of North Carolina, Chapel Hill|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 20, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253641||35827|
NCT02321046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D133FR00101|An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer)|An epidemiOlogy Study to deteRmine the Prevalence of EGFR muTations in RUSsian Patients With Advanced NSCLC (ORTUS)|ORTUS|AstraZeneca|No|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Cytology and plasma samples|Both|N/A|N/A|No|Non-Probability Sample|Target study population will be treatment-naive patients of both sexes, 18 years and        older, with cytologically-verified advanced (stage IIIB-IV) non-squamous, mixed subtypes        of NSCLC and NSCLC-NOS (Non-Small Cell Lung Cancer - Not Otherwise Specified), diagnosed        before enrolment into the study, consented to participate in this non-interventional        study, who visit the oncology hospitals/departments in the Russian Federation.|March 2016|March 1, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02321046||30654|
NCT02323724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/617|APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.|APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.||Corporacion Parc Tauli||Recruiting|December 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological        diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014        in Corporació Parc Taulí|December 2014|December 18, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323724||30448|
NCT02243787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVA322-SAD-Psoriasis-001|Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis|A Randomised, Double-blind, Sequential, Ascending Single-dose Study to Evaluate Safety, Tolerability, Biological Activity, and Systemic Exposure of COVA322, a Bispecific TNF-α / IL-17A Antibody Fusion Protein, in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis||Covagen|Yes|Terminated|April 2014|||September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|September 9, 2014||No|Based on the observed safety profile of COVA322, the sponsor decided to stop the clinical    study.|No||https://clinicaltrials.gov/show/NCT02243787||36585|
NCT02242084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK 23 - 14|Thrombolysis in Ischemic Spinal Cord Stroke|Thrombolysis in Ischemic Spinal Cord Stroke||Rabin Medical Center|No|Not yet recruiting|October 2014|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|85 Years|No|||September 2014|September 15, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242084||36716|
NCT02313493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-Baby Triple P|Efficacy and Feasibility of Baby Triple P - a Pilot Study|Improving Mental Health in First Time Parents - A Randomized Controlled Pilot Study||Ruhr University of Bochum|No|Active, not recruiting|September 2012|November 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|78|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313493||31233|
NCT02241876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC+Cisplatin2014|THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS|EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS||University of Campinas, Brazil||Not yet recruiting|October 2014|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2014|September 13, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02241876||36732|
NCT02247258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3121|Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.|Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.||Universitaire Ziekenhuizen Leuven|No|Terminated|October 2005|May 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|63|||Both|16 Years|75 Years|No|||September 2014|May 28, 2015|September 19, 2014||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT02247258||36318|
NCT02257918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0014|Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea|A Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of a Single Dose of Oral AZD0914 Compared to Intramuscular Ceftriaxone in the Treatment of Male and Female Subjects With Uncomplicated Gonorrhea||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|55 Years|No|||January 2016|January 28, 2016|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257918||35502|
NCT02510157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711/19-3-15|Effect of Dexamethasone on the Action of Sugammadex|||Attikon Hospital|No|Recruiting|May 2015|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 26, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02510157||16143|
NCT02510170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM150035CTIL|Fetal and Maternal Head Circumference During Pregnancy in Israeli Population|Fetal and Maternal Head Circumference During Pregnancy||Clalit Health Services|Yes|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|520|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|January 2016|February 11, 2016|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02510170|1 Day|16142|
NCT02497690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1103|Effectiveness of Therapy Via Telemedicine Following Cochlear Implants|Effectiveness of Therapy Via Telemedicine Following Cochlear Implants|TACIT|University of Colorado, Denver|Yes|Recruiting|September 2013|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|6 Months|6 Years|No|||January 2016|January 12, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02497690||17101|
NCT02497898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNHL001|Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma|A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma||The First People's Hospital of Changzhou|Yes|Not yet recruiting|July 2015|July 2040|Anticipated|July 2038|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||June 2015|July 12, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02497898||17085|
NCT02246439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHB-102-01|RHB-102 (Bimodal Release Ondansetron) for Acute Gastroenteritis or Gastritis (GUARD)|Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis|GUARD|RedHill Biopharma Limited|No|Recruiting|September 2014|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|12 Years|85 Years|No|||October 2015|October 6, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246439||36381|
NCT02245399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 14-086|Canola-Mediterranean Diet Study in T2DM|Canola Enriched Mediterranean Type Weight Loss Diet in Type 2 Diabetes||St. Michael's Hospital, Toronto|No|Recruiting|October 2014|December 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|N/A|No|||January 2016|January 7, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02245399||36461|
NCT02245412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1007-GIGVHD-201|A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute GI GVHD|A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-versus-Host Disease Involving the Lower Gastrointestinal Tract|GIGVHD|Alexion Pharmaceuticals|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245412||36460|
NCT02250131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFT|The Goal dIrected perFusion Trial in Cardiac Surgery|A Multi-center, Randomized Controlled Trial of Goal-directed Perfusion in Cardiac Surgery|GIFT|IRCCS Policlinico S. Donato|No|Recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Both|19 Years|N/A|No|||March 2016|March 15, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250131||36097|
NCT02316262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR Prosthetic Control|Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation|Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation||Northwestern University|Yes|Recruiting|October 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|No|||July 2015|July 16, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316262||31021|
NCT02320851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EO1401|Tailored Care for Somatoform Vertigo/Dizziness|Tailored Care for Somatoform Vertigo/Dizziness - From Diagnostics to Therapy||Technische Universität München|Yes|Not yet recruiting|January 2015|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320851||30669|
NCT02323568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIVROVAIRE 2|Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.|Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.|VIVROVAIRE 2|Centre Francois Baclesse|Yes|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323568||30460|
NCT02242890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-8070-2|Pilot #2 of Social Network Intrauterine Contraceptive (IUC) Intervention|Pilot #2: The Woman-to-Woman Dissemination Project: Harnessing the Power of Social Networks to Increase IUC Use||University of California, San Francisco|Yes|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242890||36654|
NCT02245854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-Scope|Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps|Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Subcentimetric Colorectal Polyps: the E-scope (Efficacy and Safety of COld PolypEctomy) Trial||Istituto Clinico Humanitas|Yes|Completed|September 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02245854||36426|
NCT02313233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC01110908|Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia|Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia||Golden Biotechnology Corporation|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Male|40 Years|N/A|No|||October 2015|November 27, 2015|December 5, 2014||No||No|September 3, 2015|https://clinicaltrials.gov/show/NCT02313233||31253|
NCT02325245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAIL-01|Effects of Metformin in Pre-frail Elderly|Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly||Indonesia University|Yes|Recruiting|March 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|60 Years|N/A|No|||March 2016|March 3, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325245||30331|
NCT02248701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1449-R|Testosterone Plus Finasteride Treatment After Spinal Cord Injury|Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI||VA Office of Research and Development|Yes|Not yet recruiting|May 2016|June 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248701||36207|
NCT02247713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14PRI|An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries|An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries|PERTAIN|The Netherlands Cancer Institute|No|Not yet recruiting|September 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|520|||Both|18 Years|N/A|No|Probability Sample|The retrospective cohort study includes at least 250 patientswith stage III NSCLC with        curative intent chemoradiotherapy (sequential or concurrent), 125 patients in the first        arm (non PET staged) and 125 patients (PET staged) in the second arm. The prospective        cohort study includes at least 250 patients (PET staged) receiving concurrent        chemoradiotherapy based on PET/CT RTP. In total, we aim to include a number of 519        patients.|September 2014|September 19, 2014|August 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02247713||36283|
NCT02247726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-M-203|RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.|A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life||Novavax|Yes|Active, not recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02247726||36282|
NCT02317250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00815-02|Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II|Early and Long-Term Health Outcomes of Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II||University of California, Los Angeles|Yes|Not yet recruiting|June 2018|December 2022|Anticipated|October 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|1500|||Both|65 Years|N/A|No|||January 2016|February 4, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02317250||30945|
NCT02322554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR002|Cellular and Tissue Based Therapy Registry|The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers|CTPR|U.S. Wound Registry|Yes|Recruiting|January 2005|||January 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50000|||Both|N/A|N/A|No|Non-Probability Sample|All patients seen at participating hospital based outpatient wound centers to whom CTPs        are applied|May 2015|May 28, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02322554|2 Months|30538|
NCT02247271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-775-Diabetes|The Role and Effectiveness of Diabetes Coaches in British Columbia|The Role and Effectiveness of Diabetes Coaches in British Columbia||University of Victoria|No|Not yet recruiting|September 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247271||36317|
NCT02247557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL011|Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis|Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study||Buddhist Tzu Chi General Hospital|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|80 Years|No|||September 2014|September 23, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247557||36295|
NCT02254551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 50|Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In||SCRI Development Innovations, LLC|No|Terminated|January 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 29, 2014|Yes|Yes|Safety lead-in data did not support continuation of study.|No||https://clinicaltrials.gov/show/NCT02254551||35757|
NCT02241382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKK-CCS-2014|Cologne Cardioversion Study|Randomized Controlled Trial Comparing Internal vs External Cardioversion in ICD Patients||Universitätsklinikum Köln|Yes|Recruiting|September 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|99 Years|No|||December 2015|December 18, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02241382||36770|
NCT02498132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R41MH108219-01|Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems|Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems||University of Maryland||Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02498132||17067|
NCT02499237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AfterDmab|Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation|The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass|AfterDmab|424 General Military Hospital|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|50 Years|N/A|No|||July 2015|July 14, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499237||16982|
NCT02250521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0365|McGrath MAC ISR-McGRATH MAC Video Laryngoscope Study|McGRATH MAC Video Laryngoscope - To View or Not To View?||The University of Texas Health Science Center, Houston|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250521||36067|
NCT02250066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IlamUMS|Prevention of Type 2 Diabetes Mellitus by Changes in Diet|Effect of Diet Therapy on Prevention of Type 2 Diabetes Mellitus Among 322 Adults Over 20 Years With Abnormal Glucose Metabolism||Ilam University of Medical Sciences|Yes|Completed|January 2012|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|322|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02250066||36102|
NCT02253394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPS_PAH|The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study|The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)||Brigham and Women's Hospital|No|Recruiting|September 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|30|||Both|16 Years|75 Years|No|||March 2016|March 1, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253394||35846|
NCT02325102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC102-13|Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children Hospitalized in Pediatric Department|Potential Clinical and Biological Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children in Pediatric Department||Hillel Yaffe Medical Center|Yes|Completed|June 2014|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|400|||Both|N/A|17 Years|No|Non-Probability Sample|otherwise healthy children admitted in pediatric department|December 2014|December 19, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02325102||30342|
NCT02324491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-203|An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability||Zafgen, Inc.|Yes|Terminated|December 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 18, 2014||No|Sponsor decision to analyze available safety and efficacy data|No||https://clinicaltrials.gov/show/NCT02324491||30389|
NCT02314117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15372|A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)|RAINFALL|Eli Lilly and Company|Yes|Recruiting|January 2015|April 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|616|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314117||31186|
NCT02314130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1732/08|No-commercial Enteral Diet for Patients in Home Nutritional Therapy: Effects on Anthropometric and Biochemical Indices|No-commercial Enteral Diet for Patients in Home Nutritional Therapy: Effects on Anthropometric and Biochemical Indices||Federal University of São Paulo|No|Completed|May 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|60 Years|80 Years|No|||March 2013|December 10, 2014|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02314130||31185|
NCT02249910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4145|Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects|An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects||Novo Nordisk A/S|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249910||36114|
NCT02316990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00056|China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients|China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients|SUP|AstraZeneca|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|The subject population that will be included in the NIS are the consecutive discharged        patients ≥18 years old who were hospitalized to Neurosurgical departments and whose        GCS≤10[4] within 24 hours of lesion/admission. The subjects will be focused on brain        trauma, cerebral haemorrhage or postoperative brain tumour population.|December 2015|December 14, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02316990||30965|
NCT02314156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 2013-01-03|Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy|Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy||Northwestern University|Yes|Recruiting|October 2015|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314156||31183|
NCT02251574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001418|Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults|Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults||University of Kansas Medical Center|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251574||35986|
NCT02252497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308015|Tranexamic Acid in Total Hip Arthroplasty.|Tranexamic Acid in Total Hip Arthroplasty: Single Preoperative Administration vs Perioperative Administration. A Randomized Control Trial.|PORTO|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|April 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252497||35915|
NCT02322567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0808|Left Ventricular Diastolic Dysfunction in Kidney Recipients|Influence of Left Ventricular Diastolic Dysfunction on Graft Function and Postoperative Complication in Patients Undergoing Elective Kidney Transplantation||Severance Hospital|No|Completed|January 2012|October 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|242|||Both|19 Years|70 Years|No|Non-Probability Sample|Elective kidney transplantation patients|February 2016|February 24, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02322567||30537|
NCT02322580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56818|An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients|Intermittent Versus Continuous Treatment: an Observational Monocentric Study Investigating the Association Between Trough Levels of Enbrel and Therapy Regimen|DERM|Universitaire Ziekenhuizen Leuven||Enrolling by invitation|January 2015|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Psoriasis patients who receive Enbrel® therapy according to the current EU Summary of        Product Characteristics (SmPC)|December 2014|January 8, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02322580||30536|
NCT02254616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-5696A3|Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery|Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery: A Follow up Study on Brain Reorganization, Motor Performance of Upper Extremity, Daily Function, and Activity Participation||Chang Gung Memorial Hospital|No|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|80 Years|No|||December 2015|December 28, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02254616||35752|
NCT02246244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002159-25|Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress|Randomized, Double Blind, Efficacy Study of Escitalopram Versus Placebo in ENT Cancer Patients Suffering From Emotional Distress|TADDOR|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|April 2009|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||September 2014|September 18, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246244||36396|
NCT02502630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-MW-001|Microwave Ablation for Pulmonary Metastases From Colorectal Cancer|CT-guided Percutaneous Microwave Ablation for Pulmonary Metastases From Colorectal Cancer||The First People's Hospital of Changzhou|Yes|Completed|June 2010|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502630||16721|
NCT02499978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deNUC|Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity|Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (The 'deNUC' Study; TMC114HIV2030)|TMC114HIV2030|Stanford University|No|Not yet recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499978||16925|
NCT02500498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-370|Safety Profile of Nulojix in Home Infusion Settings|Safety Profile of Nulojix in Home Infusion Settings||Bristol-Myers Squibb|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|Home infusion service visit|July 2015|July 15, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500498||16885|
NCT02254876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4496/2013|Effectiveness of NeuroMuscular Taping on Painful Hemiplegic Shoulder|Effectiveness of NeuroMuscular Taping in a Population of Post Stroke Hemiplegic Patients Suffering From Painful Shoulder Syndrome - Randomized Controlled Trial (RCT)||University of Bologna|No|Completed|September 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||May 2015|May 28, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254876||35732|
NCT02257957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|plasmadry10|Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye|Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye||Universidad Nacional de Colombia|Yes|Not yet recruiting|November 2014|||September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02257957||35499|
NCT02241460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Promescent|Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation|A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation|Promescent|Kaiser Permanente|Yes|Enrolling by invitation|March 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|No|||September 2014|September 12, 2014|May 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241460||36764|
NCT02312973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17767|To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects|Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Oral Doses of 75 mg Molidustat in Male and Female Subjects With Renal Impairment Requiring Hemo- or Peritoneal Dialysis Compared to Age- and Weight-matched Healthy Subjects in a Single-center, Non-controlled, Non-blinded Study With Group Stratification||Bayer|No|Active, not recruiting|January 2015|February 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|40|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312973||31273|
NCT02314143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116613|Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib|Phase II Biomarker Study Evaluating The Upfront Combination Of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus The Combination After Eight Weeks Of Monotherapy With Dabrafenib Or Trametinib In Patients With Metastatic And Unresectable Stage III Or IV Melanoma Harbouring An Activating BRAF Mutation||GlaxoSmithKline|No|Recruiting|November 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02314143||31184|
NCT02317497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODERNISE_Prot_HD|Sedation Depth in Neurocritical Care|MOderate vs DEep Regimen in NeuroIntensive Care SEdation|MODERNISE|Heidelberg University|No|Not yet recruiting|January 2015|November 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02317497||30926|
NCT02247063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70766|Motor Cortex as a Research & Therapeutic Target in TMD|Motor Cortex as a Research and Therapeutic Target in TMD||University of Michigan|No|Completed|September 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247063||36333|
NCT02247076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-038|Does Meal Timing Affect Energy Expenditure|Does Meal Timing Affect Energy Expenditure|GRAZING|Pennington Biomedical Research Center|No|Recruiting|October 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247076||36332|
NCT02247089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01584|The Effect of Massage Therapy to Control Night Shift Related Stress|The Effect of Massage Therapy to Control Night Shift Related Stress: A Pilot Prospective Randomized Crossover Trial||University of British Columbia|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|10|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02247089||36331|
NCT02321579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF14261B|Vitamin B-6 and Glutathione on Inflammation, Homocysteine, Oxidative Stress and Antioxidant Capacities|The Effects of Vitamin B-6 and Glutathione on Inflammatory Responses, Homocysteine Metabolism, Oxidative Stress and Antioxidant Capacities in Patients With Liver Cirrhosis or Hepatocellular Carcinoma||Taichung Veterans General Hospital|No|Recruiting|December 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|25|||Both|20 Years|80 Years|No|||December 2014|December 19, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02321579||30613|
NCT02318602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS011-14-030|Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder|A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric and Adult Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029, INS011-14-024, or INS011-14-25||INSYS Therapeutics Inc|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|232|||Both|1 Year|30 Years|No|||February 2016|February 29, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318602||30841|
NCT02256163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10023|Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm|Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm (TAA)|TAA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|275|Samples With DNA|Blood sample.|Both|18 Years|N/A|No|Non-Probability Sample|Enrollement of individuals and families followed in the reference centers and the        competence centers,          -  search for mutations in one of known genes such as FBN1, TGFBR1, TGFBR2, ACTA2, or             MYH11.          -  search for new genes in families and individuals with TAA who without mutation in one             of the known genes.|March 2016|March 17, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256163||35633|
NCT02256618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000014903|Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy|A Pilot Feasibility and Safety Study of Autologous Umbilical Cord Blood Cell Therapy in Infants With Neonatal Encephalopathy||Neonatal Encephalopathy Consortium, Japan|Yes|Recruiting|August 2014|February 2018|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|24 Hours|No|||October 2014|October 1, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256618||35599|
NCT02322918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01136|The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder|BC Psychosis Program Biobank and Database for Investigating Genetic Polymorphisms of Brain-derived Neurotrophic Factor and Catechol-o-methyl Transferase and Their Associations With Psychosis Disorder|BCPP BIODA|University of British Columbia|No|Recruiting|July 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|200|Samples With DNA|We will be collecting and retaining whole blood samples and saliva samples for genomic      testing.|Both|18 Years|N/A|No|Non-Probability Sample|The population will include all patients who have been admitted to the British Columbia        Psychosis Program (BCPP). BCPP provides intensive inpatient care for individuals who have        psychosis-related treatment challenges, including pharmacologic, biophysical, and        psychosocial services. Admission criteria to BCPP include the following: 1) Must be 18        years or older; 2) Diagnosis of schizophrenia, schizoaffective disorder, mood disorder        with psychosis; 3) History of no response or inadequate response of positive symptoms to        at least 2 adequate trials of antipsychotics (one of which is a second generation agent)        by health authority tertiary clinical teams; 4) Incomplete recovery of social, vocational,        and occupational functioning and 5) If present, substance use disorder, pervasive        developmental disorder, developmental disability, personality disorder, aggression, or        head injury are not the primary focuses of treatment.|November 2015|November 30, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02322918|6 Months|30510|
NCT02255773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0511|Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures|Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2014|||November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255773||35663|
NCT02503046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D139206062|Estimation of Pentraxin3 and PGingivalis Levels in Patients With Knee Joint and Gum Diseases|Estimation of Pentraxin 3 and Porphyromonas Gingivalis Levels in Patients With Rheumatoid Arthritis and Periodontitis- An Observational Study|EP3PGKG|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Recruiting|February 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|90|Samples With DNA|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for asseessment of      levels of PGingivalis.      5ml of blood to be collected from each subject, centrifuged, to separate the plasma for      estimation of Pentraxin3 (Quantikine ELISA)|Both|30 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Total 90 Subjects of whom 30 subjects belong to the Arthritis and Periodontitis group,30        subjects belong to the Periodontitis group and 30 subjects from the healthy group|July 2015|October 29, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02503046||16689|
NCT02505789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS/CIHR_201209-293922|Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients|Transfusion-related Epstein-Barr Virus (EBV) Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients: a Multicenter Prospective Cohort Study (TREASuRE Study)|TREASuRE|St. Justine's Hospital|No|Recruiting|May 2013|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|324|||Both|N/A|21 Years|No|Non-Probability Sample|Only allogeneic HSCTs will be considered (no autologous grafts) because allogeneic grafts        require a higher degree of immune suppression, which is known to increase risk with regard        to EBV infection, development of PTLD and other EBV complications|July 2015|July 20, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505789||16478|
NCT02505074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015805|Natural History of Melody Valve in the Mitral and Tricuspid Position|Natural History of Melody Valve in the Mitral and Tricuspid Position||Children's Hospital Boston|No|Active, not recruiting|December 2014|June 2018|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|All patients who have had a Melody valve inserted via surgical intervention prior to        December, 2014, into either the mitral or tricuspid positions, will be eligible.|June 2015|July 20, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02505074||16533|
NCT02500979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5570C00002|Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus|A Randomized, Single-Blind, Two-Way Crossover, Placebo-Controlled Phase I Study to Compare the 24-hour Glucose Profile and Safety of Pramlintide and Insulin, Co-Administered in a Fixed-Dose Ratio, Versus Placebo and Insulin in Patients With Type 1 Diabetes Mellitus With Inadequate Glycemic Control||AstraZeneca|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02500979||16848|
NCT02242162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00630-57|Establishment of a Non-invasive and Indirect Measure of Volitional Pimax|Establishment of a Non-invasive and Indirect Measure of Volitional Pimax|PI MAX STIM|Centre d'Investigation Clinique et Technologique 805|Yes|Completed|May 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|75|||Both|6 Years|N/A|No|Probability Sample|neuromuscular diseases|March 2016|March 1, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242162||36710|
NCT02242500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130/2010|Coronally Advanced Flap With or Without Porcine Collagen Matrix for Root Coverage|Phase IV Study of Coronally Advanced Flap With or Without Porcine Collagen Matrix for Treatment of Gingival Recession: a Randomized Controlled Clinical Trial||University of Campinas, Brazil|No|Completed|December 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||December 2015|December 26, 2015|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02242500||36684|
NCT02241642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P190-00|Safety and Performance Study of Large Hole Vascular Closure Device|Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER II Study|FRONTIER II|Vivasure Medical Limited|Yes|Recruiting|October 2013|January 2016|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||September 2014|September 15, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241642||36750|
NCT02245542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.68|The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)|The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)||Boehringer Ingelheim||Completed|April 2005|||February 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5775|||Male|N/A|N/A|No|Non-Probability Sample|BPH patients who are indicated for treatment with ALNA®OCAS® with special respect to        nocturia recruited at urologists|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245542||36450|
NCT02316730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQTS1212|A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)|Single-dose, Open, Randomized, Two-period, Crossover Comparative Bioavailability Study of Sanchi-Tongshu Capsule and Sanchi-Tongshu Capsule (Enteric Coated Pellets) in Chinese Healthy Adult Male Subjects||Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd.|No|Completed|June 2014|December 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|April 30, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316730||30985|
NCT02323672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chemerin_MMP-9_Oral_cancer|Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions|Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma.||Cairo University|No|Completed|February 2014|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|55|Samples Without DNA|serum and whole unstimulated saliva|Both|40 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|55 individuals were subdivided into 3 groups, 20 patients suffering from oral squamous        cell carcinoma lesions, 20 patients suffering from oral premalignant lesions (OPL) and 15        individuals having age, gender and periodontal status matched with both patients groups        acting as a control group.|February 2016|February 2, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323672||30452|
NCT02325141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM201040|Laparoscopic Sleeve Gasterectomy With or Without Pyloric Botulinum Neurotoxin Injection|Laparoscopic Sleeve Gasterectomy With or Without Pyloric Sphincter Botulinum Neurotoxin Injection: a Comparative Study||Mansoura University|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|50 Years|No|||December 2014|December 19, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325141||30339|
NCT02250716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN1|A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women|A Comparison of Immediate Treatment of CIN1 With Cryotherapy and Regular 12 Month Cytology Follow up in HIV Seropositive Women||University of Witwatersrand, South Africa|No|Active, not recruiting|October 2012|August 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Female|18 Years|65 Years|No|||December 2015|December 1, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250716||36052|
NCT02253524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAU-1179|Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo|Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo||Pamukkale University|Yes|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||September 2014|September 27, 2014|September 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253524||35836|
NCT02253537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST001_USA5|Evaluation of the QuantiFERON-TB Test.|||QIAGEN Gaithersburg, Inc|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with bacteriologically confirmed and untreated TB disease.|January 2016|January 26, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253537||35835|
NCT02253654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110208|If Alternate Dosing is Superior at Maintaining Hb Between 10.0 to 11.0 g/dL in CKD Subjects on HD vs the Current USPI|A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis||Amgen|No|Active, not recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02253654||35826|
NCT02322827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-236-1642|Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART|Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed a Single Tablet Regimen (STR) Versus Multi Tablet Regimen (MTR).|HOST|Triple O Research Institute PA|No|Recruiting|November 2014|August 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|650|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are HIV infected and taking antiretroviral therapy|December 2014|December 17, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02322827||30517|
NCT02322840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-1403|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||March 15, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322840||30516|
NCT02325050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106479|A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1, Randomized, Placebo-Controlled, Observer-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous and Homologous Prime-Boost Regimens Using MVA-BN-Filo® and Ad26.ZEBOV Administered in Different Doses, Sequences and Schedules in Healthy Adult Subjects||Crucell Holland BV|Yes|Active, not recruiting|January 2015|June 2017|Anticipated|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Anticipated|164|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325050||30346|
NCT02325063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2013/MV-01|Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia|Leukocyte and Platelet Rich Plasma Versus Type A Botulinum Toxin Versus Glucocorticoids for the Treatment of Lateral Epicondylalgia: a Randomized, Multicenter, Double-blind, Therapeutic Trial With Three Parallel Arms|LET|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|216|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325063||30345|
NCT02243800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0205|Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency|Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency|SCORPION|University Hospital, Clermont-Ferrand||Recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|164|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243800||36584|
NCT02243813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00036973|Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion|||Johns Hopkins University||Recruiting|March 2015|||July 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243813||36583|
NCT02312726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM HSC 13-440|Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience|Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience|PIPPI|University of New Mexico|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|118|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit women from the University of New Mexico Hospital (UNMH) affiliated        antenatal clinics. We will also recruit women from the UNMH obstetric units, provided the        women are not in labor. Women will be approached about participation in the study if,        after routine antenatal contraceptive counseling conducted in the third trimester, they        report that they would like to undergo postplacental IUD insertion. We will use        convenience sampling.|December 2015|December 9, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02312726||31292|
NCT02505802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013KYB163|The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults|Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults||Sir Run Run Shaw Hospital|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505802||16477|
NCT02510495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepatopancreatobiliary Surgery|Effect of Endoscopic Papillary Balloon Dilation on ERCP Complications|Effect of Different Endoscopic Papillary Balloon Dilation Duration Time on Complications of Common Bile Duct Stone Patient||Hepatopancreatobiliary Surgery Institute of Gansu Province|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|3000|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510495||16117|
NCT02510508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48307.028.14|Group Version of CRAFT Compared to Self-Directed CRAFT Delivery and Non-intervention: a Three-armed RCT|A Group Version of Community Reinforcement and Family Training (CRAFT) Compared to Self-Directed CRAFT Delivery and Non-intervention: a Three-armed Randomized Clinical Trial||IrisZorg|Yes|Recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|218|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02510508||16116|
NCT02501239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15151|Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women|Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women: A Randomized Controlled Trial||Dartmouth-Hitchcock Medical Center|No|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501239||16828|
NCT02501252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC674|Effectiveness and Acceptability of Availing Skilled Birth Attendance (SBA) Services Through Community Reproductive Health Nurses (CORN) to a Household Level at Rural Communities of Ethiopia; A Cluster Community Trial in Gedeo Zone, SNNPR|Effectiveness and Acceptability of Availing Skilled Birth Attendance (SBA) Services Through Community Reproductive Health Nurses (CORN) to a Household Level at Rural Communities of Ethiopia A Cluster Randomized Controlled Community Trial in Gedeo Zone, SNNPR|CORN|Dilla University|No|Completed|November 2014|January 2016|Actual|January 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2670|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||July 2015|January 19, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501252||16827|
NCT02247830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|radiodermatite01|Management Radiodermatitis in Patients With Breast or Head and Neck Cancer|Prophylactic Interventions in the Management of Radiodermatitis in Patients With Breast or Head and Neck Cancer: a Randomized Clinical Trial|PRBHNC|University of Brasilia|No|Enrolling by invitation|August 2015|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247830||36274|
NCT02246504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/BG/NT|Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.|Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.||Theraclion|No|Active, not recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246504||36376|
NCT02499861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEC-GEN001|Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies|A Phase I/IIa Study of Decitabine in Combination With Genistein in Pediatric Patients With Relapsed or Refractory Solid Tumors and Leukemia||St. Justine's Hospital|Yes|Recruiting|July 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|2 Years|20 Years|No|||July 2015|July 24, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499861||16934|
NCT02249676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2013-055-02|Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders|Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study||Tianjin Medical University General Hospital|Yes|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|80 Years|No|||September 2014|September 22, 2014|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249676||36132|
NCT02321280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC 2014|The Efficacy of Denosumab in Active Crohn's Disease|Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease||University of Manitoba|No|Recruiting|February 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321280||30636|
NCT02321566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHM IRB NA_00093333|Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain.|Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain.||Johns Hopkins University||Recruiting|February 2015|February 2021|Anticipated|February 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321566||30614|
NCT02325219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103833|An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis||Janssen Pharmaceutical K.K.|Yes|Recruiting|January 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|226|||Both|20 Years|N/A|No|||March 2016|March 11, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325219||30333|
NCT02253134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNARR-FLASH STUDY - ITHO04|Monitoring of Syncopes and/or Sustained Palpitations of Suspected Arrhythmic Origin With External Loop-Recorder (SpiderFLASH)|Monitoring of Syncopes and/or Sustained Palpitations of Suspected Arrhythmic Origin With External Loop-Recorder (SpiderFLASH)|ITHO04|LivaNova|No|Completed|August 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|395|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that present unexplained Syncope and/or palpitations events of a suspected        arrhythmic origin|September 2014|September 30, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02253134||35866|
NCT02253147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEO-RHA-1402|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2014|||||N/A|N/A|N/A||||||||||||||November 3, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253147||35865|
NCT02241733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1325-R|Sustainability of Rehabilitation Gains in COPD|Sustainability of Rehabilitation Gains in COPD||VA Office of Research and Development|Yes|Recruiting|October 2014|September 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|40 Years|N/A|No|||December 2015|December 17, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241733||36743|
NCT02241746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2014-088|Malnutrition in Chinese Hospitalized Patients and Optimizing the Usage of Nutritional Screening Tools|||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||Completed|August 2012|||September 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|856|||Both|18 Years|N/A|No|Non-Probability Sample|tertiary general hospital|September 2014|September 16, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241746||36742|
NCT02312466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIS 2015|Swiss National Iodine Survey 2015|Swiss National Iodine Survey 2015; A Cross-sectional Study to Assess Iodine Status in School Children, Women of Reproductive Age and Pregnant Women|SIS|Swiss Federal Institute of Technology||Enrolling by invitation|March 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|2390|||Both|6 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|school aged children, 6-12 years pregnant women, 18-44 years women of reproductive age,        18-44 years|March 2015|March 9, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02312466||31312|
NCT02312479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT2014A|Safety and Performance Study of the Nyxoah SAT System for Treating OSA|Safety and Performance Study of the Use of the Nyxoah SAT System for the Treatment of Obstructive Sleep Apnea||Nyxoah S.A.|Yes|Active, not recruiting|December 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|21 Years|70 Years|No|||October 2015|March 23, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312479||31311|
NCT02310685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-M75-14B|the Canadian Health Improvement Network to Upgrade Prevention Services|The Canadian Health Improvement Network to Upgrade Prevention Services (CHIN-UPS) - Evaluating a Multidisciplinary Health Promotion Program.|CHIN-UPS|McGill University|Yes|Enrolling by invitation|January 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1200|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02310685||31449|
NCT02310932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100311|Improving Mental Health Through Integration With Primary Care in Rural Karnataka|Improving Mental Health Through Integration With Primary Care in Rural Karnataka||University of California, San Francisco|Yes|Recruiting|February 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2500|||Both|30 Years|N/A|No|||December 2015|December 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02310932||31430|
NCT02248493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEC-MF-10|Intravenous Paracetamol for Postoperative Pain|The Effect of Intravenous Paracetamol in Combination With NSAIDs for Postoperative Pain in Children|IVPARACET|Lithuanian University of Health Sciences|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|1 Year|18 Years|No|||December 2015|December 2, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248493||36223|
NCT02247999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999913037|Improving Cervical Cancer Screening Among HIV-Infected Women in India|Improving Cervical Cancer Prevention Among HIV-Infected Women Using Novel HPV Based Biomarker Assays||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Female|18 Years|N/A|No|||April 2015|March 11, 2016|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02247999||36261|
NCT02248012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002524-16|Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)|Everolimus and Temozolomide as 1-line Treatment in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) With a Ki67 of 20-55%||Haukeland University Hospital|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02248012||36260|
NCT02317458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3BS-C-12-01|Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial THE CHART-2 TRIAL|EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR IMPROVING EXERCISE CAPACITY IN SUBJECTS WITH ADVANCED CHRONIC ISCHEMIC HEART FAILURE THE CHART-2 TRIAL|CHART-2|Celyad (formerly named Cardio3 BioSciences)|Yes|Not yet recruiting|December 2014|August 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||November 2014|December 15, 2014|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317458||30929|
NCT02244593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSN-REB 20140103-01H|FAST MRI Study in Breast Cancer Survivors|FAST MRI Study in Breast Cancer Survivors||Ottawa Hospital Research Institute|No|Recruiting|October 2014|June 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02244593||36523|
NCT02496780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK101402-01A1|The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients|The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|80|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496780||17170|
NCT02497391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14629|A Study of Different Particle Sizes of Evacetrapib in Healthy Participants|A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Particle Sizes||Eli Lilly and Company|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|148|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497391||17123|
NCT02248025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT/ANSM: 2014-A01034-43|Can Capillary Refill Time Variation During Passive Leg Raising Predict Fluid Responsiveness|Can Capillary Refill Time Variation Induced by Passive Leg Raising Predict Capillary Refill Time Variation After a Fluid Load in Patients With Circulatory Failure.||Hopital Louis Pradel|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patient hospitalized in our intensive care unit who are in circulatory failure and for        whom the intensivist as decided to administer a 500 ml crystalloid infusion.|February 2016|February 26, 2016|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02248025||36259|
NCT02254681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPSR-1401|Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma|A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma||Allina Health System|Yes|Recruiting|September 2014|January 2020|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2014|October 1, 2014|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254681||35747|
NCT02254746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-DO-HYPORT-2013|A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer|A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer||Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|September 2014|March 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02254746||35742|
NCT02503267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIoG|"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"|"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects" (CARDIoG)|(CARDIoG)|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|Through the blood sample we will:        -  Identify Antitrombin III deficiency        -  Evaluate the glycosylation degree of different glycoproteins        -  Do a genetic analysis|Both|18 Years|90 Years|No|Non-Probability Sample|250-300 adult patients who are most likely to have a congenital disorder of glycosylation        of proteins, such as ventricular and atrial septal defects and especially conotruncal        defects|January 2016|January 28, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02503267||16672|
NCT02241473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136/14|Hypoxic Training in Obese Patients|Changes in Body Composition, Metabolic and Mechanical Responses to Hypoxic Walking Training in Obese Patients|HYPOBESE|University of Lausanne|Yes|Recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02241473||36763|
NCT02325739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFGF401X2101|Safety and Efficacy of FGF401 in Patients With Solid Malignancies|A Phase I/II, Multicenter, Open-label Study of FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression||Novartis|No|Recruiting|December 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325739||30293|
NCT02313818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062853|Variable-length Cognitive Processing Therapy for Combat-Related PTSD|Variable-length Cognitive Processing Therapy for Combat-Related PTSD||Duke University|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313818||31208|
NCT02243488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0677/KW|Does Menstrual Hygiene Matter? Investigating the Impact of a Menstrual Hygiene Program on Ugandan Girls' School Absenteeism|Does Menstrual Hygiene Matter? Randomised Control Step-Wedge Trial Investigating the Impact of a Menstrual Hygiene Program (Reusable Sanitary Pad and Menstrual Health Education) on Rural Ugandan Girls' School Absenteeism||Irise International|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02243488||36608|
NCT02243501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228586|Better Nights, Better Days for Typically Developing Children|Better Nights, Better Days: Improving Psychosocial Health Outcomes in Children With Behavioural Insomnia|BNBD|IWK Health Centre|Yes|Not yet recruiting|April 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02243501||36607|
NCT02247440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-HCV|HCV-HIV Co-infected Patient Cohort in Thailand|Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand||Institut de Recherche pour le Developpement|No|Active, not recruiting|August 2014|April 2018|Anticipated|April 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|HIV-HCV co-infected adults|May 2015|May 24, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02247440||36304|
NCT02317263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS089369|A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis|||University of California, Los Angeles|Yes|Not yet recruiting||||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Male|18 Years|60 Years|No|||June 2015|June 3, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317263||30944|
NCT02317276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNE AD 431|A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal|A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal|GNE-AD|University of California, San Francisco|No|Recruiting|December 2014|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02317276||30943|
NCT02314884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10159-I-02|Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid Tumours|A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Cafusertib Hydrochloride in Patients With Advanced Solid Tumors||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|November 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||November 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314884||31127|
NCT02315170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rkm006|Assessment of Novel Intraocular Injection Guide|Assessment of Novel Intraocular Injection Guide||Maturi, Raj K., M.D., P.C.|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315170||31105|
NCT02251743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0417|Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD|Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD||Ohio State University|No|Recruiting|June 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|7 Years|10 Years|No|||January 2016|January 16, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02251743||35973|
NCT02252510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0208|Reliability for the Detection of Sperm DNA Damage by a Sperm Chromatin Dispersion Test (Halosperm)|Evaluation of the Reliability for the Measurement of Sperm DNA Damage by a Sperm Chromatin Dispersion Test (Halosperm)||University Hospital, Clermont-Ferrand||Completed|January 2013|June 2014|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Male|18 Years|50 Years|No|Non-Probability Sample|infertile men|September 2014|September 26, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252510||35914|
NCT02325960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSEXEN0034|A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in Type 2 Diabetes Patients Inadequately Controlled With Metformin Monotherapy|This is a Single Centre, Open-label, Randomized, Parallel Trial to Evaluate Whether Twice-daily Exenatide is Superior to Insulin Glargine on Glycemic Variability at Week 16 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Not yet recruiting|January 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||December 2014|December 24, 2014|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02325960||30276|
NCT02500680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPE002|The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)|A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects|MER4101|Nova Immunotherapeutics Limited|Yes|Recruiting|July 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500680||16871|
NCT02500953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3325-CL-0001|A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects|A Placebo-controlled, Double-blind, Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Japanese Male and Female Subjects and Caucasian Male Subjects||Astellas Pharma Inc|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|27||Actual|124|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500953||16850|
NCT02252523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-210|Dexmedetomidine-based Sedation in Neurocritical Care Patients|Feasibility of Dexmedetomidine-based Sedation in Neurocritical Care Patients : a Pilot Study||University Hospital, Clermont-Ferrand||Recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252523||35913|
NCT02255838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0689|Evaluation of a Disposable Flexible Bronchoscope|Evaluation of a Disposable Flexible Bronchoscope, a Randomized, Controlled, Cross-over Trial|BALS|University of Louisville|No|Not yet recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2014|October 2, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02255838||35658|
NCT02506036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061812|Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia|Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia||Johns Hopkins University|No|Recruiting|August 2015|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 13, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506036||16459|
NCT02247180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2014-0113|Cognitive Rehabilitation in Alzheimer`s Disease|Cognitive Rehabilitation in Alzheimer`s Disease (AD)||University of Rostock|No|Recruiting|September 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|N/A|N/A|No|||September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02247180||36324|
NCT02247427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYIH-132|Clinical Outcomes Related to Cardiac Resynchronization Therapy Deactivation of Super Responders|Midterm Clinical Outcomes Related to Cardiac Resynchronization Therapy Deactivation of Super Responders||Yuksek Ihtisas Hospital|No|Completed|January 2009|June 2014|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|19|||Both|21 Years|N/A|No|||September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02247427||36305|
NCT02312206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOD001-CL002|The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis|A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis|VITAL|Prothena Therapeutics Ltd.|Yes|Recruiting|February 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312206||31332|
NCT02318342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC-37587|Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation|Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Dysfunction With Multimodality Imaging and Its TrEatment With Anticoagulation|RESOLVE|Cedars-Sinai Medical Center|No|Recruiting|December 2014|December 2019|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 1, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02318342||30861|
NCT02248480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14375|A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan|Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Osteoarthritis and Knee Pain in Japan||Eli Lilly and Company|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|354|||Both|40 Years|79 Years|No|||July 2015|July 10, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248480||36224|
NCT02248688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q131650|Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically|Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GET LEAN)|GETLEAN|Dayton Interventional Radiology|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248688||36208|
NCT02252250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141056|Transanal Minimal Invasive Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer|A Prospective Cohort Study of Transanal Laparoscopic Total Mesentery Excision Versus Conventional Laparoscopic Surgery for Rectal Cancer||Third Military Medical University|Yes|Recruiting|October 2014|October 2021|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252250||35934|
NCT02325895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57114A|Dried Plums for Bone Health in Older Postmenopausal Women|Effect of Dried Plum on Bone and Bone Biomarkers in Older Women||San Diego State University|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|48|||Female|65 Years|79 Years|Accepts Healthy Volunteers|||December 2014|December 24, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02325895||30281|
NCT02318862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130084|Assessment of Esophageal Epithelium Integrity With Mucosal Impedance|Assessment of Esophageal Epithelium Integrity With Mucosal Impedance||Vanderbilt University|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|January 19, 2016|September 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02318862||30821|
NCT02319369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS3032-A-U102|Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies|A Phase 1 Dose Escalation Study of DS-3032b, an Oral Murine Double Minute (mdm2) Oncogene Inhibitor, in Subjects With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)||Daiichi Sankyo Inc.|No|Recruiting|November 2014|April 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319369||30782|
NCT02256982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-275|A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma|A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma||Massachusetts General Hospital|Yes|Terminated|October 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 25, 2014|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT02256982||35571|
NCT02256007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031722|Cognitive Motor Therapy Applications Using Videogame Platform|Cognitive Motor Therapy Applications Using Videogame Platform||Cedars-Sinai Medical Center|No|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|New Onset Stroke population|October 2014|October 1, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02256007||35645|
NCT02323620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHP-001|Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI|The Impact of Repeated Intracoronary Injection of Autologous Bone-marrow Derived Mononuclear Cells for Left Ventricle Contractility and Remodeling in Patients With STEMI.Prospective Randomized Study.|RACE-STEMI|American Heart of Poland|Yes|Not yet recruiting|March 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323620||30456|
NCT02249208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENTINAC-01|Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.|Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide vs. Standard Technique After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. A Randomized Controlled Trial.|SENTINAC-01|Hospital Universitari Vall d'Hebron Research Institute|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|150|||Both|18 Years|85 Years|No|||September 2014|September 29, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02249208||36168|
NCT02249221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3106_P1/2a|Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)|A Randomized (Part B), Open-label (Part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/IIa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)||Green Cross Corporation|Yes|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249221||36167|
NCT02504242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExcelOs14-02|A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion|||BioAlpha Inc.|No|Enrolling by invitation|April 2015|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|19 Years|80 Years|No|||July 2015|August 30, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504242||16597|
NCT02497612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI12805|To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|FALCI|Sanofi|Yes|Recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|662|||Both|6 Months|70 Years|No|||March 2016|March 21, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497612||17107|
NCT02504944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DROP-ROP-0.2%|Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)|Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Newborn With Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)||Azienda Ospedaliero, Universitaria Meyer|No|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|N/A|N/A|No|||July 2015|July 28, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02504944||16543|
NCT02504957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1448/2012|Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction|Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis.||Medical University of Vienna|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|N/A|N/A|No|||October 2015|October 23, 2015|July 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504957||16542|
NCT02258477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1485|A Pilot Study: Snacking, Willpower and Glucose Availability|A Pilot Study: Snacking, Willpower and Glucose Availability|SWG|University of Colorado, Denver|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|37|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|October 2, 2014||No||No|October 7, 2015|https://clinicaltrials.gov/show/NCT02258477||35459|The study questionnaire involved limitations as questions were subjective in terms of how subjects defined cravings and snacking behavior. Also, food diaries may not be fully accurate accounts of subjects' actual caloric intake and food consumption.
NCT02315105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT0151290|Resolution of Comorbidities & Safety and Efficacy of Greater Curvature Plication in Obese Patients|||Singh, Kuldeep, M.D., P.A.|Yes|Recruiting|August 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315105||31110|
NCT02246569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|Lung Volume Reduction Via Coils in Patients With COPD|Impact of Endoscopic Lung Volume Reduction Via Coils on Inspiratory Muscle Strength in Patients With COPD||RWTH Aachen University|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with severe COPD (GOLD stage III or IV)|November 2015|November 18, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02246569||36371|
NCT02246582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP292|Adult Accuracy Study of the Enlite 3 Glucose Sensor|A Performance Evaluation of the Enlite® 3 Sensor to Support a Full 168 Hours (7 Days) of Use|E3|Medtronic Diabetes|Yes|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|14 Years|75 Years|No|Non-Probability Sample|A total of up to 100 previously-diagnosed type 1 or type 2 diabetes subjects between the        ages of 14-75 years from up to 10 investigational centers.|August 2015|September 3, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246582||36370|
NCT02246595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFX-1-P2.1|Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction|A Phase II Randomized, Placebo-controlled, Double-blind, Dose Controlled Trial in Patients Suffering From Early, Newly Developing Abdominal or Pulmonary Derived Septic Organ Dysfunction to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and to Estimate Efficacy of the New Humanized Monoclonal i.v. Administered Antibody CaCP29|SCIENS|InflaRx GmbH|Yes|Active, not recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246595||36369|
NCT02326909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42100.018.12|Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma|a Prospective In-vivo Human Study to Assess the Diagnostic Accuracy of Optical Coherence Tomography for Diagnosis and Staging of Upper Urinary Tract Urothelial Carcinoma||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02326909||30204|
NCT02322801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21774|Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker|||Hoffmann-La Roche||Completed|March 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with RA who did not respond adequately to anti-TNF-alpha|March 2016|March 1, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322801||30519|
NCT02318589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERIB-IRINO-SLDTMR|Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors|A Phase I Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors||University of Kentucky|Yes|Recruiting|August 2015|June 2020|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|15 Years|39 Years|No|||December 2015|December 18, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318589||30842|
NCT02324049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGLU-CL02|Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in MPS IIIB|A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously||Alexion Pharmaceuticals|No|Active, not recruiting|December 2014|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|2 Years|12 Years|No|||August 2015|August 3, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324049||30423|
NCT02251392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBrasilia|Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis|Evaluation of Therapeutic Efficacy in Use of Chamomila Gel, Chamomila Infuse and Urea in Patients With Breast or Head and Neck Cancer That Developed Radiodermatitis|ChamomillaTH|University of Brasilia|No|Enrolling by invitation|August 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251392||36000|
NCT02243592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01585|Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment|Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders||National Cancer Institute (NCI)|No|Recruiting|September 2014|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample||March 2016|March 22, 2016|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243592||36600|
NCT02322814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29479|A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer|||Hoffmann-La Roche||Recruiting|March 2015|October 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322814||30518|
NCT02322905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERT15-17|Cancer Caregiver Burden: Targeting Emotion Regulation in a Trial|Cancer Caregiver Burden: Targeting Emotion Regulation in a Randomized Controlled Trial|ERT-ICs|University of Aarhus|No|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|69 Years|No|||August 2015|September 14, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02322905||30511|
NCT02311205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0902|Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)|A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)|COTSOM|Asan Medical Center|No|Recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|20 Years|N/A|No|||December 2014|December 8, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311205||31409|
NCT02311413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT U19-MMU-02|Fel d 1 Peptide Immunotherapy Clinical Trial|The Effect of Peptide Immunotherapy on Frequency, Memory Phenotype, Chemokine Receptor Expression and Markers of Regulatory T Cell Function Among Allergen-Specific T Cells. A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy (U19-MMU-02)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311413||31393|
NCT02248714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-32|The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes|A 4-week, Single-center, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Glucerna SR Using Continuous Glucose Monitoring System(CGMS) in Chinese Drug-naïve Subjects With Type 2 Diabetes||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Recruiting|March 2014|May 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||September 2014|September 23, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02248714||36206|
NCT02256072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-4259|Advance Planning for Home Services for Seniors|Advance Planning for Home Services for Seniors|APHS|Northwestern University|No|Active, not recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|600|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02256072||35640|
NCT02256085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6818|Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)|Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)||New York State Psychiatric Institute|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|70 Years|No|||September 2014|September 30, 2014|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256085||35639|
NCT02326519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E20PC study|Electrical Signal Collection From a 20 Pole Catheter During Routine Cardiac Procedures|Electrical Signal Collection From a 20 Pole Catheter During Routine Cardiac Procedures|E20PC|Medtronic Cardiac Rhythm Disease Management|No|Enrolling by invitation|September 2014|March 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02326519||30233|
NCT02321670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUS-URO-SUPS|Scandinavian Urethroplasty Study|Scandinavian Urethroplasty Study. A Multicentre, Prospective, Randomized Study Comparing Bulbar Urethroplasty With Excision and Primary Anastomosis or With an Onlay Grafting Procedure Using Buccal Mucosa.|SUPS|Oslo University Hospital|No|Recruiting|September 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Male|18 Years|70 Years|No|||October 2015|October 22, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321670||30606|
NCT02252198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 13-0017|Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests|Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF|FIND|Johns Hopkins University|No|Enrolling by invitation|February 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with clinical suspicion of pulmonary TB.|September 2014|September 25, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252198||35938|
NCT02257138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0344|Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)|Phase I/II Study of Ruxolitinib Plus Decitabine in Patients With Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257138||35560|
NCT02312700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270089|An Interactive Empowerment Tool for Breast Cancer Patients|Development of an Interactive Empowerment Tool in Support of Patient Empowerment.||University of Milan|No|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|74 Years|No|||December 2014|December 5, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02312700||31294|
NCT02320916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHRouen|A Randomized Controlled Trial on the Effect of Needle Gauge on the Pain and Anxiety Experienced During Arterial Puncture|A Randomized Controlled Trial on the Effect of Needle Gauge on the Pain and Anxiety Experienced During Arterial Puncture||University Hospital, Rouen|No|Completed|April 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320916||30664|
NCT02253212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120905|Safety of BBB Opening With the SonoCloud|A Study to Evaluate the Safety of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SonoCloud Implantable Device in Patients With Recurrent Glioblastoma Before Chemotherapy Administration|SONOCLOUD|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|January 14, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253212||35860|
NCT02253342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-2349-103|Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects|A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects||Wockhardt|No|Completed|September 2014|August 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253342||35850|
NCT02251015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Postural balance|Effects of the Use of Occlusal Splint on the Postural Balance of Individuals With Temporomandibular Disorder|Evaluation of Postural Balance in Individuals With Temporomandibular Disorder by Means of Force Platform After Using Occlusal Stabilizer Splint Disorder||University of Sao Paulo|Yes|Completed|July 2011|December 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02251015||36029|
NCT02251132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.5|Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers|An Open-label, Parallel Group, Multiple-dose Investigation of the Pharmacokinetics of Tipranavir Soft Elastic Capsules SEDDS and Ritonavir Soft Gel Capsules and Their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers||Boehringer Ingelheim||Completed|October 2000|||December 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|113|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251132||36020|
NCT02317718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD Study|Serum Vitamin D Level and Its Association With Ovarian Reserve and IVF Outcome|Serum Vitamin D Level in Subfertile Women and Its Association With Ovarian Reserve and IVF Outcome.||Fakih IVF Fertility Center|Yes|Recruiting|December 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|20 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing IVF between 20-42 years of age|December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02317718|6 Months|30909|
NCT02324062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-13-1|Cancer Genetics Hereditary Cancer Panel Testing|University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing|HCP|University of Southern California|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2000|Samples With DNA|Blood and Saliva|Both|N/A|N/A|No|Non-Probability Sample|High-risk cancer genetics populations. Both male and female participants will be        recruited.|January 2016|January 31, 2016|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02324062||30422|
NCT02310919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0503461|Administration of FSH and Low Dose hCG for Oocyte Maturity While Decreasing hCG Exposure in IVF Cycles|Concomitant Administration of FSH With a Low Dose of hCG (1,500 IU) Has Equivalent Oocyte Developmental Competence While Decreasing the Exposure to hCG in IVF Cycles: A Double Blind Randomized Control Trial||University of California, San Francisco|Yes|Recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310919||31431|
NCT02255396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-209|Estradiol and Testosterone Levels in Seminal Plasma of Men With Non-obstructive Azoospermia|Are Estradiol and Testosterone Levels in Seminal Plasma Predictive for Efficient Spermatogenesis in Men With Non- Obstructive Azoospermia||University Hospital, Clermont-Ferrand||Completed|January 2009|June 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|50|||Male|18 Years|55 Years|No|Non-Probability Sample|azoospermia|September 2014|September 30, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02255396||35692|
NCT02255409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V118_05E1|Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05|A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trial V118_0||Novartis||Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1400|||Both|12 Months|84 Months|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255409||35691|
NCT02249689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-001-001|Three-month Clinical Evaluation of Silicone Hydrogel Definitive 65 Contact Lenses|||Contamac Ltd||Completed|January 2014|May 2014|Actual|January 2014|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 24, 2014|January 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249689||36131|
NCT02323815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFPRI|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Mali: a Cluster Randomized Intervention Study|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Mali: a Cluster Randomized Intervention Study|PROMIS-Mali|International Food Policy Research Institute|No|Recruiting|January 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2304|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||February 2016|March 4, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323815||30441|
NCT02323828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24238/14|High Resistant Starch (RS) Cookies and Appetite Control|Effect of High Resistant Starch-cookies on Food Ingestion and Appetite Control in a Cohort of Healthy Students|RS|Catholic University of the Sacred Heart||Completed|January 2013|June 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|18|||Both|20 Years|24 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02323828||30440|
NCT02315404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBE CAP 1|Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial|Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial||Washington University School of Medicine|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|212|||Both|18 Years|95 Years|No|||December 2014|December 10, 2014|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02315404||31087|
NCT02251977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOXL-18|Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer|The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial||Sun Yat-sen University|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|188|||Both|18 Years|75 Years|No|||October 2015|October 28, 2015|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02251977||35955|
NCT02320838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|javendano|Unmodulated 5 Kilohertz Currents Versus TENS: Effect on Pain Thresholds, Tactile Threshold, and Nerve Conduction|Unmodulated 5 Kilohertz Alternating Currents Versus TENS: Effect on Mechanical and Thermal Pain Thresholds, Tactile Threshold, and Peripheral Nerve Conduction in Humans.||University of Castilla-La Mancha|No|Completed|November 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|March 3, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02320838||30670|
NCT02314598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC Study|Therapy Coil Electrogram Collection Study|Therapy Coil Electrogram Collection Study|TEC|Medtronic BRC|No|Active, not recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an Implantable Cardioverter Defibrillator (ICD) or a Cardiac        Resynchronization Therapy Defibrillator (CRT-D) device followed-up at community hospitals|March 2015|March 2, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02314598||31149|
NCT02314845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE_13768713.0.0000.0068|Optimizing Intraoperative Mechanical Ventilation Using EIT-titrated PEEP|Optimizing Intraoperative Mechanical Ventilation Using EIT-titrated PEEP||University of Sao Paulo General Hospital|No|Recruiting|August 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02314845||31130|
NCT02326350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14043DMcA-AS|ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial|ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial|STAR|Belfast Health and Social Care Trust|Yes|Enrolling by invitation|January 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||December 2014|December 26, 2014|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326350||30246|
NCT02257151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM006-001|Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, and Pharmacokinetics of BMS-986142 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257151||35559|
NCT02246322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNX-1|A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.|A Randomized Clinical Trial With a New Needle Device Comparing 25G and 22G Needle in Endoscopic Ultrasound Fine-needle Aspiration of Solid Lesions.|EUS-FNA|Istituto Clinico Humanitas|Yes|Recruiting|August 2013|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02246322||36390|
NCT02316977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133.1|Home Monitoring of Patients With Chronic Diseases - an eRehab Test-retest Study|Home Monitoring of Patients With Chronic Diseases - an eRehab Test-retest Study|eRehab|Parker Research Institute|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|85 Years|No|Non-Probability Sample|All adult patients, diagnosed with RA, referred for regular controls in the rheumatology        clinic at Copenhagen University Hospital, Bispebjerg and Frederiksberg, will be screened        via the database, DANBIO, for in- and exclusion criteria.|October 2015|October 26, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316977||30966|
NCT02323776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-28-03/09|Defining the Radiotherapy Dose and Volume Parameters Affecting Postoperative Complications in Esophageal Cancer Patients|Correlation of Radiotherapy-related Features With Postoperative Complications in Patients With Esophageal Cancer Treated With Trimodality Therapy||Maastricht Radiation Oncology|No|Terminated|December 2014|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|Oesophageal cancer patients who were initially treated with a preoperative dose of        radiation in combination with chemotherapy and who subsequently underwent surgical        resection at the Atrium Hospital in Heerlen. All patients were included in a prospectively        maintained database.|March 2016|March 17, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323776||30444|
NCT02244060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vignette2014|Eye Examinations as a Gold Standard to Evaluating Survey Instruments|Eye Examinations as a Gold Standard to Evaluating Survey Instruments||Harvard School of Public Health|Yes|Completed|September 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|4320|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 5, 2015|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02244060||36564|
NCT02257814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSP23320072909YC|Head Start Classroom-based Approaches and Resources for Emotion and Social Skill Promotion (Head Start CARES)|Head Start Classroom-based Approaches and Resources for Emotion and Social Skill Promotion (Head Start CARES)||MDRC|Yes|Completed|April 2009|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|2670|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02257814||35509|
NCT02325024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP1426|A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.|An Open-Label, Single-Dose Study to Compare the Pharmacokinetics (PK) of an Oromucosal Dose of Four Sprays of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease (ESRD), Not Requiring Dialysis, Compared to Matched Subjects With Normal Renal Function.||GW Pharmaceuticals Ltd.|No|Not yet recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|December 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325024||30348|
NCT02315157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.244|Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma|Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma||Thomas Jefferson University|Yes|Not yet recruiting||||January 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315157||31106|
NCT02245165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNMMA-UU-02|Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades|Nitric Oxide Control of the Migrating Motor Complex in Man: L-NMMA Effects in Relation to Muscarinic and Serotonergic Receptor Blockade|LNMMA|Uppsala University|No|Completed|June 2013|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|May 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02245165||36479|
NCT02253667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PalliativeHFONC|Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients|Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Patients: a Randomized Controlled Trial||Hospital Sao Joao|No|Not yet recruiting|September 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|21 Years|N/A|No|||September 2014|September 30, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02253667||35825|
NCT02314312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ATH01T|Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors|A 12 Month, Single-center, Open-label, Randomized-controlled Trial to Investigate Efficacy, Safety and Tolerability of Everolimus in Combination With Cyclosporine A and Corticosteroid in de Novo Transplant Recipients of Expanded Criteria Donor Kidneys or Acute Kidney Injury||Mahidol University|Yes|Active, not recruiting|January 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314312||31171|
NCT02314325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003240-23|Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens|Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens|PERSONAL|St. James's Hospital, Ireland|Yes|Recruiting|April 2014|October 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Male|18 Years|N/A|No|||December 2014|December 10, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02314325||31170|
NCT02311387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915023|Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali|Study of the Seroprevalence and the Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|601|||Both|6 Months|N/A|Accepts Healthy Volunteers|||November 2015|February 5, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311387||31395|
NCT02311660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPM-007|Vagus Nerve Stimulation in Crohn's Disease|Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients With Active Refractory Crohn's Disease||SetPoint Medical Corporation|No|Recruiting|December 2014|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311660||31374|
NCT02319382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091202|Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET|High Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714|INFLAPARK|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2012|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02319382||30781|
NCT02257073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBRA20140102|Cognitive-behavioral Treatment for Rheumatoid Arthritis|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|October 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257073||35564|
NCT02257099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655951-1|CT Analysis of the Patellofemoral Joint in Patients Having Knee Surgery|Comparison of a Novel Weight Bearing Cone Beam Computed Tomography (CT)Scanner Versus a Conventional CT Scanner for Measuring Patellar Instability|PF|State University of New York at Buffalo|No|Enrolling by invitation|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|16 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with acute or chronic patellar malalignment.|November 2015|November 4, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02257099||35563|
NCT02324322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCR131RG013|Non-Ambulatory SCI Walk Using a Robotic Exoskeleton: Effect on Bone and Muscle|Non-Ambulatory SCI Walk Using a Robotic Exoskeleton: Effect on Bone and Muscle||Kessler Foundation|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|21 Years|45 Years|No|||March 2016|March 10, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324322||30402|
NCT02324335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIX-BRI-205|Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer|Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancers Receiving Chemoradiation|Brilacidin|Cellceutix Corporation|Yes|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324335||30401|
NCT02319317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00NR013548|Web-based Intervention to Prevent Risky Driving|Promoting Teen Health: A Web-based Intervention to Prevent Risky Driving||University of Pennsylvania|No|Recruiting|April 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|16 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02319317||30786|
NCT02319330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH100939|Preventing & Treating HIV Comorbidities in India: Multi-tiered Strategy for Women|Preventing & Treating HIV Comorbidities in India: Multi-tiered Strategy for Women|MAHILA|Yale University|No|Recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|July 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02319330||30785|
NCT02311218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Umea university|Probiotic Lactobacillus Reuteri and Oral Microbiota|Oral Microbiota Shift After 12-week Supplementation With Lactobacillus Reuteri DSM 17938 and PTA 5289|OMICI|Umeå University|No|Completed|March 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|25 Years|N/A|Accepts Healthy Volunteers|||November 2014|December 4, 2014|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02311218||31408|
NCT02246335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE|Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly|Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly. A Randomized Controlled Trial.|HOPE|Danderyd Hospital|No|Recruiting|October 2009|October 2020|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|80 Years|N/A|No|||January 2016|January 27, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246335||36389|
NCT02322385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorin-PKD-1|Clinical Implications of DNA Analysis on ADPKD|Mutational Types and Phenotypes Relationship in Autosomal Dominant Polycystic Kidney Disease|DNAAA|Kyorin University|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Blood|Both|20 Years|80 Years|No|Non-Probability Sample|The patients with ADPKD visiting Kyorin university hospital over two years. The patients        whose clinical data including total kidney volume (TKV), eGFR, QOL data and other relevant        clinical data are available will be enrolled.|September 2015|March 12, 2016|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02322385||30551|
NCT02322398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDR-1-2014|Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization|Controlled Ovarian Stimulation With Recombinant Follicle Stimulating Hormone Plus Recombinant Luteinizing Hormone vs. Human Menopausal Gonadotropin in In Vitro Fertilization: Retrospective Analysis of Real Life Data||University of Turin, Italy|No|Completed|March 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|848|||Female|20 Years|45 Years|No|Probability Sample|Infertile women requiring IVF and classified as expected poor responders and/or expected        normal responders on the basis of age, basal FSH circulating levels, anti-mullerian        Hormone (AMH) circulating level and basal antral follicle count.|December 2014|December 17, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322398||30550|
NCT02310906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4053-101|Phase I/II Study of SRP-4053 in DMD Patients|A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping||Sarepta Therapeutics|Yes|Recruiting|December 2014|July 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Male|6 Years|15 Years|No|||November 2015|November 16, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310906||31432|
NCT02247921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMB13-161|Rehabilitation for Disabled Stroke Patients in Rural China|A Randomized Controlled Trial on Rehabilitation Through Caregiver-delivered Nurse-organized Service Programs for Disabled Stroke Patients in Rural China|RECOVER|The George Institute for Global Health, China|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|320|||Both|18 Years|79 Years|No|||February 2016|February 15, 2016|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02247921||36267|
NCT02251054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS624459|Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder|Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder|OAB|Miami VA Healthcare System|Yes|Completed|October 2012|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|47|||Female|55 Years|N/A|No|||September 2014|September 24, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251054||36026|
NCT02243280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-867|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection|An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)||AbbVie|No|Completed|August 2014|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|174|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|September 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243280||36624|
NCT02249429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQR309-002|Open-Label, Non Randomized Phase 2 Study With Safety Run-In|Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma||PIQUR Therapeutics AG|Yes|Recruiting|May 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249429||36151|
NCT02249442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.32|Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency|An Open-label Study to Determine the Pharmacokinetics of Single-dose and/or Steady-state TPV/r 500/200 mg in Subjects With Mild and Moderate Hepatic Insufficiency||Boehringer Ingelheim||Completed|October 2003|||June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249442||36150|
NCT02323087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCAREWP4FLEX|Point of Care Susceptibility Testing in Primary Care|Reducing Antibiotic Resistance: Improved Diagnostics and Treatment for Uncomplicated Urinary Tract Infection in General Practice, Denmark||University of Copenhagen|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323087||30497|
NCT02323100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPBA|Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)|A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis|GPBA|Johns Hopkins University|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323100||30496|
NCT02321371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-HE-01|Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.|||Institute of Liver and Biliary Sciences, India|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||January 2016|February 15, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321371||30629|
NCT02325440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM12_0037|Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya|A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod)|ToFingo2|University Hospital Muenster|No|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||December 2014|December 19, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02325440||30316|
NCT02249871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4141|Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects||Novo Nordisk A/S|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249871||36117|
NCT02318004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-0987-RK-CTIL|Evaluation of EarlySense Home Care Tele-monitoring Device|Study Protocol for Evaluation of EarlySense Home Care Tele-monitoring Device - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion For Early Detection of Deterioration For Cardiac Patients at Home||Sheba Medical Center|No|Not yet recruiting|December 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|21 Years|N/A|No|||December 2014|December 11, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02318004||30887|
NCT02318823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-369|Effects of Beer (Alcohol) on Social Cognition|Effects of Beer (Alcohol) on Social Cognition||University Hospital, Basel, Switzerland|Yes|Completed|December 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318823||30824|
NCT02326324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NW/1165|The UHSM Cardiovascular Magnetic Resonance Study|The University Hospital of South Manchester Cardiovascular Magnetic Resonance Study|UHSM CMR|University Hospital of South Manchester NHS Foundation Trust|No|Recruiting|December 2014|December 2029|Anticipated|December 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Peripheral blood sampling will be performed on the same day as CMR scanning|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing clinically indicated CMR scanning (i.e. patients with suspected or        confirmed cardiovascular disease)|December 2014|December 22, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326324||30248|
NCT02245841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1015|Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis|Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis|Acthar Gel|The Cleveland Clinic|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245841||36427|
NCT02246075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-027|Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication||FORUM Pharmaceuticals Inc|Yes|Withdrawn|July 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|55 Years|85 Years|No|||October 2015|October 13, 2015|September 17, 2014|Yes|Yes|Forum has decided not to proceed with this study at this time.|No||https://clinicaltrials.gov/show/NCT02246075||36409|
NCT02312440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTU-GK-010|Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty|Comparison of Topical and Intravenous Tranexamic Acid on Blood Loss and Transfusion Rates in Total Hip Arthroplasty||Shanghai Jiao Tong University School of Medicine|No|Completed|October 2014|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|173|||Both|18 Years|N/A|No|||May 2015|November 28, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02312440||31314|
NCT02247908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2861|Impact of Graphic Cigarette Warnings|A Randomized Controlled Trial Evaluating the Impact of Graphic Cigarette Warnings on Smoking Behavior||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2149|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02247908||36268|
NCT02251002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408M53005|Frontoparietal Priority Maps as Biomarkers for MTBI|Frontoparietal Priority Maps as Biomarkers for MTBI||University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with mTBI who have previously participated in MRI studies; preference will be        given to individuals with visual complaints such as blurred or double vision or headaches        while reading. Participants with no history of TBI and no visual complaints will also be        recruited into a control group.|December 2015|December 4, 2015|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251002||36030|
NCT02326870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-65-003|Evaluation of the Follow Me Mode of the AutoLap System - A Feasibility Study|Evaluation of the Follow me Mode of the AutoLap System - a Feasibility Study||M.S.T. Medical Surgery Technology LTD.|No|Recruiting|December 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02326870||30207|
NCT02326883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GroupHealthCoop|UH3 Pragmatic Suicide Prevention Trial|UH3 Pragmatic Trial of Population-based Programs to Prevent Suicide Attempt||Group Health Cooperative|Yes|Enrolling by invitation|March 2015|September 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|16000|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02326883||30206|
NCT02326896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACOCHA Score|MACOCHA Score Predicts Intubation Failure|The New MACOCHA Score Predicts Intubation Failure of Non-anesthesiologist ICU Trainees||Heinrich-Heine University, Duesseldorf|No|Completed|November 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|134|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients intubated in the ICU|December 2014|December 29, 2014|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02326896||30205|
NCT02315118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00584|Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies|Pilot Study of Autologous T Lymphocytes With Antibody-Dependent Cell Cytotoxicity in Patients With CD20-Positive B-Cell Malignancies||National University Hospital, Singapore|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|6 Months|80 Years|No|||July 2015|July 22, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02315118||31109|
NCT02315131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV46017-COPD-10046|Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017|A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV46017||Teva Pharmaceutical Industries|No|Terminated|March 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|53|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|December 9, 2014|No|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT02315131||31108|
NCT02315144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV48108-COPD-10045|An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients|A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108||Teva Pharmaceutical Industries|No|Terminated|April 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|61|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|December 9, 2014|No|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT02315144||31107|
NCT02251067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPI-CLIN-201-AD|Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes||Vascular Pharmaceuticals, Inc.|No|Recruiting|September 2014|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Both|21 Years|80 Years|No|||December 2015|December 18, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251067||36025|
NCT02253745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V81444-1CNS-01|Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)|A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD)||Vernalis (R&D) Ltd|No|Completed|July 2013|April 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|50 Years|No|||December 2015|December 9, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253745||35819|
NCT02253758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-IM-0383-CTIL|Arousal Pathways and Emergence From Sedation|Arousal Pathways and Emergence From Sedation||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 28, 2014|August 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02253758||35818|
NCT02249455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14\305|Effectiveness of Acapella and ELTGOL Technique to Promote Airway Clearance in COPD:a Comparative Study|Effectiveness of Acapella and ELTGOL (Expiration in Lateral Position With Open Glottis)Technique to Promote Airway Clearance in COPD Patients:a Comparative Study||PSG College of Physiotherapy|Yes|Recruiting|July 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|30 Years|80 Years|No|||September 2014|September 23, 2014|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249455||36149|
NCT02313727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099-14-BNZ|Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression|Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression||Bnai Zion Medical Center|No|Not yet recruiting|December 2014|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Male|18 Years|N/A|No|||November 2014|December 8, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02313727||31215|
NCT02311985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2048-14|Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics|Point-of-care Versus Standard Coagulation Tests Versus Restrictive Strategy to Guide Transfusion in Chronic Liver Failure Patients Requiring Central Venous Line: Prospective Randomized Trial|POCKET|Hospital Israelita Albert Einstein|No|Recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311985||31349|
NCT02311998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0435|Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)|A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311998||31348|
NCT02252445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRBDPPFSEVO|Propofol and Sevoflurane for Catheter-Related Bladder Discomfort|Effect of Propofol and Sevoflurane on Postoperative Catheter-Related Bladder Discomfort||Seoul National University Hospital|Yes|Not yet recruiting|October 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|76|||Both|19 Years|80 Years|No|||September 2014|September 29, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252445||35919|
NCT02240641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.334|Effect of Caldine® on Renal Function in Balanced Hypertension|Study on Protective Effect of Caldine® on Renal Function in Patients With a Balanced Hypertension||Boehringer Ingelheim||Terminated|May 1998|||September 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5417|||Both|N/A|N/A|No|Non-Probability Sample|patients with hypertension requiring treatment|September 2014|September 15, 2014|August 28, 2014||||No||https://clinicaltrials.gov/show/NCT02240641||36827|
NCT02255552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4658-301|Confirmatory Study of Eteplirsen in DMD Patients|An Open-Label, Multi-Center, 48-Week Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy|PROMOVI|Sarepta Therapeutics|No|Recruiting|September 2014|May 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Male|7 Years|16 Years|No|||January 2016|January 22, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255552||35680|
NCT02325115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00212-37|Validation of the French Warwick-Edinburgh Mental Well-being Scale (WEMWBS)|Validation of the French Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in Both Non-clinical and Clinical Populations||Hôpital le Vinatier|Yes|Completed|January 2014|October 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|515|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three different populations participated in the study: two non-clinical populations        composed of students (STUD), and working adults (WORK) and one clinical population        comprised of patients with remitted schizophrenia (PRS).|December 2014|December 19, 2014|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325115||30341|
NCT02322892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000257|Thiamine as an Adjunctive Therapy in Cardiac Surgery|Thiamine as an Adjunctive Therapy in Cardiac Surgery||Beth Israel Deaconess Medical Center|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|21 Years|N/A|No|||September 2015|September 3, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02322892||30512|
NCT02310945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPF/2013/44|Pain Sensitization and Outcome Following Physiotherapy in Patients With Knee Osteoarthritis|Pain Sensitization and the Risk of Poor Outcome Following Physiotherapy for Knee Osteoarthritis: A Protocol for a Prospective Cohort Study||University College Dublin|No|Recruiting|June 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|50 Years|N/A|No|Non-Probability Sample|The cohort will be recruited from patients with moderate/severe symptomatic knee OA        attending outpatient orthopaedic and rheumatology clinics and referred for physiotherapy        treatment by a hospital consultant or clinical specialist physiotherapist.        At the time of recruitment knee pain must be the participant's primary musculoskeletal        complaint they are seeking treatment for, and physiotherapy must be the main treatment        being undertaken over the study period|December 2014|December 4, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02310945||31429|
NCT02246777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALJ-P2013-1|Alcon Ex-PRESS™ Glaucoma Filtration Device in Japanese Patients|Assessment of Efficacy and Safety of the Filtration Surgery for Normal Tension Glaucoma Using Ex-PRESS||Alcon Research|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|September 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02246777||36355|
NCT02250898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-01052|Massage for Post Breast Surgery|Massage for Pain and Mobility in Post-Breast Surgery Patients||MetroHealth Medical Center|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Female|21 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250898||36038|
NCT02316717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-124E-2001|A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis|A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.||Immuron Ltd.|No|Recruiting|December 2014|February 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316717||30986|
NCT02321540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0602|A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer|A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Recruiting|March 2015|||June 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321540||30616|
NCT02323698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044670B|Effects of Caffeine and Low Oxygen Therapy on Leg Function in Human Spinal Cord Injury|The Effects of Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury (Caffeine Substudy)||Emory University|No|Recruiting|October 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|77 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323698||30450|
NCT02323711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCHN/IRB 13-56|Dressing Versus Glue (2-Octyl Cyanoacrylate) for Coverage of the Skin Incision After Closure During Cesarean Delivery|A Randomized Controlled Trial of Dressing Versus Glue (2-Octyl Cyanoacrylate) for Coverage of the Skin Incision After Closure During Cesarean Delivery||Danbury Hospital||Withdrawn|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|December 18, 2014|No|Yes|Investigator Preference.|No||https://clinicaltrials.gov/show/NCT02323711||30449|
NCT02251041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPITL RCT|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study|CAPITL|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|September 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251041||36027|
NCT02257281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS14008|The Effect of Therapeutic Ultrasound on Soft Tissue: An Experimentally-induced Skin Model|Chung Shan Medical University Hospital Institutional Review Board||Chung Shan Medical University|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|15|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 13, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257281||35549|
NCT02257294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12CA450|A Trial of Low-dose Adjunctive alTeplase During prIMary PCI|A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI|T-TIME|NHS Greater Glasgow and Clyde|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|618|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02257294||35548|
NCT02314013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-023|Randomized Clinical Trial for the Uncomplicated Diverticulitis in Right Colon|Prospective Randomized Clinical Trial for the Management of Uncomplicated Diverticulitis in Right Colon; Non-antibiotics Versus Antibiotics||Dongtan Sacred Heart Hospital|Yes|Recruiting|April 2014|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|80 Years|No|||December 2014|December 8, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02314013||31194|
NCT02314026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-EX-1114|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||February 22, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314026||31193|
NCT02318329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPA144-001|Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors|A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors||Five Prime Therapeutics, Inc.|No|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318329||30862|
NCT02318576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15333|Computerized Cognition Testing and Cognitive Motor Interference in MS|Computerized Cognition Testing and Cognitive Motor Interference in MS|C3PO|University of Illinois at Urbana-Champaign|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318576||30843|
NCT02244697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-FS-0191-CTIL|The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children|The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children||Tel-Aviv Sourasky Medical Center||Not yet recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|16 Years|No|Non-Probability Sample|children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia        at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre will undergo        US of the larynx.|September 2014|September 16, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02244697||36515|
NCT02253550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC435HPC2012|Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Without Cirrhosis||Peter J. Ruane, M.D., Inc.|No|Completed|October 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02253550||35834|
NCT02318290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1112|Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study|Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study|WAAICUP|Hopital du Sacre-Coeur de Montreal|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|N/A|No|Probability Sample|Patients under mechanical ventilation and receiving regular intermittent use or continuous        infusion opioids for at least 96 hours|February 2016|February 17, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318290||30865|
NCT02240654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.144|Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe|Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe||Boehringer Ingelheim||Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|New users of dabigatran etexilate in each database|March 2016|March 7, 2016|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02240654||36826|
NCT02240914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPC_ 4 2014|Vascular Ultrasound Versus Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction|Prospective, Single-arm, Single Center, Pilot Study of Vascular Ultrasound Imaging Used as an Adjunct to Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction|USG-DIVO|Instituto Dante Pazzanese de Cardiologia|Yes|Recruiting|February 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Subjects with iliac compression disease CEAP classification 3-6.|September 2014|September 13, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02240914|6 Months|36806|
NCT02255565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI185890|Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study|Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study||Seattle Children's Hospital|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Both|6 Years|16 Years|No|||September 2014|September 29, 2014|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255565||35679|
NCT02323191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29428|A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors|OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION PHASE TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF RO5509554 AND MPDL3280A ADMINISTERED IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS||Hoffmann-La Roche||Recruiting|January 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|97|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323191||30489|
NCT02323204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 12368 04|PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury|PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury||University of Iowa|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|10 Years|17 Years|No|||March 2016|March 21, 2016|November 29, 2012||No||No||https://clinicaltrials.gov/show/NCT02323204||30488|
NCT02326493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-2-046|Tailor-CRT: Better Application of Cardiac Resynchronization Therapy|Tailor-CRT: Better Application of Cardiac Resynchronization Therapy by Automated and Improved Selection of Location and Timing of Stimulation||Maastricht University Medical Center|Yes|Recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02326493||30235|
NCT02247323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 6|Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125|Ovarian Malignancy Incidence in Premenopausal Women Who Were at Moderate Risk for Malignancy by Risk of Malignancy Index With Low CA 125.(Retrospective Study)|CA125|Beni-Suef University|Yes|Recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Female|45 Years|50 Years|No|Non-Probability Sample|Premenopausal who had complex ovarian mass with low CA125 and at moderate risk for        malignancy by RMI.|December 2015|December 26, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247323||36313|
NCT02257255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cesarean|Classic Cesarean Section Versus Minimally Invasive Cesarean Section: Pain Assessment|Classic Cesarean Section Versus Minimally Invasive Cesarean Section: Pain Assessment||Universidade do Vale do Sapucai|No|Completed|May 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Female|N/A|N/A|No|||May 2015|May 27, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02257255||35551|
NCT02242071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-10|Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis|The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on Motor Neuron Disease/Amyotrophic Lateral Sclerosis||Neurogen Brain and Spine Institute|Yes|Recruiting|December 2008|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|80 Years|No|||September 2014|September 13, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02242071||36717|
NCT02321553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11066|Effect of Brown Rice on the Risk Factors for Metabolic Syndrome|Biological Functions of Brown Rice on Metabolic Syndrome: A Randomized Cross-over Pilot Study||Tufts University|No|Completed|April 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02321553||30615|
NCT02310633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1730-P|Developing Process-Specific Verbal Memory Interventions for Veterans With Traumatic Brain Injury (TBI)|Developing Process-Specific Verbal Memory Interventions for Veterans With TBI|DPSVM|VA Office of Research and Development|No|Recruiting|January 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02310633||31453|
NCT02243761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129/2012|Evaluating a Peer-Facilitated Skills-Based Intervention for Caregivers of Concurrent Disordered Youth|Canadian Institutes of Health Research (CIHR) Team in Innovations in Child and Youth Concurrent Disorders: Service Delivery and Treatment Subproject||Centre for Addiction and Mental Health|No|Completed|August 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02243761||36587|
NCT02242396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.496|A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)|A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® Under Real Clinical Conditions With the Goal to Control the Early Morning BP Rise (SURGE II)||Boehringer Ingelheim||Completed|August 2005|||November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5248|||Both|18 Years|80 Years|No|Non-Probability Sample|Hypertensive population under real life clinical practice in an ambulatory setting|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242396||36692|
NCT02317445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPERINACS|Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome|Beijing Tiantan Hospital,Capital Medical University.||Capital Medical University|Yes|Completed|January 2008|January 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|472|||Both|50 Years|73 Years|No|Non-Probability Sample|This study is a single-center and random analysis. The consecutive hospitalized patients        with ACS at Beijing Mentougou District Hospital from January 1, 2008 to December 31, 2010        were enrolled. Figure 1 is a flow diagram of the trial. There were 259 males (54.9%) and        213 females (45.1%) with an average age of 61.1 ± 11.0 years. Patient's history, physical        examination, and laboratory results were recorded. All patients were divided into the        Hp-negative group (Hp-, group 1.) and the Hp-positive group (Hp+). The Hp+ group were        randomly divided into two groups: Group 2, the Hp+ with eradication therapy (Hp+ Therapy);        and Group 3, the Hp+ without eradication therapy (Hp+No Therapy).|December 2014|December 15, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317445||30930|
NCT02323945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044670A|Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury|Mechanisms of Intermittent Hypoxia-induced Motor Recovery in Persons With SCI||Emory University|No|Recruiting|October 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|26||Anticipated|44|||Both|18 Years|77 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02323945||30431|
NCT02249624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23854|The Utility of MRI Scoring to Predict Neurodevelopmental Outcomes in Survivors of Twin-to-Twin Transfusion Syndrome|The Utility of MRI Scoring to Predict Neurodevelopmental Outcomes in Survivors||St. Louis University|No|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|3 Years|No|Non-Probability Sample|Pregnancies affected by TTTS will be identified through referrals from the St. Louis Fetal        Care Institute. Surviving infants of those pregnancies that required fetal laser surgery,        or had death of the cotwin, will be approached for enrollment.|October 2015|October 23, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02249624||36136|
NCT02244476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIZO 105356|Acoustic Tribology Validation Study|Validation Study to Evaluate the Use of Acoustic Tribology to Assess Mouthfeel of Dairy Drinks||NIZO Food Research|No|Not yet recruiting|October 2014|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|16|Samples With DNA|tongue scrapings|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|16 volunteers from the local general population|September 2014|September 16, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02244476||36532|
NCT02244489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-370-1369|Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma||Gilead Sciences|No|Recruiting|November 2014|February 2019|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02244489||36531|
NCT02326623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050791|Distraction to Reduce Pain and Distress in the Pediatric Emergency Department|Distraction to Reduce Pain and Distress: A Randomized Controlled Trial of Children Undergoing Intravenous Placement in the Pediatric Emergency Department||University of Alberta|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|11 Years|No|||October 2015|October 5, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02326623||30225|
NCT02326636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCaliforniaIrvine|Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection|Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection|FMT|University of California, Irvine|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|76|Samples Without DNA|A donor stool sample will be kept for future testing in case of contamination.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are referred for recurrent Clostridium difficile infections. Donors will be        identified by the Recipient.|December 2014|December 26, 2014|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326636||30224|
NCT02315898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMich Inhaled tPA119678|Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis|Safety and Efficacy of Inhaled Tissue Plasminogen Activator (tPA) for the Acute Treatment of Pediatric Plastic Bronchitis||University of Michigan||Not yet recruiting|November 2016|||December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315898||31049|
NCT02315911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01659671|Randomized Control Trials of Surgery for Pediatric OSA|Randomized Controlled Studies of Sugery for Pediatric OSA: Part 1 Expectancy Compared to Adeno-tonsillectomy for Mild-moderate OSA. Part 2 Adeno-tonsillectomy Compared to Adeno-pharyngoplasty for Severe OSA.||Karolinska University Hospital|Yes|Recruiting|December 2014|October 2026|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|2 Years|5 Years|No|||February 2016|February 25, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02315911||31048|
NCT02249637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLMC_2014(SLIU1)|A Novel Technique of Circumcision Incision Orchidopexy|A Novel Technique of Circumcision Incision Orchidopexy for Palpable Low Inguinal Cryptorchidism: A Preliminary Report||St. Luke's Medical Center, Philippines|Yes|Completed|September 2013|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|14|||Male|3 Months|10 Years|No|Non-Probability Sample|Children diagnosed with palpable cryptorchidism with pre-operative inguino-scrotal        ultrasound to confirm the location of the testis on the low inguinal canal and its        viability. Recruited from September 2013- September 2014|April 2015|April 5, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02249637||36135|
NCT02244788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-059|Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint|Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint||Hospital for Special Surgery, New York||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2015|August 31, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244788||36508|
NCT02244801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONEdarTreg14|Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )|Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation: A ONE Study Clinical Trial|DART|University of California, San Francisco|Yes|Recruiting|November 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|70 Years|No|||January 2015|January 21, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244801||36507|
NCT02314039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-SS-1072|Psychological Factors in Acne: A Focus on Psychological Trauma|Psychological Factors in Acne: A Focus on Psychological Trauma||Edinburgh Napier University|No|Not yet recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|The population sample will be recruited from NHS Tayside dermatology departments, i.e.        Ninewells, Stracathro, and Perth Hospital.|December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314039||31192|
NCT02314052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCR-MYC-102|Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma|Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)||Dicerna Pharmaceuticals, Inc.|No|Recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314052||31191|
NCT02314364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-370|A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC|A Phase II Trial of Integrating Stereotactic Body Radiation Therapy With Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer||Massachusetts General Hospital|Yes|Recruiting|December 2014|November 2021|Anticipated|November 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314364||31167|
NCT02250937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0431|Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Recruiting|October 2014|||October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|2 Years|70 Years|No|||February 2016|February 15, 2016|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250937||36035|
NCT02246348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP22_2|Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)||Echosense Ltd.|No|Terminated|September 2014|December 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|No|||August 2014|January 20, 2016|September 17, 2014||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT02246348||36388|
NCT02326857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915055|Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment|Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2014|December 2018|Anticipated|December 2014|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|1431|||Female|18 Years|100 Years|No|||November 2015|March 11, 2016|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02326857||30208|
NCT02314858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2809|Tailored Treatment to Enhance Risk Perception in Sleep Apnea|Tailored Treatment to Enhance Risk Perception in Sleep Apnea.||National Jewish Health|No|Recruiting|October 2014|April 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314858||31129|
NCT02250911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-208|Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden|Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden||Memorial Sloan Kettering Cancer Center|No|Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250911||36037|
NCT02250924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1410-55|Caffeinated Gum to Prevent Post-Operative Ileus: A Prospective, Randomized, Placebo-controlled Trial|Caffeinated Gum to Prevent Post-Operative Ileus: A Prospective, Randomized, Placebo-controlled Trial||The Guthrie Clinic|No|Recruiting|June 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|435|||Both|18 Years|N/A|No|||August 2015|October 5, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250924||36036|
NCT02322736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120286|Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR|A Prospective Observational Study of 1st and 2nd Line Vectibix® Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates|VISION|Amgen|No|Recruiting|November 2014|March 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|218|||Both|18 Years|N/A|No|Probability Sample|Target population will be adult patients (aged ≥ 18 years at enrollment) with a documented        diagnosis of a RAS WT mCRC preferably measurable disease per modified Response Evaluation        Criteria in Solid Tumors (RECIST v1.1) if routinely used, who are currently under (begin        up to 8 weeks before informed consent) a 1st or 2nd line treatment regimen including        Vectibix® as per indication.|March 2016|March 18, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322736||30524|
NCT02310646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-1030|Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris|A Clinical Trial Gathering Insight of Patient Reported Factors That Influence Preference Following Once Daily Topical Treatment With LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris||LEO Pharma|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|219|||Both|18 Years|N/A|No|||June 2015|August 31, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02310646||31452|
NCT02310659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090206|Study to Evaluate the Association of Testosterone Levels With Coronary Artery Calcification|Study to Evaluate the Association of Testosterone Levels With Coronary Artery in Patients With Stable Coronary Artery Disease||Zhejiang University|No|Recruiting|March 2009|April 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Male|65 Years|N/A|No|Probability Sample|Elderly male patients (age ≥ 65 years old) with stable angina and proven coronary artery        disease|December 2014|December 3, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310659||31451|
NCT02252172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104762|Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma|A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy||Janssen Research & Development, LLC|Yes|Recruiting|February 2015|November 2022|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|730|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252172||35940|
NCT02252185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPS-201303|A Clinical Study of a Spine Fusion System in Vertebral Body Fusion Surgery|A Prospective, Multicenter, Randomized, Open-label, Controlled Study to Evaluate the Safety and Efficacy of a Spine Fusion System in Vertebral Body Fusion Surgery||Johnson & Johnson Medical (Suzhou) Ltd.|No|Completed|July 2014|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2015|December 2, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02252185||35939|
NCT02252432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030109|The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy|Intraoperative Ketamine and Methadone for Laminectomy: Effect on Recovery, Postoperative Pain, and Opioid Requirements||Cedars-Sinai Medical Center|No|Recruiting|February 2013|October 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252432||35920|
NCT02310386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnro 1/2014|BEMER in the Treatment of Pain in Fibromyalgia.|The Efficacy of the BEMER Electromagnetic Field Therapy in the Treatment of Fibromyalgia.|Fibromyalgia|Central Finland Hospital District|No|Enrolling by invitation|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|60 Years|No|||December 2014|December 4, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02310386||31472|
NCT02324946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-BANG, DES-OSA|Comparison of STOP-BANG and DES-OSA as Predictive Score for Difficult Intubation.|Comparison of STOP-BANG and DES-OSA as Predictive Score for Difficult Intubation Among Patients Scheduled for Bariatric Surgery.||Astes|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for bariatric surgery|July 2015|July 18, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324946||30354|
NCT02324959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|651|Acupuncture and Computer-based Training to Improve Attention Deficits in Patients After Stroke|Evaluation of Acupuncture and Attention Training Effects on Patients After Stroke: a Study Protocol of an International Multicentre Study Using a Randomized Single Blinded Three-group Design|ACoTrain|Fujian University of Traditional Chinese Medicine|Yes|Recruiting|November 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||December 2014|December 19, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02324959||30353|
NCT02252666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1060|Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)|Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)||University of Wisconsin, Madison|No|Active, not recruiting|March 2014|March 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|90 Years|No|||November 2015|November 24, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02252666||35902|
NCT02318537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS011-14-024|Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome|A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome||INSYS Therapeutics Inc|Yes|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|2 Years|30 Years|No|||February 2016|February 23, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318537||30846|
NCT02253121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49690.048.14|Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD|GluCon-COPD|Slotervaart Hospital|No|Recruiting|February 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02253121||35867|
NCT02250378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2N-14-3|Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer|Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-small Cell Lung Cancer||University of Southern California|Yes|Withdrawn|October 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 23, 2014|Yes|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT02250378||36078|
NCT02313714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENESPHF|Effects of Neuromuscular Electrical Stimulation in Patients With Congestive Heart Failure|Effects of Neuromuscular Electrical Stimulation in Patients With Congestive Heart Failure||University of Campinas, Brazil|No|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|90 Years|No|||December 2014|December 9, 2014|November 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02313714||31216|
NCT02247609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19273-4SCAR|Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|4SCAR19273|Peking University|Yes|Recruiting|January 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|October 16, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247609||36291|
NCT02247622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1|Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis|Primary Sclerosing Cholangitis Telomere Length||Meir Medical Center|Yes|Recruiting|February 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with primary sclerosing cholangitis and inflammatory bowel disease|September 2014|September 19, 2014|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02247622||36290|
NCT02247635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINYS 410|Effect of a Treatment of Lifestyle Changes on the Prevalence of Metabolic Syndrome and Body Weight in Mexican Women|Development of a Methodology for Diagnosis and Promoting Adherence to Treatment of Patients With Chronic Diseases and Evaluation of Their Impact on Cardiovascular Risk Factors|MPATPCDNC|Mexican National Institute of Public Health|Yes|Completed|November 2008|August 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Female|20 Years|65 Years|No|||October 2014|October 30, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247635||36289|
NCT02258581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-330-1508|Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection|A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection||Gilead Sciences|No|Enrolling by invitation|December 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Participants who were treated in a Gilead-sponsored trial for hepatitis B virus infection.|March 2016|March 1, 2016|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258581||35451|
NCT02257801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-02-LUTE / D1-2011|Effects of Lutein on Learning and Memory in Chronically Stressed Subjects and in an Acute Stressful Situation (TSST - Trier Social Stress Test): A Randomized, Double-blind, Placebo-controlled Trial)|Effects of Lutein on Learning and Memory in Chronically Stressed Subjects and in an Acute Stressful Situation (TSST - Trier Social Stress Test): A Randomized, Double-blind, Placebo-controlled Trial|MemLearn|DSM Nutritional Products, Inc.|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|150|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257801||35510|
NCT02322749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00078|A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers|A Phase I, Single Centre, Randomised, Open Label, Crossover Study to Assess the Bioequivalence or Relative Bioavailability of Variants of Selumetinib (AZD6244, Hyd-Sulfate) Blue Capsules in Healthy Male Volunteers Aged 18 to 45 Years||AstraZeneca|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02322749||30523|
NCT02323022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ3202|Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)|IAC Regimen Versus IA Regimen as Induction Treatment for Initially Diagnosed AML Patients: a Randomized Controlled Phase III Clinical Trial||The First Affiliated Hospital of Soochow University|No|Recruiting|December 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|840|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323022||30502|
NCT02314871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAREC-1|Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery|Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery||The Institute of Molecular and Translational Medicine, Czech Republic|No|Recruiting|January 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02314871||31128|
NCT02256553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08607|Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)|A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis||Merck Sharp & Dohme Corp.|No|Completed|October 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|October 1, 2014|No|Yes||No|December 7, 2015|https://clinicaltrials.gov/show/NCT02256553||35604|
NCT02256566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0994|Cognitive Training for Mood and Anxiety Disorders|Cognitive Training for Mood and Anxiety Disorders||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2015|December 24, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256566||35603|
NCT02253433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI AS-1308-05887|The Houston HIIT-BAC for African Americans|The Houston Home-Based Integrated Intervention Targeting Better Asthma Control (HIIT-BAC) for African Americans|HIIT-BAC|Baylor College of Medicine|Yes|Recruiting|January 2015|September 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|235|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253433||35843|
NCT02253446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDhayri2014|A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea|A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea:A Double-Blind, Randomized Trial||Pamukkale University|Yes|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|400|||Female|18 Years|45 Years|No|||September 2014|September 27, 2014|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253446||35842|
NCT02314351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2014/315|Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial|Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial||Kocaeli University|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02314351||31168|
NCT02317757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|559/2557(EC3)|Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients|Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients: A Prospective Study||Mahidol University|No|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|70 Years|N/A|No|Non-Probability Sample|cancer patients who are older than 70 years old and receiving chemotherapy|April 2015|April 6, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317757||30906|
NCT02240667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.218|Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)|Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)||Boehringer Ingelheim||Recruiting|September 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1600|||Both|18 Years|N/A|No|Probability Sample|AF patients|March 2016|March 16, 2016|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02240667||36825|
NCT02248545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM06|Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients|Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients||University of Palermo|No|Completed|July 2011|June 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|90|Samples Without DNA|Blood samples|Both|18 Years|70 Years|No|Probability Sample|The study included consecutive adult patients with irritable bowel syndrome (IBS)-like        clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS,        referred at the Internal Medicine Department of the University Hospital of Palermo, Italy,        and at the Internal Medicine Department of the Hospital of Sciacca, Agrigento, Italy,        between July 2011 and July 2013.|September 2014|September 24, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02248545||36219|
NCT02326688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9368|Quantification of Arm Non-Use After a Stroke|Reliability of Kinematic Analysis in Assessment and Rehabilitation of the Upper Arm of Stroke Patients Following a Cerebral Vascular Accident, Hemiparetic Subjects||University Hospital, Montpellier|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02326688||30220|
NCT02326714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA for PCOS|Auricular Acupressure (AA) For Overweight/Obese Adolescent and Young Polycystic Ovary Syndrome ( PCOS)|Effect of Auricular Acupressure on Weight Loss in Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome.||Heilongjiang University of Chinese Medicine|No|Recruiting|June 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|12 Years|25 Years|No|||July 2015|July 3, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02326714||30218|
NCT02319096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedwayNHS|Vibration Training and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence|Whole Body Vibration Plate Therapy and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence||Medway NHS Foundation Trust|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||December 2015|December 27, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319096||30803|
NCT02243475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPANE STUDY|Probing the Role of Sodium Channels in Painful Neuropathies|Probing the Role of Sodium Channels in Painful Neuropathies: Observational Study||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Not yet recruiting|September 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|identification of novel mutations in the genes encoding for Nav1.7, Nav1.8, Nav1.9, Nav1.6,      and Nav1.3 sodium channels|Both|18 Years|N/A|No|Non-Probability Sample|homogeneous cohorts of patients (age >18 years) with painful and painless diabetic or        idiopathic sensory neuropathy|September 2014|September 17, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02243475||36609|
NCT02258542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00021|A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA|A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)|BORA|AstraZeneca|Yes|Recruiting|November 2014|July 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|2200|||Both|12 Years|75 Years|No|||February 2016|March 1, 2016|September 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258542||35454|
NCT02258555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-325-1348|Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma|A Phase 1b Dose-escalation Study Evaluating the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Subjects With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma||Gilead Sciences|No|Terminated|January 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258555||35453|
NCT02322957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRV-FV-1-008|A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers|A Phase 1 Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers||ContraVir Pharmaceuticals, Inc.|No|Completed|February 2015|July 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02322957||30507|
NCT02318056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR-SIUSOM-14-002|The Burn Glove Trial - Hand Burn Dressing Pilot|The Burn Glove Trial-A Randomized Controlled Trial of Dressings for Partial Thickness Hand Burns||Southern Illinois University|Yes|Not yet recruiting|December 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|8 Years|60 Years|No|||October 2015|October 26, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02318056||30883|
NCT02318069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/4-31/2 - B|New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly|Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?||Sormland County Council, Sweden|Yes|Recruiting|January 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318069||30882|
NCT02318082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-452|Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease|A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease||Dana-Farber Cancer Institute|Yes|Recruiting|February 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|N/A|No|||January 2016|January 28, 2016|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318082||30881|
NCT02250950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4636|An Examination of the Efficacy of a Self-Determination Theory and Motivational Interviewing Exercise Intervention|Decreasing Disparities in Physical Activity: An Intervention Based on Self-Determination Theory and Motivational Interviewing||Syracuse University|Yes|Completed|June 2014|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250950||36034|
NCT02242630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20140023H|Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis|Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone||Keesler Air Force Base Medical Center|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242630||36674|
NCT02323035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA150|Investigative Headgear With CPAP Mask|Investigative Headgear With CPAP Mask||Fisher and Paykel Healthcare|Yes|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 3, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323035||30501|
NCT02313246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-IBS-2015|A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome|A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome|IBS|Hamilton Health Sciences Corporation|No|Terminated|August 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||March 2016|March 24, 2016|December 5, 2014||No|Principal investigator left the institution|No||https://clinicaltrials.gov/show/NCT02313246||31252|
NCT02319356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163841|Does Dietary Nitrate Supplementation Improve Aerobic Performance|Does Dietary Nitrate Supplementation Improve Aerobic Performance in Colorectal Cancer? A Pilot Study||Royal Surrey County Hospital NHS Foundation Trust||Not yet recruiting|March 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319356||30783|
NCT02244710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0205|EndoTic - Endothelium and Ticagrelor|EndoTic - Endothelium and Ticagrelor: Pharmacological Effects Beyond Antiplatelet Therapy||Fundación Investigación Sanitaria en León|No|Recruiting|March 2015|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02244710||36514|
NCT02249364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/49|Hypnosis Before the Induction of Anesthesia|Interest of Hypnosis Before the Induction of Anesthesia. Study in Women Submitted to One Day Gynecological Surgical Procedures|Hypnose2|Hopital Foch|No|Completed|April 2014|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249364||36156|
NCT02240745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039/14|New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography|New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography|3-DSE|University Hospital Inselspital, Berne|Yes|Not yet recruiting|October 2014|July 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 consecutive subjects referred to the Department of Cardiology for elective coronary        angiography.|September 2014|September 15, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240745||36819|
NCT02317770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI534/2013|Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy|Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy||Mahidol University|No|Recruiting|November 2013|April 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317770||30905|
NCT02326363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1292-R|Mindfulness-Based Recovery in Veterans|Mindfulness-Based Recovery in Veterans With Substance Use Disorders|MBR-Veterans|VA Office of Research and Development|Yes|Recruiting|March 2015|September 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326363||30245|
NCT02326376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.Anakin-201|Kineret CAPS Post Authorisation Study|Non-interventional PASS to Evaluate Safety of Kineret in Treatment of CAPS in Routine Clinical Care With Regard to Serious Infections, Malignancies, Injection Site Reactions, Allergic Reactions, Medication Errors Including Re-use of Syringe||Swedish Orphan Biovitrum|No|Recruiting|April 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Probability Sample|All CAPS patients treated with Kineret at the selected sites.|March 2016|March 11, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02326376||30244|
NCT02247128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPTAV005|Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation|Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation|POPular-TAVI|St. Antonius Hospital|Yes|Recruiting|January 2014|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1000|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247128||36328|
NCT02253563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 146/11|Resistance Versus Balance Training in Parkinson's Disease|Resistance Training Versus Balance Training to Improve Postural Control in Patients With Parkinson's Disease - a Randomized Controlled Rater Blinded Trial||University of Kiel|No|Completed|June 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||April 2015|April 22, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253563||35833|
NCT02253680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTTKR-01|The Use of Compression Bandages in Total Knee Replacement Surgery|A Prospective, Randomised Control Trial Investigating the Use of a Two-layer, Short-stretch Compression Bandage in Elective Total Knee Replacement - Feasibility||Northumbria Healthcare NHS Foundation Trust|Yes|Active, not recruiting|November 2013|August 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02253680||35824|
NCT02253927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.32|Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers|Phase I Sequential Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose (225 Mg-450 mg) Oral Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers||Boehringer Ingelheim||Completed|May 2006|||August 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253927||35805|
NCT02310607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFL_01/2012|Non-invasive Optical Detection of Iron Deficiency|Non-invasive Optical Detection of Iron Deficiency - Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio||Klinikum der Universitaet Muenchen, Grosshadern|No|Completed|June 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|96|||Female|18 Years|N/A|No|Non-Probability Sample|Women post-partum|April 2015|April 7, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02310607||31455|
NCT02310412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00099|A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma|A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma||Cerus Corporation|No|Completed|December 2014|September 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310412||31470|
NCT02250833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS14006|CKD-828 (80/5mg) Pharmacokinetic Study|To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250833||36043|
NCT02242409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 2013-0138|Study of Gemcitabine and Abraxane for Pancreas Cancer|A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer||Georgetown University|Yes|Active, not recruiting|September 2014|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242409||36691|
NCT02242422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCho3|Serial Changes in Micturition Symptoms, Urine Flow and Bladder Voiding Efficiency Following Transobturator Tape Surgery|Serial Changes in Lower Urinary Tract Symptoms, Urine Flow and Bladder Voiding Efficiency Following Transobturator Tape Surgery for Treatment of Female Stress Urinary Incontinence||DongGuk University|No|Recruiting|August 2014|||November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Female|20 Years|90 Years|No|Non-Probability Sample|women who underwent transobturator tape surgery for treatment of female stress urinary        incontinence|September 2014|September 15, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02242422||36690|
NCT02312986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT for MDRO|FMT for Multidrug Resistant Organism Reversal|Use of Fecal Microbiota Transplantation (FMT) to Reverse Multi-Drug Resistant Organism Carriage||Washington University School of Medicine|No|Enrolling by invitation|August 2015|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312986||31272|
NCT02317731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410014830|Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation|Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation||Yale University|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317731||30908|
NCT02323841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12650/13|Feasibility Study: Conservative Treatment in Cervical Cancer|Feasibility Study: Conservative Treatment in Cervical Cancer FIGO Stage IB1-IIA1 > 2cm||Catholic University of the Sacred Heart|Yes|Active, not recruiting|March 2014|March 2015|Anticipated|March 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Female|18 Years|40 Years|No|||February 2014|December 23, 2014|April 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02323841||30439|
NCT02323854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVEMPR0437|The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)|The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)|EMPRESS|Medtronic - MITG|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323854||30438|
NCT02253602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48757.018.14|Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer|Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer: an Optimization and Pilot Study|IMPROVE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02253602||35830|
NCT02249052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-Lipoma II|Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma|A Double Blind Study to Evaluate the Safety and Efficacy of Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Lipoma||Gerut, Zachary, M.D.|No|Active, not recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|August 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249052||36180|
NCT02318017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1351-IH-CTIL|Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder|An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder||Sheba Medical Center|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|75|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02318017||30886|
NCT02318030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045186|CNTRP POSITIVE Study|CNTRP Paediatric Outcomes in Transplant: Personalising Immunosuppression to Improve Efficacy (POSITIVE Study)||The Hospital for Sick Children|No|Recruiting|June 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|1200|Samples With DNA|Genotyping and biomarkers: blood, saliva, urine Immune function testing: blood EBV      lymphoproliferation/PTLD viral sequencing: blood|Both|N/A|18 Years|No|Non-Probability Sample|End stage organ failure, Solid organ transplant|December 2014|December 11, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02318030||30885|
NCT02325388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0794|Pressure Sensing to Reduce the Risk of Pressure Ulcer Formation|Effectiveness of a Pressure-sensing System to Reduce the Risk of Pressure Ulcer Formation by Lowering Interface Pressure in Vulnerable Patient Populations: A Parallel-two-group Randomized Controlled Trial||University of Calgary|No|Recruiting|December 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|678|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325388||30320|
NCT02252458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-054|Can Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers?|Can Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers? A Prospective, Randomized, Double-blinded Crossover Study|FentaOIH-V|University Hospital, Basel, Switzerland|Yes|Completed|August 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|21|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02252458||35918|
NCT02321241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17405|Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD|A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept|TITAN|Bayer|No|Recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|225|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of wAMD refractory to ranibizumab (persistence of fluid) who        started a treatment with Anti VEGF (Aflibercept) may be included in the study|March 2016|March 24, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321241||30639|
NCT02323061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4055037|Brain Computer Interface（BCI） System for Stroke Rehabilitation|Brain Computer Interface（BCI） System for Stroke Rehabilitation||Chinese University of Hong Kong|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323061||30499|
NCT02323139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-AZA-LDE|A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients|A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients|LDE255|Groupe Francophone des Myelodysplasies|Yes|Recruiting|June 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02323139||30493|
NCT02312037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1761026|Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy|Gemtuzumab Ozogamicin (Mylotarg [Registered]) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy|AML|Pfizer||Available||||||Phase 4|Expanded Access|N/A|||||||Both|3 Months|N/A|No|||March 2016|March 7, 2016|December 4, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02312037||31345|
NCT02312323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-001-002|One-month Clinical Evaluation of Silicone Hydrogel Definitive 65 HPT Contact Lenses|||Contamac Ltd||Active, not recruiting|November 2014|||January 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 6, 2014|November 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02312323||31323|
NCT02251301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01636|Milk Plus Exercise: A Novel Strategy to Treat Diabetes.|The Effect of Adding Milk in Proximity to Exercise During an Interval Training Intervention in Type 2 Diabetes (T2D) on Metabolic and Cardiovascular Health.||University of British Columbia|No|Recruiting|January 2015|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|51|||Both|40 Years|70 Years|No|||January 2016|January 20, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251301||36007|
NCT02251444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rehabilitation program LBP|Regulation of Emotions and Coping Behaviour in Patients With Chronic Recurrent Low Back Pain|Emotionsregulation Und Bewältigungsverhalten in Zusammenhang Mit Ambulanter Rehabilitation Oder Physikalischer Therapie Bei Chronischem Rückenschmerz||Karl Landsteiner Institute of Remobilization and Functional Health||Recruiting|May 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|35 Years|65 Years|No|||January 2015|January 20, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02251444||35996|
NCT02240992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-PBSC-MSC-PGF-2014|MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment|Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant||Nanfang Hospital of Southern Medical University|Yes|Recruiting|September 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|14 Years|65 Years|No|||September 2014|September 13, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02240992||36800|
NCT02314585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15053|Fall Risk Reduction in Multiple Sclerosis (FIRMS)|Fall Risk Reduction in Multiple Sclerosis: Exercise Intervention vs. Attention Control Modification|FIRMS|University of Illinois at Urbana-Champaign|No|Recruiting|December 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|100|||Both|18 Years|64 Years|No|||August 2015|August 25, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02314585||31150|
NCT02314611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002D|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems||MicroPort Orthopedics Inc.|No|Recruiting|December 2014|December 2027|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with a PROFEMUR® Gladiator HA Coated Modular        Femoral Stem|March 2016|March 15, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314611||31148|
NCT02253485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D121100003912001|Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load|Case-control Study of Antiviral Therapy During Entire and the Third Trimester of Pregnancy in Preventing MTCT of HBV in Mothers With High Serum HBV DNA Load||Beijing Ditan Hospital|Yes|Enrolling by invitation|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|600|||Both|N/A|7 Months|No|Probability Sample|this study would enroll 600 HBsAg positive mothers, including 240 cases with high serum        HBV DNA load during pregnancy, 120 cases treated with antiviral therapy for hepatitis B,        120 cases with HBV DNA negative during pregnancy, 120 cases with high serum HBV DNA but        receive antiviral therapy in late of pregnancy, and all of their infants.|August 2012|September 29, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253485||35839|
NCT02248753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47065.068.13|Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department|Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (ACWAS-trial)|ACWAS|Maastricht University Medical Center|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|437|||Both|18 Years|N/A|No|||September 2015|February 2, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02248753||36203|
NCT02248766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-53|Clinical Performance of Habitual Wearers of Avaira Toric When Refitted With Clariti Toric Lenses|Clinical Performance of Habitual Wearers of Avaira Toric (Enfilcon A) When Refitted With Clariti Toric (Somofilcon A) Lenses for 1 Month.||Coopervision, Inc.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Both|18 Years|40 Years|No|||February 2016|February 23, 2016|September 23, 2014|Yes|Yes||No|February 23, 2016|https://clinicaltrials.gov/show/NCT02248766||36202|
NCT02317744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014705|Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo|Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo||Yale University||Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|65 Years|No|||December 2014|December 11, 2014|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317744||30907|
NCT02325999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESDLD2013|Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer|Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection:a New Therapy for Early Gastric Cancer||Beijing Friendship Hospital|Yes|Recruiting|December 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2014|December 21, 2014|December 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02325999||30273|
NCT02310425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU1|A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants|A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants|SBP|China Medical University, China|Yes|Completed|March 2013|January 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|N/A|28 Days|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02310425||31469|
NCT02244411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-164|Exercise and QUality Diet After Leukemia: The EQUAL Study|Exercise and QUality Diet After Leukemia: The EQUAL Study||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02244411||36537|
NCT02244684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-246|Effects of Maternal Folate and Folic Acid Supplementation on DNA Methylation in the Newborn Infant|||St. Michael's Hospital, Toronto||Completed|September 2010|||February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|368|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women were recruited from obstetrics clinics at St Michael's Hospital, a tertiary        teaching hospital affiliated with the University of Toronto.|September 2014|September 16, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02244684||36516|
NCT02253329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 14-3-042|NMES During the Day and Prior to Sleep|The Effect of Neuromuscular Electrical Stimulation on Post-prandial Protein Accretion During the Day and Prior to Sleep|ESPRO2|Maastricht University Medical Center|Yes|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253329||35851|
NCT02255500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-406|EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty|Evaluation of the Pharmacokinetics and Safety of Local Administration of EXPAREL in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Unilateral Total Knee Arthroplasty||Pacira Pharmaceuticals, Inc|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255500||35684|
NCT02326077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SONOPARTOGRAM|Sonopartogram. The Next Step in the Delivery Room|Intrapartum Ultrasonography - Sonopartogram. Longitudinal Evaluation of the Mechanism of Active Labor Using Ultrasound Parameters|SONOLABOR|University of Medicine and Pharmacy Craiova|Yes|Recruiting|December 2012|December 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The pregnant women admitted in active labor at term were considered eligible for the        study.        They are included in the study consecutively, depending on the availability of the US        operators involved.|December 2014|December 24, 2014|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02326077||30267|
NCT02311699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALJameelPAL|Using Cultural Ceremonies to Reduce Intimate Partner Violence and HIV Transmission|Using Cultural Ceremonies to Reduce Intimate Partner Violence and HIV Transmission||Abdul Latif Jameel Poverty Action Lab|No|Active, not recruiting|December 2014|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|6800|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02311699||31371|
NCT02311712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-03-37-27139|Non-endoscopic EC Screening Program in Northern Iran|Non-endoscopic Esophageal Cancer Screening Program in Northern Iran|NESP|Tehran University of Medical Sciences|Yes|Not yet recruiting|November 2015|December 2021|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|12000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311712||31370|
NCT02257190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-060|The Features Behind the Beneficial Effects of Interval-walking|The Features Behind the Beneficial Effects of Interval-walking|aIWS2|Rigshospitalet, Denmark|No|Completed|October 2014|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|30 Years|N/A|No|||October 2015|October 28, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02257190||35556|
NCT02246842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYAD04|A Study Comparing the Pharmacokinetics and Tolerance of D-Gam® to Rhophylac® in Rh-D-negative Healthy Volunteers.|A Randomised Study Comparing the Pharmacokinetics and Tolerance of D-Gam® 1500IU to Rhophylac® 1500IUin Rh-D-negative Healthy Volunteers.||Bio Products Laboratory||Completed|May 2004|||December 2004|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|2||||||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2014|September 19, 2014|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02246842||36350|
NCT02310893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH103076-01A1|Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care|Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care|CHAMPS|University of California, Los Angeles|No|Recruiting|January 2016|January 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|660|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02310893||31433|
NCT02248454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High fat bolus|Insulin Bolus Required for High Fat Foods in Type 1 Diabetes|Evaluation of Insulin Bolus for High Fat Meals||Joslin Diabetes Center|No|Enrolling by invitation|September 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2014|September 22, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248454||36226|
NCT02257372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201314|A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Parallel Group Study to Evaluate the Effect of Umeclidinium (UMEC) Added to Inhaled Corticosteroid/ Long-acting Beta-agonist Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease COPD||GlaxoSmithKline|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|40 Years|N/A|No|||October 2015|February 18, 2016|October 2, 2014|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT02257372||35542|
NCT02257385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116961|Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium|Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD||GlaxoSmithKline|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|967|||Both|40 Years|N/A|No|||February 2016|February 4, 2016|October 2, 2014||No||No|December 10, 2015|https://clinicaltrials.gov/show/NCT02257385||35541|
NCT02257424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02614|The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma|||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2014|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257424||35538|
NCT02321527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0611|Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients|Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Ultrasound Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321527||30617|
NCT02318043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWJ|AMP-BPT and His-BPT for Assessment of Asthma|Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?|AMPHis|Guangzhou Institute of Respiratory Disease|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02318043||30884|
NCT02323789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADSTEM001|Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa|A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa|ADSTEM|King's College London|Yes|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323789||30443|
NCT02244073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.808|Individualized Blood Glucose Control in ICU. The CONTROLING Study. A Double Blinded Multicentric Randomized Study.|Individualized Blood Glucose Control in ICU.|CONTROLING|Hospices Civils de Lyon|No|Recruiting|May 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|4200|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02244073||36563|
NCT02252718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014|Amsterdam Stool Scale: Usefulness in Clinical Setting|Amsterdam Stool Scale: Usefulness in Clinical Setting||Medical University of Warsaw|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|1 Month|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|The group will be selected from the children admitted to the Department of Pediatrics The        Medical University of Warsaw|January 2016|January 14, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252718||35898|
NCT02326012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1-31/3|Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study||Karolinska Institutet|No|Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|13 Years|17 Years|No|||January 2016|January 3, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326012||30272|
NCT02314624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH093993-02A1|PracticeGround: Transforming Training and Delivery of Mental Health EBPs|PracticeGround: Transforming Training and Delivery of Mental Health EBPs||Evidence-Based Practice Institute, Seattle, WA|No|Enrolling by invitation|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|21 Years|N/A|No|||August 2015|August 3, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02314624||31147|
NCT02249325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-2090|Quasi Experiment of Prenatal Probiotics Against Group B Streptococcus Colonization|Effects of Probiotic Use During Pregnancy on Lactobacillus and Group B Streptococcus Vaginal Colonization: A Pilot Study||Marquette University|No|Completed|January 2011|June 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02249325||36159|
NCT02249338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.10|Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of 14-Day Treatment With BIIL 284 BS on Patients With COPD (Double-Blind, Placebo-Controlled, Randomised, Parallel Group Study)||Boehringer Ingelheim||Completed|October 1999|||April 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|53|||Both|40 Years|80 Years|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249338||36158|
NCT02249351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.209|Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type|Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type||Boehringer Ingelheim||Terminated|December 1999|||May 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Both|40 Years|N/A|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249351||36157|
NCT02255513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLD200-106|A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD|A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.|CEES|Ironshore Pharmaceuticals and Development, Inc|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|6 Years|12 Years|No|||October 2014|October 16, 2014|May 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255513||35683|
NCT02244164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Incretine study|Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.|Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.||Erasme University Hospital|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|50|||Both|18 Years|75 Years|No|||September 2014|March 11, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244164||36556|
NCT02323750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TransitionCHF|TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study|Systolic Dysfunction to Congestive Heart Failure Cohort Study||IHF GmbH - Institut für Herzinfarktforschung|No|Recruiting|December 2014|December 2022|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|95 Years|No|Non-Probability Sample|The DZHK TransitionCHF Cohort Study will include patients with systolic dysfunction (NYHA        I), i.e. (1) patients without a history of HF symptoms and (2) patients who reversed from        symptomatic HF. Patients will be recruited prospectively at the seven participating DZHK        centres and eight external partners from the ALKK network (German Working Group of Leading        Hospital-based Cardiologists) and university hospitals.|August 2015|August 27, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323750|5 Years|30446|
NCT02324868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57372|Impact of Availability of Showerpatch for Patients With Intravenous Catheters|Comparison of Showerpatch Versus Other Measures to Protect Intravenous Catheter Entry Site During Bathing Activities|ISIC|Universitaire Ziekenhuizen Leuven|No|Completed|January 2016|March 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||January 2016|March 23, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324868||30360|
NCT02246855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMX03|A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy Volunteers|A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg (Vigam® Liquid and Gammaplex®) Using Standard and Accelerated Infusion Rates in Healthy Adult Volunteers (Three Treatment Arms)||Bio Products Laboratory||Completed|August 2004|||December 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|3||||||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|September 22, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02246855||36349|
NCT02246868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWFSE|An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.|An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.||Bio Products Laboratory||Completed|September 2001|||August 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|12 Years|N/A|No|||August 2014|September 19, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02246868||36348|
NCT02324361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000873|Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study|Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study|QFYT|Massachusetts General Hospital|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|July 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02324361||30399|
NCT02324374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813061|Endocytoscopy and Colorectal Neoplasia|The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia||University of Pennsylvania||Enrolling by invitation|June 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02324374||30398|
NCT02315365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481055|Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer|Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer||PeriPharm|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Post-menopausal women with ER+/HER2- locally advanced or metastatic breast cancer.|January 2016|January 13, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02315365||31090|
NCT02251379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093323|Environmental Control as Add-on Therapy in Childhood Asthma|Environmental Control as Add-on Therapy in Childhood Asthma|ECATCh|Johns Hopkins University|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|5 Years|17 Years|No|||September 2015|September 5, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02251379||36001|
NCT02253459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG01-1323L|Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer|Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer||Beijing Biostar Technologies, Ltd|Yes|Active, not recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Female|18 Years|70 Years|No|||January 2016|January 20, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253459||35841|
NCT02324452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14DPD|Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines|Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines||The Netherlands Cancer Institute|Yes|Recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1250|||Both|18 Years|N/A|No|||November 2015|February 2, 2016|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324452||30392|
NCT02323152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGEA|PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK|PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK|PROGEA|Basque Health Service|No|Enrolling by invitation|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|135|||Female|18 Years|60 Years|No|||December 2014|December 22, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323152||30492|
NCT02323230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-DPX-Survivac-05|A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL|Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)||ImmunoVaccine Technologies, Inc.|No|Recruiting|January 2015|February 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02323230||30486|
NCT02325284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Algometer/Phase 1 pilot study|Objective Measurement of Pain Using the Algometer|Phase 1 Pilot Study of an Apparatus and Method to Objectively Measure Pain in Normal Healthy Adults.||Children's Research Institute|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults.|January 2016|January 29, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325284||30328|
NCT02248987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3420130030|Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia|||Seoul National University Hospital||Recruiting|May 2014|||October 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|36|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Schizophrenia patients treated with clozapine          2. Schizophrenia patients treated with risperidone or paliperidone or olanzapine          3. Healthy volunteers|September 2014|September 22, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248987||36185|
NCT02249000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1205|BIOVALVE - I / II Clincial Investigation|Safety and Clinical Performance of the Self-expanding Transcatheter BIOVALVE Prosthesis in Subjects With Severe Symptomatic Aortic Stenosis Suitable for Transfemoral Transcatheter Aortic Valve Implantation|BIOVALVE|Biotronik AG|Yes|Recruiting|September 2014|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|65 Years|N/A|No|||January 2016|January 21, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249000||36184|
NCT02249312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.11|The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma|The Effect of BIIL 284 BS (14 Day Treatment) on Induced-sputum Variables in Patients With Bronchial Asthma (a Double-blind, Randomized, Placebo-controlled Parallel Study)||Boehringer Ingelheim||Completed|July 1999|||April 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249312||36160|
NCT02256644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575B|Genomics of Posttraumatic Stress Disorder|CSP #575B - Genomics of Posttraumatic Stress Disorder Among Veterans||VA Office of Research and Development|No|Active, not recruiting|December 2013|December 2017|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|20000|Samples With DNA|Affymetrix Axiom Biobank chip, with technical specifications including "295K tag SNPs",      "260K exomic content", "65K loss-of-function SNPs & INDELs", "25K psych content", and "23K      eQTL markers".|Both|18 Years|80 Years|No|Probability Sample|The investigators expect 70-80% European-American (EA) and 20-30% African American (AA) in        the current study|March 2016|March 24, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256644||35597|
NCT02323685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGCI-002|Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)|Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)||Prolong Pharmaceuticals|No|Recruiting|December 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323685||30451|
NCT02319122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-526 ex 13/14|A Prospective Study of Two Home Based Muscle Strengthening Programs for Children With Cerebral Palsy|A Prospective Study of Two Home Based Muscle Strengthening Programs for Children With Cerebral Palsy||Medical University of Graz|Yes|Recruiting|January 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|16 Years|No|||September 2015|September 21, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02319122||30801|
NCT02251951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/12.05|Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer|A Multicenter, Phase II, Single-Arm Clinical Trial of Nab-Paclitaxel as Salvage Treatment for Patients With Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal Junction.||Hellenic Oncology Research Group|No|Completed|September 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|19 Years|N/A|No|||October 2015|October 7, 2015|July 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02251951||35957|
NCT02251964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49534.100.14|Rituximab in Interstitial Pneumonitis|Rituximab in Life Threatening Therapy Resistant Progressive Interstitial Pneumonitis|RITUX-IP|St. Antonius Hospital|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02251964||35956|
NCT02248311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECISED ISCiii-PIE-13|"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population|"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population: a Multidisciplinary Clinical and Experimental Approach" (PRECISED)|PRECISED|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|September 2014|October 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|Samples Without DNA|Patients: 200 Control group: 60|Both|50 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|A total of 200 T2D diabetic patients without history of clinical Cardiovascular disease        will be recruited from the Outpatient Diabetic Clinic of Vall d'Hebron Hospital and the        Primary Health Care centers under its influence area. Sixty non-diabetic patients without        classic Cardiovascular risk factors matched by age will be used as a control group.        Specifically, vascular risk factors, concomitant diseases, family history of        Cardiovascular disease or stroke and the treatments taken at the time of inclusion will be        collected.|January 2016|January 22, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02248311||36237|
NCT02314065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-NonInf|Cognitive Behavioral Therapy for Health Anxiety: Internet Treatment Versus Face-to-Face Therapy|Cognitive Behavioral Therapy for Health Anxiety: a Randomized Controlled Non-inferiority Trial of Internet-delivered and Face-to-Face Therapy|HA-NonInf|Karolinska Institutet|Yes|Recruiting|December 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314065||31190|
NCT02311452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526|Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections|Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections|PIVVOT|Children's Hospital of Philadelphia|No|Completed|January 2009|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|15000|||Both|2 Months|17 Years|No|Non-Probability Sample|Children hospitalized for acute osteomyelitis, complicated pneumonia, or complicated        appendicitis, and discharged to complete a course of antibiotics.|December 2014|December 5, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311452||31390|
NCT02312024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JenaUH|International Registry on the Use of the CytoSorb Adsorber|International Registry on the Use of the CytoSorb®-Adsorber in ICU Patients|CytoSorb|Jena University Hospital|No|Recruiting|January 2015|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing treatment with the CytoSorb® adsorber|August 2015|August 21, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312024|30 Days|31346|
NCT02251106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030976|Effect of Lumbar Bracing on Spinal Function|Effect of Lumbar Bracing on Spinal Function||University of Alberta|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|October 14, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251106||36022|
NCT02251119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.55|The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers|The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers||Boehringer Ingelheim||Completed|July 2002|||January 2003|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251119||36021|
NCT02312960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16996|Radium-223 Dichloride Long-term Follow-up Program|A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride||Bayer|No|Recruiting|December 2014|September 2025|Anticipated|September 2025|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312960||31274|
NCT02321098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR29106|Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish|Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis|COOL|Galderma|No|Completed|February 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02321098||30650|
NCT02321111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140497H|The Role of TLR4 on Lipid-induced Insulin Resistance|The Role of TLR4 on Lipid-Induced Insulin Resistance|Eritoran1|The University of Texas Health Science Center at San Antonio|No|Recruiting|January 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321111||30649|
NCT02253472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-008|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|September 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||August 2015|October 12, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253472||35840|
NCT02242617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01215|Adherence and Preference of CPAP vs MAS|Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial||University of British Columbia|No|Not yet recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|65 Years|No|||November 2015|November 30, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02242617||36675|
NCT02246881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWFPK|A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.|An Open Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Severe Haemophilia A Patients.||Bio Products Laboratory||Completed|October 2001|||January 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||||||Both|12 Years|N/A||||August 2014|September 19, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02246881||36347|
NCT02313220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690L00016|Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight|A 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.|Dapalost|Uppsala University|No|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||June 2015|June 15, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313220||31254|
NCT02317705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTL-2014-OTL38-003|Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer|A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer||On Target Laboratories, LLC|No|Active, not recruiting|December 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317705||30910|
NCT02311166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140401PAO|Soft Tissue Pathology in Hip Dysplasia Before and After Periacetabular Osteotomy|Soft Tissue Pathology in 100 Patients With Hip Dysplasia Before and After Periacetabular Osteotomy||University of Aarhus|Yes|Active, not recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of hip dysplasia receiving treatment at Aarhus University        Hospital, Denmark.|March 2014|February 29, 2016|April 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02311166||31412|
NCT02314390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVHH|Group- Versus Individual-Mindfulness-Based Cognitive Therapy: a Randomized Trial|Group- Versus Individual-Mindfulness-Based Cognitive Therapy for Patients With a Chronic Somatic Disease and Comorbid Depressive Symptoms: a Randomized Trial|G/I-MBCT|University Medical Center Groningen|No|Completed|September 2013|August 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||December 2014|December 8, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02314390||31165|
NCT02314403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH Tolerance Trial|Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)|||Massachusetts General Hospital|Yes|Recruiting|February 2015|August 2021|Anticipated|March 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|December 5, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02314403||31164|
NCT02251730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406075RINC|Smoking Cessation in Head and Neck Cancer Patients Receiving Curative Radiation Therapy|A Feasibility and Efficacy Study of Smoking Cessation Program in Head and Neck Cancer Patients Receiving Curative Radiation Therapy||National Taiwan University Hospital|No|Recruiting|August 2014|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|20 Years|70 Years|No|||September 2014|September 25, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02251730||35974|
NCT02313753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH101129|Evaluation of the Coping Long Term With Active Suicide Program|Evaluation of the Coping Long Term With Active Suicide Program|CLASP|Butler Hospital|Yes|Recruiting|December 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313753||31213|
NCT02325349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110154|PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents|PET/CT Molecular Imaging of Angiogenesis in Pulmonary or Head and Neck Cancers Prior to or During Chemotherapy Including Agent With Antiangiogenic Effect. A Prospective Multicentric Study of Efficacy and Tolerability.|MLAPOCHI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02325349||30323|
NCT02325362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120703|Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation|Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover, Proof-of-mechanism Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Adult Patients With Cystic Fibrosis Homozygous for the F508del Mutation|MIGLUSTAT-CF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|August 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02325362||30322|
NCT02256345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01340|Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF|Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF||University of Pennsylvania|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256345||35620|
NCT02248324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112S269|Association of Previously Verified Gene Polymorphisms With AMD in Turkish Population|A Multicenter Study on the Investigation of Previously Verified Leading Gene Polymorphisms Related to Age-related Macular Degeneration in Turkish Population|AMD-SNP|Kocatepe University|Yes|Recruiting|November 2012|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Whole blood|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with intermediate and advanced age related macular degeneration|December 2015|December 19, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02248324||36236|
NCT02317471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAG-CS-Ga-01|Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96|Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96||Chinese PLA General Hospital|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||July 2015|July 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317471||30928|
NCT02248207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.527|Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease|Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice||Boehringer Ingelheim||Completed|January 2003|||November 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1293|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Parkinson's disease recruited at specialist neurologist (private practices        and clinics)|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248207||36245|
NCT02248220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.360|Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease|Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease||Boehringer Ingelheim||Completed|October 1998|||October 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|657|||Both|N/A|N/A|No|Non-Probability Sample|Patients with advanced idiopathic Parkinson's diease recruited at specialist practices and        hospitals|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248220||36244|
NCT02257320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMJ-1002|TMJ NextGeneration(TM) Feasibility Study|A Feasibility Study of the Bruxoff™ Device to Assess EMG Activity in Subjects Diagnosed With Sleep Bruxism Using TMJ NextGeneration(TM)|Bruxoff|Cardiox Corporation|No|Completed|November 2014|May 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257320||35546|
NCT02257333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEART VISION|Retinal Thrombosis and Atherosclerosis|High Focused Evaluation of Atherosclerotic Risk Profile in Retinal Thrombosis: Vascular Events Incidence, Sex Involvement and Interventional Outcomes Assessed by Ophthalmologists and Internists Network|HEART-VISION|University of Roma La Sapienza|No|Recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with clinical suspicion of Retinal Venous Occlusion, consecutively enrolled        at specialized ophthalmologic centers afferent to the study.|October 2015|October 7, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02257333|2 Years|35545|
NCT02317224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TangduH717544|The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor|Comparison of Safety and Efficacy Among "3-Hole" Subxiphorid Approach, Trans Sternal Approach and VATS in Surgical Treatment of Anterior Mediastinal Tumor|3-Hole|Tang-Du Hospital|Yes|Recruiting|August 2014|December 2024|Anticipated|December 2024|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|No|||December 2014|December 10, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02317224||30947|
NCT02317237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLIATH|"GOLIATH" - General Or Local Anaestesia in Intra Arterial THerapy|Anaesthetic Strategy During Endovascular Therapy: General Anaesthesia or Conscious Sedation ?|GOLIATH|University of Aarhus|No|Recruiting|March 2015|November 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02317237||30946|
NCT02311179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110224|The Effect of Implant Coating (BoneMaster) on Migration and Clinical Outcome in Hip Arthoplasty With the Exceed Cup|The Effect of Implant Coating With Hydroxyapatite Deposited Electrochemically (BoneMaster) on Migration and Clinical Outcome in Hip Arthoplasty With the Exceed Cup||University of Aarhus|Yes|Enrolling by invitation|January 2013|March 2020|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|55 Years|75 Years|No|||December 2014|December 5, 2014|November 6, 2012||No||No||https://clinicaltrials.gov/show/NCT02311179||31411|
NCT02244398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|467637|Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda|Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda||FHI 360|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|292|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244398||36538|
NCT02246894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF05|A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.|An Open Multicentre Phase III Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Severe Haemophilia A.||Bio Products Laboratory||Completed|November 2003|||January 2005|Actual|Phase 3|Interventional|N/A|1||||||Both|N/A|6 Years|No|||August 2014|September 19, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02246894||36346|
NCT02251145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.46|Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers|A Single Centre, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effects of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate 300 mg in Healthy Volunteers||Boehringer Ingelheim||Completed|May 2002|||June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251145||36019|
NCT02251158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.45|Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects|Relative Bioavailability of 500/200 mg of Tipranavir/Ritonavir Paediatric Solution Compared to 500/200 mg of Tipranavir/Ritonavir Capsules Following Oral Administration and Bioavailability of 500/200 mg Tipranavir/Ritonavir Paediatric Solution Under the Influence of Food in Healthy Female and Male Subjects. An Open-label, Randomised, Single-dose, Three-way Crossover Trial.||Boehringer Ingelheim||Completed|October 2003|||December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251158||36018|
NCT02317978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub8|Evaluation of the Role of Follicular Sensitivity Index in the Prediction of IVF/ICSI Outcome|||Cairo University||Recruiting|December 2014|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Female|20 Years|42 Years|No|Non-Probability Sample|The records of women who had IVF/ICSI without PCO will be reviewed to calculate the FSI.|February 2016|February 6, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02317978||30889|
NCT02315859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|089/14|Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle|Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle||University Hospital Inselspital, Berne|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Population with a large variety of clinical conditions leading to dyspnea (for example        hypertensive or hypertrophic heart disease, dilated cardiomyopathy), and where no        significant coronary artery disease or regional wall-motion abnormalities are identified.|January 2016|January 6, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02315859||31052|
NCT02318836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1007|Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects|Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects||US WorldMeds LLC|No|Completed|July 2014|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|July 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318836||30823|
NCT02256267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15174|A Study of LY2835219 in Healthy Participants|Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|October 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02256267||35626|
NCT02243852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/NW/0075|Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)|Evaluation of the Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) Concentration in Patients With Growth Hormone Deficiency (GHD)||University of Liverpool|No|Recruiting|September 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|48|Samples Without DNA|All patients will have a 15 ml blood sample taken for glucose, insulin, lipid profile and      liver function tests (LFTs). Insulin sensitivity will be measured by HOMA-IR. Plasma      concentrations of FGF-21 will be measured using a commercial ELISA kit (Human FGF-21;      Biovendor, Germany).      16 GHD patients, who are eligible for GH replacement therapy as part of their routine      clinical care, according to the National Institute for Clinical Excellence (NICE)      recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire      score (AGHDA score>11) will also be re-tested following 6-months of growth hormone      replacement therapy|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Secondary care clinic University advertisement|September 2014|September 18, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243852||36580|
NCT02243865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM005|Chordate System Prophylactic Migraine Clinical Investigation|A Randomized, Placebo-controlled, Double-blind, Multi-center Pilot Study to Evaluate the Prophylactic Effect and Tolerability of Intranasal Kinetic Oscillation Stimulation (KOS) Using the Chordate System S200 in Patients Diagnosed With Migraine||Chordate Medical|No|Recruiting|September 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||December 2014|December 18, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02243865||36579|
NCT02317289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9096|Assisted Device for Freezing in Parkinson Disease|Development of a Multimodal Controlled Device for Improvement and Monitoring of Freezing in Parkinsonian Patients|demarpark|University Hospital, Montpellier|Yes|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|40 Years|85 Years|No|||July 2015|July 21, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02317289||30942|
NCT02311426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP1175-14|Stroke in North of Norway and Denmark. A Prospective Cohort Study.|||University Hospital of North Norway|No|Recruiting|March 2014|||September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients with stroke admitted to the stroke units at the University Hospital of North        Norway and Århus Hospital in Denmark|December 2014|December 5, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311426|12 Months|31392|
NCT02311439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAP001|Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas|Induction Chemotherapy, Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) Followed With Concurrent Capecitabine and Radiation Therapy in Treatment of Patients With Inoperable Locally Advanced Cancer Pancreas||Assiut University|Yes|Recruiting|October 2014|April 2017|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|18 Years|75 Years|No|||December 2014|December 5, 2014|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311439||31391|
NCT02244424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HDO75974-OIAL|Tools For Teen Moms: Reducing Infant Obesity Risk|Tools for Teen Moms: Reducing Infant Obesity Risk|TFTM|Michigan State University|No|Recruiting|June 2014|April 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|15 Years|19 Years|No|||September 2015|September 17, 2015|June 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02244424||36536|
NCT02256189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300A|Sitagliptin and Glucagon Counterregulation|The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes|SITACLAMP|Lund University|No|Recruiting|April 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|28|||Both|65 Years|80 Years|No|||December 2015|December 12, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02256189||35632|
NCT02322996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001670|Phenotyping Acute Pain for Discovery Research and Directed Therapeutics|Phenotyping Acute Pain for Discovery Research and Directed Therapeutics||East Carolina University|No|Not yet recruiting|September 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or females over 18 years of age|August 2015|August 6, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02322996||30504|
NCT02251236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-236-1266|Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals|Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals||University of California, San Diego|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|60 Years|No|||June 2015|June 9, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251236||36012|
NCT02322528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47817|Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax|Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax||University of Rochester|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|50 Years|70 Years|No|||September 2015|September 17, 2015|April 16, 2014|No|Yes||No|September 17, 2015|https://clinicaltrials.gov/show/NCT02322528||30540|
NCT02322541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS48|Dietary Absorption of Garlic Metabolites Following Garlic Consumption|||USDA Beltsville Human Nutrition Research Center|No|Suspended|September 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|December 8, 2014||No|This study was suspended due to additional time needed for method development.|No||https://clinicaltrials.gov/show/NCT02322541||30539|
NCT02315378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01334|Anxiety Reduction Treatment for Acute Trauma|Anxiety Reduction Treatment for Acute Trauma||New York University School of Medicine|No|Completed|June 2008|August 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02315378||31089|
NCT02248233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FengtianH-RHL-001|Nimodipine for Treating Acute Massive Cerebral Infarction|Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study||Fengtian Hospital|No|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||October 2014|October 14, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248233||36243|
NCT02257853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140201|Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients|A Randomized Controlled Trial to Determine the Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 18, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02257853||35507|
NCT02324387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0812|Tc99m Sestamibi Molecular Breast Imaging|Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324387||30397|
NCT02321345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21301|Pre-Transplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies|Feasibility of Implementing Pre-Transplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies||Medical College of Wisconsin|No|Recruiting|February 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02321345||30631|
NCT02325154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-047|Cerebral Oxygenation in Total Hip Arthroplasty Patients|Cerebral Near-Infrared Spectroscopy and Hypotensive Anesthesia in Patients Undergoing Total Hip Arthroplasty|THANIRS|Hospital for Special Surgery, New York|No|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospital for Special Surgery patients scheduled to undergo unilateral total hip        arthroplasty under hypotensive anesthesia|November 2015|November 9, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02325154||30338|
NCT02244086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-2301-21|Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor|Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor.|EBWL|Coordinación de Investigación en Salud, Mexico|Yes|Completed|June 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|114|||Female|14 Years|45 Years|No|||September 2014|September 16, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02244086||36562|
NCT02252731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0509|A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects|A Phase 1, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of FG 4592 on the Pharmacokinetics of Warfarin in Healthy Subjects||Astellas Pharma Inc|No|Completed|September 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|June 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02252731||35897|
NCT02322944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-2013BAI09B01|China PEACE II: Quality Improvement for Acute Myocardial Infarction|China Patient-centered Evaluative Assessment of Cardiac Events II: Quality Improvement for Acute Myocardial Infarction|PEACE-QI-AMI|China National Center for Cardiovascular Diseases|Yes|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|5000|||Both|N/A|N/A|No|||August 2015|August 27, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02322944||30508|
NCT02315625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150040|Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery|A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|September 2021|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|99 Years|No|||October 2015|October 17, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315625||31070|
NCT02249013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1158-0472|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy as Front-line Therapy of Epithelial Ovarian Cancers: a Therapeutic Pilot Study for the Instituto de Medicina Integral Prof. Fernando Figueira||Professor Fernando Figueira Integral Medicine Institute|Yes|Enrolling by invitation|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||March 2015|March 12, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02249013||36183|
NCT02321033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lazysportsmen2014|Influence of Daylong Glycemia on Detraining Induced Metabolic Changes|Einfluss Der Postprandialen Glykämie Auf Inaktivitäts-induzierte Veränderungen im Stoffwechsel||University of Hohenheim|No|Completed|August 2014|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02321033||30655|
NCT02310399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01010|Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves|Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves||New York University School of Medicine|Yes|Recruiting|May 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Months|21 Years|No|||October 2015|October 26, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310399||31471|
NCT02310620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M3W2012|Computer Games to Prevent Mild Cognitive Impairment and Dementia|||Semmelweis University|No|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02310620||31454|
NCT02316106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106449|A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma|A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma||Janssen Research & Development, LLC|Yes|Recruiting|May 2015|November 2020|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316106||31033|
NCT02246062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288.712|Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone on Anxiety of Children|Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone Application on Anxiety of Children||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Completed|June 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|84|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|March 20, 2014||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT02246062||36410|
NCT02241811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boron wound|Wound Treatment With 3% Sodium Pentaborate Pentahydrate|Deep Diabetic Foot Wound Treatment With Hydrogel Including 3% Sodium Pentaborate Pentahydrate||SB Istanbul Education and Research Hospital|No|Recruiting|September 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||September 2014|September 13, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241811||36737|
NCT02315092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8303|Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice|Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice||University Health Network, Toronto|No|Enrolling by invitation|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|77|Samples Without DNA|Microbiological samples (skin and wound swabs)|Both|18 Years|N/A|No|Non-Probability Sample|Patients who present with a diabetic foot ulcer and are receiving standard wound care        treatment.|May 2015|May 12, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315092||31111|
NCT02318784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 195|Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers|Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers||SCRI Development Innovations, LLC|No|Recruiting|June 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318784||30827|
NCT02325596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-81271061|Investigate the Role of microRNA in Chronic Rhinosinusitis From DC-Th Axis|Investigate the Role of microRNA in Chronic Rhinosinusitis From DC-Th Axis|ITROMICRFDTA|First Affiliated Hospital of Chongqing Medical University|No|Enrolling by invitation|July 2014|December 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|70|||Both|18 Years|75 Years|No|Non-Probability Sample|Participants will be selected from the department of endoscopic sinus surgery in the First        Affiliated Hospital of Chongqing Medical University.|December 2014|December 24, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02325596||30304|
NCT02325609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-M22-NdYAG-14-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||March 3, 2016|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325609||30303|
NCT02246296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTREC 58-14|Reformulated F75 Milk to Treat Severe Acute Malnutrition|Randomized Controlled Trial of a Reduced Carbohydrate Formulation of F75 Therapeutic Milk Among Children With Severe Acute Malnutrition|F75|University of Oxford|Yes|Recruiting|December 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|840|||Both|6 Months|13 Years|No|||September 2014|January 6, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02246296||36392|
NCT02246309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER08282014-01|Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture|Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture at Center for Human Reproduction(CHR):an Open Label Randomized Clinical Trial||Center for Human Reproduction|No|Terminated|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||December 2015|December 26, 2015|September 18, 2014|Yes|Yes|Equipment was loaned Lifglobal, Guilford, CT, USA and had to be returned.|No||https://clinicaltrials.gov/show/NCT02246309||36391|
NCT02255526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004034|BodyGuardian Respiration and Activity Validation Testing|BodyGuardian Respiration and Activity Validation Testing||Preventice|No|Active, not recruiting|September 2014|March 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and Heart Failure patients|September 2014|October 19, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255526||35682|
NCT02255539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA110914|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||April 1, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255539||35681|
NCT02319291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13004|PS150 Total Knee Arthroplasty Outcomes Registry|Outcomes of Total Knee Arthroplasty (TKA) Using the Sigma PS150 Primary Total Knee System||DePuy Orthopaedics|No|Recruiting|February 2015|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients may be considered for inclusion in the registry if they meet the inclusion        criteria below.|January 2016|January 19, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319291|5 Years|30788|
NCT02319304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00060641|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma|Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma|GCC 1314|University of Maryland|Yes|Recruiting|March 2015|December 2021|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02319304||30787|
NCT02320734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-211|Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy|A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy|DEPTH|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|February 2015|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02320734||30678|
NCT02313064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-10-201|Oral CXA-10 Study in Healthy Volunteers|A Two-Part, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled and Open-Label Exploratory Food Effect Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers||Complexa, Inc.|No|Recruiting|January 2015|August 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313064||31266|
NCT02248467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-AOUC-2013-01|Study of the Effect of Testosterone Treatment on Metabolic Parameters and Urinary Symptoms in Bariatric Patients|Study of the Effect of Testosterone Replacement Therapy on Metabolic Parameters, Prostatic Inflammation Symptoms and Lower Urinary Tract Symptoms (LUTS) in Hypogonadal Obese Subjects Eligible for Bariatric Surgery.||University of Florence|No|Recruiting|May 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Male|25 Years|65 Years|No|Probability Sample|Male adults subjects suffering from severe obesity in a waiting list for bariatric surgery        for weight loss will be considered eligible.        The diagnosis of hypogonadism will be defined by levels of total testosterone <12nmol / l        or free testosterone <225 pmol / L (calculated according to the formula of Vermeulen).|December 2015|December 1, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248467||36225|
NCT02251314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7467|Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma|The Utility and Relevance of Exome Sequence Analysis and Circulating Tumour DNA in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma||University Health Network, Toronto|Yes|Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|6|Samples With DNA|-  Pre-mortem bloods taken to obtain ctDNA        -  Post-mortem bloods and tissue To understand to what extent circulating DNA (found in           Blood) represents the genetic content of underlying tumour metastases in BRAF mutant           melanoma, and        -  To correlate the appearance of metastasis-specific mutations in the ctDNA with           histological features in the tumours such as degree of necrosis, inflammation,           microvascular density, and location or size of primary tumour and metastases|Both|18 Years|N/A|No|Non-Probability Sample|UHN patients with BRAF mutant melanoma|March 2016|March 7, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251314|3 Years|36006|
NCT02323256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.857|Neurophysiological Measures of Auditory Perception and Rehabilitation in Cochlear Implanted Patients|Neurophysiological Measures During Sound and Speech Perception in Cochlear Implanted Patients and Development of New Speech Rehabilitation Tools|NEUROSYLLABIC|Hospices Civils de Lyon|No|Recruiting|July 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|432|||Both|1 Year|70 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02323256||30484|
NCT02311400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915030|Self-Affirmation, Emotion, and Alcohol Consumption|Self-Affirmation, Emotion, and Alcohol Consumption||National Institutes of Health Clinical Center (CC)||Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|700|||Female|18 Years|N/A|No|||October 2015|October 22, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311400||31394|
NCT02245815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-1002-7|Prevention of Necrotizing Enterocolitis of Premature Newborns Under Less Than 1500 g Using Probiotics|The Use of Probiotics (Boucardii Strain vs. Multi-species) in the Prevention of Necrotizing Enterocolitis and Their Effect on Secreting IgA in the Feces of Premature Newborns Under Less Than 1500 g|(PEPP)|Coordinación de Investigación en Salud, Mexico|No|Recruiting|December 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|27 Weeks|34 Weeks|Accepts Healthy Volunteers|||March 2015|March 12, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02245815||36429|
NCT02246049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUATTRO|A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC|A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer|QUATTRO|EPS Corporation|Yes|Active, not recruiting|May 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||September 2014|August 28, 2015|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02246049||36411|
NCT02244463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-223|A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer|A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|July 2015|January 2022|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244463||36533|
NCT02244762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX002-1002|Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment|Evaluation of the Effect of Renal Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg Capsules||Zogenix, Inc.|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|37|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244762||36510|
NCT02326922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM1983|The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding|The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding||Ain Shams Maternity Hospital|Yes|Completed|June 2014|March 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|55 Years|No|||March 2016|March 11, 2016|June 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326922||30203|
NCT02323334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15562|A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease|Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626||Eli Lilly and Company|No|Completed|December 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|11||Actual|136|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323334||30478|
NCT02323802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMI-Obesity|Diet Therapy Versus Prescriptive Educational Group Intervention in Overweight / Obese Patients at First Episode of AMI: a Randomized Controlled Trial|Diet Therapy Versus Prescriptive Educational Group Intervention in Overweight / Obese Patients at First Episode of AMI: a Randomized Controlled Trial||IRCCS Policlinico S. Matteo||Recruiting|July 2013|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||December 2014|December 18, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323802||30442|
NCT02250352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-13-2|Core Biopsies for Establishing a Breast Tumor Tissue Repository|Core Biopsies of Breast Tumor Tissue Repository||University of Southern California|Yes|Recruiting|November 2013|November 2024|Anticipated|November 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1450|Samples With DNA|Tumor Tissue Blood|Both|18 Years|N/A|No|Non-Probability Sample|Subjects seen at USC Norris Comprehensive Cancer Center and LAC+USC Medical Center will be        recruited for this trial.|October 2015|October 24, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250352||36080|
NCT02253186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01008-39|Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema|Monocentre, Controlled, Randomized, Open Label, Clinical Study to Assess Safety and Efficacy of Auto-Adjustable MOBIDERM(R) Arm Sleeve in the Management of Upper Limb Lymphoedema During Night-time of Maintenance Phase|MARILYN|Thuasne|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253186||35862|
NCT02322515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unopar-Rubens|Patellar Taping on Proprioceptive Exercises in Young Women With Patellofemoral Pain Syndrome|The Effect of a Patellar Taping on Proprioceptive Exercises in Young Women With Patellofemoral Pain Syndrome: A Single-blinded Randomized Controlled Trial.|Tapping|Universidade Norte do Paraná|Yes|Completed|January 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|35 Years|No|||November 2015|November 30, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02322515||30541|
NCT02318797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 271|Optimizing Behavioral Health Homes for Adults With Serious Mental Illness|Optimizing Behavioral Health Homes by Focusing on Outcomes That Matter Most for Adults With Serious Mental Illness|PCORI OH|University of Pittsburgh|Yes|Active, not recruiting|October 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|1229|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02318797||30826|
NCT02311907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01965|Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer|The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study||National Cancer Institute (NCI)|Yes|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|282|||Female|18 Years|N/A|No|||May 2013|May 22, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311907||31355|
NCT02311920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02404|Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma|Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma||National Cancer Institute (NCI)||Recruiting|April 2015|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311920||31354|
NCT02326467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00011128|Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age|Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age||Children's Hospital Boston|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|36 Weeks|48 Weeks|No|||January 2016|January 26, 2016|June 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326467||30237|
NCT02250742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045/11|The Effect of Dry Needling on Trunk Muscle Function in Low Back Pain Patients|The Effect of Dry Needling on Trunk Muscle Function in Low Back Pain Patients||University of Haifa||Recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 28, 2015|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02250742||36050|
NCT02242110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU1457|Brief Treatment for Trauma Nightmares in Trauma-exposed Adults With Bipolar Disorder|Efficacy of a Brief Treatment for Chronic Nightmares Among Trauma-Exposed Persons With Bipolar Disorder|BERRT|University of Tulsa|No|Recruiting|June 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02242110||36714|
NCT02325648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0854|The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study|||Yonsei University|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients who undergoing HIPEC cytoreductive surgery|February 2016|February 18, 2016|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02325648||30300|
NCT02251548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-296|A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia|iFCR|Dana-Farber Cancer Institute|Yes|Recruiting|October 2014|September 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251548||35988|
NCT02251561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVKK2013-01|Clinical Evaluation of Opti-Free III (FID 109182) Compared to Opti-Free Plus® in Japan|Clinical Evaluation of Opti-Free III Compared to Opti-Free Plus®||Alcon Research|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|20 Years|N/A|No|||June 2015|June 3, 2015|September 25, 2014||No||No|May 20, 2015|https://clinicaltrials.gov/show/NCT02251561||35987|
NCT02244151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMING|Evaluation of Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval|Evaluation of the Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval in IVF Cycles: A Simple Blind, Randomized Controlled Trial.|TIMING|Instituto de Investigacion Sanitaria La Fe|No|Recruiting|September 2014|September 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|176|||Female|18 Years|37 Years|No|||June 2014|March 23, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244151||36557|
NCT02314338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2014/1499|The Short Physical Performance Battery in Chronic Obstructive Pulmonary Disease (COPD)|The Short Physical Performance Battery in COPD - Possible Impact of a Pulmonary Rehabilitation Program and Relationships to Other Physical Performance Measures, Symptoms, and Quality of Life.||LHL Helse|No|Completed|September 2014|December 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|50|||Both|N/A|N/A|No|||September 2015|December 31, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02314338||31169|
NCT02315612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150029|Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies|Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|January 2019|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|1 Year|30 Years|No|||March 2016|March 19, 2016|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315612||31071|
NCT02250339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perhe14|A Prospective Observational Study of Family-based Interventions for Children With Neuropsychiatric and/or Psychiatric Disorders|Phase 2: A Prospective Observational Study of Feasibility and Tentative Effectiveness of Multi-Systemic and Multicomponent Family-Based Intervention for Families of Children With Neuropsychiatric and/or Psychiatric Disorder(s).||Social Insurance Institution, Finland|No|Active, not recruiting|December 2013|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|230|||Both|5 Years|12 Years|No|Non-Probability Sample|The LAKU family program service is provided in Helsinki, Kotka, Tampere and Oulu environs.        The Etä-LAKU intervention program is provided in Lapland and Kainuu/Ylä-Savo environs.        Families are admitted to the programs by the child mental health clinics in the respective        localities. The control group (treatment as usual) consists of children and families        attending the family therapy fund by the Hospital District of Southwest Finland/Turku        University Hospital's Child Psychiatry clinic (TYKS) and takes place in the Hospital        District of Southwest Finland environs. Potential participants (i.e. the families admitted        to the family-based intervention) will receive both oral and written information about the        study and an invitation to volunteer. Both parents (when applicable) and child are advised        to participate independently. Power analysis is utilized to ensure minimum necessary        number of study participants. Anticipated sample sizes are: n=125 (LAKU), n=72 (Etä-LAKU),        and n=33 (TAU group).|January 2016|January 25, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250339||36081|
NCT02250157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTE-01-14-US|A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies|A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies||Kinex Pharmaceuticals Inc|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250157||36095|
NCT02250170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|317-KOA-1401i|Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor|A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|October 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|20 Years|80 Years|No|||January 2016|January 27, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250170||36094|
NCT02314572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/124/13|Visual Acuity After the Combined Binocular Implantation of +2.5 Diopters and +3.0 Diopters ReSTOR Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of a ReSTOR +2.5 Diopters Intraocular Lens (ReSTOR SV25T0) in the Distance Dominant Eye, in Combination With a +3.0 Diopters ReSTOR Intraocular Lens (ReSTOR SN6AD1) in the Fellow Eye.||Charite University, Berlin, Germany|No|Completed|March 2013|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314572||31151|
NCT02325583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA14/299|Intraoral 30% Glucose Effect In Newborns|Baskent University Institutional Review Board||Baskent University|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Both|N/A|30 Days|No|||December 2014|December 25, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02325583||30305|
NCT02312583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iFightDepression|Efficacy of an Online Program for the Treatment of Mild and Moderate Depression|Efficacy the Online Program iFightDepression for the Treatment of Mild and Moderate Depression||Parc de Salut Mar|No|Not yet recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312583||31303|
NCT02242032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-321-101|Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease|A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease||Parion Sciences|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|80 Years|No|||May 2015|May 1, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242032||36720|
NCT02242045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-313-1380|Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia|A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia||Gilead Sciences|No|Active, not recruiting|October 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|September 13, 2014|No|Yes||Yes||https://clinicaltrials.gov/show/NCT02242045||36719|
NCT02242383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.485|Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension|Morning Hypertension and Monitoring of Metabolism (AWB Morgenhochdruck & Stoffwechselmonitoring)||Boehringer Ingelheim||Completed|January 2005|||October 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13248|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with essential hypertension|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242383||36693|
NCT02324673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS011-14-029|Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders|A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders||INSYS Therapeutics Inc|Yes|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|1 Year|17 Years|No|||February 2016|February 29, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324673||30375|
NCT02316769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120884|Comparison Study of the McGrath MAC Video Laryngoscope With the King Vision|Randomized Controlled Trial Comparing the McGrath MAC Video Laryngoscope With the King Vision Video Laryngoscope in Adult Patients.||Vanderbilt University||Completed|August 2012|||May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|December 12, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02316769||30982|
NCT02316782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSC-001|Bifurcation Lesion Analysis and STenting / BLAST|Bifurcation Lesion Analysis and STenting / BLAST|BLAST|Volcano Corporation|No|Completed|October 2008|December 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|195|||Both|18 Years|N/A|No|Probability Sample|Per Protocol Population All patients who met all inclusion/exclusion criteria, completed        the study intervention procedure as described in the protocol, and completed the 1-month        follow-up.        Intent to Treat Any subject randomized into the trial and there was an attempt to use the        IVUS but either side branch was not IVUS'd pre and post intervention.|December 2014|December 10, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02316782||30981|
NCT02313350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|: P130913|Intradiscal Discogel® in Resistant Sciatica|Non-inferiority Trial of Intradiscal Discogel® Versus Surgery in Sciatica Resistant to Conservative Treatment|EDIS|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2015|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2014|December 9, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313350||31244|
NCT02253251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009633|Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment|Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment||MiraKind|Yes|Recruiting|September 2014|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|15000|Samples Without DNA|DNA will be isolated from the submitted sample and kept with permission for additional      studies.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast and ovarian cancer patients and the family members of those that have the        KRAS-variant from primarily the US.|April 2015|April 17, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253251|10 Years|35857|
NCT02253264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027318|A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients|A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement||Johns Hopkins University|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253264||35856|
NCT02253277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107YDE19|Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients|A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients|CoRNea|Novartis|No|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02253277||35855|
NCT02322723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-987|Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA|Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA|ORIENT|AbbVie|No|Withdrawn|February 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|99 Years|No|Non-Probability Sample|moderately to severely active Rheumatoid Arthritis patients|February 2016|February 17, 2016|December 19, 2014||No|No enrollment|No||https://clinicaltrials.gov/show/NCT02322723||30525|
NCT02323399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1420RDP009|Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV|Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia||West-Ward Pharmaceutical|Yes|Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323399||30473|
NCT02323412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/12701|Antibiotics In Modic Changes|Antibiotic Treatment in Patients With Chronic Low Back Pain and Modic Changes: a Randomized Double-blind Placebo Controlled Trial|AIM|Oslo University Hospital|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||January 2016|January 18, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323412||30472|
NCT02326506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49011.000.14|Evaluation of Drainable Volume Measurements During VA-ELS|Evaluation of Drainable Volume Measurements and Their Usage for Predicting Optimal Cardiac Support in Patients Supported by Veno-arterial Extracorporeal Life Support||Maastricht University Medical Center|Yes|Recruiting|September 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02326506||30234|
NCT02326532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2014002 18|Incorporation of Patient Reported Outcomes Data in the Care of US Veterans With Rheumatoid Arthritis|Incorporation of Patient Reported Outcomes Data in the Care of US Veterans With Rheumatoid Arthritis|PRO|North Florida Foundation for Research and Education|Yes|Recruiting|February 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02326532||30232|
NCT02255487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRR-CT-901-2013-01|IrrSept vs. Standard of Care in Prevention of Surgical Site Infections|A Phase IV, Multicenter, Prospective, Randomized, Controlled Clinical Study to Compare the IrriSept System Versus Standard of Care on the Prevalence of Surgical Site Infection in Patients With Abdominal Trauma or Acute Surgical Abdomen||Irrimax Corporation|Yes|Recruiting|January 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255487||35685|
NCT02249923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0018|Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry|Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry|PPHNet|University of Colorado, Denver|Yes|Recruiting|October 2014|January 2018|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|21 Years|No|Non-Probability Sample|Pulmonary Hypertension (PH) is a syndrome characterized by vasoconstriction and abnormal        growth and function of endothelial and smooth muscle cells and other components within the        pulmonary vessels, which leads to elevation of the pulmonary artery pressure. PH may be        idiopathic (primary) without any known cause. Some cases of PH are familial. PH may also        be secondary to a specific disease process such as portal hypertension, congenital heart        disease, chronic lung disease, thromboembolic disease, connective tissue disease, HIV, and        use of anorexigens.|October 2015|October 8, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02249923|5 Years|36113|
NCT02253875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.84|Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers|A Single-centre, Open-label Study in Healthy Adult Volunteers to Determine the Effects of Multiple-dose Omeprazole (ANTRA® 40 mg qd) on the Single-dose Pharmacokinetics of Tipranavir 500 mg Coadministered With Ritonavir 200 mg||Boehringer Ingelheim||Completed|November 2005|||February 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253875||35809|
NCT02253888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.93|Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers|An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study Assessing Subjects Receiving Tipranavir 500 mg Stored at Controlled Temperature (Testproduct 30°C/70% RH) Compared With Tipranavir 500 mg Stored at Controlled Refrigerated Conditions (Reference Product 2-8°C), Orally Co-administered With Ritonavir 200 mg Under Fasting Conditions to Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|May 2005|||June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253888||35808|
NCT02318771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14P.524|Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer|An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer||Thomas Jefferson University|Yes|Recruiting|February 2015|||January 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318771||30828|
NCT02323737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-022|Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer|Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial||Chinese Academy of Medical Sciences|No|Completed|July 2010|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|70 Years|No|||December 2014|December 29, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323737||30447|
NCT02325505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4147/14/127|Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma|Clinical Profile Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Followed at Hospital Das Clínicas, University of Sao Paulo Medical School||InCor Heart Institute|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|The population of this study is composed of patients with TSC, LAM (sporadic or associated        with TSC) or AML (sporadic or associated with TSC or with LAM). The estimated sample size        for this study is about 200 patients, all of them followed at University of Sao Paulo        Medical School.|August 2015|August 24, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02325505|2 Years|30311|
NCT02252926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2HNC01|Local Anesthetic Treatment of Oral Pain in Patients With Mucositis|Clinical Trial With Lozenges as Local Anesthetic Treatment for Head/Neck Cancer Patients With Oral Mucositis||Hvidovre University Hospital|Yes|Recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2015|April 26, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02252926||35882|
NCT02252939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000827|Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition|Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition||Massachusetts General Hospital|No|Enrolling by invitation|September 2013|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|55 Years|N/A|No|||September 2014|September 26, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02252939||35881|
NCT02258243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2614|Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During LevulanTM-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome||Case Comprehensive Cancer Center|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3|||Both|15 Years|N/A|No|||January 2016|January 7, 2016|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258243||35477|
NCT02319083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Outcome After Coronary Artery Bypass Grafting|E-CABG: European Multicenter Study on the Outcome After Coronary Artery Bypass Grafting|E-CABG|University of Oulu|Yes|Recruiting|January 2015|December 2025|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population includes any patient undergoing isolated coronary artery bypass        surgery.|July 2015|July 3, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02319083||30804|
NCT02322866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1402|Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris||Warner Chilcott|No|Recruiting|December 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|9 Years|45 Years|No|||December 2015|December 23, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322866||30514|
NCT02316600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6991 17|Mobility Assessment & Follow-up in Frail Elderly: Clinic-technical Validation of a Smart Insole in Real Life|Mobility Assessment & Follow-up in Frail Elderly: Clinic-technical Validation of a Smart Insole in Real Life|RESPECT|University Hospital, Toulouse|No|Not yet recruiting|January 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316600||30995|
NCT02247973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-alternative donor SCT-SAA|Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.|PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia.||Guangzhou General Hospital of Guangzhou Military Command|Yes|Enrolling by invitation|February 2013|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|14 Years|50 Years|No|||September 2014|September 19, 2014|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247973||36263|
NCT02323074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK 525513|Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke|Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke||Chinese University of Hong Kong|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323074||30498|
NCT02249832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-310|The General Use of Robots in Stroke Recovery: the Anklebot|The General Use of Robots in Stroke Recovery: the Anklebot||Northwell Health|No|Recruiting|June 2013|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249832||36120|
NCT02249845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS|Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children|Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children||Medical University of Warsaw|No|Recruiting|September 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|108|||Both|1 Month|5 Years|No|Non-Probability Sample|Small children with acute diarrhoea admitted to the pediatric ward.|January 2016|January 15, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02249845||36119|
NCT02242604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1.1|Characterization of Neuropsychologic and Physical Performance in Geriatric Patients With Hyponatremia.|Phenotypic Characterization of Neuropsychologic and Physical Performance in Geriatric Patients Suffering From Hyponatremia.||University of Cologne|No|Recruiting|April 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|70 Years|N/A|No|Probability Sample|A total of 150 patients with the age of 70 years or above, that are admitted to the        Department for Geriatric Medicine of the University of Cologne, that have a serum sodium        of below 130 mmol/L on admission, and that have complete datasets that allow for        unequivocal determination of the etiologic cause of hyponatremia will be enrolled in this        study.|December 2015|December 1, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02242604||36676|
NCT02242929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50433.068.14|Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma|Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial|SCIN|Maastricht University Medical Center|Yes|Recruiting|January 2016|January 2021|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242929||36651|
NCT02324725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814234|Biomarkers of Injectable Extended Release Naltrexone Treatment|Biomarkers of Disease and Response to Treatment in Opioid Addiction||University of Pennsylvania|Yes|Enrolling by invitation|October 2011|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|55 Years|No|||January 2016|January 26, 2016|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324725||30371|
NCT02312258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16021|A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|April 2015|July 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|761|||Both|18 Years|N/A|No|||July 2015|July 26, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312258||31328|
NCT02313584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anam6394|Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk|||Korea University||Not yet recruiting|December 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|464|||Both|18 Years|80 Years|No|||December 2014|December 9, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313584||31226|
NCT02313597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1|VAAFT Vs SETON in the Management of High Peri Anal Fistula|Comparison of Post Operative Outcome of VAAFT vs SETON Tightening in the Management of High Perianal Fistula||Services Hospital, Lahore|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|60 Years|No|||January 2016|January 29, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02313597||31225|
NCT02245477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 5|Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction|Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction|VEGF in FGR|Beni-Suef University|Yes|Recruiting|September 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|20 Years|40 Years|No|Non-Probability Sample|Patients with gestational age 28-36 weeks were included in our study. Patients with SGA        were defined by obstetric ultrasound as estimated fetal weight was below        the10thcentile.Twice weekly CTGs and Umbilical artery (UA) Doppler were done. Women with        abnormal CTGs or UA Doppler were excluded from the study. A follow up scan was done 2        weeks later and FGR will be diagnosed if fetal weight had faltered.|December 2015|December 26, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245477||36455|
NCT02253901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.10|Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers|Study of Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir||Boehringer Ingelheim||Completed|March 2005|||May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253901||35807|
NCT02253914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.2|Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers|An Investigator Blinded, Randomized, Placebo-controlled Multiple Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers||Boehringer Ingelheim||Completed|February 2004|||December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|100|||Male|18 Years|59 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253914||35806|
NCT02326727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0095-14-HYMC|Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2015|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02326727||30217|
NCT02322853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLYMPE / 2013-005084-29|A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors|A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors|OLYMPE|Centre Francois Baclesse|Yes|Suspended|January 2015|December 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02322853||30515|
NCT02325518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALJ-P2014-1|Comparison of IOP (Intraocular Pressure)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution|The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension||Alcon Research|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|218|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325518||30310|
NCT02312310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7034|Dietary Flavanols and Dentate Gyrus Function|Dietary Cocoa Flavanols and Age-Related Memory Decline||New York State Psychiatric Institute|No|Recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|260|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312310||31324|
NCT02241161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2913|Short Term Evaluation of the Soothing and Re-epithelizing Activity of Three Topical Products and Relative Combinations|Short Term Evaluation of the Soothing and Re-epithelizing Activity of Three Topical Products and Relative Combinations||Derming SRL|Yes|Completed|December 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|September 12, 2014|July 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02241161||36787|
NCT02245503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.40|Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)|Comorbidity and Comedication During Prescription of ALNA® (Tamsulosin) for Patients With BPH (Benign Prostatic Hyperplasia)||Boehringer Ingelheim||Completed|May 2003|||October 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7391|||Male|N/A|N/A|No|Non-Probability Sample|Patients with BPH recruited at urologist offices|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245503||36453|
NCT02240979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI-10Pico-1|Establishing a Non-invasive Method to Measure Your Heart's Performance|Establishing a Non-invasive Method to Measure Heart Performance||Huntington Medical Research Institutes|No|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with normal and abnormal cardiac function will be studied.|August 2015|August 17, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02240979||36801|
NCT02322879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000070|Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing|Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing|APAPII|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|May 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02322879||30513|
NCT02311140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKJ-IVA-Nasal|Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms|Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms|KPNSI|University of Jena|No|Recruiting|July 2012|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Nasal lavage|Both|6 Years|N/A|No|Non-Probability Sample|CF patients with G551D mutation receiving Kalydeco|January 2016|January 19, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311140||31414|
NCT02325531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL120894-01|SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET|SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET|SPREAD-NET|Kaiser Permanente|No|Active, not recruiting|September 2014|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|20000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02325531||30309|
NCT02325544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP 136836|Comparing Different Treatments in Reducing Dissociative Seizure Occurrence|COgnitive Behavioural Therapy Versus Standardised Medical Care for Adults With Dissociative Non-Epileptic Seizures: A Multicentre Randomised Controlled Trial (CODES)|CODES|King's College London|Yes|Recruiting|October 2014|July 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|298|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02325544||30308|
NCT02251990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-067|Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)|A Phase III Randomized Multinational Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT 1, GT 4 and GT 6 Infection||Merck Sharp & Dohme Corp.|No|Recruiting|January 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|453|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251990||35954|
NCT02252003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.811|Development and Validation of a New Pain Scale for Children|Development of a New Pain Rating Scale for Children and Validation Against Criteria by Comparison With Faces Pain Scale - Revised (FPS-R) and Visual Analogue Scale (VAS)|NOUNOURS|Hospices Civils de Lyon|No|Not yet recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|248|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02252003||35953|
NCT02313688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH-GC-02|Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors|The Relationship Between the Length of the Proximal Resection Margin and Long-term Survival for Adenocarcinomas of the Esophagogastric Junction (Siewert-II/Siewert-III)- Randomized Controlled Trial||West China Hospital|Yes|Not yet recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|75 Years|No|||December 2014|December 9, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313688||31218|
NCT02313701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000273|Effect of Standardized Consent for Urogynecological Procedures on Patient Satisfaction|Effect of Standardized Consent for Urogynecological Procedures on Patient Satisfaction||Beth Israel Deaconess Medical Center||Recruiting|December 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|6||Anticipated|96|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 8, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02313701||31217|
NCT02314000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4046|Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude|WHISPER - A Randomized Controlled Study to Evaluate the Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude|WHISPER|Boston Scientific Corporation|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|22 Years|N/A|No|||December 2015|December 3, 2015|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02314000||31195|
NCT02252146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8400-402|Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation|Phase I/II Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Presence of the MyD88 L265P Mutation||Idera Pharmaceuticals, Inc.|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252146||35942|
NCT02248285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-SDY-019839|Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study|Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study|IMPACT|BioFire Diagnostics, LLC|No|Recruiting|April 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1500|||Both|N/A|18 Years|No|||February 2016|February 10, 2016|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248285||36239|
NCT02314546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|994|Intranasal Midazolam in Children as a Pre-Operative Sedative|Intranasal Midazolam in Children as a Pre-Operative Sedative||Bassett Healthcare|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|18 Months|7 Years|No|||June 2015|June 25, 2015|December 3, 2014|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT02314546||31153|Limitations in the number of providers and eligible patients during the two-year study period.
NCT02317029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38281|Comparison of Oxygen Interventions and Defibrillator Efficiency|A Comparison of Two Biphasic Waveforms and Impact of Oxygen on Myocardial Injury Following Cardioversion|CODE|Randers Regional Hospital|Yes|Terminated|September 2013|January 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|134|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 18, 2014||No|A major adverse event occured (pulsed biphasic waveform arm).|No||https://clinicaltrials.gov/show/NCT02317029||30962|
NCT02317042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA250814|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2015|||||N/A|N/A|N/A||||||||||||||August 9, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317042||30961|
NCT02317055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00917-38|Magnetic Resonance Imaging Evaluation of the Tissular Oxygen Saturation in Brain||GADOXY|University Hospital, Grenoble|No|Recruiting|June 2014|June 2017|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317055||30960|
NCT02324296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEI 01|PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases|PEI REGIMEN: A THERAPEUTIC OPTION IN SMALL CELL LUNG CANCER? A MONOINSTITUTIONAL EXPERIENCE OF 46 CONSECUTIVE CASES||Arcispedale Santa Maria Nuova-IRCCS||Completed|December 1998|December 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|46|||Both|18 Years|75 Years|No|Non-Probability Sample|All eligible patients had histologically or cytologically proven SCLC, with measurable        disease defined by RECIST criteria, and received at least one cycle of chemotherapy.        Patients with central nervous system (CNS) metastases were included in the study.|December 2014|December 19, 2014|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324296||30404|
NCT02324309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-151|BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance|A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin® R U-500 and Humalog® Mix75/25™ in Subjects With Type 2 DM Who Are Treated With ≥ 150 Units of Insulin Per Day||Biodel|No|Completed|May 2014|||November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324309||30403|
NCT02250105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-3037MO-004|Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia|||Arisaph Pharmaceuticals Inc|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250105||36099|
NCT02252640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC059|A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S|A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone||University of Oxford|Yes|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252640||35904|
NCT02240732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STCE2.0|Surgical Tourniquets and Cerebral Emboli|Surgical Tourniquets and Cerebral Emboli Pilot Study||University Hospitals Coventry and Warwickshire NHS Trust|Yes|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who are due to have a total knee replacement.|June 2015|June 28, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02240732||36820|
NCT02310880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X100716003|Efficacy of Enhancing Low Vision Mobility Thru Visual Training in Virtual World|Efficacy of Enhancing Low Vision Mobility Thru Visual Training in Virtual World||University of Alabama at Birmingham|No|Completed|September 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|35|||Both|19 Years|81 Years|No|Non-Probability Sample|Low vision participants will be recruited from the patient populations of the Clinics of        UAB School of Optometry and UAB Center for Low Vision Rehabilitation|December 2014|May 25, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310880||31434|
NCT02312570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC004|Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Chronic Non-Healing Pressure Ulcers|A Prospective, Randomized Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Chronic Non-Healing Pressure Ulcers||PRP Concepts, LLC|No|Not yet recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312570||31304|
NCT02245828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQCC374X2101|A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374|A Randomized, Double-blind, Placebo-controlled First-in-human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374 in Healthy Subjects||Novartis|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 20, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02245828||36428|
NCT02245256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407-114-596|Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients|Perioperative Low-dose Dexmedetomidine Decreases Incidence of Delirium in Liver Transplant Patients||Seoul National University Hospital|No|Recruiting|September 2014|July 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|100 Years|No|||November 2015|November 20, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02245256||36472|
NCT02245269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.21|Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers|A Two-way Pharmacokinetic Interaction Study of Single-Dose Atorvastatin (LIPITOR®) With Tipranavir/Ritonavir (500mg/200mg) at Steady-State and the Effect of Antacid (MAALOX®) on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir (500mg/200mg) in Healthy Volunteers||Boehringer Ingelheim||Completed|July 2003|||October 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245269||36471|
NCT02249065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US 10305|Mirvaso in Use Study|MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)||Galderma Laboratories, L.P.|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249065||36179|
NCT02311153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141421|Safety and Efficacy of Laryngeal Mask Airways in Sinonasal Surgery|Safety and Efficacy of Laryngeal Mask Airways in Sinonasal Surgery||Vanderbilt University|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02311153||31413|
NCT02326428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITS Open|SITS (Safe Implementation of Treatments in Stroke) Open Artery by Thrombectomy in Acute Occlusive Stroke Study|SITS Open Artery by Thrombectomy in Acute Occlusive Stroke Study: an Open Prospective International Multicentre Controlled Study of Safety and Efficacy of Thrombectomy in Acute Occlusive Stroke Following IV Thrombolysis With Alteplase|SITS Open|Karolinska Institutet|Yes|Recruiting|March 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02326428||30240|
NCT02257645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VFOS001|Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks|A Multicenter, Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization Against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza Type B in Infants||LG Life Sciences|No|Not yet recruiting|March 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|6 Weeks|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infant from 6 weeks of age.who is given this vaccine for active primary immunization        against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B|October 2014|October 5, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257645||35522|
NCT02318498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2 Study on Diagnosis Made by Cardiac MRI|Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2|SMINC-2|Karolinska Institutet|No|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|35 Years|69 Years|No|||February 2016|February 23, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02318498||30849|
NCT02318511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2014-10-04|An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis|An Investigation of ReNu™ Knee Injection: Monitoring the Response of Knee Function and Pain in Patients With Osteoarthritis||NuCel, LLC||Recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318511||30848|
NCT02324010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140916|Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes|Effects of Sitagliptin on Postprandial Glycaemia, Incretin Hormones and Blood Pressure in Type 2 Diabetes - Relationship to Gastric Emptying||Royal Adelaide Hospital|No|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||October 2015|October 27, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02324010||30426|
NCT02324023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-075|Endoscopic Ultrasound and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers|Endoscopic Ultrasound Scanning and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers||Roskilde County Hospital|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|74|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02324023||30425|
NCT02240875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBL01|A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo|A Phase Ia, Dose-Escalating, Safety and Immunogenicity Trial of the Monovalent Zaire Ebola Viral Vector Candidate Vaccine cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen cAd3-EBO Z and MVA-BN® Filo in Healthy UK Adults||University of Oxford|Yes|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|13||Anticipated|92|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240875||36809|
NCT02240888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/341|Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections||Vaccimil|Region Skane|No|Recruiting|October 2011|||November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 15, 2014|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02240888||36808|
NCT02252211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2014-002|Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers|A Phase I Safety and Bioimaging Trial of DS-8895a in Patients With Advanced or Metastatic EphA2 Positive Cancers|LUD2014-002|Ludwig Institute for Cancer Research|No|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02252211||35937|
NCT02252224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690L00018|Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance|Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea||AstraZeneca|No|Recruiting|September 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients with type 2 diabetes mellitus who are initiating Forxiga|March 2016|March 21, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252224||35936|
NCT02318745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070334|Preventing Health Disparities in Hispanic Youth|Preventing Health Disparities in Hispanic Youth|CIFFTA-P|University of Miami|No|Completed|June 2007|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02318745||30830|
NCT02323165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401005|A New Method for Detection of Bacteria in the Bloodstream|A New Method for Detection of Bacteria in the Bloodstream||University of Florida|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Identification of potential patients will take place during normal medical care of burn        and wound patients admitted to the Burn Intensive Care Unit.|January 2016|January 28, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323165||30491|
NCT02323178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-LMMC-Eltrombopag|A Study of Eltrombopag in Patients With CMML and Thrombocytopenia|A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia||Groupe Francophone des Myelodysplasies|Yes|Recruiting|May 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|May 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02323178||30490|
NCT02311192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|583-14|Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography|Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography||University of Nebraska|No|Not yet recruiting|February 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|170|||Both|19 Years|90 Years|No|||November 2015|November 30, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311192||31410|
NCT02315391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.06.NRC|Protein Nutrition for Muscle Hypertrophy in Older Adults|Efficacy of Isolated Whey and Micellar Whey Protein (+/- Citrulline) to Stimulate Protein Synthesis in 'Healthy' and 'Anabolically Resistant' Elderly Muscle||Nestlé|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||November 2014|December 17, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02315391||31088|
NCT02252653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR-NT-002|DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis|DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis||Alnylam Pharmaceuticals|No|Active, not recruiting|June 2014|March 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1010|Samples Without DNA|Blood samples for TTR sequencing and cardiac function biomarkers; abdominal fat-pad aspirate      for amyloid presence (optional for TTR positive patients only)|Both|18 Years|N/A|No|Non-Probability Sample|Subjects Suspected of Having Familial Amyloidotic Cardiomyopathy (FAC)|February 2016|February 12, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02252653||35903|
NCT02240927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOSUYOLU1|Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves|Comparison of Different Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves: A Randomized Clinical Trial||Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|No|Recruiting|January 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|45 Years|No|||September 2014|September 15, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02240927||36805|
NCT02245009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKK-SEED-2014|Safety of External Electrocardioversion in Device Patients|Safety of External Electrocardioversion in Device Patients - the SEED Registry|SEED|Universitätsklinikum Köln|Yes|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|All patients with implanted cardiac rhythm devices (pacemakers, ICD and CRT)|July 2015|July 30, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02245009|2 Weeks|36491|
NCT02245243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-3341-112|Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment|An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment||Melinta Therapeutics, Inc.|Yes|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245243||36473|
NCT02318303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPL/CT/2014/004/II|To Study GSP 301 in Patients With Seasonal Allergic Rhinitis|A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) and With Seasonal Allergic Rhinitis (SAR)||Glenmark Pharmaceuticals Ltd. India|No|Completed|December 2014|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|1106|||Both|12 Years|N/A|No|||May 2015|May 15, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318303||30864|
NCT02323282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yu Shan|The Study of Ropivacaine Median Effective Concentration in Ultrasound-guided Supraclavicular Brachial Plexus Block|The Study of Ropivacaine Median Effective Concentration in Ultrasound-guided Supraclavicular Brachial Plexus Block||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||Recruiting|October 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2014|December 18, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02323282||30482|
NCT02316366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00295|The Use of Warmed Saline in Vaso-occlusive Episodes|Clinical Impact of Warmed Intravenous Saline in Sickle Cell Patients With Vaso-Occlusive Episodes||Nationwide Children's Hospital|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|4 Years|21 Years|No|||July 2015|July 31, 2015|December 10, 2014||No||No|July 31, 2015|https://clinicaltrials.gov/show/NCT02316366||31013|
NCT02250118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC2014-02|Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer|Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer|BEVAP|Institut Curie|Yes|Not yet recruiting|December 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02250118||36098|
NCT02249078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6011-A001-102|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease|A Multicenter, Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease||Eisai Inc.|No|Withdrawn|December 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249078||36178|
NCT02249091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIL|A Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML|An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML||GSO Global Clinical Research BV|No|Recruiting|September 2014|April 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02249091||36177|
NCT02256709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1214.1|Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers|Safety, Tolerability and Pharmacokinetics of BIBP 5371 CL Following Oral Administration to Healthy Male and Female Volunteers (Dose Range: 10 - 350 mg). A Double-blind (Within Treatment Groups), Randomised, Placebo-controlled, Single Rising Dose Study, Including Comparisons of 50 mg vs. 100 mg Tablet and Tablet vs. Drinking Solution, and Investigation of Food Effect||Boehringer Ingelheim||Completed|April 2004|||August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|70|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256709||35592|
NCT02313090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-IOR-14005515|Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control|Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control||First Affiliated Hospital of Zhejiang University|No|Completed|January 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 7, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02313090||31264|
NCT02243579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00709|Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome|A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome||National Cancer Institute (NCI)||Active, not recruiting|October 2014|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243579||36601|
NCT02324621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051407|Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors|A Continuation Clinical Trial of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors||Rutgers, The State University of New Jersey|No|Recruiting|February 2015|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324621||30379|
NCT02324634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14110|Early Electrical Stimulation to Prevent Complications in the Arm Post-stroke - a Feasibility Study|Early Electrical Stimulation to the Wrist Extensors and Wrist Flexors to Prevent the Post-stroke Complications of Pain and Contractures in the Paretic Arm - a Feasibility Study|ESCAPS|University of Nottingham|No|Recruiting|June 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02324634||30378|
NCT02324036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1442|The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence|The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence|EMPATHy|University of California, Irvine|No|Completed|December 2014|August 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|190|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02324036||30424|
NCT02312271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.01.US.HCN|Enteral Formula Tolerance of Standard Tube Feedings|||Nestlé||Recruiting|December 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with established enteral access receiving standard tube feeding formula|July 2015|October 6, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312271||31327|
NCT02257723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2012-03|The Effect of Integrated CAM Treatment in Hospitalized Patients|The Effect of Integrated CAM Treatment in Patients Hospitalized at a Korean Medicine Hospital||Jaseng Hospital of Korean Medicine|Yes|Completed|January 2012|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2946|||Both|N/A|N/A|No|Non-Probability Sample|Musculoskeletal patients admitted to an integrated hospital that offers both complementary        and alternative medicine (CAM) and conventional medicine treatment.|January 2015|January 8, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257723||35516|
NCT02324686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8200|Vitamin K Supplementation in Patients on Hemodialysis|Vitamin K Supplementation to Improve INR Stability in Patients on Hemodialysis Taking Warfarin for Atrial Fibrillation|VISTA|University Health Network, Toronto|No|Recruiting|January 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324686||30374|
NCT02326025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15676|A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma|An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin Following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients With Advanced Soft Tissue Sarcoma||Eli Lilly and Company|No|Active, not recruiting|January 2015|April 2017|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326025||30271|
NCT02326038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14T111|Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study|Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study||Maastricht University Medical Center|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|80 Years|No|||December 2014|December 24, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326038||30270|
NCT02321657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELAX2015|RELAX Anaesthetics: the Effect of a Bespoke Relaxation App on Stress Levels in Children Undergoing Anaesthesia|RELAX Anaesthetics: the Effect of a Bespoke Relaxation App on Stress Levels in Children Undergoing Anaesthesia|RELAX-A|Royal College of Music|No|Completed|March 2015|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|2 Years|16 Years|No|||October 2015|October 26, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02321657||30607|
NCT02248779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-202|Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation|Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation: A Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples Without DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Childhood cancer survivors followed by the Pediatric Long-Term Follow-Up Program or Adult        Long-Term Follow-Up Program will be recruited for the current study.|September 2015|September 17, 2015|September 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02248779||36201|
NCT02248792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCHDer|Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.|Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.||Narayana Medical College & Hospital|No|Recruiting|November 2013|||January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||September 2014|September 22, 2014|September 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248792||36200|
NCT02253940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.33|Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers|An Open-label, Randomized, Crossover Relative BA Study of Pharmacokinetics and Safety of New SDS-containing Tablet and Capsule Formulations of BILR 355 Compared to the Current Formulation (50 mg Tablet), After Single Dose Oral Administration of BILR 355 Plus Low Dose Ritonavir in Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253940||35804|
NCT02323295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-208|Effect of High Doses of Radiation on Bone Structure and Metabolism|Pilot Study of the Effect of High Doses of Radiation on Bone Metabolism and Structure in Patients Treated With Adjuvant Radiotherapy and Surgery for Sacral Tumors||Massachusetts General Hospital|Yes|Recruiting|July 2015|July 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323295||30481|
NCT02325167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|545-12|Short-term Existential Behavioural Therapy for Informal Caregivers of Palliative Patients: a Randomised Controlled Trial|Short-term Existential Behavioural Therapy for Informal Caregivers of Palliative Patients: a Randomised Controlled Trial||Ludwig-Maximilians - University of Munich|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|21 Years|N/A|No|||December 2015|December 22, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325167||30337|
NCT02326402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THEME|TandemHeart Experiences and MEthods (THEME Registry)|THEME Registry: TandemHeart Experiences and MEthods (THEME Registry)|THEME|CardiacAssist, Inc.|No|Recruiting|December 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Consented patients in whom the TandemHeart has been inserted percutaneously (e.g. in the        cath lab or peri-operatively) for any diagnosis/condition at an institution participating        in the THEME Registry (or transferred to an institution participating in the THEME        Registry following insertion).|March 2016|March 3, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02326402||30242|
NCT02253082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPER-OCTA|Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)|Effects of OctaplasLG® on Endothelial Integrity in Patients Undergoing Emergency Surgery for Thoracic Aortic Dissections - a Randomized, Controlled, Single-blinded Investigator-initiated Pilot Trial|VIPER-OCTA|Rigshospitalet, Denmark|Yes|Recruiting|November 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253082||35870|
NCT02253095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-zinc-alb-micronut|Combined Package of Interventions for Environmental Enteropathy|Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children||Washington University School of Medicine|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||June 2015|June 2, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02253095||35869|
NCT02256722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207.26|In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects|A Randomised, Open Label, Four-way Crossover Phase I Trial to Investigate the in Vivo Specificity of a Single Oral Dose of 320 mg KUC 7483 CL Co-administered With Bisoprolol (10 mg Daily), Propranolol (160 mg Daily), and Acipimox (500 mg Daily) Over 5 Days and a Single Inhalative Dose of 100 μg Salmeterol in Healthy Male Subjects||Boehringer Ingelheim||Completed|October 2005|||November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|12|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256722||35591|
NCT02256813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.10|Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers|A Study to Evaluate the Effect of Multiple Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan Dosed Orally and Midazolam Dosed IV, in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2005|||December 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256813||35584|
NCT02256826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.8|Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects|Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir||Boehringer Ingelheim||Completed|April 2005|||June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256826||35583|
NCT02314819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-013-00CH1|A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)|A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed Two Lines of Chemotherapies|FRESCO|Hutchison Medipharma Limited|Yes|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||March 2016|March 13, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314819||31132|
NCT02314832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820115|Risk of Falling After CFNB Versus ACB|Comparison Between the Risk Falls After Total Knee Arthroplasty With Use of Femoral Nerve Block Versus Adductor Canal Block||University of Pennsylvania|Yes|Completed|September 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02314832||31131|
NCT02249273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-CARE-001|Diagnostic Tools in Patients With a Suspected Urinary Tract Infection in Primary Care|Diagnostic Process in Patients With a Suspected Urinary Trcat Infection in Danish Primary Care: Impact on Appropriate Use of Antibiotics and Patient's Recovery.||University of Copenhagen|No|Not yet recruiting|December 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|Urine sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients >0 18 years old attending primary care services during offcie hours with a        suspected urinary tract infection|September 2014|September 22, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02249273||36163|
NCT02247700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00013295|An Observational Cohort Study of Distribution of Ventilation in Infants and Children Requiring Mechanical Ventilation by Electrical Impedance Tomography|An Observational Cohort Study of Distribution of Ventilation in Infants and Children Requiring Mechanical Ventilation by Electrical Impedance Tomography|EIT|Children's Hospital Boston|No|Recruiting|October 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|17 Years|No|Non-Probability Sample|In a prospective observational trial we will objectively measure regional distribution of        ventilation by EIT in patients who require mechanical ventilation.|August 2015|August 24, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02247700||36284|
NCT02310854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL5011604414|Acute Anterior Cruciate Ligament Rupture; RecOnsTruction Or Repair?|Acute Anterior Cruciate Ligament Rupture; RecOnsTruction Or Repair?|ROTOR|Orthopedisch Centrum Oost Nederland|Yes|Active, not recruiting|December 2014|March 2026|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|30 Years|No|||March 2016|March 7, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310854||31436|
NCT02312518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC003|Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Chronic Non-Healing Venous Leg Ulcers|A Prospective, Randomized Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Chronic Non-Healing Venous Leg Ulcers||PRP Concepts, LLC|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312518||31308|
NCT02245152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFPRI-2014-001|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Burkina Faso: a Cluster Randomized Intervention Study|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Burkina Faso: a Cluster Randomized Intervention Study|PROMIS-BF|International Food Policy Research Institute|No|Recruiting|October 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2400|||Both|N/A|17 Months|Accepts Healthy Volunteers|||February 2016|March 4, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245152||36480|
NCT02245464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.479|Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension|The Post Marketing Surveillance Study Conducted With a Continuous Enrollment Method to Assess Serious Adverse Events, Adverse Events, Safety, Efficacy of Micardis Tablet (Telmisartan 20, 40, 80mg p.o. Once Daily Over 2 Weeks)||Boehringer Ingelheim||Completed|November 2000|||November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13066|||Both|N/A|N/A|No|Non-Probability Sample|Patients with essential hypertension and without prior Micardis experience|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245464||36456|
NCT02243839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOSUYOLU3|Thrombolytic Therapy Versus Surgery for Obstructive Prosthetic Valve Thrombosis|Thrombolytic Therapy Versus Surgery for Obstructive Prosthetic Valve Thrombosis: A Randomized Multicenter Study||Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|No|Recruiting|January 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||September 2014|September 16, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02243839||36581|
NCT02244138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308038999|Improving Adolescent Health Outcomes Through Preventive Care Transformation|Improving Adolescent Health Outcomes Through Preventive Care Transformation|AdolCHICA|Indiana University|No|Recruiting|September 2014|September 2016|Anticipated|October 2015|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2831|||Both|12 Years|21 Years|No|Non-Probability Sample|Adolescent from primary care clinics will be studied|April 2015|April 22, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02244138||36558|
NCT02311114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30158|Program Evaluation of Telehomecare: TeLeCare Study|Program Evaluation of Telehomecare for Patients With Heart Failure or Chronic Obstructive Pulmonary Disease: TeLeCare (TLC) Study|TLC|University of Toronto|No|Active, not recruiting|June 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|N/A||4|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health care providers, technicians, administrators/decision makers and patients enrolled        in the Telehomecare Program.|May 2015|May 7, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02311114||31416|
NCT02312531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX10002007-001-001 -1|Prevention for Mother-to-infant Transmission of HBV|HBIG for Prevention of Mother-to-infant HBV Transmission||Xi’an Jiaotong University College of Medicine|Yes|Completed|May 2012|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Female|N/A|N/A|No|||December 2014|December 8, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02312531||31307|
NCT02325466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1925|Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes|Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease (PAD) Patients With Type 2 Diabetes (T2D)||Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325466||30314|
NCT02244957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD140959|Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA|Right Ventricular Hemodynamics Using Cardiac Magnetic Resonance Imaging in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA)||University of California, San Diego|No|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||May 2015|May 27, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244957||36495|
NCT02245178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00090966|Lung Function Decline and Disease Risk From Young Adulthood to Middle Age|Lung Function Decline and Disease Risk From Young Adulthood to Middle Age|CARDIA Lung|Northwestern University|Yes|Enrolling by invitation|June 2015|August 2019|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|||Both|48 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the main Coronary Artery Risk Development in Young Adults (CARDIA) cohort        study attending the year 30 examination|April 2015|April 13, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245178||36478|
NCT02245490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.30|Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms|BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms||Boehringer Ingelheim||Completed|January 2003|||April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|153|||Male|50 Years|80 Years|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245490||36454|
NCT02253953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.4|Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers|An Open Study to Investigate the Effect of Two Times Oral 100 mg Ritonavir Capsules on Pharmacokinetics of Single Doses of BILR 355 BS (Dose Steps: 5 and 12.5 mg) Dissolved in 5 mL PEG 400 After Oral Administration in Healthy Male Volunteers, and a Double Blind, Placebo Controlled Study for Doses From 25 mg to 100 mg BILR 355 BS||Boehringer Ingelheim||Completed|November 2002|||December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|10||Actual|62|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02253953||35803|
NCT02256696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#FD-R-004794-01|Assessing PA-824 for Tuberculosis (the APT Trial)|A Phase 2 Randomized, Open-Label Trial of PA-824-Containing Regimens Versus Standard Treatment for Drug-Sensitive Sputum Smear-Positive Pulmonary Tuberculosis||Johns Hopkins University|Yes|Suspended|April 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|183|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 25, 2014|Yes|Yes|partial clinical hold by FDA|No||https://clinicaltrials.gov/show/NCT02256696||35593|
NCT02311374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150031|Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness|Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|March 2021|Anticipated|April 2019|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|83|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|January 29, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311374||31396|
NCT02311634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12401904600|A Comparison of Electrical Pudendal Nerve Stimulation and Transvaginal Electrical Stimulation for Urge Incontinence|A Comparison of Efficacies of Electrical Pudendal Nerve Stimulation Versus Transvaginal Electrical Stimulation in Treating Urge Incontinence||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Recruiting|December 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|25 Years|85 Years|No|||June 2015|August 24, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02311634||31376|
NCT02326415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUVA-CPA-JAC|Clinical Pathway With "Fast-Track" In Uncomplicated Acute Appendicitis|Prospective Randomised Study Comparing Clinical Pathway With "Fast-Track" Versus Usual Protocol In Uncomplicated Acute Appendicitis|CLIPUA|Hospital Universitario Virgen de la Arrixaca|Yes|Recruiting|May 2013|December 2016|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||December 2014|December 26, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02326415||30241|
NCT02312856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-0014|Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction|Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and|ANSWER|Pulsar Vascular|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312856||31282|
NCT02241447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPULSE|Quality of Care in AS IMPULSE Study|Study to Improve Outcomes in Aortic Stenosis. International, Multi-center, Prospective, Observation and Interventional Cohort Study|IMPULSE|Institut für Pharmakologie und Präventive Medizin|No|Recruiting|August 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02241447||36765|
NCT02242019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_TFRS_004|Study of Erchonia Low Level Laser Light Therapy to Treat Toenail Fungus|An Evaluation of the Effect of the Erchonia LUNULA on Treating Toenail Onychomycosis||Erchonia Corporation|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|N/A|No|||July 2015|July 12, 2015|September 12, 2014|Yes|Yes||No|July 8, 2015|https://clinicaltrials.gov/show/NCT02242019||36721|
NCT02241499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBG01|Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.|Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.|PALAESTRA|Lund University Hospital|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02241499||36761|
NCT02318550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-68|Safety of MRI for Patients With Non-MRI Conditional Pacemakers and ICD Non-MRI Conditional Pacemakers and ICD|A Single Institution Registry Trial Evaluating the Safety of MRI for Patients With Non-MRI Conditional Pacemakers and ICD||Lancaster General Hospital|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient with any commercially available pacemaker or ICD system implanted after 2001        who meet all of the inclusion criteria and none of the exclusion criteria, and who require        a non-cardiac, medically-indicated MRI as described above will be eligible to enroll in        the study.|May 2015|May 18, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02318550|6 Months|30845|
NCT02251925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-019|Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles|Comparison of Pregnancy Outcomes in Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles: a Randomized Controlled Trial||Royan Institute|Yes|Recruiting|September 2012|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|460|||Both|20 Years|37 Years|No|||April 2012|May 5, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02251925||35959|
NCT02251769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.11|Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir|A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r (500 mg/200 mg) on the Steady-state Pharmacokinetics of Clarithromycin (BIAXIN®) 500 mg Bid and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir||Boehringer Ingelheim||Completed|August 2003|||September 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251769||35971|
NCT02251782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPR 0026|Adherence to Minimally Invasive Testing|Adherence to Minimally Invasive CRC Screening In Non-Adherent Patients Who Have Not Completed Colorectal Cancer Screening|ADMIT|Epigenomics, Inc|No|Completed|October 2014|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|490|||Both|50 Years|76 Years|Accepts Healthy Volunteers|Probability Sample|The study population will encompass users of outpatient primary care clinics of one or        more health care systems who are considered to be at average-risk for developing        colorectal cancer (CRC), have not completed standard screening options, and are not        up-to-date with a screening program. Such health care systems may include large healthcare        networks with relatively stable patient bases such as Geisinger Health Systems (Danville,        PA), Kaiser Permanente (Portland, OR).|June 2015|June 29, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251782||35970|
NCT02315313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10153|The Link Between the Clinical Resting Heart Rate and Sympathetic Overactivation|||Ruijin Hospital|No|Not yet recruiting|December 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||4|Anticipated|1000|||Both|20 Years|80 Years|No|Non-Probability Sample|cardiovascular disease patient|December 2014|December 8, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02315313||31094|
NCT02315326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-184|Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)|A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|December 2014|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315326||31093|
NCT02321124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hacettepe University|Connective Tissue Manipulation Improves Symptoms and Quality of Life in Patients With Chronic Constipation|||Hacettepe University||Recruiting|August 2012|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2014|December 19, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02321124||30648|
NCT02249286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC-HFP|Integrating Nutrition Education & Household Food Production for Child Nutrition|Child-Centred Counselling and Home-Based Food Production to Improve Dietary Adequacy and Growth of Young Children in Southwest Ethiopia||Jimma University|No|Completed|January 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|404|||Both|3 Months|12 Months|No|||March 2016|March 4, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02249286||36162|
NCT02249299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMA-C|Experimental Medicine in ADHD - Cannabinoids|The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit/Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids)|EMA-C|King's College London|No|Recruiting|August 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|55 Years|No|||September 2014|September 23, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02249299||36161|
NCT02247986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140193|Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder|Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|0|||Both|10 Years|17 Years|No|||May 2015|May 19, 2015|September 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247986||36262|
NCT02315547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRD-20141208-GWJ|Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis|Guangzhou Institute of Respiratory Disease|BISER-2|Guangzhou Institute of Respiratory Disease|No|Recruiting|January 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02315547||31076|
NCT02312011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 598769-CS2|A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1|A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1||Ionis Pharmaceuticals, Inc.|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|55 Years|No|||January 2016|January 8, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312011||31347|
NCT02312297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237_MINOC_08|Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratories, USA (A Subsidiary of Ranbaxy Pharmaceuticals Inc. USA) With SolodynTM Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of AAI Pharma, Inc. in Healthy, Adult, Male, Human Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|September 2008|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312297||31325|
NCT02249884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCradiodermatitis|Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis|Use of Chamomilla Recutita Gel and Urea Cream to Prevent and Treat Radiodermatitis: Phase 2 Study|DRCPTR|University of Brasilia|No|Completed|February 2014|November 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|6||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02249884||36116|
NCT02241239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0901-1|A Comparison of the Estimates of Fuwai and Reynolds Risk Model|A Comparison of the Estimates of Fuwai and Reynolds Risk Model||Wuhan Asia Heart Hospital|Yes|Recruiting|August 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|adults without coronary heart disease|August 2014|November 5, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02241239||36781|
NCT02241252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU_IRB_3237|Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients|Clinical Validation of an iPhone ECG System, QT Substudy||University of Oklahoma|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02241252||36780|
NCT02316327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT|Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab|Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|July 2013|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02316327||31016|
NCT02313077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106478|A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults||Crucell Holland BV|Yes|Active, not recruiting|December 2014|March 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|87|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313077||31265|
NCT02247687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 161 L-Vir|Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)|Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Terminated|December 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 9, 2014||No|Low recruitment of participants for the study|No||https://clinicaltrials.gov/show/NCT02247687||36285|
NCT02322372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/06/2014|Femoral Blockade and Low-dose Spinal Anesthesia in Outpatient Knee Arthroscopy|Comparison of Conventional Dose Spinal Anesthesia With Low-dose Spinal Anesthesia and Femoral Blockade Combination in Outpatient Knee Arthroscopy||Ankara University|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|65 Years|No|||February 2015|February 15, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02322372||30552|
NCT02323360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315|A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC|A Randomised Phase III Trial on Stereotactic Body Radiotherapy (SBRT) After Incomplete Transcatheter Arterial Embolization (TAE) or Chemoembolization (TACE) Versus Exclusive TAE or TACE for Inoperable Hepatocellular Carcinoma (HCC)||Istituto Clinico Humanitas|No|Recruiting|November 2014|May 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323360||30476|
NCT02254057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1192.1|Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects|Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses of 0.1 mg, 0.3 mg, 1.0 mg, 2.5 mg, 5.0 mg, and 10.0 mg BIBT 986 BS (IV Infusion Over 30 Minutes) in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level||Boehringer Ingelheim||Completed|July 2002|||October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|47|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254057||35795|
NCT02254070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1192.12|Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment|Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of 1.0 mg of BIBT 986 BS Given as a Single Dose Infusion Over 30 Minutes in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment in an Open, Group Comparison Design||Boehringer Ingelheim||Completed|June 2003|||August 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254070||35794|
NCT02240615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS-US-01|The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora|The Sinopsys Lacrimal Stent Used During the Repair of the Lacrimal System in Patients With Epiphora||Sinopsys Surgical|No|Completed|October 2014|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|22 Years|N/A|No|||February 2016|February 11, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240615||36829|
NCT02244775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-090|Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device|Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device||Hospital for Special Surgery, New York||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||September 2014|September 18, 2014|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244775||36509|
NCT02250391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-06-04/C-01|Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis|Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis||Nihon Pharmaceutical Co., Ltd|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02250391||36077|
NCT02319070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17493|2-cohort Study of Adult Patients With Severe Hemophilia A in Greece|Prospective, Observational, 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece. Cost,Clinical Outcomes and Quality of Life Comparison Between on Demand and Secondary Prophylaxis Treatment Strategies|HAMLET|Bayer|No|Recruiting|January 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Male|18 Years|N/A|No|Probability Sample|This will be a single center prospective two-cohort observational study conducted in a        hospital setting.Patients will be enrolled from the biggest specialty management center in        Greece|March 2016|March 10, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02319070||30805|
NCT02324582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-SIUSOM-14-006|MK-3475/BCG in High Risk Superficial Bladder Cancer|Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer|MARC|Southern Illinois University|Yes|Recruiting|June 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324582||30382|
NCT02252159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB-MA-PV-401|Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)|Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices||Incyte Corporation|No|Recruiting|July 2014|October 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Blood sample(s), two vials, one with heparin, another with ethylenediaminetetraacetic acid      (EDTA) will be collected at enrollment and then annually thereafter until the end of study      for serum analysis of proteins and assessment of allele burden and mutations.|Both|18 Years|N/A|No|Probability Sample|An adult population (patients >18 years old) of men and women who have been diagnosed with        clinically overt PV will be enrolled. Sites will include both community and academic        centers across the United States that are representative of where patients with PV are        diagnosed and treated.|February 2016|February 3, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02252159||35941|
NCT02252016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-065|Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)|A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|October 2014|June 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252016||35952|
NCT02326961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-OA Knee|Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee|Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study|ACT-OA Knee|Cytori Therapeutics|Yes|Active, not recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|69 Years|No|||June 2015|June 26, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326961||30200|
NCT02316080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fapesp 2010120326|The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching|Evaluating Remineralizers and Desensitizers Agents in Dental Bleaching Treatment: in Vitro and in Vivo Study||University of Sao Paulo|Yes|Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT02316080||31035|
NCT02316093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20136255051502|The Effects of Obesity on 8-Hydroxy-Deoxyguanosine Levels in Patients With and Without Periodontal Disease|||Bulent Ecevit University||Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|90|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|a population who received periodontal treatment at the Periodontology Department|December 2014|December 10, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316093||31034|
NCT02316119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP2012/04930-0|Mechanistic Study of Bleeding Risk in Coronary Patients With Cerebrovascular Disease|Mechanisms Involved in the Bleeding Risk of Patients With Coronary Artery Diseased Previous Stroke or Transient Ischemic Attack in Use of Antiplatelet Therapy||University of Sao Paulo General Hospital|No|Recruiting|January 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Post-ACS patients and taking aspirin|June 2014|May 27, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02316119||31032|
NCT02253004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-166|Induction of Migraine Aura With Cilostazol|The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.||Herlev Hospital|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|50 Years|No|||August 2015|August 20, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253004||35876|
NCT02253017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-06-13|Evaluation of Therapeutic Strategies in Pediatric Cataract Surgery|Assessment Practices Registry in Congenital Cataract Surgery and Infantile|EP3C|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2014|||September 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|17 Years|No|Non-Probability Sample|ophthalmology department, Necker hospital.|July 2015|July 27, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02253017||35875|
NCT02322255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVO-1A-001|A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)|A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)||Clementia Pharmaceuticals Inc.|No|Recruiting|December 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood and urine samples for biomarker and proteomic analysis.|Both|N/A|65 Years|No|Non-Probability Sample|Individuals with classic FOP (R206H mutation).|December 2015|March 2, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02322255||30561|
NCT02321631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 57-073-13-1|Efficacy of EPA-enriched Supplement in Malnourished Head and Neck Cancer Patients Undergone Surgery|Efficacy of EPA-enriched Supplement Compared With Standard Formula on Body Weight Changing in Malnourished Head and Neck Cancer Patients Undergone Surgery: A Randomized Study||Prince of Songkla University|Yes|Recruiting|January 2015|October 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|15 Years|90 Years|No|||June 2015|June 11, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321631||30609|
NCT02248948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOMEGA-TDAH-014|Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children|Multicenter Randomized Controlled Trial for the Evaluation of Superiority of a Supplement With Omega-3 Fatty Acids Versus Placebo for the Improvement of Attention Deficit and Hyperactivity Disorder (ADHD) in Children|ECOMEGA|Laboratorios Ordesa|Yes|Active, not recruiting|September 2014|November 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|6 Years|11 Years|No|||March 2016|March 7, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248948||36188|
NCT02251756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.CIP.29114|Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.|Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.||Galderma|No|Completed|July 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251756||35972|
NCT02324608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091303|Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer|A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)||Rutgers, The State University of New Jersey|No|Recruiting|January 2015|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324608||30380|
NCT02311647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1374-SD-CTIL|Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients|Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients||Sheba Medical Center|No|Not yet recruiting|January 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|45 Years|No|Non-Probability Sample|Breast cancer patients who are:          -  < 45 years          -  premenopausal          -  Had no previous uterine operations (previous D&C is allowed)          -  Currently receiving or having received Tamoxifen for at least 1 year.|December 2014|December 22, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311647||31375|
NCT02311894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29543|A Post-Marketing Open-Label Study of the Efficacy and Immunogenicity of Nutropin AQ® in Children With Growth Hormone Deficiency|||Genentech, Inc.||Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|3 Years|14 Years|No|||March 2016|March 1, 2016|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311894||31356|
NCT02248961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC09042014|Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension|Open-label, Randomized, Multicenter, Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan), Manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, Tablets 60/120 mg and Cozaar® (Losartan), Manufactured by MERCK SHARP & DOHME B.V., Netherlands, Tablet 50/100 mg in Adult Patients With Grade I-II Arterial Hypertension||R-Pharm|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248961||36187|
NCT02248974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34286|Development & Testing of a Decision Aid for LVAD Placement|Development and User Testing of a Decision Aid for Left Ventricular Assist Device (LVAD) Placement|VADDA|Baylor College of Medicine|No|Recruiting|February 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|144|||Both|30 Years|85 Years|No|||January 2016|January 25, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02248974||36186|
NCT02250404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2O-13-1|Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide|Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer||University of Southern California|No|Recruiting|August 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|3|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Subjects seen at USC Norris Comprehensive Cancer Center and at LAC USC Medical Center with        histologically confirmed small cell lung cancer will be recruited for this trial.|October 2015|October 24, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250404||36076|
NCT02326935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO-MS-ADSC-006|Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis|Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis||American CryoStem Corporation|No|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326935||30202|
NCT02311959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 SEIN 10|Therapeutic Nipple Sparing Mastectomy.|Therapeutic Nipple Areola Skin-sparing Mastectomy.|MAPAM-01|Institut Claudius Regaud|No|Recruiting|January 2015|February 2024|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Female|40 Years|N/A|No|||December 2014|May 26, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311959||31351|
NCT02311972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051454|Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants|Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants||Duke University|Yes|Recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|N/A|24 Hours|No|||October 2015|October 20, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311972||31350|
NCT02241148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR14-003|Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome|||Universidad Autonoma de Nuevo Leon||Recruiting|February 2014|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|50 Years|No|||September 2014|September 12, 2014|July 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02241148||36788|
NCT02310594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001588|Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy|The Effect of Radiation Therapy on Tumor Immunity||Jonsson Comprehensive Cancer Center|No|Recruiting|July 2010|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult cancer patients undergoing physician directed radiation treatment.|March 2016|March 4, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02310594||31456|
NCT02321358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141338-HK|Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors|Randomized Controlled Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors: The OutPACE Trial|OutPACE|Memorial University of Newfoundland|Yes|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02321358||30630|
NCT02325076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-KAEK-215|The Association Between Pulmonary Function Tests and Difficult Airway|The Association Between Pulmonary Function Tests and Difficult Airway||Tokat Gaziosmanpasa University|No|Completed|December 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|202|||Both|18 Years|40 Years|No|||February 2016|February 10, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02325076||30344|
NCT02240940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1735|PARACHUTE China Approval Trial|PARACHUTE China: Multi-center, Prospective, Single-arm Clinical Evaluation of the Safety and Efficacy of the Parachute Percutaneous Left Ventricle Partitioning System||CardioKinetix, Inc|Yes|Active, not recruiting|September 2014|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|79 Years|No|||July 2015|July 27, 2015|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240940||36804|
NCT02324517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7563-GK-CTIL|Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders|Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders, Including Hemophilia With Inhibitors||Sheba Medical Center|No|Recruiting|March 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||10|Anticipated|300|||Both|6 Months|90 Years|No|Non-Probability Sample|patients with coagulopathies (see brief description)|December 2014|December 18, 2014|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02324517||30387|
NCT02324530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-13-0637|Evaluation of Continuous Positive Airway Pressure for Tumor Motion Management in Radiotherapy|Evaluation of CPAP (Continuous Positive Airway Pressure) in the Planning of Radiation Treatments for Lung, Upper Abdomen and Left Breast Cancers||Sheba Medical Center|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02324530||30386|
NCT02323932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZ0085|Perception of Intonation by Bimodal and Bilateral Cochlear Implant Users|Perception of Intonation by Bimodal and Bilateral Cochlear Implant Users||Bnai Zion Medical Center|No|Recruiting|December 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323932||30432|
NCT02251704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116682|An Epidemiology Study of Malaria Transmission Intensity in Children in Sub-Saharan Africa|Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa||GlaxoSmithKline||Recruiting|October 2014|June 2023|Anticipated|June 2023|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|56000|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||February 2016|March 17, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251704||35976|
NCT02257554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HospitalSS|Comparing Patients' and Surgeons' Expectations of Lumbar Spine Surgery|Comparing Patients' and Surgeons' Expectations of Lumbar Spine Surgery||Hospital for Special Surgery, New York|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for lumbar spine surgery and their surgeons|August 2015|August 31, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02257554||35529|
NCT02257567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29365|A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma|A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) AND BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA||Hoffmann-La Roche||Recruiting|October 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|224|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257567||35528|
NCT02257632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE27|Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration|A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration|TIDE AMD|Novartis|No|Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257632||35523|
NCT02318264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMU-PT-KTAP1|Influence of Elastic Tape on Activation of the Quadriceps Muscle During Selected Resisted and Weight Bearing Exercises|||State University of New York - Upstate Medical University|No|Not yet recruiting|February 2015|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318264||30867|
NCT02324543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14161|Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer|Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|76 Years|No|||January 2016|January 4, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324543||30385|
NCT02316561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46017.041.13|Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer|Single Dose Ablative Preoperative Radiation Treatment for Early-Stage Breast Cancer in Elderly Patients|ABLATIVE|UMC Utrecht|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|60 Years|N/A|No|||November 2014|December 12, 2014|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316561||30998|
NCT02251938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32-009|A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program|A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program|32-009|Santen Inc.|No|Enrolling by invitation|September 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02251938||35958|
NCT02258295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014813CTIL|Hyaluronate Injection for Lateral Epicondylitis|Hyaluronate Injection for Lateral Epicondylitis: A Double-blind Randomized Controlled Trial||Shaare Zedek Medical Center|No|Not yet recruiting|January 2015|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||September 2014|October 2, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02258295||35473|
NCT02310373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037529|Effects of Nicotine-Free Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Effects of Nicotine-Free Hookah Smoking on Blood Flow to the Heart, Muscle and Skin||Cedars-Sinai Medical Center|No|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02310373||31473|
NCT02316353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL830_3002|A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema|An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema||CSL Behring|No|Active, not recruiting|December 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|6 Years|N/A|No|||February 2016|February 8, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316353||31014|
NCT02246543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/033/13|Whey Protein Study - Identification of Sustainable Satiety|Whey Protein Study - Identification of Sustainable Satiety||University of Aberdeen|Yes|Completed|August 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|13|||Male|20 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02246543||36373|
NCT02257905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42206633|Allo SCT in Amyloidosis Non-interventional Study|A Non-interventional Prospective Study on Allogeneic Stem Cell Transplantation in Patients With AL Amyloidosis||European Group for Blood and Marrow Transplantation|No|Completed|December 2009|||July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|60 Years|No|Probability Sample|Male or female subjects, 18 years to 60 years, with AL amyloidosis who will receive        allogeneic transplantation|July 2015|July 23, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257905|5 Years|35503|
NCT02315339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC11633|European Home Mechanical Ventilation Registry|European Home Mechanical Ventilation Registry|EHMVR|ResMed|No|Recruiting|August 2014|August 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|The registry will target all adult individuals who have an indication for HMV (including        those with amyotrophic lateral sclerosis [ALS], central hypoventilation syndrome [CHS],        chronic obstructive pulmonary disease [COPD], kyphoscoliosis, obesity hypoventilation        syndrome [OHS], spinal cord injury [SCI], Duchenne muscular dystrophy [DMD], muscular        dystrophies [MDs] other than DMD, myopathies and myotonic dystrophy [Steinert's muscular        dystrophy; SMD]). All newly-diagnosed patients with chronic respiratory diseases who are        eligible for HMV treatment as part of routine care can be included in the registry.        Patients who satisfy all the inclusion criteria will be consecutively enrolled into the        registry.|December 2014|December 8, 2014|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02315339|5 Years|31092|
NCT02324647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGroningen|Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield|Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield|SERENDIPITY|University Medical Center Groningen|No|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Urine samples and serum or plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The research population consists of adult patients with a recently discovered adrenal        incidentaloma who meet the selection criteria of SERENDIPITY. A total number of 1000        patients will be included. These subjects will be recruited from the group of patients in        whom CT/MRI-scanning has been performed with visualization of the adrenal glands (i.e.        CT/MRI scans of abdomen and/or chest, as the latter often include imaging of the upper        abdominal region).|December 2015|December 1, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324647|2 Years|30377|
NCT02326389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3636|Exercise and Cognitive Training|Exercise and Cognitive Training||Boston University|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02326389||30243|
NCT02312596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC002|A Prospective, Randomized Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Non-Healing Diabetic Foot Ulcers|A Prospective, Randomized Clinical Trial of ECLIPSE PRP™ Wound Biomatrix in Non-Healing Diabetic Foot Ulcers||PRP Concepts, LLC|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312596||31302|
NCT02247401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-250|Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt|An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt||AbbVie|No|Active, not recruiting|November 2014|August 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247401||36307|
NCT02313480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01|Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?|Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?||Society of Musculoskeletal Medicine|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313480||31234|
NCT02311673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-493-010|Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome|A Ph 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors||Rhythm Metabolic, Inc.|Yes|Recruiting|February 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|16 Years|65 Years|No|||February 2016|February 10, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311673||31373|
NCT02311933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02409|Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer|A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer||National Cancer Institute (NCI)|No|Recruiting|March 2015|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|N/A|No|||January 2016|March 24, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311933||31353|
NCT02253732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEE-SAS|Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs|Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs|Brain-Muscle|Slovak Academy of Sciences|No|Recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 28, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253732||35820|
NCT02254031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191.3|Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer|An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer With Repeated Administration Courses in Patients With Clinical Benefit||Boehringer Ingelheim||Terminated|July 2003|||January 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254031||35797|
NCT02254044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191.4|Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus|An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus With Repeated Administration Courses in Patients With Clinical Benefit||Boehringer Ingelheim||Terminated|October 2003|||November 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||September 2014|September 30, 2014|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254044||35796|
NCT02243254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ibuprofen_hyperalgesia|Prevention of Remifentanil-induced Postoperative Hyperalgesia With Intravenous Ibuprofen|||Seoul National University Hospital||Completed|July 2014|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02243254||36626|
NCT02243267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00064405|GI SPORE Colon Biosample Protocol|Biospecimens for the Diagnosis, Treatment and Prevention of Colorectal Cancer||University of Michigan|No|Recruiting|September 2014|August 2021|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|Serum Plasma Buffy Coat Tissue Stool Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the University of Michigan Health System|June 2015|June 23, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02243267||36625|
NCT02324556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATA|A LAparoscopic and TransAnal Total Mesorectal Excision (TME) for Rectal Cancer Trial|A LAparoscopic and TransAnal Total Mesorectal Excision (TME for Rectal Cancer Trial|LATA|Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Rectal cancer possible to operate with an anterior resection.|August 2015|August 19, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02324556||30384|
NCT02323009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 10-0343|Esophageal Balloon Guided Weaning of the Morbidly Obese Patient|Esophageal Balloon Guided Weaning of the Morbidly Obese Patient||East Carolina University|No|Terminated|January 2011|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|19 Years|N/A|No|||December 2014|December 17, 2014|December 12, 2014|Yes|Yes|Minimal recruitment. very few patients available with eligibility criteria|No||https://clinicaltrials.gov/show/NCT02323009||30503|
NCT02240901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH2013-003-005|An Multi-center Randomized Clinical Trial About Using LMA or ETI in Elderly Patients|Effectiveness and Pulmonary Complications of Peri-Operative Laryngeal Mask Airway Used in Elderly Patients(POLMA-EP Trial): a Multi-center Randomized Controlled Clinical Trial|LMA;ETI|Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|April 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|6000|||Both|70 Years|N/A|No|||September 2014|September 15, 2014|August 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02240901||36807|
NCT02241226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBTI|Self-Directed Biological Transformation Initiative|Self-Directed Biological Transformation Initiative|SBTI|University of California, San Diego|No|Completed|September 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02241226||36782|
NCT02315079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400775|Point of Care Testing of Inflammatory Markers in Tears|Point of Care Testing of Inflammatory Markers in Tears||University of Florida|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|de-identified tear samples|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged 18-90 years of age that present to our North Central Florida Tertiary        Referral University Eye Clinics for evaluation. Patients with and without evidence of eye        inflammation will be eligible for this study.|August 2015|August 3, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315079||31112|
NCT02323867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010495|Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies|UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES|AB-CliniMACs|Children's Hospital of Philadelphia|Yes|Recruiting|October 2014|June 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|23 Years|No|||October 2015|October 19, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323867||30437|
NCT02323880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1414|Study of Selinexor in Pediatric Solid Tumors|ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.||Children's Oncology Group|Yes|Recruiting|October 2015|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|12 Months|21 Years|No|||February 2016|February 5, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323880||30436|
NCT02250729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01735-38|Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure|Anaphylaxis to Neuromuscular Blocking Agents and Pholcodine Exposure. Case-control Study|ALPHO|Central Hospital, Nancy, France|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|780|||Both|2 Years|N/A|No|||March 2016|March 7, 2016|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02250729||36051|
NCT02244996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01121876|Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum|Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum||The Hong Kong Polytechnic University|No|Recruiting|November 2014|March 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244996||36492|
NCT02320474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTRACT|Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)|Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)|ATTRACT|Poitiers University Hospital|No|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|50 Years|N/A|No|||December 2014|December 15, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320474||30698|
NCT02320487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29538|A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia|||Genentech, Inc.||Recruiting|March 2015|September 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320487||30697|
NCT02312284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMS 14-122/912|Observational Study on the Patients With Rectal Cancer|Observational Study on the Patients With Rectal Cancer: Experience From Cancer Hospital, Chinese Academy of Medical Sciences 2000-2010||Chinese Academy of Medical Sciences|Yes|Completed|January 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|3995|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical, pathological and routine laboratory characteristics for 3995 patients were        extracted from 5097 patients with rectal cancer treated in Cancer Hospital, Chinese        Academy of Medical Sciences from 2000 to 2010.The clinical data were reviewed and a        prediction nomogram based on the Cox proportional hazards model were developed.|January 2016|January 14, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312284||31326|
NCT02316587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMFAST|Assessment of Myocardial Fibrosis in Aortic STenosis|Assessment of Myocardial Fibrosis - Impact on Postoperative Outcome i Patients With Severe Aortic STenosis Undergoing Aortic Valve Replacement|AMFAST|Odense University Hospital|No|Recruiting|March 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples Without DNA|Plasma saved for biomarkers Endomyocardial biopsy Stenotic aortic valve|Both|18 Years|N/A|No|Probability Sample|Adult patients with severe aortic valve stenosis.|December 2014|December 12, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316587||30996|
NCT02312843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117|Piedmont Aging, Cognition & Exercise Study-2|A Randomized Controlled Trial to Examine the Effects of Aerobic Exercise on Cognition and Aging-related Biomarkers for Adults With Prediabetes and Mild Cognitive Impairment|PACE-2|Wake Forest School of Medicine|No|Active, not recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|50 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02312843||31283|
NCT02248662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-420|Impact of Radiation Therapy on Breast Conservation in DCIS|Impact of Radiation Therapy on Breast Conservation in DCIS||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|35000|||Female|21 Years|N/A|No|Non-Probability Sample|Retrospective analysis adult (21+) women diagnosed with ductal carcinoma in situ (DCIS)        who receive breast conserving-surgery with or without radiation therapy.|December 2015|December 1, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02248662||36210|
NCT02251613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-100-0009|Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan|Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen||Alcon Research|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|September 25, 2014|No|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT02251613||35983|
NCT02317991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 201|Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer|Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer||SCRI Development Innovations, LLC|No|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317991||30888|
NCT02244944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0972-F1V|Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD|The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD||University of Kentucky|Yes|Terminated|September 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|September 10, 2014|Yes|Yes|Failure to recruit|No||https://clinicaltrials.gov/show/NCT02244944||36496|
NCT02247414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YZUC-002|Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection|Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension|ESWAPH|Yangzhou University|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247414||36306|
NCT02310581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-14-026|Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain||INSYS Therapeutics Inc|No|Terminated|February 2015|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 1, 2014|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT02310581||31457|
NCT02311946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481041|A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib|A Phase 1, Open‑Label Fixed‑Sequence 2‑Period Crossover Study Of Palbociclib (pd‑0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Relative To Palbociclib Administration Alone Under Fasted Conditions||Pfizer|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311946||31352|
NCT02315872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-120A|ACTH for Fatigue in Multiple Sclerosis Patients|The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.|ACTH|Providence Health & Services|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315872||31051|
NCT02246283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schizophrenia-Lifelong|Schizophrenia for "Life" - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia|Schizophrenia for "Life" - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia||University of Southern Denmark|No|Recruiting|September 2013|August 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10404|||Both|55 Years|95 Years|No|Non-Probability Sample|Registry study: A nationwide register cohort study (1970-79) identifying psychiatric        admissions (aged 18-40), who were registered with a schizophrenia diagnosis. Several        Danish registers are applied.        Interview study: A cross-sectional survey where 150 randomly drawn surviving members of        the register cohort resident in the Region of Southern Denmark will be interviewed on the        basis of internationally validated assessment tools.|June 2015|June 16, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246283||36393|
NCT02245581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS-102-036|Evaluations of Optimizing Perioperative Fluid Management on Postoperative Pain Outcomes|||Kaohsiung Veterans General Hospital.||Completed|April 2013|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|N/A|No|||September 2014|September 18, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02245581||36447|
NCT02249468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alz.1.C/O/0|An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population|An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population||PTSH Holding Singapore Pte Ltd|No|Recruiting|October 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|225|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy        people|March 2015|March 30, 2015|August 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02249468||36148|
NCT02319278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002336-24|DEtection of Cellular Inflammation With FERumoxytol in the HEART|DEtection of Cellular Inflammation With FERumoxytol in the HEART|DECIFER|University of Edinburgh|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02319278||30789|
NCT02325635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002066|A Prospective Trial of an Endoscopic Quality Improvement Project|A Prospective Randomized Controlled Trial of an Endoscopic Quality Improvement Project-2 (EQUIP-2) to Improve Adenoma Detection in Screening and Surveillance Colonoscopy|Equip 2|Mayo Clinic|No|Completed|November 2013|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02325635||30301|
NCT02253069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regionskane|PHMB-based Antiseptic Use in Full-thickness Surgical Wounds|A Study of Polyhexanide-based Antiseptic in Full-thickness Surgical Wounds in Dermatologic Surgery||Region Skane|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253069||35871|
NCT02251028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130103|Value-based Cognitive Behavioral Therapy for Prevention of Chronic Whiplash-associated Disorders|Value-based Cognitive Behavioural Therapy for the Prevention of Chronic Whiplash Associated Disorders: A Randomized Controlled Trial||University of Southern Denmark|No|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02251028||36028|
NCT02251171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.44|Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers|A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Steady-state TPV/RTV (500 mg/200 mg) on the Single-dose Pharmacokinetics of Rifabutin (MYCOBUTIN®) 150 mg, and the Effects of Single-dose Rifabutin (150 mg) on the Steady-state Pharmacokinetics of TPV 500 mg (Co-administered With RTV 200 mg)||Boehringer Ingelheim||Completed|August 2003|||October 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251171||36017|
NCT02322983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3307801700P7|Conscious Sedation With Nitrous Oxide in Control of Stress During Dental Care for Individuals With Cerebral Palsy|Effect Evaluation of Conscious Sedation With Nitrous Oxide at Control of Stress During Dental Care in Individuals With Cerebral Palsy.||Universidade Cruzeiro do Sul|Yes|Completed|February 2011|September 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|77|||Both|3 Years|N/A|No|||December 2014|December 22, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02322983||30505|
NCT02316808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL_2011_Kal|Cholesterol-lowering Effects of Plant Stanol Ester|||Raisio Group||Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316808||30979|
NCT02323958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2014-6-26-01|TEAS to Improve Outcome During Emergence From General Anesthesia After Robotic Surgery|Effect of Transcutaneous Electrical Acupoint Stimulation on Outcome During Emergence From Anesthesia in Patients Undergoing Robotic Laparoscopic Gynecologic Surgery|TIGER|Fourth Military Medical University|Yes|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|65 Years|No|||January 2016|January 13, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02323958||30430|
NCT02251535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DePuy ECO257107|In-vivo Comparison of Different Levels of Femoral Rollback in a Primary Total Knee Arthroplasty|Retrospective Non-randomized In-vivo Comparison of Different Levels of Femoral Rollback in the ATTUNE Total Knee Arthroplasiy System on the Basis of Fluoroscopic and Marker-based Motion Capture Evaluation.|DePuyAttune|Charite University, Berlin, Germany|No|Recruiting|July 2014|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02251535||35989|
NCT02257437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNS-CAMB-INFANTS|Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia|Acceptability of a Locally-Produced Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement (LNS) for Children Under Two Years in Cambodia||Institut de Recherche pour le Developpement, Cambodia|No|Not yet recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|12 Months|17 Months|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257437||35537|
NCT02257541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-140|BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)||Memorial Sloan Kettering Cancer Center||Recruiting|October 2014|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257541||35530|
NCT02324465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130470|King Vision Video Laryngoscope Versus Glidescope Video Laryngoscope|King Vision Video Laryngoscope Versus Glidescope Video Laryngoscope: A Comparative Study in Ambulatory Surgery Center Patients||Vanderbilt University|Yes|Recruiting|April 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|122|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324465||30391|
NCT02324478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSSi_2|Exploration of Autonomic Nervous System by Photoplethysmography|||Ospedale L. Sacco – Polo Universitario|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|52|||Both|18 Years|50 Years|No|Probability Sample|adults scheduled for elective laparoscopic cholecystectomy under general anaesthesia|June 2015|June 23, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324478||30390|
NCT02315586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150017|Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis|Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|November 3, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02315586||31073|
NCT02315599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150028|Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials|Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|November 2014|August 2034|Anticipated|August 2034|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|24|||Both|1 Year|99 Years|No|||October 2015|December 31, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02315599||31072|
NCT02248675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 13-373|Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)|An Adjunctive Behavioral Sleep Intervention to Prevent Veteran Suicides||VA Office of Research and Development|No|Completed|February 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|54|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248675||36209|
NCT02251457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-1605|Study of Ranolazine in Myotonia Congenita and Paramyotonia Congenita|Open Label Trial of Ranolazine in Myotonia Congenita and Paramyotonia Congenita||Ohio State University|No|Recruiting|August 2014|December 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|100 Years|No|||October 2015|October 16, 2015|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251457||35995|
NCT02314806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUE 2014-12|Gentamicin Versus Clindamycin Versus Normal Saline Lavage in Axilla|Effect of Gentamicin Versus Clindamycin Versus Normal Saline Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume||Hospital General Universitario Elche|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|51|||Female|N/A|N/A|No|||December 2014|December 9, 2014|December 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314806||31133|
NCT02315066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0601002|A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors|A Phase 1, Open-Label, Dose Escalation Study Of PF-04518600 In Patients With Locally Advanced Or Metastatic Hepatocellular Carcinoma (HCC), Melanoma, Clear Cell Renal Cell Carcinoma (RCC) Or Squamous Cell Head And Neck Cancer (SCCHN)||Pfizer|No|Recruiting|April 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315066||31113|
NCT02315885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP00060091|Biomarkers to Measure Treatment Response for Alcohol Dependence|Biomarkers to Measure Treatment Response for Alcohol Dependence||University of Maryland|Yes|Not yet recruiting|July 2015|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers who drink heavily.|May 2015|May 26, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02315885||31050|
NCT02319343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_08_2014|Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Quadriceps Muscle Function in Patients Scheduled for Total Knee-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|58|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02319343||30784|
NCT02250690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkinson_tDCS_Gait_Impairment|Neuromodulation on Motor Function in Parkinson's Disease|Transcranial Direct Current Stimulation (tDCS) Associated With Gait Training in Improving Motor Function in Parkinson's Disease||Universidade Federal de Pernambuco|Yes|Enrolling by invitation|September 2013|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|40 Years|80 Years|No|||July 2014|September 24, 2014|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02250690||36054|
NCT02249936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5611C00002|A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations|A Phase 1, Single-Center, Randomized, 3-Way Cross-Over, Open Label Study to Evaluate the Pharmacodynamics of Different Formulations of AZD1722 in Healthy Volunteers Taking Omeprazole||Ardelyx|No|Completed|February 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249936||36112|
NCT02256839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST001_USA4|Evaluation of the QuantiFERON-TB Test.|||QIAGEN Gaithersburg, Inc|No|Active, not recruiting|October 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|260|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have either low-exposure rist to tuberculosis or have non-tuberculous        mycobacterial infections|January 2016|January 26, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256839||35582|
NCT02322931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02658|C-arm Cone-beam CT in Prostate Brachytherapy|Intra-operative Use of C-arm Cone-beam CT for Quality Assurance of Low-dose-rate Prostate Brachytherapy Dose Delivery|C-arm|British Columbia Cancer Agency|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02322931||30509|
NCT02322970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|impr14|Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial (IMPRESSIT)|Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial|IMPRESSIT|Università degli Studi di Brescia|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|All patients with brain injury, at risk of developing intracranial hypertension, requiring        invasive intracranial pressure monitoring.|December 2015|December 3, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02322970||30506|
NCT02312830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57284|Belgian Cross-sectional Allogeneic Transplant Survivor Study|Belgian Cross-sectional Allogeneic Transplant Survivor Study|BE-C@TS|Universitaire Ziekenhuizen Leuven|No|Enrolling by invitation|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients transplanted in UZ Leuven between 1992 and 2012 with an allogeneic        donor (i.e. being at least 2 years post-Tx) - Hematopoietic Stem Cell Transplantation,        presenting for a standard medical check up|October 2014|December 5, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02312830||31284|
NCT02316834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0474|POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer|POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2015|||June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316834||30977|
NCT02241486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU#205025|Sublingual Fentanyl and Procedural Burn Pain|A Randomized, Double-blind, Placebo-controlled, Cross-over Trial of Sublingual Fentanyl Spray (Subsys) and Oral Morphine for Procedural Wound Care in Adult Patients With Burn Injury Pain||Loyola University|No|Terminated|September 2013|March 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|November 12, 2013|Yes|Yes|No funding source.|No||https://clinicaltrials.gov/show/NCT02241486||36762|
NCT02241759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-04|Study of the Electrocardiographic Effects of TA-8995|A Phase I, Single-Centre, Randomised, Placebo and Positive- Controlled, Parallel-Group Study of the Electrocardiographic Effects of TA-8995 in Healthy Male and Female Subjects||Xention Ltd|No|Completed|August 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|August 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241759||36741|
NCT02241772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-06|A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)|||Xention Ltd||Completed|September 2014|February 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|February 12, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02241772||36740|
NCT02311608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LB2-2014|Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails|Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding|CER:T|Shanghai Zhongshan Hospital|Yes|Recruiting|February 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1320|||Both|N/A|N/A|No|Non-Probability Sample|Cirrohsis patients with acute variceal bleeding|December 2014|December 5, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02311608||31378|
NCT02311621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCIT-01|Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01|A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Autologous T-cells Lentivirally Transduced to Express CD171-specific Chimeric Antigen Receptors||Seattle Children's Hospital|Yes|Recruiting|November 2014|||November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|18 Years|No|||December 2014|December 5, 2014|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311621||31377|
NCT02323971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFI-TIC-2014-01|Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients|Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients|Ticagrelor|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Recruiting|December 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Blood|Both|18 Years|80 Years|No|Probability Sample|Patients with CKD and with normal renal function|December 2014|March 11, 2015|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323971||30429|
NCT02324075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-113016|Using Behaviour Change Messaging to Improve Communal Toilets in Dhaka, Bangladesh|Using Behaviour Change Messaging to Improve Communal Toilets in Dhaka, Bangladesh|WSUP|Stanford University|Yes|Completed|December 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4200|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02324075||30421|
NCT02325674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5560R00003|Post Authorisation Safety Registry for US Patients With Generalised Lipodystrophy Treated With Metreleptin|Metreleptin Safety Registry||Aegerion Pharmaceuticals, Inc.|No|Not yet recruiting|January 2016|October 2029|Anticipated|October 2029|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Generalised Lipodystrophy treated with Metreleptin|June 2015|June 17, 2015|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325674|10 Years|30298|
NCT02253589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01DG13020|Motivational Interviewing (MI) to Reduce Khat Use|Evaluation of Motivational Interviewing (MI) to Reduce Khat Use Among Somali Refugees in Kenya|MIkhat|University of Konstanz|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253589||35831|
NCT02253719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCH-Cervical Screening-VIA|Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia|Screening for Prevention of Cervical Cancer in HIV-positive and HIV-negative Cambodian Women Using Direct Visualization With Acetic Acid||Sihanouk Hospital Center of HOPE|Yes|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1000|||Female|30 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|The 1000 women will be recruited from the current patient base of Sihanouk hospital and        the surrounding community.|October 2015|October 6, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02253719||35821|
NCT02242955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_44|Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse|Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse|DIAMA|University Hospital, Lille|Yes|Recruiting|July 2014|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|60 Years|No|||October 2015|October 13, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242955||36649|
NCT02310347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54673|Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake|Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides||Universitaire Ziekenhuizen Leuven||Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310347||31475|
NCT02310360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56186|Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans|Measuring Food-induced Striatal and Extra-striatal Dopamine Release Using (18F)Fallypride PET|DA-Fallypride|Universitaire Ziekenhuizen Leuven||Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|12|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy females.|December 2014|December 3, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02310360||31474|
NCT02314559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB Mental Recup 001|A Psychomotor Recuperation Study After Deep Sedation for Colonoscopy Between Target Controlled and Manual Titration of Propofol|A Psychomotor Recuperation Study After Deep Sedation for Colonoscopy Between Target Controlled and Manual Titration of Propofol.||Brugmann University Hospital|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02314559||31152|
NCT02319109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/REF01|PT/INR Reference Interval IN Healthy Volunteers|A Prospective, Single-Center Study, in Healthy Volunteers to Establish a PT/INR Reference Interval for the Microvisk INR Test System|REF01|Microvisk Technologies Ltd|No|Completed|December 2014|January 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|154|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female subjects, not taking any oral vitamin K antagonist therapy, over        the age of 18 years.|December 2014|January 21, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02319109||30802|
NCT02251717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1406|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection|A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection||Gilead Sciences|Yes|Active, not recruiting|October 2014|June 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251717||35975|
NCT02318524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_35|Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients|Circulation of Pathogenic Fungi in the Domestic Environment: Clinical Impact of Mould and Pneumocystis Jirovecii Exposure on COPD Patients|FungiCOPD|University Hospital, Lille|Yes|Recruiting|August 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|Sputum, serum, oropharyngeal washing, Dust catchers|Both|35 Years|90 Years|No|Non-Probability Sample|Primary care clinic|December 2015|December 3, 2015|April 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02318524||30847|
NCT02318758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-125|Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers|Randomized, Single Dose, 4-Way Cross-over Study to Investigate the Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers|TDE-PH-125|United Therapeutics|No|Completed|September 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|32|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2014|March 20, 2015|September 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318758||30829|
NCT02324504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015242|Evaluation of Electrocardiographic Guidance in Accurate Peripherally Inserted Central Catheter Placement in Children.|Evaluation of Electrocardiographic Guidance in Accurate Peripherally Inserted Central Catheter Placement in Children.|ECG-PICC|Children's Hospital Boston|No|Recruiting|January 2016|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|N/A|17 Years|No|||February 2016|February 24, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02324504||30388|
NCT02252991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00091-46|Adaptated Physical Activity in Cancerology|APACAN study_Adaptated Physical Activity in Cancerology|APACAN|Centre Jean Perrin|No|Terminated|September 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3|||Female|18 Years|75 Years|No|||December 2015|December 23, 2015|September 11, 2014||No|Difficulty to include patients|No||https://clinicaltrials.gov/show/NCT02252991||35877|
NCT02256878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.12|Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects|A Study to Evaluate the Effect of a Single Oral Dose and Multiple Oral Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects||Boehringer Ingelheim||Completed|August 2004|||November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||||No||https://clinicaltrials.gov/show/NCT02256878||35579|
NCT02256891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04100-11-C|Rotator Cuff Repair Using Standard Double Row Technique With Platelet Rich Fibrin Membrane vs. Standard Double Row Technique|Arthroscopic Rotator Cuff Repair Using Standard Double Row Technique With Platelet Rich Fibrin Membrane vs. Standard Double Row Technique: A Randomized Blinded Outcomes Study|RCRPRFM|HealthPartners Institute|Yes|Active, not recruiting|July 2011|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 25, 2015|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02256891||35578|
NCT02241798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00435|Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit|Effects of Pre-oxygenation on Indicators of Gas Exchange and Autonomic Function During Seizures in the Epilepsy Unit||New York University School of Medicine|No|Terminated|August 2013|March 2016|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|September 12, 2014||No|Investigator is leaving the institution and has terminated the study.|No||https://clinicaltrials.gov/show/NCT02241798||36738|
NCT02311361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150027|Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer|A Pilot Study of Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|April 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|December 5, 2014|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311361||31397|
NCT02316847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZNS-EP-1025|An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures|Multi-center, Open-label, Study of Safety and Tolerability of Chronic Intermittent Usage of Diazepam Nasal Spray in Epilepsy Patients With Cluster Seizures, Including Assessment of Olfaction and Reported Changes in Taste.||Acorda Therapeutics|Yes|Recruiting|December 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|65 Years|No|||March 2016|March 11, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316847||30976|
NCT02241421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3-072|The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity|The Effect of the Knock Down of Gut Microbiota by Antibiotics on Parameters of Body Weight Control and Insulin Sensitivity|ANTIBIOTICS|Maastricht University Medical Center|No|Active, not recruiting|April 2012|November 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|57|||Male|35 Years|70 Years|No|||September 2014|September 15, 2014|October 22, 2012||No||No||https://clinicaltrials.gov/show/NCT02241421||36767|
NCT02241434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-13|Stem Cell Therapy in Duchenne Muscular Dystrophy|The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy||Neurogen Brain and Spine Institute|Yes|Recruiting|January 2009|June 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|3 Years|25 Years|No|||September 2014|September 12, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241434||36766|
NCT02250183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-021|Medihoney and Santyl for Burn Injuries|A Comparison of Medihoney® Gel With Active Leptospermum Honey and Santyl® in the Treatment of Partial Thickness Burns|MSBI|Allegheny Singer Research Institute|No|Recruiting|September 2013|May 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|N/A|N/A|No|||March 2016|March 7, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250183||36093|
NCT02315352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200661-002|Cross-over Study to Evaluate the Palatability of New ODTs of PZQ and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years|Randomized, Single Blind, Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets of PZQ and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years||Merck KGaA|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315352||31091|
NCT02325778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01007|Comparison of CTI Ablation Prior to or After LA Ablation for AF|Randomized, Single-blind, Comparative Trial of Two AF Ablation Strategies (CTI Ablation Prior to LA Ablation Versus CTI After LA Ablation) to Eliminate Persistent AF||New York University School of Medicine|No|Active, not recruiting|January 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325778||30290|
NCT02313051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCSG016|Everolimus trIal for Advanced prememopausaL Breast Cancer Patients|A Multicenter, Randomized Phase ll Study of Letrozole Versus Letrozole Plus Everolimus for Hormone Receptor-PositivePremenopausal Women With Recurrent or Metastatic Breast Cancer on Goserelin Treatment After Progression on Tamoxifen|MIRACLE|Chinese Academy of Medical Sciences|No|Not yet recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||November 2014|December 8, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02313051||31267|
NCT02244658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RhTPO-AML thrombocytopenia|Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia|Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial||Shandong University|Yes|Recruiting|September 2014|August 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|15 Years|75 Years|No|||September 2014|September 18, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02244658||36518|
NCT02244671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.27|Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)|Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)||Fox, Donald Munro, M.D., P.C.|No|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02244671||36517|
NCT02247141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIG01|A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®|A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients.||Bio Products Laboratory||Completed|June 2000|||January 2005|Actual|Phase 3|Interventional|N/A|1||||||Both|N/A|N/A|No|||August 2014|September 19, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02247141||36327|
NCT02247154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIGPSAD|A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency|A Study of the Safety and Efficacy of an Intravenous Immunoglobulin (Vigam® Liquid) in Patients With Primary or Secondary Antibody Deficiency.||Bio Products Laboratory||Completed|April 1999|||July 2001|Actual|Phase 4|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|80 Years|No|||August 2014|September 19, 2014|September 2, 2014||||No||https://clinicaltrials.gov/show/NCT02247154||36326|
NCT02247167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapienza-sdb|Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing.|Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing.||University of Roma La Sapienza|Yes|Completed|February 2012|July 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|15|||Both|3 Years|15 Years|No|||September 2014|September 18, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02247167||36325|
NCT02318277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-203|A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors||Incyte Corporation|No|Recruiting|December 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|185|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318277||30866|
NCT02324439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brard-SIUSOM-2014-004|Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission|Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission||Southern Illinois University|No|Recruiting|March 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Female|21 Years|N/A|No|||November 2015|November 3, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324439||30393|
NCT02240628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0323|Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection|In Children, Placing a Synera Patch for Intravenous Access Combined With Administration of a Propofol-Lidocaine Mixture Decreases Pain Associated With Propofol Intravenous Injection.||The University of Texas Health Science Center, Houston|No|Recruiting|August 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240628||36828|
NCT02257866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140200|Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis|Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|N/A|||Anticipated|500|||Both|5 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|October 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02257866||35506|
NCT02257879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140204|DHB Supplement Interaction Study|A Pharmacokinetic Study to Assess and Compare the Drug Interaction Risk of the Grapefruit Juice and Dietary Supplements Known to Inhibit CYP3A Enzyme Activity||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|October 10, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02257879||35505|
NCT02311686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarcadores/PNSD/1|Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol|Identifying the Profile of the Main Non-oxidative Biomarkers of Alcohol (Ethyl Glucuronide, Ethyl Sulphate, Fatty Acid Ethyl Esters) After the Experimental Exposure to Increasing Doses of Alcohol in Adults.||Parc de Salut Mar|Yes|Recruiting|December 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311686||31372|
NCT02243631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMA-022-13F|Effect of Probenecid on Synovial Fluid ATP Levels in CPPD|ANK-dependent ATP Efflux Causes Calcium Pyrophosphate Deposition in Cartilage||VA Office of Research and Development|No|Recruiting|October 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|99 Years|No|||February 2016|February 24, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243631||36597|
NCT02503722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01139|TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor|A Phase 1 Trial of MLN0128 in Combination With AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor||National Cancer Institute (NCI)||Not yet recruiting|October 2015|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2015|February 15, 2016|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503722||16637|
NCT02497677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCPH 2015-10|Copenhagen Infant Mental Health Project: Enhancing Parental Sensitivity and Attachment (CIMHP)|Copenhagen Infant Mental Health Project: A Randomized Controlled Trial Comparing Circle of Security-Parenting and Care as Usual as Interventions Targeting Infant Mental Healths Risks|CIMHP|University of Copenhagen|No|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|314|||Female|18 Years|N/A|No|||July 2015|July 14, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497677||17102|
NCT02254564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scabies 1|PCR Assay for Diagnosis of Sarcoptes Scabiei|PCR Assay for Diagnosis of Sarcoptes Scabiei||Seton Healthcare Family|No|Not yet recruiting|October 2014|||April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Superficial skin scrapings scales that are collected on microscope slides, which are used to      determine diagnosis in clinical settings. After clinicians view the slide under the      microscope, the slide is then discarded.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited upon identifying of scabies by microscopy or when a scraping is        performed for suspected tinea or demodex folliculitis|September 2014|September 29, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254564||35756|
NCT02254577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0028|Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer|A Randomized, Three-armed, Non-Inferiority Study of Vaginal Progesterone (Endometrin®) Compared to Intramuscular Progesterone in Oil (PIO) in Infertile Subjects Undergoing Frozen Embryo Transfer (FET)||Shady Grove Fertility Reproductive Science Center|Yes|Recruiting|October 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1170|||Female|18 Years|48 Years|No|||November 2015|November 17, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254577||35755|
NCT02256059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beiromat_03|Treatment of Displaced Lateral Clavicle Fractures Using a Locking Compression Plate With Lateral Extension|Treatment of Displaced Lateral Clavicle Fractures Using a Locking Compression Plate With Lateral Extension - Clinical Observational Study|LatClav|Technische Universität München|No|Completed|June 2011|September 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|85 Years|No|Probability Sample|Patients suffering from a dislocated fracture of the lateral clavicle presenting at our        emergency department.|September 2014|September 30, 2014|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02256059||35641|
NCT02509390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9239|Hyperfibrinogenemia After Major Trauma|Hyperfibrinogenemia Within the First Days After Major Trauma : Kinetic, Functionality, Impact of Fibrinogen Replacement Therapy and Trauma, Thrombosis Risk||University Hospital, Montpellier|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|December 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02509390||16202|
NCT02509403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAI-WA-0707|An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel|An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel - WIPEAWAY|WIPEAWAY|University of Alberta|No|Not yet recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509403||16201|
NCT02497885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMSG_HCW_IgG|Seroprevalence of MERS-CoV IgG in Healthcare Workers|Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient||Ewha Womans University Mokdong Hospital|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|737|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Healthcare-personnel|October 2015|October 29, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497885||17086|
NCT02254629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014SDU-QILU-G04|The Effects of Laxative-probiotic Sequential Treatment in the IBS Patients|The Effects of Laxative-probiotic Sequential Treatment on the Symptoms and Fecal Microbiota in the IBS Patients.||Shandong University|Yes|Recruiting|July 2014|March 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||April 2015|April 8, 2015|August 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254629||35751|
NCT02254642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5831|Effects of Ischemic Preconditioning After Aortic Clamping|Protective Effects of Ischemic Preconditioning on Cardiac, Renal, Pulmonary and Muscular Functions After Aortic Clamping||University Hospital, Strasbourg, France|No|Not yet recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02254642||35750|
NCT02244931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00151-40|Comparison of Three Different Assisting Devices to Power Manual Wheelchairs in Patients With Spinal Cord Injury|Comparison of Three Assisting Devices to Power Manual Wheelchairs in Patients With Spinal Cord Injury : Assessment of Biomechanical, Physiological and Functional Properties.|PAPAW|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|106|||Both|18 Years|70 Years|No|||September 2013|September 17, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244931||36497|
NCT02504697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECAMP-2|DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer|Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer||Boston University|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|880|Samples With DNA|Blood, Urine, Sputum, Nasal brushing, Buccal scraping, Bronchial Biopsy, Bronchial brushing,      lung tissue|Both|50 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Military personnel|November 2015|November 24, 2015|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02504697||16562|
NCT02504710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF_ISLPerip_Man|Kinematic Real Time Feedback Used to Learn Manual Therapy on Peripherical Joints|Kinematic Real-Time Feedback, Obtained by Inertial Sensors, Used to Learn Manual Therapy on Peripherical Joints||University of Malaga||Recruiting|February 2015|September 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02504710||16561|
NCT02251665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NationalCardioCenter|National Cerebral and Cardiovascular Center (NCVC) Stroke Registry|National Cerebral and Cardiovascular Center (NCVC) Stroke Registry||National Cerebral and Cardiovascular Center|No|Recruiting|January 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients|September 2015|September 1, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02251665||35979|
NCT02252796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU020513|Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer|Phase I Dose Escalation Study of a Hypofractionated Stereotactic Boost (HySBst) to the Primary Site in Patients With Stage II-III Non-small Cell Lung Cancer|HySBst|West Virginia University|Yes|Active, not recruiting|July 2014|||December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252796||35892|
NCT02506296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D no 1503059|Glucose Response, Excursions And Treatment (GREAT) Study|The Influence of Residual Beta Cell Function on Hypoglycaemia Risk and Treatment Response in Type 2 Diabetes|GREAT|Royal Devon and Exeter NHS Foundation Trust|No|Recruiting|October 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|54|||Both|35 Years|N/A|Accepts Healthy Volunteers|||July 2015|October 21, 2015|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506296||16439|
NCT02510664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K12DK097696|Diabetes Strengths Study|Promoting Resilience in Youth With Type 1 Diabetes: Pilot of Strengths-Based Family Intervention to Improve Diabetes Outcomes (Diabetes Strengths Study)|DSS|Baylor College of Medicine|No|Enrolling by invitation|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|12 Years|18 Years|No|||July 2015|July 27, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510664||16104|
NCT02247778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beiromat_02|Surgical Innovations in Treatment of Clavicle Fractures|Outcome of Mini-incision-technique for Treatment of Midshaft Fractures of the Clavicle|ClavFrac|Technische Universität München|No|Recruiting|April 2014|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2014|September 28, 2014|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02247778||36278|
NCT02248870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol1tdn|Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture|Analgesic Duration af a Preoperative Single-shot Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture||University of Aarhus|Yes|Terminated|March 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|55 Years|N/A|No|||March 2015|September 11, 2015|September 18, 2014||No|Less inclusions than expected with the given criteria|No||https://clinicaltrials.gov/show/NCT02248870||36194|
NCT02248883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.60|Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects|Assessment of Electrophysiological Effects of Tipranavir Co-administered With Ritonavir Given b.i.d. for 2.5 Days on the QT Interval in Healthy Female and Male Subjects. A Double-blind, Randomised, Placebo Controlled, Two-way Crossover Study With a Positive Control (Moxifloxacin) and Parallel Dose Groups||Boehringer Ingelheim||Completed|December 2005|||March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|September 24, 2014||||No||https://clinicaltrials.gov/show/NCT02248883||36193|
NCT02248896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.590|Antihypertensive Medications and the Risk of Sepsis|Antihypertensive Medications and the Risk of Sepsis||Boehringer Ingelheim||Completed|January 2010|||March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1129062|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of, or treatment for hypertension|September 2014|September 24, 2014|September 24, 2014||||No||https://clinicaltrials.gov/show/NCT02248896||36192|
NCT02506595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119-FP-15|A Trial of Treatment for Trauma-Related Nightmares in Active Duty Military Personnel|A Pilot Randomized Controlled Trial of Treatment for Trauma-Related Nightmares Compared to Waitlist Control in Active Duty Military Personnel||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02506595||16416|
NCT02502461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio#15-63|Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location|Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location in Trachea - A Randomized Controlled Trial||University of Saskatchewan|Yes|Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502461||16734|
NCT02244255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.17|FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia|An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia||Boehringer Ingelheim||Completed|August 1998|||June 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1993|||Male|45 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244255||36549|
NCT02244567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 4|Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women|Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin in Hyperandrogenic Lean PCOS Women|U-C OC IN PCOS|Beni-Suef University|Yes|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Female|20 Years|30 Years|No|||December 2015|December 26, 2015|September 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244567||36525|
NCT02257398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115775|Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers|A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers||GlaxoSmithKline|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257398||35540|
NCT02257411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346|A Method to Determine the Size of Laryngeal Mask Airway (LMA)|A Simple Method to Determine the Size of the ProSeal LMA (PLMA) in Children||Yeditepe University Hospital|No|Completed|June 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|197|||Both|N/A|15 Years|No|||October 2014|October 1, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02257411||35539|
NCT02497352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|765|Effects of Flaxseed Supplementation in Metabolic Syndrome|||National Nutrition and Food Technology Institute||Completed|February 2014|||August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||December 2014|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497352||17126|
NCT02497365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHTHO101|Besifloxacin in Bacterial Keratitis|Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study||McGill University Health Center|No|Not yet recruiting|September 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497365||17125|
NCT02502552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308018|Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort|Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort - A Monocentric Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|Samples Without DNA|blood specimen in IBD cohort of 195 patients followed in Saint-Etienne Hospital|Both|18 Years|N/A|No|Probability Sample|Ulcerative colitis and Crohn's disease patient followed in Saint-Etienne Hospital since 3        years or more|October 2015|October 30, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502552||16727|
NCT02244853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_153R_IP24|Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease|Association of Heart Rate With Cardiovascular Disease Prognosis of Patients With Stable Coronary Artery Disease: A CALIBER Study||University College, London|No|Active, not recruiting|September 2013|December 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51703|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|An open cohort of 2,23 million people covering approximately 5% of the UK population was        drawn from registrants to 225 GP practices who consented to data linkage.|September 2014|September 18, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244853||36503|
NCT02252562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00024068|Hand Hygiene and Hospital Acquired Infections|Reduction in 30-Day Postoperative Healthcare-Associated Infections Through Use of a Novel Hand Hygiene System||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2013|August 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3256|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252562||35910|
NCT02252575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-014|Assessment of Electromagnetic Interference Between E-transportation and Cardiac Implantable Electronic Devices|Assessment of Electromagnetic Interference Between E-transportation and Cardiac Implantable Electronic Devices||Deutsches Herzzentrum Muenchen|No|Active, not recruiting|September 2014|October 2015|Anticipated|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252575||35909|
NCT02502383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-1 R01 HL118734|ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity|ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity|ACTION PAC|University of New Mexico|No|Recruiting|January 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|960|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02502383||16740|
NCT02502474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408023|Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne|Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.|ColoStaph|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502474||16733|
NCT02510352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501079|Cohort of Patients With a Symptomatic Rotator Cuff Tear Treated Without Surgical Repair|Cohort of Patients With a Symptomatic Rotator Cuff Tear Treated Without Surgical Repair||Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|April 2006|October 2014|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|50 Years|75 Years|No|Non-Probability Sample|Patients having a full-thickness tear of the rotator cuff confirmed by MRI|July 2015|July 27, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510352||16128|
NCT02510365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-ACSCI/IGDB|Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients|Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation in Complete (AISA) Acute Spinal Cord Injury Patients||Chinese Academy of Sciences|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510365||16127|
NCT02255617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47057|Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study||University of Alberta|Yes|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 28, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255617||35675|
NCT02496793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF0090|Community-Based Peer Facilitator Intervention|A Community Randomized Study to Evaluate the Effect of a Community-Based Peer Facilitator Intervention on Prevention of Maternal to Child Transmission (PMTCT) of HIV Program Outcomes in Zimbabwe||Elizabeth Glaser Pediatric AIDS Foundation|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02496793||17169|
NCT02497404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306014009|Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR|Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission||Weill Medical College of Cornell University|No|Recruiting|June 2013|July 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497404||17122|
NCT02252757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV.CO.v0-01|Assess Measurements of Wireless Cardiac Output Device|Validation of Measurements From CoVa Sensor (VALIDATION-CO-1) Study to Assess Measurements of Wireless Cardiac Output Device|Remote-CO-1|Aventyn, Inc.|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|This study is targeted towards at-risk heart failure patients. An "at-risk" patient is        defined as a patient who has risk factors for Heart Failure as described in the table        below|October 2014|October 14, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02252757||35895|
NCT02255214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/0300|Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay|Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Micro Coagulation Instrument Compared With Laboratory Assay||NHS Lothian|No|Recruiting|October 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include all adult patients presenting for elective surgery who        have stopped their warfarin therapy within the last 7 days. They will be approached in the        Day Surgery Unit and Day of Surgery Assessment unit within a single centre.|September 2014|September 29, 2014|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02255214||35706|
NCT02497040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uludagu|The Effects of Scalp Block With Bupivacaine Versus Levobupivacaine|Effects of Scalp Block With Bupivacaine Versus Levobupivacaine on Haemodynamic Response to Head Pinning and Efficacy on Postoperative Analgesia||Uludag University|No|Completed|March 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497040||17150|
NCT02506166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44/15 ESCAPE - SCD|European Sleep Apnea and Sudden CArdiac Death ProjEct|European Sleep Apnea and Sudden CArdiac Death ProjEct|ESCAPE-SCD|University Hospital Olomouc|Yes|Not yet recruiting|January 2016|December 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|900|||Both|18 Years|18 Years|No|||July 2015|July 22, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506166||16449|
NCT02249507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0309|Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Trial|Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Randomized Controlled Trial||Hospital de Clinicas de Porto Alegre|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|25 Years|60 Years|No|||August 2015|August 19, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249507||36145|
NCT02502214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6195|Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders|Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders by Using Nextgeneration Sequencing||University Hospital, Strasbourg, France|No|Not yet recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|The Preimplantation Diagnosis (DPI) may be offered to couples at risk of transmitting a        serious genetic disease to their offspring|July 2015|July 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502214||16753|
NCT02508688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506012RIND|Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax|Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax: 10 Years' Experience From a Single Large-volume Center||National Taiwan University Hospital|No|Completed|January 2005|June 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|N/A|N/A|No|||July 2015|July 27, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508688||16256|
NCT02508701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506016224|A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men|A Pilot Study Comparing the Effectiveness of On-site Campus Interventions to Increase the Uptake of the HPV Three-shot Series Vaccine Among College Aged Men: A 2 X 2 Repeated Design||Purdue University|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|416|||Male|18 Years|21 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02508701||16255|
NCT02249741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastro-2012-RB-1|Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation|PROSPECTIVE STUDY OF PROFILE OF HEPATIC OSTEODYSTROPHY IN PATIENTS WITH NON-CHOLEASTATIC LIVER CIRRHOSIS AND IMPACT OF BISPHOSPHONATE SUPPLEMENTATION||Sir Ganga Ram Hospital||Completed|August 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|70 Years|No|||September 2014|September 25, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249741||36127|
NCT02249754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|879/13|Nutrition Education Package for Infants and Young Child Feeding and Health in Rural Tanzania|Effectiveness of a Nutrition Education Package in Improving Feeding Practices, Dietary Adequacy and Growth of Infants and Young Children in Rural Tanzania|NECTAc|Sokoine University of Agriculture|No|Recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||November 2014|November 17, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249754||36126|
NCT02255591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-TFB-SR|Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus|Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus: A Randomized Controlled Trial||University of Aarhus|Yes|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|April 30, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02255591||35677|
NCT02504749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KasrELAini|The Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section|Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience||Kasr El Aini Hospital|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|January 29, 2016|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02504749||16558|
NCT02504762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150338|HYbrid CoronAry Revascularization in DiabeticS|HYbrid CoronAry Revascularization in DiabeticS: A Randomized Controlled Trial (Pilot)|HYCARDS|Ottawa Heart Institute Research Corporation|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|November 20, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02504762||16557|
NCT02496572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF MDRTB Uzbek|Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan|Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan||Medecins Sans Frontieres|Yes|Active, not recruiting|September 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be referred from the facilities described below in three districts in        Karakalpakstan, Uzbekistan          1. Kegeily Rayon: Kegeily rayon is a large rayon (district) with a population of 83,000.             The rayon has 2 Polyclinics (outpatient clinics for TB care) and 21 SVPs (general             practice surgeries with staff trained in TB care).          2. Shumanay Rayon. A small rayon close to Khodjeily rayon with a population of 52,000.             There is 1 Polyclinic and 9 SVPs in the rayon          3. Nukus City Nukus city is the largest district in Karakalpakstan with a population of             268 000. There are 9 polyclinics.|July 2015|July 9, 2015|July 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02496572||17186|
NCT02256449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-BVS-2013-01|REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical prActice|Registry of Patients With Bioresorbable Device in Daily Clinical Practice. REPARA Study|REPARA|Sección Hemodinamica y Cardiologia Intervencionista|Yes|Active, not recruiting|January 2014|September 2016|Anticipated|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2440|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with native coronary artery de novo lesions with indication for revascularization        with a coronary device|September 2015|September 29, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02256449|1 Year|35612|
NCT02256462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAILOT|Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial|Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial||Schneider Children's Medical Center, Israel|No|Recruiting|May 2015|January 2019|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|17 Years|No|||June 2015|June 27, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02256462||35611|
NCT02243995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-032|Physical Training in Sarcoidosis Patients|Physical Training in Sarcoidosis Patients With Fatigue Complaints||Maastricht University Medical Center|Yes|Enrolling by invitation|January 2013|January 2015|Anticipated|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||September 2014|September 16, 2014|February 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02243995||36569|
NCT02501174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONSOG-1401|Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).|Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).||Centre Oscar Lambret|No|Recruiting|October 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|2500|||Both|65 Years|N/A|No|Non-Probability Sample|Patients included are patients followed in one of the participating centres and not        opposing the use of their medical data.|July 2015|July 15, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02501174||16833|
NCT02503956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-14-RMC|Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients|The Efficacy of Punctal Dilatation With Insertion of Perforated Punctal Plugs for the Management of Acquired Punctal Stenosis Due to Allergic Conjunctivitis||Rabin Medical Center|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|July 20, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503956||16619|
NCT02501499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manulife|Breastfeeding Buddies: An Exploratory Evaluation Study|Breastfeeding Buddies: An Exploratory Evaluation Study of a Peer Support Program||Manulife Centre for Community Health Research|No|Not yet recruiting|July 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|50|||Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women will be recruited through the Me Breastfeed workshops. It is a        self-selected community program that serves the Region of Waterloo (about 500,000 people        and 6000 births a year). Workshops are offered twice monthly and have about 20        participants at each session.        Mothers will be invited to participate in an interview 5-8 weeks past their indicated due        date.|July 2015|July 15, 2015|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501499||16808|
NCT02254473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405M50501|Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee|Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee||HealthPartners Institute|No|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|100 Years|Accepts Healthy Volunteers|||October 2015|November 25, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254473||35763|
NCT02254486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1006-01/2014 (NOCT)|Phase III Study Comparing Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 With Trisulfate Bowel Cleansing Solution Using a 2-Day Split-Dosing Regimen in Adults|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus a Trisulfate Bowel Cleansing Solution Using a 2-Day Split-Dosing Regimen in Adults||Norgine|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|621|||Both|18 Years|85 Years|No|||June 2015|January 18, 2016|October 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254486||35762|
NCT02256605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524835|Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens|||Nemours Children's Clinic||Completed|November 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|5 Years|17 Years|No|Probability Sample|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be        recruited at the time of a rountine clinic visit or lab draw that includes a 25(OH)D level        as part of a clinical practice/standard of care.|May 2015|May 28, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256605||35600|
NCT02501447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # 2012-1084|Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease|Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease||University of Illinois at Chicago|Yes|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501447||16812|
NCT02508597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiniTTT|Brief Tobacco Cessation Counselling: Mini Train-the-trainers Program|Brief Tobacco Cessation Counselling: Mini Train-the-trainers Program Among Physicians in Guangdong, China||The University of Hong Kong|Yes|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02508597||16263|
NCT02508636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15558|Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate|Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer||University of California, San Francisco|Yes|Recruiting|August 2015|June 2022|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Male|18 Years|N/A|No|||November 2015|November 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508636||16260|
NCT02258334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC55|Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines, 2014-2015 Formulations||Sanofi|No|Completed|October 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|October 2, 2014|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT02258334||35470|
NCT02244905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072011-079|Trial of Positive Deviance in Inpatient Wards to Reduce Hospital Infections|Trial of Positive Deviance in Inpatient Wards to Reduce Hospital Infections||University of Texas Southwestern Medical Center|No|Completed|August 2011|August 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16876|||Both|N/A|N/A|No|||May 2014|September 18, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244905||36499|
NCT02244918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001602|Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers|Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers||University of Kansas Medical Center|No|Recruiting|May 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244918||36498|
NCT02510131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PISA|Is Hyacinth Exercise Better Than Kegel's Exercise in Women With Urinary Incontinence?|Is Hyacinth Exercise Better Than Kegel's Exercise in Women With Urinary Incontinence?||University of Malaya|No|Not yet recruiting|August 2015|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Female|55 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02510131||16145|
NCT02510144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00064296|Skin Prep to Reduce Postoperative Shoulder Infection|Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection||University of Maryland|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02510144||16144|
NCT02506426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-0809|Endoscopic Sinus Surgery for Refractory Chronic Sinusitis|Endoscopic Sinus Surgery for Refractory Chronic Sinusitis: A Randomized, Double-blind Controlled Trial||University of Calgary|No|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|75 Years|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506426||16429|
NCT02254161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344.2|Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 1181181 Given Orally q.d. for 10 Days in Young Healthy Male and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)||Boehringer Ingelheim||Terminated|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 10, 2015|September 30, 2014||||No||https://clinicaltrials.gov/show/NCT02254161||35787|
NCT02243696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P980023/S057|Protego DF4 Post Approval Registry|Protego DF4 Post Approval Registry||Biotronik, Inc.|Yes|Recruiting|September 2014|June 2024|Anticipated|June 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1694|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigators' general patient        population according to the inclusion and exclusion criteria.|February 2016|February 24, 2016|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243696|5 Years|36592|
NCT02243709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404001031|Mifepristone for the Prevention of Relapses of Alcohol Drinking|A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking||Brown University|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|65 Years|No|||January 2016|January 16, 2016|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243709||36591|
NCT02496026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN20141|Transcranial Direct Current Stimulation and Robotic Therapy in Upper Limb Motor Recovery After Stroke|Transcranial Direct Current Stimulation and Robotic Therapy in Upper Limb Motor Recovery After Stroke||Auxilium Vitae Volterra|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|79 Years|No|||July 2015|July 21, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02496026||17228|
NCT02499627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL-BBV|A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen||FIL-BBV|Fondazione Italiana Linfomi ONLUS|No|Recruiting|October 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499627||16952|
NCT02504008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXS02-301|A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1|CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)|CREATE-1|Axsome Therapeutics, Inc.|Yes|Recruiting|July 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504008||16615|
NCT02504021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS IRB 9714|Family Meeting Study for End Stage Renal Disease|Family Consultation for High-Risk Inpatients With End Stage Renal Disease: A Randomized Trial||Wayne State University|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02504021||16614|
NCT02243332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALI-KS-001|Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain|Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain||Articulate Labs|No|Recruiting|September 2014|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|40 Years|No|||September 2014|September 19, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243332||36620|
NCT02255045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVM002|Assess of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea|Evaluation of the Effect of a Vaginal Ring With Meloxicam on Primary Dysmenorrhea in Women of Childbearing Age||Laboratorios Andromaco S.A.|No|Recruiting|July 2014|September 2016|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02255045||35719|
NCT02255123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-18|Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study|A Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study (CTOT-18)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|178|||Both|N/A|N/A|No|Non-Probability Sample|The study population was selected based on their previous participation in the parent        study (CTOT-05). Participants enrolled in this study are at least 4 years post-transplant        as of July 2014.|March 2016|March 22, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255123||35713|
NCT02503969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/YH/0028|Exploratory Analysis on the Impact of Morbidities on Colorectal Cancer Screening Uptake|Exploratory Analysis on the Impact of Morbidities on Colorectal Cancer Screening Uptake||University of Sheffield|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|8776|||Both|60 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study shall be restricted to participants in the South Yorkshire Cohort who have        ticked both boxes on the Consent Form for their data to be used (the boxes being labelled        "May we look at your health records?" and "May we use the information you provide to look        at the benefit of health treatments?"), and are eligible for screening in the NHS Bowel        Cancer Screening Programme (ages 60 to 69).|December 2015|December 1, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503969||16618|
NCT02505906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP2008-06|Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique||FUSIB|University Medical Center Groningen|No|Recruiting|January 2008|||January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with breast cancer treated with curative intent.|March 2016|March 23, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505906|5 Years|16469|
NCT02505919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0038|Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)|A Prospective Multicenter Randomized Blinded Study Comparing Aquablation of the Prostate With the AQUABEAM System and TURP for the Treatment of LUTS|WATER|PROCEPT BioRobotics|Yes|Recruiting|September 2015|September 2019|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|237|||Male|45 Years|80 Years|No|||March 2016|March 8, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505919||16468|
NCT02243930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOESURG-41580|Cap-assisted Sigmoidoscopy - Influence on Pain, Duration and Rate of Success|Cap-assisted Sigmoidoscopy - Reduction in Pain, Reduction in Investigation Time and Increased Rate of Success, When Examined by the Less-experienced Endoscopist. A Prospective Randomized Clinical Trial||Koege Sygehus|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|193|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02243930||36574|
NCT02244229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.15|Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients|MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride.||Boehringer Ingelheim||Completed|April 1998|||November 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|403|||Male|50 Years|80 Years|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244229||36551|
NCT02244242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.16|Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia|A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia||Boehringer Ingelheim||Completed|July 1998|||August 1999|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|493|||Male|45 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244242||36550|
NCT02244359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORE 2013-56|Improving the Decision Process About Location of Care With the Frail Elderly and Their Caregivers|||Centre Hospitalier Universitaire de Québec, CHU de Québec||Recruiting|September 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|560|||Both|65 Years|N/A|No|||January 2016|January 26, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244359||36541|
NCT02504346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/10301|AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies|AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies|TREM|Oslo University Hospital|No|Recruiting|July 2015|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02504346||16589|
NCT02504359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11097|Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma|A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma||OHSU Knight Cancer Institute|Yes|Recruiting|July 2015|July 2021|Anticipated|July 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02504359||16588|
NCT02504996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70178|IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia|IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia in Patients Presented With Sciatalgia to Emergency Department: A Randomized Controlled Trial||Akdeniz University|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|21 Years|65 Years|No|||July 2015|July 21, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02504996||16539|
NCT02241018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH-MSC-aGVHD-2014|MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD|Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Recruiting|September 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|65 Years|No|||September 2014|September 13, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241018||36798|
NCT02249598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16097|Competitive Carriage of Neisseria Spp(Lactamica 2)|Competitive Carriage of Neisseria Spp.; Discovering New Methods of Inhibiting Carriage of Neisseria Meningitidis (Lactamica 2)|Lactamica 2|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|July 2013|||November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|August 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02249598||36138|
NCT02497651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|h-1-2013-042|Effect of Smoking on Postprandial Gastric Emptying, Glucose Tolerance and Secretion of Gut and Pancreatic Hormones||SmokinGLP-1|University Hospital, Gentofte, Copenhagen|Yes|Active, not recruiting|May 2015|June 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02497651||17104|
NCT02508779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17117|BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant|Blood Glucose Training for Women With Type 1 Diabetes Contemplating Pregnancy|Bump2Be|University of Virginia|No|Not yet recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|58|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508779||16249|
NCT02508831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0199|Double Upper Limb Allograft: Intervention and Clinical Evaluation. A Pilot Study of 5 Cases|Double Upper Limb Allograft: Intervention and Clinical Evaluation. A Pilot Study of 5 Cases|DAMIE|Hospices Civils de Lyon|Yes|Not yet recruiting|September 2015|September 2022|Anticipated|September 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|60 Years|No|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508831||16245|
NCT02247206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL105611|VoIP Delivered Behavior Therapy for Tourette Syndrome|Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome||University of Wisconsin, Milwaukee|No|Completed|December 2012|November 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|17 Years|No|||September 2014|September 18, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247206||36322|
NCT02248402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-038|Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1/2a Study to Evaluate Safety and Efficacy of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma|Vax-DC/MM|Chonnam National University Hospital|Yes|Recruiting|October 2013|||October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||September 2014|September 24, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02248402||36230|
NCT02503059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPA-ETA-2014-01|Etanercept Survival in Elderly Population|Etanercept Survival in Elderly Population||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|November 2014|February 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|70|||Both|60 Years|N/A|No|Non-Probability Sample|All patients over 60 who received etanercept for the treatment of moderate / severe        psoriasis|July 2015|July 16, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02503059||16688|
NCT02503280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120203|The Transendocardial Autologous Cells (hMSC or hMSC and hCSC) in Ischemic Heart Failure Trial (TAC-HFT II)|A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.|TAC-HFT II|University of Miami|No|Not yet recruiting|March 2020|||March 2030|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|55|||Both|21 Years|89 Years|No|||October 2015|October 2, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503280||16671|
NCT02510638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-15-452-25624|The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia|The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia||Clinical Research Centre, Malaysia|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|322|||Both|N/A|N/A|No|Probability Sample|The study population consists of male or female patients with Dengue to be randomly        sampled from hospitals in Malaysia. Approximately 384 patients will be enrolled.        Sampling Frame: A sample of dengue cases who visited general practitioner or who were        hospitalized from year 2009 till 2015 will be sampled using PIK and Health insurance        claims database. Sampling: A random sampling will be done to select the samples. In order        to do it, each subject in the sampling frame will be given an unique number (e.g.: 001,        002, 003,… etc) according to the sequence of notification date. Then, the subjects will be        selected randomly by using randomizer.org software.|January 2016|January 28, 2016|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510638||16106|
NCT02247492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1406|BIOFLOW-III VIP Registry|Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Russia||Biotronik Russia|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)|December 2014|September 9, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247492|36 Months|36300|
NCT02247505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150DDI14013|CKD-397 Drug-drug Interaction Study (B)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tadalafil on Tamsulosin in Healthy Male Volunteers|CKD-397DDI(B)|Chong Kun Dang Pharmaceutical|No|Completed|September 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247505||36299|
NCT02247765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0445|Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion|Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well Perfused Subjects With the USB Pulse Oximetry Monitor Interface Cable||Medtronic - MITG|No|Completed|November 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers, Adults 18 to 50 years old|December 2014|December 2, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02247765||36279|
NCT02256501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Heart-004|Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy|Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells (MNC) in Idiopathic Dilated Cardiomyopathy in Pediatric Patients: Clinical Trial Phase I/II||Royan Institute|Yes|Recruiting|June 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|1 Year|16 Years|No|||May 2015|October 29, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256501||35608|
NCT02496806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAFAX11/18|The Absorption and Metabolism of Seaweed Polyphenols in Humans|Seaweed Derived Anti-inflammatory Agents and Antioxidants|SWAFAX|University of Reading|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02496806||17168|
NCT02508558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-102|Validation of Methods for Evaluating Operation Force, Motion and Visual Perception in Weightlessness||HopMot|University Hospital, Caen|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|22 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508558||16266|
NCT02249182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1116|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection|A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin Adolescents and Children With Chronic HCV-Infection||Gilead Sciences|Yes|Recruiting|November 2014|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|3 Years|17 Years|No|||February 2016|February 29, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249182||36170|
NCT02255994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/RdeT-01|UGYTEX® Mesh Versus Subvesical Plication in the Surgical Treatment of Bladder Prolapse|Comparison of Long-term Results of UGYTEX® Sub-bladder Mesh Placed Via a Transvaginal Transobturator Approach Versus Subvesical Plication Without Reinforcement in the Surgical Treatment of Bladder Prolapse|PRO-CURE II|Centre Hospitalier Universitaire de Nīmes|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Female|60 Years|N/A|No|||February 2016|February 5, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02255994||35646|
NCT02257346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine-RCT|Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery|The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Cesarean Delivery||Northwestern University|No|Not yet recruiting|November 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||October 2014|October 1, 2014|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02257346||35544|
NCT02505165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR014248|Illness Management and Parental Adjustment to Cancer Treatment|A Clinic-Based Interdisciplinary Intervention for Parents of Children With Cancer|IMPACT|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|November 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|296|||Both|2 Years|18 Years|No|||February 2016|February 1, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02505165||16526|
NCT02245919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3-024|Chronic Low Back Pain Rehabilitation in Primary Care: a Pilot Study|A Primary Care Biopsychosocial Intervention (Back on Track) for Patients With Chronic Low Back Pain in Which Psychosocial Factors Moderately Influence Daily Life Functioning: a Pilot Study||Maastricht University Medical Center|Yes|Recruiting|November 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245919||36421|
NCT02257749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-459|Trial Study of an Exercise Program for Youth With Persistent Symptoms After Concussion|Comparing Active Rehabilitation to a Comprehensive Education Intervention for Youth With Persistent Post-concussion Symptoms Following Concussion.||Holland Bloorview Kids Rehabilitation Hospital|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|No|||January 2016|January 29, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257749||35514|
NCT02502526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU424-P001|Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses|Comparison of Cumulative Dissipated Energy (CDE) and Balanced Salt Solution (BSS) Fluid Used With the Centurion® With the 45° Degree Balanced Ultrasound (U/S) Tip vs the Centurion® With Mini Flared Kelman U/S Tip vs the Infiniti® With Mini Flared Kelman U/S Tip on Hard Lenses||Alcon Research|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|177|||Both|21 Years|N/A|No|||January 2016|January 5, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502526||16729|
NCT02496104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HABIPREMA - RB 14.059|Habituation's Mechanisms in Preterm and Term Infants|Habituation's Mechanisms in Preterm and Term Infants. Behavioral Evaluation: APIB (Assessment of Preterm Infant's Behavior). Assessment of the Cortical and Vegetative Responses|HABIPREMA|University Hospital, Brest|Yes|Recruiting|July 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|10 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Preterm infants and term infants born in Brest University Hospital|January 2016|January 13, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496104||17222|
NCT02252302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01079|Exercise in Air Pollution and Lung Health in Asthmatics|The Effects of Inhaled Beta-2-Agonists and Air Pollution on Lung Function and Athletic Capacity||University of British Columbia|No|Recruiting|May 2015|November 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|8||Anticipated|20|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02252302||35930|
NCT02254980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1-H|Migration and Head Penetration of Vitamin-E Diffused Cemented Polyethylene Cup in Total Hip Arthroplasty|Migration and Head Penetration of Vitamin-E Diffused Cemented Polyethylene Cup Compared to Standard Cemented Cup in Total Hip Arthroplasty. A Randomized, Single-blinded, Clinical Trial|E1-hip|Danderyd Hospital|No|Recruiting|February 2013|January 2026|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|75 Years|No|||January 2016|January 27, 2016|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02254980||35724|
NCT02254993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3J14-201B-00|Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses|A Phase 2, Open-Label Study to Evaluate the Safety, Microbiology and Pharmacokinetics of C16G2 Administered in Single or Multiple Oral Gel Doses to Healthy Adult Subjects||C3 Jian, Inc.|No|Completed|October 2014|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|11||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254993||35723|
NCT02506049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00755-HUD|Laser Photocoagulation in Twin to Twin Transfusion Syndrome|Fetoscopic Directed Laser Photocoagulation of Communicating Placental Vessels in Twin to Twin Transfusion Syndrome|TTTS|University of Tennessee|No|Enrolling by invitation|April 2010|March 2020|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|16 Weeks|27 Weeks|No|||June 2015|July 21, 2015|July 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506049||16458|
NCT02506062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106798|A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)|A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)||Lawson Health Research Institute|No|Enrolling by invitation|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|69 Years|No|||August 2015|August 25, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02506062||16457|
NCT02497105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HON1402|Ketogenic Diet Program for Epilepsy|Ketogenic Diet Program for Epilepsy||Shriners Hospitals for Children|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02497105||17145|
NCT02252536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCIG - 006|HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder|Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|346|||Both|21 Years|N/A|No|||March 2016|March 8, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252536||35912|
NCT02244008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDS3123|Accumulative Effects of Talus Mobilization|Effects of Anteroposterior Talus Mobilization on Range of Motion, Pain, and Functional Capacity in Participants With Sub-acute and Chronic Ankle Injuries: A Randomized Controlled Trial||Federal University of Minas Gerais|Yes|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|59 Years|No|||September 2014|September 16, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244008||36568|
NCT02501200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152BE15026|CKD-391 Pharmacokinetic Study Phase I|Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02501200||16831|
NCT02504541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QST-15-005|Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism (STEADY)|A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism|STEADY|Antares Pharma Inc.|No|Active, not recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|133|||Male|18 Years|75 Years|No|||November 2015|November 11, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504541||16574|
NCT02503384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15411950401|Clinical and Basic Study for Pediatric Liver Transplantation|Clinical and Basic Study for Pediatric Liver Transplantation|CBSPLT|RenJi Hospital|No|Recruiting|July 2015|September 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|180|||Both|1 Month|17 Years|No|Probability Sample|Pediatric liver transplantation cases|July 2015|July 17, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503384||16663|
NCT02258256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-082F-C|Pilot Assessment of an Automatic Blood Pressure Monitor for Diagnosis and Management of Pre-eclampsia in a Low-resource Hospital|Pilot Clinical Assessment of the Diagnostic Capability, Usability, and Function of an Automatic Blood Pressure Monitor for Use in the Diagnosis and Management of Pre-eclampsia in a Low-resource Hospital||William Marsh Rice University|No|Not yet recruiting|August 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Female|18 Years|N/A|No|Non-Probability Sample|The study will include 10 eligible and consenting women at QECH who are clinically        identified as at-risk for pre-eclampsia or have already been diagnosed with pre-eclampsia.|May 2015|May 11, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02258256||35476|
NCT02257359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201691|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers|A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and Its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban||GlaxoSmithKline|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257359||35543|
NCT02248935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599819-2|Comparison of 2 Lightweight Y-meshes After Laparoscopic Sacrocolpopexy|Prospective Cohort Study Comparing Two Lightweight Y Meshes After Robotic-Assisted Laparoscopic Sacrocolpopexy Longterm Outcomes||Atlantic Health System|No|Enrolling by invitation|July 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|322|||Female|N/A|N/A|No|Non-Probability Sample|Women who had a robotic-assisted laparoscopic sacrocolpopexy using either mentioned Y-mesh        during the listed timeframe. All of the index cases were performed by fellowship-trained        FPMRS specialists.|September 2014|September 23, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02248935||36189|
NCT02509312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketorolac-1|Prospective Effect of Intravenous Ketorolac on Opioid Use and Complications Following Cesarean Delivery|A Prospective, Randomized, Control Trial of Ketorolac Versus Placebo on Opioid Analgesic Use and Complications Following Cesarean Delivery With Intra-Epidural Morphine||University Hospital Case Medical Center|Yes|Recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509312||16208|
NCT02505334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4174|A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|470|||Both|20 Years|N/A|No|||February 2016|February 17, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505334||16513|
NCT02250001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-244|Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C|Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C||Bristol-Myers Squibb|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|3000|||Both|20 Years|N/A|No|Probability Sample|University hospitals, General hospitals, and clinics that have relevant departments, such        as Liver Internal medicine, Gastroenterological medicine, Internal medicine, etc, where        the surveillance drug is mainly prescribed|January 2016|January 14, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250001|48 Weeks|36107|
NCT02241109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087/14|Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity|Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity|PASP|University Hospital Inselspital, Berne|No|Recruiting|September 2014|February 2017|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02241109||36791|
NCT02497417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-CDF-01-CS-001|A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients||Luminex Molecular Diagnostics|No|Recruiting|May 2015|||October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Stool|Both|N/A|N/A|No|Probability Sample|All comers|July 2015|July 10, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497417||17121|
NCT02497430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-GBS-01-CS-001|Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay|A Multi-Site Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay With Vaginal-Rectal Swab Specimens From Antepartum Pregnant Women||Luminex Molecular Diagnostics|No|Recruiting|June 2015|||October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|vaginal-rectal swab|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All comers|July 2015|August 31, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497430||17120|
NCT02254278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-HN002|Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer|A Randomized Phase II Trial for Patients With p16 Positive, Non-smoking Associated, Locoregionally Advanced Oropharyngeal Cancer||NRG Oncology|Yes|Recruiting|October 2014|||April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254278||35778|
NCT02496507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-SPS-Graves1|A Mixed-methods Evaluation of Sit-stand Workstations in an Office Setting|A Mixed-methods Evaluation of Sit-stand Workstations in an Office Setting: a Randomised Controlled Trial||Liverpool John Moores University|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496507||17191|
NCT02496520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEND/TIA|Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults|Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults|DEND/TIA|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Recruiting|September 2014|September 2021|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|40 Years|No|||June 2015|July 16, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02496520||17190|
NCT02501226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9532|Effectiveness of the First French Psychoeducational Program on Unipolar Depression|Effectiveness of the First French Psychoeducational Program on Unipolar Depression: Study Protocol for a Randomized Controlled Trial.|PURE|University Hospital, Montpellier|No|Not yet recruiting|September 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|332|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02501226||16829|
NCT02254382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA130514|Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure|Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure|ParadiseHF|ResMed|No|Not yet recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254382||35770|
NCT02248415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40355|Administration of Warm Blood Cardioplegia With or Without Roller Pump|Administration of Warm Blood Cardioplegia With or Without Roller Pump; a Randomized Controlled Trial.||St. Antonius Hospital|Yes|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Both|N/A|N/A|No|||September 2014|September 25, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02248415||36229|
NCT02255929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 5585|Gamma Knife Radiosurgery for Treatment of Essential Tremor|Gamma Knife Thalamotomy for Treatment of Essential Tremor||Swedish Medical Center|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|183|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255929||35651|
NCT02504554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001053|Beneficial Bacteria Treatment|Treating Gastrointestinal Problems in Children With Autism Using Beneficial Bacteria Treatment (BBT)|BBT|Arizona State University|Yes|Active, not recruiting|July 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|17 Years|No|||January 2016|January 6, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504554||16573|
NCT02503605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504-MAD-024-AR|Biosimilar Versus Urinary Gonadotropins|Prospective Randomized Clinical Trial to Test the Efficacy of a Biosimilar Recombinant Follicle Stimulating Hormone (FSH)vs. Urinary FSH in an Oocyte Donation Program|BEMDON|IVI Madrid|No|Not yet recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503605||16646|
NCT02240784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-AS1-NT-001|EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)|A Natural History Study of Acute Hepatic Porphyria (AHP) Patients With Recurrent Attacks||Alnylam Pharmaceuticals|No|Active, not recruiting|August 2014|November 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|Samples Without DNA|Urine and plasma samples for known proteins associated with porphyria attacks.|Both|18 Years|N/A|No|Non-Probability Sample|Acute Hepatic Porphyria|December 2015|December 11, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02240784||36816|
NCT02240797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00990|Kappa Opioid Receptor Imaging in Anorexia|Kappa Opioid Receptor Imaging in Anorexia||New York University School of Medicine|Yes|Active, not recruiting|September 2014|December 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|7|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are female, between the age range of 18 to 55, are medically healthy and        currently not taking any medications to treat any medical illness, and have a history of        anorexia nervosa and are recovered or never had a history of anorexia nervosa.|June 2015|June 25, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02240797||36815|
NCT02249260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/553 (REK)|A Prospective Cohort Study of Heart Patients Included in Exercise Based Rehabilitation in Oslo|Long-term Follow up of Exercise Based Cardiac Rehabilitation in Oslo|OsloHeartEx|Oslo University Hospital|Yes|Recruiting|March 2011|December 2020|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|20 Years|75 Years|No|||September 2014|September 22, 2014|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02249260||36164|
NCT02497053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meso-01|Four Versus Six Cycles of Pemetrexed/Platinum for MPM|Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study||Ain Shams University|No|Recruiting|June 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497053||17149|
NCT02495857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV01.2015-0863|A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee|A Double-Blind, Randomized, Study of the Effectiveness and Safety of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee||Actavis Inc.|No|Active, not recruiting|June 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|40 Years|N/A|No|||July 2015|July 10, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495857||17241|
NCT02495870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAPO 2A|The Acute Effects of Low Temperature for Long Time Heat Treatment of Pork Semitendinosus on Satiety||SAPO|University of Copenhagen|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02495870||17240|
NCT02254733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH091057|Assertive Community Treatment With CBT and SST for Schizophrenia|Enhancing Assertive Community Treatment With Cognitive Behavioral Therapy and Social Skills Training for Schizophrenia.||Veterans Medical Research Foundation|Yes|Active, not recruiting|February 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02254733||35743|
NCT02254798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI13015 PLASMA-INCA|Biomarkers for Acute Graft-versus-host Disease|Diagnostic and Prognostic Biomarkers for Acute Graft-versus-host Disease: a Prospective Single Centre Biological Study|PLASMA-INCA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|315|Samples With DNA|blood sample on day 7, 14, 21, 28 and at GVHD onset|Both|18 Years|75 Years|No|Probability Sample|All adult patients receiving an allogeneic transplant|September 2014|September 29, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02254798||35738|
NCT02246023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BronchoPropTCI|Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy|Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.||University of Zurich|Yes|Recruiting|January 2015|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|85 Years|No|||June 2015|June 25, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246023||36413|
NCT02504931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH0820117|Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems|SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis|DDx|The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2011|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|21 Years|65 Years|No|||March 2016|March 1, 2016|July 16, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504931||16544|
NCT02510469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-G315|Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells|||Hebei Medical University|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||January 2016|February 2, 2016|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510469||16119|
NCT02498938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D149206031|The Association of SERPINA1 Gene Disturbance in Patients With Lung and Gum Disorders|Evaluation of SERPINA1 Gene Polymorphisms in COPD as a Risk Factor for Periodontitis|SA1PLG|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Recruiting|March 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|60|Samples With DNA|2ml of blood sample from each subject will be collected in EDTA containing vials and kept at      -20 degrees until DNA extraction. the genomic DNA will be isolated and Z/S polumorphism in      SERPINA1 gene will be identified by PCR followed by restriction digestion pattern by Alu 1      restriction enzyme.|Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|patients,both male and female aged between 30-70yrs with COPD nd chronic periodontitis|July 2015|October 29, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498938||17005|
NCT02499718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRID-201506|Non-invasive Positive Pressure (NPPV ) for Severe Stable Chronic Obstructive Pulmonary Disease|Non-invasive Positive Pressure Ventilation for the Treatment of Severe Stable Chronic Obstructive Pulmonary Disease||Guangzhou Institute of Respiratory Disease|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|368|||Both|40 Years|80 Years|No|||July 2015|July 15, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02499718||16945|
NCT02243345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/13|Delayed Recompression for Decompression Sickness|Delayed Recompression for Decompression Sickness||Assaf-Harofeh Medical Center|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|204|||Both|N/A|N/A|No|Non-Probability Sample|Decompression sickness patients treated with hyperbaric recompression|September 2014|September 15, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02243345||36619|
NCT02256371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130604|Randomized Controlled Study of the Efficacy of Hypnosis Versus Relaxation and Control in Neuropathic Pain|Efficacy of 2 Psycho-physical Methods in the Treatment of Neuropathic Pain: a Randomized Controlled Multicentric Study|PSYCNEP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256371||35618|
NCT02256384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6421|Evaluation of Respiratory Acoustic Monitor in Children After Surgery|Evaluation of Respiratory Acoustic Monitor in Children After Surgery||Children's Hospital Medical Center, Cincinnati|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|2 Years|16 Years|No|||August 2015|August 20, 2015|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02256384||35617|
NCT02256397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0380|Home Centered Comprehensive Care (HCCC) for Children With Asthma|Home-Centered Comprehensive Care (HCCC) for Children With Severe Asthma: A Pilot Trial|HCCC|The University of Texas Health Science Center, Houston|No|Enrolling by invitation|October 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|2 Years|18 Years|No|||September 2015|September 4, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02256397||35616|
NCT02500914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRX002-001|SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma|A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma||Stemcentrx|No|Recruiting|June 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500914||16853|
NCT02505451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAPV-022015-SFC|Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes|Comprehensive Analysis of Regional Myocardial Function in Response to Dobutamine Stress in Metabolic Syndrome and Type 2 Diabetic Patients. Effect of Cardiac Adiposity, Inflammation and Hyperglycaemia||University of Avignon|No|Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|115|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02505451||16504|
NCT02505464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-03804-XP|Pregnancies Complicated by Fetal Anomalies|Characteristics of Pregnancies Complicated by Fetal Anomalies|FAR|University of Tennessee|No|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|50 Years|No|Probability Sample|All patients referred to, or being seen in the Ob-Gyn High Risk Clinics (ROH-MFM Clinic,        ROH-CHRP, ROH-Rout Center, Le Bonheur Fetal Center) will be potential participants.|June 2015|July 27, 2015|July 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505464|12 Months|16503|
NCT02243644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IESC/T-320/02.08.2013|Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT|A Clinical Trial to Study the Effects of Two Different Duration of Same Drug Albendazole in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Scan Head at the End of 6 Months||All India Institute of Medical Sciences, New Delhi|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|2 Years|18 Years|No|||December 2015|December 31, 2015|May 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243644||36596|
NCT02257307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010824|Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project|Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Ancillary Study - Implementation Project||Children's Hospital of Philadelphia|Yes|Active, not recruiting|July 2014|March 2017|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|821|||Both|32 Weeks|40 Weeks|No|Non-Probability Sample|Premature babies (N=500) with birth weights of <1251g who meet current ROP screening        guidelines in 5 NICUs in US.|April 2015|April 10, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257307||35547|
NCT02510066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12401905600|Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain|Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain: : a Randomized, Placebo Controlled Trial||Shanghai Cancer Hospital, China|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02510066||16150|
NCT02510079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150501|Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.|Emergent Expanded Access to Use Autologous Human Schwann Cell Augmentation of Nerve Autograft Repair in a Single Patient With Severe Peripheral Nerve Injury||University of Miami||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|65 Years||||December 2015|December 15, 2015|July 15, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02510079||16149|
NCT02503826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLGZB-FS-003-01|The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery|The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery||Second Affiliated Hospital of Xi'an Jiaotong University||Enrolling by invitation|January 2015|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|75 Years|No|||July 2015|July 20, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02503826||16629|
NCT02245659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN-326488|Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial|The Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial||McGill University Health Center|No|Recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02245659||36441|
NCT02245672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR001-3001|MGR001 / Advair Diskus Local Equivalence Study in Asthma|A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients||Mylan Inc.|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2725|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245672||36440|
NCT02257710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1402|BIOFLOW-III UK Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III United Kingdom Satellite||Biotronik UK Ltd.|No|Not yet recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|subjects from an all-comers patient population with all subjects requiring coronary        revascularization with a Drug Eluting Stent (DES).|October 2014|September 9, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257710||35517|
NCT02501460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPS|Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors|Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors||St. Jude Children's Research Hospital|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|73|||Both|18 Years|44 Years|No|||October 2015|October 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501460||16811|
NCT02497118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUCIH-ENDU-S001|Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC|Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Completed|August 2010|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||May 2014|July 13, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02497118||17144|
NCT02241590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGHLC20140818001|Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus||ShuGuang Hospital|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|60 Years|No|||November 2015|November 29, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241590||36754|
NCT02502877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDLSpot1|Central Temperature Variations During Midazolam vs Propofol Sedation for Loco Regional Anesthesia|Central Temperature Variations During Midazolam vs Propofol Sedation for Loco Regional Anesthesia||Hospital da Luz, Portugal|No|Recruiting|July 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 6, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02502877||16702|
NCT02510482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 15-2-023|Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis|Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis||Maastricht University Medical Center|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|Individuals with clinically stable moderate aortic valve stenosis|March 2016|March 15, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510482||16118|
NCT02499731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1402004505|Strong Hearts: Rural CVD Prevention|Strong Hearts, Healthy Communities: A Rural Community CVD Prevention Program||Cornell University|No|Active, not recruiting|March 2014|February 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|194|||Female|40 Years|N/A|No|||January 2016|January 5, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499731||16944|
NCT02500758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBLM|Effectiveness of Preoperative Surgical Scrubbing Using Clorhexidine Digluconate and Parachlorometaxylenol (ECP)|Effectiveness of Preoperative Surgical Scrubbing in Reducing Bacterial Load, Using Chlorhexidine Digluconate (CHX) and Parachlorometaxylenol (PCMX)|ECP|Universidad Complutense de Madrid|No|Enrolling by invitation|June 2015|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02500758||16865|
NCT02248363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic-pain-effect-prediction|Nationwide Evaluation of Multimodal Rehabilitation in Patients With Chronic Musculoskeletal Pain|Nationwide Evaluation of Multimodal Rehabilitation in Patients With Chronic Musculoskeletal Pain: Treatment Effectiveness and Prediction||Karolinska Institutet|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|65 Years|No|Probability Sample|Included subjects are patients with chronic pain conditions not caused by malignancies        (mainly musculoskeletal pain) aged between 18 and 65.|September 2014|September 21, 2014|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02248363|12 Months|36233|
NCT02243722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-5333A3|Establish Quantitative Measurements of Laryngeal Sensorimotor Functions and Evaluating the Grade of Phonation and Swallowing Impairment|Establish Comprehensive Quantitative Measurements of Laryngeal Sensorimotor Functions and Evaluating the Grade of Phonation and Swallowing Impairment||Chang Gung Memorial Hospital|Yes|Recruiting|July 2014|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients from a tertian referral medical center.|February 2014|September 16, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243722|3 Months|36590|
NCT02503488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKonstanz|Decreasing Youth Involvement in Violence in Burundi|Decreasing Youth Involvement in Violence in Burundi||University of Konstanz|Yes|Enrolling by invitation|June 2015|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|40 Years|No|||July 2015|July 17, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02503488||16655|
NCT02503735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-337-1777|Effect of Harvoni on Proteinuria and Estimated Glomerular Filtration Rate (eGFR) in Hepatitis C (HCV) Associated Chronic Kidney Disease (CKD)|Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease||Massachusetts General Hospital|Yes|Recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503735||16636|
NCT02509754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG062015TRN|Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function|Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial|AFARC-LVF|University of Turin, Italy|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509754||16174|
NCT02248831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP19|Evaluation of Cardiopulmonary Diseases by Ultrasound|Non-invasive Evaluation of Cardiopulmonary Diseases Using Transthoracic Parametric Doppler Based Assessment of Lung Doppler Signals||Echosense Ltd.|No|Recruiting|September 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|18 Years|N/A|No|||March 2015|January 21, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02248831||36197|
NCT02248844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-147|Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea|||Allergan|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects with Lateral Canthal Lines (Crow's Feet Lines)|December 2015|December 7, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02248844||36196|
NCT02249169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000305|Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome|Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome||Mayo Clinic|No|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|240|Samples With DNA|Plasma, serum, whole blood, stool, colonic mucosal tissue|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Motility Clinic, Clinical Research Unit, GI Department|January 2016|January 5, 2016|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02249169||36171|
NCT02244619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMCPH-13-001|PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement|Randomized, Double-Blind, Study Comparing Oral Acetaminophen Plus Intravenous (IV) Placebo to Oral Placebo Plus IV Acetaminophen Given Perioperatively for Controlling Pain in the 24hr Post-op Period After Total Hip or Knee Joint Replacement|KHEA|Kettering Health Network|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02244619||36521|
NCT02244632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-CC-005|Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer|An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer||Isofol Medical AB|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244632||36520|
NCT02496819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-Autism|Metacognitive Self-regulated Learning and Sensory Integrative Approaches for Children With Autism Spectrum Disorders|Metacognitive Self-regulated Learning and Sensory Integrative Approaches for Children With Autism Spectrum Disorders||University of Western Sydney|No|Recruiting|June 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|6 Years|12 Years|No|||July 2015|July 14, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02496819||17167|
NCT02504060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMUBC|Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment|Multicenter Randomized Double-blind Placebo-controlled Clinical Trials to Evaluate the Clinical Efficacy and Safety of N-acetyl Glucosamine Capsule for Irritable Bowel Syndrome With Diarrhea (IBS-D) Treatment||Third Military Medical University|Yes|Recruiting|June 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02504060||16611|
NCT02504073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ08/12/14|Clinical Reasoning Process of Physiotherapists When Observing Hemiplegic Gait|Clinical Reasoning Process of Physiotherapists When Observing Hemiplegic Gait||Technical University of Bern|No|Active, not recruiting|March 2015|October 2015|Anticipated|June 2015|Actual|N/A|Observational|N/A||5|Actual|54|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|physiotherapists working with stroke patients|July 2015|July 17, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02504073||16610|
NCT02249767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tret.2014.10.01.14|Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel|Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel||Spear Pharmaceuticals|Yes|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|574|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249767||36125|
NCT02249988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX203-002|Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B|Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B||Abivax S.A.|Yes|Active, not recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02249988||36108|
NCT02240862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2R|The CREST-2 Registry|The CREST-2 Registry|C2R|University of Maryland|No|Recruiting|February 2015|March 2022|Anticipated|February 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients aged 18 - 80 years old with symptomatic or asymptomatic carotid artery disease.|November 2015|November 4, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02240862|12 Months|36810|
NCT02504684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130220|Treatment of Saphenous Vein Reflux With 1920-nm Diode Laser|Endovenous Laser Ablation of the Great Saphenous Vein Comparing 1920-nm and 1470-nm Diode Laser||Instituto Vascular BH|Yes|Completed|February 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|70 Years|No|||July 2015|July 20, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02504684||16563|
NCT02504827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP-15-01273|Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis|Steady-state Pharmacokinetics of Ceftazidime/Avibactam in CF||University of Southern California|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504827||16552|
NCT02498704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403645-1|Dry Needling and Stretching vs. Stretching Alone on Hamstring Flexibility in Patients With Knee Pain|The Effectiveness of Dry Needling and Stretching vs. Stretching Alone on Hamstring Flexibility in Patients With Knee Pain: A Randomized Controlled Trial||Keller Army Community Hospital|No|Completed|November 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|40 Years|No|||February 2016|February 22, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498704||17023|
NCT02499471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 39146.068.11|Brown Adipose Tissue Activity and Thyroid Hormone|Brown Adipose Tissue Activity and Thyroid Hormone||Maastricht University Medical Center|No|Completed|March 2012|July 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02499471||16964|
NCT02246699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-041|Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers|A Study to Evaluate the Efficacy and the Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers: a Randomized, Double-blind, Parallel Groups and Placebo Controlled Clinical Trial.||Kitozyme|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|60 Years|No|||March 2015|March 30, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246699||36361|
NCT02246998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0140|Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults|A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or Other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF) Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults With eGFR ≥70 mL/Min||Gilead Sciences|No|Completed|December 2014|February 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|55 Years|No|||March 2016|March 16, 2016|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246998||36338|
NCT02505581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002345-21|Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis|Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics. A Prospective, Randomized, Controlled, Multicentric Study (PROF-ATB Trial)|PROF-ATB|Hospital Universitari Vall d'Hebron Research Institute|Yes|Not yet recruiting|October 2015|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|536|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02505581||16494|
NCT02247752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRO -2014-02|Follow-up of HBsAg Inactive Carriers Study|Follow-up of HBsAg Inactive Carriers Study|PIBAC|Centre Hospitalier Régional d'Orléans|No|Recruiting|September 2014|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|18 Years|70 Years|No|||September 2014|March 2, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247752||36280|
NCT02257580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unknown2|The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO|The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)||Hospital for Special Surgery, New York|Yes|Not yet recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|18 Years|No|||January 2015|January 16, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02257580||35527|
NCT02257593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP 71, 2008/2009|Developmental Adaptation to an Obesogenic Environment|Developmental Contribution to Macronutrient Selection and Appetite Control in Adult Survivors of Kwashiorkor and Marasmus||The University of The West Indies|No|Completed|May 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|63|||Both|17 Years|46 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02257593||35526|
NCT02248155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.618|Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)|Sifrol® Onset of Action and Impact on RLS: A 12-week Observational Study in Patients With Primary RLS||Boehringer Ingelheim||Completed|April 2006|||November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2644|||Both|N/A|N/A|No|Non-Probability Sample|Patients suffering from moderate to severe RLS recruited at office-based general        practitioners and interists|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248155||36249|
NCT02248168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.599|Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease|Mirapex PMS Study Final Report||Boehringer Ingelheim||Completed|March 2002|||January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1449|||Both|N/A|N/A|No|Non-Probability Sample|Patients with idiopathic Parkinson's disease|September 2014|September 22, 2014|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248168||36248|
NCT02509234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TrI.PReSarc V150429|Trabectedin and Irinotecan for Refractory Pediatric Sarcomas|Trabectedin and Irinotecan in Pediatric Refractory Sarcomas|TrIPReSarc|Technische Universität München|No|Active, not recruiting|February 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|10 Years|40 Years|No|Non-Probability Sample|Adolescents and young adults (age10 - 40 yoa) with refractory sarcoma|July 2015|July 24, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02509234||16214|
NCT02501525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-RIRS-UAS-03|Effect of Ureteral Access Sheath Use on Postoperative Pain Level in Patients Undergoing RIRS|Effect of Ureteral Access Sheath Use on Postoperative Pain Level in Patients Undergoing Retrograde Intrarenal Surgery (RIRS)||Selcuk University|No|Recruiting|August 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02501525||16806|
NCT02257658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 398/2590|Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM|Doxycycline Prophylaxis or Incentive Payments to Reduce Incident Syphilis Among HIV- Infected Men Who Have Sex With Men Who Continue to Engage in High Risk Sex: A Randomized, Controlled Pilot Study|DPMSM|Los Angeles LGBT Center|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02257658||35521|
NCT02257736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105505|An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)|A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)||Janssen Research & Development, LLC|No|Recruiting|November 2014|August 2021|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|960|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257736||35515|
NCT02248649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1696-I|Telemedicine Intervention to Improve Cognitive Function|A Telemedicine Intervention to Improve Cognitive Function in Patients With PD||VA Office of Research and Development|No|Recruiting|December 2014|September 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|128|||Both|40 Years|N/A|No|||January 2016|January 20, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248649||36211|
NCT02502357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-043|Healing Statements and Their Effect on Post Operative Pain|The Power of Healing Statements on Post Operative Pain Control: A Randomized Controlled Trial|PHSPOPC|Medstar Research Institute|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502357||16742|
NCT02495597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 124/13|LCI and Bronchial Inflammation in Patients With BO|Lung Clearance Index (LCI) and Bronchial Inflammation in Patients With Bronchiolitis Obliterans (BO)|FRABO-02|Johann Wolfgang Goethe University Hospitals|No|Completed|April 2013|December 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|37|Samples With DNA|blood, sputum cells, sputum supernatans|Both|6 Years|28 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffering from Bronchiolitis obliterans and controls|July 2015|July 22, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02495597||17261|
NCT02254668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH_Nr. 2012-0409|Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography|Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography|OCTandCAV|University of Zurich|Yes|Recruiting|December 2013|February 2023|Anticipated|February 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|278|||Both|18 Years|80 Years|No|||September 2014|September 29, 2014|December 29, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02254668||35748|
NCT02245789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/43|Does the Use of a Videolaryngoscope Modifies Anesthetic Induction ?|Does the Use of a Videolaryngoscope Modifies Anesthetic Induction ?|MGM-PicRemi|Hopital Foch|No|Completed|September 2014|February 2016|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02245789||36431|
NCT02510118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL2014099-Y0103|Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients|Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients：a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study||Nanjing NingQi Medicine Science and Technology Co., Ltd.|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02510118||16146|
NCT02499484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI-1764|Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy|The Use of Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy: a Randomized Placebo Controlled Trial|NEAT|Royal College of Surgeons, Ireland|No|Not yet recruiting|August 2015|October 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02499484||16963|
NCT02247466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMBDKHernia2014|Optimizing Surgical Conditions During Laparoscopic Umbilical, Incisional -and Linea Alba Herniotomy With Deep Neuromuscular Blockade|Optimizing Surgical Conditions During Laparoscopic Umbilical, Incisional -and Linea Alba Herniotomy With Deep Neuromuscular Blockade||Herlev Hospital|Yes|Recruiting|February 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|September 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02247466||36302|
NCT02254447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201713|Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions|An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|April 2, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254447||35765|
NCT02254460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202738|Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk|A Double Blind, Randomized, Two-way Cross-over Study to Investigate the Uptake of Iron From Micronutrient Fortified Powder vs. From Tailored Control in Milk.||GlaxoSmithKline|No|Completed|February 2013|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254460||35764|
NCT02496494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2012-09-010|The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients|||Kyungpook National University|Yes|Recruiting|September 2012|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|70 Years|No|||July 2015|July 13, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02496494||17192|
NCT02497066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#412770-2|Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms|Randomized, Controlled, Double-blind, Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms||Walter Reed National Military Medical Center|No|Enrolling by invitation|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|399|||Both|18 Years|90 Years|No|||June 2015|July 10, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497066||17148|
NCT02497079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUH-P-1|Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples|Comparison of the Diagnostic Accuracy of Nested and Real-time Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples in Patients With Isolated Intrathoracic Lymphadenopathy||Pusan National University Hospital|No|Recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497079||17147|
NCT02252289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154768|Fluctuation of Airway Function in Children With Asthma|Fluctuation of Airway Function in Children With Asthma Phenotype as a Predictor of Outcome||Imperial College London|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|5 Years|17 Years|No|Non-Probability Sample|Children with problematic severe asthma (PSA) will be identified from clinical records and        the existing clinical database which records all those who have been assessed as part of        the Difficult Asthma (DA) protocol. Children newly referred to the DA protocol will be        identified by notification from Clinical Nurse Specialists (CNSs) who receive the        referrals. Children with mild-moderate asthma will be identified from clinical records        only.|February 2016|February 19, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252289||35931|
NCT02255058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Linde001|MIND Score for Prolonged Mechanical Ventilation|Psychometric Validation of the Multi-INdependency Dimensions (MIND) Score for Patients Under Prolonged Mechanical Ventilation|MIND|Linde AG|No|Completed|August 2014|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients with Prolonged mechanical Ventilation and a Diagnosis of Acute lung injury,        COPD/Chronic Lung Disease, Neuromuscular Disorders, Post-Operative, Cardiovascular        Disorders, Trauma, Other.|October 2014|February 27, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255058||35718|
NCT02255474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0231|Bifocal Lenses In Nearsighted Kids|Soft Bifocal Contact Lens Myopia Control|BLINK|Ohio State University|Yes|Recruiting|September 2014|March 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|294|||Both|7 Years|11 Years|No|||August 2015|August 5, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02255474||35686|
NCT02255916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTO_03|Short-term Effects of Sound-bed Music Therapy in Healthy Caregivers of a Hospital Oncology Ward (MTO_03)|Short-term Effects of Live Sound-bed Music on Physiological and Psychological Parameters in Healthy Oncology Staff - A Randomized Controlled Trial With Crossover Design|MTO_03|ARCIM Institute Academic Research in Complementary and Integrative Medicine||Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02255916||35652|
NCT02496546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0108-1082|An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Trial Evaluating the Effect of LEO 32731 Cream 20 mg/g in Adults With Mild to Moderate Atopic Dermatitis (AD)||LEO Pharma|No|Active, not recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|N/A|No|||February 2016|February 17, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496546||17188|
NCT02502682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDiff070115|Chlorhexidine Bathing Effect on Clostridium Difficile Rates|Effect of Daily Chlorhexidine Bathing on Clostridium Difficile Rates on the General Medical Floor in Patients Receiving Antibiotics||Northwestern Medicine Delnor Hospital|No|Enrolling by invitation|July 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502682||16717|
NCT02255149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00053796|A Feasibility Study for Growth Bone Vertically With Titanium Mesh and Allograft in Lower Posterior Jaw|Vertical Ridge Augmentation Using Titanium Mesh and Allograft in Posterior Mandible: A Feasibility Study||University of Michigan|Yes|Completed|September 2011|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|September 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255149||35711|
NCT02257619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-203|Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer|A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer||Incyte Corporation|No|Active, not recruiting|June 2014|January 2019|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257619||35524|
NCT02258282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP20140688|Safety and Efficacy of Etanercept in Patients With Psoriasis|||Chengdu PLA General Hospital|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||August 2015|August 16, 2015|October 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258282||35474|
NCT02245425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014096|Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain|A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain: A Randomized Controlled Trial||A.T. Still University of Health Sciences|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|22 Years|50 Years|No|||September 2014|September 17, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02245425||36459|
NCT02504840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150158|Natural History of Multiple Sclerosis and Its Mimickers|Thematic Studies of Multiple Sclerosis and Related Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|August 2041|Anticipated|February 2041|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504840||16551|
NCT02496871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002758|Remote Delivery of Weight Management by Phone and Social Media|Remote Delivery of Weight Management by Phone and Social Media||University of Kansas Medical Center|No|Active, not recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|70 Years|No|||October 2015|October 20, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02496871||17163|
NCT02241304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADBV-ABS-0214-NEAT-3H|Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)|Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)|NEAT-3|University of Debrecen|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective surgeries requiring muscle relaxation|January 2016|January 27, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02241304||36776|
NCT02502695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-193|A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)|A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)||Dana-Farber Cancer Institute|No|Recruiting|June 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Participants that will have VATS lobectomy and segmentectomy procedures for lung cancer|July 2015|February 5, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02502695||16716|
NCT02497378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107666|A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Patients With Relapsed or Refractory Multiple Myeloma (MM)||Janssen Pharmaceutical K.K.|No|Recruiting|July 2015|November 2017|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|N/A|No|||February 2016|February 17, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497378||17124|
NCT02247479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29176|A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)|||Hoffmann-La Roche||Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|936|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|July 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247479||36301|
NCT02255695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|472552/2010-4|Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain|Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain - A Randomized, Controlled Trial||Universidade Federal de Sao Carlos|No|Completed|December 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02255695||35669|
NCT02255305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 14-331|FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI|Fecal Microbiota Transplantation Versus Standard Medical Therapy for Initial Treatment of Recurrent Clostridium Difficile Infection||NorthShore University HealthSystem|Yes|Recruiting|January 2015|December 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02255305||35699|
NCT02500394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1476-Version 6|Biomarker Guided Intervention for Prevention of Acute Kidney Injury|Biomarker Guided Intervention to Prevent Development of Acute Kidney Injury in High-risk Surgical Patients|BigpAK|University Hospital Regensburg|Yes|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02500394||16893|
NCT02497092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0021-15-RMC|Different Intravitreal Injection Techniques and Pain Level|Effect of Different Injection Techniques on Pain Level in Intravitreal Injections||Rabin Medical Center|Yes|Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497092||17146|
NCT02258451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17096|Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases||Bayer|No|Recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|311|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258451||35461|
NCT02258464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16298|Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy||Bayer|No|Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|227|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258464||35460|
NCT02244190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.124|Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers|Bioequivalence of Two Different Oral Solutions of 500 mg of Tipranavir (New Formulation vs. Current Formulation) Administered in Combination With 200 mg of Ritonavir (Oral Solution) to Healthy Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|April 2008|||May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244190||36554|
NCT02244203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1267.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers|Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial||Boehringer Ingelheim||Completed|February 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244203||36553|
NCT02244866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_01_2012|Efficacy of Pergoveris in Aged IVF Patients|A Randomized Controlled Trial to Compare the Efficacy Between Pergoveris and Follitropin Alfa in Ovarian Stimulation in Patients Aged ≥ 35 Years||Vietnam National University|No|Completed|October 2012|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|35 Years|45 Years|No|||December 2014|December 23, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02244866||36502|
NCT02245061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.865|Cortical Excitability Assessment Using Paired Pulses|Cortical Excitability Assessment of Pharmacoresistant Focal Epilepsy Using Direct Electrical Stimulation During Stereo-electroencephalography|PP|Hospices Civils de Lyon|No|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02245061||36487|
NCT02257268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAMOS REC 01|Effectiveness of a Program for Physical Activity and Healthy Eating Promotion in Hypertensives|Effectiveness of VAMOS - a Change Behavior Program for Physical Activity and Healthy Eating Promotion - in Hypertensives||Universidade Federal de Santa Catarina|No|Completed|October 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|40 Years|N/A|No|||August 2015|August 18, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02257268||35550|
NCT02500927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8273-CL-0202|A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations|Phase II Study of ASP8273 — An Open-Label, Study of the Oral Administration of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-NaïvePatients With Non-Small Cell Lung Cancer Harboring EGFR Mutations||Astellas Pharma Inc|No|Active, not recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|20 Years|N/A|No|||December 2015|December 14, 2015|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500927||16852|
NCT02501187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptosis-01|Risk of Dry Eye Post Different Surgeries for Blepharoptosis Repair|Comparison Between Three Different Surgeries for Blepharoptosis Repair and Their Impact on Dry Eye Status||Rabin Medical Center|No|Not yet recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02501187||16832|
NCT02502838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0394|The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair|The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who present to urogynecologist for surgical management|January 2016|January 26, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502838||16705|
NCT02245074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/056/HP|Non Invasive Evaluation of Bronchial Inflammation in Infants : a Study of the Sputum Cellularity After Hypertonic Saline Induction|Non Invasive Evaluation of Bronchial Inflammation in Infants : a Study of the Sputum Cellularity After Hypertonic Saline Induction|CYTOASTHME|University Hospital, Rouen|No|Terminated|June 2010|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|34|||Both|6 Months|3 Years|No|||September 2014|September 17, 2014|October 15, 2010||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT02245074||36486|
NCT02245438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.22|Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers|A Single Centre, Open-label, Randomized, Parallel Group, Multiple Dose Comparison of the Effect of TPV 750 mg and RTV 200 mg or TPV 500 mg and RTV 100 mg, Administered Twice Daily, on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol (Ortho®-1/35 ) Administered as a Single Dose, in Healthy Female Adult Volunteers.||Boehringer Ingelheim||Terminated|May 2002|||June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245438||36458|
NCT02245451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.26|Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers|A Single-centre, Open-label Study of Multiple Doses of Tipranavir 500 mg and Ritonavir 200 mg (Twice Daily) on the Pharmacokinetic Characteristics of Methadone Administered as a Single Dose in Healthy Volunteers||Boehringer Ingelheim||Completed|January 2005|||February 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245451||36457|
NCT02510391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-Preschool 2015|Modular Treatment for Preschool Anxiety|Modular Treatment for Preschool Anxiety||University of South Florida|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|7 Years|No|||October 2015|October 5, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02510391||16125|
NCT02498171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/HD07/2061U|Labour Analgesia; Comparing a Combinations of Either Fentanyl or Bupivacaine With Intrathecal Morphine|Evaluation Of Efficacy And Safety Of Labour Analgesia By Intrathecal Morphine With Fentanyl Compared To Morphine With Bupivacaine In Mulago Hospital: A Double-blinded Randomized Control Trial||Makerere University|Yes|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|138|||Female|14 Years|60 Years|No|||July 2015|July 12, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02498171||17064|
NCT02498184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0064-15-ZIV|Perioperative Acupuncture for Impacted Mandibular Third Molar Extractions|Perioperative Acupuncture for Impacted Mandibular Third Molar Extractions - a Double Blinded Randomized Controlled Trial||Ziv Hospital|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498184||17063|
NCT02246452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-13|Assessment of the Nutritional Status of Children and Adolescents With Malignancies|Assessment of the Nutritional Status of Children and Adolescents With Malignancies Aged Between 0-18, Based on BMI Percentiles and Standard Deviation Scores, at Diagnosis, During Treatment, and During Two Years Follow-up||University of Hohenheim|No|Completed|June 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|135|||Both|N/A|18 Years|No|Non-Probability Sample|Children and adolescents, treated for one of the following diseases: lymphoma, germ cell        tumor, nephroblastoma, soft tissue sarcoma, neuroblastoma, Ewing sarcoma, brain tumor, or        acute lymphoblastic leukemia (ALL)/acute myeloid leukemia (AML)|September 2014|September 19, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246452||36380|
NCT02505204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/09/2015|PVB With vs. Without Clonidine for Ventral Hernia Repair|Paravertebral Block With Versus Without Clonidine for Patients Undergoing Ventral Hernia Repair: A Prospective Double-blinded Randomized Study||Makassed General Hospital||Recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|65 Years|N/A|No|||September 2015|September 2, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505204||16523|
NCT02505373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/08|ASSIP, Attempted Suicide Short Intervention Program. Two Year Follow-Up Study|A Novel Brief Therapy for Attempted Suicide: Two Year Follow-Up Randomized Controlled Study of the Attempted Suicide Short Intervention Program (ASSIP)|ASSIP|University of Bern|No|Completed|January 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||January 2016|January 13, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02505373||16510|
NCT02502435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819453|Human Plasma Fatty Acid Oscillations|Exploratory Phase I Study to Define Plasma Fatty Acid Oscillations in Patients With Night Eating Syndrome Compared to Healthy Volunteers.||University of Pennsylvania|No|Recruiting|July 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Night-Eating Syndrome: Participants have to meet both of the criteria for        nocturnal ingestions and evening hyperphagia; eat 30% of their caloric intake after dinner        with nocturnal wake ups to eat at a frequency of ≥ 5 times per week.        Matching healthy participants: Participantswill be matched to a patient with Night-Eating        Syndrome by gender, age and BMI.|January 2016|January 28, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02502435||16736|
NCT02252068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA035297|Study of Treatment for Opioid Dependence and Anxiety Disorders|Behavioral Treatment Development for Co-occurring Opioid Dependence and Anxiety Disorders||Mclean Hospital|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252068||35948|
NCT02252081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-014-13F|Metformin in Kidney Disease|Dysmetabolism of Chronic Kidney Disease and Vascular Health||VA Office of Research and Development|Yes|Recruiting|October 2014|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252081||35947|
NCT02256631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1112|Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants|Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|April 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|N/A|N/A|No|||February 2016|February 1, 2016|October 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02256631||35598|
NCT02503943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLOOD|Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes|What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY）||Third Affiliated Hospital of Third Military Medical University|Yes|Active, not recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|35 Years|60 Years|No|||July 2015|July 19, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503943||16620|
NCT02244216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260.3178|Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease||Boehringer Ingelheim||Completed|April 2000|||June 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2914|||Both|N/A|N/A|No|Non-Probability Sample|Patinet with chronic obstructive respiratory tract disease recruited at general        practitioners, pneumologists, internists|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244216||36552|
NCT02249195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVEAL|Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia|Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia|REVEAL|University of Cape Town|Yes|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|45 Years|No|Non-Probability Sample|The patients will be recruited via a single-centre, prospective study of women with        cardiovascular disease presenting pre- or postpartum, attending Groote Schuur Hospital.        Since 1 July 2010, these patients have been seen at a weekly clinic, jointly run by        cardiologists and obstetricians, under the leadership of Prof. Karen Sliwa and Prof John        Anthony. We see about 100 new patients presenting with cardiovascular disease in pregnancy        per annum. About 200 newly diagnosed pregnant women with documented or suspected        cardiovascular disease will be screened for the indication to insert a REVEAL device.        Those patients will be part of an ongoing registry entitled: Registry of newly diagnosed        cases with cardiac disease in maternity-Phase II ( CDM-2).|September 2014|September 22, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02249195|2 Years|36169|
NCT02254434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200338|A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions|An Open-label Single-dose Pharmacokinetic Study of an Oral Formulation in Tablets Containing Eltrombopag 50 mg (Revolade, Glaxosmithkline Mexico, S.A. De C.V.) in Healthy Volunteers Under Fasting Conditions||GlaxoSmithKline|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 2, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254434||35766|
NCT02244372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHE-PI-CM|Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity|||Chonbuk National University Hospital|Yes|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 17, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02244372||36540|
NCT02504437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMMSC-1|Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease||TPAABPIHD|Academy Military Medical Science, China|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|N/A|75 Years|No|||July 2015|July 20, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02504437||16582|
NCT02504450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC6066|Outcomes of Antipsychotic Medication Used in the Emergency Department|Outcomes of Antipsychotic Medication Use in the Emergency Department: A Retrospective Comparison Study|OAMED|Advocate Health Care|No|Enrolling by invitation|April 2015|April 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Probability Sample|subjects treated in the emergency department for agitation|July 2015|July 20, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02504450||16581|
NCT02503007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2015-CS01|Effects of 14-days of HMB-free Acid on Changes in Muscle During 4-days of Survival Training|The Effects of 14-days of HMB-Free Acid on Changes in Muscle Architecture, Blood Markers of Muscle Damage and Performance During 4-Days of Survival Training||Metabolic Technologies Inc.|No|Completed|July 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|27 Years|Accepts Healthy Volunteers|||October 2015|November 24, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02503007||16692|
NCT02249520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35521|Calibration of PET-MR Imaging Protocols on Biograph mMR|Calibration of PET-MR Imaging Protocols at the Cedars-Sinai Medical Center (CSMC) Biomedical Imaging Research Institute (BIRI) Research Imaging Core||Cedars-Sinai Medical Center|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249520||36144|
NCT02502578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNT-01-001|Safety Study of CNT-01 in Patients With Idiopathic TGCV|Phase I/IIa Study of CNT-01 in Patients With Idiopathic Triglyceride Deposit||Osaka University|Yes|Recruiting|September 2015|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|N/A|No|||December 2015|December 14, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502578||16725|
NCT02496832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faza-Maestro|A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo|An Exploratory Study of Hypoxia Imaging Using 18F-FAZA-PET in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine + TH-302/Placebo (MAESTRO: EMR200592-001)||University Health Network, Toronto|Yes|Suspended|November 2014|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02496832||17166|
NCT02254343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-3564A3|Effects of Proximal and Distal Robot-assisted Therapy Combined With Functional Training|Effects of Proximal and Distal Robot-assisted Therapy Combined With Functional Training on Stroke Rehabilitation||Chang Gung Memorial Hospital|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|69|||Both|20 Years|80 Years|No|||March 2016|March 7, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254343||35773|
NCT02254356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005-FLX|Zilver Flex Post-Market Study in Japan|Zilver PTX Post-Market Surveillance Study of Bare Metal Stents for Treating Femoropopliteal Artery Disease in Japan||Cook||Active, not recruiting|May 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|239|||Both|N/A|N/A|No|||July 2015|July 21, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02254356||35772|
NCT02254369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-100-01|Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects|A Randomized, Phase 1, Double-Blind, Placebo-Controlled, First-in-Human, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects||GliaCure, Inc.||Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02254369||35771|
NCT02510417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAPS|Allogeneic Virus-specific T Cell Lines (VSTs)|Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus Infections Post Allogeneic Stem Cell Transplant||Children's Research Institute|Yes|Recruiting|October 2014|September 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|45 Years|No|||January 2016|January 27, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510417||16123|
NCT02510456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33188|Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging|Monitoring Neoadjuvant Chemotherapy Response In Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging (DOSI)|DOSI|Boston Medical Center|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|37|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510456||16120|
NCT02258425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA035409|Homeless Female Offenders Returning to the Community|Homeless Female Offenders Returning to the Community: Improving Hopeful Futures|FEM-CARE|University of California, Los Angeles|Yes|Recruiting|January 2015|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Female|18 Years|55 Years|No|||November 2015|November 30, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258425||35463|
NCT02258438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0429|Effect of Breaking up Prolonged Sitting on Metabolic Flexibility|Effect of Breaking up Prolonged Sitting on Metabolic Flexibility||University of Colorado, Denver|No|Recruiting|October 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|30|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258438||35462|
NCT02244606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCY-078-202|Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis|Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral SCY-078 vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults||Scynexis, Inc.|No|Recruiting|September 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||February 2016|March 2, 2016|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244606||36522|
NCT02507960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00052062|The Gamma Pod: A Clinical Feasibility Study Device GCC 1202: The Gamma Pod: A Clinical Feasibility Study|(GCC 1202): Tumor Bed Dose Delivery Using a Breast Specific Radiosurgery Device. The Gamma Pod : A Clinical Feasibility Study||University of Maryland|Yes|Active, not recruiting|January 2016|December 2019|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Female|60 Years|N/A|No|||January 2016|January 21, 2016|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507960||16311|
NCT02507973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063355|Study of Airway Pressure Release Ventilation and Intracranial Pressure in Patients With Severe Traumatic Brain Injury|Study of APRV and ICP in Patients With Severe Traumatic Brain Injury||University of Maryland|No|Not yet recruiting|July 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|50|||Both|14 Years|N/A|No|Probability Sample|All patients with intracranial pressure monitor requiring mechanical ventilation support        will be eligible for enrollment in the study|July 2015|July 22, 2015|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507973||16310|
NCT02500719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203600|Real-time Functional MRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD|Real-time Functional MRI and Neurofeedback of Brain Networks Mediating Trauma||University of Arkansas|No|Recruiting|August 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|27|||Female|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both groups will represent a convenience sample of participants who self-identify into a        group|October 2015|October 1, 2015|July 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500719||16868|
NCT02500732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POST6|Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope|A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6|POST6|University of Calgary|Yes|Recruiting|July 2015|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02500732||16867|
NCT02248350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Georgetown_University_MC|An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy|An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.|MIGHTY|Georgetown University|Yes|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Male|40 Years|70 Years|No|||December 2015|December 4, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248350||36234|
NCT02254525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBEC02|A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain|A Multicenter, Randomized, Double-blind, and Parallel Groups, Placebo-controlled Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain.||Biomendi S.A.U.|No|Terminated|May 2012|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|80 Years|No|||September 2014|October 1, 2014|September 25, 2014||No|Sample not reached in traumathology arm|No||https://clinicaltrials.gov/show/NCT02254525||35759|
NCT02254538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.1|A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Preliminary Pharmacokinetics Study in Healthy Male Volunteers After Oral Administration of BILR 355 BS Solved in PEG 400 (Dosage: 1 - 200 mg)||Boehringer Ingelheim||Completed|May 2002|||February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 29, 2014||||No||https://clinicaltrials.gov/show/NCT02254538||35758|
NCT02248428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB20140324|Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma|Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial.|CTd|Jinling Hospital, China|Yes|Recruiting|April 2012|September 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248428||36228|
NCT02248441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK: 1-10-72-173-14|Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure|Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure (CONDI-HF)|CONDI-HF|University of Aarhus|No|Recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02248441||36227|
NCT02510014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-13-0003|Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder|An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder||Indivior Inc.|No|Enrolling by invitation|July 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510014||16154|
NCT02503215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21833413.0.0000.0068|Effects of Compression Stockings on Obstructive Sleep Apnea in Patients Under Hemodialysis|Effects of Compression Stockings on Obstructive Sleep Apnea and Autonomic Nervous System in Patients Under Hemodialysis|COSTOSA-HD|University of Sao Paulo|No|Recruiting|August 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||July 2015|July 16, 2015|December 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02503215||16676|
NCT02254603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011003|The Effects of the Combined Therapy of Acupuncture and Yoga Exercise on Weight Loss|To Evaluate the Effects of Weight-loss by the Combined Therapy of Acupuncture and Yoga Exercise||Chang Bing Show Chwan Memorial Hospital|No|Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|74|||Both|20 Years|50 Years|No|||September 2014|September 29, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02254603||35753|
NCT02504892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150166|Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer|Phase 2 Study of Everolimus Therapy in Patients With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504892||16547|
NCT02505009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-3167C|Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy|Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study||Chang Gung Memorial Hospital|Yes|Recruiting|May 2015|March 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|125|||Both|20 Years|70 Years|No|||February 2015|July 20, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505009||16538|
NCT02246933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503815|Effects of a PUFA-rich Diet on Acute Metabolic and Inflammatory High-Fat Meal Responses|Effects of a PUFA-rich Diet on Acute Metabolic and Inflammatory High-Fat Meal Responses||University of Georgia|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246933||36343|
NCT02246946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICID14|Positive Airway Pressure on Pleural Effusion After Drainage|Efficacy of the Addition of Positive Airway Pressure to Conventional Chest Physiotherapy in the Time to Resolution of Pleural Effusion After Drainage||Universidade Cidade de Sao Paulo|No|Recruiting|December 2014|September 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246946||36342|
NCT02251821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9033|JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis|JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study||Fred Hutchinson Cancer Research Center|Yes|Recruiting|October 2014|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02251821||35967|
NCT02255643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01258|Motor Threshold and Motor Cortex Stimulation|The Relationship Between Motor Threshold and Effective Stimulation Threshold During Motor Cortex Stimulation||University of British Columbia|No|Completed|October 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02255643||35673|
NCT02496260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9481|Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy|Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure||Henry Ford Health System|No|Not yet recruiting|July 2015|||October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|Collection of approximately 20 ml of blood will be performed by venipuncture at the      specified time points. When possible, blood collection will be coordinated with other      routine blood studies. These blood samples will be drawn at the clinical blood drawing      station in the Radiation Oncology department.      For fibrosis and left ventricular dysfunction, biomarkers include galectin-3 and NT-Pro      brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative      stress, C-reactive protein, myeloperoxidase, and growth differentiation factor. Additional      blood will be collected and stored for future assessment of other candidate biomarkers.|Female|18 Years|N/A|No|Non-Probability Sample|This is a pilot study of patients receiving radiotherapy for left-sided breast cancer.|July 2015|July 9, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02496260||17210|
NCT02500121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU14-182|Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer|A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182||Hoosier Cancer Research Network|Yes|Recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500121||16914|
NCT02504723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS11-CT10-11|Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding|Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding||Kaohsiung Veterans General Hospital.|Yes|Recruiting|January 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|July 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504723||16560|
NCT02243904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHERL|Study for Promotion of Health in Recycling Lead|Study for Promotion of Health in Recycling Lead|SPHERL|Katholieke Universiteit Leuven|No|Recruiting|August 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Participants will be recruited among the work force employed at lead recycling plants in        North America.|December 2015|December 22, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02243904||36576|
NCT02243917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-101|A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients With Advanced Solid Tumors||Cleave Biosciences, Inc.|Yes|Recruiting|October 2014|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|September 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243917||36575|
NCT02497326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84/RC/KEMU|Heparin for the Treatment of Burn Wound Pain|Comparative Study of Conventional and Topical Heparin Treatments in Second Degree Burn Patients for Burn Analgesia and Duration of Wound Healing||King Edward Medical University||Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|14 Years|60 Years|No|||July 2015|July 10, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497326||17128|
NCT02497339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSTWomen|Mindfulness Training for Smoking Cessation in Women in Workplaces|Mindfulness Training for Smoking Cessation in Women in the Workplace - a Pilot Randomized Controlled Trial||The University of Hong Kong||Recruiting|January 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02497339||17127|
NCT02504853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150162|Natural History and Genetics of Food Allergy and Related Conditions|Natural History and Genetics of Food Allergy and Related Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|June 2026|Anticipated|June 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1050|||Both|2 Years|99 Years|Accepts Healthy Volunteers|||June 2015|November 25, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02504853||16550|
NCT02258191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eCOPD 001|Pilot Study Evaluating Feasibility and Benefits of Telemonitored NIV Treatment on COPD Patients|Pilot Study Evaluating Feasibility and Benefits of Telemonitored NIV Treatment on COPD Patients|eCOPD|ResMed|No|Recruiting|July 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02258191||35481|
NCT02240810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2326|PLATINUM Diversity|PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)||Boston Scientific Corporation|No|Active, not recruiting|October 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Population will be selected from clinical locations where subjects are treated with at        least one Promus PREMIER everolimus-eluting coronary stent.|August 2015|August 25, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02240810|12 Months|36814|
NCT02257528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02021|Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer|A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer||National Cancer Institute (NCI)||Suspended|May 2015|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|October 2, 2014|Yes|Yes|Scheduled Interim Monitoring|No||https://clinicaltrials.gov/show/NCT02257528||35531|
NCT02257606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME2011/315|Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial|Robot-assisted Training on the Upper Limb in Persons With MS: an RCT||Hasselt University|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257606||35525|
NCT02496559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKLM 2012/1471 RV|Children With Fever and Respiratory Symptoms at Out-of-hours Services in Norway|Children With Fever and Respiratory Symptoms at Out-of-hours Services in Norway||Uni Research|No|Terminated|January 2013|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|401|||Both|N/A|6 Years|No|||December 2015|December 2, 2015|June 25, 2015||No|Lower prevalence than expected and the inclusion was difficult.|No||https://clinicaltrials.gov/show/NCT02496559||17187|
NCT02495350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0666-14-RMC|The Correlation Between Prelabor Analgesic Plan and Actual Labor Analgesia With Satisfaction, Postpartum Depression, and Breast Feeding Success|The Correlation Between Prelabor Analgesic Plan and Actual Labor Analgesia With Satisfaction, Postpartum Depression, and Breast Feeding Success||Rabin Medical Center|No|Recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|1000|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women above 18 undergoing vaginal delivery in Beilinson Hospital|July 2015|July 10, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02495350||17280|
NCT02241031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPs-AL-2014|Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia|Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy||Nanfang Hospital of Southern Medical University|Yes|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|14 Years|65 Years|No|||September 2014|September 15, 2014|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241031||36797|
NCT02499874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT063|SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women|Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women||St Stephens Aids Trust|Yes|Recruiting|August 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|45 Years|No|||October 2015|October 15, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02499874||16933|
NCT02500459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFT1315|Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection|A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing A Clinically-Indicated Surgical Resection (IND 117,240)||Case Comprehensive Cancer Center|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500459||16888|
NCT02251834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140423|Hispanic Secondary Stroke Prevention Initiative|Hispanic Secondary Stroke Prevention Initiative|HISSPI|University of Miami|No|Recruiting|January 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251834||35966|
NCT02244333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.56|Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)|ALNA® - AWB in Pre-treated Patients With BPS||Boehringer Ingelheim||Completed|February 2004|||July 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4575|||Male|N/A|N/A|No|Non-Probability Sample|Patients with symptomatic BPS, who switched for ALNA® after preceding Terazosin therapy        recruited at urologists|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244333||36543|
NCT02244346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.58|Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)|Secotex®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)||Boehringer Ingelheim||Completed|May 2004|||November 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|811|||Male|N/A|N/A|No|Non-Probability Sample|Patients treated with Secotex® in the daily clinical practice|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02244346||36542|
NCT02500134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406106RINC|Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus|Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus||National Taiwan University Hospital|No|Active, not recruiting|March 2014|August 2017|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|6 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Healthy normal eyes without any ocular surface disease|July 2015|July 15, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02500134||16913|
NCT02510703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-085|Assessment of Coronary Endothelial Function in Diabetic Patients With Acute Coronary Syndrome Using 15O-water Positron Emission Tomography||D-TEP|University Hospital, Caen|No|Recruiting|March 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510703||16101|
NCT02248038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC-14004767|A Multicenter Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery|A Multicenter Randomized Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery in China||Huazhong University of Science and Technology|Yes|Active, not recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1300|||Both|N/A|80 Years|No|||September 2014|September 23, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02248038||36258|
NCT02248636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-014-13F|Cholinesterase Inhibitor Discontinuation|Cholinesterase Inhibitor Discontinuation|CID|VA Office of Research and Development|Yes|Recruiting|January 2015|November 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||January 2016|January 20, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248636||36212|
NCT02248909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRU-XXX-2014/2|Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions|Non-interventional Multicenter Study of Spirometry Use to Diagnose COPD and to Prescribe Treatment to COPD Patients in the Outpatient Institutions of the healthcaRe System of the Russian FederaTion|SUPPORT|AstraZeneca|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4450|||Both|N/A|N/A|No|Non-Probability Sample|Patients with COPD risk factors and patients with previously diagnosed COPD who have been        observed in outpatient medical institutions of the RF are planned to be enrolled into the        study.|June 2015|June 2, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02248909||36191|
NCT02504424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0005 AirXpanders|AirXpanders AeroForm Tissue Expander System for Breast Reconstruction|AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND II)|XPAND II|AirXpanders, Inc.|Yes|Recruiting|October 2015|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504424||16583|
NCT02504515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22858113.9.0000.5149|Effect of Homeopathy, Acupuncture or Anthroposophic Medicine in Women's Quality of Life|Evaluating Treatment With Homeopathy, Acupuncture, and Anthroposophic Medicine in Improving the Quality of Life for Women Treated at the Public Unified Healthcare System||Federal University of Minas Gerais|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|906|||Female|18 Years|N/A|No|||February 2016|February 20, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504515||16576|
NCT02510755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-035|Stress and Emotional Memory|Stress and Emotional Memory : Functional Neuroanatomy of Post-traumatic Stress Disorder in Adolescents|SEME|University Hospital, Caen|No|Completed|May 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510755||16097|
NCT02253693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-23641|Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry|Descriptive Pilot Study of Monitoring of Physical Activity in Adult Patients With Haemophilia A Arthropathy by Means of Accelerometry, Image Tests and Physical Condition Parameters. Benefits Associated With That Monitoring"||University of Valencia|Yes|Active, not recruiting|January 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with haemophilia A presenting joint disease (haemophilic arthropathy) and        who are under prophylaxis treatment with FVIII|January 2016|January 18, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02253693|2 Years|35823|
NCT02253706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFO-Rx1|Oxygen Supplementation During Bronchoscopy: High Flow Versus Low Flow Oxygen|Oxygen Supplementation During Bronchoscopy: High-Flow Nasal Cannula or Low-Flow Nasal Cannula||Shaare Zedek Medical Center|No|Not yet recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2014|September 28, 2014|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02253706||35822|
NCT02245932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143031|Resveratrol In Overweight Mild To Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)|The Effect of Resveratrol on Metabolism and Cardiovascular Risk Profile in Overweight Patients With Chronic Obstructive Pulmonary Disease (COPD)|CARMENS|Maastricht University Medical Center|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245932||36420|
NCT02245945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-130|Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females|Phase I Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females||CONRAD|No|Withdrawn||||April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|15 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245945||36419|
NCT02245958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-US-NEU-0271|A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm|||Allergan|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with cervical dystonia or blepharospasm previously treated with Xeomin® and        BOTOX® in clinical practice.|January 2016|January 6, 2016|September 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02245958||36418|
NCT02258230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4859|Laparoscopic Three-dimensional Versus Two-dimensional Sacral Colpopexy and Paravaginal Repair|Laparoscopic 3D Versus 2D Sacral Colpopexy and Paravaginal Repair for Pelvic Organ Prolapse: a Comparison of Operative Times and Complications||Olympus Corporation of the Americas|No|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|194|||Female|18 Years|N/A|No|||October 2015|October 14, 2015|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258230||35478|
NCT02258269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRA00201401|The Effect of Square Dance on Rheumatoid Arthritis|||Chengdu PLA General Hospital|Yes|Enrolling by invitation|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||August 2015|August 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02258269||35475|
NCT02502305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUFP7-30583JUB|Liveonline Training Course to Improve Food Habits and Enhance Physical Activity in Older Adults|Liveonline Training Course to Improve Food Habits and Enhance Physical Activity in Older Adults|LIFE!|Jacobs University Bremen gGmbH|No|Recruiting|February 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02502305||16746|
NCT02496611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505M72081|Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity|Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|July 2015|||July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496611||17183|
NCT02246192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinusprgf|Use of Plasma Rich in Growth Factors (PRGF) in Pilonidal Sinus Excision|Application of PRGF (Plasma Rich in Growth Factors) to Reduce the Healing Time After Pilonidal Sinus Excision. A Randomized 5-years Prospective Controlled Trial.||Hospital Quiron Sagrado Corazon|Yes|Completed|November 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|51|||Both|13 Years|65 Years|No|||March 2015|March 18, 2015|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02246192||36400|
NCT02503475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22436|Stanford Center for Back Pain|Stanford Center for Back Pain||Stanford University|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|324|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503475||16656|
NCT02504593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063521|Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis|Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis||Duke University|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|September 3, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02504593||16570|
NCT02504606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU-009-01|Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject|A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject||Huons Co.,Ltd.|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02504606||16569|
NCT02258412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-013218|Evaluation of Two Hand Hygiene Products in ICUs|Evaluation of Antimicrobial Efficacy of Two Hand Hygiene Products in ICUs Using Hand Prints||3M|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258412||35464|
NCT02464319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hrIL-2-SS1|A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome|Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome||Peking University People's Hospital|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02464319||19664|
NCT02423382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT201405|Measurement of the Retinal Oxygen Saturaiton After Long-term Silicon Oil Tamponade|Measurement of the Retinal Oxygen Saturaiton After Long-term Silicon Oil Tamponade With Oxymap||Sun Yat-sen University|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|60 Years|No|||April 2015|April 21, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02423382||22806|
NCT02425878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311-BCN-138-DG|Ulipristal Acetate 10 mg and Asisted Reproduction|Uterine Fibroids: Impact of Ulipristal Acetate 10 mg on ART Results||Instituto Valenciano de Infertilidad, IVI VALENCIA|Yes|Recruiting|May 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|282|||Female|18 Years|50 Years|No|||February 2016|February 23, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425878||22614|
NCT02425891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29522|A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)|A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer||Hoffmann-La Roche||Recruiting|June 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425891||22613|
NCT02464969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661037|Apixaban for the Acute Treatment of Venous Thromboembolism in Children|A Randomized, Open-label, Active Controlled, Safety And Extrapolated Efficacy Study In Pediatric Subjects Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event||Pfizer|Yes|Recruiting|November 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|17 Years|No|||January 2016|January 30, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464969||19614|
NCT02475915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 019|Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection|A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection||South East Asia Research Collaboration with Hawaii|Yes|Active, not recruiting|January 2015|April 2016|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||March 2016|March 6, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02475915||18772|
NCT02418000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-101-01|A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation|A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)|AML|Strategia Therapeutics|Yes|Recruiting|April 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|62|||Both|18 Years|N/A|No|||April 2015|July 1, 2015|February 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418000||23219|
NCT02425943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10321|Sculptra Aesthetic Post-Approval Study|A Prospective, Open-Label, Multicenter Study to Evaluate the Long-Term Safety of Sculptra®Aesthetic in Immuno-Competent Subjects Stratified by Fitzpatrick Skin Type I-VI)||Galderma Laboratories, L.P.|No|Recruiting|May 2015|June 2021|Anticipated|May 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|863|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425943||22609|
NCT02425956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2014-GES-0039|Non-invasive Quantification of Liver Iron With MRI|Non-invasive Quantification of Liver Iron With MRI||GE Healthcare|No|Recruiting|April 2015|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|10 Years|N/A|No|||February 2016|February 9, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425956||22608|
NCT02472639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040251|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy||Cedars-Sinai Medical Center|No|Active, not recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472639||19024|
NCT02464800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye016|Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy|Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy||Kyorin University|No|Completed|April 2007|March 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|326|||Both|20 Years|90 Years|No|Non-Probability Sample|The patients who underwent 25-gauge vitrectomy for proliferative diabetic retinopathy with        higher cutting rate instruments or conventional instruments|June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464800||19627|
NCT02464813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T93/2015|Effect of Pregabalin on Immediate Post-operative and Longterm Pain|Effect of Pregabalin on Immediate Post-operative and Longterm Pain and Spinal Cord Monitoring in Children Undergoing Instrumented Spinal Surgery.||Turku University Hospital|Yes|Not yet recruiting|June 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|10 Years|21 Years|No|||June 2015|June 4, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02464813||19626|
NCT02252471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DA034099-01|Choices-Teen: A Bundled Risk Reduction Intervention for Juvenile Justice Females|Choices-Teen: A Bundled Risk Reduction Intervention for Juvenile Justice Females||University of Houston|Yes|Completed|July 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Female|14 Years|17 Years|No|||September 2014|September 25, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02252471||35917|
NCT02325323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-DLE-GASTRIMED|Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia|Prospective Cohort Study: Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia|GASTRIMED|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Biopsy slides.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with gastric metaplasia consulting a gastroenterologist in any private or public        setting in France.|November 2014|December 19, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325323||30325|
NCT02320903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MH097349-01|Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes|Phase I - Using Mobile Technology to Enhance MST Outcomes (VillageWhere)|VillageWhere|Evidence-Based Practice Institute, Seattle, WA|No|Enrolling by invitation|April 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320903||30665|
NCT02325687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-100|A Pilot Study of Biomarkers in Obstructive Sleep Apnea|A Pilot Study of Biomarkers in Obstructive Sleep Apnea (OSA): Is There a Correlation Between Cerebrospinal Fluid and Serum Markers of Inflammation in OSA?|Cytokine OSA|Hospital for Special Surgery, New York|No|Enrolling by invitation|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|36|||Both|50 Years|84 Years|No|||February 2016|February 18, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02325687||30297|
NCT02243241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD1009|The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects|A Randomized, Double-blind, Placebo- and Positive-Controlled, Parallel Group, Dose Escalating Study of the Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets at Doses up to 160 mg on QT/QTc in Healthy Adult Subjects||Purdue Pharma LP|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|208|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243241||36627|
NCT02243540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPaick1|Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy|Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy: Comparison Between Potassium-titanyl-phosphate Photoselective Vaporization of the Prostate (PVP) and Holmium Laser Enucleation of the Prostate (HoLEP)||Seoul National University Hospital|No|Recruiting|April 2014|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1828|||Male|40 Years|90 Years|No|Non-Probability Sample|men who underwent photoselective vaporization of the prostate (PVP) or holmium laser        enucleation of the prostate (HoLEP) for benign prostatic hyperplasia refractory to medical        treatment|September 2014|September 15, 2014|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02243540||36604|
NCT02243553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.101|Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers|Evaluating the Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers||Boehringer Ingelheim||Completed|January 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|September 16, 2014|September 1, 2014||||No||https://clinicaltrials.gov/show/NCT02243553||36603|
NCT02310568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431007|POC Study in Partially Responsive Generalized Anxiety Disorder|An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder||Pfizer|Yes|Terminated|November 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|90|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|October 24, 2014|Yes|Yes|Study recruitment was terminated on 24 June 2015, due to a Pfizer business decision. This    study was not terminated for reasons of safety or efficacy|No||https://clinicaltrials.gov/show/NCT02310568||31458|
NCT02315053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12LPR|PET Response During Chemoradiation of Lung Cancer|Dynamic FDG‐PET/CT Response During Chemoradiation for NSCLC||The Netherlands Cancer Institute|No|Recruiting|February 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02315053||31114|
NCT02324231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOG 2015 FN Definition|SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia|SPOG 2015 FN Definition. A Swiss Pediatric Oncology Group (SPOG) Initiated Multi-center Open-label Randomized Controlled Multiple Crossover Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia (FN)||Swiss Pediatric Oncology Group|No|Not yet recruiting|February 2016|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|1 Year|18 Years|No|||November 2015|November 12, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02324231||30409|
NCT02252601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D-CF|Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis|An Evaluation of the High Frequency Digit Triplet Test as a Screening Tool for Early Detection of Hearing Loss in Individuals With Cystic Fibrosis|3D-CF|University of Nottingham|No|Not yet recruiting|November 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|388|Samples With DNA|Saliva and blood samples will be donated to the Nottingham Health Sciences Biobank if      participants consent to this.|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with Cystic Fibrosis will be selected from those attending clinics at        Nottingham Children's Hospital, Birmingham Children's Hopsital, The Wolfson Cystic        Fibrosis Centre, Nottingham and The West Midlands Adult Cystic Fibrosis Centre.|September 2014|September 25, 2014|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02252601||35907|
NCT02252614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiskapiYBERH|Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain|Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain and Contramal Consumption After a Lumbar Disk Surgery||Diskapi Yildirim Beyazit Education and Research Hospital|Yes|Not yet recruiting|September 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|16 Years|90 Years|No|||September 2014|September 29, 2014|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252614||35906|
NCT02240953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOSUYOLU2|Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis|Comparison of Different Anticoagulation Regiments in Patients With Prosthetic Heart Valve Non-ObstructiveThrombosis||Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|No|Recruiting|January 2009|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|80 Years|No|||September 2014|September 15, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02240953||36803|
NCT02324829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORE 18193|Automatic Physiotherapy and Rehabilitation System for Lower Body Total Joint Replacement|Automatic Physiotherapy and Rehabilitation System for Lower Body Total Joint Replacement||University of Waterloo|No|Active, not recruiting|November 2012|December 2015|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|18|||Both|N/A|N/A|No|Non-Probability Sample|Specific target audience for sensor deployment is patients who has undergone knee or hip        joint replacement and is taking physiotherapy rehabilitation sessions to recover. The        target audience of this system is rehabilitation subjects who have recently had knee or        hip replacement therapy. We would like to track several subjects over their rehabilitation        stay to see the impact of rehabilitation on their movement pattern. Recruitment will be        limited to in-patients only, as out-patients tend to be discharged from rehabilitation        because they are healthier, and would likely have movement patterns closer to healthy        subjects.|December 2014|December 18, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02324829||30363|
NCT02324283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-97|Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia|Comparison of Emergence and Recovery Time, and Evaluation of Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia in Lung Surgery- A Pilot Study||Juntendo University|No|Active, not recruiting|October 2012|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Both|20 Years|75 Years|No|||December 2014|December 25, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02324283||30405|
NCT02313311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ201102-BK20141087-BL2014003|Select Embryos by Time-lapse System for Single Embryo Transfer|Study Embryos of IVF by Time-lapse System|SETLSSET|Nanjing University|Yes|Enrolling by invitation|October 2013|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women undergoing assistant reproduction treatment|December 2014|December 7, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313311||31247|
NCT02246530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F131231006|Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma|Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma||University of Alabama at Birmingham|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|75 Years|No|||February 2016|February 6, 2016|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02246530||36374|
NCT02249039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00088046|Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study|Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study||Gauda, Estelle B., M.D.|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|12 Months|No|||September 2015|September 4, 2015|August 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249039||36181|
NCT02249390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-042|Assisted Reproductive Technology Survey (ART Survey)|ART Survey: Assisted Reproductive Technology Survey|ART|Pennington Biomedical Research Center|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the community. Parents of children who have participated        in a research study at Pennington Biomedical Research Center or patients from local        fertility clinics.|March 2016|March 24, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02249390||36154|
NCT02249403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506.203|Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type|Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type||Boehringer Ingelheim||Completed|January 1999|||January 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|362|||Both|40 Years|N/A|No|||September 2014|September 25, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249403||36153|
NCT02326220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1216|Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy|ODYSSEY ESCAPE|Regeneron Pharmaceuticals|Yes|Active, not recruiting|March 2015|May 2017|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326220||30256|
NCT02317068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMSU-Cardiology-4|Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation|||Urmia University of Medical Sciences|Yes|Completed|January 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317068||30959|
NCT02317081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXETIS FIM|Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)|Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)||Axetis AG|Yes|Recruiting|February 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|85 Years|No|||June 2015|June 25, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02317081||30958|
NCT02252978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99712|Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy|A Phase II, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial Evaluating the Role of an Empiric 2-Week Course of Ciprofloxacin on Rates of Detection of Cancer by Prostate Biopsy in Men With Abnormal Serum Prostate Specific Antigen Found at Screening (PREP Trial)||Comprehensive Cancer Center of Wake Forest University|No|Not yet recruiting|December 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|550|||Male|18 Years|N/A|No|||July 2015|July 27, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02252978||35878|
NCT02321059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-008|Validation of the Goodstrength System for Assessment of Abdominal Wall Strength in Patients With Incisional Hernia|Validation of the Goodstrength System for Assessment of Abdominal Wall Strength in Patients With Incisional Hernia|VAGSI|Bispebjerg Hospital|Yes|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients on waiting list for repair of a ventral incisional hernia and healthy volunteers.|June 2015|June 25, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321059||30653|
NCT02321267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26-035|Cohort Study of the Clinical Course of Macular Diseases in Kagawa|Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)||Kagawa University|No|Recruiting|December 2014|December 2024|Anticipated|December 2024|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|N/A|No|||September 2015|September 1, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02321267||30637|
NCT02325037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1837-CL-101|First-in-Human Single and Multiple Dose of GLPG1837|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects||Galapagos NV|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325037||30347|
NCT02325128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001501/MGH|Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps|Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps|SANAP|Massachusetts General Hospital|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|40 Years|No|||March 2016|March 14, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325128||30340|
NCT02248246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG-14-001|Harmonic ACE®+7 Shears in Laparoscopic Colectomy|Prospective, Multicenter, Observational Study Evaluating Vessel Sealing Utilizing the Harmonic ACE®+7 Shears During Laparoscopic Colectomy||Ethicon Endo-Surgery|No|Completed|August 2014|June 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects enrolled into this study will undergo elective laparoscopic colectomy        wherein dissection and transection of the IMA is indicated.|August 2015|August 3, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02248246||36242|
NCT02248259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.23|Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers|Open-label, Randomised, Two-way Crossover Study to Assess the Effect of Once Daily Itraconazole on the Pharmacokinetics of BI 409306 After a Single Oral Dose in Healthy Male Volunteers Genotyped as Poor and Extensive Metabolizers of CYP2C19||Boehringer Ingelheim||Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|September 22, 2014||||No||https://clinicaltrials.gov/show/NCT02248259||36241|
NCT02476071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1111934|Evaluating Demand Generation for Safe Voluntary Male Circumcision (VMC) for HIV Prevention (Stylish Man), Rakai, Uganda|Evaluating Demand Generation (Stylish Man) for Safe Voluntary Male Circumcision (VMC) for HIV Prevention, Rakai, Uganda||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1400|||Male|18 Years|49 Years|No|||June 2015|June 16, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02476071||18760|
NCT02476149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/SW/0107|Biomechanical Properties of Keratoconic Eyes|Biomechanical Properties of Keratoconic Eyes||University of Plymouth|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Potential participants will be identified as those patients who are due to undergo corneal        collagen crosslinking treatment|June 2015|June 18, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02476149||18754|
NCT02418260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24997313.8.0000.5505|Surgical Interventions for the Treatment of Humeral Shaft Fractures|Surgical Interventions for the Treatment of Humeral Shaft Fractures: Randomized Controlled Clinical Trial||Federal University of São Paulo|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02418260||23199|
NCT02470351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 026|Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS|Study SEARCH 026Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS in Subjects Participating in Study SEARCH 019||South East Asia Research Collaboration with Hawaii|No|Recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|HIV RNA standard quantitation will be completed using the Roche COBAS/Amplicor HIV-1 Viral      Load v2.0 assay, with a lower limit of quantitation of 20cps/mL. Single Copy Assay (SCA) HIV      RNA quantitation in the setting of ART will be performed using 5-10 ml of CSF. In addition,      cell associated HIV-DNA (total, integrated and 2LTR circles in total CD4+ T cells will be      assessed at CRC-CHUM.|Both|18 Years|60 Years|No|Non-Probability Sample|Any of the 15 subjects to be enrolled in SEARCH 019 may consent to study SEARCH 026        participation and hence a maximum of 15 subjects may enroll.|June 2015|June 9, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02470351||19200|
NCT02477033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML9449|Impact of Butyricicoccus Pullicaecorum in Healthy Subjects|A Placebo-controlled Cross-over Randomized Study to Investigate the Impact of Butyricicoccus Pullicaecorum in Healthy Human Volunteers||Katholieke Universiteit Leuven|No|Completed|February 2014|February 2015|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02477033||18686|
NCT02477046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000447|Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh|Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh||University of Virginia|Yes|Recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|810|||Both|42 Days|48 Days|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02477046||18685|
NCT02467491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500368|A New Adaptive Physical Activity Technology in Older Adults|A New Adaptive Physical Activity Technology in Older Adults (Jintronix)|Jintronix|University of Florida|No|Completed|September 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|75 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02467491||19420|
NCT02414100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13C.628|Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy|Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance||Thomas Jefferson University|Yes|Recruiting|December 2013|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood, tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with treatment naive pancreatic ductal adenocarcinoma (PDA) treated at Thomas        Jefferson University or Georgetown University|October 2015|October 20, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02414100||23519|
NCT02470949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0719|Influence of a Monopoly Game on Subtle Behaviors|Influence of a Monopoly Game on Subtle Behaviors||University of Colorado, Denver|Yes|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|9|||Both|19 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02470949||19154|
NCT02464774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-FXY-093|Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer|Impact of Breast-Conserving Therapy (BCT) on Recurrence in Patients With Triple-Negative Breast Cancer (TNBC) Compared With Mastectomy||Sun Yat-sen University|Yes|Not yet recruiting|July 2015|||December 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|464|||Female|18 Years|65 Years|No|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464774||19629|
NCT02410941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10007399|Improving the Stewardship of Diagnostic Imaging Resources in Alberta Emergency Departments|Improving the Stewardship of Diagnostic Imaging Resources in Alberta Emergency Departments||University of Calgary|Yes|Not yet recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|52058|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02410941||23762|
NCT02467088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaseehaBulbulia200700939|An Observational Study on the Efficacy of Individualised Homoeopathic Treatment on Premenstrual Syndrome|An Observational Study on the Efficacy of Individualised Homoeopathic Treatment on Premenstrual Syndrome in Indian Females||University of Johannesburg|Yes|Active, not recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02467088||19451|
NCT02469077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141862|Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function|Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function||Vanderbilt University|No|Recruiting|August 2015|May 2020|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|55 Years|No|||August 2015|August 3, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02469077||19298|
NCT02469090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTH-300|A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)||Cynapsus Therapeutics Inc|Yes|Recruiting|June 2015|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469090||19297|
NCT02477891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106626|Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma|An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent||Janssen Research & Development, LLC||Available||||||Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 9, 2016|June 15, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02477891||18620|
NCT02419326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1599|Uniting Couples In the Treatment of Eating Disorders (UNITE)|Uniting Couples In the Treatment of Eating Disorders (UNITE): Pilot Study for a Couple-based Intervention for Binge-eating Disorder|UNITE|University of North Carolina, Chapel Hill|Yes|Recruiting|September 2014|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|April 13, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02419326||23118|
NCT02473289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107171|An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder|A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|192|||Both|21 Years|64 Years|No|||March 2016|March 21, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473289||18974|
NCT02473367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-824|The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)|A Study to Evaluate the Influence of Metal Cation-Containing Antacids on MK-0518 Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen||Merck Sharp & Dohme Corp.|No|Completed|June 2015|October 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473367||18968|
NCT02472457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011628|Crohn Disease Exclusion Diet After Single Medication De-escalation|Biologic and Immunomodulator Withdrawal in Pediatric Crohn Disease With Deep Clinical Remission Using the Crohn Disease Exclusion Diet|CEASE|Children's Hospital of Philadelphia|No|Recruiting|June 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|10 Years|21 Years|No|||October 2015|October 6, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472457||19038|
NCT02474550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-OBS-14-254|Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma|Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma||Ajou University School of Medicine|Yes|Recruiting|April 2015|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|N/A|No|Non-Probability Sample|Adult patients with DLBCL in Korea|June 2015|June 15, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02474550|24 Months|18877|
NCT02474615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14099|Applicability Clinic of Cement Portland Structural White in Endodontic Surgery|Applicability Clinic of Cement Portland Structural White in Endodontic Surgery||Universidade do Vale do Sapucai|No|Completed|February 2013|January 2015|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474615||18872|
NCT02416063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of medicine-JU|Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children|Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children: A Randomised Controlled Double Blind Study||University of Jordan|Yes|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|1 Year|6 Years|No|||April 2015|April 8, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416063||23368|
NCT02473445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-MITO-002|A Long-Term Extension Study of RP103-MITO-001 to Assess RP103 in Children With Inherited Mitochondrial Disease|A Long-Term Open-Label Extension Study of RP103-MITO-001 to Assess the Safety, Tolerability and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease||Raptor Pharmaceuticals Inc.|No|Enrolling by invitation|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|17 Years|No|||June 2015|January 28, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473445||18962|
NCT02474082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457ADE06|Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.|A Randomized, Controlled, Multicenter, Open-label Study With Blinded Assessment of the Efficacy of Subcutaneous Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Plaque Psoriasis.|PRIME|Novartis|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02474082||18913|
NCT02417428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/A with our grant|Citrulline Supplementation Combined With Exercise: Effect on Muscle Function in Elderly People (CITEX Study)|Effects of Citrulline Supplementation Combined With Exercise on Muscle Function and Functional Capacity in Older Obese Men and Women|CITEX|Universite du Quebec a Montreal|No|Not yet recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|64|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02417428||23263|
NCT02416310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing H|Transcutaneous Electrical Acupoint Stimulation on Gastrointestinal Function After Cesarean Section|Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation on Gastrointestinal Function After Cesarean Section|TEAS|Xijing Hospital|No|Not yet recruiting|November 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|228|||Female|N/A|N/A|No|||October 2015|October 29, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416310||23349|
NCT02471456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015CAR76|MACCE After Endoscopic Vein Harvest for CABG|Major Adverse Cardiac and Cerebrovascular Event (MACCE) & Patients' Quality of Life (QOL) After Endoscopic Vein Harvesting as Compared to Open Vein Harvest for Coronary Artery Bypass Grafting|MAQEH|The Royal Wolverhampton Hospitals NHS Trust|No|Not yet recruiting|July 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|85 Years|No|Non-Probability Sample|Fifty patients who underwent EVH (Study group) were part of our service evaluation when        EVH was introduced to our practice. These patients were matched with patients undergoing        CABG during the same period but where the LSV was harvested by OVH (50 patients, control        group).        This service evaluation showed a significant cost benefit when EVH was used in terms of        reduction in the inhopsital stay, leg wound pain, leg wound infection and need to attend        wound clinic. The current study is an extension of the service evaluation to assess how        these patients are doing at least a year after their surgery in terms of MACCE, QOL,return        to normal activities and survival|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02471456||19115|
NCT02467465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Univ. Complutense de Madrid|Efficacy of Dry Needling in Plantar Fasciitis|Efficacy of Dry Needling in Plantar Fasciitis||Universidad Complutense de Madrid|Yes|Recruiting|May 2014|October 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02467465||19422|
NCT02413307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160094|The Development and Evaluation of a Brief CFT Intervention for Trauma|The Development and Evaluation of a Brief Self-practice Compassion Focused Therapy (CFT) Intervention as a Precursor to TAU for Trauma Patients||University of Lincoln|No|Recruiting|February 2014|January 2016|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413307||23580|
NCT02413320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-BRST-TNBC-LQT|Neoadjuvant Carboplatin and Docetaxel in TNBC|Randomized, Open Label, Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by AC in Stage I-III Triple-negative Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|70 Years|No|||July 2015|July 9, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413320||23579|
NCT02415829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501143-1|Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients|||Fudan University||Recruiting|November 2014|||January 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|75 Years|No|||April 2015|April 9, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02415829||23386|
NCT02468505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH104337|STEPS: Stepped Transition in Education Program for Students With ASD|STEPS: Stepped Transition in Education Program for Students With ASD|STEPS|Virginia Polytechnic Institute and State University|Yes|Recruiting|September 2014|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|16 Years|25 Years|No|||June 2015|June 9, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02468505||19342|
NCT02463331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0571/04|Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis|Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis||University of Sao Paulo General Hospital|Yes|Active, not recruiting|May 2003|July 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||May 2015|December 3, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02463331||19740|
NCT02426372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QBECO-UC-01|Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis|An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis||Qu Biologics Inc.|Yes|Active, not recruiting|July 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|19 Years|N/A|No|||December 2015|December 1, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426372||22576|
NCT02425826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-012|A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.|A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis|UNVEIL|Celgene|No|Active, not recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425826||22618|
NCT02476136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSDR-1173|Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis|Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis||University Medical Center Groningen|No|Active, not recruiting|May 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|8800|||Both|14 Years|N/A|No|Non-Probability Sample|The study population consists of adults aged 18 and older (with the exception of OCD        trials, which may include adolescents aged 14 and older) who have been diagnosed with        generalized anxiety disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive        disorder (OCD), post-traumatic stress disorder (PTSD), or panic disorder (PD) and who were        randomized to placebo or to treatment with a second-generation antidepressant.|December 2015|December 8, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02476136||18755|
NCT02472717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1150-8501|Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study|Clinical Evaluation of Psoriatic Arthritis Treated With Liraglutide. The PLAQUE Study: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study|PLAQUE|University Health Network, Toronto|No|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|70 Years|No|||June 2015|June 11, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02472717||19018|
NCT02417441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700623_545|TiLE (Time Lapse Eeva) Clinical Trial|A Phase IV, Prospective, Randomized, Exploratory, Multicenter, Eeva™ Trial (Time Lapse Eeva - TiLE)|TiLE|Merck KGaA|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1500|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02417441||23262|
NCT02426866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-414|Risk of CV Events With EFV vs. EFV-free Regimens|The Risk of Cardiovascular Events Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens||Bristol-Myers Squibb|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|29612|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial insurance database and Medicaid database|April 2015|April 22, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426866||22538|
NCT02469337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/EE/0395|Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance|Randomized Control Trial of Dichloroacetate, Preoperative Carbohydrate Loading and Moderate Intensity Exercise on Muscle Insulin Resistance After Major Abdominal Surgery|CARBEX|University of Nottingham|Yes|Recruiting|May 2012|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469337||19278|
NCT02469129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410102|PET Imaging of PARP Activity in Cancer|Positron Emission Tomography (PET) Imaging of Poly(ADP-Ribose) Polymerase (PARP) Activity in Cancer||Washington University School of Medicine|Yes|Recruiting|March 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02469129||19294|
NCT02412254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHIEVE-P-1|Aging, Cognition, and Hearing Evaluation in Elders Study|Aging, Cognition, and Hearing Evaluation in Elders Pilot Study|ACHIEVE-P|Johns Hopkins University|No|Not yet recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|70 Years|84 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|April 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412254||23661|
NCT02426879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48231.041.14|Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases|Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases Node Study|Node|UMC Utrecht|Yes|Recruiting|February 2015|February 2025|Anticipated|February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02426879||22537|
NCT02469571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-496 ex 13/14|Modulation of Gut Microbiota in Early Sepsis: A Pilot Study|Modulation of Gut Microbiota in Early Sepsis: A Pilot Study|MGM-sepsis|Medical University of Graz|No|Recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|100 Years|No|||October 2015|October 2, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469571||19260|
NCT02464540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUPelotas|Optical Properties of Light Cured Luting Agent on Laminate Veneer|Randomized Clinical Trial of Light Cured Luting Agents on Laminate Veneers||Federal University of Pelotas|Yes|Recruiting|March 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02464540||19647|
NCT02423486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-088|The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback|The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback||Samsung Medical Center||Recruiting|November 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|20 Years|N/A|No|||March 2015|April 17, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02423486||22798|
NCT02423538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR0302-101|First-in-Human Single Ascending Dose of SHR0302|A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers||Jiangsu HengRui Medicine Co., Ltd.|No|Active, not recruiting|April 2015|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02423538||22794|
NCT02426918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1450-ABSSSI-201|Study of Debio 1450 for Bacterial Skin Infections|A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin||Debiopharm International SA|No|Recruiting|May 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426918||22534|
NCT02413112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKM/70/626/2014|Get in Shape in the Team Research: Porukalla Kuntoon Tutkimus|Minimum Resistance Training Frequency: Effect on Motivation and Adherence to Train, Overall Health Status and Neuromuscular Performance|PoKu|University of Jyvaskyla|No|Active, not recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|105|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02413112||23595|
NCT02476877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLS-COMORBIDITY-001|A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse|A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse||Advanced Clinical Laboratory Solutions, Inc.|Yes|Recruiting|June 2014|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Each subject will be asked to provide a urine sample (minimum of 5 mL). If a subject cannot      provide a urine sample, a sample of oral fluids (1 mL) will be obtained.|Both|18 Years|N/A|No|Non-Probability Sample|Male or female subjects who are aged 18 years and older with one of four mental illnesses        (schizophrenia, major depression, bipolar disorder, or anxiety disorder) as determined by        DSM-IV criteria. Subjects who have multiple psychiatric diagnoses will be excluded from        the study.|June 2015|June 17, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476877||18698|
NCT02250079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|polyethylene29|Polyethylene Body Bags as an Alternative to Radiant Heat Lamp During the Neonatal Adaptation in Infants Older Than 29 Weeks|Features and Differences Between Neonates Undergoing Body Bag With Polyethylene and Conventional Drying During Neonatal Adaptation in Maternal and Child Headquarters Hospital and the Victoria Hospital Engativá, Bogotá, 2013||Universidad Nacional de Colombia|Yes|Completed|June 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|29 Weeks|42 Weeks|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02250079||36101|
NCT02257762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNS-CAMB-INFANTS-EFF|Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia|Efficacy of a Locally-Produced Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement (LNS) for Children Under Two Years in Cambodia||Institut de Recherche pour le Developpement, Cambodia|No|Not yet recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|422|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||October 2014|October 2, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257762||35513|
NCT02310321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0104|A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia.|Phase I Study of ASP2215 - A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia||Astellas Pharma Inc|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|69 Years|No|||December 2014|December 11, 2014|December 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02310321||31477|
NCT02310334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS47|The Pacing (Guided Vs Unguided) Strategies Study|The Impact of Real-Time Physiological Status Based Pacing Guidance on Physiological Strain for Exercising Humans||USDA Beltsville Human Nutrition Research Center|No|Completed|August 2014|December 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310334||31476|
NCT02323477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|741.STZ.2014|Human Umbilical Cord Stroma MSC in Myocardial Infarction|The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)|HUC-HEART|Ankara University|Yes|Recruiting|February 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|79|||Male|30 Years|80 Years|No|||December 2015|December 28, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323477||30467|
NCT02326545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MindLight|MindLight: A Video Game Intervention to Reduce Children's Anxiety|MindLight: A Video Game Intervention to Reduce Children's Anxiety||Queen's University|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|8 Years|16 Years|No|||August 2015|August 27, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02326545||30231|
NCT02326558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-URO-001|Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Nephron-Sparing Surgery in the Treatment of T1a Renal Cell Carcinoma|Comparison of Zero Ischemia Laparoscopic Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Nephron-Sparing Surgery in the Treatment of T1a Renal Cell Carcinoma||RenJi Hospital|Yes|Active, not recruiting|October 2014|December 2019|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|15 Years|80 Years|No|||July 2015|July 26, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02326558||30230|
NCT02248727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-52|Clinical Performance of Existing Wearers of Avaira Sphere Following a Refit With Clariti Elite Sphere|Clinical Performance of Existing Wearers of Avaira Sphere (Enfilcon A) Following a Refit With Clariti Elite Sphere (Somofilcon A) Lenses for 4 Weeks||Coopervision, Inc.|No|Completed|September 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|No|||February 2016|February 23, 2016|September 23, 2014|Yes|Yes||No|February 23, 2016|https://clinicaltrials.gov/show/NCT02248727||36205|
NCT02252679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZ Leuven - s56719|Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders|Endogenous Calcium Stable Isotope Study (eCaSIS): Evaluation of MC-ICP-MS as a Diagnostic Tool for Metabolic Bone Diseases and Disorders of Calcium Metabolism|eCaSIS|Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|Plasma, serum, spot urine and/or 24h urine collection samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Tertiary care clinical convenience sample Healthy volunteers recruited from the        communities in Leuven and neighbouring cities Siblings, parents or other relatives of        patients|November 2015|December 1, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02252679||35901|
NCT02320136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFO|Recording High Frequency Oscillations in Patients With Tumors and Epilepsy|Recording High Frequency Oscillations in Patients With Tumors and Epilepsy.|HFO|University of Zurich|No|Enrolling by invitation|June 2014|December 2021|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|1. Patients with epilepsy where a surgical resection is considered.          2. Patients where a tumor will be resected that has caused preoperative seizures.          3. Patients where a tumor will be resected that has not caused preoperative seizures.|December 2014|December 18, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02320136||30724|
NCT02320149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1401|Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne|A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris||Warner Chilcott|No|Recruiting|December 2014|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|9 Years|45 Years|No|||December 2015|December 23, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320149||30723|
NCT02313025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CatholicULeuven|A Speech Sound and Phonemic Awareness Intervention in Flemish Early Childhood Education|Spreken Verfijnen in de Kleuterklas: De Ontwikkeling Van Een Spraakdidactiek Als Uitbreiding op de Gangbare Taaldidactiek in Het Kleuteronderwijs||Katholieke Universiteit Leuven|No|Not yet recruiting|January 2015|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02313025||31269|
NCT02313298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCS DRO SBRT|Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer|A Phase II Trial of Prostate Stereotactic Radiotherapy||National Cancer Centre, Singapore|No|Recruiting|June 2013|December 2021|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Male|21 Years|N/A|No|||March 2016|March 21, 2016|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313298||31248|
NCT02241655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407128|Electroencephalography Guidance of Anesthesia|Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) Study|ENGAGES|Washington University School of Medicine|Yes|Recruiting|January 2015|October 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1232|||Both|60 Years|N/A|No|||December 2015|December 23, 2015|September 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02241655||36749|
NCT02241668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0283|Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma|Pilot Study to Assess Accuracy of Time-resolved FLT PET and MR Techniques in Determining Treatment-related Necrosis From Recurrent Glioma||M.D. Anderson Cancer Center|No|Withdrawn|June 2015|||June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 2, 2014|No|Yes|Withdrawn due to other initiatives|No||https://clinicaltrials.gov/show/NCT02241668||36748|
NCT02248740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11844|Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein|Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein: A Prospective Randomized Trial||Virginia Commonwealth University|No|Recruiting|September 2008|September 2028|Anticipated|September 2028|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02248740||36204|
NCT02324894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-FastMRI-BCS|Initial Evaluation of Ultra FAST Breast Magnetic Resonance in Breast Cancer Screening: Comparative Study With Mammography and Ultrasound.|Initial Evaluation of Ultra FAST Breast Magnetic Resonance in Breast Cancer Screening: Comparative Study With Mammography and Ultrasound.||Brugmann University Hospital|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Female|30 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324894||30358|
NCT02316795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302102|Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma|Evaluation of Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma||Washington University School of Medicine|No|Completed|February 2014|December 2015|Actual|June 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02316795||30980|
NCT02250326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-NSCL-006|Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer|A Phase II, Randomized, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Nab®-Paclitaxel (ABI-007) With Epigenetic Modifying Therapy of CC-486, and Nab®-Paclitaxel Monotherapy as Second-Line Treatment in Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Abound.2L|abound2L|Celgene|Yes|Recruiting|January 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250326||36082|
NCT02253316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411060|Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma|A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma||Washington University School of Medicine|Yes|Recruiting|January 2015|April 2021|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253316||35852|
NCT02323503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018|Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication|BIOtronik Study to Assess the CONTINUation of Existing Risk of Ventricular Arrhythmias After CRT-D Replacement for Patients With Primary Prevention Indication|BioCONTINUE|Biotronik SE & Co. KG|Yes|Recruiting|June 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|277|||Both|18 Years|N/A|No|Non-Probability Sample|Patients initially implanted with a CRT-D (cardiac resynchronization therapy with        defibrillator) device for primary prevention indication for defibrillation, requiring a        device replacement by another CRT-D because of battery depletion|January 2016|January 6, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323503|2 Years|30465|
NCT02323516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPIDIA|Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.|Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.|ASPIDIA|Centre Francois Baclesse|Yes|Withdrawn|December 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Months|N/A|No|||December 2015|December 7, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02323516||30464|
NCT02242903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15190|A Study of LY3079514 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3079514 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|September 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02242903||36653|
NCT02251626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001111|Assessing Bioavailability of CoQ10 Supplementation in Burn Patients|Assessing Bioavailability and Effects of Ubiquinol Supplementation on Biomarkers of Mitochondrial Function/Integrity, Metabolic Dysfunction, and Circulating Alarmins in Burn Patients|CoQ10|Massachusetts General Hospital|Yes|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|85 Years|No|||September 2015|September 21, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02251626||35982|
NCT02251639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0887|Diagnostic Aids for Detection and Diagnosis of Oral Cancer|Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer||M.D. Anderson Cancer Center|No|Recruiting|October 2014|||December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|September 23, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02251639||35981|
NCT02251795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.117|Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects|Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects||Boehringer Ingelheim||Completed|August 2007|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251795||35969|
NCT02325726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX RNI 02/2014|RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.|Renal Resistive Index Compared With NephroCheckTM to Predict Postoperative Acute Renal Failure in Patients Undergoing Cardiac Surgery.||University Hospital, Bordeaux|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are        at risk to develop postoperative Acute Kidney Injury.|October 2015|October 30, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02325726||30294|
NCT02313558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dentifrice-36|Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis|Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis: A 3-month Clinical Study in Adults in China||Sun Yat-sen University|Yes|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||May 2015|May 29, 2015|December 7, 2014||No||No|January 5, 2015|https://clinicaltrials.gov/show/NCT02313558||31228|The major limitation is the lack of a positive control,that is used to determine whether the dentifrice was more or less effective than it. The adoption of an inactive control is possible when the true efficacy of the dentifrice is assessed.
NCT02463071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5884C00002|AZD0585 Phase III Long-term Study in Japan|A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.||AstraZeneca|No|Active, not recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|20 Years|130 Years|No|||February 2016|February 29, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02463071||19759|
NCT02463084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00022512|Macronutrient Effects on Alzheimer's Disease (MEAL-2)|Macronutrient Effects on Alzheimer's Disease: HTN and IR (Hypertension and Insulin Resistance) (MEAL-2)|MEAL-2|Wake Forest School of Medicine|Yes|Recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02463084||19758|
NCT02423577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT02-2001|Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain|A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus||Autoimmune Technologies, LLC|Yes|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|April 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423577||22791|
NCT02424435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011801|Methylprednisolone Treatment of Friedreich Ataxia|Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA)||Children's Hospital of Philadelphia|Yes|Recruiting|June 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|N/A|No|||October 2015|October 20, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424435||22725|
NCT02424448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTSp063 / 12_DOG04_145|Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer|BIOMETHS Study. A Methodology Study to Determine the Feasibility, Evaluability and Temporal Variability in Candidate Pharmacodynamic Markers of Drug Action in Castration Resistant Prostate Cancer|BIOMETHS|Christie Hospital NHS Foundation Trust|Yes|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Original diagnostic tumour blocks will be returned at the end of the study. Biopsy samples      taken will either be retained or disposed of when the study is completed.|Male|18 Years|N/A|No|Non-Probability Sample|Males (18+) with metastatic hormone refractory prostate cancer|February 2016|February 24, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02424448||22724|
NCT02472860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000610|Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder|Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder|MGHTCT|Massachusetts General Hospital|No|Enrolling by invitation|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|13 Years|17 Years|No|||January 2016|January 15, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02472860||19007|
NCT02463006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYPDCH/12/PG16|Porous and Non-porous Bone Grafts in Intra-bony Periodontal Defects|Comparative Evaluation of Porous and Non Porous Variants of Bioactive Glass in the Treatment of Periodontal Intrabony Defects: A Cone Beam Computed Tomography Analysis||Dr. D. Y. Patil Dental College & Hospital||Completed|January 2014|May 2015|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|No|||June 2015|June 2, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463006||19764|
NCT02473003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0273401, CAN2012/631,621|Physical Training and Cancer-a Multicenter Clinical Trial|Physical Training and Cancer- Effects and Understanding of Mechanisms for Prevent and Minimizing Cancer Related Fatigue, Improve Quality of Life and Disease Outcome|Phys-Can|Uppsala University|No|Enrolling by invitation|March 2015|December 2025|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|612|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02473003||18996|
NCT02473016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C402|Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia|A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia||Capnia, Inc.|No|Recruiting|September 2015|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473016||18995|
NCT02418832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0238-13-HMO|Testis Needle Aspiration of Sperm in Men With Azoospermia|Rete Testis Needle Aspiration for Retrieval of Sperm in Men With Azoospermia Using Ultrasound Guidance||Hadassah Medical Organization|No|Not yet recruiting|November 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Male|16 Years|80 Years|No|||November 2015|November 18, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02418832||23155|
NCT02473198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|463360|Femoral Nerve Block Compared to Exparel in Total Knee Replacement|A Prospective Randomized Trial Comparing Femoral Nerve Black to Intraoperative Local Anesthetic Injection of Liposomal Bupivacaine (Exparel) in Total Knee Replacement||The New England Baptist Hospital|Yes|Active, not recruiting|January 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|312|||Both|18 Years|73 Years|No|||March 2016|March 16, 2016|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473198||18981|
NCT02463227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5340|Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption|A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|July 2015|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463227||19747|
NCT02473640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-1-004-004|A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy|A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy||Synthetic Biologics Inc.|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473640||18947|
NCT02477813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST162.09|Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation|Phase II Trial of Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation (TeRes). GOPAV03|TeRes|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|75 Years|No|||December 2015|December 30, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02477813||18626|
NCT02477826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-227|An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)|An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|CheckMate 227|Bristol-Myers Squibb|Yes|Recruiting|August 2015|December 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1980|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477826||18625|
NCT02477865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-301|Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus||Jiangsu Hansoh Pharmaceutical Co., Ltd.|No|Active, not recruiting|May 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|406|||Both|18 Years|78 Years|No|||January 2016|January 24, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02477865||18622|
NCT02414620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-40.7|Efficacy of the Dental Vibe Unit for Use of Reduction or Elimination of Pain During Dental Anesthetic Injection|Efficacy of the Dental Vibe Unit for Use of Reduction or Elimination of Pain During Dental Anesthetic Injection||University of the Pacific|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|April 10, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414620||23479|
NCT02414633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-084|Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI))|Special Investigation (Working Productivity and Activity Impairment / WPAI in Japanese Patients With Psoriatic Arthritis / PsA)||AbbVie||Recruiting|April 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|16 Years|99 Years|No|Non-Probability Sample|This is a single-arm, multi-center study with a prospective cohort.|January 2016|January 27, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02414633||23478|
NCT02471079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2014-02|TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study|TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study|THORACES|University Medical Center Groningen|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|706|||Female|18 Years|N/A|No|Non-Probability Sample|Adult, female patients with stage I-III breast cancer, who were treated with        breast-sparing surgery followed by radiation treatment.|December 2015|December 8, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02471079||19144|
NCT02471157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408015434|Hormonal Predictors of Oncologic Surgery|The Association of Hypogonadism and Post-operative Outcomes of Oncologic Surgery|HPOS|Weill Medical College of Cornell University|No|Recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Serum samples|Male|40 Years|N/A|No|Probability Sample|Men undergoing renal, bladder, and colorectal surgery for cancer|June 2015|June 10, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02471157||19138|
NCT02473757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150141|Gene Therapy Follow-up Protocol for People Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies|Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|July 2050|Anticipated|July 2050|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|99 Years|No|||May 2015|October 16, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02473757||18938|
NCT02416986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056221|Effects of Smoking Environment on Craving and Smoking|Effects of Smoking Environment on Craving and Smoking: A Pilot Study|CC2pilot|Duke University|No|Completed|October 2014|December 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02416986||23297|
NCT02424669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-19|Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients|Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients||Assistance Publique Hopitaux De Marseille||Recruiting|May 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|100|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424669||22707|
NCT02463734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15045|The Dementia Quality of Life Scale for Older Family Carers (DQoL-OC) Study|Development of the Dementia Quality of Life Scale for Older Family Carers of People With Dementia (DQoL-OC) and Evaluation of Its Psychometric Properties|DQoL-OC|University of Nottingham|Yes|Recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Older family carers: To be an old person (between 60 and 100 years old), currently        providing care for a family member with dementia (carers' self-report) at home in the UK,        to understand and speak English, to accept to participate of the study|December 2015|December 1, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463734||19709|
NCT02477553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502774679|Information With or Without Numbers For Optimizing Reasoning About Medical Decisions|Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information|INFORM|Indiana University|No|Enrolling by invitation|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|750|||Both|50 Years|75 Years|No|||March 2016|March 4, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02477553||18646|
NCT02465073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-027|The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds|The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds||Southwest Regional Wound Care Center|No|Completed|July 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 19, 2014|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT02465073||19606|
NCT02465372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL121692|Be a Champion! Comprehensive School Physical Activity Program|Utilizing Physical Activity Coordinators to Increase Physical Activity Among Youth|BAC!|University of South Carolina|No|Enrolling by invitation|August 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|5 Years|12 Years|No|||June 2015|June 4, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02465372||19583|
NCT02419885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB|Evaluation of Result and Influence Factors on Composite Graft in Fingertip Amputation|Evaluation of Result and Influence Factors on Composite Graft in Fingertip Amputation||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|A retrospective chart review study. Patients were collected since 1990,|December 1990|April 14, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02419885||23075|
NCT02467634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-AMD-201|Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD|A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|RADIANT|StemCells, Inc.|Yes|Suspended|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|50 Years|90 Years|No|||November 2015|December 23, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467634||19409|
NCT02467647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLJDT-2016|The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy|Phase 1 Study of the Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy|HLJDT-2016|Wuhan University|No|Recruiting|January 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|85 Years|No|||June 2015|June 9, 2015|June 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02467647||19408|
NCT02462707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8641021|A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors|Phase 1 Study Of Pf-03084014 To Evaluate Safety And Pharmacokinetics In Japanese Patients With Advanced Solid Tumors||Pfizer|No|Withdrawn|July 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|October 6, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462707||19787|
NCT02462720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV018|COMFORT: A Multicenter, Open-label, Randomized, Crossover Study|Multicenter Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena® Compared to Radiofrequency Ablation|COMFORT|BTG International Inc.|Yes|Completed|May 2015|March 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462720||19786|
NCT02421939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0301|A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation|A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation||Astellas Pharma Inc|Yes|Recruiting|September 2015|October 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|369|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421939||22917|
NCT02426294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-IIT-013|Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin|A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin||Pusan National University Hospital|Yes|Recruiting|February 2015|May 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|19 Years|80 Years|No|||April 2015|April 21, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02426294||22582|
NCT02425748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gd T cell and lung cancer|Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)|γδ T Cell Immunotherapy for Treatment of||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|75 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425748||22624|
NCT02425761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1403-13857|The CSF Shunt Entry Site Trial|A Randomized Controlled Trial of Anterior Versus Posterior Entry Site for Cerebrospinal Fluid Shunt Insertion||Baylor College of Medicine|Yes|Recruiting|April 2015|December 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|448|||Both|N/A|17 Years|No|||November 2015|November 16, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425761||22623|
NCT02474004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIT-Men1|Gait Analysis Meniscal Repair|||Medical University Innsbruck||Recruiting|February 2012|||February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|10 Years|60 Years|No|||June 2015|June 12, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02474004||18919|
NCT02463994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.005|A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC|A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer||University of Michigan Cancer Center|Yes|Recruiting|October 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463994||19689|
NCT02472275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-075|PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer|Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||February 2016|February 9, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472275||19052|
NCT02416999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YDCR-2015-001|Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas|Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas||Hebei Yanda Hospital|Yes|Not yet recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02416999||23296|
NCT02425228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paired CAP Trial|Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer|Paired CAP: Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer|Paired Cap|Jonsson Comprehensive Cancer Center|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Male|N/A|N/A|No|Non-Probability Sample|Men with targetable lesion on MRI, undergoing a first-time prostate biopsy driven by PSA        elevation to rule out cancer.        We choose to study men undergoing first-time biopsy, since the great challenge with        prostate biopsy today is to establish a correct diagnosis initially. The study sample is        kept uniform by excluding men with prior negative biopsies and men enrolled in the Active        Surveillance program. Men without a targetable lesion and men with a PI-RADS <2 lesion        currently undergo a mapping biopsy under an existing IRB approval; data collection on        these men would continue in parallel, but would not be part of this targeting study|February 2016|February 10, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02425228|1 Month|22664|
NCT02471807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04|Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System|Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System||Edwards Lifesciences|Yes|Recruiting|July 2015|January 2019|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471807||19088|
NCT02467725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2015-01|EnMotion, Embryo's Natural Motion|EnMotion, Embryo's Natural Motion: The Impact of Dynamic Culture on the Development of Useable Blastocysts|EnMotion|Reproductive Medicine Associates of New Jersey|No|Recruiting|May 2015|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|200|||Female|18 Years|42 Years|No|||June 2015|June 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467725||19402|
NCT02423603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009246QM|PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer|A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT).|PAKT|Queen Mary University of London|Yes|Recruiting|May 2014|January 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||April 2015|April 17, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02423603||22789|
NCT02423616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-13/11-2-16|Correlation Between Maximal Inspiratory Pressure and Hand Grip Force|Correlation Between Maximal Inspiratory Pressure and Hand Grip Force in Healthy Individuals|CBMIPHGFHI|Attikon Hospital|No|Completed|March 2012|June 2013|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02423616||22788|
NCT02412059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LichterM|Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear|Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study||St. Michael's Hospital, Toronto|No|Completed|August 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02412059||23676|
NCT02464475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterOST|Effects of OMT on Interoception|Effects of Osteopathic Manual Treatment on Interoception: 2- Armed RCT on cLBP Patients||Come Collaboration|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|50 Years|No|||January 2016|January 26, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02464475||19652|
NCT02468765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0040|Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis|Depression and Reconnaissance of Emotions in Multiple Sclerosis Patients|SepDep|Lille Catholic University|No|Recruiting|May 2015|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three groups will participate: Depressive MS patients, non depressive MS patients        and a control group|April 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02468765||19322|
NCT02475798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-625 CA-P2|PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation|Clinical Study to Collect Confirmatory Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation||Cook||Recruiting|June 2015|July 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475798||18781|
NCT02423317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN 182/FM|Comparison of Miller's Blade and Airtraq Laryngoscope in Children|A Comparative Evaluation of Airtraq Optical LaryngoscopeTM and Miller Blade in Pediatric Patients Undergoing Elective Surgery Requiring Tracheal Intubation.||Government Medical College, Haldwani|Yes|Completed|May 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|10 Years|No|||February 2016|February 11, 2016|March 29, 2015||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02423317||22811|
NCT02412592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY009|Sustained Viral Response in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon Therapy|Sustained Viral Response and Clincal Relapse in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion by Interferon Therapy||Beijing Ditan Hospital|No|Active, not recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|||Both|18 Years|60 Years|No|Non-Probability Sample|The study population in this study were composed of HBeAg positive chronic hepatitis B        patients achieved HBeAg seroconversion by interferon treatment, and serum HBsAg, anti-HBs,        HBeAg, anti-HBe, and HBV DNA would be tested every 3 months for 156 weeks after finished        treatment. The sustained viral response defined HBV DNA mantaining undetectable would be        evalued during the observation period.|April 2015|April 6, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412592||23635|
NCT02473328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREPATS 003|Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients|Non-comparative Phase II Open Study Evaluating the Efficacy of a Reduced Dose Atazanavir / Ritonavir 200/100 mg + 2 NRTI in HIV-1-infected Patients With Virological Success With Atazanavir / Ritonavir 300/100 mg + 2 NRTI|ATALOW|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|Yes|Recruiting|June 2015|August 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|N/A|No|||June 2015|October 27, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02473328||18971|
NCT02474121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IDE 13996 (CA)|Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access|MarrOwStim™ PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects With Severe Peripheral ArteriaL DiseasE (PAD) (MOBILE) - Continued Access|MOBILE-CA|Biomet, Inc.||Available||||||N/A|Expanded Access|N/A|||||||Both|21 Years|N/A||||March 2016|March 9, 2016|June 15, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02474121||18910|
NCT02474134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF530-101|Comparison Study of PF530 and Betaferon in Healthy Subjects|A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers||Pfenex, Inc|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02474134||18909|
NCT02416518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH GEMMA|Genetic Exploration of the Molecular Basis of Malignancy in Adults|Genetic Exploration of the Molecular Basis of Malignancy in Adults|GEMMA|Sanford Health|Yes|Recruiting|May 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Tissue and blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with metastatic, incurable cancer or cancer with no standard 1st-line        systemic therapy that has shown prolonged survival|July 2015|July 31, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02416518||23333|
NCT02412865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44 DA035017-0 2|Quit4Baby Evaluation|Developing and Scaling a Text Messaging Tool to Help Pregnant Smokers|Quit4Baby|George Washington University||Completed|April 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|505|||Female|14 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02412865||23614|
NCT02472405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140348|Multiplex Laser vs. PDL (Pulsed Dye Laser ) in the Treatment of Surgical Scars|Comparing the 595/1064nm Multiplex Laser to the 595nm PDL in the Treatment of Surgical Scars in a Blinded, Randomized, Controlled Trial||University of Miami|Yes|Recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02472405||19042|
NCT02472418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFN-15-CD-002|DFN15 Versus Placebo in Patients With Migraine Headaches|||Dr. Reddy's Laboratories Limited||Active, not recruiting|May 2015|February 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472418||19041|
NCT02469402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026|Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality|Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein: Content and Improved Protein Quality: LactPro-Minus||Waldkrankenhaus Protestant Hospital, Spandau|No|Recruiting|January 2014|October 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|N/A|1 Month|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469402||19273|
NCT02412540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH ABC|Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH|A Parallel Cohort Controlled Trial of Outcome of Nonalcoholic Steatohepatitis in Adolescents After Bariatric Surgery vs. Comprehensive Lifestyle Intervention (NASH ABC)||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2015|March 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|13 Years|19 Years|No|||February 2016|February 1, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02412540||23639|
NCT02413125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17882|Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions|Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions||University of Virginia|No|Recruiting|February 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 12, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02413125||23594|
NCT02465255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 22/13|Sublingual Analgesia for Acute Abdominal Pain in Children|Sublingual Analgesia for Acute Abdominal Pain in Children. Ketorolac Versus Tramadol Versus Paracetamol, a Randomized, Control Trial||IRCCS Burlo Garofolo|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|4 Years|18 Years|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465255||19592|
NCT02465593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP503-RC-1001|A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Unresectable Rectal Cancer|A Phase Ib//II Study of PEP503 (Radio-enhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Unresectable Rectal Cancer||PharmaEngine|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|80 Years|No|||June 2015|June 4, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465593||19566|
NCT02465606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS29735|A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis|AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS||Hoffmann-La Roche||Active, not recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465606||19565|
NCT02252393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7814|Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer|Prospective Randomized Comparison of Intracorporeal Versus Extracorporeal Urinary Diversion During Robotic Radical Cystectomy||Case Comprehensive Cancer Center|No|Recruiting|October 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|190|||Both|N/A|N/A|No|||February 2016|February 19, 2016|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02252393||35923|
NCT02244450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0030|Generalized Neonatal Screening of Severe Combined Immunodeficiencies|Evaluation of the Clinical Utility and Cost Effectiveness Ratio of Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs on Guthrie Cards|DEPISTREC|Nantes University Hospital|No|Recruiting|December 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200030|||Both|N/A|18 Months||||February 2016|February 22, 2016|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02244450||36534|
NCT02314793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2205-CL-0001|A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205|A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205||Astellas Pharma Inc|No|Suspended|November 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Anticipated|132|||Both|25 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|December 8, 2014||No|The study has been suspended because of operational reasons.|No||https://clinicaltrials.gov/show/NCT02314793||31134|
NCT02319031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-326|Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks|Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)||Bristol-Myers Squibb|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319031||30808|
NCT02312505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 162/10|Comparison of a New Semi-invasive Monitoring System With Transpulmonary Thermodilution in Cardiac Surgery Patients|Estimation of Cardiac Output by a New Semi-invasive Monitoring System: Accuracy and Limitations||University of Schleswig-Holstein|Yes|Completed|March 2012|December 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|65|||Both|18 Years|N/A|No|||December 2014|December 6, 2014|December 3, 2012||No||No||https://clinicaltrials.gov/show/NCT02312505||31309|
NCT02313844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H35885 Viralym-B|Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)|A Phase I Study Using Most Closely HLA-matched BK Virus-specific T Lymphocytes for the Treatment of BK Virus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-B)||ViraCyte|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||December 2015|February 5, 2016|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313844||31206|
NCT02314182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.847|GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis|GRECCAR 8 : Impact on Survival of the Primary Tumor Resection in Rectal Cancer With Unresectable Synchronous Metastasis a Randomized Multicenter Study|GRECCAR8|Hospices Civils de Lyon|Yes|Recruiting|November 2014|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|290|||Both|18 Years|75 Years|No|||November 2014|December 10, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02314182||31181|
NCT02240680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.149|Linagliptin as Add on to Basal Insulin in the Elderly|A 24 Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Once Daily Linagliptin, 5 Milligrams Orally, as Add on to Basal Insulin in Elderly Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control||Boehringer Ingelheim||Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|300|||Both|60 Years|N/A|No|||March 2016|March 22, 2016|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02240680||36824|
NCT02240693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.5|Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo|A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease (AD)||Boehringer Ingelheim||Recruiting|January 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Anticipated|288|||Both|55 Years|N/A|No|||March 2016|March 21, 2016|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02240693||36823|
NCT02240706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315.7|Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes|A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes||Boehringer Ingelheim||Recruiting|January 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 15, 2014||||No||https://clinicaltrials.gov/show/NCT02240706||36822|
NCT02311582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501072|MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas|A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas||Washington University School of Medicine|No|Recruiting|August 2015|December 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311582||31380|
NCT02311842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA1627494|To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS|To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early Ankylosing Spondylitis||Sun Yat-sen University|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|65 Years|No|Non-Probability Sample|Chinese patients with early AS|December 2014|December 4, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311842||31360|
NCT02316574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6859|The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving|The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving||New York State Psychiatric Institute|Yes|Recruiting|December 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|December 1, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316574||30997|
NCT02246257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OdenseUH|Early Rheumatoid Arthritis COR Intervention|Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis|ERACORI|Odense University Hospital|Yes|Recruiting|September 2014|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246257||36395|
NCT02246270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010477|Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)|Recurrent Urinary Tract Infections and Heparin: a Double-blind Randomized Clinical Trial (RUTIH Trial)||Oregon Health and Science University|Yes|Withdrawn|November 2014|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|85 Years|No|||November 2014|November 5, 2014|September 15, 2014|Yes|Yes|Limited Funding|No||https://clinicaltrials.gov/show/NCT02246270||36394|
NCT02252692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000956-28|Relative Bioavailability Study With Enalapril in Healthy Volunteers|Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults||Ethicare GmbH|No|Active, not recruiting|August 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02252692||35900|
NCT02252705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMEHIP|Mexican Registry of Pulmonary Hypertension|Mexican Registry of Pulmonary Hypertension|REMEHIP|Remehip|No|Active, not recruiting|July 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|2 Years|90 Years|No|Probability Sample|Mexican patients older than 2 years with diagnosis of Pulmonary Hypertension from groups I        and IV|November 2015|November 5, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252705|4 Years|35899|
NCT02312193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMB02|Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects|Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects||Neuromed IRCCS||Recruiting|January 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|||Both|30 Years|70 Years|No|Probability Sample|Subjects will be selected from patients hospitalized in the Department of Neurosurgery of        the IRCCS Mediterranean Neurological Institute Neuromed, according to specific inclusion        criteria and undergoing surgery for disc disease. Subjects included in the study will be        normotensive and hypertensive patients. Approximately 70 subjects of both genders (35        normotensive, 35 hypertensive) aged between 30 and 70 years old will be included in the        study. All the enrolled patients must have an indication for neurosurgical intervention.|February 2015|February 3, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02312193||31333|
NCT02323438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSD1304|Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum|A Randomized, Controlled Study to Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum||R.J. Reynolds Vapor Company|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|153|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323438||30470|
NCT02323451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QS20140506|Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE)|A Multicentre, Randomized, Double-blinded, Parallel-controlled, Non-inferiority Clinical Study Of Safety and Efficacy Of Medical Chitosan for Knee Osteoarthritis Compared With Sodium Hyaluronate Injection||Shanghai Qisheng Biological Preparation Co., Ltd.|Yes|Recruiting|December 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|40 Years|75 Years|No|||December 2014|December 23, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323451||30469|
NCT02252913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-504-00CH1|A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer|A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer||Hutchison Medipharma Limited|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02252913||35883|
NCT02240719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#245|Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer|Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies||University of California, Davis|Yes|Recruiting|October 2014|December 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02240719||36821|
NCT02311348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150025|Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy|Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|20|||Both|18 Years|100 Years|No|||September 2015|January 12, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311348||31398|
NCT02311595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-032|A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection|A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer Patients||Samsung Medical Center||Not yet recruiting|December 2014|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|20 Years|80 Years|No|||December 2014|December 5, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311595||31379|
NCT02324920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA103|Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope|Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope. A Randomized Double-blind Parallel Trial.|BIOSync CLS|Biotronik SE & Co. KG|No|Not yet recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|40 Years|N/A|No|||August 2015|August 20, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324920||30356|
NCT02247934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13601-000|Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)|Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)||Gilead Sciences|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|26|||Both|18 Years|70 Years|No|Non-Probability Sample|Participants will be recruited from approximately 5 clinical sites based in the United        States.|February 2016|February 8, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02247934||36266|
NCT02247947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-053|Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome|Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome||Universitätsklinikum Köln|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Serum and urine|Both|18 Years|N/A|No|Probability Sample|patients with cardiac arrest of non-trauma origin|January 2016|January 25, 2016|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02247947||36265|
NCT02258399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE-FH1109|Exercise in the Fasted State, Glucose Metabolism and Energy Balance|||University of Bath||Active, not recruiting|May 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|12|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258399||35465|
NCT02311855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1076|Duration of Immune Response to Influenza Vaccination in Patients With RA|Duration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving Treatment With Biologic Agents||Bassett Healthcare|No|Active, not recruiting|August 2014|||December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02311855||31359|
NCT02318095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058865|Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer|Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer||Duke University|No|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318095||30880|
NCT02251249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/19|Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.||GASTRIM|University Hospital, Bordeaux|No|Not yet recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251249||36011|
NCT02251262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/31|Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection|Assessment of Diagnostic Accuracy of 18FDG-PET-CT in Patients With Suspicion of Pacing or Defibrillation Lead Infection: a Prospective Multi-center Study|ENDOTEP|University Hospital, Bordeaux|No|Not yet recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251262||36010|
NCT02467218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7888-A|HBOT in Fibromyalgia|Hyperbaric Oxygen Therapy in Fibromyalgia : Effect on Global Function||University Health Network, Toronto|No|Recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02467218||19441|
NCT02424461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120116|Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection|Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial|PROSTASHORT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||November 2015|November 30, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02424461||22723|
NCT02413840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU900314|Evaluation, Psychological Intervention and Follow-up Study of Anxiety and Depression in Stable COPD Patients|Evaluation, Psychological Intervention and Follow-up Study of Anxiety and Depression in Stable Chronic Obstructive Pulmonary Disease Patients||Capital Medical University|Yes|Recruiting|December 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|75 Years|No|||April 2015|April 7, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02413840||23539|
NCT02461914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-Ii|Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Not yet recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02461914||19848|
NCT02466542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBase|Analgesic Effect of Intraoperative Esmolol in Mastectomies|Analgesic Effect of Intraoperative Esmolol in Mastectomies: Single Center, Prospective, Double-blind, Randomized and Placebo Controlled Study|Esmobreast|Hospital de Base|Yes|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|75 Years|No|||February 2016|February 18, 2016|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466542||19493|
NCT02467686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349441|Breast Cancer, Sexuality and Black Cohosh|Effects of Cimicifuga Racemosa L. Nutt Sexuality of Women With Breast Cancer Using Tamoxifen or Aromatase Inhibitor|Cimicifuga|Irmandade da Santa Casa de Misericordia de Sao Paulo|No|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|48 Years|68 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467686||19405|
NCT02467699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-51|Navigation System for in Vivo Measurement of the Kinematics of the Knee|Validation of a Noninvasive Navigation System for in Vivo Measurement of the Kinematics of the Knee||University Hospital, Strasbourg, France|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients operated in the service in 2014 to care for end-stage knee osteoarthritis by        implantation of a total knee prosthesis.|June 2015|June 7, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02467699||19404|
NCT02474329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0002607|Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease|Real-PD: Development of Clinical Prognostic Models for Parkinson's Disease From Large-scale Wearable Sensor Deployment and Clinical Data - a Population Based Trial||Radboud University|Yes|Recruiting|July 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1000|||Both|30 Years|N/A|No|Non-Probability Sample|Dutch Parkinson patients.|August 2015|August 5, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02474329|13 Weeks|18894|
NCT02424526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-14-156|Intensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral Palsy|Intensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral Palsy||California State University, Sacramento|No|Recruiting|July 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|1 Year|3 Years|No|||February 2016|February 1, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02424526||22718|
NCT02466854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USantiago|Bleeding Complications in a Multicenter Registry of Patients Discharged With Diagnosis of Acute Coronary Syndrome|Bleeding Complications in a Multicenter Registry of Patients Discharged With Diagnosis of Acute Coronary Syndrome and Underwent Percutaneous Coronary Intervention|BleeMACS|University of Santiago de Compostela|Yes|Completed|January 2015|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|15401|||Both|N/A|N/A|No|Probability Sample|Patients discharged with diagnosis of Acute Coronary Syndrome underwent percutaneous        coronary intervention with at least 1 year of follow-up (except death)|June 2015|June 8, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02466854||19469|
NCT02466360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0237|What Are the Brakes and Levers of Physical Activity Practice for Patients With Chronic Lower Back Pain?|What Are the Brakes and Levers of Physical Activity Practice for Patients With Chronic Lower Back Pain : a Qualitative Study||University Hospital, Clermont-Ferrand||Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|patients with chronic lower back pain|June 2015|June 8, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02466360||19507|
NCT02416713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-11234|Way to Safety Cellphone Blocking|Way to Safety: Cellphone Blocking Technology to Reduce Cellphone Use While Driving Among Teens||Children's Hospital of Philadelphia|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|250|||Both|16 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416713||23318|
NCT02416973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI.2015.001|Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery|||Regenesis Biomedical, Inc.||Recruiting|March 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416973||23298|
NCT02419352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331/21-9-10|Sugammadex and Cognitive Function|Effect of Sugammadex Versus Neostigmine/Atropine Combination on Cognitive Function After Elective Adult Surgery||Attikon Hospital|No|Completed|September 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|160|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02419352||23116|
NCT02473458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-01-4806|Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke|||Shiraz University of Medical Sciences|Yes|Completed|June 2012|June 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|85 Years|No|||June 2015|June 11, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02473458||18961|
NCT02411760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052014-042|Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection|Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection|BCD|University of Texas Southwestern Medical Center|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|N/A|No|Non-Probability Sample|Patients from the UTSW Breast Imaging Center referred for breast biopsy due to suspicious        mammography or ultrasound exams (SOC) with Breast Imaging-Reporting and Data System        (BI-RADS) 4 or 5.|December 2015|December 11, 2015|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411760||23699|
NCT02467374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002325|Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder|Pilot: Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder||Massachusetts General Hospital|Yes|Recruiting|December 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02467374||19429|
NCT02467387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM-104-M-CHF|A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure|A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure||CardioCell LLC|Yes|Recruiting|June 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467387||19428|
NCT02465281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503M66381|Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Strokes (Preliminary Study)|Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Strokes (Preliminary Study)||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy Control Group Stroke patient subjects|September 2015|September 29, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465281||19590|
NCT02465294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400484|The Influence of Probiotics on Body Weight and Composition|The Influence of Probiotics With a Behavioral Life Style Intervention on Body Weight and Composition in Overweight Participants: A Randomized, Double-blinded, Placebo-controlled Study.|WLP|University of Florida|No|Withdrawn|February 2016|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|June 1, 2015||No|study withdrawn due to funding|No||https://clinicaltrials.gov/show/NCT02465294||19589|
NCT02470013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECONONS|Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients|Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients|ECONONS|Charite University, Berlin, Germany|No|Recruiting|November 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|60 Years|N/A|No|||June 2015|June 9, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02470013||19226|
NCT02425696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLS-1dzx|Registry of Right-to-left Shunt Detection by Contrast-enhanced Transcranial Doppler in Chinese Population|Registry of Right-to-left Shunt Detection by Contrast-enhanced Transcranial Doppler in Chinese Population||First Hospital of Jilin University|No|Recruiting|June 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|We detect RLS through contrast-enhanced transcranial Doppler (c-TCD). The normal        individuals will be selected to group 1, while those who suffer from migraine will be        selected to group 2. Patients of group 2 with large RLS are required to take TTE and brain        MRI.|October 2015|October 30, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425696|1 Year|22628|
NCT02425709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyst 4|Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy in Post Menopausal Women|Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy in Post Menopausal Women: A Randomized Double Blind Placebo Controlled Trial||Cairo University|Yes|Recruiting|April 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|210|||Female|50 Years|65 Years|No|||January 2016|January 26, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425709||22627|
NCT02471261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10146|Elastography as Gouty Arthropathy Outcome (EGO)|Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.||Arthritis & Rheumatism Associates, P.C.|No|Recruiting|May 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|A pilot study to assess 10 subjects with tophaceous gout on urate lowering therapy or        about to begin urate lowering therapy.|June 2015|June 11, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471261||19130|
NCT02471274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-116-HEP|PK Study of Sotagliflozin in Subjects With Hepatic Impairment|A Phase 1, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Sotagliflozin in Male and Female Subjects With Mild, Moderate, and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function||Lexicon Pharmaceuticals|No|Active, not recruiting|June 2015|||December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471274||19129|
NCT02467179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150318|Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus|Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus|Amigo-AFL|University of California, San Diego|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467179||19444|
NCT02467192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-250|The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly|The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly: PneumOldCT|PneumOldCT|University Hospital, Geneva|No|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|65 Years|N/A|No|||June 2015|June 5, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02467192||19443|
NCT02411500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP734-1003|A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males|A Randomized, Open Label, Four Period, Cross-Over Study to Evaluate the Pharmacokinetics of Single Doses of Various TRV734 Formulations in Healthy Male Subjects||Trevena Inc.|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411500||23719|
NCT02464007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM-04|Study of rSIFN-co for Patients With Advanced Solid Tumors|A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity||Sichuan Huiyang Life Science and Technology Corporation|Yes|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464007||19688|
NCT02468206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRTO-NBCA-SP|Secondary Prophylaxis of Gastric Variceal Bleed|Endoscopic Cyanoacrylate Injection vs. Balloon-occluded Retrograde Transvenous Obliteration in the Prevention of Gastric Variceal Rebleeding||West China Hospital||Recruiting|June 2015|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468206||19365|
NCT02475629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMB-301|Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV|A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1||TaiMed Biologics Inc.|Yes|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475629||18794|
NCT02475642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POWDER-AF01|Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation|Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF)|POWDER-AF|VZW Cardiovascular Research Center Aalst|No|Recruiting|March 2014|August 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02475642||18793|
NCT02425644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058B301|Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis|Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis|OPTIMUM|Actelion|Yes|Recruiting|April 2015|May 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|55 Years|No|||August 2015|August 26, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425644||22632|
NCT02425670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT/pr6815/MED/14/880/2005AIIMS|Stem Cell Therapy For Acute Ischemic Stroke Patients|Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke: A Multi-Institutional Project|InVeST|All India Institute of Medical Sciences, New Delhi|Yes|Completed|January 2009|June 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02425670||22630|
NCT02426827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007493|Cervical Spinal Cord Stimulation in Cerebral Vasospasm|A Safety and Feasibility Study of the Use of Cervical Spinal Cord Stimulation for Treatment of Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage|SCSinCV|Mayo Clinic|No|Not yet recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426827||22541|
NCT02472483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D470|Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response|Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response|TCC-MBCT|Centre Hospitalier St Anne|No|Recruiting|September 2012|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|672|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02472483||19036|
NCT02413567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-20000A|Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes|Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes||Fractyl Laboratories, Inc.|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|28 Years|75 Years|No|||November 2015|November 19, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413567||23560|
NCT02413580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1305|A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations|A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations||Grifols Therapeutics Inc.|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413580||23559|
NCT02416076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-141|Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers||Ulthera, Inc|No|Completed|December 2014|January 2016|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|42|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416076||23367|
NCT02468778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartMate PHP™ SHIELD II|Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)|Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)|SHIELD II|Thoratec Corporation|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|425|||Both|18 Years|100 Years|No|||March 2016|March 24, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468778||19321|
NCT02464085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00083|Characterising Arm Recovery in People With Severe Stroke|Characterising Arm Recovery in People With Severe Stroke|CARPSS|University of British Columbia|No|Not yet recruiting|July 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Probability Sample|Stroke survivors with subacute and severe upper limb disability will be evaluated        longitudinally.|June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464085||19682|
NCT02412007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activity Based Therapy in CP|Individualized Comprehensive Home-Centred Activity Based Therapy for Children With Diplegic Cerebral Palsy|A Prospective Study (RCT) to Evaluate the Efficacy of an Individualized Comprehensive Home-Centred Activity Based Therapy for Children With Diplegic Cerebral Palsy||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|5 Years|12 Years|No|||April 2015|April 7, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02412007||23680|
NCT02468141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCRD_SJDBT_2015|Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients|Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients: A Randomized Double Blinded Placebo Controlled Pilot Study||Kyunghee University Medical Center|Yes|Recruiting|July 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|20 Years|80 Years|No|||July 2015|July 29, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02468141||19370|
NCT02465346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaarland|"Mobile Stroke Unit"-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas|"Mobile Stroke Unit"-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas||University Hospital, Saarland|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|95 Years|No|||July 2015|July 1, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02465346||19585|
NCT02465359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016957|Subcutaneous Immunoglobulin for CIDP|A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy|SCIG|University of South Florida|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|80 Years|No|||June 2015|June 4, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465359||19584|
NCT02468453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH149901|VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation|Multi-center, Multi-cohort, Prospective, Open-label Study of VELOS for Treatment of Vascular Skin Disorders||Syneron Medical|No|Recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|May 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468453||19346|
NCT02476838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s15-00200|Hand Transplantation|Microvascular VCA Transplantation||New York University School of Medicine|Yes|Not yet recruiting||||June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02476838||18701|
NCT02464982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP 2011 / 1 AMC|Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer|Areola Tattoo: the End of a Long Therapeutic Process. A Patient's Quality of Life Dedicated Technology||University Hospital, Strasbourg, France|No|Completed|February 2012|||May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Female|N/A|N/A|No|Non-Probability Sample|Women with 1 year non-invasive technology areola tattoo realized as part of 1 breast        mammary reconstruction following an operated breast cancer.|June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464982||19613|
NCT02475655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5336|Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults|A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|February 2016|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475655||18792|
NCT02475668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP2759|SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions|SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry||Nonin Medical, Inc|No|Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|July 2015|July 9, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475668||18791|
NCT02416739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amina-X-002|Anticancer Activity of Nicotinamide on Lung Cancer|Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib||Chungbuk National University|Yes|Recruiting|March 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|19 Years|80 Years|No|||November 2015|November 12, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02416739||23316|
NCT02468713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH201412002|Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition|An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Effect on Blood Lipid Profiles of Omega-3 Enriched Total Parenteral Nutrition in Healthy Korean Male Subjects||Chonbuk National University Hospital|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02468713||19326|
NCT02469909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTK 34|Comparison Between Immediate and Gradual Decannulation|Feasibility and Safety of Immediate Versus Gradual Decannulation: a Randomised Control Trial||Kaplan Medical Center|No|Recruiting|June 2015|January 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02469909||19234|
NCT02241122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72/1801/2014|MRI and Biomarkers in Prostate Cancer|Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging Targeted Biopsies and Biomarkers (Multi-institutional Study)|Multi-IMPROD|Turku University Hospital|No|Recruiting|April 2015|||November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Male|18 Years|85 Years|No|||January 2016|January 20, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02241122||36790|
NCT02241135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-7201-102|RNActive® Rabies Vaccine (CV7201) in Healthy Adults|Phase I Safety and Immunogenicity Trial of an Investigational RNActive® Rabies Vaccine (CV7201) in Healthy Adults||CureVac AG|Yes|Recruiting|October 2013|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Anticipated|172|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02241135||36789|
NCT02248298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUderma-04|Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis|Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy With Short Incubation Time for the Treatment of Facial and Scalp Actinic Keratosis: 12-month Follow-up Results of a Randomized, Prospective, Comparative Trial||Dong-A University|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|87 Years|Accepts Healthy Volunteers|||September 2014|September 20, 2014|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02248298||36238|
NCT02319044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4193C00003|Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck|A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||AstraZeneca|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|96 Years|No|||February 2016|February 17, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319044||30807|
NCT02319057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098011|Pharmacokinetic Study of Single Doses of ORM-12741|Pharmacokinetic Study of Modified Release Formulations and an Immediate Release Formulation of ORM-12741 After Single Oral Doses|Nebula PK 1|Orion Corporation, Orion Pharma|Yes|Completed|September 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02319057||30806|
NCT02324738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMEC 14-069|Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects||University of Oxford|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02324738||30370|
NCT02317302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104322|FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer|FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer||Washington University School of Medicine|No|Recruiting|June 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|December 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317302||30941|
NCT02250313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCUAL|PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study|PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study|PASCUAL|MDx Health|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|600|Samples Without DNA|Archived FFPE prostate biopsy core tissue to be analyzed for this study must have been      collected from a previous, histologically confirmed cancer-negative biopsy. Patients were      considered at risk for prostate cancer due to elevated serum PSA levels, abnormal digital      rectal exam or other risk factor.      Only archived tissues will be used in this study: no new procedures to obtain new samples      from the patient will be done.|Male|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Males aged 40 to 75 years old* that underwent a previous cancer-negative prostate biopsy        within 15 months and being considered for a repeat biopsy due to persistent or elevated        cancer-risk factors|April 2015|April 14, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02250313||36083|
NCT02244736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-DM-ATTIKON|Vascular Markers During OGTT in Diabetics and First-degree Relatives|Changes of the Endothelial Glycocalyx, the Elastic Properties of the Arteries and the Coronary Flow Reserve (CFR) During Oral Glucose Tolerance Test in Patients With New Onset Diabetes Mellitus and First-degree Relatives||University of Athens|Yes|Recruiting|February 2013|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|Samples Without DNA|Plasma in serum for fibrosis and inflammatory markers|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|90 subjects, 30 first degree relatives of diabetics withnormal OGTT (relatives), 30        withnormal OGTT and no family history of diabetes (normals), and 30 with abnormal OGTT        (diabetics).|September 2014|September 16, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02244736|2 Years|36512|
NCT02244749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2010-7851|Role of Metabolic Enzymes in Non-Melanoma Skin Cancer|Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets||University of California, Irvine|No|Completed|March 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Probability Sample|Study population will be selected from University of California Irvine Medical Cencal|August 2015|August 28, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02244749||36511|
NCT02320461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.06.0010.00|Estudo Longitudinal de Saúde do Adulto (Brazilian Longitudinal Study of Adult Health )|Estudo Longitudinal de Saúde do Adulto|ELSA-Brasil|Federal University of Rio Grande do Sul|No|Active, not recruiting|August 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15105|Samples With DNA|Frozen serum and urine samples|Both|35 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|ELSA-Brasil is a cohort study of 15,105 civil servants. All active or retired employees of        the six institutions (and, in a few instances, also of related educational or health        institutions), of both sexes, and with ages between 35 and 74 years, were eligible for the        study. The six institutions, located in three different Brazilian regions, are: the        Federal Universities of Bahia, Espirito Santo, Minas Gerais and Rio Grande do Sul, the        University of Sao Paulo and the Oswaldo Cruz Foundation.|December 2014|December 18, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320461||30699|
NCT02323386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46/13|Kinematic Analysis of a PS, FB Primary Total Knee Arthroplasty (ATTUNE Knee System) Using Dynamic RSA|Anatomo-functional Correlation Between Intra-operative Passive Kinematics Recorded by Navigation and Post-operative Kinematics Analyzed by Dynamic Weight Bearing RSA of the Operated Knee.|Attune-RSA|Istituto Ortopedico Rizzoli|No|Active, not recruiting|January 2015|January 2016|Anticipated|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|50 Years|90 Years|No|||July 2015|July 1, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02323386||30474|
NCT02250092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408M53169|Brain Stimulation and Hand Training in Children With Hemiparesis|Synergistic Effect of Combined Transcranial Direct Current Stimulation/Constraint Induced Movement Therapy in Children With Hemiparesis|tDCS/CIMT|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|21 Years|No|||November 2015|November 3, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250092||36100|
NCT02258035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s57027|Isolation of Vitamin D Binding Protein Isoforms From Human Volunteers|Isolation of Genotype-specific Isoforms of Human Vitamin D-binding Protein (DBP/Gc)||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|24|Samples Without DNA|Serum will be derived from 100-150 ml of blood and used for protein purification|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known genotype of DBP/Gc, as identified in the clinical database of the        Multidisciplinary Breast Centre, University Hospitals Leuven, and free of breast cancer        recurrence at the time of blood sampling.|November 2015|December 1, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02258035||35493|
NCT02258048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02236|The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis|The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis||New York University School of Medicine|No|Withdrawn|October 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory patients with histologic or radiographic evidence of cirrhosis|March 2016|March 9, 2016|October 2, 2014||No|Samuel Sigal no longer with NYU|No||https://clinicaltrials.gov/show/NCT02258048||35492|
NCT02324842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28431754DIA4009|Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients|Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients||The University of Texas Health Science Center at San Antonio|No|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324842||30362|
NCT02242578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-149|Treating Refractory Schizophrenia With rTMS|Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia||Seton Healthcare Family|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242578||36678|
NCT02246608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHN-RSWound-P14-N01|Effect of Oasis® Wound Matrix on Stage III and IV Trunk Pressure Wounds Treated With Negative Pressure Wound Therapy|Effect of Oasis® Wound Matrix on Stage III and IV Trunk Pressure Wounds Treated With Negative Pressure Wound Therapy (NPWT)||Kettering Health Network|No|Recruiting|August 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|89 Years|No|||February 2016|February 25, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246608||36368|
NCT02246621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15417|A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting|MONARCH 3|Eli Lilly and Company|Yes|Active, not recruiting|November 2014|July 2021|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246621||36367|
NCT02316301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Long miso/short miso/hyst|Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy|Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy; a Randomized Controlled Trial.||Cairo University|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|55 Years|No|||September 2015|September 19, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316301||31018|
NCT02313324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmutth-101-023|The Effects of Extracorporeal Shock Wave Therapy in Patients With Coccydynia: A Randomized Controlled Trial|The Effects of Extracorporeal Shock Wave Therapy in Patients With Coccydynia: A Randomized Controlled Trial|ESWT|Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|November 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|20 Years|83 Years|No|||November 2012|December 7, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02313324||31246|
NCT02253498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-009|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|June 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|October 12, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253498||35838|
NCT02242916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCOCO re-irradiation HN|State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study|In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and C-ion Therapy for Recurrent Head & Neck Tumors: A Multicentric Planning Study From the ROCOCO (Radiation Oncology COllaborative COmparison) Group|ROCOCO|Maastricht Radiation Oncology|Yes|Completed|May 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|patients with recurrent head and neck tumors|January 2016|January 21, 2016|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02242916||36652|
NCT02316535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LcACEC-201474|Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer|Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study|LcACEC|West China Hospital|Yes|Enrolling by invitation|November 2014|May 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|710|||Both|70 Years|90 Years|No|||December 2014|December 12, 2014|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02316535||31000|
NCT02324855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exacerb_BQnoFQ|Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis|Long Term Airway Clearance Therapy in Non Cystic Fibrosis Bronchiectasis: a Randomized Controlled Trial||Universidad San Jorge|Yes|Enrolling by invitation|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02324855||30361|
NCT02253615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERT-2014|Effects of Resistance Training in Untrained Older Adults|Effects of 16 Weeks of Resistance Training Using Elastic Resistance or Machines on Muscle Mass, Strength and Postural Control in Untrained Older Adults.||University of Brasilia|Yes|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253615||35829|
NCT02472756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21872|Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma|Relapsed/Refractory Follicular Lymphoma - Rituximab ThErapy in Combination With ChemoTherapy (REFLECT2)||Hoffmann-La Roche||Completed|September 2008|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients >18 years who are diagnosed with follicular lymphoma|June 2015|June 15, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472756||19015|
NCT02472769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBP-9414-010|IBP-9414 for the Prevention of Necrotizing Enterocolitis|A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.||Infant Bacterial Therapeutics||Not yet recruiting|December 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|48 Hours|No|||June 2015|June 25, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472769||19014|
NCT02413853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-13-3|Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer|PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI‐724 as First Line Treatment for Metastatic Colorectal Cancer|PRIMIER|University of Southern California|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413853||23538|
NCT02470923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0180-12-CTIL|In-patient Smoking Cessation Intervention Using Counseling, Spirometry and Nicotine Replacement Therapy|In-patient Smoking Cessation Intervention Using Counseling, Spirometry and Nicotine Replacement Therapy||Soroka University Medical Center|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||May 2015|August 24, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470923||19156|
NCT02471833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080192|Health Evaluation in African Americans Using RAS Therapy|Health Evaluation in African Americans Using RAS Therapy|HEART|Emory University|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|66|||Both|45 Years|N/A|No|||December 2015|December 17, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471833||19086|
NCT02464345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88881.068180/2014-01|Healthy Approach to weIght Management and Food in Eating Disorders (HAPIFED)|A Randomised Controlled Trial of a New Integrated Approach to Management of Eating and Weight Disorders, Namely a Healthy APproach to weIght Management and Food in Eating Disorders (HAPIFED) Compared to Cognitive Behaviour Therapy Enhanced (CBT-E): A Pilot Study|HAPIFED|Federal University of São Paulo|Yes|Recruiting|July 2015|December 2018|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||July 2015|July 14, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464345||19662|
NCT02425592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015246|Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)|Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)|ASPIRE|Yale University|No|Recruiting|April 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Male|30 Years|80 Years|No|Non-Probability Sample|This study will include men between age 30-80 with Gleason 6 prostate cancer, PSA <20,        <cT3, and a life expectancy of at least ten years.|December 2015|December 30, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425592||22636|
NCT02471027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D151100001915001|The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer|Optimization Research of Early Cervical Caner Treatment||Capital Medical University|Yes|Not yet recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|1000|Samples With DNA|frozen tissue and (or) whole blood|Female|18 Years|N/A|No|Probability Sample|2009 FIGO clinical staging IB2, IIA2 stage cervical cancer.|June 2015|June 11, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02471027|4 Years|19148|
NCT02471534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1411-061-6254|Study on Prediction of Fluid Responsiveness Using an Abdominal Compression-induced Change of Blood Pressure in Children|Study on Prediction of Fluid Responsiveness Using an Abdominal Compression-induced Change of Blood Pressure in Children||Seoul National University Hospital|Yes|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|1 Month|5 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02471534||19109|
NCT02412241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 1529|Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients|Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|June 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|21 Years|N/A|No|||January 2016|January 7, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412241||23662|
NCT02426736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:016|Effect of Dexamethasone Dose and Route on Duration of Interscalene Block After Outpatient Shoulder Surgery|Effect of Dexamethasone Dose and Route on Duration of Interscalene Brachial Plexus Block for Outpatient Arthroscopic Shoulder Surgery - A Randomized Controlled Trial||University of Manitoba|No|Recruiting|June 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02426736||22548|
NCT02462655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-PBMC|Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia|Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia|LA-PBMC|Laval University|No|Completed|October 2015|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462655||19791|
NCT02462954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-127|A Safety Study Of The Caya® Diaphragm Used With ContraGel®|A Phase I Safety Study Of The Caya® Diaphragm Used With ContraGel®||CONRAD|No|Active, not recruiting|July 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462954||19768|
NCT02462967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-026|Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis|A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis|NASH-CX|Galectin Therapeutics Inc.|Yes|Recruiting|June 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462967||19767|
NCT02462980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-AF-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2016|||||N/A|N/A|N/A||||||||||||||December 28, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462980||19766|
NCT02461758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Influenza in IBD|Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients|Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients||University of Wisconsin, Madison|No|Not yet recruiting|August 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|80|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02461758||19860|
NCT02461771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POT-CP043014|Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD|Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)|ASAP II|Apellis Pharmaceuticals, Inc.|Yes|Active, not recruiting|January 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|50 Years|N/A|No|||March 2016|March 2, 2016|June 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461771||19859|
NCT02461992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831082|Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A|An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (Moroctocog Alfa (Af-cc), Recombinant Factor Viii) In Male Chinese Subjects With Hemophilia A||Pfizer|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|6 Years|N/A|No|||September 2015|September 28, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461992||19842|
NCT02421523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400874|Strength Training in Duchenne Muscular Dystrophy|Development of a Strength Training Protocol in Duchenne Muscular Dystrophy||University of Florida|Yes|Recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|32|||Male|7 Years|9 Years|No|||December 2015|December 3, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421523||22949|
NCT02471170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02215|Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases|Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|June 2015|||June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|The frequency of research blood collection will not exceed 60 mL in a 1 week period and will      not occur more frequently than 4 times in an 8 week period.|Both|18 Years|N/A|No|Probability Sample|subjects with pancreatic diseases|June 2015|June 12, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471170||19137|
NCT02469376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET - GP1_1|Evaluation of a New Imagingtechnologie for Thrombosis|Biodistribution, Imaging Properties, and Radiation Dosimetry of [18F]-GP1 Positron Emission Tomography (PET) Tracer in Vascular Disease Imaging|PET-GP1_1|University of Zurich|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469376||19275|
NCT02469623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2014|||||N/A|N/A|N/A||||||||||||||June 9, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469623||19256|
NCT02474212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290115-1|: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery|||Tampere University Hospital|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|90 Years|No|||January 2016|January 13, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02474212||18903|
NCT02473835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoB - 3 day diet study|Effects of a Short Term Caloric Restriction on T Cell Activation in Fat|Effects of a Short Term Caloric Restriction on T Cell Activation in Fat||University of Bath|No|Completed|January 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02473835||18932|
NCT02473991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Master degree in Obs & gyn|Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight|Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight||Ain Shams Maternity Hospital|No|Recruiting|March 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|395|Samples Without DNA|placenta is weighed in grams as described by Azpurua et al.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|uncomplicated pregnant women who will attend the outpatient clinic at Ain Shams University        Maternity Hospital|June 2015|June 13, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473991||18920|
NCT02463487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18411|Negative Pressure Wound Therapy as a Drug Delivery System|Negative Pressure Wound Therapy as a Drug Delivery System|ADA NPWT|University of Texas Southwestern Medical Center|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|89 Years|No|||December 2015|December 3, 2015|April 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463487||19728|
NCT02472080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130933|Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study|Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients|THYGEMOX|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02472080||19067|
NCT02423460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046356|Threonine Requirement in IBD Adults and Healthy Adult Controls|Threonine Requirement in Healthy Adult Subjects and in Patients With Crohn's Disease and With Ulcerative Colitis Using the Indicator Amino Acid Oxidation (IAAO) Methodology||Nestlé|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|105|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02423460||22800|
NCT02423473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071/2010|Composite Resin Plus Connective Tissue Graft.|Composite Resin Plus Connective Tissue Graft to Treat Gingival Recession Associated With Non-carious Cervical Lesion. Randomized Clinical Trial||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|August 2011|February 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02423473||22799|
NCT02415608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMPD0021|Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis|A Phase II Study of Ibrutinib in Advanced Systemic Mastocytosis||Stanford University|Yes|Recruiting|March 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415608||23403|
NCT02468219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR00002509/FWA|Assessment and Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis|Multiparametric Assessment and Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis Undergoing Valve Surgery: Effects on Hemodynamics, Functional Capacity, Frailty, Prognosis and Quality of Life||Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Recruiting|March 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|90 Years|No|||June 2015|June 5, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02468219||19364|
NCT02463578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI15002|Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis|Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis: a Pilot Study Following New Vaccine Recommendations. PneumoVas Pilot 2||Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2015|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients followed for ANCA-associated Vasculitis|December 2015|February 24, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02463578||19721|
NCT02411448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15540|A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC|A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer|RELAY|Eli Lilly and Company|Yes|Recruiting|May 2015|April 2020|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411448||23723|
NCT02412072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kgog2019|Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study|||Korean Gynecologic Oncology Group|No|Recruiting|April 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Female|N/A|N/A|No|Non-Probability Sample|patients with biopsy proven endometrial hyperplasia|April 2015|April 7, 2015|April 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412072||23675|
NCT02476708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412015121|A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia|A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia|CRC|Yale University|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02476708||18711|
NCT02476721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-183|Characteristics of Patients With Missed Pulmonary Embolism in the ED: A Three Year Experience|Characteristics of Patients With Missed Pulmonary Embolism in the ED: A Three Year Experience||University Hospital, Basel, Switzerland|No|Completed|March 2014|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1251|||Both|18 Years|N/A|No|Non-Probability Sample|All patientes presented to the ED in the specified timeframe who are at risk for pulmonary        embolism|June 2015|June 18, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476721||18710|
NCT02475733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00015|Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Childern Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs)|A Single Blind, Randomised, Multi-centre, Active Controlled, Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam When Given in Combination With Metronidazole, Compared With Meropenem, in Children From 3 Months to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAIs)||AstraZeneca|Yes|Recruiting|July 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|3 Months|18 Years|No|||March 2016|March 4, 2016|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475733||18786|
NCT02475746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431009|An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects|A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06372865 In Healthy Adult Subjects||Pfizer|No|Withdrawn|July 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475746||18785|
NCT02417246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500092|Open-Labeled PK-PD Studies of Metoprolol ER|Open-Labeled Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Metoprolol ER||University of Florida|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417246||23277|
NCT02425358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA714B05-2|Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction|Timing for Intracoronary Administration of Bone Marrow Mononuclear Cells After Acute ST-elevated Myocardial Infarction: a Pilot Study||The First Affiliated Hospital of Dalian Medical University|No|Completed|February 2005|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|75 Years|No|||April 2015|April 23, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02425358||22654|
NCT02472015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 7031 08|Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms|Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms.|DETECT|University Hospital, Toulouse|No|Recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|65 Years|N/A|No|||August 2015|August 18, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02472015||19072|
NCT02468882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULisbon|Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Longitudinal Trial|Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Randomized Longitudinal Trial||University of Lisbon|No|Recruiting|March 2014|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Anticipated|200|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02468882||19313|
NCT02416271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4943|The Forteo Alendronate Comparator Trial|Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis|FACT|Eli Lilly and Company|Yes|Completed|April 2001|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|203|||Female|45 Years|85 Years|No|||April 2015|April 9, 2015|April 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02416271||23352|
NCT02471235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 COPD care program_02|Short-course Out-patient Pulmonary Rehabilitation and COPD Exacerbations|Effect of Short Course Out-patient Pulmonary Rehabilitation on the Activity and Frequency of Exacerbations of Patients With Chronic Obstructive Pulmonary Disease.||Chinese University of Hong Kong|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|136|||Both|40 Years|N/A|No|||February 2016|February 2, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02471235||19132|
NCT02477345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIUH12-025|Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion||Northwell Health|No|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|N/A|5 Years|No|||December 2015|December 23, 2015|November 27, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477345||18662|
NCT02470260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5156|Northern Manhattan Study of Metabolism and Mind|Northern Manhattan Study of Metabolism and Mind|NOMEM|Columbia University|No|Recruiting|January 2012|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|whole blood for DNA extraction, plasma, sera|Both|50 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Middle aged Hispanics from Northern Manhattan, New York City|September 2015|September 14, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02470260||19207|
NCT02423967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004472|Fresh Versus Frozen Stool for Fecal Transplant in Children|A Comparison of Efficacy of Fresh Versus Frozen Donor Stool for Fecal Microbial Transplant in Children With Recurrent Clostridium Difficile Infections||Mayo Clinic|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|18 Years|No|||November 2015|November 6, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02423967||22761|
NCT02423980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSGP-202|G-Pen™ for Hypoglycemia Rescue in T1D|G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D||Xeris Pharmaceuticals|No|Completed|April 2015|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||October 2015|October 25, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423980||22760|
NCT02471430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AI117841|Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy|A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals|ACTIVATE|Massachusetts General Hospital|Yes|Not yet recruiting|March 2016|February 2020|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471430||19117|
NCT02469584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236/2014|Small Stitch Study|Continuous Small Stitch Technique for Anterior Colporrhaphy: a Pilot Study||Medical University of Vienna|No|Recruiting|October 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||June 2015|June 8, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469584||19259|
NCT02471560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-BGT-14-10665|Tecfidera and the Gut Microbiota|The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events.||Biogen|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|December 3, 2015|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471560||19107|
NCT02471573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_ 03_2015|Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF)|The Effectiveness of a Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI)||Vietnam National University|No|Recruiting|June 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|780|||Female|18 Years|42 Years|No|||June 2015|June 30, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471573||19106|
NCT02473497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081056|Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients|Crizotinib (Xalkori(Registered)) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients With Solid Or Hematologic Malignancies That Harbor A Crizotinib-Sensitive Molecular Alteration But Who Are Unable To Swallow Crizotinib Capsules||Pfizer||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|12 Months|N/A|No|||March 2016|March 7, 2016|June 12, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02473497||18958|
NCT02245802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010.207|Multicenter Validation on Predicting Mortality for Patients With Bleeding Peptic Ulcers|Multicenter Prospective Validation Study on the Prediction of In-hospital Mortality Using CU Prediction Model for Patients With Bleeding Peptic Ulcers||Chinese University of Hong Kong|No|Completed|August 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|785|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with bleeding peptic ulcers who required endoscopic therapy|September 2014|September 19, 2014|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245802||36430|
NCT02252406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB20141202|Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome|Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.|IRMA|University of Florida|Yes|Not yet recruiting|July 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|75 Years|No|||May 2015|May 4, 2015|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252406||35922|
NCT02252237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00987-40|Pharmacokinetics of Prednisone, Prednisolone, Methylprednisolone in Children|Study of Pharmacokinetic Variability of Corticoids (Prednisone, Prednisolone, Methylprednisolone) in Children|GLUCOPED|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2014|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Buccal cell collection swab|Both|N/A|N/A|No|Non-Probability Sample|Children receiving glucocorticoids (Prednisone or Prednisolone or Methylprednisolone) are        recruited in Immuno-hematological unit, dermatological unit , in pediatric nephrological        unit or pediatric intensive care unit|September 2015|September 24, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252237||35935|
NCT02324751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2014/08|Vaccines Against Salmonella Typhi|A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningococcal ACWY), Using a Human Challenge Model of Typhoid Infection|VAST|University of Oxford|Yes|Recruiting|September 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|99|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02324751||30369|
NCT02323243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.861|Clinical Interest of the Temporary Urethral Stent Allium " Bulbar Urethral Stent " in the Treatment of Detrusor Sphincter Dyssynergia|Clinical Interest of the Temporary Urethral Stent Allium " Bulbar Urethral Stent " in the Treatment of Detrusor Sphincter Dyssynergia|ALLIUM|Hospices Civils de Lyon|No|Recruiting|September 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||February 2015|September 24, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02323243||30485|
NCT02241395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGBSI-09|Cell Therapy for Cerebral Palsy|Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy||Neurogen Brain and Spine Institute|Yes|Recruiting|August 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|6 Months|35 Years|No|||September 2014|September 15, 2014|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241395||36769|
NCT02241408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF01OA|Outcomes Data of Adipose Stem Cells to Treat Osteoarthritis|Autologous Adipose Stromal Vascular Fraction Outcomes in Osteoarthritis Research Study||StemGenex||Recruiting|September 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|June 2015|June 17, 2015|September 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02241408||36768|
NCT02248532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMEDIUM|Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM)|Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy|REMEDIUM|University Medical Centre Ljubljana|Yes|Recruiting|January 2014|January 2018|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02248532||36220|
NCT02326155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 4.3|To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)|An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)||Celltrion|Yes|Recruiting|April 2014|June 2026|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Blood samples will be collected for IGRA assessment and immunogenicity analysis (optional).      Where appropriate, the serum should be transferred into a sufficient number of transfer      vials prior to freezing. Additionally, blood samples for immunogenicity should be retained      at the central laboratory (PPD Global Central Labs) up to the End of the Study, in case      additional analysis is required.|Both|6 Years|N/A|No|Probability Sample|The study population will consist of at least 500 male and female patients with active CD,        fistulizing active CD, and UC|February 2016|February 15, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326155|5 Years|30261|
NCT02324764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140262|Use of Glidesheath Slender to Reduce Radial Artery Occlusion and Vascular Access Site Complications Following Transradial Coronary Angiography|Use of Glidesheath Slender to Reduce Radial Artery Occlusion and Vascular Access Site Complications Following Transradial Coronary Angiography|CAPITAL-PRO|Ottawa Heart Institute Research Corporation|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02324764||30368|
NCT02252887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-124|Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy|Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|January 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02252887||35885|
NCT02246361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N°IRB 5891|Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication|Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward|EDIFIP|Floralis|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|211|||Both|15 Years|N/A|No|||August 2015|August 26, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246361||36387|
NCT02246374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD003|ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease|A Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Staged, Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System||InSightec|Yes|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|N/A|No|||June 2015|June 24, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246374||36386|
NCT02316028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZB-BN-2013-002|Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)|A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer|DECIT|Universitair Ziekenhuis Brussel|No|Recruiting|March 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||December 2015|January 12, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316028||31039|
NCT02313038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-2013BAI17B00|Prospective Assessment of Efficacy and Safety of Drug Eluting Stents|Prospective Assessment of Efficacy and Safety of Drug Eluting Stents|PEACE-DES|China National Center for Cardiovascular Diseases|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6023|Samples With DNA|A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for      biomarker analysis and storage for future genetic studies; A urine samples of 40mL will be      collected at 1-month visit and 12-month visit for biomarker analysis and storage.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent the first-ever DES deployment during the index hospitalization were        consecutively recruited.|August 2015|August 27, 2015|February 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313038|1 Year|31268|
NCT02247648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unique Protocol ID|Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy|Efficacy of Extended-release, Once Daily Tramadol for Post Operative in Ambulatory Shoulder Arthroscopy||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Active, not recruiting|June 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2013|September 23, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247648||36288|
NCT02247661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_II|Hip Abductor Strengths, Limping and Trochanteric Tenderness After Hip Arthroplasty Due to Femoral Neck Fracture|Hip Abductor Strengths, Limping and Trochanteric Tenderness After Hip Arthroplasty Due to Femoral Neck Fracture: A Comparison Between the Lateral and Posterolateral Approaches|HASAP|Sundsvall Hospital|No|Completed|February 2012|May 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|||Both|55 Years|N/A|No|Non-Probability Sample|Patients admitted to Sundsvall hospital with a displaced femoral neck fracture operated        with either a total or hemiarthroplasty.|October 2015|October 13, 2015|September 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02247661||36287|
NCT02258386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #1409472204|Assessment of Delirium in Hospitalized Patients|Objective Assessment of Delirium in Hospitalized Patients||University of Arizona|No|Not yet recruiting|October 2014|September 2017|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|70 Years|N/A|No|Non-Probability Sample|Age 70 and older; hospitalized in ICU at high-risk of delirium.|October 2014|October 2, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258386||35466|
NCT02321293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-14-149|A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC|A Phase 1 Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-small Cell Lung Cancer|CURCUMIN|Lady Davis Institute|No|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02321293||30635|
NCT02321592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1754|GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma|GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma|GHSG-AFM13|University of Cologne|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321592||30612|
NCT02317822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122013-065|Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities (ASPIRE PAD)|Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities (ASPIRE PAD).|ASPIRE PAD|North Texas Veterans Healthcare System|Yes|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|90 Years|No|||December 2014|December 11, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317822||30901|
NCT02247674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMU20140829|Bilateral Movement Training for People With Stroke|Effects of Computer-aided Interlimb Force Coupling Training on Paretic Hand and Arm Motor Control Following Chronic Stroke||National Yang Ming University|Yes|Completed|November 2012|October 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|28 Years|81 Years|No|||September 2014|September 19, 2014|August 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02247674||36286|
NCT02242968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140194|Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products|Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|September 12, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02242968||36648|
NCT02242981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15517|A Study of How the Body Breaks Down and Eliminates LY2623091|Disposition of [14C]-LY2623091 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|September 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02242981||36647|
NCT02321605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaimeI08|Efficacy of Best Possible Self Intervention Over Time|Efficacy of Best Possible Self Intervention Over Time: A Randomized Control Trial||Universitat Jaume I|Yes|Completed|January 2013|October 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321605||30611|
NCT02323347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGEDEX2014|Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer|Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer||Institut Universitari Dexeus|No|Completed|January 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|1901|||Female|18 Years|49 Years|No|Non-Probability Sample|Women undergoing IVF-ICSI ad fresh embryo transfer|December 2014|December 22, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323347||30477|
NCT02325908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI091-97|Body Fluid Dynamics in Hemodialysis Patients, an Estimation of Dry Weight|Evaluation of Body Hydration Status in Hemodialysis Patients Using Segmental Bioimpedance Analysis||Renal Research Institute|No|Terminated|April 2008|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|89|Samples Without DNA|During every study day, 1 tube (3.5mL) will be collected before and 1 tube (3.5mL) after HD.      This will be done at each study day until the subject reaches optimal hydration status.      These samples will be used to assess Na+, K+, Ca++ concentrations and conductivity of the      blood. We'll also measure aldosterone monthly.In case of technical issues (which may include      device malfunction, transportation of samples, or scheduling of personnel), samples may be      frozen temporarily. Samples may also be frozen and kept for future biochemical studies (see      "Consent form for future biochemical studies").|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Stable hemodialysis patients believed to be at all levels of hydration by their treating        physician will be chosen. 100 subjects will be chosen to include approximately 50% women        in the hemodialysis program. Subjects will be selected from a wide range of ages and body        mass indexes|February 2016|February 22, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325908||30280|
NCT02243202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103086|Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects||Janssen Research & Development, LLC|Yes|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|335|||Both|18 Years|65 Years|No|||August 2015|August 7, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243202||36630|
NCT02243215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TABLT 2 Offsite|Off-site Training in Laparoscopy|Off-site vs. On-site Simulation Training in Laparoscopy a Randomized Trial||Koege Sygehus|Yes|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243215||36629|
NCT02474264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0594-14-RMC|The Link Between BRCA Mutation and Endothelial Function|The Link Between BRCA Mutation and Endothelial Function - A Pilot Study||Rabin Medical Center|Yes|Recruiting|February 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|82|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|June 12, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02474264||18899|
NCT02474277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLB-ED-08-2014|How Well Does the 30-Second Chair Stand Test Predict Rehabilitation Needs in Acutely Admitted Elderly Patients|How Well Does the 30-second Chair Stand Test Predict Rehabilitation Needs in Acutely Admitted Elderly Patients?||University of Southern Denmark|No|Completed|November 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|156|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02474277||18898|
NCT02418546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000258|Electronic-health Application To Measure Outcomes REmotely Clinical Trial|Electronic-health Application To Measure Outcomes REmotely Clinical Trial|EAT MORE|Massachusetts General Hospital|No|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418546||23177|
NCT02473185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03-10/53|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD||Landstinget Västmanland|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|60 Years|No|||November 2015|November 24, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473185||18982|
NCT02462928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-005|A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration|Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration|CDER|Allergan|Yes|Recruiting|June 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|900|||Both|50 Years|N/A|No|||March 2016|March 3, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462928||19770|
NCT02468908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOL-001|Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult Subjects||Serendex Pharmaceuticals|Yes|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468908||19311|
NCT02468921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20131|Goitres Influence on Voice Function - The Impact of Surgery|The Impact of Surgical Treatment of Benign Non-toxic Goiter on the Voice Function|SOLOIST|University of Southern Denmark|No|Recruiting|November 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|80 Years|No|Non-Probability Sample|All patients undergoing hemi- or total thyroidectomy at Odense University Hospital for        benign symptomatic non-toxic goiter|January 2016|January 6, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02468921||19310|
NCT02425605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0803|Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma|Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: a Prospective Phase 2 Trial||Yonsei University|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|20 Years|75 Years|No|||April 2015|April 20, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02425605||22635|
NCT02425618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0110|The Comparison of the Effect of Pressure-controlled Ventilation and Volume-controlled Ventilation on the Gastric Insufflations in I-gel|||Yonsei University|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|10|||Both|20 Years|N/A|No|||June 2015|June 3, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02425618||22634|
NCT02425631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1097|CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System|CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System||Zyga Technology, Inc.|No|Enrolling by invitation|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with the SImmetry System will be recruited for this study.|April 2015|April 23, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425631||22633|
NCT02473380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14-0270|Fluorescence Spectroscopy Guided Surgery|Fluorescence Spectroscopy Guided Surgery for Brain Tumors Resection: a Feasibility Study in Human|GLIOSPECT|Hospices Civils de Lyon|No|Recruiting|August 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|19 Years|N/A|No|||June 2015|October 28, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473380||18967|
NCT02475473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504792B|Circulatory Levels of Irisin in Response to Chronic Resistance Training|Circulatory Levels of Irisin in Response to Chronic Resistance Training||Texas Tech University|Yes|Completed|February 2015|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|October 19, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02475473||18806|
NCT02475486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508054|Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF|Role of the Sympathetic Nervous System (ANS) Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF (Tumor Necrosis Factor) - a Monocentric Cross-sectional Study|ANSRA|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|30 Years|65 Years|No|||March 2016|March 9, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02475486||18805|
NCT02416024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308815|Arterial Stiffness and General Anesthesia Induced Hypotension in Patients on Angiotensin-converting Enzyme Inhibitors|Arterial Stiffness as a Predictor of Refractory Hypotension After Induction of General Anesthesia in Patients Chronically Treated With Angiotensin-converting Enzyme Inhibitors||University of Iowa|No|Recruiting|August 2013|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|60 Years|85 Years|No|Non-Probability Sample|Patient who are going under surgery with age between 60 - 85|April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02416024||23371|
NCT02410954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059590|Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear|Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear|tDCS|Duke University|No|Recruiting|December 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02410954||23761|
NCT02467400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004305|Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism|Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism||Mayo Clinic|No|Recruiting|July 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|165|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467400||19427|
NCT02466633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053941|Effect of Monitoring System Design on Response Time to Cardiac Arrhythmias|Effect of Monitoring System Design on Response Time to Cardiac Arrhythmias||Duke University|Yes|Enrolling by invitation|September 2015|||March 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|320|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466633||19486|
NCT02466919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHW103-TDU-B-211-113002|Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients|Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients||National Cheng-Kung University Hospital|Yes|Enrolling by invitation|May 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02466919||19464|
NCT02415816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWSARC|Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas|Diffusion Weighted Magnetic Resonance Imaging in Pediatric Sarcomas||St. Jude Children's Research Hospital|No|Recruiting|April 2015|December 2024|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|N/A|No|||October 2015|October 15, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415816||23387|
NCT02473562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40128.029.12|Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease|Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study|VESPA|VU University Medical Center|No|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|N/A|N/A|No|||December 2015|December 28, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473562||18953|
NCT02473887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00030|Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting|Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting||Hamad Medical Corporation|Yes|Completed|September 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|3 Years|8 Years|No|||May 2015|June 14, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473887||18928|
NCT02417233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10482|Engagement to Care South Africa|Improving Engagement to HIV Prevention and Care in North West, South Africa|ICARE|University of California, San Francisco|No|Active, not recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|750|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02417233||23278|
NCT02411188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UManitoba|For Her Heart's Sake STEP Project: A Clinical Trial|For Her Heart's Sake: A Clinical Trial to Assess Strategies to Enhance Participation in Cardiac Rehabilitation - STEP Project|FHHS: STEP|University of Manitoba|No|Not yet recruiting|February 2016|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|January 6, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02411188||23743|
NCT02411201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-063|DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years|DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)||Guerbet|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|N/A|2 Years|No|||October 2015|October 22, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411201||23742|
NCT02463747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0143-15-TLV|Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia|Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia|RR|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|90 Years|No|||June 2015|June 2, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02463747||19708|
NCT02467907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29594|Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Recurrent Metastatic, Cervical Cancer|A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Recurrent Metastatic, Cervical Cancer||Hoffmann-La Roche||Recruiting|July 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02467907||19388|
NCT02475577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001|Determine Return on Investment in Heart Failure Remote Monitoring Program|A Prospective Randomized Controlled Trial to Determine Return on Investment in a Tablet/Smartphone-based Heart Failure Remote Monitoring Program||NCH Heatlhcare System Inc|No|Recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|163|||Both|18 Years|89 Years|No|||June 2015|June 17, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475577||18798|
NCT02413021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78001|The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens|Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens||Isfahan University of Medical Sciences|Yes|Not yet recruiting|May 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|N/A|No|||February 2016|February 24, 2016|January 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02413021||23602|
NCT02425150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRXL|Treatment of Keratoconus With Advanced Corneal Crosslinking|Treatment of Keratoconus With Advanced Corneal Crosslinking||Umeå University|No|Active, not recruiting|October 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02425150||22670|
NCT02471651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC2015-02|Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema|Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy|DIME|California Retina Consultants|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471651||19100|
NCT02468297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-0530A|Efficacy of the Electronic Acupuncture Shoes: A Clinical Trial for Chronic Low Back Pain||EAS|Chang Gung Memorial Hospital||Completed|April 2009|||January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|60 Years|No|||July 2015|July 27, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02468297||19358|
NCT02415803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-1|Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS|Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With Non-ST-Elevation Acute Coronary Syndrome: A Randomized Clinical Trial||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|December 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||December 2014|April 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02415803||23388|
NCT02467322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis-003|To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.|To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion||Institute of Liver and Biliary Sciences, India|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||June 2015|October 3, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467322||19433|
NCT02467335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438053|Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects|Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects||Bristol-Myers Squibb||Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02467335||19432|
NCT02464267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZK-Nr. 2014-0712|Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF|Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation of Patients Living With Cystic Fibrosis - Item Development||University of Zurich|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Cystic Fibrosis|May 2015|June 2, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02464267||19668|
NCT02463812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055553|Lipid Infusion Following Major Surgery|Energy Supplement With Lipid Emulsion Following Major Surgery||University of Alberta|No|Active, not recruiting|May 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463812||19703|
NCT02425683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13050|Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX|A Randomized, Phase II Study of High-Risk Colorectal Cancer Patients (Stage IIIC) Treated With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX||US Oncology Research|Yes|Recruiting|March 2015|September 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425683||22629|
NCT02423187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT12T|Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin|Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin||Eisai Inc.||Recruiting|March 2015|March 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1400|||Both|N/A|N/A|No|Non-Probability Sample|Participants with long-term combination therapy with low-dose aspirin|November 2015|November 4, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423187||22821|
NCT02423200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIP14-745-303|Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD|A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD||EIP Pharma, LLC|No|Recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|60 Years|85 Years|No|||November 2015|November 3, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423200||22820|
NCT02426840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-D|Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents|Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents|CAL-D|Chiang Mai University|No|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|10 Years|20 Years|No|||January 2016|January 13, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426840||22540|
NCT02426853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1037|Ultraviolet (UV) Photography in Adolescents|Sun Protection, Tanning Behaviors and Attitudes in Adolescents||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|420|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426853||22539|
NCT02476760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q13-06B|Incretin-based Drugs and Acute Pancreatitis|The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|1417914|||Both|18 Years|N/A|No|Probability Sample|In each jurisdiction, the investigators will assemble a base cohort including all patients        with a first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is        defined as the date of prescription or dispensation of the first-ever non-insulin        anti-diabetic drug. From this base cohort, a study cohort will be formed including all        patients who initiated a new anti-diabetic drug class during the year in which        incretin-based drugs entered the market in each jurisdiction or any time thereafter. Study        cohort entry is defined by the prescription date of the newly-prescribed drug class.|June 2015|June 17, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02476760||18707|
NCT02473913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0178|Milk Thistle in Trichotillomania in Children|Silymarin Treatment of Trichotillomania in Children: A Double-Blind, Placebo-Controlled, Cross-Over Study||University of Chicago|Yes|Recruiting|March 2015|June 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|10 Years|14 Years|No|||September 2015|September 23, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473913||18926|
NCT02421770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMurcia|Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treat Oral Lichen Planus|Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treatment Oral LichenPlanus|lichenPlanus|Universidad de Murcia|Yes|Completed|January 2014|July 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421770||22930|
NCT02464202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G089213N|Use of CBCT-based Tooth Replica in Tooth Autotransplantation to Improve the Outcome of Tooth Replacement in Children|Use of Stereolithographic Model in Tooth Autotransplantation and Periodontal Ligament Stem Cells for Pulp Revascularization and Reinnervation to Increase the Success Rate for Tooth Replacement in Children||Universitaire Ziekenhuizen Leuven||Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02464202||19673|
NCT02464215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM201309|Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer|Comparison of the Laparoscopy-Assisted Distal Gastrectomy(LADG) and Open Distal Gastrectomy(ODG) for Locally Advanced Gastric Cancer|SWEET|Beijing Cancer Hospital|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||March 2015|July 12, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464215||19672|
NCT02464995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5886|Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations|Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations|THERMASCORT|University Hospital, Strasbourg, France|No|Not yet recruiting|June 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464995||19612|
NCT02477358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 321-14-FB|The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth|The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth||University of Nebraska|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02477358||18661|
NCT02423993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-01-2010|Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy|Efficiency Assessment of the Structured Education Program for Type 1 Diabetes Patients on Insulin Pump Therapy|EASEDIAP|Endocrinology Research Centre, Moscow|No|Completed|October 2009|February 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|April 19, 2015||No||No|August 4, 2015|https://clinicaltrials.gov/show/NCT02423993||22759|
NCT02473406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAOPPIFSAP|Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Severe Acute Pancreatitis|Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Severe Acute Pancreatitis||Nanjing University School of Medicine|No|Not yet recruiting|August 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|510|||Both|18 Years|70 Years|No|||June 2015|June 17, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473406||18965|
NCT02461537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKMS-14-01|Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (ETAL3-ASAP)|Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML||DKMS Deutsche Knochenmarkspenderdatei Gemeinnützige Gesellschaft mbH|No|Recruiting|June 2015|May 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|75 Years|No|||November 2015|November 3, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461537||19877|
NCT02461550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001|Irreversible Electroporation Ablation for Colorectal Metastases to the Lung|Irreversible Electroporation Ablation for Colorectal Metastases to the Lung||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461550||19876|
NCT02421952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H32386|Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children|Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children|BARF|Baylor College of Medicine|No|Recruiting|April 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|336|||Both|3 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Pre-operative patients at Texas Children's Hospital|April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02421952||22916|
NCT02421965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028548|Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness|Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness: Patient Engagement, Satisfaction, and Outcomes||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|June 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02421965||22915|
NCT02473666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 2015-0175|Patient Blood Management - Use and Outcome|Patient Blood Management - Use and Outcome|PBM-USZ|University of Zurich|No|Recruiting|January 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300000|||Both|N/A|N/A|No|Probability Sample|All cases of all in hospital patients. Area of Focus: Transfusions of blood products.|June 2015|June 11, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02473666||18945|
NCT02464943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007-CA|Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissections|Zenith® Dissection Endovascular System in the Treatment of Patients With Acute, Complicated Type B Aortic Dissections||Cook||Recruiting|April 2015|August 2023|Anticipated|July 2023|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464943||19616|
NCT02465619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis-002|To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.|To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|1. Cirrhosis: based on previous liver biopsy if available or based on clinical, imaging.          2. Severe acute hepatitis [14]: fulfilling any 2 of the 3 criteria:               -  Hepatic encephalopathy,               -  Serum bilirubin equal to or more than 10 mg/dl               -  International normalized ratio (INR) more than or equal to 1.6          3. Acute on chronic liver failure [3]: Acute hepatic insult manifesting as jaundice             (serum bilirubin ≥ 5mg/dL) and coagulopathy (INR ≥ 1.5), complicated within 4 weeks             by ascites and/or encephalopathy in patients with previously diagnosed or undiagnosed             chronic liver disease/cirrhosis, and is associated with a high 28-day mortality.          4. Acute deterioration of decompensated cirrhosis [4]: Acute decompensation of cirrhosis             in the form of one or more major complications of liver disease, including ascites,             hepatic encephalopathy, gastrointestinal bleeding.|December 2015|December 21, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465619||19564|
NCT02465840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D0931|Hand Injury Patients Receiving Different Rehabilitation Programs|The Functional Outcome and Brain Functional MRI of Hand Injury Patients After Different Rehabilitation Programs||Chang Gung Memorial Hospital|No|Not yet recruiting|June 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|70 Years|No|||February 2016|February 1, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02465840||19547|
NCT02252419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoreThroatParacetamol|Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat|Combined Effect of Preoperative Dexamethasone and Intraoperative Paracetamol on Postoperative Sore Throat for Patients Undergoing Urologic Surgery||Seoul National University Hospital|Yes|Not yet recruiting|October 2014|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|242|||Both|19 Years|80 Years|No|||September 2014|October 16, 2014|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02252419||35921|
NCT02257931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8414106|Gram-negative Bacteremia in HSCT Recipients|Resistance Pattern of Gram-negative Bacteria Isolated From Blood From HSCT Recipients.|GNB|European Group for Blood and Marrow Transplantation|No|Recruiting|February 2014|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|365|||Both|N/A|N/A|No|Non-Probability Sample|eligible patients from EBMT centres|October 2014|October 17, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257931|6 Months|35501|
NCT02257944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSUHSC-8692|Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence|Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence: A Randomized Clinical Trial|VOV-RCT|Conrad, Erich J., M.D.|No|Not yet recruiting|October 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2014|October 6, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02257944||35500|
NCT02311569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 33/14|Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation|Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|Yes|Active, not recruiting|April 2015|March 2019|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311569||31381|
NCT02324166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CefazolinPain|Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain|Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery||University Health Network, Toronto|No|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|54|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02324166||30414|
NCT02246036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00989-38|Tolerance and Safety of a Duodenal Probe Monitoring the Microcirculation|Clinical Trial to Assess the Tolerance and the Safety of a Duodenal Tube Monitoring the Microcirculation in 10 Critically Ill Patients.|MC Monitor|Advanced Perfusion Diagnostics|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02246036||36412|
NCT02252484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001274|Energy Balance for Prostate Cancer Survivorship|Energy Balance for Prostate Cancer Survivorship||University of Kansas Medical Center|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Male|50 Years|72 Years|No|||September 2015|September 21, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02252484||35916|
NCT02311127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57358|SecurAcath Versus Statlock for PICC Securement|Comparing SecurAcath Versus StatLock to Secure Peripherally Inserted Central Catheters: a Randomised, Open Trial|SecurAstaP|Universitaire Ziekenhuizen Leuven|No|Completed|April 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|105|||Both|18 Years|N/A|No|||August 2015|December 23, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311127||31415|
NCT02312804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS 14-2006|Ph Ib/BGJ398/Cervix and Other Solid Tumors|A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|January 2015|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|October 1, 2014|Yes|Yes|Drug not available.|No||https://clinicaltrials.gov/show/NCT02312804||31286|
NCT02312817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102013-027|RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System|RCT of Strategies to Improve Screening Rates Among a Cohort of Cirrhotic Patients at High Risk for Developing HCC in a Safety-net Health System||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|3||Actual|1800|||Both|21 Years|N/A|No|||March 2016|March 11, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02312817||31285|
NCT02242318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.376|Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring|A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring||Boehringer Ingelheim||Completed|September 2001|||September 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|440|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242318||36698|
NCT02242331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.386|Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure|Risk of Morning Hypertension||Boehringer Ingelheim||Completed|June 2001|||May 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19805|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of essential hypertension recruited at general practitioners and        specialists in internal medicine in non-hospital practice|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242331||36697|
NCT02251470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRM_01|Home-based Balance Training Using Wii Fit After Stroke: A Feasibility Study|The Application of a Video-game System (Nintendo Wii®) as an Independent Exercise Program to Improve Mobility After Stroke - a Randomized Phase II Trial|WiiMobil|Martin-Luther-Universität Halle-Wittenberg|No|Completed|October 2014|August 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Both|60 Years|N/A|No|||December 2015|December 1, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251470||35994|
NCT02320682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fingerprint III|Bone Metabolism Adjacent to Hip Prosthetic Surfaces. A Clinical F-PET/CT Study|Bone Metabolism Adjacent to Hip Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study.|Fp-III|Uppsala University|Yes|Recruiting|December 2014|December 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|50 Years|69 Years|No|||December 2014|December 18, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02320682||30682|
NCT02320695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140617115421-THCT|Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury|Evaluation of Perception of Sting Sensation Following Application of Antibiotic Ointment and Cream Formulations After Tape Stripping Injury||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 16, 2014||No||No|September 8, 2015|https://clinicaltrials.gov/show/NCT02320695||30681|
NCT02317510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HASEKI-156|Combined Spinal Epidural Anesthesia and General Anesthesia for Laparoscopic Cholecystectomy|Combined Spinal Epidural Anesthesia and General Anesthesia for Laparoscopic Cholecystectomy: a Prospective, Randomized Study||Lütfiye Nuri Burat Government Hospital|No|Completed|December 2014|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|90 Years|No|||February 2016|February 17, 2016|December 11, 2014||No||No|May 17, 2015|https://clinicaltrials.gov/show/NCT02317510||30925|one patients had dural injury. Because of this that patient had released.
NCT02251080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00026657|Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population|Attention Deficit/Hyperactivity Disorder (ADHD) Internet Survey Study in a College Student Population||Wake Forest Baptist Health|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Approximately 44 male and female subjects ages 18 and over with ADHD and who are filling        the medication at the Wake Forest University Student Health Center pharmacy will be        eligible for recruitment. Subjects will be recruited from the Wake Forest University        Student Health Center at their clinic visit.|December 2015|December 17, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251080||36024|
NCT02247193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0335|Improvement of the Appearance of Cleft Lip Scars Using Botox|Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair||The University of Texas Health Science Center, Houston|No|Recruiting|December 2014|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|6 Months|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02247193||36323|
NCT02323269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS415|Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)|A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)|IMPROVE|Biogen|No|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in male and female patients with relapsing-remitting MS who        satisfy the therapeutic indication for DMF per the Canadian Product Monograph, and who are        either treatment-naïve or responding suboptimally to MS platform therapies (e.g., IFN or        GA), as determined by the Prescribing Physician.|October 2015|October 1, 2015|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323269||30483|
NCT02324777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS001|Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee|A Randomized Double Blind Placebo Controlled, Proof-of-concept, Crossover Clinical Trial of Vapourized Cannabis in Adults With Painful Osteoarthritis of the Knee|CAPRI|Prairie Plant Systems Inc.|Yes|Recruiting|June 2015|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|40|||Both|50 Years|N/A|No|||January 2016|January 15, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02324777||30367|
NCT02324790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-1401-CIP|Pilot Study of Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea|A Multicenter Pilot Study on the Indications of Negative Pressure Sleep Therapy System for the Treatment of Obstructive Sleep Apnea (OSA)||Somnics, Inc.|No|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|80 Years|No|||December 2014|December 18, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02324790||30366|
NCT02251288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0087|A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine|A Phase I Randomized Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|July 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|100|||Both|18 Years|47 Years|Accepts Healthy Volunteers|||September 2014|August 27, 2015|September 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02251288||36008|
NCT02251418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-ESWTULCER|Shockwave Therapy of Chronic Diabetic Foot Ulcers|Extracorporeal Shockwave Therapy (ESWT) of Chronic Diabetic Foot Ulcers||Odense University Hospital|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251418||35998|
NCT02247453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT11-21|Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study|Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study|BIOMILD|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|4000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02247453||36303|
NCT02312999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-fluides|Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery|Phase IV, Multicentric, Prospective, Controlled, Randomized, Double Blind Study Comparing a Crystalloid to a Colloid Used in the Perioperatory Hemodynamic Optimisation With a 'Closed Loop' Automatic Filling System, on the Post-surgery Morbidity in Major Abdominal Surgery.||Brugmann University Hospital|No|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312999||31271|
NCT02314416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611757|Stem Cells In Wound Healing With Collagen Matrix as a Carrier|Stem Cells In Wound Healing With Collagen Matrix as a Carrier||Georgia Regents University|Yes|Withdrawn|May 2015|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314416||31163|
NCT02314429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 2013/088|Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis|Phase I Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis|LACRING01|University Hospital, Ghent|No|Completed|September 2014|September 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02314429||31162|
NCT02247960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB#50607|Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy|Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy|Abx|University of Rochester|Yes|Active, not recruiting|July 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|August 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247960||36264|
NCT02464111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|723323-1|Short Term Response of Breast Milk Micronutrient Concentrations to a Lipid Based Nutrient Supplement in Guatemalan Women|Short Term Response of Breast Milk Micronutrient Concentrations to a Lipid Based Nutrient Supplement in Guatemalan Women||USDA, Western Human Nutrition Research Center|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02464111||19680|
NCT02424292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-Move|Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients|Evaluating the Outcome of a Personalised Oncological Rehabilitation Program in Overweight and Obese Breast Cancer Patients on Adjuvant Anti-hormonal Treatment "I-Move"|I-Move|University Medical Center Groningen|No|Recruiting|April 2015|August 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|141|||Female|18 Years|75 Years|No|Probability Sample|Female breast cancer patients treated with hormonal therapy in adjuvant setting and a BMI≥        25 kg/m2|October 2015|October 1, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02424292||22736|
NCT02462941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO8054|Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart|Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart||Columbia University|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|6 Months|25 Years|No|||February 2016|February 26, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462941||19769|
NCT02477462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703097-3|Interrogating Potential Therapeutic Targets for Primary Biliary Cirrhosis (PBC)|Interrogating Potential Therapeutic Targets for Primary Biliary Cirrhosis (PBC)||University of California, Davis|No|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Biospecimens will include serum, plasma, DNA, and RNA. In 20 subjects liver biopsies will be      performed and retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Confirmed PBC diagnosis|January 2016|January 5, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02477462|2 Years|18653|
NCT02464514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5028|Macronutrient Regulation of Ghrelin and Peptide YY|Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children With Prader-Willi Syndrome (PWS) and Children With Hypothalamic-Derived Obesity: Macronutrient Regulation Sub-study||Duke University|Yes|Completed|January 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|5 Years|17 Years|No|||June 2015|August 6, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464514||19649|
NCT02416492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI-01|A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)|A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)|STEMTRA|SanBio, Inc.|Yes|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416492||23335|
NCT02415582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130484|Post-Exercise Hypotension in Elderly Hypertensive Men|Effects of Different Exercises on Post-Exercise Blood Pressure in Elderly Hypertensive: A Cross-Over Randomized Clinical Trial|HPE|Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Male|60 Years|70 Years|Accepts Healthy Volunteers|||September 2014|April 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415582||23405|
NCT02415595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-038|Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults|A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults||Bristol-Myers Squibb|No|Active, not recruiting|May 2015|October 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|March 11, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415595||23404|
NCT02462382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.121.08|Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks|Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks Versus Placebo for Pain Control After Arthroscopic Rotator Cuff Repair||Orlando Health, Inc.|No|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02462382||19812|
NCT02421172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCJM112X2202|Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients|A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients||Novartis|No|Active, not recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|N/A|No|||March 2016|March 24, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421172||22976|
NCT02471716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPA008-002|Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor|A Phase 1/2 Study of FPA008, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)||Five Prime Therapeutics, Inc.|Yes|Recruiting|June 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471716||19095|
NCT02423408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-IS-T201|Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache|A Proof-of-Concept Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-201 for the Treatment of A Single Tension-Type Headache||Tonix Pharmaceuticals, Inc.|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|65 Years|No|||November 2015|February 26, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423408||22804|
NCT02423421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC053|Faecal Microbiota Transplantation in Irritable Bowel Syndrome|Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome||University College Cork|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||April 2015|April 17, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02423421||22803|
NCT02419599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC125|High vs Standard Energy Children's Drink Study|The Effect of Standard Versus High Energy Density, Low Volume Oral Nutritional Supplements in Children Requiring Nutritional Support - a Pilot Trial||Nutricia UK Ltd|No|Not yet recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|1 Year|12 Years|No|||April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419599||23097|
NCT02463253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|665869|Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients|Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients||University of California, Davis|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Laboratory evaluations: The UC Davis laboratory will be used for clinical chemistry, and      hematology, as well as other outside laboratories that the participants may go to        1. Hematology: Routine hematological parameters will be analyzed as indicated by standard           clinical care        2. Clinical chemistry: Routine clinical chemistry parameters will be analyzed including           basic and comprehensive metabolic profiles as indicated by standard clinical care           Immunologic Profiles: As per standard routine monitoring with both indicated and           surveillance biopsies, donor specific antibodies will be monitored|Both|18 Years|82 Years|Accepts Healthy Volunteers|Probability Sample|post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant        center. Ten subjects will be enrolled who are receiving surveillance "protocol biopsies"        and 10 subjects who will be receiving "for cause" biopsies in the setting of an elevated        serum creatinine or proteinuria. Samples of blood, and formalin-fixed, paraffin-embedded        biopsy tissue will be sent to Transplant Genomics INC. (TGI) for study purposes. In        addition, clinical data will be collected on each subject.. Blood and tissue will be        analyzed by TGI using Affymetrix microarrays, and reports will be sent to UC Davis        retrospectively. Samples may be batch-shipped and results will not be reported in real        time. These results will be compared to both the histological diagnosis, and to the        clinical course.|June 2015|June 1, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02463253|12 Months|19746|
NCT02462005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ranger SFA Registry|Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.|Ranger DEB All Comers Registry - Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter: An All Comers Registry.||Klinikum Arnsberg|No|Recruiting|February 2015|February 2018|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from an all-comers patient population with infrainguinal atherosclerotic disease        who are implanted or scheduled for an implant with a Ranger Drug coated balloon and who        fulfill the in/exclusion criteria at approved investigational centres are eligible for        participation in the Ranger DEB-Comers Registry.|June 2015|June 23, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462005|24 Months|19841|
NCT02421744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio multicentrico TOCT SM|A Task-oriented Circuit Training in Multiple Sclerosis|A Task-oriented Circuit Training in Multiple Sclerosis: a Multicentric Randomized Controlled Trial||University Hospital of Ferrara|Yes|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02421744||22932|
NCT02412774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-107|Effects of Replacing Diet Beverages With Water on Weight Loss and Plasma Glucose Control in Type 2 Diabetes|Effects of Replacing Diet Beverages With Water on Type 2 Diabetic Obese Females Attending a Weight Loss Program - a Randomized, 24 Week Clinical Trial||Novindiet Clinic|No|Enrolling by invitation|March 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|No|||April 2015|April 6, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412774||23621|
NCT02415166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBR # 2015-001-00|Influenza Challenge in Mood Disorders|Influenza Challenge in Mood Disorders||Laureate Institute for Brain Research, Inc.|No|Completed|July 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|15|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415166||23437|
NCT02467920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10352|Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM|Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial||Huazhong University of Science and Technology|Yes|Not yet recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|70 Years|No|||June 2015|June 5, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467920||19387|
NCT02471469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF UMCN 14.17|Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response|Personalizing Enzalutamide Therapy by Understanding the Relation Between the Decrease in the Expression Profile of a Panel of Preselected microRNAs, Tumor Related mRNAs and Treatment Response in Chemotherapy Naive Patients With mCRPC|ILUMINATE|Radboud University|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|18 Years|N/A|No|Non-Probability Sample|chemotherapy naive patients with metastatic CRPC|September 2015|September 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02471469||19114|
NCT02463344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT MA09-hRPE AMD -001 LTFU|Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD|Long Term Follow up to A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-RPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (AMD)||Ocata Therapeutics|Yes|Enrolling by invitation|July 2012|December 2030|Anticipated|December 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|13|||Both|55 Years|N/A|No|Non-Probability Sample|The study population is by invitation only for previous participants in the core protocol|June 2015|June 2, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463344||19739|
NCT02416726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201501|Use NGS to Detect Different Gene Mutations in Matched Samples in aNSCLC of Non-SQCC Histology|Use the Next Generation Sequence (NGS) to Compare the Different Gene Mutations Among the Primary Tumor , Metastatic LN and Peripheral Blood in Advanced Non-small Cell Lung Cancer of Non-squamous Cell Carcinoma Histology(aNSCLC-nSQCC)||Shanghai Chest Hospital|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|50|||Both|15 Years|80 Years|No|||December 2015|December 16, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02416726||23317|
NCT02426788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR130202|PRINCE Secondary Trial|The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care||King's College London|Yes|Recruiting|July 2015|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426788||22544|
NCT02464020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504M69083|A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis|A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|July 2015|July 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|8|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464020||19687|
NCT02472990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCHE-DMD|Biomechanical and Morphological Changes in Dystrophic Muscle|Determining Biomechanical and Morphological Factors That Affect Children With Duchenne Muscular Dystrophy (DMD) Who Loss of the Ability to Walk|MARCHE-DMD|University Hospital, Brest|Yes|Recruiting|July 2015|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|50|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472990||18997|
NCT02419859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQR14002|A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|A Prospective, Single Center Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus||CeQur Corporation|No|Completed|February 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02419859||23077|
NCT02421354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0962|Study of Nivolumab in Patients With Myelofibrosis|Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421354||22962|
NCT02421367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-13|Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults|A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US||U.S. Army Medical Research and Materiel Command|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|140|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||September 2015|December 1, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421367||22961|
NCT02471053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXACT2015|Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study|Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study (EXACT)|EXACT|Nova Scotia Health Authority|No|Not yet recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||June 2015|July 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471053||19146|
NCT02468791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MabionCD20-001RA|MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis||Mabion SA||Recruiting|May 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|863|||Both|18 Years|80 Years|No|||November 2015|November 6, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02468791||19320|
NCT02468596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN_2014-20|Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy|Axonal Excitability Measured by QTRAC Technique in Patients With Anti-MAG Neuropathy||Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|December 2014|||November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|No|||December 2015|December 11, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468596||19335|
NCT02468609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 15/007|Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT||RADFL|Cantonal Hospital of St. Gallen|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|90 Years|No|||January 2016|January 26, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02468609||19334|
NCT02411721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0530-14-RMB CTIL|The Effects of Dog Intervention on Anxiety Levels in Children Undergoing an MRI Examination|The Effects of Dog Intervention on Anxiety Levels in Children Undergoing an MRI Examination ; Open Label, Randomized Controlled Trail|yes|Rambam Health Care Campus|No|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|7 Years|15 Years|No|||April 2015|April 2, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02411721||23702|
NCT02411734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 00018268|Effect of Executive Dysfunction on Rehabilitation Potential|Effect of Executive Dysfunction on Rehabilitation Potential|Executive|University of South Florida|No|Terminated|April 2015|March 2016|Actual|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|60 Years|90 Years|No|Probability Sample|Patients admitted for rehabilitation after a hospitalization|March 2016|March 8, 2016|December 11, 2014||No|Administrative problems with study director|No||https://clinicaltrials.gov/show/NCT02411734|30 Days|23701|
NCT02412332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pacientes|Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients|Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients||UPECLIN HC FM Botucatu Unesp|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|40 Years|70 Years|No|||November 2015|November 3, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02412332||23655|
NCT02467868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-1401H-3001|Efficacy and Safety Study With MYL-1401H and Neulasta|Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy||Mylan Inc.|No|Completed|March 2015|February 2016|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467868||19391|
NCT02464488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cfx-adage-2015|New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study|Study of Interindividual Variability in the Response to New Oral Direct Anticoagulants (Dabigatran Etexilate, Rivaroxaban or Apixaban) in Patients 80 Years Old and Over, Using a Population Pharmacokinetics Approach.|ADAGE|Hôpital Charles Foix|No|Recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|225|Samples With DNA|Blood|Both|80 Years|N/A|No|Non-Probability Sample|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban        because atrial fibrillation|February 2016|February 18, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464488||19651|
NCT02474238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-58-093-02-1|Comparing Nd:YAG Laser and Sequential Double Frequency YAG-Nd:YAG Laser Iridotomy|Randomized Clinical Trial Comparing Neodynium:Ytrium-aluminium-garnet (Nd:YAG) Laser and Sequential Double Frequency YAG-Nd:YAG Laser Iridotomy in Patients With Dark Iris||Prince of Songkla University|Yes|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474238||18901|
NCT02474251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG049348-01A1|Brain Sleep Clearance of Amyloid-Beta Peptides|Brain Sleep Clearance of Amyloid-Beta Peptides|Brain SCRAPs|New York University School of Medicine|No|Recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|55|Samples With DNA|Cerebrospinal Fluid Blood|Both|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group A: 25 normal elderly (age 55-75) newly enrolled or currently participating in        R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at        examining the longitudinal associations between SDB and cognitive decline in the elderly.        Group B: 20 Cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index        [AHI]-all >30/hour) and good CPAP compliance|December 2015|December 17, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474251||18900|
NCT02411461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR7195|Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism|Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism||Vanderbilt University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with pseudohypoparathyroidism type 1a (PHP1a), their healthy siblings and matched        obese controls|April 2015|April 7, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02411461||23722|
NCT02411474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0008|Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD|||Yonsei University|No|Completed|March 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|21|Samples Without DNA|TEAR|Both|20 Years|60 Years|No|Non-Probability Sample|Male or non-pregnant female patients aged 20-60 years who visited the clinic 3-12 months        after SCT were included in the study.|April 2015|April 2, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02411474||23721|
NCT02468154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79/14|Efficacy of Leg Casts With Heel Off-loaded in Children|Efficacy of Leg Casts With Heel Off-loaded in Children: Open Randomized Controlled Trial||Istituto Ortopedico Rizzoli|No|Completed|November 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|57|||Both|3 Years|17 Years|No|||September 2015|November 18, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02468154||19369|
NCT02468167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRTO-NBCA-AB|Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO|Comparison of Endoscopic Cyanoacrylate Injection Versus Balloon-occluded Retrograde Transvenous Obliteration in the Management of Acute Gastric Variceal Bleeding||West China Hospital|No|Recruiting|June 2015|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468167||19368|
NCT02470208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US OI 125|Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation|A Prospective Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Events - Assessed by a CMV-Specific T-SPOT Assay: The REACT Study|REACT|Oxford Immunotec|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood|Both|18 Years|75 Years|No|Non-Probability Sample|Patients enrolled in this study will be men or women aged 18 years or older with positive        CMV serostatus (R+) who are candidates for allogeneic HSCT.        The patients enrolled are intended to be representative of those who would be anticipated        to have T SPOT.CMV testing when it is used in routine clinical practice. Enrollment will        be actively managed by the sponsor.|February 2016|February 26, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02470208||19211|
NCT02462252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-8040.06|Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome|A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)||BioLineRx, Ltd.|Yes|Recruiting|October 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462252||19822|
NCT02466672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001325|The Role and Effect of Anemia in Children With Pneumonia|The Role and Effect of Anemia in Children With Pneumonia||Massachusetts General Hospital|No|Recruiting|February 2015|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|6 Months|59 Months|No|Non-Probability Sample|Children age 6 months to 59 months admitted to the hospital with WHO-defined severe        pneumonia|June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466672||19483|
NCT02411747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-122|Power of Testing in Directed Self-regulated Flexible Cystoscopy Simulation Training|Power of Testing in Directed Self-regulated Flexible Cystoscopy Simulation Training - a Randomized Patient Transfer Trial||Rigshospitalet, Denmark|No|Completed|February 2015|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02411747||23700|
NCT02473523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOGAOT|Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia|Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital||St. Jude Children's Research Hospital|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|13 Years|17 Years|No|||December 2015|December 28, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02473523||18956|
NCT02473536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 022015-058|Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC|Safety Lead-in Phase II Trial of Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC||University of Texas Southwestern Medical Center|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|September 12, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473536||18955|
NCT02461485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU373|Effect of a Fermented Milk Product With Probiotics Alone or in Combination With Fibers on Constipation Symptoms|Evaluation of Effects of Fermented Dairy Products Containing Probiotics Alone or in Association With Fibers on Bowel Functions, Constipation Symptoms and Health Related Quality of Life in Adult Subjects With Moderate Constipation: an Exploratory Randomized Double-blind, Controlled Adaptive Study||Danone Research|Yes|Recruiting|May 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|152|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02461485||19881|
NCT02465268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400697|Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme|A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma|ATTAC-II|University of Florida|Yes|Not yet recruiting|March 2016|March 2024|Anticipated|March 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465268||19591|
NCT02465671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jhh2015024|Prognostic Value of Plasma Thrombospondin-1 Levels After Acute Intracerebral Hemorrhage|Prognostic Value of Plasma Thrombospondin-1 Levels After Acute Intracerebral Hemorrhage：A Pilot Study||Jinhua People's Hospital|Yes|Completed|August 2010|February 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|Samples Without DNA|All blood samples from the patients at admission were collected in the separator tubes and      centrifuged within 30 minutes at 1,000*g for 15 minutes. The plasma was removed and frozen      at -70°C until measurement.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua        People's Hospital within the first 24 h from stroke were enrolled.|June 2015|June 4, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465671||19560|
NCT02424084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-266-4|Bone Microcirculation After Extracorporeal Shock Wave Therapy|Effects of Extracorporeal Shock Wave Therapy in Bone Microcirculation||University of Schleswig-Holstein|No|Recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02424084||22752|
NCT02465177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3159|Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical ICU Survivors|||University of Colorado, Denver|No|Recruiting|July 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|||Male|18 Years|100 Years|No|Non-Probability Sample|Patients admitted to one of 3 medical intensive care units in the Denver metropolitan area|January 2016|January 13, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02465177||19598|
NCT02468726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER1008-01/2011 (ENE)|Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing|A Clinical Investigation to Demonstrate the Performance of NER1008 Enema in Bowel Cleansing Compared to Fleet® Enema||Norgine|No|Completed|November 2011|December 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02468726||19325|
NCT02470754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15992|Clinical Pharmacology of Electronic Cigarettes|Clinical Pharmacology of Electronic Cigarettes R01DA039264||University of California, San Francisco|Yes|Recruiting|July 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02470754||19169|
NCT02471222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-AMT-MS201|Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment|Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment||Adamas Pharmaceuticals, Inc.|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471222||19133|
NCT02241681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.22.MET|Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake|Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake||Nestlé|No|Completed|October 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||November 2014|March 25, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02241681||36747|
NCT02245230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140958|Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension|Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension||Vanderbilt University|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|34|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245230||36474|
NCT02251184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.146|Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH|Comparison of Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH by the Prior Administration of a Proton-pump Inhibitor: An Open-label 2-way Randomized Cross-over Study in Healthy Male and Female Subjects Age 40-65.||Boehringer Ingelheim||Completed|October 2000|||November 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251184||36016|
NCT02315820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POR-0085-14|Induction of Labor Versus Expectant Management of Large for Gestational Age/Macrosomic Babies at Term. A Multi-center Trial|Induction of Labor Versus Expectant Management of Large for Gestational Age/Macrosomic Babies at Term. A Multi-center Randomized Trial|IOLEMMT|The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|January 2015|July 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|474|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02315820||31055|
NCT02312778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVBA x COP|Immediate Effects of a Spinal Lumbar Manipulation|Immediate Effects of a Spinal Lumbar Manipulation on the Threshold Pressure Pain and the Postural Control in Subjects With Non-specific Low Back Pain||Federal University of Rio Grande do Sul|No|Completed|January 2015|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|60 Years|No|||May 2015|May 21, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02312778||31288|
NCT02312791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 683/2014|Prognosis of Inpatients Evaluated for Palliative Radiotherapy|Observational Study of Prognosis of Inpatients Evaluated for Palliative Radiotherapy|PROGRAD|University of Sao Paulo|No|Recruiting|December 2014|February 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|730|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients evaluated for palliative Radiation Therapy|December 2014|December 8, 2014|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02312791||31287|
NCT02257970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7781|Placebo-controlled Lymphedema Study for Arm or Leg Lymphedema|Case-controlled, Open Label Therapeutic Trial for Unilateral or Bilateral Lymphedema of Arm or Leg.|PB|Stanford University|No|Recruiting|March 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||December 2015|December 16, 2015|August 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02257970||35498|
NCT02258009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DDE25|Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Visual Impairment Due to Diabetic Macular Edema|TIDE DME|Novartis|No|Suspended|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258009||35495|
NCT02315833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-MIGPREV-1|The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients|The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients. Randomized Intervention Trial With a Medical Device (Acetium®Capsules)||Biohit Oyj|No|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02315833||31054|
NCT02317094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120166|Blood-flow Restricted Exercise in Inclusion Body Myositis|Low-intensity Blood-flow Restricted Muscle Exercise in Patients With Sporadic Inclusion Body Myositis: a Randomised Controlled Trial||University of Southern Denmark|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|35 Years|N/A|No|||October 2015|October 19, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317094||30957|
NCT02247349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA001-030|BMS-986012 in Relapsed/Refractory SCLC|A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer||Bristol-Myers Squibb|No|Recruiting|October 2014|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|136|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247349||36311|
NCT02247362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX2012Q-02|Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years|Phase 1b/2 Double Blind, Randomized, Placebo Controlled Study of Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years||VaxInnate Corporation|Yes|Active, not recruiting|November 2014|March 2016|Anticipated|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|200|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||March 2015|April 16, 2015|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02247362||36310|
NCT02258360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROID7005|Hypothermia and Hemostasis After Cardiac Arrest|The Effect of Therapeutic Hypothermia After Cardiac Arrest on the Haemostasis.||University of Aarhus||Recruiting|February 2013|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2014|November 28, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02258360||35468|
NCT02258373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DX-REPLACE-BG|A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes|A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes|REPLACE-BG|T1D Exchange Clinic Network Coordinating Center|Yes|Active, not recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|225|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02258373||35467|
NCT02326181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJH21400964|Effects of Inspiratory and Expiratory Pressure Training Methods in Patients With Chronic Obstructive Pulmonary Disease|Effects of Inspiratory and Respiratory Pressure Threshold Training in Patients With Chronic Obstructive Pulmonary Disease||Zhujiang Hospital|Yes|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|80 Years|No|||December 2014|December 24, 2014|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02326181||30259|
NCT02326194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT020|A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.|A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|December 2014|July 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|120|||Both|18 Years|60 Years|No|||August 2015|August 27, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326194||30258|
NCT02324712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0919|Cytokine and Growth Factor Changes and Correlation With Clinical Outcomes Following Acupuncture for TMD|Cytokine and Growth Factor Changes and Correlation With Clinical Outcomes Following Acupuncture for TMD||University of North Carolina, Chapel Hill|No|Withdrawn||||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|64 Years|No|||February 2016|February 22, 2016|December 19, 2014|Yes|Yes|PI relocated to another institution; study may be resubmitted at a later date.|No||https://clinicaltrials.gov/show/NCT02324712||30372|
NCT02253368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0528|Home Sleep and Metabolism|Home Sleep and Metabolism||University of Chicago|Yes|Recruiting|November 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|210|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253368||35848|
NCT02251652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0142|Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses|An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|April 2013|August 2015|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251652||35980|
NCT02312739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMHSC13-594|Nitrous Oxide for Pain Management During In-office Transcervical Sterilization|Nitrous Oxide for Pain Management During In-office Transcervical Sterilization|NEST|University of New Mexico|Yes|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 15, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02312739||31291|
NCT02325869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0013.CTIL|Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS)|DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to Assess the Safety and Performance of the ECA Bell Balloon in Subjects Undergoing Coronary Percutaneous Interventions.|DESIRE-ACS|Angioslide Ltd.|Yes|Recruiting|July 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 26, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02325869||30283|
NCT02256865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30068-01|Hormonal Mechanisms of Sleep Restriction|Hormonal Mechanisms of Sleep Restriction||Los Angeles Biomedical Research Institute|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|40|||Male|22 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02256865||35580|
NCT02251808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-001|Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease|Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease||Beijing Pins Medical Co., Ltd|Yes|Recruiting|September 2014|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|612|||Both|18 Years|80 Years|No|Non-Probability Sample|Of 612 patients implanted with the rechargeable IPGs and non-rechargeable (including 306        PD received rechargeable IPGs, 306 PD received non-rechargeable IPGs) were followed before        and 3 months after DBS surgery and completed a systematic survey of satisfaction with PINS        Stimulator System.|May 2015|October 12, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251808||35968|
NCT02316548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-GU001|Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer|Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer||NRG Oncology|Yes|Recruiting|February 2015|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|185|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316548||30999|
NCT02318355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-19E|Proving Hemodilution in a Human Model for Class I Hemorrhage|Resuscitative Effect of Two Liters of Crystalloid on Hemodilution and Base Deficit in Healthy Volunteer Blood Donors With Class I Hemorrhage.||Carolinas Healthcare System||Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02318355||30860|
NCT02318368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-299-14-206|A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label|A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label|FOCAL|AVEO Pharmaceuticals, Inc.|No|Recruiting|November 2014|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318368||30859|
NCT02251431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-149|Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome|A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS Trial)||Baylor Research Institute|Yes|Recruiting|September 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251431||35997|
NCT02256917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-21B|Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A|Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A||Octapharma|No|Recruiting|March 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|55|||Male|18 Years|N/A|No|||October 2015|October 23, 2015|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02256917||35576|
NCT02468635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ca141078|Rehabilitation of Patients With Lung Chronic Obstructive Pulmonary Disease|Analysis of Pulmonary Rehabilitation on the Physical Capacity and Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease Clinical Trial|PR|Federal University of Bahia|No|Recruiting|June 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|2|||Both|40 Years|85 Years|No|||June 2015|June 10, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02468635||19332|
NCT02415374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1314|Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical|Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical||PepsiCo Global R&D|No|Active, not recruiting|February 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|16|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02415374||23421|
NCT02466555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-15-30|Music Therapy in Sickle Cell Transition Study|The Effects of Music Therapy on Transition Outcomes in Young Adult Patients With Sickle Cell Disease||University Hospital Case Medical Center|No|Active, not recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|23 Years|No|||December 2015|December 7, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02466555||19492|
NCT02468830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14-06-1998|Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder|Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder|Mirabegron|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Active, not recruiting|April 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|5 Years|17 Years|No|||January 2016|January 27, 2016|May 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468830||19317|
NCT02468843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500366|Novel Stimulation Patterns for the Treatment of Dystonia|Novel Stimulation Patterns and Personalized Deep Brain Stimulation for the Treatment of Dystonia||University of Florida|No|Active, not recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468843||19316|
NCT02421328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS 874|Study of the Effects of CPAP and HHHFNC on Diaphragmatic Dimensions in Preterm Infants|Comparative Study of the Effects of Continuous Positive Airway Pressure and Heated, Humidified High Flow Nasal Cannula on Diaphragmatic Dimensions in Preterm Infants||Mansoura University Children Hospital|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|1 Month|No|||February 2016|February 13, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02421328||22964|
NCT02419092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRMOI-5-OSA|Effects of CPAP and Massive Weight Loss on Inflammation Induced by Obstructive Sleep Apnea|Investigation of Inflammation Induced by Obstructive Sleep Apnea: Effects of Continuous Positive Airway Pressure (CPAP), Massive Weight Loss and the Bioactive Compound Resveratrol||University of Aarhus|Yes|Recruiting|April 2015|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|25 Years|65 Years|No|||January 2016|January 25, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02419092||23136|
NCT02419105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T&D Study|Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors|Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors. Double Blind, 2x2 Factorial, Randomized Placebo-‐Controlled Clinical Trial|T&D|University of Zurich|No|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|168|||Male|75 Years|N/A|No|||September 2015|September 14, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02419105||23135|
NCT02467114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|036/15|Interactions Between Attentional Networks and Their Influence on Perception|Interactions Between Attentional Networks and Their Influence on Perception: a Project in Healthy Subjects and Hemispatial Neglect Patients|AtNet|University Hospital Inselspital, Berne|No|Recruiting|June 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|214|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02467114||19449|
NCT02462434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00072957|Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology|Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology Requiring Neonatal Surgery||University of Michigan|No|Active, not recruiting|April 2013|April 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02462434||19808|
NCT02462447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00091201|Carbon-11 Labeled Sarcosine in Prostate Cancer|Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers||University of Michigan|Yes|Recruiting|June 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|25|Samples Without DNA|Group 1 (prostate cancer patients):      Tissue biopsies from prostate cancer lesions are performed as part of routine clinical care.      These tissues will however be used for research purposes.      Group 2 (healthy men):      No biopsies are performed in volunteers.|Male|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: Subjects with confirmed or suspected prostate cancer who will undergo a planned        tissue biopsy of the known or suspected tumor        Group 2: Healthy volunteers.|December 2015|December 2, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462447||19807|
NCT02462460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-120|Rapid MR Pancreas Screening With Motion Corrected T1 and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI|Pilot Study of Rapid MR Pancreas Screening With Motion Corrected T1 and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|25 Years|N/A|No|Non-Probability Sample|MSKCC clinics|October 2015|October 29, 2015|June 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02462460||19806|
NCT02426905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNV-TRI-002|Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine|Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine||Univar BV|No|Recruiting|January 2016|May 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|1 Year|90 Years|No|||February 2016|February 23, 2016|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02426905||22535|
NCT02415387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13194|Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer Who Received Chemotherapy|The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment|IMPACT|Ohio State University Comprehensive Cancer Center|Yes|Recruiting|January 2014|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|180|||Female|45 Years|65 Years|No|||October 2015|October 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415387||23420|
NCT02415621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17981|Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer|A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||March 2016|March 24, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415621||23402|
NCT02473692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0974|Facilitating Migraine Medication Adherence and Optimizing Medication Use|Examining Feasibility and Effectiveness of an Internet-based Intervention for Facilitating Migraine Medication Adherence and Optimizing Medication Use||Wake Forest School of Medicine|No|Not yet recruiting|September 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|This study will enroll N = 300 participants. The proposed study is primarily powered to        estimate the rate at which headache patients will likely seek out the Web site within a        desired precision range (i.e., Hypothesis 1A). This sample size will allow the        characterization of the various event rates within a precise range. For example, this        sample size would allow a precision of +/- 5% around most event rates (i.e., use rates,        attrition rates, etc.). Finally, even with a large attrition rate (i.e., 50%) the proposed        sample size will allow the detection of even small changes (e.g., d = 0.20) in the        adherence measures (assuming adequate reliability, and a modest correlation between        measurement occasions).|March 2016|March 9, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02473692||18943|
NCT02473705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WakeForest|Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease|Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease|CKD&CAD|Wake Forest School of Medicine|Yes|Recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|40|||Both|60 Years|90 Years|No|||January 2016|January 13, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473705||18942|
NCT02463266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819712|Evaluation of the PACE/PACENET BHL Clinical Program|Evaluation of the PACE/PACENET BHL Clinical Program|SUSTAINIV|University of Pennsylvania|No|Enrolling by invitation|March 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|65 Years|N/A|No|||June 2015|June 2, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463266||19745|
NCT02475512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0277|Comparison of Wash Wipes and Standard Care in the Prevention of Incontinence-associated Dermatitis in Elderly|A Total Body Wash Wipe Combined With a Genital Wipe Versus Standard Care (Water and pH Neutral Soap) for Washing of Incontinent Residents in a Long- Term Care Setting: a Multicenter Prospective Randomised Controlled Clinical Trial and Health Economical Analysis in Nursing Homes||University Ghent|No|Terminated|May 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|385|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02475512||18803|
NCT02412527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-5603B|Verification of Computerized Sleep-wake Analysis in Sleep Disorders|||Chang Gung Memorial Hospital||Not yet recruiting|April 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|330|||Both|20 Years|50 Years|No|Non-Probability Sample|Patients ranged from age 20-50 with primary insomnia, periodic limb movement in sleep,        simple snores, and obstructive sleep apnea will be enrolled.|April 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02412527||23640|
NCT02425449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTIRB 200538|Fade Upon TOF Stimulation Induced by Succinylcholine|Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine||University of Toledo Health Science Campus|No|Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02425449||22647|
NCT02467660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11847|Meditation or Health & Wellness Education Via Internet for Adults 50-80 Years Old|Meditation or Health & Wellness Education Via Internet for Adults 50-80 Years Old||Oregon Health and Science University|No|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|200|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02467660||19407|
NCT02466932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-171|Effects of Birth Weight on Anterior Eye Segment Measurements in Full-Term Children by Galilei Dual-Scheimpflug Analyzer|Effects of Birth Weight on Anterior Eye Segment Measurements in Full-Term Children by Galilei Dual-Scheimpflug Analyzer||Neon Hospital|No|Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|78|||Both|30 Months|80 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children aged between 3-6- preschoolers- born at term and have birth weight        heavier than 2500g|June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466932|1 Day|19463|
NCT02412787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP609-302|Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094|An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment||Shire|Yes|Enrolling by invitation|April 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Male|N/A|18 Years|No|||November 2015|November 19, 2015|April 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412787||23620|
NCT02416505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-334|The Age of OrthoInfo: A Randomized Controlled Trial Evaluating Patient Comprehension of Informed Consent|||University of Missouri, Kansas City||Completed|September 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02416505||23334|
NCT02419898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0492|Oxfordshire Women and Their Children's Health|Oxfordshire Women and Their Children's Health- A Feasibility Study|OxWATCH|Oxford University Hospitals NHS Trust|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|SST Serum, Citrate Platelet Free Plasma, EDTA Plasma, whole blood for DNA extraction, urine      and saliva will be stored at -80°C for future studies.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be nulliparous women of reproductive age (18-40 years), who are not        pregnant but could have a planned or unplanned pregnancy during the duration of the study.        Participants must be willing to have research investigations before, during and after        pregnancy.|April 2015|April 24, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02419898||23074|
NCT02471482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study No. 6 - 2013|Effect of Mozart Music on Cerebral Oxygenation and Behavioural Response of Premature Infants|Effect of Mozart Music on Cerebral Oxygenation and Behavioural Response of Premature Infants Between 28-32 Weeks of Corrected Gestation||Coombe Women and Infants University Hospital|Yes|Completed|December 2013|July 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|35 Days|No|||February 2016|February 22, 2016|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02471482||19113|
NCT02474017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR001-1010|An Open Study to Assess the Robustness of the CRC749 Inhaler|An Open Study to Assess the Robustness of the CRC749 Device by Pharmaceutical Performance Following Twice Daily Dosing of MGR001 Administered Via Oral Inhalation in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD)||Mylan Inc.|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|12 Years|N/A|No|||September 2015|September 25, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02474017||18918|
NCT02467998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR003|Negative Pressure Wound Therapy Registry|The Registry of Negative Pressure Wound Therapy for Chronic Wounds and Ulcers|NPWTR|U.S. Wound Registry|Yes|Recruiting|January 2005|||January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50000|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing treatment with NPWT|June 2015|June 5, 2015|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02467998|3 Months|19381|
NCT02421757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062233|Treatment of Back Pain Using Transcutaneous Magnetic Stimulation (TCMS)|Treatment of Back Pain Using Transcutaneous Magnetic Stimulation (TCMS)||University of Maryland|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421757||22931|
NCT02411799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0433|Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz SystemTMd|Prospective Multi-Center Follow-up of Patients Undergoing Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz SystemTM||Ohio State University|Yes|Recruiting|April 2015|April 2023|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are candidates for hybrid thoracolumbar fixation with the Implanet Jazz        System during arthrodesis surgery.|October 2015|October 9, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411799|60 Months|23696|
NCT02468518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSMMU-007-CT|Effect of Vitamin E on Skin Aerobic Bacteria in Palmar Arsenical Keratosis|Randomized, Open Label Trial of Vitamin E on Change of Aerobic Bacterial Pattern||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Completed|March 2015|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02468518||19341|
NCT02478008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-3102-01|A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)|A Clinical Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transapical Delivery System)||CardiAQ Valve Technologies, Inc.|Yes|Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|65 Years|N/A|No|||September 2015|September 9, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02478008||18611|
NCT02478021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI-CO-1|Effects of Hydrocortisone on Social Cognition and Memory|Effekte Von Hydrocortison Auf Soziale Kognition Und Gedächtnis Unter Berücksichtigung Von Geschlechtereffekten|CORT-COG|Charite University, Berlin, Germany|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478021||18610|
NCT02478034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI-CO-2|Effects of Mineralocorticoid Receptor Stimulation on Cognition|Effekte Von Fludrocortison Auf Soziale Kognition Und Gedächtnis Unter Berücksichtigung Von Geschlechtereffekten|MR-STIM|Charite University, Berlin, Germany|No|Completed|May 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478034||18609|
NCT02423850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH3D02|Volumetric Measurements of Diabetic Foot Ulcers|Volumetric Measurements for Monitoring Ulcer Healing of Diabetic Foot Ulcers and Venous Leg Ulcers||Odense University Hospital|Yes|Not yet recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Newly admitted patients with diabetic foot ulcer or venous leg ulcer to University Centre        for Wound Healing, Odense University Hospital.|April 2015|April 19, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02423850||22770|
NCT02423863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC2014-001|In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®|In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study|Poly-ICLC|Oncovir, Inc.|Yes|Recruiting|March 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423863||22769|
NCT02473341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA-2015|Comparison of Combination Therapy of Corticosteroids and Bovine Colostrum Versus Corticosteroids and Placebo: Randomized Double Blind Placebo Controlled Trial in Treatment of Severe Alcoholic Hepatitis|Comparison of Combination Therapy of Corticosteroids and Bovine Colostrum Versus Corticosteroids and Placebo: Randomized Double Blind Placebo Controlled Trial in Treatment of Severe Alcoholic Hepatitis|COBRA|Dayanand Medical College and Hospital|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|426|||Both|18 Years|70 Years|No|||January 2016|January 23, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473341||18970|
NCT02473354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060429|Predictors of Opioid-Induced Respiratory Depression (OIRD)|Predictors of Opioid-Induced Respiratory Depression (OIRD)|(OIRD)|Duke University|No|Recruiting|April 2015|||April 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473354||18969|
NCT02472652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.AOM.2013-007|Aripiprazole, Abilify Maintena Collaborative Clinical Protocol|An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta|KISS|Gazda, Thomas D., M.D., PC|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|40 Years|No|||June 2015|June 15, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472652||19023|
NCT02472665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1005|Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease|Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Patients With Von Willebrand Disease||Grifols Biologicals Inc.|No|Recruiting|December 2013|February 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|2 Months|8 Years|No|||September 2015|September 10, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472665||19022|
NCT02473783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INEI-1A20090409|The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD|An I-123-ADAM SPECT Imaging Study to Evaluate the Serotonin Transporter (SERT) Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Assisting in Detecting MDD|STAPMDDTDM|Tri-Service General Hospital|No|Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|55|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02473783||18936|
NCT02416037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14-0333|Trans-pulmonary Pressure in ARDS|Trans-Pulmonary Pressure and Prone Position in Ards Patients|T3P|Hospices Civils de Lyon|No|Recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02416037||23370|
NCT02416258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0113-1123|A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)|A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis Vulgaris|LP0113-1123|LEO Pharma|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416258||23353|
NCT02471118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 11-0024|Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)|Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA): A Randomized Placebo-controlled Trial|OKINADA|Canadian Research & Education in Arthritis|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|40 Years|N/A|No|||January 2016|January 20, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02471118||19141|
NCT02471131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.53510.068.15|WATCHMAN Implantation During Hybrid Ablation|WATCHMAN LAAC Device Implantation During Hybrid Atrial Fibrillation Ablation|WINNING|Maastricht University Medical Center|No|Recruiting|October 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471131||19140|
NCT02469064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1755|Effects of Respiratory Muscle Training in Mechanically Ventilated Adults|Effects of Respiratory Muscle Training in Mechanically Ventilated Adults|RMTMVA|Fundacion Clinica Valle del Lili|Yes|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02469064||19299|
NCT02465060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00054|NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas|Molecular Analysis for Therapy Choice (MATCH)||National Cancer Institute (NCI)|Yes|Suspended|August 2015|||June 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|17||Anticipated|3000|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 3, 2015|Yes|Yes|Other - To conduct a study-specified planned analysis|No||https://clinicaltrials.gov/show/NCT02465060||19607|
NCT02416297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fattori-001|Three- Dimensional Evaluation of Accelerated Tooth Movement|Three- Dimensional Evaluation of Accelerated Tooth Movement||University of Sao Paulo|No|Active, not recruiting|April 2015|July 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02416297||23350|
NCT02471443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15DEV0009|Laparoscopic Surgery for Severe Recto-vaginal Endometriosis|Laparoscopic Surgery for Severe Recto-vaginal Endometriosis: A Prospective Cohort Study||Royal Surrey County Hospital|Yes|Recruiting|May 2004|January 2040|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients who underwent surgery for endometriosis with bowel involvement.|June 2015|June 10, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02471443||19116|
NCT02471586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10034|ILUMIEN III: OPTIMIZE PCI|ILUMIEN III: OPTIMIZE PCI OPtical Coherence Tomography (OCT) Compared to Intravascular Ultrasound (IVUS) and Angiography to Guide Coronary Stent Implantation: a Multicenter RandomIZEd Trial in Percutaneous Coronary Intervention (PCI)||St. Jude Medical|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|420|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471586||19105|
NCT02473744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14010 DSOPAL|Oedematous Lower Limb Subcutaneous Drainage in Palliative Care|Oedematous Lower Limb Subcutaneous Drainage in Palliative Care|DSOPAL|University Hospital, Limoges|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|31|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473744||18939|
NCT02466685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18038683BCD2001|Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients|Testing the Ability of JNJ-18038683, a Selective Serotonin (5-HT)7 Antagonist, to Improve Cognition and Reduce Residual Depressive Symptoms in Stable Bipolar Patients (18038683BCD2001)||Northwestern University|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||January 2016|January 7, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466685||19482|
NCT02466971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00835|Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer|A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer||National Cancer Institute (NCI)|Yes|Recruiting|January 2016|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Female|18 Years|N/A|No|||January 2016|March 24, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466971||19460|
NCT02416531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lichen-768168|Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser|Vulvar Lichen Sclerosus: Therapeutic Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser|VLSCBCPPTLIL|University of Nove de Julho|No|Active, not recruiting|January 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02416531||23332|
NCT02464423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD074977|Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model|Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model||Hektoen Institute for Medical Research|Yes|Recruiting|January 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|14 Years|21 Years|No|||June 2015|June 22, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02464423||19656|
NCT02470442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1504-116-668|Desflurane in Children With Laryngeal Mask Airway|Sevoflurane Vs. Sevoflurane-desflurane Anesthesia in Children With Laryngeal Mask Airways; Difference in Respiratory Event, Recovery Time and Emergence Agitation||Seoul National University Hospital|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|2 Years|7 Years|No|||September 2015|September 15, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02470442||19193|
NCT02470455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/SCB/Pharma/2011/05|Effect of Atorvastatin on Glycemic Control in Prediabetic Patients|Effect of Atorvastatin on Glycemic Control in Prediabetic Patients||Shri Ramachandra Bhanj Medical College|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|75|||Both|18 Years|65 Years|No|Probability Sample|The study population was selected from patients attending Cardiology and Medicine        Outpatient Department of S.C.B. Medical College, Cuttack, following inclusion and        exclusion criteria.|August 2015|August 14, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02470455||19192|
NCT02470533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51318.078.14|Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma|Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial|TRENDY|Erasmus Medical Center|No|Recruiting|April 2015|April 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02470533||19186|
NCT02412020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA101-CC-02|Treatment of Refractory Chronic Cough With PA101|Treatment of Chronic Idiopathic Cough and Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis With PA101||Patara Pharma|No|Completed|February 2015|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412020||23679|
NCT02412033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUD- CS|Misoprostol Prior to Intrauterine Contraceptive Device Insertion|Vaginal Misoprostol Prior to Intrauterine Contraceptive Device Insertion in Women With Previous Caesarean Section||Assiut University||Not yet recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|45 Years|No|||April 2015|April 7, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02412033||23678|
NCT02469025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/0030|Effects of Grade III Traction-mobilization in End-range Joint Position in Patients With Hip Osteoarthritis|||Universidad de Zaragoza||Recruiting|January 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|90 Years|No|||December 2015|December 8, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02469025||19302|
NCT02474069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457ADE04|Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis|A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of 16 Weeks Secukinumab Dosage Interval Shortening in Comparison to Continued Standard Treatment (4-weekly 300 mg s.c.) in Patients With Moderate-severe Plaque Type Psoriasis Who Achieved Less Than Almost Clear Skin After 16 Weeks Under the Standard Dose of Secukinumab|GAIN|Novartis|No|Not yet recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|940|||Both|N/A|N/A|No|||January 2016|January 6, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02474069||18914|
NCT02478086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2012-1002-63|Effects of High vs. Standard Protein Intake in Newborn Extreme Premature|Effects of High vs. Standard Protein Intake in the Weight Gain and Renal Function Security in Newborn Extreme Premature|experimental|Coordinación de Investigación en Salud, Mexico|Yes|Completed|August 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|52|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||June 2015|June 18, 2015|May 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478086||18605|
NCT02246803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-Progress|The Assessment of Progression of Paroxysmal AF After CABG|The Assessment of Progression of Paroxysmal Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting Through Continuous Subcutaneous Monitoring||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02246803||36353|
NCT02246816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-101-CL-002OLE|A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001|A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001||Marathon Pharmaceuticals, LLC||Withdrawn|February 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|February 16, 2015|September 19, 2014|Yes|Yes|Transfer of IND to different marketing authorization representative.|No||https://clinicaltrials.gov/show/NCT02246816||36352|
NCT02251197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599.3|Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke|A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Safety and Tolerability in 108 Patients (18 Per Dose Group) With Acute Ischemic Stroke After Intravenous Administration From 6 to 72 Hours of BIII 890, as Loading Dose Followed by Maintenance Dose, in Escalating Dose Panels From 87.5 mg up to 1495 mg (Total Dose)||Boehringer Ingelheim||Completed|July 2001|||October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251197||36015|
NCT02251210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.27|Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis|Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis||Boehringer Ingelheim||Completed|May 2001|||November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|404|||Both|18 Years|70 Years|No|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251210||36014|
NCT02316340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS 14-2015|Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer|Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|February 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316340||31015|
NCT02249611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 102-2314-B-006 -004 -MY2|Application of MT in Subjects With Overweight/Metabolic Abnormality---RCT|Application of Mobile Physical Activity Promotion Tool in Subjects With Overweight/Metabolic Abnormality---randomised Control Trial of Efficacy||National Cheng-Kung University Hospital|Yes|Completed|July 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|20 Years|60 Years|No|||October 2015|October 7, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02249611||36137|
NCT02249858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-988|Palpatory and Ultrasound Assessment of Cervical Dysfunctions and the Effect of Cervical High Velocity Low Amplitude (HVLA) Technique|Palpatory and Ultrasound Assessment of Cervical Dysfunctions and the Effect of Cervical High Velocity Low Amplitude (HVLA) Technique||New York Institute of Technology|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be 1st and 2nd year NYIT-COM medical students. 52 students will be        recruited.|January 2016|January 19, 2016|February 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02249858||36118|
NCT02245555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.73|Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia|Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia||Boehringer Ingelheim||Completed|April 2006|||December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1060|||Male|21 Years|N/A|No|Non-Probability Sample|Patients with benign prostatic hyperplasia (BPH), who require pharmacological treatment|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245555||36449|
NCT02245568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-237-020|Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)|An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)||TauRx Therapeutics Ltd|Yes|Enrolling by invitation|August 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1400|||Both|N/A|N/A|No|||September 2014|September 17, 2014|August 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245568||36448|
NCT02246101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1847|World Trade Center (WTC) RENAL|Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment||Icahn School of Medicine at Mount Sinai|Yes|Enrolling by invitation|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|550|||Both|40 Years|N/A|No|Non-Probability Sample|World Trade Center rescue and recovery workers and volunteers who are enrolled in the        World Trade Center Health Program-Clinical Center of Excellence, formerly known as the        Medical Monitoring Treatment Program and were subsequently enrolled in the WTC-CHEST        program.|October 2015|October 1, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02246101||36407|
NCT02320877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201422483|Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea|Evaluation of the Overall Effectiveness Including Cardiovascular Effects of the Custom-made, Titratable Duoblock Flex SomnoDent® MAS in the Treatment of Obstructive Sleep Apnea||University Hospital, Antwerp|No|Not yet recruiting|December 2014|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02320877||30667|
NCT02320890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC14OISI0045|Study of tDCS for Mild Cognitive Impairment|A Study for the Short- and Long-term Improvement of Cognitive Function (Evaluated by PET-CT and SNSB) After Transcranial Direct Current Stimulation in Mild Cognitive Impairment||Incheon St.Mary's Hospital|No|Recruiting|December 2014|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|65 Years|90 Years|No|||December 2014|December 16, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320890||30666|
NCT02324595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10279/14|Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study|Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study|MISSION|Catholic University of the Sacred Heart|Yes|Active, not recruiting|December 2013|February 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|90 Years|No|||August 2015|August 14, 2015|June 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02324595||30381|
NCT02324660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131295|Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes|Prospective Evaluation of a Screening Methodology for Chronic Obstructive Pulmonary Disease in Patients Admitted to Hospital for Acute Coronary Syndromes.|SCAP|University Hospital of Ferrara|Yes|Active, not recruiting|December 2014|August 2016|Anticipated|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|137|||Both|40 Years|90 Years|No|||March 2016|March 2, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02324660||30376|
NCT02250976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-PIF-103|The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca|A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers||Hanlim Pharm. Co., Ltd.|No|Recruiting|September 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|40|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250976||36032|
NCT02242656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-101-CL-001|A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals|A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals||Marathon Pharmaceuticals, LLC|No|Withdrawn|December 2014|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2014|February 16, 2015|September 10, 2014|Yes|Yes|Transfer of IND to new marketing authorization holder|No||https://clinicaltrials.gov/show/NCT02242656||36672|
NCT02316041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177/2013|Clinical Trial of the Femtosecond Laser System VisuMax for Refractive Correction of Hyperopia by Means of Lenticule Extraction|Clinical Trial of the Femtosecond Laser System VisuMax for Refractive Correction of Hyperopia by Means of Lenticule Extraction||Tilganga Institute of Ophthalmology|No|Recruiting|January 2014|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316041||31038|
NCT02325843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014MEKY059|the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn|The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn: Prospective,Double-blind, Randomized, Controlled Trial||Sun Yat-sen University|No|Not yet recruiting|July 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2014|December 20, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02325843||30285|
NCT02242591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002245-21|Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain After Total Knee Arthroplasty|Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain on the First Post-operative Day After Total Knee Arthroplasty||University Hospital, Gentofte, Copenhagen|Yes|Completed|August 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|85 Years|No|||November 2014|November 26, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02242591||36677|
NCT02255721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|416530030101|Sleep Health in Preschoolers: a Randomized Controlled Trial|Healthy Sleep Intervention For Preschool Children: A Randomized Controlled Trial of the SHIP Intervention|SHIP|Seattle Children's Hospital|No|Recruiting|November 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|30 Months|71 Months|No|||June 2015|June 12, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255721||35667|
NCT02255734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-REH3002-01|Bioequivalence of Two Formulations of Acyclovir|Bioequivalence of Two Formulations of Acyclovir||Yung Shin Pharm. Ind. Co., Ltd.|No|Completed|April 2014|||April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02255734||35666|
NCT02255747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anal Dilatation|Anal Dilatation for Infants and Children With Constipation|Anal Dilatation for Infants and Children With Constipation||Tongji Hospital||Recruiting|September 2014|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|14 Years|No|||September 2014|September 30, 2014|September 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255747||35665|
NCT02316314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408015429|Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)|Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)||Weill Medical College of Cornell University|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples With DNA|Blood Amount: Up to 88 mL of blood will be collected for the entire study and up to 57 mL of      blood will be collected for a single visit. (CBC = 5 mL per visit; Clotting = 6 mL per      visit; Chemistry = 7 mL per visit; Liver function = 5 mL per visit; Cardiac enzymes = 5 mL      per visit; Future serum = 3 mL per visit; Genetic analysis = 4 mL; HbA1c = 5mL; HIV test = 7      mL; and Anti-AAVrh.10 = 10 mL)      Urine Amount: Approximately 24 mL of urine will be collected for the entire study and      approximately 12 mL of urine will be collected for a single visit.|Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be composed of individuals with FRDA and individuals without. Individuals        without FRDA will be age, gender and ethnicity matched to the individuals with FRDA.|December 2015|December 22, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02316314||31017|
NCT02314169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02420|Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal|A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal||National Cancer Institute (NCI)|No|Active, not recruiting|May 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||December 2015|March 22, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314169||31182|
NCT02244437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202/2013|Ibuprofen vs Acetaminophen for AMS Prevention|Ibuprofen vs Acetaminophen in the Prevention of Acute Mountain Sickness: A Double Blind, Randomized Controlled Trial||Mountain Medicine Society of Nepal|Yes|Completed|October 2014|December 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|288|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02244437||36535|
NCT02255799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33646 MEMRI-TBI-D Study|Multicenter Evaluation of Memory Remediation After TBI With Donepezil|Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period|MEMRI-TBI-D|Baylor College of Medicine|Yes|Recruiting|September 2014|September 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||March 2016|March 2, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02255799||35661|
NCT02255812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 289/12/2|Taste Physiology in Healthy, Normal-weight Volunteers|Taste Physiology in Healthy, Normal-weight Volunteers||University Hospital, Basel, Switzerland|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02255812||35660|
NCT02325271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF Bio|Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers|Intra-individual Variability and Circadian Rhythm of Systemic Vascular Endothelial Growth Factor (VEGF) Levels and Interaction With Biomarkers of Inflammation in Subjects With Normal Glucose Tolerance (NGT) and Patients With Type 2 Diabetes Without Diabetic Macular Edema (DME)||GWT-TUD GmbH|No|Completed|February 2015|January 2016|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Community sample of healthy volunteers, type 2 diabetes patients of the study center|January 2016|January 21, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325271||30329|
NCT02326090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL12002 / 14-110-0005|Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye|A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye||Herantis Pharma Plc.|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326090||30266|
NCT02326103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELSINKIU|Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis|Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis in Addition to Prednisolon Therapy||Helsinki University|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|64 Years|No|||August 2015|August 17, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326103||30265|
NCT02244723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPLUS|Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia|Prospective, Observational Study of Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia|VPLUS|Groupe Hospitalier Paris Saint Joseph|No|Recruiting|June 2013|September 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|98|Samples Without DNA|-  Biochemical data (WBC count with differential, arterial blood gas)        -  Microbiological data (UTA and BAL) - UTA data must have been collected within 24 hours           of enrollment and BAL data within 12 hours of enrollment (unprotected tracheal aspirate           (UTA)- fibrobronchoscopy with protected distal sampling)|Both|18 Years|N/A|No|Non-Probability Sample|subjects will be recruited from mechanically-ventilated patients with suspected VAP in        ICUs|September 2014|September 17, 2014|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02244723||36513|
NCT02477332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031C2201|Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU|A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)||Novartis|No|Recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|360|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477332||18663|
NCT02418845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM-1219-301|A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis|A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis||Symbiomix Therapeutics|No|Active, not recruiting|May 2015|December 2015|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|12 Years|N/A|No|||November 2015|November 16, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418845||23154|
NCT02470962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD-Herz|Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy|Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy||University Children's Hospital, Zurich|No|Recruiting|May 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Male|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Boys aged 8 to 18 years with DMD/BMD confirmed genetically or by muscle biopsy          -  Control group for CMR: children without heart disease|January 2016|January 19, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470962||19153|
NCT02471014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401069|Effect of Obesity on Immune Response to Pneumovax 23|The Effect of Obesity on Immune Responses to Pneumococcal Polysaccharide Vaccine, ROVE Study|ROVE|University of Florida|No|Not yet recruiting|June 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|56|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471014||19149|
NCT02472951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46559|Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study|Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study|CutDM|Bispebjerg Hospital|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02472951||19000|
NCT02472964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-Her3001|Study of Efficacy and Safety of Hercules(Myl1401O Mylan Trastuzumab) + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.|A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study To Compare The Efficacy And Safety Of Hercules Versus Herceptin® In Patients With HER2+ Metastatic Breast Cancer|HERiTAge|Mylan Inc.|Yes|Active, not recruiting|July 2012|December 2018|Anticipated|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02472964||18999|
NCT02423369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-43|Cerebral Oxymetry and Neuronal Markers in Newborns and Infants Undergoing Surgery|Cerebral Oxymetry and Neuronal Biomarkers in Newborns and Infants During Perioperative Period|NEMARKO|Lithuanian University of Health Sciences|No|Completed|March 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|49|||Both|N/A|93 Days|No|||December 2015|December 12, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423369||22807|
NCT02425202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:163|Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy|Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial|KOSATA|University of Manitoba|Yes|Recruiting|December 2014|November 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||November 2015|December 1, 2015|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02425202||22666|
NCT02425215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7413-BE|HBOT Late Radiation Tissue Injury|Does Hyperbaric Oxygen Therapy (HBOT) Reduce Pain, Improve Depression and Impact on Patients' Quality of Life for Those Suffering From Late Radiation Tissue Injury?||University Health Network, Toronto|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing hyperbaric oxygen therapy for delayed radiation tissue injury in        the Hyperbaric Unit.|July 2015|July 29, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425215||22665|
NCT02471287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150128|Genetics of Inherited Eye Disease|The Genetics of Inherited Eye Disease||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Both|N/A|N/A|No|||January 2016|February 4, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471287||19128|
NCT02466945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP30032015003|Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults|Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults||Pierre Fabre Dermo Cosmetique|No|Not yet recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02466945||19462|
NCT02467205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14RH210|Walk for Rheumatoid Arthritis (WARA Study)|Effectiveness of Community Based Physical Activity on Step Count and Sedentary Behaviour in Patients With Rheumatoid Arthritis Within the First Five Years of Diagnosis||University of Glasgow|Yes|Recruiting|November 2014|November 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|June 8, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467205||19442|
NCT02414841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-320|A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)|Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease||Proteon Therapeutics|Yes|Recruiting|June 2015|June 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|100 Years|No|||February 2016|February 4, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414841||23462|
NCT02470897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14083|Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer|A Phase I/II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning||University of Wisconsin, Madison|Yes|Recruiting|July 2015|December 2024|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Male|N/A|N/A|No|||February 2016|February 18, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470897||19158|
NCT02463279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-006|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||January 20, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463279||19744|
NCT02467673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evidence/Unifesp|Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy|Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy: Effects on Blood Pressure, Insulin and C-reactive Protein and in Postmenopausal Women|Nanoparticle|University Potiguar|No|Recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|185|||Female|42 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02467673||19406|
NCT02462733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000029127|Efficacy of Tools of the Mind for Enhancing Self-Control in Preschoolers|Investigation of the Efficacy of Tools of the Mind for Enhancing Self-Control in Canadian Preschoolers||The Hospital for Sick Children|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02462733||19785|
NCT02462746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-2014|The Effect of Cysteine, Tryptophan and Tyrosine Supplements on Breast Milk|The Effect of Cysteine, Tryptophan and Tyrosine Supplements on Breast Milk||Centre for Addiction and Mental Health|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462746||19784|
NCT02416245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202379|Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive Variables in Indian School Children|Impact of a Beverage Powder Fortified With Multiple Micronutrients (MMN) and Bacopa Monnieri Extract (EBM) on Cognitive Variables in Indian School Children (7-12yrs; Inclusive) After 4 Months of Intervention: a Double Blind, Randomized Controlled Trial||GlaxoSmithKline|Yes|Completed|July 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|310|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||June 2015|July 2, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416245||23354|
NCT02414893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/08|Hunger/Satiety's Physiopathologic Study in Morbidly Obese Patients|Hunger/Satiety's Physiopathologic Study in Morbidly Obese Patients: Relation Between Hunger/Satiety, Gastric Emptying, Gallbladder Motility and Peripheral Neurohormonal Signs||Consorci Sanitari del Maresme|No|Completed|September 2009|July 2012|Actual|July 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group A: non obese healthy individuals Group B: morbidly obese individuals Group C:        individuals who had had a previous sleeve gastrectomy as a bariatric procedures|April 2015|April 10, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02414893|1 Day|23458|
NCT02471872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREATHE|Behavioral Research of Environment and Air Pollution Through Education||BREATHE|University of California, San Francisco|No|Recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|13 Years|15 Years|No|||May 2015|June 10, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471872||19083|
NCT02471885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0276|Effect of Remote Ischaemic Conditioning in Oncology Patients|A Single Centre Double-blinded Randomized Placebo Controlled Pilot Study Investigating the Effect of Remote Ischaemic preConditioning in ONCology Patients Undergoing Chemotherapy (ERIC-ONC)|ERIC-ONC|University College, London|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|80 Years|No|||November 2015|December 18, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471885||19082|
NCT02421536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14191|Vibrent Smartphone Mobile Application|A Feasibility Study of the VibrentTM Smartphone App for Head & Neck Cancer Patients: Supporting Pain Management of Radiation-Induced Mucositis||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|March 2016|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|100 Years|No|||March 2016|March 23, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421536||22948|
NCT02421549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60054491|Remote Interrogation in Rural Emergency Departments|Remote Interrogation of Implantable Cardiac Devices in Rural Emergency Departments|REM RED|St. Jude Medical|No|Withdrawn|December 2014|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02421549||22947|
NCT02474030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 13-12-003-3|Relationship Between Electrical Pain Tolerance Threshold of Alveolar Ridge and Individual Attributes|||Nihon University||Recruiting|February 2013|||October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|25 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Volunteers participants studying or workung at the Nihon University School of Dentistry at        Matsudo took part in the study.|October 2015|October 8, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474030||18917|
NCT02463760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTR2014-11-02|Predicting Rupture of Abdominal Aortic Aneurysm (AAA) by Anatomic and Hemodynamic Markers From In-vivo and In-vitro Imaging.|||University of Minnesota - Clinical and Translational Science Institute||Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|14|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary and specialty care clinics and emergency room visits.|July 2015|July 23, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463760||19707|
NCT02472730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36849|Cap Assisted Colonoscopy Enhances Quality Based Competency in Colonoscopy Among Trainees|Cap Assisted Colonoscopy Enhances Quality Based Competency in Colonoscopy Among Trainees||Baylor College of Medicine|No|Active, not recruiting|July 2015|November 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|260|||Both|18 Years|90 Years|No|||October 2015|October 23, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02472730||19017|
NCT02472743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/196DERM|Light Treatment for Scleroderma Finger Ulcers|Light-based Therapy as a Novel Treatment for Digital Ulcers in Patients With Systemic Sclerosis|DULight|University of Manchester|No|Recruiting|December 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02472743||19016|
NCT02411149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7016-A|Adductor Canal Block and Recovery After Total Knee Replacement Surgery|Adductor Canal Block and Functional Recovery After Total Knee Arthroplasty. A Double-Blind, Randomized Controlled Trial|ACB in TKA|University Health Network, Toronto|No|Recruiting|April 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02411149||23746|
NCT02467062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4D AORTIC FLOW MRI|Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.|Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.||Universitair Ziekenhuis Brussel|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467062||19453|
NCT02472431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-CCH-01-01-15|Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction|Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction||Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati|No|Enrolling by invitation|April 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|20 Years|75 Years|No|||September 2015|September 30, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472431||19040|
NCT02472444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP|Gustatory Evoked-related Potentials in Humans|Etude du contrôle hédonique de la Prise Alimentaire Par l'Analyse Des Potentiels évoqués Gustatifs||Centre des Sciences du Goût et de l'Alimentation|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|healthy young volunteers|June 2015|June 11, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02472444||19039|
NCT02477241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52605.068.15|Brain Areas Involved in Bladder Filling and Contraction|Study of Brain Areas Involved in the Sensation of Bladder Filling in Healthy Females and Untreated Females With Overactive Bladder (OAB) Using fMRI and Water Pressure Urodynamics||Maastricht University Medical Center|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02477241||18670|
NCT02464553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74/EK/15|EuroPainClinics® Study I (Prospective Trial)|EuroPainClinics® Study I (Prospective Randomized Double Blinded Trial)|EPCSI|Europainclinics z.ú.|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464553||19646|
NCT02410915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1807-31/2|A Comparison Between the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training Early After Stroke|Gait Training Early After Stroke - a Comparison Between Training With the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training|HAL-RCT|Danderyd Hospital|No|Recruiting|February 2014|January 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|67 Years|No|||April 2015|April 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02410915||23764|
NCT02463461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406015180|Comparison Between Multiple Wrist-worn Actigraphy Devices and Polysomnography|Comparison Between Multiple Wrist-worn Actigraphy Devices and Polysomnography||Weill Medical College of Cornell University|No|Suspended|August 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|2000|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|January 13, 2015||No|Not sure if we are going to do this study now.|No||https://clinicaltrials.gov/show/NCT02463461||19730|
NCT02477319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSPECT|A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)|A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)|PROSPECT|University of Alabama at Birmingham|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Part A N = 260 (210 CF, 50 non-CF controls)          -  Cohort 1: 50 non-CF control subjects ≥ 12 years of age, with at least 15 subjects 12             - 21 yrs of age          -  Cohort 2: 50 Partial CFTR Function CF subjects with at least one class IV/V CFTR             mutation, ≥ 12 years of age          -  Cohort 3 160 Absent CFTR Function CF subjects with two class I/II mutations ≥ 12             years of age        Part B        Up to 250 CF subjects who are homozygous for F508del mutation and who are prescribed        ivacaftor/lumicafor for clinical care will be allowed to enroll. This will include :          -  Cohort 3 subjects homozygous for F508del mutation from Part A who are prescribed             ivacaftor/lumicaftor will be invited to participate in Part B (up to 100 potential             subjects).          -  Up to 150 additional CF subjects homozygous for F508del mutation ≥ 12 years of age             who did not participate in Part A but are otherwise eligible for participation in             Part B.|November 2015|November 30, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02477319||18664|
NCT02478047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543202-01|Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting|||Tianjin University of Traditional Chinese Medicine|Yes|Not yet recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|80 Years|No|||May 2015|June 22, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02478047||18608|
NCT02421380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-205|Characterization of Hyperpolarized Pyruvate MRI Reproducibility|Characterization of Hyperpolarized Pyruvate MRI Reproducibility||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|21 Years|90 Years|No|||January 2016|January 21, 2016|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02421380||22960|
NCT02421393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFA-04|Study to Weigh the Effect of Exercise Training on BONE (SWEET-BONE) Quality and Strength in Type 2 Diabetes|Study to Weigh the Effect of Exercise Training on BONE Quality and Strength (SWEET-BONE) in Type 2 Diabetes: an Exercise Intervention Program for Reducing the Risk of Fractures|SWEET-BONE|Metabolic Fitness Association, Italy|No|Not yet recruiting|May 2015|November 2023|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|75 Years|No|||April 2015|April 15, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421393||22959|
NCT02421562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPNO-DIS|Training Nurses in Basic Hypnoanalgesia Techniques|Training Nurses in Basic Hypnoanalgesia Techniques to Reduce Procedural Distress and Pain in Children: a Pilot Study|HYPNO-DIS|St. Justine's Hospital|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|5 Years|18 Years|No|||April 2015|April 15, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02421562||22946|
NCT02473432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSM/RHB/NR/15|Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke|Neuromuscular Electroestimulation and Respiratory Muscle Training in the Management of Dysphagia of Subacute Stroke Patients||Parc de Salut Mar|No|Completed|December 2013|September 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473432||18963|
NCT02472925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30AG034546|Way to Cure: Developing Effective Strategies to Promote Adherence to Hepatitis C Therapy Among Older Adults|Way to Cure: Developing Effective Strategies to Promote Adherence to Hepatitis C Therapy Among Older Adults||University of Pennsylvania|No|Not yet recruiting|June 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|50 Years|N/A|No|||March 2015|June 11, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02472925||19002|
NCT02470000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D0921|Treatment of Chronic Myofascial Pain Syndrome Over Neck by Using Intravascular Laser Irradiation of Blood|Treatment of Chronic Myofascial Pain Syndrome Over Neck by Using Intravascular Laser Irradiation of Blood||Chang Gung Memorial Hospital|No|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2014|June 11, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02470000||19227|
NCT02423668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHBaixoVouga3|Pseudophakic Anterior Chamber Depth Measurement in Second Eye Refinement Cataract Surgery|Pseudophakic Anterior Chamber Depth Measurement in Second Eye Refinement Cataract Surgery||Centro Hospitalar do Baixo Vouga|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|Patients recruited from the electronic database of a single ophthalmological center as        having performed bilateral cataract surgery between 1st June 2013 and 24th July 2014|April 2015|April 21, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02423668||22784|
NCT02473978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-15-RMC|Cerebral Near-infrared Spectroscopy (NIRS) Monitoring Throughout Caesarean Deliveries|Cerebral Near-infrared Spectroscopy (NIRS) Monitoring Throughout Caesarean Deliveries||Rabin Medical Center|No|Not yet recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All women undergoing cesarean section in Beilinson Hospital.|June 2015|June 16, 2015|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473978||18921|
NCT02462421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058350|Pharmacogenetics of SGLT2 Inhibitors|Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors|SGLT2iPGx|University of Maryland|No|Enrolling by invitation|June 2015|September 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|125|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462421||19809|
NCT02472119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|672/10 Rif. 1907 / 22.07.2010|Wheat Flour Treatment With Microbial Transglutaminase and Lysine Ethyl Ester: New Frontiers in Celiac Disease Treatment.|Wheat Flour Subjected to Microbial Transglutaminase Enzymatic Treatment in the Presence of Lysine Ethyl Ester for Alimentary Use in the Treatment of Celiac Disease.|WHETMIT|University of Roma La Sapienza|No|Recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||June 2015|June 10, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02472119||19064|
NCT02423720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15455|Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers|Being Present: Audio-Based Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers|Mindfulness|University of California, San Francisco|Yes|Not yet recruiting|May 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423720||22780|
NCT02468466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAKENHI #70404829|A Community-based Depression Screening Intervention for Middle-aged Suicide|Impact of a Community-based Screening and Educational Intervention for Depression on Suicide Rates Among Japanese Middle-aged Adults||Aomori University of Health and Welfare|Yes|Completed|January 2005|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|89700|||Both|36 Years|64 Years|No|||June 2015|June 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468466||19345|
NCT02468479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAWV-LC|Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients With Liver Cirrhosis|Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients||General Hospital of Shenyang Military Region|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Patients with a diagnosis of liver cirrhosis who are consecutively admitted to our        department.|February 2016|February 9, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02468479||19344|
NCT02473874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMPP-SBIR-2015-1791|Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy|Spectral Comparison Between Spatially Modulated Quantitative Spectroscopy and Polarization-Sensitive Hyperspectral Multimode Dermoscopy for the Purpose of Skin Compositional Analysis||University of California, Irvine|No|Recruiting|June 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from an outpatient population of subjects at Beckman Laser        Medical Clinic, University of California, Irvine.|February 2016|February 5, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02473874||18929|
NCT02474056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018-09-EMC|The Impact of the Fluid Resuscitation on the Venous Volume and Flow Characteristics in Hypovolemic Shock|||HaEmek Medical Center, Israel||Withdrawn|January 2010|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted at haemek medical center|June 2015|June 18, 2015|June 14, 2015|||The researcher couldnt handle it|No||https://clinicaltrials.gov/show/NCT02474056||18915|
NCT02477384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8mm-TIPS|8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding|Randomised Trial of 8mm Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Propranolol for Prevention of Variceal Rebleeding||West China Hospital|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02477384||18659|
NCT02416752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remi 2011/421/D SGH|Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery|Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery||Singapore General Hospital|No|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|222|||Both|21 Years|80 Years|No|Non-Probability Sample|We studied 222 adult subjects between 21 and 80 years, over two years at Singapore General        Hospital, Singapore. All subjects were ASA I to II and scheduled for elective head and        neck surgery with minimum expected duration of 2 hours, requiring general anesthesia.|April 2015|April 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416752||23315|
NCT02471768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref No IRC/2013/Protocol/162|The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease|The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease|CAPCAD|Government Medical College, Kozhikode|Yes|Completed|April 2014|June 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|623|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|ALL CONSECUTIVE SUBJECTS UNDERGOING CORONARY ANGIOGRAM FOR THE DIAGNOSIS OF CAD DURING A 6        MONTH PERIOD|June 2015|June 15, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02471768||19091|
NCT02471976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K071203|Impact of an Early Palliative Approach|Impact of a Computer-assisted Tool to Help Reflection on the Decision to Withhold or to Withdraw Treatments for Surgical Patients in Intensive Care Units|LATAREA-IV|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|December 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2750|||Both|18 Years|N/A|No|||November 2014|June 10, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02471976||19075|
NCT02463019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAHospital|Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B|An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase||E-DA Hospital|No|Enrolling by invitation|January 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|25 Years|75 Years|No|||June 2015|June 2, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02463019||19763|
NCT02463032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200802|Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer|A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women||GTx|Yes|Recruiting|August 2015|August 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463032||19762|
NCT02250781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051403|Oral ONC201 in Treating Patients With Advanced Solid Tumors|A First-in-Human Phase I Single-Agent Open-Label Dose-Escalation Study of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors||Rutgers, The State University of New Jersey|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|July 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250781||36047|
NCT02250846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHXH-027|Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC|Phase II Study of EGFR-TKI in Patients With EGFR Mutation Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis|EABM|Wuhan Union Hospital, China|No|Not yet recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||September 2014|September 25, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250846||36042|
NCT02319265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/035/14|Dose Assessment of Melatonin in Sepsis Trial|Dose Assessment of Melatonin in Sepsis Trial|DAMSEL2|University of Aberdeen|Yes|Withdrawn|December 2014|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||November 2015|November 4, 2015|December 3, 2014||No|Study registered elsewhere and is not covered by FDA|No||https://clinicaltrials.gov/show/NCT02319265||30790|
NCT02320305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1177|MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery|Peptide Vaccine With Glucopyranosyl Lipid A - Stable Oil-in-Water Emulsion (GLA-SE) for Patients With Resected Melanoma: A Pilot Study||Mayo Clinic|Yes|Recruiting|January 2015|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320305||30711|
NCT02321644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90001-CP-002|Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study|A Two-Part, Phase 1 Study to Evaluate Pharmacokinetics and Pharmacodynamics of Multiple Dose CC-90001 and to Evaluate the Effects of Food and Formulation on Pharmacokinetics of Single Dose CC-90001 in Healthy Subjects||Celgene|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321644||30608|
NCT02252627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10102013|The Effect of Phenylephrine and Ephedrine on Microvascular Blood Flow|An Observational Study to Test the Effect of the Vasoactive Drugs Phenylephrine and Ephedrine on the Stroke Volume and Microvascular Blood Flow of Healthy Volunteers||University of Nottingham|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|8|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteers|January 2015|January 26, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02252627||35905|
NCT02251327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 13-0029|Feasibility and Accuracy of a Novel Xpert Cartridge|Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Moledular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum|(XpertDST)|Johns Hopkins University|No|Enrolling by invitation|February 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with clinical signs and/or symptoms of pulmonary TB|September 2014|September 25, 2014|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02251327||36005|
NCT02323113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C34002|Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)|An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)||Millennium Pharmaceuticals, Inc.|No|Recruiting|April 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323113||30495|
NCT02323126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEGF816X2201C|Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer|A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer|EGF816|Novartis|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323126||30494|
NCT02246634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4156|Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)|Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.|SERENADE|Royal Marsden NHS Foundation Trust|Yes|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02246634||36366|
NCT02321072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/459|Optimal Oxygenation in the Intensive Care Unit|The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS|O2-ICU|VU University Medical Center|No|Recruiting|February 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|385|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02321072||30652|
NCT02313831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/2012|Optimization of Interval Exercise Based-intensity on Ventilatory Anaerobic Threshold in Coronary Artery Disease|Influence of Interval Aerobic Exercise Training on Cardiorespiratory and Metabolic Variables and Inflammatory Markers in Patients With Different Level of Coronary Artery Lesions||Universidade Federal de Sao Carlos|Yes|Recruiting|August 2013|December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|68|||Male|40 Years|65 Years|No|||December 2014|December 13, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313831||31207|
NCT02247388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211011052|Automated Bilingual Computerized Alcohol Screening and Intervention in Latinos (AB-CASI)|Automated Bilingual Computerized Alcohol Screen and Intervention in Latinos|AB-CASI|Yale University|Yes|Recruiting|October 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|820|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02247388||36308|
NCT02243306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200942|Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis|A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis||GlaxoSmithKline|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|May 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02243306||36622|
NCT02243319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TARO-101|Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904|||Hanmi Pharmaceutical Company Limited|No|Not yet recruiting|August 2014|November 2014|Anticipated|October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|24|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02243319||36621|
NCT02321618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035347|Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study|Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black Men||Cedars-Sinai Medical Center|Yes|Recruiting|February 2015|August 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Male|35 Years|79 Years|No|||January 2016|January 26, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321618||30610|
NCT02318108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-323: 1R-01A1|Supporting Practices to Adopt Registry-Based Care|Redesigning Diabetes Work Processes for Population-Based Primary Care: Supporting Practices to Adopt Registry-Based Care|SPARC|Mathematica Policy Research, Inc.|Yes|Active, not recruiting|July 2012|March 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02318108||30879|
NCT02318121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Augmentation of labour|Amniotomy and Oxytocin for Augmentation of Labour|Concurrent Versus Sequential Administration of Amniotomy and Oxytocin for Augmentation of Labour: a Randomized Controlled Trial|AOAL|Assiut University|No|Active, not recruiting|April 2014|December 2014|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Female|18 Years|35 Years|No|||December 2014|December 16, 2014|October 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02318121||30878|
NCT02249650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNTSBA20110201|Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profiles of TSB-9-W1|A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)|TSB-9-W1|Taiwan Sunpan Biotechnology Development Co., Ltd.|Yes|Not yet recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|58|||Both|20 Years|N/A|No|||May 2015|May 11, 2015|September 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249650||36134|
NCT02249663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71336006|Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Site Study to Evaluate the Therapeutic Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray, to Dymista™ Nasal Spray||Teva Pharmaceuticals USA||Recruiting|August 2014|||February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|1535|||Both|12 Years|N/A|No|||September 2014|September 22, 2014|September 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02249663||36133|
NCT02243618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0381|The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer|||Yonsei University|No|Recruiting|September 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|19 Years|79 Years|No|||July 2014|September 15, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02243618||36598|
NCT02243878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCRN ID 18040|Stereotactic Radiotherapy for Wet AMD (STAR)|StereoTactic Radiotherapy for Wet Age-Related Macular Degeneration (STAR): A Randomised, Double-masked, Sham-controlled, Clinical Trial Comparing Low-voltage X-ray Irradiation With as Needed Ranibizumab, to as Needed Ranibizumab Monotherapy.|STAR|King's College Hospital NHS Trust|Yes|Recruiting|December 2014|October 2022|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|411|||Both|50 Years|110 Years|No|||January 2016|January 22, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02243878||36578|
NCT02323763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000003|An fMRI Study on Temporal Discounting in Bipolar Disorder|Reconceptualizing Suicide as Impaired Temporal Discounting: an fMRI Study in Bipolar Disorder||Massachusetts General Hospital|No|Recruiting|July 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|We will recruit 30 currently depressed patients (with DSM-IV bipolar I and II disorder who        are currently or previously suicidal. Enrollment will be limited to adults aged 18-65.|December 2014|December 18, 2014|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323763||30445|
NCT02326649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140550|Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD|Noninvasive Measurement of Cardiac Output Using Impedance Cardiography in Patients With Congenital Heart Disease||University of California, San Diego|No|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with congenital heart disease that is undergoing cardiac MRI without        anesthesia|December 2014|December 22, 2014|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326649||30223|
NCT02326662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMBA OPH1|Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury|Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury||Federal Research Clinical Center of Federal Medical & Biological Agency, Russia|Yes|Active, not recruiting|July 2014|December 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|30|||Both|18 Years|50 Years|No|||October 2015|October 26, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02326662||30222|
NCT02249897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE-1|PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs|PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS|PREL-AGES|University of Chile|Yes|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|25 Years|50 Years|No|||June 2015|June 5, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02249897||36115|
NCT02475057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-15-RMC|Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists|A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists||Rabin Medical Center|Yes|Recruiting|August 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Male|18 Years|90 Years|No|||May 2015|October 18, 2015|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475057||18838|
NCT02425059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rectal cancer-IRE-01|Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms: Phase I and Phase II Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||April 2015|April 22, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02425059||22677|
NCT02425137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYTG1308|A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer|A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer||TTY Biopharm|No|Recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|20 Years|N/A|No|||January 2016|January 10, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02425137||22671|
NCT02473302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Securiviande|Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing|Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing||Institut National de la Recherche Agronomique|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|24|||Male|40 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473302||18973|
NCT02475460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartMate 3 LIS|HeartMate 3™ LIS Study|Thoratec Corporation HeartMate 3™ Less Invasive Surgery (LIS) Study|HM 3 LIS|Thoratec Corporation|No|Active, not recruiting|May 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02475460||18807|
NCT02461511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole#5-Version1.0|Impact of Therapeutic Education, Being Set up Under the Authorized Program for Diabetics Patients in Hospital|Impact Des Actions d'éducation thérapeutique Mises en Place Dans le Cadre d'un Programme autorisé auprès de Patients diabétiques hospitalisés|ImETh|Hôpital Léon Bérard|No|Not yet recruiting|June 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|diabetics hospitalized patients|May 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461511||19879|
NCT02461524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10173339DOC|Endurant Evo International Clinical Trial|Endurant Evo International Clinical Trial||Medtronic Endovascular|Yes|Recruiting|May 2015|May 2021|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461524||19878|
NCT02411994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIT601714|Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria|Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya|PAAL|Royal Tropical Institute|Yes|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|6 Months|12 Years|No|||November 2015|November 2, 2015|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411994||23681|
NCT02426320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011-PED|Pilot Study for Sedation Interruption in Children|Daily Interruption of Sedative Infusions in Mechanically Ventilated Children: A Randomized Pilot Study||McGill University Health Center|Yes|Recruiting|April 2015|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|18 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426320||22580|
NCT02462993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYPCH/12/PG14|Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis|EFFECT OF LOCALLY DELIVERED ALOE VERA GEL AS AN ADJUNCT TO SCALING AND ROOT PLANING IN THE TREATMENT OF CHRONIC PERIODONTITIS: A SPLIT-MOUTH CLINICAL AND MICROBIOLOGICAL STUDY||Dr. D. Y. Patil Dental College & Hospital||Completed|February 2014|May 2015|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|60 Years|No|||June 2015|June 3, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02462993||19765|
NCT02471898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTX-011-C2015-201|A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy|HTX-011|Heron Therapeutics|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|No|||September 2015|September 22, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471898||19081|
NCT02471911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015891|KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma|A Phase I Investigator-Initiated Study of Selinexor (KPT-330) Plus RICE in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas|KPT-330+RICE|Weill Medical College of Cornell University|No|Recruiting|November 2015|June 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471911||19080|
NCT02418819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441007|A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 06412562 In Psychiatrically Stable Subjects With Schizophrenia||Pfizer|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|100|||Both|18 Years|45 Years|No|||March 2016|March 23, 2016|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02418819||23156|
NCT02473146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001395-65|Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4|Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 65 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable|ALFA1401|Central Hospital, Versailles|Yes|Recruiting|November 2015|November 2020|Anticipated|November 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|65 Years|80 Years|No|||January 2016|February 24, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02473146||18985|
NCT02471820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-GMSG-392|Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients|Phase II Open Label Study for the Assessment of the Efficacy and Safety of Lenalidomide & Adriamycin & Low Dose Dexamethasone (RAD) in Newly Diagnosed, Symptomatic Multiple Myeloma Patients|RAD|University of Athens|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||June 2015|June 10, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471820||19087|
NCT02467478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121439|Linagliptin Effect on CD34+ Stem Cells|Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.||George Washington University|No|Recruiting|April 2015|December 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||April 2015|September 2, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467478||19421|
NCT02421341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005318|Mechanisms of Altered Ventilatory Control in Heart Failure|Mechanisms of Altered Ventilatory Control in Heart Failure||Mayo Clinic|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02421341||22963|
NCT02419612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-365|A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone|A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone||Bristol-Myers Squibb|Yes|Recruiting|July 2015|August 2019|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|440|||Both|18 Years|N/A|No|||January 2016|February 25, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419612||23096|
NCT02471352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150144|Studies of Dermatologic Diseases Biospecimen Acquisition Protocol|Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|January 2027|Anticipated|January 2026|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|2 Years|99 Years|Accepts Healthy Volunteers|||June 2015|December 17, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471352||19123|
NCT02471365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915134|Study of Exposure to Chemicals in Consumer Products|NIEHS EPA Pilot Study of Exposure to Chemicals in Consumer Products||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Female|35 Years|74 Years|Accepts Healthy Volunteers|||April 2015|February 20, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471365||19122|
NCT02475538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcupBen|Electroacupuncture for Tapering Off Long-term Benzodiazepine Use|Electroacupuncture for Tapering Off Long-term Benzodiazepine Use: a Randomized Controlled Trial||The University of Hong Kong|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475538||18801|
NCT02410902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00103|A Trial of CM-AT in Children With Autism With All Levels of FCT|A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)||Curemark|No|Recruiting|May 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410902||23765|
NCT02426749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:032|Treatment and Recovery Monitoring of Post TBI Symptoms|Treatment and Recovery Monitoring of Post Traumatic Brain Injury (TBI) Symptoms||University of Manitoba|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|January 6, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426749||22547|
NCT02426762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[122]|Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery|Use of a Quick Skin Sealant in Prevention of Surgical Site Infection After Laparoscopic Tumor Resection||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|February 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|16 Years|65 Years|No|||August 2015|August 11, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426762||22546|
NCT02468245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1096|Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?|Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?||Bassett Healthcare|No|Recruiting|January 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02468245||19362|
NCT02472223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412069|Reducing Adenoviral Patient Infected Days|Reducing Adenoviral Patient Infected Days|RAPID|Washington University School of Medicine|No|Recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472223||19056|
NCT02477995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110103|Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants|Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy Infants 3 to 5 Months of Age: A Randomized, Blinded, Single-center, Positive Controlled Clinical Trial||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|December 2013|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Both|3 Months|5 Months|No|||July 2011|June 22, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02477995||18612|
NCT02415556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P-000064|Memory Aid by Intranasal Insulin in Diabetes (MemAID)|Memory Advancement by Intranasal Insulin in Type 2 Diabetes|MemAID|Beth Israel Deaconess Medical Center|Yes|Recruiting|July 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415556||23407|
NCT02470975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLS-3325-02-2014|How Family Coping With Child Cancer Affects Child's Quality of Life?|How Families Cope With Child Cancer? A Longitudinal Study on the Role of "We-appraisals" on Child's Health-related Quality of Life||University Children's Hospital, Zurich|Yes|Recruiting|June 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|300|||Both|6 Years|17 Years|No|Non-Probability Sample|Children with newly diagnosed cancer and their parents|December 2015|December 3, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470975||19152|
NCT02470988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WS/0027|Does Disciplined Personal Involvement Precede Change in CBASP?|How is Psychological Change Experienced by Individuals Receiving Cognitive Behaviour Analysis System of Psychotherapy (CBASP) and How is This Affected by Disciplined Personal Involvement? A Multiple Baseline Single Case Design||University of Edinburgh|No|Enrolling by invitation|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|64 Years|No|||June 2015|June 10, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470988||19151|
NCT02477254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/15035|Long-term Immunogenicity of a HPV Vaccine in SLE|Long-term Immunogenicity of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus: a Case-control Study||Tuen Mun Hospital|No|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|serum|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|SLE patients          1. Female patients aged 18-35 years          2. Fulfilling the American College of Rheumatology (ACR) criteria for the classification             of SLE          3. Having participated in the investigators' original HPV study in 2010          4. Able to give written informed consent        Controls          1. Women aged 18-35 years, matched those of SLE patients recruited          2. No known chronic medical diseases          3. Having participated in our HPV study in 2010|November 2015|November 3, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477254||18669|
NCT02469142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADM001|Use of Acellular Dermal in the Incarcerated Inguinal Hernia Tension-free Reconstructions|Use of Acellular Dermal in the Incarcerated Inguinal Hernia Tension-free Reconstructions||Xijing Hospital of Digestive Diseases|Yes|Active, not recruiting|January 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|85 Years|No|||June 2015|June 8, 2015|January 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02469142||19293|
NCT02469155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-302|A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment|A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia||Intra-Cellular Therapies, Inc.||Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|580|||Both|18 Years|60 Years|No|||June 2015|June 23, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469155||19292|
NCT02415569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014SDU-QILU-G07|Tailored Bowel Preparation According to Bristol Stool Form Scale|Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study||Shandong University|Yes|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|700|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415569||23406|
NCT02464501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPG-CLIN-2015-02|The COPPER-A Trial|The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above the Knee||Horizons International Peripheral Group|Yes|Recruiting|May 2015|August 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464501||19650|
NCT02469597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-260B|Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis|Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis||Northwell Health|Yes|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|48 Months|No|||January 2016|January 4, 2016|May 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469597||19258|
NCT02464826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Efficacynailprotex|A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment|A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment||Mahidol University|No|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464826||19625|
NCT02423928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT2001|Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer|A Phase I Clinical Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells in Men With Castration Resistant Prostatic Cancer and Metastases to Lymph Nodes and/or Bone Pre or Post Chemotherapy|CryoIT|Alden Cancer Therapy II|Yes|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||April 2015|May 20, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02423928||22764|
NCT02463721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBP|Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis|Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis in Nile Delta and Its Impact on Clinical Outcome of These Patients||Tanta University|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 9, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02463721||19710|
NCT02464748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17165|Telehealth in Motor Neurone Disease|Telehealth in Motor Neurone Disease: A Single Centre, Randomised Controlled Feasibility and Pilot Study of the Use of the TiM Telehealth System to Deliver Highly Specialised Care in Motor Neurone Disease at a Distance|TiM|Sheffield Teaching Hospitals NHS Foundation Trust|No|Enrolling by invitation|September 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|June 3, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02464748||19631|
NCT02464761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT01|Photodynamic Therapy for the Treatment of Vertebral Metastases|Photodynamic Therapy (PDT) for the Treatment of Vertebral Metastases: A Phase I Clinical Trial||Sunnybrook Health Sciences Centre||Recruiting|June 2011|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|85 Years|No|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464761||19630|
NCT02478112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioPro-RCMI-1505|Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)|Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)|BioPro-RCMI|Centre Oscar Lambret|Yes|Not yet recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||June 2015|June 18, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478112||18603|
NCT02468739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-EBC|Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer|The Effect of Monosialotetrahexosyl Ganglioside (GM1) in Prevention of Taxanes Induced Neurotoxicity in Breast Cancer Patients Who Received Taxanes-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial||Sun Yat-sen University|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|188|||Female|18 Years|65 Years|No|||June 2015|June 8, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02468739||19324|
NCT02468752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYK 14-16|Reduction of Venous Emboli Load After Breathing Normobaric Oxygen Compared to Air|||Göteborg University|No|Recruiting|May 2015|||November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468752||19323|
NCT02466620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719/2557(EC4)|A Comparison of Paediatric Weight Estimation Methods for Emergency Resuscitation|A Comparison of Paediatric Weight Estimation Methods for Emergency Resuscitation||Mahidol University|No|Active, not recruiting|February 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|430|||Both|6 Months|12 Years|Accepts Healthy Volunteers|Probability Sample|2 sources of study population:          1. Children from pre-school and primary school at Wat Amarintararam School, Bangkok,             Thailand          2. Children from the out-patient department at Siriraj hospital, Bangkok, Thailand|November 2015|November 15, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466620||19487|
NCT02474563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018445|Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma|A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation||Janssen Korea, Ltd., Korea|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|171|||Both|20 Years|N/A|No|Non-Probability Sample|Participants receiving VMP therapy for MM that was not eligible for autologous stem cell        transplantation will be enrolled in the study.|June 2015|June 26, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474563||18876|
NCT02425033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8327|POEM for Spastic Esophageal Disorders|Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter in Patients With Spastic Esophageal Disorders Such as Achalasia||University Health Network, Toronto|No|Recruiting|April 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||December 2015|December 10, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425033||22679|
NCT02425046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406722|Family Obesity Intervention: Motivational Interviewing and Community Support|Family Obesity Intervention: Motivational Interviewing and Community Support||University of Iowa|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|520|||Both|6 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02425046||22678|
NCT02471599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGNSIgAN-003|Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy|Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy :a Prospective,Randomized,Controlled Study.||Sun Yat-sen University|Yes|Suspended|March 2011|March 2023|Anticipated|March 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|No|||June 2015|June 10, 2015|May 19, 2015||No|This study was suspended because that few participants was enrolled.|No||https://clinicaltrials.gov/show/NCT02471599||19104|
NCT02471612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-26104-132-108296|Comparative Analysis of APACHE II and P-POSSUM|Comparative Analysis of APACHE II and P-POSSUM Scoring Systems in Predicting Postoperative Mortality in Patients Undergoing Emergency Laparotomy||Tata Main Hospital|Yes|Completed|December 2013|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|159|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing emergency laparotomy at Tata Main Hospital form 01st December 2013        to 30th November 2014 will be included in the study. All patients will be scored with        APACHE II and P-POSSUM scoring systems on the day of surgery.The patients will be followed        up till discharge, death or 30 days postoperatively.|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02471612||19103|
NCT02462694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOO-09-073|High Risk Suicidal Behavior in Veterans|High Risk Suicidal Behavior in Veterans - Assessment of Predictors and Efficacy of Dialectical Behavior Therapy||Bronx Veterans Medical Research Foundation, Inc|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462694||19788|
NCT02462499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCR 104/2014|Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population|Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population||Semmelweis University|No|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02462499||19803|
NCT02462512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulStMary|Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer|Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer|Elastography|Seoul St. Mary's Hospital|No|Recruiting|April 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|590|||Both|18 Years|N/A|No|Probability Sample|The patients with thyroid nodule who visit tertiary hospital for fine needle aspiration        biopsy|January 2016|January 6, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02462512||19802|
NCT02423785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBF-13|Ocular Blood Flow in Colorectal Cancer Patients|Exploratory Study Investigating Ocular Blood Flow in Colorectal Cancer Patients Before and After Treatment With Anti-angiogenic Therapy||Medical University of Vienna|No|Recruiting|May 2014|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|99 Years|No|Probability Sample|Patients, who are treated at the Medical University of Vienna|March 2016|March 15, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02423785||22775|
NCT02475330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 28514|Dietary Flaxseed in NSCLC|Phase II Trial of Flaxseed to Prevent Pneumonopathy After Chemoradiation for Lung Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475330||18817|
NCT02467153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-185|Vitamin D and Resistance Exercise Training; Effects on Musculoskeletal Health in Frail Older Men and Women|Influence of Combined Vitamin D Supplementation and Resistance Exercise Training on Musculoskeletal Health in Frail Older Men and Women (EXVITD)|EXVITD|University of Birmingham|No|Not yet recruiting|September 2015|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|114|||Both|70 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02467153||19446|
NCT02467166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150018|Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA|A Prospective, Non-Randomized Study to Evaluate the CIRCA Esophageal Temperature Monitoring System in Prevention of Esophageal Lesions Following Atrial Fibrillation Radiofrequency Catheter Ablation|CIRCA-EGD|University of California, San Diego|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467166||19445|
NCT02253160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5038|An Evaluation of the Spectra Optia CMNC Collection Procedure|A Randomized, Crossover Trial to Characterize the Performance of the Spectra Optia Apheresis System Versus the COBE Spectra Apheresis System for Collection of Mononuclear Cells in Healthy Adult Donors|CMNC|Terumo BCT|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|September 23, 2014|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT02253160||35864|
NCT02253173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXV14-01|Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy|REJOICE|TherapeuticsMD|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|764|||Female|40 Years|75 Years|No|||November 2015|November 2, 2015|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02253173||35863|
NCT02258308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSKC|CDC Medicaid Asthma Home Visit Project|Medicaid Asthma Home Visit Project: Improving Health and Reducing Costs of Health Care for Children With Asthma||Public Health - Seattle and King County|No|Completed|May 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|373|||Both|3 Years|17 Years|No|||October 2014|October 6, 2014|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02258308||35472|
NCT02258321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-104|Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations|A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers||Presidio Pharmaceuticals, Inc.|No|Completed|October 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02258321||35471|
NCT02326129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057460|Novel Biomarker for Development of T2D|A Novel Biomarker for Development of Type 2 Diabetes: 11Beta-Hydroxy Steroid Dehydrogenase Type 1 Activity||Duke University|No|Recruiting|February 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|Samples Without DNA|24 hour urine samples.|Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include 20 obese adolescents with Type II Diabetes, 20 obese        adolescents without Type II Diabetes, and age, gender, race and pubertal status-matched        normal weight controls.|October 2015|October 19, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326129||30263|
NCT02324699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2209|Corticosteroids With Vedolizumab in Crohn's Disease|Corticosteroids as Co-Induction Agents With Vedolizumab in Crohn's Disease: a Double-blind Placebo Controlled Randomized Trial||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|123|||Both|18 Years|70 Years|No|||December 2015|December 27, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324699||30373|
NCT02241993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11619|The Multi-Sensor Distance Accuracy Study|The Accuracy Benefit of Dual vs Single Amperometric Glucose Sensors in Persons With Type 1 Diabetes: Effect of Inter-sensor Distance||Oregon Health and Science University|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|clinical practice Type 1 patients|September 2014|September 15, 2014|November 6, 2013||No||No||https://clinicaltrials.gov/show/NCT02241993||36723|
NCT02242305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.838|Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort|A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Hyoscine Butylbromide Capsule 10mg, to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets 10 mg (20mg, 3 Times Daily, Orally) Over a Period of 3 Days for the Treatment of Occasional or Recurrent Episodes of Self-reported Gastric or Intestinal Spasm-like Pain||Boehringer Ingelheim||Completed|November 2008|||September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|70 Years|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242305||36699|
NCT02258347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/REG/NT|HIFU in Patients With Non-malignant Thyroid Nodules|Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.||Theraclion|No|Terminated|July 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 26, 2014||No|End of recruitment period - study recruitment objectives not reached|No||https://clinicaltrials.gov/show/NCT02258347||35469|
NCT02312219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000145|PET/CT Imaging Companion Study To ACTG A5314|Imaging Companion Study To ACTG A5314: Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection|PET/CTMTX|Massachusetts General Hospital|Yes|Recruiting|November 2014|May 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|91|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312219||31331|
NCT02312232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3112002|Pharmacokinetic Study in Healthy Males|Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males|NOCOF|Orion Corporation, Orion Pharma|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02312232||31330|
NCT02312245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1463|Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers||Mayo Clinic|Yes|Recruiting|July 2015|||June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|December 9, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312245||31329|
NCT02325791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2222-RSV-1332|Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants||Regeneron Pharmaceuticals|Yes|Recruiting|June 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1538|||Both|N/A|6 Months|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325791||30289|
NCT02325804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXE- 11/2014|Effect of Specific Diet and Physical Activity on Weight and/or Fat Loss|Effect of Specific Diet and Circuit-based Exercise on Weight and/or Fat Loss||Slovak Academy of Sciences|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02325804||30288|
NCT02325817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bifurcation|Drug-eluting Balloon vs. Regular Balloon Dilatation in the Treatment of Patients With Bifurcation Lesions|||Liaoning Biomedical Materials R&D Center Co., Ltd.||Active, not recruiting|December 2014|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|80 Years||||December 2014|December 24, 2014|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02325817||30287|
NCT02253225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000714|Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study|An fMRI Study of Self Processing and Self Focus in Major Depression and Bipolar Disorder||Massachusetts General Hospital|No|Recruiting|January 2013|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls will be recruited through email announcements at MGH, internet website at        Harvard, and flyers posted at the Massachusetts General Hospital and in the community        (e.g., community centers, public libraries, coffee shops, restaurants, and laundromats).        Subjects with major depression will be recruited through the Depression Clinic and        Research Program at MGH and flyers posted at MGH. Subjects with bipolar disorder will be        recruited through the Bipolar Clinic and Research Program at MGH and flyers posted at MGH.|January 2016|January 7, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253225||35859|
NCT02253238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0535|Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients|Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients||M.D. Anderson Cancer Center|No|Recruiting|January 2014|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|282|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253238||35858|
NCT02242344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.403|Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension|A Prospective, Randomized, Double-blind, Placebo-controlled, Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension After Four Weeks of Treatment||Boehringer Ingelheim||Completed|April 2006|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|77|||Both|6 Years|17 Years|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242344||36696|
NCT02242357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.427|Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension|Post-Marketing Surveillance Study Micardis® Plus||Boehringer Ingelheim||Completed|January 2003|||July 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14553|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with hypertension|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242357||36695|
NCT02251483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35543|Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth|Use of Serum-derived Immunoglobulin/Protein Isolate (SBI) for the Maintenance of Health in Subjects With Irritable Bowel Syndrome (IBS) Following Successful Treatment of Small Intestinal Bacterial Overgrowth (SIBO)||Cedars-Sinai Medical Center|Yes|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|2|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02251483||35993|
NCT02323217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2250|I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers|I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study|I2PETHV|Imperial College London|No|Active, not recruiting|January 2015|July 2016|Anticipated|February 2016|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323217||30487|
NCT02317835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 2 (02/3/2015)|Diabetic Foot Ulcer Prevention System|An Innovative System for the Early Identification, Monitoring, Evaluation and Diagnosis of Diabetic Foot Ulcers|DFUPS|King's College Hospital NHS Trust||Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317835||30900|
NCT02251093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO_2013 - 02|Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis|Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo.|GYNOCANS|Probionov|Yes|Completed|May 2014|||February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|350|||Female|N/A|N/A|No|||March 2016|March 24, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02251093||36023|
NCT02251275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-13-211|Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease|A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Enrolling by invitation|September 2014|||May 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2500|||Both|18 Years|N/A|No|||January 2016|February 17, 2016|September 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02251275||36009|
NCT02324153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_000XXXX|A Randomized Double Blind Placebo Controlled Trial of Ramelteon in the Prevention of Post-operative Delirium|A Randomized Double Blind Placebo Controlled Trial of Ramelteon in the Prevention of Post-operative Delirium in Older Patients Undergoing Orthopedic Surgery||Johns Hopkins University|Yes|Not yet recruiting|June 2016|January 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|65 Years|N/A|No|||September 2015|September 25, 2015|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324153||30415|
NCT02326051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIE2|Timing of Initiation of LMWH Administration in Pregnant Women With APS|Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome||Mansoura University|No|Recruiting|February 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|20 Years|38 Years|No|||March 2016|March 4, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326051||30269|
NCT02253303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMU1398|Evaluation of the Extraction-site, - Midline Incision vs Off-midline Incision-|Evaluation of the Extraction-site Location in Laparoscopic Colorectal Surgery - Midline Incision vs Off-midline Incision-||Wakayama Medical University|Yes|Not yet recruiting|October 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||September 2014|September 26, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02253303||35853|
NCT02324192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPaulo002|Hand Ultrasonography: Clinical and Functional Correlation in Symptomatic Osteoarthritis (OA)|Hand Ultrasonography: Clinical and Functional Correlation in Symptomatic Osteoarthritis (OA)||Federal University of São Paulo|Yes|Completed|August 2011|August 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|60|||Both|40 Years|N/A|No|||December 2014|December 23, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02324192||30412|
NCT02313532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-14-HYMC|Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study|Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|18 Years|No|Non-Probability Sample|Research population A sum of 500 patients recruited to the "curiosity" study in        Hillel-yaffe hospital        Inclusion criteria:          1. Children aged 7 days to 18 years.          2. Body temperature that is higher than 37.5°C (Rectal or Oral).          3. Informed consent obtained from parents.        Exclusion criteria:          1. Children with fever that is longer than 7 days.          2. Children diagnosed with immunodeficiency.          3. Children that receive chemotherapy.          4. Children treated with high dose steroids.|December 2014|December 7, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313532||31230|
NCT02314897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00258|Left Ventricular Pacing to Prevent Iatrogenic TR Pilot Study|Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study||National University Hospital, Singapore|Yes|Not yet recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314897||31126|
NCT02465866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCT-004|A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions|A Single-Dose, Four-Period, Four-Treatment, Four-Way Crossover Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions||Charleston Laboratories, Inc||Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465866||19545|
NCT02421159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00963|Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage|Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage|BCU|New York University|Yes|Active, not recruiting|February 2015|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421159||22977|
NCT02426229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AR065089-01A1|Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma|Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma||Medical University of South Carolina|Yes|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||February 2016|March 14, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02426229||22587|
NCT02426242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0207(1-1)|Evaluation of Risk Factors Regarding Extubation Failure in Severe Brain Injured Patients.|Observational Evaluation of Risk Factors Regarding Extubation Failure in Severe Brain-injured Patients||Nantes University Hospital|No|Completed|April 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|15 Years|85 Years|No|Non-Probability Sample|Patients hospitalized in ICU for severe brain injury|April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426242||22586|
NCT02462174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718/ NF|Topical Ketamine Versus Caudal Ketamine for Postoperative Analgesia in Children Undergoing Inguinal Herniotomy|Caudal Epidural Block Versus Topical Ketamine Application for Postoperative Pain Relief After Elective Inguinal Herniotomy|TKversusCK|Assiut University|Yes|Completed|May 2015|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|6 Months|6 Years|No|||October 2015|October 1, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462174||19828|
NCT02466113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[28]|A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy|A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Chemotherapy of Stage II Colon Cancer Based on a 6 microRNA Stratified Tool||First Affiliated Hospital, Sun Yat-Sen University|No|Not yet recruiting|January 2016|January 2026|Anticipated|January 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|430|||Both|18 Years|65 Years|No|||June 2015|June 8, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02466113||19526|
NCT02415790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2027-A001-001|Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects|A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects||Eisai Inc.|No|Recruiting|July 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|85|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415790||23389|
NCT02414373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390/14|Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function|Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Lower Urinary Tract Function: A Randomized, Controlled Study||University Hospital Inselspital, Berne|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02414373||23498|
NCT02467413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC-01|BAC in Patient With Alzheimer's Disease or Vascular Dementia|A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia||Charsire Biotechnology Corp.|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|40 Years|N/A|No|||January 2016|January 26, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467413||19426|
NCT02476279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DK104833-01|Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis|Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial|SVI|Medical University of South Carolina|Yes|Recruiting|September 2015|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1430|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02476279||18744|
NCT02476396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0289|Structural Stability of Carotid Plaque and Symptomatology|Structural Stability of Carotid Plaque and Symptomatology||University of Wisconsin, Madison|No|Recruiting|April 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|194|Samples With DNA|Subjects and controls will have 2 tubes of blood drawn. DNA will be removed and may be saved      for future testing. Some cells from the participant's blood may be kept alive and growing in      the laboratory as a "cell line". Creating a cell line will allow the investigators to get      more DNA for future research.      Subjects will have their carotid plaques removed via standard carotid endarterectomy. This      surgical procedure is part of the standard clinical care.      Blood samples will be decoded and unidentifiable, kept in a secure freezer box (with a lock      and key) and stored in chamber of 1 -800C freezer used only to store human blood and RNA      samples.      Plaque specimens will be de-identified. Samples will be kept in a secure freezer box stored      in a chamber with authorized access only.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the population of patients scheduled to undergo carotid        endarterectomy for established clinical indications. These indications include patients        scheduled to have a carotid endarterectomy due to the presence of a high-grade        atherosclerotic cervical internal carotid artery stenosis with or without clinical        symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater        without clinical symptoms; stenosis 70% or greater with clinical symptoms).|June 2015|June 19, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02476396||18735|
NCT02424565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204663|Effect of Topical Application of Iodex® Balm on Local Surface Temperature|An Exploratory Study to Assess the Effect of Topical Application of Iodex® Balm on Local Surface Temperature Using Infra Red Thermal Imaging Technique||GlaxoSmithKline|No|Completed|May 2015|June 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|35 Years|65 Years|No|||December 2015|December 21, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424565||22715|
NCT02424578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC2-14-08|Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age|A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery||Iroko Pharmaceuticals, LLC|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|16 Years|No|||September 2015|September 16, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424578||22714|
NCT02462356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY15H160034|Multiple-portal VATS Versus Uniportal VATS Lobectomy for Non-small Cell Lung Cancer|A Randomized Controlled Study: the Effect of Multiple-portal VATS Versus Conventional VATS Lobectomy for NSCLC|MVUVLC|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|35 Years|75 Years|No|||January 2016|January 2, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462356||19814|
NCT02477098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015110901|Preoperative Versus Postoperative Ultrasound-guided Rectus Sheath Block for Sleep Quality and Cytokines of Patients|Preoperative Versus Postoperative Ultrasound-guided Rectus Sheath Block for Improving Pain, Sleep Quality and Cytokine Levels of Patients With Open Midline Incisions Undergoing Transabdominal Gynaecological Operation||China Medical University, China|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|65 Years|No|||October 2015|January 30, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02477098||18681|
NCT02472093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2547-720/2012|A New Rehabilitation Tool in Fibromyalgia|A New Rehabilitation Tool in Fibromyalgia: Efficacy of Perceptive Rehabilitation Versus Group Exercises on Pain and Function: a Clinical Randomized Controlled Trial (RCT)||University of Roma La Sapienza|Yes|Completed|May 2012|May 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|88|||Female|18 Years|60 Years|No|||May 2012|June 10, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02472093||19066|
NCT02477969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-302|Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|January 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|564|||Both|18 Years|78 Years|No|||January 2016|January 24, 2016|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02477969||18614|
NCT02426957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00013929|Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide|Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide||Children's Hospital Boston|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|13 Years|17 Years|No|||February 2016|February 3, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02426957||22531|
NCT02415114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15COHH|An Open Label Study Evaluating the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10|An Open Label Pilot Study to Evaluate the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10 in Healthy Subjects and Subjects on Statins||KGK Synergize Inc.|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02415114||23441|
NCT02411214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1|Decisional Process in Male Fertility Preservation|Fertility Preservation in the Male Pediatric Population: a Patient and Parent Perspective of Factors Influencing the Decisional Process||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|348|||Both|N/A|N/A|No|Non-Probability Sample|prepubertal boys and adolescents diagnosed with cancer in a university hospital setting        between january 2005 and may 2013 and their parents|April 2015|April 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02411214||23741|
NCT02411227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150103|Neurocognitive Driving Rehabilitation in Virtual Environments (NeuroDRIVE) as an Adjunctive Intervention for Traumatic Brain Injury|Evaluation of Neurocognitive Driving Rehabilitation in Virtual Environments (NeuroDRIVE) as an Adjunctive Intervention for Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|March 1, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02411227||23740|
NCT02473848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEKZH2013-0525|Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses|A Multi-center, Open-label, Uncontrolled, Investigator-initiated Trial to Evaluate the Safety and Efficacy of Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses on the Trunk and Extremities|IMOT001|University of Zurich|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473848||18931|
NCT02463058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2235-OF-CTIL|Evaluating the Physiological Strain Induced by a BC Protective Undergarment Under Exercise-heat Stress|Evaluating the Physiological Strain Induced by a BC Protective Undergarment Under Exercise-heat Stress||Sheba Medical Center|No|Completed|August 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463058||19760|
NCT02415348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 15-35|The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers|The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers and/or Implantable Cardioverter-Defibrillators||University of Saskatchewan|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|16 Years|N/A|No|||April 2015|April 8, 2015|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415348||23423|
NCT02411513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50208|Acute Treatment of Migraine Using the CEFALY Device|Open-trial on the Acute Treatment of Migraine Using the CEFALY Device||Cefaly Technology|No|Completed|April 2015|||October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411513||23718|
NCT02472236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-Ij|Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|April 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02472236||19055|
NCT02464332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-003|Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery|A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery||Blaze Bioscience Inc.|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|21|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464332||19663|
NCT02419573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL077863-PART|Pragmatic Airway Resuscitation Trial|Pragmatic Trial of Airway Management in Out-of-Hospital Cardiac Arrest|PART|University of Washington|Yes|Recruiting|December 2015|November 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02419573||23099|
NCT02473276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP4755|2 Dose Neuraxial Morphine for Prevention of PDPH|Two Dose Neuraxial Morphine for Prevention of Postdural Puncture Headache||Columbia University|No|Not yet recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02473276||18975|
NCT02464280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000001072|Tomosynthesis of Pathologies of the Chest and Skeletal Structures in Comparison to CT|Validation of Tomosynthesis for Indications for Clinical Questions Concerning Pathologies of the Chest and Skeletal Structures: When Can CT Been Omitted?||University of Zurich|No|Not yet recruiting|December 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|390|||Both|18 Years|N/A|No|Non-Probability Sample|The population included in this study are patients who are referred to our hospital for        evaluation of lung-changes or evaluation of the wrist after fracture or surgery.|May 2015|June 2, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02464280||19667|
NCT02469350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-12|Serious Game for Parkinson's Disease Patients|Feasibility and Acceptability Study of Serious Game Rehabilitation Program in Parkinson's Disease Patients With Resistant Gait and Balance Disorders|PARKGAME|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02469350||19277|
NCT02478060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB001|Birch-SPIRE Safety and Efficacy Study|A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE||Circassia Limited|No|Active, not recruiting|July 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|64|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478060||18607|
NCT02461563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1075-004|A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)|A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461563||19875|
NCT02421575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121102|Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance|Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer||Rutgers, The State University of New Jersey|No|Active, not recruiting|July 2012|||April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|N/A|No|||October 2015|November 2, 2015|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421575||22945|
NCT02467608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDMC HUEXC030-TB1|Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis|A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis||Orient Pharma Co., Ltd.|Yes|Recruiting|December 2012|December 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|352|||Both|20 Years|N/A|No|||March 2016|March 2, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02467608||19411|
NCT02467621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-ITA-006|Stress Ulcer Prophylaxis in the Intensive Care Unit|Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)|SUP-ICU|Scandinavian Critical Care Trials Group|Yes|Recruiting|January 2016|August 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3350|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02467621||19410|
NCT02469610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0123-CTIL|Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery|Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery||Carmel Medical Center|No|Not yet recruiting|June 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469610||19257|
NCT02469415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0224|Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)|Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2015|||September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469415||19272|
NCT02469428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3697|Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers|Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers|Geminoz|Environmental Protection Agency (EPA)|No|Active, not recruiting|December 2013|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469428||19271|
NCT02469701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 317|BrUOG 317:Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease|BrUOG L317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease: A Brown University Oncology Research Group Phase II Study|317|Brown University|Yes|Recruiting|February 2016|November 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02469701||19250|
NCT02411162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201661|A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream|Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers||GlaxoSmithKline|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411162||23745|
NCT02411175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FarhanaNakhooda201007840|The Efficacy of Individualised Homeopathic Treatment on Constipation|The Efficacy of Individualised Homeopathic Treatment on Constipation||University of Johannesburg|Yes|Recruiting|October 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411175||23744|
NCT02467881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK100933-02|Physical Activity and Sedentary Behavior Change; Impact on Lifestyle|Physical Activity and Sedentary Behavior Change; Impact on Lifestyle Intervention Effects for Diabetes Translation||University of Pittsburgh|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|321|||Both|50 Years|N/A|No|||December 2015|December 22, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467881||19390|
NCT02469922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-JC-ORLK-TEP|Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer|Prospective Study Assessing Predictive Value of 18 F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose (FDG) Positron Emission Tomography During Radio-chemotherapy for Locally Advanced Epidermoid Carcinoma of Head and Neck|TEmPoRAL|Center Eugene Marquis|No|Recruiting|June 2014|January 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|123|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02469922||19233|
NCT02462057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821895|Testing Different Messaging Approaches to Increase Activation of a HealthyFood Benefit in Adults With Diabetes|Testing the Effectiveness of Different Messaging Approaches to Increase Activation of a HealthyFood Benefit Amongst Individuals With Diabetes: A Randomised, Controlled Trial||University of Pennsylvania|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Actual|5467|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02462057||19837|
NCT02424955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0048|Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation|Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation||Stanford University|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at Stanford cancer center with primary or metastatic liver tumors.|March 2016|March 10, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02424955||22685|
NCT02412839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502027RIND|Sublingual Microcirculation of Healthy Volunteers by Using the Third Generation Microcirculation Video Microscope|Population Research of Sublingual Microcirculation Data of Healthy Volunteers by Using the Third Generation Microcirculation Video Microscope||National Taiwan University Hospital|No|Recruiting|April 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|150|||Both|20 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|October 2015|October 25, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412839||23616|
NCT02472002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100102|Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients|Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients|MESHT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|80 Years|No|||June 2015|June 10, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02472002||19073|
NCT02472184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022436|Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy|Office Based Evaluation of Patients Presenting With Abnormal Uterine Bleeding and/or Uterine Fibroids With Concurrent Office Hysteroscopy and Endometrial Biopsy; Does the Order Matter?||University of South Florida|No|Recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|78|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02472184||19059|
NCT02471313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150137|Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization|A Pilot Study of an Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|99 Years|No|||May 2015|March 18, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471313||19126|
NCT02418481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gd T cell|Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)|γδ T Cell Immunotherapy for Treatment of Breast Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|April 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418481||23182|
NCT02413086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA-EHC-DFU-2014|Effectiveness and Safety of Early-Stage Amputation and External Herbs Chitosan for Diabetic Foot Ulcer|||Heilongjiang University of Chinese Medicine|Yes|Not yet recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|17 Years|70 Years|No|||April 2015|April 8, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02413086||23597|
NCT02475252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK-2|Construct Validity of a Diagnostic Hysteroscopy Training Model|Prospective Case-control Study to Assess the Construct Validity of a Diagnostic Hysteroscopy in a Pelvic Training Model Using an Objective Structured Assessment of Technical Skills (OSATS) Assessment|HSK-2|Ruhr University of Bochum|No|Terminated|April 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|May 3, 2015||No|Recruitment too slow; study completion not possible within frame|No||https://clinicaltrials.gov/show/NCT02475252||18823|
NCT02466906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-15-01|RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer|Recombinant Human Granulocyte-macrophage Colony-stimulating Factor as Adjuvant Immunotherapy in Treating Resectable Stage III Colon Cancer: A Randomized, Placebo-controlled Clinical Trial||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Recruiting|June 2015|July 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|January 18, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02466906||19465|
NCT02466984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2014/10|Subcutaneous Route and Pharmacology of Metoclopramide||SOPHA-Méto|University Hospital, Bordeaux|Yes|Not yet recruiting|July 2015|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02466984||19459|
NCT02472314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-193|Exparel for Postoperative Pain Management in Shoulder Surgery|A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation||Wayne State University|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|75|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472314||19049|
NCT02425124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPC10|Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial|Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial||University of KwaZulu|Yes|Recruiting|April 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02425124||22672|
NCT02464956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACL1011|Production of iPSC Derived RPE Cells for Transplantation in AMD|Feasibility of Production of Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelial Cells Fulfilling Regulatory Requirements for Human Transplantation in Dry Age-related Macular Degeneration||Moorfields Eye Hospital NHS Foundation Trust|No|Not yet recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Peripheral blood sample and a skin sample will be collected from the study participants|Both|50 Years|N/A|No|Non-Probability Sample|Patients affected by Age Related Macular Degeneration (AMD)|May 2015|June 3, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02464956||19615|
NCT02471521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1412-083-633|Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children|Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children: Study Using Detection of Gastric Insufflation Using Ultrasonography of the Antrum and Epigastric Auscultation||Seoul National University Hospital|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|120|||Both|1 Month|5 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02471521||19110|
NCT02241694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-4146|To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives|Haemophilia, Experiences, Results and Opportunities (HERO) in Brazil: Assessment of Psychological Effects of Haemophilia on Patients and Caregivers|HERO|Novo Nordisk A/S|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|200|||Male|18 Years|N/A|No|Non-Probability Sample|Adult males with haemophilia and parents/carers of children with haemophilia.|July 2015|July 9, 2015|September 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241694||36746|
NCT02241785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS409|Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies|A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)|ESCALATE|Biogen||Terminated|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|60 Years|No|||January 2016|January 7, 2016|September 12, 2014|No|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT02241785||36739|
NCT02242097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 14H06|Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma|A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)||Northwestern University|Yes|Recruiting|January 2015|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|September 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242097||36715|
NCT02310867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056079|Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy|Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy||Duke University|Yes|Recruiting|March 2015|December 2021|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310867||31435|
NCT02312544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-13-004|Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension|A Prospective, Multicenter, Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension||Ocular Therapeutix, Inc.|No|Active, not recruiting|November 2014|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312544||31306|
NCT02312557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11025|Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide|Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC||OHSU Knight Cancer Institute|Yes|Recruiting|November 2014|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|18 Years|N/A|No|||October 2015|October 7, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312557||31305|
NCT02247102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-NV-132-CTIL|Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose or Sucrose in Infants|Placebo-controlled Randomized Trial to Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose (Palatinose™) or Sucrose in Infants Aged 6-12 Months||Tel-Aviv Sourasky Medical Center|No|Recruiting|September 2014|August 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||December 2014|December 24, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02247102||36330|
NCT02242435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-008|Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis|A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee||Ampio Pharmaceuticals. Inc.|Yes|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|342|||Both|40 Years|85 Years|No|||February 2016|March 2, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242435||36689|
NCT02242643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201234|Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age||GlaxoSmithKline||Completed|October 2014|June 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2436|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2015|December 10, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242643||36673|
NCT02315846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S452/2013|Acetylcholinesterase in Postoperative Delirium|Role of Acetylcholinesterase for the Diagnosis of Postoperative Delirium in Patients Needing Postoperative Monitoring||Heidelberg University|No|Completed|January 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|blood-serum|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive adult patients in the head clinic of the University of Heidelberg, Germany        with surgery, that requires them to stay in Hospital for at least 3 days postoperatively|December 2014|December 9, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02315846||31053|
NCT02316054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|Evaluation of Myocardial Perfusion Heterogeneity Imaging in Diabetes Patients (EVADIAB)|Long-term Additive Prognostic Value of Heterogeneity Myocardial Perfusion Imaging of SPECT Over Clinical and Ischemia in High-risk Diabetic Patients.|EVADIAB|University Hospital, Grenoble|Yes|Completed|November 2007|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|high-risk cardiovascular type 2 diabetic patients|May 2015|May 27, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02316054||31037|
NCT02313571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/061/D|Breakthrough Pain Computer Integrated Patient Controlled Epidural Analgesia|Incidence and Characteristics of Breakthrough Pain in Parturients Using Computer Integrated Patient Controlled Epidural Analgesia|BTP|KK Women's and Children's Hospital|No|Completed|March 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|||Female|21 Years|45 Years|No|Non-Probability Sample|Women who had nulliparous requested for labour epidural analgesia|September 2015|September 3, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313571||31227|
NCT02242370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.461|Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension|An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)|MicCAT|Boehringer Ingelheim||Completed|September 1999|||November 2000|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3045|||Both|20 Years|93 Years|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242370||36694|
NCT02247115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0604|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study: A Prospective Multicenter Study Evaluating Competence in Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatogram Among Advanced Endoscopy Trainees|RATES|University of Colorado, Denver|No|Enrolling by invitation|July 2014|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|38|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Program directors and AETs at all advanced endoscopy programs registered with the ASGE        will be invited to participate in this study and will be considered as study participants.|September 2015|September 29, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02247115||36329|
NCT02255669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-187-001|Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction|Comparison Between Fully Covered and Partially Covered Self-expandable Metal Stents With Anti-migration System for Malignant Distal Biliary Obstruction||Samsung Medical Center|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|19 Years|N/A|No|||September 2014|February 10, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02255669||35671|
NCT02255682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFESTAT - Observational Study|Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|LIFESTAT|University of Copenhagen|No|Recruiting|January 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|40 Years|70 Years|No|||February 2016|February 16, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02255682||35670|
NCT02312492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1542 - Fatty Acid Kinetics|Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans|Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans.||Tufts University|No|Recruiting|January 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|6|||Female|50 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312492||31310|
NCT02325973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-018-IT-PW|Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI|Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI (AMICRO)|AMICRO|St. Jude Medical|No|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|242|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02325973||30275|
NCT02253797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.24|Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects|A Phase I Multiple Oral Dose Trial of Tipranavir 500 mg/Ritonavir 200 mg Dosed to Steady State Followed by Single-dose 14C-radiolabeled Tipranavir Co-administered With Tipranavir 500 mg/Ritonavir 200 mg to Characterize the Excretion Balance and Metabolite Profile of 14C-radiolabeled Tipranavir in Healthy Male Subjects||Boehringer Ingelheim||Completed|July 2003|||July 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02253797||35815|
NCT02244099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0102|Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic|Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic||Ohio State University|No|Completed|September 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02244099||36561|
NCT02244112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPZ009|A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies|A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies||Onyx Pharmaceuticals|Yes|Active, not recruiting|August 2014|March 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02244112||36560|
NCT02311101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120003H|Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer|Sequential Intravesical Mitomycin Plus Bacillus Calmette-Guérin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial||The University of Texas Health Science Center at San Antonio|Yes|Completed|March 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02311101||31417|
NCT02323633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGX-3006|Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of tPCS on Paediatric ADHD Participants|A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.||Braingear Technologies GmbH|Yes|Not yet recruiting|January 2015|October 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|6 Years|12 Years|No|||December 2014|December 22, 2014|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323633||30455|
NCT02323646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPV-201|A Phase 2, Study to Evaluate the Safety and Efficacy Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids|A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|No|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323646||30454|
NCT02326597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076096|Decision Aid for Therapeutic Options In Sickle Cell Disease|Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease||Emory University|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|8 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02326597||30227|
NCT02314676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci 004 CT|Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children|||GeneScience Pharmaceuticals Co., Ltd.||Recruiting|November 2014|||July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|3 Years|N/A|No|||December 2014|December 9, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02314676||31143|
NCT02311335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150024|Genes Involved in Lipid Disorders|Genes Involved in Lipid Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|No|||September 2015|September 22, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311335||31399|
NCT02318563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS011-14-025|Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome|A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome||INSYS Therapeutics Inc|Yes|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|1 Year|30 Years|No|||February 2016|February 23, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318563||30844|
NCT02250703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0131|Intranasal Dexmedetomidine Premedication in Children|Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation||University of Mississippi Medical Center|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|5 Years|19 Years|No|||October 2015|October 16, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02250703||36053|
NCT02470780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2175|Treating Bacterial Overgrowth in Parkinson's Disease|Treating Bacterial Overgrowth in Parkinson's Disease|SIBO-PD|University of Cincinnati|No|Not yet recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470780||19167|
NCT02423304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Divya Aiswairya thesis|Serological Evaluation of 77A/G and 11A/12A Gene of MMP-13 in Periodontitis Affected and Healthy Individuals|A Serological Evaluation of 77A/G and 11A/12A Associated Gene Polymorphisms of MMP-13 in Periodontitis Affected and Healthy Individuals|SEGPPAH|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Not yet recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|blood serum|Both|30 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  The study will be conducted on 100 individuals          -  50 chronic periodontitis and 50 healthy individuals will be recruited from the Out             Patient Department of Periodontics in the study.|April 2015|April 21, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423304||22812|
NCT02466867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS90200_4025_1|An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis|An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis||Merz Pharmaceuticals, LLC|No|Completed|January 2014|December 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|2 Years|11 Years|No|||January 2016|January 12, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466867||19468|
NCT02467101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-FFA|Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia|Prospective Double-blind, Placebo Controlled Study to Assess the Efficacy of Intralesional Corticoid on the Treatment of Frontal Fibrosing Alopecia|FFA|Universitat Internacional de Catalunya|No|Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||May 2015|June 4, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02467101||19450|
NCT02471417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute NO3- in DCM|Acute Dietary Nitrate in Dilated Cardiomyopathy|Dietary Nitrate Supplementation in Dilated Cardiomyopathy: An Acute, Double-blind, Randomized, Placebo-controlled, Crossover Trial.||Royal College of Surgeons, Ireland|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|12|||Both|N/A|N/A|No|||June 2015|June 10, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02471417||19118|
NCT02419846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3815|Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program|The Effectiveness of a Proposed Prostate Cancer Outreach Program in a Predominantly African American Community That Promotes Informed Decision-making for Prostate Cancer Screening and Utilizes Community Navigation||Case Comprehensive Cancer Center|Yes|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|400|||Male|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419846||23078|
NCT02419118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181114|"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "|"Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab "|DARA|Vejle Hospital|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02419118||23134|
NCT02471664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPMMLC|Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation|The Study on Safety and Feasibility of Mitral Loop Cerclage(MLC) Annuloplasty Procedure With Investigational Medical Device (MLC-B-45-75-R and Other 11 Models) : Single-centre, Open Label, Single Arm, Feasibility Test||Tau Pnu Medical Co.,Ltd.|Yes|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|80 Years|No|||June 2015|June 16, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471664||19099|
NCT02463591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI 1160.203|Reversal of Dabigatran With Prothrombin Complex Concentrate|Reversal of Anticoagulant Effect of Dabigatran® by Prothrombin Complex Concentrate (Beriplex®), Assessed With a Novel Method of Blood Loss Measurement||University Medical Center Groningen|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|June 3, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463591||19720|
NCT02414347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 123119 Protocol A|F 18 T807 Tau PET Imaging of Alzheimer's Disease|F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A|T807IND|Washington University School of Medicine|No|Recruiting|October 2014|December 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414347||23500|
NCT02463513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OREC 12/NI/0136|RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure|RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure|RIBOGENE|University of Ulster|No|Recruiting|February 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463513||19726|
NCT02463526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1154-7379|Effects of Mulligan's Technique in Subjects With Shoulder Impingement Syndrome|The Effects of Mulligan's Technique on Range of Movement, Pressure Pain Threshold, Muscle Strength, and Functionality in Subjects With Shoulder Impingement Syndrome||Universidade Federal de Sao Carlos|Yes|Completed|April 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||December 2015|December 20, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02463526||19725|
NCT02463825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0617|A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS|A Registry-Based Randomized-Controlled, Double-Blinded Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to Amyotrophic Lateral Sclerosis||University of Calgary|No|Recruiting|April 2015|December 2021|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02463825||19702|
NCT02415127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZNP-ACT-301|Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|STEADFAST|Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|25 Years|No|||February 2016|February 18, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415127||23440|
NCT02415842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201598|A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines|An Exploratory, Retrospective Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 HA Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GSK Biologicals' Pandemic Influenza Vaccines||GlaxoSmithKline||Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||9|Anticipated|1|Samples With DNA|Serum samples|Both|6 Months|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Archived serum samples to be evaluated in this study were collected from adults 18-64        years of age and children 6-35 months of age.|February 2016|February 11, 2016|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415842||23385|
NCT02463500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18776|UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository|UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository|DFUDatabase|University of Texas Southwestern Medical Center|No|Recruiting|January 2015|December 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Blood, bone and tissue samples will be banked in the UT Southwestern Department of Plastic      Surgery Laboratory and tested for bacteria, biomarkers, inflammatory cytokines and other      indicators of infection.|Both|18 Years|89 Years|No|Non-Probability Sample|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any        race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.|December 2015|December 3, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02463500|2 Years|19727|
NCT02467738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.067|Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer|A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer||Thomas Jefferson University|Yes|Recruiting|March 2015|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|90 Years|No|||February 2016|February 10, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467738||19401|
NCT02419313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010370|Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach|Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach||Yale University|Yes|Completed|August 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 27, 2014|No|Yes||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02419313||23119|
NCT02416089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14095|Tampostat for Management of Postpartum Hemorrhage|Tampostat: A Low-cost, Self-regulating Tamponade for Management of Postpartum Hemorrhage in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|344|||Female|N/A|N/A|No|||April 2015|March 24, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02416089||23366|
NCT02477202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-105|Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation|Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Female|35 Years|45 Years|No|||February 2016|February 8, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477202||18673|
NCT02468895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoMMYO|MYOPROSP - a Prospective Cohort Study in Myositis|MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy|MYOPROSP|University of Manchester|Yes|Not yet recruiting|November 2015|February 2021|Anticipated|February 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|DNA RNA Peripheral blood mononuclear cells Serum Plasma Urine Muscle biopsies Other      diagnostic tissue|Both|N/A|N/A|No|Non-Probability Sample|Idiopathic Inflammatory Myopathy, UK based patients|June 2015|June 10, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02468895|5 Years|19312|
NCT02463214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00662|Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients|Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients||University of British Columbia|No|Not yet recruiting|July 2015|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463214||19748|
NCT02469363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1191|Hemodynamic Responses of Different Laryngoscopes|Comparison of Different Laryngoscopes in Terms of Hemodynamic Responses||Istanbul University|No|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|4||Actual|170|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469363||19276|
NCT02472938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIIT0115|Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis|Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis|PROMPT|Biogen|No|Withdrawn|July 2015|July 2020|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||December 2015|December 23, 2015|May 11, 2015||No|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT02472938||19001|
NCT02461576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177B|Clinical Evaluation of the Xpert® HIV-1 VL|Clinical Evaluation of the Xpert® HIV-1 VL: A Method Comparison Study||Cepheid|No|Not yet recruiting|July 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|Leftover plasma specimens will be retained in a biobank.|Both|18 Years|N/A|No|Non-Probability Sample|Males and females >18 yours who are known HIV-1 infected and may be on treatment or        untreated with ARV therapy|June 2015|June 2, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461576||19874|
NCT02461589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4191|Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes|Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Active, not recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|13||Anticipated|706|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461589||19873|
NCT02465905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00641-42|Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study|Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study|Petit Lait|Association Poumon et Enfance|No|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|18 Years|No|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02465905||19542|
NCT02424890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sim-stress.1|Trial of Multidisciplinary Team Stress and Performance in Immersive Simulation for Management of Infant in Shock|||Poitiers University Hospital||Recruiting|August 2013|||September 2015|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|April 20, 2015|March 19, 2015||||No||https://clinicaltrials.gov/show/NCT02424890||22690|
NCT02473679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK2014 - 0665|Influence of the Education in Layperson in Out of Hospital Resuscitation|Influence of the Education in Layperson Resuscitation and Preparation the Patrol Car of the City Police With Automatic External Defibrillators and Automated Ventilation Equipment on Out of Hospital Resuscitation Outcome||University of Zurich|No|Recruiting|January 2003|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Out of hospital patients suffered or suffering cardiac arrest, who were or will be        resuscitated by laypersons, city police and/or trained emergency medical services teams        who were called to the emergency|December 2015|December 2, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02473679||18944|
NCT02473510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2560C00009|Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season|A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|FluMist|MedImmune LLC|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|301|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473510||18957|
NCT02478073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-ICU|Piperacillin Pharmacokinetics in ICU Patients|Piperacillin Pharmacokinetics in Intensive Care Unit Patients Following Standard Treatment With Intermittent and Continuous Infusion||University of Aarhus|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Critically ill patients with sepsis or septic shock, treated with piperacillin/tazobactam        in the Intensive Care Unit (ICU).|June 2015|June 17, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478073||18606|
NCT02416050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120125|Predicting Relapse After Cocaine Inpatient Cessation|Prospective Prediction of Cocaine Relapse After Inpatient Cessation by Combining Functional Imaging and Neuropsychological Biomarkers With Craving and Impulsivity Measures|QUIT-COC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|February 2015|July 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|cocaine dependent patient requiring inpatient cessation|April 2014|April 9, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416050||23369|
NCT02416284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERN4120_2012|Compliance to the Norwegian Food-Based Dietary Guidelines in Young Females|||University of Oslo||Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|14|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02416284||23351|
NCT02473614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44HD074331-02|To Determine the Therapeutic Effect of the Music Glove and Conventional Hand Exercises to Patients With Spinal Cord Injuries|||University of California, Irvine|No|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||March 2015|June 12, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473614||18949|
NCT02473627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E105|A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS|A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS||Daiichi Sankyo Inc.|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473627||18948|
NCT02466438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-4131|Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)|Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children|PIP-TAZO|St. Justine's Hospital|Yes|Not yet recruiting|July 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|141|||Both|2 Months|6 Years|No|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466438||19501|
NCT02417038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30189|Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery|Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery||Stanford University|No|Recruiting|April 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Women undergoing cesarean delivery with neuraxial anesthesia.|November 2015|November 10, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417038||23293|
NCT02476253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9260|Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill|Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)|(BICAR-ICU)|University Hospital, Montpellier|Yes|Recruiting|May 2015|January 2020|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02476253||18746|
NCT02477917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-PAR-DEPOT|A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica|A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica||BIAL Industrial Farmacéutica S.A.|No|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|60 Years|No|||June 2015|June 18, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02477917||18618|
NCT02477930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-263|Endosponge Vacuum Therapy (E-VAC) Registry of Intestinal Anastomotic Leaks and Perforations|Prospective Registry The Treatment Of Upper And Lower Intestinal Anastomotic Leaks And Perforations||Baylor Research Institute|Yes|Recruiting|November 2014|July 2025|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient's with upper and lower intestinal anastomotic leaks and perforations who are        referred for E-Vac therapy or are the primary patients of Dr. Leeds and Dr. Burdick will        be invited to participate in this registry.|June 2015|June 23, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02477930|6 Months|18617|
NCT02426489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMP-2|Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System|Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System|MRI-PEM|Weinberg Medical Physics LLC|No|Not yet recruiting|July 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|70|||Female|21 Years|N/A|No|||December 2015|December 7, 2015|April 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02426489||22567|
NCT02417285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-NHL-001|A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.|A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma||Celgene|No|Recruiting|May 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02417285||23274|
NCT02424110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xqxwk_07|Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial Fibrillation|Bipolar Radiofrequency Ablation Plus Endocardial Ablation Using Argon Beam Coagulator for Atrial Fibrillation Treatment in Patients With Rheumatic Heart Disease||Xinqiao Hospital of Chongqing|No|Recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02424110||22750|
NCT02471404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1689C00014|Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea|A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Monotherapy||AstraZeneca|No|Active, not recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|930|||Both|18 Years|74 Years|No|||March 2016|March 9, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471404||19119|
NCT02474628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sodium bicarbonate consistency|Consistencies in Responses to Sodium Bicarbonate?|Consistencies in Responses to Sodium Bicarbonate Supplementation: a Randomised, Repeated Measures, Counterbalanced and Double-blind Study||University of Sao Paulo|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02474628||18871|
NCT02474641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-2013-05, ZKS-121-001|Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer|Adjuvant Radiotherapy After Breast-conserving Surgery in Early Breast Cancer: Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation|HYPOSIB|University of Schleswig-Holstein|No|Recruiting|June 2015|June 2023|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2324|||Female|18 Years|N/A|No|||July 2015|July 14, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02474641||18870|
NCT02413359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BR00033|High Risk Popurations Among COPD Patients in Japan|Research Study in Patients With COPD in High Risk Population in Japan: Proportion of Overlap Between COPD and Asthma, and the Relationship With COPD Exacerbation||AstraZeneca|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1016|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of COPD|August 2015|August 17, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413359||23576|
NCT02469311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LifeBridgeH|Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths.|Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths in Reducing Surgical Site Infections for Total Hip and Knee Arthroplasty.|SAGE|LifeBridge Health|No|Terminated|March 2012|October 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|539|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 9, 2015|Yes|Yes|Preliminary results showed that the use of the cloths helped prevent infections.|No||https://clinicaltrials.gov/show/NCT02469311||19280|
NCT02477956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Highly dose of vitamin D3|Effect of a Monthly High Dose of Vitamin D3 on Bariatric Surgery Patients|Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects||Texas Tech University|Yes|Completed|November 2012|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|60 Years|No|||June 2015|June 22, 2015|May 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02477956||18615|
NCT02246556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14212|Dichoptic Virtual Reality Therapy for Amblyopia in Adults|Dichoptic Virtual Reality Therapy for Amblyopia in Adults||University of California, San Francisco|No|Recruiting|October 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|15 Years|40 Years|No|||December 2015|December 1, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02246556||36372|
NCT02315560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14080250|Foot Neuromodulation for Nocturnal Enuresis|Foot Neuromodulation for Nocturnal Enuresis in Children||Children's Hospital of Pittsburgh|No|Enrolling by invitation|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|5 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Children who wet the bed|December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315560||31075|
NCT02316821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-005|RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)|RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)||Kyowa Hakko Kirin Company, Limited|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|20 Years|79 Years|No|||February 2016|February 22, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02316821||30978|
NCT02250859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMX101-1|A Pharmacokinetic Study of Minocycline in Male and Female Volunteers|An Open-label, Multiple Dose Study to Assess the Pharmacokinetic Profile of Minocycline From FMX-101 Foam (4%) in Male and Female Volunteers||Foamix Ltd.|No|Completed|September 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|August 25, 2015|September 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02250859||36041|
NCT02250963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNUH-PANDA-01|Prognostic Accuracy of Coronary CT and Dobutamine Stress Echocardiography in Patient Undergoing Non-cardiac Surgery|||Gyeongsang National University Hospital|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|317|||Both|20 Years|N/A|No|Probability Sample|non-cardiac surgery patients|September 2014|September 24, 2014|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02250963||36033|
NCT02246114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000370|Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women|Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women||Milton S. Hershey Medical Center|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02246114||36406|
NCT02321085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0811|The Comparison With Clinical Impacts on Functional Capacity and Symptom Improvement According to the Rhythm Control in Patients With Heart Failure and Recent Onset Atrial Fibrillation|||Yonsei University|Yes|Recruiting|November 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|N/A|No|||November 2014|December 19, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02321085||30651|
NCT02321306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM001-202|An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis|An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis|CASCADE|Shire|No|Withdrawn|May 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|December 12, 2014|Yes|Yes|The study stopped early, before enrolling its first participant.|No||https://clinicaltrials.gov/show/NCT02321306||30634|
NCT02317523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMausbach|Alzheimer's Caregiver Coping: Mental and Physical Health|Alzheimer's Caregiver Coping: Mental and Physical Health||University of California, San Diego|No|Recruiting|September 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|55 Years|N/A|No|||December 2015|December 1, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317523||30924|
NCT02247375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543.14|Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)|A Double-blind, Randomized, Three Parallel Group Placebo-controlled Study to Investigate Pharmacokinetics, Effect on Expression of CD11b/CD18 (Mac-1), as Well as Safety and Efficacy of Two Oral Doses of BIIL 284 BS (Dosage: 25 mg Daily, 150 mg Daily) in Patients With Rheumatoid Arthritis Over Two Weeks||Boehringer Ingelheim||Completed|January 2000|||May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|65 Years|No|||September 2014|September 23, 2014|September 19, 2014||||No||https://clinicaltrials.gov/show/NCT02247375||36309|
NCT02250989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ateroloab-1|The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction|Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Ischemia/Reperfusion Lesion on Patients in Acute Phase of ST Segment Elevation Myocardial Infarction (STEMI)|INGLIVEF|University of Campinas, Brazil|Yes|Recruiting|July 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|75|Samples Without DNA|Plasma, whole blood.|Both|40 Years|70 Years|No|Non-Probability Sample|Consecutive patients with ST segment elevation myocardial infarction (STEMI) attended at        Clinics Hospital of Campinas|September 2014|September 24, 2014|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02250989||36031|
NCT02242994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003767|Data Acquisition Study for a Communication Device for Pediatric Patients With Cerebral Palsy|||Children's Research Institute||Recruiting|March 2014|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|7 Years|21 Years|No|||January 2016|January 15, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02242994||36646|
NCT02243007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-218|Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer|Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer||Massachusetts General Hospital|Yes|Recruiting|September 2014|March 2022|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243007||36645|
NCT02243020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-St-02|VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke|Study MT-St-02 - Stroke - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (MicroTransponder's Vivistim System)||MicroTransponder Inc.|No|Recruiting|October 2014|December 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|80 Years|No|||December 2015|December 2, 2015|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243020||36644|
NCT02316067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS - 70254|Traumatic Spinal Cord Injury: Effects of Corporal Suspension and Pendulum Exercises|Effect of Corporal Suspension and Pendulum Exercises on Torque, Muscle Activation, Muscle Thickness and Functionality in Patients With Traumatic Spinal Cord Injury||Federal University of Rio Grande do Sul|Yes|Completed|May 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|65 Years|No|||December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316067||31036|
NCT02321319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV02520124|Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients|An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain||Mallinckrodt|No|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|17 Years|No|||October 2015|October 21, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321319||30633|
NCT02326584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN33A-002|A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML|A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia||Seattle Genetics, Inc.|No|Recruiting|December 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326584||30228|
NCT02244125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2013-05|A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial|A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial|PCD|Institut Curie|Yes|Recruiting|April 2014|||August 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||September 2014|September 16, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02244125||36559|
NCT02315534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-251|A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma|A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma||Boston Biomedical, Inc|No|Recruiting|March 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315534||31077|
NCT02313272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17978|Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas|A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313272||31250|
NCT02313285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS14120|A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668|An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668||Sanofi|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|66 Years|No|Non-Probability Sample|Patients who received study drug in the clinical study TDU13475|March 2016|March 3, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02313285||31249|
NCT02250651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-092|Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Recruiting|December 2014|July 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250651||36057|
NCT02250664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA036114:P2S2|Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers|Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers|P2S2|University of Vermont|Yes|Not yet recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|405|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|September 23, 2014|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250664||36056|
NCT02241174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SodiumHypochloriteAD|0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis|Efficacy of 0.005% Sodium Hypochlorite Final Rinse Solution on the Reduction of Staphylococcus Aureus Colonization in Atopic Dermatitis: A Randomized Controlled Trial||Makati Medical Center|No|Withdrawn|July 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 12, 2014||No|study materials have expired, no patients were enrolled|No||https://clinicaltrials.gov/show/NCT02241174||36786|
NCT02241187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-039|Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection|Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection||Memorial Sloan Kettering Cancer Center||Recruiting|September 2014|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02241187||36785|
NCT02241200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3880_ANE_I|A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)|A Randomized, 2 Part, 4-treatment, 2-way Cross-over Study in Healthy Volunteers to Compare the Pharmacokinetic and Pharmacodynamic Profiles of 1ug/kg of DA-3880 and EU Sourced ARANESP® (Amgen) After Single Intravenous or Subcutaneous Administration||Dong-A ST Co., Ltd.|No|Recruiting|July 2014|||October 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02241200||36784|
NCT02245217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI74163|Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients|Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients||University of Utah|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245217||36475|
NCT02315807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroCog001|Neurostimulation for Cognitive Rehabilitation in Stroke|Neurostimulation for Cognitive Enhancement After Stroke (NeuroCog)|NeuroCog|Federal University of Paraíba||Recruiting|December 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||December 2015|December 4, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315807||31056|
NCT02323490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|men_micro|Augmentation of Meniscal Repair With Marrow Stimulation Techniques (Microfractures)|Augmentation of Meniscal Repair With Bone Marrow Stimulation Techniques (Microfractures): a Double Blind, Prospective, Randomized Clinical Trial of Efficacy and Safety.|men_micro|Medical Centre of Postgraduate Education, Poland|No|Recruiting|July 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||December 2014|December 22, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02323490||30466|
NCT02324413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-2011-3668|Pilot Study: Intraoperative Clonidine and Postoperative Behaviour|Randomised Controlled Pilot Study: Does Intraoperative Clonidine Reduce the Incidence of Post-hospitalisation Negative Behaviour Changes in Children Who Are Distressed During the Induction of General Anaesthesia?||University Hospitals Bristol NHS Foundation Trust|Yes|Completed|October 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|2 Years|10 Years|No|||December 2014|December 23, 2014|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02324413||30395|
NCT02252900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120901|Long-term Clinico-radiological Evolution of Patients With Brain Lesions During Infectious Endocarditis|Long-term Clinico-radiological Evolution of Patients With Symptomatic and Asymptomatic Brain Lesions During Infectious Endocarditis|POST-IMAGE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|December 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02252900||35884|
NCT02476734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12914|FDG-PET/CT Imaging as Early Predictor of DP|A Pilot Study Using FDG-PET/CT Imaging as an Early Predictor of Disease Response in Lymphoma Subjects Receiving Redirected Autologous CART- 19 T-cell Immunotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|August 2014|||February 2016|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476734||18709|
NCT02411708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGSC-005|Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis|A Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-occlusive Crises in the Infusion Clinic Setting: A Placebo-Controlled, Single-Dose, Double-Blind Study in Adult Sickle Cell Disease Patients||Prolong Pharmaceuticals|Yes|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411708||23703|
NCT02414113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312100|Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated Hematopoietic Stem Cell Transplant|A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated Hematopoietic Stem Cell Transplant||Washington University School of Medicine|No|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|-At the time of HLA confirmatory typing, 24 mL of whole blood will be collected from all      potential donors who agree to participate.|Both|18 Years|70 Years|No|Non-Probability Sample|Matched unrelated hematopoietic stem cell transplant recipients|October 2015|October 22, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414113||23518|
NCT02471183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065A304|Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension|Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension|TRANSIT-1|Actelion|No|Recruiting|July 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471183||19136|
NCT02471196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098012|Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease|Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks|Nebula|Orion Corporation, Orion Pharma|Yes|Recruiting|June 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|55 Years|90 Years|No|||January 2016|January 11, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02471196||19135|
NCT02473575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBSREC1314/39|Does a Caffeine Gum Improve 5 km Run Performance in a Competition/Field Setting?|Does a Commercial Caffeine Supplement Improve 5 km Run Performance in a Field Setting?||Sheffield Hallam University|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473575||18952|
NCT02475421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-066|Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance|Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance|MCR Glucagon|University Hospital, Gentofte, Copenhagen|Yes|Recruiting|May 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02475421||18810|
NCT02424266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-0166-13|Three Dimension Tomography of Eye Structures by White Light Imaging Device|Three Dimension Tomography of Eye Structures by White Light Imaging Device|3D-WLT|Meir Medical Center|No|Not yet recruiting|April 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 healthy subject with no ocular disease 40 subjects with moderate to severe        keratoconjunctivitis sicca or dry eye syndrome|April 2015|April 22, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02424266|4 Weeks|22738|
NCT02426892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1047|Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors|Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors||M.D. Anderson Cancer Center|No|Recruiting|December 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426892||22536|
NCT02426697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB14.03|Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy|Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis|PARABONE|Centre Henri Becquerel|No|Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|June 10, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426697||22551|
NCT02477072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.077|Optimized Heparin Regimen in Vascular Surgery|A Pilot Study on the Influence of an Optimized Heparin Regimen on the Hemostatic Environment Downstream From the Surgical Clamp in Major Vascular Surgery.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|90 Years|No|||January 2016|January 11, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02477072||18683|
NCT02467751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/10|Women With Polycystic Ovary Syndrome (PCOS)|Metabolic Profile in Women of Different Body Composition With Polycystic Ovary Syndrome|PCOS|Irmandade da Santa Casa de Misericordia de Sao Paulo|Yes|Recruiting|January 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|90|||Female|12 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Will be performed case-control study with women with Polycystic Ovary Syndrome, according        to the Rotterdam criteria and body mass index between 18 to 29.9. The control group will        consist of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9        and no other comorbidities.|March 2016|March 1, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02467751||19400|
NCT02419066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1113634|Examining HIV Treatment Adherence During Early Disease|Examining HIV Treatment Adherence During Early Disease|META|Massachusetts General Hospital|No|Recruiting|February 2015|December 2018|Anticipated|February 2018|Anticipated|Phase 0|Observational|Observational Model: Cohort||3|Anticipated|1062|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be HIV-infected adults initiating antiretroviral therapy at        recruitment sites in southwestern Uganda (Mbarara, Kabwohe) and Cape Town (Gugulethu)        South Africa. They will have either early (CD4 >350) or late (CD4 <200) HIV infection.|March 2016|March 21, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02419066||23137|
NCT02466828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-2014|qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.|Quantitative Blood Oxygenation Level Dependent (qBOLD) MR Imaging of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.||Sunnybrook Health Sciences Centre|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|27|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02466828||19471|
NCT02468258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-khalid 2|Multi-factorial Analysis of the Follicular Fluid Milieu to Explore the Discrepant Effect of Follicular Fluid Endometrial Flushing on Outcome of Assisted Reproduction Trial|Multi-factorial Analysis of the Follicular Fluid Milieu to Explore the Discrepant Effect of Follicular Fluid Endometrial Flushing on Outcome of Assisted Reproduction Trial||Benha University|Yes|Recruiting|January 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Female|19 Years|37 Years|No|||January 2016|January 27, 2016|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02468258||19361|
NCT02468011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-10|Whole Body Vibration Induced Muscle Activity and Effect of the Changes in Length of Soleus Muscle and Angle of Ankle|Whole Body Vibration Induced Muscle Activity in Different Position of Lower Extremity: Effect of the Changes in Length of Soleus Muscle and Angle of Ankle|WBVIMR-SL|Bagcilar Training and Research Hospital|No|Completed|June 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 25, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02468011||19380|
NCT02468024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 022015-069|JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer|JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial|STABLE-MATES|University of Texas Southwestern Medical Center|Yes|Recruiting|July 2015|December 2021|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|N/A|No|||August 2015|September 12, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468024||19379|
NCT02419040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KALK-001|Treatment of Calcific Tendinitis of the Rotator Cuff|Treatment of Calcific Tendinitis of the Rotator Cuff - a Multi-centre, Randomized and Sham Controlled Trial (KALK Study)||Martina Hansen's Hospital|No|Recruiting|April 2015|July 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|30 Years|100 Years|No|||December 2015|December 18, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02419040||23139|
NCT02419053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046196|Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children|Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children||The Hospital for Sick Children|No|Completed|October 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|28772|||Both|N/A|17 Years|No|Non-Probability Sample|Surgical interventions performed in Ontario for children|April 2015|April 13, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02419053||23138|
NCT02470910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-585|Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning|Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning: A Pilot Study to Quantitate the Potential to Limit Radiation Dose to Normal Tissues.||Dana-Farber Cancer Institute|Yes|Recruiting|July 2015|March 2020|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Male|18 Years|N/A|No|||January 2016|January 22, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470910||19157|
NCT02467933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPAL-LETTERS-SEROQUEL|The Effect of Informative Letters on the Prescription and Receipt of Seroquel|The Effect of Informative Letters on the Prescription and Receipt of Seroquel||Abdul Latif Jameel Poverty Action Lab|No|Active, not recruiting|April 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5055|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467933||19386|
NCT02467946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/24|Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient|A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris® and Levact® in Old Patients|HALO|Centre Antoine Lacassagne|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|60 Years|80 Years|No|||February 2016|February 2, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467946||19385|
NCT02468232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B1301|Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction||Novartis|Yes|Recruiting|June 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|N/A|No|||January 2016|January 5, 2016|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468232||19363|
NCT02472288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015008|Electroacupuncture on Post-stroke Urinary Retention|Multicenter, Randomised Controlled Trial of Electroacupuncture Versus Sham Electroacupuncture for Urinary Retention of Poststroke Patients: a Study Protocol||Kyunghee University|No|Recruiting|April 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|19 Years|N/A|No|||June 2015|June 18, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472288||19051|
NCT02472496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-2013-B0001-00245|Korean Coronary Overlapping Stenting Registy|Korean Coronary Overlapping Stenting Registy||The Catholic University of Korea|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients with coronary lesion treated with overlapping drug-eluting stents|June 2015|June 11, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472496||19035|
NCT02424734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00009|Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis|Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants With Late-Onset Sepsis||AstraZeneca|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|59 Days|No|||March 2016|March 7, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424734||22702|
NCT02424786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-068|Non-adherence and Polypharmacy in Elderly Patients|Non-adherence and Polypharmacy in Elderly Patients With Chronic Renal Failure: Predictors and an Intervention||University Hospital, Akershus|No|Enrolling by invitation|May 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||January 2016|January 20, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02424786||22698|
NCT02470936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13555|Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8|A Randomized Clinical Trial of Web-based Lifestyle Tools and Resources Versus Usual Care Among Men With Prostate Cancer|Prostate 8|University of California, San Francisco|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|76|||Male|18 Years|N/A|No|||June 2015|June 11, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470936||19155|
NCT02464033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDCR IIa|EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes|Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes||Linkoeping University|Yes|Recruiting|May 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|18 Years|No|||March 2016|March 2, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02464033||19686|
NCT02464046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107585|Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity|A Randomized, Placebo-controlled, 2-way Crossover, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder Without Psychiatric Comorbidity||Janssen Research & Development, LLC|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464046||19685|
NCT02476409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0472|Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders|Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER)|TROUPER|University of North Carolina, Chapel Hill|No|Not yet recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02476409||18734|
NCT02423746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012142740-CTSAPilot-Bush|Assessing and Addressing Behaviors in Children With Hearing Loss|Assessing and Addressing Behaviors in Children With Hearing Loss||University of Kentucky|No|Enrolling by invitation|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02423746||22778|
NCT02423759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANS-2015-03|A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy|A Randomized Controlled Trial Comparing Rectal Swab Culture Based Chemoprophylaxis Versus Combined Single-Shot Gentamycin and Ciprofloxacin Versus Ciprofloxacin Alone for Peri-procedure Chemoprophylaxis During Transrectal Prostate Biopsy.||Mansoura University|Yes|Recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|846|||Male|N/A|N/A|No|||November 2015|November 8, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423759||22777|
NCT02423772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT008398-01|Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse|Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse||University of New Mexico|Yes|Recruiting|August 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|65 Years|No|||March 2015|April 17, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02423772||22776|
NCT02471248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.037-T (Ankle)|Interactive Exoskeleton Robot for Walking - Ankle Joint|Interactive Exoskeleton Robot for Walking - Ankle Joint||Chinese University of Hong Kong|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02471248||19131|
NCT02473419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0399|Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment|Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment|VAYA-fMRI|Icahn School of Medicine at Mount Sinai|No|Enrolling by invitation|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|60 Years|No|Non-Probability Sample|Participants will be subjects participating in a Vayarin clinical trial being conducted at        NYU and The Medical Research Network in NYC.|March 2016|March 9, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473419||18964|
NCT02470546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EME-2015|Metformin Experience on Minimal Hepatic Encephalopathy|Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis|EME|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2015|June 9, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02470546||19185|
NCT02470559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-129|Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent|Treatment of High Risk or Recurrent Ovarian Cancer With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells (BATs), Low Dose IL-2, and GM-CSF (Phase I).||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|June 10, 2015|Yes|Yes|Study did not accrue any participants, the PI has left the institution.|No||https://clinicaltrials.gov/show/NCT02470559||19184|
NCT02416544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1403-244-005|The Effectiveness of Low Calorie Low Salt Lunch for Weight Reduction of Workers of a Health Promoting Hospital||HPH|Seoul National University Hospital|No|Completed|April 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|109|||Both|N/A|N/A|No|||April 2015|April 14, 2015|April 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02416544||23331|
NCT02464241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0340|Evaluation of Different Color Vision Tests in Children|Color Vision Tests in Children: Comparison of Standardized and Computer-assisted Examination||University of Zurich|No|Recruiting|January 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|4 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|80 children (girls and boys) at the age of 3-10 years without (40 children) or with (40        children) an ocular disease such as maculopathy, opticopathy or amblyopia will be        included. Probands and patients are recruited from consultations at the eye clinic of the        University hospital of Zürich. The ophthalmologic care is provided independently of the        patient's decision whether to participate in the study or not. This decision is the own        free will of the patient and his or her parents.|December 2015|December 9, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02464241||19670|
NCT02468180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRTO-NBCA-PP|Primary Prophylaxis of Gastric Variceal Bleed|Primary Prophylaxis of Gastric Variceal Bleed: Endoscopic Cyanoacrylate Injection Versus Balloon-occluded Retrograde Transvenous Obliteration||West China Hospital||Recruiting|June 2015|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468180||19367|
NCT02461979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liver cancer|The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis|The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis in Cirrhotic Patients Infected With Chronic Hepatitis C Virus||Tanta University|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02461979||19843|
NCT02461823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078 -15-RMB CTIL|The Influence of Porcelain Fused to Metal ( PFM) and Zirconia Crowns on Periodontal Health|The Influence of Porcelain Fused to Metal ( PFM) and Zirconia Crowns on Periodontal Health||Rambam Health Care Campus|No|Not yet recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 31, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02461823||19855|
NCT02421978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080062|Inflammation-Induced CNS Glutamate During Breast Cancer Treatment|Inflammation-Induced CNS Glutamate During Breast Cancer Treatment||Emory University|No|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|Cytokine Multiplex, CRP, TRP, KYN, mRNA analysis, methylation analysis, and gene analysis|Female|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female breast cancer patients who are chemotherapy treated and non chemotherapy-treated        and medically healthy women without breast cancer in the control group|November 2015|November 14, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02421978||22914|
NCT02471326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150140|VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption|An Exploratory, Open-Label Study of VRC-HIVMAB060-00-AB (VRC01) in Subjects With Chronic HIV Infection Undergoing Analytical Treatment Interruption||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|No|||May 2015|July 8, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471326||19125|
NCT02471339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150142|Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain|Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|16 Years|34 Years|No|||May 2015|December 1, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471339||19124|
NCT02462213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-3043|Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging|The Influence of Amyloid Protein on Myocardial Tissue Characteristics and Function: Prognostic and Diagnostic Significance of Cardiac Magnetic Resonance Findings|PICA-CMR|University of Cincinnati|Yes|Active, not recruiting|October 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with amyloidosis will be recruited from the hematology clinic from participating        institutions. Patients with confirmed cardiac amyloidosis will be recruited from either        the cardiology or hematology clinics of participating institutions.|June 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02462213||19825|
NCT02466347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPE14014M1|Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block|A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers Without Charcoal Block||Intech Biopharm Ltd.|Yes|Completed|June 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466347||19508|
NCT02471937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01824-43|Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection|Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection|STREPB17|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02471937||19078|
NCT02424032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 13/381|Stabilization Exercises With and Without Connective Tissue Massage for Chronic Mechanical Neck Pain|||Ataturk Training and Research Hospital||Recruiting|February 2013|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|65 Years|No|||April 2015|April 18, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02424032||22756|
NCT02464709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q282dnro3/2015|Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)|Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)||Joint Authority for Päijät-Häme Social and Health Care|No|Recruiting|June 2015|December 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02464709||19634|
NCT02464722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED15010|Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil on Anesthesia in Endoscopic Sinus Surgery|Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil for Epinephrine Local Injection in Patient With Endoscopic Sinus Surgery Under General Anesthesia||Korea University Anam Hospital|Yes|Enrolling by invitation|August 2015|September 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464722||19633|
NCT02463799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1522|Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC|A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer||Johns Hopkins University|Yes|Recruiting|December 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463799||19704|
NCT02423733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014001|Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial|Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial||University of Ottawa|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|110|||Both|18 Years|64 Years|No|||December 2015|December 11, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02423733||22779|
NCT02424149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0008|Phenazopyridine for Confirmation of Ureteral Patency|Use of Phenazopyridine for Confirmation of Ureteral Patency During Intraoperative Cystoscopy|Phenazo|Hartford Hospital|Yes|Completed|April 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|104|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02424149||22747|
NCT02464683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INERC50-13|Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis|Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases|VitaminD|Instituto Nacional de Enfermedades Respiratorias|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2015|June 3, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02464683||19636|
NCT02464696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0165|Early Non Invasive Ventilation and Hematological Malignancies|Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial||M.D. Anderson Cancer Center|Yes|Recruiting|October 2015|||October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|366|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464696||19635|
NCT02477943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-Ahead|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization|AheadCAS|BrainScope Company, Inc.|No|Recruiting|August 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Both|18 Years|30 Years|No|Non-Probability Sample|Approximately 450 male and female student-athletes from participating universities or        colleges will be invited to participate.|August 2015|September 18, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477943||18616|
NCT02418780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002343|Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease|Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease||Harvard University Faculty of Medicine|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|40 Years|75 Years|No|||January 2016|January 6, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418780||23159|
NCT02424162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0837|Comparative Study of Two Multifocal Intraocular Lens With Different Add Power|||Yonsei University|No|Recruiting|November 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02424162||22746|
NCT02472392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0167|Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma|A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings|Ewing/Allo|University of Louisville|No|Recruiting|April 2013|December 2020|Anticipated|April 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|30 Years|No|||June 2015|June 12, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02472392||19043|
NCT02464306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2257|Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection|Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection||University of Colorado, Denver||Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|85 Years|No|||December 2015|December 4, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464306||19665|
NCT02250794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14042807|Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit|Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit||Rush University Medical Center|No|Not yet recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2014|September 23, 2014|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02250794||36046|
NCT02245867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM5108|Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis|Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis||Columbia University|Yes|Recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|21 Years|N/A|No|||January 2016|January 15, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02245867||36425|
NCT02250417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0235|Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea|Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea.||Ohio State University|No|Completed|August 2014|August 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02250417||36075|
NCT02320708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-140128120904-PACT|Study of Acetaminophen (ACE) in Post-operative Dental Pain|A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Proof of Concept Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|240|||Both|17 Years|50 Years|No|||March 2016|March 21, 2016|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02320708||30680|
NCT02320721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13799|Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications|A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin|SENIOR|Sanofi|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|920|||Both|65 Years|N/A|No|||March 2016|March 15, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320721||30679|
NCT02324088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGASE 7/0002|Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer|PHASE III TRIAL ASSESSING THE INTEREST OF A MAINTENANCE CHEMOTHERAPY COMBINING DOCETAXEL (TAXOTERE) 5-FU AFTER INDUCTION TREATMENT BY AINTENSIVE CHEMOTHERAPY FOR INFLAMMATORY BREAST CANCERS|PEGASE07|UNICANCER|Yes|Completed|October 2000|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Female|18 Years|60 Years|No|||December 2014|December 23, 2014|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02324088||30420|
NCT02242006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140429|Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)|Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)||Ottawa Hospital Research Institute||Not yet recruiting|October 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|critically ill adults admitted to an ICU|September 2014|September 15, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02242006||36722|
NCT02251223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.6|Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects|An Open Label Multinational Study of the Effects of Three Dose Pairs of Tipranavir/Ritonavir (b.i.d.) on the Pharmacokinetic Characteristics of Protocol -Defined, Baseline, Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects.||Boehringer Ingelheim||Completed|February 2001|||February 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|3||Actual|208|||Both|18 Years|75 Years|No|||September 2014|September 25, 2014|September 25, 2014||||No||https://clinicaltrials.gov/show/NCT02251223||36013|
NCT02251340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrensH|Randomized Controlled Trial of an Eczema Care Plan|||Children's Hospital Boston|No|Not yet recruiting|December 2014|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02251340||36004|
NCT02323555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMA|Optimize the Requirements and Preparations in Outpatient Chemotherapy|Optimize the Requirements and Preparations in Outpatient Chemotherapy||Centre Francois Baclesse|No|Suspended|March 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|900|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 1, 2014||No|Interim analysis|No||https://clinicaltrials.gov/show/NCT02323555||30461|
NCT02325921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49616.091.14|MRI in Renal Tumors|Advanced MRI in Renal Tumors.||Radboud University|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients >18 years of age scheduled for undergoing (partial) tumor nephrectomy.|November 2015|November 9, 2015|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325921|1 Week|30279|
NCT02325934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN AKF 14.03|Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet|Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet|CRUSTRI|Radboud University|No|Completed|February 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02325934||30278|
NCT02253628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340302|The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.|The Acute Effect of Coffee Consumption on Salivary Gastrin, Alpha-amylase and Cortisol Concentrations, on Self-reported Gastrointestinal Symptoms, on Self-reported Psychometric Assessments and on Blood Pressure.||Agricultural University of Athens|No|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|40|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02253628||35828|
NCT02325427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS2014/00358|Changes in Brain Activity Associated With Upper Limb Motor Recovery|Changes in Cortical Excitability Associated With Upper Limb Motor Recovery - a Study of Neural Strategies Employed in Motor Recovery||National University Hospital, Singapore|Yes|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|119|||Both|21 Years|80 Years|No|||July 2015|July 22, 2015|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325427||30317|
NCT02321332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM2010344|Unilateral Sequential Sympathectomy for Palmar Hyperhidrosis|Unilateral Sequential Versus Bilateral Simultaneous Sympathectomy for Palmar Hyperhidrosis: a Study of 407 Cases.|ETS|Mansoura University||Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|8 Years|50 Years|No|||December 2014|December 16, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321332||30632|
NCT02314442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-PCSSC-001|A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)|A Phase 1, Randomized, Single Blind, Placebo Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN PCSSC in Subjects With Elevated Low Density Lipoprotein Cholesterol||Alnylam Pharmaceuticals|No|Completed|December 2014|November 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02314442||31161|
NCT02314663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAPALBACETE|Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia|Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia: a Randomised Clinical Trial|EFESCOM|Gerencia de Atención Primaria, Albacete|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|358|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02314663||31144|
NCT02249377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00457|PRP vs Corticosteroid in Baker's Cyst|Clinical Outcomes of Platelet Rich Plasma Injection Versus Corticosteroid Injection for Baker's Cyst||New York University School of Medicine|No|Recruiting|February 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|100 Years|No|||October 2015|October 5, 2015|September 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249377||36155|
NCT02320448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPAC|Treating Peritoneal Carcinomatosis With PIPAC|Implementation and Evaluation of PIPAC for the Treatment of Patients With Peritoneal Carcinomatosis - a Feasibility Study.||Odense University Hospital|Yes|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 28, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02320448||30700|
NCT02324907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055335|The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis|The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis||Duke University|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients will be identified in the clinic by an attending orthopaedic foot and ankle        surgeon or his physician assistant based on clinical exam and radiographic findings.        Inclusion criteria include anyone over age 18 who has ankle and subtalar arthritis and has        failed nonoperative management. Typically, these patients have multiple medical        comorbidities and therefore the only exclusion criteria will be patients who are not        healthy enough to undergo surgery. Patients of all racial, religious, and cultural        backgrounds will be included in this study. Approximately 30 patients will be recruited        for the study.|December 2015|December 14, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02324907||30357|
NCT02318316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC01|"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and the Value in Follow-up|"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and Value in Follow-up||Gazi University|No|Not yet recruiting|December 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|75 Years|No|Non-Probability Sample|allogeneic stem cell transplantation patients for hematologic malignancies and some benign        hematological diseases|December 2014|December 16, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02318316||30863|
NCT02252874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-ZK 93|Can Entertaining Action-video Games Enhance Dynamic Visual Function and Improve Balance? A Randomized Controlled Trial.|Can Entertaining Action-video Games Enhance Dynamic Visual Functions and Improve Balance? A Randomized Controlled Trial.||The Hong Kong Polytechnic University|No|Recruiting|September 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|198|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02252874||35886|
NCT02245529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.64|Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia|Secotex ®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)||Boehringer Ingelheim||Completed|March 2005|||September 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|982|||Male|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH) who require        medical treatment to improve their quality of life|September 2014|September 18, 2014|September 18, 2014||||No||https://clinicaltrials.gov/show/NCT02245529||36451|
NCT02249416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.37|Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers|A Single Center, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effect of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Zidovudine 300 mg in Healthy Volunteers||Boehringer Ingelheim||Completed|November 2001|||February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 23, 2014||||No||https://clinicaltrials.gov/show/NCT02249416||36152|
NCT02320656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMATO-BIO-IPC-2013-015|Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015|Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015|HEMATO-BIO|Institut Paoli-Calmettes|No|Recruiting|May 2014|May 2022|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02320656||30684|
NCT02320669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14798|Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass|Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass|TRICC-2|Seattle Children's Hospital|Yes|Recruiting|November 2014|October 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|N/A|5 Months|No|||December 2015|December 11, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320669||30683|
NCT02324426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48273-A|CNS Uptake of Intranasal Glutathione|Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease||University of Washington|No|Completed|December 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|April 29, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324426||30394|
NCT02313792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMTC-supp002|Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation|Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial||The Catholic University of Korea|No|Not yet recruiting|January 2015|June 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|88|||Both|16 Years|N/A|No|||December 2014|December 8, 2014|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313792||31210|
NCT02242565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHI360576424|Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia|Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia||FHI 360|No|Completed|October 2014|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|500|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|September 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02242565||36679|
NCT02242877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.510|TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older|Observational Study in Everyday Medical Practice of the Effectiveness of Telmisartan for Treatment of Isolated Systolic Hypertension in Comparison With Systolic/Diastolic Hypertension in Patients Aged 55 or Older|TELSYS|Boehringer Ingelheim||Completed|February 2006|||October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3320|||Both|55 Years|N/A|No|Non-Probability Sample|Patients aged 55 years or older with either isolated systolic- or with systolic and        diastolic hyptertension|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242877||36655|
NCT02415543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJi Hospital|SIL-TEP vs TEP for Inguinal Hernia Repair in Day Surgery|A Prospective, Randomized, Controlled Trial of Comparing Single Incisional Laparoscopic Total Extraperitoneal(SIL-TEP) Inguinal Hernia Repair With Traditional Laparoscopic Total Extraperitoneal(TEP) Inguinal Hernia Repair in Day Surgery||RenJi Hospital|Yes|Not yet recruiting|July 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|February 14, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415543||23408|
NCT02415777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_UDCA003|Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction|||Daewoong Pharmaceutical Co. LTD.||Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|19 Years|N/A|No|||January 2016|January 21, 2016|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02415777||23390|
NCT02418858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 14BN146|Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor|Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor||St. Joseph's Hospital and Medical Center, Phoenix|No|Withdrawn|February 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|March 24, 2015|No|Yes|Lack of subject enrollment|No||https://clinicaltrials.gov/show/NCT02418858||23153|
NCT02418871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIOL-2015-1|Evaluation of the FluidVisionTM AIOL With an Improved Injector|Clinical Evaluation of the FluidVisionTM Accommodating Intraocular Lens With an Improved Injector System||PowerVision|No|Active, not recruiting|April 2015|October 2018|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|50 Years|N/A|No|||September 2015|September 14, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418871||23152|
NCT02473588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18022|Long Time Interval Analysis for Non Invasive Measurement of Cardiac Output|Comparison of Retia Medical (Long Time Interval Analysis) to Deltex Esophageal Doppler for Cardiac Output Measurement||University of Virginia|No|Recruiting|June 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02473588||18951|
NCT02466646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-C-DRP-280214-0043|Evaluation of Efficacy of Full-mouth Disinfection in Generalized Aggressive Periodontitis Patients|Evaluation of Gingival Crevicular Fluid Interleukin-1β and Interleukin-17 Levels After Full-Mouth Disinfection Initial Periodontal Treatment in Generalized Aggressive Periodontitis Patients||Marmara University|No|Completed|December 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|June 4, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02466646||19485|
NCT02414581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ci-HRAEB-2015-004|Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%|Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% to Reduce the Rate Oral Colonization by Gram-negative Bacteria in Patients With Chemotherapy||Hospital Regional de Alta Especialidad del Bajio|Yes|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|November 1, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02414581||23482|
NCT02427048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0400|Clinical Practice Guidelines and Impact of Audit and Feedback in the Emergency Department|Adherence to Clinical Practice Guidelines and the Impact of Audit and Feedback in the Emergency Department||Denver Health and Hospital Authority|No|Enrolling by invitation|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|24|||Both|30 Years|70 Years|No|||June 2015|June 22, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02427048||22524|
NCT02463292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLYACHD|Quality of Life in Young Adults With Congenital Heart Disease|Quality of Life, Psychological Adjustment and Academic Achievement in Young Adults With Congenital Heart Disease||University Children's Hospital, Zurich|No|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|350|||Both|18 Years|30 Years|No|Non-Probability Sample|Yound adult patients with congenital heart disease|December 2015|December 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02463292||19743|
NCT02473926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1080|Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes|Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes||University of Colorado, Denver|No|Not yet recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|50 Years|85 Years|No|||December 2015|December 15, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02473926||18925|
NCT02473939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR942/1/001|An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma|A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics||Vectura Limited|No|Recruiting|June 2015|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|93|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473939||18924|
NCT02424591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00599|A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion|A Prospective, Randomized, Single Blinded Comparison of Intraoperative Ketamine Infusion Versus Placebo in Patients Having Spinal Fusion||New York University School of Medicine|Yes|Recruiting|August 2014|December 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424591||22713|
NCT02466841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15040063|Prospective Comparison of Techniques for Cubital Tunnel Release|Prospective Comparison of Techniques for Cubital Tunnel Release||University of Pittsburgh|Yes|Enrolling by invitation|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cubital tunnel release|June 2015|June 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466841||19470|
NCT02472249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8122-C|Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC|Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion||University Health Network, Toronto|No|Recruiting|January 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02472249||19054|
NCT02474147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G251|Processed Meat and Brain Regions Related to Reward and Addiction|Effects of Processed Meat on Brain Regions Related to Reward and Craving in Patients With Type 2 Diabetes, Obese Subjects and Healthy Controls|RewCrav|Institute for Clinical and Experimental Medicine|No|Not yet recruiting|August 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02474147||18908|
NCT02473172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVA_PSV|Impact of the Assisted Ventilation Mode on Diaphragm Efficiency in Critically Ill Patients|Impact of Pressure Support Ventilation (PSV) Versus Neurally Adjusted Ventilatory Assist (NAVA) Diaphragm Efficiency|NAVA_PSV|University of Bari|No|Completed|May 2013|May 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473172||18983|
NCT02472028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100153|Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals|LEukoaraiosis and blOod Pressure Reduction in OLD People|LEOPOLD|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|September 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|820|||Both|60 Years|85 Years|No|||July 2015|July 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02472028||19071|
NCT02477982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL(609)|Influence of Obesity on Propofol Pharmacokinetics During Cardiopulmonary Bypass|Influence of Obesity on Propofol Pharmacokinetics During Cardiac Surgeries Using Cardiopulmonary Bypass: Derivation of a Pharmacokinetic Model||Cairo University|Yes|Completed|December 2012|August 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients undergoing elective cardiac surgery using Cardiopulmonary bypass with moderate        hypothermia (defined as core body temperature of 28-32oC).|June 2015|June 18, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02477982||18613|
NCT02414867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203770|Total Energy Expenditure and Fat Oxidation in 2 Year Old Children|Total Energy Expenditure and Fat Oxidation in 2 Year Old Children||Arkansas Children's Hospital Research Institute|Yes|Recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Urine collected|Both|2 Years|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|120 toddlers born from mothers of the Glowing study (NCT01131117)|September 2015|September 9, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414867||23460|
NCT02415140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX-13-142 (70-02)|Prevalence and Predictors of Depression in COPD|Prevalence and Independent Predictors of Depression in COPD||Kwong Wah Hospital||Completed|October 2013|||February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|161|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|COPD patients with spirometry confirmed airflow limitation|April 2015|April 13, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415140||23439|
NCT02473224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0034|Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies|Phase I Study to Determine the Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting||||January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|44|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|October 22, 2015|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473224||18979|
NCT02468804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0771|Cognitive Dysfunction In Parkinson's|Cognitive Dysfunction in Parkinson's Disease|KL2|University of Colorado, Denver|No|Recruiting|August 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|120|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|October 18, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468804||19319|
NCT02468817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0250|PTH And Calcium Responses to Exercise (PACE) in Older Adults|PTH And Calcium Responses to Exercise (PACE) in Older Adults||University of Colorado, Denver|No|Recruiting|August 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|32|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02468817||19318|
NCT02474693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0920-0982|Salt Sources Study|Assessment of the Proportion of Sodium Intake From a Variety of Sources - Salt Sources Study||Centers for Disease Control and Prevention|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|450|Samples Without DNA|24 hour urine samples|Both|18 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of adults aged 18-74 years, able to read and speak English, who have        a telephone. Respondents will be excluded if they are pregnant, breastfeeding, have        diabetes insipidus, or have chronic kidney disease. Information will be collected from the        study participants in three study sites in Minnesota, Alabama, and California.|January 2016|January 27, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02474693||18866|
NCT02474706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC N 2013/COLIFOX-MAY/SR|Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli|Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli|COLIFOX|Central Hospital, Nancy, France|Yes|Recruiting|March 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02474706||18865|
NCT02424799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200196|Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264|A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264||GlaxoSmithKline||Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|70 Years|No|||September 2015|September 24, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02424799||22697|
NCT02415361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/17828|Follow Ups of Parents With Infants With Cleft Lip and Palate|Follow Ups of Parents With Infants With Cleft Lip and Palate||Oslo University Hospital|No|Recruiting|April 2015|September 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02415361||23422|
NCT02473549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-2015|Improving Motor Stroke Recovery Using Patient-tailored Non-invasive Brain Stimulation|Towards More Successful Clinical Trials: Using a Patient-tailored Approach in Brain Stimulation to Improve Recovery of Movements After Stroke||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|80 Years|No|||June 2015|June 11, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02473549||18954|
NCT02461498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0808-17148|The AHEAD Study: Monitoring Anticoagulated Patients Who Suffer Head Injury|The AHEAD Study: Monitoring Anticoagulated Patients Who Suffer Head Injury||University of Sheffield|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3556|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults who attend participating emergency departments (ED) with a head injury and also        prescribed warfarin|May 2015|May 29, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461498||19880|
NCT02474342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-15-01|Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Rotator Cuff Disease||Seoul National University Hospital|No|Recruiting|July 2015|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|19 Years|N/A|No|||May 2015|July 28, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02474342||18893|
NCT02474355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00022|Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC|Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)|ASTRIS|AstraZeneca|No|Recruiting|September 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1325|||Both|18 Years|130 Years|No|||March 2016|March 21, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02474355||18892|
NCT02468193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C1201|Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome|A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease||Novartis|No|Recruiting|September 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||November 2015|November 20, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02468193||19366|
NCT02466165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-CMR|Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy|Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy||Hasselt University|Yes|Recruiting|March 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|4||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02466165||19522|
NCT02466178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM 14-01|Efficacy Trial for the Reduction of Glabellar Lines|Multicenter Efficacy Trial of the Serene RF System for the Reduction of Glabellar Lines||Serene Medical Inc|No|Active, not recruiting|February 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult men and women with moderate to severe glabellar lines|February 2016|February 10, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466178||19521|
NCT02473809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07052015|The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function|The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function|LIRABONE|University of Aarhus|Yes|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|90 Years|No|||June 2015|November 13, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473809||18934|
NCT02473822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-24|ACL Reconstruction With the TLS Technique|ACL Reconstruction With the TLS Technique (Tape Locking Screw) and Return to Sport: Serial 5-year Independent Designers||University Hospital, Strasbourg, France|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing care of knee instability in chronic laxity of anterior cruciate        ligament by ligament according to TLS technique.|June 2015|June 12, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02473822||18933|
NCT02470468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU01|Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer|A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC||Sotio a.s.|No|Recruiting|December 2014|April 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02470468||19191|
NCT02470767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17964|An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres|An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres|SILVER-AP|Bayer|No|Active, not recruiting|May 2015|April 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1050|||Both|18 Years|N/A|No|Non-Probability Sample|patients at risk of stroke or systemic embolism on anticoagulant therapy, who have changed        their therapeutic regimen according to their doctor's decision, due to any clinical        situation and based on routine clinical practice, and who at the time of enrolment in the        study have been receiving treatment with a DOAC for at least three months|March 2016|March 7, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02470767||19168|
NCT02474485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbsorbISR|Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR|Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis|AbsorbISR|SIS Medical AG|No|Recruiting|March 2015|June 2021|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474485||18882|
NCT02425852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2015-02|A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis|A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis|ACTIVE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Not yet recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425852||22616|
NCT02425865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2015-05|Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - (TARGET)|Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - TARGET|TARGET|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Not yet recruiting|January 2016|November 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||November 2015|November 20, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425865||22615|
NCT02469051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-2015-0098|Breath-hold Cardiac Hybrid SPECT/CCTA|Usefulness of Breath-hold Triggered SPECT-MPI in Cardiac Hybrid SPECT/CCTA Imaging||University of Zurich|Yes|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02469051||19300|
NCT02469324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-018-H|A Comparative RCT of Brief Internet-based Compassionate Mind Training and Cognitive-behavioral Therapy for Mothers and Their Babies|||i4Health|Yes|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|86|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469324||19279|
NCT02468284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000200|Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer|An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy||Ferring Pharmaceuticals|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Male|18 Years|N/A|No|||October 2015|October 12, 2015|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468284||19359|
NCT02468583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2014-007|Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Recruiting|February 2015|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|20 Years|50 Years|No|||November 2015|November 18, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468583||19336|
NCT02425930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2013]A-246|The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer|The Relationship Between Complement C3 Depletion and Metastatic Gastric Cancer: A Prospective Pilot Study||First Affiliated Hospital, Sun Yat-Sen University|No|Completed|August 2013|April 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients who have a confirmed pathological diagnosis of gastric adenocarcinoma would be        selected for further observation. Those patients who subsequently underwent a radical        tumor resection can be included for final analysis.|April 2015|April 21, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02425930||22610|
NCT02469038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0548|Ultrasound-Guided Peripheral Venous Access Using AccuCath|Randomized, Controlled Study of Ultrasound-Guided Peripheral Venous Access Using AccuCath Versus Ultrasound-Guided Conventional Intravenous Catheter in the Emergency Department|AccuCath|University of Chicago|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469038||19301|
NCT02464072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 00828412.8.0000.0068|Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis|Randomized Clinical Trial of Subtotal Parathyroidectomy or Total Parathyroidectomy With Immediate Heterotopic Autograft in Chronic Renal Disease Patients Stage V Under Dialysis||University of Sao Paulo General Hospital|No|Recruiting|July 2012|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|133|||Both|N/A|N/A|No|||June 2015|June 4, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02464072||19683|
NCT02468856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500170|Effect of Armodafinil on Simulated Driving|Effect of Armodafinil on Simulated Driving, Electroencephalogram and Cognitive Performance in Sleep Deprived Healthy Subjects||University of Florida|No|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468856||19315|
NCT02427035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL112_1001|A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment|A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function||CSL Behring|Yes|Completed|May 2015|February 2016|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|85 Years|No|||February 2016|March 23, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427035||22525|
NCT02425982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65/13/03/02/2014|Finnish Tennis Elbow Trial Pilot Study|Finnish Tennis Elbow Trial Pilot Study|FINITE|Helsinki University|No|Recruiting|August 2015|May 2025|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|35 Years|60 Years|No|Non-Probability Sample|All patients who seek advice or treatment at the outpatient clinics of the centers taking        part in the study will be assessed for eligibility. Those fulfilling the criteria defined        below will be asked to participate.|February 2016|February 24, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02425982||22606|
NCT02476474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133508|GERD Following Laparoscopic Sleeve Gastrectomy|Antral Length and GERD Following Sleeve Gastrectomy for Morbid||University of California, San Francisco|No|Active, not recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02476474||18729|
NCT02476487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0377-14CTIL|The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia|The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia||Rambam Health Care Campus|No|Recruiting|August 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02476487||18728|
NCT02469103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-C2|The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis|The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis||Chinese University of Hong Kong|No|Recruiting|October 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|80 Years|No|||June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469103||19296|
NCT02469116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1023|Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma|Phase II Trial of Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in the Front-line Treatment of Patients With Advanced Stage Ovarian Carcinoma||Washington University School of Medicine|No|Terminated|January 2006|March 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||June 2015|June 8, 2015|June 1, 2015|Yes|Yes|Sponsor withdrew financial support|No||https://clinicaltrials.gov/show/NCT02469116||19295|
NCT02253381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC: 57-195-08-1|Effect of Position During Spinal Anesthesia on Hemodynamic Change in Cesarean Section|Effect of Position During Spinal Anesthesia on Hemodynamic Change in Pregnant Women Undergoing Cesarean Section: Randomized Trial||Prince of Songkla University|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Female|N/A|N/A|No|||April 2015|April 27, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02253381||35847|
NCT02250430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC102|A Phase 1 Study Assessing Local Cutaneous Effects of SB204|A Phase 1, Single-Center, Split-Face Study Assessing Local Cutaneous Effects After Application of SB204 2% and SB204 4% in Healthy Volunteers||Novan, Inc.|No|Completed|September 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|September 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250430||36074|
NCT02255578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1170-GL-CTIL|Endobarrier Treatment in Women With PCOS|Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome|EPCOS|Sheba Medical Center|No|Not yet recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|35 Years|No|||September 2014|September 29, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02255578||35678|
NCT02323048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2047|Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans|Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans: Self-report, Behavioral, and Psychophysiological Measures.|CAM|University of Chicago|No|Completed|July 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|90|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|October 30, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323048||30500|
NCT02313337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|administration route|The Comparison of Different Administration Routes of Pediatric Premedication|The Comparison of Different Administration Routes of Pediatric Premedication-Single Center,Randomized，Controlled Trial||Second Affiliated Hospital of Xi'an Jiaotong University|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|1 Year|7 Years|No|||November 2014|December 7, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02313337||31245|
NCT02246829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/18|Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START|Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD|START|University Hospital, Bordeaux|No|Recruiting|September 2014|January 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|N/A|No|||September 2014|October 22, 2014|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02246829||36351|
NCT02255630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02788|Anaerobic Power and Salbutamol|The Effects of High-dose Salbutamol on Anaerobic Cycling Power||University of British Columbia|No|Active, not recruiting|January 2015|May 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02255630||35674|
NCT02312752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140103|Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)|Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)|IES|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02312752||31290|
NCT02312765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820241|Reducing Heart Failure Re-admissions by Enhancing Sleep Apnea Treatment Adherence|Reducing Heart Failure Re-admissions by Enhancing Sleep Apnea Treatment Adherence||University of Pennsylvania|Yes|Enrolling by invitation|November 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02312765||31289|
NCT02326571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-059|Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage|Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage||Rigshospitalet, Denmark|Yes|Active, not recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|For later miRNA analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for neuro surgery admitted to Rigshospitalet, Copenhagen with        spontaneous intracerebral hemorrhage verified by CT.|October 2015|October 26, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02326571||30229|
NCT02314195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2172719|Music Therapy in Obsessive Compulsive Disorder|A Randomized Clinical Trial of Music Therapy as an Adjunct to Standard Treatment for Obsessive Compulsive Disorder and Co-morbid Anxiety and Depression in Iran||Islamic Azad University, Marvdasht|No|Completed|April 2014|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02314195||31180|
NCT02243566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.513|Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)|Morning Hypertension and Patient Self-monitoring||Boehringer Ingelheim||Completed|April 2006|||January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2707|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients with essential hypertension|September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02243566||36602|
NCT02243826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-206|Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial|Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial||University Hospital, Clermont-Ferrand||Recruiting|July 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|60 Years|No|||September 2015|September 18, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02243826||36582|
NCT02310841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2013-0034|Pilot Study for Patient-cooperative Control Strategies for Actuated Transfemoral Prostheses|Pilotstudie zu Patientenkooperativen Regelungsstrategien für Aktuierte Oberschenkelexoprothesen||Swiss Federal Institute of Technology|Yes|Completed|March 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Both|18 Years|N/A|No|||December 2014|April 27, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02310841||31437|
NCT02313012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90003-ST-001|Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors|A Phase 1a Multicenter, Open-label Safety, Tolerability and Pharmacokinetic Study of CC-90003, a Selective Extracellular Signal-Regulated Kinase (ERK) Inhibitor, in Subjects With Locally-Advanced or Metastatic, Relapsed, or Refractory BRAF or RAS-Mutated Malignancies||Celgene|No|Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313012||31270|
NCT02250625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-88|Study Vitamin D in Healthy Individuals|A Prospective Collection of Peripheral Blood Specimens to Study Vitamin D in Healthy Individuals||Fujirebio Diagnostics, Inc.|No|Completed|May 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|482|Samples With DNA|Serum and plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women greater than or equal to 18 years of age|May 2014|May 21, 2015|September 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250625||36059|
NCT02253199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZhang-02|The Effect of Age on the Median Effective Dose (ED50) of Intranasal Dexmedetomidine for Rescue Sedation Following Failed Sedation With Oral Chloral Hydrate During Magnetic Resonance Imaging|||Guangzhou Women and Children's Medical Center|Yes|Recruiting|October 2014|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|4||Anticipated|150|||Both|1 Month|36 Months|No|||October 2015|October 31, 2015|September 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02253199||35861|
NCT02253290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57182|Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease|Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2014|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|children and adolescents with neuromuscular disease|August 2015|August 20, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02253290|18 Years|35854|
NCT02312453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038.76|Posterior Parasagittal In-Plane Ultrasound-Guided Infraclavicular Brachial Plexus Block|Posterior Parasagittal In-Plane Ultrasound-Guided Infraclavicular Brachial Plexus Block - A Case Series||University of Malaya|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|80 Years|No|||December 2014|December 6, 2014|November 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02312453||31313|
NCT02323425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XIANJ-14ZD25|Effects of Limb Ischemic Postconditioning in Young sICAS|Effects of Upper Limb Ischemic Postconditioning on Collateral Circulation in Young Symptomatic Intracranial Atherosclerosis|EPIC-sICAS|Xi’an Jiaotong University College of Medicine|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|No|||July 2015|July 24, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02323425||30471|
NCT02242266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.9|Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder (5 μg and 10 μg), Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® (18 μg Tiotropium) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|July 2005|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|121|||Both|40 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242266||36702|
NCT02242279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.3|Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients|Randomised, Double-Blind, Placebo-Controlled, 4-Way Cross-Over Study to Assess the Efficacy and Safety of a Single Dose of Orally Inhaled BEA 2180 BR (Doses 80, 200 and 800 μg) in COPD Patients Followed by an Open-Label, Active-Control (Tiotropium 72 μg)||Boehringer Ingelheim||Completed|June 2004|||December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|37|||Both|40 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242279||36701|
NCT02242292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.832|Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort|A Double-blind, Placebo-controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used On-demand up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-reported Abdominal Pain, Cramping, and Discomfort Associated With Cramping in an OTC-like Study Population||Boehringer Ingelheim||Completed|April 2006|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|527|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2014||||No||https://clinicaltrials.gov/show/NCT02242292||36700|
NCT02253407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMR-01/12|Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children|A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months||Serum Institute of India Limited|No|Active, not recruiting|September 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|340|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||November 2015|November 10, 2015|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02253407||35845|
NCT02253420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16270|Copanlisib (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor Patients|An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors||Bayer|No|Recruiting|October 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|26|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253420||35844|
NCT02324998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaNCaP03|Studying the Effects of Olaparib Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy|A Study Into the Pharmacodynamic Biomarker Effects of Olaparib (a PARP Inhibitor) Given Prior to Radical Prostatectomy.|CaNCaP03|Cambridge University Hospitals NHS Foundation Trust|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Male|18 Years|73 Years|No|||December 2014|December 19, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324998||30350|
NCT02325011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP1427|An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.|An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Treatment, Four-Period, Crossover Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.||GW Pharmaceuticals Ltd.|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325011||30349|
NCT02313805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UndergradStudy|The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students|The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students: a Randomized Controlled Trial||The University of The West Indies|No|Recruiting|July 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|17 Years|40 Years|No|||November 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313805||31209|
NCT02250677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFESTAT - Cross Sectional|LIFESTAT - Living With Statins, a Cross Sectional Study|LIFESTAT - Living With Statins, a Cross Sectional Study on the Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being||University of Copenhagen|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|Samples With DNA|Samples with plasma, muscle and fat biopsies are retained for analysis after enrolment of      the last subject.|Both|40 Years|70 Years|No|Non-Probability Sample|The patients will be recruited through advertisement in pharmacies and through newspapers.        The patients will be recruited among statin users that are in primary prevention.|February 2016|February 9, 2016|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02250677||36055|
NCT02462226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s15-00221|Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)|The-Optimal-Lymph-Flow ™: An e-Health Approach to Enhancing Management of Chronic Pain and Symptoms Related to Lymphedema Among Women Treated for Breast Cancer|Lymph-Flow|New York University School of Medicine|Yes|Recruiting|May 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|21 Years|89 Years|No|||October 2015|October 7, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02462226||19824|
NCT02466373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clonidine kinetics 1.1|Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients|Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients|Clokin1|Deventer Ziekenhuis|Yes|Recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466373||19506|
NCT02419560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17983|Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL|Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma||University of Virginia|Yes|Recruiting|April 2015|December 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419560||23100|
NCT02426515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-080|Cryotherapy to Improve Outcomes in Lower Third Molar Surgery|Cryotherapy to Improve Outcomes in Lower Third Molar Surgery|COOL|University of Birmingham|No|Recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02426515||22565|
NCT02462668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNong|Fibreoptic Bronchoscopy Assisted Intubation During Noninvasive Positive Pressure Ventilation|The Efficiency and Safety of Fibreoptic Bronchoscopy Assisted Intubation During Noninvasive Positive Pressure Ventilation|FBAIDNIPPV|The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02462668||19790|
NCT02471729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010215|Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque|Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque|DENRENIC|Institute Arnault Tzanck, France|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02471729||19094|
NCT02418520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSAUHS2015|The Effect of Miswak Chewing Sticks on the Oral Helicobacter Pylori Infection|The Effect of Miswak Chewing Sticks on the Oral Helicobacter Pylori Infection|Miswak|King Saud Bin Abdulaziz University for Health Sciences|Yes|Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418520||23179|
NCT02418533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLFC-004|Mono-menotropins Versus Mixed Gonadotropin/Menotropins Protocol on Embryo Quality|A Prospective, Randomized Trial to Compare Mono-menotropins Protocol for Controlled Ovarian Stimulation (COS) Versus Mixed Gonadotropin/Menotropins Protocol on Embryo Quality Parameters||Main Line Fertility Center|No|Recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|21 Years|38 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02418533||23178|
NCT02470650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cost-Effect-Clinic|Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive|Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks||Hospital Clinic of Barcelona|No|Not yet recruiting|June 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470650||19177|
NCT02467959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH04|Diagnostic Accuracy of Emergency Physician Performed Bedside Ultrasound in Suspected Acute Appendicitis|Diagnostic Accuracy and Clinic Utility of Bedside Ultrasonography Performed by Emergency Physicians in Suspected Acute Appendicitis||Antalya Training and Research Hospital|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All patients over 18 years of age presented to emergency department with the complaint of        right lower abdominal pain|June 2015|June 9, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467959||19384|
NCT02474394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP-1|Effects of Videolaryngoscope on Intraocular Pressure|The Comparison of the Effects of McGrath Video Laryngoscope and the Macintosh Laryngoscope on Intraocular Pressure: A Randomized Trial||Tokat Gaziosmanpasa University|Yes|Completed|February 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|80|||Both|18 Years|60 Years|No|||June 2015|June 25, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02474394||18889|
NCT02474459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR014852|Mobile Decision Support System for Nurse Management of Neuromodulation Therapy|||University of Utah|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|30 Years|75 Years|No|||December 2015|December 2, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02474459||18884|
NCT02410928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USG-Vokal cord|Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy|Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy||Diskapi Teaching and Research Hospital|No|Not yet recruiting|April 2015|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|10|||Both|19 Years|70 Years|No|||February 2015|April 2, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02410928||23763|
NCT02411487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-1103|Meibomian Gland Dysfunction (MGD) and Tear Cytokines After Cataract Surgery According to Preoperative Meibomian Gland Status|||Yonsei University|No|Recruiting|February 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|TEAR|Both|55 Years|80 Years|No|Non-Probability Sample|A total of 55 eyes from 55 patients who underwent cataract surgery were included.|April 2015|April 2, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02411487||23720|
NCT02471001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEdin-15|The Levels of Anaesthetics in Heart Muscle During Heart Surgery|Coronary Sinus Blood Isoflurane Concentration in Patients Undergoing Heart Surgery|TLAHMHS|University of Edinburgh|No|Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh        using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane        will be recruited in this study.|June 2015|June 11, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02471001||19150|
NCT02477514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1986-004|A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)|A Multiple-Dose Study to Evaluate the Effects of Steady-State Tedizolid Phosphate Administration on the Pharmacokinetics and Safety of a Single Dose of Midazolam and Rosuvastatin||Merck Sharp & Dohme Corp.|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477514||18649|
NCT02477527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB001JP001|Atripla to Stribild Switch Study to Evaluate Sleep Disturbances|Switching From Atripla to Stribild Leads to Improvements in Central Nervous System Side Effects and Sleep Disturbances||Midtown Medical Center, Tampa, FL|No|Completed|February 2015|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477527||18648|
NCT02474472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-PAIN-001|Postoperative Analgesia Investigation|A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control.|PAIN|The University of Texas Health Science Center, Houston|Yes|Enrolling by invitation|October 2013|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02474472||18883|
NCT02474537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280A2106|INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function|An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function||Novartis|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474537||18878|
NCT02423707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016815-39|Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy|Intralymphatic Allergen-specific Immunity as a New Administration Route for Treatment of Pollen-induced Allergic Diseases||Karolinska Institutet|No|Active, not recruiting|August 2010|December 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|50 Years|No|||January 2016|January 23, 2016|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT02423707||22781|
NCT02462629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-004|Study of BLZ-100 in Pediatric Subjects With CNS Tumors|A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors||Blaze Bioscience Inc.|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|1 Month|30 Years|No|||November 2015|November 3, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462629||19793|
NCT02477124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052865|A See and Treat Paradigm for Cervical Pre-cancer|A See and Treat Paradigm for Cervical Pre-cancer||Duke University|No|Not yet recruiting|September 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|25 Years|N/A|No|||June 2015|June 17, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477124||18679|
NCT02477137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhONEME Prostate|Effects of an Interactive ICT-Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer|PhONEME - PartipatOn Ehealth MobilE. Effects of an Interactive Information and Communications Technology (ICT) Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer|PhONEME|Karolinska Institutet|No|Recruiting|July 2015|November 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02477137||18678|
NCT02464098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIGUT|Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients|Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients||St. Jude Children's Research Hospital|No|Recruiting|July 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|All stool, blood and respiratory samples will be saved frozen for future testing.|Both|N/A|18 Years|No|Non-Probability Sample|Participants will be pediatric oncology patients including patients with recent diagnoses        of solid tumor or hematologic malignancy, or patients undergoing hematopoietic stem cell        transplant.|February 2016|February 8, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464098||19681|
NCT02419586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC03|Effectiveness of Gum Chewing on Ileus in Chinese Colorectal Patients Underwent Laparoscopic Colorectal Surgery|Effectiveness of Gum Chewing on Reduction of Postoperative Paralytic Ileus for Chinese Colorectal Cancer Patients Underwent Laparoscopic Colorectal Surgery and Enhanced Recovery Program||Hospital Authority, Hong Kong|Yes|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|92|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02419586||23098|
NCT02462915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502043RINC|A Study Comparing the Supraglottic Airway Devices and Endotracheal Tube During Controlled Ventilation for Laparoscopic Surgery|A Study Comparing the Supraglottic Airway Devices and Endotracheal Tube During Controlled Ventilation for Laparoscopic Surgery||National Taiwan University Hospital|No|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|80 Years|No|||November 2015|November 13, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02462915||19771|
NCT02472678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150501|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor|WIN|University Medical Center Groningen|No|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|90 Years|No|||October 2015|October 1, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02472678||19021|
NCT02472691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZALENA-2013/RV-MDS-PI-0777|Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT|Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation|AZALENA|Heinrich-Heine University, Duesseldorf|Yes|Recruiting|June 2015|September 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02472691||19020|
NCT02465385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17803|Single-dose Linaclotide for Capsule Endoscopy Preparation|Single-dose Linaclotide for Capsule Endoscopy Preparation||University of Virginia|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465385||19582|
NCT02465684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKA-Tourniquet|Effect of Tourniquet on UKA|The Role of a Thigh Tourniquet in Unicondylar Knee Arthroplasty: a Randomized Controlled Trial||Medical University Innsbruck||Not yet recruiting|June 2015|||January 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465684||19559|
NCT02419872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFS-AS-40087|Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease|A Phase IV Real-World Multi-Country Observational Study on Patients' Disease Control and Self-Reported Outcomes During Fixed Dose Combination Inhaler Treatment for Persistent Asthma and COPD|SPRINT|Teva Pharmaceutical Industries|No|Recruiting|May 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with asthma or COPD and on a stable dose of Inhaled corticosteroid        (ICS)/Long-acting beta2-agonists (LABA) Fixed dose combination (FDC) administered by dry        powder inhaler (DPI) twice daily for the previous 3 months|March 2016|March 1, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419872||23076|
NCT02469948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8BC0781|Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities|Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities||Chang Gung Memorial Hospital|No|Not yet recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||September 2015|October 12, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02469948||19231|
NCT02417688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409006|PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis|PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb||Washington University School of Medicine|No|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|21 Years|N/A|No|||December 2015|December 14, 2015|April 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417688||23243|
NCT02421783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM07|Osteoporosis In Non-Celiac Wheat Sensitivity Patients|Osteoporosis In Non-Celiac Wheat Sensitivity Patients||University of Palermo|No|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|270|Samples Without DNA|Biopsy specimens will be obtained from the bulb and the second duodenal portion|Both|18 Years|65 Years|No|Probability Sample|The study will include consecutive adult patients with irritable bowel syndrome (IBS)-like        clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS,        referred at the Internal Medicine and at the Gastroenterology Units of the University        Hospital of Palermo, between may 2015 and may 2017.|November 2015|November 30, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421783||22929|
NCT02421991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8298|Telephone-Delivered Interventions for Smoking Cessation|Telephone-Delivered Interventions for Smoking Cessation|TALK|Fred Hutchinson Cancer Research Center|No|Enrolling by invitation|November 2015|November 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1168|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02421991||22913|
NCT02471625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-011|Traumatic Brain Injury Feasibility Study (EPIC-011)|Traumatic Brain Injury (TBI) Feasibility Study to Determine Possible Prognostic Indicators as Provided by the EPIC ClearView™|TBI|Epic Research & Diagnostics, Inc.|No|Active, not recruiting|April 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women ages 18-65 who present to the ER with suspected head trauma and meet all        inclusion and no exclusion criteria will be approached for consent to participate in the        study.|November 2015|November 18, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02471625||19102|
NCT02471638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP 115|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||July 22, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471638||19101|
NCT02465853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8C0771|Hemiplegic Shoulder Pain and Rotator Cuff Injuries|Clinical Outcome in Subacute Stroke Patients With Hemiplegic Shoulder Pain and Rotator Cuff Injuries After Hyaluronic Acid Injection||Chang Gung Memorial Hospital|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|70 Years|No|||November 2014|June 11, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02465853||19546|
NCT02466100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44610E/K|Goals of Care Communication|Goals of Care Communication in Advanced Heart Failure|GoC|University of Washington|Yes|Active, not recruiting|June 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02466100||19527|
NCT02470819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMEM-2014-DOD001|Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer|A Phase II Pilot Study Utilizing Genomic and Proteomic Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer||Avera McKennan Hospital & University Health Center|Yes|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02470819||19164|
NCT02412553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001134|Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis|||Massachusetts General Hospital|No|Recruiting|October 2014|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||March 2016|March 14, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412553||23638|
NCT02464436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN03-CP-0001|Safety and Tolerability of hRPC in Retinitis Pigmentosa|First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)|hRPCRP|ReNeuron Limited|Yes|Recruiting|December 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464436||19655|
NCT02464449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-350|Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools|Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools|AI CBT|VA Office of Research and Development|Yes|Not yet recruiting|February 2016|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|276|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02464449||19654|
NCT02464462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220|The Role of Vitamin D3 and Calcium Supplementation in Attenuating T2DM Severity|The Role of Vitamin D and Calcium Supplementation in the Pathogenesis of Type 2 Diabetes Mellitus||York University||Completed|May 2010|December 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Female|40 Years|70 Years|No|||June 2015|June 4, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464462||19653|
NCT02477904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HON1403|Ketogenic Diet Therapy for Autism Spectrum Disorder|Ketogenic Diet Therapy for Autism Spectrum Disorder||Shriners Hospitals for Children|Yes|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02477904||18619|
NCT02418234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZFH CA15-02|T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure|Frequency and Abundance of T790M Mutation on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment Failure: a Perspective Observational Study||First People's Hospital of Hangzhou|Yes|Recruiting|May 2015|October 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Non small cell lung cancer (NSCLC) after EGFR-TKI failure|December 2015|December 3, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02418234||23201|
NCT02412306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130265|Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)||Amgen|Yes|Recruiting|June 2015|April 2021|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|N/A|N/A|No|||December 2015|December 18, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02412306||23657|
NCT02412319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW002|The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection|The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial||Shineway Pharmaceutical Co.,Ltd|Yes|Active, not recruiting|October 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|65 Years|No|||April 2015|April 5, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02412319||23656|
NCT02472210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7474|The Use of Botox in Advanced Parkinson's Patients Experiencing Pain|A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study||University Health Network, Toronto|No|Active, not recruiting|July 2014|September 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472210||19057|
NCT02472977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA212-115|Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors|A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors|CXCessoR4|Bristol-Myers Squibb|Yes|Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|195|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472977||18998|
NCT02413814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA035944-01A1|Computerized Anger-Reduction Treatment for Smoking Cessation|Computerized Anger-Reduction Treatment for Smoking Cessation||Florida State University|Yes|Recruiting|April 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02413814||23541|
NCT02414061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-13-131017|Metabolic and Appetite Parameters Following Addition of Whey Protein to a Carbohydrate-based Breakfast|The Influence of Whey Protein Addition to a Carbohydrate-based Breakfast on Metabolic and Appetite Parameters Following a Second Meal||Northumbria University|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414061||23522|
NCT02414074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH097832|Adaptive Intervention Strategies in Conduct Problems Prevention|Adaptive Intervention Strategies in Conduct Problems Prevention||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|June 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|10 Years|17 Years|No|||December 2015|December 1, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02414074||23521|
NCT02412566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34444|SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury|Compassionate Use of an Intravenous Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil for Children With Parenteral Nutrition Induced Liver Injury|SMOF|Baylor College of Medicine||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|1 Year||||January 2016|January 13, 2016|March 25, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02412566||23637|
NCT02412579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #014-121|Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation|Circulating MicroRNA Isoforms as Biomarkers in Hepatocellular Carcinoma and Associated Liver Transplantation||Baylor Research Institute|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10|Samples With DNA|Hepatocellular carcinoma tumor tissue Background liver tissue|Both|18 Years|75 Years|No|Probability Sample|Hepatocellular Carcinoma Clinic Pre-Liver Transplant Clinic|January 2016|January 15, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412579||23636|
NCT02472197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6043|Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy|Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy|RESMO|University Hospital, Strasbourg, France|No|Not yet recruiting|July 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||June 2015|June 10, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02472197||19058|
NCT02476370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-6060-BO MBM_Hernio|Effects of Preoperative Relaxation and Intensified Surgery Education in Patients Undergoing Herniotomy|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Herniotomy - a Randomized Controlled Trial|MBM_Hernio|Universität Duisburg-Essen|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|108|||Male|18 Years|N/A|No|||January 2016|January 7, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476370||18737|
NCT02468869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACOP2|Improving Discharge Communication|Improving Discharge Communication in the Emergency Department Through Information Structuring: A Cluster Randomized Controlled Trial|BACOP2|University Hospital, Basel, Switzerland|Yes|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02468869||19314|
NCT02423798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 296|New Generation Enlite Accuracy Study|Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home||Medtronic|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|74 Years|No|||February 2016|February 10, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02423798||22774|
NCT02423811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-104-105|To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy|To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy||National Cheng-Kung University Hospital||Recruiting|April 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|75 Years|No|||April 2015|April 21, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02423811||22773|
NCT02423824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8561-A|Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists|Exploring the Neural Substrates of Cognitive Dysfunction With Glucagon-like Peptide-1 Agonists|COGDYS-GLP1|University Health Network, Toronto|No|Recruiting|May 2015|February 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|45 Years|No|||August 2015|August 17, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423824||22772|
NCT02412852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheraVasc-TV1001-003|A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain|A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)||TheraVasc Inc.|Yes|Active, not recruiting|May 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412852||23615|
NCT02465242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#8657|Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury|Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury||Our Lady of the Lake Regional Medical Center|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|74|||Both|18 Years|N/A|No|Probability Sample|Adult trauma patients age 18 years or older with evidence of traumatic brain injury and        intubated requiring mechanical ventilation.|June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465242||19593|
NCT02473770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915133|Rapid Acquisition of Pre- and Post-Incident Disaster Data|Rapid Acquisition of Pre and Post-Incident Disaster Data Study||National Institutes of Health Clinical Center (CC)||Not yet recruiting|May 2015|May 2025|Anticipated|May 2025|Anticipated|N/A|Observational|N/A|||Anticipated|500|||Both|21 Years|N/A|No|||May 2015|June 13, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02473770||18937|
NCT02242942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25323|A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia|||Hoffmann-La Roche||Recruiting|December 2014|January 2020|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|432|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02242942||36650|
NCT02243228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT 01|Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)|A Prospective Study of Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Mild-to-moderate Autoimmune Pulmonary Alveolar Proteinosis in China: a Randomized Open-label Study||Peking Union Medical College Hospital|No|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02243228||36628|
NCT02255604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILIT|Effect of Intralymphatic Immunotherapy|Effect of Intralymphatic Immunotherapy at Basophil Response and Plasmacell Kinetic in Patients With Allergic Rhinitis.||University of Aarhus|Yes|Active, not recruiting|August 2013|August 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|40 Years|No|||January 2015|December 1, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02255604||35676|
NCT02311868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-cres Probinul|Effect of Short-term Synbiotic Treatment on Plasma P-cresol Levels in Hemodialysis Patients|||Federico II University||Recruiting|December 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||December 2014|December 8, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311868||31358|
NCT02311881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202195|A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis|An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects With Osteoarthritis||GlaxoSmithKline|No|Recruiting|January 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|804|||Both|40 Years|80 Years|No|||August 2015|September 24, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311881||31357|
NCT02250872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1408264002|Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury|Effect of DPP4 Inhibitors on Cisplatin-induced Acute Kidney Injury||Seoul National University Bundang Hospital|No|Recruiting|December 2014|October 2016|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|70 Years|No|||December 2014|December 26, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250872||36040|
NCT02250885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC-003|KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors|Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors||Gabrail Cancer Center Research|No|Recruiting|August 2014|June 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|August 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250885||36039|
NCT02242669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000153|Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders|Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders||Massachusetts General Hospital|Yes|Recruiting|November 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit participants from a large DBSA chapter at McLean Hospital. Subjects will        be recruited at the beginning of the weekly meetings, through flyers, the DBSA website,        and word of mouth. 200 current DBSA members and 60 new DBSA members will be assessed for        Aims 1 and 2, respectively. 100 people who have never attended a DBSA will be assessed for        Aim 3 and will be recruited from MGH and McLean Hospitals through the use of flyers,        clinic announcements, and via our online clinical and research infrastructures.        Participants in all Aims must be 18 years or older and self-report a diagnosis of any type        of mood disorder. For Aims 1 and 2, participants must have attended at least one DBSA        meeting.|April 2015|April 6, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02242669||36671|
NCT02317484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIEND1413|Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes|Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes|HARUKAS|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|20 Years|79 Years|No|Non-Probability Sample|Primary care clinic and hospital|February 2015|February 15, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317484||30927|
NCT02317783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI69515|Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment|Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment||University of Utah|Yes|Recruiting|December 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317783||30904|
NCT02250612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL040012_IV|SYL040012, Treatment for Open Angle Glaucoma|A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension|SYLTAG|Sylentis, S.A.||Completed|October 2014|January 2016|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|184|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02250612||36060|
NCT02249026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0501|Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study|Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study||Gauda, Estelle B., M.D.|Yes|Recruiting|October 2014|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|7 Days|No|||September 2015|September 4, 2015|August 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02249026||36182|
NCT02315300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-030|Predicting Hypoglycaemia and Arrythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease|Predicting Hypoglycaemia and Arrythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease|HypoArryth|RWTH Aachen University|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02315300||31095|
NCT02317796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-MD-201|Adult Subjects With Uncontrolled Type 2 Diabetes|A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes||Melior Pharmaceuticals|Yes|Active, not recruiting|December 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|149|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317796||30903|
NCT02252861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAAC|French Database of Left Atrial Appendage Closure|French Database of Left Atrial Appendage Closure|FLAAC|Henri Mondor University Hospital|Yes|Recruiting|October 2013|September 2020|Anticipated|September 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred for percutaneous Left Atrial Appendage Closure to one of the French        centers involved in this database|February 2016|February 17, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02252861|5 Years|35887|
NCT02316275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026474|Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery|IMpact of Unrestricted ACTIVity Following Mid-Urethral Sling Surgery (I'M ACTIVe): Quality of Life and Cost Implications||Cedars-Sinai Medical Center|Yes|Recruiting|December 2011|December 2031|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316275||31020|
NCT02316288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT007939-01A1|Development of a Couple-based Mindfulness Intervention for Chronic Pain|Preliminary Test of an Integrative Intervention to Alleviate Chronic Pain and Improve Quality of Life||Wayne State University|Yes|Recruiting|December 2014|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|21 Years|N/A|No|||December 2015|December 8, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02316288||31019|
NCT02324348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-3|Efficacy and Safety Study of Deferred Stenting in Patients With STEMI|Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-segment Elevation Myocardial Infarction|INNOVATION|Korea University Anam Hospital|Yes|Completed|June 2013|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02324348||30400|
NCT02324400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRNS003|Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients|||Nephera Ltd.|No|Not yet recruiting|January 2015|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|85 Years|No|||December 2014|December 18, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02324400||30396|
NCT02246790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LABARFA|Surgical Ablation of Long-standing Persistent AF During CABG|Surgical Ablation of Long-standing Persistent Atrial Fibrillation During CABG Through Continuous Subcutaneous Monitoring|LABARFA|Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|December 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02246790||36354|
NCT02240966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-1 75|Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors|Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors||Rigshospitalet, Denmark|No|Enrolling by invitation|August 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Testicular cancer survivors|September 2014|September 12, 2014|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02240966||36802|
NCT02241213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv-Aphasia|Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients|Effects of Repetitive Magnetic Transcranial Stimulation of Low Frequency on Speech Production in Patients With Non-fluent Aphasia Post-ischemic Stroke|Aphasia-ACV|Fundación Cardiovascular de Colombia|Yes|Recruiting|August 2014|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|70 Years|No|||September 2014|September 12, 2014|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02241213||36783|
NCT02312713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1331|Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis|Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis|PATH-IN|University of North Carolina, Chapel Hill|No|Recruiting|November 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|350|||Both|N/A|N/A|No|||January 2016|January 19, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02312713||31293|
NCT02317315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WinthropUH|Biomarkers Associated With Spontaneous Preterm Birth Less Than 32 Wks Gestation|Non-Invasive Sampling of Inflammatory Mediators Associated With Spontaneous Preterm Birth Less Than 32 Weeks Gestation||Winthrop University Hospital|Yes|Recruiting|January 2013|||October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples Without DNA|1. Saliva - We will collect saliva in a sterile container.        2. Maternal Blood - Blood samples will be collected during routine blood draws and into           serum separator tubes, spun, and the serum stored at -80°C.        3. Urine - Urine samples will be collected into a sterile container.        4. Cervical and vaginal secretions - During speculum exam, we will simultaneously insert           two Weck-Cell Sponges directly into the cervical os for collection of cervical           secretions then another two sponges will be applied in the posterior fornix for           collection of vaginal fluid.|Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant females between the age of 18-40 who present in preterm labor will be asked to        participate.|December 2014|December 10, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317315||30940|
NCT02253043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-002|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease||Beijing Pins Medical Co., Ltd|Yes|Recruiting|May 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|80 Years|No|||January 2015|October 12, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02253043||35873|
NCT02253056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIFT-Trial|Monday is Fasting Day - Non-Randomized Trial on Intermittent Fasting|Montag Ist Fasten-Tag (German) - MIFT [Monday is Fasting Day]|MIFT|Charite University, Berlin, Germany|Yes|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02253056||35872|
NCT02466386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD-489-348|Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder|A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder||Shire|Yes|Recruiting|July 2015|January 2021|Anticipated|January 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|5 Years|No|||September 2015|September 21, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466386||19505|
NCT02424188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH104553|Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH|Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH|TRIUMPH|Johns Hopkins University|Yes|Not yet recruiting|July 2015|||June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|April 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424188||22744|
NCT02427009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/GA-01|Maintaining a Prone Position After Use of an Epidural Blood Patch for the Treatment of Post-dural Puncture Headache|Effectiveness of Maintaining a Prone Position After Use of an Epidural Blood Patch for the Treatment of Post-dural Puncture Headache|UpSideDown|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427009||22527|
NCT02467127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Headache 2015|Vitamin D Plasma Level and Its Role in Headache|The Role of Vitamin D Plasma Levels in the Development of Headache|VITDHEAD|University of Cantanzaro|Yes|Recruiting|April 2015|April 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02467127||19448|
NCT02476162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FABRIC|Assessing Blood Pressure Remotely in Childhood Cancer Survivors|Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor)||St. Jude Children's Research Hospital|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476162||18753|
NCT02476175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14-06-1998-2|Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder|Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder|Add-on-Mira|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Enrolling by invitation|April 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|5 Years|17 Years|No|||January 2016|January 27, 2016|June 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476175||18752|
NCT02476266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3992|Two Resistance Training Protocols to Reduce the Risk of Falls in Parkinson's Disease|Power Training to Reduce Falls in Parkinson's Disease||Sun Life Financial Movement Disorders Research and Rehabilitation Centre|No|Not yet recruiting|August 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476266||18745|
NCT02423655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502010|Routine and Deferred Dialysis Initiation|A Randomized, Controlled Trial to Evaluate Routine and Deferred Dialysis Initiation in Chinese Population|RADDI|Peking University People's Hospital|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1700|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02423655||22785|
NCT02473133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB14.04/IFCT14-02|Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC|Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy|RTEP7|Centre Henri Becquerel|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||November 2015|November 26, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473133||18986|
NCT02472041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20300313.9.0000.5404|Effectiveness of Reanimator Muller in Patients With Chest Tube|Effectiveness of Reanimator Muller in Patients With Chest Tube||University of Campinas, Brazil|Yes|Recruiting|January 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|June 10, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02472041||19070|
NCT02472054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120109|Treatment of Familiar Lymphohistiocytosis|First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®)|C-HLH|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|17 Years|No|||November 2015|November 30, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02472054||19069|
NCT02464566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaudiCHS|12 Weeks Intensive Lifestyle Intervention Program in Primary Care Obesity Clinic for Obese Adults: Jeddah 2015|12 Weeks Intensive Lifestyle Intervention Program in Primary Care Obesity Clinic for Obese Adults: Randomized Control Trial, Jeddah 2015||Saudi Commission for Health Specialties, Saudi Arabia|No|Active, not recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|20 Years|N/A|No|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464566||19645|
NCT02419339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368-15-EP|Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction|Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction||University of Nebraska|No|Recruiting|May 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|31|||Both|N/A|6 Months|No|Non-Probability Sample|Infants (under 6 months of age) undergoing an extravesical ureteral reimplant for primary        obstructed megaureter or ectopic ureter.|December 2015|December 7, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02419339||23117|
NCT02473237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C 22-12|Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)|Efficacy and Acute Effects on Walked Distance froM basEline and Post Dose of indacateRol vs Tiotropium in Women With modeRAte to Severe COPD Secondary to Biomass Exposure: Open Label Crossover Clinical Trial|EMERAL|National Institute of Respiratory Diseases, Mexico|Yes|Completed|April 2013|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|50 Years|N/A|No|||October 2015|October 14, 2015|May 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473237||18978|
NCT02465008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERPRO2014_V2|Analgesic Effect of Levobupivacaine in Breast Augmentation|Analgesic Efficacy of Levobupivacaine Administration in Periprosthetic Breast Augmentation With Implants||Valencia University General Hospital|No|Not yet recruiting|June 2015|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|65 Years|No|||June 2015|June 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465008||19611|
NCT02465021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30422|Innovation of Breakfast Cereals and Snacks for Control of Appetite and Post-Prandial Glycemia|Innovation of Breakfast Cereals and Snacks for Control of Appetite and Post-Prandial Glycemia||University of Toronto|No|Active, not recruiting|March 2015|March 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465021||19610|
NCT02464839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fungalhallux|Prevalence and Clinical Characteristics of the Fungal Nail and Feet Infection in Patients With Hallux Valgus|Prevalence and Clinical Characteristics of the Fungal Nail and Feet Infection in Patients With Hallux Valgus||Mahidol University|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who were diagnosed hallux valgus foot deformity by specialists of physical        medicine and rehabilitation based on clinical presentation at Foot Clinic, Siriraj        hospital|September 2015|September 8, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464839||19624|
NCT02424656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013-186|Alterations in the Brain's Connectome After Severe Traumatic Brain Injury|Alterations in the Brain's Connectome in Severe Traumatic Brain Injury|ABC in TBI|Danish Research Centre for Magnetic Resonance||Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. 30 Patients that have suffered a close-head TBI with associated DOC and that are             admitted to neurorehabilitation at the TBI unit of Glostrup Hospital.          2. 20 Healthy participants without history of neurological disorders, age-, gender-, and             socioeconomically-matched to the included patients.|April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02424656||22708|
NCT02467075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00097944|Double-Blind Placebo-Controlled CIN Trial|Phase IV Randomized Double-Blinded Placebo-Controlled Noninferiority Study of the Effect of Intravenous Low-Osmolality Iodinated Contrast Material On Renal Function in Postoperative Adults With Stage IIIb or Stage IV Chronic Kidney Disease||University of Michigan|Yes|Active, not recruiting|July 2015|December 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|1|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467075||19452|
NCT02463773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G5252|Diaphragm Ultrasound Vs Transpulmonary Pressure To Set PEEP in ARDS|Diaphragm Excursion By Ultrasound As Compared To Transpulmonary Pressure To Optimize PEEP In ARDS: A Pilot Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463773||19706|
NCT02468310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-ERC: 10/09/14|Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana|Evaluating the Effects of Clinical Decision Making Support Systems on Maternal and Neonatal Mortality and Morbidity in Ghana: a Cluster Randomized Controlled Trial|Accelerate|Julius Global Health|No|Recruiting|August 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|17040|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 7, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02468310||19357|
NCT02468622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transcriptomics|Transcriptomic and Biochemical Changes During a Migraine Attack|Transcriptomic and Biochemical Changes During Spontaneous Attacks of Migraine With Aura and Migraine Without Aura||Danish Headache Center|No|Recruiting|August 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Bloodsamples|Both|18 Years|70 Years|No|Non-Probability Sample|15 patients with migraine without aura and 15 paitients with migraine with aura|January 2016|January 21, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02468622||19333|
NCT02424747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Karolinska Institutet SIR|Long-term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study|Long Term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study||Karolinska Institutet|No|Completed|January 2005|December 2011|Actual|December 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|103000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population was provided by the Swedish Intensive Care register and included        patients receiving intensive care treatment between January 2005 and January 2011|April 2015|April 23, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424747|5 Years|22701|
NCT02467348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF and Cirrhosis-01|Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.|To Study the Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.||Institute of Liver and Biliary Sciences, India|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|75 Years|No|||December 2015|December 21, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467348||19431|
NCT02467361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-201CIT|A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers|A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers||Boston Biomedical, Inc||Recruiting|August 2015|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467361||19430|
NCT02477579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-CLP-01|A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions|A Prospective, Multi-Center, Non-randomized, Single Arm, Open Label, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions||Nitiloop Ltd.|Yes|Not yet recruiting|June 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|80 Years|No|||September 2015|September 24, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477579||18644|
NCT02465632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLK-1403|To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (Valeant Pharmaceuticals, US) in the Treatment of Acne Vulgaris.||Glenmark Pharmaceuticals Ltd. India|No|Completed|April 2015|December 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1100|||Both|12 Years|40 Years|No|||December 2015|December 11, 2015|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465632||19563|
NCT02469636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-006|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||June 9, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469636||19255|
NCT02470273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGA-0860|Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)|Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)||Rockefeller University|No|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|Dermatology patients with a suspicious lesion that will be biopsied as standard of care|February 2016|February 17, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470273||19206|
NCT02424812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ciff001|Evaluation Of The Unilever Lifebuoy School-Based Handwashing Campaign (School Of 5) In Rural Bihar, India|Evaluation Of The Unilever Lifebuoy School-Based Handwashing Campaign (School Of 5) In Rural Bihar, India||London School of Hygiene and Tropical Medicine|No|Recruiting|February 2016|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5300|||Both|N/A|12 Years|Accepts Healthy Volunteers|||February 2016|March 18, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424812||22696|
NCT02424825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011383|Rouxbe Pilot for MS|A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis||Oregon Health and Science University|No|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||April 2015|April 22, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02424825||22695|
NCT02463968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150352|Chikungunya Arthritis in the Americas|A Pilot Study of the Pathogenesis of Chikungunya Arthritis in the Americas||University of Miami|No|Not yet recruiting|August 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|35|Samples With DNA|Cohort 1 CHRONIC CHIKUNGUNYA: Blood samples include one cell preparation tube with Sodium      Citrate will be collected for cytokine analysis by mesoscale and mass spectrophotometer      analyses, one blood RNA tube for PCR and one blood DNA tube for HLA typing. Synovial fluid      samples will be drawn for chronic patients with a knee effusion with one CPT and a blood RNA      tube.      Cohort 2 ACUTE CHIKUNGUNYA: Blood samples include one CPT for evaluation of biomarkers by      mass spectrophotometry, two blood RNA tubes drawn for mass spectrophotometry of viral      signaling and genomic analysis and one blood DNA tube for genomic analysis.      Cohort 3 HEALTHY CONTROLS: Participants will have one blood RNA tube, one blood DNA tube,      and one CPT tube drawn as controls for the other measurements.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients living in Baranquilla, Colombia during the study period.|August 2015|August 24, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463968||19691|
NCT02463981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESTC-SCAN-02|Anterior Insula Regulation and Pain Empathy|Voluntary Anterior Insula Regulation Impacts Pain Empathy and Functional Connectivity: a Real-time fMRI Study||University of Electronic Science and Technology of China||Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463981||19690|
NCT02464228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO-TIP-002|Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma|An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma|PTCL|Kura Oncology, Inc.|No|Recruiting|September 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464228||19671|
NCT02477852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D141107005214002|The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis|The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients||Beijing Chest Hospital|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|15 Years|75 Years|No|||June 2015|June 22, 2015|May 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477852||18623|
NCT02426307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGHS.HJE.01|Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed With 4D CT|Subclinical Aortic Valve biOprosthesis thRombosis Assessed With 4D Computed tomographY Imaging|SAVORY|Rigshospitalet, Denmark|No|Enrolling by invitation|April 2015|April 2020|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|75|||Both|55 Years|N/A|No|Probability Sample|A random subset of patients undergoing transcatheter aortic valve replacement (TAVR) or        surgical aortic valve replacement (SAVR) because of aortic valve stenosis.|October 2015|October 11, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426307||22581|
NCT02425800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 85A15|Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells|Optimizing Human Prostate Extracellular Matrix as a Structure for Maintenance and Studying of Prostate Cancer Stem Cells||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|March 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|prostate tissue|Male|N/A|N/A|No|Non-Probability Sample|Men scheduled for a prostatectomy|October 2015|October 22, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02425800||22620|
NCT02476045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 70/15|Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)|First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study|Valentino|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|June 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476045||18762|
NCT02470221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anesthesiologyPUMCH001|Goal-directed Intraoperative Fluid Therapy in High-risk Surgery|Effect of Goal-Directed Intraoperative Fluid Therapy on Outcomes Following Laparotomy of Gynecological Malignancies and Orthopedic Surgery||Peking Union Medical College Hospital|No|Not yet recruiting|June 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients underwent either laparotomy of gynecological malignancies or orthopedic surgery|June 2015|June 9, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02470221||19210|
NCT02474407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZNS-EP-1019|A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)|An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy||Acorda Therapeutics|Yes|Recruiting|June 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|12 Years|65 Years|No|||March 2016|March 9, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474407||18888|
NCT02416765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS10|Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes|An Open-label, Randomized, Five-way, Cross-over Study to Compare the Efficacy of Single- and Dual-hormone Closed-loop Operations Combined With Either Conventional Carbohydrate Counting or a Simplified Qualitative Meal-size Estimation, and Sensor-augmented Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416765||23314|
NCT02416778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron-COPD Pilotstudy|Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients|Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients||Otto Wagner Hospital|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||October 2015|October 15, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02416778||23313|
NCT02468492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #01979/FDA IDE#15944|Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation|Synovial Fluid Biomarker and Mesenchymal Stem Cell Response to PRP in Knee Osteoarthritis With Clinical and Imaging Outcome Correlation: Proof of Concept Study||Hunter Holmes Mcguire Veteran Affairs Medical Center|Yes|Active, not recruiting|September 2014|January 2017|Anticipated|November 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|18|||Both|40 Years|N/A|No|||July 2015|February 17, 2016|May 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468492||19343|
NCT02463552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSergipe|Naproxen on Tooth Sensitivity Caused by In-office Bleaching|Rior Use of Naproxen on Tooth Sensitivity Reduction After In-office Bleaching: Randomized Clinical Trial||Universidade Federal de Sergipe|No|Active, not recruiting|May 2015|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463552||19723|
NCT02463565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quality control programme|Assessment of Food Intake in Hospitalized Patients|Assessment of Food Intake in Hospitalized Patients: A Prospective Hospital Survey|UN+|University Hospital, Geneva||Active, not recruiting|September 1998|||November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4152|||Both|18 Years|N/A|No|Non-Probability Sample|Adult hospitalized patients in all wards|June 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02463565||19722|
NCT02426424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0305-14-ctil|Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients|Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients||Soroka University Medical Center|No|Not yet recruiting|April 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02426424||22572|
NCT02416323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-4131|Effectiveness and Implementation of a Mental Health Intervention for ASD|Effectiveness and Implementation of a Mental Health Intervention for ASD|AIM HI|University of California, San Diego|Yes|Enrolling by invitation|April 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|607|||Both|5 Years|13 Years|No|||April 2015|April 9, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416323||23348|
NCT02476786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506112|Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score|Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score||Washington University School of Medicine|No|Not yet recruiting|February 2016|February 2028|Anticipated|February 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|75 Years|N/A|No|||November 2015|November 30, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476786||18705|
NCT02476825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168769|A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers|A Randomized, Open-labelled Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids (ICS) on Adult Healthy Volunteers||University Hospitals, Leicester|No|Not yet recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476825||18702|
NCT02475863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMU-1527|Model-based Versus Traditional Warfarin Dosing in Children|A Study to Compare Model-based Warfarin Dosing to the Traditional Approach in Children After Congenital Heart Surgery at Glenfield Hospital, Leicester|WATCH|De Montfort University|No|Not yet recruiting|August 2015|January 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|45|||Both|N/A|18 Years|No|||June 2015|June 19, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475863||18776|
NCT02417701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00545|TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer|A Phase 2 Study of MLN0128 in Patients With Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations||National Cancer Institute (NCI)|Yes|Not yet recruiting|May 2015|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|February 15, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417701||23242|
NCT02416557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intraoperative hypothermia|Effect of PEEP on Intraoperative Hypothermia|Effect of Positive End Expiratory Pressure on Intraoperative Body Temperature in Patients Undergoing Spine Surgery; a Prospective Randomized Study||Seoul National University Hospital|No|Not yet recruiting|May 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|42|||Both|20 Years|65 Years|No|||April 2015|April 9, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02416557||23330|
NCT02476383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400928|Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain|Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain||University of Florida|No|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476383||18736|
NCT02473653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25914|Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer|Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive||University of Pennsylvania||Temporarily not available|June 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 1|Expanded Access|N/A|||||||Female|18 Years|N/A|No|||February 2016|February 24, 2016|June 4, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02473653||18946|
NCT02414321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51128.042.15|The Role of the Pulmonary Vasculature in the Fontan Circulation|The Role of the Pulmonary Vasculature in the Fontan Circulation||University Medical Center Groningen|No|Recruiting|June 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients (≥18 years), who attend the University Medical Center Groningen for        follow-up after a Fontan completion.        Additionally 5 adult patients (≥18 years) without a Fontan circulation and without a        univentricular heart-like diagnosis but with a clinical indication for right heart        catheterization and normal values at right heart catheterization measurements will be        included to serve as controls for the pulmonary artery OCT analysis.|October 2015|October 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02414321||23502|
NCT02417298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|668842|Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department|Ketamine Infusion for Acute Sickle Cell crisiS in the Emergency Department|KISS|The Brooklyn Hospital Center|No|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 13, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417298||23273|
NCT02469883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XNTK-I-03|A Study of Sinotecean on Tolerance and Pharmacokinetics|A Phase I Study of Sinotecean on Tolerance and Pharmacokinetics||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Recruiting|March 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02469883||19236|
NCT02469896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015TCZALS-001|A Trial of Tocilizumab in ALS Subjects|A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects|TCZALS-001|Barrow Neurological Institute|Yes|Recruiting|November 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469896||19235|
NCT02475980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-248|Providing Adolescent Contraception in the Emergency Room|Providing Adolescent Contraception in the Emergency Room (PACER)|PACER|University of New Mexico|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Female|13 Years|18 Years|No|Non-Probability Sample|Adolescent girls presenting to a pediatric emergency department for non-emergent        complaints|June 2015|October 27, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475980||18767|
NCT02475993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062922|SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge|SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge||Duke University||Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475993||18766|
NCT02248506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY-LAC-01-2012|Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis|Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis.||Instituto Palacios|Yes|Completed|June 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|56|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02248506||36222|
NCT02248519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47444.041.14|Laparoscopic Versus Open Gastrectomy for Gastric Cancer|Laparoscopic Versus Open Gastrectomy for Gastric Cancer, a Multicenter Prospectively Randomized Controlled Trial (LOGICA-trial)|LOGICA|UMC Utrecht|Yes|Recruiting|December 2014|January 2023|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02248519||36221|
NCT02242448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140158|Imaging Techniques in CT: Technical Development|Imaging Techniques in CT: Technical Development||National Institutes of Health Clinical Center (CC)||Recruiting|July 2014|January 2021|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|45 Years|N/A|Accepts Healthy Volunteers|||May 2015|November 18, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02242448||36688|
NCT02315573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMHC #14-30|Lidocaine With Epinephrine vs. Bupivacaine With Epinephrine as Local Anesthetic Agents in Wide-awake Hand Surgery|Lidocaine With Epinephrine vs. Bupivacaine With Epinephrine as Local Anesthetic Agents in Wide-awake Hand Surgery: an Outcome Study of Patients' Pain Perception.||St. Mary's Research Center, Canada|Yes|Recruiting|October 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315573||31074|
NCT02317328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150020|Adaptive Optics Retinal Imaging|Adaptive Optics Retinal Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|12 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 27, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317328||30939|
NCT02253511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2014|A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma|A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma||Beijing Weida Cancer Hospital of Chinese Traditional Medical Sciences|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||September 2014|September 29, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02253511||35837|
NCT02325375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS CD163|sCD163 in ALS Patients|Inflammation in Amyotrophic Lateral Sclerosis - a Study of Soluble Cluster of Differentiation 163 in the Cerebrospinal Fluid||University of Aarhus|Yes|Active, not recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|N/A||3|Anticipated|20|Samples Without DNA|spinal fluid and blood sample for identification of different factors|Both|18 Years|N/A|No|Non-Probability Sample|Patients with ALS, treated or newly diagnosed|December 2014|December 7, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325375||30321|
NCT02310555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUVA-MSS-JL|Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS)|Prospective Randomised Study Comparing Surgical Techniques in Patients With Diabetes Mellitus-II And Obesity|MSS|Hospital Universitario Virgen de la Arrixaca|No|Recruiting|October 2014|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02310555||31459|
NCT02323308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HB EP 03 CISOVAC|Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination|Study of Immunological, Virological, Serological Characteristics of HIV+ Patients Harboring Isolated Anti-HBc Profile and Response to Hepatitis B Vaccination|ANRSHBEP03|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|December 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|55|||Both|N/A|N/A|No|Non-Probability Sample|Patients with HIV infection and presenting with "isolated anti-HBc" profile. HBV        vaccination is recommended fot these patients.|December 2014|December 22, 2014|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02323308||30480|
NCT02323321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-CAR-012014|International EXPAND Heart Pivotal Trial|International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (EXPAND Heart Trial)|EXPANDHeart|TransMedics|Yes|Recruiting|September 2015|November 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323321||30479|
NCT02253108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-125-14|The OCT SORT-OUT VIII Study|Randomized Comparison of the Biolimus-eluting Biomatrix Neoflex™ og Everolimus-eluting SYNERGY™ Stents in All-comer Patients With Ischemic Heart Disease - The OCT SORT-OUT VIII|OCT SORT-OUT|Aarhus University Hospital Skejby|Yes|Active, not recruiting|May 2014|December 2025|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02253108||35868|
NCT02320292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS138D|Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma|The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation||Mayo Clinic|Yes|Recruiting|February 2015|||January 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02320292||30712|
NCT02323373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMSP|Topical Versus Intravenous Tranexamic Acid in Total Knee Arthroplasty|Topical Versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: a Randomized Clinical Trial With 90 Patients|TRANEXTKA|Irmandade da Santa Casa de Misericordia de Sao Paulo|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|90|||Both|N/A|N/A|No|||January 2015|January 12, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02323373||30475|
NCT02324270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DICLO-13-01|Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain|Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing the Safety and Efficacy of Generic Diclofenac Epolamine to Flector® Patch in the Treatment of Acute Pain Due to Minor Ankle Sprain||Actavis Inc.|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|658|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324270||30406|
NCT02241980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0191|Survey of Patient and Physician Knowledge and Perception Regarding Medicare Part D Plan Selection|Survey of Patient and Physician Knowledge and Perception Regarding Medicare Part D Plan Selection||Ohio State University|No|Recruiting|August 2014|||October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of Martha Morehouse General Internal Medicine Clinic at the Ohio State University        Wexner Medical Center|September 2014|September 15, 2014|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02241980||36724|
NCT02244970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIND2014|Mindfulness RCT for Early Psychosis|Brief Mindfulness-Based Intervention for Early Psychosis: A Randomized Controlled Study|MBIp|The University of Hong Kong|No|Not yet recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2014|September 16, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02244970||36494|
NCT02244983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUKNO_Protokoll_17-07-14|Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?|Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?|FUKNO|University Hospital, Basel, Switzerland|Yes|Recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|547|Samples With DNA|Bloodsamples|Both|65 Years|N/A|No|Non-Probability Sample|All fall patients aged 65 years and older who presented to the emergency department giving        written informed consentent|March 2016|March 24, 2016|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02244983|30 Days|36493|
NCT02245204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYS-I-01|Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Cancer|Phase 1 Trial of Tolerance and Pharmacokinetic of Chlorogenic Acid for Injection in the Advanced Malignant Tumor Subjects||Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02245204||36476|
NCT02320864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566-2013|The Strong Brain Study|A Pilot Study to Evaluate the Role of Brain Integrity on Post-hospital Sarcopenia||University of Florida|Yes|Recruiting|July 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will comprise two age-matched participant groups: 1.) 'Healthy' non-demented        (n=20) patients undergoing elective total knee arthroplasty, and 2.) age, education, and        disease matched (osteoarthritis knee pain; n=20) non-surgery peers. We expect to screen 60        potential participants to yield 40 participants who complete the protocol. All        participants will be recruited with the assistance of the Orthopedic Surgery Department at        UFHealth. The parallel control group will originate from the parent study physician. Only        right-handers will participate in this experiment because left-handedness is associated        with greater variability in white matter organization and cognitive functions.|October 2015|October 14, 2015|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02320864||30668|
NCT02313545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAV-MAE-101-IL|Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV|Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis||Izun Pharma Ltd|No|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||December 2014|April 7, 2015|December 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313545||31229|
NCT02250638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-68|Longitudinal Pancreatic Cancer Study|A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer||Fujirebio Diagnostics, Inc.|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|Serum and Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 140 subjects will be enrolled in this study. Women and men greater than or        equal to 18 years of age with a histologically/pathologically confirmed diagnosis of        pancreatic cancer and a minimum of three serial blood draws collected at disease        evaluation time points, as determined by the treating physician's standard of care, will        be eligible.|November 2015|November 4, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02250638||36058|
NCT02246907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1234|Exercise and Quality of Life in Leukemia Patients|Effects of Exercise on Patient Reported Outcomes in Newly Diagnosed Adults With Acute Leukemia During Induction Treatment: Exercise and Quality of Life in Leukemia Patients (EQUAL)|EQUAL|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|January 2014|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|21 Years|N/A|No|||October 2015|October 7, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02246907||36345|
NCT02246920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71336007|Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis||Teva Pharmaceuticals USA|No|Completed|March 2014|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|1110|||Both|12 Years|N/A|No|||September 2014|September 18, 2014|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02246920||36344|
NCT02316522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00043 [JIRB]|Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population|Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population||Weill Medical College of Cornell University|Yes|Active, not recruiting|May 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|240|Samples With DNA|Blood Urine|Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from Hamad Medical Corporation.|December 2015|December 18, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316522||31001|
NCT02323581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE# G130193|Feasibility and Safety of Endovascular Thoracoabdominal Aortic Aneurysm Repair Using a Standard-Configuration Stent Graft With Branches and Fenestrations in Patients at High Risk for Open Surgical Repair|Feasibility and Safety of Endovascular Thoracoabdominal Aortic Aneurysm Repair Using a Standard-Configuration Stent Graft With Branches and Fenestrations in Patients at High Risk for Open Surgical Repair|TAAA IDE|New York Presbyterian Hospital|Yes|Recruiting|January 2014|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323581||30459|
NCT02323594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-111|A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir|A Bioequivalence Study of the 90-mg Daclatasvir Tablet Relative to the 3 × 30-mg Daclatasvir Phase 3 Tablets, and Relative Bioavailability Studies of Chewable Pediatric Tablets of Daclatasvir and Asunaprevir in Healthy Adult Subjects||Bristol-Myers Squibb|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|88|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|February 23, 2015|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323594||30458|
NCT02323607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14169|Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations|Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations||Ohio State University Comprehensive Cancer Center|Yes|Suspended|January 2016|||May 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 18, 2014|Yes|Yes|per FDA|No||https://clinicaltrials.gov/show/NCT02323607||30457|
NCT02243189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105491|Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma|A Phase 1 Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in a Double-Blind, Randomized, Placebo-Controlled Setting in Healthy Subjects, and by an Open-Label Assessment in Atopic Subjects With Mild to Mild-Persistent Asthma With and Without Nasal Allergen Challenge Prior to Dosing||Janssen Research & Development, LLC|No|Terminated|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|September 16, 2014|No|Yes|Under enrollment and IP supply expiring.|No||https://clinicaltrials.gov/show/NCT02243189||36631|
NCT02471547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-1760-JR-CTIL|Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT|Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study||Sheba Medical Center|No|Not yet recruiting|July 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02471547||19108|
NCT02414087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-104-DR-29|Therapeutic Effects of Customized Insoles on Children With Flat Foot|Therapeutic Effects of Customized Insoles on Children With Flat Foot||Taipei Medical University|No|Not yet recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|52|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02414087||23520|
NCT02414334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2015-02|SABR-SCAN Trial for Pulmonary Oligometastases|Immediate Versus Delayed Stereotactic Ablative Radiotherapy (SABR) for Patients With Pulmonary Oligometastases From Colorectal Cancer: SABR SCAN Trial A Randomised Clinical Trial|SABR-SCAN|University Medical Center Groningen|No|Recruiting|June 2015|||June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02414334||23501|
NCT02415179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-2015|Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients|Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients||Mahidol University|No|Recruiting|May 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|15 Years|70 Years|No|||July 2015|July 14, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415179||23436|
NCT02471378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915147|Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates|In-Vitro Testing of Pregnancy Malaria Vaccine Candidates||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1200|||Female|15 Years|25 Years|No|||June 2015|June 23, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471378||19121|
NCT02471495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITE-2|RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)|A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect With Mitomycin C in Non-Muscle Invasive Bladder Cancer Patients With BCG-refractory CIS||Medical Enterprises Europe B.V.|Yes|Not yet recruiting|April 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471495||19112|
NCT02463357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0254|Three New Ideas to Protect Special Forces From the Stress of High Altitude|Three New Ideas to Protect Special Forces From the Stress of High Altitude||University of Colorado, Denver|Yes|Recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|140|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463357||19738|
NCT02424513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2M-04.00|A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer|A Phase 2 Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer||ImaginAb, Inc.|Yes|Withdrawn|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|18 Years|N/A|No|||May 2015|May 29, 2015|April 14, 2015|Yes|Yes|Clinical trial was postponed as a result of restructured business priorities.|No||https://clinicaltrials.gov/show/NCT02424513||22719|
NCT02462148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00032807|Perineural Steroids for Peripheral Nerve Blocks|Perineural Steroids for Saphenous Peripheral Nerve Blocks: An Equivalency Dosing Study.||Wake Forest Baptist Health|No|Recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|115|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462148||19830|
NCT02477488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14106|Optimal Administration of Allopurinol in Dialysis Patients|Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial||Maisonneuve-Rosemont Hospital|Yes|Recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|N/A|No|||June 2015|June 22, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477488||18651|
NCT02469168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRNNMC 391911-5|Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Spray Skin Applied Over Bilayered Wound Matrix|Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Skin Cell Harvesting Device in Combination With Widened Meshed Autograft Applied Over Bilayered Wound Matrix||Walter Reed National Military Medical Center|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|November 9, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469168||19291|
NCT02469441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-062|Does Coffee Intake Reduce Postoperative Ileus After Elective Colorectal Surgery|Does Coffee Intake Reduce Postoperative Ileus After Elective Colorectal Surgery - a Prospective, Randomized Controlled Study - the COFFEE STUDY|COFFEE|Kantonsspital Baden|Yes|Recruiting|August 2014|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|N/A|No|Probability Sample|Patients with elective colorectal surgery and primary anastomosis > 6cm above the anal        verge without stoma formation|June 2015|June 11, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02469441||19270|
NCT02425332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2015 0020|Validation of a Novel Robot-aided Assessment of Gait Ability|Validation of Lokomat-aided Assessment of Gait Ability||University of Zurich|Yes|Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425332||22656|
NCT02425345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI 1 U01 HL122273-01A1|Women's Health Initiative Strong and Healthy Study|Women's Health Initiative Strong and Healthy Study|WHISH|Fred Hutchinson Cancer Research Center|Yes|Enrolling by invitation|April 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52000|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425345||22655|
NCT02463474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401002|Mobile Health (mHealth) Black Women With Breast Cancer|Piloting the Acceptability of a Culturally Tailored Evidence-Based mHealth Intervention for Low-Income Black Women With Breast Cancer||University of Florida|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Female|21 Years|N/A|No|||January 2016|January 21, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463474||19729|
NCT02469714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-AD1306-01419|Integrated Care & Patient Navigators for Latinos With Serious Mental Illness|Integrated Care & Patient Navigators for Latinos With Serious Mental Illness||Illinois Institute of Technology|No|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469714||19249|
NCT02414594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONIS-APO(a)-LRx|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)|A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)||Ionis Pharmaceuticals, Inc.|No|Completed|April 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02414594||23481|
NCT02414854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13579|Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma||Sanofi|Yes|Recruiting|April 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1638|||Both|12 Years|N/A|No|||March 2016|March 15, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414854||23461|
NCT02471066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7311 02|rTMS Effect in Functional Psychogenic Movement Disorders Applied Alone Then Combined With Hypnotherapy|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Functional Psychogenic Movement Disorders Followed by a Feasibility Study of a Hypnotherapy Treatment as Adjuvant Therapy.|MOVHYSTIM|University Hospital, Toulouse|No|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|85 Years|No|||December 2015|December 22, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02471066||19145|
NCT02468531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.7-2017.7|The Clinic Trial On Protection Of Xenon Anaesthesia Against Perioperative Acute Lung Injury For Standford A Acute Aortic Dissection|||Beijing Anzhen Hospital|Yes|Active, not recruiting|January 2015|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02468531||19340|
NCT02468544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO7902|Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention|Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention||Columbia University|No|Not yet recruiting|May 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|55 Years|No|||January 2016|January 26, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02468544||19339|
NCT02476292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRC 5536|Impact of Vasculitis on Employment and Income|Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry||University of South Florida|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|426|||Both|18 Years|N/A|No|Non-Probability Sample|All individuals with vasculitis participating in the VCRC Patient Contact Registry, living        in the USA or Canada, and with a follow-up period ≥1 year since the diagnosis of        vasculitis.|January 2016|January 26, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02476292||18743|
NCT02412046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95022|Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics|Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics||University Hospital, Montpellier|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Both|18 Years|90 Years|No|||September 2015|September 3, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02412046||23677|
NCT02471144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2310|Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis||Novartis|Yes|Recruiting|September 2015|December 2022|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|6 Years|17 Years|No|||March 2016|March 16, 2016|May 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471144||19139|
NCT02469649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SVT-008|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||September 22, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469649||19254|
NCT02469662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2014-06E|Clinical Outcomes Study of the Nexel Total Elbow|Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow||Zimmer, Inc.|No|Recruiting|June 2015|December 2028|Anticipated|December 2027|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469662||19253|
NCT02469935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1025-31/1|Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study|Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study||Karolinska Institutet|No|Completed|October 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Patients referred to the radiology department for an abdominal ultrasound.|June 2015|June 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469935||19232|
NCT02474290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorafenib-Flt3 AML-2015|Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML|Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|June 2015|August 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||June 2015|June 14, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02474290||18897|
NCT02474303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1084414|Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal|A Demonstration Project of HIV Pre-exposure Prophylaxis (PrEP) With Tenofovir DF/Emtricitabine (TDF/FTC Among Female Sex Workers in Dakar, Senegal||Réseau Africain de Recherche sur le SIDA|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02474303||18896|
NCT02412293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKU-AKHSP|Community-based Perinatal and Newborn Care in Gilgit District, Northern Areas, Pakistan: an AKU-AKHSP Collaboration|Community-based Perinatal and Newborn Care in Gilgit District, Northern Areas, Pakistan: an AKU-AKHSP Collaboration||Aga Khan University|No|Completed|July 2001|September 2007|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3200|||Both|14 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 5, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02412293||23658|
NCT02467894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3117|Group-based Chronic Kidney Disease Care|Group-based Chronic Kidney Disease Care||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|August 2014|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|N/A|No|||June 2015|June 8, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467894||19389|
NCT02463045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-01|Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects|A Phase I Study to Evaluate the Safety/Tolerability and Pharmacokinetics of TOP1288 Rectal Single and Multiple Ascending Doses in Healthy Subjects and Multiple Doses in Subjects With Ulcerative Colitis||Topivert Pharma Ltd||Recruiting|May 2015|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02463045||19761|
NCT02423525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.229|Safety Study of Afatinib for Brain Cancer|A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer||University of California, San Diego|Yes|Not yet recruiting|June 2015|||December 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423525||22795|
NCT02411773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078214|Sympatholysis in Chronic Kidney Disease|Functional Sympatholysis and Exercise Intolerance in Chronic Kidney Disease|Sym-CKD|Emory University|No|Recruiting|May 2015|||June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|110|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411773||23698|
NCT02411786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14072|A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF|A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer||University of Wisconsin, Madison|Yes|Recruiting|July 2015|December 2022|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|March 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411786||23697|
NCT02464254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303013686|Intervention to Support Participation in Regular Exercise in the Elderly (INSPIRE)|Intervention to Support Participation in Regular Exercise in the Elderly (INSPIRE)|INSPIRE|Weill Medical College of Cornell University|Yes|Not yet recruiting|July 2015|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|N/A|No|||June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464254||19669|
NCT02477878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-008|Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant|A Phase I/II Study of Donor BPX-501 T Cell Infusion for Adults and Children With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant||Bellicum Pharmaceuticals|No|Not yet recruiting|July 2015|December 2030|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Year|65 Years|No|||June 2015|June 18, 2015|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477878||18621|
NCT02417987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-052a|High Volume Injection or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy|High Volume Injection (HVI) or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy: A Randomized Controlled Double Blinded Trial||Bispebjerg Hospital|No|Completed|May 2012|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02417987||23220|
NCT02422004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH100|Healing of Human Achilles Tendon Rupture|Healing of Human Achilles Tendon Rupture: Loading Pattern After Surgical Repair to Achieve Optimal Mechanical Properties and Clinical Outcome||Bispebjerg Hospital|Yes|Recruiting|August 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|67 Years|No|||April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422004||22912|
NCT02424019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-01-15-004|Phase 4 IOP Signals Associated With ILUVIEN®|A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg|PALADIN|Alimera Sciences|No|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|N/A|No|||February 2016|February 26, 2016|April 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424019||22757|
NCT02471781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001 CA|Zenith® TX2® Low Profile TAA Endovascular Graft|Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study||Cook||Active, not recruiting|April 2013|January 2021|Anticipated|January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471781||19090|
NCT02471794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063493|Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study|Personalized Health Planning in Shared Medical Appointments for Individuals With Type II||Duke University|No|Recruiting|December 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471794||19089|
NCT02467985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1042|A Trial to Reduce Referred Pain in the Shoulder Following a Laparoscopic Gynecological Surgery|FIGARO : A Double-blinded RCT to Reduce Referred Pain in the Shoulder Following a Laparoscopic Gynecological Surgery|FIGARO|Université de Sherbrooke|Yes|Recruiting|April 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|175|||Female|18 Years|65 Years|No|||June 2015|June 5, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02467985||19382|
NCT02423681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-101|A Comparison of CPAP With and Without Humidification: A Pilot Study|Evaluation of Overall Therapy Cost Comparing First Intention and Second Intention Heated Humidification for CPAP: A Pilot Study.||Fisher and Paykel Healthcare|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02423681||22783|
NCT02423694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01|Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression|||Guangdong Provincial Hospital of Traditional Chinese Medicine||Recruiting|September 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Female|45 Years|55 Years|No|||April 2015|April 19, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02423694||22782|
NCT02425462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17444|To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis|EffectiveNess of VISanne® in Improving Quality of Life in asIan wOmen With eNdometriosis|ENVISIOeN|Bayer|No|Recruiting|April 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|870|||Female|18 Years|N/A|No|Probability Sample|Asian patients at least 18 years of age with Clinical or surgical diagnosis of        endometriosis, and patients with endometriosis associated pelvic pain|March 2016|March 7, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425462||22646|
NCT02464735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 15-142|Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation|Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation|SLEEWE|St. Michael's Hospital, Toronto|No|Not yet recruiting|September 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|17 Years|N/A|No|Non-Probability Sample|Mechanically ventilated Intensive Care Unit patients who have a spontaneous breathing        trial planned for the next day.|December 2015|December 11, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02464735||19632|
NCT02408484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMA-04|Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency|Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency||Octapharma|Yes|Not yet recruiting|December 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|12 Years|No|||October 2015|October 14, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408484||23951|
NCT02506491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMAFI/24/14|A Pilates Exercise Program for Improving Core Strength, Balance and Functional Autonomy in Aged Women|A Pilates Exercise Program for Improving Core Strength, Balance and Functional Autonomy in Aged Women: Study Protocol for a Randomized Controlled Trial||Universidad Católica San Antonio de Murcia|Yes|Active, not recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506491||16424|
NCT02498041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCambridge|The Efficacy and Patient Tolerance of Ultrathin Nasal Endoscopy to Detect Barrett's Oesophagus|Study to Compare the Efficacy and Patient Tolerance of Ultrathin Nasal Endoscopy to Detect Barrett's Esophagus Compared With Conventional Endoscopy to Inform a Future Multicentre Screening Trial|NOSE|University of Cambridge|Yes|Completed|April 2009|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|115|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02498041||17074|
NCT02498054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3135718|Diabetic Mellitus Patients Glucose Range Awareness After Experiencing a New Blood Glucose Meter Feature|Diabetic Mellitus Patients Glucose Range Awareness After Experiencing a New Blood Glucose Meter Feature||LifeScan|No|Not yet recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|16 Years|N/A|No|||July 2015|July 14, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02498054||17073|
NCT02405975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC-CUH-001|RCT Assessing the Impact of Online Training on Doctors' Prescribing for Older Patients|A Randomized Controlled Trial Assessing the Impact of an Online Educational Tool on Doctors' Knowledge and Confidence With Regards to Prescribing for Older Patients||University College Cork|No|Recruiting|August 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|100|||Both|N/A|N/A|No|||April 2015|April 7, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02405975||24142|
NCT02405988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI-15-001|Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid|Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid|OPI-15-001|Norwegian University of Science and Technology|Yes|Completed|April 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02405988||24141|
NCT02408588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1996|Evaluation of Compensatory Reserve in Obstetrical Patients|Evaluation of Compensatory Reserve in Obstetrical Patients||University of Colorado, Denver|No|Enrolling by invitation|February 2015|October 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Female|14 Years|44 Years|No|Non-Probability Sample|Enrollment is limited to pregnant females because only pregnant females undergo fetal        surgery and/or labor and childbirth.|December 2015|December 3, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408588||23943|
NCT02496702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15006703|Playware Technology for Balance Training|Efficacy of Interactive Modular Tiles Training Versus "Usual Care" on Physical Attributes Among Elder Adults 70+. A Randomized Controlled Trial|IMT|Technical University of Denmark|No|Active, not recruiting|July 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496702||17176|
NCT02406573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015024|A Pilot Study to Assess Nominal Versus Controlled Stimuli on Dentinal Hypersensitivity|||Procter and Gamble||Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406573||24098|
NCT02404194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH105246|Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis|Optimizing Cognitive Training to Improve Functional Outcome in Clinical High Risk (CHR)||Harvard University|Yes|Recruiting|March 2015|||September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|15 Years|30 Years|No|||March 2015|March 26, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02404194||24279|
NCT02404207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS50|Soybean Oil Trial of cArdiovascular Risk|The Effect of High-Oleic Soybean Oil on Biomarkers of Risk for Metabolic Syndrome|STAR|USDA Beltsville Human Nutrition Research Center|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02404207||24278|
NCT02402296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al-Azhar 1-2013|Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis|Efficacy of β-glucan in Treatment of Localized Aggressive Periodontitis: A Short Term Double-blinded, Placebo-controlled, Randomized Clinical Trial||Al-Azhar University|No|Completed|January 2013|August 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|27 Years|No|||May 2015|May 21, 2015|March 6, 2015|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT02402296||24423|No limitations or caveats were reported throughout the study period.
NCT02415088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.26/anesth15.01|Ultrasound-guided Selective Shoulder Block Versus Ultrasound-guided Interscalene Brachial Plexus Block, an RCT|Treatment of Postoperative Pain After Shoulder Surgery. Ultrasound-guided Block of the Axillary and Suprascapular Nerves (Selective Shoulder Block) Versus Ultrasound-guided Interscalene Brachial Plexus Block: An Observer-blinded RCT||Jessa Hospital|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415088||23443|
NCT02407847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS_in_spoedzorg|The Effect of Substitution of Out-of-hours Care From General Practitioners to Nurse Practitioners|The (Cost-)Effectiveness of Substitution in Out-of-hours Primary Care; Towards an Optimal Balance Between General Practitioners and Nurse Practitioners.||Radboud University|No|Recruiting|May 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|12000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407847||24000|
NCT02419378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM12_0026|Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential|Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential|ALAIN01|University Hospital Muenster|No|Recruiting|May 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|55 Years|No|||October 2015|November 2, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02419378||23114|
NCT02419391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-MVA-001|Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine|A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine in Healthy Adult Subjects||Bavarian Nordic|No|Active, not recruiting|August 2015|June 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419391||23113|
NCT02415322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICURE|Cohort Study on Internet Game and Smart Phone Addiction|A Prospective Cohort Study to Identify Pathogenesis and Risk Factors on Internet Game and Smart Phone Addiction||National Clinical Research Coordination Center, Seoul, Korea|Yes|Recruiting|May 2015|August 2019|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|10 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Tatal 3,000 elementaty and sencondary school students|March 2016|March 9, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02415322||23425|
NCT02398383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014580|Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes|Role of Glucagon in Glucose Control in Cystic Fibrosis Related Diabetes||Yale University|No|Recruiting|March 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02398383||24724|
NCT02415868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-14-0004|Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women|Development of an Ex-vivo High-throughput Screening Assay for the Vaginal Microbiota of Post-menopausal Women|FLORA|Kimberly-Clark Corporation|No|Completed|December 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|Samples Without DNA|Microbiota from Vaginal Swab|Female|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Post-menopausal women|February 2016|February 22, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415868||23383|
NCT02420340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27956|Using The HOPES Program in Transition Care|||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|September 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Both|50 Years|N/A|No|||April 2015|April 16, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02420340||23040|
NCT02398695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272-2012 SubStudy|Oral Alkali Production and Caries Prevention in Children (Longitudinal)|Oral Alkali Production and Caries Prevention in Children (Longitudinal Component)||University of Florida|No|Active, not recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|310|Samples With DNA|Saliva and Plaque|Both|2 Years|7 Years|No|Probability Sample|The study population will consist of unrelated children aged between 2 and 5 years with        different levels of caries experience.|December 2015|December 4, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398695||24700|
NCT02420080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-305|A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304|A Multicenter Non-Interventional Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304||Chimerix|No|Enrolling by invitation|February 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|260|||Both|2 Months|75 Years|No|Non-Probability Sample|allogeneic hematopoietic cell transplant (HCT) recipients who were at risk of progression        to disseminated AdV disease. Allogeneic hematopoietic cell transplant recipients with        disseminated AdV disease|February 2016|February 25, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420080||23060|
NCT02421887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOXI|Males, Antioxidants, and Infertility Trial|Males, Antioxidants, and Infertility (MOXI) Trial|MOXI|Yale University|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|790|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421887||22921|
NCT02421900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0090|Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application|||Yonsei University|No|Not yet recruiting|April 2015|November 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|40cc blood sampling|Both|19 Years|N/A|No|Non-Probability Sample|patients with atrial fibrillation|April 2015|April 15, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421900||22920|
NCT02395874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-LOGA|tDCS and Speech Therapy to Improve Aphasia|MP-LoGa: Bi-hemispheral Transcranial Direct Current Stimulation to Improve the Severe Aphasia in Subacute Stroke Patients: a Randomized, Placebo-controlled, Double Blinded Multi-center Trial|MP-LOGA|Medical Park AG|Yes|Recruiting|May 2015|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|90 Years|No|||September 2015|September 30, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395874||24917|
NCT02408926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cev002|Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand|Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand||Universiteit Antwerpen|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408926||23917|
NCT02418117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|613/15|Accuracy of Computer Guided Implant Surgery|Accuracy of Computer Guided Implant Surgery With the Use of R2Gate Stereolitographic Template|STIMPLANTSRG|Concordia Dent Srl|No|Completed|July 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418117||23210|
NCT02418130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_UDCA004|A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.|||Daewoong Pharmaceutical Co. LTD.||Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|19 Years|N/A|No|||April 2015|April 15, 2015|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02418130||23209|
NCT02418143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PR-1169|A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope|A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope|JUMP|CorMatrix|No|Withdrawn|September 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of any subject who has received the CorMatrix CanGaroo        ECM Envelope for an implantable electronic device placement following a battery change out        or upgrade.|January 2016|January 26, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418143||23208|
NCT02402543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS: M13-226|Pre-Emptive Analgesia in Ano-Rectal Surgery|Pre-Emptive Analgesia in Ano-Rectal Surgery|PEAARS|University of Vermont|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402543||24404|
NCT02497729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150897|Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial|Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial|Check-UP|Vanderbilt University|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|170|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497729||17098|
NCT02495701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-260-15|Complications Related to Arthroscopic Surgery of the Hip - a Prospective Cohort Study|Complications Related to Arthroscopic Surgery of the Hip - a Prospective Cohort Study||University of Aarhus|No|Recruiting|June 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing hip arthroscopic surgery at Horsens Hospital, Denmark|June 2015|July 10, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02495701||17253|
NCT02495714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KristianiaUC|HOPPLearning - Active Learning in Elementary Schools|HOPPLearning - Active Learning in Elementary Schools in Horten Municipality|HOPPLearning|Kristiania University College|Yes|Enrolling by invitation|January 2015|December 2020|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2800|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02495714||17252|
NCT02400580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13110403|IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy|Intravenous Acetaminophen Versus Saline in Postoperative Analgesia After Laparoscopic Hysterectomy: A Randomized, Double Blind, Placebo Controlled Trial||University of Pittsburgh|Yes|Recruiting|February 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|154|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400580||24555|
NCT02402816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|MPP Narrow QRS:Pilot Study on Multipoint Pacing in Patients With QRS Beetwen 100 and 130 Msec|MPP Narrow QRS:Pilot Study on Multipoint Pacing in Patients With Narrow QRS||Humanitas Hospital, Italy|No|Not yet recruiting|May 2016|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402816||24385|
NCT02507011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504M69361|Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy|Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507011||16384|
NCT02507700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiskapiTRH 2015|Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral Palsy|Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral Palsy||Diskapi Teaching and Research Hospital|No|Recruiting|June 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|15 Years|No|||July 2015|July 24, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507700||16331|
NCT02406599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-07-001|MarginProbe® System U.S. Post-Approval Study|MarginProbe® System U.S. Post-Approval Study Protocol CP-07-001||Dune Medical Devices|No|Recruiting|June 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|440|||Female|18 Years|N/A|No|||January 2016|January 24, 2016|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406599||24096|
NCT02406482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN8855|Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan|Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan|MFKZ|Columbia University|No|Not yet recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|520|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406482||24105|
NCT02406495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-58|Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week|Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week||Coopervision, Inc.|No|Completed|April 2015|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|40 Years|No|||July 2015|July 23, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406495||24104|
NCT02406508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-HCC-201|Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC|An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma||Delcath Systems Inc.|Yes|Recruiting|October 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406508||24103|
NCT02508324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014939|IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia|Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia||Weill Medical College of Cornell University|No|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508324||16284|
NCT02508337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDD-1002-065|Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain|A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation||Xigen SA|No|Active, not recruiting|July 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508337||16283|
NCT02500082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00017250|Triheptanoin (UX007) to Treat Citrate Transporter Deficiency|Compassionate Use of Triheptanoin (UX007) to Treat Citrate Transporter Deficiency||Children's Hospital Boston||No longer available||||||N/A|Expanded Access|N/A|||||||Both|4 Years|9 Years||||January 2016|January 27, 2016|July 14, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02500082||16917|
NCT02401139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 15009|Ketamine Trial for the Treatment of Depression|Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase||The University of New South Wales|No|Recruiting|March 2015|September 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|N/A|No|||March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401139||24512|
NCT02404116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|: z83hdhmg|Metacognitive Therapy for Health Anxiety|Metacognitive Therapy for Health Anxiety: A Randomised Control Trial||University of Manchester|Yes|Recruiting|March 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404116||24285|
NCT02406651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-652-02|Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD|A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)||Generon (Shanghai) Corporation Ltd.|No|Not yet recruiting|May 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406651||24092|
NCT02507258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002K|PMCF Study for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components||MicroPort Orthopedics Inc.|No|Not yet recruiting|July 2016|September 2028|Anticipated|September 2028|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with a PROFEMUR® Am Femoral Stem and PROCOTYL®        O HA-Coated Acetabular Component|March 2016|March 15, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507258||16365|
NCT02507856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODAST|Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA|Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA|PRODAST|University Hospital, Essen|Yes|Recruiting|July 2015|December 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with recent (≤ 1 week from index) ischemic stroke or TIA and with confirmed        non-valvular AF (documented by 12 lead ECG, ECG rhythm strip, pacemaker/ICD        electrocardiogram, or Holter ECG) will be included.|July 2015|July 29, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02507856|3 Months|16319|
NCT02396849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4689673|Modulation Of Airway Reactivity With Chronic Mechanical Strain|Modulation Of Airway Reactivity With Chronic Mechanical Strain||Indiana University|Yes|Recruiting|January 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|17 Years|No|||November 2015|December 10, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396849||24842|
NCT02399943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOBILITY-001|A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies||University Health Network, Toronto|No|Not yet recruiting|June 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399943||24604|
NCT02501759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10086|Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer|Pilot Study of Transrectal Multiparametric MRI-Guided Biopsy: Role in Prostate Cancer Evaluation||OHSU Knight Cancer Institute|Yes|Recruiting|May 2015|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|512|||Male|N/A|N/A|No|||February 2016|February 11, 2016|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501759||16788|
NCT02496468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZL_DA_AA-1|Kinder-Register Asthma Clinical Cohort|The Kinder [Children]-Register Asthma (KIRA) Clinical Cohort of the German Centre for Lung Research (DZL), Disease Area Asthma Allergy|KIRA|Klinikum der Universitaet Muenchen|No|Recruiting|January 2013|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|whole blood (EDTA), serum, stool samples, whole blood cell pellets, primary nasal epithelial      cells, induced sputum cells|Both|6 Months|18 Years|Accepts Healthy Volunteers|Probability Sample|preschool children with wheeze and school children as well as adolescents with asthma|February 2016|February 4, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02496468||17194|
NCT02397187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003-15-SHA|Efficacy of a Structured, Dimension-based, STI in De-compensated Personality-disorder, Hospitalized, Patients|The Assessment of the Efficacy of a Structured, Dimension-based, STI (Short Term Intervention) in De-compensated Personality-disorder, Hospitalized, Patients|LOOP-PersDis|Shalvata Mental Health Center|No|Not yet recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||March 2015|March 23, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02397187||24816|
NCT02400398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2014-03-Hendifar-PanCa|Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients|A Longitudinal, Single Institution Study Evaluating Weight Stability in Advanced Pancreatic Cancer Patients With Cachexia Who Are Receiving Enteral Feeding|PanCax|Cedars-Sinai Medical Center|No|Recruiting|April 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|37|||Both|18 Years|N/A|No|Probability Sample|Pancreatic cancer patients with cachexia receiving enteral feedings by way of        gastrojejunal or jejunal tube.|December 2015|December 28, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02400398||24569|
NCT02506699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-025|Observational Study of the Analgesic Effect of Treatment With rTMS in Patients With Chronic Neuropathic Pain|Observational Study of the Analgesic Effect of Treatment With rTMS in Patients Suffering From Chronic Neuropathic Pain Refractory to Conventional Treatment and Monitored and Evaluated in Consultation Multidisciplinary Chronic Pain in Lower Normandy|rTMSDOULNEURO|University Hospital, Caen|No|Recruiting|June 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|70 Years|No|Non-Probability Sample|Chronic Neuropathic Pain|July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506699||16408|
NCT02496754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCZZU-New protocol|The Application of a New Ovarian Stimulation Protocol in IVF|The Application of a New Ovarian Stimulation Protocol in IVF: a Randomized Controlled Study||The First Affiliated Hospital of Zhengzhou University|No|Recruiting|June 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|22 Years|38 Years|No|||July 2015|July 13, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496754||17172|
NCT02500641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIN/14/FEB-PWV/001|Intensive Urate Lowering Therapy With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout|The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial|FORWARD|Menarini International Operations Luxembourg SA||Recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02500641||16874|
NCT02409472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GILDA|Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma|A Randomized Trial Of Intensive Versus Minimal Surveillance Of Patients With Resected Dukes B2-C Colorectal Carcinoma|GILDA|Mario Negri Institute for Pharmacological Research|No|Completed|April 1998|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1242|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409472||23875|
NCT02396628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIG-P000814|Ruxolitinib In GvHD|Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Graft-versus-Host Disease (GvHD)|RIG|University Hospital Freiburg|No|Not yet recruiting|September 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02396628||24859|
NCT02498990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/628-31|Low Calorie Diet and Diabetes|Long-term Metabol Control After Weight Reduction With Low Calorie Diet in Type 2 Diabetes|LCD|Karolinska University Hospital|No|Enrolling by invitation|August 2015|August 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02498990||17001|
NCT02499003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETN-1 GOAL|GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma|The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma||Johannes Gutenberg University Mainz|Yes|Recruiting|August 2015|October 2021|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02499003||17000|
NCT02499016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFGS-SSILA-01|Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Appendectomy: a Randomized Controlled Trial|Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Multiport Appendectomy: a Randomized Controlled Trial||Nanfang Hospital of Southern Medical University|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|No|||March 2015|July 13, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02499016||16999|
NCT02400047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14_9853_DEXA OP|Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP|Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP|DEXA OP|Rennes University Hospital|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|567|||Both|1 Year|16 Years|No|||August 2015|August 10, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400047||24596|
NCT02398214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203083RIC|A Sleep Hygiene-based Intervention Program for Infants and Toddlers|A Sleep Hygiene-based Intervention Program for Infants and Toddlers||National Taiwan University Hospital|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|350|||Both|6 Months|2 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02398214||24737|
NCT02398227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH095767|Treatment of PTSD in Residents of Battered Women's Shelters|Treatment of PTSD in Residents of Battered Women's Shelters|HOPE|The University of Akron|Yes|Enrolling by invitation|January 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Female|N/A|N/A|No|||November 2015|November 30, 2015|May 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02398227||24736|
NCT02405377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14KMM02|Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy|Chinese People's Liberation Army General Hospital||Chinese PLA General Hospital|Yes|Completed|February 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|264|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405377||24188|
NCT02405624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401043RINA|CPAP for Infantile Pompe Disease|Efficacy of Continuous Positive Airway Pressure of Treatment of Hypernasality of Children With Infantile Pompe Disease||National Taiwan University Hospital|No|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|4 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02405624||24169|
NCT02499796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981|Short-term Effects of Humidification Devices on Respiratory Pattern and Work of Breathing During Invasive Ventilation|Short-term Effects of Humidification Devices on Respiratory Pattern and Work of Breathing During Invasive Ventilation||Fondazione Salvatore Maugeri|No|Recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02499796||16939|
NCT02506738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUGetafe|mHealth to Early Detect Exacerbation for Older People With Heart Failure|(in Spanish) Utilidad de un Instrumento telediagnóstico en la detección de la reagudización de la Insuficiencia Cardiaca crónica en Ancianos|mobileHF|Hospital Universitario Getafe|Yes|Completed|August 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|90|||Both|75 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506738||16405|
NCT02502058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University_of_Minnesota2|Dental Implant Stability When Using the Densah Bur™ Bone Compaction Process to Prepare Dental Implant Sites|Observational, Case-Series Study Evaluation of Bone Width and Dental Implant Stability When Using the Densah Bur™ Bone Compaction Process to Prepare Dental Implant Sites||University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study subjects will include 40 healthy adult patients who seek dental implant        placement to replace missing teeth in their mouths.|September 2015|September 29, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02502058||16765|
NCT02403037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20150213001|Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients|The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot and Feasibility Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Recruiting|July 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|114|||Female|18 Years|N/A|No|||September 2015|September 7, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403037||24368|
NCT02397499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-18|Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat|A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects|AbCONTOUR1|Neothetics, Inc|No|Completed|April 2015|||December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397499||24792|
NCT02506816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedOPP044|Preoperative Olaparib Endometrial Carcinoma Study (POLEN)|A Preoperative "Window-opportunity", Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma|Polen|MedSIR|No|Not yet recruiting|September 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|36|Samples With DNA|Tumor cells Plasma|Female|18 Years|90 Years|No|Non-Probability Sample|Patinets diagnosed with endometrial carcinoma prior surgery|June 2015|July 21, 2015|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506816||16399|
NCT02508727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-156|Myocardial Deformation in Real-time 3D Ultrasound. Normal Values in Adults and Validation Against the Tagged MRI||DIRECT|University Hospital, Caen|No|Recruiting|March 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508727||16253|
NCT02406105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSRSPD-COI-03|An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease|An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|January 2015|December 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02406105||24132|
NCT02399644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHSAM_RS2010/002|Physical Activity and Acceptance and Commitment Therapy as Treatment for Long Term Pain|Physical Activity and Acceptance and Commitment Therapy as Treatment for Long Term Pain. A Randomized Controlled Trial|FACTA|Linkoeping University|No|Recruiting|January 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02399644||24627|
NCT02397746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002J|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems||MicroPort Orthopedics Inc.|No|Enrolling by invitation|July 2015|April 2029|Anticipated|April 2028|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with PROFEMUR® Gladiator femoral stems|October 2015|October 16, 2015|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397746||24773|
NCT02397759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-54|Metabolomic Profile and Proteasic Activity as Biomarkers for Early Detection of Arterial Vasospas in Arterial Vasospasm After Aneurysmal Subarachnoid Hemorrhage|Analysis of Cerebral Spinal Fluid and Plasma After Aneurysmal Subarachnoid Hemorrhage by Evaluating a Metabolomic Profile and the Proteasic Activity as Biomarkers for Early Detection of Arterial Vasospasm||Assistance Publique Hopitaux De Marseille|No|Recruiting|November 2013|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02397759||24772|
NCT02496182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C34-11|Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment|Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment|Picheon|Grupo Medifarma, S. A. de C. V.|Yes|Recruiting|July 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|85 Years|No|||July 2015|July 13, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496182||17216|
NCT02496195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150146|Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders|Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|15|||Both|1 Year|100 Years|No|||April 2015|December 19, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02496195||17215|
NCT02403947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 394 03|MEsenchymal StEm Cells for Multiple Sclerosis|Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study|MESEMS|University Hospital, Toulouse|Yes|Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|50 Years|No|||February 2016|February 14, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02403947||24298|
NCT02403778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0948.cc|Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma|Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma||University of Colorado, Denver|Yes|Recruiting|September 2015|March 2020|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|No|||February 2016|February 3, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403778||24311|
NCT02397733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREMER-TRIAL|Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)|Phase III Trial Evaluating Memory Preservation of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in Small Cell LUNG Cancer (PREMER-TRIAL)||Grupo de Investigación Clínica en Oncología Radioterapia|No|Recruiting|March 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02397733||24774|
NCT02507635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535|Anti-inflammatory H1 Antihistamines Allergic Rhinitis|In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis||Iuliu Hatieganu University of Medicine and Pharmacy|Yes|Completed|February 2009|May 2013|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02507635||16336|
NCT02506556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL14/02|Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer|A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.|PIKNIC|Peter MacCallum Cancer Centre, Australia|No|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506556||16419|
NCT02394353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interventions|Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass|||Ministry of Health, Brazil|Yes|Completed|January 2013|February 2016|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394353||25034|
NCT02397993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helios 6/1/15|Serum Parameter Prior and After EUS-guided Fine Needle Aspiration of the Pancreas|Serum Lipase, Amylase and CA 19-9 Prior and After EUS-guided Fine Needle Aspiration of the Pancreas||Helios Albert-Schweitzer-Klinik Northeim|No|Recruiting|March 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|208|Samples Without DNA|Pancreatic cells obtained by fine needle aspiration during endosonography Blood samples      prior and after EUS with a assessment of CA19-9, Lipase and Amylase|Both|18 Years|N/A|No|Non-Probability Sample|Patients with independent indication for endoscopic ultrasound-guided fine needle        aspiration of the pancreas due to pancreatic disease (e.g. pancreatitis, pancreatic        masses) no volunteers accepted|February 2016|February 17, 2016|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02397993||24754|
NCT02500823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY20140813-2|Association Between Mitochondrial DNA Content and Risk of Coronary Heart Disease|Association Between Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Coronary Heart Disease||Fourth Military Medical University|No|Recruiting|April 2015|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|Samples With DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy      production, modulation of oxidation-reduction status, generation of reactive oxygen species      and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome      comprised of independently replicating double stranded DNA (mtDNA).|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|A total of 200 eligible CHD patients were anticipated to include in this study.Moreover,        The 200 healthy controls without previous CHD history were also recruited from individuals        who visited investigator's hospital for physical examination during the same time period.|July 2015|July 16, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500823||16860|
NCT02397616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0013|Effects of Position and a Test Meal on Esophago-gastric Junction Morphology and Function Assessed by High-resolution Impedance Manometry (HRM)|Effects of Position and a Test Meal on Esophago-gastric Junction Morphology and Function Assessed by High-resolution Impedance Manometry (HRM)||University of Zurich|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to hour unit for high resolution manometry (patients with dysphagia,        reflux or other complaints)|December 2015|December 10, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397616||24783|
NCT02398864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203-2015|Accuracy and Safety of Endobronchial Ultrasound (EBUS) in Suspected Non-malignant Mediastinal Lymphadenopathy|Accuracy and Safety of Endobronchial Ultrasound (EBUS) in Suspected Non-malignant Mediastinal Lymphadenopathy|EBUS-nonM|Hannover Medical School|No|Not yet recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02398864||24687|
NCT02419469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0396|Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|30 Years|No|||November 2015|November 13, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419469||23107|
NCT02409524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-022-HCC-BKK-VAX+S|An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects|Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma||Immunovative Therapies, Ltd.|No|Not yet recruiting|April 2016|April 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409524||23871|
NCT02393963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013-089|Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty|Role of Low Dose Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty: A Randomized Placebo Controlled Study||Orthopaedic Innovation Centre|Yes|Recruiting|July 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393963||25064|
NCT02411266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008 0406 II|Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage|Remote Ischemic Preconditioning to Ameliorate Delayed Ischemic Neurological Deficit After Aneurysmal Subarachnoid Hemorrhage: a Safety and Feasibility Study|PreLIMBS|University of Miami|No|Recruiting|January 2008|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 20, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411266||23737|
NCT02411331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0232|Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci|Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci|Etha-LOCK|University Hospital, Clermont-Ferrand||Recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411331||23732|
NCT02411344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS.T.R.O.BC01-13|Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy|PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study|PER-ELISA|Istituto Oncologico Veneto IRCCS|No|Recruiting|February 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02411344||23731|
NCT02411357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA036670|Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II|||University of Vermont|Yes|Recruiting|March 2015|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|195|||Female|18 Years|44 Years|No|||April 2015|April 2, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02411357||23730|
NCT02409537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011|Effects of Dietary Antioxidants to Prevent Cardiovascular Disease|Cardiovascular Risk and Benefits From Antioxidant Dietary Intervention With Red Wine in Asymptomatic Hypercholesterolemics|RWTAC|Aeromedical Center, Thessaloniki|Yes|Completed|March 2013|March 2015|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02409537||23870|
NCT02402946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)200/2011 ammendment|Placebo-controlled, Randomized Trial of a Simplified Biofeedback Technique for the Treatment of Rumination|Valoración Objetiva y Tratamiento de la rumiación||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|February 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|85 Years|No|||November 2015|November 11, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402946||24375|
NCT02420028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMT-CT-003-ONC|A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic Population|A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic Population||Optomeditech Oy|No|Recruiting|April 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|334|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02420028||23064|
NCT02427126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005109-19|Apixaban for Treatment of Embolic Stroke of Undetermined Source|Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)|ATTICUS|University Hospital Tuebingen|No|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|February 12, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427126||22518|
NCT02427139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSS-ALP 01|ANSiStim Study for Active Labor Pain|Study of ANSiStim for Pain Relief During Active Labor Phase Through Continues Checking of VAS SCORE|ANSS-ALP|DyAnsys, Inc.|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427139||22517|
NCT02395861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120915|Prognosis of Brain Reflexes|Evaluation of the Clinical and Electrophysiological Responses of the Brainstem in Patients With Alteration of Consciousness in Relation or Not With Sedation: Prognostic Study of Brain Reflexes|PRORETRO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|September 24, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02395861||24918|
NCT02396121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.01.FR.NHS|Micronutrient and Malnourished Elderly|Évaluation de l'évolution du Statut Nutritionnel en Micronutriment Chez Les Patients âgés dénutris bénéficiant d'Une complémentation Nutritionnelle Orale|Reboot|Nestlé|No|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|70 Years|N/A|No|||February 2015|March 17, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02396121||24898|
NCT02408822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-03|Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS)|Superiority of Drug-eluting Balloon Angioplasty Versus Plain Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis : a Multicentre, Randomized, Controlled Trial|B3AV|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408822||23925|
NCT02422823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Volumes|Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis|Comparative Evaluation of the Anesthetic Efficacy of 1,8mL and 3,6mL of 4% Articaine With 1: 100,000 Epinephrine in Blocking the Inferior Alveolar Nerve in Patients With Irreversible Pulpitis of Mandibular Molars|Volumes|University of Sao Paulo|No|Recruiting|April 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02422823||22849|
NCT02424981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Threshold IMT1|Efficiency of Inspiratory Muscle Training in Elderly People|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|April 2015|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02424981||22683|
NCT02424994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13_096R|Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study|Morbidity and Mortality in Patients Diagnosed With Hypertrophic Cardiomyopathy: a CALIBER Study|HCM|University College, London|Yes|Active, not recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12464|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients registered in Clinical Practice Research Datalink (CPRD) practices|April 2015|April 20, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424994||22682|
NCT02425007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spiro93|Efficacity of Incentive Spirometry in Elderly People|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|60 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02425007||22681|
NCT02400450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:041|Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes|Assessment of Designer Functional Foods on Parameters of Metabolic and Vascular Status in Individuals With Prediabetes.|PREFFER-2014|University of Manitoba|No|Not yet recruiting|September 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|115|||Both|21 Years|75 Years|No|||March 2016|March 8, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02400450||24565|
NCT02394561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AIT01|A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)|A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)|SUPREME|Novartis|Yes|Not yet recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|406|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02394561||25018|
NCT02425839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408203|Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter|Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter, in Rest and Maximal Voluntary Contraction|EVEREST|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|20 Years|40 Years|No|||November 2015|November 5, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02425839||22617|
NCT02425904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005|Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis|Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis||Dana-Farber Cancer Institute|Yes|Recruiting|April 2015|September 2022|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|April 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425904||22612|
NCT02406352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-35|Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia|Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia|MDCwProbe|Brookdale University Hospital Medical Center||Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|618|||Female|18 Years|N/A|No|||April 2015|April 9, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02406352||24114|
NCT02503241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRICESEOBESE|Open Lung Strategy in Critically Ill Morbid Obese Patients|Open Lung Strategy in Critically Ill Morbid Obese Patients Lung Imaging and Heart-lung Interaction||Massachusetts General Hospital|No|Not yet recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503241||16674|
NCT02499575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH2-15-0005|Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures|Exparel Pericapsular Injection: A Prospective Evaluation of Postoperative Pain in Bunion Surgery, First Metatarsophalangeal Joint Fusion, and Cheilectomy||OhioHealth|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02499575||16956|
NCT02403843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP10012|RNS® System Epilepsy PAS|RNS® System Post-Approval Study in Epilepsy||NeuroPace|Yes|Enrolling by invitation|April 2015|May 2023|Anticipated|May 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|375|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals 18 years of age or older with partial onset seizures who have undergone        diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two        or more antiepileptic medications, and currently have frequent and disabling seizures.|November 2015|November 25, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403843||24306|
NCT02393833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 22-00 Serum Substudy|Serum Protein Research Substudy|Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in Serum Samples of Patients Participating in Trial IBCSG 22-00||International Breast Cancer Study Group|Yes|Active, not recruiting|June 2002|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|136|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|March 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02393833||25074|
NCT02497937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201881|A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure|A Randomized, Double-blind, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure||GlaxoSmithKline|No|Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|21 Years|N/A|No|||March 2016|March 17, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497937||17082|
NCT02497950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartMate 3™ Registry|HeartMate 3 ELEVATE™|Evaluating the HeartMate 3™ in a Post-Market Approval Setting: The HeartMate 3 Registry (ELEVATE™)|ELEVATE™|Thoratec Corporation|No|Recruiting|February 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|All patients that receive the HeartMate 3 LVAS in the post-approval setting|February 2016|February 18, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02497950|2 Years|17081|
NCT02509949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRT|Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients|||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|May 2015|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|59 Years|No|||July 2015|July 27, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509949||16159|
NCT02396251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43VZ1407|Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation|||Q-Med AB|No|Recruiting|February 2015|July 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02396251||24888|
NCT02399098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016-15-HYMC|The Effectiveness of Attentional Strategies on Throwing Performance and Gaze Behavior of Self-paced Tasks Under Fatigue and Non-fatigue Conditions|The Effectiveness of Attentional Strategies on Throwing Performance and Gaze Behavior of Self-paced Tasks Under Fatigue and Non-fatigue Conditions||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 22, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02399098||24669|
NCT02404233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC278HIV4003|Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects|A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)|PREZENT|Therapeutic Concepts|No|Not yet recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404233||24276|
NCT02507726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-1501|Multicenter and Open Pilot Clinical Study on the Safety of a New One-piece Convex Appliance in Patients With Enterostomy|Multicenter and Open Pilot Clinical Study on the Safety of a New One-piece Convex Appliance in Patients With Enterostomy||BBraun Medical SAS|No|Recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02507726||16329|
NCT02507791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-15-03|Impact of Fitbit Plus Weight Management Program on Physical Activity and Metabolic Disease in Obese Adolescents|Impact of Fitbit Plus Weight Management Program on Physical Activity and Metabolic Disease in Obese Adolescents||University Hospital Case Medical Center|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|18 Years|No|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507791||16324|
NCT02404129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003-15-COM|Validity of TURN 180 Test to Distinguish Between the Fallers and Non-Fallers|Validity of TURN 180 Test to Distinguish Between the Fallers and Non-fallers||Clalit Health Services|No|Not yet recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|75|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02404129||24284|
NCT02498483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN7406|Acetaminophen and Post Circumcision Pain Control|Acetaminophen and Post Circumcision Pain Control||Columbia University|No|Suspended|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|N/A|36 Hours|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 30, 2015|Yes|Yes|Maternity leave of PI|No||https://clinicaltrials.gov/show/NCT02498483||17040|
NCT02510092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Im-CAD-001|Coronary Artery and Systemic Autoimmune Disease: Diagnostics and Treatment|In Vivo Intravascular Diagnostics and Evaluation of New Therapeutic Modalities in Systemic Autoimmune and Coronary Artery Disease Patients||Semmelweis University Heart and Vascular Center|No|Recruiting|July 2015|July 2021|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Systemic autoimmune patients with either:          -  rheumatoid arthritis          -  systemic lupus erythematosus          -  systemic sclerosis          -  mixed connective tissue disease        with concomittent coronary artery disease may be enrolled|July 2015|July 24, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02510092||16148|
NCT02400853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/061/HP|Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants|Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants: HEMO PREMA Study|HEMO PREMA|University Hospital, Rouen|No|Recruiting|July 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|1 Day|No|||September 2015|September 28, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02400853||24534|
NCT02400866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSWOG 15-01|A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy|||Korean South West Oncology Group|No|Not yet recruiting|May 2015|April 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|19 Years|N/A|No|||March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400866||24533|
NCT02404532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316-13-206B|Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)|OSMITTER 316-13-206B Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period|OSMITTER|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|February 2015|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404532||24253|
NCT02408133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1165-5043|Effectiveness of Home-based Exercise in Quality of Life and Physical Fitness in Older Woman in Breast Cancer Treatment|Effectiveness of Home-based Exercise in Quality of Life and Physical Fitness in Older Woman in Breast Cancer Treatment: Randomized Clinical Trial||Professor Fernando Figueira Integral Medicine Institute|No|Not yet recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|60 Years|74 Years|No|||April 2015|April 2, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02408133||23978|
NCT02498769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061607|Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery|Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery||Duke University|Yes|Recruiting|September 2015|July 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|50 Years|90 Years|No|||January 2016|January 25, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498769||17018|
NCT02500628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150618|Heart Rate Variability in Response to Metformin Challenge|Heart Rate Variability in Response to Metformin Challenge||Woodinville Psychiatric Associates|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|96|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02500628||16875|
NCT02401152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGP-001|A Low-osmolaric Glucose Polymer Drink for Gastric Distress and Running Performance|The Effect of a Potato Based Low-osmolaric Glucose Polymer Drink on Gastric Distress and Running Performance||InnoSportNL|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|43|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02401152||24511|
NCT02404701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0076|Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk|Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk||University of Wisconsin, Madison|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404701||24240|
NCT02404909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVCindex|Inferior Vena Cava Index in Patients Undergoing Liver Resection|Does Inferior Vena Cava Collapsibility Correlate With Fluid Regimen and Outcome in Patients Undergoing Liver Resection?|IVC|University of Milan|No|Completed|January 2005|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|91|||Both|34 Years|85 Years|No|Non-Probability Sample|Patients underwent liver resection for primary and secondary liver disease|March 2015|March 26, 2015|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02404909||24224|
NCT02494635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-15-5|Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer|Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness||University of Southern California|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Tissue, bladder washings, and urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients at the USC/Norris Comprehensive Cancer Center facilities with bladder cancer will        be recruited.|July 2015|July 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02494635||17335|
NCT02500875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AISLeC-004|Treatment of Infected Surgical Wounds With Negative Pressure Topical Therapy and Instillation (With or Without Antiseptic) Versus no Instillation|Treatment of Infected Surgical Wounds With Negative Pressure Topical Therapy and Instillation (With or Without Antiseptic) Versus no Instillation|PTN-INSTILL|Associazione Infermieristica per lo studio delle Lesioni Cutanee|Yes|Recruiting|January 2015|January 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|July 15, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02500875||16856|
NCT02397941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2015-0008|Diastasis Recti Abdominis and Abdominal Muscles|Diastasis Recti Abdominis and Abdominal Muscles in Pregnant and Non-pregnant Women||University of Zurich|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inclusion:          -  non-pregnant women aged 20-45 y with a BMI < 30 kg/m2 who never were pregnant          -  pregnant women aged 20-45 y with a BMI < 30 kg/m2 before pregnancy|December 2015|December 9, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02397941||24758|
NCT02402504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-1|PERFECT Project - Part 1 - Study 1|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 1||University of Manitoba||Active, not recruiting|March 2015|July 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02402504||24407|
NCT02400658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18004|Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer|A Prospective Single-Arm Phase II Study To Investigate The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer||University of Virginia|Yes|Recruiting|March 2015|September 2023|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|260|||Female|45 Years|N/A|No|||March 2016|March 1, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02400658||24549|
NCT02505568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107121|A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease|An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease|BEGIN|Janssen Korea, Ltd., Korea|No|Recruiting|July 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|19 Years|75 Years|No|||March 2016|March 2, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02505568||16495|
NCT02403661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000973|Electrical Stimulation to Enhance Peripheral Nerve Regeneration|The Effectiveness of a New Treatment for Patients With Peripheral Nerve Injuries in the Upper Limb||University of Alberta|No|Recruiting|March 2013|March 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02403661||24320|
NCT02403674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439A-021|Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2015|February 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|680|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403674||24319|
NCT02402751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A0012148|Development, Implementation and Initiation of Normative Database Quantitative Ultra High Field MRI Paramaters|Development, Implementation and Initiation of Normative Database Quantitative Ultra High Field MRI Paramaters||Assistance Publique Hopitaux De Marseille|No|Recruiting|March 2015|September 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402751||24388|
NCT02402764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18150|Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)|Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|July 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402764||24387|
NCT02410590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8616-104|Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)|Randomized, Parallel Group, Controlled Trial to Compare Two Different "NMB + Reversal" Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery|BENN|Merck Sharp & Dohme Corp.|No|Withdrawn|July 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410590||23789|
NCT02410603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000373|Circulating Tumor Cells Using the ClearCell® FX EP+ System During the Course of Treatment for Lung Cancer|Isolating and Testing Circulating Tumor Cells Using the ClearCell® FX EP+ System During the Course of Treatment for Lung Cancer||Mayo Clinic|No|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced stage lung cancer who are scheduled to undergo conventional or        targeted chemotherapy at the Mayo Clinic in Rochester, MN.|January 2016|January 18, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410603||23788|
NCT02506751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061965|A Phase 1b, Open-label Study of Liothyronine in MS|A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS||Johns Hopkins University|Yes|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|58 Years|No|||July 2015|July 21, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506751||16404|
NCT02400268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHORTEN|Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae|Phase 4, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove That the 7 Day Course of Treatment for Enterobacteriaceae Bacteremia is More Efficient and Equally Safe Than 14 Day Scheme|SHORTEN|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|September 2014|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02400268||24579|
NCT02406456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAINTRAINPILOT|Optimisation of Functional MRI-based Neurofeedback for Alcohol Use Disorders|Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence - Protocol Optimisation Phase||Cardiff University|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02406456||24107|
NCT02406469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-SC-07-A2-01|Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior|Comparative Effects of Milk With A2 Type Beta Casein Versus Milk With A1 and A2 Beta Casein Proteins on Gastrointestinal Physiology, Symptoms and Cognitive Behavior for the Health People Who Are Intolerant to Traditional Cow Milk||a2 Milk Company Ltd.|No|Completed|October 2014|February 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|45|||Both|25 Years|68 Years|Accepts Healthy Volunteers|||March 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406469||24106|
NCT02402322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTCCAP|Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support|Internet-based Self-help Treatment for Panic Disorder: A Randomised Controlled Trial of Two Ways of Administrating the Complementary Psychological Support (Scheduled vs. Non-scheduled)||Universitat Autonoma de Barcelona|No|Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|60 Years|No|||October 2015|October 27, 2015|March 20, 2015||No||No|August 7, 2015|https://clinicaltrials.gov/show/NCT02402322||24421|
NCT02496715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-2014-075|Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics|Randomized, Parallel, Placebo-controlled, Multiple Dose, Multicenter Study to Compare the Efficacy of Fluticasone/Salmeterol (Test) to Advair® Diskus (GSK) in Adult Asthma Patients||Actavis Inc.|No|Not yet recruiting|September 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1053|||Both|12 Years|75 Years|No|||July 2015|July 13, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496715||17175|
NCT02396524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pHFIT123|Hockey Fans in Training (Hockey FIT): A Pilot Pragmatic Randomized Controlled Trial|Hockey Fans in Training (Hockey FIT): A Pilot Pragmatic Randomized Controlled Trial of an Exercise and Healthy Living Program for Middle-aged, Overweight and Obese Men||University of Western Ontario, Canada|No|Active, not recruiting|April 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02396524||24867|
NCT02403791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoC-BLUE-Plus One|Point-of-Care Bedside Lung Ultrasound Examination Advanced Trial Protocol|A Prospective, Multi-center, Open-label and Double-blind, Standard-controlled, Non-inferiority, Diagnostic Study of Lung Ultrasound for Management of Mechanical Ventilation in Neonatal Acute Respiratory Distress Syndrome|PoCBLUEPlus|Nanjing Medical University|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1000|||Both|N/A|31 Days|No|||March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02403791||24310|
NCT02403804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1783|Dietary Supplementation to Increase Serum Choline Levels|Dietary Supplementation to Increase Serum Choline Levels||University of Colorado, Denver|Yes|Active, not recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403804||24309|
NCT02402582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMSU|Effect of Family-Centered Empowerment Model|Family-Centered Empowerment Model With Four-stage Including Perceived Threat With Group Discussion Method, Self-efficacy With Problem Solving Method, Self-esteem With Educational Partnership, and Outcome and Process Evaluations||Baqiyatallah Medical Sciences University|Yes|Completed|June 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|70|||Both|45 Years|85 Years|No|||March 2015|March 27, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02402582||24401|
NCT02500329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRMH 26-2014-124|Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients|Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)||Seoul National University Hospital||Recruiting|September 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|20 Years|80 Years|No|||July 2015|July 14, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02500329||16898|
NCT02406248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00103|Brilinta Taiwan Post Approval Safety Study|A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction||AstraZeneca|No|Active, not recruiting|July 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406248||24122|
NCT02409550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/2014|CARATKids: Italian Validation of Asthma and Allergic Rhinitis Control Test in Children|CARATKids: Italian Validation of Asthma and Allergic Rhinitis Control Test in Children||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Recruiting|April 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|113|||Both|6 Years|12 Years|No|Non-Probability Sample|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3        months will be enrolled for the validation process at outpatient clinic of Pediatric        Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the        Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council        (CNR) of Palermo (RDRC-IBIM CNR), Italy.|December 2015|December 18, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409550||23869|
NCT02401750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELI-003-2014|A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery|A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Capsules Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (b) for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery||Elite Laboratories, Inc|No|Completed|June 2015|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|163|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401750||24465|
NCT02401763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412126RIND|Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis|Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis||National Taiwan University Hospital|Yes|Not yet recruiting|April 2015|||April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|NPC and salivary gland tumor diagnosed and treated in HTUH|March 2015|March 31, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02401763||24464|
NCT02496429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBF1502|Evaluation of the Reliability and Usability of the Reusable "BrownieForSymphony" Pump Set|ESP Evaluation of the Reliability and Usability of the Reusable "BrownieForSymphony" Pump Set|ESP|Medela AG|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496429||17197|
NCT02500563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6032|Exploratory/Proof of Principle Microbiota Study|Exploratory/Proof of Principle Microbiota Study||Mead Johnson Nutrition|No|Recruiting|July 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|80|||Both|N/A|7 Days|Accepts Healthy Volunteers|||February 2016|February 10, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02500563||16880|
NCT02510677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-176|Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT||FAST DOGS|University Hospital, Caen|No|Recruiting|June 2013|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510677||16103|
NCT02510690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-14-1275-22205|Factors Associated With Poor Dengue Outcomes in Malaysia|Factors Associated With Poor Dengue Outcomes in Malaysia||Clinical Research Centre, Malaysia|No|Active, not recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|All dengue cases that registered under e-Dengue Information System 2013-2014|July 2015|July 28, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510690||16102|
NCT02399033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCheng|Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy|Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial||Eastern Hepatobiliary Surgery Hospital|No|Recruiting|June 2014|December 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|20 Years|70 Years|No|||February 2015|March 22, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02399033||24674|
NCT02399046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPS-201302|A Clinical Trial Study of Knee System in Primary Total Knee Arthroplasty in China|A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China||Johnson & Johnson Medical (Suzhou) Ltd.|No|Not yet recruiting|May 2016|August 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399046||24673|
NCT02402049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS-14|Homeopathic Treatment of Premenstrual Syndrome|Is Homeopathic Treatment a Placebo Treatment? - Homeopathic Treatment of Premenstrual Syndrome- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial||Shaare Zedek Medical Center|No|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|12||Anticipated|180|||Female|18 Years|50 Years|No|||March 2015|March 24, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02402049||24442|
NCT02402062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE-1408|A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours|A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)||Grupo Espanol de Tumores Neuroendocrinos|Yes|Recruiting|February 2015|April 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02402062||24441|
NCT02507141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-128|Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology|Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Potential research subjects in the Head and Neck Service will be identified by a member of        the patient's treatment team, the protocol investigator, or a member of the research team        at Memorial Sloan Kettering Cancer Center (MSK).|December 2015|December 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507141||16374|
NCT02507154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK0906|Reactivating NK Cells in Treating Refractory Head and Neck Cancer|Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Cetuximab for Patients With EGFR-Positive Nasopharyngeal Carcinoma or Head and Neck Squamous Cell Carcinoma|NKEXPHNC|National University Hospital, Singapore|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|21 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507154||16373|
NCT02402205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH095208|TF-CBT for Adjudicated Youth in Residential Treatment|TF-CBT for Adjudicated Youth in Residential Treatment||Allegheny Singer Research Institute|Yes|Completed|July 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|210|||Both|13 Years|17 Years|No|||March 2015|March 27, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402205||24430|
NCT02404558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14191|Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis|An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis||Sanofi|No|Active, not recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|N/A|No|||February 2016|February 17, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404558||24251|
NCT02427022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN-271-2010-00032-C|Implementation, Fidelity, and Outcomes Following Novel and Usual Critical Time Intervention Training|Phase II Evidence-Based Practice in Community-Based Social Work: A Multi-Media Strategy||Center for Social Innovation, Massachusetts|No|Completed|September 2010|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|179|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|April 24, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02427022||22526|
NCT02395588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055798|Improving Heart Failure Outcomes Rural|Improving Heart Failure Outcomes (IHO)|IHO Rural|University of Maryland|No|Recruiting|April 2014|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients admitted to participating rural hospitals with a diagnosis of heart        failure.|March 2015|March 17, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395588||24939|
NCT02415647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543389-8|Longitudinal Family/Molecular Genetic Study to Validate Research Domain Criteria|Longitudinal Family/Molecular Genetic Study to Validate Research Domain Criteria||State University of New York - Upstate Medical University|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2800|Samples With DNA|Whole blood samples.|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Child probands with psychiatric disorders will be recruited from psychiatric clinics,        child psychiatrists, and mental health providers in Onondaga County. Non-disordered        psychiatrially normal comparison groups will be recruited from a pediatric primary care        clinic.|December 2015|December 17, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02415647||23400|
NCT02415465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14090501|Continuous Adductor Canal Block (CACB) vs. Combined Spinal Epidural (CSE) in Total Knee Arthroplasty|Continuous Adductor Canal Block (CACB) vs. Combined Spinal Epidural (CSE) in Total Knee Arthroplasty||Rush University Medical Center|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02415465||23414|
NCT02415686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48765.058.15|Cardiac Arrhythmias in Dravet Syndrome|Cardiac Arrhythmias in Dravet Syndrome: an Observational, International, Multicentre Study||Stichting Epilepsie Instellingen Nederland|No|Recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|60|||Both|6 Years|N/A|No|Non-Probability Sample|the Netherlands (coordinating centre: SEIN). Procedure: The UMCU Medical Genetics        department is the key referral centre in the Netherlands for DS (Brilstra, UMCU). Cases        will be recruited from the UMCU database. Prior to inclusion, a panel (Gunning, Brilstra,        Thijs) will review clinical data to ensure diagnostic consistency.        Additional DS subjects will be recruited from the local DS databases at Universität Bonn        (25 subjects; 4 adults; local coordinator R Surges) and UCL (100 subjects; 15 adults;        local coordinator S Sisodiya).        We will select historical controls (subjects with epilepsy without DS) from the video-EEG        databases of the participating centres.|April 2015|June 11, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415686||23397|
NCT02419742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28714|Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen|An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety & Efficacy of Trastuzumab in HER2 Positive, and High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC -->TH) or Docetaxel and Carboplatin (TCH)||Hoffmann-La Roche||Recruiting|August 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|109|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02419742||23086|
NCT02404766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP23/2012|Effects of C0-C1 Mobilization in the Neutral Position in Subjects With Upper Cervical Rotational Hypomobility|||Universidad de Zaragoza||Completed|December 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404766||24235|
NCT02408731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-430-CENT-2012|A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PMZ-2010 (Centhaquin) in Healthy Male Volunteers||Pharmazz, Inc.|Yes|Completed|October 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|24|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 26, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02408731||23932|
NCT02422706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELICOBACTER NEW TREATMENT|Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori|Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori||Tanta University|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|N/A|N/A|No|||October 2015|October 24, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422706||22858|
NCT02412969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034219|Impact of Dural Puncture Epidural Versus Traditional Lumbar Epidural on Onset of Labor Analgesia|Impact of Dural Puncture Epidural Versus Traditional Lumbar Epidural on Onset of Labor Analgesia||Medical University of South Carolina|Yes|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|August 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02412969||23606|
NCT02394275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI.FMT.2|A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection|A Prospective Open-Labelled Multi-Centre Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection||McMaster University|Yes|Recruiting|March 2015|May 2025|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394275||25040|
NCT02413424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412080|Metabolic Effects of Non-nutritive Sweeteners|Metabolic Effects of Non-nutritive Sweeteners|NNS|Washington University School of Medicine|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413424||23571|
NCT02414282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 123119|F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)|F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction Due to Alzheimer Disease|Protocol E|Washington University School of Medicine|No|Recruiting|March 2015|September 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|45 Years|N/A|No|||March 2016|March 8, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414282||23505|
NCT02409173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|742.865/2014|NPPV on Inflammatory Markers and Sleep in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery|Effects of Noninvasive Positive Pressure Ventilation on Inflammatory Markers, Sleep, Pulmonary Function and HRQoL in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery. A Randomized Controlled Clinical Trial||University of Nove de Julho|Yes|Enrolling by invitation|January 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|17|||Both|18 Years|65 Years|No|||November 2015|November 27, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409173||23898|
NCT02399241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18185|Using Remote Telemonitoring to Detect Early Decline in Lung Function & Streamline Clinics in Adults With Cystic Fibrosis|Using Remote Telemonitoring to Detect Early Decline in Lung Function & Streamline Clinics in Adults With Cystic Fibrosis|RIGHT-CF|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|16 Years|N/A|No|||January 2016|January 29, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02399241||24658|
NCT02399514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF001 sleep|Improvement of Sleep Quality by RePneu® Coils in Advanced Pulmonary Emphysema|Verbesserung Der Schlafqualität Durch RePneu® Coils Zur Behandlung Des Fortgeschrittenen Lungenemphysems||Institut für Pneumologie Hagen Ambrock eV|No|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399514||24637|
NCT02408003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFredholm|Comparing the Effects on Cardiac Function of Levosimendan Versus Milrinone.|Comparing the Lusitropic Effect of Levosimendan and Milrinone Using Strain Analysis in Patients Undergoing Open Aortic Valve Replacement Surgery||Sahlgrenska University Hospital, Sweden|No|Recruiting|March 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408003||23988|
NCT02508194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4420C00005|A Study to Evaluate the Efficacy of MEDI7510 in Older Adults|A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults||MedImmune LLC|Yes|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1900|||Both|60 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508194||16293|
NCT02507544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-001|A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer|A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer||TaiRx, Inc.|No|Recruiting|September 2015|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507544||16343|
NCT02507609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160087|Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium|The Effect of Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium of Elderly Patients Undergoing Total Hip Arthroplasty||Konkuk University Medical Center|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|82|||Both|50 Years|N/A|No|||July 2015|July 24, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507609||16338|
NCT02406430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREUZOT 2013|Prognostic Factors in Epiretinal Membrane Surgery|Preoperative Prognostic Factors and Predictive Score in Patients Operated on for Combined Cataract and Idiopathic Epiretinal Membrane.||Centre Hospitalier Universitaire Dijon||Completed|April 2009|||October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|142|||Both|50 Years|N/A|No|Non-Probability Sample|Patients operated on for combined cataract and idiopathic epiretinal membrane|March 2015|March 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406430||24109|
NCT02398838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.4.5|Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia|Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia: A Study of 400 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 63 Days Gestation||Gynuity Health Projects|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|622|||Female|18 Years|55 Years|No|||April 2015|April 2, 2015|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02398838||24689|
NCT02503423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTX660-01|Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas|Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas||Astex Pharmaceuticals|Yes|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02503423||16660|
NCT02495493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0548|S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma|S-1 Plus Cisplatin-based Chemoradiotherapy After Induction Chemotherapy for Locally Advanced Gastric Adenocarcinoma : Phase II Trial||Yonsei University|Yes|Active, not recruiting|July 2013|June 2019|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|N/A|No|||February 2016|February 2, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495493||17269|
NCT02400086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15004|Bacterial Colonization in Tracheostomized Patients With Neurological or Neuromuscular Disease|Study of Bacterial Colonization of the Respiratory Tract in Long-term Tracheostomized Patients With Neurological or Neuromuscular Disease|ECOTRACH|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|February 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|patients with a long-term tracheostomy and suffering from a neurological or neuromuscular        disease|October 2015|October 14, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400086||24593|
NCT02404389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFX453X2201|Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients|A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Topical LFX453 Formulations in Patients With Actinic Keratosis||Novartis|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|78|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404389||24264|
NCT02498249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U9-2015|Immediate Effect of Irradiation With Low-level Laser Therapy on the Electromyographic Activity of the Upper Trapezius Muscles and the Level of Pain Among Patients With Non-specific Neck Pain|Immediate Effect of Irradiation With Low-level Laser Therapy on the Electromyographic Activity of the Upper Trapezius Muscles and the Level of Pain Among Patients With Non-specific Neck Pain: a Randomized, Double-blinded, Sham-controlled, Crossover Study||University of Nove de Julho|Yes|Completed|May 2015|July 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|No|||July 2015|July 10, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02498249||17058|
NCT02510027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1094|Triage Strategies in Cervical Cancer Prevention|Molecular Triage in Cervical Cancer Prevention: The Tlaxcala Study|FRIDA|Instituto Nacional de Salud Publica, Mexico|Yes|Recruiting|August 2013|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|Samples With DNA|Two cervical samples will be collected using a Cervex-Brush® (Rovers®). The first collected      sample will be placed in a vial containing BD CytoRich™ preservative (BD Diagnostics,      Burlington, NC), and the second sample will be placed in a ThinPrep® vial (Hologic, Inc.,      Bedford, MA). Both samples will be temporarily stored at room temperature at the health      center until they are delivered to the lab facilities. Women who refuse a pelvic examination      will be offered the option to self-collect a vaginal sample at the health facility or at      their home that can be used for hrHPV testing. Only HR-HPV positive participants will move      onto the cytology/molecular triage testing phase. After triage procedures, all remaining      samples collected in either of the vials from HR-HPV positive women will be stored      independently for additional analysis as required by the study procedures.|Female|30 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a population-based study that includes all women aged 30 to 64 years living in the        32 municipalities in Tlaxcala covered by Sanitary Jurisdiction No. 1 of Tlaxcala Health        Services|July 2015|July 27, 2015|July 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510027||16153|
NCT02406716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-2401-ZV|Semaphorins 3A and 4D Levels in Heart Failure Patients|Semaphorins 3A and 4D Levels in Heart Failure Patients: Pathogenesis and Clinical Correlation||Bnai Zion Medical Center|No|Not yet recruiting|April 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood samples|Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with new onset or previously diagnosed heart failure|March 2015|March 30, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02406716|6 Months|24087|
NCT02408562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0031-004|Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD|A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease||Newron Sweden AB|Yes|Terminated|January 2015|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|30 Years|75 Years|No|||January 2016|January 26, 2016|March 5, 2015||No|Issues with development and supply of infusion system for delivery of IMP. Prolonged approval    process for the clinical study sNN0031-004.|No||https://clinicaltrials.gov/show/NCT02408562||23945|
NCT02394119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFA2|Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome|Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.||Istituto Giannina Gaslini|Yes|Recruiting|June 2015|May 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|2 Years|18 Years|No|||June 2015|June 10, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02394119||25052|
NCT02394132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZMTG 02.12|Radiotherapy or Imiquimod in Complex Lentigo Maligna|A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails|RADICAL|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|May 2015|November 2019|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|120 Years|No|||January 2016|January 6, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394132||25051|
NCT02503852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-A-II|STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia|Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial|STYLE|Kerastem Technologies, LLC|No|Recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503852||16627|
NCT02496247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFN GB 2015|Canned Herring for Prevention of Childhood Malnutrition During the Early Rainy Season in Rural Guinea-Bissau|Effectiveness of Canned Herring for Prevention of Childhood Malnutrition During the Early Rainy Season in Rural Guinea-Bissau||Global Food & Nutrition Inc.|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1200|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02496247||17211|
NCT02404324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment of Esotropia|Conservative Treatment of Esotropia in Children up to 3 Years Old|Prescription of Full Optical Correction in Refractive Errors to Treat Esotropia in Children up to 3 Years Old||National Centre of Ophthalmology named after academician Zarifa Aliyeva|Yes|Active, not recruiting|January 2012|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|3 Months|3 Years|No|||March 2015|March 26, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02404324||24269|
NCT02409355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29432|A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111]|A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) Compared With Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409355||23884|
NCT02408146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lianxin-001|The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection|||First Affiliated Hospital of Harbin Medical University||Recruiting|January 2014|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|70 Years|No|||March 2014|April 2, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02408146||23977|
NCT02503865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103RK00112|Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome|Phase 1-2 Study of Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome|DRWMNTMS|Republican Scientific Center for Emergency Medicine|Yes|Completed|January 2003|December 2014|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|351|||Both|25 Years|74 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 10, 2015||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT02503865||16626|We acknowledge the randomized clinical trial have not a large sample size
NCT02503878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037965|Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test|Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test)||Medical University of South Carolina|No|Terminated|December 2014|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be 10 adult patients over 18 years old scheduled for Wada Testing at        MUSC. One of the study team members will inform patients scheduled to undergo surgery        about the opportunity to participate in the study prior to surgery. Patients will review        and sign a written informed consent with a research study team member.|February 2016|February 29, 2016|July 17, 2015||No|There was to much artifact on the readings and could not be interpreted|No||https://clinicaltrials.gov/show/NCT02503878||16625|
NCT02510105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0236|Tomodensitometric Study of Pulmonary Effects of Intrapulmonary Percussive Ventilation in ARDS Patients|Tomodensitometric Study of Pulmonary Effects of Intrapulmonary Percussive Ventilation in ARDS Patients|PERVE-ARDS|University Hospital, Clermont-Ferrand||Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02510105||16147|
NCT02501837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT_BOND|The Influence of Oxytocin on Pair-bonding and Emotion Regulation|The Influence of Oxytocin on Pair-bonding and Emotion Regulation||University Hospital, Bonn|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501837||16782|
NCT02404480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC596-ONC-001-AST|PTC596 in Patients With Advanced Solid Tumors|A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors||PTC Therapeutics|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404480||24257|
NCT02396329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antisepsis 1|Chlorhexidine Versus Povidone-Iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection|Chlorhexidine Versus Povidone-iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection Rate:a Randomized Controlled Trial||Ain Shams Maternity Hospital|Yes|Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|410|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02396329||24882|
NCT02396342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AMT-060-01|Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B|A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately Severe Hemophilia B||UniQure Biopharma B.V.|Yes|Recruiting|May 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Male|18 Years|N/A|No|||August 2015|August 27, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396342||24881|
NCT02504125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJODCT2014002|The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty|The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty: a Randomized, Double-blind, Controlled Trial||Xijing Hospital|Yes|Completed|January 2013|June 2015|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02504125||16606|
NCT02510339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.047.04|Tibial Shaft Nailing Treated With Suprapatellar Nailing|The Incidence of Associated Intra-articular Knee Pathology With Concomitant Tibial Shaft Fractures Treated With Suprapatellar Nailing||Orlando Health, Inc.|No|Not yet recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include skeletally mature patients of Level One Orthopaedics,        presenting to Orlando Regional Medical Center with open or closed fractures of the tibial        shaft.|October 2015|October 29, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02510339||16129|
NCT02406209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2-02|A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis|A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis||Aldeyra Therapeutics, Inc.|No|Active, not recruiting|March 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|85 Years|No|||October 2015|January 19, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406209||24125|
NCT02394665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140540|MRSI Guided Dose Escalated Radiation in Glioblastoma|Phase II Study of Dose Escalated, Targeted Radiation Therapy Using 3D Magnetic Resonance Spectroscopy Imaging (MRSI) in Newly Diagnosed Glioblastoma||University of Miami|Yes|Recruiting|March 2015|||March 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394665||25010|
NCT02405143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAK1010001|Restoration of Vision After Stroke|Electrical Stimulation for Restoration of Vision After Stroke in the Damaged Visual Field of Patients With Unilateral Stroke (REVIS Helsinki)|REVIS|Helsinki University Central Hospital|Yes|Not yet recruiting|April 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02405143||24206|
NCT02507297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HL122461-01A1|Sleep-Disordered Breathing and PAP in Perinatal Depression|Sleep-Disordered Breathing and PAP in Perinatal Depression||University of Michigan|Yes|Recruiting|January 2016|June 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|No|||February 2016|February 17, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507297||16362|
NCT02405936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-009-002|Prospective Data Collection of Patients Undergoing Gynecologic Surgery|Prospective Data Collection of Patients Undergoing Gynecologic Surgery||Kangbuk Samsung Hospital|No|Recruiting|March 2015|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Female|16 Years|80 Years|No|Probability Sample|All patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015|April 2015|April 2, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02405936||24145|
NCT02395965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMM Utilization AOA 11-04-634|OMM Utilization in the Clinical Setting|Use and Effectiveness of Osteopathic Manipulative Medicine (OMM) in the Clinical Setting||A.T. Still University of Health Sciences|No|Completed|July 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1960|||Both|18 Years|N/A|No|Non-Probability Sample|Study participants are recruited from participating physicians' office during patient        hours for patients expected to receive OMT.|January 2014|March 18, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02395965||24910|
NCT02406313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00464-43|Fibromyalgia Therapeutic Education in Thermal Cure|Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients|FiETT|Association Francaise pour la Recherche Thermale|No|Recruiting|March 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|152|||Both|18 Years|65 Years|No|||December 2015|January 27, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406313||24117|
NCT02397304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_15-036|Nutrition, Exercise and Muscle Metabolism in Obesity|Influence of Pre- or Post-exercise Food Intake on Muscle Metabolism in Obesity||University of Birmingham||Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|8|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397304||24807|
NCT02508623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3250/AO/14|Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices|Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol|ERASE|University of Padua|No|Recruiting|July 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508623||16261|
NCT02403726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/896|Osteoporosis Associated Vertebral Fractures - Medical and Socio-economic Aspects in Austria|||Medical University of Vienna||Completed|January 2011|||March 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|694|||Both|50 Years|N/A|No|Non-Probability Sample|This study was a retrospective case series of 694 patients, in which the fracture was        caused due to primary or secondary osteoporosis, and who were treated at the department of        trauma surgery at our level-I trauma center.|March 2015|March 25, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02403726||24315|
NCT02395276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-0616-13|Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit for Suspected for Brain Injury|Efficacy of Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit in Children Suspected for Brain Injury|Coolheart|Sheba Medical Center|Yes|Not yet recruiting|April 2015|April 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|N/A|7 Years|No|||March 2015|March 21, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395276||24963|
NCT02506829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72426|Financial Incentives for Smoking Treatment|A Randomized Comparative Effectiveness Trial Of Financial Incentives Versus Usual Care For Smokers Hospitalized In The Veterans Affairs Hospital System|FIESTA|New York University School of Medicine|No|Recruiting|July 2015|December 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|182|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02506829||16398|
NCT02506842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPAC-010|Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection|A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection||Fudan University|Yes|Recruiting|June 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|July 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506842||16397|
NCT02501590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-14-LOE|Differences in Muscle Activity Patterns and Graphical Product Quality in Children With Graphomotor Impairment Copying and Tracing Activities on Horizontal or Vertical Surfaces|Differences in Muscle Activity Patterns and Graphical Product Quality in Children With Graphomotor Impairment Copying and Tracing Activities on Horizontal or Vertical Surfaces||Loewenstein Hospital||Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|45|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of Forty five 4-6 years old children, referred to occupational therapy|July 2015|July 15, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02501590||16801|
NCT02501603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0244|Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer|A Randomized, Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol(Paclitaxel) Versus Taxol(Paclitaxel) as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer||Yonsei University|No|Not yet recruiting|March 2016|May 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|19 Years|N/A|No|||February 2016|February 2, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02501603||16800|
NCT02401126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6012610|Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure|Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial||Queen's University|No|Enrolling by invitation|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||October 2015|October 15, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401126||24513|
NCT02406755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-Senses|H-Senses Project - Self Care Mediated by the Senses|H-SENSES PROJECT Self Care Mediated by the Senses: Assessing the Impact on Self-esteem, Stress and Well-being of Female Health Professionals||Hospital Israelita Albert Einstein|Yes|Completed|July 2014|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|123|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02406755||24084|
NCT02494596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17003|A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors|A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors||Hoffmann-La Roche||Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|July 8, 2015||No||No|July 30, 2015|https://clinicaltrials.gov/show/NCT02494596||17338|
NCT02494869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-093|Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer|Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 16, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494869||17317|
NCT02506907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC-VAMMPRIS|Characterizing Hemodynamic Compensation in Patients With Intracranial Stenosis|Vanderbilt Assessment of Multi-modal MRI in Patients At-Risk for Stroke With Intracranial Stenosis|VAMMPRIS|Vanderbilt University|No|Recruiting|August 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with intracranial stenosis who have had a stroke within the past 60 days|July 2015|July 27, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506907||16392|
NCT02396823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OICB101489|Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury|Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury||University of Louisville|No|Recruiting|June 2010|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02396823||24844|
NCT02406677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130R00030|Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study|Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study|ARTEMIS|AstraZeneca|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|11000|||Both|18 Years|130 Years|No|||March 2016|March 24, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406677||24090|
NCT02500576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0922|MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)|Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|Yes|Recruiting|August 2015|||August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500576||16879|
NCT02494999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT022|A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants||Jiangsu Province Centers for Disease Control and Prevention|No|Not yet recruiting|July 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|900|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02494999||17307|
NCT02495012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeesPahrm_Anfibatide_Phase2b|Anfibatide Treatment in STEMI Patients|A Multi-centered, Randomized, Double-blinded, Placebo-Parallel Controlled Phase IIb Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin Injection for the Treatment of Patients With ST Segment Elevation Myocardial Infarction (STEMI) Before Receiving PCI Therapy.||Lee's Pharmaceutical Limited|Yes|Not yet recruiting|August 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495012||17306|
NCT02403869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-CMM-2013-01|Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy|Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy|DD-CMM|Celgene|No|Recruiting|March 2014|June 2017|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|MBC patients, older than or equal to 18 years of age, on second line of treatment with        chemotherapy regimens in monotherapy and Her-2/neu-negative status|March 2015|March 26, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403869||24304|
NCT02406794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS-UMA_01-13|Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors|Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women: Randomised Controlled Trial|KITMYCAN|University of Malaga|Yes|Recruiting|February 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406794||24081|
NCT02497781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00016|Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)|A Single Blind, Randomised, Multi-centre, Active Controlled, Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)||AstraZeneca|Yes|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|3 Months|18 Years|No|||March 2016|March 4, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497781||17094|
NCT02498002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMF-02|Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes|Impacts of Intermittent Fasting in Adults on Energy Balance, Body Composition, Postprandial Hormone Profiles and Gene Expression in Adipose Tissue||University of Bath|No|Recruiting|May 2015|September 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02498002||17077|
NCT02394041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081233|Randomised Controlled Trial of the Efficacy of Acupuncture Versus Placebo on the Caesarean Section Rate in Case of Cervical Dystocia in Full-term Pregnancy|A Randomised Controlled Multicenter Trial Evaluating the Efficacy of Acupuncture Versus Placebo on the Caesarean Section Rate in Case of Cervical Dystocia in Full-term Pregnancy|ACUCESAR|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|142|||Female|18 Years|N/A|No|||February 2015|March 19, 2015|March 16, 2015||No|insufficient recruitment: 142 patients instead of 2,220 planned|No||https://clinicaltrials.gov/show/NCT02394041||25058|
NCT02495623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-2-010-001|A Study of the Effect of SYN-010 on Subjects With IBS-C|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared With Placebo on Breath Methane Production in Breath Methane-Positive Subjects With IBS-C||Synthetic Biologics Inc.|No|Completed|June 2015|November 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495623||17259|
NCT02412176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CharlesUCR|Right Ventricular Apical Versus True Mid-septal Pacing|A Comparison Between Right Ventricular Apical Pacing and True Mid-septal Pacing, Verified With Computed Tomography: a Randomized Study|MS-R|Charles University, Czech Republic|No|Recruiting|January 2014|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02412176||23667|
NCT02399709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADDICSTATINE|Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation|Pilot Randomized Double Blind, Placebo Controlled Trial of the Efficacy of Simvastatin for Smoking Cessation|ADDICSTATINE|Poitiers University Hospital|No|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399709||24622|
NCT02397837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0237|Targeting Cognition in Bipolar Disorder With Pramipexole|Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)|PRAM-BD|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397837||24766|
NCT02398084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/2286|Particle Sizing of Masticated Tree Nuts - Cashews and Walnuts|Particle Sizing of Masticated Tree Nuts - Cashews and Walnuts||King's College London|No|Active, not recruiting|February 2015|April 2016|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02398084||24747|
NCT02419989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICK13A0.2|PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis|Cystic Fibrosis Nontuberculous Mycobacteria Treatment Protocol|PATIENCE|National Jewish Health|No|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|serum sputum NTM isolates|Both|7 Years|82 Years|No|Non-Probability Sample|Male and female subjects with CF age 7 years and older with a confirmed diagnosis of NTM        disease who are initiating treatment for NTM.|February 2016|February 22, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02419989||23067|
NCT02419755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELMLL|Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies|A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies||St. Jude Children's Research Hospital|No|Recruiting|April 2015|April 2029|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|21 Years|No|||December 2015|December 8, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419755||23085|
NCT02427061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14080673|Engendering Healthy Masculinities to Prevent Sexual Violence|Engendering Healthy Masculinities to Prevent Sexual Violence||University of Pittsburgh|No|Recruiting|April 2015|August 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|840|||Male|13 Years|19 Years|No|||December 2015|December 11, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02427061||22523|
NCT02406963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-169|Photographic Email Correspondence for Pediatric Urology Post-Operative Patients|Photographic Email Correspondence for Pediatric Urology Post-Operative Patients||McMaster Children's Hospital|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|N/A|18 Years|No|||March 2016|March 21, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02406963||24068|
NCT02393989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-3/50|Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite|Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite||Ege University||Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02393989||25062|
NCT02413177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT007922|Augmenting Mindfulness Training Through Experience-driven Neurofeedback|Augmenting Mindfulness Training Through Experience-driven Neurofeedback|ATTEND|University of Massachusetts, Worcester|Yes|Enrolling by invitation|April 2015|October 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02413177||23590|
NCT02417636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST/0111/15|Sharing HIV/AIDS Responsibilities and Efforts|Impact of Task Shifting Type II for ART Delivery on Patient and Process Outcomes in Uganda|SHARE|Makerere University|Yes|Recruiting|February 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1600|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02417636||23247|
NCT02417649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIRRI/CT/001|Advanced Immunological Approach in COPD Exacerbation|Sublingual Administration of a Polyvalent Mechanical Bacterial Lysate in Patients With Moderate, Severe or Very Severe COPD According to GOLD Classification: a Multicenter, Double Blind, Randomized, Controlled, Phase IV Study|AIACE|Lallemand Pharma International|Yes|Completed|September 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|40 Years|N/A|No|||April 2015|April 10, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02417649||23246|
NCT02399969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0360|Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department|Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399969||24602|
NCT02398942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000177|Proximal Pole Fractures of the Scaphoid|A Prospective Study of Proximal Pole Fractures of the Scaphoid||Massachusetts General Hospital|No|Enrolling by invitation|March 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|79|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with proximal pole fracture of the scaphoid|March 2015|March 20, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02398942||24681|
NCT02398955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BELLINI01|Biomime Stent in All-comers PCI Patients Registry|Biomime Biosorbable Polymer Sirolimus-ELuting Stent in alL-comers patIeNts Treated With Percutaneous Coronary Interventions: the BELLINI Registry|BELLINI|Azienda Ospedaliero Universitaria Maggiore della Carita|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All comers patients with coronary artery disease treated with percutaneous coronary        intervention and a Biomime stent, age > 18 years|March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02398955|1 Year|24680|
NCT02417870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation|Safety and Efficacy of Treatment With Ultra-low Dose Subcutaneous IL-2 to Promote Regulatory T Cells Post Renal Transplantation||Brigham and Women's Hospital|Yes|Not yet recruiting|June 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417870||23229|
NCT02417948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1615|Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans|Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans||Case Comprehensive Cancer Center|Yes|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|143|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02417948||23223|
NCT02417961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00029|Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home|A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)||AstraZeneca|Yes|Active, not recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417961||23222|
NCT02407821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)|A Pilot Study to Evaluate the Feasibility and Safety of Performing a Double Blind, Placebo-controlled, Randomized Controlled Trial of the Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment|RoSIE|University Health Network, Toronto|Yes|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|N/A|No|||September 2015|September 23, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02407821||24002|
NCT02397811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019850|Astaxanthin Formulation Bioavailability|Bioavailability Testing of Astaxanthin Formulations||Cyanotech Corporation|No|Recruiting|June 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Anticipated|12|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|July 13, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397811||24768|
NCT02408653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/0319(2)|EEG@HOME (Phase 2 of the Project)|||University Hospital, Ghent|Yes|Completed|April 2014|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|4|||Both|6 Years|80 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408653||23938|
NCT02408744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pirfenidona 001|Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease|Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease||University of Guadalajara|Yes|Completed|September 2009|September 2013|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|10 Years|40 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408744||23931|
NCT02413931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCBorstel_MNI_001|Nosocomial Transmission of MDR-TB in Bucharest, Romania|Nosocomial Transmission of Multidrug-resistant Tuberculosis at the Marius Nasta Institute in Bucharest, Romania||Research Center Borstel|No|Recruiting|May 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Sputum, blood and urine samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with microbiologically confirmed pulmonary MDR-TB admitted to the MDR-TB ward of        the Marius Nasta Instiute|November 2015|November 3, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02413931||23532|
NCT02413944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BnaiZionMC|Standardized 1µg Adrenocorticotropic Hormone Stimulation Test, and Salivary Cortisol Concentration During the Test|Standardized Protocol for 1µg Adrenocorticotropic Hormone (ACTH) Stimulation Test, Minimizing Technical Issues That Could Influence Test Accuracy; and Determining Salivary Free Cortisol Concentration in Healthy Controls During the Test||Bnai Zion Medical Center|No|Not yet recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02413944||23531|
NCT02398591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107003|A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants|A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Subjects||Janssen Sciences Ireland UC|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398591||24708|
NCT02507557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDFTCQ2015|Effects of Intraoperative Goal-Directed Fluid Therapy on the Incidence of Postoperative Complications|Effects of Intraoperative Goal-Directed Fluid Therapy on the Incidence of Postoperative Complications Following Gastrointestinal Surgery||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|July 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergone gastrointestinal surgery|July 2015|July 22, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02507557||16342|
NCT02497742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150083|Once Versus Twice Daily Electrolyte Monitoring in CHF|Once Versus Twice Daily Electrolyte Monitoring in CHF; a Study Monitoring Electrolytes in Congestive Heart Failure Patients Being Actively Diuresed in Hospital||Vanderbilt University|Yes|Not yet recruiting|August 2015|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497742||17097|
NCT02509910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKGMGDT|Implementation of a GDT Algorithm for Major Surgery Patients|Implementation and Effects of Pulse-contour-automated SVV/CI Guided Goal Directed Fluid Therapy Algorithm for the Routine Management of Major Abdominal Surgery Patients||Philipps University Marburg Medical Center|No|Completed|July 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing major abdominal surgery (Colorectal and pancreatic surgery)|July 2015|July 25, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509910||16162|
NCT02509936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WK-2015-003|Promoting Physical Growth and Positive Development in Severely Stunted Guatemalan Children|Crowd Funding and Social Networks as a Novel Mechanism to Promote Sustainable Physical Growth and Positive Psychosocial and Neurodevelopmental Outcomes in Severely Stunted Guatemalan Children||Wuqu' Kawoq, Maya Health Alliance|No|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|322|||Both|6 Months|24 Months|No|||December 2015|December 8, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02509936||16160|
NCT02396017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLIT-PEG-CE|Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy|Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy Is Timing of Preparation for Capsule Endoscopy the Key for the Best Small-bowel Cleansing?||Centro Hospitalar Lisboa Ocidental|Yes|Recruiting|March 2015|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396017||24906|
NCT02404064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134-14|Laparoscopic Appendectomy for Uncomplicated Appendicitis: Does Antimicrobial Prophylaxis Really Matter?|Laparoscopic Appendectomy for Uncomplicated Appendicitis: Does Antimicrobial Prophylaxis Really Matter? Randomized Control Trial||HaEmek Medical Center, Israel|No|Not yet recruiting|March 2015|March 2017|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|288|||Both|18 Years|80 Years|No|||March 2015|March 26, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02404064||24289|
NCT02404077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00256|Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions|||Nationwide Children's Hospital|No|Enrolling by invitation|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|ICU patients who have been on prolonged dexmedetomidine infusions.|October 2015|October 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02404077||24288|
NCT02508259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0134|University of California, San Diego (UCSD) Suramin Treatment Trial for Autism|The UCSD Suramin Autism Treatment Trial||University of California, San Diego|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|4 Years|17 Years|No|||July 2015|July 23, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508259||16288|
NCT02499848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302-2-07|Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer|Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion||Sophiris Bio Corp|No|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|40 Years|N/A|No|||July 2015|July 13, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02499848||16935|
NCT02403999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203080|A Tolerability Assessment Study of Three Wash Products in Infants|A Clinical Study in Infants to Assess the Tolerability of Three Wash Products||GlaxoSmithKline|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Both|N/A|18 Months|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403999||24294|
NCT02408068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUR-004|Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only|Open Label Randomised 3 Period Crossover Study to Evaluate Bioavailability of Modified Release Hydrocortisone (HC) Under Fasting & Fed Conditions & Immediate Release HC Tablets Under Fasting Conditions in Dexamethasone-suppressed Subjects||Diurnal Limited|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02408068||23983|
NCT02503436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816R00009|C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population|C-PATROL - a Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population|C-PATROL|AstraZeneca|No|Recruiting|October 2015|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Probability Sample|300 patients in 80 sites (approx. 40 hospitals and 40 outpatient practices) in Germany.        Each site should enrol 2-30 patients|February 2016|February 26, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02503436|66 Months|16659|
NCT02495727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoB-SRS-01|Two Weeks of Reduced Activity and Skeletal Muscle Health in Older Men|Effect of 14-days of Reduced Physical Activity on Muscle Function and Size, Inflammatory Profile, and Exercise-induced Activation of Stress Responses in Skeletal Muscle in Healthy Older Males||University of Bath|No|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02495727||17251|
NCT02496000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-D-007|Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Diet and Metformin||Oramed, Ltd.|No|Active, not recruiting|June 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|20 Years|75 Years|No|||February 2016|February 1, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496000||17230|
NCT02396550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-1900|Influence of Patient Expectations With Lateral Epicondylalgia in Applying Mobilization With Movement|Influence of Patient Expectations With Lateral Epicondylalgia in Applying Mobilization With Movement. Clinical Trial||University of Alcala|Yes|Recruiting|January 2015|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02396550||24865|
NCT02396563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LABORCA|Effect of Epidural Analgesia on the Length of Labor and Delivery and Fetal Outcomes|||University of Cagliari|No|Not yet recruiting|June 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|18 Years|50 Years|No|Non-Probability Sample|Women who come to the Gynecological nd obstetric Department of University Hospital to        deliver|March 2016|March 8, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02396563||24864|
NCT02399384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6352|Pericardial Fat and Inflammation in HIV Patients and Controls|Myocardial Adipose Inflammation and Pericardial Adipose Volume as Markers for Coronary Artery Disease In HIV Positive Patients||University of Cincinnati|No|Recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|12|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected persons with a history of a positive or negative coronary angiography or        cardiac computed tomography angiography (CTA) will be invited to participate in this study        from the Infectious Diseases Center practice where there are 1800 persons receiving care.        Additionally 4 subjects will be recruited from the cardiology practice at UCMC who have        coronary artery disease but do not have HIV.|January 2015|March 20, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399384||24647|
NCT02508402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KasrELAiniH|Effect Of Intra-muscular Administration of Dexamethasone in Induction of Labour|Effect Of Intra-muscular Administration of Dexamethasone on the Duration of Induction of Labour in Primigravida Post-term Pregnancy.||Kasr El Aini Hospital|Yes|Active, not recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|January 29, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508402||16278|
NCT02500355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qhd20150712|Carpal Tunnel Release Via Two Small Incisions Comparing With Via Standard Incision And Under Endoscope|Carpal Tunnel Release With Partial Excision of the Flexor Retinaculum Through Two Small Incisions|CTR|The Second Hospital of Qinhuangdao|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|68 Years|No|||July 2015|July 15, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02500355||16896|
NCT02500368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-36|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2015|||||N/A|N/A|N/A||||||||||||||July 16, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500368||16895|
NCT02409368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-171|An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC|An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC|Checkmate 171|Bristol-Myers Squibb|Yes|Recruiting|April 2015|March 2021|Anticipated|March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|800|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409368||23883|
NCT02396082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90059611|MIND: Care Coordination for Community-living Person With Dementia|MIND: An RCT of Care Coordination for Community-living Person With Dementia|MIND at Home|Johns Hopkins University|Yes|Recruiting|August 2014|April 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|21 Years|120 Years|No|||March 2016|March 16, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02396082||24901|
NCT02396095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808392|Oocyte Cryopreservation Study (Egg Banking)|Live Birthrate Following Oocyte Cryopreservation||University of Pennsylvania|No|Terminated|August 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|oocytes|Female|15 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Penn Fertility Care|March 2015|March 17, 2015|March 17, 2015||No|American Society of Reproductive Medicine guidelines, October 2012.|No||https://clinicaltrials.gov/show/NCT02396095||24900|
NCT02507128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301xnk|Effects of Glucagon Like Peptide-1 on No-reflow|Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Chinese PLA General Hospital|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507128||16375|
NCT02501902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481059|Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC|An Open-Label Phase Ib Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Abraxane (Registered) (Nab-Paclitaxel) In Patients With Metastatic Pancreatic Ductal Adenocarcinoma||Pfizer|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501902||16777|
NCT02399540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2014-203|Late LTP-like Plasticity Effects of tDCS in Chronic Stroke Patients|||Erasmus Medical Center|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|79 Years|No|||December 2015|December 14, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02399540||24635|
NCT02399553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP 2103-32724|Effect of the Interaction Between the Type of Artificial Turf and Boots Model of Bone Health in Children Soccer Players|Effect of the Interaction Between the Type of Artificial Turf and Boots Model of Bone Health in Children Soccer Players|FUTBOMAS|Universidad de Zaragoza||Active, not recruiting|September 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|129|||Both|11 Years|13 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399553||24634|
NCT02409420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16805|A Trial of Brief Physiotherapy Informed by Acceptance and Commitment Therapy for Chronic Low Back Pain: the PACT Study|A Randomised Controlled Trial of Brief Physiotherapy Informed by Acceptance and Commitment Therapy for Chronic Low Back Pain: the PACT Study|PACT|King's College London|Yes|Recruiting|November 2014|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409420||23879|
NCT02409433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100739|Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management|Prospective, Randomized, Single-blinded Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management||Lawson Health Research Institute|No|Terminated|August 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 1, 2015||No|due to slow recruitment and budgetary restraints study was prematurely terminated|No||https://clinicaltrials.gov/show/NCT02409433||23878|
NCT02507206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1279|A D1 Agonist For Working Memory|A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|April 2013|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507206||16369|
NCT02501980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-PRO-001|Hepatocellular Cancer (HCC) Screening in Zhongshan City|Searching for Early Detection Biomarkers and to Reduce Mortality Rate of Hepatocellular Cancer (HCC) in Zhongshan City|HCC|Zhongshan People's Hospital, Guangdong, China||Recruiting|January 2012|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50000|Samples With DNA|Blood, saliva, urine, fecal samples|Both|35 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy residences in Zhongshan City.|July 2015|July 16, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02501980|10 Years|16771|
NCT02394678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093205|Rheolytic Thrombectomy For Adult Intraventricular Haemorrhage|Rheolytic Thrombectomy For Adult Intraventricular Haemorrhage|rtIVH|Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02394678||25009|
NCT02408887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150105|Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer|Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|April 2025|Anticipated|April 2025|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|100 Years|No|||February 2016|March 8, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02408887||23920|
NCT02410577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002|89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme|A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|26 Years|79 Years|No|||November 2015|November 30, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410577||23790|
NCT02495415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN T-14|Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas|Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)||CerRx, Inc.|Yes|Recruiting|January 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495415||17275|
NCT02495428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-010|Effect of Kinesio Taping in Muscle Fatigue|Effect of Kinesio Taping in Muscle Fatigue||CEU San Pablo University|No|Completed|January 2015|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02495428||17274|
NCT02395978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phase II BLI-1005-002|A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder|||BioLite, Inc.|No|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|20 Years|65 Years|No|||January 2016|January 13, 2016|September 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395978||24909|
NCT02395991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS_2015_ISS|Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI|Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI||Seoul National University Hospital|Yes|Active, not recruiting|April 2015|March 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI        using gadoxetic acid.|February 2016|February 2, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02395991||24908|
NCT02400554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42810-EG|Yappalli - The Road to Choctaw Health|Yappalli - The Road to Choctaw Health||University of Washington|Yes|Recruiting|March 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400554||24557|
NCT02394977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMSU-390-5-5904|Effect of the Cardio First Angle Device on CPR Outcomes|Pilot Study of the Effect of Cardio First Angel (CFA) Device on CPR Outcomes:|CFA|Baqiyatallah Medical Sciences University|Yes|Completed|January 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|80|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02394977||24986|
NCT02402075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASze_DF_001|Spinal Motor Evoked Potentials in Brain Surgery|Spinal Motor Evoked Potentials During Neurosurgical Procedures Within the Central Region||Heinrich-Heine University, Duesseldorf|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with glioma|March 2015|March 27, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02402075||24440|
NCT02496442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS-01|Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan|Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan||Flowmed|No|Not yet recruiting|July 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496442||17196|
NCT02406014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-1120|Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp|Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp||LEO Pharma|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406014||24139|
NCT02399345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-310|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults|An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|99 Years|No|||November 2015|November 18, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399345||24650|
NCT02498730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRJ-01|Interval Training in Bipolar Disorder|Can the High Intensity Interval Training (HIIT) Deliver Superior and Rapid Decrease of Symptoms of Bipolar Disorder? a Controlled and Randomized Study|HIIT|Universidade Federal do Rio de Janeiro|Yes|Recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498730||17021|
NCT02507921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST/0112/15|Resistance in HIV+ in North and South|Comparing Type and Prevalence of HIV Drug Resistance in Treatment Experienced and naïve HIV-infected Adults in Uganda and Switzerland|RHINOS|Makerere University|No|Recruiting|May 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2750|Samples Without DNA|Plasma for HIV viral load and serum for storage|Both|18 Years|N/A|No|Non-Probability Sample|Study participants will be all HIV-1 infected adults presenting to the Infectious Disease        Institute in Kampala during a defined study period, who are either treatment naïve or have        been on a stable antiretroviral regimen for longer than 6 months.|July 2015|July 22, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02507921|1 Day|16314|
NCT02404597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078576|Cardiac Output Monitoring in Burn Patients|Non-invasive Cardiac Output Monitoring in Patients With Burn Injuries||Emory University|No|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404597||24248|
NCT02404610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 13-3746|Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department|Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department||Minneapolis Medical Research Foundation|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02404610||24247|
NCT02400372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0079-14|The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site|The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site||HaEmek Medical Center, Israel|No|Not yet recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|90 Years|No|||February 2015|March 23, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02400372||24571|
NCT02400385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703131-1|A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma|A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma||California Pacific Medical Center Research Institute|No|Recruiting|March 2015|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2015|May 15, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400385||24570|
NCT02498964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Buck-IRB 2015B0264|Use of High Fidelity Simulation in Cardiac-specific Anesthesia Scenarios for Resident Education and Assessment|Use of High Fidelity Simulation in Cardiac-specific Anesthesia Scenarios for Resident Education and Assessment||Ohio State University|No|Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|14|||Both|N/A|N/A|No|Non-Probability Sample|Resident physicians who have completed at least one month of cardiac rotation are        included.This high fidelity simulation lab course if offerred to every resident that meets        the criteria.This is a part of their educational activity.At the beginning of the course        they are given the option to participate in the survey.If they do not wish to participate        in the survey it will not affect their education.Participitaion in the survey is purely        voluntary.|July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498964||17003|
NCT02498977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASF/001-01|Liver Immunosuppression Free Trial|Prospective Randomised Marker-based Trial to Assess the Clinical Utility and Safety of Biomarker-guided Immunosuppression Withdrawal in Liver Transplantation|LIFT|King's College London|Yes|Recruiting|October 2015|March 2021|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|148|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02498977||17002|
NCT02508792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37904814.0.0000.5345|Low Level Laser Therapy in Heart Failure Patients.|Acute Effects of Low Level Laser Therapy in Muscle Function of Patients With Heart Failure.||Federal University of Health Science of Porto Alegre|No|Recruiting|August 2015|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|55 Years|75 Years|No|||August 2015|August 12, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508792||16248|
NCT02401633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT|Compression Only-CPR Versus Standard-CPR - the Run-in Phase|A Randomized Trial Comparing the Effect of a Simplified Form of Cardiopulmonary Resuscitation (CPR) Consisting of Only Chest Compressions Compared to CPR With Compressions and Rescue Breaths - the Run-in Phase|TANGO2|Karolinska Institutet|No|Recruiting|February 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02401633||24474|
NCT02395471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-271|Cytosponge Adequacy Study Evaluation II|Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms|CASEII|Medtronic - MITG|No|Recruiting|August 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|175|Samples With DNA|Tissue samples will be retained at the clinical sites|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1) Subjects undergoing surveillance of BE who have had at least a C1 or M3 segment        confirmed within the last 3 years, and 2) in subjects with GERD undergoing screening for        BE.|July 2015|December 2, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02395471||24948|
NCT02410642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUHThoraxLL2|NAG-excretion During Cardiopulmonary Bypass|Effects of Cardiopulmonary Bypass on Urinary Secretion of NAG|CPBNAG|Sahlgrenska University Hospital, Sweden|No|Completed|November 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Probability Sample|60 patients scheduled for complex cardiac surgery|March 2016|March 7, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410642||23785|
NCT02507063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0326|Optic Nerve Sheath Diameter and Intracranial Pressure (ICP) in Children|Determining the Correlation of Optic Nerve Sheath Diameter With Intracranial Pressure in Children||University of Louisville|Yes|Not yet recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|18 Years|No|Non-Probability Sample|Children who are 0 - 18 years old who have an invasive intracranial ICP monitoring device        admitted to PICU and children who are 0-18 years old who are determined to require a shunt        revision following evaluation in the ED.|July 2015|July 22, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02507063||16380|
NCT02401113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UrsolicAcid|Effect of Ursolic Acid of Loquat Extract on Function of Muscle|Effect of Ursolic Acid of Loquat Extract on Function of Muscle in Human||Pusan National University Hospital|Yes|Completed|November 2014|October 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401113||24514|
NCT02401373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR2015VCT001|A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.|A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China||First Affiliated Hospital of Zhejiang University|Yes|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401373||24494|
NCT02409576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB 2014/00452|Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas|Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas|NKEXPSARC|National University Hospital, Singapore|Yes|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|80 Years|No|||April 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409576||23867|
NCT02406846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatic Cancer CTC 001|The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.|The Detection of Circulating Tumor Cells (CTCs) in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage pancreatic cancer come to Fuda Hospital for treatment.|December 2015|December 28, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406846|2 Years|24077|
NCT02504151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412015000|Cannabidiol Treatment in Patients With Early Psychosis|Cannabidiol Treatment in Patients With Early Psychosis|CBD|Yale University|Yes|Not yet recruiting|August 2015|October 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504151||16604|
NCT02506023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080329|Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers|Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers||Emory University|No|Enrolling by invitation|July 2015|May 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|25|||Female|18 Years|60 Years|No|||July 2015|July 21, 2015|July 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506023||16460|
NCT02398994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N065|A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis|A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children|STRIVE|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|March 2015|September 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|1 Year|N/A|No|||January 2016|January 18, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02398994||24677|
NCT02399007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPS-201301|A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China|A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China||Johnson & Johnson Medical (Suzhou) Ltd.|No|Recruiting|June 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|55 Years|80 Years|No|||March 2016|March 15, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399007||24676|
NCT02406664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02271568|The Effect of Bariatric/Metabolic Surgery on GFR|Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome||Hanyang University|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02406664||24091|
NCT02406781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2014-04|Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial|Combination of MK3475 and Metronomic Cyclophosphamide in Patients With|PEMBROSARC|Institut Bergonié|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|163|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02406781||24082|
NCT02417194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-2015-310|Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma|Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Renal Cell Carcinoma||Seoul National University Hospital|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|238|||Both|20 Years|80 Years|No|Non-Probability Sample|Enrolled patients should be diagnosed with renal cell carcinoma by ultrasonography and/or        CT scan, MRI. In addition, the participants should be treated with radical or partial        nephrectomy.|May 2015|May 5, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02417194|36 Months|23281|
NCT02404571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GiFT|GDP in Frontline Chemotherapy for Patients With PTCL-NOS|The Efficacy and Toxicity of GDP Chemotherapy in Patients With Peripheral T-cell Lymphoma: An Open-label, Single-arm, Phase II Clinical Trial||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2011|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404571||24250|
NCT02404753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISCA2015001/LAP|A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy|A Randomized, Single Center, Controlled Phase II Study to Compare Laparoscopic Versus Open Distal Gastrectomy in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy|REALIZATION|Peking University|No|Recruiting|March 2015|June 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404753||24236|
NCT02402647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-005-14S|Cognitive Rehab and Exposure Treatment for Hoarding|Cognitive Rehabilitation and Exposure Therapy for Veterans With Hoarding Disorder|CREST|VA Office of Research and Development|No|Recruiting|October 2015|October 2020|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402647||24396|
NCT02422537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML11202|Effect of Different Bran-based Dietary Platforms on the Colon Metabolism in Healthy Volunteers|The Effect of One Single Dose of Different Bran-based Dietary Platforms on the Colon Metabolism - A Study With (Stable) Isotopes in Healthy Volunteers||Katholieke Universiteit Leuven|No|Active, not recruiting|February 2015|||July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02422537||22871|
NCT02427113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZurichUAS|What Are the Effects of Music on Temporomandibular Disorder Symptoms?|What Are the Effects of Music on TMD Symptoms?|TMD|University of Toronto|No|Not yet recruiting|May 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 24, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02427113||22519|
NCT02412709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30147-01|Long QT Syndrome Screening in Newborns|ECG Device for Long QT Syndrome Screening in Newborns||QT Medical, Inc.|Yes|Recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|4000|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412709||23626|
NCT02395354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtDilat-3-2013|PROTDILAT (PROtesis DILATation)|Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease: Metal Self-expanding Prosthesis Balloon Dilatation||Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|No|Recruiting|September 2013|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|75 Years|No|||March 2015|March 17, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395354||24957|
NCT02395601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205-01|A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas|A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas||Constellation Pharmaceuticals|No|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395601||24938|
NCT02398708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400992|Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT|Comparison of the Fecal Microbiome, Peripheral Inflammatory Markers, and Symptoms in Individuals Discordant for GVHD After Allogeneic Hematopoietic Stem Cell Transplant||University of Florida|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|Whole blood and stool specimens|Both|18 Years|N/A|No|Non-Probability Sample|20 allo-Hematopoietic Stem Cell Transplantation (HSCT) recipients with chronic        graft-versus-host disease (cGVHD) and 20 allo-Hematopoietic Stem Cell Transplantation        (HSCT) recipients without chronic graft-versus-host disease (cGVHD)|November 2015|November 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398708||24699|
NCT02417571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-ABPM|Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD|Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of Chronic Kidney Disease|ACCURATE|Seoul National University Hospital|No|Recruiting|April 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|19 Years|70 Years|No|||April 2015|April 22, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02417571||23252|
NCT02421692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2388|Improving Physical Function in Skilled Nursing Facility Residents|Improving Physical Function in Skilled Nursing Facility Residents|SNF|University of Colorado, Denver||Recruiting|April 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|153|||Both|55 Years|N/A|No|||October 2015|October 20, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02421692||22936|
NCT02421705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51573|Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)|Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors||Katholieke Universiteit Leuven|No|Recruiting|February 2010|January 2099|Anticipated|January 2099|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|99999999|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02421705||22935|
NCT02404974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00028445|Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis|Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis|exercise/OA|Dartmouth-Hitchcock Medical Center|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|50 Years|85 Years|No|||January 2016|January 21, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02404974||24219|
NCT02405728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM-FEDII-PICC-001|Vascular Access in Hematological Patients - PICC Versus CVC|Vascular Access in Hematological Patients - PICC Versus CVC in a Phase IV Randomized Controlled Trial||Federico II University|No|Active, not recruiting|February 2015|February 2016|Anticipated|August 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|90 Years|No|Probability Sample|Adult Patients (>18 yrs) with hematological malignancies planned for chemotherapy that        required a vascular access with a projected life expectancy of at least four weeks.|April 2015|April 8, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02405728||24161|
NCT02420899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40068860-9|Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients|Effect of Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in Chinese ACS Patients||Beijing Friendship Hospital|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|75 Years|No|||June 2015|June 6, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02420899||22997|
NCT02424630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-52|Interscalene Brachial Plexus Block Combined With Suprascapular Nerve Block|The Effect of Sono-Guided Interscalene Brachial Plexus Block Combined With Arthroscopy-Guided Suprascapular Nerve Block in Arthroscopic Rotator Cuff Repair: A Randomized Controlled Trial||Chuncheon Sacred Heart Hospital|Yes|Completed|August 2013|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|20 Years|80 Years|No|||April 2015|April 22, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424630||22710|
NCT02424643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065333A|Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study|Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study||Emory University|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|1131|||Male|18 Years|34 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02424643||22709|
NCT02397824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-2012-1677|Orodental Manifestations of Rare Diseases|||University Hospital, Strasbourg, France|No|Recruiting|January 2015|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Routine care hospitalization patient|December 2015|December 17, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02397824||24767|
NCT02398045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBT-1111|Developing Computerised CBT for Adults With OCD|Developing Computerised Cognitive Behavioural Therapy for Adults With Obsessive-compulsive Disorder|CCBT|Institute of Psychiatry, London|Yes|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02398045||24750|
NCT02410213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT13036|A Study to Characterize the Pharmacokinetics and Pharmacodynamics Profile of Intravenous Ferric Carboxymaltose in Pediatric Subjects 1-17 Years Old With Iron Deficiency Anemia (IDA)|A Multi-center, Open-label, Single Arm Study to Characterize the Pharmacokinetics and Pharmacodynamics Profile of Intravenous Ferric Carboxymaltose in Pediatric Subjects 1-17 Years Old With Iron Deficiency Anemia (IDA)||Luitpold Pharmaceuticals|Yes|Recruiting|February 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|1 Year|17 Years|No|||November 2015|November 16, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410213||23818|
NCT02410226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R115|Ultrasound Versus Palpation for Epidural Catheterization|Comparison Between Ultrasound-assisted and Conventional Palpation Techniques for Epidural Catheterization Before Cesarean Section||Mansoura University|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|19 Years|40 Years|No|||September 2015|September 21, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02410226||23817|
NCT02417883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT15-920|Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease|Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease|FST-IFTA|Instituto Nacional de Cardiologia Ignacio Chavez|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417883||23228|
NCT02403336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI/1100693|Health Education in Perimenopausal Women to Promote Self-care and Quality of Life|Health Education in Perimenopausal Women to Promote Self-care and Quality of Life: Randomized Clinical Trial||Gerencia de Atención Primaria, Madrid|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|356|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403336||24345|
NCT02497755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47871-EG|Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety|Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety||University of Washington|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02497755||17096|
NCT02495246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBL05|A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV|A Phase I, Safety and Immunogenicity Trial of the Heterologous Prime-boost Regimen Combining the Monovalent Zaire Ebola Viral Vector Candidates ChAd3-EBO-Z and Ad26.ZEBOV in Healthy UK Adults||University of Oxford||Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02495246||17288|
NCT02399865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHR 11/60/01|Family and Social Intervention for Young People|A Randomised Controlled Trial of Family and Social Network Intervention for Young People Who Misuse Alcohol and Drugs: a Feasibility Study [Y-SBNT]|YSBNT|University of Birmingham|No|Active, not recruiting|May 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399865||24610|
NCT02408016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2727.00|Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma|Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor||Fred Hutchinson Cancer Research Center|Yes|Recruiting|May 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408016||23987|
NCT02408055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-07|ADME Study in Healthy Male Subjects With TA-8995|A Phase I Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolism and Excretion of 14C-TA-8995 in Healthy Male Subjects||Xention Ltd|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02408055||23984|
NCT02507622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-103|E-NOSE for Breath Gas Analysis Under Microgravity Conditions||E-NOSE|University Hospital, Caen|No|Recruiting|September 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507622||16337|
NCT02510924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409/14|Role of Airtraq Mobile to Improve Intubation Conditions With Airtraq|Role of Airtraq Mobile to Improve Intubation Conditions With Airtraq in Adults With a Simulated Difficult Airway With a Cervical-spine Collar|AirtraqMob|University of Lausanne Hospitals|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510924||16084|
NCT02510937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90001-CP-003|Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis|A Phase 1b, Multicenter, Open-label, Staggered-dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of CC-90001 for 3 Months in Patients With Pulmonary Fibrosis||Celgene|No|Recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510937||16083|
NCT02510950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510022|Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma|A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma||Washington University School of Medicine|No|Recruiting|November 2015|March 2019|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510950||16082|
NCT02409290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78372190|The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB|STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB|STREAM|IUATLD, Inc|Yes|Not yet recruiting|July 2015|December 2021|Anticipated|April 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|1155|||Both|18 Years|N/A|No|||March 2015|April 3, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409290||23889|
NCT02395536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0, 23 January 2015|Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States|Reveal LINQ™ In-Office 2 (RIO 2) Study United States|RIO 2|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|540|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395536||24943|
NCT02395549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL15001|A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris|||Mimetica Pty Limited||Recruiting|April 2015|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|360|||Both|16 Years|65 Years|No|||January 2016|January 21, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395549||24942|
NCT02395562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUP063|Viral Reactivation and Skin Cancer|Association of Viral Reactivation and Skin Cancer in Organ Transplant Recipients||University of Zurich||Recruiting|January 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|organ transplant recipients within the STCS.|December 2015|December 9, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395562||24941|
NCT02506894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mgso4 for neuroprotection|Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection|Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection||Cairo University|Yes|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Female|20 Years|40 Years|No|||January 2016|January 29, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506894||16393|
NCT02506959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0516|Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma|Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506959||16388|
NCT02500095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fasting8000|Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting|Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting in Overweight and Obese Human Subjects and the Impact of Growth Hormone Receptor Blockade||University of Aarhus|Yes|Active, not recruiting|July 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|10|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02500095||16916|
NCT02400333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5139C00003|Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet|An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects||AstraZeneca|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|98|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02400333||24574|
NCT02400593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1938|Health Experiences & Early Life Disadvantages|An Affective Intervention to Reverse the Biological Residue of Low Childhood SES|HEELD|University of North Carolina, Chapel Hill|No|Recruiting|August 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|128|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400593||24554|
NCT02404402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1773-P|LED Treatment to Improve Cognition and Promote Recovery in TBI|Noninvasive LED Treatment to Improve Cognition and Promote Recovery in Blast TBI|LED-TBI|VA Office of Research and Development|No|Recruiting|May 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|21 Years|55 Years|No|||March 2016|March 15, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02404402||24263|
NCT02501681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atadek 2014-723|Evaluation of Different Priming Solutions Effects on Microcirculation, Oxidative Stress and Morbidity in Cardiovascular Surgery Patients|Evaluation of Different Priming Solutions Effects on Microcirculation, Oxidative Stress and Morbidity in Cardiovascular Surgery Patients|Acibadem|Medical Centre Leeuwarden|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501681||16794|
NCT02501694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00532-45|Evaluation of Patients With Suspected Endofibrosis|Enregistrement Des Bruits Vasculaires de l'artère Iliaque Externe Par STETHOscope électronique en Post - Effort Chez le SPORTif|Stethosport|University Hospital, Angers|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Athletes referred for exercise tests|February 2016|February 11, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501694||16793|
NCT02510053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14030310568|Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit|PK-PD of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|No|Enrolling by invitation|July 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 26, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02510053||16151|
NCT02397434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/0630|Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer|Adjuvant Radiotherapy After Cystectomy for Patients With Muscle Invasive Bladder Cancer: a Phase II Trial.||University Hospital, Ghent|No|Recruiting|October 2014|October 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02397434||24797|
NCT02404714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFQuantum003|A Multi-Center Study of the CF Quantum® Sweat Test System|A Multi-Center Study of A New Method of Sweat Testing: The CF Quantum® Sweat Test||Polychrome Medical, Inc.|No|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples Without DNA|Sweat samples will be collected per standard sweat testing procedure.|Both|N/A|N/A|No|Probability Sample|The study population includes those individuals with a previous diagnosis of CF or cystic        fibrosis related metabolic syndrome (CRMS) and those individuals who have been referred to        the sweat test lab for clinical reasons by a physician. The groups will be selected from        the investigator's normal clinical practice.|March 2015|April 6, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02404714||24239|
NCT02494648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408189|Effects of Inspiratory Muscles Strengthening Among Coronary Patients on the Sleep Apnea Obstructive Syndrome|Effects of Inspiratory Muscles Strengthening Among Coronary Patients on the Sleep Apnea Obstructive Syndrome (SAOS)|RICAOS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|40 Years|80 Years|No|||February 2016|February 19, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494648||17334|
NCT02494661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-14-00591|Nutritional Video Intervention Using Mindfulness-based Principles|Healthy Plate Program in East and South Los Angeles: Testing "Mindfulness-inspired" Video in Community Settings||University of Southern California|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|218|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02494661||17333|
NCT02399566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTEBMTLA-2015|Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma|Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma||Hunan Province Tumor Hospital|No|Not yet recruiting|May 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||March 2015|March 25, 2015|March 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399566||24633|
NCT02397668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PR-1101|CorMatrix ECM Tricuspid Valve Replacement|CorMatrix ECM Tricuspid Valve Replacement Safety and Early Feasibility||CorMatrix Cardiovascular, Inc.|Yes|Recruiting|May 2015|December 2020|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Years|70 Years|No|||January 2016|January 27, 2016|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397668||24779|
NCT02397681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTO-2015|Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup|Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup||Danish Pain Research Center|Yes|Completed|January 2015|August 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02397681||24778|
NCT02400138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTS-01|Home-based Respiratory Training After Stroke|Effects of Home-based Respiratory Training After Stroke: A Randomized Controlled Trial||Federal University of Minas Gerais|No|Recruiting|February 2016|December 2017|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||February 2016|February 2, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400138||24589|
NCT02400411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY_RAV_Breadmeal|The Glycemic and Insulinemic Responses Elicited by Meals Containing Whole Grain Rye Bread or White Wheat Bread|The Effects of Margarine and Ham or Vegetable Soup on the on the Glycemic and Insulinemic Responses Elicited by Whole Grain Rye Bread or White Wheat Bread||Helsinki University|No|Active, not recruiting|March 2015|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|6||Anticipated|15|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400411||24568|
NCT02494934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|379631|Effectiveness of Cognitive Behavioural Therapy and Physical Therapy for Provoked Vestibulodynia|A Randomized Comparison of Individual Cognitive-behavioural Therapy and Pelvic Floor Rehabilitation in the Treatment of Provoked Vestibulodynia||Queen's University|No|Completed|September 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||August 2015|August 30, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02494934||17312|
NCT02399800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00134|Celiac Plexus Block for Chronic Pancreatitis RCT|Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis||University of Southern California|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||March 2015|March 21, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02399800||24615|
NCT02398812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILMA|The Interprofessional Medication Assessment for Older Patients|The Interprofessional Medication Assessment for Older Patients - a Multicenter Randomized Trial in Primary Care Setting||East Savo Hospital District|No|Active, not recruiting|February 2015|December 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|514|||Both|65 Years|N/A|No|||October 2015|December 15, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02398812||24691|
NCT02396979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA025943|Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia|Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia|Harapan|Yale University|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02396979||24832|
NCT02396992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM2013-14|Minimal-Massive Intervention in Elderly Patients With Dysphagia|Evaluation of a Minimal-massive Intervention in Elderly Hospitalized Patients With Oropharyngeal Dysphagia|MMI|Hospital de Mataró|No|Active, not recruiting|March 2014|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|62|||Both|70 Years|N/A|No|||March 2015|March 24, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02396992||24831|
NCT02499549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRL02|Two Treatment Regimens of Cocamide DEA Lotion for Head Lice|A Randomised, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion in the Treatment of Head Louse Infection.||Medical Entomology Centre|No|Terminated|October 1999|December 1999|Actual|December 1999|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|4 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 10, 2015||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT02499549||16958|
NCT02400567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoPal - UC-0140/1404|Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women|Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women|NeoPAL|UNICANCER|Yes|Recruiting|January 2015|April 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02400567||24556|
NCT02404285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-003|A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne|A Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne||Next Science TM|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|12 Years|N/A|No|||April 2015|October 14, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404285||24272|
NCT02399059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURJ2015-01|Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome|Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution During Elective Colorectal Cancer Surgery on the Oncologic Outcome||Hospital General Universitario Elche|Yes|Completed|January 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|N/A|N/A|No|||March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399059||24672|
NCT02506764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 34487|Zone-Model Predictive Control on the Diabetes Assistant (DiAs) Platform Safety and Feasibility|Use of Zone-Model Predictive Control (MPC) Controller on the Diabetes Assistant (DiAs) Platform With Fault Detection in Adolescents With Type 1 Diabetes in the Outpatient Setting (UCSB Study)||Stanford University|Yes|Not yet recruiting|July 2015|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|10 Years|19 Years|No|||July 2015|July 22, 2015|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506764||16403|
NCT02501356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/09|Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults|Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults|ISOThrive|Griffin Hospital|No|Recruiting|April 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|105|||Both|18 Years|75 Years|No|||July 2015|July 15, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02501356||16819|
NCT02396225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2013-242-13|Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration|||University of Aarhus|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Male|18 Years|70 Years|No|||December 2015|December 2, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396225||24890|
NCT02400827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0229|Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors|Study About Contamination of Ovarian Tissue by RT-PCR in Children With Solid Tumors.|OVAMAR|University Hospital, Clermont-Ferrand||Recruiting|November 2014|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|80|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients treated for a solid tumor during infancy|March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400827||24536|
NCT02403297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1R43DE024015-01|Rapid Point-of-Care Salivary Diagnostic for Periodontal Health|Rapid Point-of-Care Salivary Diagnostic for Periodontal Health||Innovative Diagnostics Inc|Yes|Recruiting|March 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|174|Samples Without DNA|5ml of saliva will be collected. A small sample of the saliva will be used chair side to      analyze on the device. The remaining saliva will be aliquoted into five samples and kept      frozen until analyzed on a Luminex machine.|Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of individuals will be recruited: those that are orally healthy and do not        have any oral discomfort (N=58), those who have gingivitis (i.e., bleeding gums; N=58),        and those who have periodontal disease (N=58). The groups will be matched by gender and        smoking status. Women are predicted to account for 50% of the participants. The age        distribution will be 18 to 95 years. Subjects will not be excluded based on race, gender,        or ethnicity.|March 2015|March 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02403297||24348|
NCT02503839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/692|Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic|Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors|TBCOX2|Oslo University Hospital|No|Not yet recruiting|September 2015|October 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02503839||16628|
NCT02509715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAH-2015-17|Effect of Intraoperative Nerve Monitoring on Voice Quality During Thyroid Surgery|Effect of Intraoperative Nerve Monitoring on Voice Quality During Thyroid Surgery||Lütfiye Nuri Burat Government Hospital|No|Not yet recruiting|August 2015|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509715||16177|
NCT02407873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013001|Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery|Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery||University Hospital of Liege|No|Recruiting|February 2014|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|75 Years|N/A|No|Non-Probability Sample|Patient aged 75 year and over undergoing elective cardiac surgery|October 2015|October 29, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02407873|30 Days|23998|
NCT02407886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0649|Retinal Ganglion Cell Layer in Patients With Intracerebral Processes|||University of Zurich|No|Active, not recruiting|March 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|60 Years|No|Probability Sample|patients with intracerebral lesions|December 2015|December 9, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02407886||23997|
NCT02404506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 25/14|Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer|Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Recruiting|August 2015|October 2023|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Female|70 Years|N/A|No|||January 2016|January 6, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404506||24255|
NCT02504086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F14-01764|Online Support for Diabetes Self-Management|Online Support for Diabetes Self-Management||University of British Columbia|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02504086||16609|
NCT02504099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-726|A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma|Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir With or Without Ribavirin (RBV) in Adult Patients With GT1 or GT4 Chronic HCV Infection and Response to Prior Treatment of Early Stage Hepatocellular Carcinoma (GEODE - I)||AbbVie|No|Active, not recruiting|July 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02504099||16608|
NCT02496962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015-091-01|Protective Effect of Statin on Sleep Deprivation|Protective Effect of Statin on Arrhythmia and Heart Rate Variability in Healthy People With 48 Hours of Sleep Deprivation||Chinese PLA General Hospital|Yes|Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02496962||17156|
NCT02404818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI-1431-HL02|Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy|UFPTI 1431 - HL02: Investigating Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Survivors Treated With Either Photon or Proton Radiation||University of Florida|No|Enrolling by invitation|April 2015|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|N/A|No|Non-Probability Sample|Hodgkin's lyphoma survivors that have received radiation at UF Health Proton Therapy        Institute and also received chemotherapy.|March 2016|March 3, 2016|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404818||24231|
NCT02407938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-0176|Normal Values for Esophageal High Resolution Manometry in an Advanced Protocol Including Liquid Swallows and a Solid Test Meal|Normal Values for Esophageal High Resolution Manometry in an Advanced Protocol Using a Test Meal|Rice|University of Zurich|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02407938||23993|
NCT02399904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shoulder taping|Effect of California Tri-pull Taping Method on Shoulder Subluxation, Pain, Active Range of Motion and Upper Limb Functional Recovery After Stroke - A Pre Test Post Test Design|Effect of California Tri-pull Taping Method on Shoulder Subluxation, Pain, Active Range of Motion and Upper Limb Functional Recovery After Stroke - A Pre Test Post Test Design|CTPT|Maharishi Markendeswar University|Yes|Completed|November 2012|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|35 Years|70 Years|No|||March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399904||24607|
NCT02398006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIAE orthopaedics|Conservative Interventions for Treating Clavicle Fractures in Adults|Figure-of-eight Bandage Versus Arm Sling for Treating Middle Third Clavicle Fractures in Adults: Study Protocol for a Randomised Controlled Trial||Hospital Israelita Albert Einstein|Yes|Not yet recruiting|April 2015|December 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398006||24753|
NCT02398318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-YY2015-CRODS|China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study|China Refractory-Obsessive Compulsive Disorder Deep Brain Stimulation Study|CRODS|Ruijin Hospital|Yes|Not yet recruiting|April 2015|April 2018|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2015|March 26, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398318||24729|
NCT02508857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP0792010|Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries|Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries: a Double-blind Randomized Controlled Trial.|Magnesium|Instituto do Cancer do Estado de São Paulo|Yes|Completed|January 2010|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|65 Years|No|||July 2015|July 24, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02508857||16243|
NCT02508870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29754|A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes|A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes||Hoffmann-La Roche||Recruiting|September 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508870||16242|
NCT02404090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS-001|Impact of the Excess Weight Loss on Mineralization Patterns of the Knee After Bariatric Operations|Impact of the Excess Weight Loss on Mineralization Patterns of the Knee After Bariatric Operations - a Prospective CT-osteoabsorptiometry-based Study|CT-OAM|Spital Limmattal Schlieren|Yes|Not yet recruiting|August 2015|August 2021|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Bariatric patients with BMI > 35 kg/m2 with knee pain (VAS > 2).|March 2015|March 26, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404090||24287|
NCT02404259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 131|PK TDF in Thai HIV-infected Children|Pharmacokinetics Study of Tenofovir in HIV-infected Thai Children Using Tenofovir-based Regimen||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|June 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|32|||Both|8 Years|18 Years|No|||March 2015|March 30, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02404259||24274|
NCT02396043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBL-308|Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma|Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study||Sun Yat-sen University|Yes|Recruiting|March 2015|March 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396043||24904|
NCT02398617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-192|End-Of-Life Decision Making and Preparedness Planning Among Heart Failure Patients Hospitalized for Advanced Disease|Facilitating End-Of-Life Decision Making and Preparedness Planning Among Heart Failure Patients Hospitalized for Advanced Disease||Saint Luke's Health System|No|Suspended|December 2014|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 20, 2015||No|Low enrollment and need to refine protocol|No||https://clinicaltrials.gov/show/NCT02398617||24706|
NCT02403388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0265|Assessment of a Multifaceted Risk Management Program in French Multiprofessional Offices in Primary Care|Implementation and Assessment of a Multifaceted Risk Management Program in French Multiprofessional Offices in Primary Care : the PRisM Study|PRisM|Hospices Civils de Lyon|No|Not yet recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Multiprofessional primary care offices in France (MSP, SS, PS)|March 2015|March 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403388||24341|
NCT02508740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5945-REN-13-03|Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment|Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects||Cubist Pharmaceuticals LLC|No|Terminated|September 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|31|||Both|18 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 22, 2015|No|Yes|Development of compound has been put on hold.|No||https://clinicaltrials.gov/show/NCT02508740||16252|
NCT02403245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SID010|Social Interactions Between People With Dementia in Nursing Home|The Impact of a Social Stimulation on Social Interactions in Institutionalized People With Dementia||Paris West University Nanterre La Défense|No|Completed|March 2012|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|60|||Both|75 Years|N/A|No|||March 2015|March 25, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02403245||24352|
NCT02393846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAU2015/05|Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain|Comparison of Topical Dexketoprofen Versus Placebo in Patients Presented With Ankle Sprain to the Emergency Department: A Randomised Placebo Controlled Trial||Akdeniz University|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||July 2015|July 3, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393846||25073|
NCT02421289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 05-56-13|Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients|Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study||Mahidol University|No|Recruiting|April 2013|||April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02421289||22967|
NCT02424682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21201|Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer|Safety of Herceptin in Metastatic Breast Cancer||Hoffmann-La Roche||Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|69|||Female|18 Years|N/A|No|Non-Probability Sample|Women with human epidermal growth factor receptor (HER) 2 positive metastatic breast        cancer|March 2016|March 1, 2016|April 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02424682||22706|
NCT02406924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversidadeSP|Bone Augmentation Using Particulated Biomaterial and Autogenous Bone, Stabilized by Collagen Membrane and Pins (PaMP)|Maxillary Horizontal and Vertical Bone Augmentation Using Particulated Biomaterial Associated With Autogenous Bone, Covered and Stabilized by a Collagen Membrane and Pins|PaMP|University of Sao Paulo|No|Not yet recruiting|April 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406924||24071|
NCT02408627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/1283|EEG@HOME (Phase 3a of the Project, Comparison of EEG-recordings)|||University Hospital, Ghent|Yes|Enrolling by invitation|January 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|5|||Both|6 Years|80 Years|No|||December 2015|December 7, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408627||23940|
NCT02408640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1374-31/5-1|Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial|Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial||Karolinska Institutet||Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|352|||Both|16 Years|N/A|No|||January 2016|January 11, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02408640||23939|
NCT02412917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRV-FV-2-007|A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia|A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain||ContraVir Pharmaceuticals, Inc.|Yes|Recruiting|June 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|825|||Both|50 Years|N/A|No|||September 2015|September 1, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412917||23610|
NCT02417389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02A605_2006|Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism|Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism|CA-PHP|Istituto Auxologico Italiano|No|Completed|May 2008|December 2012|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|50 Years|75 Years|No|||April 2015|April 11, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02417389||23266|
NCT02399982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0454|Smartphone Technology and CBT-GSH in Binge Eaters|Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters||Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|February 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|55 Years|No|||January 2016|January 12, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399982||24601|
NCT02403479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106309|The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis|Phase 2 Study Examining the Effects of Topical Intranasal Silver Colloid in Patients With Recalcitrant Chronic Rhinosinusitis|CRS|Lawson Health Research Institute|No|Recruiting|September 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403479||24334|
NCT02420665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0368|Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia|Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia||M.D. Anderson Cancer Center|Yes|Recruiting|September 2015|||September 2025|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|800|||Female|21 Years|N/A|No|||February 2016|February 11, 2016|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02420665||23015|
NCT02420678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2015-0229|Quality of Life in Patients With Hepatocellular Carcinoma|Validation of Questionnaire Module for Quality of Life and Analysis of Its Association With Clinical Outcomes; a Cohort Study in Patients With Hepatocellular Carcinoma||Asan Medical Center|No|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Admitted hepatocellular carcinoma (HCC) patients will be screened to determine study        eligibility.|December 2015|December 29, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02420678||23014|
NCT02420691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0371|LEE011 in Neuroendocrine Tumors of Foregut Origin|A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin (CLEE011 XUS02T)||M.D. Anderson Cancer Center|No|Recruiting|August 2015|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420691||23013|
NCT02424929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1994|Asleep Versus Awake Deep Brain Stimulation Surgery|Asleep Versus Awake Deep Brain Stimulation Surgery||Providence Medical Research Center|No|Recruiting|April 2015|November 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 12, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02424929||22687|
NCT02424942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU13828|First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee|A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Intra-articular Dose of the TrkA Inhibitor, GZ389988, in Patients With Painful Osteoarthritis of the Knee||Sanofi|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|60 Years|No|||December 2015|December 11, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02424942||22686|
NCT02407028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLR-NIH-2015|Hyperbaric Oxygen Brain Injury Treatment Trial|Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial|HOBIT|Minneapolis Medical Research Foundation|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|65 Years|No|||November 2015|November 6, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407028||24063|
NCT02410200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS202|Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS|Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years|FOCUS|Biogen|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|10 Years|17 Years|No|||September 2015|September 17, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410200||23819|
NCT02425813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98115|Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract|Intra-Arterial Steroid Administration of De Novo Acute Graft-vs-Host Disease of the Gastrointestinal Tract: A Phase II Study||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|October 2015|||October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02425813||22619|
NCT02423213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-013|DISCOVER Study: Microscope-integrated Intraoperative OCT Study|Determination of Feasibility of Intraoperative Spectral Domain Microscope Combined/Integrated OCT Visualization During En Face Retinal and Ophthalmic Surgery: DISCOVER Study|DISCOVER|The Cleveland Clinic|No|Recruiting|January 2014|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes any patient requiring ophthalmic surgery who meets the        inclusion criteria for feasibility of OCT imaging.|March 2016|March 9, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02423213||22819|
NCT02410837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVENBP0475|NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™|NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™||Medtronic - MITG||Recruiting|April 2015|||July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Subjects that meet the various inclusion/exclusion criteria will be enrolled consecutively        by each participating site.|March 2016|March 7, 2016|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410837|2 Years|23770|
NCT02402114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4712|Hydrocortisone for Prevention of Post-Traumatic Stress Disorder|Hydrocortisone for Prevention of Post-Traumatic Stress Disorder|HP-PTSD|Albert Einstein Healthcare Network|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402114||24437|
NCT02395939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-CROP|Comparing Diagnostic Yield Between R-EBUS Guided Cryo Biopsy Vs. CT Guided Biopsy for PPL|Randomised Controlled Trial Comparing the Diagnostic Yield of Radial Endo-Bronchial Ultra-Sound (R-EBUS) Guided Cryo-biopsy Vs. CT-guided Transthoracic Biopsy in Patients With Parenchymal Lung Lesion, Suspected of Lung Cancer (CT-CROP)|CT-CROP|Middlemore Hospital, New Zealand|Yes|Recruiting|July 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|158|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|March 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395939||24912|
NCT02395952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001309|Healing of Persistent Epithelial Defects|Comparison of Standard of Care Treatments for Post-operative Non-healing Epithelial Defects||Milton S. Hershey Medical Center|No|Recruiting|March 2015|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395952||24911|
NCT02426476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-006-14F|HRV Biofeedback in Pain Patients|HRV Biofeedback in Pain Patients: Pilot Intervention for Pain, Fatigue & Sleep|HRVB-PP|VA Office of Research and Development|No|Not yet recruiting|January 2015|December 2019|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||October 2015|October 15, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02426476||22568|
NCT02426528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBologna|R.CULT.HEA - URban Environment, CULTural Social Use of Space and HEAlth / Well-being Effect on Population|UR.CULT.HEA - URban Environment, CULTural Social Use of Space and HEAlth / Well-being Effect on Population: Study Protocol for a Cluster Randomized Trial|URCULTHEA|University of Bologna|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|625|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02426528||22564|
NCT02407964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX09303-001|A Retrospective Study on Drug Induced Liver Injury in China|A Retrospective Epidemiologic Study on Incidence and Treatment Status of Hospitalized Drug Induced Liver Injury Patients in Mainland China|DILI-R|Drug Induced Liver Disease Study Group|No|Recruiting|March 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|Patients who were hospitalized during 2012 to 2014.|August 2015|August 5, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407964||23991|
NCT02501551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0573|Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy|A Phase II Study to Evaluate the Efficacy of Regorafenib in C-kit Mutated Metastatic Malignant Melanoma Failed First-Line Dacarbazine, Temozolomide or Immune Therapy||Yonsei University|No|Recruiting|February 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||July 2015|July 16, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02501551||16804|
NCT02499588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0509-15-U375|User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™|Observational User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™|OSMOSE|ConvaTec Inc.|No|Recruiting|June 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with colostomy, ileostomy or urostomy|July 2015|July 15, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02499588||16955|
NCT02499601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD_CRL_0403|CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)|CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) Safety and Feasibility||CorAssist Cadiovascular Ltd.||Recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02499601||16954|
NCT02403856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0019|Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection|Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection: A Double Blind Controlled Study|CALCECHO|Nantes University Hospital|No|Recruiting|April 2015|April 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02403856||24305|
NCT02403986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 05DF1404|An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face|A Randomised, Multi-centre, Parallel-group, Efficacy and Safety Study Evaluating Two and Three Initial Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face||Q-Med AB|No|Active, not recruiting|April 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|35 Years|45 Years|No|||August 2015|August 25, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403986||24295|
NCT02395315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tamirshalev|Alveolar Bone Changes in Diabetes (ABCD) Study|Placement of Hydrophilic TiZr Implants to Enhance Implant Survival in Diabetic Patients: A Prospective, Two-arm, Cohort Study|ABCD|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2015|December 2017|Anticipated|February 2017|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|42|||Both|18 Years|85 Years|No|Non-Probability Sample|Adult patients with diagnosed type II DM exhibiting at least one edentulous site in the        posterior mandible or canine region presenting with levels of HbA1c >7.5% & <10% for        enrollment in the PC group and HbA1c ≤ 7.0% for enrollment in the WC group.|January 2016|January 4, 2016|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395315||24960|
NCT02497963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIM 2015-079|Foreskin Graft Tubularized Incised Plate Urethroplasty vs Tubularized Incised Plate for Primary Hypospadias (FGTIP-TIP)|Foreskin Graft Tubularized Incised Plate Urethroplasty (TIP) vs Tubularized Incised Plate (TIP) for Primary Hypospadias. Randomized Clinical Trial (FGTIP-TIP)|FGTIP-TIP|Hospital Infantil de Mexico Federico Gomez|Yes|Not yet recruiting|August 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Male|3 Months|18 Years|No|||July 2015|July 14, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02497963||17080|
NCT02497014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-03|The European Bifurcation Club Left Main Study|The European Bifurcation Club Left Main Study: A Randomised Comparison of Single Versus Dual Stent Implantation for Distal Left Main True Coronary Bifurcation Lesions|EBC MAIN|European Cardiovascular Research Center|Yes|Recruiting|February 2016|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497014||17152|
NCT02396862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17285|Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment|A Prospective, International, Longitudinal, Observational Study of the Patient Functioning and Well-being, Resource Utilisation, and Clinical Impact of Hemophilia A and Its Treatment|ECHO|Bayer|No|Recruiting|December 2015|March 2021|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|16 Years|N/A|No|Probability Sample|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or        severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe =        FVIII activity ≤1%)|March 2016|March 15, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396862||24841|
NCT02501772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MMHIS139|The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy|||Mackay Memorial Hospital|Yes|Recruiting|September 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||July 2015|July 27, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501772||16787|
NCT02404142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REIMS-LAB14-01|Curarisation and Intubation Conditions During Videolaryngoscopy With Glidescope Titanium||GICAC|CHU de Reims|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02404142||24283|
NCT02404155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063484|Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)|Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)|BEN|University of Maryland|Yes|Recruiting|July 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|64 Years|No|||July 2015|July 22, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404155||24282|
NCT02404168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063848|BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients|Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients||University of Maryland|No|Not yet recruiting|April 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|6|||Both|18 Years|76 Years|No|||March 2015|March 25, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404168||24281|
NCT02408094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81403364|Screening Protein Markers in Patients With Rheumatoid Arthritis and Hot-dampness and Blood Stasis Syndrome|Screening Sensitive Protein Markers and Exploring Application in Syndrome Diagnosis of Hot-dampness and Blood Stasis Syndrome in Patients With Rheumatoid Arthritis||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|May 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with rheunmtoid arthritis and "heat-dampness and blood stasis" syndrome|February 2016|February 16, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408094||23981|
NCT02498496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-1|Magnesium Sulfate to Prevent Hospitalisation of Acute Exacerbations of Chronic Obstructive Pulmonary Disease|MASTER-ED : Magnesium Sulfate to Prevent Hospitalisation of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Seen in the Emergency Department||Hôpital de Verdun|Yes|Not yet recruiting|September 2016|November 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|35 Years|N/A|No|||February 2016|February 17, 2016|July 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02498496||17039|
NCT02498509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153PAR14017|Clinical Trial to Evaluate the Efficacy and Safety of CKD-342|A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients||Chong Kun Dang Pharmaceutical|No|Recruiting|May 2015|May 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|459|||Both|13 Years|N/A|No|||July 2015|July 13, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02498509||17038|
NCT02501746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0233|Bridging Income Generation With Group Integrated Care|Bridging Income Generation With Group Integrated Care (BIGPIC)|BIGPIC|Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|January 2017|January 2020|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|3600|||Both|35 Years|N/A|No|||January 2016|January 15, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501746||16789|
NCT02501824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115/10|Effectiveness of Anthroposophic Speech Therapy in Patients With Asthma|Effectiveness of Anthroposophic Therapeutic Speech in Patients With Asthma in a Real-life Outpatient Setting - a Randomised, Controlled, Multicentre Cross-over Trial||University of Bern|No|Completed|October 2010|November 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|N/A|No|||July 2015|July 15, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02501824||16783|
NCT02401685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-5103-001-13|POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer|POSNOC - POsitive Sentinel NOde: Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance or Axillary Radiotherapy. A Randomised Controlled Trial of Axillary Treatment in Women With Early Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes|POSNOC|Derby Hospitals NHS Foundation Trust|Yes|Recruiting|January 2014|||March 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1900|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02401685||24470|
NCT02408692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 11419|Emergency Contraception and Body Weight: Pilot Study|Emergency Contraception and Body Weight: Pilot Study||Oregon Health and Science University|No|Completed|February 2015|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 4, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408692||23935|
NCT02408705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG_T1_EGP|Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects|A Randomized, Double Blind, Two-period Cross-over Trial Investigating the Effect of Liraglutide as Add on to Intensive Insulin Treatment on the Endogenous Glucose Production in Subjects With C-peptide Positive Type 1 Diabetes Mellitus||Medical University of Graz|Yes|Active, not recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|64 Years|No|||March 2016|March 1, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02408705||23934|
NCT02499029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021986|N-acetylcysteine in the Treatment of PTSD and Addiction|Glial Regulators for Treating Comorbid Posttraumatic Stress and Substance Abuse Disorders|NAC|Medical University of South Carolina|Yes|Completed|February 2013|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||June 2015|July 13, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499029||16998|
NCT02403531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICNOIC|Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer|A Phase II Randomized Trial of Induction Chemotherapy Versus no Induction Chemotherapy Followed by Definitive Chemoradiotherapy in Patients With Inoperable Thoracic Esophageal Cancer||Sun Yat-sen University|Yes|Recruiting|May 2015|July 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403531||24330|
NCT02401971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DREAM-002|Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer|Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial|ITAGC|Zhengzhou University|Yes|Recruiting|August 2014|August 2018|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|75 Years|No|||September 2014|March 27, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02401971||24448|
NCT02404935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prodige 28 - UCGI 27 (TIME)|Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)|Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer|TIME|UNICANCER|Yes|Recruiting|February 2014|June 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404935||24222|
NCT02404948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-Koro-Study-001|PRV-based Detection of CAD in Comparison to Standard Methods|Comparison of a Pulse Wave Based Approach for Detection of Coronary Artery Disease Compared to Standard Methods|PRV-KORO|University Medicine Greifswald|No|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects referred to first coronary angiography due to suspected CAD|November 2015|November 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404948||24221|
NCT02499302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBA part 2|Mental Training for CFS Following EBV Infection in Adolescents|Mental Training for Chronic Fatigue Syndrome (CFS/ME) Following EBV Infection in Adolescents: A Randomised Controlled Trial||University Hospital, Akershus|No|Not yet recruiting|October 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|20 Years|No|||July 2015|July 14, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02499302||16977|
NCT02403583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X140304009|Jamii Bora: A Home-Based Couples Intervention|Jamii Bora: A Home-based Couples Intervention||University of Alabama at Birmingham|No|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|204|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02403583||24326|
NCT02402803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037026|Dried Blood Spot- Statin Pilot Study|Dried Blood Spot- Statin Pilot Study|DBS|Cedars-Sinai Medical Center|No|Not yet recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|cholesterol panel (total cholesterol, LDL-C, triglycerides, HDL-C), Apo A-I, Apo B, Apo E,      IgM, plasminogen, TIMP-1, Von Willebrand factor, antithrombin III, cystatin C, mesothelin,      C-reactive protein, SAA, LPS-binding protein, mannose-binding lectin, myeloperoxidase,      fibrinogen, alpha-1-acid glycoprotein, soluble transferrin receptor, haptoglobin.|Both|18 Years|N/A|No|Non-Probability Sample|Men and women age> 18 years who are initiated on statin therapy in the clinical setting|October 2015|October 19, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402803||24386|
NCT02401776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03-0069|Effect of Caffeine on Heart Function|An Evaluation of the Heart Rate, Blood Pressure and Repolarization Effects of an Energy Drink as Compared to Coffee||University of Texas at Austin|No|Recruiting|March 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02401776||24463|
NCT02401789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-D 2013-017|Dimensional Alterations of the Edentulous Ridge Following Removal of Multiple Adjacent Teeth|Dimensional Alterations of the Edentulous Ridge Following Removal of Multiple Adjacent Teeth||Institute Franci|No|Recruiting|January 2015|December 2021|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02401789||24462|
NCT02506504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308189|Prevention of Post-exercise Muscle Fatigue and Effect on Exercise Training in Severe Patients With COPD.|Prevention of Post-exercise Muscle Fatigue Using a Non Invasive Ventilation and Effect on Exercise Training in Severe Patients With COPD. QUADRIVEND Study|QUADRIVEND|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|June 2014|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|28|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02506504||16423|
NCT02506517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOBILITY-003|A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies||University Health Network, Toronto|Yes|Not yet recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02506517||16422|
NCT02406586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009277a|Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)|Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects (Aim #2)|FFAADA|Emory University|Yes|Completed|July 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|March 30, 2015|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT02406586||24097|
NCT02403050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14ON144|Feasibility Study of Fiducial Markers in Oesophageal Cancer|Feasibility Study to Assess the Benefit of Using Fiducial Markers for Patients Receiving Radiotherapy for Cancer of the Oesophagus||NHS Greater Glasgow and Clyde|No|Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|A retrospective group of patients images without markers, will be compared to a        prospective group of patients who will be imaged and treated following implantation of        fiducial tumor markers.|March 2015|March 25, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02403050||24367|
NCT02498470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-registry|Prospective Registry to Assess the Cath Lab Percutaneous Coronary Intervention Long-term Outcomes: a Single Center|Prospective Registry to Assess the Cath Lab Percutaneous Coronary Intervention Long-term Outcomes: a Single Center|PCI-registry|Sun Yat-sen University|No|Recruiting|January 2008|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|20 Years|90 Years|No|Non-Probability Sample|All the patients receiving coronal artery angiography or percutaneous coronary        intervention therapy in the first affiliated hospital of sun yat-sen university|July 2015|July 13, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02498470|5 Years|17041|
NCT02503618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078950|Understanding Substance Use and Incident HIV/STI Among Young Black MSM|Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)|ele[men]t|Emory University|No|Recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|476|Samples With DNA|Dried blood spot testing, whole blood|Male|18 Years|29 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young black men who have sex with men in Atlanta, Georgia will be recruited in a variety        of venues in Atlanta. If needed, there will be targeted recruitment via Facebook.|January 2016|January 27, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503618||16645|
NCT02507843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150511|Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis|Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial|VIDB|Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507843||16320|
NCT02404454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MulticentricMetroplasty|Prevention of Intrauterine Adhesions After Hysteroscopic Metroplasty With Autocross-linked Hyaluronic Acid Gel|||University of Cagliari|No|Not yet recruiting|June 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404454||24259|
NCT02508116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820899|Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention|Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT)|ADAPT|University of Pennsylvania|No|Recruiting|November 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508116||16299|
NCT02508129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14070337|Hypertension With Unsatisfactory Sleep Health|Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients|HUSH|University of Pittsburgh|Yes|Recruiting|August 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|625|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508129||16298|
NCT02497560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 20144|A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms|A Randomized Double Blind Placebo-Controlled Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms||Physician Recommended Nutriceuticals||Suspended|March 2015|||March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|120|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|July 6, 2015||No|Role of calcium in menopause is not clear. Product maybe reformulated and the study    relaunched.|No||https://clinicaltrials.gov/show/NCT02497560||17111|
NCT02397889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0265|Repeated-Dose Intravenous Ketamine for PTSD|Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|April 2015|June 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397889||24762|
NCT02404519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC143058|Vitamin K2 Effect on Vascular Stiffening in Subjects With a Poor Vitamin K-status|Intervention Study on the Effect of Vitamin K2 (Menaquinone-7) Supplementation on the Vascular Stiffness in Subjects With Poor Vitamin K-status||Maastricht University Medical Center|No|Not yet recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404519||24254|
NCT02508168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322MET-1003|Phase 1 Bioavailability Study of SYR-322MET|An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects||Takeda|No|Not yet recruiting|April 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508168||16295|
NCT02508181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2015/14|Comparison of Intra Ocular Pressure After Insertion of the I-gel and LMA Supreme in Pediatric Patients|Intra Ocular Pressure After I-gel and Supreme Insertion||Kocaeli University|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|2 Years|7 Years|No|||March 2016|March 2, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508181||16294|
NCT02503696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05|Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)|Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)||Exact Sciences Corporation|No|Active, not recruiting|September 2014|February 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Provide anonymous, clinically characterized specimens for bio-repository for future      colorectal cancer-related test development.|Both|18 Years|84 Years|No|Non-Probability Sample|Patients are at risk of developing colorectal cancer at the time of their colonoscopy and        the colonoscopy resulted in normal findings.|October 2015|October 29, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503696||16639|
NCT02393729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 155 02|Functional MRI Study in Children With a Developmental Coordination Disorder (DCD) and/or Developmental Dyslexia (DD)|Functional MRI Study of the Involvement of Cortico-cerebellar and Cortico-striatal Networks in Children With a Developmental Coordination Disorder (DCD) and/or Developmental Dyslexia (DD)|FMRI-DCD-DD|University Hospital, Toulouse|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|65|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393729||25082|
NCT02398162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO1402|Scrub Typhus Pediatric Immunology Study|The Natural Immune Response In Pediatric Scrub Typhus In Chiangrai|STP|University of Oxford||Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|170|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Male and female patients ≤ 18 years of age with acute scrub typhus (n=60).        Controls: people exposed to scrub typhus (approx. 40 children and 40 adults from        Chiangrai, total n=80) preferably age-matched, healthy and non-febrile, and healthy adult        scrub typhus-naïve controls from Bangkok (n=30), total n=170.|October 2015|October 5, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02398162||24741|
NCT02403882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AuburnU|Behavioral Economic Interventions at Food Pantries|An Analysis of Behavioral Economic Interventions at Client-Choice Food Pantries||Auburn University|No|Enrolling by invitation|October 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|443|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 29, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02403882||24303|
NCT02403895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2274C00001|AZD2014 and Weekly Paclitaxel in Squamous NSCLC|A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy||AstraZeneca|No|Active, not recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|130 Years|No|||March 2016|March 4, 2016|March 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403895||24302|
NCT02403908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRZZ-2014 Project Number:2505|Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH|Catheter Denervation of Pulmonary Arteries in The Treatment of Idiopathic (PAH) & Secondary Pulmonary Hypertension (PH)|CADOPA|Clinical Hospital Centre Zagreb|Yes|Recruiting|February 2015|January 2019|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2015|March 25, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02403908||24301|
NCT02402855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARDOU PREPS 2014|NAITRE (PreNAtal Care in deprIvaTed enviRonnEment)|Impact of Conditional Financial Support on Pregnancy Outcomes in Pregnant Women With Low Incomes: Pragmatic Randomized Cluster Trial, With Parallel Arms||Centre Hospitalier Universitaire Dijon||Not yet recruiting||||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|4000|||Female|18 Years|N/A||||March 2015|April 2, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02402855||24382|
NCT02403375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD002177|Insight Kids Study: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes|Insight Kids Study: Reaching HbA1c Targets in Children and Adolescents With Type 1 Diabetes: A Randomized, Controlled Trial Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections||Hoffmann-La Roche||Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|98|||Both|2 Years|17 Years||||February 2015|March 1, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403375||24342|
NCT02497534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500369|Biomarkers in Friedreich's Ataxia|Biomarkers in Freidreich's Ataxia||University of Florida|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|8 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Friedreich's ataxia OR healthy control subjects.|October 2015|October 8, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497534||17113|
NCT02497547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYPEP201|An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy|A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled, Multiple-Dose Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy||PeP-Tonic Medical AB|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|227|||Female|40 Years|65 Years|No|||October 2015|October 20, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497547||17112|
NCT02406391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-40|Adherence to Preventive Care for Cervical Cancer|Adherence to Screening and Follow-up Diagnostic and Treatment Services for Cervical Cancer Prevention|Adh-NYC-EP|Brookdale University Hospital Medical Center||Not yet recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|||Female|21 Years|N/A|No|Non-Probability Sample|Eligible patients who present to the gynecology clinic for a Pap smear exam or a        colposcopy exam following an abnormal Pap smear.|April 2015|April 9, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02406391||24112|
NCT02400112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-111|Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures|Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures||University of Tennessee|No|Enrolling by invitation|March 2015|December 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|March 23, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400112||24591|
NCT02495376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00093614|Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology|REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology|REDEFINEAYAO|Northwestern University|No|Recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|39 Years|No|||June 2015|July 9, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02495376||17278|
NCT02501993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-PRO-002|Nasopharyngeal Carcinoma Screening in Zhongshan City|Serology Screening Test for the Detection of Nasopharyngeal Carcinoma in Zhongshan City||Zhongshan People's Hospital, Guangdong, China|No|Recruiting|March 2012|December 2022|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25000|Samples With DNA|Serum and tissue samples|Both|30 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Zhongshan City|July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501993||16770|
NCT02502006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820715|Variability in Response to Non-steroidal Anti-inflammatory Drugs|A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs||University of Pennsylvania|No|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|288|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02502006||16769|
NCT02405897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810|A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis|A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis||Postgraduate Institute of Medical Education and Research|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|12 Years|90 Years|No|||October 2015|October 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405897||24148|
NCT02398292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10376|A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis|Meals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis|M3|Oregon Health and Science University|Yes|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398292||24731|
NCT02398305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2011-233|Shortening Compression Time After Radial Access for Cardiac Catheterisation|Shortening Compression Time of the Access Site After Cardiac Catheterisation Through the Radial Artery||University Medical Center Groningen|No|Completed|October 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|173|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02398305||24730|
NCT02424695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-IIT-0031|Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome|Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System||Cleveland Sleep Research Center|No|Not yet recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424695||22705|
NCT02413489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106660|An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma|An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma||Janssen Research & Development, LLC|No|Recruiting|September 2015|September 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413489||23566|
NCT02395094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00342|Study to Examine the Effects of Child Life Interventions on Children's Anxiety Levels at Induction of Anesthesia|Study to Examine the Effects of Child Life Interventions on Children's Anxiety Levels at Induction of Anesthesia|ChildLife|University of British Columbia|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|3 Years|10 Years|No|||November 2015|November 30, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395094||24977|
NCT02409719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR14-005|Home Rehabilitation in Patients After Primary Total Knee Arthroplasty|Home Rehabilitation in Patients After Primary Total Knee Arthroplasty||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|July 2014|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||April 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02409719||23856|
NCT02393976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cirugía2|IMMUNONUTRITION IN FAST-TRACK SURGERY|NUTRITIONAL EFFECTS AND INFLUENCE IN THE MORBIDITY AND MORTALITY OF DIET IMMUNOMODULATORY IN FAST-TRACK SURGERY||Hospital General Universitario Elche|Yes|Completed|January 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02393976||25063|
NCT02417337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Khartoum|Efficacy of Different Drugs to Control Post Root Canal Treatment Pain|Efficacy of Pain Control Following Root Canal Treatment Using Paracetamol Alone and in Combination With Three Different Non-Steroidal Anti-Inflammatory Analgesics||University of Khartoum|No|Completed|August 2012|January 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|170|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417337||23270|
NCT02421497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410M54981|MRI Technical Development and Applications in Kidney Disease|||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|April 2015|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|180|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study populations vary across specific aims: normal healthy or control volunteers for        Specific Aim 1, CKD patients and renal transplant recipients for Specific Aim 2.|July 2015|July 23, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421497||22951|
NCT02409095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penta-01/12|Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants|A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study Comparing Safety And Immunogenicity Of DTP-HB-Hib Vaccination by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Healthy Infants In India||Serum Institute of India Limited|No|Terminated|January 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|211|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||November 2015|November 10, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02409095||23904|
NCT02409108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G130154|Perfusion-Induced Hyperthermia in Lung Cancer|An Early Feasibility Study Of Perfusion-Induced Hyperthermia For Metastatic Non-Small Cell Lung Carcinoma||University of Kentucky|Yes|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409108||23903|
NCT02409121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00100126|A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers|A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers||University of Michigan Cancer Center|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|10 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409121||23902|
NCT02410187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-1503-001-002|SBRT for Extra-cranial Oligorecurrent Tumor|Stereotactic Body Radiotherapy for Extra-cranial Oligorecurrent Tumor: Randomized Phase II Clinical Trial||Korea Cancer Center Hospital|No|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02410187||23820|
NCT02425774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56328|Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway|Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway: A Potential New Therapeutical Intervention for Postoperative Ileus||Katholieke Universiteit Leuven|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02425774||22622|
NCT02413723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00674-43|McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope for Orotracheal Intubation in Critical Care Unit|McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope for Orotracheal Intubation in Critical Care Unit|MACMAN|Centre Hospitalier Departemental Vendee|No|Recruiting|May 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|370|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02413723||23548|
NCT02414022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC2E|Economic Analysis of Alliance A041202 CLL Study|A Prospective Economic Analysis NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)||Canadian Cancer Trials Group|Yes|Recruiting|April 2015|December 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|65 Years|N/A|No|Non-Probability Sample|Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)|December 2015|March 22, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414022||23525|
NCT02395614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140231|Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation|Incidence of Surgical Site Infection After Irrigation of Surgical Pocket With 0.05% Chlorhexidine Compared to Triple Antibiotic Solution in Post-mastectomy Breast Reconstruction||Vanderbilt University|No|Not yet recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|81 Years|No|||February 2015|March 20, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395614||24937|
NCT02400190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.111|The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)|The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)||University of Michigan Cancer Center|Yes|Recruiting|March 2015|March 2026|Anticipated|March 2026|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|50 Years|69 Years|No|||December 2015|December 15, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400190||24585|
NCT02395718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELDER|Acute Medical Admissions of ELDERly Patients (ELDER)|Acute Medical Admission of ELDERly Patients (≥75yrs) to Either Fast Track or Traditional Inward Hospitalisation. A Randomised Controlled Trial|ELDER|Holbaek Sygehus|Yes|Recruiting|January 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|430|||Both|75 Years|N/A|No|||February 2016|February 23, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02395718||24929|
NCT02417584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPBP-01|Efficacy of PAP Therapy on Blood Pressure|The Role of Compliance With Positive Airway Pressure Use on Blood Pressure in Patients With Obstructive Sleep Apnea||University of Crete|No|Completed|June 2009|May 2014|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1168|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02417584||23251|
NCT02417597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HE-006|A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)|Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years||Xiamen Innovax Biotech Co., Ltd|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 11, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02417597||23250|
NCT02415504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-45|Comprehensive Care Transition: A Trial of an Enhanced Care Transition Process in Dementia|Comprehensive Care Transition: A Randomized Control Trial of an Enhanced Care Transition Process in Dementia||Baycrest|No|Enrolling by invitation|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|55 Years|N/A|No|||February 2016|February 19, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02415504||23411|
NCT02407327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2010-2303193|Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling|Trattamento Personalizzato Del Tumore NSCLC Avanzato: Potenziali Applicazioni Della Caratterizzazione Fenotipica e Molecolare Delle Cellule Tumorali Circolanti (CTC)|2012/52|Istituto Oncologico Veneto IRCCS|Yes|Recruiting|December 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Whole blood.|Both|18 Years|80 Years|No|Probability Sample|Primary care clinic|February 2016|February 24, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407327||24040|
NCT02416336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLN-USA-1|Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes|||Oncovision Inc||Recruiting|May 2015|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||October 2015|October 6, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416336||23347|
NCT02416570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14102|Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?|Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?||University of Nottingham|No|Terminated|April 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 6, 2015||No|At 6 months 1 participant recruited. Study deemed not feasible and discontinued.|No||https://clinicaltrials.gov/show/NCT02416570||23329|
NCT02415257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-FT-02|Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function|Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function||Lund University|No|Recruiting|April 2015|December 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415257||23430|
NCT02395029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMD-MSC-PD-01|Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD|Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease|PMD-MSC-PD-01|Z Urology|Yes|Completed|August 2013|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||March 2015|March 16, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02395029||24982|
NCT02395042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201025-001|A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions|||Allergan|No|Recruiting|April 2015|June 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|76|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395042||24981|
NCT02506725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OswaldoCruz|Quarenta Semanas: Innovative Intervention in Prenatal Care for Reduction of Prematurity|Quarenta Semanas: Innovative Intervention in Prenatal Care for Reduction of Prematurity|quarenta|Oswaldo Cruz Foundation|Yes|Recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Female|18 Years|45 Years|No|||December 2015|December 2, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506725||16406|
NCT02509533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008042|Comparison of the Use of VAC System in Transplants of Leg Ulcers Versus Usual Dressing Method|Comparison of the Use of VAC (Vacuum Assisted Closure) System in Transplants of Leg Ulcers Versus Usual Dressing Method. A Monocentric, Prospective, Randomized, Parallel Groups Study||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|September 2010|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 21, 2015||No|difficulties to recruit patients.|No||https://clinicaltrials.gov/show/NCT02509533||16191|
NCT02509377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24890|Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0|Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0|MOMSto40BMI|St. Louis University|No|Recruiting|July 2015|||July 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|50 Years|No|||February 2016|February 5, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509377||16203|
NCT02409238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-LM 3|Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study|Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial|IRMCI|SingHealth Polyclinics|No|Recruiting|April 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|55 Years|N/A|No|||May 2015|May 5, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02409238||23893|
NCT02409251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR-103-ANA|Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints|Requesting Behaviour of Rheumatologists Regarding Antinuclear Antibodies (ANA) in Patients With Rheumatologic Complaints||Sint Maartenskliniek|No|Completed|February 2012|July 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|29|||Both|N/A|N/A|No|||March 2015|March 31, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02409251||23892|
NCT02404246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH073605-01|Pilot Trial of Peer Support for Bipolar Disorder|Pilot Trial of Peer Support for Bipolar Disorder||Group Health Cooperative|No|Completed|December 2005|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|December 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02404246||24275|
NCT02503254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2R-REXC-06-EU|Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.|A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) Compared to Continuing to Use Conventional Cigarettes During 5 Days in Confinement.||Philip Morris Products S.A.|No|Active, not recruiting|July 2015|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503254||16673|
NCT02401165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01416-37|Quantification of GADD34 Expression in RA|Quantification of GADD34 Expression in Rheumatoid Arthritis|GADD34-RA|University Hospital, Grenoble|No|Completed|March 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401165||24510|
NCT02401438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m2494|Accuracy of 5D LB Ultrasound in Predicting Birth Weight of Preterm Fetuses : A Pilot Study|||Ain Shams University||Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women between 28 and 34 weeks scheduled for termination of pregnancy due to        medical or obstetric cause|January 2016|January 13, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02401438||24489|
NCT02399670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMD_III|The Influence of Global Femoral-offset Changes After Total Hip Arthroplasty|The Influence of Global Femoral-offset Changes After Total Hip Arthroplasty on Function, Quality of Life and Abductor Muscle Strength: a Prospective Cohort Study||Sundsvall Hospital|No|Completed|September 2010|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|222|||Both|N/A|N/A|No|Non-Probability Sample|All patients with unilateral primary osteoarthritis (OA) treated with total hip        arthroplasty were considered for inclusion operated between September 2010 and December        2013. Patients with secondary OA, previous spinal, pelvic, or lower limb injuries or        fractures were excluded.|October 2015|October 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399670||24625|
NCT02399683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trichuris trichiura|Immune Modulation From Trichuris Trichiura|Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual||University of Aarhus|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1|Samples With DNA|Blood cell and intestinal biopsies|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|A single healthy volunteer|March 2015|March 25, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02399683||24624|
NCT02404415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110881|The Vanderbilt Atrial Fibrillation Ablation Registry|The Vanderbilt Atrial Fibrillation Ablation Registry|VAFAR|Vanderbilt University|Yes|Recruiting|October 2011|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Adults scheduled to undergo an atrial fibrillation ablation|March 2015|March 25, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02404415|10 Years|24262|
NCT02498522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin in pregnancy|Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome|Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome|MIP|Ain Shams University|No|Completed|August 2015|March 2016|Actual|February 2016|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|166|||Female|25 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498522||17037|
NCT02498782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-CH-FEXI-001|Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease|Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease.||Drugs for Neglected Diseases|Yes|Recruiting|July 2014|February 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|140|||Both|18 Years|50 Years|No|||July 2015|July 14, 2015|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02498782||17017|
NCT02509988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13597|Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health|Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health "(NiPPeR)"|NiPPeR|University of Southampton|Yes|Recruiting|July 2015|February 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|1800|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02509988||16156|
NCT02510001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO-049|MErCuRIC1: MEK and MET Inhibition in Colorectal Cancer|A Phase 1 Study of MEK 1/2 Inhibitor PD-0325901 With cMET Inhibitor PF-03241066 in RASMT and RASWT (With Aberrant c-MET) Colorectal Cancer Patients|MErCuRIC1|University of Oxford|Yes|Recruiting|November 2014|July 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|48|||Both|16 Years|N/A|No|||October 2015|October 1, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02510001||16155|
NCT02510040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS1|A Prospective Observational Study of Adult Strabismus|A Prospective Observational Study of Adult Strabismus|SAS1|Jaeb Center for Health Research|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|650|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|February 2016|February 22, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510040||16152|
NCT02409316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821717|[18F]FES PET/CT in Endocrine Refractory Breast Cancer|[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer||University of Pennsylvania|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Female|18 Years|N/A|No|||October 2015|October 18, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409316||23887|
NCT02395848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI.FIDAXOMICIN.1|Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection|Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile Infection||McMaster University|Yes|Recruiting|July 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02395848||24919|
NCT02503644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVA_01_337_HSSC_15_001|Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis|A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis|FASST|Inventiva Pharma|No|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02503644||16643|
NCT02503657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-001-IPF-201|Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||MediciNova|No|Not yet recruiting|December 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|21 Years|80 Years|No|||July 2015|July 17, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503657||16642|
NCT02497586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15ON255|Feasibility of Magnetic Resonance Spectroscopy in Lung Cancer|Feasibility of Magnetic Resonance Spectroscopy in Lung Cancer|MRS|NHS Greater Glasgow and Clyde|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02497586||17109|
NCT02406001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIG08-002|Reconstruction of Peri-implant Osseous Defects: A Randomized Trial|Reconstructive Surgical Treatment of Peri-implant Intra-osseous Defects - A MULTICENTER RANDOMIZED PROSPECTIVE CLINICAL STUDY||Tigran Technologies AB|Yes|Completed|June 2010|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406001||24140|
NCT02394093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17494|To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.|An Open Label Crossover Pharmacokinetic Trial of Aspirin Dry Powder Versus Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adult Subjects|Icicle|Bayer|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|March 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02394093||25054|
NCT02396355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-PCACC1|Accuracy Evaluation of the BD FACS Presto System|Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay||Becton, Dickinson and Company|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|583|||Both|N/A|N/A|No|||July 2015|July 14, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396355||24880|
NCT02396368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1513|A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer|A Phase I/Ib Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer|Radium-223|Sidney Kimmel Comprehensive Cancer Center|Yes|Withdrawn|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||November 2015|November 17, 2015|February 25, 2015|Yes|Yes|Phase III study results for the drug Tesquinimod were not promising so it was a drug    development decision to stop using the drug|No||https://clinicaltrials.gov/show/NCT02396368||24879|
NCT02505997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-3341-118|Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects|A Phase I Study to Evaluate the Effect of Repeated Oral Doses of Delafloxacin on the Pharmacokinetics of a Single Oral Dose of Midazolam in Healthy Subjects||Melinta Therapeutics, Inc.|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|July 21, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505997||16462|
NCT02506010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0499|Accuracy Validation of a Pulse Oximetry Monitor|SpO2 Accuracy Validation of a USB Pulse Oximetry Monitor Interface Cable Via Reference Co-Oximetry||Medtronic - MITG|No|Not yet recruiting|November 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be ten to fifteen male and female subjects of any race, ranging        in pigmentation from light to dark to meet the study design requirements|February 2016|February 25, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506010||16461|
NCT02509598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV3-18|A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping|A Prospective, Open-Label, Multicenter Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping||Navidea Biopharmaceuticals|Yes|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|32|||Both|N/A|17 Years|No|||March 2016|March 8, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509598||16186|
NCT02405793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL2-14-05|Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain|A Phase 2b, Multicenter, Randomized, Single Blind, Fixed Dose, Parallel Group Study to Evaluate the Efficacy and Safety of Meloxicam SoluMatrix® [Test] Capsules and Meloxicam Tablets in Patients With Pain Due to Osteoarthritis of the Knee or Hip||Iroko Pharmaceuticals, LLC|No|Withdrawn|May 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|40 Years|N/A|No|||July 2015|July 8, 2015|March 27, 2015|Yes|Yes|Internal business decision not to move forward with study|No||https://clinicaltrials.gov/show/NCT02405793||24156|
NCT02406066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERL-001|Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)|Phase 1 Combined Single and Multiple Rising Dose Study of the Safety and Pharmacokinetics of Metyrapone/Oxazepam Combination (EMB-001)||Embera NeuroTherapeutics, Inc.|No|Active, not recruiting|March 2015|February 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|April 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02406066||24135|
NCT02408770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHSM0315|Breast Cancer - Anti-Progestin Prevention Study 1|A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk|BC-APPS1|University Hospital of South Manchester NHS Foundation Trust|No|Not yet recruiting|September 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408770||23929|
NCT02506244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 3.5|mHealth Screening to Prevent Strokes|mHealth Screening to Prevent Strokes (mSToPS)|mSToPS|Scripps Translational Science Institute|Yes|Enrolling by invitation|November 2015|September 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|55 Years|N/A|No|||November 2015|November 30, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02506244||16443|
NCT02509624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-223-1018|Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function|A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function||Gilead Sciences|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509624||16184|
NCT02405858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106841|A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy|A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy||Janssen Pharmaceutical K.K.|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Male|20 Years|N/A|No|||March 2016|March 15, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405858||24151|
NCT02405871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-APAE2015001Reg|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||March 27, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405871||24150|
NCT02405923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRITO-14|Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy|Clinical Trial Evaluating the Effects on Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula Compared to a Cow's Milk Extensively Hydrolysed Protein Formula in Infants With Cow's Milk Protein Allergy|GRITO-14|Laboratorios Ordesa|Yes|Recruiting|November 2014|November 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|10 Months|No|||January 2016|January 8, 2016|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02405923||24146|
NCT02406326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO1TR/MLS/100209|An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial|A Prospective Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial|MeriT-II|Meril Life Sciences Pvt. Ltd.|No|Active, not recruiting|January 2009|December 2017|Anticipated|December 2012|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of 250 patients with an obstructive coronary artery        disease with few exclusion criteria.|March 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406326|12 Months|24116|
NCT02406339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1143|Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's|Analysis of the Effectiveness of Neuromuscular Electrical Stimulation Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's Basketball of High Performance. Blind Randomized Clinical Trial||University of Sao Paulo|No|Recruiting|July 2014|February 2018|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Male|16 Years|36 Years|Accepts Healthy Volunteers|||March 2015|March 29, 2015|March 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02406339||24115|
NCT02506673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-394|Audiovisual Aid Pilot Study|The Effect of Audiovisual Aids on Perioperative Stress Response, Pain and Overall Experience - a Randomized Controlled Pilot Study||Hospital for Special Surgery, New York|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02506673||16410|
NCT02508584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001027|Personalized Immunotherapeutics for Antibiotic-resistant Infection|||Brigham and Women's Hospital|No|Enrolling by invitation|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|N/A|No|||July 2015|July 24, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508584||16264|
NCT02395289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075221|Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)|The Efficacy of Cognitive-Based Compassion Training for Enhancing Immune Restoration and Psychological Adaptation in Individuals Living With HIV Disease||Emory University|No|Recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395289||24962|
NCT02508077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15117|FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer|A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non-anti-EGFR Containing Regimen||City of Hope Medical Center|Yes|Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508077||16302|
NCT02509442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9530|Measure of the Potential Evoked by Electric Stimulation|Pilot Study: Measure of the Potential Evoked With Electroencephalography and Electrocorticography by Electric Stimulation of the Brain During the Neurosurgery Awakened of the Infiltrative Glioma of Low Grade (OMS Type II)|PE&CE|University Hospital, Montpellier|No|Not yet recruiting|July 2015|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|30 Years|50 Years|No|||July 2015|July 23, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509442||16198|
NCT02406703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLV07|The Impact of Chloroprocaine 3% for Ambulatory Foot Surgery on Perioperative Process Costs|||Ospedale Regionale Bellinzona e Valli|No|Completed|January 2014|||October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|ASA I-III scheduled for elective, unilateral, ambulant minor foot surgery (percutaneous        hallux valgus correction, osteotomies, tenotomies, mallet and hammer toes correction,        screws and/or plaques removal)|March 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406703||24088|
NCT02407808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015211|Cannabinoids, Learning, and Memory|Cannabinoids, Learning, and Memory|THC-Memory|Yale University|No|Recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407808||24003|
NCT02406625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBT001|Dialectical Behavioral Therapy in Adolescents With Suicidal Behaviors|Clinical and Neural Changes Associated With Dialectical Behavioral Therapy in Adolescents With Suicidal Behaviors|DBT|Fundacion Clinic per a la Recerca Biomédica||Recruiting|November 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02406625||24094|
NCT02406638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE12805313800005505|Pelvic Floor 3D USG Three Years After Mid-urethral Slings ( TVT-R, TVT-O, TVT-S)|Pelvic Floor 3D Ultrasound of Women Who Underwent TVT-R, TVT-O, TVT-S Surgery at Three Years Follow-up||Federal University of São Paulo|No|Completed|April 2013|March 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|158|||Female|18 Years|90 Years|No|Probability Sample|Women who underwent stress urinary incontinence surgery with synthetic midurethral sling,        by different approaches ( TVT, TVT-O and TVT-Secur) in a period of 2 to 4 years before        clinical and 3D USG evaluation|March 2015|April 1, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406638||24093|
NCT02495636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015233|Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer|Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer||Yale University|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495636||17258|
NCT02501369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15059|Investigating the Use of a Positive Parenting Programme to Improve Treatment Adherence in Cystic Fibrosis|A Case Series Examining the Impact of a Positive Parenting Program (Self Directed Teen Triple P) on Treatment Adherence in Families With an Adolescent With Cystic Fibrosis||University of Manchester|No|Not yet recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02501369||16818|
NCT02402478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1621|Clinical Cohorts in Coronary Disease Collaboration|Clinical Cohorts in Coronary Disease Collaboration|4C|University College, London|Yes|Completed|July 2009|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3345|Samples With DNA|DNA, plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing investigation for new-onset, non-acute chest pain at four        UK NHS hospitals.|March 2015|March 24, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02402478||24409|
NCT02410551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0786|Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)|Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN)||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2015|||July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410551||23792|
NCT02495909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCZ/A/1964|Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment|Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment||University of Edinburgh|No|Not yet recruiting|March 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Zimbabwean pre-school children male and female|July 2015|July 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02495909||17237|
NCT02501798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU-2012-000492-17|The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD|The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD: A Randomised Placebo Controlled Trial||VU University of Amsterdam|No|Active, not recruiting|January 2013|December 2015|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|61|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|April 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02501798||16785|
NCT02398175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008|Thoracic Injuries in Pediatric Polytraumatized Patients: Epidemiology, Treatment and Outcome|||Medical University of Vienna||Completed|January 2008|||January 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|71|||Both|N/A|18 Years|No|Non-Probability Sample|All pediatric (age < 18 years) polytrauma patients with associated thoracic injuries,        admitted to this Level I Trauma center, between January 1992 and December 2008|March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02398175||24740|
NCT02410694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_MM-1|Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Not yet recruiting|April 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02410694||23781|
NCT02494882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-272|Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older|Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|N/A|No|||February 2016|February 11, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494882||17316|
NCT02495155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00095498|Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer|Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer|PROSPECT|University of Michigan|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|45|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495155||17295|
NCT02503904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAD4SSI|Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection|Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection: A Multicenter Open Label Randomized Clinical Trial||Klein, Jeffrey A., M.D.|Yes|Not yet recruiting|October 2015|December 2019|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|December 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503904||16623|
NCT02397408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145511|11C- and 18F-Choline PET/MR Imaging for Prostate Cancer|Phase 2 Study of 11C- and 18F-Choline PET/MR Imaging in Patients With Unfavorable Intermediate to High-Risk Prostate Cancer||University of California, San Francisco|Yes|Recruiting|April 2015|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397408||24799|
NCT02404025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201793|Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects|A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy||Novartis|No|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404025||24292|
NCT02404038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol A: UChoose|A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods|An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options in Healthy HIV-Uninfected Female Adolescents, 16-17 Years of Age, as Proxy for HIV Prevention Methods|UChoose|Desmond Tutu HIV Centre|No|Recruiting|July 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|150|||Female|16 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404038||24291|
NCT02499510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not_applicable|First-in-man Study of Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent|First-in-man Study to Assess Efficacy and Safety of a Novel Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent||Chinese University of Hong Kong|No|Recruiting|October 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02499510||16961|
NCT02498314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/00061|Clinical Effects of Translatoric Grades of Movement in Hip Osteoarthritis Patients|Clinical Effects of Translatoric Grades of Movement in Hip Osteoarthritis Patients||Universidad de Zaragoza||Recruiting|April 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||July 2015|July 20, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02498314||17053|
NCT02504164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0310|Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection|||Yonsei University|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|72|||Both|19 Years|N/A|No|||March 2016|March 3, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02504164||16603|
NCT02394938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 14123|Effects of Recorded Music in Heart Failure Patients|A Randomized Controlled Trial of Listen Recorded Music for Hearth Failure Patients|EMSC|Azienda Usl di Bologna|No|Enrolling by invitation|May 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|80 Years|No|||March 2015|March 17, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02394938||24989|
NCT02402309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-003|A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)|Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)||Aldeyra Therapeutics, Inc.|No|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|6 Years|N/A|No|||January 2016|January 5, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402309||24422|
NCT02413502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-046|Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US|Collection and Storage of Biological Samples Obtained by Leukapheresis for the Future Study of Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US (A-046)||Aeras|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02413502||23565|
NCT02399722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WICVAC 1.0|Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone|Prospective Randomized Trial Comparing the Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone: The WICVAC Study||Wilhelminenspital Vienna|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399722||24621|
NCT02398396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2014/12|Investigating Meningococcal Vaccines in Adults|Investigating Meningococcal Vaccines in Adults - An Exploratory, Open-label, Immunogenicity Study of a Licensed Meningococcal Capsular Group B Vaccine (4CMenB, Bexsero®) in Adults||University of Oxford|No|Active, not recruiting|April 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398396||24723|
NCT02398409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 12-415|Informal Caregivers ANSWERS|Telephone Assessment and Skill-Building Intervention for Informal Caregivers||VA Office of Research and Development|Yes|Recruiting|November 2014|March 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|330|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02398409||24722|
NCT02420522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:134|Magnetic Brain Stimulation in the Treatment of Mild Cognitive Impairment|The Use of Repetitive Transcranial Magnetic Stimulation in the Treatment of Mild Cognitive Impairment Due to Brain Injury||University of Manitoba|No|Enrolling by invitation|September 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420522||23026|
NCT02424851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-MMY2070|Optimising Renal Outcome in Myeloma Renal Failure|A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min|OPTIMAL|Oxford University Hospitals NHS Trust|Yes|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424851||22693|
NCT02407665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11552|Tai Chi Intervention and Brain Imaging Study Among Fibromyalgia Patients and Healthy Controls|A Pilot fMRI Study of Fibromyalgia: Tai Chi Intervention|fMRI/FMEX|Tufts Medical Center|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02407665||24014|
NCT02407678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGEN2015|REP1 Gene Replacement Therapy|An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|REGENERATE|University of Oxford|Yes|Not yet recruiting|September 2015|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|90 Years|No|||March 2015|March 30, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02407678||24013|
NCT02395419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-TAT-2015-F1|A Comparison of Tracheal Intubation Using the Totaltrack vs the Airtraq Laryngoscope in Routine Airway Management|||Complexo Hospitalario Universitario de A Coruña||Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|100 Years|No|||November 2015|November 30, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395419||24952|
NCT02413736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSGXXII|Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST|Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study||Helsinki University Central Hospital|No|Recruiting|May 2015|May 2028|Anticipated|May 2028|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|100 Years|No|||March 2016|March 4, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413736||23547|
NCT02417662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0594|Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer|Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase III Trial|SARON|University College, London|Yes|Not yet recruiting|March 2016|||March 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|N/A|N/A|No|||March 2016|March 10, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02417662||23245|
NCT02409147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138-15-FB|Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center|Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center||University of Nebraska|Yes|Not yet recruiting|January 2016|||September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409147||23900|
NCT02416102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140722|Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis|Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis||University of Miami|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|January 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02416102||23365|
NCT02421237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH094310-02|Trial of Treatment for Internalized Stigma in Schizophrenia|Randomized Controlled Trial of Treatment for Internalized Stigma in Schizophrenia||John Jay College of Criminal Justice, City University of New York|Yes|Recruiting|March 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|21 Years|65 Years|No|||February 2016|February 22, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421237||22971|
NCT02421250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0167|Noninvasive Hemoglobin Monitor in the ER|Comparison of Accuracy and Clinical Outcomes of a Continuous Noninvasive Hemoglobin Monitor in the Emergency Room Setting|SpHb|University of Chicago|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421250||22970|
NCT02418754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2176-3-AMD-1417|Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)|A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration|CAPELLA|Regeneron Pharmaceuticals|No|Recruiting|April 2015|April 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|50 Years|N/A|No|||February 2016|February 26, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418754||23161|
NCT02418767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-007|Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers|A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers||Opko Biologics|No|Completed|January 2015|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|October 28, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418767||23160|
NCT02408211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00256|Preoperative Antibiotic PNL Study|The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1||University of British Columbia|No|Enrolling by invitation|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|19 Years|N/A|No|||March 2016|March 21, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408211||23972|
NCT02397551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22015|Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day|Supplementing the Luteal Phase With Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase||Cairo University|No|Recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|37 Years|No|||March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397551||24788|
NCT02419911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSA-0001|Comparison FloShield Air System Versus Clearify Visualization System (D-HELP)|Prospective, Randomized Comparison of the Use of FloShield Air System Versus Clearify Visualization System (D-HELP) During Laparoscopic Surgery to Evaluate the Operative Interruption for Lens Cleaning||Minimally Invasive Devices, Inc.|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|62|||Both|18 Years|N/A|No|||May 2015|September 25, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419911||23073|
NCT02419924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009864|Proof of Concept: "Bottom's Up" Seat to Treat Constipation|Proof of Concept: A Commode Assist Device for Excessive Perineal Descent||Mayo Clinic|No|Enrolling by invitation|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02419924||23072|
NCT02419456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-028|Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048|Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|June 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419456||23108|
NCT02399397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROC1314730-0|Influence of Age and Sepsis on Rocuronium Pharmacokinetics|Influence of Sepsis and Age on OATP1A2 Activity Using Rocuronium Pharmacokinetics-pharmacodynamics in Surgical Patients as a Model.|ROCSEPSIS|Universidade Estadual Paulista Júlio de Mesquita Filho|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02399397||24646|
NCT02509546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14269|8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia||City of Hope Medical Center|Yes|Recruiting|September 2015|||September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509546||16190|
NCT02497976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-201|Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis|Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis||ICStudy, LLC|Yes|Recruiting|December 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497976||17079|
NCT02509481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5375011|Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study|Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study|RIMDAMAL|Colorado State University|No|Active, not recruiting|June 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2700|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509481||16195|
NCT02509962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tissue Salt 3|Increased Salt Intake in Healthy Men|Effects of Increased Salt Intake on Metabolic, Cardiovascular and Immunoregulatory Functions in Healthy Men|BSALT|Charite University, Berlin, Germany|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509962||16158|
NCT02396576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH-12-11-4168|Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas|Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas||University of California, Los Angeles|No|Recruiting|March 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|340|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02396576||24863|
NCT02506803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-GEMABR|Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.|Phase I Study of Neoadjuvant Chemotherapy of Gemcitabine Plus Nab-paclitaxel for Patients With Borderline Resectable Pancreatic Cancer.||Wakayama Medical University|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|79 Years|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506803||16400|
NCT02402959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZR81230086|Individualized Treatment With Traditional Chinese Medicine for the Patients With Insomnia Disorder: a Cohort Study|Individualized Treatment With Traditional Chinese Medicine Pattern Differentiation for the Patients With Insomnia Disorder: a Cohort Study||China Academy of Chinese Medical Sciences|No|Recruiting|March 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||10|Anticipated|600|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with the diagnosis of insomnia, who come to the experts' clinic for treatment,        will be invitated and included in his cohort.|March 2015|March 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02402959||24374|
NCT02402972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IICCAC|A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer|A Multi-center Randomized Controlled Trial: Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer||Fudan University||Recruiting|February 2015|February 2022|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|75 Years|No|||January 2015|March 25, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402972||24373|
NCT02405299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNOVillefranche|Assessment of Neurocognitive Rehabilitations of Inhibition of Disorders in ADHD in Children (ERNTITDAH)|Evaluation Des rééducations Neuropsychologiques Des Troubles de l'Inhibition Chez l'Enfant Avec un TDAH|ERNTITDAH|L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône|No|Enrolling by invitation|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|9 Years|13 Years|No|||March 2015|March 31, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02405299||24194|
NCT02405312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630092|Shared Decision Making and Renal Supportive Care|Shared Decision Making and Renal Supportive Care|SDMRSC|Baystate Medical Center|No|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|320|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02405312||24193|
NCT02408497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC DRO 3D-us CS|Use of Non-invasive 3D Ultrasound Clarity System in Prostate IMRT/RapidArc Therapy|Evaluation of the Use of Non-invasive 3D Ultrasound Clarity System in Real-time Tracking of the Target Volume in Prostate IMRT/RapidArc Therapy||National Cancer Centre, Singapore|No|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Male|21 Years|N/A|No|Non-Probability Sample|Prostate cancer patients who are going to receive IMRT/RapidArc therapy at site and are        not participating any other clinical studies.|November 2015|November 8, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408497||23950|
NCT02504138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2013-0454|A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation|||Yonsei University|No|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|136|||Both|20 Years|N/A|No|||March 2016|March 11, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02504138||16605|
NCT02510963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AHCR2014-013|Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy|An Open-label, Randomized, Controlled Clinical Trial to Determine the Optimal Time for Tenofovir of Anti-HBV Treatment During the Pregnancy Among Chronic HBV-infected Pregnant Women With Normal Liver Function||First Affiliated Hospital Xi'an Jiaotong University||Not yet recruiting|July 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Female|20 Years|40 Years|No|||July 2015|July 27, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510963||16081|
NCT02397200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc000214ctil|Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls|Double Blind, Randomized , Placebo Controlled Study to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls||Rabin Medical Center|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Female|10 Years|14 Years|No|||June 2015|November 23, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02397200||24815|
NCT02399956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACOUT|Lactation Outcomes Among Survivors of Pediatric Cancer|Lactation Outcomes Among Survivors of Pediatric Cancer||St. Jude Children's Research Hospital|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|471|||Female|18 Years|N/A|No|Non-Probability Sample|Females who are childhood cancer survivors and have reported at least one live birth after        cancer diagnosis and treatment.|December 2015|December 8, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399956||24603|
NCT02506972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-1404|Effect of Serving Size and Addition of Sugar on the Glycemic Response Elicited by Oatmeal|Effect of Varying Amounts of β-glucan and Sucrose in Oatmeal on Glycemic Response|Panther|Glycemic Index Laboratories, Inc|No|Completed|November 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|38|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506972||16387|
NCT02507037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gum-1|Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy|Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study||Changhai Hospital|Yes|Completed|July 2014|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02507037||16382|
NCT02507050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1060|Ivabradine and Post-revascularisation Microcirculatory Dysfunction|Can Ivabradine Attenuate Post-revascularisation Microcirculatory Dysfunction in Flow Limiting Coronary Artery Disease?|MICRO-PCI|Liverpool Heart and Chest Hospital NHS Foundation Trust|Yes|Withdrawn|March 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 22, 2015||No|Funding not achieved|No||https://clinicaltrials.gov/show/NCT02507050||16381|
NCT02403505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDA208414|Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms|Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.|Drugs-SNPs|Medicine Invention Design, Inc|Yes|Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|22 Years|75 Years|No|||March 2016|March 15, 2016|March 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403505||24332|
NCT02394106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFA1|Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome|Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial||Istituto Giannina Gaslini|Yes|Recruiting|July 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|18 Years|No|||August 2015|August 31, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02394106||25053|
NCT02398513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15823|Regorafenib Phase I Study in Mainland Chinese Patients|Uncontrolled, Open-label, Non-randomized, Phase I Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Regorafenib in Chinese Patients (China Mainland) With Advanced, Refractory Solid Tumors)||Bayer|No|Active, not recruiting|April 2015|October 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398513||24714|
NCT02401243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLARGL07496|Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients|A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients|TITRATION|Sanofi|No|Active, not recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02401243||24504|
NCT02509611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506M74261|Effects of Yoga on Parkinson's Disease|Effects of Yoga on Redox Status, Motor Function and Psychosocial Well-being in Individuals With Parkinson's Disease|HYPD|University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|August 2015|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|45 Years|75 Years|No|||July 2015|July 27, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02509611||16185|
NCT02395432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-TT-2015-D1|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Difficult Airway|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Difficult Airway: a Randomised, Controlled Clinical Trial||Complexo Hospitalario Universitario de A Coruña|No|Recruiting|September 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|100 Years|No|||September 2015|November 5, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02395432||24951|
NCT02394366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01202015|Topical Salve for Skin Oxygenation and Blood Flow|Effects of Topical Herbal Salve on Cutaneous Oxygenation and Peripheral Blood Flow|OHS|National College of Natural Medicine|No|Not yet recruiting|March 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|16|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02394366||25033|
NCT02396641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060650|PCRC Best Supportive Care (PCRC BSC)|Implementation of Consensus-based Standards for Best Supportive Care in a Clinical Trial: a Pilot Study|PCRC BSC|Duke University|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|N/A|N/A|No|||December 2015|December 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396641||24858|
NCT02396654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m2492|5D LB Ultrasound in Determination of Fetal Weight in Normal Pregnancy : A Pilot Study|Accuracy of Five Dimensional Ultrasound Long Bones Fetal Biometry (5DUS LB ) for Prediction of Fetal Weight Compared to Two Dimensional Ultrasound: a Pilot Study||Ain Shams University||Completed|March 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Normal pregnant women|January 2016|January 13, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396654||24857|
NCT02509637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP 2015-3|Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients|Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients||University of Sao Paulo|Yes|Recruiting|June 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|28|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02509637||16183|
NCT02395731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90060237|Comprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in Maryland|Comprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in Maryland||Johns Hopkins University|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|600|||Both|N/A|N/A|No|||March 2016|March 16, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395731||24928|
NCT02394990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14NU421|Violence Brief Intervention Pilot v1.1|A Randomised Controlled Trial to Evaluate a Violence Brief Intervention (VBI) for Adult Male Patients With Facial Injuries Sustained as a Result of Interpersonal Violence||NHS Greater Glasgow and Clyde|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Male|16 Years|28 Years|No|||March 2015|March 30, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394990||24985|
NCT02395003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015459|Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents|Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents||Yale University|No|Not yet recruiting|May 2015|||May 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|104|Samples Without DNA|Basal plasma samples for measurements of glucose and glycerol enrichment, and glucose,      insulin FFAs, leptin, C-peptide, glucagon, adiponectin, cortisol, growth hormone,      catecholamines and amino acids, will be collected.|Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese adolescents|March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395003|12 Weeks|24984|
NCT02498223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2156-OF-CTIL|Adjusting the Load Carried by the Soldier According to Body Composition Measurements and Aerobic Capacity|Adjusting the Load Carried by the Soldier According to Body Composition Measurements and Aerobic Capacity|LCI|Sheba Medical Center|No|Not yet recruiting|September 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02498223||17060|
NCT02496208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02379|Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors|A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors||National Cancer Institute (NCI)|No|Recruiting|July 2015|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02496208||17214|
NCT02496221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201834|A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects|A Randomized, Double-blind, Single-dose, Placebo Controlled, 2-way Cross-over Study Evaluating Effect of Albiglutide on Cholecystokinin-induced Gallbladder Emptying in Fasting Healthy Subjects||GlaxoSmithKline|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496221||17213|
NCT02397161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17120515|Mental Attention-neuromuscular Training for Children With Developmental Coordination Disorder|Improving Mental Attention, Timing of Muscle Activation and Reactive Balance Control in Children With Developmental Coordination Disorder: A Randomized Controlled Trial||The University of Hong Kong|Yes|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|172|||Both|6 Years|9 Years|No|||December 2015|December 13, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02397161||24818|
NCT02397174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEMED1|Mediterranean Diet Versus Hypocaloric Diet in PCOS|Mediterranean Diet Versus Hypocaloric Diet: What is the Best Choice for the Treatment of Polycystic Ovary Syndrome (PCOS)?||Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona|No|Recruiting|June 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02397174||24817|
NCT02399657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXTINCT|Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema|A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema||Inje University|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|20 Years|80 Years|No|||April 2015|April 2, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02399657||24626|
NCT02399917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0862|An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia|An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia||M.D. Anderson Cancer Center|Yes|Recruiting|April 2015|||April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399917||24606|
NCT02495389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU207102|Mirabegron and Urinary Urgency Incontinence|Mirabegron and Urinary Urgency Incontinence: The Clinical Response and the Female Urinary Microbiome||Loyola University|No|Active, not recruiting|January 2015|July 2020|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|18 Years|N/A|No|||July 2015|July 10, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495389||17277|
NCT02397629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 85B10|Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis|Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|May 2013|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Serum samples for measurement of PTHrP|Male|40 Years|N/A|No|Probability Sample|Men > 40 years old scheduled for a prostate biopsy|July 2015|July 28, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02397629||24782|
NCT02395484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetagenomeNanjing|Metagenome Analysis of Gut Microbiota in CC Patients|Species and Metagenome Analysis of Gut Microbiota in Chronic Constipation Patients||Jinling Hospital, China|Yes|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|50 faecal samples were obtained from constipation patients and 50 faecal samples were        obtained from healthy volunteers|May 2015|May 1, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395484||24947|
NCT02395497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00089306|Human Penile Allotransplantation|Human Penile Allotransplantation||Johns Hopkins University|Yes|Recruiting|June 2014|June 2024|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|69 Years|No|||March 2016|March 8, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395497||24946|
NCT02500017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015417|Melatonin Treatment for Night-Eating Syndrome|Melatonin Treatment for Night-Eating Syndrome|MLT|Yale University|No|Recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02500017||16922|
NCT02509182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507016157|The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy|The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy: A Randomized Controlled Trial||Yale University|Yes|Not yet recruiting|December 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509182||16218|
NCT02405273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2011-02351711|Pulmonary Resection And Intensive Rehabilitation|Effects of Early Pulmonary Rehabilitation and Long-term Exercise on Functioning, Quality of Life and Postoperative Outcome in Lung Cancer Patients|PUREAIR|Arcispedale Santa Maria Nuova-IRCCS|No|Recruiting|March 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02405273||24196|
NCT02396069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-NC-P1-14|The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers.||Jeil Pharmaceutical Co., Ltd.|Yes|Not yet recruiting|March 2015|||August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02396069||24902|
NCT02396316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17584|Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients|A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma|VEGA|Bayer|No|Recruiting|April 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396316||24883|
NCT02500290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-AAS-2014-01|Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Crossing Antiplatelet|Antiplatelet Therapy in Acute Coronary Syndrome (ACS). Safety and Efficacy of Crossing Antiplatelet||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|November 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with acute coronary syndrome|July 2015|July 14, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02500290||16901|
NCT02500537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVRRBT0451|A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology|A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology||Medtronic - MITG|Yes|Recruiting|May 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2015|July 14, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02500537||16882|
NCT02497794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787|The Effect of Gum Chewing on Bowel Function After Cesarean Section|Efficacy and Effectiveness of Gum Chewing on Bowel Function After Cesarean Section: a Randomized Controlled Trial||Sisli Etfal Training & Research Hospital|No|Not yet recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||June 2015|October 2, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02497794||17093|
NCT02402725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33781|A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma|A Phase II, Open-label, Single Center Study of Ultra-High Dose Dexamethasone (UHDD) Administered Intravenously and Orally as Monotherapy for the Treatment of Relapsed Multiple Myeloma|UltraDex|Boston Medical Center|Yes|Recruiting|May 2015|April 2040|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402725||24390|
NCT02499263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-346|A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice|A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice||AbbVie|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Fecal samples : Fecal calprotectin and the composition of Fecal microbiota Blood samples :      Trough level of adalimumab & Antibodies against adalimumab|Both|19 Years|99 Years|No|Probability Sample|General Hospital|January 2016|January 27, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499263||16980|
NCT02401919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|520002003|Basic Care Revisited_Communication for Patient Participation|BASIC CARE REVISITED - Building the Evidence Base in Core Nursing Practice|BCR_C|Radboud University|No|Recruiting|May 2014|May 2019|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|175|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02401919||24452|
NCT02409914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-153|Brain Metabolism in Polycystic Ovary Syndrome|Brain Metabolism in Women With Polycystic Ovary Syndrome: a PET/MRI Study||Université de Sherbrooke|No|Completed|March 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7|Samples Without DNA|Blood plasma|Female|18 Years|35 Years|No|Non-Probability Sample|Women with PCOS (n=7) were referred by physician specialist in endocrinology between        April, 2010 and September, 2013. The diagnosis of PCOS was based on clinical examination        using the Rotterdam criteria.|April 2015|April 6, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409914||23841|
NCT02409927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-391|Effect of MCT Emulsification on Ketogenesis in Human Adults|Effect of Medium-chain Triglycerides Emulsification on Ketogenesis and Adverse Effects in Human Adults||Université de Sherbrooke|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409927||23840|
NCT02505347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057067|Early Functional Return to Work Following Distal Biceps Repair|Early Functional Return to Work Following Distal Biceps Repair||Shoulder & Upper Extremity Research Group of Edmonton|No|Not yet recruiting|July 2015|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|65 Years|No|||June 2015|July 20, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02505347||16512|
NCT02505516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021|BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS|BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS ON METFORMIN THERAPY IN A WEST AFRICA SUB-REGION||University of Cape Coast|No|Completed|June 2013|February 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|150|||Both|25 Years|86 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505516||16499|
NCT02506270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/307.14|Effect of Airseal System Valve-less Trocar on the Ventilatory Parameters During Robotic-assisted Radical Cystectomy|||Regina Elena Cancer Institute||Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02506270||16441|
NCT02509455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-071|Balance Measures During Stance and Gait: Comparison of Gyroscopic Measurements of Trunk Sway|Quantified Balance Measures During Stance and Gait: Comparison of a New Micro-mechanical Gyro-system (Sensoro Von Hocoma AG) With SwayStar (Balance Int. Innov.) for Measurements of Balance Control of Healthy Controls.||University Hospital, Basel, Switzerland|Yes|Recruiting|June 2015|June 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|February 2016|February 4, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02509455||16197|
NCT02403258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014S298|The Effect and Safety of Plum-blossom Needle for Tourette Syndrome|The Effect and Safety of Plum-blossom Needle for Tourette Syndrome: a Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|January 2015|May 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|18 Years|No|||October 2015|October 15, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403258||24351|
NCT02403271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1135-CA|A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors|A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors||Pharmacyclics|Yes|Recruiting|March 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403271||24350|
NCT02408198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D 2013/066|The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia|The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia||King's College London|No|Active, not recruiting|February 2015|May 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408198||23973|
NCT02405676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCG-BNHL-2015|BNHL-2015 for Children or Adolescents in China|Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China|BNHL-2015|Children's Cancer Group, China|No|Recruiting|January 2015|December 2024|Anticipated|June 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|N/A|16 Years|No|||March 2015|March 28, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02405676||24165|
NCT02403193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBFCC07|Trial of PBF-509 in Patients With Advanced NSCLC|Phase I Trial of PBF-509 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|AdenONCO|Palobiofarma SL|No|Recruiting|August 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|15|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403193||24356|
NCT02423005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-13-1001|Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US|A Single-blind, Multi-centre, Randomised, Controlled, Non-inferiority, Clinical Study to Assess the Safety and Performance of the Neurotech Vital Compact Device Compared to the Itouch Sure Pelvic Floor Exerciser for the Treatment of Stress Urinary Incontinence in Female Patients||Bio-Medical Research, Ltd.|No|Recruiting|April 2015|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|65 Years|No|||January 2016|January 25, 2016|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423005||22835|
NCT02413788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fcmscsp|Impact of Aerobic Training and Combined in Inflammatory Markers in Patients With Adolescent Idiopathic Scoliosis|Impact of Aerobic Training and Combined in Inflammatory Markers in Patients With Adolescent Idiopathic Scoliosis||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Recruiting|September 2015|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|18 Years|No|||August 2015|March 8, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02413788||23543|
NCT02414009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPTEM|Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients|Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer|CAPTEM|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02414009||23526|
NCT02397343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBO-SHA|The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model|The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model|HBO-SHA|Rigshospitalet, Denmark|Yes|Recruiting|February 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|July 3, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02397343||24804|
NCT02399527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00007182|Lymphatic Anomalies Registry|Lymphatic Anomalies Registry||Children's Hospital Boston|No|Recruiting|June 2013|||June 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Both domestic and international patients with complex lymphatic anomalies, as described        above, are eligible to participate. Travel to Boston is not required for participation.        Eligible patients are identified through active referral in the Vascular Anomalies Center        at Boston Children's Hospital. Physicians and patients may also refer eligible patients        directly to the Lymphatic Anomalies Registry. Patients may indicate interest in        participation themselves by contacting the registry team through the "Contact Us" link on        www.lymphaticregistry.org.|November 2015|November 4, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02399527|15 Years|24636|
NCT02417350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCHF-100|Ketogenic Diet - a Randomized, Controlled, Cross-over Study|A Randomized Controlled Diet Intervention Comparing Effects of a Ketogenic Diet Versus a National Food Administration Recommended Diet Among Healthy Female Adults||Umeå University|No|Completed|April 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Female|18 Years|30 Years|No|||November 2015|November 4, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02417350||23269|
NCT02422914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R6314|Benefits of Tobacco Free Cigarette|Benefits of Tobacco Free Cigarette Among Heavy Smokers Undergoing a Lung Cancer Screening Program: a Randomized Controlled Study|BETOFREE|University of Milan|No|Recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|April 21, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02422914||22842|
NCT02423070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915115|Genome Transplant Dynamics|Genome Transplant Dynamics||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|November 2024|Anticipated|November 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|215|||Both|18 Years|80 Years|No|||February 2016|March 3, 2016|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02423070||22830|
NCT02407743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500153|TEMporal PostOperative Pain Signatures|Finding Good TEMporal PostOperative Pain Signatures (TEMPOS)|TEMPOS|University of Florida|No|Recruiting|August 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for surgery will be invited to participate in this study.|February 2016|February 11, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02407743||24008|
NCT02407756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1412|A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)|A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Active, not recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|6 Years|17 Years|No|||November 2015|November 11, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407756||24007|
NCT02419625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-15-0021-CTIL|The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors|The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study||Carmel Medical Center|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|18 Years|75 Years|No|||March 2015|April 14, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02419625||23095|
NCT02426398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18419|Developing a New EEG Method for the Early Diagnosis of Dementia|Developing a New EEG Method for the Early Diagnosis of Dementia. Using Novel EEG Analyses to Create a Diagnostic Test and Biomarker for Use With People With Dementia||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria        (McKhann et al., 2011, Dubois et al., 2007)|April 2015|April 21, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426398||22574|
NCT02426411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMA401-006|Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN|A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia||Spinifex Pharmaceuticals Pty Ltd|No|Withdrawn|June 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426411||22573|
NCT02427282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999|Distalization by Miniscrew|Miniscrew-supported Versus Standard Frog Molar Distalizing Appliances (Clinical Study)|AU|Ain Shams University|Yes|Completed|July 2012|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|11 Years|16 Years|No|||April 2015|April 30, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02427282||22506|
NCT02427295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BKR08T|Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues|Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study|acromegaly|Asan Medical Center|No|Recruiting|March 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02427295||22505|
NCT02397564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.1075|Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG|Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG|Er:YAG|University of Louisville|Yes|Not yet recruiting|March 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 24, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397564||24787|
NCT02402933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG109|Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents|A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D||Locemia Solutions ULC|No|Active, not recruiting|March 2015|May 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|4 Years|17 Years|No|||March 2016|March 7, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402933||24376|
NCT02422043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-28|Description of Socio-cognitive and Clinic Changes for Type 1 Diabetes Adolescents Cohort With Therapeutic Patient Education Program|Description of Socio-cognitive and Clinic Changes for Type 1 Diabetes Adolescents Cohort With Therapeutic Patient Education Program||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|12 Years|17 Years|No|||October 2015|October 22, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422043||22909|
NCT02427321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14056|Cystoscopic Imaging Collection and Enhancement pROject|Cystoscopic Imaging Collection and Enhancement pROject: A Prospective, Non-randomised, Observational Proof-of-concept Study of Flexible Cystoscopic Examination Recordings From a Symptomatic Adult Population|CICERO|Biosignatures Limited|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Both|18 Years|N/A|No|Non-Probability Sample|Adults referred to Urology clinic for cystoscopic surveillance after treatment for bladder        cancer, and adults referred for cystoscopic investigation of haematuria or lower urinary        tract symptoms (LUTS) that raise the suspicion of an undiagnosed bladder cancer.|January 2016|January 13, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02427321||22503|
NCT02403349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-12-049-HJM|Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol|Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol|FAVOR|Ajou University School of Medicine|No|Active, not recruiting|May 2012|September 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|30 Years|N/A|No|||March 2015|March 26, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02403349||24344|
NCT02403362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-EPOP2b|Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis|A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney Disease Not Requiring Dialysis.||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||March 2015|March 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02403362||24343|
NCT02497989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH000518|Evaluating Demand Creation Strategies for Voluntary Medical Male Circumcision (VMMC) in Kenya|Male Circumcision for HIV Prevention in Kenya: Seeking Effective Strategies to Recruit Older Men|TASCO|Impact Research & Development Organization|No|Recruiting|February 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|4932|||Male|25 Years|39 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02497989||17078|
NCT02503670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Movember A03-B15-14B|An Intervention Study to Evaluate a Website Tailored to New Dads to Promote Mental Health|HealthyDads.Ca-Development and Pilot Evaluation of a Multimodal E-Health Intervention to Promote the Mental Health of Men at Risk for Depression||McGill University|No|Recruiting|December 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503670||16641|
NCT02510911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaCo, Chir201401|Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?|Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy? - A Randomized, Placebo-controlled Trial|CaCo|Cantonal Hospital of St. Gallen|Yes|Recruiting|August 2015|July 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510911||16085|
NCT02400879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH-1160080|Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery|Comparisons of Postoperative BIS Profile and Extubation Time After Valvular Heart Surgery: Remifentanil-based Propofol-supplemented Versus Sevoflurane-sufentanil Balanced Anesthesia Regimen||Konkuk University Medical Center|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|19 Years|70 Years|No|||August 2015|August 13, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02400879||24532|
NCT02408419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol2tdn|Obturator Nerve Block in Patients With Hip Fracture|Proximal Obturator Nerve Block After Insufficient Analgesic Effect of Femoral Nerve Block in Patients With Hip Fracture|OPAD|University of Aarhus|Yes|Withdrawn|March 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|55 Years|N/A|No|||March 2015|September 11, 2015|March 31, 2015||No|The study was completely redesigned|No||https://clinicaltrials.gov/show/NCT02408419||23956|
NCT02509559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBEmoMem_G|Effects of Propranolol (vs. Placebo) on Information Processing During Presentation of Emotionally Arousing Pictures|Effects of Propranolol (vs. Placebo) on Information Processing During Presentation of Emotionally Arousing Pictures After Single Dose (80 mg) Administration and Relationships Between ß1- and ß2-adrenoreceptors Genotype and Both the Information Processing and the Propranolol Effects in 64 Healthy Male Subjects|BBEmoMem_G|University Medicine Greifswald|Yes|Completed|October 2013|January 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509559||16189|
NCT02509572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004169|Improvement of STI Detection in Adolescent Emergency Department Patients|Improvement of STI Detection in Adolescent Emergency Department Patients|SHS|Children's Research Institute|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|800|||Both|14 Years|19 Years|No|||January 2016|January 11, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02509572||16188|
NCT02509585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV3-19|A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection|A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection||Navidea Biopharmaceuticals|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509585||16187|
NCT02405494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10029V|Effect of Liquid Volume and the Amount of Incorporated Gas Into a Carbohydrate/Protein Beverage on Satiety|Effect of Liquid Volume and the Amount of Incorporated Gas Into a Carbohydrate/Protein Beverage on Satiety: a Response-surface-model Study||Unilever R&D|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02405494||24179|
NCT02409888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2013003944|Evaluating Interventions for Alcohol Use Disorder|||Rutgers, The State University of New Jersey|Yes|Recruiting|November 2015|July 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409888||23843|
NCT02395575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-10018|A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay|Prospective Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna Test (Assay) in the Management of Early-stage Breast Cancers||NanoString Technologies, Inc.|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|FFPE breast tumor tissue samples|Female|N/A|N/A|No|Probability Sample|Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women        who meet the entry criteria,|March 2016|March 21, 2016|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395575||24940|
NCT02507765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15032|Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Pilot Trial of Stereotactic Body Radiation Therapy (SBRT) to Induce Tumor Hyperemia in Combination With Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|July 2015|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507765||16326|
NCT02497300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140508008|Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease|Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease|VEMAKD|University of Alabama at Birmingham|No|Recruiting|March 2015|July 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497300||17130|
NCT02401451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACB1-1001-1941|SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])|SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])|SL-AF|Cardiocity Limited|No|Recruiting|October 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401451||24488|
NCT02404545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140277|Prevention of Parastomal Hernia by Mesh Placement|A Randomized Study of the Utility of Composite Mesh Placement to Prevent Parastomal Hernia in Patients Undergoing Urinary Diversion With Ileal Conduit||University of Miami|Yes|Recruiting|August 2015|April 2021|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404545||24252|
NCT02501850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHI-GLP-2014-01|The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)|The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)|EGLIPA|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|October 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|65 Years|No|||July 2015|July 20, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02501850||16781|
NCT02405754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AACU|Clinical Utility of an Age, Sex, and Gene Expression Score|Clinical Utility of an Age, Sex, and Gene Expression Score in the Diagnostic Management of Obstructive Coronary Artery Disease in African American Patients in a Primary Care Setting||CardioDx|No|Completed|February 2014|August 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|667|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects, who received Corus CAD testing, will be considered for enrollment by conducting        a retrospective review of medical charts. Subjects who satisfy the following inclusion and        exclusion criteria will be included for data abstraction.|March 2015|March 31, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405754||24159|
NCT02398526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17550|Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases|PARABO - Pain Evaluation in Radium-223 (Xofigo®) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers|PARABO|Bayer|No|Recruiting|March 2015|December 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|18 Years|N/A|No|Non-Probability Sample|The study population will consist of castration resistant prostate cancer patients with        bone metastases treated with Radium-223.|March 2016|March 11, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398526||24713|
NCT02508207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-111|A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated||Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508207||16292|
NCT02508220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-Oxy-Tin|Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus|Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus||University of Regensburg|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||July 2015|November 30, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02508220||16291|
NCT02495675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-HDWOBSS|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects|HDWOBSS|Laval University|No|Recruiting|June 2015|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02495675||17255|
NCT02495688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plx vs GA|Regional or General Anesthesia for Distal Radius Fracture Surgery in a Day Surgery Setting|Regional or General Anesthesia for Distal Radius Fracture Surgery in a Day Surgery Setting - A Randomized Clinical Trial||Karolinska Institutet|No|Recruiting|March 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|74 Years|No|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495688||17254|
NCT02400060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13252|Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer|Increasing Adherence to Adjuvant Hormonal Therapy Among Breast Cancer Patients: Phase 2 - Pilot Test of Intervention for Feasibility||Ohio State University Comprehensive Cancer Center|No|Recruiting|March 2014|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|64|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400060||24595|
NCT02398539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150110|Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue|Randomized Clinical Trial Comparing Silver Nitrate Application With Topical Corticosteroids for Hypergranulation Tissue at Gastrostomy Sites||Akron Children's Hospital|No|Recruiting|April 2015|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|18 Years|No|||May 2015|May 28, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398539||24712|
NCT02402517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-2|PERFECT Project - Part 2 - Study 1|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 1||University of Manitoba|No|Recruiting|October 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02402517||24406|
NCT02401516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 16952113.5.0000.5544|Reprogramming Insoles In Regulating Blood Pressure In Hypertensive Subjects|Effect Of Postural Reprogramming Insoles In Regulating Blood Pressure, Posture And Quality Of Life In Hypertensive Subjects|RIBP|Escola Bahiana de Medicina e Saude Publica|Yes|Enrolling by invitation|May 2014|December 2017|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|60 Years|No|||January 2016|January 19, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02401516||24483|
NCT02495961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Study of Chronic Degenerative Diseases|Study of Chronic Degenerative Diseases, Translational Medicine Approach||Asociación Científica Latina A.C.|No|Completed|June 2015|February 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary school students.|February 2016|February 15, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02495961||17233|
NCT02400281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-010|Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients|Phase I-II Study of Crenolanib Combined With Idarubicin and Cytarabine, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations||Arog Pharmaceuticals, Inc.|No|Recruiting|September 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400281||24578|
NCT02400294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0227|Prevention of Ventilator Associated Pneumonia With Toothbrushing in Oral Care of Critically Ill Mechanically Ventilated Patients|Prevention of Ventilator Associated Pneumonia With Toothbrushing in Oral Care of Critically Ill Mechanically Ventilated Patients||University Hospital, Clermont-Ferrand||Recruiting|July 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|mechanically ventilated patients|March 2015|March 26, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02400294||24577|
NCT02399358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2439|Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide|Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide: Prospective Cohort Study||Hospital Italiano de Buenos Aires|No|Not yet recruiting|December 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Adult patients (Over 18 years) admitted for high-dose cyclophosphamide.|December 2015|December 16, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399358||24649|
NCT02399371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1381|Pembrolizumab in Treating Patients With Malignant Mesothelioma|A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma||University of Chicago|No|Recruiting|April 2015|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399371||24648|
NCT02503397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/06/10/145|Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants|Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants||Sir Ganga Ram Hospital|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|N/A|3 Days|Accepts Healthy Volunteers|Non-Probability Sample|All neonates born between 34 - 42 weeks of gestation at Sir Ganga Ram Hospital during        study period would be evaluated for enrolment in the study till 30 neonates each enrolled        in the three groups: appropiate for gestational age, small for gestational age, infants of        diabetic mother.|July 2015|July 17, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02503397||16662|
NCT02503410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P-000663|Augmenting Back Pain Exercise Therapy Using an Interactive Gaming-based Intervention in the Home Setting|Augmenting Back Pain Exercise Therapy Using an Interactive Gaming-based Intervention in the Home Setting||Spaulding Rehabilitation Hospital|No|Not yet recruiting|August 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||July 2015|July 17, 2015|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503410||16661|
NCT02501070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00091|Impact on Public HEalth of a Network in Acute Myocardial Infarction Care|Impact of Implantation of PROGALIAM Network (Galician Program of Care in Acute Myocardial Infarction) in Cardiovascular Health in the Northern Area of Galicia.|iPHENAMIC|Complexo Hospitalario Universitario de A Coruña|No|Recruiting|April 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|The study will gather patients with STEMI (ST segment Elevation Myocardial Infarction)        according to the third consensus definition of myocardial infarction treated at Northern        Galician Network of Acute Myocardial Infarction.|October 2015|October 2, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501070||16841|
NCT02401932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-013|Retrospective Analysis for Patients With Hemophagocytosis in Bone Marrow|Comparison of Malignant and Non-malignant Disorders Associated Bone Marrow Hemophagocytosis: A Single Center Experience||Samsung Medical Center|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|90 Years|No|Probability Sample|The investigators reviewed the electronic data base of medical records at the Samsung        Medical Center, and selected 264 patients who had evidence of hemophagocytic histiocytosis        in bone marrow aspiration and biopsy between January 2000 and June 2014.|November 2015|November 8, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02401932||24451|
NCT02401945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35-002|A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration|A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect of Intravitreal Injections of DE-120 as Monotherapy and With a Single Eylea® Injection in Subjects With Treatment-Naive Exudative Age-Related Macular Degeneration|VAPOR1|Santen Inc.|Yes|Recruiting|April 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||May 2015|May 18, 2015|March 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401945||24450|
NCT02404376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBAT-MI|COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial|COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial|COMBAT-MI|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|March 2016|September 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02404376||24265|
NCT02499770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1T28-02|G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)|Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin||G1 Therapeutics, Inc.|Yes|Recruiting|June 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499770||16941|
NCT02497248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERSONALIZE-AF|Non-invasive Characterization of the Mechanisms of Atrial Fibrillation Maintenance|PERSONALIZE-AF: Non-invasive Characterization of the Mechanisms of Atrial Fibrillation|PERSONALIZE|Hospital General Universitario Gregorio Marañon|Yes|Recruiting|February 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|AF patients with different mechanisms of maintenance (i.e. paroxysmal, persistent,        valvular) and clinical indication for AF ablation.|July 2015|July 10, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02497248||17134|
NCT02497261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:052|Early Life Origins of the Food Allergy Epidemic|Early Life Origins of the Food Allergy Epidemic||University of Manitoba|No|Enrolling by invitation|July 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood for immunological markers of peanut allergy|Both|4 Years|10 Years|No|Non-Probability Sample|Participants will be recruited from among the participants of the Canadian Healthy Infant        Longitudinal Development (CHILD) Study (http://www.canadianchildstudy.ca) who have        completed their 5-year-old study visit.|June 2015|July 9, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02497261||17133|
NCT02402218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055591|CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS|CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS|CHAMPS|Johns Hopkins University|Yes|Enrolling by invitation|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|164|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402218||24429|
NCT02399930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0682|Automated Respiration Rate to Improve Accuracy of the Electronic Cardiac Arrest Risk Triage Score (eCART) Algorithm|Automated Respiration Rate Evaluation to Improve Accuracy of the Early Warning Score Procedure Determined by the Electronic Cardiac Arrest Risk Triage Score (eCART) Algorithm||University of Chicago|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Data will be collected from all adult inpatients providing consent who are admitted to a        36 bed adult inpatient oncology unit at the University of Chicago.|December 2015|December 1, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399930||24605|
NCT02400125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-2011BAI11B21|China Cardiovascular Surgery Registry|China Cardiovascular Surgery Registry|CCSR|China National Center for Cardiovascular Diseases|Yes|Recruiting|March 2013|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90000|||Both|N/A|N/A|No|Non-Probability Sample|patients underwent isolated or combined coronary artery bypass grafting and/or surgical        treatment for heart valve diseases|December 2015|December 15, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02400125|1 Year|24590|
NCT02505971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048673|Nadolol Versus Propranolol in Children With Infantile Hemangiomas|Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial||The Hospital for Sick Children|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|1 Month|6 Months|No|||January 2016|January 4, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505971||16464|
NCT02501811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-15-0413|Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure|A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic Heart Failure|CONCERT-HF|The University of Texas Health Science Center, Houston|Yes|Recruiting|October 2015|February 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|21 Years|79 Years|No|||January 2016|January 21, 2016|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501811||16784|
NCT02393768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB EpiCard|Epigenetic Reprogramming of Monocytes in Patients With Coronary Atherosclerosis|Epigenetic Reprogramming of Monocytes in Patients With Coronary Atherosclerosis||Radboud University|No|Recruiting|October 2014|||June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Adult patients >18 years who have underwent CCTa scanning beacuse of chest pain.|March 2015|March 18, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393768||25079|
NCT02397915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201474|Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays|A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects With Allergic Rhinitis||GlaxoSmithKline|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|300|||Both|18 Years|65 Years|No|||December 2015|January 28, 2016|March 19, 2015||No||No|January 28, 2016|https://clinicaltrials.gov/show/NCT02397915||24760|
NCT02401490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BETA|Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy|Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy|BETA|Hospital Universitari Vall d'Hebron Research Institute||Recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|85 Years|No|||July 2015|July 6, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401490||24485|
NCT02506218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015661|Optimizing Meal and Snack Timing to Promote Health|Optimizing Meal and Snack Timing to Promote Health|S43|Purdue University|No|Active, not recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|25 Years|39 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02506218||16445|
NCT02506465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-03|Pivotal Study to Assess the Safety and Effectiveness of the iTIND Device|Multi-center Prospective Study to Assess the Safety and Effectiveness of Medi-Tate i-Temporary Implantable Nitinol Device (iTIND) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)||Medi-Tate Ltd.|Yes|Recruiting|October 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Male|50 Years|80 Years|No|||January 2016|January 31, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506465||16426|
NCT02501616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRMH 26-2014-148|Effect of Dapagliflozine on Systemic and Renal Endothelial Function|Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial)||Seoul National University Hospital||Recruiting|December 2014|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|20 Years|80 Years|No|||July 2015|July 15, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02501616||16799|
NCT02501629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072-AS-30027|An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils|A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils||Teva Pharmaceutical Industries|Yes|Recruiting|September 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|12 Years|N/A|No|||March 2016|March 1, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501629||16798|
NCT02405533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14_0866|Phase II Evaluation of AHCC for the Eradication of HPV Infections|Phase II Randomized, Double-blind, Placebo-controlled Evaluation of AHCC (Active Hexose Correlated Compound) for the Eradication of HPV Infections in Women With HPV Positive Pap Smears|AHCC4HPV|The University of Texas Health Science Center, Houston|No|Recruiting|March 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|30 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02405533||24176|
NCT02395796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106323|Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural in Laboring Patients|Efficacy of the Presence of a Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural Needle and Catheter in Laboring Pregnant Patients: a Feasibility Study||Lawson Health Research Institute|No|Terminated|July 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|March 10, 2015||No|Negative results were obtained in all subjects that were analyzed (n=10)|No||https://clinicaltrials.gov/show/NCT02395796||24923|
NCT02395809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM201215|Transcutaneous Posterior Tibial Nerve Stimulation for Treatment of Chronic Anal Fissure|Randomized Clinical Trial of Transcutaneous Electrical Posterior Tibial Nerve Stimulation Versus Lateral Internal Sphincterotomy for Treatment of Chronic Anal Fissure.||Mansoura University|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02395809||24922|
NCT02395822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LS092|MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients|MT2014-25: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||October 2015|October 2, 2015|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395822||24921|
NCT02505178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106856|Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression|Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression; an Open-label Prospective Pilot Study.||Lawson Health Research Institute|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|60 Years|85 Years|No|||August 2015|August 24, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02505178||16525|
NCT02505191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ze117-1-2014-01a|Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117|A Pilot Phase I, Randomised, Open Mono-center, Multiple Dose, Two Parallel Groups Clinical Trial Investigating the Pharmacokinetics of a Prolonged-release Formulation in Comparison to an Immediate-release Formulation of St. John's Wort Extract Ze 117 in Healthy Male Volunteers Under Fasting Condition||Max Zeller Soehne AG|No|Not yet recruiting|November 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02505191||16524|
NCT02508662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0300|Registry Study for Personalized Cancer Therapy|Registry Study for Personalized Cancer Therapy||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood (about 4 teaspoons) drawn to check for any genetic mutations.|Both|18 Years|N/A|No|Non-Probability Sample|Participants with advanced solid cancer with known genomic aberrations at MD Anderson        Cancer Center.|October 2015|October 27, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508662||16258|
NCT02508675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50258.028.14|Non-fatal Outcome After Trauma|Prevalence, Recovery Patterns and Risk Factors of Non-fatal Outcome and Costs After Trauma; a Prospective Follow up Study|βioς|Network Emergency Care Brabant|No|Enrolling by invitation|August 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6500|||Both|18 Years|N/A|No|Non-Probability Sample|patients seen at the Emergency Department (ED) which are admitted to the Intensive Care        Unit (ICU) or ward after getting injured, with a minimal age of 18 years old.|August 2015|August 25, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508675|2 Years|16257|
NCT02404831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L13099|An Evaluation of Web Based Pulmonary Rehabilitation|An Evaluation of Web Based Pulmonary Rehabilitation- Pilot Study|webbasedPR|University of Glasgow|No|Completed|April 2014|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02404831||24230|
NCT02393742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG013038-19|Nitrite Supplementation for Improving Physiological Function in Older Adults|Efficacy of Oral Sodium Nitrite for Improving Physiological Functions in Older Adults|NITRITE|University of Colorado, Boulder|No|Recruiting|March 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|92|||Female|60 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393742||25081|
NCT02396056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StonyBrookU|Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane|Enhanced Guided Bone Regeneration in Localized Osseous Alveolar Defects by Using a Novel Perforated Resorbable Barrier Membrane||Stony Brook University|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396056||24903|
NCT02508311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1910-P|Albuterol to Improve Respiratory Strength in SCI|The Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in SCI||VA Office of Research and Development|No|Not yet recruiting|February 2016|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02508311||16285|
NCT02509468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN14-AM/PERFORMUS|suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS|Treatment of Superficial Voluminous Complicated Slow-flow Vascular Malformations With Sirolimus: a Phase 2 Trial in Children Observational-phase Designed|PERFORMUS|University Hospital, Tours|Yes|Recruiting|September 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|18 Years|No|||February 2016|February 25, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02509468||16196|
NCT02501954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-07|Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol|Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel||Women's Cancer Care Associates, LLC|No|Recruiting|March 2015|March 2023|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|N/A|No|||July 2015|July 15, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501954||16773|
NCT02501967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410014812|Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II|Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II|COMET|Yale University|No|Recruiting|April 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|110|||Both|65 Years|N/A|No|||July 2015|July 15, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02501967||16772|
NCT02406053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YYU-016|Oxidative Damage and Antioxidant Mechanisms in COPD|Evaluation of Oxidative Damage and Antioxidant Mechanisms in COPD, Lung Cancer, and Obstructive Sleep Apnea Syndrome||Yuzuncu Yıl University|Yes|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|111|||Both|38 Years|79 Years|No|Probability Sample|A total of 111 participants (35 females, 76 males) with OSAS (n=29), COPD (n=26) and LC        (n=28), and healthy controls (n=28) were included in the study.|March 2015|March 27, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406053||24136|
NCT02406170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.51666|Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma|The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study|REPEAT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Not yet recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02406170||24127|
NCT02406898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-43|Evaluation of a Hysteroscopic Morcellator in Hysteroscopic Treatment of Submucosal Fibroids|Operative Hysteroscopy for Fibroma by Classic Resection Versus Morcellation: a Ramdomised Study||Assistance Publique Hopitaux De Marseille|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||May 2015|September 28, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406898||24073|
NCT02416687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62798|Etonogestrel Implant and Postpartum Insertion|Immediate Post-partum Initiation of Etonogestrel-releasing Implant: a Randomized Controlled Trial on Breastfeeding Impact||University of Sao Paulo|No|Completed|March 2014|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416687||23320|
NCT02416947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TateLyle Ca41|Soluble Corn Fiber Effect on Bone Resorption in Post Menopausal Women|The Effect of Soluble Corn Fiber (SCF) on Bone Resorption in Post-Menopausal Women Using 41Calcium Technology||Purdue University|No|Completed|March 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|14|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02416947||23300|
NCT02407574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR2015|Assessment of the Force Frequency Relationship of the Myocardium After On-pump CABG Surgery|||University Hospital of Liege|Yes|Not yet recruiting|May 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02407574||24021|
NCT02407587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01997|Neuroplastic Changes Seen in Cochlear Implants With Preserved Hearing|Cortical Activity in Subjects With Unilateral Cochlear Implants and Preserved Ipsilateral Residual Hearing and the Evolution of Temporal Cortex Changes in New Recipients of Cochlear Implants.||Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|May 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 2, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02407587||24020|
NCT02410161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-389|Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids|Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma n-3 Polyunsaturated Fatty Acids in Young Compared to Older Adults||Université de Sherbrooke|No|Completed|July 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 1, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02410161||23822|
NCT02395185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEX-102|A Randomized Controlled Trial of Three Non-pharmacologic Analgesic Techniques for Casting of Clubfoot Infants|A Randomized Controlled Trial of Three Non-pharmacologic Analgesic Techniques for Casting of Clubfoot Infants||Shriners Hospitals for Children|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|65|||Both|N/A|6 Months|No|||March 2015|March 19, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395185||24970|
NCT02413190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00031738|Bone Health in Facioscapulohumeral Muscular Dystrophy|Bone Health in Facioscapulohumeral Muscular Dystrophy: A Cross-sectional Study|FSHD|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|July 2014|||September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The population consists of individuals with Facioscapulohumeral Muscular Dystrophy.|April 2015|April 14, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413190||23589|
NCT02413437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014YJZ31|A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms|A Multi-center Randomized Controlled Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Occupied Lesion||Beijing Cancer Hospital|Yes|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1800|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02413437||23570|
NCT02417207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(2014)2-127|Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation|Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||April 2015|April 10, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02417207||23280|
NCT02401555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP.BVD.GEHIV.02|Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay|Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay||Bio-Rad Laboratories|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|419|Samples Without DNA|Serum and plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV1 Positives: Individuals with confirmed HIV1 positive records AIDS Positives:        Individuals with proved CDC stage 3 (AIDS) Low Risk patients: Low Risk individuals        including potential military recruits, soldiers and civilians who have not reported any        high risk behavior for HIV infection.|March 2015|March 27, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401555||24480|
NCT02419365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCD_Registry_BESTCILIA|International Prospective Patient Registry for Primary Ciliary Dyskinesia (PCD)|Prospective Primary Ciliary Dyskinesia (PCD) Registry for Systematic Data Collection on Incidence, Clinical Presentation, Treatment and Course of the Disease||University Hospital Muenster|No|Recruiting|January 2014|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|Individuals with a diagnosis of Primary Ciliary Dyskinesia.|April 2015|April 13, 2015|February 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02419365|20 Years|23115|
NCT02421081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKCD|Effect of Cell Surface Markers and Lymphoid Cell Distribution on the Arterial Tissue Repair (ECLAR)|Effect of Cell Surface Markers Like CD 34 - CD 133 - CD 309 and Lymphoid Cell Distribution on the Wrist Laceration With Radial or Ulnar Arterial Tissue Repair|ECLAR|TC Erciyes University|No|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|March 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02421081||22983|
NCT02421094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-028|Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis|Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis|NASH-FX|Galectin Therapeutics Inc.|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421094||22982|
NCT02423135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 06/14|Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion in Anti-doping|Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion Using a Combination of Multiple Biomarkers in Different Matrices.||Centre Hospitalier Universitaire Vaudois|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02423135||22825|
NCT02423148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-441|A Pilot Study of a Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer in Combination With Indo-Cyanine Green|A Pilot Study of a Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer in Combination With Indo-Cyanine Green||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2015|March 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423148||22824|
NCT02397538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FARC-CT-101|Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects|An Open-label, Fixed-sequence, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects||Boryung Pharmaceutical Co., Ltd||Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2015|July 21, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397538||24789|
NCT02414997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHaipeng|The Effect of Remote Ischemic Preconditioning (RIPC) on Blood Pressure and Its Vascular Protection Effect|The Effect of Remote Ischemic Preconditioning (RIPC) on Blood Pressure and Its Vascular Protection Effect Among Chinese Young Healthy Adults and Primary Hypertensive Patients Stage I||First Affiliated Hospital, Sun Yat-Sen University|No|Active, not recruiting|February 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02414997||23450|
NCT02415010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PMK-1401|Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms|A Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms|SUNRISE-2|Codman & Shurtleff|No|Recruiting|July 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Subjects with both ruptured and non-ruptured aneurysms will be enrolled into the study,        with a parent vessel diameter of ≥ 2.0 mm and ≤ 4 mm|March 2016|March 16, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415010||23449|
NCT02411409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1C1CMS330997|Impact of the CommunityRx Program on Health, Service Utilization and Costs|Impact of the CommunityRx Program on Health, Service Utilization and Costs||University of Chicago|No|Recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02411409||23726|
NCT02411422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-30|Comparison of Efficiency Between I-gel Blind Intubation and I-gel Bronchoscopic Intubation During Resuscitation|Comparison of Efficiency Between I-gel-Assisted Blind Intubation and I-gel-assisted Bronchoscopic Intubation During Cardiopulmonary Resuscitation: Randomized Simulation Study|i-gel_br|Hallym University Kangnam Sacred Heart Hospital|No|Completed|April 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|23|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02411422||23725|
NCT02412085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1371|Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission|Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis|UC-GOL|Istituto Clinico Humanitas|No|Recruiting|March 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412085||23674|
NCT02412098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-372-1048|Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function|A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function||Gilead Sciences|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412098||23673|
NCT02412163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0123|Ellipse Intramedullary Nail High Tibial Osteotomy Study|A Multicenter Study of Patients Treated With the Ellipse Technologies Intramedullary High Tibial Osteotomy (IM HTO) Nail System for Osteoarthritis and Varus Malalignment of the Knee|IM HTO|Ellipse Technologies, Inc.|No|Recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412163||23668|
NCT02395055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-057-1|Evaluation of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers|Single Center Comparative Double Blind Randomized Clinical Study of Pharmacokinetics, Tolerance and Safety of Single Subcutaneous Injection of BCD-057 (CJSC "BIOCAD", Russia) and Humira in Healthy Volunteers||Biocad|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|94|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395055||24980|
NCT02395068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-PK-001|Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors|Pharmacokinetics Study of Nimotuzumab Single-dose and Multiple-dose in Combination With Irinotecan in Patients With Solid Tumors||Biotech Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|November 2012|December 2015|Anticipated|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|70 Years|No|||October 2012|August 17, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02395068||24979|
NCT02503683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-AAT-001|A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease|A Phase 1/2, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease||Alnylam Pharmaceuticals|No|Recruiting|July 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 18, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02503683||16640|
NCT02496767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4031|Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year|A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)|VITALITY-ALS|Cytokinetics|Yes|Recruiting|August 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496767||17171|
NCT02497001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010006|A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)|A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease||Pearl Therapeutics, Inc.|Yes|Recruiting|July 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1800|||Both|40 Years|80 Years|No|||January 2016|January 6, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02497001||17153|
NCT02405052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286934|Validation of the Panic Screening Score in Patient With Unexplained Chest Pain|A Prospective Cohort Study to Refine and Validate the Panic Screening Score for Identifying Panic Attacks Associated With Unexplained Chest Pain in the Emergency Department||Hôtel-Dieu de Lévis||Recruiting|July 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Patients in the emergency department|March 2015|March 31, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02405052||24213|
NCT02408432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0519|Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy|Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy||M.D. Anderson Cancer Center|Yes|Recruiting|January 2016|||January 2023|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408432||23955|
NCT02498262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ame2_Pro00013008|Using Virtual Reality and Robotics Technologies for Vocational Evaluation, Training and Placement|Using Virtual Reality and Robotics Technologies for Vocational Evaluation, Training and Placement|VR4VR|University of South Florida||Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02498262||17057|
NCT02498275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP29018|Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients|||Hoffmann-La Roche||Suspended|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chinese population: healthy volunteers, treatment naive CHB patients and nucleoside or        nucleotide analogue treated CHB patients|September 2015|September 1, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498275||17056|
NCT02498288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200115|A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition|Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study||GlaxoSmithKline|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|May 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02498288||17055|
NCT02394301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medimix Pharm-04|Efficacy of Novel Drug-combinations for Relief of Psoriasis|Efficacy of Novel Drug-combinations for Relief of Psoriasis (ENDURE)|ENDURE|Medimix Specialty Pharmacy, LLC|Yes|Suspended|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult participants with psoriasis vulgaris that are prescribed a combination compounded        topical psoriasis formulation.|May 2015|May 15, 2015|March 9, 2015||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT02394301|12 Weeks|25038|
NCT02397954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH2002|A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)|A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)||Ophthotech Corporation|Yes|Active, not recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|50 Years|N/A|No|||September 2015|September 3, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397954||24757|
NCT02400671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48580-EJ|Mobile Strategies for Women's and Children's Health: Optimizing Adherence and Efficacy of PMTCT/ART|Evaluation of Mhealth Strategies to Optimize Adherence and Efficacy of PMTCT/ART|Mobile WAChx|University of Washington||Not yet recruiting||||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|845|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02400671||24548|
NCT02400684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6017|ENDmetriosis and Reserve Ovarienne|ENDmetriosis and Reserve Ovarienne|ENDRO|University Hospital, Strasbourg, France|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|130|Samples Without DNA|3 times blood sample retrieval and use serum to measure AMH the primary end point but also      FSH, LH, estradiol which are study usually.|Both|18 Years|37 Years|No|Non-Probability Sample|Female between 18 and 38 years old Deep endometriosis stage III or IV endometriosis of        AFSr classification who undergo laparoscopy|September 2015|September 14, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400684|1 Year|24547|
NCT02403206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTW860-P001|Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts|Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts||Alcon Research|No|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|425|||Both|21 Years|N/A|No|||December 2015|December 2, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403206||24355|
NCT02403492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000026523|Treatment of Obstructive Sleep Apnea in Children: An Opportunity for Cardiovascular Risk Modification|Treatment of Obstructive Sleep Apnea in Children: An Opportunity for Cardiovascular Risk Modification|TREAT|The Hospital for Sick Children|Yes|Recruiting|August 2013|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|130|||Both|10 Years|18 Years|No|||March 2015|March 25, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02403492||24333|
NCT02405559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ly-Occl-Pressure-2|Lymphatic Occlusion Pressure in Lower Limb|The Occlusion Pressure of Superficial Lymphatics in the Lower Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach||Centre Hospitalier Universitaire Saint Pierre|No|Not yet recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02405559||24174|
NCT02408601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KamineniIDS|A Clinical Trial to Assess the Retention and Caries Preventive Effect of Resin Based Sealants Versus ART Sealants|||Kamineni Institute of Dental Sciences|No|Active, not recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02408601||23942|
NCT02498795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P115/0017|Comparative Research Among 3 Action Protocol in Other to Approach Chronic Patellar Tendinopathy|Comparative Research Among 3 Action Protocol in Other to Approach Chronic Patellar Tendinopathy||Universidad de Zaragoza|Yes|Not yet recruiting|February 2016|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|40 Years|No|||January 2016|January 16, 2016|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02498795||17016|
NCT02394886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-DFU-101|Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers|A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers||Anterogen Co., Ltd.|Yes|Completed|November 2014|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||March 2015|October 15, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02394886||24993|
NCT02395211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio_CRPS_gloreha|Effects of Proprioceptive Stimulation Under Visual Feedback in Patient With CRPS|Effects of Proprioceptive Stimulation Under Visual Feedback in Patient With CRPS: An Exploratory Study||University Hospital of Ferrara|Yes|Recruiting|January 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|No|||December 2015|December 1, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395211||24968|
NCT02399813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADXS001-06|Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum|PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANORECTAL CANAL||Advaxis, Inc.|No|Active, not recruiting|September 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02399813||24614|
NCT02497716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17992|Phase I Study on Rivaroxaban Dry Powder Suspension in Children|Single-dose Study Testing a Rivaroxaban Dry Powder Formulation for Oral Suspension in Children From 6 Months to 12 Years With Previous Thrombosis||Bayer|Yes|Recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|48|||Both|6 Months|12 Years|No|||March 2016|March 8, 2016|July 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497716||17099|
NCT02500589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-300|Telephone-based Smoking Cessation|Adjunctive Mood Management for Telephone-based Smoking Cessation in Primary Care||VA Office of Research and Development|No|Not yet recruiting|February 2016|June 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|350|||Both|N/A|N/A|No|||January 2016|January 8, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02500589||16878|
NCT02500602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLE-001-14F|CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders|CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders|Doxazosin|VA Office of Research and Development|Yes|Not yet recruiting|August 2015|April 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|21 Years|65 Years|No|||July 2015|July 14, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02500602||16877|
NCT02403960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU3|Probiotic Use in Chronic Periodontitis Patients|The Effect of a Streptococcus Probiotic in Periodontal Therapy: a Randomized Controlled Trial||Cukurova University|No|Completed|June 2010|May 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|35 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02403960||24297|
NCT02402530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF7013-01|Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I|A Randomized, Double-blind Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)||Grünenthal GmbH|Yes|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402530||24405|
NCT02508298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGT0037|Surrogate Markers of Portal Pressure|Surrogate Markers of Portal Pressure and Changes in Portal Pressure in Patients With Compensated Cirrhosis Undergoing Anti-viral Therapy||VA Connecticut Healthcare System|No|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|33|||Both|18 Years|85 Years|No|||July 2015|July 22, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02508298||16286|
NCT02500836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCA4vs10-002|Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia|Phase III Topical Application of Cocaine HCl 4% Solution on Safety/Efficacy & Cocaine HCl 4% & 10% Solution on Safety in Local Anesthesia for Diagnostic Procedures & Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities||Lannett Company, Inc.|No|Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|620|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500836||16859|
NCT02500849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14017|Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients|A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients||City of Hope Medical Center|Yes|Recruiting|July 2015|||July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500849||16858|
NCT02404103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.1024|Flunisolide HFA in Children With Small Airway Disease|Flunisolide HFA in Children With Small Airway Disease||University of Louisville|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|18 Years|No|||November 2015|November 30, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404103||24286|
NCT02404220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-1560|Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)|A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)||Gilead Sciences|No|Recruiting|May 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404220||24277|
NCT02508012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9535|Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases|Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF Agents in the Management of Patients With Inflammatory Bowel Disease Treated With Anti-TNFalpha Biotherapy.|ATAIM|University Hospital, Montpellier|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508012||16307|
NCT02507778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468-14-RMC|Circulating Tumor Cells Spillage After Pulmonary Biopsy|Circulating Tumor Cells Spillage After Pulmonary Biopsy||Rabin Medical Center|No|Recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|95 Years|No|||March 2016|March 22, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02507778||16325|
NCT02404844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOM-02282|Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer|Molecularly Stratified Parallel Cohort, Single Arm Phase II Trial of the Phosphoinositide 3-kinase (PI3K) Inhibitor Buparlisib (BKM120) in Combination With Tamoxifen in Patients With Hormone Receptor-positive, HER2-negative Inoperable (Locally Advanced or Metastatic) Breast Cancer With Prior Exposure to Antihormonal Therapy|PIKTAM|University Hospital, Essen|No|Recruiting|December 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02404844||24229|
NCT02410525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7871003|A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning|A Phase 1, Open-label, 3-period, Randomized, Partially Fixed Sequence, 2-way Crossover Study With A Microdose Of [11c]Pf-06427878 Administered With And Without Two Non-radioactive Doses Of Pf-06427878 To Characterize Tissue Distribution Using Positron Emission Tomography In Healthy Adult Male Subjects||Pfizer|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02410525||23794|
NCT02395510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOR-ITT-0024|A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder|A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder||Siyan Clinical Corporation|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395510||24945|
NCT02505711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01ER1201|Food and Agricultural Approaches to Reducing Malnutrition|Reducing Young Child Undernutrition Through an Integrated Agricultural Project With Women's Groups: A Cluster-randomized Trial in Rural Bangladesh|FAARM|Heidelberg University|No|Enrolling by invitation|August 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2700|||Female|15 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02505711||16484|
NCT02505724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305-2013|Peer-coaching to Teach Faculty Surgeons an Advanced Laparoscopic Skill|||Sunnybrook Health Sciences Centre|No|Completed|July 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|18|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505724||16483|
NCT02501083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRHF-MD|Cardiac Function Assessment and Management of Patients With Muscular Dystrophies|Cardiac Function Assessment and Management of Patients With Muscular Dystrophies||Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|July 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|170|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult patients with musculardystrophies|June 2015|July 15, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02501083||16840|
NCT02501096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-111|Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors|A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors||Eisai Inc.||Recruiting|July 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|99 Years|No|||November 2015|November 6, 2015|July 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02501096||16839|
NCT02405026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057348|Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients|HIV and Asthma in the Post-ART (Antiretroviral Therapy) Era||Duke University|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|73|Samples With DNA|serum, plasma, sputum supernatant, sputum cell pellet|Both|18 Years|N/A|No|Probability Sample|HIV infected patients. Patients will be identified from the populations of the Duke        Infectious Disease Clinic, and surrounding communities.        HIV unifected patients. Patients will be identified through the Duke Asthma, Allergy and        Airway Center, as well as from primary care physicians, and surrounding communities.|February 2016|February 2, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02405026||24215|
NCT02410538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_3678|Frequently Asked Questions for ICU Patients' Families|Frequently Asked Questions as an Help to Improve the Information of ICU Patients' Families.|FamiréaXVII|Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|relative of each patient admitted in intensive care, intubated and mechanically ventilated        in the first 48 hours of the stay.|March 2015|May 29, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410538||23793|
NCT02506933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14295|Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant|A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant||City of Hope Medical Center|Yes|Recruiting|November 2015|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|115|||Both|18 Years|75 Years|No|||February 2016|February 15, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02506933||16390|
NCT02506946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7793|NAFLD in Adolescents and Young Adults With PCOS|Nonalcoholic Fatty Liver Disease (NAFLD), Insulin Resistance and Dyslipidemia in Adolescents and Young Adults With Polycystic Ovary Syndrome (PCOS)||Columbia University|No|Recruiting|July 2013|July 2020|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples Without DNA|Blood samples will be stored in a freezer for assays requiring batch testing|Female|14 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adolescent girls and young women 14 - 25 years with and without PCOS|July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506946||16389|
NCT02497573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15ON249|Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer?|Study of Diffusion Weighted MRI as a Predictive Biomarker of Response During Radiotherapy for High and Intermediate Risk Squamous Cell Cancer of the Oropharynx (MeRInO Study)|MeRInO|NHS Greater Glasgow and Clyde|No|Not yet recruiting|August 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients with intermediate or high risk oropharyngeal squamous cell carcinoma (OPSCC),        scheduled to undergo either radiotherapy or chemoradiotherapy as primary treatment in the        Beatson West of Scotland Cancer Centre may be suitable for study participation. Suitable        patients will be identified at MDT meetings or from the radiotherapy bookings database and        approached by the direct clinical care team as they attend for radiotherapy planning        appointments. 80 patients will be recruited to the study.        Each patient will have at least one target lesion (either lymph node or primary site) for        ADC analysis and clinical follow up. MnayMany patients will have 2 or more target lesions.        The total number of target lesions is therefore highly likely to be greater than 80.|July 2015|July 13, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497573||17110|
NCT02397928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-23|Safety and Efficacy of TTFields Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma|Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With NovoTTF Therapy as First-line Treatment in Malignant Pleural Mesothelioma|STELLAR|NovoCure Ltd.|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02397928||24759|
NCT02398188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-19|Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)|A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects||Neothetics, Inc|No|Active, not recruiting|April 2015|||December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398188||24739|
NCT02405611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682|A Multi-component Intervention on Improving Fruit and Vegetable Consumption in Teenagers and Their Mothers|A Multi-component Intervention on Improving Fruit and Vegetable Consumption in Teenagers and Their Mothers||Qazvin University Of Medical Sciences|No|Recruiting|March 2015|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02405611||24170|
NCT02507024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRC 5537|The ANCA Vasculitis Questionnaire (AAV-PRO©)|The ANCA Vasculitis Questionnaire (AAV-PRO©)|AAV-PRO|University of Pennsylvania|No|Active, not recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with AAV participating in the V-PPRN.|October 2015|October 19, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02507024|3 Months|16383|
NCT02509299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0055UG|Effect of Physiotherapy on Perceived Health Status in Hospitalized COPD Patients|Effect of Different Physiotherapy Treatments on Perceived Health Status in Hospitalized COPD Patients||Universidad de Granada|Yes|Recruiting|May 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|N/A|No|||December 2015|December 3, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02509299||16209|
NCT02394327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-MDB-11-318|Endoscopic Nasogallbladder Drainage Versus Gallbladder Stenting Before Cholecystecomy|Endoscopic Naso-gallbladder Drainage Versus Gallbladder Stenting Before Elective Cholecystectomy in Patients With Acute Cholecystitis and a High Suspicion of Common Bile Duct Stone; A Prospective Randomized Preliminary Study||Ajou University School of Medicine||Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|20 Years|N/A|No|||January 2016|January 4, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02394327||25036|
NCT02394340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1012|Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris|An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris||Bausch & Lomb Incorporated|No|Recruiting|February 2015|July 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394340||25035|
NCT02400632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGIC TOUCH|MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions|Assessment of the Novel MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions|MAGIC-TOUCH|Scitech Produtos Medicos Ltda|No|Recruiting|June 2015|December 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400632||24551|
NCT02400905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID-100|Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System|MIMICS-2: Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System in the Femoropopliteal Arteries of Patients With Symptomatic Peripheral Arterial Disease|MIMICS-2|Veryan Medical Ltd.|Yes|Recruiting|June 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Both|19 Years|85 Years|No|||January 2016|January 21, 2016|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400905||24530|
NCT02508233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-130|Cross-cultural Adaptation and Validation of the Ankle Osteoarthritis Scale (AOS) for Use in French-speaking Populations|Cross-cultural Adaptation and Validation of the Ankle Osteoarthritis Scale (AOS) for Use in French-speaking Populations||Université de Sherbrooke|No|Completed|September 2009|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The "Test of the Pre-final version" will be performed using subjects with no ankle        osteoarthritis who will answer the questionnaire and evaluate their comprehension of each        item.        Patients with isolated ankle degenerative changes at the orthopaedic outpatient clinic of        the Centre Hospitalier Universitaire de Sherbrooke (CHUS) will be used to validate the        questionnaire. Patients have to consider French as their mother tongue and be able to read        and write in French. Patients under 18 years old and those with additional foot and/or        ankle pathologies will be excluded.|July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508233||16290|
NCT02508246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9168|AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck|A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC)||University of Washington|No|Recruiting|August 2015|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2015|October 6, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508246||16289|
NCT02501928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221109|Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.|Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047||Pfizer|Yes|Recruiting|June 2015|June 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|9|||Both|6 Years|17 Years|No|||March 2016|March 23, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02501928||16775|
NCT02501941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-056|Spreading Depolarization and Ketamine Suppression|Spreading Depolarization and Ketamine Suppression|SAKS|University of New Mexico|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|90 Years|No|||July 2015|July 15, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501941||16774|
NCT02398461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM22-MS-1033|An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse|A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse||Acorda Therapeutics|Yes|Recruiting|April 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|March 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02398461||24718|
NCT02400918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WilfridLU|Self-help for Treating Social Anxiety Disorder: An Evaluation of a Mindfulness and Acceptance-based Approach|||Wilfrid Laurier University||Recruiting|March 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400918||24529|
NCT02401191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXHYL07477|A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis|A Non-controlled, Open Study for Assessing the Safety and Effectiveness of a Twice-daily FEX 60 mg - PE 10 mg (FEX60/PE10) Fixed Combination Tablet in Patients With Allergic Rhinitis||Sanofi|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|15 Years|N/A|No|||November 2015|November 26, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401191||24508|
NCT02496390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB ID106715|Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD|Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease|FMT|Lawson Health Research Institute|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496390||17200|
NCT02496403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1592-H|Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence|Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence||Kaiser Permanente|No|Recruiting|December 2015|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496403||17199|
NCT02498327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XoliswaRoseMazibuko200729488|The Efficacy of Venavine Intensive® on the Quality of Life in Females With Chronic Venous Insufficiency|The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 on the Quality of Life in Females With Chronic Venous Insufficiency||University of Johannesburg|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02498327||17052|
NCT02394652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXMET1|The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial|The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial||University Health Network, Toronto|Yes|Recruiting|May 2015|May 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394652||25011|
NCT02409953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5979|Effect of Immersion, Performed Under the Conditions of Obstetrical Dilatation Bath, on Diuresis and Hemodynamic Variables in Young Women|Effect of Immersion, Performed Under the Conditions of Obstetrical Dilatation Bath, on Diuresis and Hemodynamic Variables in Young Women|IMMERSION|University Hospital, Strasbourg, France|No|Recruiting|April 2015|||October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409953||23838|
NCT02421913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCampinas|Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain|Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain: a Randomized Controlled Trial||Centro Medico Campinas|Yes|Completed|June 2012|February 2015|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421913||22919|
NCT02397044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 7438|"Prospective Evaluation of Immediate & Early Loading of Zimmer Hydroxyapatite Coated Dental Implants"|Immediate and Early Loading of Hydrothermally Treated, Hydroxyapatite-Coated Dental Implants:a Controlled Randomized Prospective Clinical Study||Louisiana State University Health Sciences Center in New Orleans|No|Active, not recruiting|December 2010|December 2017|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers over the age of 18 needing a tooth replacement.|March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397044||24827|
NCT02397057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT14037|Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS|A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)||Luitpold Pharmaceuticals|No|Recruiting|January 2015|November 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397057||24826|
NCT02395198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12748|Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients|Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients: Factors Influencing Treatment Initiation and Seroconversion|ECHO|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|August 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Opioid dependent outpatients in opioid substitution treatment regardless of treatment        setting|January 2016|January 23, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395198|12 Months|24969|
NCT02417155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INADRI|Increasing Plasma Adrenaline Levels Through Breathing Techniques - an Explorative Study|Increasing Plasma Adrenaline Levels Through Breathing Techniques - an Explorative Study|INADRI|Radboud University|No|Completed|November 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02417155||23284|
NCT02422784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2013:045|Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals|A Double-Blind, Randomized, Control Study to Examine the Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals.|VITD-2013|University of Manitoba|No|Not yet recruiting|July 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|65|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02422784||22852|
NCT02407197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-T1-MC|International T1 Multicentre CMR Outcome Study in Patients With Nonischaemic Cardiomyopathies|International T1 Multicentre CMR Study|T1-CMR|King's College London|No|Recruiting|January 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients fulfilling criteria of NICM in the absence of CAD and/or infarct-type LGE OR        Subjects with high pretest probability for cardiomyopathy.|March 2015|March 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407197|1 Year|24050|
NCT02407210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-AQST-2014|Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension|A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension||Jiangsu HengRui Medicine Co., Ltd.||Recruiting|January 2015|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|70 Years|No|||January 2015|March 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407210||24049|
NCT02411253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121001|Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes|European Phase-IIb Clinical Trial Evaluating Efficacy of Low Dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes DIABIL-2|DIABIL-2|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|12 Years|35 Years|No|||February 2016|February 15, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02411253||23738|
NCT02411526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX003-1401|Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia|An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder||Zogenix, Inc.|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|60 Years|No|||July 2015|September 16, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411526||23717|
NCT02426346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DK10098101A1|A Scalable Weight Control Intervention for Adolescents|TEEN JOIN: A Scalable Weight Control Intervention for Adolescents|TEEN JOIN|The Miriam Hospital|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426346||22578|
NCT02426359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q301-ADP2-US-01|Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients|||Qurient Co., Ltd.|No|Active, not recruiting|April 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426359||22577|
NCT02415309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2015.0048|Premedication With Melatonin in Lumbar Medial Branch Block Procedure|Premedication With Melatonin vs. Placebo in Patients Undergoing Interventional Pain Procedure||United States Naval Medical Center, San Diego|Yes|Not yet recruiting|February 2016|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|50 Years|No|||January 2016|January 14, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02415309||23426|
NCT02401828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51858.078.14|The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial|The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial|DOMONO|Erasmus Medical Center|No|Recruiting|March 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401828||24459|
NCT02401841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Policlinico 12|Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex|Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex||Policlinico Hospital||Recruiting|January 2015|||March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Great obese patients undergoing videolaparoscopic surgery|October 2015|October 19, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02401841||24458|
NCT02422017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2014_843_0022|Topical Timolol Benefit in Venous Ulcers|Topical Timolol Benefit in Venous Ulcers|EETUV|Centre Hospitalier Universitaire, Amiens|No|Not yet recruiting|April 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422017||22911|
NCT02422030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146DDI14030|CKD-337(2) Drug-drug Interaction Study|A Randomized, Open-label, Multiple Dosing, 3-way Crossover Study to Evaluate the Drug-drug Interaction Between Atorvastatin and Fenofibric Acid in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Recruiting|March 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|30|||Male|19 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 20, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02422030||22910|
NCT02411812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HASA|Effects of the Herbst Appliance With Skeletal and Dental Anchorage in Lower Incisors in Class II Malocclusion|Effects of the Herbst Appliance With Skeletal Anchorage and Dental Anchorage in Lower Incisors in Class II Malocclusion: A Randomized Clinical Trial|HASA|Rio de Janeiro State University|No|Recruiting|August 2015|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|14 Years|No|||August 2015|August 13, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02411812||23695|
NCT02419209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LindaMcGrath201016316|The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause|The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause||University of Johannesburg|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02419209||23127|
NCT02415751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|742726-1|The Impact of a Heart Failure Review on Self-Care Knowledge, Adherence and Clinical Outcomes|The Impact of a Heart Failure Review on Self-Care Knowledge, Adherence and Clinical Outcomes||Creighton University|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|N/A|No|Non-Probability Sample|adults ages 19 and older with heart failure|March 2016|March 3, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02415751||23392|
NCT02415764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MH105013-01|OnTrack>An Online Role-Playing Game|OnTrack>An Online Role-Playing Game||Center for Social Innovation, Massachusetts||Not yet recruiting|June 2015|||September 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|38|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|April 13, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02415764||23391|
NCT02408107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID800|A Home-based Physical Activity Intervention in Breast Cancer Survivors|Randomised Controlled Trial of a Home-based Physical Activity Intervention in Breast Cancer Survivors|PHAB|Dudley Group NHS Foundation Trust|No|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Female|18 Years|N/A|No|||April 2015|April 12, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02408107||23980|
NCT02415634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GilmartinSept2014|REhabilitation After Critical Illness Assisted Discharge Pack (RECAP)|Investigation of Physiotherapy Led ICU Discharge Facilitation Using the REhabilitation After Critical Illness Assisted Discharge Pack (RECAP) Model; a Pilot Randomized Controlled Trial.|RECAP|St Vincent's University Hospital, Ireland|No|Completed|November 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2015|November 16, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02415634||23401|
NCT02416180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201909|Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler|An Open-label Study Investigating Critical and Overall Errors Following 14 Days of Treatment With SERETIDE Metered Dose Inhaler (EVOHALER) in Adult Subjects With Controlled Asthma Currently Using the SERETIDE DISKUS Inhaler||GlaxoSmithKline|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416180||23359|
NCT02416414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST007_10|Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients|||QIAGEN Gaithersburg, Inc|No|Recruiting|July 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|215|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who have either received a solid organ transplant or who are healthy.|January 2016|January 26, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416414||23341|
NCT02400151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/APM-01|Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents|Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents: Prospective, Randomized, Controlled Trial|VIDADO|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|66|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400151||24588|
NCT02400164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-AAR-007|A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites|A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites|MOSAIC|Sequana Medical AG||Recruiting|March 2015|November 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||January 2016|January 6, 2016|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400164||24587|
NCT02507583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJU-14379-102|Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma|Phase I Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide (IGF-1R/AS ODN) in 32 Patients With Newly Diagnosed Malignant Glioma||Thomas Jefferson University|No|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507583||16340|
NCT02405234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-RH-002|Ascension PyroCarbon Radial Head Study|Safety and Effectiveness Study of Ascension PyroCarbon Radial Head Compared to Ascension Metal Radial Head|CMRH|Integra LifeSciences Corporation|Yes|Active, not recruiting|January 2009|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|203|||Both|18 Years|85 Years|No|||March 2016|March 23, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405234||24199|
NCT02409836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000393|A Study to Assess the Ingestion of Dentifrice by Children|A Study to Assess the Ingestion of Dentifrice by Children||Procter and Gamble|No|Completed|May 1993|July 1993|Actual|July 1993|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|90|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02409836||23847|
NCT02409849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJT-NEC-002|Octreotide LAR as Maintenance Treatment for Patients With NEC|Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas||Peking University|No|Not yet recruiting|April 2015|June 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|N/A|N/A|No|||April 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409849||23846|
NCT02395328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-674-A-12-00002-FFGS|Home Visiting for OVC in Tshwane Townships of South Africa|The Impact of Future's Families Orphans and Vulnerable Children Home Visiting Program in Tshwane Townships of South Africa||Tulane University School of Social Work|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|483|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02395328||24959|
NCT02503891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-01|AL-2 MP-1 (Polyimide) Acetabular Liner|Total Hip Replacement - MP-1 Acetabular Liner||M.M.A Tech Ltd.|No|Not yet recruiting|September 2015|April 2019|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 18, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02503891||16624|
NCT02399280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-106|Effect of High Caloric Intake at Lunch Against Dinner on Weight Loss|Effect of High Caloric Intake at Lunch Against Dinner on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program, a Randomized Clinical Trial||Novindiet Clinic|No|Enrolling by invitation|February 2015|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399280||24655|
NCT02399293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnrc_nback|Computer-based Attention Training in Patients With Acquired Brain Injury|Computer-based Attention Training in Patients With Acquired Brain Injury||University of Aarhus|No|Completed|April 2013|September 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|78|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02399293||24654|
NCT02401984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0575|Zurcher Adolescent Screening for Mental Disorder|Zürcher Adoleszenz-Screening-Instrument Psychischer Störungen|ZASMD|Zurich University of Applied Sciences|No|Recruiting|March 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|16 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited in Institutions Coaching unemployed Young People.|March 2015|March 27, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02401984||24447|
NCT02401997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2011-110|The Effect of the Sexual Abstinence Period on the Production of Reactive Oxygen Species in Patients Who Planned to Take Part in Intrauterine Insemination|||Gazi University||Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|90|||Male|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02401997||24446|
NCT02508103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1153|Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study|Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study||University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508103||16300|
NCT02495194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-15-016|Effects of Horticultural Therapy on Asian Elderly' Mental Health|Effects of Horticultural Therapy on Asian Elderly' Mental Health: A Randomized Controlled Trial|HTRCT|National University, Singapore|No|Active, not recruiting|April 2015|May 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|69|||Both|60 Years|85 Years|No|||December 2015|December 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02495194||17292|
NCT02495207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OMFS-03-2015|A Comparison Between Conventional Surgery and Piezosurgery|A Histo-immunological Comparative Study of Bone Cutting by Conventional Surgery and Piezosurgery on the Secretion of Heat Shock Protein 70 (HSP70) and on the Bone Cells||Damascus University|Yes|Recruiting|June 2014|January 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|16 Years|35 Years|No|||March 2016|March 15, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02495207||17291|
NCT02495441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROM|Rapid Immunoassay Tests for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes||De Soysa Hospital for Women|No|Recruiting|August 2015|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|The study population includes the pregnant mothers presenting to the De Soysa Hospital for        Women, Colombo with alleged leakage of amniotic fluid. This is an urban population with        multiple ethical back grounds.|July 2015|August 6, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02495441||17273|
NCT02405741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238/14|Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients|Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)?||Assaf-Harofeh Medical Center|No|Recruiting|March 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405741||24160|
NCT02394600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEU-MERCK 001|The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation|The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation||Queen's University|No|Active, not recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394600||25015|
NCT02393794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-CL-PI-002783|Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)|Phase I/II Trial of Cisplatin Plus Romidepsin in Locally Recurrent or Metastatic Triple Negative Breast Cancer or BRCA1 or BRCA2 Mutation Associated Locally Recurrent or Metastatic Breast Cancer.||University of Kansas Medical Center|Yes|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|54|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393794||25077|
NCT02393807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7411002|The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation|A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects||Pfizer|No|Withdrawn|June 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393807||25076|
NCT02396108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/01282|Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer|Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer||National University Hospital, Singapore|No|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|21 Years|N/A|No|||March 2015|March 17, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02396108||24899|
NCT02505763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7418 15|Thoracic Ultrasound in the Treatment of Pleural Effusion|Treatment of Pleural Effusion by Routine Thoracic Ultrasound|ECHOPLEV|University Hospital, Toulouse|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505763||16480|
NCT02505776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-089|Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan|||Allergan|No|Recruiting|December 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with eyelash hypotrichosis|January 2016|January 22, 2016|July 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505776||16479|
NCT02399826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers||Lower Extremity Institute for Research and Therapy|No|Recruiting|March 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399826||24613|
NCT02399839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR- 733-027|Global Lomitapide Pregnancy Exposure Registry|Global Lomitapide Pregnancy Exposure Registry||Aegerion Pharmaceuticals, Inc.|Yes|Enrolling by invitation|October 2014|March 2028|Anticipated|March 2028|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|30|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant Females|October 2014|January 13, 2016|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02399839|2 Years|24612|
NCT02402244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC14B1|Project: Every Child for Younger Patients With Cancer|The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study||Children's Oncology Group|Yes|Recruiting|October 2015|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|33000|Samples With DNA|tissue, blood, bone marrow, plasma, serum, buccal cells, saliva, cerebrospinal fluid, or      urine|Both|N/A|25 Years|No|Non-Probability Sample|Patients with relapsed solid tumors, lymphomas and Central Nervous System (CNS) tumors.|September 2015|October 29, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402244||24427|
NCT02402257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00089190|Central Venous Catheter Insertion Train the Trainer|Dissemination of a Simulation-based Mastery Learning Curriculum for Central Venous Catheter Insertion at Veterans Affairs Hospitals: A Quantitative Study||Northwestern University|No|Enrolling by invitation|January 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|100000|||Both|18 Years|N/A|No|Non-Probability Sample|1. Trainees undergoing simulation-based mastery learning for CVC insertion          2. De-identified patient information from patients with a CVC.|January 2016|January 8, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402257||24426|
NCT02406079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ-001|Impact of Tracheotomy on Procalcitonin|Impact of Tracheotomy on Levels of Serum Procalcitonin in Patients Without Sepsis: a Prospective Study||First People's Hospital of Chenzhou|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406079||24134|
NCT02503020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ayham|Arachidonic Acid Supplementation in Very Preterm Infants|Effects of Different Arachidonic Acid Supplementation on Psychomotor Development in Very Preterm Infants, a Randomized Controlled Trial||Health Research Institute of Santiago|No|Completed|July 2011|March 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Actual|45|||Both|N/A|2 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02503020||16691|
NCT02507596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanobone_IBD|Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in Management of Periodontal Intrabony Defects|Clinical and Radiographic Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in the Treatment of Human Periodontal Intrabony Defects: A Randomized Controlled Clinical Trial||Cairo University|No|Recruiting|April 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507596||16339|
NCT02406261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16014|A Drug-drug Interaction Study of AZD3293 (LY3314814) in Healthy Participants|A Study to Characterize AZD3293 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of AZD3293 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects||Eli Lilly and Company|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406261||24121|
NCT02406222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13/10758|Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)|Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)|MUK seven|University of Leeds|Yes|Not yet recruiting|September 2015|September 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02406222||24124|
NCT02497924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBT440-002|A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects|A Phase 1 Study to Investigate Absorption, Metabolism, and Excretion After Establishment of Steady State Via GBT440 Loading and Maintenance Dosing Followed by a Single Oral Dose Administration of [14C]-GBT440 in Healthy Male Subjects||Global Blood Therapeutics|No|Active, not recruiting|June 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|7|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497924||17083|
NCT02507674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062947|Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study|Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study||Duke University|No|Not yet recruiting|August 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|Potential subjects must be 0-18 years of age, presenting to the pediatric emergency        department for evaluation of right lower abdominal pain and suspected appendicitis. The        clinical diagnostic plan before subject enrollment must include abdominal ultrasound        and/or abdominal CT.|July 2015|July 23, 2015|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507674||16333|
NCT02507687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-093|Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Recruiting|August 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507687||16332|
NCT02406404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2013-0031|Change of Pulmonary Function After Incentive Spirometer Training in Children With Cerebral Palsy|||Yonsei University|No|Recruiting|August 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|45|||Both|4 Years|18 Years|No|||March 2015|March 29, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02406404||24111|
NCT02406417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTFPI2015|Reflective Testing for Early Diagnosis of Pituitary Dysfunction|The Use of Reflex Strategies and Reflective Testing in the Clinical Chemistry Laboratory for Early Detection of Pituitary Dysfunction in Patients From Primary Care.||Nova Scotia Health Authority|Yes|Not yet recruiting|August 2015|April 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|16 Years|N/A|No|||March 2015|March 30, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02406417||24110|
NCT02410460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MercyFPSC|Anesthetics in Rhytidoplasty - A Comparison Study|The Use of Propofol/Ketamine Anesthesia With Bispectral Monitoring (PKA-BIS) Versus Inhalational Anesthetics in Rhytidoplasty - A Prospective, Double-blinded, Randomized Comparison Study||Mercy Facial Plastic Surgery Center|Yes|Completed|September 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|30|||Female|18 Years|N/A|No|||April 2015|April 6, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02410460||23799|
NCT02410512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29674|A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors|A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 AND MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS||Genentech, Inc.||Recruiting|April 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410512||23795|
NCT02494895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0066|Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)|||Yonsei University|Yes|Not yet recruiting|July 2015|July 2020|Anticipated|May 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3056|||Both|19 Years|79 Years|No|||July 2015|July 7, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02494895||17315|
NCT02495168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT-2015-075-0AA|Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients|A Randomized, Parallel Group, Placebo-controlled, Multi-dose, Study Comparing the Generic Budesonide/Formoterol 4.5 mcg to Symbicort® 80/4.5 in Adult Asthmatic Patients||Actavis Inc.|No|Not yet recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1200|||Both|16 Years|75 Years|No|||July 2015|July 10, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495168||17294|
NCT02509351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POMCS|Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section?|Randomized, Placebo-controlled Double Blind Study of Preoperative Misorostol for Reduction of Intraoperative Bleeding in Women Delivered by Ceserean Section||Ain Shams University|Yes|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|40 Years|No|||February 2016|February 17, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02509351||16205|
NCT02500862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2015-08|Characterization of Potential Biomarkers of Eye Disease and Vision|Characterization of Potential Biomarkers of Eye Disease and Vision Loss.|EYE-MARKER|Association for Innovation and Biomedical Research on Light and Image|No|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Any patient followed under the normal clinical practice at AIBILI Clinical Trial Centre,        and with a AIBILI signed informed consent form for data collection, Imp. 11-7-2        "Consentimento Informado para tratamento de dados".|January 2016|January 18, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02500862|10 Years|16857|
NCT02408861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00461|Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors|A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|August 2015|||December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|19 Years|N/A|No|||February 2016|March 11, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408861||23922|
NCT02408874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150104|Inhaled Nanosilver Study|Study to Assess the Impact of Inhaled Silver Nanoparticles on Lung Cell Immune Response||National Institutes of Health Clinical Center (CC)||Not yet recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02408874||23921|
NCT02408965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP Trial 2015|Uterotonic Prophylaxis Trial||UPT|University of California, San Francisco|Yes|Recruiting|March 2015|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|284|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408965||23914|
NCT02395523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-15-042|Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma|A Phase II Study Using Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma||National Cancer Center, Korea|No|Recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395523||24944|
NCT02400931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0036|The Necessity of Routine Mask Ventilation in Adults|||Yonsei University|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|288|||Both|20 Years|N/A|No|||January 2016|January 26, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400931||24528|
NCT02506868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-066-2|Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients|Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis||Biocad|No|Not yet recruiting|September 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|75 Years|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506868||16395|
NCT02506881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-066-1|Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers|International Multicenter Comparative Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Safety of BCD-066 and Aranesp® After Single Subcutaneous and Intravenous Injection in Healthy Volunteers.||Biocad|No|Completed|March 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02506881||16394|
NCT02509130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2015/15|MISSION Severe Asthma Modern Innovative Solutions to Improve Outcomes in Severe Asthma.|MISSION Severe Asthma: Modern Innovative Solutions to Improve Outcomes in Severe Asthma. A Mixed Methods Observational Comparison of Clinical Outcomes in MISSION Versus Current Care Delivery.|MISSION|Portsmouth Hospitals NHS Trust|No|Recruiting|June 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants with uncontrolled or potentially severe asthma identified from GP records by        the MISSION team and new referrals to an asthma specialist clinic at Queen Alexandra        Hospital between May and August 2014.        Study participants for qualitative interview will be recruited from patients who attended        MISSION SAAC days and staff who attended MISSION RAAC or SAAC days.|July 2015|July 23, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02509130||16222|
NCT02408978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXP005-002|Pilot Study of OXP005 to Assess Gastroduodenal Irritation|||Oxford Pharmascience Ltd||Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|March 31, 2015||||No||https://clinicaltrials.gov/show/NCT02408978||23913|
NCT02393755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 265514|Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer|A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer||Roswell Park Cancer Institute|Yes|Recruiting|May 2015|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393755||25080|
NCT02395835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-06-2009|Methylation of the PPARg Promoter Region in Pregnancy|Methylation Evaluation of the PPARg Promoter Region (-351 to -260) in Pregnancy||Materno-Perinatal Hospital of the State of Mexico|No|Completed|September 2009|March 2011|Actual|August 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|41|Samples With DNA|Leukocytes were obtained according to the ACK-lysing buffer (LONZA) protocol. Briefly, a      peripheral blood sample was placed in EDTA tube and then centrifuged at 2500 rpm for 10 min.      All samples were kept at -80°C until further analysis.      DNA was extracted from leukocytes (4000-10,000 cells) in the MagnaPure (Roche) using the      MagNAPure LC DNA Isolation Kit 1 (Roche, Germany).|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women attended at the Maternal-Perinatal Hospital "Mónica Pretelini Sáenz".|March 2015|March 17, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02395835|1 Year|24920|
NCT02495402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT2HIV|Substance Abuse Treatment to HIV Care (SAT2HIV)|Substance Abuse Treatment to HIV Care (SAT2HIV)||RTI International|Yes|Recruiting|August 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2592|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02495402||17276|
NCT02501642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-196-1|Smart Phone Application for Postconcussion Symptom Reduction|Smart Phone Application for Postconcussion Symptoms Reduction||James A. Haley Veterans Administration Hospital|No|Active, not recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|486|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02501642||16797|
NCT02402491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISR-DAPT|Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis|Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis||Beijing Anzhen Hospital|Yes|Active, not recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||March 2015|March 27, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02402491||24408|
NCT02408367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KValens|Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study|Intensity Depended Impact of a Single Exercise Bout on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study||Klinik Valens|No|Recruiting|February 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|20|||Both|19 Years|80 Years|No|Probability Sample|Persons with multiple sclerosis holding an score of 1.5-6.0 on the Expanded Disability        Staus Ccale (EDSS)|April 2015|April 20, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408367||23960|
NCT02495649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMO-15-ES-0606-14-TLV-CTIL|Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA|Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 8, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02495649||17257|
NCT02497807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU_CCBD_TouretteS|The Pathophysiology of Tourette Syndrome: a Multimodal Study|fMRI Study on Iron Deficiency in the Pathological Mechanism of Tourette Syndrome|PTS|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Recruiting|December 2013|April 2016|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|40|None Retained|no biospecimens are to be retained|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Patients were recruited from outpatients or inpatients with Tourette syndrome.|July 2015|July 11, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02497807|1 Day|17092|
NCT02398201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7406|A Study of Bezafibrate in Mitochondrial Myopathy|A Feasibility Study of Bezafibrate in Mitochondrial Myopathy||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|64 Years|No|||October 2015|October 8, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398201||24738|
NCT02402738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH102466-01A1|Adjunctive Psychotherapy for Perinatal Bipolar Disorder|Adjunctive Psychotherapy for Perinatal Bipolar Disorder||Brown University|No|Recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02402738||24389|
NCT02404675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKTN-NSCLC-01|High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation|High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation: a Randomized, Open-label Study||Betta Pharmaceuticals Co.,Ltd.|No|Active, not recruiting|April 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|No|||July 2015|July 14, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404675||24242|
NCT02404688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015208|Ethanol and THC Effects on Simulated Driving and Related Cognition|Intravenous Ethanol and THC Effects on Simulated Driving and Related Cognition|THC-ETOH|Yale University|No|Recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404688||24241|
NCT02496156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 805|Shared Medical Decision Making in Pediatric Diabetes|Shared Medical Decision Making in Pediatric Diabetes||Nemours Children's Clinic|No|Enrolling by invitation|February 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|166|||Both|11 Years|17 Years|No|||April 2015|July 13, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02496156||17218|
NCT02496169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eucaLimus2015|Prospective multicEntric NonranDomized Registry|A Prospective, Multi-centric, Nonrandomised Interventional Study of a Sirolimus-eluting Stent With a Biodegradable Polymer for Percutaneous Coronary Revascularization|ExPEND|Eucatech AG|Yes|Not yet recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02496169||17217|
NCT02498028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBORTYC01|Clinical Outcome After Anterior Cervical Decompression and Fusion and Cervical Total Disc Replacement|Clinical Outcome After Anterior Cervical Decompression and Fusion and Cervical Total Disc Replacement||University Hospital, Bonn|Yes|Recruiting|January 2011|August 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of the University Hospital of Bonn who are suffering from neck and        cervicobrachial pain that cannot be treated anymore by conservative methods and have to        undergo surgery such as cervical fusion or cevical disc arthroplasty.|July 2015|July 14, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02498028||17075|
NCT02403011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G014/14|Investigating the Effectiveness of Mobilization on Congenital Muscular Torticollis and Deformational Plagiocephaly|A Randomized Controlled Study in the Efficiency of Soft Tissue Mobilization in Babies With Congenital Muscular Torticollis and Deformational Plagiocephaly||Hacettepe University|Yes|Recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|6 Months|No|||November 2015|November 6, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02403011||24370|
NCT02404896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00094843|Expanded Access Metreleptin Study|Expanded-Access for the Use of Metreleptin in Patients With Partial Lipodystrophy Associated With Diabetes Mellitus or Hypertriglyceridemia||University of Michigan|No|Enrolling by invitation|January 2015|January 2025|Anticipated|January 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404896||24225|
NCT02501031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCF 2014-grant|Flaxseed Intervention Study to Assess Sex Hormone Levels Among Post-Menopausal Women|Effect of Dietary Flaxseed on Circulating Sex Hormone Levels Among Post-menopausal Women - an Intervention Trial to Explore Flaxseed Intake as a Possible Breast Cancer Prevention Strategy||Cancer Care Ontario|No|Not yet recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|280|||Female|57 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501031||16844|
NCT02507713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMAFI10/14|Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS)|Ultrasound Markers for the Diagnosis, Disease Progression and Prognosis of Amyotrophic Lateral Sclerosis|ALS|Universidad Católica San Antonio de Murcia||Completed|September 2013|||April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient with Amyotrophic Lateral Sclerosis.|July 2015|July 23, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02507713||16330|
NCT02399332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-0673|Involvement of Community Pharmacists in Complex Care Plans for Diabetic Patients, a Pilot Study|A Collaborative Care Model for Chronic Disease Management in Diabetes - Involvement of Community Pharmacists in Complex Care Plans, a Pilot Study||University of Calgary|No|Not yet recruiting|April 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 22, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02399332||24651|
NCT02396303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67365|Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage|||Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Yes|Not yet recruiting|June 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396303||24884|
NCT02427243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29172|A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose|A Phase 1, Single-Dose, Randomized, Open-Label, Parallel Group Study to Assess the Relative Bioavailability and Tolerability of Two Formulations of Crenezumab in Healthy Subjects Following Subcutaneous Administration||Genentech, Inc.||Completed|April 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02427243||22509|
NCT02427256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCON-SP-1P-US-0002|Second Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements|Comparative Study of the Topcon Specular Microscope SP-1P and the Konan Specular Microscope CELLCHEK XL (Predicate Device) for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area, ％ Hexagonality, Central Corneal Thickness||Topcon Medical Systems, Inc.|No|Completed|February 2015|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|76|||Both|18 Years|80 Years|No|Non-Probability Sample|Ophthalmology Practice|December 2015|December 1, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427256||22508|
NCT02401295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201311791|ATRA, Celecoxib, and Itraconazole as Maintenance|An Open-Label Phase I Trial to Evaluate the Safety and Tolerability of ATRA, Celecoxib, and Itraconazole Administered As Maintenance Treatment Post-Autologous Transplantation in Relapsed Multiple Myeloma||University of Iowa|Yes|Recruiting|May 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401295||24500|
NCT02401308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 14BN147|Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease|Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease||St. Joseph's Hospital and Medical Center, Phoenix|No|Terminated|January 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|March 24, 2015|No|Yes|Lack of subject enrollment.|No||https://clinicaltrials.gov/show/NCT02401308||24499|
NCT02399254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-06-001 E|The Trajectory of Physical Activity Following Pulmonary Rehabilitation|The Trajectory of Physical Activity Following Pulmonary Rehabilitation||Saint Francis Care|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|40 Years|N/A|No|Non-Probability Sample|Pulmonary Rehabilitation Center|October 2015|October 29, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02399254||24657|
NCT02420925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|celblockgastro|Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis|Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis||Stanford University|No|Recruiting|October 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420925||22995|
NCT02427269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0444|UNC Barrett's Esophagus and Esophageal Cancer Biorepository|UNC Barrett's Esophagus and Esophageal Cancer Biorepository|BEECAB|University of North Carolina, Chapel Hill|No|Enrolling by invitation|May 2015|May 2025|Anticipated|May 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|Samples With DNA|-  1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection        -  Up to 10 research-specific biopsies (tissue samples) obtained from the esophagus during           the routine care EGD.        -  Pathology slides from routine care biopsies taken during the procedure|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are receiving routine care upper endoscopy at UNC and meet the eligibility        criteria detailed below.|February 2016|February 16, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427269||22507|
NCT02408081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNR-H-6-2014-109-5|Family Focused Nursing for Elderly Medical Patients|Family-Focused Nursing for Elderly Medical Patients and Their Family: A Randomized Controlled Trial||University of Southern Denmark|No|Suspended|April 2015|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|212|||Both|65 Years|N/A|No|||November 2015|November 30, 2015|March 31, 2015||No|not able to be completed|No||https://clinicaltrials.gov/show/NCT02408081||23982|
NCT02415192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ZVOS001|Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients|A Multicenter, Prospective Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Patient With Essential Hypertension||LG Life Sciences|No|Recruiting|July 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2001|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with essential hypertension|April 2015|April 13, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415192||23435|
NCT02414724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 262914|Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of CDK4/6 Inhibitor LEE011 Combined With Gemcitabine in Patients With Advanced Solid Tumors or Lymphoma||Roswell Park Cancer Institute|No|Active, not recruiting|May 2015|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414724||23471|
NCT02418468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BHK02|Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations|Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations||Novartis|No|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|40 Years|N/A|No|||June 2015|June 5, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418468||23183|
NCT02407262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6419/002|Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes|Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes||University College, London|Yes|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407262||24045|
NCT02411825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR13700|Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus||Sanofi|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411825||23694|
NCT02422862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMU.01.001|Clinical Effects of Upper Cervical Translatoric Mobilization in Patients With Headache|||Universidad de Zaragoza|No|Completed|January 2014|January 2016|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422862||22846|
NCT02423031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150109|Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress|Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|285|||Both|8 Years|21 Years|No|||March 2016|March 16, 2016|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02423031||22833|
NCT02406911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIANO6|Ticagrelor and Anti-inflammatory Effects|Relationship of Dose of Ticagrelor and Anti-inflammatory Effect in Patients With End Stage Renal Disease on Hemodialysis: PIANO-6 Randomized Crossover Study||Kyunghee University Medical Center|Yes|Recruiting|February 2015|August 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|20 Years|80 Years|No|||March 2015|March 30, 2015|March 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02406911||24072|
NCT02408120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078695|Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes|Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen||Emory University|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408120||23979|
NCT02419976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009226|Electronic Nose Identification of Fasting and Non-fasting Breath Profiles|Electronic Nose Identification of Fasting and Non-fasting Breath Profiles|Fast Breath|Mayo Clinic|No|Enrolling by invitation|February 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02419976||23068|
NCT02405390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141780|Head Motion in Pediatric Patients Endotracheally Intubated With Video Laryngoscopy Versus Direct Laryngoscopy|Comparison of Head Motion in Pediatric Patients Endotracheally Intubated With Video Laryngoscopy (Storz C-Mac®) Versus Direct Laryngoscopy||Nicklaus Children's Hospital f/k/a Miami Children's Hospital|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|N/A|8 Years|No|||August 2015|August 26, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02405390||24187|
NCT02494947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/210|Coronary Disease and the Effect of High-intensity Interval Training|Physical Activity and Lipid Content of Coronary Artery Atheromatous Plaques: a Randomised Trial Using Novel Intracoronary Imaging Techniques|CENIT|Norwegian University of Science and Technology|No|Recruiting|February 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02494947||17311|
NCT02499042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF14/2953-2014001634|rEduction of oXygen After Cardiac arresT: a Pilot Study|rEduction of oXygen After Cardiac arresT (EXACT): a Pilot Study|EXACT|Monash University|No|Recruiting|July 2015|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|209|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02499042||16997|
NCT02394028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA29144|A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease|A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE||Hoffmann-La Roche||Recruiting|March 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1250|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394028||25059|
NCT02397694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-141-1475|Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Active, not recruiting|March 2015|May 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|March 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397694||24777|
NCT02400424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 01-14|Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor|Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.|GFPC_01-14|Centre Leon Berard|Yes|Recruiting|February 2015|January 2021|Anticipated|August 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02400424||24567|
NCT02507648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 1/12/01CAREOSELT|A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)||Genuine Research Center, Egypt|No|Completed|March 2013|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507648||16335|
NCT02507661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/21|Effect of Alveolar Ridge Preservation on Implant Esthetic Outcomes|Esthetic Outcomes of Implant-supported Crowns After Alveolar Ridge Preservation With Beta Tricalcium Phosphate and Collagen in the Maxillary Esthetic Zone||University of Belgrade|No|Recruiting|June 2015|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|75|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02507661||16334|
NCT02403596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPER|Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban|Study ESPER: Blood-sparing During the Placement of a Total Hip Prosthesis With the Exacyl® in Patients Treated With Rivaroxaban, Phase IV|ESPER|University Hospital, Brest|Yes|Recruiting|October 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|219|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02403596||24325|
NCT02405325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150336|Peer Empowerment Program for Physical Activity in Low Income and Minority Seniors|PEP4PA - Peer Empowerment Program for Physical Activity in Low Income and Minority Seniors|PEP4PA|University of California, San Diego|No|Recruiting|July 2015|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|408|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02405325||24192|
NCT02497144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gazi University3|Neuromuscular Electrical Stimulation in Patients With Interstitial Lung Disease|Effects of Neuromuscular Electrical Stimulation on Functional Exercise Capacity and Quality of Life in Patients With Interstitial Lung Disease||Gazi University|No|Recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|July 10, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497144||17142|
NCT02497157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICC1414|Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer|Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer|BeTRI|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|70 Years|No|||August 2015|August 24, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02497157||17141|
NCT02499562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNI-F351-201402|A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis|Randomed and Double-blinded Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis|HBV|Shanghai Genomics, Inc.|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|65 Years|No|||May 2015|July 13, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02499562||16957|
NCT02499809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tarntula 1|The Effects of Vibration Therapy as a Recovery Tool After Intense Exercise|||Wingate Institute|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499809||16938|
NCT02394613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/0351|A Phase I Clinical Trial of DARC|A Phase I, Storer Design, Open-label, Cross-sectional, Single Site Trial of ANX776 in Healthy Volunteers, Progressive Glaucoma/Glaucoma-suspect/Ocular Hypertensive Subjects and Non-arteritic Anterior Ischaemic Optic Neuropathy Subjects||University College, London|Yes|Active, not recruiting|May 2015|January 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|December 2, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02394613||25014|
NCT02398240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-568|Brentuximab for Newly Diagnosed Hodgkin Disease|A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma||New York Medical College|No|Recruiting|May 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|1 Year|29 Years|No|||March 2016|March 23, 2016|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02398240||24735|
NCT02398253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-105|Effects of Cognitive Behavioral Therapy (CBT) on Weight Maintenance After Successful Weight Loss|Effects of Cognitive Behavioral Therapy After a Successful Weight Loss by a Comprehensive Weight Loss Plan (NovinDiet Plan) on Weight Maintenance in Healthy Obese Female Adults: a Randomized Clinical Trial||Novindiet Clinic|No|Enrolling by invitation|February 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398253||24734|
NCT02400970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0230|Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors|Study About Contamination of Testicle Tissue by RT-PCR in Children With Solid Tumors|TESTIMAR|University Hospital, Clermont-Ferrand||Recruiting|November 2014|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|40|||Male|N/A|N/A|No|Non-Probability Sample|patients treated for a solid tumor during infancy|March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400970||24525|
NCT02507830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meshg2|Mesh Fixation With a Synthetic Glue in Primary Inguinal Hernia Repair|Mesh Fixation With a Synthetic Glue in Primary Inguinal Hernia Repair||Rambam Health Care Campus|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|adults older than 18 undergoing a primary inguinal hernia repair|March 2016|March 2, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02507830||16321|
NCT02507908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500365|5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'|'5-HIAA in Urine Versus 5-HIAA in Plasma in Patients With a Serotonin Producing Neuroendocrine Tumor'|5-HIAA|University Medical Center Groningen|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|blood and urine|Both|18 Years|N/A|No|Probability Sample|60 Plasma and urine collections are used of adult patients with serotonin-producing        neuro-endocrine tumors.|October 2015|October 1, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507908||16315|
NCT02403830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 10583 IISR|Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine|Effect of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the Pharmacokinetic and Pharmacodynamic Profiles of Ticagrelor in Patients Receiving Morphine: a Prospective, Randomized Placebo-controlled Trial||University of Florida|Yes|Recruiting|August 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403830||24307|
NCT02406118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0033|Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal TME|Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal Total Mesorectal Excision||National Cancer Center, Korea|Yes|Recruiting|March 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|80 Years|No|||November 2015|November 25, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406118||24131|
NCT02406092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28964|Safety Study of Rituximab|An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL OR CD20+ Follicular NHL Grade 1 TO 3A||Hoffmann-La Roche||Not yet recruiting|March 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|80 Years|No|||May 2015|May 11, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406092||24133|
NCT02394379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|858|Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL|A Prospective, Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)||Bausch & Lomb Incorporated|No|Recruiting|March 2015|June 2021|Anticipated|March 2021|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|Subjects will be chosen from 30-50 clinical sites in the US. All subjects who meet        Eligibility Criteria (below) will be consecutively offered enrollment until the site meets        the maximum number of enrollees.|March 2016|March 24, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394379||25032|
NCT02511106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5164C00001|AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy|A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)|ADAURA|AstraZeneca|Yes|Recruiting|October 2015|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|130 Years|No|||March 2016|March 1, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511106||16070|
NCT02511132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL-121|Randomized Phase IIb Trial of Vigil™ Versus Gemcitabine + Docetaxel for Ewing's Sarcoma|Randomized Phase IIb Trial of Vigil™ (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) Versus Gemcitabine + Docetaxel for Ewing's Sarcoma||Gradalis, Inc.|Yes|Recruiting|July 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|2 Years|N/A|No|||March 2016|March 23, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511132||16068|
NCT02509169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAp53-110|Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma|Trans-catheter Arterial p53-gene-embolization Using Gelatin Sponge Particles in Treatment of Patients With Advanced Hepatocellular Carcinoma: A Phase II Study||Shenzhen SiBiono GeneTech Co.,Ltd|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||July 2015|July 23, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02509169||16219|
NCT02396836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-170|Randomised Controlled Trial (RCT) of 6 Versus 3 Steps for Hand Hygiene|Randomised Controlled Trial of the Effectiveness of Two Hand Hygiene Techniques Using Alcohol Based Hand Rub on Hand Surface Coverage and Reducing Bacterial Hand Contamination|SHoRT|Glasgow Caledonian University|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|120|||Both|N/A|N/A|No|||March 2015|March 23, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02396836||24843|
NCT02394691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/113|Effect of Repeated tDCS Sessions on Cognitive Improvement in Patients With Disorders of Consciousness|Effect of Daily Left Prefrontal Dorsolateral Transcranial Direct Current Stimulation Sessions on Cognitive Improvement in Patients With Disorders of Consciousness|rtDCS in DOC|University Hospital of Liege||Recruiting|July 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02394691||25008|
NCT02503228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002628|Clinical Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS|Clinical Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS|MTF-MOPS|University of Missouri-Columbia|No|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02503228||16675|
NCT02509286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000760|Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus|Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus|ESOPEC|University Hospital Freiburg|Yes|Recruiting|January 2016|June 2023|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509286||16210|
NCT02401646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Memory_2015|Clinical Trials for the Effects of Polygoni Multiflori Radix Complex Extract on Memory Improvement|Clinical Trials for the Effects of Polygoni Multiflori Radix Complex Extract on Memory Improvement||Korean Medicine Hospital of Pusan National University|Yes|Not yet recruiting|March 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|54|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401646||24473|
NCT02401659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T431 v 2.0|Importance of Patient´s Satisfaction With Telemedicine Based on Monitoring Systems||VALIOSA|Medtronic Bakken Research Center|No|Recruiting|May 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an implantable cardiac device and using CareLink® program for the remote        monitoring of the device.|March 2015|March 24, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02401659||24472|
NCT02395016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPL-Nim-PC-1|A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer|A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer||Biotech Pharmaceutical Co., Ltd.|No|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|75 Years|No|||June 2015|July 31, 2015|January 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395016||24983|
NCT02395302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6020|Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers|||Tactile Medical|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395302||24961|
NCT02499523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMAT003|Monocentric Study on Acetabulum Patient-specific Pin Drilling Guides|Prospective Randomised Controlled Monocentric Study on Acetabulum Patient-specific Pin Drilling Guides||Materialise|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499523||16960|
NCT02505542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS0005|Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo|A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo|C-OPTIMISE|UCB Pharma|No|Recruiting|July 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|750|||Both|18 Years|45 Years|No|||March 2016|March 18, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505542||16497|
NCT02509052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15140|Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma||City of Hope Medical Center|Yes|Recruiting|November 2015|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509052||16228|
NCT02509065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001260|The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance|The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance||Massachusetts General Hospital|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|6||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509065||16227|
NCT02400944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-047|Determinants of Bladder Cancer Recurrence Study (The DETER Study)|Determinants of Bladder Cancer Recurrence Study (The DETER Study)||Memorial Sloan Kettering Cancer Center||Recruiting|March 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Saliva and/or urine sample|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinic|March 2016|March 10, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02400944||24527|
NCT02495181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-AMD-2015-09|Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy|A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.|ATLANTIC|Association for Innovation and Biomedical Research on Light and Image|No|Recruiting|January 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||January 2016|January 18, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02495181||17293|
NCT02397655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUS-ICVD|Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study|Screening Carotid Artery and Intracranial Arteries by Ultrasound in Chinese Population With Transient Ischemic Attack and Ischemic Stroke: a Multi-center Registry Study||Xuanwu Hospital, Beijing|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|12000|||Both|40 Years|N/A|No|Probability Sample|In hospital patients with transient ischemic attack and ischemic stroke.|January 2016|January 12, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397655||24780|
NCT02397902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTexasAustin|Destiffening and Hypotensive Effects of Whole Milk and Full-fat Dairy Products|Destiffening and Hypotensive Effects of Whole Milk and Full-fat Dairy Products||University of Texas at Austin|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|80 Years|No|||June 2015|June 5, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397902||24761|
NCT02401204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODEL1402|Bacterial Transmission Dynamics Study|Bacterial Transmission Surveillance in Neonatal Intensive Care Unit: Transmission Dynamics and Drug Resistance Patterns|BTS|University of Oxford|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Stool Tracheal suction swab Rectal swab|Both|N/A|1 Month|No|Non-Probability Sample|Neonates up to one month old|October 2015|October 5, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401204||24507|
NCT02499536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0189-002|Relationship Between Atelectasis on Ultrasound and PaO2/FiO2|Relationship Between Intraoperative Atelectasis Findings on Transthoracic Lung Ultrasound and PaO2/FiO2||Severance Hospital|Yes|Recruiting|July 2015|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|26|||Both|20 Years|65 Years|No|||July 2015|July 15, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02499536||16959|
NCT02510430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0449|The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors|Randomized Controlled Trial of Sitting Time Interventions in Breast Cancer Survivors||University of Wisconsin, Madison||Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Female|N/A|N/A|No|||February 2016|February 2, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510430||16122|
NCT02510443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18097|Observational Study on Contraception With Essure in France|Survey on Use and Characteristics of Definitive Contraception With ESsure®|SUCCES II|Bayer|No|Active, not recruiting|June 2008|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2546|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patients concerned are adult women wishing to undergo tubal sterilization for        contraceptive purposes, in accordance with legal provisions, who had given their consent        for collection of the data.|January 2016|January 11, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02510443||16121|
NCT02405546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC0001|ETT Rotation During Nasal Fiberoptic Intubation|Effect of 90° Degree Counterclockwise Rotation of the Endotracheal Tube on Its Advancement Through the Larynx During Nasal Fiberoptic Intubation in Children: A Randomized and Blinded Study||Nemours Children's Clinic|Yes|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|40|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405546||24175|
NCT02397486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ph.D 20|The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients|The Impact of Pentoxifylline and Vitamin E on The Incidence and Severity of Radiotherapy- Induced Oral Mucositis and Dysphagia in Patients With Head and Neck Cancer||Ain Shams University|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397486||24793|
NCT02499783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-233|Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein||AbbVie|No|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499783||16940|
NCT02504177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0387|Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation|||Yonsei University|No|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|433|||Both|19 Years|N/A|No|||July 2015|July 19, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02504177||16602|
NCT02504190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAM|Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)|Non-interventional Study Evaluating Efficacy and Tolerance on TEAM Conditioning (Thiotepa/Etoposide/Aracytin/Melphalan) Followed by Autologous Haematopoietic Stem Cells Transplantation in Patients With Lymphoma|TEAM|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Lymphoma patients will be recruited in on the French site|August 2015|August 27, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504190||16601|
NCT02504203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG150501|Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial|Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial|BCGrural|Bandim Health Project|Yes|Recruiting|November 2015|February 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5079|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||November 2015|November 8, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02504203||16600|
NCT02405910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU020514|Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.|A Phase II Randomized Study of Nab-paclitaxel With Gemcitabine at Two Different Dose Combinations to Determine Efficacy in Patients With Advanced Non- Squamous Non-small Cell Lung Cancer (NSCLC).||West Virginia University|Yes|Withdrawn||April 2023|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|March 24, 2015|Yes|Yes|PI Left Institution|No||https://clinicaltrials.gov/show/NCT02405910||24147|
NCT02410564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10761|CBT-I Intervention for Insomnia in Newly Diagnosed Cancer Patients|Testing an Accessible Cognitive Behavioral Therapy for Insomnia (CBT-I) Intervention in Newly Diagnosed Cancer Patients||Virginia Commonwealth University|Yes|Terminated|December 2014|January 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 11, 2015||No|insufficient staff|No||https://clinicaltrials.gov/show/NCT02410564||23791|
NCT02500797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00260|Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma|Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma||National Cancer Institute (NCI)|No|Suspended|July 2015|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 15, 2015|Yes|Yes|Other - Suspension of pre-reg due to rapid accrual|No||https://clinicaltrials.gov/show/NCT02500797||16862|
NCT02506478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-3980|Juice Preference in the Emergency Department|Journey to Understand and Interpret Juice Preference in the Emergency Department|JUICED|Minneapolis Medical Research Foundation|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|All Emergency Department patients, of any age, who are cleared by their treating physician        to drink juice, and are able to communicate a juice preference.|March 2016|March 24, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02506478||16425|
NCT02503917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4342|Gynaecologic Organ Segmentation and Motion Tracking Using Ultrasound||GENIUS|Royal Marsden NHS Foundation Trust||Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteer cohort: Healthy female adult volunteers patient volunteer cohort:        Patients receiving radiotherapy for cervical cancer who will receive a planning CT scan        and daily CBCT scanning as part of their treatment.|July 2015|July 17, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503917||16622|
NCT02405832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 14-206|Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome|Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome: A Randomized, Double-blinded, Placebo-controlled Prospective Study||University of Vermont|No|Recruiting|March 2015|March 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405832||24153|
NCT02405845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSN-REB 20150092-01H|Prospective Evaluation of Carotid Free-floating Thrombus|Prospective Evaluation of Intraluminal Internal Carotid Artery Free-Floating Thrombus||Ottawa Hospital Research Institute|No|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|N/A|N/A|No|||October 2015|October 26, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02405845||24152|
NCT02408991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0553|Use Art-assist and Neupogen to Treat Chronic Limb Ischemia|Proteomics and Stem Cell Therapy as a New Vascularization Strategy||University of Chicago|Yes|Withdrawn|September 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|85 Years|No|||August 2015|August 10, 2015|March 13, 2015|Yes|Yes|PI left University|No||https://clinicaltrials.gov/show/NCT02408991||23912|
NCT02496416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-876-15|Aquatic Exercise Intervention in Multiple Sclerosis|Aquatic Exercise Intervention in Multiple Sclerosis: A Randomized Clinical Trial||Kessler Foundation|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|No|||July 2015|July 9, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496416||17198|
NCT02510716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064813|Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention|Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention: Testing the Feasibility of the Textto4gotobacco Intervention||Duke University|No|Recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 11, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02510716||16100|
NCT02510729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15005609|SPG Neurostimulation in Cluster Patients|Sphenopalataine Ganglion (SPG) Stimulation in Cluster Headache Patients||Danish Headache Center|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|N/A|N/A|No|||July 2015|July 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510729||16099|
NCT02510742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-152|Physiological Changes With SPG Stimulation in Migraine Patients|Physiological Changes Induced With SPG Stimulation in Migraine Patients - Amendment to the Pathway M-1 Trial||Danish Headache Center||Recruiting|July 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|N/A|N/A|No|||July 2015|July 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510742||16098|
NCT02404012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1410015305|Iron Supplement to Improve Iron Status Following Bariatric Surgery|Comparison of Iron Supplement Formulations to Improve Iron Status Following Roux-en-Y and Sleeve Gastrectomy Bariatric Surgery||Purdue University|No|Recruiting|November 2014|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|50 Years|No|||March 2015|March 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404012||24293|
NCT02401477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUMC-LYJ-ILA01|Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection|Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea||Il-Yang Pharm. Co., Ltd.|Yes|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|19 Years|80 Years|No|||November 2015|November 2, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401477||24486|
NCT02414542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11|Minima Clinical Study|A Multicentre, Prospective, Observational Clinical Study Evaluating the Outcomes of a Cementless Metaphyseal Short Stem After Hip Arthroplasty||Limacorporate S.p.a|No|Active, not recruiting|September 2013|August 2020|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected for recruitment into the study from the general diagnosis        population of patients requiring a primary hip arthroplasty, due to symptomatic painful        degenerative joint diseases (NDJD). Patients requiring a revision of a previous failed        stem cannot be enrolled into the clinical evaluation.|March 2016|March 1, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02414542||23485|
NCT02414802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL2014030|Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis|Study on the Application of a Novel Aspiration Thrombectomy Device Combined With Catheter-directed Thrombolysis for the Treatment of Acute Iliofemoral Deep Venous Thrombosis||Xuzhou Medical College|No|Enrolling by invitation|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02414802||23465|
NCT02407132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203482|Family Model of Diabetes Self-Management Education in the Marshallese Community|Family Model of Diabetes Self-Management Education in the Marshallese Community||University of Arkansas|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407132||24055|
NCT02419131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140339H|Cognitive-Behavior Therapy for Posttraumatic Headache|Coalition to Alleviate PTSD: Randomized Clinical Trial of Cognitive-Behavior Therapy for Posttraumatic Headache||Wake Forest School of Medicine|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|285|||Both|18 Years|70 Years|No|||February 2016|February 8, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02419131||23133|
NCT02426255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0207(1)|Post Traumatic Critical Complications: a Prospective Cohort Study (ATLANREA)|Prospective Cohort of Severe Trauma Patients Hospitalized in West French Intensive Care Units||Nantes University Hospital|No|Recruiting|February 2013|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples Without DNA|Plasma, sera, peripheral blood mononuclear cells, RNA|Both|15 Years|N/A|No|Non-Probability Sample|Patients hospitalized in ICU for severe trauma|March 2016|March 16, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426255||22585|
NCT02426268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORE-SIGHT 13-000448|FORE-SIGHT Tissue Oximeter During Cardiac Surgery|CAS Medical Systems FORE-SIGHT Elite Tissue Oximeter During Cardiac Surgery|FORE-SIGHT|University of California, Los Angeles|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|Cardiothoracic surgical population at UCLA|December 2015|December 1, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426268||22584|
NCT02426281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-061|Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma||Samsung Medical Center|No|Not yet recruiting|May 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02426281||22583|
NCT02415075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060.007.15.00-3.005-JUB|Prevention of Reduced Employability With an Expert System With Telephone, Motivational Interviews Supporting Self-management|Experten-Prävention Bei gefährdeter Erwerbsfähigkeit Durch Telefonische, Motivierende Interviews Zur Unterstützung Des Selbstmanagements|EXPERTIS|Jacobs University Bremen gGmbH|No|Recruiting|October 2014|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|926|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|In the study insurants of the Deutsche Rentenversicherung Oldenburg-Bremen with a granted        medical rehabilitation treatment will be asked to fill out a questionnaire when arriving        at the rehabilitation clinic as well as to take part in two subsequent telephone        interviews after 6 and 12 months.|April 2015|April 8, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02415075||23444|
NCT02397070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Federal University of Ceara|Effectiveness of a Jaw Exercise Program in Temporomandibular Disorders Patients|Effectiveness of a Jaw Exercise Program in Temporomandibular Disorders Patients||Universidade Federal do Ceara|Yes|Recruiting|January 2015|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|20 Years|45 Years|No|||March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397070||24825|
NCT02397083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0944|Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer|Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|September 2015|||September 2026|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397083||24824|
NCT02419638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000242|Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS|||Brigham and Women's Hospital|Yes|Withdrawn|May 2015|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|65 Years|No|Probability Sample|This is a single center study conducted at the Partners Multiple Sclerosis Center.        Patients who are planning to start a new disease modifying treatment for        relapsing-remitting MS will be offered enrollment in this study of two commonly used MS        treatments by their treating physician. Potential subjects will undergo        inclusion/exclusion review by the study nurse. Those meeting criteria will be enrolled by        overall study PI or treating physician. Subjects will be identified from the Partners MS        Center at the Brigham and Women's Hospital. Potential subjects will initially be        approached by their treating physician concerning the study.|February 2016|February 26, 2016|April 14, 2015||No|Collaborative decision between study PI and sponsor.|No||https://clinicaltrials.gov/show/NCT02419638||23094|
NCT02419651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyst 3|Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy|Tramadol Versus Diclofenac for Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial||Cairo University|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|210|||Female|20 Years|50 Years|No|||January 2016|January 26, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419651||23093|
NCT02418949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00078099|Altering Activation Patterns Post-stroke|Altering Activation Patterns in the Distal Upper Extremity After Stroke||Rehabilitation Institute of Chicago|No|Not yet recruiting|September 2015|October 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|21 Years|80 Years|No|||April 2015|April 13, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02418949||23146|
NCT02425397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00405-34|Cancer and Hearing Loss Related in Children|Cancer and Deafness Associated With the Use of Platinum Derivatives in Children|OTOPLAT|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2011|March 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|103|Samples With DNA|Saliva|Both|4 Years|N/A|No|Non-Probability Sample|180 patients will be included : 60 patients with grade 3 or 4 Brockototoxicityand 120        patients controls with no signs of ototoxicity (separate complete audiograms for each ear)|April 2015|April 23, 2015|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02425397||22651|
NCT02408159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6041|Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy|A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy||Innovaderm Research Inc.|No|Suspended|October 2016|June 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|50 Years|N/A|No|||June 2015|June 9, 2015|March 31, 2015|No|Yes|Study has been put on hold until 2016|No||https://clinicaltrials.gov/show/NCT02408159||23976|
NCT02415400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-316|Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention|An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention||Bristol-Myers Squibb|Yes|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|4600|||Both|18 Years|95 Years|No|||March 2016|March 15, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415400||23419|
NCT02411916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QHC11-237|Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery|Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery||New York City Health and Hospitals Corporation|No|Recruiting|April 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411916||23687|
NCT02411929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-020|A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)|A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence, Study to Assess the Absolute Bioavailability and Fraction Absorbed of Ertugliflozin in Health Male Subjects Using a 14^C-Microdose Approach||Merck Sharp & Dohme Corp.|No|Completed|October 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 3, 2015|No|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT02411929||23686|
NCT02396134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13494|Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant|A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant||City of Hope Medical Center|Yes|Recruiting|May 2015|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|96|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396134||24897|
NCT02394834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panitumumab-4004|An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer.|An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Phase III, Randomized, Controlled Study Comparing the Efficacy and Safety of mFOLFOX6 + Bevacizumab Therapy vs. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Wild-type RAS(KRAS/NRAS) Unresectable Advanced or Recurrent Colorectal Cancer||Takeda|No|Recruiting|May 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|800|||Both|20 Years|79 Years|No|||August 2015|August 3, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394834||24997|
NCT02394847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14835|Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose ?|Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose?||Ankara University|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|10|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02394847||24996|
NCT02412111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-109|A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor|A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|N/A|No|||January 2016|January 11, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412111||23672|
NCT02416362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTB2014|Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris and Balance|Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris and Balance of Healthy Women: a Randomized Controlled Trial||Universidade Federal do Rio Grande do Norte|No|Completed|August 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|60|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02416362||23345|
NCT02420418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULondrina|The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers|The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers in Patients With Tobacco Use Disorders and Bipolar Disorders ..|nac|Universidade Estadual de Londrina|Yes|Not yet recruiting|July 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02420418||23034|
NCT02496650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234|Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU|Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study||Bogomolets National Medical University|No|Completed|January 2013|June 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02496650||17180|
NCT02499055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FearFighter-RHP2015|A Randomised Feasibility Trial With Internet Based Self-help Therapy|Internet Based Self-help Therapy With FearFighter™ Versus no Intervention for Anxiety Disorders in Adult Persons: a Randomised Feasibility Trial|IBT|Mental Health Services in the Capital Region, Denmark|Yes|Recruiting|August 2015|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02499055||16996|
NCT02499315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110247|Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis||Amgen|No|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Female|25 Years|70 Years|No|||November 2015|November 6, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499315||16976|
NCT02398981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004429|Implementation of a Web Based Real Time Clinical Decision Support Tool.|Design and Pilot Implementation of a Web Based Real Time Clinical Decision Support Tool. (Checklist for Early Recognition and Treatment of Acute Illness in Pediatrics. CERTAINp|CERTAINp|Mayo Clinic|Yes|Active, not recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|720|||Both|N/A|17 Years|No|||March 2015|March 20, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02398981||24678|
NCT02399267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST-001|Frequency of Screening and SBT Technique Trial|The Frequency of Screening and SBT Technique Trial|FAST|St. Michael's Hospital, Toronto|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|100|||Both|16 Years|N/A|No|||October 2015|October 13, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02399267||24656|
NCT02401698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36990314.4.0000.0068|Exploring Cerebellar Inhibition of the Motor Cortex in Stroke Patients|Exploring Cerebellar Inhibition of the Motor Cortex in Stroke Patients||University of Sao Paulo General Hospital|Yes|Suspended|December 2014|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|N/A|No|Non-Probability Sample|8 a 19 patients who have suffered a unilateral ischemic stroke up to 2 years and who will        undergo motor rehabilitation at the study center will be asked to participate in the study|January 2016|January 8, 2016|November 26, 2014||No|To perform a interim analyzes|No||https://clinicaltrials.gov/show/NCT02401698||24469|
NCT02508064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-054|Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet|A Two-Part Study to Evaluate the Bioavailability of BMS-626529 Administered as Prodrug BMS-663068 From Prototype Low-Dose Extended-Release Tablets (Part 1) and Prototype Multi-Particulate Formulations (Part 2) Relative to the 600 mg Extended Release Tablet in Healthy Subjects||Bristol-Myers Squibb|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|11||Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|March 4, 2016|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508064||16303|
NCT02499328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5660C00004|Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck|A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||AstraZeneca|No|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|147|||Both|18 Years|130 Years|No|||March 2016|March 18, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499328||16975|
NCT02405949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG) 86/2013|GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY|GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY: HOW TO IDENTIFY THE PATIENTS IN WHICH BARIATRIC SURGERY WILL FAIL?|OBEGEN|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|July 2013|March 2015|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|100|Samples With DNA|Blood sample|Female|18 Years|60 Years|No|Probability Sample|The trial aimed to recruit a total of 100 female subjects who underwent a gastric bypass        in our cente with more than one year of monitoring. These 100 subjects were distributed        into 4 subgroups according to the percentage of excess weight loss (%EWL) and the presence        or absence of type 2 diabetes before surgery:        15 women with %EWL <40% without diabetes 15 women with <40%EWL with type 2 diabetes 35        women with a %EWL> 75% without comorbidities 35 women with a %EWL> 75% with type 2        diabetes|March 2015|March 31, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02405949||24144|
NCT02410174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-11|To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors|Phase I Trial of Stereotactic Body Radiotherapy (SBRT) of the Primary Tumor in Renal Cell Carcinoma (RCC)||Beth Israel Medical Center|No|Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410174||23821|
NCT02501291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD201501|Thalidomide in Treating Crohn's Disease|Thalidomide in Inducing and Maintaining Remission of Crohn's Disease||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02501291||16824|
NCT02507323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34665: Ticagrelor v Prasugrel|Ticagrelor vs. Prasugrel Effects on Infarct Size|TIPRIS: Ticagrelor vs. Prasugrel Effects on Infarct Size: A Head to Head Comparison With Prasugrel|TIPRIS|Baylor College of Medicine|Yes|Not yet recruiting|February 2016|November 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507323||16360|
NCT02399579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-HypoScore-001|Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients|Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients||University of Zurich||Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02399579||24632|
NCT02405572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.32.US.INF|Feeding Tolerance Evaluation|Feeding Tolerance Evaluation||Nestlé|No|Active, not recruiting|February 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|N/A|2 Months|Accepts Healthy Volunteers|||February 2015|October 6, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405572||24173|
NCT02405585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0605|Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer|An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer||NewLink Genetics Corporation|No|Recruiting|April 2015|April 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405585||24172|
NCT02508155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5680C00001|A Study of MEDI7352 in Painful Osteoarthritis of the Knee|A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee.||AstraZeneca|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|160|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02508155||16296|
NCT02495454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_GAEL|GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma|GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma A Phase II Study of the Fondazione Italiana Linfomi (FIL)|FIL_GAEL|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|May 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|65 Years|N/A|No|||July 2015|July 8, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02495454||17272|
NCT02495467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM53|Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)|A Randomised, Double-blind, Placebo-controlled, Home Use, Cross-over Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)||Futura Medical Developments Ltd.|No|Recruiting|July 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02495467||17271|
NCT02500056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10100|Single-centre Single-blinded Randomised Study Evaluating the Impact of Mesh Pore Size on Chronic Pain After Lichtenstein Hernioplasty|Single-centre Single-blinded Randomised Study Evaluating the Impact of Mesh Pore Size on Chronic Pain After Lichtenstein Hernioplasty||Tartu University Hospital|No|Completed|January 2011|April 2015|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02500056||16919|
NCT02406131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A. 1238|Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty|Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty: A Pilot Randomized Control Trial||National University of Ireland, Galway, Ireland|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02406131||24130|
NCT02394392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FMS-OB-401|Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)|Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient: a Prospective, Cross-sectional and Open-label 8 Week Switching Study|K-HEMS|Boryung Pharmaceutical Co., Ltd|No|Recruiting|July 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|14000|||Both|20 Years|N/A|No|Non-Probability Sample|14,000 hypertensive patients anticipated 30% of hypertensive patients who does not        satisfied their anti-hypertensive drugs|March 2014|March 19, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394392||25031|
NCT02398825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML1315|Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib|Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib||Gruppo Italiano Malattie EMatologiche dell'Adulto|Yes|Not yet recruiting|December 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02398825||24690|
NCT02501668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-005|The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease|The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease||Keimyung University Dongsan Medical Center|No|Completed|July 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||11|Actual|1375842|||Both|40 Years|N/A|No|Probability Sample|This is a retrospective cohort study based on data collected from the HIRA national        database. HIRA is a government-affiliated organization that builds an accurate claims        review and is a quality assessment system for the National Health Insurance (NHI). The NHI        is the only public medical insurance system operated by the Ministry of Health and Welfare        in Korea.        Korean Health Insurance Review and Assessment Service (HIRA) provided sample database,        spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001)        was based on random sampling of outpatients from whole population. The sample cases are        total 1,375,842. Among them 670,258 cases (age > 40) were evaluated.|July 2015|July 16, 2015|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02501668||16795|
NCT02496728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SFRN20480260|NUYou:mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health|American Heart Association Strategically Focused Research Network: mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health|NUYou|Northwestern University|Yes|Enrolling by invitation|May 2015|July 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|17 Years|26 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02496728||17174|
NCT02496741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBA|Metformin And Chloroquine in IDH1/2-mutated Solid Tumors|Phase Ib Study of Metformin and Chloroquine in IDH1/2-mutated Patients With Glioma, Intrahepatic Cholangiocarcinoma or Chondrosarcoma|MACIST|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|November 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 14, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02496741||17173|
NCT02399072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29639|An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Proxima B)|A MULTICENTER, PROSPECTIVE EPIDEMIOLOGIC STUDY OF THE PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION||Hoffmann-La Roche||Recruiting|March 2015|May 2022|Anticipated|May 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with unilateral geographic atrophy (GA) secondary to age-related macular        degeneration (AMD) or patients with GA secondary to AMD in one eye and choroidal        neovascularization (CNV; active or treated) secondary to AMD in the contralateral eye|March 2016|March 1, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399072||24671|
NCT02399085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR208C203|A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL|A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)||MorphoSys AG|No|Recruiting|December 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399085||24670|
NCT02510547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-010|Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial|||North Texas Veterans Healthcare System|Yes|Enrolling by invitation|September 2015|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510547||16113|
NCT02496975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0469-F6A|Traumatic Brain Injury and Effects of Acute Cyclosporine A|Oxidative Damage and Calcium-Activated Proteolytic Biomarkers After Traumatic Brain Injury and Effects of Acute Cyclosporine A||University of Kentucky|Yes|Active, not recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02496975||17155|
NCT02404623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR -0292-14-CTIL|The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity|The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity During the First Year of Life||Soroka University Medical Center|No|Recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|33 Weeks|37 Weeks|Accepts Healthy Volunteers|||February 2016|February 18, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02404623||24246|
NCT02400645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-132|TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain|Comparison of Laparoscopically Assisted Transversus Abdominis Plane Block Using Liposomal Bupivacaine With Pre-incisional Bupivacaine for Post-operative Pain Control in Patients Undergoing Laparoscopic or Robotic Hysterectomy|LATAP|University of Tennessee|No|Not yet recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02400645||24550|
NCT02505555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUFH-4DF|Feasibility of Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue for Assessment of Tubal Patency|Accuracy and Tolerability of Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue for Assessment of Tubal Patency||Peking University First Hospital||Recruiting|February 2013|||February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|380|||Female|N/A|N/A|No|Non-Probability Sample|Women who have infertility and try to evaluate tubal patency by 4D-HyCoSy in our hospital        will be recruited.|July 2015|July 21, 2015|July 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02505555||16496|
NCT02496988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLICIK002|Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas|A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas||The First People's Hospital of Changzhou|Yes|Not yet recruiting|July 2015|July 2030|Anticipated|July 2028|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|80 Years|No|||July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02496988||17154|
NCT02397421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002742-42|Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes|Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus|REFORM|University of Dundee|No|Recruiting|March 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397421||24798|
NCT02397642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12015|Dual Trigger Versus Booster Dose of HCG|Dual Trigger Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase||Cairo University|No|Recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|37 Years|No|||March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397642||24781|
NCT02405130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTORE-SIRIO|The RESTORE-SIRIO Randomized Controlled Trial|Impact of intRacoronary adrEnaline on Myocardial reperfuSion in STEMI paTients With Persistent Impaired cORonary Flow After pErcutaneous Coronary Intervention: the RESTORE-SIRIO Randomized Controlled Trial|RESTORE-SIRIO|Heinrich-Heine University, Duesseldorf|No|Withdrawn|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405130||24207|
NCT02499289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS FASTING|Does Prolonged Fasting Break the Vicious Circle of Polycystic Ovarian Syndrome ? SYNDROME OF INSULIN RESISTANCE|Does Prolonged Fasting Break the Vicious Circle of Polycystic Ovarian Syndrome of Insulin Resistance ?||Ain Shams University|Yes|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|• Females with PCO in child bearing age who presented at reproductive and endocrinology        clinics at Ain Shams University Maternity Hospital, and welling to fast for 30 days from 5        am until 7 pm and do not plan to induce her ovulation in the next 4 months to get        pregnant.|February 2016|February 17, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02499289||16978|
NCT02501720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2335|Comparison of Outcome of Post Burn Flexion Contracture Release Under Tourniquet Verses Tumescent Technique in Children|Comparison of Outcome of Post Burn Flexion Contracture Release Under Tourniquet Verses Tumescent Technique in Children||King Edward Medical University|Yes|Not yet recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|12 Years|No|||July 2015|July 16, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02501720||16791|
NCT02501733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121416-01|Medacta GMK Sphere® Multicenter Post-Market Outcomes Study|Medacta GMK Sphere® Medial Pivot, Cruciate Substituting Multicenter, Post-Market Outcomes Study||Medacta USA|No|Recruiting|June 2015|December 2023|Anticipated|July 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02501733||16790|
NCT02402231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASTXP2013|Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy|Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair|FASTX|Karolinska Institutet|Yes|Active, not recruiting|October 2013|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|12 Years|22 Years|No|||February 2016|February 24, 2016|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02402231||24428|
NCT02405364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 568 03|Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction|Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old|IFM-CRd|University Hospital, Toulouse|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|October 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02405364||24189|
NCT02505984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001100|Preventing Postpartum Depression With Intranasal Oxytocin|Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD|IN-OXT|Massachusetts General Hospital|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|50 Years|No|||February 2016|February 9, 2016|July 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02505984||16463|
NCT02502071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0541|Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes|Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial|Alk-UA|University of Colorado Denver School of Medicine Barbara Davis Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|45 Years|No|||July 2015|July 16, 2015|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502071||16764|
NCT02398500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMG324-2201|Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration|An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration||Alcon Research|No|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|106|||Both|50 Years|N/A|No|||March 2016|March 15, 2016|March 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398500||24715|
NCT02403284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028|The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans|The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans||Phoenix VA Health Care System|No|Recruiting|March 2013|September 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|35|||Both|40 Years|75 Years|No|||March 2015|March 25, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403284||24349|
NCT02401503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2-BAG|Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)|A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL Patients||German CLL Study Group|No|Active, not recruiting|May 2015|April 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401503||24484|
NCT02406560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461050|A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food|A Phase 1, Open-label, Randomized, Crossover, Oral, Single Dose Study To Estimate The Relative Bioavailability Of Pf-06291826 (Tafamidis) Following Administration Of A Tafamidis Free Acid Tablet Formulation In Healthy Subjects Under Fasted And Fed Conditions||Pfizer|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406560||24099|
NCT02506231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0197-15-RMC|The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome|The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study||Rabin Medical Center|No|Not yet recruiting|October 2015|||October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||June 2015|July 23, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02506231||16444|
NCT02510651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAH555|Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo|Effect of Procedural-Related Variables on Melanocyte-Keratinocyte Suspension Transplantation in Non-Segmental Stable Vitiligo: A Clinical and Immunohistochemical Study||Cairo University|Yes|Completed|January 2010|June 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510651||16105|
NCT02396615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B318|SATIN WP4 Acute Effect on Appetite of Pineapple Juice With Viscofiber and Red Ginseng|SATIN WP4 - The Acute Effect on Appetite of Pineapple Juice With Viscofiber and Red Ginseng|SATIN|University of Copenhagen|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396615||24860|
NCT02507102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAT-105|A Feasibility Study of the Nativis Voyager™ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia|A Feasibility Study of the Nativis Voyager™ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia||Nativis, Inc.|No|Recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507102||16377|
NCT02507115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA021014-01A1|Text Messaging as a Novel Alcohol Intervention for Community College Students|Text Messaging as a Novel Alcohol Intervention for Community College Students|TMAP|The Miriam Hospital|No|Completed|July 2012|June 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507115||16376|
NCT02509364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH150715|Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)|||Shanghai Pulmonary Hospital, Shanghai, China||Enrolling by invitation|August 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|300|Samples With DNA|Sputum, throat swab, BALF and blood will be collected in this study.|Both|54 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject cohorts: Cohort 1: Stable IPF group (n>150); Cohort 2: AE-IPF group (n>50); Cohort        3: healthy control group (n>100). All the IPF patients have been enrolled according to        relevant diagnosis criteria. The criteria of AE-IPF include: diagnosed IPF patient        experiences unexplained dyspnea within 1 month, with objective evidence of hypoxia and new        onset of pulmonary infiltration based on imaging examination, and with other diagnosis        like pulmonary embolism, pneumothorax or heart failure excluded.Serial observation of the        change of pathogens based on at least two times of sample collection. Healthy control        group recruits healthy population based on physical exam, with no definite respiratory        disease and normal chest X ray results.|July 2015|July 24, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02509364||16204|
NCT02394639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2015/0140|EEG@HOME (Phase 4 of the Project)|||University Hospital, Ghent|Yes|Enrolling by invitation|April 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|10|||Both|4 Years|80 Years|No|||December 2015|December 7, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394639||25012|
NCT02394912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140201|Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System|Evaluation of the Technical Success of Intravascular Ultrasound (IVUS) Guided Vena Cava Filter (VCF) Placement Using the LUMIFI™ With Crux® VCF System (LUMIFI Clinical Study)||Volcano Corporation||Suspended|June 2015|||July 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|148|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|March 5, 2015|Yes|Yes|Unsatisfactory filter deployment in several cases|No||https://clinicaltrials.gov/show/NCT02394912||24991|
NCT02394925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5672|Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes|Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02394925||24990|
NCT02396927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D_vs_2D_chol|3D HD Versus 2D HD in Cholecystectomy|Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Cholecystectomy: a Clinical Controlled Randomized Double Blinded Trial.||Herlev Hospital|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02396927||24836|
NCT02396940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D_vs_2D_ing|3D HD Versus 2D HD in Laparoscopic Inguinal Hernia Repair: a Randomized Controlled Trial|Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Inguinal Hernia Repair.||Herlev Hospital|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02396940||24835|
NCT02500303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN13DI563|Influence of Diabetes on Lower Limb Amputation|Rehabilitation & Function Following Lower Limb Amputation: the Influence of Diabetes||University of Glasgow|Yes|Recruiting|March 2014|December 2016|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|No|Non-Probability Sample|All persons over 18 years old undergoing a lower limb amputation for Diabetes and / or        peripheral arterial disease within the Greater Glasgow & Clyde area.|July 2015|July 20, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02500303|18 Months|16900|
NCT02495259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081067|Comparison of Double Lumen Tube Placement Techniques|Comparison of Placement of Double-lumen Endobronchial Tube Using GlideScope With 2 Different Stylet Configurations vs Standard Macintosh Laryngoscopy||Emory University|No|Recruiting|July 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495259||17287|
NCT02409602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLITDOP-001|Influence of BIIAL Following PPH on Dorsal Clitoral Artery Blood Flow and FSFI|Comparison of the Dorsal Clitoral Artery Doppler Examination Results and the Female Sexual Function Index in Women With Postpartum Hemorrhage Who Underwent Bilateral Internal Iliac Artery Ligation and Age-matched Healthy Postpartum Women||Near East University, Turkey|Yes|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|18-35 year old women with postpartum hemorrhage who did and did not undergo bilateral        internal iliac artery ligation (BIIAL)|March 2016|March 20, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409602||23865|
NCT02405104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-151-MU-Klorz|Chlorzoxazone in Hip and Knee Arthroplasty|Analgetic Effects of Chlorzoxazone in Total Hip and Knee Arthroplasty|chlorzoxazon|Northern Orthopaedic Division, Denmark|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405104||24209|
NCT02405117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH100460|A Mobile Behavioral Monitoring Intervention for Bipolar Disorder|A Mobile Behavioral Monitoring Intervention for Bipolar Disorder||Northwestern University|Yes|Recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405117||24208|
NCT02417974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P-000100|Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)|Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)||Beth Israel Deaconess Medical Center|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417974||23221|
NCT02408029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-229|Trauma Equivalency Study of the CORA® and TEG® 5000 Systems|Trauma Equivalency Study of the CORA® and TEG® 5000 Systems||Coramed Technologies LLC|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|325|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years or over undergoing care for trauma.|January 2016|January 26, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408029||23986|
NCT02408042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WG2014035|Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)|A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)||Western Regional Medical Center|No|Withdrawn|April 2015|||November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2015|February 19, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408042||23985|
NCT02421588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-C-004-14|Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients|Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)|CORAIL|PharmaMar||Recruiting|May 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||September 2015|January 14, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421588||22944|
NCT02421601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6603/1132|A Study of SI-6603 in Patients With Lumbar Disc Herniation|A Multicenter, Open-label Study of SI 6603 in Patients With Lumbar Disc Herniation (Phase III)||Seikagaku Corporation||Recruiting|March 2015|||August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|30 Years|70 Years|No|||August 2015|January 7, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421601||22943|
NCT02414217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0229|Intervention to Enhance Numeracy in Diabetes (IntEND)|Intervention to Enhance Numeracy in Diabetes|IntEND|University of Colorado, Denver|No|Enrolling by invitation|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|220|||Both|18 Years|89 Years|No|||June 2015|June 18, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02414217||23510|
NCT02418221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Provokamin01|A Provocation Study Using Biogenic Amines to Show the Efficacy of Oral Diamine Oxidase Supplementation|A Doubleblind, Placebo-controlled, Cross-over Provocation Study Using Biogenic Amines to Show the Efficacy of Oral Diamine Oxidase (DAOSiN®) Supplementation in Case of DAO Enzyme Deficiency||IPSC AG|Yes|Completed|February 2014|April 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|72|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02418221||23202|
NCT02425280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275804|Effectiveness of Narrative Exposure Therapy Among Refugee Children and Adolescents|How to Help War-affected Children and Adolescents: the Role of Memory Functions in Therapeutic Intervention||University of Tampere||Recruiting|November 2014|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02425280||22660|
NCT02402127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLT567-P001|Lubricity Post-Wear - Competitive Lenses Pilot|Lubricity Post-Wear - Pilot Evaluation of Daily Disposable Silicone Hydrogel Contact Lenses After Wear||Alcon Research|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402127||24436|
NCT02402374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-WH-02|Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer|Randomized, Placebo-controlled, Blind-assessor Study to Evaluate the Safety and Efficacy of Autologous Platelet Rich Plasma Gel Prepared With the RegenKit-BCT Plus Family of Kits for the Treatment of Diabetic Foot Ulcer||Regen Lab SA|No|Not yet recruiting|June 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|95 Years|No|||May 2015|May 7, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402374||24417|
NCT02422745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014D001652|COcoa Supplement and Multivitamin Outcomes Study|COcoa Supplement and Multivitamin Outcomes Study|COSMOS|Brigham and Women's Hospital|Yes|Recruiting|June 2015|October 2020|Anticipated|March 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|18000|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02422745||22855|
NCT02411123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP0002|Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders|Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders||AltheaDx|No|Completed|March 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|220|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02411123||23748|
NCT02397356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14066M|Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia|Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia||Tampere University Hospital|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|65 Years|No|||December 2015|December 21, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397356||24803|
NCT02419950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|634/2008|Mesh Fixation inTEP Inguinal Hernia Repair|Impact of Mesh Fixation on Chronic Pain in Total Extraperitoneal (TEP) Inguinal Hernia Repair - a National Register Based Study|register|Skane University Hospital|No|Completed|November 2008|September 2013|Actual|May 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Actual|1110|||Male|30 Years|75 Years|No|Non-Probability Sample|Men between 30-75 years with primary inguinal hernia|April 2015|April 14, 2015|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02419950|5 Years|23070|
NCT02422069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25212|Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan|Registry on Post Menopausal Osteoporosis in Gynecology Setting in Pakistan (REPOSE)||Hoffmann-La Roche||Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|624|||Female|50 Years|N/A|No|Non-Probability Sample|The study will enroll gynecology outpatients in Pakistan who meet eligibility criteria for        observation.|June 2015|June 1, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422069||22907|
NCT02415933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-1481|Child Protective Outcomes Among Ultra-poor Families in Burkina Faso|Evaluating Child Protective Effects of Economic Strengthening and Child Rights Interventions Among Ultra-poor Families in Burkina Faso||University of Chicago|No|Active, not recruiting|September 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|720|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02415933||23378|
NCT02415946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRUA1GR-2013-00000168|Sinus Lift: Saving Time and Reducing Morbidity|Efficacy of a Novel Simplified, Minimally-invasive Procedure for Sinus Floor Elevation in the Atrophic Posterior Maxilla: a Multicenter, Randomized Study|SmartLiftRER|University Hospital of Ferrara|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02415946||23377|
NCT02400177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB32455|Parents Workgroup About Emotion Regulation|Parenting Workshop on Emotion Regulation||Stanford University|Yes|Not yet recruiting|March 2015|November 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400177||24586|
NCT02398929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200 006 621|BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)|An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)|BRAVE|Chinese University of Hong Kong|No|Recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|79 Years|No|||March 2015|March 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02398929||24682|
NCT02420184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-0055|Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease|Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease||University of Calgary|Yes|Enrolling by invitation|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420184||23052|
NCT02420431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156682 (RP-PG-1211-20011)|Treating Depression and Anxiety in the Cardiac Rehabilitation Pathway|Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in the Cardiac Rehabilitation Pathway: A Single-blind Randomised Controlled Trial|PATHWAY|University of Manchester|Yes|Recruiting|July 2015|August 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02420431||23033|
NCT02500784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL0004APR|Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease|Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease||Palo Alto Veterans Institute for Research|No|Recruiting|January 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||August 2015|August 13, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500784||16863|
NCT02507076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-411|Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma|Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases||Albert Einstein College of Medicine of Yeshiva University|Yes|Withdrawn|April 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No|no enrollment|No||https://clinicaltrials.gov/show/NCT02507076||16379|
NCT02507167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCK8/RIFA-2012|Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8|Impact of Two Genetic Variants of OATP 1B3 or MRP 2 or Rifampin Mediated Transporter Inhibition on Systemic Disposition and Biological Efficacy of CCK-8 in 36 Healthy Male Individuals||University Medicine Greifswald|Yes|Completed|November 2012|December 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507167||16372|
NCT02403518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0071|Clinical Outcomes of the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain|A Prospective, Multi-National, Post-Marketing Study of the Clinical Outcomes of Wireless Neuromodulation Via the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain||Stimwave Technologies||Not yet recruiting|March 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403518||24331|
NCT02403544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-048|Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma|Image-Guided Radiation Therapy (IGRT) Associated With Concurrent Capecitabine and Oxaliplatin in the Treatment of Locally Advanced or Inoperable Hepatocellular Carcinoma (HCC): A Phase I Study||Chinese Academy of Medical Sciences|Yes|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02403544||24329|
NCT02403557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-Forte-Older-Adults-Anx|Internet-delivered Cognitive Behaviour Therapy for Older Adults With Anxiety|Individually-tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Older Adults With Anxiety and Depression: a Randomized Controlled Trial||Linkoeping University||Completed|February 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|60 Years|N/A|No|||March 2016|March 1, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403557||24328|
NCT02405065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-RAFI-101|Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573|Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors||Hanmi Pharmaceutical Company Limited|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02405065||24212|
NCT02405078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0022|Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model|Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection Of A Tumor-Specific Clonotype and Metabolic Profiling of Blood Of In Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma To Predict Response To Standard Immunochemotherapy||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02405078||24211|
NCT02405091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1402|Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia|A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia|Kinect 4|Neurocrine Biosciences|No|Active, not recruiting|March 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405091||24210|
NCT02496910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH22162-102|PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton|A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers||Yuhan Corporation|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|180|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02496910||17160|
NCT02501018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBS12-01|Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)|A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)||Caladrius Biosciences, Inc.|Yes|Not yet recruiting|January 2016|July 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|35|||Both|20 Years|80 Years|No|||July 2015|July 23, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501018||16845|
NCT02507245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verbale N°4/2013|Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)|Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD): Lung Function Parameters Assessment; Quality of Life Assessment; Stress Parenting Assessment (Pneumo GHD)|GHD|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Completed|January 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Both|5 Years|15 Years|No|Non-Probability Sample|48 children affected by GH deficiency , recruited in the outpatient clinic of Pediatric        Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the        Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council        (CNR) of Palermo (RDRC-IBIM CNR), Italy.|July 2015|July 22, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507245||16366|
NCT02495974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-MA-1002|European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)|A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|PREMISE|Astellas Pharma Inc|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1930|||Male|N/A|N/A|No|Non-Probability Sample|Patients with metastatic castration resistant prostate cancer prescribed enzalutamide as        part of standard clinical practice|February 2016|February 23, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02495974||17232|
NCT02396004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB 2013/379/E|NIRS in PDA VLBW Infants|Near-Infrared Red Spectroscopy (NIRS) to Measure Cerebral Perfusion During and After Patent Ductus Arteriosus (PDA) Treatment in Very Low Birth Weight (VLBW) Infants||Singapore General Hospital|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|6 Months|No|Non-Probability Sample|VLBW (defined as birthweight less than 1500g) infants with hemodynamically significant PDA        (patent ductus arteriosus) requiring treatment, either medical or surgical|March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396004||24907|
NCT02397967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 113 01|Reading Disability in Children With NF1|Neuropsychological Characterisation of Cognitive Deficits Involved in Reading Disability in Children With NF1||University Hospital, Toulouse|No|Completed|June 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|181|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02397967||24756|
NCT02398266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sonazoid in PAD|Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid|Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid||Oregon Health and Science University|No|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398266||24733|
NCT02509429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9525|Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children|Assessment of the Efficacy on the Reduction of Nocturnal Hypoglycemia in Children With Type 1 Diabetes of a Closed-loop Insulin Therapy (Artificial Pancreas) Compared to Insulin Pump Therapy Combined With Continuous Glucose Monitoring With Threshold Low Glucose Suspend of Infusion in Home-like Conditions|SHAN|University Hospital, Montpellier|No|Recruiting|June 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|7 Years|12 Years|No|||July 2015|July 23, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02509429||16199|
NCT02511067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29813|Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study|Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema.|READ-4|University of Nebraska|Yes|Not yet recruiting|February 2016|October 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511067||16073|
NCT02509013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI198103|Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease|Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease: a Prospective, Multi-center, Hospital-based Study||Peking University First Hospital|No|Not yet recruiting|August 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|100 eligible sites over the country will participate. Each site will recruit patients who        fit the inclusion standard in chronological order|July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509013||16231|
NCT02403739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z001|Visual Interpretation of Neonatal Growth Charts|Visual Interpretation of Neonatal Growth Charts: A Comparison of Z-score Charts and Traditional Charts||University of California, Davis|No|Recruiting|March 2015|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|It will include UC Davis Medical Center healthcare personnel who interpret growth charts        for preterm infants. This may include the following:          -  Attending Neonatologists          -  Attending Pediatricians          -  Dietitians          -  Medical Students          -  Neonatal Fellows          -  Neonatal Nurse Practitioners          -  Pediatric Residents This study will exclude persons who do not routinely interpret             growth charts for preterm infants as part of their clinical responsibilities.|November 2015|November 30, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403739||24314|
NCT02393820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&N02|Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma|Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma|PACSA|UNICANCER|Yes|Active, not recruiting|August 2013|August 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393820||25075|
NCT02497456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Linkage to pre-ART care|The Effectiveness of a Counselling Intervention on the Uptake of HIV Care Services Among HIV Infected Patients in Uganda|The Effectiveness of a Counselling Intervention on the Uptake of HIV Care Services Among HIV Infected Patients in Uganda||MRC/UVRI Uganda Research Unit on Aids|No|Completed|March 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|338|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497456||17118|
NCT02500069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-14-3-006|Location Specific Differences in Intestinal Brake Activation|The Effect of Intestinal Brake Activation at Different Locations in the Gut on Food Intake and Hormone Release||Maastricht University Medical Center|Yes|Completed|May 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|March 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02500069||16918|
NCT02507388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTH258-E003|Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration|A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration||Alcon Research|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|65|||Both|50 Years|N/A|No|||December 2015|December 8, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507388||16355|
NCT02396537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130917005|Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration|Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration: A Double-blind, Randomized, Placebo-controlled Trial||University of Alabama at Birmingham|Yes|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|76|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396537||24866|
NCT02403934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0033|Jaw Elevation Device in Deep Sedation Study|The Use of Jaw Elevation Device in Deep Sedation||United States Naval Medical Center, San Diego|No|Recruiting|October 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|48 Years|No|Probability Sample|Adult female patients undergoing egg retrieval for infertility requiring deep sedation or        MAC as their anesthetic method.|March 2015|March 31, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403934||24299|
NCT02498743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Effect of Television Cartoons in Patients Younger Than 3.5 Years During Echocardiography|Effect of Television Cartoons in Patients Younger Than 3.5 Years During Echocardiography.A Prospective Randomized Study||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Completed|February 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|58|||Both|6 Months|43 Months|No|||July 2015|July 14, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02498743||17020|
NCT02498756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melanoma001|Cytokine-induced Killer Study for Patients With Stage II Melanoma|A Study of Ipilimumab Plus Cytokine-induced Killer Immunotherapy for Stage II Melanoma Patients||The First People's Hospital of Changzhou|Yes|Not yet recruiting|August 2015|August 2040|Anticipated|August 2038|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02498756||17019|
NCT02401386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141107002514094|Lu Eight Brocades for Treating Patients With Fibromyalgia|A Randomized Controlled Trial of Lu Eight Brocades to Improve Quality of Life in Patients With Fibromyalgia||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401386||24493|
NCT02401399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUE15-2|Preoperative Diet Before Sleeve Gastrectomy|Preoperative Regular Diet of 900 Kcal/Day vs Balanced Energy High Protein Formula vs Immunonutrition Formula: Effect on Postoperative Pain After Laparoscopic Sleeve Gastrectomy||Hospital General Universitario Elche|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|N/A|N/A|No|||March 2015|March 24, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401399||24492|
NCT02401412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5787-O|The Advocate Study|A Study Determining Variances in Ostomy Skin Conditions And The Economic Impact.||Hollister Incorporated|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401412||24491|
NCT02404051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM16-FEVEX|Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer|Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI|FEVEX|Consorzio Oncotech|Yes|Not yet recruiting|May 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|745|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404051||24290|
NCT02410395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH060804|NIche Development With Closure of Cesarean Uterotomy by Modified or Conventional Two-layer Technique|NIche Development With Closure of Cesarean Uterotomy by Modified or Conventional Two-layer Technique (NICUM Study)|NICUM|University of Aarhus|No|Recruiting|March 2015|March 2023|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|230|||Female|18 Years|N/A|No|||March 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02410395||23804|
NCT02494609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-120-NRM|Oral Contraceptive DDI Study|A Two-way Study to Evaluate the Potential Pharmacokinetic Interactions Between Sotagliflozin (LX4211) and Ortho-Cyclen®, an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol, in Healthy Premenopausal Women||Lexicon Pharmaceuticals|No|Active, not recruiting|July 2015|||November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494609||17337|
NCT02494622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK8|Alternative Treatment of Giant Spinal Schwannomas|Alternatives to The Surgical Approach for Giant Spinal Schwannomas: A Clinic Trial||Umraniye Education and Research Hospital|No|Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|18|||Both|16 Years|76 Years|No|Non-Probability Sample|Patients, who underwent surgery for benign spinal schwannoma Sridhar Type III, IV and V        (all tumors were larger than 2.5 cm).|July 2015|July 7, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02494622||17336|
NCT02500615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31DA040319-01|The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects|The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects||Virginia Commonwealth University|No|Not yet recruiting|July 2016|October 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|5||Anticipated|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02500615||16876|
NCT02408757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 077/15|Sonographic Monitoring of Weaning of Cerebrospinal Fluid Drainages|Multimodal Sonographic Monitoring of Cerebral Perfusion, Ventricle Seize and Optic Nerve Diameter During Weaning of Cerebrospinal Fluid Drainage Catheters: a Single Centre Observational Trial||University Hospital Inselspital, Berne|No|Recruiting|September 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|80 Years|No|Non-Probability Sample|The study population consists of consecutive patients undergoing clamping of EVD/LD        treated at the Departments of Neurosurgery or Intensive Care Medicine at the University        Hospital Bern|December 2015|December 9, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408757||23930|
NCT02404922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP730.1002|Multiple Ascending Dose Study in Healthy Volunteers|A Phase I Single Center, Double-Blind, Placebo-Controlled, Multiple Dose-Ascending Study to Evaluate the Pharmacokinetics and Tolerability of CTP-730 Immediate Release at Steady State in Healthy Adults||Concert Pharmaceuticals|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|February 3, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02404922||24223|
NCT02506790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBC 2|Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer|Phase II Multicenter Randomized Study to Compare Neoadjuvant Toremifene With Melatonin or Metformin Versus Toremifene in the Therapy of Locally Advanced Breast||Petrov Research Institute of Oncology|Yes|Recruiting|July 2015|April 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02506790||16401|
NCT02501109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMG-ARI-140052|Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers|A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers||CMG Pharmaceutical Co. Ltd|No|Completed|October 2015|March 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501109||16838|
NCT02501122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-00264|Retrospective Analysis in Quality of Care Measures in Pediatric Adenotonsillectomy Patients|Cost Savings From Non-pharmacological Interventions for Pediatric Patients Undergoing Diagnostic Imaging at Nationwide Children's Hospital||Nationwide Children's Hospital|No|Enrolling by invitation|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000000|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have undergone anesthesia for adenotonsillectomy, tonsillectomy or        adenoidectomy during 2013-2015 at Nationwide Children's Hospital.|July 2015|July 15, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02501122||16837|
NCT02401958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP UNIFESP -|Acute Effect of Resistance Training in Inflammatory Markers in Women With Rheumatoid Arthritis|||Federal University of São Paulo|Yes|Active, not recruiting|March 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02401958||24449|
NCT02408237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0281|Transcranial Direct Current Stimulation Apparatus for Domiciliary Use|Development of Apparatus of Transcranial Direct Current Stimulation (tDCS) for Domiciliary Use||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02408237||23970|
NCT02408289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-CUNY 66522-0044|The Randomized Controlled Cocoa-Appetite Trial|A Pilot Randomized Human Trial on The Effects of Cocoa on Appetite.||Brooklyn College of the City University of New York|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|28|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02408289||23966|
NCT02505737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150001714|Telephone-Based Counseling for Depression in Parkinson's Disease|Improving Access to Depression Care in Parkinson's Disease: A Telehealth Approach|TH-CBT|Rutgers, The State University of New Jersey|No|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|35 Years|85 Years|No|||July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505737||16482|
NCT02505750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/14|Phase III Study Comparing, Efficacy and Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma|European Phase III Study Comparing, in Association With Neoadjuvant Chemoradiotherapy, a Radiation Dose Escalation Using 2 Different Approaches: External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma cT2-T3 a,b < 5cm in Diameter in Distal and Middle Rectum|OPERA|Centre Antoine Lacassagne|Yes|Recruiting|March 2015|March 2021|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505750||16481|
NCT02497274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-77|Obesity and Lipids: a Matter of Taste?|Obesity and Lipids: a Matter of Taste? Impact of Bariatric Surgery on Taste Receptors|HumanFATaste|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Female|18 Years|55 Years|No|||July 2015|July 15, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02497274||17132|
NCT02497287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107148|A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression|An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression|SUSTAIN-2|Janssen Research & Development, LLC|Yes|Recruiting|September 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1071|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497287||17131|
NCT02405286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rockall score|Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage|Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage||Ain Shams University|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult Egyptian patients with acute upper gastrointestinal bleeding|March 2015|March 31, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405286||24195|
NCT02408302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0075-CTIL|Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children|Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study||Carmel Medical Center|No|Not yet recruiting|April 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Both|5 Months|6 Years|No|||March 2015|April 8, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408302||23965|
NCT02397291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-517|Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies|Project 01-517, Part 1) To Determine Whether the Transplacental Gradients for 6 Polyols and Mannose Are Altered in IUGR Pregnancies Compared to Normal Pregnancies. Project 01-517, Part 2) To Determine Transplacental Transport vs Production of Both Myoinositol (the Major Polyol) and Mannose in IUGR and Normal Pregnancies||University of Colorado, Denver|No|Recruiting|January 2001|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397291||24808|
NCT02507466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00103739|Very Intensive Variable Repetitive AmbulatioN Training|Very Intensive Variable Repetitive AmbulatioN Training|VIVRANT|Rehabilitation Institute of Chicago|No|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|30 Years|85 Years|No|||July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507466||16349|
NCT02400541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130905|Efficacity of Cognitive Remediation Treatment Compared to a Controlled Group in Young Patient With Anorexia Nervosa|Prospective Evaluation of Neuropsychological and Clinical Impact of Cognitive Remediation Program Among Children and Adolescents Treated for Anorexia Nervosa|RECOGAMEA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Female|8 Years|16 Years|No|||July 2015|July 27, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02400541||24558|
NCT02403713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFL1503|A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers|A Randomised, Open-label, 2-group PK (3-period) and PD (5-period) Crossover Study to Compare Systemic Exposure and Pharmacodynamic Effects of Fluticasone/Formoterol BAI and pMDI in Healthy Volunteers||Mundipharma Research Limited|No|Completed|August 2014|September 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403713||24316|
NCT02507570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-PCA-02 EnzaRadiCate|Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis|Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis||Carolina Research Professionals, LLC|No|Recruiting|September 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02507570||16341|
NCT02494726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-09-0156|Prospective Analysis of the Use of TEG in Stroke Patients|Prospective Analysis of the Use of Thromboelastography in Stroke Patients|TEG|The University of Texas Health Science Center, Houston|Yes|Completed|November 2009|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|178|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All stroke patients admitted to Memorial Hermann Hospital Emergency Department receiving a        confirmatory CT or MRI scan.|July 2015|July 9, 2015|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494726||17328|
NCT02494739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniYog-2015x|Antioxidant and Anti-inflammatory Effects of Yogurt Enriched With Polyphenols|Investigation of the Antioxidant and Anti-inflammatory Effects of Yogurt Enriched With Polyphenols||University of Thessaly|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02494739||17327|
NCT02394054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003565-3|Vasopressin and the Social Brain|Vasopressin's Effect on Behavior and Neural Activity During Social Cognition Tasks||University of California, Los Angeles|Yes|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394054||25057|
NCT02394067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150217|Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension|Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension||Nova Scotia Health Authority|No|Not yet recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Participants will be recruited from the neuro-ophthalmology service at the Queen Elizabeth        II Health Center. Neuro-ophthalmology service in Nova Scotia sees approximately 20 new        diagnoses of IIH per year.|July 2015|July 27, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394067||25056|
NCT02394080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-03-EUHUM-01|Safety and Efficacy Study of the Treatment of Humerus Fractures|CE Marking Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Humerus Fractures||IlluminOss Medical, Inc.||Recruiting|February 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|50 Years|N/A|No|||March 2016|March 9, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394080||25055|
NCT02401737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVR3-778-101B|Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients|A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection||Novira Therapeutics, Inc.|Yes|Active, not recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|84|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401737||24466|
NCT02495922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMMG HD6|A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma|A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma|GMMG-HD6|University of Heidelberg Medical Center|Yes|Recruiting|June 2015|March 2022|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|516|||Both|18 Years|70 Years|No|||July 2015|July 10, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02495922||17236|
NCT02495935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-478|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2015|||||N/A|N/A|N/A||||||||||||||August 20, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495935||17235|
NCT02501876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)32/2015|Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease|Type 2 Diabetes Mellitus as Accelerator for the Progression to Alzheimer's Disease in Patients With Mild Cognitive Impairment|DIACEA|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|May 2015|May 2016|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|220|Samples With DNA|Whole blood will be preserved in order to perform a genetic study of 10 genes related both      with type 2 diabetes and Alzheimer´s disease.|Both|65 Years|90 Years|No|Non-Probability Sample|A retrospective case-control study will be conducted in the Department of Endocrinology        and Nutrition Hospital Vall d'Hebron, in collaboration with the department of Neurology        and Laboratory. We will review the medical records and the complete neuropsychological        evaluation of 110 subjects with MCI and DM-2 matched by age, sex, and cardiovascular risk        factors with 110 non-diabetic subjects with MCI. We will select the patients (diabetic or        non-diabetic) with a minimum follow-up of 2 years, and whose neuropsychological assessment        has been performed using the battery NBACE to ensure a uniform evaluation criteria. In        addition, only patients who have determined the ApoE genotype and those who have        previously undergone brain MRI will be included.|July 2015|July 20, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02501876|2 Years|16779|
NCT02398474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003383-21|Ultrasound TFP (Transversalis Fascia Plane) for Analgesia After Iliac Crest Bone Graft Harvest|Intérêt du TFP (Transversalis Fascia Plane) Bloc échoguidé Pour l'analgésie du prélèvement Osseux de crête Iliaque|TFP|Rennes University Hospital||Not yet recruiting|April 2015|||April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398474||24717|
NCT02402023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014258|Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery|Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery||Yale University|No|Recruiting|October 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02402023||24444|
NCT02402036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0133|A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer|Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study||Georgetown University|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402036||24443|
NCT02508272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stv26/2007|Transcriptomic Profiling in Severely Injured Patients|Transcriptomic Profiling in Severely Injured Patients||University of Zurich|No|Completed|December 2009|July 2015|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|Samples Without DNA|total RNA. Serum, Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Trauma patients with systemic inflammation due to multiple injuries (Polytrauma: ISS ≥ 17        points)|July 2015|July 22, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02508272||16287|
NCT02507739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-097|Evaluation of the Impact of an Outpatient Obstetric Epidurals During Labor||PERIAMBU|University Hospital, Caen|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|320|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507739||16328|
NCT02401620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUN-TOC-2014-01|Validation of a Tolerability Questionnaire in Rheumatoid Arthritis|Validation of a Specific Questionnaire to Assess the Tolerability of the Different Therapeutic Strategies in Rheumatoid Arthritis||Corporacion Parc Tauli|No|Recruiting|January 2014|December 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|66|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with Rheumatoid Arthritis|March 2015|March 24, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02401620||24475|
NCT02396277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/86 (REK)|Structural and Functional Nerve Changes Following Immobilisation After Distal Radius Fracture - a Pilot Study (NRP)|Structural and Functional Nerve Changes Following Immobilisation After Distal Radius Fracture - a Pilot Study (NRP)|NRP|University of Tromso|No|Not yet recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients referred to the Emergency Clinic at The University Hospital in North Norway        Tromso day time|March 2015|March 23, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02396277||24886|
NCT02396290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0998|Clinical Effect of Platelet Rich Plasma Combined With Laser on Scar|Clinical Study on Efficacy and Safety of Platelet Rich Plasma Combined With Laser for Scar Treatment||Seoul National University Hospital|Yes|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||July 2013|March 17, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02396290||24885|
NCT02409004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-026-HV|Effects of Rifampin on the Pharmacokinetics of Ataluren|A Phase I Study Assessing the Effects of Rifampin on the Pharmacokinetics of Ataluren in Healthy Subjects||PTC Therapeutics|No|Not yet recruiting|March 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02409004||23911|
NCT02409017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690224-2|A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial|A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial||WellSpan Health|No|Recruiting|April 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02409017||23910|
NCT02397252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-M103-14B|Cervical And Self-Sample In Screening Study|Cervical And Self-Sample In Screening (CASSIS) Study: Diagnostic Performance of Molecular HPV Testing With the Eve Medical Self-collection System© for Detecting Cervical Intraepithelial Neoplasia|CASSIS|McGill University|Yes|Recruiting|June 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02397252||24811|
NCT02423083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150117|Oral Guanabenz for Multiple Sclerosis|Phase I Study of Oral Guanabenz for Multiple Sclerosis||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|No|||February 2016|February 20, 2016|April 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423083||22829|
NCT02396745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-024|TECR & ECM Placement for Esophageal High Grade Dysplasia|A Prospective Feasibility Study to Evaluate the Safety and Efficacy of Transoral Endoscopic Circumferential Esophageal Resection With Extracellular Matrix (ECM) Placement to Treat Barrett's Esophagus With High-grade Dysplasia (HGD)||Allegheny Singer Research Institute|No|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396745||24850|
NCT02410967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH2MH101470|Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety|Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety||Florida International University|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|8 Years|16 Years|No|||February 2016|February 1, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02410967||23760|
NCT02411240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIFA_TN|Air Pollution Reduction in the Elderly and Cardiovascular and Cognitive Outcomes|Air Pollution Reduction in the Elderly and Cardiovascular and Cognitive Outcomes, an Intervention Study|ELIFA|Hasselt University|No|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|July 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02411240||23739|
NCT02418702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2014.0031|A Study to Decrease Suicidal Thinking Using Ketamine|A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine||United States Naval Medical Center, San Diego|Yes|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02418702||23165|
NCT02425293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274/11|INCAS - Integrated Care of Asthma in Switzerland||INCAS|Cantonal Hosptal, Baselland|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|223|||Both|18 Years|59 Years|No|||April 2015|April 20, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02425293||22659|
NCT02410863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bottom_2012|Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma|Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma|BOTTOM|University Hospital, Essen|No|Recruiting|June 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410863||23768|
NCT02407912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXY 01|Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer|Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer.||Shantou University Medical College|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407912||23995|
NCT02421796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM08|Malnutrition In Non-Celiac Wheat Sensitivity Patients|Malnutrition In Non-Celiac Wheat Sensitivity Patients||University of Palermo|No|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|270|Samples Without DNA|Biopsy specimens will be obtained from the bulb and the second duodenal portion|Both|18 Years|65 Years|No|Probability Sample|The study will include consecutive adult patients with irritable bowel syndrome (IBS)-like        clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS,        referred at the Internal Medicine and at the Gastroenterology Units of the University        Hospital of Palermo, between may 2015 and may 2017.|November 2015|November 30, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421796||22928|
NCT02422056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1167-4683|Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty|Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty : Randomized Study||Professor Fernando Figueira Integral Medicine Institute|No|Completed|December 2013|March 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|66|||Both|6 Months|N/A|No|||April 2015|April 20, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02422056||22908|
NCT02411617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC:02|Single vs. Double Drain in Modified Radical Mastectomy|Single vs. Double Drain in Modified Radical Mastectomy: A Randomized Control Trial||Memon Medical Institute|Yes|Completed|January 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411617||23710|
NCT02411630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 123|Factors Affecting PrEP Adherence|Structural and Partnership Factors Affecting Adherence to Pre-exposure Prophylaxis (PREP)Among Young Men Who Have Sex With Men||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|June 2013|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Male|15 Years|22 Years|Accepts Healthy Volunteers|||December 2014|April 2, 2015|January 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411630||23709|
NCT02415517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogTrain-HF|Cognitive Training in Heart Failure Study (CogTrain-HF)|Cognitive Training in Heart Failure Study (CogTrain-HF)|CogTrain-HF|Saarland University|No|Enrolling by invitation|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|85 Years|No|||February 2016|February 4, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02415517||23410|
NCT02415530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501097642|Early Family Based Intervention in Preterm Infants|Early Family-Based Intervention for Developmental Enforcement of Premature Infants||Seoul National University Hospital|Yes|Recruiting|March 2015|December 2023|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|150|||Both|N/A|6 Months|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02415530||23409|
NCT02402387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0050|The Influence of Head and Neck Position on the Oropharyngeal Leak Pressure Using Air-Q SP Airway|||Yonsei University|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|51|||Both|20 Years|N/A|No|||April 2015|April 5, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02402387||24416|
NCT02402634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0989|Inflammatory Gene Polymorphism and Prolonged Mechanical Ventilation After Liver Transplantation|||Yonsei University|No|Recruiting|January 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|20-65 years old, scheduled for liver transplantation.|July 2015|July 6, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402634||24397|
NCT02402920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1003|Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer|Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2023|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402920||24377|
NCT02411838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201307106|Calorie Restriction in Multiple Sclerosis Patients|A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients||Washington University School of Medicine|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|60 Years|No|||April 2015|April 3, 2015|December 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02411838||23693|
NCT02427152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Satt|Pre-meal Planning and Expected Satiety|||University Hospital Tuebingen||Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|lean and overweight/obese healthy volunteers|March 2015|April 24, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02427152||22516|
NCT02405169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-D-2012-031|4 vs 6 Implants in Totally Edentulous Patient in Maxilla With Ti. Cad-cam Framework|Four Versus Six Endosseous Implants to be Used in the Rehabilitation of Totally Edentulous Patient in the Maxilla With Titanium Milled Framework||Institute Franci|No|Active, not recruiting|December 2013|February 2021|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02405169||24204|
NCT02422992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12A-1330|Haptoglobin and Iron in Parkinson's Disease|Haptoglobin Phenotype and Smoking: Effects on Iron Levels in Parkinson's Disease|HPPD|Bastyr University|Yes|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|442|Samples Without DNA|We collect serum and plasma samples during the study, that are tested for total serum iron      and iron-binding proteins.|Both|35 Years|92 Years|Accepts Healthy Volunteers|Probability Sample|Parkinson's disease patients will be included in the study if they received a diagnosis of        Parkinson's disease that meets the United Kingdom Brain Bank (UKBB) clinical criteria of        Parkinson's disease diagnosis.        Control participants will be included in the study if free of neurodegenerative diseases.        A subset of the study participants (60 total) receive Magnetic Resonance Imaging to        estimate brain iron|January 2016|January 15, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02422992||22836|
NCT02410096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-360/14|Bronchial Inflammation and Hyperresponsiveness After Oil Supplementation|Examination of Bronchial Inflammation and Hyperresponsiveness After Oil Supplementation With Middle-chain and Polyunsaturated Fatty Acids in an Exercise-induced Asthma Provocation Model||Johann Wolfgang Goethe University Hospitals|No|Recruiting|March 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|12 Years|44 Years|No|||April 2015|April 13, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02410096||23827|
NCT02506439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODINWP4DMAT|Nutritional Requirements for Vitamin D in Pregnant Women|Randomized Controlled Trial to Determine the Nutritional Requirement for Vitamin D for Prevention of Deficiency During Pregnancy and in the Early Neonatal Period (D-MAT)|DMAT|University College Cork|No|Recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|192|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02506439||16428|
NCT02506452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALQ.BIO.2015.01|Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers|Evaluation of Biovance, a Dehydrated Decellularized Human Amniotic Membrane Allograft, in Diabetic Foot Ulcers||Alliqua BioMedical, Inc|No|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506452||16427|
NCT02405884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20328813.0.0000.0037|Intraocular Pressure and Hemodialysis Midwestern Brazil|Effects of Hemodialysis on Intraocular Pressure in a University Hospital Located in Midwestern Brazil|EHPIOBRAZIL|VER Excelência em Oftalmologia|No|Completed|January 2014|October 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|18 Years|75 Years|No|||March 2015|March 31, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405884||24149|
NCT02410135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYRB-14B03|Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)|Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)||Southern Illinois University|No|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients with lower urinary tract symptoms and sleep disturbance|October 2015|October 22, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410135||23824|
NCT02410148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aICP Ophtha|aICP in Glaucoma and Papilledema|Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema|aICP Ophtha|Kantonsspital Aarau|No|Recruiting|April 2015|March 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02410148||23823|
NCT02501278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1411|A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer|A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|May 2016|May 2021|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|126|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02501278||16825|
NCT02495987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2393|White Adipose Tissue in Pregnancy Study|Adaptations in Subcutaneous and Visceral Adipose Tissue Metabolism During Normal and Pathological Pregnancies|WAT|Imperial College London|No|Recruiting|March 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Adipose tissue, serum|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with or without ICP or GDM|February 2016|March 21, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02495987||17231|
NCT02400840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/153/HP|Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging|Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging|DRAGON|University Hospital, Rouen|No|Recruiting|January 2015|May 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02400840||24535|
NCT02403063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGC03|Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade|Electromyographic Activity of the Diaphragm and of the Rectus Abdominis and Intercostal Muscles During Neostigmine, Sugammadex, or Neostigmine-sugammadex Enhanced Recovery After Neuromuscular Blockade With Rocuronium. A Randomised Controlled Study in Healthy Volunteers|REDNESII|Onze Lieve Vrouw Hospital|Yes|Completed|September 2015|November 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02403063||24366|
NCT02507089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYULangone|Tailored Sleep Health Education: A Community Engaged Approach||TASHE|New York University Langone Medical Center|Yes|Active, not recruiting|July 2014|||March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507089||16378|
NCT02498236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21|Target Engagement for Oxytocin: Dose Ranging Study|Target Engagement for Oxytocin: Response to 8 Doses|R21Dose|University of California, Los Angeles|No|Not yet recruiting|September 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|48|||Both|18 Years|65 Years|No|||July 2015|July 14, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498236||17059|
NCT02509026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801381|Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA|A Multicenter Open-label Study Of Etanercept Withdrawal And Retreatment In Subjects With Non-radiographic Axial Spondyloarthritis Who Achieved Adequate 24 Week Response|RE-EMBARK|Pfizer|No|Recruiting|September 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|49 Years|No|||March 2016|March 22, 2016|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509026||16230|
NCT02509039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-ST-002|A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)|A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma||Celgene||Not yet recruiting|August 2015|July 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||July 2015|July 23, 2015|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509039||16229|
NCT02406027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106978|An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum|A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|June 2024|Anticipated|February 2024|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|100|||Both|50 Years|85 Years|No|||March 2016|March 9, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406027||24138|
NCT02398552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-RCC-150212|A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.|A Randomized Phase II Trila of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.||Beijing Cancer Hospital|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|February 27, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398552||24711|
NCT02398565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-2015-009|Pregnancy Subsequent to Ventral Hernia Repair|Pregnancy Subsequent to Ventral Hernia Repair: a Nationwide Cohort Study||Bispebjerg Hospital|No|Completed|March 2015|October 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|7612|||Female|20 Years|60 Years|No|Non-Probability Sample|Nationwide study population of patients registered with a ventral hernia repair in The        Danish Hernia Database between January 1 2007 and December 31 2014|January 2016|January 11, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02398565||24710|
NCT02502851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK 108 -- 120/14|The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC)|The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC): A Prospective Randomized Controlled Trial of Rotational Atherectomy Versus Cutting/Scoring Balloon in Severely Calcified Coronary Lesions|PREPARE-CALC|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH|Yes|Recruiting|September 2014|August 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02502851||16704|
NCT02502864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18118|Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide|Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|January 2016|February 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Female|65 Years|N/A|No|||January 2016|January 26, 2016|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02502864||16703|
NCT02507505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822632|Regional Versus General Anesthesia for Promoting Independence After Hip Fracture|A Randomized Controlled Trial of Regional Versus General Anesthesia for Promoting Independence After Hip Fracture|REGAIN|University of Pennsylvania|Yes|Recruiting|February 2016|||December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2424|||Both|50 Years|N/A|No|||March 2016|March 14, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507505||16346|
NCT02509104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201897|Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects|An Open-label, Randomized, Single Dose, Two-way Crossover Study to Determine the Bioavailability of One Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of One Dutasteride 0.5 mg Capsule and One Tamsulosin Hydrochloride 0.2 mg Tablet in Healthy Male Subjects in the Fed and Fasted States||GlaxoSmithKline|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509104||16224|
NCT02404298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111122|Transcriptome Analysis of the Peripheral Blood in CIDP|Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells|PHARMACOPID|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02404298||24271|
NCT02404311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 100|A Safety and Immune Response Study of 2 Experimental HIV Vaccines|A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|252|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02404311||24270|
NCT02406768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 035.4|A Sub-study of PREDICT Neurodevelopment Protocol|The Neurodevelopment in Normal Children in Cambodia and Thailand||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|1 Year|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV negative unexposed and HIV-negative children born to HIV-infected mothers|March 2015|March 30, 2015|March 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02406768||24083|
NCT02394405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OD-CABG-2015|Myocardial and Cerebral Dysfunction by Oxidative Stress Caused by On-pump Surgery|Myocardial and Cerebral Dysfunction by Oxidative Stress Caused by On-pump Surgery||Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy|No|Not yet recruiting|March 2015|October 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|75 Years|No|Non-Probability Sample|primary care clinic|March 2015|March 16, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02394405||25030|
NCT02504112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2015-12K|Zimmer CAS PSI X-Ray Knee in TKA (Total Knee Arthroplasty)|Evaluation of Zimmer® CAS PSI X-Ray Knee in Total Knee Arthroplasty (TKA): Technical Outcomes||Zimmer, Inc.|No|Not yet recruiting|July 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 years old with indication of Total Knee Arhtroplasty|July 2015|July 20, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02504112||16607|
NCT02508428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2015-0100|Marathon and Enduron Polyethylene at Long-Term Follow-up|A Prospective, Randomized Clinical Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty at Long-Term Follow-up||Anderson Orthopaedic Research Institute|No|Enrolling by invitation|June 2015|December 2030|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508428||16276|
NCT02500342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/11_2|Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism|Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism|TRUST FATIGUE|University Hospital Inselspital, Berne|Yes|Recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02500342||16897|
NCT02507934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUB0115MD|Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE)|A 2 Week, Randomized, Double-masked, Controlled, Parallel Group and 1 Week Follow-up Study to Evaluate Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE)||Dompé Farmaceutici S.p.A|No|Completed|June 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02507934||16313|
NCT02404467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST-TAVI|Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation|Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation The FAST-TAVI Study|FAST-TAVI|Institut für Pharmakologie und Präventive Medizin|No|Recruiting|January 2015|March 2017|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 250 consecutive patients with severe aortic stenosis selected for TF TAVI at        the respective site will be enrolled. Beyond the applicable criteria of the IFU no further        in- and exclusion criteria are defined.|December 2015|December 3, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404467|1 Year|24258|
NCT02410408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/310|Apps to Reduce the Impact That Adverse Events Among Health Professionals|Designing Guides and Tools to Reduce the Impact That Adverse Events Also Have Among Professionals and Health Institutions|ASV|Universidad Miguel Hernandez de Elche|No|Completed|January 2016|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|84|||Both|25 Years|65 Years|No|||December 2015|January 2, 2016|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02410408||23803|
NCT02499276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOREPS-2013-0802|Comparative Effects of Variable Pressure Support, NAVA and PAV|Comparative Effects of Variable Pressure Support, Neurally Adjusted Ventilatory Assist (NAVA) and Proportional Assist Ventilation (PAV) on the Variability of the Breathing Pattern and on Patient Ventilator Interaction||Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|Yes|Completed|May 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2015|December 28, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02499276||16979|
NCT02508987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYO.DIS.1904.13.002|Obesity and Oxidative Stress in Patients With Different Periodontal Status|Obesity and Oxidative Stress in Patients With Different Periodontal Status: A Cross-sectional Study||Ondokuz Mayıs University|Yes|Completed|September 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||6|Actual|93|Samples Without DNA|gingival crevicular fluid|Both|35 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Systemically healthy 45 normal weight adults and 48 class I obese adults|July 2015|July 23, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02508987||16233|
NCT02401425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1984|Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion|Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion: Randomised Controlled Trial||Ain Shams University|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|423|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 27, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401425||24490|
NCT02401672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pro00032313|rTMS for Smoking Cessation|Developing rTMS as a Potential Treatment for Nicotine Addiction||Medical University of South Carolina|No|Recruiting|May 2014|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02401672||24471|
NCT02494908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2372-15-SMC|Evidence of Neuroplasticity After Performing a Cognitive Task in Idiopathic Parkinson's Disease Patients|Can Diffusion Tensor MRI Brain Scan Demonstrate Microstructural Changes as Evidence of Neuroplasticity Following a Learning Process in Patients With Idiopathic Parkinson's Disease ?||Sheba Medical Center|No|Not yet recruiting|July 2015|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494908||17314|
NCT02494921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145515|LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC|A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer||University of California, San Francisco|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494921||17313|
NCT02510378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-072|Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases|Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases||Chinese Academy of Medical Sciences|No|Recruiting|January 2014|December 2022|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02510378||16126|
NCT02405039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-4|Study of EBI-005 in Dry Eye Disease (DED)|A Multi-Center, Double-Masked, Randomized, One-Year Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle-Control in Subjects With Dry Eye Disease (DED)|EBI-005|Eleven Biotherapeutics|Yes|Active, not recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|188|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405039||24214|
NCT02396953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-52030-309|Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly|Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR||Ipsen|Yes|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396953||24834|
NCT02396966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52030-306|Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.|A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel® Treatment.|ACRO QLQ|Ipsen|No|Recruiting|December 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Specialist care clinic and hospital clinic.|February 2016|February 29, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396966||24833|
NCT02507362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC/S/9341|Adapted Fluence Settings for Corneal Collagen Cross-linking in Mild to Moderate Progressive Keratoconus|Adapted Fluence Settings for Corneal Collagen Cross-linking in Progressive Mild to Moderate Keratoconus Aged 18 to 30||Tehran University of Medical Sciences|Yes|Active, not recruiting|August 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|30 Years|No|||July 2015|July 22, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02507362||16357|
NCT02507453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-028|Influence of Gravity on the Size-mass Illusion||Massper|University Hospital, Caen|No|Recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507453||16350|
NCT02501382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIONEC2-MBH-2015|Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment|Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response|BIONEC-II|Rigshospitalet, Denmark|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|112|Samples Without DNA|Whole blood and plasma/serum|Both|18 Years|N/A|No|Probability Sample|Patients with NSTI treated with HBOT|July 2015|July 15, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02501382||16817|
NCT02393781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01906-41|Adrenomedullin and Outcome in Severe Sepsis and Septic Shock|Adrenomedullin and Outcome in Severe Sepsis and Septic Shock. The AdrenOSS Study.|AdrenOSS|Sphingotec GmbH|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Plasma samples without DNA Blood samples (heparin-, EDTA-, EDTA/aprotinin plasma) and urine      samples will be collected at the admission, day 2, day 3 and the day of discharge for      measuring ADM and other markers|Both|18 Years|N/A|No|Probability Sample|600 patients admitted in intensive care unit of 26 hospitals, in 5 countries, with        diagnosis of severe sepsis or septic shock, will be included in this study.|July 2015|January 11, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393781||25078|
NCT02401217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL12|Tolerance of Healthy Infants Fed Infant Formulas|Tolerance of Healthy Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|126|||Both|N/A|30 Days|No|||January 2016|January 11, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02401217||24506|
NCT02401230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077593|PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV|Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection||Emory University|No|Recruiting|March 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401230||24505|
NCT02500043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS-102-302|Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer|Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments||Taiho Oncology, Inc.|Yes|Recruiting|December 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500043||16920|
NCT02500316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-004-extension|Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children|Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily R-human Growth Hormone (hGH) Therapy in Pre-pubertal Growth Hormone Deficient Children||Opko Biologics|Yes|Active, not recruiting|February 2013|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|3 Years|11 Years|No|||July 2015|July 14, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500316||16899|
NCT02403817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R33MH096967|Training Attention and Eye Movement in ASD|Wireless EEG System for Training Attention and Eye Movement in ASD||University of California, San Diego|No|Recruiting|November 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|9 Years|15 Years|No|||November 2015|November 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02403817||24308|
NCT02406742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-CLL-001|A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL|Phase 1/2 Study to Determine the Safety, Pharmacokinetics and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Rituximab, CC-122 and Ibrutinib, and CC-122 and Obinutuzumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|ENHANCE|Celgene|Yes|Recruiting|July 2015|January 2020|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|440|||Both|18 Years|79 Years|No|||March 2016|March 10, 2016|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406742||24085|
NCT02410616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/15|E-Compared-CH: Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial|European Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial|E-COMPARED_CH|University of Bern|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410616||23787|
NCT02410629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44HD074331-02|To Determine the Therapeutic Effect of the Music Glove and Conventional Hand Exercises to Subacute Stroke Patients|Influence of Timing on Motor Learning||University of California, Irvine|No|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2015|April 6, 2015|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02410629||23786|
NCT02400801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55300|Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients|||Universitaire Ziekenhuizen Leuven|No|Recruiting|June 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Female|18 Years|39 Years|No|||December 2015|December 16, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400801||24538|
NCT02400814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#251|MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer|Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer||University of California, Davis|Yes|Not yet recruiting|December 2016|January 2019|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|19 Years|N/A|No|||January 2016|January 20, 2016|January 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400814||24537|
NCT02398799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 03-568|Supporting Dyads Affected by Heart Failure|Supporting Dyads Affected by Heart Failure - A Randomised Controlled Study Evaluating a Psychoeducational Intervention||Linkoeping University|No|Completed|January 2005|December 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|155|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02398799||24692|
NCT02406365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-36|Diagnostic Imaging Aid for Management of Cervical Lesions|Development and Application of a Diagnostic Imaging Aid for One-visit Management of Cervical Lesions in Low-resource Settings|FFC|Brookdale University Hospital Medical Center||Not yet recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|618|||Female|18 Years|N/A|No|||April 2015|April 9, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02406365||24113|
NCT02408471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MCP-002|Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis|Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis|MCP|Integra LifeSciences Corporation|Yes|Active, not recruiting|February 2002|May 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||August 2015|August 11, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02408471||23952|
NCT02500030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIN2013-1|Air Stacking vs Glossopharyngeal Breathing in Neuromuscular Diseases|Effects of Air Stacking Versus Glossopharyngeal Breathing on Maximum Insufflation Capacity in Children and Adolescents With Neuromuscular Disease||University of Chile|Yes|Completed|June 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|5 Years|18 Years|No|||July 2015|July 13, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02500030||16921|
NCT02501889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20154971|The Lean Living Study|Walnut Consumption in a Weight Loss Intervention: Effects on Weight Change, Satiety and Potential Mediating Factors||University of California, San Diego|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501889||16778|
NCT02403024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-Walk-CRC|Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer|I-Walk-CRC - Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer||Rigshospitalet, Denmark|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02403024||24369|
NCT02406521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-523|Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases|Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases||Dana-Farber Cancer Institute|Yes|Recruiting|April 2015|January 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406521||24102|
NCT02406534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000|A Prospective, Observational Study of COPD Patients in U.S. Hospitals|||EPI-Q|No|Withdrawn||||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A||Non-Probability Sample|COPD patients admitted for a COPD exacerbation.|May 2015|May 4, 2015|March 30, 2015||No|Study entered in error|No||https://clinicaltrials.gov/show/NCT02406534||24101|
NCT02507752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22064|An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab|An Observational, Prospective, Multicenter, Local, to Assess the Quality of Life Through the Use of Questionnaires in a Cohort of Patients With Rheumatoid Arthritis Treated With Anti-CD20 Therapy||Hoffmann-La Roche||Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Both|18 Years|N/A|No|Probability Sample|Participants with RA initiating rituximab|January 2016|January 3, 2016|July 23, 2015|No|Yes||No|October 26, 2015|https://clinicaltrials.gov/show/NCT02507752||16327|
NCT02404272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50855|Effectiveness of an Oral Feeding Educational Nurse Program on Feeding Performance in Preterm Neonates|Evaluation de la Formation Des infirmières à la Stimulation de l'oralité Des Nouveau-nés Dans Une unité de Réanimation néonatale et Néonatologie : Impact Sur Les Connaissances, Les Pratiques et Sur la qualité Des Soins|TOP|Hospices Civils de Lyon|No|Recruiting|April 2013|||April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|700|||Both|24 Weeks|34 Weeks|No|Non-Probability Sample|Preterm neonates of less than 34 weeks' of gestation requiring no surgery with        endotracheal intubation admitted to the Neonatology or Neonatal Intensive Care Unit of an        university hospital, Lyon.|March 2015|March 26, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02404272||24273|
NCT02400359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000196|Lorcaserin in Obesity: Identification of CNS Targets Using fMRI|Lorcaserin in Obesity: Identification of CNS Targets Using fMRI||Beth Israel Deaconess Medical Center|No|Active, not recruiting|October 2014|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|January 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400359||24572|
NCT02397265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM2107|Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals|Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals||Imperial College London|Yes|Suspended|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|March 21, 2016|March 5, 2015||No|Awaiting further funding|No||https://clinicaltrials.gov/show/NCT02397265||24810|
NCT02397278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2797|Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee:|Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee: Does it Help? A Clinical and Magnetic Resonance Imaging (MRI) Study.||University of Colorado, Denver|Yes|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|10 Years|17 Years|No|||March 2016|March 18, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02397278||24809|
NCT02423590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009436QM|Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers|A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers|CEDAR|Queen Mary University of London|Yes|Recruiting|June 2014|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02423590||22790|
NCT02401854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSERT-III|Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder|Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder Using Automatic Algorithms for AF Detection: A Pilot Study (ASSERT-III)|ASSERT-III|Population Health Research Institute|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|||Both|80 Years|N/A|No|Non-Probability Sample|elderly patients attending primary care clinic or ambulatory resident of a chronic care        facility, with hypertension and at least one addional risk factor for developing AF.|April 2015|April 27, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02401854|60 Days|24457|
NCT02414932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPUH 05/14|Ketamine for Depression Relapse Prevention Following ECT|Ketamine for Depression Relapse Prevention Following ECT: a Randomised Pilot Trial With Blood Biomarker Evaluation|KEEP-WELL|St Patrick's Hospital, Ireland|Yes|Recruiting|April 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414932||23455|
NCT02414945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TILs-003-Meso|Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma|Phase I/II Study Evaluating the Infusion of Tumor-Infiltrating Lymphocytes (TILs) and Low-Dose Interleukin-2 (IL-2) Therapy Following a Preparative Regimen of Non-myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients With Malignant Pleural Mesothelioma||University Health Network, Toronto|Yes|Not yet recruiting|June 2015|November 2025|Anticipated|June 2025|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414945||23454|
NCT02422576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.13.NRC|Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia|Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia||Nestlé|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|55 Years|N/A|No|||October 2015|October 21, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02422576||22868|
NCT02422589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2103|A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors|A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)||Novartis|No|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422589||22867|
NCT02410876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331/2014|Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction|Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction Reveal Common Signalling Pathways Relevant for Disease Progression and Recovery|MoVe|University Hospital Inselspital, Berne|No|Recruiting|June 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|100|Samples Without DNA|cold cup biopsies of the bladder wall|Both|18 Years|N/A|No|Non-Probability Sample|Controls: patients with cystoscopy for stone disease or microhematuria without bladder        symptoms Patients with spinal cord injury or benign prostatic obstruction.|June 2015|June 1, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410876||23767|
NCT02394262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49261.068.14|Sequential Coronary CT-angiography and Biomarkers|Prediction of Atherosclerotic Plaque Burden Progression With Sequential Coronary CT-angiography and Biomarkers|PARSEC-NET|Maastricht University Medical Center|Yes|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|140|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02394262||25041|
NCT02411539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5342|Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)|A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2015|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||March 2016|March 18, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411539||23716|
NCT02415699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015045010|DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer|Randomized Controlled Trial Comparing DC-CIK Immunotherapy Combined With Adjuvant Chemotherapy and Adjuvant Chemotherapy Alone in Stage III Colorectal Cancer.||Sixth Affiliated Hospital, Sun Yat-sen University||Not yet recruiting|August 2015|July 2020|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||April 2015|April 13, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415699||23396|
NCT02406859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-13-010|Bowel Biofeedback in Persons With SCI|Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02406859||24076|
NCT02394548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-023|Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer|A Phase I Trial Of Intensity-Modulated Radiation Therapy (IMRT) Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Non-Small Cell Lung Cancer (NSCLC) And Limited-Stage Small Cell Lung Cancer (LS-SCLC).||Massachusetts General Hospital|Yes|Recruiting|June 2015|April 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394548||25019|
NCT02416128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH-4-012015|Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology|Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology||Larkin Community Hospital|Yes|Enrolling by invitation|April 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02416128||23363|
NCT02417922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-052|Effect of Autologous Conditioned Plasma Treatment for Conservative Treated Total Achilles Tendon Tears|The Effect of Autologous Conditioned Plasma Treatment for Conservative Treated Total Achilles Tendon Tears: Randomized Double Blinded Placebo Control Trial||Bispebjerg Hospital|No|Completed|February 2011|November 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|25 Years|60 Years|No|||April 2015|April 15, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT02417922||23225|
NCT02417935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14378|A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)|A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain||Eli Lilly and Company|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|410|||Both|20 Years|79 Years|No|||March 2016|March 8, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417935||23224|
NCT02407106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|027-15-KMC|Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children|Efficacy of Streptococcus Salivarius BLIS (Bacteriocin-like Inhibitory Substance) K12 as Preventive Measure for Rheumatic Children.||Kaplan Medical Center|No|Not yet recruiting|September 2015|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|6 Years|16 Years|No|||April 2015|April 2, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407106||24057|
NCT02403154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404651343|Comparison of Subcutaneous INFIX and EXFIX for Anterior Pelvic Ring Fractures Requiring Stabilization|Prospective Randomized Comparison of Subcutaneous Internal Fixation and External Fixation for Anterior Pelvic Ring Fractures Requiring Stabilization||Indiana University|Yes|Enrolling by invitation|April 2014|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403154||24359|
NCT02403167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL449A-E001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||July 21, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403167||24358|
NCT02403180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLW681-P001|DAILIES® AquaComfort Plus® MF - Comparative Assessment of Visual Performance-PART 2|Comparative Assessment of Visual Performance Between DAILIES® AquaComfort Plus® MF and PROCLEAR 1 Day MF||Alcon Research|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|41 Years|65 Years|No|||July 2015|July 21, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403180||24357|
NCT02413697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2014.650|Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing ART Treatment|A Randomised Control Trial of Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing Artificial Reproductive Technology Treatment||Chinese University of Hong Kong|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|480|||Female|24 Years|42 Years|No|||January 2016|January 26, 2016|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02413697||23550|
NCT02413710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-1501|Effects of Soy Protein on Body Composition and General Health in Healthy Children|A Randomized, Controlled, Parallel Study to Assess the Effects of Soy Protein on Body Composition and General Health Parameters in Healthy Children||DuPont Nutrition and Health|No|Recruiting|February 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|46|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02413710||23549|
NCT02397460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-015|Effect of AF-219 on Cough Reflex Sensitivity|A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects||Afferent Pharmaceuticals, Inc.|No|Recruiting|April 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397460||24795|
NCT02506920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gender and PPL|Gender Dependent Difference in Lipemia After 6 x OFTT in Young Healthy Subjects|Gender Dependent Difference in Postprandial Lipemia and Glucose Responses After Six Different Fat Tolerance Tests in Young Healthy Subjects||Herning Hospital|Yes|Completed|January 1997|December 1997|Actual|April 1997|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|14|||Both|22 Years|28 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02506920||16391|
NCT02508961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WS/0030|WEB-Based Physiotherapy for People With Multiple Sclerosis|WEB-Based Physiotherapy for People With Multiple Sclerosis|WEB-PaMS|University of Glasgow|No|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508961||16235|
NCT02508974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N14/06/061|Prevalence of Hospital Malnutrition in Adult Patients|Prevalence and Impact of Hospital Malnutrition on Associated Outcomes||University of Stellenbosch|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|18 Years|N/A|No|Probability Sample|All adult patients admitted to the hospitals (3 in South Africa [Tygerberg Academic        Hospital, Cape Town; Grootte Schuur Academic Hospital, Cape Town; Chris Hani Baragwanath        Hospital, Johannesburg]; 2 in Kenya [Aga Khan University Hospital, Nairobi; Mbagathi        district hospital, Nairobi] and 1 in Ghana [Korle Bu Teaching Hospital, Accra]) during the        defined study periods will be eligible for inclusion in the study.|July 2015|July 24, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02508974||16234|
NCT02395757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.862|Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)|Assessment Using Microperimetry of the Risk of a Fellow Eye Progressing From Stage 3 to Stage 4 (AREDS Classification) Age-related Macular Degeneration (AMD)|PREVISION|Hospices Civils de Lyon|No|Not yet recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|50 Years|N/A|No|||March 2015|March 23, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02395757||24926|
NCT02397707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-338-1126|Pharmacokinetics of GS-9857 in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment||Gilead Sciences|No|Completed|March 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397707||24776|
NCT02509338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9053|Validation of the Implantation of a New Electrode for the Treatment of Dystonia|Validation of an Electrode Internal Globus Pallidum Deep Brain Stimulation Lead Implantation for Treatment of Dystonia|MONOCONTACT|University Hospital, Montpellier|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|64 Years|No|||July 2015|July 27, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02509338||16206|
NCT02499822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09F401|REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial|Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial|REVERENT|Istituto Auxologico Italiano|No|Recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|35 Years|75 Years|No|||February 2016|February 23, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02499822||16937|
NCT02499835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15014|Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer|Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer||University of Wisconsin, Madison|Yes|Recruiting|July 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Male|18 Years|N/A|No|||February 2016|February 19, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499835||16936|
NCT02403973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/38-31/4|Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel vs a General Surgical Ward|Randomized Clinical Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel Versus a General Surgical Ward||Danderyd Hospital|No|Completed|April 2010|November 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|151|||Female|N/A|80 Years|No|||March 2015|March 30, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02403973||24296|
NCT02503631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers|Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers||Exact Sciences Corporation|No|Recruiting|October 2014|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Provide anonymous, clinically characterized specimens and blood samples for bio-repository      for future colorectal cancer-related test development.|Both|40 Years|90 Years|No|Non-Probability Sample|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic        biopsy-based diagnosis of CRC and/or a pre-malignant colorectal lesion with large enough        residual lesion to require subsequent surgical excision or complex colonoscopic        polypectomy.|January 2016|January 21, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02503631||16644|
NCT02496234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSDX-1503|The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery|||HealthSpan Dx|No|Recruiting|July 2015|August 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|White blood cells Plasma|Both|50 Years|N/A|No|Probability Sample|All subjects entered into this study will be patients of the Duke University Health        System.|March 2016|March 6, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02496234||17212|
NCT02396238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR Trial|Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)|Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover|STAR|Cytori Therapeutics|Yes|Recruiting|July 2015|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396238||24889|
NCT02403310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18157|A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML|A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|June 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403310||24347|
NCT02403323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA29145|Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144|AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144||Hoffmann-La Roche||Recruiting|June 2015|May 2024|Anticipated|May 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403323||24346|
NCT02403921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412205RINA|Association Between Cortisol, Cortisone, Cotinine, Nicotine, Caffeine, Melatonin Levels in Hair, Serum, Urine, Saliva and Chronic Stress|||National Taiwan University Hospital|No|Not yet recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult volunteer|March 2015|March 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403921||24300|
NCT02511080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 16/2015|Efectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences|Efectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences||Osakidetza|No|Enrolling by invitation|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511080||16072|
NCT02511093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|449/13|A Team-Based Care for Hypertension Management (TBC-HTA)|A Team-Based Care for Hypertension Management (TBC-HTA): A Randomized Controlled Study|TBC-HTA|Centre Hospitalier Universitaire Vaudois|No|Recruiting|September 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02511093||16071|
NCT02509117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B8271001|First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo Controlled First-in-human Trial To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06751979 After Oral Administration Of Single And Multiple Ascending Doses To Healthy Adult And Elderly Subjects||Pfizer|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|5||Anticipated|64|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02509117||16223|
NCT02496455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-S|The Impact of the SCN9A Gene Polymorphism on Postoperative Pain|The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section||Tokat Gaziosmanpasa University|Yes|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Two ml blood will be collected from the peripheral venous before the operation and all blood      samples will be stored at -80℃. Genomic DNA will be extracted from the blood samples and      polymorphism in SCN9A gene will be identified by PCR|Female|18 Years|45 Years|No|Non-Probability Sample|The women in 36 to 40 weeks of pregnancy undergoing cesarean section will be included|March 2016|March 9, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496455||17195|
NCT02408575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-NoA-Tin|Hearing Aids With "Notched Amplification" for the Treatment of Chronic Tinnitus|Hearing Aids With "Notched Amplification" for the Treatment of Chronic Tinnitus - A Controlled Randomized Pilot Study on Safety, Tolerability and Clinical Performance|NoA-Tin|University of Regensburg|Yes|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02408575||23944|
NCT02394418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-D-P-MV-220115|Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients|Comparison of Sedative Effects of Sevoflurane, Propofol and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Mechanically Ventilated Patients||Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy|No|Not yet recruiting|April 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|80 Years|No|||March 2015|March 16, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02394418||25029|
NCT02394431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Echo-Cardio|Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease|Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease||Brugmann University Hospital|No|Recruiting|November 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Sickle cell disease patients|October 2015|October 21, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394431||25028|
NCT02508441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB1537-001|Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors|A Phase 1 Open-label First-in-human Dose-escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available||Andes Biotechnologies|No|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|91|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|July 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508441||16275|
NCT02510222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatrics MS|Magnesium Therapy in Children With Cerebral Palsy|Effect of Magnesium Therapy on Spasticity and Constipation in Children With Cerebral Palsy||Ain Shams University|Yes|Recruiting|May 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Months|12 Years|No|||July 2015|July 27, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510222||16138|
NCT02408666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/0319|EEG@HOME (Phase 1 of the Project)|||University Hospital, Ghent|Yes|Completed|April 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|6 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408666||23937|
NCT02408679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-035|Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults|A Study to Validate a Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults||Lesieur|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|March 2015|March 31, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02408679||23936|
NCT02394704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13040640|Intervention for Intrusive Negative Thinking|Graduated Sensory Salience as an Intervention for Intrusive Negative Thinking||University of Pittsburgh|No|Recruiting|November 2015|March 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02394704||25007|
NCT02505360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-052|Biochemical and Histological Comparison of Nasal and Auricular Cartilage in the Fetus and Newborn With Cleft Lip Carrier|Comparaison Biochimique et Histologique Des Cartilages Nasal et Auriculaire Chez le fœtus et le Nouveau-né Porteur de Fente Labiale|CARTOON|University Hospital, Caen|No|Recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|N/A|28 Days|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505360||16511|
NCT02510274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3325-CL-0003|Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan|A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis||Astellas Pharma Inc|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|74 Years|No|||July 2015|July 27, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02510274||16134|
NCT02510287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEI-3413-2015|A Comparison of Epidural Analgesia: Continuous Infusion Versus Programmed Intermittent Boluses|||Fundación Santa Fe de Bogota||Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|132|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02510287||16133|
NCT02404636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4357|Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis|Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis|ADDUP|University Hospital Birmingham|No|Recruiting|January 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (aged over 18 years) admitted to Queen Elizabeth Hospital Birmingham, UK|November 2015|November 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404636||24245|
NCT02404857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9431|BCI Post-stroke Neurorehabilitation|A Novel BCI-controlled Pneumatic Glove System for Neurorehabilitation Post-stroke|BCI-stroke|University Hospital, Montpellier|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02404857||24228|
NCT02408172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-HT-1|Effects of Metroprolol and Amlodipine on Blood Pressure Variation in Hypertensive Sleep Apnea Syndrome|The Study Was Approved by the Ethics Committee of Our Institution, Which is Accredited by the Office of Human Research Protection as an Institutional Review Board||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|October 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||October 2014|April 2, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02408172||23975|
NCT02408185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagicBullet/COLPHAR|Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients|Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients With Severe Infections for Dose Optimization Study|COLPHAR|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02408185||23974|
NCT02502032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ0716|Effects of Cisatracurium on Sccinylcholine-induced Fasciculations|Effects of Pretreatment With Different Doses of Cisatracurium on Succinylcholine-induced Fasciculations||Yangzhou No.1 People's Hospital|Yes|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|87|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502032||16767|
NCT02409511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECISED Substudy|Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)|Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|January 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with diabetes mellitus type 2 with microalbuminuria with and without        retinopathy.        Control groups: diabetes mellitus type 1 with microalbuminuria and retinopathy        hypertensive patients with microalbuminuria and diabetic patients with a renal biopsy.|January 2016|January 22, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409511||23872|
NCT02400957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI-FE-023-013|Addition of Silver Nanoparticles to a Orthodontic Primer in Preventing Enamel Demineralization Adjacent Brackets|Effectiveness of the Addition of Silver Nanoparticles to a Orthodontic Primer in Preventing Enamel Demineralization Adjacent Brackets. ECCA||Universidad Autonoma de San Luis Potosí|Yes|Active, not recruiting|September 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|10 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400957||24526|
NCT02495662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPMAT|The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation|The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation|LIPMAT|Leiden University Medical Center|Yes|Recruiting|November 2015|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495662||17256|
NCT02495948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLA560-P001|Comparison of Two Marketed Silicone Hydrogel Lenses|One Month Clinical Comparison of Lotrafilcon B and Samfilcon A||Alcon Research|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|168|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495948||17234|
NCT02510404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREPID|Multivirus-specific Cytotoxic T Lymphocytes (mCTL)|Treatment of EBV, CMV, and Adenovirus Infections in Primary Immunodeficiency Disorders With Viral-specific Cytotoxic T-Lymphocytes||Children's Research Institute|Yes|Recruiting|April 2014|October 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|45 Years|No|||January 2016|January 27, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02510404||16124|
NCT02398487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAPECIG 2|Personal Vaporizer vs Cigalike|Head-To-Head Comparision of Personal Vaporizers Versus Cigalike: Prospective 6-Month Randomized Control Design Study|VAPECIG 2|Universita degli Studi di Catania|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02398487||24716|
NCT02405637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMASU 7/2013|Simulated Amniotic Fluid In Preventing Feeding Intolerance and Necrotizing Enterocolitis VLBW Neonates|Enteral Administration of a Simulated Amniotic Fluid In Preventing Feeding Intolerance And Necrotizing Enterocolitis In Very Low Birth Weight Neonates||Ain Shams University|Yes|Recruiting|March 2014|May 2015|Anticipated|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|28 Weeks|36 Weeks|No|||March 2015|March 28, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405637||24168|
NCT02406547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROMOSER|Study of Narrow Band Imaging in the Characterization of Serrated Lesions|Randomised Tandem Colonoscopy of Narrow Band Imaging (NBI) and White Light Endoscopy in Patients With Serrated Lesions|CROMOSER|Parc de Salut Mar|No|Recruiting|March 2015|March 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|41|||Both|50 Years|N/A|No|||October 2015|October 19, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406547||24100|
NCT02315209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR13-108|Multicentric Evaluation of UPP, UHS and Ultra Pro Comfort Plug for Inguinal Hernia Surgery Including Quality of Life Evaluation|||University of Magdeburg|Yes|Enrolling by invitation|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive Patients with inguinal Hernia, Age >18 ys., Mesh Augmentation with Ultra        Pro Hernia System, Ultra pro Plug or Ultra pro comfort Plug|December 2014|December 9, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315209|1 Year|31102|
NCT02315222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regenium|Dietary Supplements and Periodontal Wound Healing|Impact of Dietary Supplements on Oral and Periodontal Wound Healing||University of Milan|Yes|Recruiting|November 2014|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315222||31101|
NCT02318485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG13-003|Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial|Translational Stem Cell Research in Ophthalmology - Regenerating the Anterior Cornea Through Standardized Transplantation of Limbal Epithelial Stem Cells: a Phase II Multicenter Trial|MLEC|University Hospital, Antwerp||Not yet recruiting|January 2015|||December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02318485||30850|
NCT02296320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ID-MEDI4893-1139|Study of the Efficacy and Safety of MEDI4893|A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects|SAATELLITE|MedImmune LLC|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|462|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296320||32551|
NCT02297490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL1304AV|Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials|Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials||Allergopharma GmbH & Co. KG|No|Completed|January 2014|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|158|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02297490||32462|
NCT02297503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1211|Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster|An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure Alone or Restylane/Emervel Filler Alone||Q-Med AB|No|Active, not recruiting|October 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297503||32461|
NCT02309021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHospitalSwitz|PHAST: Physical Activity in Substitution Therapy|PHAST: Influence of Exercise Training on Substance Use, Substance Craving, Quality of Life, Mental Health, Sleep, and Physical Health in Patients Suffering From Opiate Dependence While Under Substitution Therapy|PHAST|University Hospital, Basel, Switzerland|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02309021||31577|
NCT02311777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092014-050|Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain|Effects of Pre-operative Pregabalin and Ketamine to Prevent Development of Phantom Pain in Patients Undergoing Lower Extremity Amputation||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|January 2015|January 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||December 2014|December 11, 2014|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311777||31365|
NCT02300623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI-IL2|Intermittent ART in Primary HIV Infection|Long Term Follow-up of Patients Experiencing Structured Treatment Interruption (STI) With or Without Low Doses of Interleukin-2 During Primary HIV Infection (PHI)|PHI-IL2|Hospital Clinic of Barcelona|Yes|Completed|March 2000|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300623||32221|
NCT02306343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-148|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the Experimental Device|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the Experimental Device||Insuline Medical Ltd.|No|Recruiting|November 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||November 2014|November 30, 2014|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02306343||31781|
NCT02309060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sTVi-1|Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial|Narrative Intervention to Disseminate ACT for Depression in Primary Care|sTVi-Open|Butler Hospital|No|Not yet recruiting|July 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309060||31574|
NCT02322463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0533-14-RMB-CTIL|Ethnicity and Analgesic Practice in a Pediatric Emergency Department|Ethnicity and Analgesic Practice in a Pediatric Emergency Department||Rambam Health Care Campus|No|Recruiting|December 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|5000|||Both|N/A|18 Years|No|Non-Probability Sample|All patients who were admitted to the pediatric ED due to a limb fracture between 01        January 2011 and 31 October 2014|February 2015|February 2, 2015|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02322463||30545|
NCT02322658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859147-01|Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322658||30530|
NCT02436655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00011929|Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis|Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial|AVATAR|Clinical Centre of Serbia|Yes|Recruiting|May 2015|June 2021|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|312|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436655||21787|
NCT02443870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|Long-term Urodynamics in Individuals With Neurogenic Lower Urinary Tract Dysfunction|Retrospective Analysis of Long-term Urodynamics in Individuals With Neurogenic Lower Urinary Tract Dysfunction||Swiss Paraplegic Centre Nottwil|No|Enrolling by invitation|May 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|individuals with neurogenic lower urinary tract dysfunction|September 2015|September 1, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02443870||21234|
NCT02443883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15608|A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer|Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma||Eli Lilly and Company|No|Recruiting|June 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443883||21233|
NCT02492841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPD-7-16|Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth|Controlled Clinical Trial of the Effect of Calcium Hydroxide, Mineral Trioxide Aggregate (MTA) and Biodentine (Trademark) as Direct Pulp Capping Materials of Permanent Teeth Affected by Caries, in Children From 7 to 16 Years||Universidad Los Andes, Chile|Yes|Recruiting|April 2014|May 2016|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|7 Years|16 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02492841||17473|
NCT02429180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF192|Rehabilitation Training After Stroke|Community-based Rehabilitation Training After Stroke: a Pilot Randomised Controlled Trial|ReTrain|NIHR Exeter Clinical Research Facility|Yes|Active, not recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02429180||22360|
NCT02429193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARRIER-P|Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA|An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial|BARRIER-P|University Health Network, Toronto|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02429193||22359|
NCT02431975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5011|Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial|Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial|LEOPARD|Columbia University|Yes|Recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|48 Hours|No|||January 2016|January 26, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431975||22147|
NCT02478346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|684812|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Fluoescein|Florida Hospital|No|Recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02478346||18585|
NCT02429466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0508|Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors|Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors||Indiana University|No|Suspended|November 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02429466||22338|
NCT02429531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57605|Polysaccharide Antibody Response Study|The Polysaccharide Antibody Response Study: Typhim Vi Response and Allohemagglutinins Versus Pneumovax 23 Vaccine Response in the Diagnosis of Specific Polysaccharide Antibody Deficiency|PARS|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Months|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429531||22333|
NCT02429544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0011|Effects of a Group Residential Retreat on Cancer Outcomes|Effects of a Group Residential Retreat on Cancer Outcomes||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|74|||Female|50 Years|N/A|No|||November 2015|November 6, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02429544||22332|
NCT02436226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT1|Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS|Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome||Mansoura University|No|Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|35 Years|No|||January 2016|January 29, 2016|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02436226||21820|
NCT02478580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-041|Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients|The Effects of Armodafinil (Nuvigil) on Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients||University of Texas Southwestern Medical Center|No|Completed|August 2011|January 2016|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Both|18 Years|75 Years|No|||February 2015|February 22, 2016|June 8, 2015|Yes|Yes||No|February 22, 2016|https://clinicaltrials.gov/show/NCT02478580||18567|
NCT02437682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASS-C|Translation and Validation of the PASS Test for GERD Patients With Partial Response to PPI in Chinese Population: PASS-C|Translation and Validation of the PASS Test for Gastro-esophageal Reflux Disease (GERD) Patients With Partial Response to PPI in Chinese Population: PASS-C||Chinese University of Hong Kong|No|Not yet recruiting|July 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Subject has been taking any PPI and still has persistent GERD symptoms during PPI therapy|May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437682||21708|
NCT02318706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-J303|DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain|AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION||Daiichi Sankyo Inc.|No|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|750|||Both|20 Years|N/A|No|||October 2015|October 22, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318706||30833|
NCT02318719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-J304|DS-5565 Phase III Study for Post-herpetic Neuralgia|AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION||Daiichi Sankyo Inc.|No|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|750|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318719||30832|
NCT02299089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-12-455|Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)|A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®||Camurus AB|No|Active, not recruiting|January 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|March 12, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299089||32339|
NCT02301585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLR EPN 2013/1337-31/2|Optimization of Fluid Therapy in Sepsis by a Passive Leg Raising Test|Optimization of Fluid Therapy by a Passive Leg Raising Test in Patients With Septic Shock in the ICU|OFTaPLR|Karolinska Institutet|Yes|Terminated|February 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 14, 2014||No|The study was stopped because of futility due to unexpected low weight gain in both groups.|No||https://clinicaltrials.gov/show/NCT02301585||32147|
NCT02319694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045557|Intraoperative Analysis of Reward and Impulsivity in the Basal Ganglia|Intraoperative Analysis of Reward and Impulsivity in the Basal Ganglia||Duke University|No|Enrolling by invitation|July 2013|||April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|30|||Both|21 Years|N/A|No|Non-Probability Sample|Participants are patients scheduled to be implanted with Deep Brain Stimulation devices        for treatment of Parkinson's Disease or Essential Tremor.|November 2015|November 11, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319694||30758|
NCT02319707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0553-14-RMC|Management of the Third Stage of Labor|Management of the Third Stage of Labor||Rabin Medical Center|Yes|Not yet recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Female|18 Years|45 Years|No|||September 2015|September 7, 2015|December 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319707||30757|
NCT02310542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.652|Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure|Comparison of Two Extracorporeal Liver Support System (With or Without Recirculation) : MARS (Molecular Adsorbents Recirculating System) Versus SPAD (Single Pass Albumin Dialysis) in Severe Liver Failure.|MARSPAD|Hospices Civils de Lyon|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|December 4, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02310542||31460|
NCT02299284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-219CR|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia||Teachers College, Columbia University|No|Recruiting|June 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|2 Years|12 Years|No|||November 2014|November 19, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02299284||32324|
NCT02320201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14080117|Foot Neuromodulation for Overactive Bladder in Children|Foot Neuromodulation for Overactive Bladder in Children||Children's Hospital of Pittsburgh|No|Enrolling by invitation|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02320201||30719|
NCT02320214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-7555|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||February 4, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320214||30718|
NCT02320227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-7557|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||February 4, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320227||30717|
NCT02294292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-CLD-DD-01|Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality|Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality||Institute of Liver and Biliary Sciences, India|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||February 2016|February 15, 2016|June 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02294292||32707|
NCT02294305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-S001560|Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder|||The Medical Research Network|No|Not yet recruiting|December 2014|||September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2014|November 14, 2014|November 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294305||32706|
NCT02295124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0267-AE|Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery|Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery||University Health Network, Toronto|No|Active, not recruiting|August 2012|February 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02295124||32643|
NCT02299154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00156-41|Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process :|Study of Memory Problems Perceptions With the French Adaptation of the Illness Perception Questionnaire Memory, Among Patients Who Come for the First Time at a Memory Center Until Diagnosis Disclosure Post-visit|REMAD|Central Hospital, Nancy, France|No|Recruiting|December 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299154||32334|
NCT02319902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SURN0015|Standard Carbon Dioxide Gas Versus Heated Humidified Gas in Gynaecological Laparoscopy|The Effects of Using Heated Humidified Carbon Dioxide Gas on Post Operative Pain Scores, Nausea and Analgesic Requirements in Patients Undergoing Gynaecological Laparoscopy: a Randomised Controlled Trial.||Royal Surrey County Hospital|Yes|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 14, 2014|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02319902||30742|
NCT02316704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G7_RSA_v1.02|Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty|Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty: A Single-Blinded Randomized Controlled Trial Evaluating Implant Migration, Acetabular Liner Wear, and Patient Reported Outcome||Hvidovre University Hospital|Yes|Recruiting|December 2014|||December 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|98|||Both|18 Years|75 Years|No|||August 2015|August 17, 2015|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02316704||30987|
NCT02295371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPC|Medication Incidents in Primary Care Medicine|Medication Incidents in Primary Care Medicine: A Study by the Swiss Federal Sentinel Reporting System|MIPC|University of Zurich|No|Completed|January 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|213|||Both|N/A|N/A|No|Non-Probability Sample|All patients consulting primary care practices|January 2016|January 11, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02295371||32624|
NCT02308124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409066609|Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study|Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study||Seoul National University Hospital|Yes|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308124||31645|
NCT02309515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC138E|Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis|Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)||Mayo Clinic|Yes|Recruiting|June 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||November 2015|January 8, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309515||31539|
NCT02325700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR02|Total Laparoscopic Versus Open Aortic Surgery for Abdominal Aortic Disease|Total Laparoscopic Versus Open Aortic Surgery for Abdominal Aortic Disease. A Prospective Study With Propensity Analysis||University of Poitiers|Yes|Completed|January 2006|December 2014|Actual|January 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|228|||Both|30 Years|80 Years|No|Non-Probability Sample|All consecutive patients presenting with an abdominal aortic aneurysm or an occlusive        aortic disease operated from January 2006 to January 2010.        Open repair was performed in145 patients (AAA=109, AOD=36) Total laparoscopic repair was        performed in 83 patients (AAA=30, AOD=53).|December 2014|December 21, 2014|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02325700|6 Years|30296|
NCT02325713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200585-001|Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers|A Phase I, Open-label, Randomized, Four-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of a Single Oral Dose of the New 150 mg Oral Dispersible Tablet (ODT) Formulation of Praziquantel (PZQ), MSC1028703A, at Different Dose Levels vs the Current Commercial 500 mg Tablet Formulation of PZQ in Healthy Male Volunteers||Merck KGaA||Completed|January 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02325713||30295|
NCT02302508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.143|Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients|PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients|PANDDA|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|December 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|108|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|November 24, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02302508||32076|
NCT02303262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC018|SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma|A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy||Sarcoma Alliance for Research through Collaboration|Yes|Recruiting|September 2015|January 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303262||32018|
NCT02295865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106239|A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis||Janssen Research & Development, LLC|No|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295865||32586|
NCT02316132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS stress|Confocal Laser Endomicroscopy, IBS and Stress|Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS: Add on Control Group: Does Stress Cause Similar Mucosal Changes to Food Antigens?||University of Schleswig-Holstein|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02316132||31031|
NCT02319642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0078|An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044|A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.|RAPID-C OLE|UCB Pharma|Yes|Enrolling by invitation|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|303|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319642||30762|
NCT02299570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection|A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection|PUNCH CD 2|Rebiotix Inc.|Yes|Recruiting|November 2014|October 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|117|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299570||32302|
NCT02300441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI-VISION Pilot Study|HI-VISION Pilot Study|HI-VISION - Hypotension Myocardial Ischemia-Vascular Events In Noncardiac Surgery Patients: a Cohort Evaluation: Pilot Study|HI-VISION|McMaster University|No|Active, not recruiting|September 2014|June 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|45 Years|N/A|No|Non-Probability Sample|Patients aged 45 or greater who present for noncardiac surgery with 2 or more risk factors        for heart disease and will be receiving a general or spinal anesthesia with an anticipated        length of stay of 3 days or more.|March 2016|March 15, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300441||32235|
NCT02319447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMC 2012-69|Increasing Kidney Transplant Among Blacks on the Transplant Waiting List|Increasing Kidney Transplant Among Blacks on the Transplant Waiting List||St. Barnabas Medical Center|Yes|Enrolling by invitation|December 2014|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|21 Years|N/A|No|||December 2014|December 17, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319447||30776|
NCT02319499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIAP|Zinc, Iron, Vitamin A and Psychosocial Care for Child Growth and Development|Zinc, Iron and Vitamin A Supplementation for Infant Growth and Development, and the Contributing Role of Psychosocial Care||Indonesia University|No|Completed|August 1998|||February 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|800|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||December 2014|December 13, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02319499||30772|
NCT02319746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG-CON|COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE|COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE||Basque Health Service|No|Recruiting|September 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|40 Years|No|||January 2016|January 18, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02319746||30754|
NCT02307292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QualiMed|Prospective, Post Market Surveillance Q3-registry (POLARIS)|Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.|Q3-Registry|QualiMed Innovative Medizinprodukte GmbH|No|Recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|19 Years|N/A|No|Probability Sample|Patients with single significant (>50%) superficial femoral artery disease|January 2015|January 9, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02307292|24 Months|31709|
NCT02300701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT|Role of Anti-IgE in Severe Childhood Eczema|The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema|ADAPT|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|December 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|4 Years|19 Years|No|||August 2015|October 22, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300701||32215|
NCT02300714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0822|Fluoroscopically-guided Epidural Block in the Midthoracic Region: A Comparison of Anterioposterior Versus Oblique View Approach|||Yonsei University|Yes|Recruiting|November 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|30|||Both|20 Years|80 Years|No|||November 2014|November 24, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300714||32214|
NCT02312622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0067|Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer|A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)||Stanford University|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312622||31300|
NCT02316210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKD-TURB-001|Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema|Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema|TURBO|Firstkind Ltd|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02316210||31025|
NCT02316223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1401|Supporting Asthma Management Behaviors in Aging Adults|Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics|SAMBA|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|450|||Both|60 Years|N/A|No|||September 2015|September 29, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316223||31024|
NCT02326779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSFC 81302455|Low-dose Aspirin Therapy for Esophageal Cancer|Low-dose Aspirin Therapy for Stage II-III Esophageal Cancer- A Multi-Center, Open Label, Randomized Controlled Phase III Trial||Zhejiang University||Not yet recruiting|March 2016|||October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326779||30213|
NCT02296658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2013RE-088|A Phase II Study of Postoperative S-1-Based Chemoradiotherapy in Gastric Cancer|A Phase II Trial of Intensity-Modulated Radiotherapy Combined With S-1 Based Chemotherapy in Completely Resected Gastric Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296658||32525|
NCT02298907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EM/1038|CPET in Colorectal Surgery|Cardiopulmonary Exercise Variables Are Associated With Postoperative Morbidity After Major Colorectal Surgery - A Validation Study||Aintree University Hospitals NHS Foundation Trust|No|Completed|June 2010|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|170|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive colorectal cancer patients recruited via colorectal multidisciplinary meeting|June 2015|June 25, 2015|June 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02298907|1 Week|32353|
NCT02298920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4930C00003|AZD0914 Phase 1 ADME Study in Healthy Volunteers|A Phase I, Open-Label Study to Assess the Absorption, Metabolism, Excretion, Safety and Tolerability of a Single Oral Dose of Radiolabeled [14C]-AZD0914 in Healthy Male Subjects||Entasis Therapeutics|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298920||32352|
NCT02317133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOIt/2013/TAT-01|Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura|Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura|FOX-TREG|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|120|Samples With DNA|Stool samples: DNA extractions for microbiota analysis. Blood samples: DNA extractions for      bacterial translocation analysis Blood samples: samples remaining will be kept for further      analysis|Both|3 Years|17 Years|No|Non-Probability Sample|Three different populations will be included in this study: (A) patients presenting with        an acute episode of Henoch Schönlein purpura; (B) patients who have had an episode of        Henoch Schönlein purpura in the past, but currently present with no symptoms; (C) a group        of control patients recruted from elective surgery candidates at the participating        hospitals.|August 2015|September 4, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317133||30954|
NCT02320266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0358|Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery|Sensory Gating Measured With Microelectrode Recording During Deep Brain Stimulation Surgery||University of Colorado, Denver|No|Recruiting|December 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Parkinson's Disease who are planning to undergo DBS surgery. Age matched        controls without Parkinson's Disease or a history of mental illness.|March 2016|March 1, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320266||30714|
NCT02320409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-012-00CH2|A Food Effect Phase I Study of the Sufatinib in Healthy Subjects (HMPL-012)|||Hutchison Medipharma Limited|No|Completed|December 2014|April 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320409||30703|
NCT02299856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/13.2|Cardiac Magnetic Resonance in Acute Myocarditis|Cardiac Magnetic Resonance in Acute Myocarditis||University Hospital, Bonn|No|Completed|March 2014|September 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|Samples With DNA|Hematocrit is obtained prior to cardiac MR.|Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients are included in the myocarditis group if they showed clinical evidence of acute        myocarditis(acute chest pain, history of viral infection, elevated white blood cell count,        ECG changes and/or elevated troponin).|December 2015|December 9, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02299856||32280|
NCT02299869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-51|Comparative Study to Evaluate the Cosmetic Appearance of Two Brands of Color Soft Contact Lenses.|Comparative Study to Evaluate the Cosmetic Appearance of Two Brands of Color Soft Contact Lenses.||Coopervision, Inc.|No|Completed|October 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|40|||Both|18 Years|40 Years|No|||July 2015|July 23, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299869||32279|
NCT02299141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412116|Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer|A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Washington University School of Medicine|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02299141||32335|
NCT02307149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA013|Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma|Phase Ib Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma||Viralytics||Recruiting|February 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307149||31720|
NCT02311283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDC5112|Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment|Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment||University of South Florida|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with urea cycle disorders will be recruited via the RDCRN UCDC Contact Registry.        The UCDC contact registry consists of over 300 participants with urea cycle disorders.|December 2014|December 4, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02311283|1 Year|31403|
NCT02295800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF0098|The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV|The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV||Elizabeth Glaser Pediatric AIDS Foundation|No|Enrolling by invitation|April 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1216|Samples With DNA|Plasma specimens collected from the adult participants at the time of viral load testing and      dried blood spot (DBS) specimens drawn from the infant participants.|Female|N/A|N/A|No|Non-Probability Sample|Pregnant women identified as HIV infected during antenatal care and receiving PMTCT        services (regardless of ARV regimen received) in the selected antenatal clinics in Kigali,        Rwanda are eligible for study enrollment. The infants born to enrolled study women during        the study pregnancy will also be study participants up to the age of 18 - 24 months.|November 2014|November 20, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02295800||32591|
NCT02296060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6MWT pregnancy|Evaluation of Exercise Tolerance During Pregnancy|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Not yet recruiting|December 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Female|18 Years|50 Years|No|||November 2014|November 18, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296060||32571|
NCT02306759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|669443-1|Ketamine For Acute Treatment of Pain in Emergency Department|Ketamine For Acute Treatment of Pain in Emergency Department|KETAFAP|The Brooklyn Hospital Center|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306759||31750|
NCT02306772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0501|TP0501 - Pharmaco-Scintigraphic-Study|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations.||Tillotts Pharma AG|No|Completed|December 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306772||31749|
NCT02306785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0502 + A|TP0502-Pharmaco-Scintigraphic-Study and Amendment|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects and Patients With Active Ulcerative Colitis With Radio-labelled TP05-tablets to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations (and Amendment)||Tillotts Pharma AG|No|Completed|October 2012|June 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306785||31748|
NCT02306798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0502 - B|TP0502-B-Pharmaco-Scintigraphic-Study|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profile||Tillotts Pharma AG|No|Completed|September 2013|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|December 3, 2014|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306798||31747|
NCT02296463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-P-101|A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age|A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine, With or Without Aluminum Adjuvant, in Healthy Subjects 24 to <72 Months of Age||Novavax|No|Active, not recruiting|November 2014|March 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|32|||Both|24 Months|72 Months|Accepts Healthy Volunteers|||February 2016|February 22, 2016|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02296463||32540|
NCT02296476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-002|A Trial With Dose Optimization of OTX015 in Recurrent Glioblastoma Multiforme (GBM) Patients|A Phase IIa Trial With Dose Optimization of OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-terminal (BET) Proteins, in Recurrent Glioblastoma Multiforme (GBM) Patients|OTX015_107|Oncoethix GmbH|Yes|Terminated|October 2014|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296476||32539|
NCT02315729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0884|Analysis of Prognostic Cell Signaling Factors in Adolescent Idiopathic Scoliosis|Analysis of Prognostic Cell Signaling Factors in Adolescent Idiopathic Scoliosis||University of Colorado, Denver||Not yet recruiting|November 2016|||November 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Female|10 Years|13 Years|No|Non-Probability Sample|Female patients with adolescent idiopathic scoliosis|December 2015|December 10, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02315729||31062|
NCT02315742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076644|Hearts and Minds in HIV|Healing Hearts and Mending Minds in Older Persons Living With HIV||Emory University|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|N/A|No|||February 2016|February 16, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315742||31061|
NCT02296190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSP-2017-1109|Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm|Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia to Sinus Rhythm|NODE-1|Milestone Pharmaceuticals Inc.|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296190||32561|
NCT02296203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GONO 10|Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).|A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE|CRICKET|Gruppo Oncologico del Nord-Ovest||Recruiting|October 2014|||October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02296203||32560|
NCT02319564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConRCT1|CONjuGATE Wheezy Child Study|Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children|CONjuGATE|University of Calgary|Yes|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|12 Months|60 Months||||December 2014|December 13, 2014|November 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319564||30768|
NCT02296333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 2014 05|Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen|Double Blinded Study Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen|OOEOPAOA|Mustafa Kemal University|Yes|Completed|May 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|80 Years|No|||March 2015|March 12, 2015|August 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296333||32550|
NCT02301546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG045163|Cognitive Training and Practice Effects in MCI|||University of Utah|No|Recruiting|March 2015|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||December 2015|December 1, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301546||32150|
NCT02306239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012A080204018|The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients|the Surgical Intensive Care Unit||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|December 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||December 2014|December 25, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306239||31789|
NCT02309723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEVR-2013-001|How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints|A Survey of Clinicians to Assess the Influence of Beta-amyloid Imagining Information on the Diagnosis and Management of Hypothetical Patients With Cognitive Complaints||Tufts Medical Center||Completed|September 2013|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|315|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309723||31523|
NCT02309736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-14-002|ReSure Sealant Device Exposure Registry|Device Exposure Registry: A Post-Approval Observational Registry of ReSure Sealant to Track the Incidence of Endophthalmitis After Sealing Corneal Incisions in Patients Undergoing Clear Corneal Cataract Surgery||Ocular Therapeutix, Inc.|No|Not yet recruiting|January 2016|||January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4857|||Both|N/A|N/A|No|Non-Probability Sample|All patients that received at least one application of the ReSure Sealant on the operative        eye following cataract surgery will be enrolled.|October 2015|October 6, 2015|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309736||31522|
NCT02316184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA023726|Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons|Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons|REACH|Butler Hospital|Yes|Recruiting|January 2015|June 2019|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316184||31027|
NCT02304081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/8010-DASA-001|Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function|Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment||Profil Mainz GmbH & Co KG|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|30 Years|75 Years|No|||January 2016|January 28, 2016|November 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304081||31955|
NCT02307617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004662|Glutamate Probes in Adolescent Depression|Glutamate Probes in Adolescent Depression|GPII|Mayo Clinic|Yes|Recruiting|July 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|100|||Both|13 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|This protocol will plan to screen depressed children and adolescents who are seeking        treatment at Mayo Clinic in Rochester, MN, using strict inclusion and exclusion criteria.        These adolescents will represent gender and minority distribution consistent with the        Rochester metro/rural area demographic distribution. This study will be inclusive of all        races, genders, and socioeconomic classes.|December 2015|December 31, 2015|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02307617||31684|
NCT02293863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29216|A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Patients With Severe Influenza A Infection|A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION||Genentech, Inc.||Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293863||32740|
NCT02293876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU CORNEAL ULCER 01|Corneal Lesions in Intensive Care Unit (ICU) Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center|Risk for Corneal Injury in Critically Ill Patients and Effect of Nursing Interventions for Its Prevention: Randomized Controlled Trial|CORNEALPREV|Hospital Risoleta Tolentino Neves|Yes|Completed|April 2013|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|360|||Both|18 Years|93 Years|No|||November 2014|November 18, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293876||32739|
NCT02309749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-AD13-01|CAP Pilot Study for Obstructive Sleep Apnea (OSA)|||Fisher and Paykel Healthcare|No|Completed|April 2013|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|21 Years|75 Years|No|Non-Probability Sample|Sleep laboratory, DME supplier|December 2014|December 4, 2014|April 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02309749||31521|
NCT02309762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB825CLCT01|A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers|A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825||Fountain Biopharma Inc.|Yes|Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309762||31520|
NCT02437084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STANFORD|Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling|Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling||Stanford University|No|Recruiting|May 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437084||21754|
NCT02427945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1827/006|Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost|Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost||Institute for Fiscal Studies|No|Active, not recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1671|||Both|N/A|18 Months|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02427945||22455|
NCT02427958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leuprorelin-4001|A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Patients|An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty||Takeda|No|Not yet recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|1 Year|9 Years|No|||April 2015|April 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02427958||22454|
NCT02440971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFU-CM-001|Adaptive Servo Ventilation (ASV) in Heart Failure|Adaptive Servo Ventilation (ASV) in the Management of Acute Decompensated Heart Failure (ADHF)||St Vincent's University Hospital, Ireland|No|Recruiting|May 2013|September 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted into hospital for acute management of ADHF are eligible to participate        in this study (providing inclusion/exclusion criteria are met)|May 2015|May 7, 2015|December 23, 2013||No||No||https://clinicaltrials.gov/show/NCT02440971||21456|
NCT02441036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-140|Gene Expression Following Ultherapy® Treatment|Evaluation of Changes in Gene Expression Following Ultherapy® Treatment||Ulthera, Inc|No|Recruiting|March 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|15|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441036||21451|
NCT02482597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1129|Whole Body Periodic Acceleration on Blood Lactate and Recovery|The Effects of Whole Body Periodic Acceleration on Blood Lactate and Recovery in Trained Individuals||New York Institute of Technology|No|Recruiting|June 2015|||May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482597||18258|
NCT02433626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COTI2-101|A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies|A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies.|COTI2-101|Critical Outcome Technologies Inc.|No|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433626||22020|
NCT02433639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1412-023-631|Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer|||Seoul National University Hospital|No|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|N/A|No|||April 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02433639||22019|
NCT02433145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405086RINB|Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children|Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children||National Taiwan University Hospital|Yes|Recruiting|October 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|220|||Both|4 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit 100 typical developmental control and 120 ADHD high risk preschool        children at time 1, and we using the diagnosis at time 2 to have three groups in this        study (ADHD persistent, ADHD remission and typical developmental control).|April 2015|April 29, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433145||22057|
NCT02433158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5201003|Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease|An Open-label Extension Study To Evaluate The Safety Of Rivipansel (Gmi-1070) In The Treatment Of One Or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease||Pfizer|Yes|Recruiting|November 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|6 Years|N/A|No|||March 2016|March 4, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433158||22056|
NCT02435927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN001-002SG|ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin|Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin||National Cancer Centre, Singapore|No|Recruiting|August 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|21 Years|N/A|No|||November 2015|November 8, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02435927||21843|
NCT02435940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFB-Registry-01|Inherited Retinal Degenerative Disease Registry|Foundation Fighting Blindness Registry, My Retina Tracker||Foundation Fighting Blindness Clinical Research Institute|No|Recruiting|June 2014|June 2034|Anticipated|June 2034|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Affected individuals and close unaffected and genetically related family members|March 2016|March 21, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02435940|20 Years|21842|
NCT02482831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anesthesiologyPUMCH002|The Difference in Duration of Sciatic Nerve Block Between Diabetic and Non-diabetic Patients|The Difference in Duration of Sciatic Nerve Block Between Diabetic and Non-diabetic Patients|DSNBD|Peking Union Medical College Hospital|Yes|Recruiting|September 2014|August 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|53|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo unilateral lower limb surgery in Peking Union Medical College        Hospital.|June 2015|June 23, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02482831||18240|
NCT02433899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP CMM/HUAP no 162/2010|Microsurgical Versus Conventional Semilunar Coronally Advanced Flap|A Clinical Comparison of Microsurgical Versus Conventional Surgical Approaches for the Semilunar Coronally Advanced Flap||Universidade Federal Fluminense|Yes|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 4, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02433899||21999|
NCT02433431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBSTUDY2015_00000122|Mechanisms of Mindfulness and Stress Resilience: A Mobile App Mindfulness Training Study|||Carnegie Mellon University|No|Recruiting|February 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|150|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02433431||22035|
NCT02443974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1248/09|Bracing to Treat Knee Osteoarthritis in Elderly|||Federal University of São Paulo||Recruiting|May 2012|October 2015|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|60 Years|N/A|No|||August 2015|August 25, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02443974||21226|
NCT02487420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57588|Gradual Egg-tolerance Induction in Hen's Egg Allergic Children|Trapsgewijze Ei-tolerantie-inductie Bij Kippenei-allergische Kinderen (TETI Studie)|TETI|Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2015|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|12 Months|18 Years|No|||July 2015|July 6, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487420||17888|
NCT02487433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921217|A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers|A Phase 1, Randomized, Open Label, Single Dose, 2 Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (mr) 22 Mg Tablets In Healthy Volunteers||Pfizer|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487433||17887|
NCT02442154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/HD07/2134U|Early Tracheostomy Versus Standard of Care in Patients With Severe Head Injury|EARLY TRACHEOSTOMY VERSUS STANDARD OF CARE, A RANDOMIZED CONTROLLED CLINICAL TRIAL IN PATIENTS WITH SEVERE HEAD INJURY IN MULAGO HOSPITAL|E-Trac|Makerere University|No|Completed|June 2015|March 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|10 Years|N/A|No|||August 2015|March 17, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02442154||21365|
NCT02442167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008579|Performance of FISH for the Diagnosis of Malignant Biliary Strictures in Thai Patients|Fluorescence in Situ Hybridization (FISH) Improves Performance of Conventional Cytology for the Diagnosis of Malignant Biliary Tract Strictures in Thai Patients||Mayo Clinic|No|Completed|March 2010|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|Samples Without DNA|Brush samples obtained from endoscopic retrograde cholangiopancreatography|Both|18 Years|N/A|No|Non-Probability Sample|Patients being evaluated for malignant appearing biliary tract strictures who undergo ERCP|May 2015|May 8, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02442167||21364|
NCT02432950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14253|Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer|PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors||City of Hope Medical Center|Yes|Recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Female|N/A|N/A|No|||March 2016|March 3, 2016|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432950||22072|
NCT02432963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15002|Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy|A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab||City of Hope Medical Center|Yes|Active, not recruiting|November 2015|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432963||22071|
NCT02322359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-D20-VOL.21|Compression Is Life In Cardiac Arrest - Fatigue Study|Impact of a Feedback Device, CPRmeter®, on Chest Compression Quality During Extend Cardio-pulmonary Resuscitation. A Manikin Study.|CILICA-FS|University Hospital, Caen|No|Completed|August 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Volunteers from University hospital of Caen pre-hospital unit|December 2014|December 19, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02322359||30553|
NCT02303717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS Project ID162820|Xience Versus Synergy in Left Main PCI|Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population|IDEAL-LM|NHS National Waiting Times Centre Board|Yes|Not yet recruiting|December 2014|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|818|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02303717||31983|
NCT02322177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150049|Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol|Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|December 2014|October 2024|Anticipated|October 2024|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Female|14 Years|50 Years|No|||August 2015|October 6, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322177||30567|
NCT02316015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201422489|Protein-energy Enriched Milk for Infants With Bronchiolitis|Protein-energy Enriched Milk for Infants With Bronchiolitis|PEMIB|Universitair Ziekenhuis Brussel|No|Recruiting|December 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|44|||Both|N/A|2 Years|No|||June 2015|June 15, 2015|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02316015||31040|
NCT02303938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44024.008.13|Effects of Exercise on Cognitive Function in Glioma Patients|A Pilot Randomized Controlled Trial on the Feasibility and Efficacy of an Exercise Intervention to Improve Cognitive Functioning in Patients With Glioma||University of Tilburg|Yes|Completed|August 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||August 2015|August 3, 2015|July 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02303938||31966|
NCT02293616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30880|Strength Testing After Nitrate Delivery (STAND) in ICU Patients|Strength Testing After Nitrate Delivery (STAND) in ICU Patients||Wake Forest School of Medicine|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|56 Years|N/A|No|||December 2015|December 21, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293616||32759|
NCT02293629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM008-003|A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects|A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293629||32758|
NCT02293642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-268|Bone Pain Score Validation Initiative|Prospective Epidemiology Study to Validate the BOMET-QoL-10 in Patients With Bone Metastasis in Germany|ARIE|iOMEDICO AG|No|Active, not recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|370|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with bone metastases from primary cancers of the breast, kidney, lung        or prostate|February 2016|February 23, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293642||32757|
NCT02325622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1C-2014|Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes|Relationships Between Mean Plasma Glucose and HbA1c in Compensated and Decompensated Cirrhotic Patients With Hepatogenous Diabetes||Yonsei University|Yes|Recruiting|December 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|Samples Without DNA|LSP, fructosamine|Both|20 Years|70 Years|No|Probability Sample|liver cirrhosis diagnosed after combining clinical symptoms (thrombocytopenia,        gastric/esophageal varices, ascites), histologic studies, and imaging studies (ultrasound,        Fibroscan)|December 2014|December 24, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325622||30302|
NCT02297945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRA112025-002|Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome|Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks|PROMPT|HRA Pharma|No|Not yet recruiting|January 2015|September 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297945||32427|
NCT02297958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01041-46|Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma|Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma|IFFaLCCO|Rennes University Hospital||Recruiting|January 2015|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|N/A|No|Non-Probability Sample|Patient with ovarian carcinoma|January 2016|January 25, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297958||32426|
NCT02299102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12|A Study Comparing Powered Ported Bone Marrow Aspiration Procedures to Manual Standard Bone Marrow Aspiration Procedures Using Healthy Volunteers|A Study Comparing Powered Ported Bone Marrow Aspiration Procedures to Manual Standard Bone Marrow Aspiration Procedures Using Healthy Volunteers||Vidacare Corporation|No|Enrolling by invitation|October 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02299102||32338|
NCT02304939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP-2013|CHangeovers of Norepinephrine in Intensive Care|Prospective, Randomized, Multi-center Trial Aiming to Determined the Impact of Changeovers of Norepinephrine on the Blood Pressure Stability With Patients in Shock in ICU.|CHIC|University Hospital, Angers|Yes|Active, not recruiting|November 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|195|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304939||31889|
NCT02304952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lateral epicondylalgia|Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Lateral Epicondylalgia|Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Chronic Lateral Epicondylalgia - a Randomized Controlled Trial||Capio Sankt Görans Hospital|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304952||31888|
NCT02322437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDAG-0001|Home Treatment for Acute Psychiatric Care|Home Treatment for Acute Psychiatric Care in the Canton of Aargau (Switzerland): A Randomized Controlled Trial||Psychiatric Services Aargau AG|No|Not yet recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|64 Years|No|||December 2014|December 22, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02322437||30547|
NCT02294552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTCy-2014|Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT|High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation||St. Petersburg State Pavlov Medical University|No|Active, not recruiting|October 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02294552||32687|
NCT02299297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1502|An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis|An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis||Columbia University|No|Active, not recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299297||32323|
NCT02299310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2014-088|Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease|Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease||Chinese PLA General Hospital|Yes|Not yet recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||November 2014|November 29, 2014|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299310||32322|
NCT02309528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK091363|Chronic Kidney Disease Knowledge and Awareness Among American Indians|Chronic Kidney Disease Knowledge and Awareness Among American Indians||The Cleveland Clinic|No|Active, not recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 3, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02309528||31538|
NCT02314260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13802022|Modifying Cervical Bishop Scoring System|Bishop Score; Are Further Modifications Needed?||Kasr El Aini Hospital|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Female|20 Years|34 Years|Accepts Healthy Volunteers|Probability Sample|80 primigravidas undergoing induction of labour at our hospital in a prospective study        were subjected to history taking, examination, investigations & ultrasonography.        Indication for pregnancy termination was explained to each patient and a written consent        was obtained.|January 2015|January 8, 2015|December 6, 2014||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT02314260||31175|
NCT02308475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro31584|Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System|Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System||Medical University of South Carolina|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|85 Years|No|||February 2016|February 3, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308475||31618|
NCT02300194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-157|Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures|Topical Morphine for Analgesia in Pediatric Procedures. Clinical Trial Randomized, Double-blind, Placebo.||Hospital General de Niños Pedro de Elizalde|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|1 Month|10 Years|No|||February 2016|February 26, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300194||32254|
NCT02319421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010928|Reducing the Risk of Alarm Fatigue Through the Use of Focused Management in Safety Huddles|Reducine the Risk of Alarm Fatigue Through the Use of Focused Management in Safety Huddles||Children's Hospital of Philadelphia|No|Recruiting|March 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2250|||Both|N/A|N/A|No|||December 2015|December 28, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319421||30778|
NCT02322203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150042|Effects of Niacin Therapy on Lipoprotein Composition and Function|Evaluation of the Effects of Niacin Therapy on Lipoprotein Composition and Function||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02322203||30565|
NCT02304094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDN001|Morton's Neuroma: Manipulation Versus Steroid Injection|A Randomised Controlled Trial to Compare the Clinical Effectiveness of Lower Extremity Manipulation to That of Steroid Injection in the Treatment of Morton's Neuroma||Queen Margaret University|Yes|Not yet recruiting|January 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304094||31954|
NCT02306538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6543C|Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI|Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study|EMBRACE-MRI|University Health Network, Toronto|No|Recruiting|October 2013|July 2019|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women ≥18 years with stage I-III, HER2+ breast cancer|June 2015|June 17, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02306538||31767|
NCT02321722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-0125-14|The Effect of Colonoscopy on Intralocular Pressure|The Effect of Colonoscopy on Intralocular Pressure||Meir Medical Center|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population are healthy examinees, undergoing routine colonsocopy examination.        All have no ocular disese and family history of glucoma.|September 2015|September 22, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321722||30602|
NCT02322333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLD10-002|MLD10 in the Prevention of Migraine in Adults|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of MLD10 in the Prevention of Migraine Headache in Adults||Pharmalyte Solutions LLC|No|Recruiting|March 2015|||November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|142|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322333||30555|
NCT02295072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP2013-47540-R|Effects of an Exercise Program on Cognition and Brain in Overweight/Obese Preadolescent Children|ActiveBrains: Effects of an Exercise-based Randomized Controlled Trial on Cognition, Brain Structure and Brain Function in Overweight/Obese Preadolescent Children|ActiveBrains|Universidad de Granada|No|Enrolling by invitation|December 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|9 Years|10 Years|No|||September 2015|September 16, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02295072||32647|
NCT02306603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2014/5/4.3 (3972)|Long-term Outcomes of Endoscopic Resection (ER) of Lesions of the Duodenum and Ampulla|Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Duodenum and Ampulla|OERDA|Western Sydney Local Health District|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who have Duodenal and ampullary adenomas which are amendable to Endoscopic        Mucosal Resection|December 2015|December 15, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306603||31762|
NCT02306616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC-ACS-2014|CCC Project- Acute Coronary Syndrome|Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome||Beijing Institute of Heart, Lung and Blood Vessel Diseases||Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|76500|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized patients with acute coronary syndrome|January 2016|January 5, 2016|November 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02306616||31761|
NCT02316886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-13|The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics|The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics|PREVENT|Asan Medical Center|Yes|Recruiting|October 2015|June 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02316886||30973|
NCT02312154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1120048|Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces|Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces||Konkuk University Hospital|Yes|Completed|April 2014|December 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|25 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 16, 2015|December 5, 2014||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT02312154||31336|First, it did not have a double-blind design, and so the GAIS scores of the subjects could have been influenced. Second, the posttreatment follow-up period was relatively short, at 12 weeks. Finally, the patient sample in this study was small.
NCT02300428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6531|Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK.|Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK.||Medical Research Council|No|Active, not recruiting|November 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|422000|||Both|N/A|N/A|No|Probability Sample|For the 1-year cohort study we are not defining a sub-population group and will        investigate all individuals (adults and children) prescribed any type of oral iron at        least once in the time period assessed, although a breakdown by key sociodemographic (age,        gender, ethnicity) will be conducted.        For the 10-year plus cohort study, pre-menopausal women in receipt of ferrous iron        supplements are our study population of interest.        Pre-menopausal women are the population group with the largest number of individuals        affected (nearly 2M) by IDA in the UK, mainly because dietary iron intake does not        sufficiently offset menorrhagic iron losses.|September 2015|September 9, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02300428||32236|
NCT02307084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/2014/4661|Ultrasound to Prevent Leg Wound Complications in Heart Bypass.|An Investigation Into the Efficacy of Pre-operative Long Saphenous Vein Mapping Using Ultrasound for Use in Coronary Artery Bypass Grafting to Reduce Vein Harvest Site Complications.||University Hospitals Bristol NHS Foundation Trust|No|Not yet recruiting|February 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|106|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307084||31725|
NCT02320773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-MA-1002|A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice|Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)|BELIEVE|Astellas Pharma Inc|No|Active, not recruiting|November 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|863|||Both|18 Years|N/A|No|Probability Sample|Secondary care centers|October 2015|October 7, 2015|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02320773||30675|
NCT02326792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unopar-Rubens-2|Effect of Volume Training on Back Endurance|Effect of Volume Training on Endurance of Trunk Extensor Muscles in Healthy Subjects: A Randomized Control Trial.|Training|Universidade Norte do Paraná|Yes|Completed|January 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02326792||30212|
NCT02326805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02556|Prostvac (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance|Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance||National Cancer Institute (NCI)|Yes|Recruiting|June 2015|||May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Male|N/A|N/A|No|||February 2016|February 10, 2016|December 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326805||30211|
NCT02306057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063.09b|Fluid Balance in Children Undergoing Fontan Surgery|Interstitial Colloid Osmotic Pressure in Children With Congenital Heart Defect Preparing for Fontan Surgery Undergoing Preoperative Catheterization and Surgery in General Anesthesia||Oslo University Hospital|No|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|40|Samples Without DNA|Interstitial fluid Serum|Both|1 Month|10 Years|No|Probability Sample|Children with congenital heart defect scheduled for Fontan surgery|October 2015|October 23, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02306057||31803|
NCT02307162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPL554-007-2014|SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects|A Phase I, Randomised, Double Blind, Placebo Controlled, 3-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Subjects.||Verona Pharma plc|Yes|Completed|December 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02307162||31719|
NCT02300519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408185|Thrombin Generation Numerical Models Validation in Haemophilic Case|Thrombin Generation Numerical Models Validation in Haemophilic Case||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|blood|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|volunteers witch work in CHU Saint-Etienne|August 2015|August 12, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300519||32229|
NCT02300532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI01S|Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)|Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)||Eisai Inc.||Active, not recruiting|January 2013|January 2017|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|N/A|N/A|No|Probability Sample|Patients with diagnosed malignant glioma treated by surgery|November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300532||32228|
NCT02315482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate2|Effect of Pneumoperitoneum and Steep Trendelenburg on Autonomic Nervous System|||Ospedale L. Sacco – Polo Universitario|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|52|||Male|18 Years|70 Years|No|||June 2015|June 23, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02315482||31081|
NCT02315716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0500|Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma|Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT|Cardamon|University College, London|Yes|Recruiting|May 2015|May 2026|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02315716||31063|
NCT02320058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-204|A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204)|A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy||Bristol-Myers Squibb|No|Recruiting|January 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320058||30730|
NCT02300636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014T03102002|Resistive Co-contraction Training After Anterior Cruciate Ligament Reconstruction|Randomized-controlled,Resistive Co-contraction Training Enhances Strength Recovery After Anterior Cruciate Ligament Reconstruction||Hacettepe University|No|Completed|February 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Male|17 Years|40 Years|No|||March 2015|March 17, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300636||32220|
NCT02304809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1401|Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations|Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations|AcSé|UNICANCER|Yes|Recruiting|July 2014|February 2022|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304809||31899|
NCT02293603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-1002 (DYNAMIC)|Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)|A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)|DYNAMIC|Capricor Inc.|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||January 2015|June 18, 2015|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293603||32760|
NCT02320240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q12-08|Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury|Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury|SNRI-AKI|Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|3255526|||Both|12 Years|N/A|No|Probability Sample|The cohort will be formed of all patients in the databases aged 12 or older (or 65 or        older in some of the databases) with a first prescription of an antidepressant of the SNRI        or SSRI class of any dose between January 1, 1997 and March 31, 2010. The databases to be        included are eight administrative databases from Canada (Alberta, Manitoba, Nova Scotia,        Ontario, Quebec, and Saskatchewan), the United States (US MarketScan), and the United        Kingdom (CPRD).|March 2016|March 11, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320240||30716|
NCT02320253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002074|REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes|REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes||Massachusetts General Hospital|Yes|Recruiting|November 2014|December 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320253||30715|
NCT02303665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012SZ0086|Observing the Curative Effect of Assisted Reproduction by TCM Multi-channel Interventional Therapy|TCM Multi-channel Interventional Therapy for Assisting Reproduction||Chengdu University of Traditional Chinese Medicine|Yes|Not yet recruiting|November 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Female|24 Years|43 Years|No|||November 2014|November 28, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303665||31987|
NCT02303678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00053325|D2C7 for Adult Patients With Recurrent Malignant Glioma|Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma||Duke University|No|Recruiting|February 2015|May 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02303678||31986|
NCT02297230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10289|Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics|Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics||New York University School of Medicine|Yes|Completed|June 2002|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Female|18 Years|90 Years|No|||May 2015|May 13, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02297230||32482|
NCT02297243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS-US-02|Sinopsys Lacrimal Stent Indicated for Sinus Irrigation|The Sinopsys Lacrimal Stent Indicated for Sinus Irrigation Via Transcaruncular Ethmoid Sinus Access in Patients With Moderate to Severe Chronic Rhinosinusitis With Ethmoid Sinus Involvement|SLS|Sinopsys Surgical|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|22 Years|N/A|No|||February 2016|February 11, 2016|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297243||32481|
NCT02301078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain and Function - PNA vs CCH|Short-term Function and Pain After Treatment for Dupuytren's Disease|Comparing Short-term Function and Pain After Treatment With Collagenase Clostridium Histolyticum or Percutaneous Needle Aponeurotomy for Dupuytren's Disease||Sunnybrook Health Sciences Centre|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at Sunnybrook Health Sciences Centre choosing either percutaneous needle        aponeurotomy or Xiaflex injection for treatment of Dupuytren's disease.|September 2015|September 9, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02301078||32186|
NCT02301325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54 DA031659-P1S2|Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes|||University of Pittsburgh|Yes|Recruiting|November 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|240|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301325||32167|
NCT02322099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APART_2014|Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss|A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy|APART|University College Dublin|Yes|Not yet recruiting|January 2016|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|30 Years|N/A|No|||December 2015|December 2, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322099||30573|
NCT02322190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150039|Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD|Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|October 2027|Anticipated|October 2025|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|99 Years|No|||November 2015|January 29, 2016|December 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322190||30566|
NCT02300376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13034|Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium for the Calculation of GFR and Validity Compared to the Renal Clearance of Inulin|Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium, With a Limited Sampling Strategy for the Calculation of Glomerular Filtration Rate (GFR) and Validity Assessment Compared to the Renal Clearance of Inulin : DFGBay|DFGBay|University Hospital, Limoges|No|Not yet recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|80 Years|No|||November 2014|November 20, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02300376||32240|
NCT02306291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1271-201|Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML|A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia||GlycoMimetics Incorporated|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|77|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306291||31785|
NCT02297087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gweiss 13-007|Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment|Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment||Western Regional Medical Center|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02297087||32493|
NCT02317549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBS-SS201|Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148|Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)|SSAIL|Leading BioSciences, Inc|Yes|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317549||30922|
NCT02296593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-D36-VOL.22|Continuous MONItoring of Blood LActate and Glucose Levels Using a New Central Veinous Microdialysis Catheter Device|Monitorage Continu du Lactate et de la glycémie Par Microdialyse : Une étude de Validation en Chirurgie Cardiaque.|MONILAG|University Hospital, Caen|Yes|Recruiting|November 2014|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples for determination of lactate and glucose blood levels|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients of cardiac surgery. (planned or for emergencies)|March 2016|March 22, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296593||32530|
NCT02296606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU042014-043|Interrater Reliability of Subjective Pupillary Assessments|||University of Texas Southwestern Medical Center|No|Active, not recruiting|January 2014|February 2015|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|N/A|No|Probability Sample|Patients eligible for the study are those that have been diagnosed some form of brain        trauma where brain swelling has been identified and pupil dilation has been incorporated        into standard of care (e.g., TBI, stroke).|November 2014|November 19, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296606||32529|
NCT02297737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT007600-01A1|Mindful Movement Intervention for Post-MI Patients|Developing a Mindfulness Movement Intervention Program for Post-MI Patients: A Randomized 75-subject Pilot Clinical Trial of Tai Chi Versus Health Education in Post-myocardial Infarction Patients|HeartChi|San Diego Veterans Healthcare System|Yes|Enrolling by invitation|October 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|75|||Both|35 Years|N/A|No|||November 2014|November 20, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297737||32443|
NCT02297308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIS2014-001|A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications|A Single Center, Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation||Terumo Medical Corporation|No|Completed|October 2014|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of subjects with severe aortic stenosis who underwent        TAVI utilizing the SoloPath sheath for vascular access since 2011.|January 2016|January 21, 2016|October 21, 2014||No||No|November 30, 2015|https://clinicaltrials.gov/show/NCT02297308||32476|Single center, retrospective data analysis.
NCT02297321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeScribe-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2014|||||N/A|N/A|N/A||||||||||||||May 20, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297321||32475|
NCT02440009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Histo-15-IMEC-313|A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis|A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis|RIA|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||May 2015|May 6, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02440009||21530|
NCT02432404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48761-D|Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity|Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity||University of Washington|No|Not yet recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432404||22114|
NCT02432417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLOROBRAINII|The Addition of Chloroquine to Chemoradiation for Glioblastoma,|A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma||Maastricht Radiation Oncology|Yes|Not yet recruiting|January 2018|January 2022|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|70 Years|No|||April 2015|April 28, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432417||22113|
NCT02431793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS023459-01|EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use|EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use|EMC2|Northwestern University|Yes|Recruiting|May 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|816|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431793||22161|
NCT02486913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPH1C8R|Enhancing Diagnosis and Prevention of Cardiovascular Disease in Newham by Integrated Use of Electronic Health Records|Enhancing the Diagnosis and Prevention of Cardiovascular Disease in Newham by Integrated Use of Electronic Health Records||Queen Mary University of London|Yes|Not yet recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|40 Years|74 Years|No|||June 2015|June 29, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02486913||17927|
NCT02437162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107098|A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Naive Participants With Active Radiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis||Janssen Research & Development, LLC||Recruiting|September 2015|November 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|327|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437162||21748|
NCT02437292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152-6|Effect of Ischemic Compression With Stretching on Patients With Upper Back Pain|Effect of Ischemic Compression With Stretching on Pain Related Parameters in Patients With Upper Back Pain Associated With Myofascial Trigger Point||Mae Fah Luang University Hospital|Yes|Not yet recruiting|May 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|No|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437292||21738|
NCT02437240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NationalYangMingU|Pilates-based Cardiopulmonary Physical Therapy for In-Patients After Cardiac Surgery|Effects of Pilates-based Cardiopulmonary Physical Therapy for In-Patients After Cardiac Surgery|PBCPT|National Yang Ming University|No|Active, not recruiting|August 2014|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|80 Years|No|||April 2015|May 4, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02437240||21742|
NCT02443948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cf-DNA GIST|Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)|Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST): Detection and Correlation With Disease Status Assessed by Conventional Technique. Prospective Observational Study||Fondazione del Piemonte per l'Oncologia|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Cf-DNA blood samples will be collected in EDTA tubes during the routine blood test.|Both|18 Years|N/A|No|Non-Probability Sample|The target population includes adult patients with histologically confirmed GIST, either        with active disease or in follow-up.|November 2015|November 13, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02443948||21228|
NCT02487199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-461|Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-II)||AbbVie|No|Recruiting|October 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487199||17905|
NCT02437435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406-VLC-044-CG-|Physiotherapy Treatment for Uterine Blood Flow Improved Dimensional Ultrasound Evaluated With Angiography|Effectiveness of Physiotherapy Treatment to Improve the Flow on Vascular Area of the Endometrial / Subendometrial in Uterus of Infertile Women With Hypoestrogenemia Evaluated by Three-dimensional Ultrasound Angiography.||University of Valencia|Yes|Active, not recruiting|April 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|54|||Female|N/A|N/A|No|||May 2015|May 6, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02437435||21727|
NCT02437370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#252|Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer|Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer||University of California, Davis|Yes|Recruiting|August 2015|December 2019|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|May 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02437370||21732|
NCT02437383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2526|Study of Orofacial Pain and PropRANOlol|Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder|SOPPRANO|University of North Carolina, Chapel Hill|Yes|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437383||21731|
NCT02427802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-TOP-004|Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers|A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer|COACT-1|Innocoll|No|Recruiting|May 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427802||22466|
NCT02492984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831083|PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A|An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (Moroctocog-alfa (Af-cc), Recombinant Fviii) In Subjects With Hemophilia A In Usual Care Settings In China||Pfizer|Yes|Recruiting|April 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|N/A|No|||March 2016|March 21, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02492984||17462|
NCT02493010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-14-098|Arousal Training for Social Anxiety Disorder|Arousal Detection and Training for Social Anxiety Disorder (SAD)||Duke-NUS Graduate Medical School|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02493010||17460|
NCT02430818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501068|Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain|Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures||Washington University School of Medicine|Yes|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430818||22236|
NCT02437903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Voluma Temporal 2014|Open Label Study Evaluating the Efficacy and Safety of JUVÉDERM VOLUMA™ XC for the Facial Temporal Regions|Open Label, Single-center Study, Evaluating the Efficacy and Safety of JUVÉDERM VOLUMA™ XC for the Facial Temporal Regions||Baumann Cosmetic and Research Institute|No|Recruiting|May 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437903||21691|
NCT02437916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140131|Safety Study of AMG 228 to Treat Solid Tumors|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors||Amgen|No|Recruiting|April 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02437916||21690|
NCT02310308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1083/L|Effect of a Sugar-Free Chewing Gum Containing Magnolia Bark Extract on Caries Lesions in Healthy Adult Volunteers|Effect of a Sugar-free Chewing Gum Containing Magnolia Bark Extract on the Development of Caries Lesions in Healthy Adult Volunteers: a Randomized Controlled Intervention Trial||Università degli Studi di Sassari|Yes|Active, not recruiting|April 2012|November 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|480|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02310308||31478|
NCT02308306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABILITY|Predictive Markers of the Effects of Opioid Therapy|Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)|ABILITY|University of Aarhus|No|Recruiting|December 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with an insufficiently treated chronic pain condition (with non-opioids ±        adjuvants), and expected to benefit from the administration of opioids (as necessary) to        obtain freedom from pain.|December 2014|May 31, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308306||31631|
NCT02308319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-149|Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load|A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection|POWER|Samsung Medical Center|Yes|Not yet recruiting|January 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|124|||Both|18 Years|N/A|No|||November 2014|December 2, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02308319||31630|
NCT02298101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AeroSpect-01|Comparison of Lung Deposition With the Aeroneb Solo Adapter and a Standard Jet Nebulizer by SPECT-CT|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|September 2014|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298101||32415|
NCT02312089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA4|GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles|Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles||Mansoura University|No|Recruiting|July 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|20 Years|38 Years|No|||March 2016|March 4, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312089||31341|
NCT02294071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHRI IRF|Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children|Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children||Lawson Health Research Institute||Not yet recruiting|December 2014|||November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|3 Years|12 Years|No|||November 2014|November 17, 2014|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294071||32724|
NCT02306330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09HN|MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial|Assessing Time to Reporting and Clinical Management of Patients With Severe Bacterial and Fungal Infections Between Two Diagnostic Approaches: Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial|MALDITOF|Oxford University Clinical Research Unit, Vietnam|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|N/A|N/A|No|||December 2014|December 1, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306330||31782|
NCT02298413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAI-Registro Absorb Italiano|Italian Absorb Registry|Clinical Study on Absorb Polylactic, Reabsorbable Coronary Scaffold (RAI)|BVS-RAI|Ospedale Santa Croce-Carle Cuneo|No|Active, not recruiting|May 2013|May 2021|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1520|||Both|N/A|75 Years|No|Non-Probability Sample|This is an all-comers study, and includes all consecutive patients who have been treated        with 1 or more BVS in the study time lapse in each participating centre|February 2016|February 3, 2016|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02298413|5 Years|32391|
NCT02298660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rick Hansen Institute|Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI|Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury||Rick Hansen Institute|Yes|Recruiting|April 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT02298660||32372|
NCT02313649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE2|ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B|Evaluation of ShearWave™ Elastography Performances for the Non-Invasive Assessment of Liver Fibrosis in Chinese Patients With Chronic Hepatitis B Infection||SuperSonic Imagine|No|Recruiting|December 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Chinese patients with chronic viral hepatitis B admitted for the realization of an        intercostal liver biopsy in defined investigator centers.|May 2015|May 11, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313649||31221|
NCT02301975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201378|An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist||GlaxoSmithKline|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1461|||Both|12 Years|N/A|No|||March 2016|March 17, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301975||32117|
NCT02309476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03018|Sub-threshold Photocoagulation of Diabetic Macular Oedema|Manchester Pascal Endpoint Management Laser Treatment of Diffuse Diabetic Macular Oedema (DMO): A Safety and Efficacy Study|MEM|Central Manchester University Hospitals NHS Foundation Trust|No|Recruiting|October 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02309476||31542|
NCT02312635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD076418-01A1|Augmentation of Cognitive Training in Children With TBI With D-Cyloserine|Augmentation of Cognitive Training in Children With TBI With D-Cyloserine|DCS|University of California, Los Angeles|No|Recruiting|December 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|11 Years|18 Years|No|||December 2014|December 8, 2014|February 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02312635||31299|
NCT02298218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0597|Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia|||Yonsei University|No|Completed|September 2009|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298218||32406|
NCT02304614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4252|The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy|The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy|3DBCT|Royal Marsden NHS Foundation Trust|No|Not yet recruiting|January 2015|September 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have undergone Breast Conserving Therapy at least one year ago|December 2014|December 1, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304614||31914|
NCT02294669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turris|A Feasibility Study to Evaluate the TURRIS Facet Fusion System in Lumbar Spinal Surgery|A Feasibility Study to Evaluate the TURRIS Facet Fusion System as an Adjuvant to Unilateral Pedicle Screw Fixation in Lumbar Spinal Surgery||SpineWelding AG||Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02294669||32678|
NCT02319200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120138|Primary Prevention Hepatocellular Carcinoma by Metformin|PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort|METFOVIR|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|444|||Both|18 Years|77 Years|No|||October 2014|December 17, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02319200||30795|
NCT02294565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VST-1001-02|VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer|A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients With Clinically Node Negative Breast Cancer||Vestan, Inc.|No|Recruiting|June 2014|May 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|147|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294565||32686|
NCT02306486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/03|The Effect of Oxalic Acid on Cervical Restorations|The Effect of Oxalic Acid on Cervical Restorations on Hypersensitive Teeth, a Double-blind Randomized Controlled Clinical Trial. One Year Follow up|OxalicAc|University of Chile|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|December 2, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02306486||31771|
NCT02321696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1520|Physiotherapy or Acupuncture for Lateral Epicondylitis|Clinical Comparative Effect of Physiotherapy or Acupuncture Treatment of Lateral Epicondylitis; a Randomized Controlled Pilot Trial||Oslo University Hospital|No|Recruiting|February 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|67 Years|No|||January 2016|January 19, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321696||30604|
NCT02311517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0853|The Effects of Serratus Anterior Plane Block on Postoperative Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery|||Yonsei University|No|Recruiting|November 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|90|||Both|20 Years|65 Years|No|||December 2014|December 4, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311517||31385|
NCT02307890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/097|The Relationship of Initial Liver Profile and Outcome After Transplantation|The Relationship of Hepatobiliary microRNA Expression Profile and Clinical Outcome in Liver Transplantation||University of Edinburgh|No|Recruiting|August 2014|August 2020|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Liver and bile duct|Both|16 Years|N/A|No|Non-Probability Sample|Liver transplantation group|December 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02307890||31663|
NCT02307526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-11-04|Acetylcholinesterase Inhibition and Orthostatic Hypotension in SC I|Acetylcholinesterase Inhibition: A Novel Approach in the Treatment of Orthostatic Hypotension in SCI||James J. Peters Veterans Affairs Medical Center|No|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|May 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307526||31691|
NCT02307578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-409|Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332|An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)||Eisai Inc.||Available|January 2015|January 2017|Anticipated|||N/A|Expanded Access|N/A|||||||Both|12 Years|N/A|No|||February 2016|March 21, 2016|December 2, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02307578||31687|
NCT02312050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ100-CKD04|A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes|A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes||La Jolla Pharmaceutical Company|No|Active, not recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|375|||Both|18 Years|90 Years|No|||May 2015|May 16, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312050||31344|
NCT02312063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEP26-49|Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes|Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes: a Multicenter, Randomized, Prospective, Open-label, Clinical Trial|DIET|Kansai Electric Power Hospital|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|75 Years|No|||April 2015|April 4, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312063||31343|
NCT02311790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11516|Palmitoleic Isomer Study|Supplementation With Vegetable Oils Enriched in the Fatty Acids Trans-C16:1 or Cis-C16:1: Dose-response Study||Tufts University|No|Not yet recruiting|July 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311790||31364|
NCT02299843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014KYNO.51|RALPPS Venus ALPPS for Hepatocellular Carcinoma|A Prospective Randomized Controlled Trial of Radio-frequency Assisted ALPPS（RALPPS）and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy（ALPPS）in the Treatment of Hepatocellular Carcinoma.||Southwest Hospital, China|Yes|Recruiting|October 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299843||32281|
NCT02307591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASE|Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)|Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola.|EASE|Emergency NGO Onlus|Yes|Withdrawn|December 2014|July 2015|Actual|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|N/A|No|||October 2015|October 5, 2015|November 21, 2014||No|The Study could not be started due to an insufficient number of new EVD cases.|No||https://clinicaltrials.gov/show/NCT02307591||31686|
NCT02297542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01|Immune Response to High-Dose vs. Standard Dose Influenza Vaccine|Immune Response to High-Dose vs. Standard Dose Influenza Vaccine||Advanced Medical Research Institute of Canada|No|Active, not recruiting|October 2014|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|85|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|November 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297542||32458|
NCT02320539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-073|MicroRNA Diagnostics in Subarachnoid Hemorrhage 2|MicroRNA Diagnostics in Subarachnoid Hemorrhage 2||Rigshospitalet, Denmark|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|70|Samples With DNA|MicroRNA profiles from blood and cerebrospinal fluid are investigated.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group 1-2: Patients admitted to Neurointensive Department in Rigshospitalet with SAH        treated with external ventricular drain.        Group 3: Patients admitted to Neurointensive Department in Rigshospitalet with SAH treated        without external ventricular drain.        Group 4: Healthy blood donors|May 2015|May 25, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02320539|6 Months|30693|
NCT02320552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40480|Prevalence of Protein-energy Wasting and Obesity Among Danish Dialysis Patients|Prevalence of Protein-energy Wasting and Obesity Among Danish Dialysis Patients||Roskilde County Hospital|Yes|Completed|February 2014|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving regular dialysis therapy at Roskilde Hospital, Denmark in February to        June 2014.|December 2014|December 15, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320552||30692|
NCT02295306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 10880|Overnight Polysomnography and Respiratory Volume Monitor|The Evaluation of a Respiratory Volume Monitor in Patients Undergoing Overnight Polysomnography||Tufts Medical Center|No|Active, not recruiting|June 2013|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients referred to the sleep laboratory at Tufts Medical Center for a standard        polysomnogram (PSG) are eligible to be recruited.|March 2015|March 13, 2015|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02295306||32629|
NCT02295319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Discharge AAU|The Impact of Individual-based Discharges From Acute Admission Units to Home|The Impact of Individual-based Discharges From Acute Admission Units to Home on Healthcare Utilization, Quality-of-life and Patient Experience: a Randomized Controlled Study||University of Aarhus|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2014|December 1, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02295319||32628|
NCT02295514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/087/HP|Correlation Between PTP1B Expression and Organ Failure During Sepsis|Correlation Between PTP1B Expression and Organ Failure During Sepsis|SEPP1B|University Hospital, Rouen|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|54|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02295514||32613|
NCT02308488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0623|Study of Prone Accelerated Breast And Nodal IMRT|PHASE I - II STUDY OF PRONE ACCELERATED BREAST AND NODAL IMRT(Intensity-Modulated Radiation Therapy)||New York University School of Medicine|Yes|Recruiting|August 2009|December 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|134|||Female|36 Years|90 Years|No|||July 2015|July 30, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02308488||31617|
NCT02308670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA20-40|Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis|An Open-label, Prospective, Observational, Single-blinded, Longitudinal, Cross-over Study to Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week on Thalamic Pathology in Subjects With Relapsing-remitting Multiple Sclerosis||University at Buffalo|No|Enrolling by invitation|July 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|65 Years|No|Non-Probability Sample|One hundred fifty (150) consecutive RRMS patients who are on treatment with GA 20mg/daily        for at least 12 months and who switched to GA 40mg x 3/weekly, because of convenience of        application, will be recruited in the study.|February 2016|February 11, 2016|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02308670||31603|
NCT02325089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140069|ORal ApplianCes for sLeep Apnea of the Elderly|Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study|ORACLE|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|July 2014|December 2020|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|65 Years|80 Years|No|||March 2016|March 1, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02325089||30343|
NCT02312427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMHMEC2014-10|DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure|Investigation of the Impact of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Serum B-type Natriuretic Peptide (BNP) Level of Diabetic Patients With Congestive Heart Failure.||Mitsui Memorial Hospital|No|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||March 2015|March 29, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02312427||31315|
NCT02306447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rtms-rpms-tinn|Combined Transcranial and Peripheral Muscle Magnetic Stimulation in Chronic Tinnitus|Combined Transcranial and Peripheral Muscle Magnetic Stimulation in Chronic Tinnitus|rpms-tinn|University of Regensburg|No|Recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306447||31774|
NCT02296645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX-ZP-0055 (MBT# 865-101)|Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)|A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™||Zurex Pharma, Inc.|No|Completed|November 2014|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 11, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296645||32526|
NCT02308683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moringa oleifera|Effects of Moringa Oleifera on hsCRP and Hgba1c Level of Patients in Ospital ng Maynila Medical Center Diabetic Clinic|The Effects of Moringa Oleifera Supplements on hsCRP and HgbA1c Levels of Patients in Ospital ng Maynila Medical Center Diabetic Clinic: A Prospective Cohort Study||Ospital ng Maynila Medical Center|No|Completed|August 2014|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|56|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308683||31602|
NCT02320071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-118|Abdominal Wall Function and Quality of Life and Before and After Incisional Hernia Repair|Abdominal Wall Function and Quality of Life and Before and After Incisional Hernia Repair|QualiFunc|Bispebjerg Hospital|Yes|Recruiting|January 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|25 Years|75 Years|No|Non-Probability Sample|This prospective study includes 25 patients undergoing elective laparoscopic incisional        hernia repair. Patients are included from Bispebjerg Hospital and Hvidovre Hospital, two        university hospital surgical departments with unrestricted referral of patients.|September 2015|September 2, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320071||30729|
NCT02304822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER（32）2014|Comparison of Infection and Urosepsis Rates During Retrograde Intrarenal Surgery After Multiple-, Single-, Zero-dose of Ciprofloxacin Prophylaxis|Comparison of Infection and Urosepsis Rates During Retrograde Intrarenal Surgery After Multiple-, Single-, Zero-dose of Ciprofloxacin Prophylaxis: a Prospective and Randomised Study.||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|August 2014|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|No|||November 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304822||31898|
NCT02298348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANT 2013-02|Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma|NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma|N2013-02|New Approaches to Neuroblastoma Therapy Consortium|Yes|Recruiting|April 2015|June 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|30 Years|No|||December 2015|December 11, 2015|August 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298348||32396|
NCT02317107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ch174660|Examination of Balance, Vestibular, and Ocular Functions and Activity Following Concussion|A Longitudinal Examination of Dynamic Balance Control, Vestibular/Ocular Motor Function, and Activity Participation Following Concussion||Children's Hospital Boston|No|Recruiting|March 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|12 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will come from Boston Children's Hospital and The Micheli Center for Sports        Injury Prevention. Concussion will be defined consistent with the latest best-practice        consensus statement on concussion in sport as a brain injury defined as a complex        pathophysiological process affecting the brain, induced by biomechanical forces. Informed        consent will be obtained after study explanation and sufficient time to answer all        study-related questions at each respective location.|January 2016|January 26, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317107||30956|
NCT02319772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4430-101|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430|A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects||BioCryst Pharmaceuticals|Yes|Recruiting|December 2014|August 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319772||30752|
NCT02325830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVP 1627-01|CARILLON Mitral Contour System® for Reducing Functional Mitral Regurgitation|The REDUCE FMR Trial: Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated With Heart Failure|REDUCE FMR|Cardiac Dimensions Pty Ltd|Yes|Recruiting|March 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||February 2016|February 5, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02325830||30286|
NCT02307474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE10813|A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer|CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma||Case Comprehensive Cancer Center|No|Withdrawn|September 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 2, 2014|No|Yes|Funding Unavailable|No||https://clinicaltrials.gov/show/NCT02307474||31695|
NCT02307487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-BC-10|Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients|Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in NMIBC Patients||UroGen Pharma Ltd.|Yes|Recruiting|December 2014|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02307487||31694|
NCT02301260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4997A5/1|Speed of Processing Training to Improve Cognition in Multiple Sclerosis|Speed of Processing Training to Improve Cognition in Multiple Sclerosis: A Randomized Clinical Trial||Kessler Foundation|No|Recruiting|April 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|59 Years|No|||November 2014|November 21, 2014|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301260||32172|
NCT02308748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-022D|Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block|Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)||Food and Drug Administration (FDA)|No|Completed|May 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|27|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308748||31597|
NCT02309684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLM1301|Bio-ConneKt Wound Dressing for Treatment of Chronic Leg Wounds: A Pilot Study|The Clinical & Economic Evaluation of Bio-ConneKt® Wound Dressing in Treating Chronic Foot Ulcers (Diabetic and/or Venous Ulcers).||MLM Biologics Inc.,|No|Not yet recruiting|January 2015|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 20 patients with DFU (n=10) and VLU (n=10) will be considered in this study if        they sign the informed consent, and meet all inclusion criteria and none of the exclusion        criteria.|December 2014|December 4, 2014|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309684||31526|
NCT02303886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO8|Methylene Blue Intravenously and Chronic Neuropathic Pain|Evaluation of the Effects of Methylene Blue on Neuropathic Pain and Protein Biomarkers||Uppsala University|No|Completed|March 2009|November 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||November 2014|November 28, 2014|November 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303886||31970|
NCT02293590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG13/104/2B|RICE: Remission by Intra-articular Injection Plus CErtolizumab|An Open Label, Randomised Study to Compare the Efficacy of Certolizumab Pegol (CZP) Plus a Dynamic or Fixed Dose Treatment Strategy in Patients With Rheumatoid Arthritis, a Phase II Study|RICE|Cantonal Hospital of St. Gallen|No|Recruiting|November 2013|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293590||32761|
NCT02317562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10E-1306|Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302|International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302"|PRISM2|Laboratoire français de Fractionnement et de Biotechnologies|No|Recruiting|November 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317562||30921|
NCT02320357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/27|Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous|Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous|CLOPUS|University Hospital, Bordeaux|No|Recruiting|August 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320357||30707|
NCT02320370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OptES-Stress-pilot|Transcranial Electrical Stimulation in the Treatment of Acute Anxiety Induced by Stressful Life Events: A Pilot Study|Optimizing Electrical Stimulation for Clinical Applications (the OptES Study): Severe Psychological Stress - a Pilot Study (OptES-Stress-pilot)|OptesStressP|University of Eastern Finland|No|Not yet recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|65 Years|No|||December 2014|December 18, 2014|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320370||30706|
NCT02301494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48861|Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma|Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma|CTCL|Rochester General Hospital|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301494||32154|
NCT02301507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0692|Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women|Evaluation of Texting Intervention to Improve Adherence to Antiretroviral Therapy (ART) in Young Women Infected With Human Immunodeficiency Virus (HIV)||The University of Texas Health Science Center, Houston|No|Active, not recruiting|November 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Female|18 Years|40 Years|No|||July 2015|July 24, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02301507||32153|
NCT02304185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104488|Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers|A First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Dose Levels of Trimeric gp140 Protein in Healthy Adult Volunteers||Crucell Holland BV|Yes|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304185||31947|
NCT02304198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_PAH_EX|Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH|A Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)||Dong-A ST Co., Ltd.|No|Active, not recruiting|April 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304198||31946|
NCT02317848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure|PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure.|PROVE-SAS-AHF|French Cardiology Society|No|Recruiting|December 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|194|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317848||30899|
NCT02436668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1137-CA|Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma||Pharmacyclics|Yes|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|326|||Both|18 Years|N/A|No|||January 2016|March 15, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436668||21786|
NCT02435667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000320|Resistance Training in HFpEF|Resistance Exercise Training in Heart Failure With Preserved Ejection Fraction (Resist - HFpEF)||Mayo Clinic|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|80 Years|No|||November 2015|November 24, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02435667||21863|
NCT02435680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCS110Z2201|Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)|A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)|TNBC|Novartis|No|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435680||21862|
NCT02492906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osteoarthrosis Neuroimaging|Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry|Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry||University of Sao Paulo|Yes|Completed|April 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|56|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy patients and patients with primary severe knee osteoarthrosis and with chronic        knee pain were included.|July 2015|July 6, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02492906||17468|
NCT02441985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500347|rTMS Therapy for Primary Orthostatic Tremor|rTMS Therapy for Primary Orthostatic Tremor: A Novel Treatment Approach||University of Florida|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|75 Years|No|||March 2016|March 17, 2016|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441985||21378|
NCT02443935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA-001|Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection|Toll-like Receptor 9 Enhancement of Antiviral Immunity in Chronic HIV-1 Infection: a Phase 1b/2a Trial|TEACH|University of Aarhus|No|Enrolling by invitation|April 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||April 2015|March 14, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02443935||21229|
NCT02427542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 141216v3|Feasibility Trial of CBT for Depersonalisation in Psychosis|A Brief Cognitive Behavioural Therapy (CBT) Intervention for Depersonalisation/Derealisation in Psychosis: a Feasibility Study||King's College London|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02427542||22486|
NCT02492932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWJung_IJV|The Second Try During Landmark Approach of the Internal Jugular Vein: an Ultrasonographic Prelocation Study|The Second Try During Landmark Approach of the Internal Jugular Vein: an Ultrasonographic Prelocation Study||Seoul National University Hospital|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|323|||Both|20 Years|80 Years|No|||November 2015|November 22, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02492932||17466|
NCT02442089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004109|Impact of Automated Calls on Pediatric Patient Attendance in Chile|Health Call: A Randomized Control Trial of Interactive Automated Reminder Calls to Reduce Failure to Attend Rates at an Urban Referral Hospital in Chile|Health Call|Johns Hopkins Bloomberg School of Public Health|No|Recruiting|December 2013|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|564|||Both|N/A|18 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02442089||21370|
NCT02443961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULMESCEL-1|Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies|Clinical Trial: Security and Feasibility of Mesenchymal Stem Cell Therapy in Treatment and Prevention of Bronchopulmonary Dysplasia in Preterm Babies||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|1 Month|28 Weeks|No|||May 2015|May 11, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02443961||21227|
NCT02432196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMFIM -1000-PL|Safety and Early Feasibility Study of the Harpoon Medical Device|First In Man - Clinical Validation of the TSD-5|EFS|Harpoon Medical|No|Recruiting|February 2015|February 2020|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432196||22130|
NCT02480179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1164-14-SMC|CNS Modification of Food Craving by Neurofeedback|CNS Modification of Food Craving by Neurofeedback||Sheba Medical Center|No|Not yet recruiting|June 2015|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02480179||18444|
NCT02435290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Enhancement of the Prediction of Chemotherapy Prescribing Errors for Oncology Patients|Cross-sectional Study to Enhance the Prediction of Prescribing Errors for Oncology Patients||Ain Shams University|Yes|Completed|March 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|500|||Both|18 Years|80 Years|No|Non-Probability Sample|in- and out-patients, with proven malignant disease receiving chemotherapy|May 2015|May 1, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435290||21892|
NCT02435563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-182|Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling|Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp®)||University Hospital, Geneva|No|Active, not recruiting|August 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|May 5, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02435563||21871|
NCT02429284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-2013-008|U.S. CTEPH Registry|United States CTEPH Registry||University of California, San Diego|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive consenting patients recently diagnosed (< 6 months) with CTEPH at        participating study sites will be enrolled. Patients must meet inclusion criteria and have        the diagnosis of CTEPH confirmed by the Adjudication Committee (AC) to be enrolled. Adult        and pediatric patients may be enrolled and prior medical therapy will not exclude patients        from enrollment.|May 2015|May 26, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02429284|4 Years|22352|
NCT02429297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00081734|Developing Accessible Telehealth Programs for Diabetes and Hypertension Management in Bolivia|Developing Accessible Telehealth Programs for Diabetes and Hypertension Management in Bolivia||University of Michigan|No|Active, not recruiting|June 2014|September 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1000|||Both|21 Years|80 Years|No|||April 2015|April 23, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02429297||22351|
NCT02315521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM H-35770|Standardized Prenatal Clinical Care for LUTO|Validation of the Standardized Prenatal Clinical Management of Fetuses With Lower Urinary Tract Obstruction (LUTO)||Baylor College of Medicine|No|Recruiting|December 2014|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|50|||Both|11 Weeks|2 Years|No|Probability Sample|All pregnant women referred to our Fetal Center with confirmed diagnosis of fetal LUTO.        The diagnosis of fetal LUTO is based on the presence of enlarged bladder and bilateral        hydronephrosis.|January 2016|January 28, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315521|5 Years|31078|
NCT02315794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aostirct|Aesthetic Outcomes of Single Tooth Implant Using Metal Ceramic Restorations With Either Zirconia or Titanium Abutments|Aesthetic Outcomes of Single Tooth Implant-supported Restorations Using Metal Ceramic Restorations With Either Zirconia or Titanium Abutments: A Randomized Controlled Clinical Study||University of Firenze and Siena, Napoli, Italy|No|Completed|September 2009|February 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02315794||31057|
NCT02306265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124.03-2014-GES-0010|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-SCR: Recruitment Plan for Asymptomatic Women Undergoing Screening Mammography|ADAPT|GE Healthcare|No|Active, not recruiting|May 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|250|||Female|30 Years|N/A|No|||December 2015|December 8, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306265||31787|
NCT02306278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ky2013-008-01|The Effects of Gabapentin Premedication on Neurosurgery|The Effects of Gabapentin Premedication on Postoperative Pain,Nausea,Vomiting and Sedation in Patients Undergoing Neurosurgery||Capital Medical University|Yes|Recruiting|April 2014|||December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|No|||April 2015|April 25, 2015|April 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02306278||31786|
NCT02298387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B83-001|A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors|A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Recruiting|December 2014|October 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||August 2015|August 18, 2015|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02298387||32393|
NCT02298400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-270-0001|A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses|A Single-Center, Cross-over, Pilot Study Evaluating Acuvue® Oasys® Lenses (Senofilcon A), 30-Day Bausch + Lomb PureVision (Balafilcon A), and Clariti® 1-Day (Somofilcon A) Lenses, for Their Impact on Ocular Discomfort Induced by Exposure to the Turbo Controlled Adverse Environment™||ORA, Inc.|No|Recruiting|August 2014|||March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|January 5, 2015|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02298400||32392|
NCT02316652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|636-13-FB|Effect of Disinfective Solution as an Adjunct to Maintenance Therapy of Inflamed Periodontal Pockets|Using Chemical Pocket Disinfection as an Adjunct to Non-surgical Maintenance Therapy of Inflamed Periodontal Pockets||University of Nebraska|No|Active, not recruiting|October 2013|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|30 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316652||30991|
NCT02316899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-CL-0031|Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome|Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Long-term Study in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)||Astellas Pharma Inc|No|Active, not recruiting|October 2014|March 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|500|||Both|20 Years|79 Years|No|||November 2015|November 10, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02316899||30972|
NCT02297685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCJC-15|Effectiveness of Electrotherapy Techniques to Treat Low Back Pain|Effectiveness of Two Electrotherapy Techniques to Treat Chronic Low Back Pain|TENBACK|Camilo Jose Cela University|No|Completed|February 2013|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297685||32447|
NCT02294851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN002-001|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects|||Bristol-Myers Squibb|No|Active, not recruiting|December 2014|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294851||32664|
NCT02302625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT atopic|Cognitive Behavior Therapy for Atopic Dermatitis|Exposure-based CBT for Itching in Atopic Dermatitis||Karolinska Institutet|No|Completed|November 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02302625||32067|
NCT02318433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004033|Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study|Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study||Mayo Clinic|No|Enrolling by invitation|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318433||30854|
NCT02305823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZQ2005|Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis|Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II)|AZQ2005|Fundación Marques de Valdecilla|No|Completed|October 2005|May 2014|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|203|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305823||31821|
NCT02304354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI13-JM/LYRITUX|Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)|Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)|LYRITUX|University Hospital, Tours|No|Recruiting|March 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02304354||31934|
NCT02304367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX023T-CL201|Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)|A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)||Ultragenyx Pharmaceutical Inc|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02304367||31933|
NCT02320565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2D versus 3D Endometrium|2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial|Prospective Randomized Trial on 2D Versus 3D Laparoscopic Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Endometrial Cancer FIGO Stage IB-II||Catholic University of the Sacred Heart||Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|N/A|75 Years|No|||June 2015|June 5, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320565||30691|
NCT02320578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D vs 2D Cervix|2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial|Prospective Randomized Trial on2D Versus 3D Laparoscopic Radical Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Early Stage Cervical Cancer (FIGO Stages IA2-IB1-IIA<2cm) and Advanced Stage Cervical Cancer (FIGO Stages IB2-IIA>2 Cm-IIB) Submitted to NACT With Complete Clinical Response.||Catholic University of the Sacred Heart|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Female|N/A|75 Years|No|||June 2015|June 5, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320578||30690|
NCT02302235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maesc 006|Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study|Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study|GBMXRT|Mid-Atlantic Epilepsy and Sleep Center, LLC|No|Recruiting|February 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302235||32097|
NCT02302248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311006002|Effectiveness of a Crowdsourced Cognitive Reappraisal Intervention|A Randomized, Active-Controlled Trial to Investigate the Effectiveness of a Crowdsourced Cognitive Reappraisal Intervention.||Massachusetts Institute of Technology|No|Completed|April 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|270|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302248||32096|
NCT02306915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM22-PK-10036|PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants|A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects||Teva Pharmaceutical Industries|Yes|Completed|October 2014|May 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|48|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306915||31738|
NCT02315924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCCAICOCA|Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis|An Open-label, Single-centre Study Evaluating the Prevalence and Characteristics of Coronary and Cerebrovascular Arteriosclerosis as Measured by Combined Coronary and Cerebral Angiography, and Comparing the Efficacy and Safety of Simultaneous or Staged Coronary and Cerebral Interventional Strategy in Chinese Patients||Capital Medical University|Yes|Recruiting|March 2013|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|80 Years|No|||January 2016|January 13, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02315924||31047|
NCT02319408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-576/ 2013|Immune Boost In Non-Small Cell Lung Cancer|A Randomized Phase II Study of Radiation Induced Immune Boost in Operable Non-small Cell Lung Cancer|RadImmune|University Hospital Heidelberg|No|Not yet recruiting|March 2016|August 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Both|50 Years|N/A|No|||February 2016|February 23, 2016|May 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02319408||30779|
NCT02322112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050274|The Alberta FYBER (Feed Your Gut Bacteria morE fibeR) Study|The Alberta FYBER (Feed Your Gut Bacteria morE fibeR) Study: Exploring the Significance of Structure-function Relationships Between Dietary Fiber and the Gut Microbiota in Human Health.||University of Alberta|No|Recruiting|July 2015|December 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Anticipated|220|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322112||30572|
NCT02299258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ZHE008|Gastric Outlet Obstructions Tailored Covered Stents for GOO|A Multicenter Randomized Controlled Trial of Malignant Gastric Outlet Obstruction: Tailored Partially Covered Stents (Placed Fluoroscopically) Versus Standard Uncovered Stents (Placed Endoscopically)||The First People's Hospital of Yuhang District|Yes|Completed|May 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|N/A|N/A|No|||February 2015|February 10, 2015|November 17, 2014|Yes|Yes||No|November 22, 2014|https://clinicaltrials.gov/show/NCT02299258||32326|
NCT02315755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061086|Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC|Observational Study Evaluating The Efficacy Of Targeted Treatments Following Tyrosine Kinase Inhibitors In Metastatic Renal Cell Carcinoma Patients And Effects On Quality Of Life: A National, Multicenter Study||Pfizer|No|Recruiting|May 2015|October 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|152|||Both|18 Years|N/A|No|Probability Sample|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st        line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have        signed the informed consent document.|March 2016|March 2, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315755||31060|
NCT02294331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attain Performa™ PAS|Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study|Attain Performa™ Left Ventricular Quadripolar Lead Post-Approval Study||Medtronic|No|Recruiting|September 2014|||July 2022|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1778|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with an Attain Performa™ LV Lead within 30 days. All subjects must meet        Inclusion criteria and none of the Exclusion criteria.|January 2016|January 4, 2016|October 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294331||32704|
NCT02299063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000044746|Dexmedetomidine Effect on Mitochondrial Function|The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.||The Hospital for Sick Children|Yes|Active, not recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|3 Months|36 Months|No|||November 2015|November 16, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299063||32341|
NCT02297269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZ-004|The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study|The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|December 2014|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|||Both|18 Years|75 Years|No|Non-Probability Sample|participants will be selected from the department of gastrointestinal surgery in the first        affiliated hospital of chongqing medical university|November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297269||32479|
NCT02315937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50108.060.14|Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'|Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'|SATE|Catharina Ziekenhuis Eindhoven||Not yet recruiting|January 2015|||June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients undergoing spinal anesthesia for minor surgery below the umbilicus|December 2014|December 11, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02315937||31046|
NCT02315989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5215C|Early-Phase Safety of Proton Therapy Equipment|A Study of the Early-Phase Safety of Proton Therapy Equipment for Patients Suffering From Solid Cancers, and the Equipment's Operational Effectiveness.||Chang Gung Memorial Hospital|Yes|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|75 Years|No|||September 2014|November 30, 2015|October 30, 2014||No||No|November 30, 2015|https://clinicaltrials.gov/show/NCT02315989||31042|
NCT02304328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/15|Impact of Herniation on WFNS Grading in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial|Impact of Herniation on WFNS Grading and Outcome in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial|hWFNS|University Hospital Inselspital, Berne|No|Recruiting|December 2015|August 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All patients (≥18 years) with a proven spontaneous SAH will be considered for this trial|December 2015|December 8, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02304328||31936|
NCT02324972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQX-1125-204|Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis|The KINSHIP Trial: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Atopic Dermatitis by Targeting the SHIP1 Pathway|KINSHIP|Aquinox Pharmaceuticals, Inc.|No|Completed|December 2014|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324972||30352|
NCT02324985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-005|Phase II Study of AP0302 5% Versus a Vehicle Comparator|Phase II Study of the Effects of AP0302 5% Versus the Vehicle Control on Delayed Onset Muscle Soreness of the Elbow Flexors||Aponia Laboratories, Inc.|No|Recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|January 12, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02324985||30351|
NCT02299245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETAIN Study|Rosuvastatin Effect on Telomere-telomerase System in ACS|Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study||Sun Yat-sen University|No|Active, not recruiting|October 2014|November 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02299245||32327|
NCT02307188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN3357|Multipolar Mapping and Atrial Arrhythmias|Atrial Signal Analysis Using a Multipolar Catheter in Patients Undergoing Atrial Fibrillation and Flutter Ablations||Columbia University|Yes|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|45 Years|N/A|No|||February 2016|February 18, 2016|November 25, 2014|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT02307188||31717|
NCT02295644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYBuffalo|Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial|Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial||State University of New York at Buffalo|No|Active, not recruiting|November 2014|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|28|||Female|18 Years|N/A|No|||May 2015|May 13, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295644||32603|
NCT02314481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0274|Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity|Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWIN II|DARWIN II|University College, London|Yes|Not yet recruiting|January 2017|January 2023|Anticipated|January 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|119|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02314481||31158|
NCT02309099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1818|Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach|Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach||University of North Carolina, Chapel Hill|No|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|99 Years|No|||February 2016|February 11, 2016|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309099||31571|
NCT02309801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMAR/IMIM/COCADEP/2|Interaction Between a Natural Aldehyde Dehydrogenase 2 (ALDH2) Inhibitor and Alcohol|Human Pharmacology Study to Evaluate the Interaction Between a Natural Inhibitor of Aldehyde Dehydrogenase 2 (ALDH2) and Alcohol in Healthy Volunteers. Pilot Clinical Trial|COCADEP/2|Parc de Salut Mar|Yes|Completed|July 2012|November 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309801||31517|
NCT02296216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-08|Late Effects of Radiosurgery on Acromegaly Study|LateR-Ac Study: Late Effects of Radiosurgery on Acromegaly Study|LateRAc|Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|January 2, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02296216||32559|
NCT02325765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EY05.055|Study of the Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery|Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery||Shanghai Children's Medical Center|Yes|Completed|April 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|100|Samples Without DNA|Whole Blood, plasma, serum|Both|1 Month|3 Years|No|Non-Probability Sample|1-36 months 2.5-15 kilogram accepted congential cardiac surgery|November 2015|November 28, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325765||30291|
NCT02312661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30102012|Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer|Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer|OVMET|University Medical Center Groningen|Yes|Recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02312661||31297|
NCT02308280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR-MM-001|Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients|A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma||Maisonneuve-Rosemont Hospital|Yes|Recruiting|November 2014|November 2022|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02308280||31633|
NCT02295813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101H-TOLPKE|Safety and Pharmacokinetics Study of FBF001|A Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of One Single Intravenous Dose and 5-day Repeated Intravenous Doses of FBF001 in Healthy Male Subjects||Fab'entech||Completed|October 2012|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02295813||32590|
NCT02302339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX011-05|A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma|A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, in Patients With Advanced Melanoma||Celldex Therapeutics|No|Recruiting|November 2014|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302339||32089|
NCT02322268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6370700|RCT Evaluating Effects of Cosmos Caudatus (Ulam Raja) in T2DM Patients|Metabolomic Profiling on The Effect of Cosmos Caudatus (Ulam Raja) Supplementation in Patients With Type 2 Diabetes: A Randomized Controlled Trial||Universiti Putra Malaysia|Yes|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|30 Years|65 Years|No|||November 2015|November 30, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02322268||30560|
NCT02312921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF|Population-centered Risk- and Evidence-based Dental Inter-professional Care Team|Reducing Oral Health Disparity Through Outreach, Evidenced-Based Care, Global Budgeting and the Alternative Quality Contract|PREDICT|Advantage Dental Services, LLC|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|14|||Both|N/A|21 Years|Accepts Healthy Volunteers|Probability Sample|80,000 children on Medicaid nested in 14 rural Oregon Counties.|December 2015|December 28, 2015|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02312921||31277|
NCT02296073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICUDEX2014|The Efficacy and the Safety of Dexmedetomidine Sedation on the Pediatric Intensive Unit(PICU) Patients.|The Efficacy and the Safety of Dexmedetomidine Sedation on the PICU Patients-A Randomized, Controlled Study.||Anhui Provincial Children's Hospital|No|Not yet recruiting|December 2014|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|1 Month|16 Years|No|||November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02296073||32570|
NCT02296346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00083301|Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis|A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)|MSECP|University of Michigan|Yes|Recruiting|October 2014|||October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296346||32549|
NCT02306187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-ED study 2014|The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis|The Effectiveness of Eldecalcitol in the Osteoporotic Patients Who Are Bisphosphonate Non-responders After Long-term Bisphosphonate Treatment||Shinshu University|No|Recruiting|December 2014|December 2019|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306187||31793|
NCT02306200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00052866|Cardiovascular Health Improvement Project|Cardiovascular Health Improvement Project|CHIP|University of Michigan|Yes|Recruiting|August 2013|||August 2053|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|9999|Samples With DNA|Blood, Tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient clinic|December 2014|December 1, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306200|40 Years|31792|
NCT02309710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|595330-3|Male Circumcision (MC) Using the ShangRing™ Device in Malawi|Prospective Study of Male Circumcision Using the ShangRing Device in Routine Clinical Settings in Malawi||FHI 360|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|500|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309710||31524|
NCT02311491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0924|Nano-Crystalline Ceramic Coating of Orthodontic Archwires|Nano-Crystalline Ceramic Coating for the Reduction of Sliding Resistance of Orthodontic Archwires||University of North Carolina, Chapel Hill|No|Not yet recruiting|January 2016|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|10 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311491||31387|
NCT02311504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCophtaOCTplus14_C|Eye Screening in German Secondary Diabetes Care Centers|OCT Screening of Diabetes Patients: Health Care Research in Secondary Diabetes Care Centers|DiabCheckophta|University Hospital Tuebingen|No|Recruiting|January 2014|September 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|patients with diabetes in secondary care diabetes centers|December 2014|December 8, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311504||31386|
NCT02307552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-9305|Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer|Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer||University of California, Irvine|Yes|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|40 Years|80 Years|No|||December 2014|December 3, 2014|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02307552||31689|
NCT02297529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120328|Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma|A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma||Amgen||Available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|95 Years|No|||January 2016|January 20, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297529||32459|
NCT02319993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSH-CMCTC-101-001|Traditional Chinese Medicine Suan Tsao Jen Tang and Tian-Wang-Bu-Xin Dan in Patients With Primary Insomnia.|Traditional Chinese Medicine Suan Tsao Jen Tang and Tian-Wang-Bu-Xin Dan in Patients With Primary Insomnia. A Multi-center Clinical Trial||Chung Shan Medical University|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|128|||Both|20 Years|80 Years|No|||January 2016|January 18, 2016|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02319993||30735|
NCT02325882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0883|The Postoperative Analgesic Effect of Combination With Dexmedetomidine in Fentanyl-based Intravenous Patient Controlled Analgesia Compared With Conventional Thoracic Epidural and Intravenous Patient Controlled Analgesia After Radical Open Gastrectomy|||Yonsei University|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|171|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02325882||30282|
NCT02306018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-08-080-002|Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation|Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation||Samsung Medical Center|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|20 Years|70 Years|No|||December 2015|December 27, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02306018||31806|
NCT02306031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88108|Topical Diclofenac on Macular Thickness After Phacoemulsification|The Effect of Topical Sodium Diclofenac on Macular Thickness in Diabetic Eyes After Phacoemulsification: A Randomized Controlled Trial|diclofenac|hahid Beheshti University of Medical Sciences|Yes|Active, not recruiting|June 2013|||June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 29, 2014|November 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306031||31805|
NCT02307058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140627|A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy|A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy - The Miami BLaStM Trial|BLaStM|University of Miami|Yes|Recruiting|November 2014|||February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Male|35 Years|85 Years|No|||February 2016|February 15, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307058||31727|
NCT02320162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marquette U|School-based Oral Health Education Program Using Experiential Learning|"School-based Oral Health Education Program Using Experiential Learning or Traditional Lecturing in Children and Adolescents: a Clinical Trial"||Marquette University||Completed|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|351|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02320162||30722|
NCT02429687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOGCT-01|TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors|A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors|MOGCT-01|Shandong University|Yes|Enrolling by invitation|April 2015|May 2020|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|129|||Female|14 Years|65 Years|No|||February 2016|February 14, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429687||22321|
NCT02429999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART|Letrozole in Assisted Reproductive Technology|The Role of Aromatase Inhibitor (Letrozole) in Minimal Ovarian Stimulation Protocols in Assisted Reproductive Technology. A Randomized Controlled Trial||Assiut University||Recruiting|April 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|20 Years|35 Years|No|||January 2016|January 6, 2016|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02429999||22297|
NCT02441426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAL-ED-47075|Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development|Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development|MAL-ED|Foundation for the National Institutes of Health|No|Active, not recruiting|November 2008|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|1796|Samples With DNA|plasma, stool, urine, saliva|Both|N/A|17 Days|Accepts Healthy Volunteers|Probability Sample|The study population for the MAL-ED Project is a birth cohort. Pregnant women were        identified from their communities, consented and the child will be enrolled.|May 2015|May 7, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02441426||21421|
NCT02441439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-15|To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy|To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy||HaEmek Medical Center, Israel|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||May 2015|May 30, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441439||21420|
NCT02440373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC IRB# 5458|Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome|Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome||Advocate Health Care|No|Recruiting|March 2014|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood drawn within 15 minutes of arrival to the Emergency Department and at 24, 48, and 74      hours. Each sample will be processed and stored for subsequent analysis of cytochrome c and      other markers of mitochondrial injury that may become available at a later time.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients of both genders suffering acute non-penetrating traumatic injury.|December 2015|January 6, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02440373||21502|
NCT02479659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Measuring the Impact of Integrating Maternal and Newborn HIV Testing With Childhood Immunization Services|A Cluster Randomised Trial on the Impact of Integrating Early Infant HIV Diagnosis With the Expanded Programme on Immunization on Immunization and HIV Testing Rates in Rural Zambian Health Facilities||IDinsight|No|Completed|October 2013|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02479659||18484|
NCT02430298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLT-MX|Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients|Topical and Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis and Xerostomia in Head and Neck Cancer Patients||Khon Kaen University|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|January 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02430298||22275|
NCT02428231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS416|Tecfidera Slow-titration Study|A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis|TITRATION|Biogen|No|Terminated|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|April 23, 2015|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT02428231||22433|
NCT02431988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/14/0385|Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|COBALT|University College, London|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|16 Years|65 Years|No|||December 2015|December 1, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431988||22146|
NCT02479958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/10|An in Vitro Evaluation of Antimicrobial Photodynamic Therapy on Deciduous Carious Dentin|A Randomized in Vitro Evaluation of Antimicrobial Photodynamic Therapy on Deciduous Carious Dentin||University of Sao Paulo|No|Completed|May 2011|January 2014|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|58|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02479958||18461|
NCT02430571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVIRIS0465|Case Series to Evaluate the Identification of Anatomical Markers Using the KANGAROO™ Feeding Tube|A Prospective, Single-Center, Open Label, Within-Subject Case Series to Evaluate the Identification of Anatomical Markers in the Gastrointestinal Tract Using the KANGAROO™ Feeding Tube With IRIS Technology||Medtronic - MITG|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430571||22254|
NCT02428491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L35|Study of Sanofi Pasteur's DTaP-IPV Hep B-PRP-T Combined Vaccine in Infants Who Previously Received Hepatitis B Vaccine|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth||Sanofi|No|Recruiting|April 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|354|||Both|61 Days|91 Days|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428491||22413|
NCT02428504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-150|Decision Making in End of Life as Individual Preferences|Decision Making in End of Life: Individual Preferences||St. Luke's-Roosevelt Hospital Center|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from Oncology, Pulmonary and Heart Failure.|March 2016|March 8, 2016|October 15, 2012||No||No||https://clinicaltrials.gov/show/NCT02428504||22412|
NCT02436239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-23|A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder|An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder|VLZ-MD-23|Forest Laboratories|No|Recruiting|April 2015|||November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|7 Years|17 Years|No|||December 2015|December 23, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436239||21819|
NCT02436252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB650027|Study of DSP-7888 in Patients With Myelodysplastic Syndrome|Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)|MDS|Sumitomo Dainippon Pharma Co., Ltd.||Recruiting|May 2015|December 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|N/A|No|||July 2015|July 21, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02436252||21818|
NCT02484898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEEQ™ Performance Study|SEEQ™ Performance Study|||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|August 3, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484898||18081|
NCT02438501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WuhanU|Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma|A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial|WUCC-NHL02|Wuhan University|Yes|Recruiting|October 2015|October 2025|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02438501||21645|
NCT02433470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/028/15|Association of Functional Changes in the Brain and the Perception of Pain in Patients With Chronic Inflammatory Bowel Diseases (IBD)|||Charite University, Berlin, Germany||Recruiting|April 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02433470||22032|
NCT02433483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITREL|Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients|A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies||St. Jude Children's Research Hospital|No|Recruiting|May 2015|May 2023|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|N/A|21 Years|No|||March 2016|March 1, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433483||22031|
NCT02320279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|South Shore Fetal EKG study|The Fetal EKG Study|The Fetal EKG Study||Mindchild Medical Inc.|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women, women in labor, and women who are admitted to labor and delivery for        scheduled c-sections will form the eligible population for recruitment into our study.        These women will be identified by a study staff-member who will ask on-call physicians,        midwives, and nurses working on Labor and Delivery|December 2014|December 18, 2014|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320279|1 Day|30713|
NCT02294604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103HCP002|The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room|The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room||Taipei Medical University Shuang Ho Hospital|Yes|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|236|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02294604||32683|
NCT02298608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 44785.018.13|Efficacy and Safety of IRE for RMs|The Efficacy and Safety of Irreversible Electroporation for the Ablation of Renal Masses: A Prospective, Human, In-Vivo Study.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2014|December 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298608||32376|
NCT02302352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/26788-3|Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis|Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis: a Randomized Double-blind Placebo-controlled Clinical Trial|SSc|Federal University of São Paulo|No|Not yet recruiting|December 2014|January 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02302352||32088|
NCT02320032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-A105|An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia|A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia||Alkermes, Inc.|No|Active, not recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02320032||30732|
NCT02320045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650 CLP-109|Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects|A Phase 1 Study to Evaluate the Pharmacokinetics of ITCA 650 in Subjects With Mild and Moderate Renal Impairment Compared to the Pharmacokinetics of Subjects With Normal Renal Function||Intarcia Therapeutics|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|November 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320045||30731|
NCT02301702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072201|Maternal Tdap Immunization in Guatemala|Evaluation of Tdap in Pregnancy to Prevent Infant Pertussis||Emory University|No|Not yet recruiting|April 2016|April 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|376|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|November 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301702||32138|
NCT02298855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC_F-UP_V3 28/07/2006|Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.|A Randomised Study Comparing Satisfaction With Individualised Follow-up Led by a Trained Cancer Nurse Versus Conventional Medical Follow-up After Primary Treatment for Ovarian Cancer.||University College, London|No|Completed|January 2006|May 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|113|||Female|18 Years|N/A|No|||September 2014|November 21, 2014|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02298855||32357|
NCT02306681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4177|A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes|An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes||Novo Nordisk A/S|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7315|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients with T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes        Mellitus) treated with insulin for more than 12 months who are 18 years or older,        ambulatory, literate, and have signed the Informed Consent form may participate in the        study.|June 2015|June 25, 2015|November 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306681||31756|
NCT02309450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRSHC33QUATTROTURBO|Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen|Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen|QUATTROTURBO|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Withdrawn|December 2014|August 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 31, 2014||No|BMS decision|No||https://clinicaltrials.gov/show/NCT02309450||31544|
NCT02321917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143/13|Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC)|Coagulation, Inflammation and Cerebral Embolism Using a Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC): Differences to the Conventional MECC System|RheoMECC|University Hospital Inselspital, Berne|Yes|Recruiting|April 2013|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321917||30587|
NCT02294084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.242|Sitagliptin and Brown Adipose Tissue|The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men|Sita01|Leiden University Medical Center|Yes|Recruiting|March 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Male|35 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294084||32723|
NCT02294097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWC-005|Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney Transplantation|The Outcomes of Protocol-Specified Modification of Immunosuppression Directed to Histological Diagnosis by Surveillance Protocol Biopsy||Chulalongkorn University|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|17 Years|70 Years|No|||November 2014|November 15, 2014|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02294097||32722|
NCT02306863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4291|Whole-body Vibration as a Treatment for Parkinson's Disease|The Efficacy of Long-term Whole-body Vibration in the Treatment of Parkinson's Disease||Sun Life Financial Movement Disorders Research and Rehabilitation Centre|No|Recruiting|January 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306863||31742|
NCT02294201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-M-KEN|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya|SR-M-KEN|University of Notre Dame|Yes|Not yet recruiting|June 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294201||32714|
NCT02325661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0252|Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)|Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)|AKQOLVS|University of Zurich|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|N/A|No|||December 2014|December 24, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02325661||30299|
NCT02305992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-123|Regional Anesthesia for Arteriovenous Fistula|Effect of Sympathetic Blockade on the Success and Survival of Arteriovenous Fistula||McMaster University|No|Suspended|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|November 11, 2014|Yes|Yes|Looking for funding opportunities|No||https://clinicaltrials.gov/show/NCT02305992||31808|
NCT02306005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoznanUMS|Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.|Insulin Therapy and Quantitive and Qualitive Changes of Plasma Lipoproteins in Patients With Newly Diagnosed Type 1 Diabetes.|InLipoDiab1|Poznan University of Medical Sciences|No|Recruiting|November 2014|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|serum|Both|18 Years|35 Years|No|Probability Sample|A minimum of 100 people with newly diagnosed type 1 diabetes hospitalized in the        Department of Internal Medicine and Diabetology Poznan University of Medical Sciences|November 2014|November 29, 2014|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02306005||31807|
NCT02295592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZSLYEC-021|TSTstarr + for Treatment of Severe Prolapsed Hemorrhoids --- a Multi-center Randomized Controlled Clinical Trail|||Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Not yet recruiting|November 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|780|||Both|18 Years|65 Years|No|||October 2014|November 19, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02295592||32607|
NCT02321683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH30.|Evaluation of a New Coating in Cement Less Femoral Stems|No Mid-term Advantage by Electrochemical Deposition of Hydroxyl-apatite in Cementless Femoral Stems. 5-year RSA and DXA Results From a Randomized Controlled Trial||Oslo University Hospital|No|Completed|December 2003|December 2008|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|N/A|N/A|No|||December 2014|December 17, 2014|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321683||30605|
NCT02311296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI-LO Study|Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions|Effect of Bacterial Colonization and Extracellular HSP-70 Expression in Sub-Glottic Secretions on Ventilator Free Days in Patients Receiving Mechanical Ventilation for Respiratory Failure or Airway Protection||University of Tennessee, Chattanooga|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients on mechanical ventilation|December 2015|December 4, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02311296||31402|
NCT02303899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2014-002|Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma|A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma||Istituto Clinico Humanitas|No|Recruiting|November 2014|November 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02303899||31969|
NCT02307435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISMMSC001|Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture|Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved|AMSC|Indonesia University|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307435||31698|
NCT02307448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10312014|Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds|Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds||ACR Biologics, LLC|No|Recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307448||31697|
NCT02311725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sTVi-2|Storytelling Video Intervention for Depressed Primary Care Patients - Pilot Trial|Narrative Intervention to Disseminate ACT for Depression in Primary Care|sTVi-RCT|Butler Hospital|No|Not yet recruiting|March 2017|December 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02311725||31369|
NCT02311738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGO|Exercise and Genes in Obese (EGO)|The Effect of Exercise and Genes on Energy Expenditure, Appetite and Quality of Life in Morbidly Obese Patients|EGO|Sykehuset i Vestfold HF|Yes|Recruiting|January 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02311738||31368|
NCT02299076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AG044872-03|Pro-Change Smoking Cessation Intervention|Software to Translate Behavioral Economics Insights to Improve Health (Phase 2b)||VAL Health, LLC|No|Recruiting|January 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|438|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299076||32340|
NCT02304341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_20|Development of a Modified Pediatric Early Warning Score: a French Prospective Multicentre Regional Study|Development of a Modified Pediatric Early Warning Score: a French Prospective Multicentre Regional Study.||University Hospital, Lille|No|Completed|September 2012|January 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3016|||Both|N/A|18 Years|No|Probability Sample|Children admitted to the paediatric inpatient unit in 7 regional hospitals French|November 2015|November 2, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02304341||31935|
NCT02319525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-1304-6631|Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus|Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus||University of Alabama at Birmingham|No|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02319525||30770|
NCT02318966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTW- GLY- 03/14-18|Glycosade v UCCS in the Dietary Management of Hepatic GSD|A Comparison of Glycosade® and Uncooked Cornstarch (UCCS) for the Dietary Management of Hepatic Glycogen Storage Diseases (GSD)|Glyde|Vitaflo International, Ltd|No|Not yet recruiting|January 2016|March 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|2 Years|75 Years|No|||September 2015|September 7, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318966||30813|
NCT02307981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2307|Norwegian Occipital Ischemic Stroke Study|Management and Outcome of Visual Field Defects in Occipital Infarction (NOR-OCCIP)- A Multi-center Prospective Study|NOR-OCCIP|Haukeland University Hospital|No|Active, not recruiting|August 2013|June 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital based|August 2015|August 17, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02307981||31656|
NCT02307994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVZON-R-14-01|Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH|Effectiveness and Safety of uFSH for Severe Oligospermia or Azoospermia:A Multi-center,Open,Randomized,Interventional,and Phase4 Trial in China||Livzon Pharmaceutical Group Inc.||Enrolling by invitation|August 2014|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Male|25 Years|35 Years|No|||August 2014|December 4, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02307994||31655|
NCT02294188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-M-IDR|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia|SR-M-IDR|University of Notre Dame|Yes|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294188||32715|
NCT02314247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-013|Efficacy & Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma & Cutaneous T-cell Lymphoma|Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)||Karyopharm Therapeutics, Inc|No|Terminated|February 2015|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 3, 2014|Yes|Yes|Due to enrollment challenges. The termination is not a consequence of any safety concern.|No||https://clinicaltrials.gov/show/NCT02314247||31176|
NCT02307331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sirius RSA study_JT|RSA Study of Sirius Stem and Exceed Cup|RCT of the Sirius Stem Used in Conjunction With the Exceed ABT Cemented Cup and OptiPac/OptiVac Cement - Model Based RSA, Clinical and Radiographic Outcomes||Region Skane|No|Recruiting|March 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2014|December 3, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02307331||31706|
NCT02300233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS16|The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia|The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia||Ionis Pharmaceuticals, Inc.|Yes|Recruiting|December 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300233||32251|
NCT02300506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI02T|Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma|Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma||Eisai Inc.|No|Recruiting|April 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Patients with diagnosed malignant glioma treated by surgery|November 2015|November 5, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300506||32230|
NCT02318667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8259-022|Correlation of Soluble ST2 With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).|An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.|EVOLUTION|Merck Sharp & Dohme Corp.|No|Recruiting|February 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|37|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318667||30836|
NCT02317679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-PP-10|Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study|Treatment of Port-wine Stains by Bosentan in Addition to Pulsed Dye Laser (PDL) in Children or Young Adults Who Previously Failed to Respond to PDL Alone: a Monocentric Pilot Study||Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|April 2014|February 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|7 Years|60 Years|No|||December 2014|December 15, 2014|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02317679||30912|
NCT02306837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lym-Auto-RJH-2014|Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies|A Phase II Trial of Consolidation Chemothetapy for Patients With Relapse or Refractory Lymphoid Malignancies After Autologous Stem Cell Transplantation||Shanghai Jiao Tong University School of Medicine|No|Recruiting|September 2014|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|60 Years|No|||December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306837||31744|
NCT02306850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU IRB 25007|Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma|Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma|NeoPembroMel|St. Louis University|No|Recruiting|January 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||February 2016|February 5, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306850||31743|
NCT02319655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP|Morphologic Changes After Membrane Peeling With Air Tamponade and Balanced Salt Solution|Changes of the Subfoveal Hyporeflective Zone After Membrane Peeling With Air Tamponade and Balanced Salt Solution - a Pilot Study||Vienna Institute for Research in Ocular Surgery|No|Recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|21 Years|N/A|No|||February 2016|February 12, 2016|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02319655||30761|
NCT02319668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202200|Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity|A Clinical Study to Evaluate the Efficacy of Pre-procedural and Pre-surgical Rinsing With an Antimicrobial Agent in Reducing Bacteria in Dental Aerosols and in the Oral Cavity||GlaxoSmithKline|No|Recruiting|February 2015|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|44|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319668||30760|
NCT02295826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATAS002|Dabigatran Following Transient Ischemic Attack and Minor Stroke|Dabigatran Following Transient Ischemic Attack and Minor Stroke|DATAS II|University of Alberta|Yes|Recruiting|January 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295826||32589|
NCT02300129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40225E|Effect of CD07805/47 Gel in Rosacea Flushing|Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea||Galderma R&D|No|Completed|April 2014|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300129||32259|
NCT02307604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1313|SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access|Screening Platform of EORTC for Clinical Trials Access in Brain Tumors|SPECTAbrain|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|October 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|FFPE blocks of tumour tissue Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pathologically confirmed brain cancer at any stage.|August 2015|August 11, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02307604|5 Years|31685|
NCT02313116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DxP 2012-02 (Part B)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)||Diagnostic Photonics, Inc.|No|Active, not recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|Women with breast cancer undergoing lumpectomy.|February 2016|February 1, 2016|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313116||31262|
NCT02313363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1301-075-459|Patient-Centered Smartphone-Based Diabetes Care|Feasibility of a Patient-Centered Smartphone-Based Diabetes Care System: a Pilot Study||Seoul National University Hospital|Yes|Completed|December 2013|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|20 Years|80 Years|No|||December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313363||31243|
NCT02316678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818347|Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics|Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics|PPOD|University of Pennsylvania|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators will use Medicare data from 2006-2011. Patients will be required to have        at least two diagnosis of inflammatory bowel disease within the 6 months prior to        initiating anti-TNF therapy or coritcosteroids as defined below. To assure full coverage,        patients will be required to have Parts A, B, and D Medicare coverage.|December 2014|December 10, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02316678||30989|
NCT02300948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009554|Optimizing Periconceptional and Prenatal Folic Acid Supplementation|Optimizing Periconceptional and Prenatal Folic Acid Supplementation||The Hospital for Sick Children|Yes|Completed|December 2006|April 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300948||32196|
NCT02293317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX-006|Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by a Seasonal Trivalent Influenza Vaccine (TIV)|BVX006|BiondVax Pharmaceuticals ltd.|No|Completed|November 2014|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|37|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||November 2014|February 21, 2016|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02293317||32782|
NCT02296788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-062|Effects of Aerobic Exercise on Gut Microbiota|Effects of Aerobic Exercise on Gut Microbiota (EGM) - P & F Ancillary Study (E-Mechanic)|EGM|Pennington Biomedical Research Center|No|Withdrawn|June 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 18, 2014||No|Study wasn't stopped. It wasn't started. Funding.|No||https://clinicaltrials.gov/show/NCT02296788||32515|
NCT02315976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPN 01-01-13|Acute Episodes in Chronic Stable Angina: Assessment of the Use of the Coronary Vasodilator Propatyl Nitrate.|Avaliação de episódios Agudos na Angina Pectoris crônica estável: Abordagem clínico-laboratorial do Uso do Vasodilatador Coronariano Propatilnitrato.||Fundação Educacional Serra dos Órgãos|No|Active, not recruiting|April 2014|December 2015|Anticipated|December 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|50 Years|68 Years|No|||December 2015|December 4, 2015|November 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02315976||31043|
NCT02296359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-848FM|Vaccination Response in Individual Monozygotic Twins|Vaccination Response in Individual Monozygotic Twins||Michigan State University|No|Terminated|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1|Samples With DNA|If the volunteers agree,tissue is stored for usage in future research without identifiers.      This includes cells from blood and saliva and extracted DNA, RNA and protein. The cells may      be used to grow a new cell line that may be maintained in the laboratory.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Monozygotic Twins over 18 years of age with and without asthma, without gender or        ethnicity restrictions.|August 2015|August 12, 2015|November 18, 2014|No|Yes|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT02296359||32548|
NCT02301208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JiangsuCIH|Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma|A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients|NPC-RCT-WCRT|Jiangsu Cancer Institute & Hospital||Not yet recruiting|December 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|70 Years|No|||December 2014|December 5, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02301208||32176|
NCT02302586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46143867-1035|Thoracic Paravertebral Blockade in Video Assisted Thoracoscopic Surgery (VATS)|Effects of Thoracic Paravertebral Blockade on Acute and Chronic Pain After Video Assisted Thoracoscopic Surgery (VATS) - A Randomized, Clinical Trial|VATS|Istanbul University|Yes|Completed|September 2014|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02302586||32070|
NCT02322593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10056040|Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer|An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer|SOLAR|Taiho Pharmaceutical Co., Ltd.|Yes|Recruiting|December 2014|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|686|||Both|20 Years|N/A|No|||February 2016|February 23, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02322593||30535|
NCT02322775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3250C00032|Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma||AstraZeneca|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322775||30521|
NCT02313428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0342|Topical Oxygen Therapy for Diabetic Foot Ulcers|Effects of Topical Oxygen for Diabetic Foot Ulcers|TOFU|Ohio State University|Yes|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313428||31238|
NCT02310035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nWMO48|Observational Study on the Course of Plasma Glutamine Levels During Critical Illness|Observational Study on the Course of Plasma Glutamine Levels During Critial Illness||Medical Centre Leeuwarden|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|178|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are admitted to the ICU after elective surgery and non-elective        admissions|May 2015|May 12, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310035||31499|
NCT02310048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E09|Comparative Oral Bioavailability Study of MT-1303|A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects||Mitsubishi Tanabe Pharma Corporation||Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02310048||31498|
NCT02294630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206011023|Aerosolized Surfactant in Neonatal RDS|Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study|AS-02|Sood, Beena G., MD, MS|Yes|Recruiting|December 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|24 Hours|No|||September 2015|September 14, 2015|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294630||32681|
NCT02322788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4711C00001|Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3|A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Induced Bronchoconstriction in Patients With Stable, Mild to Moderate Asthma||AstraZeneca|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|95|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02322788||30520|
NCT02430012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-2013BAI09B01-2|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention|MISSION-1|China National Center for Cardiovascular Diseases|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5720|||Both|N/A|N/A|No|||June 2015|July 23, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02430012||22296|
NCT02428530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.413|Partner Involvement During Pregnancy and Its Association With Maternal Health Behaviors|Partner Involvement During Pregnancy and Its Association With Maternal Health Behaviors||Ohio State University|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|159|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Paternal support is related to positive pregnancy outcomes. We explored the relationship        between paternal involvement and maternal smoking and alcohol consumption during        pregnancy. This was an IRB-approved cross sectional study. Pregnant women between the ages        of 18 - 44 years old and their partners were surveyed in the outpatient OB/GYN offices of        Thomas Jefferson University. Women who identified their partner as their main support were        included.|April 2015|April 27, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428530||22410|
NCT02428738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 13-265|Text Message Reminders for Influenza Vaccine in Pregnancy|Text Message Reminders for Influenza Vaccine in Pregnancy||St. Michael's Hospital, Toronto|No|Completed|November 2013|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|317|||Female|18 Years|N/A|No|Non-Probability Sample|All Women cared for in the Women's Health Care Centre prenatal clinic during influenza        season|April 2015|April 23, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02428738||22394|
NCT02428062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-POCD|Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly|Effect of Target Intraoperative Blood Pressure on the Incidence of Post-operative Cognitive Dysfunction in Patients Aged 75 and Older Undergoing General Anesthesia for Non-cardiac Surgery: an International Multicenter Randomized Controlled Trial|THE BRIDGE|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|October 2014|||December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1812|||Both|75 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02428062||22446|
NCT02484144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04|Evaluation of the Information of the Patient Before a Scheduled Coronarography|Evaluation of the Information of the Patient Before a Scheduled Coronarography|INFOCORO|French Cardiology Society|No|Active, not recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|700|||Both|18 Years|N/A|No|Probability Sample|patients with scheduled coronarography|July 2015|February 2, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484144||18139|
NCT02434757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT1|Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis|Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs||Phase III Clinical Research|Yes|Recruiting|February 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|April 30, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434757||21933|
NCT02434770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-015|Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine|A Phase III Single-blind, Randomized, Controlled Study in Healthy Kenyan Infants to Assess the Immunogenicity and Safety of Beijing TiantanBio Liquid Bivalent Oral Poliomyelitis Vaccine in Comparison to a WHO Prequalified Comparator||PATH|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|750|||Both|N/A|14 Days|Accepts Healthy Volunteers|||April 2015|August 17, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434770||21932|
NCT02432651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPI-6119|Xanthohumol and Prevention of DNA Damage|Prevention of Oxidative DNA Damage by Xanthohumol||Oregon State University|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432651||22095|
NCT02435953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-FXY-086|TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma|Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Intermediate-stage Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Recruiting|April 2015|||May 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1|||Both|18 Years|75 Years|No|||May 2015|May 8, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02435953||21841|
NCT02484365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2014202(1399)|Preoperative Noninvasive Hemoglobin Monitoring in Pediatric Patients|The Accuracy of the Noninvasive Hemoglobin Monitoring for Preoperative Evaluation for Pediatric Patients||Chung-Ang University Hospital|No|Recruiting|December 2014|August 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|177|||Both|1 Month|18 Years|No|Non-Probability Sample|pediatric patients age under 18 years planning to receive elective surgery under general        anesthesia people live in South Korea|January 2016|January 26, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02484365||18122|
NCT02484625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001|The Effect of Dairy and Non-dairy Snacks on Food Intake, Subjective Appetite in Children|The Effect of Solid, Semi-solid and Fluid Dairy Products on Short-term Food Intake and Satiety in Children||Mount Saint Vincent University|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|23|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02484625||18102|
NCT02435030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-ORZY-NPC-001|A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C|A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern||Orphazyme|No|Recruiting|September 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|46|Samples Without DNA|Plasma|Both|2 Years|18 Years|No|Probability Sample|NPC1 and NPC2 patients aged 2-18 years|February 2016|February 15, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435030||21912|
NCT02435043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/352|A Trial of Nature-based Post-stroke Fatigue Rehabilitation (NASTRU)|A Randomized Controlled Trial of Nature-based Post-stroke Fatigue Rehabilitation (NASTRU)|NASTRU|Region Skane|No|Active, not recruiting|August 2012|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|55 Years|80 Years|No|||March 2015|April 30, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02435043||21911|
NCT02437500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERES-005|Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection|ECOSPOR II: An Open Label Extension of Study SERES 004 Evaluating SER 109 in Patients With Recurrent Clostridium Difficile Infection|ECOSPOR II|Seres Therapeutics, Inc.|No|Enrolling by invitation|May 2015|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|29|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437500||21722|
NCT02437747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPU/431(7) /2014|Locally Delivered Aloe Vera Gel in the Treatment of Chronic Periodontitis Patients With Diabetes Mellitus|Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis Patients With Controlled Diabetes Mellitus||Dr. D. Y. Patil Dental College & Hospital|Yes|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|30 Years|55 Years|No|||May 2015|May 5, 2015|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02437747||21703|
NCT02440503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0489|How Infant Diets Would Affect Growth in Early Childhood|Effect of Complementary Feeding With Different Macronutrient Quantities on Growth and Body Composition: a Follow-up Trial|FYI-FU|University of Colorado, Denver|No|Recruiting|June 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|42|Samples Without DNA|stool samples will be collected for microbiome analysis|Both|4 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 4-6 years of age|January 2016|January 6, 2016|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02440503||21492|
NCT02440594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807774|The PACE/PACENET Behavioral Health Laboratory Project|The PACE/PACENET Behavioral Health Laboratory Project: Evaluation of a Clinical Management Program Among Older Adults Newly Prescribed Medication for Behavioral Health Issues|SUSTAINII|University of Pennsylvania|No|Completed|August 2010|June 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3343|||Both|65 Years|N/A|No|||May 2015|October 4, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440594||21485|
NCT02493049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOM-RRMS-01|Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)|Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis||University of Calgary|No|Enrolling by invitation|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||October 2015|October 2, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493049||17457|
NCT02493920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECCANICA SLI|Sustained Lung Inflation and Pulmonary Mechanics in Preterm Infant|Evaluation of Pulmonary Mechanics in Preterm Infant Treated With Sustained Lung Inflation at Birth||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|25 Weeks|36 Weeks|No|||July 2015|July 9, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493920||17390|
NCT02442778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-302|Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatement of Agitation in Patients With Dementia of the Alzheimer's Type.||Avanir Pharmaceuticals|Yes|Recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|325|||Both|50 Years|90 Years|No|||December 2015|December 18, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442778||21317|
NCT02438579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SS/0079|Hypertonic Saline Nasal Irrigation and Gargling for the Common Cold.|Edinburgh and Lothians Viral Intervention Study (ELVIS). A Pilot Randomised Control Trial of Hypertonic Saline Nasal Irrigation and Gargling on Individuals With the Common Cold to Assess Recruitment, Retention, Side Effects & Effectiveness|ELVIS|NHS Lothian|No|Completed|August 2014|October 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|66|||Both|16 Years|N/A|No|||December 2015|December 12, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02438579||21639|
NCT02297425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7711001|A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer|Phase 1/2 Open Label Study Of Pf 06459988 (Epidermal Growth Factor Receptor T790m Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 Or L858r + - T790m) Non Small Cell Lung Cancer||Pfizer|No|Withdrawn|January 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297425||32467|
NCT02298842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5051|In-Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution|In-Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution||Terumo BCT|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298842||32358|
NCT02304172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHthyroid|The Efficacy and Safety of Thunderbeat in Thyroid Surgery|The Efficacy and Safety of Thunderbeat in Thyroid Surgery: a Prospective Randomized Study|Thunderbeat|Seoul National University Hospital|Yes|Completed|November 2014|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02304172||31948|
NCT02302365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5043|Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion|Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion|WBCD|Terumo BCT|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|43|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have undergone white blood cell depletion via the Spectra Optia Apheresis        System which is likely to include patients with severe leukocytosis in acute leukemia        (acute myeloid leukemia, acute lymphoblastic leukemia, or in chronic myelogenous leukemia        or to prevent tumor lysis syndrome.|November 2015|February 3, 2016|November 18, 2014|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT02302365||32087|
NCT02302378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02430|Taylor's Approach vs Lumbar Approach for Spinal Anesthesia|Hypotension in Spinal Anesthesia for Total Knee Joint Arthroplasty: a Comparison of Taylor's Approach With Paramedian Lumbar Approach||University of British Columbia|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|30|||Both|20 Years|N/A|No|||December 2015|December 2, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02302378||32086|
NCT02325557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADXS142-03|ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046|A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer||Advaxis, Inc.|No|Recruiting|January 2015|December 2019|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|51|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|December 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325557||30307|
NCT02325570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1004-P001|Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis|The Evaluation of the Clinical Effects of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp as an Adjunct to the Non-Surgical Treatment of Moderate to Severe Chronic Periodontitis||KLOX Technologies Inc.|No|Completed|November 2014|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02325570||30306|
NCT02305680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00049|Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension|EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension|EPICOR|AstraZeneca|Yes|Active, not recruiting|December 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|Patients with a history of acute coronary syndromes in China|January 2016|January 28, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02305680||31832|
NCT02305693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub 7|Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)|Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)||Cairo University|Yes|Recruiting|November 2014|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02305693||31831|
NCT02295137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN|Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair|Image Fusion of Pre-procedural CTA With Real-time Fluoroscopy to Guide Proper Renal and Visceral Arteries Catheterization During Advanced Endovascular Aortic Aneurysms Repair: A Feasibility Study||University Health Network, Toronto|No|Recruiting|February 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|November 14, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02295137||32642|
NCT02295150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frax001|Prophylaxis of Venous Thromboembolism After Bariatric Surgery|Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery.||Rijnstate Hospital|No|Recruiting|March 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|65 Years|No|||November 2014|November 19, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02295150||32641|
NCT02298673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BML 04-2014|Biomarker for Mucolipidosis Disorder Type I, II, III or IV|Biomarker for Mucolipidosis Disorder Type I, II, III or IV - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioML|University of Rostock|Yes|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with mucolipidosis disorder type I, II, III or IV or patients with high-grade        suspicion for mucolipidosis disorder type I, II, III or IV should be included into the        study.|January 2016|January 13, 2016|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298673||32371|
NCT02310789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31238|(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?|(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil||Stanford University|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310789||31441|
NCT02298803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X14 0314|QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia|QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring||Royal Prince Alfred Hospital, Sydney, Australia|No|Not yet recruiting|January 2015|August 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||November 2014|November 21, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02298803||32361|
NCT02295384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Polypharmacy Audit|Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia|Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia||Holdsworth House Medical Practice||Active, not recruiting|November 2014|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1104|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients attending HHMP from 1st January 2005 to 31st July 2014 inclusive,        who had at least 2 practice visits separated by ≥90 days in a year involving HIV        laboratory monitoring whilst attending HHMP (either on-site or at a co-management site).|February 2016|February 17, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295384||32623|
NCT02315651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7636|Efficacy of Combined Treatment With CoQ10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder|Efficacy of Combined Treatment With Co-enzyme Q10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder||Rabin Medical Center|No|Not yet recruiting|January 2015|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||October 2014|December 11, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02315651||31068|
NCT02313909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16573|Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)|Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg|NAVIGATE ESUS|Bayer|Yes|Recruiting|December 2014|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|7060|||Both|50 Years|N/A|No|||March 2016|March 8, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313909||31201|
NCT02313922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C301-PS|Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate|Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial||Zhejiang University||Recruiting|November 2014|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|488|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313922||31200|
NCT02294318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA024606-S|HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics|HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care||Research Foundation for Mental Hygiene, Inc.|Yes|Recruiting|June 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294318||32705|
NCT02299921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0630|Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure|Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure||University of Colorado, Denver|No|Recruiting|November 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|blood: serum cortisol, ACTH, CRH, AVP hair: cortisol urine: TP, NGAL, KIM-1 exhaled breath      condensate: CCL5 BAL: cell count and differential, total protein, cytokines/chemokines      including CCL5, TNFa, IFNg, IL-6, IL-8, IL-10, alveoloar macrophage cytokine/chemokine      production, alveolar macrophage viability, apoptosis, cytotoxicity, lymphocyte activation|Both|18 Years|90 Years|No|Non-Probability Sample|Specific Aim 1. Adult medical ICU patients admitted to the University of Colorado Hospital        for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs        Specific Aim 2. Adult medical ICU patients with respiratory failure (due to underlying        lung pathology) and who require endotracheal intubation and mechanical ventilation|December 2015|December 3, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02299921||32275|
NCT02300181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-1051|Effect of the Extract of the Flour Fermented With Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Determine the Effect of the Flour Fermentation Products by Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose Profile in Prediabetic Subjects.||Hiroshima University|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300181||32255|
NCT02315430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02411|Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum||National Cancer Institute (NCI)|Yes|Suspended|April 2015|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315430||31085|
NCT02315495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSSAXA0015|Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes|Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes||Zhongda Hospital|Yes|Recruiting|February 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|22|||Both|18 Years|70 Years|No|||July 2015|July 20, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02315495||31080|
NCT02297035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100137|Characterisation of Primary Progressives Aphasias|Linguistic, Anatomic/Metabolic and Biologic Characterisation of the Three Main Variants of Primary Progressive Aphasia : Towards the Rationale for Drug Trials and Specific Language Rehabilitations|CAPP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|155|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02297035||32497|
NCT02297048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120906|Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)|Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)|DEPROGE|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02297048||32496|
NCT02315664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01762|MONITOR-OA: Using Wearable Activity Trackers to Improve Physical Activity in Knee Osteoarthritis|Improving Physical Activity Using an Online Monitoring Tool: a New Model of Care for Knee Osteoarthritis||University of British Columbia||Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|19 Years|N/A|No|||November 2015|November 10, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02315664||31067|
NCT02319460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_4001|An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding|An Observational Cohort Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding||CSL Behring||Recruiting|March 2014|||June 2020|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|3450|||Both|18 Years|N/A|No|Non-Probability Sample|Adult members of the Kaiser Permanente Northern and Southern California health care        delivery systems, receiving chronic warfarin therapy and meeting study eligibility        criteria.|March 2016|March 4, 2016|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319460||30775|
NCT02318680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-329|Follow Home Visits After Discharge|Follow Home Visits by Hospital and Municipality After Discharge of Frail Elderly Patients From Nykøbing Falster Hospital - a Randomized Controlled Trial||Roskilde County Hospital|No|Completed|January 2013|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|545|||Both|65 Years|N/A|No|||January 2015|January 9, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02318680||30835|
NCT02318693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-355|Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)|A Randomized, Open-label, Comparative Clinical Trial to Study the Efficacy of Sitagliptin and Glibenclamide in a Short Term Treatment on the Daily Glucose Variability Using Continuous Glucose Monitoring (CGM) in Japanese Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|20 Years|75 Years|No|||December 2015|December 18, 2015|December 12, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318693||30834|
NCT02304588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-001|Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot|Vascular Occlusive Diseases Such as Diabetic Foot Treated With Mesenchymal Stem Cell||Chinese PLA General Hospital|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|78 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02304588||31916|
NCT02306161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02380|Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma|Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma||National Cancer Institute (NCI)|Yes|Recruiting|December 2014|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|50 Years|No|||December 2015|March 24, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306161||31795|
NCT02301273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16.2011|Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy|Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy: Comparison of Patient Outcomes Between Enhanced and Conventional ICU Physiotherapy||Landspitali University Hospital|No|Completed|November 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 27, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT02301273||32171|
NCT02301286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.152|A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients|A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients|ASPIRIN|Leiden University Medical Center|Yes|Recruiting|September 2014|September 2022|Anticipated|September 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1588|||Both|45 Years|N/A|No|||March 2016|March 16, 2016|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301286||32170|
NCT02321969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1006/103-002|Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer|Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer||Seoul National University Hospital|No|Completed|August 2010|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|176|||Both|19 Years|85 Years|No|||October 2015|October 26, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321969||30583|
NCT02312349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1770|Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City|Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City||Hospital Italiano de Buenos Aires|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|112|||Both|N/A|N/A|No|Probability Sample|It will generate a stratified random sample of 15% of businesses (restaurants, bars,        pizzerias and fast food outlets) located in the three selected districts. To be used to        sample a sampling frame of the selected districts conducted by the same research group        (NCT01388972).|December 2014|December 8, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02312349||31321|
NCT02322697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dialysis heart carnitine study|Effect of Carnitine on Uremic Cardiomyopathy|Effects of Chronic Intravenous Administration of L-carnitine on Myocardial Fatty Acid Metabolism in Hemodialysis Patients||Toujinkai Hospital|No|Completed|August 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|85 Years|No|||December 2014|December 23, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02322697||30527|
NCT02294825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-099-HP|The North-West Inter Regional Female Cohort for Patients With Endometriosis|The North-West Inter Regional Female Cohort for Patients With Endometriosi|CIRENDO|University Hospital, Rouen|No|Active, not recruiting|June 2009|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|50 Years|No|Non-Probability Sample|Patients surgically managed for endometriosis in one of centers involved in the study|June 2015|June 17, 2015|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02294825|7 Years|32666|
NCT02298647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGM 03-2014|Biomarker for GM1/GM2 - Gangliosidoses|Biomarker for GM1/GM2-Gangliosidoses - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioGM1BioGM2|University of Rostock|Yes|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with GM1/GM2- Gangliosidoses or high-grade suspicion for GM1/GM2 -Gangliosidoses|October 2015|October 6, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298647||32373|
NCT02307032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3037SH|Atrial Fibrillation Prediction Trial.|Atrial Fibrillation Prediction Trial of the Dynamic Changes Through the Continuous Spectrum of the Arrhythmia Evolution.|AFPRET|University of Athens|No|Recruiting|September 2014|December 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|30 Years|80 Years|No|Probability Sample|The study will include > 500 patients 30-80 years old.|January 2016|January 27, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307032||31729|
NCT02318420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R164-2013-16038|Paper-Based and Electronic Partogram Systems to Safe Lives at Birth|Paper-Based and Electronic Partogram Systems Evaluation of Their Effectiveness and Feasibility to Reduce Adverse Pregnancy Outcomes in an East African Referral Hospital|PartoMa|University of Copenhagen|No|Recruiting|October 2014|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20000|||Both|N/A|N/A|No|||December 2014|December 11, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02318420||30855|
NCT02295332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29542|A Study of RG7625 in Healthy Volunteers|||Hoffmann-La Roche||Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295332||32627|
NCT02296398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU95649|Long-term Use of Romidepsin in Patients With CTCL|Retrospective and Prospective Study of Long-term Use of Romidepsin in Patients||Northwestern University|No|Completed|January 2015|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|47|||Both|18 Years|89 Years|No|Non-Probability Sample|Medical records of patients with a diagnosis of cutaneous T-cell lymphoma that have        presented to the Northwestern Medical Faculty Foundation Dermatology clinic, who receive        romidepsin per standard of care practice will be reviewed. Retrospective chart reviews        will be conducted for data collected between January 1, 2009 (when romidepsin was        initially prescribed) to May 28, 2014. The prospective portion of the study will review        chart data collected between May 29, 2014 and December 31, 2014.|March 2016|March 10, 2016|October 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02296398||32545|
NCT02296411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-5993AB1-02|Efficacy of LAMA Added to ICS in Treatment of Asthma|A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR® pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids|ELITRA|Chiesi Farmaceutici S.p.A.|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|75 Years|No|||February 2016|February 15, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02296411||32544|
NCT02308644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80838792A|Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study|Phase 3 Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Pilot Study.||University of Sao Paulo|Yes|Completed|February 2009|February 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02308644||31605|
NCT02321839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAENCU001|Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.|Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.||Nagoya City University|Yes|Recruiting|January 2014|December 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|N/A|No|||October 2015|October 5, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321839||30593|
NCT02311010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-02-RG-234|Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism|Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation|CYRANO|Université Catholique de Louvain|Yes|Active, not recruiting|January 2011|January 2015|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|15 Years|70 Years|No|||December 2014|December 4, 2014|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02311010||31424|
NCT02317692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-2871|ADHD Treatment for Latino Families|Standard Versus Culturally-Modified ADHD Treatment||Marquette University|No|Recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|13 Years|No|||September 2015|September 23, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02317692||30911|
NCT02296996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZB-BN- 2013-001|Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients|A Phase II Clinical Trial on the Combination of Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients With Advanced BRAF V600 Mutant Melanoma||Universitair Ziekenhuis Brussel|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296996||32500|
NCT02297009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57170|Comparison of the Methylation Pattern of DNA in Buccal Swabs From Different Time Points|Comparison of the Methylation Pattern of DNA in Buccal Swabs From Different Time Points||Universitaire Ziekenhuizen Leuven||Recruiting|December 2014|September 2018|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Buccal cells|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Students and research staff|October 2014|January 13, 2015|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297009||32499|
NCT02321930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI193025|Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients|Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients||University of California, Los Angeles|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 23, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321930||30586|
NCT02321943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150281|Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study|Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study||Sykehuset Innlandet HF|No|Enrolling by invitation|February 2015|October 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|91|Samples Without DNA|Blood tests including cardiovascular risk factors and immunological parameters (cytokines).|Both|18 Years|65 Years|No|Probability Sample|Patients reffered to their first adequate treatment for broadly defines psychotic        disorders (inkluding both schizophrenia - and bipolar Spectrum disorders) in Oppland and        Hedmark counties in Norway, in 2008 - 2009 participated the base-line part of the study(E.        Haug, 2012).|December 2014|December 19, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321943||30585|
NCT02316444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U010|Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda|Strategies for the Prevention of Hepatitis B Viral Infection Among HIV Infected Adults in Uganda||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316444||31007|
NCT02316457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN_0002-01|RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID|First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients|TNBC-MERIT|Biontech AG|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||July 2015|July 21, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02316457||31006|
NCT02308176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKTIDIET|Effectiveness of a Mobile Application as an Adjunct to Medical Advice to Promote Healthy Habits|Effectiveness of a Mobile Application as an Adjunct to Medical Advice to Promote Healthy Habits (Diet and Sport) in a Population of Patients Obese or Overweight Adults Patients|AD01|Basque Health Service|No|Recruiting|September 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|45 Years|No|||September 2015|September 28, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308176||31641|
NCT02308189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14F025|The Back Exercises to Neutralize Disability Study|Novel Exercise Interventions to Improve Trunk Muscle Function: A Pilot Study|BEND|Ohio University|Yes|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|No|||October 2015|October 13, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308189||31640|
NCT02294890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHPellenberg|Knee Stiffness in Fibrosis Diathesis|Does Fibrosis Diathesis Influence the Recovery of Knee Mobility After Total Knee Replacement?||University Hospital Pellenberg|Yes|Not yet recruiting|January 2015|April 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|50 Years|N/A|No|Probability Sample|All patients who undergo a total knee arthroplasty for primary gonarthrosis at a minimal        age of 50 years showing signs of fibrosis diathesis at presentation can be included.        Patients who do not show signs of fibrosis diathesis will serve as a control group.|November 2014|November 15, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02294890||32661|
NCT02294903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-105|Focal Prostate Radiofrequency Ablation|A Prospective Development Study Evaluating Focal Therapy Using Encage Coiled Bipolar Radiofrequency Ablation in Men With Localised Prostate Cancer|ProRAFT|Trod Medical N.V.|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|40 Years|N/A|No|||November 2015|November 23, 2015|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02294903||32660|
NCT02316873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReMus R-11-85|Rhythm and Music to Rehabilitate Reading Disorders|Rhythm and Music to Rehabilitate Reading Disorders|ReMus|Aix Marseille Université|No|Completed|September 2011|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|8 Years|11 Years|No|||December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316873||30974|
NCT02320084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sobi.NTBC-005|Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care|A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care|OPAL|Swedish Orphan Biovitrum|No|Enrolling by invitation|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|All patients receiving Orfadin is eligible for the study|August 2015|August 11, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02320084||30728|
NCT02305706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROLCOL 1.0|Right or Left for Colonoscopy?|Does Right Rather Than Left Starting Position Lead to Quicker Completion of COLonoscopy?|ROLCOL|Imperial College Healthcare NHS Trust|No|Completed|April 2014|November 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|163|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|December 2, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305706||31830|
NCT02305719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LudwigMaximilians|Regional Anesthesia for Thoracoscopic Surgery|Regional Anesthesia for Thoracoscopic Surgery|RATS|Ludwig-Maximilians - University of Munich|No|Recruiting|July 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for thoracoscopic surgery ASA 1-3|November 2014|December 2, 2014|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02305719|3 Days|31829|
NCT02297256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02411|Prospective Study of Thoracolumbar Spinal Fusion Graft|Prospective Study of Thoracolumbar Spinal Fusion Graft Efficacy: Bone Marrow Aspirate Concentrate Versus Iliac Crest Bone Graft|BMAC|New York University School of Medicine|Yes|Enrolling by invitation|August 2012|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297256||32480|
NCT02297516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PDF1401|Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment|An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure/Dysport Alone or Restylane/Emervel Filler Alone||Q-Med AB|No|Active, not recruiting|October 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 31, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297516||32460|
NCT02317341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150037|Effect of Ketamine on Fatigue Following Cancer Therapy|Effect of Ketamine on Fatigue Following Cancer Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317341||30938|
NCT02317536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15CAHL|A Pilot Clinical Trial on the Efficacy of Two Carnitine-Based Products on Muscle Function in Healthy Older Adults|A Randomized Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Relative Efficacy of Two Carnitine-Based Products Purported to Promote Muscle Anabolism in Healthy Older Adults|15CAHL|KGK Synergize Inc.|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|42|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317536||30923|
NCT02325856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABISAD-3|Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients|Effect of Post-dialysis Weight Evaluated With Bioimpedance Spectroscopy on Dialysis Morbidities and Clinical Outcomes in Hemodialysis Patients: A Randomized Controlled Trial||An Hsin QingShui Clinic|Yes|Completed|October 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|298|||Both|N/A|N/A|No|||July 2015|December 29, 2015|December 22, 2014||No||No|June 24, 2015|https://clinicaltrials.gov/show/NCT02325856||30284|
NCT02301221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGS-FMT-CC-2014|Effect of Fecal Microbiota Transplantation in Chronic Constipation|A Study of Efficacy, Safety and Durability of Fecal Microbiota Transplantation in Adult Patients With Chronic Constipation|FMTCC|Jinling Hospital, China|Yes|Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02301221||32175|
NCT02305836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014S291|Effect of Electroacupuncture for Treating Alzheimer's Disease|The Effect of Electroacupuncture Versus Donepezil on Cognitive Function in Alzheimer's Disease Patients: a Protocol for a Randomized, Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|85 Years|No|||November 2015|November 12, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02305836||31820|
NCT02307006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC 56 / IIT-USA-000585/|The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection|IDC 56: A Randomized Double-blinded Study Comparing Ceftaroline to Standard of Care Therapy With Cefazolin and Vancomycin as Surgical Prophylaxis for High Risk Orthopedic and Cardiac Surgeries|PREVTAROLINE|University of Cincinnati|Yes|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307006||31731|
NCT02313610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS110326|Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis|Efficacy and Safety of Qinbudan as an Adjunct Therapy in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Trial||Shanghai University of Traditional Chinese Medicine|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|65 Years|No|||December 2014|December 7, 2014|December 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313610||31224|
NCT02317185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-1401|Clinical Evaluation of GENEX® DS in Instrumented Posterolateral Fusion|CLINICAL EVALUATION OF GENEX® DS IN INSTRUMENTED POSTEROLATERAL FUSION||Spine Wave|No|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will include adult (skeletally mature) men and women with spinal        conditions for which instrumented posterolateral fusion (PLF) has been indicated as a        course of treatment. Such spinal conditions may include symptomatic degenerative disc        disease, spondylolisthesis (Grade I or II), or lumbar stenosis. The study is limited to        those patients requiring instrumented PLF at one or two levels only. Subjects who are        undergoing other spinal procedures during the same surgery (such as interbody fusions) are        also eligible.|December 2014|December 10, 2014|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317185||30950|
NCT02296619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaziosmanpashaU|The Effects of Transversus Abdominis Plane Block in Patients Undergoing Total Abdominal Hysterectomy|The Effects of TAP Block on Hemodynamic Variables, Anaesthetic and Analgesic Requirement and Quality of Recovery in Patients Undergoing Total Abdominal Hysterectomy|TAP|Tokat Gaziosmanpasa University|Yes|Completed|September 2014|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|66|||Female|18 Years|65 Years|No|||February 2016|February 25, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02296619||32528|
NCT02299128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-20|Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion|A Feasibility Study for a Randomized Controlled Trial on the Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion||Walsh University|No|Completed|September 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|10 Years|23 Years|No|||February 2016|February 24, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299128||32336|
NCT02313857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H35887 Viralym-C|Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)|A Phase I Study Using Most Closely HLA-matched Cytomegalovirus-specific T Lymphocytes for the Treatment of Cytomegalovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-C)||ViraCyte|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||September 2015|September 16, 2015|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313857||31205|
NCT02313870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 7850|Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid|Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid|BP/MTX|University Hospital, Montpellier|No|Recruiting|January 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313870||31204|
NCT02434523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29925|Trial of the Treatment of Chronic Laryngitis With Amitryptiline|Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitryptiline||Boston Medical Center|Yes|Terminated|September 2013|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|64 Years|No|||December 2013|September 9, 2015|April 22, 2015|Yes|Yes|concern regarding study design|No||https://clinicaltrials.gov/show/NCT02434523||21951|
NCT02432664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3118001|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers|FIMTRIP|Orion Corporation, Orion Pharma|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Anticipated|206|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432664||22094|
NCT02437760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRP49103N|The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring|Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring||E-DA Hospital|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Patient with histologically proved lung cancer|May 2015|May 5, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02437760||21702|
NCT02432508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-3-2-A/CMUH103-REC2-112|Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis|Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis: A Multiple Centers, Randomized, Assessor- and Participant-blind, Controlled, Cross-over Clinical Trial||China Medical University Hospital|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 1, 2015|January 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02432508||22106|
NCT02492568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14PRT|Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC|Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer|PEMBRO-RT|The Netherlands Cancer Institute|Yes|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02492568||17494|
NCT02492581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#16117N|Use of Selincro and Impact on Usual Practice|Use of Selincro and Impact on Usual Practice|USE-PACT|University of Bordeaux|Yes|Recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients initiating Selincro because of alcohol dependence|March 2016|March 7, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492581||17493|
NCT02438046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2015|Platelet Rich Fibrin in the Treatment of Palatal Wounds|Platelet Rich Fibrin in the Treatment of Palatal Wounds After Epithelialized Free Gingival Grafts Harvesting. A Randomized Clinical Trial||G. d'Annunzio University|No|Not yet recruiting|May 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|70 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02438046||21680|
NCT02438059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B283|SoSu-liv. Mobile Media for Health Promotion|SoSu-liv. A Web- and App-based Intervention Study for Health Promotion Among Social and Health Care Workers in Denmark. A Randomized Controlled Trial||University of Copenhagen|Yes|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|566|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02438059||21679|
NCT02437396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305M34501|Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study|Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|15|Samples Without DNA|Blood samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 Gaucher disease subjects who are either naive to treatment or are stable on therapy        (specific Enzyme Replacement Therapy (ERT) / Substrate Reduction Therapy (SRT) formulation        at a specific dose) for at least 2 years.|October 2015|October 6, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02437396||21730|
NCT02440438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.806|Host Immune Response to Clostridium Difficile Infection|Factors Associated With Relapses in Patients Suffering From Clostridium Difficile Infection: Immune Response||Hospices Civils de Lyon|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440438||21497|
NCT02440490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF14/2985 - 2014001639|Optimising Cognitive Function in Patients With Chronic Pain|Optimising Cognitive Function in Patients With Chronic Pain||Monash University|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440490||21493|
NCT02492672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registry Protocol|Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease|A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease||Luitpold Pharmaceuticals|No|Recruiting|September 2014|January 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|50|||Both|2 Years|17 Years|No|Non-Probability Sample|The current registry is being undertaken to assess the long-term (12 month) safety and        tolerability of Venofer in the pediatric population with chronic kidney disease (CKD) that        requries intravenous iron maintenance therapy.|January 2016|January 22, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492672|12 Months|17486|
NCT02492685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0033|Quantificational Enhancement Pattern Analysis Using a Novel Software "Vuebox" of Contrast-enhanced Harmonic Endoscopic Ultrasonography for Differential Diagnosis Between Adenomas and Cholesterol Polyps|||Yonsei University|No|Not yet recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|19 Years|N/A|No|||July 2015|July 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492685||17485|
NCT02438267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66906|Preterm Infants and Nephrocalcinosis|Preterm Infants and Nephrocalcinosis: Diagnosis and Pathogenesis|NC|University of Utah|No|Recruiting|April 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|2 Weeks|No|Probability Sample|Infants admitted to the newborn intensive care unit.|December 2015|December 2, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02438267||21663|
NCT02441517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-MA-1008|A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide|A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Docetaxel in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting||Astellas Pharma Inc|No|Recruiting|October 2015|November 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||February 2016|February 11, 2016|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441517||21414|
NCT02428595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA005|A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women|A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women|LIBERATE|Pelvalon, Inc.|No|Recruiting|May 2015|March 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|19 Years|N/A|No|||January 2016|January 25, 2016|April 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02428595||22405|
NCT02493933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-2015|Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients|Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene||Kasr El Aini Hospital||Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Female|20 Years|40 Years|No|||July 2015|July 10, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493933||17389|
NCT02432339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611878|Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress|Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF)|MMF|Georgia Regents University|Yes|Recruiting|April 2014|April 2020|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432339||22119|
NCT02325479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152014|Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)|Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI) a Randomised Controlled Pilot Study||The Egyptian IVF-ET Center|No|Completed|January 2015|December 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|20 Years|37 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02325479||30313|
NCT02325492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aramchol006|Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study|Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study||Galmed Pharmaceuticals Ltd|No|Terminated|October 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|75 Years|No|||December 2014|October 1, 2015|November 12, 2014||No|Protocol redesign|No||https://clinicaltrials.gov/show/NCT02325492||30312|
NCT02301481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015ST-09|A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma|A Prospective, Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Concomitant Boost Intensity-Modulated Radiotherapy With S-1 in Locally Advanced Gastric Adenocarcinoma||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301481||32155|
NCT02306590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPCAL-ALS|Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis|||University of Ulm|Yes|Recruiting|December 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306590||31763|
NCT02309411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14374|EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis|30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis|EINSTEINJr|Bayer|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|5 Years|No|||March 2016|March 2, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309411||31547|
NCT02309424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/11-06-08|The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes|The Effect of Vinegar on Glucose and Lipid Metabolism in Peripheral Tissues in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes||Attikon Hospital|No|Completed|July 2008|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02309424||31546|
NCT02313415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141206|Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Blood-derived Mesenchyma Stem Cells|Clinical Study of the Treatment of Infertility Caused by Severe Intrauterine Adhesions by Collagen Scaffold Loaded With Umbilical Cord Blood-derived Mesenchymal Stem Cells||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|No|Recruiting|December 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|20 Years|45 Years|No|||December 2014|December 24, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313415||31239|
NCT02293525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-001-0201|Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain|Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain||Vital 5, LLC|No|Withdrawn||January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|85 Years|No|||January 2016|January 20, 2016|October 27, 2014|Yes|Yes|No subjects were enrolled and the sponsor suspended support at this time|No||https://clinicaltrials.gov/show/NCT02293525||32766|
NCT02299115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045463|Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms|Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms|PREDVGB|The Hospital for Sick Children|No|Not yet recruiting|March 2016|September 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Both|2 Months|24 Months|No|||November 2015|November 17, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299115||32337|
NCT02299323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC11-010-001-PL_C|INDEPENDENCE Spacer for Lumbar Fusion|Circumferential Lumbar Spinal Fusion for Treatment of Degenerative Disc Disease: A Prospective, Non-Randomized Clinical Study||Globus Medical Inc|No|Active, not recruiting|January 2012|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients between ages 18 and 65 withsevere low back pain due to lumbar disc degeneration        unresponsive to 6 months of non-operative treatm|November 2014|February 10, 2016|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02299323||32321|
NCT02321137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTurku|Left Atrial Appendage CLOSURE for the Prevention of Thromboembolisms in Patients Undergoing Aortic Bioprosthesis Surgery|A Randomized Prospective Multicenter Trial for Stroke Prevention by Surgical Occlusion of the Left Atrial Appendage in Patients Undergoing Aortic Bioprosthetic Surgery|LAA-CLOSURE|University of Turku|Yes|Recruiting|November 2014|December 2027|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1040|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321137||30647|
NCT02315001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ112/N131|Liraglutide to Improve corONary Haemodynamics During Exercise streSS|The Physiological Effects of GLP-1 on Haemodynamics During Exercise in Patients With Ischaemic Heart Disease|LIONESS|King's College London|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|26|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02315001||31118|
NCT02303561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400235|The Childhood Health and Asthma Management Program|The Childhood Health and Asthma Management Program|CHAMP|University of Florida|No|Recruiting|June 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|6 Years|12 Years|No|||December 2015|December 1, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303561||31995|
NCT02303574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6190C00001|Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study|A PHASE I, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND FOOD EFFECT OF SINGLE AND MULTIPLE ORAL DOSES OF AZD7986 IN HEALTHY VOLUNTEERS||AstraZeneca|No|Active, not recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|152|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02303574||31994|
NCT02299648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-119-009|The Screening Protocol for The VIKTORY Trial|The Screening Protocol for The VIKTORY Trial- Targeted Agent eValuation in gastrIc Cancer basKeT KORea studY: SMC-AZ GC Basket Trial Screening Protocol||Samsung Medical Center|Yes|Recruiting|July 2014|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|600|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02299648||32296|
NCT02318953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013 0094 B|The Effect of Mobile App Home Monitoring on the Number of In-Person Visits Following Ambulatory Surgery|The Effect of Mobile App Home Monitoring on the Number of In-Person Visits Following Ambulatory Surgery: A Randomized Control Trial||Women's College Hospital|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|70|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318953||30814|
NCT02299050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130330H|Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy|Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|69 Years|No|||January 2016|January 11, 2016|September 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299050||32342|
NCT02306421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondUTCM|A Multi Center Clinical Trial of Rph With the Simplified Milligan-Morgan Surgery on Treatment of Mixed Hemorrhoids|A Multi Center Clinical Trial of the Efficacy and Safety of Rph With the Simplified Milligan-Morgan Surgery on Treatment of Mixed Hemorrhoids|RPHSMMH|The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Yes|Enrolling by invitation|August 2014|May 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|3000|||Both|18 Years|65 Years|No|||November 2014|December 18, 2014|August 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02306421||31776|
NCT02306434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-CARE: Pregnancy|Fear of Childbirth - Comparison of Two Treatments|Fear of Childbirth - Comparison of Two Treatment Options: Internet Given Behavioral Therapy and Counseling by Midwife- a Clinical Randomized Controlled Trial||Uppsala University|No|Recruiting|March 2014|March 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|N/A|N/A|No|||December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306434||31775|
NCT02319434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-32211|Pilot Study: Ostom-i Alert Sensor|Gauging the Feasibility and Usability of the Ostom-i Alert Sensor||Stanford University||Recruiting|November 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|We will be seeking participants from communities of ostomy patients.|November 2015|November 30, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319434||30777|
NCT02322346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134-3866|Peritonsillar Infiltration With Levobupivacaine for Posttonsillectomy Pain|Peritonsillar Infiltration With Levobupivacaine for Relief of Posttonsillectomy Pain: Does Concentration Have Any Effect?||Ankara University|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|3 Years|12 Years|No|||December 2014|December 22, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02322346||30554|
NCT02307877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0774|Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate|Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis||University of Colorado, Denver|No|Recruiting|September 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|55 Years|No|Non-Probability Sample|MS patients who have been taking either fingolimod or glatiramer acetate for at least 2        years|January 2016|January 5, 2016|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307877||31664|
NCT02294123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-6526|Glycemic Index and Insulinemic Index of 3 Types of Tortilla in Mexican Adults|Glycemic Index and Insulinemic Index of 3 Types of Tortilla in Mexican Adults With Overweight or Diabetes or Clinically Healthy|IGIT|Mexican National Institute of Public Health|Yes|Completed|September 2013|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|81|||Both|20 Years|69 Years|Accepts Healthy Volunteers|||September 2015|March 14, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294123||32720|
NCT02298569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 13 17|Early Postnatal Discharge in a French Perinatal Network|Early Postnatal Discharge in a French Perinatal Network|SORPRISE|University Hospital, Grenoble|No|Active, not recruiting|September 2014|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02298569||32379|
NCT02307136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11013-AOR11114|Evaluation of the Impact of Within-hospital Trajectories of Patients Admitted in Intensive Care Units (ICU) From Emergency Departments|Evaluation of the Impact of Within-hospital Trajectories of Patients Admitted in Intensive Care Units (ICU) From Emergency Departments|SUREA|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50000|||Both|18 Years|N/A|No|Non-Probability Sample|The population under study is formed of patients admitted in 3 types of intensive care        units (Medical intensive care unit, Surgical Intensive Care Unit and Cardiac Intensive        Care Unit), transferred from emergency departments, either directly, or from another        Department such as a Unit of short durations of hospitalization.|February 2016|February 15, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02307136||31721|
NCT02321878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4175|Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)|Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)||Novo Nordisk A/S|No|Enrolling by invitation|December 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|N/A|18 Years|No|Non-Probability Sample|Male or female patients with T2DM who the physician has decided to start on treatment with        Victoza® in combination with insulin or oral anti-diabetes drug (OAD) other than SU        (Sulfonylurea) will be eligible for this study.|March 2016|March 2, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321878||30590|
NCT02321956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAti-001|Ultrasound Study of the Airway to Predict Endotracheal Tube Size in Anesthetized Pediatric Patients|Ultrasound Study of the Airway to Predict Endotracheal Tube Size in Anesthetized Pediatric Patients||Siriraj Hospital||Recruiting|March 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321956||30584|
NCT02322489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microcurrent|Efficacy of Microcurrent Therapy After Eccentric Exercise|Efficacy of Microcurrent Therapy After Eccentric Exercise||University Hospital of Liege|No|Completed|January 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|15|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|December 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02322489||30543|
NCT02311309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-D48-VOL.19|Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery|Epidemiology of Peroperative Bleeding and Transfusion During Scheduled Surgery.||University Hospital, Caen|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1439|||Both|16 Years|N/A|No|Probability Sample|Consecutive patients scheduled for surgery (expect cardiac, pediatric, and emergency        surgery)|December 2014|December 19, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311309||31401|
NCT02306213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cliniques Universitaires Saint|Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery|Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|January 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1564|||Both|18 Years|90 Years|No|||November 2014|November 28, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02306213||31791|
NCT02307214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 2688|Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology|Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology of Two Orphan Cardiac Diseases|ENDAUT|Ospedale San Giovanni Bellinzona|Yes|Active, not recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307214||31715|
NCT02312362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFDS_PS_v9|High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP|HFDS ab Interno - to Compare Intraocular Pressure (IOP) Lowering Effect of Combined High Frequency Deep Sclerotomy ab Interno (HFDS ab Interno) With Phacoemulsification and Phacoemulsification Alone, in Primary Open Angle Glaucoma Patients|HFDS_abinterno|Oertli Instrumente AG||Recruiting|November 2012|December 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|80 Years|No|||December 2014|December 5, 2014|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02312362||31320|
NCT02311530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244_FELOD_08|Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With PLENDIL® Extended Release Tablet (Containing Felodipine 10 mg) Manufactured by Merck & Co. Inc. for AstraZeneca in Healthy, Adult, Male, Human Subjects Under Fed Condition||Ranbaxy Inc.|No|Completed|October 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311530||31384|
NCT02315768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141106|Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.|A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib||University of California, San Diego|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|65 Years|N/A|No|||November 2015|November 30, 2015|October 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315768||31059|
NCT02299271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Christh-01|Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty|Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study||The Christ Hospital|Yes|Enrolling by invitation|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299271||32325|
NCT02308631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12267|Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY FOR CRITICALLY ILL PATIENTS WITHOUT GENERAL ANESTHESIA OR LAPAROTOMY. EXPERIMENTAL STUDY|EACC|University of Sao Paulo|No|Completed|February 2014|September 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2014|December 1, 2014|September 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02308631||31606|
NCT02321449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-59010-001|The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over|Open-label, Post-marketing Observational Study to Evaluate the Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over|QUALISLEEP|Ipsen|No|Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|55 Years|N/A|No|Non-Probability Sample|Adult male and female patients aged ≥ 55 years suffering from primary (non-organic)        insomnia characterized by poor quality of sleep|June 2015|June 29, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321449||30623|
NCT02321462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-58800-002|Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy|Efficacy, Safety and Tolerability of a Split-dose of a New Bowel Cleansing Preparation (Eziclen) in Adult Subjects Undergoing Colonoscopy: A Phase III, Multicentre, Randomised, 2 Parallel Group, Comparative Versus Fortrans®, Non-inferiority, Investigator-blinded Study|ESTOS|Ipsen|No|Active, not recruiting|March 2015|May 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|305|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321462||30622|
NCT02300103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1553|Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study|An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study||Gilead Sciences|No|Active, not recruiting|December 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300103||32261|
NCT02300116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28/OCT/2014|Smart Vision Labs Autorefractor|||Smart Vision Labs||Recruiting|November 2014|||March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|young adults: ages 18-35 year, including male and female|May 2015|May 18, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300116||32260|
NCT02301026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diafer-NIS-06|A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency|A Non-interventional Study of Diafer (5% Iron Isomaltoside 1000) Administered According to Standard Hospital Practice and Product Labelling in Subjects With Chronic Kidney Disease on Haemodialysis for Treatment of Iron Deficiency|DINO|Pharmacosmos A/S|No|Active, not recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|||Both|18 Years|N/A|No|Non-Probability Sample|Patients ≥ 18 years of age with chronic kidney disease (CKD) who have been on HD > 3        months and have received at least one dose of iron sucrose treatment within the last 6        months while being on dialysis.|February 2016|March 1, 2016|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02301026||32190|
NCT02309606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-057|Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography|||Danish Headache Center||Recruiting|December 2014|||August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Migraine patients and healthy controls.|February 2015|February 10, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02309606||31532|
NCT02311023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLH 13/0389|Intermittent Fasting in Refractory Epilepsy|A Single Centre Open Six Months Study of Intermittent Fasting for the Treatment of People With Refractory Epilepsy.||University College London Hospitals|No|Recruiting|March 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311023||31423|
NCT02295527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 27398814.7.0000.0064|Functional Later Rehabilitation in Older Adults: Effectiveness of Physical Exercises|Effectiveness of a Physical Exercise Intervention Program in Improving Functional Mobility in Older Adults After Hip Fracture in Later Stage Rehabilitation: a Randomized Clinical Trial|REATIVE|Universidade Cidade de Sao Paulo|Yes|Recruiting|November 2014|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|60 Years|N/A|No|||December 2015|December 8, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02295527||32612|
NCT02300675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01|Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy|Development and Evaluation of a Therapeutic Education Intervention Focused on the Accession of Patients Treated With Hormonal Therapy in the Management of Breast Cancer: PEPs Hormonotherapy|PEPs HORMONO|Institut de Cancérologie de la Loire|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|340|||Female|18 Years|N/A|No|||April 2014|November 21, 2014|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02300675||32217|
NCT02300688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID_BVCL013|Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers|An Open Label, Randomized, 2-sequence, 2-period, Single-dose Cross-over Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers||IlDong Pharmaceutical Co Ltd|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02300688||32216|
NCT02312869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMiNAR|Local Assessment of Management of Burn Patients|Local Assessment of Management of Burn Patients (LAMiNAR) - a Prospective Observational International Multicenter Cohort Study|LAMiNAR|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Not yet recruiting|September 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Consecutive intubated and ventilated burn patients admitted to participating ICUs during a        period of 3 months|June 2015|June 22, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312869||31281|
NCT02313103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1008|Single-dose PK and Safety of Oral Lofexidine in Renally-Impaired Subjects|Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects||US WorldMeds LLC|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313103||31263|
NCT02319941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-07|Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes|Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study|OPTIMA|Asan Medical Center|Yes|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|80 Years|No|||March 2016|March 20, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319941||30739|
NCT02319954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 105768|Intra-operative Nasal Compression After Lateral Osteotomy to Minimize Post-operative Peri-orbital Ecchymosis and Edema|Intra-operative Nasal Compression After Lateral Osteotomy to Minimize Post-operative Peri-orbital Ecchymosis and Edema||Lawson Health Research Institute|No|Not yet recruiting|January 2015|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 18, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02319954||30738|
NCT02306499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|729/2014|Outcome of ICSI Using Cryopreserved Testicular Sperm From Infertile Men With Varicocele-associated Azoospermia|Outcome of ICSI Using Cryopreserved Testicular Sperm From Infertile Men With Varicocele-associated Azoospermia||Sohag University||Recruiting|June 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|N/A|No|||November 2014|November 30, 2014|November 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306499||31770|
NCT02299674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1316|Study of Medial-Lateral Center of Pressure Displacement in Unilateral Transfemoral Amputees|Investigation of Medial Lateral Displacement of Center of Pressure and Center of Mass During Double Support in Men With Unilateral Transfemoral Amputations.||Southern California Institute for Research and Education||Active, not recruiting|November 2014|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|3|||Male|18 Years|65 Years|No|Non-Probability Sample|Persons with unilateral transfemoral amputation who are ambulatory with a prosthesis and        no assistive device.|July 2015|July 14, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02299674||32294|
NCT02319889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2514|Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma|Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma||Case Comprehensive Cancer Center|Yes|Recruiting|February 2016|July 2019|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319889||30743|
NCT02326168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140005|PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer|A Study Evaluating the Safety and Tolerability of Percutaneous Vaccination Prior to Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Mycobacteria for Non-Muscle Invasive Bladder Cancer||The University of Texas Health Science Center at San Antonio|Yes|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02326168||30260|
NCT02309983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3063-SCR-E-0|Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes|Activity Dependent Rehabilitation Model In Incomplete Spinal Cord Injury: Neuromuscular and Skeletal Changes||Kessler Foundation|No|Recruiting|December 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|58 Years|No|||March 2016|March 10, 2016|September 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02309983||31503|
NCT02302326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHM-MET-2013-01|Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome|Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome: Possible Therapeutic Implications of Insulin Sensitizers.|PI12/1984|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02302326||32090|
NCT02319876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIM3-SEPSIS|Expression of TIM-3 on Lymphocytes in Sepsis|Expression and the Clinical Significance of TIM-3 on Lymphocytes During Sepsis||Changhai Hospital|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|80|Samples Without DNA|Peripheral blood sample was collected to examine TIM-3 on CD4+ and CD8+ lymphocytes, and      CD14+ monocytes. Monocyte HLA-DR will also be determined.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted in ICU at Changhai Hospital|June 2015|July 27, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319876||30744|
NCT02313181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40-MC26810|Early Limited Formula for Treating Lactation Concerns|Early Limited Formula for Treating Lactation Concerns|ELF-TLC|University of California, San Francisco|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|328|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||May 2015|May 4, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313181||31257|
NCT02305849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RAJ4|A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment|Phase III Study of ASP015K - A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to MTX||Astellas Pharma Inc|Yes|Recruiting|July 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|510|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|December 1, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02305849||31819|
NCT02309996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-130505|SMART Supervisor Training Program to Prevent Work Disability|A Supervisor Training Program for Work Disability Prevention: A Cluster RCT||Lakehead University|No|Recruiting|December 2014|June 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02309996||31502|
NCT02294383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI05|Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions|Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions||Artann Laboratories|No|Enrolling by invitation|August 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|150|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population comprises of patients referred to a gynecologist/urogynecologist for        either regular examination or with a pelvic floor organ concern.|January 2016|January 20, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294383||32700|
NCT02294396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-112|Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.|Post-Marketing Study of Mirabegron - Long-term Add-on Therapy With Anticholinergics in Patients With Overactive Bladder Under Treatment With Mirabegron||Astellas Pharma Inc|No|Active, not recruiting|October 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|649|||Both|20 Years|N/A|No|||October 2015|October 8, 2015|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294396||32699|
NCT02317354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150041|People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial|Patient Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|11|||Male|18 Years|N/A|No|||October 2015|November 17, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317354||30937|
NCT02320604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 14.04|Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)|Pharmacokinetics of Liposomal Amphotericin B (AmBisome®) Given Intravenously to Patients Undergoing Bariatric Surgery||Radboud University|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02320604||30688|
NCT02300961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSHEM0004|Feasibility Neurocognitive Outcome After Transplant|A Risk Stratification Model for Neurocognitive Outcome After Transplant and Feasibility of an Early Cognitive Intervention Program||Stanford University|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|6 Years|21 Years|No|||December 2014|December 5, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300961||32195|
NCT02300974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||December 14, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300974||32194|
NCT02300987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2201|A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression|A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression||Novartis|No|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|15 Years|N/A|No|||October 2015|November 2, 2015|July 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02300987||32193|
NCT02304913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-5953-BO|Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy|Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial|OralAcu|Universität Duisburg-Essen||Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02304913||31891|
NCT02317575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15645|A Study of LY900014 Formulations in Healthy Participants|Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple LY900014 Formulations||Eli Lilly and Company|No|Completed|January 2015|September 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|29|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317575||30920|
NCT02437695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK3|Robot Assisted Radical Prostatecomy and Positional Injury|Robot Assisted Radical Prostatecomy and Positional Injury; 8 Years Survey||Umraniye Education and Research Hospital|No|Completed|May 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|450|||Male|45 Years|75 Years|No|Non-Probability Sample|patients undergoing robot-assisted radical prostatectomy (RARP) for prostate diagnosis.|December 2015|December 7, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437695||21707|
NCT02437825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-15-HMO-CTIL|Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery|Prospective Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy of Octreotide in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery||Hadassah Medical Organization|Yes|Recruiting|October 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02437825||21697|
NCT02437929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCPP02|Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment|Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment. A Prospective, Cross-sectional, Multicenter, National Study||Antea Associazione|No|Recruiting|June 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Terminally ill patients, cancer and non-cancer, admitted in a palliative care service        (inpatients or outpatients), that are undergoing at least one procedure considered in the        study, as a part of their Individual Care Plan (ICP).|December 2015|December 28, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02437929||21689|
NCT02491242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dolbi|Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression|The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues|DOLBI|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients who had initiate a dolutegravir-based dual therapy because of        intolerance or toxicity to nucleoside analogues|November 2015|November 4, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02491242|12 Months|17596|
NCT02491255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S6002|Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement (REPRISE Japan)|REPRISE Japan: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Clinical Evaluation in Japan||Boston Scientific Corporation|Yes|Recruiting|June 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|20 Years|N/A|No|||December 2015|December 14, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02491255||17595|
NCT02491268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRINEU1321|A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)|A Trial of Cilostazol for Prevention of Conversion From Mild Cognitive Impairment to Dementia||National Cerebral and Cardiovascular Center|Yes|Recruiting|July 2015|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|55 Years|84 Years|No|||March 2016|March 22, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491268||17594|
NCT02493894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbasi1|The Effect of Bowel Preparation on Perioperative Bleeding|By Reza Abbasi and Isfahan University of Medical Sciences||Isfahan University of Medical Sciences|Yes|Completed|July 2014|June 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|105|||Both|33 Years|82 Years|No|||July 2015|July 7, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493894||17392|
NCT02479672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150229|Comparison of the VividTrac® Videolaryngoscope to Direct Laryngoscopy in Adults Under Manual Inline Stabilization|Comparison of the VividTrac® Videolaryngoscope to Direct Laryngoscopy in Adults Under Manual Inline Stabilization||Loma Linda University|No|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479672||18483|
NCT02442700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramathibodi Hospital 01-57-18|Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir|Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-blind, Crossover Study||Ramathibodi Hospital|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|February 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442700||21323|
NCT02441478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14-0269|Co-operative Behavior and Decision-making in Frontal Lobe Epilepsy|Co-operative Behavior and Decision-making in Frontal Lobe Epilepsy||Hospices Civils de Lyon|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02441478||21417|
NCT02428309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALE08|Autologous Polyclonal Tregs for Lupus|A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|July 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02428309||22427|
NCT02493907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2014] ethics register [34]|Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy|A Prospective Clinical Trial of Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy in Chinese With Heart Failure||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|December 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|75 Years|No|Probability Sample|Heart failure patients received CRT in Sun Yat-sen Memorial Hospital, Sun Yat-sen        University. Informed consent must be obtained for all of the included patients.|July 2015|July 9, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493907||17391|
NCT02442739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-22-IRWIN-KETPREVE|Feasibility Study of Ketamine for Preventing Depression in Patients Undergoing Treatment for Head and Neck Cancer|Piloting a Randomized Feasibility Study of Oral Ketamine Versus Placebo for Prevention of Depression in Patients Undergoing Curative Intent Radiation Plus Chemotherapy for Head and Neck Cancer||Cedars-Sinai Medical Center|Yes|Recruiting|May 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442739||21320|
NCT02428985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17519|Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)|Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)|JPMS-PAH|Bayer|No|Recruiting|June 2015|January 2024|Anticipated|March 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Study population includes patients treated with Riociguat for PAH. This study is performed        as an all-case investigation. Therefore, all patients who have been treated with Riociguat        for PAH need to be registered in principle, until the target number of patients reached.|March 2016|March 23, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428985||22375|
NCT02433041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013DR4089|Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial|Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial|PRIDe|University Hospital, Basel, Switzerland|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02433041||22065|
NCT02480192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMHF-SG1|Cognitive Behavioural Therapy for Menopausal Symptoms|Cognitive Behavioural Therapy for Menopausal Symptoms: A Randomized Controlled Trial|CBTMENO|St. Joseph's Healthcare Hamilton|No|Recruiting|June 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|40 Years|60 Years|No|||August 2015|August 4, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480192||18443|
NCT02437110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150126|HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437110||21752|
NCT02437201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mac/NMP 1121|Study of Liberty Program on Women's Health and Intimate Partner Violence|Study of Liberty Program on Women's Health and Intimate Partner Violence: Multinational, Open, Randomised, Controlled Clinical Study||Macmillan Research Group UK|Yes|Active, not recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 27, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02437201||21745|
NCT02313168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AITT 2014/7|F.R.O.N.T. Formula for Pre-operative Airway Assessment and Documentation|F.R.O.N.T. Formula for Pre-operative Airway Assessment and Documentation||University of Debrecen|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|1150|||Both|18 Years|N/A|No|Probability Sample|adult patients (over 18 years) going elective surgery.|January 2016|January 12, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313168||31258|
NCT02305537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000353|Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment|Building an Outcomes Assessment Infrastructure to Assess Youth in the McLean Anxiety Mastery Program at McLean Hospital||Mclean Hospital|No|Recruiting|October 2014|October 2030|Anticipated|October 2024|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|9 Years|18 Years|No|||March 2016|March 18, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02305537||31843|
NCT02294864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #1283|A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis|A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis||VA Long Beach Healthcare System|Yes|Recruiting|April 2014|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294864||32663|
NCT02293668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients|||Istanbul University|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Female|18 Years|42 Years|No|||January 2016|January 7, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293668||32755|
NCT02293954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14238|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer|Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)||City of Hope Medical Center|Yes|Recruiting|June 2015|||June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|October 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293954||32733|
NCT02317900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 299|Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults|A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|December 2014|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317900||30895|
NCT02293785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOL-IRFMN-6554|GREAT - Good Response With Appropriate Treatment|GREAT (Good Response With Appropriate Treatment) "Factors Influencing the Analgesic Response Over Time of the Oxycodone-Naloxone Association in Painful Cancer Patients"||Mario Negri Institute for Pharmacological Research|No|Completed|November 2014|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|This study involves a pain longitudinal evaluation in cancer patients through a follow-up        of 4 weeks, which will examine in a dynamic clinical, biological and genetic aspects.|March 2016|March 18, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293785||32746|
NCT02306304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClalitHS|Ultra-sound for AAA Screening in Smoking Israeli Arab Men|Ultra-sound for AAA Screening in Smoking Israeli Arab Men||Clalit Health Services|No|Recruiting|January 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2000|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02306304||31784|
NCT02307344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002-14-HYMC|Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis||NASH NAFLD|Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02307344||31705|
NCT02311231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2012-005260-10|Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART|Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform|VALIDATE|Uppsala University|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6000|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02311231||31407|
NCT02318186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT PK Treprostinil|Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)|Multi-center, Open-label Pharmacokinetic Study of Subcutaneously and Intravenously Administered Treprostinil in Children With Pulmonary Arterial Hypertension (PAH)|UTPKRemodulin|Stanford University|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|2 mL blood sample in K3-EDTA tube and immediately place on ice; Place plasma into 2      aliquots; Freeze at -20 degrees or lower. Store until batch is complete; Batch ship all      samples on dry ice to pharmacokinetic analytical laboratory|Both|N/A|18 Years|No|Non-Probability Sample|Target enrollment for this study is a total of 50 pediatric patients among all        participating sites with a goal of 65 total blood samples. Cohorts will be: 0-12 months;        1-3 years; 4-6 years; 7-11 years; 11-16 years. Each cohort will have 10 patients with 5        patients on a dose ≤ 50ng/kg/min and 5 patients on a dose ≥51-120ng/kg/min.|November 2015|November 17, 2015|January 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318186||30873|
NCT02306356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1225-31/4|Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting|Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting||Karolinska Institutet|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|12 Years|No|||January 2016|January 18, 2016|September 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02306356||31780|
NCT02319135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUGAZA|Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|A PHASE III, MULTICENTRE, RANDOMIZED, OPEN LABEL CLINICAL TRIAL OF AZACYTIDINE (VIDAZA®) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.|FLUGAZA|PETHEMA Foundation|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|December 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319135||30800|
NCT02319148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7331022|A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers|A Phase 1, Randomized, Open-label, 3-sequence, 4-treatment, Incomplete Block Design To Estimate The Effect Of Steady State Cyp3a4 Inhibitors (Itraconazole, Diltiazem Or Verapamil) On The Pharmacokinetics Of Singe Dose Pf-00489791 In Healthy Volunteers||Pfizer|No|Completed|July 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319148||30799|
NCT02319395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100133|Behavioural Addiction and Genetics in Parkinson's Disease|Behavioural Addiction and Genetics in Parkinson's Disease|BADGE-PD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2011|January 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|One blood sampling during the study. A small number (1 to 5) of markers type "tag SNPs" or      "coding SNP" will be selected for each of the selected genes, for a total of 50 markers      (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect,      will be included as a priority. Genotyping is carried out by the method of genotyping      VeraCode Goldengate.|Both|18 Years|N/A|No|Non-Probability Sample|PD patients|July 2015|December 21, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02319395||30780|
NCT02322021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-G000-202|Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease|A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease||Eisai Inc.|Yes|Recruiting|November 2014|January 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Anticipated|700|||Both|50 Years|85 Years|No|||November 2015|November 2, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322021||30579|
NCT02322034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNINA-34/13|Interval Training and Hormones in Chronic Heart Failure|Effects of Interval Training on Hormonal Pathways in Chronic Heart Failure||Federico II University|Yes|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||March 2015|March 8, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322034||30578|
NCT02303691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23MH100259|Attention Bias Modification for Transdiagnostic Anxiety|Neural Dimensions of Attention Bias Modification for Transdiagnostic Anxiety||University of Pittsburgh|No|Recruiting|April 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|55 Years|No|||December 2015|December 1, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303691||31985|
NCT02296697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140372|Low-level Laser Therapy Versus High Frequency on Pressure Ulcers Treatment|Comparison Between the Effects of Low-level Laser Therapy, High Frequency and Wound Dressing on Pressure Ulcers Treatment: a Clinical Randomized Trial||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02296697||32522|
NCT02296710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDZNRW_KA_003_ZD|Echocardiographic Parameter and Sleep Apnea Changes After Mitral Valve Surgery|Echocardiographic Parameter and Sleep Apnea Changes After Mitral Valve Surgery|MitralHDZ|Heart and Diabetes Center North-Rhine Westfalia|No|Recruiting|August 2014|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02296710||32521|
NCT02321787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2015-16004|Ultrasonography for Confirmation of Caudal Injection|Utility of Ultrasonography for Confirmation of Successful Caudal Epidural Injection||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|7 Years|No|||January 2016|January 14, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321787||30597|
NCT02321800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409R2121|A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections|A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin||Shionogi Inc.|Yes|Recruiting|December 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321800||30596|
NCT02311062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoG INJ001|Compatibility of Different Injury Prevention Exercises in Athletes|Effects of Two Different Injury Prevention Resistance Exercise Protocols on the Hamstring Torque-Angle Relationship: A Randomized Controlled Trial||University of Greenwich|Yes|Completed|March 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02311062||31420|
NCT02298816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMvax-registry:14-98E|B-Cell Hematologic Malignancy Vaccination Registry|B-Cell Hematologic Malignancy Vaccination Registry|HMvax-Regist|Aurora Health Care|No|Enrolling by invitation|August 2014|December 2025|Anticipated|December 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients at Aurora Health Care who are newly diagnosed with:          -  Monoclonal gammopathy of undetermined significance (MGUS),          -  Smoldering multiple myeloma (SMM),          -  Multiple myeloma (MM),          -  Waldenstroms Macroglobulinemia (WM),          -  Monoclonal B-cell lymphocytosis (MBL),          -  Chronic lymphocytic leukemia (CLL), or          -  B-Cell Non-Hodgkin lymphoma (NHL).|September 2015|September 15, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298816|10 Years|32360|
NCT02304107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sub 6|Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.|Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial|FSH|Cairo University|Yes|Recruiting|November 2014|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|20 Years|40 Years|No|||August 2015|August 26, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304107||31953|
NCT02293902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC14059|A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)|A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy||Sanofi|No|Active, not recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|20 Years|75 Years|No|||February 2016|February 5, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293902||32737|
NCT02293915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-III|An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease|Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease||Shanghai Greenvalley Pharmaceutical Co., Ltd.|No|Recruiting|April 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|788|||Both|50 Years|85 Years|No|||April 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293915||32736|
NCT02311257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMDC7411|Survey on Supplement Use in Mitochondrial Disease|Survey on Supplement Use in Mitochondrial Disease||University of South Florida|No|Recruiting|September 2014|September 2015|Anticipated|December 2014|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited through the NAMDC Clinical Registry and RDCRN Contact        Registry. Additional means of recruitment may be used to direct patients to join the NAMDC        or RDCRN registries.|December 2014|December 5, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02311257|1 Day|31405|
NCT02312076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA3|GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles|Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Long Gonadotropin Releasing Hormone Agonist Protocol Cycles||Mansoura University|No|Recruiting|June 2014|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|38 Years|No|||March 2016|March 4, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312076||31342|
NCT02315508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUT032063|Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo|A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus|QUIET-1|Autifony Therapeutics Limited|Yes|Active, not recruiting|October 2014|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315508||31079|
NCT02295839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025162|Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy|Feasibility, Acceptability, and Effectiveness of a Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy for Acute Lymphoblastic Leukemia|SHARI|The Hospital for Sick Children|No|Completed|May 2011|August 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|4 Years|10 Years|No|||November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295839||32588|
NCT02298361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI Health Systems Cycle II|IMPACCT for Kids' Care|Innovative Methods for Parents And Clinics to Create Tools (IMPACCT) for Kids' Care|IMPACCT|Ochin, Inc.|No|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|103|||Both|N/A|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|For the analysis of the primary study outcome, our study population will include all        children who are "established" patients at an intervention or control clinic. Children        will be considered "established" patients if they had an assigned PCP at a given clinic        for at least two of the three study years or if they had >2 visits to the same clinic        during the 2-year period.|November 2015|November 25, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02298361||32395|
NCT02298374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/436|Evaluation of Homecare Reablement, the Trondheim Model|Evaluation of Homecare Reablement, the Trondheim Model||Norwegian University of Science and Technology|No|Withdrawn|November 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|65 Years|N/A|No|||January 2015|January 21, 2015|October 3, 2014||No|no funding|No||https://clinicaltrials.gov/show/NCT02298374||32394|
NCT02316639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:302|The Effectiveness of Neuromuscular Training in Healthy and ACL-Injured Adolescent Females|The Effectiveness of Neuromuscular Training in Healthy and ACL-Injured Adolescent Females||University of Manitoba|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02316639||30992|
NCT02315781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00867|tDCS in Parkinson's Disease With Depression|Parkinson's Disease Depression and tDCS||Pacific Parkinson's Research Centre|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||November 2015|November 14, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315781||31058|
NCT02316002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 25514|Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer|Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316002||31041|
NCT02304835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BETINA|Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion|Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion||Nordic Pharma SAS|No|Completed|May 2013|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|322|||Female|18 Years|N/A|No|Non-Probability Sample|Women asking for medical abortion|December 2014|December 4, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02304835||31897|
NCT02304848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60130|Effects of Deep Brain Stimulation (DBS) Frequency on Neural Synchrony||DBS|Stanford University||Enrolling by invitation|October 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|80 Years|No|||August 2014|November 26, 2014|August 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304848||31896|
NCT02310776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00043696|Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound|Breast Lesion Detection Using the Acuson S2000 Automated Breast Volume Scanner (ABVS) Compared With Handheld (HH) Physician-performed Ultrasound (US) Examinations||Northwestern University|Yes|Completed|June 2012|October 2015|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|501|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 25, 2014||No||No|April 21, 2015|https://clinicaltrials.gov/show/NCT02310776||31442|
NCT02308085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 48-14/BIG 8-13|Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer|A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy|POSITIVE|International Breast Cancer Study Group|Yes|Recruiting|December 2014|December 2028|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Female|18 Years|42 Years|No|||December 2015|December 1, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02308085||31648|
NCT02306694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e11104|Prospective Biomarkers of Bone Metabolism in Hemophilia A|Prospective Biomarkers of Bone Metabolism in Hemophilia A||Oregon Health and Science University|No|Not yet recruiting|December 2014|October 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|16 Years|85 Years|No|||December 2014|December 1, 2014|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306694||31755|
NCT02306707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2014/5/4.1 (3970)|Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach|Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach.|OERS|Western Sydney Local Health District|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who have stomach adenomas which are amendable to Endoscopic Mucosal Resection|December 2015|December 15, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306707||31754|
NCT02295943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/879|Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|Objective Evaluation of Postoperative Positioning in Macular Hole Surgery||Helse Stavanger HF|No|Recruiting|November 2014|September 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|320|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295943||32580|
NCT02316860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sportscardiology|The Diagnostic Performance of Tilt Test in Athletes|The Diagnostic Performance of Tilt Test in Athletes and a Novel Strategy for Its Improvement||Aristotle University Of Thessaloniki|No|Recruiting|October 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|December 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02316860||30975|
NCT02315235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mononuclear cell-based therapy|The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy|The Efficacy and Safety of Peripheral Mobilized Mononuclear Cell-based Therapy in Patients With Diabetic Painful Neuropathy||Seoul National University Hospital|Yes|Recruiting|May 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|No|||August 2015|August 3, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315235||31100|
NCT02299557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 116|The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients|A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients||RDD Pharma Ltd||Completed|November 2014|July 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|55 Years|No|||July 2015|July 26, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299557||32303|
NCT02308501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-100-0012|A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy|||ORA, Inc.|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02308501||31616|
NCT02309658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1156-1640|Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients|Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression||Professor Fernando Figueira Integral Medicine Institute|Yes|Completed|September 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|70 Years|No|||October 2015|October 14, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02309658||31528|
NCT02316626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pleyris|Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support|Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Gonadotropin Ovarian Stimulation for Intrauterine Insemination: a Pilot Randomized Controlled Study||University Magna Graecia|Yes|Recruiting|December 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|38 Years|No|||December 2014|December 10, 2014|December 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316626||30993|
NCT02326142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-OBE001-016|A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth|A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour.|TERM|ObsEva SA|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326142||30262|
NCT02307227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-18-2006|Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors|Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.||Centro di Riferimento Oncologico - Aviano|Yes|Completed|April 2006|April 2014|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|70 Years|No|||December 2014|December 1, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307227||31714|
NCT02307240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-907-102|Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors|Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors||Curis, Inc.|Yes|Recruiting|November 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307240||31713|
NCT02312674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM_Minigrad_TN|Prevention of Cancer-associated Malnutrition Through Oral Nutritional Supplements|Prevention of Malnutrition Through Oral Nutritional Supplements in Cancer Patients Receiving Palliative Therapy||University of Hohenheim|No|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|80 Years|No|||November 2014|December 8, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02312674||31296|
NCT02296086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MobiChina|MobiChina - A Prospective Multicenter Cohort Study|A Prospective Multicenter Cohort Study to Evaluate the Effect of Early Mobilization of Patients After Hip Fracture Fixation on Functional Outcomes in the Chinese Population||AO Clinical Investigation and Documentation|No|Recruiting|April 2015|March 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|248|||Both|65 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2016|January 15, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02296086||32569|
NCT02306876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7441004|A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males|A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype||Pfizer|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|101|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306876||31741|
NCT02306928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIP/TAZO-ICU|PK Analysis of Piperacillin in Septic Shock Patients|Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock - Does Standard Dosing Result in Therapeutic Plasma Concentrations?||University of Aarhus|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Critically ill patients with known or suspected septic shock admitted to the ICU, treated        with piperacillin/tazobactam.|February 2016|February 9, 2016|December 1, 2014||No||No|May 22, 2015|https://clinicaltrials.gov/show/NCT02306928||31737|
NCT02322411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0747|Effects of Oropharyngeal Strengthening on Dysphagia in Patients Post-stroke|Effects of Device-Facilitated Isometric Progressive Resistance Oropharyngeal (I-PRO) Therapy on Dysphagia Related Outcomes in Patients Post-stroke|StrokeStrong|University of Wisconsin, Madison|No|Not yet recruiting|January 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|95 Years|No|||December 2014|September 30, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322411||30549|
NCT02316925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400950|GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults|Oral Glutathione Supplementation on Cold/Flu Symptoms in Older Healthy Adults||University of Florida|No|Withdrawn|May 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|December 10, 2014||No|This study will never recruit. The protocol was renamed and will be resubmitted.|No||https://clinicaltrials.gov/show/NCT02316925||30970|
NCT02310009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEX|IL-1RA, Acute Exercise, and Beta-cell Function||ANEX|Rigshospitalet, Denmark|No|Recruiting|December 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|48|||Both|30 Years|80 Years|No|||December 2014|December 4, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02310009||31501|
NCT02310022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-70001|A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules|A Pharmacokinetic and Pharmacodynamic Study of Two Formulations of Omega-3 One Gram Capsules After Single and Multi-Dose Administrations Under Fed Conditions|PK/PD|Matinas Biopharma, Inc|No|Recruiting|November 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||March 2015|March 8, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02310022||31500|
NCT02298894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIML001|Comparison of LDL Particle Count With Other Available Lipid Tests|Comparison of LDL-P With LDLC From VAPII, NMR, and Ion Mobility|LIPID|Scripps Health|No|Recruiting|November 2014|August 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Whole blood, serum, and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are seen in the outpatient setting|October 2014|November 21, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02298894||32354|
NCT02320175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR-1306-03556|Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience|Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience||Children's Hospital Boston|No|Recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02320175||30721|
NCT02326233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB5-G12-NHV|Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects|A Randomised, Open-labelled, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of the Pre-filled Pen and PFS of SB5 in Healthy Subjects||Samsung Bioepis Co., Ltd.|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|190|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326233||30255|
NCT02326246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-Aarhus|MRI in Active Surveillance of Prostate Cancer|Multi-parametric Magnetic Resonans Imaging in the Diagnosis and Surveillance of Low-risk Prostate Cancer||Aarhus University Hospital Skejby|Yes|Recruiting|October 2014|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|18 Years|N/A|No|||January 2015|January 8, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326246||30254|
NCT02310113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anemia_NIRS|Transfusion and Skeletal Muscle Tissue Oxygenation|Red Blood Cell Transfusion and Skeletal Muscle Tissue Oxygenation in Anaemic Haematologic Outpatients||University Medical Centre Ljubljana|No|Completed|September 2013|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Hematologic anaemic patients|December 2014|December 5, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310113||31493|
NCT02310126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5570|Handling Comparison Between Two Contact Lens Types|||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310126||31492|
NCT02310165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16842|Insertion Technique in Large Volume Paracentesis|Z-tract Versus Coaxial Insertion Technique in Large Volume Paracentesis||University of Virginia|Yes|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310165||31489|
NCT02307838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2201E2|Long-term Follow-up of Fingolimod Phase II Study Patients|Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis|ACROSS|Novartis|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|177|||Both|N/A|N/A|No|||March 2016|March 8, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02307838||31667|
NCT02307903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1188|Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority|Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority (HA)|QoC HDPPP|The University of Hong Kong|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Probability Sample|Sixty patients currently being followed up at the HA on HD, PD, or are new ESRF cases will        be recruited. Both PD and new ESRF cases must fulfill certain inclusion criterion to take        part in the study. The PD patients will be enrolled into the HD PPP if they have poor        ultrafiltration, inadequate dialysis, or with frequent bacterial/fungal peritonitis that        failed to put back on PD; whereas new ESRF patients will be enrolled if they have        previously had multiple/extensive abdominal surgeries or have any abdominal pathology that        makes PD not feasible. Patients who do not have a good vascular access, are not        hemodynamically stable for HD, are not mentally sound, ambulatory and independent, are        unable to understand and communicate in Chinese language, or refuse to give consent will        be excluded from the HD PPP programme.|December 2014|December 4, 2014|August 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02307903||31662|
NCT02320331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD001660|Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project|||University of Hawaii||Recruiting|July 2013|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|13 Years|N/A|No|||December 2014|December 16, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320331||30709|
NCT02442661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2053|Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer|Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer||University of Colorado, Denver|No|Recruiting|April 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|Pre- and post-thyroidectomy patients with a pathological diagnosis of Papillary Thyroid        Cancer (PTC) who undergo cervical lymph node evaluation for detection of locoregional        metastasis will be included in this study.|February 2016|February 11, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02442661||21326|
NCT02444052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB20150016|Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation|Clinical and Histological Evaluation of Zimmer Puros® Allograft vs. Creos™ (Low-cost) Allograft for Alveolar Ridge Preservation Following Exodontia||University of Florida|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444052||21220|
NCT02481206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0126|Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study|Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study|WED-HED|Zoll Medical Corporation|Yes|Recruiting|June 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2600|||Both|50 Years|N/A|No|||June 2015|June 29, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481206||18365|
NCT02479685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORD-BILL|SORD-BILL Vs Conventional Options During Sacral Colpopexy for POP|Prospective Randomized Trial on Laparoscopic Subtotal Hysterectomy During Sacral Colpopexy for the Treatment of Severe Pelvic Organ Prolapse (POP) With Bipolar Laparoscopic Loop/Bipolar Morcellator vs Conventional Monopolar Hook/Conventional Morcellator||Catholic University of the Sacred Heart|Yes|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|50 Years|80 Years|No|||June 2015|June 19, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02479685||18482|
NCT02431910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|752.302|Immediate and Delayed Effects of Kinesio Taping on the Neuromuscular Performance|Immediate and Delayed Effects of Kinesio Taping on the Neuromuscular Performance, Balance and Lower Limb Function of Healthy Subjects: Randomized Clinical Trial|IDEKTNP|Universidade Federal do Rio Grande do Norte|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Female|18 Years|28 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02431910||22152|
NCT02428751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308-2015-005|R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma|Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study||Sun Yat-sen University|No|Recruiting|September 2015|May 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|60 Years|80 Years|No|||November 2015|November 17, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02428751||22393|
NCT02432742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43CH1408|Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds|A Randomised, Multi-center, Evaluator-blinded Study in China to Evaluate the Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds||Q-Med AB|No|Recruiting|May 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02432742||22088|
NCT02491333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSIRct|The RCT of Acupuncture on PCOS Combined With IR|The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|342|||Female|18 Years|40 Years|No|||February 2016|February 14, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491333||17589|
NCT02479971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUE 2015-5|Effect of Peritoneal Lavage With Clindamycin-gentamicin on Laparoscopic Sleeve Gastrectomy|Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Pain and Analytic Acute Phase Reactants Following Laparoscopic Sleeve Gastrectomy||Hospital General Universitario Elche|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|N/A|N/A|No|||June 2015|June 22, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479971||18460|
NCT02432105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXE844b-C001|Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)|Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion||Alcon Research|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|6 Months|12 Years|No|||December 2015|December 28, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432105||22137|
NCT02433197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCSS-UMA_04-15|Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer|Effectiveness of an Individualized Program of Muscular Strength and Endurance Program With Aerobic Training for Improving Germ Cell Cancer Related Fatigue in Men Undergoing Chemotherapy|EFICATEST|University of Malaga|Yes|Not yet recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|No|||October 2015|October 20, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433197||22053|
NCT02491398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC1315|Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia|Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Not yet recruiting|January 2016|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|189|||Both|18 Years|N/A|No|Non-Probability Sample|This cohort study will recruit chronic lymphocytic leukemia (CLL) patients who were        treated with first and second-line Bendamustine plus Rituximab (BR) from January 2008 to        December 2014 from European centres adhering to the GIMEMA group and the ERIC group.|January 2016|January 26, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491398||17584|
NCT02433353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bayne-Jones|Results From a 24 Week Trial of EMDR Combined With Venlafaxine XR|Results From a 24 Week, Double-blind, Placebo-controlled Trial of EMDR Combined With Venlafaxine XR in the Treatment of Posttraumatic Stress Disorder|EMDRVEN|Bayne-Jones Army Community Hospital|No|Withdrawn|January 2016|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 9, 2015|Yes|Yes|PI was transferred to another base. No one else available to serve as PI.|No||https://clinicaltrials.gov/show/NCT02433353||22041|
NCT02440048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-15-RMB CTIL|Using Boned-Apatite Cement at the Time of Extraction for Ridge Preservation at These Sites|Using Boned-Apatite Cement at the Time of Extractions for Ridge Preservation at These Sites||Rambam Health Care Campus|No|Not yet recruiting|May 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02440048||21527|
NCT02442869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603856|Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART|Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART|SMART|University of Nevada, Reno|Yes|Recruiting|June 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|25 Years|No|||November 2015|November 30, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02442869||21310|
NCT02317653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC2014-049|Understanding the Influence of Pregnancy on Breast Milk|Mom2Baby Pilot: Understanding the Influence of Pregnancy on Breast Milk|Mom2Baby Pilot|Louisiana State University Health Sciences Center in New Orleans|No|Active, not recruiting|February 2015|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|35|Samples Without DNA|Maternal Blood Collection: approximately 60 mL of blood will be collected over 2 timepoints      Breast Milk Collection: approximately 50-100 mL of breast milk will be collected at 1      timepoint      Infant Stool Collection: 1 fresh infant stool sample will be collected at 1 timepoint|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior        to pregnancy will be enrolled in the study.        Archive blood, archive breast milk, and clinical assessment data from 15 participants who        were considered overweight and obese at enrollment in the Expecting Success study        conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent        the overweight and obese sample.|March 2016|March 23, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02317653||30914|
NCT02298231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-831-14|Improving Balance in TBI Using Virtual Reality|Improving Balance in TBI Using a Low-Cost Customized Virtual Reality Rehabilitation Tool||Kessler Foundation||Not yet recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02298231||32405|
NCT02298244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDPVI16112014|Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension|||Krasnoyarsk Regional Hospital||Not yet recruiting|January 2015|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02298244||32404|
NCT02298868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16306|Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study|Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study||University of Virginia|No|Completed|October 2012|November 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|November 12, 2014||No||No|January 6, 2015|https://clinicaltrials.gov/show/NCT02298868||32356|
NCT02298881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43018-B|Ocular Surface Microbiome|Diversity and Dynamic Stability of the Ocular Surface Microbiome||University of Washington|No|Recruiting|July 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Swab or scrapings of the cornea|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult patients from the investigators' practices at the University of Washington Eye        Institute|November 2014|November 19, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02298881||32355|
NCT02298426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001052-13086|Body Constitution Classification Based Comprehensive Health Management Intervention on Obese Population|Body Constitution Classification Based Comprehensive Health Management Intervention on Obese Population||Peking University|Yes|Active, not recruiting|April 2014|October 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|1452|||Both|20 Years|55 Years|No|||May 2015|May 6, 2015|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02298426||32390|
NCT02321475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-00240-138|EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders|Non-interventional Prospective Observational Survey to Describe EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.|TAYPES|Ipsen|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|45 Years|No|Non-Probability Sample|Middle-age or younger patients with cognitive disorders and psycho-emotional symptoms        (principal diagnosis).|June 2015|June 29, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321475||30621|
NCT02298530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF-BEV-1803|Tea Components, Mental Stress and Blood Pressure|A Study to Determine the Acute Effects of a Tea Component on Blood Pressure and Mental Stress Challenge||Unilever R&D|No|Completed|March 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02298530||32382|
NCT02298543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-11|Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry|The Multicenter Registry to Evaluate the Natural Course of Coronary Spasm Patients Presenting Aborted Sudden Cardiac Death||Asan Medical Center|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with coronary spasm|December 2015|December 29, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298543||32381|
NCT02307357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0056-14|The Effects of Newcomball Training on Physical Fitness and Mood State of Middle Age Women in Israel|The Effects of Newcomball Training on Physical Fitness and Mood State of Middle Age Women in Israel||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Female|28 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02307357||31704|
NCT02318888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2009/123|Does Icodextrin Reduce the Risk of Small Bowel Obstruction?|Does Icodextrin Reduce the Risk of Small Bowel Obstruction?||Uppsala University|Yes|Recruiting|December 2009|December 2022|Anticipated|December 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Both|18 Years|85 Years|No|||January 2015|January 7, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318888||30819|
NCT02318199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2014-034-01|Emergence Agitation in Adult Patients After Intracranial Surgery|Emergence Agitation During Recovery From Intracranial Surgery Under General Anesthesia: a Prospective Multicenter Cohort Study||Capital Medical University|Yes|Completed|January 2015|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|80 Years|No|Probability Sample|Adult patients after craniotomy|August 2015|August 4, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02318199||30872|
NCT02318212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIS-2014-010|Dilapan-S / Dilasoft E-Registry in Induced Abortion|International Observational E-Registry on the Use of Dilapan-S/Dilasoft Osmotic Dilators for Cervical Priming Prior to Induced Abortion|DSREGISTRYIA|Medicem International CR s.r.o.|No|Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|N/A|N/A|No|Probability Sample|All patients indicated for cervical priming with Dilapan-S or Dilasoft prior to induced        abortion and meet all inclusion and exclusion criteria in centres involved in data        collection.|December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318212||30871|
NCT02307799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPECT2014|A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology|A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology (RESPECT)|RESPECT|Université Catholique de Louvain|No|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3133|||Both|35 Years|70 Years|No|Probability Sample|First component: The study population was randomly selected from the lists of the 15        participating centers (these patient lists are organized based on territories).        Second component (cohort study): All newly identified individuals with airflow limitation        before and/or after the reversibility test were included in the cohort study.        Third component: One hundred patients with COPD and a smoking history of more than 10        pack-years (cases) and one hundred patients with the same smoking history without COPD        (controls) will be included in the third study.|December 2014|December 1, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307799||31670|
NCT02307812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15263|Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France|Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France||Eli Lilly and Company||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||July 2015|July 7, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307812||31669|
NCT02307396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1723/1-1|Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients|Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial||Technische Universität München|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02307396||31701|
NCT02321384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29454|A Study in Healthy Volunteers to Investigate the Safety, Tolerability, and Pharmacokinetics of RO6889678, Food Effects of Single-Dose RO6889678, and the Effect of Multiple Dosing of RO6889678 on the Pharmacokinetics of Midazolam|A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, SINGLE AND MULTIPLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO6889678 FOLLOWING ORAL ADMINISTRATION, THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF RO6889678 AND THE EFFECT OF MULTIPLE ORAL DOSING OF RO6889678 ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY SUBJECTS||Hoffmann-La Roche||Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321384||30628|
NCT02311036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-1030404|Functional Recovery Effects on Comprehensive Rehabilitation for Post-acute Care -Cerebrovascular Diseases|Effect and Outcome Predictors on Functional Recovery After Comprehensive Rehabilitation for Post-acute Care -Cerebrovascular Diseases||Taipei City Hospital|Yes|Enrolling by invitation|December 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|165|||Both|45 Years|N/A|No|||December 2014|December 5, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02311036||31422|
NCT02311049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2013/380|Hypofractionated Radiotherapy for Prostate Cancer|Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer: Randomised Trial Comparing Toxicity Between 2 Different Hypofractionated Schedules||University Hospital, Ghent||Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Male|40 Years|80 Years|No|||December 2014|December 4, 2014|July 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02311049||31421|
NCT02293811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-04|Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa|Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa|P2RX7|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|December 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293811||32744|
NCT02294110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSAFAILURE|Effect of Diabetes Mellitus on Success of Spinal Anesthesia|Phase IV Study of Diabetes Mellitus for Spinal Anesthesia Failure||Diskapi Yildirim Beyazit Education and Research Hospital|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|patients who undergoes surgery with spinal anesthesia|August 2015|August 4, 2015|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294110||32721|
NCT02301039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC028|SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas|SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas||Sarcoma Alliance for Research through Collaboration|No|Active, not recruiting|March 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|N/A|No|||March 2016|March 17, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301039||32189|
NCT02301052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-9377-7127|Evaluation of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms|Double Blind Randomized Placebo-control Trial of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms||Shiraz University of Medical Sciences|Yes|Recruiting|September 2014|December 2014|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02301052||32188|
NCT02310971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-301|Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas||Prima BioMed Ltd|Yes|Withdrawn|February 2015|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|November 15, 2014||No|The trial has been terminated per Sponsor direction due to longer than expected clinical and    regulatory approvals.|No||https://clinicaltrials.gov/show/NCT02310971||31427|
NCT02311244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URomLS-01-2014|The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes|The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes: Identification of New Molecular Promoters of Mortality and Morbidity in Patients With Type 2 Diabetes Mellitus|SUMMER|University of Roma La Sapienza|No|Recruiting|February 2014|February 2022|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Serum and urine|Both|18 Years|80 Years|No|Probability Sample|Secondary care outpatients clinic|February 2015|February 10, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02311244||31406|
NCT02315274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003219|Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes|Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes.||Mayo Clinic|No|Recruiting|June 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|45 Years|No|||September 2015|September 22, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315274||31097|
NCT02304120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0873|Sensorimotor Training in Low-back Pain Rehabilitation|Effects of a Sensorimotor Training on Postural Control and Pain: A Parallel, Single-blinded Randomised Controlled Trial|SeMoPoP|Reha Rheinfelden|Yes|Recruiting|December 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02304120||31952|
NCT02298075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP0714|Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia|Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients affected by primary immune thrombocytopenia (pITP)|July 2015|July 31, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02298075||32417|
NCT02316405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D015017-2011-2014|Can Arm and Leg Cycling Exercise Improve Walking After Stroke|Can Arm and Leg Cycling Exercise Improve Walking After Stroke?||University of Victoria|Yes|Recruiting|July 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|N/A|N/A|No|||December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316405||31010|
NCT02316418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HET-11|Safety and Efficacy Study of Hairstetics' ANCHORING SYSTEM For Hair Extensions For Subjects Affected With Hair Thinning|A Prospective Study to Evaluate the Safety and Efficacy of Hairstetics' ANCHORING SYSTEM For Hair Extensions For Subjects Affected With Hair Thinning - A Clinical Study||Hairstetics|No|Not yet recruiting|March 2015|March 2017|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|26|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316418||31009|
NCT02319967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01275|Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes|Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO Trial)|CHICAGO|University of Illinois at Chicago|Yes|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|640|||Both|5 Years|11 Years|No|||December 2015|December 3, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319967||30737|
NCT02300415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-15|Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.|Comparison of Sensitivity Between Presepsine and Arterial Lactate for the Diagnosis of Severe Sepsis and Sepsis Shock in Emergency Department.|PREDI|Centre Hospitalier Universitaire de Nice||Recruiting|December 2014|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|total blood sample|Both|18 Years|N/A|No|Probability Sample|patient with septic shock or severe sepsis|March 2016|March 18, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300415||32237|
NCT02306954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-256A|Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer|Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer||Providence Health & Services|No|Recruiting|December 2014|June 2025|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|November 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306954||31735|
NCT02320344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD001660 - PIC|Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project Partners in Care|||University of Hawaii||Recruiting|July 2013|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320344||30708|
NCT02320097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5899|A Study of the Impact of Head Position on Foot Pressure in Stance|A Study of the Impact of Head Position on Foot Pressure in Stance.||University Hospital, Strasbourg, France|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|87|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02320097||30727|
NCT02320110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIETARYHABITS2014-CINCO|Correlation of Irisin and Adipokine Levels With Body Mass Index and Risk Factors for Metabolic Syndrome in Hispanic Children|Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children||Instituto Tecnologico y de Estudios Superiores de Monterey||Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|||Both|6 Years|12 Years|No|Probability Sample|Obese, overweight, normal weight and underweight Hispanic, school-aged children from eight        public schools representative of Monterrey, the second largest city in México.|December 2014|December 15, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02320110||30726|
NCT02306317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neonatología-2014-01|The Adding Value of Parents to Nursing Care in the Control of FiO2|Changing the Paradigm for Improving Neonatal Care: Clinical Study on Optimal Oxygen-saturation Time and the Adding Value of Parents to Nursing Care in the Control of Fi02||Hospital Universitario 12 de Octubre|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|46|||Both|N/A|9 Months|No|||December 2015|December 22, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306317||31783|
NCT02295410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03/JLS 0007|The Effects of Home-Based Telemental Health for Rural Veterans With PTSD|The Effects of Home-Based Telemental Health for Rural Veterans With PTSD|HBTMH|VA Pacific Islands Health Care System|No|Recruiting|May 2013|December 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Up to 200 Veterans with PTSD who have been referred by their CBOC to the HBTMH PTSD clinic        or a VA Clinic will be enrolled in this research study. This sample size is based on the        number of treatment subjects intended to be treated by the HBTMH clinic, the VA clinic,        and the estimated numbers of subjects who will be ineligible or choose not to participate        in the HBTMH treatment. This number should be sufficient given past effect size        differences between HBTMH treatment and TAU (Cohen's d effect size averaging about 1.0).        It will also allow us to measure changes in psychological and cognitive functioning within        treatment subjects over time.|November 2014|November 14, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02295410||32621|
NCT02299973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGent_Gastro_001|Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating|Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating: a Double Blind, Placebo Controlled Randomised Clinical Trial||University Hospital, Ghent|No|Recruiting|October 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||November 2014|November 20, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02299973||32271|
NCT02314988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ6795|Tranexamic Acid to Reduce Blood Loss in Spine Trauma Surgery|Topical Application of Tranexamic Acid to Reduce Blood Loss During Complex Combat-related Spine Trauma Surgery||Columbia University|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314988||31119|
NCT02295085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC2012-3745|Fernald Community Cohort -18 Year Observational Study|Fernald Community Cohort - 18 Year Observational Study With Bio Banked Blood and Urine Samples|FCC|University of Cincinnati|No|Active, not recruiting|September 1990|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9782|Samples With DNA|160,000 archived biosamples available, drawn from 1990-2008 (whole Bood, Plasma, Serum,      Urine, Buffered Urine), extracted DNA. Breast, Renal & Prostate cancer formalin fixed      tissue.|Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community members who lived or worked within the five mile radius of the Fernald Uranium        Processing Plant boundary for a least 2 consecutive years between January 1, 1952 and        December 18, 1984.|November 2015|November 30, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02295085||32646|
NCT02307669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA-Sun|Inhaler Adherence in Severe Unstable Asthma|A Study on Inhaler Adherence to Improve Poor Asthma Control|INCA-SUN|Beaumont Hospital|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|190|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|April 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02307669||31680|
NCT02319577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genoa trial|GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial|Randomized, Phase II Study With Gefitinib Plus Vinorelbine Versus Gefitinib Alone in Patients Affected by Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of EGFR||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Recruiting|March 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02319577||30767|
NCT02319928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG-EPOS-1|European Polyp Surveillance Trial|Randomized Controlled Trial of Comparison Between Surveillance Intervals After Excision of Colonic Adenomas|EPoS|Asociación Española de Gastroenterología|Yes|Recruiting|June 2015|December 2028|Anticipated|December 2028|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|28000|||Both|40 Years|74 Years|No|||November 2015|November 23, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319928||30740|
NCT02303535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOR-CONGENITAL|National Congenital Heart Disease Audit|National Congenital Heart Disease Audit||University College, London|Yes|Recruiting|April 2000|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120000|||Both|N/A|N/A|No|Probability Sample|All potential patients are assessed through a systematic process of clinical evaluation,        diagnostic assessment. Patient selection is effected in each individual unit through a        multidisciplinary team process. These teams consist not only of cardiac surgeons and        interventional cardiologists but also of many other medical specialties and allied        professionals. The decision as to the access route to be used is determined by the        multidisciplinary team.|March 2015|March 5, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303535||31997|
NCT02309671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000124|A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Japanese Women Undergoing an Assisted Reproductive Technology Programme||Ferring Pharmaceuticals|Yes|Active, not recruiting|December 2014|August 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|159|||Female|20 Years|39 Years|No|||December 2015|December 9, 2015|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309671||31527|
NCT02296671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412051|Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers|Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers||Washington University School of Medicine|Yes|Withdrawn|February 2015|February 2022|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 18, 2014|Yes|Yes|Was unable to accrue any patients|No||https://clinicaltrials.gov/show/NCT02296671||32524|
NCT02319785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CathayGH|Effects of Robot-Assisted Combined Therapy in Upper Limb Rehabilitation in Stroke Patients|Effects of Robot-Assisted Combined Therapy in Upper Limb Rehabilitation in Stroke Patients||Cathay General Hospital|No|Recruiting|August 2014|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|80 Years|No|||December 2014|December 15, 2014|October 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319785||30751|
NCT02319798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDV227APR2010|Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease|Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease: Randomised Controlled Trial and Economic Evaluation.||Central Manchester University Hospitals NHS Foundation Trust||Completed|July 2010|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|86|||Both|8 Years|16 Years|No|||April 2014|December 15, 2014|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02319798||30750|
NCT02312414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5700858|Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype|Effects of Carnitine on Oxidative Stress and Inflammatory Responses to Intravenous Iron Administration to Patients With CKD: Impact of Haptoglobin Genotype||The Nazareth Hospital, Israel|Yes|Recruiting|October 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|80 Years|No|||May 2015|May 15, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312414||31316|
NCT02301234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106249|Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee||Janssen Research & Development, LLC|Yes|Recruiting|March 2015|January 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|900|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301234||32174|
NCT02301247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-839-14|Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)|Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)||Kessler Foundation|No|Recruiting|November 2014|April 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|30 Years|59 Years|No|||November 2014|November 21, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02301247||32173|
NCT02309814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0133-13-EMC|Eyelid Movement Sensor Device- Blinking Characterizing|Eyelid Movement Sensor Device- Blinking Characterizing||HaEmek Medical Center, Israel|Yes|Not yet recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02309814||31516|
NCT02322151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150047|Pharmacokinetics of Granulocyte Colony Stimulating Factor in the Breast Milk of Volunteer Peripheral Blood Stem Cell Donor|Pharmacokinetics of Granulocyte Colony Stimulating Factor in the Breast Milk of Volunteer Peripheral Blood Stem Cell Donor||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|June 2017|Anticipated|November 2015|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|5|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|January 23, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322151||30569|
NCT02322164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150048|Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds|Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322164||30568|
NCT02316938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AAU13|Assessing DSA Formation, Diabetes, Viral Infections, Structural Kidney Changes With an Everolimus-based Regimen (ADVISE)|Exploring the Impact of de Novo Everolimus on Key Determinants of Long Term Outcome After Kidney Transplantation: NODAT, Viral Infection, DSA, Proteinuria and Graft Histology|ADVISE|Novartis|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02316938||30969|
NCT02316951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400424|KINECTing Postoperative Pain and Recovery Following Orthopedic Surgery|Study: KINECTing Postoperative Pain and Recovery Following Orthopedic Surgery||University of Florida|No|Recruiting|July 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|21 Years|N/A|No|||February 2016|February 11, 2016|December 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02316951||30968|
NCT02300402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAMANTIUS|Detection and Characterization of Residual Masses in Lymphomas|Automatic Detection and Characterization of Residual Masses in Patients With Lymphomas Through Fusion of Whole‐Body Diffusion‐Weighted MRI on 3 Tesla and 18F‐Fluorodeoxyglucose PET/CT|ADAMANTIUS|The Lymphoma Academic Research Organisation|No|Recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Newly diagnosed HL, DLBCL or FL At least 18 years of age Initial presentation of bulky        disease|March 2016|March 14, 2016|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02300402||32238|
NCT02293889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO 188|Impact of Physical Activity and Vitamin D on Osteoarthritic Knee Pain|The Impact of Physical Activity and Vitamin D on Osteoarthritic Knee Pain in Older Obese People||Newcastle University|No|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Both|50 Years|70 Years|No|||February 2016|February 17, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293889||32738|
NCT02313376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-004|Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes|Trial to Assess the Safety, Attenuation and Immunogenicity of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults||Seattle Biomedical Research Institute|Yes|Completed|December 2014|August 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313376||31242|
NCT02320383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLLR3|CLLR3: FC + GA101 and B + GA101 in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients|CLLR3: Fludarabine + Cyclophosphamide + GA101 (FCG) and Bendamustine + GA101 (BG) in Patients With Relapsed or Refractory CLL Followed by Maintenance Therapy With GA101 for Responding Patients||Munich Municipal Hospital|No|Recruiting|September 2014|September 2022|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02320383||30705|
NCT02320396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4117-204|Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)|A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|449|||Both|16 Years|N/A|No|||August 2015|August 10, 2015|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02320396||30704|
NCT02296372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charité-MOTAFEE-CGM|Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients|Pilot Observation of Continuous Glucose Monitoring in Critically Ill Patients Under Consideration of Accuracy, Feasibility and Acceptance by Ward Staff||Charite University, Berlin, Germany|Yes|Recruiting|November 2014|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02296372||32547|
NCT02304640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/754/B|Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients|Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients||National University, Singapore|No|Recruiting|October 2014|June 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|194|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The proposed study will be a multicenter, prospective, longitudinal, observational study        conducted at the National Cancer Centre Singapore (NCCS) and KK Women's and Children's        Hospital (KKH).|October 2015|October 5, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02304640||31912|
NCT02322424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Japan-Taiwan PD Project|Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy|Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy: Prospective Large Observational Study||Wakayama Medical University|Yes|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|3,000 patients who undergo pancreaticoduodenectomy (PD) in Japan and Taiwan|December 2014|December 17, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322424|42 Months|30548|
NCT02313194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001416|Spinal Cord Neuromodulation for SCI|Enabling Forelimb Function With Agonist Drug and Epidural Stimulation in SCI||University of California, Los Angeles|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313194||31256|
NCT02293824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058253|Effect of Feedings on Caffeine in Premature Infants|Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants||Duke University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|15 Days|No|Probability Sample|Premature infants given caffeine for the prevention or treatment of apnea of prematurity.|August 2015|January 19, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293824||32743|
NCT02294136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0693|Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection|Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|75|||Both|21 Years|N/A|No|||December 2015|December 22, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294136||32719|
NCT02322606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-137/CPH-001|A Phase 1, Single and Multiple Dose Study of TAK-137|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TAK-137 in Healthy Subjects||Takeda|No|Withdrawn|November 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|0|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02322606||30534|
NCT02431689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32015|Delayed Embryo Transfer in Poor Responders|Antagonist and Short Protocols in Invitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) Cycles With Delayed Embryo Transfer in Poor Ovarian Response||Cairo University|Yes|Recruiting|April 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|25 Years|45 Years|No|||April 2015|April 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431689||22169|
NCT02430090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-099|Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section|Comparison of Intratechal Low-Dose Levobupivacaine With Levobupivacaine-Fentanyl and Levobupivacaine-Sufentanil Combinations for Cesarean Section||Ankara Numune Training and Research Hospital|No|Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 20, 2015||No||No|May 4, 2015|https://clinicaltrials.gov/show/NCT02430090||22290|A limitation of this study is that the baricity of the local anaesthetic could have been affected as the fentanyl and sufentanil were diluted within a mixture. Using these opiods in undiluted form in future studies would remove this limitation.
NCT02485275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRMRI|Stroke Imaging Package Study||SIPS|Peking Union Medical College Hospital|No|Recruiting|July 2015|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be recruited from the collaborative stroke centers and will be followed for        the duration of their hospitalization. Patients will be followed up until at least 3        months after stroke onset.|October 2015|October 20, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02485275|3 Months|18052|
NCT02485522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822653|Diet and Stool Metabolites in Fecal Incontinence|Diet and Stool Metabolites in Women With Fecal Incontinence||University of Pennsylvania||Not yet recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with fecal incontinence from an outpatient GYN clinic.|July 2015|July 9, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485522||18033|
NCT02432820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0070|Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy|Assessment of 3D Transperineal Ultrasound Imaging With Matrix Array Transducers as a Potential Imaging Modality for Adaptive Prostate and Post-Prostatectomy Radiotherapy||Stanford University|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer patients being treated at Stanford Cancer Center|November 2015|November 11, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02432820||22082|
NCT02432833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-06235AA1-01|Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients|Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients|STEADY|Chiesi Farmaceutici S.p.A.|No|Not yet recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|445|||Both|18 Years|N/A|No|||April 2015|May 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432833||22081|
NCT02436616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307016-7|microEEG for Neonatal Apnea, Bradycardia and Desaturation|Wireless Novel microEEG for Neonatal Apnea and Community Neurological Network||Bio-Signal Group Corp.|Yes|Recruiting|January 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|30 Days|No|Non-Probability Sample|Premature Infants born in hospital at the study centers|November 2014|February 26, 2016|November 25, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02436616||21790|
NCT02432976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/503|Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients|Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial|ExeQOL|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|May 2015|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|544|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432976||22070|
NCT02481479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-267|Saxagliptin and Cardiac Structure and Function|SCARF: Saxagliptin on CArdiac StRucture and Function|SCARF|St. Michael's Hospital, Toronto|No|Recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02481479||18344|
NCT02433093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29583|A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)|A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder||Hoffmann-La Roche||Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|7||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433093||22061|
NCT02437045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/14/QRBW/350|Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response|Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low-risk Patients|MERINO II|The University of Queensland|Yes|Recruiting|April 2015|December 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437045||21757|
NCT02438358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-015/2.6-001|Feasibility Study of Intraoperative Imaging in Breast Cancer|Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer||Lumicell, Inc.|No|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|65|||Female|18 Years|N/A|No|||May 2015|September 3, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438358||21656|
NCT02481765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0262|Feasibility and Dose Tolerability of HD-tDCS in Healthy Adults and Adults With Down Syndrome|Phase I Trial of the Feasibility and Dose Tolerability of High Definition Transcranial Direct Current Stimulation in Healthy Adults and Adults With Down Syndrome||University of Wisconsin, Madison|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|October 1, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481765||18322|
NCT02481778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2014-01|Monitoring Radiation Induced Cardiac Damage by Blood Markers|Monitoring Radiation Induced Cardiac Damage by Blood Markers|CARD|University Medical Center Groningen|No|Recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|87|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with esophageal- or non small cell lung cancer treated with radiotherapy with        curative intention, with or without chemotherapy, with or without surgery, at the        department of radiotherapy at the University Medical Centre Groningen|March 2016|March 17, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02481778||18321|
NCT02436863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMU-spine-1|Influence of Laminoplasty and Internal Fixation on Vertebral Stability After Laminectomy|Influence of Laminoplasty and Internal Fixation on Vertebral Stability After Cervical, Thoracic and Lumbar Laminectomy for Tumor Resection||Southern Medical University, China|No|Recruiting|January 2015|July 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|1. Adult patients (>18 years) were enrolled.          2. The patients suffered with lesion inside the spinal canal, who underwent laminectomy             to remove the lesion.          3. The cases with pathological malignant tumors were excluded from this study.          4. Health condition of patients (KPS) > 70.|June 2015|June 26, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436863|3 Years|21771|
NCT02429518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILT 2127-3|Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis||Knight Therapeutics (USA) Inc|No|Not yet recruiting|July 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|12 Years|55 Years|No|Non-Probability Sample|persons with mucocutaneous leishmaniasis being treated with miltefosine|April 2015|April 24, 2015|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02429518||22334|
NCT02433418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 9|Tubal Flushing Using Water Soluble Media for Unexplained Infertility|Tubal Flushing Using Water Soluble Media for Unexplained Infertility: A Randomized Controlled Trial||Cairo University|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433418||22036|
NCT02433678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1972|An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin|An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin||University at Buffalo|Yes|Recruiting|November 2015|May 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|20 Years|80 Years|No|||December 2015|December 11, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433678||22016|
NCT02321202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bhzhang001|Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer|Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer||Huazhong University of Science and Technology|Yes|Completed|March 2010|November 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|320|||Both|18 Years|75 Years|No|||December 2014|December 19, 2014|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321202||30642|
NCT02302521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057343|Motion Immune Magnetic Resonance Imaging (MRI)|Examining the Clinical Utility of Motion Immune MRI Across Multiple Patient Populations||Duke University||Recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There are 4 separate cohorts of patients. Please see earlier section. 60 subjects will        participate in our study.          -  10 healthy younger adult volunteers (ages 20 to 30)          -  10 healthy older adult volunteers (ages 50 to 70) will be recruited for          -  20 tremor-dominant patients with clinically diagnosed Parkinson's disease          -  20 healthy children (4 to 8 y.o.)|January 2016|January 19, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302521||32075|
NCT02306252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1409|The CARE Program: CAncer REhabilitation Pilot Study for Older Adults|LCCC 1409: The CARE Program: CAncer REhabilitation Pilot Study for Older Adults|CARE Program|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|82|||Female|65 Years|N/A|No|||October 2015|October 29, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306252||31788|
NCT02318875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00320-41/1|Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders|Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders|Easykrill|Vivatech|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|154|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02318875||30820|
NCT02310516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-39|Prospective Evaluation of the Impact of Pre-operative Device on the Personal Experience of Brain Awake Surgery|Prospective Evaluation of the Impact of Pre-operative Device on the Personal Experience of Brain Awake Surgery: Comparative Study, Randomized|EVECHE|Assistance Publique Hopitaux De Marseille|No|Recruiting|September 2014|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|November 16, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02310516||31462|
NCT02303392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14087|Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma|A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|March 2015|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303392||32008|
NCT02303405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01-2419|Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus|Comparing the Effects of Hydroxychloroquine (HCQ) to Pioglitazone in Type 2 Diabetic Patients Failing Maximal Doses of Metformin Plus a Sulfonylurea||Charles Drew University of Medicine and Science|Yes|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02303405||32007|
NCT02296164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-079A501|Observational US Study Assessing Outcomes, Treatment Patterns, AEs, QOL in MF-CTCL Patients and Treated With Valchlor|A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®|PROVe|Actelion|No|Recruiting|November 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|January 2015|May 19, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296164||32563|
NCT02321709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR11407|Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients|A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients||Sanofi|Yes|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321709||30603|
NCT02322125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036789|Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury|Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury||University of Alberta|No|Recruiting|June 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02322125||30571|
NCT02293538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCO242-P001|FID# 114657 in Contact Lens Wearers|Evaluation of a Lubricant Eye Drop on Tear Lipid Layer Thickness in Contact Lens Wearers||Alcon Research|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|234|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02293538||32765|
NCT02293798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820|Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold|||Mofid, Mehrdad Mark, M.D.|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293798||32745|
NCT02296424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G2306|ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab|An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|ß-SPECIFIC 4|Novartis|Yes|Recruiting|November 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|2 Years|20 Years|No|||October 2015|October 8, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296424||32543|
NCT02311465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141854|A Randomized Study of Early Palliative Care|A Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Oncology Care Alone in Patients With Non-colorectal Gastrointestinal Malignancies.||Vanderbilt University|No|Withdrawn|December 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 4, 2014||No|Feasibility issues|No||https://clinicaltrials.gov/show/NCT02311465||31389|
NCT02315248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0108|Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study|Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study||University of Mississippi Medical Center|No|Not yet recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Salivary biosamples will be stored for assaying osteocalcin (OC) and deoxypyridinoline (DPD)      levels|Female|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of asymptomatic women 50 years of age or older who present        for a screening mammogram and are at risk for low bone density or osteoporosis (N=200).|December 2014|December 10, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315248||31099|
NCT02298556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSS-13-0019|An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes|A Prospective Noninterventional, Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Non-dihydropyridine Calcium Channel Blocker Single Pill Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes Mellitus|HARVEST-TR|Abbott|No|Active, not recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|270|||Both|18 Years|N/A|No|Non-Probability Sample|State Hospital|January 2016|January 22, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298556||32380|
NCT02307019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caregiver patients apraxia|Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia|Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia: Randomized Clinical Trial|CPA|Universidad de Granada|Yes|Recruiting|July 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307019||31730|
NCT02307071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTSCM|Occipital Transcutaneous Stimulation in Chronic Migraine|Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine|OSCRO|University Hospital of Liege|No|Recruiting|November 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307071||31726|
NCT02316158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2007003|PsYoungSupport - Web-based Support to Young Careers to Persons With Mental Illness|PsYoungSupport Internet and Communication Technology Based Health Programmes - Information, Education and Support to Young People Close to Persons With Mental Illness|PSYS|Vardalinstitutet The Swedish Institute for Health Sciences|No|Completed|March 2009|May 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|241|||Both|16 Years|25 Years|Accepts Healthy Volunteers|||September 2011|December 9, 2014|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT02316158||31029|
NCT02306109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUSLMO_0001_SLA|Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)|Effects of Motor Rehabilitation Treatment on Disability and Quality of Life in Amyotrophic Lateral Sclerosis (ALS).|ermoSla|Azienda Unita' Sanitaria Locale Di Modena|Yes|Active, not recruiting|July 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|85 Years|No|||February 2016|February 19, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02306109||31799|
NCT02304926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-EZE-2009-01|Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia|Study of Lipoprotein Subfractions, Inflammation, Oxidative Stress and Endothelial Function After Treatment With Simvastatin and Ezetimibe Administered Alone and in Combination in Hyperlipidemic Patients||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|November 25, 2014||No||No|April 1, 2015|https://clinicaltrials.gov/show/NCT02304926||31890|
NCT02320188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0215|Eccentric Exercise and Cachexia in Rheumatoid Arthritis|Effect of Eccentric Exercise Training in Rheumatoid Cachexia|EECRA|University Hospital, Clermont-Ferrand||Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Female|40 Years|66 Years|No|||September 2015|September 18, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320188||30720|
NCT02326701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG001-HMO-CTIL|RV Function Evaluation Assessed by Strain and Validated by MRI|RV Function by Strain and MRI||Hadassah Medical Organization|No|Not yet recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients performing MRI for any indication|October 2014|December 22, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02326701||30219|
NCT02326740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052173|An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum||XOMA (US) LLC|Yes|Recruiting|December 2014|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|58|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|December 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326740||30216|
NCT02306070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT 019|Improving Outcomes With Metformin|Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.||Ottawa Hospital Research Institute|Yes|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|79 Years|No|||November 2015|November 17, 2015|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02306070||31802|
NCT02308605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI126414 23 May 2014 V1|SMARTCap Stroke Study: A Field Deployable Blood Test for Stroke|A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology|SMARTCAP|University Hospitals Coventry and Warwickshire NHS Trust|Yes|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|320|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|320|September 2015|September 8, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02308605||31608|
NCT02295202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 4075/14/055|Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome|Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study|TREATOSA-MS|University of Sao Paulo|No|Recruiting|March 2015|December 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2015|December 23, 2015|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295202||32637|
NCT02324881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCHN14122|Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy|A Pilot Study for a Pain Management Smartphone Application for Patients Undergoing Radiation Therapy for Locally Advanced Head and Neck Cancer||Vanderbilt-Ingram Cancer Center|No|Recruiting|December 2014|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02324881||30359|
NCT02326753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0805|Gender and Proper Size of Oropharyngeal Airway: Pilot Study|||Yonsei University|No|Completed|December 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|20 Years|N/A|No|||November 2014|July 30, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326753||30215|
NCT02326766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGC_metabolites_14121|Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects|||Yonsei University|Yes|Completed|November 2011|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|20 Years|70 Years|No|||December 2014|December 26, 2014|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326766||30214|
NCT02296099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-052|Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence|The Impact of Liposomal Bupivacaine Administered Following Placement of a Retropubic Suburethral Sling for Stress Urinary Incontinence: a Randomized Placebo-controlled Trial||TriHealth Inc.|No|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|114|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296099||32568|
NCT02296112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 1457|Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations|A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|January 2015|January 2021|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296112||32567|
NCT02308332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR50959|Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning|Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning, ESCAPE Study|ESCAPE|UMC Utrecht|No|Not yet recruiting|February 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02308332||31629|
NCT02309580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-227|Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma|A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|January 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309580||31534|
NCT02319837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-13|Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)|A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy||Medivation, Inc.|Yes|Recruiting|December 2014|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1860|||Male|18 Years|N/A|No|||December 2015|February 18, 2016|December 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319837||30747|
NCT02299583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f-22834-02|Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events|Protocol for a Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events Comparing Trauma-informed and Usual Health Care Practice||Rigshospitalet, Denmark|Yes|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|684|||Both|8 Years|18 Years|No|||November 2014|November 21, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02299583||32301|
NCT02299596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physsurg C - the RCT|Physical Activity in Relation to Surgical Procedures|Physsurg - a Controlled Randomized Trial on the Effect of Physical Activity in Relation to Outcome After Surgery||Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|370|||Both|N/A|N/A|No|||August 2015|August 19, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299596||32300|
NCT02297750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033706|Optimal Timing of Double-Wire Technique For Biliary Cannulation at ERCP|Optimal Timing of Double-Wire Technique For Biliary Cannulation at ERCP||Duke University|No|Completed|August 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|161|||Both|18 Years|N/A|No|||November 2014|October 23, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297750||32442|
NCT02297763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJLSM2014|Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients|||Seoul National University Hospital|Yes|Not yet recruiting|March 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|194|||Both|19 Years|90 Years|No|||July 2014|November 18, 2014|July 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02297763||32441|
NCT02321852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014DR2154|Influence of Triflusal on Cognitive Functions in Healthy Subjects|Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Healthy Participants|Tribunal-Basel|University of Basel|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02321852||30592|
NCT02321865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-02-5|Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency|Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency||Nobelpharma|No|Active, not recruiting|January 2015|||December 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||July 2015|July 22, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321865||30591|
NCT02322684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBRI-airq|Endotracheal Intubation Using a Bougie Through the Air-Q Intubating Laryngeal Airway|Bougie-guided Tracheal Tube Placement Through the Air-Q® Intubating Laryngeal Airway: Clinical Evaluation||Theodor Bilharz Research Institute|No|Recruiting|January 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|19 Years|60 Years|No|||January 2016|January 6, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02322684||30528|
NCT02325752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/380/E|A Prospective Randomised Control Trial to Study the Effectiveness of a Health Service Innovation Using a Modified Virtual Ward Model to Prevent Unscheduled Readmission of High Risk Patients|A Prospective Randomised Control Trial to Study the Effectiveness of a Health Service Innovation Using a Modified Virtual Ward Model to Prevent Unscheduled Readmission of High Risk Patients||Singapore General Hospital|No|Completed|August 2011|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|840|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 25, 2014|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02325752||30292|
NCT02303548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BicarbonateinCPR001|Bicarbonate in Patients With Out-of-hospital Cardiac Arrest|Pilot Study of Bicarbonate Injection for Improving Outcome in Patients With Out-of-hospital Cardiac Arrest, Double-blind Randomized Control Trial||Asan Medical Center|No|Enrolling by invitation|October 2014|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02303548||31996|
NCT02307370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D024204|Atherectomy By Laser Ablation With Turbo-Elite|Atherectomy By Laser Ablation With Turbo-Elite|ABLATE|Spectranetics Corporation||Enrolling by invitation|December 2014|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307370||31703|
NCT02296684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412118|Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma|Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma||Washington University School of Medicine|No|Recruiting|March 2015|March 2022|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296684||32523|
NCT02301780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0066-14-RMC|Combined Multi-marker Screening and Randomised Patient Treatment With Aspirin for Evidence-based Pre-eclampsia Prevention|Combined Multi-marker Screening and Randomised Patient Treatment With Aspirin for|ASPRE|Rabin Medical Center|Yes|Not yet recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 26, 2014|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301780||32132|
NCT02313129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057614|Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis|Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis||Duke University|No|Recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|blood tests|Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rheumatoid Arthritis Women and Health Control Women|August 2015|August 7, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313129||31261|
NCT02313142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAMAS_v1.1_Nov2014|Responses of the Cardiovascular Systems to Leg Exercises in Microgravity-like Conditions|Responses of the Cardiovascular Systems to Leg Exercises in Microgravity-like Conditions|STAMAS|Swiss Federal Institute of Technology|No|Active, not recruiting|January 2015|||December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313142||31260|
NCT02316691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14060524|B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease|B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease|BetTeRTED|University of Pittsburgh|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|Samples Without DNA|Samples will be used to determine longitudinal effect of B cell depletion on frequencies and      functions of T helper subsets and memory B cells in blood. Any unused PBMC as well as serum      obtained from these blood draws will be banked for future use in in vitro experiments.|Both|18 Years|75 Years|No|Non-Probability Sample|The study will be introduced during a clinic visit with one of the physicians who are        investigators on this study. These will be subjects who are being referred for intravenous        glucocorticoid (IVGC) therapy due to the severe nature of their thyroid eye disease.|January 2016|January 19, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316691||30988|
NCT02306902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243_FENOF_09|Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study Comparing Fenofibrate Capsule 130 mg of Ohm Laboratories Inc., USA (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With Antara® Capsule 130 mg (Containing Fenofibrate 130 mg) of Oscient Pharmaceutical Corporation, USA in Healthy, Adult, Male Human Subjects Under Fed Conditions||Ranbaxy Inc.|No|Completed|October 2009|April 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02306902||31739|
NCT02308696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000001|The Effectiveness of Peer-to-Peer Community Support to Promote Aging in Place|The Effectiveness of Peer-to-Peer Community Support to Promote Aging in Place||University of Wisconsin, Madison|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|720|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308696||31601|
NCT02313389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130950|Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma|Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line|BLOCAGE-01|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2015|June 2021|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|295|||Both|60 Years|N/A|No|||July 2015|July 20, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313389||31241|
NCT02320617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013C2014|Application of Diffusion Weighted MRI Versus CT in Evaluation of the Effect of Treating Lung Cancer|Application of Diffusion Weighted Magnetic Resonance Imaging Versus CT in Evaluation of the Effect of Treating Lung Cancer||Fourth Military Medical University|Yes|Recruiting|December 2014|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|75 Years|No|||December 2014|December 19, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02320617||30687|
NCT02308293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|End_lac_sympt|The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia|The Effect of Exercise-induced Hyperlacticacidemia on Counterregulatory Responses, Symptoms, Cognitive Function and Brain Lactate Accumulation During Hypoglycemia in (Hypoglycemic Unaware)Type I Diabetes Patients and Normal Controls||Radboud University|No|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02308293||31632|
NCT02298634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFD 07-2014|Biomarker for Farber Disease|Biomarker for Farber Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioFarber|University of Rostock|Yes|Recruiting|November 2014|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, saliva tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with a diagnosis of Farber disease or profound suspicion for Farber disease|October 2015|October 6, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298634||32374|
NCT02317120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00088|BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival|BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival||Prof. Dr. I. Chiricuta Institute of Oncology||Recruiting|February 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|75 Years|No|Probability Sample|Womens who have been diagnosed with breast/ovarian cancer , carriers of a high risk of        gBRCA mutations based on prespecified inclusion criterias|January 2016|January 29, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317120||30955|
NCT02326207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU 2014|Weekly Versus no Routine Ventilator Circuit Changes in NICU|Weekly Versus no Routine Ventilator Circuit Changes in Neonatal Intensive Care Unit: Prospective, Randomized Study||Prince of Songkla University|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|1 Year|No|||August 2015|August 24, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326207||30257|
NCT02300649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0574|Transesophageal Echocardiographic Evaluation of the Effect of Dexmedetomidine Infusion as an Adjuvant to General Anesthesia on the Cardiac Function|||Yonsei University|No|Completed|September 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Both|20 Years|80 Years|No|||April 2015|April 16, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300649||32219|
NCT02307773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-M08|Lidocaine Spray on an Endoscope to Improve Tolerance to Endoscopy|Does Use of Lidocaine Spray on an Endoscope Immediately Before Insertion Improve Patient Tolerance to Endoscopy? A Single Center, Case-Control Study.||Cheju Halla General Hospital|Yes|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|497|||Both|16 Years|89 Years|No|Non-Probability Sample|All the patients who underwent upper gastrointestinal endoscopy in Endoscopy Room 2,        Digestive Disease Center, Halla General Hospital, Jeju, Korea were enrolled consecutively        during Nov. 4 2013 - May 7 2014.|December 2014|January 12, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307773||31672|
NCT02307825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.140|Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy|Azithromycin as add-on Therapy in Patients Failing Medical and Surgical Treatment for Chronic Rhinosinusitis: a Double-blind, Randomized, Placebo-controlled Trial|AZI-CRS|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|November 2014|October 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02307825||31668|
NCT02313883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSPD 1-2|A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis|A Phase I/II Study to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects With Periodontitis||Geistlich Pharma AG|No|Recruiting|July 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|95|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313883||31203|
NCT02317419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29387|A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors|PHASE IA/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF RO6927005, AN ANTI-MESOTHELIN (MSLN) RECOMBINANT CYTOLYTIC FUSION PROTEIN (cFP), ADMINISTERED EITHER ALONE (PART A) OR IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL (PART B) IN PATIENTS WITH MESOTHELIN-POSITIVE METASTATIC AND/OR LOCALLY ADVANCED MALIGNANT SOLID TUMORS||Hoffmann-La Roche||Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 11, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317419||30932|
NCT02317939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100.01|Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study|Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study|ELECTOR_I|Parker Research Institute|No|Recruiting|December 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|85 Years|No|||March 2016|March 22, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02317939||30892|
NCT02297997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHRM|Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy|Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study||Seoul National University Hospital|No|Enrolling by invitation|November 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|65|||Both|60 Years|N/A|No|||December 2014|December 2, 2014|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297997||32423|
NCT02298010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29471|Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial|Pattern and Clinical Implication of Lymph Node Metastasis From Gastric Cancer Which Was Resected by Radical Surgery With Extended Lymphadenectomy||Seoul National University Hospital|No|Not yet recruiting|February 2016|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|910|||Both|18 Years|N/A|No|Non-Probability Sample|Study subjects who were enrolled in CLASSIC trial (NCT00411229) and whose medical records        about the extent of the lymph node dissection and pathologic report are available.|November 2015|November 16, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298010||32422|
NCT02295397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iFAAM|Integrated Approaches to Food Allergen and Allergy Risk Management|Integrated Approaches to Food Allergen and Allergy Risk Management|iFAAM|University of Zurich|No|Recruiting|November 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|450|||Both|5 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02295397||32622|
NCT02295631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/42|ETI During Spinal Trauma|A Comparison of Conventional Tube and ETView VivaSight SL Tube for Tracheal Intubation in Patients With a Cervical Spine Immobilisation. A Randomized Cross-over Manikin Trial.||International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295631||32604|
NCT02300480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZ-005|Effects of Calot's Triangle Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Double-blind, Controlled, Clinical Trial|Effects of Calot's Triangle Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Double-blind, Controlled, Clinical Trial||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|December 2014|November 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||November 2014|November 24, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02300480||32232|
NCT02314234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20140248|Improvement of Facial Nerve Monitoring in Parotid Surgery by Sugammadex|Influence of Sugammadex on Facial Nerve Monitoring in Parotid Surgery||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|50|||Both|18 Years|80 Years|No|Probability Sample|adult patient with facial nerve monitoring undergoing parotid surgery|February 2016|February 23, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02314234||31177|
NCT02314468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/724|Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation|Comparative Study of Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation in Necrotising Soft Tissue Infections|NPWTvsGPA|University Hospital, Ghent|No|Recruiting|October 2013|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|90 Years|No|||December 2014|December 8, 2014|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02314468||31159|
NCT02436109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01152|Ultrasound Guidance for Epidural Analgesia and Anesthesia|Ultrasound Guidance for Epidural Analgesia and Anesthesia||University of British Columbia|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women|November 2015|November 3, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02436109||21829|
NCT02436382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 122014-046|Hypothermia and the Effect of Ambient Temperature|The Impact of Ambient Operative Room Temperature on Neonatal and Maternal Hypothermia|HEAT|University of Texas Southwestern Medical Center|No|Recruiting|February 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02436382||21808|
NCT02491060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-121A-301|A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris||Valeant Pharmaceuticals|No|Not yet recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|9 Years|N/A|No|||September 2015|September 11, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491060||17610|
NCT02436824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-201|A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain|A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain||Frontier Biotechnologies Co., Ltd.|No|Completed|April 2015|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|75 Years|No|||September 2015|September 1, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436824||21774|
NCT02438722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1403|Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer|A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)||Southwest Oncology Group|Yes|Recruiting|March 2015|||February 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|605|||Both|N/A|N/A|No|||September 2015|September 1, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438722||21628|
NCT02439749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPYRAL HTN-OFF MED|SPYRAL HTN-OFF MED Study|Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED)||Medtronic Vascular|Yes|Recruiting|June 2015|February 2020|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||March 2016|March 4, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439749||21550|
NCT02437942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC-Groin-001|Anatomical, Radiological and Biomechanical Examination of Athletic Groin Pain Patients and Physical Therapy Intervention|An Examination of the Anatomical and Biomechanical Diagnoses That Exist in Athletic Groin Pain Patients and the Effects of a Biomechanics Led Rehabilitation Intervention in These Same Patients||Sports Surgery Clinic, Santry, Dublin||Recruiting|April 2015|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02437942||21688|
NCT02438150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20141020002|The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge|The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge||The Hong Kong Polytechnic University|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|128|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02438150||21672|
NCT02444065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7391-B|Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder|Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder: A Randomized Controlled Trial of an Intervention to Facilitate Early Symptom Change|CBT-RR|University Health Network, Toronto|No|Recruiting|May 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|17 Years|N/A|No|||May 2015|May 13, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02444065||21219|
NCT02485808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LURN Observational V6.0|Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Prospective Observational Cohort Study Protocol|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|April 2015|May 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|Samples With DNA|Whole Blood - DNA Plasma Urine Vaginal Cultures (women) Perineal Cultures (men) Saliva|Both|18 Years|N/A|No|Non-Probability Sample|New patients with LUTS presenting to LURN clinical sites will be screened for        participation based on the inclusion and exclusion criteria (below).|May 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485808||18011|
NCT02485821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS39825273|Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol|Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol||Ain Shams University|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485821||18010|
NCT02436837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJFGV0001|Applicability of Kinect Sensor® in the Rehabilitation of Balance in the Elderly|Applicability of Kinect Sensor® in the Rehabilitation of Balance in the Elderly|AKS|Federal University of Juiz de Fora|Yes|Completed|January 2013|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02436837||21773|
NCT02439892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDR-2012-01|Rehabilitation for Head and Neck Cancer|Rehabilitation During Versus After Radiotherapy in Head and Neck Cancer - a Pilot Randomised Controlled Trial||Norwegian University of Science and Technology|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|85 Years|No|||November 2015|November 6, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02439892||21539|
NCT02444078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7292 03|Effects of Exercise on Functional Ability in People With Dementia in Nursing Homes:a Cluster Randomised Controlled Trial|Effects of a Long-term Exercise Program on Functional Ability in People With Dementia Living in Nursing Homes: a Cluster Randomised Controlled Trial. The LEDEN Study|LEDEN|University Hospital, Toulouse|No|Recruiting|August 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|65 Years|N/A|No|||August 2015|August 20, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02444078||21218|
NCT02486081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-7262B|Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population|Assistive Device Design, Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population||Chang Gung Memorial Hospital|No|Not yet recruiting|August 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|children with intellectual disabilities|April 2015|June 30, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02486081||17991|
NCT02428387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00048721|Evaluation of "My Tools 4 Care" for Family Caregivers of Persons With Dementia|Evaluation of a Transition Intervention for Family Caregivers of Persons With Alzheimer Disease and Multiple Chronic Conditions||University of Alberta|No|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02428387||22421|
NCT02428400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1050.02|Safety and Tolerability of TG1050: A Dose-finding Study|A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection||Transgene|Yes|Recruiting|October 2015|||March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02428400||22420|
NCT02443285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBP TREATMENT|Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?|Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?||Tanta University|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||October 2015|October 24, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443285||21278|
NCT02310282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 143201010021|Telemedicine for Optimized Collection of CLinical datA in Patients With Suspicion of Acute Stroke|Telemedicine for Optimized Collection of CLinical datA in Patients With Suspicion of Acute Stroke|TeleCLASS|Universitair Ziekenhuis Brussel|No|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with suspicion of acute stroke admitted to the Emergency Department or the Stroke        Unit of the Universitair Ziekenhuis Brussel|December 2015|December 10, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310282||31480|
NCT02307747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-36|Disruption of Circadian Rhythm and Healthcare-related Infection in Patients With Severe Trauma|Disruption of Circadian Rhythm and Healthcare-related Infection in Patients With Severe Trauma||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02307747||31674|
NCT02307760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL16|Evaluation of Human Milk Fortifiers in Preterm Infants|Evaluation of Two Human Milk Fortifiers in Preterm Infants||Abbott Nutrition|No|Not yet recruiting|December 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|164|||Both|N/A|21 Days|No|||December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307760||31673|
NCT02307305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cymbaltaTKR|Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?|Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?||Hanyang University Seoul Hospital|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|168|||Both|50 Years|75 Years|No|||February 2016|February 17, 2016|November 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307305||31708|
NCT02320929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14153|The Treatment of Purulent Flexor Tenosynovitis|The Treatment of Purulent Flexor Tenosynovitis - Is Postoperative Catheter Irrigation Necessary? A Prospective Randomized Trial.||University of Tampere|No|Recruiting|March 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02320929||30663|
NCT02314741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819130|Peroral Endoscopic Myotomy (POEM) for Esophageal Motility|Peroral Endoscopic Myotomy (POEM) for Esophageal Motility in Patients With a Clinical Diagnosis of Achalasia|POEM|University of Pennsylvania||Completed|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||July 2014|May 29, 2015|July 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02314741||31138|
NCT02293252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KX0805|CardioBBEAT - Randomized Controled Trial to Evaluate the Health Economic Impact of Remote Patient Monitoring|Gesundheitsökonomische Methodenentwicklung am Beispiel Der Evaluation Einer Technologiebasierten, sektorübergreifenden Intervention Zur Versorgung Chronisch Kranker Patienten||University of Bayreuth|Yes|Active, not recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|621|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293252||32787|
NCT02293265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201722|Cross-sectional Study for Identification and Description of Severe Asthma Patients|Identification and Description of Severe Asthma Patients in a Cross-sectional Study—the IDEAL Study||GlaxoSmithKline|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|767|||Both|12 Years|N/A|No|||September 2015|September 10, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02293265||32786|
NCT02300454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC2014-14|Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions||ELEGANT|Mitsui Memorial Hospital|Yes|Recruiting|June 2015|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02300454||32234|
NCT02300467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV120401-101|NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of NOV120401 (CKD-516 Tablet) in Patients With Advanced Refractory Solid Tumors||National OncoVenture|No|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||August 2015|August 13, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02300467||32233|
NCT02310477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REBECCA-1305|Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting|REBECCA: A Cohort Study of Regorafenib in the Real-life Setting in Patients Previously Treated for Metastatic Colorectal Cancer.|REBECCA|Centre Oscar Lambret|Yes|Recruiting|February 2014|December 2014|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|1119|||Both|18 Years|N/A|No|Non-Probability Sample|Patients were identified from the database of the French ATU (Temporary Authorization for        Use), approved by the French Health Authorities to provide early access to innovative, not        yet approved medicinal products such as REG.        elligible patients were those who accepted to participate to the cohort study, and whom        physicians accepted to collaborate on the REBECCA cohort.|October 2014|December 4, 2014|October 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02310477||31465|
NCT02310529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-IPT|Interpersonal Psychotherapy for Maternal Depression|Randomized Control Trial of an Interpersonal Psychotherapy for Maternal Depression||Pakistan Institute of Learning and Living|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|45 Years|No|||August 2015|August 15, 2015|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02310529||31461|
NCT02298270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002605|Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype|Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype||Massachusetts General Hospital|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02298270||32402|
NCT02300727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curcumin:I/II|Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy|A Phase I/II Study to Determine the Safety and Efficacy of Curcumin in Patients With Oral Mucositis Secondary to Chemotherapy||Aurora BayCare Medical Center|No|Recruiting|February 2015|October 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|N/A|No|||August 2015|February 4, 2016|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300727||32213|
NCT02318446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTRG/E-1/03/ 1210|Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics|Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial||Maharashtra University of Health Sciences|No|Not yet recruiting|March 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|10 Years|19 Years|No|||December 2014|December 16, 2014|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318446||30853|
NCT02318459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-257|High Intensity Interval Training in Geriatrics|High Intensity Interval Training for thE Rehabilitation of Geriatric Patients - a Feasibility Pilot studY.|HIITERGY|University Hospital, Geneva|No|Recruiting|May 2014|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|65 Years|N/A|No|||December 2014|December 11, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02318459||30852|
NCT02303912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-002|Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer|Phase 1B Open Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Nuc-1031 Given on Days 1 & 8 With Carboplatin on Day 1, q3-weekly for 6 Cycles in Participants With Recurrent Ovarian Cancer.|ProGem2|Imperial College Healthcare NHS Trust|Yes|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||September 2015|October 5, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02303912||31968|
NCT02303925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00111-46|Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease|Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease|EMBORRHOID|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|November 2014|November 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|75 Years|No|||July 2015|July 1, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02303925||31967|
NCT02293356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPL-Nim-NPC-2|Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma|Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma||Biotech Pharmaceutical Co., Ltd.|No|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|N/A|No|||August 2015|August 18, 2015|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02293356||32779|
NCT02320019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14618-202|Clinical Trial of YH14618 in Patients With Degenerative Disc Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Trial to Evaluate the Efficacy and Safety of YH14618 in Patients With Lumbar Degenerative Disc Disease||Yuhan Corporation|No|Active, not recruiting|March 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|324|||Both|19 Years|N/A|No|||February 2016|February 18, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02320019||30733|
NCT02322619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054-12|Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Comparing With Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc. in Healthy, Adult Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322619||30533|
NCT02319850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081320|Muscle Ultrasound for Sarcopenia Leading to Early Detection|Revisiting the Sarcopenia Diagnosis: New Approaches to Rapid Screening and Preventative Healthcare|MUSCLED|George Washington University|No|Active, not recruiting|February 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Enrolled subjects in this pilot study will include a healthy young reference group (18 -        29 years of age) and an older comparison group (55 - 75 years of age; n = 15 per group;        approximately 50% female), consecutively recruited from George Washington University and        the surrounding community.|December 2014|May 14, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319850||30746|
NCT02319863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chenxp5|Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy||Huazhong University of Science and Technology|Yes|Recruiting|February 1994|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|65 Years|No|||December 2014|December 15, 2014|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319863||30745|
NCT02295566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CHI0548|RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study|RATNO (Reducing Antibiotic Tolerance Using NO) Reducing Antibiotic Tolerance Using Low Dose Nitric Oxide in Cystic Fibrosis - a Phase 2 Pilot Study|RATNO|University Hospital Southampton NHS Foundation Trust.|Yes|Completed|May 2011|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|12 Years|N/A|No|||November 2014|November 17, 2014|August 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02295566||32609|
NCT02308579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDUS1|Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases|Prevalence of Chronic Cerebrospinal Venous Insufficiency in Patients With Multiple Sclerosis and Other Neurological Diseases. An Ultrasound, Blinded, Case-Controlled, Centralized Reading Assessment||University at Buffalo|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|499|||Both|5 Years|80 Years|No|Non-Probability Sample|Participants in this study will be those who had participated in the second phase of the        Combined Transcranial/Extracranial Venous Deficiency (CTEVD) study.|February 2016|February 11, 2016|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02308579||31610|
NCT02324803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUCC001|Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients|Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients||Southern China Urology Cancer Consortium|Yes|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02324803||30365|
NCT02324816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA14-005|Colder Outer Thigh Study|Non-Invasive Fat Layer Reduction in the Lateral Thighs With a Cryolipolysis System Using a Colder Treatment Parameter|OTC|Zeltiq Aesthetics|No|Active, not recruiting|December 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02324816||30364|
NCT02311543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 23/13|Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer|Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Lymph Node Dissection for Breast Cancer. A Multicenter Randomized Phase III Trial.||Swiss Group for Clinical Cancer Research|Yes|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|142|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311543||31383|
NCT02306564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14022014|Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection|Effect of Cabergoline on Subendometrial Vascularity During ICSI Cycles and Pregnancy Outcome||Kasr El Aini Hospital|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|June 22, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306564||31765|
NCT02306577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINNR STUDY|STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)|STRIBILD in Non-Nucleoside Resistant Patients, An Evaluation of Safety and Efficacy in Vulnerable Population (SINNR STUDY)|SINNR|Vancouver Infectious Diseases Centre|No|Recruiting|November 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|19 Years|70 Years|No|Non-Probability Sample|HIV infected people who are current or past illicit drug users and receive treatment for        their HIV infection|June 2015|June 1, 2015|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306577||31764|
NCT02299700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104919|Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder|A Study to Preliminarily Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder|Mentis|Janssen Research & Development, LLC|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|34|||Both|3 Years|N/A|No|Non-Probability Sample|Children and Adult participants with history of Autism Spectrum Disorder will be observed.|October 2015|October 2, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02299700||32292|
NCT02313896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013528|Cirrhosis Readmission Telehealth Project|Cirrhosis Readmission Telehealth Project||Yale University|No|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|July 6, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313896||31202|
NCT02311816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-infection|Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients|||Szeged University|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|114|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with suspected infection during their stay on the intensive care unit were        screened for eligibility. Patients were enrolled, when the attending intensive care        specialist had a suspicion of infection and decided to start empirical antibiotic therapy        and infalmmatory markers were available from the previous day.|December 2014|December 4, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311816||31362|
NCT02300662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0530|Early Mobilization for Critical Patients on Invasive Mechanical Ventilation in the Intensive Care Unit|Early Mobilization With a Cycle Ergometer for Critical Patients on Invasive Mechanical Ventilation in the Intensive Care Unit (MoVe-ICU Study): Study Protocol for a Randomized Controlled Trial|MoVe-ICU|Hospital de Clinicas de Porto Alegre|Yes|Completed|January 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02300662||32218|
NCT02309593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002A|Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems|Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems||MicroPort Orthopedics Inc.|No|Recruiting|December 2014|December 2026|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted or will be implanted with a PROFEMUR® Xm        Femoral Stem|March 2016|March 15, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309593||31533|
NCT02295657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/43|Double Lumen Tube Intubation|Comparison of Techniques for Double-lumen Tube Intubation: Standard Double-lumen Tube or VivaSight Double Lumen Tube by Paramedics. A Randomized Crossover Manikin Trial.|DLETI|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295657||32602|
NCT02295670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/51|Pediatric Difficult Intubation|Can the Vividtrac Laryngoscope Rival the Miller Laryngoscope for Child Tracheal Intubation During Chest Compression in a Manikin? A Randomized Crossover Trial.|3V-L DL|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295670||32601|
NCT02322476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSV-ITA-RH|Herpes Simplex Reactivation in Adult Critical Care Patients|Herpes Simplex Reactivation in Adult Critical Care Patients||Rigshospitalet, Denmark|No|Not yet recruiting|January 2015|August 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|blood tracheal secretions|Both|18 Years|N/A|No|Probability Sample|Adult critically ill patients|December 2014|December 22, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322476||30544|
NCT02305862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMARIROCAP|A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques|An Open-label, Single-centre Randomized Study Evaluating the Effect of Treatment With Rosuvastatin 5/20mg on Atherosclerotic Disease as Measured by High-Resolution Contrast Enhanced Magnetic Resonance Imaging in Patients With Coronary Artery Disease and Hyperlipideimia||Capital Medical University|Yes|Recruiting|January 2013|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02305862||31818|
NCT02306044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20120088|Bleeding Prediction in Thrombocytopenia|Bleeding Prediction in Thrombocytopenia Using Platelet Indices, Platelet Aggregometry and a Standardized Bleeding Questionnaire||Odense University Hospital|No|Completed|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|Samples Without DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Admitted patients with thrombocytopenia of any cause|December 2014|December 2, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02306044||31804|
NCT02312609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238_MINOC_08|Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratories, USA. (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With SolodynTM Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of AAI Pharma, Inc. in Healthy, Adult, Male, Human Subjects Under Fed Condition||Ranbaxy Inc.|No|Completed|September 2008|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02312609||31301|
NCT02312401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-172|Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy|Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy||Memorial Sloan Kettering Cancer Center||Recruiting|December 2014|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|165|||Male|18 Years|N/A|No|||January 2016|January 21, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312401||31317|
NCT02307383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Desprobioxa|Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers|Pilot Study of the Effectiveness of Probiotics and Lactitol for the Intestinal Decolonization of People Carriers of Klebsiella Pneumoniae Producers of Carbapenemase OXA-48-type: DesProbiOXA Study||Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02307383||31702|
NCT02295540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031401|Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity|Preoperative Hypofractionated Radiation Followed by Surgery in Advanced Oral Cavity Squamous Cell Carcinoma||Rutgers, The State University of New Jersey|No|Not yet recruiting|June 2016|||January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295540||32611|
NCT02302040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400921|Team Speak Collaborative Asthma Management|Team Speak: mHealth Approach to Collaborative Asthma Management for Teens & Parents||University of Florida|Yes|Not yet recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|15 Years|No|||December 2015|December 1, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302040||32112|
NCT02293330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/38/393|Continuous Versus Automated Bolus Infusion in Sciatic Nerve Catheters|Continuous Infusion Versus Automated Intermittent Bolus of Levobupivacaine 0,1% in Ultrasound Guided Subparaneural Sciatic Nerve Catheters. A Prospective Double Blind Randomised Study.||University Hospital, Antwerp|No|Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02293330||32781|
NCT02317588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:036|Gender Effects of Dietary Omega-3 Fatty Acids From Plant and Marine Sources on Oxylipins in Healthy Humans|Gender Effects of Dietary Omega-3 Fatty Acids From Plant and Marine Sources on Oxylipins in Healthy Humans|OXGEN-2014|University of Manitoba|No|Completed|December 2014|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317588||30919|
NCT02317601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002492-29|Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery|Preoperative Single-high Dose Glucocorticoid for Patients Undergoing Hip Fracture Surgery and the Effect on Postoperative Delirium.||Hvidovre University Hospital|Yes|Recruiting|December 2014|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|November 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317601||30918|
NCT02320422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1876|Adult Liver Transplant Enhanced Care|An Intervention to Improve Adherence to Medications in Adults With Liver Transplants|ALTER|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320422||30702|
NCT02301013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM01|Impact of Urethral Mobility on the Success of Sling Operations|Are Unsatisfying Results After TVT and TOT Operations Associated With Increased Urethral Mobility||Kanuni Sultan Suleyman Training and Research Hospital|No|Recruiting|March 2013|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Female|25 Years|70 Years|No|||November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301013||32191|
NCT02318160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST123-2014|Oxidative Status in Children With Autoimmune Thyroiditis|Oxidative Status in Children and Adolescents With Autoimmune Thyroiditis: A Tertiary Center Study From Upper Egypt||Assiut University|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|64|||Both|6 Years|18 Years|No|Non-Probability Sample|Our case control study was conducted on 32 children and adolescents with Autoimmune        Thyroiditis attending the Pediatric Endocrinology Clinic of Assiut University Children        Hospital, Assiut, Egypt. . Diagnosis of Autoimmune Thyroiditis had been made by elevated        anti-thyroid peroxidase antibodies (TPO Ab) and/or anti-thyroglobulin antibodies (Tg Ab)        as well as typical hypoechogenicity of the thyroid in high-resolution sonography . Another        group of 32 age and sex-matched healthy subjects as a control group.|December 2014|December 12, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02318160|3 Months|30875|
NCT02293278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/85X|Preschoolers Activity Trial|Preschoolers Activity Trial - a Pilot Randomized Controlled to Increase Physical Activity and Reduce Sedentary Behaviour||Healthy Active Living and Obesity Research Group|No|Completed|February 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|83|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02293278||32785|
NCT02293291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWI-2014|Thermal Clinic Treatment in Gulf War Illness|Thermal Clinic Treatment in Gulf War Illness|TCTGWI|American Society Of Thermalism And Climatology Inc|Yes|Recruiting|September 2014|October 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|November 7, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293291||32784|
NCT02302599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-003|Mesenchymal Stem Cells to Treat Type II Diabetes|Mesenchymal Stem Cell Infusion Therapy Between Efficacy and Safety of Chinese Type II Diabetic Subjects of Multicenter, Randomized, Double-blind, Controlled Study|UC-MSCs|Chinese PLA General Hospital|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|60 Years|No|||November 2014|November 26, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02302599||32069|
NCT02320006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstHeilongjiang|Effect of Acupuncture on Incomplete Fallopian Tube Obstructive Infertility: Study Protocol for Trial|||First Affiliated Hospital of Heilongjiang Chinese Medicine University|No|Recruiting|December 2014|||December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|22 Years|42 Years|No|||December 2014|December 18, 2014|December 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320006||30734|
NCT02312934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141584|Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study|||Vanderbilt University|Yes|Recruiting|August 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|35 Years|80 Years|No|||September 2015|November 19, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312934||31276|
NCT02310087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCLjubljana-20140041|Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures|Effect of Oral Administration of Astaxanthin on Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures|Astax-ART|University Medical Centre Ljubljana|Yes|Recruiting|November 2014|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|N/A|No|||November 2015|November 5, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310087||31495|
NCT02310100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10030|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study|TactiCathPAS|St. Jude Medical|No|Active, not recruiting|December 2014|February 2021|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02310100||31494|
NCT02300220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14IC2031|Targeted Retreatment of COPD Exacerbations|Targeted Retreatment of Incompletely Recovered COPD Exacerbations With Ciprofloxacin: a Double-blind, Randomised, Placebo-controlled, Multicentre Phase III Trial||Imperial College London|No|Recruiting|June 2014|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|45 Years|N/A|No|||February 2016|February 15, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300220||32252|
NCT02318654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU106090|Ice Versus EMLA for Pain in Laser Hair Removal|Comparing the Efficacy of Ice Pack Versus Topical EMLA for Pain Control in Laser Axillary Hair Removal: A Randomized Control Trial||Northwestern University|Yes|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318654||30837|
NCT02321007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1073|Study of Placental Function in Healthy and Pathological Pregnancies|Study of Placental Function in Healthy and Pathological Pregnancies||University of Colorado, Denver|No|Recruiting|September 2014|September 2064|Anticipated|September 2064|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1250|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women delivering at term as well as women with pregnancy complications such as        pre-term birth, intrauterine growth restriction, diabetes and obesity will be eligible for        the study.|March 2016|March 18, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02321007||30657|
NCT02321020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACFA2|Follow up of Radiofrequency Maze in Mitral Patients|Sinus Rhythm and Atrial Contractility Recovery After Radiofrequency Maze in Mitral Patients||Centro Cardiologico Monzino||Completed|January 2002|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|168|||Both|N/A|N/A|No|Probability Sample|Patients affected by atrial fibrillation undergoing mitral valve surgery|December 2014|December 18, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02321020||30656|
NCT02300493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108002406|Four Year Weight Change of Cornell Students|||Cornell University|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300493||32231|
NCT02307851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-SIQ-206|Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults|A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults||Novavax|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|400|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307851||31666|
NCT02318901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PembroMab|Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer|A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab|PembroMab|Western Regional Medical Center|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318901||30818|
NCT02318914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052171|A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum|A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum||XOMA (US) LLC|No|Enrolling by invitation|November 2014|||October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318914||30817|
NCT02439567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLEEN-C (JOA-SOF-2015-01)|Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)|Usefulness of Transient Elastography Assessing Liver Fibrosis and Portal Hypertension in Patients With HCV Cirrhosis Treated With New All Oral Antiviral Drugs|SPLEEN-C|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|90 Years|No|||April 2015|May 6, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02439567||21564|
NCT02434848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17302|A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses|A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|August 2015|July 2018|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434848||21926|
NCT02434861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11-5021-C|An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects|An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Warfarin [CYP2C9], Caffeine [CYP1A2], and Dextromethorphan [CYP2D6]) in Healthy Subjects||Tesaro, Inc.|No|Completed|May 2015|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|102|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02434861||21925|
NCT02434874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-00780|Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless Neuromodulation|Randomized, Multi-Center Pivotal Study for Sacral Nerve Stimulation to Treat Refractory Urgency Urinary Incontinence With Wireless Neuromodulation Technology||StimGuard, LLC.|Yes|Not yet recruiting|January 2016|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434874||21924|
NCT02438995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-182|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck|Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck||Northwell Health||Recruiting|May 2015|||May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438995||21607|
NCT02430415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LALI|Laryngoscope-assisted Lightwand Intubation and Cervical Spine Motion|A Randomized Trial on Comparison of Effects of Two Lightwand Intubation Techniques on Cervical Spine Motion: Laryngoscope-assisted vs. Conventional Lightwand Intubation||Seoul National University Hospital|Yes|Not yet recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|22|||Both|18 Years|80 Years|No|||April 2015|April 26, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02430415||22266|
NCT02491112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-LUZB-401|A Randomized Study Evaluating the Safety and Efficacy of Luliconazole Cream in Pediatric Subjects With Tinea Corporis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis||Valeant Pharmaceuticals|No|Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|2 Years|17 Years|No|||September 2015|September 11, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491112||17606|
NCT02491125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52300.068.15|Prebiotics and Metabolism|Effect of Prebiotic Fibre AXOS on Intestinal Health and Functioning||Maastricht University Medical Center|No|Not yet recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02491125||17605|
NCT02439008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EarlyBio-HypoRT-WP3-1504|Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response|Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response||Centre Oscar Lambret|No|Recruiting|September 2015|June 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02439008||21606|
NCT02439021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|653|Effectiveness of the New Perilaryngeal Airway in Comparison With the Laryngeal Mask Airway|Effectiveness of the New Perilaryngeal Airway (CobraPLA™) in Comparison With the Laryngeal Mask Airway (LMA™) to Improve Oropharyngeal Leak Pressure Among Obese and Overweight Patients||Qazvin University Of Medical Sciences||Completed|February 2012|||January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439021||21605|
NCT02429232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312136MIND|A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers|A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers||National Taiwan University Hospital|No|Not yet recruiting|October 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|40 Years|N/A|No|||October 2015|October 25, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02429232||22356|
NCT02430649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostatic Neoplasms-IRE-01|Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms|Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430649||22248|
NCT02430922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-150106|a Physician-inititated Trial Investigating the iVolution Nitinol Stent|EVOLUTION STUDY, a Physician-inititated Trial Investigating the Efficacy of the Self-Expanding iVolution Nitinol Stent for Treatment of Femoropopliteal Lesions||Flanders Medical Research Program|Yes|Recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430922||22228|
NCT02491190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16151|Using Multimedia Digital Health to Enable and Engage Pediatric Inpatients and Their Parents|Using Multimedia Digital Health to Enable and Engage Pediatric Inpatients and Their Parents: A Pilot Study||University of California, San Francisco|No|Not yet recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|N/A|95 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02491190||17600|
NCT02491281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA043X2101|First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement|A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement||Novartis|Yes|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|50 Years|75 Years|No|||March 2016|March 3, 2016|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491281||17593|
NCT02432287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Albert_Einstein|Metformin in Longevity Study|Metformin in Longevity Study|MILES|Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|15|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432287||22123|
NCT02429726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-H2015002|Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion|Recombinant Adenoviral Human p53 Gene With or Without Cisplatin in Treatment of Malignant Pleural - a Phase 2, Double Blinded, Randomized, Active Controlled Study||Shenzhen SiBiono GeneTech Co.,Ltd|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429726||22318|
NCT02429739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorlandet Hospital 2014/1057|Working Memory Training for Children With Dyslexia|Computerized Working Memory Training for Children With Dyslexia||Sorlandet Hospital HF|No|Active, not recruiting|October 2014|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|9 Years|16 Years|No|||April 2015|April 24, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429739||22317|
NCT02314507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-001|Gua Sha for Chronic Low Back Pain in Elderly|Effects of Gua Sha and Hot Pack for Relieving Chronic Low Back Pain in Elderly: A Crossover Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Completed|July 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|60 Years|N/A|No|||March 2015|March 17, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02314507||31156|
NCT02306148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaBiMPH-002|Effects of Foot Strengthening on the Prevalence of Injuries in Long Distance Runners|Effects of a Foot Strengthening Program on the Prevalence of Injuries, Foot Functionality and Health in Long Distance Runners: a Randomized Controlled Trial.||University of Sao Paulo General Hospital|Yes|Recruiting|April 2015|May 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|111|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|March 3, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02306148||31796|
NCT02295878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/11/0077|The Effect of Seaweed Derived Polyphenols on Inflammation and Oxidative Stress in Vivo - The SWAFAX Study|Seaweed Derived Anti-inflammatory Agents and Antioxidants|SWAFAX|University of Ulster|No|Completed|August 2011|March 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02295878||32585|
NCT02310958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ2014-247|Outcome of Laparoscopic Inguinal Herniorraphy in Children|A Single Center, Retrospective Study of the Outcome of Laparoscopic Inguinal Herniorraphy in Children||University Children's Hospital Basel|No|Enrolling by invitation|March 2010|October 2015|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|16 Years|No|Non-Probability Sample|Children aged between 1 day and 16 years who underwent laparoscopic surgical inguinal        hernia repair between March 2010 and March 2014 at a single institution.|December 2014|December 4, 2014|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02310958||31428|
NCT02314923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V920-004|Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)|A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|512|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02314923||31124|
NCT02322047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-1-0025|Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders|Effect of Prazosin and Naltrexone on Personalized Script-Induced Alcohol Craving in Individuals With Alcohol Use Disorders With and Without Comorbid PTSD|PaN|Seattle Institute for Biomedical and Clinical Research|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322047||30577|
NCT02297984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1583-660145|Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke|Changes of Serum Neuroglobin and HIF-1α Concentrations in Early-phase of Acute Ischemic Stroke||Shanghai 6th People's Hospital|No|Completed|October 2013|October 2014|Actual|September 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|42 Years|76 Years|No|Probability Sample|The patient group comprised 24 male and 16 female. Their age ranged from 42 to 76 years.        Locations of infarct, as evidenced by radiologic and neurologic symptoms or signs,        included the territories of the middle cerebral artery (13 cases), the posterior cerebral        artery (9 cases) the anterior cerebral artery (8 cases), vertebrobasilar area (7 cases),        and watershed area (3 cases with cortical and subcortical low densities crossing typical        vascular territories).|October 2015|October 20, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297984|6 Months|32424|
NCT02298257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-085|A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma|A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma|AMC-085|The Lymphoma Academic Research Organisation|No|Recruiting|June 2015|June 2022|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298257||32403|
NCT02306889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102_FENOF_10|Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two -Period, Two -Sequence, Crossover Bioequivalence Study Comparing a Single Oral Dose of Fenofibrate 130 mg Capsules of Ohm Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With Antara® 130 mg Capsules (Containing Fenofibrate 130 mg) of Oscient Pharmaceuticals Corporation USA, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|January 2010|April 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02306889||31740|
NCT02315677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02597|Nasal Intubation Using a Parker Flex-tip Endotracheal Tube Compared to a Nasal RAE Tube|Nasal Intubation Using a Parker Flex-tip Endotracheal Tube With Posteriorly Facing Bevel Compared to a Nasal RAE Tube With Left Facing Bevel: A Randomized Study||University of British Columbia|Yes|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02315677||31066|
NCT02314767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lohja Depression Treatment|A Finnish Community Randomized Psychotherapy Effectiveness Study for Major Depression|A Finnish Community Randomized Psychotherapy Effectiveness Study for Major Depression||Helsinki University Central Hospital|No|Completed|February 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|134|||Both|18 Years|64 Years|No|||December 2014|December 9, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02314767||31136|
NCT02315014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.12.NRC|Daily Protein Intake Distribution and MPS (ARCIII)|Effect of Balanced Daily Protein Distribution Supplemented With Whey Protein on Muscle Protein Synthesis in Overweight Older Men During Calorie Restriction and Exercise (ARC III)||Nestlé|No|Completed|March 2013|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||November 2014|December 10, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02315014||31117|
NCT02303704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|multanic|Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia|Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia and Continuous Controlled Warm Shot Through Vein Grafts During Proximal Ends Anastomosis in Conventional CABG|MACBC|Multan Institute of Cardiology|No|Completed|April 2013|August 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|448|||Both|N/A|N/A|No|||December 2014|December 5, 2014|November 19, 2014||No||No|November 29, 2014|https://clinicaltrials.gov/show/NCT02303704||31984|
NCT02308774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022014-007|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis (PCT)|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis|PCT|University of Texas Southwestern Medical Center|No|Completed|August 2014|October 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples Without DNA|Blood and tissue samples|Both|18 Years|89 Years|No|Non-Probability Sample|Potential subjects will be identified from the investigator's inpatient and outpatient        populations. This is not a treatment study, so subjects participating in other protocols        will also be eligible to participate.|December 2015|December 11, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02308774||31595|
NCT02306941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAP pilot ICBT 2015|Internet-delivered CBT for Functional Abdominal Pain in Adolescents - a Pilot|Internet-delivered Cognitive Behavior Therapy for Functional Abdominal Pain in Adolescents - an Open Pilot.||Karolinska Institutet|No|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|13 Years|17 Years|No|||February 2016|February 22, 2016|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02306941||31736|
NCT02315183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0419|An Observational Case Control Study to Identify the Role of MV and MV Derived Micro-RNA in Post CArdiac Surgery AKI|An Observational Case Control Study to Identify the Role of MV and MV Derived Micro-RNA in Post CArdiac Surgery Acute Kidney Injury: The MaRACAS Study|MaRACAS|University of Leicester|Yes|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|96|Samples Without DNA|Blood and Urine samples are taken at numerous timepoints upto 5 days post cardiac surgery.|Both|16 Years|N/A|No|Non-Probability Sample|The study will be carried out at a large tertiary academic cardiac surgery unit in the UK;        the University Hospitals of Leicester NHS Trust. This unit performs over 1,200 major        cardiac procedures per year, of which 300 are expected to develop acute kidney injury.|December 2014|December 9, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315183||31104|
NCT02322216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-010 (EXC458-C001)|Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects|A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects||Alcon Research|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|383|||Both|10 Years|N/A|No|||October 2015|October 28, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322216||30564|
NCT02322229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA255-P001|Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion|Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)||Alcon Research|No|Active, not recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02322229||30563|
NCT02310802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-OBE001-013|OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI|A Phase 2, Double-blind, Dose-finding, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of OBE001 to Improve Embryo Implantation Following IVF or ICSI|IMPLANT|ObsEva SA|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Female|18 Years|36 Years|No|||December 2015|December 8, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310802||31440|
NCT02308800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092014-016|Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT)|Negative Pressure Wound Therapy as a Drug Delivery System|ADA NPWT|University of Texas Southwestern Medical Center|No|Not yet recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|89 Years|No|||November 2014|December 3, 2014|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308800||31593|
NCT02297776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040114001|Circulating Biomarkers Predict Neurological Outcome After Cardiac Arrest|Circulating Biomarkers Predict Neurological Outcome After Cardiac Arrest|CABNO|Shanghai 10th People's Hospital|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|Samples Without DNA|Plasma samples are to be retained.|Both|14 Years|85 Years|No|Non-Probability Sample|transferred to or hospitalized in the emergency department or other wards of Shanghai        Tenth People's Hospital due to cardiac arrest|November 2014|November 21, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02297776||32440|
NCT02297789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-152|Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea|Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea||Fisher and Paykel Healthcare|Yes|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02297789||32439|
NCT02322632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280-01|Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2010|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322632||30532|
NCT02322645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859146-01|Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study Of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2008|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322645||30531|
NCT02326675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400628|Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant|Randomized Controlled, Open-Label Study on the Use of Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant Patients||University of Florida|No|Recruiting|March 2015|March 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02326675||30221|
NCT02300142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-003-002a|Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study|Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2||Genocea Biosciences, Inc.|Yes|Active, not recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|45|||Both|18 Years|50 Years|No|||December 2015|December 10, 2015|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02300142||32258|
NCT02300155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000005135|Improving Multivitamin Supplementation to Pregnant Women|Improving Multivitamin Supplementation to Pregnant Women||The Hospital for Sick Children|Yes|Completed|October 2004|January 2008|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1370|||Female|18 Years|50 Years|No|||November 2014|November 21, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300155||32257|
NCT02294916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/25|Pediatric Intubation by Nurses|Comparison of Pentax-AWS Airwayscope, Intubrite, AirTraq and Miller Laryngoscope for Tracheal Intubation by Nurses During Chest Compression in a Pediatric Manikin: A Randomised Crossover Trial.|NURS_ETI|International Institute of Rescue Research and Education|Yes|Recruiting|November 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 16, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02294916||32659|
NCT02294929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO-LPAF|Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation|Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Longstanding Persistent Atrial Fibrillation (the CRYO-LPAF Study)|CRYO-LPAF|Uppsala University Hospital|No|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|70 Years|No|||November 2014|November 16, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294929||32658|
NCT02294942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHRN1201|Extended-Release RANCAD in the Patients With Stable Angina Pectoris|A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Effects of add-on RANCAD on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.||TSH Biopharm Corporation Limited|Yes|Recruiting|October 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|20 Years|N/A|No|||November 2015|November 3, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294942||32657|
NCT02294955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001384-11|Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)|Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up.|CAPTAF|Uppsala University Hospital|Yes|Active, not recruiting|May 2008|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|30 Years|70 Years|No|||November 2014|November 19, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294955||32656|
NCT02313402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P131101|A New Eye-based Communication Device for ALS Patients|A Pilot Study Assessing a New Eye-writing Device Allowing Cursive Writing With Smooth Pursuit Eye Movements in Subjects With ALS|ELY-SLA|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|65 Years|No|||July 2015|November 25, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313402||31240|
NCT02313636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaBlaCa-7|Narrow Band Imaging in Flexible Cystocopy|Narrow Band Imaging in Flexible Cystocopy - DaBlaCa-7|DaBlaCa-7|Aarhus University Hospital|Yes|Completed|May 2014|November 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|892|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing flexible cystoscopy because of haematuria or previous NMIBC|December 2015|December 28, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313636|1 Day|31222|
NCT02317211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXYZM-1|Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus|Effect of Purified Anthocyanin on Oxidative Stress and Glycemic Control in Subjects With Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial||Sun Yat-sen University|Yes|Completed|February 2014|September 2014|Actual|September 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|25 Years|65 Years|No|||December 2014|November 16, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02317211||30948|
NCT02295852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Increasing Calcium Dietary Intake Helps to Control Blood Presure and Body Weight|Effects of Changes in Calcium Dietary Intake on Blood Pressure and Body Weight Control||Federico II University|Yes|Not yet recruiting|December 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|70 Years|No|||November 2014|November 17, 2014|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02295852||32587|
NCT02296125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00007|AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.|FLAURA|AstraZeneca|Yes|Recruiting|December 2014|October 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|130 Years|No|||February 2016|February 17, 2016|October 22, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296125||32566|
NCT02317432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG046149-01A1|Building Community Capacity for Disability Prevention for Minority Elders (Positive Minds - Strong Bodies)|Building Community Capacity for Disability Prevention for Minority Elders||Cambridge Health Alliance|No|Recruiting|July 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02317432||30931|
NCT02308982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2014/05|Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis|A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis|IgNiTE|University of Oxford|Yes|Not yet recruiting|August 2015|February 2020|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|308|||Both|6 Weeks|16 Years|No|||June 2015|June 29, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02308982||31580|
NCT02308995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lap.cystectomy.barbed|Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma|Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma . A Randomized Controlled Study||Aljazeera Hospital|Yes|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|55 Years|No|||January 2016|January 28, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02308995||31579|
NCT02295930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3306|Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient|Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients|MACBETH|Gruppo Oncologico del Nord-Ovest|Yes|Completed|October 2011|||March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|75 Years|No|||March 2015|March 11, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02295930||32581|
NCT02316613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20248|Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)|OLYMPE - Prospective Cohort Study on the Management of Patients With Relapsed Follicular Lymphoma||Hoffmann-La Roche||Completed|February 2007|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|260|||Both|18 Years|N/A|No|Non-Probability Sample|Recruitment of approximately 90 physicians who treat patients with follicular        non-Hodgkin's lymphoma to actively participate in this observational study. Patients with        relapsed or refractory follicular non-Hodgkin's lymphoma (World Health Organization grade        1-3) and requiring treatment are to be enrolled prospectively. Subgroup of interest:        patients receiving MabThera® (rituximab) maintenance therapy.|January 2016|January 28, 2016|November 28, 2014||No||No|November 18, 2015|https://clinicaltrials.gov/show/NCT02316613||30994|
NCT02312115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140378|Delayed Renal Allograft Function and Furosemide Treatment|DRAFFT Trial: Delayed Renal Allograft Function and Furosemide Treatment: A Randomized Prospective Double-blinded Placebo-controlled Clinical Pilot Trial|DRAFFT|Loma Linda University|Yes|Not yet recruiting|September 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312115||31339|
NCT02306369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ibs 13-17 år 2013|Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents|Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents - a Randomized Controlled Study||Karolinska Institutet|No|Active, not recruiting|November 2013|August 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|13 Years|17 Years|No|||February 2016|February 22, 2016|September 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02306369||31779|
NCT02301559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04008402357J|The Influence of the Method Pilates in Women With Primary Dysmenorrhea|The Influence of the Method Pilates in Life Quality, Intensity of Pain and Flexibility of Women With Primary Dysmenorrhea||Universidade Estadual do PiauÍ|No|Recruiting|September 2014|December 2014|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02301559||32149|
NCT02301572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711009544|Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course|Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course||Weill Medical College of Cornell University|No|Active, not recruiting|August 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|750|||Both|N/A|N/A|No|Non-Probability Sample|Patients with MS.|November 2014|November 21, 2014|August 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02301572||32148|
NCT02316392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6004|Imaging and Understanding BOS in Lung Transplantation|Imaging and Understanding BOS in Lung Transplantation||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|December 2014|December 2027|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|Biopsies of transplanted and explanted lung tissue|Both|1 Year|25 Years|No|Non-Probability Sample|Subjects who have had or are scheduled for lung transplant|February 2015|August 3, 2015|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316392||31011|
NCT02319759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105964|Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)|A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis||Janssen Research & Development, LLC|Yes|Recruiting|March 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319759||30753|
NCT02295787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014D006212|Intranasal Ketamine for Late-Life Depression and Suicidal Ideation|Intranasal Ketamine for Late-Life Depression and Suicidal Ideation||Massachusetts General Hospital|Yes|Withdrawn|July 2015|||July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|65 Years|N/A|No|||July 2015|July 22, 2015|November 18, 2014|Yes|Yes|No funding|No||https://clinicaltrials.gov/show/NCT02295787||32592|
NCT02300389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPOPROST|Randomized, Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated Combined With Androgen Deprivation Therapy in a High Risk Group of Prostate Cancer Patients|Randomized, Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated in a High Risk Group of Prostate Cancer Patients|HYPOPROST|The Greater Poland Cancer Centre|Yes|Recruiting|September 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|465|||Male|40 Years|75 Years|No|||November 2014|November 24, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02300389||32239|
NCT02293343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Histamine profile 1|24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance|24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance: Correlations Between Subjective Affliction and Measured Histamine Parameter||University of Erlangen-Nürnberg Medical School|No|Recruiting|October 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|55|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|healthy subjects, patients with high IgE level and patients with afflictions, but no high        IgE level|November 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293343||32780|
NCT02320955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZH-2014-0370|Swiss Prospective Autologous Bone Flap Resorption Study|Swiss Prospective Autologous Bone Flap Resorption Study|SPARS|University of Zurich|No|Recruiting|January 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|99 Years|No|Non-Probability Sample|All patients undergoing reimplantatioon of cryoconserved bone flaps after craniectomy|December 2015|December 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320955||30661|
NCT02312687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX023-CL203|Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)|A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)||Ultragenyx Pharmaceutical Inc|No|Enrolling by invitation|December 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||April 2015|April 6, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312687||31295|
NCT02306135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15036|Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer|Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|March 2015|||February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples With DNA|Tumor biopsy and surgical specimens obtained through routine clinical procedures and      archived in the institution's Pathology tissue bank will be used for DNA extraction for      genetic analysis.      Blood samples collected prospectively will be used to extract plasma and leukocytes, which      will be used to extract DNA for genetic analysis.|Both|18 Years|100 Years|No|Probability Sample|Patients treated with everolimus for any cancer type.|January 2016|January 20, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306135|2 Years|31797|
NCT02295891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00036743|Miradry Treatment for Focal Axillary Hyperhidrosis|Microwave Energy-induced Thermolysis of Axillary Apocrine Glands and Hair Follicles Will Result in Improvement of Secondary Psychopathology Related to Hyperhidrosis.|MiraDry Tx|Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|29 Years|No|||November 2014|November 19, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295891||32584|
NCT02295904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2014-0414|Video Analysis of Vaginal Deliveries|Video Analysis of Vaginal Deliveries to Evaluate the Impact of the Support of the Perineum||University of Zurich|No|Active, not recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women|December 2015|December 9, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02295904||32583|
NCT02295917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074-13-MMC|Computerized Evaluation of the Endometrial Myometrial Junction During a Natural Menstrual Cyle.|The Investigators Aim to Evaluate the Width of the Endometrial Myometrial Zone in Participants During Natural Menstrual Cycle by Using Specific Computerized Application on 3 Dimensions Sonographic Images of Their Uteri|EMJ|Meir Medical Center|Yes|Not yet recruiting|December 2014|July 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|patients referred for transvaginal sonography|November 2014|November 24, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295917||32582|
NCT02321163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRF12131991|Electrical Stimulation for Attenuating Muscle Atrophy|A New Paradigm of Neuromuscular Electrical Stimulation in Attenuating Muscle Atrophy: a Randomised Controlled Trial||The Hong Kong Polytechnic University|Yes|Recruiting|February 2016|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|105|||Both|35 Years|80 Years|No|||February 2016|February 24, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02321163||30645|
NCT02325180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA620|Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia|Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes||London School of Hygiene and Tropical Medicine|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Both|6 Months|N/A|No|||September 2015|September 1, 2015|December 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325180||30336|
NCT02325193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM640G|"MiniMed 640G System" User Evaluation With the Question of Reducing the Rate of Hypoglycemia|Prevention of Hypoglycaemia Using the Minimed®640G System||Kinderkrankenhaus auf der Bult|No|Completed|March 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|1 Year|21 Years|No|Probability Sample|-  patients with type 1 diabetes          -  CSII since 3 month at least|March 2016|March 2, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325193||30335|
NCT02307682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTH258-C001|Efficacy and Safety of RTH258 Versus Aflibercept|A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration||Alcon Research|Yes|Recruiting|December 2014|April 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1600|||Both|50 Years|N/A|No|||November 2015|November 18, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307682||31679|
NCT02307695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-SR-123|The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes|The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes||Nanjing Medical University|Yes|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|12 Years|65 Years|No|||July 2015|July 23, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02307695||31678|
NCT02307708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0043|Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy|Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy|TARCI|Nantes University Hospital|No|Active, not recruiting|December 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|74|||Both|18 Years|75 Years|No|||December 2014|December 1, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02307708||31677|
NCT02322281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-020 (TIGER-3)|TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy|TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy||Clovis Oncology, Inc.|Yes|Recruiting|February 2015|December 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322281||30559|
NCT02322294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14GGHF|Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight|A Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Effects of 8 Weeks Use of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight as Compared to Placebo|14GGHF|KGK Synergize Inc.|No|Recruiting|January 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322294||30558|
NCT02317198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAACS01|Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly|Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly|POPular AGE|St. Antonius Hospital|Yes|Recruiting|June 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|70 Years|N/A|No|||November 2015|November 20, 2015|October 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317198||30949|
NCT02293551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15626|A Study of Lispro Formulations in Healthy Participants|Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations||Eli Lilly and Company|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|54|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|November 13, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293551||32764|
NCT02293564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052161|Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand|An Open-label Safety Extension Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand||XOMA (US) LLC|No|Completed|March 2013|||January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|312|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293564||32763|
NCT02307786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0414B|Long Term Outcomes in β Thalassemia Major|Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|150|||Both|N/A|30 Years|No|Non-Probability Sample|The study population will be divided into the following groups:          -  Recipients that are >1 year post allogeneic HSCT from any donor          -  Patients ('Controls') enrolled on the Thalassemia Longitudinal Cohort study and/or             the Thalassemia Clinical Registry Network (TCRN) and continue to receive supportive             care|December 2014|December 3, 2014|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02307786||31671|
NCT02321761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-12-LOE|Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury|Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury||Loewenstein Hospital|Yes|Recruiting|June 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|No|||March 2016|March 2, 2016|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321761||30599|
NCT02325232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167|Enteroscopy for Early Diagnosis of Tumors in Celiac Disease|A Capsule Endoscopy and Double Balloon Enteroscopy Sequential Approach for Early Detection of Gastrointestinal Tumors in Celiac Disease: a Prospective Trial||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|February 2012|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|August 26, 2015|December 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325232||30332|
NCT02313467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-PDT2|Topical PDT Cream Without Irradiation Source in the Acne Treatment|Topical Application of 1.5% Butenyl ALA Without Light Source Irradiation in the Treatment of Acne: a Double Blinded Randomized Controlled Trial.||Seoul National University Hospital|Yes|Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313467||31235|
NCT02301741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR064430-01A1|Using an Interactive Game to Reduce Fear and Increase Spine Motion in Low Back Pain|Using an Interactive Game to Reduce Fear & Increase Spine Motion in Low Back Pain||Ohio University|Yes|Enrolling by invitation|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|50 Years|No|||April 2015|April 22, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02301741||32135|
NCT02301754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVAC1-CT-101|INVAC-1 Anti-Cancer hTERT DNA Immunotherapy|A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer||Invectys|Yes|Recruiting|November 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02301754||32134|
NCT02307864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106355|Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Multiple Dose, Four Way Crossover Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Subjects at Therapeutic and Supratherapeutic Dose Levels||Janssen Scientific Affairs, LLC|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307864||31665|
NCT02321813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUZ-QL-CRC-14|Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients|Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Protocol of a Randomised Clinical Trial in Colorectal Cancer Patients|DIQOL|Tumorzentrum Regensburg e.V.|Yes|Active, not recruiting|January 2014|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321813||30595|
NCT02311270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMDC7412|Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation|Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation||University of South Florida|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients enrolled in the NAMDC portion of the RDCRN Contact Registry|December 2014|December 4, 2014|September 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02311270|1 Day|31404|
NCT02432352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH096646|Our Family Our Future: Acceptability and Feasibility Study of a Family Prevention Program for HIV Risk and Depression|Our Family Our Future: Family Prevention of HIV Risk and Depression in HIV-endemic South Africa||Brown University|No|Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|124|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|October 16, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02432352||22118|
NCT02432365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGOG14-001/TGOG1008|Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy|Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy||Chang Gung Memorial Hospital|Yes|Recruiting|February 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||April 2015|May 1, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02432365||22117|
NCT02440646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REALITY|Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography|Natural History of Atherosclerosis Within the Concept of the Glagovian Artery Remodeling in REAL-world Chest Pain Population Underwent Computed Tomography Angiography and 3D Quantitative Coronary Angiography: Clinical potentIal and safeTY|REALITY|Ural Medical University|Yes|Terminated|May 2015|August 2020|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1080|Samples Without DNA|Blood samples to examine level of thyroid hormones and kidney function|Both|21 Years|N/A|No|Probability Sample|All-incomers of the Chest Pain Outpatient Center, CPOC (Ural Institute of Cardiology,        Yekaterinburg, Russia) with or without acute coronary syndrome underwent CTA and/ or 3D        QCA with or without further PCI.|December 2015|December 26, 2015|May 7, 2015|Yes|Yes|The study was terminated under the political pressure of the Federal Security Service of the    Russian Federation (FSB) and the Russian Society of Cardiology|No||https://clinicaltrials.gov/show/NCT02440646|5 Years|21481|
NCT02491957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0539|Impact of LOFT Therapy™ on Breast Cancer Survivors|Impact of LOFT Therapy™ on Breast Cancer Survivors: A Pilot Study||Indiana University|Yes|Recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491957||17541|
NCT02491970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT14-KR-401|Study to Evaluate Small Airway Parameters of Fluticasone/Formoterol (Flutiform®) Compared to Fluticasone/Salmeterol in Asthma Patients|A Single-blind, Randomized, Active-controlled, Multi-center and Phase IV Study to Evaluate the Small Airway Parameters of Fluticasone/Formoterol (Flutiform®) Compared to Fluticasone/Salmeterol in Asthma Patients|RECONFFIRM|Mundipharma Korea Ltd|Yes|Recruiting|June 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|19 Years|N/A|No|||July 2015|July 3, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02491970||17540|
NCT02491983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedOPP67|Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer|A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer|PARSIFAL|MedSIR|No|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Female|18 Years|N/A|No|||August 2015|September 15, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491983||17539|
NCT02427867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRINCE/43/OSR|Ischaemic PReconditioning In Non Cardiac surgEry|Ischaemic PReconditioning In Non Cardiac surgEry|PRINCE|Università Vita-Salute San Raffaele||Recruiting|April 2015|May 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1100|||Both|50 Years|N/A|No|||March 2016|March 9, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02427867||22461|
NCT02428933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC nr 2013_107|Dopaminergic Effects on Brown Adipose Tissue|Dopaminergic Effects on Brown Adipose Tissue: the DEBAT Trial|DEBAT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428933||22379|
NCT02428946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49417.018.14 METC 2014/147|Bromocriptine and Insulin Sensitivity|Bromocriptine and Insulin Sensitivity in Lean and Obese Subjects|BIS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|October 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|October 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428946||22378|
NCT02435108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03-117-003|A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy|A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy||Samsung Medical Center|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02435108||21906|
NCT02492035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20805|Lifestyle Intervention for Treating Systemic Hypertension in Primary Care Setting|Lifestyle Intervention for Treating Systemic Hypertension in Primary Care Setting||Laval University||Recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|90 Years|No|||July 2015|July 2, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02492035||17535|
NCT02428140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00051629|Post-Embolic Rhythm Detection With Implantable Versus External Monitoring|Post-Embolic Rhythm Detection With Implantable Versus External Monitoring: Pilot and Feasibility Study|PERDIEM|University of Alberta|No|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02428140||22440|
NCT02435407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB file # 14-511|The Sequential Oral Sensory Approach for Limited Food Repertoire in Children With Autism Spectrum Disorder|The Sequential Oral Sensory (SOS) Intervention in Treating Children With Autism Spectrum Disorder and Limited Food Repertoire|SOS|Holland Bloorview Kids Rehabilitation Hospital|No|Active, not recruiting|January 2015|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Years|8 Years|No|||May 2015|September 28, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02435407||21883|
NCT02492100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-158|A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors|A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors||Massachusetts General Hospital|No|Recruiting|June 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02492100||17530|
NCT02436876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBN-101-201|Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Osteosynthesis Sites|Phase 2a Randomized, Single-Blind, Placebo-Controlled, 24-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Osteosynthesis Sites||Microbion Corporation|Yes|Not yet recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|75 Years|No|||May 2015|May 6, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436876||21770|
NCT02436889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15553|Treatment of Incontinence Without Memory Problems||TRIUMPH|University of California, San Francisco|Yes|Not yet recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436889||21769|
NCT02433704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061712|Preoperative Antibiotic Dosing for Total Knee Arthroplasty|Preoperative Antibiotic Dosing for Total Knee Arthroplasty: Intraosseous Versus Systemic Infusion||Duke University|No|Withdrawn|May 2015|June 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|90 Years|No|||November 2015|November 11, 2015|April 10, 2015|Yes|Yes|Difficulty with enrollment|No||https://clinicaltrials.gov/show/NCT02433704||22014|
NCT02317913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kd2008-2012|Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012|Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012||Children's Hospital of Fudan University|Yes|Completed|April 2013|January 2016|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2402|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients with KD diagnosed during January 2008 through December 2012 in Shanghai|March 2015|March 8, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02317913||30894|
NCT02317926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397401-1|Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism|||Walter Reed National Military Medical Center||Recruiting|May 2015|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02317926||30893|
NCT02297711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03430|TEP Versus Open Minimal Suture Repair for the Sportsman's Groin|Total ExtraPeritoneal (TEP) Versus Open Minimal Suture Repair for Treatment of Sportsman's Hernia/Athletic Pubalgia: A Randomized Multi-center Trial.|SPORT|Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|No|||November 2014|November 19, 2014|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02297711||32445|
NCT02300207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL-2013163|Electroacupuncture is Effective in Cardiac Deconditioning Induced by Head-down Bed Rest|Electracupuncture Could Ameliorate Orthostatic Intolerance After Weightlessness by Improving Cardiovascular Function||Fourth Military Medical University|No|Completed|July 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|20 Years|28 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300207||32253|
NCT02318641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26-046|Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap|Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap||Kagawa University|No|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy eyes and eyes with various chorioretinal disease.|September 2015|September 1, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318641||30838|
NCT02310295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12029-2008|Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema|Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA)|IBeTA|University of Sao Paulo|No|Completed|January 2009|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02310295||31479|
NCT02303587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHlung001|Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)|Low Dose Versus High Dose Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia : a Multicenter Randomized Blinded Trial||Beijing Children's Hospital|Yes|Not yet recruiting|November 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|630|||Both|N/A|17 Years|No|||November 2014|November 25, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02303587||31993|
NCT02308410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicort Bergman Tourniquet|Effect of Tourniquet Application on Postoperative Functional Outcome Following Total Knee Arthroplasty|Effect of Tourniquet Application on Postoperative Functional Outcome Following Total Knee Arthroplasty; a Prospective Cohort Study||Medicort Sports & Orthopedic Care|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|99|||Both|50 Years|75 Years|No|Probability Sample|In a prospective cohort design, consecutive series of patients who underwent primary        unilateral total knee arthroplasty in the Bergman Clinic Naarden, the Netherlands were        investigated.|December 2014|December 2, 2014|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308410|8 Weeks|31623|
NCT02319811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MenisCryo-001|Cryopreserved Human Meniscus Transplantation|Meniscus Transplantation in Symptomatic Patients Under Fifty Years of Age: Survivorship Analysis||Cincinnati Sportsmedicine Research and Education Foundation|No|Active, not recruiting|November 1995|November 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|76|||Both|14 Years|49 Years|No|Non-Probability Sample|Minimum age: 14 Years Maximum age: 49 Years Gender: Both Accepts Healthy Volunteers: No        Patients post-meniscectomy, symptomatic with activities, early cartilage degeneration in        affected tibiofemoral compartment.|December 2014|December 15, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02319811||30749|
NCT02319239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETL R14009|Prostate Cancer Stereotactic Radiotherapy|Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.|ESKO|Tampere University Hospital|No|Recruiting|May 2014|May 2018|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Male|30 Years|N/A|No|||December 2014|December 18, 2014|May 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02319239||30792|
NCT02308787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5052|Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions|Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for Platelet Depletion Procedures.|PLTD|Terumo BCT|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have undergone platelet depletion via the Spectra Optia System and who were        likely to have had blood disorders, such as essential thrombocythemia, a        myeloproliferative disease, or reactive (secondary) thrombocytosis.|May 2015|May 6, 2015|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308787||31594|
NCT02295111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SS/1022|Electro-acupuncture (EA) and Chronic Pelvic Pain (CPP)|The BMEA Study: The Impact of Meridian Balanced Method (BM) Electro-acupuncture (EA) Treatment on Women With Chronic Pelvic Pain (CPP): A Three-arm Randomized Controlled Pilot Study.|BMEA|University of Edinburgh|No|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Female|18 Years|N/A|No|||November 2015|November 10, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02295111||32644|
NCT02308449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/SC/0439|Iron Status and Human Metabolism|Effects of Endogenous Iron Status and Intravenous Iron on Human Skeletal Muscle Metabolism at Rest and During Exercise||University of Oxford|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02308449||31620|
NCT02319161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-130-14|Comparison of Calcium Channel Blockers and Beta Blockers on Tourniquet-induced Hypertension During Intravenous Regional Anesthesia|Comparison of Calcium-channel Blockers and Beta Blockers in Tourniquet-induced Hypertension During Intravenous Regional Anesthesia||Ankara University|No|Completed|June 2014|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|50|||Both|45 Years|55 Years|No|Probability Sample|The files of patients who were operated on under intravenous regional anesthesia (IVRA) in        orthopedics clinics between January 2009 and January 2010 were retrospectively        investigated. A total of 312 patients, 164 patients with carpal tunnel syndrome and 148        patients with trigger finger were operated on under IVRA. Out of 164 patients who were        operated on due to carpal tunnel syndrome, 50 patients in which either calcium channel        blockers or beta blockers were used for treatment of critical blood pressure increase        after tourniquet inflation and in which whole data were obtained, were included in the        study.|December 2014|December 13, 2014|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02319161||30798|
NCT02310815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-13-003|ReSure Sealant Post Approval Study|ReSure Sealant Post-Approval Study: A Registry Evaluation of ReSure Sealant for Specified Adverse Ocular Events After Sealing Corneal Incisions in Patients Undergoing Clear Corneal Cataract Surgery|Clinical PAS|Ocular Therapeutix, Inc.|No|Active, not recruiting|December 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|624|||Both|22 Years|N/A|No|Non-Probability Sample|Patients treated with ReSure Sealant following cataract surgery|February 2016|February 10, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310815||31439|
NCT02315027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005950|Mesenchymal Stem Cell Therapy in Multiple System Atrophy|Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History||Mayo Clinic|Yes|Active, not recruiting|October 2012|June 2018|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|30 Years|80 Years|No|||July 2015|July 29, 2015|October 31, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315027||31116|
NCT02295358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0235|The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface|The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface||University of Colorado, Denver|No|Withdrawn|November 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|40 Years|89 Years|No|Non-Probability Sample|Diagnosis of Ocular Hypertension or Open Angle Glaucoma of mild to moderate severity, with        or without previously diagnosed dry eye syndrome, who are currently on monotherapy with a        prostaglandin analog. Age 40-89 of either gender, of any race/ethnicity|July 2015|July 8, 2015|November 13, 2014|Yes|Yes|Project never got initiated|No||https://clinicaltrials.gov/show/NCT02295358||32625|
NCT02304653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-132020|Acute Appendicitis: The Influence of C-reactive Protein and Leucocytes on Clinical Decision-making|Acute Appendicitis: The Influence of C-reactive Protein and Leucocytes on Clinical Decision-making||Odense University Hospital|Yes|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|226|||Both|15 Years|N/A|No|Non-Probability Sample|Acute abdominal pain with the suspicion of acute appendicitis|April 2015|April 30, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304653|30 Days|31911|
NCT02304666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-33|Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.|Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis|VANIN|Assistance Publique Hopitaux De Marseille|No|Recruiting|November 2014|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304666||31910|
NCT02312895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159-14|Comparing Dry Needling to Manual Therapy for Patients With Mechanical Low Back Pain|Randomized Controlled Trial Comparing the Use of Dry Needling to Manual Therapy for Patients With Mechanical Low Back Pain.||Youngstown State University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02312895||31279|
NCT02313155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-850/CPH-002|Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults|A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects||Takeda|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 5, 2014||No||No|January 20, 2016|https://clinicaltrials.gov/show/NCT02313155||31259|
NCT02311322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150022|Genetic Causes of Growth Disorders|Genetic Causes of Growth Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 2014|October 2024|Anticipated|October 2024|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|800|||Both|N/A|80 Years|No|||October 2015|October 7, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02311322||31400|
NCT02304861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|visco07012eit|Viscoat Versus Visthesia. A Comparative Study of Post-cataract Endothelial Cell Loss|Viscoat Versus Visthesia. A Comparative Study of Post-cataract Endothelial Cell Loss||Democritus University of Thrace|Yes|Completed|January 2014|November 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|80|||Both|55 Years|85 Years|No|||November 2014|December 1, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02304861||31895|
NCT02306512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140210|Mohs and Immunofluorescence for Malignant Melanoma In Situ|Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence||University of Miami|No|Withdrawn|June 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 27, 2014|No|Yes|PI is leaving the University of Miami|No||https://clinicaltrials.gov/show/NCT02306512||31769|
NCT02317640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOD SC130243|TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males|Testosterone Replacement Therapy in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males.||Kessler Foundation|Yes|Not yet recruiting|January 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Male|18 Years|58 Years|No|||December 2015|December 9, 2015|December 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317640||30915|
NCT02298790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK099512|Effect of Dietary Habits on Metabolic Health|Effect of Dietary Habits on Metabolic Health||Brigham and Women's Hospital|No|Recruiting|November 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298790||32362|
NCT02299908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP 1691514|Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial|Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial||Universidad de Caldas|No|Not yet recruiting|November 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299908||32276|
NCT02308228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG046920-01A1|Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults|Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults||University of Kentucky|Yes|Recruiting|September 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 13, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02308228||31637|
NCT02308241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-211|Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies|A Pilot Study of Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|December 2014|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308241||31636|
NCT02317887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150038|Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis|A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis||National Institutes of Health Clinical Center (CC)||Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|November 11, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317887||30896|
NCT02318173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIS-2014-009|Dilapan-S/Dilasoft E-Registry in Induction of Labor|International Observational E-Registry on the Use of Dilapan-S / Dilasoft Osmotic Dilators for Cervical Ripening Prior to Labour Induction|DSREGISTRYIL|Medicem International CR s.r.o.|No|Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|N/A|N/A|No|Probability Sample|All the patients in whom the use of osmotic dilators Dilapan-S or Dilasoft is indicated by        the Investigator after a thorough Medical examination will be included in the study unless        that the patient disagree.|December 2014|December 11, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318173||30874|
NCT02306655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Perugia|Coital Incontinence: Incidence and Quality of Life Impact.|Coital Incontinence: Incidence and Quality of Life Impact.||University of Roma La Sapienza|No|Recruiting|October 2014|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female patients with sexual activity and with stable relationship for at least six months|December 2014|December 3, 2014|November 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02306655||31758|
NCT02306668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46093-B|Ocular Surface Dry Eye Microbiome|Microbiome Analysis of the Ocular Surface in Dry Eye Disease||University of Washington|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Conjunctival swabs|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We will recruit 40 subjects from University of Washington Medicine Eye Institute with        ocular surface discomfort consistent with dry eye syndrome, and 40 control subjects|December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306668||31757|
NCT02296138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.19|Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.|A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]||Boehringer Ingelheim||Active, not recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|7800|||Both|40 Years|N/A|No|||March 2016|March 14, 2016|November 19, 2014||||No||https://clinicaltrials.gov/show/NCT02296138||32565|
NCT02319512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1818111|Effects of Chewing Gum Against Postoperative Ileus|Effects of Chewing Gum Against Postoperative Ileus After Pancreaticoduodenectomy - a Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|Yes|Terminated|January 2012|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|December 7, 2014||No|Due to a radical change in postoperative care as well as surgical technique.|No||https://clinicaltrials.gov/show/NCT02319512||30771|
NCT02321774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-14-6485|Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment|Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment||Scripps Translational Science Institute|No|Completed|November 2014|May 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|53|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be made up of 50 adult men and women who are in general good        health. Individuals will be recruited locally through fliers, word of mouth and email        blasts to the Scripps community.|May 2015|May 19, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321774||30598|
NCT02316197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR100036-001|Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia|A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia||Merck KGaA|No|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02316197||31026|
NCT02296385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.16.NRC|Genotype-related Effects of PUFA|Response to PUFA Intervention According to PPAR Genotypes||Nestlé|No|Completed|June 2012|August 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|200|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02296385||32546|
NCT02296632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036773|Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study|Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study and Preliminary Validation Effort||Cedars-Sinai Medical Center|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with rheumatoid arthritis who are candidates to undergo treatment with the drug        etanercept.|August 2015|August 18, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296632||32527|
NCT02301793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00043860|Educating Nurses About Venous Thromboembolism (VTE) Prevention|Educating Nurses About Venous Thromboembolism Prevention||Johns Hopkins University|No|Active, not recruiting|July 2014|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|900|||Both|N/A|N/A|No|||November 2015|November 16, 2015|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02301793||32131|
NCT02319681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075912|Reminiscence, Anxiety and Early Alzheimer's Disease|Reminiscence, Anxiety and Early Alzheimer's Disease||Emory University|No|Withdrawn|January 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|December 15, 2014||No|PI relocated to UNCP; Study is not being transferred|No||https://clinicaltrials.gov/show/NCT02319681||30759|
NCT02326974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-409|T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA|The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting||Dana-Farber Cancer Institute|Yes|Recruiting|December 2014|April 2022|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02326974||30199|
NCT02298062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-LF|Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial|Infliximab for Kawasaki Disease Patients Resistant to Intravenous Immunoglobulin : a Multicentre, Prospective, Randomised Trial||Fudan University|Yes|Completed|January 2013|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|2 Months|12 Years|No|||December 2014|February 2, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02298062||32418|
NCT02310217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMB03|Validation of New Tools for the Assessment of Cognitive Functions and Connectivity Network in Hypertensive Patients|Validation of New Tools for the Assessment of Cognitive Functions and Connectivity Network in Hypertensive Patients||Neuromed IRCCS||Not yet recruiting|February 2015|||June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|160|||Both|40 Years|65 Years|No|Probability Sample|Patients will be selected from the Department of Angiocardioneurology and Translational        Medicine of the IRCCS Neuromed, according to specific inclusion criteria. Approximatey 80        subjects per group, aged between 40 and 65 years, will be included in the study.|February 2015|February 26, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02310217||31485|
NCT02310230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-281|An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy|An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy||University of Vermont|No|Recruiting|September 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|21 Years|N/A|No|||March 2016|March 8, 2016|September 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310230||31484|
NCT02310243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 23-14|Study of Palbociclib in MLL-rearranged Acute Leukemias|Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1||University of Ulm|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310243||31483|
NCT02317965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-100|Non-Invasive Screening for Fetal Aneuploidy|A Prospective Clinical Study to Evaluate a Novel Non-invasive Prenatal Screening Method for Characterizing Fetal Whole Chromosome Aberrations and Other Major Defects and Deletions Found in the Maternal Blood.||Progenity, Inc.|No|Recruiting|March 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|Samples With DNA|plasma, PBMCs|Female|18 Years|54 Years|No|Non-Probability Sample|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will        receive the fetal FISH and/or karyotype results from the procedure.|October 2015|October 19, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02317965||30890|
NCT02309697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0332-0001|Neurodevelopmental Outcomes of Preterm and Term Children|Neurodevelopmental Outcomes of Preterm and Term Children||Icahn School of Medicine at Mount Sinai|No|Terminated|January 2015|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1|||Both|6 Months|42 Months|Accepts Healthy Volunteers|Non-Probability Sample|200 children born on or after January 1, 2011 at Mount Sinai or admitted to the Mount        Sinai Hospital for newborn care.|January 2016|January 13, 2016|December 3, 2014||No|Study goals rolled into a broader study|No||https://clinicaltrials.gov/show/NCT02309697||31525|
NCT02300779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMEPREP/PSM/2014|Diet for Colonoscopy Preparation in Diabetic Patients|Randomized Clinical Trial on the Efficacy of an Adapted Bowel Preparation for Diabetic Patients Undergoing a Colonoscopy. DIMEPREP Study|DIMEPREP|Parc de Salut Mar|No|Completed|December 2014|October 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300779||32209|
NCT02310490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermAvance DA-13-007|DermaVeil Versus Sculptra for the Treatment of Nasolabial Folds Wrinkles|A Controlled, Randomized, Within-subject, Multi-center Prospective Clinical Trial of DermaVeil (Injectable Poly-L-lactic Acid) Versus SCULPTRA® Aesthetic (Injectable Poly-L-lactic Acid) in the Treatment of Nasolabial Fold Wrinkles.||DermAvance|No|Recruiting|December 2014|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310490||31464|
NCT02310750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7931001|A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation|A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841||Pfizer|No|Completed|November 2014|February 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02310750||31444|
NCT02312947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0047-14-HYMC|Coblation Versus Cold Adenoidectomy -Safety and Efficiency|Coblation Versus Cold Adenoidectomy -Safety and Efficiency||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Months|10 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|December 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312947||31275|
NCT02296970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14020682|An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence|An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence||University of Pittsburgh|Yes|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 or older with the clinical diagnosis of BCC|January 2016|January 5, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02296970||32502|
NCT02296983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTREC 71-14|A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.||University of Oxford|Yes|Active, not recruiting|December 2014|September 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296983||32501|
NCT02295189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SanAntonioMMC|Ketorolac Versus Triamcinolone Knee Injections for Osteoarthritis|Ketorolac Versus Triamcinolone Intra-articular Knee Injections for the Treatment of Osteoarthritis. A Prospective, Double-Blinded Randomized Trial||San Antonio Military Medical Center|No|Completed|January 2013|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02295189||32638|
NCT02313623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304011902|MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research|MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research||Yale University|No|Recruiting|July 2013|||October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|Samples Without DNA|Research samples will be placed in separate, de-identified specimen jars. Following each      case, investigators on this protocol will provide the de-identified specimen jars to      collaborators to perform single-cell analysis. All clinical specimens will be handled by      pathology according to existing protocols.      Processing of the samples will include disassociated into a single cell suspension and      culturing the sample. This suspension can be then placed onto a microfluidic device for      processing. It is hypothesized that collection of samples in this manner will allow the      comparison of molecular profiles with clinically accepted standards to impact prospective      research on prostate cancer.|Male|18 Years|80 Years|No|Non-Probability Sample|Patients with scheduled Artemis fusion biopsy will be recruited into this study.|January 2015|January 30, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313623||31223|
NCT02320825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-233|Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases|Phase III Multicenter Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases||Memorial Sloan Kettering Cancer Center||Recruiting|December 2014|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320825||30671|
NCT02297477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR2115|The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia|Therapeutic Efficacy of Atovaquone-proguanil and Artesunate-atovaquone-proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Areas of Multidrug Resistance in Cambodia.|ASAP|Armed Forces Research Institute of Medical Sciences, Thailand|No|Completed|December 2014|||December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|65 Years|No|||January 2016|January 10, 2016|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02297477||32463|
NCT02308826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH103253-01A1|Multi-Component Early Intervention for Socially Inhibited Preschool Children|||University of Maryland||Recruiting|December 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|45 Months|64 Months|No|||December 2015|December 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308826||31591|
NCT02308839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPR12-02|GORE® EXCLUDER® Endprosthesis French Mandatory Registry|Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms||W.L.Gore & Associates|No|Active, not recruiting|July 2012|May 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|181|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring treatemtn with an endoprosthesis for the treatment of an unruptured        infra-renal aortic abdominal aneurysm.|December 2015|December 8, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308839|5 Years|31590|
NCT02310984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 13/0354|PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional|PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional|PICTURE XS|University College, London|No|Recruiting|April 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Women who have undergone breast conserving surgery for early breast cancer more than one        year ago.|October 2015|October 2, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310984||31426|
NCT02310997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/0128|Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)|Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen|MAC UCBT|University College, London|Yes|Terminated|July 2011|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|N/A|45 Years|No|||May 2015|May 26, 2015|September 18, 2014||No|Trial closed early due to poor recruitment|No||https://clinicaltrials.gov/show/NCT02310997||31425|
NCT02313987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-EndoGET-001|Endothelial Function-guided Therapy Compared to Usual Care in Patients With NOCAD|The Impact of Endothelial Function-guided Therapy Compared to Usual Care on Major Adverse Cardiovascular Events in Patients With Chest Pain and Non-obstructive Coronary Artery Disease|EndoGET|Itamar-Medical, Israel|Yes|Withdrawn|June 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|||Both|20 Years|79 Years|No|Probability Sample|Subjects with chest pain and non-obstructive coronary artery disease (20-70% diameter        luminal narrowing) will be enrolled in the study 2-30 days following the coronary        angiograms|February 2016|February 23, 2016|December 8, 2014||No|Study never began|No||https://clinicaltrials.gov/show/NCT02313987||31196|
NCT02306122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHARxMOS|Pharmacy Home Adherence Reporting and Monitoring Outcomes Study|Nudging Doctors to Collaborate With Pharmacists to Improve Medication Adherence|PHARxMOS|Brown University|No|Completed|March 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|13||Actual|2697|||Both|18 Years|N/A|No|||November 2014|November 30, 2014|November 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02306122||31798|
NCT02308865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_70|Early Palliative Care in Metastatic Lung Cancer in Northern France|Impact of Early Palliative Care on Quality of Life and Survival of Patients With Non-small-cell Metastatic Lung Cancer in Northern France|IMPAQ|University Hospital, Lille|Yes|Recruiting|October 2014|October 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308865||31588|
NCT02308878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEst-OE/PSI/UI0700/2011|Mobile Health Cognitive Stimulation in Heroin Users|Executive Functioning in Heroin Users Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial|Re@dict|Universidade Lusófona de Humanidades e Tecnologias|Yes|Active, not recruiting|October 2013|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308878||31587|
NCT02315690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPE|Evaluation of Targeted Parasite Elimination in Swaziland|Evaluating the Effectiveness and Feasibility of Reactive Targeted Parasite Elimination vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Case in Swaziland|TPE|University of California, San Francisco|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315690||31065|
NCT02315703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106152|Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention|A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention||Crucell Holland BV|Yes|Recruiting|December 2014|April 2019|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Anticipated|400|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315703||31064|
NCT02437227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4232|A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours|A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma|PanRAF|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2015|March 2019|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437227||21743|
NCT02431780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB01/14UCC|A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection|A Multi-centre, Randomised, Controlled, Clinical Investigation of a Standalone Decision Support Algorithm for Neonatal Seizure Recognition|ANSeR|University College Cork|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|166|||Both|36 Weeks|44 Weeks|No|||November 2015|November 16, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02431780||22162|
NCT02481791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146613|Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia|Study to Evaluate the Optimal Dose of Remifentanil Required to Ensure Apnoea During Magnetic Resonance Imaging of the Heart Under General Anaesthesia||Alder Hey Children's NHS Foundation Trust|No|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|1 Year|7 Years|No|||January 2016|February 9, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02481791||18320|
NCT02431871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:94/2014|Sequelae of Developmental Dysplasia of the Hip|Structural and Functional Sequelae of Developmental Dysplasia of the Hip||University of Oulu|No|Not yet recruiting|January 2016|December 2026|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|340|||Both|10 Years|30 Years|No|Probability Sample|10-30 years old patientstreated for DDH in early childhood in Oulu University Hospital|April 2015|April 27, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02431871||22155|
NCT02437357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWF-15/03|A Trial on Metacognitive Training for Depression (D-MCT)|A Randomized-Controlled Trial on Metacognitive Training for Depression (D-MCT) - an New Group Intervention for Depressed Patients||Universitätsklinikum Hamburg-Eppendorf|No|Not yet recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||May 2015|May 4, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02437357||21733|
NCT02444104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNSYS2015|Non-invasive Blood Pressure and Cardiac Output Measurement by Using Applanation Tonometry|Validation of Non-invasive Blood Pressure and Cardiac-output Measurement by Using Applanation Tonometry in Cardiological Patients||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enable for study enrollement need to suffer from one of the four cardiological        pathologies:          1. atrial fibrillation,          2. severe impaired leftventricular function,          3. severe aortic valve stenosis          4. patients having left ventricular assist device        All patients have to be clinically monitored by invasive blood pressure assessment and        transcardiopulmonary thermodilution.|October 2015|October 9, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444104||21216|
NCT02482038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSK-VLU-001|Geko Venous Leg Ulcer Study|A Single Centre Open Label Pilot Study Measuring Lower Limb Blood Flow in Patients With Venous Leg Ulcers Using the Geko™ T-2 or gekoTM Plus [R-2] Neuromuscular Electro Stimulation Device||Firstkind Ltd|No|Not yet recruiting|April 2016|December 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|80 Years|No|||March 2016|March 8, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482038||18301|
NCT02482051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0082|Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood|Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood||Denver Health and Hospital Authority|No|Enrolling by invitation|July 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|7 Years|89 Years|No|Non-Probability Sample|Hospitalized patients with bacterial blood infections.|June 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482051||18300|
NCT02432066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nixon2015|Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions|Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions||University of Florida|No|Not yet recruiting|July 2016|August 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432066||22140|
NCT02432625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7701|BBD Longitudinal Study of Osteogenesis Imperfecta|Rare Diseases Clinical Research Network Brittle Bone Disease Consortium Longitudinal Study of Osteogenesis Imperfecta||Baylor College of Medicine|Yes|Recruiting|June 2015|June 2025|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|1. Blood        2. Skin cells        3. Urine|Both|N/A|N/A|No|Probability Sample|Individuals with a diagnosis of Osteogenesis Imperfecta are eligible to enroll in the        natural history study.|January 2016|January 26, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432625||22097|
NCT02432937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHCR1201|Corever in the Treatment of Hypertension|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension||TSH Biopharm Corporation Limited|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|143|||Both|20 Years|90 Years|No|||November 2015|November 11, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432937||22073|
NCT02444143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-XXXX|A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients|A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients|Tacrolimus ER|University of Illinois at Chicago|No|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02444143||21213|
NCT02444156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0492|Rowing Away From Diabetes|Indoor Rowing in Adults With Impaired Glucose Regulation: a Pilot Study||University of Leicester|No|Enrolling by invitation|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|45 Years|65 Years|No|||May 2015|May 20, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444156||21212|
NCT02427776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/MOGMOD/CT/FIH/01|A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis|A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL)|SCLEROLYM|ImCyse|No|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|50 Years|No|||February 2016|February 23, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02427776||22468|
NCT02482298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5136C00008|A Study to Evaluate the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease|A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor 10 mg and 45 mg Bid Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease|Hestia2|AstraZeneca|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|30 Years|No|||January 2016|January 8, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482298||18281|
NCT02439398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPX01|Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI|First-in-human, Double Blind, Randomized With Placebo, Open for the 6 First Patients (Dose Ranging) to Evaluate the Safety and Efficacy of Intracoronary Infusion of Allogeneic Human CSCs in Patients With AMI and Left Ventricular Dysfunction|CAREMI|Coretherapix|Yes|Active, not recruiting|June 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|80 Years|No|||November 2015|November 17, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02439398||21577|
NCT02439411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM1401|Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain|Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain|DEIS|Grupo Español Multidisciplinar de Melanoma|Yes|Recruiting|January 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Metastasic melanoma patients treated with Dabrafenib +/- Trametinib in compassionate use.|April 2015|May 6, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02439411||21576|
NCT02437487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERES-004|SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)|ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection|ECOSPOR|Seres Therapeutics, Inc.|Yes|Recruiting|May 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|87|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437487||21723|
NCT02321488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA14-0935|Patient Centered Outcomes Research Institute (PCORI) Provider Survey on Treatment Eligibility|Patient Centered Outcomes Research Institute (PCORI) Provider Survey on Treatment Eligibility||M.D. Anderson Cancer Center|No|Recruiting|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants may be recruited through the following: The Gastrointestinal and Colorectal        Centers at MD Anderson Cancer Center, meeting for the ALLIANCE for Clinical Trials for        Oncology, or other academic or community meetings or events related to providers of        colorectal cancer care.|December 2015|December 29, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321488||30620|
NCT02321501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0890|Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression|A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2023|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321501||30619|
NCT02302534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 2014 - JEL / MOR-FO-SIA|Pilot Study of Functional and Morphometric Brain Abnormalities Related to Adolescent Idiopathic Scoliosis (MOR-FO-SIA)|Pilot Study of Functional and Morphometric Brain Abnormalities Related to Adolescent Idiopathic Scoliosis (MOR-FO-SIA)|MOR-FO-SIA|University Hospital, Tours|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Female|14 Years|16 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02302534||32074|
NCT02302547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO13-TP/TRULIGHT|Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy|Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate|TRULIGHT|University Hospital, Tours|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02302547||32073|
NCT02306811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13840|Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839|A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839||Sanofi|Yes|Active, not recruiting|February 2015|September 2017|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|168|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306811||31746|
NCT02306824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/052/14|Berlin Atrial Fibrillation Registry|Berlin Cohort Study on Oral Anticoagulation in Patients With Atrial Fibrillation and Acute Ischemic Stroke||Charite University, Berlin, Germany|No|Recruiting|December 2014|October 2018|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1080|||Both|18 Years|N/A|No|Probability Sample|Patients with known atrial fibrillation and acute ischemic stroke or transient ischemic        attack|August 2015|August 10, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02306824|2 Years|31745|
NCT02321397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3508|To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain|Randomised, Double-blind, Double-dummy, Cross-over Multicenter Study to Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Taking Oxycodone Equivalents of 120 & 160 mg Per Day as Achieved With the Higher OXN PR Tablet Strengths (OXN60/30 mg PR, OXN80/40 mg PR) BID Compared to the Identical Daily Dose Taken as a Combination of Lower Tablet Strengths in Subjects With Non-malignant or Malignant Pain That Requires Around-the-clock Opioid Therapy.||Mundipharma Research GmbH & Co KG||Active, not recruiting|November 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02321397||30627|
NCT02321410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 2674|"In Vivo" Comparison in Human Carotid Atherosclerosis: Plaque Neovascularization|Plaque Neovascularization Assessment by Contrast Ultrasounds and Plaque Magnetic Resonance: "in Vivo" Comparison in Human Carotid Atherosclerosis|PLAVASC|Ospedale San Giovanni Bellinzona|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||April 2015|April 22, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02321410||30626|
NCT02314520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00000582|Complications Associated With Central Venous Access in the NSICU: PICC vs CVC|Complications Associated With Central Venous Access in the NSICU: PICC vs CVC|NSPVC|Milton S. Hershey Medical Center|Yes|Enrolling by invitation|July 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|362|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02314520||31155|
NCT02314754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1016|Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation|Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation: A Non-inferiority Trial|XXGA|Gynuity Health Projects|Yes|Recruiting|December 2014|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|691|||Female|11 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314754||31137|
NCT02297282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAVE_Main Study|A Study to Assess the Effectiveness of Behavioural Activation Group Therapy in Individuals With Depression|A Pragmatic Randomized Trial to Investigate the Effectiveness of BehaviouRal ActiVation Group Therapy in Reducing dEpressive Symptoms and Improving Quality of Life in Patient With Depression: BRAVE Study.|BRAVE|St. Joseph's Healthcare Hamilton|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||January 2016|January 18, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02297282||32478|
NCT02322307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1195|Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life|A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322307||30557|
NCT02322710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINE4002|Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.|Multicentre, Randomized, Parallel Group, Non-inferiority, Open-label Study Aiming at Comparing the Healing Rates (With Blinded Assessment Based on Photographs) of TULLEGRAS M.S.® With URGOTUL® in the Treatment of Surgical Acute Wounds.||Mylan Inc.|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02322710||30526|
NCT02299609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTSAU1400|Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI|Therapeutic Effect of Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI||Sakarya University|Yes|Recruiting|January 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||November 2014|November 21, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02299609||32299|
NCT02299622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10-112|Personalized Sequence for Thoracic, Esophageal, and H&N Cancer|Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)||Samsung Medical Center|Yes|Recruiting|November 2013|December 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|fresh tissue|Both|21 Years|N/A|No|Probability Sample|metastatic, histologically confirmed NSCLC, head & Neck Cancer, Esophageal cancer|November 2014|November 20, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02299622||32298|
NCT02297555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_26|ENDOBARRIER® and Conventional Therapy in the Management of Metabolic Syndrome in Obese Patients|ENDOBARRIER® vs Conventional Therapy in the Management of Metabolic Syndrome in Obese Patients. Medico-economic Analysis as Part of a Randomized Controlled Multicenter Trial - ENDOMETAB|ENDOMETAB|University Hospital, Lille|Yes|Suspended|April 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|174|||Both|20 Years|60 Years|No|||December 2015|December 3, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02297555||32457|
NCT02321735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000798|DOD Long-Term Survivors of Ovarian Cancer|The Genomic, Epigenomic, and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer - Recruitment|LTSOC|Massachusetts General Hospital|No|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Female|18 Years|80 Years|No|||March 2016|March 15, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321735||30601|
NCT02321748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-EU23|Drug-Drug Interaction Study: ASP2151 and Montelukast|A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast||Maruho Europe Limited|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321748||30600|
NCT02315261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB004|Effectiveness of Epidural Anesthesia for Thoracic and Abdominal Surgery|Effectiveness of Epidural Anesthesia for Thoracic and Abdominal Surgery in Siriraj Hospital||Siriraj Hospital|No|Completed|December 2014|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|364|||Both|18 Years|N/A|No|Probability Sample|patients scheduled to have thoracic or abdominal surgery under general anesthesia combined        with epidural analgesia in Siriraj hospital|February 2016|February 22, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02315261||31098|
NCT02299882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-166|Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics|Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics||Spectrum Health Hospitals|Yes|Recruiting|August 2012|January 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|700|||Both|18 Years|N/A|No|||February 2013|November 21, 2014|February 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02299882||32278|
NCT02299895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBG:1554|Professionals' Perspectives on Facilitating and Hindering Factors of Implementing Health Promotion Programs in Organizational Settings|Professionals' Perspectives on Facilitating and Hindering Factors of Implementing Health Promotion Programs in Organizational Settings: a Qualitative Comparative Study in Austria|SCS|Ludwig Boltzmann Gesellschaft||Active, not recruiting|February 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|90|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The aim of this study is to investigate professionals' (teachers', health professionals',        care aids') views and attitudes that influence the implementation of client-oriented        health promotion programs in organizational settings in Austria. Therefore, 90        professionals will be interviewed: 30 in schools, 30 in hospitals, and 30 in        LTC-facilities.|November 2014|November 20, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02299895||32277|
NCT02316964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14040|Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Pilot Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)||Ohio State University Comprehensive Cancer Center|Yes|Suspended|April 2015|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 20, 2014|Yes|Yes|Amendment to protocol in process|No||https://clinicaltrials.gov/show/NCT02316964||30967|
NCT02295579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24580-53750|Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida|Vaginal Colonization After Treatment With Lactobacillus in Women With BV or Candida Will That Increase the Cure Rate After Treatment With Clindamycin for BV and Flucnazole for Candida||Skaraborg Hospital|Yes|Recruiting|June 2014|November 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|55 Years|No|Probability Sample|women with vaginal discharge with either bacterial vaginosis or candida infection|November 2014|November 20, 2014|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02295579|6 Months|32608|
NCT02299635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8641020|A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations|Phase 2 Study Of Single-Agent PF-03084014 In Patients With Advanced Triple-Negative Breast Cancer With Or Without Genomic Alterations In Notch Receptors||Pfizer|No|Terminated|February 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|November 20, 2014|Yes|Yes|The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014    development. There were no safety/efficacy concerns behind the decision.|No||https://clinicaltrials.gov/show/NCT02299635||32297|
NCT02299349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13055-13-034|Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection|Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection in 70 Patients Undergoing Total Knee Arthroplasty Without Femoral Nerve Block: a Double-blinded, Randomized Clinical Trial||TriHealth Inc.|No|Completed|August 2013|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|35 Years|90 Years|Accepts Healthy Volunteers|||November 2014|April 2, 2015|November 17, 2014|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT02299349||32319|
NCT02299362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-08055C|The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study|The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study|GSSG|Growing Spine Study Group|No|Recruiting|October 2008|December 2032|Anticipated|December 2032|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|18 Years|No|Non-Probability Sample|Patients receiving treatment at participating study sites who are eligible and agree to        participate in the study.|August 2015|August 25, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299362|18 Years|32318|
NCT02299687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMP_CYP2C19|Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole|A Clinical Trial to Investigate the Influence of CYP2C19 Polymorphism on Pharmacokinetic/Pharmacodynamic Characteristics of Omeprazole in Healthy Korean Volunteers||Seoul National University Hospital||Completed|September 2014|||December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|September 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02299687||32293|
NCT02320968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141619|Sleep Position May Reduce Acid Reflux Symptoms at Night|Sleep Position Reduces Acid Reflux and Decreases Extraesophageal Reflux Symptoms: A Non-randomized Prospective Study of the Amenity Health MedclineTM Sleep Assist Device||Vanderbilt University|No|Enrolling by invitation|December 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02320968||30660|
NCT02303275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSCP_CHF_Suhar|Lifestyle Change Program in Elderly Patients With Heart Failure|Comprehensive 12-week Lifestyle Change Program in Elderly Patients With Heart Failure||Scripps Center for Integrative Medicine|No|Recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|34|||Both|18 Years|90 Years|No|||November 2014|November 24, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02303275||32017|
NCT02308436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4-MW15.042|Prophylactic Effect of a CANDIDA Mouthwash, Containing the Curolox™ Peptide|Prophylactic Effect of a CANDIDA Mouthwash, Containing the Curolox™ Peptide: a Mono-centre, Not-controlled. Not Blinded, Not-randmised in Situ Study||Mibelle AG|No|Withdrawn|February 2015|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|November 27, 2014||No|Study is not realised.|No||https://clinicaltrials.gov/show/NCT02308436||31621|
NCT02309567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-597|Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?|||Cumhuriyet University||Recruiting|May 2014|||February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Lung cancer patients and patients who have suspected pulmonary lesion|November 2014|December 3, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02309567||31535|
NCT02321176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sun2|Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood|Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood||Huazhong University of Science and Technology|Yes|Recruiting|March 2014|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|20|||Both|18 Years|60 Years|No|||December 2014|December 16, 2014|June 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02321176||30644|
NCT02321189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sun3|The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness|The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness||Huazhong University of Science and Technology|Yes|Recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|34|||Both|23 Years|28 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02321189||30643|
NCT02295033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22881-10882-ROG-BCG|Randomized Boost Versus no Boost Irradiation of Early Breast Cancer|Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 1989|||May 2006|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||||||Female|N/A|70 Years|No|||November 2014|November 18, 2014|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02295033||32650|
NCT02295046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAT-BESD-03-RDL/10|Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence,Crossover, Single Dose, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fasting Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|November 17, 2014|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295046||32649|
NCT02295059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13130|Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention|Omega-3 Fatty Acids and ERPR(-) and HER-2/Neu(+/-) Breast Cancer Prevention||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|August 2014|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|N/A|No|||October 2015|October 24, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02295059||32648|
NCT02300168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-51834|Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery|Neuromuscular Blockade as a Determinant of Surgical Outcome and Post-operative Recovery, in Patients Undergoing Elective Laparoscopic Bariatric Surgery||Hopital du Sacre-Coeur de Montreal|Yes|Completed|September 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|MO patients from the bariatric surgery department of Hopital Sacre Coeur de Montreal|August 2015|August 18, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300168||32256|
NCT02312336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0476|A Pilot Study of Transcoronary Myocardial Cooling|A Safety and Feasibility Study of Transcoronary Myocardial Buffering and Cooling During Primary Coronary Angioplasty to Reduce Myocardial Reperfusion Injury in Acute Myocardial Infarction.||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|September 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02312336||31322|
NCT02319213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU 08-38|This Study Performed to Develop a New Technique for Measuring the Intra Abdominal Pressure|The Increase of Intra-abdominal Pressure Can Affect Intra-ocular Pressure.||Selcuk University|No|Completed|March 2008|November 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02319213||30794|
NCT02319226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTSN1339002N|Toward Immune Biomarkers for Tolerance and GvHD in Humans|Toward Immune Biomarkers for Tolerance and GvHD in Humans|BioGvHD|Assistance Publique - Hôpitaux de Paris||Recruiting|May 2014|October 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients transplanted from an HLA-identical sibling donor|September 2015|September 24, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02319226||30793|
NCT02301000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT CDI|IMT for Primary Clostridium Difficile Infection|Intestinal Microbiota Therapy Versus Metronidazole for Primary Clostridium Difficile Infection: a Randomized Controlled Trial||Oslo University Hospital|Yes|Recruiting|November 2014|February 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02301000||32192|
NCT02307422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-14-133-C-UCSD|Genetic Polymorphisms Associated With CAD|Genetic Polymorphisms Associating With CAD, Inflammatory Biomarkers, and Oxidized Phospholipids in a Greek Population||Interleukin Genetics, Inc.|No|Active, not recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1173|Samples With DNA|DNA has been extracted from previously obtained subject blood samples at the University      General Hospital of Ioannina, Greece study site. DNAs will be labeled by anonymized subject      ID # (de-identified), and shipped to ILI for genotyping and genetic analysis.|Both|18 Years|90 Years|No|Probability Sample|Patients between 18 years to 90 years at entry (coronary angiography) of both genders.        Patients with a previous history of coronary revascularization procedure or moderate to        severe stenosis will be excluded. Diabetics and non-diabetics, with or without known CV        disease, who are admitted in the Department of Cardiology in the University General        Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and        undergo coronary angiography for clinical purposes will be studied. The study includes        subjects who; 1) have suspected CAD and undergo a scheduled diagnostic angiogram for        clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus        undergo diagnostic angiography (with or without previous history of CAD).|March 2016|March 21, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02307422||31699|
NCT02322060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCZZU-IVA|In Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency|Ovarian Tissue Cryopreservation and Auto-transplantation for in Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency|IVADFPOI|The First Affiliated Hospital of Zhengzhou University|Yes|Recruiting|September 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Serum, ovary tissue|Female|18 Years|39 Years|No|Non-Probability Sample|Women diagnosed with POI who also want to get pregnant by IVF/ICSI-ET with their own        oocyte.|January 2015|January 11, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322060|2 Years|30576|
NCT02312128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/2010|Early Mobilization of Operatively Stabilized Distal Radius Fractures - a Randomized Controlled Trail|Early Mobilization of Operatively Stabilized Distal Radius Fractures - a Randomized Controlled Trail||Ludwig Boltzmann Gesellschaft|No|Recruiting|January 2015|October 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02312128||31338|
NCT02312141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0012|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||September 23, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312141||31337|
NCT02304575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0482-14-RMC|Quality of Life Among Testicular Cancer Survivors|Quality of Life Among Testicular Cancer Survivors||Rabin Medical Center|No|Recruiting|January 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|330|||Male|18 Years|75 Years|No|Non-Probability Sample|Group1: Testicular cancer long-term survivors Group 2: Benign testicular conditions        patients Group 3: Healthy Controls Partners of males from above 3 groups|November 2014|March 11, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304575||31917|
NCT02302066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEN-204|Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants|A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America||Takeda|Yes|Active, not recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1800|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302066||32110|
NCT02302079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8232-CL-3001|A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)|A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema|VIDI|Astellas Pharma Inc|No|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|85 Years|No|||March 2016|March 15, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302079||32109|
NCT02314715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCU_MSK_SS_001|Neuromuscular Control in Knee Osteoarthritis|Neuromuscular Control in Knee Osteoarthritis|NEKO|Glasgow Caledonian University||Completed|November 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|95|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary and secondary care clinics, and general community.|March 2015|March 2, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02314715||31140|
NCT02295761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100/2011|Promoting Overweight Adolescents Physical Activity|Promoting Overweight Adolescents Physical Activity and Adherence to Healthy Lifestyles: a Randomized Controlled Trial||University of Oulu|No|Active, not recruiting|January 2012|December 2015|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|13 Years|16 Years|No|||November 2015|November 30, 2015|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295761||32594|
NCT02295774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-17-01/08|Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA|Effect of Oral Administration of Methylene Blue MMX Tablets on Double-stranded DNA Damage Assessed by GammaH2AX Analysis of Colon Biopsy Samples||Cosmo Technologies Ltd|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 12, 2014||No||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02295774||32593|
NCT02297022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InternalFunds|Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome|Phase 1 Study of Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome|DBSPW|University of Sao Paulo General Hospital|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|15 Years|N/A|No|||November 2014|December 15, 2015|October 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02297022||32498|
NCT02308709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRO030|Novel Lung Functional Imaging for Personalized Radiotherapy|Novel Lung Functional Imaging for Personalized Radiotherapy||University of California, Davis|Yes|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02308709||31600|
NCT02314962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK ZH Nr 20140077|PET/MRI Perfusion and CT Perfusion in Solid Tumors|Diagnostic and Clinical Accuracy of Integrated Magnetic Resonance Imaging and Computed Tomography Perfusion in PET/MRI in Comparison to PET/CT in Solid Tumors|Perfusion|University of Zurich|No|Recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|30 Years|90 Years|No|Probability Sample|Patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen        who have an indication for a PET/CT|July 2015|July 27, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02314962||31121|
NCT02314975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/0056|Intermittent Vibrational Force and Orthodontic Tooth Movement|Intermittent Vibrational Force and Orthodontic Tooth Movement: a Randomised Controlled Trial||King's College London|No|Completed|June 2011|||November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02314975||31120|
NCT02318251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUIP|Stress Urinary Incontinence Physiotherapy|Stress Urinary Incontinence Physiotherapy (SUIP) - A Randomized Controlled Trial With 6-Months Follow-up||Bern University of Applied Sciences|Yes|Recruiting|January 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|70 Years|No|||January 2016|January 13, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02318251||30868|
NCT02301533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH099946|Provider and Peer Support Intervention to Improve ART Adherence Among Kenyan Men Who Have Sex With Men|Provider and Peer Support Intervention to Improve ART Adherence Among Kenyan Men Who Have Sex With Men|Shikamana|University of Washington|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Male|18 Years|N/A|No|||July 2015|July 19, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02301533||32151|
NCT02299947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45370.100.14|Bloodtranfusions After Aortic Surgery|Comparison of a Single Dose Fibrinogen With Placebo and the Number of Blood Transfusions After Ascending Aorta Surgery (FIBTEG Study)|FIBTEG|St. Antonius Hospital|Yes|Recruiting|August 2014|April 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299947||32273|
NCT02299960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-CEC|Measurement of Endothelial Function and Cardiac Output: New Methods|Pilot Study: Analysis of Endothelial Function Through Circulating Endothelial Cells and Puls-amplitude-tonometry and of Non-invasive Measurement of Cardiac Output on Exertion in Patients With Heart Failure, Pulmonary Hypertension, Arterial Hypertension and Diabetic Nephropathy||Charite University, Berlin, Germany||Active, not recruiting|August 2014|March 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|101|Samples Without DNA|Blood samples, 51,4ml per Patient|Both|35 Years|80 Years|No|Non-Probability Sample|Patients suffering from the conditions stated above|November 2015|November 21, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02299960||32272|
NCT02318407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060145|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Younger and Older Subjects With Osteoarthritis Knee Pain||Amgen|No|Completed|December 2006|March 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||December 2014|December 12, 2014|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318407||30856|
NCT02321423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040468|International Pachyonychia Congenita Research Registry||IPCRR|Pachyonychia Congenita Project|No|Recruiting|April 2004|||December 2028|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All persons with PC in all countries are being invited to register. It is not known how        many persons have PC although it is known it is a very rare disease.|December 2014|December 16, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02321423|1 Year|30625|
NCT02325206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10179|Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes|Randomized, Double-blind, Placebo-controlled, Single-center Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin as Add-on to Intravenous Insulin-infusion in Adolescents and Adults With Type 1 Diabetes|DAPA-IIT1|Kinderkrankenhaus auf der Bult|Yes|Completed|December 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|12 Years|21 Years|No|||February 2016|February 18, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325206||30334|
NCT02309892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDOS001|A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC|A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination With Pemetrexed/Carboplatin in Patients With Stage IV (TNM M1a and M1b) Recurrent or Metastatic NSCL Lung Cancer||Helix BioPharma Corporation|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 9, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02309892||31510|
NCT02296450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-236|Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments|Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|3 Years|N/A|No|Non-Probability Sample|Cancer patients and survivors who present to MSKCC's Dermatology clinics in Manhattan,        Basking Ridge, Haupaugge or West Harrison may be approached to participate in this study.|January 2016|January 21, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296450||32541|
NCT02296749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-635/08|Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fasting Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2010|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|November 19, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296749||32518|
NCT02315456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Evaluation of Centration of Intraocular Lens With Two Settings for Capsulorhexis With Femtosecond Laser|Prospective Randomized Evaluation of Centration of Intraocular Lens With Two Laser Settings for Capsulorhexis With Femtosecond Laser||Northwestern University|No|Recruiting|December 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|45 Years|95 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02315456||31083|
NCT02315469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-CC002|Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery|Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers||NRG Oncology|Yes|Active, not recruiting|February 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|228|||Female|70 Years|N/A|No|Non-Probability Sample|Patients with gynecologic cancer undergoing surgery|March 2016|March 7, 2016|December 9, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02315469||31082|
NCT02318732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553213|Evaluation of California's Armed and Prohibited Persons System|Prospective Evaluation of California's Armed and Prohibited Persons System|APPS|University of California, Davis|No|Recruiting|February 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318732||30831|
NCT02293577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 1409014566|Continuous Glucose Monitoring in Youth With Type 2 Diabetes|Continuous Glucose Monitoring in Youth With Type 2 Diabetes||Yale University|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|10 Years|21 Years|No|Non-Probability Sample|Youth with type 2 diabetes will be recruited from the type 2 diabetes clinic.|January 2016|January 4, 2016|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02293577||32762|
NCT02296762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-636/08|Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fed Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|November 19, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296762||32517|
NCT02296775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-01-003|Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis|||Dr. Reddy's Laboratories Limited|Yes|Recruiting|November 2014|May 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|276|||Both|18 Years|65 Years|No|||November 2014|November 18, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296775||32516|
NCT02440061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060865|Ghrelin and Beta Cell Function in Diabetes|Ghrelin Effect on Beta Cell Function in Health and Disease #2||Duke University||Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|50|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02440061||21526|
NCT02435654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81460218|5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia|Effcets of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia||Kunming Medical University|No|Recruiting|August 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|17 Years|No|||February 2016|February 26, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435654||21864|
NCT02486341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/08|Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin|Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin|VARQUOGLY|University Hospital, Bordeaux|No|Recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|75 Years|N/A|No|||February 2016|February 11, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02486341||17971|
NCT02436564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093484|In Vitro Models of Liver and Pancreatic Cancer|A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies||Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|July 2015|||September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|fresh tissue, frozen tissue|Both|18 Years|90 Years|No|Non-Probability Sample|Patients who are undergoing surgical resenctions of liver, biliary or pancreas cancers        that are able to give informed consent|June 2015|June 8, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02436564||21794|
NCT02436577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5139C00004|Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects|An Open-label, Randomized, Three-period, Three-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Healthy Japanese Subjects.||AstraZeneca|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|42|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02436577||21793|
NCT02444169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-144|Retrospective Evaluation of Combination Treatment With the Ulthera System|Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse||Ulthera, Inc|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|101|||Both|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults between 25 and 70 years of age who have received an Ultherapy treatment and        toxin/filler within the last two years within six months apart and meet the        inclusion/exclusion criteria.|August 2015|August 7, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444169||21211|
NCT02444117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A012740-45|Clinical and Neurophysiological Evolutions Through a Functional Rehabilitation of Social Communication in ASD|Autism Spectrum Disorders: Clinical and Neurophysiological Evolutions Through a Functional Rehabilitation of Social Communication||University Hospital, Tours|No|Recruiting|February 2015|February 2021|Anticipated|February 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|12 Months|12 Years|No|Probability Sample|Children with autism spectrum disorders|May 2015|May 11, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02444117|2 Years|21215|
NCT02444130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01677-38|Presbyopia Compensation: Looking for Electrophysiological Predictors|Presbyopia Compensation: Looking for Electrophysiological Predictors||University Hospital, Tours|No|Recruiting|February 2015|February 2016|Anticipated|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|45 Years|60 Years|No|Probability Sample|Adults with presbyopia|May 2015|July 17, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02444130|8 Weeks|21214|
NCT02486614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ114/N168|Effect of Citrate on the Coagulation System in Patients Receiving CRRT|The Effect of Regional Citrate Anti-coagulation on the Coagulation System in Critically Ill Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury - an Observational Cohort Study|Citroco|Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|June 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|adults with acute kidney injury requiring citrate based continuous renal replacement        therapy|February 2016|February 22, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02486614||17950|
NCT02436850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0116-15-CTIL|Bed Side Thoracentesis Among Non-Ventilated Patients With Respiratory Instability|Bed Side Thoracentesis Among Non-Ventilated Patients With Respiratory Instability||Soroka University Medical Center|No|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02436850||21772|
NCT02437474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-01|Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study|Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study||Verein Essen und Krebs|Yes|Recruiting|April 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will be recruited in community via print media, internet and especially        social media as well as referred by oncological clinics.|May 2015|May 7, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02437474||21724|
NCT02427789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCLim27/FAPESP2012/20002-5|Therapeutic Effectiveness of Exercise Associated to the Pharmacotherapy in Major Depression|Therapeutic Effectiveness of Exercise Associated to the Pharmacotherapy in Major Depression||University of Sao Paulo General Hospital|No|Completed|March 2012|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||January 2013|April 28, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02427789||22467|
NCT02486900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAINTRAINAD|Neurofeedback & Alcohol Dependence|Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence||Cardiff University|No|Recruiting|September 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486900||17928|
NCT02429986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9498|Adaptive Servo-Ventilation in "Real Life" Conditions : the OTRLASV Study|Observational and Transversal Study of Patients Treated in "Real Life"Conditions With Adaptive Servo-Ventilation|OTRLASV|University Hospital, Montpellier|No|Recruiting|March 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02429986||22298|
NCT02443987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/013/GHT|Time Interval Between TVT and First Void (TIBT) Study|Time Interval Between TVT and First Void (TIBT) Study|TIBT|Gloucestershire Hospitals NHS Foundation Trust|Yes|Not yet recruiting|May 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|42|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02443987||21225|
NCT02326337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOTI- TWO2DFU-01|Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers|A Multi-national, Multi-center, Prospective, Randomized, Double Blinded, Placebo-controlled Trial to Evaluate the Efficacy of HyperBox Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic Diabetic Foot Ulcers|TWO2DFU|AOTI Ltd.|Yes|Recruiting|October 2014|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|89 Years|No|||December 2014|December 26, 2014|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02326337||30247|
NCT02308384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Randomiseret iFOBT studie|A Trial of the Implementation of iFOBT in General Practice|The Use of Immunochemical Faecal Occult Blood Test (iFOBT) in General Practice. A Randomised Trial of the Implementation of iFOBT.||University of Aarhus|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|816|||Both|N/A|N/A|No|||November 2015|December 7, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02308384||31625|
NCT02310204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 141 01|Therapeutic Education Program in Psoriasis|Evaluation of a Therapeutic Education Program in Patients With Moderate to Severe Psoriasis : a Multicenter Randomized Controlled Study|EDUPSO|University Hospital, Toulouse|No|Completed|May 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|187|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310204||31486|
NCT02318979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0222|What is the Optimal Stiffness and Height of a Running-specific Prosthesis?|What is the Optimal Stiffness and Height of a Running-specific Prosthesis?||VA Eastern Colorado Health Care System|Yes|Recruiting|October 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318979||30812|
NCT02318992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-13-0119|Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea|Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea||The University of Texas Health Science Center, Houston|Yes|Recruiting|September 2013|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318992||30811|
NCT02319005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTRSC-004|ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)||Alnylam Pharmaceuticals|Yes|Recruiting|December 2014|January 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||February 2016|February 12, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319005||30810|
NCT02309333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00067432|Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database|Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database||Emory University|No|Recruiting|November 2014|July 2018|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Patients with APL treated predominantly across the states of Georgia and South Carolina,        as well as from neighboring states.|January 2016|January 14, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309333|5 Years|31553|
NCT02309346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0328|Clindamycin Once a Day in Septic Abortion|A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion.|CLINDA-PRO|Hospital de Clinicas de Porto Alegre|No|Recruiting|November 2014|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Female|13 Years|50 Years|No|||March 2016|March 24, 2016|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309346||31552|
NCT02309359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0061-C201|A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis|A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy||Ablynx|Yes|Active, not recruiting|January 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|345|||Both|18 Years|74 Years|No|||January 2016|January 7, 2016|November 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309359||31551|
NCT02301806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-282-02|Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM|A Randomized, Prospective, Parallel Design Study to Compare the Effectiveness of Sitagliptin Versus Glimepiride on Endothelial Dysfunction During an Oral Glucose Loading in Drug Naive Patients With Type 2 Diabetes.||Dokkyo Medical University|Yes|Recruiting|January 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|80 Years|No|||February 2016|February 15, 2016|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02301806||32130|
NCT02312375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fimasartan study|Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients|Effects of Fimasartan on Insulin Secretion, and Interaction With DPP4 Inhibitors in Patients With Type 2 Diabetes||Seoul National University Hospital|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|80 Years|No|||August 2015|August 3, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02312375||31319|
NCT02310828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-CLUSTPREV-1|The Efficacy of L-cysteine in Prevention of Cluster Headache|The Efficacy of L-cysteine in Prevention of Cluster Headache. Randomized Intervention Trial With a Medical Device (Acetium® Capsules)||Biohit Oyj|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02310828||31438|
NCT02311075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/049/HP|Mechanisms of Endothelial Dysfunction in Type 2 Diabetes|Determination of the Mechanisms Involved in Conduit Artery Endothelial Dysfunction in Type 2 Diabetes|DIAB-EETs|University Hospital, Rouen|No|Recruiting|December 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|66|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02311075||31419|
NCT02304133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-006|Transfer From a Point-of-care Ultrasound Course|Transfer From a Point-of-care Ultrasound Course to Diagnostic Performance on Patients - a Randomized Controlled Trial||Rigshospitalet, Denmark|No|Completed|January 2012|November 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|64|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304133||31951|
NCT02304146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144144|Long-term Ultrasound Guided Foam Sclerotherapy Versus Classical Surgical Stripping Study|Long-term Ultrasound Guided Foam Sclerotherapy Versus Classical Surgical Stripping Study||Maastricht University Medical Center|No|Recruiting|November 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|460|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who were randomized and received the allocated treatment UGFS or surgical        stripping.|December 2014|December 1, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02304146|1 Day|31950|
NCT02302092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLOMOXEF_301|Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections|A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis|FLORUS|Takeda|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302092||32108|
NCT02302612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-13-1672-H|The CREATE Wellness Study|Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study||Kaiser Permanente|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|588|||Both|40 Years|85 Years|No|||January 2016|January 4, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02302612||32068|
NCT02310724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61230-T2P2|TODAY2 Phase 2 Follow-up|Long-term Post-Intervention Follow-up of the TODAY Cohort|T2P2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Enrolling by invitation|March 2014|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|506|Samples Without DNA|Blood and urine are collected annually and shipped to the study's Central Biospecimen      Laboratory for analysis and storage.|Both|15 Years|N/A|No|Non-Probability Sample|All subjects randomized into the TODAY study are eligible to participate in T2P2. There        are no additional inclusion or exclusions criteria for participation in T2P2.|December 2014|December 4, 2014|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02310724||31446|
NCT02310737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|755|Comparison of Postoperative Pain and Neuropathy at Cesarean Sectio With Blunt or Sharp Fascia Incision|Comparison of Postoperative Pain and Neuropathy at Cesarean Sectio With Blunt or Sharp Fascia Incision: A Prospective Randomized Controlled Double-Blinded Trial|fascia|Sisli Etfal Training & Research Hospital|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|123|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 7, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02310737||31445|
NCT02326610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-DM-0713-12-TLV|Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae|Early hGH Treatment of Symmetrically Born Small for Gestational Age Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae|hGH|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Months|12 Months|No|||December 2014|December 26, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02326610||30226|
NCT02304601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8011-106-31/31.27.16|Development and Testing of a Generic Screening for Use in Application Process of Medical Rehabilitation Services|Entwicklung Und Testung Eines Generischen Screenings für Die Vorabschätzung Von Fallgruppen im Antragsverfahren|Generik|Charite University, Berlin, Germany|No|Completed|January 2011|September 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2736|||Both|18 Years|65 Years|No|Probability Sample|Members of the German Federal Pension Insurance before their medical rehabilitation|November 2014|November 26, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02304601||31915|
NCT02308527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_11-087|Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children|A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial|BEACON|University of Birmingham|Yes|Recruiting|July 2013|January 2021|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|1 Year|21 Years|No|||December 2014|December 3, 2014|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02308527||31614|
NCT02308540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-017|Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants|A Phase 1/2, Prospective, Randomized, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 10-Valent Pneumococcal Conjugate Vaccine in Healthy Young Adults, Toddlers, and Infants||PATH|Yes|Active, not recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|346|||Both|N/A|40 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02308540||31613|
NCT02294435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH VMS|Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|||Sanford Health|Yes|Recruiting|February 2015|February 2022|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294435||32696|
NCT02317367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915032|Self-Affirmation: Construct Validity|Self-Affirmation: Construct Validity||National Institutes of Health Clinical Center (CC)||Not yet recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1500|||Female|18 Years|N/A|No|||October 2015|March 23, 2016|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317367||30936|
NCT02317614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026315|SteadyRx: Smartphone ART Adherence Intervention for Drug Users|||Johns Hopkins University|No|Not yet recruiting|October 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2014|December 15, 2014|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02317614||30917|
NCT02317627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD025-206|Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy|A Phase 2, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy||Kadmon Corporation, LLC|Yes|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02317627||30916|
NCT02294799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YEH1984|Magnetic Ressonance Imaging of Temporomandibular Joint|Magnetic Ressonance Imaging Evaluation of Articular Disc Position in TMD Subjects After Mandibular Mobilization. A Double Blind, Randomized, Placebo-controlled Study|MRITMJ|University of Nove de Julho|Yes|Not yet recruiting|November 2014|December 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|45 Years|No|||November 2014|November 16, 2014|April 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02294799||32668|
NCT02304874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/11-03|Evaluation of Body Iron Stores in Overweight Healthy Volunteers|Evaluation of Body Iron Stores in Overweight Healthy Volunteers|FERNORM|Rennes University Hospital|No|Completed|July 2011|August 2014|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 27, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02304874||31894|
NCT02309554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-126|Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel|A Phase I Postcoital Testing Study of the SILCS Diaphragm Used With 3% Nonoxynol-9 Gel, ContraGel, or No Gel||CONRAD|No|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02309554||31536|
NCT02310256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2533/REK midt|A Clinical Trial on the Effects of Home-based Five Plus Exercise Training|A Randomized Clinical Trial on the Effects of Home-based Five Plus Exercise Training||Norwegian University of Science and Technology|No|Active, not recruiting|November 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|50 Years|80 Years|No|||April 2015|April 14, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02310256||31482|
NCT02310269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2410|Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease|Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)||Novartis|No|Recruiting|March 2013|April 2024|Anticipated|April 2024|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population will consist of male and female patients aged 18 years or older        with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is        not an option and who are treated with pasireotide s.c.|March 2016|March 2, 2016|September 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02310269||31481|
NCT02308566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034/11|Cerebral Embolic Load in Patients Undergoing Surgical Aortic Valve Replacement: A Comparison of the Conventional With the Minimized Extracorporeal Circulation Technique Using Transcranial Doppler Ultrasound|Aortic Valve Replacement Using Closed Extracorporeal Circuit. Minimized Versus Conventional Extracorporeal Circulation Technique: Qualitative Differences|AKE-MECC|University Hospital Inselspital, Berne|No|Active, not recruiting|June 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 9, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308566||31611|
NCT02307045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOKING-VAR-NIC-ATTIKON|Effect of Smoking Reduction on Endothelial Glucocalyx and Vascular Function|Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program.||University of Athens|Yes|Recruiting|June 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02307045||31728|
NCT02295423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29837|Follow-Up Study to Assess Implementation of Ultrasound-Guided Regional Anesthesia Skills|A Long-Term Follow-Up Study to Assess Implementation of Ultrasound-Guided Regional Anesthesia Skills Training by Practicing Anesthesiologists||VA Palo Alto Health Care System|Yes|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|We intend to enroll approximately 100 subjects (one site only) based on the estimated        number of practicing anesthesiologists who have participated in a regional anesthesia        workshop at VAPAHCS within the last 4 years. Subjects who are practicing anesthesiologists        out of residency and will likely be 40-70 years of age. We expect to recruit subjects of        both genders and all ethnic backgrounds.|December 2015|December 8, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02295423||32620|
NCT02310503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAE-MOH-2013-01|Spanish Registry of Mohs Surgery|Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]|REGESMOHS|Fundación Academia Española de Dermatología|No|Recruiting|July 2013|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Female|18 Years|N/A|No|Non-Probability Sample|All consecutive patients considered for Mohs surgery in participating centers.|August 2015|August 10, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310503|4 Years|31463|
NCT02299037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09069PP-OPMS|Predicting the Risk of Post-operative Delirium: Use of Neuropsychology, Serum and CSF Biomarkers and Genetics to Predict Risk of Post-operative Delirium|||Belfast Health and Social Care Trust|No|Recruiting|March 2012|July 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|316|Samples With DNA|serum cerebrospinal fluid DNA extracted from blood|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 65 years of age or more undergoing primary, elective hip and knee arthroplasty in        a single surgical unit.|November 2014|November 20, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02299037||32343|
NCT02308462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O1GY1337|Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents|Implementation and Evaluation of a Family-based Intervention Program for Children and Adolescents of Mentally Ill Parents - a Randomized Controlled Multicenter Trial|CHIMPs|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|4 Years|18 Years|No|||October 2015|October 26, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02308462||31619|
NCT02316145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16611|Internet-based Coaching for Young Adults With Neuropsychiatric Disorders|Internet-based Support and Coaching for Young Adults With Neuropsychiatric Disorders - A Pilot Study||Vardalinstitutet The Swedish Institute for Health Sciences|No|Completed|September 2008|December 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||December 2014|December 9, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02316145||31030|
NCT02326948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-L04|Alcohol Consumption and Gallbladder Cancer|Alcohol Consumption and Gallbladder Cancer: Case-control Study in Jeju Island, Korea.||Cheju Halla General Hospital|No|Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|156|||Both|N/A|N/A|No|Non-Probability Sample|Case group was defined as the patients newly diagnosed GBC at the Digestive Disease Center        and Department of Internal Medicine, Cheju Halla General Hospital, Jeju, Korea, during        2008 - 2013. And control groups were determined the randomly 1:1 matched subjects by the        age and sex distributions of GBC cases, among the health care check-up examinees visited        to Health Promotion Center in the same institute and same periods. Total 78 cases among        124 GBC patients and matched 78 controls from 7088 health check-up examinees were included        this study.|December 2014|December 29, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02326948||30201|
NCT02309047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-645|The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank|The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank|COLA|UMC Utrecht|No|Recruiting|October 2004|August 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|6 x 500 μL serum, 2 x 500 μL EDTAplasma en 3 x 900 μL celpellet|Female|18 Years|45 Years|No|Probability Sample|Women with cycle disturbances are referred to the outpatient clinic specialized in cycle        disturbances by 1st or 2nd line care providers for further diagnostic procedures.|November 2015|November 24, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02309047||31575|
NCT02307461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-15|Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145|A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects||Infinity Pharmaceuticals, Inc.|No|Completed|November 2014|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|103|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307461||31696|
NCT02322073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682-14|Inflammation and Obesity-associated Disease|Inflammation and Obesity-associated Disease|Adipos2|Göteborg University|No|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Obese individuals planned for Roux-en-Y gastric bypass surgery and lean healthy controls        planned for elective benign laparoscopic surgery.|January 2016|January 7, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322073||30575|
NCT02316470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA84-201|Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study|Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study||Valneva Austria GmbH|Yes|Completed|December 2014|October 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|500|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316470||31005|
NCT02308150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-14|The Asian Transcatheter Aortic Valve Replacement Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement in the Asian Pacific Population|Asian TAVR|Asan Medical Center|Yes|Recruiting|December 2014|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|All patients who will undergo TAVR in Asian Pacific countries|November 2015|November 16, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308150||31643|
NCT02308163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RAJ3|A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs|Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs||Astellas Pharma Inc|Yes|Recruiting|July 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|500|||Both|20 Years|N/A|No|||October 2015|October 23, 2015|December 2, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02308163||31642|
NCT02307539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14273|Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer|Feasibility of an Interdisciplinary Palliative Care Planning Intervention in Pancreatic Cancer||City of Hope Medical Center|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|21 Years|N/A|No|||June 2015|June 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02307539||31690|
NCT02318927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400951|A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinson's Disease|A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinson's Disease||University of Florida|Yes|Active, not recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|30 Years|75 Years|No|||March 2016|March 17, 2016|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318927||30816|
NCT02318940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRR001|Femoral Central Venous Access Comparison of 2 Methods|Comparison of Effectiveness and Safety of Two Methods for Installing Femoral Central Venous Catheters in Pediatric Intensive Care Units : Anatomical Method vs Ultrasound in Real Time.||University of Chile|No|Recruiting|December 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|15 Years|No|||May 2015|May 26, 2015|December 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02318940||30815|
NCT02299830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAO-NO.201402024-malignant1|Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture|Prospective, Open, Multicenter Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture||Tang-Du Hospital|Yes|Not yet recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|70 Years|No|||November 2014|November 20, 2014|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02299830||32282|
NCT02302053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHT-0213|Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Self-Perceived Thinning Hair||Ablon Skin Institute Research Center|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|21 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302053||32111|
NCT02319187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-064|Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial|Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study||Chinese Academy of Medical Sciences|Yes|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||April 2015|July 30, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02319187||30796|
NCT02296047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX62782296|Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD|Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease||Zhujiang Hospital|Yes|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|22|||Both|40 Years|70 Years|No|||November 2014|July 26, 2015|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296047||32572|
NCT02309853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P40907|Visual and Tactile Scanning Training in Patients With Neglect After Stroke|Visual and Tactile Scanning Training in Patients With Neglect After Stroke|ViTaTrain|HES-SO Valais-Wallis|No|Recruiting|December 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02309853||31513|
NCT02307721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI-14-001|Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use|Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use|OPI-14-001|Norwegian University of Science and Technology|Yes|Completed|December 2014|September 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02307721||31676|
NCT02321436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-197|Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression|Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb Spasticity.|ONTIME Pilot|Ipsen|No|Active, not recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|80 Years|No|||December 2015|December 21, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321436||30624|
NCT02313207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE-IBS-2|Confocal Laser Endomicroscopy in IBS Patients|Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS.||University of Schleswig-Holstein|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02313207||31255|
NCT02293304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLenzi|Performance of Universal Adhesive in Primary Molars: a Randomized Clinical Trial|Performance of Universal Adhesive in Primary Molars: a Randomized Clinical Trial||Universidade Federal de Santa Maria|No|Recruiting|May 2014|July 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02293304||32783|
NCT02301338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-213|Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing|Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|65 Years|N/A|No|||October 2015|October 15, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301338||32166|
NCT02322320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN07LT|Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)|Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322320||30556|
NCT02322450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGC001/2QG1|Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension|Multicenter, Randomized, Double-blind, Two-period, Placebo Controlled, Forced-titration Proof of Concept Crossover Study to Compare QGC001 With Placebo in Patients With Grade I or II Essential Hypertension|2QG1|Quantum Genomics SA|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||July 2015|July 13, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02322450||30546|
NCT02296580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAT-101|A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)||Nativis, Inc.|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296580||32531|
NCT02301767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-246|MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study|MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|saliva|Female|21 Years|69 Years|No|Non-Probability Sample|The three data cancer centers (MSK, Penn, Utah) will recruit 1,110 cases (women diagnosed        with breast cancer) and 1,110 matched controls (high risk women).|February 2016|February 11, 2016|November 19, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02301767||32133|
NCT02301598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-1|Femtosecond Laser-assisted Anterior Lamellar Keratoplasty|Femtosecond Laser-assisted Anterior Lamellar Keratoplasty||The S.N. Fyodorov Eye Microsurgery State Institution|No|Completed|January 2012|September 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|52 Years|No|||November 2014|November 26, 2014|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02301598||32146|
NCT02319616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-1224|Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis|A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)|TEN|University of California, Davis|Yes|Not yet recruiting|June 2015|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|7 Years|85 Years|No|||December 2014|December 17, 2014|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319616||30764|
NCT02319629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC- 0129-12 -CTIL|Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery|Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery||HaEmek Medical Center, Israel|No|Not yet recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|266|||Both|18 Years|65 Years|No|||December 2014|December 14, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02319629||30763|
NCT02428478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2014P001033A|Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A|The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects|DESOSA|Brigham and Women's Hospital|No|Active, not recruiting|March 2015|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428478||22414|
NCT02428712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX120-03|A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors|A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors||Plexxikon|No|Recruiting|April 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|107|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428712||22396|
NCT02443896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-089|The Use of Pit and Fissure Sealants in Children Requiring Caries Related Dental Extractions|A Pilot Study to Investigate the Use of Pit and Fissure Sealants in Children Requiring Caries Related Dental Extractions Under a Chair General Anaesthetic||University of Birmingham|No|Active, not recruiting|April 2014|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|5 Years|15 Years|No|||May 2015|May 26, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02443896||21232|
NCT02443909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26.01.2015|Comparison of Safety and Efficiency of 20w and 30w Holmium Laser Device in Management of 2-3 cm Diameter Kidney Stones With Retrograde Intrarenal Surgery|||Diskapi Teaching and Research Hospital|No|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|90 Years|No|||May 2015|May 13, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02443909||21231|
NCT02491502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/BG/TN/FS/2015|Treatment of Benign Thyroid Nodules With FastScan HIFU|Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU)||Theraclion|No|Recruiting|June 2015|July 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491502||17576|
NCT02439190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV004-007|CV004-007 Thrombosis Chamber Study|A Single Dose Study to Evaluate the Effect of BMS-986120 on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 11, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02439190||21592|
NCT02429245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-62|Single Cutting Guides System for the Installation of a Total Knee Replacement|Evaluation of the Accuracy of a Single Cutting Guides System for the Installation of a Total Knee Replacement||University Hospital, Strasbourg, France|No|Not yet recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients operated in the service in 2014 to care for end-stage knee osteoarthritis by        implantation of a total knee prosthesis.|April 2015|April 28, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02429245||22355|
NCT02427516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-374|Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain|Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain||Bristol-Myers Squibb|No|Active, not recruiting|January 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1505|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with NVAF or VTE and treated with VKA|March 2016|March 1, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02427516||22488|
NCT02427529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053111|Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)|Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)||Dr. Emma's Corporation|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|59|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427529||22487|
NCT02491580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreTXCa|Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer|Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer||Uppsala University|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2370|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney transplanted patients in Uppsala or Europe with or without a pre-transplant cancer.|July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02491580||17570|
NCT02491593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFecalBlood 2013/2:7|Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients|Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients|FIKA|Uppsala University|No|Enrolling by invitation|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred from primary care for investigation of symptoms potentially caused by        colorectal cancer|March 2016|March 9, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02491593||17569|
NCT02439281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14100075|Ropivacaine With Clonidine For Pediatric Rectus Sheath Blocks- The Magic Combination|ROPIVACAINE WITH CLONIDINE FOR PEDIATRIC RECTUS SHEATH BLOCKS- THE MAGIC COMBINATION? - A Double Blinded Prospective Study||Children's Hospital of Pittsburgh|Yes|Not yet recruiting|May 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|17 Years|No|||May 2015|May 6, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02439281||21586|
NCT02439294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9541|Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction||SAS-IDM|University Hospital, Montpellier|No|Recruiting|May 2015|May 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|87|||Both|18 Years|89 Years|No|||August 2015|August 31, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02439294||21585|
NCT02444195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00095520|Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients|Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial||University of Michigan|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444195||21209|
NCT02444208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT (01)|A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use|Randomized Clinical Trial (01): A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use|RCT(01)|University of Kentucky|Yes|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444208||21208|
NCT02432183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53448|Longitudinal Follow-up of High School Athletes|Longitudinal Follow-up of Exercise-induced Bronchoconstriction and Airway Inflammation in High School Athletes||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|70|Samples With DNA|induced sputum sample and venous blood (serum)|Both|11 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|A group of elite athletes at the start of their career (both from the elite sport school        in Wilrijk (n=15) and Leuven (n=35) in cooperation with 'Sportmedisch Advies Centrum'        (SMAC) UZ Leuven) are recruited. Three sport disciplines are included: basketball players,        football players and swimmers.        A group of healthy subjects (n=20) is recruited to serve as a control.|April 2015|May 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02432183||22131|
NCT02491658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-PV-MSC|Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris|A Study to Assess Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) in Patients With Psoriasis Vulgaris||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|July 3, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491658||17564|
NCT02434172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01GH000737-01|CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa|The CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa Through Early Detection and Prevention of Cryptococcal Disease|CryptoART|University of Zimbabwe|Yes|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|Samples Without DNA|Plasma, and peripheral blood mononuclear cells|Both|18 Years|N/A|No|Non-Probability Sample|The study will recruit Asymptomatic participants with severe immunosuppression at risk of        cryptococcal disease. The individuals will have a CD4 count <100cells/mm3 and can be ART        naive or ART experienced with no symptoms of active Cryptococcal disease.        They will be recruited from outpatient HIV/ART clinics.|April 2015|April 29, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02434172||21978|
NCT02428725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01913-44|Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome|Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome||Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|640|||Both|18 Years|90 Years|No|||November 2015|November 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02428725||22395|
NCT02314286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor005514ctil|Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery|Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery||Soroka University Medical Center|No|Not yet recruiting|December 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||December 2014|December 10, 2014|November 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02314286||31173|
NCT02294578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeriRx LC|Salivary Biomarkers for Non-small Cell Lung Cancer Detection|Prospective Blinded Evaluation of Salivary Transcriptome Biomarkers for Non-small Cell Lung Cancer Detection||PeriRx|No|Recruiting|December 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|166|Samples With DNA|Saliva samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients presenting for evaluation of lung lesions suspicious for the presence of        lung cancer.|August 2015|February 7, 2016|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02294578||32685|
NCT02294591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35664|NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression|NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression - A Double Blind Randomized Placebo-controlled Trial With Follow up|NACOS|Region Syddanmark|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|64 Years|No|||November 2014|November 14, 2014|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02294591||32684|
NCT02297061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEGHIP|Can Thrombelastography Predict Blood Loss in Patients With Hip Fractures|Study on the Value of Thrombelastogralhy to Pre-operatively Predict Hip Fracture Patients at Risk of Major Blood Loss During and After Surgery.||Hvidovre University Hospital|No|Completed|December 2013|August 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|N/A|N/A|No|Probability Sample|Hip fracture patients admitted to Hvidovre University Hospital in the study period.|November 2014|November 18, 2014|February 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02297061||32495|
NCT02315443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-1-005|Field Randomization of NA-1 Therapy in Early Responders|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset|FRONTIER|NoNO Inc.|Yes|Suspended|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|558|||Both|40 Years|95 Years|No|||December 2015|January 6, 2016|December 5, 2014|Yes|Yes|Need for process improvement|No||https://clinicaltrials.gov/show/NCT02315443||31084|
NCT02322502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-073|Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia|Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia: a Randomized Multicenter Controlled Trial (ACC Baxter)||RWTH Aachen University|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|342|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02322502||30542|
NCT02294838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA H14-02236|Feasibility Study of MRI Imaging on Parotid Gland Stimulation|Feasibility Study of MRI Imaging on Parotid Gland Stimulation|SPIT|British Columbia Cancer Agency|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02294838||32665|
NCT02295098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1979|Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures|Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures||University of Colorado, Denver|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|99 Years|No|||November 2015|November 6, 2015|November 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02295098||32645|
NCT02308514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-14-203-07.08|Does Adding Cryostimulation to Conservative Care Help in Managing Chronic Lateral Epicondylitis? a Pilote Study|Does Adding Cryostimulation to Conservative Care Help in Managing Chronic Lateral Epicondylitis? a Pilote Study||Université du Québec à Trois-Rivières|No|Active, not recruiting|September 2014|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02308514||31615|
NCT02317146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|complejoh4|Magnesium Sulfate in Pregnancy and Postpartum|A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum|MAG-PP|Complejo Hospitalario Dr. Arnulfo Arias Madrid|No|Recruiting|November 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|14 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317146||30953|
NCT02316236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2014-6-22-01|Dexmedetomidine to Improve Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery|Effect of Dexmedetomidine on Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery|DEALS|Fourth Military Medical University|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02316236||31023|
NCT02316249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHS-P001|Vaginal Creams to Reduce Vaginal Erosion in Pessary Users|Vaginal Creams for Reduction of Vaginal Discharge and Erosion in Patients Using Ring With Support or Gellhorn Pessaries to Reduce Pelvic Organ Prolapse||Northwell Health|Yes|Withdrawn|April 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|December 10, 2014||No|the study was not feasible|No||https://clinicaltrials.gov/show/NCT02316249||31022|
NCT02306382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Gustafsson|Multicenter Study for Diagnosis and Treatment of Perianal Abscesses|Randomized Controlled Multicenter Study for Diagnosis and Treatment of Perianal Abscesses.||University Hospital, Umeå|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 13, 2012||No||No||https://clinicaltrials.gov/show/NCT02306382||31778|
NCT02293928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000439|Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy|Impact of Hybrid Coronary Revascularization on Antiplatelet Effect of Aspirin and Clopidogrel||Aarhus University Hospital Skejby|No|Completed|October 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|4 ml serum and 4 ml sodium citrate plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary artery disease scheduled for elective hybrid coronary        revascularization. The study cohort is recruited from a prospective pilot study conducted        to assess feasibility and safety of hybrid coronary revascularization combining minimally        invasive off-pump coronary artery bypass grafting and percutaneous coronary intervention        (PCI) performed three to five days later (Clinicaltrials.gov identifier: NCT01496664).|November 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293928||32735|
NCT02293941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKB122|Liver Test Study of Using JKB-122 in HCV-Positive Patients|A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests (ALT and AST) in HCV-positive Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies (Pegylated or Standard) Either Alone or in Combination With Ribavirin|JKB122|TaiwanJ Pharmaceuticals Co., Ltd|Yes|Recruiting|May 2014|April 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|148|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293941||32734|
NCT02315950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037210|The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder|CineMRI/UDS for Evaluating the Physiologic Effect of Botox in Women With Overactive Bladder||Cedars-Sinai Medical Center|Yes|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Female|21 Years|N/A|No|||July 2015|July 28, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02315950||31045|
NCT02311088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-2013-007|Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor|Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study|TROCADERO|Uppsala University||Terminated|December 2014|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|December 4, 2014||No|Too low enrolment rate|No||https://clinicaltrials.gov/show/NCT02311088||31418|
NCT02306460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14068|Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation|Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation||Tampere University Hospital|No|Recruiting|July 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|||Both|50 Years|70 Years|No|Non-Probability Sample|A total of 80 patients will be drafted for the study. The subjects will be recruited from        Tampere University Hospital Heart Hospital Co. Total of fifty patients, men and women        between 50-70 years, undergoing left atrial catheter ablation (LACA) (30 patients) or        percutaneous left atrial appendix closure procedure (20 patients) because of paroxysmal or        persistent atrial fibrillation, will be recruited for the study.        A control group of 15 patients with paroxysmal atrial fibrillation and 15 patients with        persistent atrial fibrillation who are treated with antiarrhythmic and anticoagulation        therapies suggested by current guidelines will be tested with the same testing schema and        time points. Control group will be drafted from the cardiologic patients of the Heart        Hospital and also from Hatanpää Hospital cardiologic outpatient clinic.|September 2015|September 3, 2015|July 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02306460|1 Year|31773|
NCT02294656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27905|Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide|Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide||Soll Eye|No|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294656||32679|
NCT02308059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF2012BAP13|Ultrasonographic Evaluation of Diabetic Neuropathy|Diabetic Peripheral Neuropathy: Correlation Between Ultrasound Findings and Clinical Features||Cukurova University|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|106|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients in a University Hospital|December 2014|December 2, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02308059||31650|
NCT02320786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01702|Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach|Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach|CoPILOT|University of British Columbia|No|Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|50 Years|N/A|No|||December 2015|December 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320786||30674|
NCT02298517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carol2013|Application Breathing Exercises With Load Inspiratory Postoperative Abdominal Surgery|Application of Breathing Exercises With Load Inspiratory Postoperative Abdominal Surgery: a Randomized Clinical Trial Blind||Universidade Metodista de Piracicaba|No|Completed|December 2013|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|114|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02298517||32383|
NCT02306993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-136-6|Sickle Cell Hemoglobinopathies and Bone Health|Sickle Cell Hemoglobinopathies and Bone Heath||University of Connecticut Health Center|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|Blood will be collected once from each subject by certified study staff at UCHC, CCMC or the      participating approved community sites in a private setting.Subjects will donate ~12-15 cc      of whole blood via venipuncture. Blood will be collected into 3 vacutainer tubes: one 3.5-mL      lavender top tube for CBC and hemoglobin electrophoresis, one 3.5-mL yellow top tube for      serum calcium and phosphate, and one 5-mL red-top tube for 25-OH vitamin D, P1NP, CTX, and      PTH analysis. The|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target population includes healthy African American female volunteers with and without        SCT and African American female volunteers with SCD.|March 2016|March 14, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306993||31732|
NCT02295215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01900000|Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction|Effects of Physical Training on Sensitivity Baroreflex Patients Without Chagas' Heart Ventricular Systolic Dysfunction|CH0660/10|University of Sao Paulo General Hospital|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|25 Years|60 Years|No|||June 2013|November 14, 2014|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02295215||32636|
NCT02314494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHSCE001|Proactve Assessment of Overweight Risk During Infancy|A Feasibility Study of an Interactive, Educational Programme to Facilitate Proactive Assessment of Overweight Risk During Infancy|ProAsk|Anglia Ruskin University|No|Active, not recruiting|May 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|83|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Infants 6-8 weeks old living in the study areas (Cambridshire and Nottingham City)|December 2015|December 23, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02314494||31157|
NCT02294812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCIL-HL-CT|Effects of Cognitive Training on Speech Perception|Effects of Cognitive Training on Age-Related Hearing Loss and Speech Perception||Nova Scotia Health Authority|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|50 Years|N/A|No|||August 2015|August 24, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02294812||32667|
NCT02296151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-01816|Evaluation of Treatment Factors in the Management of Chronic Iliotibial Band Syndrome in Female Distance Runners|Evaluation of Treatment Factors in the Management of Chronic Iliotibial Band Syndrome in Female Distance Runners.||University of British Columbia|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Female|19 Years|45 Years|No|||November 2015|November 26, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296151||32564|
NCT02316379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-7643|Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration|Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration|HpXeMRCal|Children's Hospital Medical Center, Cincinnati|No|Recruiting|February 2015|March 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02316379||31012|
NCT02314728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3462|Cervical Ripening in Premature Rupture of Membranes|Cervical Ripening in Premature Rupture of Membranes||Montefiore Medical Center|Yes|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314728||31139|
NCT02303379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-8|Different Endurance Training Protocols in Cardiac Patients|Effects of Different Endurance Training Protocols on Physical Performance in Cardiac Patients||Paracelsus Medical University|No|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02303379||32009|
NCT02307110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRP-2010-02|Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy|A Cross Sectional Study Assessing the Prevalence of Different Stages of Diabetic Retinopathy and Diabetic Macular Edema Among Type 1 Diabetic Patients Treated With Long-term Intensified Insulin Therapy||Vista Klinik|No|Recruiting|August 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02307110||31723|
NCT02319590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Anti-Angiotensin-Receptor 1 (ATR1)-, Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in Cardiomyopathy|The Role of Functional Active Anti-Angiotensin-Receptor 1 (ATR1)- and Anti-Endothelin-Receptor A (ETRA)-Antibodies and Autoreactive T Cells in Cardiomyopathy|T-CARD|Zurich Regional Health Center|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|T cells|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Heart failure patients, EF < 35%, either CAD (re-vascularized) or other type of heart        failure|August 2015|August 4, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02319590||30766|
NCT02319603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX-20141022|To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats|A Randomized, Double-blind, Two Dose Group, Parallel-control Multi-center, Post-marketing Clinical Trial,to Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats.||Beijing Bozhiyin T&S Co., Ltd.|No|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|75 Years|No|||July 2015|July 22, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02319603||30765|
NCT02311803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-PANP001|Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery|Preservation Versus Excision of Denonvilliers Fascia in Laparoscopic Pelvic Autonomic Nerve Preserving Surgery for Male Mid-low Rectal Cancer Patients: a Randomized Controlled Clinical Trial||Third Affiliated Hospital, Sun Yat-Sen University||Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Male|20 Years|60 Years|No|||November 2015|November 7, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311803||31363|
NCT02306746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/MC001|The Augmented Versus Routine Approach to Giving Energy Trial|The Augmented Versus Routine Approach to Giving Energy Trial: A Randomised Controlled Trial|TARGET|Australian and New Zealand Intensive Care Research Centre|Yes|Not yet recruiting|October 2015|October 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4000|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02306746||31751|
NCT02294409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT_SA-FEP RCT|Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis|Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis: A Randomized Controlled Trial||McGill University|No|Recruiting|October 2014|||March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|35 Years|No|||March 2016|March 14, 2016|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02294409||32698|
NCT02294422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/HD07/1766U|Balloon Palpation vs Loss of Resistance Syringe for Safe Endotracheal Tube Cuff Pressure; a Randomized Clinical Trial|Achieving Recommended Endotracheal Tube Cuff Pressure; A Randomized Control Trial Comparing Loss of Resistance Syringe to Pilot Balloon Palpation.|LOR-ETCP|Makerere University|Yes|Completed|April 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|178|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|August 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02294422||32697|
NCT02312882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31790ORO|Tofacitinib for the Treatment of Alopecia Areata and Its Variants|||Stanford University|No|Active, not recruiting|December 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312882||31280|
NCT02295345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0356|Open Pilot of Cognitive Behavioural Therapy for Insomnia in Pregnancy|Open Pilot of Cognitive Behavioural Therapy for Insomnia in Pregnancy||University of Calgary||Completed|June 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02295345||32626|
NCT02295553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000036780|Ketamine and Propofol for Upper Endoscopy|Co-administration of Ketamine and Propofol for Upper Endoscopy in Children: a Dose-finding Study||The Hospital for Sick Children|No|Recruiting|July 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|56|||Both|3 Years|13 Years|No|||May 2015|May 29, 2015|December 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02295553||32610|
NCT02294643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERENADE trial|Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study|A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment|SERENADE|Seoul National University Bundang Hospital|Yes|Completed|April 2009|March 2014|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|November 10, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02294643||32680|
NCT02321904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-21944|Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children|Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children|CCM|University of Calgary|No|Active, not recruiting|June 2008|February 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|176|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Children seen at the Alberta Children's Hospital Diabetes Clinic in Calgary        Controls: 8-18 year old healthy children|December 2014|December 16, 2014|June 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02321904||30588|
NCT02307409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-SIRS-01|Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis|Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population for this study is all Acute on Chronic Liver Failure patients        admitted to the inpatient services of ILBS, New Delhi.|October 2015|October 8, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02307409||31700|
NCT02309619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kli|Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in MIE|Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in Minimally Invasive Esophagectomy: a Single-Center Randomized Controlled Trial||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|January 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02309619||31531|
NCT02309632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203640|Pancreatic Cancer Screening of High-Risk Individuals in Arkansas|Pancreatic Cancer Screening of High-Risk Individuals in Arkansas||University of Arkansas|No|Recruiting|November 2015|November 2025|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|18 Years|99 Years|No|||January 2016|January 12, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309632||31530|
NCT02309645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-13-006|The Paediatric EVICEL® Neuro Study|A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL® Used for Suture-Line Sealing in Dura-Mater Closure During Paediatric Neurosurgical Cranial Procedures||Ethicon, Inc.|No|Recruiting|October 2014|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|17 Years|No|||August 2015|August 3, 2015|October 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309645||31529|
NCT02321995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057177|A Quantitative Optical Sensor to Monitor Vascular Physiology; A Healthy Volunteer Study|A Quantitative Optical Sensor to Monitor Vascular Physiology; A Healthy Volunteer Study||Duke University|No|Recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|October 2015|March 21, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02321995||30581|
NCT02322008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anti-TNF, IBD|Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice|Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice||Regionshospitalet Viborg, Skive|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1035|||Both|18 Years|N/A|No|Non-Probability Sample|1035 patients with CD or UC|December 2014|December 22, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322008||30580|
NCT02300090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149902|A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)|A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)|Me&MyCOPD|AstraZeneca|No|Suspended|August 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|N/A||2|Anticipated|700|||Both|N/A|N/A|No|Non-Probability Sample|Males and females, of any age with a clinical diagnosis of COPD|March 2016|March 7, 2016|November 21, 2014||No|Setting up of electronic service.|No||https://clinicaltrials.gov/show/NCT02300090|12 Months|32262|
NCT02306967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCENT004|Fluorescent Visualization in Early Oral Cancer|||University of Calgary||Recruiting|September 2011|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2011|December 1, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306967||31734|
NCT02306980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|531791|Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota|Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota||University of California, Davis|No|Recruiting|October 2013|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12|||Both|N/A|7 Days|No|||December 2014|December 1, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306980||31733|
NCT02308735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3948|Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial|Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial|FAEE-IDM|University of Oklahoma|No|Recruiting|March 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|60|Samples With DNA|Urine sample, meconium sample, placental cord blood sample|Both|N/A|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Teetotaling pregnant women either without a diagnosis of diabetes (controls) or with             a diagnosis of diabetes mellitus (either gestational or pregestational).          2. The liveborn infants resulting from the concurrent pregnancies of the women listed             above.|January 2016|January 13, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308735|3 Months|31598|
NCT02310763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5161002|A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy|A Phase 2 Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study To Evaluate The Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Pf-06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy||Pfizer|Yes|Recruiting|November 2014|May 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Male|6 Years|9 Years|No|||March 2016|March 7, 2016|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310763||31443|
NCT02422875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058515|Comparative Autoantibody and Immunologic Cell Marker Study|Comparative Autoantibody and Immunologic Cell Marker Study||Emory University|No|Enrolling by invitation|August 2012|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|100|Samples With DNA|Acquisition and storage of blood and bone marrow samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Subjects with certain autoimmune conditions or if subjects have brothers, sisters,             mother, father, or children with an autoimmune condition          -  Subjects with certain infectious diseases          -  Subjects who are without an autoimmune condition or infectious disease          -  Subjects who have received or will receive a vaccination as part of their regular             standard of care from one of their healthcare providers|July 2015|July 14, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02422875|3 Days|22845|
NCT02422888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10048|Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor|Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor|REDUCE-MVI|VU University Medical Center|Yes|Recruiting|May 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|74 Years|No|||January 2016|January 2, 2016|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422888||22844|
NCT02399137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-141-07-02-02|A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer|A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer|CARRIE|Merrimack Pharmaceuticals|Yes|Recruiting|May 2015|November 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|260|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399137||24666|
NCT02399150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOMAB|Biomarkers in Acute Abdomen|Biomarkers in Acute Abdomen (BIOMAB)|BIOMAB|Hôpital de la Salpétrière|No|Recruiting|May 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|EDTA and serum blood, saliva|Both|18 Years|N/A|No|Probability Sample|patients presenting to the ED with acute abdomen|January 2016|February 26, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399150||24665|
NCT02402140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital do Rim|Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations|A Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations Early After Kidney Transplant.|PharmCare|Hospital do Rim e Hipertensão|No|Completed|February 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|128|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02402140||24435|
NCT02414958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.69|Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2)|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)||Boehringer Ingelheim||Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|720|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 8, 2015||||No||https://clinicaltrials.gov/show/NCT02414958||23453|
NCT02411058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819369|Attention to Incentives|Attention to Incentives||University of Pennsylvania|No|Completed|March 2015|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|2055|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|October 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02411058||23753|
NCT02415023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-013-00CH3|A Phase Ib Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer|A Phase Ib Clinical Study to Evaluate the Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of Fruquintinib Combined With Paclitaxel in Patients With Advanced Gastric Cancer||Hutchison Medipharma Limited|Yes|Recruiting|September 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|12|||Both|18 Years|70 Years|No|||March 2016|March 13, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415023||23448|
NCT02410018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCL503-P1-UFE-01|Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata|An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata Scheduled for Hysterectomy||IMBiotechnologies Ltd.|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410018||23833|
NCT02407782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/16|Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children|Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children: a Cluster Multicenter Randomized Trial|SCRATCH|University Hospital, Bordeaux|Yes|Not yet recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|502|||Both|N/A|16 Years|No|||March 2015|March 30, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02407782||24005|
NCT02421614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054575|Enteral Feeding Composition and Acute Respiratory Failure|Effect of Enteral Feeding's Macronutrient Composition on Inflammatory Mediators, Oxidative Stress and Outcomes in Intensive Care Unit Patients With Acute Respiratory Failure||Shahid Beheshti University|No|Completed|August 2013|December 2015|Actual|November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|48|||Both|18 Years|N/A|No|||November 2015|March 21, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02421614||22942|
NCT02415270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001996|Switching to Reduced Oxidant or Nicotine Content Cigarettes in Smokers|Switching to Reduced Nicotine Content Cigarettes or Reduced Reactive Oxygen/Reactive Nitrogen Species Cigarettes in Smokers||Milton S. Hershey Medical Center|Yes|Not yet recruiting|August 2015|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|70|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415270||23429|
NCT02490254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALA1021|Childhood Uveitis Initial Management and One-year Outcomes|Childhood Uveitis Not Associated With Juvenile Idiopathic Arthritis: Incidence, Initial Management and One-year Outcomes||Moorfields Eye Hospital NHS Foundation Trust|No|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|16 Years|No|Non-Probability Sample|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.|July 2015|July 7, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490254|1 Year|17672|
NCT02483780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/PHAD/UMMS 01-01|We Talk About Our Hypertension|Culturally Adaptive Storytelling Method to Improve Hypertension Control in Vietnam -"We Talk About Our Hypertension": a Pilot Cluster Randomized Controlled Trial||Institute of Population, Health and Development, Vietnam|No|Active, not recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|50 Years|N/A|No|||September 2015|September 8, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02483780||18167|
NCT02483793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-065|Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population|Randomized Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Discomfort in the Pediatric Population||Phoenix Children's Hospital||Not yet recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|18 Years|No|||June 2015|June 26, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483793||18166|
NCT02475031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201007846|Single-shot TAP Block vs Continuous TAP Block|Randomized, Prospective, Double Blind Study Comparing Single Shot Versus Continuous Transverses Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Live Donor Nephrectomy|TAP|Indiana University|Yes|Completed|July 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475031||18840|
NCT02481557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015069|Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental Prophylaxis|||Procter and Gamble||Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481557||18338|
NCT02488174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH2HL125119|Prevention of Severe Acute Respiratory Failure in Patients With PROOFCheck|Prevention of Severe Acute Respiratory Failure in Patients With PROOFcheck - an Electronic Checklist to Prevent Organ Failure|PROOFcheck|Albert Einstein College of Medicine of Yeshiva University||Not yet recruiting|August 2015|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|3459|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02488174||17830|
NCT02488187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABUS|Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients|Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients|ABUS|University of Kansas Medical Center|Yes|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488187||17829|
NCT02490540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506S 38P|ANI and SPI Guided Intraoperative Analgesia|ANI and SPI Guided Intraoperative Analgesia in Patients Undergoing Neurosurgical Procedures Under General Anaesthesia||University Hospital Hradec Kralove|No|Completed|June 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||November 2015|November 15, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02490540||17650|
NCT02479334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUND-AFC-STAGE3-SPICENUTROMICS|Acute Effects of Spices on Pathways Associated With Glucose Homeostasis and Inflammation on PBMCs of Healthy Subjects|Acute Effects of Spices on Pathways Associated With Glucose Homeostasis, Oxidative Stress and Inflammation in Healthy Subjects - Molecular Insights Through Transcriptomics of Peripheral Blood Mononuclear Cells (PBMC)||Lund University|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 19, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02479334||18509|
NCT02476747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0565|Cold Snare Polypectomy Versus. Endoscopic Mucosal Resection|Comparison of Efficacy Between Cold Snare Polypectomy and Endoscopic Mucosal Resection in Treatment of Small Polyp||Asan Medical Center|No|Recruiting|June 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|103|||Both|20 Years|N/A|No|||June 2015|June 23, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02476747||18708|
NCT02488629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCB01A-21|Study of SCB01A in Patient With Head and Neck Cancer|An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment||SynCore Biotechnology Co., Ltd.|Yes|Not yet recruiting|August 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||July 2015|July 1, 2015|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488629||17795|
NCT02488642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212250-29021|Medical Management of Late Intrauterine Death.|Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin.|INPer|National Institute of Perinatology|No|Completed|May 2008|May 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|N/A|N/A|No|||July 2015|July 22, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488642||17794|
NCT02488954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000835-34|Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis|Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis|EMMENTAL|Rennes University Hospital|No|Recruiting|February 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02488954||17771|
NCT02490813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALC-002|Pilot Study on Traditional Chinese Medicine and Food Allergy|Pilot Study on Traditional Chinese Medicine and Food Allergy|TCMFA|Hong Kong Sanatorium & Hospital|Yes|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|8 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490813||17629|
NCT02463175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03098|Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair|A Randomized Controlled Pilot Study to Examine the Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair|CardioQ-RP|University of British Columbia|No|Terminated|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Both|N/A|18 Years|No|||March 2016|March 24, 2016|May 29, 2015||No|Difficulties with protocol compliance in both arms. Will simplify protocol.|No||https://clinicaltrials.gov/show/NCT02463175||19751|
NCT02478931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130794|Study of Personalized Cancer Therapy to Determine Response and Toxicity|UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)|UCSD_PREDICT|University of California, San Diego|No|Recruiting|September 2013|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|Samples With DNA|Blood, urine, tissue, ascites|Both|18 Years|N/A|No|Non-Probability Sample|All patients with a diagnosis of cancer or a cancer-related condition|June 2015|June 18, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02478931||18540|
NCT02485691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14201|Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent|A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)|CARD|Sanofi|No|Recruiting|November 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485691||18020|
NCT02485704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-304-15|Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies|A Randomized, Phase 3, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies||ParaPRO LLC|Yes|Suspended|June 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|4 Years|N/A|No|||January 2016|January 7, 2016|June 19, 2015|Yes|Yes|To address FDA Advice Letter comments|No||https://clinicaltrials.gov/show/NCT02485704||18019|
NCT02485041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SID123_DDI_I_2014|Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30 mg and Mirodenafil 100 mg in Healthy Male Volunteers||SK Chemicals Co.,Ltd.|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02485041||18070|
NCT02463422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH104446|Detection of ASD at the 1st Birthday as Standard of Care: The Get SET Early Model|Detection of ASD at the 1st Birthday as Standard of Care: The Get SET Early Model||University of California, San Diego|No|Recruiting|August 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12000|||Both|12 Months|36 Months|Accepts Healthy Volunteers|Probability Sample|Two cohorts of toddlers, those in San Diego and Phoenix, will participate. Toddlers in        both cities from the general population will be screened for ASD and other delays using        the CSBS Infant-Toddler Checklist in pediatric offices at the 12, 18, and 24 month        well-baby visits.|June 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02463422||19733|
NCT02467582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/13 - Aspirin|Adjuvant Aspirin for Colon Cancer|Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial||Swiss Group for Clinical Cancer Research|No|Recruiting|July 2015|December 2028|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|185|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02467582||19413|
NCT02486679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0095-15-WOMC|A Trial of Prostaglandin E2 Tablets Versus Foley Catheter for Labor Induction|Cervical Ripening at Term With Prostaglandin E2 Tablets Versus Foley Catheter: a Randomized Controlled Trial||Wolfson Medical Center|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 21, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02486679||17945|
NCT02486692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 14-360|Pilot Evaluation of AboutFace: Novel Peer Education Resource for Veterans|Pilot Evaluation of AboutFace: A Novel Peer Education Resource for Veterans||VA Office of Research and Development|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02486692||17944|
NCT02485964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204374|A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine|A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine||University of Arkansas|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Male|18 Years|N/A|No|||February 2016|February 19, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485964||17999|
NCT02424708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1443|Phase IIb Study of Intranasal Glutathione in Parkinson's Disease|Phase IIb Study of Intranasal Glutathione in Parkinson's Disease|(in)GSH|Bastyr University|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|N/A|No|||January 2016|January 13, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424708||22704|
NCT02424721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-FMHBP-003|Sepsis Assessment in Belgian Emergency Rooms|Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein Assay to Assist in Evaluation of Patients With Suspected Infection Following Emergency Department Admission|SABER|Axis Shield Diagnostics Ltd||Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Plasma - NaCitrate and LiHep|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the Emergency Department with suspected infection|January 2016|January 4, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02424721||22703|
NCT02407379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLTC014|Diode Laser and SRP in Chronic Periodontitis|Photoablative-photodynamic (PAPD) Diode Laser Therapy Adjunctive to Scaling and Root Planing in Periodontitis|PAPD|Odontostomatologic Laser Therapy Center, Florence, Italy|No|Recruiting|January 2014|May 2019|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|27|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02407379||24036|
NCT02412345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41528915.5.0000.0068|Extracorporeal Shockwave Therapy in the Treatment for Erectile Dysfunction in Male Renal Transplant Recipients|Extracorporeal Shockwave Therapy in the Treatment for Erectile Dysfunction in Male Renal Transplant Recipients||University of Sao Paulo|Yes|Active, not recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|40 Years|70 Years|No|||December 2015|December 1, 2015|March 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412345||23654|
NCT02415855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC2012-01|Canadian Pradaxa Acute Stroke Safety Study|Canadian Pradaxa Acute Stroke Safety Study|CPASS|University of Alberta|Yes|Recruiting|March 2015|||March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Minor Stroke (NIHSS Score ≤ 3) and Transient Ischemic Attack Patients ≥ 18 years of age,        with a known history of or demonstrated atrial fibrillation (paroxysmal or persistent),        who can be treated with dabigatran following stroke.|December 2015|December 1, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415855|30 Days|23384|
NCT02426554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Braindrop|Dietary Supplementation of of DHA, Vitamin D3 and Uridine in Children|||University of Copenhagen|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426554||22562|
NCT02410785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/09|Efficacy of Polyglucosamine for Weight Loss|Efficacy of Polyglucosamine for Weight Loss - in a Randomized, Double-blind, Placebo-controlled Clinical Investigation||Certmedica International GmbH|No|Completed|August 2009|October 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|115|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||March 2015|January 26, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02410785||23774|
NCT02426567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200130161|The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria|An Exploratory Study on the Impact of a Food-based Restrictive Diet (Crohn's Disease-TReatment-with EATing/CD-TREAT Diet) and Liquid Exclusive Enteral Nutrition (EEN) on Healthy Gut Microbiota Composition and Metabolic Activity||University of Glasgow|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02426567||22561|
NCT02398682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-1111-26038|Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD)|Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) - A Pilot Study to Look at Enhancing Patient Care, Improving Patient Outcomes and Reducing NHS Costs|AKORDD|Heart of England NHS Trust|No|Active, not recruiting|October 2014|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1800|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398682||24701|
NCT02422173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tdcs002|Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke|Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial||Federal University of Paraíba|No|Completed|January 2015|April 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02422173||22899|
NCT02412618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-245|Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation|A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion|MMSAP|Medstar Research Institute|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|March 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412618||23633|
NCT02426580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chengdu 3rd Hospital|Dietary Education Intervention Impact on Dietary Protein Intake in PD|Dietary Education Intervention With Wechat Model Will Impact on Dietary Protein Intake in Patient Treated With Peritoneal Dialysis: a Prospective Randomized Controlled Pilot Trial|DIPIPD|The Second Affiliated Hospital of Chongqing Medical University|Yes|Enrolling by invitation|July 2015|July 2018|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|22 Years|85 Years|No|||April 2015|May 1, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426580||22560|
NCT02426593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-000060|Collection of Anatomical and Reference Data for Development of a Novel Non-Invasive Lung Hydration Status Technology|Collection of Anatomical and Reference Data for Development of a Novel Non-Invasive Lung Hydration Status Technology||Intersection Medical, Inc.|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general population using various media advertising as        well as through a site database. Potential subjects aged older than 30 will be recruited        for a telephone interview. If they qualify based on a very brief screening interview        regarding their suitability as a participant, and they are interested in participating,        they will be scheduled to visit the Intersection Medical, Inc., corporate office. If they        decline to participate, no further contact will be initiated.|October 2015|October 13, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426593||22559|
NCT02408393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2014-07|MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery|MIRs03: A Double-blind Randomized Trial of Paravertebral Block With Ropivacaine Before Breast Cancer Surgery: Effects on Chronic Postoperative Pain|MIRs03|Institut Curie|No|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|380|||Female|18 Years|85 Years|No|||March 2015|April 2, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02408393||23958|
NCT02395679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44330.000.14|Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients|A Phase I Study on Dendritic Cells Loaded With Allogeneous Cell Lysate in Patients With Mesothelioma as Maintenance Treatment After Chemotherapy|MesoCancerVa|Erasmus Medical Center|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02395679||24932|
NCT02416349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRETCHING RESPIRATORY MUSCLES|Acute Effects After Stretching Respiratory Muscles on Ventilatory Pattern and Volume Distribution of Chest Wall|Acute Effects After Stretching Respiratory Muscles on Ventilatory Pattern and Volume Distribution of Chest Wall in Patients With Stroke: a Randomized Crossover Clinical Trial||Universidade Federal de Pernambuco|No|Completed|November 2013|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|80 Years|No|||March 2014|April 9, 2015|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02416349||23346|
NCT02426606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SE012|Effects of Lentil Consumption on Post-prandial Blood Glucose and Insulin|The Love of Lentils (LoL) Study: The Effects of Acute Consumption of Common Lentil Varieties on Post-prandial Blood Glucose and Insulin Levels in Healthy Adult||University of Guelph|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|9||Anticipated|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426606||22558|
NCT02412514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14114|Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules|Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh||Centers for Disease Control and Prevention|Yes|Recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|456|||Both|6 Weeks|6 Weeks|Accepts Healthy Volunteers|||April 2015|July 28, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02412514||23641|
NCT02405702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-14|Importance of Patient Selection for Treatment of Infected Total Knee Prosthesis|Does the Selection of Patients Helps Healing the Infection After Change in One Step of a Knee Replacement?||University Hospital, Strasbourg, France|No|Not yet recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 years having surgery for the management of knee infection after change in        one step of a knee replacement prothesis in the participating services between 2000 and        2010.|April 2015|April 2, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02405702||24163|
NCT02408445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1720|Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment|Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment||University of Colorado, Denver|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|42 Days|108 Days|No|||September 2015|September 30, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408445||23954|
NCT02413164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2014|Effectiveness of a Physical Therapy Program on Self-assessment Health and Quality of Life in Patients With Schizophrenia|Effectiveness of a Physical Therapy Program on Self-assessment Health and Quality of Life in Patients With Schizophrenia||University of Malaga|Yes|Not yet recruiting|December 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||September 2015|December 2, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02413164||23591|
NCT02420860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0729|Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)|Phase II Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420860||23000|
NCT02420873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0926|An Open-label Phase II Study of Lorvotuzumab Mertansine|An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420873||22999|
NCT02425579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-ARDS001|Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)|A Phase I Trial of Inhaled Carbon Monoxide for the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)||Weill Medical College of Cornell University|Yes|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|7||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425579||22637|
NCT02409758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/15166-3|Comprehensive Voice Rehabilitation Program Compared With Vocal Function Exercises|The Effectiveness of the Comprehensive Voice Rehabilitation Program Compared With Vocal Function Exercises Method in Behavioral Dysphonia: A Randomized Controlled Clinical Trial.|Voicetherapy|Federal University of São Paulo|No|Completed|January 2011|August 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|50 Years|No|||April 2015|April 6, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02409758||23853|
NCT02395926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-003-01|To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers|||Hyundai Pharmaceutical Co., LTD.||Completed|October 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||February 2015|March 23, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395926||24913|
NCT02410746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECBLOCKV1|Nerve Block Versus Non-targeted Local Anaesthesia in Breast Surgery|A Prospective, Randomised Double Blinded Study Comparing a Pectoral Nerve Block With Non-targeted Local Anaesthetic in Bilateral Breast Surgery||BMI Healthcare|Yes|Not yet recruiting|May 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02410746||23777|
NCT02410759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH5|Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally|Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial||Cairo University|Yes|Recruiting|April 2015|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02410759||23776|
NCT02424331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19309213.3.0000.5208|Effect of Pursed Lips Breathing on Chest Wall, Mobility Diaphragmatic and Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease|||Universidade Federal de Pernambuco|Yes|Completed|March 2014|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|14|||Both|40 Years|80 Years|No|||April 2015|April 22, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02424331||22733|
NCT02407509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3808|Phase I Trial of RO5126766|A Phase I Trial of RO5126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma|DDU RAF/MEK|Royal Marsden NHS Foundation Trust|No|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2015|April 2, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02407509||24026|
NCT02397785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-150|Intra-vaginal Electrical Stimulation Device Compared to Sham Device for Chronic Pelvic Pain|Treatment of Pain Using a Non-implanted Intra-vaginal Electrical Stimulation Device Compared to Sham Device in Chronic Pelvic Pain||The Cleveland Clinic|Yes|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02397785||24770|
NCT02401100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmU-AL-01|Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow|Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow||Umeå University|No|Recruiting|May 2015|September 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|Preoperative and postoperative blood samples. Postoperative drain fluid samples. Tissue      samples from the perianastomotic region taken perioperatively.|Both|N/A|N/A|No|Probability Sample|Patients with rectal cancer who undergo anterior resection for rectal cancer at Umeå        University Hospital.|June 2015|June 17, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401100||24515|
NCT02419677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstPHChangzhou|Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases||The First People's Hospital of Changzhou|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||April 2015|April 14, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02419677||23091|
NCT02419690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3219|Dual Protection Project|Effectiveness of a Patient Centered Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Disease Among Adolescents||Denver Health and Hospital Authority|No|Recruiting|April 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02419690||23090|
NCT02425787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS14|Bereaved Parent Study|The Bereaved Parent Study||St. Jude Children's Research Hospital|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Parents who have lost a child at SJCRH and who consent to participate.|October 2015|October 21, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425787||22621|
NCT02424344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6570C00001|EFFECT OF ACLIDINIUM/FORMOTEROL ON LUNG HYPERINFLATION, EXERCICE CAPACITY AND PHYSICAL ACTIVITY IN MODERATE TO SEVERE COPD PATIENTS|A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).|ACTIVATE|AstraZeneca|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|269|||Both|40 Years|130 Years|No|||March 2016|March 7, 2016|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424344||22732|
NCT02409862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39-2013 SubStudy|Faces: Choices Study|Faces: Choices Study||University of Florida|No|Not yet recruiting|October 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409862||23845|
NCT02396784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EarlySTOPP-CN|Early Stockholm Obesity Prevention Program (EarlySTOPP-China)|A Randomised Controlled Trial for Overweight and Obese Parents to Prevent Childhood Obesity - China|EarlySTOPP-CN|Huazhong University of Science and Technology|No|Active, not recruiting|January 2011|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|1 Year|6 Years|Accepts Healthy Volunteers|Probability Sample|Children aged 1-6 yrs|March 2015|February 18, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396784||24847|
NCT02420041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0112|Comparing the Effects of Ultrasound Versus Fluoroscopy for Sacroiliac Joint Injections|Comparison of the Efficacy of Two Techniques for Sacroiliac Joint Injection: Ultrasound Guidance Versus Fluoroscopic Guidance||United States Naval Medical Center, San Diego|Yes|Completed|October 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 30, 2014||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT02420041||23063|
NCT02420613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0135|Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG)|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG)||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|7 Months|21 Years|No|||October 2015|October 7, 2015|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02420613||23019|
NCT02425254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15029|Preemptive Paracetamol for Postoperative Pain|Preemptive Paracetamol for Postoperative Pain: a Randomised, Double-blind, Two Way Crossover Trial|PPPP|University of Nottingham|No|Not yet recruiting|January 2016|July 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02425254||22662|
NCT02399995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-057|Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time|Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time||Memorial Sloan Kettering Cancer Center||Recruiting|March 2015|||March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled to undergo liver resection who meet the established criteria will        be approached for participation in this study during their preoperative visit. Patients        undergoing a two stage resection will have their time point frozen for up to six months        after their initial surgery. If the time before the second stage of their resection        exceeds six months, these patients will be excluded and replaced. The time point will        restart at the completion of the second time point.|November 2015|November 6, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399995||24600|
NCT02422940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALF-PS-1029|An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study||MILESTONE℠|Acorda Therapeutics|Yes|Recruiting|April 2015|November 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422940||22840|
NCT02422953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFP-Thatta|Stunting Prevention Project in Thatta and Sajawal Districts, Sindh Province, Pakistan|Effectiveness of Food/Nutrient Based Interventions to Prevent Stunting Among Children Under Five in Thatta and Sajawal Districts, Sindh Province, Pakistan||Aga Khan University|Yes|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5000|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||November 2015|November 11, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02422953||22839|
NCT02415907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15836A|Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine|Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men||H. Lundbeck A/S|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415907||23380|
NCT02420210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1120|Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma|Multicenter Phase II Study of the Bendamustine, Obinutuzumab, and Dexamethasone (BOD) Regimen in Un-fit Elderly ≥ 70 Years of Age Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL) Patients||University of Chicago|Yes|Not yet recruiting|November 2015|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|70 Years|N/A|No|||September 2015|September 30, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420210||23050|
NCT02425384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-GD001|Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents|Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents||HopeLab Foundation|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|182|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425384||22652|
NCT02400203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:115-2|FREE Living Hulled HEMP Seed and Oil Trial|FREE Living Hulled HEMP Seed and Oil Trial|FREEHEMP|University of Manitoba|No|Active, not recruiting|August 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400203||24584|
NCT02400463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.112|A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome|Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome||University of Michigan Cancer Center|Yes|Recruiting|September 2015|||January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400463||24564|
NCT02418065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0231|Multimodal Therapeutic Approach in Undernourished Maintenance Hemodialysis Patients (AMERICANO)|Multimodal Therapeutic Approach by Exercise, Oral Nutritional Supplementation, Omega 3 and Androgen in Undernourished Maintenance Hemodialysis Patients (AMERICANO)|AMERICANO|University Hospital, Clermont-Ferrand||Recruiting|December 2013|April 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02418065||23214|
NCT02423018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079-2014|Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms|Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal||Centre for Addiction and Mental Health|No|Terminated|April 2015|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|1|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|April 15, 2015||No|Low enrollment.|No||https://clinicaltrials.gov/show/NCT02423018||22834|
NCT02421731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regionale WP3|Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis Patients|Effectiveness of Robot-assisted Gait Training Versus Conventional Therapy on Mobility in Severely Disabled Multiple Sclerosis Patients||University Hospital of Ferrara|No|Recruiting|February 2014|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02421731||22933|
NCT02407899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRCMD LADA SAX 2015|Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes|A Randomized Controlled, Open-label, Multi-center Study With 104-week Fixed Dose of Saxagliptin or (and) Vitamin D3 Assessing Protective Effects on Beta Cell Function in Latent Autoimmune Diabetes in Adults (LADA) Treated With Insulin||Second Xiangya Hospital of Central South University|No|Recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407899||23996|
NCT02418338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9458|2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy Children|Evaluation of Myocardial Function by Two Dimensional Speckle Tracking Echocardiography in Children With Duchenne Muscular Dystrophy Versus Healthy Children: a Comparative Transversal Multicenter Study||University Hospital, Montpellier|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|99|||Both|N/A|17 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418338||23193|
NCT02418624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14REV|Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer|A Phase I Followed by a Randomized Phase II Trial of Two Cycles Carboplatin-Olaparib Followed by Olaparib Monotherapy Versus Capecitabine in BRCA-1 or -2 Mutated Her2 Negative Advanced Breast Cancer as First Line Treatment|REVIVAL|The Netherlands Cancer Institute|No|Recruiting|May 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418624||23171|
NCT02411643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00101294|Molecular Effects of Topical Calcipotriene on Morphea|Molecular Effects of Topical Calcipotriene on Morphea||Northwestern University|Yes|Recruiting|March 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411643||23708|
NCT02411656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0533|MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)|A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer Who Have Received Prior Chemotherapy With Clinical Response||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411656||23707|
NCT02408458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015001|Miromatrix Biological Mesh for Ventral Hernia Repair|A Prospective Post-Market Clinical Evaluation of Miromatrix Biological Mesh for Ventral Hernia Repair|MIROMESH PM-1|Miromatrix Medical Inc.|No|Enrolling by invitation|June 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||August 2015|October 30, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408458||23953|
NCT02419404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16712|Response of Pulse Pressure Variation in PA Catheter Tracing to IV Fluid Bolus in the ICU|Response of Pulse Pressure Variation in PA Catheter Tracing to IV Fluid Bolus in the ICU||University of Virginia|No|Active, not recruiting|May 2013|December 2015|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having cardiac surgery who have a pulmonary artery catheter|April 2015|April 13, 2015|May 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02419404||23112|
NCT02419417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA011-001|Study of BMS-986158 in Subjects With Select Advanced Solid Tumors|A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors|BET|Bristol-Myers Squibb|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|185|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419417||23111|
NCT02419222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-853-14|Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke|Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke Survivors With Multiple Lesions||Kessler Foundation|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||March 2016|March 10, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419222||23126|
NCT02395341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806409|The Longitudinal Ovarian Reserve Study|The Effects of Cancer Treatment on Ovarian Function: A Longitudinal Study by the Oncofertility Consortium||University of Pennsylvania|Yes|Active, not recruiting|May 2007|June 2016|Anticipated|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|serum|Female|15 Years|45 Years|No|Non-Probability Sample|Subjects will be referred for this study by their primary oncologists. Eligible        reproductive-aged girls and women newly diagnosed with cancer or another condition        requiring chemotherapeutic intervention will be enrolled|March 2015|March 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395341||24958|
NCT02409134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.020|Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat|Cognitive Function and Patient-Reported Psychological and Functional/Quality of Life Outcomes Investigation in Patients Taking Vorinostat for Graft-versus-Host Disease Prophylaxis||University of Michigan Cancer Center|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients enrolled on the primary study NCT01790568. Eligible patients who choose not to        participate in this add-on study will not be excluded from participating in NCT01790568.|December 2015|December 3, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02409134||23901|
NCT02410980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-Unilever-2014-1508|Skin Imaging to Assess the Effects of Tretinoin Cream and Skin Smoothing Laser Using Optic Imaging Technologies|In-vivo Non-invasive Skin Imaging Pilot Study to Assess the Effects of Tretinoin Cream and Skin Smoothing Laser™ Using Multi-photon Microscopy and Multi-spectral Imaging||University of California, Irvine|Yes|Recruiting|August 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Female|45 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02410980||23759|
NCT02489734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDETSC|Post Extubation Delirium and End-tidal Sevoflurane Concentration|Association Between Post Extubation Delirium and Pre-extubation End-tidal Sevoflurane Concentration in Children||Children's Hospital of Fudan University|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|2 Years|7 Years|No|||October 2015|October 14, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02489734||17712|
NCT02480049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/14/523|A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair® 10mg Tabs (Merck & Co, Egypt) to Healthy Adult Volunteers||Genuine Research Center, Egypt|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 21, 2015|June 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480049||18454|
NCT02488395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-58|Superior Colliculus Activity in Parkinson Disease: a Potential Marker?|Superior Colliculus Activity in Parkinson Disease: a Potential Marker? fMRI Brain Activation in Response to Visual Stimuli.|AGIRPARK|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|October 2015|October 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|35 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Groups of de novo Parkinson's patients and their age matching controls.|October 2015|October 14, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488395||17813|
NCT02493660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD-OR-010|A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears|A Prospective, Single Blinded, Multi-center, Randomized, Controlled, Pivotal Study to Assess the Safety and Effectiveness of the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears||OrthoSpace Ltd.|Yes|Recruiting|July 2015|December 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|184|||Both|40 Years|100 Years|No|||October 2015|December 13, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493660||17410|
NCT02461862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nº CEP: 0272/2015|Vital Signs and Pain During Insertion of IUD|Assessment of Vital Signs and Pain During Insertion of Intra Uterine Device||Federal University of São Paulo|Yes|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|285|||Female|18 Years|60 Years|No|Probability Sample|Women that attended to clinical visit to insertion of IUD|June 2015|June 1, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02461862||19852|
NCT02486666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HamiltonHSC|A Pilot Feasibility And Safety Multicenter Trial Of Administering Weight FiXET Study|A Pilot Feasibility And Safety Multicenter Trial Of Administering Weight Adjusted Fixed Dose Of Low Molecular Weight Heparin (Enoxaparin) To Neonates With Thrombosis (Fixet): Study Protocol|FiXET|Hamilton Health Sciences Corporation|Yes|Recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|N/A|60 Days|No|||March 2016|March 24, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02486666||17946|
NCT02480543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0085-15-WOMC|Different Routes of Misoprostol Prior to First Trimester Surgical Abortion|Different Routes of Misoprostol for Same-day Cervical Preparation Prior to First Trimester Surgical Abortion: a Randomized Controlled Trial||Wolfson Medical Center|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 21, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02480543||18416|
NCT02480556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A22062015|Comparing Blood Loss During Caesarean Section Between Manual Separation of Placenta & Conservative Management|Comparing Blood Loss Between Manual Separation & Conservative Management for Removal of the Placenta During Caesarean Section; a Randomized Controlled Study||Kasr El Aini Hospital|No|Completed|July 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|838|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||August 2015|March 2, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480556||18415|
NCT02483546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|High Fidelity Simulation vs Standard Teaching Training of Cardiac Resuscitation|High Fidelity Simulation In Medecine Education|SIMCARE|University of Monastir|Yes|Recruiting|January 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|181|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02483546||18185|
NCT02463188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34DA035349-02|Promoting Sleep to Prevent Substance Use in Adolescence|Promoting Sleep to Prevent Substance Use in Adolescence||University of California, Berkeley|No|Active, not recruiting|February 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02463188||19750|
NCT02478164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-163|Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma|Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma||Dana-Farber Cancer Institute|Yes|Recruiting|July 2015|April 2023|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478164||18599|
NCT02492802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSA-CRP|Effect of Inflammation on Pharmacokinetics of Posaconazole|Effect of Inflammation on Pharmacokinetics of Posaconazole||University Medical Center Groningen|No|Not yet recruiting|July 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|-  patients with hematological malignancies          -  immunocompromised patients|July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02492802||17476|
NCT02492815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-367|PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma|An Observational Study to Evaluate the Effectiveness and Safety of Ipilimumab, Administered During the European Expanded Access Programme in Pretreated Patients With Advanced (Unresectable or Metastatic) Melanoma||Bristol-Myers Squibb|No|Recruiting|October 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2500|||Both|16 Years|N/A|No|Non-Probability Sample|Patients participating in Expanded Access Program|January 2016|January 14, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02492815||17475|
NCT02479594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WE_01|Competence-feedback and Therapy Outcome|The Importance of Competence-feedback for Therapy Outcome: a Randomized Controlled Trial||Johannes Gutenberg University Mainz|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479594||18489|
NCT02467296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HL119773-01A1|Dietary Sodium Intake and Outcomes in Heart Failure|Rationale and Design of the PRevent Adverse Outcomes in Heart faIlure By limITing Sodium Study|ProhibitSodium|Stony Brook University||Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467296||19435|
NCT02482896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-421|The Danish General Rural Population Study|The Danish General Rural Population Study|GERUS|Region Sjælland|Yes|Not yet recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|25000|Samples With DNA|Blood, urine, faeces, saliva|Both|N/A|110 Years|No|Probability Sample|The population of Lolland and Guldborgsund municipalities in Denmark.|October 2015|October 27, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02482896||18235|
NCT02486419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-297-14|Human Neck Brown Adipose Tissue mRNA Profile, a Seasonal Variation Study.|Human Neck Brown Adipose Tissue mRNA Profile, a Seasonal Variation Study.||Aarhus University Hospital|Yes|Recruiting|February 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||8|Anticipated|120|Samples With DNA|Adipose tissue biopsies|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted for neck surgery at Aarhus University Hospital.|January 2016|January 11, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02486419||17965|
NCT02489136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC123|Study of Spirit Pass in Newborn and Patient|Effect of Spirit Pass on Serum Cortisol Levels, Pain, Physiological Parameters and Haematologic Response in Newborn and Patient|SSPNP|Universidade Federal do Triangulo Mineiro|Yes|Completed|July 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|July 6, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02489136||17757|
NCT02489370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/356/REK nord|CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial|CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial||University Hospital of North Norway|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|N/A|No|||July 2015|July 2, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02489370||17739|
NCT02490878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221208|Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases|Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases||Alliance for Clinical Trials in Oncology|Yes|Not yet recruiting|August 2015|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|130|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490878||17624|
NCT02475109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-01-201|Study of Topical Ocular PAN-90806 in PDR|A Phase 1 Open-Label, Single-Center Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Proliferative Diabetic Retinopathy (PDR)||PanOptica, Inc.|Yes|Active, not recruiting|August 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475109||18834|
NCT02475122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2014-02|Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)|Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)|AzyMR|University Hospital, Angers|No|Recruiting|October 2014|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2014|June 17, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475122||18833|
NCT02489903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-211-01|RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens|An Open-label, Three Stage, Three Arm Pilot Study of RRx-001 For Second Line or Greater Small Cell Lung Cancer, Third Line or Greater Non-Small Lung Cancer, and Second Line or Greater High Grade Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (TRIPLE THREAT)|TRIPLE THREAT|EpicentRx, Inc.|No|Recruiting|June 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489903||17699|
NCT02410850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00743|Long Term Oral Appliance Therapy Effectiveness for Obstructive Sleep Apnea Syndrome|Long Term Oral Appliance Therapy Effectiveness for Obstructive Sleep Apnea: A Multicenter Cohort Study||University of British Columbia|No|Not yet recruiting|January 2016|September 2022|Anticipated|September 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||13|Anticipated|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who seek Oral Appliance therapy.|November 2015|November 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02410850||23769|
NCT02408263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10106|Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores|Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores||Hospital for Special Surgery, New York|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing surgery for unilateral Total Hip Replacement and Total Knee        Replacement.|March 2015|March 31, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02408263||23968|
NCT02420015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061683|Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia|Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia||Duke University|No|Not yet recruiting|July 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420015||23065|
NCT02415452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACS|Researches of Retinal Artery Lesions and Acute Coronary Syndrome|Retinal Artery Lesions to Predict Long-term Outcomes in Patients With Acute Coronary Syndrome After Drug-Eluting Stent Implantation|REACS|Capital Medical University|No|Active, not recruiting|July 2006|January 2018|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|660|||Both|18 Years|85 Years|No|Non-Probability Sample|1. acs patients in beijing mentougou district hospital          2. acs patients in beijing shijitan hospital          3. acs patients in beijing tiantan hospital|January 2016|January 16, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415452||23415|
NCT02411981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLuc MBWN2 03|Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis|Short-term Effects of Chest Physiotherapy on Ventilation Inhomogeneity in Non-CF Bronchiectasis||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|April 2015|February 2016|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411981||23682|
NCT02405208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-HRA-002|A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing|A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing|CHRA|Integra LifeSciences Corporation|No|Suspended|May 2010|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|142|||Both|21 Years|75 Years|No|Non-Probability Sample|Subjects who require humeral head resurfacing arthroplasty.|March 2016|March 23, 2016|November 4, 2014||No|Enrollment stopped for further testing|No||https://clinicaltrials.gov/show/NCT02405208||24201|
NCT02405221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1553|Clinical Trial Safety and Feasibility of TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer|A Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|May 2016|||May 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|100 Years|No|||December 2015|December 29, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405221||24200|
NCT02412631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005230|Addressing Post Cessation Weight Gain|Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention||Mayo Clinic|Yes|Not yet recruiting|November 2015|December 2020|Anticipated|August 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412631||23632|
NCT02412696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD078515-01A1|Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)|Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea|PAP-SAP|The Miriam Hospital|Yes|Recruiting|June 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|262|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02412696||23627|
NCT02412215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0026769|Rotational Stability After Nanoflex Collamer Toric Intraocular Lens Implantation in Astigmatic Patients|Rotational Stability After Nanoflex Collamer Toric Intraocular Lens Implantation in Astigmatic Patients Undergoing Cataract Surgery|T-IOL|University of Turin, Italy|No|Recruiting|March 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|60 Years|N/A|No|||April 2015|April 8, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02412215||23664|
NCT02412228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299|BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.|BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.||Brown University|Yes|Recruiting|August 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412228||23663|
NCT02395692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00356|Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma|Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma||National Cancer Institute (NCI)||Recruiting|December 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|March 8, 2016|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395692||24931|
NCT02420158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.844|Trans-cutaneous Vagal Nerve Electrical Stimulation and Irritable Bowel Syndrome|Sympatho-vagal Balance in Patients With Irritable Bowel Syndrome, and Evaluation of a Transcutaneous Vagal Nerve Electrical Stimulation on Symptoms and Quality of Life|StVSII|Hospices Civils de Lyon|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|60 Years|No|||January 2016|January 20, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420158||23054|
NCT02420171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibnsina IVF center Sohag|Adding Insulin to IVF Culture Media Significantly Improve Outcome|||Ibn Sina Hospital|No|Recruiting|January 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420171||23053|
NCT02412956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15CA167586|SmokefreeMOM: Reaching Pregnant Smokers With Health Information Via Text Messaging|Quit4Baby: Reaching Pregnant Smokers With Health Information Via Text|SmokefreeMOM|George Washington University||Recruiting|January 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Female|13 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02412956||23607|
NCT02408796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201505|Open-Label Study of OTO-201 for Treatment of AOMT|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Supra-Tympanostomy Tube Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects||Otonomy, Inc.|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|6 Months|17 Years|No|||June 2015|June 17, 2015|March 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408796||23927|
NCT02407145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015O&G01M|Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women|Safety and Efficacy of Low-elasticity Polyvinylidene Fluoride (DynaMesh®-SIS Soft) Retropubic Tension Free Midurethral Sling in the Treatment of Stress Urinary Incontinence in Women||Norfolk and Norwich University Hospitals NHS Foundation Trust|No|Not yet recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|268|||Female|20 Years|N/A|No|Non-Probability Sample|Women presenting with urinary incontinence, presenting to the research centres through        normal referral pathways|March 2015|March 30, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02407145||24054|
NCT02395913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-002-02|Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)|||Hyundai Pharmaceutical Co., LTD.|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395913||24914|
NCT02420886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibnsina IVF center|Adding Cytokine to In Vitro Human Culture Media to Improve Embryogenesis and Implantation|||Ibn Sina Hospital|No|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420886||22998|
NCT02414256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Va-003|PECS Block in Breast Surgery: an Observational Multicenter Study|PECS Block in Breast Surgery: an Observational Multicenter Study||Ospedale di Circolo - Fondazione Macchi|No|Recruiting|January 2015|June 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Patients submitted to breast surgery|April 2015|April 9, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414256||23507|
NCT02414269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007|Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin|A Phase I Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin||Memorial Sloan Kettering Cancer Center||Recruiting|May 2015|||April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414269||23506|
NCT02407405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00456|Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery|Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas||National Cancer Institute (NCI)||Recruiting|December 2015|||June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407405||24034|
NCT02407457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0011|Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices|Multicenter, Post-Market Study to Assess Outcomes of Patients Treated With the AFX System Compared to Other EVAR Devices for Endovascular Abdominal Aortic Aneurysm Repair: LEOPARD|LEOPARD|Endologix|No|Enrolling by invitation|March 2015|September 2022|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407457||24030|
NCT02400775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Azilsartan-4001|A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.|A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.|ALIVE|Takeda||Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|20 Years|N/A|No|||February 2016|February 29, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02400775||24540|
NCT02400788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHI-1001-HCC-02|Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)|A Phase I/II Study in Combination of Resminostat and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Previously Untreated With Systemic Chemotherapy||Yakult Honsha Co., LTD||Recruiting|April 2013|||October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|N/A|No|||March 2015|March 23, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02400788||24539|
NCT02415218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662/2555(EC2)|Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency|Clinical Study of Transplantation of Autologous Cultivated Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency||Siriraj Hospital|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||April 2015|April 13, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415218||23433|
NCT02414503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2728|Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder|A Randomized, Placebo Controlled, Double-blind, 3-period Cross-over Study in Adult Patients With Autism Spectrum Disorders Evaluating Cognitive Response After Single- Dose Oxytocin 8 or 24 IU Intranasal Administration Using the OptiNose Bi-directional Nose-to-brain Device||OptiNose AS|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|18|||Male|18 Years|35 Years|No|||February 2016|February 9, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02414503||23488|
NCT02414516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBP-801-001|A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors|A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors||Oncolys BioPharma Inc|No|Recruiting|March 2015|||February 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414516||23487|
NCT02402608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-1|Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly|Whey Protein, Amino Acids and Vitamin D Supplementation With Physical Activity Increases Muscle Mass and Strength, Functionality and Quality of Life and Decreases Inflammation in Sarcopenic Elderly||Azienda di Servizi alla Persona di Pavia|Yes|Completed|January 2012|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|130|||Both|65 Years|90 Years|No|||March 2015|March 25, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02402608||24399|
NCT02409732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28525|Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis|Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis||Dartmouth-Hitchcock Medical Center|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409732||23855|
NCT02410369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS2643|Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer|Phase II Study of S-588410 as Maintenance Monotherapy After Adjuvant Chemotherapy in Patients With Completely Resected Non-small- Cell Lung Cancer||Tokyo University|Yes|Recruiting|March 2015|September 2021|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||August 2015|August 11, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02410369||23806|
NCT02422212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05|Diet-induced Thermogenesis in Patients With Postoperative Roux-in-Y Gastric Bypass (RYGBP) Weight Regain|Diet-induced Thermogenesis in Patients With Postoperative RYGBP Weight Regain|RYGBP|Gastrocirurgia, Brazil|No|Completed|January 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|45|||Female|18 Years|75 Years|No|||April 2015|April 22, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02422212||22896|
NCT02412189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDamen|Pressure-dependent Changes in Hematocrit and Plasma Volume During Anesthesia|Pressure-dependent Changes in Hematocrit and Plasma Volume During Anesthesia||Sahlgrenska University Hospital, Sweden|No|Recruiting|February 2014|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|No|||April 2015|April 4, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02412189||23666|
NCT02419807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE10114|Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer|Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Female|N/A|N/A|No|||March 2016|March 2, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419807||23081|
NCT02407561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol_CBI_RC_PVS|Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays|Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays||Castle Biosciences Incorporated|No|Enrolling by invitation|February 2015|December 2030|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Formalin Fixed Paraffin Embedded (FFPE) H&E stained tumor samples(biopsy and resection)      cDNA- tumor sample IHC Stained FFPE- tumor samples|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with newly diagnosed rectal adenocarcinoma, or anal squamous cell carcinoma (SCC)        who will undergo neoadjuvant chemoradiation prior to surgery.|March 2015|April 2, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02407561||24022|
NCT02401347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0050|Talazoparib Beyond BRCA (TBB) Trial|A Phase II Clinical Trial of BMN 673 in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency as Assessed by the HRD Assay, and (ii) Advanced HER2-Negative Breast Cancer With Either a Germline or Somatic Mutation in Homologous Recombination Pathway Genes||Stanford University|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||August 2015|August 9, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401347||24496|
NCT02401360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012135|A Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products|A Controlled Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products||Procter and Gamble||Completed|April 2013|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02401360||24495|
NCT02422251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho 14-12|Biomechanical Assessment of a High Congruency Knee Bearing|Clinical Investigation of the Functional Outcomes of High Congruency Versus Low Congruency Knee Bearings||Golden Jubilee National Hospital|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|120|||Both|35 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422251||22893|
NCT02425267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-725|Effectiveness of a Home Telerehabilitation Program for People With Proximal Humerus Fracture|Effectiveness of a Home Telerehabilitation Program for People With Proximal Humerus Fracture Treated Conservatively: a Randomized Clinical Trial.|TeleFracture|Université de Sherbrooke|No|Recruiting|June 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425267||22661|
NCT02407834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mestradopt2013|Effectiveness of Hygiene Solutions on Denture Biofilm|Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing||University of Sao Paulo|Yes|Completed|August 2012|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|64|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02407834||24001|
NCT02422849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS-ED-01-2013|Acute Combined Care for Seniors in Southern Denmark|Acute Combined Care for Seniors in Southern Denmark|ACCESS|University of Southern Denmark|No|Completed|November 2013|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|131|||Both|60 Years|N/A|No|||February 2016|February 13, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02422849||22847|
NCT02412995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M208|The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite|The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite - A Randomised, Controlled, Crossover Study of Danish Berries in Overweight and Obese Male Subjects|OPUS-WP3C|University of Copenhagen|No|Completed|October 2012|February 2015|Actual|November 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|6||Actual|18|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02412995||23604|
NCT02413255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-020-1001|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Non-Japanese Healthy Volunteers and an Ethnic Comparison With Japanese Healthy Subjects||Takeda|No|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Anticipated|136|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02413255||23584|
NCT02420626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140203|Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System|Volcano Crux Vena Cava Filter Registry||Volcano Corporation|No|Not yet recruiting|January 2016|May 2019|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|||Both|19 Years|85 Years|No|Probability Sample|Patients are eligible for inclusion if they are scheduled for a vena cava filter implant        with the Crux VCF System or have had a Crux VCF implanted within the previous 6 months for        any of the following situations:          1. Pulmonary thromboembolism when anticoagulation therapy is contraindicated;          2. Failure of anticoagulation therapy in thromboembolic disease;          3. Emergency treatment following massive pulmonary embolism where anticipated benefits             of conventional therapy are reduced; and          4. Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is             contraindicated.|December 2015|December 8, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420626||23018|
NCT02413203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818658-Part B|Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B|A Randomized, Double-blinded, Placebo-controlled Study Investigating the Pharmacological Response to Celecoxib Using ex Vivo Human Whole-blood Assay (hWBA) and Broad-spectrum Lipidomics Analysis||University of Pennsylvania|No|Active, not recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413203||23588|
NCT02395666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC003B|Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission|A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission||Spectrum Health Hospitals|Yes|Recruiting|March 2015|March 2021|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|N/A|21 Years|No|||February 2016|February 16, 2016|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395666||24933|
NCT02401048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1136-CA|A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas|A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas||Pharmacyclics|No|Recruiting|May 2015|July 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|109|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02401048||24519|
NCT02424318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2008-71|Topiramate and Cerebrovascular Response in Migraineurs|Effect of Topiramate on Cerebrovascular Response to Photic Stimulation in Migraineurs||SMG-SNU Boramae Medical Center|Yes|Completed|December 2008|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 18, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02424318||22734|
NCT02414672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1535|CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients|CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414672||23475|
NCT02416440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Motala IIS# 51223- Merck|Durban Diabetes Study:A Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent (DDS)|Durban Diabetes Study: A Population Based Cross-sectional Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent|DDS|University of KwaZulu|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|Phase 0|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1200|Samples With DNA|1. whole blood for DNA extraction and genetic analysis.        2. EDTA whole blood for Full Blood Count and Glycosylated Haemoglobin        3. EDTA whole blood for Hepatitis C Viral load test and RNA extraction for whole virus           genome sequencing.        4. Plain serum for liver function test, serum lipids, insulin and c-peptide, and for viral           markers- HIV, Hepatitis .        5. Sodium Fluoride tubes for plasma glucose|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|adult urban Africans (blacks) aged 18years and over living in the eThekwini Municipality        (also know as the city of Durban) in the province of KwaZulu-Natal in South Africa.|April 2014|April 9, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02416440||23339|
NCT02410486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0055|Early-Onset Sepsis an NICHD/CDC Surveillance Study|Early-Onset Sepsis an NICHD/CDC Surveillance Study|EOSII|NICHD Neonatal Research Network|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|480|||Both|N/A|72 Hours|No|Non-Probability Sample|The study population will include all live born infants who are at least 22 weeks GA and        have a birth weight >400 grams and are delivered at NRN centers.|March 2016|March 21, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410486||23797|
NCT02410499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1202-2005|Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria|A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria||Takeda|Yes|Withdrawn|April 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410499||23796|
NCT02409615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS001|Complementary Therapies in Spinal Fusion Patients|A Pilot Study of the Effectiveness of Complementary Therapies to Reduce Pain in Spinal Fusion Patients||Nemours Children's Clinic|Yes|Recruiting|August 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||March 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409615||23864|
NCT02409628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKT01|EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds|EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds||Neotherix Limited|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02409628||23863|
NCT02423044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150114|Spatial Context and Fear Learning|fMRI Spatial Context and Fear Conditioning||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02423044||22832|
NCT02399436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0900-P3H|Appalachians Together Restoring the Eating Environment||Appal-TREE|University of Kentucky|Yes|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|682|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02399436||24643|
NCT02402400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2028-15-SMC-EA-CTIL|Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study|Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome||Sheba Medical Center|No|Completed|July 2015|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||March 2016|March 19, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402400||24415|
NCT02415205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150005|Pain and Stress Assessment and ROP Screening|Pain and Stress Assessment and ROP Screening Examination in Premature Infants||Loma Linda University|Yes|Recruiting|April 2015|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|24 Weeks|32 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Premature infants undergoing SOC ROP eye exams|April 2015|January 28, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415205||23434|
NCT02415413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-CESAR|Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma|A Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus High-dose Therapy With Melphalan and Autologous Stem Cell Transplantation, Followed by Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients Under 65 Years With High Risk Smoldering Multiple Myeloma||PETHEMA Foundation|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|March 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415413||23418|
NCT02481284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIngvaldsen|Microcirculation of the Abdominal Skin After Deep Inferior Epigastric Artery Perforator Flap Procedure|Microcirculatory Evaluation of the Abdominal Skin in Breast Reconstruction With Deep Inferior Epigastric Artery Perforator Flap||Oslo University Hospital|No|Completed|January 2008|March 2015|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Female|N/A|N/A|No|Non-Probability Sample|20 women consecutively undergoing secondary, unilateral breast reconstruction with a DIEAP        flap were identified and recruited to participate in the study. The patients were informed        about of risks and benefits and gave written consent prior to participation. All smokers        stopped smoking 4 weeks prior to surgery.|June 2015|June 22, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02481284||18359|
NCT02481297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0933|Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients|Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481297||18358|
NCT02484222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTCA-01|Fentanyl Test in Children's Adenotonsillectomy|Fentanyl Test Results and Its Association With Morphine Requirements in Children With Obstructive Sleep Apnea Syndrome After Adenotonsillectomy||Children's Hospital of Fudan University|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|3 Years|7 Years|Accepts Healthy Volunteers|Probability Sample|children who were diagnosed with Obstructive Sleep Apnea Syndrome(OSAS) by electronic        nasopharyngoscope and underwent selective adenotonsillectomy|February 2016|February 5, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02484222||18133|
NCT02480335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49919.042.14|The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis|The Clinical Efficacy And Subclinical Effects on Arterial STIFFNESS of Bosentan Therapy Added to Usual Care in Patients With Systemic Sclerosis With Digital Ulcers|CEASESTIFF|University Medical Center Groningen|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02480335||18432|
NCT02470858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_Triple Therapy_1|Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects|Effect of Triple Direct Acting Antiviral Agents (DAAs) for Non-cirrhotic Subjects With Chronic HCV G1b Infection||Humanity & Healthy GI and Liver Centre|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470858||19161|
NCT02489279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNI-SAC-I|Training Attentional Awareness and Control in ADHD|Training Attentional Awareness and Control in Attention Deficit Hyperactivity Disorder (ADHD)|SAC-I|Think Now Incorporated|No|Recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|40 Years|No|||November 2015|November 4, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02489279||17746|
NCT02484989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALA1012|UK Surveillance of Treated Retinopathy of Prematurity|||Moorfields Eye Hospital NHS Foundation Trust|No|Completed|May 2013|July 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|270|||Both|N/A|1 Year|No|Non-Probability Sample|Babies with retinopathy|March 2016|March 15, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484989|1 Year|18074|
NCT02485197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1029-F6A|Muscle Metabolic Function in Older Adults With Different Vitamin D Status Before and After Exercise|A Pilot Study Investigating Differences in Muscle Metabolic Function in Individuals Aged 65-75 Years With Different Vitamin D Status Before and After 7-days of Aerobic Training||University of Kentucky|No|Completed|March 2013|June 2015|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|7|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|April 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02485197||18058|
NCT02488590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57767|Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases|Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases|ACOS|Katholieke Universiteit Leuven|No|Recruiting|July 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|200|||Both|30 Years|80 Years|No|||June 2015|July 7, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488590||17798|
NCT02467595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED14142|The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on Anesthesia in Adenotonsillectomy|The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on the Anesthetic Condition With Fentanyl in Children Undergoing Adenotonsillectomy||Korea University Anam Hospital|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|75|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467595||19412|
NCT02482376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063848|Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer|A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response||Duke University|No|Recruiting|October 2015|September 2022|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|50 Years|N/A|No|||November 2015|November 4, 2015|June 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482376||18275|
NCT02482389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063936|Study of Preoperative Boost Radiotherapy|A Phase II Study of Preoperative Boost Radiotherapy in Patients With Breast With Biomarker Analysis||Duke University|No|Recruiting|October 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|60 Years|No|||November 2015|November 4, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482389||18274|
NCT02482467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9434|Prognosis and Long Term Pubertal Outcome of Girls Previously Diagnosed With a Prenatal Ovarian Cyst|Prognosis and Long Term Pubertal Outcome of Girls Previously Diagnosed With a Prenatal Ovarian Cyst|KYSTOV|University Hospital, Montpellier|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|218|||Female|6 Years|24 Years|Accepts Healthy Volunteers|||February 2015|June 23, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02482467||18268|
NCT02482480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPAR-ALAT-2014|Comprehensive Management for the Treatment of Obstructive Sleep Apnea|Effects of a Comprehensive Management Program for the Treatment of Obstructive Sleep Apnea Syndrome||Hospital Clinic of Barcelona|Yes|Completed|October 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|85 Years|No|||March 2016|March 17, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02482480||18267|
NCT02483832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057568|Message Framing and Colorectal Cancer Screening|Effects of Message Framing and Risk Feedback on CRC Screening|CRC|Duke University|No|Recruiting|February 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483832||18163|
NCT02473107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDEC-02|Impact of Detecting Initial and Active Caries Lesions in Primary Teeth|CARies DEtection in Children - Cost-efficacy, Applicability and Impact on Quality of Life of Detecting Active Initial Caries Lesions in Primary Teeth||University of Sao Paulo|Yes|Recruiting|February 2015|April 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|248|||Both|36 Months|83 Months|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02473107||18988|
NCT02486432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612-013|A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)|A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach||NeuroDerm Ltd.|No|Completed|April 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 28, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02486432||17964|
NCT02491710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1322/2015|Comparison of an Inexpensive Tablet-based Laparoscopic Box Trainer With a Standard Box Trainer|||Medical University of Vienna|No|Completed|August 2015|||September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02491710||17560|
NCT02491762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-15-0029-CTIL|The Effect of Breast Reconstruction Surgery Using Tissue Expanders on Respiratory Functions|The Effect of Breast Reconstruction Surgery Using Tissue Expanders on Respiratory Functions||Carmel Medical Center|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|45|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients elected for breast reconstruction surgery using tissue expander-implant technique|July 2015|July 13, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02491762||17556|
NCT02482701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91038126|The Captivator EMR Registry|An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus||Boston Scientific Corporation|No|Not yet recruiting|August 2015|||June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Barrett's Esophagus patients with early neoplasia.|June 2015|June 23, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482701|30 Days|18250|
NCT02479880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-EU-174-1403|Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection|Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe||Gilead Sciences|No|Recruiting|July 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|12 Years|15 Years|No|||March 2016|March 8, 2016|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479880||18467|
NCT02476799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUMC 2014-07-006-001|Analgesic Effects of US Bilateral Rectus Sheath Block for Laparoscopic GY Surgery|Postoperative Analgesic Effects of Ultrasound-guided Bilateral Rectus Sheath Block for Laparoscopic Gynecologic Surgery||Ewha Womans University Mokdong Hospital|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|21 Years|60 Years|No|||June 2015|June 18, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02476799||18704|
NCT02488863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401056|NEPAL (Neuromodulatory Examination of Pain and Mobility Across the Lifespan)|Neuroimaging Age-related Versus Pain-related Changes in Pain Modulation|NEPAL|University of Florida|No|Recruiting|July 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood plasma|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Older adults over 65 years of age who experience knee pain as well as those that do not        experience knee pain|February 2016|February 2, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02488863||17778|
NCT02488876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 151/09|Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery|Non-individual Related Ongoing Collection of Blood Samples for the Compilation of a Unique Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery||RWTH Aachen University|No|Recruiting|April 2009|December 2099|Anticipated|December 2099|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients scheduled for cardiac surgery|May 2015|July 1, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02488876|7 Days|17777|
NCT02491775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201408008|Afatinib Genomic Landscape|Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib||Washington University School of Medicine|No|Recruiting|June 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from the Washington University School of Medicine and        Barnes-Jewish healthcare system who previously consented to study HRPO (Human Research        Protection Office)# 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and        Collection of Health Information from Patients with Thoracic Malignancies, Suspected        Thoracic Malignancies, or Mesothelioma").|January 2016|January 14, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02491775||17555|
NCT02419001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-1-004-003|A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy|A Phase 1b/2a, Randomized, Multi-center, Open-label, Fixed-sequence Study to Evaluate the Effect of Oral SYN-004 on the Pharmacokinetics of Intravenous Ceftriaxone in Healthy Adult Subjects With a Functioning Ileostomy||Synthetic Biologics Inc.|No|Completed|March 2015|October 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419001||23142|
NCT02398071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Khon Kaen University|The Effects of Positive Expiratory Pressure Breathing on The Rate of Post-exercise Recovery in Patients With COPD|The Effects of Breathing With a Positive Expiratory Pressure Device on The Rate of Post-exercise Recovery in Patients With COPD||Khon Kaen University|Yes|Recruiting|August 2014|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Male|40 Years|70 Years|No|||March 2015|March 19, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02398071||24748|
NCT02398370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMD-MSC-ED-01|Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED|Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Mild to Moderate Erectile Dysfunction|PMD-MSC-ED-01|Z Urology|Yes|Completed|July 2013|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|40 Years|70 Years|No|||April 2015|April 24, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02398370||24725|
NCT02419729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39495014.0.0000.0082|Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy|Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy||Faculdade de Medicina do ABC|No|Active, not recruiting|March 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Female|45 Years|65 Years|No|||April 2015|April 16, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02419729||23087|
NCT02405650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37396 CRIC VAP|CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease|Visceral Adiposity and Physical Fitness in CKD|CRIC-VAP|Baylor College of Medicine|No|Recruiting|April 2015|||July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|526|None Retained|serum, blood|Both|21 Years|79 Years|No|Non-Probability Sample|Must be participant in Prospective Cohort Study of Chronic Renal Insufficiency (CRIC).        CRIC participants are a racially and ethnically diverse group of adult patients with        mild-to-moderate CRI.|January 2016|January 11, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02405650||24167|
NCT02408276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14171|Longitudinal Evaluation of Hip Cartilage Degeneration: FAI|Longitudinal Evaluation of Hip Cartilage Degeneration: the Effect of Femoroacetabular Impingement||Hospital for Special Surgery, New York|No|Recruiting|December 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|10 Years|35 Years|No|Non-Probability Sample|35 years of age or younger enrolled in the HSS Hip Preservation Registry prior to        September 30, 2016 with an MRI confirmed diagnosis of FAI|March 2015|March 31, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408276||23967|
NCT02416843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/SW/0193|Metabolic and Immune System Responses to a Mixed Meal|Metabolic and Immune System Responses to a Mixed Meal in Human Adipose Tissue and the Circulation||University of Bath|No|Completed|September 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02416843||23308|
NCT02416921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412141|Preventing Weight Gain in African American Reproductive-Aged Women|Preventing Weight Gain in African American Reproductive-Aged Women: Pilot Program|FB--Pilot|Washington University School of Medicine|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02416921||23302|
NCT02406807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|H-reflex Responses to High-Velocity Low-Amplitude Manipulation|H-reflex Responses to High-Velocity Low-Amplitude Manipulation in Adults With Chronic Non-specific Low Back Pain||Instituto Brasileiro de Osteopatia|Yes|Completed|May 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02406807||24080|
NCT02408783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP SGA|Simplified Gestational Age Score|Validation of a New Simplified Score for Assessing Gestational Age of Newborns in Community|SGAS|NICHD Global Network for Women's and Children's Health|Yes|Recruiting|July 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|13000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Global Network Nagpur, India site will select 5 distinct Health Facilities with an        average of more than 300 deliveries per year. All women who deliver in the study Health        Facilities will be eligible for study enrolment after fulfilling the inclusion criteria.|February 2016|February 1, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408783||23928|
NCT02399774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0087-15-RMC|Dental Support Device During Breastfeeding as a Mean for Pain Control|Dental Support Device During Breastfeeding as a Mean for Pain Control||Rabin Medical Center|Yes|Not yet recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|May 17, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399774||24617|
NCT02422303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150248H|Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms|Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms||The University of Texas Health Science Center at San Antonio|No|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|65 Years|No|||December 2015|December 3, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422303||22889|
NCT02417181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA_in_spoedzorg|The (Cost-)Effectiveness of Physician Assistants Working at the Primary Out of Hours Emergency Service|The (Cost-)Effectiveness of Physician Assistants Working at the Primary Out of Hours Emergency Service||Radboud University|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|11000|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 27, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02417181||23282|
NCT02407158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015336|Pilot Study for Verifying Endotracheal Tube Repositioning Using Ultrasound|A Pilot Study to Explore Alternative Methods for Verifying Endotracheal Tube Repositioning in the Surgical Intensive Care Unit||Yale University|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Intubated patients in the SICU requiring ETT repositioning will be identified by SICU        clinicians.|December 2015|December 29, 2015|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407158||24053|
NCT02400021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT025|Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals|Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals|ProSPAR|Mount Sinai Hospital, Canada|Yes|Not yet recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400021||24598|
NCT02425475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLIMMA-01|FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA)|A Prospective, Non-controlled, Multicenter Clinical Study to Evaluate the Diagnostic Accuracy of the Stepwise Two Photon Excited Melanin Fluorescence of Potentially Malignant Pigmented Lesions as Compared to Histopathological Diagnosis|FLIMMA|University Hospital Tuebingen|No|Recruiting|August 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|This study evaluates patients with pigmented lesions, which are excised in order to        exclude or diagnose cutaneous melanoma.|July 2015|July 17, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02425475||22645|
NCT02419482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/468|Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training|Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training: A Randomized Controlled Trial.|IMPROV-IT|Norwegian University of Science and Technology|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|45 Years|No|||December 2015|December 21, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419482||23106|
NCT02419495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0640|Selinexor in Combination With Standard Chemotherapy|Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy Agents in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|251|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419495||23105|
NCT02397330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TunisianMH1|is There an Alternative to Ultrasound Guided Interscalene Block?|the Association of Ultrasound Guided Suprascapular and Supraclavicular Nerve Block Provides Adequate Analgesia in Comparison With Ultrasound Guided Interscalene Block||Tunisian Military Hospital|No|Not yet recruiting|April 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02397330||24805|
NCT02397525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-22|An Open-Label Study to Evaluate Retreatment With LIPO-202|An Open-Label Study to Evaluate Retreatment With LIPO-202||Neothetics, Inc||Active, not recruiting|March 2015|||June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397525||24790|
NCT02409459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT14038|A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer in the Treatment of Iron Deficient Patients With Fibromyalgia|A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia||Luitpold Pharmaceuticals|No|Active, not recruiting|March 2015|April 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409459||23876|
NCT02409498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1190|A Randomized Controlled Trial of Use of Pre-emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery|A Randomized Controlled Trial of Use of Pre-emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 1, 2015|April 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02409498||23873|
NCT02419430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001492|Mindfulness Based Resilience Training|Mindfulness Based Resilience Training for Employees at Mayo Clinic|MBRT|Mayo Clinic|No|Active, not recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|60|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419430||23110|
NCT02419768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONS - Warlop - 01|Effects of Exercise on Long-Range Autocorrelations in Parkinson's Disease|Locomotion of Parkinsonian Patient: Are There Relations Between the Long Range Autocorrelations and the Neurological Impairments, Walking Abilities and the Practice of Physical Exercise?||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|June 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 27, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419768||23084|
NCT02419781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000015272|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Randomized Controlled Trial||Hyogo College of Medicine|Yes|Recruiting|October 2014|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|85 Years|No|||April 2015|April 14, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02419781||23083|
NCT02407184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14- 01446|Potential Restoration of the Infant Microbiome|Potential Restoration of the Infant Microbiome|PRIME|New York University School of Medicine|Yes|Recruiting|April 2015|February 2019|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|78|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02407184||24051|
NCT02397395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106396|An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.|A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.||Janssen R&D Ireland|No|Withdrawn|May 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|March 19, 2015||No|Trial has been cancelled due to availability of new therapeutic options for patient population|No||https://clinicaltrials.gov/show/NCT02397395||24800|
NCT02411019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-188E_CIN3_P2_FU|Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation|A Prospective, Observational, Open-label, Multi-center, Follow-up Clinical Study to Determine Recurrence of Cervical Intraepithelial Neoplasia and Evaluate the Long-term Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Subjects Who Were Diagnosed With HPV(Human Papillomavirus) 16 or 18 Positive Cervical Intraepithelial Neoplasia 3 (CIN 3) and Participated in Phase 2 Trial (GX-188E_CIN3_P2)|GX-188E|Genexine, Inc.|No|Recruiting|March 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|Samples Without DNA|plasma and PBMC (peripheral blood mononeuclear cell)|Female|19 Years|50 Years|No|Non-Probability Sample|The subjects who have completed the DNA vaccine administration of each dosage (1 and 4        mg).|March 2015|July 29, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02411019||23756|
NCT02411305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060336|Feasibility Testing of the Quality-monitoring Tool, Qdact, for the Palliative Care Research Cooperative|Testing the Feasibility of a Point-of-care Quality Monitoring Infrastructure for the PCRC|QFT|Duke University||Completed|February 2015|||September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|No|Non-Probability Sample|Palliative care clinicians from sites of the Palliative Care Research Cooperative.|December 2015|February 2, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411305||23734|
NCT02420600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCHNSCC02|The Clinical Relevance of Immune Cells and CTC in HNSCC Patients|The Clinical Relevance of Immune Cells and Circulating Tumor Cells in Patients With Head and Neck Cancer||Chang Gung Memorial Hospital|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Locally advanced or recurrent/metastatic head and neck cancer|January 2015|April 15, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420600|12 Months|23020|
NCT02397798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEp-walk study|Improved Ability to Cope With Everyday Life Through a Person-centered Training Program in Elderly Patients With Rheumatoid Arthritis - PEP-walk Study|Improved Ability to Cope With Everyday Life Through a Person-centered Training Program in Elderly Patients With Rheumatoid Arthritis - PEP-walk Study||Vastra Gotaland Region||Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|65 Years|N/A|No|||October 2015|October 19, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02397798||24769|
NCT02402881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057117|Education Bundle to Decrease Patient Refusal of VTE Prophylaxis|Patient-centered Education Bundle to Decrease Patient Refusal of Venous Thromboembolism Prophylaxis||Johns Hopkins University|No|Enrolling by invitation|April 2015|April 2020|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402881||24380|
NCT02409771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP01000538|Clinical Trial With PRECIZON Presbyopic|Prospective Multicenter Clinical Trial With the PRECIZON Presbyopic Multifocal Intraocular Lens||Ophtec BV|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02409771||23852|
NCT02411318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0218|Influence of Lifestyle Factors on Neutrophil Migration Pilot Study|Influence of Lifestyle Factors on Neutrophil Migration Pilot Study||University of Wisconsin, Madison|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02411318||23733|
NCT02411591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15573|A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)|A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Recruiting|June 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411591||23712|
NCT02420119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC 59-14|Does Intravenous Iron Therapy Decrease Serum Phosphates and Vitamin D Levels in Patients With and Without Chronic Renal Failure?|Does Intravenous Iron Therapy Decrease Serum Phosphates and Vitamin D Levels in Patients With and Without Chronic Renal Failure?||HaEmek Medical Center, Israel|Yes|Recruiting|January 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|in a period of one year we will try to recruit approximately 100 men and women over the        age of 18, who have iron deficiency anemia and have been prescribed intravenous iron        treatment at the ambulatory treatment unit.|April 2015|April 20, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420119||23057|
NCT02412748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NR011182-03|The Dedicated African American Dad Study|African American Non-Resident Fatherhood Program: Effects on Child/Family Outcomes|DAAD|Rush University Medical Center|Yes|Recruiting|February 2015|May 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412748||23623|
NCT02395120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-14-15|Family Access to Dentist Study|Family Intervention With Caregivers of Children With Dental Needs|FADS|Case Western Reserve University|Yes|Active, not recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|5||Actual|402|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395120||24975|
NCT02413892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCR001|Impact of a Loading Dose of Caspofungin in Invasive Candidiasis in ICU Patients|Impact of a Loading Dose of Caspofungin on Pharmacokinetic and Pharmacodynamic Parameters Target Achievements for Severe Candida Infections in ICU Patients|CASPOLOAD|Outcome Rea|No|Not yet recruiting|April 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|The samples were collected as part of patient care in medical monitoring and resuscitation      infectious Bichat Hospital. They will be used to search within the site.      In these severe patients, arterial catheter is systematically implemented. The investigators      plan to collect thru this catheter five blood 4ml tubes on 24hours to measure the      pharmacodynamic parameters of caspofungin.|Both|18 Years|N/A|No|Probability Sample|All consecutive patients for whom the decision to start antifungal therapy with        caspofungin loading dose was taken|April 2015|April 9, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02413892||23535|
NCT02413905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMGUT|Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition|Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition||Institut Hospitalo-Universitaire Méditerranée Infection|No|Completed|January 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|Samples With DNA|Stool samples|Both|N/A|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children from Niamey and Dakar, Senegal|April 2015|April 7, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02413905||23534|
NCT02412943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPPA2 Replacement|Pappalysin 2 (PAPP-A2) Enzyme Replacement|PAPP-A2 Enzyme Replacement Therapy Using Plasma Transfusion||Children's Hospital Medical Center, Cincinnati|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412943||23608|
NCT02417220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WeightWatchersOnline2015|Weight Watchers Online 2015||WWO 2015|The Miriam Hospital|No|Active, not recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02417220||23279|
NCT02405182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0013831|MRI Biomarkers in ALS|Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis||University of Alberta|No|Recruiting|September 2014|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|195|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited predominantly from ALS clinics at: the University of Alberta        Hospital in Edmonton; the Foothills Medical Centre in Calgary; the Sunnybrook Health        Sciences Centre in Toronto; the London Health Sciences Centre in London; and the Montreal        Neurological Hospital in Montreal.|June 2015|June 8, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405182||24203|
NCT02405195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUHThoraxLL0|Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)|Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)|ECCSTUD|Sahlgrenska University Hospital, Sweden|No|Completed|October 2011|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|19 Years|N/A|No|Probability Sample|Elective complex cardiac surgery|January 2016|January 5, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405195||24202|
NCT02414139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280A2201|Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy|A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease||Novartis|No|Recruiting|June 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|276|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414139||23516|
NCT02414152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-333B|Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss|A Phase I & II Open-label Study of the Effects of Anakinra (Kineret) in Corticosteroid-resistant Subjects With Sudden Sensorineural Heaing Loss (SSNHL)|SSNHL|Northwell Health|Yes|Completed|October 2013|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||September 2015|September 8, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414152||23515|
NCT02417363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJUSH2015-1|Study on the Relationship Between Periodontitis and Renal Disease|Affiliated Hospital of Stomatology, School of Medicine, Zhejiang University||Zhejiang University|Yes|Recruiting|October 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||4|Anticipated|200|Samples Without DNA|Samples are placed into 1.5 ml Eppendorf tubes and maintained at -70℃ for further analysis|Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 individuals are recruited for each group, the factors of age and gender are matched        while selecting the incruited indiduals,all participants were in general good        health(except renal disease) and non-smoking.|April 2015|April 16, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417363||23268|
NCT02417610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/14|Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid|Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid to Viscosupplementation With Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee. Randomized, Double-blind, Controlled Study|PNHA1401|Istituto Ortopedico Rizzoli|No|Recruiting|September 2014|September 2017|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02417610||23249|
NCT02423265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0172 Buch ISR|Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries|The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries||East Carolina University|No|Not yet recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||April 2015|April 17, 2015|April 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423265||22815|
NCT02423278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010006|The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer|The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|January 2010|December 2020|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02423278||22814|
NCT02423291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_SGN01|A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL|A Phase II Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL)|FIL_SGN01|Fondazione Italiana Linfomi ONLUS|Yes|Recruiting|October 2013|December 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02423291||22813|
NCT02401061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100-202|Open-Label, Dose Escalation Study of PRTX-100 in Adults With Persistent/Chronic Immune Thrombocytopenia|A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia||Protalex, Inc.|Yes|Recruiting|September 2015|September 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401061||24518|
NCT02407626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STZ-IFA-0115|Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery|Optimierung Der Kardioprotektion Durch Inhalative Anästhetika Eine Untersuchung Bei Patienten Mit Diabetes Mellitus während Off-pump Herzchirurgie|OPT|Triemli Hospital|No|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Male|40 Years|85 Years|No|||October 2015|October 7, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02407626||24017|
NCT02419170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x043|Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)|Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)||Washington University School of Medicine|No|Not yet recruiting|January 2016|January 2023|Anticipated|January 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|February 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419170||23130|
NCT02424539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201492|A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)|A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years With Allergic Rhinitis||GlaxoSmithKline|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|360|||Both|2 Years|12 Years|No|||January 2016|March 17, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424539||22717|
NCT02424552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003|Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma|EVITA Trial: Effect of VItamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma: a Randomized, Double-blind, Placebo-controlled Trial|EVITA|Johannes Gutenberg University Mainz|Yes|Recruiting|June 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02424552||22716|
NCT02394509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12217|HOBSCOTCH Phase II|HOBSCOTCH Phase II: A Pragmatic Study of HOBSCOTCH in New England.||Dartmouth-Hitchcock Medical Center|No|Recruiting|March 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|88|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02394509||25022|
NCT02399163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203160|Evaluation of Oral Hygiene Products in an In Situ Caries Model|Clinical Evaluation of Oral Hygiene Products in an In Situ Caries Model||GlaxoSmithKline|No|Completed|April 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399163||24664|
NCT02397850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WATZKE-892|Development of a Telephone-based Continuation Treatment for Patients With Chronic Depression.|Optimizing Psychotherapeutic Aftercare for Patients Suffering From Chronic/Recurrent Depression: Development and First Evaluation of a Telephone-based Continuation Treatment (Pilot Study).||University of Zurich|No|Recruiting|February 2015|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02397850||24765|
NCT02422238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC142074|Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease|Disease Mechanisms and Markers for Non-alcoholic Steatohepatitis in a Population With Non-alcoholic Fatty Liver Disease: a Prospective Cohort Study With Biobank|NAFLD-cohort|Maastricht University Medical Center|No|Recruiting|June 2015|December 2027|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood, urine, faeces and exhaled air will be collected. The buffy coat of blood collected in      an EDTA-tube to obtain plasma, will be stored for isolation of DNA.|Both|18 Years|65 Years|No|Probability Sample|Obese ( BMI ≥ 30 kg/m2) subjects with proven NAFLD either by imaging (using MRI) or        histology, referred to secondary or tertiary care for obesity related problems will be        asked to participate in this study.|September 2015|September 8, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422238||22894|
NCT02422316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS-ED-2014-01|Non-contrast Cardiac CT as a Risk Stratification Tool in Patients With Non-cardiac Chest Pain|||University of Southern Denmark|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|248|||Both|30 Years|70 Years|No|Non-Probability Sample|The study will investigate patients with suspected Acute Coronary syndrome who have been        examined and subsequently sent home from an emergency- or cardiology department without        ACS or another obvious explanation. 750 patients, age 30-70 years|February 2016|February 16, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422316||22888|
NCT02411942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPG 1410|Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene Gel 0.3% to Differin® (Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|753|||Both|12 Years|40 Years|No|||April 2015|April 7, 2015|April 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411942||23685|
NCT02403115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLE1|Prediction of Outcome of Lupus Nephritis|Validation of the Assay of Circulating Antibodies Against Glomerular Neo-autoantigens as a Surrogate Biomarker of the Development of Lupus Nephritis||Istituto Giannina Gaslini|No|Recruiting|October 2014|||November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|800|Samples Without DNA|Serum|Both|4 Years|65 Years|No|Probability Sample|-  250 patients with newly diagnosed lupus nephritis (stage I-VI according to WHO             classification). First serum will be collected at the time of renal biopsy (study             group).          -  250 patients with incident or prevalent systemic lupus erythematosus (according to             ARA criteria) and no signs of nephropathy (control group).          -  50 patients with rheumatoid arthritis (according to ARA criteria), without documented             nephropathy (control group)          -  250 patients with histological diagnosis of membranous nephropathy (control group).|March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02403115||24362|
NCT02408536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO 22|Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer|Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer|MITO 22|National Cancer Institute, Naples|No|Recruiting|October 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|Samples With DNA|Archival tissue tumor samples in paraffin blocks for evaluation of diagnosis and biomarkers|Female|18 Years|N/A|No|Non-Probability Sample|patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian carcinoma        or with invasive recurrence after surgery for borderline serous carcinoma|November 2015|November 25, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408536||23947|
NCT02408549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0012|Saftey and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures|An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|VALUE|UCB Pharma|No|Enrolling by invitation|May 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|4 Years|N/A|No|||March 2016|March 18, 2016|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408549||23946|
NCT02419664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ga-PET version 8 (141017)|Ga-68-DOTATOC -PET in the Management of Pituitary Tumours|Ga-68-DOTATOC -PET in the Management of Pituitary Tumours||Göteborg University|No|Recruiting|January 2015|December 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419664||23092|
NCT02486406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-748|A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects|An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)|ZIRCON|AbbVie|No|Recruiting|October 2015|January 2023|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|186|||Both|3 Years|17 Years|No|||January 2016|January 13, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486406||17966|
NCT02493569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYLLSL-2015-153-01|A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China|A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China (Based on Hospital)||First Affiliated Hospital Xi'an Jiaotong University||Not yet recruiting|October 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|3000|||Female|N/A|N/A|No|Non-Probability Sample|The female breast cancer patients in Shaanxi Province of China, those study population        shoud be the hospitalized patients who are confirmed of the primary breast cancer        histologically, moreover, the date of the inpatients are within the month we chosen and        those inpatients should have been received or under receiving the relevant treatment        including surgical treatment, chemotherapy and radiotherapy.|August 2015|August 23, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493569||17417|
NCT02493582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAA|The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR|The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR||The First People's Hospital of Changzhou|No|Active, not recruiting|July 2015|July 2033|Anticipated|July 2030|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493582||17416|
NCT02475720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913R00015|Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)|Survey on the Treatment Reality of Patients With EGFR Mutation-positive Non-small Cell Lung Cancer||AstraZeneca|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Approximately 2000, Advanced Non Small Cell Lung cancer (aNSCLC) patients who fulfil the        inclusion/exclusion criteria will be recruited by 10 to 20 investigational sites in Japan.|January 2016|January 27, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475720||18787|
NCT02462577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209|Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain|Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain||Assiut University|Yes|Completed|January 2015|December 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Female|30 Years|60 Years|No|||December 2015|December 29, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02462577||19797|
NCT02478411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYCLE-ICU-001|Early Cycloergometric Physiotherapy in Critically Ill Patients With Invasive Mechanical Ventilation|Functional and Motor Effects of an Early Cycloergometric Physiotherapy Program in Critically Ill Patients With Invasive Mechanical Ventilation. A Randomized Controlled Trial||Hospital Son Llatzer|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02478411||18580|
NCT02488720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-051|Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study|Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial|LEARN|University of Southern California|Yes|Enrolling by invitation|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|blood, CSF|Both|65 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|500 subjects without evidence of elevated ABeta on screening PET scan. Subjects will have        consented to participate in the A4 trial and previously met demographic, cognitive and        clinical criteria and have an A4 screening PET scan results that fallows below the ABeta        threshold levels required for randomization into the treatment arms for the A4 trials.|March 2016|March 22, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488720||17788|
NCT02464592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CRI-2014-05|Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study|Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|85 Years|No|||March 2015|June 3, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02464592||19643|
NCT02464852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18733|Assessment of the Effects of Sheffield Support Snood in MND Patients|Assessment of the Effects of Sheffield Support Snood in MND Patients||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|16 Years|N/A|No|||June 2015|November 16, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02464852||19623|
NCT02476344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2188-OF-CTIL|Classification and Characterization of Physical Strains During Sorting Series: Physiological Aspects|Classification and Characterization of Physical Strains During Sorting Series: Physiological Aspects||Sheba Medical Center|No|Not yet recruiting|July 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Male|18 Years|22 Years|Accepts Healthy Volunteers|||July 2015|July 12, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02476344||18739|
NCT02476357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMPH-01|A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection|A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection||University of Lausanne Hospitals|No|Completed|January 2009|||December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02476357||18738|
NCT02486445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3304|Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study|Rivaroxaban for Scheduled Work-up of Patients With Suspected Deep Venous Thrombosis|Ri-Schedule|Ostfold Hospital Trust|Yes|Recruiting|February 2015|February 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|825|||Both|18 Years|95 Years|No|||June 2015|June 30, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486445||17963|
NCT02486783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VG 021-14A|Infection, Sepsis and Meningitis in Surinamese Neonates|Infection, Sepsis and Meningitis in Surinamese Neonates|InSepSur|Academic Hospital Paramaribo|Yes|Recruiting|May 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|190|Samples Without DNA|Serum samples|Both|N/A|1 Month|Accepts Healthy Volunteers|Probability Sample|Newborns at the Academic Hospital Paramaribo without signs of infection (baseline        controls) and with signs of infection admitted for infection work up and antibiotic        treatment.|January 2016|January 5, 2016|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02486783||17937|
NCT02486796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ2014018|Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer|A Comparison Study to Assess the Value of Naturopathic Medicine Given Immediately and Continuously or Delayed Until Cycle 3 in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer||Midwestern Regional Medical Center|No|Not yet recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Female|18 Years|N/A|No|||December 2015|December 28, 2015|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486796||17936|
NCT02488785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-42|Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes Mellitus|The Impact of a Comprehensive Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes||Joslin Diabetes Center|No|Recruiting|June 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|21 Years|80 Years|No|||February 2016|February 8, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02488785||17783|
NCT02476773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-DBL-01|Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults|Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel® in Brazilian Adults||Albert B. Sabin Vaccine Institute|No|Recruiting|September 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476773||18706|
NCT02478424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-0208-14|Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease|Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation||Rabin Medical Center||Not yet recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478424||18579|
NCT02478437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00097239|A Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for theTreatment of Lumbar Facet Syndrome|A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for the Treatment of Lumbar Facet Syndrome|STU00097239|Northwestern University|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|79 Years|No|||February 2016|February 16, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478437||18578|
NCT02482714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6118|Life Quality Determinant Assessment of Fibromyalgia Patients|Life Quality Determinant Assessment of Fibromyalgia Patients Related to Health Devices|FIBROQUALLIFE|University Hospital, Strasbourg, France|No|Not yet recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|20 Years|60 Years|No|||June 2015|June 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02482714||18249|
NCT02484079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SorlandetHF|Comparative Effectiveness of Hot Versus Cold Snare Polypectomy of Small Colorectal Polyps|Comparative Effectiveness of Hot Versus Cold Snare Polypectomy of Small Colorectal Polyps. A Randomized Controlled Trial|HOT/COLD|Sorlandet Hospital HF|No|Enrolling by invitation|August 2015|December 2022|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|40 Years|75 Years|No|||October 2015|October 29, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484079||18144|
NCT02463682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99796-JPIN|Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting|Early Feasibility Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAS) in the Outpatient Setting||William Sansum Diabetes Center|No|Recruiting|May 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9|||Both|21 Years|65 Years|No|||June 2015|June 3, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463682||19713|
NCT02463695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18541|Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs)|Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs): A Comparative Study of Normal Ears Versus Those With Vestibular Deficits||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|October 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02463695||19712|
NCT02478684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411015633|Delayed Cord Clamping in Preterm Neonates|The Effects of Delayed Cord Clamping on Postnatal Circulatory Status in Preterm Neonates|DCC|Weill Medical College of Cornell University|Yes|Not yet recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|28 Weeks|35 Weeks|No|||June 2015|June 17, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478684||18559|
NCT02482974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-3.1/53|Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients|Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients: A 1-year Observational Study||Ege University|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with liver transplantation who switch from sirolimus to everolimus|September 2015|September 11, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02482974||18229|
NCT02427308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 2127-1|Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry|Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry||Knight Therapeutics (USA) Inc|No|Not yet recruiting|July 2015|March 2026|Anticipated|March 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2|||Female|N/A|N/A|No|Non-Probability Sample|persons who become pregnant will taking miltefosine or for 5 months after taking        miltefosine|April 2015|April 24, 2015|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02427308|9 Months|22504|
NCT02427334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS|Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome|Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial||Cairo University|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427334||22502|
NCT02403453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-009|RHINE™ Cervical Disc Clinical Study: A Prospective Observational Study for Patients Requiring 1-2 Level C-spine Surgery|RHINE™ Cervical Disc Clinical Study||K2M, Inc.|Yes|Enrolling by invitation|January 2016|August 2021|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|166|||Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for the study enrollment will be skeletally mature patients undergoing        reconstruction of the disc from C3 to C7 following discectomy at one or two contiguous        levels for intractable radiculopathy (arm pain and/or a neurological deficit) with or        without neck pain, or myelopathy due to abnormality localized to the level of the disc        space and at least one of the following conditions confirmed by radiographic imaging (CT,        MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of        osteophytes), and/or visible loss of disc height compared to adjacent levels. Patients        should have failed at least 6 weeks of non-operative treatment or demonstrated progressive        signs or symptoms despite non-operative treatment prior to implantation.|January 2016|January 28, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403453||24336|
NCT02422082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRvBMD|The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With Osteopenia|The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With Osteopenia||Sahlgrenska University Hospital, Sweden|Yes|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|75 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02422082||22906|
NCT02422095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700323|Registry for Endoscopic Ultrasound (EUS) Evaluation of Pancreatic Cysts|Registry for Endoscopic Ultrasound (EUS) Evaluation of Pancreatic Cysts||Florida Hospital|No|Recruiting|February 2015|December 2018|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for an EUS evaluation of pancreatic cyst lesion.|February 2016|February 15, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02422095|36 Months|22905|
NCT02422160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33624|Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration|Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration||Stanford University|No|Recruiting|April 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-exudative age-related macular degneration|December 2015|December 2, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422160||22900|
NCT02427347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141107002514079|Acupuncture in the Regulation of Dai Meridian for the Metabolism of Visceral Adipose Tissue in Abdominal Obese Patients|||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|June 2014|September 2017|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||April 2015|April 29, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02427347||22501|
NCT02407015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMS 138673|The Effect of 3D Autostereoscopic Video-game Play on the Visual Fatigue in Children|A Randomised Control Trial to Evaluate the Effect of 3D Autostereoscopic Video-game Play on the Total Horizontal Fusional Vergence Amplitudes of 7 to 11 Year Old Children||University of Sheffield|No|Completed|December 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|41|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407015||24064|
NCT02395393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00017377|Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation|Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation||Children's Hospital Boston|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|6 Years|22 Years|No|||March 2015|March 17, 2015|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395393||24954|
NCT02420496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150165H|Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants|Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo (?) for the Treatment of Cholestasis in Infants||The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|March 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|39|||Both|N/A|24 Months|No|||December 2015|December 1, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420496||23028|
NCT02420509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Post surgery Chemo_Appendiceal|Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis|Phase II Study to Evaluate Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis||University of California, San Diego|Yes|Recruiting|April 2015|December 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420509||23027|
NCT02420964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12-10E|Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications|Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications||Carolinas Healthcare System|No|Completed|June 2012|April 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Female|18 Years|45 Years|No|||April 2015|April 17, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02420964||22992|
NCT02425501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17544|Special Drug Use Investigation of EYLEA for Diabetic Macular Edema|Special Drug Use Investigation of EYLEA for Diabetic Macular Edema||Bayer|No|Recruiting|January 2015|May 2020|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients with DME diagnosis will be enrolled after the investigators have        taken the decision for the treatment with EYLEA. Those patients who have had EYLEA        prescribed previously will not be included in this study. Physicians should consult the        full prescribing information for EYLEA before enrolling patients and be familiarized with        the safety information in the product package label.|March 2016|March 17, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425501||22643|
NCT02407093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK099516-01A1|Army Training at High Intensity Study|HIFT for Obesity Prevention, Fitness and Health Promotion in Military Personnel|ATHIS|Kansas State University|No|Enrolling by invitation|September 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 26, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407093||24058|
NCT02397018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059284|Cord Blood Infusion for Ischemic Stroke|Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke||Duke University|Yes|Active, not recruiting|May 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397018||24829|
NCT02405715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-12678|Therapy With an Oxytocin Adjunct for Major Depression|Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial|TOAD2015|Concordia University|Yes|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|50 Years|No|||July 2015|July 28, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02405715||24162|
NCT02412904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130120|Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist|Phase 4 Study Comparing Recombinant Follicle Stimulating Hormone (rFSH) or Ultra-pure to HMG in Patients Submitted to IVF Using Gnrh Antagonist||Hospital de Clinicas de Porto Alegre|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02412904||23611|
NCT02421276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2300|Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome|Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome||University of Colorado, Denver|Yes|Not yet recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|N/A|22 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421276||22968|
NCT02397317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 15.01 SPARK|Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring|Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction|SPARK|University of Sydney|Yes|Recruiting|February 2016|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02397317||24806|
NCT02407639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO2vsAIR|Insufflation in Children Undergoing Colonoscopy|Randomized, Double-blind Trial of CO2 vs. Air Insufflation in Children Undergoing Colonoscopy||University Medical Centre Ljubljana|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|78|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 12, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02407639||24016|
NCT02414971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500023|Relationship of Mitochondrial Enzymes With Cancer Related Fatigue|Relationship of Mitochondrial Enzymes With Cancer Related Fatigue||University of Florida|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|Buccal swabs Whole blood|Male|18 Years|N/A|No|Non-Probability Sample|Men over 18 years of age diagnosed with prostate cancer|October 2015|December 18, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414971||23452|
NCT02425657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AalborgH1|Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments|Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments||Aalborg Universitetshospital|No|Not yet recruiting|August 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Junior doctors in North Jutland Surgical Departments defined as PGY1, 2 and 3 - Danish        equivalents: introduktionsstilling, hoveduddannelse 1, 2.|April 2015|April 21, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02425657||22631|
NCT02401815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX121-01|PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors|A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate, Sunitinib Malate, and Regorafenib||Plexxikon|No|Recruiting|March 2015|September 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|92|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401815||24460|
NCT02402101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01405-42|Effect of the Transcranial Direct Current Stimulation on the Dopaminergic Transmission in Healthy Subjects|Effect of the Transcranial Direct Current Stimulation on the Dopaminergic|DOPA-STIM|Hôpital le Vinatier|Yes|Recruiting|February 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402101||24438|
NCT02410356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1106-IMM-30022|Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)|A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (dGH) in Adults With Growth Hormone-Deficiency||Teva Pharmaceutical Industries|No|Active, not recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410356||23807|
NCT02425722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-CL-1021|A Study to Evaluate Dose-responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation|Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)||Astellas Pharma Inc|No|Completed|April 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|383|||Both|20 Years|79 Years|No|||December 2015|December 16, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02425722||22626|
NCT02425735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gd T cell and Hepatocellular|Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer|γδ T Cell Immunotherapy for Treatment of Hepatocellular Liver Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|75 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425735||22625|
NCT02394782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136-591|Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)|A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart®2.0 + MSdialog™, Assessing Quality of Life (ADHERQOL)|ADHERQOL|Merck KGaA||Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|65 Years|No|Probability Sample|Participating sites will identify and recruit eligible subjects using appropriate        recruitment strategies in accordance with any local approvals/regulations for        observational studies e.g. via clinics, referrals, advertisements, patient databases etc.|September 2015|September 15, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394782||25001|
NCT02417311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0174/134/2-1|Individualized Early Risk Assessment for Heart Diseases|Individualized Early Risk Assessment for Heart Diseases|IndivuHeart|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|June 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|Skin biopsy and blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment of patients will be done by the Cardiomyopathy Outpatient Clinic which is led        by Dr. M. Patten and Dr. J. Münch at the Department of Cardiology, University Heart        Centre, UKE (Prof. Blankenberg).|December 2015|December 4, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02417311||23272|
NCT02415439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBP15-001|A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects|A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects||ReveraGen BioPharma, Inc.||Recruiting|January 2015|||December 2015|Anticipated|Phase 1|Interventional|N/A|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415439||23416|
NCT02419703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-15-03|The STAR™ Tumor Ablation Registry|The STAR™ Tumor Ablation Registry||DFINE Inc.|No|Recruiting|October 2015|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|22 Years|N/A|No|Non-Probability Sample|Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae that will be        treated with t-RFA using the STAR™ Tumor Ablation System.|March 2016|March 7, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02419703|2 Years|23089|
NCT02425176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMMC ETHICS 660.1|Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases|A Double-blind Randomised Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases||University of Malaya|Yes|Completed|September 2009|April 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425176||22668|
NCT02402894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-08|Follow-up of Person-centered Care of Young Adults With Rheumatic Disease|Follow-up of Person-centered Care of Young Adults With Rheumatic Disease Uppföljning av Personcentrerat omhändertagande av Unga Vuxna Med Reumatisk Sjukdom (Unga-vuxna Studien) (Swedish)||Vastra Gotaland Region|No|Recruiting|February 2015|December 2065|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|16 Years|23 Years|No|Non-Probability Sample|Young adults (16-23 years) with newly diagnosed rheumatoid arthritis (RA), spondartrit        (SpA) and psoriasartrit (PsA) in routine clinical care. In total 100 patients, no healthy        controls.|October 2015|October 19, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402894||24379|
NCT02407249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-FIRM-02|Topera C-FIRM Registry|Control for EU (European Union) Focal Impulse and Rotor Modulation Registry - Topera C-FIRM Registry-||I-Med-Pro GmbH|No|Recruiting|April 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Each participating site will enroll 10 consecutive conventional AF patients who are        treated according to the standard routine of the center. Patients eligible should be in        accordance with the AF Guidelines.|October 2015|December 7, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407249||24046|
NCT02410382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408439554|Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer|A Phase II Randomized Study of Short-Term Dexamethasone Versus Placebo for Fatigue in Patients Receiving Radiation Alone or Radiation and Chemotherapy for the Treatment of Head and Neck and Non-Small Cell Lung Cancers||University of Arizona|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410382||23805|
NCT02422563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACOPRAD_2015|NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB|Multicenter Prospective Randomized Study on NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Patients With Cervical Cancer FIGO Stage IB2 and IIB|NACOPRAD|Charite University, Berlin, Germany|Yes|Not yet recruiting|October 2015|October 2025|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|534|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02422563||22869|
NCT02422732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 154 02|Functional Imaging and Reading Deficit in Children With NF1|Functional Magnetic Resonance Imaging and Reading Deficit in Children With NF1 Children||University Hospital, Toulouse|No|Completed|March 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|25|||Both|8 Years|12 Years|No|||August 2015|August 18, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02422732||22856|
NCT02416960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0326|Effect of the Glycemic Index of Diet on Metabolic and Reproductive Parameters in Overweight and Obese Infertile Women|Effect of a Hypocaloric Diet With Different Glycemic Indexes on Ghrelin and Leptin Levels, Metabolic Parameters, and Reproductive Outcomes in Overweight and Obese Infertile Women: A Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|35 Years|No|||April 2015|April 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416960||23299|
NCT02400216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150100|Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis|A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|May 2019|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|March 12, 2016|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400216||24583|
NCT02400489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perimount CN001|Clinical Study to Evaluate the Performance of Perimount Heart Valve in Chinese Patients|||Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.|No|Recruiting|September 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|240|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with Perimount 6900PTFX or Perimount 2800TFX in three hospitals in        China: Wuhan Asia Heart Hospital, Shandong Provincial Hospital, Tianjin Chest Hospital.        Patients need to complete two follow up visits after surgery in hospitals.|August 2015|August 6, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400489||24562|
NCT02417831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.88|Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.|Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fasted Conditions||Boehringer Ingelheim||Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|April 13, 2015||||No||https://clinicaltrials.gov/show/NCT02417831||23232|
NCT02417844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.89|Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.|Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions||Boehringer Ingelheim||Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|April 13, 2015||||No||https://clinicaltrials.gov/show/NCT02417844||23231|
NCT02418078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geriatri Hernia|Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy|Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy at Our Institution||Diskapi Teaching and Research Hospital|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|370|||Both|19 Years|90 Years|No|Probability Sample|patients with a unilateral inguinal hernia|February 2015|April 12, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02418078||23213|
NCT02417168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-42|Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study|Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients - Pilot Study||CAMC Health System|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|17 Years|No|Non-Probability Sample|Children between the ages of birth to seventeen years who have an existing oncologic        diagnosis and who present with fever to Charleston Area Medical Center Women and        Children's Hospital|April 2015|April 24, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417168||23283|
NCT02395380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 065-14|Evaluation of the Predictive Nature of the Postoperative CRP on Postoperative Recovery in Patients Undergoing Colorectal Resection (CRP-Track)|Evaluation of the Predictive Nature of the Postoperative CRP on Postoperative Recovery in Patients Undergoing Colorectal Resection|CRP-Track|Centre Hospitalier Departemental Vendee|Yes|Recruiting|July 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|174|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02395380||24955|
NCT02395653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD2013-002|Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Patients|An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age||The Medicines Company|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395653||24934|
NCT02418091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052081|Integrated Population Program for Diabetic Kidney Disease|STOP-DKD Automated Population Program (APP)|STOP-DKD APP|Duke University|No|Recruiting|March 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|75 Years|No|||January 2016|February 15, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02418091||23212|
NCT02421666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-HBV|A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV|A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV||Temple University|Yes|Recruiting|July 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421666||22938|
NCT02414035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZX09303305|Monitor System for the Safety of Dabigatran Treatment|A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation|MISSION-AF|Second Affiliated Hospital of Nanchang University|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Samples with DNA for genetic variants test which could contribute to interindividual      variability in blood concentrations of the active metabolite of dabigatran etexilate and      influence the safety and efficacy of dabigatran.|Both|18 Years|N/A|No|Non-Probability Sample|We identified participants as those diagnosed as having artrial fibrillation, and who        initiated dabigatran after diagnosis. The diagnosis of AF was defined as having inpatient        or outpatient claims with primary or secondary International Classification of Diseases,        Ninth Revision(ICD-9), code427.31.12. The CHADS2-VAS score is calculated as the sum of all        points for a given patient and need >=1. A history of previous stroke or transient        ischemic attack is assigned 2 points; congestive heart failure, hypertension, age of 75        years or older, and diabetes are each assigned 1 point.|April 2015|April 7, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02414035||23524|
NCT02409030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-VAL-2013-01|Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease|Validation Trial for a Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease|RH-VAL|Raman Health Technologies, S.L.|No|Recruiting|January 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|700|Samples With DNA|3 tubes of blood ( 30 mL of blood in total) for further analysis of their products (plasma,      cells and DNA) in Alzheimer's research unit project CIEN Foundation would be extracted .|Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|It is estimated that a sample of 500 patients (250 with AD and 250 with FTD) and 200        controls (700 individuals in total) will be sufficient to corroborate the hypothesis that        permits validation of the new diagnostic test. The sample size estimate is based on a        hypothesis of non inferiority between the new test and the test used in normal clinical        practice, expecting a 10% delta of the 75% validity, sensitivity and specificity indices        with an alpha error of 0.05 and a beta error of 0.20.|March 2015|March 31, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02409030||23909|
NCT02397369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMHPOBEST2015|Evaluation of Efficacy of Different Methods of Tobacco Cessation Interventions Among BEST Employees in Mumbai|Comparative Evaluation of Efficacy of Different Methods of Tobacco Cessation Interventions Among BEST Employees in Mumbai : A Randomized Controlled Trial||Tata Memorial Hospital|Yes|Not yet recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|4000|||Male|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02397369||24802|
NCT02412124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14359|Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers|Quality of Life Outcomes From a Peer-to-Peer Support Program for Women With Gynecologic Cancer||City of Hope Medical Center|Yes|Recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02412124||23671|
NCT02412982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droege2015|Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients|Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies||University of Cincinnati|No|Not yet recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412982||23605|
NCT02399176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Yoga in the Treatment of Osteoporosis|Yoga in the Treatment of Osteoporosis||Manhattan Physical Medicine and Rehabilitation, LLP|No|Completed|January 2005|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|741|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 10, 2016|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399176||24663|
NCT02402413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSCA|Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS)|||University of Cagliari|No|Not yet recruiting|June 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02402413||24414|
NCT02402426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09628|Brain Health Registry|Brain Health Registry|BHR|University of California, San Francisco|Yes|Recruiting|September 2013|September 2028|Anticipated|September 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Registry is a large, online database of volunteers who would like to participate in        clinical trials and research. Anyone over the age of 18 is welcome to join the Registry,        and the intent is to concentrate all efforts on enrolling 50,000 participants age 55 years        and older.|December 2015|December 1, 2015|August 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02402426|10 Years|24413|
NCT02412384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2013|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage lung cancer come to Fuda Hospital for treatment.|February 2016|February 23, 2016|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02412384||23651|
NCT02416934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405296745|Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline|The Effects of Perioperative Steroids on Dysphagia Following Anterior Cervical Spine Surgery: A Randomized, Prospective, Double-Blind Study.|DysDexVSSal|West Virginia University|No|Active, not recruiting|July 2012|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416934||23301|
NCT02403401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16803|Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women|Multi-center, Open-label, Single-arm Study to Assess the Safety and Contraceptive Efficacy of a Levonorgestrel-containing Intravaginal Ring During a Treatment Period of One Year in Healthy Women 18 to 35 Years of Age||Bayer|No|Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1605|||Female|18 Years|35 Years|No|||March 2016|March 19, 2016|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403401||24340|
NCT02409654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK-OPD-AF|Hong Kong Outpatient AF Screening Using Single-lead ECG Device|Randomized Controlled Trial of Tailored Stroke Prevention Strategy for Newly Diagnosed Atrial Fibrillation From a Targeted Screening Program Using Handheld Single-lead ECG Device||Chinese University of Hong Kong|No|Recruiting|January 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|500|||Both|65 Years|N/A|No|||February 2016|February 16, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02409654||23861|
NCT02409667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A3302|Plaque Psoriasis Efficacy and Safety With Secukinumab|Long Term Clear Skin Maintenance Treatment Optimization in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Multicenter, Open-label With Blinded-assessment, Comparative, 52 Week Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg s.c.|OPTIMISE|Novartis|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1580|||Both|N/A|N/A|No|||February 2016|February 9, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02409667||23860|
NCT02422407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999SJ001|Sjögren's Biomarker Study|A Biomarker Study to Determine the Gene Expression Signatures of Salivary Gland and Blood in Subjects With Incident Primary Sjögren's Syndrome, Subjects With Sicca, and Healthy Volunteers||Biogen|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants with sicca and healthy volunteers will be recruited from multiple sites|February 2016|February 12, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02422407||22881|
NCT02489084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2011-03|Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP)|Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP)|HANS|University Medical Center Groningen|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients ≥18 years still alive and treated since April 2007 for HNC at the department        of Radiation Oncology of the UMCG, Groningen, the Netherlands|December 2015|December 8, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02489084||17761|
NCT02480270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0745|Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation|Prospective Clinical and Laboratory Evaluation of Outpatient Antibiotic Treatment for Pulmonary Exacerbations in Children With Cystic Fibrosis||University of Colorado, Denver|No|Recruiting|August 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|8 Years|18 Years|No|Non-Probability Sample|30 patients with cystic fibrosis will be recruited from the University of Colorado and        Children's Hospital Colorado pediatric cystic fibrosis clinic.|February 2016|February 1, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02480270||18437|
NCT02484274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140314|Iron Deficiency (ID) in Infants|Iron Deficiency in Infants : Population-wide Study of the Protective Role of Toddler Milk Formula|CARMA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2016|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|23 Months|25 Months|No|||January 2016|January 22, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484274||18129|
NCT02484287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4890|Quality Control: A Prospective Analysis of EVD Effectiveness|Quality Control: A Prospective Analysis of External Ventricular Drain (EVD) Effectiveness||University of Oklahoma|Yes|Not yet recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|252|||Both|18 Years|75 Years|No|||June 2015|June 26, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484287||18128|
NCT02462590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27022015|Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial|Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT)|PROSPECT|McMaster University|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2650|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462590||19796|
NCT02466750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-13-06|Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine|Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus||U.S. Army Medical Research and Materiel Command|No|Not yet recruiting|June 2016|June 2021|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466750||19477|
NCT02488460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|h5vadgyk|Effects of Physical Activity on Math - an RCT|Effects of a School-based Physical Activity Intervention on Math Achievement - A Randomized Controlled Trial||University of Southern Denmark|Yes|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|545|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||June 2015|July 1, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02488460||17808|
NCT02492750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC138B|Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma|A Phase I/II Double Blind Randomized Trial of Lenalidomide/ Dexamethasone/ Anakinra vs. Lenalidomide/Dexamethasone/Placebo in Patients With Early Stage Multiple Myeloma and a High Plasma Cell Growth Rate||Mayo Clinic|Yes|Not yet recruiting|July 2016|||July 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492750||17480|
NCT02468934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0141-CSP-000|Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the Smartpatch System|A Prospective Case Series Study of SPR Peripheral Nerve Stimulation (PNS) Therapy for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Utilizing Preoperative Lead Placement||SPR Therapeutics, LLC|No|Recruiting|September 2015|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|21 Years|N/A|No|||March 2016|March 17, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468934||19309|
NCT02468947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182/14|Finding Ideal Blood Culture Volume in NICU|Finding Ideal Blood Culture Volume in NICU||Shaare Zedek Medical Center|No|Not yet recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Probability Sample|All babies treated in the neonatology department of the institution undergoing sepsis        workup|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02468947||19308|
NCT02477709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-019|A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||Afferent Pharmaceuticals, Inc.|No|Completed|July 2015|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|N/A|No|||November 2015|November 19, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477709||18634|
NCT02477735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-GF-0021-15-CTIL|The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion|The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|6 Months|36 Months|No|Non-Probability Sample|Infants with COME who will be referred for TTI.|May 2015|June 17, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02477735||18632|
NCT02489708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC 2014-5592|Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke|Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke||Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|150|||Both|N/A|N/A|No|||November 2015|November 10, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02489708||17714|
NCT02478775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0474|Dysregulation of FSH in Obesity: Functional and Statistical Analysis|Dysregulation of Follicle Stimulating Hormone (FSH) in Obesity: Functional and Statistical Analysis||University of Colorado, Denver|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|68|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02478775||18552|
NCT02464865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si656/2014|Thiamin Deficiency in Obese Thai Children|Thiamin Deficiency in Obese Thai Children||Mahidol University|Yes|Not yet recruiting|June 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|124|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02464865||19622|
NCT02464878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Islet after Kidney - AAT|Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant|||Massachusetts General Hospital|Yes|Not yet recruiting|May 2016|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464878||19621|
NCT02463435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747.792|Effect of Nutritional Intervention and Olive Oil in Severe Obesity|Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial||Universidade Federal de Goias|No|Not yet recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|287|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463435||19732|
NCT02482649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12-049|EAA/Therapy for Treating Children With ADHD|Equine-Assisted Activities and Therapy for Treating Children With Attention-Deficit/Hyperactivity Disorder||Samsung Medical Center|No|Recruiting|January 2013|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|6 Years|13 Years|No|||June 2015|June 24, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02482649||18254|
NCT02487069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alternative Donor HSCT-2015|Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy|Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|June 2015|August 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|60 Years|No|||June 2015|June 27, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02487069||17915|
NCT02489032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AA021053|Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer|Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer|BigAl2|Oregon Center for Applied Science, Inc.|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|322|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02489032||17765|
NCT02489045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14F.113|Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension|Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension||Thomas Jefferson University|Yes|Recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|21 Years|N/A|No|||January 2016|January 5, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489045||17764|
NCT02468115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIS410-201|Influenza Challenge Study of VIS410 in Healthy Volunteers|A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects After a Viral Inoculation With Influenza A (H1N1)||Visterra, Inc.|Yes|Active, not recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468115||19372|
NCT02468128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1001-301|A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management|A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management||Lumosa Therapeutics Co., Ltd.|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|221|||Both|20 Years|N/A|No|||July 2015|July 1, 2015|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468128||19371|
NCT02482909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0520090|A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma|A Prospective Randomized Study to Compare the Efficacy of Radiofrequency Ablation and Hepatic Resection as a Primary Treatment for Single Small Hepatocellular Carcinoma||Seoul National University Hospital|Yes|Terminated|July 2005|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|20 Years|70 Years|No|||June 2015|June 25, 2015|June 20, 2015||No|The post-treatment recurrence rate was expected to be different between two treatment groups.|No||https://clinicaltrials.gov/show/NCT02482909||18234|
NCT02487316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-2015052005|A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib|A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib||Peking University|No|Recruiting|July 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|September 13, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487316||17896|
NCT02411695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-233|Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia|A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|40|||Both|13 Years|17 Years|No|||January 2016|January 7, 2016|May 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411695||23704|
NCT02408224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130R00029|An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)|A Non-interventional Prospective Observational Study to Understand the Usage Pattern of Ticagrelor in Indian Patients With Acute Coronary Syndrome.|TREASURE|AstraZeneca|No|Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|Male/female with Acute Coronary Syndrome on Ticagrelor on discharge or ≤ 1month|February 2016|February 29, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408224||23971|
NCT02412358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86394|Clinical Comparision of Three Types of Toothbrushes Pulsar, Crossaction and Butler on Gingivitis and Plaque Removal|Clinical Comparison of Three Types of Toothbrushes Pulsar, Crossaction and Butler on Gingivitis and Plaque Removal||Mashhad University of Medical Sciences|No|Completed|May 2008|June 2009|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412358||23653|
NCT02412371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-360|A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer|A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)||AbbVie|Yes|Recruiting|April 2015|March 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|174|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|November 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412371||23652|
NCT02412462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-16B5-101|Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy|A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy||Alethia Biotherapeutics||Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02412462||23645|
NCT02416427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637/15|Targeting the Hippo Transducer TAZ in Breast Cancer With Statins|A Phase II, Randomized, Non-comparative, Pre-surgical Study of Atorvastatin or Observation in Ki-67 Positive, TAZ-expressing Early Breast Cancer Patients (TRINACRIA Trial)|TRINACRIA|Regina Elena Cancer Institute|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|75 Years|No|||April 2015|April 9, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416427||23340|
NCT02396667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m2493|Accuracy of 5D LB Ultrasound in Prediction of Birth Weight in Macrosomic Babies : A Pilot Study|Accuracy of 5D LB Ultrasound in Prediction of Birth Weight in Macrosomic Babies: A Pilot Study||Ain Shams University||Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|20 Years|40 Years|No|Probability Sample|Pregnant women between 37 and 42 weeks with macrosomic fetuses.|January 2016|January 13, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396667||24856|
NCT02396680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR006A|Ragweed-SPIRE Follow-On Study|An Observational Follow-On Field Study to Evaluate the Continued Efficacy and Safety of Ragweed-SPIRE Treatment in Ragweed Allergic Subjects Approximately One Year After the Completion of Treatment||Circassia Limited|No|Completed|April 2015|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who completed at least 6 of 8 treatment visits in Study TR006|March 2016|March 22, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396680||24855|
NCT02397005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZL-2102-SAD/FED/MAD|Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects|Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects||Zai Lab Pty. Ltd.|Yes|Recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02397005||24830|
NCT02399501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132|Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility|Sonohysterography and 3D Ultrasonography Versus Diagnostic Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility||Cairo University|Yes|Recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|20 Years|40 Years|No|||March 2015|March 21, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02399501||24638|
NCT02425163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-URO-0047|Shear Wave Elastography of Prostate Cancer|Shear Wave Elastography of Prostate Cancer|ElaProC|University of Magdeburg|No|Completed|March 2012|January 2015|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Both|N/A|N/A|No|||April 2015|April 20, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02425163||22669|
NCT02425241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-CORE003|Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination|A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers|HIV-CORE003|University College, London|Yes|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02425241||22663|
NCT02425514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA04-CP11|Evaluation of Bone Union Following Anterior Cervical Fusion Using a NovoMax™|Evaluation of Bone Union Following Anterior Cervical Fusion Using a Bioactive Glass-Ceramic Spacer (NovoMax™): Comparison With a PEEK Cage Filled With β-Tricalcium Phosphate (Cervios ChronOs™)||BioAlpha Inc.|No|Not yet recruiting|May 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|66|||Both|20 Years|80 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425514||22642|
NCT02413775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QM-Patient survey|Patient Survey as a Tool to Quality Assurance and Quality Improvement|Patient Survey as a Tool to Quality Assurance and Quality Improvement - Department of Anesthesiology and Intensive Care, CVK/CCM, Charité - University Medicine Berlin||Charite University, Berlin, Germany|No|Recruiting|April 2015|December 2022|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|6 Years|N/A|No|Probability Sample|All Patients who underwent a procedure in anaesthesia|January 2016|January 21, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02413775||23544|
NCT02400996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGRH-SGLT-MTA|An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms|A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours.||Medical College and Hospital Kolkata|No|Completed|March 2011|November 2014|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical files and electronic records were reviewed to collect information. Patients were        categorized into functioning and nonfunctioning PENs based on their clinical behaviour,        pathology reports and serum radioimmunoassay for offending hormones. Preoperative CT scans        were used to characterize PENs and record neoplasm size and location in the pancreas.        Review of operative notes was done for the type of surgery performed and peroperative        findings recorded. Discharge summaries were used to study the surgical outcome in terms of        duration of postoperative hospital stay and postoperative complications. Patients were        followed up and any disease recurrence or disease related mortality was recorded.        Evaluation of the pathology reports was done.|April 2015|April 10, 2015|March 23, 2015||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT02400996||24523|The analysis was done from a prospectively maintained database and target followup done for a period of 5 years after surgery
NCT02409277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51002874|Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children|Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children||University of Utah|Yes|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|480|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02409277||23890|
NCT02417116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00128|Tear Osmolarity Clinical Utility in Dry Eye Disease|Tear Osmolarity Clinical Utility in Dry Eye Disease||Aston University|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|January 8, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417116||23287|
NCT02417129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301.6|BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma|A Phase III, Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate Efficacy and Safety of BI 695500 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma||Boehringer Ingelheim||Completed|April 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|99 Years|No|||December 2015|December 16, 2015|April 10, 2015||||No||https://clinicaltrials.gov/show/NCT02417129||23286|
NCT02425553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-Nr. 2015-0095|Effects of Diet on Reflux and Dyspepsia|Effects of Diet and Alcohol on Fullness, Reflux and Dyspeptic Symptoms After Meals||University of Zurich|No|Completed|April 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be all faculty and delegates attending the "Ascona II: Advances in        clinical measurement of gastrointestinal motility and function" conference that agree to        participate in the study and sign the informed consent form.|June 2015|June 26, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02425553||22639|
NCT02401256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205008739|CYP2B6 Genetics and Drug Interactions in Healthy Volunteers|Influence of Autoinhibition/Autoinduction and CYP2B6 Genetic Variantions on CYP2B6 Activity and Drug Interactions in Healthy Volunteers||Indiana University|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02401256||24503|
NCT02409303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH104302-01|An SRT Model for Early Access to ASD Intervention|A Screen-Refer-Treat (SRT) Model to Promote Earlier Access to ASD Intervention||University of Washington|No|Recruiting|July 2015|||September 2018|Anticipated|N/A|Interventional|N/A|||||||Both|16 Months|N/A||||November 2015|November 30, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02409303||23888|
NCT02419183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106702|A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment|A Randomized Cross-over, Controlled Feasibility, and Validation Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Subjects With Mild Cognitive Impairment||Janssen Research & Development, LLC|No|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 0|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|96|||Both|55 Years|84 Years|No|Probability Sample|Male and female adult normal control (NC) participants and participants with Mild        Cognitive Impairment (MCI), aged 55 to 84 years receiving healthcare in primary care        and/or neurology practice settings.|March 2016|March 23, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419183||23129|
NCT02411669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/32|Impact of Tools for the Development of Patient Centered Care at Hospital|Effectiveness and Determinants of Effectiveness of Implementation of Tools for the Development of Patient Centred Care at Hospital|MoSTRA|University Hospital, Bordeaux|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|950|||Both|18 Years|N/A|No|Non-Probability Sample|There are 2 populations participating in this trials:          -  Health care professionals : physicians, nurses and managerial staff          -  Patients|December 2015|December 10, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02411669||23706|
NCT02407119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS03-062|Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD|Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Intestinal Metaplasia in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer||National Cancer Center, Korea|No|Active, not recruiting|June 2003|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02407119||24056|
NCT02397148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 147 03|Assessment of the Morphological Concordance Between CT and Cone Beam in Sinus Imagery|Assessment of the Morphological Concordance Between CT and Cone Beam in Sinus Imagery|COSINUS|University Hospital, Toulouse|No|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02397148||24819|
NCT02421809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM09|Oral Lesions In Non-Celiac Wheat Sensitivity Patients|Oral Lesions In Non-Celiac Wheat Sensitivity Patients||University of Palermo|No|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|270|Samples Without DNA|Biopsy specimens will be obtained from the bulb and the second duodenal portion.|Both|18 Years|65 Years|No|Probability Sample|The study will include consecutive adult patients with irritable bowel syndrome (IBS)-like        clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS,        referred at the Internal Medicine and at the Gastroenterology Units of the University        Hospital of Palermo, between may 2015 and may 2017.|November 2015|November 30, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421809||22927|
NCT02421822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14080265|BMI Study for Children Ages 6-9 Years and Parents|BMI Study for Children Ages 6-9 Years and Parents||UPMC St. Margaret Family Health Centers|Yes|Not yet recruiting|April 2015|June 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|925|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02421822||22926|
NCT02411955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAZC 1308|A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multiple-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to Tazorac® (Tazarotene Cream 0.1%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|June 2014|February 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1077|||Both|12 Years|40 Years|No|||April 2015|April 7, 2015|April 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411955||23684|
NCT02399189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150301|MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma|MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma||Peking University|Yes|Recruiting|May 2014|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|65 Years|No|||April 2015|April 10, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02399189||24662|
NCT02399475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821564|Mechanistic Study of Subclinical Hypothyroidism In the Elderly|The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration||University of Pennsylvania|No|Recruiting|January 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|70 Years|N/A|No|||February 2015|March 20, 2015|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399475||24640|
NCT02419716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exact Sciences 2014-01|A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval|A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval||Exact Sciences Corporation|No|Recruiting|April 2015|July 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2173|Samples With DNA|A portion of the stool sample may be retained, if any remains after the study-related tests      for use in a sample bank for use in the future. The samples may be stored for up to twenty      (20) years. These stool samples will de-identified.|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll approximately 2,173 men and women aged 50 years and older at a        minimum of 20 sites to achieve a minimum of 1,119 subjects at the Year 3 visit. To        increase the point prevalence of CRC in the study population, subject enrollment will be        age-weighted toward a slightly older population. Enrollment of at least 65% of subjects        age 65 years or older will be targeted|March 2016|March 15, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419716||23088|
NCT02412501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 5.0 - 26Mar2015|Medtronic Resolute Onyx 2.0 mm Clinical Study|A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent Resolute Onyx 2.0 mm Clinical Study||Medtronic Vascular|Yes|Active, not recruiting|April 2015|April 2019|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412501||23642|
NCT02412735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-DR003|Safety and Efficacy Study of Rexlemestrocel-L in Subjects With Chronic Discogenic Lumbar Back Pain|A Prospective, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Discogenic Lumbar Back Pain Through 12 Months|MSB-DR003|Mesoblast, Ltd.|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412735||23624|
NCT02395107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130067|Left Atrial Volume Index in Asymptomatic Aortic Stenosis|Left Atrial Volume Index - Impact on LV Remodeling, LV Function and Functional Capacity in Asymptomatic Aortic Valve Stenosis|LAVIAS|Odense University Hospital|No|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with severe asymptomatic aortic stenosis.|March 2015|March 20, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395107||24976|
NCT02397603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-16-2015|Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy|Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy||Cairo University|Yes|Completed|February 2015|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||January 2016|January 30, 2016|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02397603||24784|
NCT02417506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB/ 140501 /LC/ OA|Study to Assess the Effect of E-OA-07 on Acute Pain Response in Subjects Suffering From Knee OA|A Double Blind Randomized Comparator Controlled Study to Assess the Effect of E-OA-07 (Lanconone) on Acute Pain Response in Subjects Suffering From Osteoarthritis of the Knee|Osteolanc|Vedic Lifesciences Pvt. Ltd.|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|40 Years|60 Years|No|||May 2015|May 6, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02417506||23257|
NCT02412683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTOX-123|Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer|Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer||Linkoeping University|No|Recruiting|January 2014|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients recieved adjuvant oxaliplatin chemotherapy after radical        surgery|April 2015|April 8, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02412683||23628|
NCT02416895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165/Gen/10|Vitamin D Status and Immune Function|Vitamin D Status and in Vivo Immune Function||Bangor University|Yes|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|264|Samples Without DNA|Blood serum collected at Week 1 (start of training) and Week 13 (end of training).|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adults who are starting basic training in the army.|February 2015|April 9, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02416895||23304|
NCT02423226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ-I125-001|Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer|Phase II Study of Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer||The First People's Hospital of Changzhou|No|Completed|October 2008|April 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02423226||22818|
NCT02423239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETS2101-004|A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours|A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours||e-Therapeutics PLC|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|112|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02423239||22817|
NCT02407496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNI-NAT-1|Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)|Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)|NAT-I|Think Now Incorporated|No|Completed|June 2014|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with Attention Deficit Hyperactivity Disorder (ADHD) from local clinics,        clinicians. ADHD community resources in the greater Los Angeles area.|September 2015|September 18, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02407496||24027|
NCT02420834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOptomEssa|Dry Eye Treatment With Artificial Tears|Dry Eye Treatment With Artificial Tears||Aston University|No|Active, not recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|January 8, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02420834||23002|
NCT02420847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0661|A Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer|A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420847||23001|
NCT02421471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PICATO-1130|PMS to Evaluate the Safety and Efficacy of Picato® Gel|Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Picato® Gel||LEO Pharma|No|Recruiting|September 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Non-Probability Sample|Consecutive adult patients with AK in involved PMS sites treated for the first time with        ingenol mebutate 0.015 or 0.05 percent gel.|March 2016|March 2, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421471||22953|
NCT02421302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST/0110/15|The Pediatric HIV Nutrition Study in Uganda|The Role of Nutrition as a Determinant of Immune Function and Pharmacological Outcome Amongst HIV Infected Malnourished Children in Uganda|NOURISH|Makerere University|No|Recruiting|February 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|6 Months|12 Years|No|||April 2015|April 15, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02421302||22966|
NCT02400502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1815|Integrated Coping and Awareness Training|Targeting Stress Reactivity in Schizophrenia: Integrating Coping Awareness Therapy (I-CAT) Pilot Trial|I-CAT|University of North Carolina, Chapel Hill|No|Active, not recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|35 Years|No|||March 2015|March 31, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400502||24561|
NCT02400736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1489-I|Supported Employment in OIF/OEF PACT|Efficacy of Supported Employment Within the OIF/OEF Patient Aligned Care Team||VA Office of Research and Development|Yes|Recruiting|August 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|N/A|No|||February 2016|February 24, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02400736||24543|
NCT02400749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6040|Apremilast in Palmo-Plantar Psoriasis|A Double-blind, Placebo-controlled, Randomized Study on the Safety and Efficacy of Apremilast in Patients With Moderate to Severe Plaque Psoriasis Involving Palms and/or Soles||Innovaderm Research Inc.|No|Active, not recruiting|May 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400749||24542|
NCT02421042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-006|A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)|||Eisai Inc.||Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|July 22, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02421042||22986|
NCT02424175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002475|Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.|Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.||Brigham and Women's Hospital|Yes|Not yet recruiting|May 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|April 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02424175||22745|
NCT02426801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_Spring_Feasibility|Feasibility Trial of a Mobile Adherence Tool for Adolescents With Asthma|Feasibility of a Mobile Intervention to Increase Adherence to Asthma Medication Among Children Age 11 to 19 in an Urban Setting||CoheroHealth|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|11 Years|19 Years|No|||April 2015|April 24, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02426801||22543|
NCT02426814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_Spring_Sinai|Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents|Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents||CoheroHealth|No|Active, not recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|11 Years|19 Years|No|||March 2016|March 22, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02426814||22542|
NCT02414048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-Nr.2014-0393|Hypoxia Analysis in Head and/or Neck Cancer|Predictive Methods Determining Tumour Hypoxia in Head and Neck Cancer Patients - a Prospective Project||University of Zurich|No|Recruiting|April 2015|October 2022|Anticipated|October 2022|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414048||23523|
NCT02401867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1403-12625|Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients|Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients||Fenway Community Health|No|Recruiting|January 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|||Female|21 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|This study aims to enroll 150 female-to-male (FTM) individuals, ages 21-64. Participants        will be recruited from the existing FTM patient population at Fenway Health, as well as        via community outreach in the greater Boston area. A diverse sample is anticipated; the        aim is to recruit 40% racial/ethnic minority FTMs.|February 2016|February 5, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02401867||24456|
NCT02416622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGTC-RS1-001|Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis||Applied Genetic Technologies Corp|Yes|Recruiting|May 2015|December 2020|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Male|6 Years|N/A|No|||October 2015|October 5, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416622||23325|
NCT02416453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107227|A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults|A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe||Crucell Holland BV|Yes|Recruiting|June 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|612|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416453||23338|
NCT02416466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|383-74|CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases|Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases|HITM-SIR|Roger Williams Medical Center|Yes|Recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416466||23337|
NCT02404987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA07|An Oral Nutritional Supplement Study in Older Malnourished Spanish Population|A Prospective, Observational Study, of a High Calorie and Protein Oral Nutritional Supplement, in an Older Malnourished Spanish Population||Abbott Nutrition|No|Recruiting|June 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|224|||Both|65 Years|N/A|No|Non-Probability Sample|Spanish patients, both free living and residing and nursing homes, who have been        identified as malnourished.|March 2015|March 27, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02404987||24218|
NCT02410083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP_CLN_01|Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent|Multicenter, Randomized, Open Study, Investigator-initiated Trial for Comparison of Eight Weeks Efficacy and Tolerability of Clopirin and Clopidogrel With Aspirin in Korean Patients With Post-Percutaneous Coronary Artery Intervention||Jeil Pharmaceutical Co., Ltd.||Completed|November 2012|||April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|448|||Both|20 Years|85 Years|No|||March 2015|April 1, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02410083||23828|
NCT02416856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-Bonilha|Brain Connectivity Supporting Language Recovery in Aphasia|Brain Connectivity Supporting Language Recovery in Aphasia||Medical University of South Carolina|No|Recruiting|June 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|74|||Both|25 Years|80 Years|No|Probability Sample|No new patients will be recruited for the current project. We will rely solely on data        collection in the tDCS-Trial (U01 DC011739, period 7/1/2012-6/31/2017). All information        used in our experiments will be available as a result of the standardized set of tests        that patients undergo in the trial.|April 2015|April 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416856||23307|
NCT02406872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR7056-002|A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations|||Jiangsu HengRui Medicine Co., Ltd.|Yes|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Actual|144|||Both|18 Years|60 Years|No|||December 2015|December 29, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02406872||24075|
NCT02398097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUHIV|Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects|Safety and Immunogenicity of Influenza Vaccine Among HIV-infected Young Subjects: Conventional Vaccine Versus Intradermal Vaccine||Korea University Guro Hospital|Yes|Completed|November 2011|April 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|88|||Both|18 Years|60 Years|No|||March 2015|March 24, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02398097||24746|
NCT02398110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121BBG70032|Transvaginal NOTES Nephrectomy Versus Conventional Laparoscopic Nephrectomy|Transvaginal NOTES Nephrectomy Versus Conventional Laparoscopic Nephrectomy: a Randomized Clinical Trial||First Affiliated Hospital of Gannan Medical University|Yes|Recruiting|March 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||August 2015|August 10, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02398110||24745|
NCT02412644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-CL-PSOR-PI-004893|Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis|Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis||Psoriasis Treatment Center of Central New Jersey|No|Recruiting|April 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|29|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412644||23631|
NCT02484768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-RLS-01|IV Iron Treatment of Restless Legs Syndrome|A Phase II, Six-week, Randomised, Comparative, Double-blind Study of Intravenous Iron Isomaltoside 1000 Versus Placebo in Subjects With Restless Leg Syndrome With a 3 Month Extension||Pharmacosmos A/S|No|Withdrawn|January 2015|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|March 30, 2015|Yes|Yes|as per GCP sponsor/company decision|No||https://clinicaltrials.gov/show/NCT02484768||18091|
NCT02489422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1549|Programs To Support You During Chemotherapy|GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy|PRO-YOU|Vanderbilt-Ingram Cancer Center|Yes|Recruiting|August 2015|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02489422||17735|
NCT02466763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000576|Prospective Study of Round Window Versus Cochleostomy Approach to CI Surgery|Prospective Randomized Controlled Double-blinded Study Comparing Cochlear Implantation Through a Round Window Versus Cochleostomy Approach||Mayo Clinic|No|Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466763||19476|
NCT02466776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459-14|Comparison of Staples Versus Subcuticular Suture in Class III Obese Women Undergoing Cesarean Delivery|Comparison of Staples Versus Subcuticular Suture in Class III Obese Women Undergoing Cesarean Delivery||MemorialCare Health System|No|Recruiting|May 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|242|||Female|18 Years|65 Years|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466776||19475|
NCT02492698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LW_clinical|Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults|Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults||Yonsei University|Yes|Completed|June 2014|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|120|||Both|20 Years|65 Years|No|||July 2015|July 5, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492698||17484|
NCT02482207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0610|Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|RESERVE II|Asan Medical Center|No|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|35 Years|80 Years|No|||December 2015|December 29, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482207||18288|
NCT02476669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-biomarkers1|Serial Plasma EBV DNA for Nasopharyngeal Carcinoma|Serial Plasma EBV DNA for Patients With Nasopharyngeal Carcinoma||The University of Hong Kong|No|Recruiting|June 2010|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients with histologically confirmed previously untreated nasopharyngeal carcinoma (NPC)        will be invited to join this study.|February 2016|February 18, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476669||18714|
NCT02464189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2014|Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )|Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )|Q-KAP|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|390|||Both|5 Years|15 Years|No|Non-Probability Sample|390 asthmatic children, recruited in the outpatient clinic of Pediatric Allergology &        Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of        Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of        Palermo (RDRC-IBIM CNR), Italy.|December 2015|December 18, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464189||19674|
NCT02479230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3113|Pilot Trial of a Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer|Pilot Trial of a Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479230||18517|
NCT02482987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|408953-1|Comparison of Two Different Alveolar Ridge Preservation Techniques|Comparison of Two Different Alveolar Ridge Preservation Techniques||Eisenhower Army Medical Center|No|Enrolling by invitation|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482987||18228|
NCT02483000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9189|Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies|Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-cell Malignancies||Fred Hutchinson Cancer Research Center|No|Not yet recruiting|April 2016|||October 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02483000||18227|
NCT02469181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0679|Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)|Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy : A Prospective Multi-modality Imaging Study Using Diastolic Stress Echocardiography, LV Vortex Flow and Cardiac MRI(RECAFTURE Trial)||Yonsei University|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|Samples Without DNA|Lyso GL-3|Both|20 Years|75 Years|No|Non-Probability Sample|Patients aged 20~75years with Fabry's disease who were confirmed by enzyme assay and gene        study|June 2015|June 8, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469181||19290|
NCT02467855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI-P4-003|Epidemiological Study in Thai Participants With Hypertension|A Multi-Centre, Non-Interventional, Hospital-Based, Cross-Sectional as Well as Longitudinal Epidemiological Study in Thai Subjects With Hypertension||Takeda|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2071|||Both|18 Years|N/A|No|Probability Sample|Participants with essential hypertension will be enrolled from outpatient hospital        departments or hospital clinics in Thailand.|November 2015|November 12, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02467855||19392|
NCT02486705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28147|Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD|Pilot Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD||VA Palo Alto Health Care System|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486705||17943|
NCT02486718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29527|Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]|A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|October 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|845|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486718||17942|
NCT02465086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol-01/2015|Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population|Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population||Roskilde University|No|Not yet recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|7 Years|12 Years|No|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465086||19605|
NCT02469454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG-implant-02|Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development|Effect of the Immediately Postpartum Insertion of the Etonogestrel Releasing Implant on Infant Growth and Development||University of Sao Paulo|No|Recruiting|June 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02469454||19269|
NCT02476812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00100068|The Positive Piggy Bank - A Positive Activities Intervention for Improving Functional Status in Patients With Back Pain|||University of Michigan|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02476812||18703|
NCT02486991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0532|Tunnel With and Without Intramucosal Vertical Incisions|Impact of Intramucosal Vertical Incisions on the Coronally Positioned Tunnel Using Acellular Dermal Matrix||University of Louisville|Yes|Not yet recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486991||17921|
NCT02492919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 14-176|Medixair® System on Surgical Site Infection in Cardiac Patients|Impact of Medixair® System on Surgical Site Infection in Patients Admitted Into the Postoperative Cardiac Intensive Care Unit||University of Valladolid|No|Completed|January 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1000|||Both|18 Years|99 Years|No|||September 2015|September 24, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02492919||17467|
NCT02416011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18127|Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes|Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|2592|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02416011||23372|
NCT02416232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202105|Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|An Open Label Non Randomized Access Study of Trametinib for Patients With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma||GlaxoSmithKline|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416232||23355|
NCT02395133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1415|A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis|SOLO-Continue|Regeneron Pharmaceuticals|Yes|Enrolling by invitation|March 2015|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395133||24974|
NCT02395146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-04-06-SUR|Neural Monitoring of the Superior Laryngeal Nerve in Thyroid Surgery|Intra-operative Monitoring of the External Branch of the Superior Laryngeal Nerve (EBSLN) During Thyroid Surgery: Does it Improve Voice Preservation?||The Royal Wolverhampton Hospitals NHS Trust|No|Not yet recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395146||24973|
NCT02416609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMed1|GemOx With Low-dose Radiotherapy and SBRT for Locally Advanced Pancreatic Cancer|Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With GemOx and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer|Pancreas-LDR|Azienda Ospedaliera - Universitaria di Modena|No|Recruiting|January 2014|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416609||23326|
NCT02416674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002556|Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects|Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects||Brigham and Women's Hospital|No|Recruiting|March 2015|February 2025|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||April 2015|April 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416674||23321|
NCT02400697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404705195|Placental Transfusion Project for Preterm Infants|Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of "Delayed" Cord Clamping and Umbilical Cord Milking||Indiana University|No|Recruiting|September 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2500|||Both|N/A|12 Months|No|Non-Probability Sample|Preterm infants less than 30 weeks gestation or less than 1500 grams and/or preterm        infants 30 weeks to less than 34 weeks gestation.|March 2016|March 9, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400697||24546|
NCT02400983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Real Life Automatic Atrial Capture Device Control|Registry on Automatic Algorhitm on Atrial Capture: REAL ACap Registry||Maria Vittoria Hospital|No|Completed|January 2014|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|318|||Both|18 Years|N/A|No|Non-Probability Sample|Patients had undergone first implantation or device replacement with a device (PM, ICD,        CRT-P, CRT-D) endowed with ACAP Confirm ® algorithm features between May 2011 and March        2012|March 2015|March 30, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400983||24524|
NCT02405468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 387 02|Identification of the Blood Microbiota in Patient Suffering From Myocardial Infraction|Identification of the Blood Microbiota in Patient Suffering From Myocardial Infraction|FLORINF|University Hospital, Toulouse|No|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|202|Samples With DNA|blood sample|Both|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|case : patients who have had a myocardial infarction within one month to one year before        the inclusion controls : patients without history of myocardial infarction, free of        coronary disease in the view of one of the following tests performed within one year        before the inclusion Effort test Echocardiographic stress test Myocardial perfusion        scintigraphy Coronarography with >= 2 major cardiovascular risk factors:          -  Treated hypertension,          -  Treated dyslipidemia          -  Current smoking          -  Diabetes mellitus|February 2016|February 14, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405468||24181|
NCT02405481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120037|SEPA III: The Effectiveness Trial|SEPA III: The Effectiveness Trial|SEPA III|University of Miami|No|Active, not recruiting|June 2013|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|320|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405481||24180|
NCT02414178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 123119 Protocol D|F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)|F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (IND #123119 Protocol D)||Washington University School of Medicine|No|Recruiting|February 2015|September 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414178||23513|
NCT02418975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECN/132|Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral Nutrition|Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral Nutrition to Improve Intra- and Post-operative Outcomes of Severely Obese Patients Undergoing Bariatric Surgery||San Giuseppe Moscati Hospital|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||November 2015|November 22, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02418975||23144|
NCT02406820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF001|Correlating Noninvasive Cardiovascular Measures to Left Ventricular End Diastolic Pressure in Heart Failure|Characterizing Noninvasive Cardiovascular Measures Collected Passively and In Response to an Isometric Handgrip Stress Test From CVInsight®, Connex ProBP, and Zio® XT Patch in Patients With Acute Decompensated Heart Failure||Intelomed, Inc.|No|Recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Acutely decompensated heart failure patients admitted to acute care setting, who require a        right heart catheterization.|April 2015|June 16, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406820||24079|
NCT02395406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-TAT-2015-D1|A Comparison of Tracheal Intubation Using the Totaltrack vs the Airtraq Laryngoscope in Difficult Airway Management|||Complexo Hospitalario Universitario de A Coruña|No|Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|100 Years|No|||November 2015|November 30, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395406||24953|
NCT02420652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081501|Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy|A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)|PRIMA|Rutgers, The State University of New Jersey|No|Recruiting|June 2015|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||October 2015|November 3, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420652||23016|
NCT02413996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRRS|Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty|Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty: A Randomised Controlled Trial||Istituto Ortopedico Galeazzi|Yes|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|45 Years|80 Years|No|||April 2015|September 1, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02413996||23527|
NCT02409706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14KH356|Micronutrients in Children in Critical Care With Cardiac Conditions|Micronutrient Deficiencies in Children and Infants With Congenital Heart Diseases (CHD) Admitted for Cardiac Surgery: A Proof-of-concept Study|MC5|NHS Greater Glasgow and Clyde|No|Enrolling by invitation|August 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood Plasma Red blood cells|Both|N/A|5 Years|No|Non-Probability Sample|Children with congenital heart defects who are admitted for elective cardiac surgery at        the Royal Hospital for Sick Children, Glasgow.|May 2015|May 8, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409706||23857|
NCT02395705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Henan CH|Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma|A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma||Henan Cancer Hospital|Yes|Recruiting|June 2015|July 2022|Anticipated|July 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|528|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02395705||24930|
NCT02426073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5312/15|Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly|Pilot Observational Study to Characterize Glucose Metabolism, Muscle Mass/Function and Inflammatory Profile in Elderly Individuals||Catholic University of the Sacred Heart||Not yet recruiting|March 2016|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|76|||Both|70 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Elderly (≥ 70 years) subjects|January 2016|January 26, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426073||22599|
NCT02419248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLEY HERTZ-001|Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|DERM EV TOPIC|Kley Hertz S/A||Completed|June 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|55|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with age from 18 to 70 years old, with skin color varying between clear caucasian        to dark.|November 2015|November 9, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419248||23124|
NCT02394223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOK 13142|FFOCT for the Diagnosis of Prostate Cancer|Full Field Optical Coherence Tomography of Prostate Biopsies for the Diagnosis of Prostate Cancer|BIOMAGIC 01|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Male|45 Years|75 Years|No|Non-Probability Sample|Patients aged 45 to 75 years old, with PSA level 4.0 ng/mL|October 2015|October 15, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394223||25044|
NCT02410772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6655|TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens|Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349|S31/A5349|Centers for Disease Control and Prevention|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2500|||Both|12 Years|N/A|No|||January 2016|January 26, 2016|February 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410772||23775|
NCT02411006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14P001|Prediction of Behavior|Prediction and Pre-commitment Mailings for Medication Adherence||University of Pennsylvania||Active, not recruiting|April 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|50000|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411006||23757|
NCT02403427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS1/B9/13/2012-I|The Expert System VoiceDiab in Children With Diabetes|The Voice Decision Support Expert System in Basal-bolus Insulin Therapy of Diabetes Patients.|VoiceDiab|Instytut Diabetologii Sp. z o.o.|Yes|Recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|42|||Both|3 Years|18 Years|No|||May 2015|May 6, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403427||24338|
NCT02403440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPOPId|A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|April 2014|||April 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02403440||24337|
NCT02420223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00024391|Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients|Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients||Medical College of Wisconsin|Yes|Recruiting|July 2015|June 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02420223||23049|
NCT02420236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1157-B|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Low Back Pain|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Low Back Pain||Norwegian University of Science and Technology|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|65 Years|No|||January 2016|January 25, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02420236||23048|
NCT02422667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HEOR_03|iCORE: Collaborative Orthopedics Outcomes Registry|iCORE: Collaborative Orthopedics Outcomes Registry|iCORE|SCRI Development Innovations, LLC|No|Recruiting|April 2015|April 2025|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years and older who undergo hip and/or knee arthroplasty. Patient must have        the ability to understand the nature of the registry and give written informed consent.|October 2015|October 22, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02422667|10 Years|22861|
NCT02422433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P001254|Capsule Marking Using an OFDI Capsule|OFDI Surveillance and Image-Guided Biopsy of the Esophagus Using an OFDI Capsule||Massachusetts General Hospital|No|Recruiting|June 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|130|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02422433||22879|
NCT02422446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013D003968|Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects|Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects: A Pilot Trial||Brigham and Women's Hospital|No|Recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|33|||Both|30 Years|75 Years|No|||March 2016|March 16, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422446||22878|
NCT02399735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(2014)2-126|Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation|Safety Study of Nature Killer Cell From Sibship to Treat the Relapse of Hepatocellular Carcinoma After Liver Transplantation||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399735||24620|
NCT02399748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703045R|A Long-term Study for the Outcome of Pompe Disease|A Long-term Study for the Outcome of Pompe Disease||National Taiwan University Hospital|No|Recruiting|April 2007|||December 2026|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|Patients of Pompe disease who under enzyme replacement therapy|March 2015|March 27, 2015|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02399748||24619|
NCT02417519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M217|Coffee Roasting and Glucose Tolerance|Acute Effects of Light and Dark Roasted Coffee on Glucose Tolerance: A Randomized, Controlled Crossover Trial in Healthy Volunteers||University of Copenhagen|No|Active, not recruiting|April 2014|November 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 11, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02417519||23256|
NCT02416908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505084|Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia|An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia||Washington University School of Medicine||Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416908||23303|
NCT02421263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01169|The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals|A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion||New York University|Yes|Recruiting|April 2015|December 2019|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|12|||Both|25 Years|76 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421263||22969|
NCT02413541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB.NO.575/56|The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis|||Chulalongkorn University||Recruiting|January 2015|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|90 Years|No|||December 2015|January 26, 2016|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02413541||23562|
NCT02413554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR0001|Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.|Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia.||Chung-Ang University Hospital|Yes|Completed|April 2013|April 2015|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|65 Years|N/A|No|||April 2015|April 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02413554||23561|
NCT02408809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-247|The War on Cigarettes: A Randomized Controlled Trial Evaluating the Impact of a Novel Orthopaedic Related Smoking Cessation Discussion|||University of Missouri, Kansas City|Yes|Enrolling by invitation|March 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408809||23926|
NCT02396758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKOS-12|Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism|Study of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in the Treatment of Acute Submassive Pulmonary Embolism|OPTALYSE PE|EKOS Corporation|No|Recruiting|April 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|96|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02396758||24849|
NCT02422966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044CF13273|Paracetamol in Patent Ductus Arteriosus|Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|25 Weeks|31 Weeks|No|||December 2015|December 29, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02422966||22838|
NCT02422979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-1929/101|Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer|A Phase I Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy||Aspyrian Therapeutics, Inc.|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422979||22837|
NCT02426775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 13/116|Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia|Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness of the Use of Carbaglu® in Patients With Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)|CAMP|King Abdullah International Medical Research Center|Yes|Recruiting|November 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|44|||Both|N/A|15 Years|No|||November 2015|November 16, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426775||22545|
NCT02421315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7006|Overlapping Neural Circuits in Pediatric OCD|Overlapping Neural Circuits Implicated in Pediatric OCD||New York State Psychiatric Institute|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02421315||22965|
NCT02407548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU002|The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia|The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia|TEDSCD|Sun Yat-sen University|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|180|||Both|18 Years|65 Years|No|||February 2016|February 19, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02407548||24023|
NCT02407613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46863.041.14|Efficacy of MR-HIFU Ablation of Breast Cancer|Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer||UMC Utrecht|No|Recruiting|March 2015|||February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02407613||24018|
NCT02424253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPL389/101|A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis||Ziarco Pharma Ltd|No|Active, not recruiting|May 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||April 2015|November 23, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02424253||22739|
NCT02409940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFA-LSBM-11|To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients|A Randomized Trial to Elucidate Effect of Mesenchymal Stem Cells on Immune Modulation in Living Related Kidney Transplant Patients||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|September 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409940||23839|
NCT02408406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15025|PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers|PatientCareAnywhere: Patient Support and Empowerment Across the Care Continuum||City of Hope Medical Center|Yes|Recruiting|March 2015|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|714|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408406||23957|
NCT02422550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-073|Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment|Development and Evaluation of Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be patients undergoing radiation therapy in the Department of        Radiation Oncology, optional normal volunteers, or a combination thereof.|December 2015|December 10, 2015|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422550||22870|
NCT02421510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-310-T1DM|Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|inTandem2|Lexicon Pharmaceuticals|Yes|Recruiting|May 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421510||22950|
NCT02427191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIPF004|Micronized dHACM Injectable for the Treatment of Plantar Fasciitis|A Prospective, Single-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to the Saline Placebo Injection in the Treatment of Plantar Fasciitis|dHACM|MiMedx Group, Inc.|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|146|||Both|21 Years|79 Years|No|||March 2016|March 1, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427191||22513|
NCT02407470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ginkgocell-ADHSC-AA-001|Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia|A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia||Navy General Hospital, Beijing|Yes|Recruiting|January 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|14 Years|70 Years|No|||March 2015|April 2, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02407470||24029|
NCT02394587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00052848|MBSR for Pain Catastrophizing in SCD|A Mindfulness-based Intervention For Pain Catastrophizing In Sickle Cell Disease||Duke University|No|Active, not recruiting|April 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||June 2015|February 19, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02394587||25016|
NCT02421120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0107|Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients|A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation||Hartford Hospital|No|Recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02421120||22980|
NCT02421133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.874|Impact of a Transitional Care Program on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward|Impact of a Transitional Care Program Involving an Advanced Practice Nurse on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward (PROUST Study)|PROUST|Hospices Civils de Lyon|No|Recruiting|July 2015|August 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|630|||Both|75 Years|N/A|No|||January 2016|February 25, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02421133||22979|
NCT02394769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-496|ASPirin Intervention for the REDuction of Colorectal Cancer Risk|ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk|ASPIRED|Massachusetts General Hospital|Yes|Enrolling by invitation|June 2015|July 2028|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|180|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02394769||25002|
NCT02402660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK001-P1002|Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease|A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease|TEASE|Alkeus Pharmaceuticals, Inc.|Yes|Recruiting|August 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|60 Years|No|||October 2015|October 27, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402660||24395|
NCT02402673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N- 20140100|Multidimensional Diagnostics and Effect of Activity Modification in Young Adolescents With Patellofemoral Pain|Multidimensional Diagnostics and Effect of Activity Modification in Young Adolescents With Patellofemoral Pain||Aalborg University|No|Enrolling by invitation|March 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02402673||24394|
NCT02417142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13T-005|Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia|Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia||University of Massachusetts, Worcester||Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417142||23285|
NCT02478138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7441|Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging|Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging|SLN Mapping|University Health Network, Toronto|No|Recruiting|May 2015|December 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02478138||18601|
NCT02488512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST202.02|Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas|Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphomas (MCL)|itTRIOlym|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02488512||17804|
NCT02490748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cervical001|Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer||The First People's Hospital of Changzhou|Yes|Active, not recruiting|July 2015|June 2040|Anticipated|June 2038|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|30 Years|70 Years|No|||February 2016|February 21, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490748||17634|
NCT02490761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15HN293|Food Intake in Older Patients|Food Intake and Preferences in Older Patients During Hospitalisation||NHS Greater Glasgow and Clyde|No|Not yet recruiting|July 2015|August 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|65 Years|N/A|No|Non-Probability Sample|Patients admitted to the geriatric wards at the South Glasgow University Hospital, Glasgow        or the Royal Alexandra Hospital, Paisley.|July 2015|July 2, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490761||17633|
NCT02470871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL689_1002|Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency|Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency||CSL Behring||Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470871||19160|
NCT02482142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUT.OO.22|The Role of Phosphorus in Diet Induced Thermogenesis (DIT) of Both Lean and Obese Subjects|The Role of Phosphorus in Diet Induced Thermogenesis of Both Lean and Obese Subjects|PinDIT|American University of Beirut Medical Center|No|Not yet recruiting|July 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|64|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|June 25, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02482142||18293|
NCT02482155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070(I)HO14386|Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study|Pharmacokinetic Study of a Single Oral Administration of MOMENT ACT ANALGESIC Granules for Oral Solution to Healthy Volunteers Under Fasting Conditions Single Centre, Single Dose, Open-label, Bioavailability Study||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02482155||18292|
NCT02486510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEMOMAR|Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication|Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication|CHEMOMAR|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Terminated|July 2012|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|June 24, 2015||No|Futility criteria|No||https://clinicaltrials.gov/show/NCT02486510||17958|
NCT02477722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0616-14-TLV|Neurofeedback as a Method to Strengthen Mental and Emotional Resilience|Neurofeedback Preventive Intervention for PTSD: a Method to Strengthen Mental and Emotional Resilience||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02477722||18633|
NCT02484911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHYDZ-1225|Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting|Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial|AOPDPCINV|First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|May 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||December 2015|January 25, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484911||18080|
NCT02483715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503120MIND|Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection|Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study||National Taiwan University Hospital|Yes|Recruiting|July 2015|November 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|20 Years|N/A|No|||January 2016|January 25, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02483715||18172|
NCT02487329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/30-197|The Effect of Laser Combined With Pulp-capping Agents on Direct Pulp Capping|Efficacy of Er,Cr:YSGG Laser Irradiation Combined With Resin Based Tricalcium Silicate and Calcium Hydroxide on Direct Pulp Capping: a Randomized Clinical Trial||Near East University, Turkey|No|Completed|January 2015|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||June 2015|June 26, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02487329||17895|
NCT02474225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-56-168-02-4-2|Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent|Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent||Prince of Songkla University|No|Completed|December 2013|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|85 Years|No|Non-Probability Sample|The patients scheduled to receive intravitreal injection of anti-vascular endothelial        growth factor agent (either bevacizumab or ranibizumab) and were recruited.|June 2015|June 16, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474225||18902|
NCT02476461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture|Prospektiv Randomisert Sammenlikning Mellom Percutan nålefasciotomi og Xiapex for Dupuytrens Kontraktur|PNFvsxiapex|Oslo University Hospital|Yes|Recruiting|April 2015|January 2021|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|June 16, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02476461||18730|
NCT02489773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP002|Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study|Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study||Asahi Kasei Pharma Corporation|No|Active, not recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|150|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|The study will include a cross-section of subjects from the intended use population who        are being monitored for glycemic control. Equal numbers of subjects with Type 1 or Type 2        diabetes will be enrolled whose HbA1c values range from 7.5% to 12% (or higher) in Group 1        and <7.5% in Group 2 at Visit 1. Group 1 will consist of 90 evaluable subjects who have a        change in diabetes management to improve glycemic control; this therapy can include oral        agents, insulin, or noninsulin injectable anti-diabetic medications. Group 2 will consist        of 40 evaluable subjects already on a stable diabetic management program, who have had no        change in treatment in the last 3 months and for whom there is no plan to make a change        during the study period.|January 2016|January 19, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02489773||17709|
NCT02479477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14076613.0.0000.5479|Impact of Labour Kinesiotherapy in the Quality Life of Auxiliary Nursing in the Surgery Center|Impact of Labour Kinesiotherapy in the Quality Life of Auxiliary Nursing in the Surgery Center||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Not yet recruiting|July 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|55 Years|No|||June 2015|June 21, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02479477||18498|
NCT02492854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33618|Standard Versus PICO Dressings in Lower-Extremity Bypass Patients|Standard Versus PICO Dressings in Lower-Extremity Bypass Patients|PICO-LEB|Boston Medical Center|No|Not yet recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|56|||Both|35 Years|N/A|No|||July 2015|July 6, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492854||17472|
NCT02492867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.035|A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer|A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer||University of Michigan Cancer Center|Yes|Not yet recruiting|July 2015|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492867||17471|
NCT02469467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDKDL001|A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis|A Dose Escalation Study of VS-505 to Evaluate the Tolerability, Safety and Efficacy in End Stage Renal Disease Patients Undergoing Hemodialysis||KDL Inc.|No|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02469467||19268|
NCT02474316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE|Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients|A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks||Ruijin Hospital|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|65 Years|No|||June 2015|December 2, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02474316||18895|
NCT02477774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT Arista|Arista for ALT Donor Sites to Reduce Drain Output|Multi-Institutional Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Anterolateral Thigh Donor Sites||University of California, San Francisco|No|Not yet recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477774||18629|
NCT02489864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005004|The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure|||Sun Yat-sen University||Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|July 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489864||17702|
NCT02479295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.197-T|Straight Versus Coiled Peritoneal Dialysis Catheter for Peritoneal Dialysis Patients|Randomized Controlled Trial of Straight Versus Coiled Peritoneal Dialysis||Chinese University of Hong Kong|No|Recruiting|June 2015|September 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479295||18512|
NCT02406950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Signal|Sitagliptin and Endothelial Dysfunction|Preventive Effects of Sitagliptin on Endothelial Dysfunction Induced by Forearm Ischemia-Reperfusion Injury Model||Kyunghee University Medical Center|Yes|Recruiting|February 2015|August 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2015|April 1, 2015|March 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02406950||24069|
NCT02399228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN005-01|A Mouth Rinse Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis|An Open-Label, Proof of Concept Trial to Evaluate the Efficacy, Safety and Tolerability Trial of a Mouth Rinse Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Induced by Radiation Therapy||Santalis Pharmaceuticals, Inc.|No|Recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399228||24659|
NCT02420379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4658-203|Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy|An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy||Sarepta Therapeutics|No|Recruiting|May 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|4 Years|6 Years|No|||March 2016|March 7, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420379||23037|
NCT02420743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 10|Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery|Third Trimester Serum Ferritin Concentration and Fetal MCA Peak Systolic Velocity as Predictors for Preterm Delivery|SFMCA|Beni-Suef University|Yes|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|40 Years|No|Probability Sample|Pregnant females during third trimester. Women should be diagnosed as having iron        deficiency anemia.|December 2015|December 26, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02420743||23009|
NCT02405663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|afhsr-1-3-2015|Methods of Placental Delivery and the Amount of Blood Loss During Cesarean Section|How Can Methods of Placental Delivery Affect the Amount of Blood Loss During Cesarean Section?||Benha University|Yes|Completed|April 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|250|||Female|20 Years|35 Years|No|||January 2016|January 6, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02405663||24166|
NCT02409225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATEGMED1\233221\3\NCBR\2014|Remote Supervision to Decrease Hospitalization Rate|Remote Supervision to Decrease Hospitalization Rate (RESULT)|RESULT|Silesian Centre for Heart Diseases|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||February 2016|February 10, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02409225||23894|
NCT02414451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200089|Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response|Trial of Propranolol in Adults and Adolescents With Autism Spectrum Disorder (ASD) and Predictors of Response||University of Missouri-Columbia|No|Not yet recruiting|November 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|30 Years|No|||November 2015|November 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02414451||23492|
NCT02422901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183A12VC|A Long-term Study to Describe the Use of PASCORBIN® 7.5 g in Patients With Vitamin C Deficiency|A Long-term Observational Study to Describe the Use of PASCORBIN® 7.5 g in Patients With Vitamin C Deficiency||Pascoe Pharmazeutische Praeparate GmbH|No|Recruiting|November 2012|December 2023|Anticipated|November 2022|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|5000|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with a vitamin C deficiency due to acute or chronic underlying diseases|April 2015|April 27, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02422901||22843|
NCT02407301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400733|Cough in Reduced True Vocal Fold Mobility|Voluntary Cough Airflow Dynamics and True Vocal Fold Kinematics in Persons With Reduced True Vocal Fold Mobility||University of Florida|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|75 Years|No|Non-Probability Sample|The participants will represent a population of patients with glottal insufficiency due to        unilateral true vocal fold immobility.|August 2015|August 20, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407301||24042|
NCT02400242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-MM-200|Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma|A Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Antitumor Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma||Acetylon Pharmaceuticals Incorporated|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400242||24581|
NCT02400255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-009|Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients|A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia||Arog Pharmaceuticals, Inc.|No|Recruiting|September 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|October 13, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400255||24580|
NCT02425371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-127071|Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)|Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF)|OPTIMIZE-HFPEF|Göteborg University|Yes|Recruiting|September 2014|July 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|410|||Both|60 Years|N/A|No|||October 2015|October 15, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02425371||22653|
NCT02419235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NangamsoBavuma200907364|The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension|The Effect of a Homoeopathic Complex (Amylenum Nitrosum 6CH, Crataegus Oxyacantha 6CH, Natrum Muriaticum 6CH and Scutellaria Lateriflora 6CH) on Blood Pressure in Refractory Hypertension||University of Johannesburg|Yes|Recruiting|October 2014|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02419235||23125|
NCT02407353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7991003|A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)|A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology||Pfizer|No|Completed|October 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407353||24038|
NCT02400528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-21|Prospective Cohort Follow-up of French Patients With Profound and Multiple Disabilities: Healthcare Pathways and Quality of Life Among Patients and Their Families|Prospective Cohort Follow-up of French Patients With Profound and Multiple Disabilities: Healthcare Pathways and Quality of Life Among Patients and Their Families|Eval-PLH|Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1200|||Both|3 Years|N/A|No|||February 2015|March 23, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02400528||24559|
NCT02414984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105492|Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab|Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia|Go-Compl-Ar|Janssen-Cilag, S.A.|No|Recruiting|April 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|113|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of Colombian rheumatoid arthritis participants, who have        been prescribed golimumab by their treating physician prior to, and independently of,        study enrollment.|March 2016|March 14, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414984|24 Months|23451|
NCT02425020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uREC0015|Meat and Whey Protein Supplementation in Athletes|Effects of Meat Protein Administration on Body Composition, Strength, Muscle Structure and Markers of Muscle Damage and Health in Athletes||University of Greenwich|Yes|Completed|February 2015|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02425020||22680|
NCT02398890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI120906|Follow-up of Oncology Patients After Hospitalization in ICU|Follow-up of Oncology Patients After Hospitalization in ICU|SALTO|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients with active solid tumor out alive from the ICU and monitoring in oncology        in the same hospital as the resuscitator investigator.|December 2014|March 20, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02398890||24685|
NCT02417051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-HITEP-140021-01-00|The Efficacy of a Brief Resilience Training Program for Hurricane Sandy Disaster Responders|The Efficacy of a Brief Resilience Training Program for Hurricane Sandy Disaster Responders||Stony Brook University|No|Enrolling by invitation|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417051||23292|
NCT02417064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107146|A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression|TRANSFORM-1|Janssen Research & Development, LLC|Yes|Recruiting|August 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|348|||Both|18 Years|64 Years|No|||March 2016|March 15, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417064||23291|
NCT02417077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-14-001|Perception of Facial Expression in Subjects With and Without Crow's Feet Lines|||Allergan|No|Completed|December 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|393|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|March 2016|March 10, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417077||23290|
NCT02415231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150100|"The Effect of Humor and Laughter on C Reactive Protein: A Pilot Study"|"The Effect of Humor and Laughter on C Reactive Protein: A Pilot Study"||Loma Linda University|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415231||23432|
NCT02415244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206753|Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging|Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging||University of Iowa|No|Recruiting|July 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|75|||Both|N/A|N/A|No|Non-Probability Sample|All age population going under cardiac surgery|November 2015|November 30, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02415244||23431|
NCT02415283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-MPBA-0514|OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI|Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI in Patients With Chronic Liver Disease||Beijing 302 Hospital|Yes|Not yet recruiting|May 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2|||Both|18 Years|N/A|No|Non-Probability Sample|The proposed study will include subjects with chronic liver disease of any cause at risk        for HCC with MRI results within 3 months prior to OBT or scheduled for MRI within the time        frame of the study, and who meet the inclusion criteria and none of the exclusion        criteria.|April 2015|April 9, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415283||23428|
NCT02415296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/10-124|Screening for Excessive Gambling Behaviors on the Internet|Screening for Excessive Gambling Behaviors on the Internet (EDEIN Study). Study of the Database of French Online Gambling Sites.|EDEIN|Nantes University Hospital|No|Not yet recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|N/A||3|Anticipated|20240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will be made up of users of French online gambling websites certified        by the ARJEL within the context of law n° 2010-476 relative to opening the online gambling        sector. Only active accounts, i.e. for which the gambler has placed at least one bet        during the last 12 months, will be taken into account.|April 2015|April 8, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02415296||23427|
NCT02407691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH100470-01|COBALT: Comorbid Affective Disorders, AIDS/HIV, and Long Term Health|The Effectiveness of an Integrated Multi-disease Management Model for Reducing Morbidity and Costs, and Improving Social Functioning and Integration of Care in Patients on Antiretroviral Therapy|COBALT|University of Cape Town|Yes|Not yet recruiting|April 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02407691||24012|
NCT02422680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AalborgH|Colonoscopy Quality Assurance With Focus on Key Quality Indicators and Patient Satisfaction at Aalborg University Hospital|Colonoscopy Quality Assurance With Focus on Key Quality Indicators and Patient Satisfaction at Aalborg University Hospital||Aalborg Universitetshospital|Yes|Recruiting|April 2015|July 2016|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to colonoscopy at the out patient clinic at Aalborg University        department. All patients deemed fit to for at colonoscopy at the outpaient clinic were        included. The patient population is a mix of screening and non-screening patients. The        study begins in april 2015.|April 2015|April 16, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02422680|1 Day|22860|
NCT02412449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0013|Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects|A Randomized, Open-Label, Single-Dose, Three-Period Crossover Study in Healthy Adults to Assess the Relative Bioavailability of Test and Reference Formulations of AKB-6548 Tablets and to Evaluate the Effect of Food on the Bioavailability of AKB-6548||Akebia Therapeutics|No|Completed|April 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412449||23646|
NCT02412670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA8141|Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer|A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma||Eastern Cooperative Oncology Group||Recruiting|April 2015|||February 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412670||23629|
NCT02416700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpigozzo|Evaluation of Peri Implant Bone Loss of Immediately Versus Conventionally Loaded Implants With a Single Prosthesis|Evaluation of Peri Implant Bone Loss of Immediately Loaded Versus Conventionally Loaded Implants With a Single Prosthesis: A Randomized and Clinical Study Split-mouth Experimental Design|Mpigozzo|University of Sao Paulo|No|Not yet recruiting|May 2015|May 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02416700||23319|
NCT02405000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14189|Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance|Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance||Dartmouth-Hitchcock Medical Center||Recruiting|April 2015|July 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405000||24217|
NCT02420353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087702|Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears|Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears||University of Michigan|Yes|Enrolling by invitation|May 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|35 Years|No|||April 2015|April 24, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420353||23039|
NCT02426710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLS-ICE randomized|Intracardiac Echocardiography in Atrial Flutter Ablation|The Usefulness of Intracardiac Echocardiography in Atrial Flutter Ablation - a Randomized Study|FLS-ICE-R|Charles University, Czech Republic|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426710||22550|
NCT02426723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-231MM-102|Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients|A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)||JW Pharmaceutical||Enrolling by invitation|October 2015|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426723||22549|
NCT02410707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4641|Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults|Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults, a Pilot Study||Albert Einstein Healthcare Network|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|April 7, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410707||23780|
NCT02396771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.LG.02|Effect of Uterine Massage Versus Sustained Uterine Compression on Blood Loss After Vaginal Delivery|Effect of Uterine Massage Versus Sustained Uterine Compression on Blood Loss and Maternal Pain After Vaginal Delivery: a Randomized Controlled Trial||American University of Beirut Medical Center|Yes|Recruiting|January 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|990|||Female|20 Years|40 Years|No|||March 2015|March 23, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02396771||24848|
NCT02401074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 16362|Airway Temperature|Role of Airway Tissue Temperature in Asthma Exacerbation||University of Kentucky|Yes|Not yet recruiting|July 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|8|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401074||24517|
NCT02414165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-15-01|P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA|A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma|Toca5|Tocagen Inc.|Yes|Recruiting|November 2015|September 2019|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414165||23514|
NCT02414425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/008/HP|Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence|Effect And Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence|FI_TOXIN|University Hospital, Rouen|No|Not yet recruiting|December 2015|July 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02414425||23494|
NCT02418364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-15|The Effect of Reflexology Treatments on IVF Outcome|Randomised ,Blind, Placebo Controlled in Meir Center. Study the Potential of Reflexology Treatments to Help Implant Pregnancy in Ivf Patients||Meir Medical Center|No|Not yet recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|240|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||February 2015|April 12, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02418364||23191|
NCT02418429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307-348|Resistant Starch and Whey Protein on Energy Metabolism|Combined Effects of Dietary Supplementation With Dietary Resistant Starch (RS) and Whey Protein on Resting Energy Expenditure and Blood Sugar and Insulin Responses in Lean and Obese Men and Women||Skidmore College|No|Active, not recruiting|August 2013|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|32|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 12, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02418429||23186|
NCT02409901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 2011-0808|Physical Activity and Diet on Kidney Transplant Recipients|Randomized Case-Control Trial About the Impact of Targeted Physical Activity and Diet Modification on Kidney Transplant Recipients' Outcome|PACK|University of Illinois at Chicago|Yes|Recruiting|October 2014|||October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02409901||23842|
NCT02408913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150107|VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults|VRC 208: Phase 1/1b Open-Label Clinical Trial to Evaluate Dose, Safety and Immunogenicity of Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine,VRC-EBOMVA079-00-VP, Administered Alone or as Boost to cAd3-Ebola Vaccines in Healthy Adults||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|64|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||February 2016|March 3, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408913||23918|
NCT02414438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-LIN-2014|Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study|Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study||Qure Healthcare, LLC|No|Completed|August 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|217|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414438||23493|
NCT02414477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501M60101|Metabolism of Deuterated NNN in Smokeless Tobacco Users|Metabolism of Deuterated NNN in Smokeless Tobacco Users||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414477||23490|
NCT02414490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS1-13-001|IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements|Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER)|GRIPPER|University of Minnesota - Clinical and Translational Science Institute||Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood taken for future use will be obtained with each serum IgG sample.|Both|18 Years|85 Years|No|Probability Sample|This study will include men and women between 18-85 years of age currently being treated        with IVIg. Up to 30 subjects with a definite or probable diagnosis of CIDP as defined by        the EFNS/PNS criteria and confirmed by outside review will be enrolled.|February 2016|February 4, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414490||23489|
NCT02418715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Water-Based Exercise Trial|Effects of Water-Based Exercise on Lipid Profile and Lipoprotein Lipase of Dyslipidemic Premenopausal Women|Effects of Water-Based Exercise on Lipid Profile and Lipoprotein Lipase of Dyslipidemic Premenopausal Women: A Randomized Controlled Trial||Hospital de Clinicas de Porto Alegre||Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|40 Years|50 Years|No|||April 2015|April 15, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02418715||23164|
NCT02394743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET_eGRF|Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)|||Korea University||Recruiting|March 2011|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|360|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who took 18FDG- PET in Korea Guro University|March 2015|March 20, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394743||25004|
NCT02394756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5615|Investigation of Ocular Signs & Symptoms in Wearers Fitted With Contact Lenses Following Digital Device Use|||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394756||25003|
NCT02409589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|An Intracavitary Electrocardiographic System for Real-time Positioning Peripherally Inserted Central Catheter Tip|A Randomized Open-labeled Multicenter Study to Assess a New Intracavitary Electrocardiographic Guiding Method for Real-time Positioning the Tip of Three-way Valve Type Peripherally Inserted Central Catheters (PROJECT_EGG)|PROJECT_EGG|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|March 2015|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|80 Years|No|||April 2015|April 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409589||23866|
NCT02412397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15Jabb|DePuy Global Unite Shoulder System|||Rothman Institute Orthopaedics||Enrolling by invitation||||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A||Probability Sample|Patients who were implanted with the DePuy Global Unite Shoulder System|April 2015|April 8, 2015|April 6, 2015||||No||https://clinicaltrials.gov/show/NCT02412397||23650|
NCT02412410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008496|Optimizing Sleep/Wake Related Cognitive Efficacy|Optimizing Sleep/Wake Related Cognitive Efficacy in Laborist Shifts: Toward Establishing Models of Safer Obstetrical Care||Mayo Clinic|No|Recruiting|February 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412410||23649|
NCT02412423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015PHB016-01|Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors|||Peking University People's Hospital||Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|N/A|N/A|No|||April 2015|April 8, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02412423||23648|
NCT02427204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1959|Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality|Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality of Life, Fatigue, Work Productivity, Liver Status and Cost-per-SVR/Health Care Utilization||Icahn School of Medicine at Mount Sinai|No|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients initiating treatment for HCV infection are the source of potential subjects.|February 2016|February 9, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427204||22512|
NCT02413528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_Fall_2014_Sinai|Pilot Study of a Mobile Asthma Adherence Intervention|Pilot Study of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents||CoheroHealth|No|Terminated|October 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|11 Years|19 Years|No|||April 2015|April 9, 2015|April 7, 2015||No|Wireless connectivity challenges with device and mobile app|No||https://clinicaltrials.gov/show/NCT02413528||23563|
NCT02396160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-04|The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence|The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence||The University of Queensland|Yes|Completed|August 2013|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02396160||24895|
NCT02396420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAE001|Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams|Phase II, Single Center, Single Arm, Open Label Investigation of Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams||South Florida Medical Imaging, PA|No|Recruiting|July 2015|November 2022|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|40 Years|89 Years|No|||January 2016|January 25, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396420||24875|
NCT02398721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 14-500|Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules|A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules||The University of Hong Kong|Yes|Active, not recruiting|May 2015|February 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|314|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398721||24698|
NCT02420275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A000321-48|Trial Estimating the Efficiency of the Light Therapy in Brain Trauma Sequel Fatigue|Controlled Randomized Trial Estimating the Efficiency of Blue Enriched White Light on Sequel Fatigue, in Victims of Severe Cranial Traumas|phototrauma|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02420275||23045|
NCT02420288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INEF-001|Effect of Physical Exercise Program on Fetoplacental Growth|Effect of Physical Exercise Program on Fetoplacental Growth: a Randomized Controlled Trial||Universidad Politecnica de Madrid|Yes|Recruiting|November 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02420288||23044|
NCT02420301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|claudiasousa_2|Effect of Self-administered Exercises on PRMD|Effects of Self-administered Exercises Based on Tuina Techniques on Musculoskeletal Disorders of Professional Orchestra Musicians||Universidade do Porto|Yes|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||March 2015|April 16, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02420301||23043|
NCT02424604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2015/351-31/1|Recurrency After Inguinal Herniorraphy With Bi-layer Mesh (BLM)|Recurrency After Inguinal Herniorraphy With Bi-layer Mesh||Karolinska Institutet|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|75 Years|No|Non-Probability Sample|patinets with relapse after inguinal hernia surgery|March 2016|March 1, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02424604||22712|
NCT02424617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGBC004|A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer|A Multi-Center Open-Label Phase I Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer||BerGenBio AS|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424617||22711|
NCT02399449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00060573|IV Iron Safety: Evaluation of Iron Species in Healthy Subjects|Evaluation of Iron Species in Healthy Subjects Treated With Generic and Reference Sodium Ferric Gluconate||University of Maryland|No|Not yet recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399449||24642|
NCT02399462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTH-101|Acthar for Treatment of Post-transplant FSGS|Acthar for Treatment of Post-transplant FSGS||University of North Carolina, Chapel Hill|No|Not yet recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|January 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399462||24641|
NCT02410109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00071007|Developing an Integrated Model for Home Visitation|||Johns Hopkins University|No|Recruiting|May 2013|March 2016|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|262|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT02410109||23826|
NCT02410122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00092688|The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy|The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4 (STGD4): A Prospective Longitudinal Observational Study of Stargardt Disease Type 4, a PROM1- Related Macular Dystrophy|ProgStar-4|Johns Hopkins University|No|Recruiting|December 2014|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|6 Years|N/A|No|Non-Probability Sample|The study shall enroll participants with PROM1 mutations and associated STGD4 phenotype at        up to 10 clinical sites.|September 2015|September 14, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02410122||23825|
NCT02420392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1407-176-598|Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell|Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell||Seoul National University Hospital|Yes|Recruiting|August 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02420392||23036|
NCT02478151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8132-B|Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation|A Single Centre Study of the Feasibility and Safety of Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation||University Health Network, Toronto|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02478151||18600|
NCT02492724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-0707|Activ C European Multicenter Study|Activ C Disc Prosthesis European Multi-Center Clinical Investigation||Aesculap AG|No|Completed|February 2007|December 2013|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|210|||Both|18 Years|65 Years|No|Non-Probability Sample|adult patients|July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02492724||17482|
NCT02479087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCG-CNS-001|Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients|IMMUNE TOLERANCE INDUCTION, BY FACTOR VIII CONCENTRATE CONTAINING VON WILLEBRAND FACTOR, IN SEVERE OR MODERATE HAEMOPHILIA A PATIENTS WITH INHIBITORS|ITI|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|January 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|N/A|12 Years|No|||June 2015|June 22, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02479087||18528|
NCT02476682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2014/9/4.4(4079)|Non-invasive Risk Stratification of CR AMN/SSP|Evaluation of Stool and Blood Based Tests for Colorectal Advanced Mucosal Neoplasia|FIT|Western Sydney Local Health District|No|Not yet recruiting|July 2016|July 2021|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1725|Samples With DNA|2mg of stool per patient 18mL of blood per patient|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will be comprised of subjects diagnosed with AMN/SSP and subjects        scheduled for screening colonoscopy.|December 2015|December 15, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02476682||18713|
NCT02486185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-19|SARCORSICA: SARC-F Questionnaire as a Screening Tool for Age-related Sarcopenia|Evaluation of the SARC-F Questionnaire, a New Screening Tool for Sarcopenia in People 65-year Old and Older in the Community|SARCORSICA|Centre Hospitalier Universitaire de Nice|No|Recruiting|August 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|366|||Both|65 Years|N/A|No|||September 2015|September 29, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02486185||17983|
NCT02490475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17021|A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors|A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Docetaxel (Taxotere) in Patients With Advanced Solid Tumors||Hoffmann-La Roche||Completed|February 2004|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|July 2, 2015||No||No|July 28, 2015|https://clinicaltrials.gov/show/NCT02490475||17655|
NCT02465710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504023RINC|Comparisons of Clinical Outcomes Between Novel Tailored Transvaginal Mesh Surgery and Vaginal Native Tissue Repair Surgery for Pelvic Organ Prolapse|Comparisons of Clinical Outcomes Between Novel Tailored Transvaginal Mesh Surgery and Vaginal Native Tissue Repair Surgery for Pelvic Organ Prolapse||National Taiwan University Hospital|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|350|||Female|20 Years|N/A|No|Probability Sample|All women who underwent surgical treatment of pelvic organ prolapse were enrolled in this        study.|December 2015|December 15, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465710||19557|
NCT02487875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maugeri1|Sit-to-stand and Peripheral Muscle Strength in COPD|The One Repetition Maximum Test and the Sit-to-stand Test in the Assessment of a Specific Pulmonary Rehabilitation Program on Peripheral Muscle Strength in COPD Patients||Maugeri Foundation|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|87 Years|No|||June 2015|June 29, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487875||17853|
NCT02487745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-37314-1|The Long-Term Treatment of Drug Addiction and Unemployment|The Long-Term Treatment of Drug Addiction and Unemployment||Johns Hopkins University|No|Not yet recruiting|June 2015|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02487745||17863|
NCT02493231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-133|Effect of Intraoperative Nefopam on Acute Pain After Remifentanil Based Anesthesia|||Hallym University Kangnam Sacred Heart Hospital||Recruiting|March 2015|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|60|||Both|20 Years|65 Years||||August 2015|August 31, 2015|July 2, 2015||Yes||No||https://clinicaltrials.gov/show/NCT02493231||17443|
NCT02492438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2113445|13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients|Immunogenicity and Safety of the 13-valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients That Are 23-valent Pneumococcal Polysaccharide Vaccine Naive and Pre-immunized.||AZ Sint-Jan AV|Yes|Completed|February 2013|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|154|||Both|50 Years|N/A|No|||July 2015|July 5, 2015|August 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492438||17504|
NCT02477748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL016|The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD|A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Alcobra Ltd.|Yes|Recruiting|June 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|March 3, 2016|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477748||18631|
NCT02477761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LisbLungo|Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes|Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes||Azienda Ospedaliero, Universitaria Pisana|No|Not yet recruiting|June 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477761||18630|
NCT02479490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST189.04|PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI|Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors|PREV|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479490||18497|
NCT02483975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107118|Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Once-daily Inhaled Fluticasone Furoate Inhalation Powder for Six Weeks on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma||GlaxoSmithKline|No|Recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|11 Years|No|||December 2015|March 17, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483975||18152|
NCT02479009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002038|Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures|Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures||Massachusetts General Hospital|No|Enrolling by invitation|June 2015|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479009||18534|
NCT02474368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-183|Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck|Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck||Dana-Farber Cancer Institute|Yes|Not yet recruiting|July 2015|June 2021|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474368||18891|
NCT02464670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBOV-001|Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers|Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers||Inovio Pharmaceuticals|No|Active, not recruiting|May 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464670||19637|
NCT02479737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Germany-ACT II|Active Clearance Technology (ACT) II German Multicenter Trial|The Active Clearance Technology (ACT) II German Multicenter Trial||Paracelsus Medical University|No|Not yet recruiting|June 2015|||October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects older than 18 years who received a PleuraFlow System following heart surgery|June 2015|June 19, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479737|30 Days|18478|
NCT02479750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZY-002|Evaluation of ColdZyme® on Prevention and Reduction of Common Cold Symptoms on Experimentally Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers|Evaluation of ColdZyme® on Prevention and Reduction of Common Cold Symptoms on Experimentally Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers. -A Double-blind, Randomized, Placebo-controlled Study|COLDPREVII|Enzymatica AB|No|Not yet recruiting|August 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|16 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02479750||18477|
NCT02420561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03323|Motivational Interviewing to Reduce Substance Use Among Depression Patients|Motivational Interviewing to Reduce Substance Use Among Depression Patients||University of California, San Francisco|Yes|Completed|October 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|307|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02420561||23023|
NCT02396381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-ERS-09-US|Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks|A Randomized, Controlled, 2-arm Parallel Group, Multi-center Study, to Evaluate Biological and Functional Changes in Healthy Smokers Switching to Tobacco Heating System 2.2 (THS 2.2) Compared to Continuing Smoking Conventional Cigarettes for 26 Weeks in an Ambulatory Setting||Philip Morris Products S.A.|No|Recruiting|March 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|950|||Both|30 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396381||24878|
NCT02403466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X10-08-0392|IIPE-PRIS Accelerating Safe Signouts|Bundling Effective Resident Handoff Tools to Improve Patient Safety: A Multi-Center Pediatric Residency Quality Improvement Initiative|I-PASS|Children's Hospital Boston|No|Completed|September 2010|August 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|875|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT02403466||24335|
NCT02425072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-NEURO-05-MCC|NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer|NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer||University of Kentucky|Yes|Recruiting|June 2015|July 2022|Anticipated|July 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|22 Years|N/A|No|||June 2015|June 17, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425072||22676|
NCT02425488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFICD|Nursing Therapeutics Education and Heart Failure (HF): a Study Protocol|Nursing Therapeutics Education and Heart Failure (HF): an Experimental Study||University of Turin, Italy|Yes|Enrolling by invitation|April 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 25, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425488||22644|
NCT02407236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106920|A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis|UNIFI|Janssen Research & Development, LLC|Yes|Recruiting|July 2015|July 2021|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|10||Anticipated|951|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407236||24047|
NCT02395159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-048|Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)|Reduction of Groin Wound Infections After Vascular Surgery in Patients With Risk Factors by the Use a Negative Pressure Wound Incision Management System (KCI Prevena)|IMS|RWTH Aachen University|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|204|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395159||24972|
NCT02395172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100070-004|Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)|A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet||EMD Serono|Yes|Recruiting|March 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395172||24971|
NCT02418663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-452 SDR|Fluid Responsiveness in the Postoperative Patient: a Prospective Study|Fluid Responsiveness in the Postoperative Patient: a Prospective Study||McGill University Health Center|No|Not yet recruiting|June 2015|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|245|||Both|18 Years|N/A|No|||April 2015|May 14, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418663||23168|
NCT02418676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEM-LaBE-01|Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers|Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Spectroscopic Evaluation of Molecular Inclusion and Use of the Complex in Gel for Healing of Pressure Ulcers||State University of Maringá|No|Completed|March 2013|July 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|15|||Both|45 Years|75 Years|No|||December 2015|December 9, 2015|April 13, 2015||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT02418676||23167|Small numbers of subjects analyzed because of the type of pressure ulcer selected.
NCT02411084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADN011|Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD|Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease||Adienne SA|No|Not yet recruiting|January 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|65 Years|No|||July 2015|July 14, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411084||23751|
NCT02396693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUMinasGerais|Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms|Successful Extubation and Noninvasive Ventilation in Preterm Infants ≤ 1500g Terms||Federal University of Minas Gerais|Yes|Completed|August 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|26 Weeks|34 Weeks|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02396693||24854|
NCT02409342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29431|A Comparative Study of Atezolizumab (MPDL3280A) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]|A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared With Cisplatin or Carboplatin + Pemetrexed for PD-L1-Selected Chemotherapy Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|July 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409342||23885|
NCT02414685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCTSK003|First Line TIP in Poor Prognosis TGCTs.|A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.|TIP|National Cancer Institute, Slovakia|Yes|Recruiting|April 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414685||23474|
NCT02423057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150116|Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors|Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|120 Years|No|||April 2015|March 2, 2016|April 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423057||22831|
NCT02397031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-MOD-2011-147|Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder|Randomized, Active-controlled, Clinical Trial Comparing Effects of Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|45 Years|No|||March 2015|March 23, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397031||24828|
NCT02409407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS20150303|Misoprostol Before Hysteroscopy in Infertile Cases|Effectiveness of Oral Versus Vaginal Misoprostol Before Office Hyteroscopy in Infertile Patients||Kasr El Aini Hospital||Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 3, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409407||23880|
NCT02419196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|perioperativeEIT|Perioperative Change of Regional Ventilation During Spontaneous Breathing|Perioperative Change of Regional Ventilation During Spontaneous Breathing||Wuerzburg University Hospital|No|Completed|January 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|72|||Both|18 Years|N/A|No|Non-Probability Sample|adult inpatients undergoing elective surgery|February 2016|February 29, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02419196||23128|
NCT02411968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48292.091.14|Follow up After Cryoablation of Small Renal Masses.|Follow up After Percutaneous MR-guided Cryoablation of Small Renal Masses.||Radboud University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|Samples Without DNA|Needle biopsy kidney tumor.|Both|50 Years|N/A|No|Probability Sample|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy on        imaging requiring treatment and planned to undergo cryotherapy.|November 2015|November 9, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411968||23683|
NCT02398903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 130942|Evaluation of Hormonal Contraceptive Treatments in Obese Women|Pharmacological Evaluation of Hormonal Contraceptive Treatments in Obese Women Before and After Bariatric Surgery|OBECO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2015|July 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|174|Samples Without DNA|Blood samples for measurement of drug Css|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese women with an indication of bariatric surgery by RYGB or sleeve gastrectomy under        oral contraceptive treatment.        Normal-weight women under oral contraceptive treatment.|February 2015|March 20, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02398903||24684|
NCT02422511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The BabySeq Project|Genomic Sequencing for Childhood Risk and Newborn Illness|Genomic Sequencing for Childhood Risk and Newborn Illness (The BabySeq Project)||Brigham and Women's Hospital|Yes|Recruiting|May 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|1440|||Both|N/A|N/A|No|||October 2015|October 25, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422511||22873|
NCT02419443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2010.0123|The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair|The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair||United States Naval Medical Center, San Diego|No|Active, not recruiting|August 2011|September 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419443||23109|
NCT02419508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLH694-P001|SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)|Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue||Alcon Research|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419508||23104|
NCT02419794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000015273|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2||Hyogo College of Medicine|Yes|Recruiting|October 2014|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|Acute cerebral large vessel occlusion admitted within 24 hours after onset.|April 2015|April 14, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02419794|90 Days|23082|
NCT02413671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPS|Nutritional Pre-Study|Comparison of Acute Effects of Lupine and Whey Protein on the Whole-body Glucose and Insuline Metabolism|NPS|DLR German Aerospace Center|No|Completed|June 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02413671||23552|
NCT02416648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uputra|Effectiveness of Clinician Client Centered Counseling on Sexual Behaviors of Antiretroviral Therapy Patients in Nigeria|Effectiveness of Clinician Client Centered Counseling on Knowledge, Attitudes and Sexual Behaviors of Antiretroviral Therapy Patients in Yola, Nigeria||Universiti Putra Malaysia|Yes|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|386|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02416648||23323|
NCT02416661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP 03-2015|LYSO-PROVE - Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease|Lyso-Gb1 as Long-term Prognostic Biomarker in Gaucher Disease - an International Multicenter Epidemiological Study (LYSO-PROVE) to Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease|LYSO-PROVE|University of Rostock|Yes|Recruiting|March 2015|May 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|lyso-Gb1 as biomarker for Gaucher Disease For the purpose of measuring lyso-Gb1 one filter      card is sent to the following laboratory, Centogene AG, Schillingallee 68, 18057 Rostock,      Germany|Both|6 Years|N/A|No|Probability Sample|male or female patients aged 6 years or older with genetically confirmed diagnosis of        Gaucher disease type 1 without treatment prior to enrollment or no treatment for more than        24 months ago|October 2015|October 6, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02416661||23322|
NCT02407769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-1103-13/14-1|Late Evening Supplementation With Branched Chain Amino Acids in Liver Transplantation|Effect of a Late Evening Supplementation With Branched Chain Amino Acids on the Nutritional Status in Patients on the Waiting List for Liver Transplantation||Universidad de Guanajuato|Yes|Recruiting|February 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|70 Years|No|||March 2015|April 2, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02407769||24006|
NCT02422797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201637|Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed (SWORD-2)||ViiV Healthcare|Yes|Active, not recruiting|April 2015|August 2021|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|510|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422797||22851|
NCT02414230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 123119 Protocol B|F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis|F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B)|T807ALS|Washington University School of Medicine|No|Recruiting|February 2015|September 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414230||23509|
NCT02414243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAF-01-015|Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy|A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy|RAF|Laboratorios Ordesa|Yes|Recruiting|April 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|29|||Both|N/A|12 Years|No|||January 2016|January 8, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02414243||23508|
NCT02394171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RebeccaLee|Health is Power: An Ecological Theory-based Health Intervention for Women of Color|Health is Power: An Ecological Theory-based Health Intervention for Women of Color|HIP|Arizona State University|No|Completed|May 2005|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Female|26 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02394171||25048|
NCT02401087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Var-001|The Anaesthesiological Approach to Varicocele Correction in Outpatients Setting: an Observational Analisy|The Anaesthesiological Approach to Varicocele Correction in Outpatients Setting: an Observational Analisy||Ospedale di Circolo - Fondazione Macchi|Yes|Recruiting|May 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|18 Years|N/A|No|Probability Sample|The patients will be identified as potentially were to be enrolled in the preoperative        anesthetic visit.|March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401087||24516|
NCT02407925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W14_099|Implementation of Optical Diagnosis for Diminutive Polyps Amongst Endoscopists: Training and Long-term Quality Assurance|Implementation of Optical Diagnosis for Diminutive Polyps Amongst Accredited Endoscopists for the Dutch Bowel Cancer Screening Program: Training and Long-term Quality Assurance|DISCOUNT2|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2015|January 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1500|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Endoscopists certified for performing Dutch screening colonoscopies. Colonoscopies in        patients performed after a positive FIT obtained for the Dutch colorectal cancer screening        program.|March 2015|March 31, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02407925||23994|
NCT02418650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104005|Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects|A Two-Part Open-Label, Single-Centre Mass Balance, Pharmacokinetics, Biotransformation and Absolute Bioavailability Study of ODM-201 in Healthy Male Subjects|ARIADME|Orion Corporation, Orion Pharma|No|Completed|March 2015|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02418650||23169|
NCT02422602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9120|Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program||MONACO|University Hospital, Montpellier|No|Active, not recruiting|November 2013|October 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|196|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422602||22866|
NCT02422615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011F2301|Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.|A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment|MONALEESA-3|Novartis|Yes|Recruiting|June 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|660|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422615||22865|
NCT02422628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201304074RIPC|Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC|Correlation Between Epithelial Growth Factor Receptor(EGFR) Mutation Using cfDNA and CTCs in Patients With Non-Small Cell Lung Cancer||National Taiwan University Hospital|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Anticipated|400|Samples With DNA|Blood samples every 3 months till disease progression or intolerable due to side effect.|Both|20 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients with NSCLC adenocarcinoma|November 2015|November 10, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02422628||22864|
NCT02394483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F901318-01-03-15|Single Ascending Oral Dose Study of F901318|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects||F2G Ltd.|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394483||25024|
NCT02394496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM8-OVER|Overcoming Endocrine Resistance in Metastatic Breast Cancer|A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy|OVER|Consorzio Oncotech|No|Recruiting|November 2007|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|396|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02394496||25023|
NCT02397096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439A-024|Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)|A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|DRIVE-SHIFT|Merck Sharp & Dohme Corp.|No|Recruiting|June 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397096||24823|
NCT02397109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR_2015-1|mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)|Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies|DDX|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|April 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with a dysthyroid orbitopathy undergoing a MRI|February 2016|February 18, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02397109||24822|
NCT02418910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150321|Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods|Comparative Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods: A Randomized, Open 52 Week Study for Persons With Bipolar Disorder||The University of Texas Health Science Center at San Antonio|No|Recruiting|October 2015|April 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|This Phase II study has the specific aim of evaluation of KIOS-Bipolar in a randomized,        open 52 week effectiveness study of 50 bipolar subjects in current treatment. Subjects are        male or female, outpatient, 18 years of age or older, Bipolar I or II disorder as assessed        by MINI 6.0, and in psychiatric outpatient treatment at UTHSCSA|December 2015|December 10, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418910||23149|
NCT02422186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107129|A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression|TRANSFORM-3|Janssen Research & Development, LLC|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|65 Years|N/A|No|||March 2016|March 18, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422186||22898|
NCT02422758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38320814.2.0000.5393|Prewarming Effect in Preventing Perioperative Hypothermia|Prewarming Effect in Preventing Perioperative Hypothermia||Universidade Estadual de Londrina|Yes|Active, not recruiting|May 2015|August 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|86|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02422758||22854|
NCT02398877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI 3396/6-1|HPA Axis Activity Due To Early Traumatic Stress and Metabolic Symptoms|Altered Hypothalamic-Pituitary-Adrenal Axis (HPA-Axis) Activity Due To Early Traumatic Stress and Its Relevance for Metabolic Symptoms|Cort-Metab|Charite University, Berlin, Germany|No|Completed|February 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|140|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02398877||24686|
NCT02397590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FMS-CT-117|Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers|A Randomized, Open-label, Six-sequence, Three-period, Multiple Dosing Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|36|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2015|July 21, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02397590||24785|
NCT02416388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-2010-03|Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR|Phase III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial|BIG-1|University Hospital, Angers|Yes|Recruiting|January 2015|||June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|3100|||Both|18 Years|61 Years|No|||April 2015|January 18, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416388||23343|
NCT02413801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 53131|Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients|Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients|RRF|University of Rochester|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|225|Samples With DNA|Peripheral blood and bone marrow samples that remain after study assays are completed may be      stored for future non-genetic research.|Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female subjects that are 18 years old and older. Due to the demographic        distribution of the disease we expect all or nearly all subjects to be Caucasian, however        no subjects will be excluded from any group based on race or ethnic origin.|December 2015|December 7, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02413801||23542|
NCT02400723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1478-W|Anxiety in Older Veterans|Reducing Anxiety and Improving Functioning in Older Veterans|BREATHE|VA Office of Research and Development|No|Not yet recruiting|May 2017|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||January 2016|January 27, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02400723||24544|
NCT02418598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMU-AAV-AADC-PD|AADC Gene Therapy for Parkinson's Disease|A Phase I /II Study of Intra-putaminal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase in Subjects With Parkinson's Disease||Jichi Medical University|Yes|Recruiting|April 2015|January 2022|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|35 Years|75 Years|No|||February 2016|February 22, 2016|April 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418598||23173|
NCT02418611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007 EA|Use of the Zenith® Dissection Endovascular System to Treat Patients With Acute, Complicated Type B Aortic Dissection|Use of the Zenith® Dissection Endovascular System in the Treatment of Patients With Acute, Complicated Type B Aortic Dissection||Cook||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||June 2015|June 3, 2015|April 13, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02418611||23172|
NCT02422719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-201501|Radotinib as 3rd or Later Line Therapy in CP-CML|Radotinib Efficacy and Safety Validation in Chronic Phase Chronic Myeloid Leukemia Patients Who Are Intolerant or Resistant to at Least Two Tyrosine Kinase Inhibitors As a Third or Subsequent Line Therapy|REVITAL|Ulsan University Hospital|No|Recruiting|April 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02422719||22857|
NCT02413242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51762.041.14|Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU|Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU|ASPIRE-ICU|UMC Utrecht|No|Recruiting|April 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples Without DNA|-  Microbiological samples:             -  Nose swabs - at day of informed consent form (ICF), day 3, day 7             -  Peri-anal swabs - at day of ICF, then twice weekly until day 30             -  Endotracheal aspirate (ETA) - at day of ICF, then twice weekly until day 30, day                of ICU pneumonia, day 7 after ICU pneumonia. This sample will only be taken if on                the specific day the subject is mechanically ventilated.             -  Sputum- twice weekly until day 30, day of ICU pneumonia, day 7 after ICU                pneumonia. This sample will only be taken if the subject on the specific day is                NOT mechanically ventilated and produces sputum             -  Broncho alveolar lavage- If available through clinical procedures, BAL specimens                will be collected for study purposes        -  Blood samples * Blood samples will be taken at day of ICF, day 7 and day 30 or day of           ICU discharge (whichever occurs first), day of ICU pneumonia, day 7 after ICU pneumonia           and day 30 after ICU pneumonia.|Both|18 Years|N/A|No|Probability Sample|ICU patients in approximately 30 sites in 6-12 European countries will be selected based        on eligibility criteria that are described below.        Inclusion will be based on S. aureus (SA) colonization status at ICU admission (ratio        1:1). These subjects will be followed through their ICU stay for assessment of the primary        outcomes.|June 2015|June 17, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02413242||23585|
NCT02405416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chenxp006|Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping|A Prospective Randomized Controlled Trial to Compare Infrahepatic Inferior Vena Cava Clamping With Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping in Hepatectomy||Huazhong University of Science and Technology|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02405416||24185|
NCT02394873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-BI-101|A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound|A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Deep Second-degree Burn Wound||Anterogen Co., Ltd.|Yes|Completed|March 2015|October 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02394873||24994|
NCT02422836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC-06-13.1|Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage|The Tolerability and Efficacy of a Three Product Anti-Aging Treatment Regimen in Subjects With Moderate to Severe Photodamage||US CosmeceuTechs, LLC|No|Completed|February 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|25|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02422836||22848|
NCT02482363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170108|Vascular Responses to UV Exposure in Pregnancy|UVA Irradiation of Skin in Pregnant Women Increases Uterine Artery Blood Flow and Reduces Blood Flow Through a Nitric Oxide Pathway||University of Edinburgh|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02482363||18276|
NCT02485899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-202|A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease|A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease||BioMarin Pharmaceutical|Yes|Active, not recruiting|February 2015|||December 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|3 Years|16 Years|No|||June 2015|June 29, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485899||18004|
NCT02481674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15/2503-N-131|VX15/2503 Treatment for Huntington's Disease|A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503|SIGNAL|Vaccinex Inc.|Yes|Recruiting|July 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481674||18329|
NCT02481960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA1018|Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma|A Phase I/II Multi Centre Single Arm, Open Label Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as a Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable High Grade Glioma|IDEB-glioma|BTG International Inc.|Yes|Active, not recruiting|July 2011|June 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2015|October 8, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481960||18307|
NCT02483286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503038RINB|Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area|||National Taiwan University Hospital|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|130|||Both|50 Years|N/A|No|||July 2015|July 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483286||18205|
NCT02462603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI589-15-002|Safety and Biomarker Study of EPI-589 in Parkinson's Disease|A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects||Edison Pharmaceuticals Inc|No|Not yet recruiting|November 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|75 Years|No|||November 2015|November 2, 2015|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02462603||19795|
NCT02462889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-AMD-1507|IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD|A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes|PRO-CON|Ophthalmic Consultants of Boston|No|Not yet recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|128|||Both|N/A|N/A|No|||June 2015|June 3, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462889||19773|
NCT02478242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH_08-0023|Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy|||Kyungpook National University|Yes|Completed|July 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478242||18593|
NCT02478502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1627 b|Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer|Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell||University Hospital, Akershus|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Male|18 Years|N/A|No|||January 2016|January 4, 2016|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02478502||18573|
NCT02470598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-aAPD-01-INT|PD-Improved Dialysis Efficiency With Adapted APD|PD-Improved Dialysis Efficiency With Adapted APD - PD-IDEA|PD-IDEA|Fresenius Medical Care Deutschland GmbH|No|Recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease (CKD) being treated or starting renal replacement        therapy with aAPD|June 2015|June 9, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02470598||19181|
NCT02489916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDC1B|Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer|Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer: Multicentre, Open-label,Phase 1B Safety Study||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|No|Completed|March 2014|December 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|70 Years|No|||October 2014|January 3, 2016|September 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02489916||17698|
NCT02480114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 1541|Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy|A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|July 2015|March 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|21 Years|N/A|No|||January 2016|January 6, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480114||18449|
NCT02465931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FXS|Decisional Capacity and Informed Consent in Fragile X Syndrome|Decisional Capacity and Informed Consent in Fragile X Syndrome||RTI International|No|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|12 Years|40 Years|No|||February 2016|February 3, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02465931||19540|
NCT02465944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFP104-002|A Pilot Study of FFP104 in Subjects With Crohn's Disease|A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease||Fast Forward Pharmaceuticals|Yes|Recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02465944||19539|
NCT02464410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-322|Primary Care Intervention to Reduce Prescription Opioid Overdoses|Primary Care Intervention to Reduce Prescription Opioid Overdoses|POST|VA Office of Research and Development|No|Not yet recruiting|January 2016|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02464410||19657|
NCT02483988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00571|The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant)|The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant). A Multi-center, Single-arm, Prospective, Open-label, Non-randomized, Observational Clinical Study|SUN|Active Implants|Yes|Recruiting|December 2015|December 2021|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|118|||Both|30 Years|75 Years|No|||January 2016|February 26, 2016|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02483988||18151|
NCT02483208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17608|Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate|Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate||Bayer|No|Completed|June 2015|December 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|65 Years|No|||February 2016|February 15, 2016|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02483208||18211|
NCT02483221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCI-PCA-002|Postoperative Pain Therapy With Hydromorphone TCI-PCA vs. Morphine PCA|Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) With Morphine After Elective Cardiac Surgery||University of Erlangen-Nürnberg Medical School|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|85 Years|No|||June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483221||18210|
NCT02461615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2214|A National Registry For Pulmonary Alveolar Proteinosis|A National Registry For Pulmonary Alveolar Proteinosis||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|April 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Capillary blood samples on diagnostic blood spot cards may be retained.|Both|N/A|N/A|No|Non-Probability Sample|Patients with Pulmonary Alveolar Proteinosis|June 2015|June 1, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461615|5 Years|19871|
NCT02485574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSong|Anterior Bridging Cage With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis|Prospective, Case Controlled Trial of Anterior Bridging Cage Augmented With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis||Zenoss Co, Ltd|No|Recruiting|March 2015|March 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02485574||18029|
NCT02484209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-07|DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)|A 16 Week PILOT Study to Determine the Frequency of Sulphonylurea-Associated Hypoglycaemia in Older Moderately Frail Patients With Type 2 Diabetes Mellitus Poorly Controlled on Metformin: an Open Label Study ( DIAFRAIL Study)|DiaFrail|Diabetes Frail Ltd|No|Not yet recruiting|February 2016|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|70 Years|N/A|No|||January 2016|January 19, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02484209||18134|
NCT02427165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPL554-008-2014|Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients|A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma||Verona Pharma plc|No|Active, not recruiting|April 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02427165||22515|
NCT02400437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-559|Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia|Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Recruiting|April 2015|September 2021|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400437||24566|
NCT02409186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXCEL1311|A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma|A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma||Shandong Cancer Hospital and Institute|Yes|Recruiting|March 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||September 2015|October 9, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02409186||23897|
NCT02418377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/CIRG/1407/2014|Whole-exome Sequencing in Childhood Obesity|Whole-exome Sequencing to Identify Genetic Variants Associated With Severe Childhood Obesity, and Tracking the Changing Prevalence of Obesity Related Complications||National University, Singapore|No|Recruiting|August 2015|February 2018|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1200|Samples With DNA|15-19mls of blood will be extracted from each subject. Blood will be processed to obtain      plasma/serum and DNA will be extracted from blood cells.      Plasma/serum and DNA samples will be stored at -80degree Celsius.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|As our study aims to identify susceptible genetic variants associated with early onset        obesity, we will be recruiting 400 obese children to participate in this genetic study, in        addition to the existing DNA samples we collected in a previous study. These 400 obese        children will be recruited through NUH paediatric clinic and School Health Clinic at        Health Promotion Board. We will also recruit family members of the obese children who are        interested to join the research study. We will be using the DNA samples and information of        250 obese children previously recruited to the Obesity Genetic Study from January 2000 to        December 2004 . We will also be performing WES on 500 lean adults (as controls) recruited        for an ongoing study.|September 2015|September 15, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02418377|3 Weeks|23190|
NCT02413476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sample20152018|Comparison of Surgical,Clinical and Oncological Outcomes Between Robotic-assisted and Laparoscopic-assisted Gastrectomy|Compared With Robotic-assisted and Laparoscopic-assisted Gastrectomy for Gastric Cancer on Surgical,Clinical and Oncological Outcomes||Chinese PLA General Hospital|No|Not yet recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||April 2015|May 17, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413476||23567|
NCT02396394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH103075-01A1|Improving ART Retention and Adherence in Uganda: The WiseMama Study|Improving ART Retention and Adherence in Uganda: The WiseMama Study|WiseMama|Boston University|No|Not yet recruiting|May 2015|||April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Female|18 Years|59 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396394||24877|
NCT02396407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD076216-01A1|Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health|Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health||University of California, Berkeley|Yes|Active, not recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1800|||Both|N/A|60 Months|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396407||24876|
NCT02400034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-667|Comparing Voiding Trials After Midurethral Sling for Stress Incontinence|A Randomized Controlled Trial Comparing Force of Stream to Traditional Retrograde Fill Voiding Trial After Midurethral Sling With or Without Vaginal Prolapse Surgery||Northwell Health|Yes|Recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400034||24597|
NCT02421211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106992|A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection|A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.||Janssen Sciences Ireland UC|No|Recruiting|May 2015|January 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421211||22973|
NCT02421224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCaliforniaBerkeley|Social and Monetary Incentives for Smoking Cessation at Large Employers|Social and Monetary Incentives for Smoking Cessation at Large Employers|SMILE|University of California, Berkeley|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|9||Anticipated|7500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421224||22972|
NCT02401269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14040373|Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study|Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study|MHEART|University of Pittsburgh|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401269||24502|
NCT02401282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH094633-04|Attention and Social Behavior in Children||BRAINS|Penn State University|No|Enrolling by invitation|December 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|240|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401282||24501|
NCT02410304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD RB 14.097|Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis to Adapt Treatment|Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment|BCD|University Hospital, Brest|No|Recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|561|||Both|18 Years|80 Years|No|||January 2016|February 4, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410304||23811|
NCT02418923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17942|HemoSonics-UVA Spinal Surgery|HemoSonics-UVA Spinal Surgery Clinical Study Protocol||University of Virginia|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Participants for this study will be recruited at the University of Virginia Medical        Center. The subject population will be representative of the local racial and ethnic        population.|November 2015|November 30, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418923||23148|
NCT02411383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 20-1000-0001|Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation|Prospective, Single-centre, Open-label Clinical Study to Investigate the Safety and Performance of the NeuRx Diaphragm Pacing System (DPS) in Patients Undergoing Bilateral Lung Transplantation||Synapse Biomedical|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|N/A|No|||April 2015|April 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02411383||23728|
NCT02401542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-701-U21|A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects Who Have Relapsed After, or Are Refractory to Standard Therapy||BioClin Therapeutics, Inc.|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|211|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02401542||24481|
NCT02410330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 3562/10/151|Therapeutic Use of Ultrasound in Acute Coronary Artery Disease|Therapeutic Use of Ultrasound in Acute Coronary Artery Disease||University of Sao Paulo General Hospital|Yes|Recruiting|May 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Blood sample|Both|30 Years|N/A|No|Non-Probability Sample|Patients with acute ST elevation myocardial infarction (STEMI) with less than 12 hours of        chest pain onset, eligible for emergent percutaneous coronary intervention therapy.|April 2015|April 7, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02410330|6 Months|23809|
NCT02410343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1106-IMM-30021|Study of TV-1106 in Growth Hormone-Deficient Adults|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety, and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment||Teva Pharmaceutical Industries|Yes|Active, not recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410343||23808|
NCT02422277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZewin132015|Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy|Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy||Mansoura University|Yes|Recruiting|March 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Male|30 Years|75 Years|No|||May 2015|May 4, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422277||22891|
NCT02416479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039040|SystemCHANGE: An Intervention for Medication Change in Adult Kidney Transplant Patients|SystemCHANGE: An Intervention for Medication Adherence in Transplant Recipients|MAGIC|University of Missouri, Kansas City|Yes|Recruiting|June 2014|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02416479||23336|
NCT02403141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREC020|Abu Dhabi Sleep Apnea (ADSA) Study|Abu Dhabi Sleep Apnea (ADSA) Study|ADSA|Imperial College London Diabetes Centre||Recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|1400|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients over the age of 18 attending ICLDC will be offered the option of taking part in        the study. Those agreeing to participate will be asked to fill in a questionnaire.|March 2015|June 15, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02403141||24360|
NCT02413398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00024|A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of Dapagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycemic Control.|DERIVE|AstraZeneca|No|Recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|302|||Both|18 Years|74 Years|No|||February 2016|February 29, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413398||23573|
NCT02422342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartBeat_V2.0_SE|Comparison Study of Non-invasive Measurement of Blood Pressure and Cardiac Output During Stress Echocardiography|Comparison Study of Non-invasive Measurement of Blood Pressure and Cardiac Output During Stress Echocardiography||HeartBeat Technologies LTD|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients that are referred to the Stress Echocardiography test and are not in the        exclusion criteria|August 2015|August 18, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422342||22886|
NCT02425098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEN-205|Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore|A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore||Takeda|Yes|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02425098||22674|
NCT02425111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002-3028|Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease|An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV||Takeda|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||November 2015|November 24, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425111||22673|
NCT02394522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-M-Zm|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia|SR-M-ZM|University of Notre Dame|Yes|Not yet recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02394522||25021|
NCT02394535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0469|Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer|Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02394535||25020|
NCT02417103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP1Bariatric|Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid|Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|December 2011|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|77 Years|No|||December 2015|December 3, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417103||23288|
NCT02417532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXPR-0001|Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|SAFE RAPPER|Rex Bionics Plc|No|Recruiting|May 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|10 Years|90 Years|No|||February 2016|February 22, 2016|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02417532||23255|
NCT02421107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.02.CE|GlySure Acute Care Settings Study|A Clinical Study to Evaluate the Safety of the GlySure Continuous Intravascular Glucose Monitoring System, and Its Performance in Comparison to Intermittent Blood Glucose Monitoring in Adult Intensive Care Unit Patients||GlySure|No|Not yet recruiting|April 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02421107||22981|
NCT02421146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-623|The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study|The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study||Northwell Health|No|Recruiting|April 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02421146||22978|
NCT02394795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panitumumab-3001|Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC).|A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer|PARADIGM|Takeda|No|Recruiting|May 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|20 Years|79 Years|No|||August 2015|August 3, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394795||25000|
NCT02394808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5625|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||November 23, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394808||24999|
NCT02394821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE-USP5571275|Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide|Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide: Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|September 2013|September 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 1, 2015|May 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02394821||24998|
NCT02417545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2014-0509|Gaze and Stair Walking in Patients With Vestibular Dysfunction|Gaze and Movement Behavior of Patients With Vestibular Dysfunction During Level Floor, Ramp, and Stair Walking|Gaze|University of Zurich|No|Recruiting|February 2015|March 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study sample includs patients with vestibular disorder and age matched healthy        participants. Patients with vestibular disorder will be diagnosed by a pathological        horizontal head impulse test to both sides (< 0.80), as assessed by using a video-based        system and the presents of saccades.|November 2015|November 10, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417545||23254|
NCT02417818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-266-3|Cutaneous Microcirculation After Plasma Therapy|Effects of Plasma Therapy in Cutaneous Microcirculation of Different Wounds||University of Schleswig-Holstein|No|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02417818||23233|
NCT02418182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F141003005|A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval|A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval||University of Alabama at Birmingham|No|Recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 25, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418182||23205|
NCT02398331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130912|Sexual Health of Spinal Cord Injured Females|Impact of an Information and Education Program on Sexuality and Social Integration in Women With a Spinal Cord Injury|SexSIFem|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|94|||Female|18 Years|70 Years|No|||February 2016|February 24, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398331||24728|
NCT02409485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1641|Improving Self-Management in Head and Neck Cancer|Improving Self-Management in Head and Neck Cancer||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409485||23874|
NCT02422108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBG-study2|TNFSF11 Inhibition and Fertility: a Prospective Study|Denosumab and Male Infertility: a Prospective Intervention Study||Rigshospitalet, Denmark|Yes|Active, not recruiting|May 2015|January 2017|Anticipated|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|65 Years|No|||February 2016|February 3, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422108||22904|
NCT02422121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.1.1.H3|Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge|A Phase IIa Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Multiple Doses of Inhaled RNS60 and Budesonide on the Late Phase Asthmatic Response to Allergen Challenge in Patients With Mild Asthma. (This Study Has Been Amended to no Longer be a Cross Over Study; it Will be a Parallel (RNS60/Placebo) 1 Period Study and no Longer Involves the Administration of Budesonide)||Revalesio Corporation|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422121||22903|
NCT02411071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-6155-BO|Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens|Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens||University Hospital, Essen|No|Active, not recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|None Retained|Cells and DNA/RNA extracted from whole blood samples|Both|18 Years|N/A|No|Non-Probability Sample|A database comprising clinical parameters (viral Ioad, antiretroviral treatment,        immunological parameters, HBV/HCV-coinfections and HIV-1 genotypes) of patients treated in        Essen in the last 10 years will be set up. These data will be used to compare different        groups of patients and will be screened for parameters associated with LLV (defined as two        consecutive viral loads between 40 and 1000 copies/ml) or PV (viral loads between above 50        copies/ml 26 weeks after start of ART). Different clinical settings will be distinguished:        First patients after the start of first line treatment regimens in the initial phase and        second patients after at least 18 months of cART.|December 2015|December 2, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02411071||23752|
NCT02398630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSG-RM|"Magnetic Resonance Imaging Hysterosalpingography for the Integral Evaluation of the Infertile Patient."|"Estudio de Histerosalpingografía Por Resonancia Magnética Para la evaluación Integral de la Paciente infértil."|HSG-RM|Diagnostico Maipu|Yes|Recruiting|September 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398630||24705|
NCT02401334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-10|Antimicrobial Hernia Repair Device Clinical Study|Feasibility Study of the Antimicrobial Hernia Repair Device for Repair of Ventral or Incisional Hernia|AMEX|Cook||Recruiting|June 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||June 2015|November 18, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401334||24497|
NCT02401594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408143|PROphylaxis in NOn Major Orthopaedic Surgery|A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery|PRONOMOS|Centre Hospitalier Universitaire de Saint Etienne|Yes|Not yet recruiting|November 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4400|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02401594||24477|
NCT02422199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-BLTN-I/II-MBC|A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab|A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab||Jiangsu HengRui Medicine Co., Ltd.|Yes|Not yet recruiting|May 2015|December 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|75 Years|No|||April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422199||22897|
NCT02411370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHONORESPI n°CPP 14079|Correlation Between Respiratory Impairment and Phonemes Alteration in Dystrophinopathy Patients With Respiratory Failure||PHONORESPI|Centre d'Investigation Clinique et Technologique 805||Completed|February 2015|September 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Dystrophinopathy patients with limitive respiratory failure.|October 2015|October 14, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411370||23729|
NCT02416193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206988|Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)|Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)|THINK-D|Loyola University|No|Recruiting|April 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||October 2015|October 2, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416193||23358|
NCT02402868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106549|Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children|Intranasal Ketamine Versus Intravenous Ketamine for Procedural Conscious Sedation in Children: a Multi-centre Randomized Controlled Non-inferiority Trial||Lawson Health Research Institute|No|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|5 Years|17 Years|No|||March 2016|March 2, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402868||24381|
NCT02394184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-14_sub|The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement for Patients With Bicuspid Aortic Valve Stenosis|Bicuspid TAVR|Asan Medical Center|No|Recruiting|May 2015|December 2022|Anticipated|May 2022|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|patients with bicuspid aortic valve stenosis|November 2015|November 1, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02394184||25047|
NCT02402153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot 2_health_v2_August 27th|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects||Hypo-Safe A/S|Yes|Recruiting|November 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02402153||24434|
NCT02402166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-211|Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder|A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder||Shire|Yes|Recruiting|March 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|5 Years|No|||March 2016|March 24, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402166||24433|
NCT02420405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201502|Apply NGS in Small Lymph Node Specimens Obtained by EBUS-TBNA in aNSCLC-nSQCC Histology|Use Next-Generation Sequencing (NGS) to Detect Gene Mutations in Lymph Node Specimens Obtained by Endobronchial Ultrasound-guided Fine-needle Aspiration (EBUS-TBNA) in Advanced Non-small Cell Lung Cancer and Non-squamous Cell Carcinoma Histology(aNSCLC-nSQCC Histology) Patients||Shanghai Chest Hospital|Yes|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|70|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02420405||23035|
NCT02405689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|open heart surgery|Myocardial Protection and Anesthetic Agents|The Effect of Sevoflurane-dexmedetomidine and Sevoflurane-remifentanil on Biochemical Markers During Open Heart Surgery||Cukurova University|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|70 Years|No|||March 2015|December 9, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02405689||24164|
NCT02421029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI-EDTA|Prolonged Gadolinium Retention After MRI Imaging|Prolonged Gadolinium Retention After MRI Imaging in Patients With Normal Renal Function||Mt. Sinai Medical Center, Miami|No|Not yet recruiting|August 2016|||July 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421029||22987|
NCT02412657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dexaISB|Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block|Impact of Two Doses of Intravenous Dexamethasone on the Analgesic Duration of a Single-shot Interscalene Block With Ropivacaine for Shoulder Arthroscopy; a Prospective, Randomized, Placebo-controlled Study||Maisonneuve-Rosemont Hospital|Yes|Recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02412657||23630|
NCT02421718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP LUNG|Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation|Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation||University Medical Center Groningen|No|Recruiting|March 2013|January 2028|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer - Limited        Disease (SCLC-LD) or thymoma or lungmetastases (treated with stereotactic radiotherapy),        receiving radiotherapy dose > 40 Gy.|March 2016|March 23, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02421718|5 Years|22934|
NCT02427217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI3023_4003|An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency|A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component||CSL Behring||Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding,        routine prophylaxis and/or use in surgery, and who may continue to prospectively receive        FCH at the discretion of the treating physician.|March 2016|March 21, 2016|April 22, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02427217||22511|
NCT02407522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU001|The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome|The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome and Its Correlation With Metabolism of Gut Microbiota|IDSBRMS|Sun Yat-sen University|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|40 Years|80 Years|No|||March 2015|April 2, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02407522||24025|
NCT02398968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-elalfy|Iron Supplementation Outcome on Recurrent Upper Respiratory Tract Infections in 6-15 Years Old Egyptian School Children|Effect of Iron Supplementation on Recurrent Upper Respiratory Tract Infections in Egyptian School Children: A One Year Prospective Study||Ain Shams University|Yes|Recruiting|August 2013|May 2015|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|1000|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02398968||24679|
NCT02412930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/8-2012|Comparative Study of Ultrasound-guided Paravertebral Block Versus Intravenous Tramadol in Percutaneous Nephrolithotomy|Comparative Study of Ultrasound-guided Paravertebral Block Versus Intravenous Tramadol for Postoperative Pain Control in Percutaneous Nephrolithotomy||Cukurova University|No|Recruiting|March 2012|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02412930||23609|
NCT02488278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin-001-00|GLUCOME USABILITY STUDY|GLUCOME USABILITY STUDY||GlucoMe|Yes|Not yet recruiting|July 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|July 2, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02488278||17822|
NCT02486250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12765|Online Neuropsychological Test Validation Project With Imaging Pilot|Online Neuropsychological Test Validation Project With Imaging Pilot|NVP|University of California, San Francisco||Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Adults age 60 years and older          -  Fluent in English          -  Able to give informed consent          -  Access and the ability to use the internet|August 2015|August 27, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486250|10 Years|17978|
NCT02487381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEI-TCP II|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System, Cognition and Neuronal Oscillations||Central Institute of Mental Health, Mannheim|No|Completed|April 2015|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487381||17891|
NCT02467309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150203|Vitamin d Levels in Children With Bacterial Meningitis|Association of Serum 25-hydroxyvitamin D Levels and Outcomes in Children With Bacterial Meningitis||Beijing Children's Hospital|No|Not yet recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Month|18 Years|No|Non-Probability Sample|patients who are diagnosed with bacterial meningitis in infectious diseases department of        Beijing Children's Hospital|May 2015|June 5, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02467309||19434|
NCT02489097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 08-021|International Substudy Enigma2 on Postoperative Cognitive Disorders|Evaluating the Incidence and Association Between Nitrous Oxide and Postoperative Cognitive Disorders in Anaesthesia|ISEP|University Hospital, Geneva|Yes|Recruiting|June 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||June 2015|July 1, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02489097||17760|
NCT02489318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107614|A Study of JNJ-56021927 (ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC|A Phase 3 Randomized, Placebo-controlled, Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)|TITAN|Janssen Research & Development, LLC|Yes|Recruiting|November 2015|December 2022|Anticipated|February 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489318||17743|
NCT02482727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2015.104|BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair|BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair|BFR DISTRAD|Brooke Army Medical Center|No|Recruiting|June 2015|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482727||18248|
NCT02475083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-13-RV|Use of Virtual Reality Games for the Treatment of Balance and Reducing the Occurrence of Falls in Patients After Stroke|Therapeutic Effect of Virtual Reality in Patients After Stroke||Pedreira, Érika, M.D.|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||August 2014|June 15, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475083||18836|
NCT02481843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOP001|Hyperoxia, Erythropoiesis and Microcirculation in Critically Ill Patient|Hyperoxia, Erythropoiesis and Tissue Oxygenation in Critically Ill Patient||Università Politecnica delle Marche|No|Completed|April 2013|March 2015|Actual|January 2015|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|Blood samples for plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|Adult (≥18-year old) patients admitted to a 12-bed medical-surgical ICU|July 2015|July 2, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02481843||18316|
NCT02481856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-03|A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber|A Dose-response Evaluation of the SQ Tree SLIT-tablet in Subjects With Moderate to Severe Allergic Rhinoconjunctivitis Induced by Pollens From the Birch Group During Controlled Exposure in an Environmental Exposure Chamber||ALK-Abelló A/S|No|Active, not recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02481856||18315|
NCT02480257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12380|UCSF TARA Study: Training for Awareness, Resilience and Action|University of California San Francisco (UCSF) TARA Study: Training for Awareness, Resilience and Action||University of California, San Francisco|No|Active, not recruiting|January 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|14 Years|18 Years|No|||June 2015|June 19, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02480257||18438|
NCT02488759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-358|A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)|Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects With Virus-Positive and Virus-Negative Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2015|June 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|199|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488759||17785|
NCT02470845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJAR001|Trial of Tian Jiu Therapy for Allergic Rhinitis|A Randomized Controlled Trial of Tian Jiu Therapy for Allergic Rhinitis||Hong Kong Baptist University|Yes|Recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|138|||Both|3 Years|N/A|No|||October 2014|June 9, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02470845||19162|
NCT02475161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107627|A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants|A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475161||18830|
NCT02485132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPOTHESIS|Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea|Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea, by Continuous Glucose monItoring System: A Multicenter Study. The HYPOTHESIS Trial||Institut de Recherches Cliniques de Montreal|No|Not yet recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|118|||Both|18 Years|N/A|No|Non-Probability Sample|T2DM already stabilized on metformin but not at goal (A1c >7.0 mmol/L), and newly        prescribed gliclazide or gliclazide MR|June 2015|June 26, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02485132||18063|
NCT02485327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14329|PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)|An Open-label, 2 Replicate Single Dose Euglycemic Glucose-Clamp Trial to Characterize PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)||Sanofi|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||November 2015|November 26, 2015|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485327||18048|
NCT02487836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPAC-IPC 2012 006|Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas|Phase II Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas|PROPAC|Institut Paoli-Calmettes|No|Completed|October 2013|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||October 2013|February 25, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487836||17856|
NCT02488096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-27|Improving Prostate Cancer Detection Using MRI-Targeted TRUS-Guided Biopsy|Improving Prostate Cancer Detection Using MRI-Targeted TRUS-Guided Biopsy||Regina Qu'Appelle Health Region|No|Not yet recruiting|December 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Male|18 Years|N/A|No|||October 2015|October 22, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488096||17836|
NCT02466464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070733|Microporous Polysaccharide Hemospheres Epistaxis|Use of Microporous Polysaccharide Hemospheres (MPH) in Management of Acute Epistaxis||Emory University|No|Enrolling by invitation|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466464||19499|
NCT02466711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-010|Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers|A Single-center, Placebo-controlled, Double-blind Study to Evaluate the Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers||Rhythm Pharmaceuticals, Inc.|No|Completed|June 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466711||19480|
NCT02488109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0504491|Multi-center Study of Refeeding in Anorexia Nervosa|Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa||University of California, San Francisco|Yes|Not yet recruiting|July 2015|||July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|24 Years|No|||July 2015|July 1, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02488109||17835|
NCT02487927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Weaning Study|The Classification of Difficult Weaning and the Predictive Value of Relative Factors for Difficult Weaning|The Classification of Difficult Weaning and the Predictive Value of Relative Factors for Difficult Weaning||Southeast University, China|Yes|Recruiting|June 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|110|||Both|16 Years|80 Years|No|Probability Sample|mechanical vetilation patients in ICU, and the patients are weaninng candidates|June 2015|June 29, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02487927||17849|
NCT02488317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109201303123|Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)|Empowering Patients On Choices for Renal Replacement Therapy (Aim 3)|EPOCH-RRT|Arbor Research Collaborative for Health|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||Actual|130|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02488317||17819|
NCT02405403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO-13-PC/MARIA|Microglial Activation Role In ALS (MARIA)|Microglial Activation Role In ALS (MARIA)|MARIA|University Hospital, Tours|Yes|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02405403||24186|
NCT02394860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5883|Influence of Periodontal Diseases on Vascular Parameters in Patients Suffering of Hypertension|Influence of Periodontal Diseases on Hemodynamic and Molecular Vascular Parameters in Patients Suffering of Hypertension||University Hospital, Strasbourg, France|No|Not yet recruiting|April 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|84|||Male|18 Years|70 Years|No|Non-Probability Sample|Will be included men with severe and moderate periodontitis|March 2015|March 16, 2015|July 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02394860||24995|
NCT02399787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-382-13|Geneexpression as a Marker of Embryo Viability|Geneexpression as a Marker of Embryo Viability||University of Aarhus|No|Recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Infertile women|December 2015|December 2, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399787||24616|
NCT02418728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME2014 /450|The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise|The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise|BALO|Hasselt University|No|Recruiting|August 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|20|||Male|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with obesity and heart failure|February 2016|February 17, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02418728||23163|
NCT02401009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1166009|Protocol for a Research Database for HCT, Other Cellular Therapies and Marrow Toxic Injuries|Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries||Medical College of Wisconsin|No|Active, not recruiting|January 1972|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Actual|390000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Donors and recipients of HCT, recipients of other cellular therapies and individuals with        marrow toxic injury|March 2016|March 21, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401009|100 Years|24522|
NCT02408939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/9/1/2015 IPDMA|Meta-analysis Assessing the Effect of Steroids on Post-resuscitation Infections|Effect of Stress-dose Steroids on the Incidence Rate of Infectious Complications After In-hospital Cardiac Arrest. An Individual Patient Data-based Meta-analysis||University of Athens|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|191|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with vasopressor-requiring, inhospital cardiac arrest, i.e., with asystole,        pulseless electrical activity, or ventricular fibrillation/pulseless ventricular        tachycardia not responsive to two attempts at defibrillation.|January 2016|January 9, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02408939||23916|
NCT02408952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07796|Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers|Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers||University of California, San Francisco|No|Active, not recruiting|October 2011|June 2016|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|9084|||Both|12 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02408952||23915|
NCT02425969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GzFFR Protocol Version 2.1|A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values|A Randomised Controlled Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values With Evaluation of the Diagnostic Utility of Invasive Coronary Physiological Indices and Quantitative Perfusion MRI. The GzFFR Study|GzFFR|Golden Jubilee National Hospital|Yes|Recruiting|April 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|No|||March 2015|June 10, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02425969||22607|
NCT02414763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131757|Pilot Study of a Brief Intervention for Medically Hospitalized Suicide Attempt Survivors|Pilot Study of a Brief Intervention for Medically Hospitalized Suicide Attempt Survivors||Western Kentucky University|Yes|Recruiting|July 2014|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02414763||23468|
NCT02414776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20140460|Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy|Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy|ABC01|Western Regional Medical Center|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414776||23467|
NCT02414789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6084|Lyme Borreliosis and Early Cutaneous Diagnostic|Lyme Borreliosis and Early Cutaneous Diagnostic|DIABOLYC|University Hospital, Strasbourg, France|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|August 6, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414789||23466|
NCT02406976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0328|Effect Physical Exercise in Morbid Obesity|Effect of Physical Exercise on Different Approaches to Treatment of Morbid Obesity||Hospital de Clinicas de Porto Alegre|No|Recruiting|August 2010|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|April 6, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406976||24067|
NCT02406989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-553-102|A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers||MingSight Pharmaceuticals Pty Limited|Yes|Completed|April 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406989||24066|
NCT02421640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC and TIL|Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC|A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes and Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma|TIL|Sun Yat-sen University|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02421640||22940|
NCT02426021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1202/CPH-001|Phase 1 Single Subcutaneous Dose Study of MLN1202|A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants||Takeda|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|44|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426021||22603|
NCT02415062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUPID-01|The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia|The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia|CUPID|Inje University|Yes|Recruiting|July 2015|December 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|80 Years|No|||August 2015|August 5, 2015|March 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415062||23445|
NCT02407041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-030|An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis|A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis||Galectin Therapeutics Inc.|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407041||24062|
NCT02407054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15798|A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer|A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer||Eli Lilly and Company|No|Recruiting|April 2015|May 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407054||24061|
NCT02396797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9747|Effect Evaluation of a Workplace Intervention Targeting Common Subjective Health Complaints|Effect Evaluation of a Workplace Intervention Targeting Common Subjective Health Complaints on Sick Leave, Coping, Health, Job Satisfaction and Social Support|atWork|Uni Research|No|Active, not recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|67 Years|No|||March 2016|March 21, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02396797||24846|
NCT02396810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028376|Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas|||Dartmouth-Hitchcock Medical Center||Recruiting|March 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|75|||Both|18 Years|90 Years|No|||January 2016|January 20, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02396810||24845|
NCT02411903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0906|The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction|||The Third Affiliated Hospital of Guangzhou Medical University||Enrolling by invitation|March 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|45 Years|85 Years|No|||April 2015|June 14, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02411903||23688|
NCT02420795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0630|Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420795||23005|
NCT02421003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2014_843_0017|Exploratory Study, Prospective, of Volume, Composition and Bacteriology of the Recovered Blood of Multi-perforated Catheter Inserted in the Drapes Thickness of Incisional Sternal Area During Heart Surgery|Exploratory Study, Prospective, of Volume, Composition and Bacteriology of the Recovered Blood of Multi-perforated Catheter Inserted in the Drapes Thickness of Incisional Sternal Area During Heart Surgery|Blood in drape|Centre Hospitalier Universitaire, Amiens|No|Recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421003||22989|
NCT02407600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-50437|Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy|Phase II, Double-blind, Placebo-controlled, Crossover Study Evaluating a 5HT3 Antagonist Plus Dexamethasone With or Without Fosaprepitant in Patients With Advanced NSCLC Receiving Carboplatin Based Chemotherapy||State University of New York - Upstate Medical University|No|Not yet recruiting|April 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|April 2, 2015|March 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407600||24019|
NCT02416830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|embocohort|Worldwide Therapeutic Embolization Cohort Post Market Registry|Worldwide Therapeutic Embolization Cohort Post Market Registry|EmboReg|EmboCoH|No|Recruiting|April 2014|October 2019|Anticipated|April 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a Visceral Aneurysm|April 2015|April 14, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02416830|12 Months|23309|
NCT02417090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIARA2|Late Metabolic Effects of Metformin Therapy in Gestational Diabetes|Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age|DIARA2|Turku University Hospital|No|Enrolling by invitation|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|317|Samples With DNA|Whole blood for DNA extraction|Both|9 Years|10 Years|No|Probability Sample|9-year old children exposed to insulin or metformin in utero because their mothers had        gestational diabetes|April 2015|April 14, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417090||23289|
NCT02412150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX_ENT|Effect of Dexmedetomidine After Thyroidectomy|Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy||Chosun University Hospital|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|20 Years|60 Years|No|||January 2016|January 26, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02412150||23669|
NCT02412436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5338|PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)|PRIDE-HT|AIDS Clinical Trials Group|Yes|Recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|46 Years|No|||January 2016|January 29, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412436||23647|
NCT02412202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273/2015|Echocardiographic Detection of Extravascular Lung Water Increase During Weaning From Mechanical Ventilation||ECHOBAG|University of Thessaly||Completed|March 2015|||December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02412202||23665|
NCT02399761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205084RIC|Newborn Screening for Aromatic L-amino Acid Decarboxylase Deficiency|Newborn Screening for Aromatic L-amino Acid Decarboxylase Deficiency||National Taiwan University Hospital|No|Recruiting|August 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200000|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|newborns whose parents agree to be tested|March 2015|March 25, 2015|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02399761||24618|
NCT02420483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49304 11/11/13|Lung Ventilation During Cardiopulmonary Resuscitation|||University of Thessaly|Yes|Recruiting|December 2015|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|55 Years|No|||December 2015|December 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02420483||23029|
NCT02426684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IdeSCSMC|Ides in Highly Sensitized Patients Awaiting Kidney Transplantation|A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.||Cedars-Sinai Medical Center|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||April 2015|June 17, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426684||22552|
NCT02400008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/120/HP|Selective Bilateral Laryngeal Reinnervation as a Secondary Treatment in Case of Bilateral Vocal Fold Paralysis|Selective Bilateral Laryngeal Reinnervation as a Secondary Treatment in Case of Bilateral Vocal Fold Paralysis: Analysis of Phonatory and Ventilatory Results|SEQLAR|University Hospital, Rouen|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400008||24599|
NCT02420639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT TBI-01|Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device|Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device in 15 Patients Suffering From Traumatic Brain Injury and Treated With Targeted Temperature Management||Advanced Cooling Therapy, LLC|No|Recruiting|August 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|August 7, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02420639||23017|
NCT02422485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salsalate PSP|A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy|A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy||University of California, San Francisco|No|Recruiting|April 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|85 Years|No|||January 2016|January 26, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422485||22875|
NCT02422498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-032|Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy|A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422498||22874|
NCT02402335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBORTAB01|Study of Different Types of Backache in Groups of Patients With Different Diagnoses of Degenerative Diseases|Study of Different Types of Pains in Groups of Patients With Different Diagnoses of Degenerative Diseases and Their Related Surgeries||University Hospital, Bonn|Yes|Recruiting|February 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|15 Years|N/A|No|Non-Probability Sample|Patients of the University Hospital of Bonn who are strongly suffering from backaches that        cannot be treated anymore by conservative methods.|March 2015|March 24, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02402335||24420|
NCT02397122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KirikkaleU|Platelet-rich Fibrin and Connective Tissue Graft in Recession Treatment|The Adjunctive Effect of Platelet Rich Fibrin to Connective Tissue Graft in the Treatment of Buccal Recession Defects. Results of a Randomized Parallel Group Controlled Trial||Kırıkkale University|No|Completed|February 2013|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02397122||24821|
NCT02397135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-102|Control Ovarian Stimulation Timing Test|Control Ovarian Stimulation Timing Test|COST2|Laval University|No|Recruiting|January 2015|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Granulosa cells as aspirated from the pre-ovulatory follicles|Female|25 Years|42 Years|No|Non-Probability Sample|IVF (In vitro fertilisation) patients infertile patients|March 2015|March 18, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02397135||24820|
NCT02411552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wisconsin Active Schools|Systematic Initiative to Increase Activity in Schools|Systematic Initiative to Increase Activity in Schools||University of Wisconsin, Madison|No|Completed|September 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4894|||Both|7 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Wisconsin schools with low socio-economic status (grades 3-8)|April 2015|April 2, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02411552||23715|
NCT02411565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17883|Fermented Wheat Germ Extract in Women With Ovarian Cancer|A Randomized, Placebo-Controlled, Trial of Fermented Wheat Germ Extract in Women With Ovarian Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|March 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411565||23714|
NCT02411578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DX Mini-dose non-Severe|Mini-Dose Glucagon for Adults With Type 1 Diabetes|Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes||T1D Exchange Clinic Network Coordinating Center|No|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|64 Years|No|||March 2016|March 24, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411578||23713|
NCT02415959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC2002|Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Abbott|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|5||Actual|70|||Both|12 Years|N/A|No|||January 2016|January 20, 2016|March 19, 2015||No||No|January 20, 2016|https://clinicaltrials.gov/show/NCT02415959||23376|
NCT02415972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179/12|Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke|Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke||University Hospital Inselspital, Berne|No|Recruiting|October 2012|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|The trial population comprises of patients with acute ischemic stroke treated at the        University Hospital Bern.|December 2015|December 17, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02415972||23375|
NCT02402595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-103|Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts|A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects|DDI|Avanir Pharmaceuticals|No|Active, not recruiting|March 2015|December 2015|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402595||24400|
NCT02408354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-53|Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood|"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant" HEMIHEP|HEMIHEP|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|15 Years|N/A|No|||February 2016|February 24, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02408354||23961|
NCT02411851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1319|Treatment of Actinic Keratoses (AK) on the Face|An Investigator-Initiated Study to Assess the Efficacy and Degree of Irritation of Ingenol Mebutate 0.015% Gel and Dermasil Lotion Versus Ingenol Mebuate 0.015% Alone in the Treatment of Actinic Keratoses (AK) on the Face.||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411851||23692|
NCT02411864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-20140570|Optimal Low B-value in Intravoxel Incoherent Motion Diffusion-weighted MR Imaging of the Brain|Can the Distribution of Low B-value and the NEX Influence the Pseudodiffusion Parameter Derived From IVIM in Brain?||Tang-Du Hospital|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|20|||Male|25 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|healthy volunteers|October 2014|April 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02411864||23691|
NCT02420977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1560|Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer|Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Male|18 Years|N/A|No|||April 2015|April 17, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420977||22991|
NCT02394197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSP CI-624|Effectiveness of Malaria Treatment in Mexico|Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico|EMTM|Instituto Nacional de Salud Publica, Mexico|Yes|Completed|February 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|1 Year|70 Years|No|||March 2015|March 19, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02394197||25046|
NCT02394210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-MIE-2012-02|Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma|Post-authorisation Observational Registry to Assess the Clinical Impact of Initiating Anti-tumour Rescue Therapy in Patients With Multiple Myeloma (MM) in Asymptomatic Biological Relapse Compared to Initiating Treatment at the Time of Symptomatic Relapse|EPA-MMBR|Celgene|No|Recruiting|May 2013|December 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|410|||Both|18 Years|N/A|No|Probability Sample|Patients with a diagnosis of MM having received first or second-line treatment who have        achieved ≥PR since their last anti-MM treatment, so that patients may be included in the        registry before relapse/biological progression while followed every 1 to 2 months based on        routine clinical practice, as well as at the time relapse/biological progression is        detected, as per the criteria of the IMW Consensus Panel 11.|March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394210||25045|
NCT02410057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SkaneUH|Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula|ALFoNS - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula Compared to Breastfed Infants||Skåne University Hospital|No|Recruiting|November 2014|December 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|320|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||April 2015|April 1, 2015|March 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410057||23830|
NCT02426138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002778|Community Servings: Food as Medicine for Diabetes|Community Servings: Food as Medicine for Diabetes||Massachusetts General Hospital|Yes|Recruiting|April 2015|April 2020|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02426138||22594|
NCT02417402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICID032015|Efficacy of Educating Physical Therapists in the Treatment of Patients With Nonspecific Chronic Low Back Pain|Efficacy of Educating Physical Therapists on Clinical Practice Guidelines and Pain Management in the Treatment of Patients With Nonspecific Chronic Low Back Pain: a Cluster Randomized Controlled Trial||Universidade Cidade de Sao Paulo|No|Not yet recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||April 2015|April 10, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02417402||23265|
NCT02417415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141523|Local Heat Stress in Autonomic Failure Patients With Supine Hypertension|Local Heat Stress in Autonomic Failure Patients With Supine Hypertension||Vanderbilt University|No|Recruiting|April 2015|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|14|||Both|18 Years|80 Years|No|||April 2015|April 14, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417415||23264|
NCT02409810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0019|Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes|Safety, Feasibility, and Acceptability of Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes||Ohio State University|No|Recruiting|March 2015|April 2020|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|89 Years|No|||March 2015|April 6, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409810||23849|
NCT02414386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaminDcitrateCRRT|Serum Vitamin D Levels in Critically Ill Patients Undergoing Regional Citrate Anticoagulation CRRT|Serum Vitamin D Levels in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Case-control Study|VitDcrrt|Publiczny Samodzielny Zaklad Opieki Zdrowotnej Wojewodzkie Centrum Medyczne|No|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|blood samples taken from the arterial catheter every 12 hours to obtain vitamin D,      parathormon, calcium, magnesium, phosphate, globulin, albumin plasma levels|Both|18 Years|N/A|No|Probability Sample|Acute Kidney Injury - CRRT group: Multi-organ failure with acute kidney injury critically        ill patients admitted to the critical care unit undergoing regional citrate        anticoagulation continuous renal replacement therapy by means of continuous veno-venous        hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory        and renal failure.        Control group: Multi-organ failure non acute kidney injury critically ill patients        admitted to the critical care unit. Multi-organ failure is defined as a respiratory and        circulatory failure.        All patients: machanically ventilated.|December 2015|December 20, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414386||23497|
NCT02416635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|60|||Both|15 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage liver cancer come to Fuda Hospital for treatment.|April 2015|December 28, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02416635||23324|
NCT02427230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-113|Treatment of Urinary Incontinence in Women With Spinal Cord Injury|The Effect of Pelvic Floor Muscle Training and Neuromuscular Electrical Stimulation on Urinary Incontinence and Quality of Life in Women With Spinal Cord Injury||Glostrup University Hospital, Copenhagen|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|75 Years|No|||February 2016|February 9, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427230||22510|
NCT02396433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS# 14-2024|Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers|Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|April 2015|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2015|August 21, 2015|February 10, 2015|Yes|Yes|lack of funding.|No||https://clinicaltrials.gov/show/NCT02396433||24874|
NCT02396706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-14-01-077|RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough|Randomized, Controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of a Liquid Containing Ivy Leaves Dry Extract vs. Placebo in the Treatment of Acute Cough||Engelhard Arzneimittel GmbH & Co.KG||Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396706||24853|
NCT02396719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO130-P001|A Real-World Registry to Investigate the Performance of LenSx® Laser in Chinese Patients|A Prospective, Single-Arm, Multicenter, Registry Study to Investigate the Performance of Femtosecond Laser-Assisted Cataract Surgery in Chinese Cataract Patients||Alcon Research|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Chinese patients who undergo cataract surgery using LenSx® Laser and phacoemulsification        in at least one eye will be eligible to participate.|February 2016|February 26, 2016|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396719||24852|
NCT02418884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10098|The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus|The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus||Sir Run Run Shaw Hospital|Yes|Not yet recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|122|||Both|18 Years|70 Years|No|||April 2015|April 13, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02418884||23151|
NCT02416869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/11-2013|Dexamethasone in Lower Third Molar Surgery|Effectiveness of Different Application Modalities of Dexamethasone on Clinical Parameters and Quality of Life After Lower Third Molar Surgery||University of Belgrade|No|Recruiting|January 2014|September 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416869||23306|
NCT02416882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC405|Exercise Genes: Genomic Association With Exercise Reinforcement|Exercise Genes: Genomic Association With Exercise Reinforcement|ExGenes|USDA Grand Forks Human Nutrition Research Center|No|Active, not recruiting|April 2015|August 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02416882||23305|
NCT02492594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB MD-AN-007-3D|Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections|Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections|FUNGITECT|St. Anna Kinderkrebsforschung|No|Recruiting|February 2015|March 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|6 Months|90 Years|No|||July 2015|July 3, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02492594||17492|
NCT02490293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seoul-05|Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?|Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?; a Multicenter Randomized Controlled Trial||Seoul St. Mary's Hospital|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02490293||17669|
NCT02464358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-272|An Information-Motivation-Behavioral Skills (IMB) Intervention to Promote Human Papillomavirus Vaccination Among Women|The Impact of an Information-Motivation-Behavioral Skills (IMB) Based Educational Intervention to Improve Gardasil Use in a Population of Undergraduate Women||University of Connecticut|No|Completed|December 2011|December 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464358||19661|
NCT02464579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHC-N-15-013|Breastfeeding Rates at the Department of Neonatology of University Hospital Cologne|Prospective Inquiry of Breastfeeding Success at the Department of Neonatology of University Hospital of Cologne and Analysis of Influencing Factors|BFRUHC|University Hospital of Cologne|No|Recruiting|May 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|7 Days|No|Non-Probability Sample|In-patients of the Department of Neonatology of Cologne.|June 2015|June 3, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464579||19644|
NCT02476227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Comparison of Operator-guided and Automatic Algorithm-guided Atrial Fibrillation Ablation|Comparison of Operator-guided and Automatic Algorithm-guided Atrial Fibrillation Ablation. Randomized Open-labeled Study||Military Institute of Medicine, Poland|No|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02476227||18748|
NCT02476240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3983|Evaluating the Influence of Single Task vs. Dual Task Exercise on Rehabilitation in Parkinson's Disease|Evaluating the Underlying Mechanism and Influence of Single Task vs. Dual Task Exercise on Rehabilitation in Parkinson's Disease: A Single Blind Randomized Controlled Trial|DT-PDSAFEx|Sun Life Financial Movement Disorders Research and Rehabilitation Centre|Yes|Not yet recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|N/A|No|||June 2015|June 16, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476240||18747|
NCT02478957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA101-SM-02|Treatment of Indolent Systemic Mastocytosis With PA101|Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis||Patara Pharma|No|Active, not recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02478957||18538|
NCT02487082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65708|Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders|Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders||Stony Brook University|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|17 Years|No|||June 2015|June 30, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487082||17914|
NCT02487095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150150|Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer|A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|October 2020|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||June 2015|July 24, 2015|June 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487095||17913|
NCT02462096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0001|A Feasibility Study of the ReLeaf Catheter System|A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein|ReLeaf|Intervene, Inc.|Yes|Recruiting|June 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|February 19, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462096||19834|
NCT02489539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA 13-03 (1)|Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms|Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms||W.L.Gore & Associates|Yes|Not yet recruiting|November 2016|November 2023|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|21 Years|N/A|No|||March 2016|March 10, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489539||17726|
NCT02489565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 14-0206|Telemedicine Qualifying Transition Between Tertiary and Primary Health Care in Stable Coronary Artery Disease Patients|Telemedicine in Qualifying Care Transition Between Tertiary and Primary Health Care Among Stable Coronary Artery Disease Patients: a Randomized Non-inferiority Trial|Tele_DAC|Hospital de Clinicas de Porto Alegre|No|Recruiting|May 2014|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|264|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02489565||17725|
NCT02484742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N227 2014P-000354|Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms|||Beth Israel Deaconess Medical Center|No|Recruiting|July 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02484742||18093|
NCT02484755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2015-167|Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease|Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease||Huashan Hospital|Yes|Recruiting|June 2015|||September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02484755||18092|
NCT02462291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18201|New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)|Effectiveness of Environmental Therapy in Patients With Alzheimer's Disease|ABCD|Universita di Verona|Yes|Completed|June 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|65 Years|N/A|No|||January 2016|January 30, 2016|May 28, 2015||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02462291||19819|
NCT02487992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZYY-CRC-001|The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer|The Randomized, Controlled, Multicenter Clinical Trial of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer||The First People's Hospital of Changzhou|No|Active, not recruiting|July 2015|July 2045|Anticipated|July 2043|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02487992||17844|
NCT02493257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0173|Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis|Double-Blinded Randomized Prospective Trial of Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis||The University of Texas Health Science Center, Houston|No|Recruiting|October 2014|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02493257||17441|
NCT02492503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA CX CHEMOTHERAPY|Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix|An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix||All India Institute of Medical Sciences, New Delhi|No|Active, not recruiting|November 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|70 Years|No|||July 2015|July 7, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02492503||17499|
NCT02472340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDR1510|Mitophagy and Autophagy in Elderly Subjects|Assessment and Reproducibility of Mitochondrial Function and Mitophagy Measurements in Human Muscle Tissue of Active and Pre Frail Elderly Males||Amazentis SA|No|Active, not recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|22|Samples With DNA|Muscle, Peripheral blood mononuclear cells (PBMC)|Both|61 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  10 active, healthy elderly, >61 years of age          -  10 sedentary, pre-frail elderly, >61 years of age|March 2016|March 16, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472340||19047|
NCT02490189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-27-02-15|Mindfulness-based Intervention Versus CBT for Social Anxiety Disorder|Comparative Trial of a Mindfulness-based Intervention Versus Cognitive Behavior Therapy for Social Anxiety Disorder||Hopital Montfort|No|Recruiting|July 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490189||17677|
NCT02493296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0066|The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study||ESCAPE|University of Leicester|No|Recruiting|August 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|146|||Both|18 Years|N/A|No|Non-Probability Sample|All participants undergoing abdominal aortic aneurysm repair who are over 18, and are able        to consent to the study.|July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493296||17438|
NCT02493309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOLE0458|FIT 2 SIT - Are Metabolic Responses to Sitting/Light Breaks Mediated by Fitness?|The Impact of Cardio-respiratory Fitness on an Individual's Metabolic Response to Sitting and Light Activity Breaks|FIT2SIT|University of Leicester|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||October 2014|December 4, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493309||17437|
NCT02413216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH096344-02|TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)|Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics||University of Utah|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|8 Years|18 Years|No|||September 2015|September 17, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02413216||23587|
NCT02413229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 1411|A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study|A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis||Taro Pharmaceuticals USA|No|Recruiting|March 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|12 Years|N/A|No|||November 2015|November 1, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413229||23586|
NCT02407171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411014879|Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC|A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC||Yale University|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407171||24052|
NCT02408835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPWT/14/1.0|Negative Pressure Wound Therapy in Groin Dissection|A Randomised Controlled Trial Comparing PICO™ Single Use Negative Pressure Wound Therapy System (Smith & Nephew Healthcare Limited, UK) to Conventional Wound Care Following Inguinal Lymphadenectomy for Metastatic Cutaneous Malignancy||South Eastern Health and Social Care Trust|No|Not yet recruiting|July 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02408835||23924|
NCT02408848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/06JAN/006|The Value of Three Dimensional Echocardiography in Congenital Cardiac Surgery|Three Dimensional Echocardiography in Congenital Cardiac Surgery|3D echo|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|March 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|Children undergoing congenital cardiac surgery with or without cardiopulmonary bypass|March 2015|March 31, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02408848||23923|
NCT02421055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2479|Longitudinal Phenotyping of Bariatric Surgery Patients|Longitudinal Phenotyping of Bariatric Surgery Patients||Imperial College London|No|Recruiting|June 2015|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|Samples With DNA|Serum, urine and stool preoperatively and at 3 months and 1 year postoperatively.      Resected stomach tissue from patients undergoing Sleeve Gastrectomy.|Both|18 Years|N/A|No|Non-Probability Sample|Obese diabetics undergoing bariatric surgery|February 2016|February 15, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421055|2 Years|22985|
NCT02421068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-47440907814|Population PK/PD of Off Label Drugs in Premature Neonates|Pharmacokinetic and Pharmacodynamic Modelling of Routinely Used Off Label Drugs in Premature Neonates|DINO|Erasmus Medical Center|Yes|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|blood|Both|N/A|32 Weeks|No|Non-Probability Sample|preterm newborn infants|August 2015|August 10, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02421068|1 Month|22984|
NCT02422771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Startup 1|Effect of the FIFA 11+ Injury Prevention Program on Performance & Movement Control in Young Female Athletes|Effect of the Fédération Internationale de Football Association (FIFA) 11+ Injury Prevention Program on Performance & Movement Control in Young Female Athletes||University of Manitoba|No|Active, not recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|47|||Female|9 Years|11 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02422771||22853|
NCT02406937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-SC-9-FH-001|New Stage 1 Formula on Gut Comfort and Gut Health|Efficacy of New Stage 1 Formula on the Improvement of Gut Comfort and Gut Health||Heilongjiang Feihe Dairy Co. Ltd.|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|180|||Both|N/A|90 Days|Accepts Healthy Volunteers|||October 2015|October 19, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406937||24070|
NCT02410291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunnybrook ID 123|Impact on Instructional Video on Patients' Compliance With Preparation During CT Planning for Prostate Cancer|Empowering Patients Through Education- Online, Written, and Personal Education Resource for Prostate Cancer Patients Who Need Radiation Therapy to Ensure Patient Preparedness (Compliance and Understanding) for Their Simulation and Treatment||Sunnybrook Health Sciences Centre|No|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02410291||23812|
NCT02410265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31629|Online, Guided Interventions to Reduce Generalized Anxiety Disorder Among Indian University Students|Using Technology to Address Anxiety and Stress in Indian University Students||Stanford University|No|Enrolling by invitation|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|193|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 21, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02410265||23814|
NCT02414464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBYP|Tooth Bleaching for Young Patients Using a Hydrogen Peroxide-based Gel|In-Office Tooth Bleaching for Young Patients Using a Hydrogen Peroxide-based Gel: a Randomized, Controlled, Clinical Trial||University of Nove de Julho|No|Active, not recruiting|February 2013|May 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|11 Years|24 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02414464||23491|
NCT02414698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3750|Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy|Single Center, Randomized PROspective Study Comparing Percutaneous HydroDiscectomy to Transforaminal Epidural Steroid Injections in the Treatment Of Radiculopathy Secondary to Lumbar Disc Herniation (PROPHESOR)||Montefiore Medical Center|No|Recruiting|March 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||April 2015|April 11, 2015|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414698||23473|
NCT02418741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1312/037-002|Head Position for Endotracheal Intubation|The Degree of Neck Flexion Does Not Influence on the Laryngeal View and Discomfort During Endotracheal Intubation in Adult Patients|THHEIEIA|National Medical Center, Seoul|Yes|Completed|August 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 18, 2015|October 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02418741||23162|
NCT02410317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract 2014-002044-41|Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section|Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section|ROMANCE|University Hospital, Grenoble|Yes|Recruiting|February 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||April 2015|April 7, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02410317||23810|
NCT02396485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0391|Early Feeding After A Cesarean Delivery Hastens Recovery Time for Bowel Function|Early Versus Late Feeding After Cesarean Delivery: A Randomized Controlled Trial||The University of Texas Medical Branch, Galveston|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|177|||Female|18 Years|55 Years|No|||March 2015|March 18, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02396485||24870|
NCT02396498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCCC005|SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy|S-1 With Cisplatin Intravenous Chemotherapy Versus S-1 Plus Cisplatin Hyperthermic Intraperitoneal Chemotherapy in Stage Ⅲ Patients After D2 Gastrectomy：a Randomized Controlled Study||Tang-Du Hospital|Yes|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02396498||24869|
NCT02396511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105CC201|Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma|Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma||Tracon Pharmaceuticals Inc.|No|Enrolling by invitation|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396511||24868|
NCT02426034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-G201|Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer|An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction||Jiangsu HengRui Medicine Co., Ltd.||Active, not recruiting|February 2015|||December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|75 Years|No|||April 2015|April 23, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02426034||22602|
NCT02414711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL25 Validation|Validation of the French Translation of the Scale HSCL25 in the Diagnosis of Depression in Primary Care|Validation of the French Translation of the Scale HSCL25 in the Diagnosis of Depression in Primary Care|HSCL25|University Hospital, Brest|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|1100|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02414711||23472|
NCT02418988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-H14006|Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma|Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma||Shenzhen SiBiono GeneTech Co.,Ltd|No|Recruiting|July 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2015|April 13, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02418988||23143|
NCT02393911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0146-14-NHR|Dysbiosis in Localized Provoked Vulvodynia (LPV)|Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV)|DMLPV|Western Galilee Hospital-Nahariya|No|Not yet recruiting|March 2015|February 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|70|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 15, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02393911||25068|
NCT02393924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29659|ESTHER: Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study|UK- a Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer||Hoffmann-La Roche||Recruiting|February 2015|March 2023|Anticipated|March 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|390|||Both|18 Years|N/A|No|Probability Sample|Participants with HER2-positive unresectable Locally Advanced or metastatic Breast Cancer        (LA/mBC)|March 2016|March 1, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02393924||25067|
NCT02420132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE29720|Study to Evaluate Home Vision Testing in Patients Receiving Ranibizumab|Decentralized Pilot Study to Evaluate MyVisionTrack Home Vision Testing in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Currently Receiving Intravitreal Lucentis Therapy.||Hoffmann-La Roche||Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Recruitment of patients who are receiving treatment for diabetic macular edema (DME) or        neovascular age-related macular degeneration (nAMD) with intravitreal Lucentis and are        being evaluated at intervals of 4-8 weeks.|March 2016|March 1, 2016|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02420132||23056|
NCT02420145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6194-BO|Yoga for Abdominal Obesity|Randomized-controlled Trial of Yoga for Women With Abdominal Obesity||Universität Duisburg-Essen|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|64 Years|No|||September 2015|September 22, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02420145||23055|
NCT02416167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-006|Study of FYU-981 in Hyperuricemia With or Without Gout|Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)||Fuji Yakuhin Co., Ltd.|No|Active, not recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|200|||Both|20 Years|N/A|No|||February 2016|February 19, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416167||23360|
NCT02420730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232411-001|Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye|||Allergan|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02420730||23010|
NCT02426658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU # 62115|Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3|A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Recruiting|May 2015|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426658||22554|
NCT02399488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC:47/10|Validation of Continuous Noninvasive Haemoglobin Monitoring by the Radical 7 Pulse CO-Oximetry Monitor After in Vivo Adjustment.|Validation of a Continuous Noninvasive Haemoglobin Determination Monitor (Radical 7 Pulse CO-Oximeter, SpHb) Compared to the Central Laboratory Coulter (LabHb) and a Point of Care (POC) Invasive Cooximeter (COoxHb) After in Vivo Adjustment.||Hospital Universitario Doctor Peset|No|Recruiting|February 2012|September 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients scheduled to any surgery of at least three hours of duration.|August 2015|August 16, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02399488||24639|
NCT02420366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 506 NH|Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae|Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|257|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with serious CRE infections identified by chart review at up to 20 sites|April 2015|April 16, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02420366||23038|
NCT02416401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-1006-14|Attention Training for Learning Enhancement and Resilience Trial|Attention Training for Learning Enhancement and Resilience Trial|ALERT|Posit Science Corporation|Yes|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|N/A|No|||November 2015|November 12, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416401||23342|
NCT02413008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITFE-2026-C10|A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting|A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting|BLISSAFE|ITF Research Pharma, S.L.U.||Recruiting|April 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|N/A|N/A|No|||February 2016|February 22, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02413008||23603|
NCT02410655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin Efficacy|An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery|An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery||New York University School of Medicine|Yes|Active, not recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|600|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410655||23784|
NCT02407392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2014/73|"Using Dilute Vinegar to Find Changes in Cells During Endoscopy for Patients With Barrett's Oesophagus" (The ABBA Study)|Acetic Acid Guided Biopsies in Barrett's Surveillance for Neoplasia Detection Versus Non-targeted Biopsies (Seattle Protocol): A Feasibility Study for a Randomised Tandem Endoscopy Trial. The ABBA Study.|ABBA|Portsmouth Hospitals NHS Trust|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02407392||24035|
NCT02422693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 04/2012|Aquatic Exercises for Patients With Chronic Low Back Pain|Aquatic Exercises Versus Aquatic Exercises Associated to Deep Water-running for Patients With Chronic Low Back Pain: Randomized Controlled Trial||Universidade Estadual de Londrina|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|60 Years|No|||April 2015|April 28, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02422693||22859|
NCT02413983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-016-002|Comparison of Postoperative Outcome of Hepatectomy for Living Donors According to Three Different Incision|Comparison of Postoperative Outcome of Hepatectomy for Living Donors According to Three Different Incision: Conventional Incision vs Minimal Incision vs Transverse Incision Assisted by Laparoscopy||Samsung Medical Center|No|Not yet recruiting|April 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study was a single center, non-randomized, observational comparative analysis of 3        different surgical technique. The living liver donors underwent hepatectomy using three        different type of incisions; 1) right subcostal incision with a midline extension 2) upper        midline incision without laparoscopic assistance 3) transverse incision with laparosocpic        assistance|April 2015|April 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02413983||23528|
NCT02426086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107170|Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor|A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor||Janssen Research & Development, LLC|No|Recruiting|June 2015|March 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426086||22598|
NCT02426099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNO22011|Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension|Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde|SPIRY|Yaounde Central Hospital|Yes|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|21 Years|75 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426099||22597|
NCT02423161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-787|PIONEER: Intraoperative and Perioperative OCT Study|Prospective Intraoperative and Perioperative Ophthalmic Imaging With Optical Coherence Tomography: PIONEER Study|PIONEER|The Cleveland Clinic|No|Active, not recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes any patient requiring ophthalmic surgery|April 2015|April 17, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02423161||22823|
NCT02407444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc150495ctil|Treatment Efficacy of Leg Cycling as Part of Physiotherapy Treatment in Elderly Patients With Hip Fracture|A Comparison of Two Physiotherapy Treatment Protocols, With and Without Cycling Training , in Elderly Patients With Hip Fractures at Their Subacute Stage Following Surgery||Rabin Medical Center|No|Recruiting|July 2015|December 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|95 Years|No|||March 2016|March 19, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02407444||24031|
NCT02422810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075811|High-Shear Microfluidic Thrombosis Assay|Characterization of a Novel High-Shear Thrombosis Assay in Normal and Aspirin-treated Patients||Emory University|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects are healthy Emory Executive Health patients over the age of 45 with no history of        myocardial infarction, ischemic stroke, or other ischemic event|April 2015|April 17, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02422810||22850|
NCT02410811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-4851|Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease|Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|October 2013|July 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|25|Samples With DNA|There will be two visits that the participants will have to give blood and urine.      Visit 1:      Sample of blood (about 2 tablespoons) for:        -  routine lab tests to check the health of the heart and the extent of participants           sickle cell disease        -  research lab tests to check for biomarkers (substances found in blood that are signs of           a disease, condition or normal/abnormal process) of heart problems, blood clotting           activity and to extract DNA for genetic testing        -  1 tablespoon of urine for routine tests to check health      Visit 2 (1 year after 1st visit):        -  Sample of blood (about 2 tablespoons) for routine and research lab tests        -  1 tablespoon of urine for routine tests to check health|Both|6 Years|65 Years|No|Non-Probability Sample|Enrolling a maximum of 25 participants in the entire study across three age strata: A, 6 -        13.9 years; B, 14 - 20.9 years; and C, 21 years and older.|December 2015|December 10, 2015|May 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02410811||23772|
NCT02415712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fomepizole-5001|Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)|Specified Drug-use Survey of Fomepizole Intravenous Infusion "Takeda" (All-case Surveillance)||Takeda|No|Recruiting|January 2015|June 2022|Anticipated|June 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|168|||Both|N/A|N/A|No|Non-Probability Sample|Ethylene glycol poisoning or methanol poisoning|December 2015|December 16, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02415712||23395|
NCT02410421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5055|e-PAT Neuromod Evaluation of Personalized rTMS for Resistant Depression|Validation of Individualized rTMS Protocol Using Non Invasive Functional Brain Imaging and Robotic Coil Placement in Resistant Depression: Comparison With Classical rTMS and tDCS||University Hospital, Strasbourg, France|No|Withdrawn||May 2020|Anticipated|May 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02410421||23802|
NCT02410434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#30344|Reducing Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma in Swaziland and Lesotho|Examining Performance Ethnography as a Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma Reducing Strategy in Swaziland and Lesotho||University of Toronto|No|Active, not recruiting|February 2015|February 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02410434||23801|
NCT02401607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0228|SEEK Study - Study on Emergency Health Care Workers' Job Strain Evaluated by Karasek Questionnaire|SEEK Study - Study on Emergency Health Care Workers' Job Strain Evaluated by Karasek Questionnaire|SEEK|University Hospital, Clermont-Ferrand||Recruiting|March 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|health care workers|March 2015|March 24, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02401607||24476|
NCT02416141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUTIV2015MDB001|Fast-release Orodispersible Tramadol as Analgesia in Termination of Pregnancy by Vacuum Aspiration.|Fast-release Orodispersible Tramadol as Analgesia in Termination of Pregnancy by Vacuum Aspiration.||Universitair Ziekenhuis Brussel|No|Not yet recruiting|April 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|April 8, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02416141||23362|
NCT02420756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEAS Study|Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study|Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study|IDEAS|American College of Radiology Imaging Network|No|Recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18488|||Both|65 Years|N/A|No|Non-Probability Sample|Participants must be Medicare beneficiaries referred by qualified dementia specialists and        must meet AUC for amyloid PET (Johnson et al. 2013).|February 2016|February 8, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420756|12 Months|23008|
NCT02410473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00016625|Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery|Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery||Children's Hospital Boston|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Collect discarded blood from 4 routine blood samples. These will be obtained at 4 different      time-points: 1. After induction of anesthesia and placement of arterial line, 2. After      cardiopulmonary Bipass (CPB), 3 minutes after protamine administration, 3. At the end of the      surgery, before transfer to CICU, 4. 24- 48 hrs post-surgery in the ICU.      Collect two 5 mL of urine samples. One sample prior to CPB, as well as following CPB, from      an routinely placed Foley catheter.|Both|N/A|N/A|No|Non-Probability Sample|Neonates and infants undergoing cardiac surgery with cardiopulmonary bypass|April 2015|April 10, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410473||23798|
NCT02409563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/2013|Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic Rhinitis|Effectiveness of Nasal Budesonide on Control of Airway Inflammation by Determining FeNO in Children With Allergic Rhinitis.||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||Completed|January 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|6 Years|14 Years|No|||April 2015|April 8, 2015|February 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02409563||23868|
NCT02416375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO1955|Home Monitoring to Predict Exacerbation in Cystic Fibrosis|A Standardized Multi-centre Analysis of Remote Monitoring in Cystic Fibrosis Adult Patients to Reduce Pulmonary Exacerbations|SmartCare|Papworth Hospital NHS Foundation Trust|Yes|Recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Daily sputum samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult Cystic Fibrosis patients who produce sputum daily and have not had a previous organ        transplant, with a history of at least one pulmoanry exacerbation within the past 12        months.|February 2016|February 16, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02416375||23344|
NCT02424474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141001|T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients|Fetal Aneuploidies Screening (21,18 and 13) by Cell Free Fetal DNA Analysis. Pilot Study in Low Risk Population and Pregnant Women After in Vitro Fertilisation (IFV)|DEPOSA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02424474||22722|
NCT02424487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00826|Intracuff Pressure During One-lung Ventilation in Infants and Children|Intracuff Pressure During One-lung Ventilation in Infants and Children||Nationwide Children's Hospital|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|Male and female from 0-18 years old having thoracic surgery and requiring one-lung        ventilation.|October 2015|October 26, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02424487||22721|
NCT02424500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD004-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||March 10, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424500||22720|
NCT02398643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0504|Examine the Impact of Early Education on COPD Management|Examine the Impact of Early Chronic Disease Management Education Following Hospital Discharge in Acute Exacerbation of COPD||University of Alberta|No|Recruiting|March 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398643||24704|
NCT02394288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1579/2014|Perioperative Cardiac Troponin Levels in Healthy Adults|Perioperative High-sensitivity Cardiac Troponin Levels in Healthy Adults Undergoing Elective Trauma Surgery||Medical University of Vienna|Yes|Completed|March 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|Plasma|Both|18 Years|35 Years|No|Non-Probability Sample|Patients undergoing extremity surgery without history of cardiovascular disease|March 2016|March 18, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02394288||25039|
NCT02394574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1460|Household Air Pollution and Pregnancy Outcome|Household Air Pollution and Pregnancy Outcome|HAP|University of Chicago|No|Active, not recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Female|N/A|35 Years|No|||June 2015|June 11, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02394574||25017|
NCT02413450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00085175|Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias|Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias (Long QT Syndrome, Brugada Syndrome, CPVT and Early Repolarization Syndrome)||Johns Hopkins University|No|Enrolling by invitation|August 2013|August 2023|Anticipated|August 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|induced pluripotent stem cells (iPSC)|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who have a mutation causing ARVD/C or LQTS or a first degree family member        with such a gene mutation. Participants, including patients with ARVD/C or LQTS and family        members, who have previously been genotyped for clinically indicated reasons will be        approached to join the study.|March 2016|March 14, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413450|1 Day|23569|
NCT02421926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-99|Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)|Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase|IDEAL-E|Asan Medical Center|No|Recruiting|October 2014|October 2023|Anticipated|October 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who were newly dianosed as chronic phase chronic myelogenous leukemia, were        enrolled to 'IDEAL' study, and were followed up|July 2015|July 1, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02421926||22918|
NCT02395900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|567|The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease|The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease||National Nutrition and Food Technology Institute|Yes|Completed|March 2014|January 2015|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02395900||24915|
NCT02414399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD079695-01A1|Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children|Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children||University of Washington|Yes|Not yet recruiting|March 2016|January 2020|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1400|||Both|1 Month|59 Months|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02414399||23496|
NCT02414412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022014031|Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults|Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults||Pusan National University Hospital|Yes|Completed|February 2015|May 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|58|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02414412||23495|
NCT02420535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00066639|An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia|An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia||University of Michigan|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|21 Years|N/A|No|||August 2015|August 6, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420535||23025|
NCT02420704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCZZU-Endometrial thickness|Effect of Endometrial Thickness on IVF Outcome|Effect of Endometrial Thickness on IVF Outcome: a Prospective Observational Study of Both Cleavage Stage and Blastocyst Stage Embryo Transfer Cycles||The First Affiliated Hospital of Zhengzhou University|Yes|Recruiting|November 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|500|||Female|22 Years|38 Years|No|Probability Sample|Patients transfrred with at least two high quality cleavage stage embryos, or with at        least one high quality blastocyst stage embryo.|April 2015|April 18, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420704||23012|
NCT02414295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6714|Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection|Management of Azoospermic Patients With Kleinfelter Syndrome Patients With Mesenchymal Stem Cell Injection||Man Clinic for Andrology, Male Infertility and Sexual Dysfunction|No|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|1|||Male|20 Years|50 Years|No|||April 2015|April 9, 2015|August 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02414295||23504|
NCT02401022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA/VA CSP - 1032|The Study of AZD8529 for Smoking Cessation in Female Smokers|The Study of AZD8529 for Smoking Cessation in Female Smokers||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02401022||24521|
NCT02401035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1791089|PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects|An Open-label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Who Are Candidates For Acid Suppression Therapy||Pfizer|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Year|16 Years|No|||March 2016|March 16, 2016|December 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02401035||24520|
NCT02421406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P30AI042853-16|An Internet-based Behavioral Weight Loss Program for HIV+ Patients|An Internet-based Behavioral Weight Loss Program for HIV+ Patients||The Miriam Hospital|No|Active, not recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02421406||22958|
NCT02420717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0521|Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)|A Phase II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|10 Years|N/A|No|||February 2016|February 24, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420717||23011|
NCT02420912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0931|Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-rRsk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420912||22996|
NCT02481895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22039|Efficacy of an Innovative E-neurocognitive Module for Bipolar Disorder|Efficacy of an Innovative E-neurocognitive Module as Adjunct to Functional Remediation for Bipolar Disorder||Centro de Investigación Biomédica en Red|No|Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|60 Years|No|||February 2016|February 24, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02481895||18312|
NCT02492360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0516|Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy|Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy||Indiana University|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Whole blood samples will be obtained from all patients so that peripheral blood mononuclear      cells (PBMCs) can be isolated and stored for the eventual creation of iPS cells. iPS cells      have the potential to make human neurons that the researchers would like to use for      functional studies of specific genes/genetic variants. All samples will also be tested for      infectious diseases (Hepatitis B, Hepatitis C, HIV 1 and HIV 2).|Male|18 Years|N/A|No|Non-Probability Sample|This study will consist of two groups: testicular cancer patients with severe neuropathy        (experimental group) and testicular cancer patients without neuropathy (control group).        One control subject will be recruited for each experimental subject with severe        neurotoxicity. Controls will be matched based on age (within 10 years), tumor type, race,        ethnicity, and chemotherapy regimen and cumulative dose of cisplatin during which the        toxicity occurred.|January 2016|January 27, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02492360||17510|
NCT02468648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150143|Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816|Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|80 Years|No|||December 2015|December 24, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468648||19331|
NCT02477657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 26813|Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology|Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|||Both|18 Years|N/A|No|Probability Sample|Adult patients with refractory malignant ascites secondary to GU or GI malignancy.|March 2016|March 18, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02477657||18638|
NCT02483429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIZZY.01|Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)|Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)|AVERT|Johns Hopkins University|Yes|Not yet recruiting|September 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|226|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02483429||18194|
NCT02492373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 033/2015|Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser|Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study||Mahidol University|Yes|Active, not recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|June 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492373||17509|
NCT02479841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV911836|Health-promoting Competence, Coping and Quality of Life in Patients With COPD|Health-promoting Competence, Coping and Quality of Life in Patients With COPD|REKV-13/1741|Helse Fonna|Yes|Active, not recruiting|February 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|225|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02479841||18470|
NCT02478658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504792|Circulatory Levels of Irisin in Response to Acute Resistance Training|Circulatory Levels of Irisin in Response to Acute Resistance Training||Texas Tech University||Completed|February 2015|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|October 19, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02478658||18561|
NCT02478671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIS2015-002|Magnetic Resonance Imaging (MRI) to Assess Radial Artery Compression and Arterial Perfusion While TR Band is Applied|Magnetic Resonance Imaging (MRI) to Assess Radial Artery Compression and Arterial Perfusion While TR Band is Applied||Terumo Medical Corporation|No|Completed|June 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|May 19, 2015||No||No|November 30, 2015|https://clinicaltrials.gov/show/NCT02478671||18560|Single center study with small sample size.
NCT02488330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29646|An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study|||Hoffmann-La Roche||Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|17|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488330||17818|
NCT02493205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501RANA|The Holding Area LINQ (Reveal LINQ Insertable Cardiac Monitor) Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial|The Holding Area LINQ Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial Designed to Occur in the Holding Area of a Hospital Operating Room or Cardiac Catheterization/Electrophysiology Laboratory|HALT|Holy Cross Hospital, Florida|No|Active, not recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 and older indicated for continuous arrhythmia monitoring with an Implantable        Cardiac Monitor|January 2016|January 18, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02493205||17445|
NCT02493218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00077391|D-Stress Baltimore: School-based Mindfulness Instruction|D-Stress Baltimore: School-based Mindfulness Instruction for Primary Prevention of Mental Health and Behavioral Problems in Middle School||Johns Hopkins University|No|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02493218||17444|
NCT02466477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCITE-013304-ARX1009.PTL|Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder|A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic||St. Joseph's Healthcare Hamilton|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|570|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466477||19498|
NCT02490059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-C094|Ultrathin Bronchoscopy for Solitary Pulmonary Nodules|Ultrathin Bronchoscopy for Solitary Pulmonary Nodules: A Randomised Pilot Trial|Babyscope|University of Zurich|No|Completed|November 2000|May 2015|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490059||17687|
NCT02480530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01461|Using Feedback Reports to Improve Medication Adherence|Evaluating Individual and Patient-Selected Family/Friend/or Reciprocal Peer Notifications to Improve Statin Medication Adherence Among Patients With Coronary Artery Disease||Philadelphia Veterans Affairs Medical Center|No|Active, not recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|224|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||August 2015|September 4, 2015|May 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02480530||18417|
NCT02480322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metab-001|Metabolomic Fingerprint After Bariatric Surgery|Metabolomic Fingerprint of Severe Obesity is Dynamically Affected by Bariatric Surgery in a Procedure-dependent Manner||eSwiss Medical & Surgical Center||Completed|May 2010|||May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||5|Actual|106|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|severely obese patients of the Interdisciplinary Obesity Center, St. Gallen, Switzerland|June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480322||18433|
NCT02475213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA271-03|Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer|A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7H3 Expressing Cancers||MacroGenics|No|Recruiting|July 2015|August 2020|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475213||18826|
NCT02482350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150817|App-delivered Therapy for Arabic Readers With Hemianopic Alexia|App-delivered Therapy for Arabic Readers With Hemianopic Alexia||University College London Hospitals|Yes|Not yet recruiting|July 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|26 Years|81 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02482350||18277|
NCT02480803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_336|INfusion VErsus STimulation in Parkinson's Disease|Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation|INVEST|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02480803||18396|
NCT02418195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F141029007|miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome|Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment Outcome||University of Alabama at Birmingham|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|240|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 5, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418195||23204|
NCT02418442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054616|Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry|Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry||Duke University|No|Recruiting|July 2015|December 2028|Anticipated|June 2028|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|The biosample collection will be in the future. This effort is currently not funded.|Both|2 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with pediatric rheumatic diseases enrolled from participating CARRA sites.|November 2015|January 19, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418442|10 Years|23185|
NCT02396147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385-1010|Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants|A Phase 1, Open-Label, Randomized, Three-Way Crossover Study Evaluating the Relative Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Subjects||Takeda|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396147||24896|
NCT02410239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LS018|MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)|MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|June 2015|July 2022|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|4 Years|N/A|No|||January 2016|January 22, 2016|March 27, 2015|Yes|Yes|Research cancelled|No||https://clinicaltrials.gov/show/NCT02410239||23816|
NCT02425917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKD-IPC-002|IPC-CALF Versus GEKO in Post-op Total Hip Patients|Comparison of Intermittent Pneumatic Compression (IPC) of the Calf and gekoTM Neuromuscular Electrostimulation (NMES) Device on Lower Limb Circulation Following Elective Total Hip Replacement (THR)||Firstkind Ltd|No|Withdrawn|May 2015|||September 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|80 Years|No|||March 2016|March 8, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02425917||22611|
NCT02414191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140117-01H|Feedback on Perioperative Temperature Management and Patient Outcomes: Three-arm Trial to Compare Feedback|Effect of Audit and Feedback on Physicians' Perioperative Temperature Management and Patient Outcomes: A Three-arm Cluster Randomized Controlled Trial to Compare Benchmarked and Ranked Feedback||Ottawa Hospital Research Institute|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02414191||23512|
NCT02410824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-02|Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism|Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism||Coopervision, Inc.|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|17 Years|N/A|No|||July 2015|July 27, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410824||23771|
NCT02398357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LSX-2015|The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis|A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis||Shanghai Zhongshan Hospital|No|Recruiting|March 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02398357||24726|
NCT02419963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008799|Analyzing IBS to Identify Biomarkers and Microbiome Signatures|A New Dimension in Modeling Irritable Bowel Syndrome (IBS) to Elucidate Novel Diagnostic Biomarkers and Microbiome Signatures||Mayo Clinic|No|Recruiting|May 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02419963||23069|
NCT02418403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110340|Consumer Engagement to Increase Advance Care Planning: Patient Randomization|Consumer-directed Financial Incentives to Increase Advance Care Planning Among Medi-Cal Patients||University of Pittsburgh|No|Completed|March 2015|August 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|376|||Both|65 Years|75 Years|No|||January 2016|January 13, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418403||23188|
NCT02418689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV120101-203|Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens|A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens||National OncoVenture|Yes|Active, not recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|19 Years|N/A|No|||February 2016|February 26, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02418689||23166|
NCT02424760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907-T-INSPYRE-RM|Clinical Outcomes in Shoulder Hemi-arthroplasty Using a PyC Spherical Interpositional Implant|A Prospective Cohort Study to Document the Clinical Outcomes in Shoulder Hemi-arthroplasty Using a PyC Spherical Interpositional Implant||Tornier, Inc.|No|Active, not recruiting|March 2011|March 2021|Anticipated|March 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Study population is a continuous series of the first 67 patients having received an        Inspyre implant in the 8 participating sites.|April 2015|April 20, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424760||22700|
NCT02398656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0 , Jan 26,2015|A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion|Long Title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in the Prevention of Disability at 3 Months in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion|TEMPO-2|University of Calgary|Yes|Recruiting|April 2015|March 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1274|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398656||24703|
NCT02398669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-A001-026|A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age|An Open-Label, Single Dose Study to Assess Pharmacokinetics, Safety and Tolerability of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age||Eisai Inc.|No|Completed|March 2015|May 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Years|11 Years|No|||November 2015|November 2, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02398669||24702|
NCT02418936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014L01|Development and Clinical Application of Two New Genetic Deafness Gene Diagnostic Kit|Development and Clinical Application of Two New Genetic Deafness Gene||Xiangya Hospital of Central South University|No|Recruiting|January 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|100|Samples With DNA|whole blood|Both|N/A|N/A|No|Non-Probability Sample|People who are diagnosised Waardenburg syndrome or large vestibular aqueduct syndrome.|April 2015|April 15, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418936||23147|
NCT02421835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLE Chronic Study 2015|Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure|Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure||University of Reading|Yes|Not yet recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|120|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02421835||22925|
NCT02424864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N14FDG|4D FDG PET in Esophageal Cancer|4D PET-CT Imaging in Esophageal Cancer||The Netherlands Cancer Institute|No|Recruiting|August 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|April 20, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02424864||22692|
NCT02424877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SandRA-WI177026|Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis|Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis|SandRA|Medcare Oy|No|Active, not recruiting|August 2013|August 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|17 Years|N/A|No|||March 2016|March 20, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424877||22691|
NCT02402907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1410|STRIPES Study: Study To Reduce Infection Post cEsarean Section|A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Cloth Reduces Infectious Morbidity in Patients Undergoing Cesarean Section||Icahn School of Medicine at Mount Sinai|No|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|930|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402907||24378|
NCT02422368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-02-124-24581|The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease|The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial||Iran University of Medical Sciences|No|Not yet recruiting|December 2016|June 2021|Anticipated|June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|70 Years|No|||December 2015|March 9, 2016|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02422368||22884|
NCT02420938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0932|Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients|Urelumab (CD137 mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420938||22994|
NCT02412761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0287|Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension|Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension||The University of Texas Health Science Center, Houston|No|Enrolling by invitation|June 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|9 Years|22 Years|No|||April 2015|April 8, 2015|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412761||23622|
NCT02407340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00033324|Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder|Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder||Johns Hopkins University|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|21 Years|50 Years|No|||November 2015|November 11, 2015|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407340||24039|
NCT02422524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0053|Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects|A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Suspended|September 2015|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|April 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422524||22872|
NCT02420951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Injection after total knee|Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery May Decrease Pain for Several More Hours|Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery||Brigham and Women's Hospital|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02420951||22993|
NCT02410668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1368|The Effects of Flaxseed Supplement on Weight and Biochemical Factors in Overweight and Obese Subject|The Effects of Flaxseed Supplement on Weight, Lipid Profile and Inflammatory Factors in Overweight and Obese Subjects||National Nutrition and Food Technology Institute|Yes|Completed|March 2014|January 2015|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|April 6, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410668||23783|
NCT02407275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHU Méditerranée Infections|Rhinosinusites Chroniques|ETUDE DU MICROBIOTE DES RHINOSINUSITES CHRONIQUES DIFFICILES A TRAITER PAR METAGENOMIQUE ET CULTUROMIQUE||Institut Hospitalo-Universitaire Méditerranée Infection|Yes|Recruiting|February 2015|||September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407275||24044|
NCT02408614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401078|Acute Effect of Exercise on Vascular Function|Acute Effect of Exercise on Vascular Function||University of Florida|No|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|200|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408614||23941|
NCT02413684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057939|PackHealth: Asthma Engagement Tool|Assessing the Impact of a Patient-Clinician Engagement Tool on Patient Reported Outcomes and Engagement in Asthma||Duke University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02413684||23551|
NCT02417909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0011|Overweight, Quality of Life and Psychological Difficulties in Teenagers|Quality of Life and Psychological Difficulties in Relation With the Weight of Teenagers|QOL-ADOB|Lille Catholic University|No|Completed|July 2011|July 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|173|||Both|11 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two categories of teenagers will be included : obese teenagers and average weighted        volonteers|May 2015|August 4, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02417909||23226|
NCT02413281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-212|A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users|A Phase 1, Single-Dose, Double-Blind, Placebo-and Active-Controlled, Randomized, 6-way Crossover Human Abuse Liability Evaluation of ALKS 5461||Alkermes, Inc.|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413281||23582|
NCT02413294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00094645|Sleep to Activate Mood Promotion|Sleep to Activate Mood Promotion- Intervention|STAMP|University of Michigan|No|Completed|April 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|65 Years|N/A|No|||March 2016|March 15, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413294||23581|
NCT02408718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3559|Assistive Device Training in Multiple Sclerosis|Assistive Device Training for Functional Mobility and Connectivity in Multiple Sclerosis|ADT|Portland VA Medical Center|No|Active, not recruiting|July 2015|April 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02408718||23933|
NCT02413918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120137|Iloperidone in Mixed States of Bipolar Disorder|Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD)||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|April 2012|February 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413918||23533|
NCT02415725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2LEED-ICG|Early Detection of Lymphedema After Cancer Treatments|Early Detection of Secondary Lymphedema After Cancer Treatments||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|September 2014|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2015|April 9, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02415725||23394|
NCT02407652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/13808/01-CCT-003|Cognitive Control Training for Remitted Depressed Patients|Cognitive Control Training as a Preventive Intervention for Depression: A Double-blind Randomized Controlled Trial Study||University Ghent|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|68|||Both|23 Years|65 Years|No|||December 2015|December 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02407652||24015|
NCT02409823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209-Re03-Reg|Clinical Registry of Patients Under Treatment With Atypical Antipsychotics|Clinical Registry of Patients Under Treatment With Atypical Antipsychotics||Pontifical Catholic University of Argentina|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|665|||Both|18 Years|N/A|No|Non-Probability Sample|patients under atypical antipsychotic therapy|October 2015|October 19, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409823||23848|
NCT02420093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBnet # 679149-4|Investigating the Clinical Effects of Supporting Neutral Pelvic Position in Sitting|Investigating the Clinical Effects of Supporting Neutral Pelvic Position in Sitting||Oakland University|Yes|Recruiting|January 2015|December 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|34|||Both|20 Years|65 Years|No|||January 2015|April 16, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420093||23059|
NCT02420106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-983|Effect of Osteopathic Manipulative Medicine on Motor Function and Quality of Life in Cervical Dystonia|Effect of Osteopathic Manipulative Medicine on Motor Function and Quality of Life in Cervical Dystonia||New York Institute of Technology|No|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|2 Years|100 Years|No|||January 2016|January 19, 2016|February 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02420106||23058|
NCT02424422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Ortho-01-2015|The Effect of Expansion on Craniofacial Sutures in Children Using 3D Imaging|The Effect of Rapid Maxillary Expansion on Craniofacial Sutures in Children Using Cone Beam Computed Tomography||Damascus University|Yes|Active, not recruiting|February 2015|April 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|8 Years|12 Years|No|Probability Sample|Growing patients between the age of 8 and 12 will be recruited from those who are visiting        the Department of Orthodontics at University of Damascus Dental School.        The study will evaluate the impact of maxillary expansion on craniofacial sutures using        CBCT imaging.|July 2015|March 15, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424422||22726|
NCT02393885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2014-1|Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach|Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation|DEEP Pivotal|AtriCure, Inc.|Yes|Recruiting|February 2015|September 2023|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393885||25070|
NCT02393898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29515|BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Ovarian Cancer Patients 70 Years and Older.|BELOVA: a Non-Interventional Study to Collect Data on the Safety and Efficacy of Frontline Bevacizumab Treatment in Ovarian Cancer Patients 70 Years and Older.||Hoffmann-La Roche||Not yet recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|70 Years|N/A|No|Probability Sample|Patients|March 2015|March 16, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02393898||25069|
NCT02397382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106796|Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis|A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis||Janssen Research & Development, LLC|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02397382||24801|
NCT02420197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1157|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Neck Pain|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Neck Pain||Norwegian University of Science and Technology|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|65 Years|No|||January 2016|January 25, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02420197||23051|
NCT02412722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0128-1004|Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies|A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Recruiting|March 2015|January 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02412722||23625|
NCT02404779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0225|Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents|Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo|THIC Cu|University Hospital, Clermont-Ferrand||Recruiting|March 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02404779||24234|
NCT02398422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3268|The Listening Project at Reiss-Davis/Vista Del Mar Child and Family Services|The Listening Project at Reiss-Davis/Vista Del Mar Child and Family Services||University of North Carolina, Chapel Hill|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|6 Years|17 Years|No|||February 2016|February 11, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02398422||24721|
NCT02417896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRO-110313|Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery|Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery||Instituto Nacional de Cardiologia Ignacio Chavez|No|Recruiting|April 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|90 Years|No|||March 2013|April 15, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02417896||23227|
NCT02423356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0483|Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin|The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin||Indiana University|Yes|Suspended|January 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|HER2(-) breast cancer, sarcoma, and lymphoma patients receiving doxorubicin chemotherapy        as part of standard protocols|November 2015|November 2, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02423356||22808|
NCT02401321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9306|Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers|A Pilot Feasibility Study: Taking Care of Her||University of Washington|No|Recruiting|March 2015|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|64|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401321||24498|
NCT02418637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000647|Pilot Study Testing Feasibility of Health Screening at Farm Site|Worksite Screening for Cardiovascular Risk Factors Among Migrant Agricultural Workers||Mayo Clinic|No|Active, not recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|November 9, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418637||23170|
NCT02418897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L15-098|Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis|Does Abnormal Neuromuscular Junction Function Play a Role in the Pathogenesis of Motor Fatigue in Women With Multiple Sclerosis?||Texas Tech University Health Sciences Center|Yes|Recruiting|April 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with relapsing remitting multiple sclerosis (MS) with motor fatigue in MS > 6        weeks. Motor fatigue equates to muscle fatigue due to physical exertion and is alleviated        with rest and associated with fatigability.|October 2015|October 21, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02418897||23150|
NCT02426177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DowUHS|Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension|Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management||Dow University of Health Sciences|Yes|Not yet recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Female|20 Years|48 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426177||22591|
NCT02426190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-347|Knee Arthroplasty Rehabilitation Outcomes Study|Knee Arthroplasty Rehabilitation Outcomes Study|KAROS|MedStar National Rehabilitation Network|No|Recruiting|October 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|360|||Both|40 Years|N/A|No|||April 2015|April 21, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02426190||22590|
NCT02417675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5601|Postpartum Adherence Clubs to Enhance Support: the PACER Study|Postpartum Adherence Clubs to Enhance Support: the PACER Study|PACER|Columbia University|Yes|Active, not recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|258|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02417675||23244|
NCT02407002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30516-01|Safety of Nitroglycerin for Field Treatment of STEMI|The Use of Nitroglycerin by Paramedics for Treatment of Acute ST-elevation Myocardial Infarction (STEMI) in the Field||Los Angeles Biomedical Research Institute|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects will be patients with STEMI identified in the field and transported to a        study site.|March 2016|March 7, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02407002||24065|
NCT02407067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106169|A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease|A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease||Lawson Health Research Institute|Yes|Enrolling by invitation|April 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|85 Years|No|||April 2015|April 11, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407067||24060|
NCT02407080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1919|Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia|Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407080||24059|
NCT02426216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412038RINB|Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention|Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention||National Taiwan University Hospital|No|Recruiting|March 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Blood, urine, prostate tissue|Male|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Subjects who are increased risk of prostate cancer|October 2015|October 25, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02426216||22588|
NCT02485912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBL06|Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination|A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.||University of Oxford|No|Completed|July 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02485912||18003|
NCT02485925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-201501|SMART China, A Multi-center Clinical Registry Study|The Effectiveness and Safety in the Treatment of Circumferential Pulmonary Vein Isolation (CPVI) for Symptomatic Paroxysmal Atrial Fibrillation With THERMOCOOL® SMARTTOUCH™ Catheter in China, A Multi-center Clinical Registry Study||Biosense Webster, Inc.|Yes|Recruiting|July 2015|October 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02485925||18002|
NCT02482493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/01/282 version 1.3|All Polyethylene Versus Metal Backed Tibial Components in Knee Replacement|A Prospective Randomised Control Trial to Compare Clinical and Radiological Outcomes of the Press-Fit Condylar All-Polyethylene Tibial Component With Metal-Backed Tibial Component Implant, in Patients Aged 75 Years or Over||Maidstone & Tunbridge Wells NHS Trust|No|Not yet recruiting|May 2016|July 2023|Anticipated|July 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|75 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02482493||18266|
NCT02482506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE-WL4AA|Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors|BRE-WL4AA Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors||University of Illinois at Chicago|Yes|Active, not recruiting|July 2011|July 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Female|18 Years|N/A|No|||June 2015|June 23, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02482506||18265|
NCT02476630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500482|Thenar Tissue Oxygen Concentration (StO2): A Non-invasive Surrogate for Central Venous Oxygen Saturation (ScvO2)|Thenar Tissue Oxygen Concentration (StO2): A Non-invasive Surrogate for Central Venous Oxygen Saturation (ScvO2)||University of Florida|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|1 Month|21 Years|No|||January 2016|January 19, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476630||18717|
NCT02463955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/182/HP|Exploration of the Pleural Cavity Using a fleXible endoscoPe|Exploration of the Pleural Cavity Using a fleXible endoscoPe Under Two-Lung ventilatiOn With contRollEd Capnothorax|EXPLORE|University Hospital, Rouen|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02463955||19692|
NCT02487641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000095|Obese Pregnant Women: Optimizing Fetal Ultrasound|Obese Pregnant Women: Optimizing Mid-trimester Fetal Ultrasound for Risk Estimation During Pregnancy and Childhood||Holbaek Sygehus|Yes|Recruiting|June 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|180|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Sixty pregnant women with BMI ≥ 30 Kg/m2, 60 pregnant women with BMI ≥ 35 Kg/m2 and 60        Kg/m2 pregnant women normal weighted (BMI: 18,5-24,9 Kg/m2) will be included.        Women will be classified by their pre-pregnancy BMI and all pregnant women with an age ≥        18 will be offered to attend the project and those who accept will be admitted. The        recruitment will be performed at Holbæk Hospital and Odense University Hospital.|November 2015|November 9, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02487641||17871|
NCT02487732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adenosine diphosphate blockers|Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting|||Korea University Anam Hospital||Active, not recruiting|July 2015|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|30 Years|70 Years|No|||February 2016|February 23, 2016|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02487732||17864|
NCT02484053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35628 Rituximab|Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders|Implementation of Rapid Infusion Rituximab in a Pilot Group of Adolescents With Hematologic, Oncologic, and Rheumatologic Disorders||Baylor College of Medicine|Yes|Recruiting|June 2015|||June 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|13 Years|19 Years|No|||February 2016|February 3, 2016|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02484053||18146|
NCT02466217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141006|Phenomics in Autoimmune and Inflammatory Diseases|Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases|TRANSIMMUNOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|July 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The investigator will study adult patients with at least one of the following IAD:        Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus        Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes        (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis,        Crohn's Disease, Ulcerative colitis, Type 1 Diabetes. This panel will be completed by        controls groups: healthy volunteers, and patients with arthritis (knee and/or hip) or        muscular dystrophy|September 2015|September 4, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02466217||19518|
NCT02480907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA765A0304|Supporting Carers of Children and Adolescents With Eating Disorders in Austria (SUCCEAT)|Supporting Carers of Children and Adolescents With Eating Disorders in Austria (SUCCEAT) - A Randomized Controlled Trial to Compare Workshop, Internet-based and Conventional Parental Support Groups|SUCCEAT|Medical University of Vienna|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|10 Years|18 Years|No|||June 2015|July 6, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02480907||18388|
NCT02482116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA.577/Vol. II/126|A Comparison of Diagnostic Approaches for Malaria and Pneumonia|Malaria and Pneumonia in Children Under the Age of Five Years Old Presenting to Primary Healthcare Centres in Benin City, Nigeria: a Comparison of Early Diagnostic Approaches||University of Nottingham|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|2 Months|4 Years|No|Non-Probability Sample|The study population are children aged 2 months to four years old who are residents in the        catchment local government area of study primary healthcare centres in Benin City, Edo        State, Nigeria.|February 2016|February 12, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482116||18295|
NCT02484976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK098466|Brain Activation and Satiety in Children: Functional Magnetic Resonance Imaging|Brain Systems and Behaviors Underlying Response to Obesity Treatment in Children|BASIC-FMRI|Seattle Children's Hospital|No|Recruiting|September 2014|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|76|||Both|9 Years|11 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02484976||18075|
NCT02462564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYu|Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC|Risk Factors for Early POCD(Postoperative Cognitive Dysfunction) in the Patients With PSM(Peritoneal Surface Malignancies )Undergoing CRS(Cytoreductive Surgery) and HIPEC(Hyperthermic Intraperitoneal Chemo-therapy)||Wuhan University|Yes|Completed|June 2014|June 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|31|Samples Without DNA|venous blood sample|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|patients with peritoneal surface malignancies undergoing cytoreductive surgery and        hyperthermic intraperitoneal chemo-therapy|August 2015|August 16, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02462564||19798|
NCT02487498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2350|Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, Two-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation.||Novartis|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|354|||Both|40 Years|N/A|No|||March 2016|March 3, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487498||17882|
NCT02485184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVT-TIPS2|TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis|TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis: A Randomized Controlled Trial||Fourth Military Medical University|No|Not yet recruiting|July 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|65 Years|No|||June 2015|June 25, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02485184||18059|
NCT02485405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP15_CarolineLinninge|Gut Permeability and Stress|Gut Permeability in Volunteers Participating in a Stress Test|SP15|Lund University|No|Active, not recruiting|June 2015|January 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|50|Samples Without DNA|Saliva Plasma/Serum|Male|19 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy men aged 19-35 years old|March 2016|March 3, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02485405||18042|
NCT02422641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14166|Prospective Evaluation of High-dose (8 g/m2) Systemic Methotrexate in Patients With Breast Cancer and Leptomeningeal Metastasis|||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2015|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02422641||22863|
NCT02422654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC14373|Taste Evaluation of Different Liquid Formulations With Eliglustat|A Single-blind, Randomized, Unbalanced Crossover Design With 5 Vehicles, 5 Periods, and 5 Sequences, Repeated-doses (With no Ingestion) Study to Assess the Palatability of Eliglustat Prototype Liquid Formulations in Healthy Subjects||Sanofi|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|15||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422654||22862|
NCT02400710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00615|Clinician-Supported PTSD Coach vs. Self-Managed PTSD Coach|Clinician-Supported PTSD Coach vs. Self-Managed PTSD Coach: A Pilot Feasibility Trial||Syracuse VA Medical Center|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|March 16, 2015||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT02400710||24545|
NCT02396212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G1301|Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA|An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)||Novartis|No|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|19 Years|No|||March 2016|March 20, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02396212||24891|
NCT02414204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150220002|Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula|Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula||University of Alabama at Birmingham|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|21|||Both|19 Years|99 Years|No|||October 2015|October 13, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02414204||23511|
NCT02418156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PR-1120|A Study on the Use of CorMatrix ®ECM® for Femoral Arterial Reconstruction|A Post Market Observational Study on the Use of CorMatrix ®ECM® for Femoral Arterial Reconstruction|PERFORM|CorMatrix|No|Enrolling by invitation|May 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients presenting for femoral arterial reconstruction with patch angioplasty.|January 2016|January 26, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02418156||23207|
NCT02418455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX003-CL203|An Open-Label Study of UX003-rhGUS Enzyme Replacement Treatment in MPS 7 Patients Less Than 5 Years of Age|||Ultragenyx Pharmaceutical Inc|No|Recruiting|July 2015|||March 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|N/A|5 Years|No|||January 2016|January 20, 2016|April 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418455||23184|
NCT02422225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-03-2015-004|A Study of tDCS for Swallowing Difficulties in Stroke Patients|Improvement of Swallowing Function of Stroke Patients by Dual Transcranial Direct Current Stimulation(tDCS)||Pusan National University School of Medicine|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422225||22895|
NCT02421653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-2014-N-35|RCT of Iodine-containing MNPs vs Oral Iodized Oil to Prevent Iodine Deficiency in Weaning Infants|A Randomised Controlled Trial of Iodine-containing Micronutrient Powders Versus Oral Iodised Oil to Prevent Iodine Deficiency in Weaning Infants||Swiss Federal Institute of Technology|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|480|||Both|6 Months|9 Months|Accepts Healthy Volunteers|||November 2015|November 11, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02421653||22939|
NCT02424773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K101201|Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients|Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients|RESPIR-OH|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2012|April 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424773||22699|
NCT02402621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0267|Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP|Comparison Between Conventional and Model-based Infusion Strategy of Intravenous Patient-controlled Analgesia in Patients Undergoing Robot Assisted Laparoscopic Radical Prostatectomy||Asan Medical Center|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Male|20 Years|69 Years|No|||November 2015|November 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02402621||24398|
NCT02416791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|513.207|Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke|Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke|ROTS|University of Sao Paulo General Hospital|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416791||23312|
NCT02416804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTDS_001|Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery|Postoperative Analgesia With Buprenorphine Transdermal System (BTDS) Versus Tramadol for Postoperative Pain Control and Quality of Life After Spinal Surgery||Seoul National University Hospital|Yes|Recruiting|February 2015|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02416804||23311|
NCT02422264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201330|Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery|Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery||GlaxoSmithKline||Not yet recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|680|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02422264||22892|
NCT02411682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCBI 057-2013-254|Breakfast on Postprandial Hyperglycemia|Effect of Breakfast on Overall Postprandial Hyperglycemia in T2D|B-PPHG|Hospital de Clinicas Caracas|Yes|Active, not recruiting|May 2014|April 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|28|||Both|30 Years|70 Years|No|||April 2015|April 7, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411682||23705|
NCT02407535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0059-CTIL|Assessing the Ultrasound Done on a the Uterus After Hysterectomy as a Diagnostic Tool for the Depth of Endometrial Carcinoma Invasion Into the Myometrium|Assesing the Ultrasound Done on a the Uterus After Hysterectomy as a Diagnostic Tool for the Depth of Endometrial Carcinoma Invasion Into the Myometrium||Carmel Medical Center||Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||April 2015|April 1, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02407535||24024|
NCT02394236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66/2011|Aerobic Exercise and Oxygen Uptake Efficiency Slope in Coronary Artery Disease|Continuous vs. Interval Exercise Training on Oxygen Uptake Efficiency Slope in Patients With Coronary Artery Disease||Hospital TotalCor|Yes|Completed|September 2012|November 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|49 Years|75 Years|No|||March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394236||25043|
NCT02413138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14VR5|Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (VRS-317)|A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)||Versartis Inc.|Yes|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|3 Years|10 Years|No|||January 2016|January 14, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02413138||23593|
NCT02426645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mibisep|Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction|Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction||University Hospital Regensburg|No|Recruiting|April 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Blood Urine|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with severe sepsis of abdominal origin within 24h after onset and performed        source control|December 2015|December 1, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426645||22555|
NCT02408900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150106|Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function|A Pilot Study of Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function||National Institutes of Health Clinical Center (CC)||Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Actual|15|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02408900||23919|
NCT02408510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0359|Pilot Project to Examine the Effects of Exercise on Nocturnal Lipolysis in Men and Women|||University of Colorado, Denver|Yes|Recruiting|August 2015|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Adults|December 2015|December 3, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02408510||23949|
NCT02408523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0982|A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications|A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|VALOR|UCB Pharma|Yes|Recruiting|April 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|4 Years|N/A|No|||March 2016|March 14, 2016|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02408523||23948|
NCT02413411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-RO1-AR-054474-5|Race and Preference for Knee Replacement: A Patient-Centered Intervention|Race and Preference for Knee Replacement: A Patient-Centered Intervention|REPAIR|University of Pennsylvania|No|Completed|May 2010|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|493|||Both|50 Years|N/A|No|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413411||23572|
NCT02426671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pearlmutter1|Tinnitus Alleviation Via Sensory Stimulation|Tinnitus Alleviation Via Sensory Stimulation (Modulation of Tinnitus Through Simultaneous Auditory and Transcutaneous Tactile Stimulation of the Tongue)||National University of Ireland, Maynooth|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02426671||22553|
NCT02407288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR G01|tDCS as an add-on Treatment in SSRI-resistant OCD|Transcranial Direct Current Stimulation as an add-on Treatment in SSRI-resistant Obsessive Compulsive Disorder : a Randomized Clinical Trial|TDCS TOC|Hôpital le Vinatier|No|Recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||September 2015|September 9, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407288||24043|
NCT02417857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMMA-LEC-1648.4-70|Comparison of Single İncision Laparoscopic Cholecystectomy Versus Laparoscopic Cholecystectomy|Quality-of-life, Body Image and Cosmesis After Single Incision Laparoscopic Cholecystectomy (SILC) Versus Conventional Laparoscopic Cholecystectomy (CLC)||Ankara Mevki Military Hospital|Yes|Completed|January 2011|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02417857||23230|
NCT02421861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48493-G|Critical Care Anxiety and Long-Term Outcomes Management||CALM|University of Washington||Enrolling by invitation|April 2015|||May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421861||22923|
NCT02421874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R42MH095516|Development and Testing of an Electronic Behavioral Health Record Specific to the Wraparound Care Coordination Process|Development, Usability Testing, and Effectiveness Evaluation of Wraparound Team Monitoring System||University of Washington|Yes|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02421874||22922|
NCT02410681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTA_2012-2015|Sleep Bruxism and (Peri-)Implant Complications|Associations Between Sleep Bruxism and (Peri-)Implant Complications: a Follow-up Study||Academic Centre for Dentistry in Amsterdam|Yes|Recruiting|March 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|98|Samples With DNA|Peri-implant intrasulcular biofilm.|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with implant-supported fixed suprastructure(s), age 18 years or older.|January 2016|January 7, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02410681||23782|
NCT02396459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriacTrial II|Triac Trial II in MCT8 Patients|Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial II||Erasmus Medical Center|Yes|Not yet recruiting|July 2016|December 2022|Anticipated|July 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|N/A|18 Years|No|||January 2016|January 25, 2016|March 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396459||24872|
NCT02396472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarnegieMU|Mental Health Pathways in Internet Support Groups|Internet Support Groups: Identifying and Improving Pathways for Mental Health||Carnegie Mellon University|No|Not yet recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|5||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|March 23, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02396472||24871|
NCT02418104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-1701-04|Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®|A Randomized, Double-Blind, 2-Period Parallel-Arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® in Healthy Subjects||Coherus Biosciences, Inc.|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|303|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418104||23211|
NCT02418351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT/GENESIS/2015/002|A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS||Genesis Limited|Yes|Terminated|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|60 Years|No|||November 2015|November 3, 2015|April 8, 2015||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT02418351||23192|
NCT02420574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B670201319330|Assessment of Drug Efficacy of Local Albendazole|Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia||University Ghent|No|Completed|February 2014|February 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|679|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02420574||23022|
NCT02420587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1049|AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)|Phase 2 Study of AMG 208 Evaluating the Tumor Microenvironment in Metastatic Castration-Resistant Prostate Cancer||M.D. Anderson Cancer Center|No|Withdrawn|October 2014|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||April 2015|April 17, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420587||23021|
NCT02398032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/0252|CPAP in SAHS Patients With Hypertension|CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension|SAHS2-3|Hospital Universitario La Paz|No|Completed|August 2011|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|April 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02398032||24751|
NCT02410447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Defocused Shock Wave Therapy for Chronic Wounds|Defocused Shock Wave Therapy for Chronic Soft Tissue Wounds of the Lower Limbs. A Pilot Study||University of Roma La Sapienza|Yes|Completed|May 2012|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02410447||23800|
NCT02422329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0111|Changes in Patient Reported Constipation|Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2015|||April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422329||22887|
NCT02398344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|'738.356|tDCS Immediate Effect on Cardiorespiratory Parameters in Hemiparetics Adults Patients Due to Stroke.|THE IMMEDIATE EFFECT OF ELECTRICAL STIMULATION TRANSCRANIAL DIRECT CURRENT (tDCS) ON CARDIORESPIRATORY PARAMETERS IN HEMIPARETICS ADULTS PATIENTS DUE TO STROKE||University of Nove de Julho|Yes|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|N/A|No|||December 2015|December 7, 2015|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02398344||24727|
NCT02401880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMLIN-001|Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology|Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment||Profil Institut für Stoffwechselforschung GmbH|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|89|||Both|30 Years|80 Years|No|||February 2016|February 23, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02401880||24455|
NCT02401893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serum 2009|Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults|Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults||Vanderbilt University|No|Completed|September 2009|January 2014|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|510|Samples With DNA|serum samples were collected|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were enrolled at Vanderbilt University Medical Center and Marshfield Clinic        Research Foundation during September and October 2009. Subjects were eligible for        recruitment if they were ≥50 years of age and had no previous allergy or reaction to        influenza vaccination.|March 2015|March 27, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02401893||24454|
NCT02422420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MinnesotaDHS|Minnesota Medicaid Incentives to Prevent Chronic Disease|Minnesota Medicaid Incentives to Prevent Chronic Disease|MMIPCD|Minnesota Department of Human Services|No|Active, not recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1500|||Both|18 Years|74 Years|No|||March 2016|March 14, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422420||22880|
NCT02416206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 1107|High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma|A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma||Northside Hospital, Inc.|No|Recruiting|April 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02416206||23357|
NCT02407418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0280-F1V|The Effects of Spinal Manipulation on Thigh Muscle Strength|The Effects of Lumbosacral Manipulation on Isokinetic Strength of the Knee Extensors and Flexors||University of Kentucky|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|21|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02407418||24033|
NCT02418312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS11-CT12-10|Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer|Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer||Kaohsiung Veterans General Hospital.|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|236|||Both|20 Years|90 Years|No|||February 2016|February 5, 2016|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02418312||23195|
NCT02418325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT/GENESIS/2015/001|A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)||Genesis Limited|Yes|Terminated|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|60 Years|No|||November 2015|November 3, 2015|April 8, 2015||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT02418325||23194|
NCT02421848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U São Paulo|Lean Mass Evaluation of Cirrhotic Patients With Ascites With the Use DXA|Body Composition Evaluation of Cirrhotic Patients With Ascites|BCECPA|University of Sao Paulo|No|Completed|January 2012|December 2014|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Will be selected patients male with liver cirrhosis (n = 112) of the Liver Transplant        Clinic of the Hospital of the Clinicas, Faculty of Medicine, University of São Paulo.|April 2015|April 20, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02421848||22924|
NCT02414308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Management of Peyronie's Disease With Adipose Tissue Stem Cell|The Role of Adipose Tissue Stem Cell Injection Through Corpora Cavernosa and Intra Dorsal Penile Artery in Management of Erectile Dysfunction Associated With Peyronie's Disease||Man Clinic for Andrology, Male Infertility and Sexual Dysfunction|Yes|Recruiting|June 2013|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|January 6, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02414308||23503|
NCT02407704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH090333-04|A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise|A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise|MEDEX|University of Pittsburgh|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|79 Years|No|||January 2016|January 5, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407704||24011|
NCT02413749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 53086|DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA|DC-STAMP and TRAF3: Regulators of Osteoclastogenesis and Biomarkers in Psoriatic Arthritis|Incubator|University of Rochester|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Peripheral blood samples that remain after study assays are completed may be stored for      future non-genetic research.|Both|18 Years|89 Years|No|Non-Probability Sample|Male and female subjects that are 18 years old and older. Due to the demographic        distribution of the disease we expect all or nearly all subjects to be caucasian, however        no subjects will be excluded based on race or ethnic origin.|December 2015|December 7, 2015|April 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02413749||23546|
NCT02413957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14178|Medication Reconciliation in Comparison to an Extensive Medication Safety Check|Pilot Project to Investigate the Influence of Medication Reconciliation and an Extensive Medication Safety Check on the Number of Adverse Drug Events in the Elderly||RWTH Aachen University|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|65 Years|N/A|No|||October 2015|October 27, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02413957||23530|
NCT02422927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPerugia01|Nutraceutical Combination in Patients With Low-grade Systemic Inflammation|Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation||University Of Perugia|No|Completed|July 2014|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|25 Years|75 Years|No|||April 2015|April 16, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422927||22841|
NCT02407977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061601|Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy|Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy||Duke University|No|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Subjects with histologically documented neoplasm of the pelvis (including gynecologic,        gastrointestinal, and genitourinary origin).|December 2015|December 7, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02407977||23990|
NCT02407990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-A317_Study_001|Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors|A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors||BeiGene|No|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407990||23989|
NCT02410720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.35|The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation|The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation: A Randomized Controlled Trial||American University of Beirut Medical Center|Yes|Completed|June 2013|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|July 10, 2013||No||No||https://clinicaltrials.gov/show/NCT02410720||23779|
NCT02413970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001|Inspire® Post-Approval Study / Protocol Number 2014-001|Inspire® Upper Airway Stimulation System (UAS): Post-Approval Study Protocol Number 2014-001||Inspire Medical Systems, Inc.|No|Recruiting|May 2015|December 2021|Anticipated|September 2021|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|127|||Both|22 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413970||23529|
NCT02478697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24RT-0035|Tobacco Treatment for Employable Californians, Total IMPACT Study|Tobacco Treatment for Employable Californians (TTEC), Improving Employability Partnership: Alliance to Curb Tobacco (Total IMPACT)|TTEC|Stanford University|No|Recruiting|October 2015|August 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478697||18558|
NCT02486809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29651|A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)|A Phase I, Randomized, Open-Label, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Bioequivalence Between a High-Concentration Formulation of Lebrikizumab Administered Subcutaneously by a Needle and Syringe and a Low-Concentration Formulation of Lebrikizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD)||Genentech, Inc.||Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486809||17935|
NCT02486822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718 - SLiP|Labor Scale Versus WHO Partograph in the Management of Labor|The Management of Spontaneous Labour in Primigravida (SLiP): Labor Scale Versus WHO Partograph|SLiP|Assiut University|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|35 Years|No|||December 2015|December 28, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486822||17934|
NCT02477683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFDxFIPilot|Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel|Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel||BioFire Diagnostics, LLC||Recruiting|October 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Plasma and Whole Blood|Both|N/A|3 Years|No|Non-Probability Sample|Pediatric patients under the age of 3 with acute fever.|January 2016|January 25, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02477683||18636|
NCT02477696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-006|Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia|A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia||Acerta Pharma BV|Yes|Recruiting|June 2015|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477696||18635|
NCT02465411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMMDI Extension|Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections|Long-term Effects of Continuous Glucose Monitoring in Patients With Type 1 Diabetes Treated With Multiple Daily Insulin Injections - Extension of CGMMDI Trial||Vastra Gotaland Region|No|Enrolling by invitation|June 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02465411||19580|
NCT02484638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL689_2001|Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors|A Multicenter, Open-label, Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors||CSL Behring|Yes|Recruiting|July 2015|May 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|54|||Male|12 Years|65 Years|No|||March 2016|March 3, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484638||18101|
NCT02490397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1607|Impact of Daylight on Patients With Acute Myocardial Infarction|Impact of Daylight on Period 2 Protein and Glycolytic Enzymes in Human Buccal Mucosa and Blood Samples||University of Colorado, Denver|No|Recruiting|July 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02490397||17661|
NCT02490410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-YILI2014-034|Effects of Whey Protein Intervention on Body Composition and Muscle Function in the Elderly With Sacropenia|A Double-blind Randomized Controlled Study About the Effects of Whey Protein Intervention on Body Composition and Muscular Function in the Elderly With Sacropenia||Sun Yat-sen University||Not yet recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|90|||Both|65 Years|N/A|No|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490410||17660|
NCT02488564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST174.09|A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer|Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab With Metformin as Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer|met-HEReMYTA|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|75 Years|No|||December 2015|December 30, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02488564||17800|
NCT02462876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPR14-03|Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)|Post-market Study: Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm||W.L.Gore & Associates|No|Recruiting|October 2015|January 2018|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the        popliteal artery, or presence of mural thrombus (< 2 cm) in the popliteal artery treated        since the date of reimbursement in France.|October 2015|October 21, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462876||19774|
NCT02482636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG2015/03|Baby Vaccine Study (Sched3)|Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines||University of Oxford|No|Recruiting|August 2015|May 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2015|December 22, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02482636||18255|
NCT02482883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00116-41|Evaluation of Transcutaneous Trigeminal Nerve Stimulation for Prevention of Cerebral Vasospasm After Subarachnoid Haemorrhage|Evaluation of the Efficacy of Transcutaneous Trigeminal Nerve Stimulation for Prevention of Cerebral Vasospasm and Its Consequences After Subarachnoid Haemorrhage Due to Ruptured Aneurysm: a Multicentre, Randomized, Double-blind Study|TRIVASOSTIM|Poitiers University Hospital|No|Not yet recruiting|July 2015|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02482883||18236|
NCT02493595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5-1|Synthetic Aperture Radar Detection of Breast Tumours|Post-CE Marking Continuing Evaluation of Multi-Static Microwave Imaging of the Female Breast in Controlled Trial to Identify Optimum Use of the MARIA Platform in the Clinical Workflow|MARIA|Micrima, Ltd.|No|Enrolling by invitation|April 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|90 Years|No|Non-Probability Sample|Female Patients with suspicion of breast lesions attending One-Stop Breast Care diagnostic        clinics|July 2015|July 8, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02493595||17415|
NCT02493608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: L15-144|Scalpel vs Diathermy in Repeat Cesarean Delivery|Scalpel vs Diathermy in Making Abdominal Wall Incision During Repeat Cesarean Delivery||Texas Tech University Health Sciences Center|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493608||17414|
NCT02484820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508059|Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor|PREMAPESSAIRE: Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor: a Prospective, Randomized Monocentric Clinical Trial|PREMAPESSAIRE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|December 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02484820||18087|
NCT02472561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059885|Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)|Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease||Duke University|Yes|Recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|N/A|No|||June 2015|November 2, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472561||19030|
NCT02472574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150403|Dose-effect Relationship of Rt-PA on ICH Evacuation|Phase 2 Study of Rt-PA Dose-effect Relationship on ICH Evacuation||Tongji Hospital|Yes|Active, not recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|80 Years|No|||June 2015|June 11, 2015|May 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472574||19029|
NCT02472587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PelvicPain|Assessing Chronic Pain Conditions in General Population|||University of Cagliari|No|Active, not recruiting|January 2013|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|2500|||Female|18 Years|70 Years|No|Probability Sample|Women attending our institute in order to do Pap test|November 2015|November 22, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02472587||19028|
NCT02488499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/2010-03|Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)|Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)|ABATE|Centre for Addiction and Mental Health|No|Active, not recruiting|July 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|9 Years|12 Years|No|||August 2015|August 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02488499||17805|
NCT02484521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0050-15-EMC|Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration|Characteristics of Prepulse Inhibition (PPI) of Startle Reflex in Patients With Schizophrenia in Relation to Type of Pharmacological Treatment and Duration of Illness||HaEmek Medical Center, Israel|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|160|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02484521||18110|
NCT02484534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC62-14|Thrombin Generation Test in Patient With Liver Cirrhosis|Thrombin Generation Test in Patient With Liver Cirrhosis||HaEmek Medical Center, Israel|No|Recruiting|May 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients (men and women) who are hospitalized in internal and surgical wards with a        diagnosis of cirrhosis of the liver.|June 2015|June 24, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02484534||18109|
NCT02466737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 75|Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery|Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Patients With Early-stage Invasive Breast Cancer and Breast-conserving Surgery: a Randomized Prospective Surgical Trial. Intergroup-Sentinel-Mamma (INSEMA)-Trial|INSEMA|University of Rostock|Yes|Recruiting|September 2015|||September 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|4||Anticipated|7095|||Female|35 Years|N/A|No|||December 2015|December 15, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02466737||19478|
NCT02489630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08302015|Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department|Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department||Carilion Clinic|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|70 Years|No|||July 2015|July 6, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489630||17720|
NCT02488694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-TRK-0114|Maintaining ERBB Blockade in EGFR-mutated Lung Cancer|A Randomized, Open-label, Phase II Study of Maintaining Pan-ERBB Blockade Following Platinum-based Induction Chemotherapy in Patients With EGFR Mutated, Metastatic Non-small-cell Lung Cancer Progressing After First Line Treatment With Afatinib|MARBLE|AIO-Studien-gGmbH|Yes|Recruiting|November 2015|April 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488694||17790|
NCT02488707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISS-TRICR|Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).|Outcomes of Transanal Minimally Invasive TME Versus Laparoscopic Intersphincteric Resection Techniques for Rectal Cancer After Initial Neoadjuvant Chemo-radiotherapy: Double Blinded Study|MISS-TRICR|Mansoura University|Yes|Enrolling by invitation|February 2014|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02488707||17789|
NCT02425085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER201504|Comparative Study of Multi-endodiathermy Retinectomy Versus Relaxing Retinectomy for Retinal Re-detachment|Comparative Study of Multi-endodiathermy Retinectomy Versus Relaxing Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye||Sun Yat-sen University|Yes|Recruiting|April 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|60 Years|No|||April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02425085||22675|
NCT02406885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035495|APB Study: Apixaban Pharmacokinetics in Bariatric Patients|APB Study: Apixaban Pharmacokinetics in Bariatric Patients||Johns Hopkins University|No|Not yet recruiting|April 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|February 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406885||24074|
NCT02416583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWP_PG_N2|Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term|Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term||Seoul National University Hospital|Yes|Recruiting|April 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|N/A|N/A|No|||April 2015|April 14, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02416583||23328|
NCT02418390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1404-050-571|The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma|The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma||Seoul National University Hospital|Yes|Recruiting|April 2015|February 2022|Anticipated|February 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|5750|||Both|20 Years|70 Years|No|||November 2015|November 1, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02418390||23189|
NCT02411097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJGG2014|Role of Femoral Nerve Block on Prevention of Postoperative Deep Venous Thromboembolism|Prevention of Deep Venous Thromboembolism: Effect of Preemptive Analgesic of Femoral Nerve Block in Patients Undergoing Total Knee Arthroplasty||General Hospital of Ningxia Medical University|Yes|Recruiting|September 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|85 Years|No|||March 2015|April 2, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02411097||23750|
NCT02411110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201025-002|A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome|||Allergan|No|Recruiting|May 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|April 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02411110||23749|
NCT02402348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV011614|Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis|Pilot Study of Metformin (MF) IN HNSCC (Head and Neck Squamous Cell Carcinoma) as Window Trial Design in Operable HNSCC, to Investigate the Effects of MF, Tumor Genotype and MF Genotype Interactions, on Tumor Metabolism and Anoikis||West Virginia University|Yes|Recruiting|December 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402348||24419|
NCT02402361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropathic Pain_DM_CTIL|Understanding Risk Factors and Determinants for Neuropathic Pain|Understanding Risk Factors and Determinants for Neuropathic Pain|Neuropathic|Rambam Health Care Campus||Not yet recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|200 patients with painful and non-painful diabetic neuropathy (males and females, ages        ≥18) will be tested in the study performed in the Rambam Medical Center. The patients will        be recruited from the neurology/diabetes clinics and by advertisement in local newspapers.        No patients will be requested to withdraw from any of their medication, or to change the        treatment regimen due to participation in the study.|March 2015|March 27, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402361||24418|
NCT02412605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGD2|Effect of Trophectoderm Biopsy for Sex Selection on the Pregnancy and Miscarriage Rates of Women Undergoing IVF/ICSI|Effect of Trophectoderm Biopsy for Sex Selection on the Pregnancy and Miscarriage Rates of Women Undergoing IVF/ICSI||Cairo University|No|Active, not recruiting|April 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|5000|||Female|20 Years|40 Years|No|Probability Sample|All women who had IVF/ICSI over the past 3 years in Dar AlTeb subfertility centre will be        included in the study|April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412605||23634|
NCT02411032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820768|Fresh Start Experiment|Fresh Start Experiment||University of Pennsylvania|No|Recruiting|April 2015|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Anticipated|15000|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411032||23755|
NCT02411045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819369-1|Dress for Success: Can Just Dressing for the Gym Help Going to the Gym?|Dress for Success: Can Just Dressing for the Gym Help Going to the Gym?||University of Pennsylvania||Completed|April 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|1310|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02411045||23754|
NCT02411396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-1402-11888|Comparison of Patient Centered Outcomes for People With SCD in the Acute Care Setting|PCORI ESCAPED Study: Comparison of Patient Centered Outcomes for People With SCD in the Acute Care Setting|ESCAPED|Johns Hopkins University|No|Recruiting|September 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with SCD inclusive of genotypes homozygous and compound heterozygous sickle        hemoglobin. In the United States, SCD primarily afflicts African-American and        Hispanic-American populations. Patients will be enrolled prior to a vaso-occlusive crisis        and data will be collected from their acute visit(s) at either the Emergency Department or        at an Infusion center (4 participating sites).|February 2016|February 12, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02411396||23727|
NCT02407483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6022|Laparoscopic Training With Laser Guidance Trial|Laparoscopic Simulator Training With or Without Laser Visual Guidance -A Randomized Trial|LVG|Rigshospitalet, Denmark|No|Enrolling by invitation|March 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|April 2, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02407483||24028|
NCT02420002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2013/PF-01|Pediatric Emergency Suture Care: a Trial Comparing the Analgesic Efficacy of Hypnosis Versus MEOPA|Suture Care in the Pediatric Emergency Department: a Randomized Trial Comparing the Analgesic Efficacy of Hypnosis Versus MEOPA|Hypno-Mo|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|17 Years|No|||November 2015|November 17, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420002||23066|
NCT02420054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFAST|Short Term Intermittent Fasting and Insulin Resistance|Effects of Short Term Intermittent Fasting on Insulin Resistance in Type 2 Diabetes|IFAST|University of Copenhagen|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02420054||23062|
NCT02411604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Envarsus® 3007|Expanded Access Study for Renal Transplant Patients With Envarsus XR ™|Expanded Access Study for Renal Transplant Patients With Envarsus XR™: Envarsus 3007||Veloxis Pharmaceuticals||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|January 19, 2016|April 2, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02411604||23711|
NCT02416219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106074|Efficacy of Surface Landmark Palpation for Identification of the Cricoid Cartilage in Obstetric Patients|Efficacy of Surface Landmark Palpation for Identification of the Cricoid Cartilage in Obstetric Patients||Lawson Health Research Institute|Yes|Completed|May 2015|March 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Term Obstetric patients coming for elective cesarean delivery|March 2016|March 2, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416219||23356|
NCT02419820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-TMG-102|Dose-escalation, Repeated and Single Oral Dosing Study|Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel||IlDong Pharmaceutical Co Ltd|No|Enrolling by invitation|March 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|16||Anticipated|144|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|January 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02419820||23080|
NCT02394249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143046|SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance|SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance|SIT LESS 3|Maastricht University Medical Center|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02394249||25042|
NCT02416596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMH-RH1|Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility|Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility: A Randomized Control Trial||Ain Shams Maternity Hospital|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|680|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416596||23327|
NCT02416817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STATA|Strategy of Transfusion in Trauma Patients - STATA Trial|Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital|STATA|University of Sao Paulo General Hospital|No|Recruiting|July 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 23, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02416817||23310|
NCT02413463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHH|Comparison Between Augmented Recession and Posterior Scleral Fixation in Partially Accommodative Esotropia|Comparison Between Augmented Recession and Posterior Scleral Fixation in Partially Accommodative Esotropia||Cairo University|No|Not yet recruiting|April 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||April 2015|April 7, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413463||23568|
NCT02407223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106995|An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis||Janssen Research & Development, LLC||Recruiting|July 2015|June 2020|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|390|||Both|18 Years|50 Years|No|||March 2016|March 15, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407223||24048|
NCT02400229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/294/13|Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease|Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies) - A Pragmatic Randomised Controlled Trial of CT Versus ICA|DISCHARGE|Charite University, Berlin, Germany|Yes|Recruiting|October 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|3546|||Both|30 Years|N/A|No|||October 2015|October 7, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02400229||24582|
NCT02413762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREC019|The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus|The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus||Imperial College London Diabetes Centre|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|2000|Samples Without DNA|Blood plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults resident in the UAE, attending ICLDC for normal healthcare.|March 2015|April 7, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413762||23545|
NCT02397772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1354|Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya|The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya|TUMIKIA|London School of Hygiene and Tropical Medicine|Yes|Recruiting|March 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30000|||Both|2 Years|N/A|Accepts Healthy Volunteers|||October 2014|May 28, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02397772||24771|
NCT02396173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CliniqueRR-03|Does the Knowledge of a "Non-return to Work" Predictive Score Influence Vocational Rehabilitation?|Does the Knowledge of a "Non-return to Work" Predictive Score Influence Vocational Rehabilitation After Orthopaedic Trauma?|WORRK|Clinique Romande de Readaptation|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|280|||Both|18 Years|62 Years|No|||March 2015|March 27, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02396173||24894|
NCT02396186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP785|An Assessment of the Glider Balloon in Complex Lesions|An Assessment of the Glider Balloon in Complex Lesions|ANTELOPE|TriReme Medical, LLC|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All cases of coronary interventions involving the Glider™ PTCA Balloon Catheter at        participating centers will be reviewed for patient eligibility. Patients from all eligible        cases should be invited to sign an IRB-approved Informed Consent.|November 2015|November 3, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396186|2 Days|24893|
NCT02400515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030/2007|Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic Individuals|Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic and Hypertensive Individuals||University of Campinas, Brazil|Yes|Completed|August 2007|June 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02400515||24560|
NCT02421432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0050|Evaluation of the Safety and the Efficacy of Transanal TME in Difficult Cases|A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision in Difficult Cases of Laparoscopic Surgery for Rectal Cancer||National Cancer Center, Korea|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|80 Years|No|||November 2015|November 25, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02421432||22956|
NCT02424383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-14-006|Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter|A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter in Arteries of the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) (SAFE-DCB U.S. Registry)|SAFE-DCB|C. R. Bard|No|Enrolling by invitation|April 2015|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|21 Years|N/A|No|Non-Probability Sample|Peripheral arterial diseases (PAD).|July 2015|July 22, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424383|3 Years|22729|
NCT02393872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|643708|Feel4Diabetes-study|Developing and Implementing a Community-based Intervention to Create a More Supportive Social and Physical Environment for Lifestyle Changes to Prevent Diabetes in Vulnerable Families Across Europe.|Feel4Diabetes|Harokopio University|No|Recruiting|January 2016|August 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|9000|||Both|6 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02393872||25071|
NCT02400762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTO-INQU05-11-14|Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery|A Prospective Study of the Safety and Efficacy of InQu® Bone Graft Extender in Transforaminal and Posterior Lumbar Interbody Fusion Surgery|Intebody|ISTO Technologies, Inc.|No|Recruiting|October 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients who have given consent for and who undergo        standard-of-care single level transforaminal or posterior lumbar interbody fusion surgery        in which InQu Bone Graft Extender is used on-label.|March 2015|March 26, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400762||24541|
NCT02421627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYS2015-01|Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome|Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Recruiting|April 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|January 22, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421627||22941|
NCT02411279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-15|Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations|Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations Derived From Non Intrusive Sensors and Devices|e-INCA|University Hospital, Strasbourg, France|No|Not yet recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Population with heart failure stage II and III|April 2015|April 2, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02411279||23736|
NCT02424357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150111|Suture Contamination Rate in Adjustable Suture Strabismus Surgery|Suture Contamination Rate in Adjustable Suture Strabismus Surgery||Bascom Palmer Eye Institute|Yes|Not yet recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424357||22731|
NCT02424396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130102|Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis|Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study|MS-IL2|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||September 2015|September 17, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424396||22728|
NCT02403128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kishore_Eylea_RAM|Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms|Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms||Illinois Retina and Eye Associates|No|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||July 2015|July 5, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02403128||24361|
NCT02397863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD02|Epidiolex and Drug Resistant Epilepsy in Children|An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy|CBD|Georgia Regents University|Yes|Available|December 2014|January 2020|Anticipated|December 2019|Anticipated|N/A|Expanded Access|N/A|||||||Both|1 Year|18 Years|No|||April 2015|April 23, 2015|March 19, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02397863||24764|
NCT02411877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECCLAIM II-S|REperfusion With Cooling in CerebraL Acute IscheMia II|REperfusion With Cooling in CerebraL Acute IscheMia II|RECCLAIM-II|WellStar Health System|No|Withdrawn|February 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|79 Years|No|||February 2016|February 16, 2016|March 25, 2015|Yes|Yes|It was decided that it was not feasible to continue this study.|No||https://clinicaltrials.gov/show/NCT02411877||23690|
NCT02411890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-AN-6-014/58|Postoperative Pain Between ACB and FNB After ACLR|The Comparison of Postoperative Analgesia Between Adductor Canal Block and Femoral Nerve Block After Arthroscopic ACL Reconstruction With Hamstring Graft: A Randomized Controlled Trial||Thammasat University|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|80 Years|No|||January 2016|January 17, 2016|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02411890||23689|
NCT02412475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epigenetic|Epigenetic Reprogramming in Relapse AML|Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitiabine and Vorinostat Followed by Fludarabine, Cytarabine, Liposomal Daunorubicin, and G-CSF (FLAG -Lipo Dauno) in Children and Young Adults With Relapsed/Refractory AML||Medical College of Wisconsin|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|25 Years|No|||January 2016|January 22, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412475||23644|
NCT02412488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1, 19 February 2015|Reveal LINQ™ In-Office 2 (RIO 2) Study International|Reveal LINQ™ In-Office 2 (RIO 2) International Study|RIO 2|Medtronic Cardiac Rhythm Disease Management|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|255|||Both|18 Years|99 Years|No|||October 2015|October 1, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412488||23643|
NCT02403414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-397/14-11-2014|Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation|Assessment of Airway in Patients With Acromegaly Undergoing Surgery: Predicting Successful Tracheal Intubation||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with Acromegaly|December 2015|December 29, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02403414||24339|
NCT02409875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-2010|The Early Stockholm Obesity Prevention Project in China|Baby-STOPP: Targeted Obesity Prevention Directed to Overweight Parents With Young Children|ES-China|Huazhong University of Science and Technology|No|Active, not recruiting|February 2011|October 2016|Anticipated|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Families living in Wuhan city, having an one year old child, willing to participanted are        welcomed to the study. A total of 300 simple size with half high-risk group and half in        low-risk group is anticipated.|April 2015|April 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409875||23844|
NCT02412137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112007-014|Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis|Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis||Texas Scottish Rite Hospital for Children|Yes|Completed|December 2007|March 2015|Actual|March 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|245|||Both|N/A|18 Years|No|||April 2015|April 14, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02412137||23670|
NCT02420990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-1403-13704|Integrated Treatment for Adolescents With ADHD|Randomized Comparison of Evidence-Based Protocols for Adolescents With ADHD in Specialty Care: Behavioral Only Versus Integrated Behavioral and Medication Interventions|CASALEAP IT2A|The National Center on Addiction and Substance Abuse at Columbia University|No|Recruiting|April 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|12 Years|18 Years|No|||February 2016|February 26, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02420990||22990|
NCT02395887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc0297-14CTIL|Postural Balance and Stability Among Patients With Cervical and Back Pain|Postural Balance and Stability Among Patients With Cervical and Back Pain||Meir Medical Center|No|Not yet recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|80 patients, men and women above 18, which suffer from back or neck pain and are        candidates for an operational intervention.|March 2015|March 24, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02395887||24916|
NCT02400476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA-NER-6201|A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide|||Puma Biotechnology, Inc.||Recruiting|February 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400476||24563|
NCT02420808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAETHON|An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study|An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study|PHAETHON|Hellenic Cardiovascular Research Society|Yes|Completed|March 2012|January 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|800|||Both|25 Years|N/A|No|Non-Probability Sample|Patients with ACS|April 2015|April 17, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420808||23004|
NCT02420821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29637|A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma|A Phase III, Open-Label, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma||Hoffmann-La Roche||Recruiting|May 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|830|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420821||23003|
NCT02410798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 20-1000-0006|Clinical Study to Investigate Safety and Performance of TransLoc Electrodes in Patients Undergoing Surgical Procedures|Early Feasibility Clinical Study to Investigate the Safety and Performance of TransLoc® Electrodes for Temporary Diaphragm Pacing in Patients Undergoing Surgical Procedures||Synapse Biomedical|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410798||23773|
NCT02409966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552264/2011-3|Effect of Periodontitis Treatment on Quality of Life and Experiences of Fear, Anxiety and Pain|Impact of Different Protocols for Treatment of Chronic Periodontitis on the Following Patient-centered Variables: Oral Health Related Quality of Life and Experiences of Fear, Anxiety and Pain: a 6 Month Randomized Clinical Trial||University of Taubate|No|Completed|February 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||March 2015|April 6, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02409966||23837|
NCT02409069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/0249|Influence of Non-invasive Neurostimulation (Transcutaneous Vagus Nerve Stimulation) on 1. the Noradrenergic Release in the Brain and 2. a Neuropsychological Memory Task|||University Hospital, Ghent|Yes|Recruiting|March 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02409069||23906|
NCT02421185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106971|Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Participants With Advanced Hepatocellular Carcinoma|A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma||Janssen Research & Development, LLC|No|Recruiting|May 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02421185||22975|
NCT02421419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 001858|Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture|Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture||Milton S. Hershey Medical Center|No|Enrolling by invitation|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|221|||Both|18 Years|90 Years|No|||June 2015|June 15, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421419||22957|
NCT02418169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T74/2015|Association Between Craniofacial Fractures and Brain Injuries: Diagnostic and Therapeutic Considerations|Association Between Craniofacial Fractures and Brain Injuries: Diagnostic and Therapeutic Considerations||Turku University Hospital|No|Not yet recruiting|May 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Patients with severe traumatic brain injury, patients with craniofacial fractures|April 2015|April 15, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418169|1 Year|23206|
NCT02423512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0651|The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness|The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Whole blood, serum, mucosal tissue|Both|18 Years|N/A|No|Non-Probability Sample|Male and female adults with a diagnosis of inflammatory bowel disease who will be started        on vedolizumab therapy as clinically indicated and in discussion with their treating        physician will be eligible. Patients will not be started on vedolizumab for the sole        purpose of this study|January 2016|January 5, 2016|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423512||22796|
NCT02396446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039256|AbStats at the Bedside|AbStats at the Bedside: Improving Patient Feeding Decisions Using an Abdominal Acoustic Score||Cedars-Sinai Medical Center|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Inpatients at CSMC|August 2015|August 3, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02396446||24873|
NCT02396732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140937|Aspirin and Enoxaparin for VTE in Trauma|The Role Of Combined Therapy With Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial||University of Miami|Yes|Not yet recruiting|October 2015|||May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02396732||24851|
NCT02414659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Effects of In-utero Cord Blood Collection on Post-operative Hemoglobin Levels|Effects of In-utero Cord Blood Collection on Post-operative Hemoglobin Levels||Ankara University|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|399|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Elective cesarean deliveries|June 2015|June 22, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02414659||23476|
NCT02418416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbnSina Hospital IVF|Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor|||Ibn Sina Hospital|No|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|284|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418416||23187|
NCT02422459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-472|Chronic Pain Self-management Support With Pain Education and Exercise|Chronic Pain Self-Management Support With Pain Education and Exercise (COMMENCE): A Randomized Controlled Trial|COMMENCE|McMaster University|No|Recruiting|September 2013|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02422459||22877|
NCT02483143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/47|NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial|N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial||Karadeniz Technical University|No|Completed|February 2014|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|231|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02483143||18216|
NCT02492295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4616|Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department|Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department||Albert Einstein Healthcare Network|Yes|Recruiting|August 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|65 Years|No|||July 2015|July 6, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492295||17515|
NCT02465424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QaLM|Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients|Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients|QaLM|Velindre NHS Trust|No|Not yet recruiting|December 2015|April 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Both|16 Years|N/A|No|Non-Probability Sample|Medullary thyroid cancer patients who are attending a thyroid cancer clinic in tertiary        care setting in the NHS|December 2015|December 7, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465424||19579|
NCT02487771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11406|Kansas University DHA Outcome Study (KUDOS) Follow-Up|Kansas University DHA Outcome Study (KUDOS) Follow-Up||University of Kansas Medical Center|No|Active, not recruiting|July 2008|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487771||17861|
NCT02484469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial|Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting||Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484469||18114|
NCT02484482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148FDI15009|Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)|A Randomized, Open-label, Single Dose, 3-treatment, 3-period, 6-sequence Crossover Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519 After Oral Administration in Healthy Adult Volunteers||Chong Kun Dang Pharmaceutical||Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|45|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02484482||18113|
NCT02480621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|623477-4|Liposomal Bupivacaine With Bupivacaine in Ankle Fracture ORIF|The Impact of Liposomal Bupivicaine on Post-Operative Pain in Orthopaedic Trauma Surgery: A Double-Blind Prospective Randomized Control Trial||Jamaica Hospital Medical Center|Yes|Recruiting|December 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480621||18410|
NCT02467036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131519|Family Based Treatment for Weight Loss With Breakfast Prescription|A Pilot Study Examining the Impact of Eggs for Breakfast on Weight Loss and Hunger in Obese Children|FAB|University of California, San Diego|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02467036||19455|
NCT02480816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-13|Cardiometabolic Response to a Sodium-bicarbonated Mineral Water|||National Research Council, Spain||Completed|March 2014|||November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480816||18395|
NCT02480829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220-001|Cystoscopic Ablation Via RF Energy Clinical Trial (CARET 2)|Cystoscopic Ablation Via RF Energy Clinical Trial (CARET 2)||Amphora Medical, Inc.|Yes|Active, not recruiting|June 2015|September 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|80 Years|No|||September 2015|September 17, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480829||18394|
NCT02493374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504M69662|Mitigation of Type 2 Diabetes by Partial Ileal Bypass|Mitigation of Type 2 Diabetes in Hypercholesterolemic Patients Undergoing a Partial Ileal Bypass||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|July 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|Samples Without DNA|blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals in need of lipid modification but are intolerant of statin drugs who are        referred for a partial ileal bypass (PIB) operation, still the most efficacious means to        treat hyperlipidemia. In the subgroup of these patients who also have type 2 diabetes,        with a functioning pancreas, we hope to perform a pilot study on the effect of PIB on type        2 diabetes.        Study blood tests:          -  Pre-PIB and at 3 month intervals postop fasting blood samples for glucose, hemoglobin             A1c, insulin, C-peptide, GLP-1, ghrelin, and glucagon.          -  Pre-PIB, 6, and 12 month intervals postop: oral glucose tolerance test consisting of             determination of blood glucose, insulin, C-peptide, GLP-1, ghrelin, and glucagon at             30, 60, 90, and 120 minutes after a mixed oral meal.|July 2015|July 22, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493374||17432|
NCT02487225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001710|Pentoxifylline Treatment in Acute Pancreatitis (AP)|Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial|AP|Mayo Clinic|Yes|Enrolling by invitation|May 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|100 Years|No|||January 2016|January 15, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487225||17903|
NCT02487485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504015604|Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects|Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects||Yale University|Yes|Not yet recruiting|August 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487485||17883|
NCT02493634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N4IPMCF2015|Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire|Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire|MRWIREPMCF|Nano4Imaging GmbH|No|Recruiting|August 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|25|||Both|N/A|N/A|No|||March 2016|March 2, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02493634||17412|
NCT02490579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00101358|Effectiveness of Video Messaging About Diet, Exercise and Weight Gain in Pregnancy in Regional and National Samples|Effectiveness of Video Messaging About Diet, Exercise and Weight Gain in Pregnancy in Regional and National Samples||University of Michigan|No|Recruiting|May 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1670|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women recruited via either the social media, clinical, or online approach will be eligible        for participation if they are aged 18 years and older, pregnant, and English-speaking.        Women will be excluded if they deny being currently pregnant, do not identify as living in        the US and aged 18 years or older, or if they report having previously participated in the        study. The Qualtrics survey will automatically conclude if potential participants provide        answers to screening questions that deem them ineligible. Participants will not be        excluded based on racial-ethnic groups. Males will be excluded, as this is a study        involving pregnant women.|September 2015|September 3, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490579||17647|
NCT02472821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F037851-00|Test of Hearing Health Education Programs for Farm and Rural Youth|Test of Hearing Health Education Programs for Farm and Rural Youth|FARMYOUTHEAR|University of Michigan|No|Recruiting|April 2015|November 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|2000|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472821||19010|
NCT02472834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P-000562|Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy|Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease: A Randomized Trial|CarRAAT-2|Massachusetts General Hospital|Yes|Recruiting|February 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472834||19009|
NCT02479204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-064-102|Drug Interaction Study of ACT-334441 With Cardiovascular Medications in Healthy Subjects|Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects||Actelion|No|Suspended|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|32|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479204||18519|
NCT02493673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0684|The Effects of CPAP Withdrawal on Cerebral Vascular Reactivity and Brain Oxygenation in OSA|The Effects of Continuous Positive Airway Pressure Therapy Withdrawal on Cerebral Vascular Reactivity and Brain Oxygenation in Patients With Obstructive Sleep Apnoea: A Randomised Controlled Trial||University of Zurich||Recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|42|||Both|20 Years|75 Years|No|||February 2016|February 3, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02493673||17409|
NCT02414529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-03213|Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents|Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents||New York University School of Medicine|Yes|Completed|November 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02414529||23486|
NCT02410252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-485|Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies|Use Feasibility of the iThermonitor in Pediatric Patients on Myelosuppresive Therapies for Acute Leukemia and Other Childhood Cancers||Massachusetts General Hospital|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|2 Years|17 Years|No|||October 2015|October 28, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410252||23815|
NCT02410278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS414|Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera|A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules|MITIGATE|Biogen|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||October 2015|January 8, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02410278||23813|
NCT02419937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKE20140029H|Short-Term Application of Tocilizumab Following Myocardial Infarction|Short-Term Application of Tocilizumab Following Myocardial Infarction|STAT-MI|Keesler Air Force Base Medical Center|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|89 Years|No|||January 2016|January 1, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02419937||23071|
NCT02407431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRN-1306-04912 IRB00060773|PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort|PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort||University of Pittsburgh|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|100 Years|No|Non-Probability Sample|The target study population is adults with IPF who receive health care at one of the PaTH        Network institutions.|November 2015|November 30, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02407431|10 Years|24032|
NCT02408328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015842|Management of Apnea in Late Preterm and Term Infants|Management of Apnea in Late Preterm and Term Infants||Children's Hospital Boston|Yes|Not yet recruiting|April 2015|April 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|3 Months|No|||April 2015|April 2, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408328||23963|
NCT02416115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUMC-14-1037|Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia|Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia After Gynecologic Surgery||Kyungpook National University|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Female|N/A|N/A|No|||April 2014|February 19, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02416115||23364|
NCT02415673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMA887599|Alignment Efficiency of Two Thermal Activated Orthodontic Archwire Sequences|Alignment Efficiency of Two Thermal Activated Orthodontic Archwire Sequences Based on Transition Temperature Range: A Randomized Clinical Trial||Faculty Sao Leopoldo Mandic Campinas|Yes|Completed|August 2010|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415673||23398|
NCT02415998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207769|Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients|Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients||University of Iowa|No|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric population going under cardiac surgery|November 2015|November 30, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02415998||23373|
NCT02393950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3117001|Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males|FIMPAM|Orion Corporation, Orion Pharma|Yes|Active, not recruiting|March 2015|February 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02393950||25065|
NCT02422290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7023|Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)|Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)||New York State Psychiatric Institute|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|14 Years|20 Years|No|||December 2015|December 8, 2015|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422290||22890|
NCT02412878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFZ014|A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)|A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing||Onyx Pharmaceuticals|Yes|Recruiting|September 2015|July 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02412878||23613|
NCT02415920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02448|The Influence of Intranasal Oxytocin on Communication|The Influence of Intranasal Oxytocin on Communication||University of British Columbia|No|Not yet recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02415920||23379|
NCT02420782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6282-CL-0001|First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology|A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6282 in Healthy Nonelderly and Elderly Male and Female Subjects, Including a Food Effect Cohort and Drug-drug Interaction Cohort With Itraconazole||Astellas Pharma Inc|No|Recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|10||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420782||23006|
NCT02426619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW12-490|Arresting Active Dental Caries in Preschool Children by Topical Fluorides|A Randomized Clinical Trial on the Use of Sodium Fluoride Varnish and Silver Diamine Fluoride Solution for Arresting Active Dental Caries in Preschool Children||The University of Hong Kong|Yes|Completed|September 2012|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|371|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02426619||22557|
NCT02399202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C2104|A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function|A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function||Novartis|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399202||24661|
NCT02399215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 259114|Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors|Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors||Roswell Park Cancer Institute|Yes|Recruiting|May 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399215||24660|
NCT02420249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410159001|Qigong for Breast Cancer Survivors|Randomised Controlled Trial of Qigong Training Programme to Alleviate Arm Oedema, ¬Reduce Shoulder Impairment, Improve Body Balance and Quality of Life in Community-dwelling Breast Cancer Survivors||The University of Hong Kong|Yes|Recruiting|March 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||December 2015|December 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02420249||23047|
NCT02420262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4185|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Active, not recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420262||23046|
NCT02417376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCD-010/55/2013|Changes in the Risk Factors of Coronary Heart Disease Observed After Scaling and Root Planing|Effect of Nonsurgical Periodontal Treatment on Systemic Risk Markers of Cardiovascular Disease Clinically and Biochemically: A Randomized Trial||Government College of Dentistry, Indore|No|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|35 Years|N/A|No|||April 2015|April 14, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02417376||23267|
NCT02397512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2014-0358|Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition|Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition|Lactulose|University of Zurich|No|Recruiting|February 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397512||24791|
NCT02407717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChietiOnco2|Venous Thromboembolism and Bleeding in Hospitalized Medical Patients With Cancer|Venous Thromboembolism and Bleeding in Hospitalized Medical Patients With Cancer||G. d'Annunzio University|No|Recruiting|January 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|715|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cancer hospitalized for an acute medical illness|March 2015|March 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02407717||24010|
NCT02407730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFORT|EFFects of Thrombophilia on the Outcomes of Assisted Reproduction Technologies|EFFects of Thrombophilia on the Outcomes of Assisted Reproduction||G. d'Annunzio University|No|Recruiting|January 2015|June 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|715|||Female|18 Years|N/A|No|Non-Probability Sample|All women 18 years or older undergoing ART|March 2015|March 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02407730||24009|
NCT02417324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-HIT-MED Registry|International HIT-MED Registry (I-HIT-MED)|International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|January 2015|December 2024|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Tumour samples|Both|N/A|N/A|No|Non-Probability Sample|Children and adults with          -  Medulloblastoma (MB)          -  Ependymoma          -  CNS-primitive neuroectodermal tumours (CNS-PNET) including CNS neuroblastoma, CNS             ganglioneuroblastoma, Medulloepithelioma, Ependymoblastoma, CNS-PNET not otherwise             specified (NOS)          -  Pineoblastoma          -  Pineal parenchymal tumour of intermediate differentiation          -  Papillary tumour of the pineal region Who are not included in prospective clinical             trials for these conditions|December 2015|December 2, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02417324|5 Years|23271|
NCT02417558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84171-B|Cognitive/Physical Computer-Game Blended Training With Personalized Brain Network Activation Technology for the Elderly|Study to Evaluate the Effectiveness of Personalized Brain Network Activation Technology in a Cognitive/Physical Computer-Game Blended Training of Elderly (Alterniity AR)|AlterniityAR|XtremeVRI AG|No|Enrolling by invitation|February 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Anticipated|800|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02417558||23253|
NCT02417623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/07 IDIAP|Smartphone Application for Weight Loss|Efficacy of a Mobile Application for Weight Loss in Overweight and Obese Adults: A Randomized Controlled Trial|OBSBIT|Jordi Gol i Gurina Foundation|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02417623||23248|
NCT02401802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIETCOL|Low-fiber Diet for Colorectal Cancer Screening Colonoscopy|Low-fiber Diet for Colorectal Cancer Screening Colonoscopy. Randomized Clinical Trial. Dietcol Study|DIETCOL|Parc de Salut Mar|No|Active, not recruiting|January 2015|November 2015|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|276|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02401802||24461|
NCT02407795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45994.091.14|Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases|A RAndomized Trial Comparing COnventional With STereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases (RACOST-trial)|RACOST|Radboud University|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|386|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407795||24004|
NCT02410993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0063|Current Treatment Strategy of Patients With Multivessel Disease or Left Main Coronary Artery Disease Indicated for Coronary Artery Bypass Graft Surgery|||Yonsei University|No|Not yet recruiting|April 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|19 Years|N/A|No|Non-Probability Sample|Hospital-based, full-service hospitals with capability of both PCI and CABG surgery in        addition to cardiac catheterization|April 2015|April 3, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02410993||23758|
NCT02415036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-HCC-202|Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma|An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma||Delcath Systems Inc.|No|Recruiting|June 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415036||23447|
NCT02415049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pyloric-1|A Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy|A Prospective Randomized Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy||Indiana University|Yes|Recruiting|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|10 Weeks|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02415049||23446|
NCT02398019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRAKI 01-2014|Clinical Trial to Evaluate the Use of an Adsorption Membrane (OXIRIS®) During Cardiopulmonary Bypass Surgery|Clinical Trial to Evaluate Facticity and Security for the Use of an Increased Adsorption Capacity Membrane (OXIRIS®) During Cardiopulmonary Bypass Surgery||Hospital Universitari de Bellvitge|Yes|Completed|March 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02398019||24752|
NCT02407860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-116|Efficacy of an Osteopathic Treatment for Mechanical Sucking Dysfunctions in Newborn|Efficacy of an Osteopathic Treatment for Mechanical Sucking Dysfunctions in Newborn||Université de Sherbrooke|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|98|||Both|N/A|6 Weeks|Accepts Healthy Volunteers|||December 2015|December 21, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02407860||23999|
NCT02411292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00079118|Enoxaparin Metabolism in Reconstructive Surgery Patients|Enoxaparin Metabolism in Reconstructive Surgery Patients||University of Utah|Yes|Recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02411292||23735|
NCT02407314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10020|Ticagrelor and Peripheral Arterial Disease|Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography||Arkansas Heart Hospital|Yes|Recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407314||24041|
NCT02417805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-266-2|Cutaneous Microcirculation After Remote Ischemic Preconditioning|Effects of Remote Ischemic Preconditioning in Cutaneous Microcirculation of Different Wounds||University of Schleswig-Holstein|No|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02417805||23234|
NCT02415985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 116|Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly|A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients||The HIV Netherlands Australia Thailand Research Collaboration|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2016|February 19, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02415985||23374|
NCT02407366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGSLC-2015|Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer|A Phase 2 Study of Icotinib With Concurrent Radiotherapy vs. Pemetrexed+ Carboplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation||People's Hospital of Guangxi|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02407366||24037|
NCT02394002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013071151|SEP Changes During Deep Anesthesia|The Effect of Burst-suppression-pattern in EEG on Generating Somatosensory Evoked Potentials|SEPinBSP|Heinrich-Heine University, Duesseldorf||Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394002||25061|
NCT02394015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICO 1402R|Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC|Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet|RETRO-ROC|Grupo Español de Investigación en Cáncer de Ovario|No|Not yet recruiting|March 2015|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|80|||Female|N/A|N/A|No|Non-Probability Sample|Patients who have received treatment with trabectedin - DLP for recurrent ovarian cancer        according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been        included in clinical trials where the IMP was trabectedin.|March 2015|March 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02394015||25060|
NCT02416154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1108501|Expression of IFN-epsilon in the Female Reproductive Tract|IFN-epsilon and Hormonal Contraceptive Modulation of the Risk of HIV Acquisition, Part 1: Expression in the Female Reproductive Tract|Epsilon|University of Pittsburgh|No|Recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|32|Samples Without DNA|whole blood plasma vaginal swabs cervical swabs Vaginal fluid collected by sponge      cervicovaginal lavage fluid cervical cells collected by cytobrush vaginal biopsies cervical      biopsies endometrial biopsies|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy females aged18 through 35 years (inclusive) at screening|February 2016|February 9, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02416154||23361|
NCT02427178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1718|MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study|MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study|MASS|Columbia University|Yes|Recruiting|March 2015|June 2023|Anticipated|June 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|5 Years|55 Years|No|||December 2015|December 17, 2015|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02427178||22514|
NCT02405429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404832|Temporal Artery Temperature Measurement in Neonates|Comparing Temporal Artery and Axillary Temperatures With Rectal Temperature in Neonates||University of Iowa|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|52|||Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Hospital nursery patients|March 2015|March 27, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02405429||24184|
NCT02405442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-395-1663|Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease|A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease||Gilead Sciences|Yes|Recruiting|April 2015|September 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|175|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405442||24183|
NCT02414737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU/1/2 C8B110|Ovarian Stimulation Single Injection Elonva|Ovarian Stimulation Single Injection Elonva- The OSSIE Study|OSSIE|Flinders Fertility|No|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|37 Years|No|||February 2016|February 1, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414737||23470|
NCT02414750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14REP|Vemurafenib Plus Cobimetinib in Metastatic Melanoma|A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics|REPOSIT|Netherlands Working Group on Immunotherapy of Oncology|No|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02414750||23469|
NCT02395081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0591-02|Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia|Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia||Brigham and Women's Hospital|Yes|Recruiting|February 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|360|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02395081||24978|
NCT02397577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2013-0338|Reference Values for Gastric Emptying|Normal Values for Gastric Emptying in a 13C-octanoate Breath Test Using a Solid Test Meal|13C|University of Zurich|No|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02397577||24786|
NCT02410733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB_0003-01|Evaluation the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma|Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma|Lipo-MERIT|Biontech RNA Pharmaceuticals GmbH|Yes|Recruiting|March 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02410733||23778|
NCT02422355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR FNS|A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures|A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures|FR_FNS|AO Clinical Investigation and Documentation|No|Not yet recruiting|June 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02422355||22885|
NCT02414815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0685|Reverse Prediction of Ion Channel Remodeling in Patients With Atrial Fibrillation Utilizing Monophasic Action Potential and Mathematical Modeling|Reverse Prediction of Ion Channel Remodeling in Patients With Atrial Fibrillation Utilizing Monophasic Action Potential and Mathematical Modeling||Yonsei University|Yes|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|19 Years|75 Years|No|||April 2015|April 7, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02414815||23464|
NCT02410005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00039|Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)|Kidney Disease in Type 2 Diabetes Mellitus: Biomarker Discovery and Novel Therapeutics|IDEAL|Weill Cornell Medical College in Qatar|Yes|Recruiting|October 2014|October 2017|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|80 Years|No|||January 2016|January 17, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02410005||23834|
NCT02401568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00845-42|Morphologic and Biomechanical Analysis of the Carpal Ligaments|Morphologic and Biomechanical Analysis of the Carpal Ligaments: a Kinematic Study on Dynamic Area Detector CT|EDLIS|Central Hospital, Nancy, France|No|Recruiting|February 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02401568||24479|
NCT02401581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-07|Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours|Study ¨PRECOCE Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours|PRECOCE|Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Male|45 Years|80 Years|No|||March 2015|March 24, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02401581||24478|
NCT02419144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-188-6|Good Oral Health - A Bi-level Intervention to Improve Older Adult Oral Health|||University of Connecticut Health Center|No|Not yet recruiting|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02419144||23132|
NCT02419157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGRE 2015|Selective Enamel Etching in Self-etching Adhesives: a 2-year Clinical Trial|Effectiveness of One- and Two-step Self-etching Adhesives Applied With or Without Selective Enamel Etching: a 2-year Randomized Controlled Clinical Trial||University of Guarulhos|Yes|Completed|October 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02419157||23131|
NCT02422472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000073|Comparison of Ultrasound Guided Peripheral IV Placement With and Without Use of a Guidewire|Comparison of Ultrasound Guided Peripheral IV Placement With and Without Use of a Guidewire||Brigham and Women's Hospital|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02422472||22876|
NCT02487264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1125|Analysis of the Status, Treatment and Outcomes of Rib Fractures|Analysis of the Status, Treatment and Outcomes of Rib Fractures||Milton S. Hershey Medical Center|No|Active, not recruiting|June 2013|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|921|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients presenting during 2010-2012 with multiple rib fractures to PSHMC emergency        department|March 2016|March 17, 2016|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02487264||17900|
NCT02487277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144515|PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma|Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma||University of California, San Francisco|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487277||17899|
NCT02479568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITRUS 14-12|Beneficial Impact of Orange Juice Consumption on Risk Factors Associated With Cardiovascular Diseases|Randomized, Parallel and Double Blind Placebo-controlled Study for the Evaluation of Both Acute and Chronic Role of Hesperidin Consumption in 100% Orange Juice|CITRUS|Technological Centre of Nutrition and Health, Spain|No|Recruiting|September 2015|January 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|252|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479568||18491|
NCT02479828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7533|Fascia Iliaca Compartment Block in Acute and Chronic Pain Management in Hip Fracture Patients|The Effect of Fascia Iliaca Compartment Block in Acute and Chronic Pain Management in Hip Fracture Patients||Asklepieion Voulas General Hospital|No|Recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|90 Years|No|||January 2016|January 9, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02479828||18471|
NCT02470299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1420|Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients|A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients||New Mexico Cancer Care Alliance|Yes|Recruiting|October 2015|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470299||19204|
NCT02489812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFMG|Music Distraction Strategy in Children Dental Care|||Federal University of Minas Gerais|Yes|Completed|March 2014|April 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02489812||17706|
NCT02488161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/00314|Factors Related to Adverse Events in Colorectal Cancer|Risk Factors of Adverse Outcomes at Short and Medium Term, and Development of Predictive Models, in Patients With Colorectal Cancer. IRYSS-coordinated Multicenter Study|CARESS-CCR|Hospital Galdakao-Usansolo|Yes|Active, not recruiting|June 2010|December 2017|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2600|None Retained|Fragments of colon or rectum obtained in the surgical intervention|Both|18 Years|N/A|No|Non-Probability Sample|This prospective cohort study included patients drawn from 22 hospitals belonging to the        Spanish National Health Service (SNS), which covers the majority (99.8%) of the population        of Spain. All covered residents have free access to their primary care physician and to        the ED of the hospitals. All of the hospitals have similar technological and human        resources.        Patients with a diagnosis of colon or rectum cancer attending the surgical services of any        of these hospitals to undergo surgery between June 2010 and December 2012 were informed of        the goals of the study and invited to voluntarily participate.|June 2015|July 1, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02488161||17831|
NCT02484547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221AD302|221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease|EMERGE|Biogen|Yes|Recruiting|September 2015|February 2022|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1350|||Both|50 Years|85 Years|No|||February 2016|March 18, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484547||18108|
NCT02472847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0242|Cannabinoid Control of Fear Extinction Neural Circuits in Humans|Cannabinoid Control of Fear Extinction Neural Circuits in Humans||University of Illinois at Chicago|No|Completed|May 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|85|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 12, 2015|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT02472847||19008|
NCT02486159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0938B|The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture|The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture||Chang Gung Memorial Hospital|Yes|Completed|September 2009|August 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|45 Years|No|||June 2015|July 1, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02486159||17985|
NCT02486172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE Ref. No. 2014.513_FR|Multi-centre Peer Support Program in Type 2 Diabetes Patients in Hong Kong|Development and Evaluation of A Peer Support Program for Type 2 Diabetes Patients in Hong Kong as Quality Improvement in Diabetes Care Service||Chinese University of Hong Kong|No|Not yet recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|434|||Both|18 Years|75 Years|No|||June 2015|June 26, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486172||17984|
NCT02485418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propofol2014|Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients|Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients||University of Texas Southwestern Medical Center|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|18 Years|No|||June 2015|June 25, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485418||18041|
NCT02475772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPAC-OV2|A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis|A Phase I, Single-arm, Open-label, Three Step Dose Escalation Study With Intraperitoneal Pressurized Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis||Ruhr University of Bochum|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|80 Years|No|||January 2016|January 19, 2016|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02475772||18783|
NCT02475785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU001|Evaluation of Mini Plates Anchorage With Forsus Fatigue Resistant Device|Evaluation of Mini Plates Anchorage in Conjunction With Forsus Fatigue Resistant Device for Correction of Skeletal Class II Malocclusion in Growing Subjects: A Randomized Controlled Trial||Cairo University|No|Active, not recruiting|January 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Female|10 Years|13 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02475785||18782|
NCT02489591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957|Characterizing Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea|Characterizing Site and Severity of Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea||Brigham and Women's Hospital|No|Recruiting|June 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|21 Years|70 Years|No|||January 2016|January 11, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489591||17723|
NCT02481115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121252|Validation of the PreSchool Confusion Assessment Method for the Intensive Care Unit (psCAM-ICU)|Pediatric Delirium in Infants and Young Children: Validation of the PreSchool Confusion Assessment Method for the Intensive Care Unit (psCAM-ICU)||Vanderbilt University|No|Active, not recruiting|February 2013|December 2015|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|6 Months|5 Years|No|Probability Sample|Critically ill pediatric patients at least 6 months to children 5 years of age, both on        and off mechanical ventilation|June 2015|June 22, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02481115||18372|
NCT02481180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T0001-P2.0|Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)|An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance、Pharmacokinetics、Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Not yet recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02481180||18367|
NCT02475837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33763|Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access|A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access||Stanford University|Yes|Not yet recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475837||18778|
NCT02483403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0003|Longitudinal 3He Magnetic Resonance Imaging of Healthy Lung|Longitudinal 3He Magnetic Resonance Imaging of Healthy Lung||Western University, Canada|No|Recruiting|September 2010|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|180|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483403||18196|
NCT02481388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jasiel02|Optoelectronic Pletysmography and Diaphragmatic Thickness in Heart Failure Patients|Effect of Cardiomegaly Associated With Inspiratory Muscle Weakness on Diaphragm Thickness and Chest Wall Volume Distribution in Patients With Heart Failure||Universidade Federal de Pernambuco|No|Recruiting|May 2014|||January 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|14|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with heart failure|June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481388||18351|
NCT02418208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-25|Normative Data Base of Brain Network Activation (BNA) Using Evoked Response Potentials|Clinical Trial Protocol for the Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents, Young Adults and Adults|Normative|ElMindA Ltd|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1500|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 1500 subjects, from both genders, aged 10 years and above will be recruited,        stratified to age groups.|January 2016|January 25, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02418208||23203|
NCT02398058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMAS|Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)|A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies|TOMAS|Italian Sarcoma Group|Yes|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02398058||24749|
NCT02422134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibnsina IVF Sohag|Novel Approach for Embryo Transfer Medium by Adding Cytokine to Hyaluronan Enriched Embryo Transfer Medium (Embryo Glue)|||Ibn Sina Hospital|No|Recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Female|18 Years|40 Years||||April 2015|April 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02422134||22902|
NCT02422147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|723324|EUS-guided Ablation of Pancreatic Cyst Neoplasms|EUS-guided Ablation of Pancreatic Cyst Neoplasms||Florida Hospital|No|Not yet recruiting|April 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Any male or female presenting to Florida Hospital Center for Interventional Endoscopy with        a pancreatic cyst will be considered for this registry pending he/she meets        inclusion/exclusion criteria.|April 2015|April 20, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02422147|12 Months|22901|
NCT02421445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.23 NRC|Analyses of Human Milk From Mother Delivering Small for Gestational Age (SGA) and Appropriate for Gestational Age (AGA) Infants|An Observational Study to Characterize Human Milk From Mothers Delivering Term SGA and AGA Infants.||Nestlé|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Healthy (normal BMI) and undernourished (low BMI) women volunteers|October 2015|October 28, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02421445||22955|
NCT02421458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15CRH|Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer|Dutch Randomized Multicenter Trial COmparing twO PalliativE RAdiaTION Schemes for Incurable Head and Neck Cancer (COOPERATION)|COOPERATION|The Netherlands Cancer Institute|No|Not yet recruiting|November 2015|November 2021|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02421458||22954|
NCT02426541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00025|Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus.|An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus|DERISC|AstraZeneca|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|35 Years|70 Years|No|||February 2016|February 29, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426541||22563|
NCT02415738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-005-YF|Changes in Cerebral Oxygenation During the Prone Position in Patients With Acute Respiratory Distress Syndrome|Changes in Cerebral Oxygenation During the Prone Position in Patients With Acute Respiratory Distress Syndrome|OXYDV|Centre Hospitalier Bretagne Atlantique|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|ARDS|April 2015|April 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02415738||23393|
NCT02419261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gauthier - Lecoq - Goffin|Assessment of Adductor Canal Blockade in Anterior Cruciate Ligament Surgery|Assessment of Sensory and Motor Blockade of the Adductor Canal Blockade Performed for Surgery of Arthroscopic Anterior Cruciate Ligament Repair|ACB|University Hospital of Liege|No|Recruiting|October 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||April 2015|April 16, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02419261||23123|
NCT02393937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-17-3-2014|A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea|||bioRASI, LLC||Active, not recruiting|February 2015|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|947|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393937||25066|
NCT02420067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0125, A|Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients|An International Collaborative Study: Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients||University of Copenhagen|No|Recruiting|February 2011|February 2026|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|15 Years|N/A|No|Non-Probability Sample|vHL patients, with or without a diagnosed ELST, who have had at least one audiological        examination AND one MRI of the brain and inner ear within a 12 month period|November 2015|November 12, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02420067||23061|
NCT02420327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00057097|Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|GalaNic|University of Maryland|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420327||23041|
NCT02419521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0 - 23Mar2015|Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study|A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study||Medtronic Vascular|Yes|Active, not recruiting|April 2015|December 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419521||23103|
NCT02398916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBG-2557-02665|Music Listening to Reduce Pain and Anxiety During LEEP|Effects of Music Listening During Loop Electrosurgical Excision Procedure on Anxiety, Pain, and Satisfaction: a Randomized Controlled Trial||Chiang Mai University|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2015|March 20, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02398916||24683|
NCT02408341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KonkukUMC-2012-01|Propofol Induction's Effect on Cardiac Function|Effect of Intravenous Propofol Anesthesia Induction on Cardiac Function||Konkuk University Medical Center|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population After approval by the institutional ethics committee and written informed        consent, we prospectively enrolled adult patients who were scheduled for elective        non-cardiac surgery. During the preoperative anesthesia visit, we selected patients with        low-risk as indicated by the revised cardiac risk index of 0 and normal LV function        (ejection fraction ≥ 60% and septal e' ≥ 8 cm/s. We excluded patients with an arrhythmia,        poor lateral axis in supine position, regional wall motion abnormality, or other        structural heart diseases. Patients with any of the following conditions were also        excluded: unfavorable airway or facemask fit, intractable coughing, hiccups, or        hypotension (mean BP < 60 mmHg) requiring IV positive inotropes or vasoconstrictors during        the study period.|March 2015|March 31, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02408341||23962|
NCT02412891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0116-14-EMC|Evaluation of "UroShield" Device Impact Upon Side Effects and Complications of Urinary Catheter Usage|Evaluation of "UroShield" Device Impact Upon Side Effects and Complications of Urinary Catheter Usage||HaEmek Medical Center, Israel|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|276|||Both|18 Years|N/A|No|||April 2015|June 17, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02412891||23612|
NCT02420548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10312013.040|Safe, Healthy, Adolescent Relationships and Peers|Preventing Drug Use and Risk Behaviors in Adolescent Girls|SHARP-Teen|University of Oregon|No|Recruiting|July 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|13 Years|18 Years|No|||December 2015|December 4, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02420548||23024|
NCT02426632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106726|Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants|A Phase 1, Double-blind, Randomized, Trial to Evaluate the Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Subjects||Janssen Sciences Ireland UC|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|12||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02426632||22556|
NCT02405455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPEIC|Cerclage vs Cervical Pessary in Women With Cervical Incompetence|Cerclage vs Cervical Pessary in Women With Cervical Incompetence|CEPEIC|Maternal-Infantil Vall d´Hebron Hospital|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02405455||24182|
NCT02422381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011A|MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)||Providence Health & Services|No|Recruiting|April 2015|April 2021|Anticipated|April 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02422381||22883|
NCT02422394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eltrombo-IT-2014|Eltrombopag for Inherited Thrombocytopenias|Eltrombopag for Inherited Thrombocytopenias||IRCCS Policlinico S. Matteo|No|Recruiting|April 2015|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|16 Years|70 Years|No|||June 2015|June 30, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02422394||22882|
NCT02413151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/DES/120249/2010|Exercise Training Following Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure|Exercise Training Following Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure||University of Lisbon|Yes|Recruiting|January 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02413151||23592|
NCT02421484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014809|Cellular Immunotherapy for Septic Shock: A Phase I Trial|Cellular Immunotherapy for Septic Shock: A Phase I Trial|CISS|Ottawa Hospital Research Institute|Yes|Not yet recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02421484||22952|
NCT02401529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bahammam-1|Effect of Steroids on Post-tonsillectomy Morbidities|Effect of Steroids on Post-tonsillectomy Morbidities||King Fahd General Hospital|No|Completed|January 2013|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|5 Years|20 Years|Accepts Healthy Volunteers|||June 2015|June 20, 2015|March 21, 2015||No||No|May 6, 2015|https://clinicaltrials.gov/show/NCT02401529||24482|
NCT02409329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140562|Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes|Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes||Vanderbilt University|Yes|Enrolling by invitation|April 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02409329||23886|
NCT02409381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-MTR-04(02/13)|Extract of Curcuma Longa Complexed With Phosphatidilcholine(Motore®)in the Treatment of Adults With Knee Osteoarthritis|Clinical Trial, Multicenter, Phase IV, Open, Randomized, Parallel, Controlled, Non-inferiority, to Evaluate the Efficacy and Safety of Motore® Compared to Alivium® in the Treatment of Adults With Knee Osteoarthritis||Ache Laboratorios Farmaceuticos S.A.|No|Recruiting|June 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|40 Years|75 Years|No|||March 2016|March 7, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409381||23882|
NCT02421198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK100805-01|Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth|Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth|EPIC Kids|University of Arizona|No|Not yet recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02421198||22974|
NCT02421679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-P202|Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions|A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions|P202|Tonix Pharmaceuticals, Inc.|No|Active, not recruiting|April 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|66 Years|No|||March 2016|March 24, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02421679||22937|
NCT02409797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSIGHT-2015V164|measurINg forceS durInG cHiropractic Treatment|measurINg forceS durInG cHiropractic Treatment (INSIGHT): A Single-Arm Clinical Case Series|INSIGHT|Palmer College of Chiropractic|Yes|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02409797||23850|
NCT02409394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPOP1c|Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects|Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 3, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02409394||23881|
NCT02396199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-09|Zenith® p-Branch® Endovascular Graft Pivotal Study|Zenith® p-Branch® Pivotal Study||Cook||Recruiting|August 2015|November 2023|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396199||24892|
NCT02415426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-MKT - 2014-0421|Metacognitive Training Program With Depression||DMKT|Psychiatric University Hospital, Zurich||Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|45|||Both|55 Years|N/A||Non-Probability Sample|patients from our ambulatorium|April 2015|April 8, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02415426||23417|
NCT02420444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-013-404|A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults|A Phase I Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults|C-013-404|Aeras|No|Completed|January 2011|November 2013|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02420444||23032|
NCT02420457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2949|Tracking Outcomes in Pain Patients Using Fitness Devices|Tracking Outcomes in Pain Patients Using Fitness Devices||University of North Carolina, Chapel Hill|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with chronic back pain|April 2015|April 14, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02420457||23031|
NCT02402088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#801003403|The Role of Emotional Arousal in Food Preference and Taste|The Purpose of This Study is to Investigate the Role of Stress in Food Craving and Food Consumption by Examining Stress Response Using Subjective, Physiological and Neurobiological Measurements||Yale University|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|January 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02402088||24439|
NCT02409446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antho 030|Metabolic, Vascular and Cognitive Effects of Treatment With Anthocyanins|Metabolic, Vascular and Cognitive Effects of Treatment With Anthocyanins in Older Adults at Risk for Adverse Outcomes - a Pilot Study||Helse Stavanger HF|No|Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 22, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02409446||23877|
NCT02415881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0050|Phase I Panitumumab IRDye800 Optical Imaging Study|Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures||Stanford University|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|43|||Both|19 Years|N/A|No|||November 2015|November 23, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415881||23382|
NCT02415478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002|Bronchioscopic Lung Volume Reduction (BLVR)|The Effect of Endoscopic Lung Volume Reduction Via Endobronchial Valves on Breath Muscle Power by Patients With COPD|BLVR|RWTH Aachen University|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with severe COPD (GOLD stage III or IV)|November 2015|November 18, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02415478||23413|
NCT02415491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-039|Cardiovascular MRI and Cardiopulmonary Exercise Capacity After Neonatal ASO) in Young Adults|Cardiovascular Magnetic Resonance at Rest and Stress in Relation to Cardiopulmonary Exercise Capacity in Young Adults After Arterial Switch Operation (ASO) for Transposition of the Great Arteries (TGA)|ASO|RWTH Aachen University|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|28 Years|No|||February 2016|February 17, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02415491||23412|
NCT02395367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeiSH|A Prospective, Observational, Real-world Study Based on the Register System of Oral and Maxillofacial Malignant Tumors|A Prospective, Observational, Real-world Study Based on the Register System of Oral and Maxillofacial Malignant Tumors.||Beijing Stomatology Hospital||Recruiting|March 2015|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with previously untreated oral and maxillofacial malignant tumors were        scheduled for radical surgery in Beijing stomatological hospital of Capital Medical        University and stomatological hospital of Peking University.|September 2015|September 26, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02395367|5 Years|24956|
NCT02420470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-2014086|The Early Warning System for the Diabetic Encephalopathy|The Early Warning System for the Central Nervous System Micro-structure Alterations During Early Diabetes Based on the Multi-mode MRIs||Tang-Du Hospital|Yes|Recruiting|April 2015|December 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|40 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|prodromal diabetes and early diabetes|July 2015|July 29, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02420470||23030|
NCT02415660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404153-1|Short-Term Response of Thoracic Spine Manipulation With or Without Trigger Point Dry Needling for Mechanical Neck Pain|Short-Term Response of Thoracic Spine Manipulation With or Without Trigger Point Dry Needling for Mechanical Neck Pain: A Randomized Clinical Trial||Brooke Army Medical Center|No|Not yet recruiting|March 2016|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|64 Years|No|||January 2016|January 12, 2016|March 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415660||23399|
NCT02415894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1025|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Ukraine||Gynuity Health Projects|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with mid-trimester pregnancy seeking abortion|March 2016|March 10, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02415894||23381|
NCT02420769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beni-Suef 9|Corpus Luteum and Uterine Artery Doppler With Serum P and CA125 in Threatened Abortion|Color Doppler of CL and Uterine Artery With Serum Progesterone and CA125 in Threatened Abortion|CL CA125|Beni-Suef University|Yes|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|20 Years|40 Years|No|Probability Sample|Pregnant females >8 weeks but < 20 weeks gestation. They are presenting with a complaint        of threatened abortion to our outpatient ANC clinic.|December 2015|December 26, 2015|April 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02420769||23007|
NCT02395627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147523|Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification|Reversing Hormone Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer||University of California, San Francisco|Yes|Recruiting|March 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395627||24936|
NCT02395640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDZL-EXELOX|The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer|The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer: An Open-label, Multi-center, Prospective and Randomised Study||Fudan University|No|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02395640||24935|
NCT02398123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUH-Feb-2015|Transversus Abdominis Plane Versus Caudal Block for Pediatrics|Transversus Abdominis Plane (TAP) Blocks Versus Caudal Block for Postoperative Pain Control After Unilateral Lower Abdominal Surgeries in Pediatrics: A Prospective, Randomized Study.||Mansoura University|Yes|Completed|March 2015|July 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|1 Year|7 Years|No|||September 2015|September 14, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02398123||24744|
NCT02420314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412760|Pharmacological Ascorbate for Lung Cancer|A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer||University of Iowa|Yes|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02420314||23042|
NCT02413268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTP1|Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial|Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial|NTP-RAO|Total Cardiovascular Solutions|No|Not yet recruiting|June 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2400|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413268||23583|
NCT02413515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17677|Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.|Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapy: A Prospective, Open-label, Multicenter, Single-arm, 8-week Study.|ADEPT|Bayer|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|276|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02413515||23564|
NCT02423096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-0721C|Neuroendocrine and Metabolite Substrates in Schizophrenia|Neuroendocrine, Metabolite Substrates, Clinical Symptoms and Cognitive Function in Schizophrenia||Chang Gung Memorial Hospital|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood samples of patients and control subjects will be obtained to measure the levels of      neuroendocrine substrates (didehydroepiandrosterone, dehydroepiandrosterone sulfate,      pregnenolone, and cortisol) and metabolite markers (lipid profiles, glycerate, eicosenoic      acid, pyruvate, b-hydroxybutyrate, Cysteine)|Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Patients with schizophrenia will be recruited from the out-patient department in             Kaohsiung Chang Gung Memorial Hospital, Kaohsiung city, Taiwan          2. Healthy controls will be recruited from the staff in Kaohsiung Chang Gung Memorial             Hospital and from the communities in Kaohsiung city, Taiwan|April 2015|April 17, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02423096|12 Weeks|22828|
NCT02423109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-13|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423109||22827|
NCT02423122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIP-VX00-745-302|A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)|A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning||EIP Pharma, LLC|No|Recruiting|April 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|60 Years|85 Years|No|||January 2016|January 20, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02423122||22826|
NCT02418962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGSPZV1|Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults|Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults||Sanaria Inc.|Yes|Completed|March 2015|February 2016|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|33|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02418962||23145|
NCT02638480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811229|Effectiveness of KneeMD on Flexion Contracture in Total Knee Arthroplasty Patients|A Prospective Randomized Trial to Examine the Effectiveness of KneeMD on Flexion Contracture in Total Knee Arthroplasty Patients|KneeMD|Anne Arundel Health System Research Institute|No|Recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638480||6292|
NCT02643914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA038467-01|Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings|Using Control Systems to Predict Individualized Dynamics of Nicotine Cravings||Stony Brook University|No|Recruiting|September 2015|December 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02643914||5874|
NCT02629250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZZD-2015007|Supernormal Oxygen Delivery for Elderly Surgical Patients|A Randomized Controlled Study of Supernormal Oxygen Delivery Goal-directed Therapy for Elderly Patients Undergoing Proximal Femoral Surgery.|SNODES|Guangzhou First Municipal People’s Hospital|Yes|Recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|70 Years|N/A|No|||December 2015|December 23, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02629250||7000|
NCT02633319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSD/CUREC1A/14-SSH_C2_15_023|Malezi Na Kilimo Bora - Skilful Parenting and Agribusiness Child Abuse Prevention Study|Malezi ne Kilimo Bora (Good Parenting and Farming) - Skilful Parenting and Agribusiness Child Abuse Prevention Study (SPACAPS)|SPACAPS|University of Oxford|No|Recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02633319||6688|
NCT02642393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-PD-P3-2014|Study of URate Elevation in Parkinson's Disease, Phase 3|A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease|SURE-PD3|Massachusetts General Hospital|Yes|Not yet recruiting|May 2016|August 2020|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|270|||Both|30 Years|N/A|No|||December 2015|December 26, 2015|December 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642393||5991|
NCT02382081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Behov|A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis|||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|March 2015|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382081||25977|
NCT02635945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2015-34|A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.|A Study to Assess the Efficacy of a 5-day, Once Daily 10- mg PBF-680 Oral Administration Course to Attenuate Allergen Bronchoprovocation-induced Late Asthmatic Responses (LAR) in Asthmatic Patients Controlled on Low-to-medium Dose Inhaled Corticosteroid Maintenance Monotherapy and Inhaled Short Acting Beta-2 Agonist as Rescue Bronchodilator||Palobiofarma SL|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02635945||6487|
NCT02644473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5435|Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients|||Albert Einstein College of Medicine of Yeshiva University|No|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1400|||Both|50 Years|100 Years|No|||December 2015|December 30, 2015|December 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644473||5831|
NCT02642887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al-Azhar 11-2014|A Modified Tunnel Approach in Treatment of Gingival Recession|Evaluation of Root Coverage Outcome Using a Modified Tunnel Approach Versus Tunnel Technique: A Randomized Clinical Trial||Al-Azhar University|No|Active, not recruiting|March 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|29 Years|47 Years|No|||December 2015|December 26, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02642887||5953|
NCT02638922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-2015-218-04161|Evaluation and Treatment of Tall Statured Girls|Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol|TallgirlsDK|Rigshospitalet, Denmark|No|Active, not recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|304|||Female|1 Year|18 Years|No|Non-Probability Sample|All patients registered in our tertiary referral centre included|December 2015|December 22, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02638922||6258|
NCT02304315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1102_P2|A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients|A Randomized, Open-label, Single-center, Phase II Trial to Explore the Safety and Efficacy of GC1102 and Determine Its Optimal Dose After Intravenous Administration in HBV-related Liver Transplant Recipients||Green Cross Corporation|No|Active, not recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|65 Years|No|||December 2015|December 7, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02304315||31937|
NCT02306395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY-2014|Endometrial Local Injury to Improve the Outcome of Embryo Transfer|Endometrial Local Injury of Frozen Cycle to Improve the Outcome of Embryo Transfer of Repeated Implantation Failure.||Navy General Hospital, Beijing|Yes|Recruiting|December 2014|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|40 Years|No|||January 2016|January 4, 2016|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02306395||31777|
NCT02309775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidade Federal Alfenas|Auriculotherapy in Tension-type Headache Due to Temporomandibular Dysfunction|Auriculotherapy in Tension-type Headache Due to Temporomandibular Dysfunction - A Randomized Study||Federal University of Minas Gerais|No|Completed|January 2012|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|30 Years|No|||December 2014|December 5, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309775||31519|
NCT02316912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX2417/001/14|First in Man Evaluation of Single and Multiple Doses of Oral ATX2417|Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food||Atopix Therapeutics, Ltd.|No|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|18||Anticipated|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 24, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02316912||30971|
NCT02301988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29505|A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer|A PHASE II RANDOMIZED, DOUBLE-BLIND, STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR TO AKT, IN COMBINATION WITH PACLITAXEL AS NEOADJUVANT TREATMENT FOR PATIENTS WITH EARLY STAGE TRIPLE NEGATIVE BREAST CANCER||Genentech, Inc.||Recruiting|February 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301988||32116|
NCT02298335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1401|Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study|A Prospective Observational Study to Assess the Efficacy an Safety of Glucocorticoid Therapy in the Treatment of Adult Idiopathic Nephrotic Syndrome||Nanjing University School of Medicine|Yes|Recruiting|June 2014|June 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|235|||Both|18 Years|65 Years|No|||November 2015|November 1, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02298335||32397|
NCT02320500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-217-12|Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis|Prospective Randomized Controlled Trial Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis||Queen's University|Yes|Recruiting|September 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02320500||30696|
NCT02326064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD064-14|Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4|Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI (Risk of Malignancy Index) and Tumor Markers Such as CA125 (Cancer Antigen 125) and HE4 (Human Epididymal Protein 4)|TORCH|Centre Hospitalier Departemental Vendee|No|Recruiting|May 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|N/A|No|Non-Probability Sample|Patient hospitalized for surgery for presumed benign ovarian tumor|January 2016|January 4, 2016|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326064||30268|
NCT02326116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54543|TTE and Dysphagia in Anterior Cervical Surgery|Investigating the Role of Tracheal Traction Exercises (TTE) in Reducing Dysphagia Following Anterior Cervical Surgery||University of Rochester|No|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|85 Years|No|||February 2016|February 19, 2016|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02326116||30264|
NCT02297698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0443|Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients|Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients|HER3+|Cancer Insight, LLC|Yes|Recruiting|October 2014|October 2019|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02297698||32446|
NCT02297971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/001|Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor|Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents|BRILIQUE|Örebro University, Sweden|Yes|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|Blood for analysis of complement, coagulation factors and other biochemical markers|Both|45 Years|85 Years|No|Non-Probability Sample|Patients who have previously had a coronary artery syndrome treated by PCI and stent        placement and who are taking the oral anti platelet drugs aspirin and ticagrelor would be        included into the study.|September 2015|September 26, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02297971||32425|
NCT02295605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Nove de Julho|Comparison Between Land-based and Water-based Exercises for Knee Osteoarthritis: Randomized Controlled Trial|Comparison Between a Land-based and Water-based Muscles Strengthening Program on Patients With Knee Osteoarthritis Randomized Controlled Trial||University of Nove de Julho|Yes|Recruiting|August 2014|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|50 Years|70 Years|No|||November 2014|November 22, 2014|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02295605||32606|
NCT02295618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/41|ETI During Intubation|Can the ETView VivaSight SL Rival the Macintosh Laryngoscopy With Conventional Tube During Adult Resuscitation by Novice Physicians: a Randomized Crossover Simulation Study.|SL|International Institute of Rescue Research and Education|Yes|Completed|November 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02295618||32605|
NCT02318394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6060C00001|A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors||MedImmune LLC|No|Recruiting|March 2015|May 2020|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|196|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02318394||30857|
NCT02631148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002161|Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.|Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.||Brigham and Women's Hospital|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631148||6854|
NCT02393157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-11,392|Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL|Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL|O-ICE|New York Medical College|Yes|Recruiting|February 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|3 Years|31 Years|No|||October 2015|October 30, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02393157||25126|
NCT02638402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405068RINA|Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers|Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers||National Taiwan University Hospital|No|Not yet recruiting|December 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|250|||Female|20 Years|N/A|No|Non-Probability Sample|Ovarian and endometrial cancer patients receiving operation in National Taiwan University        Hospital|December 2015|December 24, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02638402||6298|
NCT02641444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2865|Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects|Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects||University of North Carolina, Chapel Hill|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|22|||Female|18 Years|65 Years|No|Non-Probability Sample|This study will consist of 22 HIV positive women between 18-65 years of age (inclusive)        with an intact gastrointestinal tract, uterus and cervix who are available to complete all        study procedures at UNC.|December 2015|December 28, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02641444||6064|
NCT02641457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-015-2015|Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis|Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis||Instituto de Olhos de Goiania|Yes|Completed|March 2014|October 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02641457||6063|
NCT02640196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANESTH-03-15|Videolaryngoscopes for Double Lumen Tube Intubations in Simulated Easy and Difficult Airway|A Comparison of Three Videolaryngoscopes for Double-lumen Tubes Intubation in Simulated Easy and Difficult Airways||Dammam University|Yes|Completed|March 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|21|||Both|23 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640196||6160|
NCT02643030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2674-2012|Hypercapnia During Shoulder Arthroscopy|The Effect of Hypercapnia on Regional Cerebral Oxygen Saturation in the Sitting Position||Gachon University Gil Medical Center|Yes|Completed|March 2012|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|65 Years|No|||December 2015|December 28, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02643030||5942|
NCT02393183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106955-24580-124-03-93|The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)|The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial||Iran University of Medical Sciences|No|Not yet recruiting|December 2016|May 2021|Anticipated|May 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|235|||Both|18 Years|70 Years|No|||February 2016|March 9, 2016|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02393183||25124|
NCT02639637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151133|Effect of DPP4 Inhibition on Vasoconstriction|Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition||Vanderbilt University|Yes|Recruiting|December 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|55 Years|No|||March 2016|March 23, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639637||6203|
NCT02639858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCH&N201|Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC|A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Samyang Biopharmaceuticals Corporation|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|20 Years|79 Years|No|||December 2015|December 21, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02639858||6186|
NCT02630628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALNN-IIS-17JUL15-1|Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis|A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis||The University of Hong Kong|No|Recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02630628||6894|
NCT02635503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015SF-04|Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer|A Prospective Randomized Controlled Trial Comparing Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) Versus Conventional Laparoscopic Surgery for Sigmoid Colon or Rectal Cancer||Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Yes|Recruiting|November 2015|December 2025|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02635503||6521|
NCT02640066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117-15-ZIV|Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children|Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children: A Single Blinded Randomized Controlled Trial||Ziv Hospital|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Months|36 Months|No|||December 2015|December 24, 2015|December 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640066||6170|
NCT02638194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00370|Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars|Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars||New York University School of Medicine|No|Completed|July 2014|September 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02638194||6314|
NCT02642783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUT.AO.19|Sensory Properties of Bowel Cleansing Solutions|Sensory Evaluation of Laxative Bowel Solutions Used Prior to Colonoscopy||American University of Beirut Medical Center|Yes|Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02642783||5961|
NCT02642874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|methocarbamol|Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients|Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients||Tanta University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||December 2015|December 25, 2015|December 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642874||5954|
NCT02630706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-012|A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|Yes|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|495|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630706||6888|
NCT02630719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-152|Timolol Eye Drops in the Treatment of Acute Migraine Headache|Timolol Eye Drops in the Treatment of Acute Migraine Headache||University of Missouri, Kansas City|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630719||6887|
NCT02628093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014955|A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery|A Randomized Controlled Trial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery||Weill Medical College of Cornell University|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02628093||7089|
NCT02634073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204857|A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers|An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects||ViiV Healthcare|No|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634073||6630|
NCT02634307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK8700-A301|A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) (the EVOLVE-MS-1 Study)|A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis||Alkermes, Inc.|No|Recruiting|December 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634307||6612|
NCT02640482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-464|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection|A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)|ENDURANCE-2|AbbVie|No|Recruiting|December 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|321|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640482||6138|
NCT02640495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1504|Artemisinin Resistance In Malaria Treated With IV Artesunate|A Multicenter, Prospective, Observational Study to Assess the Effi-cacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)|ARIMTIA|University of Oxford|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|132|Samples Without DNA|Blood sample|Both|6 Months|N/A|No|Non-Probability Sample|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral        artesunate.|December 2015|December 22, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640495||6137|
NCT02631174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6716|Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support|Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|42|||Both|N/A|1 Year|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631174||6852|
NCT02638493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2767|The Compartmental Biology of HIV in the Male Genital Tract|IGHID 11526 - The Compartmental Biology of HIV in the Male Genital Tract||University of North Carolina, Chapel Hill|No|Recruiting|November 2015|November 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|16|Samples With DNA|Blood and semen samples|Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive and HIV negative men taking TDF/FTC once daily|December 2015|December 18, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02638493||6291|
NCT02634320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-A401|A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia|Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate (Invega Sustenna)||Alkermes, Inc.|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634320||6611|
NCT02634333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol W|Anti-VEGF Treatment for Prevention of PDR/DME|Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk||Diabetic Retinopathy Clinical Research Network|Yes|Recruiting|January 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|322|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634333||6610|
NCT02635113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00617|Falls Prevention: Gait-Synchronized Vibration System|Falls Prevention Using a Gait-Synchronized Vibration System||New York University School of Medicine|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635113||6550|
NCT02382575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PednephroRCT/PM/NRSMCH-33|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome||Nilratan Sircar Medical College|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|3 Years|16 Years|No|||October 2015|October 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382575||25939|
NCT02628873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lindheim2015-01|Can SIS Using Air Bubbles Replace HSG for Fallopian Tubal Patency After Essure Placement|Can Contrast Infused Sonography Using Air Bubbles Replace Hysterosalpingogram as the Diagnostic Evaluation of Fallopian Tube Patency Following Hysteroscopic Sterilization Using Essure|HyCoSy|Wright State University|No|Enrolling by invitation|December 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|36|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02628873||7029|
NCT02628886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1433|Protecting From Pneumococcus in Early Life (The PROPEL Trial)|A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial|PROPEL|Medical Research Council Unit, The Gambia|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|February 22, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628886||7028|
NCT02642042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02250|Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer|A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies||National Cancer Institute (NCI)|No|Not yet recruiting|July 2016|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|N/A|N/A|No|||January 2016|January 5, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642042||6018|
NCT02629224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0012|ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis|Pharmacokinetic (PK) Study of ASP8825 - Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Haemodialysis||Astellas Pharma Inc|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|79 Years|No|||February 2016|February 3, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629224||7002|
NCT02635399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0969|Impact of Additional DJ (Duodenojejunostomy)-Pexy on Reduction in Delayed Gastric Emptying Following Pylorus-preserving Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial|||Yonsei University|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|78|||Both|20 Years|80 Years|No|||December 2015|December 15, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02635399||6529|
NCT02629146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GabA01|Analgesic Effects of Midazolam in Human Volunteers|A Single Center, Prospective, Randomized, Double Blind, Placebo-controlled, Three-way Cross-over Study of the Analgesic Effects of Midazolam Versus Placebo With Fentanyl as an Active Control in Human Volunteers|GabA01|Wilhelminenspital Vienna|No|Completed|December 2015|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02629146||7008|
NCT02629159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-465|A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)|SELECT-COMPARE|AbbVie|Yes|Recruiting|December 2015|August 2020|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1500|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629159||7007|
NCT02637219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01439|Innate Immune Response in COPD|Innate Immune Response in COPD||VA Puget Sound Health Care System|No|Completed|March 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Male|50 Years|89 Years|No|Non-Probability Sample|Patients with a clinical history of COPD recruited from a pulmonary subspecialty clinic at        an academic medical center|December 2015|December 18, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02637219||6389|
NCT02637232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.104160|Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)|Mirvaso® Utilisation and Patient Satisfaction Evaluation|MUSE|Galderma|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|N/A|No|Non-Probability Sample|patient with persistent facial erythema of rosacea|December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637232||6388|
NCT02640677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_82OB|Safety of 4CMenB Exposure During Pregnancy|4CMenB Pregnancy Registry: an Observational Study of the Safety of 4CMenB Exposure in Pregnant Women and Their Offspring.||Novartis||Recruiting|January 2016|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include pregnant women within the US who received at least 1        dose 4CMenB vaccine within 30 days prior to LMP or at any time during pregnancy.|March 2016|March 4, 2016|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640677||6123|
NCT02383394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131|Factors Associated With Pregnancy Loss in IVF Women|Factors Associated With Second-Trimester Pregnancy Loss in Women With Normal Uterine Anatomy Undergoing In Vitro Fertilization||Cairo University|No|Not yet recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|||Female|21 Years|44 Years|No|Non-Probability Sample|Women aged 21-44 years with ongoing in vitro fertilization pregnancy (at least one fetus        with fetal heart tones at 12 weeks of gestation)|March 2015|March 6, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383394||25876|
NCT02383641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWD 04-2015|Biomarker for Wolman Disease|Biomarker for Wolman Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioWolman|University of Rostock|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml      EDTA blood, saliva tube and a dry blood spot filter card are taken. To prove the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Centogene AG,      Schillingallee 68, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with a diagnosis of Wolman disease or profound suspicion for Wolman disease|October 2015|October 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02383641||25857|
NCT02630017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00068353|Motivated Behavior in Adults With and Without ADHD|Motivated Behavior in Adults With and Without ADHD|MOBE|Duke University|Yes|Not yet recruiting|February 2016|||January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630017||6941|
NCT02642081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511075RIND|Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury in Patients With Heart Failure|Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury in Patients With Heart Failure||National Taiwan University Hospital|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Heart failure patients with prescription of NSAIDs|January 2016|January 6, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02642081||6015|
NCT02640781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0046|Comparison of Efficacy Between a Newly Designed Covered Stent and Uncovered Stent for Malignant Colorectal Obstruction|Comparison of Efficacy Between a Newly Designed Covered Stent and Uncovered Stent for Malignant Colorectal Obstruction: a Prospective, Multicenter Study||Yonsei University|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|85 Years|No|||December 2015|December 22, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02640781||6115|
NCT02383914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Subscap-042014|Clinical Study on Diagnostics and Outcome of Ruptures of the Subscapularis After Arthroscopic Refixation|Prospective Multicenter Trial on Diagnostics and Outcome of Ruptures of the Subscapularis After Arthroscopic Refixation||University of Rostock||Recruiting|March 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|The study population consists of the patients, who got the operative therapy (refixaton of        the subscapularis tendon) inclusive the post- treatment and satisfy the criteria .|March 2015|March 8, 2015|May 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02383914||25836|
NCT02638168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003056|Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD|Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With Attention Deficit Hyperactivity Disorder: A Randomized Placebo-controlled Pilot Study||Milton S. Hershey Medical Center|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|6 Years|12 Years|No|||December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02638168||6316|
NCT02638181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tjykdxykyy3|The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork|The Expression of Matrix Metalloproteinase 13（MMP13）, Tissue Inhibitor of Metalloproteinases 3（TIMP13）, and Calcium-sensing Receptor（CaSR） in Human Trabecular Meshwork||Tianjin Medical University Eye Hospital|Yes|Completed|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|50 Years|75 Years|No|||December 2015|December 17, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02638181||6315|
NCT02641548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-524811|Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes|Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes -a Randomized Controlled Trial||Region Örebro County|No|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 23, 2015||||No||https://clinicaltrials.gov/show/NCT02641548||6056|
NCT02628236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0113|Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)|A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions||DUSA Pharmaceuticals, Inc.|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628236||7078|
NCT02640703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impfstudie|Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial|Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial||University Hospital Tuebingen|No|Recruiting|March 2015|December 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|6 Months|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02640703||6121|
NCT02640716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015010|Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia|The Cog-VACCINE Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia|Cog-VACCINE|Beijing Friendship Hospital|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||December 2015|December 22, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02640716||6120|
NCT02628834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/01070|Acute Effect of Fascial Mobilization on Gait in Patients With Multiple Sclerosis|Investigating the Acute Effect of Fascial Mobilization on Dynamic Walking Parameters in Patients With Multiple Sclerosis: A Crossover Controlled Group Study||Hacettepe University|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02628834||7032|
NCT02628847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53515|Sildenafil and Stroke Recovery|Sildenafil and Stroke Recovery||University of Utah|No|Recruiting|March 2012|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||December 2015|December 9, 2015|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628847||7031|
NCT02643875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20151002004|Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters|Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters||The Hong Kong Polytechnic University||Recruiting|November 2015|March 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643875||5877|
NCT02642666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801230|The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children|The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children With ADHD Symptoms||University of California, Davis|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02642666||5970|
NCT02642679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001975|Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects|Evaluation of Opticell Ag (Chitosan Based Dressing) on Split-Thickness Skin Graft (STSG) Donor Sites in Adult Subjects|STSG|Brigham and Women's Hospital|Yes|Enrolling by invitation|January 2016|||June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02642679||5969|
NCT02640911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALT-C|An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia|||Shanghai Mental Health Center|No|Recruiting|November 2010|May 2021|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Chinese Patients with Schizophrenia|January 2016|January 4, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02640911||6105|
NCT02381496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-072-101|A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)|A Three-part Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) of ACT-453859 in Healthy Male Subjects, of Ascending Multiple Doses of ACT-453859 in Healthy Male and Female Subjects, and of Multiple Doses of Setipiprant (ACT-129968) in Healthy Male and Female Subjects||Actelion|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|11||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381496||26022|
NCT02634801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16190|A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment|A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment||Eli Lilly and Company|No|Recruiting|January 2016|January 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|162|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634801||6574|
NCT02638714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA-ON1|Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells|Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study||Stem Cells Arabia|Yes|Active, not recruiting|April 2013|March 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|55 Years|No|||December 2015|December 19, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638714||6274|
NCT02642276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCLRehab0022015|Exercise Training in Individuals With Peripheral Arterial Disease|Influence of Different Types of Exercise Training on Selected Cardiovascular Parameters in Individuals With Peripheral Arterial Disease||University Medical Centre Ljubljana||Enrolling by invitation|June 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02642276||6000|
NCT02629393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1101-MCD-202|Study of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A|A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A||Alexion Pharma GmbH|Yes|Not yet recruiting|December 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|28 Days|No|||December 2015|December 10, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629393||6989|
NCT02632084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE13/10696|Follow-up Evaluation of Photo-Dynamic Therapy for Pituitary Tumours|Follow-up Evaluation of Photo-Dynamic Therapy for Pituitary Tumours||The Leeds Teaching Hospitals NHS Trust||Completed|March 2010|September 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|100 Years|No|Non-Probability Sample|Details of previous research participants will be extracted from the study files by the        researchers, who are all members of the direct care team.|December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632084||6783|
NCT02633332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN2_2015|Use of Well Known Drugs for New Destination - RA Improvement (RANT)|Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments|RANT|Università Popolare Homo & Natura|No|Completed|February 2015|November 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02633332||6687|
NCT02642445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenanICE201502|Renal Sympathetic Denervation From The Adventitia on Hypertension|Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism|RSDAH|Henan Institute of Cardiovascular Epidemiology|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|December 31, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02642445||5987|
NCT02636205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|The Use of Armeo Spring in Upper Extremity Rehabilitation|The Use of Armeo Spring in Upper Extremity Rehabilitation||St Mary's Hospital for Children|No|Active, not recruiting|July 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|7 Years|17 Years|No|||January 2016|January 28, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636205||6467|
NCT02638805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-201|Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide|An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide||Intarcia Therapeutics|No|Recruiting|December 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638805||6267|
NCT02629497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 114405|Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus|Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus||University of Michigan|No|Recruiting|November 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|88|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02629497||6981|
NCT02637778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2_16|Modulation of Cardiovascular Risk Factors by the Diet|Intervention Study - Modulation of Cardiovascular Risk Factors by Personal Nutritional Counselling and Daily Menu Plans|MoKaRi-diet|University of Jena|No|Enrolling by invitation|February 2016|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|February 3, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637778||6346|
NCT02637791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10057|A Low Cost Virtual Reality System for Home Based Rehabilitation of the Upper Limb Following Stroke|A Low Cost Virtual Reality System for Home Based Rehabilitation of the Upper Limb Following Stroke|WiiSTAR|University of Nottingham|No|Completed|November 2009|September 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637791||6345|
NCT02312102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-213|Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation|Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation||Massachusetts General Hospital|Yes|Recruiting|March 2015|August 2020|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02312102||31340|
NCT02307734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA036749|A Family-Focused Intervention for Asian American Male Smokers|A Family-Focused Intervention for Asian American Male Smokers||University of California, San Francisco|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02307734||31675|
NCT02294175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400590|Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm From Chronic Diabetic Foot Ulcers|RCT: Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm From Chronic Diabetic Foot Ulcers||North Florida Foundation for Research and Education|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Both|21 Years|N/A|No|||August 2015|August 17, 2015|November 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294175||32716|
NCT02298036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAHRC-EM 14056|Helping Urgent Care Users Cope With Distress About Physical Complaints|Helping Urgent Care Users Cope With Distress About Physical Complaints: A Randomised Controlled Trial||University of Nottingham|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298036||32420|
NCT02297581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFC|Geriatric Fracture Centers - Evaluation of a Geriatric Co-management Program|A Prospective Multicenter Cohort Study to Evaluate the Benefit of the Geriatric Fracture Center (GFC) Concept||AO Clinical Investigation and Documentation|No|Recruiting|May 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|266|||Both|70 Years|N/A|No|Non-Probability Sample|Primary care clinic (Usual Care clinic) Geriatric center|January 2016|January 15, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297581||32455|
NCT02297594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK0529-1001|Safety, Tolerability and PK Study of AK0529 in Healthy Human|A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects||Ark Biosciences Inc.|Yes|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02297594||32454|
NCT02320799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23MH098767-01A1|Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya|Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV-infected Women Exposed to Gender Based Violence in Kenya||University of California, San Francisco|No|Recruiting|September 2015|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02320799||30673|
NCT02307565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEC-13-066|Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury|Blood Pressure, Cerebral Blood Flow and Cognition in SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|March 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|March 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307565||31688|
NCT02304627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1953-3974|Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects|Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects||Novo Nordisk A/S|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|45|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304627||31913|
NCT02304887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TH No 9-1|The Relationship Between the Residual Renal Function and Osteoporosis Treatment|The Relationship Between the Residual Renal Function and Osteoporosis Treatment||Tomidahama Hospital|No|Recruiting|January 2006|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||4|Anticipated|1000|||Both|45 Years|N/A|No|Probability Sample|Osteoporosis treatment patients|November 2015|November 3, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304887||31893|
NCT02310464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-833-001|Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197)in Gastric, Lung, Colorectal or Breast Cancer Subjects|An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy With Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/OBI-821) in Subjects With Gastric, Lung, Colorectal or Breast Cancer||OBI Pharma, Inc|Yes|Recruiting|December 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|21 Years|N/A|No|||March 2016|March 8, 2016|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02310464||31466|
NCT02314273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBK-10-01|Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL|Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia||Shanghai Children's Medical Center|Yes|Completed|September 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|18 Years|No|||November 2014|December 8, 2014|July 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02314273||31174|
NCT02317666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the DBI TMO Study|DBI - Tool for Medication Reviews in Older People|Decreasing the Load? The Drug Burden Index - A Tool for Medication Reviews in Older People (the DBI TMO Study)||University of Groningen|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|157|||Both|65 Years|N/A|No|||November 2015|November 5, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317666||30913|
NCT02302261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-572|Pleth Variability and Asthma Severity in Children|Using Pleth Variability to Triage Asthmatics in the Pediatric ED||Northwell Health|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|17 Years|No|Non-Probability Sample|We will study patients who present to the pediatric ED at Cohen Children's Medical Center        of NY with status asthmaticus.|February 2016|February 19, 2016|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302261||32095|
NCT02302274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00253|Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome|DIAGNOSTIC VALUE AND SAFETY OF FLECAINIDE INFUSION TEST IN BRUGADA SYNDROME||New York University School of Medicine|Yes|Recruiting|July 2010|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|230|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02302274||32094|
NCT02307630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-147|PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study|PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|November 2014|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|3 Years|90 Years|No|||March 2016|March 7, 2016|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307630||31683|
NCT02299934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1213|3T MR Angiography of the Hepatic Vasculature|3T MR Angiography of the Hepatic Vasculature: A Pilot Comparison Study of New Noncontrast Techniques to Post-contrast Technique and CT Angiography in Liver Donors.||University of Colorado, Denver|No|Enrolling by invitation|July 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02299934||32274|
NCT02320942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01679|Exercise Post Bone Marrow Transplant|Implementation of a Physician-prescribed Exercise Program as Standard of Care in Allogeneic Stem Cell Transplant Patients in British Columbia: a Pilot Study.|ExP-BMT|University of British Columbia|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320942||30662|
NCT02321150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KJebodhsingh|A Novel Technique for the Removal of Pterygiums|A Novel Technique for the Removal of Pterygiums||The University of The West Indies|Yes|Active, not recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02321150||30646|
NCT02635152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloridaStateU|Interpretation Bias Modification for Body Dysmorphic Disorder|Evaluation of an Internet-Based Treatment for Body Dysmorphic Disorder||Florida State University|No|Recruiting|September 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635152||6548|
NCT02378571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO3305|Medication Adherence Telemonitoring to Reduce Heart Failure Readmissions|Telemonitoring Adherence to Medications to Reduce Heart Failure Readmissions: A Pilot Randomized Clinical Trial|TEAM-HF|Columbia University|Yes|Completed|December 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||January 2016|January 28, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378571||26247|
NCT02378584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC1978MA|Natural Cycle Versus Endometrial Preparation for Healthy Blastocyst Transfer|The Clinical Results After Frozen-thawed Healthy Blastocyst Transfer in Natural Cycle Versus Cycle With Endometrial Preparation||European Hospital|Yes|Completed|February 2015|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Female|20 Years|42 Years|No|||July 2015|January 27, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02378584||26246|
NCT02643641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-BM32-004|Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response|Study to Evaluate the Effect of Different Pre-seasonal BM32 Dosing Schedules on the Rapid Induction of a Protective IgG Immune Response||Biomay AG|No|Not yet recruiting|January 2016|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|60 Years|No|||December 2015|December 30, 2015|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643641||5895|
NCT02643654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIDRA04|MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB|A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy||University of Athens|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02643654||5894|
NCT02631616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPros-HMO-CTIL|Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET|Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET||Hadassah Medical Organization|No|Not yet recruiting|February 2016|March 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02631616||6818|
NCT02643043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU15-217|UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch|UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217||Hoosier Cancer Research Network|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Collect and store whole blood and archival tumor tissue (biospecimens) from subjects and      linking molecular and biological information from those biospecimens to clinical data in      order to promote future translational research in metastatic urothelial cancer. Any DNA      analysis of blood is for research purposes only.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with histologically or cytologically confirmed metastatic urothelial cancer of        the bladder, urethra, ureter, or renal pelvis at the time of enrollment, who have agreed        to provide access to tumor tissue and blood collection for genetic studies.|February 2016|February 9, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02643043||5941|
NCT02378883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-APL001|Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study|Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study||Medtronic Neurovascular Clinical Affairs|No|Recruiting|April 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|161|||Both|N/A|N/A|No|||August 2015|August 20, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378883||26223|
NCT02378896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7059|Personalized Computerized Inhibitory Control Training for OCD|Personalized Computerized Inhibitory Control Training for OCD||New York State Psychiatric Institute|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378896||26222|
NCT02634879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823358|Behavioral Economics in Provider Incentive Design|Behavioral Economics in Provider Incentive Design||University of Pennsylvania|No|Active, not recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|83|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02634879||6568|
NCT02629588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJOT/2015/021022|Effectiveness of Sensory Stimulation for Person in a Coma or Persistent Vegetative State After Traumatic Brain Injury|Effectiveness of Sensory Stimulation for Person in a Coma or Persistent Vegetative State After Traumatic Brain Injury||Creighton University|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|9|||Both|18 Years|N/A|No|Probability Sample|Persons in a coma or persistent vegetative state (Glasgow Coma Scale below 8) after        traumatic brain injury|December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629588||6974|
NCT02629601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823617|Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program|Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program||University of Pennsylvania|No|Not yet recruiting|May 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|3800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629601||6973|
NCT02629614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||December 15, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629614||6972|
NCT02643992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGR_2014-13|Per-procedural Concentration of Direct Oral Anticoagulants||CORIDA|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|June 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|patient undergoing invasive procedure and treated with DOAC|December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02643992||5868|
NCT02640391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-151215|Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis|Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis: Prospective Observational Multicenter Study|PINQLE|Keimyung University Dongsan Medical Center|Yes|Recruiting|January 2016|July 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with inactive UC (Mayo score <3) who are scheduled to undergo colonoscopy for        surveillance or mucosal healing check-up|March 2016|March 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02640391||6145|
NCT02640404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA90|Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam|Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam||Sanofi|No|Not yet recruiting|April 2016|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|224|||Both|9 Months|55 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640404||6144|
NCT02390856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-211|Volar Plate vs. Conventus DRS Fixation|Randomized Controlled Trial: Volar Plate vs. Conventus DRS Intramedullary Fixation for Distal Radius Fractures||Hospital for Special Surgery, New York|No|Recruiting|February 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390856||25302|
NCT02390869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_RENOIR12|Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-Bendamustine for Relapsed/Refractory FL Patients|A Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-Bendamustine for Relapsed/Refractory FL Patients Not Eligible for ASCT|FIL_RENOIR12|Fondazione Italiana Linfomi ONLUS|No|Recruiting|April 2014|September 2019|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|253|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02390869||25301|
NCT02638311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP7001_6URL|99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test|Using Normal Volunteer Whole Blood or Plasma Samples to Establish the 99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test||Trinity Biotech|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|769|Samples With DNA|EDTA plasma samples|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and females >21 years of age from diverse geographical locations and        ethnicity-dispersed populations with an equal gender distribution|December 2015|December 17, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02638311||6305|
NCT02630888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORENO-2015|Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients|Efficacy of the Combination of Memantine in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Young Patients to Previous Combination Therapy of Quetiapine Plus Lithium or Quetiapine Plus Aripiprazole|ARIQUELI-ME|University of Sao Paulo|No|Recruiting|August 2014|August 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|40 Years|No|||December 2015|December 10, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630888||6874|
NCT02631421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140983|Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH|Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH||Vanderbilt University|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Probability Sample|PAH|December 2015|December 11, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02631421||6833|
NCT02628600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-312|Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212|||Insmed Incorporated||Enrolling by invitation|December 2015|||August 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628600||7050|
NCT02628613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150309|Neoadjuvant Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Epirubicin for TEKT4 Variation Breast Cancer Patients|Comparison of Paclitaxel Plus Carboplatin and Vinorelbine Plus Epirubicin for Neoadjuvant Chemotherapy in Locally Advanced (IIb-IIIc) HER-2(-) Breast Cancer With TEKT4 Variation: Efficiency and Safety||Fudan University|Yes|Recruiting|April 2015|December 2025|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|70 Years|No|||December 2015|December 10, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02628613||7049|
NCT02628626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005986|A Study of Colesevelam in Fecal Incontinence|A Placebo Controlled Study of Colesevelam in Fecal Incontinence||Mayo Clinic|No|Recruiting|November 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||December 2015|December 10, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628626||7048|
NCT02638441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADin|Psychological Profile of Women With Infertility in Egypt: A Comparative Study|Psychological Profile of Women With Infertility in Egypt: A Comparative Study||Ain Shams Maternity Hospital|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|400|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|This study will be conducted at the department of Obstetrics and Gynecology of Ain shams        university and Zagazig university and some private centres for the treatment of        infertility. It will include 400 women, divided into two groups (control group and        clinical group) starting from January 2016.|December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02638441||6295|
NCT02638454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2860|Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth|Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth||Tufts University|No|Recruiting|August 2015|January 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02638454||6294|
NCT02641613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCVEM 038/15|Retroclavicular Versus Supraclavicular Brachial Plexus Block for Hand and Forearm Surgery|The Efficacy of Retroclavicular Versus Supraclavicular Brachial Plexus Block in Patients Undergoing Forearm and Hand Surgery: a Randomized Controlled Double-blinded Trial.||Hôpital du Valais|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02641613||6051|
NCT02388555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-079-01|Perspective Analysis of Coronal Imbalance in Degenerative Scoliosis|Coronal Imbalance in Degenerative Lumbar Scoliosis||Nanjing University School of Medicine|Yes|Completed|January 2010|January 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|284|||Both|50 Years|82 Years|No|Non-Probability Sample|Patients with degenerative scoliosis|April 2015|April 7, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388555||25479|
NCT02388568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eisai-819111|Lifestyle Modification and Lorcaserin for Weight Loss Maintenance|A Randomized Controlled Trial of Lifestyle Modification and Lorcaserin for Weight Loss Maintenance||University of Pennsylvania|Yes|Recruiting|January 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|21 Years|65 Years|No|||January 2015|March 9, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02388568||25478|
NCT02632539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCYH-RCCM-01|Air-impingement Manipulation to Clear Subglottic Secretion to Prevent VAP in Prolonged Intubated Patients|Air-impingement Manipulation to Clear Subglottic Secretion to Prevent Ventilator Associated Pneumonia in Prolonged Intubated Patients：a Randomized Controlled Trial||Beijing Chao Yang Hospital|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632539||6748|
NCT02629237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-CREST-Satisfaction|Satisfaction After Glaucoma Surgery in Rural China|Impact of Multifaceted Education on Satisfaction After Glaucoma Surgery in Rural China||Sun Yat-sen University|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02629237||7001|
NCT02632461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00049756|Dietary Intervention Examining Tracking With Mobile Devices|The Dietary Intervention Examining Tracking With Mobile Devices Study|DIETMobile|University of South Carolina|No|Active, not recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632461||6754|
NCT02383056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120475|Doubleblinded RCT of the Omnilux on Lower Extremity Surgical Wounds Left to Heal by Second Intention|Doubleblinded, Randomized, Controlled Trial to Study the Effect of Omnilux Light Emitting Diode on Wound Healing Following Lower Extremity Surgical Wounds Left to Heal by Second Intention||University of Miami|No|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02383056||25902|
NCT02632734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoreBone.CTIL|The Use of CoreBone Coral Particles vs. Cones for Preservation of Alveolar Bone|Comparison Between CoreBone Coral Particles and CoreBone Coral Cones as Graft After Extraction Sockets for Alveolar Ridge Preservation|CoreBone|The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02632734||6733|
NCT02633072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/171/14|Visual Acuity After the Combined Binocular Implantation of +2.75 Diopters and +3.25 Diopters Tecnis Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of a Tecnis +2.75 Diopters Bifocal Intraocular Lens (Tecnis ZKB00) in the Distance Dominant Eye, in Combination With a +3.25 Diopters Tecnis Bifocal Intraocular Lens (Tecnis ZLB00) in the Fellow Eye.||Charite University, Berlin, Germany|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02633072||6707|
NCT02628275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP-137079|Impact of Mild or Moderate Physical Activity and Progression of Subclinical Atherosclerosis|Will Mild vs. Moderate Physical Activity Suffice to Abate the Progression of Subclinical Atherosclerosis in Sedentary Adults?|MoMA|Laval University|No|Not yet recruiting|December 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|270|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02628275||7075|
NCT02392325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 302|Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults|Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|March 2015|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392325||25190|
NCT02392377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9314|Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy|Pilot Study of Correlation Between Molecular Phenotype and Response to Two Independent Treatment Regimens, Carboplatin and Paclitaxel vs. 5-Fluorouracil and Oxaliplatin Chemotherapy in Patients With Localized Esophageal Adenocarcinoma||Case Comprehensive Cancer Center|No|Terminated|February 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Male|18 Years|N/A|No|||December 2015|December 18, 2015|March 13, 2015|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT02392377||25186|
NCT02634034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-CR-1.01US|A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers|||Kowa Research Institute, Inc.|No|Completed|December 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02634034||6633|
NCT02634047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH 009|Use of McGrath Videolaryngoscope to Assist Transesophageal Echocardiography Probe Insertion in Intubated Patients|Use of McGrath Videolaryngoscope to Assist Transesophageal Echocardiography Probe Insertion in Intubated Patients: A Prospective Randomized Controlled Trial||Antalya Training and Research Hospital|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|70 Years|No|||December 2015|December 15, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02634047||6632|
NCT02629471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG01|Study of the Effects of Light Flashes on the Visual System|Study of the Effects of Light Flashes on the Visual System||LightGuard|No|Not yet recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 13, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629471||6983|
NCT02628509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI_59|Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure|Onset and Offset of Von Willebrand Factor Multimemirization Defects in Cardiovascular Disease: the Case of the Molecular Sensor of Blood Flow|WiTAVi|University Hospital, Lille|No|Recruiting|August 2012|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|patients receiving mechanical circulatory support or undergoing aortic valve replacement|December 2015|December 18, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02628509||7057|
NCT02628522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-1|A Novel Method for Chronic Anal Fissure Treatment|A Novel Method for Chronic Anal Fissure Treatment: Adipose Derived Regenerative Cells - A Pilot Study||Clinical Centre of Serbia|No|Completed|December 2014|October 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||December 2015|December 10, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02628522||7056|
NCT02393339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0638-14-HMO-CTIL|Pre-operative Analgesics for Postoperative Pain Relief After Dental Treatment|Pre-operative Analgesics for Postoperative Pain Relief After Dental Treatment||Hadassah Medical Organization|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393339||25112|
NCT02643849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRS 1.0|Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men|Use of The Spanner® Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men Unfit for Other Treatments||SRS Medical|No|Not yet recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Male|45 Years|N/A|No|||December 2015|December 28, 2015|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643849||5879|
NCT02628249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAO-EA|Rate-limiting Amino Acids in Endurance-trained Athlete|Application of Indicator Amino Acid Oxidation Method to Investigate the Rate-limiting Amino Acids in Endurance Trained Athlete|EA|University of Toronto|No|Active, not recruiting|September 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|5|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628249||7077|
NCT02640807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-15|A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients|A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.|IRIS-7-B|Revimmune|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640807||6113|
NCT02633215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0530242N|Enhancing Plasticity in Stroke Patients With Severe Motor Deficit|Enhancing Cortical Plasticity With Nerve Stimulation in Stroke Patients With Severe Motor Deficit||University of Kentucky|No|Completed|March 2005|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|N/A|No|||December 2015|December 14, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02633215||6696|
NCT02631525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 31820014.8.0000.5149|Recovery Profile Comparison Between Remifentanil-propofol or Desflurane Anesthesia Monitored With Bispectral Index.|A Comparison of Post-operative Recovery Between Remifentanil-propofol and Remifentanil-desflurane Anesthesia Guided by Bispectral Index Monitoring||Federal University of Minas Gerais|No|Completed|August 2014|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||December 2015|December 11, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02631525||6825|
NCT02631538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201842|Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome|A Randomized, Double Blind (Sponsor Open), Comparative, Multicenter Study to Evaluate the Safety and Efficacy of Subcutaneous Belimumab (GSK1550188) and Intravenous Rituximab Co-administration in Subjects With Primary Sjögren's Syndrome||GlaxoSmithKline|Yes|Not yet recruiting|February 2016|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631538||6824|
NCT02641054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-CVXL-0107-01|Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease|Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test||CleveXel Pharma|No|Recruiting|January 2016|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|75 Years|No|||March 2016|March 7, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02641054||6094|
NCT02641067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-051|A Study Evaluating the Pharmacokinetics of Doravirine in Participants With Severe Renal Impairment (MK-1439-051)|An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment||Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641067||6093|
NCT02635971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAI-2015|Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer|A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer||Fudan University|Yes|Not yet recruiting|December 2015|||November 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635971||6485|
NCT02635984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818888|Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens|Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens|FOND-O|Georgia Regents University|Yes|Recruiting|November 2015|August 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635984||6484|
NCT02638415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-WYC02-2015|The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices|The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Recruiting|December 2015|September 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|70 Years|No|||December 2015|December 20, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02638415||6297|
NCT02642757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-214|Alcohol Brief Counseling in Primary Care|Effectiveness of a Brief Intervention for Reducing the Alcohol Use in Risky Users Delivered by Paramedics in Primary Care||Pontificia Universidad Catolica de Chile|No|Not yet recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|262|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02642757||5963|
NCT02642315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0046783|The Effect of Horizant (Gabapentin Enacarbil) on Augmentation|To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation|XP-IIT-0034|University of Missouri-Columbia|No|Not yet recruiting|January 2016|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||December 2015|December 23, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642315||5997|
NCT02633709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29840|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 (RG7916) Given by Mouth in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|93|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633709||6658|
NCT02636270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-6218|IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency|Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation.||Children's Hospital Medical Center, Cincinnati|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|10 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636270||6462|
NCT02636400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55983|Immediate IUI Versus Expectant Management in Postoperative Endometriosis Patients|Is Postoperative IUI Better Than Expectant Management in Infertile Endometriosis Patients With Good Prognosis Based on EFI Score?||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2014|December 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|37 Years|No|||December 2015|December 18, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636400||6452|
NCT02638896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015117183344589|Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis|Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis||Health and Family Planning Commission of Guangdong|No|Not yet recruiting|January 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|45 Years|No|||December 2015|December 24, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02638896||6260|
NCT02642510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073387|Improving Patient Education for Lymphoma and Leukemia Inpatients|Improving Patient Education for Newly Diagnosed Lymphoma and Acute Leukemia Inpatients||Emory University|No|Recruiting|June 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 27, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02642510||5982|
NCT02638584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMC-ILA01|Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.|Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer.||Il-Yang Pharm. Co., Ltd.|Yes|Not yet recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|19 Years|85 Years|No|||December 2015|December 20, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02638584||6284|
NCT02643927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/00134|Efficacy of 8 vs 4 Sessions Mindfulness-based Programs in a Non-clinical Population|Efficacy of 8 vs 4 Sessions Mindfulness-based Programs in a Non-clinical Population: a Controlled Study||Hospital Miguel Servet|No|Completed|February 2013|October 2013|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02643927||5873|
NCT02628145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU1415-168|Effects of a Resistance Training Program in Older Women With Sarcopenia|Effects of a Resistance Training Program in Older Women With Sarcopenia|RESTORE-ME|University of Rhode Island|No|Active, not recruiting|August 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Female|65 Years|84 Years|No|||December 2015|December 8, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02628145||7085|
NCT02633566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Clinical Trial of the Effect of Functional Orthoses in Children With Flat Feet|Randomized Clinical Trial of the Effect of Functional Orthoses on the Joint Position of the Hindfoot in Children With Flat Feet After a Year of Follow-up||Fresno, Raquel Lopez, M.D.|Yes|Completed|January 2013|May 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|3 Years|4 Years|No|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02633566||6669|
NCT02640209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18415|Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)|Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|||February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640209||6159|
NCT02640222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-285|APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study|APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study||Bristol-Myers Squibb|No|Active, not recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||8|Anticipated|18000|||Both|18 Years|N/A|No|Non-Probability Sample|AC-naive and AC-experienced patients diagnosed with non-valvular AF, initiated with either        apixaban, dabigatran, rivaroxaban or VKAs|March 2016|March 22, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640222||6158|
NCT02316665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A006336-40|Effect of Sleep Apnea Treatment on Type 1 Diabetes|Effect of Continuous Positive Airway Pressure Treatment on Nocturnal Glycemia of Patients Having Type 1 Diabetes and Sleep Apnea Syndrome: a Randomized Controlled Trial|DIADEME|University Hospital, Grenoble|No|Completed|April 2013|June 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02316665||30990|
NCT02296957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPAGE|Impact of the Decrease of Exposure to Hypnosedative Drugs in the Elderly Through the Discontinuation of Hospital-initiated Prescription|Decrease of Exposure to Hypnosedative Drugs in the Elderly Through the Discontinuation of Hospital-initiated Prescription: Impact on the Quality of Sleep and Fall Frequency|HYPAGE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|240|||Both|65 Years|N/A|No|||September 2015|September 17, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02296957||32503|
NCT02298049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBirmingham|An fMRI Study of Satiation in Healthy Volunteers.|Satiation Attenuates BOLD Activity in Brain Regions Involved in Reward and Increases Activity in an Inhibitory Control Area: an fMRI Study in Healthy Volunteers.||University of Birmingham|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298049||32419|
NCT02318134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanchanguniversity|Fecal Microbiota Transplantation for Pancreatitis|Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Intestinal Barrier Dysfunction|FMTP|The First Affiliated Hospital of Nanchang University|No|Not yet recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2014|December 16, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318134||30877|
NCT02325986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD-B2014157|Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer|Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma||Sun Yat-sen University|No|Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|70 Years|No|||November 2015|November 19, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325986||30274|
NCT02310074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ruijin-GnRH pump-002|Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism|Study on the Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism||Shanghai Jiao Tong University School of Medicine||Active, not recruiting|January 2010|||June 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Male|16 Years|35 Years|No|||December 2014|January 31, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02310074||31496|
NCT02307201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|complejoh|Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia|Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .|MAG-PIP|Complejo Hospitalario Dr. Arnulfo Arias Madrid|Yes|Completed|December 2014|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1114|||Female|14 Years|44 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307201||31716|
NCT02314455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009092|Esophageal Absorption in EoE|Esophageal Absorption in Eosinophilic Esophagitis|EoE|Mayo Clinic|No|Recruiting|September 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02314455||31160|
NCT02321215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRHP_EducationAECOPD2014|Effectiveness and Feasibility of Delivering an Education Program to Patients With an Acute Exacerbation of COPD|Effectiveness and Feasibility of Delivering an Introductory Education Program to Patients Admitted to Hospital With an Acute Exacerbation of COPD - a Pilot Randomized Controlled Trial||West Park Healthcare Centre|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|N/A|N/A|No|||December 2015|December 9, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02321215||30641|
NCT02307643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-J03|Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients|An Exploratory Study of MT-1303 in Subjects With Systemic Lupus Erythematosus (a Multicenter, Open-label Study)||Mitsubishi Tanabe Pharma Corporation|No|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|64 Years|No|||March 2016|March 16, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02307643||31682|
NCT02307656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-517|Taste Properties of Atazanavir and Cobicistat|Assessment of the Taste Properties of Atazanavir and Cobicistat and Pediatric Oral Test Formulations Containing Both Atazanavir and Cobicistat in Healthy Adults||Bristol-Myers Squibb|No|Recruiting|November 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 10, 2016|October 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02307656||31681|
NCT02306720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-HPP-501|An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)|An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)||Alexion Pharmaceuticals||Enrolling by invitation|December 2014|||December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Patients with Hypophosphatasia (HPP)|June 2015|June 10, 2015|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02306720|5 Years|31753|
NCT02306733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH 4|Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally|Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial||Cairo University|Yes|Recruiting|November 2014|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02306733||31752|
NCT02324101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsp90a2011-02|Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer||Protgen Ltd|No|Recruiting|April 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1100|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|December 22, 2014|December 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324101||30419|
NCT02324114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsp90a2011-03|Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer||Protgen Ltd|No|Recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1100|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 22, 2014|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02324114||30418|
NCT02324127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsp90a2011-05|Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer||Protgen Ltd|No|Active, not recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1100|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 14, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02324127||30417|
NCT02640976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC (705)|Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program|Assessing the Relation Between Hormone Receptors Gene Polymorphism and Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program||Cairo University|Yes|Completed|June 2013|August 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|216|||Female|25 Years|35 Years|No|||December 2015|December 22, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640976||6100|
NCT02633943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTF-303|Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy|Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector||bluebird bio|No|Enrolling by invitation|September 2013|March 2031|Anticipated|March 2031|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|27|||Both|5 Years|35 Years|No|Non-Probability Sample|Subjects with hemoglobinopathies (β-thalassemia or severe sickle cell disease) who have        been treated with ex vivo gene therapy product in bluebird bio-sponsored clinical studies|December 2015|December 15, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633943||6640|
NCT02633956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-209|Combination OCA and Statins for Monitoring of Lipids (CONTROL)|A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis|CONTROL|Intercept Pharmaceuticals|Yes|Recruiting|December 2015|August 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|85 Years|No|||February 2016|February 25, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633956||6639|
NCT02633969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND2-15-08|Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age|A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Indomethacin Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery||Iroko Pharmaceuticals, LLC|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|16 Years|No|||December 2015|December 15, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633969||6638|
NCT02632318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-36269|Dawn Simulation and Postural Hypotension|Dawn Simulation as a Passive Countermeasure to Postural Hypotension in Healthy Older Adults||VA Palo Alto Health Care System|No|Not yet recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632318||6765|
NCT02632331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0014|ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825|Pharmacokinetic (PK) Study of ASP8825 - Evaluation of the Effect of Food on the Pharmacokinetics||Astellas Pharma Inc|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632331||6764|
NCT02636309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234ERGON|Multifaceted Physioterapeutic Intervention at Workplace|How a Multifaceted Physioterapeutic Intervention Can Manage Musculoskeletal Disorders in a Hearing Aid Industry||University of Sao Paulo General Hospital|No|Completed|January 2011|March 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|172|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02636309||6459|
NCT02641041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215HV102|Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants|A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects||Biogen|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641041||6095|
NCT02634242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS08008|Study on the Antiaging Effect of Chinese Herb Drink|Study on the Antiaging Effect of Chinese Herb Drink||Chung Shan Medical University|Yes|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634242||6617|
NCT02634489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-071|EC905 Pharmacokinetic Profile Study|An Open-label, Parallel Group, Randomized, Two-way Crossover, Multiple Dose Study to Compare the Pharmacokinetic Profiles of Solifenacin Succinate and Tamsulosin HCl Following Co-administration of Single Entity Tablets and Administration of Three Different Dose Strengths of the Combination Tablet EC905||Astellas Pharma Inc|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|46|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02634489||6598|
NCT02629432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI0884|Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT|Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR COPD)|MR-COPD|University Hospital Heidelberg|Yes|Enrolling by invitation|December 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|625|||Both|40 Years|N/A|No|Non-Probability Sample|This Trial is fully embedded within the main cohort of the Cosyconet-Study: Impact of        Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health        care Ressources in Patients with COPD (COSYCONET), NCT01245933 ). Only patients included        into the main study are asked to take part in this sub-trial which is not pharmaceutical        and only has one arm including the expected number of patients (625) .|December 2015|December 9, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02629432|1 Day|6986|
NCT02629445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD14/11241|HIPACE High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias|High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias|HIPACE|The Leeds Teaching Hospitals NHS Trust|No|Recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|100 Years|No|||December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629445||6985|
NCT02642770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/2440/DM/2266|3D & Speckle Tracking Together as a Marker for Early Outcome in Cardiac Surgery|3D & Speckle Tracking Together as a Sensitive Marker for Early Outcome in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery||Postgraduate Institute of Medical Education and Research|No|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|73|||Both|18 Years|N/A|No|Probability Sample|Patients with left ventricular dysfunction (LVEF< 50%) undergoing cardiac surgery under        CPB.|December 2015|December 29, 2015|December 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02642770||5962|
NCT02629341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONEFOODS|Functional Yogurt Powder Effect on Bone Health Biomarkers|Functional Yogurt Powder Effect on Bone Health Biomarkers|bonefoods|Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|January 2015|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|79|||Female|50 Years|65 Years|No|||December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629341||6993|
NCT02629354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335.3|To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet|A Single Center, Single Dose, Open Label, Randomized, Two Period, Two Sequence Crossover Study to Evaluate the Relative Bioavailibility of Ibuprofen From a Fixed-dose Combination Tablet Containing Ibuprofen 400 mg and Caffeine 100 mg and a Tablet of Ibuprofen 400 mg in at Least 30 Healthy Males and Females Under Fed Conditions||Boehringer Ingelheim||Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|December 10, 2015||||No||https://clinicaltrials.gov/show/NCT02629354||6992|
NCT02630992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15080192|Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media|Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media||University of Pittsburgh|No|Recruiting|December 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|6 Months|23 Months|No|||December 2015|December 14, 2015|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630992||6866|
NCT02631005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2738|Walk With Ease Program For Patients With Systemic Lupus Erythematosus|Walk With Ease Program For Patients With Systemic Lupus Erythematosus|Walk SLE|University of North Carolina, Chapel Hill|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02631005||6865|
NCT02631226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPTneonat_2015_01|Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.|Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted in the Hospital: a Multicenter Study (EME Study).|EME|Corporacion Parc Tauli|Yes|Recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|580|||Female|N/A|N/A|No|Non-Probability Sample|Less than 32 weeks pregnant woman admitted to the hospital and her newborn if the mother        is a multi-resistant enterobacteriaceae carrier.|February 2016|February 10, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02631226||6848|
NCT02630641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-54-52014-218|Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.|Impact of the Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone (GnRH) Agonist Therapy Initiated by the Urologist in the Routine Practice. Evaluation by the Patient and the Partner.|EQUINOXE|Ipsen|No|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer patients and their partners recruited by urologists.|February 2016|February 29, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630641||6893|
NCT02377180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066/13|Capsaicin-induced Muscle Pain in Humans|Capsaicin-induced Muscle Pain in Humans: From Investigating Central Pain Processing to Developing Clinical Applications||University Hospital Inselspital, Berne|No|Recruiting|September 2014|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02377180||26354|
NCT02377193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 484 03|Simulect Versus ATG in Sensitized Renal Transplant Patient|Prospective, Multicenter, Randomized, Evaluating Two Induction Therapies With Simulect® Versus ATG® Fresenius Associated With Tacrolimus and Myfortic® in the Prevention of Treatment Failure, in Sensitized Renal Transplant|SATIR|University Hospital, Toulouse|Yes|Recruiting|September 2013|June 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||August 2015|August 31, 2015|June 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02377193||26353|
NCT02632968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_D012_44452|Pinhole Surgical Technique With And Without Use Of Buttons For Treatment Of Multiple Gingival Recessions: RCT|Pinhole Surgical Technique With And Without Use Of Button Application For Treatment Of Multiple Gingival Recessions: A Comparative Controlled Randomized Clinical Trial||Krishnadevaraya College of Dental Sciences & Hospital|Yes|Recruiting|November 2013|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632968||6715|
NCT02633228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/129/14|Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of an Oculentis +2.0 Diopters (Torical) Bifocal Intraocular Lens (MplusX (Toric) LU-313 MF20T/LS-313 MF20) in the Distance Dominant Eye, in Combination With a +3.0 Diopters Oculentis Bifocal Intraocular Lens (MplusX (Toric) LU-313 MF30T/LS-313 MF30) in the Fellow Eye.||Charite University, Berlin, Germany|No|Recruiting|December 2014|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02633228||6695|
NCT02644005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVAS|Automated Control of Mechanical Ventilation During General Anaesthesia|Automated Control of Mechanical Ventilation During General Anaesthesia - A Bicentric Prospective Observational Trial|AVAS|University of Schleswig-Holstein|No|Not yet recruiting|April 2016|May 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Adult patients scheduled for elective surgery in general anesthesia.|December 2015|December 30, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02644005||5867|
NCT02644018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ING-03-02-2015|Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.|Double Blind Randomized Placebo-controlled Multicenter Study to Evaluate Clinical Efficacy and Safety of Ingavirin®, Capsules 30 mg, in 3-6 Years Old Patients With Influenza and Other Acute Respiratory Viral Infections in the Course of Standard Therapy|ACCORD|Valenta Pharm JSC|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|3 Years|6 Years|No|||February 2016|March 22, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02644018||5866|
NCT02634892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14120116|Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention|Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention||University of Pittsburgh|Yes|Not yet recruiting|January 2016|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|100 Years|No|||December 2015|December 17, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02634892||6567|
NCT02631720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-20|CLAD Phenotype Specific Risk Factors and Mechanisms.|A Prospective Multicenter Observational Cohort Study to Define the Risks Factors, Mechanisms, and Manifestations of Chronic Lung Allograft Dysfunction (CLAD) Phenotypes (CTOT-20).||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|December 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Peripheral whole blood samples: DNA, RNA, Plasma, Serum Bronchoalveolar lavage (BAL):      aliquots with DNA, cells, supernatant|Both|18 Years|N/A|No|Probability Sample|Adult lung transplant recipients undergoing lung transplant at each of the participating        centers.|December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631720||6810|
NCT02633475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJK201583|Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk|Association Between Interleukin-10 Promoter-1082A/G Polymorphism With Idiopathic Recurrent Miscarriage Risk of Chinese Han||Fourth Affiliated Hospital of Guangxi Medical University|Yes|Not yet recruiting|March 2016|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|blood samples|Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female patients who referred to the Fourth Affiliated Hospital of Guangxi Medical        University or Liuzhou Maternity and Child Healthcare Hospital|December 2015|December 14, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02633475||6676|
NCT02636361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16176|A Study of Various Formulations of LY900014 in Healthy Participants|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Multiple LY900014 Formulations||Eli Lilly and Company|No|Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636361||6455|
NCT02643199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D Echocardiography|Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy|Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy||Ain Shams University|Yes|Active, not recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a Prospective pilot study that will be performed at the Fetal Care Unit at Ain        Shams University Maternity Hospital.        Ninety pregnant women will be recruited from the Fetal Care Unit who will fulfill the        inclusion criteria. They will be counseled to be included into the study.|December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643199||5929|
NCT02631577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29562|A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma|A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA||Hoffmann-La Roche||Recruiting|December 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631577||6821|
NCT02641015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 223/15|Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)|A Retrospective Observational Study to Assess the Clinical Management and Outcomes of Hospitalised Patients With Complicated Urinary Tract Infection in Countries With High Prevalence of Multidrug Resistant Gram-negative Bacteria.|RESCUING|Institut d'Investigació Biomèdica de Bellvitge|Yes|Recruiting|December 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalised patients from 1st January 2013 to the 31st December 2014. Diagnosis of cUTI        as the primary cause of hospitalisation and patients hospitalised for another reason but        who developed cUTI during their hospitalisation. Patients will be identified by searching        for any of the following ICD-9 CM or ICD-10 CM codes at discharge on the hospital        administration system: ICD-9 CM Codes: 590.1, 590.10, 590.11, 590.2, 590.8, 590.80, 590.9,        595.0, 595.89, 595.9, 99.0 ICD-10 CM Codes: N10, N12, N13.6, N15.1, N15.9, N30.0, N30.8,        N30.9, N39.0|January 2016|January 7, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02641015||6097|
NCT02392208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00095470|Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5|Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5||University of Michigan|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|8|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392208||25199|
NCT02392221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2013_843_0022|Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2008).|Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2008).|Inspired|Centre Hospitalier Universitaire, Amiens|No|Not yet recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|966|||Both|N/A|26 Years|No|Non-Probability Sample|Pediatric IBD patients in the area of EPIMAD registry Age of diagnosis < 17 years|March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392221||25198|
NCT02636374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0105|Guided Imagery: Reducing Stress and Improving Well-being in Pregnant Adolescents|Guided Imagery: Reducing Stress and Improving Well-being in Pregnant Adolescents||University of Wisconsin, Madison|No|Enrolling by invitation|November 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Female|13 Years|21 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02636374||6454|
NCT02632838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro20150001419|Improve Hypertension Monitoring and Self-management by Using mHealth|Utilizing a Mobile Health (mHealth) Application to Improve Hypertension Monitoring and Self-management in an Underserved Community: A Pilot Study||Rutgers, The State University of New Jersey|No|Not yet recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|35|||Both|18 Years|64 Years|No|||December 2015|December 14, 2015|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02632838||6725|
NCT02630433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gallstenspancreatitistudien|Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis|Randomised Controlled Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis||Karolinska Institutet|Yes|Recruiting|August 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||December 2015|December 15, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02630433||6909|
NCT02630680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-58800-001|Eziclen Drug Utilisation in Real Life Setting|A Multicentre, European, Observational, Drug Utilisation Study (DUS) of BLI800 (Eziclen®/Izinova®) as a Bowel Cleansing Preparation|DUS-BLI800|Ipsen|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1285|||Both|18 Years|N/A|No|Probability Sample|Colorectal diseases patients from specialised gastroenterology, hepatogastroenterology        departments ("referral centres") and endoscopy departments ("non referral centres").|February 2016|February 29, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630680||6890|
NCT02383069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-UNI9|Pulmonary Rehabilitation in Asthmatic Patient|Pulmonary Rehabilitation in Asthmatic Pediatric Patients: Randomized Clinical Trial||University of Nove de Julho|No|Recruiting|February 2015|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02383069||25901|
NCT02383082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3A|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2013|||||N/A|N/A|N/A||||||||||||||March 6, 2015|February 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383082||25900|
NCT02636530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1451|Effect of Two Exercise Programs on Bone Strength and Architecture|Effect of Two Exercise Programs on Bone Strength and Architecture||University of Colorado, Denver|No|Not yet recruiting|February 2016|January 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636530||6442|
NCT02637245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061249|Imaging Parameters and DME Treatment Response|Imaging Parameters Predicting Treatment Response in Patients With Diabetic Macular Edema||Duke University|No|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of DME in one or both eyes which is visually significant in the        opinion of the clinician/investigator.|December 2015|December 21, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02637245||6387|
NCT02632903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA8DEC2015|Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study|Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study||Children's Hospital of Eastern Ontario|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|8 Years|16 Years|No|||December 2015|December 15, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02632903||6720|
NCT02632916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZA9DEC2015|Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study|A Single-Blinded, Randomized, Controlled, Phase 2 Pilot Study to Evaluate the Safety and Efficacy of Denosumab Compared to Zoledronic Acid for the Treatment of Osteoporosis in Children||Children's Hospital of Eastern Ontario|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Years|16 Years|No|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02632916||6719|
NCT02393326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0644-14-HMO-CTIL|Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars|Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars||Hadassah Medical Organization|No|Not yet recruiting|May 2015|May 2019|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393326||25113|
NCT02629484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.231|Trial of Focused Cardiac Ultrasound for Fractured Neck of Femur Surgery|A Pilot Study to Assess Feasibility, Compliance, Safety and Group Separation for a Multicentre Randomised Trial of Preoperative Focused Cardiac Ultrasound for Fractured Neck of Femur Surgery|ECHONOFII|University of Melbourne|Yes|Not yet recruiting|January 2016|February 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|N/A|N/A|No|||December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02629484||6982|
NCT02633124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_67|Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.|Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants: Randomized Controlled Multicenter Study of Edelvaiss Multiline NEO Device|MultilineNEO|University Hospital, Lille|No|Recruiting|January 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|260|||Both|24 Weeks|29 Weeks|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02633124||6703|
NCT02380768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2015-252|A Comparison of the Ambu AuraGain Versus LMA Supreme in Children|A Randomized Comparison of the Ambu AuraGain™ and LMA Supreme™ in Infants and Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|3 Months|6 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02380768||26078|
NCT02380989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adwin021|Integrative Ayurveda Healing Relieves Minor Sports Injury Pain|Integrative Ayurveda Healing Relieves Minor Sports Injury Pain:Results of a Multicenter Controlled Clinical Trial||Adwin Life Care|Yes|Completed|September 2014|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|March 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02380989||26061|
NCT02631291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110233|Promoting Widowed Elders Lifestyle After Loss|A Randomized Pilot Study of Behavioral Self-monitoring to Promote Mental Health Among Spousally Bereaved Older Adults||University of Pittsburgh|Yes|Recruiting|November 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02631291||6843|
NCT02632162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRW-SDB-2015|Prevalence, Severity and Natural Course of Sleep Apnea After Cardiac Surgery|Prevalence, Severity and Natural Course of Sleep Apnea After Cardiac Surgery|SDB-ZRW|Zürcher RehaZentrum Wald|No|Not yet recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|450|||Both|N/A|N/A|No|Probability Sample|cardiac surgery < 2 weeks|December 2015|December 17, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02632162||6777|
NCT02632175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-870|Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis|A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290||AbbVie|No|Enrolling by invitation|November 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|5 Years|18 Years|No|||January 2016|January 25, 2016|December 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02632175||6776|
NCT02640989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-INF-BJJQ-01|Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military|Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military||Center for Disease Prevention and Control of Beijing Military Region|Yes|Completed|October 2014|April 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|292|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02640989||6099|
NCT02636686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMN-051-302|Extension Study of Drisapersen in DMD Subjects|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in Subjects With Duchenne Muscular Dystrophy.||BioMarin Pharmaceutical|Yes|Enrolling by invitation|December 2015|January 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Male|5 Years|80 Years|No|||February 2016|February 18, 2016|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636686||6430|
NCT02636699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPITES|Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy|A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children|PEPITES|DBV Technologies|Yes|Recruiting|December 2015|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|4 Years|11 Years|No|||March 2016|March 22, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636699||6429|
NCT02639000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|736|Effects of Blastocyst Stage Compared With Cleavage Stage Embryo Transfer in Women Below 39 Years|Effects of Blastocyst Stage Embryo Transfer Compared With Cleavage Stage Embryo Transfer in Women ≤ 38 Years|BlastoTrans|Istituto Clinico Humanitas|Yes|Recruiting|July 2010|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|388|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639000||6252|
NCT02628730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI-IIS-386|Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation|Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation (PRAISE)|PRAISE|Liverpool Heart and Chest Hospital NHS Foundation Trust|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02628730||7040|
NCT02632851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIL/aBr/2015|Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution|Non-interventional Multicentric Study on Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution||Bitop AG|Yes|Recruiting|December 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|120|||Both|5 Years|N/A|No|Non-Probability Sample|primary care or ENT units study the therapeutic process in this obvservational trial in        total of 120 patients suffering on respiratory tract infection and/or acute bronchitis|December 2015|December 14, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02632851||6724|
NCT02641158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP8757|Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.|CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.|CTN 0064|Columbia University|Yes|Enrolling by invitation|December 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|684|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02641158||6086|
NCT02638363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Precat|An Investigation of General Predictors for CBT Outcome for Anxiety Disorders in a Naturalistic Setting|An Investigation of General Predictors for Cognitive Behavioral Therapy Outcome for Anxiety Disorders in a Naturalistic Setting||University of Copenhagen|Yes|Recruiting|August 2015|December 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with anxiety disorders from outpatient clinics.|December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638363||6301|
NCT02643888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCR-ABL 001|Pre-existing Kinase Domain Mutations in Ph-positive Leukemias|Identification of Pre-existing Kinase Domain Mutations in Subclones of Ph-positive Leukemias||St. Anna Kinderkrebsforschung|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|Samples With DNA|DNA samples from CML patients obtained from bone marrow/peripheral blood and fingernail      clippings|Both|N/A|N/A|No|Non-Probability Sample|The study plan includes 30 adult patients with Ph-positive leukemia.|December 2015|December 28, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02643888||5876|
NCT02643901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tmab-GW003-NP-03|Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects|The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects||Jiangsu T-Mab Biopharma Co.,Ltd|No|Recruiting|September 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|December 29, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02643901||5875|
NCT02631811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0305|Early Palliative Care in Patient With Acute Leukaemia|Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.|Pablo Hemato|Hospices Civils de Lyon|No|Recruiting|November 2015|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02631811||6803|
NCT02629016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011301|Stress Reduction: A Pilot Study With Adolescents|Stress Reduction: A Pilot Study With Adolescents||Oregon Health and Science University||Active, not recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|320|||Both|14 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02629016||7018|
NCT02637297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9445|Hypnotherapy in Treating Chronic Pain in Cancer Survivors|Hypnosis for Pain Management With Cancer Survivors||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2016|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02637297||6383|
NCT02639416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.048|Hypoallergenic and Anti-inflammatory Feeds in Malawian Children With Severe Acute Malnutrition (SAM)|Hypoallergenic and Anti-inflammatory Feeds to Treat Intestinal Inflammation in Malawian Children With Severe Acute Malnutrition: A Pilot Randomized Controlled Clinical Trial (SAM)|SAM|Liverpool School of Tropical Medicine|Yes|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|6 Months|23 Months|No|||February 2016|February 2, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639416||6220|
NCT02642575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D Folliculometry|Automated Folliculometry Using Five-Dimensional Ultrasound|Automated Folliculometry Using Five-Dimensional Ultrasound||Ain Shams University|Yes|Active, not recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a Prospective pilot study that will be performed at the Fetal Care Unit at Ain        Shams University Maternity Hospital.        72 women will be recruited from the the Fetal Care Unit who will fulfill the inclusion        criteria. They will be counseled to be included into the study.|March 2016|March 12, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02642575||5977|
NCT02629666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHC-17-2014. 634270-2.|Exercise Referral Schemes Enhanced by Self-Management Strategies to Battle Sedentary Behaviour|Exercise Referral Schemes Enhanced by Self-Management Strategies to Battle Sedentary Behaviour|SitLESS|University Ramon Llull|No|Not yet recruiting|January 2016|May 2019|Anticipated|October 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1338|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02629666||6968|
NCT02629679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111705/2015|Sports, Education and Consumption of Substances in Adolescents|Prospective Analysis of the Factors Associated With Substance Use and Misuse in Adolescents|SESA|University of Split|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1000|||Both|14 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|The sample will comprise approximately 1,000 participants (50% males). At the beginning of        the study, the participants will be attending the 3rd year (grade) of high school, and        therefore practically all subjects will be 17 years of age at the moment the study starts        (+/- 6 months). Participants will be randomly selected from 10 to 15 high schools which        offer a 4-year high school education. Because of the prospective study design and        consequent need to repeatedly test the same participants, only those schools where the        investigators already have personal and professional contacts with the school authorities        will be used as possible test environments.|December 2015|December 11, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02629679||6967|
NCT02632344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-469|Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement|Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement||Massachusetts General Hospital|Yes|Not yet recruiting|January 2016|June 2023|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632344||6763|
NCT02639078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0139|Single Ascending Dose Study of TD-0714 in Healthy Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−0714 in Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|56|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639078||6246|
NCT02639091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17631|Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors|An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer||Bayer|No|Recruiting|February 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639091||6245|
NCT02640443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/059|Sulfamethoxazole for the Treatment of Primary PREPL Deficiency|Sulfamethoxazole for the Treatment of Primary PREPL Deficiency (In Dutch: Sulfamethoxazole Ter Behandeling Van Primaire PREPL deficiëntie)|SPPD|Universitair Ziekenhuis Brussel|No|Enrolling by invitation|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|15|||Both|2 Months|N/A|No|||October 2015|December 22, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02640443||6141|
NCT02640456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51440|Microbiology of Para- og Retropharyngeal Abscess|Mikrobiologi Ved Para- og Retropharyngeal Absces||Aarhus University Hospital|No|Not yet recruiting|February 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|72|Samples With DNA|Tonsillar surface swabs, pus aspirates, tonsillar tissues, sera|Both|18 Years|N/A|No|Non-Probability Sample|Sixty patients with para- or retropharyngeal abscess. Twelve patients with neck abscess        without relation to the pharynx or salivary glands (controls).|December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02640456||6140|
NCT02320591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSM-500-T0006|Evaluation of the Comprehensive Primary Care Initiative|Evaluation of the Comprehensive Primary Care Initiative|CPC|Mathematica Policy Research, Inc.|No|Active, not recruiting|July 2012|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|365076|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02320591||30689|
NCT02301715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELOREA01|Effects of Intranasal Oxytocin on Emotion Regulation to Stressful Interaction in Insecure Adolescents: a Study Protocol for a Double Blind Randomized Controlled Trial|||Centre Hospitalier Universitaire de Besancon|Yes|Not yet recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Male|13 Years|20 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02301715||32137|
NCT02301728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB-100|Study on Short Chain Fatty Acids Concentration in Breast Milk and Its Correlation With the Maternal Diet|Short Chain Fatty Acids in Breast Milk||Federico II University||Not yet recruiting|December 2014|May 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|parturients women at term hospitalized in the Department of Obstetrics, Gynecology and        Pathophysiology of Human Reproduction, "Federico II" University of Naples.|November 2014|November 25, 2014|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02301728||32136|
NCT02304380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2045|Care Coordination for Children With Disabilities|Improving Care Coordination for Children With Disabilities Through an Accountable Care Organization||University of North Carolina, Chapel Hill|No|Enrolling by invitation|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|3790|||Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children who qualify for Medicaid under the Aged, Blind, and Disabled category, and their        caregivers, who are part of the Nationwide Children's Hospital Partners for Kids        Accountable Care Organization (ACO) in Columbus, Ohio.|February 2016|February 10, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02304380||31932|
NCT02304393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29392|A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors|An Open-label, Multicenter, Dose Escalation Phase Ib Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With MPDL3280A (ANTI&#8722;PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors.||Hoffmann-La Roche||Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304393||31931|
NCT02320318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAK-08|12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 12-week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D).|IRIS-05|Menarini Group|No|Suspended|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|No|||April 2015|April 8, 2015|December 12, 2014||No|The Sponsor decided to put the study on hold due to the challenges faced in patient    recruitment in the active sites.|No||https://clinicaltrials.gov/show/NCT02320318||30710|
NCT02313935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84171-A|Cognitive/Physical Computer-Game Blended Training of Elderly: Neuroscientific LLM Studies|Effects of Cognitive and/or Physical Exercises Blended by Computer Games in Elderly: The LLM Project Neuroscientific Investigations in Thessaloniki, Greece by the LLM Team at the Aristotle University of Thessaloniki|LLM-AUTH|Aristotle University Of Thessaloniki|No|Completed|November 2010|April 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|581|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313935||31199|
NCT02295163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46979.091.13|Stellate Ganglion Block for Hot Flushes in Men Treated With ADT|Short-term Efficacy of Stellate Ganglion Block in Men to Reduce Hot Flushes Related to Androgen Deprivation Therapy||Rijnstate Hospital|No|Recruiting|July 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||June 2015|June 26, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02295163||32640|
NCT02295176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMP-11|Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome|Metabolic and Cardiovascular Effects of a Proprietary Nutraceutical Containing Berberine, Policosanols and Red Yeast in Subjects With Metabolic Syndrome|ARMP-11|Rottapharm|No|Completed|April 2013|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02295176||32639|
NCT02318147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanchanguniversityII|Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)|Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Infectious Complications||The First Affiliated Hospital of Nanchang University|No|Not yet recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2014|December 16, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318147||30876|
NCT02326311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOBSTMO-OPTKIMA-2014|Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response|Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response||Azienda Ospedaliera Spedali Civili di Brescia|Yes|Recruiting|June 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|502|||Both|60 Years|N/A|No|||February 2016|February 5, 2016|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02326311||30249|
NCT02306096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCANB001|Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer|SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative|SCAN-B|Lund University|No|Recruiting|August 2010|August 2031|Anticipated|August 2031|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|Samples With DNA|Tumor tissue, whole blood, serum, plasma. Collected at diagnosis and during follow-up.|Both|N/A|N/A|No|Probability Sample|All patients with suspected or confirmed diagnosis of primary breast cancer within        participating hospital systems in the South Sweden Healthcare Region, Uppsala County, and        Jönköping Country, Sweden. Additional hospital sites from within the Nordic countries are        welcome to join.|March 2016|March 22, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306096||31800|
NCT02308215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIowa201003712|Retinal Therapy Guided by 3D OCT Image Analysis|Retinal Therapy Guided by 3D OCT Image Analysis||University of Iowa|No|Recruiting|July 2010|||November 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|45 Years|N/A|No|Non-Probability Sample|The proposed research will be carried out in patients diagnosed with Choroidal        Neovascularization associated with AMD selected from retina care clinic.|December 2014|December 4, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02308215||31638|
NCT02296723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|570-10|Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|July 2011|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|November 19, 2014|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02296723||32520|
NCT02315196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041401|Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer|A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)||Rutgers, The State University of New Jersey|No|Recruiting|December 2014|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02315196||31103|
NCT02641132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0091-13-MMC|Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.|The Comparison of Endothelial Cell Count in Pterygium Surgery Relating to the Timing of MMC Application.|PHB-MMC1|Meir Medical Center|No|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02641132||6088|
NCT02641145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002477|Molecular Imaging of Primary Amyloid Cardiomyopathy|Molecular Imaging of Primary Amyloid Cardiomyopathy|MICA|Brigham and Women's Hospital|No|Not yet recruiting|April 2016|March 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|99 Years|No|||December 2015|December 28, 2015|December 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641145||6087|
NCT02637076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-2014|Xyrem and Brain Dopamine in Narcolepsy|Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation||Centre for Addiction and Mental Health|No|Recruiting|January 2016|December 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|19 Years|N/A|No|||January 2016|January 15, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637076||6400|
NCT02636543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/32|Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments|Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments|LIPEG|University Hospital, Bordeaux|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||5|Actual|325|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Group 2a-patient: 75 patients who attended a genetic counselling consultation.          -  Group 2a-public: 75 persons belonging to the general population who never attended             genetic counselling consultation.          -  Group 2b-patient: 75 patients who attended a genetic counselling consultation.          -  Group 2b-public: 75 persons belonging to general population who never attendeda             genetic counselling consultation. These persons are different than persons from group             2a-person.          -  Group 2b-professionnal: 75 genetic professionals (geneticist and genetic counsellor).|December 2015|December 17, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636543||6441|
NCT02639936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBnet study #54|New Generation IGRA in Immunocompromised Individuals|Performance of a New Generation IGRA in Immunocompromised Individuals|TBnet#54|Tuberculosis Network European Trialsgroup|No|Recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|2000|Samples Without DNA|Stimulated plasma samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Immunocompetent and immunocompromised patients|December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639936||6180|
NCT02641236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-394|Gut Decontamination In Pediatric Allogeneic Hematopoietic|A Randomized Phase 2 Study to Examine the Impact of Gut Decontamination on Intestinal Microbiome Composition in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients||Dana-Farber Cancer Institute|Yes|Not yet recruiting|January 2016|May 2023|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28|||Both|4 Years|23 Years|No|||December 2015|December 23, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641236||6080|
NCT02637336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVASF|Study to Investigate Effects of Different Therapies for the Treatment of Hypertension|Acute Cardiovascular Responses in Hypertensive Individuals||Universidade Federal do vale do São Francisco|Yes|Completed|March 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Male|40 Years|60 Years|No|||December 2015|December 21, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02637336||6380|
NCT02633514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508151-6|Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma|A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma||Fudan University|Yes|Recruiting|November 2015|||November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633514||6673|
NCT02640261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Echelo|Observational Prospective Study of the Success of Single Embryo Transfer Implantation Related to Level of Follicular Fluid Cytokines Expression in Low Responders Infertile Patients Treated With r-hLH add-on Therapy in a Second Controlled Ovarian Stimulation Cycle.|||Centro di Procreazione Assistita Demetra|No|Recruiting|January 2016|April 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Follicular Fluid|Female|18 Years|38 Years|No|Non-Probability Sample|Normogonadotropic Infertile Women that failed the first IVFcycle and require r-hLh add on        therapy as per Demetra clinical standard procedures|December 2015|February 2, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640261||6155|
NCT02629627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUCS-INTEC-MV-UKN-001|Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome|Effect of the Administration of Conjugated Linoleic Acid / Leucine Plus Metformin on Visceral Fat in Patients With Metabolic Syndrome||Centro Universitario de Ciencias de la Salud, Mexico|No|Not yet recruiting|March 2016|March 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|104|||Both|35 Years|65 Years|No|||December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629627||6971|
NCT02635737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sentimark|Magnetic Seed Localisation of Breast Cancers|Safety and Feasibility Study of Magnetic Seed Markers to Localise Breast Cancers for Surgical Excision||University Hospital of South Manchester NHS Foundation Trust|Yes|Not yet recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|99 Years|No|||December 2015|December 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635737||6503|
NCT02635750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.24|Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects|A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of BI 409306 and Donepezil in Healthy Male and Female Subjects||Boehringer Ingelheim||Active, not recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 17, 2015||||No||https://clinicaltrials.gov/show/NCT02635750||6502|
NCT02629198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16353|The Effect of Body Weight on Vitamin D Metabolism|The Effect of Body Weight on Vitamin D Metabolism||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Actual|112|Samples With DNA|serum, plasma, urine, DNA|Both|8 Years|77 Years|Accepts Healthy Volunteers|Non-Probability Sample|The total study sample will consist of 136 participants (112 adults and 24 children) who        are lean, overweight or obese. Participants will be drawn from two previous studies; 'The        effects of obesity on bone structure and strength' (STH 15688) and 'Body weight and bone'        (STH16199), in which their body composition, bone strength and biochemistry have been        documented in detail.        All participants from the previous studies will be invited to participate, and recruitment        will continue until 112 adults and 24 children across a range of body weights have been        recruited.|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629198||7004|
NCT02633774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0914|Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation|Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation: Prospective Randomized Trial||Yonsei University|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|No|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02633774||6653|
NCT02633787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA00093|Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier|Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier||Sanofi|No|Completed|December 2015|March 2016|Actual|February 2016|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633787||6652|
NCT02634385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZILPAREMBZ14|Zero Ischemia Laparoscopic Partial Nephrectomy|Zero Ischemia Laparoscopic Partial Nephrectomy in Combination With Superselective Renal Artery Embolization for Small Renal Masses: A Feasibility Trial|ZILPAREMZ|St. Joseph's Healthcare Hamilton||Withdrawn|November 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 10, 2014||No|No funding to start project.|No||https://clinicaltrials.gov/show/NCT02634385||6606|
NCT02382055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7072|Changing Habits in Anorexia Nervosa: Novel Treatment Development|Changing Habits in Anorexia Nervosa|REACH|New York State Psychiatric Institute|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|No|||October 2015|October 19, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02382055||25979|
NCT02386228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14BN104|Micro Ribonucleic Acid (miRNA) Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)|miRNA Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|March 2015|September 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|CSF and blood|Both|N/A|6 Years|No|Non-Probability Sample|infants with IVH or spina bifida|September 2015|September 23, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386228||25658|
NCT02629458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO14/11248|A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical Resection|A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy (SABR) With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer (NSCLC) cOnsidered Higher Risk of Complications From Surgical Resection|SABRTOOTHv1|The Leeds Teaching Hospitals NHS Trust|Yes|Recruiting|July 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|100 Years|No|||December 2015|February 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629458||6984|
NCT02641561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-091|Lactated Ringers Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin|IND+LRPEP|The Cooper Health System|Yes|Recruiting|October 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02641561||6055|
NCT02641574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102892|Relation Between Complication in Repeated Cesarean Sections, Newborn Outcome and Surgical Characteristics and Maternal Information|Relation Between Complication in Repeated Cesarean Sections Compared With Newborn Outcome,Surgical Characteristics and Maternal Information||Rambam Health Care Campus||Completed|January 2009|||November 2015|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|5000|||Female|17 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|All women who underwent a cesarean section at Rambam Medical Center who had at least one        cesarean section in the past|December 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02641574||6054|
NCT02391103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1072/2010|Effects of Neuromuscular Electrical Stimulation on Muscle Mass and Strength in Critically Ill Patients After Cardiothoracic Surgery|Effects of Neuromuscular Electrical Stimulation on Muscle Mass and Strength in Critically Ill Patients After Cardiothoracic Surgery. An Ultrasound-Based Randomized Controlled Trial|Catastim 2|Medical University of Vienna|No|Completed|May 2011|March 2015|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02391103||25283|
NCT02638779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0379|REAnimation Low Immune Status Markers|REAnimation Low Immune Status Markers|REALISM|Hospices Civils de Lyon|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638779||6269|
NCT02628639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/482|Optimizing the Evaluation of Awareness in Disorders of Consciousness|Using High-resolution Electroencephalography to Optimize the Evaluation of Awareness in Patients With Disorders of Consciousness|CONPHIDENSE|Centre Hospitalier Universitaire de Besancon|No|Not yet recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|28|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02628639||7047|
NCT02628652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCRO-057|Study to Evaluate the Tolerability of Prebiotics on the Microbiota|A Randomised, Single-Blind, Controlled Study to Evaluate the Tolerability of Prebiotics on the Microbiota||Kaleido Biosciences||Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|45|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02628652||7046|
NCT02631590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18435|Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma|Phase II Study of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma||H. Lee Moffitt Cancer Center and Research Institute|No|Not yet recruiting|May 2016|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631590||6820|
NCT02631603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StopEAA|Stop Exogenous Allergic Alveolitis (EAA) in Childhood|Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease|chILD-EU_EAA|Ludwig-Maximilians - University of Munich|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|6 Years|25 Years|No|||December 2015|December 15, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02631603||6819|
NCT02631668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2015-270|the Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients|The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA)||Huashan Hospital|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|December 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631668||6814|
NCT02391870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0353-01|The Staying Well Study: An Open Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depression|Phase One: An Open Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depression||University of Colorado, Boulder|Yes|Completed|November 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|49|||Female|18 Years|N/A|No|||March 2015|March 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391870||25225|
NCT02639195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBO-C2015-005|The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO|The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO||Clear Passage Therapies, Inc|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|350|||Both|18 Years|90 Years|No|Probability Sample|Population with a history of a bowel obstruction in the last 2 years.|December 2015|December 21, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639195||6237|
NCT02636985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503075RINC|Application of Ultrasonic Elastography in Lung Lesions|Transthoracic Ultrasound Elastography in Pulmonary Lesions and Diseases||National Taiwan University Hospital|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|45|||Both|18 Years|85 Years|No|Probability Sample|Patients with radiographic findings of consolidation, obstructive pneumonitis or tumors,        detected on chest computed tomography (CT), who received ultrasound study with or without        ultrasound-guided biopsy for tissue proof and UE, from December 2011 to March 2013.|December 2015|December 17, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02636985||6407|
NCT02631408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iVRCT1_0|Intrawound Vancomycin Powder in Spinal Fusion Surgery|Application of Intrawound Vancomycin Powder to Reduce Surgical Site Infections in Spinal Fusion Surgery - A Prospective, Randomized, Controlled Trial|iVRCT|Orthopedic Hospital Vienna Speising|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02631408||6834|
NCT02392286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015143|Corticosteroid Dosage for Crohn's Disease Flare|A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares||Yale University|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392286||25193|
NCT02639624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01343|Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate|Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate||New York University School of Medicine|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639624||6204|
NCT02632929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00816|Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue|Prevention of Amputation in a High Risk Population With Comprehensive Care and Amniotic Tissue||Boise VA Medical Center|No|Recruiting|July 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a diabetic foot ulcer referred to the High Risk Foot Clinic at Boise        VAMC who meet the inclusion criteria, and are willing and able to participate will be        enrolled.|December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632929||6718|
NCT02380495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verbale n°13/2013|"Studio NaVA" - National Study on Quality of Life in Adolescents Affected by Allergic Rhinitis With or Without Asthma|Studio NaVA - Studio Nazionale Sulla Qualità Della Vita in Adolescenti Con Rinite Allergica Con e Senza Asma||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1200|||Both|14 Years|17 Years|No|Probability Sample|-  600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age,             recruited from Pediatricians of the Italian territory          -  600 subject (5 for each participant Pediatrician) of the same age range, without             respiratory pathology (patient family)|December 2015|December 18, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02380495||26099|
NCT02380508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB038|Heterologous Effects of BCG in Healthy UK Adults|Evaluation of the Heterologous Effects of Bacille Calmette-Guérin (BCG) Vaccination in Healthy UK Adults||University of Oxford|No|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02380508||26098|
NCT02638077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200125_621|Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China|A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)|DTCC|Huazhong University of Science and Technology|Yes|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|None Retained|tumors samples will retained for detecting gene mutation|Both|N/A|N/A|No|Non-Probability Sample|Differentiated Thyroid Cancer patients undergo the first-time thyroidectomy and identified        as intermediate or high risk of recurrence will be recruited.|December 2015|December 18, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638077||6323|
NCT02638090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18494|Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)|A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2016|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638090||6322|
NCT02638103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV48125-CNS-30051|Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine|A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine||Teva Pharmaceutical Industries|No|Recruiting|March 2016|October 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1842|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638103||6321|
NCT02633306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511M80284|Transcranial Magnetic Stimulation for Facial Pain|Complex Oro-Facial Pain: Functional Imaging Characterization and Treatment With Transcranial Magnetic Stimulation||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|110 Years|No|||December 2015|December 14, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633306||6689|
NCT02634203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM14123|Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension|Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension|RACE|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|80 Years|No|||December 2015|December 21, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634203||6620|
NCT02635802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zdyfysicu-1|the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation|the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation||The First Affiliated Hospital of Zhengzhou University|Yes|Not yet recruiting|December 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|1500|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635802||6498|
NCT02638116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108106|A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults|Open-Label, Sequential-Design Drug Interaction Study of the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults||Janssen Research & Development, LLC|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638116||6320|
NCT02635958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004659|InBody Validation Study|Validation of the InBody 770® for the Assessment of Body Composition|InBody|Mayo Clinic|No|Recruiting|December 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|176|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with a BMI greater than 18.5 and weigh no more than 450 lbs.|January 2016|January 5, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635958||6486|
NCT02637271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109416/A16-0067-001|Brain Response to Dietary Interventions|Neural Correlates of a Nutritionally Balanced Total Meal Replacement, 3 Week Dietary Exposure: An fMRI Study|BRDI|Texas Tech University|No|Recruiting|January 2016|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|19 Years|60 Years|No|||December 2015|January 13, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637271||6385|
NCT02391493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 245 03|Neural Correlates of Language Control in Bilinguals. Functional MRI and Stimulation Mapping Data in Awake Surgery.|Neural Correlates of Language Control in Bilinguals. Functional MRI and Stimulation Mapping Data in Awake Surgery. (NEUROSWITCH)|NEUROSWITCH|University Hospital, Toulouse|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02391493||25253|
NCT02632864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-004|Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial|||Samsung Medical Center|No|Recruiting|December 2015|||October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|20 Years|N/A|No|||January 2016|January 12, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02632864||6723|
NCT02641249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#14-000804|Non-invasive Intervention for Apnea of Prematurity|Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.||University of California, Los Angeles|No|Completed|October 2014|February 2016|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|N/A|No|||March 2016|March 17, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641249||6079|
NCT02629107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160031|Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli|An All-Night Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|58|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||November 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629107||7011|
NCT02629120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160032|High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease|High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|December 2030|Anticipated|December 2025|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Years|65 Years|No|||November 2015|January 15, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629120||7010|
NCT02631824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPFX-001-AUGM|Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment|Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment: A Randomized Multicenter Clinical Trial|AFIF|Hospital Infantil Universitario de San Jose|No|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|65 Years|N/A|No|||December 2015|December 11, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02631824||6802|
NCT02633085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#002 FB vs MB|Fixed Bearing Versus Mobile Bearing Patient Satisfaction and Clinical Outcome Study|A Retrospective, Consecutive Series, Single Surgeon Study Comparing Patient Satisfaction and Clinical Outcomes in Patients With Fixed Bearing Versus Mobile Bearing Unicompartmental Knee Arthroplasty||Medacta USA|No|Recruiting|February 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients that have undergone a Unicompartment Knee Replacement with a Fixed Bearing or        Mobile Bearing prosthesis.|March 2016|March 16, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633085||6706|
NCT02636855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP-0000-001|Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC|A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Non-Small Cell Lung Cancer (NSCLC)||Adaptimmune|No|Recruiting|November 2015|November 2025|Anticipated|November 2025|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Tumor biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or        IV) or recurrent disease|January 2016|January 20, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636855||6417|
NCT02636868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-CL-1202|Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age|A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome||Discovery Laboratories, Inc.|Yes|Recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|26 Weeks|32 Weeks|No|||December 2015|December 28, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636868||6416|
NCT02644213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2664-OF-CTIL|Evaluation of Physical and Cognitive Performance After Simulated Road March Combines Physical and Cognitive Load Using a Virtual Reality Environment|Evaluation of Physical and Cognitive Performance After Simulated Road March Combines Physical and Cognitive Load Using a Virtual Reality Environment||Sheba Medical Center|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02644213||5851|
NCT02641626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COUPE|Coronariography in OUt of hosPital Cardiac arrEst|Randomized Study About the Efficacy of an Urgent Coronariography in Patients With a Non-diagnostic Electrocardiogram Following Out of Hospital Cardiac Arrest.|COUPE|Hospital San Carlos, Madrid|No|Not yet recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02641626||6050|
NCT02641639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX4325|PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer|FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer||OXiGENE|No|Not yet recruiting|May 2016|July 2018|Anticipated|June 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|436|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641639||6049|
NCT02637518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662887|Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings|A Comprehensive Validation of Frailty Assessment Tools to Screen and Diagnose Frailty in Different Clinical and Social Settings and to Provide Instruments for Integrated Care in Older Adults.|FRAILTOOLS|Hospital Universitario Getafe|Yes|Not yet recruiting|February 2016|May 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1940|||Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People older than 75 years old will be included, recruited from different clinical        settings such as clinical (hospital or primary care) and social (nursing homes).|December 2015|December 18, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637518||6366|
NCT02633982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENeRAL/J|GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence|Registry Study on the Effectiveness of Rivaroxaban in Patients With Non-valvular Atrial Fibrillation Managed by General Practitioners(GENERAL Study)|GENeRAL|Japan Cardiovascular Research Foundation|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|20 Years|N/A|No|Probability Sample|5,000|November 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02633982|2 Years|6637|
NCT02636556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508151-5|Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma|Phase Ⅰ/Ⅱ Study of Concurrent Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma||Fudan University|Yes|Recruiting|November 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02636556||6440|
NCT02641691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512140|Five Fractions of Radiotherapy Followed by FOLFOX/CapeOx Chemotherapy as Organ-Sparing Treatment for Low Risk Rectal Cancer|Pilot Study of Five Fractions of Radiotherapy Followed by FOLFOX/CapeOx Chemotherapy as Organ-Sparing Treatment for Low Risk Rectal Cancer||Washington University School of Medicine|No|Not yet recruiting|March 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641691||6045|
NCT02641704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14111-SDUpro|The Development Path|A Descriptive Study of Characteristics and Progression of Citizens Assigned to a Multidisciplinary Program Focusing on Moving Citizens From Unemployment and Social Security Benefits to Employment and Education||University of Southern Denmark|Yes|Recruiting|February 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Unemployed citizens with complex health-related problems assigned to a multidisciplinary        program in Sønderborg Municipality|February 2016|February 5, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641704||6044|
NCT02325947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iMove|Efficacy of Hand Exoskeleton Controlled by BCI in Post Stroke Patients|A Multicentre Randomized Single Blind Placebo Controlled Study to Assess Efficacy of Hand Exoskeleton Controlled by Motor Imagery Based BCI for Post Stroke Patients Movement Rehabilitation|iMove|Russian Academy of Medical Sciences|No|Not yet recruiting|January 2015|December 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2014|December 19, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02325947||30277|
NCT02307500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2014-001|Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy|An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND|RESOUND|Istituto Clinico Humanitas|No|Recruiting|December 2014|January 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02307500||31693|
NCT02307513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-BCT-002|A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease|A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease||Celgene|Yes|Recruiting|December 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02307513||31692|
NCT02307123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9N088|One-year Outcome After Prehospital Intubation|One-year Outcome After Prehospital Intubation||Tampere University Hospital|No|Completed|January 2013|April 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|483|||Both|N/A|N/A|No|Probability Sample|All non-cardiac arrest patients, whose airway was secured by the HEMS physician.|November 2014|November 30, 2014|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02307123||31722|
NCT02310191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHOG-2/2012|Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting|Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting||University Hospital Ostrava|Yes|Completed|July 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|81|Samples Without DNA|Blood samples collecting: hematology + reticulocytes, coagulation markers (PT, APTT, INR,      Fbg, Clauss), vWF antigen, PAI-1 activity, PAI-1 polymorphism 4G/g, Multiplate (ASA and      clopidogrel resistance test) anti Xa activity|Both|18 Years|90 Years|No|Probability Sample|patients with internal carotid artery stenosis >70%, indicated to carotid stenting|December 2014|December 3, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02310191||31487|
NCT02297204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG-2014-11-006|The Endurance 1 Trial|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial)|Endurance|Northern California Retina Vitreous Associates|No|Enrolling by invitation|November 2014|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Female|18 Years|N/A|No|||November 2014|November 20, 2014|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297204||32484|
NCT02297217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA.CC-14-0122|Chemoradiotherapy for Advanced Esophageal Cancer|A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus||AHS Cancer Control Alberta|No|Not yet recruiting|February 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297217||32483|
NCT02299661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1093-A-E103|Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease|An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease||Daiichi Sankyo Inc.|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|31|||Both|18 Years|70 Years|No|||June 2015|June 18, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02299661||32295|
NCT02306629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0032|Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood|An Open-label, Parallel-group, Single-dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Subcutaneous Epratuzumab in Healthy Caucasian and Japanese Subjects||UCB Pharma|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|November 29, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02306629||31760|
NCT02320760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI65|Physical Activity on Prescription in Overweight Older Adults|Physical Activity in Prevention and Treatment of Overweight, Central Obesity and the Metabolic Syndrome - a Randomised Controlled Study in Overweight 65 Year Old Women and Men||Karolinska Institutet||Completed|January 2005|May 2009|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|102|||Both|65 Years|69 Years||||December 2014|December 16, 2014|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320760||30676|
NCT02313961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-CARD-01|Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty|Evaluation of Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty|RIC-STEMI|Hospital de Braga|No|Recruiting|March 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|492|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313961||31198|
NCT02313974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSM LuNe|Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)|Lupus Flares and Histological Renal Activity at the End of the Treatment|LuFla|Hospital de Clinicas José de San Martín|Yes|Recruiting|January 2014|November 2018|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Proliferative Lupus Nephritis confirmed by renal biopsy|November 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313974|5 Years|31197|
NCT02297451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091982|Trial Comparing the Incidence of Steal Syndrome in the Two Types of anTEcubitaL Fossa Arteriovenous fistuLa AVF|Randomised Controlled Trial Comparing the Incidence of Steal Syndrome in the Two Types of anTEcubitaL Fossa Arteriovenous fistuLa AVF (STEAL Trial)|STEAL|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|February 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02297451||32465|
NCT02297464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-032|Eggs as Part of a Healthy Breakfast|Eggs as Part of a Healthy Breakfast: Lack of Association With Heart Disease Risk||University of Connecticut|No|Active, not recruiting|July 2014|August 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02297464||32464|
NCT02296736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/P/090|The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan|The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan||Plymouth Hospitals NHS Trust|No|Active, not recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|422|||Both|N/A|N/A|No|Non-Probability Sample|Retrospective review of imaging of all patients who have undergone surgery for presumed        pancreatic malignancy in Derriford Hospital.|October 2015|October 29, 2015|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02296736||32519|
NCT02319538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTG 031100-031230|Hashimoto - a Surgical Disease. Absolute Total Thyroidectomy Makes Antibodies Disappear and Ameliorates Symptoms|Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.||Sykehuset Telemark|Yes|Recruiting|February 2012|February 2016|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319538||30769|
NCT02641366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500964|Electromagnetic Tracking to Measure Tremor|Noninvasive Electromagnetic Tracking of Upper Extremity Motion Kinetics for Patients With Severe Tremor Disorders||University of Florida|No|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641366||6070|
NCT02639793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFOulu|Effects of Catheter Ablation on Burden of Atrial Fibrillation (MRICEMAN)|A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor|MRICEMAN|University of Oulu|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02639793||6191|
NCT02641587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2R-REXA-07-EU|Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.|A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.2 (CHTP 1.2), Compared to Continuing to Use Combustible Cigarettes, for 5 Days in Confinement Followed by 85 Days in an Ambulatory Setting.||Philip Morris Products S.A.|No|Not yet recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|28 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02641587||6053|
NCT02643082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003018|A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD|A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD||Pearl Therapeutics, Inc.|No|Recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||February 2016|February 17, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643082||5938|
NCT02642120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0558-15- TLV|Dental Support and the Second Stage of Labor Among Multiparous Women|Dental Support and the Second Stage of Labor Among Multiparous Women||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642120||6012|
NCT02640053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU221511I|Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome|Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial||Academic and Community Cancer Research United|Yes|Recruiting|December 2015|||November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640053||6171|
NCT02637661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JQi1|Earlobe Crease as Risk Factors of Acute Myocardial Infarction in Chinese Population|Earlobe Crease as Risk Factors of Acute Myocardial Infarction in Chinese Population|ELC-AMI-CHN|Liaoning University of Traditional Chinese Medicine|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|236|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The case group is Initial acute myocardial infarction(AMI),the control group is no        coronary heart disease|January 2016|January 8, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02637661||6355|
NCT02630381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40580.078.12|Shock Wave Therapy for Osteoporosis|Treatment of Osteoporosis With Unfocused Extracorporeal Shock Wave Therapy: Pilot Study|BOEST|UMC Utrecht||Enrolling by invitation|May 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Female|50 Years|80 Years|No|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630381||6913|
NCT02390791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH101155|New Technologies to Help Manage ADHD|Developing New Technologies to Improve ADHD Medication Continuity||Children's Hospital Medical Center, Cincinnati|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|6 Years|10 Years|No|||November 2015|November 10, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02390791||25307|
NCT02638233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIL4ME2015/01|Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy|Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy||Wilhelminenspital Vienna|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02638233||6311|
NCT02638246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD061683-02|Incentives for Internet-based Adherence to SMBG for Teens With T1D|Incentives for Internet-based Glucose Testing in Adolescent Type 1 Diabetes||Rowan University|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02638246||6310|
NCT02637674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14002/ATU|Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors|Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors|ATU|University Hospital, Limoges|Yes|Recruiting|January 2016|January 2022|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|25 Years|36 Years|No|||January 2016|January 12, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02637674||6354|
NCT02637687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOXO-TRK-15003|Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors|A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors||Loxo Oncology, Inc.|No|Recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|1 Month|21 Years|No|||February 2016|February 23, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637687||6353|
NCT02641509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|854/2015|Accuracy in Resection of Non-pedunculated Colonic Lesions 5-20 mm With/Without Using NBI|||Valduce Hospital|No|Not yet recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|918|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02641509||6059|
NCT02386241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14BN108|Identification of Genomic Changes in Families Having Multiple Members With Tumors|Identification of Genomic Changes in Families Having Multiple Members With Tumors||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|March 2015|January 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|A single saliva or blood sample measuring 10mL for genomic analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families having multiple members (1st degree) with tumors.|March 2016|March 22, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386241||25657|
NCT02392117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4189|Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus|A Multi-centre, Prospective, Non-interventional Study of Insulin Degludec Investigating the Safety and Effectiveness in a Real World Population With Type 1 and 2 Diabetes Mellitus|ReFLeCT|Novo Nordisk A/S|No|Enrolling by invitation|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1216|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients aged at least 18 years of age with either T1DM or T2DM (insulin        using) (clinically diagnosed) prior to visit 1, who signed an informed consent form, and        whose physician plans to start Tresiba® treatment are eligible for entry in this study.|January 2016|January 27, 2016|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392117||25206|
NCT02636218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTM-3007|Ketamine Infusion in Neurologic Deficit|A Pilot Study of Sub-anesthetic Ketamine Infusion for Neuroprotection After Aneurysmal Subarachnoid Hemorrhage: Effects on White Matter Integrity, Inflammatory Biomarkers and Neurocognitive Outcome|KIND|St. Michael's Hospital, Toronto|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02636218||6466|
NCT02636231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC201501|Endostar for Locally Recurrent Nasopharyngeal Carcinoma|A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients||Sun Yat-sen University|No|Recruiting|November 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02636231||6465|
NCT02634086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010CB732601|Long-term Outcome of Triple-vessel Coronary Artery Disease Underwent Three Different Strategies (LOTUS)|Long-term Outcome of Triple-vessel Coronary Artery Disease Underwent Three Different Strategies (LOTUS)|LOTUS|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|April 2004|December 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Between April 2004 and April 2018 in Fuwai Hospital, Beijing, China, consecutive patients        with angiography confirmed triple-vessel coronary disease.|December 2015|December 17, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02634086||6629|
NCT02640937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12063|Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections|Biofilm Formation Increases Treatment Failure in Staphylococcus Epidermidis Device-related Osteomyelitis in Human Patients||BG Unfallklinik|No|Completed|November 2011|November 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|124|Samples Without DNA|Bacterial samples from orthopaedic device realted infections|Both|18 Years|N/A|No|Non-Probability Sample|Orthopaedic device related infection involving longbones of the lower extermity|December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640937||6103|
NCT02377466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200719|A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|NEWBORN-1|GlaxoSmithKline|Yes|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Female|12 Years|45 Years|No|||February 2016|February 4, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377466||26332|
NCT02632305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX-CSARC-PI-0001|A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer|A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer||AHS Cancer Control Alberta|Yes|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632305||6766|
NCT02636595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-583|The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)|A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) Incorporating Amendment 1||AbbVie|No|Recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|99 Years|No|||February 2016|February 4, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636595||6437|
NCT02637024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2015-OPAR|Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation|A Phase II Randomized Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (OPAR)|OPAR|Ontario Clinical Oncology Group (OCOG)|Yes|Not yet recruiting|March 2016|June 2023|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Female|50 Years|N/A|No|||February 2016|March 4, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637024||6404|
NCT02393261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usix -2500PD-001|A Controlled and Multi-Center Study of 2500ml Huaren Peritoneal Dialysate|Validity and Security of 2500ml Huaren Peritoneal Dialysate: A Prospective, Randomized, Controlled, Multi-Center Clinical Trial||Sun Yat-sen University|No|Recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393261||25118|
NCT02629185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15688|The Effects of Obesity on Bone Structure and Strength|The Effects of Obesity on Bone Structure and Strength||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Actual|258|Samples With DNA|Serum, plasma, urine, DNA|Both|25 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Caucasians Recruited from South Yorkshire, UK|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629185||7005|
NCT02640313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL43466.068.13/ABR43466|18F-choline and 18F-FDG PET-MR of Symptomatic Carotid Plaques|Evaluation of Symptomatic Carotid Artery Plaques With Positron Emission Tomography-magnetic Resonance Imaging (ESCAPPE)|ESCAPPE|Maastricht University Medical Center|Yes|Recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640313||6151|
NCT02631707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Highproteinbariatric|The Effect of High Protein Diets on Weight Loss and Lean Muscle Mass in Patients Awaiting Bariatric Surgery|The Effect of High Protein Diets on Weight Loss and Lean Muscle Mass in Patients Awaiting Bariatric Surgery||University of Auckland, New Zealand|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02631707||6811|
NCT02393287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-A-RSD-2014-07|Retroprospective Real Life Observatory of Eribulin|Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study|ReProLine|Institut Cancerologie de l'Ouest|No|Recruiting|November 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|753|||Female|18 Years|N/A|No|Probability Sample|The population includes all patients treated by Eribulin for breast cancer whose treatment        has been starting between January 2014 and September 2015|March 2015|March 18, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02393287||25116|
NCT02393313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0670-14-TLV|Rayner Toric IOL Rotational Stability|Examination of Rayner T-flex Toric Intra-Ocular Lens for Spherical and Astigmatic Correction, and Rotational Stability|Rayner-toric|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02393313||25114|
NCT02629731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2008-R|Orthotic Dose Response Study|Quantitative Prescription of Foot Orthoses: A Dose-Response Study of Kinematics in Patients With Foot and Ankle Pain Using Biplane Fluoroscopy|ODRS|VA Office of Research and Development|No|Not yet recruiting|February 2016|November 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02629731||6963|
NCT02642419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFIRE Study|Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study|Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)|AFIRE|Japan Cardiovascular Research Foundation|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2200|||Both|20 Years|N/A|No|||December 2015|December 26, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642419||5989|
NCT02642432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-172|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis|A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)|EXPEDITION-1|AbbVie|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642432||5988|
NCT02633137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-196|Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma|Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633137||6702|
NCT02633150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9501|Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Menopausal Women|Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Menopausal Women : Study Randomized Versus Placebo|POLYGIR|University Hospital, Montpellier|No|Recruiting|October 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02633150||6701|
NCT02635724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-306|Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza|A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications||BioCryst Pharmaceuticals|No|Recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635724||6504|
NCT02643810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCLRehab0012015|Exercise Training in Adults With Corrected Tetralogy of Fallot|Influence of Different Types of Exercise Training on Selected Cardiovascular Parameters in Adult Individuals With Corrected Tetralogy of Fallot||University Medical Centre Ljubljana||Enrolling by invitation|June 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02643810||5882|
NCT02637453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiXinhua-Af|Additional Linear Ablation Beyond Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation|Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF)||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|June 2015|May 2019|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637453||6371|
NCT02634697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000552|Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation|Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation||Massachusetts General Hospital|No|Recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02634697||6582|
NCT02638207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAM-08|Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy|Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy|CIDP|Octapharma|Yes|Not yet recruiting|June 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02638207||6313|
NCT02628587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUZ001|Patent Versus Generic Clopidogrel in Acute Coronary Syndrome|Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial||Hospital Central San Luis Potosi, Mexico|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02628587||7051|
NCT02638818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064629|Outcomes in Minimally Invasive Versus Open Pancreaticoduodenectomy|A Pilot Study Evaluating Health-related Quality of Life Endpoints in Patients Undergoing Minimally Invasive Versus Open Pancreaticoduodenectomy||Duke University|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for pancreaticoduodenectomy will be eligible for this study.|December 2015|December 21, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02638818||6266|
NCT02638831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL_RUS/PMS/2012/KETG|Ketorol Gel in Gonarthrosis and Low Back Pain|Open Label Randomized Study for Evaluating Efficacy and Safety of Ketorol® and Fastum® in Gel in Patients With Gonarthrosis and Low Back Pain||Dr. Reddy's Laboratories Limited|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|20 Years|70 Years|No|||December 2015|December 21, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02638831||6265|
NCT02641821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nifedipine-HT-1.0|Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension|Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension: a Multi-center, Open-label, Observational Study||Peking University First Hospital|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|700|||Both|18 Years|75 Years|No|||December 2015|December 23, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02641821||6035|
NCT02378857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1331 (REK)|Fontan Circulation and Cardiopulmonary Function: Prognostic Factors, Hemodynamics and Long-term Effects|Fontan Circulation and Cardiopulmonary Function: Prognostic Factors, Hemodynamics and Long-term Effects||Oslo University Hospital|No|Recruiting|March 2015|September 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples Without DNA|EDTA, citrate and serum samples for analysis for inflammation markers and organ specific      markers.|Both|15 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adolescents i Norway with univentricular heart defects and Fontan type palliation|March 2015|March 9, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378857||26225|
NCT02639143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10167|Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients|Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the Infarct-related Artery in STEMI Patients: A Prospective Randomized Trial of Ticagrelor Versus Clopidogrel||First Affiliated Hospital of Harbin Medical University|Yes|Not yet recruiting|December 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|79 Years|No|||November 2015|December 20, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02639143||6241|
NCT02639156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AY:SPT1|Acceptability and Tolerance of New Oral Nutritional Supplement|Evaluation of Tolerance and Acceptability of AYMES 'LONDON' Product||Aymes International Limited|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2015|December 21, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02639156||6240|
NCT02644148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPH-0504|Uncut Roux-en-Y Gastrojejunostomy for Early Gastric Cancer Patients|The Effect of Uncut Roux-en-Y Gastrojejunostomy on Quality of Life After Laparoscopic Distal Gastrectomy for Early Gastric Cancer Patients||The First Affiliated Hospital with Nanjing Medical University|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||January 2016|January 2, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644148||5856|
NCT02644174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-XYZ-123|The Impact of Bariatric Surgery Induced Weight Loss on Lung Function in Adolescents|The Impact of Bariatric Surgery Induced Weight Loss on Lung Function in Adolescents||Rabin Medical Center|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|11 Years|18 Years|No|Probability Sample|Adolescents with morbid obesity who will undergo bariatric surgery|December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644174||5854|
NCT02637726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIVCM|Bispectral Index Under Propofol Anesthesia in Children : a Study Between TIVA and TCI|Bispectral Index Under Propofol Anesthesia in Children : a Comparative Randomised Study Between TIVA and TCI||Hôpital Armand Trousseau|No|Completed|February 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|66|||Both|4 Years|16 Years|No|||December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637726||6350|
NCT02637739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-104_DR-18|Hysteroscopy for Pregnancy of Unknown Location|Office Hysteroscopy as a Diagnostic Tool of Pregnancy of Unknown Location||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02637739||6349|
NCT02641314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1495|Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma|Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)|METRO-NB2012|University of Cologne|Yes|Not yet recruiting|January 2016|March 2020|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|2 Years|20 Years|No|||January 2016|January 4, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02641314||6074|
NCT02641379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17131|A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)|Randomized, Multicenter Study to Find Optimal Treatment Duration in Patients With Chronic Hepatitis C and Subtype 1 or 4 Depending on HCV RNA Level at Week 8 and Week 12||Hoffmann-La Roche||Completed|May 2003|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|737|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641379||6069|
NCT02633462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deepti perio PGIDS/IEC/2015/60|Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis|Effect of Non-surgical Periodontal Therapy Along With Myo-inositol on High Sensitivity C-reactive Protein and Insulin Resistance in Polycystic Ovary Syndrome Women Having Chronic Periodontitis: A Randomized Controlled Trial||Postgraduate Institute of Dental Sciences Rohtak|Yes|Active, not recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Female|15 Years|35 Years|No|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633462||6677|
NCT02638727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRC101|Assessment of Short-term Effect of L-Citrulline on Endothelial Function and Vasodilation in Known CAD Patients|Assessment of Short-term Effect of L-Citrulline on Endothelial Function and Vasodilation in Known CAD Patients:A Randomized Crossover Clinical Trial||hahid Beheshti University of Medical Sciences||Recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 19, 2015|November 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02638727||6273|
NCT02639312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160040|Natural History of Craniofacial Anomalies and Developmental Growth Variants|Natural History of Craniofacial Anomalies and Developmental Growth Variants||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|November 2030|Anticipated|November 2030|Anticipated|N/A|Observational|N/A|||Anticipated|2400|||Both|2 Years|85 Years|No|||October 2015|January 20, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02639312||6228|
NCT02639598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-04-046B|Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis|Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis||Taipei Veterans General Hospital, Taiwan|No|Completed|June 2012|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||December 2015|December 20, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02639598||6206|
NCT02631551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPL/CT/2014/016/III|Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)|GSP 301-301|Glenmark Specialty S.A.||Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1176|||Both|12 Years|N/A|No|||March 2016|March 11, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631551||6823|
NCT02631564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ral-1|Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis|An Observational Study of TACE Hepatic Arterial Infusion of Oxaliplatin, Irinotecan and Raltitrexed Treatment for Refractory Liver Metastasis From Colorectal Cancer||Fudan University|Yes|Recruiting|June 2015|December 2018|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Probability Sample|Refractory liver metastasis from colon and rectal cancer|December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631564|12 Months|6822|
NCT02629029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8151|Multi-Modality Imaging for Head & Neck Cancer Free Flap Design Assessment|Multi-Modality Imaging for Head & Neck Cancer Free Flap Design and Assessment||University Health Network, Toronto|No|Recruiting|May 2015|August 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02629029||7017|
NCT02639520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CanUTI-7|Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs|A Double-blind, Controlled, Parallel-group, Randomized, Multicenter Clinical Trial to Assess the Efficacy and Safety of a Herbal Drug Containing Centaury, Lovage Root and Rosemary Leaf (CLR) in Comparison to Fosfomycin Trometamol for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections (uUTIs) in Women||Bionorica SE|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|644|||Female|18 Years|70 Years|No|||March 2016|March 2, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02639520||6212|
NCT02639533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0624|Brain Response to Single Dose of Pregabalin in Fibromyalgia|Pregabalin Acute Effects on Cortical Excitability, Psychophysical Parameters, and Serum Markers of Neuroplastic Processes in Fibromyalgia: a Placebo Controlled, Double Blinded, Randomized, Crossover Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|December 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|27|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02639533||6211|
NCT02637349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R42CA174048-03|Polaris Oncology Survivor Transition (POST) System|Polaris Oncology Survivor Transition (POST) System|POST|Polaris Health Directions|No|Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637349||6379|
NCT02637596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT 14579-3|Quality of Life After Radiofrequency Ablation of Pancreatic Cancer|Quality of Life After Intraoperative Radiofrequency Ablation of Pancreatic Cancer||Brno University Hospital|No|Completed|February 2013|December 2015|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02637596||6360|
NCT02639650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJHGTN1211|Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor|A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor||Women's Hospital School Of Medicine Zhejiang University||Not yet recruiting|March 2016|March 2021|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|214|||Female|N/A|60 Years|No|||December 2015|December 20, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02639650||6202|
NCT02629263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soluble Fiber and GC|The Effect of Soluble Fiber on Glycemic Control|The Effect of Soluble Fibre on Glycemic Control|SF&GC|St. Michael's Hospital, Toronto|No|Active, not recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This study includes all population types.|December 2015|December 9, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02629263||6999|
NCT02391766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIED01|Group Intervention Empowerment Dementia|Psychosocial Group Intervention to Enhance Empowerment of People With Dementia and Their Caregivers: Study Protocol for a Randomized Controlled Trial||Universidad Nacional de Rosario|No|Enrolling by invitation|September 2014|October 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|180|||Both|56 Years|79 Years|No|||March 2015|March 17, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02391766||25233|
NCT02313662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaBlaCa-8|Comparison of White Light, PDD and NBI in Detection of Flat Dysplasia and CIS at TURB - a Study of Trimodality|Trimodalitets-studie Hvidt Lys vs. NBI vs. PDD Ved Detektion af Flad Dysplasi og CIS Ved TURB|DaBlaCa-8|Aarhus University Hospital|Yes|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|153|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing PDD according to the Danish guidelines|December 2015|December 28, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02313662||31220|
NCT02310061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA-EDTA-01062012|Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study).|Lung Water By Ultra-Sound Guided Treatment To Prevent Death and Cardiovascular Complications in High Risk End Stage Renal Disease Patients With Cardiomyopathy (Lust Study)|LUST|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|Yes|Recruiting|November 2013|May 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02310061||31497|
NCT02294877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-504|A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)|A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)|MARS|BioMarin Pharmaceutical|No|Recruiting|September 2014|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|583|Samples Without DNA|Blood serum; urine samples|Both|N/A|N/A|No|Non-Probability Sample|Patients with MPS IVA disease and patients treated with Vimizim, although patients are not        required to receive Vimizim to be eligible to participate in this Registry.|March 2016|March 14, 2016|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02294877|10 Years|32662|
NCT02314208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-04|Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5|Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5|SPA-M|Institut National de la Santé Et de la Recherche Médicale, France|No|Active, not recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02314208||31179|
NCT02314221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPU-14-031|Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI|A Randomized, Crossover Clinical Trial of Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI|EAWSCI|James J. Peters Veterans Affairs Medical Center|No|Recruiting|February 2015|January 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02314221||31178|
NCT02317380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915034|Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other|Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other||National Institutes of Health Clinical Center (CC)||Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|700|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02317380||30935|
NCT02317393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERMATEP|Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy|A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy|TERMATEP|Centre Francois Baclesse|Yes|Recruiting|December 2014|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|19|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02317393||30934|
NCT02317406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEC13036|Effect of Probiotics on the Digestibility and Immunity in Infants|Effect of Probiotics on the Digestibility and Immunity in Infants||Biostime Institute of Nutrition and Care|No|Completed|December 2014|||November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|133|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02317406||30933|
NCT02302001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fwa00022532|Effects of Jet Hydro Dissection in Breast Augmentation Postoperative Pain|Breast Augmentation Using Novel Method of Jet Hydro Dissection Effects on Postoperative Pain||Aristocrat Plastic Surgery and MedAesthetics|Yes|Active, not recruiting|November 2014|||February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Female|22 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302001||32115|
NCT02306642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17540|Follow-up of AKI in Neonates During Childhood Years|Long Term Follow-up of Acute Kidney Injury in Very Low Birth Weight Infants|FANCY|University of Virginia||Recruiting|December 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|80|||Both|2 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children born prematurely less than 1500 grams who stayed in the University of Virginia        NICU.|January 2016|January 19, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306642||31759|
NCT02323984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0291|Postoperative Delirium in Hip Arthroplasty Patients|Postoperative Delirium in Patients Undergoing Hip Arthroplasty|mRNAOrtho|Ohio State University|No|Recruiting|January 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|||Both|30 Years|80 Years|No|Non-Probability Sample|Subjects schedule to undergo hip arthroplasty surgery|March 2016|March 14, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02323984||30428|
NCT02323997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN3+plus|Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study|Human Papillomavirus‐Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study|CIN3+plus|University of Bern|No|Active, not recruiting|January 2015|June 2016|Anticipated|December 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|800||Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive      carcinoma of the cervix.|Female|18 Years|N/A|No|Non-Probability Sample|Women with histologically confirmed CIN3+ lesions.|January 2016|January 18, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02323997||30427|
NCT02318472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR2012-2510|Early Mobilization After Achilles Tendon Rupture|Effects of Direct Functional Mobilization After Achilles Tendon Rupture on Healing and Outcome|EarlyM-Achil|Karolinska University Hospital|No|Recruiting|November 2013|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||September 2015|September 1, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02318472||30851|
NCT02302287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rf 2013-02355394|Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD|Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease|MEDIKA|Azienda Sanitaria ASL Avellino 2|No|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02302287||32093|
NCT02301299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00102919|Community Engagement for Early Recognition and Immediate Action in Stroke|Community Engagement for Early Recognition and Immediate Action in Stroke|CEERIAS|Northwestern University|No|Recruiting|October 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301299||32169|
NCT02301312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0276|Clinical Study of POSS-PCU Vascular Grafts for Vascular Access|A Clinical Investigation to Assess the Safety and Performance of POSS-PCU Small Diameter Grafts as Conduits in Arteriovenous (AV) Access||University College, London|Yes|Not yet recruiting|January 2015|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301312||32168|
NCT02322086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-10-PS-24|A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10|A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 Aqueous Hydrogel to Plaque Psoriasis||Provectus Pharmaceuticals|No|Active, not recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322086||30574|
NCT02642094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS 15-2096|Aging Mammary Stem Cells and Breast Cancer Prevention|Aging Mammary Stem Cells and Breast Cancer Prevention||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|December 2015|December 2021|Anticipated|December 2021|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Female|18 Years|80 Years|No|||December 2015|December 29, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02642094||6014|
NCT02630758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203P11124|Mindfulness-Based Yoga Intervention for Women With Depression|Mindfulness-Based Yoga Intervention for Women With Depression||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630758||6884|
NCT02639390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1966-R|Robotic Training for Stroke Neurorehabilitation|Task-Specific Upper-Extremity Robotic Training for Stroke Neurorehabilitation||VA Office of Research and Development|No|Not yet recruiting|January 2018|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|21 Years|N/A|No|||December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639390||6222|
NCT02639403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Palliative Short-Course Radiotherapy in Rectal Cancer|Palliative Short-Course Radiotherapy in Rectal Cancer: A Phase II Study||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|October 2003|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|N/A|No|||December 2015|December 21, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02639403||6221|
NCT02630368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2014-02|A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)|A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)|METROmaJX|Institut Bergonié|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|118|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02630368||6914|
NCT02635412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-1619|Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial||MAP|The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635412||6528|
NCT02635425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFOHSS|Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome|Aspiration of Limited Number of Eggs to Prevent Severe OHSS in Suspected Cases||Ain Shams Maternity Hospital|No|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|35 Years|No|||December 2015|December 16, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02635425||6527|
NCT02635646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UG 1/2014|Family and Interdisciplinary Intervention to Prevent Diabetes|Efficacy of a Family and Interdisciplinary Intervention to Prevent Diabetes, and Effect on Family Profiles of Insulin Secretion and Insulin Resistance in Patients With Prediabetes|CARE-in-DEEP|Universidad de Guanajuato|Yes|Recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02635646||6510|
NCT02635659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 143062|Proof of Concept Study; The Effect of an Encapsulated Nutrient Mixture on Ileal Brake Activation|The Effect of an Encapsulated Nutrient Mixture on Ileal Brake Activation: A Double-blind Randomized Study to Investigate the Effects on Body Weight, Food Intake and Satiety.||Maastricht University Medical Center|Yes|Recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02635659||6509|
NCT02643979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-2139|Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy|Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643979||5869|
NCT02634164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17757|The Effects of Leucine and Isoleucine on Glucose Metabolism|The Effects of Leucine and Isoleucine on Glucose Metabolism|AA+GLU|Texas Woman's University|No|Not yet recruiting|December 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Anticipated|12|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02634164||6623|
NCT02376907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10639|Biliary Drainage in Patients With Duodenal Metal Stent|Multinational Study on Endoscopic Management of Distal Malignant Biliary Obstruction Combined With Gastric Outlet Obstruction||Tokyo University|No|Active, not recruiting|January 2010|September 2017|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who underwent the initial duodenal SEMS between Jan/1/2010 and Jun/30/2014 are        included.|February 2015|February 25, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02376907||26375|
NCT02642003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastro-2014-OL|To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis|To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis||Sir Ganga Ram Hospital||Recruiting|June 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2015|December 29, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642003||6021|
NCT02642016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN0158-CL-001|A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors|A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN0158 in Adult Patients With KIT Positive Advanced Solid Tumors.||Kolltan Pharmaceuticals, Inc.|No|Recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642016||6020|
NCT02628080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO-073|Atovaquone as Tumour HypOxia Modifier|Pre-operative Window of Opportunity Study of the Effects of Atovaquone on Hypoxia in Non-small Cell Lung Carcinoma|ATOM|University of Oxford|No|Not yet recruiting|March 2016|November 2019|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628080||7090|
NCT02643147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001433-83|Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)|Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)|IMPROVE-HF|Fundación para la Investigación del Hospital Clínico de Valencia|Yes|Recruiting|January 2015|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02643147||5933|
NCT02640846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K050711|Effects of Levosimendan and Milrinone on Left and Right Ventricular Function in Septic Cardiomyopathy|Potential Differences Between Levosimendan and Milrinone on Hemodynamic Variables in Patients With Septic Cardiomyopathy|SCLM|Sahlgrenska University Hospital, Sweden|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|December 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640846||6110|
NCT02392130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKAT-1129|A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin|A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin||LEO Pharma|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|40|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02392130||25205|
NCT02378558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagneMark_02|A Trial of a New Magnetic Breast Marking Clip|Phase 1 Study of Magnetic Breast Marking Clip System MagneMark||Maimonides Medical Center|No|Recruiting|March 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Female|18 Years|N/A|No|||October 2015|October 1, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02378558||26248|
NCT02638610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 0110-15|Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries|Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries||Meir Medical Center|No|Not yet recruiting|January 2016|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|40 Years|80 Years|No|||December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638610||6282|
NCT02638324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Juhani02|Supportive Treatment of Severe Heart Failure by Renal Denervation|Supportive Treatment of Severe Heart Failure by Renal Denervation|Heart-RND|Turku University Hospital|No|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02638324||6304|
NCT02638337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517I0231|Randomized, Double-blind, Placebo-controlled Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause|A Phase 3, Randomized, Double-blind, Placebocontrolled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause||Shionogi Inc.|No|Recruiting|December 2015|January 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Female|40 Years|80 Years|No|||December 2015|December 18, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638337||6303|
NCT02631122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001537|Supraclavicular Block vs Retroclavicular Block: Incidence of Phrenic Nerve Paralysis|Ultrasound Guided Supraclavicular Brachial Plexus Block vs Retroclavicular Brachial Plexus Block: Comparison of Impact on Ipsilateral Diaphragmatic Function||Brigham and Women's Hospital|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02631122||6856|
NCT02631135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-21/18|Cognitive Functions After TIVA With Dexmedetomidine|Cognitive Functions After TIVA With Dexmedetomidine||Uludag University|No|Completed|January 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631135||6855|
NCT02382315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150013-01H|A Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer|Efficacy of a Cognitive-Existential Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer: A Randomized Clinical Trial||Ottawa Hospital Research Institute|No|Active, not recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02382315||25959|
NCT02636244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-141-POC-0004-PTL|Safety and Efficacy Study of SHAPE Gel in Alopecia Areata|A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata||TetraLogic Pharmaceuticals|No|Not yet recruiting|February 2016|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636244||6464|
NCT02642965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML1421|CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)||Children's Oncology Group||Not yet recruiting|May 2016|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|1 Year|21 Years|No|||December 2015|December 28, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642965||5947|
NCT02628990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YD2005|Lipid-lowering Effect of Plant Stanol Ester Yoghurt Drinks|The Effect of Plant Stanol Ester Yoghurt Drinks With or Without Added Camelina Oil on Serum Lipids in Comparison to Placebo in Subjects With Mildly to Moderately Elevated Serum Cholesterol Concentrations||Raisio Group|No|Completed|June 2005|November 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|155|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02628990||7020|
NCT02640521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00742|Smoking Cessation Peds Asthma|Pilot Testing an Intervention to Increase Implementation of Evidence-based Guidelines to Achieve Smoking Cessation in Smoking Parents of Inner-city Children With Asthma||New York University School of Medicine|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640521||6135|
NCT02379936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HildaNeo test study Vietnam|Evaluation of Lactate Dehydrogenase as Decision Support for Admissions to Neonatal Ward|Evaluation of a Point of Care Analyzer for Lactate Dehydrogenase, HildaNeo, as Support for Decisions When Admitting Newborn to the Neonatal Wards at NPH|HildaNeoHan|National Hospital of Pediatrics, Vietnam|Yes|Completed|August 2013|August 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|122|||Both|N/A|36 Hours|No|||February 2015|March 4, 2015|August 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02379936||26142|
NCT02379949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R42MH060506-02|Virtual Reality Exposure Therapy for the Treatment of Social Phobia|Virtual Reality Exposure Therapy for the Treatment of Social Phobia|FOPSII|Georgia State University|Yes|Completed|August 2004|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|97|||Both|18 Years|N/A|No|||February 2015|March 4, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02379949||26141|
NCT02633501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDX-44-004|P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)|P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)||Guerbet|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633501||6674|
NCT02631629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008276|Food-based Solutions for Optimal Vitamin D Nutrition and Health|Food-based Solutions for Optimal Vitamin D Nutrition and Health|ODIN_FOOD|Technical University of Denmark|Yes|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|140|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02631629||6817|
NCT02631980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-079|HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?|Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?|HepciFer|University Hospital, Geneva|Yes|Recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02631980||6791|
NCT02380248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXI639-P001 (C-13-040)|Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects|Clinical Evaluation of Systane® Gel Drops on Corneal Staining in Indian Subjects With Dry Eye||Alcon Research|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380248||26118|
NCT02380261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXR338-P001|A Clinical Study of Systane® Lid Wipes in Brazil|Assessment Of The Skin And Ocular Tolerance Of The Product Systane® Lid Wipes (050343-01) And Assessment Of The Study Subject Acceptance, Under Normal Use Conditions||Alcon Research|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02380261||26117|
NCT02633748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047213|Mindfulness Intervention to Improve Symptomology Among Cancer Survivors; Focus on Sleep and Stress Improvement|Mindfulness Intervention to Improve Symptomology Among Cancer Survivors; Focus on Sleep and Stress Improvement||Greenville Health System|No|Active, not recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|December 14, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02633748||6655|
NCT02628210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTI-2014-02|Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion|A Prospective, Multi-Center, Non-Randomized Study to Assess Clinical Outcomes Using Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior Lumbar Interbody Fusion or Lateral Lumbar Interbody Fusion||RTI Surgical|No|Recruiting|December 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02628210||7080|
NCT02628223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21921|180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma|A Randomized Trial of 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma||Temple University|Yes|Enrolling by invitation|September 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|111|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02628223||7079|
NCT02633397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15110016|A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases|A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases||University of Pittsburgh|Yes|Not yet recruiting|April 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633397||6682|
NCT02638038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT131-RU01-2|This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years|A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis||InteKrin Therapeutics, Inc.|Yes|Active, not recruiting|February 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638038||6326|
NCT02628340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREPATS 002|Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients|Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients With a Low Total Cell-associated Blood HIV-DNA|RESACHRON|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|Yes|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|A total of 20 patients under cART with HIV-RNA pVL < 50 cp/ml and HIV DNA <200 copies/106        PBMCs will be recruited from a total of over 3,900 patients under follow-up in the        Infectious Diseases Unit Pitié-Salpêtrière Hospital, in Paris.|December 2015|December 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02628340||7070|
NCT02631044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017001|Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)|A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)||Juno Therapeutics, Inc.|Yes|Recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|February 23, 2016|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631044||6862|
NCT02642484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sherief Abd-Elsalam|Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis|Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis||Tanta University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 24, 2015|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642484||5984|
NCT02642497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342|Local Ketamine Instillation for Postoperative Analgesia|Intra-wound Ketamine Instillation Reduced Postoperative Pain Following Modified Radical Mastectomy, a Randomized, Double-blinded, Controlled Study||Assiut University|No|Active, not recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|60 Years|No|||December 2015|December 29, 2015|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642497||5983|
NCT02642549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1142975|Girls for Health: Empowering Rural Girls' Transition From School to Employment as Health Workers|Girls for Health: Empowering Rural Girls' Transition From School to Employment as Health Workers||University of California, San Diego|Yes|Not yet recruiting|April 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2700|||Female|15 Years|22 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642549||5979|
NCT02634931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-12G-2|Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex|A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex||Nobelpharma|No|Not yet recruiting|December 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|3 Years|N/A|No|||December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634931||6564|
NCT02635165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01844-43|Medico-Economic Analysis of Management of Flail Chest Between Medical Treatment and Surgical Treatment With Stracos|Medico-Economic Analysis of Management of Flail Chest Between Medical Treatment and Surgical Treatment With Stracos|EMVOLS|Poitiers University Hospital||Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|80 Years|No|||December 2015|December 15, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02635165||6547|
NCT02632708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG120-221-C-001|Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation|A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation||Agios Pharmaceuticals, Inc.|No|Recruiting|December 2015|December 2020|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632708||6735|
NCT02630836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-MT-10-03|Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture|A Pilot Clinical Trial of ex Vivo Expanded Allogenic Adult Stem Cells Combined With Allogenic Human Bone Tissue (XCEL-MT-OSTEO-BETA) in Proximal Femur Fractures in Elderly Patients||Banc de Sang i Teixits|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|70 Years|85 Years|No|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02630836||6878|
NCT02383628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13110107|Endoscopic Perfusion Utilizing ICG Fluorescence Technology|Endoscopic Perfusion Utilizing ICG Fluorescence Technology|ICG|University of Pittsburgh|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient population would include those patients with pituitary tumors, intracranial        tumors, aneurysms, and normal tissue adjacent to tumors to clarify normal from abnormal.        Also, patients with compressive syndromes to ensure patency of normal vessels. This would        be all patients undergoing endoscopic surgery, both endonasal and open (retromastoid or        transcranial).|September 2015|October 2, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02383628||25858|
NCT02630511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047054|Asthma Exacerbations and Vascular Function|Asthma Exacerbations and Vascular Function||University of Alberta||Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02630511||6903|
NCT02630524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F151001005|Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI|Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI||University of Alabama at Birmingham|Yes|Not yet recruiting|January 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|19 Years|60 Years|No|||December 2015|December 14, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02630524||6902|
NCT02631057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.254|Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan|Comparison of the Length of Stay in Patients Hospitalized and Initiated With Dabigatran or Warfarin for a Concomitant Non-Valvular Atrial Fibrillation in Real-world Japanese Therapeutic Practice (SHORT-J)||Boehringer Ingelheim||Not yet recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Japan|March 2016|March 1, 2016|December 8, 2015||||No||https://clinicaltrials.gov/show/NCT02631057||6861|
NCT02641600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/18.02.2015|Elastic Compression in Chronic Venous Disease|Randomised Trial Comparing the Effectiveness of Elastic Compression in Treating Chronic Venous Disease (CEAP C2-C5)|RECVEN|University of Patras|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||December 2015|December 28, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02641600||6052|
NCT02641392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GED-0301-CD-004|A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease||Celgene|Yes|Not yet recruiting|March 2016|January 2022|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1400|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641392||6068|
NCT02637037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00008|A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects|A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants in Healthy Subjects Under Fasting and Fed Conditions||AstraZeneca|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02637037||6403|
NCT02639364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015 approval (156)|Airway Pressure Release Ventilation (APRV) Protocol Early Used in Acute Respiratory Distress Syndrome|the Effects and Safety of the Early Application of Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVEL-APRV) Protocol and Conventional Ventilation Strategy Were Compared in ARDS Patients||West China Hospital|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||December 2015|December 24, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02639364||6224|
NCT02636062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2016.055|Predictors of Coronary Artery Calcium Progression in Adults With a Prior Zero Coronary Artery Calcium Score|Predictors of Coronary Artery Calcium Progression in Adults With a Prior Zero Coronary Artery Calcium Score||San Antonio Military Medical Center|No|Not yet recruiting|February 2016|July 2020|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|The biological specimens collected in this study will be used for future testing and      evaluation of exploratory systemic biomarkers with respect to prediction of coronary artery      disease (CAD) progression and incident development of CAD. Specifically, samples are being      collected to investigate pro-fibrotic and pro-inflammatory makers and the effect on CAD      development and progression as measured by coronary artery calcification (CAC). DNA samples      will be tested for genetic factors and identify trends amongst patients with CAC      development, particularly focusing on those with aggressive, multivessel CAC development.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients (> 18 years old) with a prior CAC score of 0 > 5 years ago or more will be        contacted to enroll and undergo repeat CAC scanning.|December 2015|December 16, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636062||6478|
NCT02636075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456ab|"Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"|"Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"||SB Istanbul Education and Research Hospital|No|Enrolling by invitation|December 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|125|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|no limitaion|December 2015|December 18, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02636075||6477|
NCT02628743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN29854|A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy|Multicenter, Open-Label, Single Arm Study to Evaluate Long-term Safety, Tolerability, and Effectiveness of 10 mg/kg Olesoxime in Patients With SMA||Hoffmann-La Roche||Recruiting|January 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|171|||Both|N/A|N/A|No|||March 2016|March 1, 2016|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628743||7039|
NCT02639325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160041|Tumor Related Epilepsy|Tumor Related Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|8 Years|N/A|No|||December 2015|January 21, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02639325||6227|
NCT02631252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-133|Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia|A Phase I Study of Combination Chemotherapy With Mitoxantrone and Etoposide (VP-16) Combined With an Autophagy Inhibitor, Hydroxychloroquine (HCQ), for the Treatment of Patients With Relapsed Acute Myelogenous Leukemia (AML)||University of Pittsburgh|Yes|Not yet recruiting|March 2016|March 2023|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|80 Years|No|||December 2015|January 21, 2016|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631252||6846|
NCT02636283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SDG25360025|Natriuretic Peptide for the Treatment of Peripheral Arterial Disease (NP-Walk)|Use of Novel Engineered Natriuretic Peptide for the Treatment of Peripheral Arterial Disease|NP-Walk|University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|February 2016|May 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636283||6461|
NCT02641951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/15.08.41|Stellate Ganglionic Block Versus Stellate Ganglionic Block Plus Pecs II Block for Mastectomy Pain|Stellate Ganglionic Block Versus Combined Stellate Ganglionic Block and Modified Pectoral Nerve Block in Treatment of Post Mastectomy Pain Syndrome.||Mansoura University|Yes|Enrolling by invitation|November 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|18 Years|70 Years|No|||February 2016|February 5, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02641951||6025|
NCT02639806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEVO-01|General Anesthesia for Endovascular Thrombectomy; A Pilot Study.|General Anesthesia for Endovascular Thrombectomy; A Pilot Study.||University of Saskatchewan|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|77|||Both|18 Years|N/A|No|Probability Sample|Adult acute ischemic stroke participants who undergo intravascular thrombectomy in        Saskatchewan will be prospectively recruited for the prospective arm.|December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02639806||6190|
NCT02644239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculdade de Saúde Pública USP|Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy|Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy|Ketonutri|University of Sao Paulo|Yes|Recruiting|June 2012|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|19 Years|No|||December 2015|December 28, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02644239||5849|
NCT02632877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMMTG.14|Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers|Efficacy of Pirfenidone Gel Combined With Modified Oxide Diallyl Disulfide (MODD) Versus Ketanserin for the Treatment of Diabetic Foot Ulcers||University of Guadalajara|No|Completed|January 2014|December 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02632877||6722|
NCT02380209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406349968|An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer|An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer||University of Arizona|Yes|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||October 2015|October 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02380209||26121|
NCT02320812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JC-01|Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa|A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)||jCyte, Inc|Yes|Recruiting|June 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02320812||30672|
NCT02301520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haitistudy|Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.|Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.|Haiti|Children's Hospital Boston|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|299|||Both|9 Months|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy infants and young children, recruited from participating local churches in three        different geographical areas of Haiti, including in the capital Port-au-Prince, a        mountainous region, and a coastal region.|June 2015|June 23, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301520||32152|
NCT02299336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Endurance 1 Trial|Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial.||Greater Houston Retina Research|No|Active, not recruiting|October 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02299336||32320|
NCT02317861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5491L00001|A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients|A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Japanese Adult Male Subjects With Gout or Asymptomatic Hyperuricemia||AstraZeneca|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|110|||Male|20 Years|70 Years|No|||June 2015|June 11, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02317861||30898|
NCT02317874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02474|Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of BMN 673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Recruiting|July 2015|||November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|March 8, 2016|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02317874||30897|
NCT02320994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS-I|Managing Aftercare for Stroke (MAS): MAS-I - a Cross Sectional Study of Post-rehabilitation Stroke Burden and Patients' Needs|Managing Aftercare for Stroke (MAS): MAS-I - a Cross Sectional Study of Post-rehabilitation Stroke Burden and Patients' Needs|MAS-I|Charite University, Berlin, Germany|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|64|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|Patients in long term course after a moderate to severe ischemic stroke|January 2016|January 20, 2016|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02320994||30658|
NCT02309255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-COR REK ID 2013/1885|The NOR-COR Study for Coronary Prevention|The NOR-COR (NORwegian CORonary) Study: Identification of CHD Patients With Poor Adherence to Secondary Prevention and Their Perceived Needs for Follow-up||Vestre Viken Hospital Trust|No|Completed|February 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|975|Samples With DNA|Salvia for genetic analyses|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|1365 CHD patients|June 2015|June 12, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02309255||31559|
NCT02308098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103013|To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product|Study Comparing Bronchodilator Efficacy of Two Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler; a Randomised, Double-blind, Double-dummy, Multicentre, Single Dose, Crossover Study in Asthmatic Subjects|BUFODIL|Orion Corporation, Orion Pharma|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|70 Years|No|||January 2015|June 29, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308098||31647|
NCT02308202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29283|DOXAZOSIN FOR PTSD|DOXAZOSIN AS A TREATMENT FOR POST TRAUMATIC STRESS SYNDROME||Baylor College of Medicine|Yes|Recruiting|January 2012|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|55 Years|No|||January 2016|January 11, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02308202||31639|
NCT02314949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPs56862|Leuven Tolerogenic Protocol for Intestinal Transplantation|A Multifactorial Immunomodulatory Protocol -Promoting T-regulatory Cells- Prolongs Graft and Patient Survival After Intestinal Transplantation|LP|Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2000|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|13|||Both|N/A|N/A|No|Non-Probability Sample|All patients who underwent intestinal transplantation|July 2013|December 8, 2014|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02314949||31122|
NCT02319473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAC2007|Jakarta Acute Coronary Syndrome Registry|Jakarta Acute Coronary Syndrome Registry|JACRegistry|National Cardiovascular Center Harapan Kita Hospital Indonesia|No|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|28812|||Both|18 Years|80 Years|No|Non-Probability Sample|All acute coronary syndrome patients admitted to the emergency department.|April 2015|April 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319473||30774|
NCT02322242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437-2013|The Effects of Dexamethasone on Low Dose Interscalene Brachial Plexus Block|Comparison of the Effects of Perineural Versus Systemic Dexamethasone on Low Dose Interscalene Brachial Plexus Block: A Randomized Control Trial|ISB-Dex|Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02322242||30562|
NCT02309320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX00171-C104|A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171|A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care.||Ablynx|Yes|Completed|November 2014|||February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|N/A|23 Months|No|||March 2016|March 15, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02309320||31554|
NCT02293369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1424|Comparison of Two Methods of Vaginal Cuff Closure at Laparoscopic Hysterectomy|Comparison of Two Methods of Vaginal Cuff Closure at Laparoscopic Hysterectomy and Their Effect on Female Sexual Function and Vaginal Length||Istanbul University|No|Completed|November 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Female|N/A|N/A|No|||January 2016|January 7, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293369||32778|
NCT02297802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130596 SHRP|A Single Patient IND for PD-0325901|A Phase I Single Patient IND for PD-0325901||Sharp HealthCare|No|No longer available|June 2013|July 2013|Actual|July 2013|Actual|Phase 1|Expanded Access|N/A|||||||Female|18 Years|N/A|No|||November 2014|November 24, 2014|May 12, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02297802||32438|
NCT02635334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSRF2015-01|Asthma in the Elderly: The Effect of Montelukast|Asthma in the Elderly: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Effect of Montelukast||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|No|||December 2015|December 21, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635334||6534|
NCT02634983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2325|QVA Mechanistic Efficacy Study (Receptor Effects, Etc)|A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD||Novartis|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|40 Years|N/A|No|||December 2015|December 15, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02634983||6560|
NCT02634996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411031DIND|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||December 21, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634996||6559|
NCT02633267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH102263-01A1|1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety|1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety||University of Michigan|Yes|Not yet recruiting|December 2015|May 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||December 2015|December 14, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02633267||6692|
NCT02634372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI15/02242|EMDR vs Supportive Therapy in Relapse Prevention in Traumatized Bipolar Patients|Single-blind, Randomized Controlled Comparison of EMDR Versus Supportive Therapy in Affective Relapse Prevention in Bipolar Patients With a History of Trauma||FIDMAG Germanes Hospitalàries|No|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02634372||6607|
NCT02634658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1557|The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients|The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients||University of Colorado, Denver|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02634658||6585|
NCT02629328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRS-2015-01|CardioCel Tri-leaflet Repair Study|CardioCel Tri-leaflet Repair Study; a Prospective, Non-randomised, Single Arm, Multi-centre Clinical Investigation|CTRS|Admedus Regen Pty Ltd.|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|85 Years|No|||December 2015|December 16, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629328||6994|
NCT02643173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC recurrence|Hepatocellular Carcinoma Recurrence and Anesthesia|||Seoul National University Bundang Hospital||Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|413|||Both|20 Years|100 Years|No|Non-Probability Sample|Patients undergoing surgery due to the HCC.|December 2015|December 29, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643173||5931|
NCT02638129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaltrexBuprop-4001|Naltrexone/Bupropion Cardiovascular Outcomes Study|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease||Takeda|No|Recruiting|January 2016|April 2022|Anticipated|February 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|8800|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638129||6319|
NCT02641977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19802015|Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate|Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate Enroled in the Ratingener Rheuma-Kohorte|MTX|Ruhr University of Bochum|No|Active, not recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|271|||Both|N/A|N/A|No|Non-Probability Sample|patients with rheumatoid arthritis|December 2015|December 29, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02641977||6023|
NCT02633527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812P202|Efficacy and Safety of SPN-812 ER in Children With ADHD|||Supernus Pharmaceuticals, Inc.||Recruiting|February 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|200|||Both|6 Years|12 Years|No|||December 2015|February 2, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633527||6672|
NCT02643784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10028|Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke|Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke|AIS|RenJi Hospital|Yes|Not yet recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|45 Years|75 Years|No|||December 2015|December 28, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02643784||5884|
NCT02641496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1799-R|Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD|Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD||VA Office of Research and Development|No|Not yet recruiting|April 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|144|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641496||6060|
NCT02381769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-lipid infusion-01|THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.|THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.||Institute of Liver and Biliary Sciences, India|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2014|March 17, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02381769||26001|
NCT02638506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF2016-1028|RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches|Randomized Controlled Trial Evaluating the Additive Value of Intranasal Fentanyl on Ibuprofen in the Pain Management of Children With Moderate to Severe Headaches||St. Justine's Hospital|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02638506||6290|
NCT02631070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-536-MDS-001|A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes|A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS WHO REQUIRE RED BLOOD CELL TRANFUSIONS|MEDALIST|Celgene|Yes|Recruiting|February 2016|June 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631070||6860|
NCT02630914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7424 15|Medical and Surgical Hybrid Treatment of Atrial Fibrillation.|Medical and Surgical Hybrid Treatment of Atrial Fibrillation: Epicardial and Endocardial Combined Approach.|HT2AF|University Hospital, Toulouse|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630914||6872|
NCT02382588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4321|Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis|A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis||Northwestern University|No|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||September 2015|September 19, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382588||25938|
NCT02391701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCSantiago|Effect of an Atlantic Diet on Anthropometric Indices and Serum Lipid Profile|Effect of an Atlantic Diet on Anthropometric Indices and Serum Lipid Profile in a General Population: a Randomised Controlled Trial|GALIAT|Hospital Clinico Universitario de Santiago|No|Recruiting|March 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|3 Years|85 Years|No|||March 2015|March 18, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02391701||25238|
NCT02643160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 14 135|Analyzing the Effect of Trunk Training on Limbs in Children With Spastic Cerebral Palsy|Analyzing the Effect of Functional Trunk Training on Upper and Lower Limb Motor Function in Children With Spastic Cerebral Palsy|FTT|Abant Izzet Baysal University|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|4 Years|18 Years|No|||December 2015|December 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02643160||5932|
NCT02636842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-A106|A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder|A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder||Alkermes, Inc.|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|65 Years|No|||December 2015|December 21, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636842||6418|
NCT02388269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GG-007|A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G|A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study of the gammaCore®-G, a Non-invasive Vagus Nerve Stimulator Device for Treatment of Symptoms Caused by Functional Dyspepsia or Irritable Bowel Syndrome||ElectroCore LLC|No|Completed|June 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|N/A|No|||September 2015|February 4, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02388269||25501|
NCT02388282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/2015/O/Sper|A New Method for Estimating Dynamic Intrinsic PEEP|A New Method for Estimating Dynamic Positive End-expiratory Pressure. Description and Validation With PEEPi Dyn Measured With Transdiaphragmatic Pressure|echoPEEPi|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|April 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with both acute or chronic respiratory insufficiency, who required respiratory        mechanics measurements for clinical purpose.|August 2015|December 28, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388282||25500|
NCT02638961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT-FES 01|Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF|Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction|TRAINING-HF|Universitat Jaume I|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|52|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02638961||6255|
NCT02638974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15438|Skin Camouflage for Women Prisoners With Self-Harm Scarring|Feasibility and Acceptability of Medical Skin Camouflage for Recovery of Women With Self-Harm Scarring in Prison|COVER|University of Manchester|No|Not yet recruiting|January 2016|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638974||6254|
NCT02629003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15001910|[11C]Cimbi-36 Dosimetry|Evaluation of Radiation Dose for [11C]Cimbi-36||Rigshospitalet, Denmark|Yes|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629003||7019|
NCT02632604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110.180/2013|Computerized Cognitive Training for the Elderly|Computerized Cognitive Training for the Elderly||Universidade Federal do Rio de Janeiro|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632604||6743|
NCT02635308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00062639|Enhancing Rehabilitation After Hip Fracture|Enhanced Rehabilitation Targeting Strength and Movement Pattern Symmetry Following Hip Fracture||University of Utah|No|Completed|April 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|50 Years|N/A|No|||December 2015|December 15, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02635308||6536|
NCT02635321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STO-GMPPB|MRI and Muscle Involvement in Patients With Mutations in GMPPB|MRI and Muscle Involvement in Patients With Mutations in GMPPB||Rigshospitalet, Denmark||Active, not recruiting|November 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Persons diagnosed with mutations in GMPPB in Denmark and France are invited to the study.|December 2015|December 15, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02635321||6535|
NCT02635633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2015/0596|Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept|Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept||University Hospital, Ghent|Yes|Enrolling by invitation|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02635633||6511|
NCT02637648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWSO0812|Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache|Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache|SOinCH|Klinik Barmelweid|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637648||6356|
NCT02636803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXF2|Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults|An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults||Johns Hopkins Bloomberg School of Public Health|Yes|Not yet recruiting|February 2017|August 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|16 Years|65 Years|No|||December 2015|December 21, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636803||6421|
NCT02636816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-03007|Cardiovascular Effects of Carbetocin Given During Elective Cesarean|Cardiovascular Effects of Carbetocin During Elective Caesarean Delivery: A Randomized Controlled Trial Comparing Infusion Versus Bolus Administration Using Nexfin™||University of British Columbia|Yes|Not yet recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Female|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636816||6420|
NCT02632214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00088-39|Plasticity and Cross-modal Interactions in Profoundly Deaf Adults|Plasticity and Cross-modal Interactions for Oral Communication in Profoundly Deaf Adults|PLASMODY|University Hospital, Grenoble|Yes|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02632214||6773|
NCT02632227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511-105-0724|Fluid Responsiveness Using TFU (Transfontanel Ultrasound) in Children With Congenital Heart Disease|Prediction of Fluid Responsiveness Using TFU (Transfontanel Ultrasound) in Children With Congenital Heart Disease After Cardiac Surgery||Seoul National University Hospital|Yes|Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|1 Year|No|Probability Sample|pediatric patients with congenital heart disease undergoing cardiac surgery|December 2015|December 13, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632227||6772|
NCT02635672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17496|Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer|An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients With Advanced Cancer||Bayer|No|Recruiting|February 2016|February 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635672||6508|
NCT02635685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/398-32|Clinical Decision Support for Stroke Prevention in Atrial Fibrillation|Clinical Decision Support for Stroke Prevention in Atrial Fibrillation - a Cluster Randomized Trial in the Primary Care Setting|CDS-AF|University Hospital, Linkoeping|No|Recruiting|January 2016|January 2023|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|442105|||Both|N/A|N/A|No|||March 2016|March 20, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02635685||6507|
NCT02635698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.21.CLI|Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight|Opti-WIN: Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight|Opti-WIN|Nestlé|No|Recruiting|November 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|March 9, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02635698||6506|
NCT02643771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1175-5481|Clinical and Microbiological Evaluation of Periodontal Treatment of Diabetic Patients: A Longitudinal Study|Clinical and Microbiological Evaluation of Non-surgical Periodontal Treatment of Diabetic and Non-diabetic Patients: A Longitudinal Study||Universidade Federal do Rio Grande do Norte|No|Recruiting|January 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643771||5885|
NCT02631889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1/2015|Study to Assess the Effectiveness of Transcollation Technology to Reduce Bleeding in Lung Surgery|A Prospective, Randomized, Controlled Study to Assess the Effectiveness of Transcollation Technology to Reduce Bleeding in Lung Surgery||University of Roma La Sapienza|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|85 Years|No|||December 2015|December 12, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02631889||6797|
NCT02633618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004L04536|Analgecine for the Treatment of Neuropathic Pain|The Clinical Study of Analgecine for the Treatment of Neuropathic Pain||VanWorld Pharmaceutical (Rugao) Company Limited|Yes|Completed|August 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02633618||6665|
NCT02632513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIDS/IEC/2014/120|Effect of Passive Ultrasonic Irrigation on Success of Primary Endodontic Treatment|Effect of Passive Ultrasonic Irrigation on Success of Primary Endodontic Treatment||Postgraduate Institute of Dental Sciences Rohtak|Yes|Completed|May 2014|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632513||6750|
NCT02628470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI/HU/2015/10|Effects of Cervical Manipulation and Mobilization on Salivary Cortisol Concentrations|Effects of Cervical Manipulation and Mobilization on Salivary Cortisol Concentrations||University of Alcala|Yes|Enrolling by invitation|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02628470||7060|
NCT02637310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-N02RS1_Phase 2B|Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis|A Multi Center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of N02RS1 in Patients With Acute Bronchitis||PharmaKing|Yes|Not yet recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|19 Years|75 Years|No|||December 2015|December 17, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02637310||6382|
NCT02637323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2015-009|Study to Characterize the Systemic PK and Local Extent and Duration of Exposure of TCA From FX006 in Patients With OA of the Knee|An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|40 Years|N/A|No|||December 2015|December 21, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637323||6381|
NCT02636504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5900|Evaluation of Three Pulp Vitality Tests|Evaluation of Three Pulp Vitality Tests||Columbia University|No|Not yet recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients that need endodontic treatment will have a consultation visit first. In most        cases, the endodontic treatment will be provided at a subsequent visit. In some cases the        endodontic treatment will be provided at the same visit. Patients who present to the        endodontic clinic for a consultation visit for endodontic treatment. The patient will have        three types of pulp vitality tests done on the tooth that is to receive endodontic        treatment.|December 2015|December 17, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636504||6444|
NCT02636088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-006802-40|Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer|A Phase II Study With Oxaliplatin + 5-FU + Ceuximab and Radiotherapy for the Treatment of Non-resectable, Locally Advanced But Not Metastatic Cancer of Oesophagus or the Cardia.|LERFOX-C|Karolinska University Hospital|No|Active, not recruiting|January 2011|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636088||6476|
NCT02635295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45/2014|Mobile Cooperation During the Clinical Practicum|Mobile Cooperation During the Clinical Practicum||University of Turku|No|Completed|January 2015|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|108|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02635295||6537|
NCT02628262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye020|Fundus Autofluorescence After Macular Hole Surgery|Fundus Autofluorescence Images in Gas-filled Eyes Immediately After Macular Hole Surgery||Kyorin University|No|Completed|April 2013|October 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|27|||Both|20 Years|90 Years|No|Non-Probability Sample|Optos ultrawide angle FAF images were taken in 27 eyes before and after MH surgery and        compared with swept source optical coherence tomographic (SS-OCT) images.|December 2015|December 8, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02628262||7076|
NCT02390882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-VICT-301|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH|A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia||Hanmi Pharmaceutical Company Limited|No|Recruiting|October 2014|July 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|474|||Male|45 Years|N/A|No|||August 2014|March 17, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02390882||25300|
NCT02392520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|luteal antag OHSS RCT|Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)|GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved||Eugonia|No|Not yet recruiting|May 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392520||25175|
NCT02634762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Acute Congestive Heart Failure Urgent Care Evaluation|Acute Congestive Heart Failure Urgent Care Evaluation: Prospective Validation of the Emergency Heart Failure Mortality Risk Grade 7-day and 30-day Algorithms in the Emergency Department|ACUTE|Institute for Clinical Evaluative Sciences|No|Recruiting|January 2011|||December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department diagnosed with heart failure at 8 centers        in Ontario, Canada|December 2015|December 16, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634762|30 Days|6577|
NCT02634775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGent_UToPaed_3|Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Interventional Study|Part 3 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|UToPaed_3|University Hospital, Ghent|No|Recruiting|October 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|18 Years|No|||December 2015|December 16, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02634775||6576|
NCT02639234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL-122|Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer||Gradalis, Inc.|Yes|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639234||6234|
NCT02628483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007-008-PRO-040414|A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil|A Randomized, Double-blind, Parallel Clinical Trial to Compare the Relative Efficacy of Two Triglyceride Forms of Fish Oil, Ultimate Omega®, and a Comparator Product, in Improving Red Blood Cell Fatty Acid Profiles in Healthy Adults (FORCE Study)||Nordic Pharma, USA|No|Recruiting|February 2016|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02628483||7059|
NCT02637050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18303|A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries|EMEA CTEPH Registry: An International Prospective Registry Investigating the Epidemiology, Diagnosis and Treatment of CTEPH Patients in EMEA Countries.|EMEA CTEPH|Bayer|No|Recruiting|March 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|CTEPH (Chronic Thromboembolic Pulmonary Hypertension) patients in Expert PH (Pulmonary        Hypertension) centers|March 2016|March 7, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02637050||6402|
NCT02630771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511M80706|Multimodal Assessment of Sensory Processing and Brain Features in Patients With Chronic Orofacial Pain|Multimodal Assessment of Sensory Processing and Brain Features in Patients With Chronic Orofacial Pain||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|January 2016|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|64|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females with age range 18-65 years|December 2015|December 10, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02630771||6883|
NCT02639221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXT-CL15-001|A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects|PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects||Prexton Therapeutics||Recruiting|January 2016|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639221||6235|
NCT02644187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VastraGotaland|Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol|Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol||Vastra Gotaland Region|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644187||5853|
NCT02637752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAZ 515|Nutrition and Physical Activity Counselling|Efficacy of Nutrition and Physical Activity Counselling for Pre-adolescent Children in a Dental Setting: A Randomized Clinical Trial||University of Toronto|No|Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|168|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02637752||6348|
NCT02391662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBABRAX|A Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma||Asociación de Oncología Médica del Hospital de Cruces|No|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|70 Years|N/A|No|||July 2015|July 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391662||25241|
NCT02391675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.17/infect12.03|The Hasselt APPendicitis Immunology and Environmental Cohort STudy|The Hasselt APPendicitis Immunology and Environmental Cohort STudy|HAPPIEST|Hasselt University|No|Recruiting|June 2012|October 2018|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Whole blood, plasma, serum, appendix tissue, stool|Both|5 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are asked to participate after presenting with acute appendicitis at the        emergency room of Jessa Ziekenhuis, Hasselt. If the patient fits the criteria, and        informed consent is signed, the patient is included in the study.|March 2015|March 12, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02391675|6 Years|25240|
NCT02637622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 90056532 PF|Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment|Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with type II diabetes.|October 2015|December 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02637622||6358|
NCT02644330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-ZH39|Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect|A Randomized Controlled Trial of Minimally Invasive Transthoracic Device Closure in the Treatment of Patients With Perimembranous Ventricular Septal Defect||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Months|N/A|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644330||5842|
NCT02644343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM 5650|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||December 30, 2015|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644343||5841|
NCT02632617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-681|coRonary assEssment of Preoperative vaLvulopathy pAtients Using ComputEd Tomographic Angiography (REPLACE)|coRonary assEssment of Preoperative vaLvulopathy pAtients Using ComputEd Tomographic Angiography (REPLACE)|REPLACE|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|December 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|40 Years|85 Years|No|Non-Probability Sample|The target population in our study comprise pre-operative individuals with valvular        disease who are recommended for ICA by the 2014 ACC/AHA guideline|December 2015|December 22, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02632617|30 Days|6742|
NCT02632630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN15-007|Nutrition Supplementation in Hospitalized Patients|Nutrition Supplementation in Hospitalized Patients: A Randomized Controlled Trial|NutriSuP|Lawson Health Research Institute|No|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|N/A|N/A|No|||December 2015|December 14, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02632630||6741|
NCT02379871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MountSMCLA 2|The Effects of Mid-thoracic Manipulation on Heart Rate Variability.|The Effects of Mid-thoracic Manipulation on Heart Rate Variability.||Mount St. Mary's College, Los Angeles, CA|No|Enrolling by invitation|January 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 28, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02379871||26147|
NCT02379884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0399-14-RMB CTIL|Mechanical Ventilation in Internal Medicine Elderly Patients - Choosing Wisely|Mechanical Ventilation in Internal Medicine Elderly Patients - Choosing Wisely|VentWise|Rambam Health Care Campus|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients requiring mechanical ventilation over the study period.        Inclusion criteria:        Males and females Age over 18 years Admitted to internal medicine wards or medical        intensive care unit|July 2015|July 23, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02379884||26146|
NCT02631837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B689201526261|Hysterectomy by Transabdominal Laparoscopy or NOTES|Hysterectomy for Benign Gynaecological Disease by Natural Orifice Transluminal Endoscopic Surgery or Laparoscopy|HALON|Imelda Hospital, Bonheiden|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02631837||6801|
NCT02639104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA15-220|Could Cervical Postural Changes Affect the Long Thoracic Nerve Electromyographic Findings?|Could Cervical Postural Changes Affect the Long Thoracic Nerve Electromyographic Findings?||Baskent University|No|Active, not recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02639104||6244|
NCT02384629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0079|PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease|PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease||Yonsei University|Yes|Not yet recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|204|||Both|19 Years|85 Years|No|||March 2015|March 4, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384629||25781|
NCT02384902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|low GI nephropathy|Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients|Effect of Dietary Glycemic Index/Load on Kidney-related Biomarkers and Inflammation in Diabetic Nephropathy Patients||Isfahan University of Medical Sciences|No|Completed|May 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|30 Years|75 Years|No|||March 2015|March 9, 2015|September 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02384902||25760|
NCT02326259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22531|Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia|Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia||Temple University|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being seen in the endocrinology clinic at Temple University Hospital.|November 2015|November 2, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02326259||30253|
NCT02309216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0715|Whole-Body MRI in Suspected Victims of Abusive Head Trauma|Whole-Body MRI in Suspected Victims of Abusive Head Trauma||The University of Texas Health Science Center, Houston|No|Recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|12 Months|No|Non-Probability Sample|Infant inpatients being evaluated for suspected abusive head trauma who are already        getting an MRI of the head and cervical spine.|December 2015|December 7, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02309216||31562|
NCT02309229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML8808|Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.|Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.|MucoSpuCo|Universitaire Ziekenhuizen Leuven|Yes|Completed|December 2012|January 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of cystic fibrosis|December 2014|December 2, 2014|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02309229|6 Months|31561|
NCT02306551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFF-1319-00103|Well Being And Resilience: Mechanisms of Transmission of Health and Risk|Well Being And Resilience: Mechanisms of Transmission of Health and Risk in Parents With Complex Mental Health Problems and Their Offspring|WARM|University of Copenhagen|No|Recruiting|September 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|||Both|16 Years|N/A|No|Probability Sample|Pregnant women referred to maternity services or psychiatric services in Denmark in Region        Zealand and Region Southern Denmark, in Scotland from NHS Greater Glasgow and Clyde|November 2015|November 5, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02306551||31766|
NCT02320513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141534|A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients|A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients|IAM|Renal Research Institute|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|75 Years|No|Non-Probability Sample|-  Receiving hemodialysis three times a week          -  On hemodialysis for more than 3 months          -  Between the ages of 18 and 75 years          -  Able to walk without assistance or assistive devices          -  Able to read and understand the English language|September 2015|September 29, 2015|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02320513||30695|
NCT02320526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-043|Interval-training in Type 2 Diabetics|Interval-training in Type 2 Diabetics - Mechanisms Behind Increased Glucose Disposal and Effects on Systemic Inflammation||Rigshospitalet, Denmark|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|14|||Both|40 Years|N/A|No|||October 2015|October 28, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02320526||30694|
NCT02326285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-TRK-0214|Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB|Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.|NeoIntercal|AIO-Studien-gGmbH|No|Recruiting|November 2015|January 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02326285||30251|
NCT02294344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT1403|The Clinical Efficacy of DFPP in Patients With AAGN|A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN)||Nanjing University School of Medicine|Yes|Recruiting|June 2014|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||November 2015|November 1, 2015|June 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02294344||32703|
NCT02296437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC14216|Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression|Pilot Study of Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression.|tDCS + CT|The University of New South Wales|No|Recruiting|November 2014|||November 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 18, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02296437||32542|
NCT02319486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanghs04|CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma|CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma||Sun Yat-sen University|Yes|Completed|January 2009|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||March 2015|March 11, 2015|December 15, 2014||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT02319486||30773|
NCT02324179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-14-22|Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls|Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls||University Hospital Case Medical Center|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|76|Samples Without DNA|plasma and serum|Both|8 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. HIv positive: subjects seen at the Special Immunology Unit          2. Controls: HIV-negative controls will be healthy people who are friends or family             members of the HIV-infected patients, or employees who are not employed by the             principal investigator or the co-investigators or recruited through researchmatch.org|March 2015|March 6, 2015|August 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02324179||30413|
NCT02315040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1.2|EVIE-Study: Slow Release Insemination Versus Standard Intrauterine Insemination Study|Testing the Effect of Intrauterine Slow Release Insemination (SRI) on the Pregnancy Rate in Women Designated for Standard Intrauterine Insemination (IUI)|EVIE|Medical University of Vienna|Yes|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|October 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02315040||31115|
NCT02298829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-810|Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease|Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806||Endo Pharmaceuticals|No|Active, not recruiting|November 2014|September 2018|Anticipated|May 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|Samples Without DNA|Blood samples for the determination of antibodies to AUX-I and AUX-II and neutralizing      antibodies to AUX-I and AUX-II will be collected at each long-term follow-up visit.|Male|18 Years|90 Years|No|Non-Probability Sample|Up to 750 subjects who received AA4500 and completed at least the first or last follow-up        visit in one of the Auxilium-sponsored studies (AUX-CC-802, AUX-CC-803, AUX-CC-804, or        AUX-CC-806).|March 2016|March 21, 2016|November 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298829||32359|
NCT02297815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010595|Comparative Effectiveness of Antibiotics for Respiratory Infections|Comparative Effectiveness of Broad vs. Narrow Spectrum Antibiotics for Acute Respiratory Tract Infections in Children|CEARI|Children's Hospital of Philadelphia|No|Recruiting|January 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|117000|||Both|6 Months|18 Years|No|Probability Sample|Visits of all patients who are seen at the CHOP Primary Care Network practices will be        identified to estimate the effectiveness and safety of antibiotics for acute respiratory        tract infections (ARTIs), while a stratified sample will be used to study additional        patient-oriented outcomes.|November 2015|November 23, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297815||32437|
NCT02298088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT01|Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis|Phase III, Randomized, Multicenter, Open Label, Non-Inferiority Trial to Explore the Safety and Efficacy of Ticagrelor Compared With Clopidogrel in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis|TREAT|Hospital do Coracao|Yes|Not yet recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3794|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02298088||32416|
NCT02311751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/2013|rTMS for Executive Function Deficits in Autism Spectrum Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) for Executive Function Deficits in Autism Spectrum Disorder and Effects on Brain Structure: A Pilot Study||Centre for Addiction and Mental Health|Yes|Recruiting|October 2014|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|November 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02311751||31367|
NCT02311764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU-14005|Carboplatin in Castration-resistant Prostate Cancer|Single Arm Open Label Phase II Pilot Study of Carboplatin in Patients With Metastatic Castrationresistant Prostate Cancer (CRPC) and PTEN Loss and/or DNA Repair Defects|PRO-PLAT|Cantonal Hospital of St. Gallen|No|Recruiting|February 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02311764||31366|
NCT02316431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0072|Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases|Diagnostic Comparison and Workflow Evaluation of Whole Body PET-magnetic Resonance and PET-CT With and Without Contrast Media in Patients With Oncologic Diseases|Workflow|University of Zurich|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|Patients with a proven or suspected oncological disease referred for a clinically        indicated PET/CT with of without contrast media.|July 2015|July 27, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02316431||31008|
NCT02629068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA039459|PURPOSE: A Social Media Intervention for Parent Support|Parents United With Responsive Parents for Online Support and Education PURPOSE: A Social Media Intervention for Parent Support||University of California, Los Angeles|Yes|Recruiting|January 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02629068||7014|
NCT02629315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP458/13|Carnoy`s Solution Versus Formalin in Rectal Cancer Specimens Following Neoadjuvant Chemoradiation: a Randomized Trial|Lymph Node Yield After Specimen Fixation With Carnoy`s Solution and 10% Neutral Buffered Formaldehyde in Patients With Rectal Cancer Specimens Following Neoadjuvant Chemoradiation: a Randomized Trial||Instituto do Cancer do Estado de São Paulo|No|Completed|May 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|130|||Both|N/A|N/A|No|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629315||6995|
NCT02638051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-CH-PCMA-14|Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT|Local Modulated Electro-Hyperthermia in Combination With Traditional Chinese Medicine Versus Intraperitoneal Chemoinfusion in Treatment of Peritoneal Carcinomatosis With Malignant Ascites: A Phase II Randomized Trial|OTMA-RII|Galenic Research Institute Ltd|No|Completed|January 2014|December 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02638051||6325|
NCT02637414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIAE_App Florescer|Flourishing App: Evaluation of the Effectiveness of a Well-being Application for Mobile Devices|Flourishing App: Evaluation of the Effectiveness of a Well-being Application for Mobile Devices||Hospital Israelita Albert Einstein|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02637414||6374|
NCT02639949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDDK_KUH|Measuring and Improving Medication Adherence in Kidney Transplant Patients|The Use of Random Telephone Calls to Measure Immunosuppressive Therapy Adherence in Patients With Renal Transplants||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|January 2010|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639949||6179|
NCT02643186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUMH|Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy|Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy , a Randomized Control Trail||Ain Shams Maternity Hospital|Yes|Recruiting|July 2015|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|62|||Female|20 Years|40 Years|No|||December 2015|December 29, 2015|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643186||5930|
NCT02641990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-116|Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects|A Phase 1, Randomized, Double-blind, Placebo-Controlled, Crossover Study to Assess the Effect of ITCA 650 on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive in Healthy Premenopausal Female Subjects||Intarcia Therapeutics|No|Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641990||6022|
NCT02632721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315.2|A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)|An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia||Boehringer Ingelheim||Not yet recruiting|May 2016|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 15, 2015||||No||https://clinicaltrials.gov/show/NCT02632721||6734|
NCT02637427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro20150001801|Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures|Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures||Rutgers, The State University of New Jersey|Yes|Not yet recruiting|January 2016|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|21 Years|N/A|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637427||6373|
NCT02640742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2287R00101|Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting|Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting-A Cross-sectional Study of Adult Asthma Patients in Japan|ACQUIRE-2|AstraZeneca|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1100|||Both|20 Years|100 Years|No|Non-Probability Sample|Adult asthma patients receiving continued treatment by physician in Japan|February 2016|February 29, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640742||6118|
NCT02640755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2270C00015|Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase|A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies|14C|AstraZeneca|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|6|||Both|18 Years|130 Years|No|||March 2016|March 2, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02640755||6117|
NCT02385955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBMT200809|Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients|Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies||Seoul National University Hospital|Yes|Not yet recruiting|April 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|65 Years|No|||March 2015|March 10, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02385955||25679|
NCT02631499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-HE-TACE|Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation|Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China||Fudan University|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|75 Years|No|||December 2015|December 20, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631499||6827|
NCT02636296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI017/2010|The Effects of 12 Weeks Pilates-inspired Exercise Training on Functional Performance in Older Women|The Effects of 12 Weeks Pilates-inspired Exercise Training on Functional Performance in Older Women: a Randomized Study||University of Sao Paulo|No|Completed|August 2010|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02636296||6460|
NCT02643290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156_2015bis|Efficacy of Peak Scoliosis Brace in Pain Management For Adult Scoliosis Patients|Efficacy of Peak Scoliosis Brace in Pain Management For Adult Scoliosis Patients||Aspen Medical Products|No|Active, not recruiting|April 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||December 2015|December 30, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02643290||5922|
NCT02635139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MealSkipping|Influence of Meal Skipping on Macronutrient Oxidation and Glucose Metabolism Under Isocaloric Conditions|Influence of Meal Skipping on Macronutrient Oxidation and Glucose Metabolism Under Isocaloric Conditions||University of Hohenheim|No|Recruiting|December 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02635139||6549|
NCT02391714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMHSC 13-289|Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion|Nitrous Oxide for Pain Management of Intrauterine Device Insertion|NIUD|University of New Mexico|Yes|Completed|October 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|12 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|March 5, 2015||No||No|August 26, 2015|https://clinicaltrials.gov/show/NCT02391714||25237|
NCT02628353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLAVOR 2014-00081|Effect of a Specific Phenolic Compound on Blood Pressure|Randomized, Cross-over, Double Blinded, Placebo-controlled Study for the Evaluation of the Postprandial Effect of a Specific PHENOLic Compound on Blood PRESSure|PHENOLPRESS|Technological Centre of Nutrition and Health, Spain|No|Recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02628353||7069|
NCT02628366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-15-302|Major Cardiovascular and Other Patient-important Outcomes With Personalized dialYsate TEMPerature|Major Cardiovascular and Other Patient-important Outcomes With Personalized dialYsate TEMPerature|MY TEMP|Lawson Health Research Institute|Yes|Enrolling by invitation|April 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|82|||Both|N/A|N/A|No|||October 2015|December 8, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02628366||7068|
NCT02631317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI08B02-02|Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China|Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China|PROMISE|First Affiliated Hospital of Jinan University|Yes|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2178|||Both|18 Years|N/A|No|Non-Probability Sample|AIS patients with an onset-to-door time of less than 3.5 h|February 2016|February 4, 2016|October 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02631317|3 Months|6841|
NCT02640430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maugerifoundation|Randomized Trial of the FreeAspire Versus PEP-bottle After Acute Exacerbation in COPD Patients|A Preliminary Randomized Trial of the FreeAspire Versus PEP-bottle After Acute Exacerbation in COPD Patients With Mucus Hypersecretion and Decreased Cough Efficiency.||Maugeri Foundation|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||December 2015|December 30, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02640430||6142|
NCT02392182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curtis 0036|Lung HIV Microbiome Project (Michigan Site)|Understanding the Lung Microbiome in HIV-Infected & HIV-Uninfected Individuals|LHMP|University of Michigan|Yes|Completed|October 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|59|Samples Without DNA|Oral rinse Nasal swap Bronchoalveolar lavage|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals with no more than mild treated chronic diseases that would not        preclude a research bronchoscopy under moderate conscious sedation. Both never-smokers and        active smokers are welcome.|January 2016|January 28, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392182||25201|
NCT02628912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-277|Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers|Pilot Study of Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|In protocol 10-111 "Surviving Oropharynx Cancer: Long-term Impact of Human Papillomavirus        (HPV) on quality of life", a population of HPV+ oropharyngeal cancer survivors was        identified. There are nearly 150 participants who have completed the one-time        questionnaire on 10-111 who may meet the eligibility criteria for this study.|December 2015|December 10, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02628912||7026|
NCT02629172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-336|Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1|Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1||AbbVie|No|Recruiting|January 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|120 Years|No|Non-Probability Sample|Chronic Hepatitis C|January 2016|January 26, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02629172||7006|
NCT02632201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-008|Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis|A Clinical Study of Adoptive Cellular Immunotherapy Using Pluripotent Killer T Cells Expressing Antibodies for Human Epidermal Growth Factor Receptor-2 (HER2) in Treating Patients With HER2-Positive Advanced Gastric Cancer With Liver Metastasis||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||September 2015|December 30, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632201||6774|
NCT02637908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1287|Mindfulness Training for Head Start Parents|Head Start Parenting||University of Wisconsin, Madison|No|Recruiting|September 2015|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02637908||6336|
NCT02643758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20151016008|Myopia Control Using Soft Bifocal Lenses|Randomised Clinical Trial: Myopia Control Using Soft Bifocal Lenses||The Hong Kong Polytechnic University|No|Recruiting|November 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|109|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02643758||5886|
NCT02644525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916042|Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa|A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02644525||5827|
NCT02632474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSCII-ART-1|ART Drug Dosage Adjustment in HIV-infected Population|ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population||Shanghai Public Health Clinical Center|No|Recruiting|April 2015|||October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632474||6753|
NCT02637960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-013|Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)|A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)|EQUINOC|Vantia Ltd|No|Recruiting|March 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|425|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637960||6332|
NCT02630810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVLHACS 1|Early Versus Late Hydration After Cesarean Section (CS)|Early Versus Late Oral Hydration After Cesarean Section: A Randomized Controlled Study||Ain Shams Maternity Hospital|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|267|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02630810||6880|
NCT02630823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201601062|MK-3475 Immunotherapy in Endometrial Carcinoma|Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma||Washington University School of Medicine|No|Recruiting|February 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630823||6879|
NCT02636998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204071|Nutrition and Cognitive Function in Preadolescents|Nutrition and Cognitive Function in Preadolescents||Arkansas Children's Hospital Research Institute|No|Recruiting|June 2015|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|116|Samples Without DNA|Blood samples and salivary samples|Both|9 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|Preadolescents and their mothers|November 2015|December 18, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02636998||6406|
NCT02633904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSODDH|Investigation of the Femoral Shortening Osteotomy in the Developmental Dislocation of the Hip (FSODDH)|Investigation of the Value of Femoral Shortening Osteotomy During Open Treatment of Developmental Dislocation of the Hip in Waliking Age Group|FSODDH|Tongji Hospital|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Months|24 Months|No|||December 2015|December 16, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02633904||6643|
NCT02636348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-21-HC|Evaluation of Calcium and Vitamin D Supplementation During Marine Corps Training|Evaluation of Calcium and Vitamin D Supplementation for Optimizing Bone Health During Marine Corps Recruit Training|MCRD-PI|United States Army Research Institute of Environmental Medicine|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|800|||Both|17 Years|N/A|Accepts Healthy Volunteers|||June 2015|December 16, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02636348||6456|
NCT02635035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-01288|Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT|Efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT)||New York University School of Medicine|No|Recruiting|November 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635035||6556|
NCT02632136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGHIreland|Lap TAP Block for Laparoscopic TEP Inguinal Hernia Repair: a Prospective, Double-blinded, Randomized, Clinical Trial|Laparoscopic-assisted Transversus Abdominis Plane (TAP) Block for Laparoscopic Total Extra Peritoneal (TEP) Inguinal Hernia Repair: a Prospective, Double-blinded, Randomized, Clinical Trial||Mayo General Hospital, Ireland|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|86|||Both|18 Years|80 Years|No|||December 2015|December 15, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632136||6779|
NCT02632149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-017|Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome|The Clinical Research on PINS Vagus Nerve Stimulator for Treatment of Lennox-Gastaut in Children||Beijing Pins Medical Co., Ltd|Yes|Recruiting|December 2015|||June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|3 Years|14 Years|No|||December 2015|March 18, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632149||6778|
NCT02637531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-549-01|A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549|A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors||Infinity Pharmaceuticals, Inc.|No|Recruiting|December 2015|September 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637531||6365|
NCT02637544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-099/2014|Treatment Efficiency of Acupuncture in Non Chronified Pain Patients With TMDs|Wirksamkeit Von Akupunktur Auf Den Nicht Chronifizierten Schmerz Bei Craniomandibulärer Dysfunktion - Eine Randomisierte, Placebokontrollierte Klinische Studie||University of Heidelberg Medical Center|No|Recruiting|April 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02637544||6364|
NCT02637804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-MKTG-201512|Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study|Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study||Coopervision, Inc.|No|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|120|||Both|18 Years|40 Years|No|||December 2015|December 18, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637804||6344|
NCT02630251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201893|Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors|A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors||GlaxoSmithKline|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630251||6923|
NCT02634541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETSPA|Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis|The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis|PETSPA|Helsinki University|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634541||6594|
NCT02634554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTC079|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||December 17, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634554||6593|
NCT02639013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAH100|an Educational Program About Abdominal Compartment Syndrome|Temporal Trend Analysis of Nurse's Knowledge and Practice Before and After Implementing an Educational Program Regarding Abdominal Compartment Syndrome|Ghada|Assiut University|Yes|Enrolling by invitation|December 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||November 2015|December 20, 2015|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639013||6251|
NCT02639026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23915|Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers|Phase I Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|||December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639026||6250|
NCT02632890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-537|Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries|Evaluation of the Effectiveness of the Abatacept (Orencia®) IV and SC Patient Alert Cards in Patients With Rheumatoid Arthritis in European Economic Area Countries||Bristol-Myers Squibb|No|Not yet recruiting|July 2016|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Cohort 1: Patients enrolled by physician or nurse based in hospital rheumatology        departments and physician clinics and offices        Cohort 2: Physician or nurse based in hospital RA department and physician clinics and        offices        Cohort 3: Patients enrolled by physician or nurse based in hospital rheumatology        departments and physician clinics and offices|March 2016|March 11, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632890||6721|
NCT02392546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000185|Elobixibat Colonic Motor Function Study|A Single Center, Placebo-controlled Trial to Evaluate the Effects of Elobixibat in Colonic Motor Functions in Patients With Chronic Idiopathic Constipation||Ferring Pharmaceuticals|No|Withdrawn|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|March 13, 2015|Yes|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT02392546||25173|
NCT02379897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL 57981|Diet, Obesity and Cardiovascular Risk Study|Diet, Obesity and Cardiovascular Risk Study||Tufts University|No|Completed|September 2000|January 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|107|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02379897||26145|
NCT02628184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13383|A Case Study of a Maternity Service Development Programme|A Case Study of a Maternity Service Development Programme and Its Influence on Inter-agency Collaboration||University of Southampton|No|Recruiting|January 2016|||September 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Service provider practitioners that have been influenced by the implementation of the        Maternity Services Development Programme (including, Children Centre Staff and        Practitioners (Centre Lead Practitioner/Manager, Family and Child practitioner and        Frontline Receptionist), Midwives, Health Visitors, Social Workers and Additional        Professional Practitioners (Nurture Practitioner, Parenting Practitioner and Early Years        Teacher). Volunteer agencies have been excluded as many local groups are made up from        community service users.|February 2016|February 3, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02628184||7082|
NCT02632422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081884|AIH-induced Walking Recovery After Subacute SCI|Intermittent Hypoxia-Induced Recovery of Overground Walking in Persons With Subacute SCI||Emory University|No|Recruiting|October 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632422||6757|
NCT02391558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2015-07|Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography|Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography|OCTA|Association for Innovation and Biomedical Research on Light and Image|Yes|Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|All patients with clinical indication for fluorescein angiography will be invited to        perform OCT angiography in the same day during a period of 6-8 months.|January 2016|January 18, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391558||25248|
NCT02391571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELI-004-2015|A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects|A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects||Elite Laboratories, Inc|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|26|||Both|18 Years|55 Years|No|||March 2015|March 19, 2015|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391571||25247|
NCT02635009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-CC003|Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer|Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer||NRG Oncology|Yes|Recruiting|December 2015|||April 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635009||6558|
NCT02637362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSCP1|Optimal Analgesia for Forefoot Surgery|Optimal Analgesia Following Metatarsal Surgery: A Prospective Randomised, Single-Blind Sham-Controlled Trial of Three Strategies||Queen Elizabeth Hospital NHS Foundation Trust|No|Not yet recruiting|June 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637362||6378|
NCT02631304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-162|Delirium in Elderly Undergoing Cardiac Surgery and the Significance of CholinEsterase Activity|Delirium in Elderly Undergoing Cardiac Surgery and the Significance of CholinEsterase Activity Measured by Point of Care Method - a Prospective Observational Study|DECCEP|RWTH Aachen University|No|Recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood|Both|65 Years|N/A|No|Probability Sample|Tertiary care clinic|December 2015|December 11, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02631304||6842|
NCT02640157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-594|A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection|A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection|ENDURANCE-3|AbbVie|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|460|||Both|18 Years|100 Years|No|||March 2016|March 13, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640157||6163|
NCT02640170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 16915|Intraoperative Imaging With ICG Registry|Intraoperative Imaging With ICG Registry||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|||December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients with a diagnosis of any resectable solid tumor, including but not limited to lung        nodule, breast, kidney,parathyroid, mediastinal, skin mass, soft tissue, prostate, stomach        pleural, head and neck, and are at risk of recurrence|December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640170|5 Years|6162|
NCT02379598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202/2011|Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy|Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy||Federico II University|No|Completed|May 2012|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|5 Months|12 Months|No|Probability Sample|Children with a sure diagnosis of cow's milk allergy|February 2015|February 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02379598||26168|
NCT02379611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130706|Study of Neurologic Development of Temporal Voice Area (TVA) in Deaf Infant|Clinical Trial Comparing Neurologic Development of Temporal Voice Area in Cochlear Implanted Deaf Infant and in Normally Hearing Infant.|Implaneuro|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|N/A|10 Months|No|||February 2016|February 23, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02379611||26167|
NCT02642731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-07|Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty|Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty|dexpolvi|Kuopio University Hospital|No|Completed|September 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|plasma for measurement of renal markers Urine for measurement of renal markers|Both|50 Years|75 Years|No|Probability Sample|patients coming to elective knee arthroplasty|December 2015|December 25, 2015|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02642731||5965|
NCT02642744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823366|Improving Coordination and Transitions of Care in Stroke Patients|Improving Coordination and Transitions of Care for Stroke Patients With an Attending Nurse: a Comparative Effectiveness Single Center Study Comparing Models of Nursing Care||University of Pennsylvania|No|Recruiting|October 2015|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642744||5964|
NCT02628717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I3MHCV|Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)|Interferon/Ribavirin-Free Sofosbuvir Based Treatment Regimens In Patients With Advanced Liver Disease - Results Of A Real-Life Austrian Ribavirin-/Interferon Free Cohort (AURIC)|AURIC|Medical University of Vienna|No|Recruiting|July 2013|December 2017|Anticipated|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with fibrosis grade F3 or F4, age >18 years, with indication for antiviral        treatment|December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02628717|3 Years|7041|
NCT02638909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV-ALK-01|Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies|A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK-Activated Gastrointestinal Malignancies||Criterium, Inc.|Yes|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638909||6259|
NCT02384395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0549|Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection|IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect|PHI 05|University of North Carolina, Chapel Hill|No|Recruiting|September 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384395||25799|
NCT02635711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Taekwondo for Children With Developmental Coordination Disorder|A Randomised Controlled Trial of the Effectiveness of Adapted Taekwondo Training on Skeletal Development and Motor Proficiency in Pre-pubertal Children With Developmental Coordination Disorder||The University of Hong Kong|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02635711||6505|
NCT02636413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH-GXL-2013-01|Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance|Evaluation of the Impact of LacTEST on Diagnostic Thinking and on Patient Management, and of the Reproducibility (Test-Retest), for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance||VenterPharma|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02636413||6451|
NCT02629276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12|Somatosensory Phenotype of Patients Suffering From Unspecific Neck and Arm Pain|Somatosensory Profiles in Patients With Non Specific Neck Arm Pain With and Without Positive Neurodynamic Tests||Swiss Paraplegic Centre Nottwil|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients (woman and men) with unilateral non specific neck-arm pain are recruited from the        Centre of Pain Medicine outpatient departments of the Swiss Paraplegic Centre in Nottwil.        A standard bedside neurological examination (light touch, muscle strength and reflexes)        and standard electro-diagnostic tests (distal ulnar and median sensory and motor latencies        and amplitudes, F-waves) are performed to exclude patients with a specific neurological        cause for their symptoms (e.g., cervical radiculopathies, myelopathies)|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629276||6998|
NCT02629289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIN-130-1505|A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants|A Phase 1 Study Assessing the Pharmacodynamic and Pharmacokinetic Equivalence of HSP-130 With US-approved Neulasta® and EU-approved Neulasta® Administered as a Single Subcutaneous Dose to Healthy Volunteers||Hospira, Inc.|No|Active, not recruiting|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629289||6997|
NCT02391506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-0116|Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis|A Prospective Study to Evaluate the Safety and Effectiveness of the Cartiva® Synthetic Cartilage Implant for CMC in the Treatment of First Carpometacarpal Joint Osteoarthritis|GRIP|Cartiva, Inc.|Yes|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391506||25252|
NCT02313441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC1|Cardio- and Renoprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention|Cardio- and Reno-protective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention. A Prospective, Non-randomized Controlled Trial.||Assiut University|No|Completed|September 2013|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|85 Years|No|||December 2014|December 24, 2014|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02313441||31237|
NCT02313454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUN-007|Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye|A Single Center, Randomized, Controlled, Single-Masked, Cross-Over Clinical Pilot Study to Evaluate the Reduction in the Exacerbation of the Symptoms of Dry Eye Upon Exposure to a Controlled Adverse Environment||Oculeve, Inc.|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|22 Years|N/A|No|||November 2015|November 20, 2015|December 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02313454||31236|
NCT02294149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4086|Vit D3 and Omega 3 in Chemo Induced Neuropathy|A Randomized Controlled Trial of Mammalian Omega 3 With Vitamin D3 in Patients at Risk of Chemotherapy Induced Peripheral Neuropathy.||McGill University Health Center||Recruiting|January 2015|November 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294149||32718|
NCT02308007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-001 (Trial 3)|Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|SMART GIVES|Curatek Pharmaceuticals, LLC|No|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|189|||Female|12 Years|N/A|No|||November 2015|November 17, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308007||31654|
NCT02308020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15450|A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain|A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma||Eli Lilly and Company|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|247|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308020||31653|
NCT02323893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261201300063|Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer|Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Humans||CellSight Technology, Inc.|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02323893||30435|
NCT02323906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-HCC-001|Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer|A Phase 1b, Multi-Center, Open-Label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma||Celgene|Yes|Recruiting|January 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02323906||30434|
NCT02313675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110464|Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol for Carpal Tunnel and Distal Radius Fracture Surgeries|Comparing Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol Administration for Carpal Tunnel Release and Distal Radius Fracture Surgeries||University of Pittsburgh|No|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02313675||31219|
NCT02318238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT001|Comparison Between 6 Minute Walk Test, 6 Minute Step Test and 4 Metre Gait Speed|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2014|October 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|74|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02318238||30869|
NCT02298582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC/13/67|Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly|Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.|FENTA|University Hospital, Grenoble|No|Recruiting|November 2014|June 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|76 Years|N/A|No|||November 2015|December 1, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02298582||32378|
NCT02301065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIRT|Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors|Analysis of KIR+CD56+ T Cells and FcRg-CD56+CD3- NK Cells in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients and Donors||St. Jude Children's Research Hospital|No|Recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|21 Years|No|Non-Probability Sample|The study is planned to enroll 50 pediatric allogeneic hematopoietic stem cell transplant        (HSCT) patients and 50 donors. All patients/donors who meet eligibility criteria and sign        the consent form will be enrolled on the study.|January 2016|January 19, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02301065||32187|
NCT02321982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15025|Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery|Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery||Dartmouth-Hitchcock Medical Center||Not yet recruiting|February 2015|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|230|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02321982||30582|
NCT02315287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triple_2|Triple Combination of Metformin, Sitagliptin and Thiazolidinedione in Drug-naïve Type 2 Diabetic Patients|Therapeutic Efficacy of Triple Combination of Metformin, Sitagliptin and Thiazolidinedione in Drug-naïve Type 2 Diabetic Patients||Seoul National University Bundang Hospital|Yes|Recruiting|September 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|20 Years|80 Years|No|||October 2015|October 23, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02315287||31096|
NCT02302560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TepSo|Identification of the Sleep Architecture in Patients With Hip Surgery (TepSo)|Identification of the Sleep Architecture in Patients With Hip Surgery (TepSo)||Charite University, Berlin, Germany|No|Recruiting|February 2015|November 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with elective hip surgery (implementation or replacement of hip joint        endoprothesis)|March 2016|March 7, 2016|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02302560||32072|
NCT02319915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-PTGexacyl-001|Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.|Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.||Brugmann University Hospital|No|Recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|18 Years|80 Years|No|||October 2015|October 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02319915||30741|
NCT02630693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA38|Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer|Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer||Canadian Cancer Trials Group|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|N/A|No|||December 2015|March 22, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630693||6889|
NCT02641964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSSRMYY-HB-1|Risk Factors for ARDS in Patients With Acute Necrotizing Pancreatitis|Risk Factors for ARDS in Patients With Acute Necrotizing Pancreatitis||Nanjing Medical University|No|Enrolling by invitation|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|the investigators reviewed all patients with a diagnosis of pancreatitis admitted to        surgical wards or ICUs at the First Affiliated Hospital with Nanjing Medical University        and Nanjing General Hospital of Nanjing Military Command from January 1, 2009, to October        31, 2015.Adult patients (age >18 years) with acute necrotizing pancreatitis were enrolled.|February 2016|February 4, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02641964||6024|
NCT02643966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14100275|Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT|Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT (Also Known as "DBTUST-Dense Breast Tomosynthesis / Ultrasound Screening Trial")|DBTUST|University of Pittsburgh|No|Recruiting|December 2015|December 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|6200|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643966||5870|
NCT02640144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-15-ZIV|The Influence of Hyaluronic Acid Injection Following Knee Arthroscopy|The Influence of Hyaluronic Acid Injection Following Knee Arthroscopy||Ziv Medical Center|No|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02640144||6164|
NCT02390700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105631|Observational Study of Golimumab Intravenous Infusion|Golimumab Intravenous Infusion Registry (GO-IV)|GO-IV|Janssen Inc.|No|Recruiting|February 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Canadian participants with rheumatoid arthritis (RA), who have been prescribed intravenous        golimumab prior to, and independently of, study enrollment.|March 2016|March 15, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390700|2 Years|25314|
NCT02636140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-36326|Color and Pupil Function|Effect of Light Spectrum on Pupil Function||VA Palo Alto Health Care System|No|Not yet recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636140||6472|
NCT02638389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASE|Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care|Phase III Multicentric Study Evaluating the Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|November 2015|October 2025|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|3 Months|70 Years|No|||January 2016|January 6, 2016|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638389||6299|
NCT02644460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083793|Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors|Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors|AflacST1501|Emory University|Yes|Recruiting|February 2016|October 2020|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|21 Years|No|||February 2016|February 9, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644460||5832|
NCT02630654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-99-52030-286|Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs|Exploratory, Non-Interventional Study For Evaluating The Diagnostic, Prognostic And Response-Predictive Value Of A Multi Biomarker Approach In Metastatic GEP NETs|EXPLAIN|Ipsen|No|Active, not recruiting|March 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|350|Samples With DNA|Frozen plasma will be saved in a biobank|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients from a specialist clinic with a suspected diagnosis of metastatic GEP NETs and        healthy controls matched by age and gender.|December 2015|December 21, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630654||6892|
NCT02630901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX003-102|Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis||Prothena Biosciences Limited|No|Recruiting|March 2016|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630901||6873|
NCT02392091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA01|Renal Tubular Acidosis is Highly Prevalent in Critically Ill Patients|Renal Tubular Acidosis is Highly Prevalent in Critically Ill Patients||Medical University of Vienna|No|Completed|April 2011|March 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients from a medical ICU|March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392091||25208|
NCT02635932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP_UNIFESP_269.012|Effectiveness of Trapeziometacarpal Splint|||Federal University of São Paulo||Recruiting|September 2014|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02635932||6488|
NCT02643303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2014-011|A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers|A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers||Ludwig Institute for Cancer Research|No|Not yet recruiting|February 2016|February 2022|Anticipated|February 2022|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|102|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643303||5921|
NCT02640352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROIMKID_15|The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children|A Randomized, Double Blind, Placebo-controlled Study to Investigate the Effect of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children||Probi AB|No|Recruiting|December 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|556|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640352||6148|
NCT02393222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14RE639|Assessing Cognitive fUnction and MEasuring the Cerebral circulatioN on HaemoDialysis|Exploring the Natural History of Cerebrovascular Disease in Patients With End-stage Renal Disease on Haemodialysis|ACUMEN-HD|NHS Greater Glasgow and Clyde|Yes|Not yet recruiting|March 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|97|Samples With DNA|Samples will be taken with consent for serum biomarkers. Consent will be sought for DNA      testing in the future, following favourable ethical review|Both|18 Years|85 Years|No|Probability Sample|All adult patients receiving haemodialysis for end-stage renal disease.|March 2015|March 18, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02393222||25121|
NCT02631785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-15|Fear Conditioning, Extinction and Its Recall in Anxious Youth|Fear Conditioning, Extinction and Its Recall in Anxious Youth: Identifying Neuro- Cognitive Abnormalities and Their Relation to Pediatric Anxiety Treatment Outcomes|FCPA|University of Haifa|No|Not yet recruiting|February 2016|February 2020|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02631785||6805|
NCT02632058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-not defined|Efficacy of Treatment for Tinnitus|Efficacy of Treatment for Tinnitus Based on Cognitive Behavioural Therapy in an Inpatient Setting: a 10-year Retrospective Outcome Analysis||Psychiatrische Dienste Graubuenden|Yes|Active, not recruiting|August 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients suffering from chronic tinnitus referred to our        clinic by their treating physician. There is a remarkable level of suffering from chronic        tinnitus in these individuals. The participants received an established routine treatment        as part of multimodal treatment at an inpatient psychiatric facility. Clinical experience        shows that the applied treatment poses a low risk and demonstrates a great amount of        benefit. At admission to our clinic all participants were of age and able to give their        consent to treatment.|December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632058||6785|
NCT02636426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.224|Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study|Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study|SOPRANO|VU University Medical Center|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636426||6450|
NCT02636582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02189|Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer|VADIS Trial: Phase II Trial of Nelipepimut-S Peptide Vaccine in Women With DCIS of the Breast|VADIS|National Cancer Institute (NCI)|Yes|Not yet recruiting|March 2016|||September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||December 2015|January 11, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636582||6438|
NCT02378870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODX-002|A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC|A Randomised, Double-blind, Placebo-controlled Multicentre Phase II Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)||DexTech Medical AB|Yes|Recruiting|January 2015|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||February 2015|March 3, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02378870||26224|
NCT02633254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-528|Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound|Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound||UMC Utrecht|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|100 Years|No|||November 2015|December 14, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02633254||6693|
NCT02636777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15084|Predictors of Self-management in Patients With Chronic Low Back Pain|Predictors of Self-management in Patients With Chronic Low Back Pain||University of Nottingham|No|Not yet recruiting|December 2015|||February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|65 Years|No|Non-Probability Sample|The study will include community ambulant adult patients attending or recently attended        outpatient physiotherapy treatment for their chronic low back pain.|December 2015|December 17, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02636777||6423|
NCT02636790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02020|Early Versus Late Surgical Wait Times|Is Prioritization of the Sinus Surgical Waitlist Required?||University of British Columbia|No|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|19 Years|N/A|No|||December 2015|December 21, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02636790||6422|
NCT02628782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-14-003I|InSeal VCD Large Bore Vascular Closure Device Safety and Effectiveness Clinical Study|InSeal VCD Large Bore Vascular Closure Device Clinical Study|InSealVCD|InSeal Medical Ltd.|No|Recruiting|November 2013|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628782||7036|
NCT02630576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADBV-ABS-0214-NEAT-2H|Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy (Volunteers|Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy Volunteers|NEAT-2|University of Debrecen|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02630576||6898|
NCT02640638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD082311|A RCT of CenteringPregnancy on Birth Outcomes|Reducing Disparities in Birth Outcomes: a Randomized Controlled Trial of CenteringPregnancy|CRADEL|Clemson University|Yes|Not yet recruiting|January 2016|May 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3160|||Female|14 Years|45 Years|No|||December 2015|December 23, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02640638||6126|
NCT02632656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001658|Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study|Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study|PEARL-HF|Massachusetts General Hospital|No|Active, not recruiting|December 2015|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Peripheral blood collected at various time points during CHF therapy, processed for ex-RNAs|Both|21 Years|N/A|No|Non-Probability Sample|The study population will consist of 200 eligible subjects. These subjects will be        enrolled from the Massachusetts General Heart Failure Center population, from the Yawkey        Center for Outpatient Care, upon discharge from the inpatient services at Massachusetts        General Hospital.|December 2015|December 14, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02632656||6739|
NCT02628054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-IDREC-C3-2014-011|Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers|Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers||University of Oxford|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02628054||7092|
NCT02628067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-158|Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)|A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)||Merck Sharp & Dohme Corp.|No|Recruiting|December 2015|March 2021|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628067||7091|
NCT02643940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B785|The Physiological Impact of CTO PCI on Coronary Pressure Measurements and Correlation in Donor Vessel|The Physiological IMPACT of Coronary Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention (PCI) on Coronary Pressure -‐Derived Measurements, Its Correlation in the Donor Vessel and the Influence of Collateral Circulation|IMPACT-CTO|Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|Samples Without DNA|Blood samples (standard care no extra samples collected)|Both|18 Years|N/A|No|Probability Sample|Patients scheduled for a PCI CTO|December 2015|December 30, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02643940||5872|
NCT02634424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140701|PK Driven Prophylaxis for Hemophilia A|Interest of Preventive Personalized Treatment in Hemophilia A|OBTC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|54|||Male|6 Years|N/A|No|||December 2015|December 15, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634424||6603|
NCT02634437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPA-PK-02|Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects|A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function||Forest Laboratories|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02634437||6602|
NCT02638935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTIQ|Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions|Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions: Can Patient Selection for Biopsy be Improved? - A Confirmatory Multi-Center-Study||Heidelberg University|Yes|Recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|1000|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02638935||6257|
NCT02629692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_15_03|Safety and Tolerability of SPARC1503|||Sun Pharma Advanced Research Company Limited||Not yet recruiting|April 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|287|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629692||6966|
NCT02638649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1511016808|Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath|Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath||Yale University|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|376|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with dyspnea|December 2015|December 22, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02638649||6279|
NCT02637258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TATDUS-0001|Can Optic Nerve Sheath Diameter Measurement Predict Negative Neurological Outcome ?|Can Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter Following the Return of Spontaneous Circulation Predict Negative Neurological Outcome in Out of Hospital Cardiac Arrest Patients?||Emergency Medicine Association of Turkey|No|Recruiting|December 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|203|||Both|18 Years|N/A|No|Probability Sample|The non-traumatic, non-intracranial event related OHCA patients in whom the ROSC is        achieved will render the sampling group|December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637258|1 Month|6386|
NCT02637817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjtuMRI|MRI-based Biomarkers for the Prognosis Judgement of Punctate White Matter Lesions in Neonates: a Longitudinal Multicenter Study|MRI-based Biomarkers for the Prognosis Judgement of Punctate White Matter Lesions in Neonates: a Longitudinal Multicenter Study|PWML|First Affiliated Hospital Xi'an Jiaotong University||Recruiting|January 2016|||June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|N/A|28 Days|No|Non-Probability Sample|PWML and non-PWML neonates|February 2016|February 3, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02637817||6343|
NCT02639546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29665|iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors|A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of The Safety And Pharmacokinetics of Cobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors - iMATRIX Cobi||Hoffmann-La Roche||Not yet recruiting|May 2016|January 2023|Anticipated|January 2023|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|30 Years|No|||February 2016|February 1, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639546||6210|
NCT02634567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107343|Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training|||London Health Sciences Centre||Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|59 Years|No|||March 2016|March 9, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02634567||6592|
NCT02642146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-IMJ-002|Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study|||Seoul National University Hospital||Not yet recruiting|January 2016|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with systemic sclerosis|December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642146|3 Years|6010|
NCT02639117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28849|Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas|Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas|PDT-Vismo|University of Arizona|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639117||6243|
NCT02639130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZBL-2007-1|GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes|Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Type 2-diabetic Patients Using Exendin [9-39] as a GLP-1 Receptor Antagonist||Diabeteszentrum Bad Lauterberg im Harz|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 20, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639130||6242|
NCT02379910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030-260-01|A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis|AM1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) With Atopic Dermatitis||AnaMar AB|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|36|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02379910||26144|
NCT02637089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-2463|Longitudinal Study of Mild Cognitive Impairment in Parkinson's Disease|Longitudinal Comparison of the Nature and Evolution of Mild Cognitive Impairment in Individuals With and Without Parkinson's Disease Characterized by Neuroimaging, Clinical Assessments and Genotyping|PD-MCI|University of Calgary|No|Not yet recruiting|January 2016|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|Samples With DNA|50 ml of blood will be collected from all participants to analyze biomarkers and DNA for      genes of interest|Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with Parkinson's disease with and without mild cognitive impairment, patients        without Parkinson's disease with and without (healthy controls) mild cognitive impairment,        60 years of age or older|December 2015|December 22, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02637089||6399|
NCT02637102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0659|The UK CAVIAR Study|The UK CArdiac and Vascular Surgery Interventional Anaemia Response Study: An Observational Cohort Study to Determine the Impact and Effect of Anaemia in Patients Awaiting Vascular and Cardiac Surgery||University College, London||Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|432|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring major cardiac or vascular surgery will be identified from routine        clinical care. Most patients are routinely referred for pre-operative assessment, although        local protocols vary between centres. Assesments at the pre-operative assessment clinic        (PAC) may include (but not limited to) routine blood tests (full blood count, urea and        electrolytes, etc.), history and examination, cardiorespiratory fitness assessment by 6        minute walk test (6MWT) or cardiopulmonary exercise testing (CPET). In some centres,        patients with anaemia will receive intravenous iron at PAC or in a separate anaemia        clinic.|November 2015|December 21, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02637102||6398|
NCT02632825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCMCHP014|Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange in Healthy Newborns|Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange During Wakefulness and Sleep in Healthy Newborn Babies in a Randomized Crossover Study Design||Research Center of Maternal and Child Health Protection, Armenia|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|3 Days|Accepts Healthy Volunteers|||September 2015|December 16, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632825||6726|
NCT02637492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/26|Development and Validation of a Clinical Prediction Rule for Lower Limb Critical Limb Ischaemia (PREDICCMI)|Development and Validation of a Clinical Prediction Rule for Lower Limb Critical Limb Ischaemia (PREDICCMI)|PREDICCMI|University Hospital, Bordeaux|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized for peripheral occlusive arterial disease|December 2015|December 28, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02637492||6368|
NCT02379364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI/01|Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome|Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome||Universidad de Zaragoza|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|16 Years|40 Years|No|||May 2015|May 27, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02379364||26186|
NCT02637375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0848|A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer|A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer||University of Chicago|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|December 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02637375||6377|
NCT02628756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/490|Endometrial Injury in Women With Unexplained Infertility|Endometrial Injury Does Not Improve Pregnancy Rates in Women With Unexplained Infertility||Mansoura Integrated Fertility Center|No|Completed|June 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02628756||7038|
NCT02384161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPernambucoMK|Exercise Intermittent Isometric Handgrip and Blood Flow Restriction|Exercise Intermittent Isometric Handgrip Associated With Different Levels of External Vascular Compression: Acute Effects on Neuromuscular Response||Universidade Federal de Pernambuco|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02384161||25817|
NCT02384382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-18|A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)|A Phase 2, Open-Label, Single-Arm Study of 18F-Sodium Fluoride PET/CT Bone Imaging in Enzalutamide-Treated Chemotherapy-Naïve Patients With Bone-Metastatic Castration-Resistant Prostate Cancer||Medivation, Inc.|No|Recruiting|November 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384382||25800|
NCT02630004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAN13004-30|Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation|Phase IB-II Clinical Trial of Melatonin Oral Gel for the Prevention and Treatment of Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation.|MUCOMEL|Spherium Biomed|No|Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|84|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02630004||6942|
NCT02634008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1502|Treatment of Recently Acquired Genotype 1 Hepatitis C With the 3D Regimen|An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.|TARGET3D|Kirby Institute|Yes|Not yet recruiting|January 2016|April 2019|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02634008||6635|
NCT02633293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-202|An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE|An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease||United Therapeutics|Yes|Enrolling by invitation|July 2016|October 2020|Anticipated|October 2020|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|266|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633293||6690|
NCT02638701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16893|Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms|Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms||University of California, San Francisco|Yes|Not yet recruiting|June 2016|December 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638701||6275|
NCT02640274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1568/REK|Individual Nurse-led Counselling Programme for Patients Early Discharged After Myocardial Infarction.|Self-management Behaviour After an Individual Nurse-led Counselling Programme for Patients Early Discharged After Myocardial Infarction: A Randomised Controlled Trial.||Central Norway Regional Health Authority||Recruiting|November 2013|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640274||6154|
NCT02391441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2014/134|Ventricular Reversed Remodeling After LTX in PAH Patients|Imaging of Ventricular Reversed Remodeling After Double Lung Transplantation in Patients With Pulmonary Arterial Hypertension|PAH-LTX|University Medical Center Groningen|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Patients with pulmonary arterial hypertension and control patients without increased        pulmonary artery pressure who are on the waiting list for double-LTX|March 2015|March 12, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02391441|6 Months|25257|
NCT02637947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-021|Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population|A Prospective, Multi-center, Post Market Randomized Controlled Trial Comparing VT Ablation Outcomes Using Remote MAGNETIC Navigation Guided Substrate Mapping and Ablation Versus Manual Approach in a Low LVEF Population|MAGNETIC-VT|Stereotaxis|No|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|382|||Both|18 Years|N/A|No|||January 2016|March 23, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637947||6333|
NCT02644356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43CA157005|Complementary Therapies in Palliative Care|Palliative Care Provider Online Education in Evidence-Based Complementary Therapies|CTPC|Collinge and Associates, Inc.|No|Completed|July 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02644356||5840|
NCT02644369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSPIRE-001|Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors|Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation|INSPIRE|University Health Network, Toronto|No|Recruiting|March 2016|June 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02644369||5839|
NCT02633865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China11|Patient Participation in Free Cataract Surgery|Patient Participation in Free Cataract Surgery: The Low-income Elderly in Urban China||Sun Yat-sen University|Yes|Completed|May 2012|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|883|||Both|50 Years|102 Years|No|Probability Sample|A free cataract surgery program was jointly initiated by the People's Government of        Guangzhou Municipality, the Bureau of Civil Affairs of Guangzhou Municipality, and the ZOC        in May 2012. Guangzhou citizens aged ≥50 years with low income who relied on social        subsidies were candidates for this activity.|December 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02633865|9 Months|6646|
NCT02633878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHM-MP|Chinese Herbal Medicine and Micronized Progesterone for Threatened Miscarriage RCT|||Heilongjiang University of Chinese Medicine|No|Not yet recruiting|December 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1656|||Female|18 Years|37 Years|No|||December 2015|December 20, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02633878||6645|
NCT02376920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-01|5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes|CLEAR Registry Study: An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-UM Multigene Assay Results and Associated Patient Outcomes.|CLEAR|Castle Biosciences Incorporated|No|Enrolling by invitation|March 2010|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2800|||Both|16 Years|N/A|No|Probability Sample|Patients diagnosed with uveal melanoma and determined by their treating physician to be        appropriate for DecisionDx-UM testing.|February 2015|March 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02376920|10 Years|26374|
NCT02376933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300000562|Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer|Phase 2 Study of Vertebral Augmentation and Radiotherapy in Painful or at Risk of Collapse Spinal Metastatic Cancer/Multiple Myeloma||University of Arizona|Yes|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02376933||26373|
NCT02317952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-VA-14-001|Formula for Children With Cow's Milk Allergy|A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein||Perrigo Nutritionals|No|Recruiting|May 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|90|||Both|N/A|13 Years|No|||October 2015|October 19, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02317952||30891|
NCT02318225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso/Placebo/hystero1|Misoprostol Prior to Office Hysteroscopy in Patients With no Risk Factors for Experiencing Unacceptable Pain|Cervical Priming With Misoprostol Before Diagnostic Office Hysteroscopy in Patients With no Risk Factors for Experiencing Unacceptable Pain. A Randomized Double Blinded Placebo-controlled Study||Cairo University|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|55 Years|No|||September 2015|September 19, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02318225||30870|
NCT02298283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAPP2|Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD|Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD|BRAPP2|The Lymphoma Academic Research Organisation|Yes|Recruiting|April 2015|February 2021|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02298283||32401|
NCT02298296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000945|Trajectory of Positive Psychological States in Patients With ACS|Trajectory of Positive Psychological States in Patients With Acute Coronary Syndrome|PEACEIIa|Massachusetts General Hospital|No|Active, not recruiting|June 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects were recruited from inpatient cardiac units in a large, urban hospital.|November 2014|November 19, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02298296||32400|
NCT02296177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-14-0269|Evidence Based Dissemination for Mammography Adherence in Safety Net Communities|Evidence Based Dissemination for Mammography Adherence in Safety Net Communities||The University of Texas Health Science Center, Houston|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5000|||Female|40 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02296177||32562|
NCT02314702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-LJH-002L|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems||MicroPort Orthopedics Inc.|No|Recruiting|September 2015|October 2027|Anticipated|October 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who have been previously implanted with PROFEMUR® L Revision Femoral Components|March 2016|March 15, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02314702||31141|
NCT02314936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2014|Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation|Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial||KGK Synergize Inc.|No|Recruiting|April 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|192|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314936||31123|
NCT02322138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL14|Gastrointestinal Tolerance of Infant Formula|Gastrointestinal Tolerance of Formula Supplemented With Prebiotics||Abbott Nutrition|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|131|||Both|N/A|8 Days|Accepts Healthy Volunteers|||July 2015|July 22, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02322138||30570|
NCT02302300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 13.125 CAPVNI|Interest of the Not Invasive Ventilation Used in Meadow and Post-operative of Cardiac Surgery|Interest of the Not Invasive Ventilation Used in Meadow and Post-operative of Cardiac Surgery, in Disease Prevention of the Cardiac and/or Lung Complications at the Patients at Risk.|CAPVNI|University Hospital, Brest|Yes|Recruiting|May 2014|February 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|216|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02302300||32092|
NCT02308111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-302|Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis|A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cirrhosis|COBALT|Intercept Pharmaceuticals|Yes|Recruiting|December 2014|April 2023|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308111||31646|
NCT02320123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032013-051|End-of-Life Care for African Americans|End-of-Life Care for African Americans: Intervention Design and Implementation||University of Texas Southwestern Medical Center|No|Active, not recruiting|September 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|1||Anticipated|116|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02320123||30725|
NCT02294357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-2014-100701|Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib|A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib||Oncotherapeutics|No|Recruiting|December 2014|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02294357||32702|
NCT02298309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001173/MGH|Test and Treat TB: A Proof of Concept Trial in South Africa||Siyasiza|Massachusetts General Hospital|Yes|Recruiting|April 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02298309||32399|
NCT02298322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA14-002|Submental IDE Study|Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis||Zeltiq Aesthetics|No|Active, not recruiting|November 2014|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||October 2014|September 2, 2015|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298322||32398|
NCT02309151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC001|Direct or Subacute Coronary Angiography for Out-of-hospital Cardiac Arrest|Direct or Subacute Coronary Angiography for Out-of-hospital Cardiac Arrest - a Randomized Study|DISCO|Uppsala University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02309151||31567|
NCT02309164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261/14|The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).|The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).||University of Sao Paulo|Yes|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02309164||31566|
NCT02309177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-ST-001|Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer|A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Metastatic Breast Cancer||Celgene|Yes|Recruiting|December 2014|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|138|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|December 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02309177||31565|
NCT02325453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes|A Multi-Institutional Chart Review to Compare the Outcomes of Robotic, Laparoscopic and Open Surgery for Gastric Cancer.||International Study Group on Minimally Invasive Surgery for Gastric Cancer|No|Recruiting|May 2015|January 2018|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|7000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects undergoing surgery for gastric cancer with robotic, laparoscopic or open        approaches and subsequent follow-up.|May 2015|May 14, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02325453||30315|
NCT02391961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1180-W|Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis|Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis||VA Office of Research and Development|No|Recruiting|April 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02391961||25218|
NCT02632292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-260|EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus|EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus|SUGAR-EVE|University of Luebeck|No|Not yet recruiting|January 2016|January 2019|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02632292||6767|
NCT02632526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7550C00001|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects|A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects||AstraZeneca|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|17||Anticipated|136|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02632526||6749|
NCT02628964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01178|Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy|Assessing the Use of Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy||New York University School of Medicine|No|Active, not recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628964||7022|
NCT02630121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00001844|Effect of Oxymetazoline Hydrochloride in Comibination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea|Effect of Oxymetazoline Hydrochloride in Comibination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Trial.||University of South Florida|No|Not yet recruiting|February 2016|August 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02630121||6933|
NCT02392000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 14-144|Mobile Sleep Intervention for OEF, OIF and OND Veterans|Mobile Sleep and Pain Intervention for OEF, OIF and OND Veterans||VA Office of Research and Development|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|65 Years|No|||February 2016|February 9, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392000||25215|
NCT02628106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOLD-1981|Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy|Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients||West China Hospital|Yes|Recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|90 Years|No|||December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02628106||7088|
NCT02628119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2151 040|Access Flow Based Intervention for Management of Arteriovenous Hemodialysis Access Dysfunction.|Access Flow Based Intervention for Management of Arteriovenous Hemodialysis Access Dysfunction. A Prospective Randomized Controlled Study.|FBI|King Faisal Specialist Hospital & Research Center|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628119||7087|
NCT02630602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LODYN 4092|Functional Goat Cheese Effect in Lipid Profile Change|Functional Goat Cheese Effect in Lipid Profile Change|LODYN|Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630602||6896|
NCT02634905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0035|A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months|A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months|EDUDA|Nantes University Hospital|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|3 Months|18 Years|No|||December 2015|December 16, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634905||6566|
NCT02378246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13031305|Iodine Status in Swedish Pregnant Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant|A Double-blinded Randomised Study of Iodine Supplementation to Pregnant Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function||Göteborg University|No|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|40 Years|No|||January 2016|January 7, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02378246||26272|
NCT02378259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578-13|Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity|AMOS-RCT (Adolescent Morbid Obesity Surgery)|AMOS-RCT|Göteborg University|No|Recruiting|September 2014|May 2021|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|13 Years|15 Years|No|||October 2015|October 26, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02378259||26271|
NCT02638623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502590723|Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery|Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery and Reduce Complications in Arthroplasty Patients?|Hydration|West Virginia University|Yes|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638623||6281|
NCT02628379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP-CLT-15-010|Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary|A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)||Foundation Medicine|No|Recruiting|May 2015|||October 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed and previously treated patients with CUP.|December 2015|December 10, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02628379||7067|
NCT02628197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perio 3 Aastha|Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women|Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women||Postgraduate Institute of Dental Sciences Rohtak|Yes|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|68|||Female|52 Years|59 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02628197||7081|
NCT02631694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKAEWC1|Disruption of Memory Reconsolidating as a Treatment for Panic Disorder|Targeting Fear Memory by Disrupting the Process of Reconsolidating: A New Intervention for Panic Disorder||VU University of Amsterdam||Not yet recruiting|April 2016|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631694||6812|
NCT02631954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151HPS14014|Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers|||Chong Kun Dang Pharmaceutical|No|Completed|September 2015|November 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02631954||6793|
NCT02379390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14022|Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz|Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy|PRIMCAB|Sanofi|No|Recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|274|||Male|18 Years|N/A|No|||March 2016|March 10, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379390||26184|
NCT02636049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMFPC-12|Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers|Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers|RMFPC-12|Rockwell Medical Technologies, Inc.|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636049||6479|
NCT02636153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuashanH|the Effects of Different Dietary Phosphorus Intake on the Circadian Pattern of Serum Phosphate in Normal Subjects|the Effects of Different Dietary Phosphorus Intake on the Circadian Pattern of Serum Phosphate in Normal Subjects||Huashan Hospital|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636153||6471|
NCT02643342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20150909002|A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye|A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye||The Hong Kong Polytechnic University|No|Recruiting|November 2015|March 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643342||5918|
NCT02642952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT001|Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.|Impact of Aortic Grafts After Open and Endovascular Repair in Central Hemodynamics and Arterial Stiffness Measured by Non-invasive Methods in Patients With Abdominal Aortic Aneurysms.||Hospital Universitario Ramon y Cajal|Yes|Recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|52|||Both|50 Years|90 Years|No|Non-Probability Sample|Patients consecutive treated for abdominal aortic aneurysm. The election of treatment is        selected based on morphology and health status.|February 2016|February 11, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02642952||5948|
NCT02635230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D/Z14.016/WOEST2|What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.|An International Prospective Registry on Concomitant Use of Oral Anticoagulants and P2Y12 Inhibitors in Patients With Atrial Fibrillation or Heart Valve Prosthesis Undergoing Coronary Revascularisation.|WOEST 2|R&D Cardiologie|No|Recruiting|June 2014|December 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2200|||Both|18 Years|N/A|No|Probability Sample|WOEST2 Registry is designed to recruit an unselected cohort of patients with AF and/or a        heart valve prosthesis undergoing coronary revascularisation (PCI/CABG) within at least        three European countries (Netherlands, Belgium, United Kingdom). The three international        cohorts of patients reflect the spectrum of our study population within the geographic        catchment regions. At least 15 hospitals of varying size and characteristics will        participate in this study.|December 2015|December 15, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02635230|24 Months|6542|
NCT02635243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14452|A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia|SAR438544 - Clinical & Exploratory Pharmacology||Sanofi|No|Not yet recruiting|April 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|44|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635243||6541|
NCT02382835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Metal-on-metal Hip Prostheses: Do They Have Systemic Effects?|Metal-on-metal Hip Prostheses: Do They Have Systemic Effects?|HipLink|Royal National Orthopaedic Hospital NHS Trust|No|Active, not recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|800000|||Both|N/A|N/A|No|Probability Sample|Description= Patients with a total hip replacement on the National Joint Registry that can        be linked to either National Institute for Cardiovascular Outcomes Research (NICOR) or the        Clinical Practice Research Datalink (CPRD) Geography = England Setting= Primary, Secondary        and Tertiary care Dates = 1st April 2003 (the start of data collection for the National        Joint Registry) to present|March 2015|March 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382835||25919|
NCT02637401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1415/002|Group Dialectical Behavioural Therapy for Mood Instability Within Bipolar Disorder: An Open Trial|Group Dialectical Behavioural Therapy for Mood Instability Within Bipolar Disorder: An Open Trial||University of Exeter|No|Active, not recruiting|March 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with frequent bipolar mood swings.|December 2015|December 17, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637401||6375|
NCT02642380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High-dose dexamethasone|Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)|Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial||Shandong University|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642380||5992|
NCT02630160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/5138/I|The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement|The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement|ILIACPCPTHR|Parc de Salut Mar|No|Completed|March 2013|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02630160||6930|
NCT02630420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015402|Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer|Combination of Cetuximab & MWT Inhibitor Savolitinib in the Treatment of Ras Wild-Type Colorectal Cancer||Yale University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630420||6910|
NCT02640118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15004078|The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects|The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects|Px-Lixi|University Hospital, Gentofte, Copenhagen|No|Enrolling by invitation|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02640118||6166|
NCT02634814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1150|The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis|Improving Disability in Knee Osteoarthritis by Targeting Neuromuscular Deficits||University of North Carolina, Chapel Hill|No|Recruiting|October 2015|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|75 Years|No|||December 2015|December 15, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634814||6573|
NCT02644070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214 in June 14, 2012|mp3 vs Apatos in Post-extractive Sockets|A Prospective Randomized-controlled Multicenter Clinical and Histological Study of Extraction Site Augmentation With mp3 vs. Apatos||Tuscan Dental Institute|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02644070||5862|
NCT02631369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0404|Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs|Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs Using the Integrated Algorithm by Heidelberg Spectralis|CySLO|University of Zurich|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02631369||6837|
NCT02631642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-689-00AU2|A Study of HMPL-689 in Healthy Volunteers|A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers||Hutchison Medipharma Limited|No|Not yet recruiting|March 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631642||6816|
NCT02632669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D12oncn0015|Hemi-Ablative Prostate Brachytherapy|A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative Low Dose Rate (LDR) Brachytherapy for Localised Prostate Cancer|HAPpy|Royal Surrey County Hospital NHS Foundation Trust|No|Recruiting|November 2013|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Male|N/A|N/A|No|||December 2015|December 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02632669||6738|
NCT02632279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tryptophan depletion in PD|Tryptophan Depletion in PD Patients Treated With STN DBS|Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions||Maastricht University Medical Center|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||November 2015|December 11, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02632279||6768|
NCT02638532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15090106|Volumetric Analysis in Autologous Fat Grafting to the Foot|Volumetric Analysis in Autologous Fat Grafting to the Foot||University of Pittsburgh|No|Recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02638532||6288|
NCT02640729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVT-102-2001|Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia|A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)||Axovant Sciences Ltd.||Recruiting|December 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|85 Years|No|||March 2016|March 11, 2016|December 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640729||6119|
NCT02391259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060132|A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus||Amgen|No|Completed|November 2006|November 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|70 Years|No|||March 2015|March 27, 2015|January 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391259||25271|
NCT02391324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0022460|Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy|Evaluation of the Effectiveness of Robotic Gait Training and Gait-focused Physical Therapy Programs for Children and Youth With Cerebral Palsy: A Mixed Methods Randomized Controlled Trial||University of Alberta|Yes|Not yet recruiting|January 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391324||25266|
NCT02391337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBCCS_RATEAF|Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)|Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy|RATE-AF|University of Birmingham|No|Not yet recruiting|December 2015|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02391337||25265|
NCT02629705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGN|Study of Carrageenan's Effect on Insulin Resistance in Humans|Investigation of the Effect of Carrageenan as Food Additive on Insulin Resistance in Humans||University Hospital Tuebingen|No|Recruiting|October 2015|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02629705||6965|
NCT02634268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL128868|Health Through Obesity Care for PatiEnts With COPD|Health Through Obesity Care for PatiEnts With COPD (HOPE)|HOPE|Seattle Institute for Biomedical and Clinical Research|Yes|Not yet recruiting|May 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|N/A|No|||December 2015|December 15, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02634268||6615|
NCT02644135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-11-33|A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo|A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo to Prevent Acute Upper Respiratory Disease and Respiratory Virus Infections||University Hospital Case Medical Center|No|Completed|January 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644135||5857|
NCT02641483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1962-W|Afferent Stimulation to Evoke Recto-colonic Reflex for Colonic Motility|Afferent Stimulation to Evoke Recto-colonic Reflex for Colonic Motility||VA Office of Research and Development|No|Not yet recruiting|January 2018|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641483||6061|
NCT02640014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1020AL001|Oral Immunotherapy in Food Allergy in Finland|Specific Oral Immunotherapy in Food Allergy - Real-life Long-term Follow up (After Milk Oral Immunotherapy), Effect on Health-related Quality of Life and Cost-utility Analyses||Helsinki University Central Hospital|No|Enrolling by invitation|December 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|6 Years|N/A|No|||December 2015|December 26, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02640014||6174|
NCT02639611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-03266|Effectiveness of Acupuncture in Post-Mastectomy Patients With Tissue Expanders|Effectiveness of Acupuncture in Post-Mastectomy Patients With Tissue Expanders||New York University School of Medicine|Yes|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|79 Years|No|||January 2016|January 27, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02639611||6205|
NCT02632591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN3-2015|Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment|Use on Human Being of a Mix Between Very Well Known Drugs, Tested Upon Registered Trial n° NCT02606929, to Consider Effectiveness of Improvement After 45 Days|NMSNT|Università Popolare Homo & Natura|No|Completed|August 2015|December 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632591||6744|
NCT02640859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-Biobank|Investigation of Metabolic Risk in Korean Adults|Investigation of Metabolic Risk in Korean Adults||Seoul National University Bundang Hospital|Yes|Recruiting|September 2015|August 2020|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|For measuring biomarkers|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Korean Adults|December 2015|December 22, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02640859|5 Years|6109|
NCT02640872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-HAPPY Cohort|A Prospective Cohort Study of Aged People for Chronic Diseases|A Prospective Cohort Study With Aged People to Elucidate Predictive Factors for Chronic Diseases|HAPPY|Seoul National University Bundang Hospital|No|Recruiting|July 2015|June 2020|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|for measuring biomarkers|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Aged 60 years and older Capable of communication with the research team Provided written        informed consent|December 2015|December 28, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02640872||6108|
NCT02384174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014GA05|Resistant Starch and Non-starch Polysaccharide (Dietary Fibre) Intake and the Colonic Microbiome in Older People|Resistant Starch and Non-starch Polysaccharide (Dietary Fibre) Intake in Relation to the Structure and Metabolic Activities of the Colonic Microbiome in Older People||University of Dundee|Yes|Not yet recruiting|May 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|70 Years|95 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02384174||25816|
NCT02639819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20160096H|Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study|A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage|MANICHAN-PILOT|The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|June 2016|July 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|February 23, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639819||6189|
NCT02638467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alloCML|Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy|Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy||University of Milano Bicocca|Yes|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02638467||6293|
NCT02641873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8809001|A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer|A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer||Sumitomo Dainippon Pharma Co., Ltd.||Recruiting|December 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|N/A|No|||December 2015|December 24, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02641873||6031|
NCT02641886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140700108a|Jian Pi Yi Shen Hua Tan Granules in Cognitive Impairment After Acute Cerebral Infarction Study|A Study to Evaluate the Safety and Efficacy of Jian Pi Yi Shen Hua Tan Granules in Patients With Cognitive Impairment After Acute Cerebral Infarction||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|80 Years|No|||December 2015|December 25, 2015|December 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641886||6030|
NCT02641899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-115|Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs|A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds||Intarcia Therapeutics|No|Completed|December 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641899||6029|
NCT02383901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-MTX-OB1|A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX|A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX|FORTO|Isofol Medical AB|No|Recruiting|October 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|2 Years|N/A|No|Probability Sample|Osteosarcoma patients, 2 years of age or older. Patients must have received at least one        course of HDMTX treatment with folate rescue in a MAP schedule. The treatment must have        been initiated by 01 January 2009 and completed by 31 May, 2014|August 2015|August 24, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02383901||25837|
NCT02642640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK102696|Interaction of Melatonin and MTNR1B Genotype on Glucose Control|Interaction of Melatonin and MTNR1B Genotype on Glucose Control||Brigham and Women's Hospital|No|Not yet recruiting|January 2016|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642640||5972|
NCT02636179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2015-A00997-42|Evaluation of the Prevalence of Asthma in a Cohort of Children Born After IVF (Aged 11-15) Compared With a Control Group|Evaluation of the Prevalence of Asthma in a Cohort of Children Born After In Vitro Fertilization (Aged 11-15) Compared With Spontaneously Conceived Children of the Same Age Range|EMCeFIV|Hospital St. Joseph, Marseille, France|Yes|Recruiting|December 2015|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1792|||Both|11 Years|15 Years|No|Non-Probability Sample|The investigators will include children born after In Vitro Fertilization/Intracytoplasmic        Sperm Injection treatment from a historic cohort and children born spontaneously (without        ART), attending schools in the same geographic area as IVF/ICSI children. Parents will be        contacted before to include children.|December 2015|December 16, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02636179||6469|
NCT02639663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|559-15-TLV|Dental Support Device During Breastfeeding as a Mean for Pain Control|Dental Support Device During Breastfeeding as a Mean for Pain Control||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639663||6201|
NCT02633358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH104-REC3-058|Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock|Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock||China Medical University Hospital|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633358||6685|
NCT02391350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS022641|Management Strategies for Patients With Low Back Pain and Sciatica|||University of Utah|Yes|Recruiting|January 2015|August 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391350||25264|
NCT02391363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1310-06824|Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities|Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities||Baylor College of Medicine|Yes|Recruiting|November 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|N/A|No|||January 2016|January 11, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02391363||25263|
NCT02634021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160088|Effect of Loading of Midazolam or Dexmedetomidine on Hemodynamics|Hemodynamic Change Between Loading of Dexmedetomidine or Midazolam as a Sedative Agents During Knee Arthroscopy||Konkuk University Medical Center|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|20 Years|N/A|No|||December 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02634021||6634|
NCT02638857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-004|Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma|A Controlled Clinic Trial of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Combination With Transcatheter Arterial Chemoembolization in Treating Patients With Advanced Hepatocellular Carcinoma||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|December 30, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02638857||6263|
NCT02629042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/09|Efficacy of Oral Prednisolone on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis|Efficacy of Oral Prednisolone Versus Partial Endodontic Treatment on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis of Mandibular Molars: Non Inferiority Randomized Clinical Trial|PULPISOLONE|University Hospital, Bordeaux|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629042||7016|
NCT02392702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP656.1001|Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects|A Two-Part Open-Label, Randomized, Sequential, Crossover, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of C-10355 and C-10358 in Healthy Volunteers, With a PK Comparison to Kalydeco®||Concert Pharmaceuticals|No|Completed|March 2015|September 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02392702||25161|
NCT02642848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS15OISI0021|Clinical Outcomes of Open Wedge High Tibial Osteotomy With Autologous Bone Marrow or Adipose-derived Stem Cell Therapy|Clinical Outcomes of Open Wedge High Tibial Osteotomy With Autologous Bone Marrow or Adipose-derived Stem Cell Therapy|HTOSC|Catholic Kwandong University|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|15 Years|65 Years|No|||January 2016|January 1, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02642848||5956|
NCT02628977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01028|Sleep Health Education and Social Support Among Blacks With OSA|Tailored Peer-Based Sleep Health Education and Social Support Among Blacks With Obstructive Sleep Apnea||New York University School of Medicine|No|Recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|398|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02628977||7021|
NCT02641782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1694|NB2013-HR German (GPOH) / Dutch (DCOG) Trial|Randomized Phase 2 Trial Comparing Experimental Immunotherapy in Recurrent High Risk Neuroblastoma Patients With Standard Immunotherapy in Patients With Recurrent and Newly Diagnosed High Risk Neuroblastoma|NB2013-HR|University of Cologne|Yes|Recruiting|November 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Months|25 Years|No|||December 2015|December 23, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02641782||6038|
NCT02641834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-123-VEG|Prevention of Cardiovascular Disease With Med or Veg Diets|Prevention of Cardiovascular Disease With the Vegetarian Diet: the CARDIVEG Study|CARDIVEG|Azienda Ospedaliero-Universitaria Careggi|No|Recruiting|May 2015|May 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641834||6034|
NCT02380976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW340-1002|Study of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers|||Daewon Pharmaceutical Co., Ltd.||Not yet recruiting|October 2015|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 1, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02380976||26062|
NCT02321228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50048.091.14|Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers|Early Salpingectomy (Tubectomy) With Delayed Oophorectomy to Improve Quality of Life as Alternative for Risk Reducing Salpingo-oophorectomy in BRCA1/2 Gene Mutation Carriers|TUBA|University Medical Center Nijmegen|Yes|Recruiting|January 2015|January 2035|Anticipated|January 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|510|||Female|25 Years|45 Years|No|||February 2016|February 1, 2016|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02321228||30640|
NCT02321514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-03|Early Feasibility Study of the Tendyne Mitral Valve System|Early Feasibility Study of the Tendyne Mitral Valve System||Tendyne Holdings, LLC|Yes|Recruiting|November 2014|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|December 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321514||30618|
NCT02302014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marie Curie FLAME trial|Palliative Care for Patients With Advanced Heart Disease|Randomised Trial of Early Versus Delayed Future Care Planning for Patients and Families Living With Advanced Heart Disease|FLAME|University of Edinburgh|No|Completed|August 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302014||32114|
NCT02300740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45141|Pharmacokinetic Analysis of Nicotinamide Riboside|||Aarhus University Hospital||Completed|December 2014|||February 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|February 26, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02300740||32212|
NCT02300753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-2010-004|Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]|Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]||Edison Pharmaceuticals Inc||No longer available||||||N/A|Expanded Access|N/A|||||||Both|8 Years|65 Years||||November 2014|November 24, 2014|November 21, 2014|Yes|Yes||||https://clinicaltrials.gov/show/NCT02300753||32211|
NCT02300766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-002|Cerebellar Mutism Syndrome Study|Nordic Study of the Cerebellar Mutism Syndrome in Children With Brain Tumours of the Posterior Fossa||Rigshospitalet, Denmark|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|A blood sample from each patient will be collected in order to make SNP analyses on the DNA      to explore the role of genomic variants on the development, severity and recovery from the      CMS.|Both|N/A|18 Years|No|Non-Probability Sample|All children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th        ventricle/brainstem ) requiring surgery or open biopsy at one of the participating        centres.|November 2015|November 1, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02300766|1 Year|32210|
NCT02319174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-082F-B|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women||William Marsh Rice University|No|Not yet recruiting|June 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant patients over the age 18 who are receiving antenatal care at the UT OB/GYN clinic        will be approached for recruitment. All pregnant women at risk of developing pre-eclampsia        or previously diagnosed with pre-eclampsia will be approached for enrollment.|May 2015|May 11, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02319174||30797|
NCT02324140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041/09_2|Inflammatory Response in Aortic Valve Replacement|The Impact of Genetic Variability on Perioperative Morbidity and Mortality. Substudy: Inflammatory Response in Patients Undergoing Aortic Valve Replacement.||University Hospital Inselspital, Berne|Yes|Completed|June 2012|May 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|101|Samples With DNA|whole blood analysis|Both|18 Years|90 Years|No|Probability Sample|Patients with severe aortic valve stenosis selected for surgical aortic valve replacement        or transcatheter aortic valve implantation.|July 2015|July 13, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02324140||30416|
NCT02306226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05|Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry|Symetis ACURATE Neo™ Valve Implantation Using TransFemoral Access: SAVI TF Registry|SAVI TF|Symetis SA|No|Recruiting|September 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|75 Years|N/A|No|Non-Probability Sample|As the ACURATE neo™ is approved for use to treat patients with severe aortic stenosis, the        inclusion criteria are broad in order to allow the device to be used in an all-comers        population and following the Instructions For Use.|August 2015|August 6, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02306226|12 Months|31790|
NCT02308956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-95699 (Ethiopia)|Task Sharing for the Care of Severe Mental Disorders in a Low-income Country|Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial|TaSCS|University of Cape Town|Yes|Recruiting|March 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|324|||Both|25 Years|N/A|No|||November 2015|November 12, 2015|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02308956||31582|
NCT02309008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1-PI-03|A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects|A Randomized, Double-blind, Placebo-controlled Multiple Dosing Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream After Transdermal Administration in Healthy Volunteers||Amorepacific Corporation|No|Not yet recruiting|November 2014|June 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|24|||Male|19 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309008||31578|
NCT02311478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75363|Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users|(TRIBE) Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users|TRIBE|University of Utah|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Female|18 Years|40 Years|No|||February 2016|February 18, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02311478||31388|
NCT02316171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA012|Safety and Clinical Activity of CAVATAK™ Alone or With Low Dose Mitomycin C in Non-muscle Invasive Bladder Cancer|A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer|CANON|Viralytics|No|Recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02316171||31028|
NCT02298595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-057|Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma|A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma||University of Pittsburgh|Yes|Not yet recruiting|September 2015|September 2023|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|62|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|November 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02298595||32377|
NCT02303951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EADO_VC_NEO_1|Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC|Neoadjuvant Treatment With the Combination of Vemurafenib and Cobimetinib (GDC-0973) in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed Phase II EADO (European Association of Dermato Oncology) Trial||University Hospital Tuebingen|No|Recruiting|January 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02303951||31965|
NCT02293382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGLU-NH01|A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB|A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB||Alexion Pharmaceuticals|No|Recruiting|July 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|30 deceased patients with MPS IIIB|November 2014|November 17, 2014|November 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02293382||32777|
NCT02293655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHDMedTEAMStudy|The Effects of ADHD Medication (TEAM) Study|The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation|TEAM|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|January 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|7 Years|11 Years|No|||January 2016|January 26, 2016|October 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293655||32756|
NCT02381210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4004-A|Diagnosis and Prediction of Pre-Eclampsia by Using Congo Red Dot Test in Bangladesh and Mexico|Diagnosis and Prediction of Preeclampsia: A Case Control Study of the Clinical Utility of Congo Red Dot Test in Bangladesh and Mexico||Gynuity Health Projects|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|urine samples collected|Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women attending Dhaka Medical College Hospital and Hospital Materno-Infantil Inguarán with        clinically confirmed cases of preeclampsia and clinically healthy women who deliver at        term will be eligible for the study.|November 2015|November 18, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02381210||26044|
NCT02381223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020|Simplified Medical Abortion Screening: A Pilot Demonstration Project|Simplified Medical Abortion Screening: A Pilot Demonstration Project||Gynuity Health Projects|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female: only female participants are being studied|March 2016|March 3, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02381223||26043|
NCT02636036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoAd1-1003|Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors|A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors|SPICE|PsiOxus Therapeutics Ltd|Yes|Recruiting|January 2016|June 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636036||6480|
NCT02636127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-37|Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis|Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis||Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636127||6473|
NCT02633046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNK14224049|Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS|Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar® Gel (PODOCYTE)|PODOCYTE|Mallinckrodt|No|Not yet recruiting|March 2016|March 2020|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|236|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633046||6709|
NCT02633280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD|Biomarkers for Diagnosis and Treatment of COPD|A Predictive "Molecular Biology Signature" for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease|BmiRCOPD|University of Cantanzaro|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|195|Samples Without DNA|blood|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|An open label, parallel groups study, will be performed after it is approve by the Ethical        committee and before the beginning of the study, all participants will be informed about        the aim, procedures, risks and benefits of the study and they will provide a written        informed consent|December 2015|December 14, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02633280||6691|
NCT02633852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOTADI- HMO-CTIL|Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema|A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema||Hadassah Medical Organization|No|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|December 14, 2015|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633852||6647|
NCT02381470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faropenem_TB|Early Bactericidal Activity Study of Faropenem(With Amoxicillin/Clavulanic Acid)in Patients With Pulmonary Tuberculosis|Trial of Faropenem (in Combination With Amoxicillin/Clavulanic Acid) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity, Whole Blood Bactericidal Activity and Effects on Novel Biomarkers||National University Hospital, Singapore|Yes|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|28|||Both|18 Years|70 Years|No|||March 2015|March 9, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381470||26024|
NCT02631265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIDE-1|Insulin-based Strategies to Prevent Hypoglycemia During Exercise|Reduction of Basal Insulin to Prevent Hypoglycemia During Exercise in Adults With Type 1 Diabetes Using Insulin Pump Therapy||Institut de Recherches Cliniques de Montreal|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|23|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02631265||6845|
NCT02636192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108054|Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents|Incidence of Diabetic Ketoacidosis Among Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors or Other Antihyperglycemic Agents- A Retrospective, Observational, New-User Cohort Study Using 4 Administrative Claims Databases in the US||Janssen Research & Development, LLC|No|Active, not recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400000|||Both|18 Years|N/A|No|Non-Probability Sample|Participants diagnosed with type 2 diabetes mellitus (T2DM) and initiated on        sodium-glucose co-transporter 2 inhibitors (SGLT2i) or other Antihyperglycemic Agents        (AHAs) were observed.|February 2016|February 16, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636192||6468|
NCT02640287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01516-43|Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia|Expression of Ku70/XRCC6 and Others NHEJ Components in Waldenström's Macroglobulinemia in Comparison With Others B-cell Lymphoproliferative Disorders and Normal B Cells.|WAL-KU|Central Hospital, Nancy, France|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640287||6153|
NCT02643056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10PANI01|Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer|Phase II Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cance|S10PANI01|Southern Europe New Drug Organization|No|Completed|January 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02643056||5940|
NCT02382328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265/14|Alpha Lipoic Acid on Clinical and Electrophysiological Recovery in Carpal Tunnel Syndrome Undergoing Surgical Release|Effectiveness of Alpha Lipoic Acid on Clinical and Electrophysiological Recovery in Patients With Carpal Tunnel Syndrome Surgical Release||Hospital Civil de Guadalajara|No|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02382328||25958|
NCT02628392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8500-A-J203|A Phase2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)|A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Active, not recruiting|November 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|335|||Both|20 Years|N/A|No|||March 2016|March 22, 2016|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628392||7066|
NCT02632123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10010803|Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis|Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis||Lawson Health Research Institute|No|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients newly diagnosed with idiopathic pulmonary fibrosis.|January 2016|January 17, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632123||6780|
NCT02642055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEURO+001|Efficacy of NEURO+ Attention Training For the Treatment of ADHD|Efficacy of NEURO+ Attention Training For the Treatment of ADHD: A Randomized, Controlled, Blinded, Clinical Trial||Neuro+|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|13 Years|No|||February 2016|February 22, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02642055||6017|
NCT02634736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R119047/195378|Cluster RCT of Falls Prevention Exergames for Older Adults|A Multi-centre, Cluster Randomised Controlled Trial Comparing Falls Prevention Exergames With Remote Monitoring Against Standard Falls Prevention Programmes for Community Dwelling Older Adults at Risk of Falls.|Profexs|University of Manchester|No|Not yet recruiting|February 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02634736||6579|
NCT02638792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPN 2015/1698-31/1|Internet-Based Exposure Therapy Vs. Stress-Management Training for Worry|Internet-Based Exposure Therapy Vs. Stress-Management Training for Worry: A Randomized Controlled Trial||Karolinska Institutet|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02638792||6268|
NCT02628457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-2015-02|Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?|Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?||CM Chungmu Hospital|Yes|Active, not recruiting|December 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|209|||Both|N/A|N/A|No|Non-Probability Sample|209 patients with degenerative rotator cuff tear who underwent single-row arthroscopic        rotator cuff repair between March 2012 and April 2015 in CM hospital|December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02628457||7061|
NCT02631967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211/15|Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease|A New Anastomotic Technique After Ileocecal Resection for Crohn's Disease. Kono-s Anastomosis vs Stapled Side-to-side Anastomosis: a Randomized Controlled Trial|SuPREMeCD|Federico II University|No|Recruiting|November 2015|November 2022|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02631967||6792|
NCT02642263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHIBerne|Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain|Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain, A Prospective Randomised Study||University Hospital Inselspital, Berne|No|Not yet recruiting|February 2016|January 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642263||6001|
NCT02391792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2012-1633|Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance|Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance||University Hospital, Strasbourg, France|No|Recruiting|March 2013|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|blood|Both|18 Years|85 Years|No|Non-Probability Sample|group patient: patients with septic shock group control: patients without septic shock|December 2015|December 17, 2015|September 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02391792|7 Days|25231|
NCT02643745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKIIQcor|Nephrologic Intervention in Patients Waiting for Cardiac Surgery|Nephrologic Intervention in Patients Waiting for Cardiac Surgery|AKIIcor|Hospital Universitari de Bellvitge|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1100|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02643745||5887|
NCT02640235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3584-001|Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding|A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General, and Vascular Surgery.|CELSTAT|Baxter Healthcare Corporation|Yes|Not yet recruiting|March 2016|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|258|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640235||6157|
NCT02640248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00902|Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Adenotonsillectomy|Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Adenotonsillectomy||Nationwide Children's Hospital|No|Enrolling by invitation|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Non-Probability Sample|Less than 18 years of age, undergoing otolaryngological surgery with endotracheal        intubation|December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640248||6156|
NCT02635269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metabolic Myopathy|Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy|Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy||Rigshospitalet, Denmark|No|Not yet recruiting|January 2016|December 2020|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|128|||Both|15 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02635269||6539|
NCT02632032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDiC-01|Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon|Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon||Yaounde Central Hospital|No|Completed|July 2013|August 2014|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|46|||Both|6 Years|23 Years|No|||December 2015|December 15, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02632032||6787|
NCT02636010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-PEMBRESID|Pembrolizumab (MK-3475) in MM Patients With Residual Disease|Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment||PETHEMA Foundation|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|January 16, 2016|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636010||6482|
NCT02644083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11364|Tecfidera and MRI for Brain Energy in MS|Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate||Oregon Health and Science University|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|18 Years|55 Years|No|Non-Probability Sample|21 patients with a diagnosis of relapsing-remitting multiple sclerosis|December 2015|December 29, 2015|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644083||5861|
NCT02630056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASYSU|Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer|Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy||Sixth Affiliated Hospital, Sun Yat-sen University|No|Not yet recruiting|December 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|||Both|N/A|N/A|No|Probability Sample|Both gender is OK and there is no limitation for age.|November 2015|December 14, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02630056||6938|
NCT02636634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071243|Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases|Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases. CV-METANEC|CV-METANEC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2010|February 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|75 Years|No|||November 2015|February 15, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02636634||6434|
NCT02636647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAJAJ0021|Fecal Transplant in Recurrent Hepatic Encephalopathy|Safety and Tolerability of Fecal MicrobiotaTransplantation in Cirrhosis and Hepatic Encephalopathy||Hunter Holmes Mcguire Veteran Affairs Medical Center|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|21 Years|75 Years|No|||December 2015|December 17, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636647||6433|
NCT02391220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC_BRIN|Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome|The Effect of a Symbiotic LCA Yoghurt on Health-related Quality of Life and the Symptoms of Irritable Bowel Syndrome in Adults: A Randomized, Double-blind, Placebo Controlled, Multicentre Clinical Trial||Clinres Farmacija d.o.o.|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||March 2015|July 27, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391220||25274|
NCT02636114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaharashtraUHS|Effect of Scaling and Root Planing on Serum Renal Function Markers in Chronic Periodontitis Subjects.|Effect of Scaling and Root Planing on Serum Renal Function Markers in Systematically Healthy Chronic Periodontitis Subjects - A Control Clinical Trial.||Maharashtra University of Health Sciences|Yes|Completed|January 2015|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|51|||Both|35 Years|60 Years|No|||December 2015|December 17, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02636114||6474|
NCT02644109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acticol - 001|Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols|Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols In Chilean Subjects With Hypercholesterolemia|ACTICOL|University of Chile|No|Recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644109||5859|
NCT02631655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/60|POSitron Emission Imaging Using 18F-FDOPA in Neurooncology|Study of the Impact of 18F-FDOPA Positon Emission Tomography on Therapeutic Proposals Made at Neurooncology Multidisciplinary Case Conferences|POSEIDON|Centre Antoine Lacassagne|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02631655||6815|
NCT02378233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12012002|Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant|A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function||Göteborg University|No|Recruiting|October 2011|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|40 Years|No|||March 2016|March 15, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02378233||26273|
NCT02636881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2200|Autologous Cartilage Implantation vs Arthroscopic Debridement|Focal Cartilage Defects in the Knee -A Randomized Controlled Trial Comparing Autologous Chondrocyte Implantation With Arthroscopic Debridement|ACI|University Hospital, Akershus|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|49 Years|No|||December 2015|December 21, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02636881||6415|
NCT02636894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Restylane Silk|Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)|Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)||Nashville Centre for Laser and Facial Surgery|No|Not yet recruiting|March 2016|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636894||6414|
NCT02630589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI for tinnitus|Implantation of an Auditory Brainstem Implant for the Treatment of Incapacitating Unilateral Tinnitus|Implantation of an Auditory Brainstem Implant for the Treatment of Incapacitating Unilateral Tinnitus||University Medical Center Groningen|No|Not yet recruiting|January 2016|January 2022|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02630589||6897|
NCT02635217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bidirectional endoscopy study|Same Day Bidirectional Endoscopies - Does the Sequence of Procedures or Choice of Insufflator Matter?|Same Day Bidirectional Endoscopies - Does the Sequence of Procedures or Choice of Insufflator Matter?||Queen's University|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02635217||6543|
NCT02391428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0019-14|The Correlation Between Blood omega3 and ADHD|The Correlation Between Blood omega3 and ADHD||Ziv Hospital|No|Not yet recruiting|April 2015|April 2016|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02391428||25258|
NCT02629718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-069|Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer|A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer|SYSGO-003|Sun Yat-sen University|Yes|Not yet recruiting|December 2015|December 2022|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Female|18 Years|65 Years|No|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629718||6964|
NCT02637700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIg-SFN|Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy|Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety.|IVIg-SFN|Academisch Ziekenhuis Maastricht|Yes|Not yet recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637700||6352|
NCT02628769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-204|A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease|A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease||Imperial College London|Yes|Recruiting|October 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|N/A|No|||November 2015|December 9, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628769||7037|
NCT02629055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/383|Respiratory EMG for NIV Titration in Stable COPD Patients|EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial||University Medical Center Groningen|Yes|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02629055||7015|
NCT02633488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16121|Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome|Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome|EJB044|University of Virginia|No|Recruiting|June 2014|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||December 2015|December 16, 2015|September 26, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02633488||6675|
NCT02628496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503127|Confocal Laser Microlaryngoscopy (CLMx)|Confocal Laser Microlaryngoscopy (CLMx): A Novel Tool for Noninvasive Evaluation of Laryngeal Lesions||Washington University School of Medicine|No|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628496||7058|
NCT02391272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-pregnancy-rhTPO-Multi|A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy|A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy||Shandong University|Yes|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|50 Years|No|||March 2015|March 12, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02391272||25270|
NCT02639910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR208C205|Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi|A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined With Idelalisib in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor||MorphoSys AG|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639910||6182|
NCT02628431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.173|The Application of the ELFI-TECH Monitor for Perioperative Hemodynamic Measurements|The Application of the ELFI-TECH Monitor for Measurement of Blood Pressure, Cardiac Output and Extend of Regional and Neuraxial Anesthesia: The Elfitor Study||Leiden University Medical Center|Yes|Recruiting|October 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|ASA 1-3 patients presenting for elective surgery under general or neuraxial anesthesia|December 2015|December 8, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02628431||7063|
NCT02628444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD65|Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age|Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines||Sanofi|Yes|Not yet recruiting|April 2016|July 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1050|||Both|9 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628444||7062|
NCT02639988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI15005|Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years|Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus|INSPIRED|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|January 2025|Anticipated|January 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients recruited in five rheumatology departments|December 2015|December 21, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02639988||6176|
NCT02641028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin501-201|A Study in a Human Laboratory Model of Smoking Behavior|A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior||Cerecor Inc|No|Not yet recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|21 Years|60 Years|No|||December 2015|December 28, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641028||6096|
NCT02392611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-350-1599|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Subjects With Advanced Solid Tumors and Lymphomas||Gilead Sciences|No|Recruiting|March 2015|February 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392611||25168|
NCT02392650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34056|Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study|Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study (BaBs)|BaBs|Baylor College of Medicine|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|526|Samples With DNA|Samples with DNA, RNA and metabolites|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who are currently pregnant who are at high risk for preterm birth; Pregnant with one        baby (not twins or triplets) and who attend regular prenatal visits. They will spend an        extra 20 minutes at 5-6 priority scheduled visits to obtain study samples and complete        questionnaires, with the last visit occurring around 6 weeks after delivery.|November 2015|November 13, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392650|10 Years|25165|
NCT02637635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTLIP1|Does Autologous Fat Transplantation Improve Results and Reduce Complications in Breast Reconstruction With Implants?|Does Pre-treatment With Autologous Fat Transplantation Improve Results and Reduce Complication Rate After Breast Reconstruction With Implants? A Randomized Controled Study||Karolinska Institutet|No|Recruiting|October 2012|January 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Female|25 Years|70 Years|No|||December 2014|December 21, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02637635||6357|
NCT02642237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-Fluenz|The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response|The Effects of an Endotoxin Challenge on the Immune Response Elicited by a Subsequent Challenge With Fluenz in Healthy Volunteers, an Explorative Study|LPS-Fluenz|Radboud University|No|Not yet recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02642237||6003|
NCT02633592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0058|Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry|Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry: a Randomized Comparison of Measurements in the Seated and Left Lateral Positions|SEAT|University of Zurich|Yes|Completed|November 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02633592||6667|
NCT02380755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385.615|Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism|Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects.||University of Sao Paulo|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Male|18 Years|50 Years|No|||March 2015|March 1, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380755||26079|
NCT02630264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E10AIII|E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck|A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region||Guangzhou Double Bioproducts Co., Ltd|No|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|December 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02630264||6922|
NCT02633800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31287-A-U203|A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck|RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK||Daiichi Sankyo Inc.|No|Recruiting|December 2015|December 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633800||6651|
NCT02633813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-13-661|BE Study of Naftifine HCL|A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints||Semler Research Center Pvt. Ltd.|No|Completed|March 2015|December 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|693|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633813||6650|
NCT02634099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00916-43|A Comparison of Three Methods of Hemoglobin Monitoring in Pediatric Patients Undergoing Major Surgery|Monitorage de l'hémoglobine au Cours de la Chirurgie à Risque hémorragique élevé en pédiatrie: étude d'équivalence de la Saturation transcutanée en hémoglobine et de l'hémocue Avec l'hémoglobine Totale sérique|Hemoped|Central Hospital, Nancy, France|No|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|1 Month|17 Years|No|||March 2016|March 21, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634099||6628|
NCT02641223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7877631|Evaluation of Objective Outcomes With the Use of an Activity Tracker During the Trial Period of Spinal Cord Stimulation|||University of California, Davis|No|Recruiting|November 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to the UCD chronic pain clinic with post-laminectomy syndrome and        demonstrate signs of neuropathic axial back pain will be considered. These patients should        also be qualified for SCS placement.|December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02641223||6081|
NCT02385188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51648.091.14|Topical 5% Imiquimod Cream for Vulvar Paget's Disease|Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response||University Medical Center Nijmegen|No|Recruiting|January 2015|January 2021|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385188||25738|
NCT02385201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA2014 US|Clinical Trial of the Senza™ SCS System in the Treatment of Chronic Upper Limb and Neck Pain|Multi-Center, Prospective, Clinical Trial of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Upper Limb and Neck Pain|SENZA-ULN|Nevro Corp|No|Recruiting|June 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385201||25737|
NCT02325258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO.HGUGM.2012-001|Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign|Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign||Hospital General Universitario Gregorio Marañon|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|300|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02325258||30330|
NCT02306174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140644|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding||University of Miami|No|Active, not recruiting|September 2014|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|85 Years|No|||October 2015|October 30, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02306174||31794|
NCT02308033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-001 (Trial 2)|Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|SMART GIVES|Curatek Pharmaceuticals, LLC|No|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Female|12 Years|N/A|No|||November 2015|November 17, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308033||31652|
NCT02308046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-001 (Trial 1)|Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|SMART GIVES|Curatek Pharmaceuticals, LLC|No|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|12 Years|N/A|No|||November 2015|November 17, 2015|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02308046||31651|
NCT02321826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M&I2015|Music for Insomnia|Better Night - Better Day: a Randomized Controlled Trial of Listening to Music for Improving Insomnia||University of Aarhus|Yes|Recruiting|February 2015|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||||||Both|18 Years|60 Years||||December 2014|February 6, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02321826||30594|
NCT02321891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OptES-Anx-pilot|A Pilot Study to Determine a Candidate Protocol for Transcranial Electrical Stimulation in the Treatment of Anxiety|Optimizing Transcranial Electrical Stimulation for Clinical Applications (the OptES Study): A Pilot Study to Determine a Candidate Protocol for Treatment of Anxiety (OptES-Anx)||University of Eastern Finland|No|Recruiting|December 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|65 Years|No|||December 2014|December 16, 2014|December 9, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02321891||30589|
NCT02314780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO-1 in the Heart|Pilot Trial: The Effects of Intravenous Heme Arginate on HO-1 Expression and Oxidative Stress in the Human Heart|||Medical University of Vienna|No|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|40 Years|85 Years|No|||March 2016|March 15, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314780||31135|
NCT02294162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104-14|Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?|Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?||Western Galilee Hospital-Nahariya|No|Recruiting|April 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02294162||32717|
NCT02297295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMA001|Impact of Exercise Medicine on Lower Limb Amputees According to the International Classification of Functioning|Impact of Exercise Medicine on Lower Limb Amputees According to the Three Domains of the International Classification of Functioning||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|June 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 16, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02297295||32477|
NCT02297568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJVITD001|Vitamin D Supplementation During Lactation|Randomized Control Trial of Vitamin D Supplementation During Lactation on Vitamin D in Maternal Milk||Rajavithi Hospital|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 19, 2015|November 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297568||32456|
NCT02319824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2721.00|NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy|A Pilot Trial of NY-ESO-1-Specific T Cells in Patients With Metastatic NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2015|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 5, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319824||30748|
NCT02297178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedwayUD|A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding|A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding||Medway NHS Foundation Trust|No|Not yet recruiting|August 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|Entry to the study will be offered to all women previously recruited into the original        randomised controlled trial. This study is a 3 year follow up of a randomised controlled        trial. Patients will be sent a letter offering a review appointment.|March 2016|March 20, 2016|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02297178||32486|
NCT02297191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLIP Block|Ultrasound Guided Local Anesthetic Block: Thoracolumbar Interfascial Plane|Ultrasound Guided Local Anesthetic Field Block Within the Thoracolumbar Interfascial Plane: Distribution of Pain and Temperature Sensation Loss in Healthy Volunteers|TLIP|Medical University of South Carolina|Yes|Completed|July 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 20, 2014|July 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02297191||32485|
NCT02304159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444284|Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics|A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3||Southern California Research Center|No|Recruiting|January 2015|November 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2015|November 21, 2015|November 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02304159||31949|
NCT02298114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130433|Mobilization With Neuromuscular Electrical Stimulation in Critical Care Patients|The Effects of Early Mobilization With Neuromuscular Electrical Stimulation in Critical Care Patients||Hospital de Clinicas de Porto Alegre|No|Recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02298114||32414|
NCT02639702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|096/2015|Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia|Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial||Centre for Addiction and Mental Health|No|Not yet recruiting|April 2016|June 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02639702||6198|
NCT02639715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55685|Morphometrics and Morphokinetics of Thawed Oocytes and Embryos|Morphometrics and Morphokinetics of Thawed Oocytes and Embryos||Katholieke Universiteit Leuven|No|Completed|January 2014|December 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1272|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with frozen thawed embryos for an ART treatment cycle|December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639715||6197|
NCT02385448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 14-097|Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery|A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery||The University of Hong Kong|No|Recruiting|February 2015|February 2019|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|144|||Female|18 Years|51 Years|No|||March 2015|April 28, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385448||25718|
NCT02385461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOST 01/2011|Study on Antithrombotic Prevention in Thrombophilia and Pregnancy Loss|A Proposal of a Prospective Study on Prevention of Pregnancy Loss in Women Carrying Inherited Thrombophilia|OTTILIA|Casa Sollievo della Sofferenza IRCCS|Yes|Recruiting|January 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|108|||Female|18 Years|45 Years|No|Probability Sample|Consecutive pregnant women with previous pregnancy loss|January 2016|January 27, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385461|10 Months|25717|
NCT02638259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP15-301|Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis|EQUIRA|Sandoz|Yes|Recruiting|November 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638259||6309|
NCT02637193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2411360|A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects|A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor Xr On Cardiac Repolarization In Healthy Adult Subjects||Pfizer|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02637193||6391|
NCT02637206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200920|Skin Irritation Study of GSK2894512 Cream|Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo Following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application Under Non-occlusive Condition in Healthy Japanese Subjects||GlaxoSmithKline|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637206||6390|
NCT02639962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Challenge|Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study|Characteristics of Culprit Lesion and Changes in Plaque Composition During Follow up in NSTEMI. A Dual Energy Cardiac CT Study|S-20130009|Odense University Hospital|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|135|Samples Without DNA|Blood samples for analyses as hs-CRP, Interleukins and other inflammatory agents.|Both|18 Years|90 Years|No|Probability Sample|Patients with verified NSTEMI and Patients with SAP|December 2015|December 21, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02639962||6178|
NCT02639975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUNFI-1509|"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers|Randomized, Double Blind, Placebo Controlled "First-in-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 ( 100 mg, 200 mg, 400 mg and 600 mg ) in Healthy Young Male Volunteers||Palobiofarma SL|No|Active, not recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639975||6177|
NCT02640651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001728|An Study of Transcranial Direct Current Stimulation in Adults With ADHD|An Open Label Pilot Study of Transcranial Direct Current Stimulation in Adults With ADHD||Massachusetts General Hospital|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02640651||6125|
NCT02385708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150309|Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections|A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post-Operative Surgical Site Infections in Colorectal Patients||Vanderbilt University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385708||25698|
NCT02385721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FMS-PASS-401|A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)|A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension||Boryung Pharmaceutical Co., Ltd|No|Recruiting|May 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|20 Years|N/A|No|Probability Sample|Hypertension Patients|March 2014|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02385721|12 Months|25697|
NCT02635841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIRCON2012V1-COMP|Compassionate Use of Deferiprone in Patients With PKAN|The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration||ApoPharma||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|7 Years|N/A||||November 2015|December 18, 2015|December 17, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02635841||6495|
NCT02643251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-291|The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy|A Multicenter, Randomized, Double Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1%, to Clonidine Hydrochloride Gel Comparator in the Management of Painful Diabetic Neuropathy||BioDelivery Sciences International|No|Recruiting|December 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643251||5925|
NCT02643264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIU2015/130-31|Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction|Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction||Linkoeping University|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02643264||5924|
NCT02643069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131208|Clinical Intervention in Frail Older People (FRAILCLINIC)|Feasibility and Effectiveness of Frailty Screening and Management Programs Implemented in Different Clinical Settings (FRAILCLINIC)|FRAILCLINIC|Hospital Universitario Getafe|Yes|Recruiting|February 2014|December 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1300|||Both|75 Years|N/A|No|||December 2015|December 29, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02643069||5939|
NCT02391610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008020|The China-Anhui Birth Cohort Study (C-ABCS)|A Prospective Population-based Cohort Study That Recruited 16766 Pregnant Women From Six Major Cities of Anhui Province in China||Anhui Medical University|Yes|Completed|November 2008|January 2015|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16766|||Female|17 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|The China-Anhui Birth Cohort Study (C-ABCS) is a prospective population-based cohort study        that recruited 16766 pregnant women from six major cities of Anhui province in China        between November 2008 and October 2010. Six cities were selected for study sites,        including Hefei, Ma'anshan, Wuhu, Jieshou, Lu'an and Ningguo. Anhui province is located in        the south-east of China. Its socio-economic development is ranked at the mid-level in        China. Six cities were selected according to their social and geographic characteristics.        These cities are located in Central, Southern and Northern regions of Anhui Province and        may represent socio-economic, geographic and cultural variations. In addition, strong        local support was one of the important factors to consider in selecting these cities.|March 2015|March 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391610||25245|
NCT02632747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.100|Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)|A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration in Patients With Type 1 Diabetes on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study||Boehringer Ingelheim||Not yet recruiting|April 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 15, 2015||||No||https://clinicaltrials.gov/show/NCT02632747||6732|
NCT02632760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068|Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery|Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery|ITACS|Bayside Health|Yes|Not yet recruiting|April 2016|October 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02632760||6731|
NCT02636608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-709|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS|VERITAS|AbbVie|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|255|||Both|18 Years|99 Years|No|Non-Probability Sample|Chronic Hepatitis C (CHC)|March 2016|March 22, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02636608||6436|
NCT02637869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF grant #71125|Evaluating Community Health Centers' Adoption of a New Global Capitation Payment|Evaluating Community Health Centers' Adoption of a New Global Capitation Payment|eCHANGE|Oregon Health and Science University|No|Active, not recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|8|||Both|2 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Health Center (CHC) and clinic patients of which CHCs are participating in the        APM demonstration (intervention) or are matched with APM CHCs (control)|December 2015|December 17, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02637869||6339|
NCT02628665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstHenanUST,cancer center|Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer|Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer||The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2015|December 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||October 2015|December 10, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02628665||7045|
NCT02628899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Risk TAVR|Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis|||Medstar Research Institute|Yes|Recruiting|January 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|N/A|No|||March 2016|March 21, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628899||7027|
NCT02632383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Young With Diabetes Type 1 - Test of an mHealth App|Young With Diabetes Type 1 - Test of an mHealth App||Nordsjaellands Hospital|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|14 Years|22 Years|No|||December 2015|December 16, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02632383||6760|
NCT02632396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076016|Ixazomib Citrate After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission|A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients With Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission||Emory University|Yes|Recruiting|March 2016|March 2022|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632396||6759|
NCT02635256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKS-121-003|Hypofractionated Radiosurgery for Localised Prostate Cancer|Hypofractionated Radiosurgery for Localised Prostate Cancer|HYPOSTAT|University of Schleswig-Holstein|No|Recruiting|December 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Male|70 Years|N/A|No|||March 2016|March 18, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02635256||6540|
NCT02393235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGZ1-UN-DOP|A Comparative Analysis of Arterial Blood Flow in Unexplained Infertility, Tubal Infertility and Fertile Groups|A Comparative Analysis of Ovarian, Uterine and Spiral Arterial Blood Flow in Unexplained Infertility, Tubal Infertility and Fertile Groups||Suleymaniye Birth And Women's Health Education And Research Hospital|No|Completed|March 2015|June 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|217|||Female|22 Years|37 Years|Accepts Healthy Volunteers|Probability Sample|Women received infertility treatment|July 2015|July 2, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393235||25120|
NCT02630290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZZD-2015008|Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)|Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study|ADRIB|Guangzhou First Municipal People’s Hospital|Yes|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||December 2015|December 23, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02630290||6920|
NCT02631343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0725-03|Community Kangaroo Mother Care for Improving Child Survival and Brain Development in Low Birth Weight Newborns|A Community-based Model of Delivery of Kangaroo Mother Care for Improving Child Survival and Brain Development in Low Birth Weight Newborns|CKMC-DEV|Society for Applied Studies|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|550|||Both|N/A|3 Days|Accepts Healthy Volunteers|||December 2015|February 16, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02631343||6839|
NCT02635347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro20150002276|Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study|Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study||Rutgers, The State University of New Jersey|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02635347||6533|
NCT02638597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072014-088|Gemfibrozil for Nicotine Smoking Cessation|Gemfibrozil for Nicotine Smoking Cessation|GEMNIC|University of Texas Southwestern Medical Center|No|Recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|64 Years|No|||December 2015|December 18, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638597||6283|
NCT02634619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K12DK083021-DvV|A Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|A Randomized Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|DvV|University of California, San Francisco|No|Active, not recruiting|November 2015|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Male|18 Years|N/A|No|||December 2015|December 15, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634619||6588|
NCT02641652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATRAX|A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension|A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension (ATRAX Trial)|ATRAX|University Hospital Olomouc|No|Not yet recruiting|April 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641652||6048|
NCT02377986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7073|Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder|Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder||New York State Psychiatric Institute|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||August 2015|February 9, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377986||26292|
NCT02638753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICID032016|Efficacy of Education on Neurophysiology of Pain Combined to Hypnosis in Patients With Chronic Low Back Pain|Efficacy of Education on Neurophysiology of Pain Combined to Hypnosis in Patients With Chronic Low Back Pain||Universidade Cidade de Sao Paulo|No|Not yet recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02638753||6271|
NCT02638766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGISTRI (GEIS 40)|Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST|Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST|REGISTRI|Grupo Espanol de Investigacion en Sarcomas|No|Recruiting|November 2015|November 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02638766||6270|
NCT02630303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-12-00756|High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin|Phase I Study of High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin||VA Northern California Health Care System|Yes|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|65|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630303||6919|
NCT02630316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-201|Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease||United Therapeutics|Yes|Recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|79 Years|No|||March 2016|March 14, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630316||6918|
NCT02636829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/ET-01|Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Rheumatoid Arthritis|Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Rheumatoid Arthritis (RA)|QALCIMUM|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|69 Years|No|||March 2016|March 21, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636829||6419|
NCT02639377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRN-2|Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis|Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis: a Randomised Controlled Clinical Trial||Universidade Federal do Rio Grande do Norte|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|90 Years|No|||December 2015|December 21, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639377||6223|
NCT02635048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(67)2015|Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones|Efficacy and Safety of Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones: A Multi-center Randomized Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1950|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635048||6555|
NCT02635061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-203|Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer|A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer||Acetylon Pharmaceuticals Incorporated||Not yet recruiting|January 2016|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635061||6554|
NCT02631902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTras|Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes|Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes: Effects on Health and Well-being||University of Trás-os-Montes and Alto Douro|No|Active, not recruiting|October 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|50 Years|80 Years|No|||December 2015|December 13, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02631902||6796|
NCT02378545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/P/020|Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis|(Feasibility) Open Label Randomised Controlled Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis|HO2T or NO2T|Plymouth Hospitals NHS Trust|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02378545||26249|
NCT02378844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-11|A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of the gammaCore|A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of the gammaCore®, a Non-invasive Neurostimulator Device, for the Prevention of Episodic Migraine||ElectroCore LLC|No|Recruiting|June 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|75 Years|No|||September 2015|February 4, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02378844||26226|
NCT02633241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00019084|A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging|A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging||Children's Hospital Boston|No|Not yet recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Female|1 Year|12 Years|No|||December 2015|December 14, 2015|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633241||6694|
NCT02629796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN_2013-9|Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study|BIOMARK|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with chronic inflammatory demyelinating polyradiculoneuropathy. Transcriptome,        metabolome and proteome analysis compared with those of healthy subjects|December 2015|December 29, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629796||6958|
NCT02629809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0281|First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)|First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-del(17p)||M.D. Anderson Cancer Center|No|Recruiting|March 2016|||March 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629809||6957|
NCT02633371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0847|A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults|A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults||University of Colorado, Denver|No|Not yet recruiting|February 2016|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|12 Years|25 Years|No|||December 2015|December 15, 2015|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633371||6684|
NCT02633384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLC.CI70.2014|Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions|Incidence and Severity of Parenteral Nutrition Associated Cholestasis in Neonates Subjected to Major Surgery, Using Two Mixed Intravenous Lipid Emulsions||Centro Hospitalar de Lisboa Central|Yes|Active, not recruiting|August 2011|May 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|48 Hours|No|||February 2016|February 23, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02633384||6683|
NCT02392416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-ATR-EL-56|Atorvastatin Study in Cardiovascular Disease Risk|Non-interventional, Multicenter Clinical Study to Assess the Treatment With Atorvastatin in Patient Compliance With Hyperlipidemia and Other Cardiovascular Risk Factors|ANTLER|Elpen Pharmaceutical Co. Inc.|No|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with dyslipidemia|September 2015|October 5, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392416||25183|
NCT02392429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00328|FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia|Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging||National Cancer Institute (NCI)|Yes|Recruiting|December 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|57|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392429||25182|
NCT02637128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Malawi TES 2014|In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria|In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014||Centers for Disease Control and Prevention|No|Completed|March 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|452|||Both|6 Months|59 Months|No|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637128||6396|
NCT02642107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010-2015-05|Individualized Elective Neck Irradiation Based on MRI in NPC Patients|The Prospective Randomized Study of Individualized Elective Neck Irradiation Based on MRI in Patients With Nasopharyngeal Carcinoma|NPC-CTVn|Sun Yat-sen University|Yes|Recruiting|January 2016|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02642107||6013|
NCT02633111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-180|DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas|DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas||Memorial Sloan Kettering Cancer Center||Recruiting|October 2015|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|425|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633111||6704|
NCT02392559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120123|Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders|Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH|HAUSER-RCT|Amgen|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|10 Years|17 Years|No|||February 2016|February 11, 2016|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392559||25172|
NCT02392598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV2015|A Hepatitis B With Hepatic Steatosis Study|Effect of Hepatic Steatosis on Prognosis and Outcomes of Patients With Chronic Hepatitis B|HBHS|Fatty Liver and Alcoholic Liver Disease Study Group, China|No|Not yet recruiting|August 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Liver tissue|Both|N/A|N/A|No|Non-Probability Sample|Any patients with chronic hepatisis B meeting eligibility criteria|August 2015|August 3, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392598||25169|
NCT02629991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-10-427-01|Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome|Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome|OXT-PWS|Montefiore Medical Center|Yes|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|5 Years|18 Years|No|||December 2015|December 10, 2015|October 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629991||6943|
NCT02633059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1582|Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|Phase 1 / 2 Trial of Idasanutlin (RO5503781) in Combination With Ixazomib (MLN9708) and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma||Mayo Clinic|Yes|Recruiting|December 2015|||May 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633059||6708|
NCT02629562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B12019-101|Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects|Single-dose, Randomised, Double-blind, Two-stage, Two-way Crossover Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta® in Healthy Subjects||Cinfa Biotech|No|Recruiting|November 2015|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629562||6976|
NCT02629575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1408|Coroflex ISAR 2000 Extended Registry|Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study|ISAR2000|B. Braun Melsungen AG|No|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Unselected patients with coronary de-novo and/or restenotic lesions|February 2016|February 26, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629575|9 Months|6975|
NCT02380482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Echo-TC|Myocardial Dysfunction at Early Phase of Traumatic Brain Injury : Evaluation by Two Dimensional and Speckle Tracking Transthoracic Echocardiography|Myocardial Dysfunction at Early Phase of Traumatic Brain Injury : Evaluation by Two Dimensional and Speckle Tracking Transthoracic Echocardiography|Echo-TC|University Hospital, Grenoble|No|Completed|December 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380482||26100|
NCT02643446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201526|Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine|Serological Survey on Monitoring the Population Immunity and Positive Rate After Vaccination of Inactivated Poliovirus Vaccine|IPV|Centers for Disease Control and Prevention, China|No|Recruiting|August 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|740|Samples With DNA|Serum, Whole blood|Both|2 Months|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|The participants will be seclected from the vaccination clinics. The study will be in five        provinces, which conduct the pilot project of IPV phased introduction into national        immunization program. In each province, 1-2 counties will be selected, and then selected        several vaccination clinics.|December 2015|December 29, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02643446||5910|
NCT02630615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0567|Circulating Tumor Cells (CTC) in Lung Cancer|Circulating Tumor Cells (CTC) in Lung Cancer||Indiana University|No|Not yet recruiting|January 2016|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll 3 cohorts for this study. Cohort A & Cohort B are for patient subjects.        Patients can participate in both cohorts simultaneously, or only one cohort per patient        preference. We anticipate that most patients who participate in Cohort B will also        participate in Cohort A because Cohort A only requires a one-time blood draw at baseline.        Cohort C is for healthy volunteers. The purpose of recruiting health volunteers is purely        for testing of the CTC chip system as we routinely spike (inject) tumor cell lines in        healthy human blood to ensure optimal CTC yield (quality control).|December 2015|December 11, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630615||6895|
NCT02641730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108046|An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis||Janssen Pharmaceutical K.K.|Yes|Recruiting|December 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|225|||Both|20 Years|N/A|No|||March 2016|March 22, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641730||6042|
NCT02634281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0239-15-SZMC|Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?|Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?||Shaare Zedek Medical Center|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634281||6614|
NCT02639039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110495|Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study|Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study||Scott and White Hospital & Clinic|No|Completed|February 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02639039||6249|
NCT02639052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23230|Itch Relieving Effect of Botox: a Study in Healthy Subjects|Itch Relieving Effect of Botox: a Study in Healthy Subjects||Temple University|No|Not yet recruiting|January 2016|January 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639052||6248|
NCT02630407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rizzoli HA-ACL|Early Viscosupplementation After ACL Reconstruction: a Randomized Controlled Trial|Early Post-op. Viscosupplementation After Primary Anterior Cruciate Ligament (ACL) Reconstruction: a Randomized, Placebo Controlled Trial|HA-ACL|Istituto Ortopedico Rizzoli|Yes|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|No|||November 2015|February 8, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02630407||6911|
NCT02393053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PositivoU|Non-Pedicled Buccal Fat Pad Graft in the Treatment of Gingival Recessions|Innovation Technique With Non-pedicled Buccal Fat Pad Graft in the Treatment of Gingival Recessions: a Randomized Controlled Clinical Trial||Universidade Positivo|No|Completed|November 2010|December 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02393053||25134|
NCT02314299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIOC-101|A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration|A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia™) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.|SPIOC-101|Stealth BioTherapeutics Inc.|No|Completed|November 2014|June 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||October 2015|October 2, 2015|December 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02314299||31172|
NCT02314533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENOD003|Evaluate the Efficacy of Fenofibrate on Microalbuminuria|A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy||Beijing Chao Yang Hospital|Yes|Not yet recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|20 Years|65 Years|No|||December 2014|December 9, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02314533||31154|
NCT02293837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN058AI|Tocilizumab (TCZ) in New-onset Type 1 Diabetes|Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)|EXTEND|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|January 2015|July 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|45 Years|No|||March 2016|March 7, 2016|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293837||32742|
NCT02293850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-OT-21|Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma|A Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma||Oncolys BioPharma Inc|Yes|Recruiting|October 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02293850||32741|
NCT02308917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039604|Canadian Children Inflammatory Bowel Disease Network (CIDsCANN)|Canadian Children Inflammatory Bowel Disease Network (CIDsCANN): A Joint Partnership of CIHR and C.H.I.L.D. Foundation: Multi-center Inception Cohort Study|CIDsCaNN|The Hospital for Sick Children|No|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood samples Urine Samples Biopsy Samples Colonoscopy Washing Samples Stool Samples|Both|24 Months|198 Months|No|Non-Probability Sample|The network will enroll all children and adolescents newly diagnosed with IBD - Crohn's,        Ulcerative Colitis or inflammatory bowel disease undefined (Paris A1a or A1b definitions        of age at diagnosis) at participating sites.|December 2015|December 2, 2015|October 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02308917|18 Months|31584|
NCT02315963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFSP Feedback Study|Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation|Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation||Cereneo AG|No|Not yet recruiting|January 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|62|||Both|N/A|N/A|No|||December 2014|December 10, 2014|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02315963||31044|
NCT02319252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tubes in liver diseases|Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases|Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases||University of Aarhus|No|Recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2014|January 13, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02319252||30791|
NCT02319980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAHMD 2014|The Adult Hemorrhagic Moyamoya Surgery Study|The Adult Hemorrhagic Moyamoya Surgery Study|AHMSS|Huashan Hospital|Yes|Active, not recruiting|May 2015|May 2023|Anticipated|May 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|60 Years|No|||February 2016|February 13, 2016|November 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02319980||30736|
NCT02298023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC_TR|Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)|Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.||Seoul National University Hospital|No|Recruiting|November 2014|April 2017|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|19 Years|90 Years|No|||November 2014|November 19, 2014|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02298023||32421|
NCT02302105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP-RT|Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer|Prospective Phase III Randomized Trial of Prostate Only or Whole Pelvic RadioTherapy in High Risk Prostate Cancer (POP-RT) Trial|POP-RT|Tata Memorial Centre|Yes|Recruiting|November 2011|||January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Male|N/A|N/A|No|||November 2014|November 24, 2014|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302105||32107|
NCT02325414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00098239|Prevention of Bone Loss After Acute SCI by Zoledronic Acid|Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy||Northwestern University|Yes|Recruiting|February 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02325414||30318|
NCT02306525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-239-14|Arthroscopic Treatment of Patients in Horsens and Aarhus With FemoroAcetabular Impingement: the HAFAI-cohort|Outcome After Arthroscopic Treatment of Patients in Horsens and Aarhus With FemoroAcetabular Impingement: the HAFAI-cohort||University of Aarhus|Yes|Recruiting|December 2014|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Femoro Acetabular Impingement and Healthy volunteers|November 2014|June 3, 2015|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02306525||31768|
NCT02318628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISVH3A2013|Advanced Approach to Arterial Stiffness|Advanced Approach to Arterial Stiffness (AAA Study - Triple A Study)|AAA|International Society for Vascular Health|No|Recruiting|December 2014|June 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|40 Years|85 Years|No|Non-Probability Sample|All patients aged 40-85 with life expectancy over 2 years will be included. Patients will        be stratified according to their age (3 groups: 40-54, 55-69, 70-85 years)) and the        presence or not of MetS.|December 2014|December 16, 2014|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02318628||30839|
NCT02640573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37290 IM-SCYTHE|Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)|Treatment of Adult Patients With Hemoglobin SC Disease||Baylor College of Medicine|Yes|Recruiting|December 2015|||December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|69 Years|No|||December 2015|December 23, 2015|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640573||6131|
NCT02391779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSL132|Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension|Flaxseed Lignan Enriched Complex for Blood Pressure Reduction in Elderly Participants With High Normal Blood Pressure or Stage I Hypertension||University of Saskatchewan|No|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02391779||25232|
NCT02643134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(53)2015|External Physical Vibration Lithecbole Versus Traditional Row of Stone After Extracorporeal Shockwave Lithotripsy(ESWL)|External Physical Vibration Lithecbole Contrast With the Traditional Row of Stone Effect After ESWL: A Multi-center Prospective Randomized Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||August 2015|December 28, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02643134||5934|
NCT02644447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-POF/IGDB|Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF|The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) With Injectable Collagen Scaffold Transplantation in Woman With Premature Ovarian Failure (POF)||Chinese Academy of Sciences|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|20 Years|39 Years|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644447||5833|
NCT02640664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002H2301E1|Rainbow Extension Study|RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|RainbowExt|Novartis|Yes|Not yet recruiting|June 2016|September 2022|Anticipated|September 2022|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|N/A|N/A|No|||December 2015|December 23, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640664||6124|
NCT02391857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGD2015|Early Gastric Decompression During Advanced Cardiopulmonary Resuscitation (EGD_ACLS)|The Clinical Study for the Identifying the Effect of Early Gastric Decompression on Improvement of Circulation During Advanced Cardiopulmonary Resuscitation|EGD_ACLS|Konkuk University Medical Center|Yes|Recruiting|March 2015|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|75 Years|No|||March 2015|March 12, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02391857||25226|
NCT02638519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-307-08312015|HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease|Hyperpolarized Xenon-129 Functional Magnetic Resonance Imaging of Healthy Volunteers and Participants With Alzheimer's Disease||Thunder Bay Regional Research Institute|No|Not yet recruiting|February 2016|||February 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02638519||6289|
NCT02643667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155514|A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer|A Phase 1/2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer||University of California, San Francisco|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|N/A|No|||December 2015|December 30, 2015|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643667||5893|
NCT02641522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMU-002|Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes|Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes||Benaroya Research Institute|No|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|45 Years|No|||December 2015|December 28, 2015|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641522||6058|
NCT02631876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0403|PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer|FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer||ImmunoGen, Inc.|Yes|Recruiting|December 2015|September 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|247|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631876||6798|
NCT02393196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SifaU|Colloid Preload Versus Colloid Coload During Cesarean Deliveries|Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study||Sifa University|Yes|Recruiting|March 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393196||25123|
NCT02393209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1117-1501|Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer||Millennium Pharmaceuticals, Inc.|No|Recruiting|June 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|155|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393209||25122|
NCT02636920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/2014-|Study and Development of Application Models of "Therapeutic Education to the Patient" (TEP) in Asthmatic Children|Study and Development of Application Models of "Therapeutic Education to the Patient" (TEP) in Asthmatic Children|TEP|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Not yet recruiting|May 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|6 Years|11 Years|No|||December 2015|December 18, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02636920||6412|
NCT02642250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Entb-1117|Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea|Chemical, Biological and Comparative Clinical Evaluation of Entoban to Determine Safety and Efficacy for the Treatment of Chronic Diarrhea|HA|Shifa Ul Mulk Memorial Hospital|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02642250||6002|
NCT02642159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14354|Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)|A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy||Sanofi|No|Recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642159||6009|
NCT02642211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICS_Phaco_1|IOP Changes Associated With SICS and Phako|An Evaluation of Intraocular Pressure Reduction Following Phacoemulsification and Manual Small Incision Cataract Surgery: A Randomized Controlled Trial||Robin, Alan L., M.D.|No|Completed|January 2014|September 2015|Actual|September 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|500|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02642211||6005|
NCT02640092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|g0097|Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers|Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers||Molecular NeuroImaging|No|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640092||6168|
NCT02632994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16161|Protocol for Continued Patient Access to Study Drug|Protocol for Continued Patient Access to Study Drug||Eli Lilly and Company||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|December 15, 2015|December 15, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02632994||6713|
NCT02633007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-008|A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma|A Phase 1 Study of the Safety and Pharmacokinetics (PK) of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma||Acorda Therapeutics|No|Recruiting|December 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|65 Years|No|||March 2016|March 14, 2016|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633007||6712|
NCT02642302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVERSO-02|Rest Time on Gain Aerobic and Anaerobic Performance|Can The Rest Interval Time Provide Superior Gains on VO2max, Aerobic and Anaerobic Performance Obtained With High Intensity Interval Training (HIIT)? a Randomized Controlled Study|Performance|Universidade Federal do Rio de Janeiro|Yes|Not yet recruiting|December 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 25, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02642302||5998|
NCT02628535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGD009-01|Safety Study of MGD009 in B7-H3-expressing Tumors|Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms||MacroGenics|No|Recruiting|September 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|114|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628535||7055|
NCT02379650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78134|Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss|RCT Assessing Hydroxychloroquine for Unexplained Recurrent Pregnancy Loss||University of Utah|Yes|Not yet recruiting|March 2015|March 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|430|||Female|18 Years|N/A|No|||February 2015|March 4, 2015|February 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379650||26164|
NCT02379923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIUCT-001|The Asahi Intecc PTCA Chronic Total Occlusion Study|The Asahi Intecc PTCA Chronic Total Occlusion Study|CTO-PCI|Asahi Intecc USA Inc|Yes|Recruiting|June 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|163|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379923||26143|
NCT02634606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOCO 11-000665|Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood|Effects of a Tocotrienol-Enriched Fraction of Palm Oil on Serum Lipids in Hypercholesterolemic Subjects|TRF|University of California, Los Angeles|No|Terminated|December 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|13|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2015|December 15, 2015|September 26, 2014|No|Yes|Unable to obtain supplement for this study. Unable to recruit.|No||https://clinicaltrials.gov/show/NCT02634606||6589|
NCT02636621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR94036|Efficacy of Oral Appliance for Upper Airway Resistance Syndrome|Efficacy of Oral Appliance for Upper Airway Resistance Syndrome: Randomized, Parallel, Placebo, Controlled Study||Associação Fundo de Incentivo à Pesquisa|No|Recruiting|October 2013|October 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|50 Years|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02636621||6435|
NCT02635438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPC-CLT-002|A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.|"A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ".|TPC|Thinq Pharma-CRO Pte. Ltd.|No|Not yet recruiting|February 2016|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635438||6526|
NCT02628860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-13-709|Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy|Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy|FCM|National Cancer Center, Korea|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|19 Years|N/A|No|||December 2015|December 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02628860||7030|
NCT02629133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|792696|Intervention for Battered Sheltered Women With Substance Use (Open Trial and Randomized Trial)|Computer-Based Intervention for Battered Sheltered Women With Substance Use (Open Trial and Randomized Trial)||Women and Infants Hospital of Rhode Island|Yes|Recruiting|March 2016|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02629133||7009|
NCT02638545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3820|Hemodynamic Effects of Dexmedetomidine in Septic Shock|Effects of Dexmedetomidine on Pressor Response to Norepinephrine in Patients With Septic Shock||University of Roma La Sapienza|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Probability Sample|patients with septic shock requiring norepinephrine to maintain MAP|December 2015|December 18, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638545||6287|
NCT02641093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCI-HN-15-01|Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma|Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma||University of Cincinnati|Yes|Recruiting|January 2016|July 2021|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02641093||6091|
NCT02390583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120140|Internet Addiction and Sleep Disorders|Internet Addiction and Sleep Disorders|ADDICSOM|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|July 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390583||25323|
NCT02390596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM13520|Anakinra and Kawasaki Disease|A Phase IIa Multicenter Trial to Assess the Efficacy, and Safety of Anakinra in Patients With Intravenous Immunoglobulin-resistant Kawasaki Disease|KAWAKINRA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|8 Months|18 Years|No|||December 2015|December 8, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390596||25322|
NCT02629406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1182-31/4.|Studies on the Adaptive Responses to Hypoxia|Studies on the Adaptive Responses (Cardiovascular, Respiratory and Angiogenetic) to Hypoxia in Patients With Type 1 Diabetes Compared to Controls|HYKRAND|Karolinska University Hospital|Yes|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|whole blood, serum|Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with diabetes are included from Department of endocrinology. Healthy controls are        included via announcement och social media.|December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629406||6988|
NCT02634827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1483|Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation|A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation||Mayo Clinic|Yes|Recruiting|December 2015|||April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|60 Years|N/A|No|||March 2016|March 8, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634827||6572|
NCT02641717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150468H|Validity of Patient-Collected Wet Mounts|Validity of Patient-Collected Wet Mounts||The University of Texas Health Science Center at San Antonio|No|Recruiting|November 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02641717||6043|
NCT02382822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sponsor- Rigshospitalet|Copenhagen Co-morbidity in HIV Infection Study|Copenhagen Co-morbidity in HIV Infection Study|COCOMO|Rigshospitalet, Denmark|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|Routine biochemistry, whole blood, plasma, peripheral blood mononuclear cells (PBMCs), DNA      and RNA from buffy coat, plasma, and red blood cells (RBC).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected patients.|November 2015|November 4, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382822||25920|
NCT02629419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-70004|CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis|A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies|CAMB|Aquarius Biotechnologies, Inc.|Yes|Recruiting|November 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629419||6987|
NCT02638844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPRC2013 ARDStrain|Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome|ARDStrain : Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome|ARDStrain|Central Hospital, Nancy, France|No|Not yet recruiting|December 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients with moderate or severe ARDS receiving invasive mechanical ventilation|December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638844||6264|
NCT02642029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001833|Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study|Cerebellar Transcranial Magnetic Stimulation (cTMS) in Psychotic Disorders: Effect on Time Perception, Executive Function, and Mood and Psychotic Symptoms||Mclean Hospital|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642029||6019|
NCT02637011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GY1340|Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life|Influence of Quality of Care and Individual Patient Characteristics on Quality of Life/ Return to Work in Survivors of the Acute Respiratory Distress Syndrome (ARDS): Prospective, Observational, Multi-centre Cohort Study|DACAPO|University Hospital Regensburg|No|Recruiting|September 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|90 Years|No|Probability Sample|Study participants will be selected of patients with ARDS treated at intensive care units        of the participating hospitals. Participating hospitals are members of the ARDS Network        Germany or other hospitals which agreed to take part in the study.|December 2015|December 19, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637011||6405|
NCT02383381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05-026-005|Lateral Rectus Muscle and Anterior Segment Optical Coherence Tomography (AS-OCT)|Pre and Post-operative Rectus Muscle Insertion Site Changing Using Anterior Segment Optical Coherence Tomography in Strabismus Patients||Samsung Medical Center|No|Completed|February 2014|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|9 Years|N/A|No|Non-Probability Sample|30 patients : 21 males and 9 females age: 9 to 60 years|February 2014|March 3, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02383381||25877|
NCT02636907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.11|Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe|Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe||Boehringer Ingelheim||Recruiting|January 2016|July 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|December 18, 2015||||No||https://clinicaltrials.gov/show/NCT02636907||6413|
NCT02637115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/02JUL/369|Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome|Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome Related to Obesity|Microbes4U|Université Catholique de Louvain|No|Recruiting|December 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|100|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02637115||6397|
NCT02637713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5661a|Management of Reflux After Sleeve Using Stretta|Radiofrequency Energy Delivery to the Lower Esophageal Sphincter (Stretta) in Sleeve Gastrectomy Patients With GERD|MaRSS|Montefiore Medical Center|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Participants will be men and women between the ages of 18 and 80 who have undergone sleeve        gastrectomy at least 6 months prior to enrollment as treatment of morbid obesity and who        have one or more of the following:          1. Symptomatic reflux: (heartburn, chest discomfort, asthma/chronic cough, laryngitis,             nocturnal aspiration or regurgitation)          2. On a PPI with GERD-related symptoms          3. On a PPI but like to discontinue them|December 2015|December 21, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637713|24 Months|6351|
NCT02639559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201602037|Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies|A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies||Washington University School of Medicine|No|Not yet recruiting|April 2016|April 2023|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639559||6209|
NCT02393352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL_435|Benefits of Dry Needling in Trigger Points on Autonomic Nervous System and Corporal Composition in Patients With Fibromyalgia Syndrome|Benefits of Dry Needling in Trigger Points on Autonomic Nervous System, Photoelectric Plethysmography, Body Composition in Patients With Fibromyalgia Syndrome.||Universidad de Almeria|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||August 2015|August 14, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02393352||25111|
NCT02393365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-HCV screening|Prevalence and Screening of Hepatitis C in Belgium in 2015|Prevalence and Screening of Hepatitis C in Belgium in 2015||Brugmann University Hospital|No|Not yet recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10000|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393365||25110|
NCT02643368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB-RRC-PR-15085|Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine|Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh||Centers for Disease Control and Prevention|Yes|Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|760|||Both|6 Weeks|7 Weeks|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02643368||5916|
NCT02630095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LSX02-2015|The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT|Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis：A Zelen-design Multicenter Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Not yet recruiting|December 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02630095||6935|
NCT02639507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008884|International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients|International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients - the ICV-DME Study|ICV-DME|Mayo Clinic|Yes|Recruiting|June 2015|December 2019|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will have the following characteristics:          -  Background diabetic retinopathy.          -  Center involving macular edema with CST > 325 µm as measured by SD-OCT.          -  Predominantly intact (80%) ELM and IS/OS lines within 500 µm of the fovea on both             horizontal and vertical SD-OCT scans.          -  Best corrected Snellen visual acuity from 20/40 to 20/280 inclusive|December 2015|December 30, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02639507||6213|
NCT02380222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL7064A|Patient-Reported Outcome Questionnaire for Systemic Mastocytosis|Patient-Reported Outcome Questionnaire Development for Symptoms of Systemic Mastocytosis||Adelphi Values LLC|No|Recruiting|July 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||5|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Residents of the United States with advanced systemic mastocytosis who volunteer to        participate in the study|February 2015|March 2, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02380222||26120|
NCT02380235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci 004 CT-2|Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)|||GeneScience Pharmaceuticals Co., Ltd.|No|Recruiting|December 2014|July 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|N/A|N/A|No|||February 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380235||26119|
NCT02633735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-025|EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care|EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care|Appy-CDS|HealthPartners Institute|Yes|Not yet recruiting|March 2016|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|8200|||Both|5 Years|19 Years|Accepts Healthy Volunteers|||November 2015|February 17, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02633735||6656|
NCT02638558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2015|Evaluation of the Impact of Direct Conversation With Patients in the Compliance With the "Split-dose" Regimen Preparation for Colonoscopy Scheduled in the First Part of the Morning|||Valduce Hospital||Not yet recruiting|January 2016|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|286|||Both|N/A|N/A|No|||December 2015|December 24, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02638558||6286|
NCT02638688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s.shazly|Measurement of Fibroid Volume and 2D, 3D US|Uterine Fibroid Volume After Myomectomy Compared to Pre-operative Measurement by Two and Three-dimensional Ultrasound||Zagazig University|Yes|Completed|September 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|3|||Female|22 Years|50 Years|No|Probability Sample|44|December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638688||6276|
NCT02633891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1651-W|Metabolic Syndrome and Fall Risk|Metabolic Syndrome and Fall Risk||VA Office of Research and Development|No|Not yet recruiting|July 2016|December 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|50 Years|70 Years|No|||December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633891||6644|
NCT02392832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01A1050243|Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence|Impact and Cost-Effectiveness of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence: a Cluster-Randomized Controlled Trial in Western Kenya|LLML|University of California, Irvine|No|Not yet recruiting|April 2015|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|200000|||Both|7 Months|N/A|No|||March 2015|March 13, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02392832||25151|
NCT02631031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ph.D (No.26)|Chronopharmacology of Valsartan in Normotensive Subjects|A Comparative Pharmacokinetic and Pharmacodynamic Study of Morning Versus Evening Administration of Valsartan in Healthy Adults||Ain Shams University|No|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631031||6863|
NCT02634112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANACARE|Spanish National Registry of ANAstomotic Leakage in CAncer of the REctum (ANACARE)|Spanish National Registry of Anastomotic Leakage in Rectal Cancer Surgery. Observational, Prospective and Multicenter Study|ANACARE|Hospital Universitario La Fe|No|Not yet recruiting|January 2016|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|It is a record of the surgical procedure performed in patients undergoing rectal cancer        surgery electively, resected with curative intent and anastomosis, with or without        protective ileostomy.        Participating Hospitals should include all patients undergoing rectal cancer surgery        CONSECUTIVE during the study period. An estimated number of centers and patients a priori        is not fixed; will depend on the publicity of the record between the members of the        Spanish Association of Surgeons and the commitment and involvement of the researchers        involved.|December 2015|December 15, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02634112|1 Month|6627|
NCT02634125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKPL-09077-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||December 15, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634125||6626|
NCT02641106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150155|VDOT for Monitoring Adherence to LTBI Treatment|Video Directly Observed Therapy (VDOT) to Monitor Short-Course LTBI Treatment|VMALT|University of California, San Diego|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|310|||Both|13 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02641106||6090|
NCT02641119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13120333|Resuscitation Fluid Choice and Clinical Outcomes|Association of Resuscitation Fluid Choice and Clinical Outcomes in Critically Ill Patients||University of Pittsburgh|No|Active, not recruiting|August 2014|August 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|65800|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to any of eight ICUs at the University of Pittsburgh Medical        Center.|March 2016|March 2, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02641119||6089|
NCT02384642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO6612|Creating Opportunities Through Mentoring, Parenting and Safe Spaces - Democratic Republic of Congo|Creating Opportunities Through Mentoring, Parenting and Safe Spaces - a Randomized Controlled Trial in Democratic Republic of Congo|COMPASS|Columbia University|No|Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1633|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02384642||25780|
NCT02638012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-057|Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)|Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)||St. Michael's Hospital, Toronto|No|Not yet recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638012||6328|
NCT02638025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMCH20151216|Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury|Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury||Huizhou Municipal Central Hospital|Yes|Completed|January 2010|July 2015|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|N/A|N/A|No|Non-Probability Sample|patients with closed globe injury were recruited, and all eyes of recruited patients had        hyphema occupying at least 1/3rd of anterior chamber volume|December 2015|December 20, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638025||6327|
NCT02642289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-270415|Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia|Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia||Universidad de Almeria|Yes|Completed|December 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02642289||5999|
NCT02642367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-DE4-15-345|Stylet Use for McGrath Videolaryngoscope|Comparison of With or Without Use of Stylet for Endotracheal Intubation With McGrath Videolaryngoscope||Ajou University School of Medicine|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|140|||Both|19 Years|70 Years|No|||December 2015|December 29, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02642367||5993|
NCT02634411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 140923|Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)|Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia : a Randomized Controlled Study (iDIAPASON)|iDIAPASON|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02634411||6604|
NCT02377791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rama 07-57-16|Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Concentrations and Outcomes in Thai Transplant Recipients|Impact of CYP3A5 Genetic Polymorphisms on Tacrolimus Concentration and Transplant Outcomes During The Early Stage Post-Transplantation in Thai Kidney Transplant Recipients||Mahidol University|No|Enrolling by invitation|July 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|170|Samples With DNA|DNA for polymorphism CYP3A5|Both|18 Years|80 Years|No|Non-Probability Sample|Thai recipients who underwent kidney transplantation between January 2011 and December        2013 and were receiving two divided daily doses of tacrolimus in their initial regimen for        prevention of allograft rejection|February 2015|March 3, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377791||26307|
NCT02319018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02475|Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors|A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors||National Cancer Institute (NCI)||Recruiting|August 2015|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|February 15, 2016|December 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02319018||30809|
NCT02297074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BreadGI|Evaluation of Glycemic Index, Glycemic Load and Insulinemic Index of Spanish Breads|Evaluation of Glycemic Index Glycemic Load and Insulinemic Index of Spanish Breads and Their Effect on Incretins and Gastrointestinal Hormones Related With Appetite Regulation|BREADGI|Organización Interprofesional Agroalimentaria de Cereales Panificables y Derivados|No|Completed|January 2013|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|6||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|October 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02297074||32494|
NCT02319720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080299|Study to Evaluate Bone Marrow Cells in the Treatment of Chronic Wounds|A Randomized Study to Evaluate the Safety of Bone Marrow Aspirate Plus Cultured Bone Marrow Cells vs. Bone Marrow Aspirate Alone vs. Cultured Bone Marrow Cells Alone in the Treatment of Chronic Wounds.||University of Miami|Yes|Terminated|July 2008|April 2014|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 15, 2014|Yes|Yes|Lack of funds|No||https://clinicaltrials.gov/show/NCT02319720||30756|
NCT02319733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/498|Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold|Plaque Stabilization and Restoration of Vascular Function by Bioresorbable Vascular Scaffold in Acute Coronary Syndrome Prone Patients||Canisius-Wilhelmina Hospital|No|Recruiting|December 2014|February 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 29, 2016|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02319733||30755|
NCT02304562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-004|Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair|Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair||Chinese PLA General Hospital|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|November 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02304562||31918|
NCT02307955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKD-ffANK-001|Firefly ANKLE Sprain Study|Firefly ANKLE Sprain Study||Firstkind Ltd|No|Completed|September 2014|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02307955||31658|
NCT02302313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 13.186 ANI-HYPNOSE|Study of the ANI Validity on Evaluation of Nociception in State of Hypnosis|Pilot Study of the ANI (Analgesia Nociception Index) Validity on the Nociception Assessment in Healthy Volunteers in State of Hypnosis, Compared to Painful Numerical Verbal Scale (EVN).||University Hospital, Brest|Yes|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02302313||32091|
NCT02302573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI08-FP : Placenta Accreta|Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population|Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population||University Hospital, Tours|No|Recruiting|May 2009|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||April 2009|November 24, 2014|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02302573||32071|
NCT02309827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7981001|Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers|A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06651600 In Healthy Subjects||Pfizer|No|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02309827||31515|
NCT02312908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14172EuiYakAn178|Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism|Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial||Seoul National University Hospital|No|Recruiting|March 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|N/A|No|||May 2015|May 28, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02312908||31278|
NCT02301182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK-44819|Comparison of Functional Results of ADM X3-MoP Cup (Stryker) and a CoC Cup (Zimmer) in Young Patients|A Single-Center Randomized, Patient-Blinded, Prospective Five-Year Study to Compare the Functional Results After Insertion of ADM X3-MoP Cup (Stryker) and a CoC Cup (Zimmer) in Primary THA||University of Aarhus|No|Enrolling by invitation|November 2014|November 2023|Anticipated|November 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|65 Years|No|||October 2014|November 24, 2014|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02301182||32178|
NCT02301195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1148|Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder|Measuring the Effects of Therapeutic Horseback Riding on School-Age Children and Adolescents With Autism Spectrum Disorders||University of Colorado, Denver|No|Active, not recruiting|October 2010|December 2016|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|127|||Both|6 Years|16 Years|No|||January 2016|January 8, 2016|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02301195||32177|
NCT02294617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30CA072720|E-cigarette vs. Nicotine Inhaler Comparisons|Comparative Evaluation of the Perceptions and Utilization of Nicotine Inhalation Devices||Rutgers, The State University of New Jersey|No|Completed|August 2012|||April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|41|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|June 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02294617||32682|
NCT02320747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adwin009|Immediate Effect of Tai Chi Exercise in Healthy Volunteers|Immediate Effect of Tai Chi Exercise in Healthy Volunteers:Randomized Controlled Study||Adwin Life Care|Yes|Completed|September 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|64|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02320747||30677|
NCT02630134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S11-00520|Device for Monitoring Pain During Intraoperative, Pre/Post Surgical Periods: Comparison With Standard of Care Monitoring|MyHealthTrendsTM Device for Pain for Monitoring Pain During the Intraoperative, Pre and Post Surgical Periods: Comparison With Standard of Care Pain Monitoring.||New York University School of Medicine|No|Terminated|March 2011|October 2012|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 2, 2014||No|Study stopped, recruitment difficult, subject compliance very difficult.|No||https://clinicaltrials.gov/show/NCT02630134||6932|
NCT02641938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0262|Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury|Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: a Double-blind Randomized Clinical Trial||Gangnam Severance Hospital|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|38|||Both|20 Years|N/A|No|||December 2015|December 25, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02641938||6026|
NCT02377765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LWH0991|Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement.|A Single Blind, Randomised, Controlled Trial to Evaluate the Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Overactive Bladder (OAB) Symptoms in Women Responders to Posterior Tibial Nerve Stimulation (PTNS)||Liverpool Women's NHS Foundation Trust|No|Recruiting|February 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377765||26309|
NCT02377778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-8|Comparative Effect of Theipoental and Propofol in IVF Outcome|||Aristotle University Of Thessaloniki|No|Completed|January 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Female|18 Years|45 Years|No|||February 2015|March 3, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377778||26308|
NCT02630329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B689201526268|Notes Adnexectomy for Benign Pathology Compared to Laparoscopic Excision|Adnexectomy for Benign Gynaecological Pathology by Natural Orifice Transluminal Endoscopy or Laparoscopy|NOTABLE|Imelda Hospital, Bonheiden|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02630329||6917|
NCT02630342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-15-368|The Use of a Mock MRI Scanner for Reducing the Use of Anesthesia in Children Undergoing Clinical MRI Scans|The Use of a Mock MRI Scanner for Reducing the Use of Anesthesia in Children Undergoing Clinical MRI Scans||University of Calgary|No|Recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|160|||Both|3 Years|7 Years|No|||January 2016|January 26, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02630342||6916|
NCT02630394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD_ACS_AZM|A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease|A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease||University of Mississippi Medical Center|Yes|Recruiting|September 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|6 Years|16 Years|No|||December 2015|December 11, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02630394||6912|
NCT02377999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1167|Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts|Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts||LEO Pharma|No|Completed|February 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2015|December 3, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02377999||26291|
NCT02628132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2151-169|Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients|Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer||King Faisal Specialist Hospital & Research Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Female|18 Years|65 Years|No|||December 2015|December 8, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02628132||7086|
NCT02636439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00032364|Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)|Study of the Effects Caloric Restriction and Exercise Training in Patients With Heart Failure and a Normal Ejection Fraction|SECRET-II|Wake Forest School of Medicine|Yes|Recruiting|August 2015|June 2022|Anticipated|July 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|60 Years|N/A|No|||December 2015|December 18, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636439||6449|
NCT02636452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80/2013|Cardiopulmonary Exercise Testing in Interstitial Lung Disease|Cardiopulmonary Exercise Testing in Interstitial Lung Disease||Wissenschaftliches Institut Bethanien e.V|No|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with Interstitial lung diseases|December 2015|December 18, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636452||6448|
NCT02631382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCAM - TRIAL - CUPPING2|Wet Cupping (AlHijamah); Double Versus Single Cupping Technique|Wet Cupping (AlHijamah); Double Versus Single Cupping Technique in Chronic Low Back Pain Patients: Randomized Comparative Clinical Trial, Pilot Study Saudi Arabia, 2015||National Center for Complementary and Alternative Medicine, Saudi Arabia|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|90|||Both|18 Years|60 Years|No|||December 2015|December 12, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02631382||6836|
NCT02631395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SorTrondelagUC|The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball|The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball||Norwegian University of Science and Technology|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|106|||Female|15 Years|17 Years|No|||January 2016|January 12, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02631395||6835|
NCT02631681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProstEx|Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy|Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy||Herlev Hospital|No|Recruiting|August 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Male|18 Years|N/A|No|||February 2016|February 10, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02631681||6813|
NCT02379130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO2957|Early Behavioral Intervention for Preterm Infants|FNI Between Mothers and Preschool Age Children|EBI|Columbia University|No|Recruiting|February 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Months|4 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02379130||26204|
NCT02639871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140708|Dynamic Neuroimaging Biomarkers in Huntington's Disease|Validation of Molecular Neuroimaging Biomarkers in Huntington's Disease in View of Therapeutic Trials Targeting the Krebs Cycle|HDeNERGY|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|September 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|80|Samples Without DNA|Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Period 1: healthy volunteers; Period 2: presymptomatic individuals, early affected HD        patients and controls|December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02639871||6185|
NCT02641743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Clinical Trial for Liquid Food (Inslow)|Increased Insulinogenic Indexes Following Liquid Food (Inslow) Intake in Impaired Glucose Tolerance and Type-2 Diabetic Subjects.||Shanghai Meiji Health Science and Technology Co., Ltd.|Yes|Completed|January 2009|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|36|||Both|52 Years|61 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02641743||6041|
NCT02628288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-57892|COmplex Bifurcation PCI: AXXESS Device + Absorb BVS, vs Modified T Stenting With Absorb BVS|COmplex Bifurcation Lesions: a RAndomized Comparison Between the AXXESS Device in Combination With Absorb BVS, and Modified T Stenting With Absorb BVS: an OCT Study.|COBRAII|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|December 2015|November 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02628288||7074|
NCT02631239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-NK-2015|MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma|The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type||Ruijin Hospital|No|Recruiting|November 2015|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|14 Years|70 Years|No|||December 2015|December 11, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02631239||6847|
NCT02637141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELIM-NRCD-001|A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease||Celimmune|Yes|Not yet recruiting|March 2016|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|63|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|November 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637141||6395|
NCT02637154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoHa|Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes|The Effect of Motivational Interview and Intensive Education on HbA1C Values and Glucose Variability in Adolescents With Poorly Controlled Type 1 Diabetes||Helsinki University Central Hospital|No|Recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|12 Years|16 Years|No|||December 2015|December 21, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02637154||6394|
NCT02640131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701840|A Bio-psychosocial Sexual Health Intervention for Prostate Cancer Survivors and Partners: a Feasibility Study|A Bio-psychosocial Sexual Health Intervention for Prostate Cancer Survivors and Partners: a Feasibility Study|BSHR|University Health Network, Toronto|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02640131||6165|
NCT02634970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ACA09|CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab|CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab|CANARI|Novartis|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|172|||Both|50 Years|N/A|No|||December 2015|December 16, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634970||6561|
NCT02635204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFD06-CD-004|A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days||Promius Pharma, LLC|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635204||6544|
NCT02638428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-008|Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy|Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy||Samsung Medical Center|Yes|Recruiting|December 2015|December 2023|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|18 Years|No|||January 2016|January 17, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02638428||6296|
NCT02644499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIP/IEC/SC/2013/5/433|Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis|Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis||Jawaharlal Institute of Postgraduate Medical Education & Research|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644499||5829|
NCT02630940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152379 (113-08-15)|Exhaled Breath Condensate Biomarkers and Cough in IPF|Exhaled Breath Condensate Biomarkers and Cough in People With Idiopathic Pulmonary Fibrosis||University of East Anglia|No|Recruiting|January 2016|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|47|||Both|40 Years|N/A|No|Non-Probability Sample|Male or Female Idiopathic pulmonary fibrosis sufferers over the age of 40, who have been        diagnosed in accordance with either a multi-disciplinary review of their clinical history,        thoracic high resolution computed tomography and/or surgical lung according to        international guidelines|February 2016|February 2, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630940||6870|
NCT02633722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAdelaide|Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?|Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?||University of Adelaide|No|Not yet recruiting|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|24|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633722||6657|
NCT02643212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005523-27|Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis||CIRROXABAN|Hospital Clinic of Barcelona|Yes|Recruiting|January 2016|November 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02643212||5928|
NCT02643225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes mellitus|The Role of Umbilical Cord Thickness in Prediction of Fetal Macrosomia in Patients With Gestational Diabetes Mellitus|The Role of Umbilical Cord Thickness, Interventricular Septum Thickness and HbA1C Levels in Prediction of Fetal Macrosomia in Patients With Gestational Diabetes Mellitus||Ain Shams University|Yes|Completed|April 2015|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|This prospective case control study will be carried out at Ain shams university maternity        hospital between April 2015 and October 2015 on 80 patients. The patients will be divided        into two groups, 40 pregnant women as case group with gestational diabetes mellitus and 40        non diabetic pregnant women as control group after being approved by the local hospital        ethics and research committee. A verbal consent will be taken from each patient.|December 2015|December 29, 2015|December 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02643225||5927|
NCT02631928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSULCT002|Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III|Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin 30/70 and Huminsulin® Profil III||Julphar Gulf Pharmaceutical Industries|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|49|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02631928||6795|
NCT02631941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7200J04|Clinical Study to Evaluate Z7200 Pharmacokinetics Profile|An Open-Label, Randomized, Five-Period Cross-over, Single-dose Study to Compare Pharmacokinetics Profiles of Z7200 Midium Strength and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.||Zambon SpA|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631941||6794|
NCT02392260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140008054|Non-invasive Screening of the Status of the Vascular System: Feasibility Test|Non-invasive Screening of the Status of the Vascular System: Feasibility Test|NISTAS1|University of Pavia|No|Not yet recruiting|April 2015|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392260||25195|
NCT02392273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ausanil Study 001|A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil|A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil||VR1 Corporation|No|Recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients in a Clinical headache practice (outpatient) with a diagnosis of a primary        headache disorder.|March 2015|March 18, 2015|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392273||25194|
NCT02633995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mina|Spinal Anaesthesia and Severe Preeclampsia|Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study)||Kasr El Aini Hospital||Recruiting|December 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|40 Years|No|Probability Sample|two equal groups (n=30), Pregnant females with severe pre-eclampsia : (group A) and        normotensive parturients (group B) presenting for full term delivery with caesarean        section using spinal anesthesia at Kasr Al Aini hospital in the duration of 3 months from        december 2015 to march 2016 will be included.|December 2015|December 14, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02633995||6636|
NCT02638662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903010295|Stress Level and the Relationship With IVF Outcomes.|Does Stress Affect In-Vitro Fertilization (IVF) Outcome?||Weill Medical College of Cornell University|No|Recruiting|July 2010|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Female|20 Years|44 Years|No|Non-Probability Sample|IVF patients doing IVF for the first time, or doing it for the third or more time doing it        for the sole purpose to donate their eggs|December 2015|December 18, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02638662||6278|
NCT02638675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4L-01|Financial Health Incentives to Promote Physical Activity Among Hospital Employees: A Randomized Control Trial|Examining Financial Health Incentives to Promote Physical Activity Among Inactive Hospital Employees: A Web-based Randomized Control Trial||University of Toronto|No|Not yet recruiting|July 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638675||6277|
NCT02641210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23115-010215/2011-16|Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin|Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin: a Clinical Trial||Federal University of Maranhao|Yes|Completed|January 2015|October 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02641210||6082|
NCT02390661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-931M; i044456|Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal|Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal||Michigan State University|Yes|Recruiting|November 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|45 Years|N/A|No|||September 2015|September 28, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390661||25317|
NCT02632981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-14-01|IL-32 Levels in Patients With Chronic Periodontitis|IL-32 Levels in Gingival Crevicular Fluid and Saliva of Patients With Chronic Periodontitis After Periodontal Treatment.||Bulent Ecevit University|No|Completed|July 2014|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|54|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632981||6714|
NCT02632370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRMC 15-086|5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor|A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632370||6761|
NCT02641769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA-INF1|Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.|Intra-Testicular Transplantation of Purified Autologous Clusters of Differentiation (CD) 34+,133+, and 271+ Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.||Stem Cells Arabia|No|Recruiting|January 2014|January 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|21 Years|50 Years|No|||December 2015|December 30, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02641769||6039|
NCT02390804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC14EISI0026|Postoperative Pain After Total Laparoscopic Hysterectomy: a Comparison of Single-port and Three-port Laparoscopy|Postoperative Pain After Total Laparoscopic Hysterectomy: a Comparison of Transumbilical Single-port Access and Conventional Three-port Laparoscopic Surgery||The Catholic University of Korea|Yes|Completed|March 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||March 2015|March 11, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02390804||25306|
NCT02643329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BABE-P14-095|Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations|Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations||Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643329||5919|
NCT02642562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15CA190|Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN|Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)|IRONMAN|University of Glasgow|Yes|Not yet recruiting|February 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1300|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642562||5978|
NCT02640469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00496|Alcohol Versus Chlorhexidine With and Without Water|Efficacy of the Use of Alcohol-bases Solutions Versus Chlorhexidine With or Without Water for Hand Sanitation Prior to Surgical Procedure||New York University School of Medicine|No|Not yet recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640469||6139|
NCT02381249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFSJ 0057|The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery|The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery||St. James's Hospital, Ireland|No|Enrolling by invitation|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381249||26041|
NCT02630563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA16497|Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids|A Study of the Safety, Tolerability and Pharmacokinetics of Oral CellCept® (Mycophenolate Mofetil, MMF) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids||Hoffmann-La Roche||Terminated|May 2003|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|3 Months|12 Years|No|||December 2015|December 14, 2015|December 11, 2015|No|Yes|Due to extremely slow recruitment, infrequent use of combination triple therapy (MMF,    cyclosporine, steroids), study was discontinued; Part 2 was not conducted.|No||https://clinicaltrials.gov/show/NCT02630563||6899|
NCT02633540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-083|Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function|A Phase II Investigation of Contralateral Arytenoid Sparing IMRT for T1a and T2a Larynx Cancer With Detailed Analysis of Post-treatment Laryngeal Function||Fox Chase Cancer Center|Yes|Recruiting|November 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633540||6671|
NCT02640950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|794736-5|An Open Label Trial of TMS Therapy for Bipolar Depression|||Sheppard Pratt Health System|No|Recruiting|December 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640950||6102|
NCT02384408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10979112.1.3001.5479|Hormone Replacement Therapy on the Postmenopausal Endometrium|Comparative Effects of Drospirenone and Tibolone on the Postmenopausal Endometrium||Universidade do Vale do Sapucai|Yes|Completed|November 2014|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384408||25798|
NCT02637388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueenMUsz2|Effects of Beta-glucan on Energy Intake and Satiety|The Effect of a Breakfast Meal Containing 4g Oat Beta-glucan on Perceived Satiety and ad Libitum Food Intake in Normal-weight and Overweight Subjects. A Double-blinded, Randomized, Placebo-controlled Cross-over Study.||Queen Margaret University|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02637388||6376|
NCT02643394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052015-068|Efficacy of Oral vs. Intravenous Acetaminophen|The Comparative Efficacy of Oral vs. Intravenous Acetaminophen in Sinus Surgery Patients||University of Texas Southwestern Medical Center|No|Recruiting|October 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 29, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02643394||5914|
NCT02642185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAVERRIC|Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases|Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases|MAVERRIC|Karolinska Institutet|No|Recruiting|December 2015|December 2028|Anticipated|December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|European multicentre prospective cohort study with propensity score matching for number or        tumours, age, gender and response to chemotherapy (no chemo - response/stable disease -        progression).        Patients with colorectal liver metastases are evaluated at a weekly liver        multidisciplinary conference and a treatment strategy is decided. In this decision process        patients that are resectable and have tumours of 30mm or less and not more than 5 in        number, and deemed as both ablatable and resectable, will be offered treatment with an        ablative strategy using state of the art targeting and microwave ablation devices.|December 2015|December 31, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02642185|10 Years|6007|
NCT02642133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC ENT|Breastfeeding Improvement Following Tongue-tie and Lip-tie Release|Breastfeeding Improvement Following Tongue-tie and Lip-tie Release: A Prospective Cohort Study||The Oregon Clinic|No|Completed|June 2014|December 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|N/A|12 Weeks|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02642133||6011|
NCT02377219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 571 01|Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.|Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.|FIVPHENOL|University Hospital, Toulouse|No|Recruiting|October 2014|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1388|||Both|28 Years|34 Years|No|||March 2016|March 9, 2016|December 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02377219||26351|
NCT02635854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7738 02|Study of Platelet Activation in Septic Shock Patients|Study of Platelet Activation in Septic Shock Patients|PASS|University Hospital, Toulouse|No|Not yet recruiting|February 2016|September 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02635854||6494|
NCT02638870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-109|Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome|Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome||Samsung Medical Center|No|Not yet recruiting|January 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|118|||Both|18 Years|75 Years|No|Probability Sample|Patients with IBS according to the Rome III criteria were recruited in the outpatient        clinic at Samsung Medical Center. Inclusion criteria were age 18-75 years and no evidence        of inflammatory bowel disease or malignancy on colonoscopy.|December 2015|December 23, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02638870||6262|
NCT02638883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM 5630|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2016|||||N/A|N/A|N/A||||||||||||||December 21, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638883||6261|
NCT02630147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-1043|Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants|Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants|Vanilla|Université de Sherbrooke|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|4 Weeks|No|||December 2015|December 14, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02630147||6931|
NCT02392884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033072|HIV Medication Adherence in Underserved Populations|A Cognitive Rehabilitation Program to Promote Treatment Adherence for Individuals Who Are HIV Positive With Mild Neurocognitive Difficulties||Cedars-Sinai Medical Center|Yes|Recruiting|September 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02392884||25147|
NCT02643524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 2324|Weight Change With Controlled Ankle Movement (CAM) Walker Boot Use|Weight Change With Controlled Ankle Movement (CAM) Walker Boot Use||Milton S. Hershey Medical Center|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643524||5904|
NCT02634359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-CLC-2015_Prot_1_FERT|Evaluation of EarlySense for Monitoring Ovulation Cycles and Detection of Early Stages of Pregnancy in Home Environment|Protocol for Evaluation of EarlySense - a Contact-less Heart and Respiration Device for Monitoring Ovulation Cycles and Detection of Early Stages of Pregnancy in Home Environment||EarlySense Ltd.|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02634359||6608|
NCT02642692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16373713.1.0000.5479|Hamstrings X Patellar Tendon for ACL Reconstruction in Soccer Players - RCT|Hamstrings X Patellar Tendon for Anterior Cruciate Ligament Reconstruction in Soccer Players - RCT||Faculdade de Ciências Médicas da Santa Casa de São Paulo|No|Recruiting|June 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|40 Years|No|||January 2016|January 5, 2016|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02642692||5968|
NCT02382341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15000946|BIOSURE™ HEALICOIL™ PK Bone In-growth Study|A Radiographic Study of Patients Treated With the BIOSURE™ HEALICOIL™ PK Interference Screw for ACL Repair With Soft Tissue Fixation||Smith & Nephew, Inc.|No|Active, not recruiting|September 2014|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients undergoing ACL reconstruction|March 2015|March 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02382341||25957|
NCT02636322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0147|A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma|A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636322||6458|
NCT02296944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1798756|Anatomical and Functional Results of Surgery of the Tympanic Membrane Perforation of the Child|Anatomical and Functional Results of Surgery of the Tympanic Membrane Perforation of the Child|PERFOPED|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|1000|||Both|3 Years|35 Years|No|Non-Probability Sample|Pediatric ENT Head and Neck Surgery, Necker hospital.|July 2015|July 27, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02296944||32504|
NCT02297724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB_Placenta2013|MRI Assessment of Placental Health|MRI Assessment of Placental Health||Children's Hospital Boston||Recruiting|April 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  pregnant mothers with twin gestation with diagnosis of selective IUGR          -  pregnant mothers with singleton gestation with diagnosis of IUGR          -  singleton pregnant mothers and twin pregnant mothers with no apparent medical             complication on fetuses|December 2015|December 15, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02297724||32444|
NCT02301819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-5-14 V2|ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock|ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock|ECMO-CS|Na Homolce Hospital|No|Recruiting|September 2014|September 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02301819||32129|
NCT02322671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200107|Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects|An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg From Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|June 4, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02322671||30529|
NCT02325401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCI-HN-14-01|Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma|A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||University of Cincinnati|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02325401||30319|
NCT02307968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-OPN-14005516|Comparative Study of Insulin Therapy Between Inner and Outer Upper Thigh|Comparison of Patient's Preference, Pain Perception, and Usability Between Inner and Outer Upper Thigh for Insulin Therapy|CUSTIOT|First Affiliated Hospital of Zhejiang University|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|diabetes population|February 2016|February 3, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02307968||31657|
NCT02306473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00043414|The Leaky Lung Test|A Novel Non-invasive Way to Measure Airway Epithelial Permeability in Human Subjects||University of Rochester|Yes|Recruiting|October 2015|November 2018|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|December 1, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02306473||31772|
NCT02297828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278/13|Effect of Boussignac CPAP Ventilation on PaO2 and PaO2/FiO2 Ratio in Morbidly Obese Patients Undergoing Bariatric Surgery|Effect of Boussignac Continuous Positive Airway Pressure Ventilation on PaO2 and PaO2/FiO2 Ratio Immediately After Extubation in Morbidly Obese Patients Undergoing Bariatric Surgery: a Randomized Controlled Trial||Centro Hospitalar do Porto|Yes|Completed|October 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02297828||32436|
NCT02317159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAGE-201|Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia|Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia||Cttq|Yes|Not yet recruiting|February 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317159||30952|
NCT02317172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF-03|Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases|Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases||Dental Innovation Foundation Under Royal Patronage|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|120|||Both|60 Years|N/A|No|||December 2014|December 11, 2014|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02317172||30951|
NCT02304796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-14-SHA|Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders|Randomized Controlled Trial Examining the Effectiveness of Two Group Psychotherapies for Anxiety Disorders: Unified Cognitive-behavioral Therapy vs. Combined Cognitive Behavioral and Dance/Movement Therapy||Shalvata Mental Health Center|No|Active, not recruiting|January 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|65 Years|No|||January 2015|March 20, 2015|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02304796||31900|
NCT02298621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175|Pomegranate Juice and Metabolic Syndrome|The Effect of Pomegranate Juice Intake on Cardiometabolic Factors in Subjects With Metabolic Syndrome.||Urmia University of Medical Sciences|Yes|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|November 19, 2014|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02298621||32375|
NCT02304900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI09-PJP / IOL et sommeil|Effect of the Color of the Intra-eye Implant in the Cataract Surgery on the Sleep|Effect of the Color of the Intra-eye Implant in the Cataract Surgery on the Sleep|IOL et sommeil|University Hospital, Tours|No|Completed|December 2009|December 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Both|60 Years|90 Years|No|||November 2014|November 27, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02304900||31892|
NCT02310711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCTMM01|Multi-scale Modeling of Breast Conserving Therapy|A Pilot Study for the Identification of Targets for Clinical Improvement in Breast Conserving Therapy|BCT|The Methodist Hospital System|No|Recruiting|May 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Female|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with breast cancer who are having BCT and who satisfy the following criteria will        be considered for participation in this study.|December 2014|December 4, 2014|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02310711||31447|
NCT02640183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMLA-Hsc|EMLA Cream in Hysteroscopy Practice|Lidocaine-Prilocaine (EMLA®) Cream in Hysteroscopy Practice: A Prospective Randomized Non-blinded Controlled Study||Ain Shams Maternity Hospital||Not yet recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Female|18 Years|N/A|No|||December 2015|December 22, 2015|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640183||6161|
NCT02642978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRCLM|Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases|The Safety and Effect of Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer： Randomized Control Trial Study||Fudan University|Yes|Recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02642978||5946|
NCT02642991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-41|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642991||5945|
NCT02381782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZGS2014125|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment|UHEAR|General Hospital Groeninge||Completed|December 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|70 Years|N/A|No|Probability Sample|All consenting patients, aged ≥ 70, who are referred for anti-cancer treatment in the        General Hospital Groeninge and who are in need of a CGA.|July 2015|July 28, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381782||26000|
NCT02381795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001CA|Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache|An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache||Cady, Roger, M.D.|No|Recruiting|July 2015|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381795||25999|
NCT02631018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0484|Sisters in Health: A Weight Loss Study for African American Women|Sisters in Health: A Weight Loss Study for African American Women||University of North Carolina, Chapel Hill|No|Not yet recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02631018||6864|
NCT02635776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC003|Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)|Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)|PALISADE|Aimmune Therapeutics, Inc.|Yes|Recruiting|December 2015|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|4 Years|55 Years|No|||March 2016|March 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635776||6500|
NCT02635074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0036|Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia||Stanford University|Yes|Not yet recruiting|January 2016|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635074||6553|
NCT02382068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12003|Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin|Prevention of Cisplatin-Induced Ototoxicity by Intratympanic Dexamethasone||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|August 2014|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382068||25978|
NCT02386254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5089|Adaptation of a Premorbid Function Scoring System as a Predictor for Intensive Care Unit Mortality|Adaptation of a Premorbid Function Scoring System as a Predictor for Intensive Care Unit Mortality|ECOG|University of Oklahoma|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the critical care units of Presbyterian Hospital under the care of        the medical ICU service with any diagnosis will be assessed for enrollment.|March 2015|March 10, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386254||25656|
NCT02632552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 15-101|A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD|A Technology-Assisted Care Transition Intervention for Veterans With Chronic Heart Failure or Chronic Obstructive Pulmonary Disease|TACT|VA Office of Research and Development|Yes|Not yet recruiting|April 2016|March 2019|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02632552||6747|
NCT02642198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900_OPBG_2015|Non-Invasive Blood Pressure Monitor Accuracy in Neonatal Subjects|Clinical Investigation for Non-invasive Blood Pressure Monitor Accuracy Validation Performed on Neonatal, Infants and Children up to 3 Years Old||Mortara Instrument|No|Recruiting|October 2015|||March 2016|Actual|Phase 1|Observational|Observational Model: Case-Only||1|Anticipated|25|||Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include a minimum of 25 patients for the Method 1 and 20 patient for the        Method 2, male and female, with the following weight and age (as defined by date of birth        to current date; not gestational age) ranges:          -  At least 3 patients < 1,000 g in weight.          -  At least 3 patients 1,000 g to 2,000 g in weight.          -  At least 3 patients > 2,000 g in weight.          -  At least 3 patients ≥ to 29 days and < 1 year of age.          -  At least 3 patients ≥ 1 year and < 3 years of age.|March 2016|March 22, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642198||6006|
NCT02641301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBEMO2|Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects|Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2)|OBEMO2|Hopital Lariboisière|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 2, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02641301||6075|
NCT02634502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-2013|Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis|Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis: Correlation Analysis of Prognosis and microRNA Expression||Fudan University|Yes|Recruiting|October 2013|||December 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634502||6597|
NCT02629744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29503|A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants|A PHASE 1, OPEN-LABEL, SINGLE-ARM STUDY In HEALTHY SUBJECTS To EVALUATE PAIN, TOLERABILITY, SAFETY, And USABILITY Of A PREFILLED AUTOINJECTOR To SELF-ADMINISTER ETROLIZUMAB SUBCUTANEOUSLY||Genentech, Inc.||Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02629744||6962|
NCT02629757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSNO2015001|A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment|A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment|β-elemene|Sun Yat-sen University|No|Recruiting|April 2015|May 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629757||6961|
NCT02630875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlbireoPharma|A4250, an IBAT Inhibitor in Pediatric Cholestasis|An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus||Albireo|Yes|Recruiting|August 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|24|||Both|1 Year|18 Years|No|||December 2015|December 14, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630875||6875|
NCT02630173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIDS/IEC/2014/111|Evaluation of Endodontic Status on Periodontal Healing of Concomitant Endodontic Periodontal Lesions|Evaluation of Endodontic Status on Periodontal Healing of Concomitant Endodontic Periodontal Lesions||Postgraduate Institute of Dental Sciences Rohtak|Yes|Completed|May 2014|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630173||6929|
NCT02635815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|699|Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension|Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension||Ain Shams University|Yes|Completed|January 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|N/A|N/A|No|Probability Sample|Egyptian patients with non-cirrhotic portal hypertension (NCPH) with oesophageal varices,        presenting with or without variceal bleeding|March 2016|March 2, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635815||6497|
NCT02635893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150605|Lower Limb Function After Spinal Cord Injury|Corticospinal Excitability of Leg Muscles After Spinal Cord Injury||University of Miami|No|Recruiting|October 2015|October 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|257|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635893||6491|
NCT02643706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qiluexcellentyouth|Relationship Between ALDH2 and CIN|Relationship Between the Gene Polymorphism of Aldehyde Dehydrogenase 2 and Contrast Induced Nephropathy|REACTION|Qilu Hospital|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|5 ml vein blood samples were collected from peripheral vein before coronary angiography or      percutaneous coronary intervention.The blood is used to detecte the renal function , the      genotype of aldehyde dehydrogenase 2 and aldehyde dehydrogenase activity. Another 5 ml vein      blood samples were collected from peripheral vein to detecte the renal function 24-72 hours      after the surgery. The samples would be centrifuged and saved in a -80℃ ultra-low      temperature refrigerator.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective coronary intervention or coronary angiography in Qilu        hospital from December 2015 to December 2016|December 2015|December 28, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02643706||5890|
NCT02631096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARB-001467-002|Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy|A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy||Arbutus Biopharma Corporation|Yes|Recruiting|December 2015|July 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02631096||6858|
NCT02629900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107401|The Effect of Time Restricted Feeding on Fat Mass in Overweight Women|The Effect of Time Restricted Feeding on Fat Mass in Overweight Women||University of Western Ontario, Canada|Yes|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629900||6950|
NCT02629913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mementor somnium|Is Internet-based Self-help Effective for the Treatment of Insomnia Disorder?|||University of Zurich||Not yet recruiting|January 2016|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629913||6949|
NCT02637882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ghada 021|The Effect of Applying Multidisciplinary Bundle Intervention on the Delirium Incidence in Critically Ill Patients|The Effect of Applying Multidisciplinary Bundle Intervention on the Delirium Incidence in Critically Ill Patients|Ghada|Assiut University|Yes|Enrolling by invitation|December 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|50|||Both|18 Years|60 Years|No|||December 2015|December 20, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637882||6338|
NCT02631746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02126|Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma|Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|June 2016|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|March 18, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631746||6808|
NCT02644031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7203|Evaluation of Post-endodontic Pain After Root Canal Treatment With Two Rotary Systems : Mtwo & Safe-sider|Evaluation of Post-endodontic Pain After Root Canal Treatment With Two Rotary Systems : Mtwo & Safe-sider||Zahedan University of Medical Sciences|Yes|Recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644031||5865|
NCT02644044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0166-15-TLV|Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study|Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study|ITMTXPMS|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02644044||5864|
NCT02640560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2012|One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish|One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|200|||Both|1 Year|14 Years|No|Non-Probability Sample|200 Italian children with or without food allergy|December 2015|December 23, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02640560||6132|
NCT02631109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-DEP-EBV-HLH|L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis|L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis||Beijing Friendship Hospital|Yes|Recruiting|December 2015|November 2019|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|75 Years|No|||December 2015|December 11, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02631109||6857|
NCT02631161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHyComp|Glass Hybrid Versus Composite Restorations of Non-carious Cervical Lesions|Randomized Controlled Trial on Glass Hybrid Versus Composite Restorations of Non-carious Cervical Lesions||Charite University, Berlin, Germany|No|Recruiting|November 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02631161||6853|
NCT02391155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA13/161|Follicular Flushing Outcomes in Singles Versus Double Lumen Oocyte Retrieval Needles in Poor Responding Patients|Follicular Flushing Outcomes in Singles Versus Double Lumen Oocyte Retrieval Needles in Poor Responding Patients:a Randomized Controlled Trial|needles(opu)|Baskent University|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|80|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|November 9, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02391155||25279|
NCT02636517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010531|Fecal Microbiome Transplant|Fecal Microbiome Transplant in Pediatric C. Difficile||Children's Hospital of Philadelphia|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|21 Years|No|||December 2015|December 21, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636517||6443|
NCT02631850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0151|Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation|Comparative Effectiveness of a Low-Cost Virtual Reality Gaming Platform for Neurorehabilitation of Hemiparesis||Ohio State University|No|Recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02631850||6800|
NCT02631863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDZJALA-201510|Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)|A Pilot Study of Photodynamic Therapy (PDT) Using Aminolaevulinic Acid (ALA) in Patients With HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Recruiting|February 2016|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|25 Years|50 Years|No|||February 2016|February 15, 2016|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02631863||6799|
NCT02637284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPK-1A/B-1.3|PCO-02 - Safety and Pharmacokinetics Trial|Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source.||PharmaCotherapia d.o.o.|No|Active, not recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|8||Anticipated|42|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|December 17, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637284||6384|
NCT02636712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1913|Observation of ImageReady™ MR Conditional Pacing System in China|Observation of ImageReady™ MR Conditional Pacing System in China||Boston Scientific Corporation|No|Recruiting|December 2015|November 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects included in the MR China Study should be selected from the investigator's general        patient population indicated for single or dual chamber pacemaker implantation.|December 2015|December 22, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02636712||6428|
NCT02643238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111009|Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation|Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation|BrainPort|Akron Children's Hospital|No|Recruiting|October 2011|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|10 Years|24 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643238||5926|
NCT02632188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-005|Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma|A Controlled Clinic Trial to Survey the Outcome of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Treating Patients Underwent Radical Surgery for Hepatocellular Carcinoma||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|December 30, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632188||6775|
NCT02392312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG-MA-ACN001|Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients|Safety and Efficacy of Individual Batches of ATG-F in Kidney Transplant Recipients: Multicentre, Prospective, Observational Study||Astellas Pharma Inc|No|Recruiting|January 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1440|||Both|18 Years|N/A|No|Non-Probability Sample|Governmental Hospital|February 2016|February 16, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392312||25191|
NCT02636725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150932|Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas|A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)||University of Miami|Yes|Not yet recruiting|March 2016|||March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||December 2015|December 17, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636725||6427|
NCT02637440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA 2015|The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI|Multi Centre Open Label Randomised Controlled Parallel-group Three Arm Trial To Compare The Use Of Fractional Flow Reserve (FFR) Guided and Angiographically Guided Revascularization To The Treatment Of Infarct Related Artery Only In Patients With STEMI And Multivessel Disease|FAIO|University of Limerick|Yes|Not yet recruiting|December 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|560|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637440||6372|
NCT02632435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-089|Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.|A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).|OTT 15-06|Ottawa Hospital Research Institute|No|Not yet recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|19 Years|N/A|No|||December 2015|December 22, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02632435||6756|
NCT02632448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPS-001|A Study of LY2880070 in Patients With Advanced or Metastatic Cancer|A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer||Esperas Pharma Inc.|No|Not yet recruiting|April 2016|April 2020|Anticipated|April 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|93|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632448||6755|
NCT02632643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B707201525923|Assessment of the Efficacy of a Sensorimotor Approach After Three Sessions in Subjects With TMD With Hypertonia|Assessment of the Efficacy of a Sensorimotor Approach After Three Sessions in Subjects With Symptomatic Temporomandibular Dysfunction (TMD) With Hypertonia: A Prospective, Multicenter Case Study.||Osteovox|No|Recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|77 Years|Accepts Healthy Volunteers|||January 2016|January 16, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02632643||6740|
NCT02392351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2333|Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)|A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE||Boston Scientific Corporation|Yes|Recruiting|April 2015|May 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392351||25188|
NCT02392364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-CRC|Variable Interval Versus Set Interval Aflibercept for DME|Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)|EVADE|California Retina Consultants|No|Recruiting|March 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392364||25187|
NCT02630277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELYSIAN|Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN|Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)|ELYSIAN|Valley Retina Institute|No|Not yet recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630277||6921|
NCT02632409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-274|A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma|A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)|CheckMate 274|Bristol-Myers Squibb|Yes|Recruiting|February 2016|October 2020|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632409||6758|
NCT02637466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150753|Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers|A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer.||University of Miami|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|75 Years|No|||December 2015|December 23, 2015|December 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02637466||6370|
NCT02640547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-767|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C|Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)||AbbVie|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|||Both|18 Years|99 Years|No|Non-Probability Sample|Chronic Hepatitis C (CHC)|January 2016|January 13, 2016|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02640547||6133|
NCT02635867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1163|Clinical Comparison of Vital Pulp Capping Restorative Protocols|Clinical Comparison of Vital Pulp Capping Restorative Protocols: A Randomized Controlled Double-Blind, Prospective Study||University of Illinois at Chicago||Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|150|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635867||6493|
NCT02635880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-15-EN08|A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal|A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal||Cutera Inc.|No|Active, not recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635880||6492|
NCT02634593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140825002|The Snack Study: The Feasibility of Changing Night-time Food Choices to Improve Glucose Tolerance in Pregnancy|The Snack Study: The Feasibility of Changing Night-time Food Choices to Improve Glucose Tolerance in Pregnancy||University of Alabama at Birmingham|No|Not yet recruiting|February 2016|December 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|16 Years|45 Years|No|||December 2015|December 15, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02634593||6590|
NCT02633553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508151-4|Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection|An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection||Fudan University|Yes|Recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633553||6670|
NCT02629302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-153|Effects of Animal Assisted Therapy on Patients With Severe Disorders of Consciousness|Effects of Animal-assisted Therapy in Patients With Severe Disorders of Consciousness at REHAB Basel: a Randomised-controlled Trial||Swiss Tropical & Public Health Institute|No|Not yet recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629302||6996|
NCT02392715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/15|Inspiratory Muscle Training Combined With General Exercise Training in COPD|Inspiratory Muscle Training Combined With General Exercise Training, Compared to General Exercise Training Alone in Patients With COPD: Randomized Controlled Trial|IMTGET|Hôpital Riviera-Chablais, Vaud-Valais|No|Not yet recruiting|April 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||March 2015|March 27, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392715||25160|
NCT02643407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1501|Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer|Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study||Guangdong Association of Clinical Trials|Yes|Recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|488|||Both|18 Years|75 Years|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643407||5913|
NCT02630355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-15-091|Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury|Randomized Controlled Trial of Remote Ischaemic Preconditioning to Protect Against Dialysis Induced Cardiac Injury in Haemodialysis: Low Vs. High Intensity||Western University, Canada|No|Not yet recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02630355||6915|
NCT02642172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN-837|Prebiotics in Patients With Non-alcoholic Liver Disease|A Randomized, Double - Blind Study With Two Parallel Arms for 4 Months (20 Weeks), Evaluating the Effectiveness of the Prebiotics in Patients With Non-alcoholic Liver Disease.||Kaplan Medical Center|No|Not yet recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02642172||6008|
NCT02381808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG1502|Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China|Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China||Guangdong Association of Clinical Trials|Yes|Recruiting|December 2014|August 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Frozen tissue or tissue block|Both|18 Years|N/A|No|Non-Probability Sample|NSCLC (SageI-IV)|March 2015|March 5, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381808||25998|
NCT02638636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2015/1528-31/1|Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.|Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.||Karolinska Institutet|No|Recruiting|December 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|100 Years|No|||December 2015|December 22, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02638636||6280|
NCT02642861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muscle cramps treatment|Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis|Cyclobenzaprine Treatment for Muscle Cramps in Cirrhotic Patients||Tanta University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||December 2015|December 29, 2015|December 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642861||5955|
NCT02634190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aptima Study|Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens|Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HPV HC2® Test in Women 30 Years of Age or Older Using LBC ThinPrep® Pap Test Specimens||Hologic Deutschland GmbH|No|Active, not recruiting|June 2009|June 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|10000|Samples With DNA|liquid based cytology LBC Specimens (ThinPrep® Pap Test)|Female|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Women 30 years of age or older coming for routine cervical screening are enrolled in        gynaecological practices.|December 2015|December 15, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02634190||6621|
NCT02377505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ECP-2013-20|Deep Brain Stimulation in Treatment Resistant Schizophrenia|Deep Brain Stimulation in Treatment Resistant Schizophrenia: Randomized, Controlled, Crossover Pilot Study|DBS-SCHIZO|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|55 Years|No|||September 2015|September 16, 2015|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377505||26329|
NCT02377518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5601|DECT Ventilation Imaging|Quantitative Ventilation Imaging With Dual Energy Computed Tomography||University Hospital, Strasbourg, France|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|85 Years|No|||August 2015|August 6, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377518||26328|
NCT02631278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4962/14|Radio Frequency Ablation (RFA STUDY )|Tissue Effect in Extirpated Uterine Fibroid Tissue Using Existing Olympus Radiofrequency Probes for Fibroids Ablation (Radio Frequency Ablation RFA STUDY )|RFA|Catholic University of the Sacred Heart|Yes|Recruiting|December 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Female|25 Years|70 Years|No|||December 2015|December 11, 2015|January 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631278||6844|
NCT02639065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCRC-ESO14-012|A Study of Durvalumab (MEDI4736) in Esophageal Cancer|A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012||Big Ten Cancer Research Consortium|Yes|Not yet recruiting|February 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639065||6247|
NCT02642796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/34|Transcutaneous Nerve Stimulation for Post-operative Acute and Chronic Pain|Comparison of the Efficacy of Two Different Transcutaneous Electrical Nerve Stimulation Application Sites in Reducing Postoperative Pain After Hip Fracture Surgery||Mustafa Kemal University|Yes|Recruiting|March 2013|March 2018|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|120|||Both|19 Years|N/A|No|||February 2016|February 4, 2016|December 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02642796||5960|
NCT02636335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEXI-MO|Light, Exercise Intensity and Mood in Overweight|Light, Exercise Intensity and Mood in Overweight|LEXI-MO|University of Basel|No|Not yet recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02636335||6457|
NCT02638740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCIndore|To Study the Beneficial Effect of Mustard Oil and Salt Massaging With Oral Prophylaxis in Patients With Gum Diseases|To Assess the Efficacy of Mustard Oil and Salt Massage as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis: A Clinical Study||Government College of Dentistry, Indore|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|28 Years|65 Years|No|||February 2016|February 12, 2016|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02638740||6272|
NCT02300935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MEL 40|Study of Trametinib and Nab-paclitaxel in Patients With Melanoma|Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma||SCRI Development Innovations, LLC|No|Withdrawn|January 2016|November 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 21, 2014|No|Yes|Study concept was terminated.|No||https://clinicaltrials.gov/show/NCT02300935||32197|
NCT02302027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCUC|Feasibility Study of Normobaric Oxygen Delivered by a High Flow Concentrator in the Treatment of Chronic Headache|Feasibility Study of Normobaric Oxygen Delivered by a High Flow Concentrator in the Treatment of Chronic Headache With or Without Abuse of Painkillers|O214|Association pour la Recherche au Centre d'Urgence des Céphalées|No|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02302027||32113|
NCT02309125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|immediate_early_loading|Comparing the Secondary Stability of Dental Implants: Immediate Gradual Loading Versus Early Loading Protocol in Posterior Maxilla|Split Mouth Clinical Study to Compare the Secondary Stability of Dental Implants Using Immediate Gradual Loading Versus Early Loading Protocol in Posterior Maxilla. A Randomized Controlled Trial||Cairo University|Yes|Recruiting|December 2014|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|10|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||November 2014|December 4, 2014|December 3, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02309125||31569|
NCT02312388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1303-113-478|Comparison of the Central Venous Catheter Insertion Techniques|Comparison of the Central Venous Catheter Insertion Techniques: the Thin-wall Needle Versus the Catheter-over-the-needle Technique in Children||Seoul National University Hospital|No|Completed|July 2013|May 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|138|||Both|N/A|5 Years|No|||December 2014|December 8, 2014|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02312388||31318|
NCT02312648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICID|Impact of Mobilization on Cardiac Surgery|Impact of an Early Mobilization Program on Functional Capacity After Coronary Artery Bypass Surgery: a Protocol of Randomized Controlled Trial.||Universidade Cidade de Sao Paulo|No|Not yet recruiting|January 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|21 Years|90 Years|No|||December 2014|December 8, 2014|November 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02312648||31298|
NCT02297438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481027|A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]|A Multicenter, Randomized, Double-Blind Phase 3 Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With ER (+), HER2 (-) Advanced Breast Cancer||Pfizer|Yes|Recruiting|March 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Female|18 Years|70 Years|No|||March 2016|March 3, 2016|November 19, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02297438||32466|
NCT02294370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Botnia012014|Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring|Glucose Excursions at Early Stages of Diabetes, MOSAIC Prospective Study||Folkhälsan Researech Center|No|Completed|December 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|Samples With DNA|serum, plasma, urine|Both|40 Years|75 Years|No|Non-Probability Sample|Individuals with impaired glucose tolerance (2h plasma glucose during oral glucose        tolerance test >7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose >        7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria        fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short        duration (<3 years); 40 from Padova University Hospital, 60 from the Botnia Study or the        PPP-Botnia Study in Finland. The Botnia Study and the PPP-Botnia Study are population        based studies investigating type 2 diabetes in western Finland.|March 2016|March 11, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02294370||32701|
NCT02318381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSachinisPhD1|Suprascapular Neuropathy in the Setting of Rotator Cuff Tears: Results of Arthroscopic Treatment|Suprascapular Neuropathy in the Setting of Rotator Cuff Tears; Results of Arthroscopic Treatment|SupraCufTear|Aristotle University Of Thessaloniki|No|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02318381||30858|
NCT02320981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 140987|Mucosal Impedance in Pediatric Population|Assessment of Esophageal Epithelium Integrity With Mucosal Impedance in Pediatric Patients||Vanderbilt University|Yes|Recruiting|August 2014|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|198|||Both|1 Year|18 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric patients of our Vanderbilt Pediatric Gastroenterology Clinic undergoing routine        evaluation of dyspepsia with endoscopy that meet the inclusion/exclusion criteria as        defined above.|December 2015|January 19, 2016|July 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02320981||30659|
NCT02293226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETI/2014/19|Video-laryngoscopy During Chest Compression|Comparison of Four Video-laryngoscopes During Pediatric Intubation During Simulated Resuscitation|VIDEO|International Institute of Rescue Research and Education|Yes|Not yet recruiting|November 2014|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293226||32789|
NCT02293239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS Tumor 01|Effects of WB-EMS and Dietetic Treatment on Cancer Patients|Effects of Whole Body Electromyostimulation (WB-EMS) and Dietetic Treatment on Patients With Malignant Disease in a Curative or Palliative Treatment Situation||University of Erlangen-Nürnberg Medical School|No|Recruiting|August 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02293239||32788|
NCT02309112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTREC 534-14|Yoga in Adult Cancer: A Feasibility Trial|Yoga for Health-related Quality of Life in Adult Cancer: A Randomized Controlled Feasibility Trial|Y-ACT|University of Oxford|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|15|||Both|19 Years|N/A|No|||November 2014|February 9, 2015|November 21, 2014||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT02309112||31570|As a feasibility study, the sample size is underpowered and quantitative results are unreliable.
NCT02314689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-124700.|A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease|||University of Mississippi Medical Center|Yes|Completed|January 2015|||December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|25 Years|No|||March 2016|March 7, 2016|December 5, 2014|No|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02314689||31142|
NCT02314910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAI_040413|Bone Innervation Around Implants|Exploring Bone Innervation Around Osseointegrated Implants||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2013|July 2018|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Implant surrounded by bone material|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of which the implant needed to be removed|April 2013|December 10, 2015|April 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02314910|5 Years|31125|
NCT02643004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-62|The Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses|The Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses||Coopervision, Inc.|No|Recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643004||5944|
NCT02643017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0621|Effect of Dexmedetomidine on Postoperative Cognitive Function in Patients Undergoing Shoulder Arthroscopy With Beach Chair Position Under Desflurane Anesthesia|||Yonsei University|No|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02643017||5943|
NCT02385968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140085|Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR|Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR||Sygehus Lillebaelt|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Biopsies of Nucleus|Both|18 Years|65 Years|No|Probability Sample|Patient with MRI-confirmed lumbar disc herniation. Lumbar disc herniation. Age between 18        and 65 years. No prior spine surgery. No diagnosed dementia.|March 2015|March 10, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02385968||25678|
NCT02385981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASOKLIF 1301/PA|Vagal-stimulation-PAVK-tcpO2-study|Clinical Study to Review the Effects of an Auricular and Percutaneous Electric Stimulation of Nervus Vagus on the Oxygen Supply of Skin of Patients With Severe Claudicatio Intermittens||Payrits, Thomas, M.D.|Yes|Recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02385981||25677|
NCT02635789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-12G-1|Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)|A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex||Nobelpharma|No|Not yet recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|N/A|No|||December 2015|December 21, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02635789||6499|
NCT02639923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wolf-7|The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury|The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury A Pilot Study|mRNA|Medical University of Vienna|No|Recruiting|January 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|7ml serum are drawn from peripheral blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We plan to include 60 patients with minor head injury (MHI) GCS 13-15 admitted to our        hospital within one year (1-2 each week).|January 2016|January 14, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02639923||6181|
NCT02634671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01247- 42|Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome|Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation|FaSchi22|Hôpital le Vinatier|Yes|Active, not recruiting|November 2015|November 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||December 2015|January 13, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634671||6584|
NCT02386267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ru0001|L-leucine in Diamond Blackfan Anemia Patients|Therapeutic Use of the Amino Acid Leucine in the Treatment of Transfusion-Dependent Diamond Blackfan Anemia Patients||Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache|No|Recruiting|September 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|20 Years|No|||March 2015|March 5, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02386267||25655|
NCT02386280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMTEPA|Prevention of Drug Use in Adolescence: Intervening in Parenting Styles|Prevention of Drug Use in Adolescence: Intervening in Parenting Styles||Federal University of Health Science of Porto Alegre|Yes|Recruiting|August 2014|March 2016|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02386280||25654|
NCT02636738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7110|Vela China Study: in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population|A Prospective, Multicenter, Single-arm, Non-controlled Study to Evaluate The Safety and Utility of VelaTM XL Thulium Laser in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population||Boston Scientific Corporation|No|Not yet recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||October 2015|December 17, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02636738||6426|
NCT02641665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016001|Plasma Biomarkers in Cardiac Valve Surgery|Measurement of Four Plasma Biomarkers for Risk Stratification and Determination of Functional Recovery After Cardiac Valve Surgery||University Hospital of Liege|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Arterial blood|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing elective or urgent cardiac valve surgery in isolation of in        combination with CABG.|December 2015|December 22, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641665||6047|
NCT02641678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRACK-AF|Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.|Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.|TRACK-AF|University Hospital Muenster|No|Completed|March 2013|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stroke of unknown etiology|January 2016|January 20, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641678||6046|
NCT02643095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015W0197|Efficacy of Scleral Contact Lenses for Daily Wear for Regular and Irregular Refractive Errors Compared to Habitually Worn Scleral Lenses|||Ohio State University||Not yet recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643095||5937|
NCT02637583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2014-004013-85|Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels|Sequential Versus Simultaneous Vaccination With Pneumococcal Conjugate Vaccine (Prevenar 13) and Pneumococcal Polysaccharide Vaccine (Pneumovax 23) in Elderly: Immunological Memory and Antibody Levels||Jena University Hospital|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|74|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02637583||6361|
NCT02633761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1019|Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death|Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial||Gynuity Health Projects|Yes|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02633761||6654|
NCT02634060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58392|Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny|Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny|HELP-AID|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|January 2016|January 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634060||6631|
NCT02635100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00605|Multinight CPAP for Sleep Apnea Patients|Evaluation of a Multinight (MNT) CPAP Titration Algorithm in Patients With Sleep Apnea.||New York University School of Medicine|No|Recruiting|May 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635100||6551|
NCT02636465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_105/2013|Hypoxia in Flight Simulation in Obese Patients|Hypoxia in Flight Simulation in Obese Patients||Wissenschaftliches Institut Bethanien e.V|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|21|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|obese (BMI>30 kg/m2) healthy adults, obese patients with obesity hypoventilation Syndrome,        obese patients with COPD|November 2015|December 16, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02636465||6447|
NCT02630446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E/01447/15|An In-home Respite Care Program to Support Informal Caregivers of People With Dementia|Effectiveness and Cost-effectiveness of an In-home Respite Care Program to Support Informal Caregivers of People With Dementia: a Comparative Study||University Ghent|No|Recruiting|January 2016|February 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|372|||Both|N/A|N/A|No|||February 2016|February 18, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02630446||6908|
NCT02638376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R963/72/2012|Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus|A Study Evaluating the Safety and Efficacy of the KXL System With vibeX Rapid (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes Having Keratoconus and Post LASIK Ectasia||Singapore Eye Research Institute|No|Recruiting|March 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02638376||6300|
NCT02630030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083003|Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma|Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma||Emory University|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|3|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630030||6940|
NCT02630043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC011|Trial of Tolcapone With Oxaliplatin for Neuroblastoma or Medulloblastoma|A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma or Medulloblastoma||Spectrum Health Hospitals|Yes|Recruiting|December 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|N/A|21 Years|No|||December 2015|December 14, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630043||6939|
NCT02636478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_23/2013|Travelling in Patients With Sleep Related Breathing Disorders|Travel Activities in Patients With Sleep Related Breathing Disorders||Wissenschaftliches Institut Bethanien e.V|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|345|||Both|18 Years|80 Years|No|Probability Sample|patients with sleep related breathing disorder|December 2015|December 18, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02636478||6446|
NCT02644486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1406|A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy|||Nanjing University School of Medicine||Not yet recruiting|January 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644486||5830|
NCT02630953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seamos Activas|Culturally and Linguistically Adapted Physical Activity Intervention for Latinas|Culturally and Linguistically Adapted Physical Activity Intervention for Latinas||University of California, San Diego|Yes|Recruiting|December 2015|||August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630953||6869|
NCT02630966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vedolizumab-4003|Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease|A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Efficacy of 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease|ENTERPRISE|Takeda|No|Not yet recruiting|January 2016|August 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630966||6868|
NCT02635906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49068315.0.0000.5505|Reduced in Bed Rest After Coronary Arteriography or Coronary Angioplasty|Effectiveness of Reduced in Bed Rest After Coronary Arteriography or Coronary Angioplasty in Patients With Acute Coronary Syndrome: 4 Hours Versus 2 h.Clinical Trial||Federal University of São Paulo|No|Not yet recruiting|March 2016|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|296|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02635906||6490|
NCT02635997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catholic University|Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America|Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America||Pontifical Catholic University of Argentina|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|425|||Female|21 Years|N/A|No|Non-Probability Sample|Postmenopausal women with a diagnosis of osteoporosis o with a high risk of developing it        in the near future.|December 2015|December 16, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02635997||6483|
NCT02629770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZR_2014-3|Clindamycin-rifampin Drug Interaction in the Treatment of Bone and Joint Infections|Clindamycin-Rifampin Interactions: Effect of Rifampin's Enzyme-induction (Cytochrome P450 3A4/3A5) on Plasma Clindamycin Concentrations, With Clindamycin Given Intravenously and Orally to Treat Bone-and-joint Infections|CLIRIFA|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|December 2015|||November 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|patients hospitalized for medical-surgical management of OAIs in the Department of Trauma        and Bone Surgery|December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629770||6960|
NCT02631356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[22]|The Effect of Succinylated Gelatin on the Blood Viscosity and Oxygen Delivery|||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|November 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02631356||6838|
NCT02377739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV-ILD|Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study|Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Recruiting|February 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||February 2015|March 3, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377739||26311|
NCT02377752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15678|A Study of Olaratumab in Japanese Participants With Advanced Cancer|A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors||Eli Lilly and Company|Yes|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02377752||26310|
NCT02638948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM006-016|Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis|Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors||Bristol-Myers Squibb|Yes|Recruiting|February 2016|July 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|408|||Both|18 Years|120 Years|No|||February 2016|March 11, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638948||6256|
NCT02636972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPAI-001|The Progression From Dysmenorrhoea to Chronic Pelvic Pain|The Progression From Dysmenorrhoea to Chronic Pelvic Pain: Investigation of the Role of Chronic Inflammatory Pain Phenotype in Peripheral Blood as a Potential Biomarker.||University of Adelaide|No|Active, not recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||7|Anticipated|56|Samples With DNA|Blood sample retained for future analysis (may include DNA analysis)|Female|16 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Nulliparous women in good general health (can experience dysmenorrhoea (abscent, mild or        severe), with or without pelvic pain and with or without contraceptive pill use)|December 2015|December 21, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02636972||6408|
NCT02640586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNTRRC-MRI|Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI|Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI||Beijing Cancer Hospital|Yes|Not yet recruiting|February 2016|December 2020|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02640586||6130|
NCT02635386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP15-008|DAPA, EQW, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)|Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women||Woman's|Yes|Recruiting|March 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|135|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635386||6530|
NCT02379117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15005|Eating Behaviour in Crohn's Disease|Eating Behaviour in Crohn's Disease||University of Nottingham|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|16 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment        The chief investigator is a specialist in Inflammatory Bowel disease and also an associate        professor of gastroenterology at the University of Nottingham and Nottingham University        Hospital which is a tertiary-level care academic institution covering a population of        approximately 1 million people for secondary-level care and 4.5 million people for        tertiary-level care. Collectively we manage approximately 4000 IBD patients.        Participants shall be recruited from two sources:          1. Crohn's Disease patients from clinic.          2. Crohns Disease patients and Healthy Volunteers via the study flyer and social media.|December 2015|December 8, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379117||26205|
NCT02639169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26404414.9.0000.0096|Music Therapy Improves the Mood of Patients Undergoing Hematopoietic Stem Cells Transplantation|The Impact of Music Therapy on Mood Control in Hospitalized Patients for Transplantation of Hematopoietic Stem Cells|MTHSCT|Universidade Federal do Paraná|Yes|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|65 Years|No|||December 2015|February 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02639169||6239|
NCT02639182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-16C3F-15-3|A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma|A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma||Astellas Pharma Inc|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639182||6238|
NCT02632110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0112|Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face|A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy With Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratoses on the Face||DUSA Pharmaceuticals, Inc.|No|Recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|125|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632110||6781|
NCT02637505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2202|Norwegian Cartilage Project - Microfracture|Focal Cartilage Defects in the Knee - A Randomized Controlled Trial Comparing Arthroscopic Microfracture With Arthroscopic Debridement||University Hospital, Akershus|Yes|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|50 Years|No|||January 2016|January 21, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637505||6367|
NCT02379377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 14124|18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant|PET Imaging of Hepatocellular Carcinoma With 18F-FSPG||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|March 2015|March 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379377||26185|
NCT02639832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-15-0060|A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Previously Treated Non-metastatic Triple Negative Breast Cancer|||Cynvenio Biosystems||Recruiting|December 2015|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|N/A|No|Non-Probability Sample|Previously Treated Non-metastatic Triple Negative Breast Cancer.|December 2015|December 21, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02639832||6188|
NCT02639845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDIT Phase I|Eye Drop Application Monitor, Pilot Study|A Novel Eye Drop Application Monitor to Assess Patient Compliance With a Prescribed Regimen||Retina Health Center|No|Recruiting|November 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who are scheduled to receive prescription eye drops, one of which must be applied        at least once a day.|December 2015|December 24, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02639845||6187|
NCT02642068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401024RINC|Neuropsychology, Neuroimage and Neurophysiology in Adults With ADHD|Neuropsychology, Neuroimage and Neurophysiology in Adults With Attention-Deficit Hyperactivity Disorder: An Endophenotype and Follow-up Study||National Taiwan University Hospital|Yes|Recruiting|August 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|300|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments|Both|16 Years|30 Years|No|Non-Probability Sample|This 5-year proposal consists of two parts: (1) a 3-year case-control study with        unaffected siblings and adult neurotypicals as controls to investigate the brain        structural connectivity, functional connectivity, neurophysiological, neuropsychological        functioning in 60 probands with ADHD, their unaffected siblings (at least 30 same-sex        siblings, n=30~60) and age-, sex-, handedness-, and IQ-matched neurotypicals (n=90~120)        with estimated total sample size as at least 180 up to 240. (2) a 2-year follow-up study        to repeat the neuropsychological and MRI assessments and to assess electrophysiology        related to inhibition controls of 40 adolescents and young adults with childhood diagnosis        of ADHD and 40 neurotypicals who had same neuropsychological and imaging assessments in        2010.8-1013.7.|December 2015|December 24, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02642068||6016|
NCT02637765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO 121|Life ImproVed by Exercise (LIVE Trial)|Effect of a Short Program (8 Week) of Increased Physical Activity on Quality of Life of Sedentary Women With Previous Breast Cancer. A Prospective Randomized Trial.|LIVE|European Institute of Oncology|No|Recruiting|July 2014|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Female|18 Years|70 Years|No|||December 2015|December 17, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02637765||6347|
NCT02640768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOParma|Governance of Diabetes Management in Non-specialistic Hospital Settings|Governance of Diabetes Management in Non-specialistic Hospital Settings||Azienda Ospedaliero-Universitaria di Parma|No|Completed|January 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1449|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02640768||6116|
NCT02379624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSF81270884|Pectin Start Early Enteral Nutritional Support in Critically Ill Patients|Pectin Start Early Enteral Nutritional Support in Critically Ill Patients||Nanjing University|Yes|Completed|August 2014|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||February 2015|March 4, 2015|August 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379624||26166|
NCT02379637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2160-A-201|Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple-Dose, Proof-of-Concept Study to Evaluate the Efficacy of N-acetylcysteine Capsules in the Treatment of the Common Cold (Viral URTI) Associated With Cough in an Adult Population|NAC cold cough|Novartis|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||April 2015|April 2, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379637||26165|
NCT02634294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai1st|Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT|Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|No|Recruiting|August 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|14 Years|60 Years|No|||December 2015|December 15, 2015|December 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634294||6613|
NCT02637479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-51|Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery|Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery: A Multicenter, Prospective, Randomized Study|Hyporadoul|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02637479||6369|
NCT02640625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2015/2125|Improving Prognosis in HIV Infection|Adjuvant Mucosal Therapy in HIV-infected Men With Insufficient Response to Antiretroviral Therapy||Oslo University Hospital|No|Enrolling by invitation|January 2016|December 2020|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640625||6127|
NCT02638220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018CTXX15001|Cerebrotendinous Xanthomatosis (CTX) Prevalence Study|An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed With Early-Onset Idiopathic Bilateral Cataracts||Retrophin, Inc.|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|||Both|2 Years|21 Years|No|Probability Sample|Early-Onset Idiopathic Bilateral Cataracts|January 2016|February 29, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02638220||6312|
NCT02638350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7423 15|Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient|Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient Over 65 Years, Admitted to a Host of Vital Emergency Services|ECHOP|University Hospital, Toulouse|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|123|||Both|65 Years|N/A|No|||December 2015|December 17, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02638350||6302|
NCT02638298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028423|Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds|Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds. A Prospective Randomized Clinical Trial||Medical University of South Carolina|Yes|Recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638298||6306|
NCT02638571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULSE-HEW|Evaluation Nutrition Education Intervention on Pulse and Cereal Mix for Complementary Food in Southern Ethiopia|Evaluation of the Effectiveness of Nutrition Education Intervention Among Rural Mothers on Pulse and Cereal Mix Complementary Food and Nutritional Status of Children Age 6-24 Months in Sidama Zone, Southern Ethiopia||University of Saskatchewan|No|Not yet recruiting|January 2016|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|766|||Both|6 Months|15 Months|Accepts Healthy Volunteers|||January 2016|February 16, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02638571||6285|
NCT02633605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSM-002|Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results|Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results||First Sense Medical, LLC|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633605||6666|
NCT02393430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH 0123|Clinical Effect of Rebamipide on Chronic Gastritis|Clinical Effect of Rebamipide on Chronic Gastritis||Tianjin Medical University General Hospital|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|N/A|N/A|No|||March 2015|March 15, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02393430||25105|
NCT02376946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10436|Third Molar Extraction and Pulsed Electromagnetic FieldTherapy|Evaluation of Postoperative Edema and Pain Following Third Molar Extraction With Application of Pulsed Electromagnetic Field (PEMF) Therapy|PEMF|Tufts University School of Dental Medicine|No|Recruiting|January 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2015|March 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02376946||26372|
NCT02630797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB2015|Effect of Blueberries on Bone Turnover|Berries and Bones:The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover||Purdue University|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|22|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630797||6881|
NCT02633826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pre-formed alloreactivity|Pre-formed Alloreactivity in Renal Transplant Recipients|The Role of Pre-formed Alloreactive T Cells on Acute Rejection Episodes and Long-term Graft Outcome in Patients After Living Donor Renal Transplantation||Saarland University|No|Recruiting|November 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Transplant recipients of a kidney from a living donor|December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633826||6649|
NCT02642224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN2013-67786|Trauma Services Intervention to Prevent Violence|Trauma Services Intervention to Prevent Violence|TSI|University of Pittsburgh|Yes|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|60 Years|No|||December 2015|December 29, 2015|December 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02642224||6004|
NCT02636101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-DAIVOBETGEL-1210|Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study|Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study|BODYGUARD|LEO Pharma|No|Recruiting|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with body psoriasis who (at their physician's discretion) are eligible        to receive topical treatment with calcipotriol/betamethasone gel|January 2016|January 19, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636101||6475|
NCT02436317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor12115ctil|Point of Care Ultrasonography|Influence of Point of Care Ultrasonography on Outcome of Inpatients Admitted To the Internal Ward||Soroka University Medical Center|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02436317||21813|
NCT02428465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33740|Purposeful Parenting: Enhanced Anticipatory Guidance for the First Year of Life|Purposeful Parenting: Enhanced Anticipatory Guidance for the First Year of Life||Boston Medical Center|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02428465||22415|
NCT02434900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAM1|Vitamin D and Angiogenic Markers in Odense Child Cohort 1|Vitamin D and Angiogenic Markers in Odense Child Cohort 1: A Prospective Cohort Study on Their Role in Early Pregnancy Adverse Outcome|VITAM|Odense University Hospital|Yes|Active, not recruiting|January 2010|December 2031|Anticipated|December 2031|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2874|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Odense Child Cohort Study (OCC) is a population-based cohort study, comprising        pregnant women recruited between January 1st 2010 and December 31st 2012. All women who        were pregnant in the municipality of Odense during this time were eligible for        participation, and 6,707 women were approached directly with recruitment material.        The study complied with the Helsinki declaration and was approved by the Regional        Scientific Ethical Committee for Southern Denmark, no. S-20090130. All participants gave        informed consent. From a population base of 6,70 pregnant women, 2,874 (42.9%) enrolled in        the OCC up to December 31st, 2012. The children will be followed until 18 years of age.|April 2015|May 5, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02434900|18 Years|21922|
NCT02440932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200130139|Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis|Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis||University of Glasgow|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02440932||21459|
NCT02486107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECD|Prospective Cohort Study of Outcome After Minimally Invasive Posterior Cervical Spine Surgery|Prospective Cohort Study of Outcome After Minimally Invasive Posterior Surgery (Posterior Percutaneous Endoscopic Foraminotomy or Tubular Retractor Assisted Micro-foraminotomy) for Single Level Cervical Foraminal Stenosis|PECD|Seoul National University Hospital|No|Recruiting|May 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|156|||Both|20 Years|80 Years|No|Probability Sample|Alpha = 0.05, Beta = 0.2, q1 = 0.5, effect size = 0.6 drop rate 12% 52 patients in each        group|November 2015|November 15, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486107||17989|
NCT02486354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-III01-V2|Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy|Safety and Efficacy of Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy: a Single-arm, Phase 3 Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Completed|March 2010|April 2012|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|75 Years|No|||June 2015|June 28, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02486354||17970|
NCT02439866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93222|Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy|The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial|NAION|hahid Beheshti University of Medical Sciences||Recruiting|February 2014|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|N/A|No|||January 2014|May 8, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439866||21541|
NCT02439918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-054|Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa|Epidemic History and Iatrogenic Transmission of Blood-borne Viruses||Université de Sherbrooke|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|839|Samples With DNA|Laboratory assays Dry blood spots were made from capillary blood deposited on Whatman 3      filter paper (serology) and Whatman Protein Saver Card (molecular biology). To document our      two main outcomes (HCV and HTLV-1 infections), serological assays were performed as detailed      in Web extra material, Appendix. For HCV, PCR amplification of the NS5b (485-nt) and core/E1      (1026-nt) genome regions was attempted on reactive samples. For HTLV-1, the gp21 env gene      was amplified (885-nt).|Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will attempt to recruit into this cross-sectional study participants aged 70 years or        more living in various districts of Kinshasa. According to countrywide demographic data,        1.4% of the Congolese population is aged 70 years or more.40 Assuming that the population        of Kinshasa is around 8 million, and that the proportion of elderly is similar to that of        the whole country, there could be within the capital approximately 112.000 residents aged        70 years or more. As we are interested in documenting the mechanisms of virus transmission        within the city itself, we will enrol only individuals who have lived in Kinshasa for at        least 35 years.|April 2015|May 6, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02439918||21537|
NCT02427477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5698|A Comparison of Two Daily Disposable Soft Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427477||22491|
NCT02443220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY20140704-3|Electroacupuncture in Reducing the Dose of Analgesic in Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Effects of Regional or Distant Combination of Acupoints Stimulated With Electroacupuncture on Patients Undergoing Off-pump Coronary Artery Bypass Grafting||Xijing Hospital|Yes|Completed|June 2014|June 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|186|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02443220||21283|
NCT02443233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-270|Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong|||The University of Hong Kong||Recruiting|January 2014|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|Maternal and paternal hepatitis B carrier|December 2015|December 1, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02443233||21282|
NCT02486627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-009|A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)|A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults||Achaogen, Inc.|Yes|Recruiting|January 2016|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486627||17949|
NCT02433379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91026550|Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction|Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction|UNTOUCHED|Boston Scientific Corporation|No|Recruiting|June 2015|June 2021|Anticipated|June 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|2015|||Both|21 Years|N/A|No|||January 2016|January 5, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02433379||22039|
NCT02404350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2342|Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)|FUTURE5|Novartis|No|Not yet recruiting|September 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|990|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02404350||24267|
NCT02404363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130936|Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy|A Phase III Multi-centre Double-blind Placebo Controlled Study Analysing the Efficacy and Safety of Daily Administration of a P2Y12 Inhibitor (Clopidogrel) for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer|PANCREADOGREL|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02404363||24266|
NCT02495896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-15-5|Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors|A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors||University of Southern California|Yes|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 6, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495896||17238|
NCT02496130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000230|Perioperative Outcomes of Common Methods of Minimally Invasive Contained Tissue Extraction|A Partners Prospective Study Assessing the Perioperative Outcomes of Common Methods of Minimally Invasive Contained Tissue Extraction||Brigham and Women's Hospital|No|Enrolling by invitation|August 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Female|18 Years|N/A|No|Non-Probability Sample|70 adult women scheduled to undergo a laparoscopic myomectomy or hysterectomy|July 2015|July 9, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496130||17220|
NCT02498301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-080|Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD|A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel||Uniformed Services University of the Health Sciences|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|375|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02498301||17054|
NCT02404337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130908|Betaine METABOLISM OF PATIENTS With Homocystinuria|Betaine METABOLISM OF PATIENTS With Homocystinuria|HCTBETAINE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|1 Year|18 Years|No|||July 2015|July 27, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02404337||24268|
NCT02399423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project number 60315/1|The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS)|The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS) - Does Adipose Tissue Expandibility Differ Between South Asians and Europeans and Does This Contribute to Differences in Cardio-metabolic Disease Risk?|GlasVEGAS|University of Glasgow|No|Recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02399423||24644|
NCT02508935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNK15000300|PK and Safety Study of XARTEMIS® XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of XARTEMIS® XR (7.5 Oxycodone Hydrochloride/325 mg Acetaminophen) in Postsurgical Adolescent Subjects (Ages 12 to 17) With Moderate to Severe Acute Pain||Mallinckrodt|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Years|17 Years|No|||July 2015|July 23, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508935||16237|
NCT02495220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008711068|Efficacy of Dexmedetomidine for Postoperative Analgesia in Infantile Cataract Surgery|Subtenon Versus Intravenous Dexmedetomidine for Postoperative Analgesia and Vomiting Control in Infantile Cataract Surgery||Assiut University|Yes|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|1 Month|12 Months|No|||July 2015|July 10, 2015|July 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495220||17290|
NCT02394899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Improving Parental Psychosocial Functioning and Early Developmental Outcomes in Children With Sickle Cell Disease|Integrating a Parenting Intervention With Routine Care to Improve Parental Psychosocial Functioning and Early Developmental Outcomes in Children With Sickle Cell Disease||The University of The West Indies|No|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|6 Months|12 Months|No|||December 2015|December 4, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02394899||24992|
NCT02406235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816R00006|Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer|Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer - ENGAGE Study|ENGAGE|AstraZeneca|No|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|N/A|N/A|No|Probability Sample|patients diagnosed with epithelial ovarian/fallopian tube/primary peritoneal cancer prior        to, or at enrolment in this study|March 2016|March 11, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02406235||24123|
NCT02497469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002-3026|An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis|A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis||Takeda|No|Recruiting|July 2015|November 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|658|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497469||17117|
NCT02495480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHBeijing|Disposable Sheathed Gastroscopic System for Cecal Intubation|A Novel Disposable Sheathed Gastroscopic System for Cecal Intubation：Safety and Efficacy in Unsedated Colonoscopies||General Hospital of Beijing PLA Military Region||Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02495480||17270|
NCT02444091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTS-7-2015|Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)|Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months|CycloME|Haukeland University Hospital|Yes|Active, not recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444091||21217|
NCT02491346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICU_2014-11|A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU|A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU||Peking Union Medical College Hospital|Yes|Recruiting|October 2014|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||May 2015|July 7, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02491346||17588|
NCT02439034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOCOL-1304|Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)|Paracetamol With or Without Ketoprofen in the Management of Pain During Hospitalisation and at Home for Patients Receiving Brachytherapy: Phase-2 Randomized Study|KETOCOL-1304|Centre Oscar Lambret|No|Recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||April 2015|May 5, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02439034||21604|
NCT02439047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESO-PATCH-1408|Preliminary Study to the Manufacturing of a Non-stick Membrane for Surgery Using Patient's Own Cells (MESO-PATCH)|Non-stick Patch of Mesothelial Cells in a Hydrogel Matrix : Exploratory Analysis Assessing the Morphotype and Mesothelial Phenotype After Culture From 2 Cells Sources of Human Origin.|MESO-PATCH|Centre Oscar Lambret|No|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02439047||21603|
NCT02435901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08057|HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity|ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN||Northwell Health|Yes|Recruiting|December 2008|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|21 Years|No|||November 2015|November 25, 2015|April 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435901||21845|
NCT02435914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223575-002|Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease|||Allergan|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|236|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435914||21844|
NCT02439086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBA (ethics)|Prediction of Response to Neoadjuvant Therapy in Rectal Cancer|Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.|PRENT-LARC|Colchester General Hospital|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|N/A|No|||May 2015|May 8, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02439086||21600|
NCT02439099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/002/13|Retinoic Acid Homeostasis in Major Depression|Retinoic Acid Homeostasis in Major Depression|RA-MDD|Charite University, Berlin, Germany|No|Recruiting|March 2015|February 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|128|Samples With DNA|peripheral venous blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Out- and inpatients are eligible and will be recruited from patients seeking medical        treatment at the Department of Psychiatry, Campus Benjamin Franklin, Charité, University        Medicine Berlin.|December 2015|December 23, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02439099||21599|
NCT02429700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCST-01|TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors|A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors|SCST-01|Shandong University|Yes|Enrolling by invitation|April 2015|May 2020|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Female|14 Years|65 Years|No|||February 2016|February 14, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429700||22320|
NCT02429713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUPH|The Effects of Tourniquet Use in Total Knee Arthroplasty|The Effects of Tourniquet Use in Total Knee Arthroplasty: A Randomized Controlled Trial||Peking University People's Hospital|No|Completed|January 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|N/A|No|||April 2015|April 24, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02429713||22319|
NCT02431767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 098|Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|August 2015|||November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Anticipated|94|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431767||22163|
NCT02486874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283/52|Clinical Evaluation of PoreSkin|Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix||Chulalongkorn University|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|60 Years|No|||May 2015|June 29, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02486874||17930|
NCT02486887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2014/234|Home Electronic Monitoring of Chronic Heart Failure|Monitoring Electronique à Distance Des Patients Insuffisants Cardiaques|MEDIC|Centre Hospitalier Universitaire de Besancon|Yes|Not yet recruiting|June 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|210|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02486887||17929|
NCT02434146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14068|Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy|A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation||University of Wisconsin, Madison|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434146||21980|
NCT02434328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTH258-C002|Efficacy and Safety of RTH258 Versus Aflibercept - Study 2|A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration||Alcon Research|Yes|Recruiting|July 2015|March 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1200|||Both|50 Years|N/A|No|||February 2016|February 26, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434328||21966|
NCT02440087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Refill|Evaluation of the Dietary Supplement Refill Bypass to Reduce Nutritional Deficiencies of Patients Who Underwent Bariatric Surgery|Evaluation of the Dietary Supplement Refill Bypass Administered Sublingually to Reduce Nutritional Deficiencies of Patients Who Underwent Bariatric Surgery Type Gastric Bypass|Refill|Refill France|No|Recruiting|June 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Obese patients who underwent bariatric surgery|July 2015|July 3, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02440087|12 Months|21524|
NCT02494037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3974|The Canadian/US Integrative Oncology Study|The Canadian/US Integrative Oncology Study (CUSIOS): Advanced Integrative Oncology Treatment for Patients With Advanced Stage Cancer: A Prospective Outcomes Study|CUSIOS|The Canadian College of Naturopathic Medicine|No|Recruiting|January 2015|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|All stage 4 breast or colorectal cancer patients and all stage 3 or 4 ovarian and        pancreatic cancer patients seeking care at the participating AIO clinical sites meeting        inclusion/exclusion criteria are eligible to participate in this study.|February 2016|February 8, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02494037||17381|
NCT02478554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS|Antenatal Development Evaluated Prospectively|Customized Versus Population Fetal Growth Curves: A Randomized Controlled Pilot Trial|ADEPT|The University of Texas Health Science Center, Houston|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|1200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02478554||18569|
NCT02429154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-204|Assessment of Cerebral Vasoreactivity Using Near-infrared Spectroscopy (NIRS) in Infants (VARO)|Assessment of Cerebral Vasoreactivity Using Near-infrared Spectroscopy (NIRS) in Infants|VARO|University Hospital, Geneva|No|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|16|||Both|N/A|1 Year|No|||April 2015|April 23, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02429154||22362|
NCT02429167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHC-TBI-PoNS-RT001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||March 21, 2016|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429167||22361|
NCT02438098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025/15|Rivaroxaban in Bariatric Surgery|Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban in Obesity Patients Before and After Bariatric Surgery||University Hospital Inselspital, Berne|No|Completed|June 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02438098||21676|
NCT02429037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-J1002|P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer|Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study||Shenzhen SiBiono GeneTech Co.,Ltd|No|Not yet recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|April 23, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02429037||22371|
NCT02483858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQR309-003|Study of Oral PQR309 in Patients With Advanced Solid Tumors|Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors||PIQUR Therapeutics AG|No|Recruiting|January 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483858||18161|
NCT02439385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIRB2015-87|Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis|First Line Avastin/FOLFIRI in Combination With Curcumin-containing Supplement in Colorectal Cancer Patients With Unresectable Metastasis||Gachon University Gil Medical Center|Yes|Not yet recruiting|May 2015|March 2019|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|20 Years|N/A|No|||May 2015|May 7, 2015|May 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439385||21578|
NCT02434796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVRI49-WEI2014|Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania|A Mixed Methods Study to Test the Preliminary Effect of Together to End Violence Against Women (TEVAW): a Program to Address Intimate Partner Violence in Northern Tanzania|TEVAW|Boston University|No|Not yet recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434796||21930|
NCT02437643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057509|An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition|An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition|DDYNAMO|Duke University|Yes|Recruiting|October 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|60 Years|N/A|No|||December 2015|January 4, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437643||21711|
NCT02484118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01931|Hemodialysis Blood Flow and Urea Clearance|Examining the Effect of Blood Flow Rate on Hemodialysis Urea Clearance||University of British Columbia|No|Completed|May 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|No|||December 2015|December 7, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02484118||18141|
NCT02489461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-VM1500-04|Efficacy, Safety and Optimal Dose Selection VM-1500 in Comparison to Efavirenz When Added to Standard-of-care Antiretroviral Therapy|International, Multicenter, Randomized, Partially Blind Clinical Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients||Viriom|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489461||17732|
NCT02437669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP5709|Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.|Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.||Columbia University|Yes|Recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|4 Years|17 Years|No|||November 2015|November 11, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437669||21709|
NCT02438540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingUTCM|Comparative Evaluation of the Therapeutic Effect of Metformin Monotherapy With Metformin and Acupuncture Combined Therapy on Weight Loss and Insulin Resistance in Diabetic Patients|Placebo-controlled, Randomized, Double Blind Trial, What is the Therapeutic Effect of Metformin and Acupuncture Combined Therapy in Comparison With Metformin Monotherapy on Weight Loss and Insulin Resistance in Diabetic Patients||Nanjing University of Traditional Chinese Medicine|No|Completed|May 2014|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|20 Years|65 Years|No|||May 2015|May 5, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02438540||21642|
NCT02429596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM9A8J83|A Trial of Generic Substitution of Antiepileptic Drugs|A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs||IRCCS National Neurological Institute "C. Mondino" Foundation|No|Recruiting|May 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|90 Years|No|||April 2015|April 28, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02429596||22328|
NCT02492204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL33/ST2|The Role of IL33/ST2 Axis in ARDS Patients|||Hospital Universitari Vall d'Hebron Research Institute||Recruiting|July 2015|||July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ARDS criteria according to Berlin definition or risk pathologies|July 2015|July 3, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02492204|60 Days|17522|
NCT02492256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPT15429|Atrial Ganglionated Plexi Ablation Guided by the SUMO Technology With and Without Conventional Pulmonary Vein Isolation in Patients With Persistent AF|Atrial Ganglionated Plexi Ablation Guided by the SUMO Technology With and Without Conventional Pulmonary Vein Isolation in Persistent Atrial Fibrillation Patients: Prospective Randomized Study||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02492256||17518|
NCT02431637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP14C21|Experimental Falciparum Transmission to Anopheles|Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum|EFITA|Medicines for Malaria Venture|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|June 4, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02431637||22173|
NCT02431650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP15C05|Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent|A Proof-Of-Concept Study to Assess the Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent in Experimental P. Falciparum Infection|OZGAM|Medicines for Malaria Venture|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02431650||22172|
NCT02430376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915111|dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell|dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|9999|||Both|N/A|N/A|No|||March 2015|April 25, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02430376||22269|
NCT02434380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUBMC-GE-HF-2|Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes|Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D||American University of Beirut Medical Center|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|December 3, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434380||21962|
NCT02492269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00088|Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study|||Nationwide Children's Hospital|No|Enrolling by invitation|May 2014|December 2022|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|1 Month|12 Months|No|||July 2015|July 7, 2015|July 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492269||17517|
NCT02439203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JM-010CS01|Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia|A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010|LID|Bukwang Pharmaceutical|No|Completed|May 2015|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02439203||21591|
NCT02442440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-013|Anisodamine Critically Ill SeptIc Shock|Effectiveness of Anisodamine for the Treatment of Critically Ill Patients With Septic Shock: a Randomized Controlled Trial|ACIdoSIS|Jinhua Central Hospital|Yes|Recruiting|April 2015|||June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|15 Years|N/A|No|||April 2015|January 22, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02442440||21343|
NCT02434627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro35228|Sodium Nitrate for Muscular Dystrophy|Sodium Nitrate for Muscular Dystrophy||Cedars-Sinai Medical Center|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|15 Years|45 Years|No|||January 2016|January 26, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02434627||21943|
NCT02434640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16742|Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women|Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women||Bayer|No|Active, not recruiting|April 2015|February 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|5||Actual|51|||Female|18 Years|68 Years|Accepts Healthy Volunteers|||January 2016|January 1, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434640||21942|
NCT02482844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0239|Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB)After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm|Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB) After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm|LBBB-TAVI|University Hospital, Clermont-Ferrand||Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02482844||18239|
NCT02433392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA1021|Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.|A Phase 1 Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.||BTG International Inc.|Yes|Active, not recruiting|December 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|October 8, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433392||22038|
NCT02431247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107277|A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects|A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects||Janssen Sciences Ireland UC|Yes|Recruiting|July 2015|April 2020|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|670|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431247||22203|
NCT02478619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP 2015-2|Preoperative Inspiratory Muscle Training in Gastroplasty|Effects of Preoperative Inspiratory Muscle Training in Patients Undergoing Gastroplasty||University of Sao Paulo|Yes|Recruiting|January 2015|July 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||June 2015|June 23, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478619||18564|
NCT02435056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215366|Medication Overuse Headache (MOH) and an Innovative Approach|Continuous Monitoring of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System|COMOESTAS|IRCCS National Neurological Institute "C. Mondino" Foundation|No|Completed|July 2008|June 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|690|||Both|18 Years|N/A|No|||April 2015|May 5, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02435056||21910|
NCT02431949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02891|The Music Study in Refractory Psychosis|A Cross-sectional Analysis of Musical Ability in Patients With Refractory Schizophrenia|MARS|University of British Columbia|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participant population will include all patients who have been admitted to the British        Columbia Psychosis Progarm (BCPP) at the University of British Columbia (UBC) Hospital.        Admission criteria to BCPP include the following: 1) Must be 18 years or older who are        medically stable; 2) Diagnosis of schizophrenia, schizoaffective disorder, mood disorder        with psychosis, or non-substance-related psychosis requiring diagnostic clarification; 3)        History of no response or inadequate response of positive symptoms to at least 2 adequate        trials of antipsychotics (one of which is a second generation agent) by health authority        tertiary clinical teams; 4) Incomplete recovery of social, vocational, and occupational        functioning likely to respond to active intervention. Control subjects will be age and        gender matched with patient participants.|November 2015|November 3, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431949|2 Weeks|22149|
NCT02491034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0336|DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment|DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment|DESEO|The University of Texas at Arlington|No|Enrolling by invitation|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491034||17612|
NCT02491047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BonyPid-1000TM-103|Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures|Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures||PolyPid Ltd.|No|Recruiting|October 2015|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||July 2015|November 30, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491047||17611|
NCT02438007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMOR3-SV|A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC|ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)|ARMOR3-SV|Tokai Pharmaceuticals|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438007||21683|
NCT02431702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106193|A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform|A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics|DREaM|Janssen Scientific Affairs, LLC|No|Recruiting|July 2015|October 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|275|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431702||22168|
NCT02431234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111105|Arterial Calcification in the Diabetes|Study of the Mechanisms of the Arterial Calcification of the Members Subordinates in the Diabetes (Implication of the System RANK / RANKL / OSTEOPROTEGERINE)|DIACART|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|188|Samples Without DNA|serum|Both|50 Years|N/A|No|Non-Probability Sample|Men and women with type 2 diabetes and known coronary artery disease|November 2015|November 5, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02431234||22204|
NCT02492555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48121|Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?|Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?||Nordsjaellands Hospital|Yes|Recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|March 1, 2016|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492555||17495|
NCT02434185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCAM-BLD-1|The Bilateral Deficit Phenomenon, Functional and Dynamometric Assessment in Postmenopausal Women|The Bilateral Deficit Phenomenon, Functional and Dynamometric Assessment in Postmenopausal Women||Universidad Católica San Antonio de Murcia|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Female|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausal women not experienced in strength training or resistance, without        musculoskeletal, neurological diseases, and cardiovascular limiting-factor.|May 2015|May 21, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434185||21977|
NCT02427724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU200401|The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser|The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser||Northwestern University|Yes|Recruiting|April 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|48|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02427724||22472|
NCT02431507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15689|Magnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety|Magnetic Apnea Prevention (MAGNAP) Device to Treat Obstructive Sleep Apnea: First-In-Human Study of Feasibility and Safety|MAGNAP|University of California, San Francisco|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|70 Years|No|||September 2015|September 1, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431507||22183|
NCT02492659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Femtosecond Laser|Clinical Research of Femtosecond Laser-Assisted Cataract Surgery|Clinical Research of Femtosecond Laser-Assisted Cataract Surgery: Randomized Clinical Trial|FLACS|Wenzhou Medical University|Yes|Completed|October 2013|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|38 Years|86 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492659||17487|
NCT02499757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408014434|Does Sweet Taste Potentiate Nicotine Cue Reactivity?|Does Sweet Taste Potentiate Nicotine Cue Reactivity?|FNC-nicotine|Yale University|Yes|Completed|May 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02499757||16942|
NCT02501707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|echocardiographyRILI|Echocardiography for RILI Prediction|The Value of Echocardiography for Prediction of Radiation-induced Lung Injury in Non-small Cell Lung Cancer Patients Treated With Chemoradiation: an Onco-cardiac Prospective Cohort Study.||Maastricht Radiation Oncology|No|Not yet recruiting|January 2016|September 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Bloodsamples and saliva samples will be collected according to the biobank protocol at      Maastro clinic to explore the prognostic value of mitochondrial DNA for development of      radiation-induced lung injury.      Cardiac bloodmarkers: B-type Natriuretic Peptide (BNP), cardiac Troponin I and T will be      measured.      Haemoglobin and inflammatory parameters (CRP, IL-6 and TNFa)|Both|18 Years|N/A|No|Probability Sample|All patients referred to MAASTRO Clinic with non-small cell lung cancer stage I-III        disease can be included in this study (approximately 160 patients per year).|November 2015|November 20, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501707||16792|
NCT02501785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-145|Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population|Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and caregivers will be recruited prior to the patient's scheduled surgery during        a clinic visit within the four target services. (Breast, Gynecology, Head and Neck, and        Urology|January 2016|January 15, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501785||16786|
NCT02405013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12311 TAC|Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir and Ribavirin for the Treatment of Genotype 1, 2 and 4 Hepatitis C Virus-infected Patients in West and Central Africa|TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir and Ribavirin for the Treatment of Genotype 1, 2 and 4 Hepatitis C Virus-infected Patients in West and Central Africa|TAC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02405013||24216|
NCT02405247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160R00003|TAURAS - T790 AURA ScreenFailure SOC Registry Study|TAURAS - T790 AURA ScreenFailure SOC Registry Study|TAURAS|AstraZeneca|No|Terminated|June 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|NSCLC patients who have failed first line TKI treatment (defined radiological        documentation of disease progression during treatment for advanced or metastatic NSCLC        with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the        AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3        designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular        Systems). Only sites that are participating in the AURA3 study, and patients who had the        T790M mutation tested for AURA3 screening (and determined not to have the T790M mutation)        will be included.        The study plans to enroll approximately 400 patients from approximately 136 sites in an        estimated 17 countries globally.|July 2015|July 30, 2015|March 16, 2015||No|Team's request.|No||https://clinicaltrials.gov/show/NCT02405247||24198|
NCT02405260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP399-202|Add Glucokinase Activator to Target A1c|A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin|AGATA|vTv Therapeutics|No|Active, not recruiting|March 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405260||24197|
NCT02409979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG.2015/3645|Impact of Carbon Dioxide Insufflation and Water Exchange on Post-Colonoscopy Outcomes|Impact of Carbon Dioxide Insufflation and Water Exchange on Post-Colonoscopy Outcomes: A Randomized Controlled Trial||Presidio Ospedaliero Santa Barbara|Yes|Completed|April 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|246|||Both|18 Years|80 Years|No|||October 2015|November 4, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02409979||23836|
NCT02409992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH100279|Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions|Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions|HNC-EC|University of Washington|Yes|Not yet recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|3 Years|7 Years|No|||April 2015|April 1, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02409992||23835|
NCT02500004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142071|Brown Adipose Tissue Activity and Energy Metabolism in Cachexia|Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease|BAT-Cachexia|Maastricht University Medical Center|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|50|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02500004||16923|
NCT02506530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7425 15|Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment|Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.|ELOCS|University Hospital, Toulouse|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|93|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02506530||16421|
NCT02406690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2014-04|Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects|Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|November 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|One tube of serum (approximately 3.5 mL) will be collected from participant at each visit      via venipuncture. An uterine aspiration and endometrial biopsy sample will be taken at Day 6      of Progestrone Adminstration.|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have undergone a synthetic endometrial proliferation cycle in preparation for        an embryo transfer that were identified as having a proliferative phase defect will serve        as the subjects. Normal, healthy patients who are undergoing infertility treatment for        single gene disorder, family balancing, or male factor infertility will serve as controls.        The study will occur as part of a cryosynthetic preparatory cycle prior to embryo        transfer. There will be 10 cases and 10 controls recruited for participation in the study.|April 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406690||24089|
NCT02409680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP ASPIRIN|Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)|Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)|ASPIRIN|NICHD Global Network for Women's and Children's Health|Yes|Recruiting|March 2016|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|11000|||Female|18 Years|40 Years|No|||March 2016|March 23, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409680||23859|
NCT02409693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00179|Retrospective Analysis of Perioperative Anesthetic Care and Analgesia Management of Patient Undergoing Bilateral Myringotomy With Tube Insertion|||Nationwide Children's Hospital|No|Active, not recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have undergone anesthesia for surgical ear tube placement at Nationwide        Children's Hospital from January 1, 2015 through February 28, 2015.|October 2015|October 22, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02409693||23858|
NCT02404961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD058608|Women's Health Study: Immunological Factors and Risk of Vulvodynia|Immunological Factors and Risk of Vulvodynia||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30675|Samples With DNA|Venous Blood and Vulvar punch biopsy|Female|18 Years|40 Years|No|Non-Probability Sample|Women aged 18-40 years who were seen for any reason within a 2-year period at one of the        metro-area's Fairview Health Services outpatient clinics|March 2015|March 26, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02404961||24220|
NCT02495233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-5101|A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)|A Phase 1b/2 Study of ASP2215 in Combination With Erlotinib in Subjects With EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)||Astellas Pharma Inc|No|Recruiting|July 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02495233||17289|
NCT02400073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA230315|AutoSet for Her Quality of Life Clinical Trial|Assessment of a New AutoSet Device Designed for Female Obstructive Sleep Apnea Patients on the Quality of Life of Users|FEM-PAP|ResMed|No|Not yet recruiting|April 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400073||24594|
NCT02406144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM2014MAIN|Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma|||PETHEMA Foundation|Yes|Recruiting|November 2014|December 2021|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|67 Years|No|||October 2015|October 12, 2015|March 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406144||24129|
NCT02407951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0437-17-TLV|Group Intervention for Children With Chronic Tics Syndrome or Tourette Syndrome: CBIT vs Psycho-Educational Intervention|Tel Aviv Sourasky Medical Center||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|9 Years|15 Years|No|||March 2015|March 31, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02407951||23992|
NCT02503033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-523-00AU1|A Study of HMPL-523 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas or Chronic Lymphocytic Leukemia|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas or Chronic Lymphocytic Leukemia||Hutchison Medipharma Limited|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02503033||16690|
NCT02499341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637|A Comparison Study Between Ketamine Versus Tramadol for Pain Management After Major Upper Abdominal Surgery|Comparison Between Ketamine and Tramadol for Pain Management After Major Upper Abdominal Surgery||Attikon Hospital||Completed|July 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|July 14, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02499341||16974|
NCT02499354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVOR-IDA|Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)|Double-blind Comparator of Efficacy of Oral (Ferrous Sulfate) vs. Intravenous Iron (Ferumoxytol) for Treatment of the Restless Legs Syndrome (RLS) Occurring With Iron Deficient Anemia (IDA)||Auerbach Hematology Oncology Associates P C|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02499354||16973|
NCT02403687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1960fp-expr-201501|Prospective Analgesic Compound Efficacy (PACE) Study|Prospective Analgesic Compound Efficacy (PACE) Study|PACE|Express Specialty Pharmacy|No|Enrolling by invitation|June 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|85 Years|No|Probability Sample|The patient population will be taken from the patients normally treated at 1960 Family        Practice. Patients not approached for the study will have known medical issues consistent        with the exclusion criteria. Patients who can meet the medical requirements of the        inclusion criteria for the study will be asked to participate. Patients who do not meet        the inclusion criteria, meet any of the exclusion criteria, or decline to be involved in        the study will be treated with traditional standard medical practices, and their standard        of care will not change in any way.|January 2016|January 19, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02403687|52 Weeks|24318|
NCT02430935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/24/2015|A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis|A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis||Centre for Addiction and Mental Health|No|Recruiting|April 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|29 Years|No|||November 2015|November 4, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02430935||22227|
NCT02482571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503M65382|Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia|Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482571||18260|
NCT02482584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiaBOSA|Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea|DiaBOSA: Impact of CPAP Treatment on Arterial Stiffness in Patients With Type 2 Diabetes and Newly Diagnosed Obstructive Sleep Apnoea||Nordsjaellands Hospital|Yes|Recruiting|April 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02482584||18259|
NCT02428647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1347-UCALIF-07|Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation|Lao Zinc Study: The Effects of Two Forms of Daily Preventive Zinc Supplementation Versus Therapeutic Zinc Supplementation for Diarrhea on Young Children's Physical Growth and Risk of New Episodes of Diarrhea||University of California, Davis|Yes|Recruiting|September 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|3400|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02428647||22401|
NCT02437565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRP/2013/046|Checking Occlusion During Stainless Steel Crown Placement|Checking Occlusion During Stainless Steel Crown Placement in Children Under General Anesthesia - Evaluation of a Novel Technique||Riyadh Colleges of Dentistry and Pharmacy|Yes|Completed|August 2013|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|4 Years|7 Years|No|||May 2015|May 4, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02437565||21717|
NCT02437578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBG study3|Clinical Tests to Predict the Success of Assisted Reproductive Techniques|Development of Clinical Tests to Predict the Success of Assisted Reproductive Techniques in a Fertility Clinic||Rigshospitalet, Denmark|Yes|Recruiting|May 2015|April 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Serum Seminal plasma follicular fluid DNA granulosa cells|Both|18 Years|43 Years|No|Probability Sample|All infertile couples referred to Dansk Fertilitetsklinik will be invited to participate.        Anticipated 800-1000 IUI and 400 IVF/ICSI will be conducted during the planned study        period. The investigators assume that up to 600 IUI and 200 IVF/ICSI wish to participate.        Thus 600-800 treatments is the estimated target for inclusion in this study. The        investigators expect a small retraction rate (< 20) because of high motivation and no        adverse effects.|February 2016|February 3, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02437578||21716|
NCT02443272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-14-114|Comparison of Loop Drainage Versus Incision and Drainage for Abscesses in Children|A Randomized Comparison Study of Minimally Invasive Loop Drainage Versus Standard Incision and Drainage for Skin Abscesses in Children||Seton Healthcare Family|No|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|17 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443272||21279|
NCT02443298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.14|Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.|A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066 as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.||Boehringer Ingelheim||Recruiting|June 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|May 11, 2015||||No||https://clinicaltrials.gov/show/NCT02443298||21277|
NCT02478307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQueensland|Coping Skills Training for Living With Chronic Low Back Pain|Mechanisms of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Low Back Pain||The University of Queensland|Yes|Recruiting|May 2015|December 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|63|||Both|18 Years|N/A|No|||July 2015|July 5, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02478307||18588|
NCT02478320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0920|Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors|A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial||M.D. Anderson Cancer Center|No|Not yet recruiting|December 2015|||December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478320||18587|
NCT02478333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107180|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Subjects||Janssen Pharmaceutical K.K.|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478333||18586|
NCT02432846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-201|Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)|An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients|MERECA|Immunicum AB|Yes|Recruiting|April 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02432846||22080|
NCT02432859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D52/2509|Electrical Stimulation and Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer|The Effect of Electrical Stimulation on the Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer||Tarbiat Modarres University|No|Completed|November 2013|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02432859||22079|
NCT02433951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-ACAB study|Exercise Tolerance in Patients With CABG and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery|Exercise Tolerance in Patients With Coronary Artery Bypass Surgery (CABG) and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery|ENDO-ACAB|Hasselt University|No|Completed|February 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|55|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing CABG surgery or endo-ACAB surgery.|August 2015|August 17, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433951||21995|
NCT02436213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS/22|Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs|Hypoxemia, Dyspnea, and Exercise Tolerance in Patients With Pulmonary Arteriovenous Malformations||Imperial College London|No|Recruiting|April 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 16, 2012||No||No||https://clinicaltrials.gov/show/NCT02436213||21821|
NCT02491489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCEMG|Activity of the Rotator Cuff During Glenohumeral Mobilization|A Comparison of the Effects of Glenohumeral Mobilization on Rotator Cuff Activity in Normal and Painful Shoulders||Texas Woman's University|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|July 7, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02491489||17577|
NCT02437058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011111045|Validity of Scales to Assess Severity in Acute Heart Failure|Validition of Scales for the Assessment of Sverity in Acute Decompensated Heart Failure|AHFRS|Hospital Galdakao-Usansolo|No|Completed|January 2011|May 2015|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1854|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptoms of acute decompensated heart failure who attended the emergency        departments of 3 hospitals belonging to the Basque National Health Service|April 2013|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437058|3 Months|21756|
NCT02433132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120913|Cystic Fibrosis Diagnosis by Analyzing Nasal Brushing|Study of Ion Transport From Nasal Epithelial Cells Collected by Brushing (CCBN) in the Diagnosis of Atypical Forms of Cystic Fibrosis|MUCO-BROCC|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 29, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433132||22058|
NCT02440100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7991002|A Phase 1 Study to Characterize the Safety, Tolerability, PK and PK of Repeat Doses of PF-06648671 in Healthy Adults and Healthy Elderly Subjects|An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects||Pfizer|No|Recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|9||Anticipated|92|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440100||21523|
NCT02482792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|d7k8fj2m|Norwegian Psychomotor Physiotherapy in Patients With Long-lasting Musculoskeletal Pain.|Norwegian Psychomotor Physiotherapy Versus Cognitive Patient Education and Active Physiotherapy|NPMP|University of Bergen|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02482792||18243|
NCT02482805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAD - Hormones|Hormones and Social Anxiety Disorder Treatment|Effect of Hormones on Response to Exposure Therapy for Social Anxiety Disorder||University of Texas at Austin|Yes|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02482805||18242|
NCT02433613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLD AF|Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)|Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)||Medtronic Atrial Fibrillation Solutions|No|Recruiting|April 2015|February 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible are all patients with paroxysmal, persistent and long-standing persistent AF who        fulfill all inclusion criteria.|December 2015|December 3, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02433613|12 Months|22021|
NCT02443415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077046|Diabetic Ketoacidosis: Brain Morphology and Cognition|Acute and Long-term Neuroanatomical and Cognitive Evaluation of Adult Patients With First and Recurrent Episodes of Diabetic Ketoacidosis|DKA-Cog|Emory University|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with diabetic ketoacidosis (DKA) will be recruited from Emory University Hospital        and Grady Memorial Hospital patients when DKA is treated. Diabetic subjects and        age-matched controls will be recruited from physician referrals.|November 2015|November 16, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443415||21268|
NCT02433223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QElizabethH COPD|Retrospective Evaluation of COPD Patient Care|Retrospective Evaluation of COPD Patient Care||The Queen Elizabeth Hospital|No|Active, not recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|150|||Both|40 Years|N/A|No|Non-Probability Sample|New patients to the Respiratory Nursing Service in 2006, 2011 & 2013 with a diagnosis of        Chronic Obstructive Pulmonary Disease|April 2015|May 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433223||22051|
NCT02429453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00078143|FFP Versus PCC in Intracranial Hemorrhage|Fresh Frozen Plasma Versus Four Factor Prothrombin Complex Concentrate for Reversal of Vitamin K Antagonists in Intracranial Hemorrhage||University of Utah|Yes|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|July 24, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429453||22339|
NCT02433886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GammaOCD_IPq_HCor|Efficacy and Adverse Events of Bilateral Single-shot VC/VS Gamma Capsulotomy for OCD: a Pilot Study|Efficacy and Adverse Events of Bilateral Single-shot Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-compulsive Disorder: a Pilot Study||University of Sao Paulo General Hospital|No|Recruiting|December 2014|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||April 2015|May 4, 2015|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433886||22000|
NCT02438293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14.303|'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'|'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'|RISK|Leiden University Medical Center|No|Recruiting|June 2015|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|nasopharyngeal swabs serum EDTA plasma|Both|N/A|12 Years|No|Probability Sample|Children (<12 year) with a congenital heart disease undergoing elective cardiac surgery|December 2015|December 1, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02438293||21661|
NCT02438306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-14-001-02|CardiAMP™ Heart Failure Trial|Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients With Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)||BioCardia, Inc.|Yes|Not yet recruiting|January 2016|April 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|21 Years|90 Years|No|||October 2015|October 8, 2015|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438306||21660|
NCT02442843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00089481|Non Invasive Brain Stimulation for PTSD|Non-invasive Brain Stimulation for Post-Traumatic Stress Disorder||University of Michigan|No|Recruiting|May 2015|June 2020|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|105|||Male|18 Years|88 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442843||21312|
NCT02489474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0411|Association of Genetic Polymorphism and Acute Kidney Injury After Liver Transplantation|||Yonsei University|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood obtained from enrolled patients before surgery|Both|19 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients scheduled for liver transplantation|March 2016|March 1, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489474||17731|
NCT02441244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT 022A|Probiotic Visbiome for Inflammation and Translocation in HIV Ι|Probiotic Visbiome for Inflammation and Translocation in HIV I (PROOV IT I)|PROOV IT I|University Health Network, Toronto|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|19 Years|N/A|No|||March 2016|March 10, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02441244||21435|
NCT02443506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040147|A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus|A Randomized Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Single Dose Administration in Subjects With Systemic Lupus Erythematosus||Amgen|No|Completed|October 2004|June 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|No|||April 2015|May 13, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443506||21262|
NCT02443519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4684|Bronx MBCT-Migraine|Bronx Mindfulness Based Cognitive Therapy for Migraine: a Randomized Clinical Trial|BMBCT-M|Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02443519||21261|
NCT02433769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH14-266|Acceleromyographic Assessment of Neuromuscular Blockade: TOF-Watch-SX Versus TOFscan|Acceleromyographic Assessment of Neuromuscular Blockade: TOF-Watch-SX Versus TOFscan||NorthShore University HealthSystem Research Institute|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02433769||22009|
NCT02480673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2015-785-047|EFFECT OF Salvia Hispanica l. (CHIA) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS|EFFECT OF Salvia Hispanica L. ( CHIA ) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS IN PATIENTS IN THE NATIONAL MEDICAL CENTER WEST OF THE MEXICAN SOCIAL SECURITY INSTITUTE||Instituto Mexicano del Seguro Social|Yes|Recruiting|June 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|100|||Both|18 Years|50 Years|No|||June 2015|June 25, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480673||18406|
NCT02436070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409-082|Use of Text Messages to Improve Care For Children Following an ED Visit for Asthma|Use of Text Messages to Improve Care For Children Following an ED Visit for Asthma||Children's Hospitals and Clinics of Minnesota|No|Active, not recruiting|October 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|195|||Both|4 Years|17 Years|No|||May 2015|May 5, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436070||21832|
NCT02434835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1101|Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects|||Kissei Pharmaceutical Co., Ltd.||Recruiting||||October 2015|Anticipated|Phase 1|Interventional|N/A|1||||||Male|35 Years|55 Years||||April 2015|May 4, 2015|April 21, 2015||||No||https://clinicaltrials.gov/show/NCT02434835||21927|
NCT02442479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AG017896|Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults|Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults||University of Alabama at Birmingham|No|Completed|April 2007|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|127|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02442479||21340|
NCT02493348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH REB 15-0140-E|A Study of the Effect of Rhythmic Sensory Stimulation and Music on Fibromyalgia|A Study of the Effect of Rhythmic Sensory Stimulation and Music on Fibromyalgia||Mount Sinai Hospital, Canada|No|Recruiting|September 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493348||17434|
NCT02428673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Truong POSNA|Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions|Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions||Gillette Children's Specialty Healthcare|Yes|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|3 Years|14 Years|No|||April 2015|April 28, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02428673||22399|
NCT02430623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urinary Bladd Neoplasms-IRE-01|Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms|Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430623||22250|
NCT02441192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U.Barcelona|Different Training (Aerobic, Resistance or Mixed) Physical Programs Affect to Physiological Responses (TRAINING2014)|Cardiovascular and Cardiorespiratory Coupling After Different Types of Training and Detraining|TRAINING2014|University of Barcelona|No|Completed|January 2013|May 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|40|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02441192||21439|
NCT02441257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH|Gastroesophageal Reflux During LMA in Control Ventilation (LMA, Laryngeal Mask Airway)|Incidence of Gastroesophageal Reflux During LMA Application in Control and Spontaneous Ventilation|LMA|Eastern Hepatobiliary Surgery Hospital|No|Not yet recruiting|August 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02441257||21434|
NCT02487212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614/2556 (EC2)|Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery|Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery||Mahidol University|Yes|Completed|April 2014|May 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|April 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487212||17904|
NCT02437305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200459|Melanoma Perception and Health Literacy in People of Color|Melanoma Perception and Health Literacy in People of Color: A Targeted Educational Intervention||Northwestern University|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02437305||21737|
NCT02437318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719C2301|Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.|A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment|SOLAR-1|Novartis|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|820|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437318||21736|
NCT02440074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra-CT2008-001191-68|Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)|Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)|MSV-DISC|Red de Terapia Celular|Yes|Withdrawn|June 2011|December 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||May 2015|May 6, 2015|May 4, 2015||No|Not funded Administrative formalities not completed|No||https://clinicaltrials.gov/show/NCT02440074||21525|
NCT02442518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1837|Antenatal Diagnosis of Placental Attachment Disorders|Antenatal Diagnosis of Placental Attachment Disorders|ADoPAD|Università degli Studi di Brescia|Yes|Recruiting|February 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2254|Samples Without DNA|histopathological samples from women with placenta previa diagnosed with ultrasound in the      3rd trimester of pregnancy|Female|18 Years|N/A|No|Non-Probability Sample|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of        pregnancy (lower placental edge within 20 mm from the internal os above 26 week's        gestation)|December 2015|December 14, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02442518||21337|
NCT02490891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB14.02|Study of the Angiogenesis by PET/CT in Patients With Diffuse Large B Cells Lymphoma|Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Diffuse Large B Cells Lymphoma : a Preliminary Study|RGDLymphome|Centre Henri Becquerel|No|Recruiting|July 2015|November 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490891||17623|
NCT02490995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9392|Inform and Reduce Pre-surgical Anxiety of the Child and His Parents: Interest of an Explanatory Movie.|Inform and Reduce Pre-surgical Anxiety of the Child and His Parents: Interest of an Explanatory Movie About the Pathway of the Child in Pediatric Surgery.||University Hospital, Montpellier|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|12 Years|No|||July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490995||17615|
NCT02482623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i14-01960|The Dementia Symptom Management at Home Program|The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.|DSM-H|New York University|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|65 Years|N/A|No|||June 2015|June 25, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482623||18256|
NCT02439242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ΔPP/HR vs ΔSV|Correlation Between ΔPP/HR and ΔSV During Fluid Challenge.|Correlation Between the Pulse Pressure / Heart Rate Ratio Variations and Stroke Volume Variations During Fluid Challenge.|ΔPP/HRvsΔSV|University Hospital, Caen|No|Recruiting|June 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|General anaesthesia.Orotracheal intubation and mechanical ventilation Advanced        Haemodynamic Monitoring intraoperative ( arterial pressure catheter, oesophageal Doppler)|May 2015|May 7, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02439242||21588|
NCT02436681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015002|Miromatrix Biological Mesh for Hiatal Hernia Repair|A Prospective Post-Market Clinical Evaluation of Miromatrix Biological Mesh for Hiatal Hernia Repair|MIROMESH PM-2|Miromatrix Medical Inc.|No|Enrolling by invitation|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|May 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02436681||21785|
NCT02480361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOIGC-13|Effect of Acupuncture on Postoperative Ileus After Gastric Surgery (EAPIG)|Effect of Acupuncture on Postoperative Ileus After Gastrectomy in Patients With Gastric Cancer: A Pilot Study|EAPIG|Daegu Catholic University Medical Center|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02480361||18430|
NCT02480374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL 201-14-101|Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer|A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Celsion|Yes|Recruiting|September 2015|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480374||18429|
NCT02427360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1409|Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers|Evaluating the Efficacy of Artesunate-mefloquine on the Thai-Myanmar Border and the Relative Roles of Resistance Genetic Markers: A Retrospective Cohort Study|MMA|University of Oxford|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1022|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with uncomplicated P.falciparum malaria or mixed infection (P.falciparum + a        non-falciparum species) treated at the clinics of Shoklo Malaria Research Unit between        2003-2013. Medical records and stored/left-over samples from these patients will be        reviewed/extracted and used for this study.|December 2015|December 14, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427360||22500|
NCT02436629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 153006|Nitrate for High Intensity Intermittent Exercise|The Effect of Nitrate Supplementation on Sport Performance: High Intensity Intermittent Performance in Recreational Athletes|NITR-ITE|Maastricht University Medical Center|No|Active, not recruiting|April 2015|June 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436629||21789|
NCT02479152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol ID 11, March 2015|The Haemodynamic Effects of Mechanical Standard and Active Chest Compression-decompression During Out-of-hospital CPR|The Haemodynamic Effects of Mechanical Standard and Active External Chest Compression-decompression During Out-of-hospital Cardiopulmonary Resuscitation||Physio-Control|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02479152||18523|
NCT02479165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The NSAID trial|Pain Management After Cardiac Surgery - Opioids or NSAID|Pain Management After Cardiac Surgery - Opioids or NSAID? A Randomized Prospective Study||Aalborg Universitetshospital|No|Completed|May 2009|September 2013|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479165||18522|
NCT02431936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611851|Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress|Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress in a Randomized Double Blind Placebo Controlled Design||Georgia Regents University|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431936||22150|
NCT02435446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWS_2015_18|Cone Beam and CT Scan for the Diagnosis of Otosclerosis (TACOS)|Comparison of Cone Beam With CT Scan for the Diagnosis of Otosclerosis|TACOS|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|October 2015|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|133|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02435446||21880|
NCT02479386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX29633|An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Proxima A).|An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age Related Macular Degeneration||Hoffmann-La Roche||Recruiting|August 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|50 Years|N/A|No|Non-Probability Sample|Patient with bilateral geographic atrophy (GA) secondary to age-related macular        degeneration (AMD)|September 2015|September 3, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479386||18505|
NCT02505529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14F038|The UNCODE Study: Unravelling the Neural Contributors Of Dynapenia in Elders|Neural Mechanisms of Dynapenia||Ohio University|No|Recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|100|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02505529||16498|
NCT02498015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1405|A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection|A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy|D3FEAT|Kirby Institute|Yes|Not yet recruiting|November 2015|October 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02498015||17076|
NCT02394314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5670C00001|A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers|A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers||MedImmune LLC|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|362|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02394314||25037|
NCT02396602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0599|miPlan: A Trial of miPlan Intervention vs. Standard of Care|miPlan: A Randomized Controlled Trial of miPlan Intervention vs. Standard of Care||University of Chicago|No|Recruiting|February 2015|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|225|||Female|15 Years|29 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02396602||24861|
NCT02505698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960-CLP-ISR-IR8|A Data Collection Study for the Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment|A Data Collection Study for the Evaluation of Real Imaging's Real Imager 8 (RI-8) Developed for Risk Assessment of Breast Cancer||Real Imaging Ltd.|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Female|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 30 years and older, and who regardless of this clinical trial are summoned for        routine breast cancer screening exam or breast biopsy due to suspicious finding in recent        screening exam.|July 2015|July 20, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02505698||16485|
NCT02508883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP621/14|Evaluation of Prognostic Scores in Patients With Upper Gastrointestinal Bleeding and Cancer|Comparison Among the Scores of Glasgow-Blacthford, Rockall and AIMS65 for the Prediction of Rebleeding and Mortality in Patients With Cancer and Upper Gastrointestinal Bleeding||Instituto do Cancer do Estado de São Paulo|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|All patients referred to the Endoscopy Unit of ICESP because of upper gastrointestinal        bleeding will be included consecutively, according to the selection criteria mentioned        below.        The analysis of our recent data base allows us to estimate an accrual of about 300        patients at the end of 1 year of study.|February 2016|February 23, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02508883||16241|
NCT02398136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1781|To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD|Randomized Controlled Trial of Repeated Dose Ketamine in Post Traumatic Stress Disorder (PTSD)||Icahn School of Medicine at Mount Sinai|Yes|Withdrawn|December 2014|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|November 7, 2014|Yes|Yes|FDA and IRB recommended different mode of medication administration|No||https://clinicaltrials.gov/show/NCT02398136||24743|
NCT02398149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12-002-E|Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis|Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis||Mount Sinai Rehabilitation Hospital|No|Active, not recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|267|||Both|18 Years|N/A|No|Probability Sample|Persons with MS who receive care at the Mandell Center for Multiple Sclerosis.|March 2016|March 22, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02398149||24742|
NCT02396875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1765|Selective Coronary Vein Sampling in Left Bundle Branch Block and CRT|Selective Coronary Vein Sampling in Dyssynchronous Heart Failure and Cardiac Resynchronisation Therapy to Assess Physiological Response to Exercise and Characterise Regional Release of Novel Biomarkers|MicroCRT|Guy's and St Thomas' NHS Foundation Trust|Yes|Not yet recruiting|April 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|October 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02396875||24840|
NCT02396888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71-13|Effects of Local Insulin on Wound Angiogenesis|Effects of Local Insulin on Angiogenesis in Acute Wounds in Non-diabetic Patients||Hospital Central "Dr. Ignacio Morones Prieto"|Yes|Active, not recruiting|October 2014|May 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02396888||24839|
NCT02496143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-18-001|A Safety and PK Study of EC-18 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Administration of EC-18 in Healthy Subjects||Enzychem Lifesciences Corporation|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02496143||17219|
NCT02496377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9408|Cross Iron (Comparative Randomized Oral Versus Systemic IRON)|Comparison of Preoperative Haemoglobin Level After Administration of Epoetin Alfa Associated With an Oral Versus Intravenous Iron Supplementation|Cross Iron|University Hospital, Montpellier|Yes|Recruiting|August 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|July 9, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02496377||17201|
NCT02499068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMETE|Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring|Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).|PROMETE|Universidad Autonoma de Madrid|Yes|Active, not recruiting|December 2013|September 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|50 Years|90 Years|No|||July 2015|July 14, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02499068||16995|
NCT02406157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-MPLD|577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema|Pure Yellow (577nm) Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema:A Prospective, Randomized, Paralleled Clinical Trial||Sun Yat-sen University|Yes|Recruiting|January 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|19 Years|80 Years|No|||October 2015|October 17, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02406157||24128|
NCT02398279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011D01101013|L-arginine add-on Therapy in Patients With Schizophrenia|L-Arginine add-on Treatment for Schizophrenia: A Randomized, Double Blind, Placebo Controlled, Cross Over Study||Hacettepe University|No|Completed|June 2011|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02398279||24732|
NCT02398578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1135-01|Cystoscopic Ablation Via RF Energy Clinical Trial|Cystoscopic Ablation Via RF Energy Clinical Trial|CARETI|Amphora Medical, Inc.|No|Active, not recruiting|November 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Female|18 Years|80 Years|No|||September 2015|September 17, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02398578||24709|
NCT02508142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KocaeliU|Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis|Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study|HNB|Kocaeli University|Yes|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508142||16297|
NCT02507518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB13.01|Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer|Role of 18FDG PET in the Evaluation of Early Response to Maintenance Treatment With Bevacizumab or Pemetrexed in Advanced Non-small-cell Lung Cancer|CALMETTE|Centre Henri Becquerel|No|Recruiting|December 2013|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507518||16345|
NCT02406274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-053|Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities|Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities||Memorial Sloan Kettering Cancer Center||Recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Female|25 Years|N/A|No|||November 2015|November 11, 2015|March 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02406274||24120|
NCT02406287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS102|A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers|||Aerie Pharmaceuticals|No|Active, not recruiting|April 2015|||February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406287||24119|
NCT02435641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002793|Patient and Caregiver Psychological Functioning Following Neuro-ICU Admission: A Prospective Investigation|A Prospective Study to Investigate Relationships Between Patient and Family Caregiver Distress Following Neuroscience ICU Admission||Massachusetts General Hospital|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted to the Neuro-ICU and their family caregivers|November 2015|November 20, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02435641||21865|
NCT02487186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012/2009|Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy.|Evaluation of PLGA Microspheres Loaded With Doxycycline Associated to Periodontal Debridement in the Treatment of Chronic Advanced Periodontitis.||University of Campinas, Brazil|Yes|Completed|March 2010|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|60 Years|No|||June 2015|June 27, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487186||17906|
NCT02432573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0245|Timing of Morning Rounds for Postpartum Hospitalized Women|Timing of Morning Rounds for Postpartum Hospitalized Women: A Randomized Controlled Quality Improvement Trial|PP rounds|The University of Texas Health Science Center, Houston|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|150|||Female|N/A|N/A|No|||February 2016|February 11, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02432573||22101|
NCT02432586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042014-061|Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes|Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes|TotCamp|University of Texas Southwestern Medical Center|No|Active, not recruiting|July 2014|December 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|34 Months|68 Months|No|||January 2016|January 12, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02432586||22100|
NCT02437591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-MA-1003|Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)|Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)|PROFILE|Astellas Pharma Inc|Yes|Recruiting|June 2015|October 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437591||21715|
NCT02443324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15787|A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium|An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium||Eli Lilly and Company|No|Recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|92|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443324||21275|
NCT02443337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15799|A Study of LY3023414 and Necitumumab in Squamous Lung Cancer|A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung||Eli Lilly and Company|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443337||21274|
NCT02428283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-422|Scalp Nerve Block on Emergence Agitation|The Effect of Scalp Nerve Block on the Emergence Agitation in Children Undergoing Nevus Surgery During Sevoflurane Anesthesia||Ajou University School of Medicine|Yes|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|1 Year|7 Years|No|||October 2015|October 13, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428283||22429|
NCT02482818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011734-01H|Efficacy of Pregabalin on Chronic Cough|Efficacy of Pregabalin on Chronic Cough: A Double Blind, Randomized Control Trial Comparing Pregabalin With Placebo in Patients With Non-asthmatic Chronic Cough||Ottawa Hospital Research Institute|Yes|Recruiting|September 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|84 Years|No|||September 2015|September 21, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02482818||18241|
NCT02437006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB- 20130376|Early Intervention With a Low-intensity Leg Cycling Exercise Program for Individuals After Stroke|Early Intervention With a Low-intensity Leg Cycling Exercise Program for Individuals After Stroke||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||March 2014|May 4, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02437006||21760|
NCT02437071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-069|Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients|Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437071||21755|
NCT02437721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05-06-MTHF|Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants|Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants|MEFOLIN|DSM Nutritional Products, Inc.|No|Recruiting|May 2015|June 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|360|||Both|N/A|27 Days|Accepts Healthy Volunteers|||January 2016|January 21, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02437721||21705|
NCT02443311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDASU-RECD 1214401|Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus|A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus||Ain Shams University|Yes|Completed|September 2010|August 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|25 Years|60 Years|No|||May 2015|May 12, 2015|May 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443311||21276|
NCT02478567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052012-017|Exercise Training Sequence for Subacromial Impingement Syndrome|The Effect of Axioscapular and Rotator Cuff Exercise Training Sequence in Patients With Subacromial Impingement Syndrome: A Randomized Crossover Trial||University of Texas Southwestern Medical Center||Completed|August 2012|January 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||June 2015|June 17, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478567||18568|
NCT02439164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014MP06|Case-cohort Study of Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma|Case-cohort Study of Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma: Comparison With a Control Group Without Intracranial Pathology||Beijing Tiantan Hospital||Recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|140|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02439164||21594|
NCT02437461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW77|Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis|Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis||Uppsala University|Yes|Recruiting|April 2015|April 2021|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437461||21725|
NCT02427503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PEN-2015-11|ATP Project (Asthma afTer Polypectomy)|Sinonasal Functional Impact of Endoscopic Surgery for Bilateral Polyposis on Bronchial Inflammation, Control and Lung Function in Asthma|ATP|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Not yet recruiting|May 2015|February 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|70 Years|No|Probability Sample|Patients with persistent asthma and grade II and III bilateral sinonasal polyposisand, by        voluntary decision of the otolaryngologist and the patient, who will offer alternatives        treatment to the candidate patient, following the recommendations of clinical practice        guidelines.        If the patient is indicated in routine clinical practice FESS-BP, will be offer to enter        to the study.        If the patient is NOT indicated in routine clinical practice FESS-BP or reject        intervention, will be also offer to enter to the study.|March 2015|April 30, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02427503|6 Months|22489|
NCT02487173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP15001|Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B|A Prospective Multi-Centre Study of the Respirio Flu Test Performance Versus Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Sofia® Influenza A+B Fluorescent Immunoassay (FIA) for the Rapid Detection of Influenza A/B||Ellume Pty Ltd|No|Terminated|September 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|83|||Both|1 Year|N/A|No|||February 2016|February 16, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487173||17907|
NCT02437266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55218152-5|Effect of Scapular Mobilization on Patients With Scapular Pain|Effect of Scapular Mobilization on Patients With Scapular Pain Associated With Myofascial Trigger Point||Mae Fah Luang University Hospital|Yes|Not yet recruiting|May 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|50 Years|No|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437266||21740|
NCT02437279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N14OPC|Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients|Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients|OpACIN|The Netherlands Cancer Institute|No|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02437279||21739|
NCT02430857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-5-2015|Osteopathy and Latent Hypothyroidism|Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism||Diekmann, Emanuel Amier|Yes|Not yet recruiting|October 2015|January 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|65 Years|No|||May 2015|May 17, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430857||22233|
NCT02438384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0986|Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial|Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial|BETTER_Pilot|University of North Carolina, Chapel Hill|No|Recruiting|September 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||March 2016|March 17, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438384||21654|
NCT02438605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StM 596|Dynamic CT Imaging After Nellix Endoprosthesis Implantation|Dynamic CT Imaging After Nellix Endoprosthesis Implantation||Rijnstate Hospital|No|Recruiting|April 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients eligible for endovascular aortic repair using the Nellix endovascular sealing        system|May 2015|May 6, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438605||21637|
NCT02489058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-061|A Study of Long-Term Responders on Olaparib|A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours|OLALA|University Health Network, Toronto|No|Not yet recruiting|July 2015|December 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|-  Archival tumor tissue sample for biomarker research        -  Optional fresh tumor tissue sample for biomarker research (if participants are still on           olaparib and their disease progressed)        -  Blood sample for pharmacokinetics (if participants are still on olaparib)        -  Blood sample for pharmacogenomics (if participants are still on olaparib and their           disease progressed)        -  Blood samples for circulating tumor DNA (if participants are still on olaparib)        -  Blood sample for germline BRCA1/2 testing if not previously done (if participants are           still on olaparib and their disease progressed)|Female|18 Years|N/A|No|Probability Sample|Epithelial ovarian cancer (including fallopian tube or peritoneal cancer) patients that        are or had received treatment with Olaparib.|June 2015|July 1, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02489058||17763|
NCT02489240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH301|Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy|Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy||Chinese PLA General Hospital|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489240||17749|
NCT02434159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0583|Role of Cardiac Computed Tomography in Optimising Response to Cardiac Resynchronisation Therapy|Role of Cardiac Computed Tomography and Cardiac Magnetic Resonance in Optimising Response to Cardiac Resynchronisation Therapy||University College, London||Recruiting|May 2012|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||April 2015|April 30, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434159||21979|
NCT02437422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGTP-001|Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease|A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)||Prolong Pharmaceuticals|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437422||21728|
NCT02443467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20397|A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer|||Hoffmann-La Roche||Completed|July 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|211|||Female|18 Years|N/A|No|Non-Probability Sample|Participants with HER2-positive early breast cancer|March 2016|March 1, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443467||21265|
NCT02443480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01714|Development and Validation of the Saint Paul's Endoscopy Comfort Scale (SPECS) for Colonoscopy and Upper Endoscopy|Do You Have Your SPECS in Order? Development and Validation of the Saint Paul's Endoscopy Comfort Scale (SPECS) for Colonoscopy and Upper Endoscopy||University of British Columbia|No|Active, not recruiting|September 2014|May 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|N/A|No|Non-Probability Sample|Outpatients referred to Saint Paul's Hospital for colonoscopy and upper endoscopy|February 2016|February 1, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443480||21264|
NCT02429336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01368-XP|Characteristics of Women With Reproductive Concerns|Clinical Characteristics of Women Presenting to the Reproductive Endocrinology Clinic||University of Tennessee|No|Recruiting|January 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Female|8 Years|N/A|No|Probability Sample|Population: All patients presenting to the reproductive endocrinology clinic.|April 2015|April 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02429336||22348|
NCT02492191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4765|RAPP- Systematic E-assessment of Postoperative Recovery in Patients Undergoing Day Surgery|RAPP- Systematic E-assessment of Postoperative Recovery in Patients Undergoing Day Surgery|RAPP|Örebro University, Sweden|No|Not yet recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02492191||17523|
NCT02431338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48241|Cost-effectiveness of Remote Ischemic Conditioning as an Adjunct to Primary Percutaneous Coronary Intervention|Cost-effectiveness of Remote Ischemic Conditioning as an Adjunct to Primary Percutaneous Coronary Intervention in Patients With ST-elevation Myocardial Infarction||University of Aarhus|Yes|Active, not recruiting|February 2007|September 2015|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|333|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02431338||22196|
NCT02431351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-014|Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients|A Phase 2, Open-Label, Single Arm Study Evaluating the Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Erythropoietin (EPO)-Refractory Lower-Risk Myelodysplastic Syndrome (MDS)|SIER|Karyopharm Therapeutics, Inc|No|Withdrawn|November 2015|May 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 27, 2015|Yes|Yes|Trial never opened.|No||https://clinicaltrials.gov/show/NCT02431351||22195|
NCT02431416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-430981|Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty|Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Precocious Puberty||Region Örebro County|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Female|1 Year|N/A|No|||April 2015|May 4, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02431416||22190|
NCT02438878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIC NEI-12-TX|Supporting Baby Behavior Through Pediatric Offices|Supporting Baby Behavior Through Pediatric Offices||University of California, Davis|No|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438878||21616|
NCT02484885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB0030|Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility|Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility||Western University, Canada|No|Recruiting|August 2011|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484885||18082|
NCT02439125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBS-ELTO-201|A Study to Examine the Efficacy and Safety of Eltoprazine HCl for Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease||Amarantus BioScience Holdings, Inc.|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|30 Years|85 Years|No|||June 2015|June 1, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439125||21597|
NCT02439138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-040|Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia|Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Suspended|October 2015|May 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 29, 2015|Yes|Yes|Pending safety review|No||https://clinicaltrials.gov/show/NCT02439138||21596|
NCT02439931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00959|Remote Psychosocial Intervention for Brain Tumour Survivors|Feasibility Study of a Remote Psychosocial Intervention for Brain Tumour Survivors||British Columbia Cancer Agency|No|Not yet recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||May 2015|May 12, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439931||21536|
NCT02441114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM_COPD_PILOT|A Pilot Study to Investigate Pharmacokinetic Characteristics After Co-administration of HCP0910 and HGP1011|A Pilot Study to Investigate Pharmacokinetic Characteristics After Co-administration of HCP0910 and HGP1011||Seoul National University Hospital|No|Not yet recruiting|June 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|10|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441114||21445|
NCT02482610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0088B|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat||Ohio State University|No|Recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02482610||18257|
NCT02432885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095/08|Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial|Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy||InCor Heart Institute|No|Completed|June 2009|June 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|6 Years|N/A|No|||April 2015|May 1, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02432885||22077|
NCT02432898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topcon-001-2014|Non-Invasive Imaging of the Human Eye|Non-Invasive Imaging of the Human Eye||Topcon Medical Systems, Inc.|No|Withdrawn|July 2014|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Normal subjects will be recruited from Topcon Medical Systems.|April 2015|April 28, 2015|November 20, 2014||No|No subjects were enrolled in this protocol|No||https://clinicaltrials.gov/show/NCT02432898||22076|
NCT02435082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varia-REG 1.0|Vascular Assessment of Regulation Index Arrays Registry|Vascular Assessment of Regulation Index Arrays Registry|VARIA|NeuroChaos Solutions, Inc.|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients contacting a clinic to schedule an appointment for evaluation of the brain (pre        or post injury) will be informed about the registry and will be given the option to        participate.|March 2016|March 21, 2016|April 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435082|6 Months|21908|
NCT02430987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40594814.4.0000.5479|Prevalence of Metabolic Syndrome in Postmenopause Woman With Hypoactive Sexual Desire Disorder|Prevalence of Metabolic Syndrome in Postmenopause Woman With Hypoactive Sexual Desire Disorder||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Recruiting|September 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430987||22223|
NCT02493712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD98-M-2002|A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M|A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients With Active, Mild to Moderate Ulcerative Colitis||Holy Stone Healthcare Co., Ltd|No|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493712||17406|
NCT02493725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100069|JET-GBS - Japanese Eculizumab Trial for GBS|A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME||Chiba University||Recruiting|July 2015|March 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|99 Years|No|||October 2015|October 13, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493725||17405|
NCT02493777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLD200-107|A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting|A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting||Ironshore Pharmaceuticals and Development, Inc|No|Completed|July 2015|March 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|6 Years|12 Years|No|||August 2015|March 16, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493777||17401|
NCT02439879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPAEP25082009|Alpha Lipoic Acid for Treatment of Diabetic Neuropathy|Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading||Universidad Popular Autónoma del Estado de Puebla|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|N/A|N/A|No|||February 2016|February 2, 2016|May 4, 2015||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02439879||21540|
NCT02440022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0023-01|Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae|A Prospective, Global, Multicenter, Randomized, Controlled Study Comparing Lutonix® 035 AV Drug Coated Balloon PTA Catheter vs. Standard Balloon PTA Catheter for the Treatment of Dysfunctional AV Fistulae||C. R. Bard|Yes|Recruiting|June 2015|September 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|284|||Both|21 Years|N/A|No|||March 2016|March 24, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440022||21529|
NCT02441998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131998|Real-Time Characterizations of Diminutive Colorectal Polyps Using Narrow Band Imaging|Prospective Multi-Center Study Evaluating Real-Time Characterizations of Diminutive Colorectal Polyps Using Narrow Band Imaging: Implications for the Resect and Discard Strategy||University of Michigan|No|Completed|October 2013|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|N/A|N/A|No|Non-Probability Sample|Practicing gastroenterologists from 2 academic medical centers|May 2015|May 12, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441998||21377|
NCT02427490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002215|A Problem-Solving Intervention for Family Caregivers in Palliative Oncology|A Problem-Solving Intervention for Family Caregivers in Palliative Oncology||University of Missouri-Columbia|No|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 6, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02427490||22490|
NCT02480140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-CIMT|Self-regulated Constraint-induced Movement Therapy in Subacute Stroke Patients|Self-regulated Constraint-induced Movement Therapy in Subacute Stroke Patients||University of Western Sydney|No|Completed|September 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Both|60 Years|N/A|No|||June 2015|June 26, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02480140||18447|
NCT02436044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-011|HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC|Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Temporarily not available|April 2015|May 2020|Anticipated|May 2020|Anticipated|Phase 2|Expanded Access|N/A|||||||Both|18 Years|75 Years|No|||May 2015|May 8, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02436044||21834|
NCT02428205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001935|Combined Effects of Early Behavioral Intervention and Propranolol on ASD|||University of Missouri-Columbia|No|Recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Years|8 Years|No|||December 2015|December 2, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02428205||22435|
NCT02442102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DC013569|PReventing the EffectS of Intubation on DEglutition|Understanding and Improving Dysphagia After Mechanical Ventilation|PRESIDE|Johns Hopkins University|No|Recruiting|July 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|100 Years|No|||February 2016|February 22, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02442102||21369|
NCT02484573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-1116-14/15-1|Evaluation of Genes Involved in the Duodenal Epithelial Integrity Pre and Post Treatment With Betablockers in Cirrhotics|Evaluation of Genes Involved in the Duodenal Epithelial Integrity, Inflammatory Citosin and Lipopolysaccharide in Cirrhotic Patient Pre and Post Treatment With Non Selective Betablockers (Propanolol)|PERMEABETA|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||June 2015|June 24, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484573||18106|
NCT02484586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTC2014-04|Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses|Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses||Brien Holden Vision|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484586||18105|
NCT02431065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GyAne-1|Ultrasonography-guided and Surgical Rectus Sheath Block in Single-port Access Laparoscopy|Comparing the Analgesic Effects of Ultrasonography-guided and Direct-surgical Rectus Sheath Block in Single-port Access Laparoscopy Patients||Chungnam National University Hospital|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|20 Years|70 Years|No|||April 2015|April 30, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02431065||22217|
NCT02439762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH 14-1-0005|Intervening to Reduce Suicide Risk in Veterans With Substance Use Disorders|||University of Michigan|Yes|Recruiting|July 2015|November 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02439762||21549|
NCT02435121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT14205|A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification|Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients With Advanced Pretreated Non-Small Cell Lung Cancer (NSCLC) Harboring MET Gene Amplification||Sanofi|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435121||21905|
NCT02435134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIRROM|Examination Chair for Hip Internal Rotation Range of Motion Measurement|Validation of a Test Protocol for Measuring the Hip Internal Rotation Range of Motion Using a Newly Developed Examination Chair|HIRROM|Schulthess Klinik|No|Not yet recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants|April 2015|May 5, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435134||21904|
NCT02435433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15755|A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein|Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib|REACH-2|Eli Lilly and Company|Yes|Recruiting|July 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|399|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435433||21881|
NCT02483611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5362/2013|Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block|Effect of Intravenous Infusion of Magnesium Sulfate Associated or Not to Lidocaine On the Neuromuscular Blockade Induced by Muscle Relaxant Cistracurium||University of Sao Paulo|Yes|Completed|July 2015|September 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|48|||Both|18 Years|60 Years|No|||December 2015|December 10, 2015|June 18, 2015||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT02483611||18180|-It was not possible to measure Magnesium sulfate and Lidocaine levels
NCT02483624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.02.107T|3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus|A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE)||Northwell Health|Yes|Terminated|January 2016|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|6|||Female|18 Years|50 Years|No|||January 2016|January 29, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02483624||18179|
NCT02483637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012|Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients|A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients|Feasibility|CSA Medical, Inc.|Yes|Recruiting|February 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|40 Years|75 Years|No|||February 2016|February 1, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483637||18178|
NCT02437552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP 2015-1|Cycle Ergometer Exercise in Phase I of Cardiac Rehabilitation After Cardiac Surgery|Cycle Ergometer Exercise in Phase I of Cardiac Rehabilitation After Cardiac Surgery||University of Sao Paulo|Yes|Active, not recruiting|March 2015|March 2019|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|70 Years|No|||May 2015|May 6, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02437552||21718|
NCT02436408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.022|VISmodegib for ORbital and Periocular Basal Cell Carcinoma|VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)|VISORB|University of Michigan Cancer Center|Yes|Recruiting|May 2015|||August 2019|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436408||21806|
NCT02440308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0069|68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer|68Ga-DOTA-Bombesin PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study||Stanford University|Yes|Active, not recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|19 Years|N/A|No|||August 2015|August 11, 2015|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02440308||21507|
NCT02483897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6015429|Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion|Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion||Queen's University|Yes|Not yet recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483897||18158|
NCT02508376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0109|Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects|A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|October 2015|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|70|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|October 22, 2015|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508376||16280|
NCT02508389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-201|A Study of GC4419 Protection Against Radiation Induced Oral Mucositis in Patients With Head & Neck Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx||Galera Therapeutics, Inc.|Yes|Recruiting|October 2015|June 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02508389||16279|
NCT02506257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042SI|Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects|Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects||SIFI SpA|Yes|Active, not recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02506257||16442|
NCT02399306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scch2015001|Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma|A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma||Sichuan Cancer Hospital and Research Institute|No|Recruiting|March 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02399306||24653|
NCT02399592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toco-Ovar|Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer|Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer|Toco-Ovar|Vejle Hospital|Yes|Recruiting|March 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02399592||24631|
NCT02399605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cirugia1|Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus|Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus in Colorectal Surgery|SESPI|Hospital General Universitario Elche|No|Active, not recruiting|March 2015|June 2015|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2015|March 21, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02399605||24630|
NCT02401711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0073|How Should Surgical Residents Be Educated About Patient Safety|How Should Surgical Residents Be Educated About Patient Safety in the Operating Room: a Pilot Randomized Trial||The University of Texas Health Science Center, Houston||Active, not recruiting|February 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|58|||Both|20 Years|40 Years|No|||June 2015|June 14, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02401711||24468|
NCT02401724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN13NE562|NonInvasive Brain Stimulation in Stroke Patients|A Randomised Trial of Non-Invasive Brain Stimulation (NIBS) in Stroke Survivors|RTNIBS|NHS Greater Glasgow and Clyde|No|Not yet recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|90 Years|No|||March 2015|March 27, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02401724||24467|
NCT02506686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERO0001|Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment|Evaluation of Meropenem Penetration Across Blood-Brain Barrier in Patients With Central Nervous System Infection After Neurosurgery and Optimization of Meropenem Treatment||Huashan Hospital|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02506686||16409|
NCT02494960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MegaRCT|Brief Tobacco Cessation Intervention|Brief Tobacco Cessation Intervention: a Randomized Controlled Trial in Guangdong, China||The University of Hong Kong|Yes|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|16000|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494960||17310|
NCT02402699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-414|Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan|Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan|Yervoy RMP|Bristol-Myers Squibb|No|Recruiting|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|All adult unresectable, recurrent, or Metastatic Melanoma patients with HBV or HCV treated        with at least 1 dose of Ipilimumab therapy in Taiwan|February 2016|March 11, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02402699|6 Months|24392|
NCT02402712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29159|Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer|||Hoffmann-La Roche||Recruiting|May 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402712||24391|
NCT02400892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105952|Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries|Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries||Lawson Health Research Institute|No|Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|The study population will involve adult patients planned to undergo an elective, primary        hip or knee replacement surgery at one of the hospitals of the London Health Sciences        Centre (University Hospital or Victoria Hospital).|March 2015|March 26, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02400892||24531|
NCT02500277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1815/Res/2439|Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy|A Study to Evaluate the Yield of Pleural Biopsy With a Flexible Cryoprobe Versus Flexible Forceps During Semirigid Thoracoscopy: a Comparative Study|COFFEE|Postgraduate Institute of Medical Education and Research|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|12 Years|79 Years|No|||July 2015|July 14, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02500277||16902|
NCT02507401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/035/15|Mixed-species Biofilms and Silicone Device Longevity|Mixed-species Biofilm Composition as a Predictor of Device Longevity in Patients Using Silicone Medical Devices||University of Aberdeen|No|Recruiting|September 2015|February 2018|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|27|Samples Without DNA|Microbes isolated from in-dwelling medical device (voice prostheses) and oral rinse. No      patient biomaterial will be collected or retained.|Both|18 Years|N/A|No|Non-Probability Sample|Users of voice prostheses who are registered at the Speech and Voice Clinic, Aberdeen        Royal Infirmary.|July 2015|September 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507401|12 Months|16354|
NCT02507414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-021|Mesenteric Traction Syndrome During Upper Gastrointestinal Surgery|Characterization of the Mesenteric Traction Syndrome During Upper Gastrointestinal Surgery for Malignant Disease||Rigshospitalet, Denmark|No|Enrolling by invitation|August 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02507414||16353|
NCT02395458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-3609-22|Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens|Efficacy on Helicobacter Pylori Eradication With Sequential Antibiotic Compared to Triple Therapy for 14 Days||Coordinación de Investigación en Salud, Mexico|Yes|Completed|March 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02395458||24949|
NCT02403076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSK006|Gastrointestinal Bleeding Management|Management of Patients With Gastrointestinal Bleeding - a Prospective Single Center Registry Study||Dr. Horst Schmidt Klinik GmbH|No|Active, not recruiting|January 2015|||January 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients that will be admitted to our hospital with a gastrointestinal bleeding.|July 2015|July 6, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02403076|7 Days|24365|
NCT02507427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1504-070-664|Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)|Safety and Efficacy of Pelvic Autonomic Nerve Monitoring and Mapping During Robot Assisted Laparoscopic Radical Prostatectomy for Preservation of Erectile Function||Seoul National University Hospital|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|19 Years|80 Years|No|||December 2015|December 8, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507427||16352|
NCT02507440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2017|Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's|Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's||Bassett Healthcare|No|Recruiting|September 2015|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507440||16351|
NCT02507531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNX-041|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||July 22, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507531||16344|
NCT02509858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ΒΠΠΚ 50/11-02-09|The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.|The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, at All Stages of Type 2 Diabetes Mellitus.||Attikon Hospital|No|Completed|February 2009|July 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02509858||16166|
NCT02509871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00633-46|Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)|Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer|MetaCa2|Centre Jean Perrin|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02509871||16165|
NCT02395770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPPQ-Apr2013|Effects of a Movement Training for Subacromial Pain Syndrome|Effects of a Movement Training Oriented Rehabilitation Program on Symptoms, Functional Limitations and Acromiohumeral Distance in Individuals With Subacromial Pain Syndrome|MTforSPS|Laval University|No|Completed|June 2013|September 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02395770||24925|
NCT02444182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD04/13|Effects of Probiotics on Oral Health|Effect of Lactobacillus Rhamnosus LGG and Bifidobacterium Lactis BB-12 on Gingival Health and Dental Plaque in Healthy Adolescents: a Randomized Controlled Clinical Trial||Kuwait University|No|Completed|December 2014|June 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Male|13 Years|15 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|May 12, 2015|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT02444182||21210|limitations of this study include:short period: only 4 weeks to reach maximum compliancenumber of participants: just above the minimum sample size due to refusal of many parents to give consent for their children participation.
NCT02491892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO16934|A Study of Pertuzumab in Participants With Metastatic Breast Cancer|Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2||Hoffmann-La Roche||Completed|February 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|June 11, 2015|Yes|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT02491892||17546|Recruitment was halted within the planned study design. The study was designed to stop recruitment following the interim analysis if the response rate (CR or PR) was <1 of 23 participants per arm after all participants completed at least 2 cycles.
NCT02436941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53191|Radiation Medicine Patient Registry, Loma Linda University Medical Center|Loma Linda University Medical Center Department of Radiation Medicine Patient Registry||Loma Linda University|No|Enrolling by invitation|October 2003|October 2040|Anticipated|March 2025|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|75000|||Both|N/A|N/A|No|Probability Sample|Any patients who have proton or conventional x-ray therapy|May 2015|May 4, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02436941|99 Years|21765|
NCT02443363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFR/KTx/2015/04|Estimated Glomerular Filtration Rate After Kidney Transplantation - the Formula MDRD, CKD-EPI or Cockroft-Gault?|Estimated Glomerular Filtration Rate After Kidney Transplantation - the Formula Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or Cockroft-Gault?|eGFR|Medical University of Warsaw|Yes|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|170|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 300 consecutive patients after kidney transplantation admitted to routine visit        in Transplant Centre|September 2015|September 30, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02443363||21272|
NCT02430051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE024978-01|Sensory Adapted Dental Environments to Enhance Oral Care for Children|Sensory Adapted Dental Environments to Enhance Oral Care for Children (SADE-2)|SADE-2|University of Southern California|Yes|Not yet recruiting|May 2015|April 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02430051||22293|
NCT02491931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glutamine-2015|Oral Glutamine in Cardiopulmonary Bypass|Oral Glutamine Reduces Myocardial Damage After Coronary Revascularization Under Cardiopulmonary Bypass||Instituto Mexicano del Seguro Social|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491931||17543|
NCT02479126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01882|Interstitial Lung Diseases in the Veterans Administration|Interstitial Lung Diseases in the Veterans Administration Health System - A Retrospective Description of Patient Characteristics, Management, and Outcomes||Durham VA Medical Center|No|Not yet recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|All adults with encounters at any VISN6 healthcare facility during specified time period|January 2016|January 19, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479126||18525|
NCT02439684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-299|Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?|Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?||The University of Hong Kong|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1357|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Chinese adult subjects who are classified to have IFG will be recruited from various GOPCs        from the Hong Kong West Cluster and New Territories East Cluster.|March 2016|March 4, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02439684||21555|
NCT02439697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.2 18thApril, 2015|A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients|A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients||The University of Hong Kong|Yes|Recruiting|November 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02439697||21554|
NCT02443376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWV/CP/HD/2015/05|The Effects of Hemodialysis Session on Vascular Stiffness|The Effects of Hemodialysis Session on Pulse Wave Velocity and Central Arterial Pressure|PWV/CP/HD|Medical University of Warsaw|Yes|Completed|May 2015|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 80 consecutive patients on maintenance hemodialysis and 30 healthy subjects        were included in this study.|September 2015|September 30, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02443376||21271|
NCT02430363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIK-W/33-15|Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475|Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)||Medical Research Council|No|Enrolling by invitation|March 2013|June 2018|Anticipated|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02430363||22270|
NCT02428569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00051812|Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: The PREPARE NOW Study|Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: Partnering to Break the News, Review All Options, Weigh Pros and Cons (PREPARE NOW)|PREPARE NOW|Duke University|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02428569||22407|
NCT02432703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106641|A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.||Janssen Research & Development, LLC|No|Suspended|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|64 Years|No|||January 2016|January 22, 2016|April 29, 2015|Yes|Yes|On-hold as serious adverse events reported in another company's Phase1 safety study with    experimental drug in this class|No||https://clinicaltrials.gov/show/NCT02432703||22091|
NCT02483312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP-IL-12|A Study of IL-12 in Patients With Acute Myelogenous Leukemia (AML)|Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12||University Health Network, Toronto|Yes|Not yet recruiting|August 2015|February 2021|Anticipated|August 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483312||18203|
NCT02442986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URostock|Neurological Outcome in Surgical and Non-surgical Septic Patients|Prospective Observational Study: Comparison of Neurological Outcome in Septic Surgical, Septic Non-surgical and Non-septic Patients on ICU|NOSEPP|University of Rostock|No|Recruiting|November 2012|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|39|||Both|18 Years|N/A|No|Probability Sample|All patients with severe sepsis and septic shock and fulfilling the inclusion criteria        should be screened for the study on two surgical (septic surgical patients), one medical        intensive care unit (septic non-surgical patients) and one neurological intensive care        unit (non-septic patients) at the university hospital of Rostock, Germany.|December 2015|December 7, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02442986||21301|
NCT02431962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10007170|Alberta Lung Cancer Screening Program|Alberta Lung Cancer Screening Program||University of Calgary|No|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|800|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431962||22148|
NCT02478853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCER 14-15 -15|Impact of a Regional Program Agir Sur Sa SantE|Agir Sur Sa SantE- Impact of a Regional Integrated Prevention and Management of Cardio-metabolic Chronic Diseases Program in Primary Care||Université de Sherbrooke|No|Recruiting|March 2015|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All healthcare professionals involved in CMCD management in the targeted clinics will be        invited to participate (questionnaires and group interviews). All adult patients        prospectively presenting at the targeted clinics will receive an invitation letter        describing the project.|June 2015|November 30, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02478853||18546|
NCT02439996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD(2015-2016)|Different Doses of IVIG for Kawasaki Disease|Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial||Children's Hospital of Fudan University|Yes|Recruiting|January 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|1 Month|12 Years|No|||January 2014|January 31, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439996||21531|
NCT02434822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC03|A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic|Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (ShancholTM) in Subjects Aged 1 Year and Older in Dominican Republic||Sanofi|No|Active, not recruiting|April 2015|July 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|336|||Both|1 Year|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434822||21928|
NCT02440412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kine015|Effect of Massage Therapy in Cortisol Level|Effects of a Single Session of Massage Therapy in Salivary Cortisol Levels in Asymptomatic Persons With Administrative Tasks and / or Office Work.|MTCL|University of Chile|No|Completed|July 2014|March 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02440412||21499|
NCT02440425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18207|Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer|Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|August 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440425||21498|
NCT02492113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOBTRIAL|Effects of Different PEEP Levels on Work of Breathing in Morbidly Obese Patients Prior to and After Extubation|Effects of Different PEEP Levels on Work of Breathing in Morbidly Obese Patients Prior to and After Extubation||Massachusetts General Hospital|No|Recruiting|November 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02492113||17529|
NCT02492126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002020|Esophageal Motility in Reflux Induced Cough|Chronic Cough and Reflux: Is Esophageal Motility the Key?||Mayo Clinic|No|Recruiting|January 2016|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|87|||Both|18 Years|75 Years|No|Probability Sample|Chronic cough patients|January 2016|January 19, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02492126||17528|
NCT02437539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-730|Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography|68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human|uPAR-PET|Rigshospitalet, Denmark|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|80 Years|No|||August 2015|August 21, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02437539||21719|
NCT02431143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAP 0714|Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa|An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa||Drugs for Neglected Diseases|No|Active, not recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|12 Years|No|||October 2015|October 29, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02431143||22211|
NCT02431403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMACEL|ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma|Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma||Pusan National University Hospital|No|Recruiting|February 2015|||February 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|94|||Both|20 Years|N/A|No|||May 2015|May 3, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02431403||22191|
NCT02438319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optic Disc Planimetry|Automatic vs. Manual Optic Disc Planimetry|Automatic vs. Manual Optic Cup and Optic Disc Segmentation in Glaucoma|Planimetry|University of Zurich|No|Not yet recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|152|||Both|18 Years|N/A|No|Non-Probability Sample|patients with a diagnosis of open-angle glaucoma|May 2015|May 5, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02438319||21659|
NCT02433509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH101-IRB1-114|Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke|Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke||China Medical University Hospital|Yes|Recruiting|May 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|45 Years|80 Years|No|||December 2015|February 14, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433509||22029|
NCT02480166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33196|Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6|Comparative Efficacy of Fixed-dose Combination of Sofosbuvir and Ledipasvir for 8 or 12 Weeks for Chronic Hepatitis C Genotype 6||Stanford University|No|Recruiting|June 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480166||18445|
NCT02435784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-170|The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong|The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong: an Open Label Randomized Controlled Trial||The University of Hong Kong|Yes|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|84|||Both|15 Years|64 Years|No|||September 2015|September 21, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435784||21854|
NCT02440555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBS2014-2|Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose|Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose Compared to Current Screening in the Priority Health Area of Saint-Etienne and the Sainté Diabète Network.|Sainté Diabète|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1305|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population is composed by patients living in the Saint-Etienne area, 45 years or older,        not known as diabetics, and viewed in a pharmacy or a hospital.|May 2015|May 7, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440555||21488|
NCT02440568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0181|AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients|AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients|AML-02|University of Illinois at Chicago|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|64 Years|No|||May 2015|May 8, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440568||21487|
NCT02440581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0976-F6A|Renal Osteodystrophy: An Individual Management Approach|Renal Osteodystrophy: A Fresh Approach||University of Kentucky|Yes|Recruiting|July 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|21 Years|N/A|No|||December 2015|December 1, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440581||21486|
NCT02492139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBF1503|Evaluation of the Reliability and Usability of the Reusable "BrownieForSymphony" Pump Set in Home Use|ESP II Evaluation of the Reliability and Usability of the Reusable "BrownieForSymphony" Pump Set in Home Use|ESPII|Medela AG|No|Completed|July 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492139||17527|
NCT02492152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0090-15|Does the Use of Dianatal Reduce the Rate of Episiotomy and Vaginal Tears in Birth?|Randomised ,Open Label in Meir Medical Center. Study the Potential of Dianatal Gel to Reduce the Rate of Episiotomy and Vaginal Tears in Birth||Meir Medical Center|No|Not yet recruiting|August 2015|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02492152||17526|
NCT02428426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G04|Mucosal Microbiome in Human Gastric Intestinal Metaplasia and Duodenal Tissue.|Mucosal Microbiome in Human Gastric Intestinal Metaplasia and Duodenal Tissue.||Shandong University|Yes|Recruiting|September 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|The metagenome was obtained from biopsy specimen.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospective patients scheduled for pCLE examination at Qilu Hospital, Shandong University|April 2015|April 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428426||22418|
NCT02428439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015-0305-0003|Identification of Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression|Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression||Asan Medical Center|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|whole blood sample for GWAS(Genome-Wide Association Study)|Both|11 Years|18 Years|No|Non-Probability Sample|Children and adolescents between 11 years and 18 years in depressed psychiatric        outpatients.        increased suicidal ideation: 14 people, non-increased suicidal ideation: 54 people,        patient drop-out rate: 20%, total 80 people.|November 2015|November 26, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02428439||22417|
NCT02430688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Extremities Neoplasms -IRE-01|Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms|Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430688||22245|
NCT02430974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFYYXWK-CKC1102|Chemotherapy of NSCLC With or Without Icotinib|Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer||Nanfang Hospital of Southern Medical University||Active, not recruiting|January 2011|January 2018|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 26, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430974||22224|
NCT02486926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-I069|The Effects of Remifentanil and Remifentanil-Alfentanil Administration in Children|The Effects of Remifentanil and Remifentanil-Alfentanil Administration on Emergence Agitation After Brief Ophthalmic Surgery in Children||Hallym University Medical Center|Yes|Completed|November 2012|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|102|||Both|3 Years|9 Years|No|||July 2015|July 2, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02486926||17926|
NCT02437175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pronutri-IIIa-001|Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study|Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study||Laboratoires Pronutri|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||February 2016|March 2, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437175||21747|
NCT02437188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AT008349-01|Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT|Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT|PreACT|University of Iowa|Yes|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02437188||21746|
NCT02441920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_09-196|Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis|Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis||University of Birmingham|No|Active, not recruiting|November 2010|November 2030|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have already consented to their participation in a co−existing study will be        eligible for inclusion: 04/Q2702/18 submitted 08/06/ 2004 "Establishment of an inception        cohort for the prospective evaluation of predictors of cardiovascular morbidity and        mortality in patients with rheumatoid arthritis."|May 2015|May 8, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441920||21383|
NCT02441933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0074|Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)|A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane Versus Anthracyclines Followed by Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patients With Triple-negative Breast Cancer||Yonsei University|Yes|Recruiting|December 2015|June 2023|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|840|||Female|19 Years|N/A|No|||December 2015|December 29, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02441933||21382|
NCT02490826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIS73|Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders|Intervention Software for Children With Speech Sound Disorders||Aveiro University|No|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|42 Months|78 Months|No|||July 2015|July 6, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02490826||17628|
NCT02478372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/ORTH/01|Patient Controlled Epidural Analgesia Versus Local Infiltration Analgesia Following Knee Arthroplasty|Patient Controlled Epidural Analgesia Versus Local Infiltration Analgesia Following Knee Arthroplasty Within an Enhanced Recovery Programme - a Randomised Controlled Trial||Golden Jubilee National Hospital|No|Completed|April 2010|November 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 2, 2015||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT02478372||18583|
NCT02482337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-103|Per-Oral Endoscopic Myotomy for Esophageal Swallowing Disorders|Prospective Evaluation of Per-Oral Endoscopic Myotomy (POEM) of the Lower Esophageal Sphincter for the Treatment of Esophageal Swallowing Disorders|POEM|Baylor Research Institute|Yes|Recruiting|June 2014|December 2025|Anticipated|January 2025|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|85 Years|No|||June 2015|June 23, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02482337||18278|
NCT02430311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081BC00002|The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.|A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|June 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|100 Years|No|||March 2016|March 18, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02430311||22274|
NCT02430324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prot.1937/2009|The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study|Post Traumatic Cerebral Infarction Increases Mortality and Morbidity in Patients With Moderate or Severe Head Trauma. The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study||Azienda Ospedaliera Spedali Civili di Brescia|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|143|||Both|16 Years|N/A|No|Non-Probability Sample|patients with moderate or severe brain injury, monitored with invasive intracranial        pressure.|April 2015|April 27, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02430324||22273|
NCT02431741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxT Ag 03|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds|Title: A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds||Molnlycke Health Care AB|No|Recruiting|October 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431741||22165|
NCT02431754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15734|A Study of Tadalafil (LY450190) in Participants With Benign Prostatic Hyperplasia (BPH)|A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)||Eli Lilly and Company|No|Completed|April 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|171|||Male|45 Years|N/A|No|||February 2016|February 19, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431754||22164|
NCT02484313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001(2)|The Effect of Snacks on Glycaemic Regulation in Children|The Effect of Dairy and Non-Dairy Products on Blood Glucose Regulation in Children||Mount Saint Vincent University|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02484313||18126|
NCT02484326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14FCJJ01|Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction|Development and Validation of a Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction||Chinese PLA General Hospital|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3779|||Both|18 Years|80 Years|No|Non-Probability Sample|ST-elevation myocardial infarction patients who were admitted from January 2012 to January        2013|May 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02484326||18125|
NCT02437786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-20|Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®|Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®|GT-20|ALK-Abelló A/S|Yes|Completed|September 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|58|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437786||21700|
NCT02431390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-03-2015-002|Upper Limb Biofeedback Rehabilitation System (RAPAELⓇ Smart Glove Digital Treatment System) Training for Stroke Recovery|Effect of RAPAELⓇ Smart Glove Digital Treatment System on Upper Limb Functional Recovery and Brain Plasticity in Stroke Patients||Pusan National University School of Medicine|Yes|Not yet recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|80 Years|No|||April 2015|April 27, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02431390||22192|
NCT02429310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2042|Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC|Adjuvant Benefit of Neuromuscular Electrical Stimulation to Supervised Exercise in Patients With Intermittent Claudication|AdjIC|Imperial College London|Yes|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02429310||22350|
NCT02429323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8|Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients|Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients: Incremental Versus High Concentration Inhalation Induction||University of Sulaimani|No|Completed|June 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|100|||Both|2 Years|7 Years|No|||April 2015|April 28, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02429323||22349|
NCT02490904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000956-29|Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)|Double-blind Placebo-Controlled Randomised Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenon After Renal Tranplantation : Effect on Graft Function at 3 Months.|EPURE|Central Hospital, Nancy, France|Yes|Not yet recruiting|May 2016|May 2030|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490904||17622|
NCT02435771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359128-8|Efficacy Of Ergocalciferol In Adults According To BMI|Efficacy Of Ergocalciferol In Adults According To BMI||Walter Reed National Military Medical Center|Yes|Recruiting|July 2011|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02435771||21855|
NCT02427932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29664|Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients|PK and PD Modeling of Ampicillin and Gentamicin in Peripartum Patients||Stanford University|No|Recruiting|May 2015|May 2017|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|50|||Female|18 Years|55 Years|No|Non-Probability Sample|Women receiving ampicillin or gentamicin|November 2015|November 10, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02427932||22456|
NCT02440256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP313184|Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial|The Expanded HIV Care in Opioid Substitution Treatment (EHOST) Stepped-wedge, Cluster-randomized Trial|EHOST|Simon Fraser University|No|Not yet recruiting|May 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|46|||Both|N/A|N/A|No|||May 2015|May 11, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02440256||21511|
NCT02492412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huons|Efficacy and Safety of HE10 for Dry Eye Syndrome|Multi-center, Randomized, Double-blind, Active Comparator- Controlled, Parallel Study Evaluating the Efficacy and Safety of HE10 in Subjects With Dry Eye Syndrome||Huons Co.,Ltd.|No|Completed|May 2013|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|21 Years|N/A|No|||July 2015|July 5, 2015|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492412||17506|
NCT02442609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMCurrieU|Internet for Anesthesia Information : a Patient Questionaire|Does Patient Look to Internet for Anesthesia Information Before Surgery : a Prospective International Questionaire Study|e-anesth|Pierre and Marie Curie University|Yes|Recruiting|May 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult (> 18 yrs), schedulled for surgery under local, regional or general surgery|May 2015|May 27, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02442609|1 Day|21330|
NCT02442648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carfilzomib|B-Cell Targeted Carfilzomib Desensitization|B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation||University of Cincinnati|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442648||21327|
NCT02441387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDLLD10446|Predictors of the Outcome of Late Life Depression|Clinical Characteristics and Structural Changes in Magnetic Resonance Imaging: Importance for the Outcome of Late Life Depression||University of Sao Paulo General Hospital|Yes|Recruiting|April 2015|August 2017|Anticipated|January 2017|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Peripheral venous blood (10mL) will be collected from participants, venocubital puncture      into tubes with anticoagulant ethylenediamine tetraacetic acid (EDTA). After collection, the      tubes will be properly stored at 4 ° C until the time of extraction. The genomic      deoxyribonucleic acid (DNA) will be extracted using a salting out technique (Miller et al.      1988). After DNA extraction, the achieved concentration will be measured by reading the Gene      Quant spectrophotometer (Pharmacia Biotech).|Both|60 Years|N/A|No|Probability Sample|Patients who are 60 years old or older with Major Depression (DSMIV-TR).|July 2015|October 26, 2015|July 10, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441387|18 Months|21424|
NCT02427555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-Y8-2015|Effects of Barley Based Food Products on Metabolism and Gut Microflora|Effects of Barley Based Food Products on Metabolism and Gut Microflora||Lund University||Active, not recruiting|April 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02427555||22485|
NCT02427568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA-1|MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening Illness|Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness||Multidisciplinary Association for Psychedelic Studies|No|Recruiting|April 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427568||22484|
NCT02492477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-TRIAL-2014-1.2|TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients|TOP-TRIAL The Safety of Not Flushing the Non-used PORT-A-CATH® in Cancer Patients - a Prospective, Two-arm Phase I Trial, Pilot Trial||Krankenhaus Barmherzige Schwestern Linz|Yes|Recruiting|October 2015|June 2019|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|90 Years|No|||June 2015|October 8, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02492477||17501|
NCT02496663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01053|EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor|A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor||National Cancer Institute (NCI)|Yes|Not yet recruiting|April 2016|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02496663||17179|
NCT02508805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-01RUS|Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy|Open Randomised Comparative Study of the Efficacy and Safety of Neuromultivit (Solution for Injections, 2 ml) in Patients With Vertebrogenic Radiculopathy|NMRUS|Valeant Pharmaceuticals International, Inc.|No|Active, not recruiting|May 2015|November 2015|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||September 2015|September 27, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02508805||16247|
NCT02403570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T125/2014|Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis|Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis|ROMUS|Turku University Hospital|No|Recruiting|February 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|65 Years|No|Probability Sample|MS patients with relapsing-remitting or secondary progressive MS will be recruited from        amongst the MS patients in the neurological outpatient policlinics in the Hospital        District of Southwestern Finland.|March 2015|March 25, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02403570||24327|
NCT02405338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-FDC-001|DC Vaccination for Post-remission Therapy in AML|Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens||Medigene AG|Yes|Recruiting|March 2015|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02405338||24191|
NCT02405351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAMS02102014|Telerehabilitation for Attention and Memory in Stroke|Telerehabilitation for Attention and Memory in Stroke (TEAMS): Development and Initial Evaluation of an Internet-Based Training Program|TEAMS|Nova Scotia Health Authority|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||January 2016|January 14, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02405351||24190|
NCT02496923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2043|High Flow Nasal Oxygen Therapy (Optiflow™) in High-risk Cardiac Surgical Patients|A Randomised Controlled Trial of High-flow Nasal Oxygen (Optiflow™) and Standard Oxygen Therapy in High-risk Patients After Cardiac Surgery||Papworth Hospital NHS Foundation Trust||Not yet recruiting|August 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|74|||Both|19 Years|N/A|No|||July 2015|July 9, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02496923||17159|
NCT02498821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAS-14-004|Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation|Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation: A Comparison Between Standard of Care (Chest X-ray) and Sherlock 3CG® TCS||C. R. Bard|No|Recruiting|May 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|22 Years|N/A|No|||November 2015|November 23, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498821||17014|
NCT02405507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI001|The Effect of Wheat Germ on Gastrointestinal Discomfort, Blood Cholesterol and Postprandial Glycaemic Response|The Effect of Wheat Germ on Gastrointestinal Discomfort, Blood Cholesterol and Postprandial Glycaemic Response in Healthy Volunteers||Universidade do Porto|No|Active, not recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02405507||24178|
NCT02405520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-004|Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine|A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years||Xiamen University|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|144|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02405520||24177|
NCT02410031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17195|Risk Minimisation Study for Diane-35 and Its Generics|Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study||Bayer|No|Completed|June 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|N/A||1|Actual|759|||Both|18 Years|N/A|No|Non-Probability Sample|Physicians eligible to participate who have recently prescribed (e.g., within previous 6        months) Diane-35 or its generics|March 2016|March 15, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02410031||23832|
NCT02396901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 4163/14/143|Goal Direct Therapy to Prevent Acute Kidney Injury|Goal Direct Therapy to Prevent Acute Kidney Injury After Cardiac Surgery|GDT-AKI|University of Sao Paulo|Yes|Not yet recruiting|April 2015|April 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|214|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02396901||24838|
NCT02505958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22331|How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?|How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?||Temple University|No|Active, not recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|1|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02505958||16465|
NCT02509793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0878|A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)|A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)|TBZ|The University of Texas Health Science Center, Houston|No|Recruiting|April 2014|||December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509793||16171|
NCT02399319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403899155|Comparison of INFIX and Plating for Pelvic Ring Injuries With Symphysis Disruptions|Prospective Randomized Comparison of Subcutaneous Internal Fixation ("INFIX") and Plating for Pelvic Ring Injuries With Symphysis Disruptions||Indiana University|Yes|Enrolling by invitation|October 2014|October 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399319||24652|
NCT02409264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JessicaLeske201005638|The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females|The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females||University of Johannesburg|Yes|Recruiting|January 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02409264||23891|
NCT02497495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|736.438|Behaviour After Exercise of Biological, Clinical and Metabolic Variables as From Different Temperatures and Times of Immersion Cold Water Application|Effects Post-exercise of Biological, Clinical and Metabolic Variables as From Different Temperatures and Times of Immersion Cold Water Application in Active Individuals||Paulista University|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|105|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497495||17116|
NCT02494973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005110-32|Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases|Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial|PACHA-01|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|May 2015|||May 2025|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494973||17309|
NCT02494986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107451|A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies|An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N[t]RTIs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in the Rilpivirine Pediatric Studies||Janssen R&D Ireland|No|Recruiting|July 2015|December 2030|Anticipated|December 2030|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|11 Years|N/A|No|||March 2016|March 9, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494986||17308|
NCT02399618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Freeze-dried FMT-2015|Freeze-dried, Capsulized FMT for RCDI|Freeze-dried, Capsulized Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection||Jinling Hospital, China|Yes|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02399618||24629|
NCT02428023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404 General Military Hospital|B-Thalasaemia Trait and Its Possible Cardioprotective Role|B-Thalasaemia Trait and Its Possible Cardioprotective Role||404 General Military Hospital, Larissa|No|Recruiting|March 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|2500|||Both|18 Years|57 Years|Accepts Healthy Volunteers|Probability Sample|2500 subjects who serve in military units in Thessaly Greece|January 2016|January 8, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428023|5 Years|22449|
NCT02428036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI1401-01|A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions|A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions||Takara Bio Inc.|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|20 Years|N/A|No|||June 2015|June 22, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02428036||22448|
NCT02478866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-CM-I01|Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors|Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase I, Open-label, Dose-escalation Study||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|70 Years|No|||June 2015|June 22, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02478866||18545|
NCT02478879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2015-005|A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen|An Open-label Crossover Study to Determine the Patient Preference Between ZP-PTH Patches and Forteo Pens After Daily Treatment for 14 Days in Women 55-85 Years of Age||Zosano Pharma Inc.|No|Active, not recruiting|June 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Female|55 Years|85 Years|No|||July 2015|July 14, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478879||18544|
NCT02439528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.819|Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome|Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome|GENES-SEF|Hospices Civils de Lyon|No|Recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|August 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02439528||21567|
NCT02433964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Vale of Paraíba|Evaluation of Therapeutic Effects of LED (627 +/- 10nm) The Initial Phase of the Ankle Sprains Treatment|EVALUATION OF THERAPEUTIC EFFECTS OF LED (627 +/- 10nm) THE INITIAL PHASE OF THE ANKLE SPRAINS TREATMENT - A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL||Universidade do Vale do Paraíba|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|22 Years|No|||April 2015|May 4, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02433964||21994|
NCT02433977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110207|The Effects of NOx and Conjugated Linoleic Acid on Asthmatics With the Metabolic Syndrome|A Proof of Concept Study to Determine the Effects of NOX and Conjugated Linoleic Acid on Asthmatics With the Metabolic Syndrome|NICLA|University of Pittsburgh|Yes|Recruiting|September 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433977||21993|
NCT02432443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCH-0415|Play and Pre-Literacy Among Young Children|Play and Pre-Literacy Among Young Children|PLAY|McMaster University|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|36|||Both|36 Months|59 Months|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02432443||22111|
NCT02432456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00024679|Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients|Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients||Medical College of Wisconsin|No|Recruiting|September 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432456||22110|
NCT02479139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1207-HHID-205|Clinical Trial To Evaluate ANT-1207 In Subjects With Primary Axillary Hyperhidrosis|Clinical Trial to Evaluate ANT-1207 in the Treatment of Primary Axillary Hyperhidrosis in Adults||Anterios Inc.|No|Active, not recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|146|||Both|18 Years|70 Years|No|||January 2016|January 4, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479139||18524|
NCT02483338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8824|FASS (Facial Action Summary Score) Scale to Differentiate the Pain of Postoperative Anxiety in Children Under 7 Years|Does the FASS (Facial Action Summary Score) Scale Allow to Differentiate the Pain of Postoperative Anxiety in Children Under 7 Years?|FASS|University Hospital, Montpellier|No|Recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|N/A|7 Years|No|||June 2015|July 8, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483338||18201|
NCT02434250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT after Phaco-ELT|Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy|Effectiveness of Selective Laser Trabeculoplasty (SLT) After Failed Phacoemulsification Cataract Extraction Combined With Eximer Laser Trabeculectomy (Phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension|SLT|University of Zurich|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02434250||21972|
NCT02434263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI-CL-HYDRA-02|A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve|A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve||Vascular Innovations Co. Ltd.|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|55 Years|N/A|No|||December 2015|December 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434263||21971|
NCT02432716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HealthPartnersRF|Investigation of the Safety of Intranasal Glulisine in Down Syndrome|A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome||HealthPartners Institute|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|35 Years|80 Years|No|||November 2015|November 24, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432716||22090|
NCT02428881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/0216|Botulinum Toxin A Injections in Patients With Fowler's Syndrome|Open Label Pilot Study to Treat Women With Chronic Urinary Retention or Voiding Dysfunction Due to a Primary Disorder of Sphincter Relaxation (Fowler's Syndrome) With Outpatient Urethral Injections of Botulinum Toxin A (BoNT-A)||University College, London|Yes|Completed|November 2009|||July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02428881||22383|
NCT02428894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1376|Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation|Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation||University of Colorado, Denver|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Change in plasma proteins. [Time Frame, Days 7, 14, 30, 60, 90, and 180 post-LVAD      implantation][Designated as safety issue: No]|Both|21 Years|90 Years|No|Non-Probability Sample|Study participants will be recruited from the University of Colorado Hospital Advanced        Heart Failure Program.|October 2015|October 23, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02428894||22382|
NCT02434224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0655|Creative Music Therapy for Premature Infants|Creative Music Therapy for Premature Infants: Testing a Possible Influence on Brain Structure, Function and Neurobehavioral Outcome||University of Zurich|No|Recruiting|January 2015|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|14 Days|No|||April 2015|April 29, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434224||21974|
NCT02434237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 04 2005|Robot-Aided Neurorehabilitation of the Upper Extremities|||University of Zurich|No|Completed|March 2005|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects and neurological patients after stoke or spinal cord injury|April 2015|May 4, 2015|October 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02434237||21973|
NCT02436434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriServiceGH|The Effect of Intra-articular Pulsed Radiofrequency in Osteoarthritis|The Effect of Intra-articular Pulsed Radiofrequency in Osteoarthritis||Tri-Service General Hospital|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|75 Years|No|||February 2016|February 1, 2016|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436434||21804|
NCT02483572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363-15-FB|Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control|Treatment of Severe Destructive Behavior: Functional Communication Training Versus Wait-List Control||University of Nebraska|No|Not yet recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|12 Years|No|||June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02483572||18183|
NCT02430805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPERCARE(english v. 1.0)JRPB3|Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure|Genetics and Genomics of Hypertension Associated With Microinflammation, Oxydative Stress, Chronic Renal Disease and Heart Failure (A2-B2-B3)|Hypercare|Central Hospital, Nancy, France|Yes|Completed|November 2008|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|April 27, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT02430805||22237|
NCT02435277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-0100-01E|An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients|An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes||NuSirt Biopharma|No|Active, not recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435277||21893|
NCT02438111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK BE 205/13|The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)|The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)||University Hospital Inselspital, Berne|No|Recruiting|November 2013|November 2019|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|blood serum/ stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with age related macular degeneration (AMD)|January 2016|January 4, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02438111||21675|
NCT02429349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-02542-FB|Preservation of Ovarian Tissue and Chemo-Radiotherapy|Surgical Ovarian Preservation in Females Undergoing Chemo-Radiotherapy||University of Tennessee|No|Recruiting|May 2015|March 2021|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|8 Years|40 Years|No|||April 2015|July 28, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02429349||22347|
NCT02479945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06811|Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer|Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|January 2012|||December 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Actual|6|||Male|18 Years|N/A|No|||June 2015|June 23, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02479945||18462|
NCT02441166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7387 08|Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis|Evaluation of the Diagnostic Value of Level of Bone Marrow Tryptase in Adult Systemic Mastocytosis|EvaTryMS|University Hospital, Toulouse|No|Recruiting|October 2015|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02441166||21441|
NCT02441179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027|Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training for Incomplete Spinal Cord Injury Patients|Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training: a Potential Therapy for Incomplete Spinal Cord Injury Patients||Instituto de Rehabilitación Infantil Teletón Chile|No|Active, not recruiting|March 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02441179||21440|
NCT02438332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-CAN-PLS-0337|Retrospective Study of Reoperation After Primary Augmentation With NATRELLE® INSPIRA® Breast Implants||RANBI-I|Allergan|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|350|||Female|22 Years|N/A|No|Non-Probability Sample|Subjects that have undergone a primary breast augmentation for aesthetic reasons with        NATRELLE® INSPIRA® TruForm® 1 or TruForm® 2 implant.|October 2015|October 20, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438332||21658|
NCT02438618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C50|Minimally Invasive Surgery for Ponto Bone Anchored Hearing Implants|Minimally Invasive Surgery for Ponto Bone Anchored Hearing Implants|C50|Oticon Medical|No|Recruiting|October 2014|March 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02438618||21636|
NCT02438865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MElsh112015|Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.|Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.||Mansoura University|Yes|Recruiting|January 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438865||21617|
NCT02484612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AME2P Laboratory|Exercise Intensity and Appetite in Adolescents|Effect of Acute Exercise Intensity on Energy Intake in Adolescents: Effect of Weight Status||Université Blaise Pascal, Clermont-Ferrand|No|Not yet recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|12 Years|15 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02484612||18103|
NCT02439073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-028|Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA)|Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA) - A Randomized Clinical Trial With Blinded Effect Evaluation|PROLUCA|Rigshospitalet, Denmark|Yes|Recruiting|April 2014|November 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02439073||21601|
NCT02435069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ksj-1|A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children|A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children||Nemours Children's Clinic|Yes|Not yet recruiting|June 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|12|||Both|3 Years|12 Years|No|||April 2015|April 30, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435069||21909|
NCT02438553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRLF-0086-14-MMC-CTIL|Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain|A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain||Neurolief Ltd.|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|May 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438553||21641|
NCT02429830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4600|A Study of Reflux Management With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy|RELIEF Study: A Prospective, Multicenter Study of REflux Management With the LINX® System for Gastroesophageal REFlux Disease After Laparoscopic Sleeve Gastrectomy|RELIEF|Torax Medical Incorporated|No|Not yet recruiting|July 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|No|||November 2015|December 17, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429830||22310|
NCT02429843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150128005 (UAB 1504)|A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer|A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer||University of Alabama at Birmingham|Yes|Recruiting|January 2016|||January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|19 Years|N/A|No|||January 2016|February 18, 2016|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02429843||22309|
NCT02493322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLCEMS0514OR-III|Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control||EMS|Yes|Not yet recruiting|June 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|213|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493322||17436|
NCT02432612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP1450|A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer|An Open-label, Multi-centre, Single-dose Clinical Trial to Assess the Pharmacokinetic (PK) Properties and Tolerability of a Single Oromucosal Dose of 6 Sprays of Sativex® in Patients With Advanced Cancer Currently on Background Step III Opioid Therapy||GW Pharmaceuticals Ltd.|No|Withdrawn|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432612||22098|
NCT02441855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pneumonia|Potential Role for Echocardiography in Adult Patients With Community-Acquired Pneumonia|Is There a Potential Role for Echocardiography in Adult Patients With Community-Acquired Pneumonia Who Require Hospitalization ? A Pilot Study||Muğla Sıtkı Koçman University|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|210|||Both|18 Years|N/A|No|Non-Probability Sample|Pneumonia group is defined as patients with community acquired pneumonia diagnosis        hospitalised through emergency department. The control group will be consisted of        consecutive sex- and age-matched patients admitted to the emergency department.|June 2015|June 2, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441855||21388|
NCT02441868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDOS-Family|Feasibility Testing of a Hospice Family Caregiver Intervention to Improve Patient Dyspnea Care|Feasibility Testing of a Hospice Family Caregiver Intervention to Improve Patient Dyspnea Care||Wayne State University|No|Recruiting|June 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02441868||21387|
NCT02490787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7415-4159|Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects|A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)||Novo Nordisk A/S|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Male|18 Years|64 Years|No|||February 2016|February 9, 2016|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02490787||17631|
NCT02479620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0173|Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization|LIMBO-ATX: Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization|LIMBO-ATX|Mercator MedSystems, Inc.|No|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479620||18487|
NCT02493530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HEM 1538|TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea|TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|July 2015|July 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493530||17420|
NCT02439723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regorafenib 1.0|Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients|A Phase I, Open Label Study of the Effects of Lean Body Mass (LBM) and Proton Pump Inhibitors (PPIs) on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients||AHS Cancer Control Alberta|No|Not yet recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439723||21552|
NCT02439736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-06x|EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY|A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY|ALERT-TBIx|Banyan Biomarkers, Inc|No|Recruiting|June 2015|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects eligible for study participation will be over the age of 18 with a standard of        care head CT that has been confirmed to be CT-positive for acute intracranial lesions        based on the local neuroradiologist's review and can undergo blood draw within 12 hours of        head injury. Subjects who will be permitted into the study include those who will meet all        the inclusion criteria and will have none of the exclusion criteria.|January 2016|January 26, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439736||21551|
NCT02431455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-019|The Effect of Postoperative Incentive Spirometry on Pulmonary Function and Pulmonary Complications in Bariatric Surgery|The Effect of Postoperative Incentive Spirometry on Pulmonary Function and Pulmonary Complications in Bariatric Surgery||Lahey Clinic|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02431455||22187|
NCT02431468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTRP-101-202|A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease|A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease||Neurotrope Bioscience, Inc.|Yes|Recruiting|November 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|55 Years|85 Years|No|||March 2016|March 4, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431468||22186|
NCT02479906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-PTSD-01|A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)|A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Brainsway (HAC-Coil) Deep Transcranial Magnetic Stimulation (DTMS) System for the Treatment of Post-Traumatic Stress Disorder (PTSD)||Brainsway|Yes|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|22 Years|68 Years|No|||July 2015|July 23, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479906||18465|
NCT02435758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-PANP01|Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery|||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|April 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Male|20 Years|60 Years|No|||November 2015|November 7, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02435758||21856|
NCT02434783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/204|The Relationship Between Peripheral Arterial Disease and Mitochondrial Respiratory Capacity|The Relationship Between Peripheral Arterial Disease and Mitochondrial Respiratory Capacity||Norwegian University of Science and Technology|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|56|Samples With DNA|gastrocnemicus muscle biopsy|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with arterial insufficience at 1 of three levels, either asymptotic, intermittent        claudication or critical limb ischemia; and healthy persons in a control group|October 2015|November 1, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434783||21931|
NCT02438787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107099|A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis||Janssen Research & Development, LLC|Yes|Recruiting|July 2015|February 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|483|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438787||21623|
NCT02436200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH1909|Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication|Neuromuscular Electrical Stimulation in Patients With Intermittent Claudication|IC|Imperial College London|Yes|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||August 2015|December 1, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02436200||21822|
NCT02436421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045379|Impact of Best Practice Alerts in Cardiology Outpatient Clinics|Impact of Best Practice Alerts in Cardiology Outpatient Clinics||Duke University|No|Active, not recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|7000|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436421||21805|
NCT02490839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504037MINB|Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection|Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study||National Taiwan University Hospital|Yes|Recruiting|July 2015|November 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|20 Years|N/A|No|||January 2016|January 25, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490839||17627|
NCT02440139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458420|Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC|Computer-Aided System for the Improvement of Nodule Detection and Characterization in Thoracic CT Based on a Novel Vessel Suppressed CT Volume||Virginia Polytechnic Institute and State University|Yes|Enrolling by invitation|April 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|12|||Both|55 Years|77 Years|No|||May 2015|May 6, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440139||21520|
NCT02436122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1504-293|Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer|Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer||Seoul National University Hospital|Yes|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|264|||Male|20 Years|80 Years|No|Non-Probability Sample|Enrolled patients should be diagnosed with prostate cancer by TRUS-guided 12 cores biopsy.        In addition, the participants should be treated with radical prostatectomy.|May 2015|May 17, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02436122||21828|
NCT02434016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #15-073|Assessing Diaphragm Muscle Inactivity in Mechanically Ventilated ICU Patients||DIVIP|St. Michael's Hospital, Toronto||Recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted to the ICU in whom the attending clinician has decided to insert the        dedicated feeding tube (EAdi catheter) in the ICU or < 12 hours before admission|December 2015|December 23, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434016||21990|
NCT02434341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20140207G|Sleep in Critically Ill Patients on Mechanical Ventilation in ICU|Sleep Investigation in 3 Homogeneous Groups of Wake Mechanically Ventilated Patients in ICU: 1st Group - Septical Patients; 2nd Group - COPD Patients; 3rd Group - Surgical Patients, in Order to Define Common Sleep Features Within the Groups||University of Southern Denmark|Yes|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|N/A|No|Probability Sample|wake|June 2015|June 23, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434341||21965|
NCT02491879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24924|Ketoprofen Gel vs Placebo in Low Back Pain|Ketoprofen Gel vs Placebo in Patients Presented With Low-back Pain to Emergency Department: A Ranodmized Controlled Trial||Akdeniz University|No|Recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491879||17547|
NCT02438735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-7/12|Endometrioma Related Reduced Ovarian Reserve|The Effect Of The Presence Of Endometriomas On Ovarian Reserve|ERROR|Uludag University|No|Recruiting|April 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Follicle stimulating hormone (FSH) Luteinizing hormone (LH) ESTRADİOL Anti-mullerian hormone      (AMH)|Female|18 Years|40 Years|No|Probability Sample|Patients with endometrioma diagnosis and who has not required surgery for treatment will        be recruited. All patients will be at reproductive period. At first visit the patients        will be evaluated for ovarian reserve markers. Serum samples will be collected in early        follicular phase . Six months later patients will be assesed for the same markers and all        markers will statistically compared.|April 2015|May 13, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438735||21627|
NCT02432378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-128|Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines|A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines||University of Pittsburgh|Yes|Recruiting|July 2015|December 2020|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432378||22116|
NCT02432391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16293|Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations|Self-Monitoring of Blood Glucose (SMBG) as an Educational Tool and a Negative Feedback Loop to Reinforce Blood Glucose Lowering and Discourage Blood Glucose Elevating Self-Management Behaviors in Adults With T2DM||University of Virginia|No|Completed|May 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|24 Years|80 Years|No|||April 2015|April 28, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02432391||22115|
NCT02443766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11G.488|Use of a Functional Neuroimaging Battery for the Evaluation of a Meditation Retreat|Use of a Functional Neuroimaging Battery for the Evaluation of a Meditation|FETZER|Thomas Jefferson University|No|Enrolling by invitation|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02443766||21242|
NCT02431377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.23.INF|Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula|Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula: An Uncontrolled, Open-label, Descriptive Study||Nestlé|No|Completed|April 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|N/A|35 Days|Accepts Healthy Volunteers|||October 2015|November 2, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02431377||22193|
NCT02428244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00061647|Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients|Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients. A Prospective Randomized Trial|STOP|University of Maryland|Yes|Recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02428244||22432|
NCT02428517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ALLO-044|Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)|A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission|ATLAS2015|Asan Medical Center|No|Recruiting|April 2015|December 2024|Anticipated|December 2019|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|110|||Both|15 Years|N/A|No|Non-Probability Sample|Patients who are diagnosed as acute lymphoblastic leukemia, who achieve hematologic        complete remission for the first time or for the second time after chemotherapy, and who        wil receive allogeneic hematopoietic cell transplantation|July 2015|July 1, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428517||22411|
NCT02432222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YorkU-AD1|Effects of Visual Arts and Music Interventions on Dementia|Effects of Visual Arts and Music Interventions on Dementia||York University|No|Not yet recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|65 Years|N/A|No|||April 2015|April 27, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02432222||22128|
NCT02432495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/10|Anterior Screw Fixation Versus Halo Immobilization of Type II Odontoid Fractures in Geriatric Patients With Increased Anesthesia Risk|||Medical University of Vienna||Completed|April 2008|||January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|80|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients aged 65 years or older with an ASA score of 2 or higher who had undergone either        anterior screw fixation or halo immobilization of type II odontoid fractures|April 2015|April 28, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02432495||22107|
NCT02493855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-242|Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults|An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Recruiting|June 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|100 Years|No|||January 2016|January 20, 2016|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493855||17395|
NCT02493868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107128|A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression|SUSTAIN-1|Janssen Research & Development, LLC|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|333|||Both|18 Years|64 Years|No|||March 2016|March 17, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493868||17394|
NCT02501304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV-001|Feasibility Study of the ReVENT Sleep Apnea System|Feasibility Study of the ReVENT Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)|REV-001|Revent Medical International B.V.|No|Completed|May 2011|September 2015|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02501304||16823|
NCT02494687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP2014022|Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy|Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy||Eastern Regional Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2016|January 20, 2016|July 8, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02494687||17331|
NCT02405962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20150109001|Training Parents by Acceptance and Commitment Therapy for Managing Childhood Asthma Care|Effects of a Parental Training Program Using Group-based Acceptance and Commitment Therapy for Managing Children With Asthma: a Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Not yet recruiting|April 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|3 Years|12 Years|No|||April 2015|April 1, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02405962||24143|
NCT02409043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201200330|Neuronal and Glial Biomarkers in Stroke|Neuronal and Glial Biomarkers in Stroke||University of Florida|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|99|Samples Without DNA|Serum and packed red blood cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals experiencing stroke symptoms who present at the University of Florida Shands        Emergency Department or non-stroke control participants. These individuals will be invited        to participate as study participants by a study representative within the first 24 hours        after having a blood draw in the emergency department.|March 2016|March 17, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02409043||23908|
NCT02409056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGeorgia|Putting CDSMP to Work|Putting CDSMP to Work: Implementation of the Live Healthy, Work Healthy Program|WorkCDSMP|University of Georgia|Yes|Recruiting|November 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|800|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02409056||23907|
NCT02508025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG15/079|Towards Better Understanding of FCE Performance in Different Societal Contexts|Towards Better Understanding of FCE Performance in Different Societal Contexts|FCEinternat|Klinik Valens|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|65 Years|No|Probability Sample|Persons with non-specific sub-acute or chronic musculoskeletal pain|July 2015|July 22, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02508025||16306|
NCT02507336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150402|Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165|Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165||University of Miami|Yes|Enrolling by invitation|November 2015|||November 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507336||16359|
NCT02394626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368/14|Surgery for Recurrent Glioblastoma|RESURGE - Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence|RESURGE|University Hospital Inselspital, Berne|Yes|Recruiting|May 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02394626||25013|
NCT02396914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OraFlow-UB2|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||January 21, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02396914||24837|
NCT02402010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1401-001|Pilot Study of Adjunctive Yoga for Bipolar Depression|Pilot Study of Adjunctive Yoga for Bipolar Depression||Brown University|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402010||24445|
NCT02506777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBC1|Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.|Phase II Multicenter Randomized Study to Compare Neoadjuvant FDC With Melatonin or Metformin Versus FDC Alone in The Therapy of Locally Advanced Breast Cancer.|MBC1|Petrov Research Institute of Oncology|Yes|Recruiting|July 2015|April 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506777||16402|
NCT02494700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1046|Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma|Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494700||17330|
NCT02494713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-14-101|Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer|Neoadjuvant Androgen Deprivation Therapy and Chemotherapy Followed by Radical Prostatectomy in Patients With Prostate Cancer||The University of Texas Health Science Center, Houston|Yes|Recruiting|October 2015|February 2027|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||October 2015|October 19, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494713||17329|
NCT02406443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8616|The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion|Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion|INDORSE|University Health Network, Toronto|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|32|||Both|18 Years|70 Years|No|||March 2015|April 1, 2015|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02406443||24108|
NCT02394717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD079422-01|Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards|Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards||University of South Carolina|Yes|Recruiting|August 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|760|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394717||25006|
NCT02501317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|435522|Scientific Validation of the "Active Perineal Rehabilitation" Protocol to Urinary Incontinence Treatment|Scientific Validation of the "Active Perineal Rehabilitation" Protocol to Urinary Incontinence Treatment||Federal University of São Paulo|No|Active, not recruiting|January 2015|September 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|20 Years|75 Years|No|||July 2015|July 15, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02501317||16822|
NCT02499367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N15TON|Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients|Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial|TONIC|The Netherlands Cancer Institute|Yes|Recruiting|August 2015|August 2022|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|84|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02499367||16972|
NCT02499380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0017|Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment|Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment||PneumRx, Inc.|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Adult subjects diagnosed with emphysematous type of COPD|August 2015|August 14, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02499380||16971|
NCT02436447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPICP-101|A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function|A Phase 1, 7 Day Repeat Dose, Parallel-Group, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Intravenous Infusion of MTP-131 Administered in Subjects With Impaired Renal Function||Stealth BioTherapeutics Inc.|No|Completed|May 2015|October 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02436447||21803|
NCT02436720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSCPUL|Upper Limb Assessment in Duchenne Muscular Dystrophy|Performance of Upper Limb (PUL) in Duchenne Muscular Dystrophy|PUL in DMD|Catholic University of the Sacred Heart|No|Active, not recruiting|January 2013|May 2015|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|4 Years|35 Years|No|Probability Sample|Boys and adults affected by Duchenne muscular dystrophy|May 2015|May 6, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02436720||21782|
NCT02483065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012111139|Impact of Hospital Admission on Patients With Dementia|Impact of Hospital Admission on Patients With Dementia||Hospital Galdakao-Usansolo|No|Active, not recruiting|January 2012|||January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|413|||Both|N/A|N/A|No|Probability Sample|For this prospective matched cohort study, the investigators recruited two groups of        adults aged 75 years and older with an unplanned medical admission to any medical        speciality between January 2012 and December 2014 in the Galdakao-Usansolo Hospital in the        Basque Country (northern Spain), a 400-bed general teaching hospital serving a population        of 300,000. It is one of the networks of public hospitals of the Basque Health Service,        which provides free unrestricted care to nearly 100% of the population. One group        (patients with dementia cohort) was drawn from patients with dementia, and a second group        (patients without dementia cohort) of patients without dementia.|June 2015|June 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483065||18222|
NCT02434510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76754|Bacterial Contamination of Operative Splash Basins|Bacterial Contamination of Operative Splash Basins: Can it be Prevented?||University of Utah|Yes|Completed|March 2015|February 2016|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|111|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for primary total joint arthroplasty|February 2016|February 26, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434510||21952|
NCT02437604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-AS-10042|Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older|An Open-Label, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of High Strength Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older||Teva Pharmaceutical Industries|No|Completed|May 2015|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Both|12 Years|N/A|No|||October 2015|October 6, 2015|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437604||21714|
NCT02440243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC56871/12|Grass Pollen Subcutaneous Immunotherapy in Elderly Patients|Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen|SCITelderly|Medical University of Silesia|No|Completed|January 2011|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|60 Years|75 Years|No|||May 2015|May 6, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02440243||21512|
NCT02483585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120297|Study to Evaluate the Efficacy and Safety of AMG 334 Compared to Placebo in Migraine Prevention|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 Compared to Placebo in Migraine Prevention|ARISE|Amgen|Yes|Recruiting|July 2015|March 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483585||18182|
NCT02483598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bus-000|Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone|||North Dakota State University|No|Enrolling by invitation|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02483598||18181|
NCT02430259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81373064|Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention|Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China||Huashan Hospital|Yes|Recruiting|March 2015|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|566|||Male|18 Years|65 Years|No|||April 2015|April 25, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02430259||22278|
NCT02430272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC-01-choe|Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine|Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine||Inje University||Completed|May 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|84|||Both|12 Months|8 Years|No|||April 2015|April 29, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02430272||22277|
NCT02430285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARLY-EUS|Early EUS in Acute Biliary Pancreatitis|Early Endoscopic Ultrasound (EUS) in Acute Biliary Pancreatitis: a Prospective Pilot Study||Istituto Clinico Humanitas|Yes|Completed|January 2010|June 2013|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|181|||Both|N/A|N/A|No|||April 2015|April 29, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02430285||22276|
NCT02437734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16467|Virtual Coronary Physiology: an Angiogram is All You Need|Virtual Coronary Physiology: an Angiogram is All You Need||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|August 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||May 2015|May 7, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437734||21704|
NCT02487394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0462|Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma|Protein Biomarker Discovery and Validation in COPD And Asthma|Proteomics|The University of Texas Medical Branch, Galveston|Yes|Recruiting|May 2014|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|65 Years|No|||June 2015|August 24, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02487394||17890|
NCT02487407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3119001|Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis|Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension|ALS|Orion Corporation, Orion Pharma|Yes|Recruiting|July 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487407||17889|
NCT02433106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAA intervention|The Effects of an Exercise Programme on Neuromuscular Outcomes in Gaelic Sport|The Effects of an Exercise Based Injury Prevention Programme on Neuromuscular Outcomes in Gaelic Football and Hurling Players, a Randomised Controlled Trial||University College Dublin|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02433106||22060|
NCT02433366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.149|Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation|Post-authorisation Study to Evaluate the Effectiveness of the Risk Minimisation Activities in the Treatment of SPAF||Boehringer Ingelheim||Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1213|||Both|18 Years|N/A|No|Probability Sample|Physicians prescribing dabigatran for patients with atrial fibrillation|February 2016|February 17, 2016|March 25, 2015||||No||https://clinicaltrials.gov/show/NCT02433366||22040|
NCT02437864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-307|Apneic Oxygenation During Airway Management in Pediatric Patients|Effect of Peri-intubation Apneic Oxygenation Via Nasal Cannula on Pediatric Patients' Oxygen Saturation During Airway Management||University of New Mexico|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|8 Years|No|||November 2015|November 2, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02437864||21694|
NCT02437877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFerrer|The Influence of Breathing in Writing|The Influence of Mouth Breathing in the Discrimination of Sonority Perception in Writing||University of Campinas, Brazil|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|||Both|7 Years|13 Years|Accepts Healthy Volunteers|Probability Sample|200 children, 100 previously diagnosed with oronasal breath (51 females and 49 males) who        participated in the study group and 100 nasal breathers (54 females and 46 males) which        were the control group.|May 2015|May 7, 2015|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT02437877||21693|
NCT02443350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH 201411101|Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area||MuPRaNE|Beijing Tongren Hospital||Recruiting|June 2014|||May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|6 Months|N/A|No|Non-Probability Sample|The unexplained encephalitis patients in Beijing area|May 2015|May 10, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02443350|24 Months|21273|
NCT02492048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2199|Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients|Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients||LifeBridge Health|No|Recruiting|February 2016|August 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492048||17534|
NCT02492061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/HD07/18256U|Demand Creation for Couples' HIV Counseling and Testing|Demand Creation for Couples' HIV Counseling and Testing, Linkage to and Retention in HIV Care Among Married Couples in Rakai, Uganda||Makerere University|No|Active, not recruiting|August 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3076|||Both|15 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02492061||17533|
NCT02438488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODIN 1|Vitamin D and Mortality: an Individual Participant Data Meta-analysis of Standardized 25-hydroxyvitamin D|Vitamin D and Mortality: an Individual Participant Data Meta-analysis of Standardized 25-hydroxyvitamin D in 26916 Individuals of a European Consortium||Medical University of Graz|No|Completed|April 2015|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26916|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The fourth Tromsø study, the Ludwigshafen Risk and Cardiovascular Health Study (LURIC),        the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES Reykjavik), the New Hoorn        Study (NHS), the Aarhus Mammography Cohort Study, the German Health Interview and        Examination Survey for Adults (DEGS) and the old and young cohort of the Longitudinal        Study on Ageing in Amsterdam (LASA).|November 2015|November 24, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02438488||21646|
NCT02427672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821313|The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior|The Effect of Transcranial Direct Current Stimulation of the Prefrontal Cortex on Antisocial and Aggressive Behavior||University of Pennsylvania|No|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02427672||22476|
NCT02442375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPGRADE-RT v3.1 dd20151210|Uniform FDG‐PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity|Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma|UPGRADE-RT|Radboud University|Yes|Not yet recruiting|April 2016|April 2024|Anticipated|April 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02442375||21348|
NCT02433522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110146 extended|Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab|Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial|MAINRITSAN3|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|January 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02433522||22028|
NCT02484352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2014115(1311)|Optimal Dose of Intravenous Oxycodone for Endotracheal Intubation|Optimal Dose of Intravenous Oxycodone for Attenuation of Hemodynamic||Chung-Ang University Hospital|Yes|Active, not recruiting|March 2015|August 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|95|||Both|20 Years|65 Years|No|||January 2016|January 26, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02484352||18123|
NCT02431078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|experiment20152018|The Expression of ZEB1 in CTCs Associated With Metastasis and Recurrence for Gastric Cancer|The Expression of Zinc Finger E-Box Binding Homeobox 1 (ZEB1) in Circulating Tumor Cells(CTCs) Associated With Metastasis and Recurrence for Gastric Cancer||Chinese PLA General Hospital|No|Active, not recruiting|June 2015|July 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Circulating Tumor Cells|Both|18 Years|80 Years|No|Non-Probability Sample|Approximate 150 consecutive patients with gastric cancer and CTCS(+) will be enrolled in        this study.|April 2015|July 28, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02431078||22216|
NCT02442388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9308|Postoperative Pain of Root Canal Therapy With Three Techniques|||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|96|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442388||21347|
NCT02442401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030/55|Role of Negative Pressure Wound Therapy in Latissimus Dorsi Flap Donor Site Seroma Prevention|Role of Negative Pressure Wound Therapy in Latissimus Dorsi Flap Donor Site Seroma Prevention||Chulalongkorn University|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|20 Years|60 Years|No|||May 2015|May 14, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02442401||21346|
NCT02440477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ק018/2015|The Effect of Changing Posture in Sitting on Selected Clinical Shoulder Tests|The Effect of Changing Posture in Sitting on Selected Clinical Shoulder Tests in Patients With Rotator Cuff Degenerative Tears|EOCPIS|Meir Medical Center|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged over 40 years with partial rotator cuff degenerative tears that were        diagnosed by ultrasound.|October 2015|March 15, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440477||21494|
NCT02491671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMOPATCH/FAP/2014|Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection|Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®||Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|No|Recruiting|November 2015|May 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|276|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02491671||17563|
NCT02491684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6230C00001|A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations|INEXAS|AstraZeneca|No|Recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|99 Years|No|||March 2016|March 14, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02491684||17562|
NCT02428166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-004/2015|Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye|Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye||Heidelberg University|No|Active, not recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|50 Years|No|Non-Probability Sample|Eligible keratoconus patients aged 18-50 years who underwent unilateral crosslinking        treatment in our ophthalmology department and completed a postoperative follow-up of 3-9        months|September 2015|September 24, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428166||22438|
NCT02428179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/14|Impact of Structured Communication in the OR on Surgical Site Infections: Prospective Observational Clinical Trial|StOP?-Trial: Impact of Structured Communication in the OR on Surgical Site Infections: Prospective Observational Clinical Trial|StOP|University Hospital Inselspital, Berne|Yes|Recruiting|April 2015|October 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|3650|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing abdominal surgery|December 2015|December 10, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428179||22437|
NCT02442427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14302/14|"Palivizumab Therapy for RSV-bronchiolitis"|Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)||Hamad Medical Corporation|Yes|Recruiting|September 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|3 Months|No|||May 2015|May 25, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02442427||21344|
NCT02434042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304/PTEKIND/650689|Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children|Study on Oral Administration of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses Compared to Placebo||University of Science Malaysia|No|Active, not recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|520|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02434042||21988|
NCT02434055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150190H|Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS|Evaluation of a Novel Method of Contrast Volume Quantification - The AVERT PLUS|AVERT-PLUS|The University of Texas Health Science Center at San Antonio|No|Terminated|April 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Subjects with cardiovascular disease undergoing clinically indicated coronary or        peripheral angiography|June 2015|June 16, 2015|April 29, 2015|No|Yes|Business purposes|No||https://clinicaltrials.gov/show/NCT02434055||21987|
NCT02482324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZT-002|Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers|A Phase I, Randomized, Open-Labeled Pharmacokinetic Study of ALZT-OP1 in Normal Healthy Volunteers||AZTherapies, Inc.|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482324||18279|
NCT02437097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1115|The Effect of Aerobic Exercise and Gaming on Cognitive Performance|The Effect of Aerobic Exercise and Gaming on Cognitive Performance||New York Institute of Technology|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437097||21753|
NCT02431182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/02060|Trial to Evaluate the Effectiveness of Memory Training Workshops in People From 65 to 80 Years|Randomized Control Trial to Evaluate the Effectiveness of Memory Training Workshops in People From 65 to 80 Years||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|January 2012|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|300|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||December 2014|April 27, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02431182||22208|
NCT02435628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002755|Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF|Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis||Massachusetts General Hospital|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis|November 2015|November 20, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02435628||21866|
NCT02479893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80/30-04-2015|Cold Snare,Hot Snare and APC Polypectomy for the Complete Removal of Small Left Sided Colon Polyps|Cold Snare Polypectomy vs Hot Snare Polypectomy vs APC for the Complete Removal of Left Sided Colon Polyps. A Prospective,Randomized Trial||Evangelismos Hospital|Yes|Recruiting|January 2015|May 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|108|Samples With DNA|colonic polyps tissue samples|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients with colonic left sided small polyps|January 2016|January 24, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02479893||18466|
NCT02494141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0902|Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD|Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD||University of Colorado, Denver|Yes|Recruiting|November 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|6 Years|25 Years|No|||January 2016|January 6, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494141||17373|
NCT02429492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-21|Spinal Interneuron Excitability in ALS|Electrophysiological Biomarkers of Spinal Neural Activity: Study in Healthy Subjects Matched to ALS Patient Group|SpineBioMark|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|September 2015|September 2021|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02429492||22336|
NCT02429505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 2127-4|Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry|Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry||Knight Therapeutics (USA) Inc|No|Not yet recruiting|July 2015|March 2021|Anticipated|March 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|12 Years|N/A|No|Non-Probability Sample|leishmaniasis patients who are administered miltefosine|April 2015|April 24, 2015|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02429505|6 Months|22335|
NCT02435888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIC 0244.0.0203.000-10|Predictive Equations for Resting Energy Expenditure|Accuracy and Agreement of Predictive Equations for Resting Energy Expenditure Among Overweight Patients With Polycystic Ovary Syndrome||Federal University of Minas Gerais|No|Completed|December 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Polycystic ovary syndrome patients, as defined according to the Rotterdam criteria        (ESHRE/ASMR, 2004): the presence of at least two of the following factors: chronic        anovulation, clinical or biochemical signs of hyperandrogenism and presence of polycystic        ovaries;|May 2015|May 5, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02435888||21846|
NCT02484092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPK-9001-101|A Gene Therapy Study for Hemophilia B|Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B||Spark Therapeutics|Yes|Recruiting|September 2015|January 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484092||18143|
NCT02437656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METCAP-1404|Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).|Phase II Study Evaluating the Efficacy of the Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.||Centre Oscar Lambret|No|Recruiting|April 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437656||21710|
NCT02439229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITFBL|The Vitamin D and Fetal Bone Length Study (VITFBL)|Decreased Femoral Bone Length by Fetal Ultrasound in Pregnant Women With Low Serum 25-hydroxyvitamin D: An Odense Child Cohort Study||Odense University Hospital|Yes|Active, not recruiting|January 2010|December 2031|Anticipated|December 2031|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2874|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Odense Child Cohort Study (OCC) is a population-based cohort study, comprising        pregnant women recruited between January 1st 2010 and December 31st 2012. All women who        were pregnant in the municipality of Odense during this time were eligible for        participation, and 6,707 women were approached directly with recruitment material.        The study complied with the Helsinki declaration and was approved by the Regional        Scientific Ethical Committee for Southern Denmark, no. S-20090130. All participants gave        informed consent. From a population base of 6,70 pregnant women, 2,874 (42.9%) enrolled in        the OCC up to December 31st, 2012. The children will be followed until 18 years of age.|May 2015|May 6, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02439229|18 Years|21589|
NCT02442024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPPO|Metabolic Effects of the Manipulation of Nutrient Sequence in the Main Meals in Type 2 Diabetic Patients|Metabolic Effects of the Manipulation of Nutrient Sequence in the Main Meals in Type 2 Diabetic Patients||Azienda Ospedaliero, Universitaria Pisana|No|Recruiting|January 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||May 2015|May 8, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442024||21375|
NCT02428998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGC-S-01|Safety for 24 Weeks Intake of Korean Red Ginseng in Adults|Safety Evaluation for 24 Weeks Intake of Korean Red Ginseng in Adults: A Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center, Exploratory Trial||Korea Ginseng Corporation|No|Active, not recruiting|September 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02428998||22374|
NCT02491840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6042|Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study|Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study||University Hospital, Strasbourg, France|No|Not yet recruiting|September 2015|January 2024|Anticipated|January 2024|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02491840||17550|
NCT02430779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pelvis ureter Neoplasms-IRE-01|Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms|Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 26, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430779||22239|
NCT02439580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|406/H2.F1/ETIK/2013|Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells|Effect of Annona Muricata Leaves on Nutritional Status, Quality of Life, Fecal Butyrate, Inflammation, and Colorectal Cancer Cells||Indonesia University|Yes|Completed|October 2013|October 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439580||21563|
NCT02439593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEATPAC|Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study|A Phase II Randomized Study of Concurrent Hyperthermia and Chemoradiotherapy vs. Chemoradiotherapy Alone Following Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (HEATPAC)|HEATPAC|Kantonsspital Aarau|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|80 Years|No|||May 2015|May 8, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02439593||21562|
NCT02438852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-14-4|Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer|Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study||University of Southern California|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438852||21618|
NCT02480660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00044255|Adolescent to Adult-Oriented Health Care Transition Survey: Study of a Video-Based Educational Intervention|Adolescent to Adult-Oriented Health Care Transition Survey: Study of a Video-Based Educational Intervention||University of Rochester|No|Completed|November 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|152|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||June 2015|February 19, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02480660||18407|
NCT02428413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05|Evaluation and Control of WAG in PACU Within Patient and Caregiver Breathing Zone|Evaluation and Control of Waste Anesthetic Gas (WAG) in the Post Anesthesia Care Unit (PACU) Within Patient and Caregiver Breathing Zone||Teleflex|No|Completed|April 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|125|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428413||22419|
NCT02439775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPYRAL HTN-ON MED|SPYRAL HTN-ON MED Study|Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)||Medtronic Vascular|Yes|Recruiting|June 2015|October 2019|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||March 2016|March 4, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439775||21548|
NCT02439788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33272, GINAKIT|3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA|3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT)|GINAKIT|Baylor College of Medicine|Yes|Not yet recruiting|August 2016|October 2030|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|18 Years|No|||December 2015|December 18, 2015|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02439788||21547|
NCT02432001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125519|Radiologically Guided Biopsies of mCRPC|Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance||University of California, San Francisco|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate Cancer|October 2015|October 1, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432001||22145|
NCT02432209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIT-Plese|Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility|Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility|FIT-PLESE|Yale University|Yes|Recruiting|August 2015|November 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Female|18 Years|40 Years|No|||February 2016|February 8, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432209||22129|
NCT02493803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ114/N306|Impact of Dietary Advice on the Progression of Tooth Wear|Impact of Dietary Advice on the Progression of Tooth Wear|DAI|King's College London|No|Active, not recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02493803||17399|
NCT02493816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LENTICOL-F|Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa|Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblasts in Adults With Recessive Dystrophic Epidermolysis Bullosa.||King's College London|Yes|Not yet recruiting|July 2015|August 2019|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||July 2015|July 7, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02493816||17398|
NCT02435576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP2007-03|Standard Follow-up Program (SFP) for Head and Neck Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation|Standard Follow-up Program (SFP) for Head and Neck Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation (SFP Head & Neck)|H&NTOX|University Medical Center Groningen|No|Recruiting|March 2007|January 2028|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with head and neck cancer planned for curatively intended primary or        postoperative radiotherapy will be included.|March 2016|March 22, 2016|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435576|5 Years|21870|
NCT02491177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0331|Mother and Infant Visit Adherence and Treatment Engagement Study|Maximizing Adherence and Retention for Women and Infants in the Context of Option B+|MOTIVATE!|University of Colorado, Denver|No|Active, not recruiting|May 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1336|||Female|18 Years|N/A|No|||July 2015|July 10, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02491177||17601|
NCT02479399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL002|Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients|Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)|STELLALONGTERM|Astellas Pharma Inc|No|Active, not recruiting|July 2014|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|11412|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes who first use Suglat Tablets during the period from July 17,        2014 to July 16, 2015|February 2016|February 8, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02479399||18504|
NCT02479412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3741C00003|A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma|A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTHMA||AstraZeneca|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|110|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479412||18503|
NCT02498548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0386|Training of Eccentric Knee Function After SCI|Eccentric Motor Control Training to Improve Human Spinal Cord Injury: Knee Function During Walking||Ohio State University|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 11, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02498548||17035|
NCT02397473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15780|A Study of LY2951742 in Participants With Episodic Cluster Headache|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache||Eli Lilly and Company|Yes|Recruiting|May 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397473||24794|
NCT02397720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0861|A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia|An Open-label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02397720||24775|
NCT02507271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01918|Speed of Processing Training in Traumatic Brain Injury|Speed of Processing Training in Traumatic Brain Injury||New York University School of Medicine||Recruiting|August 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02507271||16364|
NCT02507284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN011|Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease|An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)||Azevan Pharmaceuticals|Yes|Not yet recruiting|January 2016|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507284||16363|
NCT02399852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-028|Effects of Lomitapide on Carotid and Aortic Atherosclerosis|Effects of Lomitapide on Carotid and Aortic Atherosclerosis in Patients Treated With Lomitapide in Usual Care (CAPTURE)||Aegerion Pharmaceuticals, Inc.|Yes|Not yet recruiting|April 2015|||April 2021|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|57|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled in LOWER|March 2015|March 25, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02399852|2 Years|24611|
NCT02402270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-002|Safety and Tolerability Study of an Edible Colon Preparation|An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.||ColonaryConcepts LLC|Yes|Recruiting|May 2015|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|5||Anticipated|110|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402270||24425|
NCT02405598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201308031MINC|Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease|Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease||National Taiwan University Hospital|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|N/A|No|||March 2015|March 27, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02405598||24171|
NCT02497170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO201500001877|Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes|Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes||Rutgers, The State University of New Jersey|Yes|Completed|September 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497170||17140|
NCT02497183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0053-15-EMC|Impact of Oral Contrast in the Large Intestine on the Recognition of Appendix|Impact of Presence of Oral Contrast Material in the Large Intestine on the Recognition of Appendix During an Ultrasound Exam||HaEmek Medical Center, Israel|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|14 Years|N/A|No|||July 2015|July 13, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02497183||17139|
NCT02499081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203444|UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment|Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients||University of Arkansas|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02499081||16994|
NCT02499094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIO-001|Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder|Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder: Protocol for a Randomized Controlled Study||Ginger.io|Yes|Completed|December 2014|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|1004|||Both|18 Years|65 Years|No|||July 2015|July 14, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02499094||16993|
NCT02396030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGSO4-2015|Different Schemes of Magnesium Sulfate for Preeclampsia|Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial|MGSO4|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Recruiting|March 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|2000|||Female|14 Years|50 Years|No|||November 2015|November 17, 2015|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02396030||24905|
NCT02399111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-485|A Trial to Evaluate Negative Pressure Incision Management System for Groin Wounds in Vascular Surgery Patients|A Prospective Randomized Control Trial to Evaluate Negative Pressure Incision Management System for Groin Wounds in Vascular Surgery Patients||Northwell Health|No|Terminated|October 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|11|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 24, 2015|Yes|Yes|PI Decision|No||https://clinicaltrials.gov/show/NCT02399111||24668|
NCT02508454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-042|The Miami Heart Study at Baptist Health South Florida|The Miami Heart Study at Baptist Health South Florida: A Prospective Study of Sub-Clinical Cardiovascular Disease and Emerging Cardiovascular Risk Factors in Asymptomatic Young & Middle-Aged Adults|MiHEART|Baptist Health South Florida|No|Recruiting|August 2014|May 2023|Anticipated|May 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4000|Samples With DNA|Approximately 115 mls of blood will be drawn by a Registered Nurse. Blood samples will be      tested for markers of the diseases and health conditions under investigation. These will      include standard markers (cholesterol, blood sugar, etc) and novel markers which are not      commonly evaluated by a physician. Additionally, any remaining blood samples will be stored      and kept for future risk factor evaluation, biomarker testing and genetic studies.      Whole blood and serum will be retained.|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Since the MiHEART Study is primarily concerned with the determinants and natural history        of subclinical cardiovascular disease, participants with known clinical disease will not        be recruited. Most exclusion criteria relate to the long-term nature of the study or to        incompatibility with certain study procedures. Eligibility (or ineligibility) status will        be determined from self-reported information.|March 2016|March 3, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02508454||16274|
NCT02510898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062054|Examining the Role of Expressive Writing (EW) to Improve Resilience|Examining the Role of Expressive Writing (EW) to Improve Resilience Among Those Experiencing an Emotional Upheaval or a Physical Health Challenge||Duke University|No|Active, not recruiting|January 2016|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02510898||16086|
NCT02403752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14943|Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)|Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers|PairedPLIE|University of California, San Francisco|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02403752||24313|
NCT02403765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMN01|Diagnostic Tools for Parkinson's Disease|Realization of Diagnostic Tools for the Early Analysis of Parkinson's Disease Through the Identification of Genetic Risk Profiles||Neuromed IRCCS|No|Not yet recruiting|April 2015|April 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|500|Samples With DNA|Blood samples for DNA extraction|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be selected from the Center for Parkinson's disease of the IRCCS Neuromed,        according to specific inclusion criteria. Approximatey 500 subjects, 30 years of age or        older, recruited with a family-based approach, will be included in the study.|April 2015|April 1, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403765||24312|
NCT02406612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD-028|X-Seal EU Post-Market Clinical Follow-Up Protocol|X-Seal 6F Vascular Closure Device EU Post-Market Clinical Follow-Up Protocol||Essential Medical, Inc.|No|Active, not recruiting|April 2015|March 2016|Anticipated|January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02406612||24095|
NCT02440178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-micafungin|Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia|Phase II Trial of Micafungin Prophylaxis During Induction Chemotherapy for Patients With Acute Leukemia||Seoul National University Hospital||Not yet recruiting|May 2015|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|66|||Both|18 Years|75 Years|No|||April 2015|May 6, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02440178||21517|
NCT02483078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140_CD 02|A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects|A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects|PRO 140|CytoDyn, Inc.|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483078||18221|
NCT02483325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX-PK-IPC 2013-016|Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases|Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases|BX-PK|Institut Paoli-Calmettes|No|Recruiting|September 2014|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|55 Years|N/A|No|||February 2016|February 25, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483325||18202|
NCT02437812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOA-TCOM1|Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma|A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||Gynecologic Oncology Associates|No|Recruiting|January 2014|April 2021|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||May 2015|May 5, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02437812||21698|
NCT02444000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130097|gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas|A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial.|POLCA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2015|June 2024|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444000||21224|
NCT02428582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2013-476|Covered Stents Versus Bare-Metal Stents|Covered Stents Versus Bare-Metal Stents in Chronic Atherosclerotic Gastrointestinal Ischemia||Erasmus Medical Center|No|Not yet recruiting|May 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02428582||22406|
NCT02489487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM-1500-002|Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500|Phase I, Drug-drug Interaction Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 When Administered Orally, in Combination With Raltegravir or Darunavir||Viriom|No|Completed|September 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489487||17730|
NCT02434731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 20/13|Vibration and Cold for Pain Relief During Peripheral Intravenous Cannulation in Children With Intellectual Disability|Randomized Controlled Trial to Evaluate the Effectiveness of Vibration and External Cold (Buzzy Device) for Pain Relief During Venipuncture or Intravenous Cannulation in Children With Intellectual Disability.||IRCCS Burlo Garofolo|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Both|4 Years|17 Years|No|||August 2015|August 5, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434731||21935|
NCT02434744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD026-201|Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus||Kadmon Corporation, LLC|No|Active, not recruiting|April 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|120|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434744||21934|
NCT02444013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-2015|Folic Acid for Prevention of Contrast Induced Nephropathy|Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty|FAPCIN|Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|N/A|No|||May 2015|May 11, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444013||21223|
NCT02437773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00091368|Neurocircuit Mechanisms of OCD Across the Lifespan|Neurocircuit Mechanisms of OCD Across the Lifespan||University of Michigan|No|Recruiting|January 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|220|||Both|13 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02437773||21701|
NCT02491996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223|The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers|The Efficacy of Cognitive-behavioral Therapy Focused on Desire-satisfaction for Treatment-seeking Disordered Gamblers|ETFDDG|Kurihama Medical and Addiction Center|No|Recruiting|June 2013|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02491996||17538|
NCT02437149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150548|Effectiveness of Distracted Driving Campaign|Effectiveness of Distracted Driving Campaign for Teenagers in the Emergency Department||Nicklaus Children's Hospital f/k/a Miami Children's Hospital|Yes|Recruiting|June 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|273|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02437149||21749|
NCT02443402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080209|Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery|Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery|SITACABG NonDM|Emory University|Yes|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443402||21269|
NCT02428790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABITransitTimeHammel|Gastrointestinal Transit Time in Patients With Severe Acquired Brain Injury|Gastrointestinal Transit Time in Patients With Severe Acquired Brain Injury||University of Aarhus|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|79 Years|No|Non-Probability Sample|Patients at Hammel Neurocenter and University Clinic, during rehabilitation after aquired        brain injury|January 2015|December 1, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02428790||22390|
NCT02428803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X141112004|Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis|Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis|Telemedicine|University of Alabama at Birmingham|No|Recruiting|April 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|40|||Both|19 Years|100 Years|No|Probability Sample|UAB patients on peritoneal dialysis that are living in a different county other than        Jefferson county and has been on stable therapy for 2 months.|November 2015|November 2, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428803||22389|
NCT02479646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-1401H-1001|Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta|Single Center, Randomized, Double-blind, 3-Period, 3-Treatments, 3-Way Crossover Pharmacokinetics (PK)/Pharmacodynamics (PD) Trial to Assess PK, PD,Safety and Tolerability of MYL-1401H After Single Subcutaneous Injection at One Dose Level (2 mg) Comparing to an EU and US Marketed Drug Product (Neulasta®) in Healthy Volunteers.||Mylan Inc.|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|218|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02479646||18485|
NCT02431897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG047290-01|Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen|Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen|IMPROVE|University of Texas Southwestern Medical Center|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|222|||Female|48 Years|N/A|No|||September 2015|September 23, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431897||22153|
NCT02429557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140634|Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure|Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure||Vanderbilt University|No|Recruiting|April 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02429557||22331|
NCT02438397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC-17782|the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin|Explore the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin in Chinese Type 2 Diabetes by CGMS|CGMS|Shanghai 6th People's Hospital|No|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|70 Years|No|||May 2015|May 5, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438397||21653|
NCT02491606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-7540|Evaluation of Weekly Tafenoquine|Evaluation of Weekly Tafenoquine (SB 252263 / WR 238605) Compared to Placebo for Chemosuppression of Plasmodium Falciparum in Western Kenya||U.S. Army Medical Research and Materiel Command|No|Completed|May 1997|September 1998|Actual|September 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|249|||Both|18 Years|55 Years|No|||July 2015|July 2, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491606||17568|
NCT02435550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500073|iCare for Cancer Patients|iCare for Cancer Patients||University of Florida|Yes|Recruiting|June 2015|June 2021|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|180|||Both|18 Years|N/A|No|Probability Sample|30 patients for each of the 5 different cancer types (acute myeloid leukemia, acute        lymphoblastic leukemia, myelodysplastic syndromes, myelofibrosis, and multiple myeloma).|February 2016|February 4, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02435550||21872|
NCT02429752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140764|Low Back Pain and Breathing Pattern Dysfunction|The Association of Breathing Pattern Dysfunction and Low Back Pain Presentation and Outcomes Following Physical Therapy|LBP&BPD|University of Miami|No|Recruiting|October 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02429752||22316|
NCT02429765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1744-14|Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease|Effect of Aclidinium Bromide/Formoterol on Nighttime Lung Function, Respiratory Mechanics and Early Morning Symptoms in Chronic Obstructive Pulmonary Disease (COPD)||Queen's University|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||November 2015|November 19, 2015|November 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02429765||22315|
NCT02429609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDO1009|Exploring the Psychophysics of Keratoconus Using the Moorfields Acuity Chart|Exploring the Psychophysics of Keratoconus Using the Moorfields Acuity Chart|MACK|Moorfields Eye Hospital NHS Foundation Trust|No|Not yet recruiting|May 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02429609||22327|
NCT02493270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EsCAPE|Effect of Smoking Cessation on Non-surgical Periodontal Therapy|Effect of Smoking Cessation on Non-surgical Periodontal Therapy|EsCAPE|University of Sao Paulo|No|Completed|May 2007|June 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|177|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493270||17440|
NCT02493283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dapson - 2010|Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration|Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses||University Medicine Greifswald|Yes|Completed|September 2011|March 2015|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493283||17439|
NCT02432313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-PK-002|Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations|3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK||Rock Creek Pharmaceuticals, Inc.|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432313||22121|
NCT02432326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI401-101|A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors|A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors||Boston Biomedical, Inc||Recruiting|April 2015|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432326||22120|
NCT02430064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01|Effects of Chronic Intake of Processed Foods on Circulating Inflammatory Markers in Healthy Men|Effects of Chronic Intake of Processed Foods on Circulating Inflammatory Markers in Healthy Men||University of Leicester|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02430064||22292|
NCT02438891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1358|Internet-based CBT for Tinnitus|Evaluation of an Internet-based Sound and Cognitive Behavioral Therapy Course for Treatment for Tinnitus||University of California, Irvine|No|Recruiting|March 2015|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438891||21615|
NCT02486640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18016|Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon|BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence|BETAPREDICT|Bayer|No|Recruiting|September 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with relapsing remitting multiple sclerosis        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with        Betaferon or will be treated with Betaferon according to the attending physician's        decision and for whom the patient and the physician have agreed to use the BETACONNECT        device.|March 2016|March 16, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486640||17948|
NCT02439554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01842|Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients|Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients||Hospital Galdakao-Usansolo|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1352|||Female|18 Years|N/A|No|Probability Sample|Patients diagnosed with both in situ and infiltrating breast cancer|April 2015|May 6, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02439554|2 Years|21565|
NCT02441829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-372-1589|Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function|A Phase 1 Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Renal Function||Gilead Sciences|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441829||21390|
NCT02441881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1232|Trial of Radiofrequency Thermo-ablation Treatments of Great Saphenous Varicose Veins|A Double Blind Randomised Controlled Trial of Radiofrequency Thermo-ablation Treatments of Great Saphenous Varicose Veins: Venefit (Closurefast) vs. Radiofrequency Induced Thermal Therapy (RFITT) vs. Endovenous Radiofrequency (EVRF).||Worcestershire Acute Hospitals NHS Trust|No|Recruiting|September 2014|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|80 Years|No|||May 2015|May 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02441881||21386|
NCT02428543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-000268-27|Ponatinib AML: Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML in First CR|A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission|PONATINIB AML|Central Hospital, Versailles|Yes|Recruiting|July 2013|December 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|August 2, 2013||No||No||https://clinicaltrials.gov/show/NCT02428543||22409|
NCT02483845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBM-2013|Natalizumab in Inclusion Body Myositis (IBM)|Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis|IBM-NAT|Phoenix Neurological Associates, LTD||Recruiting|May 2013|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|21 Years|85 Years|No|||November 2015|November 30, 2015|May 31, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483845||18162|
NCT02434536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI06/1010|Appropriate Admission in COPD Exacerbation From Emergency Department. Multicenter Study|Assessment of the Appropriateness Admission From Emergency Departments in the Exacerbation of COPD. Validity of Explicit Criteria and Study of the Variability Between Different Centers of NHS. Multicenter Study IRYSS-Appropriateness-COPD.|COPD|Hospital Galdakao-Usansolo|No|Completed|October 2006|September 2010|Actual|September 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2487|||Both|18 Years|N/A|No|Probability Sample|Patients with an exacerbation of chronic obstructive pulmonary disease attending the        emergency departments (ED) of 16 hospitals in Spain|April 2015|April 30, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434536|2 Months|21950|
NCT02441946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15805|A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer|neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer|neoMONARCH|Eli Lilly and Company|No|Recruiting|August 2015|February 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441946||21381|
NCT02442011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2918|Hematology Biobank : Invitro Study of Blood Disorders|Hematology Biobank : Invitro Study of Blood Disorders||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|January 2014|December 2025|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood samples will be processed fresh or frozen and stored in cryo vials at -80°C for      future isolation of DNA. DNA isolation will be done using commercially available kits such      as Applied Biosystems' "DNA Isolation from Fresh and Frozen Blood, Tissue Culture"      http://tools.lifetechnologies.com/content/sfs/manuals/cms_041387.pdf Plasma needed for      biomarkers analysis we be obtained from whole blood samples. Whole blood will be spun down,      plasma and sediment will be separated and stored in cryo vials at -80°C. Red cells and      platelets will be stored at 4C. Red cell hemolysate may be stored at 4C or stored in cryo      vials.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects >18 years of age and able to consent|December 2015|December 28, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442011||21376|
NCT02490800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI-CS-002/3.0|Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors|An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors||Basilea Pharmaceutica|No|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490800||17630|
NCT02439983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PHX-0002|Brain Imaging Study|A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Proprietary Nutritional Supplement on Brain Health||Pharmanex|No|Recruiting|April 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02439983||21532|
NCT02427919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSCTC-R02-DeGREE|Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML|The DEtection of G-CSF REceptor With Flow Cytometry and Identification of the Effect of G-CSF After Salvage Chemotherapy in Relapsed or Refractory AML|DeGREE|Seoul St. Mary's Hospital|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|56|||Both|17 Years|64 Years|No|||April 2015|April 22, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427919||22457|
NCT02429011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1385|MRI Studies of Emotion in Depression|Functional MRI Studies of Emotion in Depression and Rapid Antidepressant Response||Icahn School of Medicine at Mount Sinai|No|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|112|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429011||22373|
NCT02429024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3132245|Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences|Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences||LifeScan|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|142|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429024||22372|
NCT02480387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-337-1821|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection|A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection||Peter J. Ruane, M.D., Inc.|No|Completed|May 2015|January 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480387||18428|
NCT02435537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORG0006563/reference. no. 64|Combined Intrathecal Morphine and Dexmedetomidine Analgesia|Safety and Efficacy of Dexmedetomidine Addition to Intrathecal Morphine for Postoperative Analgesia in Cancer Patients Undergoing Major Abdominal Surgery|ITMandDEX|Assiut University|Yes|Completed|May 2013|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|30 Years|60 Years|No|||May 2015|May 5, 2015|April 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435537||21873|
NCT02427711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVH-2013-037|Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer|Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer - A Prospective Cohort Study With Retrospective Controls||Hvidovre University Hospital|No|Completed|October 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2015|August 13, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427711||22473|
NCT02440399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-15|To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine|To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine||HaEmek Medical Center, Israel|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||October 2015|October 14, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440399||21500|
NCT02485288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064600|PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort|PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort||University of Pittsburgh|No|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Potential participants for the PaTH Clinical Data Research Network (CDRN) Atrial        Fibrillation (AF) Clinician-Patient Partnership Cohort will include patients identified        through EHRs at the participating PaTH sites, using the eligibility criteria described        below. We aim to recruit as many patients as possible from the target population, with one        of the recruitment strategies producing a 50% enrollment rate.|November 2015|November 30, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485288|10 Years|18051|
NCT02432872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHBDH-IIT2015002|Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years|A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old||Chinese Academy of Medical Sciences|Yes|Not yet recruiting|April 2015|May 2021|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|55 Years|65 Years|No|||April 2015|May 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432872||22078|
NCT02441374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPSantos|Checking a Security Protocol of Modified FUT and Efficacy Reducing the Constriction the Movement Time in 12 Hours|Checking a Security Protocol of Modified Forced Use Therapy and Efficacy Reducing the Constriction the Movement Time in 12 Hours||University of Sao Paulo|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02441374||21425|
NCT02427464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMDN-003|Phase 3 Gene Therapy for Painful Diabetic Neuropathy|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy||ViroMed Co., Ltd. dba VM BioPharma|Yes|Not yet recruiting|April 2016|October 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|477|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427464||22492|
NCT02491099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015437|A Phase II Evaluation of Afatinib|A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma|Afatinib|Yale University|Yes|Recruiting|June 2015|June 2021|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||July 2015|July 21, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491099||17607|
NCT02479178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIND-014-008|A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck|iNSITE2|BIND Therapeutics||Recruiting|June 2015|January 2020|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479178||18521|
NCT02439450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS110-102|A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer|A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)||Heat Biologics|Yes|Active, not recruiting|April 2015|March 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439450||21573|
NCT02439463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/13/03/02/2014/7|Traumatic Below-knee Amputees With Prosthetics: Health-related Quality of Life and Locomotor Capabilities|Traumatic Below-knee Amputees With Prosthetics: Health-related Quality of Life and Locomotor Capabilities||Helsinki University Central Hospital|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Below-knee amputees who use limb prosthesis|February 2016|February 8, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02439463|2 Years|21572|
NCT02432157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.557|Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:|Hypertonic Saline Solution in Aneurysmal Subarachnoid Hemorrhage: A Randomized - Phase II Single Blinded Clinical Trial|HS3|Thomas Jefferson University|Yes|Recruiting|January 2015|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 10, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02432157||22133|
NCT02432430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrensRI|Comparison of Immunization Quality Improvement Dissemination Study||CIzQIDS|Children's Research Institute|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2186|||Both|3 Months|18 Months|Accepts Healthy Volunteers|||April 2015|May 1, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02432430||22112|
NCT02480946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120011A|Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis|A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate||Modern Biosciences plc|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|108|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02480946||18385|
NCT02483650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR004|Hyperbaric Oxygen Therapy Registry|The Registry of Hyperbaric Oxygen Therapy Treated Patients|HBOTR|U.S. Wound Registry|Yes|Enrolling by invitation|January 2005|||January 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients seen at participating hospital based outpatient wound and hyperbaric centers        where HBOT was administered.|June 2015|June 24, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02483650|2 Months|18177|
NCT02510326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STT|Evaluation of Motion in the Arthritic Wrist Joint|||Clalit Health Services|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Five patients being treated by the PI that have a diagnosis or a finding of STT joint        arthritis stage 3 on X-ray will be included in the study.|July 2015|July 27, 2015|March 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02510326||16130|
NCT02506543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP6855|Creating Opportunities Through Mentoring, Parental Involvement and Safe Spaces - Ethiopia|Creating Opportunities Through Mentoring, Parental Involvement and Safe Spaces - Ethiopia|COMPASS|Columbia University|No|Active, not recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|940|||Female|13 Years|19 Years|No|||September 2015|September 29, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02506543||16420|
NCT02398760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEPJMF-5402|Relationship Between Clinical Tests and Clinical Outcomes After Motor Control Exercises Intervention|Relationship Between Clinical Tests and Clinical Outcomes After Motor Control Exercises Intervention for Non-specific Chronic Low Back Patients||Universidade Estadual Paulista Júlio de Mesquita Filho|Yes|Recruiting|July 2014|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|60 Years|No|||March 2015|March 25, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02398760||24695|
NCT02398773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00383|FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy|[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Recruiting|February 2016|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|99|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|March 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02398773||24694|
NCT02398786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDF001|Myotonic Dystrophy Family Registry|Myotonic Dystrophy Family Registry|MDFR|Myotonic Dystrophy Foundation|Yes|Recruiting|February 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Participants will volunteer to participate in this study and enter their own information.        The study will be advertised through neuromuscular disease clinics and the Myotonic        Dystrophy Foundation and Myotonic Dystrophy Family Registry websites.|March 2015|March 24, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02398786|5 Years|24693|
NCT02402556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013605|Mother and Child Education Program in Palestinian Refugee Camps|Implementation and Impact Evaluation of the Mother and Child Education Program (MOCEP) Among Children and Families in Palestinian Refugee Camps in Beirut, Lebanon||Yale University|Yes|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|3 Years|6 Years|No|||February 2016|February 19, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02402556||24403|
NCT02496936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC508|Acute Effects of Fats on Satiety and Energy Needs|Acute Effects of Fats on Satiety and Energy Needs||USDA Grand Forks Human Nutrition Research Center|No|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|23|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02496936||17158|
NCT02497196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000365|Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain|Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain||Spaulding Rehabilitation Hospital|No|Recruiting|July 2015|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|66|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|March 2, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02497196||17138|
NCT02509767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012433|Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood|Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood|DSAS|Planned Parenthood Federation of America|No|Active, not recruiting|August 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Female|15 Years|44 Years|Accepts Healthy Volunteers|||March 2016|March 5, 2016|July 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02509767||16173|
NCT02403609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL003|An Online Study of the Reliability of the Brain Performance Test (BPT)|An Online Study of the Reliability of the Brain Performance Test (BPT)||Lumos Labs, Inc.|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1357|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403609||24324|
NCT02403622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410006671|Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection|Safety of Fecal Microbiota Transplantation: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection|STOOL|Microbiome Health Research Institute|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult outpatients with third or further documented CDI episode.|March 2015|March 25, 2015|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403622||24323|
NCT02409082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOFTDEM|Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures|The Presence of Pre-Alzheimers/Alzheimers Disease (AD) and Neuromarkers Related to Morbidity/Mortality in Patients With Acute Hip Fractures|ADhipfract|Sahlgrenska University Hospital, Sweden|No|Recruiting|September 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|AD correlated factors like betamayloid and tau as well as interleukins|Both|N/A|N/A|No|Non-Probability Sample|All patients with an acute hip fracture receiving a spinal anesthesia|March 2015|March 31, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02409082||23905|
NCT02509195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT064|SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over|An Open Label Study to Investigate the Safety and Efficacy of Abacavir/Lamivudine/Dolutegravir and the Pharmacokinetic Profile of Dolutegravir in HIV-infected Patients of 60 Years of Age and Older||St Stephens Aids Trust||Recruiting|July 2015|||March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||March 2016|March 22, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02509195||16217|
NCT02509208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM-UK-001|A Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding|A Multicenter Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding||St. Teresa Medical|No|Active, not recruiting|July 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02509208||16216|
NCT02400346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16160A|Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment|Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment||H. Lundbeck A/S||Active, not recruiting|March 2015|||June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|65 Years|N/A|No|||February 2016|February 12, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400346||24573|
NCT02403089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14006|Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients|Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients|NEOMAIT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|funds tubes samples taken as part of routine care for newborns and in allograft recipients      children will be recovered. Mononuclear cells from cord blood will be isolated and stored in      liquid nitrogen in the laboratory of Immunology before achieving functional tests.      • Rectal swabs and gastric aspirates aliquots made as part of routine care for newborns, and      rectal swabs made as part of routine care in HSCT allograft recipients, will be stored at      -80 ° C in the laboratory of Immunology.|Both|N/A|18 Years|No|Non-Probability Sample|newborns hospitalized in the Neonatal Intensive Care Unit of the Hospital Robert Debré and        grafted children hospitalized in the Hematology-Immunology Pediatric Service of the        Hospital Robert Debré|February 2015|December 21, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02403089||24364|
NCT02403102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0036 CCR4236|Imageguided Theranostics in Multiple Myeloma|Imageguided Theranostics in Multiple Myeloma|iTIMM|Institute of Cancer Research, United Kingdom|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Patients who undergo autograft have regular blood tests and marrow sampling and we will use      these samples, to look at other factors which influence patient outcomes such as genetics,      without compromising routine care. Some of the genetic tests performed on the bone marrow      are not routine so we will obtain additional consent to do this.|Both|18 Years|N/A|No|Probability Sample|Patients with myeloma planned for autograft.|February 2016|February 3, 2016|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403102||24363|
NCT02508467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLU-554-1101|A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma||Blueprint Medicines Corporation|No|Recruiting|July 2015|May 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02508467||16273|
NCT02506712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00758-41|Evaluation of Physiological and Biomechanical Efficiency of the PAPAW|Evaluation of Physiological and Biomechanical Efficiency of the PAPAW|SmartDrive|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|July 2015|November 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506712||16407|
NCT02496481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00096047|A Brief MI Intervention in the ED to Increase Child Passenger Restraint Use|A Brief Motivational Interviewing Intervention in the Emergency Department to Increase Size-Appropriate Child Passenger Restraint Use||University of Michigan|No|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|344|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496481||17193|
NCT02406729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEN-03-IB|Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine|Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine||Butantan Institute|Yes|Recruiting|January 2016|November 2021|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16944|||Both|24 Months|59 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406729||24086|
NCT02428049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/169|Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma|Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma||Sykehuset i Vestfold HF|Yes|Recruiting|October 2013|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|lung cancer patients in stages IA-IIIA|December 2015|December 6, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02428049||22447|
NCT02428296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150120|Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation|Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|3 Years|65 Years|No|||March 2016|March 22, 2016|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428296||22428|
NCT02489253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFH FH Study|Atherosclerosis in Familial Hypercholesterolemia|Incidence and Characteristics of Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia According to Monogenic Versus Polygenic Status||University College, London|Yes|Recruiting|April 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50 monogenic FH and 50 polygenic hypercholesterolemia|July 2015|July 1, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489253||17748|
NCT02442271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-225|A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III)||AbbVie|No|Active, not recruiting|April 2015|October 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442271||21356|
NCT02431091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSTP-OCTHIV|Evaluation of the Role of OCT in the Detection of HIV-associated Neurocognitive Disorder|Evaluation of the Role of Optical Coherence Tomography (OCT) in the Detection of HIV-associated Neurocognitive Disorder|OCT-HIV|Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02431091||22215|
NCT02433171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401013294|Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery|Studies of Methionine-PET and PBR28-PET in Brain Metastases to Differentiate Tumor Recurrence and Radiation Necrosis Following Stereotactic Radiosurgery||Yale University|No|Recruiting|January 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who received SRS for melanoma or NSCLC brain metastases with regrowing lesions        who are candidates for surgical intervention (biopsy or excision) at the Smilow Cancer        Center or are candidates for monitoring by serial imaging will be screened for eligibility        and offered enrollment|April 2015|May 1, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02433171||22055|
NCT02433184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR10/9592|Very Early Versus Delayed Etanercept in Patients With RA|A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis|VEDERA|University of Leeds|No|Recruiting|July 2011|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||April 2015|April 28, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433184||22054|
NCT02432729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-SCR-01|A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation|A Multi-center, Multi-region Smoking Cessation Study to Understand the Biological and Functional Changes Related to Smoking Cessation in Healthy Smokers Who Are Continuously Abstinent From Smoking for One Year|RIBESC|Philip Morris Products S.A.|No|Recruiting|May 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|950|Samples Without DNA|Blood and urine bio-banking samples|Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult, smoking subjects willing to quit smoking with no restriction on race and        ethnicities will be enrolled in this study.|December 2015|December 1, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02432729||22089|
NCT02493075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIs-304|Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population|Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population: A Prospective Randomized Single-center Trial||Sir Run Run Shaw Hospital|No|Recruiting|March 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|140|||Both|18 Years|75 Years|No|||July 2015|July 8, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02493075||17455|
NCT02438033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC PC+S|Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease|Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease||University of California, Los Angeles|Yes|Withdrawn|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|75 Years|No|||February 2016|February 24, 2016|April 28, 2015|Yes|Yes|Not approved by CMS|No||https://clinicaltrials.gov/show/NCT02438033||21681|
NCT02440295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-253|Pilot Study to Assess the Use of Spy Elite for Assessment of Amputation Healing|||Spectrum Health Hospitals|No|Not yet recruiting|May 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|No|Probability Sample|Currently there are no proven, reliable, objective tests to predict wound healing for        amputations. Successful wound healing relies heavily on perfusion of the tissue flaps        during amputation, which may already be compromised in peripheral vascular patients.        Amputation failure results in repeat hospitalizations, surgeries and prolonged immobility        for patients. The financial burden for patients and hospitals are significant, as is the        psychological and emotional burden for patients facing repeat amputation. Failure rates        for BKA and AKA amputations are 10% and 7% respectively. In elderly patients, readmission        rates are as high as 27% with a mortality rate of 9% at 30 days.1 With improved ability to        identify amputation sites at risk for wound complication and failure, we hope to decrease        the need for readmission and repeat surgery.|May 2015|May 6, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02440295||21508|
NCT02479373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00071505|Exercise and Body Composition in Juvenile Idiopathic Arthritis|"Joint Fitness": A Double-Armed Controlled Intervention to Assess the Safety and Effectiveness of Resistance Exercise Training on Muscle, Bone, Strength, Symptoms, Quality of Life and Biological Parameters in Children and Young Adults With JIA|Joint Fitness|Johns Hopkins University|No|Recruiting|July 2012|||October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study|2||||||Both|10 Years|21 Years|No|||June 2015|June 19, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02479373||18506|
NCT02483871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062343|Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy|||Duke University|No|Recruiting|October 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|N/A|N/A|No|||October 2015|October 23, 2015|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02483871||18160|
NCT02439853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00073634|Communication Bridge Speech Therapy Research Study|Communication Bridge Speech Therapy Research Study: Using Internet-Based Speech Therapy to Improve Quality of Life and Access to Care||Northwestern University|No|Recruiting|March 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|N/A|No|||January 2016|January 22, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02439853||21542|
NCT02430545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371015|Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics|A Phase 1, Open-label, Fixed-sequence, 2-period Study In Healthy Volunteers To Investigate The Effect Of Multiple Doses Of Rifampin On Single Dose Glasdegib (Pf-04449913) Plasma Pharmacokinetics||Pfizer|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02430545||22256|
NCT02430558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00002-47|Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft|Second Line Treatment of Knee Osteochondral Lesion With Decellularized Treated Osteochondral Allograft. Phase IIa Trial|ODPHOENIX2|TBF Genie Tissulaire|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|55 Years|No|||April 2015|April 29, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02430558||22255|
NCT02430610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uterine Cerv cancer-IRE-01|Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms|Irreversible Electroporation(IRE) For Unresectable Uterine Cervical Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430610||22251|
NCT02433015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004-00|Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes|Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes|ECIG|Laureate Institute for Brain Research, Inc.|No|Recruiting|January 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433015||22067|
NCT02484131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00849|Bone Health Management for Women Diagnosed With Breast Cancer|Bone Health Management for Women Diagnosed With Breast Cancer: A Pilot Study||University of British Columbia|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Female|65 Years|75 Years|No|||February 2016|February 19, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02484131||18140|
NCT02491463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201974|A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults|A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults||GlaxoSmithKline||Active, not recruiting|July 2015|February 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02491463||17579|
NCT02436603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-15|Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)|Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)||Beth Israel Medical Center|Yes|Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02436603||21791|
NCT02439320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-301|Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:|A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study|SAMURAI|CoLucid Pharmaceuticals|No|Recruiting|April 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2225|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439320||21583|
NCT02433990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-28847|Risk Factors for Acquired Cardiovascular Disease in Adults With Congenital Heart Disease|Risk Factors for Acquired Cardiovascular Disease in Adults With Congenital Heart Disease||Stanford University|No|Active, not recruiting|April 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Adults with Moderate or Complex Congenital Heart Disease|September 2015|September 4, 2015|May 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02433990||21992|
NCT02440945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9114|Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People|Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People|DBSage|University Hospital, Montpellier|No|Recruiting|October 2013|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|160|||Both|N/A|N/A|No|||April 2013|May 7, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02440945||21458|
NCT02493244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20714|Lipid Layer Thickness Pre and Post Lid Scrubs With Cliradex||HONDA|University of Waterloo|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|17 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02493244||17442|
NCT02438748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:102|Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression|The Role of Biological Stress Markers in Predicting Treatment Response to Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder||University of Manitoba|No|Enrolling by invitation|May 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|10ml of blood will be extracted at each collection. Patients will give two samples. Controls      will give one sample. Following collection, blood samples will be spun to separate and      extract plasma. The amount of oxidized phosphatidylcholines in the plasma will then be      quantified.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 patients with Major Depressive Disorder who have been deemed eligible for rTMS        treatment. Eligible persons will be identified by a psychiatrist from amongst patients at        the outpatient Neuromodulation and Neuropsychiatric Unit at St Boniface Hospital.|November 2015|November 19, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438748||21626|
NCT02434276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX2012Q-03|Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years|A Phase II, Multicenter, Randomized, Double-Blind, Active Comparator Controlled Study of the Immunogenicity and Safety of VAX2012Q, A Quadrivalent Influenza Vaccine in Healthy Adults 18-64 Years||VaxInnate Corporation|Yes|Active, not recruiting|May 2015|June 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|450|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434276||21970|
NCT02434289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51834.081.14|Feasibility of a Resistance Exercise and Dietary Protein Intervention in Elderly People in Practice (ProMuscle 65PK)|Pilot Study to Study the Feasibility and Potential Impact of a Combined Resistance Exercise and Increased Protein Intake Intervention in (Frail) Elderly People, in a Real-life Setting||Wageningen University|No|Completed|April 2015|||September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|23|||Both|65 Years|N/A|No|||October 2015|October 7, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02434289||21969|
NCT02433782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|He-Fascial|Myofascial Therapy in Patients With Hemophilic Arthropathy|Physiotherapy Protocol by Myofascial Therapy and Randomized Clinical Study in Patients With Hemophilic Arthropathy|He-Fascial|Universidad Católica San Antonio de Murcia|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Male|18 Years|65 Years|No|||September 2015|October 13, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02433782||22008|
NCT02481531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3387-1|Growth and Tolerance of Cow's Milk-Based Infant Formulas|Growth and Tolerance of Cow's Milk-Based Infant Formulas||Mead Johnson Nutrition|No|Active, not recruiting|July 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|315|||Both|N/A|14 Days|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02481531||18340|
NCT02481817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150917|Treatment Alternatives in iSGS (NoAAC PR-02 Study)|Treatment Alternatives in Adult Rare Disease; Assessment of Options in Idiopathic Subglottic Stenosis North American Airway Collaborative PR-02 Study (NoAAC PR-02 Study)|NoAAC PR-02|Vanderbilt University|No|Recruiting|August 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Biospecimens collected during routine standard of care from each patient (such as tracheal      biopsies obtained during surgery, or surgical specimens generated thru open reconstructive      surgeries), will be annotated in the EDC with such data including specimen collection,      specimen type (e.g., frozen biopsy tissue; FFPE block), and storage location. We may examine      excess tissue obtained at standard of care surgical biopsy. Additionally if blood is      collected during standard of care (i.e., medically indicated labs, operative or office-based      procedures), we will ask participants to provide a one-time, 30 mL blood specimen for      research.|Both|18 Years|N/A|No|Non-Probability Sample|All clinically confirmed iSGS patients at the participating institutions are eligible for        enrollment.|February 2016|February 9, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481817||18318|
NCT02437032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-GV-04-2009-01|Gonadotropin Type in Ovarian Stimulation|Type of Gonadotropin During Controlled Ovarian Stimulation Affects the Endocrine Profile in Follicular Fluid and Apoptotic Rate in Granulose Cells||IVI Madrid|No|Completed|April 2009|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|November 21, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02437032||21758|
NCT02434588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFO_2014-27|Evaluation of an Iris Dilatation Ring in Cataract Surgery (ADICC-ID)|Evaluation of an Iris Dilatation Ring in Cataract Surgery|ADICC-ID|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|April 2015|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02434588||21946|
NCT02441049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G00007105|Latino Mothers as Primary Agents of Change|Latino Mothers as Primary Agents of Change||San Diego State University|Yes|Active, not recruiting|July 2007|July 2016|Anticipated|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|361|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441049||21450|
NCT02493491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METIS M930901001; WI P150999|Neurogenic Dysphonia/Dysphagia Registry|Neurogenic Dysphonia/Dysphagia Registry|StrongVoice|Merz Pharmaceuticals, LLC|Yes|Recruiting|June 2015|December 2020|Anticipated|June 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with neurogenic dysphonia/dysphagia treated with vocal fold augmentation|March 2016|March 2, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02493491|5 Years|17423|
NCT02494089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM STRESS|Analysis of the Stress Induced by in Situ Simulation|Analysis of the Stress Induced by in Situ Simulation|SIMSTRESS|Centre Hospitalier Universitaire de Besancon|No|Enrolling by invitation|June 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|team members|July 2015|July 7, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02494089||17377|
NCT02429219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-URO-00033|Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate|Prospective Study of Monitoring the Alcohol Concentration in Breathing Air During Transurethral Prostate Resection of Benign Prostate Hyperplasia (BPH) Assessing the Uptake of Irrigation Fluids|SATURN-P|University of Magdeburg|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|N/A|N/A|No|||April 2015|April 28, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02429219||22357|
NCT02434198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57678|Falling in Patients With COPD Referred to Pulmonary Rehabilitation: Incidence, Risk Factors and Prediction Tools|||Katholieke Universiteit Leuven|No|Recruiting|January 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|All patients referred to the outpatient pulmonary rehabilitation (PR) program in the        Gasthuisberg University Hospital (Leuven, Belgium) will be screened for eligibility.|April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434198||21976|
NCT02428556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028203|FDA "Breakthrough Drugs": A Trial Testing the Effect of Alternative Language on Public Perceptions|FDA "Breakthrough Drugs": A Randomized Trial Testing the Effect of Alternative Language on Public Perceptions||Dartmouth-Hitchcock Medical Center|No|Completed|June 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|5||Actual|458|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02428556||22408|
NCT02490722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15006949|Effect of Patient Education on Functions in Patients With Non-specific and/or Degenerative Low Back Pain|The Effect of Interdisciplinary Group Based Patient Education on Functions in Patients With Non-specific and/or Degenerative Low Back Pain||Nordsjaellands Hospital|No|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490722||17636|
NCT02482090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY1508|TIL Therapy for Metastatic Ovarian Cancer|T Cell Therapy for Patients With Metastatic Ovarian Cancer||Herlev Hospital|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Female|18 Years|70 Years|No|||February 2016|February 22, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482090||18297|
NCT02482103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-RDN_REG|The Dutch National Renal Denervation Registry|Safety, Success Rate and Long Term Consequences of Renal Denervation in Patients With Therapy Resistant Hypertension. The Dutch National Renal Denervation Registry|NL_RDN_REG|UMC Utrecht|No|Recruiting|April 2013|April 2020|Anticipated|April 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients treated with (or evaluated and refused for) renal denervation in Dutch hospitals.        Indications for RD (by Dutch consensus) are therapy resistant hypertension defined as a        blood pressure above treatment goal despite use of 3 or more antihypertensive agents        preferably including a diuretic or intolerance for (additional) antihypertensives.        Secondary hypertension is excluded beforehand.|June 2015|June 25, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02482103|5 Years|18296|
NCT02435524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9066|Alive & Thrive Evaluation in Burkina Faso|Alive & Thrive Evaluation in Burkina Faso||London School of Hygiene and Tropical Medicine|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2400|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435524||21874|
NCT02438514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410014845|Biological Biomarkers in MOMS Partnership|Biological Biomarkers in MOMS Partnership||Yale University|No|Recruiting|November 2014|||November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Low-income, racially and ethnically diverse, un- or under-employed, biological mothers of        children in New Haven.        Primary source of recruitment will be the screening/needs assessment from our affiliated        MOMS Partnership protocol, however, we will actively respond to inquiries from any        preliminarily eligible biological mother in the New Haven community who expresses interest        in the study|January 2016|January 7, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02438514||21644|
NCT02438527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151136|Flowchart-Assisted Resuscitation. Standard CPR vs. Chest Compressions Only: What Happened to the Quality?|Flowchart-Assisted Resuscitation. Standard CPR vs. Chest Compressions Only: What Happened to the Quality?||Medical University of Vienna|No|Not yet recruiting|June 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02438527||21643|
NCT02428764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1010|Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma|A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma||Sun Yat-sen University|Yes|Recruiting|April 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428764||22392|
NCT02428777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyst 5|Tramadol Versus Diclofenac for Prevention of Pain in Operative Outpatient Hysteroscopy|Tramadol Versus Diclofenac for Prevention of Pain in Operative Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial||Cairo University|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|210|||Female|20 Years|60 Years|No|||January 2016|January 26, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02428777||22391|
NCT02491814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC_31012|The Effect of Dairy and Non-dairy Alternatives on Satiety and Post-meal Glycemia in Healthy Young Adults|The Effect of Commercially-available Dairy and Non-dairy Alternatives When Consumed With a High Glycemic Cereal on Subjective Appetite Ratings and Post-meal Glycemia in Healthy Young Adults||University of Toronto|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|28|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02491814||17552|
NCT02431130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2596|Low-fidelity Simulation to Teach Anesthetists' Non-technical Skills in Rwanda|||Dalhousie University||Completed|February 2012|September 2014|Actual|January 2013|Actual|N/A|Interventional|N/A|2||Actual|20|||Both|18 Years|N/A||||April 2015|April 27, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431130||22212|
NCT02433743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCheikhAntaDiop|Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA|Daily Consumption of Ready-to-use Peanut-based Therapeutic Food Increased Fat Free Mass, Improved Anemia Status But Has no Impact on Zinc Status of People Living With HIV/AIDS (PLWHA)|PLWHA|Cheikh Anta Diop University, Senegal|No|Completed|October 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|78 Years|No|||April 2015|April 29, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02433743||22011|
NCT02433756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|RESponders and QUadripolar LV Lead in CRT|Responders and Quadripolar LV Lead in CRT|ResQ CRT|Ospedale Santa Croce-Carle Cuneo||Recruiting|March 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Failure|April 2015|April 29, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02433756|18 Months|22010|
NCT02485080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33431|Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1|Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN||Stanford University|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|72 Years|No|||September 2015|September 15, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485080||18067|
NCT02438462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOFIE 2015-A00094-45|Soluble Fibrin for Diagnosing Pulmonary Embolism|Evaluation of Performances of Soluble Fibrin Assay for Diagnosing Pulmonary Embolism|SOFIE|Diagnostica Stago R&D|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|Frozen heparinized and citrated Poor Platelets Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients from Emergency or Respiratory and Intensive Care Medicine Units, in a French        Hospital.|July 2015|July 23, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438462||21648|
NCT02438475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vascular Closure Venous Mynx|The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure|||Medstar Research Institute|No|Not yet recruiting|June 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438475||21647|
NCT02432131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVER-PFO_ver1.1|Decompression Sickness in Divers With or Without Patent Foramen Ovale|Incidences of Decompression Sickness in SCUBA DIVERs With or Without Patent Foramen Ovale (DIVER-PFO); A Double-blinded, Prospective Cohort Study|DIVER-PFO|Sejong General Hospital|No|Recruiting|May 2015|February 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Recreational SCUBA (self-contained underwater breathing apparatus) divers|July 2015|July 14, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432131|3 Years|22135|
NCT02432144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX003-CL202|A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7|A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7||Ultragenyx Pharmaceutical Inc|No|Recruiting|October 2015|February 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|N/A|No|||February 2016|February 23, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432144||22134|
NCT02430948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGARA CAN-264|Improving Compliance With Medical Testing Guidelines|Improving Compliance With Medical Testing Guidelines||Beth Israel Medical Center|No|Recruiting|January 2014|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|218|||Both|30 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|September 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02430948||22226|
NCT02431208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29695|A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)|A Phase IB Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With Lenalidomide in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)||Hoffmann-La Roche||Recruiting|July 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431208||22206|
NCT02491294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3278H|Fuel for Fun: Cooking With Kids Plus Parents and Play|Cooking With Kids 2.0: Plus Parents and Play|FFF|Colorado State University|No|Recruiting|July 2012|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|2640|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491294||17592|
NCT02436954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160084|Regional Cerebral Oxygen Saturation in Laparoscopic Surgery|Impact of Neuromuscular Blockade on Cerebral Oxygen Saturation in Laparoscopic Surgery Employ Carbon Dioxide-pneumoperitoneum||Konkuk University Medical Center|No|Not yet recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|60 Years|No|||June 2015|June 17, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02436954||21764|
NCT02431442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-493-002|Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM 493 Administered to Healthy Obese Non-diabetic Volunteers||Rhythm Metabolic, Inc.|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|12||Actual|57|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431442||22188|
NCT02431728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DuquesneU|The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program|The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program: A Randomized, Double Blind, Placebo, Controlled Trial|M-PAWS|Duquesne University|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||August 2015|August 25, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431728||22166|
NCT02480647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44827415200005404|Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis|Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis||University of Campinas, Brazil|Yes|Not yet recruiting|July 2015|January 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480647||18408|
NCT02483377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-14-7|Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer|Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women||University of Southern California|Yes|Recruiting|March 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Self-identified Latina (or Hispanic) who is receiving ongoing care at LAC+USC Medical        Center will be recruited.|June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483377||18198|
NCT02428699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202359|Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil|Comparison of Plasma Levels of n-3 Fatty Acids After Ingestion of an Emulsified Cod Liver Oil Product and a Non Emulsified Cod Liver Oil Product||GlaxoSmithKline|No|Completed|May 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02428699||22397|
NCT02437617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA12-0360|Genomic Profiling Assay in Phase I|A Study Exploring the Use of the Foundation Medicine Genomic Profiling Assay in a Phase I Solid Tumor Patient Population||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2012|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Tumor specimens collected from patients for DNA extraction. All samples residual samples      from previously performed biopsies.|Both|N/A|N/A|No|Non-Probability Sample|Participants from MDACC/Phase I historical archives, and participants actively on        MDACC/Phase I studies.|August 2015|August 18, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02437617||21713|
NCT02485067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THVD-201_OAB_III_2014|Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB|Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study||SK Chemicals Co.,Ltd.|Yes|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|85 Years|No|||June 2015|June 25, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02485067||18068|
NCT02436811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 27273314.1.0000.0102|Oral Health Literacy and Oral Education|Literacy and Information Retention in Pregnancy||Universidade Federal do Paraná|Yes|Recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|180|||Female|12 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 4, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02436811||21775|
NCT02502019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC 2015-001|HEMOBLAST Pilot Clinical Investigation|Prospective, Multicenter, Single-arm Pilot Clinical Investigation Evaluating the Use of a Surface Bleeding Severity Scale (SBSS) and the Safety and Efficacy of a New Hemostatic Device in Abdominal and Orthopedic Lower Extremity Surgeries||Biom'Up SA|Yes|Completed|August 2015|March 2016|Actual|March 2016|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02502019||16768|
NCT02498561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-62550515-02|The Effects of Obesity on Glutathione Levels in Patients With Chronic Periodontitis Before and After Periodontal Therapy|Phase 1 Study of Periodontal Disease and Obese Individuals That Investigate of Local and Systemic Antioxidant Levels of Before and After Periodontal Treatment||Bulent Ecevit University|No|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|60|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02498561||17034|
NCT02403635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M522101-EU24|Drug-Drug Interaction Study: ASP2151 and Midazolam|A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Midazolam in Healthy Men||Maruho Europe Limited|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02403635||24322|
NCT02403648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-101|Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons|Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Glucagon for Injection (Eli Lilly) and GlucaGen® (Novo Nordisk) Administered by Subcutaneous and Intramuscular Injection in Normal, Healthy Volunteers||Biodel|No|Completed|November 2014|||March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02403648||24321|
NCT02409160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220506/2009|Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.|Sleep, Pulmonary Function, Systemic and Adipose Immune Response and Quality of Life in Severe Obese Patients Undergoing Bariatric Surgery. A Protocol of Randomized Controlled Clinical Trial||University of Nove de Julho|Yes|Enrolling by invitation|March 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|17|||Both|18 Years|65 Years|No|||March 2016|March 12, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409160||23899|
NCT02409199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-G301|A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer|A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction||Shanghai Zhongshan Hospital|Yes|Recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02409199||23896|
NCT02500810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW-N-1501|Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients|A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients||Beijing Cancer Hospital|No|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|106|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02500810||16861|
NCT02502045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310012895|Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's|A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease||Yale University|No|Completed|May 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|18|||Female|65 Years|N/A|No|||January 2016|January 11, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02502045||16766|
NCT02406040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not assigned|Effects of Short-term Energy Deficit on Muscle Protein Turnover|Effects of Short-term Energy Deficit on Muscle Protein Turnover||McMaster University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02406040||24137|
NCT02397980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUMC2014-12-028|Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia|A Multicenter, Randomized Trial to Assess Efficacy of Therapeutic Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia|I-care|Ewha Womans University Mokdong Hospital|Yes|Not yet recruiting|March 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02397980||24755|
NCT02501538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012015-051|Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers|Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers|EO2|University of Texas Southwestern Medical Center|No|Recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|89 Years|No|||January 2016|January 12, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02501538||16805|
NCT02508090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29711|Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin|Long-Term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection||Hoffmann-La Roche||Active, not recruiting|August 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Blood and urine samples will be collected over a course of 7 study visits to obtain      hematology, chemistry, urinalysis, coagulation, HCV RNA, and viral resistance data.|Both|N/A|N/A|No|Non-Probability Sample|This study will enroll null responders with CHC genotype 1 virus infection who have        participated in Study SPC3649-207.|September 2015|September 1, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508090||16301|
NCT02510872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-160|Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection||TEPVAD|University Hospital, Caen|No|Completed|December 2011|||April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510872||16088|
NCT02404493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-141020101115-THCT|Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin|A Clinical Trial to Evaluate the Efficacy of an Investigational Nighttime Moisturizing Balm in the Management of Mild to Moderate Atopic Dermatitis in Infants and Toddlers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Recruiting|March 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Months|47 Months|No|||February 2016|February 3, 2016|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404493||24256|
NCT02408380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DCA05T|Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)|Analysis of a Biomarker Signature, Consisting of Toll-like Receptor 2 (TLR2), TLR4 and CCR1, by Flow Cytometry in Patients With MS Treated With Gilenya (FTY720)|MS|McGill University|No|Recruiting|September 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|216|Samples Without DNA|Cryopreserved peripheral blood mononuclear cells.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated with Gilenya compared with age-matched healthy controls|March 2015|April 2, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02408380||23959|
NCT02509520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00056749|Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes|Rehabilitation, NMES and High Protein to Reduce Post ICU Syndrome in the Elderly|ExPrEs|University of Maryland|Yes|Recruiting|May 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|60 Years|N/A|No|||July 2015|July 23, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02509520||16192|
NCT02402686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29719|Non-Interventional Study of Tocilizumab Subcutaneous Monotherapy in Patients With Rheumatoid Arthritis|Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)||Hoffmann-La Roche||Recruiting|May 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment for rheumatoid arthritis (RA) with tocilizumab subcutaneous        (SC) according to standard of care and in line with the current summary of product        characteristics (SPC) and/or local labeling and who have no contraindication to        tocilizumab therapy as per the local label. This can include patients who have received        tocilizumab SC monotherapy treatment within 8 weeks prior to the enrollment visit.|March 2016|March 1, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402686||24393|
NCT02396264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEMED2|Mediterranean Diet as Treatment for Normal Weight Women With PCOS|Mediterranean Diet: A New Nutritional Approach for the Treatment of Normal Weight Women With Polycystic Ovary Syndrome (PCOS)?||Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona|No|Recruiting|June 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02396264||24887|
NCT02432469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-2013BAI09B01-3|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence|MISSION-2|China National Center for Cardiovascular Diseases|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02432469||22109|
NCT02432482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA037042-01|A Mobile Intervention to Promote Cessation in HIV-infected Smokers|A Mobile Intervention to Promote Cessation in HIV-infected Smokers||Montefiore Medical Center|Yes|Not yet recruiting|August 2015|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|October 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02432482||22108|
NCT02493036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-2-010-002|A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C|A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation||Synthetic Biologics Inc.|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493036||17458|
NCT02431104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-15-EN02|Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser|||Cutera Inc.|No|Not yet recruiting|May 2016|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431104||22214|
NCT02438124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9193-2|Rhythmic Auditory Stimulation Optimalization for Gait Improvement in Parkinson's Disease - BeatPark Study|Rhythmic Auditory Stimulation Optimalization for Gait Improvement in Parkinson's|BeatPark|University Hospital, Montpellier|Yes|Recruiting|September 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02438124||21674|
NCT02438137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00080121|Dimethyl Fumarate for Obstructive Sleep Apnea|A Randomized Clinical Trial of Dimethyl Fumarate as a Novel Therapeutic Agent for Obstructive Sleep Apnea||University of Michigan|No|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02438137||21673|
NCT02436733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1205|Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM|EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|April 2016|November 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|85 Years|No|||January 2016|January 21, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02436733||21781|
NCT02442362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ-GA-001|TOF Versus SOX in Metastatic Gastric Cancer|Paclitaxel/Oxaliplatin/Fluorouracil (TOF) Regimen Versus S-1/Oxaliplatin (SOX) Regimen Metastatic Gastric Cancer Patients||The First People's Hospital of Changzhou|Yes|Completed|January 2012|June 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||May 2015|May 12, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02442362||21349|
NCT02428959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-0029912|Prospective Study to Assess the Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)|Prospective Study to Assess the Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)|Amyl Nitrite|Johns Hopkins University|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|April 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02428959||22377|
NCT02428972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-55/06.02.2015|Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor|Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor - a Comparison of Two Anaesthetic Techniques||All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|August 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02428972||22376|
NCT02428816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-52|Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes|Evaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes|MultiPAMS|Institut National de la Santé Et de la Recherche Médicale, France|No|Active, not recruiting|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2013|April 23, 2015|January 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02428816||22388|
NCT02483884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM2-01-01-14|PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer|An Open-label, Multi Center PET/CT Study for Investigation of Safety and Diagnostic Performance of the 68Ga Labeled PET Tracer [68Ga]RM2 in Patients With Primary Prostate Cancer||Piramal Imaging SA|No|Recruiting|May 2015|December 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|80|||Male|45 Years|N/A|No|||November 2015|November 23, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02483884||18159|
NCT02430792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDnr. 106471|Effectiveness of Community-based Football in Prostate Cancer|Effectiveness of Community-based Football Compared With Usual Care on Quality of Life in Men With Prostate Cancer: the FC Prostate Community Randomized Controlled Trial|FC-PC|Rigshospitalet, Denmark|No|Recruiting|May 2015|November 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430792||22238|
NCT02434575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NE/0128|UK ROPE Register Study|ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolisation (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE)|UK ROPE|Cardiff and Vale University Health Board|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Male|N/A|N/A|No|Non-Probability Sample|Men with LUTS BPE who have consented to PAE, TURP, Open prostatectomy or laser surgery at        a participating UK site.|April 2015|May 4, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02434575|12 Months|21947|
NCT02434809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-225|Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies|Investigation of Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02434809||21929|
NCT02437968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH086438|Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety|Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety|Cats&Dogs|Temple University|No|Active, not recruiting|December 2010|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02437968||21686|
NCT02438176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0170|Comparison of Single Groin and Single Trans-septal Puncture and Conventional Bilateral Groin Puncture and Double Trans-septal Puncture in Catheter Ablation for Atrial Fibrillation|||Yonsei University|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|105|||Both|19 Years|75 Years|No|||May 2015|May 7, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02438176||21670|
NCT02491515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB9-2|Effects of Denosumab Therapy for Japanese|Effects of Denosumab Therapy for Japanese Osteoporotic Patients||Tomidahama Hospital|No|Recruiting|July 2012|December 2020|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|45 Years|N/A|No|Probability Sample|Osteoporotic patients who admit to our hospital|July 2015|July 2, 2015|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02491515||17575|
NCT02439333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-KE-63|Prospective Randomized Study of Nasal High Flow in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease|||Beijing Chao Yang Hospital|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|40 Years|90 Years|No|||December 2015|December 15, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439333||21582|
NCT02438826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15781|A Study of LY2951742 in Participants With Chronic Cluster Headache|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache||Eli Lilly and Company|Yes|Recruiting|June 2015|March 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438826||21620|
NCT02439632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prulifloxacin aulut ZK-004|A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control|A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control||Lee's Pharmaceutical Limited|No|Completed|February 2014|July 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Female|18 Years|65 Years|No|||May 2015|July 15, 2015|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02439632||21559|
NCT02429856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002407|Posterior Cruciate Retaining (PCR) Versus Posterior Cruciate Substituting (PCS) Total Knee Arthroplasty (TKA)|SCORPIO™ Posterior Stabilized Versus Posterior Retained Total Knee Arthroplasties: Long-term Functional and Radiographic Outcome|SCORPIO™|University of Alberta|No|Completed|February 1999|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02429856||22308|
NCT02429869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVTR-EVE|Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant|Impact of Everolimus on HIV Persistence Post Kidney (and Kidney/Pancreas) or Liver Transplant|HIVTR-EVE|University of California, San Francisco|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429869||22307|
NCT02481258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006469|A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification|A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis|CAVS|Mayo Clinic|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2016|January 12, 2016|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481258||18361|
NCT02427893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1517|Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma|An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2015|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427893||22459|
NCT02439645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008A055317|A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes|A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes|BA-TdP|Massachusetts General Hospital|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood samples from patients with a history of torsade de pointes.|Both|18 Years|N/A|No|Non-Probability Sample|Any patient in which informed consent can be obtained, with a history of torsade de points        (see below designation).|May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02439645|20 Years|21558|
NCT02438631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIANO|Placental Passage and Disposition of Drugs: A Physiology-based Approach|Placental Passage and Disposition of Drugs: A Physiology-based Approach|PIANO|Radboud University|No|Recruiting|February 2015|February 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|Placental tissue is retained, limited sample. DNA will not be analysed.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|January 2016|January 25, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438631||21635|
NCT02438644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29740|Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina|Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina||Hoffmann-La Roche||Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|N/A|N/A|No|Non-Probability Sample|The study population is characterized by patients who are prescribed vismodegib in        Argentina, according to standard of care and in line with the current SPC and local        labeling. Data collection will be prospective except in the cases when a treating        physician contacts the vendor for the first time after the patient has started treatment        with vismodegib. In these cases the vendor will retrospectively collect data from the        start of treatment. Only patients with laBCC or mBCC will be considered in the        effectiveness analysis.|March 2016|March 1, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438644||21634|
NCT02486367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH IRB # 06-14-33|Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)|Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)||University Hospital Case Medical Center|Yes|Not yet recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486367||17969|
NCT02439801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK5|Comparison of Effects of PEEP Levels on Respiratory Mechanics in Patients Undergoing Laparoscopic Cholecystectomy|Comparison of Effects of 3 Different PEEP Levels on Hemodynamic, Respiratory Mechanics and Elimination of Volatile Anesthetic Agent in Patients Undergoing Laparoscopic Cholecystectomy||Umraniye Education and Research Hospital|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|75|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients who will undergo for elective laparoscopic cholecystectomy|May 2015|May 6, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02439801|2 Days|21546|
NCT02430909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0123|Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis|A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis||UCB Pharma|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|102|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430909||22229|
NCT02430467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057512|Caregiver-Guided Pain Management Training in Palliative Care|Caregiver-Guided Pain Management Training in Palliative Care||Duke University|Yes|Recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|472|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02430467||22262|
NCT02494102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPITALSTUDY00002957|Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea|A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea|ModOSA|Milton S. Hershey Medical Center|Yes|Recruiting|February 2016|October 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494102||17376|
NCT02435225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH10126001|Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder Not Otherwise Specified (NOS)|Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder NOS||Stanford University|Yes|Recruiting|January 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|August 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02435225||21897|
NCT02434211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03|Interventional Research in Schools - Second Part|Interventional Research in Schools - Second Part|RISCOLAIRE2|Institut de Cancérologie de la Loire|No|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|291|||Both|9 Years|11 Years|No|||April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434211||21975|
NCT02438280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49073-D|Accelerated Tooth Movement With AcceleDent® and Aligners - a Pilot Project|||University of Washington|No|Recruiting|May 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|May 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02438280||21662|
NCT02433210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1214453|A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients|A Clinical Study Comparing the Basic Performance and Blood Compatabilty Characteristics of Nipro ELISIO-15H, Gambro Polyflux Revaclear and Fresenius Optiflux 160 NR Dialyzers||University of Missouri-Columbia|No|Not yet recruiting|June 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Both|18 Years|85 Years|No|||April 2015|April 28, 2015|December 16, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433210||22052|
NCT02491736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16445|Ketoprofen Gel vs Placebo in Children With Ankle Sprain|Ketoprofen Gel vs Placebo in Children Presented With Ankle Sprain to the Emergency Department: A Randomised Controlled Trial||Akdeniz University|No|Recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|8 Years|18 Years|No|||December 2015|December 2, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491736||17558|
NCT02491749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFTA & LOS|Impact of Immediate Versus Delayed Tracheal Extubation on Length of ICU Stay of Cardiac Surgical Patients|Impact of Immediate Versus Delayed Tracheal Extubation on Length of ICU Stay of Cardiac Surgical Patients||Cairo University|Yes|Completed|February 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02491749||17557|
NCT02437513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB for HNC|NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration|NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration||ProTiP Medical|No|Not yet recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Recruitment of patients will primarily be from the department of Ear, Nose and Throat at        the hospitals participating in the study. Secondary recruitment could also include        associated clinics that treat patients with laryngeal dysfunction and aspiration, such as        swallowing therapy clinics, speech language therapy clinics, and linguistics clinics.|May 2015|May 4, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02437513||21721|
NCT02427698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU200346|Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite|Comparison of the Efficacy Between Cryolipolysis Versus Cryolipolysis Plus Subcision For Treatment of Cellulite: A Prospective Randomized Control Trial||Northwestern University|Yes|Recruiting|August 2015|May 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02427698||22474|
NCT02433496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0280|Physician Coaching to Reduce Opioid-related Harms|Physician Coaching to Reduce Opioid-related Harms||University of Wisconsin, Madison|No|Enrolling by invitation|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinicians with prescribing authority at community-based primary care clinics|February 2016|February 10, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02433496||22030|
NCT02480153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5381002|A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).|A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06410293 And Adalimumab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate||Pfizer|Yes|Recruiting|June 2015|November 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480153||18446|
NCT02484859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/14|Remifentanil and Controlled Hypotension for Functional Endoscopic Sinus Surgery: Comparison With Tramadol and Metoprolol|Remifentanil and Controlled Hypotension for Functional Endoscopic Sinus Surgery: Comparison With Tramadol and Metoprolol||Rize Üniversitesi|Yes|Recruiting|January 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|90|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 25, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484859||18084|
NCT02430519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/98/12|Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects|Effect of Autologous Platelet Rich Fibrin In Human Mandibular Molar Grade II Furcation Defects- A Clinical and Radiological Study|PRFMMFD|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|50 Years|No|||April 2015|April 29, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02430519||22258|
NCT02430532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS308|BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis|INSPIRE|Biogen|Yes|Terminated|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|58 Years|No|||November 2015|November 12, 2015|April 27, 2015|Yes|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT02430532||22257|
NCT02438592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 125|PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders|PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders||Westat|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|924|||Both|13 Years|24 Years|No|Non-Probability Sample|1. Behaviorally-infected, HIV-positive adolescents and young adults who are currently             receiving or plan to receive their medical care at any clinical site that is part of             the AMTU;          2. Ages 13 through 24, inclusive, at the Baseline visit;          3. Males and females;          4. Ability to understand spoken English; and          5. Ability for the AMTU staff to access the subject's medical records for a maximum of             78 weeks after enrollment or through February 2017, whichever occurs first.|March 2016|March 1, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02438592||21638|
NCT02491203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIR-937-0214|Post-stroke Upper Limb Rehabilitation Using Telerehabilitation Interactive Virtual Reality System in the Patient's Home|Maximizing Post-stroke Upper Limb Rehabilitation Using a Novel Telerehabilitation Interactive Virtual Reality System in the Patient's Home||Université de Montréal|No|Recruiting|September 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02491203||17599|
NCT02428153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-KAEK-025 (Ethics Committee)|Effect Of Static And Dynamic Stretching On Muscle Tendon Unit|Investigation Of Muscle-Tendon Unit By Ultrasound After Static And Dynamic Stretching||Tokat Gaziosmanpasa University|No|Completed|April 2015|July 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|28|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428153||22439|
NCT02436135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-397-1245|Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease|A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease||Gilead Sciences|No|Recruiting|June 2015|July 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02436135||21827|
NCT02436148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/13/03/02/2014/1|Reliability and Validity of the Finnish Version of the Prothesis Evaluation Questionnaire|Reliability and Validity of the Finnish Version of the Prothesis Evaluation Questionnaire||Helsinki University Central Hospital|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Actual|140|||Both|18 Years|95 Years|No|Probability Sample|Patients with major lower extremity amputation who has been prothetized.|December 2015|December 8, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02436148|1 Year|21826|
NCT02436161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG2010111182|Effectiveness of a Multidisciplinary Care Management Program for High-risk Patients With Heart Failure (PROMIC)|Effectiveness of a Multidisciplinary Care Management Program for High-risk Patients Who Are Admitted at Hospital Because of Heart Failure (PROMIC)|PROMIC|Basque Health Service|Yes|Completed|May 2011|April 2015|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|250|||Both|40 Years|N/A|No|||May 2015|May 3, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02436161||21825|
NCT02492542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D151100001915003|Effect of Pelvic Floor Stimulation on the Pelvic Floor Function in Cervical Cancer Patients With Type III Hysterectomy|Effect of Pelvic Floor Stimulation on the Pelvic Floor Function in Cervical Cancer Patients With Type III Hysterectomy||Peking University People's Hospital|Yes|Enrolling by invitation|April 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|208|||Female|18 Years|60 Years|No|||July 2015|July 7, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02492542||17496|
NCT02439710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIREB-15-260D|Patient Reported Outcomes Burdens and Experiences - Phase 2|Patient Reported Outcomes Burdens and Experiences - Phase 2 - Pilot Feasibility Study|PROBE|McMaster University|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Moderate / Severe PWH (Age bands or limits may be utilized to narrow the study        population). Patients will be recruited according to the final inclusion criteria. No        randomization will be required. Two moderate to large test runs of the inventory will be        conducted in each country three months apart to demonstrate reproducibility. PWH        participating in each of the two test runs may, but would not necessarily be the same.|October 2015|October 19, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02439710|1 Year|21553|
NCT02436174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02480|Assessment Of Shivering With iSeismograph|Assessment Of Shivering With iSeismograph In Parturients Undergoing Surgical Procedures Under Epidural Anesthesia||University of British Columbia|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|November 2015|November 3, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02436174||21824|
NCT02436187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG/13/81/30474|Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study|Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study||University of Leeds|No|Completed|January 2003|||June 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|389057|||Both|18 Years|N/A|No|Non-Probability Sample|The study population comprised of 389,052 patients with non ST-elevation myocardial        infarction admitted to hospital and were entered into Myocardial Ischaemia National Audit        Project database between January 2003 and December 2013.|May 2015|May 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02436187|10 Years|21823|
NCT02442583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060174|Reducing Sedentary Behaviors Among Colorectal Cancer Survivors|Reducing Sedentary Behaviors Among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project||Duke University|No|Active, not recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442583||21332|
NCT02484846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-20650|Impaired Vigilance, and Its Effects on Cognition and Behavior|||VA Palo Alto Health Care System|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484846||18085|
NCT02436538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13546|Correlation Between Serum Anti-Müllerian Hormone & Müllerian Ducts Anomalies in Infertility|Correlation Between Serum Anti-Müllerian Hormone (AMH) Levels & Müllerian Ducts Anomalies in Patients Undergoingintracytoplasmic Sperm Injection (ICSI)||Kasr El Aini Hospital|No|Recruiting|April 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|female undergoing intraCytoplasmic sperm injection for treatment of infertility|May 2015|May 6, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436538||21796|
NCT02436551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESDICA|Gestational Diabetes in Central Asia: Prevalence and Management|Gestational Diabetes in Central Asia: Prevalence and Management|GESDICA|Ludwig-Maximilians - University of Munich|No|Recruiting|September 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women in rural setting; pregnant women in urban setting;|March 2016|March 7, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436551||21795|
NCT02432118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0053|Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy|A Feasibility Study of Radiofrequency Identification (RFID) Localization of Breast Lesions||Stanford University|Yes|Not yet recruiting|May 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432118||22136|
NCT02437630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO2014LF017B|Intrinsic PEEP and Laryngeal Aperture in COPD|An Investigation Into the Pressure and Airflow/Volume Changes Which Accompany Partial Closure of the Larynx During Expiration in Patients With COPD and the Effect of Applying a Positive End Expired Pressure by Facemask on These Parameters||Royal Brompton & Harefield NHS Foundation Trust|No|Not yet recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|20 patients with chronic obstructive pulmonary disease (COPD) Gold stage 11 as severity of        disease aged 40+ male and female at least 1 pack/day of cigarettes for >10 years        10 normal subjects no evidence of Chronic obstructive pulmonary disease (COPD) on        spirometry < 1 pack of cigarettes /day for 10 years age >40 male and female|May 2015|May 12, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02437630||21712|
NCT02438449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA-2015-04|Cost-Effectiveness of Abdominal-based Autogenous Tissue vs Tissue Expander-Implant Reconstruction - A Feasibility Study|A Cost-Effectiveness Analysis Comparing Abdominal-based Autogenous Tissue (AAT) and Tissue Expander- Implant (TE/I) Reconstruction of the Breast After Mastectomy- A Feasibility Study||McMaster University|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include patients undergoing breast reconstruction after        mastectomy on one or both breasts being seen by one of the participating plastic surgeons.        If patients qualify for the trial according to the inclusion and exclusion criteria, they        will be invited to participate in the study and will be required to provide written        informed consent.|November 2015|November 3, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02438449||21649|
NCT02507180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150546-01H|Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer|Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer: the LEaD Study. A Prospective Cohort Study.|LEaD|Ottawa Hospital Research Institute|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|366|Samples Without DNA|At presentation, a blood sample will be collected for clinical D-dimer tested in real time      and a sample will be collected and the plasma will be frozen for analysis at the end of      study using Vidas D-dimer on all patient samples.|Female|16 Years|N/A|No|Probability Sample|Unselected pregnant women presenting with suspected deep vein thrombosis|July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507180||16371|
NCT02507193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.037.04.|Fibular Fixation in Ankle Fractures:Plate Verses Nail.|Fibular Fixation in Ankle Fractures: a Randomized-Controlled Trial Comparing Plating Versus Intramedullary Nailing||Orlando Health, Inc.|No|Recruiting|July 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|December 10, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02507193||16370|
NCT02498574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16-15-015|Performance Enhancement and Non-Invasive Brain Stimulation|||Bruyere Research Institute||Not yet recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02498574||17033|
NCT02406183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 2015/0025|Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma|Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Immune Checkpoint Inhibitors in Metastatic Melanoma: Dose Limiting Toxicity and Abscopal Effect||University Hospital, Ghent|No|Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02406183||24126|
NCT02394951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501067|Investigation of Somatosensory Predictors of Response to Pregabalin in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)|Investigation of Somatosensory Predictors of Response to Pregabalin in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)||Washington University School of Medicine|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02394951||24988|
NCT02394145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIANO-genetics|Genotype and Platelet Reactivity in Patients on Hemodialysis|The Relationship Between Genotype and Platelet Reactivity in Patients Treated With Ticagrelor Versus Clopidogrel: PIANO Genotype Study||Kyunghee University Medical Center|Yes|Recruiting|September 2009|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|20|||Both|20 Years|80 Years|No|||March 2015|March 19, 2015|March 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02394145||25050|
NCT02508415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMalaya|Relationship Between Obesity and Periodontal Disease|Relationship Between Obesity and Periodontal Disease|ROPD|University of Malaya|Yes|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02508415||16277|
NCT02498834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2628|Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement|Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement||University of North Carolina, Chapel Hill|No|Recruiting|July 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|11 Years|17 Years|No|||December 2015|December 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02498834||17013|
NCT02395224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1361|A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway|A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway||Norwegian University of Science and Technology|Yes|Recruiting|September 2014|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosis of metastatic colorectal cancer treated with a curative or non-curative        intention, or local disease not treated with a curative intention.|September 2015|September 28, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395224||24967|
NCT02402829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14040182|A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture|A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture|CVL#2|Children's Mercy Hospital Kansas City|No|Recruiting|November 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Male|1 Year|21 Years|No|Non-Probability Sample|Subjects with moderate or severe Hemophilia A or B.|January 2015|March 27, 2015|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402829||24384|
NCT02507349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR-1306-02474|Person-Centered Versus Measurement-Based Care in Mental Health|Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health|PCORI-SDM|UPMC|Yes|Active, not recruiting|August 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2405|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02507349||16358|
NCT02496013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM007|Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis||Peking Union Medical College Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|July 10, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496013||17229|
NCT02409745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCZZU-EEI|The Effectiveness of Endometrial Injury in IVF|The Effectiveness of Endometrial Injury in Different Phase of Menstrual Cycle:a Prospective Controlled Clinical Study||The First Affiliated Hospital of Zhengzhou University|Yes|Recruiting|February 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 18, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02409745||23854|
NCT02394470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246 BLUE MOON|BioImpedentiometry, Lung UltraSound and cONgestion in Heart Failure|BioImpedentiometry and Lung UltraSound Examination to MOnitor cONgestion in Heart Failure|BLUEMOON|Niguarda Hospital|No|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02394470||25025|
NCT02394730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-ADV|Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints|A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication|ADVICE|Kirby Institute|Yes|Recruiting|September 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||January 2016|January 4, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394730||25005|
NCT02497768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WS/0104|Particle Sizing of Masticated Tree Nuts - Pistachios and Brazils|Particle Sizing of Masticated Tree Nuts - Pistachios and Brazils||King's College London|No|Active, not recruiting|June 2015|April 2016|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02497768||17095|
NCT02404792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2207|Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause|Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause||University of Colorado, Denver|No|Recruiting|April 2015|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|72|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404792||24233|
NCT02404805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0106|Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers|Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers||University of Colorado, Denver|No|Recruiting|February 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404805||24232|
NCT02400606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2013-FSP-6|The Effect of Constructing Virtual Patient Cases|The Effect of Constructing Versus Solving Virtual Patient Cases on Transfer of Learning: A Randomized Trial||Rigshospitalet, Denmark|No|Completed|January 2013|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|39|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02400606||24553|
NCT02436460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT285|Neihulizumab in Treating Patients With Steroid Refractory Acute Graft-versus-Host Disease After Donor Stem Cell Transplant|A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation||Stanford University|Yes|Recruiting|May 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02436460||21802|
NCT02485119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15404|Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies|An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies||Bayer|No|Recruiting|August 2015|November 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|N/A|No|||March 2016|March 19, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485119||18064|
NCT02435797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W201416|Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction|Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction||Xuzhou Central Hospital|Yes|Recruiting|April 2015|October 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|80 Years|No|||May 2015|May 5, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435797||21853|
NCT02440698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31523|Experiences With a Genetic Test for Personalized Nutrition Test for Personalized Nutrition|Experiences With a Healthcare Professional-mediated Genetic Test for Personalized Nutrition||University of Toronto||Enrolling by invitation|May 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants (n=80) are employees of a large multi-national food company's R&D division        located in Australia, Switzerland, USA and the UK. They underwent a genetic test for        personalized nutrition in March 2015 that was offered at no cost through the company        wellness program.|May 2015|May 11, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440698||21477|
NCT02440789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5337|Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive ART|Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy||AIDS Clinical Trials Group|Yes|Recruiting|August 2015|January 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440789||21470|
NCT02480400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lu-Pl-001|The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression|The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment of Patients With Major Depressive Disorder.||Abarbanel Mental Health Center|No|Completed|June 2010|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|52|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480400||18427|
NCT02480413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0191 - Part 1|Evaluation of an Algorithm for Length Based Weight Estimation|Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Already Known Devices Like the Pediatric Emergency Tape (Pädiatrisches Notfalllineal - PNL)||University Children's Hospital, Zurich|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|16 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric patients planned for elecitve surgery in general anaesthesia|November 2015|November 11, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480413||18426|
NCT02431364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-335-701|Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects||Karyopharm Therapeutics, Inc|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431364||22194|
NCT02433444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039663|Computer Aided, Non-invasive, Acoustic Gastrointestinal Surveillance in Post-ERCP Pancreatitis|Computer Aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Post-ERCP Pancreatitis (PEP)||Cedars-Sinai Medical Center|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Investigators will recruit patients presenting to Cedars-Sinai Medical Center for        outpatient ERCP to be performed by one of the study investigators/treating physicians.|April 2015|April 29, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02433444||22034|
NCT02433457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-292-CP-002|Relative Bioavailability Study of CC-292|An Open-label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect and Dose Proportionality of CC-292 Spray Dried Dispersion Formulation in Healthy Volunteers||Celgene|No|Completed|May 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|March 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433457||22033|
NCT02433028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMSC_1_3|Swiss Multiple Sclerosis Cohort-Study|Swiss Multiple Sclerosis Cohort-Study: A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options|SMSC|University Hospital, Basel, Switzerland|No|Recruiting|June 2012|||January 2042|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|blood samples|Both|N/A|N/A|No|Non-Probability Sample|Clinically isolated Syndrome, Radiologically isolated syndrome, Multiple Sclerosis, Devic        Syndrome|October 2015|October 28, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02433028||22066|
NCT02491372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B15/01|A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population|A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population||Queen's University, Belfast|No|Not yet recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02491372||17586|
NCT02491450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/15/562|A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)||Genuine Research Center, Egypt|No|Completed|February 2015|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|June 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491450||17580|
NCT02435017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001798|Dietary Phosphate and Serum Phosphorus|Nutrition Risk Screening in Chronic Kidney Disease (CKD) From the National Health and Nutrition Examination Survey||The Methodist Hospital System|No|Completed|January 2003|July 2009|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7895|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Participants in the continuous NHANES program from 2003-2006 who met the        inclusion/exclusion criteria were included in the analysis. NHANES samples the general US        population to determine prevalence of major diseases and health risks by combining        physical examination with laboratory studies and questionnaires in a standardized        environment using trained personnel. Participants are selected through a complex,        multistage, probability sampling approach.|March 2016|March 15, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435017||21913|
NCT02437890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0061-C204|A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus|A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus||Ablynx|Yes|Recruiting|July 2015|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|300|||Both|18 Years|64 Years|No|||March 2016|March 2, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437890||21692|
NCT02440347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/5-2015|Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block|Efficacy and Safety of Pulpal Anesthesia After Anterior and Middle Superior Alveolar (AMSA) Nerve Block Obtained by Articaine Computer-controlled and Conventional Delivery||University of Belgrade|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02440347||21504|
NCT02440360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-016|Pay For Success: Permanent Supportive Housing for the Chronically Homeless|Evaluation of Provision of Permanent Supportive Housing for Chronically Homeless Individuals Through Pay for Success|PFS:PSH-CH|University of California, San Francisco|No|Not yet recruiting|May 2015|July 2021|Anticipated|July 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 17, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02440360||21503|
NCT02493153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-2013-N|Hepatic Steatosis After Cholecystectomy|A Prospective Study for the Effect of Cholecystectomy to the Liver in Consideration of Hepatic Steatosis 3months After Cholecystectomy With Ultrasound|HSAC|Soonchunhyang University Hospital|No|Active, not recruiting|October 2013|July 2016|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|82|Samples Without DNA|Liver biopsy was performed during cholecystectomy using liver wedge resection in 10 patients      who had provided informed consent preoperatively. All specimens were reviewed by two      pathologists with single blinded method. Sections were stained with hematoxylin and eosin      (H&E) and examined at X40 magnification. Steatosis was divided into four stages using the      Brunt criteria.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|From Oct, 2013 to Jul, 2014, a cohort of 82 consecutive patients with cholecystectomy was        prospectively collected and followed-up.|November 2015|November 20, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493153||17449|
NCT02493166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-PFE-JRA01|Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis|Cognitive Motor Interference During Dual Tasking With Movements of the Upper Limb in Persons With Multiple Sclerosis|DTC|Hasselt University|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493166||17448|
NCT02427906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-151|Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients|Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota and Associated Inflammatory Factors in Cirrhotic Patients||West China Hospital|Yes|Recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|whole blood, serum，stool|Both|18 Years|75 Years|No|Non-Probability Sample|Cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt for any        indication at West China Hospital|October 2015|October 26, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02427906|6 Months|22458|
NCT02430636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stomach Neoplasms -IRE-01|Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms|Irreversible Electroporation(IRE) For Unresectable Stmoach Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430636||22249|
NCT02490605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simone|Effect of the Use of an Occlusal Plate on the Postural Alignment|Effect of the Use of an Occlusal Plate on the Postural Alignment and Balance of Individuals With Signs and Symptoms of Temporomandibular Joint Disorder|Simone|University of Sao Paulo|Yes|Not yet recruiting|July 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02490605||17645|
NCT02486120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915152|Are Genetic Counselors Screening for Adolescent Suicide Risk?|||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|450|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||June 2015|February 5, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02486120||17988|
NCT02486133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUA-1463-SPI-0320-I|Dual Therapy With Boosted Darunavir + Dolutegravir|A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study|Dualis|Technische Universität München|Yes|Recruiting|July 2015|June 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02486133||17987|
NCT02432092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403919054|Pediatric Cardiomyopathy Mutation Analysis|Pediatric Cardiomyopathy Mutation Analysis||Indiana University|No|Recruiting|April 2014|April 2021|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Whole Blood, Saliva, Tissue|Both|N/A|N/A|No|Non-Probability Sample|Families affected by cardiomyopathy|February 2016|February 23, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432092||22138|
NCT02440984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00082-47|Anorectal Dysfunction in Patients Suffering From Spina Bifida : From Clinic to Neuro-epithelial Function (ANOSPIN)|Anorectal Dysfunction in Patients Suffering From Spina Bifida : From Clinic to Neuro-epithelial Function|ANOSPIN|Rennes University Hospital|No|Recruiting|May 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02440984||21455|
NCT02493439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI013|A Positive Activity Intervention to Promote Wellbeing in Romanian Immigrants|A Positive Activity Intervention to Promote Optimism and Psychological Wellbeing in Romanian Immigrants||Universitat Jaume I|Yes|Recruiting|May 2015|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493439||17427|
NCT02439424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0024|The REACT-ICD Trial|The Effect of Reactive ATP™ on the Burden of Atrial Fibrillation in ICD Patients: The REACT-ICD Trial|REACT-ICD|Hartford Hospital|No|Recruiting|December 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02439424||21575|
NCT02439437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055890|Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain|Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain||Duke University|Yes|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|21 Years|99 Years|No|||September 2015|September 28, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02439437||21574|
NCT02431169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407158|Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression|Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib||Washington University School of Medicine|No|Recruiting|April 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|-  Specimen (tissue and blood) acquisition will take place under Washington University's           study HRPO# 201305031 and will be analyzed under this study.        -  Fresh tissue will be taken at the time of diagnosis of metastatic disease and again at           progression.|Both|18 Years|N/A|No|Non-Probability Sample|Study population will consist of participants with stage IIIB/IV non-small cell lung        cancer with presence of known sensitizing mutations in the EGFR TK domain and absense of        known resistant mutations in the EGFT TK domain.|October 2015|October 14, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02431169||22209|
NCT02490709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-LE|Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy|Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial||National Cancer Center, Korea|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|20 Years|N/A|No|||July 2015|July 2, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490709||17637|
NCT02490774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15731|To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development|Multi-center, Randomized, Comparator-controlled, Single-blind, Parallel-group Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of an Intrauterine System Releasing BAY 1007626, as Compared With Mirena and Jaydess, in a Combined Proof-of-concept and Dose-finding Study in Healthy Pre Menopausal Women Treated for 90 Days||Bayer|No|Active, not recruiting|June 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|176|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490774||17632|
NCT02435238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EGB01|AWARE - Chronic Urticaria|AWARE: A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation|AWARE|Novartis|No|Recruiting|September 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Urticaria Patients|October 2015|October 13, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02435238||21896|
NCT02439658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001851|Genetics of QT Prolongation With Antiarrhythmics|Genetics of QT Prolongation With Antiarrhythmics|DOFEGEN|Massachusetts General Hospital|Yes|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Blood samples for DNA extraction|Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted for dovetailed or sotalol initiation for clinical purposes.|May 2015|May 8, 2015|May 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02439658||21557|
NCT02427412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-134|Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty|Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty - A Randomized, Prospective, Placebo-Controlled Study||Hvidovre University Hospital|Yes|Completed|January 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2015|August 13, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427412||22496|
NCT02427425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1308/09|Effectiveness of Transcutaneous Electrical Nerve Stimulation in Patients With Acute Low Back Pain|||Federal University of São Paulo|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02427425||22495|
NCT02438163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HopitalVinatier|Study of Neuroplasticity on Depressed Patients : Modulation of MEP Induced by Theta Burst Stimulation|Study of Neuroplasticity on Depressed Patients Versus Healthy Subjects : Modulation of the MEP Size Induced by Theta Burst Stimulation|DEPLAS|Hôpital le Vinatier|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02438163||21671|
NCT02479919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00424-45|Treating Social Cognition With Theta Burst Stimulation: a Multicentric Study|Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Multicentric Study|TBS-COG|University Hospital, Caen|Yes|Not yet recruiting|September 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|61|||Both|18 Years|50 Years|No|||January 2016|February 9, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02479919||18464|
NCT02479932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77-2015|A Comparison of Extraperitoneal Versus Transperitoneal Cesarean Section|A Comparison of Skin to Delivery Time at Exztraperitoneal vs. Transpirational Cesarean||Ataturk University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02479932||18463|
NCT02437526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001678|Analytic Treatment Interruption (ATI) to Assess HIV Cure|Analytic Treatment Interruption of Antiretroviral Therapy to Assess for HIV Cure||Mayo Clinic|No|Enrolling by invitation|May 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02437526||21720|
NCT02438371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0134|Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor|Nifedipine Alone or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor: An Open Label, Randomized Comparative Effectiveness Controlled Trial||The University of Texas Health Science Center, Houston|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Female|18 Years|50 Years|No|||December 2015|December 3, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438371||21655|
NCT02484872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP01501|Has Inflammation a Significant Implication in Lung Cancer Evolution?|L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?||European Lung Cancer Working Party|No|Recruiting|May 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Blood sampling (serum)|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed untreated lung neoplasms|January 2016|January 26, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484872||18083|
NCT02491138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15-083|An Evaluation of Appearance-based Interventions for the Promotion of Sleep|||Yale-NUS College||Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491138||17604|
NCT02435251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458943-7|Changes in Anthropometry Following Ambulatory Orthopaedic Surgery|Changes in Anthropometry Following Ambulatory Orthopaedic Surgery|CAS|State University of New York at Buffalo|No|Active, not recruiting|January 2014|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients who are scheduled to undergo ambulatory orthopaedic surgery at our institution.|January 2016|January 4, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435251||21895|
NCT02435264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-137|Choosing Healthier Eating Options at Work and School|Assessing the Barriers and Motivators to Providing and Consuming Healthier Foods in the Singaporean Hawker Center Setting and Evaluating the Healthier Hawker Programme (Now Called the Healthier Dining Program)|Project CHEW|National University, Singapore|No|Active, not recruiting|October 2014|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|476|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02435264||21894|
NCT02435810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150125|Inflammatory and Infectious Diseases of the Nervous System|Natural History Study of Inflammatory and Infectious Diseases of the Nervous System||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|November 2060|Anticipated|November 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|2 Years|N/A|No|||March 2016|March 16, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02435810||21852|
NCT02439489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-11-F01b|Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors|Phase Ib Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors||Fondazione Michelangelo|No|Recruiting|December 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02439489||21570|
NCT02440334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15P.039|Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation|||Thomas Jefferson University|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02440334||21505|
NCT02430428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisuMax-2014-1|Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser|Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism||Carl Zeiss Meditec, Inc.|No|Active, not recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|22 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430428||22265|
NCT02492451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zeynepkamil|Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles|Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|No|Recruiting|June 2015|February 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02492451||17503|
NCT02432300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R41HD077967-01A1|The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury|The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury||EmotEd|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02432300||22122|
NCT02432599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APACH1|Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas|Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas|APACH1|Centre Francois Baclesse|Yes|Recruiting|March 2015|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|May 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432599||22099|
NCT02439619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TechCare-LCFT|TechCare: Mobile-AssessmenT and ThErapy for PsyCHosis: An Intervention for Clients Within the EArly InteRvention SErvice|TechCare: Mobile-AssessmenT and ThErapy for PsyCHosis: An Intervention for Clients Within the EArly InteRvention SErvice|TechCare|Lancashire Care NHS Foundation Trust|Yes|Recruiting|October 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|16|||Both|18 Years|35 Years|No|||May 2015|May 6, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02439619||21560|
NCT02434614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMU-01|Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|A Randomized Phase III Non-inferiority Study of Induction Chemotherapy Followed by IMRT Alone Versus Induction Chemotherapy Followed by IMRT Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma||Guilin Medical University, China|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|70 Years|No|||April 2015|April 30, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434614||21944|
NCT02434887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLEY HERTZ-004|Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women|Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women|CLIN ST EF EV|Kley Hertz S/A|No|Completed|June 2015|August 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|26|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02434887||21923|
NCT02429479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37476|Preparing Family Caregivers to Make Medical Decisions for Their Loved Ones|Preparing Family Caregivers of Very Ill Patients for End-of-Life Decision Making||Milton S. Hershey Medical Center|Yes|Recruiting|July 2013|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429479||22337|
NCT02427971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01476-41|A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane|A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane|ConsoHalo|Saint Antoine University Hospital|No|Recruiting|January 2015|April 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|75 Years|No|Probability Sample|ASA 1/2 adult patients undergoing a general anesthesia of more than one hour.|April 2015|April 27, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02427971||22453|
NCT02427984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORizzoli|Pending Failure in Hard-hard Total Hip Arthroplasty|Early Diagnosis of Pending Failures of Total Hip Arthroplasty With Hard to Hard Bearings|PF|Istituto Ortopedico Rizzoli|Yes|Recruiting|August 2012|November 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|103|Samples With DNA|Whole blood, serum, synovial fluid, urines, periprosthetic tissues, at -80°C|Both|20 Years|90 Years|No|Non-Probability Sample|All the patients (no septic) afferent to our ward and wearing hip prosthesis MoM or CoC. A        group of control patients, waiting for primary total hip arthroplasty.|April 2015|April 27, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02427984||22452|
NCT02491918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-009|Clinical Trial : Complications of in the Bag IOL Versus Optic Capture of IOL in Pediatric Cataract Surgery|Visual Axis Obscuration and Postoperative Complications Following Pediatric Cataract Surgery With Introacular Lens Implantation In-the-bag Versus Posterior Optic Capture : A Randomized, Clinical Trial||Iladevi Cataract and IOL Research Center|Yes|Completed|April 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|61|||Both|N/A|4 Years|No|||July 2015|July 2, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02491918||17544|
NCT02438228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-138|Cardiac Output by Nine Different Pulse Contour Algorithms|Estimation of Cardiac Output by Nine Different Pulse Contour Algorithms Compared With Transpulmonary Thermodilution||University of Schleswig-Holstein|Yes|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02438228||21666|
NCT02431312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-001|Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects|Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients||Inovio Pharmaceuticals|No|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|126|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|April 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431312||22198|
NCT02437123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02718|The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs|||University of British Columbia|No|Enrolling by invitation|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|19 Years|N/A|No|||May 2015|May 4, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02437123||21751|
NCT02442284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-251|A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection|An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)||AbbVie|No|Active, not recruiting|November 2005|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442284||21355|
NCT02442297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31973-iCAR|T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma|Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With Glioblastoma|iCAR|Baylor College of Medicine|Yes|Not yet recruiting|February 2016|January 2031|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442297||21354|
NCT02490943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRB2015|A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS|A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis|PEG-Thermal|Brown, Theodore R., M.D., MPH|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02490943||17619|
NCT02490956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RabiesPID|Diagnostic Immunization With Rabies Vaccine in Patients With PID|Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders||Chulalongkorn University|Yes|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|12 Months|60 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490956||17618|
NCT02496676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150161|Magnesium Supplementation in People With XMEN Syndrome|A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients With XMEN Syndrome||National Institutes of Health Clinical Center (CC)||Not yet recruiting|June 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Male|6 Years|N/A|No|||June 2015|September 24, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02496676||17178|
NCT02496689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-HPP-405|Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)|An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)||Alexion Pharma GmbH||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||October 2015|October 28, 2015|July 8, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02496689||17177|
NCT02507869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-098-SMIJ|A Trial of an Affect-Guided Physical Activity Prescription|A Pilot Randomized Controlled Trial of an Affect-Guided Physical Activity||Southern Methodist University|No|Completed|April 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507869||16318|
NCT02507882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELH - 2015 - IL28|Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma|Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma||Egyptian Liver Hospital||Not yet recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|405|||Both|10 Years|N/A|No|||July 2015|July 22, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507882||16317|
NCT02394964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408014402|The Human Microbiome in Immune-Mediated Diseases|The Human Microbiome in Immune-Mediated Diseases||Yale University|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|90|Samples With DNA|whole blood, oral swab, skin swab, stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with immune-mediated disorders including but not limited to: systemic lupus,        cutaneous lupus, Sjogren's Syndrome, mixed connective tissue disease,        dermatomyositis/polymyositis, celiac sprue with or without dermatitis herpetiformis,        scleroderma, ANCA-associated vasculitis|January 2016|January 13, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02394964||24987|
NCT02399631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHCRC005|Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery|Implementation of an Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery||Kyungpook National University|Yes|Recruiting|January 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|20 Years|80 Years|No|||March 2015|March 21, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02399631||24628|
NCT02398604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140718|Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome|Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.|ELPIS|University of Miami|Yes|Recruiting|April 2015|October 2022|Anticipated|October 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|28 Days|No|||October 2015|October 2, 2015|December 24, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02398604||24707|
NCT02507947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1332|SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access|SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access||European Organisation for Research and Treatment of Cancer - EORTC|No|Not yet recruiting|December 2015|||December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|FFPE block of tumor tissue, blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Pathologically confirmed melanoma of any stage|July 2015|July 23, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02507947|5 Years|16312|
NCT02395237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEQ14393|COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.|An Open-label, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two Batches of the Same Fixed Dose Combinations Amaryl® M IR 2/1000 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.||Pharmaceutical Research Unit, Jordan|No|Not yet recruiting|April 2015|May 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395237||24966|
NCT02395250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-20150313|Anti-GPC3 CAR T for Treating Patients With Advanced HCC|Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC||RenJi Hospital|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395250||24965|
NCT02409212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 18624|Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer|Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer: the PANTERA Trial (Prostate cAncer Novel ThERApy)|PANTERA|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|May 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|N/A|N/A|No|||June 2015|June 9, 2015|January 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02409212||23895|
NCT02497209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGD5064|International AGD Database; Determinants of AGD and Establishment of Normative Data|International AGD Database; Determinants of AGD and Establishment of Normative Data|iAGD|Rigshospitalet, Denmark|No|Enrolling by invitation|August 2015|August 2025|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|6000|||Both|N/A|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|An international AGD database (IAGD) will be established and located in the Department of        Growth and Reproduction and EDMaRC, Rigshospitalet, Copenhagen, Denmark. The database will        consist of anonymised data from multiple studies. For each approved research project,        appropriate data will be exported from the contributing studies to the international        database.        International AGD Consortium An international AGD consortium will provide the governance        framework for the international AGD database. This consortium will consist of the founding        members and a member from each of the contributing studies. They will be responsible for        advising on the design and structure of the database, evaluating and approving specific        research projects.|July 2015|July 13, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02497209||17137|
NCT02501044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-446|Oxygen Desaturation During Hemodialysis|Oxygen Desaturation During Hemodialysis: Clinical Correlates and Association With Adverse Outcomes||Renal Research Institute||Completed|January 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5500|||Both|18 Years|N/A|No|Non-Probability Sample|Renal Research Institute hemodialysis patients|July 2015|July 15, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501044||16843|
NCT02402452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-338-1125|Pharmacokinetics of GS-9857 in Adults With Normal Renal Function and Severe Renal Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment||Gilead Sciences|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|March 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02402452||24411|
NCT02397213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004610-29|Ciclosporin to Protect Renal Function In Cardiac Surgery|Ciclosporin to Protect Renal Function In Cardiac Surgery: CiPRICS A Phase II Double Blind Randomized Placebo Controlled Study|CiPRICS|Region Skane|Yes|Recruiting|April 2015|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|N/A|No|||April 2015|April 16, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397213||24814|
NCT02399696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|540|Primary Care-Based Mindfulness Intervention for Veterans With PTSD|Primary Care-Based Mindfulness Intervention for Veterans With PTSD||Syracuse VA Medical Center|No|Completed|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399696||24623|
NCT02503449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYN-316|Clinical Trial of Pulmonary Cryptococcosis in China|Multi-center Clinical Trial of Pulmonary Cryptococcosis in China|MCTOPCIC|Chinese PLA General Hospital|Yes|Enrolling by invitation|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|260|Samples Without DNA|sputum,whole blood,pleural effusion,lung tissue,cerebrospinal fluid,fungus(smear      examination,culture and identification,antigen detection,drug sensitive test)|Both|N/A|N/A|No|Non-Probability Sample|1. Improve the understanding of the risk factors of pulmonary cryptococcosis.          2. Improve the awareness of pulmonary cryptococcosis clinical and imaging             manifestations.          3. Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in             different conditions.          4. Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.|July 2015|July 17, 2015|December 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02503449|1 Month|16658|
NCT02393703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-015|Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer|Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|March 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|blood, pancreatic fluid, and pancreas tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinic|January 2016|January 21, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02393703||25084|
NCT02393716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10173341DOC|Endurant Evo US Clinical Trial|Endurant Evo US Clinical Trial||Medtronic Endovascular|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393716||25083|
NCT02404870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140195|Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers|Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 30, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404870||24227|
NCT02440607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH15-111|Effect of an Electronic Cognitive Aid Versus Static Cognitive Aid on the Management of a Simulated Crisis|The Effect of an Electronic Dynamic Cognitive Aid Versus a Static Cognitive Aid on the Management of a Simulated Crisis||NorthShore University HealthSystem|No|Recruiting|March 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||October 2015|October 6, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02440607||21484|
NCT02440685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASN002-101|A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors|A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of Asn002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors||Asana BioSciences|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440685||21478|
NCT02493088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P08040|Conduct Disorder in Prison: Search for Prospective and Retrospective Recurring and Contextual Elements|Passage à l'Acte en Maison d'arrêt : Recherche d'éléments Contextuels récurrents Prospectifs et rétrospectifs|CoDiRCE|Groupe Hospitalier de la Rochelle Ré Aunis|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Male|18 Years|N/A|No|Non-Probability Sample|Individuals diagnosed with antisocial personality disorder have been chosen for this study        due to their propensity of aberrant driving behaviors, including torts.        Individuals detained in prison Rochefort and with a despcription fitting a psychopathic        profile (impulsive, lack of empathy, repeated misconducts, repeat offenses ...) are        informed of the study.|January 2016|January 26, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493088||17454|
NCT02438761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2014-10 LAM-PIK|PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)|Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.|LAM-PIK|Institut Curie|No|Not yet recruiting|June 2015|June 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2015|May 6, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438761||21625|
NCT02438774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZ-2011|Intervention in Minimizing Aflatoxins and Fumonisins Exposure to Children Through Food and Breastfeeding in Tanzania|Effectiveness of Post-harvest Intervention Package in Minimizing Aflatoxins and Fumonisins Exposure to Infants and Young Children Through Maize Based Complementary Foods and Breastfeeding in Rural Tanzania||Tanzania Food and Drugs Authority|Yes|Active, not recruiting|November 2013|October 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|N/A|8 Months|Accepts Healthy Volunteers|||May 2015|June 28, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438774||21624|
NCT02441556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLH-NEURO-2015-001|Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment|Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment|BEST|Jinling Hospital, China|Yes|Recruiting|January 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|344|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02441556||21411|
NCT02441569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH086048|Common Engagement Strategies (Common Factors) for Childhood Anxiety|Common Engagement Strategies (Common Factors) for Childhood Anxiety||Johns Hopkins Bloomberg School of Public Health|No|Enrolling by invitation|September 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|12 Years|No|||May 2015|May 11, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441569||21410|
NCT02429063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITE|Light Therapy to Increase Energy in Adolescents With Solid Tumors: A Pilot Study|Light Therapy to Increase Energy in Adolescents With Solid Tumors: A Pilot Study||St. Jude Children's Research Hospital|No|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|55|||Both|12 Years|18 Years|No|||October 2015|October 27, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429063||22369|
NCT02485314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO14/553|Reliability and Validity of Turkish Version of PEM-CY|Reliability and Validity of Turkish Version of the Participation and Environment Measure for Children and Youth||Hacettepe University|No|Not yet recruiting|December 2016|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|650|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Caregivers of children with and without disabilities|September 2015|February 18, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02485314||18049|
NCT02436083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKG-2007|Antibiotics in Free Flaps Reconstructions|The Value of Perioperative Antibiotics on the Success of Oral Free Flap Reconstructions||Technische Universität München|No|Completed|July 2007|December 2014|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|90 Years|No|||May 2015|May 5, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02436083||21831|
NCT02436096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F301|A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia|A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia|AFFIRM|Tonix Pharmaceuticals, Inc.|No|Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||October 2015|October 18, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436096||21830|
NCT02438345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140 2102|PRO 140 for Human Immunodeficiency Virus|A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen||Drexel University|Yes|Recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438345||21657|
NCT02437981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrEP-30 demonstration project|Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic|Thai Red Cross AIDS Research Centre (TRC-ARC)|PrEP-30|Thai Red Cross AIDS Research Centre|No|Enrolling by invitation|December 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|MSM and other individuals at risk for HIV infection|May 2015|May 5, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02437981||21685|
NCT02437994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|933|Pulmonary Rehabilitation Program and PROactive Tool|Impact of a Pulmonary Rehabilitation Program on the PROactive Tool|PROactive|Thorax Research Foundation|No|Recruiting|October 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|40 Years|70 Years|No|||November 2015|November 3, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02437994||21684|
NCT02493114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Functional Status in Patients Undergoing Curative Treatment for Lung Cancer|Functional Status in Patients Undergoing Curative Treatment for Lung Cancer: a Prospective Follow-up Study|FSLC|Hasselt University|No|Recruiting|July 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Blood plasma samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients with a diagnosis of lung cancer (both small cell and non-small cell        lung cancer) who will undergo curative treatment (surgery AND/OR (adjuvant) chemotherapy        AND/OR (adjuvant) radiotherapy) will be eligible for inclusion.        Healthy matched volunteers will carry out the same assessments once to develop normative        values.|December 2015|December 9, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02493114||17452|
NCT02438254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-410H|Texas Family Health Patterns: A Study Across Generations|Oklahoma Family Health Patterns: A Study Across Generations||The University of Texas Health Science Center at San Antonio|No|Recruiting|September 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|175|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young adults with at least one parent with an alcohol or other drug use disorder        history (FH+) or no alcohol or other drug use disorders in any parents or grandparents        (FH-).|November 2015|November 20, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02438254||21664|
NCT02444026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2012-553-12|Feasibility and Efficacy of Internet-delivered CBT for Insomnia in a National Cohort of Danish Breast Cancer Survivors|Feasibility and Efficacy of an Internet-delivered Cognitive-behavioral Intervention for Insomnia in a National Cohort of Danish Breast Cancer Survivors||University of Aarhus|Yes|Recruiting|December 2014|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|May 13, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02444026||21222|
NCT02444039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCON-004-2014|Slit Lamp and Digital Camera Attachment|Slit Lamp Model SL-D-301 and DC-4 Digital Camera Attachment||Topcon Medical Systems, Inc.|No|Completed|November 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Any Willing and able subjects will be recruited from Topcon Medical Systems.|November 2015|November 30, 2015|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02444039||21221|
NCT02429050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152002|Morphine for Treatment of Dyspnea in Patients With COPD|Morphine for Palliative Treatment of Refractory Dyspnea in Patients With Advanced COPD: Benefits and Respiratory Adverse Effects|MORDYC|Maastricht University Medical Center|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429050||22370|
NCT02480985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-06-2040-21|The PIT-TBI Pilot Study|Clinical Outcomes and Predictors of PITuitary Disorders in Patients With Moderate and Severe Traumatic Brain Injury: the PIT-TBI Prospective Multicenter Pilot Cohort Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|March 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02480985||18382|
NCT02433405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAAFA1|Serum Amyloid A Protein And Fetuin A Levels|Serum Amyloid A Protein And Fetuin A Protein Levels In Periodontal Health And Disease||Bulent Ecevit University|No|Completed|December 2013|November 2014|Actual|April 2014|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|Samples Without DNA|Gingival crevicular fluid and Serum|Both|28 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The study population consisted totally 60 subjects whose age (28-45) and sex (33 men, 27        female) were matched.|April 2015|April 29, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433405||22037|
NCT02434601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Federal University of Pelotas|Dentin Treatments for Restorations of Cervical Lesions Non-Carious|Dentin Treatments for Restorations of Cervical Lesions Non-carious: a Randomized Clinical Trial of Three Years||Federal University of Pelotas|Yes|Active, not recruiting|March 2011|October 2016|Anticipated|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|28|||Both|13 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02434601||21945|
NCT02478840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-10|Evaluation of Long-term Efficacy of Treatment With Lamazym|A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials|rhLAMAN-10|Zymenex A/S|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|N/A|No|||July 2015|July 14, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02478840||18547|
NCT02436967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN 020 DECTA|Classification of Carotid Plaque With Computed Tomography With Fast kVp (Kilovolt Peak)-Switching Technique|Classification of Carotid Plaque With Computed Tomography With Fast kVp-switching Technique: A Comparison With Histology and 3-Tesla MRI||Karolinska Institutet|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|The comparison CT vs histology requires a operated plaque for histology.|Both|50 Years|N/A|No|Non-Probability Sample|Patients that are scheduled for CEA (carotid endarterectomy) and volunteer to participate        in this study (fulfilling the incl and excl criteria).|February 2016|February 26, 2016|March 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02436967||21763|
NCT02441790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-2013-07|Early Range of Motion in 5th Metacarpal Fracture|Early Range of Motion in 5th Metacarpal Fracture: A Randomized Controlled Trial||McMaster University|Yes|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02441790||21393|
NCT02441803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0358|Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)|Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|60 Years|No|||March 2016|March 24, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441803||21392|
NCT02430142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-428M-MA|Microcirculatory Oxygen Uptake in Sepsis|Microcirculatory Oxygen Uptake in Sepsis, Severe Sepsis and Septic Shock||Universitätsmedizin Mannheim|No|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Patients admitted a surgical intensive care unit within the last 24 hours and the        diagnosis of sepsis, severe sepsis and septic shock according to the Surviving Sepsis        Campaign.|April 2015|April 25, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02430142||22286|
NCT02430155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uterine balloon tamponade|Balloon Tamponade for Atonic Primary Postpartum Hemorrhage|Comparison of Condom-Loaded Foley's Catheter Versus Bakri Balloon for Treatment of Primary Postpartum Hemorrhage: A Randomized Controlled Trial|UBT|Assiut University||Active, not recruiting|July 2014|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|20 Years|40 Years|No|||March 2015|April 25, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02430155||22285|
NCT02430168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-4 cm RIRS vs PCNL|Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones|||Diskapi Teaching and Research Hospital|No|Recruiting|December 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||April 2015|April 29, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02430168||22284|
NCT02494076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1106|Positive Expiratory Pressure for the Treatment of Acute Asthma in Children|Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations in Children: A Randomized Controlled Trial||University of Colorado, Denver|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|18 Years|No|||January 2016|January 8, 2016|October 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494076||17378|
NCT02428686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM EPO QoL|Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)|Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome With Analysis of the Impact on Quality of Life and Functional Capacity of Patients|EPO-QoL|Groupe Francophone des Myelodysplasies|No|Completed|June 2010|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT02428686||22398|
NCT02435394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R44HL117482|Web System for Engaging Families & Doctors in Continuous Asthma Quality Improvement|Web System for Engaging Families & Doctors in Continuous Asthma Quality Improvement|Asthma|Total Child Health, Inc.|Yes|Not yet recruiting|July 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|5440|||Both|N/A|19 Years|No|||April 2015|April 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02435394||21884|
NCT02479347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-81/12|Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine|A Randomized, Blinded, Single Center Study to Assess the Incidence of Surgical Site Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine 2% in Alcohol 70% (CHLORAPREP ®) Versus 10% Povidone-iodine||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|March 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2160|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02479347||18508|
NCT02479607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhONEME Breast|Effects of an ICT-platform for Assessment and Management of Patient-reported Symptoms During Treatment for Breast Cancer|PhONEME - ParticipatOn Ehealth MobilE. Effects of an Interactive ICT-platform for Assessment and Management of Symptoms in Patients Treated for Breast Cancer.|PhONEME|Karolinska Institutet|No|Recruiting|June 2015|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02479607||18488|
NCT02439671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Max Bell / McGill x-209094|Transition Support Program for Young Adults With Autism Spectrum Disorders|A Service Delivery Model to Better Support Young Adults With Autism Spectrum Disorders in the Transition From School to the Community||McGill University|No|Active, not recruiting|May 2012|June 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|30 Years|No|||May 2015|May 6, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02439671||21556|
NCT02435589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX 043 - EP2|The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes in ICU|The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes: A Randomized Interventional Clinical Study||Cyprus University of Technology|No|Recruiting|March 2015|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 2, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02435589||21869|
NCT02440217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardMet|Myocardial Metabolism in Patients With Dilated Cardiomyopathy|Abnormal Glucose Tolerance is Associated With a Reduced Myocardial Metabolic Flexibility in Patients With Dilated Cardiomyopathy||Azienda Ospedaliero, Universitaria Pisana|No|Enrolling by invitation|May 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|15|Samples Without DNA|Serum, whole blood|Both|21 Years|69 Years|No|Non-Probability Sample|Cardiology Department of the Institute of Clinical physiology|May 2015|May 7, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02440217||21514|
NCT02440230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1503|Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients|Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study|SEAT|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|May 2015|November 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||December 2015|December 29, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02440230||21513|
NCT02484599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS ID 160749|Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients|Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients|CAT|King's College London|No|Recruiting|June 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484599||18104|
NCT02439840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2015-001|Use of Bispectral Index Monitoring to Detect Deep Sedation in Mechanically Ventilated Patients: Validity Study|Use of Bispectral Index Monitoring to Detect Deep Sedation in Mechanically Ventilated Patients: Validity Study||Capital Medical University|Yes|Completed|March 2015|August 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|45|||Both|18 Years|65 Years|No|Probability Sample|Adult patients admitted to 3 ICUs in University Affiliated Hospital will be screened daily        and enrolled consecutively.|August 2015|August 4, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439840||21543|
NCT02430831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF/FC|Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old|Randomized Controlled Trial Testing the Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old||University of Bari|No|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|12 Weeks|No|||April 2015|April 28, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02430831||22235|
NCT02430844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-34-IMP-83|Role of Biomarkers in Predicting Contrast-induced Acute Kidney Injury in Critically Ill Patients|"Role of Biomarkers in Predicting Contrast-induced Acute Kidney Injury in Critically Ill Patients: a Prospective Observational Study"||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All adult critically ill patients having normal renal function will be consider for        inclusion in this study, who will require a contrast-enhanced CT scan of any organ system        as decided by the treating clinician and also met study criteria as predefined.|January 2016|January 16, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430844||22234|
NCT02440269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|narcotrend|The Effect of Circadian Rhythms on Norctrend Index in Anesthesia|||Southwest Hospital, China|Yes|Recruiting|May 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|65 Years|No|Probability Sample|patients who receive surgery and general anesthesia|May 2015|May 8, 2015|May 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440269||21510|
NCT02440282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-1022|Comparison of Anesthetic Modalities on Hemodynamic Stability and Postoperative Pain in Diabetic Foot Patients Undergoing Minor Lower Extremity Amputation|||Yonsei University|No|Completed|January 2012|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|86|||Both|29 Years|88 Years|No|Non-Probability Sample|consecutive 86 diabetic foot patients who underwent minor LEA|July 2015|July 1, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02440282||21509|
NCT02491151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-14O28|Variability of Fluconazole Concentration in Critically Ill Patients|Fluconazole Exposure in Critically Ill Patients and the Value of Therapeutic Drug Monitoring||University Medical Center Groningen|No|Recruiting|October 2014|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Whole blood, serum|Both|18 Years|N/A|No|Probability Sample|All patients admitted to the University Medical Center Groningen who receive fluconazole|July 2015|July 2, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02491151||17603|
NCT02438241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36851514.6.0000.5335|Transcutaneous Electrical Nerve Stimulation Post-thoracic Surgery in a Intensive Care Unit|Transcutaneous Electrical Nerve Stimulation Post-thoracic Surgery in a Intensive Care Unit: Randomized Clinical Trial|TENS|Irmandade Santa Casa de Misericórdia de Porto Alegre|Yes|Active, not recruiting|April 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|30 Years|75 Years|No|||December 2014|May 7, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02438241||21665|
NCT02427438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0672|Home Program Education for Patients With Low Back Pain|Home Program Education for Patients With Low Back Pain: Does it Matter? A Prospective Study||University of Wisconsin, Madison|No|Suspended|February 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|September 30, 2015|April 22, 2015||No|Not recruiting subjects currently|No||https://clinicaltrials.gov/show/NCT02427438||22494|
NCT02427451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14266|Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia|Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|July 2015|||August 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427451||22493|
NCT02430441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tBPC-CGMH-103-5872C|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||April 29, 2015|April 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430441||22264|
NCT02430662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gallbladder Neoplasms-IRE-01|Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms|Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430662||22247|
NCT02485548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014NL-035|Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer|A Multicenter Phase Ⅲ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer||Jiangsu Cancer Institute & Hospital|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485548||18031|
NCT02436902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TACE/S-HCC|Adjuvant Therapies for Patients With HCC and MVI|Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion|A-TACE/S-HCC|Guangxi Medical University||Not yet recruiting|February 2016|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02436902||21768|
NCT02443168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-221-CP-002|Radiolabeled Study of AG-221 in Healthy Male Subjects.|A Phase 1, Open-Label, Two-Part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects||Celgene|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443168||21287|
NCT02443181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48809-A|Demand-driven Management of Essential Tremor|The Application of DBS Technologies for Demand-driven Management of Essential Tremor||University of Washington|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443181||21286|
NCT02481492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBDYYY2015001|Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique|Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique||Ningbo No. 1 Hospital|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Male|7 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 1, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481492||18343|
NCT02481505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHL.1/02-2014|Chloroprocaine 1 % - Spinal Block|Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration: a Prospective, Randomised, Observer-blind Study in Adult Patients||Sintetica SA|No|Completed|June 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|45|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|June 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481505||18342|
NCT02481518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2558/172|Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity|Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity|PRAGMATIC|Mahidol University|No|Recruiting|May 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2015|June 24, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02481518||18341|
NCT02433912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-HUAP 0129.0.258.000-08|Clinical Evaluation of Single-stage Advanced Versus Rotated Flaps in the Treatment of Gingival Recessions|Clinical Evaluation of Single-stage Advanced Versus Rotated Flaps in the Treatment of Gingival Recessions:Longitudinal, Controlled Clinical Trial.||Universidade Federal Fluminense|Yes|Completed|June 2002|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|May 4, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02433912||21998|
NCT02442180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6|Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid|Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study|GraCiAH|Chuncheon Sacred Heart Hospital|Yes|Recruiting|July 2015|December 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|268|||Both|21 Years|79 Years|No|||December 2015|December 1, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02442180||21363|
NCT02480959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0041-15-MMC|Medial Retinacular Plication Versus Medial Patellofemoral Ligament Reconstruction for Recurrent Patellar Instability|Functional Outcome of Surgical Treatment for Recurrent Patellar Instability: A Prospective Comparative Study Between Medial Retinacular Plication Versus Medial Patellofemoral Ligament Reconstruction||Meir Medical Center|No|Not yet recruiting||December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|35 Years|No|||June 2015|June 22, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02480959||18384|
NCT02431325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002669|A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV|A Study to Investigate Gastrointestinal Epithelial Integrity and Arterial Inflammation in Individuals With and Without HIV||Massachusetts General Hospital|Yes|Recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|60 Years|No|||December 2015|December 29, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431325||22197|
NCT02436057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023|Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform|Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform||Cedars-Sinai Medical Center||Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|255|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436057||21833|
NCT02439905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410035MINC|The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery|The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery||National Taiwan University Hospital|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||November 2015|November 19, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02439905||21538|
NCT02429791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201636|Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed (SWORD-1)||ViiV Healthcare|Yes|Active, not recruiting|April 2015|August 2021|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|510|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429791||22313|
NCT02442193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHALIFA/020415|Individual Placement and Support for Patients With Offending Histories|Individual Placement and Support (IPS) for Patients With Offending Histories: Feasibility of an Evidence-based Approach in Forensic Mental Health Settings|IPSOH|Nottinghamshire Healthcare NHS Trust|Yes|Recruiting|March 2016|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442193||21362|
NCT02481219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-205|Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure|MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure||Medtronic - MITG|No|Active, not recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||June 2015|December 3, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02481219||18364|
NCT02481232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV4-001|A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine|A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine||Lanzhou Institute of Biological Products Co., Ltd|Yes|Recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|2 Months|55 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481232||18363|
NCT02427633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1405|Study of Body Positions in Unconsciousness|A Randomised Controlled Study of the Use of Recovery Positions for Comatose Patients in a Resource Limited Setting||University of Oxford|Yes|Recruiting|September 2014|June 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|1377|||Both|18 Years|N/A|No|||March 2015|May 11, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02427633||22479|
NCT02427646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18445|Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease|Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease||Western University, Canada|No|Enrolling by invitation|October 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|No|||October 2015|October 26, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427646||22478|
NCT02500550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-AIR-008|Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor||Kiadis Pharma|Yes|Recruiting|October 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02500550||16881|
NCT02510768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELAPR-P1C|A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba|A Randomized, Within-Subject, Placebo-Controlled, Single-Blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Women With Striae Distensae (SD) Alba||Elastagen Pty Ltd|No|Not yet recruiting|August 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|18|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02510768||16096|
NCT02399878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2015|Intra-operative Inspiratory Oxygen Fraction and Postoperative Respiratory Complications|Intra-operative Inspiratory Oxygen Fraction and Postoperative Respiratory Complications||Massachusetts General Hospital||Active, not recruiting|January 2007|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70000|||Both|18 Years|N/A|No|Probability Sample|All non-cardiothoracic surgical patients aged 18 years or above receiving general        anesthesia at Massachusetts General Hospital between January 2007 and August 2014|March 2015|March 25, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399878||24609|
NCT02402569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIV2|Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease|Implantation Feasibility Study of a Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease (Smart in Vivo 2)|SIV2|University Hospital, Grenoble|Yes|Recruiting|December 2014|December 2022|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5|||Both|18 Years|70 Years|No|||August 2015|August 28, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02402569||24402|
NCT02507804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTSp099|A Study to Evaluate a Diary for Patient Reported Outcome Measures (PROMs)|A Single Centre Randomised Controlled Study to Evaluate a Diary for Patient Reported Outcome Measures (PROMs)|PROMs|Christie Hospital NHS Foundation Trust|No|Recruiting|July 2015|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|164|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02507804||16323|
NCT02507817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604-14-RMB CTIL|Correlation Between LIF (Leukemia Inhibitory Factor ) Levels in Cord and Maternal Blood in Women Treated With Mg|The Correlation Between LIF Levels in Cord Blood to Maternal Blood in Women Treated With Mg During Labor||Rambam Health Care Campus||Not yet recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|Samples without DNA|Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for             neuroprotection.          2. Women in 33-34 weeks gestation that per protocol are not entitled for treatment with             Magnesium Sulphate for neuroprotection.          3. Women that had severe preeclampsia and where treated with Magnesium Sulphate for             seizure prophylaxis and delivered after 34 weeks of gestation.          4. Low risk pregnanacies in similar weeks to group 3 that did not require any special             teatment and delivered after 34 weeks of gestation|August 2015|August 4, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02507817||16322|
NCT02510807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8868-BE|The PaWS (Pedometer and Walking Study)|The PaWS (Pedometer and Walking Study): Comparing Education Alone and Education With Pedometer/Exercise Log Use in Self-monitored Walking in Peripheral Arterial Disease (PAD)|PAWS|University Health Network, Toronto|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02510807||16093|
NCT02399020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169/13/03/03/2011|Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland|Social Cognition and Interaction Training (SCIT) for Adults With Psychotic Disorder: An Open Pilot Study in Finland||Helsinki University Central Hospital|No|Completed|January 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399020||24675|
NCT02394444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-094|Impact of an Intervention Program on Parenting Stress After Preterm Birth|Impact of a Psychological Post-hospital Intervention Aimed at Facilitating Parents-child Attachment and Preventing the Preterm Infants' Psycho-emotional, Social and Cognitive Disturbances|IDEX|University Hospital, Caen|Yes|Completed|June 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|89|||Both|28 Weeks|35 Weeks|No|||March 2015|March 16, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02394444||25027|
NCT02507895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI-LL2012/00658|Effect of Brain-Computer Interfaced-Assisted Motor Imagery for Gait Retraining in Stroke Patients|Brain-Computer Interface-Assisted Motor Imagery for Gait Retraining in Neurorehabilitation||National University Hospital, Singapore|Yes|Recruiting|October 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|70 Years|No|||July 2015|July 23, 2015|December 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507895||16316|
NCT02404584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/LM-01bis|The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer|The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer: Searching for Pharmacogenetic Determinants|GenCInibs-Suni|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|December 2015|September 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|The study population consisted of patients with renal cell carcinoma treated with        sunitinib (Sutent).|January 2016|February 5, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404584||24249|
NCT02401178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IndonesiaU|The Role of Filaggrin and FADS Genes on the Concentrations of PUFA Towards Its Effect on Atopic Dermatitis in Infants|The Role of Fillagrin Gene Mutations and FADS Genes Variation Through Its Effect on the Concentration of Polyunsaturated Fatty Acids Towards the Occurance of Atopic Dermatitis in Indonesian Infants|FLG-FADSgen|Indonesia University|No|Active, not recruiting|May 2014|March 2016|Anticipated|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Buffy coat-plasma-cheeck cell|Both|N/A|12 Months|Accepts Healthy Volunteers|Probability Sample|Target population is healthy term newborns. Affordable population is healthy term newborns        in Jakarta. Study samples are healthy term newborns in Jakarta born in Primary Health Care        in Kemayoran District, Central Jakarta whose parents consent to take part in this study.|August 2015|August 24, 2015|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02401178||24509|
NCT02405156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305172|Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion|A Prospective Double-Blind, Randomized, Placebo-Controlled Trial on the Use of Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion||Ain Shams University|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 22, 2015|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405156||24205|
NCT02507479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0874-AN-CTIL|Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies|Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL||Sheba Medical Center|No|Recruiting|September 2015|July 2019|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02507479||16348|
NCT02507492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-493-011|RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients|RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients||Charite University, Berlin, Germany|No|Recruiting|January 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02507492||16347|
NCT02398734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ20150305|SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy|Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy by the Ultrasound Activation of Endogenous Fibrinolytic System Using Sonolysis (Transcranial Doppler Monitoring)|SONOBIRDIE|University Hospital Ostrava|Yes|Recruiting|October 2015|January 2023|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1408|||Both|40 Years|85 Years|No|||December 2015|December 22, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02398734||24697|
NCT02398747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2270C00008|Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies||AstraZeneca|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|80 Years|No|||March 2016|March 1, 2016|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02398747||24696|
NCT02409784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-214|PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis|PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis||Université de Sherbrooke|No|Completed|March 2014|January 2015|Actual|January 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 1, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02409784||23851|
NCT02428829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID-1|Does Rapid Mobilisation Improve Length of Stay and Outcomes Post THR|Does Rapid Mobilisation as Part of an Enhanced Recovery Pathway Improve Length of Stay, Return to Function and Patient Satisfaction Post Primary Total Hip Arthroplasty?|RAPID|The Royal Bournemouth Hospital|No|Recruiting|April 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428829||22387|
NCT02493946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-214|Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines|Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication||Ipsen|No|Active, not recruiting|April 2015|March 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|605|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02493946||17388|
NCT02493959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STKBM-PI14|Degradation of the Anorexic Hormone Peptide YY|Degradation of the Anorexic Hormone Peptide YY||Hvidovre University Hospital|Yes|Completed|May 2014|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493959||17387|
NCT02442830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H00006661|Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding|A Comparison of Early Deployment of a Video Capsule (Endocapsule EC-10: Olympus Tokyo. Japan) in the Emergency Department Versus Standard of Care Workup of Non-hematemesis Gastrointestinal Bleeding|EDCAP|University of Massachusetts, Worcester|No|Enrolling by invitation|April 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442830||21313|
NCT02429570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-068|Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary|Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02429570||22330|
NCT02489435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/HIV/2010|Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers||Viriom|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489435||17734|
NCT02493127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000879|The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness|The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness||Massachusetts General Hospital|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02493127||17451|
NCT02439151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-KE-143|Applied Research of New Lung Ventilation Strategies Guided by Transpulmonary Pressure in Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome|||Beijing Chao Yang Hospital|Yes|Not yet recruiting|May 2015|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 6, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02439151||21595|
NCT02441660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150322H|Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain|Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain|Capsaicin|The University of Texas Health Science Center at San Antonio||Not yet recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441660||21403|
NCT02429778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32239|Relaxation Treatment for Anxiety in Adults Aged 60 or Older|Reducing Late-Life Anxiety and Improving Functioning With Self-Directed Relaxation|BREATHE|Stanford University|No|Recruiting|May 2015|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|No|||July 2015|July 9, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02429778||22314|
NCT02440841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-010|Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon|Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin||Vantia Ltd|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440841||21466|
NCT02480686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_Neutrino Therapy|Neutrino Regimen for Treatment-experienced HCV GT1 Patients|Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients||Humanity & Healthy GI and Liver Centre|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|June 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480686||18405|
NCT02427386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUSP|Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis|Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis||University of Sao Paulo General Hospital|Yes|Active, not recruiting|May 2014|August 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|No|||May 2015|May 2, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02427386||22498|
NCT02429258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690L00026|Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin|Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin||AstraZeneca|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|226|||Both|18 Years|75 Years|No|||December 2015|December 22, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429258||22354|
NCT02429271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00137|A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study||MIRTOS|Hellenic Cardiovascular Research Society|No|Not yet recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|358|||Both|18 Years|75 Years|No|||August 2015|August 7, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02429271||22353|
NCT02433236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-051|Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy|A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050||Rigel Pharmaceuticals|No|Withdrawn|September 2015|||September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|72 Years|No|||October 2015|October 21, 2015|April 29, 2015|Yes|Yes|Study withdrawn prior to enrollment of first subject|No||https://clinicaltrials.gov/show/NCT02433236||22050|
NCT02433249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 KL2 TR 113-3|Developing a Intervention to Enhance Motivation for Physical Activities Known to Reduce Fall Risk|Enhancing Motivation for Physical Activity to Reduce the Risk of Falls Among Community-Dwelling Older Adults: A Wellness Intervention.|ReadySteady|University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2014|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|103|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 14, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02433249||22049|
NCT02485860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD018-15|Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst|Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst|Pilomiel|Centre Hospitalier Departemental Vendee|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485860||18007|
NCT02437708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56810 (ML10723) B322201421941|Regenerative Endodontic Procedure of Immature Permanent Teeth With L-PRF: a Pilot Controlled, Clinical Trial|Regenerative Endodontic Procedure of Immature Permanent Teeth With the Use of Autologous L-PRF: a Pilot Controlled, Clinical Trial||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2014|September 2020|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Years|25 Years|No|||May 2015|November 16, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02437708||21706|
NCT02441582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-1178/2014|The Effect of 12 Lead ECG Telemetry on Reperfusion Time in Resource-limited Settings|||Karolinska Institutet|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02441582||21409|
NCT02441595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K63103043a|Mindfulness Based Childbirth and Parenting Education - RCT of Effects on Parent and Child Health|Mindfulness Based Childbirth and Parenting Education - RCT of Effects on Parent and Child Health|MBCP|Karolinska Institutet|No|Enrolling by invitation|January 2015|September 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|170|||Female|18 Years|N/A|No|||May 2015|May 7, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02441595||21408|
NCT02483052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013|RejuvenAir Lobectomy for Safety and Histology|A Prospective Study of RejuvenAir System Radial Spray Cryotherapy to Determine Safety and Delayed Histological Effect in the Lung|LobectomyCAN|CSA Medical, Inc.|Yes|Completed|August 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|21 Years|75 Years|No|||February 2016|February 1, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483052||18223|
NCT02493387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goteborg Flimmer|Supervised Exercise Compared to PAP in Patients With Permanent Atrial Fibrillation|Should Elderly Patients With Atrial Fibrillation be Offered Physiotherapist Group Exercise or Can Physical Activity on Prescription (PAP) be Used as an Alternative||Göteborg University|No|Recruiting|January 2013|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|65 Years|85 Years|No|||January 2016|January 11, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493387||17431|
NCT02493400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goteborg follow up flimmer|Physiotherapist Led Group-exercise Compared Physical Activity on Prescription, a 3 Months Follow-up|Physiotherapist Led Group-exercise Compared Physical Activity on Prescription in Older Patients With Atrial Fibrillation, a 3 Months Follow-up||Göteborg University|No|Recruiting|August 2014|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|90|||Both|65 Years|85 Years|No|Non-Probability Sample|Patients who have completed the primary study will be offered a follow-up after 3 months|January 2016|January 11, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493400||17430|
NCT02428192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02403|Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma|A Phase 2 Study of Nivolumab in Advanced Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)||Recruiting|April 2015|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Female|18 Years|N/A|No|||November 2015|January 11, 2016|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428192||22436|
NCT02428452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-192|Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: Trial of a Parent-Mediated Intervention|Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: RCT of a Parent-Mediated Intervention||Holland Bloorview Kids Rehabilitation Hospital|No|Completed|May 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|12 Months|30 Months|No|||April 2015|April 27, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428452||22416|
NCT02430896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013-0373-0014|Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD|Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD)||Asan Medical Center|No|Recruiting|February 2015|February 2020|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|whole blood sample for GWAS (Genome-Wide Association Study)|Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Total 600 children and adolescents will be enrolled in this study. 500 patients in        psychiatric outpatient will be enrolled. 100 persons of healthy volunteers will be        recruited via advertisements.|November 2015|November 26, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02430896||22230|
NCT02490657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0283|Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation|||Yonsei University|No|Recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|40 Years|80 Years|No|||July 2015|July 27, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02490657||17641|
NCT02490670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16062|A Study of Cephalexin Liquid in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex® Liquido Made in Mexico by Eli Lilly y compañía De méxico, s.a. De cv. Vs. Keflex® Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y compañía de México, s.a. De c.v.) in Fasting Healthy Volunteers||Eli Lilly and Company|No|Completed|July 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02490670||17640|
NCT02481830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-331|Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer|An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)|CheckMate 331|Bristol-Myers Squibb|Yes|Recruiting|August 2015|November 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481830||18317|
NCT02434978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130140|Doppler-guided Endoscopic Treatment in Peptic Ulcer Bleeding|||Odense University Hospital|No|Recruiting|January 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|100 Years|No|||October 2015|October 19, 2015|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02434978||21916|
NCT02433925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeniseMafra|Resveratrol's Effects on Inflammation and Oxidative Stress in Chronic Kidney Disease|Effects of Supplementation With Resveratrol on Inflammation and Oxidative Stress of Non-dialysis Chronic Kidney Disease Patients||Universidade Federal Fluminense|No|Completed|January 2013|December 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|45 Years|80 Years|No|||April 2015|April 29, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433925||21997|
NCT02433938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jm-001|Role of Tibial Nerve Stimulation for Enhanced Postoperative Recovery After Colorectal Surgery|Role of Tibial Nerve Stimulation for Enhanced Postoperative Recovery After Colorectal Surgery|TiRex|University of Florence|No|Active, not recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|100|||Both|N/A|N/A|No|||December 2015|December 3, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02433938||21996|
NCT02441738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.52951.068.16|Hybrid Versus Catheter Ablation in Persistent AF|Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation Versus Repeated Transvenous Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|HARTCAP-AF|Maastricht University Medical Center|Yes|Not yet recruiting|May 2016|May 2020|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02441738||21397|
NCT02441816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002381-73|VITAL - Individualising Therapy for Neovascular AMD With Aflibercept|VITAL - Individualising Therapy for Neovascular AMD With Aflibercept|VITAL|Moorfields Eye Hospital NHS Foundation Trust|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|N/A|No|||April 2015|May 7, 2015|October 20, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441816||21391|
NCT02483559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0389|Seeing the World Through Assorted Glasses|Seeing the World Through Assorted Glasses (SWAG)|SWAG|University of North Carolina, Chapel Hill|No|Active, not recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02483559||18184|
NCT02438800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0665|Video Counseling for Effective Postpartum Contraception|Video Counseling for Effective Postpartum Contraception: a Randomized Clinical Trial||University of North Carolina, Chapel Hill|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|84|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438800||21622|
NCT02429804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0063|NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer|Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study||Stanford University|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|15|||Male|19 Years|N/A|No|||May 2015|May 1, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02429804||22312|
NCT02429817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aerospect-02|Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|April 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|March 23, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02429817||22311|
NCT02435004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSI-TD-002|Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy:|Clinical Study Protocol Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy|NSI-TD-002|Ospedale Regionale di Lugano|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02435004||21914|
NCT02439372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Report Number 2015-0129|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis (ACE-UC)|ACE-UC|Asan Medical Center|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Moderate to severe ulcerative colitis (Eligible patients had active UC with a Mayo score        of 6-12 points)|May 2015|May 7, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02439372||21579|
NCT02439476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM-2015-03|Non-interventional Study on Salvage Auto in Relapsed Myeloma|Non-interventional Study Evaluating Plerixafor-based Mobilization for Salvage Autologous Hematopoietic Stem Cell Transplantation in Relapsed Myeloma|IFM-2015-03|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|No|Not yet recruiting|November 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Relapsed multiple myeloma patients will be recruited in sites from the French        collaborative IFM group in France|July 2015|July 22, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02439476||21571|
NCT02430103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUPHBC-001|Study of Preservation of Ovarian Reserve Function During Chemotherapy for Breast Cancer Patients at Reproductive Age|A PhaseⅡ, Prospective, Non-randomized, Open-label ,Single-center Study of Effect of Gonadotropin-releasing Hormone Agonist (Goserelin) on the Preservation of Ovarian Reserve Function During (Neo)Adjuvant Chemotherapy for Breast Cancer Patients at Reproductive Age|PORF|Peking University People's Hospital|No|Not yet recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Female|18 Years|45 Years|No|Non-Probability Sample|240 premenopausal breast cancer patients of age 45 years or younger treated in Peking        University People's Hospital Breast Center|April 2015|April 25, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02430103||22289|
NCT02430116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wangyanbin123|Mitochondrial Apoptotic Pathway Induced by Myocardial Ischemia-Reperfusion Injury in Human|Mitochondrial Apoptotic Pathway Induced by Myocardial Ischemia-Reperfusion Injury in Human||Shenzhen Sun Yat-sen Cardiovascular Hospital||Recruiting|June 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|40|||Both|21 Years|59 Years|No|||April 2015|April 29, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02430116||22288|
NCT02492386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501059DIPB|Bioabsorbable Everolimus-Eluting Stents for Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction|Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)||National Taiwan University Hospital|Yes|Not yet recruiting|July 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|20 Years|N/A|No|||July 2015|July 5, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02492386||17508|
NCT02427880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7308|Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema|Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Hydrochlorothiazide and Furosemide Followed by Furosemide for the Treatment of Adults With Refractory Nephrotic Edema: A Randomized, Double-Blind Trial||Shiraz University of Medical Sciences|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427880||22460|
NCT02443090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-F15-202|Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men|An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men||NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)|No|Active, not recruiting|May 2015|April 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Male|18 Years|64 Years|No|||November 2015|November 11, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443090||21293|
NCT02443103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0506|Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis|Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis||Indiana University|Yes|Recruiting|May 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443103||21292|
NCT02492399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-435|Comparisonof Extended Myoectomy and Myoectomy by Morrow in Patients With Hypertrophic Obstructive Cardiomyopathy (HOCM)|Compare the Results for the Extended Myoectomy and Standard Morrow's Myoectomy in Patients With Ventricular Obstruction of the Left Ventricular Output||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 19, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492399||17507|
NCT02439541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-IVY-SC-001|Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Ischemic Cardiomyopathy|UCMSC-Heart|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02439541||21566|
NCT02441335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821376|CellulaR Injury and Preterm Birth|CellulaR Injury and Preterm Birth|CRIB|University of Pennsylvania|No|Recruiting|January 2015|||January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1120|Samples With DNA|1. Collect blood, urine and cervicovaginal cells from women with preterm labor and term      labor in order to investigate:        1. What is the role of bioenergetics in pregnancy and what are the pertubations in cell           metabolism that lead to spontaneous preterm birth        2. What are the interactions between the microbiome (oral, gut, cervicovaginal, and           placental) and host metabolic function in pregnancy        3. How do interactions between cell metabolism and the microbiome influence cervical           remodeling and placental function leading to spontaneous preterm delivery        4. What genetic and environmental factors influence the metabolic function of reproductive           tissues leading to spontaneous preterm delivery|Female|18 Years|45 Years|No|Non-Probability Sample|At HUP, there are approximately 4,200 deliveries a year, of which approximately 10 percent        (420) deliver preterm. Among these preterm births, two-thirds (280) are spontaneous, which        is the focus of our research. Many women who ultimately have a preterm birth, first        present with preterm labor. Women who have advanced dilatation, preterm rupture of        membranes, etc are at high risk for having a preterm birth. The investigators anticipate,        based on the number of spontaneous preterm births at HUP per year, enrolling about 40-50%        of those eligible and understanding that about 40% of those enrolled will have a preterm        birth, we should be able to enroll about 112 women per year over 5 years. The coordinators        will enroll cases who are admitted to the hospital with PTL, PPROM, or cervical        insufficiency at 20-0/7 to 36-6/7 weeks.|December 2015|December 22, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441335||21428|
NCT02440880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qasr Elainy|Dexamethasone With TAP Block Increasing the Duration of the Peripheral Nerve Block in Caesarian Section|Dexamethasone With TAP Block Increasing the Duration of the Peripheral Nerve Block in Caesarian Section||Cairo University|Yes|Not yet recruiting|May 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02440880||21463|
NCT02485847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS Registry|IRIS Registry: Intelligent Research in Sight Registry|IRIS Registry: Intelligent Research in Sight Registry|IRISRegistry|American Academy of Ophthalmology|Yes|Recruiting|March 2014|January 2100|Anticipated|January 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000000|||Both|6 Months|N/A|No|Non-Probability Sample|To ensure the IRIS Registry infrastructure is properly developed with features and        functionalities that meets the needs of ophthalmologists, the IRIS Registry is currently        only open to Academy members practicing in the United States and its territories.|January 2016|January 4, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02485847|1 Year|18008|
NCT02442557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-001|Safety and Dose-finding Study of DC-TAB in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers||Delta Crystallon BV|No|Completed|December 2009|July 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02442557||21334|
NCT02429583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI-0844|Effects of Persistent Innate Immune Activation on Vaccine Efficacy|Effects of Persistent Innate Immune Activation on Vaccine Efficacy||Rockefeller University|No|Recruiting|April 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429583||22329|
NCT02485535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1426|Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant|Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation||University of Chicago|Yes|Recruiting|September 2015|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||January 2016|January 5, 2016|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485535||18032|
NCT02439060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-14-2|Biologic Mesh in Preventing Hernia in Patients With Bladder Cancer Undergoing Radical Cystectomy With Ileal Conduit Diversion|Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: Randomized Clinical Trial||University of Southern California|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|N/A|N/A|No|||September 2015|September 1, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439060||21602|
NCT02428218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS309|Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis||Biogen|Yes|Not yet recruiting|May 2016|January 2027|Anticipated|January 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|172|||Both|10 Years|17 Years|No|||September 2015|September 17, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428218||22434|
NCT02442310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA46-0114|Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers|Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose||ApoPharma|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2015|July 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02442310||21353|
NCT02440542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-025|Popliteal Nerve Block for Postoperative Pain Control in Ankle and Hindfoot Reconstruction|Popliteal Nerve Block for Postoperative Pain Control in Patients Undergoing Ankle and Hindfoot Reconstruction About the Talus||University of Tennessee|No|Enrolling by invitation|May 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be patients undergoing ankle or hindfoot reconstruction about        the talus (ankle arthrodesis, subtalar arthrodesis, or ankle arthroplasty) who will be        receiving a sciatic nerve block in the popliteal region while in the PACU, following        surgery. Patients will be identified as potential subjects from within the practices of        two fellowship-trained foot and ankle orthopaedic surgeons. Patients will be enrolled in        the study by Informed Consent|May 2015|May 6, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02440542||21489|
NCT02485834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A021302|FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer|Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study||Alliance for Clinical Trials in Oncology|Yes|Recruiting|August 2015|||June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|162|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485834||18009|
NCT02486094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4324|Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging|Study Of PRoliferation and Apoptosis in Rectal caNcer as Predictive and Prognostic biOmarkers: a Histopathology and Imaging Analysis|SOPRANO|Royal Marsden NHS Foundation Trust|No|Recruiting|June 2015|June 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|45|Samples With DNA|Pre-treatment biopsy and post surgical tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with rectal cancer, diagnosed between 2011 and 2013, who have had an mrTRG score        in a post-radiotherapy MRI scan.|June 2015|June 26, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02486094||17990|
NCT02431598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059192|Eovist vs. Dotarem Healthy Volunteer MRI|Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact||Duke University|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431598||22176|
NCT02431611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001144-02|Biomarker Feedback to Motivate Cessation in Pregnancy|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) - Phase 3 Pilot Clinical Trial|MAW Phase 3|Mayo Clinic|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02431611||22175|
NCT02431624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1508|An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion|A Two Period, Randomised, Open-label, Crossover Study to Assess the Adhesion of Buprenorphine Transdermal Delivery System 40 µg/h Patch and 20 µg/h Patch, in Healthy Volunteers||Mundipharma Research Limited|No|Completed|March 2015|November 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02431624||22174|
NCT02508350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015Dapto|The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock|The Pharmacokinetics and Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock||Zhongda Hospital|No|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|75 Years|No|||July 2015|July 22, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02508350||16282|
NCT02508363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-163|Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers|Taxi HAILL: A Three-Arm Cluster Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|July 2015|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|900|||Male|21 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02508363||16281|
NCT02495506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/692|Transfusion of Cold-stored Platelet Concentrates|Transfusion Therapy in Patients Undergoing Cardiac Surgery in Combination With Late Withdrawal of Drug Induced Platelet Inhibition or Prolonged Extra-corporal Circulation Time|4CPLT|Haukeland University Hospital|No|Recruiting|March 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02495506||17268|
NCT02404181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46622.041.13|Validation of a Delirium Monitor|Validation of a Delirium Monitor in Postoperative Elderly Patients||UMC Utrecht|Yes|Recruiting|March 2014|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|154|||Both|60 Years|N/A|No|Probability Sample|The source population will consist of frail, elderly patients (≥60 years) who will undergo        elective surgery in the University Medical Center Utrecht, Isala Clinics Zwolle, Radboud        University Medical Center Nijmegen, or Charité Universitätsmedizin Berlin, and who will be        expected to remain admitted for at least two postoperative days. These patients will be        informed on this study before admission to the hospital.|March 2015|March 30, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02404181|4 Days|24280|
NCT02408250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0226|Tolerance of Early Exercise in Intensive Care Unit|Tolerance of Early Exercise in Intensive Care Unit||University Hospital, Clermont-Ferrand||Not yet recruiting|April 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|critical care unit patients|March 2015|April 2, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02408250||23969|
NCT02497235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-935_1003|A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935|An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.||Takeda|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497235||17135|
NCT02497508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N14MPN|Nivolumab in Patients With Recurrent Malignant Mesothelioma|A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study|NivoMes|The Netherlands Cancer Institute|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02497508||17115|
NCT02495740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2012/164|E-Bike Versus Classic Bike Intervention Trial|E-Bike Study - Endurance Capacity Following 1 Month Training of Classic Bike Versus Electric-assisted Bike|E-bike|University of Basel|No|Completed|May 2012|April 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02495740||17250|
NCT02402192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411-MAD-079-CB|Type of Gonadotropin and Embryo Kinetics of Development|A Prospective Randomized Trial to Analyze the Effect of the Gonadotropin Administered During Control Ovarian Stimulation on Embryo Kinetics of Development|PEM-ESD|IVI Madrid|No|Not yet recruiting|April 2015|April 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|201|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02402192||24431|
NCT02403700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079/09|Dimensional Soft and Hard Tissue Alterations Following Single Tooth Extraction in the Anterior Maxilla - A Prospective Clinical Study|Ridge Alterations Following Single Tooth Extraction in the Anterior Maxilla - A Prospective Clinical Study|Alterations|University of Bern|No|Completed|October 2009|November 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The group is selected from the referred patient pool. Age 18 or older. Absence of        significant medical conditions. Sites with a need for single tooth extraction in the        anterior maxilla.|March 2015|March 25, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403700||24317|
NCT02398851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 5429|TacTIC- Trans-disciplinary Chronic Disease Continuity of Care Model|TacTIC- Trans-disciplinary Chronic Disease Continuity of Care Model|TacTIC|Hackensack University Medical Center|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2957|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02398851||24688|
NCT02497521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|The German ADPKD Tolvaptan Treatment Registry|The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.|AD(H)PKD|University of Cologne|No|Recruiting|November 2015|December 2027|Anticipated|November 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with diagnosis of ADPKD and therapy with tolvaptan|January 2016|January 15, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02497521|10 Years|17114|
NCT02501564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAPCOD2013|Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis|Randomized, Double-blind and Placebo-controlled Evaluation of Efficacy and Safety of Naproxen Sodium and Codeine Phosphate Combination in Osteoarthritis||Istanbul Medeniyet University|No|Completed|May 2013|November 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|40 Years|65 Years|No|||February 2016|February 24, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501564||16803|
NCT02406833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTH-01-111|Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy|A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy||Isarna Therapeutics GmbH|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||February 2016|February 10, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02406833||24078|
NCT02496637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506S74643|A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen|A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen: A Randomized Clinical Trial||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Female|18 Years|20 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02496637||17181|
NCT02494674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036795|Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using the Bite Counter|Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using a Wearable Bite Counter to Assist With Dietary Self-monitoring|Bites|University of South Carolina|No|Completed|July 2015|November 2015|Actual|August 2015|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02494674||17332|
NCT02403219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI-2013-/06/06|Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye|Paralysis of the Orbicularis Muscle of the Eye by Using Botulinum Toxin Type A in the Treatment for Dry Eye||Instituto de Oftalmología Fundación Conde de Valenciana|Yes|Completed|May 2013|January 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02403219||24354|
NCT02403232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study|Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study|ASPEFIC1|Papa Giovanni XXIII Hospital||Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02403232||24353|
NCT02397447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHDM2|Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion|Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment||University of Guadalajara|No|Completed|March 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|35 Years|60 Years|No|||January 2016|January 8, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02397447||24796|
NCT02433262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-2015-067|WHO Versus IADPSG Diagnostic Criteria of Gestational Diabetes Mellitus and Their Associated Maternal and Neonatal Outcomes|World Health Organisation (WHO) Versus International Association of Diabetes and Pregnancy Study Group (IADPSG) Diagnostic Criteria of Gestational Diabetes Mellitus and Their Associated Maternal and Neonatal Outcomes||Universiti Kebangsaan Malaysia Medical Centre|No|Not yet recruiting|April 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|506|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02433262||22048|
NCT02433275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/2014|CHildhood ASthma and Environment Research Study - CHASER Study|CHildhood ASthma and Environment Research Study - CHASER Study||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Recruiting|April 2015|December 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|5 Years|16 Years|No|Non-Probability Sample|Asthmatic children of both sex aged 5-16 years|December 2015|December 18, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433275||22047|
NCT02480426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-overlay|3D CT Guidance for Transjugular Intrahepatic Portosystemic Shunt Creation|Guidance for TIPS Creation: CT-image Versus CO2 Portography||West China Hospital|No|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480426||18425|
NCT02480439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-648-1003|A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants|A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of a TAK-648 Tablet Compared With a TAK-648 Oral Solution, and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants||Takeda|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480439||18424|
NCT02432911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHBDH-IIT2015003|Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old|A Multicenter，Open-label，Randomized Study on the Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old||Chinese Academy of Medical Sciences|Yes|Not yet recruiting|April 2015|May 2021|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|65 Years|75 Years|No|||April 2015|May 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432911||22075|
NCT02432924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-14/15-10|Using Combined Instantaneous and Multidimensional Feedback to Support a Change in Physical Activity Behaviour|The Effect of Using Combined Personalised Instantaneous and Multidimensional Physical Activity Feedback on Motivation and Behaviour||University of Bath|No|Completed|October 2014|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|57|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02432924||22074|
NCT02433730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22102014|Testosterone Therapy in Hypogonadal Men Treated With Opioids|The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease||Odense University Hospital|Yes|Not yet recruiting|May 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|59 Years|No|||April 2015|April 29, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433730||22012|
NCT02491632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0436|Exercise + Dexamethasone for Cancer-Related Fatigue|Effects of Physical Activity Plus Short Course of Dexamethasone for Cancer-Related Fatigue in Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|August 2015|||August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491632||17566|
NCT02493972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00615-44|Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis||CARPEMAN|Centre Francois Baclesse|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|18 Years|N/A|No|||June 2015|July 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02493972||17386|
NCT02493998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250-901|A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|A Prospective, Observational Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)||BioMarin Pharmaceutical|No|Recruiting|November 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|1 Year|10 Years|No|Non-Probability Sample|Study Population: Subjects diagnosed with MPS IIIB        Males and females 1 through 10 years of age (ie, until they turn 11) with a documented        diagnosis of MPS IIIB are eligible to participate in this observational study. Up to        approximately 5 subjects 6 to 10 years old, inclusive, will be enrolled; the remaining        subjects will be 1 to 5 years old, inclusive. Additional entry criteria follow.|January 2016|January 14, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02493998||17384|
NCT02427399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cervical Cancer Screening|Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Women|Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Women at an Urban Community Health Center||Fenway Community Health|No|Active, not recruiting|January 2013|January 2017|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|5||Actual|5279|||Female|21 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02427399||22497|
NCT02430077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062014-033|Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients|Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|January 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430077||22291|
NCT02434003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3896|Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis|Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis||St. Justine's Hospital|Yes|Recruiting|May 2014|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|10 Years|15 Years|No|Non-Probability Sample|A total of 1200 patients will be recruited from the scoliosis clinic at eight (8) tertiary        care facilities located around the world. All consecutive patients seen at these clinics        will be screened for the presence of scoliosis first by clinical examination and followed        by radiographic confirmation using the EOS™ system.|May 2015|May 4, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02434003||21991|
NCT02429362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03383-XP|Obstetrical Repository of Biological Materials|Obstetrical Repository of Biological Materials||University of Tennessee|No|Recruiting|May 2015|April 2020|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Sample collections for purposes of: understanding of normal events in pregnancy; disease      conditions of the woman/baby during pregnancy; and future use in studies to develop cell      lines for research, create tests to diagnose disease, or develop treatments.|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All English speaking female patients who are seen in the Regional One Health perinatal        clinics and/or deliver at Regional One Health will be asked to participate in the study.|December 2015|January 25, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02429362|1 Day|22346|
NCT02485561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO201501019|Evaluating Strategies to Present Colon Cancer Screening Information|Comparing Screener vs. Survivor Role Models to Improve Colon Cancer Screening||Washington University School of Medicine|No|Recruiting|June 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|400|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02485561||18030|
NCT02431663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2013-004396-12|Ketamine in Refractory Convulsive Status Epilepticus|Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study.|KETASER01|Meyer Children's Hospital|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|1 Month|18 Years|No|||April 2015|May 4, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02431663||22171|
NCT02431676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14148|Survivorship Promotion In Reducing IGF-1 Trial|Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors|SPIRIT|Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02431676||22170|
NCT02433717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501049MINC|A Pharmacokinetic Study of Paliperidone ER|A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER||National Taiwan University Hospital|Yes|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|65 Years|No|||November 2015|November 19, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02433717||22013|
NCT02438189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHM2|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing|PHM2|In Home Closed Loop Study Group|Yes|Active, not recruiting|June 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|15 Years|45 Years|No|||December 2015|December 14, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438189||21669|
NCT02438202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECTAD|Electroconvulsive Therapy for Treatment of Alzheimer´s Disease|Electroconvulsive Therapy for Treatment of Alzheimer´s Disease|ECTAD|Central Institute of Mental Health, Mannheim|No|Not yet recruiting|January 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|65 Years|N/A|No|||May 2015|May 11, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02438202||21668|
NCT02494050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200085|Telemedicine for Women With Anhedonia in Bipolar and Unipolar Disorder|Telemedicine for Women With Anhedonia in Bipolar and Unipolar Disorder: Patient Preferences and Outcomes||Northwestern University|Yes|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|21|||Female|21 Years|65 Years|No|||July 2015|July 9, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02494050||17380|
NCT02443012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-13-1296-13714|Topical Nepafenac as Supplement for Diabetic Macular Edema|Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema||University of Science Malaysia|No|Completed|March 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|70 Years|No|||May 2015|May 8, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02443012||21299|
NCT02443077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00668|Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype||National Cancer Institute (NCI)||Not yet recruiting|September 2015|||July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|302|||Both|18 Years|N/A|No|||May 2015|December 14, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443077||21294|
NCT02427763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|luiza2014|Microbiological and Epithelial Evaluation Related to the Use of Orthodontic Thermoplastic Device|Epithelial Changes and Streptococci Mutans and Lactobacilli Quantify Related With the Use of Thermoplastic Aligner||Universidade Positivo|Yes|Completed|October 2014|March 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|105|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02427763||22469|
NCT02488798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62014|Office Hysteroscopy and 3D Power Doppler Vaginal Ultrasound in Assessment of Postmenopausal Bleeding|The Role of Office Hysteroscopy and Endometrial Power Doppler Using the International Endometrial Tumor Analysis Group Classification in the Evaluation of Postmenopausal Bleeding||Cairo University|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Sample from the uterine endometrium for histopathological analysis|Female|47 Years|64 Years|No|Non-Probability Sample|Women with postmenopausal bleeding|June 2015|June 30, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488798||17782|
NCT02488824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAN-15-013|Effect of Heat Exposure on Cognition in Persons With Tetraplegia|Effect of Heat Exposure on Cognition in Persons With Tetraplegia||James J. Peters Veterans Affairs Medical Center|No|Recruiting|April 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02488824||17781|
NCT02494063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEEGOG CX-01|Sentinel Lymph Node Biopsy Versus Systematic Pelvic Lymphadenectomy in Patients With Early Stages Cervical Cancer|A Phase III Randomized Clinical Trial Comparing Sentinel Lymph Node Biopsy Versus Systematic Pelvic Lymphadenectomy in Patients With Early Stages Cervical Cancer (SENTIX - Sentinel in Cervix Cancer)|SENTIX|Charles University, Czech Republic|No|Not yet recruiting|October 2015|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Female|18 Years|75 Years|No|||July 2015|July 11, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02494063||17379|
NCT02433665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059984|Customized Contrast Media Dose Clinical Trial|Clinical Trial of a Novel Evidence-Based Formula for Customizing the Contrast Media Dose and Rate Administered During Multidetector-Row CT (MDCT) Scanning of the Abdomen and Pelvis||Duke University|No|Enrolling by invitation|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433665||22017|
NCT02435095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-082|Antipsychotic Induced Structural and Functional Brain Changes|Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies|APIC|RWTH Aachen University|Yes|Recruiting|May 2015|April 2019|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|666|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02435095||21907|
NCT02479100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIOL/2015/CONTEND|Contrast Enhanced Spectral Mammography (CESM) Study|An Assessment of the Impact of CONTrast ENhanceD Mammography (CESM) on Patient Management and Comparison With MRI (CONTEND Study)|CONTEND|Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|85 Years|No|||December 2015|December 31, 2015|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479100||18527|
NCT02483299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRA COMBI|Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome|||University Medical Centre Ljubljana|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|55 Years|No|||June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483299||18204|
NCT02434991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009073|Sensorimotor Dysfunction in Achalasia|Sensorimotor Dysfunction in Achalasia||Mayo Clinic|No|Not yet recruiting|January 2016|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02434991||21915|
NCT02438072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-14051|Drug Metabolism and Antidepressant|Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study|METADEP|University Hospital, Geneva|No|Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|70 Years|No|||May 2015|May 5, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02438072||21678|
NCT02438085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073132|Prospective Registry of Acute Coronary Syndromes in Ferrara|Acute coRonary sYndrOmes proSpective regisTry Of Ferrara|ARYOSTO|University Hospital of Ferrara|Yes|Recruiting|June 2014|June 2020|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples Without DNA|whole blood, plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to hospital with diagnosis of acute coronary syndromes according current        European guidelines|January 2016|February 2, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02438085|5 Years|21677|
NCT02428257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2015008AR|Continuous Spinal Anesthesia With Hypobaric Bupivacaine to Preserve Hemodynamics in Elderly|Hypobaric Rather Than Isobaric Bupivacaine to Prevent Anesthesia-induced Hypotension in Patients Undergoing Surgical Repair of Hip Fracture Under Continuous Spinal Anesthesia: a Prospective Randomized Controlled Study.||Institut Kassab d'Orthopédie||Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|65 Years|N/A|No|||April 2015|April 27, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428257||22431|
NCT02428270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOBILITY-002|A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer||University Health Network, Toronto|Yes|Not yet recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428270||22430|
NCT02489448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014537|Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer|Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer||Yale University|Yes|Recruiting|November 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489448||17733|
NCT02429674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7089|The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances|The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances||New York State Psychiatric Institute|No|Recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|17 Years|No|||December 2015|December 3, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02429674||22322|
NCT02429973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-444 OSTEOSARC|Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma|Multicenter and Prospective Phase II Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma|GEIS-29|Broto, Javier Martín, M.D.|No|Completed|July 2012|April 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|80 Years|No|||April 2015|April 28, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429973||22299|
NCT02443558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90886|Brainwave Control of a Wearable Robotic Arm for Rehabilitation and Neurophysiological Study in Cervical Spine Injury|Brainwave Control of a Wearable Robotic Arm for Rehabilitation and Neurophysiological Study in Cervical Spine Injury|CSI:Brainwave|Aristotle University Of Thessaloniki|No|Not yet recruiting|July 2016|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|30|||Both|14 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02443558||21258|
NCT02434029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUL-1/EEA|Budesonide Effervescent Tablet vs. Placebo in Active Eosinophilic Esophagitis|Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis|EOS-1|Dr. Falk Pharma GmbH|Yes|Recruiting|November 2015|January 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434029||21989|
NCT02491008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/11_3|Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction|Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment|TRUST BONE|University Hospital Inselspital, Berne|Yes|Recruiting|January 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|145|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491008||17614|
NCT02491073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP093-451|Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)|Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate||Sunovion|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and Females greater than or equal to 18 years of age, either exposed to drug or not        exposed to drug|February 2016|February 26, 2016|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491073||17609|
NCT02438020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-AN|Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity|Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity||Universidad Autonoma de San Luis Potosí|No|Not yet recruiting|June 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|17 Years|No|||May 2015|May 5, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02438020||21682|
NCT02443584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHG-1430-PGxAMG|Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis|Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified With Avera Medical Group Clinics|PGX-AMG|Avera McKennan Hospital & University Health Center|Yes|Recruiting|February 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02443584||21256|
NCT02434367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1412|The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older|Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation||The West Clinic, Memphis|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|65 Years|N/A|No|||January 2016|January 27, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02434367||21963|
NCT02481245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000862|BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study|A Pan-PPAR Agonist Treatment for Bipolar Depression: A Proof of Concept Study||Massachusetts General Hospital|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|65 Years|No|||June 2015|June 23, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481245||18362|
NCT02432079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403871897|Molecular Genetics of Heterotaxy and Related Congenital Heart Defects|Molecular Genetics of Heterotaxy and Related Congenital Heart Defects||Indiana University|No|Recruiting|July 2009|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole Blood, Tissue Sample, Cheek Swabs, Saliva|Both|N/A|N/A|No|Non-Probability Sample|children affected with heterotaxy syndrome and/or congenital heart defects and their        relatives|February 2016|February 23, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432079||22139|
NCT02431923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150122|Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up|Partnership for Research on Ebola Virus (PREVAIL) III: Ebola Natural History Study||National Institutes of Health Clinical Center (CC)||Not yet recruiting|April 2015|May 2025|Anticipated|May 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|7500|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||April 2015|December 3, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02431923||22151|
NCT02435823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-0015|Safety Study of the PulseRider® in Patients Undergoing Treatment for Bifurcation Intracranial Aneurysms|Adjunctive Wide-neck Aneurysm Reconstruction Device Post Market Clinical Study Europe|AWARD|Pulsar Vascular|No|Recruiting|March 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435823||21851|
NCT02440828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP-2014|Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia|Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment|VAPORISE|Erasmus Medical Center|Yes|Recruiting|March 2015|July 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02440828||21467|
NCT02478593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000485|Impact of Patient Education on Benzodiazepine Use in the Elderly|Impact of Patient Education on Benzodiazepine Use in the Elderly||University of Vermont|No|Not yet recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478593||18566|
NCT02478606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.102.297|Passive Static Stretching and Proprioceptive Neuromuscular Facilitation in Musculoskeletal Aspects|Comparison of Four Weeks of Passive Static Stretching and Proprioceptive Neuromuscular Facilitation (PNF) in Musculoskeletal Aspects of the Hamstrings: a Randomized Controlled Trial||Federal University of Rio Grande do Sul||Not yet recruiting|July 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Female|20 Years|30 Years|No|||June 2015|June 23, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478606||18565|
NCT02429206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQIN-01|Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis|Prospective, Double Blind, Randomized Phase II/III Study to Assess the Safety and Efficacy of SQIN™ on Xerosis in Adults Suffering of Mobility Impairment and/or Complete Paralysis Associated With Chronic Spinal Cord Injury.||Nordic Life Science Pipeline Inc.|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||August 2015|August 19, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02429206||22358|
NCT02431156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PseudoPresbADL|Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Mini-monovision Correction|Retrospective Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Mini-monovision Correction With Bilateral Implantation of Aspheric Monofocal Intraocular Lenses||Democritus University of Thrace|Yes|Recruiting|March 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|50 Years|60 Years|No|Non-Probability Sample|Presbyopic patients that underwent mini-monovision correction with bilateral myopic        defocus with monofocal intraocular lenses implantation|April 2015|April 29, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02431156||22210|
NCT02431429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILT 2127-2|Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis||Knight Therapeutics (USA) Inc|No|Not yet recruiting|July 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|55|||Male|18 Years|55 Years|No|Non-Probability Sample|mucocutaneous leishmaniasis patients|April 2015|April 27, 2015|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431429||22189|
NCT02430961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 15-9107|Predictors of Apnea and Prediction of Time to Death in Donation After Cardiac Death|||University Health Network, Toronto|No|Not yet recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|158|||Both|N/A|80 Years|No|Non-Probability Sample|We will include all patients who are deemed eligible for DCD by Trillium Gift of Life        Network (TGLN) and in whom informed consent for DCD is obtained from the substitute        decision maker. All patients will be included in the study if they undergo withdrawal of        life sustaining therapy for the potential of donation (whether they successfully donate or        not). Any patient on mechanical ventilation who is 80 years of age or under is a potential        DCD candidate if there is a plan for elective WLST.|April 2015|April 29, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430961||22225|
NCT02492464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monasc10_15|Effects of 10 mg Monacolins on Vascular Health: a Clinical Trial|Double-blind, Randomized Clinical Trial on the Middle-term Effect of the Red Yeast Rice Intake on Endothelial Function and Arterial Stiffness in Subjects With Suboptimal LDL-cholesterol Level in the Context of the Mediterranean Diet|Monasc10_15|University of Bologna||Recruiting|May 2015|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||July 2015|July 7, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02492464||17502|
NCT02478892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 26214|Screening for PDAC in BRCA1/2 Patients|Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With BRCA1/2 Mutations||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2015|||May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|patients at high risk for pancreatic cancer, specifically those with BRCA1/2 mutations.|June 2015|June 22, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02478892||18543|
NCT02431117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP29688|Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30|A Multicenter, Longitudinal, Non-drug Study to Assess the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Japanese Individuals With Down Syndrome Aged 6-30||Chugai Pharmaceutical||Active, not recruiting|June 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|6 Years|30 Years|No|Probability Sample|People with Down syndrome|January 2016|January 8, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02431117||22213|
NCT02435303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVsurgery_PAH|Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)|Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease|SUPERIOR|Asan Medical Center||Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|N/A|N/A|No|||December 2015|December 28, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02435303||21891|
NCT02434354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01615|A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma|A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2015|||April 2022|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434354||21964|
NCT02439957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-307|SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)||BCV CMV vGCV|Chimerix|Yes|Active, not recruiting|September 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|520|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439957||21534|
NCT02439970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-303|SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients|SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipient|BCV CMV vGCV|Chimerix|Yes|Active, not recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|750|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439970||21533|
NCT02491359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9228|Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease|Carfilzomib for Treatment of Chronic Graft vs. Host Disease||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2015|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491359||17587|
NCT02428660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genelex 2014-02|Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM|Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients||Genelex Corporation|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|300|||Both|65 Years|N/A|No|||February 2016|March 15, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428660||22400|
NCT02432638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-01966|Pierre Robin Sequence Outcome Assessment Multi Institutional Study|Pierre Robin Sequence Outcome Assessment Multi Institutional Study (PROMIS)|PROMIS|New York University School of Medicine|No|Recruiting|April 2015|April 2034|Anticipated|January 2034|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|6 Months|No|Non-Probability Sample|This study will include all infants under the age of 6 months who undergo mandibular        distraction. We will include all racial and ethnic groups as well as both genders. We will        not include patients over the age of 6 months.|November 2015|November 11, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02432638|19 Years|22096|
NCT02431494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08291420Exp|Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris|Safety and Preliminary Efficacy of Combination Blue Light Phototherapy and Microcurrent Therapy for the Treatment of Acne Vulgaris||Nova Southeastern University|No|Recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|30 Years|No|||April 2015|April 30, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431494||22184|
NCT02491424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01|Intraosseous Transcutaneous Amputation Prosthesis|Direct Skeletal Fixation of Prosthetic Limbs Following Trans- Femoral Amputation - Study of an Intraosseous Transcutaneous Amputation Prosthesis (ITAP)|(ITAP)|Stanmore Implants Ltd.|Yes|Active, not recruiting|January 2007|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||June 2015|July 2, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02491424||17582|
NCT02491437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-625|A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)|A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)|LOTUS II|Abbott|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1066|||Female|19 Years|41 Years|No|||March 2016|March 14, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02491437||17581|
NCT02436330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209418|Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management|Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management||University of Illinois at Chicago|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|84|||Both|8 Years|12 Years|No|||November 2015|November 5, 2015|April 20, 2015||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT02436330||21812|Limitations: incomplete data collection (baseline & follow-up), those lost to follow-up may have been unwilling to continue because of weight gain, low enrollment numbers, and control subjects were offered intervention activities after 6 months.
NCT02496949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1114ICR|A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors|A Phase Ib ,Single Center, Open-labeling, Multiple Oral Dose Study to Assess the Safety, Tolerability，PK and Efficacy Profile for Advanced Solid Tumor Patients in China||Chinese Academy of Medical Sciences|No|Completed|November 2011|August 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02496949||17157|
NCT02497222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.1.1.H4|Pilot Study of RNS60 in Allergen-induced Bronchoconstriction|Pilot Study of RNS60 in Allergen-induced Bronchconstriction||Revalesio Corporation|No|Not yet recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|50 Years|No|||October 2015|October 29, 2015|July 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02497222||17136|
NCT02401906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR_2015-8|MRI and Orbital Tumours (MEDORT)|MRI for the Etiological Diagnosis of Orbital Tumours|MEDORT|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient aged over 18 years, with an orbital mass for which a biopsy or a resection is        planned, coming for an MRI, before any surgical treatment|September 2015|September 8, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02401906||24453|
NCT02402179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048461|Metabolic Availability of Tryptophan From White Maize|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Tryptophan From White Maize Protein, in Young Adult Men||The Hospital for Sick Children|No|Recruiting|March 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|7|||Male|20 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02402179||24432|
NCT02409641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-011214|A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality|A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality||Medical University of Vienna||Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02409641||23862|
NCT02393859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120215|Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL|Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL||Amgen|Yes|Recruiting|November 2015|December 2021|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|N/A|17 Years|No|||March 2016|March 23, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02393859||25072|
NCT02501330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871036|Safety And Efficacy Of Bosutinib|Drug Use Investigation Of Bosutinib For CML (Post Marketing Commitment Plan)|BLF|Pfizer|No|Active, not recruiting|July 2015|September 2023|Anticipated|September 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|659|||Both|18 Years|N/A|No|Probability Sample|The patients who have been treated with Bosutinib|March 2016|March 9, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501330||16821|
NCT02501343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADIS (SVH 14/157)|Alkaline Diet for Insulin Sensitivity|Alkaline Diet for Insulin Sensitivity|ADIS|Garvan Institute of Medical Research|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501343||16820|
NCT02402439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGS|Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol|Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol||University of California, San Francisco|Yes|Recruiting|December 2014|January 2021|Anticipated|January 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402439||24412|
NCT02406300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-14 (165-DEFI/193-CES)|Anesthesia And Post-operative Mortality After Proximal Femur Fractures|Contribution Of Anesthesia Technique For Post-operative Mortality Reduction After Proximal Femur Fractures Surgical Treatment - A Randomized Clinical Trial||Centro Hospitalar do Porto|No|Enrolling by invitation|April 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|60 Years|N/A|No|||April 2015|April 1, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02406300||24118|
NCT02402842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epitopes-HPV02|Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma|Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.|Epitopes-HPV02|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|September 2014|September 2021|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|February 23, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02402842||24383|
NCT02501577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sadfoi|Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation|Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation|supraview|University of Regensburg|No|Recruiting|March 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02501577||16802|
NCT02507375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO20024|A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Phase Ib, Open-label, Multi-center Study of the Combination of Pertuzumab and Erlotinib in Patients With Locally Advanced or Metastatic (Stage IIIb/IV) NSCLC After Failure of at Least One Prior Chemotherapy Regimen.||Hoffmann-La Roche||Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|July 14, 2015|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT02507375||16356|Per Version A the protocol was halted for 2 DLTs (grade 3 manageable rash common for erlotinib) in the first 6 patients. Ethics committee approved redefining DLT and starting anew with Version B. No further DLTs were observed throughout the study.
NCT02398435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSD-2014-001|Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease|Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks||AB2 Bio Ltd.|Yes|Recruiting|February 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02398435||24720|
NCT02398448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-101(QCL116986)|IVIVR Assessing PK Parameters Used to Establish Bioequivalence|In Vitro-In Vivo Relationship Study to Assess the Impact of the In Vitro Dissolution Profile on the Pharmacokinetic Parameters Used to Establish Bioequivalence||Ardea Biosciences, Inc.|No|Completed|April 2015|September 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02398448||24719|
NCT02404649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HarvardMS|A Prospective Clinical Trial Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Staged Sinus Floor Elevation Procedures|A Prospective Clinical Trial Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Staged Sinus Floor Elevation Procedures||Harvard Medical School|Yes|Active, not recruiting|July 2012|October 2016|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404649||24244|
NCT02404662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRA-POR-2014-598|Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression|Single Blind Randomised Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression||St Patrick's Hospital, Ireland|Yes|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|70 Years|No|||April 2015|April 2, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02404662||24243|
NCT02500524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRL01|Cocamide DEA vs Permethrin for Head Lice|A Randomised, Controlled, Assessor-blind, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion and a Permethrin Creme Rinse in the Treatment of Head Lice||Medical Entomology Centre|No|Terminated|July 1998|January 1999|Actual|January 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|4 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 10, 2015||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT02500524||16883|
NCT02498808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20892|Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?|Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?|ILAND|University of Oxford|No|Not yet recruiting|September 2015|June 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|85|Samples With DNA|Blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers will be recruited as staff or patients attending secondary care or        accompanying patients but who do not have vasculitis or any form of inflammatory arthritis        Patients with vasculitis or arthritis who are attending secondary care will be invited to        participate if they fulfill eligibility criteria.|September 2015|September 3, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02498808||17015|
NCT02405806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140917-281|Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms|Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms||Region Skane|No|Enrolling by invitation|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02405806||24155|
NCT02405819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14178|Patient and Provider Initiated Survivorship Care Planning|Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02405819||24154|
NCT02401464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536/CPH-101|A Phase I Bioequivalence Study of TAK-536 Pediatric Formulation|A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Tablet in Healthy Adult Male Subjects||Takeda|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02401464||24487|
NCT02404883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-265|Decisional Conflict of Young Cancer Patients With Regard to Fertility Preservation|Decisional Conflict of Young Cancer Patients With Regard to Fertility Preservation - Effects of an Online Decision-aid Tool|Fertionco|University Hospital, Basel, Switzerland|No|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Female|16 Years|40 Years|No|||October 2015|October 1, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02404883||24226|
NCT02491476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6899 15|Recording "Fast Ripples" Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy|Feasibility and Interest of Recording "Fast Ripples" Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy|Epi-FaR|University Hospital, Toulouse|Yes|Recruiting|March 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|12 Years|65 Years|No|||July 2015|July 7, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491476||17578|
NCT02433600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6035|The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US|The Effect of Feeding Infant Formula With Enriched Protein Fractions||Mead Johnson Nutrition|No|Terminated|August 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|2|||Both|N/A|90 Days|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 27, 2015||No|Study was terminated due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT02433600||22022|
NCT02437214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-030|Music to Decrease Pain and Anxiety During Head CTs Performed at the PEds ED|Randomized Single Blinded Clinical Trial on Effects of Nursery Songs in Infants and Young Children's Anxiety Prior and During Head CT||University of New Mexico|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|1 Month|36 Months|Accepts Healthy Volunteers|||February 2016|February 3, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02437214||21744|
NCT02437331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503067RIND|Experience in Being With Advanced Heart Failure Patients|National Taipei University of Nursing and Health Science||National Taiwan University Hospital|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|the study population is diagnosis of advanced heart failure with NYHA class 3 to 4.|November 2015|November 19, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02437331||21735|
NCT02439814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO42135|Pregnenolone and Marijuana Dependence|Effect of Pregnenolone on Cue-reactivity in Marijuana-dependent Individuals||Medical University of South Carolina|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02439814||21545|
NCT02439827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversidadeFSC|The "Fortaleça Sua Saúde" Program for Active and Healthy Lifestyle Among Brazilian Students|The "Fortaleça Sua Saúde" Program: A Cluster-randomized Controlled Trial to Promote Active and Healthy Lifestyle Among Brazilian Students||Universidade Federal de Santa Catarina|No|Completed|July 2014|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1085|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02439827||21544|
NCT02482285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6731|Assessment of Frailty in Elderly Patients With Advanced Cancers|Assessment of Frailty in Elderly Patients With Advanced Cancers|FAC-C|Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|December 2013|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood samples and baseline, week 12 and weeks 24|Both|70 Years|N/A|No|Non-Probability Sample|Patients with advanced cancers|October 2015|October 5, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02482285||18282|
NCT02486588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822607|Increasing Engagement With a Healthy Food Benefit|Increasing Engagement With the Vitality HealthyFood Benefit: A Randomized Field Trial Proposal||University of Pennsylvania|No|Not yet recruiting|July 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|4668|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02486588||17952|
NCT02480699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10|Intra Individual Evaluation of Uremic Toxin Levels in Hemodialysed Patients|Intra Individual Evaluation of Uremic Toxin Levels in Hemodialysed Patients|EVITUPH|Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480699||18404|
NCT02437344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7057|Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence|Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence||New York State Psychiatric Institute|Yes|Recruiting|January 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|8|||Both|21 Years|60 Years|No|||April 2015|May 4, 2015|April 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02437344||21734|
NCT02442934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AO1696-37|Reducing Discomforts in Critically Ill Patients: the IPREA3 Study|A Multicomponent Intervention to Reduce Perceived Discomforts in Critically Ill Patients: a Randomized Controlled Trial|IPREA3|Centre Hospitalier of Chartres|Yes|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|5411|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02442934||21305|
NCT02434302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NR31|Characteristics and Outcomes of Childhood Moyamoya in the UK|Characteristics and Outcomes of Childhood Moyamoya in the UK||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|N/A|18 Years|No|Non-Probability Sample|Children (0-18y) with moyamoya in the UK over study period (2014-2016 August)|April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434302||21968|
NCT02492828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-323|Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden|Adherence of Apixaban and Warfarin in Patients With Atrial Fibrillation in Real-world Setting in Sweden||Bristol-Myers Squibb|No|Active, not recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|The study will include all patients with filled prescriptions for apixaban or warfarin        between May 29, 2013 and Dec 31, 2014 that are identified with a hospital diagnosis of        non-valvular atrial fibrillation (NVAF)|July 2015|July 6, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02492828||17474|
NCT02493179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ser.01|Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery|Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery||Hayat Pharmaceutical Co. PLC|Yes|Not yet recruiting|June 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493179||17447|
NCT02436369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umsu.rec.1393.3|The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic Patients|The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic||Urmia University of Medical Sciences|No|Completed|September 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|20 Years|65 Years|No|||April 2015|May 3, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02436369||21809|
NCT02438566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654455|Non-inferiority Trial of Oral Tranexamic Acid vs. Intravenous Tranexamic Acid in Joint Replacement Surgery|Non-inferiority Trial of Oral Tranexamic Acid (OTA) vs. Intravenous Tranexamic Acid (IVTA) to Prevent Blood Loss in Joint Replacement Surgery||The New England Baptist Hospital|Yes|Active, not recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|118|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438566||21640|
NCT02440893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX_000018|Metformin and Corus CAD|Understanding the Effect of Metformin on Corus® CAD (MET Study)|MET|CardioDx|No|Completed|September 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|37|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02440893||21462|
NCT02481271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-6061-BO MBM_Galle|Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Cholecystectomy|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Cholcystectomy - a Randomized Controlled Trial|MBM_Galle|Universität Duisburg-Essen|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481271||18360|
NCT02434484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0501-M065-501|Symbenda Post-Marketing Surveillance (PMS)|Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients||Eisai Inc.||Not yet recruiting|June 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda        will be enrolled in the study.|March 2016|March 9, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02434484||21954|
NCT02432170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48992-A|Weight-Bearing Tomosynthesis In Evaluation of Foot/AnkIe|Weight-Bearing Tomosynthesis In Evaluation of Foot/AnkIe||University of Washington|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432170||22132|
NCT02481544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT008033-01A1|The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients|The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients|GRAT2015|University of California, San Diego|No|Enrolling by invitation|April 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|108|||Both|35 Years|N/A|No|||May 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481544||18339|
NCT02437838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0455|Optimizing Drug Doses in Critically Ill|Optimizing Drug Doses to Improve Outcomes of Critically Ill Patients||University of North Carolina, Chapel Hill|No|Recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|40 patients with traumatic brain injury requiring levetiracetam admitted to the University        of North Carolina Intensive Care Unit and University of Kentucky Chandler Medical Center        Intensive Care Unit|December 2015|December 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02437838||21696|
NCT02437851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-092|Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection|A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons||AIDS Malignancy Consortium|No|Recruiting|April 2015|July 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|N/A|N/A|No|||November 2015|March 2, 2016|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437851||21695|
NCT02441673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS/15/01|Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering|Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block||Lagos State Health Service Commission|No|Not yet recruiting|September 2015|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02441673||21402|
NCT02441686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-508|Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma|A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Recruiting|December 2015|August 2022|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441686||21401|
NCT02489227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-1420-02|Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis|PsOsim|Coherus Biosciences, Inc.|Yes|Active, not recruiting|August 2015|March 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|545|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489227||17750|
NCT02437409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T01-072012|Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)|Akute Rekanalisation Eines ischämischen Schlaganfalls Mittels pREset|ARTESp|Phenox GmbH|No|Completed|February 2013|August 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|100 patient harboring an acute ischemic stroke in at least one of the major intracranial        arteries|October 2015|October 7, 2015|April 28, 2015||No||No|September 3, 2015|https://clinicaltrials.gov/show/NCT02437409||21729|
NCT02443259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/ECHR/2014/165|Neurobehavioural Outcomes in Late Preterm Neonates|Short Term Neurobehavioural Outcomes in Late Preterm Neonates Born to Pre Eclamptic Mothers : a Prospective Observational Study|PRENB|Lady Hardinge Medical College|No|Recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|34 Weeks|37 Weeks|No|Probability Sample|SAMPLE SIZE 60 intramural neonates divided in a group of 30 each. STUDY SUBJECTS Thirty        late-preterm infants born to mothers with preeclampsia ---late preterms defined as infants        born between 34 0/7 weeks and 36 6/7 weeks of gestation.        CONTROL SUBJECTS Thirty late preterm infants born to mothers without preeclampsia.|May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443259||21280|
NCT02432989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00307|Establishing Early Exercise Interventions in Concussion Recovery|Rest vs. Early Return to Exercise Following Concussion (H15-00307)||University of British Columbia|No|Not yet recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|15 Years|25 Years|No|||April 2015|April 28, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02432989||22069|
NCT02433002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_13-176|Accuracy of Glomerular Filtration Rate (GFR) Estimation Using Creatinine and Cystatin C and Albuminuria|Accuracy of Glomerular Filtration Rate Estimation Using Creatinine & Cystatin C & Albuminuria for Monitoring Disease Progression in Patients With Stage 3 Chronic Kidney Disease: Prospective Longitudinal Study in a Multi-ethnic Population|eGFR-C|University of Birmingham|No|Recruiting|April 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1320|Samples Without DNA|Serum/plasma and urine will be stored for potential analysis of future markers.|Both|18 Years|N/A|No|Non-Probability Sample|Adults with stage 3 CKD.|April 2015|April 28, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02433002||22068|
NCT02493478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007253|Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs|Observation of Multi-center Quality Improvement Project: Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs|NEAR4KIDs|Children's Hospital of Philadelphia|No|Recruiting|March 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150000|||Both|N/A|N/A|No|Non-Probability Sample|All advanced airway events (tracheal intubations, laryngeal mask placement, emergency        tracheostomy and cricothyrotomy) in PICUs, CICUs, NICUs, DRs and EDs during study period.        Information regarding airway management events as well as select information regarding        circumstances up to the event will be collected.|January 2016|January 8, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493478||17424|
NCT02434718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221AD104|Single and Multiple Ascending Dose Study of BIIB037 in Japanese Participants With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Aducanumab (BIIB037) in Japanese Subjects With Mild to Moderate Alzheimer's Disease|PROPEL|Biogen|Yes|Active, not recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|55 Years|85 Years|No|||March 2016|March 3, 2016|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02434718||21936|
NCT02431715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01795|18F-FDOPA PET in Neuroendocrine Tumours|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours||British Columbia Cancer Agency||Available|October 2012|August 2018|Anticipated|August 2017|Anticipated|N/A|Expanded Access|N/A|||||||Both|1 Month|N/A||||January 2016|March 10, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02431715||22167|
NCT02440126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRA-001|Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk|Longitudinal Meta-Analysis and Further Sample Collection To Evaluate Potential Host Markers for PML Risk|SRA-001|Rocky Mountain MS Research Group, LLC|No|Recruiting|October 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|200|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Up to 200 patients with relapsing forms of multiple sclerosis. All subjects will receive        open label natalizumab according to their prescribing physician.|May 2015|May 6, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02440126||21521|
NCT02492308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF-LR|Induction With SVF Derived MSC in Living-related Kidney Transplantation|Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Living-Related Kidney Transplants: A Randomized Controlled Trial||Fuzhou General Hospital|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||July 2015|July 4, 2015|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02492308||17514|
NCT02427659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41673|VR High Tech Pain Control Burn Wound Care|High Technology Pain Control During Burn Wound Care|VRH2O|National Institute of General Medical Sciences (NIGMS)|No|Active, not recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|3||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|November 24, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02427659||22477|
NCT02435602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-1-09-01-14|The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers|The Role of Narrow Band Imaging (NBI) Endoscopy Compared With Lugol Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers: a Prospective Randomized Study||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Recruiting|December 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02435602||21868|
NCT02443025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-14-0729|Teens Against Tobacco Use: A Model for Universal Tobacco Prevention and Youth Advocacy|Teens Against Tobacco Use: A Model for Universal Tobacco Prevention and Youth Advocacy|TATU|The University of Texas Health Science Center, Houston|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2414|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 8, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02443025||21298|
NCT02485301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202091|A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa||GlaxoSmithKline||Active, not recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2796|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485301||18050|
NCT02436590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1403PSOA|Efficacy and Safety of an Active Pulsed Electromagnetic Field for the Treatment of Osteoarthritis of the Knee|A Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of an Active Pulsed Electromagnetic Field for the Treatment of Osteoarthritis of the Knee||Orthofix Inc.|No|Not yet recruiting|June 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|N/A|No|||May 2015|May 6, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436590||21792|
NCT02435836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-97-303|A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia|An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|April 1998|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|631|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|April 15, 2015|No|Yes|Study terminated when aripiprazole available commercially per protocol|No|July 1, 2015|https://clinicaltrials.gov/show/NCT02435836||21850|The study was terminated prematurely by the sponsor. The protocol specified that the study would run until Abilify (aripiprazole) was commercially available in all site countries.
NCT02439606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-1074|GlideRite® Rigid Stylet Versus Parker Flex-It Stylet|GlideRite® Rigid Stylet Versus Parker Flex-It Stylet for Orotracheal Intubation by GlideScope||King Saud University|No|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02439606||21561|
NCT02430675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laryngeal Neoplasms-IRE-01|Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430675||22246|
NCT02434913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026976|HUD: PIP Joint Implant|HUD: Proximal Interphalangeal (PIP) Joint Implant Finger Prosthesis||The Hawkins Foundation||No longer available|July 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|100 Years||||March 2016|March 7, 2016|September 15, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434913||21921|
NCT02483091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G241013 R.E Strauss X-C 218563|Testing the Feasibility of Intervening to Optimize Chiropractic Care for Adults With Neck Pain Disorders|Chiropractors Can Do: Testing the Feasibility of Intervening to Optimize Chiropractic Care for Adults With Neck Pain Disorders: A Pilot Cluster Randomized Controlled Trial||McGill University|Yes|Active, not recruiting|June 2015|April 2016|Anticipated|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|32|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02483091||18220|
NCT02433652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 300|Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2|A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|September 2015|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02433652||22018|
NCT02435849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTL019B2202|Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia|ELIANA|Novartis|Yes|Recruiting|April 2015|April 2021|Anticipated|April 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|3 Years|21 Years|No|||February 2016|February 1, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435849||21849|
NCT02435862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD-202|A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy|Protocol PVD-202: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD in Non-Proliferative Diabetic Retinopathy||Allegro Ophthalmics, LLC|Yes|Recruiting|April 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|45 Years|N/A|No|||April 2015|May 5, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435862||21848|
NCT02435875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renji1501|Perioperative Baroreflex Sensitivity|The Analysis of Perioperative Baroreflex Sensitivity in Hypertensives||RenJi Hospital|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing ordinary thoracic surgery|April 2015|April 30, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02435875||21847|
NCT02440191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KROG 15-03|3DCRT vs. IMRT in Early Breast Cancer|Postoperative Radiotherapy With Intensity-modulated Radiation Therapy (IMRT) Using Simultaneous Integrated Boost Versus 3-dimensional Conformal Radiotherapy (3D-CRT) in Early Breast Cancer: a Prospective Randomized Trial||Seoul St. Mary's Hospital|Yes|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|690|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02440191||21516|
NCT02483351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150433-01H|Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome|Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome - A Pilot Randomized Controlled Trial|SAHaRA Pilot|Ottawa Hospital Research Institute|Yes|Recruiting|October 2015|March 2019|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483351||18200|
NCT02483364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMQUIRI/12ES01|A Clinical Trial to Assess the Effect of HC-SVT-1001 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (BONECURE)|A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones|BONECURE|Salvat|Yes|Recruiting|May 2015|April 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||June 2015|June 25, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02483364||18199|
NCT02435316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRHMC 016-12|Comparison of Educational Methods for Teaching Peripheral Blood Smears|A Randomized, Controlled Cross Over Trial of Two Educational Methods and Their Additive Effects in the Recognition of Abnormal Peripheral Blood Smears|PBS|The Reading Hospital and Medical Center|No|Completed|April 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|May 5, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02435316||21890|
NCT02440113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP-14-857|Post-operative CT Follow up After Nellix Endoprosthesis Implantation|Post-operative CT Follow up Measurement After Nellix Endoprosthesis Implantation in Patients With Abdominal Aortic Aneurysms.||Rijnstate Hospital|No|Active, not recruiting|December 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients who underwent Nellix endovascular aortic repair|May 2015|May 6, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02440113||21522|
NCT02440464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1302|Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)|Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|August 2015|August 2022|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440464||21495|
NCT02492646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSeo_Saline|Effect of Saline Lubrication on Post-intubation Complications|Effect of Normal Saline Lubrication of Endotracheal Tube on Post-intubation Complications: A Prospective Non-inferiority Trial|Lubrication|Seoul National University Hospital|Yes|Not yet recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|20 Years|80 Years|No|||June 2015|July 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02492646||17488|
NCT02492737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG881-C-001|Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation|A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation||Agios Pharmaceuticals, Inc.|No|Recruiting|July 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492737||17481|
NCT02433119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT_EH_IV|The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy|A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial to Compare the Efficacy and Safety of OROSARTAN® Tablet 5/160mg Versus CODIOVAN® Tablet 160/12.5mg in Patients With Essential Hypertension Uncontrolled With Valsartan 160mg Monotherapy||Dong-A ST Co., Ltd.||Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|19 Years|N/A|No|||April 2015|April 29, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433119||22059|
NCT02435420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-4542-03|A Retro-prospective Study of Total Hip Arthroplasty With EMPERION Modular Primary Stem in Australian Centres (HISTORIC)|A Retro-prospective Study of Total Hip Arthroplasty With EMPERION Modular Primary Stem in Australian Centres|HISTORIC|Smith & Nephew, Inc.|No|Not yet recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|156|||Both|N/A|N/A|No|Non-Probability Sample|Subjects that have been implanted with the EMPERION modular primary stem for primary total        hip arthroplasty.|November 2015|November 18, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02435420||21882|
NCT02492763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8521-004|A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)|A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Recruiting|July 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|21 Years|65 Years|No|||February 2016|February 2, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492763||17479|
NCT02492776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-020|A Multiple-Dose Pharmacokinetics Study of Two AF-219 Formulations|A Study in Healthy Subjects to Assess the Multiple-Dose Pharmacokinetics of Two AF-219 Formulations||Afferent Pharmaceuticals, Inc.|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492776||17478|
NCT02492789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR-1210-01|A Trial to Evaluate Safety and Tolerability of SHR-1210 in Cancer Patients|An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of SHR-1210 in Patients With Advanced Solid Tumors||Atridia Pty Ltd.|No|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02492789||17477|
NCT02439112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reum,fys/ergo 1|Exercise in Patients With Multiple Myeloma|Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.|EMMY|Roskilde County Hospital|Yes|Enrolling by invitation|May 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02439112||21598|
NCT02439177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-V-1503|Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus|Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus||B. Braun Melsungen AG|No|Terminated|May 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 20, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02439177||21593|
NCT02501057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA023163-01|Reducing Alcohol Dependence Among HIV-Positive Individuals|HealthCall: Enhancing Brief Intervention for HIV Primary Care Alcohol Dependence||Research Foundation for Mental Hygiene, Inc.|Yes|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02501057||16842|
NCT02397876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2009|Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients|Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients||Icahn School of Medicine at Mount Sinai|No|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|6 Months|18 Years|No|||December 2015|December 23, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02397876||24763|
NCT02396589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCMRR 1611R03HD079841-01A1|Community Participation Transition After Stroke|Feasibility of a Novel Intervention to Improve Participation After Stroke|COMPASS|Washington University School of Medicine|No|Recruiting|December 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|N/A|No|||December 2015|December 11, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02396589||24862|
NCT02399124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMRC-01|Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell Carcinoma|ICE-SECRET ICE-SENSE™3 Cryotherapy For Renal Cell Carcinoma Trial|ICE-SECRET|IceCure Medical Ltd.|No|Recruiting|July 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02399124||24667|
NCT02399410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGHENT|Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis|BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis||University Hospital, Ghent|Yes|Not yet recruiting|May 2015|April 2020|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02399410||24645|
NCT02507310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X141114013|Influence of Ambient Temperature on Office Behaviors|||University of Alabama at Birmingham||Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|25|||Female|19 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02507310||16361|
NCT02395263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yuxintine Capsule-MDD-Ⅱb|Comparison of Yuxintine With Placebo in Treatment of MDD|Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial||Shanghai Mental Health Center|Yes|Not yet recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||March 2015|March 20, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02395263||24964|
NCT02395783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120113|Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease|Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease in Very Preterm Infants|PREMELIP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|60 Years|No|||July 2015|July 27, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02395783||24924|
NCT02408315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE|Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)|Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium|IMPROVE|Indiana University|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|300|||Female|14 Years|45 Years|No|||September 2015|September 24, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02408315||23964|
NCT02501915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26582214.4.0000.5289|Kinesio Taping Effects Applied With Different Directions and Tensions|Kinesio Taping Effects Applied With Different Directions and Tensions on Electromyography, Electroencephalography, Local Temperature and Muscle Strength||Universidade Estadual de Goiás|Yes|Completed|February 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|February 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02501915||16776|
NCT02402985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMLEV-Project|Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics|Comparison of a High-protein, Carbohydrate-restricted Diet With a High Proportion of Leguminous Protein Compared to Animal Protein on Metabolic Control in Patients With Type 2 Diabetes, "LeguAN Study"|LeguAN|German Institute of Human Nutrition|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|80 Years|No|||April 2015|April 29, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02402985||24372|
NCT02402998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP0815|Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia|Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02402998||24371|
NCT02410044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM - 11279|Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer|Open-labeled, Multicenter, Non-interventional Prospective PRO/QoL Registry for Patients With Osteoprotective Treatment for Bone Metastases of Breast or Prostate Cancer|PROBone|iOMEDICO AG|No|Recruiting|December 2014|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastasized breast or prostate cancer at the start of first systemic        osteoprotective treatment for bone metastases|March 2016|March 11, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02410044||23831|
NCT02397226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varicerstudien|Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery|Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery. A 5-year Follow-up Using Duplex Ultrasound, Plethysmography, VCSS, AVVQ and EQ-5D||University Hospital, Linkoeping|No|Recruiting|September 2014|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 3, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397226||24813|
NCT02506205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407035RINC|The Effect of LSVT LOUD for Mandarin-speaking Individuals With Hypokinetic Dysarthria Due to Parkinson's Disease|||National Taiwan University Hospital||Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|N/A|No|||July 2015|July 21, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506205||16446|
NCT02395445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-TT-2015-F1|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Routine Airway Management|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Routine Airway Management: a Randomised, Controlled Clinical Trial||Complexo Hospitalario Universitario de A Coruña|No|Recruiting|September 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|100 Years|No|||September 2015|November 5, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02395445||24950|
NCT02395744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPG-CLIN-2015-01|The COPPER-B Trial|The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Below the Knee|COPPER-B|Horizons International Peripheral Group|No|Recruiting|March 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02395744||24927|
NCT02410070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011126|A Comparison of Minimal Approach With Conventional Approach for Distal Radial Fractures|A Comparison of Minimal Approach With Conventional Approach for Distal Radial Fractures||The Second Hospital of Qinhuangdao|Yes|Completed|January 2011|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|70 Years|No|||March 2015|April 1, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02410070||23829|
NCT02482025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-059|The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial|The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial|SMMRT|VA Office of Research and Development|No|Not yet recruiting|March 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1400|||Both|18 Years|99 Years|No|||February 2016|February 5, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482025||18302|
NCT02436915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002|The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults|The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults|BrainSTIM|Hebrew Rehabilitation Center, Boston|Yes|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|No|||February 2016|February 22, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02436915||21767|
NCT02436928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-MV-21|A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects|||Medigen Vaccinology Corp.|Yes|Active, not recruiting|April 2015|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|200|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 20, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02436928||21766|
NCT02442895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uospmacg2|Biomarkers of Ovarian Reserve and Correlation With IVF Treatments|Predictors of Ovarian Response in Women Undergoing Ovarian Stimulation for IVF||U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti|No|Completed|February 2014|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|236|||Female|N/A|N/A|No|Non-Probability Sample|Women with primary or secondary infertility who underwent ovarian stimulation for in vitro        fertilization in our centre.|May 2015|May 8, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02442895||21308|
NCT02442921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-2015-1560-SK-CTIL|Colchicine for Diabetic Nephropathy Trial|The Effect of Colchicine Treatment on the Progression of Proteinuria in Patients With Diabetic Nephropathy.|CDNT|Sheba Medical Center|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02442921||21306|
NCT02440152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15|The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention|The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention||Ruijin Hospital|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|60 Years|No|||May 2015|May 6, 2015|March 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440152||21519|
NCT02486601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOXAGAST -D14-1|NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma|Phase II Study of NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma|FOXAGAST|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Recruiting|June 2015|June 2022|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02486601||17951|
NCT02433860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A20010724157261|Evaluation of the Effectiveness of Pharmacists in Implementing the SCRIPT Protocol|Evaluation of the Effectiveness of Pharmacists in Implementing the Smoking Cessation and Reduction in Pregnancy and Treatment (SCRIPT) Protocol||Providence Medical Research Center|No|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|May 5, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02433860||22002|
NCT02433873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115796|Prebiotic Effects of Isomalto-oligosaccharide|Prebiotic Effects of Isomalto-oligosaccharide||George Mason University|No|Active, not recruiting|April 2015|April 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02433873||22001|
NCT02442973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rivanna Clin-002|Handheld 3D Lumbar Spine Navigation: A Clinical Validation Study RM002|Handheld 3D Lumbar Spine Navigation: A Clinical Validation Study RM002||University of Virginia|No|Not yet recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|40 Years|No|Non-Probability Sample|Patients between the ages of 18 and 40 presenting for delivery and planning epidural        anesthesia.|May 2015|May 12, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02442973||21302|
NCT02439944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095/2014|Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement|Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement: A Randomized, Controlled Pilot Study in Motivated Smokers Unable to Quit With Standard Dosing|iT-NRT|Centre for Addiction and Mental Health|No|Recruiting|July 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|65 Years|No|||November 2015|November 12, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02439944||21535|
NCT02493985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36485|Studying Physiological and Anatomical Cerebral Effects of Carbon Dioxide and Tilt|Studying Physiological and Anatomical Cerebral Effects of Carbon Dioxide and Tilt|SPACE-COT|Baylor College of Medicine|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02493985||17385|
NCT02494011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00300|Closed Kinetic Chain Exercise Versus Russian Current Stimulation in Rehabilitation of Colles' Fracture.|Closed Kinetic Chain Exercise Versus Russian Current Stimulation in Rehabilitation of Colles' Fracture.||October 6 University|Yes|Completed|January 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Both|20 Years|50 Years|No|||August 2015|August 1, 2015|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494011||17383|
NCT02494024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2N-8E12-WW-104|Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy|A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy||C2N Diagnostics|Yes|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|32|||Both|50 Years|85 Years|No|||January 2016|January 13, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494024||17382|
NCT02480998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_Q120|Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults|A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects||Il-Yang Pharm. Co., Ltd.|Yes|Completed|February 2015|||April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02480998||18381|
NCT02439216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-1004-201|Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy|A Phase 1/2 Study of CAT-1004 in Pediatric Patients With Duchenne Muscular Dystrophy|MoveDMD|Catabasis Pharmaceuticals|Yes|Not yet recruiting|April 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Male|4 Years|7 Years|No|||March 2016|March 21, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439216||21590|
NCT02441725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAND-UP Study|Validation of the 1-minute Sit-to-stand Test in Patients With COPD|1-minute Sit-to-stand Test: A Multicentre Validation Study of a Simple Exercise Capacity Test in Patients With Chronic Obstructive Pulmonary Disease|STAND-UP|University of Zurich|No|Active, not recruiting|April 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|72|||Both|40 Years|N/A|No|||December 2015|December 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02441725||21398|
NCT02429622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-133/923|Phase Ⅰ/Ⅱ Study of Simultaneous Integrated Boost and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma|A Phase Ⅰ/Ⅱ Study of Simultaneous Integrated Boost Technique of IMRT and Concurrent Chemotherapy in Patients With Locally Advanced Esophageal Carcinoma||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2015|October 2020|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|18|||Both|18 Years|72 Years|No|||December 2015|December 9, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429622||22326|
NCT02437136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0601|Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma|A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma||Syndax Pharmaceuticals|No|Recruiting|July 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437136||21750|
NCT02430025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJPH20150101|Fujian Province Cardiovascular Diseases Study|Fujian Province Cardiovascular Diseases Study|FJCVD|Fujian Provincial Hospital|Yes|Not yet recruiting|June 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|8000|Samples Without DNA|Approximately 30 mls of blood will be dispensed as follows :      3 x 10 mls EDTA Tube (Blood was collected from overnight-fasted subjects into ice-cold tubes      containing EDTA) (6 mmol/L final concentration).|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The control subjects had no clinical history of cardiovascular diseases, no family history        of premature cardiovascular diseases.Subjects had all arteries＜50% stenotic lesion on        cardiocerebral vascular angiography. Subjects with stable CAD had clinically established        atherosclerotic vascular disease but had been stable for ≥3 months. Subjects with CAD also        had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial        infarction, percutaneous coronary intervention, or coronary artery bypass grafting. ACS        was confirmed with urgent coronary angiography; all subjects had at least one ≥50%        stenotic lesion with ruptured plaque or thrombus.|April 2015|April 28, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430025||22295|
NCT02430038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2428|Transperineal Ultrasound to Assess the Progress of Labour|The Sono-VE Study: Assessing the Acceptability and Feasibility of Transperineal Ultrasound and Developing an Ultrasound Based Predictive Model for Labour Outcome.||Imperial College London|No|Recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: acceptability and feasibility group        Group 2: predictive model group|April 2015|April 28, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02430038||22294|
NCT02436694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.236(174-DEFI/199-CES)|Nerve Blocks With Dexamethasone and Local Anaesthetic to Improve Postoperative Analgesia|Can the Association of Dexamethasone and Local Anaesthetic in a Single-shot Femoral and Sciatic Nerve Block Improve Analgesia Postoperatively in Patients Submitted to Total Knee Arthroplasty||Centro Hospitalar do Porto|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436694||21784|
NCT02436707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY17|Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma|A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma||Canadian Cancer Trials Group|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|16 Years|65 Years|No|||February 2016|March 22, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436707||21783|
NCT02491554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000847|Deep braIn Stimulation for Tremor TractographIC Versus Traditional|Deep braIn Stimulation for Tremor TractographIC Versus Traditional|DISTINCT|University Hospital Freiburg|No|Recruiting|August 2015|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|25 Years|80 Years|No|||September 2015|September 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02491554||17572|
NCT02491567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62/17-2-2014|DNA Methylation and Autoimmune Thyroid Diseases|Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases|THYRODNA|Aristotle University Of Thessaloniki|No|Active, not recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|Samples With DNA|Blood samples will be collected and centrifuged and then White Blood Cells (WBCs), plasma      and serum will be separated.|Both|4 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children and adolescents of Greek origin, aged 4-18 years old with a diagnosis of        Hashimoto Thyroiditis and Graves Disease as well as healthy controls.|December 2015|December 29, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02491567||17571|
NCT02434705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000883|Food Antigen in Eosinophilic Esophagitis|Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis|EoE|Mayo Clinic|No|Recruiting|April 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02434705||21937|
NCT02443142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NorthwesternU|Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury|Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury|IVAMTBI|Northwestern University|No|Not yet recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|21 Years|60 Years|No|||March 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443142||21289|
NCT02443155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9828-4150|Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function||Novo Nordisk A/S|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|304|||Both|18 Years|45 Years|No|||January 2016|January 22, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443155||21288|
NCT02427997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-NG-063-CTIL|VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis|Virtual Reality-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||April 2015|April 27, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02427997||22451|
NCT02428010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-1402|Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study|Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation||Twelve, Inc.|No|Recruiting|September 2014|September 2021|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428010||22450|
NCT02491645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIMER-HS|Comparison of Effectiveness of Home Based Sensory Interventions Along With Standard Therapy Versus Standard Therapy Alone in Autistic Children With Sensory Processing Abnormalities|Comparison of Effectiveness of Home Based Sensory Interventions Along With Standard Therapy Versus Standard Therapy Alone in Autistic Children With Sensory Processing Abnormalities :An Open Label Randomized Study||Postgraduate Institute of Medical Education and Research|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|3 Years|12 Years|No|||July 2015|July 8, 2015|July 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491645||17565|
NCT02439515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2010-2312228-SF|Fall Prevention and Locomotion Recovery in Post-stroke Patients: A Multimodal Training|Fall Prevention and Locomotion Recovery in Post-stroke Patients: A Multimodal Training||Fondazione Salvatore Maugeri|No|Recruiting|December 2014|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|85 Years|No|||February 2016|February 3, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02439515||21568|
NCT02430597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hilus pulmonis -IRE-01|Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms|Irreversible Electroporation(IRE) For Unresectable Hilus Plumonis Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|May 14, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430597||22252|
NCT02435329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charcodiab13|Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study|Bone Metabolism and Endothelial Function in Patients With Type 2 Diabetes Mellitus and Charcot Foot - an Observational Comparative Study||Tameside General Hospital|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|Analysis of serum samples for markers of endothelial function, inflammation and bone      metabolism|Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|40 patients with type 2 diabetes mellitus will be considered eligible for the study.        Patients with a previous diagnosis of type 2 diabetes mellitus and newly diagnosed type 2        DM seen at Tameside Hospital will be recruited into the study. In addition, eligible        patients will be identified and referred from University Hospital of South Manchester        (UHSM) and appropriate GP practices (from Oldham, Tameside and Wythenshawe).        Source of healthy controls: Hospital staff and spouses/ partners of patients will        volunteer as healthy subjects.|March 2016|March 14, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435329||21889|
NCT02437955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2014-N-37|Fe Absorption in Mother and Child Pairs From Wheat Fortified With Iron With and Without Phenolic Containing Beverages|Evaluating the National Fortification Policy in Senegal Assessment of Iron Bio-availability in Mother and Child Pairs From Wheat Flour Fortified With Iron With and Without Phenolic Containing Beverages|Fe_Senegal|Swiss Federal Institute of Technology|No|Completed|April 2015|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|34|||Both|3 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02437955||21687|
NCT02479633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU5|Predetermination for Gingival Recession|Predetermınatıon of Root Coverage for Recessıons Treated wıth Coronally Advanced Flap wıth Connectıve Tissue Graft: An Exploratıve Study||Cukurova University|No|Completed|January 2013|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|122|||Both|20 Years|42 Years|No|||June 2015|June 19, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02479633||18486|
NCT02437799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18900|Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia|Analysis of Changes in the Pulse Oximeter Waveform and Blood Pressure During Spinal Anaesthesia for Caesarean Section: an Observational Study|DINOCS|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|50 Years|No|Non-Probability Sample|Women undergoing planned caesarean section under spinal anaesthesia|November 2015|November 20, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02437799||21699|
NCT02435368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501001|The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear|The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and Lipopolysaccharide on Interleukin-1β Secretion by Mononuclear||The Third Affiliated Hospital of Southern Medical University|Yes|Recruiting|April 2015|March 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|Samples Without DNA|Peripheral blood was obtained from healthy donors,mononuclear cells (PBMCs) were isolated      using Ficoll density gradient centrifugation, and LPS (1 μg/ml) and/or MPA were added. After      12 hours, the supernatants were harvested and stored at -80°C for ELISA.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers,age 18-60.|April 2015|April 30, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02435368||21886|
NCT02440659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109201303132|Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)|Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)|EPOCH-RRT|Arbor Research Collaborative for Health|No|Completed|February 2015|December 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1960|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients currently consented in the Dialysis Outcomes and Practice Patterns Study        (DOPPS) or the Peritoneal Outcomes and Practice Patterns Study (PDOPPS).|January 2016|January 13, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02440659||21480|
NCT02440672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4049-06|JOURNEY™ II CR Total Knee System|A Prospective, Non-randomized, Single Cohort, Multicenter Study to Evaluate the Clinical Outcomes of Total Knee Arthroplasty (TKA) Using the JOURNEY™ II CR Total Knee System||Smith & Nephew, Inc.|No|Recruiting|September 2015|February 2027|Anticipated|December 2026|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|22 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02440672||21479|
NCT02480972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-082-618|Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging|Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging (MRI)||Seoul National University Hospital|Yes|Recruiting|June 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02480972||18383|
NCT02485093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01266-49|To Pace or Not to Pace in Sinus Node Disease|Comparison of Ventricular Septal Pacing With Optimized Atrioventricular (AV) Delay to no Pacing in Sinus Node Disease (SND) Patients.|OPTIMIST|St. Jude Medical|No|Completed|June 2009|October 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|July 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02485093||18066|
NCT02431884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01629-XP|Tissue Samples and Bodily Fluid Specimens Banking|Tissue and Bodily Fluid Specimens From Women Presenting to the Reproductive Endocrinology Clinic||University of Tennessee|No|Recruiting|January 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|A portion of blood/tissue specimens that will be generated during the participants office      visit or surgery.|Female|8 Years|N/A|No|Probability Sample|POPULATION: Patients identified among all women presenting to the reproductive        endocrinology clinic.|April 2015|September 17, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431884|1 Day|22154|
NCT02439502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD 1978|EndoChoice's Fuse® Endoscopic System Performance In Routine Practice|Single Center, Prospective, Open Label Post Marketing Study of EndoChoice's Fuse® Endoscopic System Performance In Routine Practice|Fuse®|EndoChoice Innovation Center, Ltd.|No|Active, not recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439502||21569|
NCT02440763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/05|The EUROSCA Natural History Study|The EUROSCA Natural History Study|EUROSCA-NHS|Ataxia Study Group|No|Recruiting|July 2005|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|DNA is obtained for genetic testing.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with spinocerebellar ataxia type 1,2,3 and 6.|May 2015|May 7, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02440763||21472|
NCT02440776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-010|Pathway CH S&E Registry|Pathway CH S&E Registry: Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache - ATI Neurostimulation System is Branded Internationally as Pulsante™ Microstimulator System|SER|Autonomic Technologies, Inc.|No|Recruiting|April 2015|May 2023|Anticipated|May 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who meet the CE marked labeling for cluster headache for the Pulsante        Microstimulator System|March 2016|March 8, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02440776|5 Years|21471|
NCT02492321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-005-AC-2|A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis|EBI-005-AC-2|Eleven Biotherapeutics|No|Completed|July 2015|December 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492321||17513|
NCT02492334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3733318|Doxazosin for PTSD and Alcohol Use Disorder|Doxazosin in the Treatment of Co-occuring PTSD and Alcohol Use Disorder||Medical University of South Carolina|Yes|Not yet recruiting|August 2016|March 2019|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|21 Years|65 Years|No|||February 2015|July 2, 2015|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492334||17512|
NCT02439307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-CNIC-2013-55|Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth|Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis||Coordinación de Investigación en Salud, Mexico|No|Not yet recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||May 2015|May 11, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02439307||21584|
NCT02430870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-648-1002|TAK-648 in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Multiple Oral TAK-648 Doses in Healthy Japanese Subjects and Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|April 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|48|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430870||22232|
NCT02430883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.12.2014 18/15|Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery?|||Diskapi Teaching and Research Hospital|No|Recruiting|January 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|5||Anticipated|300|||Both|18 Years|90 Years|No|||April 2015|April 27, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430883||22231|
NCT02487446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2349|Efficacy and Safety Study of QVA149 in COPD Patients|A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, 2-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation||Novartis|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|354|||Both|40 Years|N/A|No|||March 2016|March 7, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487446||17886|
NCT02437448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0573|Breath Analysis in Lung Fibrosis|Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Pulmonary Fibrosis||University of Zurich|No|Recruiting|April 2015|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|None Retained|Exhaled breath|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Confirmed diagnosis of idiopathic pulmonary fibrosis based on clinical, radiologic and/or        pathologic data without evidence or suspicion of an alternative diagnosis that may        contribute to their interstitial lung disease. Patients must fulfill all of the following        criteria:|December 2015|December 7, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02437448||21726|
NCT02440035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107409|A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants|Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Volunteers||Crucell Holland BV|Yes|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02440035||21528|
NCT02442531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-CL01|A Study of CriPec® Docetaxel Given to Patients With Solid Tumours|A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours|NAPOLY|Cristal Therapeutics|No|Recruiting|August 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02442531||21336|
NCT02442570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-002|A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis||Delta Crystallon BV|Yes|Completed|September 2012|February 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|No|||May 2015|August 26, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02442570||21333|
NCT02443727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001225|The Role of Oxytocin in the Perception of Faces|The Role of Oxytocin in the Perception of Infant Faces||Penn State University|Yes|Enrolling by invitation|April 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2015|May 13, 2015|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443727||21245|
NCT02443740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B8001001|Safety, Tolerability and Pharmacokinetics of PF-05251749|A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics And Relative Bioavailability Of Single Escalating Oral Doses Of Pf-05251749 In Healthy Adult Subjects||Pfizer|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443740||21244|
NCT02489500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33808|Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis|Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis|VelRand|Boston Medical Center|Yes|Recruiting|June 2015|May 2040|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489500||17729|
NCT02478905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0228|Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting|TransFLUas: Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting: A Prospective Study Over Two Consecutive Influenza Seasons|TransFLUas|University of Zurich|No|Not yet recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1440|Samples With DNA|Virological analyses        -  Influenza A and B PCR from nasal swabs        -  Whole genome sequencing of positive swabs|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This project is a prospective study following patients in medical wards and acute care HCW        (including nursing staff (nurses and assistant nurses), physiotherapists, house staff with        direct patient contact and medical doctors (clinical fellows) working on the same wards at        the University Hospital Zurich. Inpatients and HCW will be recruited from general medical        and infectious diseases wards, pulmonology wards, hematology wards and from the stem cell        transplant unit. All HCW and inpatients on the ward under surveillance are eligible for        the study|June 2015|June 22, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02478905|1 Year|18542|
NCT02439346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17450|Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel|An Open-label, Non-randomized, Multicenter Phase I Study to Characterize the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of Oral MKNK1 Inhibitor BAY 1143269 Given Alone or in Combination With Intravenous Docetaxel in Subjects With Advanced Solid Tumors||Bayer|Yes|Recruiting|June 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|117|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02439346||21581|
NCT02439359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF 301-101|A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects|A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects||ContraFect|Yes|Active, not recruiting|May 2015|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439359||21580|
NCT02440529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-248|Surgeon-Patient Communication: A Randomized Controlled Trial Evaluating the Impact of an Orthopaedic Related Smoking Cessation Discussion After Fracture Surgery|||University of Missouri, Kansas City||Recruiting|January 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440529||21490|
NCT02431221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-PHX-003|Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure|A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure||Heart Metabolics Limited|Yes|Not yet recruiting|March 2016|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431221||22205|
NCT02481804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05012015|Optimal Feeding for NET Patients|Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; a Pilot Study|DIVIT-pilot|University Medical Center Groningen|No|Completed|May 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|90 Years|No|||March 2016|March 21, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02481804||18319|
NCT02482064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-RemPro-01-2015|Using Flexible Resin in Maxillary Obturators|A Clinical Comparative Study of Two Types of Maxillary Obturators Made of Heat Cure Acrylic Resin or Flexible Resin||Damascus University|Yes|Active, not recruiting|May 2015|May 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|10 Years|75 Years|No|||March 2016|March 11, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482064||18299|
NCT02437019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106344|Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|An Early Access Program (EAP) for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)||Janssen-Cilag Farmaceutica Ltda.||Available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 11, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02437019||21759|
NCT02436395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH-GC-03|Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs|Comparison the Influence of the Povidone-iodine or the Normal Saline Cleaning the Incision for the Incidence of the Surgical Site Infections for Gastric Cancer Patients With Gastrectomy- Randomized Controlled Trial||West China Hospital|Yes|Not yet recruiting|May 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|75 Years|No|||May 2015|May 3, 2015|December 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02436395||21807|
NCT02436642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-6432|AVERT Plus Post-Market Registry|AVERT Plus Post-Market Registry||Osprey Medical, Inc|No|Recruiting|May 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be included if they are scheduled for a coronary diagnostic or PCI procedure        using manual manifold injection with the AVERT System and Contrast Monitoring System        according to the labeled indications for these devices.|May 2015|May 8, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436642||21788|
NCT02482077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_HCV G2 Study|Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients|Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection||Humanity & Healthy GI and Liver Centre|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482077||18298|
NCT02482311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6015C00001|Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours|A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|99 Years|No|||February 2016|February 5, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482311||18280|
NCT02428907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-58-0028|Simulation Training of Endoscopy Staff to Improve Patient Experience in Colonoscopy|Simulation Based Team Training of Endoscopy Staff May Improve Patients' Perception of Colonoscopy||Aalborg Universitetshospital|No|Completed|October 2012|April 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|539|||Both|18 Years|N/A|No|Probability Sample|All patients for colonoscopy under minimal sedation|April 2015|April 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02428907||22381|
NCT02507219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-007-00|Study of Ibuprofen Effects on Brain Function|Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function||Laureate Institute for Brain Research, Inc.|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507219||16368|
NCT02507232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150158|A Phase II Study of NovoTTF-100A Alone and With Temozolomide in Patients With Low-Grade Gliomas|A Multicenter Phase II Study of NovoTTF-100A Alone and Combined With Temozolomide in Patients With Low-Grade Gliomas||University of California, San Diego|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02507232||16367|
NCT02402465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1199|Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis|Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis||University of Chicago|No|Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02402465||24410|
NCT02400619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuroshockwaves|Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Crossover RCT|Comparative Study of Extracorporeal Shockwaves Therapy and Botulinum Toxin Type A( TBA) for the Treatment of Spasticity in Lower Extremity in Patients With Cerebral Palsy. A Crossover Randomized Clinical Trial (RCT)||University Ramon Llull|No|Recruiting|September 2014|January 2017|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|5 Years|55 Years|No|||October 2015|October 28, 2015|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02400619||24552|
NCT02404727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holstebro Hospital|Evaluation of Cemented and Cementless Fixation of Dual-mobility Hip Prosthesis in Elderly Patients With Osteoarthritis|Evaluation of Cemented and Cementless Fixation of Dual-mobility Hip Prosthesis in Elderly Patients With Osteoarthritis||University of Aarhus|Yes|Recruiting|October 2014|October 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2014|March 30, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02404727||24238|
NCT02404740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1995|Noninvasive Intracranial Pressure and Hydrocephalus Patients|Continuous Noninvasive Estimation of Intracranial Pressure to Assess Ventriculoperitoneal Shunt Malfunction in Patients With Hydrocephalus||University of Colorado, Denver|No|Enrolling by invitation|February 2015|October 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|31 Days|17 Years|No|Non-Probability Sample|VP shunted patient, Normal intracranial pathology patient|December 2015|December 3, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02404740||24237|
NCT02501863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN1|Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty|Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty||National Medical Center, Seoul|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02501863||16780|
NCT02404428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02/2014|Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer|Effect of Sulforaphane on Prostate CAncer PrEvention-imagING Evaluation|ESCAPE-ING|Institute of Food Research|No|Enrolling by invitation|February 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Male|18 Years|80 Years|No|||March 2015|March 26, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02404428||24261|
NCT02404441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDR001X2101|Phase I/II Study of PDR001 in Patients With Advanced Malignancies|Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies||Novartis|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02404441||24260|
NCT02399891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA20111211|Acute Myocardial Infarction Quality Assurance Project|Acute Myocardial Infarction Quality Assurance Project|AMIQA|University of Calgary|No|Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients surviving an acute MI.|November 2015|November 20, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02399891|2 Years|24608|
NCT02400099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-2015|Protein-rich Diet and NAFLD in Bariatric Surgery|Protein-rich Diet and Non-Alcoholic Fatty Liver Disease in Bariatric Surgery||Catholic University of the Sacred Heart||Not yet recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|60 Years|No|||March 2015|March 23, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02400099||24592|
NCT02394158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM1971|Preventing Recurrent Gestational Diabetes With Metformin|Preventing Recurrent Gestational Diabetes Mellitus With Early Metformin Intervention|PRoDroME|Imperial College London|Yes|Recruiting|December 2014|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|112|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|February 12, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02394158||25049|
NCT02394457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVALMCSD|Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache|Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache (PDPH)|PDPH|United States Naval Medical Center, San Diego|No|Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||March 2015|March 16, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02394457||25026|
NCT02498535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-CF-02E|Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients|Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients||Novoteris, LLC|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 12, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02498535||17036|
NCT02508922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHVitDASD|Trial of Vitamin D3 Supplementation in Paediatric Autism|Vitamin D3 for Autism Spectrum Disorder: a Randomized, Double-blind, Placebo-controlled Trial.||University of Dublin, Trinity College|No|Recruiting|September 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|3 Years|12 Years|No|||October 2015|October 21, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02508922||16238|
NCT02405767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grenoble University Hospital.|BioimPEDance of Diabetic Foot Ulcers|Characterisation by Electric Impedance Measurements of the Different Wound Healing Phases of Diabetic Foot Ulcers|BIPPED|University Hospital, Grenoble|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02405767||24158|
NCT02405780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKB327-003|A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients|An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate|ARABESC-OLE|Fujifilm Kyowa Kirin Biologics Co., Ltd.|No|Recruiting|June 2015|May 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|544|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02405780||24157|
NCT02397239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-103-062|Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer|||National Cheng-Kung University Hospital|Yes|Active, not recruiting|March 2015|||December 2018|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|122|Samples Without DNA|Blood hemoglobin, white blood cell, absolute neutrophil count, platelet count, total      bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine|Both|20 Years|N/A|No|Probability Sample|Patients with metastatic non-squamous mon-small-cell lung cancer|April 2015|April 5, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02397239||24812|
NCT02402283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-GT007|Study to Determine the Equivalence of Two Products Containing Metronidazole Benzoate|Comparative Randomized, Single Dose, Two-Way Crossover Open Label Bioequivalence Study of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules) Versus Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablet), After An Oral Administration Of 400 mg to Healthy Adults Under Fasting Conditions||Verisfield UK Ltd. Greek Branch|No|Completed|May 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02402283||24424|
NCT02506855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0238|Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)|Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP): Modifying an Existing Technique for Ease of Administration and Increased Accuracy|GYNTAP|University of Mississippi Medical Center|No|Recruiting|June 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Female|18 Years|N/A|No|||July 2015|July 21, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02506855||16396|
NCT02506985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0275-F6A|XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis|XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis|XENITH|University of Kentucky|No|Not yet recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02506985||16386|
NCT02506998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-13-001|Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts|Evaluation of Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts as an Adjuvant||National Polytechnic Institute, Mexico|Yes|Completed|August 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|14 Years|60 Years|No|||July 2015|July 24, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02506998||16385|
NCT02400307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-141-1479|Pharmacokinetics of GS-9883 in Adults With Normal and Impaired Renal Function|A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function||Gilead Sciences|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02400307||24576|
NCT02400320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202201|Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate and Menthol|Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel||GlaxoSmithKline|No|Not yet recruiting|September 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02400320||24575|
NCT02438839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WW2|Curative Chemoradiation of Low Rectal Cancer|Curative Chemoradiation of Low Rectal Cancer. A Prospective Multicenter Observational Study|WW2|Vejle Hospital|Yes|Recruiting|April 2015|||December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|No|Probability Sample|Patients with low rectal cancer (tumor located ≤ 6 cm from the anal verge) who are        referred to the participating departments and who fulfill the inclusion criteria.|October 2015|October 28, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438839||21619|
NCT02486328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UfukU|The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy|The Effect of Different Sedation Regimes Administered by Anesthesiologists or Endoscopists on Cognitive Functions in Lower Gastrointestinal System Endoscopy||Ufuk University|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|65 Years|No|||June 2015|June 26, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486328||17972|
NCT02433691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001411|Memory and Exercise Training Study in Older Adults With Subjective Memory Complaints|Simultaneous Aerobic Exercise and Memory Training in Older Adults With Subjective Memory Complaints|MET|University of California, Los Angeles|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|90|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02433691||22015|
NCT02431195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SCW-SOCIOB|Analysis of Changes in Eating Habits on Post Bariatric Surgery Patients and Their Family Members|Analysis of Changes in Eating Behaviors and Physical Activity on Post Bariatric Surgery Patients and Their Family Members : Comparison Between Men and Women|SOCIOB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients who will undergo bariatric surgery (bypass or sleeve) and live together with        their families.|February 2016|February 10, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02431195||22207|
NCT02431481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2116|Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011|A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function||Novartis|No|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431481||22185|
NCT02491411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1548|Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel|A Pilot Study of Dexamethasone Therapy Prior to Rechallenge With Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial)|DEXTER|Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||August 2015|August 10, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491411||17583|
NCT02436980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499|Premedication for ERCP With Midazolam or Tramadol|Effects of Midazolam or Tramadol Premedication on Early Cognitive Function in ERCP: a Randomized Controlled Double-Blind Study||Karadeniz Technical University|No|Completed|January 2009|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|70 Years|No|||May 2015|May 12, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02436980||21762|
NCT02436993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 14-67|Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting|A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting||University of California, Irvine|Yes|Recruiting|April 2015|February 2037|Anticipated|February 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||May 2015|May 12, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436993||21761|
NCT02440204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFMC-15036|Optimal Sevoflurane Concentration for Intubation in Combination of Clincal Remifentanil Doses|Optimal Sevoflurane Concentration for Intubation Without Using Muscle Relaxants in Combination of Different Clinical Bolus Doses of Remifentanil||Severance Hospital|No|Recruiting|May 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|70|||Male|19 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 3, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02440204||21515|
NCT02482558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoN-URDC GI trial|Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects|Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects||Unilever R&D|No|Completed|February 2013|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482558||18261|
NCT02481011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/7958|Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs|Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Study|RICH|St. Olavs Hospital|No|Active, not recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|72000|||Both|18 Years|N/A|No|Non-Probability Sample|patients with intracranial hemorrhage admitted to hospitals in Norway 2008-2014|June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481011||18380|
NCT02481024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1_18_06_15|Impact of Care Transition on Medication Adherence in Cardiac Patients|'Moving From Hospital to Home' - Exploring the Impact of Care Transition on Medication Adherence in Cardiac Patients: a Qualitative Study Protocol||King's College London|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalised after an acute coronary syndrome event.|February 2016|February 26, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02481024||18379|
NCT02427685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP2687|Dysfunctional Hemoglobin CO-ox|Dysfunctional Hemoglobin||Nonin Medical, Inc|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers|April 2015|June 16, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427685||22475|
NCT02430389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00007835|Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy|Effect of Remifentanil Administration on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy||Northwestern University|No|Terminated|July 2012|December 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|April 25, 2015|Yes|Yes|A priori hypothesis confirmed with interim analysis.|No|May 21, 2015|https://clinicaltrials.gov/show/NCT02430389||22268|Study terminated early due to interim analysis with patients in placebo group having substantially higher systemic HTN requiring rescue meds compared to study drug group. Another limitation is difficulty defining baseline BP preoperatively.
NCT02430402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013.5|Rehabilitation of Young Patients With Rheumatic Diseases in a Warm Climate|Effect of Rehabilitation of Young Patients With Rheumatic Diseases in a Warm Climate. A Pilot Randomised Controlled Trial||Norwegian University of Science and Technology|No|Recruiting|May 2015|August 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|35 Years|No|||October 2015|November 1, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02430402||22267|
NCT02434315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-UK-PMS-14024|FreeStyle Libre Pro Use in Primary & Secondary Care|Evaluation of the FreeStyle Libre Pro for Individuals With Insulin Managed Type 2 Diabetes in Primary & Secondary Care||Abbott Diabetes Care|No|Active, not recruiting|April 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|170|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434315||21967|
NCT02492880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91051317|CoverEdge Algorithm Programming Study|Study to Characterize the Effects of Programming Features of the Boston Scientific Precision Spectra™ Spinal Cord Stimulator System Using the CoverEdge™ Surgical Leads||Boston Scientific Corporation|No|Recruiting|July 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492880||17470|
NCT02492893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820294|Yoga Intervention for Substance Use and ART Adherence in Community Reentry|Yoga Intervention for Substance Use and Antiretroviral Therapy Adherence in Community||University of Pennsylvania|No|Recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02492893||17469|
NCT02439255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14135|Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers|Interactive Omics: Black Raspberry Metabolites and the Oral Microbiome in Smokers||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2014|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02439255||21587|
NCT02434549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BATCP|Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial|Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial|BATCP|Karolinska Institutet|Yes|Recruiting|August 2015|||April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434549||21949|
NCT02434562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54034|Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation|Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation by Human Serum||Universitaire Ziekenhuizen Leuven|No|Enrolling by invitation|April 2012|||April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|200|Samples With DNA|Serum and urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the department of Endocrinology/Andrology, Urology and Oncology|April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434562||21948|
NCT02443389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X140917002|Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates|Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates|AWAKEN|University of Alabama at Birmingham|No|Enrolling by invitation|March 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|2000|||Both|N/A|2 Weeks|No|Non-Probability Sample|The investigators will conduct a multi-center retrospective cohort study. The        investigators will enroll eligible infants who meet inclusion and exclusion criteria at        each center for 3 consecutive months. Based on average admissions for 2013 at our centers        who meet inclusion and exclusion criteria, it is estimated that it can enroll        approximately 3000 infants during this time. All infants admitted to the NICU between        January 1, 2014 and march 31, 2014 will be screened for the study.|May 2015|May 27, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443389|120 Days|21270|
NCT02479113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401-0691|Maternal Hypertriglyceridaemia Study|Pregravid Body Mass Index (BMI), Maternal Hypertriglyceridemia During Pregnancy and Body Composition/Metabolic Health of Asian GDM Offspring||University of Malaya|Yes|Recruiting|March 2014|December 2024|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|400|Samples With DNA|Placental tissue for epigenetic studies of the leptin gene, and cord blood for leptin and      micro RNA29 (miR29) will be collected|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This study is implemented in 2 phases.        In Phase 1 , N=400, pregnant women (lean with NGT 150, obese with NGT 100, GDM 150) of        Asian descent will be recruited from the UMMC Antenatal Clinic.        In Phase 2, the offspring of 150 GDM mothers, 40 lean NGT controls and 40 obese NGT        mothers from Phase 1 form a cohort that will continue to be followed up at intervals (6        months, 1 year, 3 years, 5 years, 7 years and 10 years) till age 10 years with evaluation        of body composition, growth, pubertal development and metabolic health. Equal numbers of        girls and boys will be recruited. Data will be collected on breastfeeding practices and        diet/physical activity.|June 2015|June 24, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02479113||18526|
NCT02437253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30535|Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI|Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI||Los Angeles Biomedical Research Institute|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4|||Both|5 Years|N/A|No|||January 2016|January 8, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02437253||21741|
NCT02430337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21MH098244-02|A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare|A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare||Georgia State University|No|Enrolling by invitation|April 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 26, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02430337||22272|
NCT02430350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-23-02|Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke|Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial||Jiangsu Simcere Pharmaceutical Co., Ltd.|Yes|Recruiting|May 2015|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|35 Years|80 Years|No|||April 2015|July 5, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02430350||22271|
NCT02432677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0217|Evaluation of the Potentiating Effect of tDCS on Opioid Analgesia of Pain Threshold in Humans|Evaluation of the Potentiating Effect of Transcranial Direct Current Stimulation (tDCS) on Opioid Analgesia of Pain Threshold in Humans||Hospital de Clinicas de Porto Alegre|No|Recruiting|July 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02432677||22093|
NCT02432690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-205GYN-M|A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation|A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation||Boston Biomedical, Inc||Recruiting|June 2015|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432690||22092|
NCT02479360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N174|Reliability of Functional Outcome Measures in Neurofibromatosis 1|A Study Investigating the Inter- and Intra- Rater Reliability of a Battery of Functional Standardised Outcome Measures in Neurofibromatosis 1||Guy's and St Thomas' NHS Foundation Trust|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|16 Years|N/A|No|Non-Probability Sample|All adults (over the age of 16 years) with a clinical diagnosis of neurofibromatosis 1 who        attend the neurofibromatosis clinic for appointments at Guys hospital, London and who fit        the inclusion/exclusion criteria for the trial are eligable to participate in the study.|June 2015|October 5, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479360||18507|
NCT02484105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15001924|Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction|Comforting Conversation During Colonoscopy: A Randomised Controlled Trial on Patient Satisfaction|ComConEndo|Copenhagen University Hospital at Herlev|No|Recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|62|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02484105||18142|
NCT02434497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D356NC00001|A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia|An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)||AstraZeneca|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|6 Years|18 Years|No|||January 2016|January 5, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434497||21953|
NCT02435342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-03|A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis|A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 in Active Plaque Psoriasis||Kineta Inc.|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Both|18 Years|65 Years|No|||May 2015|May 1, 2015|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435342||21888|
NCT02435355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sadir Association|Efficiency of a Phone Coaching for Sleep Apnea Hypopnea Syndrome Patients|Efficiency of a Phone Coaching Program on Adherence to Continuous Positive Airway Pressure in Sleep Apnea Hypopnea Syndrome||Sadir Association|No|Completed|April 2010|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|379|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 5, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02435355||21887|
NCT02442856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822483|Non-invasive Measurement of Cerebral Dynamic Autoregulation||TOMCAT|University of Pennsylvania|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|50 Years|N/A|No|||December 2015|December 23, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02442856||21311|
NCT02440165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1353|Basic Care Revisited: Early Nutrition Intervention for Outpatients|Basic Care Revisited: an Early Nursing Nutrition Intervention for Outpatients in Need of Surgery|BCR_N|Radboud University|No|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02440165||21518|
NCT02484339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|α-RT|Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)|Phase II Open-label Study to Evaluate the Efficacy and Safety of Radium in Combination With External Beam Radiotherapy (EBRT) vs. EBRT Alone in the Treatment of Castration Resistant Prostate Carcinoma With Limited Bone Metastases|α-RT|University Hospital Freiburg|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|274|||Male|18 Years|85 Years|No|||June 2015|June 24, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02484339||18124|
NCT02427373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10701|A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil|A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil|KOMPARE|DSM Nutritional Products, Inc.|No|Completed|June 2014|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|66|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427373||22499|
NCT02438813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTOUR|Condition of Submental Fullness and Treatment Outcomes Registry|CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)|CONTOUR|Kythera Biopharmaceuticals|No|Recruiting|May 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients considering treatment to reduce SMF will be recruited from practices that see a        large number of aesthetic patients with a variety of issues, including SMF.|March 2016|March 11, 2016|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02438813|12 Weeks|21621|
NCT02430129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0741|Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With Anteromedial Osteoarthritis of the Knee|Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With Anteromedial Osteoarthritis of the Knee||Alberta Hip and Knee Clinic||Not yet recruiting|February 2016|August 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|40 Years|80 Years|No|||January 2016|January 5, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02430129||22287|
NCT02485106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS-SAH-001|Rifaximin Use in Severe Alcoholic Hepatitis|Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis||Saint Vincent's Hospital, Korea|No|Not yet recruiting|July 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|19 Years|75 Years|No|||June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485106||18065|
NCT02492217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversidadeNL|Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients|Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry||Universidade Nova de Lisboa|Yes|Recruiting|May 2015|August 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|75 Years|No|||August 2015|August 5, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02492217||17521|
NCT02436343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFHSRMREC/2015/OB/GYNAE/061|Cardiac Performance in Pregnant Obese Women:Are They in Jeopardy?|Cardiac Performance in Pregnant Obese Women:Are They in Jeopardy?||Benha University|No|Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|20 Years|35 Years|No|Probability Sample|Any pregnant woman in her 1st trimester with a singleton live healthy pregnancy will be        eligible for inclusion in the study. Eligible women will be further categorized into case        and control groups. Women with body mass index equals or more than 30kg/m2 will be        considered case. Control women will be with BMI equals or less than 25 kg/m2.|January 2016|January 16, 2016|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02436343||21811|
NCT02436356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141125|New Tools for Assessing Fracture Risk|New Tools for Assessing Fracture Risk||Vanderbilt University|Yes|Enrolling by invitation|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02436356||21810|
NCT02430454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43084815.0.0000.0068|Impact of Bed Availability and Cognitive Load on Intensive Care Unit Bed Allocation: a Vignette-based Clinical Trial|Vignette-based Randomized Controlled Trial of the Decision Making Process of Bed Allocation in the Intensive Care Unit: Impact of Bed Availability and Cognitive Load.||University of Sao Paulo General Hospital|No|Active, not recruiting|April 2015|June 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|178|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02430454||22263|
NCT02478359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPSC IRB 12345|Walk On! Physical Activity Coaching|Patient-Centered Physical Activity Coaching in COPD: A Pragmatic Trial||Kaiser Permanente|Yes|Enrolling by invitation|June 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1650|||Both|41 Years|N/A|No|||July 2015|July 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02478359||18584|
NCT02428920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-2004|Grenada Heart Project - Community Health Action to Encourage Healthy Behaviors|Grenada Heart Project - Community Health Action to Encourage Healthy Behaviors|GHP CHANGE|Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|18 Years|70 Years|No|||April 2015|April 24, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02428920||22380|
NCT02435381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30334|Carisbamate as a Potential Treatment for Alcohol Dependence|Carisbamate as a Potential Treatment for Alcohol Dependence||Baylor College of Medicine|Yes|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|10|||Both|18 Years|55 Years|No|||January 2016|January 11, 2016|September 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435381||21885|
NCT02435615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140009|Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis|Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis||University of Miami|Yes|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|N/A|No|Non-Probability Sample|Our study population is patients with suspected dengue fever living in Santo Domingo,        Dominican Republic.|November 2015|November 30, 2015|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435615||21867|
NCT02442492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00899|Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction|STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada)|STRIDER Canada|University of British Columbia|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||December 2015|December 10, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02442492||21339|
NCT02443701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1169-4661|Light Therapy and Electrical Stimulation on Functional Performance in Volleyball Athletes|Low Level Laser Therapy and Neuromuscular Electrical Stimulation on Knee Extension Strength and Jump in Volleyball Athletes: a Randomized Controlled Trial||Centro de Traumatologia do Esporte|Yes|Completed|July 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Anticipated|36|||Male|17 Years|18 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443701||21247|
NCT02493790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5S-DYSCO|Cognitive Dysfunction in COPD Patients : Role in the Performance of Cognitive-motor Dual Task Situation?|Impact of Cognitive Dysfunction in Chronic Obstructive Pulmonary Disease on Performance in Cognitive-motor Dual Task Situation|DysCo|5 Santé|No|Active, not recruiting|October 2014|||June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|45|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|COPD patients, entered in a rehabilitation program in Clinique du Souffle were included|July 2015|July 7, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02493790||17400|
NCT02430584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-101-SAMPLES|Whole Blood Specimen Collection From Pregnant Subjects|Whole Blood Specimen Collection From Pregnant Subjects||Progenity, Inc.|No|Not yet recruiting|April 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Study will collect up to 50 mL of whole blood at one or more monthly clinic visits (≥25 days      apart) from pregnant women carrying a single fetus of 10 to 26 weeks of gestational age|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|GENDER: Female ETHNICITY: All ethnicities RACE: All races AGE: Subjects 18 years of age or        older|April 2015|April 29, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430584||22253|
NCT02427737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2CTOSUD2015|Comfort Talk and Economic Outcomes in MRI|Amelioration of Claustrophobia and Disruptive Patient Motion in MRI Imaging (Phase 2 Randomized Training of Sites)|ComfortTalk®|Hypnalgesics, LLC|Yes|Enrolling by invitation|April 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|12|||Both|N/A|N/A|No|||April 2015|April 27, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427737||22471|
NCT02427750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_40S|A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal®) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults.||Novartis|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|April 13, 2015||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT02427750||22470|
NCT02431520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/07|Patient Compliance to Self-collection for Detection of HPV-DNA|Patient Compliance to Self-collection for Detection of HPV-DNA in Cervical Cancer Prevention: A Clinical Trial||Oswaldo Cruz Foundation|No|Completed|May 2007|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Female|25 Years|59 Years|No|||May 2015|May 5, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02431520||22182|
NCT02431806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-11|Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder|A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder||Forest Laboratories|No|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|660|||Both|12 Years|17 Years|No|||March 2016|March 1, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431806||22160|
NCT02482857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA-dos|Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting|||Karolinska University Hospital|Yes|Active, not recruiting|December 2011|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02482857||18238|
NCT02483104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-488|Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer|A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer||AbbVie|Yes|Active, not recruiting|July 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|20 Years|99 Years|No|||March 2016|March 13, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483104||18219|
NCT02393508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-16748|The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population|The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population|ABC-TOP|University of Calgary|No|Enrolling by invitation|September 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02393508||25099|
NCT02377115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID|Risk Assessment for Postoperative Delirium|Risk Assessment for Postoperative Delirium: Derivation of a Self-Administered Tablet Computer-based Clinical Screening Tool|RAPID|University Hospital, Basel, Switzerland|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|65 Years|N/A|No|||November 2015|November 17, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02377115||26359|
NCT02377128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-15-WOMC|Ovarian Reserve Following Bilateral Salpingectomy Versus Tubal Ligation During Cesarean Section|||Wolfson Medical Center||Enrolling by invitation|March 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2015|July 21, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02377128||26358|
NCT02458300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBARRIX|Clinical Evaluation of the Response to Chest Physiotherapy in Children With Acute Bronchiolitis|FIBARRIX "Clinical Evaluation of the Response to Chest Physiotherapy in Infants With Acute Bronchiolitis"|FIBARRIX|Universidad Católica San Antonio de Murcia|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|1 Month|2 Years|No|||May 2015|March 1, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02458300||20126|
NCT02459860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1403-13904|Programa Esperanza (Project Hope): A Depression Program for Older Latinos With Chronic Medical Conditions|Programa Esperanza (Project Hope): A Depression Program for Older Latinos With Chronic Medical Conditions||University of Southern California|Yes|Active, not recruiting|January 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|55 Years|N/A|No|||July 2015|July 3, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02459860||20006|
NCT02388334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS 13-0227|Impact of Multiple Sclerosis From the Viewpoint of the Caregivers|Impact of Multiple Sclerosis From the Viewpoint of the Caregivers : Exploring Their Quality Of Life and Their Expectations Concerning the Quality of Professional Management|AQUASEP|Rennes University Hospital|Yes|Not yet recruiting|March 2015|June 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|730|||Both|18 Years|N/A|No|Non-Probability Sample|Natural caregivers of Multiple Sclerosis patients|March 2015|March 13, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388334||25496|
NCT02383771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Reversal of the Anti-platelet Effects of Ticagrelor|Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease|REVERSAL|The First Affiliated Hospital with Nanjing Medical University|No|Recruiting|March 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02383771||25847|
NCT02377401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117104|Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults|A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir After Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults||GlaxoSmithKline|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377401||26337|
NCT02377414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117168|Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women|A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women||GlaxoSmithKline|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||June 2015|July 30, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377414||26336|
NCT02458404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2014-03|Effects of Varied Estrogen Doses on Endometrial Receptivity|Effects of Varied Estrogen Doses on Endometrial Receptivity||Reproductive Medicine Associates of New Jersey|No|Recruiting|March 2015|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02458404||20118|
NCT02380807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL- 423|Effects of Dry Needling on Spinal Mobility and Trigger Points in Patients With Fibromyalgia Syndrome.|Effects of Dry Needling on Posture, Spinal Mobility and Trigger Points on Spinal Muscles in Patients With Fibromyalgia Syndrome.||Universidad de Almeria|No|Completed|March 2015|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02380807||26075|
NCT02384707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00448-31|Master Allergen Child Nutrition. Reintroduction of Small Doses|Reintroduction of Small Doses of Food in Allergic Children to Lightening the Elimination Diet.|MANOE|University Hospital, Angers|No|Recruiting|May 2011|December 2015|Anticipated|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|9 Months|16 Years|No|||November 2014|March 9, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02384707||25775|
NCT02387892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-14-01-P2|Fortified Cheese and Yogurt Products and Vitamin D Status in Young Children? Phase 2|Do Vitamin D Fortified Cheese and Yogurt Products Support Vitamin D Status and Functional Outcomes in Young Children? Phase 2|D-KIDS|McGill University|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|51|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387892||25530|
NCT02387905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0561|Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery|Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial||M.D. Anderson Cancer Center|Yes|Recruiting|March 2015|||March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387905||25529|
NCT02628405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU051417I|R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma|Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Academic and Community Cancer Research United|Yes|Not yet recruiting|December 2015|||November 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628405||7065|
NCT02641470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA9301_01|The Effect of DA9301 on Tablet Computer-Induced Asthenopia|Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans||DongGuk University|No|Completed|January 2014|||February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02641470||6062|
NCT02629822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439A-030|Safety and Efficacy of MK-1439A in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)|A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations|DRIVE BEYOND|Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02629822||6956|
NCT02635516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.01.01|Traumatic Brain Injury in Veterans and Near-Infrared Phototherapy|Treatment of Mild and Moderate Traumatic Brain Injury in Veterans Using Near-Infrared Phototherapy||Cerehealth Corp.|No|Completed|April 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|21 Years|50 Years|No|||December 2015|December 18, 2015|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635516||6520|
NCT02633436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJK201518|Research on the Role of SLC1A5 in the Development of Esophageal Cancer|Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer||Fourth Affiliated Hospital of Guangxi Medical University|Yes|Recruiting|December 2015|May 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|100|Samples With DNA|Tissue specimens of esophageal cancer patients will be collected and stored in liquid      nitrogen after operations|Both|18 Years|N/A|No|Probability Sample|Patients with histologically proven esophageal cancer|December 2015|December 16, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02633436||6679|
NCT02633449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EE1403F|Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS|Augmentation of Cognitive-Behavioral Psychotherapy With Prefrontal Direct Current Stimulation in Major Depression (Psychotherapy Plus)||Charite University, Berlin, Germany|Yes|Recruiting|February 2016|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|192|||Both|20 Years|65 Years|No|||February 2016|February 1, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633449||6678|
NCT02639208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-326|Novel Social Media Intervention For Older Br CA Patients|Improving Support for Older Patients Receiving Neo/Adjuvant Chemotherapy for Breast Cancer Using a Novel Social Media Intervention||Dana-Farber Cancer Institute|No|Recruiting|December 2015|December 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Female|60 Years|N/A|No|||December 2015|December 23, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639208||6236|
NCT02630108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015-146R|TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma|Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma||Shanghai Zhongshan Hospital|No|Recruiting|December 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02630108||6934|
NCT02640794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTE2|Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve.|Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)|ARTE|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02640794||6114|
NCT02640885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCB|The Foley's Catheter Balloon to the Bleeding From Placenta Previa|Use of Foley's Catheter Balloon Tamponade to Control Placental Site Bleeding Resulting From Placenta Previa During Cesarean Section||Assiut University|No|Completed|May 2015|November 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|20 Years|40 Years|No|||December 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02640885||6107|
NCT02641431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-01-2015|Brugada Syndrome: A New Treatment Approach Driven by Clinical Experience|Brugada Syndrome: A New Treatment Approach Driven by Clinical Experience|BRUGADA_I|IRCCS Policlinico S. Donato|No|Recruiting|June 2015|April 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02641431||6065|
NCT02636959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02550|A Postoperative Study on HVSI vs LVSI Treatment of Chronic Rhinosinusitis|High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial||University of British Columbia|No|Recruiting|December 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02636959||6409|
NCT02382523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32884 Acthar IgA Nephropathy|Acthar on Proteinuria in IgA Nephropathy Patients|Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria||Baylor College of Medicine|Yes|Recruiting|February 2015|January 2020|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382523||25943|
NCT02447432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200799|A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants|Study to Compare Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants||GlaxoSmithKline|Yes|Active, not recruiting|June 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|320|||Both|42 Days|76 Days|Accepts Healthy Volunteers|||September 2015|September 3, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02447432||20961|
NCT02388958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140295|Weight Changes During and After Pregnancy in Women With Gestational Diabetes|Weight Changes During and After Pregnancy in Women With Gestational Diabetes||Vanderbilt University|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All women receiving prenatal care at Vanderbilt University Medical Center who do not        already carry a diagnosis of type 1 or type 2 diabetes are screened for GDM between weeks        24-28 of pregnancy with a non-fasting 50-gram glucose tolerance test (GTT). Blood glucose        values greater than or equal to 140 on this screening test are considered positive. Women        with a positive screening test undergo a diagnostic fasting 100-gram 3-hour GTT. GDM is        diagnosed if a woman has 2 or more abnormal values on the 3-hour GTT (abnormal values are        fasting blood glucose greater than or equal to 95, 1-hour blood glucose greater than or        equal to 180, 2-hour blood glucose greater than or equal to 155 and/or 3-hour blood        glucose greater than or equal to 140). By reviewing the electronic medical record of women        with singleton pregnancies undergoing GTT on a weekly basis, we will identify women with        and without GDM.|March 2015|March 9, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388958||25448|
NCT02391194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVB620-C-001|Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery|A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery||Avelas Biosciences, Inc.|No|Recruiting|April 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|18 Years|N/A|No|||August 2015|August 13, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391194||25276|
NCT02379585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1145332|Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer|A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study)|STEFNE|Western Regional Medical Center|No|Terminated|January 2013|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 12, 2015||No|PI Decision|No||https://clinicaltrials.gov/show/NCT02379585||26169|
NCT02384928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-CT-2015-03|Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation|Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation: a Three-armed, Randomized, Double-blind Controlled Pilot Study||Jaseng Medical Foundation|No|Recruiting|September 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|September 9, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02384928||25758|
NCT02384941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-309-T1DM|Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|inTandem1|Lexicon Pharmaceuticals|Yes|Active, not recruiting|March 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384941||25757|
NCT02385877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00088601|Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines|Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET||University of Michigan|No|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|February 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385877||25685|
NCT02391064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/23|Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)|Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) - BICAFMS Study (Brief Cognitive Assessment in French MS Patients)|BICAFMS|University Hospital, Bordeaux|No|Recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|470|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02391064||25286|
NCT02385214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZMTG 03.12|MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma|A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma|MelmarT|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|December 2014|December 2029|Anticipated|December 2029|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02385214||25736|
NCT02385227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaVinci|Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes|A Proof-of-Concept Study to Characterize Biomarkers of Tobacco Exposure, Product Use, and Urge-to-Smoke Following Short-Term Exclusive and Dual Ad Lib Use of Electronic Cigarettes in a Controlled Clinical Setting||Lorillard Tobacco Company|Yes|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|105|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02385227||25735|
NCT02385240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-14-022|Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea|||Perrigo Company|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|552|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385240||25734|
NCT02387840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7314|Feasibility and Clinically Application of Magnetic Resonance Fingerprinting|Feasibility and Clinically Application of Magnetic Resonance Fingerprinting||Case Comprehensive Cancer Center|Yes|Recruiting|March 2015|January 2023|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|80|||Both|N/A|35 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387840||25534|
NCT02391233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN8409|Multimedia WORTH With Black Drug-Involved Women on Probation|Multimedia HIV/STI Prevention for Black Drug-Involved Women on Probation|E-WORTH|Columbia University|Yes|Not yet recruiting|May 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|420|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391233||25273|
NCT02391298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuffolkU|An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis|An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.||Suffolk University|No|Active, not recruiting|December 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02391298||25268|
NCT02390024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI13/02204|Influence of Patient/Ventilador Decoupling in Neurocognitive and Psychopathological Sequelae in ICU Patients|Influence of Persistent Patient / Ventilator Decoupling in Cognitive and Psychopathological Sequelae in Critically Ill Patients: A Multicenter Clinical and Mechanisticstudy|PVI-NCOG|Corporacion Parc Tauli|Yes|Recruiting|June 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|ICU patients undergoing mechanical ventilation and monitored with and advanced continuous        monitoring system.|February 2016|February 23, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02390024||25366|
NCT02390037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV PED 09|Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study|Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study|PFLEX|Medtronic Neurovascular Clinical Affairs||Active, not recruiting|March 2015|||December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Neuroradiologists and surgeons practice|January 2016|January 28, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02390037||25365|
NCT02388035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHAEREDS-2015|Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis|Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis||Nasser Institute For Research and Treatment|Yes|Completed|March 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|254|||Both|N/A|N/A|No|||June 2015|June 3, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388035||25519|
NCT02388048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC1215|Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia|A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Not yet recruiting|May 2015|November 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388048||25518|
NCT02388295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00023|AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients|A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy||AstraZeneca|Yes|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|30 Years|80 Years|No|||February 2016|February 29, 2016|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388295||25499|
NCT02378961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1169|Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection|A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection||Gilead Sciences|No|Completed|February 2015|January 2016|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|128|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378961||26217|
NCT02383212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2810-ONC-1423|Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies|A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies||Regeneron Pharmaceuticals|No|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|973|||Both|18 Years|N/A|No|||November 2015|January 7, 2016|February 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383212||25890|
NCT02386995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6060-BE|BIS and Entropy in Deep Brain Simulation|Comparison of Bispectral Index and Entropy Monitoring in Patients Undergoing Internalization of Deep Brain Simulation||University Health Network, Toronto|Yes|Completed|July 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a general anesthesia post DBS insertion for the internalization of DBS.|March 2015|March 6, 2015|November 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02386995||25599|
NCT02390102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICURE|Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement|Combined ErythroPoietin and Iron Therapy for AnemiC Patients With Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve REplacement- The EPICURE Trial A Prospective Double Blind Randomized Trial|EPICURE|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Recruiting|June 2012|June 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||March 2015|March 16, 2015|January 21, 2013||No||No||https://clinicaltrials.gov/show/NCT02390102||25360|
NCT02390115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|966.636|Effects of Elastic Tape in Shoulder Movements in Hemiparetic Subjects|Effects of Elastic Tape in Proprioception and Performance of Shoulder Movements in Chronic Hemiparetic Subjects||Universidade Federal de Sao Carlos|No|Active, not recruiting|March 2015|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02390115||25359|
NCT02449005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELKE-90467|Transplantation of Autologous Bone Marrow Mesenchymal Stem Cells for the Regeneration of Infrabony Periodontal Defects|A Phase I/II Double-Blind Randomised Controlled Clinical Trial To Study The Safety and Efficacy Of A Novel Regenerative Treatment Of Infrabony Periodontal Defects Using Autologous Bone-Marrow Mesenchymal Stem Cells (BM-MSCs).|PerioRegen|Aristotle University Of Thessaloniki|No|Recruiting|January 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 2, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449005||20840|
NCT02383459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPALINE|Observatory of Food Preferences in Infants and Children|Longitudinal Study of Food Liking in Eatrly Childhood||Centre des Sciences du Goût et de l'Alimentation|No|Completed|January 2005|July 2011|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|319|Samples Without DNA|Saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|March 2015|March 6, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383459||25871|
NCT02387151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4724400013|Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients|Safety of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients|Neptune|Leiden University Medical Center|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387151||25587|
NCT02390193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368856/2010|Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease|Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease||University of Nove de Julho|Yes|Enrolling by invitation|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|52|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390193||25353|
NCT02377804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBMA-URJC|Dry Needling for Spasticity in Stroke|Changes in Spasticity, Range of Motion and Pressure Pain Sensitivity in Patients With Stroke After the Application of Dry Needling in the Shoulder Musculature||Universidad Rey Juan Carlos|Yes|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|65 Years|No|||April 2015|April 5, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02377804||26306|
NCT02381938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2438|Care2BWell: Worksite Wellness for Child Care|Care2bWell: A Worksite Physical Activity & Wellness Program for Child Care Staff||University of North Carolina, Chapel Hill|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|416|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02381938||25988|
NCT02385942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1206/158-001|KT(KT Corporation)-SNUBH(Seoul National University Bundang Hospital) U-health Cooperative Research|KT-SNUBH U-health Cooperative Research: Target Selection and Consumers' Intention Research for Commercialization of the Pressure Ulcer Management u-Health Solution||Seoul National University Hospital|No|Completed|July 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|60|||Both|21 Years|N/A|No|||March 2015|March 10, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02385942||25680|
NCT02392897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8292|theFRESHstudy: FRequency of Eating and Its Influence on Satiety and Health|Eating Frequency and Its Influence on Satiety and Biomarkers of Health & Disease||Fred Hutchinson Cancer Research Center|No|Recruiting|April 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02392897||25146|
NCT02376725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R796/80/2010|Comparing Phaco/IOL Versus Phaco/IOL + Goniosynechialysis in Subjects With PACG|A Randomized Clinical Trial Comparing Phacoemulsification and Goniosynechialysis With Phacoemulsification Alone in the Management of Primary Angle Closure||Singapore National Eye Centre|Yes|Completed|June 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|30 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02376725||26389|
NCT02378155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF I|Cerebral Oxygen Saturation Measurement During Cardioversion Because of Atrial Fibrillation|||Hasselt University|No|Completed|February 2015|||June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02378155||26279|
NCT02386215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3040|The Use of HIV Self-tests to Promote Partner and Couples Testing: a Randomized Trial|The Use of HIV Self-tests to Promote Partner and Couples Testing: a Randomized Trial||University of North Carolina, Chapel Hill|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|600|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386215||25659|
NCT02378285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArthrexFR-001|Treatment of Epicondylitis by Ultrasound-guided Local Injections of PRP (Platelet Rich Plasma)|Treatment of Epicondylitis by Ultrasound-guided Local Injections of Autologous Conditioned Plasma (ACP®): a Double-blind Placebo-controlled Randomized Clinical Trial With One-year Follow-up||Arthrex SAS|No|Completed|October 2010|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|35 Years|65 Years|No|||February 2015|February 26, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378285||26269|
NCT02376738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REAL-CAD|Regional Activation of Leukocytes in Coronary Artery Disease|Regional Activation of Leukocytes in Coronary Artery Disease|REAL-CAD|Sint Franciscus Gasthuis|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|75 Years|No|Probability Sample|Patients undergoing coronary angiography|February 2015|February 25, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02376738||26388|
NCT02387164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiAPREV/2014|Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies|Double-blind, Investigator-initiated Study to Determine the Effect of Alum-GAD (Diamyd) in Combination With Vitamin D3 on the Progression to Type 1 Diabetes in Children With Multiple Islet Autoantibodies|DiAPREV-IT2|Lund University|Yes|Enrolling by invitation|March 2015|March 2022|Anticipated|March 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|4 Years|18 Years|No|||March 2016|March 9, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02387164||25586|
NCT02388022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC13-005-PL_A|A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.|A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.||Globus Medical Inc|No|Active, not recruiting|January 2014|March 2015|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Both male and female between the ages of 18 and 80 with objective evidence of degenerative        disc disease between L2 and S1 at 1-2 contiguous levels.|March 2015|March 12, 2015|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388022||25520|
NCT02388633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDL Apheresis|Acute Microvascular Changes With LDL Apheresis|||Oregon Health and Science University|Yes|Recruiting|March 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|19 Years|N/A|No|Probability Sample|Patients with hyperlipidemia undergoing clinically indicated LDL apheresis|October 2015|October 23, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388633||25473|
NCT02378766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 14.342|Evaluation of Web-based Interventions to Support People Living With HIV in the Adoption of Health Behaviors|Evaluation of a Tailored Virtual Intervention as an Instrument of Prevention and Support to Improve the Health of PLHIV and Reduce Comorbidity Associated With HIV (MP-02-2015-5853)|LHIVEHEALTHY|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|750|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02378766||26232|
NCT02388256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2014-012|Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection|Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection||Korean Medicine Hospital of Pusan National University|No|Recruiting|March 2015|April 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02388256||25502|
NCT02383147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-ORL-KT-001|Efficacy Study for Development and Use of Neurofeedback-trainings for Patients Suffering From Chronic Tinnitus|A Monocentric Study for Development and Use of Tomographic Neurofeedback Protocols for Patients Suffering From Chronic Tinnitus||University of Zurich||Enrolling by invitation|March 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|75 Years|No|||June 2015|June 11, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02383147||25895|
NCT02386072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-MA-1006|A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)|A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB)|PERSPECTIVE|Astellas Pharma Inc|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Sites that include medical specialties involved in the treatment of OAB, such as general        practice/internal medicine, nurse practitioners, obstetricians/ gynecologists, urologists,        and uro-gynecologists|March 2016|March 17, 2016|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02386072||25670|
NCT02382965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tFUS_deepbrain|Ultrasound in Deep Brain Stimulation|Transcranial Focused Ultrasound for Deep Brain Stimulation in Humans||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|May 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382965||25909|
NCT02381457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-024-NPT|SNP-based Microdeletion and Aneuploidy RegisTry (SMART)|SNP-based Microdeletion and Aneuploidy RegisTry|SMART|Natera, Inc.|No|Recruiting|April 2015|November 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|-  Maternal residual blood sample        -  Placental tissue        -  Child dried blood spot        -  Child buccal sample|Female|18 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|October 2015|October 15, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381457|2 Years|26025|
NCT02381756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01641-46|Ultrasound and Left Ventricular Systolic Function|Ultrasound Evaluation of the Left Ventricular Systolic Function in Intensive Care Unit.|EFESE|Fondation Ophtalmologique Adolphe de Rothschild|No|Suspended|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients intubated and ventilated|October 2015|January 7, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381756||26002|
NCT02379143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Practice of the Short Wave Diathermy (SWD) Application|A Probe Into Practice of the Short Wave Diathermy (SWD) Application in Private Physiotherapy Clinics: a Survey From Ethical Practice & Safety Perspective.||TPCT's Terna College of Physiotherapy|Yes|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|49|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|49 PRACTICING PHYSICAL THERAPIST IN PRIVATE CLINICS|February 2015|February 26, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02379143||26203|
NCT02389387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00079596|Reducing Disparities in Access to Kidney Transplantation (RaDIANT) Regional Study|Reducing Disparities in Access to Kidney Transplantation: The RaDIANT Regional Study||Emory University|No|Enrolling by invitation|March 2015|June 2021|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389387||25415|
NCT02392780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009-15-RMC|Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease|Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease||Rabin Medical Center|Yes|Not yet recruiting|April 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392780||25155|
NCT02392793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMNIRN|Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies|A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies||St. Jude Children's Research Hospital|No|Recruiting|March 2015|March 2020|Anticipated|October 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Months|25 Years|No|||December 2015|December 1, 2015|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392793||25154|
NCT02392806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU Protocol # 24949|Comparative Effectiveness Study of Bubble CPAP Devices in the NICU|Comparative Effectiveness Study of Bubble CPAP Devices in the NICU||St. Louis University|No|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|100 Days|No|||October 2015|October 22, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392806||25153|
NCT02449746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609/M/C/1368|Study of Immunotherapy in Autoantibody Positive Psychosis|An Unblinded Study of the Feasibility of Plasmapheresis or Intravenous Immunoglobulin, Combined With Corticosteroids, in Patients With Acute Psychosis Associated With Anti-neuronal Membrane Auto-antibodies|SINAPPS-1|University of Cambridge|No|Recruiting|August 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|10|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449746||20783|
NCT02384694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-033|Effects of a Zumba Dance Program for Postmenopausal Women With Metabolic Syndrome|ZumBeat: Effekte Eines Rhythmusorientierten Aeroben Tanz-Bewegungsprogrammes für Postmenopausale Frauen Mit Metabolischem Syndrom|ZumBeat|University of Basel|Yes|Completed|May 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|45 Years|65 Years|No|||March 2015|March 4, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02384694||25776|
NCT02388074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODA-002|Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer||bioAffinity Technologies Inc.|Yes|Completed|March 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|March 4, 2015||No||No|May 5, 2015|https://clinicaltrials.gov/show/NCT02388074||25516|
NCT02381431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000265|Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India|Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India||Massachusetts General Hospital|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|18 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381431||26027|
NCT02459873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01767|Modeling and Testing Change in Mental Abilities in Childhood|Modeling and Testing Change in Mental Abilities in Childhood Through Computer-based Interventions||University of Southern California|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|84 Months|132 Months|Accepts Healthy Volunteers|||May 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02459873||20005|
NCT02445690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP|Thrombin Generation in Crohn's Disease|Correlation Between Thrombin Generation and Endoscopic Activity in Crohn's Disease||University of Sao Paulo General Hospital|Yes|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|5ml of plasm|Both|18 Years|N/A|No|Probability Sample|Patients with established Crohn's disease with stable treatment and clinical remission|May 2015|October 5, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02445690|12 Months|21094|
NCT02391883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOP-HIPFX study|Hip-Fracture Surgery on Patients in Clopidogrel Therapy|||Hvidovre University Hospital|Yes|Completed|January 2011|February 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|356|||Both|N/A|N/A|No|Non-Probability Sample|A total of 356 patients were included in the final analysis. Out of this group we        identified 36 patients taking Clopidogrel. 24 of these were in DAPT. 12 patients were in        Clopidogrel therapy alone. The indications for treatment were: CNS thrombosis (n=14);        Unstable Angina (n=8); Peripheral Atherosclerosis (n=3); Myocardial Infarction (n=2);        Insertion of stent >24 months earlier (n=1); and Unknown indication (n=8). All patients        had their treatment discontinued on admission.        All analyzed patients were operated within 24 hours of admission (n=356).|March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391883||25224|
NCT02387632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-079|Airway Pressure During Humidified High Flow Nasal Cannula Therapy in Children|Airway Pressure During Humidified High Flow Nasal Cannula Therapy in Children||McMaster University|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|18 Years|No|Probability Sample|Children under 18 years, admitted to PCCU, who require respiratory support using HHFNC, as        determined by the caring physician; and informed consent of substitute decision maker will        be included in the study.|November 2015|March 14, 2016|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02387632||25550|
NCT02387645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1237/2014|LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma||LUDEC|Medical University of Vienna|No|Recruiting|May 2014|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|18 Years|80 Years|No|||March 2015|March 12, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02387645||25549|
NCT02381717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000304|Ultrasound Guided Femoral Nerve Block|Comparison of Ultrasound Guided Femoral Nerve Blockade and Standard Parenteral Opioid Pain Management Alone in Patients With Hip Fracture in the Emergency Department||Beth Israel Deaconess Medical Center|Yes|Recruiting|August 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|101 Years|No|||September 2015|September 29, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02381717||26005|
NCT02459899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-206-T1DM|Dose-ranging Study in Patients With Type 1 Diabetes Mellitus|A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study in Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|inTandem4|Lexicon Pharmaceuticals|Yes|Recruiting|July 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459899||20003|
NCT02459912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15009|Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer|Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer in Potent Men: A Prospective, Phase II Trial|POTENT-C|Winthrop University Hospital|Yes|Recruiting|April 2015|September 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Male|40 Years|69 Years|No|||December 2015|December 8, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02459912||20002|
NCT02385006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.727|Thromboelastography and Pancreas-kidney Transplantation|Thromboelastographic Profile During Simultaneous Pancreas-kidney Transplantation|TEG-PKT|Hospices Civils de Lyon|Yes|Completed|February 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Actual|152|||Both|18 Years|N/A|No|||March 2013|March 4, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02385006||25752|
NCT02629978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-YY-006|Radiofrequency Ablation of Malignant Pulmonary Nodules|Efficacy and Safety of Radiofrequency Ablation of Malignant Pulmonary Nodules||Chinese PLA General Hospital|No|Active, not recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|No|||October 2015|December 14, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02629978||6944|
NCT02632565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA08/83|Intra-Articular 0.5 % Lidocaine Injection for Osteoarthritis|Intra-Articular 0.5 % Lidocaine Injection Under Ultrasound Guidance in Chronic Knee Pain Due To Osteoarthritis||Baskent University|No|Completed|December 2009|August 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632565||6746|
NCT02629835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MontrealGH|Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks|A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks||Montreal General Hospital|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629835||6955|
NCT02628301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2014DES001|Microvascular Dysfunction and the Development of Whole-body Insulin Resistance|Is Microvascular Dysfunction an Early Phenomenon in the Development of Skeletal Muscle Insulin Resistance? A Dietary Intervention Study in Healthy Men|DESIRE|VU University Medical Center|Yes|Recruiting|December 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|34|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02628301||7073|
NCT02628795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD084124|Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement|Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement|TWEAK|University of Alabama at Birmingham|Yes|Recruiting|April 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|40 Years|80 Years|No|||December 2015|December 11, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02628795||7035|
NCT02636491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-01|Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D)|Open-label, 3 Center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of 60 Hours Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy at T1D Patients at Home|DREAM5|Kinderkrankenhaus auf der Bult|Yes|Recruiting|December 2015|October 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|10 Years|65 Years|No|||February 2016|February 26, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636491||6445|
NCT02636660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)136/2011|Health-related Quality of Life and Nursing-sensitive Outcomes in Mechanically Ventilated Patients|Health-related Quality of Life and Nursing-sensitive Outcomes in Mechanically Ventilated Patients in an Intensive Care Unit||Hospital Universitari Vall d'Hebron Research Institute||Completed|June 2012|December 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|184|||Both|18 Years|N/A|No|Non-Probability Sample|All mechanically ventilated patients admitted to our intensive care unit that fulfill the        inclusion criteria.|December 2015|December 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02636660||6432|
NCT02628678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G006-HU-PD|A Study to Evaluate the Effect of Diet on the Tolerability of FOS in Healthy Volunteers|An Open-label Study to Evaluate the Effect of Diet on the Tolerability of FOS, a Commercially Available Prebiotic, in Healthy Volunteers||Kaleido Biosciences||Active, not recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02628678||7044|
NCT02634138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2036|Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia|Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia|CLI|Imperial College London|Yes|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02634138||6625|
NCT02634151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-301|Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on High-Intensity Stable StatinTherapy (ROYAL-1)|A Phase 2 Randomized, Double-Blind, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Hypercholesterolemia on a High Intensity Stable Statin Therapy (ROYAL-1)||Gemphire Therapeutics, Inc.|No|Not yet recruiting|May 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|212|||Both|18 Years|N/A|No|||December 2015|March 12, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634151||6624|
NCT02640898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH201510|Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer|the Ethic Committee of Shanghai First Hospital||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|December 2015|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02640898||6106|
NCT02640963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO 1823|Feasibility and Benefits of Group Based Exercise in Residential Aged Care Adults|Feasibility and Benefits of Group Based Exercise in Residential Aged Care Adults: a Pilot Study for the GrACE Programme||Bond University|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|37|||Both|65 Years|100 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640963||6101|
NCT02391922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1844(REK)|Better First Aid With First Aid Training and Dispatcher Central Instructions?|Bedre førstehjelp Med førstehjelpstrening og AMK-veiledning?||University of Tromso|No|Suspended|October 2014|March 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|December 31, 2014||No|Pilot completed as per protocol. Suspended while pilot is evaluated|No||https://clinicaltrials.gov/show/NCT02391922||25221|
NCT02632045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP9506|Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer|A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer||Columbia University|Yes|Recruiting|March 2016|December 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632045||6786|
NCT02644421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P-002050|Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica)|Phase Ib Randomized, Double-Blind, Latin Square Crossover, Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 v. Lidocaine v. Placebo in Lumbar Radiculopathy|LMR|Brigham and Women's Hospital|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644421||5835|
NCT02644434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China_NCCD|Conventional Versus Intentional StraTegy in Lesions With High Risk PrEdiction of Side Branch OccLusion in InterVEntion|A Randomized Comparison of Conventional Versus Intentional StraTegy in Patients With High Risk PrEdiction of Side Branch OccLusion in Coronary Bifurcation InterVEntion: the CIT-RESOLVE Trial|CIT-RESOLVE|China National Center for Cardiovascular Diseases|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|566|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02644434||5834|
NCT02388503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1946|The Effect of a Natural Extract on the Post-prandial Blood Glucose Response After Bread Consumption: a Dose-response of Efficacy|The Effect of a Natural Extract on the Post-prandial Blood Glucose Response After Bread Consumption: a Dose-response of Efficacy||Unilever R&D|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02388503||25483|
NCT02451345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14557|Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model|Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)||University of California, San Francisco|Yes|Recruiting|March 2015|April 2025|Anticipated|April 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Male|18 Years|N/A|No|||December 2015|December 3, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451345||20660|
NCT02377843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1873|Making Effective Human Papillomavirus (HPV) Vaccine Recommendations|Making Effective HPV Vaccine Recommendations||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02377843||26303|
NCT02380664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP2011-29093|Swimming Training Repercussion on Metabolic and Structural Bone Development; Benefits of the Incorporation of Whole Body Vibration or Plyometric Training: The RENACIMIENTO Project|Swimming Training Repercussion on Metabolic and Structural Bone Development; Benefits of the Incorporation of Whole Body Vibration or Plyometric Training. The RENACIMIENTO Project||Universidad de Zaragoza||Active, not recruiting|January 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|180|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380664||26086|
NCT02384616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 14-039|Hyperoxygenation in Anesthetized Children|Impact of Intraoperative High Inspired OXygen Fraction on Pulmonary Function, Surgical Site Infection, Postoperative Nausea and Vomiting in PEDiatric Anesthesia, the OXPED Study|OXPED|University Hospital, Geneva|No|Not yet recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|4 Years|16 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02384616||25782|
NCT02387515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILOT2013TM01|Technology-supported Exercise Therapy for Patients With Chronic Low Back Pain|Technology-supported Exercise Therapy for Patients With Chronic Low Back Pain: Pilot Study||Hasselt University|No|Active, not recruiting|December 2013|September 2015|Anticipated|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02387515||25559|
NCT02387528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP639061|Mindfulness, Burnout, Physical and Psychological Well-being of Primary Health Care Professionals|Mindfulness, Burnout, Physical and Psychological Well-being of Primary Health Care Professionals: a Randomized and Controlled Trial.|MINDFULNESS|Federal University of São Paulo|No|Enrolling by invitation|September 2014|December 2016|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 26, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02387528||25558|
NCT02386917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2379|Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers|Impact of Body Weight, Low Calorie Diet and Gastric Bypass on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers|COCKTAIL|The Hospital of Vestfold|No|Recruiting|March 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02386917||25605|
NCT02386930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032013-07|Behavioral Lifestyle Intervention Study (BLIS) in Patients With Type 2 Diabetes in UAE: A Randomized Controlled Trial in Real Life Setting|||Rashid Centre for Diabetes and Research|No|Completed|July 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|No|||March 2015|March 7, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02386930||25604|
NCT02379845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBTXR3-301|NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall|MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)||Nanobiotix|Yes|Recruiting|February 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02379845||26149|
NCT02379858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO24196|Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair|Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair: A Single-Center, Randomized, Double-Blind, Trial of Alvimopan and Placebo||Medical College of Wisconsin|Yes|Recruiting|July 2015|July 2022|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02379858||26148|
NCT02387762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-RA-001|ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate|A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate||Acerta Pharma BV|Yes|Recruiting|April 2015|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||November 2015|November 4, 2015|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387762||25540|
NCT02393027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO14-MJR / LBT-999|Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999|Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999|LBT 999|University Hospital, Tours|Yes|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||February 2015|April 7, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02393027||25136|
NCT02377089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-2-0125|Neuromodulation for Post-Traumatic Stress Disorder|Neuromodulation as a New Treatment for Post-Traumatic Stress Disorder in Veterans: Evaluating the Effectiveness of Trigeminal Nerve Stimulation||University of California, Los Angeles|Yes|Recruiting|May 2015|||September 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|21 Years|65 Years|No|||January 2016|January 26, 2016|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02377089||26361|
NCT02391090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUG-FeNO-2013|FeNO After Hypoxia in Asthma Patients|Effects of Intermittent Hypoxia on the Asthmatic Inflammation of Asthma Patients - a Pilot Study||Medical University of Graz|Yes|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02391090||25284|
NCT02377232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1976|Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care|Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care|CRCSreening|University of Colorado, Denver|No|Recruiting|February 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|500|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377232||26350|
NCT02383225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1641|Culturally Grounded Early Substance Use Prevention for American Indian Families|Culturally Grounded Early Substance Use Prevention for American Indian Families||University of Colorado, Denver|Yes|Recruiting|March 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|832|||Both|10 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02383225||25889|
NCT02391311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K99AG048762|A Novel Neurorehabilitation Approach for Cognitive Aging With HIV|Speed of Processing Training With Transcranial Direct Current Stimulation in Older HIV+ Adults (HtDCS)|HtDCS|University of Alabama at Birmingham|Yes|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|50 Years|N/A|No|||February 2016|February 14, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02391311||25267|
NCT02391402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1189-I|Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD|Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD|CABA|VA Office of Research and Development|No|Recruiting|May 2015|March 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02391402||25260|
NCT02391142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSB-CHF|Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure|Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure|CSB-CHF|First Affiliated Hospital of Harbin Medical University|No|Active, not recruiting|June 2014|January 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|70 Years|No|||May 2014|March 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391142||25280|
NCT02385760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-4430-AV-201|CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris|A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris||Celtaxsys, Inc.|No|Active, not recruiting|April 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|16 Years|44 Years|No|||February 2016|February 10, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385760||25694|
NCT02385994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-14-EN01|A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin|A Prospective Multi-Center Study of a Novel Dual-Wavelength, Dual-Pulse Duration Laser for the Treatment of Melasma and Lentigines in Asian Skin||Cutera Inc.|No|Enrolling by invitation|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|No|||September 2015|September 9, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385994||25676|
NCT02387593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END-1302-14/15-1|Usefulness of Endocuff in the Adenoma Detection Rate. Comparative Study|Usefulness of Endocuff in the Adenoma Detection Rate. A Randomized Clinical Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||Recruiting|September 2014|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|March 12, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387593||25553|
NCT02387827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-104|Comparing of Long Bout and Short Bouts of Similar Volume of Walking in Obese on Weight Loss During a Weight Loss Program|||Novindiet Clinic|No|Enrolling by invitation|February 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387827||25535|
NCT02391415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPM1002-ZA-2.13TB|Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa|Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants||Serum Institute of India Limited|Yes|Recruiting|June 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Anticipated|416|||Both|N/A|12 Days|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02391415||25259|
NCT02391207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-SparingHx|Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence|Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence: Validation on Intention-to-treat Analysis of a IOUS-guided Approach||University of Milan|No|Completed|January 2009|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|28 Years|79 Years|No|Probability Sample|Patiens undergoing hepatectomy for primary and secondary liver tumors|March 2015|March 17, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02391207||25275|
NCT02382094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-PC-QLS 2004|Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy|||Karolinska University Hospital|Yes|Completed|June 2005|July 2012|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|110|||Male|N/A|N/A|No|||March 2015|March 5, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02382094||25976|
NCT02388373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR00213|A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down|A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down||Research in Real-Life Ltd||Active, not recruiting|July 2014|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|224|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02388373||25493|
NCT02385890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:114-5|PERFECT Project - Part 1 - Study 3|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 3||University of Manitoba||Active, not recruiting|March 2015|July 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02385890||25684|
NCT02446769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1426-BBACK-MS|A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD|A Pilot, Multi-Center, Randomized, Open-Label, Parallel Group Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD|STOP-BBACK|Philips Respironics|Yes|Not yet recruiting|February 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446769||21011|
NCT02388581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2214|First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL|Multicentre, Prospective Study of First-line Antibiotic Therapy for Early-stage H. Pylori-Positive Gastric Pure (de Novo) Diffuse Large B-cell Lymphoma and Potential Predicting Factor for Treatment Outcome||National Health Research Institutes, Taiwan|Yes|Recruiting|December 2014|December 2024|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||December 2015|March 23, 2016|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02388581||25477|
NCT02388594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-728mR|A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients|A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 Delta-32 Mutation, Pre-treated With Cyclophosphamide||University of Pennsylvania|Yes|Recruiting|February 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388594||25476|
NCT02378025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAY0001AGG|Treating Chronic Pain in Gulf War Illness|A Multimodal Evaluation of the Comparative Efficacy of Yoga Versus a Patient Centered Support Group for Treating Chronic Pain in Gulf War Illness||Palo Alto Veterans Institute for Research|No|Recruiting|October 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|42 Years|85 Years|No|||October 2015|October 1, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378025||26289|
NCT02378038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNT2258-04-Richter's|PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)|A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)||ProNAi Therapeutics, Inc|Yes|Recruiting|August 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378038||26288|
NCT02380833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2014-457|Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, in Women.|The Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, on Physical Conditioning in Women: a Randomized Controlled Trial.||Clemson University|No|Recruiting|April 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|40|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02380833||26073|
NCT02381067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2015-01-01|A Prospective Study of NuCel® in Cervical Spine Fusion|A Prospective, Efficacy Study of NuCel® in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Cervical Spine||NuCel, LLC|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||October 2015|October 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381067||26055|
NCT02382211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US OI 124|T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays|A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T Cell-mediated Acute Graft Rejection|PROTECT|Oxford Immunotec|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|75 Years|No|Non-Probability Sample|Active candidate for a kidney transplant. Age equal to or greater than 18 years.        Male or female.|February 2016|February 10, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02382211||25967|
NCT02447094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.044|Quality of Life After Stroke Using a Telemedicine-based Stroke Network|Assessing the Impact of Care in A Telemedicine-based Stroke Network Using Patient-Centered Health Related Quality of Life Outcomes|STROKE TeleQOL|Thomas Jefferson University|No|Recruiting|February 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|This research will be performed only in AIS patients who are routinely admitted to our        "Hub" and participating "spoke" centers.|February 2016|February 8, 2016|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02447094||20986|
NCT02382614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13|Spiration Valves Against Standard Therapy|Safety and Effectiveness of the Spiration Valve System (SVS) in Air Leaks|VAST|Spiration, Inc.|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382614||25936|
NCT02381314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA271-02|Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer|A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non Small Cell Lung Cancer, and Other B7H3 Expressing Cancers||MacroGenics|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381314||26036|
NCT02392481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2087|Asthma Biomarker Study|An Exploratory, Prospective, Non-interventional Study Comparing Biomarker Signatures Between Patients With Asthma and Healthy Volunteers and to Investigate Biomarkers Associated With Known Phenotypes Across Asthma Severities||Boehringer Ingelheim||Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|85|Samples With DNA|Blood and sputum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthma and healthy subject|March 2016|March 21, 2016|March 18, 2015||||No||https://clinicaltrials.gov/show/NCT02392481||25178|
NCT02447380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-168|Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment|||Samsung Medical Center|No|Not yet recruiting|September 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|20 Years|No|||September 2015|September 15, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447380||20965|
NCT02447393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111580|Phase 1 Study of Levocetirizine|A Single Blind, Randomized, Cross-over Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and Parallel Study to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and Cetirizine, Following||GlaxoSmithKline||Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|20|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT02447393||20964|
NCT02378597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-524|Resiliency Program for Medical Interpreters|Developing a Resiliency Program for Medical Interpreters in Cancer Care|CARE|Massachusetts General Hospital|No|Completed|January 2014|June 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2015|March 3, 2015|June 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02378597||26245|
NCT02378610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP14_CarolineLinninge|Relationship Between the Gut Microbiota and Stress|Relationship Between the Gut Microbiota and Stress||Lund University|No|Active, not recruiting|February 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|130|Samples With DNA|Fecal samples|Male|19 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Men, 19-35 years old.|March 2016|March 3, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378610||26244|
NCT02385812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10007822|Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma|Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma||University of Calgary|No|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02385812||25690|
NCT02385825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-03|IM Recombinant Ricin Toxin Vaccine (RVEc) — 3-Dose Primary Series With Boost|Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster||U.S. Army Medical Research and Materiel Command|No|Not yet recruiting|April 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385825||25689|
NCT02385838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutrinet SM1|Impact of Nutrition Labels on Consumer Purchasing Intentions|Impact of Different Front-of-pack Nutrition Labels on Consumer Purchasing Intentions: Randomized Trial in the NutriNet-Santé Study||University of Paris 13||Enrolling by invitation|December 2014|June 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|5||Anticipated|13000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02385838||25688|
NCT02382744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02912|Saphenous Nerve Block for Foot and Ankle Surgery|A Comparison of Ultrasound-Guided and Ultrasound-Guided With Nerve Stimulation Saphenous Nerve Blockade Utilizing the Transsartorial Approach||University of British Columbia|No|Recruiting|February 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02382744||25926|
NCT02387307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rSIFN-01|A Study of rSIFN-co in Subjects With Advanced Solid Tumors|A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer|rSIFN-01|Sichuan Huiyang Life Science and Technology Corporation|No|Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|21 Years|N/A|No|||December 2015|December 10, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02387307||25575|
NCT02451618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epidermal Electronics|Novel Epidermal Recording and Detection of Seizures|A Pilot Study of Seizure Detection in Neonates Using Multimodal Temporary Epidermal Electronics|NERDS|Sharp HealthCare|No|Recruiting|May 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Any newborn admitted to the NICU that requires an EEG for clinical care. Must be less than        or equal to 44 weeks corrected gestational age.|May 2015|May 21, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02451618||20639|
NCT02386644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Transperineal Ultrasonography and Premature Rupture of Membranes|Premature Rupture of Membranes Assessment Via Transperineal Ultrasonography as an Alternative to Speculum Examinations||Ankara University|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|105|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 11, 2015|February 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02386644||25626|
NCT02386657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Edu|Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department|Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department||Brugmann University Hospital|No|Active, not recruiting|November 2012|March 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Sickle Cell Disease patients, entering the Emergency Department of the Brugmann Hospital        for a vaso-occlusive crisis.|July 2015|July 23, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02386657||25625|
NCT02389218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1113|A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF|A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation|METACSA|University Hospital, Ghent|Yes|Not yet recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|167|||Both|21 Years|75 Years|No|||March 2015|March 16, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02389218||25428|
NCT02387463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY008|Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients|Efficacy of Extended Peginterferon Alpha 2a(PEG-IFN a-2a) Treatment in HBeAg Positive Chronic Hepatitis B Patients||Beijing Ditan Hospital|No|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|60 Years|No|Non-Probability Sample|the population in this cohort study was composed of HBeAg positive chronic hepatitis B        patients defined as HBsAg positive, HBeAg positive, and detectable HBV DNA load with ALT        level ≥41 U/L for more than 6 months.|March 2015|March 12, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02387463||25563|
NCT02388529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIHF-202|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure|A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction||Stealth BioTherapeutics Inc.|Yes|Withdrawn|May 2015|October 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02388529||25481|
NCT02388542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGRESS-IND-1022015|Effect of Peer-mentor Mediated Interventions on Cardiovascular Risk Factors at Worksites|Policy and Peer Mentor Intervention Programs on Cardiovascular Disease at Small to Medium Sized Worksites in 3 South Asian Countries - a Pilot Study for a Definitive Large International Cluster Randomized Trial|PROGRESS|St. John's Research Institute|No|Not yet recruiting|May 2015|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3000|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||January 2015|March 9, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388542||25480|
NCT02383680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS_2014_01|Yellow Fever Vaccination Under Low Dose Methotrexate Therapy|Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study|MTX_YF|University of Zurich|No|Recruiting|December 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Serum|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Travelers seeking pre-travel advice with an indication for yellow fever vaccination will        be addressed in 6 Swiss Travel Clinics of the Cantonal Hospital Aarau, the University        Hospital in Bern, the University of Zurich, teh University Hospital of Geneva and the        Swiss Tropical and Public Health Instutute in Basel|March 2015|March 3, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02383680||25854|
NCT02377310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography|A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography: The VERIFY 2 Study|VERIFY2|Golden Jubilee National Hospital|No|Completed|September 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients undergoing FFR assessment for standard clinical indications.|August 2015|August 11, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377310||26344|
NCT02376829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRF-002|Class II Correction Study Using the Invisalign System|Class II Correction Study Using the Invisalign System||Align Technology, Inc.|No|Recruiting|March 2015|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|11 Years|19 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02376829||26381|
NCT02456246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 15-8972-CE|Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT|Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT|SBRT FLT-PET|University Health Network, Toronto|No|Recruiting|May 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456246||20284|
NCT02388087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAM-ROX NMS|The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study|The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study|SHAM-ROX NMS|Eastbourne General Hospital|No|Not yet recruiting|May 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||March 2015|March 22, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388087||25515|
NCT02379234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49RC13_0209|Simulation for Continuous Veno-venous Hemofiltration in Intensive caRe|SIMulation for HEmofiltration in Intensive caRe Unit|SIMHeR|University Hospital, Angers|No|Recruiting|January 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02379234||26196|
NCT02379247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719XUS06T|BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer|Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|February 2015|August 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|54|||Female|18 Years|N/A|No|||December 2015|December 11, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379247||26195|
NCT02387502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123-IEC/01/13|Comparison of Three Laryngoscopes in Difficult Laryngoscopy|Comparative Evaluation of Macintosh, MacCoy and Airtraq Laryngoscope in Simulated Difficult Laryngoscopy Using Rigid Neck Collar||Government Medical College, Haldwani|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|60 Years|No|||April 2015|April 28, 2015|March 2, 2015||No||No|March 27, 2015|https://clinicaltrials.gov/show/NCT02387502||25560|The intubating anesthetist was not blind to the randomization of the laryngoscope. This could have led to bias. However, the primary outcome i.e. time of intubation was well defined and objective.
NCT02450279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AeroVent-02|Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Not yet recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450279||20742|
NCT02450292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|758594-1|Retrospective CT Imaging of BioComposite Interference Screw With BTB|Retrospective CT Imaging of BioComposite Interference Screw in Patients Undergoing Anterior Cruciate Ligament Reconstruction With Bone-Patellar Tendon-Bone Graft||State University of New York at Buffalo|No|Not yet recruiting|September 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|50 Years|No|Non-Probability Sample|Adults aged 18+ who had an anterior cruciate ligament (ACL) reconstruction about 5 years        ago performed by one of the study investigators.|May 2015|May 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450292||20741|
NCT02380560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129|Myometrial Thickness as a Predictor for the Latency Interval in PPROM|Sonographic Assessment of Myometrial Thickness as a Predictor for the Latency Interval in Women With Preterm Premature Rupture of Membranes||Cairo University|No|Not yet recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The total number of pregnant women will be enrolled in the study is 100 women. These wwill        be divided into three groups:          -  Group I: includes 50 women with preterm premature rupture of membranes (PPROM, n=50)             with gestational age from 24 to 34 weeks.          -  Group II: includes 25 term non-labor control (T-CTR, n=25) with gestational age from             37 to 41 weeks.          -  Group III: includes 25 preterm non-labor control (P-CTR, n=25) with gestational age             from 24 to 34 weeks.|March 2015|March 2, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02380560||26094|
NCT02387710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2012P000956B|Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea|Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea|TESSA|Brigham and Women's Hospital|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|79 Years|No|||November 2015|November 30, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387710||25544|
NCT02387723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCC_ASC1|CSCC_ASC Therapy in Patients With Severe Heart Failure|Allogeneic Adipose Tissue-derived Stromal/Stem Cell Therapy in Patients With Ischemic Heart Disease and Heart Failure - a Safety Study||Rigshospitalet, Denmark|Yes|Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|30 Years|80 Years|No|||February 2016|February 1, 2016|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02387723||25543|
NCT02445950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332885 With-Me-Occ|With-Me - Technology-Aided Phone Coaching for Occupational Health Study|With-Me - Technology-Aided Phone Coaching for Occupational Health Study||VTT Technical Research Centre of Finland|No|Active, not recruiting|November 2014|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02445950||21074|
NCT02445963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-15-19|Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers|A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity||U.S. Army Medical Research and Materiel Command|No|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02445963||21073|
NCT02388711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1221|A Trial of the C-TraC Intervention for Dementia Patients|A Randomized Control Trial of the Coordinated-Transitional Care (C-TraC) Intervention for Dementia Patients||University of Wisconsin, Madison|No|Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1100|||Both|65 Years|N/A|No|||October 2015|October 6, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02388711||25467|
NCT02634255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rocuronium onset|The Onset Time of Rocuronium in Emergency and Elective Surgery|The Prospective Randomized Comparison of the Onset Time of Rocuronium in Patients Undergoing Emergency and Elective Surgery||Diskapi Yildirim Beyazit Education and Research Hospital|No|Not yet recruiting|December 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02634255||6616|
NCT02636751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOIP2015|Effects of Tele- or In-person Prehabilitation in Candidates Awaiting Total Hip or Knee Arthroplasty|Effects of a Tele-prehabilitation Program or an In-person Prehabilitation Program Compared to a Usual Care Control Group in Participants Awaiting Total Hip or Knee Arthroplasty: A Pilot Single Blind Randomized Controlled Trial||Université de Montréal|No|Recruiting|January 2016|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02636751||6425|
NCT02633839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-007|A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults|A Phase 1 Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults||Acorda Therapeutics|No|Recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|65 Years|No|||March 2016|March 14, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633839||6648|
NCT02639338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1173|Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis||Gilead Sciences|Yes|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639338||6226|
NCT02639351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205496|Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine|A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).||GlaxoSmithKline|Yes|Recruiting|March 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639351||6225|
NCT02632773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DC014709-01|Parent Language Intervention for Autism|The Role of Parent Phenotype in Parent-Mediated Language Interventions for Autism||Northwestern University|Yes|Recruiting|August 2015|January 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|108|||Both|24 Months|36 Months|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02632773||6730|
NCT02632786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOD001-201|The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction|PRONTO|Prothena Therapeutics Ltd.|Yes|Not yet recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632786||6729|
NCT02639455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1268|Survey of the Collective 16s rRNA Genes From Bacterial Populations From Exercising and Non-exercising Participants|||University of Wisconsin, Madison|Yes|Not yet recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|300|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02639455||6217|
NCT02639468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVEIT|Electric Impedance Tomography|Electric Impedance Tomography|SVEIT|Centre Suisse d'Electronique et Microtechnique SA|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|90 Years|No|||December 2015|December 21, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639468||6216|
NCT02391935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCS-01-001-2014|Study of Intradermal Injections of RCS-01 in Male and Female Subjects|Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)||RepliCel Life Sciences, Inc.|No|Recruiting|September 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391935||25220|
NCT02635919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064767|Stage Ib Trial of mSMART|Stage Ib Trial of mSMART: Mobile Application Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|mSMART-Ib|Duke University|No|Not yet recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635919||6489|
NCT02636023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHENO_CLIN_003|Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI)|A Clinical Study to Determine the Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI).||Heart Force Medical Inc.|No|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02636023||6481|
NCT02630069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH_ATS|CDP-choline Treatment in ATS Users|Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents||Ewha Womans University Mokdong Hospital|Yes|Not yet recruiting|March 2016|May 2020|Anticipated|May 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|160|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02630069||6937|
NCT02630082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11704|Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru|A Cohort Study in Lima, Peru to Evaluate Feasibility of Measuring Immune Responses & Activation Levels in the Foreskin & Rectosigmoid Mucosa in HIV-negative, Uncircumcised Men Who Have Sex With Men & Who Are at High Risk for HIV Acquisition|HVTN 914|National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Male|21 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02630082||6936|
NCT02390531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP1|Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity|Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity|ROP1|Jaeb Center for Health Research|Yes|Recruiting|April 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|112|||Both|N/A|6 Months|No|||February 2016|February 22, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390531||25327|
NCT02460120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 43|Evaluation of the Archimedes™ System for Transparenchymal Nodule Access|Evaluation of the Archimedes™ System for Transparenchymal Nodule Access|EAST|Broncus Medical Inc|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|21 Years|75 Years|No|||July 2015|July 13, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460120||19986|
NCT02460133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIL-001|Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment|Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project||Nova Scotia Health Authority|No|Active, not recruiting|July 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|70 Years|No|||May 2015|February 1, 2016|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460133||19985|
NCT02460198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-164|Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)|A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02460198||19980|
NCT02382432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718|Dexmedetomidine in Post Spinal Anesthesia Shivering|Safety and Efficacy of Dexmedetomidine in Treating Post Spinal Anesthesia Shivering: A Clinically Controlled Dose-finding Study.||Assiut University|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|60 Years|No|||March 2015|March 3, 2015|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382432||25950|
NCT02384551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-006-14S|Dietary Carbohydrate and GERD in Veterans|Dietary Carbohydrate Effects on GERD in Obese Veterans: Nutritional or Hormonal?|DietGERD|VA Office of Research and Development|Yes|Recruiting|January 2016|December 2020|Anticipated|January 2020|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Both|21 Years|N/A|No|||February 2016|February 4, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384551||25787|
NCT02384564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2015-304|King Vision Video Laryngoscope aBlade vs. Direct Laryngoscopy in Children|A Randomized Comparison of the King Vision Video Laryngoscope aBlade vs. Direct Laryngoscopy in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Not yet recruiting|August 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|140|||Both|N/A|11 Years|No|||July 2015|July 27, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384564||25786|
NCT02445430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15BN031|Genetics of Arteriovenous Malformations|Genetics of Arteriovenous Malformations||St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|May 2015|September 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Saliva, blood, tissue (if undergoing AVM resection)|Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female persons with AVM and their immediate family members|December 2015|December 17, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445430||21114|
NCT02376660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1205|Effect of Oats on Lipid Profile|A Randomized Controlled Trial to Evaluate the Efficacy of 3 g of Soluble Fiber From Oats on the Lipid Profile of Men and Women With Elevated Lipid Levels Aged Between 20 and 50 Years||PepsiCo Global R&D|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|20 Years|50 Years|No|||February 2015|February 25, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376660||26394|
NCT02392663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyperosmolar_NCFB|Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis|Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis: a Randomized, Double-blind, Crossover Trial||Hospital Clinic of Barcelona|No|Recruiting|March 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392663||25164|
NCT02376790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130207|Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis|A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis||Amgen|No|Recruiting|March 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|840|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376790||26384|
NCT02376803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRange|The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT|The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT||University of Alberta|No|Recruiting|February 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376803||26383|
NCT02384876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0248|Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age.|Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age. A Randomized, Controlled, Open-label, Dose Escalation Study.|EPHEDRINE|Hospices Civils de Lyon|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|6 Months|No|||March 2016|March 15, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02384876||25762|
NCT02384889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411735324|DFMO in Children With Type 1 Diabetes|Targeting Polyamines Using DFMO in Persons With Type 1 Diabetes: A Randomized, Double-Masked, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses||Indiana University|Yes|Recruiting|April 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|12 Years|40 Years|No|||February 2016|February 29, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384889||25761|
NCT02376959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31078414.5.0000.5411|Effect of Spiritist "Passe" Energy Therapy in Reducing Anxiety in Volunteers|Effect of Spiritist "Passe" Energy Therapy in Reducing Anxiety in Volunteers||Associação Médico Espírita de Botucatu|No|Recruiting|September 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02376959||26371|
NCT02379728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC-S7-0629-01-10-ACC|Ghana PrenaBelt Trial|A Maternal Device to Reduce the Risk of Stillbirth and Low Birth-Weight||IWK Health Centre|No|Active, not recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02379728||26158|
NCT02381132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-MNK-155-01C|A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain|A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain||Lotus Clinical Research, LLC|No|Terminated|November 2014|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|99|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381132||26050|
NCT02385162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL 01/2015|Biomarker for Glycogen Storage Diseases|Biomarker for Glycogen Storage Diseases - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioGlycogen|University of Rostock|Yes|Recruiting|March 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry7,5 ml EDTA      blood, saliva tube and a dry blood spot filter card are taken. To prove the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Centogene AG,Schillingallee      68, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients with a diagnosis of glycogen storage disease or profound suspicion for glycogen        storage disease|January 2016|January 13, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385162||25740|
NCT02381509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01482|Predicting the Safety and Effectiveness of Inferior Vena Cava Filters|Predicting the Safety and Effectiveness of Inferior Vena Cava Filters|PRESERVE|New England Research Institutes|Yes|Recruiting|October 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2100|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects requiring the placement of one of 7 IVC filters for the prevention of PE.|October 2015|March 22, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381509||26021|
NCT02381522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150015|Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage|Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage|RIPC-SAH|Loma Linda University|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02381522||26020|
NCT02387229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIN-001|Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation|Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF)|BRAIN-AF|Montreal Heart Institute|Yes|Recruiting|March 2015|February 2021|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6396|||Both|30 Years|60 Years|No|||December 2015|December 10, 2015|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387229||25581|
NCT02377375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57471|Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD): Improving Targeting Precision|Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD) in the Bed Nucleus of the Stria Terminalis (BNST): Improving Targeting Precision||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|January 2015|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|20 Years|65 Years|No|||January 2016|January 26, 2016|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377375||26339|
NCT02388308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4267|Evaluation of Clarity Ultrasound Guidance for Prostate Therapy|Evaluation of Clarity Ultrasound Guidance for Prostate Therapy|Clarity-Pro|Institute of Cancer Research, United Kingdom|No|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|53|||Male|18 Years|N/A|No|Non-Probability Sample|Patients undergoing radiotherapy for prostate cancer|May 2015|August 24, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02388308||25498|
NCT02377674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEL-CR-05|Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection|To Assess the Initial Safety and Performance of COR-VG-001 Conduit in Pediatric Patients Undergoing Extracardiac Total Cavopulmonary Connection (EC-TCPC)|EC-TCPC|Xeltis AG|No|Active, not recruiting|October 2013|September 2019|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|18 Years|No|||February 2015|January 19, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02377674||26316|
NCT02380456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-119|dHACM in Lumbar Decompression and Microdiscectomy Surgery|A Randomized, Single Blind, Controlled Trial of Clinical Outcomes of Dehydrated Human Amnion/Chorion Membrane (dHACM) in Lumbar Decompression and Microdiscectomy Surgery||Hospital for Special Surgery, New York|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02380456||26102|
NCT02386358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAENA|Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial|Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial|TRAENA|Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben|Yes|Completed|March 1999|April 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|910|||Both|20 Years|55 Years|No|||March 2015|March 5, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386358||25648|
NCT02388386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTEUS-LVAD|Monitoring Medication Adherence in Left Ventricular Assist Device Recipients|Pilot Study of Wireless Observed Therapy With an Ingestible Micro-Sensor Among Patients With Heart Failure and Left Ventricular Assist Devices||Scripps Translational Science Institute|Yes|Recruiting|February 2015|September 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|N/A|N/A|No|||March 2015|March 9, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02388386||25492|
NCT02393014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-30|Physical Activity and Fall Prevention in Geriatric Inpatients in Acute caRe: Feasibility Study|Activité Physique et prévention de la Chute du Patient âGé hospItalisé en Court séjouR: Etude de faisabilité (AGIR)|AGIR|University Hospital, Angers||Not yet recruiting|April 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|330|||Both|65 Years|N/A|No|||February 2015|March 18, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02393014||25137|
NCT02450760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821743|Connected Health Blood Pressure Monitoring In Stroke and TIA Patients||CHAMPS|University of Pennsylvania|No|Recruiting|November 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450760||20705|
NCT02382380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206338|Evaluation of Gadoterate in Patients With Decreased Kidney Function|Evaluation of Gadoterate in Patients With Renal Dysfunction||Loyola University|No|Not yet recruiting|March 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382380||25954|
NCT02385578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015-048|the Train the Trainer (TTT) Plan, to Improve the Young Endoscopist's Ability to Find the Early Gastric Cancer|An Educational Intervention, the First Step of the Train the Trainer (TTT) Plan, to Improve the Young Endoscopist's Ability to Find the Early Gastric Cancer:Prospective Study With Historical Control||Shanghai Zhongshan Hospital|Yes|Not yet recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|16000|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||February 2015|March 10, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02385578||25708|
NCT02386137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/05|Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids|Volumetric MR-HIFU Ablation of Uterine Fibroids: Factors Influencing Intraprocedural Thermal Parameters|PERAGUS|University Hospital, Bordeaux|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02386137||25665|
NCT02450994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK15-2015_V1|Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude|Dexamethasone for Prophylaxis of Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease (COPD) Travelling to Altitude||University of Zurich|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Both|20 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450994||20687|
NCT02386462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA insertion|Determine the ED50 of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction|To Determine the Median Effective Dose (ED50) of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction With Propofol 2.0 mg/kg||Guangzhou General Hospital of Guangzhou Military Command|No|Recruiting|November 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|55 Years|No|||December 2014|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386462||25640|
NCT02388984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM9001-04|Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy|A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis)||Tasly Pharmaceuticals, Inc.|Yes|Recruiting|May 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|30 Years|70 Years|No|||November 2015|February 19, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02388984||25446|
NCT02379299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHCL2014|DiaCon Dual-Hormone Closed-Loop Glucose Control|Dual-Hormone Closed-Loop Glucose Control in Type 1 Diabetes||Hvidovre University Hospital|Yes|Not yet recruiting|May 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|13|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379299||26191|
NCT02451306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK018/15|Effect of Quetiapine on Brain Activity Patterns in Patients With Heightened Risk of Bipolar Disorder|Cognitive Control and Functional Connectivity During Resting State in Patients With Heightened Risk of Bipolar Disorder - a Quetiapine Challenge||RWTH Aachen University|No|Not yet recruiting|June 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|54|||Both|18 Years|45 Years|No|||May 2015|May 18, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02451306||20663|
NCT02451319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26.01.2015 19/17|Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS|Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS||Diskapi Teaching and Research Hospital|No|Recruiting|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|90 Years|No|||May 2015|May 20, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02451319||20662|
NCT02382861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/12|A Randomized Controlled Trial of Conventional vs. Neurally Adjusted Ventilatory Assist in Difficult Weaning From Mechanical Ventilation|A Prospective, Randomized and Controlled Study Estimating the Neurally Adjusted Ventilatory Assist (NAVA) Versus the Pressure Support Ventilatory (PSV) in Difficult Weaning From Mechanical Ventilation|SENA|University Hospital, Bordeaux|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382861||25917|
NCT02389101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T164/2014|Molecular and Whole-body MR Imaging in Lymphomas|Molecular and Whole-body MR Imaging in Lymphomas|MILY|Turku University Hospital|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|75 Years|No|||November 2015|November 3, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02389101||25437|
NCT02389114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00383|Effect of Soy Protein and Polydextrose on Food Intake in Young Chinese Adult Males|||Clinical Nutrition Research Centre, Singapore|No|Completed|June 2013|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|27|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389114||25436|
NCT02387320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396717|Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients|Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients||Samueli Institute for Information Biology|No|Recruiting|July 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02387320||25574|
NCT02458274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5254|Microparticles and Bronchiolitis Obliterans Syndrome|Circulating and Pulmonary Microparticles for Early Diagnosis of Bronchiolitis Obliterans Syndrome After Lung Transplantation|MIBO|University Hospital, Strasbourg, France|No|Recruiting|July 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Plasma Broncho-alveolar lavage fluid|Both|18 Years|N/A|No|Probability Sample|60 patients with a lung transplantation will be included in one center (Strasbourg) 30 -40        lung transplantations are performed each year in our centre, with a survival rate of 80%        at three year post transplantation. Approx. 30% patients will develop BOS at three year        post transplantation. So we expect at three year post transplantation 15 patients with BOS        and 37 patients without BOS (52 patients alive at three years post transplantation).        Consequently, the total duration of the study will be five years (two years for inclusion        and three years of follow-up)|May 2015|May 27, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02458274||20128|
NCT02389283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBHGM-EONC004-2014|Reduced Ultrasound Counts in Rheumatoid Arthritis|Sensitivity to Change of Different Reduced Ultrasound Counts in Rheumatoid Arthritis||Hospital General Universitario Gregorio Marañon|No|Recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid arthritis patients with more than 6 months and less than 5 years of active        evolution (DAS28 > 3.2 or SDAI > 11) and which start treatment with biologic therapy for        the first time independently of the combination with synthetic DMARDs. The patients will        be evaluated according to clinical practice (clinical evaluation and inflammation markers)        at baseline and 3 and 6 months after the initiation of the treatment with the biologic        DMARD.|March 2015|March 18, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389283||25423|
NCT02377050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB NEO 013|Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates|Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates||University of Alabama at Birmingham|Yes|Recruiting|January 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|224|||Both|N/A|1 Month|No|||September 2015|September 21, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02377050||26364|
NCT02377297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPOART2014|Occlusal ART Restorations in Primary Molars Using 3 Different GIC|Survival Rate and Cost Effectiveness of Occlusal ART Restorations in Primary Molars Using 3 Different Glass Ionomers Cements - a Randomized Clinical Trial||University of Sao Paulo|Yes|Active, not recruiting|November 2014|March 2017|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377297||26345|
NCT02389738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14155|Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration|Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02389738||25388|
NCT02389751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0815|A Study of Ganetespib in Combination With Chemoradiation|GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2015|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389751||25387|
NCT02389764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0464|Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)|A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-negative Inflammatory Breast Cancer (IBC)||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389764||25386|
NCT02386774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208180|Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa|Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa : Study of a Handheld in Vivo Confocal Microscope and of a Fluorescent in Vivo Confocal Microscope|INNOV-EYE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|April 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02386774||25616|
NCT02382159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YYP-OS-001|A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.|Observational, Retrospective, Multi-center Study for Therapeutic Practice Pattern of Lipid-lowering Drug and Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.||Yooyoung Pharmaceutical Co.,Ltd.|Yes|Completed|October 2010|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1000|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|1. Base-line (The starting time of treating lipid-lowering drug within 3 months period             of 2010 ~ 2013 years)               -  Background of Patients: Basic information(Height, Weight), Smoking, Drinking and                  other related illness.               -  Hypoglucemic agent, Diabetes test(Fasting blood glucose, GL test, Glycated                  Hemoglobin)               -  At the time of Starting the treating lipid-lowering drug, total Cholesterol, TG,                  LDL-C, HDL-C checked before treating lipid-lowering drug.          2. After 3±1 months from base-line               -  Hypoglycemic agent, Diabetes test               -  Total Cholesterol, TG, LDL-C at the point of 3±1 months from treating changed                  lipid-lowering drug, and the reason of drug dosage and pharmacotherapy          3. After 3±1 months from treating by changed lipid-lowering drug               -  Hypoglycemic agent, Diabetes test               -  Total Cholesterol, TG, LDL-C, HDL-C at the point of 3±1 months from treating                  changed lipid-lowering drug.|July 2015|July 15, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02382159||25971|
NCT02381171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA-TMS|Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in Myofascial Chronic Pain Patients|Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in the Rehabilitation of Patients With Myofascial Chronic Pain||Hospital de Clinicas de Porto Alegre|No|Recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|70 Years|No|||March 2015|March 5, 2015|March 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02381171||26047|
NCT02459639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-37|Existential Genomics: Effects of Multimodal Rehabilitation and Integrative Care on Patients With Chronic Pain|Existential Genomics (ExiGence): Effects of Multimodal Rehabilitation and Integrative Care on Pain, Quality of Life, and Genomic Stability in Patients With Chronic Pain|ExiGence|The Integrative Care Science Center|Yes|Not yet recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Leucocyte cell extracts|Both|18 Years|N/A|No|Non-Probability Sample|100 pain patients will be recruited into the study. They will be invited to participate in        the study upon admission to Integrative Care pain rehabilitation at the Vidar Clinic        (n=50) or the Pain Clinic, University Hospital, Linköping (n=50).|June 2015|June 2, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459639||20023|
NCT02391805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28938|A Study of Treatment With RO6864018 in Entecavir-Treated Patients With Chronic Hepatitis B Virus (HBV) Infection|A Multicenter, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Entecavir-Treated Patients With Chronic Hepatitis B Virus Infection||Hoffmann-La Roche||Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02391805||25230|
NCT02383511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMT C11003|Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet|A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet||Summit Therapeutics|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Male|5 Years|13 Years|No|||August 2015|August 25, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383511||25867|
NCT02390284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140587|Stop Retinal Ganglion Cell Dysfunction Study|Stop Retinal Ganglion Cell Dysfunction Study|STOP-RGCD|University of Miami|No|Recruiting|September 2014|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|500|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390284||25346|
NCT02459470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-080|Stroke Volume Variation and Pulse Pressure Variation as Predictors of Fluid Responsiveness During Kidney Transplantation|Utility of Stroke Volume Variation and Pulse Pressure Variation for Predicting Fluid Responsiveness in Chronic Renal Failure Patients Undergoing Kidney Transplantation||Samsung Medical Center|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|42|||Both|20 Years|70 Years|No|||December 2012|May 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02459470||20036|
NCT02460939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12704102|The Study on the Pulmonary Vessel Disease and Its Changes in Metabolism of Small Molecules|The Study on the Pulmonary Vessel Disease and Its Its Changes in Metabolism of Small Molecules||Beijing Chao Yang Hospital|Yes|Recruiting|August 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|18|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ARDS and sepsis or only sepsis aged between 45 and 85|June 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02460939||19923|
NCT02384460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-005|Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa|A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa||Scioderm, Inc.|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|1 Month|N/A|No|||February 2016|February 26, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384460||25794|
NCT02391077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-11|A Trial Assessing Efficacy of Various Antimicrobial Techniques for Reducing Bacterial Load|A Randomized, Open Label, Two Phase Trial, to Assess Various Antimicrobial Techniques for Reducing Bacterial Load Prior PrePex Removal|RMC-11|Ministry of Health, Rwanda|No|Not yet recruiting|April 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|33|||Male|21 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02391077||25285|
NCT02390336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-002|Mobilization With Movement in Patients With Osteoarthritis of the Hip|The Immediate Effects of Mulligan Mobilization With Movement Technique in Pain, Range of Motion and Physical Function in Patients With Osteoarthritis of the Hip|MWM|Escola Superior de Tecnologia da Saúde do Porto|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|N/A|No|||May 2015|May 27, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02390336||25342|
NCT02450513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53297|Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study|Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|March 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serum|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who are naïve to TNF antagonist treatment and who will be started on adalimumab        for treatment of active refractory Crohn's disease. All patients should be in need for TNF        antagonist therapy and should fulfill standard reimbursement criteria (Belgium).|November 2015|December 1, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02450513||20724|
NCT02377011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAHRC-EM 14059|RCT of the Clinical and Cost Effectiveness of Cognitive Behaviour Therapy (CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm|Randomised Controlled Trial of the Clinical and Cost Effectiveness of NICE Recommended Problem Solving Cognitive Behaviour Therapy (PS CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm|eDASH|University of Nottingham|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|30 Years|No|||February 2015|February 25, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377011||26367|
NCT02637609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI 90056532|Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling|Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with type II diabetes.|October 2015|December 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02637609||6359|
NCT02639884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DROV0007|Correlation Endoscopic View of Airway Obstruction With RRa in OSA Patients Under DEX Monitored With SedLine EEG|Correlation of Endoscopic View of Airway Obstruction With RRa Signal in OSA Patients Under Dexmedetomidine Anesthesia Monitored With SedLine EEG||Masimo Corporation||Not yet recruiting|December 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|No|Non-Probability Sample|patients undergoing sleep endoscopy for OSA|December 2015|December 21, 2015|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639884||6184|
NCT02639897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/10/15/901|Evaluation of Functional Dimensions of Macintosh Laryngoscope Blade During Direct Laryngoscopy in Patients With Normal Mouth Opening|Evaluation of Functional Dimensions of Macintosh Blade During Laryngoscopy in Patients With Normal Mouth Opening: Development of a Feasibility Model for Facilitation of Laryngoscopy in Cases of Mouth Opening Restriction Due to Submucous Fibrosis||Sir Ganga Ram Hospital|Yes|Not yet recruiting|December 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|65 Years|No|Non-Probability Sample|Patients scheduled for surgery under general anaesthesia with airway control by direct        laryngoscopy and tracheal intubation|December 2015|December 21, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02639897||6183|
NCT02639299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160039|Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge|Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1500|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|December 23, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02639299||6229|
NCT02639728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030891|The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.|Prospective Study of the Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.||Cedars-Sinai Medical Center|No|Active, not recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02639728||6196|
NCT02630238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10009692|The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction|The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction||University of Western Ontario, Canada|Yes|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|16|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02630238||6924|
NCT02634515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSULCT001|Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal|A Randomized, Single-center, Double-blind, 2-period Crossover, Euglycemic Glucose Clamp Study in Healthy Subjects to Demonstrate PK and PD Equivalence of Julphar Insulin R and Huminsulin® Normal||Julphar Gulf Pharmaceutical Industries|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02634515||6596|
NCT02636933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9/2014|Longitudinal Observational Study in Prematurely Born Preschool Children: Assessment of Lung Function Parameters|Longitudinal Observational Study in Prematurely Born Preschool Children: Assessment of Lung Function Parameters (PRE-AR) (PREMATURELY BORN CHILDREN- ASTHMA AND ALLERGIC RHINITIS )||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Recruiting|March 2015|December 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|52|||Both|3 Years|5 Years|No|Non-Probability Sample|A study population of 52 prematurely born children (of both sex and 3-5 years old)        attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory        Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular        Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR).        A Control group of full-term born children (N=26), recruited by a collaborative        Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM)        of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.        The subjects will be paired up according to the sex and to the age, with a ratio 1:1.|December 2015|December 18, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02636933||6411|
NCT02636946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-095|A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Recruiting|February 2016|October 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02636946||6410|
NCT02641808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-00150|Does Follicular Flushing Improve the Outcome in Monofollicular IVF Therapy?|Does Follicular Flushing Improve the Outcome in Monofollicular IVF Therapy?||University Hospital Inselspital, Berne|No|Not yet recruiting|February 2016|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02641808||6036|
NCT02380963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152341|Effect of Soy Protein and Colorado Diet on Weight Loss and Maintenance|The Effect of Incorporating Soy Protein Foods in the Colorado Diet for Weight Loss and Maintenance||DuPont Nutrition and Health||Active, not recruiting|February 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380963||26063|
NCT02638142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUR-AHF|Loop Diuretic Therapy in Acutely Decompensated Heart Failure|Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome|DIUR-AHF|University of Siena|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|patients who met diagnostic criteria for ADHF due to systolic dysfunction and left        ventricular ejection fraction (LVEF) <45% by exhibiting: at least one symptom at rest        between dyspnea, orthopnea, peripheral edema and major fatigue; and at least two clinical        signs including rales, pulmonary congestion on chest radiography, jugular vein dilatation        and a third heart sound. An elevation in blood BNP >400 pg/ml was considered supportive        for a diagnosis of ADHF|December 2015|December 18, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02638142||6318|
NCT02634840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG381601-3|Assessment of Nerve Function After Mandible Surgery With a Modified Bilateral Sagittal Split Osteotomy Technique|A Modified Technique of Mandibular Ramus Sagittal Split Osteotomy for Prevention of Inferior Alveolar Nerve Injury: A Prospective Cohort Study and Outcome Assessment||Chang Gung Memorial Hospital|No|Completed|January 2013|February 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|15 Years|N/A|No|||December 2015|January 4, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634840||6571|
NCT02634853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIM-727|A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye|A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye||Mimetogen Pharmaceuticals USA, Inc.|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634853||6570|
NCT02461056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03-108|Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain|Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain||Samsung Medical Center|Yes|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Female|19 Years|80 Years|No|||May 2015|June 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461056||19914|
NCT02392624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29510|A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)|A Phase IV, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria||Genentech, Inc.||Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|207|||Both|12 Years|75 Years|No|||September 2015|September 1, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392624||25167|
NCT02392637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0524|Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers|A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers||M.D. Anderson Cancer Center|No|Recruiting|April 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392637||25166|
NCT02393625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2120C|Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer|A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)||Novartis|No|Recruiting|May 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393625||25090|
NCT02449473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2210C00014|Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)|MESOS|AstraZeneca|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449473||20804|
NCT02381002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMASU 1078/2012|Effect of Weight Reduction Program on Overweight and Obese Children|EVALUATION OF DIETARY REGIMEN AND PHYSICAL ACTIVITY ON IRON AND LIPID STATUS IN OVERWEIGHT AND OBESE CHILDREN 6 Months Prospective Study|"ironobese"|Ain Shams University|Yes|Completed|March 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|150|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02381002||26060|
NCT02381015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011784|Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a|Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a||Wake Forest School of Medicine|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|700|||Male|40 Years|49 Years|Accepts Healthy Volunteers|||February 2015|March 5, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02381015||26059|
NCT02379455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222033/H10|Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study|Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study|COOP|Oslo University Hospital|No|Recruiting|March 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|70 Years|N/A|No|||October 2015|October 14, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379455||26179|
NCT02379468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEPI_ PED_001|Efficacy & Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment|Phase IIIb, A Prospective, Open Label, Randomized, Controlled, Parallel Group, Multicenter Clinical Trial of 3 Months Duration Comparing Topical Application of Royal Jelly and Panthenol (PEDYPHAR® Ointment) to Panthenol Ointment Only for Diabetic Foot Ulcers Treatment.|PEDFUT|European Egyptian Pharmaceutical Industries|No|Completed|April 2013|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||February 2015|March 4, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02379468||26178|
NCT02380885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIT3C|RCT Social Cognition Training and Therapeutic Alliance Focused Therapy for Persons With Severe Mental Illness|Randomized Controlled Trial of Social Cognition Training and Therapeutic Alliance Focused Therapy for Persons With Severe Mental Illness|RCT SCIT|Bar-Ilan University, Israel|No|Recruiting|January 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380885||26069|
NCT02445651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.141|Physiological Effects of Nutritional Support in Patients With Parkinson's Disease|Physiological Effects of Nutritional Support in Patients With Parkinson's Disease||Thomas Jefferson University|No|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|65|||Both|30 Years|80 Years|No|||December 2015|December 3, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02445651||21097|
NCT02381262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-201|Fitbit / Healthy Weight Management Study|Fitbit / Healthy Weight Management Study||Lancaster General Hospital|No|Not yet recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|213|||Both|18 Years|N/A|No|||February 2015|March 5, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02381262||26040|
NCT02384746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D13036|Phase I Study of the Combination of MLN9708 and Fulvestrant|Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer|Millennium|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|March 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|November 20, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02384746||25772|
NCT02384759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE25|Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers|Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers|FOLFA|Federation Francophone de Cancerologie Digestive|Yes|Active, not recruiting|February 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|65 Years|N/A|No|||March 2015|March 4, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02384759||25771|
NCT02384772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-MKT-001|Survey of Patients Taking IOP-Lowering Eye Drops|A Multi-Site Questionnaire-Based Study to Assess Attitudes Regarding Current IOP-Lowering Eye Drops and Products in Development for Sustained Release of Medication in Glaucomatous and Ocular Hypertensive Subjects||ForSight Vision5, Inc.|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|Patients prescribed IOP-lowering eye drops.|June 2015|June 9, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02384772||25770|
NCT02385084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15709|A Study of LY2409021 Formulations in Healthy Participants|A Single Dose Pharmacokinetic Study of LY2409021 in Healthy Subjects to Bridge Formulations From Capsules to Commercial Tablets||Eli Lilly and Company|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|72|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385084||25746|
NCT02385097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHL.2/01-2014/M|Chloroprocaine 2% - Axillary Block|A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery||Sintetica SA|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02385097||25745|
NCT02445924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2858/11/14|Micro RNA Genetic Signature in NSCLC Egyptian Patients|Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients||Tanta University|Yes|Active, not recruiting|May 2015|May 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|40|Samples With DNA|blood, bronchial lavage, bronchial biopsies|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will be carried out on 40 subjects at Chest department Tanta university        hospital.        The subjects will be classified into three groups:          -  Group I: will include ten non smoker volunteers (control group I).          -  GroupII: will include ten smoker volunteers (control groupII).          -  Group III: will include twenty NSCLC patients confirmed by pathological examination             of bronchoalveolar examination (BAL), brush and/or biopsy.|January 2016|January 29, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445924||21076|
NCT02386020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/10E/2013-14|Aloe Vera in Chronic Periodontitis With Type 2 Diabetes Mellitus|Clinical Efficacy of Locally Delivered Aloe Vera Gel as an Adjunct to Non-surgical Periodontal Therapy in Chronic Periodontitis Subjects With Type 2 Diabetes Mellitus: a Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|June 2014|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||February 2015|March 5, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02386020||25674|
NCT02380053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPET1|Chronic Beta-blockade and Cardiopulmonary Exercise in COPD|Proof of Concept Study to Assess the Differential Effects of Chronic Beta-blockade (Celiprolol Versus Bisoprolol) on Cardiopulmonary Outcomes at Rest and During Exercise in Chronic Obstructive Pulmonary Disease|CPET1|University of Dundee|No|Not yet recruiting|April 2015|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|40 Years|80 Years|No|||February 2015|February 27, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380053||26133|
NCT02380066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AYPB-MDD-Ⅱa-1401|Comparison of Anyu Peibo With Placebo in Treatment of MDD|Proof Of Concept Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial||Shanghai Mental Health Center|No|Not yet recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|120|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380066||26132|
NCT02381405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enterade 11/11/14|A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)|A Randomized Open Label Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)||21st Century Oncology||Terminated|February 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 3, 2015||No|Lack of enrollment.|No||https://clinicaltrials.gov/show/NCT02381405||26029|
NCT02380183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3414|Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade|A Randomized Controlled Study Comparing Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade||Montefiore Medical Center|Yes|Recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 4, 2015|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02380183||26123|
NCT02380196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02515|The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer|The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood Collection|Both|18 Years|N/A|No|Probability Sample|Non-small cell lung cancer (NSCLC)|March 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380196||26122|
NCT02377531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020026|Early Screen and Treatment for Gestational Diabetes|Gestational Diabetes Mellitus: Does Early Screening and Treatment for Patients at Increased Risk for Gestational Diabetes Impact Perinatal Outcomes? A Randomized Controlled Trial||University of South Florida|No|Recruiting|March 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1020|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377531||26327|
NCT02392754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCREEN-AF|Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older|Program for Identification of "Actionable" Atrial Fibrillation (PIAAF): Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older: the SCREEN-AF Randomized Trial|SCREEN-AF|Population Health Research Institute|No|Recruiting|April 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|822|||Both|75 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02392754||25157|
NCT02392767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS815/14|Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function|Effect of a Dietary Supplement on Endothelial Function in Volunteers With Light to Moderate Hypertension - a Randomised, Double-blind, Placebo Controlled Cross-over Study||Dr. Loges & Co. GmbH|No|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02392767||25156|
NCT02381691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-11|Analgesic Effect of Maternal Breast Milk Odor in Preterm Neonates: a Randomised Controlled Trial|Analgesic Effect of Maternal Breast Milk Odor in Preterm Neonates: a Randomised Controlled Trial||Assistance Publique Hopitaux De Marseille||Active, not recruiting|January 2013|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|N/A|10 Days|No|||September 2015|September 29, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02381691||26007|
NCT02385695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scientific Research 2015 (06)|Study to Evaluate Safety and Effectiveness of Dynamic Stabilization Versus Lumbar Fusion in Treatment of Multilevel Lumbar Disc Degeneration Disease|A Prospective Comparative Study to Evaluate Safety and Effectiveness of Dynamic Stabilization Versus Lumbar Fusion in Treatment of Multilevel Lumbar Disc Degeneration Disease|MLIDH|Third Military Medical University|No|Recruiting|March 2015|August 2021|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|102|||Both|30 Years|75 Years|No|Non-Probability Sample|Patients of The Third Medical University/Southwest Hospital with multilevel lumbar        degenerative disk disease.|September 2015|September 24, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02385695||25699|
NCT02388932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8314|Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer|Phase I Dose Escalation Study of Stereotactic Body Radiotherapy for p16 Negative Squamous Cell Carcinoma of the Head and Neck in High Risk Patients Who Are Ineligible/Refuse Standard of Care Therapy||Case Comprehensive Cancer Center|No|Recruiting|March 2015|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388932||25450|
NCT02393105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411051RINB|Sense of Hope Alleviates Fatigue in Breast Cancer Survivors|The Sense of Hope Alleviates Fatigue in Breast Cancer Survivors||National Taiwan University Hospital|No|Recruiting|January 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|180|||Female|20 Years|90 Years|No|Non-Probability Sample|breast cancer survivors,complete chemotherapy and radiotherapy|March 2015|March 22, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02393105||25130|
NCT02378779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETUP|Consultations Reason for Genital, Urinary or Psychological Humans in General Practice|Consultations Reason for Genital, Urinary or Psychological Humans in General Practice|GETUP|University Hospital, Brest|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02378779||26231|
NCT02378792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-012|Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy|The Clinical Research on TsingHua Vagus Nerve Stimualtor for Treatment of Refractory Epilepsy|VNSRE|Beijing Pins Medical Co., Ltd|Yes|Recruiting|August 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|60 Years|No|||March 2015|October 12, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378792||26230|
NCT02458066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedicalCareDev|Trial to Compare Effectiveness of 2 Insecticides in Preventing Malaria|Cluster Randomised Trial to Compare Effectiveness of Bendiocarb and Deltamethrin (Long‐Lasting) in Preventing Malaria Infection||Medical Care Development, Inc.|No|Completed|February 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2800|||Both|2 Years|14 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02458066||20144|
NCT02386397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM2013/09|Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer|Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)|BREGO|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|September 2014|April 2019|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02386397||25645|
NCT02386410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGJA-02|Selective Prevention of Anxiety Disorders in Children: A Parent Training Intervention for Anxious Parents|Selective Prevention of Anxiety Disorders in Children: A Randomized Controlled Preliminary Study of a Parent Training Intervention for Anxious Parents||Karolinska Institutet|No|Active, not recruiting|August 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 7, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386410||25644|
NCT02388880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSI 450-0003|Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion (4hour)|Physiological Effects of Intrathoracic Pressure Regulation in Patients With Decreased Cerebral Perfusion Due to Brain Injury or Intracranial Pathology (4 Hour Use)||Advanced Circulatory Systems|Yes|Recruiting|February 2015|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388880||25454|
NCT02392455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.211|VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)|Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung||Boehringer Ingelheim||Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|NSCLC patients|February 2016|February 17, 2016|March 17, 2015||||No||https://clinicaltrials.gov/show/NCT02392455||25180|
NCT02392468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.27|Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimers Disease, and Healthy Volunteers|Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimers Disease, and Age-comparable Healthy Volunteers||Boehringer Ingelheim||Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 17, 2015||||No||https://clinicaltrials.gov/show/NCT02392468||25179|
NCT02458144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1392/2012|Comparison of MIS Anterior Versus MIS Anterolateral Approach|Comparison of Two Minimally Invasive Approaches to the Hip-anterior Versus Anterolateral - Which Technique is Less Invasive? A Prospective, Randomized, Controlled Pilot Study||Medical University of Vienna|No|Recruiting|January 2013|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|80 Years|No|||May 2015|May 28, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458144||20138|
NCT02448446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML259577|The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates|The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Foveal Involving Edema and Lipid Exudates||South Coast Retina Center; Carson, McBeath, Boswell, Inc.||Recruiting|August 2015|July 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448446||20883|
NCT02389166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/28|Optiflow in Sequential Non-Invasive Ventilation|Randomized Clinical Trial Comparing High Flow Oxygen Delivery System (Optiflow) With Oxygen Therapy Under High-concentration Mask on Oxygenation of Patients Who Receive Sequential Non-Invasive Ventilation (NIV) Sessions|VNI-HD|University Hospital, Bordeaux|Yes|Recruiting|June 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02389166||25432|
NCT02393170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1764-HW-CTIL|Home-based -Virtual Reality Intervention for Stroke Rehabilitation|Virtual Reality Intervention for Stroke Rehabilitation - Home Based (Stage 2)|Home-VR|Sheba Medical Center|No|Completed|November 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||February 2016|February 12, 2016|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02393170||25125|
NCT02383823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2104-99|Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects|Postprandial Lipidemia and Glucose Metabolism After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects||Herning Hospital|No|Not yet recruiting|August 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|5||Anticipated|64|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02383823||25843|
NCT02383836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005-X14-HYMC|Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler|Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients referred for a TEE with bubble injection to rule out a cardiac source of brain        emboli following an acute neurological embolic event.|March 2015|March 3, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02383836||25842|
NCT02458196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgG4-02|Study of Treatment Response on IgG4 Related Disease (IgG4RD)|A Randomized Trial of Treatment in Patients With IgG4-Related Disease||Peking Union Medical College Hospital|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||May 2015|May 29, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02458196||20134|
NCT02458209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481026|Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab In Healthy Adult Subjects For Comparisons Of Drug Substance Manufactured At Two Different Locations And Administration Via Prefilled Syringe Vs. Prefilled Pen||Pfizer|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|470|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458209||20133|
NCT02386540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-08123E|Health Coach Program to Improve Chronic Disease Outcomes Following an Emergency Department Visit|||Alameda County Medical Center||Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A||||March 2015|March 6, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02386540||25634|
NCT02376751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-EA01|An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency|AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY||Alexion Pharmaceuticals||Available||||||N/A|Expanded Access|N/A|||||||Both|8 Months|N/A||||November 2015|November 16, 2015|February 25, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02376751||26387|
NCT02376764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER.ALL.2014.04.A|Biomarkers in Post Thrombotic Syndrome|New Biomarkers in Post Thrombotic Syndrome|BIPOSTO|University of Cantanzaro|Yes|Completed|February 2012|February 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|235|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with Deep Vein Thrombosis of lower limbs during their first episode.|March 2015|March 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376764||26386|
NCT02389660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W73/7. PR/2014|European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland|European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland [Europejskie Badania Porównawcze Nad Efektywnością Interwencji Internetowej Dla Osób z Depresją] (E-COMPARED)|E-COMPARED|University of Social Sciences and Humanities, Warsaw|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02389660||25394|
NCT02444468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-study|Preoperative Treatment of Malleolar Fractures|A Randomized Study of In-cast Intermittent Pneumatic Foot-compression in the Preoperative Treatment of Malleolar Fractures||Hospital of Southern Jutland|Yes|Recruiting|March 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||March 2015|May 13, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02444468||21188|
NCT02389296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0021-15|The Forensic Psychiatric Nurse - Warden or Empathic Caregiver|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|212|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Psychiatric nurses working in either general hospitals or in mental health centers in 10        medical centers in Israel.|March 2015|March 10, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389296||25422|
NCT02389309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0692|A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors|A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|12 Months|20 Years|No|||October 2015|October 7, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389309||25421|
NCT02379988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409500149|Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy|Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy||University of Arizona|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||October 2015|October 15, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379988||26138|
NCT02381886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDH305X2101|A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations|A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations||Novartis|No|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381886||25992|
NCT02381899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1|Observational Study in CLL Patients Receiving BR|Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Bendamustine and Rituximab||Czech CLL Study Group|No|Recruiting|January 2015|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic lymphocytic leukemia.|March 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381899||25991|
NCT02379780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mengücek gazi hospital|Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy|Comparison of the Effects of Perioperative Anesthesia Consumption of Ultrasound Guided Subcostal Transversus Abdominis Plane and Paravertebral Block in Laparoscopic Cholecystectomy||Cukurova University|No|Completed|September 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02379780||26154|
NCT02447640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX48621-104|PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration|An Open Label PET Imaging Study to Evaluate the mGlu5 Receptor Occupancy Following ADX48621 (Dipraglurant) Administration||Johns Hopkins University|No|Active, not recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447640||20945|
NCT02447653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETAU09|Hydroxyapatite (HA) Coating Versus Plasma Porous Spray (PPS) in Press-fit Acetabular Components Early Outcomes With DEXA|A Randomised Controlled Study Comparing Hydroxyapatite (HA) Coating Versus Plasma Porous Spray in Press-fit Acetabular Components Early Outcomes With Dual Energy X-ray Absorptiometry (DEXA)||Biomet, Inc.|No|Not yet recruiting|February 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||December 2015|December 10, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02447653||20944|
NCT02389322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-IIb-healthy|Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65|Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method|IIb-healthy|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|No|Completed|March 2015|September 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|1044|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02389322||25420|
NCT02380287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-085-1|First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of BCD-085 in Healthy Subjects|Open-label, Phase I Dose-escalation Clinical Study of the Safety, Tolerability and Pharmacokinetics of Single Subcutaneus Dose of BCD-085, Monoclonal Antibody Against IL-17, in Healthy Subjects||Biocad|No|Completed|March 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380287||26115|
NCT02386956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC.CLQ.01.15|Hamstring Stretch Effect (STRETCH-HAMS)|Evaluation of Hamstrings Elongation After Different Physiotherapy Stretching Techniques|STRETCH-HAMS|Universidad Miguel Hernandez de Elche|No|Completed|April 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|September 17, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02386956||25602|
NCT02386176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110472|Assessment of Automated Breast Ultrasound|The Assessment of the Role of Automated Breast Ultrasound (ABUS) in Screening Women With Dense Breasts for Early Detection of Breast Cancer||University of Pittsburgh|No|Recruiting|August 2015|November 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 40 to 75 years of age with a defined region of extremely dense breast tissue or        heterogeneously dense or extremely dense parenchyma by prior digital mammography report        (i.e., "dense breasts"), presenting for routine annual mammography with digital breast        tomosynthesis.|January 2016|January 26, 2016|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386176||25662|
NCT02445469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8743|Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes|Contribution of Magnetic Resonance Imaging (Diffusion Tensor Imaging and Magnetic Susceptibility Imaging and Resting Activation Imaging) in the Diagnosis of Parkinsonian Syndromes in Elderly Subjects.|PARKIMAGE|University Hospital, Montpellier|No|Recruiting|December 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|170|||Both|70 Years|90 Years|Accepts Healthy Volunteers|||October 2015|December 4, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02445469||21111|
NCT02380313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201672|Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone|A Phase I, Open-Label, Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide (Xtandi) or Abiraterone (Zytiga) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)||GlaxoSmithKline|No|Not yet recruiting|October 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|60|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380313||26113|
NCT02387437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014ZDSYLL124.1|Different Effects of Three Recruitment Maneuvers on the Lung Heterogeneity of Acute Respiratory Distress Syndrome|Evaluation of Different Effects of Three Recruitment Maneuvers on the Lung Heterogeneity of Acute Respiratory Distress Syndrome|DEOTRMOARDS|Southeast University, China|No|Recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|93|||Both|18 Years|75 Years|No|||December 2014|March 12, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02387437||25565|
NCT02377960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH500SH01|Check and Support -Enhancing the Treatment of Hypertension in Outpatient Care, a Multicenter Study|Check and Support -Pragmatic Randomized Controlled Study of the Effectiveness of 12 Month SMS-Text Message Support and IMB-based Initiation of Medication in Adults With Hypertension for Better Blood Pressure Control and Medication Adherence||Kuopio University Hospital|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|180|||Both|30 Years|75 Years|No|||March 2016|March 10, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02377960||26294|
NCT02378194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-003|Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug|||Hyundai Pharmaceutical Co., LTD.|No|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|20 Years|75 Years|No|||February 2015|February 26, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02378194||26276|
NCT02460952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22704102|The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period|The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period||Beijing Chao Yang Hospital|Yes|Recruiting|August 2014|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|500|||Both|45 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients accept Operation with general anesthesia|June 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02460952||19922|
NCT02388347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5450C00001|A Study to Assess the Safety of MEDI7836 in Healthy Adults.|A Phase 1a, Randomised, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI7836 in Healthy Adults||MedImmune LLC|Yes|Active, not recruiting|March 2015|April 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|79|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388347||25495|
NCT02388360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaisonneuveRH|The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma|The Impact of Topical Prostaglandin Analogs on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma||Maisonneuve-Rosemont Hospital|Yes|Recruiting|May 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|40 Years|85 Years|No|||February 2015|March 9, 2015|December 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02388360||25494|
NCT02379260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11|Development of a Therapeutic Education Program for Patients Operated for Prostate Cancer|Development of a Therapeutic Education Intervention Improving Sexuality in Patients With Prostate Cancer Treated With Radical Prostatectomy|PEPs PROSTATE|Institut de Cancérologie de la Loire|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|19|||Male|18 Years|N/A|No|||February 2016|February 25, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379260||26194|
NCT02378207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 602 / AERAS A-042|Phase 1b Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents|A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants|A-042|Aeras|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|84|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02378207||26275|
NCT02459561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM2015|EndoBarrier TM Gastrointestinal Liner Diabetes Trial|A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes|EndoBarrier|Imperial College London|Yes|Recruiting|November 2014|April 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02459561||20029|
NCT02460965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-2|Understanding Hallucinations (Part II)|Understanding Hallucinations (Part II) - fMRI and EEG|UH-2|UMC Utrecht|Yes|Recruiting|November 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||8|Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants will consist of 7 different diagnostic categories. Individuals with        hallucinations will have to experience at least one episode of hallucinations over the        last month. The control group will consist of non-hallucinating individuals who have the        same disorder as the hallucinating individuals and are matched group-wise for severity of        the disease, medication, age, sex, handedness and education.|May 2015|June 2, 2015|February 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02460965||19921|
NCT02381587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCQ and sjogren|the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients|Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome|HAS|Meir Medical Center|No|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that diagnosis in sjogren in treated in Meir Medical center|March 2015|March 2, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02381587||26015|
NCT02640079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001761|A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea|A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea||University of California, Los Angeles||Recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|16 Years|25 Years||||January 2016|January 21, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02640079||6169|
NCT02628171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS52|Impact of Cashew Nuts in the Human Diet: Measured Energy Value and Effects on Cardiovascular Disease Risk Factors|||USDA Beltsville Human Nutrition Research Center|No|Active, not recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|42|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02628171||7083|
NCT02641756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS 52777|HIV Sequencing After Treatment Interruption to Identify the Clinically Relevant Anatomical Reservoir|In Depth Sampling and Subsequent Treatment Interruption to Identify the Anatomical Reservoir|HIV-STAR|University Hospital, Ghent|No|Enrolling by invitation|April 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02641756||6040|
NCT02641795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-13-12-011779|Robotic Assisted Cochlear Implantation Feasibility Study|Robotic Assisted Cochlear Implantation Feasibility Study|MIRACI|University Hospital Inselspital, Berne|Yes|Recruiting|July 2014|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02641795||6037|
NCT02639741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZLTNS99|Preoperative Melatonin or Vitamin C Administration on Postoperative Analgesia|Comparison Of The Effects Of Preoperative Melatonin Or Vitamin C Administration On Postoperative Analgesia||Cukurova University|No|Active, not recruiting|November 2014|March 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|55|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02639741||6195|
NCT02634528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSULCT003|Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal|Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin N and Huminsulin® Basal||Julphar Gulf Pharmaceutical Industries|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|49|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02634528||6595|
NCT02637895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150534|Vortioxetine for Posttraumatic Stress Disorder|Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder||University of Miami|Yes|Not yet recruiting|February 2016|June 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637895||6337|
NCT02644512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160043|MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas|Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|99 Years|No|||December 2015|January 21, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644512||5828|
NCT02629848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-AB030103|Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer|A Global Phase 3, Randomized, Placebo Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)||Takeda|Yes|Terminated|July 2012|March 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 10, 2015||No|Sponsor decision to terminate the study because the study did not meet the primary endpoint.|No||https://clinicaltrials.gov/show/NCT02629848||6954|
NCT02629861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV48125-CNS-30050|Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine||Teva Pharmaceutical Industries|No|Recruiting|January 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|786|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629861||6953|
NCT02385175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166405|The Accuracy of Tests of Eustachian Tube Function|The Accuracy of Tests of Eustachian Tube Function||Cambridge University Hospitals NHS Foundation Trust||Recruiting|July 2015|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|250|||Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults with Eustachian tube dysfunction|December 2015|December 29, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02385175||25739|
NCT02643121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDAR 19 - 1|Utility of Presepsin in Children Sepsis|Diagnostic and Prognostic Utility of Presepsin for Sepsis and Systemic Inflammatory Response Syndrome in Children||Brno University Hospital|No|Active, not recruiting|January 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|1 Month|216 Months|Accepts Healthy Volunteers|Probability Sample|Childrens with SIRS or septic state who will be admitted to the Department of Anesthesia        and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections,        sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be        defined according to commonly used criteria - by International pediatric sepsis consensus        conference. The samples from children undergoing elective surgery will be used as a        controls, i.e. samples from patients without signs of infection.|December 2015|December 31, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02643121||5935|
NCT02378805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alport-UMG2010|European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome|European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies||University Hospital Goettingen|No|Recruiting|July 1995|July 2019|Anticipated|July 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|500|Samples Without DNA|Urine and serum-samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Currently there are no causal therapeutic options which are proven to delay renal failure        in AS. We established the European Alport Registry to collect data over several        generations of Alport families across Europe. The different steps of disease enabled us to        assess if earlier introduction of ACE-inhibition at earlier degrees of disease is more        effective than later therapy in delaying the time to dialysis and improving        life-expectancy.        Heterozygous COL4A3/COL4A4 mutations result in the phenotype "familial benign hematuria"        or "thin basement membrane nephropathy" (TBMN).        For the first time, the present study compares the risk of renal impairment, end stage        renal disease and premature death in between heterozygous carriers of XLAS and of ARAS        mutations. Additionally, the nephroprotective effect of RAAS-blockade in patients with        heterozygous Alport-mutations is evaluated.|November 2015|November 30, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378805|10 Years|26229|
NCT02379078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-014|Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes|Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes - A Pilot Cluster Randomized Controlled Trial||St. Michael's Hospital, Toronto|No|Not yet recruiting|April 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02379078||26208|
NCT02447965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203780|Rectus Sheath Blocks for Improving Abdominal Surgery Conditions|Rectus Sheath Blocks for Improving Abdominal Surgery Conditions: A Prospective Randomized Double-Blind Placebo Controlled Study||University of Arkansas|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447965||20920|
NCT02448186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012230|Intervention Development for Social Stress, Mental Health, and HIV Risk MSM|Intervention Development for Social Stress, Mental Health, and HIV Risk Among MSM|ESTEEM|Yale University|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|63|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448186||20903|
NCT02379221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20140012H|Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers.|Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers||David Grant U.S. Air Force Medical Center|No|Enrolling by invitation|September 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379221||26197|
NCT02377102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2152|Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis|Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis||University of North Carolina, Chapel Hill|No|Recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377102||26360|
NCT02455700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IER V1 06.03.2015|Pain Associated With Interproximal Enamel Reduction in Orthodontics: a RCT|A Hospital Based Prospective Randomised Controlled Clinical Trial Comparing Pain Experience Using Manual and Rotary Interproximal Enamel Reduction Techniques in Orthodontic Patients|IER|Royal Surrey County Hospital NHS Foundation Trust|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 23, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455700||20326|
NCT02385513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/01|PCV10 Immunogenicity Study Nepal 2015|A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children||University of Oxford|Yes|Recruiting|May 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|304|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||November 2015|November 6, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385513||25713|
NCT02384252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_09|Characterization of Obesity-related Cardiomyopathy Through Exploration of Human Atrial Trabeculae Contraction|Characterization of Obesity-related Cardiomyopathy Through Exploration of Human Atrial Trabeculae Contraction||University Hospital, Lille|No|Recruiting|February 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|144|Samples Without DNA|Right atrial tissue obtained during cannulation of the right atrium in preparation for      cardiac surgery with extracorporeal circulation.|Both|18 Years|N/A|No|Probability Sample|consecutive patients undergoing coronary artery bypass graft surgery or aortic valve        replacement surgery with extracorporeal circulation|October 2015|October 13, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384252||25810|
NCT02384811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-86-882|Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma|Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal||Fudan University|Yes|Recruiting|December 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|75 Years|No|||March 2015|March 9, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02384811||25767|
NCT02449720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150219|Intraperitoneal Local Anaesthetic in Bowel Surgery|The Effect of Intraperitoneal Local Anaesthetic on Functional Recovery Following Bowel Resection: A Prospective Randomised Blinded Trial||Royal Adelaide Hospital|No|Enrolling by invitation|May 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|90 Years|No|||July 2015|July 25, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02449720||20785|
NCT02449733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00079727|Comprehensive HIV Prevention Package for MSM in Port Elizabeth|Comprehensive HIV Prevention Package for MSM in Port Elizabeth||Emory University|No|Enrolling by invitation|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449733||20784|
NCT02385773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1372|Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease|A Double Blind, Randomized, Placebo-Controlled Trial to Assess the Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease||University of Colorado, Denver|No|Recruiting|March 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|12 Months|35 Months|No|||January 2016|January 13, 2016|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385773||25693|
NCT02388399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT723631|Invasive Measurement of Axial Plaque Stress, the Pilot Study|Relevance of Invasively Measured Axial Plaque Stress and Wall Shear Stress Using Invasive Coronary Imaging and Hemodynamic Data|REASSURE|Seoul National University Hospital|No|Not yet recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with angina pectoris|March 2015|March 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388399||25491|
NCT02393664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410045RINB|Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection|Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection: A Prospective Randomized Trial||National Taiwan University Hospital|No|Recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||July 2015|July 1, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02393664||25087|
NCT02450006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024811|Intermountain INSPIRE Registry|INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry)||Intermountain Health Care, Inc.|No|Recruiting|April 2015|April 2050|Anticipated|April 2050|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|50000|Samples With DNA|Examples of the biological samples that may be collected are as follows (but not limited      to):        -  Blood/Plasma        -  Bone Marrow        -  Buccal smear (cheek)        -  Cartilage        -  Cerebrospinal fluid        -  Mucus        -  Saliva        -  Sputum        -  Stool        -  Sweat        -  Synovial fluid        -  Tears        -  Tissue samples (e.g. muscle, skin, nails, tumor, etc)        -  Urine        -  Seminal fluid        -  Genetic material extracted from any biological sample        -  Other biological samples as identified by the Principal Investigator or           Co-Investigators and agreed by the patient.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with any healthcare-related conditions who are seen at facilities        affiliated with Intermountain Healthcare, including patients and their family members, the        general population, including disease-free subjects.|February 2016|March 14, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02450006|50 Years|20763|
NCT02388737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438_305|Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis|A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438, 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis||Takeda|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388737||25465|
NCT02385370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92181|Bleb Function and Morphology With Intratendon Injection of MMC Compared With Standard Method|Bleb Function and Morphology With Intratendon Injection of 0.1 mg MMC in Comparison With Conventional Subtenon Application of 0.02% MMC Soaked Sponges in Trabeculectomy|conj mmc|hahid Beheshti University of Medical Sciences|Yes|Recruiting|December 2014|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|20 Years|N/A|No|||December 2014|March 10, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385370||25724|
NCT02385435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of jordan|Caudal Bupivacaine vs Bupivacaine Plus Two Doses of Dexmedetomidine for Postoperative Analgesia in Children|Comparison of Caudal Bupivacaine Alone With Bupivacaine Plus Two Doses of Dexmedetomidine for Postoperative Analgesia in Pediatric Patients Undergoing Infra-umbilical Surgery: A Randomized Controlled Double Blinded Study||University of Jordan|Yes|Completed|January 2014|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|91|||Both|1 Year|6 Years|No|||March 2015|March 10, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385435||25719|
NCT02381821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127|3D Measurement of Junctional Zone and Its Relation to Implantation|Thickness of the Junctional Zone Measured by 3D Ultrasound and Its Relation to the Success/Failure Implantation Rates in Assisted Reproduction Techniques||Cairo University|No|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|19 Years|39 Years|No|Probability Sample|women with primary or secondary infertility and were scheduled for a first IVF/ICSI        treatment cycle due to Pelvic Inflammatory disease, ovulatory dysfunction, tubal        infertility, unexplained infertility , combined infertility with normal transvaginal        ultrasound.|March 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381821||25997|
NCT02380339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0098-14-HMO|A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia|||Hadassah Medical Organization|No|Recruiting|July 2015|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380339||26111|
NCT02380352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFER 001 PSI|Short-course Antimicrobial Therapy for Paediatric Respiratory Infections|Short-course Antimicrobial Therapy for Paediatric Respiratory Infections|SAFER|Hamilton Health Sciences Corporation|Yes|Not yet recruiting|March 2016|May 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|6 Months|10 Years|No|||March 2016|March 24, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380352||26110|
NCT02385630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFSJ 0058|Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer|Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer||St. James's Hospital, Ireland|No|Active, not recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385630||25704|
NCT02446496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201529|A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects|Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated Tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions||GlaxoSmithKline|No|Completed|March 2014|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446496||21032|
NCT02446509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SN-13-0579|A Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder|A Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder: A Feasibility Study||The University of Texas Health Science Center, Houston|No|Recruiting|September 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02446509||21031|
NCT02378922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9183|Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma|Autologous Transplantation and Stem Cell Based-Gene Therapy With LVsh5/C46 (CAL-1), a Dual Anti-HIV Lentiviral Vector, for the Treatment of HIV-Associated Lymphoma||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|April 2016|||June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|66 Years|No|||February 2016|February 22, 2016|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378922||26220|
NCT02380612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP001-6|ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries|Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries||Avita Medical|No|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|N/A|No|||March 2015|March 4, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380612||26090|
NCT02383329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTh112Med|Effects of Oral Nutrition Supplements in Children With Disease Associated Underweight|Effects of Oral Nutrition Supplements in Children With Disease Associated Underweight|MIntS|Aristotle University Of Thessaloniki|No|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|213|||Both|24 Months|12 Years|No|||February 2016|February 1, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02383329||25881|
NCT02459743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS20140005575|Molecular Disease Profile of Hematological Malignancies|Molecular Disease Profile of Haematological Malignancies. A Prospective Registry Study by the Rete Ematologica Lombarda (REL) Clinical Network|RELab1|University of Pavia|No|Recruiting|February 2015|December 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|We developed a protocol to couple high-throughput sample handling with the power of      massively parallel sequencing to sequence all coding exons of a target list of candidate      genes in the cancer cells (i.e. peripheral blood granulocytes for myeloid malignancies and      mononucleated cells or CD19+ cells for limphoproliferative neoplasms), and normal control      cells (i.e. T lymphocytes for myeloid malignancies and buccal cells [swab] for      lymphoproliferative diseases), from a large, well-characterized prospective cohort of      patients with hematological malignancies|Both|18 Years|N/A|No|Probability Sample|Patients with a conclusive diagnosis of haematological malignancies according to WHO        criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be        prospectively enrolled. The investigators will analyse genomic DNA extracted from        hematopoietic cells at different time points of patient disease. The study contemplates        the use of two optimized molecular platforms aimed at the identification of recurrent        mutations in myeloid and lymphoid neoplasms, respectively.|June 2015|June 4, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02459743|2 Years|20015|
NCT02389023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15371|Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery|Multicenter, Prospective, Randomized Clinical Trial of a Negative Pressure Incision Management System in High Risk Vascular Surgery Patients||University of Vermont Medical Center|No|Recruiting|September 2015|April 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|242|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389023||25443|
NCT02389036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-CCT070115|The SuDDICU Study of Antibiotic Prophylaxis in Critical Illness|The SuDDICU Study- A Randomised Trial of the Effectiveness and Cost-effectiveness With a Contemporaneous Study of the Ecological Impact of Selective Decontamination of the Digestive Tract in Critically Ill Patients Treated in ICUs.|SuDDICU|The George Institute|Yes|Not yet recruiting|April 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24000|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02389036||25442|
NCT02393144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography|Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography||Ankara University|No|Recruiting|February 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|1000|||Female|16 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 14, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02393144||25127|
NCT02379039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORRIS_1|Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer|Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer in Head & Neck, Lung, Oesophagus, Anal Canal and Uterine Cervix - a Basis for Personalised Radiotherapy|MORRIS|Umeå University|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|412|Samples With DNA|Tumour biopsies, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with previously untreated squamous carcinoma aimed for radiotherapy with curative        intent of the oral cavity, oropharynx, uterine cervix, oesophagus, anal canal or lung.|June 2015|June 16, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379039||26211|
NCT02448459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGO482|COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study|COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study|COOL-COS|University of Sao Paulo|Yes|Enrolling by invitation|May 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|40 Years|No|||February 2016|February 18, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448459||20882|
NCT02379416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150086|Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors|Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults With Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|120 Years|No|||January 2016|February 3, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02379416||26182|
NCT02381327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mando-1|Reduction of the Speed of Eating as an Intervention in Obesity|Phase 1 Study of the Effect of Mandometer on Speed of Eating and Body Weight in Patients With Binge Eating Disorder||Mando Group AB|Yes|Completed|February 2015|November 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|386|||Both|28 Years|56 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381327||26035|
NCT02381340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39402.068.12|ACE Stapler Sub Study|Effect of the BaroSense ACE Stapler Procedure on Food Intake, Food Reward, Gastric Emptying, Hormone Release, Inflammatory Profile, Gut Microbiota and Behaviour Towards Food.||Maastricht University Medical Center|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|plasma samples, faeces|Both|18 Years|50 Years|No|Probability Sample|Patients that will undergo an ACE stapling procedure for the treatment of obesity.|March 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381340||26034|
NCT02379676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XC14MIMI0092k|Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation|Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome||Seoul St. Mary's Hospital|No|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|20 Years|N/A|No|||March 2015|March 5, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02379676||26162|
NCT02381626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-247|DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)|DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|December 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|42|||Male|21 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02381626||26012|
NCT02379546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GaziosmanpashaU-2|The Effect of Anaesthesia Depth on Oculo-cardiac Reflex|The Effect of Anaesthesia Depth on Oculo-cardiac Reflex in Strabismus Surgery||Tokat Gaziosmanpasa University|Yes|Completed|August 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|64|||Both|3 Years|16 Years|No|||May 2015|May 27, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02379546||26172|
NCT02384083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POMDEFIL|Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients|Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients||PETHEMA Foundation|Yes|Not yet recruiting|September 2015|December 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|March 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384083||25823|
NCT02449226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00718-41|Accuracy of Point-of-Care Measurement With the RapidPoint 500 Blood Gas Analyser|Accuracy of Point-of-Care Measurement of Electrolytes, Glucose, Hemoglobin and Hematocrit With the RapidPoint 500 Blood Gas Analyser|(POCREA)|Hôpital Européen Marseille|No|Completed|May 2015|February 2016|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|All patients staying in our ICU and equipped with an indwelling arterial catheter for whom        clinicians prescribe together an arterial blood gas analysis and a biological laboratory        analysis.        The study will take place over a 1 month period. A total of 300 pairs of samples is        targeted.|February 2016|February 21, 2016|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02449226||20823|
NCT02449239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB4-845-02-IIIA|Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG|Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG||Viventia Bio|Yes|Recruiting|August 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|134|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449239||20822|
NCT02380001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI-FE-028-014|Analgesic Preoperative/Postoperative Dexketoprofen Trometamol in Third Molar Surgery|Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration||Universidad Autonoma de San Luis Potosí|Yes|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|February 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02380001||26137|
NCT02384213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14_198R|Incidence of and Prognostic Factors Associated With Heart Failure Following Myocardial Infarction: a CALIBER Study|Incidence of and Prognostic Factors Associated With Heart Failure Following Myocardial Infarction (iHF): a CALIBER Study|iHF|University College, London|Yes|Active, not recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|55000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All adults aged 18 years and over, registered in CPRD practices in England consenting to        data linkage, with at least one year of validated pre-study follow-up data, and who        experienced a first MI recorded in CALIBER from 1998 to 2010 are potentially eligible.        Definition MI: MI as recorded in HES or ONS (ICD-10 codes I21-I23), CPRD or MINAP. The        type of MI (ST-elevation MI, STEMI; non ST-elevation MI, NSTEMI; or MI not otherwise        specified) is coded in MINAP and CPRD.        Patients will be right censored at end-of-study, which corresponds to the administrative        censoring date of the CPRD dataset, patient death or patient deregistration from the        general practice.|March 2015|March 4, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384213||25813|
NCT02386852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunway-979|Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity|Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity||Sunway University||Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386852||25610|
NCT02384304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1761-31/5|Guided and Unguided Internet Treatment for Problematic Alcohol Use|Guided and Unguided Internet Treatment for Problematic Alcohol Use: A Randomized Pilot Study||Karolinska Institutet|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384304||25806|
NCT02451865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001595|Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer|A Phase IB Dose Escalation and Expansion Trial of MEK 162 With Docetaxel in Previously Treated Stage IV, Non-small Cell Lung Cancer (NSCLC)||Jonsson Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451865||20620|
NCT02380300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Registry Study of Clinical Application of MRI Compatible CIED|||Biotronik (Beijing) Medical Device Ltd.||Not yet recruiting|March 2015|||December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with ProMRI CIED implanted，including ProMRI Pacemaker/CRT and ProMRI ICD/CRTD|March 2015|March 4, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380300|2 Years|26114|
NCT02384447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTIRB 0000200125|Comparing the Ultrasound Appearance of the Sciatic Nerve With Its Appearance Under a Microscope|Correlation of the Ultrasound Appearance of the Sciatic Nerve With Its Histologic Appearance in Pathology Specimens Obtained From Patients Undergoing Above Knee Amputation||University of Toledo Health Science Campus|No|Withdrawn|June 2014|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Amputated extremity for histologic examination of the sciatic nerve.|Both|18 Years|90 Years|No|Non-Probability Sample|Subjects suffering from long standing diabetes and scheduled to undergo an above knee        amputation|August 2014|March 4, 2015|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02384447||25795|
NCT02393495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22012015|Ultrasound Guided Intra-uterine Device Insertion|A Further Step Towards Painless Intrauterine Device Insertion, a Randomized Control Trial||Woman's Health University Hospital, Egypt|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|102|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 30, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02393495||25100|
NCT02390232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7319 02|Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH|Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH|Coli-NASH|University Hospital, Toulouse|No|Recruiting|February 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|feces, liver, blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Non Alcoholic Fatty Liver Disease|August 2015|August 26, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02390232|1 Day|25350|
NCT02450032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC5|Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer|An Open, Multi-center Study to Determine the Antibody Response to 500µg G17DT Given at Weeks 0, 2, and 6 in the Treatment of Patients With Gastric Cancer|GC5|Cancer Advances Inc.|Yes|Completed|February 2000|May 2001|Actual|May 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|August 27, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02450032||20761|
NCT02384226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1173|User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study|User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study||University of Colorado, Denver|No|Recruiting|September 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|45 Years|No|Probability Sample|Potential participants will be identified via the Perinatal Clinical & Translational        Research Center (CTRC) at the University of Colorado at Anschutz Medical Campus.|November 2015|November 10, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384226||25812|
NCT02382536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-14SCARL06|Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults|Infusion Pressure Delivering Insulin Diluent - BD's Scarlett vs. Medtronic's (MDT) Quickset in Healthy Adults||Becton, Dickinson and Company|No|Completed|August 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382536||25942|
NCT02382549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17700|A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma|A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus BRAF Inhibition (Mel61)|Mel61|University of Virginia|Yes|Not yet recruiting|February 2016|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382549||25941|
NCT02446210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140997|Neural Control of Bilateral Movements After SCI|Neural Control of Bilateral Hand, Arm, and Leg Movements After Spinal Cord Injury||University of Miami|No|Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|514|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446210||21054|
NCT02376699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGNS40-001|Safety Study of SEA-CD40 in Cancer Patients|A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies||Seattle Genetics, Inc.|No|Recruiting|February 2015|March 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||February 2016|March 23, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02376699||26391|
NCT02376712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICU2015-2|Diagnostic Value of Urinary Indices in Differentiating Pre-renal and Renal Acute Kidney Injury|||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|||May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Serum, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed acute kidney injury at ICU admission or during ICU stay|February 2015|March 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376712||26390|
NCT02384525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0791|The Assessment of Volume Status by BIA and Lung Ultrasound in Septic AKI Patients Undergoing CRRT|||Yonsei University|No|Not yet recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384525||25789|
NCT02384538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-171|A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-981 to Placebo in Subjects With Erosive Hand Osteoarthritis||AbbVie||Active, not recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|35 Years|80 Years|No|||January 2016|January 25, 2016|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384538||25788|
NCT02382809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC0071 BB 4 05|Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction|Efficacy of DC071 Mouthwash (0.2% Chlorhexidine Digluconate) in Peri-surgical Care for Preventing Alveolar Osteitis After Third Molar Extraction||Pierre Fabre Medicament||Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|414|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382809||25921|
NCT02460991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLACE|A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma|A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma|SOLACE|Boston Scientific Corporation|Yes|Recruiting|November 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460991||19919|
NCT02392494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1075-002|Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)|A Single Rising Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-1075 in HCV-Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392494||25177|
NCT02392507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15529|A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC|A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Recruiting|October 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392507||25176|
NCT02632097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Histoacryl1|Histoacryl™ vs. Suture for Mesh Fixation in Lichtenstein Hernioplasty: A Randomized Prospective Double-Blinded Study|Randomized Prospective Double-Blinded Study of Histoacryl™Mesh Fixation Compared to Conventional Non-absorbable Suture Fixation During Lichtenstein Hernioplasty|Histoacryl1|Hospital Plató|No|Recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|85 Years|No|||December 2015|December 13, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632097||6782|
NCT02629510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACO_1234|the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)|A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer|TACO|Asan Medical Center|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|268|||Female|20 Years|N/A|No|||December 2015|December 10, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02629510||6980|
NCT02629523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.271|Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA|A Phase II, Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients With Activating Epidermal Growth Factor Receptor Mutation in Circulating Tumor DNA|LiquidLung-A|Chonnam National University Hospital|No|Not yet recruiting|March 2016|March 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|19 Years|N/A|No|||December 2015|December 11, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02629523||6979|
NCT02640300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4962|Switching Antipsychotics: Abrupt Discontinuation Versus Overlap|Switching Antipsychotics: Abrupt Discontinuation Versus Overlap||Centre for Addiction and Mental Health|No|Completed|May 1999|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|N/A|N/A|No|||January 2016|January 5, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640300||6152|
NCT02637921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284438/WP3|Planetary Habitat Simulation: Bone Metabolism Studies|Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)|PlanHab|University of Nottingham|Yes|Completed|March 2012|September 2015|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02637921||6335|
NCT02640105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/14|Cluster Headache, Addictions and Vascular Function|Cluster Headache (CH), Addictions and Vascular Function|CHAD|University Hospital, Bordeaux|No|Recruiting|June 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with cluster headache|December 2015|December 21, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02640105|12 Months|6167|
NCT02628418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Feasibility and Efficacy of a Robotic Device for Hand Rehabilitation|Feasibility and Efficacy of a Robotic Device for Hand Rehabilitation in Hemiplegic Stroke Patients: a Randomized Pilot Controlled Study||Fondazione Salvatore Maugeri|No|Completed|May 2013|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02628418||7064|
NCT02633345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8-2014-014|Effects on Tablets Containing Probiotic Candidate Strains|Effects on Tablets Containing Probiotic Candidate Strains on Clinical and Cytokine Markers of Gingival Inflammation and Composition of the Salivary Microbiome||University of Copenhagen|No|Recruiting|September 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|50 Years|No|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02633345||6686|
NCT02633579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ErythromycinHungerFoodIntake|Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways|The Role of Induced Phase 3 Contractions in the Control of Hunger and Food Intake||Universitaire Ziekenhuizen Leuven|No|Completed|October 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|December 14, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02633579||6668|
NCT02391688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-061|Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail|||University Hospital, Geneva|No|Active, not recruiting|November 2014|September 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02391688||25239|
NCT02635022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506039RIND|Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study|Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study in Rural Area||National Taiwan University Hospital|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|new fragility fracture Adults treated with anti-osteoporosis medicines (AOMs)|December 2015|December 20, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02635022||6557|
NCT02639429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0895|Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial|The Efficacy of Transcervical Foley Balloon Plus Vaginal Misoprostol Versus Vaginal Misoprostol Alone For Cervical Ripening In Nulliparous Obese Women: A Randomized, Comparative Effectiveness Trial|CROWN|The University of Texas Health Science Center, Houston|No|Recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639429||6219|
NCT02639676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509123588|Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development|The Effects of Maternal Preeclampsia on the Development of Pulmonary and Vascular Dysfunction in Infants||Indiana University|No|Recruiting|November 2015|||May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood, Cord Blood, and Placenta Samples.|Both|26 Weeks|36 Weeks|No|Non-Probability Sample|Investigators are recruiting two groups of infants born between 26+0 and 36+6 weeks of        gestation. The first group are infant's born to mother's with preeclampsia and the second        are infants born to mother's with a normotensive pregnancy.|December 2015|December 23, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02639676||6200|
NCT02389894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-0009|Neuroprotection in Patients Undergoing Aortic Valve Replacement|Neuroprotection In Patients Undergoing Aortic Valve Replacement||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|535|||Both|60 Years|N/A|No|||February 2016|February 22, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389894||25376|
NCT02387346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4247|The Cerebellum as a Potential Treatment Site for PD Motor Symptoms|The Contribution of the Cerebello-thalamo-cortical Circuit to the Pathology of Non-dopaminergic Responsive Parkinson's Disease Symptoms||Sun Life Financial Movement Disorders Research and Rehabilitation Centre|No|Recruiting|April 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||April 2015|April 8, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02387346||25572|
NCT02383745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH507T011|EEG in In-hospital Patients With Seizure or Altered Mental State|Integrating EEG Into Acute Medicine: EEG in In-hospital Patients With Seizure or Altered Mental State Who Have Been Consulted by Medical Emergency Team||Kuopio University Hospital||Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|In-hospital patients, who have seizure or altered mental state and have been consulted by        MET-team|October 2015|October 14, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383745||25849|
NCT02384005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-13-0671|The Feasibility of Self or Partner-assisted Digital Anal Exam Screening|The Feasibility of Self or Partner-assisted Digital Anal Exam Screening||The University of Texas Health Science Center, Houston|Yes|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Male|27 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02384005||25829|
NCT02381704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.03.08|Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System Following Surgery Coverage|Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System||Florida Hospital|No|Completed|April 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|64 Years|No|Non-Probability Sample|Study subjects will include any individual having been approved for surgery that consents        to the review of their records and additional survey information pertaining to medication        use, dosage, anthropometrics and medical-related days taken. Study subjects would include        male and female gender, all ethnicities, ages 18 to 65 years, and exclude populations who        do not meet the criteria for bariatric surgery|March 2015|March 5, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381704||26006|
NCT02381951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01356-41|Spinal Cord Stimulation in the Treatment of Parkinson's Disease||STIMUPARK|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Not yet recruiting|September 2015|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|40 Years|75 Years|No|||March 2015|August 13, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381951||25987|
NCT02459327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD07639001A1|Integrated Model for Promoting Parenting and Early School Readiness in Pediatrics|||New York University|No|Enrolling by invitation|May 2015|||May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02459327||20047|
NCT02459340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLUZH-1|Emotional and Cognitive Self-regulation, an EEG Study|Effectiveness of Therapeutic Treatment: Hot and Cold Self-regulation in Posttraumatic Stress Disorder, Dissociative Disorder, and Borderline Personality Disorder|ECSR|Clienia Littenheid AG|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|175|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||May 2015|September 26, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02459340||20046|
NCT02388321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-20-MMC|Pediatric Ketamine Study for Pain Management|Comparison of Sub-dissociative Dose Intranasal Ketamine to Intranasal Fentanyl for Treatment of Moderate to Severe Pain in Pediatric Patients Presenting to the Emergency Department: a Prospective, Randomized, Double-blind Study||Maimonides Medical Center|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|17 Years|No|||October 2015|October 27, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388321||25497|
NCT02388620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011A2109|Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011|A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.||Novartis|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Male|18 Years|75 Years|No|||February 2016|February 19, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388620||25474|
NCT02393638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403004RIND|ERCP Mechanical Simulator (EMS) Practice for Training Endoscopic Sphincterotomy|ERCP Mechanical Simulator (EMS) Practice for Training Endoscopic Sphincterotomy||National Taiwan University Hospital|No|Recruiting|April 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|20|||Both|20 Years|70 Years|No|||March 2015|March 18, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02393638||25089|
NCT02455934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-D-alloluse01|Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level|The Dose-response Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level in Healthy Volunteers and Volunteers With Impaired Fasting Glucose||Chiang Mai University|Yes|Completed|April 2015|December 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 30, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455934||20308|
NCT02459418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN1002|Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application|Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application. A Randomised, Open Label, 2-way Cross-over Study||Finox AG|No|Recruiting|May 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02459418||20040|
NCT02388646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRKDJO-RWB-15|Energy Dispersive Bracing for Conservative Treatment of Knee Osteoarthritis|||Orthopaedic Research Foundation||Recruiting|March 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|80 Years|No|||March 2015|March 9, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388646||25472|
NCT02388659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU022014-048|Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas|Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas||University of Texas Southwestern Medical Center|No|Recruiting|February 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|105|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388659||25471|
NCT02390973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remission|Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)|Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)|REMISSION|Laval University|No|Recruiting|March 2015|March 2021|Anticipated|March 2021|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|408|||Both|18 Years|60 Years|No|||March 2016|March 10, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02390973||25293|
NCT02390986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LON002-003|An Extension Study of LON002 in Patients With Cancer|An Extension Study of LON002 in Patients With Cancer||LondonPharma Ltd.|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02390986||25292|
NCT02377687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-58-0004|Is Life Worth Living After Major Emergency GI Surgery? Patient Reported Outcome in Elderly Emergency Surgery Patients|Is Life Worth Living After Major Emergency GI Surgery? Patient Reported Outcome in Elderly Emergency Surgery Patients||Hvidovre University Hospital|No|Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|75 Years|N/A|No|Non-Probability Sample|We will identify all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy        between the 1st of November 2014 and the 30st of April 2015. We will also include        reoperations after elective surgery (major bleeding, anastomotic leakage etc.) and        endoscopic procedures converted during the intervention (upper GI-bleeding, unsuccessful        stenting of obstructing colorectal cancer etc.).|February 2016|February 23, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377687||26315|
NCT02456233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECONFIRM2015|Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF|Randomized Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human Atrial Fibrillation (RECONFIRM): A Randomized Clinical Trial|RECONFIRM|Stanford University|Yes|Not yet recruiting|July 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|22 Years|N/A|No|||May 2015|May 27, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02456233||20285|
NCT02378311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRIPS-F-V4.15|Handlebar Grip Related Injury Prevention (GRIP) Study: Are Exposed Metal Handlebar Ends a Risk Factor for Injury?|A Multicentre Observational Case-controlled Feasibility Study: In Children Who Ride Bikes or Scooters, is the Risk of Sustaining a Serious Injury Greater When Metal Handlebar Ends Are Exposed Than When They Are Covered by Intact Grips?|GRIP|Birmingham Children's Hospital NHS Foundation Trust|No|Completed|March 2015|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|N/A|15 Years|No|Probability Sample|Children attending either one of two tertiary paediatric hospital emergency departments        and paediatric surgical units in the United Kingdom.|January 2016|January 13, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378311||26267|
NCT02384473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11S-14-1|Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma|Real-Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in Sarcomas||University of Southern California|Yes|Recruiting|December 2014|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|January 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384473||25793|
NCT02384486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVS12022015 SA SoM PAPsych PhD|Efficacy of Training Programme to Reduce Stress|Evaluating the Efficacy of a Proposed Training Programme to Reduce Stress in Mothers of Children With Autism Spectrum Disorder (ASD) in Saudi Arabia: A Pilot Study||University of Nottingham|Yes|Active, not recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|70|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384486||25792|
NCT02392910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5427-06/07|Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.|Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study||Hospital Aleman|Yes|Completed|March 2006|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02392910||25145|
NCT02446158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAHP99020|Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients|A Randomized Trial of Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients for Bacterial Decolonization and Prevention of Infection||E-DA Hospital|Yes|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|89|||Both|20 Years|N/A|No|||May 2015|May 13, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02446158||21058|
NCT02386332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPH|A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies|A Randomized Multicenter Study Comparing Unrelated Umbilical-cord Blood Transplant Versus Human Leukocyte Antigen (HLA)-Haploidentical Related Hematopoietic Stem Cell Transplant for Adult Patients With Hematologic Malignancies||Instituto de Investigacion Sanitaria La Fe|No|Not yet recruiting|March 2015|March 2020|Anticipated|February 2020|Anticipated|Phase 3|Observational|Time Perspective: Prospective||2|Anticipated|206|||Both|18 Years|55 Years|No|Probability Sample|Diagnosed with acute leukemia or myelodysplastic syndrome in which allogeneic        transplantation is considered the most potentially curative therapeutic option|March 2015|March 5, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02386332||25650|
NCT02384733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Skagen Trial 1|Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost|The Skagen Trial 1, Moderately Hypofractionated Loco-regional Adjuvant Radiation Therapy of Early Breast Cancer Combined With a Simultaneous Integrated Boost: a Randomised Clinically Controlled Trial||Danish Breast Cancer Cooperative Group|Yes|Recruiting|March 2015|March 2036|Anticipated|March 2036|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02384733||25773|
NCT02385032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_UDCA001|Comparative Bioavailability Study of UDCA|||Daewoong Pharmaceutical Co. LTD.||Completed|February 2015|May 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385032||25750|
NCT02392949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20140926001|Does Passive Spinal Mobilization Improve Shoulders Strength in Healthy Adults?|Does Passive Spinal Mobilization Improve Shoulders Strength in Healthy Adults?||The Hong Kong Polytechnic University|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02392949||25142|
NCT02392962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIH 201014-2|Dynamic and Static Stretching on Postural Stability, Reaction Time and Countermovement Jump of Sprinters|Efectos de la Fatiga en el Rendimiento físico en el Ejercicio de Sentadillas||Universidad Católica San Antonio de Murcia|Yes|Completed|December 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02392962||25141|
NCT02450487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20657913.7.0000.5417 CAAE|Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery|Influence of Genotype of Cytochrome P450 (CYP2C9) on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery||University of Sao Paulo|Yes|Completed|October 2012|December 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|102|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450487||20726|
NCT02386787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308170|Ultrasound Assessment of Gastric Content for Semi Emergency Surgery|Ultrasound Assessment of Gastric Content for Semi Emergency Surgery|ECHO-GAST|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02386787||25615|
NCT02386800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2X01B|CINC424A2X01B Rollover Protocol|An Open Label, Multi-center, Phase IV Roll-over Protocol for Patients Who Have Completed a Prior Global Novartis or Incyte Sponsored Ruxolitinib (INC424) Study and Are Judged by the Investigator to Benefit From Continued Treatment||Novartis|No|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|129|||Both|N/A|N/A|No|||March 2016|March 21, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386800||25614|
NCT02385591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK102016|Innovative Physical Activity Interventions for Overweight Latinos|Innovative Physical Activity Interventions for Overweight Latinos|SMS-Stanford|Stanford University|Yes|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|376|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385591||25707|
NCT02388477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002143|Trial of the Use of Doxycycline After Rotator Cuff Repair|Randomized Controlled Trial of the Use of Doxycycline After Rotator Cuff Repair||Milton S. Hershey Medical Center|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388477||25485|
NCT02388490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X25016|Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas|A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas|Bretuximab|Seoul National University Hospital|No|Not yet recruiting|April 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388490||25484|
NCT02448160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-AAR-009|Alfapump-albumin Replacement Therapy|Study Into the Effects of Albumin Replacement Therapy on Renal and Circulatory Function in Patients Implanted With the Alfapump||Sequana Medical AG|No|Not yet recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02448160||20905|
NCT02379156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAN-14-045|Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia|Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia||James J. Peters Veterans Affairs Medical Center|No|Recruiting|April 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379156||26202|
NCT02379169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBEYE|Effects of Sea Buckthorn Oil and Lutein on Eye Health||SBEYE|Turku University Hospital|No|Not yet recruiting|February 2015|August 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||November 2014|February 26, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02379169||26201|
NCT02381080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106609|Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy|A Drug-drug Interaction Study of Ibrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-cell Malignancy||Janssen Research & Development, LLC|No|Recruiting|May 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381080||26054|
NCT02383550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNO-002|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension|CogMS-Ext|Clinique Neuro-Outaouais|No|Recruiting|December 2014|January 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|47|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple sclerosis who are receiving Tysabri per indication.|August 2015|August 6, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383550||25864|
NCT02453295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HopePilot|Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema|Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema||University of Ottawa|No|Not yet recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|N/A|N/A|No|||May 2015|May 22, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453295||20510|
NCT02383693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00244-49|Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study|Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study|TMS/DEP|Centre hospitalier de Ville-Evrard, France|No|Recruiting|January 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||March 2015|March 3, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02383693||25853|
NCT02386085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMT Adverse Events Study|Patient-reported Adverse Events From Osteopathic Manipulative Treatment|Patient-reported Adverse Events From Osteopathic Manipulative Treatment||A.T. Still University of Health Sciences|No|Enrolling by invitation|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is patients who receive osteopathic manipulative treatment from a        licensed practitioner for any reason.|February 2015|March 6, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386085||25669|
NCT02389582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 3877/13/002|Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease|Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease||University of Sao Paulo General Hospital|No|Completed|May 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||August 2014|December 15, 2015|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02389582||25400|
NCT02389595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401012|A T Cell-based HIV Vaccine|Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes||University of Florida|No|Recruiting|May 2015|May 2024|Anticipated|May 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|Samples With DNA|Serum Whole Blood T cells|Both|18 Years|65 Years|No|Non-Probability Sample|HIV positive individuals between 18 and 65 years old|October 2015|October 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389595||25399|
NCT02459769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56965|Exercise Intervention for LGBT Cancer Survivors|Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender (LGBT) Cancer Survivors and Caregivers||University of Rochester|Yes|Recruiting|May 2015|||May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 20, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459769||20013|
NCT02459782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424-2011|Ultrasound Guided Peribulbar Anaesthesia - A Novel Dual Quadrant Injection Technique|Ultrasound Guided Peribulbar Anaesthesia: a Real-time Ultrasound Guided Technique With a Novel Dual Quadrant Injection||Sunnybrook Health Sciences Centre|No|Completed|January 2012|August 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|90 Years|No|||May 2015|May 28, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02459782||20012|
NCT02459795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-15-002|To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis|||Perrigo Company|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|465|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459795||20011|
NCT02383966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR062202-060|Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer|A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|CHANGE2|Merck KGaA|Yes|Recruiting|July 2015|March 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383966||25832|
NCT02386748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFHSR 1-3-2015|Chewing Gums to Stimulate Intestinal Motility After Cesarean Section|Chewing Gums to Stimulate Intestinal Motility After Cesarean Section: A Randomized Controlled Trial||Ain Shams University|No|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|450|||Female|20 Years|35 Years|No|||March 2015|March 17, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386748||25618|
NCT02384096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90968587|A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes|COVERAGE - A Study to Evaluate the Effect of Precision Spectra™ SCS System's Programming Features and Lead Options on Patient Outcomes|COVERAGE|Boston Scientific Corporation|No|Active, not recruiting|February 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|February 16, 2016|January 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384096||25822|
NCT02453880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29456|Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness|Web-based "Self-Help" Cognitive Behavioral Therapy for Symptoms of Mild-to-Moderate Anxiety and Depression in Adolescents and Young Adults With Chronic Illness||Stanford University|No|Active, not recruiting|January 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|15 Years|25 Years|No|||May 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453880||20465|
NCT02453893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HC103/PRO/Ⅱ|Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia|Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|November 2013|||June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|65 Years|No|||March 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453893||20464|
NCT02392741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1161-5873|Effects of a Physical Exercise Program on Microcirculation and Pregnancy Outcomes in Obese Pregnant Women|Effects of a Physical Exercise Program on Microcirculation and Pregnancy Outcomes in Obese Pregnant Women: Randomized Clinical Trial||Professor Fernando Figueira Integral Medicine Institute|No|Not yet recruiting|March 2015|March 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||March 2015|March 18, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02392741||25158|
NCT02458391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIndianapolis|Complete Decongestive Therapy in Breast Cancer-Related Lymphedema|Therapeutic Quantity of Complete Decongestive Therapy in Breast Cancer-Related Lymphedema: A Double Blinded Randomized Control Trial||University of Indianapolis|Yes|Withdrawn|July 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|95 Years|No|||August 2015|August 5, 2015|November 17, 2014||No|No participants available|No||https://clinicaltrials.gov/show/NCT02458391||20119|
NCT02387788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-9778_CI-4001|Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO|Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion||Aerpio Therapeutics|No|Recruiting|January 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||July 2015|July 13, 2015|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387788||25538|
NCT02383277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPEFT2015|Acute Effects of a Stretching Program of the Rib Cage Muscles on Patients With COPD During Exercise|Acute Effects of a Stretching Program of the Rib Cage Muscles on the Regional Distribution of Ventilation and the Diaphragmatic Mobility of Patients With COPD During Exercise: a Randomized Crossover Clinical Trial||Universidade Federal de Pernambuco|Yes|Active, not recruiting|November 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|80 Years|No|||August 2015|August 7, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02383277||25885|
NCT02377713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6640-002|A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.|A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.||Kyowa Hakko Kirin Company, Limited|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|84 Years|No|||February 2016|February 22, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377713||26313|
NCT02459379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G150066|Cardiac Implantable Electronic Device Magnetic Resonance Imaging Registry|Cardiac Implantable Electronic Device Magnetic Resonance Imaging Registry (CIED-MRI Registry)|CIED-MRI|New York University Langone Medical Center|No|Not yet recruiting|July 2015|||July 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CIED that is not labeled as MRI Conditionally Safe that require an MRI scan        for their clinical care.|May 2015|May 28, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02459379|3 Months|20043|
NCT02459457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505146-13|Compare Paclitaxel and Cisplatin，Paclitaxel and Fluorouracil， Paclitaxel and Carboplatin Concurrent With Radiotherapy in Local Advanced ESCC|A Phase III Trial to Compare Paclitaxel and Cisplatin，Paclitaxel and Fluorouracil， Paclitaxel and Carboplatin Concurrent With Radiotherapy in Local Advanced Esophageal Squamous Cell Carcinoma||Fudan University|Yes|Recruiting|July 2015|December 2021|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|414|||Both|18 Years|75 Years|No|||May 2015|July 4, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02459457||20037|
NCT02388100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRADE_CAP|The GRADE Capillary Blood Collection Pilot Study|The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study) Capillary Blood Collection: A Pilot Study||GRADE Study Group|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|30 Years|N/A|No|Non-Probability Sample|All GRADE study participants scheduled for a follow-up visit at selected GRADE clinical        sites.|December 2015|December 2, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02388100||25514|
NCT02388113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1405|Effect of Exercise Frequency on Metabolic Control and Heart Function in Type 2 Diabetes|The Effect of Accumulated Versus Traditional Exercise Training on Metabolic Control and Heart Function in Individuals With Type 2 Diabetes||Norwegian University of Science and Technology|No|Completed|October 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|70 Years|No|||November 2015|November 5, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388113||25513|
NCT02379013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRD0714|Measure of Fatigue in Functional MRI|Development and Evaluation of a Cognitive-motor System for a Quantitative and Objective Measure of Fatigue in Functional MRI|FATIGUE|Centre Hospitalier René Dubos|No|Completed|February 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379013||26213|
NCT02386189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 14-392|Veteran Dual Use of Health Systems|Dual Health Systems Users: Strategies to Implement Optimal Care Coordination||VA Office of Research and Development|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02386189||25661|
NCT02386202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1491|ARC in Hemorrhagic Stroke|Augmented Renal Clearance in Hemorrhagic Stroke Patients Admitted to the Neurosciences Intensive Care Unit||University of North Carolina, Chapel Hill|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|30 patients with hemorrhagic stroke admitted to the University of North Carolina        Neurosciences Intensive Care Unit|December 2015|December 1, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386202||25660|
NCT02383654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH103-REC2-072|Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis|An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis With Brain Transplants of Autologous Adipose-Tissue Derived Stem Cells (ADSCs)||China Medical University Hospital|Yes|Completed|January 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|35 Years|50 Years|No|||January 2016|January 29, 2016|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02383654||25856|
NCT02383667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orbital|Clinical Comparison of Electrocardiograms Collected Using an Ambulatory Holter||Orbital|University of Toledo Health Science Campus|No|Recruiting|February 1999|June 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|All patients within the hospital either for a procedure or for admission|December 2014|March 3, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02383667||25855|
NCT02381301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 14-4-117|Biomarkers and Cardiac CT|Biomarkers and Cardiac Computed Tomography: Relationship Between Cardiovascular Biomarkers and Coronary Artery Disease in Patients Undergoing Cardiac Computed Tomography||Maastricht University Medical Center|No|Recruiting|February 2015|December 2029|Anticipated|December 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients referred from the Cardiology clinic for routine CCTA for diagnostic purposes,        will be included in this study, after given written informed consent.|September 2015|September 24, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381301||26037|
NCT02386514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9107|Emergency Department, Rapid Assessment for Sexually Transmitted Infection||ED-RASTI|Henry Ford Health System|No|Recruiting|March 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients greater than 18 years of age presenting with a complaint that triggers the        providing clinician to obtain a gonorrhea and chlamydia test by the traditional format.|March 2015|March 15, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02386514||25636|
NCT02389439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cambodia1|Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria|Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria||University of Oxford|Yes|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|7 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389439||25411|
NCT02387736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026/2014|DBT for Chronically Self-harming Individuals With BPD: Evaluating the Clinical &Cost Effectiveness of a 6 mo. Treatment|Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment|FASTER-DBT|Centre for Addiction and Mental Health|Yes|Recruiting|February 2015|March 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02387736||25542|
NCT02387749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACULTY OF MEDICINE,CAIRO U|Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .|Effect Of Mesenchymal Stem Cells Transfusion on the Peripheral Neuropathy in Diabetic Patients Measured by Nerve Conduction.||Cairo University|Yes|Active, not recruiting|May 2014|August 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|45 Years|No|||January 2016|January 29, 2016|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387749||25541|
NCT02446834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2015]018K|Research of Intensive Lifestyle Intervention for PCOS Patients With IGT|Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment||RenJi Hospital|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Female|14 Years|50 Years|No|||May 2015|May 27, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02446834||21006|
NCT02378376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s55383|In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon|In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon After Consumption of Different Cereal Fractions.||Katholieke Universiteit Leuven||Completed|July 2013|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378376||26262|
NCT02631486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMH 277|Does Early Mobilisation Improve Outcomes After Rotator Cuff Repair?|Does Early Mobilisation After Surgical Repair of Rotator Cuff Tears Improve Biomechanical and Clinical Outcomes?||University of Central Lancashire|Yes|Not yet recruiting|April 2016|July 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|40 Years|70 Years|No|||March 2016|March 2, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02631486||6828|
NCT02636569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150814005|Topical Chemoprevention of Skin Cancer Biomarkers|Topical Chemoprevention of Skin Cancer Biomarkers||University of Alabama at Birmingham|Yes|Not yet recruiting|February 2016|August 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636569||6439|
NCT02633098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0154|A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer|Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer|NeoART|St George's, University of London|Yes|Not yet recruiting|May 2016|May 2023|Anticipated|May 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|March 14, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02633098||6705|
NCT02640534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/14 - IMPROVE|Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone|Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial||Swiss Group for Clinical Cancer Research|No|Not yet recruiting|June 2016|June 2026|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Male|18 Years|N/A|No|||December 2015|December 28, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640534||6134|
NCT02631759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-845|Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage|Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage|PEACH|Hospices Civils de Lyon|No|Not yet recruiting|April 2016|April 2019|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02631759||6807|
NCT02631772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-337-1830|LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients|Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients||Medical University of South Carolina|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||October 2015|December 14, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631772||6806|
NCT02632357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMilanoBicocca|Longitudinal Experimental Study on ULNTT and Cervico-Thoracic Spine Motion Patterns Relationship|Longitudinal Experimental Study on ULNTT1 and Cervico-Thoracic Spine Motion Patterns Relationship||University of Milano Bicocca|Yes|Completed|December 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 28, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02632357||6762|
NCT02632578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kent001|Influenza Vaccine in HIV Study|A Comparison of Immune Responses to the Licensed Trivalent Inactivated Influenza Vaccine in HIV-positive and HIV-negative Subjects||University of Melbourne|No|Completed|February 2015|December 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|Samples With DNA|Serum, plasma, peripheral blood mononuclear cells|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from two sites in Melbourne, Australia:          -  Melbourne Sexual Health Centre (HIV-positive and HIV-negative subjects)          -  The University of Melbourne at the Peter Doherty Institute for Infection and Immunity             (HIV-negative subjects only)|December 2015|December 15, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632578||6745|
NCT02640417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHCN-03-12-15|Nucleotides and B Vitamins in the Treatment of Low Back Pain|Avaliação clínica-terapêutica Comparativa em Lombalgias de Etiologia Traumato-compressivas Utilizando-se Vitaminas do Complexo B e nucleotídeos||Fundação Educacional Serra dos Órgãos|No|Not yet recruiting|March 2016|October 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02640417||6143|
NCT02640508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS 15-2139|Eribulin and Lenvatinib in Advanced Solid Tumors|Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)||The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640508||6136|
NCT02377492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043231|Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy|Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy: A Randomized Controlled Trial||University Hospital Case Medical Center|No|Not yet recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|March 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377492||26330|
NCT02381483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1032/2013|Vitamin A in Brown Fat Activity|The Role of Vitamin A in Brown Fat Activity and Energy Metabolism||Medical University of Vienna|Yes|Recruiting|February 2014|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|82|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02381483||26023|
NCT02638285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShirazSUMSnew|Pregnancy Rate by HCG Administration Versus Urinary LH Surge Method in Patients Undergoing IUI|||Shiraz University of Medical Sciences|Yes|Completed|January 2009|||August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|86|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02638285||6307|
NCT02642653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|520144|Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome|Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome||University of California, Davis|Yes|Recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|10 Years|17 Years|No|||January 2016|January 26, 2016|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02642653||5971|
NCT02390960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-6006-007-01|A Phase 2a, Single-Dose, Double-Blind, Placebo-Controlled, 2-Way Crossover Study Using Penile Plethysmography to Evaluate the Efficacy and Safety of SST-6006, a Topical Sildenafil Cream (5% w/w), Compared to Placebo in the Treatment of Erectile Dysfunction|A Phase 2a, Single-Dose, Double-Blind, Placebo-Controlled, 2-Way Crossover Study Using Penile Plethysmography to Evaluate the Efficacy and Safety of SST-6006, a Topical Sildenafil Cream (5% w/w), Compared to Placebo in the Treatment of Erectile Dysfunction||Strategic Science & Technologies, LLC|No|Recruiting|March 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|70 Years|No|||October 2015|October 2, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390960||25294|
NCT02391012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0198-12-MMC|Fecal Transplantation for Inflammatory Bowel Disease|Fecal Transplantation for Inflammatory Bowel Disease|FMT IBD|Meir Medical Center|No|Not yet recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02391012||25290|
NCT02389608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/18128-6|The Immediate Effect of Electrical Stimulation Transcranial Direct Current (tDCS) Associated With the Use of FES, in Muscle Activity of the Tibialis Anterior Muscle, Balance and Plantar Pressure Distribution of Individuals With Hemiparesis Due to Stroke|The Immediate Effect of Electrical Stimulation Transcranial Direct Current (tDCS) Associated With the Use of FES, in Muscle Activity of the Tibialis Anterior Muscle, Balance and Plantar Pressure Distribution of Individuals With Hemiparesis Due to Stroke - Randomized, Double Blind||University of Nove de Julho|Yes|Recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||November 2015|November 30, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02389608||25398|
NCT02389621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1423M0634|Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures|A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)|L-PLUS 2|Shionogi Inc.|Yes|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|February 16, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389621||25397|
NCT02379000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2404|TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy|Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy||Charite University, Berlin, Germany|No|Active, not recruiting|January 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 29, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379000||26214|
NCT02387476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000-01|Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea|Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea||FRESCA Medical|No|Completed|October 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|70 Years|No|||December 2015|December 15, 2015|October 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387476||25562|
NCT02389790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E14|Extension Study of MT-1303 in Subjects With Crohn's Disease|A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease Who Have Completed the MT 1303-E13 Study||Mitsubishi Tanabe Pharma Corporation|Yes|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389790||25384|
NCT02446782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1816/Res/2440|Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy|A Study to Evaluate the Efficacy and Safety of a Single Dose of an Injectable Antibiotic for the Prophylaxis of Surgical Site and Pleural Space Infection After Medical Thoracoscopy|APT|Postgraduate Institute of Medical Education and Research|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|12 Years|80 Years|No|||May 2015|May 13, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02446782||21010|
NCT02377544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKUI-RSCM|The Role of Bifidobacterium Animalis Ssp Lactis DR10 Supplementation in Women During Pregnancy and Lactation on Breast Milk IL-8 and Gut Mucosa Integrity in Infant|The Role of Bifidobacterium Animalis Ssp Lactis DR10 Supplementation in Women During Pregnancy and Lactation on Breast Milk IL-8 and Gut Mucosa Integrity in Infant||Indonesia University|Yes|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|70|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377544||26326|
NCT02377557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFDS2014-20384|Observational Study to Assess Safety and Utility Pattern of Topical Steroids|Topical Steroid Registry: Observational Study to Assess Safety and Use Pattern in Korea||Hanyang University|No|Recruiting|February 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1400|||Both|19 Years|69 Years|No|Non-Probability Sample|All patients or guardian of child purchased topical steroids in Korea|April 2015|April 29, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377557|6 Months|26325|
NCT02387398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02387398|Early Coronary Angiography Versus Delayed Coronary Angiography|A Pilot Randomized Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography for Post-Cardiac Arrest Patients Without ECG ST Segment Elevation|PEARL|University of Arizona|Yes|Recruiting|December 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02387398||25568|
NCT02387411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not applied|High-intensity Interval Versus Combined Exercise Training in CHF|High-intensity Interval Versus Combined High-intensity Interval and Strength Exercise Training in Chronic Heart Failure||University of Athens|No|Active, not recruiting|May 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||March 2015|March 12, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02387411||25567|
NCT02377388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of São Paulo GH|Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function|Saxagliptin in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function||University of Sao Paulo General Hospital|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377388||26338|
NCT02459431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIMERpulmoIndia|RCT Comparing 21 and 22 G Needle in the Diagnosis of Sarcoidosis by EBUS TBNA|Impact of Needle Size on the Diagnosis of Sarcoidosis by Endobronchial Ultrasound Guided Transbronchial Needle Aspiration: Randomized Trial Comparing 21-Gauge and 22-Gauge Needles||Postgraduate Institute of Medical Education and Research|No|Recruiting|December 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|99 Years|No|||October 2015|October 20, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02459431||20039|
NCT02446795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUASAR - 2014-001|Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial|Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial|QUASAR|Consorzio Oncotech|No|Not yet recruiting|April 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02446795||21009|
NCT02377817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC-S7-0629-01-10-HAL|Halifax PrenaBelt Trial|A Maternal Device for the Prevention of Stillbirth and Low Birth-Weight||IWK Health Centre|No|Recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02377817||26305|
NCT02378298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTX -TAO|Rituximab (RTX) Therapy in Patients With Active TAO|Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO||Göteborg University|Yes|Recruiting|December 2011|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|January 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378298||26268|
NCT02382237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM2013/31|Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition|Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition Assessed by F-FDG Petscan|PETANC|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|October 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|February 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02382237||25965|
NCT02459535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILIAS-1|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1|ILIAS-1|German Institute of Human Nutrition|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Anticipated|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|June 1, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02459535||20031|
NCT02382874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Kidney-005|Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)|Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical Trial||Royan Institute|Yes|Recruiting|May 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|2 Years|14 Years|No|||November 2015|December 3, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382874||25916|
NCT02388139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REN-ACS|Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (REN-ACS)|Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (AMI) Included in the Romanian National Programme of Primary Percutaneous Revascularisation - a Single Center Observational Study|REN-ACS|Grigore T. Popa University of Medicine and Pharmacy|No|Recruiting|October 2014|June 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|serum creatinine, serum urea, lipid profile, glycemia, haemoglobin, etc|Both|18 Years|N/A|No|Non-Probability Sample|-  inclusion criteria: study population consists of all consecutive patients admitted             with AMI (<12h) diagnostic confirmed;          -  included in the Romanian National Programme of Primary Percutaneous Revascularisation             (for who the Guidelines recommend primary PCI);          -  have read and signed standard informed consent for angiography in AMI;|January 2016|January 12, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388139||25511|
NCT02378168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK ZH 2014-0040|6-month Follow up After Sevoflurane Postconditioning|Late Postconditioning After Cardiac Surgery - Bridge From Surrogate Markers to Clinical Outcome||University of Zurich|No|Completed|April 2014|November 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|108|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients who had successfully completed the late postconditioning trial (NCT00924222)        were included in this retrospective follow-up analysis.|February 2015|February 27, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378168||26278|
NCT02450227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M220|Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices|Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices - a Explorative Study in Short-bowel Patients and Healthy Controls - The "Popeye-study"|Popeye|University of Copenhagen|No|Terminated|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|May 17, 2015||No|It is considered non-achievable to recruit the target number of subjects in the short bowel    group (n = 12). 10 participants were recruited.|No||https://clinicaltrials.gov/show/NCT02450227||20746|
NCT02450240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002|Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders|T-1000: Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders||Laureate Institute for Brain Research, Inc.|No|Recruiting|January 2015|January 2021|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1200|Samples With DNA|Whole Blood, Serum, Plasma, Microbiome|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|March 2016|March 1, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02450240||20745|
NCT02450253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0189|Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial|Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial|PASTIS|St George's, University of London|No|Recruiting|September 2015|August 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|54|||Both|55 Years|N/A|No|||September 2015|September 28, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450253||20744|
NCT02388828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 33514|CART-meso Long-term Follow-up|Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-meso Gene Therapy Products in Cancer Studies||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2015|||March 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Subjects who have received lentiviral-based CARTmeso therapy|March 2016|March 18, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388828||25458|
NCT02388919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-03-IIB|Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）|A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer|ALTER0303|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02388919||25451|
NCT02393066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407023MINA|Comparison of Hemodynamics Between Dexmedetomidine and Propofol for Sedation in Patients With Abdominal Surgery|A Comparison of Hemodynamic Effects Between Dexmedetomidine and Propofol for Sedation in Patients With Major Abdominal Tumor Surgery||National Taiwan University Hospital|No|Completed|October 2014|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|N/A|No|||August 2015|August 3, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02393066||25133|
NCT02378480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTK0796-ABSI-1108|Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)|A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)||Paratek Pharmaceuticals Inc|Yes|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378480||26254|
NCT02382757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3982|Changing Diabetes in Children|Changing Diabetes in Children (CDiC): Type 1 Diabetes in Economically Underprivileged Children in India|CDiC|Novo Nordisk A/S|No|Terminated|September 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3089|||Both|N/A|18 Years|No|Probability Sample|Children with type 1 diabetes aged below 18 years will be included.|February 2015|March 3, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382757||25925|
NCT02458014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0844|Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease|Phase II Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458014||20148|
NCT02389335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGEAH-2|Roles of T Helper 1 Cytokines in Type 1 Diabetes|Roles of Interferon Gamma, Interleukin-2 and Tumor Necrotizan Factor Alpha in the Pathogenesis of Type 1 Diabetes||Istanbul Medeniyet University|No|Completed|April 2013|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|128|Samples Without DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study included 98 T1DPs and 30 healthy subjects (CG). All subjects        were matched on age and gender. β-cell function of 98 T1DPS was assesseed by measuring        C-Peptide levels        after mixed-meal tolarence test (MMTT)s. T1DPs were divided into 3        groups according to the C-Peptide levels after MMTTs and the groups        were as follows: patients with undetectable ≤0.1 ng/mL(group 1a, n=30)        C-Peptide levels; minimal 0.1-0.8 ng/mL(group1b, n=30); and sustained        ≥0.8ng/mL(group1c, n=38) C-peptide levels which increased at the 90th        minute after the meal ≥150% of fasting C-peptide level.|March 2015|March 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389335||25419|
NCT02389348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP14C12|A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265|A Proof-of-concept Study to Assess the Effect of a Range of Doses of Combined Therapy With OZ439 and DSM265 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants|OZ/DSMCombo|Medicines for Malaria Venture|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02389348||25418|
NCT02389400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCH-MA-001|Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis|Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis|MAALCH|Peking Union Medical College Hospital|No|Recruiting|January 2014|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||March 2015|March 10, 2015|February 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389400||25414|
NCT02389413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBD01071|Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease|A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease|SAPHIR|Probiodrug AG|Yes|Recruiting|March 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|50 Years|89 Years|No|||January 2016|March 14, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02389413||25413|
NCT02390271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m trousselard|How Reducing Anxiety in Schizophrenia|Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia||Institut de Recherche Biomedicale des Armees|Yes|Completed|June 2010|June 2011|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|65 Years|No|||March 2015|March 10, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02390271||25347|
NCT02453048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-80|Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine|Phase Ib (High Dose), Single Centre, Dose-escalating, Placebo-controlled, Randomized Study of a Live Attenuated B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Volunteers||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|54|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02453048||20529|
NCT02385851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-1701-03|Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)|A Randomized, Double-Blind, Crossover Study to Compare the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects||Coherus Biosciences, Inc.|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|116|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385851||25687|
NCT02390323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-012|Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic Blocks|Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic Blocks||Hospital for Special Surgery, New York|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02390323||25343|
NCT02390388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242890|Pudendal Block Versus Caudal Block for Hypospadias|A Comparison of Effectiveness of Pudendal Nerve Block vs Caudal Block for Hypospadias Surgery in Children||Istanbul University|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Male|1 Year|10 Years|No|||August 2015|August 25, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02390388||25338|
NCT02459275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP uP Surgical RCT|PEP uP Protocol in Surgical Patients|PEP uP Protocol (Enhanced Protein-Energy Provision Via the Enteral roUte Feeding Protocol) in Surgical Patients||Clinical Evaluation Research Unit at Kingston General Hospital|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02459275||20051|
NCT02459353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSDAPA0006|Effect of Dapagliflozin on Glycemic Variability|Effect of Dapagliflozin on Glycemic Variability as an add-on Therapy in Subjects With Type 2 Diabetes Mellitus With in Inadequate Glycemic Control in Insulin: a Multicenter, Placebo-controlled, Double-blind, Randomized Study|DIVE|The Catholic University of Korea|No|Not yet recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|70 Years|No|||May 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02459353||20045|
NCT02387047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SDE-PACTEQ|Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly|Screening for Phobia of Falling in the Elderly: Validity and Feasibility of a Self-administered Questionnaire|PACTE-q|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|41|||Both|70 Years|N/A|No|Non-Probability Sample|Consecutive patients aged 70 years or more, consulting in geriatric day hospital,        presenting walking difficulties and/or disturbance of the balance and/or at least one fall        during the course of the last 5 years and/or a fear of falling, living in community|October 2015|November 3, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02387047||25595|
NCT02387203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2014-53|Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin|Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on the Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)||Mercy Medical Center|No|Recruiting|January 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|January 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387203||25583|
NCT02393378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT203-2004|Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate|A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate|TELLUS|Takeda|No|Recruiting|April 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|March 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02393378||25109|
NCT02393391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-14-SB-600-CTIL|A Novel Non Invasive Brain Stimulation Based Treatment for Chronic Low Back Pain (CLBP)|Novel Non Invasive Brain Stimulation Based Treatment for Chronic Low Back||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2015|||May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2015|March 18, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02393391||25108|
NCT02390440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRA_IIT_Exparel_RibFractures|Exparel for Pain Control During Care of Rib Fractures|Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures||University of Kansas Medical Center|No|Withdrawn|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390440||25334|
NCT02448706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DC012289-01|Variability In Hearing Aid Outcomes In Older Adults|Characterizing Variability in Hearing Aid Outcomes Among Older Adults||Northwestern University|No|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|55 Years|N/A|No|||March 2016|March 14, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448706||20863|
NCT02391519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2178|Effects of High Altitude on AMPK Activation and PPARγ Regulation|Effects of High Altitude on 5' Adenosine Monophosphate-activated Protein Kinase (AMPK) Activation and Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Regulation||University of Colorado, Denver|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|84|Samples With DNA|Myometrial tissue, Cord Blood, Placental Tissue.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women scheduled for cesarean delivery at University of Colorado Hospital (Denver, 1600 m)        and St. Anthony's Summit Medical Center (Summit County, 3000 m) will be identified. In        order to avoid any possible confounding effects of labor or prematurity, only women with        elective cesarean deliveries will be approached for enrollment (cesarean delivery at a        prescheduled time without any labor, typically at 39 weeks gestation).|March 2016|March 18, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02391519||25251|
NCT02378415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2011.0063|Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression|Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression||United States Naval Medical Center, San Diego|No|Terminated|December 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|March 3, 2015|August 15, 2012|Yes|Yes|Discrepancies in medication orders|No||https://clinicaltrials.gov/show/NCT02378415||26259|
NCT02392676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00009|Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Whose Tumours Carry Loss of Function Somatic BRCA Mutation(s) or Loss of Function Mutation(s) in Tumour Homologous Recombination Repair -Associated Genes||AstraZeneca|Yes|Not yet recruiting|July 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|167|||Female|18 Years|96 Years|No|||January 2016|February 8, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392676||25163|
NCT02392689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-EU|Improve Management of Heart Failure With Procalcitonin|Improve Management of Heart Failure With Procalcitonin - Biomarkers in Cardiology 18|IMPACT-EU|Brahms AG|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|792|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02392689||25162|
NCT02459444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1163-0679|Impact of Inspiratory Muscle Training in Maximum Inspiratory Pressure|Impact of Inspiratory Muscle Training Using Powerbreathe in Maximum Inspiratory Pressure of Hospiralized Patients|IMT|Federal University of Bahia|No|Recruiting|May 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02459444||20038|
NCT02387359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-04|The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|IBS-C|Synergy Pharmaceuticals Inc.|No|Recruiting|December 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1050|||Both|18 Years|85 Years|No|||February 2016|February 29, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387359||25571|
NCT02387372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-007|Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)|A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients||Cubist Pharmaceuticals LLC|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387372||25570|
NCT02387567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-block-Pain|Paraspinal Block in Nonspecific Low Back Pain|Study on the Effects of Paraspinal Lidocaine Injection on Nonspecific Low Back Pain||University of Sao Paulo|Yes|Completed|January 2007|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|378|||Both|20 Years|60 Years|No|||March 2015|March 12, 2015|May 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02387567||25555|
NCT02393456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003565-2|Oxytocin and the Social Brain|Oxytocin's Effects on Behavior and Neural Activity During Social Cognition Tasks||University of California, Los Angeles|Yes|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|140|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393456||25103|
NCT02393482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMENORREA|Psychological Impact of Amenorrhea in Women With Endometriosis|Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study||University of Cagliari||Not yet recruiting|June 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|No|||March 2016|March 8, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393482||25101|
NCT02390609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106946|A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults|Open-Label, Randomized, Parallel Group, 3- or 4-Way Crossover Bioavailability Study of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults||Janssen Research & Development, LLC|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390609||25321|
NCT02444689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065277|EMPower: Electronic Media Powering Positive Health Changes in Youth|||Johns Hopkins University|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|13 Years|22 Years|No|||February 2016|February 3, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444689||21171|
NCT02449486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5070221|Ropivacaine After Sternotomy||NAROSYD|Kuopio University Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||May 2015|August 5, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449486||20803|
NCT02391727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN004-001|Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors|A Phase 1, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses|SYN004_Ph_1|Synermore Biologics Co., Ltd.|Yes|Not yet recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391727||25236|
NCT02391740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00239-38|Therapeutic Patient Education and Cancer Pain|THERAPEUTIC PATIENT EDUCATION AND CANCER PAIN|EFFADOL|Centre Francois Baclesse|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Probability Sample|Patients with cancer and pain|March 2016|March 3, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391740||25235|
NCT02387268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL00005|Evaluation of the Performance of the CleanC System-Israel|Evaluation of the Performance of the "CleanC" System||Motus GI Medical Technologies Ltd|Yes|Completed|May 2015|November 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 2, 2015||No||No|October 6, 2015|https://clinicaltrials.gov/show/NCT02387268||25578|
NCT02391051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOKAL-BT|Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial|Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial|FOKAL-BT|University of Erlangen-Nürnberg Medical School|No|Recruiting|October 2014|July 2027|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|July 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02391051||25287|
NCT02382263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHR-2012-01|Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer|Phase I/II Study to Assess the Efficacy and Safety of Nab-paclitaxel in Combination With Gemcitabine for the Treatment of Fragile Patients With Advanced or Metastatic Pancreatic Cancer|FRAGANCE|PH Research, S.L.|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|236|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02382263||25963|
NCT02382276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339-14-002|A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence|||Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|December 2014|August 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|20 Years|N/A|No|||October 2015|October 16, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02382276||25962|
NCT02392442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150091|Effects of Bronchial Segmental Endotoxin Instillation in Humans|Pulmonary Effects of Bronchial Segmental Endotoxin Instillation in Humans||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|58|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|January 12, 2016|March 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392442||25181|
NCT02384278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID10|Internet Based Cognitive Behavior Treatment for Alcohol Problems|Internet Based Cognitive Behavior Treatment for Alcohol Problems: A Pilot Study|ICBT-AP|Karolinska Institutet|No|Enrolling by invitation|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384278||25808|
NCT02390687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUL_PERIO-RG_01|Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients|Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients-A Randomized Placebo Controlled Study.||Next Gen Pharma India Pvt. Ltd.|No|Active, not recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|35 Years|49 Years|No|||September 2015|September 22, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390687||25315|
NCT02386761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-06001AA1-08|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001|A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doseS in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001|CHF6001Ext|Chiesi Farmaceutici S.p.A.|No|Recruiting|November 2014|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02386761||25617|
NCT02389517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0899|Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant|Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma||University of Chicago|Yes|Recruiting|March 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389517||25405|
NCT02393586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faro-WBA|Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers||National University Hospital, Singapore|No|Active, not recruiting|February 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 20, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02393586||25093|
NCT02390778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM#8118|Reducing Secondary Distress in Violence Researchers: a Randomised Trial of the Effectiveness of Group Debriefings.|Reducing Secondary Distress in Violence Researchers: a Randomised Trial of the Effectiveness of Group Debriefings.||London School of Hygiene and Tropical Medicine|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390778||25308|
NCT02383927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO-TIP-001|Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations|An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations||Kura Oncology, Inc.|No|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383927||25835|
NCT02382913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V113_01E1|Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)|Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01||Novartis|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|10||Actual|315|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 27, 2015||No||No|January 14, 2016|https://clinicaltrials.gov/show/NCT02382913||25913|
NCT02635763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB001|Peripheral Nerve Blocks in Elderly Patients With Hip Fracture|A Randomized Controlled Trial of Comparing Two Methods of Nerve Block in Combination With Laryngeal Mask Anesthesia Effect for Hip Fracture on Post-operative Quality of Recovery in Elderly Patients||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|No|Recruiting|October 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|85 Years|No|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02635763||6501|
NCT02644382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-288|Improving Surgical Decision-making in Young Women With Breast Cancer|Improving Surgical Decision-making in Young Women With Breast Cancer||Dana-Farber Cancer Institute|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||3|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young Women with a history of breast cancer and providers who care for them.|December 2015|January 4, 2016|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02644382||5838|
NCT02644395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2012-417|Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus|Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus|TT|Erasmus Medical Center|No|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644395||5837|
NCT02639481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560-15|Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness|Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness|EriCOS|Ludwig-Maximilians - University of Munich|No|Not yet recruiting|January 2016|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02639481||6215|
NCT02639494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2360|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2016|||||N/A|N/A|N/A||||||||||||||March 15, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639494||6214|
NCT02640690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 15-151|Trauma-Sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma|Trauma-sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma|PSL II|VA Office of Research and Development|No|Recruiting|January 2016|December 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640690||6122|
NCT02635828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0170|Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis|Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia||Ohio State University|No|Completed|October 2009|October 2011|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|85 Years|No|||December 2015|December 16, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02635828||6496|
NCT02636764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51391715.1.0000.5511|Influence of Using Physical Therapy Resources for Knee Osteoarthritis|Influence of Using Physical Therapy Resources for Knee Osteoarthritis|osteoarthritis|University of Nove de Julho|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|40 Years|80 Years|No|||December 2015|December 17, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02636764||6424|
NCT02629874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI-EA230-LPS-2014|PK/PD of EA-230 During Endotoxemia|Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia||Radboud University|Yes|Active, not recruiting|February 2015|December 2015|Anticipated|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02629874||6952|
NCT02629887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5848|Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation|Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation: A Pilot Study||University of Oklahoma|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|30 Minutes|No|||December 2015|December 10, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629887||6951|
NCT02385734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-62550515-03|Concentrated Growth Factor in the Treatment of Gingival Recessions|Concentrated Growth Factor Membrane in the Treatment of Adjacent Multiple Gingival Recessions: A Split Mouth Randomized Clinical Study||Bulent Ecevit University|No|Completed|April 2013|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385734||25696|
NCT02385747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130|Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding|Assessment of Uterine Cavity and Endometrial Steroid Receptors in Women With Peri- and Post Menopausal Bleeding||Cairo University|Yes|Not yet recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|45 Years|65 Years|No|||March 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02385747||25695|
NCT02643628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-1503|A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars|||Suneva Medical, Inc.|No|Recruiting|November 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|21 Years|N/A|No|||December 2015|December 29, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643628||5896|
NCT02631330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAREMAVA2015|Effect on Falls Reduction of a Multimodal Intervention in Frail and Pre-frail Elderly Community-dwelling People|Effect on Falls Reduction of a Multimodal Intervention in Frail and Pre-frail Elderly Community-dwelling People in Madeira Island (Portugal) and Valencia (Spain)|FAREMAVA|Hospital de la Ribera|Yes|Recruiting|December 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|466|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 12, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02631330||6840|
NCT02379338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820959|Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET/CT|Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluotriopride ([18F]FTP) by PET/CT||University of Pennsylvania|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 1, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02379338||26188|
NCT02379351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77591|Use Of An In-Home Non-Stress Test Device For Remote Fetal Monitoring|Use Of An In-Home Non-Stress Test Device For Remote Fetal Monitoring In A Local High-Risk Obstetric Population||University of Utah|No|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|N/A|No|||July 2015|July 30, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02379351||26187|
NCT02380781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-14-40|Contraceptive Counseling in the Postpartum Period|Contraceptive Counseling in the Postpartum Period||University Hospital Case Medical Center|No|Recruiting|March 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|250|||Female|18 Years|N/A|No|||December 2015|December 6, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380781||26077|
NCT02384018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-BMMSC15-001|Mesenchymal Stem Cell and Islet Co-transplantation|A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Chronic Pancreatitis Patients Who Undergo Total Pancreatectomy and Islet Autotransplantation.||Medical University of South Carolina|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|69 Years|No|||March 2016|March 23, 2016|December 16, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02384018||25828|
NCT02389855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAISE|Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry|Laser Ablation in Stereotactic Neurosurgery||Monteris Medical|No|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients previously treated with NBS (up to 300)|January 2016|January 27, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389855||25379|
NCT02389868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14221|Effects of Lovastatin on Human Platelet Proteome||LovaC|Université de Sherbrooke||Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|March 5, 2015||||No||https://clinicaltrials.gov/show/NCT02389868||25378|
NCT02451878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MQ14PE_25|Improving Wellbeing and Social Anxiety Symptoms (Shyness)|Effectiveness and Cost-effectiveness of a Fully Self-guided Internet-based Intervention for Shyness and Sub-clinical Social Anxiety Symptoms in the General Population: Pragmatic Randomised Controlled Trial|SocWell|University of Oxford|No|Not yet recruiting|May 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 21, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451878||20619|
NCT02382406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN LUN13-175|Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC|A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC)||Hoosier Cancer Research Network|Yes|Recruiting|June 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|67|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02382406||25952|
NCT02381964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L4|The Effects of Differing Cognitive Task Demands on Whole-body Energy Metabolism and Cerebral Blood-flow: Modulation by Multivitamins/Minerals and Coenzyme Q10|Pilot, Randomized, Placebo-controlled, Double-blind, 3-arm Parallel Groups Trial in Healthy Females to Assess Cerebral Haemodynamics and Energy Expenditure During Cognitive Performance After Supplementation With Two Different Multivitamin / Mineral Preparations.||Northumbria University||Completed|March 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|106|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02381964||25986|
NCT02382224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-0025|Worry Exposure for Generalized Anxiety Disorder|Worry Exposure for Generalized Anxiety Disorder||University of Texas at Austin|Yes|Recruiting|September 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02382224||25966|
NCT02447107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409015460|Mobile Phone Technology for Chronic Pain Patients- A Feasibility Study|The Utilization of Mobile Phone Technology to Quantitatively Assess Functional Outcomes of Chronic Pain Patients- A Feasibility Study||Weill Medical College of Cornell University|No|Recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|65 Years|No|Non-Probability Sample|All study subjects will be chronic pain patients being treated for moderate to severe        chronic pain|February 2016|February 16, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02447107||20985|
NCT02382627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2348|Choroidal Thickness in Optic Neuropathy|Choroidal Thickness in Optic Neuropathy||University of Colorado, Denver|No|Recruiting|March 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Inclusion criteria: age greater than 18 years old, diagnosis of optic neuropathy, willing        and able to sign an informed consent.        Exclusion criteria: steroid use within the past 4 weeks, inability to cooperate with OCT        testing, relevant ocular comorbidities in the affected or unaffected eye, such as        glaucoma, uveitis, optic nerve hypoplasia, age related macular degeneration, refractive        error greater than 5 spherical diopters, and inability to give informed consent.|March 2016|March 18, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382627||25935|
NCT02380846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00589|The Metabolic Effects of Consuming Carbohydrate With Different Protein Types|The Metabolic Effects of Consuming Carbohydrate With Different Protein Types||Clinical Nutrition Research Centre, Singapore|No|Active, not recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|15|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02380846||26072|
NCT02387684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTXY007|Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients|Efficay of Extended Peginterferon Alpha 2a(PEG-IFN a-2a) Treatment in HBeAg Negative Chronic Hepatitis B Patients||Beijing Ditan Hospital|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|60 Years|No|Non-Probability Sample|Population in this cohort study was composed of HBeAg negative chronic hepatitis B        patients defined as HBsAg positive, HBeAg negative,and detectable HBV DNA load with ALT        level ≥41 U/L for more than 6 months.|March 2015|March 8, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02387684||25546|
NCT02387697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICAVAL|Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)|Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve||Charite University, Berlin, Germany|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|50 Years|N/A|No|||March 2015|March 12, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02387697||25545|
NCT02447406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-169|Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment|||Samsung Medical Center|No|Recruiting|March 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|20 Years|No|||September 2015|September 15, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447406||20963|
NCT02386553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232SM201|A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy|An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.|NURTURE|Biogen|Yes|Recruiting|May 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|N/A|6 Weeks|No|||February 2016|February 19, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386553||25633|
NCT02386670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-2014|Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)|Prevention of Alzheimer's Dimentia With Cognitive Remediation Plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression|PACt-MD|Centre for Addiction and Mental Health|Yes|Recruiting|January 2015|February 2021|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|375|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02386670||25624|
NCT02393040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UICatalunya|Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia|A Prospective Double Blind, Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia|PRP|Universitat Internacional de Catalunya|No|Active, not recruiting|January 2014|November 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02393040||25135|
NCT02380079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVX-SCD-101-11|Dose-Escalation Study of SCD-101 in Sickle Cell Disease|Phase IB, Open-Label, Non-Randomized, Single-Site, Dose-Escalation Study of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia||Invenux, LLC|No|Recruiting|February 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|No|||February 2016|February 22, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380079||26131|
NCT02382497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|763_OPBG_2014|New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment|New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment||Bambino Gesù Hospital and Research Institute|No|Recruiting|July 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|13 Years|18 Years|No|||March 2015|March 3, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02382497||25945|
NCT02457936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002481|Examining Cognitive Mechanisms of Clinical Improvement Following Mindfulness Based Therapy for Depressed Individuals|Examining Cognitive Mechanisms of Clinical Improvement Following Mindfulness Based Cognitive Therapy for Depressed Individuals||Massachusetts General Hospital|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457936||20154|
NCT02378623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-008633|Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli|PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli|PARADOX|Mayo Clinic|Yes|Recruiting|May 2015|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|85 Years|No|||December 2015|December 30, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378623||26243|
NCT02378636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600C-EU-401|Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens|Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens||Rayner Intraocular Lenses Limited|No|Not yet recruiting|June 2015|August 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378636||26242|
NCT02380365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2602-2015|QT-Prolongation in Lung Transplantation|QT-Prolongation in Lung Transplantation|TX-QTC|Hannover Medical School|No|Not yet recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|||Both|18 Years|N/A|No|Non-Probability Sample|Follow-up Patients after lung transplantation|March 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380365||26109|
NCT02382770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15|International Register of Open Abdomen|International Register of Open Abdomen|IROA|A.O. Ospedale Papa Giovanni XXIII||Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who may require to be undergone to open abdomen procedure|April 2015|April 26, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02382770|1 Year|25924|
NCT02382978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150037-01H|Feasibility Study of Nurse-Provided Well Child Care|Feasibility Study of Nurse-Provided Well Child Care in Family Health Team in Ontario, Canada||Ottawa Hospital Research Institute|No|Not yet recruiting|April 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|6 Weeks|4 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02382978||25908|
NCT02459704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038/2012|Semilunar Coronally Positioned Flap With or Without Enamel Matrix Derivative for the Treatment of Gingival Recessions|Semilunar Coronally Positioned Flap With or Without Enamel Matrix Derivative for the Treatment of Miller Class I Gingival Recessions: Randomized Clinical Trial||University of Campinas, Brazil|Yes|Completed|June 2014|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||May 2015|October 6, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459704||20018|
NCT02378649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839-14-SMC|PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension|A Randomized, Placebo Controlled, Single Center Clinical Trial for Evaluation of Efficacy and Safety of Sildenafil Administration in the Cardiac ICU Following Mitral Valve Surgery in Patients With Pulmonary Hypertension||Sheba Medical Center||Not yet recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378649||26241|
NCT02377323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE156|Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif|Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study|RLO|Centre hospitalier de l'Université de Montréal (CHUM)|No|Enrolling by invitation|January 2014|December 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02377323||26343|
NCT02379806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB14.012 SYMPTOMS|The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study|Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study|SYMPTOMS|University Hospital, Brest|Yes|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|5030|||Both|70 Years|N/A|No|||January 2016|January 21, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02379806||26152|
NCT02380157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KARAASS-1|Blood Pressure Regulation - Role of Potassium|Oral Potassium Supplementation in Healthy Men - Interactions With the Renin-angiotensin-aldosterone System and the Sympathetic Nervous System||Glostrup University Hospital, Copenhagen|No|Recruiting|March 2015|October 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|25|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02380157||26125|
NCT02383420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6M2375|Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors|Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors||Carestream Health, Inc.|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will consist of adult cadaver, and adult live human subject repeat        exposures. These captures will be used to confirm diagnostic image quality as compared to        the cleared predicate device.|March 2015|May 1, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383420||25874|
NCT02383433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5214|Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer|A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer||Case Comprehensive Cancer Center|No|Not yet recruiting|September 2016|September 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383433||25873|
NCT02389543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-011|Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients|A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|SLAM|Karyopharm Therapeutics, Inc|No|Withdrawn|July 2015|February 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 10, 2015|Yes|Yes|Terminated this trial and added a Lenalidomide arm to KCP-330-017|No||https://clinicaltrials.gov/show/NCT02389543||25403|
NCT02380170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Epidemiology and Outcomes of Gram Negative Urosepsis|Epidemiology and Outcomes of Gram Negative Urosepsis|SERPENS|European Association of Urology Research Foundation|No|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|The population to be observed will be adults patients with clinical diagnosis of        urosepsis. Observations will be inititated when a patient is diagnosed with urosepsis        based on the clinical symptoms and findings as part of routine clinic practice through        emergency and accident, urology or internal medicine units.|January 2016|January 21, 2016|November 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02380170||26124|
NCT02380417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309M42821|Paravertebral Catheter for Lung Transplant|Paravertebral Catheter Use for Postoperative Pain Control in Patients After Lung Transplant Surgery: A Prospective Observational Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|80 Years|No|Probability Sample|All patients who presented for a lung transplant and had a clamshell incision either        single or bilateral.|February 2015|February 27, 2015|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380417||26105|
NCT02460484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443002|Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke|Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal||Florida Hospital|Yes|Recruiting|April 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Weeks|6 Years|No|||May 2015|May 29, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460484||19958|
NCT02378116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-017|Left Atrial Appendage Closure During Open Heart Surgery|Can We Protect the Brain Against Thrombus Embolism by Closing the Left Atrial Appendage During Open Heart Surgery|LAACS|Frederiksberg University Hospital|No|Recruiting|October 2011|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|March 3, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02378116||26282|
NCT02380430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 1319|Medical Management Survey : Organization of Perioperative Practices in Anesthesia and Ambulatory Surgery|Organisation PERiopératoire de l'anesthésie et de la Chirurgie Ambulatoire|OPERA|University Hospital, Grenoble|No|Completed|April 2014|March 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2174|||Both|N/A|N/A|No|Non-Probability Sample|All patients managed for ambulatory surgery by medical structures.|July 2015|July 28, 2015|July 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02380430||26104|
NCT02385396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUL024|Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment|Evaluation Concerning the Influence of Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment||Medical University of Lublin||Completed||||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|217|||Female|27 Years|35 Years|No|||March 2015|March 11, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02385396||25722|
NCT02453594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-087|Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)|A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|June 2015|April 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453594||20487|
NCT02379429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150087|Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue|Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|100 Years|No|||January 2016|March 22, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02379429||26181|
NCT02390505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2015_843_0001|Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery|Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery|CRPS-VITC|Centre Hospitalier Universitaire, Amiens|No|Not yet recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02390505||25329|
NCT02390518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI71940|Stereotactic Radiosurgery Dose Escalation for Brain Metastases|Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases||University of Utah|Yes|Recruiting|May 2015|||May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02390518||25328|
NCT02444975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU369|The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST|The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST|S-HYDRACYST|Danone Research|No|Recruiting|December 2013|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|May 12, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02444975||21149|
NCT02391623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7871002|A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of Pf-06427878 Co Administered With And Without Food In Healthy Adult Subjects||Pfizer|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391623||25244|
NCT02391636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage|Comparison Between Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage: A Randomized Controlled Trial||Ghamra Military Hospital|No|Active, not recruiting|February 2015|April 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|264|||Female|20 Years|40 Years|No|||February 2016|February 9, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02391636||25243|
NCT02378714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00100303|Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers|Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers||Northwestern University|Yes|Recruiting|June 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|576|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378714||26236|
NCT02378727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-INT14-01|CompuFlo® Assessment Study for the Epidural Space Verification|CompuFlo® Assessment Study (COMPASS): A Randomized, Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Effectiveness of the Epidural Space Verification With the CompuFlo® Epidural Computer Controlled System|COMPASS|Milestone Scientific, Inc|Yes|Recruiting|January 2015|June 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|316|||Both|18 Years|90 Years|No|||February 2015|March 3, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378727||26235|
NCT02378740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00102734|A Prospective, Block Randomized, Double-Blind Placebo-Controlled Trial of Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion|A Prospective, Block Randomized, Double-Blind Placebo-Controlled Trial of Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion||Northwestern University|No|Withdrawn|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|February 27, 2015|Yes|Yes|PI is leaving the University|No||https://clinicaltrials.gov/show/NCT02378740||26234|
NCT02380911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11526941|An Educational Intervention to Improve Physician Effectiveness in the Detection, Treatment and Control for Patients With Hypercholesterolemia and High Cardiovascular Disease (CVD) Risk in Low-resource Settings in Argentina|An Educational Intervention to Improve Physician Effectiveness in the Detection, Treatment and Control for Patients With Hypercholesterolemia and High Cardiovascular Disease (CVD) Risk in Low-resource Settings in Argentina|EPRINA|Institute for Clinical Effectiveness and Health Policy|No|Not yet recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|350|||Both|40 Years|75 Years|No|||January 2015|March 1, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02380911||26067|
NCT02455947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TelAvivMC|IBSR Meditation Technique for Teachers' Burnout|The Effect of Inquiry Based Stress Reduction (IBSR) Meditation Technique on Levels of Burnout and Wellbeing Among Teachers.||Tel Aviv Medical Center|Yes|Completed|September 2013|February 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|20 Years|62 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455947||20307|
NCT02455960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arginine 01|Protective Effects of Oral L-Arginine CI-AKI|Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection||Phramongkutklao College of Medicine and Hospital|Yes|Recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02455960||20306|
NCT02380027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRF-2014-07-146|PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?|A Randomized Control Trial of Magnetic Resonance Imaging-targeted Biopsy Compared to Standard Trans-rectal Ultrasound Guided Biopsy for the Diagnosis of Prostate Cancer in Men Without Prior Biopsy|PRECISION|University College, London|Yes|Recruiting|January 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|470|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380027||26135|
NCT02384044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015012|A Pilot Clinical Study to Evaluate the Safety and Efficacy of Marketed Oxalate Strips Compared to a Marketed Safety Pen|||Procter and Gamble||Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384044||25826|
NCT02384057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC-2013-04-036|Cognitive Rehabilitation With C8 Sciences|Cognitive Rehabilitation for Participants With Stroke or Brain Injury Using C8 Sciences||National Rehabilitation Center, Seoul, Korea|Yes|Recruiting|December 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02384057||25825|
NCT02385929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-074|Pre-habilitation of Patients With Head and Neck Cancer|Bimodal Pre-habilitation Program to Improve Symptom Control After Treatment for Head and Neck Cancer|SYNK|Rigshospitalet, Denmark|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02385929||25681|
NCT02460913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/02|Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department|Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department. An Efficacy and Safety Study|AcuMAP|University of Monastir|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||May 2015|June 6, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02460913||19925|
NCT02381054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Italian PRO-CTCAE|Translation, Cross-cultural Adaptation and Validation of PRO-CTCAE for Italian-speaking Cancer Patients|Translation, Cross-Cultural Adaptation and Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Italian-speaking Cancer Patients|PRO-CTCAE|Italian PRO-CTCAE Study Group|No|Recruiting|May 2015|October 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|396|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients receiving or having recently received cancer therapy (chemotherapy,        biologic therapy, and or radiation therapy) will be recruited from 17 Italian Cancer        Institutes and Hospitals throughout Italy. Sampling will be performed to ensure that the        target population is matched for gender, age and area of residence (North, center, and        Southern Italy). Recruitment of at least 25% of patients with lower levels of educational        attainment (i.e., primary school or no education) will also be ensured.|December 2015|December 22, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02381054||26056|
NCT02389270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pOAB-CHZ-00|Urinary Neurotrophin Levels in Healthy Children|Age and Daytime Variations in Urinary Neurotrophin Levels in Healthy Children Without Lower Urinary Tract Symptoms||Children's Hospital Zagreb|No|Not yet recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples Without DNA|Urine ultrafiltrate|Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will include a group of healthy children recruited from a primary care clinic.|March 2016|March 5, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389270||25424|
NCT02378220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-003|Pharmacogenetic Testing Among Home Health Patients|A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits||Genelex Corporation|No|Active, not recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|110|||Both|50 Years|N/A|No|||March 2016|March 15, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02378220||26274|
NCT02382289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mour2014/60|Radiofrequency in Sacroiliac Arthropathy;Bipolar RF 6 Points Versus Monopolar RF at 6 and 3 Points|Radiofrequency Ablation for the Treatment of Chronic Sacroiliac Joint Arthropathy; Comparing the Use of Bipolar RF at Six Points Versus Monopolar RF at Six Points and Three Points|RFSIBIMONO6|King Hamad University Hospital, Bahrain|Yes|Recruiting|September 2014|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382289||25961|
NCT02388893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-221|Endocarditis Registry of the University Hospital of Cologne (ER-UHC)|Endocarditis Registry of the University Hospital of Cologne (ER-UHC)||University of Cologne|No|Recruiting|January 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|100 Years|No|Probability Sample|Adult patients with definitive IE|November 2015|November 30, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388893|1 Year|25453|
NCT02388906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-238|Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)|A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)||Bristol-Myers Squibb|Yes|Active, not recruiting|March 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|15 Years|N/A|No|||August 2015|March 11, 2016|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388906||25452|
NCT02378090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-2014|A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico|An Observational Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico: The Mexican Emerging Infectious Disease Clinical Research Network (La Red)||Mexican Infectious Disease Network|No|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7488|Samples With DNA|Samples will only be identified by the unique identifier assigned to each participant for      the study. All repository samples will be stored for a maximum of 15 years after the last      enrollment into the study; any remaining samples after this time will be destroyed,      following Mexican and United States of America (USA) Federal regulations.|Both|N/A|N/A|No|Probability Sample|Subjects will be selected from hospitalized (within the last 24 hours) patients and        outpatients that seek medical care due to ILI at the sites of La Red Network and meet        inclusion criteria. Those who accept participation will be invited to participate, the        study will be explained and informed consent will be obtained. The study population will        include children and pregnant women.|March 2016|March 17, 2016|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02378090||26284|
NCT02378363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|Representations and Prevention of Cancers in Schools|Representations and Prevention of Cancers in Schools|RISCOLAIRE|Institut de Cancérologie de la Loire|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|191|||Both|9 Years|12 Years|No|Non-Probability Sample|students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th|February 2015|February 27, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02378363||26263|
NCT02379767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v1.2_201502|Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET|Effects of Electroconvulsive Therapy on Monoamine Oxidase A Distribution Volume in Treatment-Resistant Depression Investigated With PET||Medical University of Vienna|Yes|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|||Both|16 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|18 patients with severe unipolar depression determined by a structured clinical interview        for DSM-IV (SCID) and the 17-item Hamilton Rating Scale for Depression (HAM-D score ≥ 23)        who did not respond to conventional pharmacological antidepressant treatment (at least two        adequate trials with antidepressants of different pharmacological classes over a minimum        period of one month, equivalent to 150mg of tricyclic antidepressants) will be recruited        at the Department of Psychiatry and Psychotherapy at the General Hospital of Vienna.        Additionally, 18 healthy age- and sex-matched controls will participate in this        longitudinal study.|September 2015|September 23, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02379767||26155|
NCT02378532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLOROBRAIN|The Addition of Chloroquine to Chemoradiation for Glioblastoma|A Phase I Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma|CHLOROBRAIN|Maastricht Radiation Oncology|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02378532||26250|
NCT02386878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHE# ZA.09.0257|HIV/AIDS Orphaned and Vulnerable Children Public Health Evaluation|The Effectiveness of Two Promising Interventions for Reducing HIV Risk and Improving the Wellbeing of Orphaned and Vulnerable Adolescents in the Eastern Cape of South Africa|PHE|Tulane University School of Social Work|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2302|||Both|14 Years|17 Years|No|||March 2015|March 16, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386878||25608|
NCT02386943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD022|Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp|An Open-label, Randomized,Three-way Cross-over, Single Dose Study to Explore the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|December 2013|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|40 Years|60 Years|No|||March 2015|March 11, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02386943||25603|
NCT02637986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0173-13-EMC|The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy|The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy - a Prospective Randomized Double Blind Placebo-control Study||HaEmek Medical Center, Israel||Not yet recruiting|January 2016|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|320|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637986||6330|
NCT02637999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYR201A|Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With Chronic Hepatitis Delta|Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta||Hepatera Ltd.|No|Active, not recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|No|||December 2015|December 20, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02637999||6329|
NCT02629211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB 17701|Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD|Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD||Smart Medical Systems Ltd.|No|Not yet recruiting|December 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629211||7003|
NCT02391844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNK795-ICRI-001|Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery|Open-Label Parallel Group Flexible Dosing & Titration Study to Evaluate the Efficacy, Safety of Oxycodone/APAP Extended Release Formulation Xartemisxr® in the Management of Post-Operative Pain Following Outpatient Arthroscopic Knee Surgery||International Clinical Research Institute|No|Completed|May 2014|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||November 2015|January 5, 2016|May 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02391844||25227|
NCT02638064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mansourau25|Treatment of Pilonidal Sinus Disease Using Surgiflo as a Sealant: A New Concept|Treatment of Pilonidal Sinus Disease Using Surgiflo as a Sealant: A New Concept||Mansoura University|Yes|Completed|March 2013|November 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|14 Years|45 Years|No|||December 2015|December 20, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02638064||6324|
NCT02644408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|megestrol and cancer|Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma|Two-arm Phase III Study of Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma in the Chemoradiotherapy||The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|45 Years|75 Years|No|||July 2015|January 23, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02644408||5836|
NCT02634398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-SMI-2015|A Post Market Study on DRG Stimulation in FBSS (SYMPATHY)|A Post Market ObServational StudY on the Effect of DRG StiMulation in PATients witH Chronic Pain Following Surgical Lumbar DiscectomY (Failed Back Surgery Syndrome): SYMPATHY||St. Jude Medical|No|Not yet recruiting|December 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from chronic pain post discectomy surgery|December 2015|December 15, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02634398||6605|
NCT02393118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCB14-492|A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury|Safety and Efficacy of the BrainPort V200 Device in Individuals Blinded by Traumatic Injury||Wicab|No|Active, not recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393118||25129|
NCT02393131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412029RINB|Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases|Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With or Without Hippocampal Avoidance for Brain Metastases: A Phase II Single Blind Randomized Trial||National Taiwan University Hospital|Yes|Recruiting|February 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||November 2015|November 13, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02393131||25128|
NCT02632071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ3709|ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer|Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer||Columbia University|Yes|Recruiting|February 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02632071||6784|
NCT02635087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[112]|microRNAs Tool for Stratifying Stage II Colon Cancer|microRNAs Tool for Stratifying Stage II Colon Cancer:a Perspective Study of Adjuvant Chemotherapy||First Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|December 2015|July 2025|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|630|Samples Without DNA|We will use the samples to make q-RT-PCR of our miRNA tool,then predict the patients as high      risk one or not.|Both|20 Years|75 Years|No|Non-Probability Sample|The patients who had stage II colon cancer and received surgery.They agree to use miRNA        tool to test their postoperative specimen.|December 2015|December 29, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635087||6552|
NCT02384356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00071766|A Longitudinal Survey of Health in Bolivia|A Longitudinal Survey of Health in Bolivia||University of Michigan|No|Enrolling by invitation|June 2014|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients visiting clinics associated with Universidad Católica Boliviana, including        SEDES La Paz and Universidad Mayor San Andres, in La Paz and El Alto, Bolivia for a        non-urgent health problem.|March 2015|March 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384356||25802|
NCT02384369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNC-102-221 PT|Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder|Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin|PTSD|Synchroneuron Inc.|No|Not yet recruiting|June 2016|August 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384369||25801|
NCT02385253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00082564|Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance|Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance||Northwestern University|Yes|Enrolling by invitation|September 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02385253||25733|
NCT02387879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-PASS-TR|A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR|A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey||Celgene|No|Recruiting|December 2013|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|It will continue until 250 subjects have commenced the third cycle of treatment with        lenalidomide. As a condition of market authorization, subjects should be chosen among        relapsed/refractory multiple myeloma patients who have received at least one prior        antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with        adequate dose and duration (≥2 cycles) or who have relapsed/refractory multiple myeloma        after stem cell transplantation. Patients who are eligible for the study will be        consecutively enrolled in the study until the targeted patient number is reached. The        responsible investigator will be requested to keep a log of subjects who are invited to        enter the study. In the case of any of these subjects will not be enrolled in the study,        this information will be documented together with its reason.|December 2015|December 21, 2015|February 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387879||25531|
NCT02388152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16026A|A Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease|Open-label, Dose-escalation, Multiple Immunisation Study on the Safety, Tolerability and Immunogenicity of Lu AF20513 in Patients With Mild Alzheimer's Disease||H. Lundbeck A/S|Yes|Recruiting|March 2015|||May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|35|||Both|60 Years|85 Years|No|||March 2016|March 21, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02388152||25510|
NCT02378181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411|Testing the Effectiveness of a Graphic Novel Health Education Curriculum for Patients With Addiction|Testing the Effectiveness of a Graphic Novel Health Education Curriculum for Patients With Addiction||Treatment Research Institute|Yes|Not yet recruiting|October 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378181||26277|
NCT02386371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM-URC2014/07|Intraoperative Radiotherapy After Local Recurrence in Breast Cancer|Feasibility Clinical Trial of Intraoperative Radiotherapy (IORT) and Second Breast-conserving-surgery After Local Recurrence of Breast Carcinoma|RE-IORT01|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|March 2014|March 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|50 Years|N/A|No|||March 2015|March 10, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02386371||25647|
NCT02392988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002-15|Does Acupuncture Therapy Reduce the Need for Labor Induction After Postdate (Week 41)|Randomised ,Single Blind, Placebo Controlled in Meir Medical Center. Study the Potential of Acupuncture Therapy to Reduce the Need for Labor Induction After Postdate (Week 41)||Meir Medical Center|No|Not yet recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 18, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02392988||25139|
NCT02393001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400739|Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques|Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques||University of Florida|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will        have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin|November 2015|November 24, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393001||25138|
NCT02387489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03-221|A Clinical Trial of SBIRT Services in School-based Health Centers|A Randomized Clinical Trial of Screening, Brief Intervention, and Referral-to-Treatment (SBIRT) Services in School-based Health Centers||Friends Research Institute, Inc.|Yes|Enrolling by invitation|October 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|14 Years|18 Years|No|||November 2015|November 3, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02387489||25561|
NCT02389959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29501|Intranasal Bevacizumab for HHT-Related Epistaxis|Intranasal Bevacizumab for HHT-Related Epistaxis||Stanford University|Yes|Recruiting|August 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389959||25371|
NCT02452229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-G-SR-HHV|Review of Human Herpes Viruses in Burns|Human Herpes Viruses in Burn Victims: A Systematic Review||The University of Texas Medical Branch, Galveston|No|Completed|March 2015|||May 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|10267|||Both|N/A|N/A|No|Non-Probability Sample|Every year, about 500,000 citizens of the United States of America were burned; 50,000 of        them were admitted to Burn Center. Bacterial and viral infections including cellulitis,        pneumonia, wound infections and septicemia are among the top ten complications of burn        injuries. Severe burn injury causes an increased inflammatory response and an overall        immunosuppression. As a result severely burned patients are more prone to infections and        septicemia. Early treatment of sepsis and prevention of infections are key to reducing        morbidity and improving the long-term outcome of burn victims.|May 2015|May 19, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02452229||20592|
NCT02386475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELEIS|Effect of Serotonin and Levodopa in Ischemic Stroke|Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction|SELEIS|Hospital de Granollers|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386475||25639|
NCT02380859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F15047|Visual Adaptation Study|Treatment of Gait Disturbance in Parkinson's Disease With Visual Adaptation||Dartmouth-Hitchcock Medical Center|No|Recruiting|February 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|85 Years|No|||January 2016|January 20, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02380859||26071|
NCT02390011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149516|Pilot Study of Coil Arrays in Patients With Advanced Solid Tumor Malignancies|A Pilot Study of Novel Magnetic Resonance Coil Arrays to Improve the Characterization of Liver Metastases in Patients With Advanced Solid Tumor Malignancies||University of California, San Francisco|Yes|Not yet recruiting|April 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Advanced Solid Tumor Malignancies|December 2015|December 4, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390011||25367|
NCT02452515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17055|A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction|A Single-blind, Multicenter Pilot Study to Investigate the Safety and Tolerability of a 14 Day Oral Treatment With Different Doses of the Chymase Inhibitor BAY1142524 in Comparison to Placebo in Clinically Stable Patients With Left-ventricular Dysfunction After Myocardial Infarction|CHIARA MIA 1|Bayer|No|Active, not recruiting|July 2015|March 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|49|||Both|40 Years|79 Years|No|||March 2016|March 4, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452515||20570|
NCT02460224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAG525X2101C|Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies|A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies||Novartis|Yes|Recruiting|June 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460224||19978|
NCT02389049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1225|Genetics of Primary Ciliary Dyskinesia|Research Genetic Testing for Primary Ciliary Dyskinesia Using a Panel of Genes||University of North Carolina, Chapel Hill|Yes|Recruiting|February 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|280|Samples With DNA|Blood or buccal samples|Both|N/A|N/A|No|Non-Probability Sample|Study participants should have 2 or more clinical features of PCD.|November 2015|November 2, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02389049||25441|
NCT02385045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM2185|i-Scan for the Detection of Helicobacter Pylori|i-Scan for the Detection of Helicobacter Pylori||Imperial College London|No|Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385045||25749|
NCT02387944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468/14|Bedside Evaluation of Coagulation in Children With Congenital Heart Disease|"Point-Of-Care" Evaluation of Hemostasis in Children With Congenital Heart Disease|POCHEMO|Centre Hospitalier Universitaire Vaudois|No|Recruiting|March 2015|April 2019|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|16 Years|No|Probability Sample|Children with congenital heart defect|March 2015|March 12, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02387944||25526|
NCT02387957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1006|An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)|||Ophthotech Corporation|No|Recruiting|February 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||August 2015|August 10, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387957||25525|
NCT02459626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.02|Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction|Comparison of Non-invasive Assessment of Cardiac Fibrosis by MRI Derived T1-Mapping and Ventricular Intrinsic Diastolic Function by Pressure-volume-analysis in Patients With Heart Failure With Preserved Ejection Fraction|STIFFMAP|University of Leipzig|No|Recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Recruitment of consequtive patients from our general cardiology clinic that present with        signs of heart failure or suspected CAD with indication for invasive assessment and        fullfill eligibility criteria.|November 2015|November 30, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02459626||20024|
NCT02383160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-0849|Scaphoid Non-union and Low-intensity Pulsed Ultrasound|A Randomized Controlled Trial Comparing Low-Intensity, Pulsed Ultrasound to Placebo in the Treatment of Operatively Managed Scaphoid Non-Unions||University of Calgary|No|Recruiting|September 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02383160||25894|
NCT02385331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501004|Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis|Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis|MMNNIRP|The Third Affiliated Hospital of Southern Medical University|Yes|Recruiting|March 2015|February 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples With DNA|whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers，age 18-65.|March 2015|March 10, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385331||25727|
NCT02388217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07419-10-HMO|The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study|The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study||Hadassah Medical Organization|No|Active, not recruiting|April 2013|November 2020|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic pain patients with lack of satisfactory analgesic response or intolerable adverse        effects with at least two analgesics from 2 different drug classes at full dose. Eligible        for cannabis treatment following Israeli Ministry of Health approval.|March 2016|March 7, 2016|April 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02388217||25505|
NCT02390154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15022|Roniciclib Mass Balance Study|A Phase I, Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics of Orally Administered [14C]-Roniciclib (BAY 1000394) in Patients With Solid Tumors||Bayer|No|Active, not recruiting|April 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|99 Years|No|||February 2016|February 2, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390154||25356|
NCT02390167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-PRO-2014-004-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||May 1, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390167||25355|
NCT02447913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant #2011-37081|Integrating Family Planning With Immunization to Improve Maternal and Child Health|To Observe the Effectiveness of a Demand-Side Financing Project in Increasing Demand and Utilization of Contraceptives for Birth Spacing Among Women From Poorest Two Quintiles in Faisalabad District of Pakistan||Greenstar Social Maketing|No|Recruiting|September 2011|July 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28000|||Female|15 Years|49 Years|No|||May 2015|May 14, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02447913||20924|
NCT02382640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Febuxostat XR-1010|Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule|A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral Administration of a 80 mg Febuxostat Extended-Release (XR) Capsule Formulation||Takeda|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382640||25934|
NCT02381639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0301|Impairment of Central Coherence in Restrictive Anorexia Nervosa (CoCA)|Impairment of Central Coherence in Restrictive Anorexia Nervosa: Single-center and Case-control Study|CoCA|Nantes University Hospital|No|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Female|15 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02381639||26011|
NCT02381652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cingal 13-02|Repeat Injection of Cingal® for Osteoarthritis of the Knee|Cingal 13-02: An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee||Anika Therapeutics, Inc.|Yes|Completed|February 2015|May 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|242|||Both|40 Years|75 Years|No|||June 2015|June 19, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381652||26010|
NCT02381665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-14|Efficacy of Interferential Therapy in Chronic Constipation (CON-COUR)|INTERFERENTIAL THERAPY IN THE TREATMENT OF CHRONIC CONSTIPATION IN ADULTS: A RANDOMIZED MULTI-CENTER TRIAL|CON-COUR|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|March 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02381665||26009|
NCT02384837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect of TCFA|Effect of TCFA on Neointimal Coverage After PCI at 9 Months Follow-up|Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|December 2014|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|55|||Both|18 Years|75 Years|No|Probability Sample|This study will plan for a total of 55 patients with Non ST-ACS (all of the patients was        selected in different blood vessels, a total of up to two target disease Variable and each        target lesion 1 stents, such as placing stents need more than one in the operation,        require the use of EXCEL stents, mix does not recommend the same patients Other brand        support, unless save extra stents.) Choose lesions reference diameter of 2.5 mm to 4.0 mm        (visual), each lesion length 32 mm or less (visual), participants must conform to the        standard can be selected.|January 2015|February 24, 2016|December 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02384837||25765|
NCT02459210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000285|Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis|CLUES (Cognition for Learning and for Understanding Everyday Social Situations): An Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis|CLUES|Beth Israel Deaconess Medical Center|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|16 Years|25 Years|No|||January 2016|January 13, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02459210||20056|
NCT02459223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBT|Study of Blood Parameters of the Malnourished Children: Before and After Giving Nutritional Biscuit's Treatment|Open Label Prospective Parallel Group Active Comparator Interventional Study to Determine the Efficacy of the Therapeutic Nutritional Intervention in SAM Category Malnourished Children of Satpuda Region.||Maharashtra University of Health Sciences|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|1 Year|5 Years|No|||May 2015|May 31, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02459223||20055|
NCT02386904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|• KLEE-EFF-002-01|Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy|Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema)||Nabiqasim Industries (Pvt) Ltd|No|Recruiting|March 2015|August 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|60 Years|No|||March 2015|March 16, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02386904||25606|
NCT02377635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-284|Selenium and Arsenic Pharmacodynamics|Selenium and Arsenic Pharmacodynamics|SEASP|University of Saskatchewan|Yes|Not yet recruiting|February 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02377635||26319|
NCT02377648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CART|Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy|Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study|CART|Universita di Verona|No|Recruiting|January 2015|December 2019|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02377648||26318|
NCT02377895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-100-0008|Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Allergen BioCube Study Evaluating the Efficacy and Safety of Nasapaque Nasal Solution in a Population of Adult Subjects With Seasonal Allergic Rhinitis||3E Therapeutics Corporation|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377895||26299|
NCT02385123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0071|Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers|Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|April 2015|||April 2021|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|November 12, 2015|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385123||25743|
NCT02389478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNF201421|Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants|Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants：Effects on Secretory Immunoglobulin A||Children's Hospital of Fudan University|Yes|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|N/A|1 Month|No|||November 2015|November 9, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02389478||25408|
NCT02389491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNF201426|Effect of a High Density Formula on Growth and Safety in Congenital Heart Disease Infants|Effect of a High Density Formula on Growth and Safety in Early Postoperative Infants With Congenital Heart Disease Duration of Cardiac Intensive Care Unit（CCU）Stay: a Randomized Clinical Trial|CHD|Children's Hospital of Fudan University|Yes|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|N/A|12 Months|No|||November 2015|November 9, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02389491||25407|
NCT02386865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2008|Risk Factors Predicting Prognosis and Outcome of Elderly Patients With Isolated Traumatic Brain Injury|Risk Factors Predicting Prognosis and Outcome of Elderly Patients With Isolated Traumatic Brain Injury||Medical University of Vienna|No|Completed|January 2008|January 2012|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|292|||Both|65 Years|N/A|No|Non-Probability Sample|: All elderly patients (age ≥ 65 years) with isolated severe head injury, admitted to this        Level I trauma center, during a period of 16 years (from January 1992 to December 2008)        were identified from the trauma registry. Stepwise logistic regression analysis was used        to identify risk factors for a poor prognosis and outcome.|March 2015|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386865||25609|
NCT02385409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074-OJ5|Incidence and Reasons for Preoperative Anemia in Elective Lower Joint Arthroplasty|Incidence and Reasons for Preoperative Anemia in Elective Lower Joint Arthroplasty - A Descriptive Study||Rigshospitalet, Denmark|No|Active, not recruiting|May 2013|May 2015|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for elective primary hip- and knee replacement during a 1 year        sampling period at the department of orthopedic surgery, Hvidovre Hospital, Denmark|March 2015|March 5, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02385409||25721|
NCT02459366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412156RINA|Correlation of Thoracolumbar Fascia Mechanical Properties and Compensate Mechanisms of Asymmetric Skeletal Muscle|Study of School and Graduate Institute of Physical Therapy College of Medicine in Taiwan||National Taiwan University Hospital|No|Recruiting|May 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|270|||Both|20 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|December 2015|December 29, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02459366||20044|
NCT02383446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-13-0292-SMC|Efficiency of Hydraulic Microprocessor Prosthetic Foot for Traumatic Transtibial Amputees|Evaluation of the Efficiency of Hydraulic Microprocessor Prosthetic Foot for Traumatic Transtibial Amputees||Sheba Medical Center|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|20 Years|70 Years|No|||January 2016|January 21, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02383446||25872|
NCT02382458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037276|Developing the Dietary Inflammatory Index for Clinical Application|Developing the Dietary Inflammatory Index for Clinical Application|IMAGINE|University of South Carolina|No|Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02382458||25948|
NCT02380690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-070|Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms|Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms (ECLIPSE)|ECLIPSE|VA Office of Research and Development|No|Recruiting|May 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380690||26084|
NCT02449499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-32272|Adjunct Interpersonally Focused Psychodynamic Group Psychotherapy for Residual Depression Symptoms|Interpersonally Focused Psychodynamic Group Psychotherapy as Adjunct Treatment for Residual Symptoms of Major Depressive Disorder||Stanford University|Yes|Enrolling by invitation|April 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with major depression, adjustment disorder, generalized anxiety        disorder, panic disorder, social phobia, or other depression NOS diagnosis currently in        treatment with individual psychotherapist, continuing to experience symptoms even after at        least six months in standard individual treatment with a psychiatrist or psychologist.|May 2015|May 15, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449499||20802|
NCT02379689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parker 1001|Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration|A Randomized, Double-Blinded, Placebo-Controlled With Crossover Study to Evaluate the Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration||Semmes-Murphey Foundation||Recruiting|December 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||November 2015|November 16, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379689||26161|
NCT02380014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-PILOT-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||March 2, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380014||26136|
NCT02382718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST2015|FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy|A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish|FASTIIb|University of Athens|Yes|Recruiting|October 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02382718||25928|
NCT02382939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4043|A Trial to Compare the Safety of Once Weekly Dosing of NNC0195-0092 With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency|A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of NNC0195-0092 With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency|REAL 2|Novo Nordisk A/S|No|Completed|February 2015|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|79 Years|No|||January 2016|January 15, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382939||25911|
NCT02385916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00279|The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females|A Randomised, Double Blind, Placebo Controlled, Cross-over Trial Evaluating the Effects of EstroSense®/MD (PNO) vs Placebo in Increasing 2:16α Ratio and Improving the Estrogen Profile in Females||University of British Columbia|No|Recruiting|April 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385916||25682|
NCT02459548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010111082|Continuous Positive Airway Pressure (CPAP) for Primary Care|Validation of a Programme of Treatment and Follow-Up for Obstructive Sleep Apnea (OSA) Patients to be Applied by General Practitioners (GPs). Collaborative Network System Between GPs, CPAP Provider Enterprise and Sleep Specialists|CPAP-SU-MAP|Hospital Universitario Araba|No|Recruiting|February 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|252|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02459548||20030|
NCT02383979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2010.0007|Perioperative Mirror Therapy and Phantom Limb Pain|Perioperative Visual Therapy May Help Prevent Phantom Limb Pain||United States Naval Medical Center, San Diego|Yes|Active, not recruiting|August 2010|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|115|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383979||25831|
NCT02388438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-13-Bongener|Demineralized Bone Matrix in Opening Wedge Osteotomy for Hallux Valgus Deformity|Efficiency and Safety of Demineralized Bone Matrix in the Proximal Opening Wedge Osteotomy for Hallux Valgus Deformity|DBM|Severance Hospital|No|Active, not recruiting|April 2013|December 2015|Anticipated|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|75 Years|No|||March 2015|March 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388438||25488|
NCT02390635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0616|Extramedullary Leukemia (EML) in Newly Diagnosed Acute Myeloid Leukemia (AML) is Underreported|PET/CT and Whole Body Magnetic Resonance Imaging (MRI) in Newly Diagnosed Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Not yet recruiting|August 2016|||August 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390635||25319|
NCT02460926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3399/11|Acute Phase Response & Periodontal Treatment|Acute Phase Response Following Full Mouth Versus Quadrant Non-Surgical Periodontal Treatment. A Randomized Clinical Trial|PERIOSYST-1|University of Pisa|No|Completed|May 2012|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|No|||May 2015|May 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460926||19924|
NCT02386059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCatania|Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia|A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia||University of Catania|No|Not yet recruiting|March 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|1200|||Both|18 Years|85 Years|No|||March 2015|March 10, 2015|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386059||25671|
NCT02393573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-264-SDR|Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism|Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism In Patients Undergoing Major Lung or Abdominal Surgery||McGill University Health Center|No|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02393573||25094|
NCT02382302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1106/063-005|Research to Evaluate Efficiency in U-health Solution Service for the Chronic Wound Management|A Smart Phone-based Tele-consultation System in the Management of Chronic Pressure Ulcer||Seoul National University Hospital|No|Completed|July 2011|February 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|21 Years|N/A|No|||March 2015|March 2, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02382302||25960|
NCT02379663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-012|Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty|Efficacy and Safety for Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty||Samsung Medical Center|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|639|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2014|March 4, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02379663||26163|
NCT02379962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2014-087|Public Perception and Attitude of Chinese Towards Biomedical Research and Biobanking in China|Public Perception and Attitude of Chinese Towards Biomedical Research and Biobank in China||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|No|Completed|November 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|478|||Both|18 Years|N/A|No|Probability Sample|Chinese people|March 2015|March 1, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379962||26140|
NCT02382679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.529|Vitamin Therapy in Concussion Management: A Randomized Control Trial|Vitamin Therapy in Concussion Management: A Randomized Control Trial||Thomas Jefferson University||Active, not recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|11 Years|22 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382679||25931|
NCT02382562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0340|Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients|Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients||University of Mississippi Medical Center|No|Not yet recruiting|March 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|64 Years|No|||March 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382562||25940|
NCT02383043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA033364-02|Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer|||University of Kentucky|No|Recruiting|February 2015|||February 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|18|||Both|21 Years|45 Years|No|||November 2015|November 30, 2015|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383043||25903|
NCT02389010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014|Clinical Efficacy of Platelet Gel From Cord Blood for the Treatment of Diabetic Foot Ulcers|Clinical Efficacy of Platelet Gel From Cord Blood for the Treatment of Diabetic Foot Ulcers|CBPG-DFU|Centro Nazionale Sangue|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389010||25444|
NCT02379975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SantosMU 01|Evaluation of Non-surgical Periodontal Therapy in Patients With Rheumatoid Arthritis|Evaluation of Non-surgical Periodontal Therapy in Patients With Rheumatoid Arthritis||Santos Metropolitan University|Yes|Completed|February 2013|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 1, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02379975||26139|
NCT02393677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN57/FM|Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine|Supraclavicular Brachial Plexus Block Using Ropivacaine Alone or Combined With Dexmedetomidine for Upper Limb Surgery: A Prospective, Randomized, Double-blinded, Comparative Study||Government Medical College, Haldwani|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|March 15, 2015||No||No|April 17, 2015|https://clinicaltrials.gov/show/NCT02393677||25086|
NCT02393690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU241306I|Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer|Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers||Academic and Community Cancer Research United|Yes|Recruiting|May 2015|||March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393690||25085|
NCT02642926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Monobimen|Comparison of the Efficiency of Bipolar Energy Versus Monopolar Energy in Endometrial Ablation in Women Having Menorrhagia|Randomized Controlled Trial Comparing the Efficiency of the Bipolar Energy Compared With the Monopolar Energy in Endometrial Ablation in Women Having Menorrhagia||Brugmann University Hospital|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|98|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02642926||5950|
NCT02642939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIF-01-2014|Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens||Check, Jerome H., M.D., Ph.D.|No|Recruiting|December 2015|October 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642939||5949|
NCT02634346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALKS-3831-A305|A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)|A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia||Alkermes, Inc.|No|Recruiting|December 2015|April 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|390|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634346||6609|
NCT02640326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_UCATh|McMaster Catheterization for Thoracoscopic Surgery Study|A Prospective Randomized Control Trial Comparing Routine Urinary Catheterization vs. No-Urinary Catheterization at the Time of Thoracoscopic Pulmonary Resection (McMaster Catheterization for Thoracoscopic Surgery Study - UCATh Study)|UCATh|McMaster University|No|Recruiting|March 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640326||6150|
NCT02640339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01391|Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease|Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease||New York University School of Medicine|No|Recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will select patients from our clinic and take advantage of the infrastructure used in        the ongoing NIH-funded Natural History of Autonomic Disorders study (ClnicalTrials.gov:        NCT01799915), which prospectively follows patients with synucleinopathies with        standardized neurological measures overtime.|February 2016|February 3, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640339||6149|
NCT02380469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R82-A5445|Improvement of Information to Cancer Patients' Caregivers|Improvement of Information to Cancer Patients' Caregivers: a Randomised Intervention Study||Bispebjerg Hospital|No|Not yet recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02380469||26101|
NCT02380742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206945|Topical Anesthetic Use In Pessary Management|Topical Anesthetic Use In Pessary Management: A Randomized Double Blinded Placebo Controlled Trial||Loyola University|No|Active, not recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380742||26080|
NCT02643108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1238-31/2|Lateral Episiotomy or Not in Vacuum Assisted Delivery in Primiparae|Randomized Controlled Clinical Trial of Lateral Episiotomy Versus no Episiotomy in Vacuum or Forceps Assisted Delivery in Primiparae|LEVA|Karolinska Institutet|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Female|18 Years|N/A|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643108||5936|
NCT02629783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150111|Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain.|Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain - a Randomized Controlled Trial.|PsychShoP|Vejle Hospital|No|Not yet recruiting|March 2016|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02629783||6959|
NCT02641925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-07-010|Omentectomy for Metabolic Syndrome in Gastric Cancer Patients|The Effect of Visceral Fat Removal for Gastric Cancer Patients With Metabolic Syndrome, Randomized Pilot Study: Omentectomy for Metabolic Syndrome (OMS)||Keimyung University Dongsan Medical Center|No|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02641925||6027|
NCT02378272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS 1938-2013|Care Manager - Coordinating Care for Person Centered Management of Depression in Primary Care|RCT on Care Manager Organization for Management of Mild-moderate Depression in the Primary Care Setting, Sweden|PRIM-CARE|Göteborg University|No|Enrolling by invitation|December 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02378272||26270|
NCT02636387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3768|Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease|Desmopressin as a Therapy for Nocturnal Enuresis in Patients With Sickle Cell Disease||Montefiore Medical Center|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|8 Years|21 Years|No|||December 2015|December 18, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02636387||6453|
NCT02639689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU PROMOTEUR 2013/12|Evaluation of the Increase of the Driving Speed With Walkaide® Medical Device|Evaluation of the Increase of the Driving Speed After the Apparatus by Walkaide® Medical Device in Deficits Levator Foot of Central Origin.|WALKAIDE|University Hospital, Angers|No|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639689||6199|
NCT02390570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008621|Incorporating Patient Capacity Into the Clinical Landscape|||Mayo Clinic|No|Enrolling by invitation|September 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|490|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02390570||25324|
NCT02390648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|732/2557(EC1)|Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting|Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting: Randomised Double-blind Placebo-control Cross Over Study||Mahidol University|No|Completed|March 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390648||25318|
NCT02388061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTA1401|Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke|Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase|EXTEND-IA TNK|Neuroscience Trials Australia|Yes|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388061||25517|
NCT02391948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43611-B|On Track: Monitoring Development of Children With Cerebral Palsy or Gross Motor Delay|Developmental Trajectories of Impairments, Health, and Participation of Children With Cerebral Palsy||University of Washington|No|Active, not recruiting|July 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Months|11 Years|No|Non-Probability Sample|Children with cerebral palsy of gross motor delay, ages 18 month to 11 years, and their        parents.|December 2015|December 2, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02391948||25219|
NCT02382783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008535|Optimizing the Management of Flares in Patients With Rheumatoid Arthritis (RA)|Optimization of the Flare Management in Rheumatoid Arthritis (RA) by Implementing Patient-driven Systematic Changes to the RA Ambulatory Care Stream||Mayo Clinic|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|178|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02382783||25923|
NCT02382796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471055|A Rollover Protocol of Dacomitinib For Patients In Japan|Treatment Access Protocol For Patients Previously Treated With Dacomitinib On A Clinical Trial In Japan||Pfizer|No|Active, not recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||March 2016|March 10, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382796||25922|
NCT02458612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 15/135-43|Effects of Mirror Therapy Combined With Progressive Strength Training in Unilateral Spastic Cerebral Palsy|Effectiveness of Mirror Therapy Combined With Progressive Strength Training on Upper Limb Function in Children With Unilateral Spastic Cerebral Palsy||Hacettepe University|No|Not yet recruiting|June 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|18 Years|No|||September 2015|February 18, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458612||20102|
NCT02458625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0133-14|A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia|A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia||HaEmek Medical Center, Israel|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458625||20101|
NCT02458638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29518|An Open-Label Study of Atezolizumab in Advanced Solid Tumors|An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors||Hoffmann-La Roche||Recruiting|July 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458638||20100|
NCT02388841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YYU-015|Thrombus Localization and Accompaying Disorders and Risk Factors|Assessment of the Association Between Thrombus Localization and Accompaying Disorders ,Rısk Factors, D-Dimer and Red Cells Distribution Witdh In Pulmonary Embolisim||Yuzuncu Yıl University|Yes|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|148|||Both|18 Years|81 Years|No|Probability Sample|The data confirmed on 148 patients having PE by CTPA in the Clinic of Chest Diseases,        Medical School, Yüzüncü Yıl University, Van, Turkey, in the period between January 2012        and August 2014 were retrospectively studied. The patients' accompanying disorders, risk        factors, and the dosing of D-dimer performed on the same day of the CTPA and RDW levels        were noted. The patients who had a story of hospitalising for reasons other than surgery        such as Pneumonia, apses, brucella, encephalitis and the bedridden patients such as        hemiplegia and long-term immobilised patients (>72 hours) after surgery were listed in the        immobilisation group.        Patients receiving the diagnosis of PE with no CTPA performed and 6 patients whose        haemoglobin values were below 11 were not included in this study.|March 2015|March 15, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388841||25457|
NCT02379481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT_NS|Effects of Deer Bone Extract NS on Improvement in Cognitive-Bio-Markers of Cognitive Functions|||Ewha Womans University||Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|March 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02379481||26177|
NCT02378493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/AS-01b|Evaluation of the Antibiofilmogramme® Test During Diabetic Foot Infections|Evaluation of the Antibiofilmogramme® Test During Diabetic Foot Infections|BioFilm PieDia|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|December 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|The S aureus strains encountered will be maintained in a collection for future ancillary      studies.|Both|18 Years|N/A|No|Probability Sample|The study population is composed of diabetic patients with foot wounds (at least stage        >=2) that are infected by at least 1 strain of S. aureus.|December 2015|December 21, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02378493||26253|
NCT02379052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-EE-1324|Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE)|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis||Regeneron Pharmaceuticals|No|Recruiting|January 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|50 Years|No|||September 2015|September 28, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379052||26210|
NCT02459106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 729828|Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans|Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans|miRNA|Translational Research Institute for Metabolism and Diabetes, Florida|No|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Muscle and adipose tissue biopsies will be obtained.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy obese insulin-resistant individuals Healthy lean insulin-sensitive individuals|October 2015|October 27, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02459106||20064|
NCT02388945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usix-APD-001|A Study of Domestic Automated Peritoneal Dialysis Machine|Validity and Security of Domestic Automated Peritoneal Dialysis Machine: A Prospective, Randomized, Controlled, Multi-Center Clinical Trial||Sun Yat-sen University|No|Recruiting|January 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||March 2015|March 9, 2015|February 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388945||25449|
NCT02385058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003685|Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population|Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population||Janssen-Cilag Ltd.|No|Completed|October 2005|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|10 Years|75 Years|No|||April 2015|April 13, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385058||25748|
NCT02379065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C&W13/087|Aerogen Nebuliser Versus Standard Nebulised Therapy in Acute Chronic Obstructive Pulmonary Disease|Mesh Nebuliser Versus Standard Jet Nebuliser Therapy in Acute Chronic Obstructive Pulmonary Disease in the Emergency Department||Chelsea and Westminster NHS Foundation Trust|No|Recruiting|February 2015|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||February 2015|March 3, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02379065||26209|
NCT02383849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1106|IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants|IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Enrolling by invitation|July 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|158|Samples With DNA|Cell pellets from PK sampling once will be combined and stored for a DNA extraction,      amplification, and gel electrophoresis. The genotype analysis will be completed one time per      study participant. All subjects receiving INH will be genotyped for NAT2. All subjects      receiving NVP will be genotyped for CYP 2B6. These genotypes will be used as covariates in      the population PK analyses of NVP and INH to determine their impact on CL/F (clearance      [apparent]).|Both|N/A|84 Days|No|Non-Probability Sample|Low birth weight (LBW) infants less than or equal to 2500 grams at birth who are receiving        or will be receiving as part of clinical care nevirapine (NVP) prophylaxis, tuberculosis        (TB) prophylaxis or treatment and/or combination antiretroviral (ARV) treatment containing        lopinavir/ritonavir (LPV/r)|February 2016|February 12, 2016|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02383849||25841|
NCT02460328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|794/2557(EC4)|Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome|Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome||Mahidol University|No|Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|43|||Both|N/A|15 Years|No|Probability Sample|22q11.2 deletion syndrome diagnosed from Fluorescence in situ hybridization (FISH) for        22q11|March 2016|March 22, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02460328||19970|
NCT02460341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1794|The Effects of Ondansetron on Brain Function|The Effects of Ondansetron on Brain Function||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460341||19969|
NCT02388997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14427|Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus|An Evaluation of Treatment With Omalizumab to Improve the Asthmatic Response to an Experimental Infection With Rhinovirus||University of Virginia|Yes|Recruiting|February 2013|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|42|||Both|18 Years|40 Years|No|||March 2015|March 13, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388997||25445|
NCT02390076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMHR-0001|Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time|Influence of Low-Level Light Therapy on Attention Bias Modification and Mood Change in Dysphoric Individuals||University of Texas at Austin|No|Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|35 Years|No|||March 2015|March 16, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02390076||25362|
NCT02390141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP4207-15007|Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207|A Randomized, Placebo-controlled, Double-blind Trial of Multiple Ascending Doses of ZP4207 Administered to Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP4207||Zealand Pharma|No|Completed|April 2015|August 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02390141||25357|
NCT02447666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-JMML-001|Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)|A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Azacitidine and to Compare Azacitidine to Historical Controls in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia Before Hematopoietic Stem Cell Transplantation||Celgene Corporation|Yes|Recruiting|September 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|1 Month|18 Years|No|||March 2016|March 24, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447666||20943|
NCT02386683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kY2014-031-02|Intraoperative Lung-Protective Ventilation in Neurosurgery|Intraoperative Lung-Protective Ventilation in Neurosurgery||Capital Medical University|Yes|Recruiting|September 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|40 Years|80 Years|No|||March 2015|March 6, 2015|October 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02386683||25623|
NCT02389127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203867|Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis|Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis: a Pilot Study to Better Characterize and Standardize the Test||University of Arkansas|Yes|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cirrhosis with and without T2DM|October 2015|October 12, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02389127||25435|
NCT02390219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-809-106|Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease|A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated||Recruiting|March 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|12 Years|N/A|No|||January 2016|January 4, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390219||25351|
NCT02386813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-03-071|International Extranodal NK/T-cell Lymphoma Project|International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment|PINK|Samsung Medical Center|Yes|Recruiting|January 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Both|20 Years|90 Years|No|Probability Sample|1. Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31,             2012;          2. Patients treated with non-anthracycline based therapy as an initial treatment.|March 2015|March 16, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386813||25613|
NCT02385864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00908-37|CPAP Effect on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension|Effect of the Continuous Positive Airway Pressure on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension|POP-ART|University Hospital, Grenoble|No|Recruiting|September 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|166|||Both|18 Years|75 Years|No|Probability Sample|Patients with resistant hypertension|March 2016|March 4, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02385864||25686|
NCT02389803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc067614ctil|Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Boys|Double Blind, Randomized , Placebo Controlled Study to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Boys||Rabin Medical Center|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Male|11 Years|15 Years|No|||June 2015|July 8, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02389803||25383|
NCT02389816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004/CCT-004|A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder||Takeda|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|20 Years|75 Years|No|||January 2016|January 28, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389816||25382|
NCT02460432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRA-003|Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)|A Prospective, Randomized, Single Blind Study to Evaluate the Effectiveness and Safety Comparing Niti-S Mira-Cover III Biliary Stent With ComVi Biliary Covered Stent in Patients With Malignant Biliary Obstruction||Taewoong Medical Co., Ltd.|Yes|Recruiting|May 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|106|||Both|19 Years|N/A|No|||March 2016|March 15, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460432||19962|
NCT02378935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1168|Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection|A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences|No|Active, not recruiting|February 2015|April 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|205|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378935||26219|
NCT02378948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52591.060.15|Nutritional Route In Esophageal Resection Trial II|Nutritional Route in Esophageal Resection Trial II (NUTRIENT II): a Randomized Controlled Trial|NUTRIENTII|Catharina Ziekenhuis Eindhoven|No|Enrolling by invitation|October 2015|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|148|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02378948||26218|
NCT02381912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSBC-2015|Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer|Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer||Herlev Hospital|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|210|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with primary hematuria.|March 2016|March 8, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381912||25990|
NCT02382172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2804|Social Cognition and Interaction Training for Autism|Social Cognition and Interaction Training for Autism (SCIT-A)|SCIT-A|University of North Carolina, Chapel Hill|No|Recruiting|January 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|10 Years|69 Years|No|||September 2015|September 14, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02382172||25970|
NCT02389881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-058-1002|Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058||Takeda|Yes|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389881||25377|
NCT02448979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKTRDP-2015BAI12B08-01|Esophagectomy in Middle and Lower Thoracic Esophageal Cancer Patients Through Left Versus Right Transthoracic Approach|Randomized Control Study on Surgical Treatment for Middle and Lower Thoracic Esophageal Cancer Patients Without Upper Mediastinal Lymph Node Metastasis Through Left Versus Right Transthoracic Approach||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|75 Years|No|||May 2015|May 17, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02448979||20842|
NCT02448992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-6591A3|Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer|Neuropsychological and Oncological Outcomes After Hippocampal-Sparing Prophylactic Cranial Irradiation in Postoperative Patients With Pathologically Nodal Positive Non-Small-Cell Lung Cancer - A Prospective Follow-up Study||Chang Gung Memorial Hospital||Active, not recruiting|August 2015|||July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02448992||20841|
NCT02379182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAL|Effect Of Vitalstim In Patients With Chronic Post-stroke Oropharyngeal Dysphagia|Randomized Controlled Trial To Evaluate The Effect Of Vitalstim In Patients With Chronic Post-stroke Oropharyngeal Dysphagia|VITAL|Hospital de Mataró||Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2015|March 3, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379182||26200|
NCT02390921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)275/2014|The Effectiveness of Liposomated Iron in Patients With Previous Bariatric Surgery Which Are Currently Receiving Parentheral Therapy With Iron|The Effectiveness of Oral Treatment With Liposomated Iron in Patients With Previous Bariatric Surgery Which Are Currently Receiving Parentheral Therapy With Iron|BARIFER|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|February 2015|November 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||July 2015|July 16, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02390921||25297|
NCT02390934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-001070-34|Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer|Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer|RAD-THYR|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|October 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02390934||25296|
NCT02389972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-518|Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study|Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study||Bristol-Myers Squibb|No|Active, not recruiting|April 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be naive to dasatinib before the enrollment period, be over the age of 18        years with a confirmed diagnosis of any phase CML by the treating physician, and are to        initiate treatment with dasatinib based on the physician's clinical judgement|July 2015|December 21, 2015|October 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02389972||25370|
NCT02444481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX401-08|Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis|Open Multicenter Clinical Study of the Efficacy of the Local Treatment With Polygynax of Mycotic and/or Bacterial Vaginitis||Laboratoire Innotech International|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Female|18 Years|65 Years|No|||May 2015|May 11, 2015|May 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02444481||21187|
NCT02387385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15HH|Hypothermia for Encephalopathy in Low and Middle-Income Countries Trial|Hypothermia for Encephalopathy in Low and Middle-Income Countries Trial|HELIX|Thayyil, Sudhin|Yes|Recruiting|August 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|408|||Both|N/A|6 Hours|No|||August 2015|August 15, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02387385||25569|
NCT02382705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03253|SB3 Battery Life Observational Study|Clinical Impact of Longer Battery Life on Small Bowel Capsule Endoscopy: a Prospective Observational Study||University of British Columbia|No|Recruiting|February 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing small bowel capsule endoscopy|August 2015|August 25, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382705||25929|
NCT02385656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1302/191-003|The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study|The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study||Seoul National University Bundang Hospital|No|Recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|65 Years|No|||March 2015|March 10, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385656||25702|
NCT02385669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17780|A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma|A Phase I/II Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Advanced Melanoma (Mel62; 6PAC)|Mel62; 6PAC|University of Virginia|Yes|Recruiting|April 2015|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385669||25701|
NCT02453906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XNKQ-15|XNKQ Acupuncture Compared to Control Interventions Measured With EEG and fMRI|Cerebral Response of Healthy Subjects to a Somatosensory Stimulation With XNKQ Acupuncture Compared to Control Interventions Measured With EEG and fMRI||Charite University, Berlin, Germany|No|Recruiting|May 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02453906||20463|
NCT02383706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056786|Obstructive Sleep Apnea in Pregnancy|Obstructive Sleep Apnea in Pregnancy: Development of a Pregnancy-Specific Screening Tool|OSAinPreg|Duke University|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women, ages 18-50 years old, BMI > or equal to 40 kg/m2, without a prior        diagnosis of obstructive sleep apnea or chronic narcotic use.|January 2016|January 20, 2016|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383706||25852|
NCT02383719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conveng - 002|Mask Comfort Feasibility|Oro-nasal Mask Patient Comfort Evaluation|mask|Convergent Engineering, Inc.||Not yet recruiting|March 2015|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383719||25851|
NCT02387125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMDZ-C131|A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1|A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1||Immune Design|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387125||25589|
NCT02387138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM2013/47|A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan|A Phase I Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- or Second-line Treatment|SIRINOX|Institut du Cancer de Montpellier - Val d'Aurelle|No|Recruiting|April 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02387138||25588|
NCT02390180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055040|Sorting of Oral Sensations|Sorting of Oral Sensations||Purdue University|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|107|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy men and women at least 18 years of age, not on any medication that alters taste        sensation, and not allergic to dairy or nut products (samples contained a dairy protein        and some sugars that were processed in facilities that also process nuts). Participants        also had to pass a screening test to determine they could detect 0.5% linoleic acid        emulsion compared to a blank solution.|May 2015|May 11, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02390180||25354|
NCT02377427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200363|Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children|An Open-label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children From 6 to 11 Years of Age With Severe Eosinophilic Asthma||GlaxoSmithKline|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|28|||Both|6 Years|11 Years|No|||March 2016|March 17, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377427||26335|
NCT02445196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22977|PTSD Coach App Evaluation|PTSD Coach App Evaluation||Stanford University|No|Completed|February 2014|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445196||21132|
NCT02387801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15454|A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis|Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis||Eli Lilly and Company|No|Active, not recruiting|April 2015|August 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387801||25537|
NCT02387814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15538|A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment|A Single-Dose Pharmacokinetic Study of Abemaciclib (LY2835219) in Subjects With Varying Degrees of Hepatic Impairment||Eli Lilly and Company|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387814||25536|
NCT02393560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-402|DECT Study in Allopurinol-Treated Gout Patients|A Study to Determine the Presence and Volume of Monosodium Urate Crystals as Assessed by Dual-Energy Computed Tomography in Gout Patients Treated With Allopurinol||Ardea Biosciences, Inc.|No|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood sample may be used for optional genetic testing in subjects who give consent.      Serum aliquots will be collected and may be used for the analysis of potential analytes and      biomarkers, but may not be used for genetic testing without the subject's written consent.|Both|18 Years|85 Years|No|Non-Probability Sample|Gout subjects taking a stable dose of at least 300 mg allopurinol daily for at least 12        weeks prior to Day 1 as the sole urate-lowering therapy|January 2016|January 26, 2016|March 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02393560||25095|
NCT02377973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D209|Diet and Well-being of Young Danish Children Born by Obese Mothers|The SKOT II Cohort - a Prospective Cohort Study of Diet and Well-being in Young Danish Children Born by Obese Mothers|SKOT II|University of Copenhagen|No|Completed|January 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|184|Samples With DNA|Urine, faeces, white cells, plama/serum|Both|9 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young Danish infants born by obese morthers, who during pregnancy were part of a        intervention study at Hvidovre Hospital. In the intervention at Hvidovre Hospital study        the mothers were asked to join SKOT II,|February 2015|March 3, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02377973||26293|
NCT02445976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-VT-464-CL-003|Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.|A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.||Innocrin Pharmaceutical|No|Recruiting|May 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|148|||Male|18 Years|N/A|No|||May 2015|May 21, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445976||21072|
NCT02383108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMILE (PENTA 17)|Strategy for Maintenance of HIV Suppression With Elvitegravir + Darunavir/Ritonavir in Children|A Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Elvitegravir (EVG) Administered With Darunavir/Ritonavir (DRV/r)Compared to Current Standard Antiretroviral Therapy in HIV-1 Infected, Virologically Suppressed Paediatric Participants.|SMILE|PENTA Foundation|Yes|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|6 Years|17 Years|No|||January 2016|January 26, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383108||25898|
NCT02383121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76683|Midodrine for Ischemic Stroke With Penumbra|Midodrine for Ischemic Stroke With Penumbra|MISP|University of Utah|No|Not yet recruiting|February 2016|September 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383121||25897|
NCT02389374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14053|A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh|A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh||Menzies School of Health Research|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|181|||Both|12 Months|N/A|No|||April 2015|April 8, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02389374||25416|
NCT02379533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/14786-0|Effects of Home-based or Center-based Aerobic Exercise in Patients With Chronic Kidney Disease|Effects of Home-based or Center-based Aerobic Exercise on Physical Function, Nutritional Status Ans Cardiopulmonary Parameters in Patients With Chronic Kidney Disease|HBCKD|Federal University of São Paulo|Yes|Completed|August 2009|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|45|||Both|30 Years|65 Years|No|||March 2015|March 24, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02379533||26173|
NCT02390310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1084493|Simplifying the Shang Ring Technique for Circumcision of Men and Boys|Simplifying the Shang Ring Technique for Circumcision of Men and Boys||EngenderHealth|Yes|Recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|575|||Male|10 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02390310||25344|
NCT02384200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150013|A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])|The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1||University of California, San Diego|No|Recruiting|March 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384200||25814|
NCT02386839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP607-201|Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of ROP|Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care|PEDAL|Shire|Yes|Enrolling by invitation|March 2015|April 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|40 Weeks|52 Weeks|No|Non-Probability Sample|Subjects randomized in Study ROPP-2008-01, Section D are eligible to enroll in this study;        completion of Study ROPP-2008-01 Section D is not required. Subjects in Study ROPP-2008-01        are premature infants (gestational age of 23 weeks + 0 days to 27 weeks + 6 days) who are        randomized to receive either treatment with rhIGF-1/rhIGFBP-3 or standard neonatal care.        Up to 120 subjects are planned to be randomized in Study ROPP-2008-01 Section D.|November 2015|November 19, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02386839||25611|
NCT02383524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|418120|Genetic Predictors of Responsiveness to Radiofrequency Denervation in Chronic Low Back Pain|Does the Brain-derived Neurotrophic Factor Val66Met Gene Polymorphism Predict Inter-individual Variation in Responsiveness Following Lumbar Radiofrequency Denervation? A Single-centre, Prospective, Exploratory Study in Subjects Diagnosed With Zygapophysial Joint Pain||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|February 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from chronic and debilitating low back pain with a diagnosis of lumbar        zygapophysial joint mediated pain which has not been effectively treated with conservative        pharmacological treatment or alternative non-invasive treatments|March 2015|March 10, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383524||25866|
NCT02383537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-14-HMO|Biological Changes in the Adipose Tissue Among Pregnant Women With Diabetes|Biological Changes in the Adipose Tissue (RNA Profile) Among Pregnant Women With Diabetes||Hadassah Medical Organization|No|Not yet recruiting|April 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women with diabetes. Healthy women will serve as a reference group|March 2015|March 4, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383537||25865|
NCT02390375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-0929_P301|Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia|||Daewon Pharmaceutical Co., Ltd.||Active, not recruiting||||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|342|||Both|19 Years|N/A|No|||February 2015|March 16, 2015|March 11, 2015||||No||https://clinicaltrials.gov/show/NCT02390375||25339|
NCT02384434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO 14-001|Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma|Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma||University of Pittsburgh|Yes|Recruiting|April 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|37|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384434||25796|
NCT02378103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IACUC-20140214090|A Single-center Trial of Patients With Aortic Dissection in the Chinese XinJiang Province|||First Affiliated Hospital of Xinjiang Medical University||Active, not recruiting|February 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|Between March, 2015 and March, 2016, we aim to collect 100 patients with AD as the case        group. As the control group, 100 patients without AD were obtained from the hospitalized        patients in the same period.|February 2016|February 3, 2016|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02378103||26283|
NCT02378389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLTN-Id|Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer|A Phase I Study of Pyrotinib In Combination With Docetaxel In Patients With HER2 Positive Advanced Gastric Cancer||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|September 2014|August 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|70 Years|No|||February 2015|February 27, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02378389||26261|
NCT02630537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB-A1 (UREA-CMV-EBV)|Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients|Clinical Validation of Lophius Kits T-Track® CMV and T-Track® EBV to Assess the Functionality of Cell-mediated Immunity (CMI) in Hemodialysis Patients||Lophius Biosciences GmbH||Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|133|||Both|18 Years|N/A|No|Non-Probability Sample|Patient being hemodialysis-dependent due to end-stage kidney disease|December 2015|December 10, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630537||6901|
NCT02630550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15042|Validation of the Cheetah NICOM by Comparison to TEE During Open Vascular Surgery - Pilot Study|Validation of the Cheetah NICOM by Comparison to TEE During Open Vascular Surgery - Pilot Study||Maisonneuve-Rosemont Hospital|No|Recruiting|November 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|90 Years|No|Probability Sample|Patients undergoing either an open aortic aneurysm repair surgery or a femoral        endarterectomy under general anesthesia.|December 2015|December 10, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630550||6900|
NCT02639247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1170|Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor||Gilead Sciences|Yes|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639247||6233|
NCT02639260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160036|A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DEX-M74 in Subjects With Primary Podocyte Diseases|A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DEX-M74 in Subjects With Primary Podocyte Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|99 Years|No|||December 2015|January 13, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639260||6232|
NCT02629536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Churack Chair|Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.|Effect on Migraine Frequency of Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT Study|MIGRANT|University of Notre Dame Australia|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02629536||6978|
NCT02629549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822782|Intraoperative Imaging of Pituitary Adenomas by OTL|A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma||University of Pennsylvania|Yes|Recruiting|October 2015|December 2020|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629549||6977|
NCT02384915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC07|Spinal Anesthesia Versus Combined Sciatic-femoral Nerve Block for Outpatient Knee Arthroscopy|Spinale Unilaterale o Blocco Nervoso Periferico Per le Artroscopie di Ginocchio in Day Surgery. Confronto Prospettico Randomizzato||ASST Gaetano Pini-CTO|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2015|May 7, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02384915||25759|
NCT02391584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2909-001|XprESS Eustachian Tube Dilation Study|XprESS Eustachian Tube Dilation Study||Entellus Medical, Inc.|No|Recruiting|February 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391584||25246|
NCT02630784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00844-43|Efficacy and Safety of Non-invasive Ventilation by Calibrated Leak in the Treatment of Respiratory Acidosis in ICU||VNI Versus|University Hospital, Grenoble|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|January 6, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02630784||6882|
NCT02634632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-22|Assessments and Recommendations for the Implementation of Advance Directives in Oncology|Assessments and Recommendations for the Implementation of Advance Directives in Oncology|DA|Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|100|||Both|18 Years|85 Years|No|||December 2015|December 18, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634632||6587|
NCT02641353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-CP-032|Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and a Study to Assess Effect of Food on the Pharmacokinetic (PK) of the Oral Suspension|A Phase 1, Open-label, Randomized, Three-period, Six-sequence Crossover Study in Healthy Adult Subjects to Evaluate the Bioavailability of an Oral Suspension Formulation Relative to the Tablet Formulation of Apremilast and to Assess the Effect of Food on the Pharmacokinetics of the Oral Suspension Formulation||Celgene|No|Recruiting|January 2016|September 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641353||6071|
NCT02633683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP110|An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome|RLS|XenoPort, Inc.|No|Recruiting|January 2016|July 2024|Anticipated|May 2024|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|144|||Both|13 Years|17 Years|No|||December 2015|March 2, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633683||6660|
NCT02633696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-SIL-FARMA03|Study to Investigate the Absolute Bioavailability of Oral Sylibin|Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability of Oral Sylibin||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|October 2013|November 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02633696||6659|
NCT02628925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHAG-001-2014|Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale|Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale (Nu-DESC DK)|Nu-DESC DK|Naestved Hospital|No|Completed|September 2014|April 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff on 2 different wards|December 2015|December 10, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02628925||7025|
NCT02628938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUGRP/2013/114|Effect of Miswak and Miswak Extract on Oral Malodor|Effect of Miswak and Miswak Extract on Oral Malodor||Riyadh Colleges of Dentistry and Pharmacy|No|Completed|March 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|212|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628938||7024|
NCT02628951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-11-110|Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis|Phase II Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis||Samsung Medical Center|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02628951||7023|
NCT02376816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00718|Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy|Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.Micro-dystrophin||Nationwide Children's Hospital|Yes|Enrolling by invitation|March 2015|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Male|7 Years|N/A|No|||February 2015|February 26, 2015|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376816||26382|
NCT02449213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8006|A Biobehavioral Model of Diabetes Risk in Chinese Immigrants|A Biobehavioral Model of Diabetes Risk in Chinese Immigrants||Fox Chase Cancer Center|No|Recruiting|January 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Serum, plasma, and hair samples will be obtained|Both|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|600 foreign-born Chinese Americans|March 2016|March 1, 2016|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02449213||20824|
NCT02376985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral Care-BC|Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT|Evaluation of Oral Care to Prevent Oral Mucositis in Estrogen Receptor Positive Metastatic Breast Cancer Patients Treated With Everolimus: Phase III Randomized Control Trial||Comprehensive Support Project for Oncology Research|Yes|Recruiting|March 2015|March 2019|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|N/A|No|||March 2015|March 3, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02376985||26369|
NCT02377245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIR-001|Juvenile Inflammatory Rheumatism (JIR) Cohorte|Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases|JIR-cohorte|University of Lausanne Hospitals|Yes|Enrolling by invitation|January 2014|December 2023|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|18 Years|No|Non-Probability Sample|All patients with juvenile inflammatory diseases|March 2016|March 18, 2016|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02377245|10 Years|26349|
NCT02380625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVD-003|Multiple Treatments for Ebola Virus Disease (EVD)|An Adaptive Randomized Trial Comparing Multiple Treatments for Ebola Virus (EBOV) Infected Children and Adults||Clinical Research Management, Inc.|Yes|Not yet recruiting|April 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|6 Months|N/A|No|||March 2015|March 1, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380625||26089|
NCT02390622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSA-FMT|Biotherapy for MRSA Enterocolitis|Fecal Microbiota Transplantation Restores Dysbiosis in Patients With Methicillin Resistant Staphylococcus Aureus Enterocolitis||Jinling Hospital, China|Yes|Recruiting|July 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||March 2015|March 11, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390622||25320|
NCT02460081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA-002-DFU-003|Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease|A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGE FINDING STUDY TO EVALUATE THE SAFETY, HEMODYNAMIC EFFECTS AND EFFICACY OF INTRAMUSCULAR INJECTION OF HUMAN PLACENTA-DERIVED CELLS (PDA-002) IN SUBJECTS WHO HAVE DIABETIC FOOT ULCER WITH PERIPHERAL ARTERIAL DISEASE||Celgene|Yes|Active, not recruiting|June 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460081||19989|
NCT02460094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN002-003|Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy|CN002-003|Bristol-Myers Squibb|No|Recruiting|September 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|41 Years|86 Years|No|||January 2016|January 12, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460094||19988|
NCT02377830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIREB 14-531|CYCLE Pilot Randomized Trial|CYCLE Pilot: A Pilot Randomized Study of Early Cycle Ergometry Versus Routine Physiotherapy in Mechanically Ventilated Patients|CYCLE Pilot|McMaster University|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377830||26304|
NCT02384499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2014-0271|Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study|Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study||Yonsei University|Yes|Recruiting|December 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|21|||Both|19 Years|N/A|No|||February 2015|March 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02384499||25791|
NCT02383563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H028|Metformin for HIV Inflammation|Open-Label, Randomized, 24-Week Pilot Study of Metformin vs Observation for Persistent Immune Activation in Chronic HIV Infection||University of Hawaii|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|45 Years|N/A|No|||March 2015|March 3, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383563||25863|
NCT02383576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29587|Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223|||Hoffmann-La Roche||Completed|April 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|125|||Both|18 Years|N/A|No|Probability Sample|All participants randomized in IMELDA (MO22223)|March 2016|March 1, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383576||25862|
NCT02383589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29330|A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris|A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY ACTIVE-COMPARATOR MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB VERSUS MMF IN PATIENTS WITH PEMPHIGUS VULGARIS||Hoffmann-La Roche||Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383589||25861|
NCT02460172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty|A Prospective, Randomized Controlled Post-market Study to Compare the Use of the Zip® Surgical Skin Closure Device Versus Conventional Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty||ZipLine Medical Inc.|No|Recruiting|May 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 1, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460172||19982|
NCT02460185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPEX|Role of Maternal Physical Exercise on Spontaneous Labor Onset|The Role of Maternal Physical Exercise on Spontaneous Labor Onset - A Randomized Clinical Trial||Centro Hospitalar Lisboa Norte|No|Recruiting|January 2012|January 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02460185||19981|
NCT02389192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150094|Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers|A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389192||25430|
NCT02384109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-000310|A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program|A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program||University of California, Los Angeles|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384109||25821|
NCT02448173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-2005-04|A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer|A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer||Vaccinogen Inc|Yes|Recruiting|May 2015|July 2022|Anticipated|July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448173||20904|
NCT02378051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000867|Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children|Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children: A Preliminary Examination of Efficacy||Massachusetts General Hospital|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|6 Years|N/A|No|||February 2015|February 26, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02378051||26287|
NCT02378064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-10|Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation|Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation|FACE|Asan Medical Center|Yes|Recruiting|May 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378064||26286|
NCT02376777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 15 09|Comparison of Accidents and Their Circumstances With Oral Anticoagulants|Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study|CACAO|CNGE IRMG Association|No|Enrolling by invitation|April 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4162|||Both|18 Years|N/A|No|Probability Sample|All adult patients with anticoagulant medication consulting their general practitioner        will be included (N=7846), and after stratification, 4162 patients will be followed|February 2015|March 2, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02376777||26385|
NCT02379312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-0291|Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams|Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams||Unilever R&D|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|February 26, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02379312||26190|
NCT02389179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D|Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics|Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis||University of Malaya|Yes|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389179||25431|
NCT02377063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000274|The Effect of Fruit/Vegetable Drinks on the Human Intestine|Study of the Effect of Fruit/Vegetable Based Supplementation on Microbiome||University of California, Los Angeles|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|October 9, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02377063||26363|
NCT02379559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Georgetown_University_MC1|Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men|An Exercise Intervention on Metabolic Syndrome and Prostate Cancer Risk Among Black Men|STRONG|Georgetown University|Yes|Recruiting|July 2013|December 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|84|||Male|40 Years|40 Years|Accepts Healthy Volunteers|||September 2014|March 4, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02379559||26171|
NCT02379793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1080|Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects|Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects||LEO Pharma|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2015|April 21, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02379793||26153|
NCT02452736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-Resolute Integrity China|Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)|CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study||Medtronic Vascular|Yes|Completed|May 2015|December 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02452736||20553|
NCT02452749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB042115|Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement|Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement||National College of Natural Medicine|No|Not yet recruiting|May 2015|||February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452749||20552|
NCT02453035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-1503|DESolve® X-Pand Global Post Market Registry|X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree Of Selection Criteria|X-Pand|Elixir Medical Corporation|No|Recruiting|May 2015|May 2019|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|patients who have received implants of one or more DESolve scaffold(s)|November 2015|November 6, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02453035|3 Years|20530|
NCT02392143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|542376|Promoting CRC Screening in an Urban Minority Population|Promoting CRC Screening in a Hard-To-Reach, Low-Income Minority Population||Teachers College, Columbia University|No|Completed|January 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Actual|564|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392143||25204|
NCT02379208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T58/2012|Evaluation of Rate of Progression With Perimetry in Newly Diagnosed Open Angle Glaucoma|||Turku University Hospital|No|Enrolling by invitation|April 2015|May 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to Turku University Central Hospital for suspected or newly diagnosed        open angle glaucoma|February 2015|February 26, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02379208||26198|
NCT02392104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1296|Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service|Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service||William S. Middleton Memorial Veterans Hospital|Yes|Enrolling by invitation|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02392104||25207|
NCT02393274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412045RINA|Microcirculation in Venoarterial Extracorporeal Membrane Oxygenation Life Support|Investigation of Microcirculation in Patients With Venoarterial Extracorporeal Membrane Oxygenation Life Support||National Taiwan University Hospital|No|Recruiting|April 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|20 Years|79 Years|No|Non-Probability Sample|Patients who require venoarterial extra-corporeal membrane oxygenation (ECMO) life support|October 2015|October 25, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02393274||25117|
NCT02453061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-62|A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease|A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease|TRIHEP3|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2015|December 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02453061||20528|
NCT02382887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225/08|Comparison by Neuromonitoring of Two Techniques of Tracheal Intubation in Patients With Unstable Cervical Spine|Comparison by Neuromonitoring of Two Techniques of Tracheal Intubation in Patients With Unstable Cervical Spine||University of Lausanne Hospitals|No|Recruiting|March 2009|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|16 Years|N/A|No|||March 2015|March 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382887||25915|
NCT02386098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-048|Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults|A Phase 2b Randomized, Active-Controlled, Staged, Open-label Trial to Investigate Safety and Efficacy of BMS-955176 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults||Bristol-Myers Squibb|No|Recruiting|June 2015|January 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02386098||25668|
NCT02393300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTU-GK-011|Comparison of Topical Versus Intravenous Tranexamic Acid in TKA|Comparison of Topical Versus Intravenous Tranexamic Acid in Primary Total Knee Arthroplasty：A Prospective Randomized Study||Shanghai Jiao Tong University School of Medicine|No|Recruiting|September 2014|July 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|March 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393300||25115|
NCT02453308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1502|A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)|A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies (TACTs) Com-pared to Artemisinin-based Combination Therapies (ACTs) in Uncomplicated Falciparum Malaria and to Map the Geographical Spread of Artemisinin and Partner Drug Resistance|TRACII|University of Oxford|Yes|Recruiting|August 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2040|||Both|6 Months|65 Years|No|||December 2015|December 2, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02453308||20509|
NCT02453321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13110481|Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Knee Arthroplasty|A Comparison Between Continuous Selective Femoral Blocks and Continuous Adductor Canal Blocks at Mid-Thigh in Total Knee Arthroplasty: What is the Best Method to Optimize Functional Achievement and Analgesia in Early Rehabilitation?|FemVsACB|University of Pittsburgh|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453321||20508|
NCT02383173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-071|Evaluation of Methods for Implementation of a Comfort Care Order Set|Evaluation of Methods for Implementation of a Comfort Care Order Set|BEACON II|VA Office of Research and Development|No|Recruiting|March 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|48|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02383173||25893|
NCT02383186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614521|Dermal Suturing Only Versus Layered Cutaneous Closure|Dermal Suturing Only Versus Layered Cutaneous Closure: A Randomized Split Wound Comparative Effectiveness Trial||University of California, Davis|No|Active, not recruiting|July 2014|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02383186||25892|
NCT02378129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPel|Evaluation of Dentin Hypersensitivity Using Glass Ionomer Cements|Evaluation of the Effectiveness of Dentin Hypersensitivity Treatment Using Glass Ionomer Cements: A Randomized Clinical Trial||Federal University of Pelotas|No|Active, not recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|28 Years|70 Years|Accepts Healthy Volunteers|||February 2015|March 3, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02378129||26281|
NCT02378142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-3006|Pazopanib for Treating Uterine Leiomyosarcoma|A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||Gynecologic Oncology Group|Yes|Withdrawn|March 2015|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378142||26280|
NCT02378428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00656|MIBG Therapy for Patients With MIBG Avid Tumors|A Phase II Study of <131>I-Metaiodobenzyguanidine (<131>I-MIBG) Therapy for Patients With MIBG Avid Tumors|MIBG|Nationwide Children's Hospital|Yes|Recruiting|March 2014|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|12 Months|40 Years|No|||September 2015|September 24, 2015|March 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378428||26258|
NCT02376842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3675309|Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert|Single-blind Randomized Trial of a Commercially Sold Electronic Health Record Based Severe Sepsis Early Warning Best Practice Alert.||Stanford University|No|Completed|November 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|1149|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02376842||26380|
NCT02376855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1023|A Study of the Implementation of an Electronic Consultation ("eConsult") Platform|A Study of the Implementation of an Electronic Consultation ("eConsult") Platform to Increase Specialist Access for Patients in Underserved Populations: Impact on Provider Experience, Wait Times and Cost||Community Health Center, Inc.|No|Completed|October 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|March 2, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02376855||26379|
NCT02376868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaestroAPII|Maestro Agreement and Precision Study II|Topcon 3D OCT-1 Maestro Agreement and Precision Study II||Topcon Medical Systems, Inc.|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376868||26378|
NCT02449252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUCC-NHL01 Trial|Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma|Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial||Wuhan University|Yes|Recruiting|October 2015|October 2025|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449252||20821|
NCT02392299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUR(14/17)|Risk of Falling in Chronic Kidney Disease 5|Frailty, Cardiovascular Function and Risk of Falling in Patients Receiving Haemodialysis Treatment||Queen Margaret University|No|Recruiting|September 2015|August 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Stage 5 Chronic Kidney Disease patients|October 2015|October 8, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392299||25192|
NCT02386969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408207|Repetitive Transcranial Magnetic Stimulation in Central Neuropathic Pain|Long-term Efficacy of Repetitive Transcranial Magnetic Stimulation on the Primary Motor Cortex (M1) in Central Neuropathic Pain||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2015|September 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386969||25601|
NCT02386982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMM0103|Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients|A Single-centre, Randomized, Open-label, 2-arm, 4-week Treatment Study to Investigate the Beta Cell Function and Related Pharmacodynamics in Type 2 Diabetes Mellitus (T2DM) Patients||Hua Medicine Limited|Yes|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386982||25600|
NCT02390089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401059|Cough According to Stimulus Type in PD|Airway Protection Deficits According to Stimulus Type in Parkinson's Disease||University of Florida|No|Recruiting|April 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|150|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|February 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390089||25361|
NCT02460887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sun Yat-sen University HPY|The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT|A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Not yet recruiting|June 2015|June 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|65 Years|No|||May 2015|May 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460887||19927|
NCT02387580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_15_001|Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets|A Phase I Bioavailability Study of Selected Oral Prototype Granule Formulations of OZ439 in Healthy Subjects, to Evaluate the Pharmacokinetics of OZ439 When Co-Administered With Piperaquine Phosphate Tablets in the Fasted State||Medicines for Malaria Venture|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|March 5, 2015|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02387580||25554|
NCT02391025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145512|Gallium-68 Citrate PET Used in Prostate Cancer|Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer||University of California, San Francisco|Yes|Recruiting|March 2015|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|28|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02391025||25289|
NCT02377440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0634|Effects of ACEI on Bone Turnover|Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover||The University of Texas Health Science Center, Houston|No|Completed|October 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|serum samples|Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 60 patients (30 men and 30 women) 45 years or older will be recruited at        designated outpatient clinics and randomly allocated 1:1 to receive ACEI vs. a non        RAS-related antihypertensive medication.|December 2015|December 3, 2015|March 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02377440||26334|
NCT02382003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0331-00|Web-based Interpretation Training For Anxiety|Testing Target Engagement and Effectiveness of Web-based Interpretation Training For Anxiety||University of Virginia|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|233|||Both|18 Years|N/A|No|||August 2015|August 1, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02382003||25983|
NCT02449759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166325|An ACT Manual-based, Guided Self-help Intervention Pilot|Evaluating Acceptance and Commitment Therapy as a Low-intensity, Manual-based, Guided Self-help Intervention for Anxiety and Depression: A Pilot Study|ACT|University of Edinburgh|No|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|65 Years|No|||May 2015|May 15, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02449759||20782|
NCT02392390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/LM-01|Effects of Topical Dynamic Phototherapy on the Microbiota of Chronic Wounds|Effects of Topical Dynamic Phototherapy (TDP) on the Microbiota of Chronic Wounds: a Pilot Study|PDT-Bactério|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|October 2015|March 2016|Anticipated|March 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392390||25185|
NCT02392403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTD5446|Clinical Investigation of the Nucleus® CI532 Cochlear Implant|Clinical Investigation of the Nucleus® CI532 Cochlear Implant||Cochlear|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392403||25184|
NCT02379286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-02|Impact of Media Images, Alcohol and Tobacco to Youth|Impact of Media Images, Alcohol and Tobacco to youthImpact Study and Development of a Prevention Program|IMAJE|Institut de Cancérologie de la Loire|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|14 Years|17 Years|No|Non-Probability Sample|Tennagers aged between 14 and 17 years|February 2015|February 27, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379286||26192|
NCT02382029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZagreb|Acupuncture Versus Clonazepam in Burning Mouth Syndrome|The Effectiveness of Acupuncture Versus Clonazepam in the Patients With Burning Mouth Syndrome|ACUCLONBMS|University of Zagreb|Yes|Completed|March 2014|November 2014|Actual|November 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02382029||25981|
NCT02382042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N32-FY13Q1-S1-P00642|Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans|Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans|IRI|VA Nebraska Western Iowa Health Care System|Yes|Active, not recruiting|September 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|450|||Both|19 Years|N/A||||March 2015|March 2, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02382042||25980|
NCT02383407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111239|Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)|Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)|MTLE-DBS|George Washington University|Yes|Recruiting|December 2013|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|February 16, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383407||25875|
NCT02386618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 07|Endoscopic Treatment for Local Residual Neoplasia|Endoscopic Treatment for Local Residual Neoplasia After Endoscopic Mucosal Resection of the Colorectal Lateral Spreading Tumors (LST)||Vitkovice Hospital|Yes|Completed|October 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|September 19, 2013||No||No||https://clinicaltrials.gov/show/NCT02386618||25628|
NCT02377856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960056|Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection|Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|June 2007|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||February 2016|February 29, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02377856||26302|
NCT02377869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018-14-BNZ|Heavy Light Chain in Chronic Lymphocytic Leukemia|Heavy Light Chain in Chronic Lymphocytic Leukemia||Bnai Zion Medical Center|No|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Age>18 years Patients diagnosed with CLL|February 2015|February 25, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377869||26301|
NCT02387931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00007860|Supplementation in Adolescent Girls With Endometriosis|SAGE: Supplementation in Adolescent Girls With Endometriosis|SAGE|Children's Hospital Boston|Yes|Recruiting|September 2014|September 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Female|12 Years|25 Years|No|||March 2015|March 9, 2015|May 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02387931||25527|
NCT02448147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/08990-1|Interval Versus Continuous Training in Heart Failure|Interval Training Versus Continuous Training on Peripheral Perfusion and Sympathetic Activity in Patients With Heart Failure||University of Sao Paulo|Yes|Completed|May 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|30 Years|60 Years|No|||May 2015|May 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02448147||20906|
NCT02387034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAVLE-2014-FAR|Swedish PAP in Osteoarthritis - a RCT Study|The Effect on Swedish Physical Activity on Prescription (PAP) in Patients in Primary Care With Osteoarthritis in Knee or Hip - a RCT-study.||Uppsala University|No|Recruiting|June 2010|March 2017|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|40 Years|75 Years|No|||June 2010|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02387034||25596|
NCT02393651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2014-503|Late LTP-like Plasticity Effects of tDCS in Subacute Stroke Patients|Late LTP-like Plasticity Effects of tDCS in Subacute Stroke Patients||Erasmus Medical Center|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|79 Years|No|||December 2015|December 14, 2015|March 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02393651||25088|
NCT02388204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPaulo1|Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease|Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease|SCSPD|University of Sao Paulo|Yes|Recruiting|June 2014|December 2017|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|45 Years|70 Years|No|||March 2015|March 12, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02388204||25506|
NCT02448433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015007|Phototherapy in Young People With Depression|Phototherapy in Young People With Depression; Investigating Associations Between Changes in Actigraphic Sleep-wake Profile and Depressive Symptoms||University of Ottawa||Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|13 Years|30 Years|No|||May 2015|May 14, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448433||20884|
NCT02387190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETURN-001|REmoTe TelenURsiNg on Lung Function of Heart Failure Outpatients|Effectiveness of Telenursing Program on Lung Function of Heart Failure Patients: a Randomized Clinical Trial Protocol|RETURN-001|Federal University of Bahia|No|Active, not recruiting|November 2013|March 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02387190||25584|
NCT02383264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO-2015-NIRS|Splanchnic Oxygenation After the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance.|Splanchnic Oxygenation Patterns in Response to the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance and Correlation With Abnormal Antenatal Doppler.|NIRS-SO|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|February 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|61|||Both|N/A|30 Days|No|Non-Probability Sample|Due to the exploratory nature of this study, at least 60 preterm infants admitted to the        Neonatal Intensive Care Unit of Sant'Orsola-Malpighi University Hospital and fulfilling        the inclusion criteria are going to be enrolled.|February 2016|February 7, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383264||25886|
NCT02634580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140234|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4|A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Japanese Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects||Amgen|Yes|Recruiting|February 2016|February 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|80 Years|No|||March 2016|March 16, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634580||6591|
NCT02642471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-073|Sentinel Lymph Node Biopsy Versus Systematic Pelvic Lymphadenectomy in Early-stage Cervival Cancer|Application of Sentinel Lymph Node Biopsy (SLNB) in Early-stage Cervical Cancer: A Prospective Study||Sun Yat-sen University|Yes|Recruiting|December 2015|December 2022|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Female|18 Years|65 Years|No|||December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642471||5985|
NCT02634177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNM-PROT MDD-01|Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD|An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)||Genomind, LLC|No|Recruiting|January 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02634177||6622|
NCT02641847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506147-4|TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature|Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's Efficacy||Fudan University|Yes|Recruiting|July 2015|||June 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|503|||Female|18 Years|65 Years|No|||December 2015|December 24, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02641847||6033|
NCT02377206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTS13-CH / NICAD|Neuroinflammation and Cognitive Decline in Alzheimer Disease|Neuroinflammation and Cognitive Decline in Alzheimer Disease (AD) : Pilot Study of Translocator Proteins Ligand PET Imaging With [18F]DPA-714|NICAD|University Hospital, Tours|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|60 Years|85 Years|No|||June 2015|June 22, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02377206||26352|
NCT02377479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043234|Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles|||University Hospital Case Medical Center|No|Not yet recruiting|March 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|March 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377479||26331|
NCT02634788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS005-15-062|Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of Buprenorphine Sublingual Spray (0.5 mg TID, 0.25 mg TID, and 0.125 mg TID) for the Treatment of Moderate to Severe Pain||INSYS Therapeutics Inc|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|312|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634788||6575|
NCT02642536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7886-W|Improving Obesity Self-Care Among Mentally Ill Veterans|Improving Obesity Self-care Among Mentally Ill Veterans|MH MOVE!|VA Office of Research and Development|No|Active, not recruiting|August 2014|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02642536||5980|
NCT02630927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG519-C-001|A Safety and Tolerability Study of AG-519 in Healthy Subjects|A Phase I Randomized, Double-blind, Three-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of AG-519, the Relative Bioavailability of Prototype Tablet Formulations Compared With a Suspension Formulation, and to Evaluate the Pharmacokinetics of a Selected Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects||Agios Pharmaceuticals, Inc.|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02630927||6871|
NCT02634918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15-145|Ultrasonography in Hemophilic Joint Disease and Serum Markers|Ultrasonography in Hemophilic Joint Disease||Northwell Health|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|plasma samples for angiogenic and cartilage degradation markers|Male|6 Months|18 Years|No|Non-Probability Sample|Boys with hemophilia and inherited bleeding disorders with and without a history of        hemarthroses|December 2015|December 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634918||6565|
NCT02636673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-dVSR-001|Robotic-assisted Versus Laparoscopic Sigmoid Resection|Robotic-assisted Versus Laparoscopic Sigmoid Resection: a Retrospective Chart Review of Benign and Malignant Sigmoid Disease||Intuitive Surgical|No|Recruiting|November 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects that have undergone robotic-assisted or laparoscopic sigmoid resection for        benign and malignant disease will be considered for inclusion except those that had        emergency procedures.|February 2016|February 22, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02636673||6431|
NCT02637063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HL095229|Interactive Web Program and Health Coaching for Prehypertensive Adults|Interactive Web Program and Health Coaching for Prehypertensive Adults|Prehype|Oregon Center for Applied Science, Inc.|No|Active, not recruiting|November 2013|December 2015|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label|3||Anticipated|201|||Both|18 Years|N/A|No|||November 2015|December 17, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02637063||6401|
NCT02633020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELIM-RCD-002|Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma||Celimmune|Yes|Not yet recruiting|March 2016|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|November 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633020||6711|
NCT02633033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNK14130050|Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse|A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse||Mallinckrodt|No|Recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|260|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a relapsing form of MS who initiate treatment with Acthar Gel for an        MS exacerbation|December 2015|December 15, 2015|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633033|24 Months|6710|
NCT02381418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFL3014|Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Southern Hemisphere Season 2015. An Open-Label, Baseline-Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age||Abbott|No|Completed|March 2015|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381418||26028|
NCT02453867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDUCE|REDUCE - Multicenter RCT to Investigate the Efficacy and Safety of a Reduced Immunosuppressive Therapy With Tacrolimus Once Daily vs. Standard Triple Therapy in Senior Renal Transplant Recipients|REDUCE Study - Multicenter, Prospective, Randomized Study Investigating the Efficacy and Safety of a Reduced Immunosuppressive Therapy With Tacrolimus Once Daily in Comparison to Standard Triple Immunosuppression in Senior Renal Transplant Recipients||Charite University, Berlin, Germany|Yes|Not yet recruiting|June 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|65 Years|N/A|No|||May 2015|May 21, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02453867||20466|
NCT02459093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4655|Subcuticular Suture for Cesarean Skin Incision Closure|Comparison of Subcuticular Suture Type in Post-Cesarean Wound Complications||Montefiore Medical Center|Yes|Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|550|||Female|18 Years|45 Years|No|||May 2015|May 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459093||20065|
NCT02381834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/190X|Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department|Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department||Children's Hospital of Eastern Ontario|No|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|N/A|90 Days|No|||January 2016|January 8, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381834||25996|
NCT02382393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL002(p)|Reliability and Validity of Online Cognitive Assessments|Reliability and Validity of Online Cognitive Assessments||Lumos Labs, Inc.|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|1152|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382393||25953|
NCT02384512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP1012-CNS-40090|Azilect® In Wearing-Off (AIWO)|Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)|AIWO|Teva Pharmaceutical Industries|No|Completed|January 2014|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|261|||Both|18 Years|N/A|No|Probability Sample|Participants will be patients with Parkinson's disease in Germany|April 2015|April 9, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384512||25790|
NCT02379091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1-1188_202|Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)|A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Followed by a 48-Week Active Extension Study||Takeda|No|Recruiting|February 2015|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|324|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02379091||26207|
NCT02447679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMF-IRB-97-1291A|Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence|Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study||Chang Gung Memorial Hospital|Yes|Recruiting|August 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|20 Years|75 Years|No|||October 2008|May 14, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02447679||20942|
NCT02381847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDTHNanjingUMS|Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients|Prospective Phase III Trial Using Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Including Adenocarcinoma of the Esophagogastric Junction||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|January 2015|March 2020|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||February 2015|March 4, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02381847||25995|
NCT02388165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3451002|Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Safety And Efficacy Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Adults Undergoing Elective Posterior Instrumented Lumbar Spinal Fusion Procedures|STRIVE|Pfizer|Yes|Recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2600|||Both|18 Years|85 Years|No|||January 2016|January 25, 2016|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388165||25509|
NCT02447926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00097231|Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies|Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies||Northwestern University|No|Enrolling by invitation|July 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|89 Years|No|||January 2016|January 12, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02447926||20923|
NCT02447939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201020|Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma|A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib With Trametinib in Chinese Subjects With Melanoma||GlaxoSmithKline|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02447939||20922|
NCT02447952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201283|Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis|An Exploratory Study to Investigate the Use of Biotelemetry to Identify Markers of Disease Progression in Subjects With Amyotrophic Lateral Sclerosis||GlaxoSmithKline|No|Recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447952||20921|
NCT02378350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8339-001|Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China|A Multicenter, Randomized, Open-Label Study of Quality of Life in Peritoneal Dialysis and Conventional In-Center Hemodialysis (ChinaQ Study)||Baxter Healthcare Corporation|Yes|Recruiting|August 2013|July 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|577|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02378350||26264|
NCT02378662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-EP-RF-03|TARGTEPO Treatment for Anemia in PD|Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO||Medgenics Inc.|No|Recruiting|April 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02378662||26240|
NCT02389231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/29|Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment|" Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment|ANEMIL|University Hospital, Bordeaux|Yes|Not yet recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02389231||25427|
NCT02389244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0150/1309|A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas|A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas|REGOBONE|UNICANCER|Yes|Recruiting|September 2014|March 2019|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02389244||25426|
NCT02389257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINIMAG|Optically Pumped 4He Magnetometers Performances Compared With Medical Reference Methods (ECG and MEG)|Optically Pumped 4He Magnetometers Performances Compared With Medical Reference Methods : Electrocardiography (ECG) and Magnetoencephalography (MEG)|MINIMAG|University Hospital, Grenoble|No|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02389257||25425|
NCT02392013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHHU0024-14|Home Hazard Removal Program to Reduce Falls|Removing Home Hazards for Older Adults|HARP|Washington University School of Medicine|No|Recruiting|December 2014|November 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02392013||25214|
NCT02392026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1401|Safety and Tolerability of Metronidazole Gel 1.3%|A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis||Watson Pharmaceuticals|No|Recruiting|March 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|12 Years|17 Years|No|||February 2016|February 19, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392026||25213|
NCT02452255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0441|Fenofibrate and Propranolol in Burn Patients|Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients||The University of Texas Medical Branch, Galveston|Yes|Recruiting|November 2015|December 2022|Anticipated|December 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|330|||Both|N/A|80 Years|No|||November 2015|February 9, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452255||20590|
NCT02381093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OttawaHRI|Does Contextual Interference Improve Retention of Basic Life Support Skills? A Randomized Controlled Trial|Does Contextual Interference Improve Retention of Basic Life Support Skills? A Randomized Controlled Trial||Ottawa Hospital Research Institute|No|Recruiting|July 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381093||26053|
NCT02381106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAI|The ADRB3 Receptor in Pregnancy|The ADRB3 Adrenergic Receptor - a Possible New Target for Controlling Pre-eclampsia and Hypertension in Pregnancy and Uterine Contractions in Non-pregnant and Pregnant Myometrium||Karolinska Institutet|No|Recruiting|November 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|uterine specimen placental specimen|Female|18 Years|50 Years|No|Non-Probability Sample|Pregant women undergoing cesarian section.|November 2015|November 25, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02381106||26052|
NCT02384317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL005_168|Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade|An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade||ChemoCentryx|No|Active, not recruiting|February 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384317||25805|
NCT02392065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD14_2014|Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Cardiac Surgery|Chronic Obstructive Pulmonary Disease as a Predictor of 2-year Mortality in Patients Undergoing Coronary Artery Bypass Graft Surgery||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|18 Years|80 Years|No|Non-Probability Sample|All patients scheduled for coronary artery bypass surgery during one year will be screened        and approached|March 2016|March 14, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392065||25210|
NCT02459171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGYFLU2|Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers|Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers||St. Jude Children's Research Hospital|No|Recruiting|June 2015|June 2022|Anticipated|June 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|Samples With DNA|Subjects who agree to participate in this study will have blood samples collected for      influenza testing, antibody determination and viral typing. Subjects will be asked for      permission to keep any remaining samples for possible use in future research studies such as      testing for antibodies or evidence of infection with another influenza virus or other      pathogen. Some samples will be stored indefinitely at the laboratory at the National      Research Centre (NRC), Egypt, or St. Jude Children's Research Hospital (SJCRH).|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be conducted on rural Egyptian poultry growers in areas where avian        influenza is endemic in Egypt. The study sample is expected to have the same composition        as the general population in that area.|December 2015|December 3, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459171||20059|
NCT02460367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0401|Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer|A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)||NewLink Genetics Corporation|Yes|Recruiting|January 2016|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460367||19967|
NCT02378324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ScreenFee|Effect of Fee on Attendance in Cervical Cancer Screening|Effect of Fee on Attendance in Cervical Cancer Screening-results From ScreenFee a Swedish Population Based Randomised Trial||Göteborg University|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|2||Actual|3124|||Female|23 Years|60 Years|No|||February 2015|February 27, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02378324||26266|
NCT02381353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007145|Exparel Injection for Postoperative Orbital Pain|Postoperative Pain Control After Enucleation or Evisceration, a Double-Masked Randomized Controlled Trial of Standard Versus Slow-release Bupivacaine||Mayo Clinic|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381353||26033|
NCT02381366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-BPD-US001|Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study|A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)||Medipost America Inc.|Yes|Recruiting|March 2015|May 2018|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|N/A|14 Days|No|||March 2016|March 22, 2016|February 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381366||26032|
NCT02384590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14120495|Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications|Feasibility of Implementing Mental Health Treatment in Routine Adult Sickle Cell Disease Care Using Online Cognitive Behavioral Therapy and a Mobile Technology-Based Intervention|CaRISMA|University of Pittsburgh|No|Recruiting|March 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384590||25784|
NCT02460406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 14/224|Progressive Functional Strength Training in Unilateral Spastic Cerebral Palsy|The Effects of Lower Limb Progressive Functional Strength Training Protocol on Body Functions and Activity in Children With Unilateral Spastic Cerebral Palsy: a Single-blind Randomized Controlled Trial||Hacettepe University|No|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|7 Years|16 Years|No|||September 2015|February 18, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460406||19964|
NCT02448719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-792-1001|Single-Dose Phase 1 Study of TAK-792|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose of TAK-792 in the Healthy Japanese and Adult||Takeda||Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|103|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448719||20862|
NCT02383732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076337|A Study of the Elopement Prevention and Safety Training Program|A Feasibility Study of the Elopement Prevention and Safety Training Program||Emory University|No|Recruiting|February 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|4 Years|12 Years|No|||December 2015|December 18, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02383732||25850|
NCT02377661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1-19012014|Lowering Blood Pressure in Primary Care in Vienna|Lowering Blood Pressure in Primary Care in Vienna|Low BP Vienna|Wilhelminenspital Vienna|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|840|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02377661||26317|
NCT02380703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33720|Aggression Prevention Training for Caregivers of Persons With Dementia (APT)|Aggression Prevention Training for Caregivers of Persons With Dementia (APT)|APT|Baylor College of Medicine|Yes|Enrolling by invitation|February 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|N/A|No|||March 2015|March 4, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380703||26083|
NCT02380716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBE 14-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||October 12, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380716||26082|
NCT02460809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Home tDCS|Home-based Non-invasive Brain Stimulation and Hand Tracking Rehabilitation for People With Chronic Stroke|Home-based tDCS and Hand Tracking Rehabilitation for Chronic Stroke||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|6|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02460809||19933|
NCT02387060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-389|Use of Intrathecal Fentanyl and Development of Hyperalgesia in Patients Undergoing Elective Cesarean|Use of Intrathecal Fentanyl and Development of Hyperalgesia in Patients Undergoing Elective Cesarean||Pontificia Universidad Catolica de Chile|No|Recruiting|August 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|No|||March 2015|March 7, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02387060||25594|
NCT02392156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997HA401|Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes|A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes|FORWARD|Biogen|No|Terminated|July 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|3|||Male|N/A|N/A|No|Probability Sample|Participants will be recruited at various locations by prescribing physicians.|January 2016|January 14, 2016|March 12, 2015|No|Yes|Study terminated due to recruitment challenges.|No||https://clinicaltrials.gov/show/NCT02392156||25203|
NCT02392169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4835A3|Neuroendocrine Substrates, Candidate Genes and Endophenotypes in ADHD|Relationship Between the Neuroendocrine Substrates, Candidate Genes and Endophenotypes in Patients With Attention-deficit/Hyperactivity Disorder||Chang Gung Memorial Hospital|Yes|Recruiting|August 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|oral mucosal cells|Both|6 Years|16 Years|No|Non-Probability Sample|Patients from Kaohsiung, Taiwan by specialist clinical diagnosis of ADHD.|March 2015|March 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392169||25202|
NCT02380924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ery51Cr-01-2014|Recovery and Survival of EryDex in Non-patient Volunteers|Determination of the in Vivo Recovery and Survival of EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) in Non-patient Volunteers||Erydel|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380924||26066|
NCT02460835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.039|A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma|A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma||University of Michigan Cancer Center|Yes|Recruiting|December 2015|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460835||19931|
NCT02387216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-01-02-09|A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC|A Phase 2 Study of MM-121 in Combination With Docetaxel or Pemetrexed Versus Docetaxel or Pemetrexed Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Merrimack Pharmaceuticals|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387216||25582|
NCT02392234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-108|A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|12 Years|N/A|No|||December 2015|December 2, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392234||25197|
NCT02382731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#06683|Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction|Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction|ISLAND|Women's College Hospital|No|Enrolling by invitation|September 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|2571|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382731||25927|
NCT02381184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khalid-walid|Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome|Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome||Benha University|No|Recruiting|June 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|35 Years|No|||January 2016|January 27, 2016|February 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381184||26046|
NCT02453607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-158-GEN|The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease|The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease||McGill University Health Center|Yes|Recruiting|May 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|225|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with a diagnosis of CD ,age 18-70 years, who are treated with IFX (standard 5        mg/kg/q8 weeks maintenance dose) or IFX (standard maintenance dose)/thiopurine (stable        dose for at least 3 months) combination for <12 months.|May 2015|May 22, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453607||20486|
NCT02380326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150302V02|Innovation in Endobronchial Sampling|Innovation in Endobronchial Sampling : Integration of Virtual Bronchoscopic Navigation in the Current Diagnostic Algorithm and the Use of Micro-CT for Tissue Analysis||Katholieke Universiteit Leuven|No|Recruiting|October 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|transbronchial biopsy|Both|18 Years|75 Years|No|Probability Sample|Lung transplant recipients and diffuse interstitial lung disease without certain diagnosis|October 2015|October 12, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380326||26112|
NCT02380573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150410H|Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease|Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease|MB2|The University of Texas Health Science Center at San Antonio|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|240|||Both|45 Years|89 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380573||26093|
NCT02390999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuroprognostication in CA|Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest|Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest||University of Aarhus|No|Recruiting|March 2013|September 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2015|March 18, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02390999||25291|
NCT02377141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS 81135|Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding|Early Use of Transjugular Intrahepatic Portosystemic Shunt (TIPSS) in Patients With Cirrhosis and Variceal Bleeding|Early TIPSS|University of Edinburgh|No|Recruiting|April 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02377141||26357|
NCT02377154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-532/2014|Comparability of Keratometry of VERION Image Guided System With Established Measuring Devices|Comparability of Keratometry and Intraocular Lens (IOL) Calculation of VERION Image Guided System With Established Measuring Devices in Ophthalmologically Healthy Individuals||Heidelberg University|No|Active, not recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02377154||26356|
NCT02445482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1301|SOLTI Breast Cancer Molecular Screening Program (AGATA)|SOLTI Molecular Screening Program: a Pilot Study to Implement Personalized Therapy for Patients With Advanced or Metastatic Breast Cancer|AGATA|SOLTI Breast Cancer Research Group|No|Recruiting|October 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples With DNA|Collection of the archived initial or metastatic tumor sample (one 60 μm formalin-fixed,      paraffin-embedded tumor block). If archived material is not available, a biopsy of the      metastatic cancer should be performed to obtain such material|Both|18 Years|70 Years|No|Probability Sample|The study will be conducted in eight sites located in Spain, and up to 260 patients with        advanced or metastatic breast cancer will be screened. These patients will be about to        receive, or receiving, or will have received treatment for their disease in either a        clinical trial or the healthcare setting|May 2015|May 14, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445482||21110|
NCT02392338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-10-090|Comparison of Success Rate of Totally Thoracoscopic Ablation Versus Hybrid Procedure in Patients With Persistent Atrial Fibrillation|||Samsung Medical Center|Yes|Recruiting|March 2014|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|85 Years|No|||March 2015|March 18, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02392338||25189|
NCT02378753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-6689|STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)|[rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone||Centers for Disease Control and Prevention|Yes|Active, not recruiting|April 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|October 5, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378753||26233|
NCT02382016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-404|PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial|A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension|PORTICO|Actelion|No|Recruiting|June 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382016||25982|
NCT02456259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504S17P|Postoperative Patency of Internal Jugular Vein After Neck Cannula Insertion|Postoperative Patency of Internal Jugular Vein After Neck Cannula Insertion in Patients Undergoing Minimally Invasive Cardiac Surgery||University Hospital Hradec Kralove|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing cardiac surgery both from conventional sternotomy without neck        cannula and from right mini thoracothomy reguiring neck cannula insertion into right        internal jugular vein.|June 2015|June 2, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02456259||20283|
NCT02380820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/CEDMH-01|Comparative Measurements of Interface Pressures Between Two Pressure-ulcer Prevention Mattresses: Softform Premier and Airsoft Duo|Comparative Measurements of Interface Pressures Between Two Pressure-ulcer Prevention Mattresses: Softform Premier and Airsoft Duo|SPA2-INVACARE|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|June 2015|April 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|65 Years|N/A|No|||March 2016|March 21, 2016|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380820||26074|
NCT02383316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7315 02|Study of Metabolic Modifications in Children With Noonan Syndrome|Study of Metabolic Modifications in Children With Noonan Syndrome|MetabNoonan|University Hospital, Toulouse|No|Recruiting|January 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|7 Years|18 Years|No|||March 2016|March 9, 2016|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02383316||25882|
NCT02390258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEN-D0103-CL-01|Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103|A Single Centre, Randomised, Double-blind, Placebo-controlled, Fed-fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 in Healthy Subjects||Xention Ltd|Yes|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390258||25348|
NCT02447887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-071|Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)|Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)||Fox Chase Cancer Center|Yes|Suspended|August 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 6, 2015|Yes|Yes|Toxicity Evaluation|No||https://clinicaltrials.gov/show/NCT02447887||20926|
NCT02386631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC_HVFP|Hallux Valgus and Custom Orthotic Prescription|Hallux Valgus and the Effects of Custom Orthotic Prescription on the Efficacy of Forward Propulsion||Wilfrid Laurier University|No|Completed|January 2015|April 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02386631||25627|
NCT02388815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-UK-VAL-14022|Abbott Sensor Based Glucose Monitoring System Paediatric Study|Evaluation of the Accuracy of the Abbott Sensor Based Glucose Monitoring System - Paediatric Label Extension Study (CE)|BEAGLE|Abbott Diabetes Care|No|Completed|March 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|89|||Both|4 Years|17 Years|No|||October 2015|October 8, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02388815||25459|
NCT02382445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS-Diako-Ma-2014|Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction|Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction by a Higher Load of Neurotrophic Drugs|BIS & Dementia|Universitätsmedizin Mannheim|No|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|110 Years|No|||January 2016|January 14, 2016|August 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02382445||25949|
NCT02389907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ERA-14-01|Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care|Assessing the Association Between Patients' Perceptions of Success With Post-Operative Pain Management and Overall Experience With Care||The Medicines Company|No|Recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will include adults 18 years of age or older who have undergone either a        total hip replacement or hysterectomy.|June 2015|June 23, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02389907|14 Days|25375|
NCT02389920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-112|Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib|||Samsung Medical Center||Not yet recruiting|April 2015|December 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||March 2015|March 16, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02389920||25374|
NCT02389933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2318M|Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)|Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)||Novartis||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2015|October 1, 2015|March 10, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02389933||25373|
NCT02389946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOFLOW-V|Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions|BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V|BIOFLOW-V|Biotronik, Inc.|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1334|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389946||25372|
NCT02452502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOU52256|The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke|The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke|SEATIS|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Recruiting|January 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||May 2015|May 31, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452502||20571|
NCT02453009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN-CHEIRON|Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer|CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer|CHEIRON|Santa Chiara Hospital|No|Recruiting|October 2014|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Male|18 Years|N/A|No|||May 2015|May 22, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453009||20532|
NCT02377882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980170|The Optimal Dosage of Rocuronium for Intraoperative Neuromonitoring During Thyroid Surgery|The Optimal Dosage of Neuromuscular Blocking Agent for Intraoperative Neuromonitoring During Thyroid Surgery|IONM|Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2009|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|||Both|20 Years|70 Years|No|Probability Sample|Patients who were planned to receive thyroidectomy|February 2015|February 26, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT02377882||26300|
NCT02389998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00003158|Efficacy of Open Label Placebo in Children With FGIDs|Evaluation of the Efficacy of Open Label Placebo in Children With FGIDs (Functional Gastrointestinal Disorders)|Placebo|Children's Hospital Boston||Recruiting|July 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|8 Years|21 Years|No|||March 2015|March 10, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02389998||25368|
NCT02390050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1442-C-449|A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus|A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus||Theracos|Yes|Active, not recruiting|May 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|20 Years|N/A|No|||February 2016|February 19, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390050||25364|
NCT02453022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201037|A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole|A Single Centre, Open-label, 5-Period, Cross Over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets||GlaxoSmithKline|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||August 2015|September 17, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453022||20531|
NCT02458846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000045972|Vision Care for Children in Ontario|A Comparison of Tests for Preschool Vision Screening and Analysis of Their Cost-Effectiveness for Universal Use in Ontario||The Hospital for Sick Children|No|Recruiting|September 2014|||June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|780|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02458846||20084|
NCT02390817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wakeup01|Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup|Effect of Sugammadex in Wakeup Procedure||Cukurova University|No|Recruiting|January 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|40|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390817||25305|
NCT02387424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0353-02|Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depressive Relapse/Recurrence|Phase Two: A Pilot Randomized Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depressive Relapse/Recurrence||University of Colorado, Boulder|Yes|Completed|July 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|86|||Female|18 Years|N/A|No|||March 2015|March 12, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02387424||25566|
NCT02638155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505490|Food Addiction and Hormone Study|Food Addition and Hormone Study||Texas Tech University|No|Not yet recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|men and women 18-65 who are able to come to TTU for testing and meet eligibility criteria|December 2015|December 17, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02638155||6317|
NCT02641860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMG-Allo-KOA-1.1|Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis|A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis||Cellular Biomedicine Group Ltd.|Yes|Active, not recruiting|December 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|70 Years|No|||December 2015|December 24, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02641860||6032|
NCT02641912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204870|Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms|A Clinical Study to Evaluate the Efficacy of an Experimental Mouthwash Formulation||GlaxoSmithKline|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02641912||6028|
NCT02381236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-202-005|G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer|G-202-005: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 Administered in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate||GenSpera, Inc.|No|Not yet recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||March 2015|March 2, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381236||26042|
NCT02385474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU765213M|Effectiveness of SDF in Arresting Dental Caries in Preschool Children|Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries in Preschool Children: a Randomized Clinical Trial With Different Periodicity and Concentration.||The University of Hong Kong|No|Active, not recruiting|March 2013|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|888|||Both|3 Years|4 Years|No|||March 2015|March 10, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02385474||25716|
NCT02638272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1898|Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures|Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures for the Treatment of Thoracic and Lumbar Spinal Tuberculosis||The Second Hospital of Anhui Medical University||Completed|January 2009|September 2015|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|14 Years|67 Years|No|||December 2015|December 18, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02638272||6308|
NCT02631083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00960|The Influence of Glucose Flux on Fat Synthesis in a Whole Body Calorimeter|The Impact of a Low Glycaemic Index (GI) Diet on Daily Blood Glucose Profiles and Energy Flux in Male Chinese Adults.||Clinical Nutrition Research Centre, Singapore|No|Active, not recruiting|November 2014|September 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02631083||6859|
NCT02629926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED07/8440|Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors|A Phase IV, Single-Centre, Non-Randomised, Controlled, Open-Label Study to Assess the Use of Growth Hormone (GH) Replacement Therapy (NutropinAq®) During Transition in GH Deficient Survivors of Childhood Cancer to Optimise Somatic Growth & Well-Being||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|October 2010|||October 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Both|16 Years|22 Years|No|Probability Sample|Patients will be identified in the late effects endocrine clinic aged between 16-22 years,        which are severely growth hormone deficient.|December 2015|December 14, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02629926||6948|
NCT02629939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0136-15-COM1|Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge|Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge||Meir Medical Center|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 10, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02629939||6947|
NCT02639572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVSIDS/PERIO/1/2014|Evaluation of SilOss® in Periodontal Surgery|Evaluation of the Efficacy of a Novel Synthetic Bone Regeneration Material (Sil-Oss®) In the Treatment of Periodontal Intrabony Osseous Defects||SVS Institute of Dental Sciences|Yes|Completed|January 2014|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 20, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02639572||6208|
NCT02639585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESDAC|Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C|Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study|ESDAC|Pusan National University Hospital|No|Recruiting|December 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639585||6207|
NCT02637167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GutHeart version 2|GutHeart: Targeting Gut Microbiota to Treat Heart Failure|GutHeart: Targeting Gut Microbiota to Treat Heart Failure||Oslo University Hospital|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|74 Years|No|||November 2015|December 17, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02637167||6393|
NCT02637180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEMMO/FLS/2015|Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece|A Multiple Center, Prospective Study Targeting the Secondary Prevention of Fractures in Greece: Evaluation of the Fracture Liaison Service in Multiple Hospital Settings||Hellenic Society for the Study of Bone Metabolism|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|50 Years|N/A|No|Non-Probability Sample|Patients over 50 years old with low energy fractures|December 2015|December 21, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02637180|2 Years|6392|
NCT02386163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMO-IF-MSC-01|Large-scale ex Vivo Expansion and Characterization of Two Kinds of MSC From Knee for Clinical Application|Large-scale ex Vivo Expansion and Characterization of Synovial Membrane MSC (SM-MSC) and Infrapatellar Fat Pad MSC (IF-MSC) for Clinical Application||EMO Biomedicine Corporation|No|Completed|May 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|MSC from synovial membrane and infrapatellar fat pad|Both|20 Years|N/A|No|Non-Probability Sample|For patients who have an operation of total knee replacement.|September 2015|September 8, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02386163||25663|
NCT02387333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEl-Sawy132015|Role of Mesh Stoma Reinforcement Technique (MSRT) in Prevention of Parastomal Hernia After Ileal Conduit Urinary Diversion|Role of Mesh Stoma Reinforcement Technique (MSRT) in Prevention of Parastomal Hernia After Ileal Conduit Urinary Diversion: A Randomized Controlled Trial||Mansoura University|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387333||25573|
NCT02459262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004542-10|Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.|A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.|MVX13211|Minervax ApS|Yes|Recruiting|May 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|310|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02459262||20052|
NCT02386033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014AB|Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects|Clinical Efficacy of Subgingivally Delivered Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial .||Government Dental College and Research Institute, Bangalore|Yes|Completed|November 2013|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||November 2014|March 5, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02386033||25673|
NCT02389140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1582|Blood Flow Within Active Myofascial Trigger Points Following Massage|Blood Flow Within Active Myofascial Trigger Points Following Massage||University of Colorado, Denver|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|21 Years|49 Years|No|||November 2015|November 30, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02389140||25434|
NCT02451644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2043-15-SMC|The Association Between Physical Activity and Pregnancy Rate Following Embryo Transfer|The Association Between Physical Activity and Pregnancy Rate Following Embryo Transfer||Sheba Medical Center|No|Not yet recruiting|May 2015|June 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Male|18 Years|45 Years|No|||May 2015|May 21, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02451644||20637|
NCT02451891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBL04|A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of MVA-EBO Z Alone and a Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy UK Volunteers||University of Oxford||Active, not recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02451891||20618|
NCT02386046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0175|Oxygen Saturation and Caffeine Post-Discharge||OCPDPS|University of Calgary|No|Recruiting|February 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|180|||Both|26 Weeks|46 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Newborn infants admitted at two NICU centers in Calgary born prematurely between 26 weeks        and 34 weeks of gestational age.        Newborn infants admitted directly to the normal nursery in those two centers born less        than 38 weeks.|December 2015|December 8, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386046||25672|
NCT02390908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA022302|Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings|Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings|PLUS|Hunter College|Yes|Recruiting|August 2013|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02390908||25298|
NCT02391974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEO-PER-1401|Efficacy and Safety of a Commercially Available Injectable Hyaluronic Acid Dental Filler for Periodontal Pockets|Filling of Periodontal Pockets With a Commercially Available Injectable Cross-linked Hyaluronic Acid Dental Filler Versus Oral Hygiene Alone, After Scaling and Root Planing and Chlorhexidine Disinfection, for the Treatment of Periodontitis: A Single-blinded, Multi Center, Prospective, Randomized Controlled Trial||Teoxane SA|No|Recruiting|February 2015|April 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391974||25217|
NCT02391987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001448|Integrated Tele-monitoring and Patient-centric Health Coaching Strategy in Patients Hospitalized With Heart Failure|A Randomized Study of the Effectiveness of an Integrated Tele-monitoring and Patient-centric Health Coaching Strategy (Tele-HC) in Adult Patients Recently Hospitalized With Acute Decompensated Heart Failure (ADHF) Compared to Standard Care|Tele-HC|Mayo Clinic|No|Active, not recruiting|May 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|304|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391987||25216|
NCT02451904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1407|Severe and Cerebral Malaria Investigated Through Host Metabolomics|Microvascular and Metabolic Dysregulation in the Pathogenesis of Severe and Cerebral Malaria Investigated Through Host Metabolomics||University of Oxford|No|Not yet recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|840|Samples With DNA|Blood, Urine, CSF, Stool|Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In total, up to 840 patients may be enrolled in this study.|May 2015|May 19, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02451904||20617|
NCT02452242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX464-003|Safety, PK and PD Study of ABX464 in Untreated HIV Patients|A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius||Abivax S.A.|Yes|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||May 2015|September 25, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02452242||20591|
NCT02382900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-2014|Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City|Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.).||Universidad Nacional Autonoma de Mexico|Yes|Recruiting|February 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|500|||Both|10 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382900||25914|
NCT02383199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/2013|Polypropylene Mesh in Prolapse Surgery|Polypropylene Mesh in Prolapse Surgery; Long-term Outcome and Complications.||Turku University Hospital|No|Completed|September 2013|November 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|161|||Female|N/A|N/A|No|Non-Probability Sample|195 first patients with pelvic organ prolapse operated on a in Turku University Hospital        using polypropylene mesh|March 2015|March 26, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02383199||25891|
NCT02391532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/618|Effect of Probiotic Bacteria on Oral Candida in Frail Elderly|Effect of Probiotic Bacteria (L. Reuteri) on Oral Candida Counts in Frail Elderly||University of Copenhagen|No|Completed|September 2013|June 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|215|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02391532||25250|
NCT02390752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150093|PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)|Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|3 Years|30 Years|No|||February 2016|February 25, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390752||25310|
NCT02390765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150096|Children s Growth and Behavior Study|Children's Growth and Behavior Study||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|December 2028|Anticipated|December 2028|Anticipated|N/A|Observational|N/A|||Anticipated|1500|||Both|8 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02390765||25309|
NCT02460536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009341|Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth|Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth||Tel Aviv University|No|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|10 Years|18 Years|No|||January 2016|January 25, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460536||19954|
NCT02382107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-IMPH-Bucharest-01|A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania|A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania||Ludwig-Maximilians - University of Munich|Yes|Recruiting|March 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples Without DNA|Blood, urine, sputum|Both|18 Years|N/A|No|Non-Probability Sample|TB suspects who presented themselves to the pumonology ambulatory at the Marius Nasta        Institute|March 2016|March 2, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02382107||25975|
NCT02382120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23022015|Accuracy of Non-invasive Effective Pulmonary Perfusion Measurement by CO2|Accuracy and Precision of Non-invasive Effective Pulmonary Perfusion Measurement Using Volumetric Capnography||Hospital Privado de Comunidad de Mar del Plata|Yes|Not yet recruiting|March 2015|November 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|80 Years|No|Non-Probability Sample|Cardiac surgical ASA II-III patients.|February 2015|March 5, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02382120||25974|
NCT02385344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501|Registry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery|Registry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery|REQUEST|Medistim ASA|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Subject has been scheduled for coronary bypass surgery|September 2015|September 21, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02385344|2 Weeks|25726|
NCT02389426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. 1432101422450|Transcranial Doppler in Multiple Sclerosis|Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis|TRADOMS|Universitair Ziekenhuis Brussel|No|Completed|December 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|April 16, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02389426||25412|
NCT02392078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAANTERN|Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System|Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry|LAANTERN|Monteris Medical|No|Recruiting|October 2015|September 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients who preferred management for soft tissue through interstitial irradiation or        thermal therapy by the NeuroBlate® System, in the opinion of the treating physician|January 2016|January 27, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392078||25209|
NCT02460380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-06-03|The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome|The Effects of Vitamin D on Transforming Growth Factor-beta1 in Vitamin D Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial||Maimonides Medical Center|No|Completed|October 2013|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|93|||Female|18 Years|38 Years|No|||May 2015|May 28, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02460380||19966|
NCT02448472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150315|Epidemiology of Sepsis in China|Chinese Epidemiological Study of Severe Sepsis.(CHESS Study)||Southeast University, China|Yes|Completed|November 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|Sepsis patient who admitted into ICU|October 2015|February 14, 2016|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02448472||20881|
NCT02382419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-538|Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants|Expanded Phase II Trial of a Carrageenan-Containing Gel for Prevention of HPV Infection||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|August 2014|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|19 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02382419||25951|
NCT02386501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164-05|Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors|A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors||Advaxis, Inc.|No|Active, not recruiting|September 2015|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386501||25637|
NCT02385604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/009/2011|The Predictive Value of CT-PET in Esophageal Cancer|CT-PET for Prediction of Histopathologic Response, Nodal Status and Oncologic Outcome Following Neoadjuvant Chemoradiation for Esophageal Cancer||St. James's Hospital, Ireland|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|No|Non-Probability Sample|Records for all patients with locally advanced esophageal and junctional tumors undergoing        potentially curative multimodal therapy between November 2008 and November 2014 will be        assessed.|March 2016|March 9, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385604||25706|
NCT02389686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGHBCRG-IORT-NSM|Intra-operative Radiotherapy For Breast Cancer Women After NSM|Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer After Nipple-sparing Mastectomy||Guangdong Academy of Medical Sciences|Yes|Recruiting|October 2014|October 2024|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|17 Years|80 Years|No|||March 2015|March 10, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389686||25392|
NCT02452762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITdAL-PICU-01|Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial|Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial|VITdAL-PICU|Children's Hospital of Eastern Ontario|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|17 Years|No|||January 2016|January 12, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02452762||20551|
NCT02388126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T22/2015|Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies||PROMANEG|Turku University Hospital|No|Recruiting|March 2015|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Male|40 Years|80 Years|No|||November 2015|November 5, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02388126||25512|
NCT02382185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOR-A02333|Non Invasive Cardiac Output Monitoring to Guide Goal Directed Fluid Therapy in High Risk Patients Undergoing Urgent Surgical Repair of Proximal Femoral Fractures|Non Invasive Cardiac Output Monitoring to Guide Goal Directed Fluid Therapy in High Risk Patients Undergoing Urgent Surgical Repair of Proximal Femoral Fractures|ClearNOF|York Teaching Hospitals NHS Foundation Trust|No|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|50 Years|N/A|No|||January 2016|January 26, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382185||25969|
NCT02382198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OttawaHRI REB 2015-0043|Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease|A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease|GLYCOPAR|Ottawa Hospital Research Institute|Yes|Not yet recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|30 Years|N/A|No|||March 2015|March 5, 2015|January 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382198||25968|
NCT02384603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053/14|Effects of Physical Therapy in Pain and Posture of Fibromyalgia Patients|Effects of Two Physiotherapeutic Treatments in Pain and Posture of Fibromyalgia Patients: Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Recruiting|February 2015|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|30 Years|60 Years|No|||December 2015|December 4, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02384603||25783|
NCT02384850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENTINEL|Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer|An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer|SENTINEL|GSO Global Clinical Research BV|No|Recruiting|March 2015|April 2018|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02384850||25764|
NCT02392195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00004233|Brain Characteristics Noted Prior to and Following Treatment|Brain Characteristics Noted Prior to and Following Treatment of Deformational Plagiocephaly With a Helmet||Children's Hospital Boston|Yes|Recruiting|February 2013|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|N/A|8 Months|Accepts Healthy Volunteers|Non-Probability Sample|Deformational Plagiocephaly in full term, healthy infants.|March 2015|March 18, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392195||25200|
NCT02377908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-RRW EU survey|European Postgraduate Training in Geriatric Medicine|European Postgraduate Training in Geriatric Medicine||Klinikum Nürnberg|No|Recruiting|October 2013|March 2015|Anticipated|June 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|47|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Experts in geriatric medicine and member of one of the organizations European Union of        Medical Specialists (UEMS), European Academy for the Medicine of Ageing (EAMA) or European        Union Geriatric Medicine Society (EUGMS).|February 2015|February 26, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02377908||26298|
NCT02377921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX001-CL301|Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)|GNEM|Ultragenyx Pharmaceutical Inc|Yes|Recruiting|May 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|No|||March 2016|March 7, 2016|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377921||26297|
NCT02384863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502032|The Evaluation and Management of Patients With Acute Chest Pain in China|The Evaluation and Management of Patients With Acute Chest Pain in China||Qilu Hospital|Yes|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18000|||Both|N/A|N/A|No|Probability Sample|consecutive patients attending the emergency department in 7 Chinese grade Ⅲ hospitals|March 2015|March 9, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384863|1 Year|25763|
NCT02385136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zjzlyy 2015-1-5|Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases|Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases: A Randomized Trial||Zhejiang Cancer Hospital|Yes|Not yet recruiting|April 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|135|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02385136||25742|
NCT02444988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#141349|Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit|Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit|SMART-MED|Vanderbilt University|Yes|Recruiting|June 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444988||21148|
NCT02392247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTU-002-007|Hemosonics- VCU Cardiac Surgery Clinical Study|Hemosonics- VCU Cardiac Surgery Clinical Study Protocol||Virginia Commonwealth University|No|Recruiting|April 2015|||August 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Both|18 Years|89 Years|No|Non-Probability Sample|Participants for this study will be recruited at the Virginia Commonwealth University        Medical Center. The subject population will be representative of the local racial and        ethnic population.|June 2015|June 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392247||25196|
NCT02387658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dallas VA IRB Protocol #14-076|Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient|Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient||North Texas Veterans Healthcare System|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with claudication symptoms and femoropopliteal disease referred for peripheral        angiography and possible revascularization.|March 2015|March 12, 2015|March 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02387658||25548|
NCT02385149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51389.081.14|Improving Resilience With Whole Grain Wheat|Improving Resilience With Whole Grain Wheat|Graandioos|Wageningen University|No|Completed|January 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||March 2015|November 19, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02385149||25741|
NCT02460861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-URO-00021|Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy|Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy (RPVE) in Prostate Cancer (PCA) Patients for Molecular Tumor Marker Analysis|iPROLOGX|University of Magdeburg|No|Active, not recruiting|November 2011|December 2015|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|279|||Male|N/A|N/A|No|||May 2015|May 29, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460861||19929|
NCT02385019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREGeneration-Portugal|A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease|TREGeneration|Instituto de Medicina Molecular|Yes|Recruiting|March 2015|December 2019|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 6, 2016|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02385019||25751|
NCT02378441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_ATM_105|Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor 20mg/Glucophage SR 750mg|||CJ HealthCare Corporation|No|Not yet recruiting|February 2015|April 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||February 2015|March 3, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02378441||26257|
NCT02378454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLuc MBWN2 02|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children: A Comparison of Two Commercially Available Devices||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|100|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|CF : primary care clinic HC : community sample|July 2015|July 29, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378454||26256|
NCT02382952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2888|Pilot Study Differential Dissector™ for Blunt Dissection|Pilot Study Differential Dissector™ for Blunt Dissection||University of North Carolina, Chapel Hill|No|Enrolling by invitation|March 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382952||25910|
NCT02381730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01717-38|Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment||PCV|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|January 2014|||January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|45 Years|N/A|No|||October 2015|October 27, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381730||26004|
NCT02381743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33241|The mCME Project:Delivering Continuing Medical Education for Community Health Workers Via SMS Text Messages|The mCME Project:Delivering Continuing Medical Education for Community Health Workers Via SMS Text Messages|mCME project|Boston University|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|638|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02381743||26003|
NCT02382601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1360|Longitudinal Study of Intra-Uterine Growth Restriction|Longitudinal Study of Intra-Uterine Growth Restriction (IUGR)||University of Colorado, Denver|No|Recruiting|April 2015|April 2019|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Maternal peripheral blood and umbilical cord blood|Female|18 Years|45 Years|No|Non-Probability Sample|University of Colorado School of Medicine is a referral center for women carrying fetuses        with IUGR. Care providers routinely evaluate more than 300 patients per year at our        outreach sites alone whose fetuses have estimated fetal weights below the 10th percentile.        Of these, the investigators will initially enroll 200 patients per year between 24 and 36        weeks over a two-year period.|February 2016|February 19, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382601||25937|
NCT02380586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU_IBA1026|Obstetric Anaesthesia And Analgesia Month Attributes - International|A National Survey on Obstetric Anesthesia and Analgesia Care - International|OBAAMA-INT|Brno University Hospital|Yes|Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Female|16 Years|70 Years|No|Non-Probability Sample|Women in labor|January 2016|January 9, 2016|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02380586||26092|
NCT02385292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUN-003|Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation|Randomized, Controlled, Crossover, Multicenter Trial Comparing Quality of Tears Produced by Nasal Neurostimulation Versus Sham for Dry Eye||Oculeve, Inc.|No|Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|35|||Both|22 Years|N/A|No|||January 2016|January 25, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385292||25730|
NCT02383784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40501156099|Effects of Low- or High-glycemic Index Diets on Metabolic and Inflammatory Responses in Diabetics|Effects of Low- or High-glycemic Index Diets in Metabolic and Inflammatory Responses in Type 2 Diabetics||Federal University of Vicosa|Yes|Completed|March 2007|December 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|40 Years|No|||March 2015|March 3, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02383784||25846|
NCT02385682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XC13RIMI0060k|CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction|CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction Registry (COREA-AMI)|COREA-AMI|Seoul St. Mary's Hospital|No|Completed|January 2004|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4748|||Both|20 Years|N/A|No|Non-Probability Sample|Acute myocardial infarction who were treated with percutaneous coronary intervention|April 2015|April 16, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385682|5 Years|25700|
NCT02445703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HAB-4005|Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine|Phase IV Immunogenicity and Safety Study of Different Immunization Schedules of Inactivated Hepatitis A Vaccine (HAV) and/ or Combined Hepatitis A and Hepatitis B Vaccine (HABV) in Healthy Chinese Infants||Sinovac Biotech Co., Ltd|No|Completed|May 2014|||January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|301|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445703||21093|
NCT02385565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/0401|Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy|Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy|MITOX|University Hospital, Lille|No|Completed|February 2004|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|5 Years|21 Years|No|||March 2015|March 10, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385565||25709|
NCT02387671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33650|Weight Management Among Breast Cancer Survivors|Evaluation of mHealth Counseling for Lifestyle Behaviors Among Breast Cancer Survivors||Boston Medical Center|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Female|18 Years|N/A|No|||January 2015|July 27, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02387671||25547|
NCT02389829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM vs CPZ|Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine|Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study||Montefiore Medical Center|Yes|Recruiting|March 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Both|21 Years|N/A|No|||June 2015|June 8, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389829||25381|
NCT02447900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310-01|Marker Guided Breathhold Radiotherapy in NSCLC|Proof of Concept Study Evaluating Safety and Performance of a Gel Marker (BioXmark) Used for Image Guidance in Deep Inspiration Breathhold Radiotherapy (DIBH IGRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)||Rigshospitalet, Denmark|No|Active, not recruiting|July 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447900||20925|
NCT02379403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150085|Effects of Tart Cherry and Aroniaberry Supplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults: Interactions With Genotype and Proteome|Effects of Tart Cherry and Aroniaberry Supplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults:Interactions With Genotype and Proteome||National Institutes of Health Clinical Center (CC)||Not yet recruiting|February 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|96|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||November 2015|December 15, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02379403||26183|
NCT02386735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBL2015-017|Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD|Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The "RECUT"-Trial)|RECUT|Cantonal Hosptal, Baselland|Yes|Recruiting|March 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|470|||Both|40 Years|N/A|No|||February 2016|February 11, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02386735||25619|
NCT02389530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14100616|Use of Fluorescein Dye for the Removal of Brain Tumors|Use of Fluorescein Dye for the Removal of Brain Tumors||University of Pittsburgh|No|Recruiting|May 2015|||June 2018|Anticipated|Phase 1/Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age or above pending elective removal of an intraparenchymal brain        tumor.|October 2015|October 6, 2015|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389530|1 Month|25404|
NCT02380404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|958_2013|Effectiveness of Removable Prosthesis Retained by 4 Implant-supported Locator-Attachments|Clinical Outcomes of a Cost-effective Implant Treatment in the Edentulous Upper Maxilla: Effectiveness of Removable Prosthesis Retained by 4 Implant-supported Locator-Attachments.|LOC|University Hospital of Liege|No|Recruiting|June 2014|November 2019|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Department of Periodontology and Oral Surgery, CHU of Liège|October 2015|October 9, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02380404|5 Years|26106|
NCT02458508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Pisa|Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy|Retrospective Evaluation of Prognostic and/or Predictive Profile of Melanocortin Receptor-4 Gene Polymorphisms in Patient With a Diagnosis of Glioblastoma Treated With Upfront Concomitant Radio-chemotherapy or Chemotherapy|GLIOMELA|University of Pisa|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|120|Samples With DNA|Blood samples (3 ml) will be collected in EDTA tubes and stored at -80°C from glioblastoma      patients|Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with        temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation.|December 2015|December 1, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02458508||20110|
NCT02458521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # [397662]|Transcranial Magnetic Stimulation (TMS) to Treat mTBI and PTSD|A Study of Bilateral Prefrontal Transcranial Magnetic Stimulation (TMS) to Treat the Symptoms of Mild TBI (mTBI) and PTSD||Walter Reed National Military Medical Center|No|Recruiting|August 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02458521||20109|
NCT02390713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P131002|Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy|Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy in Non Cirrhotic Patient|MODHEP1|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390713||25313|
NCT02390726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15373|Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis|Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis|FMTUC|University of Vermont|Yes|Recruiting|December 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390726||25312|
NCT02382926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 14-053|Reha Drive: Capacitive Electrocardiography in Car Seat in Cardiological Patients|Capacitive Electrocardiography in the Driver`s Seat and Elevation of Vital Signs Via Camera During Cardiac Rehabilitation|RehaDrivecECG|RWTH Aachen University|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382926||25912|
NCT02387255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013H0416|Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms|Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms|AAA-MRE|Ohio State University|No|Recruiting|October 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|165|Samples Without DNA|We will collect a small aortic tissue sample for biomechanical testing from patients      undergoing standard of care surgical repair of their abdominal aortic aneurysm.|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Normal volunteers are control group          2. Patients who are being monitored for diameter of AAA          3. Patients who will undergo surgical repair of AAA|October 2015|October 1, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02387255||25579|
NCT02380677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX301-101|Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors|Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies||Cerulean Pharma Inc.|No|Recruiting|April 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380677||26085|
NCT02458859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/044/PIC|Trial of PICO Versus Standard Care in Chronic and Sub-acute Wounds|A 100 Patient, Prospective, Randomised, Clinical Evaluation Comparing Clinical and Health Economic Outcomes Between Patients With Chronic or Sub-acute Wounds Treated With Either PICO or Standard Care Dressings and a Qualitative Study to Explore the Experiences of Patients Receiving PICO With Particular Emphasis on Concordance||Smith & Nephew Medical Ltd|No|Terminated|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 18, 2011||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT02458859||20083|
NCT02445456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R37025/CN339|Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer|Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer|SentiRect|Oxford University Hospitals NHS Trust|No|Not yet recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|90 Years|No|||May 2015|May 15, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02445456||21112|
NCT02381028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/318b|Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children|Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children: A Small, Randomized, Split Body, Controlled, Blinded Pilot Study||Oslo University Hospital|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|N/A|6 Years|No|||March 2015|March 4, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02381028||26058|
NCT02385266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00085782|Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain|Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain|UCPPS|Northwestern University|No|Active, not recruiting|September 2013|December 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|N/A|No|||January 2016|January 13, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385266||25732|
NCT02393534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01863|Feasibility of Telephone Follow-up Visits in Primary Care|The Feasibility of Replacing Follow-up Visits With Telephone Calls in Primary Care: A Randomized Clinical Trial||New York University School of Medicine|Yes|Recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393534||25097|
NCT02643576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK098152|Grocery Assistance Program Study|Designing a Food Benefit Program to Optimize Diet Quality for Obesity Prevention|GAPS|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|April 2013|March 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|296|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02643576||5900|
NCT02631512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBG-03|Evaluation of Woulgan in Diabetic Foot Ulcer|Evaluation of Woulgan in Diabetic Foot Ulcer Compared With a Commercial Hydrogel||Biotec Pharmacon ASA|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02631512||6826|
NCT02630849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222/13|Does a Multimodal no‐Compression Suture Technique of the Intercostal Space Reduce Chronic Post‐Thoracotomy Pain?|Does a Multimodal no‐Compression Suture Technique of the Intercostal Space Reduce Chronic Post‐Thoracotomy Pain? A Prospective Randomized Study||University of Roma La Sapienza|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|25 Years|80 Years|No|||December 2015|December 14, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630849||6877|
NCT02630862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IULIANO_Carotids|Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization|Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization: Effect of Antithrombotic Treatment|ICAR|University of Roma La Sapienza|Yes|Completed|September 2010|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|240|||Both|50 Years|90 Years|No|||December 2015|December 10, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02630862||6876|
NCT02641288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURJC15-77|Intraperitoneal Ropivacaine Irrigation in Bariatric Surgery|Intraperitoneal Ropivacaine Irrigation in Patients Undergoing Bariatric Surgery||Hospital General Universitario Elche|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|N/A|N/A|No|||December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02641288||6076|
NCT02385487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01349|Inflammation in Type 2 Myocardial Infarction|Inflammation in Type 2 Myocardial Infarction||New York University School of Medicine|No|Withdrawn|March 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Venous blood samples|Both|21 Years|N/A|No|Non-Probability Sample|Adults admitted to the Medical Intensive or Coronary Care Units (MICU or CCU)|July 2015|July 1, 2015|February 26, 2015|No|Yes|Logistics and feasibility|No||https://clinicaltrials.gov/show/NCT02385487||25715|
NCT02643615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0208|Safety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery|A Pilot Study to Determine the Efficacy and Safety of Detecting Subtle Visual Changes During Visual Evoked Potential (VEP) Monitoring Using SightSaver ™ Flash Visual Evoked Potential Stimulator in Spine Prone Surgery|SightSaver|Ohio State University|No|Active, not recruiting|September 2014|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643615||5897|
NCT02634866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000000336|Cardiovascular Response to Exercise in Hypertension|Multivariate ASSEssment of CardiovascUlar Response to the Controlled Exercise in Patients With Hypertension - Prospective and Observational Study (ASSECURE Study)|ASSECURE|Military Institute of Medicine, Poland|No|Recruiting|January 2015|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|40 Years|75 Years|No|Probability Sample|No less than 120 hypertensive subjects (both sexes, aged 40-75 years) will be enrolled,        including those with: 1/ no symptoms of HF and normal LV diastolic function (group N, no        less than 40 subjects), 2/ no symptoms of HF and LVddf (group D, no less than 40        subjects), 3/ with symptoms of both HF and LVddf (group D_HF, no less than 40 subjects).|December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634866||6569|
NCT02640001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO.HGUGM-2015-080|PCR Technique to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples|Impact of the Introduction in a Heart Surgery ICU of a PCR Technique (Cepheid Xpert® SA Nasal Complete Assay) to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples||Hospital General Universitario Gregorio Marañon|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the Heart Surgery-ICU|December 2015|March 6, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02640001||6175|
NCT02630498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 105321|Preventing Chronic Post Surgical Pain After Limb Surgery|The Role of Single Shot Brachial Plexus Block in Preventing Chronic Post Surgical Pain After Upper Limb Trauma Surgery|PCPSPAULS|Lawson Health Research Institute|No|Recruiting|August 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02630498||6904|
NCT02644538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APACE|Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides|A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides||The Second Affiliated Hospital of Chongqing Medical University|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644538||5826|
NCT02643953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108041|Increasing Women's Access to Skilled Pregnancy Care to Reduce Maternal Mortality in Nigeria|Increasing Women's Access to Skilled Pregnancy Care to Reduce Maternal and Perinatal Mortality in Nigeria: A Randomized Control Trial||University of Ottawa|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02643953||5871|
NCT02389673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGHBCRG-IORT-DCIS|Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer|Intra-operative Radiotherapy After Breast-conversing Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer||Guangdong Academy of Medical Sciences|Yes|Recruiting|October 2014|June 2026|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Female|18 Years|70 Years|No|||March 2015|March 10, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389673||25393|
NCT02389777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-06-14|Amnion-derived Cellular Cytokine Solution in UV-induced Inflammation|Effect of ACCS in UV-induced Inflammation|ACCS|Stemnion, Inc.|No|Not yet recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|March 16, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389777||25385|
NCT02446522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVH vs OVH|Compare Endoscopic and Open Methods of Vein Harvesting for Coronary Artery Bypass Grafting|Comparative Results of Endoscopic and Open Methods of Vein Harvesting for Coronary Artery Bypass Grafting: a Prospective Randomized Parallel-group Trial.||Meshalkin Research Institute of Pathology of Circulation||Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|80 Years|No|||May 2015|May 15, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02446522||21030|
NCT02388763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLY838-P001|Clinical Evaluation of MyDay™ and 1-DAY ACUVUE® TruEye®|Clinical Evaluation of MyDay™ Daily Disposable Silicone Hydrogel Contact Lenses||Alcon Research|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388763||25463|
NCT02377570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407-003|Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode|Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode - A Pilot Study||Baxter Healthcare Corporation|Yes|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|N/A|No|||October 2014|July 9, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02377570||26324|
NCT02391376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUCM/1261/B326e/2013|Heat Transfer by Three Types of Packs and Its Implication on the Flexibility of the Lower Back|Heat Transfer by Three Types of Packs and Its Implication on the Flexibility of the Lower Back: a Randomized, Controlled Trial||Universidad Católica del Maule|Yes|Completed|March 2012|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02391376||25262|
NCT02391389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17444|VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping|VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping||University of Virginia|No|Recruiting|September 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||March 2015|March 11, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02391389||25261|
NCT02383342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26908.091.12|Pain Processing and Chronic Pain in Humans: Exploring Genetic Factors and Biomarkers|Pain Processing and Chronic Pain in Humans: Exploring Genetic Factors and Biomarkers||Radboud University|Yes|Not yet recruiting|March 2015|March 2027|Anticipated|March 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10000|None Retained|Blood for DNA, RNA and serum|Both|18 Years|80 Years|No|Probability Sample|All adult patients undergoing elective major surgery at Radboud university medical center        (Nijmegen, The Netherlands) in the categories 1) extremities, 2) extra-abdominal, 3)        intra-abdominal, 4) intrathoracic, 5) extrathoracic are eligible for participation.        Patients will be recruited prospectively and consecutively via the anaesthetic        preoperative outpatients' clinic.|March 2015|March 6, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02383342|2 Years|25880|
NCT02383355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50681.091.14|Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation|Switch From an NNRTI or PI-based Regimen to a RAltegravir-based Regimen in Virologically Suppressed HIV-infected Patients: Effects on Platelet Reactivity, Platelet-monocyte Aggregation and the Inflammatory anD Thrombotic State of Monocytes|RAPID|Radboud University|Yes|Enrolling by invitation|March 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|January 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383355||25879|
NCT02460237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14282|HPV Self-Test Intervention in Ohio Appalachia|Pilot Testing an HPV Self-Test Intervention: A Novel Strategy for Reducing Cervical Cancer in Appalachia||Ohio State University Comprehensive Cancer Center|Yes|Not yet recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|110|||Female|30 Years|65 Years|No|||October 2015|October 13, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460237||19977|
NCT02389062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.389|Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients|Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients: Prospective, Randomized,Placebo Controlled, Double Blind Clinical Trial||Thomas Jefferson University|Yes|Recruiting|February 2015|February 2019|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|36|||Both|18 Years|80 Years|No|||March 2015|March 9, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02389062||25440|
NCT02384785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9941-IGA-CTIL|Effectiveness of of Therapeutic Currents in Clinical Dimension and Penetration Depth Dimension in Lower Back|Effectiveness of Different Types of Therapeutic Currents in Clinical Dimension and Penetration Depth Dimension in Lower Back||Sheba Medical Center|No|Enrolling by invitation|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|21 Years|75 Years|No|Non-Probability Sample|Participants who undergo electrodes implantation in lumbar spine due to chronic pain.        Thease patients arrives 7 days after implantation to the clinic for a procedure of        removing the electrodes.|November 2015|November 19, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02384785||25769|
NCT02391454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-2014|Self-monitoring Physical Activity With a SMARTphone Application in Cancer Patients: a Feasibility Study (SMART)|Self-monitoring and Empowering Physical Activity With a SMARTphone Application During or After Cancer Treatment in a 12 Week Follow-up: a Randomized Feasibility Study (SMART-trial)|SMART|University Medical Center Groningen|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02391454||25256|
NCT02390674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D 6327|Ciclosporin to Reduce Reperfusion Injury in Primary PCI|Evaluating the Effectiveness of Intravenous Ciclosporin on Reducing Reperfusion Injury in Patients Undergoing Primary Percutaneous Intervention: a Double-blind Randomised Controlled Trial|CAPRI|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|March 2015|March 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390674||25316|
NCT02390739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150090|Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer|Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|70 Years|No|||January 2016|February 3, 2016|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390739||25311|
NCT02460497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10330|Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia|Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II)||Galderma Laboratories, L.P.|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|60 Years|No|||January 2016|January 20, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460497||19957|
NCT02387073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-PRO|The Efficacy of Electrical Version of Patient Reported Outcome|The Efficacy of Electrical Version of Patient Reported Outcome: Patient Survey||Seoul National University Hospital|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|||Both|15 Years|80 Years|No|Non-Probability Sample|the patients who have experienced paper questionnaire|July 2015|July 6, 2015|November 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02387073|1 Month|25593|
NCT02381119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9618|Effects of Personalized Dietary Advice on Health Status of Diabetes Type 2 Patients|The Personalized Dietary Advice Services: Effects of Use by the Dietician on Health Status of Diabetes Type 2 Patients|PDA(4)T2D|TNO|No|Completed|May 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|30 Years|80 Years|No|||January 2016|January 10, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02381119||26051|
NCT02381379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-13-1186-15491|Malaysia Stop Tyrosine Kinase Inhibitor Trial|A Randomized Control Trial Comparing Peginterferon-α-2a Versus Observation After Stopping Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia With Deep Molecular Response for at Least Two Years|MSIT|Ministry of Health, Malaysia|No|Recruiting|March 2015|March 2019|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381379||26031|
NCT02379572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nch1|Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas|Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial||University Hospital Tuebingen|Yes|Recruiting|June 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|276|||Both|18 Years|80 Years|No|||November 2015|November 10, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02379572||26170|
NCT02461134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058C202|Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD|A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy||Actelion|Yes|Recruiting|September 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461134||19908|
NCT02389556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMOSES|Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children|Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study||Korea University|No|Completed|January 2006|December 2011|Actual|December 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|457|Samples Without DNA|Serum was obtained from each subject after the subjects had fasted overnight for more than 8      hrs.|Both|9 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Participants in this study were selected from the Korean Metabolic disorders & Obesity        Study in Elementary School children (KMOSES).|February 2016|February 29, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389556|3 Years|25402|
NCT02390830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT_SM_Falls|Falls Prevention and Balance Rehabilitation in Multiple Sclerosis|Falls Prevention and Balance Rehabilitation in Multiple Sclerosis: a Bi-centre Randomized Control Trial||Fondazione Don Carlo Gnocchi Onlus||Completed|March 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|N/A|N/A|No|||March 2015|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02390830||25304|
NCT02379819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-5573-HYB-PMA|Hybrid L24 New Enrollment Post Approval Study|Nucleus Hybrid L24 Implant System: New Enrollment Study|HNE|Cochlear|No|Recruiting|February 2015|March 2022|Anticipated|March 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379819||26151|
NCT02452528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2004|Study of ARC-520 in Patients With HBeAg (Hepatitis B e Antigen) Positive Chronic Hepatitis B Virus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection||Arrowhead Research Corporation|Yes|Recruiting|May 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||May 2015|November 9, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452528||20569|
NCT02386696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1436/15|Pleural Sliding During Valsalva and Muller Maneuvers|Pleural Sliding and Contraction of Intercostal Muscles: Ultrasound Findings During Valsalva and Muller Maneuvers|VALMUL|Catholic University of the Sacred Heart|No|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02386696||25622|
NCT02392039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0880|Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma|Randomized, Placebo Controlled Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma||M.D. Anderson Cancer Center|Yes|Recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02392039||25212|
NCT02392052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|713234|Enhancing Self-Efficacy for Caregivers of Family Members With Spinal Cord Injury|Enhancing Self-Efficacy for Caregivers of Family Members With Spinal Cord Injury||Craig Hospital|No|Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02392052||25211|
NCT02393248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 54828-101|Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies||Incyte Corporation|No|Recruiting|January 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393248||25119|
NCT02460653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00009490|Effects of High Flow Nasal Cannula on Deadspace Reduction and Regional Distribution of Ventilation|Effects of High Flow Nasal Cannula on Deadspace Reduction and Regional Distribution of Ventilation|HFNC|Children's Hospital Boston|No|Recruiting|May 2014|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|N/A|17 Years|No|||May 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460653||19945|
NCT02392845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.356|A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study|A Pilot Dose Escalation Phase I Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study|MODEL1|Hospices Civils de Lyon|No|Completed|June 2005|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||March 2015|March 13, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02392845||25150|
NCT02387281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073518|Freezing of Gait: Clinical, Cognitive, and Imaging Features|Freezing of Gait: Clinical, Cognitive, and Imaging Features|FOG|Emory University|Yes|Enrolling by invitation|March 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|112|Samples Without DNA|Plasma|Both|18 Years|80 Years|No|Non-Probability Sample|Freezing of gait (FOG) patients with Parkinson disease (PD) will be selected from the        Emory Movement Disorders Center.|March 2016|March 9, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02387281||25577|
NCT02387294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FABNovo-H-16|Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents|Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|Yes|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02387294||25576|
NCT02390245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-441|Improving Glaucoma Detection and Management|Wills Eye Community Intervention to Improve Glaucoma Detection and Follow-Up Care||Wills Eye|No|Enrolling by invitation|March 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|300|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390245||25349|
NCT02390297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-INT-00|Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients|Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Contruct||Calimmune, Inc.|No|Enrolling by invitation|March 2015|January 2032|Anticipated|January 2031|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|18|Samples With DNA|Cryopreserved white blood cells and DNA and RNA extracted from peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|Eligibility for this protocol is dependent on prior exposure to a Cal-1 modified        hematopoietic cellular product. The study population will thus consist of individuals with        HIV-1 infection, who have met criteria for participation in a Cal-1 phase I/II clinical        trial and received a dose of Cal-1 modified hematopoietic cells as part of a previous        study|March 2015|March 11, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390297||25345|
NCT02444702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0006-15-MMC|Clinical, Morphological and Functional Success Predictors Following Lumbar Spinal Surgery in Patients With Chronic Low Back Pain and Degenerative Disorders.|Clinical, Morphological and Functional Success Predictors Following Lumbar Spinal Surgery in Patients With Chronic Low Back Pain and Degenerative Disorders.||Meir Medical Center|Yes|Not yet recruiting|June 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|40 Years|80 Years|No|Non-Probability Sample|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed        by CT imaging who were recommended surgery and chose to undergo surgery will be recruited        from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel.        Included participants will be men or women, aged 40-80 years, of any race or ethnic        background. Participants' diagnosis may include unstable degenerative spondylolisthesis,        radicular pain, or documented stenosis with referred pain|April 2015|May 17, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444702||21170|
NCT02444715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSYS-201205/08-1|Computer-Aided Prevention System|Study on Improved Prevention Methods for Cerebro-cardiovascular Diseases Based on a Computer-aided Prevention System|CAPSYS|Luxembourg Institute of Science and Technology|Yes|Completed|January 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|94|||Both|20 Years|N/A|No|||January 2016|January 20, 2016|May 12, 2015||No||No|June 8, 2015|https://clinicaltrials.gov/show/NCT02444715||21169|
NCT02379442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150088|Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids|A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers||National Institutes of Health Clinical Center (CC)||Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|4 Years|99 Years|No|||December 2015|January 7, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379442||26180|
NCT02382471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159753|Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD|Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With Coronary Artery Disease||Tehran University of Medical Sciences|Yes|Completed|December 2011|October 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|45 Years|65 Years|No|||March 2015|March 2, 2015|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382471||25947|
NCT02390349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-1001|"CuraMed" and "Curamin" in Osteoarthritis|||EuroPharma, Inc.||Recruiting|April 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|201|||Both|40 Years|80 Years|No|||January 2016|January 19, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390349||25341|
NCT02390362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMP001|Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome|Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)|RAMP|Nationwide Children's Hospital|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|1 Year|18 Years|No|||January 2016|March 16, 2016|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390362||25340|
NCT02449772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-14083R|Emergency Department (ED) Triage of Alcohol Abuse|Evaluation of ED Triage of Adult Patients With Alcohol Abuse||University Hospital, Geneva|No|Completed|April 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|775|||Both|16 Years|N/A|No|Non-Probability Sample|all adult patients admitted during one year in the ED for alcoholic abuse|December 2015|December 24, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02449772||20781|
NCT02449785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2014/11|Assessment of Cystic Fibrosis Lung Involvement With UTE Pulse Sequences|Assessment of Lung Involvement in Cystic Fibrosis Patients Using 1.5T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences|MucoIRM|University Hospital, Bordeaux|No|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|33|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449785||20780|
NCT02379702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METSAR-II|Metabolic Syndrome Prevalence Study|Turkey Metabolic Syndrome Prevalence Study - METSAR II||Abdi Ibrahim Ilac San. ve Tic A.S.|No|Completed|June 2014|November 2014|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|1659|||Both|N/A|N/A|No|Non-Probability Sample|The previous study included 4.264 patients from 47 cities and we are going to try to get        in contact all those patients. Data obtained from available patients will be analysed and        the change trend will be evaluated|March 2015|March 2, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02379702|10 Years|26160|
NCT02380040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181/14|Plethismographic Perfusion Index in Neonates|Examination of Perfusion Index in Term and Preterm Newborns Through Plethismography||Shaare Zedek Medical Center|No|Not yet recruiting|March 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Term and Preterm newborns admitted to the neonatology department|February 2015|March 1, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380040||26134|
NCT02391649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15401114|Problem-solving-based Bibliotherapy Program for Family Caregivers|A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Schizophrenia Spectrum Disorders|PSBBP|The Hong Kong Polytechnic University|Yes|Recruiting|February 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|129|||Both|18 Years|60 Years|No|||February 2016|February 17, 2016|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391649||25242|
NCT02390414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-056|The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study|The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study||Dana-Farber Cancer Institute|Yes|Recruiting|April 2011|April 2021|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|290|||Both|60 Years|75 Years|No|Non-Probability Sample|Eligible patients will be 60 to 75 years old with a diagnosis of MDS or related disorder        (eg, MDS/MPD or CMML) who have disease that is advanced enough to warrant RIC HSCT        (defined by high-risk cytogenetics OR int-2 or high-risk on IPSS OR transfusion dependence        as defined by WPSS) and who are physically fit enough to undergo RIC HSCT as assessed by        pre-determined measures of organ function. Patients whose baseline donor status is known        will be excluded; however, knowledge of HLA status is allowed as long as a donor search        has not been performed.|January 2016|January 4, 2016|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02390414||25336|
NCT02390466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVVAC-3S/P2|Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1|Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1||InnaVirVax|Yes|Active, not recruiting|April 2015|April 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||October 2015|October 22, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02390466||25332|
NCT02445209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JagiellonianU-01|Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma|||Jagiellonian University|No|Completed|September 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02445209||21131|
NCT02388971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1202-2006|Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease|A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging||Takeda|No|Withdrawn|April 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|35 Years|80 Years|No|||December 2015|December 8, 2015|February 23, 2015|Yes|Yes|Study has withdrawn.|No||https://clinicaltrials.gov/show/NCT02388971||25447|
NCT02383290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02979|The Implementation of Pharmacogenomics Into Primary Care in British Columbia|The Implementation of Pharmacogenomics Into Primary Care in British Columbia|IPPC|University of British Columbia||Completed|April 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|190|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02383290||25884|
NCT02383303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08350-032|Assets for Independence Evaluation|Assets for Independence (AFI) Program Evaluation: a Randomized Control Trial of Matched Savings Accounts (Individual Development Accounts or IDAs) for Low-income Households.|AFI|Urban Institute|No|Active, not recruiting|January 2013|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|808|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02383303||25883|
NCT02385422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-WYC-2015|The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding|The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Recruiting|March 2015|November 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Both|18 Years|70 Years|No|||March 2015|March 9, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02385422||25720|
NCT02386449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000180|A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy|A Randomized, Controlled, Parallel Group, Assessor-Blinded Study To Compare The Efficacy, Tolerability, And Safety Of Oral Sodium Picosulfate (PicoPrep®) Versus Oral Mannitol and Bisacodyl, For Colon Cleansing In Colonoscopy Preparation Of Adult Outpatients|CLEAR PREP|Ferring Pharmaceuticals|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|184|||Both|18 Years|60 Years|No|||January 2016|January 11, 2016|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386449||25641|
NCT02389075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1507|The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis|The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis||University of Colorado, Denver|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|Samples With DNA|Colon pinch biopsies, white blood cells.|Both|18 Years|70 Years|No|Non-Probability Sample|Inflammatory Bowel Disease, Ankylosing Spondylitis, and Healthy Controls|March 2016|March 18, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02389075||25439|
NCT02389088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-2016|Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.|Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH||University of California, San Diego|No|Completed|April 2006|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|9|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 9, 2015|No|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT02389088||25438|
NCT02388191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000436|Naproxen for Pain Control With Intrauterine Device Insertion|Naproxen for Pain Control With Intrauterine Device Insertion: A Randomized Double-Blind Placebo Controlled Trial||Planned Parenthood League of Massachusetts|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388191||25507|
NCT02390544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-5123|A Pharmacokinetic Study of Melphalan in Children|Melphalan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Study||Children's Hospital Medical Center, Cincinnati|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 13, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390544||25326|
NCT02382848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001746|Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD|Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD||Milton S. Hershey Medical Center|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Female|18 Years|45 Years|No|||February 2016|February 18, 2016|February 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382848||25918|
NCT02383095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5937|Art-therapy and Psychotic Disorders|Efficiency of Art-therapy in Psychotic Disorders||University Hospital, Strasbourg, France|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||August 2015|August 6, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02383095||25899|
NCT02389205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH-105-165|The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia|Rehabilitation Department of Tri-Service General Hospital||Tri-Service General Hospital|No|Not yet recruiting|April 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Male|20 Years|65 Years|No|||March 2015|March 18, 2015|November 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02389205||25429|
NCT02389842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4191|PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib|PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers|PIPA|Royal Marsden NHS Foundation Trust|No|Recruiting|February 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|93|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02389842||25380|
NCT02380131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alien-Craft 0002|Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis|Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis||Hebei Medical University|No|Recruiting|February 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||February 2015|March 4, 2015|October 8, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02380131||26127|
NCT02452216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRNCNS0007|Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS|MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI||Stanford University|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|2 Years|N/A|No|||June 2015|June 10, 2015|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452216||20593|
NCT02383940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-204-T1DM|Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C||Lexicon Pharmaceuticals|Yes|Recruiting|March 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|30 Years|No|||January 2016|January 22, 2016|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383940||25834|
NCT02383953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 054|SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins|Non Genetic Factors in the Pathogenesis of Inflammatory Bowel Disease in Twins||St Stephens Aids Trust|No|Recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Blood (plasma), stool, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200|March 2016|March 24, 2016|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02383953||25833|
NCT02377609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1215|To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks|Cross-validation of the Finger Prick Dried Blood Spot Assay Method With the Established Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients||Astellas Pharma Inc|No|Terminated|October 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|108|Samples With DNA|Dried blood spot and blood collected by venepuncture|Both|18 Years|N/A|No|Non-Probability Sample|Stable kidney or liver transplant recipient receiving Advagraf® (tacrolimus) therapy|May 2015|May 14, 2015|February 26, 2015|No|Yes|DBS method not be validated against the standard of care venepuncture method due to quality of    blood sample and variable tacrolimus extraction|No||https://clinicaltrials.gov/show/NCT02377609||26321|
NCT02377622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407-001|Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode|Comparison of the Clinical Performance of 2 THERANOVA 400 Dialyzer Prototypes in HD With a High-Flux Dialyzer in HD and a High-Flux Dialyzer in hvHDF - A Pilot Study||Baxter Healthcare Corporation|No|Completed|February 2015|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||February 2015|June 17, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02377622||26320|
NCT02384824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU CT003|Delayed Plaque Morphology in Patients With STEMI After Thrombus Aspiration During Primary PCI|Evaluation of Delayed Plaque Morphology by Optical Coherence Tomography (OCT) in Patients With Acute ST Segment Elevated Myocardial Infarction (STEMI) After Thrombus Aspiration During Primary Percutaneous Intervention (PCI)|STEMI-OCT|Second Affiliated Hospital, School of Medicine, Zhejiang University|No|Not yet recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients with acute STEMI|March 2015|March 9, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02384824||25766|
NCT02385110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0989|Alemtuzumab in Combination With Etoposide and Dexamethasone|Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 18, 2015|March 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385110||25744|
NCT02445183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2815|COPDGene/Lung Cancer Center Database|COPDGene/Lung Cancer Center Database||National Jewish Health|No|Enrolling by invitation|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|250|||Both|40 Years|N/A|No|Non-Probability Sample|Subjects eligible for study are those enrolled in the COPDGene®. Subjects will be screened        for enrollment through the COPDGene® longitudinal follow-up questionnaire or during their        Phase 2 visit. Those patients that answer yes to "since the last follow up have you been        diagnosed with cancer?" will be contacted by a study coordinator and offered enrollment in        the COPDGene®/Lung Cancer Database.|May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445183|5 Years|21133|
NCT02445443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4042-01|LEGION Hinge Safety and Efficacy Study|A Prospective, Multi-center Clinical Study Evaluating the LEGION™ Hinge Knee System|LINKS|Smith & Nephew, Inc.|No|Recruiting|August 2015|August 2021|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients requiring a revision total knee arthroplasty (TKA) using the LEGION Hinge Total        Knee system.|January 2016|January 28, 2016|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445443||21113|
NCT02380794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG-PAD|Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule|Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule||Chinese University of Hong Kong|Yes|Recruiting|September 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|226|||Both|40 Years|N/A|No|||February 2016|February 19, 2016|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02380794||26076|
NCT02393521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1421077978677|The Effect of Vibration Therapy Over Neck Myofascial Trigger Points|The Effect of Vibration Therapy on Pressure Pain Thresholds Over Neck Myofascial Trigger Points: a Randomized Controlled Study|vibraMTrP|University of Valencia|No|Active, not recruiting|August 2014|April 2015|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||March 2015|March 15, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02393521||25098|
NCT02385383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074-OJ4|An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study|An Intravenous Iron Based Protocol for Optimizing Haemoglobin in Anaemic Patients Prior to Fast-track Hip and Knee Arthroplasty - An Observational Follow up Study||Rigshospitalet, Denmark|No|Recruiting|October 2014|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective hip or knee arthroplasty presenting with preoperative        anemia.|March 2015|March 10, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02385383||25723|
NCT02445664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP_77|Effect of a Tablet-administered Educational Video on Patients´ Knowledge on Osteoporosis and Treatment|Effect of a Tablet-administered Educational Video on Patients´ Knowledge on Osteoporosis and Treatment - a Randomized, Controlled Trial||University of Southern Denmark||Completed|August 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|67|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445664||21096|
NCT02385526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-40|Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation|ASCEND: Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation|ASCEND|Cyberonics, Inc.|No|Recruiting|March 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|12 Years|N/A|No|Probability Sample|The study shall include adults and adolescents over 12 years of age with partial onset        seizures that are refractory to antiepileptic medications and eligible for VNS Therapy        indicated for use as an adjunctive therapy in reducing the frequency of seizures.|January 2016|January 6, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385526||25712|
NCT02388672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCB1|Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables|Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables- a Randomized, Placebo-controlled and Double-blinded Study in Healthy Subjects||University Hospital Tuebingen|No|Withdrawn|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 19, 2015||No|Personnel changes|No||https://clinicaltrials.gov/show/NCT02388672||25470|
NCT02379741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14-1013-C-01|ADC-1013 First-in-Human Study|A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally Administered ADC-1013||Alligator Bioscience AB|No|Recruiting|April 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02379741||26157|
NCT02636166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0772|Project-0027. Lay User Usage Study|Project-0027 Lay User Usage Study||SPD Development Company Limited|No|Completed|July 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|943|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|December 16, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02636166||6470|
NCT02634645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2371|TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)|A Multicenter Prospective Study Evaluating Outcomes of Endoscopic Eradication Therapy in Patients With Barrett's Esophagus Associated Neoplasia: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium||University of Colorado, Denver|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Formation of a multi-site prospective database of patients with BE associated neoplasia        referred for consideration for EET and EAC.        Women and minorities will be included as they are found to have BE, BE related dysplasia,        and EAC. It is well recognized that the majority of patients diagnosed with BE are white        males. However, we will actively seek to include all women and minorities with a diagnosis        of BE associated neoplasia for the study.|December 2015|December 15, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02634645||6586|
NCT02630667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12641|The Acute Effects Fortified Nutritional Supplementation on Childhood Cognition|The Acute Effects of Fortified Nutritional Supplementation on Cognition, Memory, & Achievement||University of Illinois at Urbana-Champaign|No|Active, not recruiting|June 2012|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|113|||Both|9 Years|10 Years|Accepts Healthy Volunteers|||June 2015|December 10, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02630667||6891|
NCT02393079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCLT/DIP|Analysis of TCLT in TBI Patients: a Prospective, Randomized Controlled Trial|The Effects of Transcranial LED Therapy (TCLT) in Patients With Traumatic Brain Injury (TBI): a Prospective, Randomized Controlled Trial||University of Sao Paulo General Hospital|No|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||March 2015|March 13, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02393079||25132|
NCT02393092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20002499|Violence Prevention Study for Youth Age 10-15|A Youth Violence Prevention Initiative: A VCUHS and Boys and Girls Club of Metro Richmond Initiative||Virginia Commonwealth University|No|Recruiting|July 2015|May 2022|Anticipated|May 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|72|||Both|10 Years|15 Years|No|||February 2016|February 26, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02393092||25131|
NCT02631798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microcapsule Chromo-122015|Chromocolonoscopy With Food-grade Dyes|Mucosal Staining After Oral Administration of Food Grade Dyes in Subjects Undergoing Outpatients Colonoscopy||University of Schleswig-Holstein|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02631798||6804|
NCT02639442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CP-10|Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia|Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia||ProArc Medical|No|Not yet recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|50 Years|85 Years|No|||December 2015|December 20, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02639442||6218|
NCT02640365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOUBLIRI C13-4|A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer|A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI|DOUBLIRI|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Recruiting|October 2015|September 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|75 Years|No|||December 2015|March 14, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640365||6147|
NCT02640378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018|Semiquantitative Urine Pregnancy Test Results At ≥9 Weeks of Gestation|||Gynuity Health Projects|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|122|||Female|10 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women at >9 weeks gestation|December 2015|December 24, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02640378||6146|
NCT02634749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Umu_2014-363-31|OTIS - Optimized Complementary Feeding Study|OTIS - Optimized Complementary Feeding Study|OTIS|Umeå University|No|Recruiting|April 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|4 Months|18 Months|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02634749||6578|
NCT02628691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-Monitoring|Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia|Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia (HCV-Monitoring)|HCV-Monitoring|Institute of Tropical Medicine, Belgium|No|Recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Left over biological samples (whole blood plasma and serum)|Both|18 Years|N/A|No|Non-Probability Sample|Adult HIV-infected patients of the SHCH cohort who have chronic HCV infection (all        genotypes) with no-to-moderate hepatic fibrosis and not considered in immediate need of        HCV treatment.|January 2016|January 8, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02628691||7043|
NCT02628704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-015|Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma|Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug|SCORE|Karyopharm Therapeutics, Inc|Yes|Not yet recruiting|December 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|March 23, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628704||7042|
NCT02451631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB02|The Mobile Diabetes Mgmt. Study With Type 2 Diabetes|A Multi-center, Randomized, Parallel, Open Clinical Trial to Evaluate the Glycemic Control Effect of the Mobile Healthcare Service in Patients With Type 2 Diabetes Mellitus||Healthconnect|No|Recruiting|April 2015|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|20 Years|80 Years|No|||May 2015|May 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451631||20638|
NCT02381574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDL|French Lumbar Total Disk Replacement Observational Study|French Lumbar Total Disk Replacement Observational Study (FLTDR Observational Study)|PTDL|Medtronic France SAS|No|Recruiting|June 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Analysis of the first 600 patients implanted with a PTDL (first 200 prostheses implanted        for each laboratory involved in the observational study): Medtronic, LDR Médical et        Synthes SAS) during an estimated inclusion period from 6 to 18 months and a follow-up        period of 5 years.        An additional follow-up from 3 to 5 years will be envisaged in a protocol amendment if        requested by Authorities.|February 2015|March 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02381574||26016|
NCT02380638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP2009-09183|Effects of Whole-body Vibration Training on Body Composition in Adolescents With and Without Down Syndrome|Effects of Whole-body Vibration Training on Bone Mass and Bone Metabolism in Adolescents With Down Syndrome / Efectos Del Entrenamiento Vibratorio en la Masa ósea y el Metabolismo óseo de Adolescentes Con síndrome de Down||Universidad de Zaragoza||Completed|January 2010|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|58|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02380638||26088|
NCT02380651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324/13/03/02/2014/1|Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage|Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study||Helsinki University Central Hospital|No|Recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|100 Years|No|Non-Probability Sample|Upper extremity sarcoma patient who underwent limb-salvage surgery|February 2016|February 8, 2016|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02380651||26087|
NCT02389985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX101-209|A Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A PHASE Ib STUDY OF CRLX101 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER||Cerulean Pharma Inc.|No|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|March 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389985||25369|
NCT02461069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMAT-MS|Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis|A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)|DIMAT-MS|University Hospital Muenster|No|Recruiting|May 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|December 8, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461069||19913|
NCT02448199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zodiac Produtos Farmacêuticos|Study of Association of Anti-inflammatory and Anti-rheumatic|Phase III Study Comparing Association of Anti-inflammatory and Anti-rheumatic|ZDPC00213|Zodiac Produtos Farmaceuticos S.A.|No|Not yet recruiting|July 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|40 Years|85 Years|No|||May 2015|May 18, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448199||20902|
NCT02378077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001288|Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue|Immunomodulatory Role of Eosinophils in Determining Inflammation and Insulin Sensitivity in Human Adipose Tissue- Aims 1&2||Mayo Clinic|No|Recruiting|August 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|35|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|September 17, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02378077||26285|
NCT02378337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27558714.4.0000.0048|Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality||pet-ct|Hospital Sao Rafael|No|Completed|September 2014|||August 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|335|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Will be observed all patients who perform PET / CT examinations, independent of clinical        indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in        participating in the study, will be provided free and informed consent form (ICF) for your        appreciation. This evaluation will serve for analysis and quantification of PET-CT images.|August 2015|August 19, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02378337||26265|
NCT02391467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver006|Validity of Elastography During Pregnancy|Validity of Non-invasive Liver Fibrosis Assessment by Ultrasound-based Elastography at the Third Trimester of Pregnancy: a Prospective Study||Hopital Lariboisière|No|Suspended|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women with HBV or HCV chronic hepatitis|September 2015|September 30, 2015|March 12, 2015||No|issue concerning safety of elastography during pregnancy|No||https://clinicaltrials.gov/show/NCT02391467|6 Months|25255|
NCT02379325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lets Quit|Text Message Stop Smoking Among Young Population|4-Weeks Intervention of Mobile Phone Text Messaging (Let's Quit!) on Smoking Cessation Among University Students: A Non Randomized Controlled Trial||Universiti Kebangsaan Malaysia Medical Centre|Yes|Completed|April 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||February 2015|March 3, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02379325||26189|
NCT02461082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-EMST-TMS|EMST and TMS for Treatment of Dysphagia in Parkinson's Disease|Expiratory Muscle Strength Training (EMST) and Transcranial Magnetic Stimulation (TMS) for Treatment of Swallowing Disorders in Parkinson's Disease||University Hospital Muenster|No|Recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461082||19912|
NCT02392728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-VES-91|Virtual Environments in Patients Receiving Treatment for Lung Cancer|The Effectiveness of Virtual Environment on the Adverse Psychological Effects in Patients Receiving Treatment for Lung Cancer|VE|Cyprus University of Technology|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02392728||25159|
NCT02386111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1127-04|A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma|A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma||Celldex Therapeutics|No|Recruiting|May 2015|March 2019|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386111||25667|
NCT02386124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140994|Frailty in Elderly Patients Receiving Cardiac Interventional Procedures|Frailty Assessment in eldeRly Admitted to hoSpital for acutE caRdiac Disease Prospective Study|FRASER|University Hospital of Ferrara|Yes|Recruiting|December 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|70 Years|N/A|No|||March 2016|March 10, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386124||25666|
NCT02383862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410447721|PROMIS Measures in Primary Care Practice|Incorporating PROMIS Symptom Measures Into Primary Care Practice||Indiana University|Yes|Not yet recruiting|March 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02383862||25840|
NCT02383875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opticourses|An Interventional Study to Reduce Social Disparities in Diet Quality in the Northern Districts of Marseille|An Interventional Study to Reduce Social Disparities in Diet Quality in the Northern Districts of Marseille (Opticourses)|Opticourses|Institut National de la Recherche Agronomique|No|Completed|September 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|189|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 3, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02383875||25839|
NCT02448732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sun Yat-sen Un|Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases|Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases||Sun Yat-sen University|Yes|Recruiting|December 2014|June 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448732||20861|
NCT02386423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorg1|RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome|Efficacy and Safety of the RESTIFFIC™ Brand Pressure Application System, the Restless Leg Relaxer to Reduce the Symptoms of Moderate to Severe Restless Leg Syndrome|RESTIFFIC|Lake Erie Research Institute|Yes|Completed|April 2009|November 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386423||25643|
NCT02386436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201246|A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects|A Phase I, Randomised, Double-blind (Sponsor Open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects||GlaxoSmithKline|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386436||25642|
NCT02386488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16060A|Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women|A Randomised, Open-label, Single-centre, Single- and Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women||H. Lundbeck A/S|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02386488||25638|
NCT02377076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526.005|Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics|||Federal University of Vicosa|No|Recruiting|September 2014|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|59 Years|No|||March 2015|March 3, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377076||26362|
NCT02379832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B14-07-2037|Pre-Eclampsia And Growth Restriction: a Longitudinal Study|Pré-Eclampsie et Retard de Croissance: Une étude Longitudinale Évaluative (PERLE)|PEARL|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|Samples Without DNA|Maternal serum Cord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous pregnant women|March 2015|March 12, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02379832|8 Months|26150|
NCT02460601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCMSBL-09006|The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study|||Wuhan Union Hospital, China||Completed|December 2013|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460601||19949|
NCT02389504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14070006|An Investigation of Return to Play Exertion Protocol in Concussed Adolescents|An Investigation of Return to Play Exertion Protocol in Concussed Adolescents||University of Pittsburgh|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|14 Years|17 Years|No|||December 2015|December 1, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02389504||25406|
NCT02377336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-279-1503|GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of GS-6615 in Subjects With Chronic Stable Angina and Coronary Artery Disease||Gilead Sciences|No|Withdrawn|May 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|February 26, 2015|Yes|Yes|Anticipated recruitment challenges|No||https://clinicaltrials.gov/show/NCT02377336||26342|
NCT02377349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116945|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women|Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix™ (263855) in Pregnant Women||GlaxoSmithKline||Recruiting|February 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|680|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02377349||26341|
NCT02377362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLWL-SMP|A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01|A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01||GLWL Research Inc.|No|Recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|106|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|February 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02377362||26340|
NCT02380443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-019-CORK-CRYVAC|Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer|In-Situ Cancer Vaccine: Phase IIb, Open-Label Study to Assess Safety of Allostim in Combination With Cryoablation in Metastatic Colorectal Cancer Third Line Therapy in KRAS/BRAF-Mutant Disease||Immunovative Therapies, Ltd.|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|18|||Both|18 Years|80 Years|No|||December 2015|February 23, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380443||26103|
NCT02449265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUCC-NHL03 Trial|Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma|Efficacy of Consolidative Involved-site Radiotherapy Following Sufficient Chemotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center -NHL03 Trial||Wuhan University|Yes|Recruiting|October 2015|October 2025|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449265||20820|
NCT02380599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MountSMCLA 3|A Study of the Effects of Mid-Thoracic Spinal Manipulation and Spinal Mobilization on Heart Rate Variability|A Comparative Study of the Effects of Mid-Thoracic Spinal Manipulation and Spinal Mobilization on Heart Rate Variability||Mount St. Mary's College, Los Angeles, CA|No|Enrolling by invitation|January 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02380599||26091|
NCT02391480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-546|A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer||AbbVie|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|March 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391480||25254|
NCT02391246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150094-01H|Radionecrosis and FDG PET|A Dual Time Point FDG-PET to Differentiate Between Recurrent Brain Tumor and Radionecrosis|DTPI FDG-PET|Ottawa Hospital Research Institute|No|Recruiting|June 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|62|||Both|18 Years|N/A|No|Probability Sample|Participants will be patients who have previously been treated with radiochemotherapy for        high grade gliomas who are clinically assessed with a brain MRI for suspected disease        recurrence.|February 2016|February 23, 2016|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02391246||25272|
NCT02449512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP_LUT|Somatosensory Evoked Potentials From the Lower Urinary Tract|Somatosensory Evoked Potentials From the Lower Urinary Tract in Individuals With Neurogenic Lower Urinary Tract Dysfunction as a Result of Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Not yet recruiting|January 2016|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|26|||Both|18 Years|N/A|No|Probability Sample|individuals with neurogenic lower urinary tract dysfunction as a result of spinal cord        injury|September 2015|September 1, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02449512||20801|
NCT02449525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKG-ECP|Extracorporeal Perfusion of Microvascular Free Flaps|Extracorporal Perfusion of Free Flaps in the Head and Neck||Technische Universität München|No|Recruiting|June 2013|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|100 Years|No|||March 2016|March 7, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02449525||20800|
NCT02383992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU200234|Postoperative Care of Sutured Wounds|Comparing the Efficacy of Hydrogen Peroxide Versus Normal Saline in Postoperative Care of Sutured Wounds||Northwestern University|Yes|Enrolling by invitation|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383992||25830|
NCT02384239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147522|A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer|Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers||University of California, San Francisco|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384239||25811|
NCT02387450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ongoing recording|Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication|Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil||University Hospital, Angers|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|30 Years|90 Years|No|||March 2015|March 12, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02387450||25564|
NCT02376881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERS139|Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)|||Tehran University of Medical Sciences|Yes|Not yet recruiting|March 2015|September 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|40 Years|No|||September 2014|February 24, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02376881||26377|
NCT02376894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF-TSCPM01|An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients|An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients||Taiwan Cancer Palliative Medicine|No|Recruiting|February 2015|||June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1200|||Both|20 Years|N/A|No|Non-Probability Sample|cancer patient|February 2015|February 25, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02376894||26376|
NCT02386345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-FIRM 02|Topera E-FIRM Registry|EU Focal Impulse and Rotor Modulation Registry -Topera E-FIRM Registry-||I-Med-Pro GmbH|No|Recruiting|March 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who are receiving a FIRM guided AF ablation and are selected in accordance with        the current AF guidelines are eligible for the participation in the registry|December 2015|December 7, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02386345||25649|
NCT02384720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Freefol_PKPD_2013|Study of Freefol-MCT PKPD in Healthy Volunteers|||Daewon Pharmaceutical Co., Ltd.||Not yet recruiting||||January 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only||3|Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Adults over 20years old|April 2014|March 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02384720||25774|
NCT02378467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHIP001|Saline Hypertonic in Preschoolers|Saline Hypertonic in Preschoolers|SHIP|University of Washington, the Collaborative Health Studies Coordinating Center|Yes|Recruiting|March 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|3 Years|5 Years|No|||March 2016|March 22, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378467||26255|
NCT02377167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETPOINT2|Early Tracheostomy in Ventilated Stroke Patients 2|Stroke-Related Early Tracheostomy Versus Prolonged Orotracheal Intubation in Neurocritical Care Trial 2|SETPOINT2|University Hospital Heidelberg|Yes|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02377167||26355|
NCT02382354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-417|Remifentanil for the I-gel and Laryngeal Mask Airway Insertion|Comparison of the Effect-site Concentration of Remifentanil for Insertion of the I-gel and Laryngeal Mask Airway During Propofol Anesthesia||Ajou University School of Medicine|Yes|Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|41|||Female|19 Years|60 Years|No|||October 2015|October 13, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02382354||25956|
NCT02382367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.835|Prevalence of Alpha-1 Antitrypsin Dysfunction in Pulmonary Emphysema||DysA|Hospices Civils de Lyon|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|190|||Both|18 Years|80 Years|No|||December 2015|December 4, 2015|December 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02382367||25955|
NCT02377024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBI_CT_TF|Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions|Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions in Healthy Adults With Subjective Cognitive Impairment: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments||Ewha Womans University||Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|40 Years|65 Years|No|||June 2015|June 30, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377024||26366|
NCT02377037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transitions study|Metabolic Cost of Sitting, Standing, and Transitions|What is the Metabolic Cost of Sitting, Standing, and Sit/Stand Transitions? A Randomized Controlled Trial||Technical University of Lisbon|Yes|Completed|November 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02377037||26365|
NCT02387918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2015|Prevention of POV After Paediatric Tonsillectomy|Vomiting After Tonsillectomy in Children: A Comparison of Dexamethasone and Acupuncture||Assiut University|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|2 Years|8 Years|No|||January 2016|January 20, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02387918||25528|
NCT02390479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-112-01/10|Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment|Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment||Bulent Ecevit University|No|Completed|December 2013|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|54|||Both|25 Years|49 Years|Accepts Healthy Volunteers|||March 2015|September 28, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02390479||25331|
NCT02388685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-HSR# 16084|Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3|Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3||University of Virginia|No|Recruiting|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|35 Years|85 Years|No|||November 2015|November 30, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388685||25469|
NCT02377284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818836|Prevention and Management of Food Allergies|Engaging Food Service Workers in the Prevention of Food Allergy-related Adverse Events||University of Pennsylvania|No|Completed|October 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|187|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02377284||26346|
NCT02391818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599231-1|The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients|The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients|IPMR Balance|The Institute of Physical Medicine and Rehabilitation|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|44|||Female|N/A|N/A|No|Non-Probability Sample|Patients from cancer treatment clinic and radiation oncology clinics|March 2015|March 12, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02391818||25229|
NCT02393547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007240|Lorcaserin for Preventing Weight Gain Among Smokers|Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study||Mayo Clinic|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02393547||25096|
NCT02377726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1758-31-2|Anonymous Treatment on the Internet for Alcohol Dependence: A Randomised, Controlled Trial|Internet Based Treatment for Alcohol Dependence Among Anonymous Help Seekers on the Internet : A Randomized Controlled Trial||Karolinska Institutet|No|Recruiting|April 2015|March 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2400|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377726||26312|
NCT02386527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13115|Consortium of Early Arthritis Cohorts USA|Consortium of Early Arthritis Cohorts USA - A Prospective Cohort Study of Adults With New Consent Inflammatory Arthritis Symptoms to Understand Predictors of Optimal Outcomes|CATCH-US|Hospital for Special Surgery, New York||Recruiting|December 2014|||December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|Samples With DNA|Maximum of 7 tubes of blood will be collected|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Most patients will have been referred by their primary care providers (PCP) for an        expedited assessment and all will have met inclusion criteria. If the patient is        appropriate for inclusion into the cohort, the study will be explained to the patient by        the rheumatologist or designate. If he/she is interested, the information sheet and        consent form will be reviewed with the study nurse or coordinator and consent will be        obtained. As this is a study of usual care, study data is the information collected during        regular clinic visits. Therefore, the patient will be consenting to have the data from        their regular assessments entered into the study database. A schedule of regular visits        has been identified in advance in keeping with best clinical practice and management of        ERA.|March 2015|March 19, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02386527|3 Years|25635|
NCT02377596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANUS1108|Assessment of a Feeding Difficulties Diagnostic Tool Questionnaire For Children With Oral Feeding Resistance|Assessment of a Feeding Difficulties Diagnostic Tool Questionnaire For Children With Oral Feeding Resistance|FDDT|Children's Research Institute|No|Withdrawn|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|12 Months|60 Months|No|Non-Probability Sample|This prospective, observational pilot study will be conducted in a single private        pediatric office. The pediatricians have incorporated the FDDT questionnaire as a part of        the routine evaluation of children coming for "well baby visits". To complete the study we        will recruit at least 40 of the children perceived by their parents or guardian to have        feeding difficulties. To be sure this number is obtained we will aim to recruit 50        subjects.|February 2015|February 25, 2015|May 14, 2012||No|Not enough participants|No||https://clinicaltrials.gov/show/NCT02377596||26322|
NCT02382146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yeditepe universty hospital|Prevention of Postoperative Nausea and Vomiting|A Prospective Randomize Study: Prevention of Nausea and Vomiting in Plastic Surgery||Yeditepe University Hospital|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|65 Years|No|||March 2015|March 2, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382146||25972|
NCT02380144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-2013-097|Bioavailability of Carotenoids and Flavonoids From Fresh Oranges and Orange Juice.|Bioavailability of Carotenoids and Flavonoids From Fresh Oranges and Orange Juice.||University of Hohenheim|No|Active, not recruiting|January 2014|July 2016|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|23 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380144||26126|
NCT02458443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNewEngland|Isometric Handgrip Exercise for Blood Pressure Management|Cardiovascular Response to Isometric Resistance Training in People With Hypertension for Blood Pressure Management||University of New England|No|Not yet recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02458443||20115|
NCT02386891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X140206006|Influence of Ambient Temperature on Food Intake Through a Randomized Control Trial in an Office Setting|Influence of Ambient Temperature on Food Intake Through a Randomized Control Trial in an Office Setting||University of Alabama at Birmingham|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|20|||Both|19 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386891||25607|
NCT02380534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-20140023880|Use of Apheretic Technologies in Cardiovascular Disease|Use of H.E.L.P. Apheresis in Patients With High Cardiovascular Disease Lp(a)-Related||University of Pavia|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|70 Years|No|||February 2015|February 27, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380534||26096|
NCT02382692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_27_02_2015|Cerebrospinal Fluid Rhinorrhea After Functional Endoscopic Sinus Surgery|AUFTRETEN VON OKKULTEM ASYMPTOMATISCHEM LIQUORVERLUST NACH NEBENHÖHLENOPERATIONEN EINE PROSPEKTIVE KOHORTENSTUDIE||University of Zurich||Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with indication to a sinus intervention without planned opening of the skull base|December 2015|December 1, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382692||25930|
NCT02392858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01023-44|Severe Influenza Cohort|ANTIGRIPPE:" Identification, Chez Les Patients hospitalisés Pour Une Infection Respiratoire Grippale sévère, d'un Marqueur Biologique prédictif de l'évolution Vers un Tableau de détresse Respiratoire nécessitant Des Soins Lourds de réanimation."|ANTIGRIPPE|Hospices Civils de Lyon|No|Recruiting|January 2015|||March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|N/A|No|||March 2015|March 19, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02392858||25149|
NCT02392871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZMTG 02.14|Radiotherapy & Combi in Metastatic Melanoma|An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients With Unresectable (Stage IIIc) and Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma|CombiRT|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02392871||25148|
NCT02450019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/INT/2015|Protective Ventilation in Neurosurgery, a Pilot Study|Protective Ventilation in Neurosurgery, a Pilot Study|NeuroVentOR|IRCCS San Raffaele|Yes|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02450019||20762|
NCT02458287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481046|Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia|A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia|SPIRE-AI|Pfizer|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|299|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458287||20127|
NCT02384980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.12|Saving Life and Limb: FES for the Elderly With PAD|Saving Life and Limb: Functional Electrical Stimulation for the Elderly With Peripheral Artery Disease||MultiCare Health System Research Institute|Yes|Recruiting|September 2014|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|85 Years|No|||October 2015|October 1, 2015|November 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02384980||25754|
NCT02384993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1434|aeRobic Exercise and Cognitive Health|Aerobic Exercise for Alzheimer's Disease Prevention in At-Risk Middle-Aged Adults|REACH|University of Wisconsin, Madison|No|Enrolling by invitation|January 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02384993||25753|
NCT02379494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC#5031|First Trimester Prediction of Preeclampsia and Fetal Growth Restriction|First Trimester Prediction of Preeclampsia and Fetal Growth Restriction Using Uterine Artery Doppler, Maternal Blood Pressure, Maternal Characteristics, Placental Volume and Maternal Serum Factors||Fetal Medicine Foundation|Yes|Recruiting|March 2013|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples Without DNA|A 5cc maternal blood sample will be obtained through standard blood draw. The blood will      first be transferred onto a dry blood requisition form card. The blood sample will be      refrigerated and the serum and dried blood spot samples will be sent to Perkin Elmer      Laboratories (see attachment C for collection protocols). The maternal serum levels of      PAPP-A, PLGF, AFP, and free β hCG will be measured according to a protocol established by      Perkin Elmer Laboratories.|Female|18 Years|50 Years|No|Probability Sample|All pregnant patients during their first trimester|February 2016|February 15, 2016|February 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02379494||26176|
NCT02379507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECI1200|DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study|DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study||Medicus Research, LLC|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|March 4, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02379507||26175|
NCT02393404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27100614|Functional Movement-power Training for Children With Developmental Coordination Disorder: A Randomised Controlled Trial|Enhancing Neuromuscular Performance and Central Nervous System Plasticity Through Functional Movement-power Training to Improve Balance Strategies in Children With Developmental Coordination Disorder: A Randomised Controlled Trial||The University of Hong Kong|Yes|Active, not recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|87|||Both|6 Years|10 Years|No|||March 2015|March 18, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02393404||25107|
NCT02393417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFW-2D|Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)||Nielsen BioSciences, Inc.|No|Recruiting|February 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393417||25106|
NCT02450266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy|Prospective Multicenter, Randomized Study Comparing the Diagnostic Efficacy of a Targeted MRI/Ultrasound Fusion-guided Prostate Biopsy Versus a Systematic Transrectal Ultrasound-guided Biopsy in Men With at Least on Negative Prostate Biopsy|PROFUSE|Heinrich-Heine University, Duesseldorf|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|586|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450266||20743|
NCT02450500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SW/1047|Prohealth@Home: A Feasibility Study Investigating the Use of a Lifestyle App in People at Risk of Type 2 Diabetes|Prohealth@Home: A Feasibility Study Investigating the Application of a Web Based Lifestyle App to Improve Glycaemic Control by Changing Dietary and Activity Behaviours in Individuals at High Risk of Type 2 Diabetes||University of Plymouth|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02450500||20725|
NCT02376686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2013-0544|Music Intervention in the Treatment of Sleep Disorders for Depressed Patients|Musik Als Nicht-pharmakologische Intervention Zur Behandlung Von Schlafstörungen Bei Patienten Mit Depressiven Erkrankungen||Sanatorium Kilchberg AG|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2015|February 25, 2015|August 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02376686||26392|
NCT02384031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1083/REK nord|Post-dural Puncture Headache - Needles and Biomarkers in CSF|Quincke vs. Sprotte and Post-dural Puncture Headache - a Randomised Controlled Trial||Nordlandssykehuset HF|No|Recruiting|February 2012|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02384031||25827|
NCT02638987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0740|EMG Activity Before, During and After Dry Needling|EMG Activity, Muscle Tone, Elasticity and Stiffness of the Upper Trapezius Before, During and After Dry Needling||University Ghent|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Female|25 Years|55 Years|No|||March 2016|March 1, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02638987||6253|
NCT02628158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye019|Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane|Correlation of Postoperative Vision and Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane||Kyorin University|No|Completed|April 2013|October 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|91|||Both|20 Years|90 Years|No|Non-Probability Sample|The patients with epiretinal membrane who underwent vitrectomy with epiretinal membrane        and internal limiting membrane removal|December 2015|December 8, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02628158||7084|
NCT02639273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160037|Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation|Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2015|July 2020|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||November 2015|December 23, 2015|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639273||6231|
NCT02639286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160038|Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension|A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy With an Open-Label Extension||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|February 27, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02639286||6230|
NCT02634684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH059803-15|Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis|Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis||University of California, San Diego|No|Recruiting|July 2014|December 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02634684||6583|
NCT02378012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12207|iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant|Project BUCKiPAD: The Evaluation of an iPAD Distribution Program on Anxiety and Depression in Bone and Marrow Transplant Patients|BUCKiPAD|Ohio State University Comprehensive Cancer Center|Yes|Recruiting|March 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|124|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378012||26290|
NCT02636257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-5010|Comparative Study of Two Operations for Lacrimal Duct Obstruction|Comparative Study of Reverse Imbeding Silicone Tube of Spherical Cephalon Under Nasal Endoscopy With Dacryocystorhinostomy for Lacrimal Duct Obstruction|CSOTOFLDO|Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02636257||6463|
NCT02641535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2689-OF-CTIL|Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall|Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall||Sheba Medical Center|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02641535||6057|
NCT02640599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01231|Stationary Bike Study|The Effect of Vestibular and Exertion Training on Gait, Balance and Dizziness in Individuals With Concussion||New York University School of Medicine|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02640599||6129|
NCT02640612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.3|Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis|Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab||Boehringer Ingelheim||Recruiting|January 2016|October 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|December 18, 2015||||No||https://clinicaltrials.gov/show/NCT02640612||6128|
NCT02637934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18815|Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT|Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637934||6334|
NCT02637973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EmLiFa001|Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes|Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes|EmLiFa|German Diabetes Center|No|Recruiting|December 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|75 Years|No|||December 2015|December 20, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637973||6331|
NCT02632799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCMCHP012|Airway Pressure During Nasal High Flow and CPAP in Neonates|Airway Pressure During Nasal High Flow and CPAP in Neonates||Research Center of Maternal and Child Health Protection, Armenia|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|10|||Both|N/A|3 Days|Accepts Healthy Volunteers|||September 2015|December 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632799||6728|
NCT02632812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 025/14|Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo|Double-blind Trial on the Gastrointestinal Integrity Evaluation After Daily Naproxen 1100 mg + Rebamipide 200mg for 7 Days Versus Naproxen 1100mg + Placebo for 7 Days||Biolab Sanus Farmaceutica|No|Completed|October 2014|||December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02632812||6727|
NCT02377947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIDJ001|A Retrospective Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) (The RETRO Study)|A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE)||Abbott|No|Not yet recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Retrospective study - data charts of the cirrhotic patients having grade III and IV and        who were administered lactulose enema will be reviewed.|December 2015|December 14, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02377947||26295|
NCT02382510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRN-157-102|Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Two-Way Cross-Over, Phase 2a Study to Evaluate the Safety and Bronchodilator Activity of TRN-157 in Stable Mild and Moderate Asthmatics||Theron Pharmaceuticals, Inc.||Recruiting|February 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|February 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382510||25944|
NCT02460042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1309|Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW)|CONSEQUENT ALL COMERS Clinical PMCF on Peripheral Arteries Treated With SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population|CONSEQUENT|B. Braun Melsungen AG|Yes|Recruiting|May 2015|August 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients with peripheral artery occlusive disease (PAOD)|December 2015|December 7, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460042||19992|
NCT02447419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-029|Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors|||Samsung Medical Center|No|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||March 2016|March 1, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447419||20962|
NCT02385799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|663866|A Trial of Sertraline in Young Children With Autism Spectrum Disorder|A Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder|Sert2|University of California, Davis|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|24 Months|72 Months|No|||January 2016|January 26, 2016|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385799||25691|
NCT02385617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFSJ 0026|Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer|Food Intake and Gut Hormone Release in Patients in Cancer Remission Who Have Undergone Upper Gastrointestinal Surgery||St. James's Hospital, Ireland|No|Enrolling by invitation|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385617||25705|
NCT02391038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26004|MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C|A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)||Millennium Pharmaceuticals, Inc.|No|Recruiting|January 2015|October 2018|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02391038||25288|
NCT02382653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2970/12/14|Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain|The Analgesic Efficacy of Oral Piroxicam Versus Buccal Fentanyl in Cancer Breakthrough Pain in Patients With Bone Metastases||Tanta University|No|Completed|December 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|60 Years|No|||April 2015|April 5, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02382653||25933|
NCT02382666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11-5022-C|A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers|A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers||Tesaro, Inc.|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382666||25932|
NCT02380872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ege Uni School of Dentistry|Cytokine and MMP Levels in Gingival Crevicular Fluid in the Treatment of Localized Gingival Recessions|Cytokine (IL-1ß) and Matrix Metalloproteinase (MMP) Levels in Gingival Crevicular Fluid After Use of Platelet Rich Fibrin or Connective Tissue Graft in the Treatment of Localized Gingival Recessions||Ege University|No|Completed|October 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02380872||26070|
NCT02383602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Community-based Test and Treat|Study to Evaluate the Feasibility of Community-based Test and Treat Strategies Among Men Who Have Sex With Men and Transgender Women to Increase the Uptake of HIV Testing and Treatment Services in Thailand|Thai Red Cross AIDS Research Centre (TRC-ARC)||Thai Red Cross AIDS Research Centre|Yes|Recruiting|August 2014|||August 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|6000|||Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|1. SWING Drop-In Center, Bangkok, Thailand          2. RSAT Drop-In Center, Bangkok, Thailand          3. Chiang Mai Buddy Station, Northern Thailand          4. SWING Drop-In Center, Pattaya, Chonburi, Eastern Thailand          5. Sisters Drop-In Center, Pattaya, Chonburi, Eastern Thailand          6. RSAT Drop-In Center, Songkhla, Southern Thailand|November 2015|November 2, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02383602|18 Months|25860|
NCT02448485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASS-2|High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis (Tyrolean Aortic Stenosis Study-2)|High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis|TASS-2|Medical University Innsbruck|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1100|||Both|N/A|N/A|No|Non-Probability Sample|One patient cohort consists of patients with severe symptomatic aortic stenosis admitted        for planned valve operation since 2010, when our institution started to routinely analyse        hsTnT plasma levels.        The other patient cohort consists of asymptomatic patients with aortic stenosis diagnosed        at our department and treated conservatively.|July 2015|July 12, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448485||20880|
NCT02379715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-327|Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane|Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane||Ajou University School of Medicine||Completed|December 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|26|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379715||26159|
NCT02385500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007|Fesoterodine on Urgency Episodes in Parkinson's Disease Population|Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Not yet recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||March 2015|March 17, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02385500||25714|
NCT02389361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTES - ZIH|Comparison of Oral Zaldiar With Intravenous Paracetamol and Tramadol|ZIH Study : Comparison of Oral Zaldiar (Combination of Paracetamol and Tramadol) With Intravenous Paracetamol and Tramadol for Postoperative Analgesia After Inguinal Hernia Repair||Astes|No|Completed|April 2011|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 18, 2015|February 27, 2015||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT02389361||25417|
NCT02378675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11072|Adipocytokines, Gestational Diabetes Mellitus and Lipid Metabolism|Influence of the Adipocytokines Apelin, Omentin, Resistin and Visfatin on Lipid Metabolism and Gestational Diabetes Mellitus||Medical University of Vienna|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|Samples With DNA|Serum|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|150 pregnant women with diagnosed gestational diabetes mellitus (Study group) and 150        pregnant women with normal oral glucose tolerance test (OGTT).|February 2015|March 3, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378675||26239|
NCT02381392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21283-01|A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED|A Comparison of Accuvein to Standard Intravenous Access in Children 0 to 24 Months of Age in the Pediatric Emergency Department||Los Angeles Biomedical Research Institute|Yes|Recruiting|August 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|N/A|24 Months|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381392||26030|
NCT02381678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Edwards-CN-001|A Retrospective Study to Collect the Data From the Patients Who Had the Perimount Heart Valve Replacement Surgery in China During 2001 to 2007|||Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.||Completed|May 2014|January 2016|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|225|||Both|N/A|N/A|No|Non-Probability Sample|The patients who had the Perimount Heart Valve (Type: 6900P and 2900) Replacement Surgery        during 2001-2007 in Guangdong General Hospital in China|January 2016|January 4, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381678||26008|
NCT02384122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLOCEAN.50514.091.14|Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Small Bowel Angiodysplasias|A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Small Bowel Angiodysplasias|OCEAN|Radboud University|Yes|Recruiting|September 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|45 Years|N/A|No|||December 2015|December 9, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384122||25820|
NCT02444494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-215|Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke|Observational Prospective Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke, Under Conditions of Routine Clinical Practice|PSAS REGISTRY|Ipsen|Yes|Active, not recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from post-stroke arm spasticity and scheduled to receive injection of        Dysport in post stroke upper limb spasticity drug programme.|February 2016|February 26, 2016|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02444494|9 Months|21186|
NCT02378974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-CST-101|Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Cordstem-ST in Patients With Cerebral Infarction|A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction||CHABiotech CO., Ltd|No|Recruiting|February 2015|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|19 Years|80 Years|No|||February 2015|March 31, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02378974||26216|
NCT02379195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM1413|Peginterferon and TIL Therapy for Metastatic Melanoma|T Cell Therapy in Combination With Peginterferon for Patients With Metastatic Melanoma||Herlev Hospital|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379195||26199|
NCT02381925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061739|Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism|Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism||Duke University|No|Withdrawn||December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects will include all patients, aged 18 years or older, who underwent parathyroid        surgery from July 2009 to July 2016.|September 2015|September 17, 2015|March 3, 2015||No|The study never opened due to funding issues|No||https://clinicaltrials.gov/show/NCT02381925|6 Months|25989|
NCT02384330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-188|Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke|Cost Determination Study For Different Botulinum Toxin A Preparations In The Treatment Of Upper Limb Spasticity Post-Stroke In Portugal|P_Dysport_CS|Ipsen|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||3|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital ambulatory patients|November 2015|November 30, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384330||25804|
NCT02384343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050115|Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia|Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia: A Randomized Controlled Trial||St. Justine's Hospital|No|Not yet recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384343||25803|
NCT02386007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW 3101_201|Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients|A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation||Daewon Pharmaceutical Co., Ltd.||Not yet recruiting|July 2015|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|20 Years|75 Years|No|||February 2015|March 5, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02386007||25675|
NCT02386293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611881|Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans|Effectiveness of Avapro in the Treatment of Salt Sensitivity in Both Normotensive and Untreated Hypertensive Obese African Americans: A Randomized Double Blind Placebo Controlled Trial|Avapro3|Georgia Regents University|Yes|Recruiting|September 2014|May 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386293||25653|
NCT02385305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001841|The Effect of Pressure Support Ventilation on Spontaneous Breathing in Anesthetized Subjects|The Effect of Pressure Support Ventilation on Minute Alveolar Ventilation and End-tidal Carbon Dioxide in Anesthetized Spontaneously Breathing Subjects||Massachusetts General Hospital|No|Not yet recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|27|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02385305||25729|
NCT02385318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-14-019|To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis|||Perrigo Company|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|515|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02385318||25728|
NCT02377934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2011-02|Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study|Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study|MRI-HART|University Medical Center Groningen|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with stage III NSCLC|September 2015|September 14, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02377934||26296|
NCT02380729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2_107_14|Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality|Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality|MENDEL|Charite University, Berlin, Germany|No|Recruiting|January 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|DNA extracted from peripheral blood cells of the index patient and of his/her parents.|Both|N/A|18 Years|No|Non-Probability Sample|Index patients: Children (age newborn to 18 years) who present with a suspected genetic        disorder        Parents: biological mother and father of each index case.|March 2015|March 2, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02380729||26081|
NCT02380937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104/14-ff|Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking|Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking: Pilot Study Using a Combination Imricor and Philips Interventional System||Heartcenter Leipzig GmbH|No|Terminated|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||November 2015|November 14, 2015|February 16, 2015||No|The study was terminated prematurely on 05May 2015 because of the unavailability of study    devices.|No||https://clinicaltrials.gov/show/NCT02380937||26065|
NCT02386306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-100-02|Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease||GliaCure, Inc.||Completed|February 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|55 Years|85 Years|No|||July 2015|February 1, 2016|February 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02386306||25652|
NCT02386319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melatonin1234|Analgesic and Anxiolytic Effects of Melatonin: a Randomized, Double-blinded, Placebo-controlled Clinical Study|Analgesic and Anxiolytic Effects of Melatonin: a Randomized, Double-blinded, Placebo-controlled Clinical Study||Herlev Hospital|Yes|Not yet recruiting|August 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Female|N/A|N/A|No|||February 2016|February 17, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02386319||25651|
NCT02388789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB_CMTS|Foot Skin Temperature and Balance Control|Effects of Changes in Foot Skin Temperature on Plantar-surface Mechanoreceptor Sensitivity and Balance Control||Wilfrid Laurier University|No|Completed|February 2015|April 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02388789||25461|
NCT02391545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-19|A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)|A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)||Infinity Pharmaceuticals, Inc.|No|Recruiting|December 2014|January 2020|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391545||25249|
NCT02380950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 13/046|Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass|||eSwiss Medical & Surgical Center||Completed|June 2013|||September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02380950||26064|
NCT02388607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5972|Sustained Attention Abilities in Schizophrenia|Sustained Attention Abilities, Attentional Resources and Cognitive Control Mechanisms in Schizophrenia|ACCRAS|University Hospital, Strasbourg, France|No|Not yet recruiting|March 2015|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|40 schizophrenic patients versus 40 healthy subjects matched|March 2015|March 9, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02388607||25475|
NCT02388867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER.ALL.2014.10.A|Matrix Metalloproteinases in Patients With Critical Limb Ischemia Undergoing Surgical Revascularization|Predictive Role of Matrix Metalloproteinases for the Outcome of Surgical Revascularization in Patients With Critical Limb Ischemia|ROMAMETA|University of Cantanzaro|Yes|Completed|January 2012|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388867||25455|
NCT02382484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute FIM Study - China|Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients|Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients: An Acute Study in Patients Undergoing an Electrophysiology Study or Pacemaker Implant||BackBeat Medical Inc|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02382484||25946|
NCT02381197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4004-B|Longitudinal Study: Diagnosis and Prediction of Pre-Eclampsia by Using Congo Red Dot Test in Bangladesh and Mexico|Diagnosis and Prediction of Preeclampsia: A Longitudinal Study of the Clinical Utility of Congo Red Dot Test in Bangladesh and Mexico||Gynuity Health Projects|Yes|Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|urine samples collected|Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|In Bangladesh, pregnant women will be identified during monthly home visits of Community        Health Workers (CHW) affiliated with Matlab in Chandpur and asked to participate. In        Mexico, women will be identified at routine antenatal appointments at Hospital        Materno-Infantil Inguarán.|February 2016|February 11, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02381197||26045|
NCT02386384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01-FB-0004|TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure|TNFα (Tumor Necrosis Factor Alpha) and MFG-E8 (Milk Fat Globule-Epidermal Growth Factor 8): Novel Biomarkers to Predict Implantation Failure||Eastern Virginia Medical School|No|Enrolling by invitation|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Female|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|women 21-35 years old attending an infertility clinic in an academic center|March 2015|March 10, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02386384||25646|
NCT02381600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ק096/2014|An Evaluation of the Effect of Vitamin D Supplementation on the Cognitive Function of Older Subjects With Low Levels of This Vitamin|An Evaluation of the Effects of Vitamin D Supplementation on Specific Cognitive Functions and Depressive Symptoms of Older Subjects With Low Levels of This Vitamin||Meir Medical Center|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|65 Years|N/A|No|||November 2015|November 16, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02381600||26014|
NCT02381613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP U-12-001|Postprandial Differences After Herring and Beef|Postprandial Plasma Nutrient Differences Between Baked Beef, Baked Herring and Pickled Herring.||Chalmers University of Technology|No|Completed|January 2012|March 2015|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|17|||Male|35 Years|67 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02381613||26013|
NCT02391753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVU1/13-1|Evaluation of Labor Related Pelvic Floor Changes: A 3D Transperineal Ultrasound Study|Optimal Time For Evaluation of Labor Related Pelvic Floor Changes: A 3D Transperineal Ultrasound Study|OTELaPFC|Bezmialem Vakif University|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|primiparous women who vaginally delivered singleton babies that eligible for trial were        examined within 36 h of delivery|March 2015|March 12, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391753||25234|
NCT02377453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-5783B|A Longitudinal Study of Function and Participation in Patients With Stroke|A Longitudinal Study of Function and Participation in Patients With Stroke: An Integrated Brain Imaging and Biomechanical Analysis||Chang Gung Memorial Hospital|Yes|Recruiting|April 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control and experimental groups|February 2016|February 15, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377453||26333|
NCT02378909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UManchester|Wound Healing Process in Diabetic Neuropathy and Diabetic Neuroischemia|Diabetic Wound Healing and Its Relationship to Vascular Circulation.|Geko|University of Manchester|Yes|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|85 Years|No|||March 2015|March 24, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02378909||26221|
NCT02383134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TunisianMH|Maximal Distance for Successful Supraclavicular Block|The Maximum Effective Needle-to-Nerve Distance for Anesthetic Ultrasound-Guided Supraclavicular Brachial Plexus Block||Tunisian Military Hospital||Not yet recruiting|May 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing upper limb surgery surgery (hand, forearm, elbow)|March 2015|May 12, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02383134||25896|
NCT02381873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NE/1216|Determinants of Early Functional Outcome After Reconstructive Surgery|Exploratory Study of Determinants of Early Functional Outcome Following Reconstructive Knee Surgery||Queen Margaret University|No|Recruiting|February 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|blood serum samples|Both|18 Years|N/A|No|Non-Probability Sample|Males and females over the age of 18, diagnosed with severe osteoarthritis and awaiting        primary total knee arthroplasty (TKA).|October 2015|October 15, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02381873||25993|
NCT02379026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueenMU|Lifestyle Modifications for the Treatment of Sarcopenic Obesity|Improving Body Composition, Strength, Function and Health Related Quality of Life in Older Individuals With Sarcopenic Obesity Through Lifestyle Modifications||Queen Margaret University|No|Recruiting|October 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02379026||26212|
NCT02379273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-5563-HYB-PMA|Nucleus Hybrid L24 Extended Duration Post Approval Study|The Nucleus Hybrid L24 Implant System: Extended Duration Post Approval Study|HED|Cochlear|No|Enrolling by invitation|January 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379273||26193|
NCT02381444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-322|Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy|Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany, Austria and Switzerland - BALANCE|BALANCE|AbbVie|No|Recruiting|April 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|266|||Both|18 Years|99 Years|No|Non-Probability Sample|Advanced Parkinson Disease|January 2016|January 12, 2016|March 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381444||26026|
NCT02388724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438_303|Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Patients With Erosive Esophagitis|A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis||Takeda|No|Recruiting|March 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388724||25466|
NCT02388802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Human Clinical Trial of Uterine Transplantation in the United Kingdom|The First Human Clinical Trial of Uterine Transplantation in the United Kingdom||Womb Transplant UK|Yes|Not yet recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|36 Years|No|||March 2015|March 9, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02388802||25460|
NCT02386592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33473|Prevention of Nosocomial Bacteremia Among Zambian Neonates|Prevention of Nosocomial Bacteremia and Mortality Among Neonates at a Tertiary Referral Center in Zambia||Boston University|Yes|Recruiting|September 2015|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|11400|||Both|N/A|28 Days|No|||October 2015|October 6, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02386592||25630|
NCT02386605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1851-W|Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers|Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers||VA Office of Research and Development|No|Not yet recruiting|March 2016|January 2020|Anticipated|June 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|No|||March 2016|March 24, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02386605||25629|
NCT02384577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFS-AS-40074|Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment|Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp® SPIROMAX® and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment||Teva Pharmaceutical Industries|No|Active, not recruiting|July 2014|December 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult asthma or COPD-patients|March 2016|March 1, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02384577||25785|
NCT02444962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC142065|BioComp Implants in Anaplastology - Pilot Study|Safe and Easy Application of BioComp Implants for Prosthetic Reconstruction of Craniofacial Defects||Maastricht University Medical Center|Yes|Not yet recruiting|June 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||May 2015|May 12, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02444962||21150|
NCT02380547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5957|Sonographic Evaluation of Diaphragmatic Function in Critical Care Patients With Use of Non Invasive Ventilation|Sonographic Evaluation of Diaphragmatic Function in Critical Care Patients With Use of Non Invasive Ventilation|ECHODIA|University Hospital, Strasbourg, France|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Critical care patients (surgical or medical)|November 2015|November 13, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02380547||26095|
NCT02384681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01904-43|Evaluation of Auditory Fatigue in Medical Regulation Assistants|Effects of Auditory Fatigue in Medical Regulation Assistants Working With Headset: Objective Measures|EchoSam|Central Hospital, Nancy, France|Yes|Not yet recruiting|March 2015|March 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Medical regulation assistants working with or without headset|March 2015|March 9, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02384681||25777|
NCT02387099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 86|Dose EScalation Induction of EvERolimus|A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer|Desiree|German Breast Group|Yes|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02387099||25591|
NCT02387112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZHK VAD Study|Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation|Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation||German Heart Institute|Yes|Recruiting|July 2015|December 2022|Anticipated|August 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|60 Years|No|||March 2015|August 11, 2015|June 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02387112||25590|
NCT02598453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18058|PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia|An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate||Hoffmann-La Roche||Completed|January 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|545|||Female|N/A|N/A|No|||March 2016|March 1, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598453||9363|
NCT02602327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tas-102 with Radioembolization|Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases|Phase I Study of Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases||University of California, San Francisco|Yes|Not yet recruiting|September 2016|September 2020|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02602327||9065|
NCT02600676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020891|Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis|Randomized, Double Blind, Placebo Controlled Trial of Sacral Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis||University of Aarhus|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|6 Years|14 Years|No|||September 2015|November 6, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600676||9192|
NCT02619175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|loe150021ctil|Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals|Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals||Loewenstein Hospital||Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 29, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619175||7775|
NCT02606942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-2079-15-SMC|Prevalence of Chondromalacia Patella Among Adolescent Dancers - Correlation Between Symptoms and Sonography Findings|Prevalence of Chondromalacia Patella Among Adolescent Dancers - Correlation Between Symptoms and Sonography Findings||Sheba Medical Center|No|Not yet recruiting|January 2016|December 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|||Female|14 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|young adolescent female athletes or dancers|January 2016|January 21, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02606942||8713|
NCT02596672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.30|Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study.|Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study.||Queen's University, Belfast|No|Recruiting|September 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596672||9500|
NCT02596737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0247|WittyFit - Live Your Work Differently|WittyFit - Live Your Work Differently|WittyFit|University Hospital, Clermont-Ferrand||Recruiting|May 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02596737||9495|
NCT02596750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252160|The Effect of Microneedle Pretreatment on Topical Anesthesia|The Effect of Microneedle Pretreatment on Topical Anesthesia||University of California, Davis|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|21|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02596750||9494|
NCT02619487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes|The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes|Edu4U|University of Louisville|No|Enrolling by invitation|July 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|178|||Both|8 Years|18 Years|No|||March 2015|November 30, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02619487||7751|
NCT02378519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHSAM3_TAILORED_WEB_SSED|Interactive Web-based Program and CBT-coaching With Physiotherapy for Patients With Chronic Musculoskeletal Pain|Individualised Interactive Web-based Self-help Program and CBT-coaching in Combination With Physiotherapy for Patients With Persistent Musculoskeletal Pain||Luleå Tekniska Universitet|No|Recruiting|September 2014|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|63 Years|No|||March 2015|March 6, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02378519||26251|
NCT02388009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2A-1|Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a|Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers||LimmaTech Biologics AG|No|Completed|February 2015|September 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388009||25521|
NCT02461017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0164|Endotracheal Tube Audible Leak Test|Endotracheal Tube Audible Leak Test: What is the Accuracy?||University of Mississippi Medical Center|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|86|||Both|1 Month|8 Years|No|Non-Probability Sample|Children aged between 1 month (post-natal) and 8 years scheduled for ENT surgery requiring        general anesthesia with an endotracheal tube.|October 2015|October 16, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461017||19917|
NCT02447133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topcon 001-2015|TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro|TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro||Topcon Medical Systems, Inc.|No|Completed|May 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447133||20983|
NCT02386566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHE-TYS-12-10341|Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab|A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab|PROTYS|Biogen|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|88|||Both|18 Years|65 Years|No|Probability Sample|Participants diagnosed with relapsing remitting multiple sclerosis (RRMS) that have been        prescribed natalizumab under standard clinical care.|December 2015|December 10, 2015|February 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02386566||25632|
NCT02384070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20095|Simplified Anti-Thrombotic Therapy for FFR|Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve|SMART-FFR|Odessa Heart Institute|Yes|Completed|January 2009|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Actual|300|||Both|N/A|N/A|No|||March 2015|March 4, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02384070||25824|
NCT02384135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-191|Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study|Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study|ADJUST-DVT|University Hospital, Geneva|No|Not yet recruiting|March 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|3300|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02384135||25819|
NCT02384148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-015|Study of Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.|Measure and Comparison of Molecular Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.||University Hospital, Geneva||Active, not recruiting|June 2011|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|One hundred normolipidemic healthy individuals, one hundred T2D subjects divided into two        sub-groups (T2D non-obese and T2D obese) and one hundred obese non diabetic patients will        be included.|December 2015|December 1, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02384148||25818|
NCT02389465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH098260-02|Late-Life Stress and Inflammation|Stress and Inflammation in the Pathophysiology of Late Life Depression|S&I|University of Pennsylvania|No|Recruiting|August 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02389465||25409|
NCT02392572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0731|ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS)|Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2022|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|March 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392572||25171|
NCT02392585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATAUNİ23|Single or Triple Uterine Tourniquet at Myomectomy|Triple Tourniquet vs. Single Tourniquet to Reduce Haemorrhage During Myomectomy: a Prospective Randomised Controlled Trial||Ataturk University|No|Recruiting|March 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|48 Years|No|||March 2015|March 19, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392585||25170|
NCT02385357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Puleva|Effect of a Protein-enriched Drink on Muscle Function|Effect of a Protein-enriched Drink on Muscle Function Recovery Following an Acute High Intensity Exercise Bout|SPORTEUS|Puleva Biotech|Yes|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02385357||25725|
NCT02599168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/04/15/807|Effect of Dexmedetomidine on Propofol Requirement During Anesthesia|The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study||Sir Ganga Ram Hospital|Yes|Recruiting|December 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|20 Years|65 Years|No|||December 2015|December 11, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02599168||9308|
NCT02605005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-1:5484-3/2013.|The Impact of a Beach Chair Position During Shoulder Arthroscopy on Regional Cerebral Oxygen Saturation : Comparison of Interscalene Block and General Anesthesia|||Osijek University Hospital|No|Completed|December 2013|||January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Probability Sample|patients for elective arthroscopy of the shoulder|November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605005||8861|
NCT02606877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.229|A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination|Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study Followed by Nintedanib Open Label Treatment)||Boehringer Ingelheim||Not yet recruiting|April 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|40 Years|N/A|No|||March 2016|March 21, 2016|November 16, 2015||||No||https://clinicaltrials.gov/show/NCT02606877||8718|
NCT02609139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7921004|Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects|A Phase 1, Open Label, Single‑Dose, Within Cohort Randomized, 2‑Way Crossover Study To Evaluate The Pharmacokinetics Of A Modified Release Formulation Of Pf‑06650833 Under Fasting And Fed Conditions In Healthy Adult Subjects||Pfizer|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609139||8545|
NCT02608645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPHESUS trial|A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)|Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)|EPHESUS|Muğla Sıtkı Koçman University|No|Not yet recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving lipid-lowering therapy within the secondary prevention group in Turkey|November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608645||8583|
NCT02604056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHLTCAPDP|Pragmatic Cluster Trial for Nursing Home Antipsychotic Prescribing|Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes||Women's College Hospital|No|Active, not recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|N/A|N/A|No|||November 2015|November 11, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02604056||8934|
NCT02605343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP0006|Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures|Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures Compared to Historical Data||AltheaDx|No|Recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the site for a prep-op visit prior to undergoing a major bowel        surgery, major urologic procedure or major ventral hernia repair. The pre-op visit must        occur at least 3 days prior to the surgical procedure.|November 2015|November 13, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605343||8835|
NCT02605356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17451|Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma|A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma||Bayer|Yes|Withdrawn|June 2016|December 2021|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605356||8834|
NCT02597556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16EN|The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam||Oxford University Clinical Research Unit, Vietnam|Yes|Recruiting|February 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||November 2015|February 23, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597556||9432|
NCT02597569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177-2015|Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment|Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment: An Evidence-based, Multi-faceted, Knowledge Translation Approach|CO-OP_KT|Sunnybrook Health Sciences Centre|No|Not yet recruiting|December 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|34|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to an inpatient rehabilitation unit with a primary diagnosis of stroke        and have a cognitive impairment.|November 2015|November 5, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02597569||9431|
NCT02595216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF20161|Treatment With the Profound System for Submental Laxity|Clinical Study to Evaluate the Performance of Profound System With Nominal Angle of 75° to the Skin's Surface for Submental Laxity||Syneron Medical|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595216||9612|
NCT02594995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJUNeuro|The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion|The Impact of NBP on the Collateral Circulation in Acute Acute Internal Carotid Artery(ICA)/Middle Cerebral Artery(M1) Occlusion|INCIMO|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|568|||Both|18 Years|N/A|No|||August 2015|October 30, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594995||9629|
NCT02607774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2110|Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis|An Open-label, Single Sequence Crossover, Study Investigating the Influence of Secukinumab Treatment on the Pharmacokinetics of Midazolam as a CYP3A4 Substrate in Patients With Moderate to Severe Plaque Psoriasis||Novartis|No|Recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607774||8650|
NCT02550262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 10 ml of Bupivacaine 0.0625% Plus Fentanyl 2 mcg/ml.||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02550262||13066|
NCT02600260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37431414.9.0000.0068|Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial|Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial||University of Sao Paulo General Hospital|No|Recruiting|December 2013|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|9000|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02600260||9224|
NCT02604407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP465-306|Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)|A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)||Shire||Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|258|||Both|18 Years|55 Years|No|||December 2015|December 8, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604407||8907|
NCT02604511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-359|Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing|Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing||Dana-Farber Cancer Institute|Yes|Recruiting|January 2016|February 2023|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604511||8899|
NCT02595918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01913|Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer|A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-metastatic, Renal Cell Carcinoma||National Cancer Institute (NCI)|Yes|Not yet recruiting|May 2016|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595918||9558|
NCT02608762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-5729A3|Neurobehavioral Outcomes and Quality of Life in Pediatric Patients With Brain or Head/Neck Tumors Receiving Proton or Photon Radiotherapy|||Chang Gung Memorial Hospital||Recruiting|September 2014|||August 2017|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|72|||Both|1 Month|18 Years|No|Non-Probability Sample|Pediatric/adolescent patients, who are diagnosed with brain tumors or head/neck cancers,        were prospectively recruited.|September 2014|November 17, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02608762||8574|
NCT02546557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1421|Optilene® Suture for Coronary Artery Bypass Graft Surgery|Assessment of the Performance of a New Suture Material (Optilene® Suture) for Coronary Artery Bypass Graft Surgery. An Observational Post CE-mark Study|OPTICABG|Aesculap AG|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|25 Years|N/A|No|Non-Probability Sample|adult patients|January 2016|January 29, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02546557||13351|
NCT02604615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|capecitabine-oxaliplatin|The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy|Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial|DCOECRT|The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|75 Years|No|||January 2016|January 16, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604615||8891|
NCT02609165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2318561|Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema|Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial|NEMO|Ospedale San Raffaele|No|Active, not recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02609165||8543|
NCT02609178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-REV-2015039|Basic Study of Fabricating Biomorphic Crowns|Basic Study of Fabricating Biomorphic Crowns||Fourth Military Medical University|Yes|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609178||8542|
NCT02598414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICG-COLORECTAL|The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery|The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial||Acibadem University|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598414||9366|
NCT02606526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-114|The Efficacy of Deferring BCG Vaccination to 14 Weeks of Age in HIV-1 Exposed Infants in Uganda|A Randomised Controlled Trial of the Efficacy of Deferring BCG Vaccination to 14 Weeks of Age in HIV-1 Exposed Infants in Uganda||Makerere University|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2192|||Both|N/A|1 Day|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606526||8744|
NCT02597205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014HHSC0016|The Adherence and Knowledge Exchange Heart and Stroke Medicines Study|TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study|TAKEmeds|Duke Kunshan University|No|Active, not recruiting|May 2015|June 2016|Anticipated|December 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|190|||Both|18 Years|N/A|No|||November 2015|January 20, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02597205||9459|
NCT02601651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC/520/015|Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty|Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty||B.P. Koirala Institute of Health Sciences|Yes|Recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|65 Years|No|||July 2015|November 24, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601651||9117|
NCT02601703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLK-1501|To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product Protopic® (Tacrolimus) Ointment, 0.1% (Astellas Pharma US, Inc.) in the Treatment of Moderate to Severe Atopic Dermatitis (AD)||Glenmark Pharmaceuticals Ltd. India|No|Recruiting|August 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1071|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601703||9113|
NCT02601716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC.2015.0009|PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults|Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults||Sanaria Inc.|Yes|Recruiting|January 2016|June 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601716||9112|
NCT02608359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107096|A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer|A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga (Abiraterone Acetate Tablets 250 mg) in Indian Patients With Metastatic, Castration Resistant Prostate Cancer as Per Locally Approved Prescribing Information||Johnson & Johnson Private Limited|No|Not yet recruiting|April 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|103|||Male|18 Years|N/A|No|Non-Probability Sample|Indian participants with metastatic, castration-resistant prostate cancer will be enrolled        in this study.|March 2016|March 18, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608359||8605|
NCT02606630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-561|[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis|A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis||AbbVie|No|Suspended|October 2015|April 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|November 13, 2015|No|Yes|Awaiting data evaluation|No||https://clinicaltrials.gov/show/NCT02606630||8736|
NCT02597907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2014-05-016|Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant|||Kyungpook National University|No|Completed|July 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Female|18 Years|65 Years|No|||November 2015|November 4, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02597907||9405|
NCT02602119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822153|Intraoperative Imaging of Pulmonary Nodules by OTL38|Intraoperative Imaging of Pulmonary Nodules by OTL38||University of Pennsylvania|Yes|Recruiting|May 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602119||9081|
NCT02611232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiraAAB18-30|Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults|Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults||University of Oulu|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|42|||Both|18 Years|30 Years|No|||November 2015|November 20, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611232||8385|
NCT02607657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 055/15|Pharmacokinetics of Eplerenone Tablet|Phase I Trial Comparing Eplerenone Pharmacokinetics (Tablet) in Different Dosages: 25mg, 50mg,100 mg Per Day and 100 mg (One 50 mg Tablet Every 12 Hours).||Biolab Sanus Farmaceutica|No|Not yet recruiting|May 2016|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|March 7, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607657||8659|
NCT02608450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-03-01/25|A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)|A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris||Cassiopea SpA|No|Recruiting|November 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|9 Years|N/A|No|||January 2016|January 20, 2016|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608450||8598|
NCT02608463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204737|Neuropathic Pain in Pregnancy|Neuropathic Pain in Pregnancy||University of Arkansas|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|130|||Female|18 Years|45 Years|No|||November 2015|November 16, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608463||8597|
NCT02598219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENTIRAD-1502|Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.|Randomized Study Comparing Sentinel Node (SN) Policy to Current French Initial Staging Protocols in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence|SENTIRAD|Centre Oscar Lambret|Yes|Recruiting|November 2015|April 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02598219||9381|
NCT02598232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-DL-14-001|The Efficacy and Safety of the 1,414 nm Nd:YAG Laser System for Alleviating Back Pain in a Lumbar Disc Patient|A 24-week, Single-center, Open-label, Clinical Study to Evaluate the Efficacy and Safety of the 1,414nm Nd:YAG Laser System Added to PEN to Further Alleviate Back Pain in a Lumbar Herniated Intervertebral Disc Patient||LUTRONIC Corporation|No|Active, not recruiting|October 2014|April 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|19 Years|79 Years|No|||October 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598232||9380|
NCT02607865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4222|Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes|Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes|PIONEER 3|Novo Nordisk A/S|No|Recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1860|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607865||8643|
NCT02598115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS/2014/JMK-01|Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older|Impact of the Implementation of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older|MEDREV|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|May 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|630|||Both|65 Years|N/A|No|||January 2016|January 18, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598115||9389|
NCT02601248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-309-00CH1|Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor|Single Site, Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors||Hutchison Medipharma Limited|No|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02601248||9148|
NCT02601521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000002/MGH|Comparative Effectiveness of Two Tobacco Cessation Interventions for Employees of Partners HealthCare, Inc.|Comparative Effectiveness of Two Tobacco Cessation Interventions for Employees of Partners HealthCare, Inc.|PiHQ|Massachusetts General Hospital|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601521||9127|
NCT02596074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-010|Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN|A Phase 2, Randomized, Double-Blind, Parallel-Group Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With Usual Type Vulvar Intraepithelial Neoplasia||Cutanea Life Sciences, Inc.|No|Recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Female|18 Years|N/A|No|||November 2015|November 24, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02596074||9546|
NCT02606851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1844R00002|Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease|China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease||AstraZeneca|Yes|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|65 Years|No|Non-Probability Sample|The subject population that will be included in the NIS are the consecutive outpatients        between 18 and 65 years old with Gerd Q ≥ 8, who will not have endoscopy within 4 weeks        while gastroenterologists already prescribe PPI as empirical treatment.|March 2016|March 1, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02606851||8720|
NCT02607943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504075MINC|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke: A Multi-center, Randomized Control Study|ICAS|National Taiwan University Hospital|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||November 2015|November 23, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02607943||8637|
NCT02607956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-380-1490|Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults||Gilead Sciences|Yes|Recruiting|November 2015|January 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607956||8636|
NCT02609815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-INTESTINE2015|Initial Combination of Gemigliptin and Metformin on Microbiota Change|Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study)|INTESTINE|Seoul National University Bundang Hospital|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02609815||8493|
NCT02609828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091061|Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Background Opioid Therapy||Pfizer|Yes|Recruiting|October 2015|January 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02609828||8492|
NCT02600299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504-00102|Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment|||National University, Singapore|No|Recruiting|July 2015|March 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Female|21 Years|99 Years|No|||March 2016|March 22, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600299||9221|
NCT02607007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC_31936|The Effect of Dairy and Non-dairy Breakfasts on Satiety and Post-meal Glycemia in Healthy Older Adults|The Effect of Dairy and Non-dairy Breakfasts on Subjective Appetite Ratings, Food Intake, and Post-meal Glycemia in Healthy Older Adults||University of Toronto|No|Active, not recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|29|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607007||8709|
NCT02610166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048447|Jointly Managing JIA Online: An Internet-based Psycho-educational Game for Children With JIA and Their Parents|Jointly Managing JIA Online: An Internet-based Psycho-educational Game for Children With Juvenile Idiopathic Arthritis (JIA) and Their Parents||The Hospital for Sick Children|No|Not yet recruiting|January 2016|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|11 Years|No|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610166||8466|
NCT02610179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35564|Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial|Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial||Baylor College of Medicine|No|Recruiting|April 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|617|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610179||8465|
NCT02609880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287-2009|Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer|Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer||University of Florida|No|Recruiting|July 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|90 Years|No|||November 2015|November 17, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02609880||8488|
NCT02609893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA039333|Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs|Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs|BYE-C|San Francisco Department of Public Health|Yes|Not yet recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02609893||8487|
NCT02606448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-ACL|Exparel Infiltration in Anterior Cruciate Ligament Reconstruction|Liposomal Bupivacaine Versus Femoral Nerve Block for Pain Control After Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Trial||Henry Ford Health System|Yes|Completed|August 2014|November 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 20, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606448||8750|
NCT02606461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-020|KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma)|A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)|SEAL|Karyopharm Therapeutics, Inc|Yes|Recruiting|December 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|245|||Both|12 Years|N/A|No|||February 2016|February 5, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606461||8749|
NCT02598791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASOLIN sub 1|GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake|GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake|GASOLIN|University Hospital, Gentofte, Copenhagen|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|18|||Male|25 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 7, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02598791||9337|
NCT02602704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUHRD-SPE-15-05|Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients|Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients||Hanyang University|No|Not yet recruiting|November 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|114|||Female|45 Years|N/A|No|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602704||9036|
NCT02609932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1643|Effect of IFN-γ on Innate Immune Cells|Effect of Interferon-gamma 1-b on Innate Immune Cells||University of Colorado, Denver|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609932||8484|
NCT02600767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-2015-204|Artemeter-lumefantrine for Treatment of P. Falciparum Malaria in Brazil|Evaluating the Efficacy of Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Cruzeiro do Sul, Acre, Brazil||Centers for Disease Control and Prevention|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|5 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 6, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02600767||9185|
NCT02610920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-AAAP8967|Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection|Identification of Sentinel Lymph Nodes by Ultrasound Utilizing Iron Tracer Injection and Preoperative Biopsy in Women With Breast Cancer||Columbia University|No|Not yet recruiting|December 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|November 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610920||8408|
NCT02608177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50084-A|Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management|Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management|CANDY-CANE|University of Washington|No|Recruiting|November 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608177||8619|
NCT02594852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-288-14|Laser - a New Possibility in Fertility Treatment - a Pilot Study|Laser - a New Possibility in Fertility Treatment - a Pilot Study||Regionshospitalet Viborg, Skive|Yes|Recruiting|March 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02594852||9640|
NCT02602340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-006-01|Neurocognitive Predictors of Behavioral Therapy Response in Depression|Neurocognitive Predictors of Behavioral Therapy Response in Depression||Laureate Institute for Brain Research, Inc.|No|Recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|55 Years|No|||October 2015|November 9, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02602340||9064|
NCT02604589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-233|Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures|Prime "Rib" Time: Randomized Control Trial Evaluating the Use of Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures||William Beaumont Hospitals|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|375|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604589||8893|
NCT02604602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0011|Coagulation Factors and Postpartum Hemorrhage|Peripartal Concentration of Coagulation Factors and Postpartum Hemorrhage||University of Zurich|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women before delivery|November 2015|November 11, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604602|2 Weeks|8892|
NCT02608827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2010/11413-6|Sympathetic and Blood Pressure Responses to Aerobic Exercise and Guided Respiration in Hypertensives|Sympathetic and Blood Pressure Responses to Aerobic Exercise and Guided Respiration in Hypertensives||University of Sao Paulo General Hospital|Yes|Active, not recruiting|January 2011|December 2015|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|60 Years|No|||November 2015|November 18, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02608827||8569|
NCT02608840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200555|Auditory Stimulation of Slow Wave Sleep and Memory in Mild Cognitive Impairment and Older Adults|Auditory Stimulation of Slow Wave Sleep and Memory in Mild Cognitive Impairment and Older Adults||Northwestern University|No|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02608840||8568|
NCT02606175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58561|Medication Knowledge, Medication Adherence and Health Literacy in Patients Who Underwent a Kidney Transplantation.|Medication Knowledge, Medication Adherence and Health Literacy in Patients Who Underwent a Kidney Transplantation.||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|November 12, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02606175||8771|
NCT02561195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5091009|A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years|A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years||Pfizer|Yes|Active, not recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|854|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561195||12226|
NCT02561208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-CE_CCU|Evaluation of an Mhealth Intervention to Increase Adherence to Triage of HPV+ Women|Evaluation of an Mhealth Intervention to Increase Adherence to Triage of HPV+ Women Who Have Performed HPV-Test Self-collection||Centro de Estudio de Estado y Sociedad|No|Not yet recruiting|September 2016|September 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|7200|||Female|30 Years|N/A|No|||September 2015|September 24, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02561208||12225|
NCT02597426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 15-9063-CE|Nasopharyngeal Carcinoma Post IMRT|A Comprehensive Prospective Cross Sectional Study on the Late Effects of Radical Chemoradiotherapy in Nasopharyngeal Carcinoma Patients Treated in the Intensity-Modulated Radiotherapy Era||University Health Network, Toronto|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after        definitive management with radiotherapy +/- chemotherapy who were treated with        Intensity-Modulated Radiotherapy (IMRT)|November 2015|November 3, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02597426||9442|
NCT02601131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Post-transf-PLC|Post-transfusion Platelet Count|Post-transfusion Platelet Count||Region Skane|No|Recruiting|February 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|65|Samples With DNA|Pending the analyses of complement factors and endothelial markers plasma is stored in -80      degrees Celcius. All samples are destroyed after analyses.|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Clinic of Hematology Diseases, Skåne University Hospital, Lund,        Sweden|February 2016|February 8, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02601131||9157|
NCT02605863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52539|Enzalutamide for Bladder Cancer Chemoprevention|The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention||University of Rochester|Yes|Recruiting|January 2016|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Male|18 Years|N/A|No|||January 2016|January 21, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605863||8795|
NCT02600923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481053|Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate|Study Of Palbociclib In Combination With Letrozole As Treatment Of Postmenopausal Women With Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate||Pfizer|No|Not yet recruiting|April 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Female|18 Years|99 Years|No|||March 2016|March 3, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600923||9173|
NCT02600936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1497|Sinai Vein Stent Registry|Sinai Vein Stent Registry||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|December 2015|December 2022|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patient has undergone or will undergo vein stent placement for proximal venous outflow        obstruction in the ilio-femoral vein, inferior vena cava, subclavian vein, brachiocephalic        vein, or superior vena cava.|November 2015|November 6, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600936|5 Years|9172|
NCT02600949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1029|Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma|Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600949||9171|
NCT02391116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17119|Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.||Bayer|No|Active, not recruiting|May 2015|January 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|120 Years|No|||March 2016|March 17, 2016|February 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02391116||25282|
NCT02388243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMH 0092-04|The Computer-based Drug and Alcohol Training Assessment in Kenya|The Computer-based Drug and Alcohol Training Assessment in Kenya|eDATA K|Africa Mental Health Foundation|No|Recruiting|September 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1090|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388243||25503|
NCT02447146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-PD|Resistance Training in Patients With Parkinson`s Disease.|Effects of Resistance Training on Bradykinesia and Physical Function in Patients With Parkinson`s Disease.||University of Brasilia|No|Completed|January 2013|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02447146||20982|
NCT02384187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-47-2014|Gabapentin Premedication and Adenotonsillectomy in Pediatric Patients|The Effects of Oral Gabapentin Premedication on Postoperative Nausea and Vomiting and Early Postoperative Recovery Profile in Pediatric Patients Undergoing Adenotonsillectomy||Cairo University|Yes|Completed|January 2015|August 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Both|3 Years|12 Years|No|||December 2015|December 22, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02384187||25815|
NCT02386579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-069|Characterization of Local and Systemic Bone Markers in Diabetes Patients With Charcot Osteoarthropathy|||Bispebjerg Hospital|Yes|Enrolling by invitation|February 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|16|Samples Without DNA|blood serum samples|Both|N/A|N/A|No|Non-Probability Sample|Diabetes patients with and without acute charcot foot|March 2015|March 6, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02386579||25631|
NCT02386709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A000357-40|Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer|Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Treatment in Patients With Mammary Gland Cancer|TREN|Centre Georges Francois Leclerc||Recruiting|March 2015|||March 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|275|||Both|18 Years|N/A|No|||February 2015|March 25, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02386709||25621|
NCT02389452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV03809|Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment|A Multicenter, Prospective, Open-Label Study of the Safety and Efficacy of 6 mL Synvisc-One ® (Hylan G F 20) in Indian Patients With Symptomatic Osteoarthritis of the Knee(s) After Initial and Repeat Treatment|OASIS|Sanofi|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|394|||Both|30 Years|N/A|No|||May 2015|May 5, 2015|March 4, 2015|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT02389452||25410|
NCT02390492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29067|A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Ipatasertib (GDC-0068) Following a Single Oral Dose and to Investigate the Absolute Bioavailability Following Single Oral and Intravenous Doses in a Single Cohort of Healthy Male Subjects||Genentech, Inc.||Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390492||25330|
NCT02390557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014000899|Persons With Disabilities Quality Monitoring Intervention|Persons With Disabilities Generating Quality Metrics to Inform Integrated Care|PDQMI|Massachusetts General Hospital|No|Enrolling by invitation|July 2015|April 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|480|||Both|21 Years|64 Years|No|||October 2015|October 1, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02390557||25325|
NCT02380521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10139|Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes|Effect of Exenatide Once Weekly on Cardiovascular Risk Markers in Patients With Type-2 Diabetes||University of Palermo|No|Recruiting|January 2015|November 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2015|February 27, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02380521||26097|
NCT02378987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1917B|The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis|The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis||Chang Gung Memorial Hospital|Yes|Completed|October 2010|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|46|||Both|4 Years|8 Years|Accepts Healthy Volunteers|Probability Sample|children with CP having language ability greater than 3 years|August 2010|March 10, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02378987||26215|
NCT02391181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZAD-BE01|Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers|An Open-label, Randomized, Crossover-design Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers Under Fasting Conditions||Azad Pharma AG|No|Completed|November 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02391181||25277|
NCT02389712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003545-1|16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression|16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response|FLAME|Mayo Clinic|Yes|Active, not recruiting|March 2015|April 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389712||25390|
NCT02603276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhytoRed|Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination|Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination in Moderately Hypercholesterolemic Subjects in Primary Prevention for Cardiovascular Diseases: a Randomized, Double Blind, Clinical Trial||University of Bologna|No|Recruiting|April 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02603276||8993|
NCT02603289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-300313-00|One Week Aligner Evaluation|One Week Aligner Evaluation||Align Technology, Inc.|No|Recruiting|September 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Invisalign patients from selected pool of investigators|November 2015|November 10, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603289||8992|
NCT02609230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-077|A Dose-Escalation Study of Onc201 Administered Every One, Two, or Three Weeks in Advanced Solid Tumors and Multiple Myeloma|A Phase I Dose-Escalation Study of Onc201 Administered Every One, Two, or Three Weeks in Advanced Solid Tumors and Multiple Myeloma||Fox Chase Cancer Center|Yes|Recruiting|November 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609230||8538|
NCT02609152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/ML-01|Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock|Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock: a Multicentre, Randomized, Double-blind Trial|BétaSep|Centre Hospitalier Universitaire de Nīmes|Yes|Not yet recruiting|July 2016|August 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609152||8544|
NCT02599623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02415543|Safety and Efficacy of Local Anesthesia in Emergency Inguinal Hernia Surgery|Safety and Efficacy of Local Anesthesia in Emergency Inguinal Hernia Surgery, a Prospective Randomized Trial||RenJi Hospital|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599623||9273|
NCT02597335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120141|Non Invasive Detection of IDH1/2 Mutation in Gliomas|Non Invasive IDentification of Gliomas With IDH1/2 Mutation by Analysis of Circulating Plasmatic DNA, D-2-hydroxyglutarate Dosage in Biological Liquids and Detection by Brain SPEctro-MRI: Impact for Diagnosis and Follow-up|IDASPE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02597335||9449|
NCT02606253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU-IRB-TBD|Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure|Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure||Vanderbilt University|No|Recruiting|February 2016|September 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606253||8765|
NCT02594748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK2014011|The Effects of Self-management Education Based on Theory of Planned Behavior on Patients With Type 2 Diabetes|The Effects of Self-management Education Based on Theory of Planned Behavior on Self-management and Quality of Life of Patients With Type 2 Diabetes and the Other Influencing Factors of Quality of Life||University of Turku|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|320|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 31, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02594748||9648|
NCT02603679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDIX LumB|Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases|PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|PREDIX LumB|Karolinska University Hospital|No|Recruiting|February 2015|June 2024|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603679||8963|
NCT02599493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14_9741_EVRIOS|EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin|EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin in the Treatment of Staphylococcal Bone and Joint Infections|EVRIOS|Rennes University Hospital|Yes|Recruiting|November 2015|February 2020|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599493||9283|
NCT02599818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-07-224|Navigation Services to Avoid Rehospitalization (NavSTAR)|Navigation Services to Avoid Rehospitalization (NavSTAR) Among Substance Users|NavSTAR|Friends Research Institute, Inc.|Yes|Not yet recruiting|January 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|420|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599818||9258|
NCT02599831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYSNXD-CC|A Comparison of Electrical Pudendal Nerve Stimulation and Pelvic Floor Muscle Training for Male Stress Incontinence|||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Not yet recruiting|November 2015|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|25 Years|85 Years|No|||October 2015|November 6, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02599831||9257|
NCT02599870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0007|Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures|Prospective Randomized Clinical Study to Evaluate the Clinical Impact of Pharmacogenetics-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures||AltheaDx|No|Recruiting|September 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|99 Years|No|||November 2015|November 5, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02599870||9254|
NCT02599883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImagingCOPD_Multicenter|Evidence-based Analysis of Low-dose CT in Management of COPD|Impact of Low-dose Computed Tomography on the Management of Chronic Obstructive Pulmonary Disease Patients: an Evidence-based Study||Azienda Ospedaliero-Universitaria di Parma|No|Completed|September 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|195|||Both|40 Years|90 Years|No|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599883||9253|
NCT02599896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160018|Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected Adults|VRC 606: A Phase 1, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB080-00-AB (VRC01LS), Administered Intravenously or Subcutaneously to Healthy Adults||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|August 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|March 11, 2016|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599896||9252|
NCT02608710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-112|RDEA3170 PK/PD Study|A Phase 1, Randomized, Open-Label Study in Healthy Adult Male Subjects to Assess the Pharmacokinetics and Pharmacodynamics of RDEA3170||Ardea Biosciences, Inc.|No|Not yet recruiting|November 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608710||8578|
NCT02604147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIMEP|Inspiratory Muscle Training in Wheelchair Basketball Players|Inspiratory Muscle Training in Wheelchair Basketball Players: Effects on Physical Performance and Cardiopulmonary Variables||Universidade Metodista de Piracicaba|Yes|Completed|January 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02604147||8927|
NCT02606981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30456|Automatic Chlorination and Child Health in Urban Bangladesh|Evaluating Low-cost Automatic Water Disinfection Systems to Improve Water Quality and Child Health in Urban Bangladesh||Stanford University|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|N/A|60 Months|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02606981||8711|
NCT02600871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150722H|Skin and Soft Tissue Infection (SSTI) Study|Skin and Soft Tissue Infection (SSTI) Study||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600871||9177|
NCT02600884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SN-15-0091|Efficacy Trial of a Brief Parent-Based Adolescent Sexual Health Intervention|Efficacy Trial of a Brief Parent-Based Adolescent Sexual Health Intervention||The University of Texas Health Science Center, Houston|No|Not yet recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1060|||Both|11 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600884||9176|
NCT02598141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/NC-01|Grinding Versus Standard Methods for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis|Comparative Evaluation of Two Techniques for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis: Grinding (Ultra Turrax) Versus Standard Methods|IOAP Turrax|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|September 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|122|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598141||9387|
NCT02600273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00067757|Novel Approaches to Reducing Tobacco Related Harm|Novel Approaches to Reducing Tobacco Related Harm Among HIV-Infected Smokers||Duke University|No|Not yet recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600273||9223|
NCT02600494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-401|Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder||Intra-Cellular Therapies, Inc.|No|Recruiting|December 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|550|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600494||9206|
NCT02610036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT 18 /2011Cardiovascular|Obliterating Diabetic Microangiopathy of the Diabetic Foot|Pilot Study on the Presence of Microangiopathy in Diabetic Foot Ulcer||IRCCS Multimedica|No|Completed|March 2012|October 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Probability Sample|30 diabetic patients with only neuropathy, 30 diabetic patients with critical limb        ischemia|March 2012|November 19, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT02610036||8476|
NCT02596152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-231/232|Mini-trampoline Intervention vs. Nordic Walking: Balance, Fitness and Neuropsychological Effects|Comparison of 12-week Mini-trampoline Intervention With a Nordic Walking Intervention: Balance, Fitness and Neuropsychological Effects|TraWaFit|University of Basel|No|Recruiting|August 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02596152||9540|
NCT02602743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRK01|Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy|Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy||Cukurova University|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602743||9033|
NCT02597647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11-000326-CR-00003|Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection|Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection||University of California, Los Angeles|No|Completed|February 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597647||9425|
NCT02602106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFLO_UPM_12|Regular Aquatic Activities and Pregnancy Outcomes|Effects of Regular Aquatic Activities on Pregnancy Outcomes|aquapreg|Universidad Politecnica de Madrid|Yes|Recruiting|June 2011|June 2017|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|November 9, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02602106||9082|
NCT02605382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRN|Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis|Efficacy of 0.12% Chlorhexidine Gluconate for Non-surgical Treatment of Peri-implant Mucositis||Universidade Federal do Rio Grande do Norte|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|90 Years|No|||November 2015|November 12, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02605382||8832|
NCT02607176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZY3-CCCX-3-1001|Heweizhixie capsuleTherapy on Patients With Diarrhea|A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea||Shanghai University of Traditional Chinese Medicine|No|Recruiting|October 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2400|||Both|18 Years|80 Years|No|||November 2015|December 7, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02607176||8696|
NCT02609334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSPR-007|RSPR-007 Mannitol Challenge Trial|A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma||RSPR Pharma AB|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|50 Years|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609334||8530|
NCT02594904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|whuang201500601|Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency|A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency||Southern Medical University, China|No|Recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|N/A|7 Days|No|||October 2015|October 31, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02594904||9636|
NCT02597920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.247|Patient Convenience Study|Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation||Boehringer Ingelheim||Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|European patients with non valvular atrial fibrillation|March 2016|March 21, 2016|November 4, 2015||||No||https://clinicaltrials.gov/show/NCT02597920||9404|
NCT02605616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000013|Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)|A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)||Mayo Clinic|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|21 Years|75 Years|No|||January 2016|January 5, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605616||8814|
NCT02607670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAT4 B1|Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds|A Phase 2, Randomized, Double-blind, Placebo-controlled Study of TAT4 Gel for the Reduction of Nasolabial Folds||Topokine Therapeutics, Inc.|No|Recruiting|January 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|111|||Both|35 Years|60 Years|No|||January 2016|January 2, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607670||8658|
NCT02598856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 15-002|Bioavailability of Nasal Naloxone and Injected Naloxone Compared|Bioavailability of Nasal Naloxone and Injected Naloxone Compared. A Randomized, Open Label, 4-way Cross-over Study|OPI-15-002|Norwegian University of Science and Technology|Yes|Not yet recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02598856||9332|
NCT02595177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PresbyIOL|Multifocal Intraocular Lens x Monovision x Hybrid Monovision After Bilateral Cataract Surgery|Multifocal Intraocular Lens vs. Monovision vs. Hybrid Monovision After Bilateral Cataract Surgery||Federal University of São Paulo|Yes|Completed|July 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 1, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02595177||9615|
NCT02603042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHP 08-2015|Biomarker for Hypophosphatasia Disease|Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioHypophos|University of Rostock|Yes|Recruiting|November 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml      EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of      Hypophosphatasia in those patients where up to the enrollment in the study no genetic      testing has been done, sequencing of Hypophosphatasia disease will be done.      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany|Both|2 Months|N/A|No|Probability Sample|Patients with Hypophosphatasia Disease based upon biochemical and/or genetic criteria or        no valid criteria for profound suspicion of Hypophosphatasia disease|March 2016|March 14, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603042||9011|
NCT02603055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT025|A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults|A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China||Jiangsu Province Centers for Disease Control and Prevention|No|Recruiting|July 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603055||9010|
NCT02601872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDehong_NNICU4|Erythropoietin in Premature Infants to Prevent Encephalopathy|Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China||The People's Hospital of Dehong Autonomous Prefecture|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|48 Hours|No|||November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601872||9100|
NCT02601885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-173|A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis|An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis Receiving Maintenance Glatiramer Acetate Treatment||AbbVie|No|Not yet recruiting|June 2016|March 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601885||9099|
NCT02602496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNebraskaLincolnFDST1|Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals|Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals Through Intake of Whole Wheat Products in Comparison With Fruits and Vegetables||University of Nebraska Lincoln|Yes|Active, not recruiting|October 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02602496||9052|
NCT02609477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-017|A Study to Evaluate Abuse Potential of Istradefylline|A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Istradefylline in Recreational Drug Users||Kyowa Hakko Kirin Pharma, Inc.|No|Active, not recruiting|January 2016|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609477||8519|
NCT02600312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oXiris|Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock|Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock|oXiris|Skåne University Hospital|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02600312||9220|
NCT02604264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0001|Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap|Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap||Pursuit Vascular, Inc.|No|Completed|December 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3500|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604264||8918|
NCT02595034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBG 1412|A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris|A Randomized Double Blind Multiple Center Placebo Controlled Study Comparing CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|January 2015|November 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1000|||Both|12 Years|40 Years|No|||November 2015|November 8, 2015|November 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595034||9626|
NCT02595047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2012]23|Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint)|Phase 1/2 Study of Autologous Tissues/Body Surface Organs Prefabrication in Tissue Reconstruction||Shanghai Jiao Tong University School of Medicine|No|Active, not recruiting|January 2013|December 2016|Anticipated|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02595047||9625|
NCT02598362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004638-24|Pharmacokinetics of Ciprofloxacin in Pediatric Patients|Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion||University Hospital, Ghent|Yes|Recruiting|April 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|3 Months|17 Years|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598362||9370|
NCT02598375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EREN-IFABP IN PICU|Evaluation of Status of Early Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children|Stage 1Evaluation of Status of Early Enteral Nutrition in Critically Ill Children in the PICU (EREN in PICU) Stage 2 IFABP as Biomarker of Feeding Intolerance in Critically Ill Children in the PICU(IFABP in PICU)|ERENIFABPICU|Gazi University|Yes|Recruiting|January 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|Samples Without DNA|Urine and blood will be collected from critically ill children in PICU|Both|1 Month|16 Years|No|Probability Sample|The critically ill children in PICU who stay at least for 4 days|February 2016|February 9, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598375|10 Days|9369|
NCT02597608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601059.001.001|Impact Evaluation of the DFID Programme to Accelerate Improved Nutrition of the Extreme Poor in Bangladesh|Impact Evaluation of the DFID Programme to Accelerate Improved Nutrition of the Extreme Poor in Bangladesh||International Food Policy Research Institute|No|Active, not recruiting|July 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Anticipated|11340|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|February 23, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02597608||9428|
NCT02597621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/XDR_BIO_01|Biomarkers for Therapy Response in Drug-resistant Tuberculosis|Biomarkers for Therapy Response in Drug-resistant Tuberculosis||Research Center Borstel|No|Recruiting|March 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|Samples With DNA|Urine, blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with microbiologically confirmed pulmonary MDR-TB|May 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597621||9427|
NCT02604134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silver Nitrate Study|Medical Management of Caries in the Primary Dentition Using Silver Nitrate|Medical Management of Caries in the Primary Dentition Using Silver Nitrate: A Pilot Study||University of Iowa|No|Enrolling by invitation|July 2014|July 2018|Anticipated|July 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02604134||8928|
NCT02595320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IIT-X7-7|Capecitabine in Metastatic Breast and GI Cancers|Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.|X7-7|University of Kansas Medical Center|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595320||9604|
NCT02608008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EchoNav|Safety and Efficacy of EchoNavigator System Release II During Structural Heart Interventions|Safety and Efficacy of EchoNavigator System Release II (Philips, Andover, MA) During Structural Heart Interventions|EchoNav|Heinrich-Heine University, Duesseldorf|No|Recruiting|September 2014|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Adult male or female patients undergoing structural heart interventions like transfemoral        aortic valve Implantation (TAVI), MitraClip implantation, patent foramen ovale (PFO),        atrial septal defect (ASD) and left atrial appendage (LAA) with or without the        periintervention use of the EchoNavigator System Release II.|November 2015|November 19, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608008||8632|
NCT02597881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00086185|Achondroplasia Natural History Multicenter Clinical Study|Achondroplasia Natural History Multicenter Clinical Study||Johns Hopkins University|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Achondroplasia patients seen at one of the participating sites|November 2015|November 4, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02597881|2 Years|9407|
NCT02598167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29715|Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition|Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis||Hoffmann-La Roche||Recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|220|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at        least 3 months|February 2016|February 1, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598167||9385|
NCT02596295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM001|Human Milk Sample Composition in Israeli Mothers and Correlation With Their Diet|Human Milk Sample Collection From Israeli Mothers and Its Analysis and Correlation Between Composition, Demographics and Diet||Enzymotec|No|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Human milk|Female|15 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|General healthy lactating mothers|November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596295||9529|
NCT02602652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB456/56|Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine|Immunogenicity of a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine in Thai Children||Chulalongkorn University|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602652||9040|
NCT02602912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INJ-SPINE-01|Identification of Spine Structures by Using BIP-Needles|INJ-SPINE-01 Identification of Spine Structures by Using BIP-Needles||Injeq Ltd|No|Recruiting|May 2015|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602912||9021|
NCT02608086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-196|Psychological First Aid (PFA): RCT Adults Non-intentional Trauma Emergency Room|Psychological First Aid: A Randomized-controlled Trial of Adults Affected by Non-intentional Trauma in the Emergency Room|PFA|Pontificia Universidad Catolica de Chile|No|Recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02608086||8626|
NCT02598180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-FG-001|VergenixTM Flowable Gel in Patients With Lower Limb Ulcers|Single Arm,Open Label Study, to Evaluate the Safety and Performance of VergenixTM Flowable Gel in Patients With Lower Limb Ulcers (CP-FG-001)|CP-FG-001|Collplant|Yes|Recruiting|November 2014|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 4, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02598180||9384|
NCT02598193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA29895|Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)|An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis||Hoffmann-La Roche||Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|40 Years|80 Years|No|||March 2016|March 1, 2016|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02598193||9383|
NCT02598440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA17843|A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis|A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study||Hoffmann-La Roche||Completed|March 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|341|||Female|N/A|N/A|No|||March 2016|March 1, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598440||9364|
NCT02604225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZUP 1501|Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B|A Phase 3 Double-blind Placebo-controlled Randomized Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of Transrectal Ultrasound-guided Prostate Biopsy|TRUSB|University of Sydney|No|Not yet recruiting|December 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Male|18 Years|N/A|No|||November 2015|November 15, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604225||8921|
NCT02604238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Azienda USL1 Massa e Carrara|Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism|Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial|MONALYSE|Azienda U.S.L. 1 di Massa e Carrara|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604238||8920|
NCT02595892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01910|Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase 2 Study of VX-970 (NSC# 780162) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer||National Cancer Institute (NCI)|Yes|Not yet recruiting|July 2016|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595892||9560|
NCT02599103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-IRB02-102083|The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects|||Academia Sinica, Taiwan|Yes|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|10||Actual|17|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 5, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02599103||9313|
NCT02609997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China9|Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens|Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens Via Scheimpflug Imaging System||Sun Yat-sen University|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|60 Years|85 Years|No|||November 2015|November 18, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02609997||8479|
NCT02609776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108064|A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer||Janssen Research & Development, LLC|No|Not yet recruiting|March 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609776||8496|
NCT02598609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPREVEN|An Educational Program to Prevent Adverse Events in Neonates : a Randomised Trial.|An Multifaceted Educational Program for Caregivers to Prevent Adverse Events in Neonatal Intensive Care Unit Patients, a Stepped Wedge Cluster Randomised Trial.|SEPREVEN|Centre Hospitalier Intercommunal Creteil|No|Recruiting|November 2015|January 2020|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|14000|||Both|N/A|20 Weeks|No|||December 2015|December 7, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598609||9351|
NCT02608346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2014-05|Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)|Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)||Institut Curie|Yes|Recruiting|November 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|30 Years|N/A|No|||November 2015|November 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608346||8606|
NCT02597439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR54654|Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe|Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe|PURPOSE|UMC Utrecht|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02597439||9441|
NCT02597452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821412-UPCC24114|Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner|Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner|iBE|University of Pennsylvania|No|Recruiting|March 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597452||9440|
NCT02608918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-065|Taste Properties of HIV Inhibitor|An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||November 2015|December 8, 2015|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608918||8562|
NCT02608931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01577|The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia|The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia||New York University School of Medicine|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|60 Years|No|||November 2015|November 18, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608931||8561|
NCT02607449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-004 V 1.0|FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis|Randomized, Placebo-controlled Study of Safety and Therapeutic Efficacy of the Drug FS-1 in the Oral Dosage Form in Drug-resistant Pulmonary Tuberculosis||Scientific Center for Anti-infectious Drugs, Kazakhstan|No|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02607449||8675|
NCT02379520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36021 HESTIA|HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA|HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers|HESTIA|Baylor College of Medicine|Yes|Recruiting|September 2015|October 2033|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02379520||26174|
NCT02390843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078790|Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors|A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors|AflacST1402|Emory University|Yes|Recruiting|February 2015|February 2021|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|1 Year|29 Years|No|||October 2015|October 28, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390843||25303|
NCT02384421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30880|Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease|Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease|aDBS|Stanford University|Yes|Enrolling by invitation|January 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|February 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02384421||25797|
NCT02387008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2429|Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space|Prospective, Comparative Assessment of Alveolar Bone Augmentation Using Guidor Membrane in the Bound Edentulous Space||University of North Carolina, Chapel Hill|No|Not yet recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|February 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387008||25598|
NCT02392533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1556|Ultrasound and Neuraxial Anesthesia in Pregnancy|Ultrasound Confirmation of Neuraxial Anesthetic Vertebral Level in Post-partum Patients|USPREG|University of Chicago|No|Not yet recruiting|August 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|450|||Female|18 Years|N/A|No|Non-Probability Sample|Post-partum patients who had neuraxial anesthesia for their delivery.|March 2015|March 19, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02392533||25174|
NCT02390128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153466|Mothers and Babies at Yorkhill Thyroid Health Cohort|Giving Children the Best Start in Life: the Mothers and Babies at Yorkhill Thyroid Health|MABY|University of Glasgow|No|Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|697|Samples With DNA|urine, blood, hair, breastmilk|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and their newborn baby|March 2015|March 16, 2015|November 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02390128||25358|
NCT02381145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL31421.068.10|Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans|Long-term Supplementation of Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers||Maastricht University Medical Center|No|Completed|August 2012|September 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|August 20, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381145||26049|
NCT02448966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKTRDP-2015BAI12B08-02|Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy|Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic/Laparoscopic Esophagectomy for cT1b-3N0-1M0 Thoracic Esophageal Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|75 Years|No|Non-Probability Sample|cT1b-3N0-1M0 thoracic esophageal cancer.|May 2015|May 19, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02448966||20843|
NCT02384954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-803-02-14|ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab|A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab||Altor Bioscience Corporation|Yes|Recruiting|March 2015|June 2023|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02384954||25756|
NCT02384967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 165 DARULIGHT|Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients|Phase II Trial Assessing the Efficacy of a Reduced Dose Strategy of Darunavir to 400 mg/d in HIV-1 Infected Patients Virologically Suppressed Under a Once Daily Regimen Including Darunavir 800 mg/d and Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), to Maintain the Viral Load Lower Than 50 Copies / mL at 48 Weeks of Treatment|DARULIGHT|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02384967||25755|
NCT02383472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00002527|LED Therapy for the Treatment of Concussive Brain Injury|Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury||Children's Hospital Boston|No|Recruiting|September 2012|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|11 Years|N/A|No|||January 2016|January 26, 2016|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383472||25870|
NCT02389725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007501|The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates|The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates||Mayo Clinic|No|Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389725||25389|
NCT02610374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1692|Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients|Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients||University of Colorado, Denver|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|98|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02610374||8450|
NCT02598258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1807|Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects|Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects||Montreal Heart Institute|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02598258||9378|
NCT02599636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Althaia|To Survive After ICU Discharge|Multicenter Prospective Study: To Survive After ICU Discharge||Althaia Xarxa Assistencial Universitària de Manresa|No|Recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|99 Years|No|Non-Probability Sample|All patients at ICU discharge|October 2015|November 5, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02599636||9272|
NCT02608853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-4259|Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants|Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants||Novo Nordisk A/S|No|Completed|January 2015|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|9999|||Both|N/A|N/A|No|Non-Probability Sample|The study will include a cohort of patients with type 2 diabetes mellitus (T2DM) who        initiated liraglutide and two cohorts of patients with T2DM standardized to have similar        baseline covariates, including use of antidiabetic medicines, relative to the liraglutide        initiators (the Liraglutide-like Cohort) and to participants in the LEADER™ Trial        (LEADER™-like Cohort).|November 2015|November 17, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02608853||8567|
NCT02601755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000047495|iCanCope With Pain: A Smartphone and Web Self-management Program for Adolescents and Young Adults With Chronic Pain|iCanCope With Pain: An Integrated Smartphone and Web Self-management Program for Adolescents and Young Adults With Chronic Pain||The Hospital for Sick Children|No|Not yet recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|25 Years|No|||November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02601755||9109|
NCT02596581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-116-17-06|Chemerin and IL-6 Levels in Diabetes and Periodontitis|Association of Gingival Crevicular Fluid Chemerin and IL-6 Levels in Chronic Periodontitis With and Without Type 2 Diabetes Mellitus After Non-Surgical Periodontal Therapy||Bulent Ecevit University|No|Completed|July 2014|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596581||9507|
NCT02601287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-151|A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients|||Allergan|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601287||9145|
NCT02599558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004741|Cytosponge and Dietary Therapy in EoE|A Pilot Trial of Dietary Therapy Directed by the Esophageal Sponge in the Management of Eosinophilic Esophagitis.||Mayo Clinic|No|Recruiting|November 2015|May 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02599558||9278|
NCT02608944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 58133|Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging|Comparison of New MRI Methods for Quantitative Assessment of Myocardial Perfusion With Quantitative PET Perfusion Imaging||University of Utah|No|Recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608944||8560|
NCT02601742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-09|Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute|Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute in Mexican Children: Randomized Double-blind Study||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Not yet recruiting|November 2015|November 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|6 Months|5 Years|No|||October 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601742||9110|
NCT02560896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001209|Understanding Genetic Incidental Findings in Your Family (UNIFY Study)|Genomic Incidental Findings Disclosure (GIFD) in a Cancer Biobank: An Ethical, Legal and Social Implications (ELSI) Experiment (Protocol for Aim 3 Intervention)|UNIFY|Mayo Clinic|Yes|Enrolling by invitation|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Familial Pancreatic Cancer Kindred|September 2015|September 25, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02560896|6 Months|12249|
NCT02604303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic A1231656|A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms|A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms||VA Northern California Health Care System|No|Enrolling by invitation|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Patient monocytes from peripheral blood|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans of VA Northern California Health Care System|November 2015|November 10, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02604303||8915|
NCT02604394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rheo-STEMI|Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden|Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden|Rheo-STEMI|Magdi Yacoub Heart Foundation|Yes|Recruiting|November 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 14, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604394||8908|
NCT02603926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720668|Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone|Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone||University of California, Davis|Yes|Enrolling by invitation|October 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|50 Years|85 Years|No|||November 2015|November 10, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603926||8944|
NCT02604784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-IRCCS-27F-1|Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors|Feasibility, Efficacy and Safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) With Oxaliplatin, Cisplatin and Doxorubicin in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancers and Primary Tumors of the Peritoneum: An Open-label, Single-arm, Phase II Clinical Trial PI-CaP|PI-CaP|Fondazione del Piemonte per l'Oncologia|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|78 Years|No|||November 2015|November 12, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02604784||8878|
NCT02597842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijingmazui79|Transcutaneous Electrical Acupoint Stimulation(TEAS) for Postoperative Nausea and Vomiting in Laparoscopic Operation|Efficiency of Transcutaneous Electrical Acupoint Stimulation(TEAS) With Single Acupoint or Two Acupoints for Postoperative Nausea and Vomiting in Laparoscopic Operation: A Single Center, Randomized, Double-blinded, Controlled Clinical Trial||Xijing Hospital|Yes|Not yet recruiting|December 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597842||9410|
NCT02602262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHUHIVDD|Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients|Observational Study of HIV+ Deceased Donor Solid Organ Transplant for HIV+ Recipients||Johns Hopkins University|No|Enrolling by invitation|November 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Plasma, serum, peripheral blood mononuclear cells, tissue|Both|18 Years|N/A|No|Non-Probability Sample|All individuals with end-stage organ disease and HIV infection who meet standard clinical        criteria for transplantation and the study inclusion and exclusion criteria will be        eligible for participation in the study.|January 2016|January 4, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602262||9070|
NCT02606370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVERSITY CARDENAL HERRERA|Effects of Unstable Shoes on Trunk Muscle Activity, Lumbar Spine Kinematics and Pain in Patients With Low Back Pain|Effects of Unstable Shoes on Trunk Muscle Activity, Lumbar Spine Kinematics and Pain in Patients With Low Back Pain||Cardenal Herrera University|Yes|Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|65 Years|No|||November 2015|November 14, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606370||8756|
NCT02606383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 007/15|Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis|Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis||Biolab Sanus Farmaceutica|No|Not yet recruiting|June 2016|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|16 Years|60 Years|No|||February 2016|February 10, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606383||8755|
NCT02596646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECUT PRECOCE/01|Early Precut in Difficult Biliary Cannulation|Early Precut Sphincterotomy During ERCP With Difficult Biliary Access (Italian: Esecuzione Del Pre-cut Precoce in Corso di ERCP Con Difficoltosa Incannulazione Della Via Biliare)||Università Vita-Salute San Raffaele|Yes|Terminated|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|375|||Both|18 Years|85 Years|No|||November 2015|November 5, 2015|September 7, 2015||No|Interim analysis recommended terminating the study|No||https://clinicaltrials.gov/show/NCT02596646||9502|
NCT02606123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-506-CS-0001|Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer||ESSA Pharmaceuticals|No|Recruiting|October 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|166|||Male|18 Years|N/A|No|||December 2015|December 15, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606123||8775|
NCT02602522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-V3.0|Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea|The Comparison of the Effect on Danshen-Jiang-Fu Granule Prepared by Danshen (Salvia Miltiorrhiza) From Different Producing Areas (Shandong and Sichuan) for Primary Dysmenorrhea: a Cross-over, Randomized, Double-blind Controlled Trials||China Academy of Chinese Medical Sciences|No|Recruiting|November 2015|||January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|14 Years|25 Years|No|||November 2015|November 10, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02602522||9050|
NCT02608229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201601098|BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer|Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer||Washington University School of Medicine|No|Not yet recruiting|March 2016|March 2020|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608229||8615|
NCT02604199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2002|A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic HBV Infection|A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection||Arrowhead Research Corporation|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 11, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604199||8923|
NCT02596893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GED-0301-CD-002|Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease|A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter, Induction Study to Investigate the Efficacy and Safety of GED-0301 For the Treatment of Subjects With Active Crohn's Disease||Celgene|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1064|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596893||9483|
NCT02601430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-BOLD-15|BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI|Functional Magnetic Resonance Angiographic Imaging Using Blood Oxygen Level Determination (BOLD) Assessment as a Surrogate of Improved Skeletal Muscle Oxygenation After Endovascular Therapy for the Treatment of Chronic Lower Limb Ischemia||Biomet, Inc.|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|19 Years|89 Years|No|||October 2015|November 9, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02601430||9134|
NCT02608294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15238913.9.0000.5208|Influence of Kinesio Taping® in Paretic Tibialis Anterior Muscle During Patient Gait and Balance After Stroke|Influence of Kinesio Taping® in Paretic Tibialis Anterior Muscle at Joint Dynamics During Patient Gait and Balance After Stroke: A Pilot Study||Universidade Federal de Pernambuco|No|Completed|July 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|N/A|No|||November 2015|November 17, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02608294||8610|
NCT02602574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP 2015|ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?|Endoscopic Retrograde Cholangiopancreatography (ERCP)-Induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?||University Hospital Rijeka|Yes|Enrolling by invitation|December 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|66|Samples With DNA|plasma, mononuclear cell suspension|Both|18 Years|75 Years|No|Probability Sample|All patients with indication for ERCP and all patients with acute pancreatitis admitted        through Emergency Department|November 2015|November 12, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02602574||9046|
NCT02605330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193/15|Kinetics of Plasma Fibrinogen in Cardiac Surgery|Kinetics of Plasma Fibrinogen During Cardiac and Thoracic Aortic Surgery||University Hospital Inselspital, Berne|No|Recruiting|November 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|90 Years|No|||December 2015|December 7, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02605330||8836|
NCT02605395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201528|Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions|Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Raperazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions||GlaxoSmithKline|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02605395||8831|
NCT02607592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507003|A Prospective Multi-center Phase III Randomized Controlled Trial|Nadaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial|NACA|Sun Yat-sen University|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|293|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607592||8664|
NCT02599454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#258|Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer||University of California, Davis|Yes|Recruiting|February 2016|November 2019|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599454||9286|
NCT02602808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatitis-1|Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis|Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis||Changhai Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|600|Samples Without DNA|Peripheral blood samples were collected from patients within the first 24 h after hospital      admission. Serum, plasma and blood cells was isolated after blood collection by      centrifugation at room temperature.|Both|18 Years|N/A|No|Non-Probability Sample|All patients 18 years of age or older who were hospitalized in our hospital with acute        pancreatitis.|November 2015|November 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602808||9028|
NCT02610582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-CNGA3-01|Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients With CNGA3-linked Achromatopsia|Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients With CNGA3-linked Achromatopsia Investigated in an Exploratory, Dose-escalation Trial||STZ eyetrial|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610582||8434|
NCT02610595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZY3-CCCX-3-2001|Study on the Therapeutic Effect of TCM Treatment for MDR MN|A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation)||Shanghai University of Traditional Chinese Medicine|No|Not yet recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|75 Years|No|||August 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610595||8433|
NCT02601937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZH-102|A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma|A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma||Epizyme, Inc.|No|Recruiting|December 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|6 Months|21 Years|No|||February 2016|March 17, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601937||9095|
NCT02601950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZH-202|A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma|A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma||Epizyme, Inc.|Yes|Recruiting|December 2015|January 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|16 Years|N/A|No|||February 2016|February 19, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601950||9094|
NCT02599727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-20151104002|Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure|Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure||Carrick Institute for Graduate Studies|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599727||9265|
NCT02606266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140310|Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance|Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance|GANCIMVEAR|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|6 Months|12 Years|No|||November 2015|November 13, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02606266||8764|
NCT02606721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-FA-001|Food Allergy Challenge Diagnostic Study|An Exploratory Pilot Study Evaluating Various Diagnostic Measurements Taken During an Escalating Dose Oral Food Challenge to Patient Response||ORA, Inc.|No|Not yet recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|5 Years|35 Years|No|Non-Probability Sample|Subjects with suspected food allergy and scheduled upcoming oral food challenge will be        recruited.|November 2015|November 13, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02606721||8730|
NCT02606734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-6463|DyeVert Pilot Trial|DyeVert Pilot Trial||Osprey Medical, Inc|No|Recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02606734||8729|
NCT02607371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18242|Anticoagulation Preference by AF Patients Study|AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study|PRiSMA-AF|Bayer|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients in primary care / general outpatient practices and outpatient clinics in        German-speaking Switzerland.|March 2016|March 21, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02607371||8681|
NCT02610751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-063|Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels|Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels||TriHealth Inc.|No|Not yet recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|58|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smoking and non-smoking women greater than 18 years of age with a current singleton        pregnancy with known female fetus confirmed by ultrasound.|December 2015|December 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02610751||8421|
NCT02604277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00084800|Suicidal Behavior in African Americans With Bipolar Disorder|Suicidal Behavior in African Americans With Bipolar Disorder: Explaining the Roles of Childhood Maltreatment and Substance Use||Emory University|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|64 Years|No|||January 2016|January 12, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604277||8917|
NCT02599597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rel-prev|Prevention of Depressive Relapse by Means of Physical Exercise and Lifestyle|Prevention of Depressive Relapse by Means of Physical Exercise and Lifestyle||Lund University|No|Recruiting|February 2016|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599597||9275|
NCT02599610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|Effects of Digital Vaginal Examination During Labor on Pain and Anxiety Levels|Effects of Digital Vaginal Examination During Labor on Pain and Anxiety : a Randomised Controlled Trial||Ankara University|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 14, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599610||9274|
NCT02602717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-06|The Evaluation of the Diagnostic Properties of Intra-operative In-situ Thyroglobin Levels of Cervical Lymph Nodes, in the Discrimination Between Benign and Malignant Lymph Nodes in Thyroid Cancer: a Prospective Multicentre Study.||Tgcyto|Assistance Publique Hopitaux De Marseille||Recruiting|February 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|No|||October 2015|November 10, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02602717||9035|
NCT02601534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-330|Be Healthy, So Easy: FAMILY Education Project|Be Healthy, So Easy: FAMILY Education Project||The University of Hong Kong|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 8, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601534||9126|
NCT02600091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG12976-10|Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control in Type 1 Diabetes|Exploring the Effectiveness of Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control Among Adults With Type 1 Diabetes||University of Aberdeen|No|Recruiting|January 2016|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|January 20, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600091||9237|
NCT02600104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF17271|Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction|Clinical Study to Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction||Syneron Medical|No|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600104||9236|
NCT02598648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8157060555|Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates|Daping Hospital of the Third Military Medical University||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|40|||Both|N/A|1 Week|No|||November 2015|November 24, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598648||9348|
NCT02601781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOBolognini|Use of BVS in ST-segment Elevation Myocardial Infarction (STEMI): the BVS STEMI STRATEGY-IT Prospective Registry|A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry|STRATEGY-IT|Azienda Ospedaliera Bolognini di Seriate Bergamo|Yes|Recruiting|October 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02601781||9107|
NCT02600533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14117|Increasing Minority Participation in Clinical Trials|Increasing Minority Group Participation in Clinical Trials a Randomized Controlled Study of an Office-based Educational Video||Meharry-Vanderbilt Alliance|No|Recruiting|December 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600533||9203|
NCT02600546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-50545|Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With SD-OCT|||Optovue||Enrolling by invitation|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Seeing eye doctor for routine or follow-up care|November 2015|November 6, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600546||9202|
NCT02607137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 14-601|Evaluation of Training Program on Promoting Family Holistic Health|Evaluation of Training Program on Promoting Family Holistic Health||The University of Hong Kong|Yes|Recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 14, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02607137||8699|
NCT02595606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03SHDD|0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients|0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients||Sun Yat-sen University|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|17 Years|70 Years|No|||January 2016|January 11, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595606||9582|
NCT02598869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00011584|Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema|Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME)||Oregon Health and Science University|Yes|Not yet recruiting|November 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598869||9331|
NCT02602028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-1437-11/1539|The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF|The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial||Gulhane Military Medical Academy|No|Completed|April 2011|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|5 Years|16 Years|No|||November 2015|November 9, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602028||9088|
NCT02606669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/00815|The Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese Subjects|The Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese Subjects: a Pilot Randomized Control Trial||Khoo Teck Puat Hospital|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02606669||8734|
NCT02600611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICL-23-ABSSSI1|Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1|A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1|REVIVE-1|Motif Bio|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|March 20, 2016|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600611||9197|
NCT02603445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCL201X2102C|Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL|A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)||Novartis|No|Recruiting|November 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603445||8980|
NCT02603458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01975|NRX-1074 in Early Course Schizophrenia|A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia||New York University School of Medicine|Yes|Withdrawn||||August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||February 2016|February 4, 2016|November 9, 2015|Yes|Yes|The study was withdrawn by the sponsor.|No||https://clinicaltrials.gov/show/NCT02603458||8979|
NCT02610842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOP01|Hands on - a Hand Care Guide in Systemic Sclerosis|Hands on - a Hand Care Guide in Systemic Sclerosis||University of Campinas, Brazil|No|Active, not recruiting|January 2015|December 2016|Anticipated|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|December 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02610842||8414|
NCT02598271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1223/2015|Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery|Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial|InCreAS|Medical University of Vienna|No|Recruiting|November 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing an elective cardiac surgical intervention.|November 2015|November 4, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02598271||9377|
NCT02602678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0430|Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis|Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis|BRONCHIO-DV|Hospices Civils de Lyon|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|6 Months|No|||January 2016|January 27, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602678||9038|
NCT02596204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506-073|Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring|Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring|DCT1A|Children's Hospitals and Clinics of Minnesota|No|Active, not recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|8 Years|17 Years|No|||March 2016|March 22, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02596204||9536|
NCT02548793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822593|CPR Education Via a Mobile Application Compared to VSI Kit|CPR Education for Families of Cardiac Patients Before Hospital Discharge||University of Pennsylvania|Yes|Enrolling by invitation|January 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02548793||13179|
NCT02549066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUHThoraxLL4|Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation|Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation|ICAROX|Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549066||13158|
NCT02601599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC1126|Medical Student INtervention to Promote Effective Nicotine Dependence and Tobacco HEalthcare|Medical Student INtervention to Promote Effective Nicotine Dependence and Tobacco HEalthcare: GrAduate Entry Programme (MIND-THE-GAP) Feasibility Randomised Trial|MIND-THE-GAP|Royal College of Surgeons, Ireland|No|Recruiting|November 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|December 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02601599||9121|
NCT02598830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trainsome 2014#004|COPing With Life Through Exercise and Vitamin D|COPing With Life Through Exercise and Vitamin D: a Double-blinded RCT in Chronic Obstructive Pulmonary Disease Patients (COPD)|Coping|Lillehammer University College|Yes|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|45 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02598830||9334|
NCT02608437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBIT-M4|A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients|A Phase 1b, Open-label, Dose Escalation Study Investigating Different Doses of SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients|NIBIT-M4|Italian Network for Tumor Biotherapy Foundation|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608437||8599|
NCT02384798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUBahia914311|Ventilatory Support Associated With Exercise in Heart Failure|Noninvasive Ventilatory Support Associated With Concurrent Training in Improved Functional Capacity and Quality of Life in Patients With Heart Failure|SVNI|Federal University of Bahia|No|Completed|January 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||March 2015|March 4, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02384798||25768|
NCT02378818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14-P012|Characterization of the Motivational Deficit in Schizophrenia and Depression|SCHIZOBAT/DEPBAT : Characterization of the Motivational Deficit in Schizophrenia and Depression|SCHIZOBAT|Centre Hospitalier St Anne|No|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|140|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|August 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02378818||26228|
NCT02378831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP200/U-adolescence- 001|Comparison of In-lab PSG to WP200 for Assessing Sleep Parameters|Testing for Sleep Apnea in Adolescence Subjects With the WP200/WP200U Compared to an In-lab Overnight PSG Testing||Itamar-Medical, Israel|No|Withdrawn|March 2016|||July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|The study population will include adolescence subjects, age 12-17, referred to the        clinical sleep laboratory for an overnight sleep study|February 2015|August 25, 2015|February 17, 2015|Yes|Yes|has not begun yet.|No||https://clinicaltrials.gov/show/NCT02378831||26227|
NCT02387021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2015002/AR|Continuous Adductor Canal Block for Total Knee Arthroplasty Analgesia|Prospective Comparison Between Continuous Femoral Nerve Block and the Association of Adductor Canal Block and Sciatic Nerve Block in Total Knee Arthroplasty.||Institut Kassab d'Orthopédie|Yes|Not yet recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||March 2015|March 7, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02387021||25597|
NCT02378688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E13|Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease|A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease||Mitsubishi Tanabe Pharma Corporation|Yes|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378688||26238|
NCT02383238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-210|Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content|Randomized, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content|Dapa|University of Erlangen-Nürnberg Medical School|Yes|Completed|March 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02383238||25888|
NCT02381158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000573|Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing|Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|2 Years|5 Years|No|||December 2015|December 18, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02381158||26048|
NCT02453581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP12C10|Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers|An Experimental Study To Characterize the Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection In Healthy Volunteers||Medicines for Malaria Venture|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|May 21, 2015||No||No|June 18, 2015|https://clinicaltrials.gov/show/NCT02453581||20488|
NCT02453854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smallchanges2011|Small Changes a One Year Protocol for Weight Management|Study Protocol: Small Changes, a One-year Weight Management Intervention for Adults Who Are Overweight or Obese||Small Changes|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02453854||20467|
NCT02387775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106185|Temperature Control With an Esophageal Cooling Device in Post Cardiac Arrest Patients|Temperature Control With an Esophageal Cooling Device: A Feasibility Study in Post Cardiac Arrest Patients|E-Chill|Lawson Health Research Institute|No|Recruiting|December 2015|October 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387775||25539|
NCT02387242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High Rif-WBA|Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single 'High' Doses of Rifampicin in Healthy Volunteers||National University Hospital, Singapore|No|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02387242||25580|
NCT02610946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StanfordU TeenTransplant|Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?|Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?||Stanford University|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|12 Years|18 Years|No|||November 2015|November 19, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02610946||8406|
NCT02610959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/879|Iodine Status During Pregnancy and Its Effect on Infant Development.|Iodine Status During Pregnancy and Its Effect on Infant Development; a Randomized Intervention Study With Cod|Mommy'sFood|National Institute of Nutrition and Seafood Research, Norway|Yes|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|142|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610959||8405|
NCT02609958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN001-005|ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy|A Phase 2A, Single Arm, Multicentre, Study of ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy||Aslan Pharmaceuticals|No|Recruiting|October 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02609958||8482|
NCT02609971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07042915KA|Whole Body Vibration in Individuals Submitted to ACL|Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris in Individuals Submitted to Anterior Cruciate Ligament Reconstruction: A Randomized Clinical Trial||Universidade Federal do Rio Grande do Norte|No|Active, not recruiting|February 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Male|18 Years|45 Years|No|||November 2015|November 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609971||8481|
NCT02608866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509057RIND|Single Versus Multiple Fractionated SSRS for Spinal Metastases|A Prospective Randomized Clinical Trial of Single Versus Multiple Fractionated Stereotactic Spine Radiosurgery for Patients With Spinal Metastases||National Taiwan University Hospital|Yes|Recruiting|November 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608866||8566|
NCT02607995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384f|Structured Psychoeducation for Unemployed Adolescents With Extreme Obesity in a Multicenter Observational Study Focusing on Feasibility|Structured Psychoeducation for Unemployed Adolescents With Extreme Obesity in a Multicenter Observational Study Focusing on Feasibility|STEREOplus|University of Ulm|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|14 Years|24 Years|No|Probability Sample|obese adolescents or young adults presenting at 5 different job centers|November 2015|November 17, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02607995||8633|
NCT02601560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5780C00002|Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics, of MEDI6012 in Subjects With Stable Coronary Artery Disease|A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease||MedImmune LLC|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|56|||Both|40 Years|75 Years|No|||December 2015|December 24, 2015|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601560||9124|
NCT02603861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15511|A Study of LY3154207 on Sleep in Healthy Male Participants|An Evaluation of the Impact of Single Doses of LY3154207 on Sleep Latency in Sleep-Deprived Healthy Subjects||Eli Lilly and Company|No|Active, not recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603861||8949|
NCT02604290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSK063|Kinesio Taping Efficacy in Chronic Low Back Pain Treatment (KITALO)|Kinesio Taping Method for Chronic Mechanical Low Back Pain: a Randomised Controlled Trial|KITALO|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Recruiting|January 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|65 Years|No|||November 2015|November 29, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604290||8916|
NCT02595359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis|Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis||Universidade Federal de Pernambuco|No|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595359||9601|
NCT02607722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.202|All-Case Surveillance of Ofev in Patients With IPF in Japan|The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan||Boehringer Ingelheim||Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|N/A|N/A|No|Non-Probability Sample|1000 Japanese patients with IPF|March 2016|March 16, 2016|September 2, 2015||||No||https://clinicaltrials.gov/show/NCT02607722||8654|
NCT02546063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100/15|Carbohydrate Estimation Supported by the GoCARB System|Carbohydrate Estimation Supported by the GoCARB System in Individuals With Type 1 Diabetes||University Hospital Inselspital, Berne|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02546063||13389|
NCT02606812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversidadJAT|Effect of Food Consumption on microRNA Related to Metabolic Syndrome|Effect of Food Consumption on microRNA Related to Metabolic Syndrome. A Randomized Clinical Trial|EFCMRNAMS|Universidad Juárez Autónoma de Tabasco|Yes|Not yet recruiting|October 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|50|||Both|20 Years|22 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02606812||8723|
NCT02609022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-0002|Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis|A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis||CuraVac|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|64 Years|No|||December 2015|December 3, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02609022||8554|
NCT02602275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEURIM, C1501|Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands|Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands - A Randomized, Placebo-controlled, Double-blind, Cross-over Trial of Mode of Action and Response Prediction by Functional Magnetic Resonance Imaging MRI|NEURIM|Biologische Heilmittel Heel GmbH|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Male|31 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02602275||9069|
NCT02597140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAng|Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement in Facial Plastic Surgery|Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement During Monitored Anesthesia Care in Facial Plastic Surgery||Chung-Ang University Hospital|Yes|Recruiting|August 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|20 Years|65 Years|No|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597140||9464|
NCT02597153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HE154/PRO/Ⅱ|Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas|A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|October 2015|October 2020|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597153||9463|
NCT02605044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB12006|Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer|A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid) to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer||AB Science||Recruiting|January 2014|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605044||8858|
NCT02607462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP THA 092015|PRP Therapy to m. Gluteus Medius During THA|Single Injection of Platelet-rich Plasma (PRP) to m. Gluteus Medius During Total Hip Arthroplasty Using Direct Lateral (Hardinge) Approach||Satakunta Central Hospital|No|Not yet recruiting|November 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02607462||8674|
NCT02606435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEED|Thrombus Aspiration in Patients With STEMI|Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI)||Xijing Hospital|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||November 2015|November 12, 2015|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606435||8751|
NCT02607046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1927-P|Post-revascularization Rehabilitation to Improve Function in Veterans With PAD|Post-revascularization Rehabilitation to Improve Function in Veterans With PAD||VA Office of Research and Development|No|Recruiting|October 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|52|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607046||8706|
NCT02609607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15100104|Treating Anorectal Dysfunction in MS|Treating Anorectal Dysfunction Associated With Multiple Sclerosis||University of Pittsburgh|Yes|Not yet recruiting|January 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609607||8509|
NCT02605551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH-2-022015|Hypertension and Osteopathic Treatment|The Utilization of Osteopathic Manipulation (OMT) as an Adjunct Therapy in the Treatment of Hypertension|HOT|Larkin Community Hospital|No|Enrolling by invitation|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02605551||8819|
NCT02610556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-071-Dept. of RT|Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma|Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial||Sun Yat-sen University|No|Recruiting|January 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610556||8436|
NCT02598635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1419|Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis|Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Recruiting|October 2015|June 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|100 Years|No|||November 2015|November 10, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02598635||9349|
NCT02604004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUD_04_12|Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers|Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet 150 mg (Test) and EPIVIR of Glaxosmithkline in Healthy Volunteers of Both Genders in Fasting Condition||Universidade Federal de Pernambuco|Yes|Completed|April 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02604004||8938|
NCT02604017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-590|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)||AbbVie|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604017||8937|
NCT02605759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0013|Coldplay Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia|Clinical Study to Evaluate the Safety, Feasibility and Efficacy of the Coldplay CryoBalloon Focal Ablation System for the Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia||C2 Therapeutics, Inc.|No|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02605759||8803|
NCT02598037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31573114.1.0000.5257|Association Between the Change of the FTO Gene With Hormones and Food Consumption of Obese|Association Between the Change of the FTO Gene With the Hormones Ghrelin and Leptin and Food Consumption of Obese||Universidade Federal do Rio de Janeiro|No|Recruiting|September 2014|March 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|78|||Female|20 Years|50 Years|No|||November 2015|November 3, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02598037||9395|
NCT02605902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|online-tics iCBIT|Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders|Randomized Observer Blind Clinical Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders|ONLINE-TICS|Hannover Medical School|No|Not yet recruiting|February 2016|September 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605902||8792|
NCT02605993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1210-PNH-201|A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria|A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria||Alexion Pharmaceuticals|Yes|Recruiting|November 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605993||8785|
NCT02606214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBA-354-CL-002|A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects||Global Alliance for TB Drug Development|No|Terminated|November 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|18|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 5, 2015|No|Yes|Clinical Hold from FDA|No||https://clinicaltrials.gov/show/NCT02606214||8768|
NCT02595541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087140|Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension|Effects of Adding Oral Sildenafil to Intravenous Milrinone on Postoperative Pulmonary Hypertension in Pediatric Undergoing Repair of Ventricular Septal Defect||Assiut University|Yes|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|2 Months|24 Months|No|||November 2015|November 10, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595541||9587|
NCT02594800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10688|Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis|The Impact of Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Evaluated by Computed Tomography Perfusion (CTP)||Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Not yet recruiting|November 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|No|||September 2015|November 1, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594800||9644|
NCT02610829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1291|Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects|Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects|Gammadose|University of North Carolina, Chapel Hill|No|Recruiting|November 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02610829||8415|
NCT02596815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE0072015-3|Hypoalgesic Effect of Median Nerve Neural Mobilization Compared to a Controlled Group|Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group||Universidad Europea de Madrid|Yes|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|45 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596815||9489|
NCT02606799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM_CS_001|Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy|Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - a Randomized Study (EXCESS)|EXCESS|Universitätsklinikum Hamburg-Eppendorf|No|Not yet recruiting|December 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02606799||8724|
NCT02607436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1111/139-007|Effect of Sarpogrelate, a Serotonin Receptor Antagonist on Coronary Artery Disease|Effect of Sarpogrelate, a Serotonin Receptor Antagonist on Progression of Coronary Artery Disease|SAGE-CAD|Seoul National University Bundang Hospital|No|Recruiting|July 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607436||8676|
NCT02609841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-008|POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study|POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis (PORTEND): A Multicenter, Prospective, Observational Study|PORTEND|ZS Pharma, Inc.|No|Recruiting|September 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects has ESRD and has been stable and compliant (as determined by the investigator) on        3 times weekly maintenance hemodialysis for at least 60 days.|November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609841||8491|
NCT02606396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510035|Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer|Palliation of Malignant Dysphagia With Spray Cryotherapy in Patients With Advanced Esophageal Cancer: A Pilot Study||Washington University School of Medicine|Yes|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606396||8754|
NCT02604771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00249|Egypt Hypertension Study|An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension||AstraZeneca|No|Not yet recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be collected from private care clinics.|November 2015|November 11, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02604771||8879|
NCT02602964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50874.091.14|A Trial Comparing Deep Versus Moderate Neuromuscular Block - in Low Pressure Pneumoperitoneum|A Randomized Controlled Trial Comparing Deep Versus Moderate Neuromuscular Block - in Low Pressure Pneumoperitoneum - to Optimize the Surgical Conditions During Laparoscopic Donor Nephrectomy|LEOPARD-3|Radboud University|No|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02602964||9017|
NCT02607488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-15-10-47|Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery|Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Laparoscopic Bariatric Surgery: A Dose Dependent Study||Mansoura University|Yes|Recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|180|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02607488||8672|
NCT02609906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-15|Operative Treatment of 2-fragment-fractures (AO 11-A3) of the Proximal Humerus in the Elderly: Cement Augmented Locking Plate Philos vs. Proximal Humerus Nail MultiLoc|||Klinikum der Universitaet Muenchen|Yes|Recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609906||8486|
NCT02604173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35330|Altitude Sickness Prevention and Efficacy of Comparative Treatments|A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments|ASPECT|Stanford University|Yes|Not yet recruiting|August 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02604173||8925|
NCT02606474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obgyn. . .|Placenta Accreta&Its Complications in Placenta Previa Cases|Incidence of Placenta Accreta & it's Complications in Cases of Previous Cesarean With Placenta Previa Anterior||Kasr El Aini Hospital|No|Not yet recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|Pregnant with gestational age more than 30 weeks with previous one or more cesarean        section with placenta previa anterior|November 2015|November 13, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02606474||8748|
NCT02595619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 0068144|Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal|Combined Strategy of Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal in Patients With Acute Kidney Injury||University of Turin, Italy|No|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||November 2015|November 2, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02595619||9581|
NCT02600364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP64/BO1507|Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device|Prospective, Multicenter, Single Arm Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device||Phenox GmbH|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|107|||Both|18 Years|N/A|No|Non-Probability Sample|The target population for this non-interventional study are patients with ruptured or        unruptured aneurysms and segmental diseases in the anterior circulation. Patients can be        included in the study if they meet all of the inclusion and none of the exclusion criteria        (Chapter 8.3 Subjects on page 21) and have provided written informed consent.|March 2016|March 22, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600364||9216|
NCT02603224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG201-30-001|Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers and Patients With Cutaneous Scleroderma|A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of MRG-201 Following Local Intradermal Injection in Normal Healthy Volunteers and Patients With Cutaneous Scleroderma||miRagen Therapeutics, Inc.|No|Recruiting|November 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603224||8997|
NCT02609945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIP-AM-1035|Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults|A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults||Acorda Therapeutics|Yes|Active, not recruiting|November 2015|April 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609945||8483|
NCT02596867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E15123|Neoadjuvant Propanolol in Breast Cancer|Pilot "Window of Opportunity" Neoadjuvant Study of Propranolol in Breast Cancer|NPBC|Texas Tech University Health Sciences Center, El Paso|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|No|||November 2015|November 3, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596867||9485|
NCT02597179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08-065|Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer|Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer||Samsung Medical Center|No|Recruiting|September 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|350|||Both|21 Years|N/A|No|Probability Sample|Histologically or cytologically conrfirmed breast cancer that is either metastatic or        young breast cancer(≤ 40 years of age) with feasible biopsy site.|November 2015|November 4, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02597179||9461|
NCT02605421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LS108|Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma|Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma||Masonic Cancer Center, University of Minnesota|Yes|Not yet recruiting|January 2016|January 2023|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|30 Years|No|||November 2015|November 12, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605421||8829|
NCT02607618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICL-24-ABSSSI2|Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2|A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2|REVIVE-2|Motif Bio|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|March 20, 2016|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607618||8662|
NCT02607631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04-132-005|A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor|A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy||Samsung Medical Center|Yes|Not yet recruiting|November 2015|August 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02607631||8661|
NCT02597894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000360|Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy|Feasibility of Repeat Targeted Biopsies in Patients Undergoing High-Dose-Rate Prostate Brachytherapy||Jonsson Comprehensive Cancer Center|Yes|Not yet recruiting|December 2015|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|8|||Male|18 Years|N/A|No|||October 2015|November 3, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597894||9406|
NCT02602626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2178|The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study|The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study||University of North Carolina, Chapel Hill|No|Not yet recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women will be recruited from the hospital based UNC Obstetric and Gynecology (UOG) Clinic        including the resident clinic, faculty clinics and maternal fetal medicine clinics. The        UOG Clinic cares for a diverse population of women from the immediate geographical area as        well as referrals from 14 surrounding funded health centers.|November 2015|November 9, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602626||9042|
NCT02607033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1788-W|Exercise and Weight Loss to Improve Mobility Function in Veterans With PAD|Exercise and Weight Loss to Improve Mobility Function in Veterans With PAD|Action3|VA Office of Research and Development|Yes|Recruiting|October 2015|April 2021|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|60 Years|80 Years|No|||November 2015|November 25, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607033||8707|
NCT02600689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFF-378875|Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis|Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis|EXPLORE-IPF|University of Alabama at Birmingham|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600689||9191|
NCT02600702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444/2557(EC4)|A Study of Siriraj Home Exercises Protocol for Primary Osteoarthritis of the Knee|A Randomized Control Study of Siriraj Home Exercises Protocol for Primary Knee Osteoarthritis Patients Versus Usual Orthopedic Outpatient Consultation in Primary Knee Osteoarthritis Patients||Mahidol University|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|50 Years|N/A|No|||November 2015|November 6, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600702||9190|
NCT02603029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Belinal 01-2015|Influence of of Cream With the Silver Fir Wood Extract (Belinal) on Skin|Placebo Controlled Study of Influence of Cream With the Silver Fir (Abies Alba) Wood Extract on the Skin||Higher School of Applied Sciences (VIST)|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|10|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||November 2015|March 7, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603029||9012|
NCT02604719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA&Ethamsylate-PPH|Tranexamic Acid and Ethamsylate For Preventing PPH in Patient Undergoing LSCS at High Risk For PPH|Tranexamic Acid and Ethamsylate For Preventing Post Partum Hemorrhage in Patient Undergoing LSCS at High Risk For Post PartumHemorrhage : A Randomized Controlled Trial||Ain Shams University|Yes|Not yet recruiting|November 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604719||8883|
NCT02607163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0672|The Effect of Dexmedetomidine on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery|||Yonsei University|No|Recruiting|September 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|108|||Both|20 Years|100 Years|No|||November 2015|November 16, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02607163||8697|
NCT02596490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0275|Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners|Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners||M.D. Anderson Cancer Center|No|Not yet recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02596490||9514|
NCT02596503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0659|A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors|A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors||University of Colorado, Denver|Yes|Recruiting|October 2015|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|13 Years|30 Years|No|||November 2015|November 3, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596503||9513|
NCT02389569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE nº: 27790214.1.0000.541|Clinical Study of Biosilicate Under Resin Composite Restorations in Caries Affected Teeth|A Prospective, Double-blind, Randomized, Group Controlled Clinical Study on the Use of Biosilicate Under Resin Composite Restorations in Caries Affected Teeth||University of Sao Paulo||Recruiting|February 2015|December 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|March 10, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02389569||25401|
NCT02393599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lorcaserin-Phase 1b-001|Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin|Phase 1, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin||National Institute on Drug Abuse (NIDA)|No|Completed|May 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02393599||25092|
NCT02383368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4132-CL-0001|A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma|An Open-Label, Dose-escalation/Expansion, Phase 1 Study of ASP4132, Given Orally to Subjects With Advanced Refractory Solid Tumors and Lymphoma||Astellas Pharma Inc|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383368||25878|
NCT02383615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201302730|Comparison of Two Different Ultrasound Guided Techniques for Saphenous Nerve Block|A Comparison of Two Different Ultrasound-Guided Approaches to the Saphenous Nerve Block - Adductor Canal vs. Distal Trans-sartorial: A Prospective, Randomized, Blinded, Non-Inferiority Trial||University of Iowa|No|Completed|April 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02383615||25859|
NCT02383888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346.4|Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Japanese and Chinese Male Subjects (Randomized, Double-blind, Placebo-controlled Design Within Dose Groups)||Boehringer Ingelheim||Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|49|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|March 6, 2015||||No||https://clinicaltrials.gov/show/NCT02383888||25838|
NCT02389153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kollaborative Behandlung-01287|Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease|Feasability and Effectiveness of a Collaborative Care Intervention in the Secondary Prevention of Coronary Heart Disease - A Pilot Study||University of Göttingen|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02389153||25433|
NCT02383251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-OV231|Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer|A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance|TAPAZ|ARCAGY/ GINECO GROUP|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Female|18 Years|95 Years|No|||October 2015|October 22, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383251||25887|
NCT02387086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELI|Gefitinib Combined With Thalidomide to Treat NSCLC|A Phase III, Multi Center, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination Gefitinib With Thalidomide in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer With EGFR Mutation||Shaanxi Provincial People's Hospital|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|75 Years|No|||March 2015|March 11, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387086||25592|
NCT02385903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8546|Randomized Controlled Trial on the Use of Flammacerium in Necrotic Arterial Wounds of the Lower Limb Versus Standard Treatment||Flammacérium|University Hospital, Montpellier|Yes|Terminated|September 2009|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 24, 2015||No|Decision of the Independent Review Committee|No||https://clinicaltrials.gov/show/NCT02385903||25683|
NCT02386150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-05|ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost|Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intradermally to Healthy Adults as a 3-Dose Primary Series and Booster||U.S. Army Medical Research and Materiel Command|No|Not yet recruiting|October 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|February 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02386150||25664|
NCT02458963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG3|IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS|In Vitro Fertilization Versus Gonadotropin Therapy in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome||Mansoura University|No|Not yet recruiting|January 2016|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|35 Years|No|||January 2016|January 29, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458963||20075|
NCT02459080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126|Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|COPD|Theravance Biopharma R & D, Inc.||Recruiting|September 2015|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|618|||Both|40 Years|N/A|No|||September 2015|September 22, 2015|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459080||20066|
NCT02376673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CincinnatiChildrens|Comparing Children's Book to Brochures for Safe Sleep Education in a Home Visiting Program|A Randomized Controlled Trial Comparing a Children's Book to Brochures for Safe Sleep Education in an At-Risk Population Enrolled in a Home Visitation Program||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|June 2014|March 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|230|||Both|15 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02376673||26393|
NCT02376972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFX-VAG/003/2012|Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis|VARIANT|Alfa Wassermann S.p.A.|Yes|Recruiting|March 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|626|||Female|18 Years|50 Years|No|||June 2015|June 17, 2015|February 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02376972||26370|
NCT02392975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1917|Fast MR for Young Children With Traumatic Brain Injury|Fast MR for Young Children With Traumatic Brain Injury||University of Colorado, Denver|No|Recruiting|April 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|400|||Both|N/A|72 Months|No|||September 2015|September 23, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02392975||25140|
NCT02380391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVERE2ST-HIV|EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome (ST+/ST-) in HIV|EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.|EVERE2ST-HIV|Saint Antoine University Hospital|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|260|Samples With DNA|Each blood sample is composed of 5 tubes, for a total volume of 25 ml of blood :        -  1 x 4.5 ml citrated tube : standard light transmission aggregometry        -  1 x 4.5 ml citrated tube : Bedside test VerifyNow        -  2 x 4.5 ml citrated tubes : flow cytometry        -  1 x 7 ml EDTA tube : genetic analysis of cytochrome P450 2C19      Blood samples do not require fasting.|Both|18 Years|N/A|No|Non-Probability Sample|Adults with a history of acute coronary syndrome (at least one month before inclusion)        with or without coronary revascularization and under any antiplatelet therapy.        Controls matched on age (±5 years), sex, and known diabetes.|February 2015|February 28, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02380391||26107|
NCT02384291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-BG-01|Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone vs. Commercially Available Bone Graft|Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone Versus Commercially Available Bone Graft. A Prospective Randomized Clinical Trial||Alpha - Bio Tec Ltd.|Yes|Active, not recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02384291||25807|
NCT02598934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18057|A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis|A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients||Hoffmann-La Roche||Completed|August 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Female|N/A|N/A|No|||February 2016|February 10, 2016|November 4, 2015|Yes|Yes||No|February 10, 2016|https://clinicaltrials.gov/show/NCT02598934||9326|
NCT02599181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNC-Inf|Local Inflammation Does Not Correlate With Bacterial Colonization and Contamination of Perineural Catheters|Local Inflammation Does Not Correlate With Bacterial Colonization and Contamination of Perineural Catheters||Balgrist University Hospital|No|Completed|January 2013|May 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02599181||9307|
NCT02599246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIVLEAKS1|FiO2 in Chronic Obstructive Pulmonary Disease (COPD) Patient Normobaric O2 Versus NIV|Measured FiO2 With Nasal Canula O2 Versus Noninvasive Ventilation (NIV) With the Same O2 Flow, in COPD Patients the NIV LEAKS Study|NIVLEAKS|Breas Medical S.A.R.L.|No|Not yet recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with chronic obstructive pulmonary disease. With day time oxygenotherapy and        nocturnal NIV and O2 supply|November 2015|November 5, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02599246|1 Day|9302|
NCT02595086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLASS-04|Comparison of Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy|Multicenter Randomized Controlled Trial Comparing Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy for the Middle Third Early Gastric Cancer (KLASS-04)|KLASS-04|Seoul National University Hospital|Yes|Recruiting|July 2015|June 2023|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|20 Years|80 Years|No|||June 2015|November 1, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595086||9622|
NCT02609347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1050061|Manual Therapy After Ankle/Hindfoot Fractures|Immediate Effects of Manual Therapy for Patients After Ankle/Hindfoot Fractures||Intermountain Health Care, Inc.|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02609347||8529|
NCT02609360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1897|Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming|Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|May 2013|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02609360||8528|
NCT02604667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411015653|Mechanisms of Ischemic Stroke in Cancer Patients|Mechanisms of Ischemic Stroke in Cancer Patients|MOST-CA|Weill Medical College of Cornell University|No|Recruiting|November 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|165|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|We plan to enroll three groups of 55 patients each. Group 1 will consist of patients with        acute ischemic stroke and active solid tumor cancer, Group 2 will include patients with        acute ischemic stroke and no cancer, and Group 3 will include patients with active solid        tumor cancer and no stroke.|March 2016|March 3, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604667||8887|
NCT02606695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.IGA1503|Comprehensive Spinal Alignment Planning Study|A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used||NuVasive|No|Enrolling by invitation|November 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|At least 300 patients will be enrolled in this multicenter observational study. The        following eligibility criteria are designed to identify existing clinic patients for whom        study under this protocol are considered appropriate. All subjects must meet the        inclusion/exclusion criteria below in order to be considered for enrollment.|January 2016|January 15, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02606695||8732|
NCT02600390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGSC-009|SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer|An Open-label, Repeated-dose, Dose Escalation Study of the Safety and Effectiveness of SANGUINATE™ for the Treatment of Leg Ulcers in Adult Patients With Sickle Cell Disease|LU|Prolong Pharmaceuticals|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|November 6, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600390||9214|
NCT02608671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adhesive tape&episiotomy|Adhesive Tape in Episiotomy Repair|SKIN ADHESIVE TAPE COMPARED WITH CONTINUOUS SUTURE IN PERINEAL SKIN REPAIR AFTER EPISIOTOMY: RANDOMIZED TRIAL||Ain Shams University|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608671||8581|
NCT02604082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0367|Comparison of Three Technical Airway Clearance in Mechanical Ventilated Patients|Comparison of Three Technical Airway Clearance in Mechanical Ventilated Patients|ClearanceMV|Hospital de Clinicas de Porto Alegre|No|Completed|September 2011|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02604082||8932|
NCT02604095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melatonin|Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism|Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism||Shanghai 10th People's Hospital|Yes|Completed|May 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|No|||November 2015|November 13, 2015|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604095||8931|
NCT02596347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2877|The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)|The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease||National Jewish Health|No|Recruiting|April 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|12|Samples With DNA|Bronchoalveolar lavage fluid 4 heparin tubes for PBMC|Both|18 Years|80 Years|No|Non-Probability Sample|Those diagnosed with Beryllium Sensitization. Those diagnosed with Chronic beryllium        disease|September 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02596347||9525|
NCT02596360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0248|Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers|Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers|Hydex|University Hospital, Clermont-Ferrand||Not yet recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02596360||9524|
NCT02595645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENESIS|GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps|GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps|GENESIS|University of Ulm|No|Recruiting|August 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02595645||9579|
NCT02608138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153NU2|Iodine Status in Portuguese Children and the Role of Salt Fortification in School Canteens|Iodine Status in Portuguese Children and the Role of Salt Fortification in School Canteens|IoGeneration|Universidade do Porto||Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|4800|Samples Without DNA|Urine|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|School aged children (6-12 years)|October 2015|January 28, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608138||8622|
NCT02602054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-07|The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants|The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Recruiting|October 2015|October 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|30 Days|No|||November 2015|November 16, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02602054||9086|
NCT02604992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS004-15-059|Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers|An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions||INSYS Therapeutics Inc|Yes|Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604992||8862|
NCT02610465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160019|High Image Matrix CT Reconstruction|High Image Matrix CT Reconstruction||National Institutes of Health Clinical Center (CC)||Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|99 Years|No|||October 2015|November 21, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02610465||8443|
NCT02610491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143036|The Effect of Hesperidin on Glucose / Insulin Metabolism|The Effect of Hesperidin Administration on Glucose / Insulin Metabolism||Maastricht University Medical Center|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02610491||8441|
NCT02598102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INU/RRC/01/2014-15|Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia|Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia||Institute of Nephro Urology, Bangalore|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Male|18 Years|60 Years|No|||November 2015|November 23, 2015|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598102||9390|
NCT02609529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8847|SBI in Children With d-IBS|Double-Blind, Randomized Pilot Study Evaluating Oral Serum-Derived Bovine Immunoglobulin Protein Isolate (SBI) on Nutritional Status in Children With Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609529||8515|
NCT02609555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MansouraU26|TEM Assisted Perineal Rectopexy in Treatment of Rectal Prolapse|Trans-anal Endoscopic Microsurgery (TEM) Assisted Perineal Rectopexy With Postanal Repair and Anal Cerclage In Treatment of Rectal Prolapse (Novel Technique)||Mansoura University|Yes|Recruiting|October 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|80 Years|No|||November 2015|November 18, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609555||8513|
NCT02597400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMM0104|Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM|A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Glucokinase (GK) Activator HMS5552 and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)||Hua Medicine Limited|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|October 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597400||9444|
NCT02597413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/MN-01|Evaluation of Post-voiding Residual Urine: a Before-after, Post-partum Study|Evaluation of Post-voiding Residual Urine: a Before-after, Post-partum Study|RPM-Eval|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|368|||Female|18 Years|N/A|No|Non-Probability Sample|The study population is all paturient women admitted to delivery rooms.|November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02597413||9443|
NCT02601365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCH0001|Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia|A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia|iGRASP|Milton S. Hershey Medical Center|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|2 Months|18 Years|No|||November 2015|November 6, 2015|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601365||9139|
NCT02601378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLXS196X2101|A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma|A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma||Novartis|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601378||9138|
NCT02601638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411097|Laryngectomy Education|Effect of Total Laryngectomy Preoperative Education on Postoperative Complications and Unplanned Hospital Readmission||Washington University School of Medicine|No|Recruiting|November 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601638||9118|
NCT02607540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF and esophageal cancer|Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer|Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer|PFCRTESC|The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|45 Years|75 Years|No|||January 2016|January 10, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607540||8668|
NCT02599155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1507-061-687|The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery|The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery||Seoul National University Hospital|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|7 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599155||9309|
NCT02599441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733368-1|Computed Tomography for Evaluating Supination-external Rotation Type Ankle Fractures|Comparison of a Novel Weight Bearing Cone-beam Computed Tomography (CT) Scan to Gravity Stress X-ray for Determining Instability of Supination-external Rotation Type Ankle Fractures||State University of New York at Buffalo|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients who have been diagnosed with unstable supination-external rotation type ankle        fractures|November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599441||9287|
NCT02594969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523979|The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis|The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis|AD|University of California, Davis|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|July 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02594969||9631|
NCT02597712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-016|YF476 in Barrett's Esophagus|Randomized, Placebo-controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus||Trio Medicines Ltd.|No|Enrolling by invitation|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597712||9420|
NCT02597725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urodynamics in prostate cancer|Salvage Radiotherapy After Radical Prostatectomy|Changes in Bladder Function After Surgery and Radiation Therapy for Prostate Cancer|SRT|University of Aarhus|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Male|50 Years|90 Years|No|Probability Sample|The patients in this cohort had surgery for prostate cancer in the period from 1999-2009.        Because of a locale disease relapse the patients were treated with Salvage radiation        therapy in the period from 2006-2010.|October 2015|November 4, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02597725||9419|
NCT02601729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM-RESCUE|Reimbursement Study of Continuous Glucose Monitoring in Belgium|Clinical Impact of RT-CGM Reimbursement in Belgium: a Multicenter Real-life Observational Study|RESCUE|Katholieke Universiteit Leuven|No|Active, not recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|selected group of type 1 diabetic patients by means of a so-called "CGM convention". In        order to be a candidate for reimbursement, patients have to be on an insulin pump and use        their RT-CGM device for more than 70 % of the time (see www.riziv.be, Nota CGV 2014/228).        Reimbursement via the CGM convention has been granted for an initial period of three        years. As part of the requirements of the current convention, the Belgian health care        authorities demanded for an evaluation after 2 years.|November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601729||9111|
NCT02595242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HE1505/PRO/Ⅰ|Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma|Safety and Efficacy Study of Mitoxantrone Hydrochloride Liposome Injection Plus Cyclophosphamide,Vincristine and Prednison (CNOP)in Diffuse Large B Cell Lymphoma||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595242||9610|
NCT02606617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDBG|A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes|What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo||Third Military Medical University||Not yet recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Years|65 Years|No|||November 2015|November 15, 2015|October 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606617||8737|
NCT02607696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 057/15|Pharmacokinetics of Zolpidem Orodispersible Tablet|Phase I Randomized Clinical Trial of Evaluation of Zolpidem Hemitartarate Pharmacokinetics (Orodispersible Tablet 1.75 mg and 3.50 mg) After Single Dose Oral Administration in Male and Female Healthy Subjects||Biolab Sanus Farmaceutica|No|Not yet recruiting|May 2016|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607696||8656|
NCT02607800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1172|Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects With Chronic HCV Infection|POLARIS-2|Gilead Sciences|Yes|Recruiting|November 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|780|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607800||8648|
NCT02609750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS2011/005|WorkUp. Structured Care With Workplace Interventions to Improve Work Ability in Patients With Neck and/or Low Back Pain|WorkUp. Early Structured Care Including Workplace Interventions to Improve Work Ability in Patients With Neck and/or Back Pain. A Prospective Pare Wise Cluster Randomized Controlled Trial in Primary Care With One Year Follow up|WorkUp|Lund University|No|Active, not recruiting|January 2013|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|67 Years|No|||March 2016|March 3, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609750||8498|
NCT02609763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPK-SCALE-03|Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale|Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale||Topokine Therapeutics, Inc.|No|Completed|November 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|||Both|25 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Eligible adults with varying degrees of lower eyelid steatoblepharon|November 2015|November 29, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609763||8497|
NCT02599792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP656.1002|Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656|A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656||Concert Pharmaceuticals|No|Recruiting|November 2015|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|5||Anticipated|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599792||9260|
NCT02599285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50169.098.15|Fixation of the Posterior Malleolus in Trimalleolar AO Weber C Fractures.|Operative Treatment of AO Weber C Fibular Fractures With Additional Medium-sized Posterior Malleolar Fragment: Syndesmotic Reduction and Functional Outcome After Syndesmotic Positioning Screws or Posterior Fragment Fixation. POSTFIX-C Trial: a Prospective Comparative Observational Study.|POSTFIX-C|Medical Center Haaglanden|No|Recruiting|November 2015|||December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|54|||Both|18 Years|70 Years|No|Non-Probability Sample|All patients presenting with a trimalleolar AO-Weber C fracture with additional posterior        fragment (5-25% of the involved articular surface, AO type 44-C1, 44-C2, 44-C3) in the        participating hospitals between the age of 18 and 70 could be included in our study.|November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599285||9299|
NCT02599298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC CSA 2015|Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome|Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome|SGMT|National University, Singapore|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|22 Years|N/A|No|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599298||9298|
NCT02599389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/40|Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis|Economic Evaluation Comparing Standard Balloon Angioplasty Versus Drug-eluted Balloon or Laser-Excimer in Association With Drug-eluted Balloon in the Treatment of Femoropopliteal Artery In-stent Restenosis.|INTACT|University Hospital, Bordeaux|Yes|Not yet recruiting|November 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|252|||Both|18 Years|N/A|No|||October 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599389||9291|
NCT02599402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-401|Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma|Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401|CheckMate 401|Bristol-Myers Squibb|Yes|Active, not recruiting|December 2015|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|615|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599402||9290|
NCT02617667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYS-002|CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)|A Phase 2, Multi-center, Randomized, Double-masked, Placebo (Vehicle)-Controlled Clinical Study With an Open Label Comparator Arm to Assess the Efficacy, Safety and Tolerability of Topical CyclASol® for Treatment of Dry Eye Disease||Novaliq GmbH|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|99 Years|No|||January 2016|January 11, 2016|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617667||7890|
NCT02596880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-02-159-30278|Sofosbuvir, Daclatasvir, Ribavirin for HCV Cirrhotics|Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin|SD100|Tehran University of Medical Sciences|No|Active, not recruiting|September 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 27, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596880||9484|
NCT02601625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3461C00006|A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects|A Randomized, Phase 1, Placebo-controlled, Double-blind, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Subjects.||AstraZeneca|No|Active, not recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601625||9119|
NCT02604641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q10 01-2014|Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin|Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin: Randomised, Double-blind, Placebo-controlled Pilot Study||Higher School of Applied Sciences (VIST)|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|33|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||November 2015|March 7, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02604641||8889|
NCT02604654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWYY-YQTLKL|Effectiveness and Safety of Yiqitongluo Granule for Stroke|Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome||First Hospital of Jilin University|Yes|Enrolling by invitation|November 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2400|||Both|18 Years|85 Years|No|||November 2015|November 20, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604654||8888|
NCT02608658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLouisU 25320|Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites|Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites||St. Louis University|No|Recruiting|August 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02608658||8582|
NCT02595151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G001|Real-time Observation of Microcirculatory Hemodynamics in Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy|Real-time Observation of Microcirculatory Hemodynamics in Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy: a Feasibility Study||Shandong University|Yes|Recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|94|Samples Without DNA|Targeted fresh biopsy samples from each examined site were fixed in 10% pH neutral formalin,      and embedded in paraffin. Slides of 4-um sections were deparaffinized and hydrated. After      antigen retrieval and blocking procedures, Immunology and Histology Chemistry (IHC) staining      for CD34 was performed by mouse anti-CD34 monoclonal antibody (ZM-0046, ZSGB-BIO, Beijjing,      China) as per the manufacturers' instructions.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients with GIM under endoscopic surveillance or examination at Qilu        Hospital from March 1 to September 31, 2015 were recruited into this study. 94 patients        were eligible for analysis (50 males and 44 females; average age 53 years, range 22-80        years).|September 2015|November 1, 2015|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595151||9617|
NCT02597114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT-181-103|Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181 in Adult Patients With Mucopolysaccharidosis Type I|An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102||ArmaGen, Inc|Yes|Enrolling by invitation|November 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597114||9466|
NCT02597127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-PCS-15-01|Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)|A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C|ORION|The Medicines Company|Yes|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|99 Years|No|||January 2016|January 11, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597127||9465|
NCT02596308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT017|Immunogenicity and Safety of Subunit Plague Vaccine|Immunogenicity and Safety of Subunit Plague Vaccine Comprised by Fraction 1 Capsule (F1) and Virulence-Associated (V) Antigens: A Random Phase 2a Clinical Trial||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|October 2014|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596308||9528|
NCT02608736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BarretosCH - Head and Neck|Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid|Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated|GAMA|Barretos Cancer Hospital|Yes|Recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|December 30, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608736||8576|
NCT02607501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-15-009|European eCLIPS™ Safety, Feasibility and Efficacy Study|A Multi-center Post Marketing Study Evaluating the Safety, Technical Feasibility, and Efficacy of the eCLIPs™ Family of Products for the Treatment of Bifurcation Intracranial Aneurysms.|EESIS|Evasc Medical Systems Corp.|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|19 Years|N/A|No|||November 2015|November 19, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607501||8671|
NCT02595411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA_Reliability_2015|Reliability of the Melbourne Assessment|Reliability of the Melbourne Assessment||University Children's Hospital, Zurich|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|30 Months|20 Years|No|Probability Sample|Children with central motor disorders and impaired upper limb function|September 2015|February 4, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595411||9597|
NCT02606565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-118|Effectiveness of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections|Acceptability and Effectiveness of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections in Lira District, Northern Uganda: A Randomised Controlled Trial||Makerere University|Yes|Not yet recruiting|June 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|N/A|2 Days|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606565||8741|
NCT02596620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8C0201|Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication|The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies||Chang Gung Memorial Hospital|Yes|Completed|October 2013|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|80 Years|No|||November 2015|November 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596620||9504|
NCT02605083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eFT508-0001|A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors|A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors||Effector Therapeutics|No|Recruiting|November 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605083||8855|
NCT02605239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-18a|Phycosocial Impact of Bleaching Teeth|Effect on Oral Health, Phycosocial Impact and Esthetics Perception of Bleaching Teeth|PSYBLE|University of Chile|Yes|Completed|March 2013|October 2015|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605239||8843|
NCT02607566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT008830|Yoga for Type 2 Diabetes|Yoga as a Complementary Therapy for Type 2 Diabetes: An Initial Investigation||The Miriam Hospital|No|Recruiting|September 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607566||8666|
NCT02610816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2187|Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids|Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|January 2016|April 2018|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|292|||Both|6 Years|17 Years|No|||January 2016|January 4, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610816||8416|
NCT02601079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endodrill I|Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis|Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis in Tumors of the Distal Esophagus and Cardia||Region Skane|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|85 Years|No|||November 2015|November 7, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02601079||9161|
NCT02598323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-24|Prevention and Treatment of Premature Labour for Asymptomatic Pregnant Women|Premature Labour Screening by Cervical Ultrasound for Asymptomatic Pregnant Women in the PACA Region. Various Treatment Strategies : 1. Progesterone 200mg (Vaginal Way) 2. Pessary 3. Vaginal Stitching 4. Rest|Echo-col|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3500|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598323||9373|
NCT02595957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160017|Clinical Center Genomics Opportunity Secondary Findings Analysis and Return|Clinical Center Genomics Opportunity Secondary Findings Analysis and Return||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|N/A|100 Years|No|||October 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02595957||9555|
NCT02595970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AFR01|Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis|A 52-week, Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Participants Suffering From Moderate to Severe Psoriasis|IPSI-PSO|Novartis|No|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02595970||9554|
NCT02618889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4496|OnabotulinumtoxinA in the Management of Psychogenic Dystonia|OnabotulinumtoxinA in the Management of Psychogenic Dystonia||University of Cincinnati|No|Not yet recruiting|November 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618889||7797|
NCT02605811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GACA1501|Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer|Radiation Versus Temozolomide in Preventing Brain Metastases in Limited Stage Small Cell Lung Cancer||Guangzhou Medical University|Yes|Recruiting|September 2015|April 2021|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|426|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605811||8799|
NCT02611206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505M71821|Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms|Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|30|||Both|12 Years|18 Years|No|||November 2015|November 18, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611206||8387|
NCT02611219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406031|Deconditioning in Transplant|Effect of Increased Activity on Deconditioning in Pediatric Stem Cell Transplant Recipients: A Feasibility Study||Washington University School of Medicine|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|7 Years|17 Years|No|||November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02611219||8386|
NCT02606201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130927|Peri-sphincter Injection of Autologous Myofibres to Treat of Urinary Incontinence by Sphincter Deficiency|Peri-sphincter Injection of Autologous Myofibres to Treat of Urinary Incontinence by Sphincter Deficiency|IPSMA|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Female|18 Years|N/A|No|||October 2015|November 13, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02606201||8769|
NCT02609802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09-028|The Different Hypnotic Potency of Volatile Anesthetics at Equi-MAC: EEG Based Study|The Different Hypnotic Potency of Sevoflurane and Desflurane at Equi-minimum Alveolar Concentration: EEG Based Study||Kangbuk Samsung Hospital|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|89|||Both|19 Years|65 Years|No|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609802||8494|
NCT02609854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-01|Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions|Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions||ZetrOZ, Inc.|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|60 Years|No|||November 2015|November 17, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609854||8490|
NCT02607241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKJ-TCP-3|Comparison of Paclitaxel-Coated Balloons Against Everolimus-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT|Comparison of a Paclitaxel-Coated Balloon Without Stent Implantation Against an Everolimus-Eluting Bioresorbable Scaffold for Treatment of Stable Coronary Artery Disease: A Prospective Randomized Study Using Optical Coherence Tomography|OCTOPUS-3|University of Jena|Yes|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02607241||8691|
NCT02607306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-4183|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus|DUAL™ I Japan|Novo Nordisk A/S|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|807|||Both|20 Years|N/A|No|||December 2015|December 3, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607306||8686|
NCT02600962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Initial diagnosis study|Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction|Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction: A National Cohort Study||University of Leeds|No|Completed|January 2003|||April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|564412|||Both|18 Years|100 Years|No|Non-Probability Sample|The study population comprises 725,860 patients hospitalised for acute myocardial        infarction and entered into the Myocardial Ischaemia National Audit Project (MINAP)        database between April 2004 and March 2013.|November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600962||9170|
NCT02600975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC056|A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B|A Phase I Study to Assess the Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With AS01B in Healthy UK Volunteers||University of Oxford||Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600975||9169|
NCT02393612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR202-III-04|Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease|A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate in Efficacy and Safety of DP-R202 and Anplag Tab in Patients With Artery Occlusive Disease|DAVICI|Alvogen Korea|No|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|20 Years|N/A|No|||March 2015|March 18, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02393612||25091|
NCT02389634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10BN048|Identification of Novel Molecular Markers for Vasospasm|Identification of Novel Molecular Markers for Vasospasm From the Cerebrospinal Fluid (CSF) of Patients With Aneurysmal Subarachnoid Hemorrhage||St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|September 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|blood and cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with aneurysmal subarachnoid hemorrhage|January 2016|January 27, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389634||25396|
NCT02390427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-024|Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer|Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|April 2015|October 2020|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02390427||25335|
NCT02380274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-MA-1004|Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)|A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States|TRUMPET|Astellas Pharma Inc|No|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|18 Years|N/A|No|Non-Probability Sample|Adult male patients diagnosed with CRPC. Eligible patients will be enrolled by urologists        and medical oncologists.|January 2016|January 6, 2016|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380274||26116|
NCT02392923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoL normal Swedes|Quality of Life in a Representative Swedish Population|Quality of Life and Body Functions in a Representative Swedish Population|Normalen|Göteborg University|No|Completed|June 2014|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|30 Years|89 Years|No|Probability Sample|Swedish cohort aged 30-89, representatvie for entire Swedish population age 30 -89|February 2016|February 9, 2016|June 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02392923||25144|
NCT02392936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU Besancon|Evaluation of Peri-operative Risk Factors for Surgery Site Infection in Cardiac Surgery||PRISCCA|Centre Hospitalier Universitaire de Besancon|No|Not yet recruiting|March 2015|November 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Blood samples during and after intervention, for routine tests, and eventually dosing      plasmatic concentration of the antibiotic administered for prophylaxis. Microbiological      analyses concerning wound and blood samples.|Both|18 Years|N/A|No|Probability Sample|Every patient undergoing a cardiac procedure with sternotomy, including coronary artery        bypass, " , aortic surgery, or combined procedures, scheduled or on emergency, under        extracorporeal circulation or not.|March 2015|March 18, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02392936|2 Years|25143|
NCT02446171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00035|A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution|An Open-Label, Randomized, 4-Period, 4-Treatment, Crossover, Single-Center, Single-Dose Bioavailability Study With Alternate Methods of Administration of Crushed Naloxegol Tablets, 25 mg and of a Naloxegol Solution Formulation, 25 mg, Compared to Whole Naloxegol Tablets, 25 mg, in Healthy Subjects||AstraZeneca|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|44|||Both|18 Years|55 Years|No|||July 2015|July 28, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02446171||21057|
NCT02446184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM H33626|Fetal Cystoscopy for Lower Urinary Tract Obstruction|Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction - a Prospective Trial||Baylor College of Medicine|Yes|Recruiting|January 2016|December 2021|Anticipated|December 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|16 Weeks|26 Weeks|No|||January 2016|January 28, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02446184||21056|
NCT02381535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00256|Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin|A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin||National Cancer Institute (NCI)|No|Recruiting|September 2015|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|70 Years|No|||February 2016|March 23, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381535||26019|
NCT02381548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00257|Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia|A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia||National Cancer Institute (NCI)|No|Recruiting|August 2015|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381548||26018|
NCT02378701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0636|Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease|Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Probability Sample|Participants with myelodysplastic syndrome (MDS) taking part in the 2014-0112 study.|November 2015|November 19, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378701||26237|
NCT02391831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NatHis-SMA|Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy|Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy|NatHis-SMA|Institut de Myologie, France|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|2 Years|30 Years|No|||December 2015|December 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02391831||25228|
NCT02619981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP/2012/48|The Effect of Parental Presence on Dental Fear|An Objective Assessment of Dental Fear, and the Influence of the Parental Presence on the Behavior of Anxious Children on Their First Restorative Dental Visit||Riyadh Colleges of Dentistry and Pharmacy|No|Completed|November 2012|February 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|150|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02619981||7713|
NCT02603627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N106|Prevalence of COPD in Our Lung Cancer Population, Compared to Controls|Cross-sectional Study to Compare the Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in Patients Newly Diagnosed With Lung Cancer, Compared to Controls||Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|December 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the multidisciplinary lung cancer clinic at Guy's        Hospital.        Controls will be recruited from the smoking cessation clinic at Guy's and St Thomas' NHS        Foundation Trust.|October 2015|November 10, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02603627||8967|
NCT02603640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-45|" Virtual Brain "-Based Interpretation of Electrophysiological Signals in Epilepsy|" Virtual Brain "-Based Interpretation of Electrophysiological Signals in Epilepsy|VIBRATIONS|Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02603640||8966|
NCT02599649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0934|Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)||M.D. Anderson Cancer Center|No|Recruiting|March 2016|||March 2025|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599649||9271|
NCT02600143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2012/085|Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.|Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.|COLIPI|University Medical Center Groningen|No|Recruiting|August 2013|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Intestinal biopsies, whole blood samples, stool samples|Both|18 Years|N/A|No|Probability Sample|300|November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600143||9233|
NCT02597855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUMC2015-08-036|Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography|||Yeungnam University College of Medicine|No|Recruiting|October 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|90 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597855||9409|
NCT02597868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJCH15003|The Efficacy of Sequential Therapy in Metastatic Breast Cancer Patients|A Multi-sites Study About the Efficacy of Sequential Therapy: Capecitabine vs. Endocrine Therapy, in Metastatic Breast Cancer Patients With Hormone Receptor(HR)-Positive & HER2-negative After Capecitabine-base Chemotherapy||Zhejiang Cancer Hospital|Yes|Recruiting|January 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|March 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02597868||9408|
NCT02604680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI1100-203|A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris|A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris||Braintree Laboratories|No|Recruiting|October 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|500|||Both|12 Years|45 Years|No|||November 2015|November 12, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604680||8886|
NCT02604693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2866|Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)|||National Jewish Health|No|Recruiting|December 2014|||January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|We will enroll subjects using standard case and control definitions. We will enroll up to        150 subjects. Controls will be frequency matched on age, gender, race and smoking status        to limit methylation changes related to these factors.|October 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604693||8885|
NCT02595866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01906|Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms|Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm||National Cancer Institute (NCI)|Yes|Not yet recruiting|November 2015|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|February 29, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595866||9562|
NCT02596100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-020|A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations|A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations||Portola Pharmaceuticals|No|Active, not recruiting|September 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|November 2, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596100||9544|
NCT02605473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0450 Phase II|Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion|A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma||M.D. Anderson Cancer Center|Yes|Withdrawn|September 2008|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|November 12, 2015||No|Study terminated following Phase I NCT00791271, no progression to Phase II due to toxicity and    lack of efficacy.|No||https://clinicaltrials.gov/show/NCT02605473||8825|
NCT02607332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1501|A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib|||Asan Medical Center|No|Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607332||8684|
NCT02597582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCVGH-1037004C|LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients|A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients||Taichung Veterans General Hospital|No|Completed|January 2014|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|41|||Both|20 Years|80 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597582||9430|
NCT02597829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShafranGC|Does Clinical Response Correlate With Serum Certolizumab Levels?|Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO)|APOLLO|Shafran Gastroenterology Center|No|Not yet recruiting|November 2015|October 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597829||9411|
NCT02606318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YIPPE-1|Adjusting Challenge-Skill Balance to Improve the Elderly's Quality of Life|Adjusting Challenge-Skill Balance to Improve the Elderly's Quality of Life: A Randomized Controlled Trial||Harue Hospital|No|Completed|December 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|56|||Both|62 Years|95 Years|No|||November 2015|November 19, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02606318||8760|
NCT02601105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637397|Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks|Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks||University of California, Davis|No|Completed|October 2014|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 7, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02601105||9159|
NCT02600637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1893-P|Wellness Programs for Brain-Injured Individuals|Evaluation of Wellness Programs for Brain-Injured Individuals|WPBI|VA Office of Research and Development|No|Recruiting|November 2015|May 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||November 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600637||9195|
NCT02598427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061309|Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer|Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis||Duke University|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02598427||9365|
NCT02608515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-GENESIS-MM-GRC-002|A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease|A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, "The LEGEND Study"|LEGEND|Genesis Pharma S.A.||Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|220|||Both|18 Years|N/A|No|Probability Sample|A total of approximately 220 patients with RRMM that started second-line treatment with        lenalidomide/dexamethasone between 01 January 2009 to 01 March 2014 and who fulfill all        study-specific eligibility criteria at the investigators' discretion will be included in        this study|November 2015|December 7, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608515||8593|
NCT02608528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15515|Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy|Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2015|||September 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608528||8592|
NCT02597218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2611|Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.|Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.||Hospital Italiano de Buenos Aires|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients older than 18 years following hepatectomy of any kind for oncologic/non-oncologic        disease between 04/09/2012 and 08/28/2015 were enrolled. Follow-up concluded 90 days after        surgery or at occurence of event (Venous thromboembolism / portal thrombosis / death).|November 2015|November 4, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597218||9458|
NCT02598674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500264|Severe Sepsis in Children - IMPRESS-C|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in in Children - IMPRESS-C|IMPRESS-C|University of Florida|No|Not yet recruiting|November 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|Samples Without DNA|serum and urine|Both|5 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Contact and enroll subjects with severe sepsis related AKI subjects without sepsis related        AKI and a sample of age and sex-matched healthy controls.|November 2015|November 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02598674||9346|
NCT02602366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quatro|The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy|The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy Among Young Women in Zimbabwe and South Africa||CONRAD|No|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|400|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602366||9062|
NCT02605213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9311366004|Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients|Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.||Tehran University of Medical Sciences|No|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||November 2015|November 11, 2015|October 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605213||8845|
NCT02598349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI-1510-PC04|Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas (PC04)|A Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma|PC04|University of Florida|Yes|Not yet recruiting|January 2016|October 2040|Anticipated|October 2039|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598349||9371|
NCT02603536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F12-05361|WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia|WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia|WelTelOAKTREE|BC Women's Hospital & Health Centre|No|Active, not recruiting|April 2013|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|14 Years|N/A|No|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603536||8974|
NCT02603770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY02405/CT-USA-102|Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers|A Single Site, Randomized Open Label Cross-Over Study to Compare Pharmacokinetic Profiles (PK) of XueZhiKang (XZK) Capsules Versus Lovastatin Tablets in Healthy Male Volunteers||Luye Pharma Group Ltd.|No|Recruiting|November 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603770||8956|
NCT02599220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056034|Clinical Outcomes and Cost of Gram Negative Bacteremia|Epidemiology, Outcomes, and Costs Associated With Gram Negative Bacteremia||Duke University|No|Completed|January 2002|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|Samples With DNA|Human DNA from patients with gram negative bacteremia|Both|18 Years|N/A|No|Non-Probability Sample|The Duke Bloodstream Infection Biorepository (BSIB) contains prospectively collected        clinical data on ~2000 unique inpatients at Duke with monomicrobial gram negative bacteria        bloodstream infections.|October 2015|November 5, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02599220||9304|
NCT02601664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-083|Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions|Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions|CONCERTO|North Texas Veterans Healthcare System|Yes|Enrolling by invitation|November 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02601664||9116|
NCT02609672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ResilienceAtWork|Resilience for Older Workers With OA Through Exercise|Resilience and Longevity for Older Workers With Arthritis Through Exercise||McMaster University|Yes|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|54|||Both|45 Years|N/A|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609672||8504|
NCT02609685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2014-13-Ho-PMCAS|Active Surveillance of Papillary Thyroid Microcarcinoma|Active Surveillance of Papillary Thyroid Microcarcinoma|PMCAS|Cedars-Sinai Medical Center|No|Recruiting|December 2015|December 2030|Anticipated|December 2030|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|216|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609685||8503|
NCT02599532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1455|Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome|Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome||University of North Carolina, Chapel Hill|No|Recruiting|November 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599532||9280|
NCT02608580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Transition|Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.|Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.||Brugmann University Hospital|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|16 Years|N/A|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608580||8588|
NCT02597790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001792 (CTSI-PLACE)|A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects|Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study|CTSI-PLACE|University of California, Los Angeles|No|Recruiting|October 2013|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|HIV/HCV coinfected and HIV monoinfected adults with well-controlled HIV|November 2015|November 3, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02597790||9414|
NCT02597088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0156-15-SZMC|Development of Methods for Enhance Human Milk Presentation During Storage and Warming|Development of Methods for Enhance Human Milk Presentation During Storage and Warming||Sharron Bransburg-Zabary Consulting services|Yes|Not yet recruiting|November 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|20|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breastfeeding mothers. Up to 6 months PP. The milk will be mixed. The tested milk cannot        be connected to specific donor.|September 2015|November 3, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02597088||9468|
NCT02597101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-6059|Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes|Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients||Allegheny Singer Research Institute|Yes|Recruiting|November 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|21 Years|75 Years|No|||December 2015|December 28, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597101||9467|
NCT02608619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-268|Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement|Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5|Samples Without DNA|tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients for this study will be recruited by physicians from the Departments of Neurology.|February 2016|February 17, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608619||8585|
NCT02608632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7452RDNHFS|HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure|High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure||Meshalkin Research Institute of Pathology of Circulation|Yes|Active, not recruiting|February 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|80 Years|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608632||8584|
NCT02603237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Postprandial metabolomics|Metabolic Response to Fat and Glucose|Metabolic Response to Fat and Glucose||Saarland University|No|Not yet recruiting|March 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|111|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02603237||8996|
NCT02561039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20713|A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease|Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies||Hoffmann-La Roche||Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561039||12238|
NCT02561052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52.290.028.15|Oxygen Reserve Index (ORI) Validation in Healthy Volunteers|A Single-Center, Prospective Study in Healthy Subjects to Validate a New OXYGEN RESERVE INDEX (ORI)|ORIval|Masimo Corporation|No|Recruiting|September 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02561052||12237|
NCT02608697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-2054-201|A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia||Catabasis Pharmaceuticals|No|Active, not recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|74 Years|No|||March 2016|March 21, 2016|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608697||8579|
NCT02599701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFIP06/2015|Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men|Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial||Associação Fundo de Incentivo à Pesquisa|No|Terminated|September 2015|December 2015|Anticipated|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|July 21, 2015||No|Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.|No||https://clinicaltrials.gov/show/NCT02599701||9267|
NCT02618148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Estrogen Herbals|Hormone Estradiol Replacement Therapy Additional Herbals|The Natural Ingredients and Artificial Made Ready, a Good Combination Reduced the Risk of Thrombosis, Concerns With Their Use of HRT|WH|Triệu, Nguyễn Thị, M.D.|Yes|Completed|January 2009|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618148||7854|
NCT02600559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201507|Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes|An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes||Otonomy, Inc.|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|6 Months|17 Years|No|||November 2015|November 5, 2015|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600559||9201|
NCT02604355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29948|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients|A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients||Hoffmann-La Roche||Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|165|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604355||8911|
NCT02604368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEG-411-01|Sickle Cell Omega-3 Treatment Trial (SCOT Trial)|A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-center Study of SC411 for Sickle Cell Disease|SCOT|Sancilio and Company, Inc.|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|213|||Both|5 Years|17 Years|No|||November 2015|January 4, 2016|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604368||8910|
NCT02597751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-00397|DCD Imaging-Intervention Study|Developmental Coordination Disorder: Integrating Brain Imaging and Rehabilitation to Improve Outcomes||University of British Columbia|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02597751||9417|
NCT02595424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2142|Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery|Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas||Eastern Cooperative Oncology Group|Yes|Recruiting|November 2015|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595424||9596|
NCT02610764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-CTC (Pilot)|Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC|Resectable Esophageal Adenocarcinoma: The Influence of Multimodal Therapy on the Prevalence and Enumeration of Circulating Tumor Cells in Comparison With Conventional Response Evaluation in a Feasibility Study|ESO-CTC|University Hospital Freiburg|No|Recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02610764||8420|
NCT02600780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUHS-GTZ-MD-001-13|Zurig (Febuxostat) 40mg Efficacy and Safety Trial|Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout|ZEST|Getz Pharma|Yes|Completed|November 2013|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02600780||9184|
NCT02608788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-2453A3|S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat|Comparing the Efficacies Between the Spray of S.L. Spray Solution and Difflam and Acular to Release Postoperative Sore Throat||Chang Gung Memorial Hospital|Yes|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|380|||Both|20 Years|85 Years|No|||October 2015|November 18, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608788||8572|
NCT02595684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TADALAFIL-OB|Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.|Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.||University of Guadalajara|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Male|30 Years|50 Years|No|||October 2015|November 2, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02595684||9576|
NCT02597634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST0225-013|Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy, and Safety of SST-0225, a Topical Ibuprofen Cream, in the Treatment of Delayed Onset Muscle Soreness (DOMS)|DOMS|Strategic Science & Technologies, LLC|No|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597634||9426|
NCT02609698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJOU-CV-0001|ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)|A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial||Ajou University School of Medicine||Recruiting|August 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|906|||Both|N/A|N/A|No|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609698||8502|
NCT02609711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCA_DI_1501|Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects|||Ahn-Gook Pharmaceuticals Co.,Ltd||Active, not recruiting|November 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609711||8501|
NCT02602158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-Nr. 2015-0450|13C Trioctanoate Breath Test as a Measurement of Gastric Fat Volume Emptying|The13C Trioctanoate Breath Test as a Measurement Method for the Gastric Emptying of Fat; a Randomised, Single Blinded, Cross Over Study|13CTriOBT|University of Zurich|Yes|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02602158||9078|
NCT02600429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-NK-301|Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy|Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy|NK|ReGenTree, LLC|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600429||9211|
NCT02561156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-653-1001|Phase 1 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects||Takeda|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02561156||12229|
NCT02610387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS and Spasticity|The Effects of tDCS Combined With Balance Training on Lower Limbs Spasticity in Chronic Stroke Patients|The Effects of tDCS Combined With Balance Training on Lower Limbs Spasticity in Chronic Stroke Patients ( A Randomized Controlled Trial)||hahid Beheshti University of Medical Sciences|Yes|Active, not recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610387||8449|
NCT02610400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1089413_Namibia_TPE|Evaluation of Targeted Parasite Elimination (TPE) in Namibia|Effectiveness and Feasibility of Targeted Parasite Elimination vs. Reactive Case Detection, With/Without Reactive Vector Control, as a Community Intervention in Response to Confirmed Passively Identified Index Cases, Zambezi Region, Namibia||University of California, San Francisco|Yes|Not yet recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|6579|||Both|6 Months|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610400||8448|
NCT02598089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVACFLU-S-01|Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study In Healthy Adult Volunteers In Vietnam To Examine The Safety And Immunogenicity Of A Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced By IVAC|IVACFLU-S|Institute of Vaccines and Medical Biologicals, Vietnam|Yes|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|February 22, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02598089||9391|
NCT02609035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014163|Immunization Services Model for Adult Rate Improvement|Immunization Services Model for Adult Rate Improvement|ImmuSMART|Pharmacy Quality Alliance|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30000|||Both|19 Years|N/A|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609035||8553|
NCT02605512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSN_2015-A00990-49|BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study|Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients|BACCARAT|Institut de Radioprotection et de Surete Nucleaire|No|Recruiting|October 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Female|50 Years|70 Years|No|||November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605512||8822|
NCT02605525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181501|Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy|A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)||Baxalta US Inc.|Yes|Withdrawn|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605525||8821|
NCT02605538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/251-31/2|Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively|Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively||Karolinska University Hospital|No|Recruiting|October 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|1 Year|N/A|Accepts Healthy Volunteers|||November 2015|November 11, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02605538||8820|
NCT02598557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01821|Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer|Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial||National Cancer Institute (NCI)|Yes|Not yet recruiting|January 2016|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Female|N/A|75 Years|No|||November 2015|January 11, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598557||9355|
NCT02598336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP01/0010|Validation of Structured Light Plethysmography|Validation of Structured Light Plethysmography Against Spirometry in Children and Adults|SLPvsPNT|Pneumacare Ltd|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|80|||Both|6 Years|80 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02598336||9372|
NCT02607787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0061 (EXACT Study)|EXercise And Colo-Rectal Cancer Trial|The Feasibility and Effects of a Home-based Walking and Strengthening Intervention on Physiological, Biochemical and Psychological Outcomes in Colo-rectal Cancer Survivors|EXACT|University of Ulster|No|Recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02607787||8649|
NCT02380118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR/CT 0309/2014 (SC)|IM Olanzapine Versus Haloperidol or Midazolam|Intramuscular Olanzapine Versus Haloperidol or Midazolam for the Management of Acute Agitation in the Emergency Department - a Multicentre Randomised Clinical Trial||The University of Hong Kong|Yes|Recruiting|December 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|January 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380118||26128|
NCT02448693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROMOPIE|Study of Narrow Band Imaging in the Characterization of Residual Neoplasia After Endoscopic Piecemeal Mucosal Resection|Randomised Tandem Colonoscopy of Narrow Band Imaging (NBI) and White Light Endoscopy in Patients With Endoscopic Piecemeal Mucosal Resection|CROMOPIE|Parc de Salut Mar|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448693||20864|
NCT02384668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12122012|D-vitamin And Graves' Disease; Morbidity And Relapse Reduction|The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.|DAGMAR|University of Aarhus|No|Recruiting|March 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02384668||25778|
NCT02378402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2772A3|Myocardial Lipid and Creatine of Heart Failure on MRS|Exploring Myocardial Lipid and Creatine as Imaging Biomarkers for Patients of Heart Failure||Chang Gung Memorial Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|180|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acute HF episode with hospitalization treatment within 12 months were        enrolled.|March 2015|March 4, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02378402||26260|
NCT02393443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003565-1|Oxytocin and Learning for Teaching|The Effects of Oxytocin on Learning With Social Versus Nonsocial Motivation||University of California, Los Angeles|Yes|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|140|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02393443||25104|
NCT02451020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK15-2015_V2|Acclimatization of Healthy Subjects During a Stay at 3200 m|Acclimatization of Healthy Subjects During a Stay at 3200 m||University of Zurich|No|Recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|10|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451020||20685|
NCT02451332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15/1418|Prenatal Inflammation and Perinatal Outcomes|Prenatal Inflammation and Perinatal Outcomes||University of Calgary||Recruiting|October 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451332||20661|
NCT02385786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07162|Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment|Mindfulness-Based Cognitive Therapy Depression Efficacy and Effects on Inflammatory Biomarker Levels||University of California, San Francisco|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385786||25692|
NCT02383758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076608|An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders|An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders||Emory University|No|Recruiting|February 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|5 Years|21 Years|No|||December 2015|December 18, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02383758||25848|
NCT02390206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-202|Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients|An Observational, Prospective, Multicentre, National Trial on the Benefit of Botulinum Toxin Type A (BoNT-A) Injections in Untreated Chronic Post-stroke Spastic Brazilian Patients|B-CAUSE|Ipsen|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|244|||Both|18 Years|80 Years|No|Non-Probability Sample|Untreated chronic post-stroke spastic patients|December 2015|December 21, 2015|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390206||25352|
NCT02606591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA15-0677|Houston Independent School District (HISD) Yoga Evaluation|Houston Independent School District (HISD) Yoga and Wellness Program Evaluation||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606591||8739|
NCT02595580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-GPI-II-2015|The GlucoPred Investigation II|An Open, Controlled Investigation of Measurement Precision, System Accuracy and User Performance Evaluation in Subjects With Diabetes Mellitus Type 1 Using GlucoPred, a Non-invasive Continuous Blood Glucose Measurement Device|GPI-II|Norwegian University of Science and Technology|Yes|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595580||9584|
NCT02605265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-R005|Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1|A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer|CinClare|Fudan University|Yes|Recruiting|October 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|75 Years|No|||December 2015|December 24, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605265||8841|
NCT02605460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCMNSZ REF 917|Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission|Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Recruiting|February 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||October 2015|November 12, 2015|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605460||8826|
NCT02602535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00078615|Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care|Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care||University of Utah||Not yet recruiting|November 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|100 Years|No|||November 2015|November 9, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02602535||9049|
NCT02600806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pi QA-2004-35|Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients|Evaluation of a Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|Yes|Recruiting|May 2005|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|16 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600806||9182|
NCT02607345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/030|25gr. Glucomedics vs 25gr. Zusto|25gr. Glucomedics vs 25gr. Zusto||AZ-VUB|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|10|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607345||8683|
NCT02601989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09-14|Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study|Effects on Insulin Resistance With the Phosphodiesterase-5 Inhibitor Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study|MAKROTAD|Göteborg University|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|25|||Both|40 Years|70 Years|No|||November 2015|November 9, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02601989||9091|
NCT02596828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIST-rPB-2015-P|Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma|Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma||University of Regensburg|No|Not yet recruiting|April 2016|April 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|N/A|25 Years|No|||January 2016|January 14, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02596828||9488|
NCT02601573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-083|Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection||Merck Sharp & Dohme Corp.|No|Active, not recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601573||9123|
NCT02604901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOPHIL|Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications|Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications|ECO-PHIL|University of Pittsburgh|No|Completed|June 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|1091|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02604901||8869|
NCT02604914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612-005|A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects|1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel||NeuroDerm Ltd.|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||September 2015|November 11, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02604914||8868|
NCT02605889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|772.509|Acupuncture in the Complementary Treatment of Diabetes Mellitus Type II|Acupuncture in the Treatment of Diabetes Mellitus Supplemental Type II : Applied Clinical Intervention by Nurses Acupuncturists|ACT-DM|Universidade Federal do Rio de Janeiro|Yes|Recruiting|October 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02605889||8793|
NCT02603003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Longhua Hospital|the"Fuzzing" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs|A Study on the"Fuzzing"Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation|CTC-TCM-FZ|Shanghai University of Traditional Chinese Medicine|No|Active, not recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02603003||9014|
NCT02601118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|micro-expression reading|Micro-expression Reading Skill Training in Medical Students|Effects of Micro- and Subtle-expression Reading Skill Training in Medical Students||Pusan National University Hospital|Yes|Completed|March 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|82|||Both|25 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601118||9158|
NCT02601157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOST-IDEA trial|Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial|Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial|HOST-IDEA|Seoul National University Hospital|Yes|Recruiting|December 2015|||November 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2132|||Both|N/A|N/A|No|||March 2016|March 1, 2016|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02601157||9155|
NCT02601170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-102-05-019|Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy|||Tri-Service General Hospital|No|Completed|June 2014|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|20 Years|65 Years|No|||January 2016|January 20, 2016|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02601170||9154|
NCT02603263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBirmingham-SNS7|The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace Restaurant Setting: an Observational Study|The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace||University of Birmingham|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|N/A||1|Actual|9445|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Customers at workplace restaurants.|November 2015|November 9, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02603263||8994|
NCT02605148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEFA/2015|TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function|TEFA TEDDY Family Prevention - Gluten Free Diet to Preserve Beta-cell Function in Subjects With Islet Autoimmunity.|TEFA|Lund University|No|Enrolling by invitation|December 2015|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|2 Years|49 Years|No|||November 2015|November 13, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02605148||8850|
NCT02610504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13DUR503|Prospective Single Center Open Label Study of Shoulder OA Pain|A 26 Week Prospective Open Label Clinical Study Evaluating A Single Intra-Articular Injection of Durolane 3ml for Treatment of Osteoarthritis Pain of the Shoulder||Bioventus LLC|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|85 Years|No|||February 2016|February 9, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610504||8440|
NCT02610517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F121009007|ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment|Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)|ARCH|University of Alabama at Birmingham|No|Recruiting|June 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02610517||8439|
NCT02610543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS0004|UCB Proof of Concept Study in Patients With Primary Sjogren's Syndrome|A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome||UCB Pharma|No|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610543||8437|
NCT02601443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/15|Prevention of Preterm Birth With a Pessary in Triplet|||Federico II University|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|50 Years|No|||February 2016|February 14, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601443||9133|
NCT02596256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-301|Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301): a Randomised Controlled Trial.|||Chinese PLA General Hospital|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596256||9532|
NCT02596542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 153038|Cold Water Immersion and Recovery|Cold Water Immersion as a Strategy to Promote Post-exercise Recovery in Healthy Young Men|CWI|Maastricht University Medical Center|Yes|Recruiting|November 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596542||9510|
NCT02596555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEITHO-2|Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.|Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism|PEITHO-2|Johannes Gutenberg University Mainz|Yes|Not yet recruiting|December 2015|July 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|700|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596555||9509|
NCT02603328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB16-0024|Atorvastatin Therapy in Cerebral Cavernous Malformation: A Proof of Concept Phase I/II Trial|Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cerebral Cavernous Malformation|AT-CCM I/II|University of Chicago|Yes|Not yet recruiting|July 2016|June 2021|Anticipated|June 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603328||8989|
NCT02606058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34236|APTS: Australian Placental Transfusion Study|APTS: Australian Placental Perfusion Study; Should Very Preterm Babies Receive a Placental Transfusion at Birth? A Randomized Controlled Trial|APTS|Baylor College of Medicine|Yes|Not yet recruiting|November 2015|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|216|||Both|N/A|64 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02606058||8780|
NCT02606071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPP04|Italian Registry On Multipoint Left Ventricular Pacing|Italian Registry On Multipoint Left Ventricular|IRON-MPP|University of Rome Tor Vergata|No|Active, not recruiting|August 2013|September 2016|Anticipated|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|436|||Both|18 Years|N/A|No|Non-Probability Sample|HF patients treated in clinical practice with a CRT-D device with the ability to deliver        MPP|November 2015|November 16, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02606071|12 Months|8779|
NCT02605668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EE1402A|Providing Tools for Effective Care and Treatment of Anxiety Disorders|Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction|PROTECT-AD|Technische Universität Dresden|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|15 Years|70 Years|No|||November 2015|November 13, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02605668||8810|
NCT02605681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL069.0|Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis|Relationship of Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis||Southeast University, China|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Plasma|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients who diagnosed for sepsis|November 2015|November 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605681|28 Days|8809|
NCT02605694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-21|Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)|A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)||Infinity Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|December 2021|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605694||8808|
NCT02596789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00316-37|Cortical Excitability Using Transcranial Magnetic Stimulation and Neuronavigation Device|Study of Cortical Excitability in Healthy Subjects With Transcranial Magnetic Stimulation (TMS) and a Neuronavigation Device|RC-TMS|University Hospital, Grenoble|Yes|Recruiting|June 2012|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|108|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|November 3, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02596789||9491|
NCT02596802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0796|Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|FETO|The University of Texas Health Science Center, Houston|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|45 Years|No|||February 2016|February 3, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596802||9490|
NCT02603601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000259|A Trial of Lifestyle Interventions to Control Weight After Bariatric Surgery|A Randomized Controlled Trial of Lifestyle Interventions to Control Weight After Bariatric Surgery||Beth Israel Deaconess Medical Center|Yes|Completed|March 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02603601||8969|
NCT02599038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serine-NAFLD|Serine Supplementation for Obese Subjects With Fatty Liver Disease|Serine Supplementation in Nonalcoholic Fatty Liver Disease||Sahlgrenska University Hospital, Sweden|No|Recruiting|October 2015|April 2016|Anticipated|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|20 Years|65 Years|No|||February 2016|February 18, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599038||9318|
NCT02602223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207009182|Comparison of Amnion Chorion Membrane vs. Dense Polytetrafluoroethylene Membrane in Ridge Preservation Procedures|A Randomized Split-mouth Clinical Trial on Effectiveness of Amnion-Chorion Membranes in Alveolar Ridge Preservation: a Clinical, Radiological, & Morphometric Study||Indiana University|No|Completed|September 2012|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02602223||9073|
NCT02601001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150134|Safety Study of Omecamtiv Mecarbil in Healthy Japanese Subjects|A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects||Amgen|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02601001||9167|
NCT02601014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15119|Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7|Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)|STARVE-PC|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2016|||February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||February 2016|February 2, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601014||9166|
NCT02606331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Ortho-03-2015|Efficacy of Minimally Invasive Surgical Technique in Accelerating Orthodontic Treatment|Evaluation the Efficacy of Flapless Corticotomy Accomplished by Either Hard-laser or Piezosurgey in Accelerating Upper Canine Retraction and Evaluation of the Dento-alveolar Changes and the Levels of Acceptance and Discomfort.||Damascus University|Yes|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|14 Years|27 Years|No|||March 2016|March 11, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606331||8759|
NCT02606344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nmp/22186|Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV|Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV: a Multi-centric Randomized Trial||NMP Medical Research Institute|Yes|Completed|September 2014|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|561|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 13, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02606344||8758|
NCT02597244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620141940|Effectiveness of Percutaneous Foraminotomy|Effectiveness of Percutaneous Foraminotomy in Patients With Lumbar Foraminal Stenosis: A Prospective, Pilot Study||Seoul National University Hospital|Yes|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|45 Years|85 Years|No|||November 2015|November 3, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02597244||9456|
NCT02547831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 13/12|Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients|Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|July 2013|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients affected by extra-abdominal primary fibromatosis|September 2015|September 10, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02547831||13253|
NCT02605018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDehong_NNICU1|Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy|A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China||The People's Hospital of Dehong Autonomous Prefecture|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|24 Hours|No|||November 2015|November 11, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02605018||8860|
NCT02605031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDehong_NNICU6|Epidemiology Study on Neonatal Seizure|A Multi-Centre Epidemiology Study on Neonatal Seizure in China||The People's Hospital of Dehong Autonomous Prefecture|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1400|||Both|N/A|28 Days|Accepts Healthy Volunteers|Probability Sample|All inpatients and Outpatients of neonates|November 2015|November 11, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02605031||8859|
NCT02597517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sept-1-2015|New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy|Optical Enhancement System ™ Plus Optical Magnification Utility in the Identification of Normal Gastric Mucosa, Helicobacter Pylori Associated Gastritis, and Gastric Atrophy||Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Recruiting|November 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples Without DNA|Histological biopsies from gastric mucosal|Both|18 Years|N/A|No|Probability Sample|Two groups of functional dyspeptic patients will be selected randomly. Functional        dyspepsia will be considered according to the Rome III. Criteria. It will include        Epigastric pain Syndrome defined as located pain or burning in the upper abdomen, at least        once a week, intermittent, not generalized, not relieved by defecation and without        criteria of gall bladder or sphincter of Oddi pathology; and Postprandial distress        Syndrome defined as the presence of one or both conditions including nagging feeling of        postprandial fullness after normal volume meals, several times a week and early satiety        that prevents the completion of a regular meal, several times a week. The criteria must be        present in the last three months and have started at least 6 months before diagnosis.|November 2015|November 3, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02597517||9435|
NCT02603471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use|Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use|ALCTXT|University of California, Los Angeles|Yes|Recruiting|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|July 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02603471||8978|
NCT02603497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK11|Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function|Pharmacokinetic (PK) Study of ASP015K -Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Subjects With Normal Renal Function-||Astellas Pharma Inc|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603497||8977|
NCT02561078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14902|An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus|Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial|VIVID|Eli Lilly and Company|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561078||12235|
NCT02561104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092014-020|Resident-Performed Laser-Assisted vs Manual Traditional Phacoemulsification Cataract Surgery|Outcomes of Resident-Performed Laser-Assisted vs Manual Traditional Phacoemulsification||University of Texas Southwestern Medical Center|No|Not yet recruiting|September 2015|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561104||12233|
NCT02604381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13GOHJ|A Double Blind, Placebo Controlled Parallel Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.|A Double Blind, Placebo Controlled Parallel Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.|13GOHJ|KGK Synergize Inc.|No|Recruiting|November 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|200|||Both|45 Years|70 Years|No|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604381||8909|
NCT02606955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REST./COLLABORATIVE STUDY|Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test|Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?||Miulli General Hospital|Yes|Recruiting|February 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02606955||8712|
NCT02601690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-010|Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America|Observational, Cross-sectional Analysis of T Cell Responses to Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs) for Multiple Allergens in Subjects With Allergy in North America||Adiga Life Sciences, Inc.|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood samples for Peripheral Blood Mononuclear Cells (from whole blood), Immunoglobulin E      (from serum), and potential tissue typing (from whole blood).|Both|18 Years|65 Years|No|Non-Probability Sample|The study population will consist of subjects aged from 18 to 65 years, with a documented        history of allergy to one or more of the following: cat, short ragweed, Rye grass, or        House Dust Mite.|November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601690||9114|
NCT02599935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/02428|Nutritional Improvement in Chronic Heart Failure Patients|Impact on Nutrition and Quality of Life of Patients With Heart Failure After a Nurse Intervention on Nutrition Improvement|VAINICA|Hospital General Universitario Gregorio Marañon|No|Completed|September 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02599935||9249|
NCT02599948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003835|FRench-speAking Icu (Intensive Care Unit) Nutritional Survey|FRench-speAking Icu (Intensive Care Unit) Nutritional Survey|FRANS|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1215|||Both|18 Years|99 Years|No|Non-Probability Sample|Adults hospitalized patients in ICU|August 2014|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599948||9248|
NCT02610777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pevonedistat-2001|An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)|A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and and Low-Blast Acute Myelogenous Leukemia||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|January 2016|November 2021|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610777||8419|
NCT02604485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X358602|A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism|A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI)||XOMA (US) LLC|No|Recruiting|October 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604485||8901|
NCT02604498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCNN-150830-1|Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function|Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function||Zhejiang Medicine Co., Ltd.|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02604498||8900|
NCT02598063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18376|A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B|A Randomized, Open-label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) or Adefovir Dipivoxil (ADV) in Patients With Lamivudine-resistant HBeAg Positive Chronic Hepatitis B||Hoffmann-La Roche||Completed|October 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598063||9393|
NCT02598076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001152|Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures|Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures: A Model of Patient Engagement in Functional Neurological Symptom Disorders||Brigham and Women's Hospital|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598076||9392|
NCT02600182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA 801|Bilevel Positive Airway Pressure in Cardiac Surgery|Effects of Bilevel Positive Airway Pressure in Postoperative Cardiac Surgery: A Randomized Clinical Trial||Universidade Federal de Santa Maria|Yes|Recruiting|August 2015|January 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02600182||9230|
NCT02618655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z151100004015029|Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever|Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever||Beijing Friendship Hospital|No|Recruiting|March 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood, serum|Both|N/A|N/A|No|Non-Probability Sample|all the people who have fever with unknown origin|December 2015|December 11, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02618655|2 Weeks|7815|
NCT02618668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Momen01098983009|Haemodynamic Stability of Ketamine/Propofol Admixture "Ketofol" in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography|Haemodynamic Stability of Ketamine / Propofol Admixture "Ketofol" in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography|Assiutu|Assiut University||Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|60 Years|No|||November 2015|November 28, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618668||7814|
NCT02597985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004180|Prehabilitation to Improve Functional and Clinical Outcomes in Patients With Aortic Stenosis|Prehabilitation to Improve Functional and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: TAVR-FRAILTY Trial|TAVR-FRAILTY|Mayo Clinic|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|No|||November 2015|November 3, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02597985||9399|
NCT02597998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.26|Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration of 25 mg [14C]-BI 409306 as Oral Solution in Healthy Male Volunteers||Boehringer Ingelheim||Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|September 30, 2015||||No||https://clinicaltrials.gov/show/NCT02597998||9398|
NCT02606890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGNO_001|Stroke Lesion Pattern on MRI and Atrial Fibrillation|Is the Lesion Pattern on Magnetic Resonance Imaging in Acute Ischemic Stroke Patients Associated With Atrial Fibrillation?|SLPAF|Charite University, Berlin, Germany|No|Active, not recruiting|August 2015|October 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|894|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke proven by MRI admitted to Department of Neurology,        Charite Campus Benjamin Franklin|December 2015|December 8, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02606890||8717|
NCT02606903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.6|Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector|Randomized, Single-dose, Parallel-arm, Open-label Phase I Trial to Investigate and Compare the Pharmacokinetics, Safety and Tolerability of BI 695501 Administered Subcutaneously Via Prefilled Syringe or Autoinjector||Boehringer Ingelheim||Recruiting|October 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|November 16, 2015||||No||https://clinicaltrials.gov/show/NCT02606903||8716|
NCT02605941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epigene-13151|DNA Methylation Biomarkers for Cervical Cancer Screening|DNA Methylation Biomarkers for Cervical Cancer Screening||iStat Biomedical CO., Ltd.|Yes|Recruiting|February 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|cervical cells|Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Investigators plan to recruit 5,000 women to participate this study in Taiwan.        Papanicolaou test, high-risk HPV typing and DNA methylation will be co-tested. It is        expected to find an optimal solution for molecular cervical cancer screening. The        participant will be recruited by Mackay Memorial Hospital, Chang Gung Memorial Hospital,        and Lin-Hsin Hospital.|November 2015|November 12, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605941||8789|
NCT02605954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1823|Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects||Gilead Sciences|No|Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605954||8788|
NCT02605967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDR001X2201|Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma|A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment||Novartis|No|Not yet recruiting|December 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605967||8787|
NCT02602795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA037797|Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence|Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence||Rhode Island Hospital|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|95|||Both|18 Years|N/A|No|||November 2015|January 27, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602795||9029|
NCT02599259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-007.2|Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.|Using Artificial Intelligence on Mobile Devices to Automate Directly Observed Therapy (DOT), Confirm Medication Ingestion, and Optimize Treatment in Patients on Anticoagulation Therapy.||AiCure|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02599259||9301|
NCT02599571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066144|Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers|Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers|ADHDenic|Duke University|No|Not yet recruiting|January 2016|March 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|350|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|November 11, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599571||9277|
NCT02603419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991007|Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)|A Phase 1 Pharmacokinetic-Pharmacodynamic Study Of Avelumab (MSB0010718C) In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma||Pfizer|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603419||8982|
NCT02596776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0663|Cold Induced Changes in White Adipose|Cold Induced Changes in Human Subcutaneous White Adipose||University of Kentucky|Yes|Not yet recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|90|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596776||9492|
NCT02595528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-009|A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia|||Allergan|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|40 Years|50 Years|No|||February 2016|February 11, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595528||9588|
NCT02595762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28801|An Observational Study of Greek Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|Greece - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer||Hoffmann-La Roche||Not yet recruiting|June 2016|June 2024|Anticipated|June 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Disease registry data will be collected among participants with HER2-positive unresectable        LABC or MBC.|March 2016|March 1, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02595762||9570|
NCT02602873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683292136|Study of Tacrolimus Used for Pediatric Patients With Nephrotic Syndrome Based on Pharmacogenomics and Metabonomics|Guangzhou Women and Children's Medical Center||Guangzhou Women and Children's Medical Center|No|Recruiting|August 2015|August 2020|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|150|Samples With DNA|DNAs extracted from whole blood are stored in freezer with -80 centigrade.|Both|1 Month|14 Years|No|Non-Probability Sample|pediatric patients with nephrotic syndrome|November 2015|November 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602873||9024|
NCT02603939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0056|Understanding Pain Perception in Osteoarthritis|Understanding Pain Perception in Osteoarthritis: a Mechanistic Study in People With Knee Osteoarthritis|PAPO|St George's, University of London|No|Recruiting|June 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood collected|Both|35 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|People with symptomatic knee osteoarthritis who are in pain and are being considered for        joint replacement surgery|November 2015|November 11, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603939||8943|
NCT02609087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH-2015-159|Effect on Cerebral Oxygenation by Sevoflurane or Propofol Using Near-infrared Spectroscopy in Carotid Endarterectomy|Comparison the Effect on Cerebral Oxygenation by Sevoflurane-remifentanil or Propofol-remifentanil Anesthesia Using Near-infrared Spectroscopy in Patients Undergoing Carotid Endarterectomy)||Chonnam National University Hospital|Yes|Recruiting|August 2015|July 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609087||8549|
NCT02383797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH2013336|Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox|Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy||Helsinki University Central Hospital|No|Enrolling by invitation|February 2015|February 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|12 Months|N/A|No|||March 2015|March 3, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02383797||25845|
NCT02383810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIDE-13-22|Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)|Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Different Doses of s.c. Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)||Helsinn Healthcare SA|No|Recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02383810||25844|
NCT02453282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419AC00001|Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).|MYSTIC|AstraZeneca|Yes|Recruiting|July 2015|May 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|780|||Both|18 Years|130 Years|No|||February 2016|February 23, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453282||20511|
NCT02387541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NZ10145|Effects of Total Knee Replacement on Early Postoperative Cognitive Function in Elderly Patients|Effects of Total Knee Replacement on Early Postoperative Cognitive Function in Elderly Patients|POCD|General Hospital of Ningxia Medical University|Yes|Completed|March 2012|January 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Serum|Both|65 Years|N/A|No|Probability Sample|We included 96 ASA I or Ⅱ patients aged ≥65 years performed total knee replacement under        general anesthesia.|March 2015|March 12, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02387541|1 Week|25557|
NCT02387554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALCH-101|Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405|A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|Yes|Completed|August 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|33|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||May 2015|June 11, 2015|December 17, 2014||No||No|May 22, 2015|https://clinicaltrials.gov/show/NCT02387554||25556|
NCT02383485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL087923-02S1|Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children|Exercise and Overweight Children's Cognition (Supplement)|SMART|Georgia Regents University|No|Completed|May 2008|April 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|175|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02383485||25869|
NCT02383498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150118|The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma|A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|100 Years|No|||April 2015|February 12, 2016|March 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02383498||25868|
NCT02393469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP_01|Effects of Pulmonary Rehabilitation on Respiratory, and Cardiovascular Functional Capacity in COPD|Effects of Pulmonary Rehabilitation on Function Cardiovascular, Respiratory and Functional Capacity of People With Chronic Obstructive Pulmonary Disease in the Municipality of Santa Cruz do Sul - Rio Grande do Sul.||University of Santa Cruz do Sul|No|Active, not recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|70|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02393469||25102|
NCT02458547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0088|Effect of Anesthesia Technique on Outcome After Hip Fracture Surgery in Elderly Adult Patients|||Yonsei University|No|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|186|||Both|65 Years|N/A|No|||May 2015|May 29, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458547||20107|
NCT02608606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKoral-sl|Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors|Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors|FKosl|Pontificia Universidad Catolica de Chile|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608606||8586|
NCT02545621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0243|A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study|A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study||University Hospital, Clermont-Ferrand||Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|95 Years|No|Non-Probability Sample|ICU patients without ARDS and under mechanical ventilation for less than 24 hours|September 2015|September 8, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545621||13423|
NCT02545634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APB-C1|Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children|Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children||Acadia University|No|Recruiting|June 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|6 Years|14 Years|No|||September 2015|September 8, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02545634||13422|
NCT02595853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0077|Efficacy of a Novel Hemostatic Powder in GI Bleeding|A Novel Hemostatic Powder for the Endoscopic Treatment of Gastrointestinal Bleeding: Evaluation of Efficacy, Feasibility and Rebleeding Predictive Factors Results From a Multicenter Prospective Study Performed in Routine Practice|GRAPHE|Nantes University Hospital|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients who received hemostatic powder for upper GI bleeding will be included        in the study. Pregnant and adult under guardianship will be excluded.|October 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02595853||9563|
NCT02607254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054498|Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy|Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy||Johns Hopkins University|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607254||8690|
NCT02609269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRD001|Decipher Genomics Resource Information Database (GRID)|Applications of Clinical Genomics to Urologic Patient Care Through the Genomics Resource Information Database||GenomeDx Biosciences Corp|No|Recruiting|October 2015|||December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|||Male|N/A|N/A|No|Non-Probability Sample|Patients must have previously been identified for or already undergone testing with the        Decipher test in the clinical setting. It is understood that the Decipher test results        will be used as a part of normal clinical care. Any prostate cancer patient meeting the        following criteria who has been tested with Decipher can participate in the study.|November 2015|February 26, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609269|1 Year|8535|
NCT02608307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AYACA|Medical Treatment Decision Making Using Adaptive Conjoint Analysis|Adolescent and Young Adult, Parental, and Health Care Provider Decision Making Using Conjoint Analysis||St. Jude Children's Research Hospital|No|Recruiting|January 2016|June 2022|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|13 Years|N/A|No|Non-Probability Sample|Participants will be patients at St. Jude Children's Research Hospital, their parents and        health-care providers who consent to enroll in the study. All participants must meet        inclusion criteria.|January 2016|January 14, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608307||8609|
NCT02608320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108060|A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants|A Randomized, Partially-blinded, Two-arm, Single-application, 3-way Crossover Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects||Janssen Research & Development, LLC||Recruiting|November 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment|24||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608320||8608|
NCT02604745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201771|Degenerative Mitral Regurgitation in Intermediate Risk Patients|Degenerative Mitral Regurgitation in Intermediate Risk Patients 65 or Older: Exercise Echocardiogram and HRQOL Post Surgery Preliminary Analysis|DMR|Northwestern University|No|Not yet recruiting|December 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|65 Years|99 Years|No|Non-Probability Sample|Patients with a history of mitral valve surgery for Degenerative Mitral Regurgitation        (Type II).|November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604745||8881|
NCT02597543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1186278|Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction|Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction||Stanford University|No|Not yet recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|November 4, 2015|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597543||9433|
NCT02608060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18055|A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment||Hoffmann-La Roche||Terminated|September 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 16, 2015||No|Due to poor enrollment this study was terminated prematurely.|No||https://clinicaltrials.gov/show/NCT02608060||8628|
NCT02608073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18123|A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer|A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma||Hoffmann-La Roche||Completed|November 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608073||8627|
NCT02601820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151633|The Patient-Reported Outcomes Project of HCV-TARGET|The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)|PROP-UP|University of North Carolina, Chapel Hill|No|Recruiting|November 2015|July 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|||Both|21 Years|N/A|No|Non-Probability Sample|Patients being evaluated for Hep C treatment in 8 large academic liver centers in the US.|December 2015|December 17, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02601820||9104|
NCT02610439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02292|Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples||National Cancer Institute (NCI)||Recruiting|March 2014|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|575|||Both|N/A|N/A|No|Non-Probability Sample||December 2015|December 24, 2015|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610439||8445|
NCT02607384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00032063|The Baltimore Reading and Eye Disease Study|A School-based Intervention to Diagnose and Treat Vision Problems in Elementary School Children With Reading Difficulty|BREDS|Johns Hopkins University|No|Active, not recruiting|November 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607384||8680|
NCT02607397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCOCO LGG|ROCOCO - Low Grade Glioma|In Silico Clinical Trial on Irradiation Low Grade Glioma, Comparing Photon and Proton Therapy: A Multicentric Planning Study Based on a Reference Dataset of Patients|ROCOCO LGG|Maastricht Radiation Oncology|No|Recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|25 patients. Each patient will function as his or her own control.|November 2015|November 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607397||8679|
NCT02609451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB-REF-NR-266/07_Ileostomy|Closure of Protective Ileostomy 2 vs. 12 Weeks After TME|Closure of Protective Ileostomy 2 vs. 12 Weeks Following Total Mesorectal Excision (TME) for Rectal Surgery: Interim Analysis of a Multicentre, Randomized, Controlled Study|Closure2vs12|Kantonsspital Liestal|No|Terminated|November 2007|March 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||November 2015|February 23, 2016|September 24, 2015||No|Evidence of bad outcome after interims analysis|No||https://clinicaltrials.gov/show/NCT02609451||8521|
NCT02609464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15P01|The Use of Barbed Sutures in Total Hip Arthroplasty|The Use of Barbed Sutures in Total Hip Arthroplasty: A Prospective, Randomized, and Controlled Clinical Trial||Rothman Institute Orthopaedics||Not yet recruiting|December 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||||||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609464||8520|
NCT02598726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1511|Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Older Patients With Cancer|Phase 1 Pilot Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Symptoms in Cancer Patients Fifty Years of Age and Older||Mayo Clinic|Yes|Recruiting|March 2016|||March 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|50 Years|N/A|No|||March 2016|March 7, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598726||9342|
NCT02598739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0196/11|Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis|Resistance Training in Patients With Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life|PSA|Federal University of São Paulo|No|Completed|May 2014|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|41|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|August 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02598739||9341|
NCT02605629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLUME|EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors|EValuation of the Impact of a TOpical Lotion, CG428, on Permanent Chemotherapy Induced Hair and Scalp Disorders in Cancer SUrvivors: A randoMized, Single-center, Double-blind placEbo Controlled Trial (a Pilot Study)|VOLUME|Samsung Medical Center|No|Recruiting|January 2016|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|32|||Female|19 Years|70 Years|No|||January 2016|January 31, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02605629||8813|
NCT02605486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-207|Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)|Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605486||8824|
NCT02609659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-582|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)|GEODE II|AbbVie|No|Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|100 Years|No|||February 2016|February 15, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609659||8505|
NCT02595736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15577|A Study of LY3200327 in Healthy Participants|A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects||Eli Lilly and Company|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595736||9572|
NCT02594709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRON-SM|Multisession Radiosurgery for Optic Nerve Sheath Meningiomas|Observational Study on Multisession Radiosurgery for Optic Nerve Sheath Meningiomas|ONSMsmSRS|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Recruiting|January 2011|December 2025|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02594709||9651|
NCT02597491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART|SMART for Smoking Cessation in Lung Cancer Screening|Adaptive Interventions for Smoking Cessation in Lung Cancer Screening Programs||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1000|||Both|55 Years|79 Years|No|||November 2015|November 10, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597491||9437|
NCT02607553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-202-006|Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA|G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA||GenSpera, Inc.|No|Not yet recruiting|December 2015|August 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607553||8667|
NCT02600481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015K060|Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery|Comparison of the Impacts of Prolonged Low-pressure and Standard-pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery in the Trendelenburg Position: a Bi-center, Randomized Controlled Trial||Huadong Hospital|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|80 Years|No|||November 2015|November 8, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600481||9207|
NCT02608541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH19022|Sheffield Multiple Rib Fractures Study:|Sheffield Multiple Rib Fractures Study: Evolution of Classification, Management and Outcomes|SMuRFS|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple rib fractures (+/- flail chest) presenting to Sheffield Major        Trauma Centre or the surrounding Trauma Units|November 2015|November 18, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02608541||8591|
NCT02607605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507004|A Prospective, Observational Trial on the Diagnostic and Prognostic of LM|A Prospective, Observational Trial on the Diagnostic and Prognostic Value of Cell-free DNA in Advanced Lung Cancer With Leptomeningeal Metastases|ctDNA|Sun Yat-sen University|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|patient's cerebrospinal fluid|Both|18 Years|75 Years|No|Non-Probability Sample|Clinical symptoms and imaging tests are highly suspicious of advanced lung cancer with        leptomeningeal metastases|November 2015|November 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607605||8663|
NCT02607683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XOPH5-OINT-3|Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)|A Phase 2b/3, Multicenter, Dose-ranging, Randomized, Double-masked, Placebo-controlled Study of XAF5 Ointment for Reduction of Lower Lid Steatoblepharon||Topokine Therapeutics, Inc.|No|Recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|40 Years|70 Years|No|||January 2016|January 2, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607683||8657|
NCT02600728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC006|Training Based On Declarative Memory Cues Improved Gait In Patients With Parkinson's Disease|Improvement In Gait Performance After Training Based On Declarative Memory Cues In Patients With Parkinson's Disease: A Randomized Clinical Trial||University of Sao Paulo General Hospital|Yes|Completed|March 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|65 Years|80 Years|No|||November 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600728||9188|
NCT02595554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSGO002(2015-FXY-068)|Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer|Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer|SYSGO002|Sun Yat-sen University|Yes|Recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595554||9586|
NCT02595814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPORTHF|Global Non-interventional Heart Failure Disease Registry|International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure|REPORT-HF|Novartis|No|Recruiting|July 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|N/A|No|Probability Sample|Enrollment of adult patients hospitalized with a primary diagnosis of acute Heart Failure        (HF), i.e. new-onset (first diagnosis) HF or decompensation of chronic HF|October 2015|November 2, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02595814|3 Years|9566|
NCT02603913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZA-Endopreg-2015-1|Oxidative Stress and Endothelial Function in Pregnancy Complications|Oxidative Stress and Endothelial Function in Pregnancy Complications: Development of a New Screening Algorithm|ENDOPREG|Universiteit Antwerpen|No|Recruiting|November 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|330|Samples Without DNA|Blood and placenta samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be included at one of the participating tertiary obstetrical centers (UZA,        ZOL, Erasmus MC, MUMC).        They will be included at the beginning of pregnancy in the longitudinal studies. In the        case-control study, they will be included at the moment of diagnosis and compared to        normotensive controls, matched for maternal and gestational age, parity, smoking behavior,        BMI and ethnic group.|November 2015|November 18, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02603913||8945|
NCT02607293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700623_547|A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation|An Exploratory Study to Explore the Correlation Between the Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response Using New Gonal-f® Pen in Assisted Reproductive Technology (ART) Treatment in China|ARTIST|Merck KGaA|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Female|20 Years|35 Years|No|Non-Probability Sample|Infertile women undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol        using Gonal-f® new pen who are expected to be normal or high responders.|December 2015|December 7, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607293||8687|
NCT02609386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRX-2 2015-A|IRX-2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity|A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity|INSPIRE|IRX Therapeutics|Yes|Recruiting|December 2015|December 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609386||8526|
NCT02595827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68295|Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo|Universal Versus Conditional Follow Up for Children With Unclassified Fever at the Community Level: A Cluster-Randomized, Community-based, Non-Inferiority Trial in Kalemie, Democratic Republic of Congo (DRC)||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3700|||Both|2 Months|60 Months|Accepts Healthy Volunteers|||November 2015|November 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595827||9565|
NCT02601144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-014|Variable Frequency Stimulation of Subthalamic Nucleus for Freezing of Gait in Parkinson's Disease|Randomized,Double-Blind Trial of Variable Frequency Stimulation for Freezing of Gait in Parkinson's Disease||Beijing Pins Medical Co., Ltd|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|March 18, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601144||9156|
NCT02594878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48438|Chronic Non-bacterial Osteomyelitis Treated With Pamidronate|Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial|CNOPAM|University of Aarhus|Yes|Recruiting|October 2015|August 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|9 Years|65 Years|No|||October 2015|November 2, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02594878||9638|
NCT02594891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001-004|Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis|Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis on Patients With choledocholithiasis--a Prospective Randomized Trial||First People's Hospital of Hangzhou|Yes|Completed|November 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|75 Years|No|||February 2016|February 12, 2016|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02594891||9637|
NCT02601794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140010H|A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer|Delivering an Intervention to Accompany Supportive Care|DIVAS|The University of Texas Health Science Center at San Antonio|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Female|25 Years|70 Years|No|||November 2015|November 9, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02601794||9106|
NCT02601807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0926|ActiPatch Therapy for Back Pain|A Randomised Controlled Trial to Assess the Benefits of ActiPatch-Pulsed Shortwave Therapy for Chronic Lower Back Pain||University of Oxford|Yes|Recruiting|August 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||November 2015|November 6, 2015|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601807||9105|
NCT02601417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1452|The Necessity of Bile Cultures in Patients With Acute Cholangitis|The Necessity of Bile Cultures in Patients With Acute Cholangitis||Seoul National University Hospital|No|Recruiting|August 2015|February 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|20 Years|80 Years|No|||November 2015|November 8, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02601417||9135|
NCT02605447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2073|EVOLVE Short DAPT Study|A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System||Boston Scientific Corporation|Yes|Recruiting|January 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605447||8827|
NCT02548091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00399-40|Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Edema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension|Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Oedema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension|OPR_VNI|Centre Chirurgical Marie Lannelongue|Yes|Not yet recruiting|February 2016|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|236|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02548091||13233|
NCT02597192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU-7|Clinical Effects of Bacillus Containing Oral Hygiene Products on Gingivitis: a Randomized Controlled Trial|Professor Doctor, Cukurova University Faculty of Dentistry||Cukurova University|No|Completed|June 2014|October 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02597192||9460|
NCT02605876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0838|Vibratory Stimuli, A Novel Rehabilitation Method for Preventing Post - Traumatic Knee Osteoarthritis|||University of North Carolina, Chapel Hill|Yes|Recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|75|||Both|18 Years|35 Years|No|||November 2015|November 13, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605876||8794|
NCT02603744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rep-Bio-Royan-001|Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)|Evaluate the Safety and Feasibility of Intra-ovarian Injection of Autologous Adipose Derived Mesenchymal Stromal Cells (ADMSC) in Women With Premature Ovarian Failure(POF)||Royan Institute|Yes|Recruiting|June 2015|November 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Female|20 Years|39 Years|No|||November 2015|November 10, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02603744||8958|
NCT02603978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15F018|Interventions for Sanctioned Ohio University Students|Examining the Efficacy of Interventions for Sexual Assault: A Preliminary Randomized Controlled Trial||Ohio University|No|Enrolling by invitation|August 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02603978||8940|
NCT02597374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-Promoteur 2015-A00985-44|EEG in Children With Unilateral Cerebral Injury During Action and Action Observation(AOE)|Exploration du système Des Neurones-miroirs Par Enregistrement EEG du Rythme mu Chez l'Enfant Atteint de lésion cérébrale unilatérale Lors d'Action, d'Observation et d'Imagination d'Action du Membre supérieur. " Action-Observation-EEG "|AOE|University Hospital, Angers|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|6 Years|20 Years|No|||December 2015|December 4, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02597374||9446|
NCT02597387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HE153/PRO/Ⅱ|Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs|A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|August 2015|October 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||November 2015|November 4, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597387||9445|
NCT02607098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065075|Understanding Adaptive Challenges Associated With Male-factor Infertility|Understanding Adaptive Challenges Associated With Male-factor Infertility||Duke University|No|Recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|50 Years|No|Non-Probability Sample|This study will recruit a convenience sample of 10 men and their partners seeking        consultation from a fertility urologist following the detection of male-factor        infertility.|October 2015|November 13, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607098||8702|
NCT02607111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107283|A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients|A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients: A Prospective Study||Lawson Health Research Institute|No|Not yet recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607111||8701|
NCT02601911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AzadUMS P/66/D|Effect of Premedication on Success of Inferior Alveolar Nerve Block Injection|Comparison of Ketorolac and Ketorolac/Acetaminophen on Success of Inferior Alveolar Nerve Block Injection||Azad University of Medical Sciences|Yes|Enrolling by invitation|September 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02601911||9097|
NCT02605720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LihirMC|Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns|Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission|ECG-Lihir|Lihir Medical Centre|Yes|Completed|September 2015|February 2016|Actual|January 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|3 Years|49 Years|Accepts Healthy Volunteers|||February 2016|March 2, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605720||8806|
NCT02561143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-339/08.10.2014|Effectiveness of Nutritional Counselling and "Improved Atta" Supplementation in Cachexic Adult Indian Cancer Patients|To Evaluate the Effectiveness of Nutritional Counselling and "Improved Atta" Supplementation in Delaying Progression of Cachexia to Refractory Cachexia in Adult Cancer Patients in Indian Population||University of Westminster|Yes|Active, not recruiting|April 2015|May 2016|Anticipated|November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|150|||Female|18 Years|N/A|No|||December 2015|December 12, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02561143||12230|
NCT02602392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR77R-2RR|Online Asthma Self-Management for Children Aged 5-10 and Their Parents|Online Asthma Self-Management for Children Aged 5-10 and Their Parents|ChildAsthma|Oregon Center for Applied Science, Inc.|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|622|||Both|5 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|May 31, 2013||No||No||https://clinicaltrials.gov/show/NCT02602392||9060|
NCT02611193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOM-STC|Efficacy of Manipulative Treatment for Carpal Tunnel Syndrome|Efficacy of Manipulative Treatment for Carpal Tunnel Syndrome: a Randomized Clinical Trial||Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|No|Not yet recruiting|May 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02611193||8388|
NCT02608281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00215154|Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI|Clinical Study to Evaluate Diagnostic Accuracy of Low Dose Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI|CEDEM|Siemens Healthcare QT|No|Not yet recruiting|November 2015|December 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02608281||8611|
NCT02595983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTRSC-005|The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant|An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant||Alnylam Pharmaceuticals|Yes|Recruiting|October 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02595983||9553|
NCT02595229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2759/10|Pronator Quadratus Repair After Volar Plating of Distal Radius Fractures|Pronator Quadratus Repair After Volar Plating of Distal Radius Fractures or Not? - Results of a Prospective Randomized Trial||Technische Universität München|No|Completed|May 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2015|November 1, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02595229||9611|
NCT02603653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-02|Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease|Cognitive Sequels of Cushing Syndrome|MEMOCUSH|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|November 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02603653||8965|
NCT02610530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/S01|Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1|Efficacy of Surgical Intervention for the Treatment of Diabetes Mellitus Type 2 in Overweight Non-responders in Comparison With Conventional Nonsurgical Medical Treatment|SIT-DOWN-1|Turkish Metabolic Surgery Foundation|No|Enrolling by invitation|December 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|90|||Both|18 Years|65 Years|No|Non-Probability Sample|Overweight, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI= 25-29.9        kg/m2|November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610530||8438|
NCT02601508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHH-2015-135|Compare of Surgical Condition and Complications With Moderate and Deep NM Block|A Randomized, Parallel Design, Single-center Study to Compare of Surgical Condition and Postoperative Complications With Moderate and Deep Neuromuscular Blockade in Laparoscopic Gastrectomy|MISPCNUHH|Chonnam National University Hospital|No|Not yet recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||November 2015|November 8, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02601508||9128|
NCT02600286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6100|Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A|LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A|UPACOMT|University Hospital, Strasbourg, France|No|Not yet recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Male|18 Years|70 Years|No|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600286||9222|
NCT02594761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myl-Her 1002|Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion|Pharmacokinetic Study Comparing Hercules, EU-approved Herceptin® and US-Licensed Herceptin® Administered as a Single Intravenous Infusion to Healthy Male Volunteers||Mylan Pharmaceuticals|No|Completed|August 2013|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|132|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594761||9647|
NCT02596165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-327|Validation of the Schiller BR-102 Plus PWA Device to Measure Central and Peripheral Hemodynamics|Validation of the Schiller BR-102 Plus PWA Device to Measure Central and Peripheral Hemodynamics|BR-102|University of Basel|No|Not yet recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02596165||9539|
NCT02597075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/14 - ACTIVE-2|Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy|Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Phase III Trial||Swiss Group for Clinical Cancer Research|No|Recruiting|January 2016|December 2026|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|524|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02597075||9469|
NCT02388451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Benefits of the Use of the Feuerstein Cognitive Training Method on Cognitive Function in Community-dwelling Older Patients With Mild Cognitive Impairment: a Pilot Study|The Benefits of the Use of the Feuerstein Cognitive Training Method on Cognitive Function in Community-dwelling Older Patients With Mild Cognitive Impairment: a Pilot Study||Meir Medical Center|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|65 Years|N/A|No|||November 2015|December 15, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02388451||25487|
NCT02388464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIHF-101|A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure|A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia™ (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction||Stealth BioTherapeutics Inc.|Yes|Completed|July 2014|June 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|45 Years|80 Years|No|||September 2015|September 16, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02388464||25486|
NCT02458911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luminor|Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions and Restenosis From Prior Endovascular Procedures in This Sector.|Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions (Superficial Femoral Artery (SFA), Popliteal Artery (PA) and Tibial Arteries (ATs)) and Restenosis From Prior Endovascular Procedures in This Sector.||iVascular S.L.U.|No|Recruiting|May 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with peripheral artery disease due to occlusive lesions, stenosis of ingraguinal        arteries and restenosis after previous angioplasty with/without stent in that sector|November 2015|February 23, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458911|1 Year|20079|
NCT02390895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141202|Prenatal Endoscopic Repair of Fetal Spina Bifida|Prenatal Endoscopic Repair of Fetal Spina Bifida|ENDOSPIN|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|February 2016|September 2022|Anticipated|March 2022|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|February 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02390895||25299|
NCT02391896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7549-CE|Design and Evaluation of Mobile X-ray for Rapid and Accurate Diagnosis of Thoracic Disease|Design and Evaluation of Innovative Mobile X-Ray Technology for Rapid and Accurate Diagnosis of Thoracic Disease in Critically Ill Patients||University Health Network, Toronto|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|19 Years|N/A|No|||March 2015|March 17, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391896||25223|
NCT02382250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i14-01623_MOD1|Relationship Between Diet, Lifestyle, and the Severity of Coronary Artery Disease|The Relationship Between Diet, Perception of Healthy Lifestyle and the Severity of Coronary Artery Disease in Patients Referred for Coronary Angiography.||New York University School of Medicine|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred for coronary angiography or presenting to general medicine clinic at New        York University Langone Medical Center and Bellevue Hospital Center.        Subjects will include both men and women. Every effort will be made to include equitable        numbers of each gender.        Subjects more than 18 years of age will be eligible to participate in the study. The        research in question applies to the entire adult population and therefore all adults may        participate.        Subjects of any racial or ethnic background may participate in the study. There will be no        enrollment restrictions based on race or ethnic origin.        The study will not include vulnerable subjects as defined by current regulations.|October 2015|October 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02382250||25964|
NCT02460016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK0529-1002|A Study of AK0529 in Infants Hospitalized With RSV|A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection||Ark Biosciences Inc.|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|1 Month|24 Months|No|||October 2015|October 19, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460016||19994|
NCT02446821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ContraMed|Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception|Evaluation of the Effectiveness, Safety and Tolerability of the ContraMed VeraCept Intrauterine Copper Contraceptive for Long-Acting Reversible Contraception||ContraMed LLC|No|Completed|June 2015|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|286|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446821||21007|
NCT02388698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPVDNA01|FDG-PET and Circulating HPV in Patients With Cervical Cancer|FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation||Sunnybrook Health Sciences Centre|No|Recruiting|June 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388698||25468|
NCT02388750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Palonosetron|Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)|Prospective Study of Palonosetron in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting (RINV) - a Phase II Study||Sunnybrook Health Sciences Centre|Yes|Recruiting|April 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02388750||25464|
NCT02387606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106786|Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection|A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects||Janssen Sciences Ireland UC|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387606||25552|
NCT02387619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP-1401-P1-DI|The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine in Healthy Male Volunteers||Jeil Pharmaceutical Co., Ltd.|No|Completed|February 2015|||March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 15, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02387619||25551|
NCT02387853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-1108|A Trial Evaluating the Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis|Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis||LEO Pharma|No|Not yet recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|17 Years|No|||March 2015|March 12, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387853||25533|
NCT02387866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-221-CP-001|PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects|A Phase 1, Single Ascending Dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of AG-221 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects||Celgene|No|Completed|March 2015|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|62|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387866||25532|
NCT02597036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15580|A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors|A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Recruiting|November 2015|April 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|105|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597036||9472|
NCT02597049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15361|A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus|A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus|AWARD-10|Eli Lilly and Company|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|357|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597049||9471|
NCT02597062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYX1|High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma|A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies||Canadian Cancer Trials Group|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597062||9470|
NCT02549794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0173|Comparison of Image Quality of Coronary Computed Tomography Angiography bEtweeN High concenTRATion and Low concEntration Contrast Agents(CONCENTRATE Trial)|||Yonsei University|No|Recruiting|April 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|318|||Both|20 Years|N/A|No|||September 2015|September 14, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02549794||13102|
NCT02600585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC13|Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults|Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults 18 Years of Age and Older||Protein Sciences Corporation|No|Active, not recruiting|November 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|25000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will include adults 18 years of age and older who are vaccinated with        either Flublok or IIV within the same time period, e.g. month of the year.|November 2015|November 5, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600585||9199|
NCT02597270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107065|An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection|Mapping Natural Polymorphisms of Hepatitis C Virus NS3/4A Protease and NS5A Region Among Brazilian Chronic Patients (MAPPING)|MAPPING|Janssen-Cilag Ltd.|No|Not yet recruiting|March 2016|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|Samples With DNA|The total blood volume to be collected will be approximately 15 milliliters (mL) (3 tubes,      5mL each). Fasting is not required. The blood sample collection scheme was designed to      collect the minimum number of blood samples that is necessary to accomplish the study      objective. Blood samples will be frozen and incinerated 30 days after blood collection at      the national central laboratory.|Both|18 Years|65 Years|No|Non-Probability Sample|Brazilian participants with Genotype 1 HCV infection treatment naive patients or        previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in        the trial.|March 2016|March 15, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597270||9454|
NCT02594917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070005|Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension|Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension||University of Pittsburgh|Yes|Recruiting|October 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|60 Years|No|Probability Sample|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations        of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart        failure, or exercise intolerance. It will also include ten additional patients (ages 18-60        yrs) who are unaffected first-degree family members of the above subjects.|November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594917||9635|
NCT02594930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-11/145|Comparison of Two Different Techniques of Synovial Biopsy in Periprosthetic Joint Infections|Comparison of Directed Versus Undirected Synovial Biopsy in Culture-negative Periprosthetic Joint Infections of the Knee|COSPI|Technische Universität München|No|Recruiting|September 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594930||9634|
NCT02598518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA023001-01A1|Integrating Combined Therapies for Persons With Co-occurring Disorders|Integrating Combined Therapies for Persons With Co-occurring Disorders|ICT|Dartmouth-Hitchcock Medical Center|Yes|Enrolling by invitation|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02598518||9358|
NCT02598531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0244|Surgical Weight-Loss to Improve Functional Status Trajectories Following Total Knee Arthroplasty (SWIFT Trial)|Surgical Weight-Loss to Improve Functional Status Trajectories Following Total Knee Arthroplasty (SWIFT Trial)|SWIFT|Geisinger Clinic|Yes|Recruiting|January 2016|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Blood Samples Synovial Fluid|Both|22 Years|80 Years|No|Non-Probability Sample|Study population is defined using the inclusion and exclusion criteria below. Demographic        information (with the exclusion of age) is not used to determine the study population.|November 2015|March 24, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02598531||9357|
NCT02611284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Less Invasive Beractant Administration in Preterm Infants|Less Invasive Beractant Administration in Preterm Infants: a Pilot Study.||Hospital General Universitario Gregorio Marañon||Completed|October 2013|March 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|N/A|3 Days|No|||November 2015|November 18, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611284||8381|
NCT02611297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CRI-2013-142|Cryoprobe Transbronchial Lung Biospy in Patients With Mechanical Ventilation|||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|November 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|85 Years|No|||October 2015|November 19, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02611297||8380|
NCT02600897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29834|A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma||Hoffmann-La Roche||Recruiting|December 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600897||9175|
NCT02609438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USRG-3046|An Intervention to Reduce Sitting Time at Work: Effects on Metabolic Health and Inactivity|The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs|Up4Health|Kansas State University|No|Completed|March 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|49|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609438||8522|
NCT02604823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17700|A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)|Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B||Hoffmann-La Roche||Completed|November 2003|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02604823||8875|
NCT02604836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18056|A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia|A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate||Hoffmann-La Roche||Completed|June 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1711|||Female|N/A|N/A|No|||March 2016|March 1, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604836||8874|
NCT02596906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBH-MCI-tDCS|Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment|Brain and Cognitive Changes After Reasoning Training in Individuals With Cognitive Complaints||The University of Texas at Dallas|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02596906||9482|
NCT02597777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691537|Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin|Pilot Randomized Double-Blind Controlled Trial of Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin||University of California, Davis|No|Not yet recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02597777||9415|
NCT02595476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesthésie Trousseau 002|Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus|The Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus Under Steady-state Remifentanil Analgesia||Hôpital Armand Trousseau|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|10 Years|20 Years|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595476||9592|
NCT02595489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23596|A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy|A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy||Stanford University|Yes|Not yet recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Male|3 Years|10 Years|No|||November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02595489||9591|
NCT02595502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5743|Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses|||Johnson & Johnson Vision Care, Inc.|Yes|Active, not recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595502||9590|
NCT02602834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/97/REK sør-øst A|Imminently Effect of Interval Training With High Intensity (HIT) After Heart Transplantation|Changes in Blood Measured Before, During and After Exercise in Heart Transplant Recipients. Imminently Effect of Interval Training With High Intensity Compared With Continuous Moderate Intensity||Oslo University Hospital|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602834||9027|
NCT02609542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0029|Memorisation of Phonologic Information Among Children With Oral Language Developement Disorder|Coding and Memorisation of Phonologic Information Among Preschool and School Children With Oral Language Developement Disorder.|MEMENTO|Lille Catholic University|No|Recruiting|March 2014|March 2020|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|264|||Both|45 Months|95 Months|Accepts Healthy Volunteers|Non-Probability Sample|STOL children between 45 and 95 months of age at inclusion recruited at the neuropediatric        consultation and control children of the same age recruited at schools|November 2015|November 17, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02609542||8514|
NCT02607475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-01|Evaluation of Robotic Telesonography|Evaluation of Robotic Telesonography for Obstetric and Adult and Pediatric Abdominal Imaging||University of Saskatchewan|No|Recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|5 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02607475||8673|
NCT02596022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6716|The Effect of Glutamatergic Modulation on Cocaine Self-administration|||New York State Psychiatric Institute|No|Completed|June 2013|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|55 Years|No|||October 2015|November 2, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596022||9550|
NCT02596243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-EU-001|Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3)||Genexine, Inc.|Yes|Recruiting|July 2015|December 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|60 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596243||9533|
NCT02598960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA009-002|A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors|A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598960||9324|
NCT02601391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPFT-1|An Evaluation of an Adapted STEPPS Group Within Forensic Services|Adapting the Systems Training and Emotional Predictability and Problem Solving Group (STEPPS) for Service Users With Complex Needs. A Pilot Evaluation of STEPPS High Intensity (STEPPS HI) Within Forensic Inpatient Services|STEPPS-HI|Sussex Partnership NHS Foundation Trust|No|Not yet recruiting|March 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02601391||9137|
NCT02596984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308173|Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients|Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients|CaspoKin|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596984||9476|
NCT02596997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-351|Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease|An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease||Chimerix||Available||||||N/A|Expanded Access|N/A|||||||Both|2 Months|N/A||||November 2015|November 3, 2015|November 3, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02596997||9475|
NCT02609217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58593|Parents' Expectations and Experiences Around Cesarean Section in Belgium|Parents' Expectations and Experiences Around Cesarean Section in Belgium||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|||Female|18 Years|50 Years|No|Probability Sample|Pregnant women planned to undergo term elective cesarean section selected from antenatal        low-risk clinic.|November 2015|November 26, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02609217||8539|
NCT02609282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlasgowCU|The Impact of Hourly Prompts on Reducing Prolonged Sitting at Work|Pilot Study to Assess the Impact of Hourly Prompts, Delivered by Microsoft Outlook, on Reducing Prolonged Sitting at Work||Glasgow Caledonian University|No|Completed|February 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02609282||8534|
NCT02606019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-15-1045-25937|The Use of Biomarkers in Predicting Dengue Outcome|The Use of Biomarkers in Predicting Dengue Outcome||Universiti Tunku Abdul Rahman|No|Recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|108|Samples Without DNA|Serum/plasma samples|Both|15 Years|N/A|No|Probability Sample|The patients will be recruited from primary care and followed up in the hospital if they        were admitted.|November 2015|November 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02606019||8783|
NCT02606305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0402|Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer|A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin or Pegylated Liposomal Doxorubicin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer||ImmunoGen, Inc.|No|Recruiting|November 2015|October 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|145|||Female|18 Years|N/A|No|||December 2015|December 10, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606305||8761|
NCT02598817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.17.INF.ME|Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula|Acceptability of "High-Sn-2" Infant Formula in Non-breast Fed Healthy Term Infants Regarding Gastrointestinal Tolerability by Both Parents and Pediatrician: An Open Label Pilot Trial Evaluation in the Middle East||Nestlé|No|Not yet recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|4 Months|Accepts Healthy Volunteers|Non-Probability Sample|100 healthy, full-term, formula fed infants|October 2015|November 4, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02598817||9335|
NCT02597283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFHMU20150902|Coronary Bifurcation Lesions Treated With Biguard Stent System|A Prospective, Multi-center, Randomized Trial Comparing Biguard Stent With Regular Sirolimus-eluting Stent System for Patients With Coronary Bifurcation Lesions|BIGUARD|The First Affiliated Hospital with Nanjing Medical University|Yes|Not yet recruiting|December 2015|August 2020|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02597283||9453|
NCT02597296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-180|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||March 22, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597296||9452|
NCT02597309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS# 2015-03|The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin|The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With ≥200 Units Per Day of U-500 Insulin|I-Can|Joslin Diabetes Center||Suspended|November 2015|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597309||9451|
NCT02609295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-ALA-hyperchol|Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects|Effects of α-linolenic Acid Supplementation in the Form of Perilla Oil on Collagen-epinephrine Closure Time, Activated Partial Thromboplastin Time and Lp-PLA2 Activities in Nondiabetic and Hypercholesterolemic Subjects||Yonsei University|Yes|Completed|February 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|86|||Both|40 Years|68 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02609295||8533|
NCT02599805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tba|Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers?|Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers?||St. Michael's Hospital, Toronto|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599805||9259|
NCT02608593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BROWSE|Breast Reconstruction Outcomes With and Without StratticE|Breast Reconstruction Outcomes With and Without StratticE (BROWSE)|BROWSE|University Hospital of South Manchester NHS Foundation Trust|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|400|||Female|18 Years|N/A|No|Non-Probability Sample|-  Patients age 18 years or older at the time of surgery.          -  Patients who have undergone immediate Implant-based breast reconstruction with or             without Strattice™ with a minimum follow-up of six months.          -  Patients capable of providing informed consent.|October 2015|November 17, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02608593||8587|
NCT02610790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|383/15|BRacelet And Physical actiVity Evaluation (BRAVE)|Evaluation of Pre- and Post-operative Physical Activity on Postoperative Rehabilitation After Colorectal Surgery With a Connected Device|BRAVE|University of Lausanne Hospitals|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo colorectal surgery|November 2015|November 18, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02610790||8418|
NCT02610803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISPACs|Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke|Paroxysmal Atrial Fibrillation and Brief Runs of Premature Atrial Complexes in Patients With Acute Ischemic Stroke: A Historical Cohort Study||Odense University Hospital|No|Completed|September 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|863|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke, admitted to our hospital between August 2008-April        2011|November 2015|November 19, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610803||8417|
NCT02610725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001362|Online Yoga for Individuals With Mood Disorders|Online Yoga for Individuals With Mood Disorders||Massachusetts General Hospital|No|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02610725||8423|
NCT02610738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/14/036|Junior KICkOFF: Diabetes Education for Children Under 11 Years|Junior KICk-OFF. Development and Pilot Evaluation of Structured Self-management Education Packages for Children 11 Years of Age and Under With Type 1 Diabetes, Their Parents and Carers.||Sheffield Children's NHS Foundation Trust|No|Enrolling by invitation|January 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|4 Years|11 Years|No|||November 2015|November 24, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02610738||8422|
NCT02600039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37906314.3.0000.5208|The Short-term Effect of ELTGOL on Pulmonary Ventilation Valued Through Electrical Impedance Tomography in Cystic Fibrosis Patients|The Short-term Effect of ELTGOL on Pulmonary Ventilation Valued Through Electrical Impedance Tomography in Cystic Fibrosis Patients: Randomized Crossover Study||Universidade Federal de Pernambuco|Yes|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|N/A|No|||November 2015|November 6, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02600039||9241|
NCT02605252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3rd-sysu-hbv-functional cure|New Strategy Study of Functional Cure of Chronic Hepatitis B|A Study on Optimizing HBsAg Clearance in CHB Patients With Sequential Treatment of Pegylated Interferon Alpha-2b and Nucleoside Analogues||Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02605252||8842|
NCT02605434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 11 004|A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients|Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients|Accordance|Intec Pharma Ltd.|Yes|Recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|35 Years|85 Years|No|||March 2016|March 13, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605434||8828|
NCT02599142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4362|Comparing Immobilisation Shells in Cranial Radiotherapy|A Randomised Controlled Trial Comparing the Accuracy and Acceptability of Closed-face and Open-face Thermoplastic Immobilisation Shells in Cranial Radiotherapy|CORIOLIS|Royal Marsden NHS Foundation Trust|No|Enrolling by invitation|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599142||9310|
NCT02603510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY13502|Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion|A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)||Sanofi|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|19 Years|N/A|No|||February 2016|February 16, 2016|November 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603510||8976|
NCT02604810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1502|Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency|An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency||Grifols Therapeutics Inc.|No|Recruiting|December 2015|March 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|75 Years|No|||January 2016|January 26, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604810||8876|
NCT02610114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPROLUKS 002|Improvement of Cell Selection in Reproductive Techniques|A New Method to Improve the Selection of Zygotes in the Context of Assisted Reproductive Medicine. A Randomized Controlled Blinded Monocenter Study||Luzerner Kantonsspital|No|Not yet recruiting|December 2015|November 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02610114||8470|
NCT02610127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241302|Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A|Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A||Baxalta US Inc.|No|Recruiting|December 2015|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610127||8469|
NCT02605655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiUTCM-01|Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome|Phase 0 Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome||Shanghai University of Traditional Chinese Medicine|No|Completed|June 2014|April 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|65 Years|No|||November 2014|January 5, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02605655||8811|
NCT02608021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00586|Neurotrack Test Validation Protocol|Neurotrack Test Validation Protocol||New York University School of Medicine|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals will be recruited from among participants at the NYU Alzheimer's Disease        Center ADC, at the affiliated Center for Brain Health (CBH), and from other ongoing NYU        research studies of the Center for Cognitive Neurology (CCN) that are affiliated with the        ADC and for which participants receive the standard ADC research diagnostic assessment        (the ADC Clinical Evaluation).|November 2015|November 17, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608021||8631|
NCT02608034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29475|A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State|A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State||Genentech, Inc.||Not yet recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608034||8630|
NCT02608047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508020263|Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou|Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou||Guangzhou 8th People's Hospital|No|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|2000|Samples With DNA|Peripheral blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Dengue patients|November 2015|November 17, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02608047||8629|
NCT02602041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501074|Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study|Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners||University Medical Center Groningen|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The investigators will invite 10 women with early stage breast cancer (BC) and 10 men with        disseminated testicular cancer (TC) and their partners (20 couples in total).|November 2015|November 7, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02602041||9087|
NCT02601859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014MH08|Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment|Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment||University of Dundee|No|Not yet recruiting|November 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02601859||9101|
NCT02611154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84225|Intranasal Delivery of Testosterone and Its Effect on Doping Markers|Intranasal Delivery of Testosterone and Its Effect on Doping Markers|Intranasal|University of Utah|Yes|Active, not recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611154||8391|
NCT02608125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN1371-001|A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors|A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations||Principia Biopharma, Inc.|No|Recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608125||8623|
NCT02595437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMFPC-11|Triferic Pediatric Pharmacokinetic Protocol|Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis||Rockwell Medical Technologies, Inc.|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|17 Years|No|||February 2016|February 16, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595437||9595|
NCT02618408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P301|Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)|||Supernus Pharmaceuticals, Inc.|No|Recruiting|January 2016|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|291|||Both|6 Years|12 Years|No|||February 2016|February 11, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618408||7834|
NCT02597465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_15_07|Study of SPARC1507|||Sun Pharma Advanced Research Company Limited|No|Not yet recruiting|April 2016|November 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597465||9439|
NCT02597686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEastAnglia|The STAGE Study for Bipolar Disorder|A Pilot Study of a Brief Self-distancing and Perspective Broadening Training Package for Bipolar Disorder||University of East Anglia|No|Recruiting|October 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|February 5, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02597686||9422|
NCT02606097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17298|Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation|A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation||Chang Gung Memorial Hospital|No|Recruiting|April 2014|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|20 Years|N/A|No|||November 2015|November 19, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606097||8777|
NCT02606110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMC 14-11|Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer|||Eastern Regional Medical Center||Withdrawn|June 2014|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A||Non-Probability Sample|Patients with breast cancer and chemotherapy induced peripheral neuropathy|November 2015|November 13, 2015|May 26, 2015||No|PI decided no longer to pursue|No||https://clinicaltrials.gov/show/NCT02606110||8776|
NCT02611167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-Schiess MSC PD|Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease|Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|May 2016|November 2019|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|45 Years|70 Years|No|||December 2015|December 22, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611167||8390|
NCT02608216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822997|[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer|[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy||University of Pennsylvania|Yes|Recruiting|November 2015|||November 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|October 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608216||8616|
NCT02548585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5670C00002|A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes|A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects With a History of Type 2 Diabetes Mellitus||MedImmune LLC|No|Recruiting|October 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548585||13195|
NCT02605590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-110-CF01|Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AIR-DNase When Administered by Inhalation to Healthy Adult Subjects||Protalix|No|Recruiting|December 2015|||February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|February 29, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02605590||8816|
NCT02605603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-LDRTC-02|SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease|Effect of Two Different Therapeutic Interventions: SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease||Lysosomal and Rare Disorders Research and Treatment Center, Inc.|No|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Gaucher disease, and are currently on Enzyme replacement therapy (ERT) or on        Substrate reduction therapy (SRT).|November 2015|November 11, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02605603||8815|
NCT02597764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03205|Diaphragmatic Breathing as an Adjunctive Therapy in the Management of Children With Bladder and Bowel Disorders|Use of Diaphragmatic Breathing (DB) in the Management of Bladder and Bowel Disorders in Children: A Pilot Randomized Trial||University of British Columbia|No|Recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|18 Years|No|||November 2015|November 3, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02597764||9416|
NCT02595996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP9262|Propranolol Dose Escalation in Lymphedema in Patients|An Intra-patient Dose Escalation Study of Propranolol in Patients With Lymphedema||Columbia University|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595996||9552|
NCT02600013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-15093|Locomotor Training With Exoskeleton EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a Hospital Setting|Locomotor Training With the Exoskeleton EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a Hospital Setting: an Observational Study||Montecatone Rehabilitation Institute S.p.A.|No|Recruiting|December 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|40|||Both|18 Years|70 Years|No|Probability Sample|Incomplete motor SCI patients in a setting of inpatient intensive rehabilitation (3rd        level hospital)|December 2015|December 9, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600013||9243|
NCT02606825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VILMA|VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years|VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years or Not Candidates for Intensive Chemotherapy||PETHEMA Foundation|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged ≥60 years, diagnosed of AML or not candidates to intensive chemotherapy|October 2015|January 16, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02606825||8722|
NCT02606838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2014-001-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||January 29, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606838||8721|
NCT02595931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01915|VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Clinical Trial of VX-970 in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Not yet recruiting|July 2016|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||November 2015|January 11, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595931||9557|
NCT02608983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/09/003|Hydrocolloids as Functional Food Ingredients for Gut Health|Hydrocolloids as Functional Food Ingredients for Gut Health|HYFFI|University of Ulster|No|Completed|April 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02608983||8557|
NCT02608996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000577-13|Nesiritide in Uncontrolled Hypertension|Therapeutic Effects of BNP in Uncontrolled Hypertensive Patients|TENSE1|Oslo University Hospital|Yes|Recruiting|December 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|79 Years|No|||October 2015|January 18, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02608996||8556|
NCT02604329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7421 15|Feasibility Study of a Protocol to Treat Pediatric Oral Mucositis by Low-level Laser Therapy|Feasibility Study of a Treatment Protocol of Pediatric Chemo- and Radiotherapy-induced Oral Mucositis by Low-level Laser Therapy|PEDIALASE|University Hospital, Toulouse|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|3 Years|16 Years|No|||November 2015|November 12, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02604329||8913|
NCT02599844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500238|Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults - IMPRESS YA|IMPRESS-YA|University of Florida|No|Not yet recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|Samples Without DNA|serum and urine|Both|5 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Intent to contact and enroll subjects with severe sepsis related AKI subjects without        sepsis related AKI and a sample of age and sex-matched healthy controls.|November 2015|November 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02599844||9256|
NCT02601768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.11/VI/15|Occluder Size Determination in Transcatheter ASD II Closure Based on 3D TEE Assessment|Occluder Size Determination in Transcatheter Closure of Ostium Secundum Atrial Septal Defect Based on Three-Dimensional Echocardiography Assessment||Institute of Cardiology, Warsaw, Poland|Yes|Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|16 Years|N/A|No|Probability Sample|50 consecutive adult patients with ASD II closed percutaneously in our center in the study        time frame i.e.|November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601768||9108|
NCT02602002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111000|Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)|Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers in a Randomised, Double Blind, Placebo Controlled, 2 Way Cross-over Design With an Opioid Analgesic (Remifentanil)||GlaxoSmithKline|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT02602002||9090|
NCT02390063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANCE01|VAccination in Prostate caNCEr (VANCE)|A Randomized Phase I Study to Determine the Safety and Immunogenicity of ChAd-MVA Vaccination Compared to MVA Alone With and Without Low Dose Cyclophosphamide in Low and Intermediate Risk Localised Prostate Cancer||University of Oxford|Yes|Recruiting|June 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|48|||Male|18 Years|75 Years|No|||February 2016|February 16, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02390063||25363|
NCT02445677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-535|Using TENS to Relieve Pain and Potentiate the Rehabilitation of Pain Patients|Using Transcutaneous Electrical Nerve Stimulation (TENS) to Relieve Pain and Potentiate the Rehabilitation of Pain Patients: a Double Blind, Randomized Study Among Patients at the CSSS-IUGS Day Hospital||Université de Sherbrooke|No|Not yet recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|65 Years|N/A|No|||August 2015|August 14, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445677||21095|
NCT02445937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14090204|PARTNER II: Improving Patient and Family Centered Care in Advanced Critical Illness|Stepped Wedge Trial of an Intervention to Support Proxy Decision Makers in ICUs||University of Pittsburgh|Yes|Recruiting|June 2015|September 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445937||21075|
NCT02381275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lighten Cohort Study|The Lighthouse Tenofovir Cohort Study|Baseline Characteristics and Long Term Clinical Outcomes of Patients Using Malawi's New First Line Antiretroviral Regimen at Lighthouse: The Lighthouse Tenofovir Cohort|LighTen|Lighthouse Trust|No|Recruiting|August 2014|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients initiating Tenofovir based ART regimen at the Lighthouse clinics|March 2015|March 5, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02381275||26039|
NCT02380092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4042-01|Post Market Clinical Follow Up of LEGION™ Primary TKS With VERILAST™|A Multicentre, Prospective, Post Market Clinical Follow Up Study of the LEGION™ Primary Total Knee System With VERILAST™ Bearing Surface||Smith & Nephew, Inc.|No|Recruiting|September 2015|June 2026|Anticipated|June 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|158|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects who are scheduled to have Total Knee Arthroplasty with the Legion Primary Total        Knee System due to Degenerative Joint Disease.|March 2016|March 2, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02380092||26130|
NCT02388230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4220|Quantification of Breast RadioTherapy Associated Late Toxicity Using Novel UltraSound Techniques|Quantification of Breast RadioTherapy Associated Late Toxicity Using Novel|QuaRTUS|Institute of Cancer Research, United Kingdom|No|Not yet recruiting|July 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|64|||Female|18 Years|N/A|No|Non-Probability Sample|Patients undergoing radiotherapy for breast cancer|March 2015|March 9, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02388230||25504|
NCT02447120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maestro_NDB_II|Topcon 3D OCT-1 Maestro Reference Database Study II|Topcon 3D OCT-1 Maestro Reference Database Study II||Topcon Medical Systems, Inc.|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|504|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02447120||20984|
NCT02377258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2015-01|IBD Cancer and Serious Infection in Europe|IBD Cancer and Serious Infection in Europe|I-CARE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|Yes|Not yet recruiting|September 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|17600|||Both|18 Years|N/A|No|Non-Probability Sample|17600 patients in 17 European countries, enrolled by 800 investigators (22 subjects per        investigator)|April 2015|April 26, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02377258||26348|
NCT02391909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIV-PASS-01|Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers|Phase 4 Observational Prospective Cohort Study to Assess the Safety of Vivotif at Different Release Titers Among Travelers||PaxVax, Inc.|No|Recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|950|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Travelers attending travelers' vaccination clinics, and for whom typhoid vaccination with        Vivotif is recommended, according to standard practice|October 2015|October 19, 2015|March 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02391909||25222|
NCT02601495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-009|Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery|Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery||Laureate Institute for Brain Research, Inc.|No|Enrolling by invitation|November 2015|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole Blood, Serum, Plasma, Microbiome|Female|18 Years|55 Years|No|Non-Probability Sample|Women enrolled in a court diversion program called Women in Recovery.|November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601495||9129|
NCT02607917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL126041|Testing a Community Intervention to Increase Aspirin Use|Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2014|November 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|10800|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607917||8639|
NCT02604043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131893|Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients|Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients||Vanderbilt University|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|November 11, 2015|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604043||8935|
NCT02604628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Increasing Community-acquired Pneumonia Protocol Adherence by Antibiotic Stewardship|Community-acquired Pneumonia: Increasing Protocol Adherence by Antibiotic Stewardship in a Stepped Wedge Cluster- Randomized Trial|CAP-PACT|UMC Utrecht|No|Recruiting|November 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5400|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604628||8890|
NCT02600650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151004|EndogenousTestosterone Response to a Testosterone Boosting Supplement|EndogenousTestosterone Response to a Testosterone Boosting Supplement||Canadian Memorial Chiropractic College|No|Not yet recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600650||9194|
NCT02603952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6000C00002|A Phase 1b/2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza|A Phase 1b/2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza|MEDI8852|MedImmune LLC|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603952||8942|
NCT02599467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDLR1985|EMG at Performing ULTN 1 in Breast Cancer Patients|Evoked EMG Muscle Activity at Performing ULTN 1 in Breast Cancer Patients||University of Alcala|Yes|Completed|January 2015|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|124|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02599467||9285|
NCT02599480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta3_LVH V1.0|Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure|A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease|Beta3_LVH|Université Catholique de Louvain|Yes|Not yet recruiting|March 2016|January 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|297|||Both|18 Years|90 Years|No|||November 2015|November 4, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02599480||9284|
NCT02602067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENATUMOMAB/ST2146-CR-14-001|131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients|A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients|Tenatumomab|sigma-tau i.f.r. S.p.A.|Yes|Active, not recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602067||9085|
NCT02596659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESWTonLE201309|Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow|Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow||Chang Gung Memorial Hospital|Yes|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2015|November 3, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02596659||9501|
NCT02600598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1228|Biological Effects of LEO 43204 in Actinic Keratosis|Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology||LEO Pharma|No|Not yet recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600598||9198|
NCT02605122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-203|Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia|A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents (12 to 17 Years of Age, Inclusive) and Children (≥2 Months to <12 Years of Age) With Suspected or Confirmed Community-Acquired Bacterial Pneumonia||Cempra Inc|Yes|Not yet recruiting|December 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Months|17 Years|No|||November 2015|November 13, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605122||8852|
NCT02598154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/JF-01|Metrological Characteristics of the Inertial Unit "FOX HiKoB©" in Comparison With the Reference System for the Adaptive Trigger System "Functional Electrical Stimulation" of Foot Elevators in Hemiplegic Post-stroke Patients|Evaluation of the Metrological Characteristics of the Inertial Unit FOX HiKoB© in Comparison With the Reference System for the Adaptive Trigger System "Functional Electrical Stimulation" of Foot Elevators in Hemiplegic Post-stroke Patients|MASEA 2|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|75 Years|No|Non-Probability Sample|The study population consists of patients whose age is between 20 and 75 years and who        experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients        or patients consultating in the neurological rehabilitation service (NHS) at the Grau du        Roi Medical Center, Nîmes University Hospital.|November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598154||9386|
NCT02608385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-1130|Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors|Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors||University of Chicago|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608385||8603|
NCT02608398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2685|The Effect of a Structured Weight-loss Programme on the Metabolic Profiles of Obese and Overweight Children|The Effect of a Structured Weight-loss Programme on the Metabolic Profiles of Obese and Overweight Children||Imperial College London|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|urine and stool samples will be collected from those who consent|Both|8 Years|17 Years|No|Non-Probability Sample|Overweight or obese children aged between 8-17 years attending the MORElife weight loss        Summer Camp|July 2015|November 16, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608398||8602|
NCT02608411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOV-SCLC-1-2014 TIMES|TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)|TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage|TIMES|Istituto Oncologico Veneto IRCCS|No|Recruiting|October 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02608411||8601|
NCT02600819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1825|Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis|A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis||Gilead Sciences|Yes|Recruiting|December 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600819||9181|
NCT02605278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI14/00573|Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care|Assessment of a Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care. Cluster Randomized Clinical Trial|DROP|Jordi Gol i Gurina Foundation|No|Recruiting|January 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|80 Years|No|||September 2015|November 13, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02605278||8840|
NCT02599987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48538315.4.0000.5208|Inspiratory Muscle Training in Patients With End-stage Renal Disease|Effectiveness of Inspiratory Muscle Training in Respiratory Muscle Strength, Chest Wall Volume, Diaphragm Thickness and Mobility in Patients With End-stage Renal Disease: Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|59 Years|No|||November 2015|December 16, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599987||9245|
NCT02605772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FifthSunYetSen|Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes|A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese||Fifth Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|December 2015|March 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|75 Years|No|||November 2015|November 16, 2015|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605772||8802|
NCT02605785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004618|A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy|A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy||Mayo Clinic|No|Recruiting|November 2015|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|134|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605785||8801|
NCT02598310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC BC-04|Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer|Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer||Osaka Medical College|Yes|Recruiting|November 2015|||October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|70 Years|No|||November 2015|November 4, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598310||9374|
NCT02596724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMENEO-100|TME Neoadjuvant Breast Registry|TME Neoadjuvant Breast Registry (The NEAT Registry)||Targeted Medical Education|No|Enrolling by invitation|July 2015|July 2022|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with histologically proven invasive breast cancer who have started or are        scheduled to start neo-adjuvant chemotherapy or endocrine therapy. Aged 18-90.|November 2015|November 4, 2015|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596724|5 Years|9496|
NCT02600221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2287R00102|A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China|A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China||AstraZeneca|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|40 Years|N/A|No|Non-Probability Sample|The study population will be about 2000 outpatients, men or women, over age 40, with a        clinical diagnosis of asthma, COPD or ACOS with persistent airflow limitation（post-BD        FEV1/FVC<0.7）in China from Q4,2015 to Q3,2016.|March 2016|March 16, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02600221||9227|
NCT02600234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||February 19, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600234||9226|
NCT02603068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-204|Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis|Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis||United Therapeutics|No|Withdrawn|February 2016|July 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|79 Years|No|||February 2016|February 5, 2016|November 10, 2015|Yes|Yes|Study design was inadequate and would not achieve study endpoints|No||https://clinicaltrials.gov/show/NCT02603068||9009|
NCT02605837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP621-301|A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved|Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study||Shire|No|Recruiting|November 2015|July 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|11 Years|55 Years|No|||February 2016|February 19, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605837||8797|
NCT02605850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-001605|Effects of Phytonutrients on Vascular Health|Effects of Phytonutrients on Vascular Health|PomPAT|University of California, Los Angeles|No|Not yet recruiting|January 2016|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|November 13, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605850||8796|
NCT02601469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 1503|Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients With Plaque Psoriasis.||Taro Pharmaceuticals USA|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|N/A|No|||November 2015|November 8, 2015|November 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601469||9131|
NCT02610699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074526|Community Pediatric Acceptability Study (CPAS)|CellScope Oto - Community Pediatric Acceptability Study (CPAS)|CPAS|Emory University|No|Completed|November 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|75|||Both|6 Months|18 Years|No|||January 2016|January 22, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610699||8425|
NCT02595255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHANCE (CHildren, Amh, caNCEr)|AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)|Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients|CHANCE|Erasme University Hospital|No|Recruiting|April 2014|April 2031|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|275|Samples Without DNA|serum for hormonal assessment|Female|3 Years|14 Years|No|Non-Probability Sample|The population for this trial is patients between 3 and 14 year old newly diagnosed with        cancer or benign diseases treated by chemotherapy and/or pelvic irradiation with high or        moderate risk of inducing premature ovarian insufficiency. The "no risk" group includes        patients with chronic benign diseases (as pneumology or gastroenterology diseases,        congenital hypothyroidism, growth hormone deficiency or RCIU…) or malignancies who will        not receive any chemotherapy or other gonadotoxic treatment.|November 2015|November 3, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595255||9609|
NCT02603393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2316|Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD|A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD||Novartis|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|N/A|No|||January 2016|January 21, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02603393||8984|
NCT02601963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study FX2015-10|Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea|A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Two Different Doses of a Topical Minocycline Foam Compared to Vehicle in the Treatment of Papulopustular Rosacea - Study FX2015-10|EMIRA|Foamix Ltd.|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02601963||9093|
NCT02610712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63/13|Clinical Trial of the Use of Ketamine in Treatment Resistant Depression|Clinical Trial of the Use of Ketamine in Treatment Resistant Depression||National Institute of Neurology and Neurosurgery, Mexico||Recruiting|May 2014|||December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610712||8424|
NCT02603848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibuprofen vs. Morphine|Ibuprofen Compared to Morphine as a Pediatric Postoperative Pain Management Tool Following Inguinal Surgery|Assessing the Effectiveness of Ibuprofen Compared to Morphine as a Pediatric Postoperative Pain Management Tool Following Inguinal Surgery||McMaster University|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Months|5 Years|No|||November 2015|November 10, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02603848||8950|
NCT02596932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809018|Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus|Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus and Its Impact on Neonatal Blood Glucose Levels||Women and Infants Hospital of Rhode Island|No|Recruiting|February 2016|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02596932||9480|
NCT02599129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0549|A Study of Secukinumab for the Treatment of Alopecia Areata|An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599129||9311|
NCT02596568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020393|The Effect of tDCS Applied During Sleep on Memory Consolidation|The Use of Transcranial Direct Current Stimulation During Slow Wave Sleep in Healthy Students and Older Adults||Medical University of South Carolina|No|Completed|January 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|November 2, 2015|March 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02596568||9508|
NCT02604186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 48177315.9.1001.5404|Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia|Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study|SPASTOX|University of Campinas, Brazil|No|Not yet recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604186||8924|
NCT02604251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1002-P010|Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds|A Prospective Randomized Clinical Study Evaluating the Safety and Efficacy of the KLOX BioPhotonic WoundGel System When Compared With Silicone Sheets in the Treatment of Surgical Wounds||KLOX Technologies Inc.|No|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Female|18 Years|75 Years|No|||November 2015|November 12, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02604251||8919|
NCT02609412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpM2015-002|Immediate Effects of Self-myofascial Release on Latent Trigger Point Sensitivity|||Goethe University|No|Recruiting|May 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02609412||8524|
NCT02603523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/07704-9|Effects of Senior Dance on Risk Factors for Falls|Effects of Senior Dance on Risk Factors for Falls in Older Adults: A Randomized Controlled Trial|DanSE|Universidade Estadual Paulista Júlio de Mesquita Filho|No|Recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603523||8975|
NCT02606916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYX2015-012|Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.|A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.||Sun Yat-sen University|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|70 Years|80 Years|No|||November 2015|November 14, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02606916||8715|
NCT02598011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-15-03|A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care|The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care|Toca7|Tocagen Inc.||Not yet recruiting|March 2016|||November 2022|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02598011||9397|
NCT02598024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPA/2/2015|Treating Earthquake in Nepal Trauma (TENT) Trial 2016|The Effectiveness of 4-session Narrative Exposure Therapy and 2-session Group Control-focused Behavioural Treatment on PTSD in Nepal Earthquake Survivors After 12 Months: Study Protocol for the Randomised Waiting-list Controlled Trial|TENT2016|Nepalese Psychological Association|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02598024||9396|
NCT02611141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1848/2015|Retromolar Route Access With and Without A Retromolar Gap|Retromolar Route Access With and Without A Retromolar Gap - A Visualization Study Of The Vocal Cords||Medical University of Vienna||Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|99 Years|No|||November 2015|November 19, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02611141||8392|
NCT02595164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2191-EGA-CTIL|Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders|Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders||Sheba Medical Center|No|Not yet recruiting|November 2015|November 2019|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|100|||Female|13 Years|30 Years|No|Non-Probability Sample|For our research we will recruit 100 participants from a sample of female patients,        diagnosed with Eating Disorders and suicidal behavior, admitted to mental health        departments in general and psychiatric hospitals. Diagnosis will be made by the hospital        staff. After receiving approval from the medical staff participants will be interviewed,        handed questionnaires and computerized tasks.|November 2015|November 1, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02595164||9616|
NCT02604966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMPE - ITM- P.f|P. Falciparum Resistance to Artemisinin in Vietnam|Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam||National Institute of Malariology, Parasitology and Entomology, Vietnam|No|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|1 Year|N/A|No|||October 2015|December 18, 2015|October 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604966||8864|
NCT02604979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0607|The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study|||Yonsei University|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients who were undergoing robot- assited laparoscopic gastrectomy|November 2015|November 11, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02604979||8863|
NCT02605200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081257|Identification and Treatment of Diabetes In Solid Organ Transplant Recipients|Identification and Treatment of Diabetes In Solid Organ Transplant Recipients||Emory University|No|Enrolling by invitation|August 2015|December 2025|Anticipated|December 2025|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|500|||Both|1 Year|18 Years|No|||November 2015|November 12, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605200||8846|
NCT02597257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1720150047|Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain|Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study||Seoul National University Hospital|Yes|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|20 Years|80 Years|No|||November 2015|November 3, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02597257||9455|
NCT02595450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22190|A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer|A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.||Hoffmann-La Roche||Completed|September 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|299|||Both|35 Years|86 Years|No|Non-Probability Sample|Participants with locally advanced or metastatic NSCLC that are planned to receive        erlotinib containing regimen according to label will be included in this trial.|December 2015|December 17, 2015|November 2, 2015|No|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02595450||9594|
NCT02561117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4660|Once Daily Metronidazole for Perforated Appendicitis|Metronidazole Every 24 Hours as Part of Triple Antibiotic Therapy for Ruptured Appendicitis in Children Managed Operatively (METRO): a Noninferiority Randomized Controlled Trial|METRO|Children's Hospital of Eastern Ontario|Yes|Not yet recruiting|November 2015|||October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|18 Years|No|||September 2015|September 24, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561117||12232|
NCT02561130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMIT-Dapa|Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga|Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga||Population Health Research Institute|No|Not yet recruiting|October 2015|March 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|30 Years|80 Years|No|||September 2015|September 24, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02561130||12231|
NCT02602093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 80-83700-98-15503|Percutaneous Transforaminal Endoscopic Discectomy vs. Open Microdiscectomy for Lumbar Disc Herniation (PTED-study)|(Cost) Effectiveness of Percutaneous Transforaminal Endoscopic Discectomy vs. Open Microdiscectomy for Patients With Symptomatic Lumbar Disc Herniation||VU University Medical Center|No|Recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|682|||Both|18 Years|70 Years|No|||February 2016|February 21, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602093||9083|
NCT02611180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201405065|Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease|Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease||Washington University School of Medicine|No|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Skin samples and blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with current or suspected acute or chronic GVHD of the skin|November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02611180||8389|
NCT02595697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R324A150094|Communication Intervention for Toddlers With Autism|An Efficacy Trail of Enhanced Milieu Teaching Language Intervention Plus Joint Attention, Engagement, Regulation Intervention for Toddlers With Autism|J-EMT|Vanderbilt University|No|Recruiting|July 2015|June 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|24 Months|36 Months|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595697||9575|
NCT02602561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2015-CS02|Effects of HMB Supplementation on Recovery Following ACL Surgery|Effects of HMB Supplementation on Muscle Mass Following ACL Reconstructive Surgery||Metabolic Technologies Inc.|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602561||9047|
NCT02610335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/36|Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration|Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration. Randomized and Comparative Study: Kyphosis Reeducation Versus Spinal Mobility Reeducation|CLEMOB|University Hospital, Bordeaux|No|Not yet recruiting|December 2015|July 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|50 Years|N/A|No|||June 2015|November 18, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02610335||8453|
NCT02603198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34147114500000068|2%-Mepivacaine With Two Different Vasoconstrictors Solutions in Third Molar Surgery a Comparative Study|2%-Mepivacaine With Two Different Vasoconstrictors; 1:20.000 Levonordefrin or 1:100.000 Epinephrin for Local Anesthesia in Third Molar Surgery: A Comparative Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|August 2014|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02603198||8999|
NCT02600442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/27NICB|Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers|Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Molecular Markers||Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|December 2020|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|168|Samples Without DNA|somatic molecular analyses|Both|N/A|N/A|No|Non-Probability Sample|Stage II-III Breast cancer|November 2015|December 8, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600442||9210|
NCT02604212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2003|A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic HBV Infection|A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection||Arrowhead Research Corporation|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||November 2015|November 11, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604212||8922|
NCT02595307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1015947|Improving Informed Consent for Cleft Palate Repair|Role of a Written Summary on Risk Recall During Consent Process for Cleft Palate Repair||IWK Health Centre||Recruiting|May 2014|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|16 Years|N/A|No|||May 2014|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595307||9605|
NCT02603211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22050|Tactile Breast Imaging Sensor for Tumor Malignancy Characterization|Tactile Breast Imaging Sensor for Tumor Malignancy Characterization||Temple University|No|Active, not recruiting|March 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Female|30 Years|80 Years|No|Non-Probability Sample|Women who had mammogram and are getting biopsy.|November 2015|November 10, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603211||8998|
NCT02610283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK209|A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery|A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery||Quark Pharmaceuticals|Yes|Recruiting|December 2015|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|340|||Both|45 Years|N/A|No|||March 2016|March 9, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610283||8457|
NCT02610062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS67E-15-2|A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)|A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)||Astellas Pharma Inc|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610062||8474|
NCT02606773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVP-14C|"Novo C Plus" Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects|Open-label, Randomized Comparator Study for Evaluation the Bioavailability of "Novo C Plus" Vitamin C Containing Dietary Supplement in Healthy Subjects||Semmelweis University|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606773||8726|
NCT02603874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02787|The Development of a Vertebra Localizing Aid Medical Device|The Development of a Vertebra Localizing Aid Medical Device||Target Tape|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|99 Years|No|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02603874||8948|
NCT02603887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0371|Pembrolizumab for Smoldering Multiple Myeloma (SMM)|Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma||M.D. Anderson Cancer Center|No|Not yet recruiting|July 2016|||July 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603887||8947|
NCT02599909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916012|Gut Microbiota in Patients With HCC|Gut Microbiota in Patients With HCC||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|88|||Both|18 Years|99 Years|No|||October 2015|March 4, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02599909||9251|
NCT02609048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB8025-21528|Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)|A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)||CymaBay Therapeutics, Inc.|Yes|Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609048||8552|
NCT02380898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketorolac|Preemptive Ketorolac for Shoulder Tip Pain During Cesarean Section|Preemptive Ketorolac for Intraoperative Shoulder Tip Pain During Cesarean Section: A Double‑Blind Randomized Clinical Trial.||Assiut University||Completed|March 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|N/A|N/A|No|||December 2015|December 8, 2015|March 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02380898||26068|
NCT02450773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501157|Prevention of Severe Postpartum Hypertension|Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial||Washington University School of Medicine|No|Recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|248|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450773||20704|
NCT02451007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-B-005-14-QT|Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors|Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors||PharmaMar||Recruiting|August 2015|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|N/A|65 Years|No|||September 2015|February 8, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451007||20686|
NCT02385539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPAVSAR|Intrathecal Administration of Levobupivacaine and Opioids in Elderly|Intrathecal Anesthesia for Elderly Patients Undergoing Surgery Lasting >45 Minutes: A Randomized, Controlled, Dose and Combination Finding Study||Šarić, Jadranka Pavičić, M.D.|No|Recruiting|January 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Male|65 Years|95 Years|No|||March 2015|March 5, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02385539||25711|
NCT02388178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERO-2014-CAI-02-RPS|To Determine the Ability of a New Product Formulation to Remineralize an Early Caries Lesion by an In-situ Study|Assessment of 1450 Ppm Fluoride/Arginine Toothpaste Using an Intra-oral Remineralization-demineralization Model.||Colgate Palmolive|No|Not yet recruiting|April 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|March 6, 2015|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388178||25508|
NCT02390453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG045157|Cognitive and Aerobic Resilience for the Brain|Cognitive and Aerobic Resilience for the Brain|CARB|Indiana University|Yes|Recruiting|January 2015|||April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|160|||Both|65 Years|N/A|No|||December 2015|December 4, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02390453||25333|
NCT02451033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-CSF and GH in cirrhosis|Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study|Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|April 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||March 2016|March 13, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02451033||20684|
NCT02451046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00839-40|Usefulness of Alpha-GST in Liver Transplantation|Predictive Ability of Alpha-GST to Detect Graft Primary Dysfunction After Liver Transplantation|GST-LT|Beaujon Hospital|No|Recruiting|March 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France)|May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451046|7 Days|20683|
NCT02381288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-448-2002|Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone|A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone||Takeda|No|Recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|66|||Male|60 Years|N/A|No|||November 2015|November 17, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02381288||26038|
NCT02381561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00258|Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy|Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers||National Cancer Institute (NCI)|Yes|Recruiting|February 2016|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02381561||26017|
NCT02380378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMPN2015|Registry of Philadelphia-Negative Myeloproliferative Neoplasms|Registry of Philadelphia-Negative Myeloproliferative Neoplasms|MPN|Hospital Israelita Albert Einstein|Yes|Not yet recruiting|March 2015|April 2020|Anticipated|March 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are followed in hematological centers with confirmed diagnosis of        Myeloproliferative Neoplasms since 2000.|March 2015|March 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02380378|5 Years|26108|
NCT02607930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-380-1489|Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults||Gilead Sciences|Yes|Recruiting|November 2015|January 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607930||8638|
NCT02606240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSL-AC-11-11-15|Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG|Extracorporeal CO2 Removal (ECCO2R) With a Renal Replacement Platform (PRISMALUNG) to Enhance Lung Protective Ventilation in Patients With Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)||Groupe Hospitalier Pitie-Salpetriere|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Mild to Moderate ARDS according to the Berlin definition of ARDS|November 2015|November 13, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606240||8766|
NCT02611258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGO|Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs|Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome|ERGO|University of Roma La Sapienza||Not yet recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||November 2015|November 20, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611258||8383|
NCT02607267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF 83/2015|Edmonton Obesity Staging System: Post-operative Outcome and 30-day Mortality|The Importance of the Edmonton Obesity Score System in Predicting Postoperative Outcome and 30 Day Mortality After Metabolic Surgery||Sana Klinikum Offenbach|No|Completed|October 2014|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|534|||Both|19 Years|73 Years|No|Probability Sample|Patients undergoing either LSG, LRYGB or LOLGB, being the first surgical treatment for        severe obesity|November 2015|February 7, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607267||8689|
NCT02607280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-J313|DS-5565 Phase III Study for Renal Impairment in Japanese Subjects|A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT||Daiichi Sankyo Inc.|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|20 Years|N/A|No|||December 2015|December 21, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607280||8688|
NCT02603549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro39357|Pituitary Function and Spontaneous Intracranial Hypotension|Spontaneous Spinal Cerebrospinal Fluid Leaks and Intracranial Hypotension||Cedars-Sinai Medical Center|No|Active, not recruiting|July 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Spontaneous intracranial hypotension (SIH)|November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603549||8973|
NCT02603562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATYR1940-C-003|Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy|An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy|FSHD|aTyr Pharma, Inc.|Yes|Recruiting|November 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|12 Years|25 Years|No|||March 2016|March 8, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603562||8972|
NCT02605161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150770-01H|Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease|Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease||Ottawa Hospital Research Institute|No|Not yet recruiting|November 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|N/A|N/A|No|Probability Sample|Patients having movement disorders undergoing deep brain stimulation (DBS) of the internal        segment of the globus pallidus for treatment of motor symptoms refractory to medical        therapy at the Ottawa Hospital, Civic Campus, will be recruited to participate in this        pilot study. The cohort will include 10 PD patients and 10 control subjects. The PD        subjects will have received a diagnosis of PD using established clinical criteria        following clinical assessment at the Movement Disorders Clinic of The Ottawa Hospital. The        10 control subjects will consist of those undergoing DBS and assessed in the same clinic        with a clinical diagnosis of either essential tremor or cervical dystonia.|November 2015|November 12, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02605161||8849|
NCT02605226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-IR-004|Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer|A Prospective Multi-center Study to Compare the QOL and Efficacy of External Beam Radiation Therapy or Cryoablation Therapy for Stage III Prostate Cancer|CRYO-PCA-III|Tianjin Medical University Cancer Institute and Hospital|Yes|Active, not recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Male|18 Years|80 Years|No|||November 2015|November 12, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02605226||8844|
NCT02607358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-390|Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)|NATIS: Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke|NATIS|Roskilde County Hospital|Yes|Recruiting|January 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Acute Ischemic stroke patients|November 2015|November 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607358||8682|
NCT02607410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERS2015|Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D|Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes||University of Sao Paulo General Hospital|No|Completed|January 2010|July 2014|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|70 Years|No|||November 2015|November 17, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02607410||8678|
NCT02602756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/02|Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas|Phase II Trial, Randomized, Under Single-blind Conditions, Assessing Two Models of Modified Hypofractionated Proton-therapy on Patients With Large Choroidal Melanomas|HYGROMEL|Centre Antoine Lacassagne|Yes|Recruiting|November 2015|June 2021|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602756||9032|
NCT02602587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7166 03|Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients|Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients. Modulations of the Balance During Cytarabine/Anthracycline Treatment - OxyLAM|OXYLAM|University Hospital, Toulouse|No|Recruiting|September 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02602587||9045|
NCT02602600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAP|Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis|Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels|GAP|Bispebjerg Hospital|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|40 Years|75 Years|No|||February 2016|February 21, 2016|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02602600||9044|
NCT02605408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI742-P001|Cataract Surgery in Indian Patients With or Without LenSx® Laser|A Phaco ± LenSx® Procedure Patients Registry in Indian Tertiary Medical Centers||Alcon Research|No|Not yet recruiting|April 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|21 Years|N/A|No|Probability Sample|Adults with cataracts who are receiving phacoemulsification (with or without LenSx®        procedure) consecutively during the registry period|February 2016|February 29, 2016|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605408||8830|
NCT02607423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA5123|Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery|Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC||Eastern Cooperative Oncology Group||Recruiting|November 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|68|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607423||8677|
NCT02596451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLK-1402|To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc) in Patients With Osteoarthritis (OA) of the Knee||Glenmark Pharmaceuticals Ltd. India|No|Recruiting|August 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1410|||Both|35 Years|N/A|No|||December 2015|December 11, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596451||9517|
NCT02596464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-MUST-01-15|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||November 2, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596464||9516|
NCT02604030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|869.208|Surgical Intervention and Physiotherapy in Breast Cancer: Effects in Scapular Kinematics, Pain and Upper Limb Function|Scapular Kinematics and Upper Limb Function in Women Who Had Undergone Breast Cancer Surgery Subjected to Upper Limb Stretching and Strengthening Exercises Program||Universidade Federal de Sao Carlos|No|Recruiting|August 2015|February 2017|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 11, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02604030||8936|
NCT02609503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1509|Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin|Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|29|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609503||8517|
NCT02594722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01690-47|Metabolism and Oxygen Consumption During Functional Electrical Stimulation Cycling in COPD|||University Hospital, Rouen|No|Not yet recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594722||9650|
NCT02594735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 111418|Abatacept in Juvenile Dermatomyositis|Abatacept for the Treatment of Refractory Juvenile Dermatomyositis|AID|George Washington University|No|Recruiting|November 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Years|N/A|No|||November 2015|November 16, 2015|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594735||9649|
NCT02602665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98248|Central Line Placement-EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION|Central Line Placement Study -EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION||University of Michigan|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|130|||Both|N/A|18 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602665||9039|
NCT02601183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThirdMMU-tl|Cranial Temperature Early Diagnose Hemorrhagic and Ischemic Stroke|Cranial Temperature, as an Early Diagnosis Marker for Hemorrhagic and Ischemic Stroke|CTedHI|Third Military Medical University|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|The patients with a symptom and sign of acute stroke admitted to a specialized stroke        service within 4.5 hours.|November 2015|November 7, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02601183||9153|
NCT02601456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1834-EGA-CTIL|Changes in Trans Tibial Amputee Running Asymmetry During Prolonged Effort|The Effect of Prolonged Effort on the Bilateral Asymmetry in Trans Tibial Amputee Running With Running Specific Prosthesis||Sheba Medical Center|No|Enrolling by invitation|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|20 Years|60 Years|No|Non-Probability Sample|community sample|November 2015|November 9, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601456||9132|
NCT02606227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140106|Financial Incentive for Smoking Cessation in Pregnancy|Financial Incentive for Smoking Cessation in Pregnancy|FISCP|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Female|18 Years|N/A|No|||November 2015|November 19, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02606227||8767|
NCT02594982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15007689|DANish DELIrium Study On Neurointensive Care Patients|DANish DELIrium Study On Neurointensive Care Patients. A Two Phase Intervention Study|DANDELION|Rigshospitalet, Denmark|No|Recruiting|August 2015|September 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|112|||Both|18 Years|99 Years|No|||November 2015|November 7, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02594982||9630|
NCT02609568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-055|Salivary Biomarkers in Pediatric Traumatic Brain Injury|Studying the Significance of Salivary Biomarkers in Pediatric Traumatic Brain Injury||Maricopa Integrated Health System|No|Recruiting|August 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|Samples Without DNA|Salivary biomarkers: S100B, neuron-specific enolase, GFAP|Both|N/A|18 Years|No|Non-Probability Sample|1) Children aged 0 to 20 who present to the pediatric ED or trauma bay with an isolated        acute head injury (moderate or severe) and are admitted for inpatient management; 2)        pediatric patients who present to the ED with non-trauma complaints; and 3) pediatric        patients who present to the ED with non-head trauma such as musculoskeletal injuries.|November 2015|November 17, 2015|October 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02609568||8512|
NCT02609620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-150630835CTIL|Safety & Initial Efficacy of the LunGuard PFT Sys. on Enteral-Fed, Sedated and Mechanically Ventilated Patients Peristaltic Feeding Tube|A Single-Center, Open Label, Randomized, Controlled Study to Evaluate the Safety & Initial Efficacy of the LunGuard PFT System, and Its Impact on GER in Enteral-Fed, Sedated and Mechanically Ventilated Critically Ill Patients|PFT|LunGuard Ltd.|No|Not yet recruiting|December 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|85 Years|No|||December 2015|December 30, 2015|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609620||8508|
NCT02596035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-374|A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)|A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)|CheckMate 374|Bristol-Myers Squibb|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596035||9549|
NCT02599545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065480|Testosterone and Cortisol Levels in Infants|Testosterone and Cortisol Levels in Infant Health and Development||Duke University||Recruiting|October 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|A blood sample will be obtained only from the infant by collecting the leftover cord blood      from the hospital lab. If no remnant blood is available, a blood specimen will not be      collected. Mothers will be asked to provide a saliva sample within 72 hours of delivery,      then mother and infant saliva sampling will be collected in the morning on the same day when      the infant reaches 40 weeks postmenstrual age (PMA) or discharge from the Duke Intensive      Care Nursery (ICN) (whichever comes first), 12 months, and 24 months corrected age (CA)(+/-      1 month).|Both|N/A|72 Hours|No|Probability Sample|Mothers will be eligible for consent if they are a patient in the Duke University Hospital        Labor & Delivery department and meet all eligibility criteria. Potential mothers will be        approached about the study before delivery or within 72 hours after delivery. 150        mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final        sample size of 120 pairs. English or Spanish speaking mothers may participate. If the        mother is between 15-17 years of age, a minor mother consent will be used. If the mother        is Spanish speaking, a Spanish short form consent will be used with a Spanish interpreter.        If the mother is pre-consented, the infant may or may not be enrolled at delivery. The        infant could be excluded if he/she is delivered at a gestation or weight that is outside        of study limits, or if she/he has a severe health problem/congenital anomaly detected at        birth.|October 2015|November 5, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02599545||9279|
NCT02608554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taichi for PCOS|Taichi for Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome (PCOS)|Taichi for Treating Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome (PCOS)||Heilongjiang University of Chinese Medicine|No|Recruiting|October 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|19 Years|35 Years|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608554||8590|
NCT02609646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbioKin|Antibiotic Pharmacokinetics in Critically Ill Patients|Antibiotic Kinetics||Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|1500|Samples Without DNA|Blood samples to measure antibiotic plasma concentration|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Intensive Care Unit (ICU)|November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609646||8506|
NCT02596269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203-082-402|Nefopam/Fentanyl Postoperative Intravenous Patient-Controlled-Analgesia|A Randomized Controlled Trial on the Effect and Safety of Intravenous Nefopam/Fentanyl Postoperative Patient-Controlled-Analgesia in Patients Undergoing Laparotomy||Seoul National University Hospital|Yes|Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|20 Years|65 Years|No|||November 2015|November 3, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02596269||9531|
NCT02606578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006921|PerOral Endoscopic Myotomy (POEM) vs. Laparoscopic Modified Heller Myotomy and Anti-Reflux Procedures|PerOral Endoscopic Myotomy (POEM) vs. Laparoscopic Modified Heller||Mayo Clinic|Yes|Recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing PerOral Endoscopic Myotomy (POEM) or Laparoscopic Modified Heller        Myotomy and Anti-Reflux Procedures at Mayo Clinic Rochester|November 2015|November 13, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02606578||8740|
NCT02600858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00085073_UL|Exogenous Effects of Standard Medical Care (Dopamine) on Motor Learning of an Upper Limb Task in Parkinson Disease|Exogenous Effects of Standard Medical Care (Dopamine) on Motor Learning of an Upper Limb Task in Parkinson Disease||University of Utah|No|Recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|50 Years|80 Years|No|||January 2016|January 7, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600858||9178|
NCT02602977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISPENDO|the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia|the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia, a Pilot Proof-of-principle Study|RISPENDO|Radboud University|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602977||9016|
NCT02617433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inbody|Relationship Between Muscle Mass and Muscle Relaxation Time|Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and Muscle Relaxation||Korea University Anam Hospital|Yes|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Male|19 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617433||7908|
NCT02617446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVie2015002|The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure|The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study||Lee's Pharmaceutical Limited|Yes|Not yet recruiting|December 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||November 2015|November 25, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02617446||7907|
NCT02606682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT200-11-001|Phase 1 Study of NPT200-11 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects||Neuropore Therapies Inc.|No|Completed|July 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|February 12, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606682||8733|
NCT02596334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRO 2015-03|Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients|Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients|MONCAY|Centre Hospitalier Régional d'Orléans|Yes|Recruiting|November 2015|September 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|January 20, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02596334||9526|
NCT02596633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14094|A RCT of Telephone-supported ACT in MS|A Feasibility Randomized Control Trial (RCT) of Telephone-supported Acceptance and Commitment Therapy (ACT) for Low Mood in Multiple Sclerosis (MS)||University of Nottingham|No|Active, not recruiting|January 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02596633||9503|
NCT02596698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498141|Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders|Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|We will keep de-identified saliva and blood samples for analysis until the completion of the      study. Samples will then be destroyed.|Both|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents with mood disorders will be recruited from the University of Minnesota        outpatient and inpatient clinical services, through physician referral, and through        community postings. Recruitment of healthy controls will be done through flyers and online        postings in the community.|November 2015|November 3, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02596698||9498|
NCT02608684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-13-Walsh-PemCiGem|A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer|A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer|PemCiGem|Cedars-Sinai Medical Center|No|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608684||8580|
NCT02598505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R111/14 CCM 89|Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation|Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation||Centro Cardiologico Monzino|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02598505||9359|
NCT02602639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2014:174|Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury|Development of a Spinal Cord Injury-specific Exercise-based Capacity|FES|University of Manitoba|No|Recruiting|October 2015|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|6|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602639||9041|
NCT02596945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22000|Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis|Non-Interventional Observation Trial to Investigate the Efficacy, Safety and Usability of Mircera in PD Patients in Daily Use||Hoffmann-La Roche||Completed|July 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|223|||Both|18 Years|N/A|No|Non-Probability Sample|Participants on peritoneal dialysis who are in need of ESA therapy and have been        prescribed methoxy polyethylene glycol beta by the doctor|December 2015|December 7, 2015|November 3, 2015|No|Yes||No|December 7, 2015|https://clinicaltrials.gov/show/NCT02596945||9479|
NCT02596958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21217|Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants|Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology||Hoffmann-La Roche||Completed|September 2007|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|996|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with unresectable advanced, metastatic or recurrent non-small cell lung        cancer other than predominantly squamous cell and with or without adenocarcinoma histology        will be selected.|February 2016|February 5, 2016|November 3, 2015|Yes|Yes||No|February 5, 2016|https://clinicaltrials.gov/show/NCT02596958||9478|
NCT02599415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/044/14|Anti-psoriatic Effect of TL01 Light Therapy|Studying the Effect of Narrow Band Ultraviolet B Phototherapy on Skin Dendritic (DCs) Cells in Psoriasis Patients||University of Aberdeen|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|70 Years|No|||March 2016|March 24, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02599415||9289|
NCT02599428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE 1-16|Recovery After ICU Treatment: A Prospective Cohort Study|Recovery After ICU Treatment: A Prospective Cohort Study||Roskilde County Hospital|Yes|Recruiting|February 2016|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the ICU at University Hospital Zealand, Køge, in the study period|February 2016|February 5, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599428||9288|
NCT02607059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM 2015|Epidemiologic Registry PETHEMA LMA 2015|Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015)||PETHEMA Foundation|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with acute myeloid leukemia|October 2015|November 16, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607059|3 Years|8705|
NCT02607215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2015-19|Platinum Rechallenge in Patients With Platinum-sensitive mTNBC|Platinum Retreated in Second- or Third-line Patients With Platinum Sensitive Metastatic Triple Negative Breast Cancer (Randomised, Phase II, NPN Trial)||Fudan University|No|Recruiting|November 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|70 Years|No|||December 2015|December 27, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607215||8693|
NCT02607228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-350-1604|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer|A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer||Gilead Sciences|No|Recruiting|December 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|112|||Male|18 Years|N/A|No|||February 2016|February 23, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607228||8692|
NCT02610153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17943|Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies|A Prospective Observational Study Assessing the Management of Anticoagulation With Vitamin K Antagonists in Patients With Nonvalvular Atrial Fibrillation Treated in Cardiology Practices|SULTAN|Bayer|No|Recruiting|October 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with non-valvular atrial fibrillation who are going to start        vitamine K antagonist treatment or have started over the previous two months and that        attend the Cardiology Units at Spanish hospitals (as outpatients).|March 2016|March 18, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02610153||8467|
NCT02599714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2270C00020|Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer|A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients With Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation Followed by a Randomised, Double-Blind, Placebo-controlled, Parallel Group Extension|PASTOR|AstraZeneca|No|Recruiting|December 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|225|||Female|18 Years|130 Years|No|||January 2016|January 7, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599714||9266|
NCT02548325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CorporacionPT|Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study|Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study||Corporacion Parc Tauli|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|450|||Both|18 Years|90 Years|No|Probability Sample|The are Included consecutively for one year ( 1 June 2014 to 31 May 2015 ) all patients        who are in the inclusion criteria|September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548325||13215|
NCT02605369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-121|SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan|SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan||Makerere University|Yes|Not yet recruiting|June 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 15, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605369||8833|
NCT02597530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijingmazui|Different Stimuli of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia|Effect of Different Time of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia|TEAS|Xijing Hospital|No|Not yet recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02597530||9434|
NCT02599961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX007G-CL202|Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome||Ultragenyx Pharmaceutical Inc|No|Recruiting|September 2015|December 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|1 Year|N/A|No|||November 2015|November 5, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599961||9247|
NCT02600195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-194|Reduction of Infection in Neonatal Intensive Care Units Using the Evidence-based Practice for Improving Quality|Reduction of Infection in Neonatal Intensive Care Units Using the Evidence-based Practice for Improving Quality: A Cluster Randomised Trial||Children's Hospital of Fudan University|Yes|Recruiting|May 2015|December 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|15600|||Both|N/A|120 Days|No|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600195||9229|
NCT02605304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5348|12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF|Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens||AIDS Clinical Trials Group|Yes|Recruiting|December 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605304||8838|
NCT02605317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADYU|Use of WhatsApp for Communication Between Consulting Physicians and the Emergency Physicians|Use of whatsApp Messenger (a Messaging Program for Smart Phones) in Communication Between Consulting Physicians and the Emergency Physicians: A Retrospective Observational Study|whatsapp|Adiyaman University Research Hospital|No|Completed|January 2014|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|500|||Both|19 Years|70 Years|No|Non-Probability Sample|Patients who were consulted with whatsApp and who were admitted to Emergency Department.|January 2016|January 13, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02605317||8837|
NCT02599012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-011-001|The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients|||Samsung Medical Center||Not yet recruiting|November 2015|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02599012||9320|
NCT02610478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160022|Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A|A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Teatment of Severe Influenza A||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|November 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|99 Years|No|||November 2015|January 21, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610478||8442|
NCT02605980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177149|Acute Effects of Sitting Time in Older Adults|The Acute Effects of Sitting Time on Physiological and Psychological Function in Older Adults|ACUSIT|University of Birmingham|No|Not yet recruiting|November 2015|August 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|130|Samples With DNA|Saliva and serum from living donors|Both|70 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community-dwelling healthy older adults aged 70 years or over. Must be ambulatory with or        without a walking aid.|November 2015|November 12, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02605980||8786|
NCT02606188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-ke-091|Modified HFNC Oxygen in Patients Undergoing Bronchoscopy.|Modified High-flow Nasal Cannula Oxygen in Patients Undergoing Bronchoscopy.||Beijing Chao Yang Hospital|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|136|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 14, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02606188||8770|
NCT02606643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLouisU|Balloon Catheter for Cervical Ripening|Balloon Catheter for Cervical Ripening With or Without Traction: A Randomized Controlled Trial|25148|St. Louis University|No|Recruiting|October 2014|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|126|||Female|14 Years|55 Years|No|||November 2015|November 16, 2015|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606643||8735|
NCT02599272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/00729|Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study|Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study|PSP|Clinical Nutrition Research Centre, Singapore|No|Recruiting|October 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|24|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02599272||9300|
NCT02610296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK306|QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant|A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant|ReGIFT|Quark Pharmaceuticals|Yes|Recruiting|December 2015|December 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|634|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610296||8456|
NCT02594865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51918.100.14|The Glycaemic Effects of Glucerna® in Critically Ill Patients.|Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.|GluCip|Onze Lieve Vrouwe Gasthuis|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02594865||9639|
NCT02598687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-27-03/09|Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.|A Phase I Trial Testing TH-302, a Tumor-selective Hypoxia-Activated Cytotoxic Prodrug, in Combination With Preoperative Chemoradiotherapy in Patients With Distal Esophageal and Esophago-gastric Junction Adenocarcinoma||Maastricht Radiation Oncology|Yes|Not yet recruiting|November 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02598687||9345|
NCT02597166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-CA-337-1960|Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection|The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection||University Health Network, Toronto|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|November 4, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02597166||9462|
NCT02606994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OralDefenseMucositisStudy|Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis|Comparison of the Healing of Chemotherapy-Induced Oral Mucositis Using Oral Defense Toothpaste Versus Crest Toothpaste and Magic Mouth Rinse|TPvsM|Oral Defense, LLC|No|Not yet recruiting|January 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 15, 2015|November 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606994||8710|
NCT02603432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991001|A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)|A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy||Pfizer|Yes|Recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|668|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603432||8981|
NCT02610088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1507/307-006|Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide|Effect of Dapagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide||Seoul National University Bundang Hospital|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|40 Years|70 Years|No|||November 2015|November 18, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02610088||8472|
NCT02385643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST 103-2628-B-532 -001 -MY3|The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients|||Taipei City Hospital|No|Recruiting|September 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||March 2015|March 5, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02385643||25703|
NCT02458456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNewEngland1|Isometric Handgrip Exercise for Blood Pressure Management|Isometric Handgrip Exercise for Blood Pressure Management. A Randomized, Controlled Trial||University of New England|No|Recruiting|August 2014|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|50|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02458456||20114|
NCT02458534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0020|The Comparison of Mcgrath Mac, C-MAC, and Macintosh Laryngoscope in Novice Users: a Manikin Study|||Yonsei University|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458534||20108|
NCT02459964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0086|Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain|A Randomized Trial to Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain in Cancer Patients in the Emergency Department Setting||M.D. Anderson Cancer Center|Yes|Recruiting|September 2015|||September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|84|||Both|N/A|N/A|No|||March 2016|March 15, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459964||19998|
NCT02376998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERRATASTUDY|Endovascular Repair for the Descending Thoracic Aorta|Endovascular Repair for Acute Traumatic Transection of the Descending Thoracic Aorta|ERRATA|University of Cantanzaro|Yes|Completed|November 2002|February 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02376998||26368|
NCT02391168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLD2015|Fatty Liver Disease Collaborative Research in China|A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China|FLDCR|Fatty Liver and Alcoholic Liver Disease Study Group, China|No|Recruiting|July 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Liver tissue|Both|N/A|N/A|No|Non-Probability Sample|any person with fatty liver disease|August 2015|August 3, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02391168|5 Years|25278|
NCT02460055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32691|Trial- Dysphagia From ETT or GI Endoscopy|Randomized Controlled Trial Examining Effect Of Endotracheal Tube Intubation On Dysphagia In Children Presenting For Upper GI Endoscopy||Baylor College of Medicine|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|194|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460055||19991|
NCT02460107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CatholicUKSPH|Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy|Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy|BTXADMPPNP|Catholic University of Korea Saint Paul's Hospital|Yes|Recruiting|May 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|20 Years|N/A|No|||October 2015|October 2, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02460107||19987|
NCT02385552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1502-003-644|Development of Quality Indicators and Quality Improvement Plan of Colonoscopy in Experienced Endoscopist|Seoul National University Hospital Healthcare System Gangnam Center Colonoscopy Quality Upgrade Project (Gangnam-CUP): Development of Quality Indicators and Quality Improvement Plan of Colonoscopy in Experienced Endoscopist.||Seoul National University Hospital|Yes|Recruiting|March 2011|December 2019|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Customers who received colonoscopy in Seoul National University Hospital Healthcare System        Gangnam Center from 2011 to 2019.|May 2015|May 19, 2015|March 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02385552|8 Years|25710|
NCT02609256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k(2015)32|Stereotactic Infarct Tissue Aspiration for Malignant Infarction of Middle Cerebral Artery|Stereotactic Infarct Tissue Aspiration (SITA) for Malignant Infarction of Middle Cerebral Artery|SMART|General Hospital of Shenyang Military Region|No|Not yet recruiting|December 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|90 Years|No|||November 2015|November 17, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02609256||8536|
NCT02596282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004524|Enhanced Provision of Male Circumcision (MC) for HIV Prevention, Rakai, Uganda|A Randomized Trial of the Acceptability and Safety of Early Infant Male Circumcision (EIMC) Conducted by Nurse Midwives and Clinical Offices Using the Mogen Clamp||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|October 2014|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|501|||Male|N/A|28 Days|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02596282||9530|
NCT02596386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k001.HMO-CTIL|Examination of Potassium Levels in Saliva in ESRD Patients|Examination of Potassium Levels in Saliva in ESRD Patients||Hadassah Medical Organization|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|ESRD patients on Hemodialysis|October 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596386||9522|
NCT02595944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01916|Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer|Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers|ANVIL|National Cancer Institute (NCI)|Yes|Not yet recruiting|June 2016|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|714|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595944||9556|
NCT02610569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01674-41|Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis|Comparison of the PillCamCOLON (C2) Capsule With Standard Endoscopy for the Evaluation of the Severity and the Endoscopic Healing of Patients With Ulcerative Colitis (UC)|VCC2-RCH|Société Française d'Endoscopie Digestive|No|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02610569||8435|
NCT02609308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR15-008|Lateral Ankle Sprain and Platelet Rich Plasma|Platelet Rich Plasma and Lateral Ankle Sprain. A Comparative Study||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|August 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609308||8532|
NCT02611115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-4-167|Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.|Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.|OptIPeCT|Maastricht University Medical Center|No|Recruiting|September 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients referred for CTPA with a clinical suspicion of pulmonary embolism        will be included.|November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02611115||8394|
NCT02611128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17633|Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia|Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia|DENND1A|University of Virginia|Yes|Recruiting|August 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|65|Samples With DNA|Optional sample banking for later genetic analysis: At the time of study, the investigators      will request consent/assent to bank saliva samples for later genetic analysis (e.g., if      additional highly-promising gene candidates for adolescent hyperandrogenemia/PCOS are      identified). If subjects and parents do not provide assent/consent that would allow      specimens to be banked for later genetic analysis, the samples and the means of linking      specimens to data will be destroyed (once analysis for all participants is completed).|Female|8 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Peripubertal girls, Tanner breast stages 1-5|November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02611128||8393|
NCT02596178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00017859|Titration of PEEP During Mechanical Ventilation in Patients With ARDS Using Electrical Impedance Tomography.|||Children's Hospital Boston|Yes|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|35 Years|No|||November 2015|November 2, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596178||9538|
NCT02609373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-701007|Improving Cancer-Related Outcomes in Shift Workers|Improving Cancer-Related Outcomes in Shift Workers|ICOS|University of British Columbia|No|Active, not recruiting|July 2011|January 2016|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|47|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609373||8527|
NCT02595190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.29SROSWH-2015|Treatment of the Symptomatic Sacral Perineurial Cysts|A Randomized Controlled Trial to Compare the Efficacy of Medicine Conservative Treatment and Surgical Treatment for Symptomatic Sacral Perineurial Cysts (Tarlov Cysts) and the Applied Value of Resting State Functional Magnetic Resonance Imaging (rfMRI).|TSSPC|Southwest Hospital, China|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 1, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595190||9614|
NCT02605564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5140361|Effects of Gluten Free Diet on Type 1 Diabetes Mellitus in Children|Effect of a Gluten Free Diet on Ameliorating New Onset Type 1 Diabetes Mellitus in Children and Adolescents||Loma Linda University|No|Enrolling by invitation|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|17 Years|No|||November 2015|November 20, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02605564||8818|
NCT02609516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14_179|Impact of Socioeconomic Inequalities in Transition Between Health, Multimorbidity and Death Amongst Older People|What is the Impact of Socioeconomic Inequalities in the Rates of Transition Between Health, Multimorbidity and Death Amongst Older People in England?||University College, London|Yes|Active, not recruiting|January 2015|January 2017|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1300000|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients included in the CALIBER dataset.|November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609516||8516|
NCT02600910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004974|Natural History of Shoulder Pathology in Manual Wheelchair Users|Natural History of Shoulder Pathology in Manual Wheelchair Users|NHSSI|Mayo Clinic|No|Recruiting|November 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 new manual wheelchair users with traumatic or non-traumatic spinal cord injuries (SCI)        will be recruited & consented during the first 2 years of this project. Subjects will be        recruited at sites that treat & rehabilitate people with acute SCI. SE MN & neighboring        states will be the 1st regions of recruitment. The inclusion and exclusion criteria were        chosen to include a sample of the population of people with new SCIs who will use MWCs as        their primary mode of mobility inside and outside the home. For 25 SCI participants, an        age, sex, and activity level able-bodied matched participant will be recruited from the SE        MN area.|November 2015|November 18, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600910||9174|
NCT02610647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/ADKT-001|Functional Significance of Complexity Measures in the Sensory-motor Behavior|Functional Significance of Complexity Measures in the Sensory-motor Behavior: Are There Potential Clinical Applications?|NEURO COMP|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610647||8429|
NCT02598973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2012-W|Effect of Exercise in Parkinsonism|Effect of Exercise on Recovery in Drug-Induced Parkinsonism and Parkinson Disease||VA Office of Research and Development|No|Not yet recruiting|January 2016|December 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|89 Years|No|||November 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598973||9323|
NCT02609633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD002489|Accu-Chek(R) Connect at School (CATS) Pediatric Study|Accu-Chek(R) Connect at School (CATS) Pediatric Study||Hoffmann-La Roche||Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|6 Years|18 Years|No|||November 2015|November 18, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609633||8507|
NCT02609594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMNIOVLU01|Amnioband and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers|A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Amnioband Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers||SerenaGroup, Inc.|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609594||8510|
NCT02610673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBR-02821|WiCS-LV Post Market Surveillance Registry|WiCS-LV Post Market Surveillance Registry||EBR Systems, Inc.|No|Enrolling by invitation|November 2015|November 2021|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with heart failure meeting standard criteria for CRT based upon the current        European Society of Cardiology / European Heart Rhythm Association (ESC/EHRA) guidelines        and meeting inclusion criteria.|November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610673|5 Years|8427|
NCT02599233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/JLH-01|Characterization of Post-operative Pain Trajectories Over Seven Days and Links With Chronicity|Characterization of Post-operative Pain Trajectories Over Seven Days and Their Potential Links With Chronicity After 3 Months: a Single-center, Prospective, Pilot Cohort Study at the Nîmes University Hospital|PATCH|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|March 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|The study population consists of adult surgery patients at the Nîmes University Hospital,        with recruitment based on the operating theater program for a predefined three month        period and for a predefined list of surgeries. The latter list of surgical acts was        established according to the Medicalization of Information Systems Progam (PMSI) database.        Patients are recruited either the day before or the day after surgery, in their respective        departments.|March 2016|March 18, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599233||9303|
NCT02598596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-001|Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect|Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect|TRIPLE|Ampel BioSolutions, LLC|No|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598596||9352|
NCT02598804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-251|Evaluation of the Effectiveness of Self Management Program on Changes in Physical Activity Level of Knee Osteoarthritis Patients in Spa Therapy|Evaluation of the Effectiveness of Self Management Program on Changes in Physical Activity Level of Knee Osteoarthritis Patients in Spa Therapy|GEET One|University Hospital, Clermont-Ferrand||Recruiting|July 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|142|||Both|50 Years|75 Years|No|||November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02598804||9336|
NCT02608333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00696-43|Efficiency of Early Intervention for Autism Spectrum Disorder|Impact of Early Intervention on the Global Development of Children With Autism Spectrum Disorder in a European French-speaking Population Dr Marie-Maude GEOFFRAY Le Vinatier Hospital|IDEA|Hôpital le Vinatier|No|Recruiting|September 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|15 Months|36 Months|No|||November 2015|January 8, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02608333||8607|
NCT02600247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duloxetine|Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient|Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient : A Randomized, Controlled, Double-Blind Trial||The Catholic University of Korea|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600247||9225|
NCT02603341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19115|Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial|Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial||Abramson Cancer Center of the University of Pennsylvania|Yes|Not yet recruiting|February 2016|November 2030|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1720|||Both|21 Years|65 Years|No|||February 2016|February 25, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02603341||8988|
NCT02603614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDNP-578-02|Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment|A Randomized, Double Blind, Placebo-Controlled, Dose Escalating, Cross Over Designed Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Chronic Stable Heart Failure Subjects With Moderate Renal Impairment||Capricor Inc.|No|Recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603614||8968|
NCT02596685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15098|Effects of Electronic Cigarette Use on the Lungs|Effects of Electronic Cigarette Use on the Human Lung||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2015|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|60|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596685||9499|
NCT02608424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|parkgo-1-ICH|Effects of Feet Mechanical Stimulation on Cardiovascular Autonomic Profile and Inflammation in Parkinson's Disease|Effects of Feet Mechanical Stimulation on the Inflammatory State and Cardiovascular Autonomic Profile in Patients With Parkinson's Disease|parkgo-1|Istituto Clinico Humanitas|No|Recruiting|March 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|50 Years|80 Years|No|||November 2015|November 16, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02608424||8600|
NCT02617147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ophth04012014|Choroidal Thickness Vitrectomy|Influence of Vitrectomy and Membrane Peeling on Choroidal Thickness||Medical University of Vienna|No|Recruiting|June 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with epiretinal membrane scheduled to undergo vitrectomy|November 2015|November 26, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617147||7930|
NCT02596087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001846-14|Improving Quality by Maintaining Accurate Problems in the EHR|Improving Quality by Maintaining Accurate Problems in the Electronic Health Record|IQ-MAPLE|Brigham and Women's Hospital|Yes|Not yet recruiting|April 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|2386|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02596087||9545|
NCT02596321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITI3001|A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)|A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites||Abbott|No|Recruiting|October 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596321||9527|
NCT02605096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N294|Pilot Study to Test the Feasibility of the Use of MRI in Suspected Scaphoid Fractures|A Single Centre Randomised, Non-blinded, Prospective Pilot to Test the Feasibility Associated With the Use of MRI as the Initial Imaging Modality in the Investigation of Patients Presenting With Suspected Scaphoid Fracture||Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|16 Years|N/A|No|||October 2015|November 12, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02605096||8854|
NCT02560974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO17527|A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer|A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma||Hoffmann-La Roche||Completed|June 2006|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1035|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560974||12243|
NCT02560987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM 5631|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||September 24, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560987||12242|
NCT02561000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-PZ128-02|Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)|TRIP-PCI|Tufts Medical Center|Yes|Not yet recruiting|December 2015|June 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|80 Years|No|||September 2015|September 24, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561000||12241|
NCT02601092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS-002|Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Mini Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Mini Gastric Bypass: A Randomized Controlled Trial|MGB|Spital Limmattal Schlieren|Yes|Not yet recruiting|November 2015|December 2022|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||November 2015|November 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02601092||9160|
NCT02601612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 308|Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cpΔM2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2015|||May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|45|||Both|6 Months|60 Months|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02601612||9120|
NCT02602171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN_23_10_15|Virtual Acoustic Localization Experiment|Virtual Acoustic Localization Experiment for the Evaluation of a Dereverberation Algorithm in Terms of Speech Intelligibility & Localization Performance of Normal Hearing & Hearing Impaired Subjects|VALEEvE|University of Zurich|No|Active, not recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|November 9, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02602171||9077|
NCT02602184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-AR-2015-01|Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds|Prospective, Placebo-controlled, Double Blind, Randomized Intra-individual Comparative Clinical Study to Assess the Safety and Efficacy of AR/101 Compared to Placebo in Accelerating Re-epithelialization of Split Thickness Wounds||Arava Bio Tech Ltd.|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 28, 2015|November 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602184||9076|
NCT02595463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-741|Intravenous Lidocaine for Post-Tonsillectomy Pain in Pediatric Patients|Intravenous Lidocaine to Decrease Postoperative Pain in Pediatric Patients Undergoing Tonsillectomy: A Randomized, Double Blind, Placebo Controlled Trial||Ann & Robert H Lurie Children's Hospital of Chicago|No|Not yet recruiting|November 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|4 Years|10 Years|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595463||9593|
NCT02603315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-81|Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)|To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )|VITMPM|Ain Shams University|No|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|50|||Both|39 Years|84 Years|No|Probability Sample|Egyptian patients with confirmed malignant pleural mesothelioma|October 2015|February 8, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02603315||8990|
NCT02595788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130032|Haemodynamic Changes During Anaesthesia in the Prone Position, Evaluated Using Transoesophageal Ultrasound|Haemodynamic Changes During Anaesthesia in the Prone Position, Evaluated Using Transoesophageal Ultrasound||Odense University Hospital|No|Recruiting|March 2014|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for spinal surgery in the prone position. Body mass index above 30.|November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595788||9568|
NCT02606045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070638|Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease|Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease: The VWD Minimize Study|VWDMin|University of Pittsburgh|Yes|Not yet recruiting|July 2016|June 2021|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||November 2015|November 12, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606045||8781|
NCT02611271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-11-Studienanmeldung|Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy|Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients With Sepsis and Acute Kidney Injury||Heinrich-Heine University, Duesseldorf|No|Not yet recruiting|November 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients treated for sepsis on surgical intensive care unit undergoing        renal replacement therapy.|November 2015|November 19, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02611271||8382|
NCT02603757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D & Colorectal Cancer|Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer|Prospective Pilot Study to Assess the Effectiveness of Vitamin D Supplementation for Patients Requiring Adjuvant Chemotherapy for Stage III Colorectal Cancer||Legacy Health System|No|Recruiting|March 2016|December 2022|Anticipated|December 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|99 Years|No|||March 2016|March 23, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603757||8957|
NCT02598947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRF-2014-05-003|The Effectiveness of a Treatment for Posterior Shoulder Tightness: A Feasibility Study|The Effectiveness of Treatment for Posterior Shoulder Tightness in Combination With 'Best Care' Compared With 'Best Care' Alone in Individuals With Shoulder Impingement Syndrome: A Feasibility Study||Western Sussex Hospitals NHS Trust|No|Not yet recruiting|April 2016|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02598947||9325|
NCT02598570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-460|Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma|An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma||AbbVie|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|20 Years|99 Years|No|||January 2016|January 23, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02598570||9354|
NCT02602886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD#020|Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder|Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder||Ruijin Hospital|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602886||9023|
NCT02602444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUMK202B|Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients|Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction Patients|PINPOINT|Collegium Medicum w Bydgoszczy|No|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients with STEMI or NSTEMI admitted to the study centre, designated to invasive        strategy.|November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602444||9056|
NCT02602691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0455|Cost-utility Analysis of the AlloMap® Test|Cost-utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation|CUPIDON|Hospices Civils de Lyon|Yes|Not yet recruiting|December 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|216|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602691||9037|
NCT02610413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02289|Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples||National Cancer Institute (NCI)||Recruiting|March 2014|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|354|||Both|N/A|N/A|No|Non-Probability Sample||December 2015|December 24, 2015|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610413||8447|
NCT02603991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-015|Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE)|Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE)||Beijing Pins Medical Co., Ltd|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|4 Years|18 Years|No|Probability Sample|patients at age 4-18; diagnostic criteria for epilepsia brain disorders; having tried        appropriate anti-epileptic drugs (AEDs) more than 1 year and at least 6 seizures per        month; patients or his(her) familys could understand this method and sign the informed        consent; Patients with good compliance and could complete postoperative follow-up；without        the vagus nerve lesion and damagement, progressive neurological diseases, cardiopulmonary        anomaly, respiratory system diseases, digestive system diseases|November 2015|November 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02603991||8939|
NCT02602353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAD-PhII-050|Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)|A Phase 2, Randomized, Double-Blind, Parallel-Group and Placebo-Controlled Pilot Study to Assess the Safety and Efficacy of a New Pain Patch Versus Placebo and No Treatment for the Treatment of Delayed Onset Muscle Soreness (DOMS)||Lead Chemical Co.,Ltd.|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|March 14, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602353||9063|
NCT02610270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-2|Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes|Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes in Response to Omega-3 Supplementation: A Dose-Response|O3Sport|Centre d'Alt Rendiment|Yes|Completed|June 2014|April 2015|Actual|January 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610270||8458|
NCT02602938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015KY163|Aspirin on CTCs of Advanced Breast and Colorectal Cancer||ACABC|Zhejiang Provincial People’s Hospital|Yes|Recruiting|November 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602938||9019|
NCT02605733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-Prem|The Neu-Prem Trial: Neuromonitoring of Preterm Newborn Brain During Birth Resuscitation|The Neu-Prem Trial: Neuromonitoring of Preterm Newborn Brain During Birth Resuscitation|Neu-Prem|Sharp HealthCare|No|Recruiting|October 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|72 Hours|No|Non-Probability Sample|Premature infants delivered at 23 to 31 +6 weeks gestational age at Sharp MBHWN.|March 2016|March 18, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02605733||8805|
NCT02594956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RennesUH|Impact of the Absence of Nasogastric Decompresssion After Pancreaticoduodenectomy|Impact of the Absence of Nasogastric Decompresssion After Pancreaticoduodenectomy : A Prospective and Randomized Study|IPOD|Rennes University Hospital|Yes|Recruiting|December 2015|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594956||9632|
NCT02599519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-03283-FB|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2015|||||N/A|N/A|N/A||||||||||||||November 5, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599519||9281|
NCT02603367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15359|COMFORT Caregiver Intervention in Improving Communication and Reducing Distress in Caregivers of Patients With Lung Cancer|The COMFORT Caregiver Intervention (CCI)|COMFORT|City of Hope Medical Center|Yes|Recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603367||8986|
NCT02595658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|West-Walker4|Insulin Dose Adjustments for Meals Differing in Fat Content in T1DM|||Northumbria University|Yes|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Male|18 Years|50 Years|No|||October 2015|November 2, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02595658||9578|
NCT02608970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV010-001|Safety and Tolerability Study of BMS-986177 in Healthy Subjects|A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMS-986177 in Healthy Subjects||Bristol-Myers Squibb|No|Not yet recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608970||8558|
NCT02596516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-0249-15|A Comparison of Colonic Bile Acid Content Following Right and Left Colectomies|A Comparison of Colonic Bile Acid Content Following Right and Left Colectomies||Meir Medical Center|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients palnned to undergo colon resection.|November 2015|November 5, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596516||9512|
NCT02596841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCCS 2015|Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias|Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias|Dm&Vc|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|February 2013|August 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|60|||Both|N/A|N/A|No|Probability Sample|The investigators used retrospectively collected data of 60 Caucasian patients with        clinical and radiological features of Idiopathic Interstitial Pneumonias referred to        Respiratory Pathophysiology Unit for a complete pulmonary function evaluation.|November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02596841||9487|
NCT02596854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2015-GES-0056|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||February 8, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596854||9486|
NCT02603380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelApp phase A|Feasibility of a Software App for Testing Inattention in Delirium|Feasibility Study of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium||University of Edinburgh|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|Royal Infirmary of Edinburgh (RIE) general wards and intensive care units.|November 2015|November 9, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02603380||8985|
NCT02610972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4005A|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study||Gynuity Health Projects|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|urine samples collected|Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women attending Hospital Materno-Infantil Inguarán with clinically confirmed cases of        preeclampsia and clinically healthy women who deliver at term will be eligible for the        study.|November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610972||8404|
NCT02599376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/028/14|Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women|Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women||University of Aberdeen|No|Recruiting|December 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|2||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02599376||9292|
NCT02602548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407463823|The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery|The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery Study Protocol: A Pilot Study||Methodist Sports Medicine|No|Enrolling by invitation|May 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with mechanical problems associated with their shoulder who elect to undergo        shoulder surgery|November 2015|November 9, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02602548||9048|
NCT02595593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HEOR_02|Rib Fixation for Clinically Severe Rib Fractures From Trauma|A Multicenter Prospective Randomized Trial on the Intervention of Rib Fixation for Clinically Severe Rib Fractures From Trauma||SCRI Development Innovations, LLC|Yes|Recruiting|April 2015|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|90 Years|No|||November 2015|November 2, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02595593||9583|
NCT02610348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L47|Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age|Persistence of Anti-Hep B Antibodies at 12 to 18 Months of Age in Children Having Received Hep B Vaccine at Birth and a DTaP-IPV-HB-Hib Hexavalent Vaccine (Hexaxim® or Infanrix Hexa®) Concomitantly With Prevnar® at 2, 4 and 6 Months of Age||Sanofi|No|Completed|November 2015|March 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|124|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610348||8452|
NCT02610361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-283-AU-001|Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors|A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors||BeiGene|No|Recruiting|November 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610361||8451|
NCT02602769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00018387|Metabolic Phenotyping in Children With ROHHAD Syndrome|Metabolic Phenotyping in Children With ROHHAD Syndrome||Children's Hospital Boston|No|Recruiting|November 2015|November 2020|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|12|Samples Without DNA|The investigators will retain blood samples for future measurement of hormones involved in      regulation of weight, appetite and satiety.|Both|2 Years|20 Years|No|Probability Sample|Children diagnosed with ROHHAD (Rapid onset Obesity, Hypoventilation, Hypothalamic        dysfunction, Autonomic Disturbances), and age-, sex- and BMI-matched controls.|November 2015|November 11, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02602769||9031|
NCT02602782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD-06-1346|Physiologic Signals and Signatures With the Accuryn™ Monitoring System in Intensive Care Patients|Physiologic Signals and Signatures With the Accuryn™ Monitoring System in Intensive Care Patients||Potrero Medical||Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Significantly injured trauma ICU patients receiving a Foley catheter and transfusion|November 2015|November 10, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602782||9030|
NCT02377700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEL-CR-06|Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis|Initial Safety and Performance of the COR-VP-001 Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis|XEL-CR-06|Xeltis AG|No|Active, not recruiting|June 2014|December 2019|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Months|16 Years|No|||February 2015|January 19, 2016|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02377700||26314|
NCT02459977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0209|The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea|||Asan Medical Center|Yes|Recruiting|April 2012|||June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459977||19997|
NCT02446197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-203|Self Directed Stations for the Stroke Patient|Self Directed Stations for the Stroke Patient||Baylor Research Institute|No|Recruiting|October 2014|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|77|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02446197||21055|
NCT02381041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-00115-vs|Comparative Evaluation of Cocaine and Adrenaline as Topical Vasonconstrictor Agents in Cosmetic Rhinoplasty|Comparative Evaluation of Cocaine and Adrenaline as Topical Vasonconstrictor Agents in Cosmetic Rhinoplasty||Clínica Fernández|Yes|Completed|March 2013|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Female|N/A|N/A|No|Non-Probability Sample|Healthy females elegible for cosmetic rhinoplasty.|April 2015|April 20, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381041||26057|
NCT02379754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-FT-01|Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function|Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function||Lund University|No|Recruiting|January 2015|December 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02379754||26156|
NCT02382991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20PT002-FR-01-0614|Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)|Randomized, Cross-over Study Comparing the Efficacy of the 3C60 Knee Against Non-microprocessor Controlled Knees on the Risk of Falling and Locomotor Skills of Moderately Active Persons With Leg Amputation Above Knee or Knee Disarticulation||Otto Bock France SNC|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|December 11, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02382991||25907|
NCT02383004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010770|Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement|Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement||Oregon Health and Science University|Yes|Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02383004||25906|
NCT02383017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Florida StateU|Effects of Shroom Tech Sport Supplementation and Concurrent Training|Effects of Shroom Tech Sport Supplementation and Concurrent Training on Body Composition, Performance and Health in Collegiate-aged Men||Florida State University|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02383017||25905|
NCT02383030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM18-FUMANCE|Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients|Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients|FUMANCE|Consorzio Oncotech|No|Recruiting|November 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|156|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02383030||25904|
NCT02461043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-046|Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma|Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial||Chinese Academy of Medical Sciences|Yes|Recruiting|April 2015|December 2023|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|386|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02461043||19915|
NCT02388854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOSNPs|Influence of Genetic Polymorphisms in the Pathogenesis of Endometriosis in Sardinian Population|Influence of Genetic Polymorphisms in the Pathogenesis of Endometriosis in Sardinian Population: an Observational Case Control Study||University of Cagliari|No|Not yet recruiting|December 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|EDTA blood samples|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with hystological diagnosis of endometriosis|March 2016|March 8, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388854||25456|
NCT02384265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P60MD006923|Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control|Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)|FRIENDS-Text|University of California, Los Angeles|No|Recruiting|December 2015|December 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|124|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02384265||25809|
NCT02597595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2771/09/14|Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major|Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major||Tanta University|Yes|Active, not recruiting|November 2014|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|60|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||September 2015|January 30, 2016|September 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597595||9429|
NCT02600351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1746|Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies||Gilead Sciences|No|Recruiting|November 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600351||9217|
NCT02600416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRE study|The CIRE Study (CItrate REcirculation Study)|Effects of AV Port Reversal in Citrate CVVH - The CIRE Study (CItrate REcirculation Study)|CIRE|Ziekenhuis Oost-Limburg|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02600416||9212|
NCT02594943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endodrill II|Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer|Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer||Region Skane|No|Not yet recruiting|November 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|85 Years|No|||October 2015|October 30, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02594943||9633|
NCT02598544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.17/REVA14.02|Endocrine Regulation of Lipolysis in Obesity and Diabetes|Atrial Natriuretic Peptide (ANP)-Induced Lipid Mobilization Regulation in Different Adipose Tissue Depots of Obese Subjects|ERLO|Hasselt University|No|Completed|May 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|55|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02598544||9356|
NCT02597738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204803|A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine|Scientific and Methodological Advancements in Human Specimens to Further the Development of Lung Cancer-based Precision Medicine - A Feasibility Study||University of Arkansas|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02597738||9418|
NCT02600663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10|Identification of Patients at Risk of Chronic Back Pain Using Questionnaires|Identification of Patients at Risk of Chronic Back Pain Using Questionnaires|chron_pain|Swiss Paraplegic Centre Nottwil|Yes|Not yet recruiting|January 2016|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|20 Years|60 Years|No|Non-Probability Sample|patients with acute back pain presenting at the general pratcioner|December 2015|December 23, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600663||9193|
NCT02595203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1450-105|Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects|A Phase I, Two-part, Open-label, Non-randomised Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects||Debiopharm International SA|No|Completed|November 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595203||9613|
NCT02609399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHUIRB00080405|ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir|ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir||Johns Hopkins University|No|Recruiting|November 2015|September 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|100 Years|No|||December 2015|December 20, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609399||8525|
NCT02609490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhaoke-201505-Azilsartan|Azilsartan in Chinese Patients With Mild and Moderate Hypertension|A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension||Lee's Pharmaceutical Limited|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609490||8518|
NCT02598050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002400|Preoperative Cognitive Screening in Older Surgical Patients Utility for Predicting Morbidity|NIH Explanatory/Developmental Research Grant Program: Preoperative Cognitive Screening in Older Surgical Patients: Feasibility and Utility for Predicting Morbidity||Brigham and Women's Hospital|No|Recruiting|February 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|White blood cells and plasma|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This project is designed as a prospective, single-center observational study. The cohort        will consist of 250 consenting subjects ≥ 65 years of age who present to the BWH Weiner        Center for Preoperative Evaluation (CPE) prior to elective lower extremity joint        replacement surgery. Eligibility criteria include: patients ≥ 65 years of age with an ASA        physical status of I-IV presenting for elective joint replacement. Exclusion criteria will        include planned ICU admission postoperatively, uncorrected vision or hearing impairment        (unable to see pictures or read or hear instructions); limited use of the dominant hand        (limited ability to draw); and or inability to speak, read, or understand English.|March 2016|March 14, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02598050||9394|
NCT02606162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 13018|Outcomes of Severe Osteoporotic Fractures Hospitalized in France: the CROSS Cohort|Outcomes of Severe Osteoporotic Fractures Hospitalized in France: the CROSS Cohort|CROSS|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|June 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2200|Samples With DNA|Whole blood|Both|60 Years|N/A|No|Non-Probability Sample|Men and women hospitalized for severe fragility fractures in response to low-energy trauma|November 2015|November 13, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606162||8772|
NCT02609581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF HDM/Titra/2015/D|Tolerability of SLIT With LAIS® Mites Allergoid Tablets|Non-Interventional Study (NIS) on the Tolerability of Sublingual Immunotherapy With LAIS® Mites Tablets in Consideration of the Chosen Titration Schedule in Everyday Practice||University Hospital of Cologne|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients aged 18 years or older can be enrolled in the NIS if sublingual specific        immunotherapy has been indicated due to allergic rhinoconjunctivitis or allergic bronchial        asthma induced by the allergens to be investigated (mites).|November 2015|November 23, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609581||8511|
NCT02595515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|-14/1206|The Effect of Chiropractic Treatment of Infantile Colic|The Effect of Chiropractic Treatment of Infantile Colic. A Randomized, Controlled Trial||Nordic Institute of Chiropractic and Clinical Biomechanics|No|Not yet recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|N/A|10 Weeks|No|||November 2015|November 3, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595515||9589|
NCT02602847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.720|Study of Covalently Closed Circular DNA (cccDNA) in Liver Transplant Patients With B Virus Markers|Study of cccDNA in Liver Transplant Patients With B Virus Markers|ECOGREFFE-B|Hospices Civils de Lyon|No|Recruiting|November 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with liver transplantation planned|November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602847||9026|
NCT02602860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0074|A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers|A Single-center, Open-label Positron Emission Tomography Study to Evaluate the Time-course of Displacement of [11C]UCB-J by Brivaracetam and Levetiracetam After Intravenous Administration in Healthy Volunteers||UCB Pharma|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02602860||9025|
NCT02595346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/074/HP|Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome|Efficiency of Hydroxychloroquine on the Endothelial Dysfunction in Antiphospholipid Syndrome (APLAQUINE)|APLAQUINE|University Hospital, Rouen|No|Not yet recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595346||9602|
NCT02595632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0187|Breath Analysis in Healthy Controls|Exhaled Breath Analysis by Secondary Electrospray Ionization (SESI-MS) in Healthy Controls||University of Zurich|No|Recruiting|November 2015|||October 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects will be included according to the predefined inclusion and exclusion        criteria. They will be recruited from the general population by printed flyers, newspaper        advertisements and personal communication.|November 2015|November 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595632||9580|
NCT02608255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01378-41|A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage|A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2016|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02608255||8613|
NCT02608268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMBG453X2101|Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies|Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies||Novartis|No|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608268||8612|
NCT02595749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00657|Effects of Intranasal Oxytocin on Cigarette Smoking|Effects of Intranasal Oxytocin on Cigarette Smoking||University of Southern California|No|Not yet recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595749||9571|
NCT02603081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1005-151|Study to Evaluate SPI-1005 in Adults With Meniere's Disease|Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease||Sound Pharmaceuticals, Incorporated|No|Recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|19 Years|70 Years|No|||December 2015|December 10, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603081||9008|
NCT02603094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH Nr. 2011-0034 Amend3|Gastric pH in Intubated Children - Part Two|Untersuchung Des Magen-pH in lntubationsanästhesie Bei Kindern - Teil Zwei||University Children's Hospital, Zurich|No|Not yet recruiting|November 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|180|||Both|1 Year|15 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603094||9007|
NCT02603159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capecitabine and esophageal|Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy||DCECRT|The First Affiliated Hospital of Henan University of Science and Technology|Yes|Recruiting|October 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|75 Years|No|||October 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02603159||9002|
NCT02598388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108062|Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo|A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo||Crucell Holland BV|Yes|Recruiting|December 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|575|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598388||9368|
NCT02598401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185365|The British Osteonecrosis Study|The British Osteonecrosis Study: A Prospective Multi-centre Study to Examine the Natural History of Osteonecrosis in Older Children, Teenagers and Young Adults With Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma|BONES|University of Leeds|No|Not yet recruiting|February 2016|February 2021|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|10 Years|25 Years|No|Non-Probability Sample|Children, teenagers or young adults between the age of 10 (including the day of the 10th        birthday)and 24 years 364 days (at the time of diagnosis) with a first diagnosis of acute        lymphoblastic leukaemia or lymphoblastic lymphoma (T-NHL or SmIg negative precursor B-NHL)        diagnosed under standard criteria are eligible for BONES.|November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598401||9367|
NCT02560935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121383|Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II|Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II|SPRING|Vanderbilt University|Yes|Not yet recruiting|January 2016|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Both|5 Years|12 Years|No|||December 2015|December 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02560935||12246|
NCT02560948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT009|Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis|A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis||BioTech Tools S.A.|Yes|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|654|||Both|18 Years|64 Years|No|||September 2015|January 26, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560948||12245|
NCT02606487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000049033|Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations|Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations||The Hospital for Sick Children|No|Recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|8 Years|18 Years|No|Probability Sample|Patients aged 8-18 with cystic fibrosis admitted for inpatient treatment with a clinical        diagnosis of pulmonary exacerbation|November 2015|November 16, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02606487||8747|
NCT02600624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200504|Prenatal Alcohol Biomarker Study in Uruguay|Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay||Northwestern University|No|Not yet recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1800|Samples With DNA|Maternal alcohol biomarker assays will include ethylglucuronide (EtG) in hair and nails and      PEth in blood obtained at the time of delivery. Newborn umbilical cord and routine 48 hour      heel stick blood will be collected to assess newborn PEth levels|Female|18 Years|N/A|No|Probability Sample|Women who are admitted public health care hospitals in Montevideo, Uruguay (Hospital        Pereira Rossell) for obstetrical care will be recruited to participate in the study.|November 2015|November 6, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600624||9196|
NCT02598882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExerRehab|Virtual Reality as a Tool for Rehabilitation on Elderly People|Physical Activity With an Active Video Game Provides Bigger Energy Expenditure and Less Muscle Fatigue||University of Nove de Julho|Yes|Active, not recruiting|September 2014|November 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|13|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02598882||9330|
NCT02599116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 2015-53|Gastrointestinal Microbiome Study of Appendiceal Cancer|A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread||Mercy Medical Center|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|80 Years|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599116||9312|
NCT02560961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidade Nove de Julho|Is Kinesio Taping Better Than Placebo Taping for Improving Performance During Unilateral Vertical Jump and Hop Tests?|Is Kinesio Taping Better Than Placebo Taping for Improving Performance During Unilateral Vertical Jump and Hop Tests? Protocol Study for a Randomized, Placebo-controlled, Double-blind, Clinical Trials.||University of Nove de Julho|Yes|Not yet recruiting|September 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Male|15 Years|20 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02560961||12244|
NCT02600793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeftarolineCSF2013|Ceftaroline Diffusion Into Cerebrospinal Fluid of Children|Ceftaroline Diffusion Into Cerebrospinal Fluid of Children With Ventriculitis Due to Ventriculoperitoneal Shunt (VPS) Infection||Wayne State University|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|6 Months|17 Years|No|||November 2015|November 6, 2015|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600793||9183|
NCT02609321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC0001|Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer|Efficacy of Thoracic Paravertebral Block vs Local Anesthesia of the Surgical Wound in Reduction of Acute Post-surgical Pain in Patients With Breast Cancer. Controlled Phase III, Randomized, Single-blind, Superiority Clinical Trial.||Instituto de Cancerología S.A.|No|Recruiting|November 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Female|18 Years|70 Years|No|||November 2015|November 17, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02609321||8531|
NCT02607969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G014/15|Investigating the Effectiveness of Control Frequency on and Deformational Plagiocephaly|Comparison the Effectiveness Control Frequency of Physiotherapy Home Program on Deformational Plagiocephaly||Hacettepe University|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Month|6 Months|No|||November 2015|November 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607969||8635|
NCT02607982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HangzhouCH03|CCRT for Esophageal Cancer.|Long-term Results of Definitive Concurrent Chemoradiotherapy Using Paclitaxel Plus Oxaliplatin in Unresectable Locally Advanced Esophageal Cancer.||Hangzhou Cancer Hospital|No|Completed|January 2005|November 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|80 Years|No|||February 2016|February 14, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607982||8634|
NCT02547597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARVEDILOL|Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris|Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris||Gachon University Gil Medical Center|No|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|20 Years|80 Years|No|||September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547597||13271|
NCT02597699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94602|Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide|Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide: A Phase III Randomized Trial|FOETIVA2|University Hospital, Montpellier|No|Active, not recruiting|October 2015|March 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|66|||Female|18 Years|N/A|No|||October 2015|November 3, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02597699||9421|
NCT02611245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB707702|NIR Fluorescence Imaging Technique in Thoracic Surgery With ICG|Phase 1 Study of NIR Fluorescence Guided Thoracic Surgery Using ICG||Chinese Academy of Sciences|Yes|Enrolling by invitation|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611245||8384|
NCT02599974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 12020 ASAINT|PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy|Role of Fluorodeoxyglucose (FDG) PET-CT in the Initial Staging of Breast Cancer (ASAINT 1) and in the Early Assessment of Response to Neoadjuvant Chemotherapy (ASAINT 2)|ASAINT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2006|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Women with large breast cancer treated with neo-adjuvant chemotherapy regimen.|November 2015|December 8, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02599974||9246|
NCT02595801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000046454|Surgery in Early Life and Child Development at School-entry: A Population-based Study|Surgery in Early Life and Child Development at School-entry: A Population-based Study||The Hospital for Sick Children||Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|188628|||Both|N/A|6 Years|No|Non-Probability Sample|Children attending public or Catholic school in Ontario who have completed the Early        Development Instrument|November 2015|November 16, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595801||9567|
NCT02610660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPP-2|Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension|Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension|TOPP-2|Association for Pediatric Pulmonary Hypertension|No|Recruiting|August 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|3 Months|18 Years|No|Non-Probability Sample|1. Children and adolescents, newly diagnosed with PH (incident PePH patients), meeting             the inclusion criteria. A patient is considered an incident patient if the time             elapsed between the diagnostic RHC and the initial visit at the site including the             patient is less than or equal to three months.          2. Ex-incident patients from the previous TOPP-1 registry.|January 2016|January 11, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02610660|3 Years|8428|
NCT02594839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILD-01|Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease|A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease||Federal Research Clinical Center of Federal Medical & Biological Agency, Russia|Yes|Recruiting|February 2013|September 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|80 Years|No|||November 2015|November 2, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02594839||9641|
NCT02608723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304|Shock Wave Therapy: Do the External Appearance of the Device Influence Clinical Outcomes?|Chronic Plantar Fasciitis Treated With Shock Wave Therapy: Do the External Appearance of the Device Influence Clinical Outcomes? A Randomized Controlled Clinical Trial.||Asociacion Colaboracion Cochrane Iberoamericana|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02608723||8577|
NCT02603588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-acupuncture-1|The Effects of Sphenopalatine Ganglion Acupuncture on Nasal Function|Effects of Sphenopalatine Ganglion Acupuncture on Nasal Ventilation and Autonomic Nervous Activity in Healthy Volunteers||Beijing Tongren Hospital|Yes|Completed|February 2014|August 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02603588||8970|
NCT02602899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-013|Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy|Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy|ANT-DBS-RE|Beijing Pins Medical Co., Ltd|Yes|Recruiting|April 2015|July 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|60 Years|No|||October 2015|March 18, 2016|October 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602899||9022|
NCT02606513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR_CT_URO|MR Urography vs CT Urography|Opacification of the Upper Urinary Tract With MR Urography Compared to CT Urography||Kuopio University Hospital|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606513||8745|
NCT02610426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02291|Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples||National Cancer Institute (NCI)||Recruiting|March 2014|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|162|||Both|N/A|N/A|No|Non-Probability Sample||December 2015|December 24, 2015|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02610426||8446|
NCT02608775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANI|Usefulness and Predictive Capacity of ANI and SPI of the Hemodynamic Response|Usefulness and Predictive Capacity of ANI and SPI of the Hemodynamic Response to Standardized Stimuli During Neuro- and Urologic Surgery Under Target Controlled Infusion of Propofol and Sufentanil.||Universitair Ziekenhuis Brussel|No|Not yet recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608775||8573|
NCT02605135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207001|Host Response to Pessaries in Microbial Communities of the Postmenopausal Vagina|Host Response to Pessaries in Microbial Communities of the Postmenopausal||Loyola University|No|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|Samples Without DNA|Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage at each study      visit.|Female|51 Years|N/A|No|Non-Probability Sample|Subjects must be female, postmenopausal, and have symptomatic pelvic floor disorders as        evidenced by presenting to our tertiary care clinic.|November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605135||8851|
NCT02598778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5583|Comparing Mouth Rinses in Regard to Streptococcus Mutans Reduction|Comparing Chlorhexidine Gluconate, Sodium Fluoride, Coconut Oil and Water Mouth Rinses in Regard to Streptococcus Mutan Reduction||Montefiore Medical Center|No|Not yet recruiting|November 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598778||9338|
NCT02610452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/SB-01|Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study|Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study|OUPS|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610452||8444|
NCT02608892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/176X|Caring for Babies During the Newborn Screening Blood Test|Caring for Babies During the Newborn Screening Blood Test: How do Parents Help? A Pilot RCT||Children's Hospital of Eastern Ontario|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02608892||8564|
NCT02608957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-0002|Evaluation of the Latella™ Knee Implant System for Medial Osteoarthritis Pain Reduction|Evaluation of the Latella™ Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-US Study)|Latella-US|Cotera, Inc.|No|Not yet recruiting|December 2015|April 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|30 Years|70 Years|No|||November 2015|November 17, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608957||8559|
NCT02599779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-065|A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients|A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients|OZM-065|Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02599779||9261|
NCT02604121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 045 03|Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity|Interest of Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity by Transepithelial Brushing in Liquid-based|Cytobuccale|University Hospital, Toulouse|No|Recruiting|February 2013|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|20 Years|N/A|No|||November 2015|November 12, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02604121||8929|
NCT02606708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11105|Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy|Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study||New York University School of Medicine||Active, not recruiting|September 2003|||December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Female|19 Years|90 Years|No|||November 2015|November 13, 2015|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606708||8731|
NCT02599662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207194|Intraoperative Radiation Therapy for Resectable Pancreas Cancer|Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma|IORT|Loyola University|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599662||9270|
NCT02596529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL45763.098.13|Fixation of the Posterior Malleolus in Medium-sized Trimalleolar AO Weber-B Fractures.|Medium-sized Posterior Fragments in AO-Weber B Fractures, Does Open Reduction and Internal Fixation Improve Outcome? A Multicenter Randomized Controlled Trial. The POSTFIX-trial.|POSTFIX|Medical Center Haaglanden|No|Recruiting|January 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596529||9511|
NCT02601222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-RZZY-JN-RS|Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema|A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema||Guizhou Tongjitang Pharmaceutical Co.,Ltd|No|Not yet recruiting|November 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||November 2015|November 8, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02601222||9150|
NCT02604342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO29750|Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib|Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Doectaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy And Crizotinib||Hoffmann-La Roche||Recruiting|November 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604342||8912|
NCT02596126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|633765|Secondary Prevention of Cardiovascular Disease in the Elderly Trial|Secondary Prevention of Cardiovascular Disease in the Elderly Trial|SECURE|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3206|||Both|65 Years|N/A|No|||October 2015|November 2, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596126||9542|
NCT02596399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29259|A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers|A PHASE I, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF DSTA4637S IN HEALTHY VOLUNTEERS||Genentech, Inc.||Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596399||9521|
NCT02603731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-DELIR1-15|Delirium at the Intensive Care Unit - a Retrospective Cohort Study|Delirium at the Intensive Care Unit - a Retrospective Cohort Study||Roskilde County Hospital|No|Completed|August 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the ICU at Køge Hospital in the study period|February 2016|February 4, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02603731||8959|
NCT02610205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Touch-ED|Caring Touch as a Bodily Anchor for Patients After Sustaining a Motor Vehicle Accident|Integrative Care at the Emergency Department||Karolinska University Hospital|No|Completed|September 2012|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|A recruitment of potential study participants was made up from a list of incoming        patients, arriving at the emergency department following an MVA, and who upon medical        examinations were given an injury severity score (ISS) between 0-3 and subsequently        discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating        of 0 indicates no physical injury, 1-3 represents minor physical injuries; and 8        corresponds to a life-threatening injury|November 2015|November 20, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02610205||8463|
NCT02610855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005602|Effect of Treatment on Activity and Muscle Function in Pediatric Patients With Scoliosis|Effect of Treatment on Activity and Muscle Function in Pediatric Patients With Scoliosis (SAMUS SCOLI)|SAMUS SCOLI|Mayo Clinic|No|Recruiting|November 2015|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|9 Years|16 Years|No|||November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02610855||8413|
NCT02601053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15.146|The Fear F8ctor Study - Does Fear Induce a Blood Curdling State?|The Fear F8ctor Study - Does Fear Induce a Blood Curdling State? The Origin Behind the Phrase Unravelled|FF8|Leiden University Medical Center|No|Completed|June 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601053||9163|
NCT02601066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIO-2015-01 LMNA|Cardiac Arrhythmias and Sudden Death in Patients Affected With Laminopathies|Identification of Predictors of Cardiac Arrhythmias and Sudden Death in Pediatric Patients Affected With Laminopathies||Hospital Sant Joan de Deu|Yes|Recruiting|September 2015|September 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|1 Year|25 Years|No|||November 2015|November 7, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02601066||9162|
NCT02599584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLESS 2015|Performance and Team Pre-critical Staff Before Critical Event in High Fidelity Simulation for Anesthesiology Residents|Improvement of Team Performance With a Pre-critical Staff Within the Team Prior to Admission of Critical Simulated Patient in High Fidelity Simulation Session for Anesthesiology Resident During Their Education Curriculum|Simstaf&perf|Claude Bernard University|No|Not yet recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|44|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599584||9276|
NCT02595125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508153|Study Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique|Comparative Study, Prospective, Randomized , Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique. A Monocentric Study|DIRECTE|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|N/A|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595125||9619|
NCT02595138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-039|Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer|||Chinese Academy of Medical Sciences|No|Active, not recruiting|October 2015|December 2023|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Female|18 Years|N/A|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595138||9618|
NCT02610244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD-MCT-09092015|Examining Benefits of Modified Cogmed Training With ADHD at Cambridge Memorial Hospital(CMH)|Examining Benefits of Modified Cogmed Training With ADHD Youth at Cambridge Memorial Hospital (CMH)|CMH|Cambridge Memorial Hospital|Yes|Recruiting|November 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|8 Years|16 Years|No|||November 2015|November 18, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02610244||8460|
NCT02610257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58674|Somatosensory Dysfunction as the Underlying Mechanism of Upper Limbs Motor Blocks in People With Parkinson's Disease|The Role of Somatosensory Dysfunction as the Underlying Mechanism of Upper Limbs Motor Blocks in People With Parkinson's Disease With and Without Freezing of Gait||Katholieke Universiteit Leuven|Yes|Recruiting|January 2016|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|5||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610257||8459|
NCT02381977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANGEA|Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment|Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment|PANGEA|University of Pittsburgh|No|Completed|November 2011|September 2014|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|922|||Both|N/A|17 Years|No|Non-Probability Sample|Critically-ill children with acute neurologic injury|March 2015|March 2, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02381977||25985|
NCT02381990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URN-13-1010|Fuse Image MRI Guided Prostate Cryotherapy|Office Based Fuse Image MRI Guided Prostate Cryotherapy: Outcomes Registry|FIPC|Urological Research Network, LLC|Yes|Recruiting|July 2013|June 2023|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Male|55 Years|N/A|No|Non-Probability Sample|As written in Initial Section|March 2015|March 24, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02381990|10 Years|25984|
NCT02446535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiulliGH|Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?|REST/Collaborative Study Initiative With the Aim of Providing More Objective Information on Volume Status and Guiding Physicians in the Quest for DW|REST|Miulli General Hospital|Yes|Recruiting|February 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02446535||21029|
NCT02446808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProPep B-016-001|Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy|Clinical Assessment of Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy||ProPep Surgical, LLC|Yes|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446808||21008|
NCT02385279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRI-005|Study Comparing the MiStent SES Versus the XIENCE EES Stent|Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries|DESSOLVE III|ECRI bv|Yes|Active, not recruiting|March 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1404|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02385279||25731|
NCT02385071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106516|A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants|A Phase 1, Open-label, Randomized, 2-panel, 3-way Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of Simeprevir Following Single Dose Administration of Age-appropriate Oral Formulation Candidates, Compared to the 150-mg Oral Capsule, and to Assess the Effect of Food on the Bioavailability of Simeprevir Following Single Dose Administration of a Selected Age-appropriate Oral Formulation Candidate||Janssen Sciences Ireland UC|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02385071||25747|
NCT02388516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039072-ARI|Maternal Vitamin D for Acute Respiratory Infections in Infancy|Maternal Vitamin D for Acute Respiratory Infections in Infancy (MDARI): a Nested Sub-study in a Randomized Controlled Trial of Vitamin D Supplementation During Pregnancy and Lactation in Dhaka, Bangladesh|MDARI|The Hospital for Sick Children|Yes|Recruiting|December 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|1300|||Both|N/A|26 Weeks|Accepts Healthy Volunteers|||September 2015|September 21, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02388516||25482|
NCT02447445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM MED1250|Grip Strength Routine Implementation (GRImP)|Implementing Grip Strength Measurement Into Routine Clinical Practice; a Feasibility Study (GRImP)||University Hospital Southampton NHS Foundation Trust.|Yes|Not yet recruiting|July 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|80 Years|N/A|No|Probability Sample|Grip strength of older patients admitted to the MOP will be measured by a ward nurse.|May 2015|May 18, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447445||20960|
NCT02447692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR-327433, ISR-2014-10481|Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study|Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study|PROMIZING|Lawson Health Research Institute|Yes|Recruiting|February 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|512|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02447692||20941|
NCT02377583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/24|Hypothalamo-pituitary Adrenal Axis Activity and Neuropsychological Consequences in Type 1 Diabetes in Childhood|Hypothalamo-pituitary Adrenal Axis Activity: Relation With Neuropsychological Consequences in Type 1 Diabetes in Childhood. The CORTICODIAB Study|CORTICODIAB|University Hospital, Bordeaux|Yes|Recruiting|August 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|90|Samples With DNA|20ml blood sample in order to evaluate:        -  NR3C1 (GR) gene        -  NR3C2 (MR) gene        -  FKBP5 gene        -  CRH gene        -  CRHR1 gene        -  CBG gene|Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Age: The investigators will limit the study to children at least 6 years, to ensure             the successful completion of saliva samples and MRI without anesthesia. The             investigators limit themselves to prepubescent children do not have to take into             account the influence of sex steroids on the AC activity.          -  Gender: Although it is expected differences in hippocampal volume and CA activity             between boys and girls, the relationship between these two variables is not             necessarily different for boys and girls. Thus, the inclusion of both sexes in the             analysis is not necessarily problematic, and will be more informative. So it has been             finally decided to include boys and girls in the sample of subjects undergoing MRI.          -  Population control: The constitution of a control group from the siblings will enable             to study the specific effect of diabetes on anxiety and depression, regardless of the             children's education mode in the same family environment.|February 2015|February 25, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02377583||26323|
NCT02388412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT7895126|18F-NaF-PET for Identification of TCFA|Evaluating the Diagnostic Accuracy of 18F-sodium Fluoride Positron Emission Tomography for Identification of High-risk Vulnerable Coronary Atherosclerotic Plaque in Patients With Coronary Artery Disease|NaF-PET|Seoul National University Hospital|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|96|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with angina pectoris|February 2016|February 21, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02388412|12 Months|25490|
NCT02388425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||March 9, 2015|March 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388425||25489|
NCT02602301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oxytocin|The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels|The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels .A Prospective Randomized Controlled Trial.||Kasr El Aini Hospital|No|Active, not recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|327|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602301||9067|
NCT02602314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML1415|Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia|Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415|SUSTRENIM|Gruppo Italiano Malattie EMatologiche dell'Adulto|Yes|Not yet recruiting|March 2016|February 2024|Anticipated|February 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02602314||9066|
NCT02600741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106399|Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)|A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment|FIRST|Janssen Scientific Affairs, LLC|No|Recruiting|July 2015|December 2018|Anticipated|September 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Study population will consist of a paired patient and caregiver. A caregiver is defined as        a person who has accepted responsibility for providing the patient with both assistance        with activities of daily living and protection from harm. The patient will have a        diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder.|March 2016|March 22, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02600741||9187|
NCT02600754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MD009675|Telehealth Depression Treatments for Older Adults|Telehealth Treatments for Depression With Low-Income Homebound Seniors||University of Texas at Austin|No|Not yet recruiting|January 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|276|||Both|50 Years|N/A|No|||November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600754||9186|
NCT02601274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-309-00CH1|Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor|Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors|HMPL-309|Hutchison Medipharma Limited|Yes|Recruiting|April 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02601274||9146|
NCT02605057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1081|Dermatopharmacokinetic Trial of LEO 80185 Gel|Dermatopharmacokinetic Trial of LEO 80185 Gel||LEO Pharma|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605057||8857|
NCT02605070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSH_IMEN|Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia|Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia||Instituto de Investigacion Sanitaria La Fe|No|Not yet recruiting|November 2015|November 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Male|30 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02605070||8856|
NCT02605707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011Y1-00033-6|Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke|Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke||Southern Medical University, China|No|Recruiting|November 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 12, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605707||8807|
NCT02599194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARIMG0006|18F-FSPG PET/CT for Cancer Patients on Therapy|An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy||Stanford University||Recruiting|July 2015|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599194||9306|
NCT02560844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0638|Cardiomyopathy Arrhythmia Risk Evaluation|Cardiomyopathy Arrhythmia Risk Evaluation|CARE|University Health Network, Toronto|No|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients with cardiomyopathy and primary prevention ICDs|September 2015|September 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560844||12253|
NCT02602145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|386-14-FB|Optimal Stent Selection for the Femoropopliteal Artery|Optimal Stent Selection for the Femoropopliteal Artery|SFA stent|University of Nebraska|No|Recruiting|December 2014|||October 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe peripheral artery disease already treated with a stent.|November 2015|November 9, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02602145||9079|
NCT02605915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29831|Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer|A Phase Ib, Open-Label, Two-Arm Study Evaluating The Safety And Pharmacokinetics of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab And Pertuzumab in Patients With Her2 Positive Breast Cancer||Hoffmann-La Roche||Recruiting|December 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|59|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605915||8791|
NCT02605928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INJ-INAR-01|Use of BIP-Needles in Rheumatologic Injections|INJ-INAR-01 Use of BIP-Needles in Rheumatologic Injections||Injeq Ltd||Completed|October 2014|January 2016|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|79|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02605928||8790|
NCT02599740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-2093|Natural Fruit Extract Versus the Assumed Key Active Compound in Reducing the Post-prandial Blood Glucose Level|The Bioequivalence of a Natural Extract Versus the Assumed Key Active Compound in Reducing the Post-prandial Blood Glucose Levels||Unilever R&D|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599740||9264|
NCT02599753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-4874A|Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients|Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging||Chang Gung Memorial Hospital|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02599753||9263|
NCT02598752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-274|Performance Testing in Older Patients Undergoing Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome|Feasibility and Safety of Functional Performance Testing in Older Patients Undergoing Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|50 Years|N/A|No|Non-Probability Sample|This study is open to patients with AML or MDS scheduled to undergo HCT at MSKCC. These        patients will be identified and recruited from the Adult Bone Marrow Transplantation        clinics at MSKCC.|November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598752||9340|
NCT02602431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31861414.4.0000.0075|Low Laser Light Therapy After Impacted Third Molar Removal|A Unique Application of Low Laser Therapy After Third Molar Surgery: A Randomized Controlled Clinical Trial||University of Sao Paulo|No|Recruiting|March 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02602431||9057|
NCT02608203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-46|[68 Ga]-DOTANOC PET/CT in GEP-NETs|Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study.|GEP-NOC|Assistance Publique Hopitaux De Marseille||Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02608203||8617|
NCT02597803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-259|Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome|A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye|DES|ReGenTree, LLC|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|306|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597803||9413|
NCT02599766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref.Nr.EK:296/13|Effects of Animal-assisted Therapy on Brain-injured Patients|Short-term Effects of Animal-assisted Therapy on the Rehabilitation Process of Brain-injured Patients at REHAB Basel||Swiss Tropical & Public Health Institute|No|Recruiting|February 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02599766||9262|
NCT02606357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTUL07225|Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan|Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan|NEWLAN|Sanofi|No|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|290|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606357||8757|
NCT02600117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-CA-174-1708|Use of TDF in Patients With Inactive Chronic Hepatitis B Infection|The Use of Tenofovir Disoproxil Fumarate (TDF) in the Management of Patients With Inactive Chronic Hepatitis B (CHB) Infection||University Health Network, Toronto|No|Enrolling by invitation|November 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600117||9235|
NCT02598128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCT-0000497|Study to Evaluate Safety, Tolerability and Fat Absorption Using a Novel Enteral Feeding In-line Digestive Enzyme Cartridge (Relizorb)|Study to Evaluate Safety, Tolerability and Fat Absorption Using a Novel Enteral Feeding In-line Digestive Enzyme Cartridge (RELIZORB) in Patients With Cystic Fibrosis Receiving Enteral Feeding||Alcresta|Yes|Recruiting|November 2015|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|4 Years|45 Years|No|||March 2016|March 16, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02598128||9388|
NCT02600000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38572614.1.3001.5192|Inspiratory Muscle Training Effectiveness in Sympathetic Activity and Functional Capacity in Patients With Heart Failure|Effectiveness of Inspiratory Muscle Training Associated With a Cardiac Rehabilitation Program in Sympathetic Activity and Functional Capacity in Patients With Heart Failure: a Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|30|||Both|21 Years|60 Years|No|||August 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600000||9244|
NCT02606409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718/1548|Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients|Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients|DEXsedation|Assiut University|Yes|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||November 2015|November 14, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606409||8753|
NCT02609724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT150178|Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL|Effectiveness of Fluoroscopy-guided Manual Lymph Drainage (MLD) Versus Traditional MLD or Placebo MLD, as Part of Decongestive Lymphatic Therapy, for the Treatment of Breast Cancer-related Lymphoedema (BCRL): a Randomised Controlled Trial|EFforT-BCRL|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|January 2016|June 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|201|||Both|18 Years|N/A|No|||November 2015|January 12, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609724||8500|
NCT02609737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-161|Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors|Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609737||8499|
NCT02602509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celecoxib_WBA|Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers|Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers||National University Hospital, Singapore|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602509||9051|
NCT02546804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCDIndore|A Clinical Trial to Study the Effects of Two Home Made Mouthwashes in Patients With Gum Diseases|Evaluate the Efficacy of Potassium Permanganate Mouthwash and Hot Salt Water Mouthwash and Their Comparison With Chlorhexidine Mouthwash on Plaque Index,Gingival Index and Periodontal Probing Depth||Government College of Dentistry, Indore|Yes|Recruiting|June 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02546804||13332|
NCT02595840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trans-MARBLE|A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)|A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)||AIO-Studien-gGmbH||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2015|November 2, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02595840||9564|
NCT02602730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR80RR-II|Internet-Based Nonsmoking Program for Postpartum Women|Internet-Based Nonsmoking Program for Postpartum Women|PostPartum_2|Oregon Center for Applied Science, Inc.|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|307|||Both|18 Years|90 Years|No|||November 2015|November 10, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02602730||9034|
NCT02547090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-124|Minimizing Complications in Scoliosis Surgery in Children With Cerebral Palsy|The Effect of Two Surgeons on Blood Loss and Operative Time in Cerebral Palsy (CP) Patients Undergoing Posterior Spinal Fusion||Phoenix Children's Hospital|No|Completed|February 2012|March 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|N/A|18 Years|No|Non-Probability Sample|The study group consisted of 25 consecutive patients with CP and progressive neuromuscular        scoliosis who underwent PSF in 2012 with the use of a two surgeon team. The control group        consisted of a consecutive series of patients with CP who underwent PSF by a single        surgeon from 2008-2010 at the same institution. The control group was a cohort of patients        matched for age, gender, weight and Cobb angle.|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547090||13310|
NCT02547324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/00141|Slump Sitting X-ray of the Lumbar Spine Is Better Than Conventional Flexion View|Slump Sitting X-ray of the Lumbar Spine Is Better Than Conventional Flexion||National University Hospital, Singapore|No|Terminated|May 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|45 Years|N/A|No|||September 2015|September 9, 2015|August 20, 2015||No|Study results were too significant|No||https://clinicaltrials.gov/show/NCT02547324||13292|
NCT02604888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXIS-ALOPECIA AREATA-2015|Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females||MEXISAREATA|Mexis George|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604888||8870|
NCT02601547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 154 02|PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma|PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma Patients -Implication in the Evaluation of Neuro-cognitive Function Alteration (LYMCOTEP)|LYMCOTEP|University Hospital, Toulouse|Yes|Completed|September 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|85 Years|No|||November 2015|November 9, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02601547||9125|
NCT02602405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1582|Return to Work After Potential Severe Injury|Return to Work After Potential Severe Injury; a Population Based Observational Study||Norwegian University of Science and Technology|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1700|||Both|16 Years|65 Years|No|Non-Probability Sample|All patients in working age received by a trauma team in any of the eight hospitals within        the region of Central Norway in the period from June 1st, 2007 to May 30th, 2010|December 2015|December 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602405||9059|
NCT02607735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1171|Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy|A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection|POLARIS-1|Gilead Sciences|Yes|Recruiting|November 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|380|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607735||8653|
NCT02602197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 13/100|Intravenous Paracetamol Compared Dexketoprofen for Postoperative Analgesia After Septoplasty|The Efficacy of Intravenous Paracetamol Versus Dexketoprofen for Postoperative Pain Management After Septoplasty: A Prospective Randomized Double Blind Study||Baskent University|Yes|Active, not recruiting|August 2013|February 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02602197||9075|
NCT02608151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-08|Effect in the Short and Medium Term of Different Techniques of Tactile Stimulations on Neurological Development in a Population of Very Preterm Infants|Effect in the Short and Medium Term of Different Techniques of Tactile Stimulations on Neurological Development in a Population of Very Preterm Infants||Assistance Publique Hopitaux De Marseille||Active, not recruiting|September 2011|April 2016|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|36|||Both|N/A|33 Weeks|No|||October 2015|November 16, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02608151||8621|
NCT02608164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/15/0083|A Comparison of Capsules and Oral Spray Solution as Methods of Delivering Vitamin D3 and Raising Status|A Comparison of Capsules and Oral Spray Solution as Methods of Delivering Vitamin D3 and Raising Status: a Randomised Crossover Study|SCD3|University of Ulster|No|Recruiting|August 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02608164||8620|
NCT02600026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|799824-2|Video Feedback Intervention for Cognitively Impaired Older Drivers|Video Feedback Intervention for Cognitively Impaired Older Drivers||Rhode Island Hospital|Yes|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|50 Years|90 Years|No|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600026||9242|
NCT02595710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312m46162|Bartonella in Liver Transplant Patients|Undetected Bartonella Spp. Infection Puts Liver Transplant Patients at Great Risk||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|December 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid      culture, enriched agar plating and molecular techniques. Four-mm skin biopsies from      non-lesional skin will be acquired from the same patients, processed using our published      techniques, and imaged using confocal microscopy and compared to BAPGM test results. Urine      samples will be collected and analyzed for microRNAs. Blood smears will be analyzed for      intra-erythrocytic Bartonella spp.|Both|18 Years|N/A|No|Non-Probability Sample|This study includes subjects ages 18 and above. Patients of the University of Minnesota        Transplant Center who meet the inclusion/exclusion criteria will be given the opportunity        to participate in this study. Dr. Lake has several liver transplant clinics and        appropriate patients will be offered the opportunity to participate in this study.|November 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02595710||9574|
NCT02595723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032015-004|Phenytoin for Memory Impairment Secondary to Megestrol|Phenytoin for Memory Impairment Secondary to Megestrol||University of Texas Southwestern Medical Center|No|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595723||9573|
NCT02610686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM- NIMPE|Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam|Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam||National Institute of Malariology, Parasitology and Entomology, Vietnam|No|Recruiting|March 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|N/A|No|||October 2015|March 22, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02610686||8426|
NCT02595099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15098|Mindfulness for Osteoarthritis-related Knee Pain|Feasibility and Acceptability of a Mindfulness-based Intervention for People With Osteoarthritis (OA) Related Knee Pain.||University of Nottingham|No|Not yet recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02595099||9621|
NCT02595112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508154|Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery|Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery. A Monocentric Study|SREENSTAPH2|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595112||9620|
NCT02596009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2403|Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices|Multicenter Open-label Cross-over Study to Compare Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Dry Powder Inhaler Devices||Novartis|No|Not yet recruiting|November 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|40 Years|N/A|No|||November 2015|November 2, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02596009||9551|
NCT02596217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.16|Safety, Tolerability and Pharmacokinetics of BI 655066 in Healthy Asian and Caucasian Male Volunteers|Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066 in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Active, not recruiting|August 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Anticipated|80|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 12, 2015||||No||https://clinicaltrials.gov/show/NCT02596217||9535|
NCT02594696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-293|Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness|Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness||Massachusetts General Hospital|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594696||9652|
NCT02603133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-34547|Web-based Implementation for the Science of Enhancing Resilience Study|Web-based Implementation for the Science of Enhancing Resilience Study|WISER|Stanford University|Yes|Not yet recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02603133||9004|
NCT02595372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0555|Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy|Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy||Indiana University|Yes|Recruiting|November 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595372||9600|
NCT02595385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134964|Blood Conservation in Adult Cardiac Surgery, What is the Way Forward in Today's Practice?||CONSERVE|Belfast Health and Social Care Trust|No|Recruiting|February 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|240|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02595385||9599|
NCT02596230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.188|RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism|Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE||Boehringer Ingelheim||Recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|14000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute venous thromboembolism|March 2016|March 21, 2016|October 28, 2015||||No||https://clinicaltrials.gov/show/NCT02596230||9534|
NCT02604160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16045|A Study of LY3113593 in Participants With Chronic Kidney Disease|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Patients Receiving Hemodialysis||Eli Lilly and Company|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604160||8926|
NCT02606539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTN and surgery|Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms|Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial|SVCGTN|Mansoura University|Yes|Recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|40 Years|N/A|No|||November 2015|November 16, 2015|August 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606539||8743|
NCT02595021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zsfud-obgyn-004|Total/Subtotal Colectomy in Ovarian Cancer|A Phase II Study of Total or Subtotal Colectomy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)||Shanghai Gynecologic Oncology Group|Yes|Recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|75 Years|No|||October 2015|October 30, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02595021||9627|
NCT02602951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15-P006|4D FLOW: Feasibility Study of a Sequence 4D of Flow Applied to the Cervico-encephalic Vascular Pathologies|4D FLOW: Feasibility Study of a Sequence 4D of Flow Applied to the Cervico-encephalic Vascular Pathologies|4D-FLOW|Centre Hospitalier St Anne|No|Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602951||9018|
NCT02601235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDEMS0214NA-III|Clinical Study Evaluating the Efficacy and Safety of Pediatric Drugs in Improving Nasal Congestion.|Clinical Study Evaluating the Efficacy and Safety of Pediatric Naridrin® (Naphazoline Hydrochloride + Mepyramine Maleate + Dexpanthenol) Compared to 0.05 % Oxymetazoline Hydrochloride in Improving Nasal Congestion.||EMS|No|Not yet recruiting|March 2016|January 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|10 Years|17 Years|No|||November 2015|November 9, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601235||9149|
NCT02606786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17919|Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain|Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain||Texas Woman's University|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02606786||8725|
NCT02600832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24034|AABM to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study|Alcohol Approach Bias Modification to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study|AABM|University of California, San Francisco|No|Not yet recruiting|January 2016|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||November 2015|November 6, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600832||9180|
NCT02600845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD002206|ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)|ACCU-CHEK Connect Personal Diabetes Management Study (PDM)||Hoffmann-La Roche||Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|18 Years|75 Years||||October 2015|December 1, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600845||9179|
NCT02607709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG-79-2015|Lymphadenectomy in Urothelial Carcinoma|Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter||University Hospital Roskilde|Yes|Not yet recruiting|January 2016|January 2032|Anticipated|January 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02607709||8655|
NCT02610868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-SIAL-351|Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults|A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects|OPTIMYST|US WorldMeds LLC|No|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|85 Years|No|||March 2016|March 3, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610868||8412|
NCT02601300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GED-0301-UC-002|An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis|A Phase 2, Open-Label, Multicenter Study to Explore the Efficacy and Safety of MONGERSON (GED-0301) in Subjects With Active Ulcerative Colitis.||Celgene|No|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601300||9144|
NCT02601313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTE-C19-102|A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma|A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)|ZUMA-2|Kite Pharma, Inc.|Yes|Recruiting|November 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601313||9143|
NCT02603666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1957/31/3|Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects|Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects||Karolinska University Hospital|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|155|||Both|1 Year|N/A|No|||November 2015|November 10, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02603666||8964|
NCT02599675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trainsome 2015#006|Vitamin D Supplementation and Muscle Characteristics in Trained Subjects|Effects of 12 Weeks of Vitamin D Supplementation on Muscle Characteristics in Trained Subjects||Lillehammer University College|Yes|Recruiting|November 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599675||9269|
NCT02599688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LipoLat-CS203|Open Label Extension of LipoLat-CS202|An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma||Peregrine Ophthalmic|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients who were randomized to received POLAT-001 and successfully completed        LipoLat-CS202|November 2015|November 20, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599688||9268|
NCT02610881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081930|Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children|Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children||Emory University|No|Enrolling by invitation|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|110|||Both|6 Months|23 Months|No|||December 2015|December 30, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610881||8411|
NCT02598479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol V1- 08-12-2015|A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer|The IPTLD QoL Broad Study A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer|IPTLDAZCAM|Best Answer for Cancer Foundation|Yes|Recruiting|November 2015|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over the age of 18 who have chosen to receive IPTLD with nutrition therapy|November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598479||9361|
NCT02387970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO5901|Immediate or Delayed Provisionalization in Posterior Healed Sites|Non-inferiority Study of Immediate or Delayed Provisionalization at Posterior Healed Sites Using NobelParallelCC Implants||Columbia University|No|Recruiting|March 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|February 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387970||25524|
NCT02387983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5592-117|Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)|Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections||Merck Sharp & Dohme Corp.|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|65|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|March 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02387983||25523|
NCT02387996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-275|A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer|A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent||Bristol-Myers Squibb|No|Active, not recruiting|March 2015|October 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|242|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02387996||25522|
NCT02450786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-1089|Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)|||Yonsei University|No|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||March 2016|March 11, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02450786||20703|
NCT02388776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404014977|Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients|Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients: A Prospective Pilot Study||Weill Medical College of Cornell University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|3 Years|100 Years|No|||February 2016|February 16, 2016|February 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02388776||25462|
NCT02391129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1674/2014|Locking Compression Plate Fixation Versus Revision- Prosthesis of Vancouver-B2, B3 and C Periprosthetic Femoral Fractures After Total Hip Replacement|Locking Compression Plate Fixation Versus Revision- Prosthesis of Vancouver-B2, B3 and C Periprosthetic Femoral Fractures After Total Hip Replacement||Medical University of Vienna||Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|102|||Both|18 Years|N/A|No|Non-Probability Sample|We retrospectively reviewed a consecutive series of 102 patients with Vancouver type-B2,        B3 and C periprosthetic fractures and unstable femoral stem, which had been prospectively        entered, in our hip-trauma database.|March 2015|March 17, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02391129||25281|
NCT02389647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13BN094|Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury|Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury||St. Joseph's Hospital and Medical Center, Phoenix|No|Enrolling by invitation|March 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Subjects presenting to facility and diagnosed with ischemic stroke, intracranial        hemorrhage, or elective endovascular coiling of unruptured aneurysm.|March 2016|March 22, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02389647||25395|
NCT02392819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LundU|Effects on Metabolism and Cognitive Functions of a Commonly Used Commercial Food Supplement|Food Design for Improved Cognitive Performance||Lund University|No|Completed|January 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|22|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02392819||25152|
NCT02390947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-FMTN-CRC-FACT|Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）|A Multicenter，Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma|FACT|Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|January 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|75 Years|No|||January 2016|January 18, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02390947||25295|
NCT02384655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0652-14-TLV-RM|Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content|Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2015|September 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|60 Years|No|||March 2015|March 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02384655||25779|
NCT02382133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201408123|Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion|Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion||Washington University School of Medicine|No|Enrolling by invitation|October 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|No|||March 2015|March 5, 2015|February 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02382133||25973|
NCT02391285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18128 V1.0, 05 April 2014|Mitigating Chronic Pelvic Floor Dysfunction Following Childbirth by Pelvic Floor Dynamometry|Mitigating Chronic Pelvic Floor Dysfunction Following Childbirth by Pelvic Floor Dynamometry||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|August 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||March 2015|November 18, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02391285||25269|
NCT02609204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-426E|Building Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) Modules of Diopsys NOVA|NOVA™ PERG and FERG: Establishment of Reference Values for PERG and FERG Measurements|DIOPSYS-ND|Wills Eye|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02609204||8540|
NCT02598245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012|Comparison of TOT 8/4 Versus TOT 6/3|Comparison of the Distance Between the Transobturator Tape (TOT) and the Urethra According to Two Different Placement Techniques of the Tape (TOT 8/4 vs TOT 6/3)|URGE-III|Klinikum der Universität Köln|No|Recruiting|January 2015|April 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Female|N/A|N/A|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598245||9379|
NCT02611089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SG01|Muscle Connective Tissue in Limb Development and Disease|Muscle Connective Tissue in Limb Development and Disease||King's College London|No|Recruiting|February 2016|August 2036|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples With DNA|Tissue biopsies measuring no more than 5 x 10 mm, consisting of muscle, muscle connective      tissue, tendon, fat and skin, or a combination of the above, and / or; Tissue normally      discarded during the patient's routine reconstructive hand surgery.|Both|N/A|18 Years|No|Non-Probability Sample|Cases - Any patient attending Great Ormond Street Hospital for reconstructive hand surgery        for radial dysplasia.        Controls - Any patient attending Chelsea and Westminster or the Royal Free Hospital for        reconstructive hand surgery.|March 2016|March 8, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611089||8396|
NCT02611102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#404482-2|Effect of Butter & MCT Oil on Lipoproteins - A RCT|Effects of Daily Butter & Medium-Chain Triglyceride Oil on Lipoproteins When Added to Baseline Diet a Randomized Controlled Trial||Walter Reed National Military Medical Center|No|Not yet recruiting|January 2016|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02611102||8395|
NCT02608099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-373|Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation|Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation|AEIOU|Harvard Clinical Research Institute|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02608099||8625|
NCT02608112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29256|Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year|Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year||Hoffmann-La Roche||Recruiting|December 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|410|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with moderate to severe RA not previously treated with TCZ (IV or SC) for        whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in        combination with another csDMARD.|March 2016|March 1, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02608112||8624|
NCT02545842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTUL07190|Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)|Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study||Sanofi|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|934|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02545842||13406|
NCT02602379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR14090|Evaluation of NoL Index and ANI After Nociceptive Stimulation at Different Infusion Rates of Remifentanil Infusion|Evaluation of NoL Index and ANI Variations After Nociceptive Stimulation Under Different Rates of Infusion of Intravenous Remifentanil in Patients Undergoing Laparotomies With Intraoperative Epidural Analgesia||Maisonneuve-Rosemont Hospital|Yes|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for elective abdominal surgery by laparotomy (general surgery or        gynaecological surgery) who will receive a thoracic epidural (around T9-T10/T10-T11) and        general anesthesia.|November 2015|November 9, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02602379||9061|
NCT02607020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTOMOVEMS01|Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis|Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial|AUTOMOVEMS|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|December 2015|January 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02607020||8708|
NCT02608190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danckert|Rehabilitating Unilateral Neglect Using Spatial Working Memory Training|Using Working Memory Training to Rehabilitate Unilateral Visual Neglect||University of Waterloo|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02608190||8618|
NCT02603783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 152005|Esophageal capsaïcin Infusion and Mucosal Integrity|"Effect of capsaïcin Infusion on Esophageal Mucosal Integrity - a Role for TRPV1-mediated Neuropeptides?"||Maastricht University Medical Center|Yes|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|13|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|March 17, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603783||8955|
NCT02602613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL4-0001P|AMENDTM Mitral Valve Repair System, Annuloplasty Ring Applied in a Transcatheter Method|||Valcare Medical Ltd.||Not yet recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602613||9043|
NCT02607150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00889|Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood|Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood||Nationwide Children's Hospital|No|Recruiting|December 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Spinal surgery patients.|January 2016|January 13, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607150||8698|
NCT02597816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU|Role of Three Dimensional Ultrasound in the Diagnosis of Septate Uterus|Three Dimensional Trans-vaginal Ultrasound to Reevaluate Arcuate Uteri Diagnosed by Hystro-salpingography||Assiut University|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Female|20 Years|40 Years|No|||October 2013|December 17, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02597816||9412|
NCT02546310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9936-103|Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects||Heptares Therapeutics Limited|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|54|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02546310||13370|
NCT02595268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107446|A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants|A Phase 1, Open-label, Sequential Study to Investigate the Effect of JNJ 63623872 on Pitavastatin in Healthy Subjects||Janssen Research & Development, LLC||Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595268||9608|
NCT02595281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01511-46|HE4 as a Relapse Biomarker in Ovarian Cancers|Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.|PRONOV4IR|Institut de Cancérologie de Lorraine|Yes|Active, not recruiting|November 2015|October 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Female|18 Years|N/A|No|||October 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02595281||9607|
NCT02604797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SShen|Analgesia Effects of Nalbuphine vs Sulfentanil|Analgesia Effects of Nalbuphine vs Sulfentanil in Patient-controlled Intravenous Analgesia After Cesarean Section||Fudan University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|November 11, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604797||8877|
NCT02602236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-1401|Multicenter Pilot Study to Describe the Performance of a New Device in Patients With Colostomy|Multicenter Pilot Study to Describe the Performance of a New Device in Patients With Colostomy||BBraun Medical SAS|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|December 9, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02602236||9072|
NCT02602249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doing-003|Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.|Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.||Beijing Doing Biomedical Co., Ltd.|No|Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|80 Years|No|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02602249||9071|
NCT02595567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108320|Catheter Placement for Hepatic Hydrothorax|Indwelling Tunneled Catheter Placement for Treatment of Hepatic Hydrothorax||Washington University School of Medicine|Yes|Recruiting|October 2010|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595567||9585|
NCT02595905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01912|Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer|Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer||National Cancer Institute (NCI)|Yes|Not yet recruiting|July 2016|||October 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|235|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595905||9559|
NCT02596139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-0704B|Reliability and Validity of the Taiwan-version of Multidimensional Fatigue Inventory and Fatigue Severity Scale|||Chang Gung University|Yes|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|N/A||1|Actual|123|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy people|November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596139||9541|
NCT02607904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1447 Open-label Extension|An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy|A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy||GW Research Ltd|No|Not yet recruiting|March 2016|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|55 Years|No|||November 2015|November 16, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607904||8640|
NCT02600507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-402|Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder||Intra-Cellular Therapies, Inc.|No|Recruiting|December 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|550|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600507||9205|
NCT02601027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0058|Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA|A Phase III Study of Pre-operative Transversus Abdominis Plane Blocks Using the Nimbus Ambulatory Infusion System in Patients Undergoing Abdominal Free Flap-based Breast Reconstruction||Stanford University|No|Recruiting|November 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|128|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02601027||9165|
NCT02600572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-20151104003|Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements|Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements||Carrick Institute for Graduate Studies|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600572||9200|
NCT02604940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306055796|Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients|Evaluation of a Single Intra-operative Dose of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Surgery Patients||West Virginia University|Yes|Recruiting|August 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|55 Years|No|||November 2015|November 11, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02604940||8866|
NCT02608879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00082|Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis|Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis|OMDP|New York University School of Medicine|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608879||8565|
NCT02601040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEPI-004|Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines|Phase IV Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine in Health Chinese Children and Adult||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|November 2011|October 2015|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|13500|||Both|18 Months|65 Years|Accepts Healthy Volunteers|||October 2015|November 6, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02601040||9164|
NCT02601261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAWAII|How Anxiety in Pregnant Hospitalized Women Change wIth Internet Use|How Anxiety in Pregnant Hospitalized Women Change wIth Internet Use|HAWAII|University of Padova|No|Not yet recruiting|November 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|109|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study has been powered to detect a difference on the average STAI state score (range        20-80) of 6 points between women with some access to internet during stay (at least 10        minutes/days of web browsing, besides e-mails) and those no accessing internet during        stay. Assuming a Standard Deviation of the difference in STAI scores of about 8 points        (art. 30-art. 33), and assuming that the ratio between the rate of women not using        internet and that of women using internet is 0,42 (art. 31-art. 32) for specified alpha =        0.025 and power (1 - beta) of 90.0% a total of 109 women must be recruited (using a        two-sample t-test with unknown variance).        Data entry will be based on e-CRF running on the REDCAP Clinical Data Management System of        the Service for Clinical Trials and Biometrics (Department of Cardiology, Thoracic and        Vascular Sciences, University of Padova).|November 2015|November 5, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02601261||9147|
NCT02610101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15606|Nutritional Therapy Study in Pediatric Crohn's Disease|A Blinded, Nutritional Therapy Study, Using a Modified Specific Carbohydrate Diet in Pediatric Crohn's Disease||Seattle Children's Hospital|Yes|Recruiting|November 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|21|||Both|12 Years|21 Years|No|||November 2015|November 18, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02610101||8471|
NCT02596412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15-043-1|Augmented Reality to Reduce Pain During Botulinum Toxin Injections in Cerebral-palsied Children|MINIDOCS : Contribution of Augmented Reality to Reduce Pain During of Botulinum Toxin Injections in Cerebral-palsied Children. A Randomized Controlled Trial|MINIDOCS|Hospices Civils de Lyon|Yes|Not yet recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|3 Years|8 Years|No|||November 2015|November 3, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02596412||9520|
NCT02596425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-007|Pulmonary Recruitment Maneuver for Postlaparoscopic Shoulder Pain|Pulmonary Recruitment Maneuver to Reduce Postlaparoscopic Shoulder Pain: Randomized Controlled Trial||Kangbuk Samsung Hospital|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Female|19 Years|65 Years|No|||January 2016|January 21, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596425||9519|
NCT02598661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107947|Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment||Janssen Research & Development, LLC|No|Recruiting|November 2015|May 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598661||9347|
NCT02598895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9381|Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway|A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway||University of Washington|No|Recruiting|January 2016|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Male|18 Years|N/A|No|||October 2015|February 11, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02598895||9329|
NCT02604550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083740|Anterior Cruciate Ligament Pain Study|Comparison Between Femoral Nerve Block and Adductor Canal Block for Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Controlled Trial||Emory University|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|N/A|No|||November 2015|November 11, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604550||8896|
NCT02605824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17919|Clinical Trial of NAC in Asthma|Clinical Trial of NAC in Asthma|CONA|University of California, San Francisco|Yes|Not yet recruiting|March 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||March 2016|March 14, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605824||8798|
NCT02602210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOTCH|Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis|Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis|SCOTCH|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|January 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|356|||Both|18 Years|80 Years|No|||September 2015|November 9, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02602210||9074|
NCT02606136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-079|Trial of FG-3019, a Monoclonal Antibody to CTGF, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy|Trial of FG-3019, a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy|DMD|FibroGen|Yes|Recruiting|November 2015|September 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Male|12 Years|N/A|No|||December 2015|December 23, 2015|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606136||8774|
NCT02609789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108073|A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus||Janssen Research & Development, LLC|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02609789||8495|
NCT02598284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 023921-01|Healthy Hearts in the Heartland|Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)|H3|Northwestern University|No|Recruiting|November 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|89 Years|No|||November 2015|November 3, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02598284||9376|
NCT02598297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2353|Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.|A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations||Novartis|Yes|Not yet recruiting|February 2016|March 2021|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02598297||9375|
NCT02599077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSantafeBogota|Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas|Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas in Women With Diameters Smaller Than 4 Centimeters Thereof, at University Hospital Fundación Santa Fe de Bogota, Between the Years 2015-2017||Fundación Santa Fe de Bogota|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|50 Years|No|||November 2015|November 5, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599077||9315|
NCT02599090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0059 Phase II|Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|Phase II Portion of Multi Phase Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma||M.D. Anderson Cancer Center|No|Withdrawn|December 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 4, 2015|Yes|Yes|Multi phase study did not progress to Phase II. Phase I registered as NCT00734526.|No||https://clinicaltrials.gov/show/NCT02599090||9314|
NCT02600208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT13BTθ51|Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device|BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies||Medical College of Wisconsin|Yes|Recruiting|October 2015|December 2022|Anticipated|December 2019|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|N/A|23 Years|No|||March 2016|March 15, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600208||9228|
NCT02600455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-515|Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL|Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL||Bristol-Myers Squibb|No|Active, not recruiting|March 2014|February 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|370|||Both|18 Years|N/A|No|Probability Sample|Patients who are treated with ORENCIA according to the approved indications, and dosage        and administration.|November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600455||9209|
NCT02606279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUHS-28769|Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients|Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients|RAS-HIV|Wake Forest School of Medicine|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|60 Years|No|||November 2015|November 12, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606279||8763|
NCT02606292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204145|Photoacoustic Endoscopy of Barrett's Esophagus|Photoacoustic Endoscopy of Barrett's Esophagus||Washington University School of Medicine|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606292||8762|
NCT02598583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALXN1210-PNH-103|An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria|An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria||Alexion Pharmaceuticals|Yes|Active, not recruiting|November 2015|August 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||November 2015|February 4, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598583||9353|
NCT02600468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-516|Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg|Outline of Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg||Bristol-Myers Squibb|No|Active, not recruiting|July 2011|March 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patient's survival and development of malignancies after treatment discontinuation|November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600468||9208|
NCT02600715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003056|Reduction of Bladder Injection Pain With Belladonna Opiate Suppository|Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial)|ROBIN|University of Kansas Medical Center|No|Enrolling by invitation|November 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|26|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02600715||9189|
NCT02599207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065043|Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy|Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy||Duke University|Yes|Recruiting|November 2015|May 2018|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|1 Year|6 Years|No|||February 2016|February 4, 2016|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599207||9305|
NCT02599506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20l5MaySP529|Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment|Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment and Follow-up Into Survivorship of 100 Breast Cancer patients-a Pilot Study|FORECAST|University of St Andrews|No|Not yet recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Probability Sample|In this study, 100 breast cancer patients receiving radiotherapy at the Edinburgh Cancer        Centre will be recruited.|November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599506||9282|
NCT02606604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|534378-1|Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS|Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking Performance and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study|MSCycling|Stony Brook University|No|Recruiting|November 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606604||8738|
NCT02600988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alovita-1|Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant|Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant|Alovita-1|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|July 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02600988||9168|
NCT02606552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0074|Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease|||Yonsei University|Yes|Not yet recruiting|November 2015|November 2022|Anticipated|November 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|670|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606552||8742|
NCT02599025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ziv-0089015|Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy|Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy||Ziv Hospital|No|Not yet recruiting|February 2016|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|24|||Both|6 Years|10 Years|No|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02599025||9319|
NCT02610218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiquidBiopsy|Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer|||Peking University|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Peripheral blood samples of 12.5 mL were collected from the patients for cfDNA and CTCs      analysis|Both|18 Years|N/A|No|Probability Sample|Anticipated 100 patients with histologically confirmed HER2 positive advanced/metastatic        gastric cancer|November 2015|December 1, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610218||8462|
NCT02608905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-35985|Effect of Dapagliflozin on Inflammation and Endothelial Function|The Effect of Dapagliflozin on Inflammation and Endothelial Function||Baylor College of Medicine|No|Recruiting|November 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|21 Years|70 Years|No|||November 2015|November 18, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608905||8563|
NCT02601339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001713|NIRS Monitoring in Premature Infants|Beside Monitor of Cerebral Metabolism in Premature Infants With Intraventricular Hemorrhage and Post-Hemorrhagic Hydrocephalus||Massachusetts General Hospital|No|Recruiting|April 2015|April 2020|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|170|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will include premature and full-term neonates with and without        GM-IVH less than 3 months old corrected age at first measure.|November 2015|November 6, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02601339||9141|
NCT02601352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHuang15_17|Air Pollution and Cardiometabolic Study|Characterization and Health Risk Assessment of Exposure to Source-Specific PM2.5 in Subjects With Hypertension in Beijing||Peking University|Yes|Active, not recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood and urine|Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Living in PU community neighborhood,Beijing, China|November 2015|November 9, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02601352||9140|
NCT02605642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOB-INF-1505|Post-marketing Use of Inflectra (Infliximab) for Standard of Care Treatment of Rheumatoid Disease Who Are Naïve to Biologics or Switched From Remicade™|PERSIST: Prospective ObsErvational CohoRt Study to Assess Persistence of Inflectra™ (Infliximab) in Patients With Rheumatoid Diseases Who Are Either Naïve to Biologics or Switched From sTable Remicade™ (Infliximab)|PERSIST|Hospira, Inc.|No|Recruiting|September 2015|August 2018|Anticipated|July 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|The target study population will include biologic naive rheumatoid arthritis, ankylosing        spondylitis, and psoriatic arthritis patients receiving Inflectra™ or those switched to        Inflectra™ from stable treatment with Remicade™.|February 2016|February 17, 2016|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605642||8812|
NCT02596191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10|Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers|Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers|CMT-TOOLS|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02596191||9537|
NCT02596477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-188-09|Evaluation of Vepoloxamer in Chronic Heart Failure|A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure||Mast Therapeutics, Inc.|Yes|Recruiting|October 2015|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||February 2016|February 8, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596477||9515|
NCT02598206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9421019|Food Effect Study PF-04136309|A Phase I Randomized Open Label, Single Dose, 2-period Crossover Study To Evaluate Food Effect On The Pharmacokinetics Of Pf-04136309 In Healthy Volunteers.||Pfizer|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598206||9382|
NCT02598466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-572|Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa|Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa||Bristol-Myers Squibb|No|Completed|July 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|69|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|February 2016|February 5, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598466||9362|
NCT02604472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013046|Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients|Stage-specified Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Locoregionally-advanced Nasopharyngeal Carcinoma - A Retrospective, Population-based Study||Sun Yat-sen University|Yes|Completed|January 1998|October 2015|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|12206|||Both|N/A|N/A|No|Probability Sample|firstly diagnosed NPC in SYSUCC from Jan 1st, 1998 to Jun 1st, 2013|November 2015|November 12, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604472||8902|
NCT02611011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4005B|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey||Gynuity Health Projects|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|198|Samples Without DNA|urine samples collected|Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women attending Hospital Materno-Infantil Inguarán for prenatal care will be eligible for        the study.|November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611011||8402|
NCT02611024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-014-15|Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors|Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors||PharmaMar|No|Not yet recruiting|August 2016|August 2019|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611024||8401|
NCT02603965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13F.412|Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery|A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men Undergoing Radical Prostatectomy||Thomas Jefferson University|Yes|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Male|21 Years|N/A|No|||February 2016|February 10, 2016|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603965||8941|
NCT02598492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001945|Imputation of PaO2 From SaO2|Imputation of PaO2 From SaO2 in the Respiratory Component of the Sequential Organ Failure Assessment (SOFA) Score||Brigham and Women's Hospital|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adults > 18 years old who are invasively mechanically ventilated in an ED or ICU|November 2015|November 17, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598492|1 Year|9360|
NCT02390401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15054|Vacuum Assisted Closure for Cesarean Section|Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese|VACCS|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|March 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02390401||25337|
NCT02378506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801359|Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects|A Single-arm, Open-label Study To Assess The Immunogenicity, Safety, And Efficacy Of Etanercept Manufactured Using The High Capacity Process Administered To Subjects With Rheumatoid Arthritis||Pfizer|No|Recruiting|April 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02378506||26252|
NCT02459652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JASPAC 05|Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer||Japan Adjuvant Study Group of Pancreatic Cancer||Recruiting|September 2012|September 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|75 Years|No|||March 2016|March 15, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02459652||20022|
NCT02377271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000848-14|ENDOTHELION Study Group: Effect of Bosentan in NAION Patients|Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy|ENDOTHELION|University Hospital, Grenoble|Yes|Not yet recruiting|March 2015|January 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|50 Years|N/A|No|||September 2014|February 24, 2015|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02377271||26347|
NCT02381860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUKK2|Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function|Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function||Northumbria University|Yes|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|28|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02381860||25994|
NCT02389699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGHBCRG-IORT-WRT-DCIS|Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ|Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ||Guangdong Academy of Medical Sciences|Yes|Active, not recruiting|June 2014|June 2024|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|70 Years|No|||March 2015|March 10, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02389699||25391|
NCT02379104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSE2015|ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals|ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals|ROSI-EVA|Tem Innovations GmbH|Yes|Recruiting|February 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patients with expected bleeding and coagulation problems during elective surgery or             at the ICU, or trauma patients          -  Healthy volunteers|May 2015|May 28, 2015|February 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02379104||26206|
NCT02387177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000702|Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype|Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype||Massachusetts General Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02387177||25585|
NCT02386722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269/13|Intervention to Improve Inhalative Adherence|Impact of a Pharmaceutical Care Intervention to Improve Adherence of Inhaled Medication in Asthma and COPD Patients||Cantonal Hosptal, Baselland||Recruiting|January 2014|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|154|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02386722||25620|
NCT02386826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 365|INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients|Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer (mCRC) and Metastatic Renal Cell Carcinoma (mRCC) Patients||SCRI Development Innovations, LLC|No|Recruiting|July 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02386826||25612|
NCT02380105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200/11-P CEP/UFRN|Effectiveness of a Counseling Program for Temporomandibular Disorders (TMD) Treatment|Effectiveness of a Counseling Program for TMD Treatment||Universidade Federal do Rio Grande do Norte|No|Completed|March 2012|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||February 2015|February 27, 2015|November 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02380105||26129|
NCT02610192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIO.CR.APSPFO.001.15|nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis|A Prospective Study of a Single Intra-Articular Injection of Autologous Protein Solution in Females With Primary Patellofemoral Osteoarthritis||Biomet, Inc.|No|Recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Female|40 Years|65 Years|No|Non-Probability Sample|Females with isolated and symptomatic patellofemoral osteoarthritis for which there is a        continued need for treatment within 3 months of a corticosteroid or hyaluronic acid        treatment.|November 2015|March 22, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02610192||8464|
NCT02601833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00097829|Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques|The Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques: A 12 Month Randomized Controlled Trial||University of Michigan|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|3 Years|10 Years|No|||January 2016|January 26, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601833||9103|
NCT02597504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPR-15-44|Development of a Neurocognitive Screening Test|Development of a Neurocognitive Screening Test||ImPACT Applications, Inc.|No|Recruiting|October 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1600|||Both|6 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597504||9436|
NCT02601898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAvsPROG|Vaginal Administration of ALA vs Progesterone for the Subchorionic Hematoma Treatment|Vaginal Administration of Alpha Lipoic Acid vs Progesterone for the Subchorionic Hematoma Treatment||Azienda USL Ferrara||Completed|January 2015|||November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Female|24 Years|37 Years|No|||January 2016|January 7, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02601898||9098|
NCT02607644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2181|Laryngeal Tube vs Laryngeal Mask Airway|Clinical Evaluation of Laryngeal Tube and Laryngeal Mask Airway for Cardiac Arrest Treatment in Emergency Ambulances in Singapore||Singapore General Hospital|Yes|Not yet recruiting|November 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|875|||Both|13 Years|100 Years|No|||November 2015|November 17, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02607644||8660|
NCT02550028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU3|Levetiracetam Treatment of Neonatal Seizures|Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China||Children's Hospital of Fudan University|Yes|Recruiting|September 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02550028||13084|
NCT02594813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bleeding rate|Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents||EGD|Showa Inan General Hospital|No|Enrolling by invitation|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Excised specimens after taking biopsy or doing polypectomy|Both|20 Years|90 Years|No|Non-Probability Sample|All patients who continue to take antithrombotic drugs undergo EGD including biopsy and        colonoscopy including biopsy and polypectomy.|November 2015|November 2, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594813||9643|
NCT02595060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOL-ARDS-002|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration|GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study|GI-HOPE|Serendex Pharmaceuticals|Yes|Recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02595060||9624|
NCT02610608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPERT (RB13.160)|Medical Assistance for the Procreation and Risk of Thrombosis.|Assistance Médicale à la Procréation et Risque Thrombotique|AMPERT|University Hospital, Brest|No|Recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|One blood sample for each women particpating in the study|Female|18 Years|N/A|No|Non-Probability Sample|Women undergoing assisted reproductive thechnology|October 2015|February 3, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610608||8432|
NCT02610634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6601|Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues|Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues||Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|July 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's disease participants will be recruited from Movement Disorder Clinics in        Newcastle upon-Tyne.        Healthy control older adults will be recruited locally within the Newcastle upon Tyne        region.|November 2015|November 18, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610634||8430|
NCT02605577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMFLPIN|Research of Systemic Management for Late Preterm Infants Nutrition in China|Research of Systemic Management for Late Preterm Infants Nutrition in China|NLP|Peking Union Medical College Hospital|Yes|Enrolling by invitation|January 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|N/A|N/A|No|||December 2015|December 30, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605577||8817|
NCT02605798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/15/567|A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)|Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)||Genuine Research Center, Egypt|No|Completed|August 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02605798||8800|
NCT02595073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 1504|Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.||Taro Pharmaceuticals USA|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|6 Months|N/A|No|||November 2015|November 1, 2015|November 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595073||9623|
NCT02595333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-Wang|Incision Pain and Uterine Contraction Pain After Cesarean Section|Differences in Incision Pain and Uterine Contraction Pain After Cesarean Section Between Primary Section and Repeat Section||Fudan University|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|November 2, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595333||9603|
NCT02601976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETZ-UNIP- 4010810|Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population|Response Evaluation of Peginterferon Alfa-2a 180µg 20kDa (Unipeg®) Plus Ribavirin (Ribazole®) in Treatment naïve Pakistani Population With Chronic Hepatitis C Infection|EUROP|Getz Pharma|Yes|Completed|August 2010|September 2014|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|55 Years|No|||November 2015|November 9, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02601976||9092|
NCT02600052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06704028420|Efficacy of Pattern Respiratory PNF Associated Aerobic Training on Lung Volumes and 6MWT Test in Parkinson Individuals|Efficacy of Pattern Respiratory Proprioceptive Neuromuscular Facilitation Associated With Aerobic Training on the Volumes, Lung Capacity and Six-minute Walking Test in Individuals With Parkinson: Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Not yet recruiting|December 2015|April 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600052||9240|
NCT02609074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDA No.(2013):3460199|Pilot Clinical Trial of CPC/rhBMP-2 Microffolds as Bone Substitute for Bone Regeneration|Pilot Clinical Trial of CPC/rhBMP-2 Microffolds as Bone Substitute for Bone Regeneration||East China University of Science and Technology|No|Completed|March 2013|October 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|16 Years|70 Years|No|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609074||8550|
NCT02607826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Starvation Study|Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors|Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors||University Hospital Tuebingen|No|Not yet recruiting|December 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|298|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02607826||8646|
NCT02560909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9503|Adjuvanted Influenza Vaccine in Stem Cell Transplant|A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.||University Health Network, Toronto|No|Not yet recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02560909||12248|
NCT02560922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1189|Pain Coping Skills Training for African Americans With Osteoarthritis|Pain Coping Skills Training for African Americans With Osteoarthritis|STAART|University of North Carolina, Chapel Hill|No|Not yet recruiting|March 2016|August 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02560922||12247|
NCT02600325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2015-003210-24|Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV|Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)|DAHHS-2|Erasmus Medical Center|No|Recruiting|February 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600325||9219|
NCT02600130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0000-01|A Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease|A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease||Longeveron LLC|Yes|Not yet recruiting|January 2016|October 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|55 Years|75 Years|No|||November 2015|November 6, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02600130||9234|
NCT02600377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vegetarian diets 2015|A Series of Systematic Reviews and Meta-analyses of the Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk|Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk: Systematic Reviews and Meta-analyses of Randomized Controlled Dietary Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Diabetes|November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02600377||9215|
NCT02608814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUDIO|Advanced Ultrasound in Pleural Infection|Advanced Ultrasound in Pleural Infection|AUDIO|University of Oxford|No|Recruiting|May 2015|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02608814||8570|
NCT02604316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/063/13|SATIN: Satiety Innovation. Study 2- University of Aberdeen|SATIN: Satiety Innovation, Study 2. Effect of Novel Fibres (Arabinoxylan and Beta-glucan) in Appetite, Metabolic and Gut Health.|SATIN|University of Aberdeen|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|February 23, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02604316||8914|
NCT02604732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/00512|Pre-operative Withdrawal of Aspirin in Laparoscopic Inguinal Hernia Repair|Randomized Controlled Trial on Pre-operative Withdrawal Versus no Withdrawal of Aspirin in Laparoscopic Inguinal Hernia Repair||National University Hospital, Singapore|No|Not yet recruiting|December 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Anticipated|100|||Both|21 Years|80 Years|No|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604732||8882|
NCT02604875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-266|The Circadian Rhythm of Copeptin|The Circadian Rhythm of Copeptin|Co-Rhythm|University Hospital, Basel, Switzerland|Yes|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|March 2016|March 2, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604875||8871|
NCT02610075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6015C00003|Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.|A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.||AstraZeneca|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|130 Years|No|||March 2016|March 17, 2016|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610075||8473|
NCT02609243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiNA-P|Diabetes Nutrition Algorithm - Prediabetes|Diabetes Nutrition Algorithm - Prediabetes (Dietary Strategies in the Prevention of Diabetes Mellitus Type 2 in a High-risk Cohort)|DiNA-P|German Institute of Human Nutrition|Yes|Recruiting|July 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02609243||8537|
NCT02602990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQUID|Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent|Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent||Emboflu|No|Recruiting|August 2015|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a cerebral AVM for whom endovascular treatment is indicated.|November 2015|November 10, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02602990|6 Months|9015|
NCT02604446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO-150|Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo|Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty. A Double Blinded Randomized Controlled Study. Tapentadol vs Oxycodone vs Placebo||St. Olavs Hospital|No|Recruiting|September 2015|January 2021|Anticipated|January 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604446||8904|
NCT02597478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0137|Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea||M.D. Anderson Cancer Center|Yes|Recruiting|January 2016|||January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597478||9438|
NCT02601924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU 1394.215|Efficacy of Pressure Massage and Topical Gel on Pain During Intra Oral Injections|Efficacy of Pressure Massage and Topical Gel on Pain During Inferior Alveolar Nerve Block and Maxillary Anterior Injections: A Single-Blind Randomized Clinical Trial||Azad University of Medical Sciences|Yes|Enrolling by invitation|November 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 14, 2015|November 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601924||9096|
NCT02609425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esophagogastric Anastomosis|Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX|Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX||Henry Ford Health System|Yes|Not yet recruiting|December 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609425||8523|
NCT02603250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703581-3|Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda|Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda||PATH|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|132|||Both|6 Months|59 Months|No|Probability Sample|Participants will be children 6 to 59 months of age, receiving outpatient care from Centre        Hospitalier Universitaire de Kigali (CHUK) and providing a venous blood sample for their        health care.|September 2015|January 6, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02603250||8995|
NCT02606760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1434|Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis|A Randomized, Double-blind, Vehicle-controlled, Parallel Group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis||Polichem S.A.|No|Recruiting|November 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|80 Years|No|||November 2015|December 4, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606760||8727|
NCT02610621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-11-Giuliano-SNBO|Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy|IIT2015-11-Giuliano: Safety and Efficacy of Omission of Sentinel Node Biopsy for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy||Cedars-Sinai Medical Center|No|Recruiting|December 2015|April 2020|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610621||8431|
NCT02606149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO1135-44|Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life|Impact of a Truthful Information Concerning Chemotherapy on Chemotherapy Prescription at the End of Life : a Randomized Controlled Study in Non-curable Lung Cancer Patients|HIPPOCRATE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|June 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|210|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606149||8773|
NCT02607852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000553/SHC|BOQ Feedback Study|System for Feedback of Patient Reported Outcomes in Children With Burns||Shriners Hospitals for Children||Recruiting|April 2015|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Screening|1||Anticipated|25|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02607852||8644|
NCT02597361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140918|Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)|Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.|ARCADE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2016|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02597361||9447|
NCT02603822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003603|Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability|Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability||Mayo Clinic|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02603822||8952|
NCT02603835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G120029/S007|Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)|A Multi-Center Evaluation of the Delivery of Intracoronary Hyperoxemic Supersaturated Oxygen Therapy for 60 Minutes in Anterior Acute Myocardial Infarction Patients With Successful Reperfusion (Via PCI) ≤ Six Hours After Symptom Onset|IC-HOT|TherOx|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 5, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603835||8951|
NCT02602132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/63|Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.|Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.||Hospital Universitario Fundación Alcorcón|No|Recruiting|March 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|242|||Both|18 Years|85 Years|No|||March 2016|March 18, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02602132||9080|
NCT02607189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDehong_NNICU2|Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units|Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units||The People's Hospital of Dehong Autonomous Prefecture|Yes|Not yet recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|28 Days|No|Non-Probability Sample|The study population will be recruited from Hospital inpatient population, primarily the        neonatal intensive care unit who has some anomaly or abnormal laboratory testing        suggestive of a genetic disease.|November 2015|November 14, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02607189||8695|
NCT02607202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-IRCC-10IIS-14|A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)|A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial|AGNOSTOS|Fondazione del Piemonte per l'Oncologia|No|Recruiting|March 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607202||8694|
NCT02608242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH22189-102|PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin|A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22189 in Comparison to Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers||Yuhan Corporation|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02608242||8614|
NCT02596061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1071|In It To Quit: Commitment Contracts for Smoking Cessation|In It To Quit: Commitment Contracts for Smoking Cessation|I2Q|Community Health Center, Inc.|No|Recruiting|November 2015|December 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02596061||9547|
NCT02602418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH099951-01|Neural Correlates of Working Memory Training for HIV Patients|Neural Correlates of Working Memory Training for HIV Patients: A Randomized Control Clinical Trial||University of Hawaii|Yes|Recruiting|September 2012|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02602418||9058|
NCT02602457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150427|Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)|Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)||Ottawa Heart Institute Research Corporation|No|Recruiting|November 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|108|||Both|40 Years|N/A|No|||March 2016|March 24, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02602457||9055|
NCT02602470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18575|Preferences & Treatment Satisfaction Drivers in Rosacea Patients|A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients With Rosacea||Bayer|No|Active, not recruiting|April 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||8|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients who are using topical rosacea treatment|March 2016|March 14, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02602470||9054|
NCT02602483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAN12006-01|Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).|Randomized, Double Blind, Placebo Controlled Exploratory Study To Assess the Efficacy and Safety of a Triple Combination of Ibuprofen+Mg+Ascorbic Acid for Acute Pain Treatment in Temporomandibular Join Disorder (TMJD) Patients||Spherium Biomed|Yes|Recruiting|December 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02602483||9053|
NCT02608372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M221|Brown Seaweeds Effect on Glucose Tolerance and Appetite Response|Effect of Brown Seaweeds on Glycaemia, Gastric Emptying, and Appetite: A Randomized, Controlled Crossover Meal Study||University of Copenhagen|Yes|Completed|May 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608372||8604|
NCT02604069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM-2015-10|Detection of Flap Ischemia Using Interstitial Glucose Monitor|Postoperative Monitoring of Tissue Perfusion in Microvascular Free Flaps Using Continuous Interstitial Glucose Monitoring Device: A Pilot Study||Hamilton Health Sciences Corporation||Not yet recruiting|November 2015|||February 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604069||8933|
NCT02604108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-083|Training Program for Happy Family Kitchen Movement Project|Training Program for Happy Family Kitchen Movement, A Community-based Research to Enhance Family Health, Happiness and Harmony in Hong Kong||The University of Hong Kong|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02604108||8930|
NCT02594774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/6312/I|Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents|Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents||Parc de Salut Mar|No|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|16 Years|No|||October 2015|November 2, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594774||9646|
NCT02594787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAU.SOAS.MB1.2012.R1.11|The Effect of Phosphorus on Diet Induced Thermogenesis|||Lebanese American University|Yes|Completed|March 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|23|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02594787||9645|
NCT02599350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/MRE00/32|Assessing Gas Exchange in Intensive Care Patients on a Ventilator|Evaluation of a New Computer Slide Rule Method for Assessing Gas Exchange in Intensive Care Patients on a Ventilator||University of Aberdeen|No|Completed|May 2009|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|16 Years|N/A|No|Probability Sample|30 adult patients admitted to Aberdeen Royal Infirmary ICU, requiring invasive mechanical        ventilation and with impaired gas exchange will be recruited.|November 2015|November 5, 2015|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT02599350||9294|
NCT02599363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06115|A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer|A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599363||9293|
NCT02608476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-03-01/26|A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)|A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris||Cassiopea SpA|No|Recruiting|November 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|9 Years|N/A|No|||November 2015|January 20, 2016|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608476||8596|
NCT02608489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHUH 2013-12-012|Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery|Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial||Soonchunhyang University Hospital|Yes|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|90 Years|No|||November 2015|November 20, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02608489||8595|
NCT02608502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-E-301|A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults|A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults||Novavax|No|Active, not recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11850|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02608502||8594|
NCT02596594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110; 3/15-08-2012|Intraumbilical Amino Acids and Glucose Supplementation Via Port by Severe IUGR in Human Fetuses|Intraumbilical Amino Acids and Glucose Supplementation Via Subcutaneously Implanted Port System by Severe IUGR Human Fetuses|port-IUGR|Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|January 2010|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02596594||9506|
NCT02596607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0076|STUDY OF THE PERFORMANCE OF STROKE MANAGEMENT IN THE RHONE AREA|STUDY OF THE PERFORMANCE OF ACUTE STROKE MANAGEMENT IN THE RHONE AREA AFTER IMPLEMENTATION OF A MULTI-ACTION PROGRAM|STROKE 69|Hospices Civils de Lyon|No|Not yet recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients treated for a stroke suspicion at the acute phase|November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596607||9505|
NCT02603146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ARA08|Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis|Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis|StopRA|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|March 2016|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603146||9003|
NCT02610231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-018|Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease|A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease||Kyowa Hakko Kirin Pharma, Inc.|No|Enrolling by invitation|December 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|30 Years|N/A|No|||March 2016|March 16, 2016|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610231||8461|
NCT02609984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMDZ-C232|Trial of CMB305 and Atezolizumab in Patients With Sarcoma|A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1|IMDZ-C232|Immune Design|Yes|Recruiting|October 2015|July 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|November 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609984||8480|
NCT02610049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-04|Trial of Art Therapy During Cognitive Processing Therapy for PTSD|Randomized, Controlled Trial of Art Therapy During Cognitive Processing Therapy for PTSD|Art_Tx_PTSD|Hampton VA Medical Center|No|Enrolling by invitation|November 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02610049||8475|
NCT02463201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-404|Obstructive Sleep Apnea in Obese Children and Teenagers - Occurrence and Importance of Intervention|Obstructive Sleep Apnea in Obese Children and Teenagers - Occurrence and Importance of Intervention||Roskilde County Hospital|No|Recruiting|April 2015|April 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|6 Years|18 Years|No|Non-Probability Sample|The cohort consists of children attending the Childrens Obesity Clinic in Holbaek.|March 2016|March 16, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463201||19749|
NCT02483910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081144|Direct Instruction Language for Learning in Autism Spectrum Disorder|Efficacy of the Direct Instruction Language for Learning Program to Promote Expressive and Receptive Language in Children With Autism Spectrum Disorder|DILL ASD|Emory University|No|Recruiting|October 2015|July 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Months|95 Months|No|||December 2015|December 29, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483910||18157|
NCT02489968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.13|Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus|A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 25 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 25 mg Plus Placebo in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16-week Treatment With Empagliflozin (10 mg or 25 mg) Alone Once Daily.||Boehringer Ingelheim||Active, not recruiting|May 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|880|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|May 27, 2015||||No||https://clinicaltrials.gov/show/NCT02489968||17694|
NCT02489981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.525|Specific Use-result Surveillance of Spiriva Respimat in Asthmatics|Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (Patients With Severe Persistent Asthma)||Boehringer Ingelheim||Recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|15 Years|N/A|No|Non-Probability Sample|patients with severe asthma|March 2016|March 16, 2016|May 21, 2015||||No||https://clinicaltrials.gov/show/NCT02489981||17693|
NCT02489994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF15911|Performance of the ePrime System for Cellulite|Clinical Study to Evaluate the Performance of the ePrime System for the Treatment of Cellulite||Syneron Medical|No|Active, not recruiting|October 2014|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489994||17692|
NCT02483247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI503-201|A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer|A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer||Boston Biomedical, Inc||Recruiting|September 2015|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483247||18208|
NCT02483260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-13-08|Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever|Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever)||U.S. Army Medical Research and Materiel Command|No|Not yet recruiting|June 2016|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483260||18207|
NCT02464605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEL-037/101|Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels|An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels||Selecta Biosciences, Inc.|No|Active, not recruiting|May 2015|January 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|21 Years|75 Years|No|||November 2015|November 30, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464605||19642|
NCT02484157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-I0814|Comparison of ACT Between Hemochron Jr and ACT Plus|Comparison of Activated Coagulation Time Between Hemochron Jr and ACT Plus During Cardiac Surgery for Patient Using Acute Normovolemic Hemodilution||Hallym University Medical Center|No|Completed|December 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|26|||Both|20 Years|N/A|No|||December 2012|June 26, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02484157||18138|
NCT02482922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3515|Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors|Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk|IETnutrition|University of North Carolina, Chapel Hill|No|Enrolling by invitation|May 2015|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482922||18233|
NCT02486523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI.1836-554994|Benefits of a Household WASH Package to Community-based Management of Acute Malnutrition (CMAM) Program, Chad|Benefits of a Household WASH Package to Community-based Management of Acute Malnutrition (CMAM) Program, Chad|OUADINUT|Action Contre la Faim|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1572|||Both|6 Months|59 Months|No|||May 2015|March 2, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486523||17957|
NCT02465099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG 14-004|Posterior Spinal Fusion With Two Energy Dissection Techniques|Perioperative Outcomes of Multilevel Posterior Spinal Fusion in Adolescent Scoliosis With Two Energy Dissection Techniques||Ethicon Endo-Surgery|No|Recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|21 Years|No|||February 2016|February 25, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465099||19604|
NCT02487654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13SM0713|The Role of Nerves in the Heart That Trigger Pulmonary Vein Extra Beats|The Role of Left Atrial Ganglionated Plexi Sites That Trigger Pulmonary Vein Ectopy in the Pathogenesis of Paroxysmal Atrial Fibrillation||Imperial College London|No|Recruiting|December 2013|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||June 2015|June 30, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02487654||17870|
NCT02412800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412036RINC|Risk Factors of Postoperative Acute Lung Injury Following Liver Transplantation|Risk Factors of Postoperative Acute Lung Injury Following Liver Transplantation||National Taiwan University Hospital|No|Recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|6 Months|75 Years|No|Non-Probability Sample|Liver transplant recipients in NTUH, Taipei, Taiwan. From 2004-2014.|October 2015|October 28, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412800||23619|
NCT02412813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-4050-05|LEGION™ Revision Metal Hypersensitivity Study|A Prospective, Randomized, Multi-Center, Metal Hypersensitivity Study Comparing OXINIUM and Cobalt Chrome Femoral Components in Failed Total Knee Arthroplasty||Smith & Nephew, Inc.|No|Withdrawn|January 2016|April 2025|Anticipated|April 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||March 2016|March 8, 2016|March 5, 2015||No|Overhaul of Study Design|No||https://clinicaltrials.gov/show/NCT02412813||23618|
NCT02471755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-012|Electro-acupuncture for Menopausal Transition Symptoms|A Randomized Pilot Study of Electro-acupuncture for Menopausal Transition Symptoms||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|40 Years|55 Years|No|||October 2015|October 22, 2015|June 7, 2015||No||No|July 4, 2015|https://clinicaltrials.gov/show/NCT02471755||19092|
NCT02466087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-337|Role of Magnesium Supplementation in the Treatment of Depression|Role of Magnesium Supplementation in the Treatment of Depression||University of Vermont|No|Recruiting|May 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466087||19528|
NCT02476981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-I039|Comparison of Remifentanil and Dexmedetomidine for Monitored Anaesthesia Care During Vertebroplasty and Kyphoplasty|Comparison of Remifentanil and Dexmedetomidine for Monitored Anaesthesia Care||Hallym University Medical Center|No|Completed|August 2012|October 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|75|||Both|65 Years|N/A|No|||June 2015|June 22, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476981||18690|
NCT02424006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503-001|Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty|A Prospective, Randomized, Open Label Clinical Trial to Evaluate the Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea Compared to Human Cornea in Patients Requiring Anterior Lamellar Keratoplasty||L.V. Prasad Eye Institute|Yes|Not yet recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02424006||22758|
NCT02461927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY 0002|Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder|Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder||VA Connecticut Healthcare System|No|Recruiting|January 2015|December 2019|Anticipated|October 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|65|||Both|21 Years|65 Years|No|||July 2015|July 13, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461927||19847|
NCT02476994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6344-001|Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion|A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (Lipid Injectable Emulsion, USP) 20% or Standard-of-Care Soybean Oil-Based Lipid Emulsion||Baxter Healthcare Corporation|Yes|Active, not recruiting|May 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|17 Years|No|||June 2015|September 29, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476994||18689|
NCT02463370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122014|Four vs. Ten Local Anesthetic Injections for SMR|Effectiveness of Four Versus Ten Local Anesthetic Injections for Post-submucosal Resection Pain Relief: a Randomized, Double Blinded Clinical Trial||Makassed General Hospital|No|Recruiting|May 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|120|||Both|15 Years|65 Years|No|||June 2015|June 2, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02463370||19737|
NCT02417727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150102|Feasibility Study of Deep Brain Recordings for Learning and Memory|A Feasibility Study of Deep Brain Recordings for Learning and Memory||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02417727||23240|
NCT02417740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150108|Natural History of Noncirrhotic Portal Hypertension|Natural History of Noncirrhotic Portal Hypertension||National Institutes of Health Clinical Center (CC)||Recruiting|March 2015|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|12 Years|N/A|No|||February 2016|February 20, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02417740||23239|
NCT02465775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF18361|Fat Reduction in the Flanks Area vs. Control|Clinical Study to Evaluate the Performance of the UltraShape Device for Fat Reduction Treatment in the Flanks Area vs. Control||Syneron Medical|No|Not yet recruiting|July 2015|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465775||19552|
NCT02463786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-4-074|Improving Knowledge To Efficaciously RAise Level of Contemporary Treatment in Heart Failure (|Improving Knowledge To Efficaciously RAise Level of Contemporary Treatment in Heart Failure|INTERACTinHF|Maastricht University Medical Center|No|Recruiting|July 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with the following inclusion criteria are suitable for participation in the        study: age ≥18 years, signs, diagnosis or suspicion of heart failure and are contractually        capable and mentally able to understand and follow the instructions of the study personnel        (i.e. speaking and understanding the local language, being able to have a conversation for        about an hour, being able to hear and speak). All subjects have to be able to give        informed consent. Patients who had undergone heart transplantation are excluded.        Otherwise, no exclusion criteria apply. The health care providers of these patients        (cardiologists, GP's and HF-nurses) are also contacted to participate in this study.|June 2015|June 2, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02463786|1 Day|19705|
NCT02477150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/15029|Safety and Immunogenicity of a Zoster Vaccine in SLE|Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial||Tuen Mun Hospital|No|Recruiting|November 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 26, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477150||18677|
NCT02477215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00024991|Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma||Medical College of Wisconsin|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477215||18672|
NCT02425527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40109/14|Digital Gaming for Persons With Traumatic Brain Injury|Digital Gaming Used to Improve the Cognitive Functioning and Well-being of People With Traumatic Brain Injury: a Feasibility Study|PLAY|University of Turku|Yes|Active, not recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|90|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425527||22641|
NCT02425540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55783|Characterization of Ovarian Masses Unable to Classify With Gynecological Ultrasonography: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging|Characterization of Ovarian Masses Unable to Classify With Gynecological Ultrasonography: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging|IOTAMRI|Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2015|December 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|74|||Female|N/A|N/A|No|Probability Sample|Patients with ovarian mass not able to classify by gynecological ultrasound|August 2013|April 20, 2015|August 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02425540||22640|
NCT02462369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondNanjingMU|Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients|The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose||The Second Hospital of Nanjing Medical University|No|Enrolling by invitation|June 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|20 Years|70 Years|No|||April 2015|July 27, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02462369||19813|
NCT02466035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2815|Epigenetic Effects Involved in Children With Cow's Milk Allergy|Epigenetic Effects Involved in Children With Cow's Milk Allergy: A Possible Effect of Atopic March of Lactobacillus GG||Federico II University||Recruiting|May 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Months|60 Months|No|||February 2016|February 29, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02466035||19532|
NCT02477423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0053|Antibiotic Stewardship and Protection of the Developing Preterm Infant Microbiome|Antibiotic Stewardship and Protection of the Developing Preterm Infant Microbiome||University of Chicago|Yes|Not yet recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|80|||Both|N/A|6 Hours|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477423||18656|
NCT02477436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avanafil-Korea|Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction|A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Exploratory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction||Pusan National University Hospital|Yes|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|159|||Male|19 Years|70 Years|No|||June 2015|June 23, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02477436||18655|
NCT02468323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Palonosetron01|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia: Study Single Center, Prospective, Double-blind, Randomized, Placebo Controlled|PONV|Hospital de Base|Yes|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|50 Years|No|||October 2015|October 8, 2015|June 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468323||19356|
NCT02415153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02182|Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors|A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive or Refractory CNS Tumors||National Cancer Institute (NCI)||Recruiting|July 2015|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|3 Years|20 Years|No|||February 2016|March 14, 2016|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02415153||23438|
NCT02473250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7056|Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging|Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging||New York State Psychiatric Institute|No|Recruiting|January 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473250||18977|
NCT02483481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 15060244|Using Ultrasound Elastography to Predict Development of SOS|Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome||Children's Mercy Hospital Kansas City|No|Not yet recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|21 Years|No|Probability Sample|Pediatric bone marrow transplant patients|June 2015|June 25, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483481||18190|
NCT02474498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035/2007|EMD and/or Bone Substitute for the Treatment of Class II Furcations|Enamel Matrix Protein Derivative and/or Synthetic Bone Substitute for the Treatment of Mandibular Class II Buccal Furcation Defects. A 12-month Randomized Clinical Trial||University of Campinas, Brazil|Yes|Completed|March 2013|June 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|75 Years|No|||June 2015|June 12, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474498||18881|
NCT02464930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0009|Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia|Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus||Midwest Biomedical Research Foundation|No|Recruiting|April 2015|December 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|220|Samples With DNA|blood, bile and tissue in a repository|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited at the Kansas City VA Hospital and the Mobile Medical unit of        the Kansas City VA. The Mobile Medical Unit (MMU) travels to multiple counties to provide        health care to the veterans at their doorstep. This is a program that has been in place        for several years and continues to grow. Currently, the MMU provides services such as        basic health evaluations and phlebotomy to ~600 veterans per week.|June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464930||19617|
NCT02481102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QT-0020|EASYER (EpiAccess SYstem Registry) A Post Market Observational Registry|EASYER (EpiAccess SYstem Registry) - A Post Market Observational Registry|EASYER|EpiEP, Inc.|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are clinically indicated for a procedure requiring pericardial access are        eligible for the study.|October 2015|February 8, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02481102|4 Days|18373|
NCT02480881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-019|A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers|Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects|DDI|Bristol-Myers Squibb|No|Active, not recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480881||18390|
NCT02480894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-052|A Open-label, Drug-Drug Interaction With Maraviroc|A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects|DDI|Bristol-Myers Squibb|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480894||18389|
NCT02473068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-170|Non Invasive Ventilation Comfort Study|Non Invasive Ventilation Comfort Study||Fisher and Paykel Healthcare||Recruiting|June 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473068||18991|
NCT02473081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 101-2314-B-006-001-|Minimal Psychological Intervention in Diabetes Patients|The Long-term Effect of a Minimal Psychological Intervention on Type 2 Diabetes Patients' Depressive Symptom, Diabetes-related Distress and Glycemic Control||National Cheng-Kung University Hospital||Completed|October 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|182|||Both|50 Years|N/A|No|||June 2015|June 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02473081||18990|
NCT02486146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575191-4|GI Biorepository of Tissue and Bodily Fluids|GI Biorepository of Tissue and Bodily Fluids||University of California, Davis|Yes|Recruiting|October 2014|||October 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals to be included will be all consenting adults aged 18 years or older with an        appointment with a healthcare professional in the Division of Gastroenterology or the        Department of Surgery. During their routinely scheduled appointment or procedure, eligible        individuals will be informed of the program by the attending physician and encouraged to        participate in order to establish a diverse collection of samples of GI-related        pathologies and matched controls. The investigators' exclusion criteria will include        minors, pregnant women, prisoners, and all other vulnerable populations who are unable to        consent.|June 2015|June 27, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02486146||17986|
NCT02480517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM14-003|Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension|Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension||Kona Medical Inc.|Yes|Not yet recruiting|September 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480517||18418|
NCT02480777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130722|Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair|Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair||University of Miami||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|December 15, 2015|June 21, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02480777||18398|
NCT02488538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS 1|Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome|The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial||Cairo University|Yes|Recruiting|July 2015|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02488538||17802|
NCT02488551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-314|A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs|A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs||Central Arkansas Veterans Healthcare System|No|Not yet recruiting|July 2017|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488551||17801|
NCT02474654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-009|Implementation of a Pain Management Protocol for Total Knee Arthroplasty|An Analysis of the Functional Benefit, Narcotic Use and Time to Discharge Readiness Following the Implementation of a Comprehensive Pain Management Protocol for Primary Total Knee Arthroplasty||Advanced Medical Research Institute of Canada|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|220|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02474654||18869|
NCT02477839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0967|Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥1 Month to <4 Years of Age With Partial-onset Seizures||UCB Pharma|Yes|Recruiting|June 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|244|||Both|1 Month|47 Months|No|||March 2016|March 18, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477839||18624|
NCT02484963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Insomnia-001|The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia|The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia||Institute of Liver and Biliary Sciences, India|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||December 2015|December 21, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02484963||18076|
NCT02494349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP-1207-P1-PK|The PK Characteristics of the JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg) and Co-administration of Solifenacin and Tamsulosin in Healthy Male Volunteers.|A Randomized, Open-label. Single Dose, Two-way Crossover Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg) and Co-administration of Solifenacin and Tamsulosin in Healthy Male Volunteers.||Jeil Pharmaceutical Co., Ltd.|No|Not yet recruiting|August 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494349||17357|
NCT02467543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZuleikaSaem200819247|The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea|The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea||University of Johannesburg|Yes|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02467543||19416|
NCT02480218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130-2015|Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women|Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women||Sunnybrook Health Sciences Centre|No|Not yet recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|65 Years|N/A|No|Non-Probability Sample|chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post        surgical resection, who are prescribed either tamoxifen, anastrozole or letrozole.|June 2015|June 23, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02480218||18441|
NCT02480231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-0455|Mid-Urethral Sling Tensioning Trial|Mid-Urethral Sling Tensioning Trial|MUST|University of Calgary|No|Not yet recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2|||318|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02480231||18440|
NCT02493881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEEAH01|Recurrent Laryngeal Nerve's Motor Function: Sometimes Motor Fibers May Also Be Located in The Posterior Branch|Descriptive in Vivo Study of Evaluating the Motor Function of Recurrent Laryngeal Nerve's Extralaryngeal Branching Electromyographically.||Sisli Etfal Training & Research Hospital|No|Completed|January 2012|March 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|337|||Both|18 Years|80 Years|No|||July 2015|July 9, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02493881||17393|
NCT02482454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chol001|Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma||The First People's Hospital of Changzhou|No|Active, not recruiting|July 2012|July 2033|Anticipated|July 2030|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|80 Years|No|||February 2016|February 21, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02482454||18269|
NCT02486302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801385|A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.|A Prospective, Multicenter Non-interventional Study To Evaluate The Efficacy Of Enbrel (Registered) (Etanercept) Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis With Particular Focus On The Clinical Status Improvements Still Observable After 12 Weeks Of Treatment|ADEQUATE|Pfizer|No|Recruiting|March 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2100|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory and Hospital care patients treated for Rheumatoid Arthritis, Axial        Spondyloarthritis, Psoriasis Arthritis or Plaque Psoriasis in Germany|March 2016|March 9, 2016|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02486302||17974|
NCT02490072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0284|Echocardiographic Evaluation of the Effects of Dexmedetomidine in Diastolic Dysfunction|||Yonsei University|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|40 Years|80 Years|No|||August 2015|August 6, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02490072||17686|
NCT02478216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160078|The Effect of Remote Ischemic Preconditioning on Postoperative Cognitive Dysfunction in Total Knee Replacement|The Effect of Remote Ischemic Preconditioning on Postoperative Cognitive Dysfunction in Total Knee Replacement||Konkuk University Medical Center|No|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|108|||Both|30 Years|N/A|No|||June 2015|June 18, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02478216||18595|
NCT02482766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot. rs 25882/14|Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS|Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With Respiratory Distress Syndrome During Non Invasive Ventilation: a Randomized Controlled Trial||Catholic University of the Sacred Heart|Yes|Recruiting|November 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|24 Weeks|27 Weeks|No|||January 2016|January 28, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02482766||18245|
NCT02468388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS 10-341|Re-mineralization Effects of Sugar Free Chewing Gum Sweetened With Different Sugar-substitutes|Study on the Effect of Chewing Sugar-free Gum on Re-mineralization of Early Caries Via Quantitative Light-induced Fluorescence||Roquette Management (Shanghai) Co., Ltd.|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|482|||Both|8 Years|13 Years|No|||June 2015|June 7, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468388||19351|
NCT02487888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB008|A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care|Randomized, Blinded, Controlled Trial to EValuate the EcOnomic and ClinicaL Outcomes of Utilizing Genetic Testing to Improve Therapeutic Decision-Making COmpared to Empiric Prescribing as the StaNdard of Care|REVOLUTION|Proove Bioscience, Inc.|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Anticipated|100000|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487888||17852|
NCT02490020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zssy20150624|A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death|||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Enrolling by invitation|January 2016|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Anticipated|260|||Both|18 Years|60 Years|No|||July 2015|July 2, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490020||17690|
NCT02483026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSGD1HMO-CTIL|Nutritional Deficiencies Preventive Treatment Prior to Laparoscopic Sleeve Gastrectomy|Nutritional Deficiencies Preventive Treatment Prior to Laparoscopic Sleeve Gastrectomy: Controlled Clinical Study|LSG|Hadassah Medical Organization|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|60 Years|No|||June 2015|June 23, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483026||18225|
NCT02475174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP nº 13408/2013|Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer|Blood Circulation Assessment of the Superior Member in Women in Post-surgery for Breast Cancer Submitted to the Manual Lymphatic Drainage||University of Sao Paulo|Yes|Not yet recruiting|June 2015|March 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|40 Years|60 Years|No|||June 2015|June 15, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02475174||18829|
NCT02491528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB021L012015|A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety|A Multi-center, Randomized, Open-label, Parallel-group, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Insulin Aspart Injection in Patients With Diabetes Mellitus Compared to NovoRapid®||Tonghua Dongbao Pharmaceutical Co.,Ltd|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|75 Years|No|||July 2015|July 2, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02491528||17574|
NCT02478749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1504-069-664|Influence of Arm Retraction on the Supraclavicular Approach for Subclavian Vein Catheterization|Influence of Arm Retraction on the Relative Position of Clavicle and the Subclavian Vein,During Supraclavicular Approach for Central Venous Catheterization in Adults and Children||Seoul National University Hospital|Yes|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|60|||Both|N/A|60 Years|No|||February 2016|February 22, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02478749||18554|
NCT02483182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEP - 002 - IL|Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores|A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).||Shulov Innovate for Science Ltd. 2012|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483182||18213|
NCT02487355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087123|Pediatric Caudal Dexmedetomidine Enhances Postoperative Analgesia of Magnesium Sulphate in Lower Abdominal Surgeries|Pediatric Caudal Epidural Dexmedetomidine Enhances Postoperative Analgesia of Magnesium Sulphate and Quality of Caudal Anesthesia in Lower Abdominal Surgeries|JASayed|Assiut University|Yes|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|6 Months|6 Years|No|||June 2015|June 30, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487355||17893|
NCT02487368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRM_2009|Effects of a Mechanical Needle Stimulation Pad on Chronic Low Back Pain|Effects of a Mechanical Needle Stimulation Pad on Chronic Low Back Pain|NRM_2009|Universität Duisburg-Essen|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|18 Years|75 Years|No|||July 2015|July 1, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487368||17892|
NCT02469506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 14-3-050|Neuromuscular Electrical Stimulation During Immobilization Due to Ankle Fractures|The Effects of Daily Neuromuscular Electrical Stimulation on Muscle Mass During Long-term Unilateral Ankle Immobilization in Adults With Ankle Fractures|ANKL-ES|Maastricht University Medical Center|Yes|Recruiting|February 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02469506||19265|
NCT02480751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100CRS01/533-CL-00|TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)|||Toray Industries, Inc|Yes|Completed|October 2005|||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|113|||Both|20 Years|79 Years|No|||June 2015|June 26, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480751||18400|
NCT02480764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_305|TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension|A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension||Takeda|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480764||18399|
NCT02485210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|832.657|Effectiveness of Photodynamic Therapy for Endodontic Treatment of Deciduous Teeth|Evaluation of the Effectiveness of Photodynamic Therapy as a Supporting for Endodontic Treatment of Deciduous Teeth||University of Nove de Julho|No|Not yet recruiting|August 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485210||18057|
NCT02485431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-026|Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers|A Single-Dose, Single-Center, Randomized, Five Period Crossover Study Comparing Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers||Marathon Pharmaceuticals, LLC|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485431||18040|
NCT02463383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M215|Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women|Alcohol-related Breast Cancer in Postmenopausal Women - Effect of PPARG2pro12ala Polymorphism on Female Sex-hormone Levels and Interaction With Alcohol Consumption and NSAID Usage|EPPNASE|University of Copenhagen|No|Active, not recruiting|September 2013|December 2015|Anticipated|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463383||19736|
NCT02470637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14324|Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus|A Randomized, Controlled, 6-treatment, 6-sequence, 6-period Cross-over Dose Response Study of 3 Single Doses of Afrezza Inhaled Technosphere Insulin and of 3 Single Doses of SC Insulin Lispro in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique||Sanofi|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|June 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470637||19178|
NCT02488473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-JH-14|Does Perineural Dexmedetomidine Prolong Duration of a Nerve Block?|Does Perineural Dexmedetomidine Prolong the Duration of an Adductor Canal Block When Controlling for a Systemic Effect? - A Randomised Paired Trial in Healthy Volunteers.||Koege Sygehus|Yes|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|January 4, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488473||17807|
NCT02481687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-Scan-CLE-IBD|The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease|The Value of Virtual Chromoendoscopy With i-SCAN and Confocal Laser Endomicroscopy in the Assessement of Dysplasia on Patients With Inflammatory Bowel Disease|I-Scan-CLE-IBD|University of Medicine and Pharmacy Craiova|Yes|Recruiting|June 2015|October 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|15|Samples With DNA|One ml of whole blood and tissue biopsies from normal tissue and from modified areas of 2 to      3 mm each for molecular analysis.|Both|18 Years|80 Years|No|Probability Sample|Patients with active ulcerative colitis or Crohn's disease who meet the inclusion and        exclusion criteria will be included in the study. Personal data (name, surname, age, sex),        results from previous investigations, clinical evaluation (stools frequency, rectal        bleeding, fever, abdominal pain, extra intestinal manifestation, abdominal mass) and blood        count for activity index calculator (Mayo score for ulcerative colitis, respectively CDAI        score for Crohn disease), endoscopic findings, histological and immunohistochemical        findings, molecular analysis findings, will be registered in the study. p-CLE has shown        its utility in both upper and lower GI tract. I-SCAN isn't widely used, so more studies        are needed to prove its utility. Anyway, signed informed consent for colonoscopy, i-SCAN        colonoscopy and pCLE examination is required for participation in the study|June 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481687||18328|
NCT02464371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508014|Interest of Plasma microRNAs Assay in ICU Acquired Muscle Weakness Diagnosis|Interest of Plasma microRNAs Assay in ICU Acquired Muscle Weakness Diagnosis||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|58|Samples Without DNA|Blood samples will be drawn to compare the kinetics of microRNAs (miR-1, miR-21, miR-133,      miR-155, miR-206, miR-208a, miR-208b, miR-486, miR-499).|Both|18 Years|N/A|No|Non-Probability Sample|septic shock patients admitted into ICU.|March 2016|March 9, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464371||19660|
NCT02483923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0363|Analgesic Effect to Postoperative Pain After Mastectomy: Ultrasound-guided Serratus Anterior Plane Block|||Yonsei University|No|Recruiting|June 2015|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|20 Years|80 Years|No|||June 2015|June 24, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483923||18156|
NCT02480712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1202|Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection|A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection||Gilead Sciences|No|Active, not recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480712||18403|
NCT02479503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATC|Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey|Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey|ATC|University Hospital, Caen|No|Recruiting|March 2015|July 2015|Anticipated|June 2015|Actual|N/A|Observational|N/A||1|Anticipated|22|||Both|18 Years|80 Years|No|Non-Probability Sample|All French centers perfoming adult heart transplantation in 2015.|June 2015|June 19, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02479503||18496|
NCT02479516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP242122|Community Health Assessment Program in the Philippines|Community Health Assessment Program in the Philippines|CHAP-P|McMaster University||Not yet recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|45|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02479516||18495|
NCT02487342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-12-290413|Metabolic, Endocrine and Appetite-related Responses in Healthy, Adolescent Males After Acute and Daily Milk Consumption|Metabolic, Endocrine and Appetite-related Responses in Healthy, Adolescent Males After Acute and Daily Milk Consumption||Northumbria University|No|Completed|June 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Male|15 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02487342||17894|
NCT02469740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RON004|Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI|Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone Percutaneous Coronary Intervention - a Randomised, Crossover Study.||University Hospital of Limerick|No|Completed|July 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|61|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469740||19247|
NCT02487004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAU-1440|The Study of Association Between Intradialysis Sodium Balance and Clinical Outcomes in Chronic Hemodialysis Patients|||Chung-Ang University|Yes|Not yet recruiting|July 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|20 Years|N/A|No|Non-Probability Sample|patients with end-stage renal disease requiring chronic hemodialysis|June 2015|June 27, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487004||17920|
NCT02487017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Hepatocellular Carcinoma|DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma|Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487017||17919|
NCT02492243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A V1CAMI 2010|Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction andpREServed Lef venTricle Ejection Fraction (ARREST)|Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction and pREServed Left venTricle Ejection Fraction||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|August 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|75 Years|No|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02492243||17519|
NCT02470039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1953-4163|Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy|An 8-week Randomised, Double-blind, Parallel, Multiple Dose Trial Comparing NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy||Novo Nordisk A/S|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470039||19224|
NCT02470052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMSC-1401|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema|A Prospective, Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema||Olympus Corporation|No|Recruiting|August 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|20 Years|75 Years|No|||October 2015|October 19, 2015|June 5, 2015||||No||https://clinicaltrials.gov/show/NCT02470052||19223|
NCT02469688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4070-CL-0010|A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy|A Phase 1 Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Cedar Pollinosis When Administered as Intramuscular (IM) Vaccination and Intradermal (ID) Vaccination||Astellas Pharma Inc|No|Active, not recruiting|June 2015|September 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Anticipated|66|||Both|20 Years|64 Years|No|||December 2015|December 14, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469688||19251|
NCT02417012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-TURN|Lifestyle and Glucose Lowering Medication in T2DM|Does Intensive Life Style Intervention Reduce the Need for Glucose Lowering Medications in Patients With Type 2 Diabetes? The U-TURN Project||Rigshospitalet, Denmark|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02417012||23295|
NCT02473796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1|Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT|Effect of Home Based Child Care on Child Mortality and Malnutrition in a Tribal Population of Melghat, India: Cluster Randomised Control Field Trial|HBCC|MAHAN Trust|Yes|Completed|January 2004|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7594|||Both|N/A|5 Years|No|||March 2016|March 15, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473796||18935|
NCT02478099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29755|MPDL3280A-treatment-IST-UMCG|MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Bladder and Triple Negative Breast Cancer After Investigational Imaging||University Medical Center Groningen|No|Not yet recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02478099||18604|
NCT02478125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14177|Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer|A Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer||Johns Hopkins University|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|23|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478125||18602|
NCT02463110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110155|Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin|Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin: The ANDROS Study|ANDROS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02463110||19756|
NCT02425319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapMotion|CapFlex-PIP© Motion|Motion Analysis of the Proximal Interphalangeal Joint in Healthy Hands, as Well as in Osteoarthritis Hands Following Implantation With the New CapFlex-PIP© Implant Compared With Silicone Implants||Schulthess Klinik||Not yet recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with proximal interphalangeal joint osteoarthritis in the index or middle finger,        treated with a CapFlex-PIP© implant or with a silicone implant and with a follow-up time        between 12 and 60 months after primary implantation or patient with one untreated healthy        hand without joint osteoarthritis|April 2015|April 20, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425319||22657|
NCT02425410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10061|Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset|Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset|ISIS-VIRUS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2010|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|Samples With DNA|whole blood (already collected for the Isis-Diab project)|Both|6 Months|N/A|No|Non-Probability Sample|patients of the Isis-Diab cohort, i.e. T1D patients aged more than 6 months, already        sampled for genetic analysis.|December 2015|January 29, 2016|August 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02425410||22650|
NCT02465554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011874|Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions|||Oregon Health and Science University|Yes|Not yet recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|35 Years|55 Years|No|Non-Probability Sample|Patients referred for clinically-indicated CT coronary angiography.|June 2015|June 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465554||19569|
NCT02465567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010005|Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)|A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)||Pearl Therapeutics, Inc.|Yes|Recruiting|June 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|8000|||Both|40 Years|80 Years|No|||December 2015|December 22, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465567||19568|
NCT02471300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150136|Effect of Fasting on the Asthma Inflammasome|Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|18 Years|60 Years|No|||April 2015|June 19, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471300||19127|
NCT02467764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-20|"Score Infectivity" During Reoperation on Total Hip or Knee Prosthesis|Definition of a "Score Infectivity" During Reoperation on Total Hip or Knee Prosthesis||University Hospital, Strasbourg, France|No|Not yet recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients operated in the service in 2014 to care for end-stage hip or knee osteoarthritis        by implantation of a total hip or knee prosthesis.|June 2015|June 7, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02467764||19399|
NCT02467777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-025|Comparison of Forced Air and Conductive Patient Heating Systems During Ambulatory Surgeries|||Fox Valley Orthopedic Institute|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467777||19398|
NCT02424097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCAmerica-WS|MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study|MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study|GC-WS|University of California, San Francisco|No|Completed|May 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|11 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424097||22751|
NCT02469844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18174|Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures|||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|October 2014|||July 2015|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with epilepsy admitted for three- to five-day diagnostic or pre-surgery        video-electro-encephalography and ECG (VT) monitoring in the video telemetry unit at the        Royal Hallamshire Hospital in Sheffield will be recruited for the study.|June 2015|June 11, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469844||19239|
NCT02467972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPFCF194 CEPFCF18|Functional Ingredients: Effect in Gastrointestinal System|Functional Ingredients: Effect in Satiety and Intestinal Health||University of Sao Paulo|Yes|Completed|April 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|61|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467972||19383|
NCT02474927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15010152|Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation|Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)||University of Pittsburgh|Yes|Active, not recruiting|November 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474927||18848|
NCT02414880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Suga-Neo|Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection|Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study||Cairo University|Yes|Completed|December 2014|September 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|60 Years|No|||January 2016|January 30, 2016|April 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414880||23459|
NCT02466282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0019|A Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold|A Randomized Controlled Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold||Yonsei University|Yes|Recruiting|June 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|414|||Both|19 Years|N/A|No|||February 2016|February 5, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466282||19513|
NCT02464059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00060778|Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD|Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD||Johns Hopkins University|No|Enrolling by invitation|June 2015|September 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464059||19684|
NCT02477267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS009-15-033|Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers|A Pivotal, Phase 1, Open-Label, Randomized, Crossover, Single-Dose, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers||INSYS Therapeutics Inc|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|September 1, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477267||18668|
NCT02418559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106762|A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Subjects||Janssen Infectious Diseases BVBA|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|April 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02418559||23176|
NCT02461940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/1188/2008|STI/HIV Prevention Intervention for Adolescents in Singapore|A Randomized Controlled Trial of an STI/HIV/AIDS Prevention Intervention for Adolescents Attending a Public STI Clinic in Singapore||National University, Singapore|Yes|Active, not recruiting|November 2009|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|700|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||May 2015|May 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461940||19846|
NCT02488226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306012246|Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder|Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder|ASD|Yale University|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|220|||Both|18 Months|60 Months|No|||June 2015|July 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02488226||17826|
NCT02461849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-074|Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy|A Phase II, Open-label, Study in Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy||Samsung Medical Center|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461849||19853|
NCT02485873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18073|Real-Life Evidence on Stroke Prevention in SPAF|REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation|RELIEF|Bayer|No|Completed|May 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|8607|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation (NVAF)|November 2015|November 10, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02485873||18006|
NCT02485678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2015-ATOM|A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer|A Pragmatic Cluster-Randomized Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer (AToM)|AToM|Ontario Clinical Oncology Group (OCOG)|No|Recruiting|February 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1460|||Female|18 Years|N/A|No|||February 2016|March 18, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02485678||18021|
NCT02485028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SID123_DDI_I_2013|Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30mg and Mirodenafil 50mg in Healthy Male Volunteers||SK Chemicals Co.,Ltd.|No|Completed|October 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02485028||18071|
NCT02488434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA15/132|The Effects of Using Fertile Chip in Sperm Selection for Intracytoplasmic Sperm Injection in Unexplained Infertility|The Effectiveness of Using Fertile Chip on Intracytoplasmic Sperm Injection Undergoing Ivf Programme in Unexplained Infertile Couples||Baskent University|Yes|Recruiting|June 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|20 Years|40 Years|No|||July 2015|July 2, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488434||17810|
NCT02488603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCKorea|Decision Aids for Tamoxifen Treatment in Breast Cancer Patients|Utilization of Decision Aids for Tamoxifen Treatment in Breast Cancer Patients: A Randomized Controlled Trial.||National Cancer Center, Korea||Not yet recruiting|August 2015|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|360|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02488603||17797|
NCT02484716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0063|Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo|Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo|TEMPO|Hospices Civils de Lyon|Yes|Recruiting|June 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02484716||18095|
NCT02484729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6400C00001|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males|A Phase I, Randomized, Single-blind, Placebo-controlled Study to Access the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Single Ascending Dose Administration to Healthy Male Subjects||AstraZeneca|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|88|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02484729||18094|
NCT02494336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41111|Trans-incisional vs Laparoscopic Guided Rectus Sheath Block for Pediatric Single Incision Laparoscopic Cholecystectomy|Trans-incisional Rectus Sheath Block Versus Laparoscopic Guided Rectus Sheath Block for Pediatric Single Incision Laparoscopic Cholecystectomy: A Prospective, Randomized Study||All Children’s Hospital Johns Hopkins Medicine|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|10 Years|21 Years|No|||February 2016|February 9, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494336||17358|
NCT02462278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-001|Measuring Core Body Temperature Using TempuRing|A Study Measuring Core Body Temperature Using TempuRing in Women of Childbearing Age||Prima-Temp, Inc|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462278||19820|
NCT02465762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF18001|UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat and Circumference Reduction||Syneron Medical|No|Not yet recruiting|December 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465762||19553|
NCT02488928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1676|E- Predict: EBUS ELASTOGRAPHY STRAIN Pattern Analysis in Lung Cancer|E-PREDICT Evaluating the Predictive Value of EBUS ELASTOGRAPHY STRAIN Pattern Analysis in Patients With (Suspected) Lung Cancer|E-PREDICT|Radboud University|No|Recruiting|July 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected or proven lung cancer are eligible if there is an indication for        EBUS, EUS or combined EBUS and EUSb (single scope, EUS with EBUS scope). Eligible are        patients with no contra-indications for EBUS.|February 2016|February 22, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02488928||17773|
NCT02481427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T127/2015|Finnish Unicompartmental and Total Knee Arthroplasty Investigation|Total Knee Arthroplasty Versus Unicondylar Knee Arthroplasty: a Randomized, Double-blind Multicenter Trial|FUNCTION|Turku University Hospital|No|Recruiting|September 2015|August 2027|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|45 Years|79 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02481427||18348|
NCT02477280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03-10/11|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder||Landstinget Västmanland|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|60 Years|No|||November 2015|November 24, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477280||18667|
NCT02487043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 1-314/2013 SOF, KI|A Telephone-based Case-management Intervention for Caries Prevention in Children With Severe Early Childhood Caries|A Telephone-based Case-management Intervention for Caries Prevention in Children With Severe Early Childhood Caries||Karolinska Institutet|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|N/A|6 Years|No|||June 2015|June 26, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02487043||17917|
NCT02490449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHBC 2014-05-021-002|Dexlansoprazole MR in Nonerosive Reflux Disease|||Soonchunhyang University Hospital||Enrolling by invitation|December 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|356|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|December 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02490449||17657|
NCT02491086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409176211|Motivating Smokers at Outdoor Public Smoking Hotspots to Have Quit Attempt With Nicotine Replacement Therapy Sampling|Motivating Smokers at Outdoor Public Smoking Hotspots to Have Quit Attempt With Nicotine Replacement Therapy Sampling: A Randomized Controlled Trial||The University of Hong Kong|No|Recruiting|July 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491086||17608|
NCT02464384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPEDRA01_01.07.2013|Prediction of Erosive Disease in Early Rheumatoid Arthritis (RA) by Ultrasound and Cartilage Biodegradation Markers|Multicenter, Prospective, Open-label, Cohort Study With Collection of Blood Samples and Ultrasound / MRI and X-ray Examination||University of Zurich|No|Not yet recruiting|April 2016|October 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02464384||19659|
NCT02464631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HCV-001|To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis|To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis" - A Randomized Open- Label Study||Institute of Liver and Biliary Sciences, India|No|Terminated|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|75 Years|No|||January 2016|February 4, 2016|May 22, 2015||No|In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir    and Ledipasvir which have proven better efficacy in the HCV cure|No||https://clinicaltrials.gov/show/NCT02464631||19640|
NCT02480478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|518|Serum Autotaxin Levels in Cholestasis of Pregnancy|Diagnostic Accuracy of Serum Autotaxin Levels in Cholestasis of Pregnancy||Sisli Etfal Training & Research Hospital|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples Without DNA|5ml whole blood sample|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients who are admitted to obstetrics and gynecology department due to cholestasis of        pregnancy|June 2015|June 23, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480478||18421|
NCT02480491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS-1|Study of Free DNA Content of Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment|Study of Cell Free DNA Content of Human Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment in ICSI Treatment Cycles||Sadat City University|No|Completed|January 2014|May 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|100|Samples With DNA|cell free DNA content of the culture medium of the human embryo|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ICSI Treatment Cycles females|June 2015|June 23, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02480491||18420|
NCT02482688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/SC/1339|A New Rehabilitation Treatment Following Stroke|A Randomised Controlled Study of Early vs. Late, and Unisensory vs. Multisensory Rehabilitation for Stroke Patients With Perceptual and Cognitive Impairments.||University of Oxford||Recruiting|April 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|30 Years|N/A|No|||June 2015|June 25, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482688||18251|
NCT02486562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-MS-PPRN-001|iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis||iCMS|Accelerated Cure Project for Multiple Sclerosis|No|Recruiting|November 2014|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|20000|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anyone 21 years of age or older is welcome to participate. Primary cohort is people with        multiple sclerosis.|June 2015|June 29, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02486562||17954|
NCT02475096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot child ICBT FGID|Internet-delivered CBT for Children With Functional Gastrointestinal Disorders - an Open Pilot Study|Internet-delivered Cognitive Behavior Therapy for Children With Pain-predominant Functional Gastrointestinal Disorders - an Open Pilot Study||Karolinska Institutet|No|Active, not recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Years|12 Years|No|||February 2016|February 5, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475096||18835|
NCT02490202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGTP-002|Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant|A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant||Prolong Pharmaceuticals|Yes|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490202||17676|
NCT02490345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507497375|Gabapentin as Adjunctive Treatment for Postoperative Pain Control|Effect of Gabapentin on Postoperative Pain Control After a Cesarean Section||Indiana University|Yes|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490345||17665|
NCT02478476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBNet#673096|DNA Single Nucleotide Polymorphisms as Predictors of Toxicity|DNA Single Nucleotide Polymorphisms as Predictors of Platinum and Taxane Related Adverse Events in Ovarian, Fallopian Tube, and Peritoneal Cancer Patients||OvaGene Oncology, Inc.|Yes|Not yet recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with pathologically confirmed ovarian, fallopian tube, or peritoneal cancer        scheduled to receive platinum and/or taxane based chemotherapy.|June 2015|June 18, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478476||18575|
NCT02487134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrevMesh|Trial of Routine Abdominal Wall Closure Versus Reinforcement With TIGR Matrix Onlay|Trial of Routine Abdominal Wall Closure Versus Reinforcement With TIGR Matrix Onlay|PrevMesh|Karolinska Institutet|No|Recruiting|June 2015|June 2023|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 21, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02487134||17910|
NCT02494167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36346 ADSPAM|Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)|Administration of Donor Derived Multi-Tumor-Associated Antigen (TAA)- Specific T Cells to Patients With AML or MDS (ADSPAM)||Baylor College of Medicine|Yes|Recruiting|February 2016|February 2024|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|N/A|N/A|No|||February 2016|February 22, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494167||17371|
NCT02476526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Barack0001|Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease|Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease||VA Greater Los Angeles Healthcare System|No|Recruiting|September 2008|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476526||18725|
NCT02481050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-M001-216|Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer|To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer||Eisai Inc.|No|Recruiting|June 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481050||18377|
NCT02481063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF_US20015|Adaptation in Lower Extremity After 3 Running Days, With a Group Trained by Eccentric Overload|Differences in Muscle (Vastus Laterals and Gastrocnemius Medialis) and Tendon Adaptation (Patellar and Achilles) in Lower Extremity After 3 Running Days With a Group Trained by Eccentric Overload, Measured by Ultrasound and Thermography||Universidad San Jorge|Yes|Completed|June 2015|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|19|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|August 20, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02481063||18376|
NCT02487862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCDS|Role of Stress Reduction Protocol on Outcome of Periodontal Therapy|Evaluating the Adjunctive Effect of Stress Reduction Protocol in the Non-Surgical Periodontal Therapy of Chronic Periodontitis Subjects Associated With Stress: A Randomized Control Pilot Study||Krishnadevaraya College of Dental Sciences & Hospital|Yes|Recruiting|February 2015|December 2015|Anticipated|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||September 2015|November 20, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02487862||17854|
NCT02494245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARFISH RCT|Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone App|Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Randomised Controlled Study||University of Glasgow|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02494245||17365|
NCT02494219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HamadMC|Pharyngitis,Group A Streptococcal Infection,Rapid Streptococcal Test,Throat Swab Culture|Comparison of Immunochromatographic Test for Rapid Detection of Group A Streptococcal Antigen With Culture in Pediatric Patients||Hamad Medical Corporation|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|906|||Both|1 Year|14 Years|No|||June 2015|July 7, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02494219||17367|
NCT02494232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antalya TRH|Emergency Management of Minor Blunt Thoracic Trauma|To Review the Management and Follow-up of Patients With Minor Thoracic Injuries Treated by Emergency Physicians.||Antalya Training and Research Hospital|No|Completed|July 2013|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|186|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who admitted within the first 6 hours after injury to hospital due to blunt        thoracic trauma without concomitant major injury were considered to have minor thoracic        trauma and were included in the study|July 2015|July 8, 2015|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02494232||17366|
NCT02476097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003|PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms|Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study|PROGRESS|University Hospital, Geneva|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|90 Years|No|||June 2015|June 18, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02476097||18758|
NCT02484950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15042702|Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair|A Prospective Randomized Trial of Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Arthroscopic Rotator Cuff Repair||Rush University Medical Center|No|Recruiting|November 2015|November 2020|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484950||18077|
NCT02489149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25445|Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Multi-sector Intervention|Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Intervention Based on Traditional Food Practices, Healthy Eating Promotion and Enforceability of Human Right to Adequate Food||Federal University of Rio Grande do Sul|No|Recruiting|March 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4|||Both|18 Years|N/A|No|||June 2015|July 1, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02489149||17756|
NCT02467530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1961|Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis|Effect of a Low AGE Diet on Human Microbiome||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467530||19417|
NCT02477566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL2014003|Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI|Comparative Study of Long-acting and Short Acting Triptorelin on Pituitary Down-regulation in Long Protocol in PCOS Patients Who Underwent IVF/ICSI Treatment||Nanjing University||Recruiting|December 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|22 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477566||18645|
NCT02493140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00160-49|Evaluation of Efficacy of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers|Evaluation of Efficacy and Safety of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers: a Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial||Dialpha|No|Recruiting|July 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493140||17450|
NCT02493192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V03_020911|Birth Ball Versus Meperidine and Haloperidol Injection for Pain Relief During First Stage of Labour|||Hospital General Universitario Gregorio Marañon|No|Not yet recruiting|July 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|45 Years|No|||June 2015|July 8, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02493192||17446|
NCT02486003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150361|Testing mTBI in Athletes|The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology for the Diagnosis of Dizziness Associated With Mild Traumatic Brain Injury (mTBI)||University of Miami|No|Active, not recruiting|May 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the population of athletes in the intercollege athletic        programs at the University of Miami. This will include athletes in NCAA Sports as well as        intercollege club sports. Aged and sex matched controls will be collected from the general        student body of the University of Miami.|June 2015|June 26, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486003||17996|
NCT02469480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FERINJECT|Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.|Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.||Krankenhaus Nordwest|Yes|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02469480||19267|
NCT02474784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXKU01-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2014|||||N/A|N/A|N/A||||||||||||||June 15, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474784||18859|
NCT02480725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1702-14 SMC|The Role of the Coagulation Pathway at the Synapse in Prion Diseases|The Role of the Coagulation Pathway at the Synapse in Prion Diseases||Sheba Medical Center|No|Not yet recruiting|June 2015|July 2025|Anticipated|July 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|Samples Without DNA|CSF samples|Both|35 Years|90 Years|No|Non-Probability Sample|CJD and non-CJD patients|June 2015|June 23, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480725||18402|
NCT02485600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-506|Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients|Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)||AbbVie|No|Recruiting|October 2015|October 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Probability Sample|The patient population will consist of patients eligible for DUODOPA treatment according        to the DUODOPA Product Monograph (DPM) approved by Health Canada and according to the        reimbursement criteria accepted by the Canadian Provincial Health Authorities or private        insurance companies.|January 2016|January 12, 2016|June 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485600||18027|
NCT02483442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2014-PEGeD|D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism|D-dimer Testing,Tailored to Clinical Pretest Probability to Reduce the Use of CT Pulmonary Angiography in Suspected Pulmonary Embolism: A Management Study (The Pulmonary Embolism Graduated D-dimer [PEGeD] Study)|PEGeD|McMaster University|Yes|Not yet recruiting|December 2015|January 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients (either outpatients or inpatients) with clinically suspected        Pulmonary Embolism.|December 2015|December 18, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483442||18193|
NCT02493556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38076514.0.0000.5345|Effect of Low-level Laser Therapy on Exercise-induced Muscle Damage|Effect of Low-level Laser Therapy on Exercise-induced Muscle Damage: a Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Completed|June 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|October 13, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493556||17418|
NCT02474901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1752|Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults|Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults|QLAIV|University of Colorado, Denver|Yes|Active, not recruiting|July 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|110|||Both|2 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474901||18850|
NCT02487589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2010-2310662|Falls in Elderly and Telehealth: a Multidisciplinary Feasibility and Cost-effectiveness Study|Feasibility and Cost-effectiveness of a Multidisciplinary Home-telehealth Intervention Programme to Reduce Falls Among Elderly Discharged From Hospital: a Pilot Randomized Controlled Trial||Fondazione Salvatore Maugeri|No|Active, not recruiting|May 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|290|||Both|65 Years|N/A|No|||January 2016|February 5, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02487589||17875|
NCT02490124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17099|The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans|The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans|EJB046|University of Virginia|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|7|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 Diabetes Healthy Controls|January 2016|January 12, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490124||17682|
NCT02479308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-213|A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers|The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers||Alkermes, Inc.|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479308||18511|
NCT02474966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3403/23.10.14|Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study|Effects of Deep Transcranial Magnetic Stimulation on the Permeability of the Blood-brain Barrier in Patients With Glioblastoma Multiforme: a Pilot Study||University of Roma La Sapienza|Yes|Completed|November 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474966||18845|
NCT02474979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN2014/529|Reduced Pressure for Less Pressure Ulcers|Reduced Pressure for Less Pressure Ulcers. Effect of the CBPM-system in a Swedish University Hospital||Uppsala University|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|190|||Both|50 Years|N/A|No|||March 2016|March 11, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02474979||18844|
NCT02475759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU 015|Nutritional Prehabilitation Program and Cardiac Surgery Outcome in Pediatrics|Nutritional Prehabilitation Program and Cardiac Surgery Outcome in Pediatrics. A Randomized Controlled Trial||Ain Shams University|Yes|Completed|February 2014|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||June 2015|June 16, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475759||18784|
NCT02423330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14072904|A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula|A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula||Rush University Medical Center|Yes|Recruiting|March 2015|||March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|22 Years|N/A|No|||April 2015|April 17, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423330||22810|
NCT02423343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15702|A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma|A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer, Hepatocellular Carcinoma, or Glioblastoma (Phase 2)||Eli Lilly and Company|No|Recruiting|October 2015|March 2019|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423343||22809|
NCT02465190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatFluVaccSA_v2_11/03/2015|Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa|Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa||National Institute for Communicable Diseases, South Africa|No|Not yet recruiting|June 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|175|Samples With DNA|Nasopharyngeal swabs and aspirates|Both|N/A|N/A|No|Probability Sample|The study will be conducted in Gauteng Province and Western Cape Province in South Africa.        Both are urban areas with good access to hospital care for mothers and infants. Babies        born to women who were eligible to receive influenza vaccination during pregnancy (i.e.        pregnant from April onwards but actual date will be determined based on actual campaign        dates and resident in the area where vaccination was offered) will be the study        population. Investigators will conduct surveillance for hospitalisations amongst infants        <6 months of age. Investigators will conduct surveillance for adverse birth outcomes at        identified hospitals. Investigators will conduct surveillance for LRTI hospitalisations        among pregnant and postpartum women.|June 2015|June 3, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02465190|1 Day|19597|
NCT02469298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201682|Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682)||GlaxoSmithKline|No|Recruiting|June 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|64 Years|No|||October 2015|October 15, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02469298||19281|
NCT02463305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3054|Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)|Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)||University of Colorado, Denver|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463305||19742|
NCT02463318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-01-30-17019|The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects|||Tehran University of Medical Sciences|Yes|Recruiting|September 2012|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|34|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463318||19741|
NCT02467504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hrIL-2 RA|Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis|A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-Naive Patients With Rheumatoid Arthritis||Peking University People's Hospital|Yes|Recruiting|July 2015|June 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2015|November 10, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467504||19419|
NCT02467517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0235|Ketamine and Neuropathic Pain|Ketamine and Neuropathic Pain|KETAPAIN|University Hospital, Clermont-Ferrand||Not yet recruiting|June 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02467517||19418|
NCT02414360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487776|Using a Systematic Review in Clinical Decision Making: a Pilot Parallel, Randomized Controlled Trial|Using a Systematic Review in Clinical Decision Making: a Pilot Parallel, Randomized Controlled Trial||University of Toronto|No|Completed|July 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|56|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02414360||23499|
NCT02469870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH102845-02|ASD Parent Trainer: Online Coaching for Parents of Children With Autism||APT|IRIS Media Inc|No|Not yet recruiting|November 2016|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469870||19237|
NCT02470156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55195|Coalition for a Healthier Community—Utah Women and Girls - Phase II (UWAG-II)|Coalition for a Healthier Community—Utah Women and Girls - Phase II|UWAG-II|University of Utah|No|Active, not recruiting|May 2012|May 2019|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|August 8, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02470156||19215|
NCT02477371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20130050|Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial|Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial|FARGO|Odense University Hospital|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02477371||18660|
NCT02474160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00863|Collection and Storage of Tissue and Blood Samples From Patients With Cancer|Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)||National Cancer Institute (NCI)||Recruiting|May 2015|||May 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample||November 2015|March 22, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02474160||18907|
NCT02425423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-01-SONAR|Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula||SONAR|United Pharmaceuticals|No|Completed|June 2013|June 2014|Actual|March 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|5 Months|No|||April 2015|April 23, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02425423||22649|
NCT02425436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tibonina/ IUGR|Role of Ginkgo Biloba Extract in IUGR|Effects of Oral Ginkgo Biloba Extract on Pregnancy Complicated by Asymmetrically Intrauterine Growth Restriction: a Double-blinded Randomized Placebo-controlled Trial||Assiut University|No|Completed|May 2014|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Female|20 Years|35 Years|No|||March 2016|March 20, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02425436||22648|
NCT02472379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN|Writing About Experiences and Health in Older Adults|Writing About Experiences and Health in Older Adults||University of California, Los Angeles||Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|70|||Female|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472379||19044|
NCT02472067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-01166|Psychologically-Based Physical Therapy Treatment for Deployed U.S. Sailors and Marines With Musculoskeletal Injuries|A Pilot Study to Test the Efficacy of Psychologically-Based Physical Therapy Training for Treating Deployed U.S. Sailors and Marines With Musculoskeletal Injuries||New York University School of Medicine|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|600|||Both|N/A|N/A|No|||November 2015|November 5, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02472067||19068|
NCT02472262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG1|The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 6-11 Months|Randomized, Single-blinded, Prospective Clinical Trials Comparing the Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction and Stunting in Rural Malawian Children 6-11 Months||Washington University School of Medicine|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|5 Months|12 Months|Accepts Healthy Volunteers|||December 2015|December 17, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02472262||19053|
NCT02419833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440/VII/1|Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients|Randomized Study of ImmeDiate Versus DeLayEd Invasive Intervention in Patients With Non ST-segment Elevation Myocardial Infarction|RIDDLE-NSTEMI|Clinical Centre of Serbia|Yes|Active, not recruiting|September 2009|February 2018|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02419833||23079|
NCT02418286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-102|Korean Medicine Registry for Low Back Pain-prospective Observational Multicenter Study (KLOS)|Korean Medicine Registry for Low Back Pain-prospective Observational Multicenter Study (KLOS)|KLOS|Gachon University Gil Medical Center|No|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with low back pain who are visiting oriental rehabiliation clinic|April 2015|April 15, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418286|3 Months|23197|
NCT02470377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003-01|Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome|Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome||Laureate Institute for Brain Research, Inc.|No|Recruiting|January 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02470377||19198|
NCT02468271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/L011263/1|Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK|Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK||Queen's University, Belfast|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood plasma and sputum specimens|Both|18 Years|100 Years|No|Non-Probability Sample|Patients with bronchiectasis|October 2015|October 6, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468271||19360|
NCT02475005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44HD066920-03A1|An Intervention to Improve Adolescent Headache Self-management|An Intervention to Improve Adolescent Headache Self-management|TH|Inflexxion, Inc.||Not yet recruiting|May 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|13 Years|17 Years|No|||March 2016|March 8, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02475005||18842|
NCT02424968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT288|CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma|Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidative Therapy After Non-myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Leukemia and Lymphoma||Stanford University|Yes|Recruiting|June 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|February 1, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424968||22684|
NCT02466568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18147|Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung|A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung||H. Lee Moffitt Cancer Center and Research Institute|No|Not yet recruiting|May 2016|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466568||19491|
NCT02492607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1401|Management of Low-risk DCIS|Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Randomized, Multicentre, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance|LORD|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|December 2015|December 2029|Anticipated|December 2029|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1240|||Female|45 Years|N/A|No|||October 2015|October 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02492607||17491|
NCT02492620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05D|Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D|A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D|05D|Denver Nephrologists, P.C.|No|Recruiting|March 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02492620||17490|
NCT02466724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02390|Study on the Impact of Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy|Randomized Prospective Study on the Impact of the Patient Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy||University of British Columbia|No|Active, not recruiting|February 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|450|||Both|19 Years|N/A|No|||February 2016|February 1, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02466724||19479|
NCT02488252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-CM-1|Semi-structured Chinese Medicine Treatment as an Adjuvant Therapy to the Management of Diabetic Nephropathy|Semi-structured Chinese Medicine Treatment as an Adjuvant Therapy to the Management of Diabetic Nephropathy - A Pilot Comparative Clinical Trial||The University of Hong Kong|Yes|Not yet recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|35 Years|N/A|No|||June 2015|June 29, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488252||17824|
NCT02488421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-371|Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany and the UK: REACT-AF2|Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany and the UK: REACT-AF 2|REACT-AF2|Bristol-Myers Squibb|No|Active, not recruiting|June 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|38122|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|March 2016|March 1, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02488421||17811|
NCT02488941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metabolic liver function NAFLD|Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease|Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease||University of Aarhus|No|Recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Liver biopsy Blood : serum and plasma|Both|18 Years|N/A|No|Probability Sample|Patients with varying degrees of NAFLD|June 2015|June 30, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02488941||17772|
NCT02493686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR_16_09_2014|Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects|Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects||University of Zurich|Yes|Completed|September 2014|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1093|||Both|20 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons which have a normal hearing threshold level in the airconduction.|November 2015|November 2, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493686||17408|
NCT02489188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-139|Gait Asymmetry Assessed Using Portable Gait Analysis System|Gait Asymmetry in Orthopaedic Conditions of the Lower Extremity Assessed Using Portable and Laboratory Based Systems: Cross-sectional Observational Single-centre Pilot Study|Asymmetry|University Hospital, Basel, Switzerland|No|Recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from patients visiting the outpatient clinic or are scheduled        for arthroplasty or LSS decompression at the University Hospital Basel and from the        surrounding community.|January 2016|January 19, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02489188||17753|
NCT02475265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000463|Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa|Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa|1180|Massachusetts General Hospital|No|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|30 Years|50 Years|No|||December 2015|December 10, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02475265||18822|
NCT02475278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-210|Serologic Assay Validation, Proficiency Testing Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine|Phase II, Single Arm, Open Label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine||Takeda|Yes|Completed|February 2015|September 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475278||18821|
NCT02490553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_32/1003|Epidemiological Study on the Relationship Between Respiratory Health and Air Pollution From Industrial Sources|ELISABET : Enquête LIttoral Souffle Air Biologie Environnement|ELISABET|University Hospital, Lille|No|Completed|January 2011|February 2014|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|3276|Samples With DNA|-  A 2 ml aliquot of heparinized plasma stored at -20 ° C        -  Five 0.5 ml aliquots of EDTA plasma stored at -80 ° C        -  Two 1-ml aliquots of EDTA blood stored at -80 ° C        -  An aliquot of 10 ml and three aliquots of 5 ml of urine stored at -80 ° C        -  Two locks of hair preserved in an envelope at room temperature        -  Six 0.250 ml aliquots of condensate stored at -80 ° C        -  DNA extraction.|Both|40 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|The participants were selected from electoral rolls by random sampling, with        stratification for gender, age and centercentre (Lille or Dunkirk). All participants were        all recruited between January 2011 and November 2013. Each selected participant received a        letter asking him/her to contact the coordinating team and make an appointment for data        collection. In the absence of a reply, participants were contacted by telephone. Data was        collected at home (occasionally during a consultation in a healthcare establishment). In        all cases, a trained, registered nurse administered a detailed questionnaire and performed        spirometry testing.|July 2015|July 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490553||17649|
NCT02488681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micra CA|Micra Transcatheter Pacing System Continued Access Study Protocol|Medtronic Micra Transcatheter Pacing System Continued Access Study||Medtronic|No|Recruiting|June 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488681||17791|
NCT02481154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG881-C-002|Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation|A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation||Agios Pharmaceuticals, Inc.||Recruiting|June 2015|October 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|February 10, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481154||18369|
NCT02481167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZ-ZYY-DRYEYE|Evaluation of Meibomian Gland Dysfunction in Chinese Old Patients|||Wenzhou Medical University||Recruiting|January 2015|January 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|40 Years|80 Years|No|Probability Sample|This study was consisted of patients with older than 40 years of age who complained with        dry eye. The institutional review board of Wenzhou Medical College approved the study        protocol, and all patients provided their informed consent.|June 2015|June 24, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481167||18368|
NCT02467257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlNeelainU|Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia|Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients||Al-Neelain University|No|Completed|April 2014|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|5 Years|50 Years|No|||June 2015|June 5, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467257||19438|
NCT02467270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-14-203|Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses|A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses|OPTIC|Ariad Pharmaceuticals|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|January 7, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467270||19437|
NCT02486380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-162|Simplus and Eson Evaluation in Obesity Hypoventilation Syndrome (NZ)|Simplus and Eson Evaluation in Obesity Hypoventilation Syndrome (NZ)||Fisher and Paykel Healthcare|Yes|Enrolling by invitation|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486380||17968|
NCT02486393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR/Helsinki/ORL/|Complications in Parotid Surgery|Complications in Parotid Surgery - a Prospective Cohort Study||Helsinki University Central Hospital|No|Completed|November 2011|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|178|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent parotid surgery at the Department of Otorhinolaryngology - Head and        Neck Surgery, Helsinki University Hospital, Helsinki, Finland, between September 2011 and        November 2012 were prospectively enrolled|June 2015|June 28, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02486393||17967|
NCT02493504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHBMU-001124|Effects of Heparin on Arteriovenous Fistula Patency|Effects of Heparin on Early Patency of Arteriovenous Fistula in Angioaccess Surgery of Patients With End-Stage Renal Disease||hahid Beheshti University of Medical Sciences|No|Completed|January 2011|January 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|N/A|N/A|No|||July 2015|July 7, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493504||17422|
NCT02481622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-15|First Event of Infection by HIV-1 of Uterine Vaginal Tissue|Inhibition by the Antibody, First Event of Infection by HIV-1 of Uterine Vaginal Tissue||University Hospital, Strasbourg, France|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|600|||Female|18 Years|50 Years|No|Probability Sample|Women whose age ≤50 years and ≥18 years, for which surgery type laparoscopy or        hysterectomy is necessary as part of a benign pathology.|June 2015|June 24, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02481622||18333|
NCT02485483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29326|Validation of Standardized Questionnaires on Depression for Rheumatoid Arthritis (RA) (VADERA I) and Investigation of the Frequency of Depression in RA (VADERA II)|||Hoffmann-La Roche||Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1004|||Both|18 Years|N/A|No|Non-Probability Sample|Study population included participants 18 years or older with RA.|September 2015|September 9, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485483||18036|
NCT02463656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2127|Growth Arrest in Focal Dermal Hypoplasia|||University of Colorado, Denver||Enrolling by invitation|July 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|3 Years|18 Years|No|Non-Probability Sample|Children with focal dermal hypoplasia|January 2016|January 5, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463656||19715|
NCT02484170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01260|Mannitol Cream for Post Herpetic Neuralgia|Mannitol Cream in the Treatment of Post-herpeticNeuralgia;a Randomized Placebo-Controlled Crossover Pilot Study|MannitolPHN|University of British Columbia|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|No|||November 2015|November 9, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02484170||18137|
NCT02484183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055734|CPAP Improving Mortality for Pneumonia in African Children Trial|Effectiveness of Bubble Continuous Positive Airway Pressure (CPAP) in Reducing Childhood Pneumonia Mortality in Malawi|IMPACT|Johns Hopkins University|Yes|Recruiting|June 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1210|||Both|1 Month|59 Months|No|||February 2016|February 22, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484183||18136|
NCT02490462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUBahia060278|Impact of an Education Program for Parents of Children With Cerebral Palsy|Impact of Physical Therapy Associated With a Program of Education of Caregivers in Functioning and Quality of Life of Children With Cerebral Palsy||Federal University of Bahia|No|Recruiting|May 2015|August 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Months|12 Years|No|||February 2016|February 4, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02490462||17656|
NCT02480920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASTurkey|Adherence to New Oral Anticoagulation Therapy in Turkey|Drug Adherence in Patients Taking New Oral Anticoagulation Therapy in Turkey|NOAC-TR|Cardiovascular Academy Society, Turkey|No|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Outpatients using a NOAC for at least 3 months duration, with a primary diagnosis of        new-onset, non-valvular atrial fibrillation|July 2015|July 1, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02480920||18387|
NCT02480933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentroHLO|Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens|Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens|SISYPHUS|Centro Hospitalar Lisboa Ocidental|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|768|||Both|40 Years|N/A|No|||November 2015|November 27, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02480933||18386|
NCT02484430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01000|TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia|A Phase 2 Study of MLN0128 in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)|Yes|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||July 2015|February 15, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484430||18117|
NCT02487056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JournayHF-TR|Patient Journey in Hospital With Heart Failure in Turkish Population|A Multicentre, Prospective, Observational, Hospital-based Registry of Patients With Acute Heart Failure Those Whose Care Was Guided by a Cardiologist in Turkey|JournayHF-TR|Ege University|No|Recruiting|September 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Hospitalized patients with acute heart failure|September 2015|September 7, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02487056||17916|
NCT02476422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAT458M2402|A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain|A Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Tolerability of 50 mg Diclofenac Potassium Soft Gelatin Capsules Compared With 400 mg Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain||Novartis|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476422||18733|
NCT02480738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035434|Effectiveness of Computerized Cognitive Training in the Elderly With Cognitive Impairment|Effectiveness of Computerized Cognitive Training Apparatus (CoCoTA) in the Elderly With Normal Cognition, Subjective Cognitive Impairment, Mild Cognitive Impairment|CoCoTA|Seoul National University Bundang Hospital|No|Active, not recruiting|June 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|51 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480738||18401|
NCT02482961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-128|Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection|Prospective Observational Study, Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection||DongGuk University|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients (aged ≥18 years)had Microbiological evidence (sputum, urine, blood) of        infection due to carbapenem-resistant Acinetobacter baumannii result during the study        period at Dongguk University Ilsan Hospital|June 2015|June 23, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02482961||18230|
NCT02494180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR-15-021(83-22)|A Non-inferiority Trial on Pain Relief During Oocyte Retrieval|A Prospective, Non-inferiority Randomized Double-blinded Trial Comparing Fentanyl and Midazolam vs Diazepam and Pethidine for Pain Relief During Oocyte Retrieval||Kwong Wah Hospital|No|Not yet recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|170|||Female|18 Years|40 Years|No|||July 2015|July 20, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02494180||17370|
NCT02494193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC|Indirect Pulp Capping With Resin Modified Glass Ionomer|Indirect Pulp Capping With Resin Modified Glass Ionomer: a Randomized Controled Clinical Trial||Universidade Federal de Sergipe|No|Recruiting|June 2015|July 2017|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|112|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02494193||17369|
NCT02465138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16365|A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis|A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis||University of California, San Francisco|No|Not yet recruiting|April 2016|August 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|85 Years|No|||January 2016|January 19, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02465138||19601|
NCT02484937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14100602|Improving Outcomes and Lowering Costs by Integration of Primary Care Providers and Pain Medicine Physicians for Pain Pts|Improving Functional Outcomes and Lowering Health Care Costs by Enhanced Integration of Primary Care Providers and Pain Medicine Physicians for Chronic Non-cancer Pain Patients||Rush University Medical Center|No|Recruiting|January 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02484937||18078|
NCT02494258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-GEN-001|A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.|A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hematological Disorders||Celgene|No|Recruiting|October 2015|December 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494258||17364|
NCT02480075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB010|Observational Study Linking Genetic Variants With Clinical Outcomes in Pain Management|Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Associations With Pain Management Outcomes|TROJAN|Proove Bioscience, Inc.|No|Not yet recruiting|August 2015|August 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be adult patients seeking treatment at the Pain Clinic at the University of        Southern California, Keck School of Medicine, in Los Angeles. Patients will have a chronic        pain diagnosis and are receiving routine medical visits for their care. Treatment includes        pharmacological, non-pharmacological treatment, interventional or infusion procedures,        including ketamine infusion.|June 2015|June 25, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02480075||18452|
NCT02491307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1059|Ginger.io Behavioral Health Study|Ginger.io Behavioral Health Study||Community Health Center, Inc.|No|Terminated|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|December 4, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491307||17591|
NCT02491320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSAPct|The Clinical Trial of Acupuncture Pre-treatment on PCOS|Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome|PCOSAPct|The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|August 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Female|20 Years|40 Years|No|||February 2016|February 14, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491320||17590|
NCT02477163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSAM/IECHR/13-14/362-2|Ayurvedic Management of Chronic Kidney Disease|An Observational Clinical Study to Determine the Effect of Multi-modal Ayurvedic Treatment in the Patients of Chronic Kidney Disease||J.S. Ayurveda College|Yes|Recruiting|January 2014|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be selected from the out-patient and in-patient department of the P D Patel        Ayurveda Hospital, Nadiad, India where the patients came from every corner of the India.|February 2016|February 23, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02477163||18676|
NCT02477176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US CONTROL-001|Lumbar Discectomy Control Study, Risk Factors for Reherniation|A Prospective, Multicenter Study Investigating Reherniation Risk Factors and Associated Costs in Primary Lumbar Disc Herniation Patients||Intrinsic Therapeutics|Yes|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|21 Years|75 Years|No|Probability Sample|Patients diagnosed with single level, symptomatic lumbar disc herniation|January 2016|January 28, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02477176||18675|
NCT02488291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPMCH|Effect of Sufentanil and Ropivacaine|Effect of 0.5µg/ml Sufentanil and Ropivacaine Towards Pregnant Women and Fetus in Analgesia Labor||Fudan University|Yes|Completed|April 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|25 Years|35 Years|No|||June 2015|June 30, 2015|June 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488291||17821|
NCT02488304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2015-141|Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)|Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)||FLUIDDA nv|No|Recruiting|July 2015|July 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488304||17820|
NCT02492009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS project ID 166207|Patient Decision Aid for Antidepressant Use in Pregnancy|Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy: a Pilot RCT||King's College London|No|Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02492009||17537|
NCT02475070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350A|Vildagliptin Versus Dapagliflozin on Glucagon|Study of Ther Effect of Vildagliptin Versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects With Type 2 Diabetes||Lund University|No|Recruiting|January 2016|March 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Both|20 Years|70 Years|No|||June 2015|March 1, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475070||18837|
NCT02462902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis with sepsis-01|Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension|Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension||Institute of Liver and Biliary Sciences, India|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|70 Years|No|||May 2015|December 29, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02462902||19772|
NCT02482402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG 43|Iloprost for Bridging to Heart Transplantation in PH|Iloprost for Bridging to Heart Transplantation in Patients With Pulmonary Hypertension and Left Heart Failure A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial|BRIDGE|Heidelberg University|Yes|Withdrawn|February 2015|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 31, 2014||No|Delay in recruitment|No||https://clinicaltrials.gov/show/NCT02482402||18273|
NCT02482415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130121|Effects of a Psycho-educational Intervention for Family Caregivers in Palliative Care|||Ersta Sköndal University College||Active, not recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|270|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482415||18272|
NCT02492087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-14-1034-20129|Topical Tranexamic Acid in Caesarean Section|Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding|TXACS|Ministry of Health, Malaysia|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|84|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02492087||17531|
NCT02474836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-STD-003|Determination of Biological Activity of Three Allergen Extracts|Biological Standardization of Artemisia Vulgaris and/or Platanus Acerifolia Pollen Extract and Dermatophagoides Farinae Mite Extract in Patients Sensitized to Them||BIAL Industrial Farmacéutica S.A.|No|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|176|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|September 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02474836||18855|
NCT02474849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAT4215006|Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects|A Pharmacokinetic Study to Compare Nicotine Delivery From e Cigarettes and a Conventional Cigarette in Healthy Subjects During a Brief Period of ad Libitum Use||British American Tobacco (Investments) Limited|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|18|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474849||18854|
NCT02488447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-ALE-2014-01|Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis|Prospective Study for Evaluating Life Quality and Its Determinant Factors as Treatment Adherence and Immunotherapy Satisfaction in Patients With Rhinoconjunctivitis With or Without Asthma, Sensitized at Least to One Aeroallergen|ÍCARA|BIAL Industrial Farmacéutica S.A.|No|Recruiting|May 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|589|||Both|12 Years|N/A|No|Non-Probability Sample|Patients affected by Rhinoconjunctivitis with or without asthma|February 2016|February 26, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02488447|1 Year|17809|
NCT02494414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR12068|Outcome of Cardiac Arrest Survivors|Outcome of Cardiac Arrest Survivors: Prospective Cohort of Ile-de-France|DESAC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be prospectively included if they are discharged alive from intensive care        after being resuscitated from a cardiac arrest|October 2015|October 13, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02494414||17352|
NCT02479581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liman20150516|The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass|The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study|ERAS|Xiangya Hospital of Central South University|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|226|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02479581||18490|
NCT02475824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DankookU|Midazolam With Meperidine and Dexmedetomidine vs. Midazolam With Meperidine and Propofol for Sedation During ERCP|A Randomized Comparison of Midazolam With Meperidine and Dexmedetomidine Versus Midazolam With Meperidine and Propofol for Sedation During ERCP||Dankook University|Yes|Recruiting|May 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02475824||18779|
NCT02479763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-077 MUHC|A Comparison Between Conventional and Waveform-Confirmed Loss-of-Resistance for Thoracic Epidural Blocks|A Randomized Comparison Between Conventional and Waveform-Confirmed Loss-of-Resistance for Thoracic Epidural Blocks||Montreal General Hospital|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|80 Years|No|||January 2016|January 23, 2016|June 22, 2015||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT02479763||18476|
NCT02483494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014\00793|Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions|Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions and Health Related Outcomes Amongst Patients Post Acute Myocardial Infarction: ALTRA Study|ALTRA|National University Heart Centre, Singapore|No|Not yet recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|21 Years|85 Years|No|||June 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02483494||18189|
NCT02483507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9420|Ultrasound-guided Peripheral Vascular Access: What Approaches in Paediatrics?|Ultrasound-guided Peripheral Vascular Access: What Approaches in Paediatrics?||University Hospital, Montpellier|Yes|Recruiting|May 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|300|||Both|N/A|18 Years|No|||June 2015|June 26, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02483507||18188|
NCT02461628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063384|Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2)|Innovative Partnership to Target Antimalarial Subsidies in the Retail Sector||Duke University|No|Recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|95220|||Both|1 Year|N/A|Accepts Healthy Volunteers|||June 2015|July 27, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461628||19870|
NCT02461797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|biopsystudy|Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients|Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients||Universitaire Ziekenhuizen Leuven|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|May 29, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461797||19857|
NCT02461810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKOS - EU2014-05|Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques|A Prospective, Multicenter, Randomized, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp|SAKOS|Vexim SA|Yes|Recruiting|April 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|50 Years|N/A|No|||December 2015|December 8, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461810||19856|
NCT02412267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC1001|Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)|An Open-label, Non-randomized Phase 2 Study of Ofatumomab (O) in Combination With ICE (Ifosfamide, Carboplatin, Etoposide)-Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|DLBL|National Cancer Centre, Singapore|No|Completed|April 2011|March 2016|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02412267||23660|
NCT02412280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6|Validity of Different Prognostic Models Assessing 1 Year Survival After Liver Transplantation||ProgModels|Mansoura University|Yes|Completed|April 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|200|||Both|20 Years|60 Years|No|Non-Probability Sample|liver failure|April 2015|April 6, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412280||23659|
NCT02471989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/02|FODMAPs and Refractory GERD|Randomized Controlled Study of Low-FODMAP Diet in Patients With GERD Refractory to Protons Pump Inhibitors|EFFORR|University Hospital, Bordeaux|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471989||19074|
NCT02467439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCPM 21414|Acute Partner and Social Contact Referral: iKnow|Acute Partner and Social Contact Referral: iKnow||University of North Carolina, Chapel Hill|No|Recruiting|June 2015|June 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5975|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02467439||19424|
NCT02467452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-07|Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)|A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|No|Recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1630|||Both|40 Years|N/A|No|||June 2015|June 16, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02467452||19423|
NCT02473029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEL_2014_01|Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease||HORTIM|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|December 2014|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Fondation Ophtalmologique Adolphe de Rothschild with a suspected        Horton disease|December 2015|December 30, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473029||18994|
NCT02473042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0170|Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)|Intraoperative Electrical Stimulation of the Acupoint P6 to Prevent Post-Operative Nausea and Vomiting in Women Undergoing Breast Cancer Surgery||M.D. Anderson Cancer Center|Yes|Recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|176|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473042||18993|
NCT02417753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150112|AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites|A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|99 Years|No|||February 2016|March 8, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417753||23238|
NCT02417766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150113|NIAID Clinical Center Genomics Opportunity Protocol|NIAID Clinical Center Genomics Opportunity Protocol||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2015|June 2020|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|58|||Both|N/A|100 Years|No|||February 2016|March 10, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02417766||23237|
NCT02472613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407001-6B|Acupuncture for Ischemic Post-stroke Depression|Comparison of Acupuncture and Fluoxetine for of Ischemic Post-stroke Depression：A Multicentre Randomized Controlled Trial||The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|208|||Both|45 Years|80 Years|No|||February 2016|February 3, 2016|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472613||19026|
NCT02463539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 15001|Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis|Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1||Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients followed for Anti-neutrophil cytoplasmic antibody (ANCA)-associated Vasculitis|December 2015|February 24, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02463539||19724|
NCT02467712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-67|Fungal Infection on a Joint Prosthesis|Change in Joint Prosthesis in One Step Due to Fungal Infection||University Hospital, Strasbourg, France|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|4|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 years having surgery for the management of fungal infection after change        in one step in joint replacement prothesis in the participating services in 2014.|June 2015|June 7, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02467712||19403|
NCT02474875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI14 / 008|Explain Pain in Fibromyalgia Patients|Explain Pain in Fibromyalgia Patients||Cardenal Herrera University|No|Completed|June 2013|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02474875||18852|
NCT02419534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/4293|Pediatrics Anal Fissures Treatment With Polyethylene Glycol|Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal ﬁssure in Children||King Saud University|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|N/A|13 Years|No|||February 2016|February 27, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02419534||23102|
NCT02414607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211953|Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment|Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment||University of Missouri-Columbia|No|Not yet recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||November 2015|November 30, 2015|March 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414607||23480|
NCT02462161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026106|Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart|Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart|SNIFF-Quick|Wake Forest School of Medicine|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|89 Years|No|||June 2015|June 2, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462161||19829|
NCT02476539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemay022-002|Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer|An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer||Tianjin Hemay Pharmaceutical Co.,Ltd|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476539||18724|
NCT02476552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-30-5015-C|Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer|Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer||Tesaro, Inc.|No|Recruiting|February 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476552||18723|
NCT02423174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMW-IT-02|Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery|Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery||Domain Surgical, Inc.|No|Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with an indication for surgical intervention for a total mesorectal excision|April 2015|April 21, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423174||22822|
NCT02424903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJI04/2014|European Prosthetic Joint Infection Cohort Study- Hip, Knee and Shoulder Prosthetic Joint Infection|European Prosthetic Joint Infection Cohort Study (EPJIC): Evaluation of the Treatment Approach for Hip, Knee and Shoulder Prosthetic Joint Revision Surgery|EPJIC|Pro-Implant Foundation|No|Not yet recruiting|May 2015|December 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to hospital|April 2015|April 20, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02424903||22689|
NCT02424916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0261|Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study|Adoptive Transfer of CD8+ T Cells, Sorted With HLA-peptide Multimers and Specific for Melan-A and MELOE-1 Melanoma Antigens, to Metastatic Melanoma Patients. A Phase I/II, Non-randomized, Open Monocentric Study|MelSort|Nantes University Hospital|Yes|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|75 Years|No|||June 2015|June 9, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02424916||22688|
NCT02473211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_SOF plus DCV treatment|SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients|Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection||Humanity & Healthy GI and Liver Centre|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473211||18980|
NCT02472470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 076/2014-01|Efficacy and Biological Targets of Response to rTMS Therapy in Youth Depression|Efficacy and Biological Targets of Response to rTMS Therapy in Youth Depression||Centre for Addiction and Mental Health|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|24 Years|No|||December 2015|December 17, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472470||19037|
NCT02476578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023-15-COM|Low Indexes of Metabolism - Information to Teams (LIMIT)|Sending Advisory Electronic Mail to Primary Care Staff, Addressing Low Metabolic Measures: Assessing the Health Outcomes for Patients Above Age 75|LIMIT|Clalit Health Services|No|Active, not recruiting|October 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8584|||Both|75 Years|N/A|No|||December 2015|December 5, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476578||18721|
NCT02421016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No S03914|Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)|A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus ABSORB Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)||Deutsches Herzzentrum Muenchen|No|Recruiting|May 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||April 2015|June 1, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02421016||22988|
NCT02426203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02016|3D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary Endarterectomy|Three-dimensional Echocardiographic Assessment of Right Ventricular Function in Patients Undergoing Pulmonary Endarterectomy||Papworth Hospital NHS Foundation Trust|No|Not yet recruiting|May 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic thromboembolic pulmonary hypertension who are undergoing pulmonary        endarterectomy surgery|April 2015|April 27, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426203||22589|
NCT02471092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14JN004|The Effect of Milk Proteins on Satiety, Food Intake and Metabolic Control (Glycemia) in Early Adulthood|The Effect of Milk Proteins on Satiety, Food Intake and Metabolic Control (Glycemia) in Early Adulthood||University of Guelph|No|Active, not recruiting|November 2014|September 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|32|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02471092||19143|
NCT02480608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68|Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)|Treatment of CML Patients With Imatinib and Hydroxyurea|CML2004|University of Leipzig|Yes|Completed|April 2004|May 2013|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02480608||18411|
NCT02472808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM Thesis|A Trial to Compare Two Methods of Obtaining Tissue for Diagnosis of Sarcoidosis Namely the Conventional Method or the Ultrasound Guided Method|Diagnostic Utility of EBUS-TBNA Versus Conventional TBNA With Rapid on Site Evaluation in the Diagnosis of Sarcoidosis: a Randomised Study||All India Institute of Medical Sciences, New Delhi|No|Recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|80|||Both|18 Years|90 Years|No|||June 2015|July 6, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02472808||19011|
NCT02490332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-112556|The Effects of Ventilation Tubes - The SIUTIT Trial|The Effects of Ventilation Tubes Versus no Ventilation Tubes for Recurrent Acute Otitis Media or Chronic Otitis Media With Effusion in 9 to 36 Month Old Greenlandic Children - a Randomised Clinical Trial|SIUTIT|Roskilde County Hospital|Yes|Recruiting|February 2016|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|230|||Both|9 Months|36 Months|No|||February 2016|February 14, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02490332||17666|
NCT02493699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/02/2011|Martial Arts Therapy in Autism Spectrum Disorders|The Effect of Karate Techniques Training on Communication Deficit of Children With Autism Spectrum Disorders||University of Isfahan|No|Completed|May 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|5 Years|16 Years|No|||July 2015|July 6, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02493699||17407|
NCT02493738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-ITR-CT-101|A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers|A Phase I Single-Center, Randomized, Open-label, Single Dose, Crossover Study in Korean Healthy Male Volunteers to Evaluate Pharmacokinetics of Lozanoc and Sporanox||Boryung Pharmaceutical Co., Ltd|Yes|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493738||17404|
NCT02490735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCC-CZYY-01|CIK in Treating Patients With Esophageal Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Esophageal Carcinoma||The First People's Hospital of Changzhou|Yes|Not yet recruiting|August 2015|August 2042|Anticipated|August 2040|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|80 Years|No|||July 2015|July 2, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490735||17635|
NCT02463149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRJ49IH|Pilot Evaluation of Youth Chef Academy|Pilot Evaluation of Youth Chef Academy: A Plant-based Cooking Program for Urban Middle School Students|YCA|University of Wisconsin, Milwaukee|No|Completed|August 2011|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|248|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02463149||19753|
NCT02463162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054953|Trial of Advance Care Planning (ACP) & Goals of Care Designations (GCD) Discussions|Effectiveness and Economic Impact of Advance Care Planning and Goals of Care Designations Discussions: A Randomized Controlled Trial||University of Alberta|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|240|||Both|19 Years|N/A|No|||October 2015|March 15, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02463162||19752|
NCT02483117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/02012|Adaptation and Validation of the Clinical Assessment Inventory for Eating Disorders (CIA)|Adaptation and Validation of the Clinical Assessment Inventory (CIA) for Eating Disorders. Assessment of Its Relation With Other Clinical Measures|CIA|Hospital Galdakao-Usansolo|No|Completed|January 2010|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|244|||Both|18 Years|65 Years|No|Probability Sample|We conducted a prospective study of all patients diagnosed with and treated for an ED in        the Eating Disorders Outpatient Clinic of the Psychiatric Services at the        Galdakao-Usansolo Hospital, in Bizkaia, Spain. This institution, which serves a population        of 300,000 inhabitants, is part of the Basque Health Care Service, which provides free,        unrestricted care to nearly 100% of the population. The diagnosis was verified via chart        review. Throughout the 2-year study period, each patient received a psychopharmacologic        and psychotherapeutic treatment program consisting of cognitive-behavioural treatment;        nutritional orientation and counselling; psycho-education; motivational therapy; social        skills training; and therapy to modify distorted perception of body image.        Sample size was calculated according to the recommended 10:1 ratio of the number of        subjects to the number of test items (Kline, 1998). The study was approved by the        institutional review board of Galdakao-Usansolo Hospital.|June 2015|June 23, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02483117||18218|
NCT02493361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15852|Trial of pIL-12/MK-3475 in Metastatic Melanoma|An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation||University of California, San Francisco|Yes|Recruiting|July 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493361||17433|
NCT02481362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK IRB-15-02330-XP|Food Choices in Healthy Weight Women|Food Choices in Healthy Weight Women||University of Tennessee|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481362||18353|
NCT02485236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000716|Postoperative Nasal High Flow Versus Oxygen for Positive Airway Pressure Non-Compliance Sleep Apnea Patients|Randomized Nasal High Flow Therapy Versus Oxygen Supplementation in Postoperative Care of Obstructive Sleep Apnea Patients With Continuous Positive Airway Pressure Non-Compliance||Mayo Clinic|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02485236||18055|
NCT02474381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-xjs-06|Autologous Endothelial Progenitor Cells Treatment of Diabetic Foot|Efficacy Study of Autologous Endothelial Progenitor Cells Treatment of Diabetic Foot With Infrapopliteal Arterial Stenosis/Occlusion||Shanghai 10th People's Hospital|No|Recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2012|June 12, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02474381||18890|
NCT02488837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140225003|Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders|Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing Deep Brain Stimulation for Movement Disorders||University of Alabama at Birmingham|No|Recruiting|June 2014|December 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|19 Years|N/A|No|Probability Sample|Patients who undergo deep brain stimulation as part of routine clinical care for movement        disorders (Parkinson's disease, essential tremor, dystonia, Tourette's syndrome).|February 2016|February 15, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488837||17780|
NCT02488850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL42081.078.12|Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC|Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage Non-small Cell Lung Cancer HAMLET Study|HAMLET|Erasmus Medical Center||Recruiting|December 2012|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488850||17779|
NCT02481635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCAP-GA|A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer|A Phase I/II Study Evaluating the Feasibility and Safety of Neoadjuvant Gemcitabine/Nab-paclitaxel (GA) and Concurrent Gemcitabine and Radiation Therapy Followed By Pancreatic Resection and Major Arterial Resection for Adenocarcinoma of the Pancreas (ARCAP) in Patients With Advanced Disease||University Health Network, Toronto|Yes|Not yet recruiting|July 2015|January 2021|Anticipated|July 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||June 2015|June 23, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481635||18332|
NCT02490319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC002|Study on the Biological Prediction Models of Radiation Pneumonitis|Study on the Biological Prediction Models of Radiation Pneumonitis||Huazhong University of Science and Technology|No|Recruiting|September 2008|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|From peripheral blood|Both|18 Years|80 Years|No|Non-Probability Sample|Lung cancer patients treated with radiation therapy at Tongji Hospital, Huazhong        University of Science and Technology (Wuhan, Hubei Province, China).|July 2015|July 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490319||17667|
NCT02467829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_15-057|Effects of Altering Handle Height of Posterior Walkers|What Are the Effects of Altering Handle Height of Posterior Walkers on Gait Parameters in Children With Spastic Cerebral Palsy?||University of Birmingham|No|Recruiting|January 2016|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Both|5 Years|18 Years|No|||January 2016|January 7, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02467829||19394|
NCT02487537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILIAS-2|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 2|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 2|ILIAS-2|German Institute of Human Nutrition|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02487537||17879|
NCT02478996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSM-01|Internet-based Perioperative Exercise Program in Patients With Barrett's Carcinoma Scheduled for Esophagectomy|Internet-based Perioperative Exercise Program in Patients With Barrett's Carcinoma Scheduled for Esophagectomy (iPEP Study) A Prospective Randomized-controlled Pilot Trial|iPEP|University of Leipzig||Recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|75 Years|No|||October 2015|October 14, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02478996||18535|
NCT02485509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM-1500-001|Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection|Phase Ib/IIa, Single-Centre, Placebo-Controlled Randomized Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection||Viriom|Yes|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02485509||18034|
NCT02468674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338E2202E1|A Randomized Withdrawal Extension Study of Bimagrumab 70, 210, 700 mg in Older Adults With Sarcopenia Previously Participating in the Core Study|A 28 Week Randomized Withdrawal Extension of a Double-blind, Placebo-controlled, Parallel Group Study to Assess Durability of Effect on Skeletal Muscle Strength and Function Upon Withdrawal of Bimagrumab 70, 210, 700 mg in Older Adults With Sarcopenia||Novartis|Yes|Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|240|||Both|70 Years|N/A|No|||March 2016|March 7, 2016|April 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468674||19329|
NCT02468687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/14/MH/159|NMP in Relapsed / Refractory Myeloma|A Phase I, Open Label Dose Escalation Trial of Orally Administered N-methyl-pyrrolidone (NMP) in Patients With Relapsed or Refractory Myeloma||Peter MacCallum Cancer Centre, Australia|Yes|Recruiting|August 2015|February 2019|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02468687||19328|
NCT02487576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG grant KFO218 PF164/16-1|The CLOCK Study - A Human Dietary Intervention Study on Peripheral Circadian Clocks and Energy Metabolism|Interplay of Peripheral Circadian Clocks With Energy Balance and Body Weight Regulation|CLOCK|German Institute of Human Nutrition|No|Completed|January 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|32|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02487576||17876|
NCT02494154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-HDWOBPT|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.|HDWOBPT|Laval University|No|Recruiting|May 2015|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|16|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494154||17372|
NCT02494115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP12|Comfort Subcutaneous Drainage: a Descriptive Study Among Palliative Phase Cancer Patients|Comfort Subcutaneous Drainage: a Descriptive Study Among Palliative Care Cancer Patients Presenting Severe Refractory Lower Limbs Lymphedema||Centre Hospitalier Universitaire de Nice|Yes|Not yet recruiting|July 2015|January 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02494115||17375|
NCT02494128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H152014/397|Early Group Based Parental Support Within Child Health Service - Group Leadership|Early Group Based Parental Support Within Child Health Service - Group Leadership||Lund University|No|Completed|September 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|56|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02494128||17374|
NCT02464904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008715|Intrapleural Cryotherapy for Malignant Pleural Mesothelioma|Pilot Study Evaluating the Effects of Intrapleural Cryotherapy on Tumor Infiltrating Lymphocytes in Malignant Pleural Mesothelioma Using Cryospray Therapy||Mayo Clinic|No|Recruiting|July 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02464904||19619|
NCT02484677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-41|Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy|Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy|5-FU|Assistance Publique Hopitaux De Marseille|No|Recruiting|June 2015|||June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||June 2015|June 29, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02484677||18098|
NCT02487303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041193|Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery|Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery||Medical University of South Carolina|Yes|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|141|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487303||17897|
NCT02491216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC1215-2|A Study on Effects of Acupressure Among the Frail Elderly in Residential Care Services for the Elderly|A Study on Effects of Acupressure Among the Frail Elderly in Homes for the Aged and Care and Attention Homes for the Elderly||The University of Hong Kong|Yes|Active, not recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|65 Years|N/A|No|||December 2015|December 29, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02491216||17598|
NCT02491229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKES HEPA V2.0|"Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)|Clinical Trial for Investigating the Effects of "Hepafast" on Non-alcoholic Fatty Liver Disease (NAFLD)||University of Hohenheim|No|Completed|January 2015|December 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491229||17597|
NCT02469233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH105513|A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes|A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes||University of California, Berkeley|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469233||19286|
NCT02469246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-311-1717|Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC|A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC||Gilead Sciences|Yes|Recruiting|June 2015|June 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469246||19285|
NCT02487680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoubleGood Lund|Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism on Healthy Subjects|Effect of a Table Water Enriched With Amino Acids and Chromium on Blood Glucose and Insulin Levels After a Meal||DoubleGood AB|No|Active, not recruiting|June 2015|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487680||17868|
NCT02487693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ovarian001|Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma|||The First People's Hospital of Changzhou|Yes|Active, not recruiting|July 2015|June 2040|Anticipated|June 2038|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|30 Years|70 Years|No|||February 2016|February 21, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487693||17867|
NCT02480283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1957|Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response|Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response||University of Colorado, Denver|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|100|Samples With DNA|1. Urine        2. Exhaled Breath Condensate        3. Blood/Plasma        4. Bronchial brushings        5. Bronchoalveolar Lavage        6. Oral rinse|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 18 to 55 who have been exposed to chronic cannabis smoking (without a history        of tobacco smoking) and health, non-smoking controls.|December 2015|December 21, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02480283||18436|
NCT02485002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-RIRS-UAS-02|Differences in Urine NGAL Levels in Patients Undergoing RIRS With or Without Ureteral Access Sheath|Differences in Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels in Patients Undergoing Retrograde Intrarenal Surgery (RIRS) With or Without Ureteral Access Sheath (UAS)||Selcuk University|No|Completed|June 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485002||18073|
NCT02481752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-0023|The Effect of AAT Training in Smokers|The Effect of AAT Training in Smokers||University of Texas at Austin|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02481752||18323|
NCT02465749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC20150503|Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa|Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa||Sun Yat-sen University|Yes|Not yet recruiting|May 2015|June 2025|Anticipated|June 2025|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|404|||Both|18 Years|60 Years|No|||June 2015|June 4, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02465749||19554|
NCT02493101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBRTA1168/2556|The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients|Potential of Periostin as a Tissue and Urinary Biomarker in Lupus Nephritis and IgA Nephropathy Patients||Chulalongkorn University|Yes|Completed|April 2013|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|Samples Without DNA|urine and kidney tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients visiting at the Department of Medicine, Phramongkutklao Hospital, Bangkok,        Thailand|July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493101||17453|
NCT02481414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202790|A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions|A Phase II Clinical Trial of PepCan Randomized and Double-Blinded to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions||University of Arkansas|No|Recruiting|October 2015|August 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Female|18 Years|50 Years|No|||December 2015|December 15, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481414||18349|
NCT02463890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508033|Effect of Exercise Training on Obstructive Sleep Apnea Syndrome Severity|Effect of Exercise Training on Obstructive Sleep Apnea Syndrome Severity|EXESAS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|40 Years|80 Years|No|||February 2016|February 19, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02463890||19697|
NCT02464137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052014-085|HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer|A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer|HYDRA|University of Texas Southwestern Medical Center|Yes|Recruiting|April 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|99 Years|No|||February 2016|February 12, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464137||19678|
NCT02483663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38970-D|Brain Regulation of Appetite in Twins|Brain Regulation of Appetite in Twins|BRAT|University of Washington||Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|108|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Monozygotic and dizygotic twins recruited from the University of Washington Twin Registry|November 2015|November 30, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02483663||18176|
NCT02486458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOPBioq005|Long-term Release of Fluoride Formed on Enamel by Fluoride Gel or Varnish to Biofilm Fluid|Retention of Fluoride Formed on Enamel by Fluoride Gel or Varnish Application and Its Release to Dental Biofilm Fluid - in Vivo Study||University of Campinas, Brazil|No|Recruiting|April 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|64|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486458||17962|
NCT02478515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRNNCU001|Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion|Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion.||Nagoya City University|No|Recruiting|January 2014|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||June 2015|June 18, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02478515||18572|
NCT02475681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-007|Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL|A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL||Acerta Pharma BV|Yes|Recruiting|June 2015|||August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|510|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475681||18790|
NCT02475694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20080016|Acute Lung Injury After Cardiac Surgery: Pathogenesis|Acute Lung Injury After Cardiac Surgery: Pathogenesis|ALI|Aalborg Universitetshospital|Yes|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Plasma samples stored at -80 degrees of Celcius|Both|18 Years|90 Years|No|Probability Sample|Patients scheduled for elective coronary artery bypass grafting (CABG)|June 2015|June 16, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02475694||18789|
NCT02475707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37042 STELLA|Administration of Donor MultiTAA-Specific T Cells for ALL|Administration of Donor-Derived Multi-Tumor-Associated Antigen (TAA)-Specific T Cells to Patients With ALL|STELLA|Baylor College of Medicine|Yes|Recruiting|February 2016|March 2023|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|N/A|N/A|No|||February 2016|February 24, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475707||18788|
NCT02491697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ1H-BC-001|Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer|Randomized Controlled Trial Comparing Dendritic Cells Co-cultured With Cytokine-induced Killer Cells Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer||The First People's Hospital of Changzhou|No|Active, not recruiting|February 2016|August 2033|Anticipated|August 2030|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||July 2015|February 21, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491697||17561|
NCT02479529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2014_843_0014|Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.|Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.|SNEAD|Centre Hospitalier Universitaire, Amiens|No|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|70 Years|No|||June 2015|June 23, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02479529||18494|
NCT02479776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CC37|A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure|A Randomized Study of Autologous Bone Marrow Derived Stem Cells in Pediatric Dilated Cardiomyopathy||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Completed|May 2008|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||June 2015|June 23, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02479776||18475|
NCT02484066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201503|VBN-EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs|Diagnostic Value of Virtual Bronchoscopic Navigation (VBN) Combined With Endobronchial Ultrasound (EBUS) With a Guide Sheath (GS) for Peripheral Pulmonary Lesions (PPLs) Without Fluoroscopy: a Randomized Controlled Trial||Shanghai Chest Hospital|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02484066||18145|
NCT02465723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-104|Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers|Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers||Memorial Sloan Kettering Cancer Center||Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465723||19556|
NCT02489656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUDLUIV1201EC|Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study)|Effect of a Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing F-URS for Kidney Stone; a Comparative Randomized Multicenter Clinical Study.||Coloplast A/S|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||May 2015|July 1, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489656||17718|
NCT02483728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14318|Cutaneous and Systemic Reactions to Metal Implants|Cutaneous and Systemic Reactions to Metal Implants: Utility of Patch Testing Prior and Post Placement of Metal Orthopedic Implants||Winthrop University Hospital|No|Recruiting|August 2014|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02483728||18171|
NCT02484001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-311/EXT|Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures: a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study - Open-label ESL Extension||Bial - Portela C S.A.|No|Enrolling by invitation|October 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02484001||18150|
NCT02488239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rally-CRT-P-02-2015|Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)|Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)|Rally CRT-P|Guidant Corporation|No|Recruiting|May 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|62|||Both|18 Years|N/A|No|Non-Probability Sample|Planned to be implanted or replaced with a VISIONIST Ingenio 2 CRT-P device        The Ingenio 2 CRT-Ps are indicated for patients who have symptomatic congestive heart        failure (CHF) including left ventricular (LV) dysfunction and wide QRS, and/or one or more        of the following conditions:        Symptomatic paroxysmal or permanent second- or third-degree atrioventricular (AV) block        Symptomatic bilateral bundle branch block Symptomatic paroxysmal or transient sinus node        dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia,        sinus arrest, sinoatrial [SA] block) Bradycardia-tachycardia syndrome, to prevent        symptomatic bradycardia or some forms of symptomatic tachyarrhythmias Neurovascular        (vaso-vagal) syndromes or hypersensitive carotid sinus syndromes.|June 2015|July 1, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488239||17825|
NCT02465957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-001|Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)|Phase II Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)||NantKwest, Inc.|No|Recruiting|August 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465957||19538|
NCT02465892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061381|Pillars4Life Trial|Pillars4Life Randomized Control Trial|Pillars4Life|Duke University|No|Recruiting|May 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465892||19543|
NCT02417025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034989|Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma|Do You Really Expect Me to Get MST Care in a VA Where Everyone is Male? Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma (MST)||Medical University of South Carolina|Yes|Recruiting|August 2014|July 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|21 Years|N/A|No|||September 2015|October 1, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02417025||23294|
NCT02475395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD001|Study of the Consumer Use of a New Home Test to Measure Sperm Concentration|A Clinical Study Evaluating Consumer Use of a New Device (TRAK) to Measure Sperm Concentration From Human Semen Samples, and Comparing TRAK Test Results With Laboratory Reference Method Testing||Sandstone Diagnostics||Recruiting|May 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|225|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2015|October 8, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475395||18812|
NCT02471690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-15-01|Study to Evaluate the Safety,Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers|A Randomized, Double-Blind, Single Center Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of a Single 1200MG IV Dose of Oritavancin in Healthy Volunteers||The Medicines Company|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471690||19097|
NCT02471703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-132|Clinical Outcome Following Total Hip Arthroplasty With the SMF Stem|Clinical Outcome Following Total Hip Arthroplasty With the SMF Stem|SMF-S&E|Smith & Nephew, Inc.|No|Active, not recruiting|September 2010|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|126|||Both|18 Years|75 Years|No|Probability Sample|Patients requiring total hip replacement.|January 2016|January 4, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471703||19096|
NCT02474810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dialysis Catheter Protcols|Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol|Comparison of an Intensive Versus a Standard Hemodialysis Central Venous Catheter Dysfunction Protocol Using Alteplase||Nova Scotia Health Authority|No|Active, not recruiting|January 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|N/A|N/A|No|||June 2015|June 17, 2015|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474810||18857|
NCT02424305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1077|Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions|Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions||LEO Pharma|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02424305||22735|
NCT02472626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22115|6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients||Comprehensive Cancer Center of Wake Forest University|No|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|60 Years|N/A|No|||October 2015|October 22, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472626||19025|
NCT02471846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29779|A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471846||19085|
NCT02471859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB29751|A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects||Genentech, Inc.||Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471859||19084|
NCT02419547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-P-000241|Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia|Inducibility and Stability of Ventricular Tachycardia in Patients With Structural Heart Disease Undergoing VT Ablation Under General Anesthesia (Pilot Study)||Brigham and Women's Hospital|No|Recruiting|July 2014|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02419547||23101|
NCT02418039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2014-785-007|High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy|Effect of a High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy. Double-blind Clinical Trial||Coordinación de Investigación en Salud, Mexico|No|Not yet recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||April 2015|April 15, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02418039||23216|
NCT02465788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH141302|Combined 755nm Alexandrite Laser With Bipolar RF for Hair Reduction|LASER HAIR REDUCTION BY COMBINED BIPOLAR RF AND 755 nm LASER ENERGIES||Syneron Medical|No|Recruiting|April 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|May 28, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465788||19551|
NCT02466022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U of S BIO 15-76|Dexmedetomidine for Sedation in Total Knee Replacements|Does Single Dose Dexmedetomidine for Procedural Sedation Reduce Post-operative Pain in Total Knee Arthroplasty? A Randomized Control Study||University of Saskatchewan|No|Recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466022||19533|
NCT02465034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081268|Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke|Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke||Emory University|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465034||19609|
NCT02469974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2106|Ruxolitinib in Combination With Autotransplant|Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469974||19229|
NCT02410889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_06-167|EEG-fMRI: Towards a Useful Clinical Tool in Epilepsy|EEG-fMRI: Towards a Useful Clinical Tool in Epilepsy||University of Birmingham||Recruiting|January 2007|||January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|50|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with epilepsy with interictal epileptic discharges evident on scalp EEG.|April 2015|April 2, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02410889||23766|
NCT02426151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-EPCL009|Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects|A Randomized, Open Label, Single-dose 2x2 Crossover Study to Compare Pharmacokinetic, Pharmacodynamic Profiles, and Tolerability of EPO (BEPO-A (4000 IU)) and EPO (REPO-A (4000 IU)) in Healthy Male Subjects||LG Life Sciences|No|Completed|April 2015|September 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||April 2015|March 17, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426151||22593|
NCT02426164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|633913|Liposomal Bupivacaine in Total Knee Arthroplasty|Analgesic Efficacy of Liposomal Bupivacaine in Total Knee Arthroplasty||Miller Orthopedic Specialists||Withdrawn|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||April 2015|March 18, 2016|April 14, 2015|Yes|Yes|Could not receive facility approval|No||https://clinicaltrials.gov/show/NCT02426164||22592|
NCT02476591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150722|Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care|Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care: Physician Awareness of ICU Charge Environment: The PRICE Study|PRICE|Vanderbilt University|No|Enrolling by invitation|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|16 Years|N/A|No|Non-Probability Sample|All patients admitted to the Vanderbilt University Medical Center Cardiovascular,        Surgical, Burn, Medical and Neuroscience ICUs will be included|March 2016|March 21, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476591||18720|
NCT02423252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX 043 - EP1|Effects of a Psycho-cognitive Nursing Intervention on Patients' Outcomes in Critical Illness|The Effects of a Psycho-cognitive Nursing Intervention on Clinical and Psychological Outcomes of Critically Ill Patients: A Randomized Controlled Trial||Cyprus University of Technology|No|Recruiting|March 2015|May 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 17, 2015|March 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02423252||22816|
NCT02418572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.TTRANSPORT|Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial|Transdermal Testosterone Gel for Poor Ovarian Responders. A Multicenter Double-blind Placebo Controlled Randomized Trial|T-TRANSPORT|Universitair Ziekenhuis Brussel|Yes|Recruiting|April 2015|June 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|43 Years|No|||November 2015|November 11, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418572||23175|
NCT02418585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107147|A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression|TRANSFORM-2|Janssen Research & Development, LLC|Yes|Recruiting|August 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|64 Years|No|||March 2016|March 11, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418585||23174|
NCT02473471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JordanUST|Micro-osteoperforation and Tooth Movement|Micro-osteoperforation and Tooth Movement: A Randomized Controlled Clinical Trial||Jordan University of Science and Technology|Yes|Enrolling by invitation|March 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|22|||Both|16 Years|26 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473471||18960|
NCT02473484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_27|Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas|Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas|GLIOMIC|University Hospital, Lille|Yes|Recruiting|June 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|tumoral DNA|Both|18 Years|N/A|No|Probability Sample|high grade glioma|December 2015|December 3, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473484||18959|
NCT02484807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-01|Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH|Effect of Pharmacologic Interaction Between Endothelin-Receptor-Antagonists and Phosphodiesterase-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients Wih Pulmonary Arterial Hypertension|EPIC|Heidelberg University|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|patients with pulmonary arterial hypertension receiving disease-targeted combination        therapy|October 2015|October 21, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02484807||18088|
NCT02462863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6677|Treatment of Type 2 Diabetes With Immunonutrients|Treatment of Type 2 Diabetes With Immunonutrients||The Christ Hospital|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462863||19775|
NCT02482870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/96|Efficiency of the King Vision Video Laryngoscope|Correlation of the Mallampati Classification With the King Vision Video Laryngoscope and Macintosh Laryngoscope||Rize Üniversitesi|Yes|Completed|January 2014|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|388|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|All patients scheduled for general anesthesia during the period from January 2014 to June        2014.|June 2015|June 25, 2015|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482870||18237|
NCT02481648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMMPC|Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer|A Pilot Study to Evaluate Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy|EMMPC|Vancouver Prostate Centre|No|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Male|19 Years|N/A|No|||July 2015|July 28, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02481648||18331|
NCT02481739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-15|Laparoscopic Surgical Management of Endometriosis on Fertility|Study of the Impact of Laparoscopic Surgical Management of Endometriosis on Fertility||University Hospital, Strasbourg, France|No|Not yet recruiting|July 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Female|18 Years|38 Years|No|Probability Sample|This work concerns patients aged 18-38 years, operated by laparoscopy for endometriosis in        our department between 2006 and 2014|June 2015|June 24, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02481739||18324|
NCT02485496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SECURE|E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms|SECURE - A poSt-market Registry in Patients With infrarEnal aortiC Aneurysm Undergoing endovasculaR Stenting With the New E-tegra Stent Graft System|SECURE|JOTEC GmbH|No|Recruiting|June 2015|October 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients with infrarenal aortic or aorto-iliac aneurysm who are eligible        for treatment with an abdominal stent graft according to the instructions for use for the        E-tegra stent graft system, and scheduled for implantation of the E-tegra stent graft        system at their physician's discretion in accordance with the inclusion and exclusion        criteria.|February 2016|February 23, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485496||18035|
NCT02467283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2013 / 15|Gene Expression Profiles in Chronic Periodontitis|Gene Expression Profiles in Chronic Periodontitis: A Gene Network-based Microarray Analysis||Kocaeli University|No|Active, not recruiting|February 2013|August 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The patientswere recruited from those patients seeking dental treatment in Kocaeli        University, Faculty of Dentistry Periodontology Clinics.|June 2015|June 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467283||19436|
NCT02487563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOOCHOW-HY-2015|Prospective Study of Patients With Thrombocytopenia Following HSCT|A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation||The First Affiliated Hospital of Soochow University|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|65 Years|No|||June 2015|June 29, 2015|June 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487563||17877|
NCT02481375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00933|Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?|Is Iron Deficiency the Cause of Anemia Among Women of Reproductive Age in Cambodia? A 2 x 2 Factorial Double Blind Randomized Controlled Trial of Oral Iron and Multiple Micronutrient Supplementation||University of British Columbia|No|Active, not recruiting|July 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|800|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02481375||18352|
NCT02485951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShaheedBMU54|Central Versus Peripheral Air Injection for DALK (Deep Anterior Lamellar Keratoplasty)|Big-bubble Deep Anterior Lamellar Keratoplasty: Central Versus Peripheral Air Injection||hahid Beheshti University of Medical Sciences||Recruiting|January 2014|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|50 Years|No|||June 2015|June 27, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02485951||18000|
NCT02489409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XinjiangMU001|Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer|EndostarTM Injection Combined With Gemcitabine+Platinum (GP)/Navelbine+Platinum (NP)/Gemcitabine+Xeloda (GX)/Navelbine+Xeloda (NX) in Treatment of Recurrent Metastatic Breast Cancer: A Randomized, Opened and Controlled Clinical Study||Xinjiang Medical University|Yes|Recruiting|October 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|70 Years|No|||March 2016|March 23, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489409||17736|
NCT02490852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS/015513|Study of Nutritional Suitability of a New Infant Formula for Term Infants|Study of Nutritional Suitability of a New Infant Formula for Term Infants||Ausnutria Hyproca B.V.||Recruiting|August 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|258|||Both|N/A|13 Days|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490852||17626|
NCT02475356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18252|Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea|Special Drug Use Investigation of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea|J-MIRAI|Bayer|No|Recruiting|August 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|N/A|N/A|No|Non-Probability Sample|Female patients with Heavy menstrual bleeding (HMB) and/or dysmenorrhea in whom a decision        to initiate treatment with Mirena has already been made will be enrolled in the study.|March 2016|March 21, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02475356||18815|
NCT02478385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fremtidensfødemiljø|Birth Environment of the Future|Birth Environment of the Future - a Randomised Controlled Study||Herning Hospital|Yes|Recruiting|May 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|656|||Female|18 Years|45 Years|No|||June 2015|June 18, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02478385||18582|
NCT02478398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3641-008|Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)|A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma||Merck Sharp & Dohme Corp.|Yes|Recruiting|July 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|4 Years|17 Years|No|||March 2016|March 23, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478398||18581|
NCT02486211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15GRNT25680021|Amantadine to Speed Awakening After Cardiac Arrest|Amantadine to Speed Awakening After Cardiac Arrest|AWAKE|University of Pittsburgh|No|Not yet recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486211||17981|
NCT02486471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLPO-1|Hemostatic Procedure After Biopsy of the Cervix|Is a Hemostatic Procedure Required After Biopsy of the Cervix Uteri in Women Undergoing Colposcopy for Cervical Dysplasia? A Multicenter Randomized Non-inferiority Trial||Zydolab - Institute of Cytology and Immune Cytochemistry|No|Completed|July 2015|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|166|||Female|18 Years|N/A|No|||February 2016|February 13, 2016|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02486471||17961|
NCT02490969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIC 19|Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19|Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19|proCORE|Charite University, Berlin, Germany|No|Recruiting|September 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult men and women who present to an ED/CPU with signs and symptoms suggestive of acute        coronary syndrome (NSTE-ACS) and an intermediate-to low risk profile in whom an early        rule-out strategy for AMI is applied and who therefore undergo single combined troponin        and copeptin testing at admission as part of standard management.|February 2016|February 16, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490969|28 Days|17617|
NCT02474914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sandostatin PD|Sandostatin in the Prevention of Postoperative Complications After Pancreaticoduodenectomy|Efficacy of Sandostatin in the Prevention of Postoperative Complications After Pancreaticoduodenectomy|PD|Mansoura University|No|Active, not recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|10 Years|70 Years|No|||June 2015|June 17, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02474914||18849|
NCT02489760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS08019|Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study|Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study||Chung Shan Medical University|No|Active, not recruiting|July 2008|October 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||January 2016|January 18, 2016|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02489760||17710|
NCT02484248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14110467|Trial of Ketotifen in Children and Adolescents|Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia|Ketotifen|Children's Mercy Hospital Kansas City|No|Not yet recruiting|July 2015|||March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|8 Years|17 Years|No|||June 2015|June 24, 2015|January 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02484248||18131|
NCT02462070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-118A-301|301 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Recruiting|July 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462070||19836|
NCT02475902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC053013|Health in Motion- Interactive Exercises for Safer Mobility|Health in Motion- Interactive Exercises for Safer Mobility|HiM-O|Blue Marble Rehab Inc|Yes|Not yet recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475902||18773|
NCT02489851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ch23031404|Quadratus Lumborum Block vs Tranversus Abdominis Plane Block for Cesarean Section|Quadratus Lumborum Block vs Tranversus Abdominis Plane Block for Post Cesarean Section Analgesia. A Randomised Controlled Study||Corniche Hospital|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|45 Years|No|||July 2015|December 23, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02489851||17703|
NCT02479269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P-92-6517|The Influence of Aerobic Exercise on Serum Brain Natriuretic Peptide and C- Reactive Protein in Cardiovascular Disease|The Influence of Aerobic Exercise on Serum Brain Natriuretic Peptide and C- Reactive Protein in Cardiovascular Disease|AEBNPCRP|Islamic Azad University, Shiraz|Yes|Completed|March 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|40 Years|65 Years|No|||June 2015|June 19, 2015|June 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479269||18514|
NCT02479282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nsc_123|Effect of Natural Cesarean Section on Breastfeeding|Effect of Natural Cesarean Section in Comparison to Traditional Cesarean Section on Maternal and Fetal Recovery||Ain Shams University|No|Not yet recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02479282||18513|
NCT02491164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC TWO|Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe|Exploratory Clinical Study of Intrapulmonary Microdosing of Gram-negative Optical Molecular Imaging BACterial Detection Probe|BAC TWO|University of Edinburgh|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|16 Years|N/A|No|||July 2015|July 6, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491164||17602|
NCT02468986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 012011034|Study of Venous Endothelial Cells in Rheumatoid Arthritis|Analysis of Endothelial Cells in Rheumatoid Arthritis||University of Texas Southwestern Medical Center|No|Recruiting|November 2011|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|Samples Without DNA|Serum collected by serum separator tube. Will be processed and frozen at -80degrees.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rheumatoid arthritis patients will be selected from arthritis clinics associated with UT        Southwestern Medical Center and Parkland Memorial Hospital. Healthy controls will be        collected from primary care clinics who refer to these specialty clinics.|March 2014|June 8, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02468986||19305|
NCT02487615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3852|Genetical, Anthropometrical and Biochemical Factors Influencing High Risk Subclinical Atherosclerosis|Subclinical Atherosclerosis: Biomarkers of Early Disease||Instituto Dante Pazzanese de Cardiologia|No|Completed|February 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|340|Samples With DNA|Plasma, Whole blood, DNA|Both|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive individuals attended at the outpatient clinic of Dyslipidemia and of        Hypertension and Nephrology Medical Sections of Dante Pazzanese Institute of Cardiology, a        cardiologic tertiary hospital in São Paulo - Brazil.|July 2015|July 2, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487615||17873|
NCT02489955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM14/11283|Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis|Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis (CF)||The Leeds Teaching Hospitals NHS Trust||Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||||||Both|18 Years|N/A|No|||July 2015|July 2, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489955||17695|
NCT02494206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-085|Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)|Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Female|18 Years|70 Years|No|||December 2015|December 16, 2015|July 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494206||17368|
NCT02481453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-66|Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis|Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"|RAPAMI|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|July 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|45 Years|85 Years|No|||May 2015|September 8, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02481453||18346|
NCT02481466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB # 14-316|The Combined Portfolio Diet and Exercise Study|The First Cross-Canada Trial of the Nutrition Trialists' Network--Enhanced Dietary Portfolio and Exercise on Arterial Damage (MRI-Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk)|PortfolioEx|St. Michael's Hospital, Toronto|Yes|Not yet recruiting|April 2016|January 2021|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|No|||February 2016|February 25, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02481466||18345|
NCT02476032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503M65361|An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity|An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity|SSDH|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02476032||18763|
NCT02490098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-13|Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes|An Open-label, Randomized, Five-way, Cross-over Study to Compare the Efficacy of Single- and Dual-hormone Closed-loop Operations Combined With Either Conventional Carbohydrate Counting or a Simplified Qualitative Meal-size Estimation, and Sensor-augmented Pump Therapy in Regulating Glucose Levels in Children and Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|8 Years|N/A|No|||December 2015|December 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490098||17684|
NCT02490215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICU2015_1|Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs|Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the participating ICUs during a 6-month period(from January 1,        2015 to July 1,2015 )|May 2015|July 1, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02490215||17675|
NCT02490228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAURFUC|Effectivity and Safety Study of Trans-artificial-urethral Resection of Female Urethral Caruncle|||Peking University First Hospital||Not yet recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|N/A|N/A|No|||July 2015|July 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490228||17674|
NCT02488967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-BR003|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer|A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer||NRG Oncology|Yes|Recruiting|July 2015|||April 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|990|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488967||17770|
NCT02488980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9467|An Evaluation of Weekly Tafenoquine|A Randomized, Double Blind, Placebo Controlled Evaluation of Weekly Tafenoquine (WR 238605/SB252263) Compared to Mefloquine for Chemosuppression of Plasmodium Falciparum in Western Kenya||U.S. Army Medical Research and Materiel Command|No|Completed|May 2000|March 2003|Actual|October 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|55 Years|No|||June 2015|July 1, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488980||17769|
NCT02486315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTC005|Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation|Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation|CARINAX|Clinica Mediterranea|Yes|Completed|April 2012|June 2015|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|163|||Both|18 Years|N/A|No|Non-Probability Sample|all consecutive patients with de novo bifurcation lesions treated at the Clinica        Mediterranea (Naples) and at the "Umberto I" University (Rome) were screened for potential        inclusion in the present study.|June 2015|June 30, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486315|9 Months|17973|
NCT02470338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404631-1|Modified Brostrӧm Procedure With and Without Possible Arthroscopy for Lateral Ankle Instability|A Single-Blinded Randomized Controlled Trial Comparing Modified Brostrӧm Procedure With and Without Diagnostic Arthroscopy for Treatment of Lateral Ankle Instability||William Beaumont Army Medical Center|No|Recruiting|June 2015|June 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470338||19201|
NCT02482168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APX005M-001|Study of the CD40 Agonistic Monoclonal Antibody APX005M|Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors||Apexigen, Inc.|No|Recruiting|May 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482168||18291|
NCT02485743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEXS-B292|A Trial Comparing a Diet Including Products Aimed at Targeting Satiety|A Randomized, Double-blind Multi-centre Trial Comparing a Diet Including Satiating Products Compared to Control Products - SATIN Satiety Diet - Proof of Concept|SATIN|University of Liverpool|No|Not yet recruiting|February 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02485743||18016|
NCT02469194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09915|Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity|Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|Samples With DNA|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques|Both|18 Years|N/A|No|Probability Sample|Subjects will be recruited from the inpatient and outpatient clinical practices in the        University of Pennsylvania Health System. There will be no attempt to advertise enrollment        on this protocol to physicians outside of the treating departments (i.e. Radiation        Oncology, Surgery, Medical Oncology).|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469194||19289|
NCT02469207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093532|Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology|A Study Utilising Tissue From Deceased Organ Donors to Investigate Regenerative Cellular Therapies and Related Physiological and Developmental Processes|RCT|Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|DNA data from tissue samples from donated organs may be retained anonymously for a period up      to 10 years|Both|16 Years|92 Years|Accepts Healthy Volunteers|Non-Probability Sample|All deceased organ donors for whom informed consent is available from the donor family|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469207||19288|
NCT02487550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIKRC001|DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating|||The First People's Hospital of Changzhou||Not yet recruiting|August 2015|July 2030|Anticipated|July 2028|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|80 Years|No|||June 2015|June 29, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02487550||17878|
NCT02479243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xin Lou-ChinaPLAGH|Assessment and Quantification of Collateral by ASL MRI|Arterial Spin Labeling MRI Assessment and Quantification of Collateral Circulation in Unilateral Middle Cerebral Artery Atherosclerotic Stenosis||Chinese PLA General Hospital|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|Symptomatic and asymptomatic patients with MCA atherosclerotic moderate to severe        stenosis(500%-99%) confirmed by conventional angiography or magnetic resonance        angiography.|June 2015|June 23, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479243|3 Months|18516|
NCT02483013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01546412.4.0000.5419|Clinical Study of the Whitening Dentifrices on Tooth Color and Sensitivity|Clinical, Controlled, Double-blind Study on the Effect of Whitening Dentifrices on Tooth Color and Tooth Sensitivity||University of Sao Paulo|Yes|Completed|August 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02483013||18226|
NCT02483234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2301T|Psoriasis-Arthritis & Bone Program|Evaluation of Inflammatory and Structural Joint Damage in Patients With Psoriasis and Psoriatic Arthritis Treated With Secukinumab: A Phase 2, Single Arm, Single Centre Mode of Action Study (Psoriasis-Arthritis & Bone Program, PSARTROS)|PSARTROS|University of Erlangen-Nürnberg Medical School|No|Recruiting|May 2015|September 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483234||18209|
NCT02465437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBT101-SSc-001|Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis|A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis||Corbus Pharmaceuticals Inc.|No|Recruiting|August 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|70 Years|No|||January 2016|January 15, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465437||19578|
NCT02481882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15037|Baseline Cortical Haemodynamics in MS|Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis|CortHaem|University of Nottingham|No|Not yet recruiting|June 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02481882||18313|
NCT02484014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SANSEHER2015_0001|Evaluation of School-based Health Promotion Programmes in Bihar, India|Strengthening the Evidence Base on Effective scHool Based intErventions for pRomoting Adolescent Health (SEHER)|SEHER|Sangath|Yes|Not yet recruiting|June 2015|August 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|15000|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02484014||18149|
NCT02489019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204821|Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia|Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia|Fentanyl|Loyola University|No|Recruiting|July 2013|December 2018|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|60 Years|N/A|No|||July 2015|July 1, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489019||17766|
NCT02470312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10051|MediGuide Registry|MediGuide Registry||St. Jude Medical|No|Enrolling by invitation|May 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|CRT Group All patients from participating sites who are indicated for a CRT-D/P device        implant, including an upgrade with a new left ventricular (LV) lead implant and are        implanted with St. Jude Medical pulse generators and willing to provide written Informed        Consent can be enrolled in this study. Patients can be implanted with non-St. Jude Medical        leads        EP Group All patients from participating sites who are indicated for an atrial        fibrillation, atrial flutter or ventricular tachycardia (VT) ablation procedure for which        market approved MediGuide™-enabled ablation catheter is available and willing to provide        written Informed Consent can be enrolled in this study.|December 2015|December 16, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02470312|5 Days|19203|
NCT02481037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400389|Primary Care Pathway for Childhood Asthma|Primary Care Pathway for Childhood Asthma||University of Alberta|No|Recruiting|June 2015|March 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|22|||Both|1 Year|17 Years|No|||February 2016|February 4, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02481037||18378|
NCT02493621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040998|Compare Epidural vs. Lumbar Plexus Analgesia After Hip Arthroplasty|Compare Effectiveness of Epidural vs. Lumbar Plexus Blocks in Total Hip Arthroplasty (THA) Patients Using Multimodal Pain Control||Medical University of South Carolina|No|Completed|December 2014|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study team will identify subject by the Primary Diagnosis of THA, (identified by CPT        code 27130) and 2) either a) Epidural (CPT code 62319) or b) Lumbar plexus peripheral        nerve block (CPT 62311 or 64449) with the administration of multimodal medication.|February 2016|February 25, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02493621||17413|
NCT02493647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSCR012015|Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk|Reducing Urban Women's HIV Risk: Soap Opera Videos on Mobile Devices|LSC|Northeastern University|Yes|Recruiting|September 2015|March 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|912|||Female|18 Years|29 Years|No|||October 2015|October 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02493647||17411|
NCT02470611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE- 22493714.5.0000.5149|Sodium Alendronate in Non Surgical Periodontal Therapy|Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial|SANSPET|Federal University of Minas Gerais|No|Completed|November 2012|November 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|30 Years|60 Years|No|||June 2015|June 9, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02470611||19180|
NCT02470806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-052-PIC|Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)|A Prospective, Randomized, Comparative Effectiveness Study of a Single-Use, Negative Pressure Wound Therapy System (PICO) Versus a Traditional Negative Pressure Wound Therapy System (tNPWT) in the Treatment of Lower Extremity Ulcers|NPWT|Healthpoint|No|Recruiting|July 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470806||19165|
NCT02423876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14030|Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery|UW14030: Epidural Anesthesia as Part of an Enhanced Recovery Pathway in Gynecologic Surgery||University of Wisconsin, Madison|Yes|Recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423876||22768|
NCT02465203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2313|3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study|A Multi-centre 3-year Follow-up Study to Assess the Viral Activity in Patients Who Failed to Achieve Sustained Virologic Response in Novartis-sponsored Alisporivir-studies for Chronic Hepatitis C Patients||Novartis|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|105|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465203||19596|
NCT02465216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-TBVPX-203|Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion||IDRI|Yes|Recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|60 Years|No|||October 2015|October 12, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465216||19595|
NCT02465229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406071RINA|Comparison of Diagnostic Accuracy Before or After Stricture Dilation in Biliary Stricture|Comparison of Stricture Dilation Before or After Multimodal Tissue-sampling for the Diagnosis of Malignant Biliary Stricture: a Prospective Study||National Taiwan University Hospital|No|Not yet recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|20 Years|N/A|No|||December 2015|December 17, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02465229||19594|
NCT02476500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLETZ-1|Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model|Prospective Case-control Study to Assess the Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model|LLETZ-1|Ruhr University of Bochum|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 28, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02476500||18727|
NCT02419274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZL-GHD-ERA|Adult Asthma Registry of the German Center for Lung Research (DZL)|Deep-phenotyping of Adult Asthma Patients of All Severity Grades in a Clinical Registry in Northern Germany|ERA|LungenClinic Grosshansdorf|No|Recruiting|March 2014|March 2017|Anticipated|October 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Collection of blood, nasal secretions, sputum and exhaled breath, such as pharyngeal and      nasopharyngeal swabs|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthma of all severity grades, both allergic and non-allergic. Age of Onset childhood and        adulthood. Smokers and non-smokers.        Proven Asthma either by positive Methacholin Provocation Test or positive Broncholyses or        reversible obstruction.        Healthy Control Group.|April 2015|April 16, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02419274|2 Years|23122|
NCT02419287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRU1|Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas|Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas||University of Milano Bicocca|No|Recruiting|April 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02419287||23121|
NCT02413372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB130-045|A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis||Bristol-Myers Squibb|Yes|Recruiting|May 2015|September 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|105|||Both|21 Years|75 Years|No|||February 2016|March 11, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413372||23575|
NCT02417779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-266-1|Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy|Effects of Extracorporeal Shock Wave Therapy in Cutaneous Microcirculation of Different Wounds||University of Schleswig-Holstein|No|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|8||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02417779||23236|
NCT02476513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1354|Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders|Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders||University of Alabama at Birmingham|Yes|Recruiting|February 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|The H&E sections of all biopsy specimens will be reviewed by a GI diagnostic pathologist,      Leona Council, MD, for histopathologic parameters including histologic grade and type. The      histology will be characterized according to the scale depicted in figure 1, where 0      represents the earliest possible injury and 3 represents malignancy. All specimens will be      processed in the typical manner, but reviewed by Dr. Council in the pathology department.|Male|25 Years|75 Years|No|Non-Probability Sample|The goal of the study is to further clarify the relationship among esophageal disorders,        obesity and inflammatory mediators that may identify a high risk patient profile that        would warrant more frequent screening. We will accrue 60 men between the ages of 25 and 75        who are referred for upper endoscopy for the first time or subject who have had a normal        upper endoscopy in the last 10 years. It is anticipated that some of the participants will        not have symptoms of reflux or dyspepsia. Due to the pattern of referral, however, most        will exhibit risk factors of esophageal disorders.|December 2015|December 23, 2015|October 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02476513||18726|
NCT02424838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618366|Trial of EUS-FNA of Pancreatic Masses|Randomized Trial Comparing suction-in Versus no Suction (SINS) for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) of Solid Pancreatic Mass Lesions Using 22 Gauge and 25 Gauge Needles|SINS|Florida Hospital|No|Recruiting|October 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|352|||Both|19 Years|89 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02424838||22694|
NCT02470169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 11|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis: A Randomized Controlled Trial||Cairo University|Yes|Recruiting|June 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02470169||19214|
NCT02472886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1463|Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection.|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection||Gilead Sciences|No|Active, not recruiting|June 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472886||19005|
NCT02470234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-BP-PK003|Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD|A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition|PK003|Rhodes Pharmaceuticals, L.P.|Yes|Recruiting|February 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|4 Years|5 Years|No|||February 2016|February 5, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470234||19209|
NCT02415101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/748-31-3|Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer|Randomized Clinical Trial Comparing the Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Cancer of the Esophagus or Gastric Cardia|NeoResII|Karolinska University Hospital|Yes|Recruiting|February 2015|August 2021|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|February 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02415101||23442|
NCT02413879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0001|Cleancision IntRaoperative Contamination prEvention Study|An Evaluation of the Safety and Efficacy of the CleanCision Wound Retraction and Protection System in Protecting Surgical Incisions From Intraoperative Contamination When Used During Colorectal Surgery|CIRCE|Prescient Surgical|No|Recruiting|March 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413879||23536|
NCT02461706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401013|Treatment of Drug Resistant Epilepsy|Physician Expanded Access to Investigational New Drug Cannabidiol for the Treatment of Drug Resistant Epilepsy|Cannabidiol|University of Florida||Available||||||N/A|Expanded Access|N/A|||||||Both|2 Years|16 Years||||October 2015|October 9, 2015|June 1, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02461706||19864|
NCT02461719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCS_P3|Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes|Multicenter, Randomized, Double-blind phⅢ Study of TJCS Eye Drops Group and Restasis Eye Drops Group for 12 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease.||Taejoon Pharm Co., Ltd.|No|Completed|January 2014|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|20 Years|N/A|No|||May 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461719||19863|
NCT02465307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400546|Motion Analysis of Delirium in the ICU|Motion Analysis of Delirium in Intensive Care Units|ICU_Delirium|University of Florida|No|Recruiting|February 2016|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465307||19588|
NCT02411136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040250|A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Multi-dose Administration in Subjects With Systemic Lupus Erythematosus||Amgen|No|Completed|May 2005|October 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|April 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411136||23747|
NCT02411435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117010|Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects|Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects||ViiV Healthcare|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02411435||23724|
NCT02426463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T65/2015|Clinical Trial on Individual Characteristics Affecting Pain Drug Therapy in Neonates|Individualising Drug Therapy in Neonates Using Pharmacogenomic Profiling, Population Based Modeling and Simulations|NeoPopGen|Turku University Hospital|No|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|24 Weeks|40 Weeks|No|||November 2015|November 3, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02426463||22569|
NCT02426502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01441|Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients|Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients: A Pilot Study|OnceDaily|University of British Columbia|Yes|Not yet recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02426502||22566|
NCT02462395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANODECCH|Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Episodic and Chronic Cluster Headache|Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Episodic and Chronic Cluster Headache: a Pilot Trial.|ANODECCH|University Hospital of Liege|Yes|Enrolling by invitation|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462395||19811|
NCT02467023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500109|Project 4B: Lower Extremity Strength Training in ICU Patients|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care: Project 4B: Lower Extremity Strength Training in ICU Patients||University of Florida|Yes|Recruiting|September 2015|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02467023||19456|
NCT02487524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/13/03/00/14|Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer|Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer||Helsinki University Central Hospital|No|Enrolling by invitation|October 2014|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Anticipated|400|||Female|18 Years|75 Years|No|||June 2015|June 29, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487524||17880|
NCT02486224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502689413|Post-exercise Hydration With Deep Sea Mineral Water on Exercise Performance|The Impact of Post-exercise Hydration With Deep Sea Mineral Water on Exercise Performance, Rehydration and Recovery||University of Arizona|Yes|Not yet recruiting|July 2015|||November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02486224||17980|
NCT02486237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Complications in Central American Diabetic Patients: Historic Cohort|Complications in Central American Diabetic Patients: Historic Cohort||Clínica Los Yoses|No|Recruiting|September 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|225|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients with type 2 diabetes mellitus|September 2015|September 20, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02486237||17979|
NCT02474797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01942-45|Ultrasound Diaphragmatic Thickening to Monitor Its Dysfunction in Patients With Sepsis|Assessment of Diaphragmatic Function by Ultrasonographic Measure of Diaphragmatic Thickening in Severe Sepsis or Septic Shock Patients Hospitalized in ICU: Diaphragmatic Dysfunction Frequency, Prognosis Values and Associated Factors|US-Diamonds|Groupe Hospitalier Paris Saint Joseph|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02474797||18858|
NCT02489747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCF2_2013_WBE|Effects of Wheat Bran Extract on Cognitive and Memory Function|Efficacy and Safety of Wheat Bran Extract on Improvement of Cognitive and Memory Function||Chonbuk National University Hospital|Yes|Completed|November 2013|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02489747||17711|
NCT02489123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9340|Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide||University of Washington|Yes|Recruiting|August 2015|||July 2023|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489123||17758|
NCT02493751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991002|A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)|A Phase 1b, Open-Label, Dose-Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer||Pfizer|No|Recruiting|October 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493751||17403|
NCT02490865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.1.2.H8|Systemic Bioactivity of Inhaled Nebulized RNS60|Systemic Bioactivity of Inhaled Nebulized RNS60||Revalesio Corporation||Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02490865||17625|
NCT02463409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 150497|Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)|Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a||Vanderbilt University|Yes|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|10 Years|21 Years|No|||June 2015|June 2, 2015|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02463409||19734|
NCT02483390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ק007/2015|Use of Online Communications to Support Patients and Their Families in the Hospice Unit|Use of Online Communications to Support Patients and Their Families in the Hospice Unit||Meir Medical Center|Yes|Not yet recruiting|June 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02483390||18197|
NCT02489357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1534|Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer|A Pilot Study of MK-3475 With Cryotherapy for Men With Newly Diagnosed Oligo-metastatic Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|No|||November 2015|November 10, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489357||17740|
NCT02482246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-1260|Coagulation Profile Surrounding Normal Cesarean Delivery|Coagulation Profile Surrounding Normal Cesarean Delivery||University of Chicago|No|Completed|January 2014|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Blood|Female|18 Years|60 Years|No|Non-Probability Sample|Pregnant women|December 2015|December 1, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02482246||18285|
NCT02482259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6730|Assessment of Frailty in Patients With Advanced Hepatocellular Cancers|Assessment of Frailty in Patients With Advanced Hepatocellular Cancers|FAC-L|Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|December 2013|May 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Hepatocellular cancer|October 2015|October 6, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02482259||18284|
NCT02476084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149600|Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients|Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients: a Pilot Observational Study|BMUS|University of Oxford|Yes|Recruiting|October 2014|October 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|100|Samples With DNA|Blood and and Biologic samples collected will be processed in the CTU Translational Research      Lab and stored within the Botnar Research Centre adhering to local guidelines on sample      requirements, handling and storage. All biological samples will be available for future      studies for biomarker profiling.      The following blood samples will be drawn in order:        1. Two (10.0ml) K2EDTA tube        2. One (5.0ml) SST tube        3. One (3 ml) Tempus RNA tube        4. One (6 ml) DNA EDTA tube (only during Visit 1)|Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid Arthritis Patients|June 2015|June 16, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02476084||18759|
NCT02479724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC_CareTaker_01|A-line/CareTaker Comparison Study in ICU Patients|A-line/CareTaker Comparison Study in ICU Patients||Empirical Technologies Corporation|No|Completed|January 2012|June 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|(23 m/11 f, mean age: 44.05 y, SD: 13.9 y, mean height: 173.3 cm, SD: 9.4 cm, mean weight:        95.3 kg, SD: 27.4 kg) hospitalized in University of Virginia Medical Intensive Care Units        (MICUs)|June 2015|June 22, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02479724||18479|
NCT02488369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01154-35|Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents|Study on the Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents|TEP-LYMPHOME|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|March 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|2 Years|21 Years|No|||February 2016|February 9, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488369||17815|
NCT02466451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/2012|Study in Children With the Diagnosis of Congenital Diaphragmatic Hernia (CDH) and Oesophageal Atresia (EA)|Observational Longitudinal Study in Children With the Diagnosis of Diaphragmatic Hernia and/or Oesophageal Atresia for Assessing Lung Function Parameters and Quality of Life|CDH-EA|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Completed|March 2014|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|5 Months|12 Years|No|Non-Probability Sample|33 Children operated at birth on diaphragmatic hernia and/or oesophageal atresia (age        range : 5 months - 12 years old)|March 2016|March 11, 2016|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466451||19500|
NCT02477059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120206|Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis|Double-blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Two Infusions Four Weeks Apart of Interleukin-6-Receptor Inhibitor (Tocilizumab) on Pain Relief in Patients With Severe Osteoarthritis of the Hand Refractory to Usual Treatment|TIDOA|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|September 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|85 Years|No|||July 2015|July 7, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02477059||18684|
NCT02464917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|491-14|Supplemental Oxygen Study|Supplemental Oxygen Study|SOS|MemorialCare Health System|Yes|Recruiting|June 2015|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|70|||Female|18 Years|N/A|No|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464917||19618|
NCT02480010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17004|A Study of Pertuzumab in Participants With Prostate Cancer|An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy||Hoffmann-La Roche||Terminated|September 2003|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|19 Years|N/A|No|||August 2015|August 18, 2015|June 5, 2015|Yes|Yes|The study was terminated at the time of interim analysis since none of the participants showed    a PSA response.|No|July 22, 2015|https://clinicaltrials.gov/show/NCT02480010||18457|The study was terminated at the time of interim analysis since none of the participants showed a PSA response.
NCT02484508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-15-01|Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis|A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis||Guizhou Bailing Group Pharmaceutical Co Ltd|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|70 Years|No|||June 2015|June 24, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02484508||18111|
NCT02481193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YZYY-610|Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia|Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia||Yangzhou No.1 People's Hospital|Yes|Completed|March 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481193||18366|
NCT02475967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDEN-IFRE 01|Study Assessing the Feasibility of Mini-MobileHeart's E-learning Module|Pilot Study Assessing the Feasibility of Mini-MobileHeart's E-learning Module|mi-mob-heart|Hasselt University|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02475967||18768|
NCT02490085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-12|Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy|An Open-label, Randomized, Two-way, Cross-over Multicenter Study to Assess the Efficacy of Closed-loop Strategy as Compared to Multiple Daily Injections in Regulating Glucose Levels During 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy||Institut de Recherches Cliniques de Montreal|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|60 Years|N/A|No|||November 2015|November 13, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490085||17685|
NCT02479789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04091501|Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring|Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring||Bronx-Lebanon Hospital Center Health Care System|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02479789||18474|
NCT02479802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1309|Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis|Pilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral Sclerosis||Grifols Biologicals Inc.|No|Active, not recruiting|November 2014|November 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||September 2015|September 10, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02479802||18473|
NCT02486068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABB-02|ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis|ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis|Compare Absorb|European Cardiovascular Research Center|Yes|Not yet recruiting|September 2015|March 2022|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2100|||Both|18 Years|80 Years|No|||June 2015|June 30, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486068||17992|
NCT02477111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-4601|European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms|A Multicenter, Open Label, Prospective, Post Approval Study of the INCRAFT® Abdominal Aortic Aneurysm (AAA) Stent Graft System in Subjects With Abdominal Aortic Aneurysms|INSIGHT|Cordis Corporation|No|Recruiting|March 2015|April 2020|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are eligible for endovascular repair of an abdominal aortic aneurysm|June 2015|June 17, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02477111||18680|
NCT02480504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1702 (REK)|Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity|Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity||Oslo University Hospital|No|Recruiting|September 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2015|October 29, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02480504||18419|
NCT02491944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00020|A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291|A Phase I, Open-label, Single Dose, Single-Centre Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9291 With Respect to an Intravenous Microdose of [14C]AZD9291 in Healthy Male Subjects||AstraZeneca|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|July 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02491944||17542|
NCT02462811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCL-003|A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)|A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)||Charleston Laboratories, Inc|No|Completed|September 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|552|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462811||19779|
NCT02462824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00100697|Patient Centered Home Exercise Program for Peripheral Artery Disease|HOme-based moNitORed Exercise for PAD: The HONOR Study||Northwestern University|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 21, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02462824||19778|
NCT02463123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.2015|Energy Expenditure Estimation in Cardiac Surgery|Resting Energy Expenditure in Cardiac Patients Operated Under Cardiopulmonary Bypass||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after cardiothoracic interventions using cardiopulmonary bypass|March 2016|March 18, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02463123||19755|
NCT02477501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTEM NAD|Ephedrine vs. Nor Epinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Section|Ephedrine vs. Nor-epinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Section||University Tunis El Manar|No|Not yet recruiting|July 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477501||18650|
NCT02477540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellgram-CLI|A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia|An Open Labeled, Single-center, Phase I Study Assessing the Safety and Efficacy of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia||Pharmicell Co., Ltd.|No|Not yet recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years|No|||June 2015|June 22, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02477540||18647|
NCT02486198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TianjinCIH20141201|Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer|Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|May 2015|May 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||May 2015|June 30, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02486198||17982|
NCT02490501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC0806-A101|Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects|An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Fibroblast Growth Factor 1 on a Biodegradable Device in Subjects With Traumatic Spinal Cord Injury||BioArctic Neuroscience AB|Yes|Recruiting|June 2015|May 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490501||17653|
NCT02492022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smoking Cessation|Efficacy of 2 Probiotics During Nicotine Replacement Therapy on Withdrawal Symptoms Associated With Smoking Cessation|A Double-blind Randomized Placebo-controlled Trial Assessing the Effectiveness of Two Probiotic Products During Nicotine Replacement Therapy for Managing Withdrawal Symptoms Associated With Smoking Cessation||Lallemand Health Solutions|No|Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|75|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02492022||17536|
NCT02474745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0238|Study of the Type of Pushing at Delivery|Effect of the Type of Maternal Pushing During the Second Stage of Labor on Obstetric and Neonatal Outcome: a Multicenter Randomized Trial|EOLE|University Hospital, Clermont-Ferrand||Recruiting|July 2015|April 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02474745||18862|
NCT02474758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-0420|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||June 15, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474758||18861|
NCT02474771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Innovator's Clinical Trial|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||June 15, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474771||18860|
NCT02489617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-174|The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy|The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy||Dana-Farber Cancer Institute|Yes|Recruiting|September 2015|June 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|210|||Female|18 Years|N/A|No|||October 2015|October 19, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02489617||17721|
NCT02483169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICASSO-IMT|PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study|Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol|PICASSO-IMT|Asan Medical Center|Yes|Active, not recruiting|June 2009|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|800|||Both|20 Years|N/A|No|||December 2015|December 23, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483169||18214|
NCT02487108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV46763-CNS-30031|Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Patients With Moderate to Severe Pain Following Bunionectomy|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets (TV-46763) at Doses of 5.0 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg Every 4 to 6 Hours in Patients With Moderate to Severe Pain Following Bunionectomy||Teva Pharmaceutical Industries|No|Recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|560|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487108||17912|
NCT02487121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK081607|Improving Weight Loss Maintenance Through Alternative Schedules of Treatment|Improving Weight Loss Maintenance Through Alternative Schedules of Treatment|ImWeL|University of Alabama at Birmingham|No|Completed|April 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487121||17911|
NCT02470065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08115|Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.|Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group|REMNANT|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Suspended|January 2016|January 2021|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|90 Years|No|||January 2016|January 21, 2016|June 10, 2015||No|Study never started|No||https://clinicaltrials.gov/show/NCT02470065||19222|
NCT02485353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0525|Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML|Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML||Indiana University|Yes|Recruiting|October 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|60 Years|N/A|No|||January 2016|January 27, 2016|June 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485353||18046|
NCT02488200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRU ID 15002474|Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis|Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis|Peridialysis|Herlev Hospital|No|Recruiting|January 2015|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|1 Month|95 Years|No|Non-Probability Sample|Patients with Chronic Kidney Disease Stage 5 WHO start dialysis therapy for ESRD|June 2015|June 30, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02488200|1 Year|17828|
NCT02488343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0061-CTIL|Profile of Adherence to Therapy and Interventions to Promote Adherence in MS|Personal Profile of Adherence to Therapy and Tailored Interventions to Promote Adherence in Multiple Sclerosis Patients||Carmel Medical Center|Yes|Recruiting|August 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02488343||17817|
NCT02475564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140626|Resveratrol for Pain Due to Endometriosis|The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial|ResvEndo|Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Female|20 Years|50 Years|No|||May 2015|June 17, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02475564||18799|
NCT02485886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM09|68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis|Safety and Diagnostic Performance of 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485886||18005|
NCT02488057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0478|Improving Beta Cell Function in Mexican American Women With Prediabetes|Improving Beta Cell Function in Mexican American Women With Prediabetes||Ohio State University|No|Not yet recruiting|July 2015|September 2020|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Female|18 Years|40 Years|No|||July 2015|July 7, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488057||17839|
NCT02479854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/14/520|Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck) to Healthy Adult Volunteers Conditions.||Genuine Research Center, Egypt|No|Completed|April 2014|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 21, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479854||18469|
NCT02479867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/13/515|A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)||Genuine Research Center, Egypt|No|Completed|March 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 21, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479867||18468|
NCT02475603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-334N-MA|Clinical, Biochemical and Neurophysiological Consequences of Intraoperative Tourniquet During Total Knee Arthroplasty|Clinical, Biochemical and Neurophysiological Consequences of Intraoperative||Universitätsmedizin Mannheim|No|Recruiting|September 2012|January 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||September 2012|June 15, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02475603||18796|
NCT02475616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO001US|A Single Ascending Dose Study of PCO371 in Healthy Volunteers|A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers||Chugai Pharmaceutical||Terminated|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475616||18795|
NCT02477410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15003581|Effects of Hydrolysed Porcine Proteins on Muscle Protein Synthesis and Appetite|Effects of Hydrolysed Porcine Proteins on Muscle Protein Synthesis and Appetite|SEPA|University of Copenhagen|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|22|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02477410||18657|
NCT02477449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVie2015001|Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers|A Phase I Dose Escalating Study Evaluating the Pharmacokinetics, Tolerability and Safety of Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers||Lee's Pharmaceutical Limited||Recruiting|May 2015|August 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02477449||18654|
NCT02425189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02344|The Canadian National Long QT Syndrome Registry|National Long QT Syndrome Registry: Canadian Genetic Heart Rhythm Network /Research Data Registry and Bio Bank|LQTSREG|University of British Columbia|No|Recruiting|November 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Blood Samples drawn:      1 X 5ml Red Top Tube serum size 3 X 9 ml EDTA      1 X 9ml PaxGene vacutainer      DNA/RNA/Plasma samples for bio banking will be stored long-term|Both|N/A|N/A|No|Probability Sample|Patients with positive LQTS diagnosis and their family members reviewed in collaborating        Canadian Inherited Arrhythmia Clinics will be invited to participate in the registry.        Optional bio bank donation will be offered. Consenting participants will have blood work        drawn in their local outpatient laboratory.|April 2015|April 20, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02425189|3 Years|22667|
NCT02425306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17860|Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma|A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)|Mel63; CHAMP|University of Virginia|Yes|Recruiting|May 2015|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|74|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425306||22658|
NCT02469558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-464 ex 13/14|Probiotics in Diabesity: A Pilot Study|Probiotics in Diabesity: A Pilot Study|Diabesity|Medical University of Graz|No|Not yet recruiting|September 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|99 Years|No|||October 2015|October 2, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469558||19261|
NCT02469857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATB-202|Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections|Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)|ACCUTE|Atox Bio Ltd|Yes|Recruiting|September 2015|January 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|12 Years|N/A|No|||February 2016|February 21, 2016|June 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469857||19238|
NCT02464527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073588|Stimulus-Stimulus Pairing Study|A Pilot Feasibility Study to Increase Vocal Language in Minimally Verbal Children Diagnosed With Autism Spectrum Disorders||Emory University|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|24 Months|47 Months|No|||August 2015|August 18, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02464527||19648|
NCT02417792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|The Association Between Psoriasis and Intestinal Bacterial Population|The Association Between Psoriasis and Intestinal Bacterial Population|PIB|Assuta Hospital Systems|No|Not yet recruiting|May 2015|March 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|Samples Without DNA|stool|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both psoriasis patients and healthy participants (as a control group) will be recruited        for the study.|March 2015|April 16, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02417792||23235|
NCT02461459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00013585|Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)|Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)||Children's Hospital Boston|Yes|Recruiting|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood draw for future correlative studies in the TSC Biorepository of the Developmental      Synaptopathies Consortium.|Both|3 Years|21 Years|No|Non-Probability Sample|A total of 100 children between the ages of 3-21 years with TSC and suspected or diagnosed        ASD, ID, or combined ASD/ID will be enrolled into the study. Diagnosis of TSC will be        based on established clinical or genetic criteria. Twenty (20) subjects will be enrolled        from current and new TSC patients at each of the 5 centers.|February 2016|February 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02461459||19883|
NCT02464787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L15-148|Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following a Dietary Supplement-based Intervention|Evaluation of Changes in Skin Carotenoid Score in Medical Students Following a Dietary Supplement-based Intervention|SCS2015|Texas Tech University Health Sciences Center|Yes|Enrolling by invitation|May 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02464787||19628|
NCT02427087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9022|Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity|Anthropometric Evaluation and Body Composition in Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity||University of Sao Paulo General Hospital|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|35 Years|75 Years|No|||April 2015|April 24, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02427087||22521|
NCT02427100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062014-031|Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults|Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults: A Pilot Study||University of Texas Southwestern Medical Center|No|Not yet recruiting|April 2015|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 24, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02427100||22520|
NCT02466048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02SGF|Efficacy and Safety of SurgiFill™ on Spinal Fusion|Clinical Trial to Evaluate the Efficacy and Safety of SurgiFill™ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFill™ and Autograft in Spinal Fusion-||Sewon Cellontech Co., Ltd.|Yes|Recruiting|August 2013|January 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02466048||19531|
NCT02466061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREC 1190|TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors|Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)||Fred Hutchinson Cancer Research Center|No|Recruiting|July 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|300|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02466061||19530|
NCT02476656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro#00037264|Placental Inflammation in Prenatal Care|Placental Inflammation in Prenatal Care|PINC|Greenville Health System|No|Active, not recruiting|June 2015|May 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Female|18 Years|N/A|No|Probability Sample|preganant women who present for delivery at term at Greenville Health System with the        Obstetrics Teaching Service|February 2016|February 12, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02476656||18715|
NCT02419027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-GS14|A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome|||Seoul National University Hospital||Not yet recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Both|19 Years|70 Years|No|||April 2015|April 16, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02419027||23140|
NCT02418299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J013|Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)|Prospective, Single Centre Study of Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)||Juna d.o.o.|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Female|18 Years|N/A|No|||April 2015|April 16, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02418299||23196|
NCT02466308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN-01|Long Duration Therapeutic Ultrasound for Tendon Healing|Long Duration Therapeutic Ultrasound for Tendon Healing||ZetrOZ, Inc.|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466308||19511|
NCT02470481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103908|A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics|Psoriatic Arthritis In Skin Clinics (PARIS) Study. A Multicentre, Observational, Descriptive Cross-Cultural Validation Study and Estimate of the Proportion of Patients With Psoriatic Arthritis Among Psoriasis Patients Attending Dermatology Clinics Selected for This Study|PARIS|Janssen Research & Development, LLC|No|Recruiting|March 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants with psoriatic arthritis among psoriasis participants attending dermatology        clinics.|March 2016|March 14, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470481||19190|
NCT02470494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP00009|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2015|||||N/A|N/A|N/A||||||||||||||December 29, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470494||19189|
NCT02415335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-707|Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis|Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis||Nordsjaellands Hospital|Yes|Completed|April 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02415335||23424|
NCT02426996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/OM-01|The Latarjet-type Procedure Using the SEM Positioner: Using a Scan to Assess Consolidation|Treatment of Chronic Anterior Shoulder Instability by a Latarjet-type Bone Block Procedure Using the SEM (Science Et Medecine) Positioning Tool: Using a Scan to Assess Consolidation and Return to Normal Activity at 3 Months|IACE Scan|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|May 2016|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|45 Years|No|||February 2016|February 3, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02426996||22528|
NCT02466880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEAS001|Intervention for Diabetes With Education, Advancement and Support|Intervention for Diabetes With Education, Advancement and Support (IDEAS) Study|IDEAS|Monash University|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466880||19467|
NCT02488993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ2014GL03|Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)|PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN®/XIFAXAN®) 550 mg|PROSPER|Norgine|No|Recruiting|June 2015|January 2018|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||3|Anticipated|550|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cirrhosis aged 18 years or over who are enrolled within 12 weeks of        resolution of an episode of overt HE associated with a hospital visit, who are eligible        for treatment with rifaximin-α 550 mg.|December 2015|December 10, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02488993|2 Years|17768|
NCT02489006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-058|A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer|NEO|University Health Network, Toronto|No|Not yet recruiting|June 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Female|18 Years|N/A|No|||April 2015|June 30, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02489006||17767|
NCT02489175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202/15|Stomaplasty Ring (KoringTM) for Prevention of Parastomal Hernia|International Prospective Randomized Multicenter Trial to Analyze the Stomaplasty Ring (KoringTM) for Prevention of Parastomal Hernia|StoKo|University of Lausanne Hospitals|No|Not yet recruiting|July 2015|July 2018|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02489175||17754|
NCT02473094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOMETRE201501|Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer|Metformin in Association to Chemoradiotherapy for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized, Placebo-controlled Phase II Study|NEOMETRE|University of Campinas, Brazil|Yes|Recruiting|July 2015|May 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02473094||18989|
NCT02489669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT004|Renal Insufficiency Following Contrast Media Administration Trial III|Renal Insufficiency Following Contrast Media Administration Trial III (REMEDIAL III): Renalguard System Versus Left-ventricular End-diastolic Pressure-guided Hydration in High-risk Patients for Contrast-induced Acute Kidney Injury|REMEDIALIII|Clinica Mediterranea|Yes|Not yet recruiting|July 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1272|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02489669||17717|
NCT02490033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD13/11009|The VERISMART Trial|Randomised Trial Comparing Conventional Versus Contact Force and Electrical Coupling Index in Atrial Flutter Ablation|VERISMART|The Leeds Teaching Hospitals NHS Trust|No|Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|120|||Both|18 Years|90 Years|No|||July 2015|July 2, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02490033||17689|
NCT02490917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130941|ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence|Randomised Comparative Prospective Study of the Treatment of Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency : ACT™ Balloon Versus Artificial Urinary Sphincter ( AMS800™)|SU-ACT|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|September 2015|December 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Female|18 Years|80 Years|No|||August 2015|December 15, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490917||17621|
NCT02490930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14168|A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma|A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|N/A|No|||July 2015|November 4, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490930||17620|
NCT02475954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-353|Telehealth Cognitive Behavioral Therapy for Depression in Parkinson's Disease (PD)|Telehealth Cognitive-Behavioral Therapy for Depression in Parkinson's Disease|TH-CBT|VA Office of Research and Development|Yes|Active, not recruiting|January 2016|January 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|35 Years|85 Years|No|||February 2016|February 12, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02475954||18769|
NCT02479711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dep of Pedodontics, Ege|A Clinical Evaluation of a Glass Ionomer Cement (GIC) Based Restorative System Versus Bulk Filled Resin-based Composite|A Clinical Evaluation of a Glass Ionomer Cement (GIC) Based Restorative System||Ege University|Yes|Active, not recruiting|January 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479711||18480|
NCT02493764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7655A-014|Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia|RESTORE-IMI 2|Merck Sharp & Dohme Corp.|Yes|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|536|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493764||17402|
NCT02481999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Narco-Kids|Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years|Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years||Charite University, Berlin, Germany|No|Recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|550|||Both|6 Months|8 Years|No|Probability Sample|Children for elective surgery aged from 0, 5 to 8 years|December 2015|December 18, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481999||18304|
NCT02467556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helsinki University Hospital|Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome|Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome|MultiModCRPS|Helsinki University Central Hospital|No|Completed|March 2011|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|65 Years|No|||June 2015|June 24, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467556||19415|
NCT02467569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemay020P1 2014|Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer|Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer||Tianjin Hemay Pharmaceutical Co.,Ltd|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|70 Years|No|||August 2015|November 2, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02467569||19414|
NCT02487602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-100-006|A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects|A Randomized, Partially-blinded, Cross-over Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects||Gelesis, Inc.|No|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|16|||Male|22 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487602||17874|
NCT02493829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2494|B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)|A Phase I Study of B7.1 (CD80)/IL-2 Immune Gene Therapy for High Risk Acute Myeloid Leukaemia Patients Unsuitable for Allogeneic Haematological Stem Cell Transplant||King's College London|Yes|Not yet recruiting|September 2015|September 2021|Anticipated|September 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02493829||17397|
NCT02493842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-602547-5|Direct Nerve Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|EPIONE|Aalborg Universitetshospital|Yes|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|70 Years|No|||June 2015|July 7, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02493842||17396|
NCT02486042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140253|Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity|Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity: Proposal for a Prospective Randomized Controlled Masked Clinical Trial With Lipidomic and Transcriptomic Analyses||University of California, San Diego|Yes|Recruiting|March 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|7 Days|No|||December 2015|December 1, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486042||17994|
NCT02475850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AG048270|Strategies to Reduce Injuries and Develop Confidence in Elders|Randomized Trial of a Multifactorial Fall Injury Prevention Strategy|STRIDE|Brigham and Women's Hospital|Yes|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6000|||Both|75 Years|N/A|No|||November 2015|November 16, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02475850||18777|
NCT02477020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-063-2002|A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia||Takeda|No|Recruiting|July 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||January 2016|January 18, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477020||18687|
NCT02483962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FayroozKarriem200800851|Venavine Intensive® in the Treatment of Symptoms Associated With Chronic Venous Insufficiency|The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 in the Treatment of Symptoms Associated With Chronic Venous Insufficiency||University of Johannesburg|Yes|Recruiting|February 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483962||18153|
NCT02491827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE 001|Confocal Laser Endomicroscopy (CLE) During Medically Induced Neurosurgery in Craniobasal and Glioma Tumours|Adjoint Intra-operative Confocal Laser Endomicroscopy (CLE) to Present Tissue on the Cellular Level in Defined Lesions of the Central Nervous System (CNS) During Medically Induced Neurosurgery in Subcranial Tumors and Glioma|Cleopatra|Charalampaki, Cleopatra, M.D.|No|Recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|75 Years|No|Probability Sample|patients suffering from either subcranial Tumors or cerebral gliomata|February 2016|February 2, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491827||17551|
NCT02470832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29402|A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects|||Hoffmann-La Roche||Recruiting|May 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|June 9, 2015|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470832||19163|
NCT02474823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012|Neck Grasp as a Predictor of Sleep Apnea|Neck Grasp as a Predictor of Sleep Apnea||Bassett Healthcare|No|Recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474823||18856|
NCT02469519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0033|Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes|A Randomized Double-blinded Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome in the Patient With Prelabor Premature Rupture of the Membranes|ACSinPROM|Mednax Center for Research, Education and Quality|Yes|Recruiting|March 2016|November 2019|Anticipated|September 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469519||19264|
NCT02484196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDODISP14|Dyspareunia in Women With Endometriosis: Impact of Surgery on Sexual Health|||University of Cagliari|No|Not yet recruiting|June 2016|October 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women, and their parteners, affected by endometriosis with dyspareunia, referred to the        Obstetrics and Gynecological Department of the University Hospital for the treatment of        endometriosis|March 2016|March 8, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02484196||18135|
NCT02488525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_06|Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support|Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support|PHAM|University Hospital, Lille|Yes|Recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02488525||17803|
NCT02485795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB007|Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management|A Multicenter Longitudinal Observational Study Evaluating Genotypic Association wIth Clinical Outcomes in Interventional Pain Management Modalities|MOSAIC|Proove Bioscience, Inc.|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be adult patients who are candidates for interventional pain management        treatments, including Injections, Radio-frequency, Intrathecal pump implants, etc. All        patients are receiving routine medical visits for their care and will have Proove        laboratory genetic testing performed.|July 2015|July 21, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485795||18012|
NCT02486055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP 0312-01|A Safety Study of Orally Administered BPM31510 in Healthy Subjects|A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects||Berg, LLC|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02486055||17993|
NCT02477085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAP-2014-030|Methods of Labor Induction and Perinatal Outcomes|Methods of Labor Induction and Perinatal Outcomes : a Prospective National Study in France|MEDIP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3100|||Female|N/A|N/A|No|Non-Probability Sample|all women who have an induced labor|December 2015|January 5, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02477085||18682|
NCT02480244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK096429|PASOS: Improving the Health of Immigrant Workers|Translating Obesity and Diabetes Prevention Into the Worksite for Immigrant Populations||University of California, Davis|Yes|Not yet recruiting|July 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02480244||18439|
NCT02484781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 2015-0576|Gait Analyses After Resurfacing Hip Arthroplasty Versus Metal on Metal Total Hip Arthroplasty, an Exploratory Study|Gait Analyses After Resurfacing Hip Arthroplasty Versus Metal on Metal Total Hip||Rijnstate Hospital|No|Enrolling by invitation|May 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|58|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02484781||18090|
NCT02462538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_ALCL1|Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL|A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Recruiting|May 2015|June 2021|Anticipated|June 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02462538||19800|
NCT02462798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chalmers0002|Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?|Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?||Chalmers University of Technology|No|Active, not recruiting|January 2010|December 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|102|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462798||19780|
NCT02465476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 6901 15|Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine|Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine|Telemalrares|University Hospital, Toulouse|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 11, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02465476||19575|
NCT02465489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA51-0115|Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers|Single-dose Pharmacokinetic Study of Deferiprone Extended Release Tablets Versus Ferriprox Immediate Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers||ApoPharma|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2015|January 27, 2016|June 4, 2015||No||No|December 18, 2015|https://clinicaltrials.gov/show/NCT02465489||19574|
NCT02465502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17217|Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer|An Uncontrolled, Open-label Phase IIb Trial of Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer||Bayer|No|Recruiting|July 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465502||19573|
NCT02484690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29647|AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration||Hoffmann-La Roche||Recruiting|August 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|271|||Both|50 Years|N/A|No|||September 2015|September 9, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484690||18097|
NCT02484703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP28760|A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 26-Week Dose-Investigating Study to Explore the Pharmacokinetics, Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of RG1662 in Children With Down Syndrome Aged 6 to 11 Years||Hoffmann-La Roche||Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|36|||Both|6 Years|11 Years|No|||March 2016|March 1, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484703||18096|
NCT02481141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIP12-002F|Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes|Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes||SBI Pharmaceuticals Co, Ltd.|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|53|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02481141||18370|
NCT02467244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T/EM-F/Pharm/14/03|Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism|Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism||All India Institute of Medical Sciences, Bhubaneswar|No|Not yet recruiting|July 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467244||19439|
NCT02462616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANRA_Dr.Tang|Risk Analysis for Cardiovascular Autonomic Neuropathy|The Risk Analysis for Cardiovascular Autonomic Neuropathy in General Chinese Population||Shanghai Tongji Hospital, Tongji University School of Medicine||Active, not recruiting|January 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2100|Samples With DNA|DNAs were extracted and genetyped.|Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|We recruited participants from rural and urban communities in Shanghai. Survey        participants with undiagnosed CAN, aged 30-90 years, were included in this study. Our        study invited a total of 3,012 subjects to a screening visit between 2011 and 2012.|November 2015|November 4, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02462616||19794|
NCT02489877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fcmscsp-HERV|Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus|Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|84|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study group will be composed by patients diagnosed with multiple sclerosis and with        other neurological diseases ( Lateral AmniotroficSclerosis, Headache, Parkinson's,        Dementia and Epilepsy). And the control group will be composed by blood donors who are        considered healthy control.|July 2015|July 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02489877||17701|
NCT02478255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059856|Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment|Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment||Duke University||Recruiting|February 2016|||August 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02478255||18592|
NCT02475590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01590-55|Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass|Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Morbidly Obese Patients: a Prospective Randomized Clinical Trial||IHU Strasbourg|No|Active, not recruiting|March 2009|July 2022|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||December 2015|December 3, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02475590||18797|
NCT02480452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57844|Brain Lesions in Relation to Motor Profiles of Children With Cerebral Visual Impairment.|Brain Lesions in Relation to Motor Profiles of Children With Cerebral Visual Impairment.||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|May 2015|June 2020|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|600|||Both|3 Years|6 Years|No|Non-Probability Sample|All children with a mental age between 3 and 6 years old consulting at the CVI clinic|June 2015|June 23, 2015|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02480452||18423|
NCT02480465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39DM14010|Efficacy and Safety of Lobeglitazone Versus Sitagliptin|Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study||Chong Kun Dang Pharmaceutical|No|Recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|19 Years|N/A|No|||May 2015|July 6, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480465||18422|
NCT02487940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUH1234|Assessment of Intralipid Efficacy in Patients With Repeated Unexplained Implantation Failure|Assessment of the Efficacy of Intralipid 20% in Management of Patients With Unexplained Repeated Implantation Failure in IVF Cycles||Dar El Teb Institute|Yes|Completed|October 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|95|||Female|20 Years|38 Years|No|||January 2016|January 21, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02487940||17848|
NCT02494427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K110104|Comparison of Conventional and CAD/CAM Dental Restorations|Medico-economic Comparative Assessment of Conventional and CAD/CAM Dental Restorations; Impact on Hospital Dentistry Departments|EVACFAOD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|July 9, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02494427||17351|
NCT02475369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000375|Pancreatic Enzyme Supplementation for Celiac Disease|Pilot Study of the Efficacy of Pancreatic Enzyme Supplementation for Symptom Control in Celiac Disease Not Responding to the Gluten Free Diet||Beth Israel Deaconess Medical Center|No|Recruiting|May 2015|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475369||18814|
NCT02488031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500202|Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia|Dysmetria in Motor Function in SCA: Mechanisms and Rehabilitation|SCA|University of Florida|No|Recruiting|March 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|85 Years|No|||March 2016|March 21, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488031||17841|
NCT02494310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRME-UH2|HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings|Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings|HRME-UH2|Barretos Cancer Hospital|No|Not yet recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02494310||17360|
NCT02490631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150310|2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients|A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post op Surgical Site Infections in Spine Patients (Decrease SSI or DeSSI)|DeSSI|Vanderbilt University|Yes|Recruiting|August 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|19 Years|90 Years|No|||June 2015|August 11, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490631||17643|
NCT02490644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0764|Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Valvular Heart Surgery|||Yonsei University|No|Recruiting|November 2014|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|20 Years|N/A|No|Non-Probability Sample|people who undergo valvular heart surgery|June 2015|July 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490644||17642|
NCT02462109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 1330|Catatonia in Nodding Syndrome and Lorazepam Treatment|Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study|CINS|Makerere University|No|Completed|March 2013|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|10 Years|21 Years|No|||June 2015|June 2, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02462109||19833|
NCT02488616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-11|Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 5 Days in Free-living Outpatient Conditions in Patients With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Not yet recruiting|March 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488616||17796|
NCT02494440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5D LB|Automated Fetal Femur Length Measurement by Five-Dimensional Ultrasound|Automated Fetal Femur Length Measurement by Five-Dimensional Ultrasound||Ain Shams University|Yes|Active, not recruiting|May 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a Prospective pilot study that will be performed at the Fetal Care Unit at Ain        Shams University Maternity Hospital.        Ninety pregnant women will be recruited from the the Fetal Care Unit who will fulfill the        inclusion criteria. They will be counseled to be included into the study.|December 2015|December 28, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494440||17350|
NCT02489201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDE1B|A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer|A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|No|Active, not recruiting|June 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||June 2015|July 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02489201||17752|
NCT02462304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END-DME1|To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema|To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema|END-DME|The University of Hong Kong|Yes|Recruiting|June 2015|May 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02462304||19818|
NCT02462317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 140 01|Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment|Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen.|BacloTox|University Hospital, Toulouse|No|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|80 Years|No|||June 2015|June 1, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02462317||19817|
NCT02462785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000042623|An Evaluation of Internet-based Carbohydrate Counting Education for Adolescents With Type 1 Diabetes|Carbohydrate Counting and Type 1 Diabetes: A Randomized Controlled Trial of Internet-based Teaching for Adolescents Learning to Count||The Hospital for Sick Children|No|Recruiting|July 2014|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|12 Years|17 Years|No|||November 2015|November 16, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02462785||19781|
NCT02463097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 294|Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes|Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes||Medtronic Diabetes|Yes|Active, not recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|14 Years|75 Years|No|||January 2016|January 16, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463097||19757|
NCT02413619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIREF|Refractive Consequences of Epiretinal Membrane Surgery|Refractive Consequences of Epiretinal Membrane Surgery|EPIREF|Glostrup University Hospital, Copenhagen|No|Recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||April 2015|April 7, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02413619||23556|
NCT02413866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036519|Weight Outlooks by Restriction of Diet and Sleep|Weight Outlooks by Restriction of Diet and Sleep|WORDS|University of South Carolina|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413866||23537|
NCT02465580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hrIL-2-SLE|A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus|A Phase II Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus||Peking University People's Hospital|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465580||19567|
NCT02469389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1293-R|Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia|Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia||VA Office of Research and Development|No|Recruiting|August 2015|July 2019|Anticipated|March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469389||19274|
NCT02414555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v1.104112014|Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support|Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support, a Randomized Controlled Double-blind Trial|KATECHOL|Medical University of Vienna|Yes|Recruiting|March 2015|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414555||23484|
NCT02414568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVAB|Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin|A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin|PVAB|The Lymphoma Academic Research Organisation|Yes|Recruiting|July 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|61 Years|N/A|No|||October 2015|October 16, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02414568||23483|
NCT02426060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARXBDDI-1|A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers|Effect of Imrecoxib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|January 2015|April 2015|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426060||22600|
NCT02465801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG01N-0778|Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein|Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients||Tianjin SinoBiotech Ltd.|No|Recruiting|December 2014|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|216|||Female|18 Years|65 Years|No|||November 2015|November 2, 2015|November 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02465801||19550|
NCT02469675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAR-15-001|Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS|Paired Stimulation to Increase Cortical Transmission to Hand Muscles: Pilot Study||Bronx VA Medical Center|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|30|||Both|21 Years|65 Years|No|||October 2015|October 14, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469675||19252|
NCT02469961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/07/VA07|Dexmedetomidine vs Propofol TIVA (Total Intravenous Anesthesia) and Interscalene Block|Dexmedetomidine vs Propofol TIVA and Interscalene Block for Shoulder Surgeries in a Beach Chair Sitting Position|TIVA|Maimonides Medical Center|No|Completed|October 2010|July 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|21 Years|N/A|No|||February 2016|February 10, 2016|June 3, 2015||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT02469961||19230|There was no limitations
NCT02426112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA698|Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children|Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children|BREATHE|London School of Hygiene and Tropical Medicine|Yes|Not yet recruiting|June 2016|October 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|6 Years|16 Years|No|||March 2016|March 18, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426112||22596|
NCT02426125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15679|A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy|RANGE|Eli Lilly and Company|Yes|Recruiting|July 2015|March 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|524|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02426125||22595|
NCT02470702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-15-02|Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects|A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects||The Medicines Company|Yes|Active, not recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|May 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470702||19173|
NCT02470715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMEM-2014-CCD001|Identifying Molecular Drivers of Cancer|Identifying Molecular Drivers of Cancer||Avera McKennan Hospital & University Health Center|Yes|Recruiting|April 2014|April 2024|Anticipated|April 2024|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|Samples With DNA|Participants will have up to 3 blood tubes (about 30 ml) drawn under the condition that      protocol criteria for blood sampling is met. Blood samples may be collected each time a      participant undergoes a provider-ordered blood draw. Urine samples may also be collected      approximately every 4-6 weeks.      Participants may be asked to provide approximately 60-120 ml of first-morning-void urine.      Tissue from a standard care surgical procedure or biopsy may be obtained. Additional core      biopsies (for research) or excess surgical waste will be collected during each biopsy      procedure when appropriate and will be processed and stored.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with cancer|June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02470715||19172|
NCT02462018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLV-0192-15|Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy|Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|21 Years|No|||April 2015|May 31, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02462018||19840|
NCT02423915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0150|Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention|Pilot Study of Infusion of Fucosylated Regulatory T Cells to Prevent Graft Versus Host Disease||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|80 Years|No|||March 2016|March 7, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423915||22765|
NCT02424058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-56/32|The Investigation of Thoracic Spinal Curvature and Mobility in Subjects With and Without Neck Pain: Cut-off Points|The Investigation of the Sagittal Thoracic Spinal Curvature and Mobility in Subjects With and Without Chronic Neck Pain: Cut-off Points and Pain Relationship||Ataturk Training and Research Hospital||Recruiting|July 2014|||July 2015|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Chronic neck pain and heatlhy subjects|April 2015|April 18, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02424058||22754|
NCT02426385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaneriPODAYFT/PODAYT|Comparison of Viusal Outcomes After Implantation of the POD 26% FineVision Toric (PhysIOL) and POD 26% Toric (PhysIOL)|Comparison of Viusal Outcomes After Implantation of the POD 26% FineVision||Physiol|No|Recruiting|April 2015|April 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pseudophakic patients implanted with one of the two IOLs|April 2015|April 21, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02426385||22575|
NCT02471040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010648|Brain Ketone Metabolism in Type 1 Diabetes|Impact of Recurrent Hypoglycemia on Brain Ketone Metabolism in Type 1 Diabetes||Yale University|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02471040||19147|
NCT02476695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-DDT-14004429|FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis|Research on FibroTouch Noninvasive Evaluation of Liver Fibrosis and Cirrhosis||Wuxi Hisky Medical Technology Co Ltd||Recruiting|May 2014|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|||Both|18 Years|65 Years|No|Non-Probability Sample|The subjects with chronic hepatitis B (CHB), who underwent a liver biopsy in hospital and        meets all of the inclusion criteria and none of the exclusion criteria, may participate in        this study. Within three months of FibroTouch examination, subjects are required to have        qualified histological specimens of liver biopsy for analysis and comparison.|June 2015|June 16, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02476695||18712|
NCT02419300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDIA|Could Colour Dopper Improve the Diagnosis of Retained Placental Fragments After Second Trimester Miscarriage ?|Value of Pelvic Ultrasonography and Colour Doppler in Diagnosing Retained Placental Fragments After Mid Trimester Miscarriage||Ain Shams University|Yes|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|82|||Female|16 Years|50 Years|No|Non-Probability Sample|Patients visiting The Obstetrics department in Ain Shams University Hospital complaining        of early second trimesteric abortion|February 2016|February 15, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02419300||23120|
NCT02424071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-2015-1841-HB-CTIL|The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery|The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery: a Prospective Randomised Controlled Cohort Study||Sheba Medical Center|No|Not yet recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02424071||22753|
NCT02414906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BarretosCH-UTI 1|Goal Directed Therapy for Acute Kidney Injury in Critical Ill Patients|Goal Directed Therapy in the Early Phase of Acute Kidney Injury in Critical Ill Patients|GDT-AKIN|Barretos Cancer Hospital|No|Completed|June 2010|December 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||March 2015|April 8, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414906||23457|
NCT02414919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17714|Duration of Use of Highly Effective Reversible Contraception|Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review||Bayer|No|Active, not recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13880|||Female|15 Years|44 Years|No|Non-Probability Sample|Women who had an IUD or contraceptive implant inserted at the University of Utah        healthcare system|March 2016|March 21, 2016|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02414919||23456|
NCT02471209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mzk-0003-2011|Biliary Atresia, Hepatic Buffer Response and Sevoflurane|||Children's Hospital of Fudan University|No|Completed|January 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|1 Month|3 Months|No|Probability Sample|infants with biliary atresia scheduled for a Kasai procedure|June 2015|June 10, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02471209||19134|
NCT02490683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150056|Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.|The Effect of Soy-based Dietary Supplements on Cardiometabolic Risk Factors in Individuals at High Risk for Cardiovascular Disease||Loma Linda University|No|Active, not recruiting|October 2015|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|24|||Both|35 Years|75 Years|No|||January 2016|January 4, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490683||17639|
NCT02475889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFAOO2|Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer|Hepatic Radiofrequency Ablation Increases T Cell Infiltraion and PD-L1 Expression in Primary Tumor in Patients With Synchronous Colorectal Cancer Liver Metastases||The First People's Hospital of Changzhou|No|Completed|November 2007|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|78|Samples Without DNA|Paraffin-embedded tissues of endoscopic biopsy specimen and matched resected primary tumor      specimen|Both|32 Years|78 Years|No|Non-Probability Sample|A total of 391 consecutive patients with synchronous colorectal cancer liver metastases        were initially included in this study. Among of them, 38 patients who received initial        hepatic RFA followed by primary tumor resection were identified as RFA group, and the        other 40 patients who received initial primary tumor resection were identified as Non-RFA        group.|June 2015|June 16, 2015|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02475889||18774|
NCT02479438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-008|Gastroesophageal Reflux Disease Prospective Registry|Gastroesophageal Reflux Disease Prospective Registry|GERD|Baylor Research Institute|Yes|Recruiting|January 2014|July 2030|Anticipated|January 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of GERD or a similar disease of the stomach, esophagus or        digestive tract.|June 2015|June 23, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02479438|10 Years|18501|
NCT02479451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001231|Helping Olfaction and Nutrition On Renal Replacement|Helping Olfaction and Nutrition On Renal Replacement|HONORR|Massachusetts General Hospital|Yes|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479451||18500|
NCT02478229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8883-A|Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)|Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)||University Health Network, Toronto|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2016|February 8, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02478229||18594|
NCT02463929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDiponegoro|Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric|Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric||Universitas Diponegoro|Yes|Completed|April 2014|July 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|2 Months|24 Months|No|||June 2015|June 2, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463929||19694|
NCT02483949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALD-GDM|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|HEALD-GDM|Athabasca University|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02483949||18154|
NCT02481934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-VS-MM|Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma|Phase 1 Clinical Trial to Evaluate Security and Dose of Expanded and Activated Autologous NK Cells Infusions in Consolidation of Multiple Myeloma Patients Treatment on Second or Later Relapse.|NK-VS-MM|Hospital Universitario 12 de Octubre|No|Active, not recruiting|March 2013|April 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|80 Years|No|||June 2015|June 25, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02481934||18309|
NCT02481947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI400-301|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults||Braintree Laboratories|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|459|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481947||18308|
NCT02485782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.I/HD/2015/06|Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis|Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis|CI/HD|Medical University of Warsaw|Yes|Completed|June 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 80 consecutive patients on maintenance hemodialysis were included in this        study.|September 2015|September 20, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485782||18013|
NCT02474862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR014540-01A1|Healthy Expectations - A Program for Pregnant Women Experiencing Depressive Symptoms|RCT of a Tailored Walking Program to Reduce Stress Among Pregnant Women|HE|Butler Hospital|Yes|Recruiting|March 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474862||18853|
NCT02489825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008/13|Study About the Effect of Preventive Adjacent Level Cement Augmentation After Osteoporotic Vertebral Compression Fractures|Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?||University of Bern|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|N/A|No|||July 2015|July 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02489825||17705|
NCT02489838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULAB11069|Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma|Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma||University of Rochester|No|Recruiting|September 2011|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer Patients at the University of Rochester|September 2015|September 17, 2015|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02489838||17704|
NCT02482194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFBMTC-SCI-2013|Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study|Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells in Patients of Spinal Cord Injury-Phase I Clinical Trial||Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan|Yes|Active, not recruiting|June 2013|August 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|No|||June 2015|June 25, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02482194||18289|
NCT02482441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131R10-001|A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10|A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer||OncoMed Pharmaceuticals, Inc.|No|Recruiting|June 2015|May 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482441||18270|
NCT02493517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-52030-289|Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly|A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly|LANTERN|Ipsen|No|Recruiting|October 2014|April 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|July 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02493517||17421|
NCT02464644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS/2012/2|Frequency of Common Medical Conditions in People With and Without HHT|A Questionnaire Study on Hereditary Hemorrhagic Telangiectasia (HHT) and Other Medical Conditions, Compared to the General Population||Imperial College London|No|Completed|April 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2174|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|June 3, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT02464644||19639|
NCT02464657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0907|Nivolumab in Acute Myeloid Leukemia (AML)|Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464657||19638|
NCT02487810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn 822238|Intuition vs. Deliberation in Medical Decision Making|Intuition Versus Deliberation in Decisions About Life-Sustaining Medical Therapies||University of Pennsylvania|No|Recruiting|June 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|200|||Both|60 Years|N/A|No|||June 2015|June 30, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487810||17858|
NCT02487823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCMPC-BKM-IPC 2012-009|Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer|Phase Ib Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer|NCMPC-BKM|Institut Paoli-Calmettes|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Male|18 Years|N/A|No|||February 2016|February 25, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487823||17857|
NCT02480309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0272|MMPPC: A Probabilistic Closed-loop Artificial Pancreas to Handle Unannounced Meals and Exercise|MMPPC: A Probabilistic Closed-loop Artificial Pancreas to Handle Unannounced|MMPPC|University of Colorado, Denver|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|14 Years|55 Years|No|||December 2015|December 30, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480309||18434|
NCT02462850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCT-006|A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip|A Phase 3 Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip||Charleston Laboratories, Inc||Completed|October 2014|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462850||19776|
NCT02477228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biliary cannulation|Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation|Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation. A Prospective Randomized Study|ERCP|Mansoura University|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||June 2015|June 17, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02477228||18671|
NCT02487914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|386|Evaluation of Pressure Sense Threshold and Tactile Sensation After Lidocaine Iontophoresis Using Interferential Current|Iontophoresis Effects on Senses||Shiraz University of Medical Sciences|No|Completed|January 2013|March 2015|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|July 1, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02487914||17850|
NCT02491853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GulfICD|The Gulf Implantable Cardioverter-Defibrillator Registry|The Gulf Implantable Cardioverter-Defibrillator Registry (GulfICD)|GulfICD|Gulf Heart Association|No|Recruiting|January 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patient receiving de nove implantable cardioverter defibrillator for primary or secondary        prevention of sudden cardiac death|July 2015|July 7, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02491853|1 Year|17549|
NCT02491866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-22|Computerized Adaptative Testing of Self-perceived Quality of Care in Psychiatry|Development and Implementation of a Computerized Adaptative Testing (CAT) of Self-perceived Quality of Care in Psychiatry|QDS Psy - CAT|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|September 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1400|||Both|19 Years|64 Years|No|||June 2015|July 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491866||17548|
NCT02462265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-AM-P2-01 Version 0.1|Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients|A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients||Oshadi Drug Administration|Yes|Not yet recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02462265||19821|
NCT02462525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-467|Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma||AbbVie|No|Recruiting|May 2015|April 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|161|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462525||19801|
NCT02465151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.09.NRC|Assessment of the Optimal Amount of Proteins at Breakfast for Children|Assessment of the Optimal Amount of Proteins at Breakfast for Children||Nestlé|No|Recruiting|April 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02465151||19600|
NCT02484443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01001|Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma|A Phase II Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody Dinutuximab (ch14.18,NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma||National Cancer Institute (NCI)|Yes|Recruiting|November 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|N/A|29 Years|No|||November 2015|March 24, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484443||18116|
NCT02488733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESINODOP|Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients|Laparoscopic Sleeve Gastrectomy Versus Conventional Medical Therapy in Patients With Newly Diagnosed Type 2 Diabetes and Body Mass Index 30-42 Kg/m2: a Randomized Clinical Trial|ESINODOP|Azienda Ospedaliera Santa Maria, Terni, Italy|Yes|Not yet recruiting|September 2015|September 2024|Anticipated|September 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|65 Years|No|||June 2015|June 30, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488733||17787|
NCT02466997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/05|Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC|Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study|VITAC|University Hospital, Bordeaux|Yes|Recruiting|July 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02466997||19458|
NCT02470104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4127|Donor Human Milk in Young Children Receiving Bone Marrow Transplantation|A Randomized Study of Enteral Donor Human Milk in Young Children Receiving Bone Marrow Transplantation||Children's Hospital Medical Center, Cincinnati|No|Recruiting|March 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|4 Years|No|||November 2015|November 10, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02470104||19219|
NCT02470117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|567/57|Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy|Comparison of the Efficacy of Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy : A Randomized Double-Blind Controlled Trial||Chulalongkorn University|Yes|Recruiting|June 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02470117||19218|
NCT02488148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12-0043|The Effect of Bikram Yoga on Arterial Stiffness and Endothelial Function in Middle-Aged Adults|Bikram Yoga and Vascular Health||University of Texas at Austin|Yes|Recruiting|September 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|80|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02488148||17832|
NCT02485470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.073|Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy|Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy||University of Michigan Cancer Center|Yes|Recruiting|February 2016|||February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|40 Years|N/A|No|||March 2016|March 3, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485470||18037|
NCT02472548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI1204|A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine|A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Containing Respiratory Syncytial Virus (RSV) SHe Antigen and a Novel Adjuvant DepoVaxTM, or SHe A Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50-64 Years of Age||Dalhousie University|Yes|Recruiting|May 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|40|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472548||19031|
NCT02466802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13-09812|Study of Regorafenib and Sildenafil for Advanced Solid Tumors|Phase I Study of Regorafenib and Sildenafil for Advanced Solid Tumors||Virginia Commonwealth University|Yes|Recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466802||19473|
NCT02466815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107460|A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets|Open-Label, Randomized, 3-Way Crossover Design to Assess the Relative Bioavailability of JNJ-42756493 Tablets||Janssen Research & Development, LLC||Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02466815||19472|
NCT02478970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087911|Specular Microscopy Study|Comparison of Clinical Evaluation of Endothelial Cells With Paracentral and Central Specular Microscopy||University of Michigan|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02478970||18537|
NCT02482740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGOG1005|A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix|An Open, Randomized, Multi-center, Phase 2 Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix: the Efficacy and New Biomarkers|TGOG1005|Buddhist Tzu Chi General Hospital|Yes|Recruiting|May 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Female|30 Years|85 Years|No|||June 2015|June 23, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02482740||18247|
NCT02482753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM301|Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer|A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)||Chipscreen Biosciences, Ltd.|Yes|Recruiting|July 2015|March 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|348|||Female|18 Years|75 Years|No|||January 2016|January 29, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02482753||18246|
NCT02485587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Health-F2-2013-602805|Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents|Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents (Part of EC FP7 Project Aggressotype: Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders)||Central Institute of Mental Health, Mannheim|Yes|Not yet recruiting|September 2015|February 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02485587||18028|
NCT02490423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040522|Improvement in Medication Compliance Through the Implementation of Personalized Nudges: the ENCOURAGE Trial|Improvement in Medication Compliance Through the Implementation of Personalized Nudges|ENCOURAGE|Intermountain Health Care, Inc.|No|Recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490423||17659|
NCT02490436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFK3 / 062202_281|Novel Treatment Option for Neuropathic Pain|A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain|NoTOPain|Sorlandet Hospital HF|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02490436||17658|
NCT02479321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 15/03|Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring in Patients With Hip Fracture|Efficacy of Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring to Reduce Perioperative Complications in Patients With Hip Fracture||Althaia Xarxa Assistencial Universitària de Manresa|No|Recruiting|March 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|568|||Both|65 Years|N/A|No|||December 2015|December 30, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479321||18510|
NCT02461654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9N-2015|EuroPainClinics® Study III (Prospective Observational Study)|EuroPainClinics® Study III (Prospective Observational Study)|EPCSIII|Europainclinics z.ú.|Yes|Recruiting|May 2015|December 2019|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Trial will compare evolution of patient's health state, changes of low back pain and other        neurological conditions during time period (6 and 12 month) after miniivasive        interventional algesiologic procedure - disc FX.|January 2016|January 23, 2016|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461654||19868|
NCT02461875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cabergoline / GnRH antagonist|Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome|Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: a Randomized Controlled Trial||Aljazeera Hospital|Yes|Recruiting|May 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|236|||Female|18 Years|40 Years|No|||November 2015|November 15, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02461875||19851|
NCT02492425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20150401|A Registry Study on Hospitalized Patients With Community-acquired Pneumonia in Real-life of China|Evaluating the Adherence to Guidelines' Empirical Antibiotic Recommendations and Outcome of Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia|CAP-China|Capital Medical University|No|Not yet recruiting|January 2016|May 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|14 Years|N/A|No|Non-Probability Sample|3000 patients with community acquired pneumonia who meet the below inclusion/ exclusion        criteria will be recruited in China|October 2015|October 14, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02492425||17505|
NCT02481128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SenSzi (GBG80)|Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer|Randomized Controlled Multicenter Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer; SenSzi (GBG80)||Kliniken Essen-Mitte|No|Active, not recruiting|May 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1210|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02481128||18371|
NCT02478541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxlip-2013_expt2|Understanding Liver Fat Metabolism: Studies to Understand the Role of Dietary Sugars on Liver Fat Metabolism|Investigating Intra-hepatic Fatty Acid Partitioning and Its Regulation in Man. Studies to Understand the Role of Dietary Nutrients in Liver Fat Metabolism in Relation to Obesity in Man||University of Oxford|No|Recruiting|March 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478541||18570|
NCT02466230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01944644|Antidepressant Mechanisms of Transcranial Magnetic Stimulation|Predictive and Response Biomarkers of Effective Treatment With Transcranial Magnetic Stimulation for Major Depressive Disorder||Weill Medical College of Cornell University|No|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466230||19517|
NCT02482129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LME636-2201|Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis|A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of LME636 in Patients With Acute Anterior Uveitis||Alcon Research|No|Active, not recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482129||18294|
NCT02480062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mWELLCARE 107/11|mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease|mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease|mWELLCARE|Public Health Foundation of India|Yes|Not yet recruiting|June 2015|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3600|||Both|30 Years|N/A|No|||June 2015|June 19, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02480062||18453|
NCT02490696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB14.01|Comparative Study of the Hypoxia Measured in FAZA and F-miso TEP/CT Scan in Patients With Non-small Cell Lung Cancer at the Time of Diagnosis : Correlation With Immunohistochemistry|Comparative Study of the Hypoxia Measured in FAZA and F-miso TEP/CT Scan in Patients With Non-small Cell Lung Cancer at the Time of Diagnosis : Correlation With Immunohistochemistry|RTEP6|Centre Henri Becquerel|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|July 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490696||17638|
NCT02466490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMA-MEX-12-01|Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension|A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension|FIRME-1|Stendhal Americas, S.A.|No|Completed|April 2013|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|272|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466490||19497|
NCT02467231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809406|Ovarian Reserve After Cancer: Longitudinal Effects|Ovarian Reserve After Cancer: Longitudinal Effects A Multicenter Prospective Cohort Study by the Oncofertility Consortium|ORACLE|University of Pennsylvania|No|Recruiting|February 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|181|Samples With DNA|whole blood, serum|Female|11 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenarchal females, ages 11-35, who will require chemotherapy; An unexposed cohort        balanced to the exposed cohort with respect to age and oral contraceptive use.|June 2015|June 5, 2015|July 22, 2013||No||No||https://clinicaltrials.gov/show/NCT02467231||19440|
NCT02470182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010124|Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors|Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors||Oregon Health and Science University|No|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|21 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants must be age 21-89 and have no self-reported sleep breathing problems.        Participants must not use a breathing assistance device (such as a continuous positive        airway pressure, or CPAP, machine) during sleep.|October 2015|October 22, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02470182||19213|
NCT02473900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OSTA-101|Evaluating the Bioequivalence of HIP1403, HGP0919|An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|April 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 14, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02473900||18927|
NCT02474095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 247213|Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer|Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study||Roswell Park Cancer Institute|Yes|Recruiting|November 2014|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474095||18912|
NCT02418494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-A02|Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions|Development of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)||AIDS Malignancy Consortium|No|Recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|35 Years|N/A|No|Non-Probability Sample|Participants diagnosed with HSIL within the prior 6 months enrolled at Weill Cornell        Medical College/New York Presbyterian Hospital, Montefiore Medical Center, and Laser        Surgery Care Center|February 2016|February 1, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418494||23181|
NCT02418507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PPHU|An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation||KGK Synergize Inc.|No|Active, not recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418507||23180|
NCT02470390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAZA-PK-401|Opel Label Cross Over Study Pharmacokinetics (PK) Study in Healthy Volunteers Recieving Various Forms of Fentanyl|An Open-Label Single-Dose Crossover Study Comparing the Plasma and Cerebrospinal Fluid Pharmacokinetics and Bioavailability of Fentanyl Delivered Intranasally Versus Sublingually Versus Intravenously in Healthy Volunteers||Depomed|No|Completed|November 2014|April 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470390||19197|
NCT02470403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIK066X2201|Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index|A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index||Novartis|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|176|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|June 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02470403||19196|
NCT02474108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAF|Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement|Pilot, Randomized,Single Blind Trial of Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|90 Years|No|||March 2016|March 15, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02474108||18911|
NCT02476643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6183-BO InteGast|Integrative Gastroenterology - an Observational Trial|Integrative Therapy in Gastroenterology - a Prospective Observational Trial in a Department of Internal and Integrative Medicine|InteGast|Universität Duisburg-Essen|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|100 patients with Inflammentory Bowel Disease admitted to the Department of Internal and        Integrative Medicine.        100 patients with Irritable Bowel Syndrome admitted to the Department of Internal and        Integrative Medicine.|January 2016|January 7, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02476643||18716|
NCT02423941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|616.36-089.843-008.6-07-037|A Study of Retrograde rEperfusion in Dbd Donor LIver Transplantation|A Randomized Clinical Study of Retrograde Caval or Antegrade Portal Reperfusion for Early Graft Dysfunction Prevention in Deceased Brain Dead Donor Liver Transplantation|REDLIT|Republican Scientific and Practical Center for Organ and Tissue Transplantation|Yes|Recruiting|April 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|69 Years|No|||April 2015|April 26, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02423941||22763|
NCT02423954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WG2015001|Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)|A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)|NivoPlus|Western Regional Medical Center|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|49|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423954||22762|
NCT02424045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12-012|Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma|A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial||Samsung Medical Center|No|Not yet recruiting|May 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02424045||22755|
NCT02413632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/50 - 2014-A01358-39|Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER)|Asymptomatic Sexually Transmitted Infections (STI) : Comparison of Two Screening Strategies Routine Screening Versus Screening as Reported by the Risks Taken by the Patient, in a Cohort of HIV Outpatients Men Who Have Sex With Men|DRIVER|Hopital Foch|No|Recruiting|April 2015|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|800|||Male|18 Years|75 Years|No|||November 2015|November 25, 2015|March 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02413632||23555|
NCT02473315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015- A00337-42|Assessment of Whole Body Cryotherapy in Treatment of Active Axial Spondylarthritis|Assessment of Whole Body Cryotherapy in Treatment of Active Axial Spondylarthritis||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473315||18972|
NCT02461953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-011|Combination of Hemodialysis With Hemoperfusion：A Clinical Study|HA130 Hemoperfusion Apparatus Combined Hemodialysis to Improve Quality of Life in Patients Undergoing Maintenance Hemodialysis：A Perspective, Randomized, Controlled Multicenter Clinical Study||Chinese PLA General Hospital|Yes|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02461953||19845|
NCT02465658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503073RIND|Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse|Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse||National Taiwan University Hospital|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Female|20 Years|N/A|No|Non-Probability Sample|Women with uterine prolapse and underwent vaginal total hysterectomy|December 2015|December 15, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465658||19561|
NCT02465879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRT-2015|Allied Health in Rheumatology Triage Project|Allied Health in Rheumatology Triage Project|AHRT|Sunnybrook Health Sciences Centre|No|Enrolling by invitation|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465879||19544|
NCT02413593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1701|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection|A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection||Gilead Sciences|No|Completed|April 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413593||23558|
NCT02426983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013008|Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination|A Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Auditory Sensory Memory Processing||University of Ottawa||Not yet recruiting|April 2015|April 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02426983||22529|
NCT02473393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-13-002|A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis|||Otsuka Pharmaceutical Co., Ltd.|Yes|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|19 Years|74 Years|No|||December 2015|December 18, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473393||18966|
NCT02466126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 13-315|Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs|Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs|My Brief CBT|VA Office of Research and Development|Yes|Not yet recruiting|December 2015|August 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02466126||19525|
NCT02470793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|Technique And Results In Endothelial Keratoplasty|Technique And Results Evaluation In Endothelial Keratoplasty|TREK|Hospital Mutua de Terrassa|Yes|Recruiting|September 2014|December 2025|Anticipated|December 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|June 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02470793||19166|
NCT02413827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1127-03|A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma|A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma||Celldex Therapeutics|Yes|Recruiting|April 2015|December 2020|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413827||23540|
NCT02470130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLESS 2014|Relaxation Before Debriefing and Memorization in High Fidelity Simulation in Healthcare|Effect of a Debriefing Conversational Relaxation on Memorization of Critical Key Points in Resident High Fidelity Simulation Education Program|RELAXSIMHF|Claude Bernard University|No|Recruiting|October 2014|March 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02470130||19217|
NCT02477007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130921|Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children|Phase III Clinical Trial Studying Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children|MORPHAPAIN|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|August 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|304|||Both|2 Years|17 Years|No|||May 2015|June 17, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02477007||18688|
NCT02481440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-MSC-SCI|Umbilical Cord Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury|Umbilical Cord Mesenchymal Stem Cells Transplantation for the Treatment of Spinal Cord Injury: A Prospective Cohort Study||Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|60 Years|No|||June 2015|June 22, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02481440||18347|
NCT02481726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XijingH|68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT|||Xijing Hospital||Completed|March 2014|||October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|75 Years|No|||June 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481726||18325|
NCT02463669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCUSIM01|The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department|The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department||Jewish General Hospital|Yes|Not yet recruiting|October 2015|June 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|||Both|10 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Convenience sample of patients between October 2015 and November 2016. Inclusion criteria        are patients aged between 10 and 35 year-old presenting to the ED with suspected acute        infectious mononucleosis.|July 2015|July 21, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02463669||19714|
NCT02483689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-047|Evaluation of Local Anesthetic at Incision Site|The Evaluation of Pre-incisional and Post-closure Local Anesthetic vs. Normal Saline on Postoperative Pain in Pediatric Appendectomies||Valley Anesthesiology Consultants|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02483689||18174|
NCT02483195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500433|The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia|The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia||University of Florida|No|Not yet recruiting|August 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483195||18212|
NCT02480127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|royan-Emb-021|Molecular Evaluation of Endometrium After Endometrial Injury|Molecular Evaluation of Endometrium Obtained From Women With Repeated Implantation Failure (RIF) After Endometrial Injury in Compare to Women Without Endometrial Injury; Phase 3 Clinical Trial||Royan Institute|Yes|Recruiting|June 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|40 Years|No|||June 2015|June 19, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02480127||18448|
NCT02468089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-SBP-001|To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis|A Randomized Study to Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis||Institute of Liver and Biliary Sciences, India|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02468089||19374|
NCT02468102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17543|Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)|A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden||Bayer|No|Recruiting|June 2015|April 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40000|||Both|N/A|N/A|No|Non-Probability Sample|Residents of Sweden: The study population will be identified using data from the Swedish        national health registers that are maintained by the national Board of Health and Welfare.|March 2016|March 3, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02468102||19373|
NCT02486497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-IMGPB-2015-01|Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining|Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining After Curative Surgery of Pancreatic Cancer||Seoul National University Hospital|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02486497||17959|
NCT02476019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 463588-CS2|A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients|A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 (ISIS-FGFR4RX, an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4) Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients|FGFR4-CS2|Ionis Pharmaceuticals, Inc.|No|Enrolling by invitation|June 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476019||18764|
NCT02479997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1410201-2|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Therapy(Chemotherapy, Hormonal Therapy, Targeted Therapy); Clinical Study for 130 Patients||National Cancer Center, Korea|Yes|Recruiting|April 2015|May 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|130|||Female|20 Years|70 Years|No|||February 2016|February 4, 2016|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02479997||18458|
NCT02486757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000513|Investigation of Female Reproductive Hormone Dynamics During Adolescence|Investigation of Female Reproductive Hormone Dynamics During Adolescence||Massachusetts General Hospital|Yes|Recruiting|April 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|45|||Female|12 Years|16 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486757||17939|
NCT02486770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC-11-01|Study of Single Doses of IV Aerucin in Healthy Adults|A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects||Aridis Pharmaceuticals, Inc.|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486770||17938|
NCT02491021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1402/39|Outpatient Based Physical Rehabilitation for Survivors of Prolonged Critical Illness|Outpatient Based Physical Rehabilitation for Survivors of Prolonged Critical Illness - a Randomised Controlled Trial||University Hospital Birmingham NHS Foundation Trust|No|Completed|October 2007|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491021||17613|
NCT02469259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16676|The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD|The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder|POP|University of California, San Francisco|No|Not yet recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469259||19284|
NCT02469272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Committee # 2014-15|Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study|Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study||Lifespan|Yes|Recruiting|May 2015|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02469272||19283|
NCT02492945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1411/276-004|Bundang Rehabilitative Impact Study of the Elbow Epicondylitis|Safety and Effects of PDRN(Polydeoxyribonucleotide) Injection in Patient With Elbow Epicondylitis in Randomized Double-blind Active-control Comparative Study|BundangRISEe|Seoul National University Bundang Hospital|Yes|Recruiting|June 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|64 Years|No|||July 2015|July 6, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02492945||17465|
NCT02484794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59093007|Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application|Efficacy and Acceptability of Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application: A Pilot RCT||Nova Scotia Health Authority|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|17 Years|N/A|No|||December 2015|December 7, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02484794||18089|
NCT02467816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12-7010|Technology and Design Innovation for School Lunch|Technology and Design Innovation to Support 21st Century School Nutrition||University of California, Berkeley|Yes|Active, not recruiting|March 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|14520|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467816||19395|
NCT02461901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/NW/1398|Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?|Does Using Fidaxomicin to Treat Clostridium Difficile Infection (CDI) Reduce the Recovery of C. Difficile From Patients' Faeces, Skin and Their Immediate Environment, Compared to Treatment With Vancomycin or Metronidazole?||University of Leeds|No|Recruiting|January 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Isolates of Clostridium difficile|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Clostridium difficile infection.        CDI is defined as the presence of both:          -  a positive C. difficile toxin assay result on a fecal sample, and          -  diarrhea (Bristol stool type 5-7) >/= 3 times in any 24 hour period in the last 7             days|June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461901||19849|
NCT02492997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0615|Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference|Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference||Venus Concept|Yes|Active, not recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492997||17461|
NCT02480595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCHYTAS|AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft|ARCHYTAS: AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft|ARCHYTAS|Lombard Medical|Yes|Recruiting|April 2015|April 2022|Anticipated|April 2017|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|The ARCHYTAS Registry will meet objectives only if appropriate patients are enrolled.        Patients presenting with AAA who fulfill inclusion criteria and are not ruled out by        exclusion criteria will be included. Each investigator will record all potential        participants screened for inclusion and document reasons for ineligibility. The implanting        physician will consider all relevant medical and nonmedical factors when determining if a        particular patient is suitable for inclusion in the Registry. In order to prevent        selection bias, sites will be asked to screen and enroll patients consecutively. In        circumstances where patients are screened and subsequently enrolled, but for various        reasons are not implanted with the Aorfix™ device, only the screening and procedural data        will be collected.|June 2015|June 22, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02480595|5 Years|18412|
NCT02466698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106184|Intestinal Lavage for the Treatment of Severe C. Difficile Infections|A Feasibility Randomized Trial of Intestinal Lavage for the Treatment of Severe C. Difficile Infections||Lawson Health Research Institute|No|Not yet recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02466698||19481|
NCT02469792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-CCH-03-01-14|Effectiveness and Safety of Autologous ADRC for Treatment of Anterior Cruciate Ligament Partial Rupture|Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Anterior Cruciate Ligament Partial Rupture||Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati|No|Enrolling by invitation|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469792||19243|
NCT02469805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 12|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility: A Randomized Controlled Trial||Cairo University|Yes|Recruiting|June 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469805||19242|
NCT02488044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB1102-101A|A Study of AEB1102 in Patients With Arginase I Deficiency|A Phase 1 Open-label, Dose-escalation Study of AEB1102 in Patients With Arginase I Deficiency and Hyperargininemia||Aeglea Biotherapeutics|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488044||17840|
NCT02491905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-HS-HP-09-1|Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients|Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients||Huons Co.,Ltd.|Yes|Completed|November 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|69|||Both|19 Years|75 Years|No|||July 2015|July 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491905||17545|
NCT02472327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlbanyMC|Decreasing Patient Dissatisfaction With Unplanned Cesarean Sections|Decreasing Patient Dissatisfaction With Unplanned Cesarean Sections: A Prospective Trial||Albany Medical College|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|N/A|N/A|No|||January 2016|January 20, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02472327||19048|
NCT02477475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HL00020|Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes|NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to Investigate Treatment Response to NEXIUM in Patients With Reflux Esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes||AstraZeneca|No|Recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Since the target patient population of the S-CEI is symptomatic RE patients, the patients        fulfilling the inclusion criteria and not the exclusion criteria shown below will be        enrolled as the subjects of this investigation.|March 2016|March 14, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02477475||18652|
NCT02493062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCI-22581|Evaluation of Hysterotomy Site After Open Fetal Surgery|Evaluation of Hysterotomy Site After Open Fetal Surgery|Hysterotomy|St. Louis University|No|Recruiting|January 2015|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|50 Years|No|||February 2016|February 5, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02493062||17456|
NCT02490306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGR 01|Evaluating Use of Microwave Technology to Differentiate Hemorrhagic Stroke From Infarction Before Arrival to Hospital|An Open Multicenter Study on Suspected Stroke Patients Evaluating the Possibility to Use Microwave Technology to Differentiate Hemorrhage From Infarction Before Arrival to Hospital|AmbuStroke|Sahlgrenska University Hospital, Sweden|No|Recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|500|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490306||17668|
NCT02490488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB12008|Masitinib in Ovarian Cancer|A Prospective, Multicenter, Open-label, Centrally Allocated, Activecontrolled, Phase 2 Study to Evaluate the Efficacy and Safety of Masitinib in Ovarian Cancer||AB Science|Yes|Active, not recruiting|April 2014|June 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Female|18 Years|N/A|No|||July 2015|July 2, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490488||17654|
NCT02475018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL/CL-004|The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human|The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human||Inner Mongolia Yili Industrial Group Co., Ltd|No|Completed|July 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|179|||Both|18 Years|65 Years|No|||July 2014|June 16, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02475018||18841|
NCT02487511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTX Duration|Eradication Rate Between 1- and 2-Week Helicobacter Pylori Eradication Therapy|Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication||St.Paul's Hospital, Korea|No|Recruiting|June 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|75 Years|No|||June 2015|June 30, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487511||17881|
NCT02482935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15536|A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food.|The Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation of Abemaciclib in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482935||18232|
NCT02482948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derma-MH001|MEDIHONEY® Gel Versus Collagenase for Wound Debridement|"Prospective, Randomized, Multi-Center, Efficacy Non-inferiority Study of MEDIHONEY® Gel Versus Collagenase for Wound Debridement"||Derma Sciences, Inc.|Yes|Terminated|June 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|December 1, 2015|June 12, 2015||No|Poor enrollment.|No||https://clinicaltrials.gov/show/NCT02482948||18231|
NCT02483156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELH - 2015|Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Tablet of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection|Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Tablet of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection||Egyptian Liver Hospital||Completed|July 2015|||August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02483156||18215|
NCT02486835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABO-cough-2015|Efficacy & Tolerability of a Specific Plantain,Thyme and Honey Cough Syrup vs Placebo in Child Cough Due to Common Cold|Efficacy & Tolerability of a Specific Plantain,Thyme and Honey Cough Syrup vs Placebo in Child Cough Due to Common Cold||Clalit Health Services|Yes|Not yet recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|1 Year|5 Years|No|||June 2015|June 29, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02486835||17933|
NCT02464891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL006_168|Complement Inhibition in aHUS Dialysis Patients|An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome|ACCESS|Mario Negri Institute for Pharmacological Research|No|Recruiting|May 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02464891||19620|
NCT02465112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERAVECT D13-2|Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor|A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases.|TERAVECT|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Recruiting|September 2015|December 2023|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02465112||19603|
NCT02465125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-426|The Transfusion Triggers in Vascular Surgery Trial|The Transfusion Triggers in Vascular Surgery Trial: Two Different Transfusion Triggers for Postoperative Haemoglobin Separation and Adherence to Transfusion Strategies in Vascular Surgery: a Randomised Clinical Feasibility Trial|TV|Naestved Hospital|Yes|Recruiting|June 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|40 Years|N/A|No|||July 2015|July 16, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465125||19602|
NCT02488265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tamine Capato 02|Protocol: Balance Training in Parkinson's Disease|Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease||University of Sao Paulo General Hospital|Yes|Not yet recruiting|July 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|70 Years|No|||June 2015|June 29, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02488265||17823|
NCT02479256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20092009|Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs|Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial||Ain Shams University|Yes|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|600|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 14, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479256||18515|
NCT02483819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0362|Changes of the Hemodynamic Profiles on Bio Reactance Technique During TURP in Elderly Patients|||Yonsei University|No|Not yet recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|65 Years|80 Years|No|Probability Sample|elderly patients undergoing transurethral resection of the prostate under spinal        anesthesia|June 2015|June 24, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483819||18164|
NCT02488772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMED-214-15|Improving Sleep and the Patient Experience in the Emergency Department|SOULMAN Study - A Randomized Controlled Trial of Sound and Light Manipulation in the Emergency Department to Improve Sleep and the Patient Experience|SOULMAN|Kingston General Hospital|No|Not yet recruiting|July 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02488772||17784|
NCT02465970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14_9808|Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy|BRAINSTIM : Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy|BRAINSTIM|Rennes University Hospital|No|Recruiting|November 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|15 Years|N/A|No|||February 2016|February 23, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02465970||19537|
NCT02481336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ER-103-395|To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity|Integrating Clinical and Genomic Profiles for Prediction and Prevention of Chemotherapy-induced Neuropathy Via Big Bio-Data Analytics||National Cheng-Kung University Hospital|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood Sample Collection with DNA|Both|20 Years|N/A|No|Probability Sample|Total 300 cancer patients will be enrolled in National Cheng Kung University Hospital from        March, 2015 to March, 2017. The subjects are stage I-IV ovarian cancer patients receiving        chemotherapy Paclitaxel/Carboplatin, stage II-IV endometrial cancer patients receiving        chemotherapy Paclitaxel/Carboplatin, stage III & high risk stage II colorectal cancer        patients receiving chemotherapy with mFOLFOX.|June 2015|June 22, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02481336||18355|
NCT02485730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA-FPM-0311|Early Identification of Markers in Alzheimer's Families / ALFA|Cohort Study for Early Identification of Markers in Cognitively Healthy Family Members of Patients With Alzheimer's Disease|ALFA Cohort|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Not yet recruiting|April 2016|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Whole blood, urine and CSF samples collection and analysis.|Both|45 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Offsprings of subjects diagnosed of probable AD before reaching 75 years of age, according        to McKhann et al. [McKhann et al., 1984] criteria, will be selected from spontaneous        volunteers and Alzheimer's patients associations members.|January 2016|January 19, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02485730||18017|
NCT02485977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16502|Cardiac MRI in Pulmonary Hypertension|||University of California, San Francisco|No|Not yet recruiting|July 2015|||June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with pulmonary hypertension referred for cardiac catheterization at UCSF|June 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485977||17998|
NCT02482545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0543|Breakfast Meal Replacement|Breakfast Meal Replacement Use on Body Composition and Health-related Quality of Life in Overweight Men and Women: a Randomized Controlled Trial|MRP|University of North Carolina, Chapel Hill|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482545||18262|
NCT02482779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082014-039|Smartphone Application-Based Vital Sign Monitors|Comparison of Smartphone Application-Based Vital Sign Monitors to Devices Used in Clinical Practice||University of Texas Southwestern Medical Center|No|Completed|January 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers from the UT Southwestern Department of Anesthesiology & Pain Management|August 2015|August 11, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02482779||18244|
NCT02470325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101-14-WOMC|The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients|A Randomized Double Blind Study of Cannabis on Dystonia and Spasticity in Pediatric Patients||Wolfson Medical Center|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|1 Year|18 Years|No|||August 2015|August 17, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02470325||19202|
NCT02485613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1501|Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis|Bortezomib With Dexamethasone as the First-line Treatment for Immunoglobulin Light Chain(AL) Amyloidosis||Nanjing University School of Medicine|No|Completed|January 2009|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|72|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients from hospital，who were diagnosed AL amyloidosis by renal or other type biopsy.|June 2015|June 25, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485613||18026|
NCT02484235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pro-001|Effects of High Intensity Interval Training and Strength Training in Obese|Effects of High Intensity Interval Training, Strength Training and the Combination in Overweight and Obese|EHITSTR|University of Chile|No|Recruiting|June 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 25, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02484235||18132|
NCT02484495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPHI_FSNRD_CF_MNP002|Extended Pilot Project Community Based Production of Complementary Food in Ethiopia|Evaluate the Impact of Package of Interventions on Growth and Micronutrient Status of Infant and Young Children||Ethiopian Public Health Institute|Yes|Enrolling by invitation|March 2015|August 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1800|||Both|6 Months|29 Months|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02484495||18112|
NCT02478814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAO-YM|Protein Requirements In Active Populations|Evaluation of Protein Requirements in Active, Young Adult Males||University of Toronto|No|Active, not recruiting|April 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|7|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478814||18549|
NCT02478827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-0526|A Trial of Cognitive Training in Schizophrenia|||University of Calgary||Not yet recruiting|January 2016|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|81|||Both|18 Years|65 Years|No|||November 2015|November 25, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478827||18548|
NCT02470624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurology-stroke|Chinese Acute Ischemic Stroke Treatment Outcome Registry|Chinese Acute Ischemic Stroke Treatment Outcome Registry|CASTOR|Peking University First Hospital|Yes|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|acute ischemic stroke patients|October 2015|October 22, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470624|18 Months|19179|
NCT02476435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14-P009|Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation|Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation of Right Angular Gyrus.|PERSONA|Centre Hospitalier St Anne|No|Recruiting|June 2015|September 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476435||18732|
NCT02472522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR9851450|Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks|Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in Transversus Abdominis Plane (TAP) Block for Post-operative Analgesia in Patients Undergoing Cesarean Sections||Tata Main Hospital|Yes|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|40 Years|No|||December 2015|December 21, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472522||19033|
NCT02472535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB8025-21427|Study to Evaluate the Effects of MBX-8025 in Patients With HoFH|A 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)||CymaBay Therapeutics, Inc.|Yes|Completed|April 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02472535||19032|
NCT02417467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3|Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial|Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial||McGill University|Yes|Not yet recruiting|September 2015|June 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|486|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417467||23260|
NCT02417480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043598|Differences in Eating Frequency Between Vegan and Omnivorous Diets|Differences in Eating Frequency Between Vegan and Omnivorous Diets|VeganBytes|University of South Carolina|No|Completed|April 2015|February 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02417480||23259|
NCT02472899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT4525|Biomarker Study for Alzheimer's Disease|Peripheral Markers of Inflammation in Patients With Alzheimer's Disease Compared to Cognitively Normal Elderly|BiomarkerAD|Beersheva Mental Health Center|No|Recruiting|February 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|150|Samples Without DNA|Frozen serum|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will include males and females older than 60 years diagnosed as having clinical        AD according to DSM-IV criteria. The control group will comprise cognitively normal        community dwelling males and females older than 60 years. In addition, a group of healthy        young male and female controls aged 20-30 years will serve as the reference group. The        diagnosis of both older patients and controls will be determined independently by a        multidisciplinary team of experts at the Memory Clinic of the Beersheva Mental Health        Center.|June 2015|June 15, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472899||19004|
NCT02472912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-HEB-1001|Adalimumab PK Bioequivalence Study to EU and US Sourced Humira|Single Center, Randomized, Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira, Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults||Mylan Inc.|No|Completed|December 2014|June 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|270|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02472912||19003|
NCT02476058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107002|A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder|An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder||Janssen-Cilag International NV|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|64 Years|No|||March 2016|March 7, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02476058||18761|
NCT02423642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB.NO.136/56|Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy|||Chulalongkorn University|Yes|Completed|July 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||April 2015|April 19, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423642||22786|
NCT02413034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/5533/I|The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures|||Parc de Salut Mar||Completed|November 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|March 24, 2015||||No||https://clinicaltrials.gov/show/NCT02413034||23601|
NCT02426931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy in Renal Calculi|Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy for the Treatment of Renal Calculi < 3 cm - Efficacity Prospective Randomized Multicentre Trial||Changhai Hospital|Yes|Not yet recruiting|April 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|75 Years|No|||April 2015|April 22, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02426931||22533|
NCT02426944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAGUE - 17|Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation|Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)|PRAGUE-17|Charles University, Czech Republic|Yes|Active, not recruiting|April 2015|May 2020|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426944||22532|
NCT02473263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01030-47|Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock|Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock|SSS|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02473263||18976|
NCT02461784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0487|The Effect of Methotrexate on Sperm Quality in Men With Inflammatory Bowel Disease|The Effect of Methotrexate on Sperm Quality in Men With Inflammatory Bowel Disease||University of Wisconsin, Madison|No|Recruiting|June 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Male|18 Years|40 Years|No|Non-Probability Sample|The subject population will consist of individuals with inflammatory bowel disease|December 2015|December 7, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02461784||19858|
NCT02414828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-010-402|A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB|A Phase II Double-Blind, Randomized, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary Tuberculosis|C-010-402|Aeras|Yes|Completed|October 2008|November 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02414828||23463|
NCT02418052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kli2|Effect of Neck Flexion on Esophagogastric Anastomotic Leakage After MIE|Effect of Neck Flexion on Post-operative Esophagogastric Anastomotic Leakage After Minimally Invasive Esophagectomy: a Single-center Randomized Controlled Trial||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02418052||23215|
NCT02466321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-U02|Anatomical Shoulder™ IR Study|Anatomical Shoulder™ Inverse/Reverse Post-Market Surveillance Study||Zimmer, Inc.|No|Active, not recruiting|September 2005|September 2023|Anticipated|September 2023|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466321||19510|
NCT02470507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP88220|Immune Function in Acute Kidney Injury|Evaluation of Immune Function in Patients With Acute Kidney Injury||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|June 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Hospitalised patients|June 2015|June 19, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470507||19188|
NCT02470520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ113/N062|Essential Nutrients in Critically Ill Patients With Severe AKI Treated With and Without CRRT|Observational Study Measuring Essential Nutrients in Critically Ill Patients With Severe Acute Kidney Injury Treated With and Without Continuous Haemofiltration||Guy's and St Thomas' NHS Foundation Trust|No|Active, not recruiting|August 2013|December 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients with severe acute kidney injury|May 2015|June 19, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470520||19187|
NCT02417714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140188|Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)|Prospective Evaluation of Next Generation CT Reconstruction||National Institutes of Health Clinical Center (CC)||Recruiting|September 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|August 5, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02417714||23241|
NCT02414646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU011301I|Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer|Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer||Academic and Community Cancer Research United|Yes|Recruiting|May 2015|||June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|65 Years|N/A|No|||January 2016|January 26, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02414646||23477|
NCT02462187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-WA201|Topical NVN1000 for the Treatment of External Genital and Perianal Warts|A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts||Novan, Inc.|Yes|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|50 Years|No|||October 2015|October 15, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462187||19827|
NCT02466581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-STAR|Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity|A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity||Karolinska Institutet|Yes|Recruiting|February 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02466581||19490|
NCT02476006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14245|Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies|A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies||Sanofi|No|Recruiting|June 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1100|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476006||18765|
NCT02462759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232SM202|A Study to Assess the Safety and Tolerability of ISIS 396443 (ISIS SMNRx) in Participants With Spinal Muscular Atrophy (SMA).|A Phase 2, Randomized, Double-blind, Sham-procedure Controlled Study to Assess the Safety and Tolerability and Explore the Efficacy of ISIS 396443 (BIIB058) Administered Intrathecally in Subjects With Spinal Muscular Atrophy Who Are Not Eligible to Participate in the Clinical Studies ISIS 396443-CS3B or ISIS 396443-CS4|EMBRACE|Biogen|Yes|Recruiting|June 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|N/A|N/A|No|||February 2016|February 19, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462759||19783|
NCT02418013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAIRB_BD_V.5.1_F011|Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma|A Randomized, Double-blinded and Placebo-controlled Pilot Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma by Clinical Markers of Frailty in Adult Who Defined Pre-Frailty||Bundang CHA Hospital|No|Active, not recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|64|||Both|55 Years|N/A|No|||January 2016|January 11, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02418013||23218|
NCT02472600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-266|Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy|A Randomized Controlled Multicenter Trial of a Five Day Course of Oral Colistin and Neomycin Followed by Restoration of the Gut Microbiota Using Fecal Transplantation to Eradicate Intestinal Carriage of Extended Spectrum Beta-lactamase or Carbapenemase-producing Enterobacteriaceae in High-risk Patients|R-GNOSIS WP3|University Hospital, Geneva|No|Recruiting|February 2016|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02472600||19027|
NCT02461693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150410009|Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT|Evaluating the Role of Expectations in Response to Caffeine Consumption: A Randomized Control Trial||University of Alabama at Birmingham|Yes|Completed|June 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|205|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461693||19865|
NCT02462681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211|Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery|Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery||Assiut University|No|Recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Female|25 Years|70 Years|No|||December 2015|December 29, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02462681||19789|
NCT02467426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Isolated Thoracic Perfusion (ITP-F) for MPM|Isolated Thoracic Perfusion With Hemofiltration (ITP-F) for Pretreated and Progressive Malignant Pleural Mesothelioma||Medias Klinikum for Surgical Oncology|No|Completed|September 2009|May 2015|Actual|January 2015|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|80 Years|No|Probability Sample|Patients with progressive malignant mesothelioma after failure of convetional multimodal        therapy including resection|June 2015|June 9, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02467426||19425|
NCT02485249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-007|Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema|Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema||Eyegate Pharmaceuticals, Inc.|No|Recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||August 2015|January 19, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485249||18054|
NCT02467842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP607-QIV_FluA_III_2014|Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607) in Adults and Elderly Subjects|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects||SK Chemicals Co.,Ltd.|No|Completed|September 2014|May 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1503|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02467842||19393|
NCT02489292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP002|Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)|Prospective, Open Label, Multicenter, Efficacy and Safety Study of Several Infusions of HepaStem in Urea Cycle Disorders Paediatric Patients||Promethera Biosciences|Yes|Recruiting|October 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|12 Years|No|||June 2015|July 2, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02489292||17745|
NCT02489305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105160|Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)|A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment||Janssen Research & Development, LLC|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|64 Years|No|Non-Probability Sample|Participants with major depressive disorder who have responded to an oral antidepressant        regimen will be observed.|March 2016|March 11, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489305||17744|
NCT02487979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01037|Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma|A Phase II Study of GPNMB-Targeted Antibody-Drug Conjugate, Glembatumumab Vedotin (CDX-011, CR011-vcMMAE), in Recurrent or Refractory Osteosarcoma||National Cancer Institute (NCI)|Yes|Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|12 Months|49 Years|No|||February 2016|March 24, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487979||17845|
NCT02484560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56733164/203|Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2|Efficacy of Allogenic Mesenchymal Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2||University of Gaziantep|Yes|Active, not recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|8 Years|14 Years|No|||June 2015|June 30, 2015|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02484560||18107|
NCT02475239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 57-0082-13-1|Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo|Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo||Prince of Songkla University|Yes|Recruiting|December 2014|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02475239||18824|
NCT02475304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSA-201-DMF|Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis|A Randomized, Double Blind, Placebo-controlled Proof-of-concept Study of FP187 in Patients With Mild to Moderate Psoriatic Arthritis||Skåne University Hospital|No|Recruiting|May 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|May 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475304||18819|
NCT02486965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOUFISPORT (RB 14.076)|Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects|Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects|DOUFISPORT|University Hospital, Brest|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|110|||Female|18 Years|60 Years|No|||October 2015|October 15, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486965||17923|
NCT02486978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 14-029|Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.|Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.||University of Leeds|Yes|Recruiting|June 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02486978||17922|
NCT02490150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDQ-COR-2014-01|Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill|Administration of Corifollitropin Alfa on Day 5 Versus Day 7 After Last Oral Contraceptive Pill in a GnRH (Gonadotropin-releasing Hormone ) Antagonist Protocol in Donors||Institut Universitari Dexeus|No|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02490150||17680|
NCT02493452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-05|Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)|Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|IBS-C|Synergy Pharmaceuticals Inc.|No|Recruiting|June 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1050|||Both|18 Years|85 Years|No|||February 2016|February 29, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493452||17426|
NCT02493465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR33T|Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study|Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study||Instituto de Urologia e Nefrologia|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|65 Years|No|||July 2015|July 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02493465||17425|
NCT02464163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC26|Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older|Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older|PSC26|Protein Sciences Corporation|Yes|Active, not recruiting|July 2015|November 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464163||19676|
NCT02487238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-364|Pediatric FEcal Microbial Transplant for Ulcerative Colitis|A Single-Blind, Randomized, Placebo-Controlled Trial of Human Fecal Microbial Transplantation for the Therapy of Pediatric Ulcerative Colitis and Inflammatory Bowel Disease Unclassified|PediFETCh|McMaster Children's Hospital|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|17 Years|No|||December 2015|December 22, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487238||17902|
NCT02490280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00083366|Examining Cortisol and Alpha Amylase in a Healthy Sample of Youth and Adults|Examining Biomarkers of Anxiety in a Healthy Sample of Youth and Adults||Johns Hopkins University|Yes|Completed|April 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|11 Years|34 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490280||17670|
NCT02480634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPRA-1023-SK|Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer|Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|No|Not yet recruiting|October 2015|December 2018|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|March 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480634||18409|
NCT02477189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-0115|Retrospective Analysis of the Safety and Effectiveness of Using the Silicone Block in Penile Surgery|Retrospective Analysis of the Safety and Effectiveness of Using the Silicone Block in Penile Surgery||International Medical Devices, Inc.|Yes|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|400|||Male|18 Years|N/A|No|Non-Probability Sample|Men age 22 and older who had a penis implant from 2009-2014|June 2015|June 19, 2015|May 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477189||18674|
NCT02461680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6021|Treatment for Partial Lesions of the Fingers Flexor Tendons : Tangential Resection or Direct Suture|Management Of The Partial Lesions Of The Fingers Flexor Tendons, Prospective Randomized Trial Of 2 Surgical Procedures: Tangential Resection Versus Direct Suture|FLEXOR|University Hospital, Strasbourg, France|No|Not yet recruiting|July 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|June 2, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461680||19866|
NCT02481089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|warburg snp|Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma|||Hunan Province Tumor Hospital||Recruiting|June 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|npc patients who can tolerable and agree for IMRT and concurrent chemotherapy|February 2016|February 17, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02481089||18374|
NCT02489162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiMuMS|The Role of a Device to Evaluate the Neuromuscular Function in Assessing Muscle in Facial Paralysis Patients|The Role of MyotonPro in Assessing the Biomechanical Properties of Facial Muscles in Facial Paralysis Patients and Its Role in Monitoring Recovery Following Facial Reanimation Surgery|MyotonPRO|Universitair Ziekenhuis Brussel|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|August 6, 2015|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489162||17755|
NCT02481349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0013|Couple-Based Yoga Program for Glioma Patients and Their Partners|Couple-Based Yoga Program for Glioma Patients and Their Partners||M.D. Anderson Cancer Center|Yes|Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481349||18354|
NCT02481596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140562_A|Family-Focused Mobile Health Intervention|Family-Focused Mobile Health Intervention: Targeting Family Behaviors to Improve Type 2 Diabetes Management Among Adults||Vanderbilt University|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481596||18335|
NCT02485015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZYY-GAS-001|The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer|The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer||The First People's Hospital of Changzhou|No|Active, not recruiting|June 2015|June 2033|Anticipated|June 2030|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|70 Years|No|||February 2016|February 18, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485015||18072|
NCT02472132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0131-15-CTIL|The Use of Point of Care Ultra Sound for Correct Placement of Central Venous Catheter|The Use of Point of Care Ultra Sound for Correct Placement of Central Venous Catheter and for the Detection of Complications||Soroka University Medical Center|Yes|Active, not recruiting|July 2015|July 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|186|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02472132||19063|
NCT02477293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B120014|The Effectiveness and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine|The Effectiveness and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine||Kyung Hee University Hospital at Gangdong|Yes|Not yet recruiting|August 2015|||August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||June 2015|June 23, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02477293||18666|
NCT02477306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC1/14/516GSKRABFST|A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)||Genuine Research Center, Egypt|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02477306||18665|
NCT02493023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3385|Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS|Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS)||St. Olavs Hospital|No|Completed|October 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02493023||17459|
NCT02480855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIDAS|Early Identification of Persons at Risk for Sick-leave Due to Work-related Stress|Early Identification of People at Risk for Sick-leave Due to Work-related Stress - A Randomized Controlled Study of People With Mental Disorders and Physical Complaints Consulting Primary Health Care|TIDAS|Göteborg University|No|Enrolling by invitation|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|420|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02480855||18392|
NCT02480868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTEBONE 01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2014|||||N/A|N/A|N/A||||||||||||||January 12, 2016|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480868||18391|
NCT02474940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46765-B|MS Symptom Management Study|Enhancing the Benefits of Pain and Fatigue Treatment in MS|ENHANCE|University of Washington|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02474940||18847|
NCT02474953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15PCHB|A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product|A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Formulation to a Comparator Curcumin Product|15PCHB|KGK Synergize Inc.|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02474953||18846|
NCT02462343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|walk test trial|Comparison of the Two and Six- Minute Walk Tests in Evaluating Oxygen Desaturation in Patients With Severe COPD|Comparison of the Two and Six- Minute Walk Tests in Evaluating Oxygen Desaturation in Patients With Severe COPD||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|March 2007|August 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|26|||Both|N/A|N/A|No|||June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462343||19815|
NCT02481908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STI in COPD|STI Combined to Valsalva Maneuver for the Diagnosis of Left Ventricular Dysfunction in COPD Exacerbations|a New and Non Invasive Method to Calculate STI ( Systolic Time Intervals) Combined to Valsalva Maneuver in Patient With Acute Exacerbation of COPD|STICOPD|University of Monastir|Yes|Recruiting|September 2014|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|166|||Both|18 Years|N/A|No|Probability Sample|It is a prospective study of patients visiting the emergency department of the hospital        Fattouma Bourguiba Monastir with decompensated chronic obstructive pulmonary disease COPD|June 2015|June 22, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02481908|1 Year|18311|
NCT02490618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s57667|The Use of a Probiotic Lozenge in the Treatment of Residual Pockets After Classical Non-surgical Therapy|The Use of a Probiotic Lozenge in the Treatment of Residual Pockets After Classical Non-surgical Therapy||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||May 2015|October 12, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02490618||17644|
NCT02463643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z215-01|To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis|A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Z-215 Compared With Rabeprazole Sodium in the Treatment of Erosive Esophagitis||Zeria Pharmaceutical|No|Active, not recruiting|May 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463643||19716|
NCT02489578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20150101|A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)|Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China|RSCAP-China|Capital Medical University|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3000|||Both|14 Years|N/A|No|Non-Probability Sample|3000 patients with community acquired pneumonia who meet the below inclusion/ exclusion        criteria will be recruited in China.|October 2015|October 14, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02489578||17724|
NCT02487849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPEC-OVAR-REZIDIV-2014-1.1|HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma|Feasability of an Unique Intraoperative Given Hyperthermal Intraperitoneal Chemotherapy With Carboplatin During a Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma|HIPEC|Krankenhaus Barmherzige Schwestern Linz|Yes|Not yet recruiting|November 2015|||December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||May 2015|June 29, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02487849||17855|
NCT02494401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1310-08323.|Taking Charge of Systemic Sclerosis|Taking Charge of Systemic Sclerosis: Improving Patient Outcomes Through Self-management|TOSS|University of Michigan|No|Not yet recruiting|October 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02494401||17353|
NCT02479061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPA-10|An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers.|An Observational Study of the Prevalence of Patients Requiring Palliative Care in the French Anti Cancer Centers.|PREPA-10|Centre Leon Berard|No|Active, not recruiting|June 2015|June 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|846|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients hospitalized in a conventionnal medical service of a French anti cancer        center.|February 2016|February 24, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479061||18530|
NCT02469753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2014/36|Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes|Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes|STOP|University Hospital, Bordeaux|No|Recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469753||19246|
NCT02491619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sendyk001|Correlation Between Dental Inclination and Bone Thickness in Patients With Class III Dentofacial Deformities|Correlation Between Buccolingual Dental Inclination and Bone Thickness After Orthodontic Decompensation in Patients With Class III Dentofacial Deformities||University of Sao Paulo|Yes|Recruiting|July 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02491619||17567|
NCT02483741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-OMFS-04-2015|The Use of Manuka Honey to Improve Healing After Third Molars Surgery|The Effect of Topical Application of Manuka Honey on Healing After Extraction of Impacted Lower Third Molars: A Split-Mouth Design Randomized Controlled Trial||Damascus University|Yes|Recruiting|June 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|37 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483741||18170|
NCT02478294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-SR-113|Comparison Between Thoracoscopic Left Atrial Appendage Excision and Warfarin for the Secondary Prevention of Stroke in Patients With AF|Evaluation of Thoracoscopic Left Atrial Appendage Excision With Warfarin for the Prevention of Stroke And Non-Central Nervous Systemic Embolism in Patients With Atrial Fibrillation and Thromboembolism: Cohort Study||The First Affiliated Hospital with Nanjing Medical University|No|Active, not recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Serum and plasma|Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients with non-valvular AF and a previous history of stroke are eligible for        inclusion of this study.|June 2015|June 22, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02478294||18589|
NCT02470078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-155|Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke|Randomised Controlled Trial of Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke Patients||University Hospital Muenster||Not yet recruiting|July 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||June 2015|June 11, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02470078||19221|
NCT02470091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST1321|Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma|Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma||Children's Oncology Group|Yes|Recruiting|October 2015|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|11 Years|49 Years|No|||January 2016|January 7, 2016|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470091||19220|
NCT02485366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021487|Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery|Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery||Duke University||Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|N/A|18 Years|No|||January 2016|January 7, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485366||18045|
NCT02490046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0384|D-mannose for the Prevention of UTIs in Multiple Sclerosis|Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis||University College, London|Yes|Recruiting|February 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02490046||17688|
NCT02476331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-0767|A Trial of Cognitive Training in Euthymic Bipolar Disorder|A Randomized Control Trial of Cognitive Training in Euthymic Bipolar Disorder||University of Calgary|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2015|June 16, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02476331||18740|
NCT02488135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6601059|Management of Persistent Epistaxis Using Floseal Hemostatic Matrix|Management of Persistent Anterior Epistaxis Using Floseal Hemostatic Matrix vs. Traditional Nasal Packing: A Prospective Randomized Controlled Trial.||University of Alberta|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488135||17833|
NCT02488356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQP1200|Litramine for Weight Loss|Safety and Efficacy of Litramine IQP G-002AS for Weight Loss: A Randomised, Double-blind, Placebo-controlled, Parallel-group Study||InQpharm Group|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488356||17816|
NCT02483039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization|Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization (FUSION): Vanguard Phase of a Randomized Controlled Trial|FUSION|St. Michael's Hospital, Toronto|No|Recruiting|September 2015|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483039||18224|
NCT02476448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 15-015|Evaluation of Ureteral Jets on Cystoscopy|Evaluation of Ureteral Jets on Cystoscopy: A Randomized Controlled Trial|JET|Cleveland Clinic Florida|Yes|Active, not recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|177|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02476448||18731|
NCT02474719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULIPE|Transfer and Ultrafiltration In Peritoneal Dialysis|Transfer and Ultrafiltration In Peritoneal Dialysis|TULIPE|Centre Hospitalier Universitaire de Besancon|No|Recruiting|January 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02474719||18864|
NCT02424240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-Ayman-789|Growth Hormone (GH) Deficiency & Insulin Like Growth Factor 1 (IGF-I)/ Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio|The Emerging Role of Serum IGF-I/IGFBP-3 Ratio in the Diagnosis of Children With Growth Hormone Deficiency||University of Jordan|No|Completed|May 2011|||August 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|134|||Both|4 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|192 children presented to JUH outpatient endocrinology clinic for the evaluation of short        stature (SS). The target population of our study was male and female children, aged 4-16        years, with short stature.|April 2015|April 21, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02424240||22740|
NCT02426047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR00007655|Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy|The Feasibility and Tolerability of Medium Chain Triglycerides as an Adjunct to the Dietary Management of Epilepsy in Women With a Catamenial Seizure Pattern on the Modified Atkins Diet||Johns Hopkins University|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02426047||22601|
NCT02476916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG348-C-003|A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency|A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency||Agios Pharmaceuticals, Inc.|No|Recruiting|June 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476916||18695|
NCT02476968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0816C00012|To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer|An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA)|ORZORA|AstraZeneca|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Female|18 Years|130 Years|No|||February 2016|February 11, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02476968||18691|
NCT02465814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17541|Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids|A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids|ASTEROID 2|Bayer|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|120|||Female|18 Years|50 Years|No|||March 2016|March 10, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02465814||19549|
NCT02465047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH17299|Stress and Seizures - Can a Brief Self-help Book Help?|Stress and Seizures - Can a Brief Self-help Book Help?||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|November 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|No|||June 2015|June 3, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02465047||19608|
NCT02413047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502834262|Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator|A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator||Indiana University|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413047||23600|
NCT02417259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2161|Near Infrared Spectroscopy in Cyanotic Congenital Heart Disease|Changes in Cerebral and Somatic Near Infrared Spectroscopy Monitoring Before and After Surgery for in Children With Cyanotic Heart Disease||KK Women's and Children's Hospital|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|18 Years|No|Non-Probability Sample|Children with cyanotic congenital heart disease undergoing cardiac surgery|February 2016|February 23, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417259||23276|
NCT02413658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1CSC2015|Phenytoin in the Healing of Clean Surgical Wounds|Phenytoin in the Healing of Clean Surgical Wounds||Children's Surgical Center, Cambodia||Recruiting|March 2015|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|80 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02413658||23553|
NCT02469285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarniMari-HY|The Effect of Pork With Modified Fat Composition and Berries on Plasma Fatty Acids and Fecal Compounds in Healthy Adults|The Effect of Pork With Modified Fatty Acid Composition on Plasma Lipids and Fatty Acids and the Effect of Pork and Berries on Fecal Compounds in Healthy Adults||Helsinki University|No|Completed|September 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|65|||Both|20 Years|68 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|December 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02469285||19282|
NCT02461472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCANRA_Dr.Tang|Risk Analysis for Diabetic Cardiovascular Autonomic Neuropathy|The Risk Analysis for Diabetic Cardiovascular Autonomic Neuropathy in General Chinese Population||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Recruiting|January 2013|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The investigators recruited participants from rural and urban communities in Shanghai.        Survey diabetic participants with undiagnosed DCAN, aged 30-90 years, were included in        this study. Our study invited a total of 3000 subjects to a screening visit between 2013        and 2015.|December 2015|December 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461472||19882|
NCT02465320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-1077-07|COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy|A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy||Juniper Pharmaceuticals, Inc.|Yes|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|40 Years|75 Years|No|||July 2015|July 15, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465320||19587|
NCT02465333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110358|Fat Grafting and Retention for Heel Fat Pad Atrophy|Fat Grafting and Retention for Heel Fat Pad Atrophy||University of Pittsburgh|No|Recruiting|May 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02465333||19586|
NCT02418793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-5-001|A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B|A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B||Opko Biologics|Yes|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|24|||Male|18 Years|65 Years|No|||November 2015|February 19, 2016|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418793||23158|
NCT02418806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cuiDem/FBB-0113|Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres|Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres|cuiDem|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Completed|January 2014|September 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|231|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02418806||23157|
NCT02426333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN AKF-14.07|Optimizing Abiraterone Therapy|Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC|OPTIMUM|Radboud University|No|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood samples for abiraterone concentrations and also blood samples to assess biomarkers      (some contain DNA)|Male|18 Years|N/A|No|Non-Probability Sample|Male patients with metastatic castration resistant prostate cancer who are asymptomatic or        mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is        not yet clinically indicated|September 2015|September 16, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02426333||22579|
NCT02470728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES07|Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.|Pain Management Options for Opioid Tolerant Patients: a Randomized Controlled Trial|Pain Redesign|University of California, Irvine|Yes|Recruiting|January 2016|November 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02470728||19171|
NCT02470741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15678|Pilot of Letrozole for Uterine Myomas||PLUM|University of California, San Francisco|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|21 Years|N/A|No|||August 2015|August 20, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470741||19170|
NCT02475928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cirrhosis01|Zinc Supplementation in Cirrhotic Patients|Zinc Supplementation as Treatment of Dysgeusias in Cirrhotic Patients|ZnDCP|Fundación Clínica Médica Sur|Yes|Recruiting|April 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||May 2015|June 16, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02475928||18771|
NCT02475941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24664|Early Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients|Early Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients||St. Louis University|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|64 Years|90 Years|No|||June 2015|January 25, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02475941||18770|
NCT02423434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP3DK104386|Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes|Multinational Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|Yes|Enrolling by invitation|September 2014|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|729|||Both|18 Years|N/A|No|Non-Probability Sample|This longitudinal observational cohort study of diagnosis involves follow-up in two study        groups:        A. Five- to seven-year follow-up re-examination of 5 well-characterized type 1 diabetes        (T1D) cohorts (N=516) comprising a neuropathic subset and a non-neuropathic subset.        B. Three- to six-year follow-up re-examination of 4 well-characterized type 2 diabetes        (T2D) cohorts (N=524) each comprising a neuropathic subset and a non-neuropathic subset.        T1D Subjects. The five study sites are composed of cohort studies for T1D initiated        between 2008 and 2011. Together, the five sites have studied 516 subjects at baseline with        T1D, 363 without DPN and 151 with DPN at baseline.        T2D Subjects. Four of the sites have studied subjects with T2D. Together, the four sites        have studied 524 subjects at baseline with T2D, 241 without DPN and 283 with DPN at        baseline.        Of the 1040 total subjects examined in baseline procedures, we anticipate follow-up of 70%        for a total re-examined cohort 729.|February 2015|April 17, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02423434||22802|
NCT02469818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH005|Diagnostic Accuracy of Bedside Ultrasonography in the Management of the Shoulder Dislocations|Diagnostic Accuracy of Bedside Point of Care Ulrasound (POCUS) in the Management of the Shoulder Dislocations||Antalya Training and Research Hospital|No|Recruiting|January 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|15 Years|N/A|No|Non-Probability Sample|All patients over 14 years of age with the complaint of shoulder pain and suspected        glenohumeral dislocations|June 2015|June 12, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469818||19241|
NCT02469831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|low pressure lap chole.|Respiratory Mechanics and Metabolic Changes During Low Pressure Laparoscopic Cholecystectomy|Respiratory Mechanics and Metabolic Changes During Low Pressure Laparoscopic Cholecystectomy With Deep Versus Intermediate Neuromuscular Blockade. A Randomized Clinical Study||Assiut University||Completed|October 2014|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|60 Years|No|||January 2016|January 8, 2016|May 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469831||19240|
NCT02466594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBogenhausen|Impact of Active Thermoregulation on the Microcirculation of Free Flaps|Impact of Active Thermoregulation on the Microcirculation of Free Flaps||Klinik Bogenhausen|Yes|Completed|November 2013|April 2015|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 5, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02466594||19489|
NCT02462772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 014|Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa|Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa|CAPRISA014|Centre for the AIDS Programme of Research in South Africa|Yes|Withdrawn|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462772||19782|
NCT02423499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO13-ML/REMBAU|Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder (REMBAU)|Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder|REMBAU|University Hospital, Tours|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|ASD subjects will be recruited at Centre Universitaire de Pédopsychiatrie, CHRU de Tours,        FRANCE.        BD subjects will be recruited at Clinique Psychiatrique Universitaire, CHRU de Tours,        FRANCE.        Healthy volunteers will be recruited at Centre d'Inverstigation Clinique, CHRU de Tours,        FRANCE.|May 2015|May 19, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02423499||22797|
NCT02423564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14PCHN|A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation|A Double-blind, Placebo-controlled, Parallel Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation||KGK Synergize Inc.|No|Recruiting|May 2015|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02423564||22792|
NCT02466269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hui_owen|Treatment of Diacapitular Condylar Fractures|A Modified Preauricular Approach to Treat Diacapitular Condylar Fractures: The Supratemporalis Approach||West China College of Stomatology|Yes|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Both|4 Years|70 Years|No|Probability Sample|patients with diacapitular condylar fractures|June 2015|June 8, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466269||19514|
NCT02471677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|elonva_hyper-responders|Corifollitropin Alfa Versus Follitropin Beta in High Responders|Corifollitropin Alfa (Elonva) Versus Follitropin Beta in High Responders: A Randomized Controlled Trial||Eugonia|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02471677||19098|
NCT02493413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001563777|The Stress-release Effects of Exercise in Obese Are Determined by DS14 Score and T-cell Activation Status|The Stress-release Effects of Exercise in Obese Are Determined by DS14 Score and T-cell Activation Status||Institute for Preventive Medicine, Trzaska|Yes|Completed|January 2012|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|30 examinees, 14 men of average age 56,3 ± 15,5 years old and 16 women of average age of        53,5. ± 4,2 years old made the owerweight/obese group of chronic (coronary heart disease)        patients. Subjects were matched by gender, age, body mass index and had all been regular        visitors (patients) of The Institute of Preventive Medicine.|July 2015|July 8, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02493413||17429|
NCT02475187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2015/139|Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture|Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture|thro-fract15|Vestre Viken Hospital Trust|No|Recruiting|September 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|220|Samples Without DNA|Blood tests for Measurments of thrombotic properies. No storage of specimens|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to our hospital for proximal femur fracture and receive orthopedic        surgery with concomittant thrombosis prophylaxis with LMWH or anticoagulation with        Warfarin, and are capable to sign/accept informed concent|February 2016|February 7, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02475187||18828|
NCT02478944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastrolabor-IBD UKE|Esophageal Motility Disease Screening in Patient With Suspicion or Diagnosis of IBD|Esophageal Motility Disease Screening in Patient With Suspicion or Diagnosis of IBD|EMSIBD|University Hospital Erlangen|No|Recruiting|October 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|November 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02478944||18539|
NCT02492958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3451003|SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults|A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults||Pfizer|Yes|Active, not recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|136|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02492958||17464|
NCT02492971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kcheng|Function-oriented Assistive Technology Indexing System Development and Promotion|Development of a Function-oriented Assistive Technology Indexing System and Its Promotion in the Disabled Population||Chang Gung Memorial Hospital|No|Not yet recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|the disabled and their caregivers|August 2015|August 25, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02492971||17463|
NCT02475135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107430|Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination|A Single-dose, Open-label, Randomized, Crossover Study to Assess the Impact of Food on the Pharmacokinetics of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Administered as a Fixed-dose Combination Tablet, and the Relative Bioavailability||Janssen Sciences Ireland UC|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475135||18832|
NCT02476890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-014|Effect of AF-219 on Cough Reflex Sensitivity (Cough Challenge)|A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects||Afferent Pharmaceuticals, Inc.|No|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|November 19, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476890||18697|
NCT02489604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST100.11|Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors|Peptide Receptor Radionuclide Therapy (PRRT) With Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors, 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET Negative Patients: a Prospective Phase II Randomized Study|LUNET|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|December 2013|December 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02489604||17722|
NCT02478489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32911|Alcohol Use Disorder hOsPital Treatment Trial|Oral v. Injection Naltrexone in Hospital Comparative Effectiveness for Alcoholism|ADOPT|Boston University|No|Not yet recruiting|December 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02478489||18574|
NCT02490982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE15.016|Teriflunomide Observational Effectiveness Study|Teriflunomide Observational Effectiveness Study||Centre hospitalier de l'Université de Montréal (CHUM)|No|Enrolling by invitation|July 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Relapsing Remitting Multiple Sclerosis patients followed at three MS Clinics.|January 2016|January 25, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02490982||17616|
NCT02468401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-15-MMC|Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions|The Efficacy of a New Protocol for Preventing Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions||Meir Medical Center||Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2015|November 11, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468401||19350|
NCT02468414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-EP-RF-04|TARGTEPO Treatment for Anemia in PD US Trial|Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO||Medgenics Inc.|Yes|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468414||19349|
NCT02489643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11134/14|Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis|Role of an Individualized Medical Training in Improving Efficacy and Adherence to a 4-week Treatment With Calcipotriol and Betamethasone Dipropionate Gel for Mild-to-moderate Plaque Psoriasis||Catholic University of the Sacred Heart||Completed|May 2014|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02489643||17719|
NCT02489682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A016520|Clinical Informed Consent Format Evaluation|Clinical Informed Consent Format Evaluation||Carnegie Mellon University|No|Completed|December 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02489682||17716|
NCT02489695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXIPAP|Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma|Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)|AXIPAP|Centre Leon Berard|No|Recruiting|October 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02489695||17715|
NCT02478762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-160|Glycemic Objectives of Women With Gestational Diabetes Mellitus|Reevaluation of the Glycemic Objectives of Women With Gestational Diabetes Mellitus||Université de Sherbrooke|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02478762||18553|
NCT02485262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience|Outcome of New Direct Acting Agents For Hepatitis C||Arrowhead Regional Medical Center|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|18 Years|75 Years|No|Probability Sample|Targeted subjects are HCV patients are ARMC who received one of the SOF based treatment        regimens from December 20, 2013 to May 2015|June 2015|June 29, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02485262|12 Months|18053|
NCT02486653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1494|Prevention of Post-operative Urinary Retention|Pre-operative Tamsulosin for the Prevention of Post-operative Urinary Retention: a Randomized, Double-blind, Placebo-controlled Trial|POUR|University of Wisconsin, Madison|Yes|Recruiting|July 2015|September 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|372|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486653||17947|
NCT02485171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7420 15|SAFEWALKER Contribution to the Rehabilitation of Older People After a Post-fall Syndrome|Post-fall Syndrome of the Aged Person : Contribution of SAFEWALKER for Rehabilitation|SAFEER|University Hospital, Toulouse|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|70 Years|N/A|No|||June 2015|June 29, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02485171||18060|
NCT02494362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2015|Tele-rehabilitation in the Home With Gaming as a Method of Improving Upper Extremity Function After Stroke|Tele-rehabilitation in the Home With Gaming as a Method of Improving Upper Extremity Function After Stroke||University of Manitoba|No|Not yet recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|40 Years|70 Years|No|||July 2015|July 7, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02494362||17356|
NCT02474420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANALI|Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients|The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia|CANALI|University Health Network, Toronto|Yes|Active, not recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474420||18887|
NCT02474433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0083-15-WOMC|Same-day Cervical Preparation With Misoprostol Before Hysteroscopy|Same-day Cervical Preparation With Misoprostol Before Hysteroscopy: a Randomized Trial of Different Routes of Administration||Wolfson Medical Center||Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 21, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02474433||18886|
NCT02474446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/14/053|Getting Vitamin D Dosing Right|Determining the Effects of Race, Skin Colour and Genotype on the Response to Vitamin D Therapy||Sheffield Children's NHS Foundation Trust|No|Completed|December 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02474446||18885|
NCT02465983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CART-meso-19|Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer|Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer||University of Pennsylvania|Yes|Active, not recruiting|May 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465983||19536|
NCT02465996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G02|Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy|Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy||Shandong University|Yes|Recruiting|July 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02465996||19535|
NCT02485379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0440|Assessment of Prostate MRI Before Prostate Biopsies|Improvement in the Detection of Aggressive Prostate Cancer by Targeted Biopsies Using Multiparametric MRI Findings|MRI-FIRST01|Hospices Civils de Lyon|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Male|18 Years|75 Years|No|||March 2016|March 9, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02485379||18044|
NCT02485392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH 2014-0114|A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder|A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder||Kantonsspital Winterthur KSW|No|Recruiting|July 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02485392||18043|
NCT02489396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029898|Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment|Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment||University of Vermont|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All orders placed on any of the Rosie sites or apps in the study period will be included.        No active recruiting of participants will take place, data will only be collected from        existing Rosie customers. Participants will not be informed that manipulations are        happening on the website, other than notices the company occasionally displays when they        are revising features of the website. In order to determine whether any of the proposed        "mindless" interventions actually work, it is imperative that consumer attention not be        drawn to changes in the site. It is expected that 400-1000 orders per month will be        included as part of the study during each two-month intervention period.|June 2015|June 30, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02489396||17737|
NCT02474888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508058|Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis|Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)|MONITUX|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|October 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|blood specimen for serum rituximab level and serum anti-rituximab level|Both|18 Years|N/A|No|Probability Sample|Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill        criterions), with or without detectable ANCA|October 2015|October 30, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02474888||18851|
NCT02462135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301045|Protocol of Virtual Interactive Memory-Training Program|The Development and Evaluation of the Effectiveness of a Virtual Interactive Memory Training Program for Older Adults With Mild Cognitive Impairment: Protocol of a Randomized Controlled Study||Ministry of Science and Technology, Taiwan|Yes|Recruiting|March 2014|July 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02462135||19831|
NCT02481609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130996|NAC Trial for Anosmia|Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia||University of Miami|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|June 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481609||18334|
NCT02485652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EMSI-202|ELUXA 1: Phase II Trial of HM61713 (BI 1482694) for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung|A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 (BI 1482694) in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor||Hanmi Pharmaceutical Company Limited|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|20 Years|N/A|No|||February 2016|February 4, 2016|June 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485652||18023|
NCT02485223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15022 [Sponsor reference]|Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis|Single Test to ARrive at MS Diagnosis. A Prospective, Longitudinal, Investigator Blinded, Pilot Study Assessing the Accuracy of a Single 3 Tesla MRI Scan in Predicting Multiple Sclerosis in Cases of Diagnostic Uncertainty|STAR-MS|University of Nottingham|No|Enrolling by invitation|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Probability Sample|The investigators will recruit patients who attend the general neurology and MS clinics at        Nottingham University Hospitals (NUH) NHS Trust, UK. The researchers anticipate that the        study population will comprise of two groups: the common presentation of young individuals        following the first neurological symptoms suggestive of MS, however the neuroradiologist's        report of the MRI will not be in agreement with the neurological impression; and a group        of patients who present with atypical symptoms for MS but the MRI scan is reported as        suggestive of MS.|December 2015|December 1, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02485223||18056|
NCT02463396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48776.091.14|Mindfulness Training in Adults With ADHD|Mindfulness Training Versus Treatment as Usual in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Radboud University|No|Recruiting|September 2014|December 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02463396||19735|
NCT02466529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-NHR10311|Natural History of Spinal Muscular Atrophy Type 1 in Taiwan|Natural History of Spinal Muscular Atrophy Type 1 in Taiwan||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|N/A|20 Years|No|Non-Probability Sample|Spinal muscular atrophy Type 1|March 2015|July 27, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466529||19494|
NCT02485938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-1002-DMD-01|HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)|A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy|HOPE|Capricor Inc.|No|Recruiting|August 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|12 Years|N/A|No|||February 2016|February 10, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485938||18001|
NCT02482519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000624|The Effects of Acute Weight Gain and Acute Calorie Deprivation on Marrow Adipose Tissue|||Massachusetts General Hospital|No|Recruiting|November 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|34|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02482519||18264|
NCT02468960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPreNBiS|Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS)|Optimal Lesion Preparation With Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) -OPRENBIS Study||SIS Medical AG|No|Recruiting|March 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02468960||19307|
NCT02480205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-4083|A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns|A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns|NeuroPAP|St. Justine's Hospital|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|1 Month|No|||November 2015|November 20, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02480205||18442|
NCT02490267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALA1020|Quality of Life in Children Glaucoma and Cataract|Health- and Vision-Related Quality of Life in Children and Young People With Childhood Glaucoma, Childhood Cataract and Congenital Eye Defects||Moorfields Eye Hospital NHS Foundation Trust|No|Completed|June 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|200|||Both|2 Years|16 Years|No|Non-Probability Sample|We will recruit children who attend the children's eye clinics at Moorfields Eye Hospital        at City Road. We will recruit children with healthy eyes and normal vision amongst the        siblings who accompany new patients in Child Vision Clinics and the paediatric A&E. This        approach will ensure that families have not previously been burdened with frequent        hospital appointments.|March 2016|March 15, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02490267||17671|
NCT02479074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcadMed1002015|The Utility of feNO in the Differential Diagnosis of Chronic Cough|The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast|TUF|Hull and East Yorkshire Hospitals NHS Trust|Yes|Not yet recruiting|July 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479074||18529|
NCT02483533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-23|Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202|A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study||Neothetics, Inc|No|Enrolling by invitation|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|1600|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483533||18186|
NCT02475291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0025|Clinical Usefulness of Fractional Flow Reserve Measurement for Significant Stenosis in Proximal Coronary Artery|||Yonsei University|No|Not yet recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with significant lesions with more than 70% diameter stenosis at proximal part of        one or more major coronary arteries, regardless of revascularization strategy.|June 2015|June 17, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02475291||18820|
NCT02481570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500120|Anesthetic Optimization in Scoliosis Surgery|Evaluation of an Anesthetic Optimization Technique in Adolescent Idiopathic Scoliosis Surgery|AIS|University of Florida|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|10 Years|18 Years|No|||December 2015|December 16, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481570||18337|
NCT02481869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002117|Platelet Rich Plasma Injection in Pilon Fractures|Does Early Platelet Rich Plasma Injection Decrease the Risk of Post-traumatic Arthritis in Pilon Fractures Undergoing Two-staged Open Reduction With Internal Fixation?||University of Missouri-Columbia|No|Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02481869||18314|
NCT02488070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0068|68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer|68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study||Stanford University|Yes|Active, not recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|19 Years|N/A|No|||November 2015|November 4, 2015|June 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488070||17838|
NCT02482272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTADE|Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B|Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy||Asan Medical Center|No|Recruiting|May 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|N/A|No|||December 2015|December 29, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02482272||18283|
NCT02488655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/BG/FA/FS/2015|Treatment of Breast Fibroadenoma With FastScan HIFU|Treatment of Breast Fibroadenoma With FastScan High Intensity Focused Ultrasound (HIFU)||Theraclion|No|Recruiting|June 2015|October 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02488655||17793|
NCT02488668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-602547-1|Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|EPIONE|Aalborg University|No|Recruiting|June 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|July 19, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488668||17792|
NCT02492230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241592LLAPCI|Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI|Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent Percutaneous Coronary Intervention||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|May 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|75 Years|No|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02492230||17520|
NCT02486848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-DRUG-MINOXIDIL-001|Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil|Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil||Applied Biology, Inc.|No|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|55 Years|No|||June 2015|January 30, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02486848||17932|
NCT02486861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349/2015|OCT-Features in Culprit and Not Culprit Coronary Plaque in ACS Patients|OCT-Features Of moRphology, coMposItion anD instABility of Culprit and Not Culprit Coronary pLaquE in ACS Patients|OCT-FORMIDABLE|Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Recruiting|May 2015|||June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|The OCT-FORMIDABLE register will include with a retrospective fashion all consecutive        patients that perform OCT on culprit and not culprit plaque in any subset in patients with        ACS. Clinical and OCT data will be included in the register according to the dataset.        SAMPLE SIZE: the recent paper of Niccoli et al11 showed a percentages of plaque rupture of        60% in ACS. According to the paper of Pedruzzi et al12, at least 100 patients are needed        to evaluate independent predictive power of clinical presentation (STEMI vs NSTEMI vs UA),        diabetes mellitus, previous use of aspirin, of statin and age.|June 2015|June 29, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486861|12 Months|17931|
NCT02462122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-118A-302|302 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Not yet recruiting|July 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462122||19832|
NCT02492490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVF-DCD|Effect of SVF Derived MSC in DCD Renal Transplantation|Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Randomized Controlled Trial||Fuzhou General Hospital|No|Recruiting|December 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||November 2014|July 4, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02492490||17500|
NCT02492711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAH22-04|Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer|A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment|SOPHIA|MacroGenics|Yes|Recruiting|July 2015|May 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02492711||17483|
NCT02487147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00031388|Evaluation of Free Air Portable Air Powered Respirator|Evaluation of Free Air Portable Air Powered Respirator System for Prevention of Influenza Transmission||Wake Forest Baptist Health|No|Not yet recruiting|April 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|86|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487147||17909|
NCT02487160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL-INI-02-13|Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens|Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens||Lenstec Incorporated|No|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|510|||Both|22 Years|N/A|Accepts Healthy Volunteers|||August 2015|October 28, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487160||17908|
NCT02462330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 142 01|Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)|Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.|MESAMI2|University Hospital, Toulouse|Yes|Not yet recruiting|June 2015|May 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462330||19816|
NCT02419014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52H13|Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome|Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome|CES in RLS|Tripler Army Medical Center|Yes|Recruiting|February 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02419014||23141|
NCT02413099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBMSI-2 Study|The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction|The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Pusan National University Hospital|No|Completed|February 2012|||November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|44|||Male|19 Years|40 Years|No|||April 2015|April 8, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413099||23596|
NCT02465827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BispebjergH|Ultrasound-guided Selective Blockade of the Saphenous and Obturator Nerves Following Total Knee Arthroplasty|Selective Blocks for Total Knee Arthroplasty||Bispebjerg Hospital|Yes|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02465827||19548|
NCT02469987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-1402O-1002|Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers|A Single Center, Randomized, Double-blind, 3-arm Parallel Phase1 Study to Assess PK, Safety, and Tolerability of a Single 90 Min iv Infusion of 1 mg/kg MYL-1402O, EU Avastin®, and US Avastin® in Healthy Male Volunteers||Mylan Inc.|No|Active, not recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|111|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02469987||19228|
NCT02423395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|muscle cramps in cirrhotics|A Randomized Placebo Controlled Study of Orphenadrine` in the Treatment of Muscle Cramps in Patients With Cirrhosis|A Randomized Placebo Controlled Study of Orphenadrine` in the Treatment of Muscle Cramps in Patients With Cirrhosis||Tanta University|Yes|Recruiting|January 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 27, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423395||22805|
NCT02471950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 LO 0366|Isoflurane During Cardiopulmonary Bypass|The Depth of Anaesthesia Associated With the Use of 2.5% Isoflurane During Cardiopulmonary Bypass||University of Edinburgh|No|Recruiting|April 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Arterial and venous blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Those patients scheduled for elective heart surgery over the age of 18 requiring        cardiopulmonary bypass|June 2015|June 10, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02471950||19077|
NCT02471963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC2014EMPA|Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function|Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function||University of Erlangen-Nürnberg Medical School|Yes|Active, not recruiting|December 2014|June 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02471963||19076|
NCT02466074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0450|The Role of Enhanced Cerebral Perfusion in Lesion Evolution|The Role of Enhanced Cerebral Perfusion in Lesion Evolution||The University of Texas Health Science Center, Houston|No|Not yet recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||June 2015|June 8, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466074||19529|
NCT02470247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14_9899_IPC-Angio Trial|Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients|IPC-Angio Trial : Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy (Post-diagnostic Imaging) in Patients at High Risk of Contrast-induced Nephropathy|IPC-Angio|Rennes University Hospital|No|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02470247||19208|
NCT02423837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL-RUS-2013|Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma|Prospective Multicenter Study: Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma|BRiF|National Research Center for Hematology, Russia|No|Recruiting|December 2013|April 2021|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||April 2015|April 19, 2015|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02423837||22771|
NCT02426970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2014/AD-01|Are Acceptance and Commitment Related to Treatment Response in Chronic Low Back Pain|Are Acceptance and Commitment Related to Treatment Response in Chronic Low Back Pain|COP-PAIN|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|74 Years|No|Non-Probability Sample|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in        the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and        Montpellier University Hospitals.|October 2015|October 30, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02426970||22530|
NCT02473861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00888|EXercise Influence on Taxane Side Effects (EXIT) Study|EXercise Influence on Taxane Side Effects (EXIT) Study|EXIT|University of British Columbia|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|43|||Female|19 Years|N/A|No|||November 2015|November 24, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02473861||18930|
NCT02462473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106922|A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry|A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry||Janssen Research & Development, LLC|No|Active, not recruiting|May 2015|March 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|155|||Both|18 Years|70 Years|No|||December 2015|December 18, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02462473||19805|
NCT02462486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-006|Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration|Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration||Allergan|Yes|Recruiting|June 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|900|||Both|50 Years|N/A|No|||March 2016|March 7, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462486||19804|
NCT02423447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27689|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With Cystic Fibrosis (CF)||Stanford University|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|25|||Both|8 Years|N/A|No|||December 2015|December 7, 2015|February 3, 2015|No|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT02423447||22801|
NCT02472353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMEM-2014-MET001|Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer|A Phase II Pilot Study Using Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients||Avera McKennan Hospital & University Health Center|Yes|Recruiting|July 2014|July 2025|Anticipated|July 2025|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472353||19046|
NCT02471105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57304|Investigation of IOP and Tolerability of Bimatoprost 0.1% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml|IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy|SPORTII|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|67|||Both|18 Years|N/A|No|||March 2015|June 12, 2015|March 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02471105||19142|
NCT02466958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-USA-000620|Trial of Levomilnacipran in Geriatric Depression|Double-blind Placebo-controlled Trial of Levomilnacipran in Geriatric Depression|LMIL|University of California, Los Angeles|Yes|Not yet recruiting|July 2015|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||June 2015|June 8, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02466958||19461|
NCT02424370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11069|Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation|Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation. Multicenter Observational Study|EVA-G-TAVI|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|75 Years|N/A|No|Non-Probability Sample|person aged over 75 years with indication for implantation of TAVI|March 2015|April 22, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424370||22730|
NCT02424409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130943|Evaluation of the Relapse Rate One Month After Discharge From Emergency Department for Asthmatic Patients Given a Strict Formalized Follow up Protocol|Evaluation of the Relapse Rate One Month After Discharge From Emergency Department for Asthmatic Patients Given a Strict Formalized Follow up Protocol. Multicenter, Prospective, Cluster-randomized|ASUR-R|Assistance Publique - Hôpitaux de Paris|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424409||22727|
NCT02470364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGQOL-15|Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F|Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F|MGQOL-15-F|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2014|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with auto-immune myasthenia gravis|October 2014|June 12, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470364||19199|
NCT02470663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1957-15|Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium|Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium: A Prospective Randomized Multicenter Trial||Sheba Medical Center|No|Not yet recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|No|||June 2015|June 11, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470663||19176|
NCT02464293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHDN Seed Fund Project 561|A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease|A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease||Lancaster University|No|Active, not recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02464293||19666|
NCT02468557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-385-1577|Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma||Gilead Sciences|No|Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468557||19338|
NCT02493426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT Challenge|Single Dose Intranasal Oxytocin and Cognitive Effects in Autism|Single Dose Intranasal Oxytocin (IN-OT) Versus Placebo in Autism: Examining Cognitive Effects||University of Minnesota - Clinical and Translational Science Institute||Active, not recruiting|May 2014|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|5 Years|40 Years|No|||July 2015|July 8, 2015|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02493426||17428|
NCT02476851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100380|Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder|Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder||Haemonetics Corporation|No|Completed|June 2015|September 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476851||18700|
NCT02487251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-68001-23239|Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschools|Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschoolers|SimplyDinner|Michigan State University|No|Recruiting|September 2015|March 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|770|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02487251||17901|
NCT02465697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 05-1110|Changes in the Brain as Borderline Patients Learn to Regulate Their Emotions|An fMRI Study of the Enhancement of Emotion Regulation in Borderline Patients||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Anticipated|288|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465697||19558|
NCT02464176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00032805|Systemic Steroids for Peripheral Nerve Blocks|The Effects of Systemic Steroids on the Duration of a Psoas Compartment Block.||Wake Forest Baptist Health|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|115|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464176||19675|
NCT02479217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20367|Safety of Xeloda in Solid Tumours|Safety of Xeloda in Solid Tumours||Hoffmann-La Roche||Completed|July 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1268|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with early or metastatic colon cancer, and patients with metastatic breast        cancer, no age limit|June 2015|June 23, 2015|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479217||18518|
NCT02483468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036590|The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain|The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain||Medical University of South Carolina|Yes|Recruiting|January 2015|June 2020|Anticipated|January 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2015|June 24, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483468||18191|
NCT02483754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20140901|Application and Revision of Montreal Cognitive Assessment in Chinese Retirees|Application and Revision of Montreal Cognitive Assessment in Military Retirees With Mild Cognitive Impairment|ARMOCA|Xijing Hospital|Yes|Completed|January 2011|March 2014|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|304|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Three hundred and four retired military cadres.They can be divided by age, level of        education and physical exercise and cerebral apoplexy to evaluate their mild cognitive        impairment.|June 2015|June 24, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02483754||18169|
NCT02480348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V2 04Mar2015|Medtronic RevElution Trial|Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|RevElution|Medtronic Vascular||Recruiting|June 2015|February 2021|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02480348||18431|
NCT02475317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP625-101|Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion|A Randomized, Blinded, Placebo-controlled, Phase 1 Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Subjects, as Assessed by Fecal Bile Acid Excretion||Shire|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|8||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|June 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475317||18818|
NCT02475382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-169|Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen|Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC|CheckMate 169|Bristol-Myers Squibb||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2016|January 11, 2016|June 16, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02475382||18813|
NCT02479464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002523|Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting|A Pilot Study for the Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting|HAMM|Mayo Clinic|No|Completed|October 2009|August 2014|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|80 Years|No|||July 2015|July 1, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02479464||18499|
NCT02484027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10580|Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS)|Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients|REPAIRS|Second Affiliated Hospital of Soochow University|Yes|Not yet recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|456|||Both|35 Years|80 Years|No|||June 2015|June 24, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484027||18148|
NCT02461836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAN2015-030|Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)|An Open-Labeled, Randomized Phase II Trial of Adjuvant Chemotherapy in Combination With Stereotactic Body Radiation Therapy (SBRT) Versus Adjuvant Chemotherapy Alone for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)||Second Affiliated Hospital, School of Medicine, Zhejiang University|No|Not yet recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2015|May 31, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461836||19854|
NCT02466191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0438|Treatment of Pendular Nystagmus in OPT|Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study||Hospices Civils de Lyon|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02466191||19520|
NCT02489071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7277-CE|Cognitive Intervention After a Brain Tumor|Cognitive Intervention After a Brain Tumor||University Health Network, Toronto|No|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02489071||17762|
NCT02489110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pz-A104a|Webnovela for Hispanic Dementia Family Caregivers|Webnovela for Hispanic Dementia Family Caregivers||Photozig, Inc.||Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02489110||17759|
NCT02481700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57824|Epidemiological Study on the Surgical Removal of Third Molars|Epidemiological Study on the Surgical Removal of Third Molars||Universitaire Ziekenhuizen Leuven|No|Enrolling by invitation|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All included patients are referred from primary dental providers for the surgical removal        of one or more third molars|March 2015|June 22, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481700|7 Days|18327|
NCT02481713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1790-R|Enhancing Adherence to Cognitive Rehabilitation|Enhancing Adherence to Cognitive Rehabilitation||VA Office of Research and Development|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02481713||18326|
NCT02475434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37231|Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants|A Randomized Trial of the Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants||Baylor College of Medicine|No|Enrolling by invitation|July 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|N/A|14 Days|No|||December 2015|December 15, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02475434||18809|
NCT02486939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-0214-05|A Long Term Safety Extension Study (CHS-0214-05)|An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)||Coherus Biosciences, Inc.|Yes|Recruiting|July 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486939||17925|
NCT02486952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20390|MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma|Open, Non-Interventional, Multicenter Trial of MabThera in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma||Hoffmann-La Roche||Completed|August 2005|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|154|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with aggressive B-cell lymphoma (Diffuse Large B-Cell Lymphoma [DLBCL])|January 2016|January 22, 2016|June 29, 2015|No|Yes||No|November 17, 2015|https://clinicaltrials.gov/show/NCT02486952||17924|
NCT02489331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FESI5001|Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".|Post Marketing Surveillance of Safety and Efficacy for Cholib® in Korean Patients Under the "New Drug Re-examination".||Abbott|No|Recruiting|July 2015|||November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|N/A|No|Probability Sample|Patients who are prescribed Cholib as per doctor's medical judgement in normal medical        parctice setting|March 2016|March 24, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02489331||17742|
NCT02489344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS14116|Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease|An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease||Sanofi|Yes|Enrolling by invitation|July 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489344||17741|
NCT02494375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0219|Sleep and Type 1 Diabetes|Sleep and Glycemic Control in Type 1 Diabetic Children|SLEEPT1D|Hospices Civils de Lyon|No|Recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|82|||Both|6 Years|17 Years|No|||July 2015|July 7, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02494375||17355|
NCT02463136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-IDREC-C2-2013-014|FMRI-BASED NEUROFEEDBACK WITH ANXIOUS ADOLESCENTS STUDY|Using Real-time fMRI-based Neurofeedback With Anxious Adolescents|NF-AA|University of Oxford|Yes|Not yet recruiting|August 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Female|14 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02463136||19754|
NCT02466256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005|Intra and Postoperative Outcomes With 3 Injectors|Comparison of Intraoperative Performance and Incision Morphology Using Three Injector Devices : Randomized, Clinical Trial||Iladevi Cataract and IOL Research Center|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|40 Years|85 Years|No|||June 2015|June 8, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466256||19515|
NCT02485665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-2015-298|Efficacy of Extracorporeal Biofeedback Device for Post-prostatectomy Incontinence|Efficacy of Personalized Extracorporeal Biofeedback Device for Pelvic Floor Muscle Training on Post-prostatectomy Incontinence||Seoul National University Hospital|Yes|Recruiting|July 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|84|||Male|20 Years|85 Years|No|||November 2015|November 16, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485665||18022|
NCT02490176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015-095-01|Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters|Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure||Chinese PLA General Hospital|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02490176||17678|
NCT02468661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280B2201|A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification|A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)||Novartis|Yes|Recruiting|September 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468661||19330|
NCT02487472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201926|Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France|Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France: the POSTHER Study||GlaxoSmithKline||Not yet recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Both|50 Years|N/A|No|Probability Sample|The study has been designed to include 250 patients ≥ 50 years old with a first visit for        diagnosis of HZ during a 6-month inclusion period (HZ cohort) and 40 expected cases of PHN        after 3 months of HZ rash onset.|January 2016|January 18, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02487472||17884|
NCT02489786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL (312)|A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital|A Prospective Randomized Study of Different Digoxin Treatment Regimens in Egyptian Hospital||Cairo University|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|71|||Both|18 Years|70 Years|No|||July 2015|July 3, 2015|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02489786||17708|
NCT02486536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-045k|The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy|The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single−Blind, Randomized, Multi-center Study||Shanghai Jiao Tong University School of Medicine|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|5||Anticipated|410|||Both|18 Years|75 Years|No|||June 2015|June 30, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486536||17956|
NCT02486549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|artroscopy|Supraclavicular Versus Interscalene Block for Shoulder Surgery|A Prospective Randomized Comparison of Ultrasound-guided Supraclavicular and Interscalene Block in Patients Undergoing Arthroscopic Shoulder Surgery||Tokat Gaziosmanpasa University|Yes|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486549||17955|
NCT02474667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-15|Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney|A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney||Angion Biomedica Corp|Yes|Recruiting|January 2016|October 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474667||18868|
NCT02474680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHG-1420-PGxTIME|Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes|Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes|PGx-TIME|Avera McKennan Hospital & University Health Center|Yes|Recruiting|February 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|serum|Both|18 Years|N/A|No|Probability Sample|Participants must be enrolled in the Avera Care Coordination Program and have insurance        coverage through the Avera Health Plans|December 2015|December 28, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02474680||18867|
NCT02485340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-071|The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache|The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model||Danish Headache Center|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02485340||18047|
NCT02478983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|995.7|A Randomized Comparison of LMA (Laryngeal Mask Airway) Supreme and LMA Proseal in Infants Below 10kg|A Randomized Comparison of LMA Supreme and LMA Proseal in Infants Below 10kg||University of Malaya|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Months|2 Years|No|||March 2016|March 21, 2016|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02478983||18536|
NCT02483806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0325|The Effects of Positive End-expiratory Pressure on Intrapulmonary Shunt, Oxygenation and Cardiac Function During One-lung Ventilation|The Effects of Positive End-expiratory Pressure on Intrapulmonary Shunt, Oxygenation and Cardiac Function During One-lung Ventilation : Prospective, Cross-over Study||Yonsei University|No|Recruiting|June 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Anticipated|36|||Both|40 Years|80 Years|No|||June 2015|June 24, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02483806||18165|
NCT02476617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-243|Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults|An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks||AbbVie|No|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 7, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02476617||18718|
NCT02461641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2014-08-03|NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers|The NuTech NuShield Ande Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)||NuCel, LLC|No|Recruiting|March 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|19 Years|N/A|No|||March 2016|March 23, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461641||19869|
NCT02494297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2014_04|Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries|Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries||Center for Epidemiology and Health Research, Germany|No|Recruiting|March 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|5000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during the        study period.|December 2015|December 21, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02494297||17361|
NCT02480582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDS-2015-ABC|The Impact of Snacks Which Vary Nutritionally in Their Satiating Potential on Measures of Appetite Control|The Impact of Snacks Which Vary Nutritionally in Their Satiating Potential on Measures of Appetite Control||University of Leeds|No|Active, not recruiting|June 2015|December 2015|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|42|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02480582||18413|
NCT02463630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT|Posterior Compression Distraction Reduction （CDR）Technique in the Treatment of BI-AAD|Posterior Compression - Distraction Reduction (CDR) Technique in the Treatment of Basilar Invagination Associated With Atlantoaxial Dislocation|CDR|Xuanwu Hospital, Beijing|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|70 Years|No|||January 2015|June 1, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02463630||19717|
NCT02467790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-Ih|Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function|Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|February 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|31 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 23, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02467790||19397|
NCT02476188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15-P007|Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke|Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke|NETs|Centre Hospitalier St Anne|No|Recruiting|July 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476188||18751|
NCT02476201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_789|Quartet Lead and Resynchronization Therapy Options III|Quartet Lead and Resynchronization Therapy Options - Assessing the Response Rate at 6 Months in CRT Patients Implanted With a Quartet Left Ventricular(LV) Quadripolar Lead and the MultiPoint Pacing (MPP) Feature Activated|QUARTO III|St. Jude Medical|No|Not yet recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476201||18750|
NCT02476214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/2015ק|Comparison of Group Guidance to Routine Care for Pregnant Women at Low Risk|Comparison of Prenatal Care With Group Guidance to Routine Care for Pregnant Women at Low Risk in Maternal and Child Health Clinics||Meir Medical Center|Yes|Not yet recruiting|July 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|291|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02476214||18749|
NCT02478177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059817|Addressing Real-world Anticoagulant Management Issues in Stroke|Management of Acute Stroke Patients on Treatment With Novel Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry|ARAMIS|Duke University|No|Enrolling by invitation|September 2015|February 2020|Anticipated|August 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had an acute ischemic stroke that has taken either dabigatran,        rivaroxaban, apixaban, or edoxaban at least 7 days prior to admission OR patients who have        had an intracerebral hemorrhage that has taken warfarin or one of the novel oral        anticoagulants at least 7 days prior to admission.|October 2015|October 21, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02478177|6 Months|18598|
NCT02481973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoniqueChavannes200570791|The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome|The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome||University of Johannesburg|Yes|Active, not recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02481973||18306|
NCT02463864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCork|A Twice-Daily Individual Targeted Exercise Program in Frail Hospitalised Older Medical In-patients (RCT)|A Randomised Controlled Trial to Measure the Effects of Twice-Daily Individual, Targeted, Strengthening, Balance and Endurance Exercise Sessions on Mobility, Quality of Life and Healthcare Utilisation for Frail Older Medical In-patients|APEP|University College Cork|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|65 Years|N/A|No|||June 2015|June 2, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02463864||19699|
NCT02463877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minimally-Invasive|A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy|A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy||University of California, San Diego|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463877||19698|
NCT02466789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-25321|Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)|Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)|VWF-phV|Bleeding and Clotting Disorders Institute Peoria, Illinois|No|Recruiting|July 2015|December 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Sodium Citrated Plasma samples|Both|2 Years|N/A|No|Non-Probability Sample|New subjects undergoing evaluation for the diagnosis of VWD that are determined to have        VWF:ag or VWF:RCo <50 IU/dl and or a VWF:RCo/VWF:ag ratio of <0.7. Also subjects will be        included if Type 2N VWD is suspected|February 2016|February 22, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02466789||19474|
NCT02481583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHXH-Levosul|Pharmacokinetic Study of Levosulpiride|Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular and Intravenous Administration of Levosulpiride After Single and Multiple Doses in Fasting Healthy Chinese Volunteers||Wuhan Union Hospital, China|Yes|Completed|March 2013|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|42|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|May 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481583||18336|
NCT02481401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0256 Project 2|Family-based Approach to Promotion of Health Project 2|Family-based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health|FAMILIA|Icahn School of Medicine at Mount Sinai|No|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481401||18350|
NCT02481661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH|Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLC|A Phase III Randomized Trial of Anatomical Segmentectomy Versus Lobectomy by Minimal Incision for Stage IA Peripheral Non-Small Cell Lung Cancer (≤ 2cm)||Zhejiang Cancer Hospital|Yes|Not yet recruiting|July 2015|July 2022|Anticipated|July 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|610|||Both|18 Years|70 Years|No|||June 2015|June 24, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02481661||18330|
NCT02464124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepatic encephalopathy|Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy|A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy||Tanta University|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02464124||19679|
NCT02467049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECG-PICC|ECG Versus Ultrasound-guided Positioning of the Peripherally Inserted Central Catheter (PICC) Tip|ECG Versus Ultrasound-guided Positioning of the Peripherally Inserted Central Catheter (PICC) Tip||Universitair Ziekenhuis Brussel|No|Recruiting|June 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02467049||19454|
NCT02476110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quality program ONSHUG 2015-04|The ONSHUG Survey : A Quality Care Programme|Oral Nutritive Supplements : Indications, Prescription and Follow-up for Hospitalized and Out-patients at Nutritional Risk or With Malnutrition. A Quality Care Programme at the Geneva University Hospital : The ONSHUG Survey||University Hospital, Geneva|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Hospitalized adults patients with Oral Nutritive Supplements in medical and surgical wards        of the Geneva University Hospital, site of Cluse-Roseraie|June 2015|June 16, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02476110||18757|
NCT02427074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180/09|Comparison Between Radiofrequency and Balloon Compression in the Treatment of Idiopathic Trigeminal Neuralgia|Comparative Study Between Radiofrequency and Balloon Compression of the Gasserian Ganglion in the Treatment of Idiopathic Trigeminal Neuralgia||University of Sao Paulo|No|Recruiting|February 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02427074||22522|
NCT02417493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0140|Self-injection and Self-management|Epinephrine Self-injection and Self-management of Food Allergies||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|13 Years|17 Years|No|||January 2016|January 7, 2016|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02417493||23258|
NCT02470195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLESS PROSIDIAIR 2014|Procedural Simulation for Difficult Airway Training in Anesthesiology Resident Education Program|Anesthesiology Education Implementation by Procedural Simulation Workshop for Difficult Airway Management: a Controlled Interregional French Study|PROSIDIAIR|Claude Bernard University|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02470195||19212|
NCT02475811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137|3D Ultrasonography Fetal Lung Volume Measurement and Neonatal Respiratory Function|The Role of 3D Ultrasonography Fetal Lung Volume Measurement in the Prediction of Neonatal Respiratory Function Outcome||Cairo University|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|40 Years|No|Non-Probability Sample|One hundred healthy women with singleton pregnancies presented in the 1st stage of labour|June 2015|June 16, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475811||18780|
NCT02462031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD101-102|To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects|A Randomized, Double-blind, Placebo-controlled, Single or Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects||Kwang Dong Pharmaceutical co., ltd.|No|Recruiting|March 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|38|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2015|June 2, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02462031||19839|
NCT02473952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1408|A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis||Grifols Therapeutics Inc.||Recruiting|July 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|85 Years|No|||November 2015|November 19, 2015|June 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473952||18923|
NCT02473965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTI1306|Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis||Grifols Therapeutics Inc.||Recruiting|June 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||November 2015|November 19, 2015|June 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02473965||18922|
NCT02470416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/14/WMEAD/226(4028)|Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal Adenomas|A Prospective Case Control Study on the Prevalence of Small Bowel and Colonic Polyps in Patients With Duodenal Adenomas/Ampullomas Who do Not Have Familial Adenomatous Polyposis (FAP) or Peutz Jeghers Syndrom (PJS).|SPIDA|Western Sydney Local Health District||Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 15, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02470416||19195|
NCT02470429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXK947-P001|Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION|Evaluation of Clinical Outcomes Following the Use of SYSTANE® HYDRATION in Subjects With Dry Eye||Alcon Research|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470429||19194|
NCT02475876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00057185|PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children|Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK|PBPK|Duke University|No|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|54|||Both|1 Month|16 Years|No|||January 2016|January 4, 2016|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475876||18775|
NCT02413333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCD913-P001|Clear Care® Plus vs. PeroxiClear™|Comparison of Two One-Step Hydrogen Peroxide Lens Care Solutions in Symptomatic Contact Lens Wearers||Alcon Research|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|133|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413333||23578|
NCT02414126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014 A1907-40|Evaluation of Breathing, Sleep and the Effects of Continuous Positive Airway Pressure During Wakefulness in Children With Heart Failure|Evaluation of Breathing, Sleep and the Effects of Continuous Positive Airway Pressure During Wakefulness in Children With Heart Failure|IC-E-PPC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|45|||Both|8 Months|17 Years|No|||January 2016|January 14, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02414126||23517|
NCT02462200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506053|Shave Margins in Breast Conservation Therapy|Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial|SMART|Washington University School of Medicine|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|550|||Female|18 Years|85 Years|No|||December 2015|December 19, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02462200||19826|
NCT02466659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IndianU|Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|CIAO|Indiana University|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|3 Years|11 Years|No|||March 2016|March 7, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02466659||19484|
NCT02426437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038838-2|Examining Pulmonary Rehabilitation on Discharged COPD Patients|How Does Early Rehabilitation Affect Patient-centred Health Outcomes and Cardiovascular Risk in COPD Patients||University of Alberta|No|Recruiting|February 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02426437||22571|
NCT02426450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC001|RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC|RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study||Sun Yat-sen University|Yes|Active, not recruiting|April 2015|April 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02426450||22570|
NCT02461446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00013150|Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations|Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations||Children's Hospital Boston|Yes|Recruiting|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|Samples With DNA|Blood draw for future correlative studies in the PTEN Biorepository of the Developmental      Synaptopathies Consortium.|Both|3 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|120 patients will be enrolled for this study, ages 3 to 21.|February 2016|February 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02461446||19884|
NCT02474043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1360|A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin|A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin|Hep-Net|University of Wisconsin, Madison|No|Active, not recruiting|August 2014|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|225|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02474043||18916|
NCT02472509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ursolit_Hemolytic disorders|The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders|The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders||Shaare Zedek Medical Center|No|Recruiting|December 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|32|||Both|4 Years|N/A|No|||June 2015|November 17, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02472509||19034|
NCT02413606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKZ 2014-6677|ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?|ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? Randomized Controlled Trial to Evaluate Patient Satisfaction and Cost-effectiveness of a Reduced Follow-up Schedule|ENSURE|Comprehensive Cancer Centre The Netherlands|No|Not yet recruiting|April 2015|April 2022|Anticipated|April 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|282|||Female|N/A|N/A|No|||April 2015|April 9, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02413606||23557|
NCT02473159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-1410202-2|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer: Interventional Pilot Study for 5 Patients||National Cancer Center, Korea|Yes|Recruiting|March 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Female|20 Years|70 Years|No|||June 2015|June 17, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473159||18984|
NCT02468570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-303|A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302|A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302|PRISM303|BioMarin Pharmaceutical|No|Active, not recruiting|July 2015|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects with PKU who are currently enrolled in 165-302 Part 2.|November 2015|November 30, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468570||19337|
NCT02484300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150465|The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea|The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea||University of California, San Diego|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|60|||Male|18 Years|70 Years|No|||September 2015|September 28, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02484300||18127|
NCT02463942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBE-LB2014|Tick-borne Encephalitis and Positive Borrelial Antibodies|Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results|TBE-LB2014|University Medical Centre Ljubljana|No|Recruiting|September 2014|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|July 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02463942||19693|
NCT02490111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_UDCA005|Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer|Efficacy and Safety of DWJ1319 in the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study||Daewoong Pharmaceutical Co. LTD.||Recruiting|April 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|519|||Both|19 Years|N/A|No|||July 2015|July 1, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02490111||17683|
NCT02480023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|osteopenia during pregnancy|Assessment of Bone Mineral Density During Pregnancy|Changes in Bone Mineral Density as Measured by Calcaneal Quantitative Ultrasound in Third Trimester of Pregnancy||Ain Shams University|Yes|Completed|June 2015|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|173|||Female|20 Years|40 Years|No|||January 2016|January 9, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02480023||18456|
NCT02479542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU 34186|Addition of Negative Pressure Wound Therapy to Standard Gauze Dressings for Acute Wounds in a Limited-Resource Setting|Randomized Trial Comparing the Negative Pressure Wound Therapy to Standard Gauze Dressings for Acute Wounds in Mbingo Baptist Hospital, Cameroon||Stanford University|No|Withdrawn|June 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|15 Years|N/A|No|||November 2015|November 17, 2015|June 21, 2015|No|Yes|Regulatory issues|No||https://clinicaltrials.gov/show/NCT02479542||18493|
NCT02479555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0169|Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization|LIMBO-PTA: Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization|LIMBO-PTA|Mercator MedSystems, Inc.|No|Recruiting|January 2016|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479555||18492|
NCT02470026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU3106/2-1|Noradrenergic Activity, Cognition and Major Depressive Disorder|Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder|YohCog|Charite University, Berlin, Germany|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02470026||19225|
NCT02468700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-14-006|Feasibility Study Evaluating Safety and Efficacy of OTX-DP (Sustained Release Dexamethasone, 0.4mg) for Treatment of Dry Eye|A Prospective, Multicenter, Randomized, Parallel-Arm, Bilateral, Double-Masked, Vehicle Controlled Feasibility Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye||Ocular Therapeutix, Inc.|No|Active, not recruiting|December 2014|April 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468700||19327|
NCT02483130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRCNAC|Effect of N-acetylcysteine on Brain Glutamate|A Randomised Controlled Double Blind Crossover Study of the Effect of a Single Dose of N-acetylcysteine Versus Placebo on Brain Glutamate in Patients With Psychotic Disorders|NAC|King's College London|No|Recruiting|June 2015|||February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Samples are collected for two purposes.        1. Participants are invited to donate samples to the BRC Bioresource. These samples may be           used in the future for genetic, epigenetic, metabolomic or proteomic analysis.        2. Participants will also be asked for a blood sample after completion of each MRI scan.           These will be used to measure blood glutathione levels, which may be altered by           N-acetylcysteine and therefore provide indication of pharmacological effect.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified:          1. Via South London and Maudsley (SLaM) clinical teams.          2. If they have previously indicated to local research teams that they would like to be             contacted about future research.        2. Through the SLaM NIHR Bioresource, including patients in CRIS, the research informatics        database, who have given consent to be contacted about research projects.|February 2016|February 25, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02483130||18217|
NCT02488083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF17991|UltraShape Device for Thigh Fat and Circumference Reduction vs. Control|Clinical Study to Evaluate the Performance of the UltraShape Device for Thighs Fat and Circumference Reduction vs. Control||Syneron Medical|No|Not yet recruiting|June 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488083||17837|
NCT02484833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004299-41|Erbitux MEtastatic Colorectal Cancer Strategy Study|Erbitux MEtastatic Colorectal Cancer Strategy Study: A Phase III Randomized Two Arm Study With FOLFIRI + Cetuximab Until Disease Progression Compared to FOLFIRI + Cetuximab for 8 Cycles Followed by Cetuximab Alone Until Disease Progression in First Line Treatment of Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer|ERMES|Catholic University of the Sacred Heart|Yes|Recruiting|February 2015|February 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02484833||18086|
NCT02485054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOA_2014-32|A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)|Development and Validation of a Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances|VASCO|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|June 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Adults having had a transient visual disturbance during the last 8 days and seen at the        fondation ophtalmologique Adolphe de Rothschild|December 2015|December 29, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02485054||18069|
NCT02476929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ONA-2011-146|Detection and Use of Nasal Nitrous Oxide and the Electronic Nose|AssEssment and New Perspectives on Pathophysiogenesis, detectiOn and Use of NAsal Nitrous Oxide and the Electronic Nose (EPONA Project)|EPONA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|January 2013|December 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|112|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02476929||18694|
NCT02483702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-063|Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair|The Affect of Radiated Versus Non-Irradiated Blood on Extracellular Potassium Levels in Infants Undergoing Craniosynostosis Repair||Valley Anesthesiology Consultants||Not yet recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02483702||18173|
NCT02488213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0585|Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus|Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|30 Years|80 Years|No|||June 2015|June 30, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02488213||17827|
NCT02491788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-34778|Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers|||VA Palo Alto Health Care System|Yes|Recruiting|February 2016|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|July 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02491788||17554|
NCT02466204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_ 01_2015|Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients|An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment.||Vietnam National University|No|Recruiting|June 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|35 Years|42 Years|No|||June 2015|June 11, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466204||19519|
NCT02478632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202094|Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen|An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen||ViiV Healthcare|No|Active, not recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478632||18563|
NCT02478645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-1065|Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery|||Yonsei University|No|Recruiting|June 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|177|||Both|20 Years|70 Years|No|||June 2015|June 18, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478645||18562|
NCT02483676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1699-R|Ankle Robot to Reduce Foot-drop in Stroke|Adaptive Ankle Robot Control System to Reduce Foot-drop in Chronic Stroke||VA Office of Research and Development|Yes|Recruiting|September 2015|June 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|40 Years|85 Years|No|||December 2015|December 1, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02483676||18175|
NCT02493543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMM14|Autoantibodies on Spinal Cord Injury|Role of Autoantibodies in Spontaneous Functional Recovery After Spinal Cord Injury||Hospital Nacional de Parapléjicos de Toledo|No|Enrolling by invitation|July 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|110|Samples Without DNA|Blood serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acute spinal cord injury admitted to the Spanish National Hospital for        Paraplegics|August 2015|August 4, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493543||17419|
NCT02478190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-3931|ED Management of Severe Hyperglycemia: A Clinical Trial|ED Management of Severe Hyperglycemia: An Open-Label Randomized Clinical Trial||Minneapolis Medical Research Foundation|No|Recruiting|June 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 27, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02478190||18597|
NCT02485756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD130139|Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics|An Educational Intervention to Increase Knowledge of Drug-drug Interactions Between Antiepileptics and Hormonal Contraception Among Reproductive-aged Women With Epilepsy.||University of California, San Diego|No|Recruiting|June 2013|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Female|18 Years|45 Years|No|||June 2015|June 29, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02485756||18015|
NCT02463903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140001|Coping Effectiveness Training in Patients With Chronic Heart Failure|Coping Effectiveness Training in Patients With Chronic Heart Failure - a Randomized Controlled Trial||Karolinska Institutet|No|Completed|March 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|103|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02463903||19696|
NCT02463916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC056|A Trial to Determine the Effects of Exercise in Inflammatory Bowel Disease and Rheumatoid Arthritis|The ExMET-IBD Study: A Randomized Control Trial to Determine the Effects of Exercise on Intestinal Microbiota and Immunological Markers in Patients With Inflammatory Bowel Disease and Rheumatoid Arthritis|ExMET-IBD|University College Cork|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|No|||June 2015|June 3, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02463916||19695|
NCT02489266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150153|In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma|A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Suspended|June 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|December 15, 2015|July 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489266||17747|
NCT02478203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU KAEK 2014/108|Intubation on a Paediatric Manikin by Emergency Staff: a Comparison of Airtraq and Glidescope|Intubation on a Pediatric Manikin by Emergency Medical Staff: a Comparison of Direct Laryngoscopy, Airtraq and Glidescope in Normal, Tongue Edema and Face-to-face Intubation Models||Kocaeli University|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|13|||Both|2 Years|7 Years|No|||August 2015|August 31, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02478203||18596|
NCT02481986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL123797|Asthma Action at Erie Trial|Asthma Action at Erie Trial||University of Illinois at Chicago|Yes|Recruiting|January 2016|March 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02481986||18305|
NCT02468063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis-001|To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock|A Prospective Study to Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock||Institute of Liver and Biliary Sciences, India|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||December 2015|December 21, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02468063||19376|
NCT02468375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-052|Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.|A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.||Samsung Medical Center|No|Not yet recruiting|June 2015|||May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|434|||Both|20 Years|N/A|No|||June 2015|June 7, 2015|June 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02468375||19352|
NCT02487459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-U-005|Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies|A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, TCR αβ+T Cell Depleted HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse||Bellicum Pharmaceuticals|No|Not yet recruiting|July 2015|December 2030|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||June 2015|June 29, 2015|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02487459||17885|
NCT02489721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICC/MIDLINE1|Major Complications Related to PICC and Midline Insertion|PICC and Midline Related Complications: A Multicenter Observational Study|PICC/MIDLINE|Azienda Ospedaliera S. Maria della Misericordia|No|Recruiting|June 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|547|||Both|18 Years|90 Years|No|Non-Probability Sample|The study will be conducted in all the patients undergoing PICC or Midline catheter        insertion which fall in the inclusion criteria|March 2016|March 4, 2016|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489721|2 Years|17713|
NCT02490566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140732|Enhanced Primary Care and Technology for Children With Chronic Disease|Piloting Enhanced Pediatric Care for Children With Chronic Condition/Technology Trial||University of Miami|No|Recruiting|July 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|5 Years|18 Years|No|||January 2016|January 21, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490566||17648|
NCT02474602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nove de Julho University|Phototherapy Applied in Association With Strength Training|Phototherapy Applied in Association of Muscle Training: Evaluation of Different Irradiation Protocols||University of Nove de Julho|Yes|Completed|June 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|48|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02474602||18873|
NCT02489526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVZ149-POP-P2-US001|Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectal Surgery||Vivozon, Inc.|No|Recruiting|August 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489526||17727|
NCT02479698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0279|BK Specific Cytotoxic T Lymphocytes (CTL) Lines for Stem Cell Transplant (SCT) Recipients|Phase II Study Assessing the Effect of BK Specific Cytotoxic T Lymphocytes (CTL) Lines Generated by ex Vivo Expansion in Stem Cell Transplant Recipients With BK Infection||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02479698||18481|
NCT02478710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAINTVAP|Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia|Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study|AAINTVAP|Wright State University|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02478710||18557|
NCT02478723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-08|A Study Evaluating the Sonendo GentleWave™ System|An Observational Study Evaluating the Sonendo GentleWave™ System and the EndoTechnologies CPoint™ Obturation for Treatment of Molar Teeth Requiring Root Canal Therapy|To The Point|Sonendo, Inc.|No|Active, not recruiting|April 2015|April 2019|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age or older, who have a 1st or 2nd molar tooth that received root        canal therapy with the Sonendo GentleWave System and obturation with CPoint and BC Sealer        in at least one canal.|June 2015|June 22, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478723||18556|
NCT02494388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINE-Cyst|Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions|Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions|CINE-Cyst|University of Medicine and Pharmacy Craiova|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort||5|Anticipated|200|Samples With DNA|Pancreatic cyst fluid|Both|18 Years|N/A|No|Probability Sample|The study will consist of two major arms:          1. Retrospective analysis of previous prospectively included patients with cystic             pancreatic neoplasms examined by EUS, EUS-FNA and EUS-nCLE with a final confirmation             of the diagnosis after EUS-FNA (cytopathology) or surgery (histopathology).          2. Prospective analysis will include patients referred for EUS, EUS-FNA and EUS-nCLE of             suspected cystic pancreatic lesions during a 24-months period. The indication for             this investigation will be based on the patient's clinical history and previous             imaging studies (abdominal ultrasound, CT scan, MRI with MRCP, etc.).|July 2015|July 9, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02494388||17354|
NCT02475551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-HMedIdeS-03|Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation|A Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Ascending Doses of IdeS in Kidney Transplantation||Hansa Medical AB|Yes|Recruiting|June 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02475551||18800|
NCT02469220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M224|Effect of a Low FODMAP Diet in Patients With Ulcerative Colitis|Effect of a Low FODMAP Diet on Gut Microbiota, Inflammation and Gastrointestinal Symptoms in Patients With Ulcerative Colitis in Remission||University of Copenhagen|No|Recruiting|June 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2015|June 10, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469220||19287|
NCT02488122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSFBK1|Effect of the High Impact Exercise on Bone Density in Prepuberal Girls|Effect of the High Impact Exercise on Bone Density in Prepuberal Girls in 12 Private Schools in Bogota - Colombia During 2016 - 2017. Open Label Randomized Controlled Trial||Fundación Santa Fe de Bogota|No|Suspended|February 2016|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|276|||Female|8 Years|10 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 30, 2015||No|Because the study has not yet sponsorship.|No||https://clinicaltrials.gov/show/NCT02488122||17834|
NCT02491541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120002|A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects|A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|August 2012|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491541||17573|
NCT02483455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-ALC-919-US|ALC-919 For The Treatment Of Common Warts|ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris)||ALC Therapeutics, LLC|Yes|Completed|April 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|8 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02483455||18192|
NCT02488408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGBC003|Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML|A Phase I Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With Acute Myeloid Leukemia||BerGenBio AS|Yes|Recruiting|September 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488408||17812|
NCT02488577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISS-TRICKR2|Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer|Outcomes Comparison of TAMIS-TME Versus Transanal Minimally Invasive Locoregional Resection for T2 Low Rectal Cancer: an Open Label Study|TAMIS|Mansoura University|Yes|Enrolling by invitation|June 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||July 2015|July 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02488577||17799|
NCT02465736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOCRTEC-2.0|Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer|A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma||Sun Yat-sen University|No|Not yet recruiting|July 2015|July 2023|Anticipated|July 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02465736||19555|
NCT02485145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54321|The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands|The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands||Transdermal Therapeutics, Inc.|Yes|Not yet recruiting|July 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|79 Years|No|||June 2015|June 25, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485145||18062|
NCT02487901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SONO1|Comparison of Ultrasonic Osteotome and Conventional Drill Osteotome|Randomized Controlled Trial: Comparison of Ultrasonic Osteotome and Conventional Drill Osteotome|SONO|Seoul National University Hospital|No|Recruiting|June 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|20 Years|N/A|No|||November 2015|November 15, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487901||17851|
NCT02480842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPaulo PT 3|Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction|Randomized Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction||Federal University of São Paulo||Recruiting|June 2015|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|N/A|No|||June 2015|June 25, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02480842||18393|
NCT02485444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-80|Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion|Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage Management After Second-trimester Abortion: A Randomized Clinical Trial||Ataturk University|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|17 Years|45 Years|No|||July 2015|July 3, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02485444||18039|
NCT02467803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO13/55|Shoulder Functional Outcomes of Patients With Proximal Humerus Fractures: Comparison of Two Different Treatment Protocol|||Hacettepe University||Not yet recruiting|June 2015|||January 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|75 Years|No|||May 2015|June 5, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02467803||19396|
NCT02461888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13/10993|Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.|A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib.|MUK Eight|University of Leeds|Yes|Not yet recruiting|July 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461888||19850|
NCT02482662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-159|Diagnosis Test for Gestational Diabetes Mellitus|Assessment of the Diagnosis Test for Gestational Diabetes Mellitus||Université de Sherbrooke|No|Active, not recruiting|November 2014|September 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Female|18 Years|N/A|No|Probability Sample|Women with abnormal GDM screening test.|January 2016|January 4, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02482662||18253|
NCT02486263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00734|Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial|Pathophysiology of the Aerodigestive Reflex in Infants: GERD Management Trial|GMT|Nationwide Children's Hospital|Yes|Recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|34 Weeks|60 Weeks|No|||February 2016|February 2, 2016|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486263||17977|
NCT02468050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17796|Study of Exercise to Manage Distress During Breast Screening|Effectiveness of Exercise Training and Self Management in the Attenuation of Anxiety and Depressive Symptoms Following Breast Biopsy||University of Western Ontario, Canada|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|7|||Female|18 Years|69 Years|No|||June 2015|June 5, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT02468050||19377|
NCT02468336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-1302|AngioDefender Versus Brachial Artery Ultrasound Imaging|Vascular Reactivity Assessment by a Novel Diagnostic Device, ANGIODEFENDER, Compared to Using Brachial Artery Ultrasound Imaging||Everist Genomics, Inc|No|Active, not recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|152|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|June 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02468336||19355|
NCT02473120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 15.01|Study of ESR1 Mutations in Metastatic Breast Cancer|Determination of ESR1 Mutations by Digital PCR During Aromatase Inhibitor Treatment in Metastatic Breast Cancer|FMER|Centre Henri Becquerel|No|Recruiting|June 2015|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 12, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02473120||18987|
NCT02485626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49405.031.14|Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors|HARBOR Study: Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors|HARBOR|The Netherlands Cancer Institute|No|Recruiting|April 2015|December 2019|Anticipated|April 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|628|Samples With DNA|Consent is obtained from participants to draw blood for DNA-analyses to evaluate whether      specific genes modify the risk of treatment-induced cardiovascular disease.|Female|40 Years|50 Years|No|Probability Sample|Participants will be recruited from a large retrospective cohort of BC patients.|June 2015|June 25, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02485626|2 Years|18025|
NCT02485639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0059|Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination|Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|December 2015|||June 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Anticipated|55|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|March 17, 2016|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485639||18024|
NCT02488889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23FT-0102|Effects of Varenicline in Heavy Drinking Smokers||VAR|University of California, Los Angeles|No|Not yet recruiting|August 2015|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|21 Years|55 Years|No|||July 2015|July 5, 2015|February 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488889||17776|
NCT02485990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15113|Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)|An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|September 2015|||September 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|68|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485990||17997|
NCT02490163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|doc20150414113301_CDF|Comparison of Two Automated Mononuclear Collection Systems in Patients Undergoing Extracorporeal Photochemotherapy. A Cross-over Equivalence Study. (MNC_CMNC)|Comparison of Two Automated Mononuclear Collection Systems (Spectra Optia CMNC and MNC) in Patients Undergoing Extracorporeal Photochemotherapy. A Cross-over Equivalence Study.|CMNC_MNC|IRCCS Policlinico S. Matteo|No|Completed|August 2015|January 2016|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|51|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02490163||17679|
NCT02468349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00793|IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.|IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.|IMMACULATE|National University Heart Centre, Singapore|No|Recruiting|June 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|21 Years|85 Years|No|||January 2016|January 24, 2016|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02468349||19354|
NCT02468362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISR-TME|Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.|Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer: a Double Blind Randomized Clinical Trial|ISR-TME|Mansoura University||Enrolling by invitation|April 2014|October 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02468362||19353|
NCT02476123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-013|Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors|Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors||Kyowa Hakko Kirin Company, Limited|Yes|Recruiting|June 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Both|20 Years|N/A|No|||November 2015|November 12, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02476123||18756|
NCT02477631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-1908-DM-CTIL|Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients|The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome||Sheba Medical Center|No|Not yet recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02477631||18640|
NCT02423889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITS13.001|SBRT in Prostate Cancer|Stereotactic Radiotherapy in Low Risk Prostate Cancer: a Phase II Study||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||Recruiting|April 2013|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02423889||22767|
NCT02423902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI001-203|A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer|A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First- or Second-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer||Ziopharm|No|Recruiting|April 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||April 2015|August 4, 2015|April 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02423902||22766|
NCT02425995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0358|Interest of Additional Arthroscopic Portals in Diagnosis of Hidden Lesions of the Medial Meniscus in Pediatrics Knees With ACL Deficiency|Prevalence and Diagnosis of Hidden Lesions of the Posterior Horn of the Medial Meniscus in Pediatric Anterior Cruciate Ligament (ACL) Lesions : Interest of Arthroscopic Intercondylar and Posteromedial Portals||Hospices Civils de Lyon|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|12 Years|17 Years|No|||May 2015|May 12, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02425995||22605|
NCT02426008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbnSina IVF|Improving Embryogenesis by Adding Growth Factors to In Vitro Human Culture Media|||Ibn Sina Hospital|No|Recruiting|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|400|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02426008||22604|
NCT02473601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015001|Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis|To Observe Mivacurium Chloramine Muscle Relaxation Effect in the Operation Anesthesia Patients With Liver Cirrhosis||Tang-Du Hospital|No|Recruiting|October 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||August 2015|August 20, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02473601||18950|
NCT02462044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 13-1-033|Contrast Enhancement on Coronary Computed Tomographic Angiography|Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial)|EICAR|Maastricht University Medical Center|Yes|Completed|August 2014|September 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|200|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02462044||19838|
NCT02424123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/ET-02|Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adult?|Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adult? A Prognostic Cohort Study|SeizS100B|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples Without DNA|Processing of blood samples: 4-5ml of the blood sample will be centrifuged to isolate serum;      S100B, IL-1b, IL-6, NSE levels will be investigated at D0 (T0+6h, T0+12h where T0 is seizure      time) D14-D28. The remaining blood and cells will be stored at -80°C for future analyses.|Both|18 Years|59 Years|No|Non-Probability Sample|The study population is composed of patients between 18 and 60 years of age, of both        sexes, recruited during consultations for a first cryptogenic epileptic seizure at the        emergency department of Nîmes and Marseille Hospitals (CHRU).|October 2015|October 20, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424123||22749|
NCT02424201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LagosSU|Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.|Comparative Study on Effects of Sublingual Misoprostol in Addition to Standard Active Management of Third Stage of Labour in Low Risk Parturients in Lagos State University Teaching Hospital, Ikeja.||Lagos State University|Yes|Not yet recruiting|June 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|660|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02424201||22743|
NCT02412826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038455|Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis|Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis||Cedars-Sinai Medical Center|No|Active, not recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be patients who present to Cedars-Sinai Medical Center with the        diagnosis of acute pancreatitis.|March 2016|March 1, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02412826||23617|
NCT02465541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-13005|Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors|Lifestyle Interventions to Improve Physical Function and Quality of Life in Endometrial Cancer Survivors: The Role of a Gentle Yoga Based Exercise Program||Ohio State University Comprehensive Cancer Center|No|Recruiting|July 2013|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|N/A|N/A|No|||March 2016|March 4, 2016|May 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02465541||19570|
NCT02473718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310111|Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock|||Washington University School of Medicine|Yes|Completed|January 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473718||18941|
NCT02473731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN3379-CL-002|A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients|A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients||Kolltan Pharmaceuticals, Inc.|No|Recruiting|October 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02473731||18940|
NCT02462239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2013-PETMUSE|Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging|Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging|PET MUSE|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|January 2016|September 2020|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|291|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02462239||19823|
NCT02417454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000229|Study on the Effects of a Probiotic on Autonomic and Psychological Stress|A Double Blind Placebo Controlled Study on the Effects of a Probiotic on Autonomic and Psychological Stress Responses in Volunteers||McMaster University|No|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02417454||23261|
NCT02469532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0181|DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes|DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes||Mercator MedSystems, Inc.|No|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female at least 18 years of age presenting with a de novo or nonstented restenotic        lesions >90 days from prior angioplasty and/or atherectomy of lesions causing >70%        narrowing in the superficial femoral and/or popliteal arteries and totalling up to 15 cm        in length (with no greater than 3 cm length of contiguous intervening normal artery),        Rutherford Category 2-4, and with a reference vessel diameter of 3 to 8 mm.|January 2016|January 13, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469532|1 Year|19263|
NCT02466607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-15-0017|Study of Stimulus Parameters in Flicker Electroretinogram (ERG)|Study of Stimulus Parameters in Flicker Electroretinogram (ERG)||LKC Technologies, Inc.|No|Recruiting|March 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466607||19488|
NCT02466893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00043325|COMPASS Trial: a Direct Aspiration First Pass Technique|COMPASS Trial: a Direct Aspiration First Pass Technique|COMPASS|Medical University of South Carolina|Yes|Recruiting|June 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||September 2015|December 18, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02466893||19466|
NCT02472106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302-001|Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following TAVI Procedure|Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following Medtronic CoreValve or Other Self-Expanding TAVI Procedure (PostCorE)|PostCorE|InterValve, Inc.|Yes|Enrolling by invitation|June 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic - Patients at each enrolling clinic who are to be treated with the        Medtronic CoreValve or other self-expanding TAVI device are eligible for enrollment.|February 2016|February 29, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472106||19065|
NCT02472301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG2|The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 1-3 Year Olds|Randomized, Single-blinded, Prospective Clinical Trial Comparing the Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction and Stunting in Rural Malawian Children 1-3 Year Olds||Washington University School of Medicine|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||December 2015|December 17, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472301||19050|
NCT02413346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1403|A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris|A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris||Warner Chilcott|No|Active, not recruiting|March 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|490|||Both|9 Years|N/A|No|||December 2015|December 1, 2015|April 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02413346||23577|
NCT02466009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55555|Regorafenib in Metastatic Colorectal Cancer|Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study||University of Rochester|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|70 Years|N/A|No|||December 2015|December 24, 2015|April 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466009||19534|
NCT02462408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|949.14|Conventional Versus Posterior Approach in Ultrasound-Guided Parasagittal In-Plane Infraclavicular Brachial Plexus Block|A Prospective, Randomized Comparison Between Lateral and Posterior Approach In Ultrasound-Guided Parasagittal In-Plane Infraclavicular Brachial Plexus Block||University of Malaya|No|Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|80 Years|No|||June 2015|June 1, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02462408||19810|
NCT02418273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504269855|Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders|Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study||Indiana University|Yes|Not yet recruiting|June 2017|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|4 Years|16 Years|No|||February 2016|February 22, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02418273||23198|
NCT02462642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08068B|Effect of Bacopa Monniera Extract on Cognition and Anxiety and Exploration of PK Properties|Chronic Effect of Brahmi on Cognition Performance and Anxiety in Healthy Indian Adults and Exploration of Pharmacokinetic Properties of Brahmi Components in Healthy Adult Males.|Yaaddasht|Unilever R&D|Yes|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|84|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02462642||19792|
NCT02472704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG-DC/01/01|Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo|Lymphocytic Enteritis and Suspected Coeliac Disease: Double-blind Gluten vs Placebo Rechallenge||Hospital Mutua de Terrassa|Yes|Completed|September 2011|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02472704||19019|
NCT02489214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDG1B|Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer|A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|No|Active, not recruiting|May 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|75 Years|No|||June 2015|June 30, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02489214||17751|
NCT02468427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACUUM-OSATS|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Delivery by Vacuum Extraction|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Operative-Vaginal Delivery by Vacuum Extraction on a Pelvic Training Model|VAC-OSATS|Ruhr University of Bochum|No|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|137|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02468427||19348|
NCT02468440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7314 02|Evaluation of ESPAIR, an Educational Therapy's Program of Patients With Renal Insufficiency Before Kidney Transplant|Evaluation of ESPAIR, an Educational Therapy's Program of Patients With Renal Insufficiency Before Kidney Transplant|ESPAIR|University Hospital, Toulouse|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|224|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02468440||19347|
NCT02480036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206824|Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases|Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases|KYPHO-IORT|Loyola University|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|N/A|No|||March 2016|March 14, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02480036||18455|
NCT02484456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150151|Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder|An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||June 2015|June 27, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484456||18115|
NCT02483767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-BC-ovarian suppression|Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer|Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer|POF|Peking Union Medical College Hospital|Yes|Not yet recruiting|June 2015|June 2022|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|260|||Female|18 Years|45 Years|No|||June 2015|June 24, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02483767||18168|
NCT02474576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMN_2015-1|Percutaneous Aponeurotomy in the Treatment of Dupuytren's Disease||APADUP|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|September 2015|||August 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02474576||18875|
NCT02474589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SigaTech|A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat|SIGA 246-008 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects|SIGA246-008|SIGA Technologies|Yes|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|422|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474589||18874|
NCT02476903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015Salvo|Viscosupplementation in the Hip Following Hip Arthroscopy|Viscosupplementation in the Hip Following Hip Arthroscopy||Rothman Institute Orthopaedics||Not yet recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|N/A|||||||Both|18 Years|N/A|No|||June 2015|June 19, 2015|June 17, 2015||||No||https://clinicaltrials.gov/show/NCT02476903||18696|
NCT02483416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.227|Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance|Evaluation of the Impact of a Nurse-led Telephone Follow-up on Treatment Compliance of Patients Treated From a Locally Advanced or Metastatic Non-small-cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) Mutation(s).The PARTAGE Study.||Boehringer Ingelheim||Recruiting|November 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|100 Years|No|Probability Sample|NSCLC EGFR mutated|March 2016|March 18, 2016|April 9, 2015||||No||https://clinicaltrials.gov/show/NCT02483416||18195|
NCT02491723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150619|Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa|Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa Via NLRC4 Inflammasome Signaling Pathway||Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02491723||17559|
NCT02461602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061054|Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients|Eliminate Thromboembolism (ELITE): Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients|ELITE|Duke University|No|Not yet recruiting|December 2015|||March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Atrial Fibrillation patients|December 2015|December 7, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02461602|6 Months|19872|
NCT02464397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-010|Comparison of Strut Coverage With OPTIMAX Versus SYNERGY Stents|A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography|OPTIMAX-OCT|The Hospital District of Satakunta|No|Recruiting|February 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02464397||19658|
NCT02487706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTG_HD|Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease|Removal of Dolutegravir by Hemodialysis in HIV-infected Patients With End-stage Renal Disease||Fundacio Lluita Contra la SIDA|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|99 Years|No|||September 2015|September 30, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487706||17866|
NCT02487719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0475|Different Iron Supplements for Prevention of Anemia in Pregnancy|Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe|EDISA|University of Zurich|No|Recruiting|June 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02487719||17865|
NCT02491801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC_31323|The Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Normal Weight and Overweight/Obese Adults|The Effect of Solid, Semi-solid and Liquid Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Normal Weight and Overweight/Obese Adults||University of Toronto|No|Recruiting|March 2015|August 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|40|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02491801||17553|
NCT02470572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0010|Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens|Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens|PrimeDx|Omnyx, LLC|No|Active, not recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|N/A|N/A|No|||June 2015|June 11, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02470572||19183|
NCT02470585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-694|Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||AbbVie|Yes|Recruiting|July 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1100|||Female|18 Years|99 Years|No|||January 2016|January 13, 2016|June 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02470585||19182|
NCT02483936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLCEMS0215|Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With HYZAAR® in Hypertension Control||EMS|Yes|Not yet recruiting|June 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02483936||18155|
NCT02481921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-293|Group Medical Visits in Heart Failure|Group Medical Visits in Heart Failure for Post-Hospitalization Follow-Up|MEDIC-HF|VA Office of Research and Development|No|Recruiting|June 2015|June 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|375|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02481921||18310|
NCT02490514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25065|A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis|Mircera In Patients With CKD Stages III-IV Not On Dialysis: Observational, Non-interventional Cohort Study||Hoffmann-La Roche||Completed|December 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|153|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients 18 to 75 years old with stage III-IV chronic kidney disease not on dialysis|August 2015|August 17, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02490514||17652|
NCT02490527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB|Effects of Epicatechin (Component of Dark Chocolate) on Patients With Statin-induced Mitochondrial Dysfunction and Impaired Exercise Capacity|||University of California, San Diego|Yes|Recruiting|June 2015|||June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02490527||17651|
NCT02468076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGNITE-1|Radiofrequency Ablation for Biliopancreatic Malignancy|Investigation of the Effect of Intraductal Radiofrequency Ablation in Inoperable Biliopancreatic Tumors Complicated With Obstructive Jaundice|IGNITE-1|Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2014|June 5, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02468076||19375|
NCT02474992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR006|The Kanyakla Study: a Social Network Intervention for Promoting Engagement and Retention in HIV Care|The Kanyakla Study: a Social Network Intervention for Promoting Engagement and Retention in HIV Care||University of California, San Francisco|No|Not yet recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02474992||18843|
NCT02478918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6013364|Automated Telephone Reminder for Colonoscopy|Automated Telephone Reminder Prior to Outpatient Colonoscopy and the Effect on Bowel Preparation Quality||Queen's University|No|Enrolling by invitation|June 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478918||18541|
NCT02479191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0016|LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair|The LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair|LUCY|TriVascular, Inc.|No|Recruiting|August 2015|August 2018|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|225|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll male and female subjects 18 years of age and older that have an AAA        and meet all other inclusion/exclusion criteria.|November 2015|November 24, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479191|1 Year|18520|
NCT02482181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAKYA22|Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions|Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions|DWIMRICSPL|Trakya University|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|20 Years|78 Years|Accepts Healthy Volunteers|Probability Sample|Magnetic resonance imaging (MRI) was applied to a total of 46 patients between January        2011 and July 2011, who presented.|June 2015|June 25, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02482181|12 Months|18290|
NCT02485769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7921002|Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Sequential Group, Multiple Ascending Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Orally Administered Pf 06650833 In Healthy Subjects||Pfizer|No|Recruiting|June 2015|April 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02485769||18014|
NCT02486016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transdermal Patch CVD 2000|Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl Patches in Healthy Adults|Determination of Serum Fentanyl Levels After Using Reference and Generic Transdermal Fentanyl Patches With and Without Standardized Heat Application in Healthy Human Volunteers||University of Maryland|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02486016||17995|
NCT02474511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|仁济伦审[2015]058K|the Influence of General Anesthesia on Tumor Metastasis and Recurrence|||RenJi Hospital|Yes|Recruiting|June 2015|April 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|blood|Both|18 Years|65 Years|No|Probability Sample|the patient with primary liver cancer.|June 2015|June 16, 2015|June 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02474511||18880|
NCT02474524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/119|Self-Management and Recovery Technology Psychosocial Intervention Trial|Psychosocial Intervention Using Online Resources to Promote Personal Recovery in Users of Specialist Mental Health Services|SMARTTherapy|Swinburne University of Technology|No|Recruiting|January 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02474524||18879|
NCT02489513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG120-C-003|Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 Following Single Oral Dose Administration in Healthy Male Subjects||Agios Pharmaceuticals, Inc.|No|Completed|June 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|July 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02489513||17728|
NCT02478463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201767|Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers|A Phase 1, Multicompartment Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers||ViiV Healthcare|No|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02478463||18576|
NCT02482233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15274|The END Perioperative Smoking Pilot Study|A Pilot Randomized Controlled Clinical Trial - "Electronic Nicotine Delivery Device (E-cigarette) for Perioperative Smoking Cessation in Veterans"||University of California, San Francisco|No|Recruiting|August 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02482233||18286|
NCT02475525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONS2015|Oral Nutritional Supplement in Reducing Surgical Site Infections|The Role of an Arginine Enriched Oral Nutritional Supplement in the Prevention of Wound Complication in Patients Undergoing Lower Limb Revascularization||University of Limerick|Yes|Recruiting|June 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02475525||18802|
NCT02479984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-555|Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer|A Prospective Study Investigating the Role of Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer||National Cancer Center, Korea|No|Recruiting|August 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|193|||Both|15 Years|80 Years|No|||June 2015|June 23, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02479984||18459|
NCT02482675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0088|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk||Ohio State University|No|Active, not recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02482675||18252|
NCT02469493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543203|The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting|||Xidian University|Yes|Recruiting|January 2015|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|160|||Both|18 Years|75 Years|No|||June 2015|June 18, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02469493||19266|
NCT02475226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK7|Cases With Traumatic and Non Traumatic Brain Damage Treated in the Intensive Care|Distribution and Mortality Factors of Cases With Traumatic and Non Traumatic Brain Damage Treated in Intensive Care; Retrospective Clinical Trial||Umraniye Education and Research Hospital|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||3|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|a total of 1004 patients treated in the ICU in a 2-year period were retrospectivly        reviewed. 135 patients, determined with traumatic or nontraumatic brain damage, with a        more than 24-hour stay in the ICU, included the study.|June 2015|June 17, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02475226||18825|
NCT02481310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 14H09|Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma|A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen||Northwestern University|Yes|Not yet recruiting|September 2015|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02481310||18357|
NCT02481323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrevSVD-2015|Lacunar Intervention Trial 1 (LACI-1)|Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease|Prevent-SVD|University of Edinburgh|Yes|Not yet recruiting|October 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|35 Years|N/A|No|||July 2015|July 31, 2015|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02481323||18356|
NCT02487953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063900|Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment|Electronic Nicotine Delivery Systems (ENDS) as a Smoking Cessation Treatment|ENDS-P50|Duke University|No|Not yet recruiting|January 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487953||17847|
NCT02487966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001065|Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)|Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)||Spaulding Rehabilitation Hospital|No|Recruiting|July 2015|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02487966||17846|
NCT02490592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 25687413.8.000.5176|Comparison of the Effect of Fluoride Remineralizer Gel and Foam|Comparison of the Effect of Fluoride Remineralizer Gel and Foam: a Randomized Clinical Trial||University Center of João Pessoa|Yes|Completed|March 2014|August 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|58|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02490592||17646|
NCT02491385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12-129|Thoracic Epidural for Postoperative Ileus|Effect of Thoracic Epidural Analgesia on Bowel Function Recovery in Major Upper Abdominal Surgeries||Samsung Medical Center|No|Completed|April 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02491385||17585|
NCT02469766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upper ureteric stones|Treatment of Upper Ureteric Stones Ureteroscopy and Extracorporeal Shockwaves Lithotripsy (SWL) in The Management of Proximal Ureteric Stones|A Comparison Between Flexible Ureteroscopy, Semirigid Ureteroscopy and Extracorporeal Shockwaves Lithotripsy (SWL) in The Management of Proximal Ureteric Stones. A Randomized Controlled Trial||Mansoura University|Yes|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|240|||Both|14 Years|80 Years|No|||June 2015|June 10, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469766||19245|
NCT02469779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0296|Middle and High School Students' Reactions to a Health Interactive Website: ASPIRE Reactions|Middle and High School Students' Reactions to a Health Interactive Website: ASPIRE Reactions||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2013|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02469779||19244|
NCT02488018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Honey-1|Investigation of the Glycemic Index of Ethiopian Honey|Investigation of Ethiopian Honey: Botanical Origin, Physicochemical, Antioxidant, Microbial Quality, Glycemic Index and Sensory Properties||Addis Ababa University|Yes|Enrolling by invitation|June 2015|April 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|20 Years|24 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02488018||17842|
NCT02492347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8442|Effect of Antenatal SSRI Exposure on the QT Interval of Neonates|Is Antenatal Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) Associated With Prolongation of the QT Interval in Term Neonates (Greater Than 37 Complete Weeks Gestation)?|SSRIs|University of Southampton|No|Not yet recruiting|August 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|242|||Both|N/A|3 Days|No|||July 2015|July 3, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02492347||17511|
NCT02485457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/17|Validation of Nicom Device to Measure Stoke Volume Variation|Validation of NICOM for the Detection of Modification of Stroke Volume|NICOM-VAL|Hopital Foch|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02485457||18038|
NCT02485717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-303-15|Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies|A Randomized, Phase 3, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Natroba (Spinosad) for the Treatment of Scabies||ParaPRO LLC|Yes|Suspended|June 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|4 Years|N/A|No|||January 2016|January 7, 2016|June 19, 2015|Yes|Yes|To address FDA Advice letter comments|No||https://clinicaltrials.gov/show/NCT02485717||18018|
NCT02466503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPE14015M1|Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block|A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers With Charcoal Block||Intech Biopharm Ltd.|Yes|Completed|August 2014|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466503||19496|
NCT02466516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-384-1497|Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3|A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3||Gilead Sciences|Yes|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|70|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466516||19495|
NCT02486731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-59|Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes|Consequences of Noonan Syndrome/LEOPARD Syndrome Associated Shp2 Mutations on Different Signaling Pathways Activation: Relationship With Hormonal Sensitivity|NOLEO|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Not yet recruiting|November 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|27|Samples Without DNA|Fibroblasts, adipocytes, serum|Both|5 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Data collected in patients with Noonan or LEOPARD syndromes will be compared to data of        healthy subjects.|November 2015|November 6, 2015|March 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02486731||17941|
NCT02492178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACH|Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria||REACH|University of Oxford|Yes|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|82|||Both|N/A|N/A|No|||December 2015|December 2, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02492178||17524|
NCT02473055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KangarooCareEEG|Kangaroo Care and Premature Infant Sleep|A Randomized Controlled Trial of Kangaroo Care (Skin-to-Skin) Effects on Sleep in Premature Infants||Case Western Reserve University|Yes|Completed|January 2003|May 2015|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|37 Weeks|No|||June 2015|June 16, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02473055||18992|
NCT02477605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRH172-P001|Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes|Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes||Alcon Research|No|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|22 Years|N/A|No|||November 2015|November 4, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477605||18642|
NCT02477618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-SSE-301|A Study With SAGE-547 for Super-Refractory Status Epilepticus|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus||Sage Therapeutics|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|2 Years|N/A|No|||March 2016|March 18, 2016|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477618||18641|
NCT02488902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8340|A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum|A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana||U.S. Army Medical Research and Materiel Command|No|Completed|August 1998|March 2003|Actual|September 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|521|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488902||17775|
NCT02488915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP002|Analysis of Revascularization in Ischemic Stroke With EmboTrap|ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) Study|ARISE II|Neuravi Inc.|Yes|Recruiting|November 2015|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|June 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02488915||17774|
NCT02492282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIVA-15517889|Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System|Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System: a Randomized Controlled Trial.||Universidad de Antioquia|Yes|Recruiting|June 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 7, 2015|July 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02492282||17516|
NCT02476604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375278-3|Seton Hill University--Personal Empowerment Program|Seton Hill University--Personal Empowerment Program|SHU-PEP|Walter Reed National Military Medical Center|No|Completed|January 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02476604||18719|
NCT02477644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-OV125b|Platine, Avastin and OLAparib in 1st Line|Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment|PAOLA-1|ARCAGY/ GINECO GROUP|Yes|Recruiting|April 2015|April 2022|Anticipated|April 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|612|||Female|18 Years|N/A|No|||October 2015|November 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02477644||18639|
NCT02463708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819012|Evaluation of the PACE/PACENET BHL Caregiver Program|Evaluation of the PACE/PACENET BHL Caregiver Outreach and Telehealth Education Program|CREST|University of Pennsylvania|No|Enrolling by invitation|November 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Caregivers of PACE/PACENET beneficiaries who are participating in the BHL COTP.|June 2015|October 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463708||19711|
NCT02418247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS13-671|Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer|Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients||National Cancer Center, Korea|Yes|Recruiting|May 2013|December 2020|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|556|||Both|18 Years|79 Years|No|||April 2015|April 15, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02418247||23200|
NCT02413385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HealtheSteps3|Evidence-Based Lifestyle Prescription Program: Pilot Study|Canadian Diabetes Strategy Research Project - HealtheSteps™: Exercise and Healthy Eating Prescriptions to Reduce the Risk of Diabetes in Rural and Remote Communities: A Pilot Pragmatic Randomized Controlled Trial (Project 3).|HeSP|University of Western Ontario, Canada|No|Active, not recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02413385||23574|
NCT02413645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iHIVARNA|A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy|A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy||Fundacion Clinic per a la Recerca Biomédica|Yes|Recruiting|June 2015|October 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|21|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02413645||23554|
NCT02466139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEregister2012-2015|Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis|Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes Among Infective Endocaridtis Patients in a Tertiary-care Centre in Kerala|CRP-IE|Government Medical College, Kozhikode|Yes|Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|N/A|No|Probability Sample|Consecutive patients with infective endocarditis treated in a tertiary care centre|June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02466139|6 Months|19524|
NCT02466152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201851|Pharmacokinetic Study of Topical GSK2894512 Cream|A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically Applied GSK2894512 Cream in Subjects With Atopic Dermatitis||GlaxoSmithKline|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||December 2015|January 4, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02466152||19523|
NCT02413060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42500653-9|The Impact of Resistance Training on Type 2 Diabetes Patients.|||Huashan Hospital||Enrolling by invitation|March 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02413060||23599|
NCT02469545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133-47818|Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment|Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment||Medical University of Bialystok|Yes|Active, not recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02469545||19262|
NCT02461966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aflatoxin|Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta|Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta||Tanta University|Yes|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|75|Samples Without DNA|5ml were centrifuged and serum was kept in 2 epindorf tubes frozen at -20°c and serum      aflatoxin b1 estimation by ELISA|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|After the approval of research ethics committee at Tanta Faculty of Medicine, this study        was conducted in tropical medicine department, Tanta university hospital on 75        individuals; 40 patients diagnosed as HCC were included as group I. Their household        relatives sharing same economic and environmental conditions were invited to share in the        study. All of them gave an informed consent to share in the study; 20 cirrhotic patients        who were included as group II, and 15 healthy non hepatic individuals were included as        control (group III).|March 2016|March 9, 2016|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02461966||19844|
NCT02466399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LipoLat-CS202|POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma|An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma||Peregrine Ophthalmic|No|Active, not recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|99 Years|No|||February 2016|February 23, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466399||19504|
NCT02466412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2M-PK-04-JP|Nicotine Pharmacokinetic Profile of the CHTP 1.1 M|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes||Philip Morris Products S.A.|No|Completed|May 2015|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|23 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02466412||19503|
NCT02466425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP465-305|Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|6 Years|17 Years|No|||March 2016|March 11, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466425||19502|
NCT02424214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbnSina Oocyte activation|Artificial Oocyte Activation Comparing Tow Different Agents|||Ibn Sina Hospital|No|Recruiting|January 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|450|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02424214||22742|
NCT02424279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUG10|Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder|Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder||Medical University of Gdansk|No|Recruiting|September 2014|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|January 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02424279||22737|
NCT02472145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107273|An Efficacy and Safety Study of Decitabine (DACOGEN) Plus JNJ-56022473 (Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy|A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy||Janssen Research & Development, LLC|Yes|Recruiting|August 2015|August 2018|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|406|||Both|65 Years|N/A|No|||March 2016|March 24, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472145||19062|
NCT02472158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISD-15|Chlorhexidine-Impregnated Sponge Dressing: A Clinical Trial|Use of Chlorhexidine-gel-Impregnated Dressing Compared to Transparent Polyurethane Film Dressing as Coverage of the Site of Insertion of Central Venous Catheter, in the Evaluation of Catheter Colonization in Critically Ill Adults Patients: A Randomized Controlled Trial|CISDCT|University of Sao Paulo|No|Active, not recruiting|April 2014|February 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|December 1, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02472158||19061|
NCT02471391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/148|ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)|A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)|AIM|Peter MacCallum Cancer Centre, Australia|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|August 27, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02471391||19120|
NCT02463604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01281-46|Renal PRotection Against Contrast mEdium-induced nephroPathy in High Risk Patients undErgoing Coronary Angiography|Renal PRotection Against Contrast mEdium-induced nephroPathy in High Risk Patients undErgoing Coronary Angiography|PREPARE|University Hospital, Angers|No|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|220|||Both|19 Years|N/A|No|||June 2015|August 27, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463604||19719|
NCT02463617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPULSPARK|Impulsivity and Parkinson's Disease : a Neuropsychology With Magnetic Resonance Imaging Study|Impulsivity and Parkinson's Disease : a Neuropsychology With Magnetic Resonance Imaging Study||Poitiers University Hospital|Yes|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02463617||19718|
NCT02418026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/P01/034|Improving Cesarean Section Experience Through Hypnotherapy|Improving Cesarean Section Experience Through Hypnotherapy: a Prospective Single Center Case-control Study||Groupe Hospitalier de la Rochelle Ré Aunis|No|Completed|February 2013|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|79|||Female|18 Years|N/A|No|||April 2015|April 16, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02418026||23217|
NCT02470143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDEN-IFRE 02|a Bike Application to Support Cardiac Patient|Pilot Study, How a Bike Application Can Support Cardiac Patients in Their Rehabilitation Program?|BackonBike|Hasselt University|No|Recruiting|August 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Probability Sample|Low risk coronary artery disease patients that completed phase II of cardiac        rehabilitation.|February 2016|February 23, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470143||19216|
NCT02467140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2307PG|Comparing Pain After Laparoscopic Hernia Repair Using Two Different Types of Mesh Fixation|A Clinical Study of Postoperative Pain Following Laparoscopic Transabdominal Preperitoneal Inguinal Hernioplasty. Comparing Parietex ProGrib With Tacks for Mesh Fixation||University of Aarhus|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Male|18 Years|N/A|No|||May 2015|June 5, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02467140||19447|
NCT02474186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-58|Phase II Study for Solid Metastatic Tumors|Phase II Study of Chemo-Radiation-Induced Abscopal Effect in Metastatic Breast Cancer and in Other Metastatic Sites of Solid Tumors||New York University School of Medicine|Yes|Completed|April 2003|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|19 Years|90 Years|No|||March 2016|March 2, 2016|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474186||18905|
NCT02474199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-12|Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction|Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12)|ARTEMIS|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|September 2015|December 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02474199||18904|
NCT02424227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-C-00006|Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation|Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients|DART|CareDx|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|cfDNA samples collected in Cell-Free DNA BCT and mRNA collected in PAX gene tubes will be      retained|Both|18 Years|N/A|No|Non-Probability Sample|Adult de novo living and deceased donor kidney transplant recipients will be eligible to        participate in this study.|January 2016|January 27, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02424227||22741|
NCT02466295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0280|The Comparison of the Effect of Pressure-controlled Ventilation and Volume-controlled Ventilation on the Gastric Insufflations in I-gel|||Yonsei University|No|Completed|June 2015|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|68|||Both|20 Years|N/A|No|||March 2016|March 11, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02466295||19512|
NCT02475408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCTP000000901|Effect of Permanent Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply|Effect of Permanent Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply|IMAO|University Hospital Inselspital, Berne|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02475408||18811|
NCT02475447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMP2006|Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis|A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis||Tioga Pharmaceuticals|No|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02475447||18808|
NCT02465398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-U03|Anatomical Shoulder™ Fracture Study|Anatomical Shoulder™ Fracture Post-Market Surveillance Study||Zimmer, Inc.|No|Active, not recruiting|August 2006|August 2022|Anticipated|August 2022|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465398||19581|
NCT02476864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-121|Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults|Single-center, Open-label, Randomized, Two-treatment, Single-dose, Crossover Study in Healthy Subjects to Investigate the Biocomparison of the Adult and Pediatric Formulation of Macitentan||Actelion|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02476864||18699|
NCT02488486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/24|Postoperative Sedation After Cardiac Surgery|Postoperative Sedation After Cardiac Surgery: Pilot Study|SEDCAR|Hopital Foch|No|Recruiting|May 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488486||17806|
NCT02488382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1852-AN-CTIL|Lonquek for Autologous Stem Cell Mobilization|Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma||Sheba Medical Center|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02488382||17814|
NCT02462083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-118A-303|Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Not yet recruiting|July 2015|September 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462083||19835|
NCT02477800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221AD301|221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease|ENGAGE|Biogen|Yes|Recruiting|August 2015|February 2022|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1350|||Both|50 Years|85 Years|No|||February 2016|March 18, 2016|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477800||18627|
NCT02487628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL-QX-YYZZBP-2014|Evaluation of HQ® Matrix Soft Tissue Mesh for the Treatment of Inguinal Hernia|Multi-center, Randomized, Active-controlled, Single-blind, Parallel Two-group Trial of HQ® Matrix Soft Tissue Mesh and ULTRAPRO® Partially Absorbable Lightweight Mesh for the Treatment of Inguinal Hernia||Zhejiang Xingyue Biotechnology Co., Ltd.|Yes|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02487628||17872|
NCT02479815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPHI_FSNRD_CF_MNP001|Impact of Low Dose Iron-containing Micronutrient Powders on Iron Status and Morbidity of Young Children in Ethiopia|Assessing the Safety of Iron Supplementation in Micronutrient Powder (MNPs)||Ethiopian Public Health Institute|Yes|Enrolling by invitation|March 2015|August 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2340|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02479815||18472|
NCT02465918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01420|Cyclization of Motor Cortex Stimulation|The Relationship Between Cyclizing Stimulation and Effective Stimulation During Motor Cortex Stimulation||University of British Columbia|No|Recruiting|July 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|November 20, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465918||19541|
NCT02468999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402/2014B01|Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans|||University Hospital Tuebingen|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|21|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02468999||19304|
NCT02490384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThomasJeffersonU|Physical Exam Indicated Cerclage in Twin Gestations|Randomized Control Trial Physical Exam Indicated Cerclage in Twin Gestations|TWIN-PEIC|Thomas Jefferson University|Yes|Recruiting|June 2015|July 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Female|18 Years|60 Years|No|||July 2015|July 14, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02490384||17662|
NCT02480088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0583|Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism|||Yonsei University|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|20 Years|85 Years|No|||June 2015|June 21, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02480088||18451|
NCT02480101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-H7N9-01|Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine||Research Institute of Influenza, Russia|Yes|Completed|October 2014|April 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02480101||18450|
NCT02474732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-0419|Usability Study for the Beactive Brace Instructions for Use|Assessment of User Comprehension of the BeActive™Brace User Guide||Benjamin L. England and Associates, LLC|No|Completed|February 2015|March 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|22 Years|79 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|June 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474732||18863|
NCT02487667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14/001|Therapeutic Exercise Training in the Elderly|Effects of a Therapeutic Exercise Program by a Feedback a Motor Control System in the Elderly||Universidad de Zaragoza|Yes|Recruiting|June 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02487667||17869|
NCT02486484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RaficHaririUH|Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection|Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study|Zaltrap|Rafic Hariri University Hospital|Yes|Recruiting|March 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||July 2015|July 1, 2015|May 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02486484||17960|
NCT02486744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-2015|Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population|Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population||Youngstown State University|No|Recruiting|March 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 26, 2015|June 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02486744||17940|
NCT02478268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060259|Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis|Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis||Duke University|Yes|Recruiting|May 2015|||April 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|79|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02478268||18591|
NCT02475044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0439-14|Mild Traumatic Brain Injuries in Children: Predicting Behavioral and Emotional Deficits|Mild Traumatic Brain Injuries in Children: Predicting Behavioral and Emotional Deficits||Rabin Medical Center|No|Not yet recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|6 Years|17 Years|No|||May 2015|June 15, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02475044||18839|
NCT02476305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6018|Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Treatment|Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical|CRYODESMO01|University Hospital, Strasbourg, France|No|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02476305||18742|
NCT02484391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22215|CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma|An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|September 2015|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|October 22, 2015|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02484391||18120|
NCT02484404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150145|Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer|Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|323|||Both|18 Years|99 Years|No|||May 2015|March 12, 2016|June 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02484404||18119|
NCT02484417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150148|Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers|A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|March 24, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484417||18118|
NCT02487030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1643|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection|A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection||Gilead Sciences|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487030||17918|
NCT02492516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Nerve-008|Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS|Evaluation the Safety of Intravenous Injection of Adipose Derived Mesenchymal Stem Cell in Patients With ALS||Royan Institute|Yes|Recruiting|September 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|55 Years|No|||December 2015|December 31, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02492516||17498|
NCT02492529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01123-44|Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease|Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease|EPMR-MA|Rennes University Hospital|No|Recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|100|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|November 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02492529||17497|
NCT02475499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q13-06A|Incretin-based Drugs and Pancreatic Cancer|The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|March 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|886172|||Both|18 Years|N/A|No|Probability Sample|In each jurisdiction, a base cohort will be assembled including all patients with a        first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is defined        as the date of prescription or dispensation of the first-ever non-insulin anti-diabetic        drug. From this base cohort, a study cohort will be formed consisting of all patients who        initiated a new anti-diabetic drug class during the year in which incretin-based drugs        entered the market in each jurisdiction or any time thereafter. Study cohort entry is        defined by the prescription date of the newly-prescribed drug class.|March 2016|March 11, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02475499||18804|
NCT02479425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of Medicine 09052011|Two Points Versus Three Points Turning in Prevention of Bed Sores in Critically Ill Patients|Two Pints Versus Three Points Turning in Prevention of Bed Sores in Critically Ill Patients||Faculty of Medicine, University of Alexandria|No|Completed|May 2011|July 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|16 Years|N/A|No|||July 2015|July 5, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02479425||18502|
NCT02482428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFX453X2202|Efficacy and Tolerability of Topical LFX453 for External Genital Warts|A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)||Novartis|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Male|18 Years|60 Years|No|||March 2016|March 3, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02482428||18271|
NCT02486276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8-2014-009|The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache|The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model||Danish Headache Center|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02486276||17976|
NCT02486289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI002|Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication|A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population|NBMI|Ermes Medical Company Ltd|No|Active, not recruiting|August 2015|April 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02486289||17975|
NCT02464618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-14-MED-11|Using Patients' Social Contact to Improve Out-Patient Endoscopy Among Blacks|Improving Attendance to Outpatient Endoscopy Among Blacks||Howard University|No|Recruiting|May 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02464618||19641|
NCT02484924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|680/15|The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome|The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome|ROBOT-ACS|Aintree University Hospitals NHS Foundation Trust|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers treated for ACS above the age of 18 with either clopidogrel or ticagrelor|January 2016|January 4, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02484924||18079|
NCT02487758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0531|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting||University of Louisville|No|Not yet recruiting|August 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02487758||17862|
NCT02478788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelBello/McNamara Neuroimaging|Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder|Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder||University of Cincinnati|Yes|Recruiting|July 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|240|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||June 2015|September 16, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02478788||18551|
NCT02478801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAO-E|Protein Requirements in Endurance-trained Athlete|Evaluation of Protein Requirements in Male Endurance Athletes|EP|University of Toronto|No|Active, not recruiting|March 2015|||January 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478801||18550|
NCT02476565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131507|Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme|Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme||Vanderbilt University|No|Recruiting|September 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476565||18722|
NCT02487797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201148|Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation|A Randomized Double Blind Clinical Trial Comparing Oxytocin Low-dose and High-dose Regimens for Labor Augmentation||Northwestern University|Yes|Recruiting|September 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1002|||Female|18 Years|45 Years|No|||October 2015|October 1, 2015|June 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487797||17859|
NCT02494271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI_anesthesia|TIVA, Inhalation Anesthesia, and Surgical Site Infection|||Seoul National University Bundang Hospital||Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2046|||Both|20 Years|90 Years|No|Non-Probability Sample|Adult patients who underwent elective colorectal surgery under general anesthesia from        January 2011 to December 2013 at SNUBH.|July 2015|July 9, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02494271||17363|
NCT02494284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2014-09|Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation|Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation : STAMP-DES Trial|STAMP-DES|Asan Medical Center|Yes|Recruiting|June 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1393|||Both|19 Years|N/A|No|||March 2016|March 21, 2016|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02494284||17362|
NCT02480296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYK461-003|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers|A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple Oral Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MYK-461 in Healthy Volunteers||MyoKardia, Inc.|Yes|Recruiting|August 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02480296||18435|
NCT02478281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1MBL12002|Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults|A One-Period, Single-Dose, Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Injection USP Following a 1 mg/kg Intravenous Dose in Healthy Adult Volunteers||Luitpold Pharmaceuticals|No|Completed|October 2012|March 2013|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478281||18590|
NCT02482012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC#34099|Minor Increase Over Minimal Risk Research in NICU|Minor Increase Over Minimal Risk Without Direct Patient Benefit Research in the NICU: Parental and Staff Perspectives||Christiana Care Health Services|No|Completed|June 2014|May 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|NICU staff and parents of infants|February 2016|February 24, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02482012||18303|
NCT02461667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014G|Alendronate Compared to Metformin in Chronic Periodontitis|Comparative Evaluation of Subgingivally Delivered 1% Metformin and 1% Alendronate Gel in Treatment of Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|108|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 31, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02461667||19867|
NCT02481076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-140|Compression in Anklefracture Treatment, The CAT-study|Compression in Anklefracture Treatment, The CAT-study|CAT|Hillerod Hospital, Denmark|No|Recruiting|November 2013|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02481076||18375|
NCT02489383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthmatic exercise training|Comparison Between Continuous Versus Interval Exercise Training in Asthmatic Patients|Comparison to Short and Medium-term Effects of Continuous and Interval Aerobic Exercise Training in Improving Aerobic Capacity, Psychosocial Factors and Impact on the Level of Physical Activity in Patients With Asthma Moderate and Severe||University of Sao Paulo General Hospital|Yes|Recruiting|October 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|59 Years|No|||October 2015|October 16, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02489383||17738|
NCT02472782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|076/AD7592/S1684/6-5-2015|Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication|Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication|IASIS|251 Hellenic Air Force & VA General Hospital|No|Recruiting|May 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|35 Years|N/A|No|Non-Probability Sample|Female patients with postmenopausal osteoporosis        Male patients ≥ 50 years old with idiopathic osteoporosis        Male and female patients with steroid-induced osteoporosis|December 2015|December 7, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02472782|2 Years|19013|
NCT02472795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-064A201|Clinical Trial to Evaluate the PK, PD, Biological Activity and Safety of ACT-334441 in SLE|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus||Actelion|Yes|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|64|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02472795||19012|
NCT02470884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2327|FAST Feasibility Study|Fully Absorbable Scaffold Feasibility Study||Boston Scientific Corporation|No|Recruiting|June 2015|December 2020|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02470884||19159|
NCT02479022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1957-4195|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects||Novo Nordisk A/S|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|84|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02479022||18533|
NCT02479035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-030|Red Raspberries and Insulin Action|Red Raspberries and Insulin Action: Understanding the Role of Red Raspberry Consumption on Oxidative Stress- and Inflammatory- Mediated Insulin Action in Humans|RRB|Institute for Food Safety and Health, United States|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|24|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479035||18532|
NCT02479048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-001|Avocado Fruit on Postprandial Markers of the Glycemic Response, Satiety/Appetite and Cardiometabolic Risk|The Impact of Avocado Fruit on Postprandial Markers of the Glycemic Response, Satiety/Appetite and Cardiometabolic Risk: An Acute Dose Response Study|AVOC1|Institute for Food Safety and Health, United States|No|Active, not recruiting|June 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|24|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02479048||18531|
NCT02475200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150201|Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems|Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems||Volcano Corporation|No|Enrolling by invitation|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|This study will include patients who are scheduled to receive atherectomy with the Phoenix        Atherectomy System used according to local standards.|March 2016|March 17, 2016|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02475200|12 Months|18827|
NCT02463448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-134|Autologous Muscle Derived Cells for Underactive Bladder|Autologous Muscle Derived Cells for Underactive Bladder||William Beaumont Hospitals|Yes|Recruiting|December 2015|August 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02463448||19731|
NCT02478450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QALS-101|Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)||Q Therapeutics, Inc.|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02478450||18577|
NCT02482220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU 1178|Physical Activity Program and Energy Intake Control in Obese Adolescents|Physical Activity and Energy Intake Control in Obese Adolescents: Effect of Exercise Programs of Various Intensities||Université Blaise Pascal, Clermont-Ferrand|No|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|70|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02482220||18287|
NCT02475343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.018|A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz Tonometer|A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz||Shandong Provincial Hospital|No|Recruiting|February 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02475343||18816|
NCT02477670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-202|Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia.||Avanir Pharmaceuticals|No|Recruiting|September 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||December 2015|December 18, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477670||18637|
NCT02484378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-001-CLIN-010|CER-001 Atherosclerosis Regression ACS Trial|CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome|CARAT|Cerenis Therapeutics, SA|Yes|Recruiting|August 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484378||18121|
NCT02423551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-12HC|MRE Consumption and Gut Health|Effects of Meal, Ready-to-Eat (MRE) Consumption on Gut Health||United States Army Research Institute of Environmental Medicine|No|Recruiting|April 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02423551||22793|
NCT02423629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0019|Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects|Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects (OCD)||Cartiheal (2009) Ltd|No|Recruiting|May 2014|||August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02423629||22787|
NCT02469012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228/14|Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy|Evaluation of Quality of Life, Neurocognitive Performance, Fatigue, and Emotional State in HCV Patients Before, During, and in the (Long-term) Follow-up of an IFN-free Antiviral Therapy|IFNfreeCOG|University of Wuerzburg|No|Recruiting|October 2014|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|75 Years|No|||June 2015|June 8, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02469012||19303|
NCT02461732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0486|Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence|Randomized Controlled Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence||The University of Texas Health Science Center, Houston|Yes|Recruiting|August 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2015|June 2, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02461732||19862|
NCT02461745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPSC IRB 10568|Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs|A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes||Kaiser Permanente|No|Enrolling by invitation|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|May 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461745||19861|
NCT02471742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 177/13|NAC Sparing Mastectomy After Neo-adjuvant Chemotherapy|Nipple Areolar-complex Sparing Mastectomy After Neo-adjuvant Chemotherapy: Evaluation of Local Oncologic Safety in a Cohort Study Analysis||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|January 2004|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|573|||Female|23 Years|77 Years|No|Non-Probability Sample|Both the population of patients treated with neoadjuvant chemotherapy (NAC-PC and PC        groups) were T2-T3 N0-N1 breast cancer.        The population of patients who underwent NAC-sparing mastectomy as primary therapy        (NAC-group) were T1-T3 N0-1 M0 breast cancer patients.|September 2015|September 15, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471742||19093|
NCT02417272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/40|Total Disc Replacement Versus Anterior Cervical Decompression and Fusion|Comparison of 2 Surgical Approaches in the Treatment of Cervical Degenerative Disc Disease: Total Disc Replacement Versus Anterior Cervical Decompression and Fusion|CERVIDISC|University Hospital, Bordeaux|No|Recruiting|November 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|110|||Both|18 Years|60 Years|No|||November 2015|November 5, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02417272||23275|
NCT02472171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|537073|Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans|Suppression of Postprandial Monocyte Activation by Fruit Rich in Anti-inflammatory Polyphenols or Docosahexaenoic Acid in Humans||USDA, Western Human Nutrition Research Center|No|Recruiting|June 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02472171||19060|
NCT02472366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-01-13-002|A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy|||Alimera Sciences|No|Completed|January 2014|May 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|June 10, 2015|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT02472366||19045|
NCT02466334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tba|CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients|CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients||Danish Headache Center|Yes|Not yet recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|45|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02466334||19509|
NCT02471924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00314-45|Predicting Hypotension Related to Spinal Anesthesia for Caesarean Section With Ultrasonography|Predicting Hypotension Related to Spinal Anesthesia for Caesarean Section With Ultrasonography||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|June 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|18 Years|45 Years|No|||June 2015|June 10, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02471924||19079|
NCT02413073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35872014.8.00005208|Whole Body Vibration in Kidney Disease|Effectiveness of Whole Body Vibration for Patients With Chronic Kidney Disease Terminal in the Interdialytic Period on Muscle Strength, Balance, Quality of Life and Functional Capacity: Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Enrolling by invitation|April 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|74 Years|No|||May 2015|May 26, 2015|November 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02413073||23598|
NCT02474173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00866|HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer|Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer||National Cancer Institute (NCI)||Recruiting|January 2016|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02474173||18906|
NCT02477397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART2014|Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD|Effectiveness of Single Inhaler Maintenance and Reliever Therapy With Spiromax® Budesonide/Formoterol (SMART) Versus Fixed Dose Treatment With Diskus® Fluticasone/Salmeterol in Patients With a Chronic Obstructive Pulmonary Disease (COPD)||University Medical Center Groningen|Yes|Recruiting|May 2015|July 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|40 Years|80 Years|No|||June 2015|June 19, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02477397||18658|
NCT02468037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00020094|Effect of Iron Reduction by Phlebotomy for Type 2 Diabetes|Iron Reduction by Phlebotomy for the Prevention and Treatment of Type 2 Diabetes||University of Utah|Yes|Completed|April 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|35 Years|65 Years|No|||June 2015|June 5, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02468037||19378|
NCT02424136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAAP (14/12/12/4.12)|PEAnut Anaphylaxis Predictors|PEAnut Anaphylaxis Predictors|PEAAP|John Hunter Children's Hospital|No|Recruiting|July 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|6 Years|17 Years|No|||December 2015|December 7, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02424136||22748|
NCT02472873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0062-15|Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas|Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas - a Prospective Case Control Study|EASLETE|Meir Medical Center|No|Enrolling by invitation|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|45 Years|No|||June 2015|June 15, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02472873||19006|
NCT02471508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITS/283/13|Safety and Efficacy of Body-mapping Tank Top Equipped With Biofeedback System for Adolescent With Early Scoliosis|An Innovative Body-Mapping Tank Top Equipped With Biofeedback System for Adolescents With Early Scoliosis||The Hong Kong Polytechnic University|Yes|Recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|10 Years|13 Years|No|||June 2015|June 12, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02471508||19111|
NCT02463838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14737|San Francisco Health Plan Care Support Trial|San Francisco Health Plan Care Support Intervention: A Randomized Trial|SFHP_CBCM|University of California, San Francisco|No|Recruiting|May 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02463838||19701|
NCT02463851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2014.01|PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation|PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation|GOLD-FORCE|R&D Cardiologie|No|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02463851||19700|
NCT02425566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141218|Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension|Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension||Vanderbilt University|No|Recruiting|April 2015|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02425566||22638|
NCT02470676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0096-14-HYMC|Cervical Pessary vs Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial|Cervical Pessary vs. Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Female|18 Years|N/A|No|||June 2015|June 9, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02470676||19175|
NCT02470689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-SE-135-14-CTIL|Diacerin for the Treatment of Epidermolysis Bullosa Simplex|Diacerin for the Treatment of Epidermolysis Bullosa Simplex||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|19 Years|No|||May 2015|June 9, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02470689||19174|
NCT02465645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis-004|To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Large Esophageal Varices.|A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Large Esophageal Varices||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|February 18, 2016|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02465645||19562|
NCT02469727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15563|mHealth Intervention to Promote Cancer Survivors' Physical Activity|mHealth Intervention to Promote Cancer Survivors' Physical Activity||Seattle Children's Hospital|No|Enrolling by invitation|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02469727||19248|
NCT02477787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1091|Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS|Randomized Comparative Study for Efficacy and Safety Evaluation of HLA-haploidentical Hematopoietic Cell Transplantation With or Without Post-transplant Allogeneic Donor-derived Natural Killer Cell Infusion in High-risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome|DNKI-4|Asan Medical Center|Yes|Recruiting|June 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02477787||18628|
NCT02493335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUL-2/EER|Maintenance of Remission With Budesonide Effervescent Tablets vs. Placebo in Eosinophilic Esophagitis|Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis|EOS-2|Dr. Falk Pharma GmbH|Yes|Not yet recruiting|February 2016|June 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|204|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02493335||17435|
NCT02494323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Segmented Electrodes|Evaluation of Dual Channel vs. Single Channel FES for Dropfoot|The Evaluation of Dual Channel vs Single Channel FES for Dropfoot||Bioness Neuromodulation|No|Enrolling by invitation|March 2015|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|July 8, 2015|March 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02494323||17359|
NCT02467010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG REMM|Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance|Bortezomib in Combination With Continuous Low-dose Oral Cyclophosphamide and Dexamethason Followed by Maintenance in Primary Refractory or Relapsed Bortezomib naïve Multiple Myeloma Patients. A Prospective Phase II Study.|REMM|University Medical Center Groningen|Yes|Completed|September 2008|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|80 Years|No|||June 2015|June 8, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02467010||19457|
NCT02465164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFM 2900|Cervical Ripening With Cook Catheter Plus Low Dose Oxytocin|||Henry Ford Health System||Not yet recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465164||19599|
NCT02465515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116174|Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus|A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (HARMONY Outcomes)||GlaxoSmithKline|Yes|Recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|9400|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465515||19572|
NCT02465528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2407|Ceritinib Rare Indications Study in ALK+ Tumors|A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)||Novartis|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|1 Year|N/A|No|||October 2015|October 8, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02465528||19571|
NCT02490241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00200026|Lithium Therapy: Understanding Mothers, Metabolism and Mood|Lithium Therapy: Understanding Mothers, Metabolism and Mood|LiThiUM|Northwestern University|Yes|Recruiting|April 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|blood serum and urine to measure lithium levels and creatinine clearance|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pre-conception planning and pregnant women taking lithium for the purpose of mood        stabilizing will be recruited broadly from Northwestern clinical services, including        Internal Medicine, OB/GYN, Family Medicine, and Psychiatry, registries, and from the local        Chicagoland community. Patients that sign consent, complete the evaluation and meet        criteria will be enrolled into the study.|January 2016|January 8, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02490241||17673|
NCT02484040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TwoArc trial|Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer|Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial||Seoul St. Mary's Hospital|Yes|Recruiting|December 2015|July 2021|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02484040||18147|
NCT02470286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJSA001|Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers||Samjin Pharmaceutical Co., Ltd.||Not yet recruiting|June 2015|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02470286||19205|
NCT02476942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH29768|A Prospective Study to Collect High-Quality Documentation of Bleeds Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A and Factor VIII (FVIII) Inhibitors Treated With Standard-of-Care Treatment|A Single-Arm, Multicenter, Non-Interventional Study Evaluating Bleeding Incidence, Health-Related Quality of Life, And Safety in Patients With Hemophilia A And Inhibitors Against Factor VIII Under Standard-of-Care Treatment||Hoffmann-La Roche||Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|70|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with hemphillia A and inhibitors against FVIII under standard-of-care treatment        are to be enrolled.|September 2015|September 9, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02476942||18693|
NCT02476955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 092-102|Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel|An Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel in Subjects With Selected Solid Tumors||ArQule|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02476955||18692|
NCT02480790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV-VTE|Venous Thromboembolic Complications in Ovarian Cancer|Venous Thromboembolic Complications in Patients With Ovarian Cancer Compared to Patients With Benign Ovarian Tumours||Aalborg Universitetshospital|Yes|Recruiting|November 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Tumor tissue and also healthy tissue for comparison are taken at surgery. Blood samples.|Female|18 Years|N/A|No|Non-Probability Sample|Women referred to the outpatient clinic with suspected ovarian cancer, where the initial        examinations with ultrasound scan and measurement of ca-125 in blood reveal a Risk        Malignancy Index (RMI) ≥ 200 indicating a high risk of ovarian cancer.|May 2015|June 22, 2015|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02480790||18397|
NCT02484261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004062|Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children|Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children||Children's Research Institute|Yes|Recruiting|May 2015|August 2019|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|22 Months|21 Years|No|||January 2016|January 26, 2016|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484261||18130|
NCT02488746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FROST|Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)|Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)||Kliniken Ludwigsburg-Bietigheim gGmbH|No|Recruiting|March 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in which a subepithelial gastric tumor has been detected (in our hospital, other        hospitals or by transferring doctor).|June 2015|June 30, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02488746||17786|
NCT02462551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21024/ PSY.ZN.03|Focal Electrically Administered Seizure Therapy for the Treatment of Depression|Investigating the Effects of Focal Electrically Administered Seizure Therapy (FEAST) for the Treatment of Depression|FEAST|American University of Beirut Medical Center|No|Recruiting|September 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||June 2015|June 2, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462551||19799|
NCT02462837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYRB-14B02|Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement|||Southern Illinois University|No|Recruiting|May 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02462837||19777|
NCT02489929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01797-40|Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine|Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplasic Syndrom or an Acute Myeloid Leukemia and Treated by Azacytidine||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|August 2015|March 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|85 Years|No|||July 2015|July 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02489929||17697|
NCT02489942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.94|Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE® Tablets in Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Recruiting|June 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|3,000 Japanese patients with the assessment of 3-year completed administration|March 2016|March 16, 2016|May 21, 2015||||No||https://clinicaltrials.gov/show/NCT02489942||17696|
NCT02489799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1549|Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families|Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families|ACPvideo|Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|July 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|84|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02489799||17707|
NCT02482532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mel-2012-01-01|Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma|Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma|MARVSmALo|University of Kansas Medical Center|Yes|Recruiting|January 2016|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|66 Years|No|||March 2016|March 11, 2016|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02482532||18263|
NCT02476318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-008|A Study to Evaluate the Safety and Performance of ArterX™ Vascular Sealant in Sealing Synthetic Arterial Grafts|A Study to Evaluate the Safety and Performance of ArterX™ Vascular Sealant in Sealing Synthetic Arterial Grafts||Tenaxis Medical, Inc.|No|Completed|June 2007|November 2007|Actual|August 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02476318||18741|
NCT02487784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0530|Ridge Augmentation: Particulate v/s Block Graft|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Versus Corticocancellous Particulate Allograft Mixed With Autogenous Bone Chips||University of Louisville|Yes|Not yet recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02487784||17860|
NCT02489890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLAD001|CIK in Treating Patients With Bladder Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Urinary Bladder Carcinoma||The First People's Hospital of Changzhou|Yes|Active, not recruiting|February 2016|July 2030|Anticipated|July 2025|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02489890||17700|
NCT02478528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projet Cellule Innovation 2014|Study of Effects of Light on the Vigilance and Cognitive Performance Following a Night Without Sleep|Study of Effects of Light on the Vigilance and Cognitive Performance Following a Night Without Sleep|LUMI|University Hospital, Strasbourg, France|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|June 17, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02478528||18571|
NCT02464150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1237|Gluten Challenge in Celiac Disease and Gluten Sensitivity|Gluten Challenge in Celiac Disease and Gluten Sensitivity||Oslo University Hospital|No|Active, not recruiting|November 2014|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|86|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02464150||19677|
NCT02484651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.145|Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?|Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade: a Randomized Controlled Study Assessing Propofol and Remifentanil Requirements and Quality of Recovery in Patients With a Standard Practice of Non-deep Rocuronium Neuromuscular Blockade Versus Deep Neuromuscular Blockade Reversed With Sugammadex||Centro Hospitalar do Porto|Yes|Not yet recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02484651||18100|
NCT02484664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000954|COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC|COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC|COLA|Brigham and Women's Hospital|Yes|Recruiting|January 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|70 Years|No|||January 2016|January 11, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02484664||18099|
NCT02487290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TripleMed 001|Feasibility Study of ANEUFIX: a Novel Approach to Treat Type II Endoleaks Using ACP-T5|Feasibility Study of ANEUFIX: a Novel Approach to Treat Type II Endoleaks Using ACP-T5||TripleMed B.V.|Yes|Not yet recruiting|August 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|45 Years|N/A|No|||June 2015|June 29, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02487290||17898|
NCT02490007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVID/2015-02|Pertussis Immunisation and Food Allergy|Case-control Study of the Association Between Pertussis Vaccination in Infancy and the Risk of IgE-mediated Food Allergy|PIFA|Telethon Kids Institute|No|Recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|11000|||Both|14 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have        received their first pertussis vaccination before the age of 16 weeks. They will have been        born during the period of change over from whole cell pertussis vaccine to acellular        pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics        associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy        as defined by the case description and as ascertained by their medical records.|February 2016|February 24, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02490007||17691|
NCT02492633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAHHU0025-14|Prospective Evaluation of a Comprehensive Smoke-Free Public Housing Policy in a Multi-State Setting|Prospective Evaluation of a Comprehensive Smoke-Free Public Housing Policy in a Multi-State Setting||Harvard School of Public Health|No|Enrolling by invitation|June 2015|April 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02492633||17489|
NCT02468973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-0046-14|Supporting Patients in Lifestyle Health Behavior Change by Medical Students at Primary Care Clinics in Zefat Israel|Accompanying and Supporting Patients in Lifestyle Health Behavior Change by Medical Students at Primary Care Clinics in Zefat Israel||Clalit Health Services|No|Not yet recruiting|October 2015|September 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|20 Years|80 Years|No|||June 2015|June 8, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02468973||19306|
NCT02488005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0878|The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction|The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction||Icahn School of Medicine at Mount Sinai|No|Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|6 Years|21 Years|No|||January 2016|January 5, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02488005||17843|
NCT02490358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENA003|Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers|A Sputum Sample Collection Protocol for Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-Smokers||Respivert Ltd|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|25|Samples With DNA|Sputum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Up to 20 of each of the following populations will be recruited in this study:          -  Healthy smoking subjects          -  Smoking subjects with COPD          -  Ex-smoking subjects with COPD|February 2016|February 2, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02490358||17664|
NCT02490137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWisconsin|Brain Changes With Game Training in Aging|Brain Changes With Game Training in Aging|BrainGame|University of Wisconsin, Madison|No|Recruiting|June 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|July 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02490137||17681|
NCT02478736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0319|Preoperative Transcranial Doppler as a Predictor for Delirium Following On-pump Cardiac Surgery|||Yonsei University|No|Recruiting|June 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|117|||Both|60 Years|100 Years|No|Non-Probability Sample|patients undergoing on-pump cardiac surgery|June 2015|October 2, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02478736||18555|
NCT02483273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1-BE-2-19/2011|Alterations of Conjunctival Microcirculation in Brain Dead Patients|Alterations of Conjunctival Microcirculation in Brain Dead Patients||Lithuanian University of Health Sciences|Yes|Completed|May 2011|March 2016|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|All single center tertiary level Neurosurgery Intensive Care unit patients        angiographically confirmed brain dead.|March 2016|March 2, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02483273||18206|
NCT02483520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR014737|Supporting Family Caregivers With Technology for Dementia Home Care|Supporting Family Caregivers With Technology for Dementia Home Care|FamTechCare|University of Iowa|Yes|Recruiting|March 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02483520||18187|
NCT02465450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBT101-CF-001|Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis|A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis||Corbus Pharmaceuticals Inc.|Yes|Recruiting|September 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|70|||Both|16 Years|65 Years|No|||March 2016|March 16, 2016|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465450||19577|
NCT02465463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077804|Early FMT for C.Difficile|A Pilot Study Examining the Safety and Efficacy of Early Fecal Transplant in Patients Infected With Clostridium Difficile at High Risk of Relapse||Emory University|Yes|Recruiting|June 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|79 Years|No|||March 2016|March 1, 2016|November 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02465463||19576|
NCT02490371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-2015-QEHHK|Low Frequency rTMS With Structured PT Training on Restoring Upper Extremity Function|The Effectiveness of Combination of Low Frequency Repetitive Transcranial Magnetic Stimulation With Structured Physiotherapy Training Program on Restoring Upper Extremity Function for Patients After Stroke|PT|Queen Elizabeth Hospital, Hong Kong|No|Not yet recruiting|September 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|N/A|85 Years|No|||July 2015|July 2, 2015|May 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02490371||17663|
NCT02480569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-033|Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter|Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter||North Texas Veterans Healthcare System|No|Completed|June 2015|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02480569||18414|
NCT02486575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUTOR LAP SYM|Trial on Laparoscopic Simulation Based on Mentoring|Comparison of Laparoscopic Simulation Training Between Mentoring and Self-learning Technique||Università degli Studi di Brescia|No|Completed|January 2014|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|24 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|January 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02486575||17953|
NCT02466243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBT101-DM-001|Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis||Corbus Pharmaceuticals Inc.|No|Recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|June 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02466243||19516|
NCT02485158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-0534|Individual Differences in the Response to Drugs|A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol|TDS|University of Chicago|No|Completed|July 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|24|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|June 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02485158||18061|
NCT02492074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEI-TCP I|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function||Central Institute of Mental Health, Mannheim|No|Not yet recruiting|April 2016|May 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02492074||17532|
NCT02492165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC13|Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects|Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given to Healthy Subjects in Vietnam||Sanofi|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|250|||Both|9 Months|60 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02492165||17525|
NCT02475148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107482|A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants|A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Subjects||Janssen-Cilag International NV|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|76|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02475148||18831|
NCT02477592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|仁济伦审[2014]116K|a Novel Individualized Substrate Modification Approach for the Treatment of Long-standing Persistent Atrial Fibrillation|A Prospective Randomized Study of a Novel Individualized Substrate Modification Approach Versus Stepwise Ablation for the Treatment of Long-standing Persistent Atrial Fibrillation||RenJi Hospital|Yes|Recruiting|January 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|72 Years|No|||January 2015|June 17, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02477592||18643|
NCT02535520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-50547|Evaluation of RTVue XR With SSADA|Clinical Evaluation of RTVue XR With SSADA in Retinal Patients||Optovue|No|Active, not recruiting|August 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Seeing eye doctor for routine or follow-up care|October 2015|October 13, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535520||14197|
NCT02535780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2716|Transcranial Treatments in Eating Disorders|Novel Transcranial Treatments to Modulate Taste Reward and Body Perception Pathways in Eating Disorders||University of Colorado, Denver|No|Recruiting|August 2015|||August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|128|||Female|18 Years|65 Years|No|||February 2016|February 29, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02535780||14177|
NCT02530853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32909414.4.1001.5238|Acupuncture as a Complementary Treatment for Hypertension (ACT-HAS)|Acupuncture as Applied Technology to Nursing Care Adult Hypertensive: An Experimental Study.|ACT-HAS|Universidade Federal do Rio de Janeiro|Yes|Recruiting|August 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|30 Years|75 Years|No|||August 2015|August 21, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530853||14554|
NCT02538692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81373644|Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome|Traditional Chinese Medicine Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome: a Randomized Placebo-controlled Trial and a Mechanistic Study||Chengdu University of Traditional Chinese Medicine|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|75 Years|No|||August 2015|September 1, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02538692||13953|
NCT02530502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 15C01|Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma|Phase I/II Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)||Northwestern University|Yes|Recruiting|September 2015|||March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530502||14581|
NCT02535182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24391|Pilot Study Using Propranolol To Promote Prenylation Of The Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients|Pilot Study Using Propranolol To Promote Prenylation Of The Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients||Medical College of Wisconsin|No|Recruiting|August 2015|June 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples      collected from patients at the three designated time points (Baseline, Day -2, and Day +28).      Members of Dr. Carol Williams' laboratory (Professor, Pharmacology and Toxicology, MCW) will      conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to      determine the distribution of Rap1 in the different fractions, and the status of Rap1      prenylation in the cells.|Both|18 Years|75 Years|No|Non-Probability Sample|Patients who are enrolled in the parent study are eligible for this ancillary study.|March 2016|March 17, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535182||14223|
NCT02532478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DrLutfi|Fortune of Temporary Ileostomies in Patients After Rectal Cancer Surgery|Fortune of Temporary Ileostomies in Patients Treated With Laparoscopic Low Anterior Resection for Rectal Cancer||Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|No|Completed|February 2007|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|patients who underwent laparoscopic low anterior resection for rectal cancer with a        diverting ileostomy between 2007 and 2014.|August 2015|August 21, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02532478||14431|
NCT02540733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81271530|MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes|MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes||Zhejiang University|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|with a definition of stroke within 3 to 7 days after onset|September 2015|September 1, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02540733||13797|
NCT02535104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMIR1402HPV|Safety and Efficacy Study of Topical Rapirnase to Treat Genital Warts (HPV)|Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV||Tamir Biotechnology, Inc.|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||February 2016|February 25, 2016|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02535104||14229|
NCT02539121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenMai6|Influence of Acupuncture in the Postpartum Blood Loss|Influence of Acupuncture in the Postpartum Blood Loss||Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias|No|Not yet recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02539121||13920|
NCT02535208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01514|Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions|A Pilot Randomized Trial of Restrictive Red Blood Cell Transfusion Guidelines Used in Combination With Near-infrared Spectroscopy Splanchnic-cerebral Oxygenation Ratio Evaluations Versus Liberal Red Blood Cell Transfusion Guidelines in Preterm Infants||New York University School of Medicine|Yes|Recruiting|August 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|82|||Both|N/A|3 Days|No|||August 2015|August 26, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02535208||14221|
NCT02553057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DrSamah|Low Tidal Volume for Lung Protection During Anesthesia of Laparoscopic Surgery in Trendlenburg Position||lapVent|Mansoura University|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|20 Years|50 Years|No|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553057||12851|
NCT02553304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1914|Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients|Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|September 2015|July 2020|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|The molecular markers to be tested in this project include (but not limited to) cytogenetic      abnormalities by fluorescent-in-situ hybridization (FISH), immunoglobulin heavy chain      variable region (IGHV) hypermutation status, gene mutations for Notch1, SF3B1, p53, MyD88,      and BIRC3, and the expressions for ZAP70 and stem cell factor (SCF).|Both|20 Years|N/A|No|Probability Sample|Chronic lymphocytic leukemia (CLL)Patient|July 2015|January 13, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553304|2 Years|12832|
NCT02552615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Go 14/19|Effectiveness of Exercises in Adolescent Idiopathic Scoliosis|Investigation of the Effects of Spinal Stabilization and Body Awareness Exercises on Subjective Vertical Perception, Curve Magnitude, Body Symmetry and Quality of Life in Adolescent Idiopathic Scoliosis||Hacettepe University|Yes|Completed|January 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|10 Years|16 Years|No|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552615||12885|
NCT02555046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-161|Muscle and Cerebral Oxygenation Under EVAR of AAA: GA vs LA|Muscle and Cerebral Oxygenation Under Endovascular Aortic Repair (EVAR) of Abdominal Aortic Aneurysm: General Versus Local Anesthesia - an Randomised Controlled Trial Study||Rigshospitalet, Denmark|Yes|Not yet recruiting|October 2015|July 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|September 18, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02555046||12698|
NCT02555059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18235|Special Drug Use Investigation of Ciproxan Injection in Pediatrics|Special Drug Use Investigation of Ciproxan® Injection in Pediatrics||Bayer|No|Not yet recruiting|April 2016|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|14 Years|No|Non-Probability Sample|Female and male pediatric patients (less than 15 years old) with a diagnosis of        complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by        ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli,        Pseudomonas aeruginosa, are enrolled after the decision for treatment with Ciproxan        injection has been made by the investigator.|March 2016|March 21, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555059||12697|
NCT02545777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-ZYLC-001|The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid|||Beijing University of Chinese Medicine||Recruiting|May 2014|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||September 2015|September 10, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545777||13411|
NCT02528318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-CL-1401|Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA|A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA||Discovery Laboratories, Inc.|Yes|Recruiting|August 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|64|||Both|26 Weeks|28 Weeks|No|||November 2015|November 19, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528318||14749|
NCT02533284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy|Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy||Mansoura University|No|Not yet recruiting|January 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|90|||Both|16 Years|50 Years|No|||August 2015|August 22, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02533284||14369|
NCT02533583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guangdongwchhi1|Pulse Oximetry With Clinical Observation to Screen for Lung Disease in Neonates|Pulse Oximetry With Clinical Observation to Screen for Lung Disease in Neonates||Guangdong Women and Children's Hospital and Health Institute|No|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|15000|||Both|N/A|3 Days|No|Non-Probability Sample|All infants will born in guangdong women and children hospital|August 2015|August 26, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02533583||14346|
NCT02535390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYC-152-14|Action-Based Cognitive Remediation to Improve Vocational Outcomes in Depression|Action-Based Cognitive Remediation to Improve Vocational Outcomes in Depression|ABCR|Queen's University|No|Recruiting|December 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02535390||14207|
NCT02535650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-039|Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma|An Open Label Phase II Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma||Samsung Medical Center|No|Not yet recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||August 2015|August 26, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535650||14187|
NCT02539836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COIF_001|Study on Dietary Nutrition Intervention Techniques for Children Obesity|Study on Dietary Nutrition Intervention Techniques for Children Obesity||Chinese Academy of Sciences|No|Not yet recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539836||13866|
NCT02536625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPANK|Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)|RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)|RAPANK|Centre Leon Berard|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|36|||Female|18 Years|N/A|No|Probability Sample|Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) eligible for a        treatment with everolimus in this application|October 2015|October 13, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02536625||14112|
NCT02544425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-035|Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK/T-cell Lymphoma|Open-labeled, Multicenter Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK/T-cell Lymphoma||Samsung Medical Center|No|Not yet recruiting|September 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|65 Years|No|||September 2015|September 6, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02544425||13515|
NCT02536222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|762488-1|Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts|Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts||PATH|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30000|||Both|2 Months|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02536222||14143|
NCT02533505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589CC00014|Phase IV O2 Consumption Study in COPD Patients|A Phase 4, Randomized, Double-blind, Multicenter, Placebo-Controlled Two Way Cross-Over Study to Evaluate Changes in Oxygen Consumption and Cardiac Function in COPD Patients With Resting Hyperinflation After Administration of Symbicort pMDI 160/4.5 μg||AstraZeneca|No|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||March 2016|March 23, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533505||14352|
NCT02533518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008041|Ultra-Violet Fluorescence Bronchial Cancer Location|Ultra-Violet Fluorescence Bronchial Cancer Location|UVFBCL|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02533518||14351|
NCT02539862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9454|Evaluating the Efficacy of the Management of an Online Program of Cognitive Behavioral Therapy for Primary Insomnia|Pilot Study Evaluating the Efficacy of the Management of an Online Program of Cognitive Behavioral Therapy for Primary Insomnia|NEXPERTSANTE|University Hospital, Montpellier|No|Not yet recruiting|August 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|46|||Both|20 Years|65 Years|No|||August 2015|August 31, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02539862||13864|
NCT02539875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTW2015|Promoting Smoking Cessation in the Community Via QTW 2015|Building Capacity and Promoting Smoking Cessation in the Community Via "Quit to Win" Contest 2015: a Randomized Controlled Trial on Brief Intervention (AWARD Model) and Active Referral to Smoking Cessation Services||The University of Hong Kong|Yes|Recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|1350|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02539875||13863|
NCT02535910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD|Effect of vitaminD3 or 25(OH)D3 Fortified Dairy on Vitmain D Status and CVD Risk Markers|Fortification of Milk and Butter With Either vitaminD3 or 25(OH)D3: The Effect on Vitamin D Status and Cardiovascular Disease Risk Markers in Humans||University of Reading|Yes|Enrolling by invitation|August 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|18|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02535910||14167|
NCT02544191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AzoospermiaNanjing|GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia|GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia: A Single-center Prospective Study in China||Jinling Hospital, China|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|45 Years|No|||December 2015|December 18, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02544191||13533|
NCT02544204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-007|SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease|A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss|STOP-PAD|Juventas Therapeutics, Inc.|Yes|Recruiting|November 2015|November 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|85 Years|No|||March 2016|March 24, 2016|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02544204||13532|
NCT02534558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 102-5462B|Pathomechanism of MicroRNA-29 in Shoulder Stiffness|Pathomechanism of MicroRNA-29 in Shoulder Stiffness||Chang Gung Memorial Hospital|Yes|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|80 Years|No|||April 2015|August 25, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02534558||14271|
NCT02538497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/614REK nord|Northern Babies: A Study of Predictors of Postpartum Depression and Parent-infant Interaction Difficulties|Predicting Postpartum Depression and Improving Parent-infant Interaction During the Perinatal Period: The Newborn Behavioral Observation Intervention||University of Tromso|No|Recruiting|August 2015|April 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02538497||13968|
NCT02528227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0074|NICU Parent Education Program|NICU Parent Education Program|NICU PEP|Women and Infants Hospital of Rhode Island|No|Recruiting|January 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|23 Weeks|32 Weeks|No|||August 2015|August 18, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02528227||14756|
NCT02532114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9390|Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer|A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer||University of Washington|No|Recruiting|December 2015|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|No|||January 2016|January 5, 2016|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532114||14458|
NCT02532127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56942|Dentomaxillofacial Paediatric Imaging: An Investigation Towards Low Dose Radiation Induced Risks|Dentomaxillofacial Paediatric Imaging: An Investigation Towards Low Dose Radiation Induced Risks|DIMITRA|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|December 2014|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|N/A|22 Years|No|||December 2014|September 2, 2015|December 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02532127||14457|
NCT02632682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE-08|Confocal Laser Endomicroscopy vs Conventional Histology for the Identification of Intestinal Metaplasia|Real-time Diagnosis of Barrett's Esophagus: Comparing Confocal Laser Endomicroscopy With Conventional Histology for the Identification of Specialized Intestinal Metaplasia||Minnesota Institute for Minimally Invasive Surgery|No|Not yet recruiting|February 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Age >18          -  Clinical diagnosis of GERD          -  Undergoing upper endoscopy for reflux evaluation|December 2015|December 14, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02632682||6737|
NCT02640820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-SCP-1502|Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)|A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years||RXi Pharmaceuticals, Corp.|Yes|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640820||6112|
NCT02538627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-151-01-01-02|Phase 1 Combination Study of MM-151 and MM-121|A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients||Merrimack Pharmaceuticals||Recruiting|August 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538627||13958|
NCT02541097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPSASA-15-362999|Preventing Language Decline in Dementia|Preventing Language Decline in Dementia||Baycrest|No|Not yet recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|N/A|N/A|No|||September 2015|September 3, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541097||13770|
NCT02532413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81461130019C5|Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B|Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B||Wuhan Union Hospital, China|No|Recruiting|July 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|60 Years|No|||August 2015|August 22, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02532413||14436|
NCT02532426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108100|Influence of Chronic Hypoxia on Oxidative Phenotype in Patients With Chronic Obstructive Pulmonary Disease|Influence of Chronic Hypoxia on Oxidative Phenotype in Patients With Chronic Obstructive Pulmonary Disease|OXYPHEN|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|52|||Both|18 Years|N/A|No|Non-Probability Sample|COPD patients with chronic hypoxemia and with normoxemia|March 2016|March 9, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532426||14435|
NCT02643316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 15-092|Morning-Only 4 L PEG vs Split Dose Prep for Afternoon Colonoscopies, Endoscopist-Blinded Prospective Study|Morning-Only 4 Liter Polyethylene Glycol vs. Split Dose for Afternoon Colonoscopies, a Randomized Endoscopist-Blinded Prospective Study||Cleveland Clinic Florida|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643316||5920|
NCT02543099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150811|Efficacy and Safety Study of Policosanol|The Effect of Policosanol on Elderly Patients With Endothelial Dysfunction||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||August 2015|September 3, 2015|August 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543099||13617|
NCT02543112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201956|A Long-term Access Programme for Subjects With Severe Asthma|A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study||GlaxoSmithKline|No|Recruiting|August 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|6 Years|N/A|No|||March 2016|March 17, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543112||13616|
NCT02528708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1504015615|A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)|A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)|PERFECT PPH|Yale University|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||August 2015|August 18, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528708||14719|
NCT02528721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2-HP-0715|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||February 11, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528721||14718|
NCT02532699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS11043|Anti-hypertensive Effect of Mycelia of Antrodia Cinnamomea|Anti-hypertensive Effect of Fermented Mycelia of Antrodia Cinnamomea Among Mild Hypertensive Subjects in a Double-blinded Randomized Trial||Chung Shan Medical University|Yes|Completed|June 2011|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|41|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 23, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02532699||14414|
NCT02641418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1808|Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication|Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication|SEIC|University of Hull|No|Recruiting|May 2015|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|45 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02641418||6066|
NCT02642601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS62014|Role of Indomethacin in Difficult Embryo Transfer.|Role of Indomethacin in Cases of Difficult Embryo Transfer in Intra Cytoplasmic Sperm Injection Cycles||Cairo University|Yes|Recruiting|March 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|38 Years|No|||December 2015|December 24, 2015|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642601||5975|
NCT02642614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.16|Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD|A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation||Boehringer Ingelheim||Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|120|||Both|40 Years|80 Years|No|||March 2016|March 21, 2016|December 23, 2015||||No||https://clinicaltrials.gov/show/NCT02642614||5974|
NCT02536365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3795|Sensory Integration Therapy in Autism: Mechanisms and Effectiveness|Sensory Integration Therapy in Autism: Mechanisms and Effectiveness||Albert Einstein College of Medicine of Yeshiva University|No|Not yet recruiting|September 2015|October 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|6 Years|102 Months|No|||August 2015|August 28, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536365||14132|
NCT02536378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM-2015-02|REGISTRY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE|REGISTRY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE. The ROADSTER 2 Registry||Silk Road Medical|No|Recruiting|September 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with atherosclerotic extracranial internal carotid stenosis (ICA) with or without        involvement of the contiguous common artery (CCA) determined by duplex ultrasound, CT/CTA,        MR/MRA or angiography to be:          -  Symptomatic: greater than or equal to 50% stenosis or          -  Asymptomatic: greater than or equal to 80% stenosis|January 2016|January 15, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536378|30 Days|14131|
NCT02536391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29868|Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects|A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects||Genentech, Inc.||Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536391||14130|
NCT02544984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0476|The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease|The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease: a Double Blinded RCT||The University of Texas Health Science Center, Houston|No|Recruiting|October 2015|May 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|92|||Both|6 Months|6 Years|No|||March 2016|March 24, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544984||13472|
NCT02544997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-078|A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 Mutation or Activated AR Pathway|A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 Mutation or Activated AR Pathway||Samsung Medical Center|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||October 2015|October 29, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02544997||13471|
NCT02533973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1079|Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population|||LEO Pharma|No|Recruiting|September 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533973||14316|
NCT02533986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGBERRY-BR|Effects of Berry Peel Intake on Glucose Metabolism in Healthy Subjects|Effects of Berry Peel Intake on Glucose Metabolism in Healthy Subjects||Lund University|No|Completed|August 2015|January 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533986||14315|
NCT02529124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHSREC10_45|Nutrient Support to Body Composition and Healthy Ageing|An Investigation of the the Effect of Nutrient Support, or Nutrient Plus Physical Activity on Musculoskeletal Health and Function in Men and Women Aged 55 to 70 Years|BCHA|University of Limerick|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|300|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02529124||14687|
NCT02533427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1909|Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol|A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol||Gilead Sciences|No|Active, not recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02533427||14358|
NCT02543021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113398|Virtual Chromoendoscopy for Colitis Surveillance: A Feasibility Study|A Study to Assess the Feasibility and Patient Acceptability of a Randomised, Crossover Design to Compare Virtual vs Conventional Chromoendoscopy for the Detection of Dysplasia in Colitis||King's College Hospital NHS Trust|Yes|Not yet recruiting|November 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2015|September 4, 2015|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543021||13623|
NCT02543034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTF14-KR-401|Study of Petrolatum Gauze, Allevyn, and New Antiseptic Dressing, Betafoam® Dressing, in the Management of Split-Thickness Skin Graft Donor Site|Randomized, Controlled, Phase IV Study of Petrolatum Gauze, Allevyn, and New Antiseptic Dressing, Betafoam® Dressings, in the Management of Split-Thickness Skin Graft Donor Site||Mundipharma Korea Ltd|Yes|Recruiting|June 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|81|||Both|19 Years|N/A|No|||March 2015|March 4, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02543034||13622|
NCT02538016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16726|TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study|Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation|TCUPS|Children's Hospital Boston|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|12 Years|25 Years|No|||August 2015|August 31, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02538016||14005|
NCT02538094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00033581|tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis|Transcranial Direct Current Stimulation and Cognition in Adults With Multiple Sclerosis or Encephalitis||Johns Hopkins University|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02538094||13999|
NCT02540928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/15/004|AMG 319 in Human PapillomaVirus (HPV) Negative HNSCC|A Cancer Research UK (CRUK) Randomised, Double-blind, Placebo-controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)||Cancer Research UK|No|Recruiting|October 2015|||October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|March 22, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540928||13782|
NCT02544269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP/FUSION#1|Hemodynamic Effect of Lumbosacral Plexus Blockade Versus Spinal Anesthesia|Surgical Anesthesia for Elective Hip Surgery - Hemodynamic Effect of Lumbosacral Plexus Blockade Compared to Spinal Anesthesia||University of Aarhus|Yes|Not yet recruiting|April 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|December 21, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544269||13527|
NCT02530814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401073|Organochlorine Pesticide Exposure in Residents Near Lake Apopka|Organochlorine Pesticide Exposure in Residents Near Lake Apopka||University of Florida|Yes|Completed|November 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples With DNA|Blood samples will be collected for analysis of organochlorine pesticides and      auto-antibodies.|Both|21 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Participants for this study will be recruited from the Florida Farmworker Association of        Florida, Lake Apopka, FL.|March 2016|March 16, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530814||14557|
NCT02534285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dresden EK30012015|Study to Investigate the Impact of Noise on Requirements of Anesthetics During General Anesthesia|||Technische Universität Dresden|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534285||14292|
NCT02534298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 204 02|Functional Magnetic Resonance Imaging Study of the Central Auditory System After Single Sided Deafness|Reorganization of Central Auditory System After Single Sided Deafness: a Functional Magnetic Resonance Imaging Study|SSD|University Hospital, Toulouse|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02534298||14291|
NCT02533869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTICAP|The Optimization of a Low-dose Computed Tomography Protocol in Patients With Suspected Uncomplicated Acute Appendicitis|The Optimization of a Low-dose Computed Tomography Protocol in Patients With Suspected Uncomplicated Acute Appendicitis (OPTICAP)|OPTICAP|Turku University Hospital|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|60 Years|No|||August 2015|August 24, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02533869||14324|
NCT02537106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508-S23P|A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation|A Comparison of the Effect of 1.5% Versus 3% NaCl on Brain Relaxation and Microcirculation During the Supratentorial Brain Tumor Surgery, and Natremia and Ssmolarity in Postoperative Period||University Hospital Hradec Kralove|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537106||14075|
NCT02531048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701035|Normative Values Laser Nociceptive Evoked Potentials Depending on the Age|Normative Values Laser Nociceptive Evoked Potentials Depending on the Age||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2008|December 2013|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531048||14539|
NCT02534545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RICA|Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)|Remote Ischemic Conditioning for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerotic Stenosis||Capital Medical University|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|40 Years|80 Years|No|||January 2016|February 24, 2016|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534545||14272|
NCT02534753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGP-101|A Pharmacokinetics Study of Intravenous Ascorbic Acid|A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers||McGuff Pharmaceuticals, Inc.|No|Completed|September 2015|January 2016|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534753||14256|
NCT02538406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37320|The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate.|The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate. A Randomized Controlled Clinical Trial.||Baylor College of Medicine|Yes|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|80 Years|No|Probability Sample|Study participants will be recruited from patients ages 18-80 scheduled for a screening        colonoscopy at Baylor College of Medicine. Informed consent will be obtained from the        patients during their Gastroenterology clinic visit if the procedure scheduled by        gastroenterologist or during their pre-procedure assessment appointment if they were        referred by a primary care doctor. Participation in the study will be voluntary. We use        the split prep protocol in preparation for colonoscopy in all patients undergoing        colonoscopy in our unit.|September 2015|September 2, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538406||13975|
NCT02544321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1309|Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes|Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes||University of Colorado, Denver|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|133|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544321||13523|
NCT02531607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|649074|Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds|Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds Biomarkers in Bile and Serum in the Diagnosis of Malignant Biliary Strictures||Florida Hospital|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|bile and blood|Both|19 Years|95 Years|No|Probability Sample|Patients scheduled for ERCP at CIE|February 2016|February 15, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02531607||14496|
NCT02536040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Stopping Cavities Study: Diammine Silver Fluoride|Pragmatic Trial of Topical Diammine Silver Fluoride for Dental Caries Arrest||Advantage Dental Services, LLC|No|Not yet recruiting|January 2016|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|24 Months|60 Months|Accepts Healthy Volunteers|||November 2015|November 22, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536040||14157|
NCT02538315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 15-21|Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients|Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients||University of Saskatchewan|No|Not yet recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Parkinson's patients screened by Dr. I. Mendez|December 2015|December 2, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538315||13982|
NCT02529189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0555|Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina|A Randomised, Double-blind, Placebo-controlled Study Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina|NITRATE-OCT|Queen Mary University of London|Yes|Recruiting|November 2015|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|85 Years|No|||November 2015|November 6, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02529189||14682|
NCT02534662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOMINA|Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) for Gastric Reduction|A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction||Theodor Bilharz Research Institute|No|Recruiting|May 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534662||14263|
NCT02543307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P270248_151704|Effects of Nurse-led Patient Pathways|Quality and Process Improvement Using Nurse-led Patient Pathways in an Orthopedic Hospital|NPP|Zurich University of Applied Sciences|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|607|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543307||13601|
NCT02535039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shengjing hospital|Methylprednisolone Combined Electric-acupuncture on Cognitive Function|Methylprednisolone Combined Electric-acupuncture Treatment Effects on Cognitive Function After Surgery for Elderly Patients With General Anesthesia||Shengjing Hospital|Yes|Recruiting|May 2015|September 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535039||14234|
NCT02535312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00127|Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed|Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors, With Expansion Cohort in Mesothelioma / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed||National Cancer Institute (NCI)|No|Recruiting|August 2015|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535312||14213|
NCT02538549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6015291|Pilot RCT to Test Effectiveness of the ACE4 (Activity Challenge- 4 Areas) for Depression and Anxiety|A Pilot Randomized Controlled Trial to Test Effectiveness of the ACE4 (Activity Challenge - 4 Areas) for Depression and Anxiety: A Behavioural Activation Based Game.||Queen's University|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|65 Years|No|||August 2015|August 29, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02538549||13964|
NCT02538757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERVE-Pilot|Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)|Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)|VERVE|University of Alabama at Birmingham|Yes|Recruiting|October 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|125|||Both|50 Years|N/A|No|||August 2015|August 30, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538757||13948|
NCT02538770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPSHP93/2014|Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization|The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial||University of Oulu|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|900|||Both|16 Years|N/A|No|||January 2016|January 8, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538770||13947|
NCT02542319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagiCal-CKD|Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease|The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial|MagiCal-CKD|Nordsjaellands Hospital|No|Recruiting|November 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2015|November 17, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542319||13676|
NCT02535572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00042678|Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment|Focal Electrically-Administered Seizure Therapy (FEAST): Studies at Two Enrolling Sites to Further Test and Refine the Treatment|FEAST|Medical University of South Carolina|No|Recruiting|August 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||August 2015|August 27, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535572||14193|
NCT02538614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-1579|Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia|A Phase 1b/2 Study of Idelalisib in Combination With BI 836826 in Subjects With Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Recruiting|November 2015|November 2021|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538614||13959|
NCT02544308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0291|Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma|Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma|IDRIS|University College, London|Yes|Not yet recruiting|December 2015|December 2025|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02544308||13524|
NCT02535195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-03-161-27265|Effect of Ginger Supplement on Non-alcoholic Fatty Liver|||National Nutrition and Food Technology Institute||Completed|March 2013|August 2015|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535195||14222|
NCT02540057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCRAPLRCT|FCR or APL in LRTI - A Single Surgeon Randomized Controlled Trial|Flexor Carpi Radialis or Abductor Pollicis Longus in Ligament Reconstruction and Tendon Interposition - A Randomized Controlled Trial||Nova Scotia Health Authority|No|Not yet recruiting|November 2015|November 2021|Anticipated|November 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|N/A|No|||October 2015|October 19, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540057||13849|
NCT02531386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1525-BL|System Accuracy Evaluation of 6 CE-marked Blood Glucose Monitoring System Following ISO 15197:2013|System Accuracy Evaluation of Accu-Chek Aviva Nano (Roche Diagnostics), Accu-Chek Performa Nano (Roche Diagnostics), FreeStyle Lite (Abbott Diabetes Care), OneTouch Verio IQ (LifeScan), Contour Next Link 2.4 (Bayer Consumer Care), One Additional CE-marked Blood Glucose Monitoring System Following ISO 15197:2013||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|August 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|N/A|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|November 6, 2015|August 7, 2015||||No||https://clinicaltrials.gov/show/NCT02531386||14513|
NCT02538861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-062|Acute Chest Pain Imaging in the ED With the Combine CCTA and CT Perfusion|Acute Chest Pain Imaging in Emergency Department With Combined Approach of Coronary CT Angiography and CT Myocardial Perfusion||Baptist Health South Florida|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|250|||Both|35 Years|N/A|No|||November 2015|November 11, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02538861||13940|
NCT02542579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010691|Gastric Microbiota and Helicobacter Pylori Test Findings|Impact of the Composition of Gastric Microbiota on the Accuracy of Helicobacter Pylori Test||Konkuk University Medical Center|Yes|Recruiting|July 2015|April 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Microbiota on the gastric biopsied specimen|Both|20 Years|N/A|No|Non-Probability Sample|Adult population who visited our center for gastrointestinal endoscopy and H. pylori tests|January 2016|January 4, 2016|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02542579||13657|
NCT02555917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL reconstruction|Comparison of Remnant Preserving Versus Remnant Resecting Anterior Cruciate Ligament Reconstruction|Tibia and Femoral Tunnel Location Comparison of Remnant Preserving Versus Remnant Resecting Anterior Cruciate Ligament Reconstruction||The Catholic University of Korea|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|40|||Both|19 Years|N/A|No|||September 2015|September 19, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02555917||12632|
NCT02560623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004540|Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma|Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma by a Sponge on String Device||Mayo Clinic|No|Recruiting|October 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02560623||12270|
NCT02555566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/150/HP|Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study|Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy|TRANSPLANTEETs|University Hospital, Rouen|No|Recruiting|March 2014|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555566||12659|
NCT02561325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0244|Comparative Evaluation of the Effect on Blood Pressure of an Equivalent Content of Sodium in the Form of Bicarbonate of Sodium and in the Form of Sodium Chloride, on "Sensitive Sodium" Subjects|Comparative Evaluation of the Effect on Blood Pressure of an Equivalent Content of Sodium in the Form of Bicarbonate of Sodium and in the Form of Sodium Chloride, on "Sensitive Sodium" Subjects|SODIVASC|University Hospital, Clermont-Ferrand||Recruiting|September 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02561325||12216|
NCT02550444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 05847312.8.0000.0068|Intrathecal Clonidine in Cesarean Section May Lead to Worse Blood Gas Results in the Newborns|Comparison Between Intravenous and Intrathecal Clonidine in Post-cesarean Analgesia||University of Sao Paulo General Hospital|No|Completed|April 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02550444||13052|
NCT02533011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602986|Evaluation of the Heparin Binding Protein Levels in Sepsis|Heparin Binding Protein (HBP) in Sepsis for the Prediction of Disease Progression|HBP|Christiana Care Health Services|No|Recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted through the emergency department with infection.|March 2016|March 3, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02533011||14390|
NCT02538133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49RC14_0072|Study Assessing Hybrid SPECT-CT With Labeled Leukocytes for Diagnosis of Vascular Prosthesis Infections|Tomoscintigraphie Hybride Aux Leucocytes Marqués Dans le Diagnostic Des Infections de Prothèses Vasculaires.|LEUCOPRO|University Hospital, Angers|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02538133||13996|
NCT02540603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-179|Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ|Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ||Fisher and Paykel Healthcare|No|Completed|September 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02540603||13807|
NCT02544087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015DFA31130|Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction|Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|40 Years|80 Years|No|||September 2015|September 9, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544087||13541|
NCT02544100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU5|Neonatal Neurologic Intensive Care Network of China|Neonatal Neurologic Intensive Care Network of China||Children's Hospital of Fudan University|Yes|Recruiting|September 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|Samples With DNA|Blood, Urine and CSF samples|Both|N/A|28 Days|No|Non-Probability Sample|Neonatal with severe encephalopathy or suspected severe encephalopathy.|March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544100||13540|
NCT02543515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP/asp|Psychosocial and Clinical Characteristics Predicting Women's Acceptance of Office Hysteroscopy|Psychosocial and Clinical Characteristics Predicting Women's Acceptance of Office Hysteroscopy: An Observational Study||Centro Hospitalar Tondela-Viseu|No|Enrolling by invitation|March 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult women scheduled for office hysteroscopy.        Eligibility criteria and informed consent:        Written informed consent; diagnosis of uterine abnormal bleeding, sonographic evidence of        thickened endometrium, sterility workup, endometrial polyps or sub mucous myoma, foreign        body extraction or insertion (i.e. sterilization) or other condition with indication for        procedure and who meet study eligibility criteria; ability to fill in the study        questionnaires|September 2015|September 4, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02543515|1 Day|13585|
NCT02539641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50111.091.14|Bariatric Procedures and Changes in Incretins and Gastric Emptying|Bariatric Procedures and Changes in Incretins and Gastric Emptying|BIG|Rijnstate Hospital|No|Enrolling by invitation|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|32|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02539641||13880|
NCT02530931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC15.173|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease|PROSPER|University Hospital, Grenoble|No|Not yet recruiting|September 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|47|||Both|50 Years|N/A|No|||August 2015|August 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530931||14548|
NCT02544126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080145|Computer-Based Intervention in HIV-Positive Young Adults|Computer-Based Intervention in HIV-Positive Young Adults||Emory University|Yes|Suspended|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|23 Years|35 Years|No|||December 2015|December 16, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544126||13538|
NCT02540096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43659515.4.0000.5103|Effects of Mental Practice for Mobility in Post-stroke Hemiparesis|Effects of Mental Practice for Mobility in Post-stroke Hemiparesis: Randomized Controlled Trial of Efficacy.||Federal University of Juiz de Fora|No|Recruiting|November 2015|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|73 Years|No|||February 2016|February 4, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540096||13846|
NCT02528630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP UNIFESP|Progressive Strength in Hand Osteoarthritis|Effectiveness of a Progressive Resistance Strength Program on Hand Osteoarthritis: a Randomized Controlled Trial||Federal University of São Paulo||Completed|October 2013|October 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||August 2015|February 2, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528630||14725|
NCT02540824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-1407|Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer|A Phase II Clinical Trial to Investigate Efficacy and Safety of Apatinib as a Single Agent in RET-fusion Gene Positive Non-small Cell Lung Cancer Who Failed to Previous Treatment.||Tongji University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02540824||13790|
NCT02543593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-169|Efficacy of Transcranial Direct-Current Stimulation (tDCS) for Provoked Vestibulodynia : a Triple Blind Randomized Controlled Trial||PVD/tDCS|Université de Sherbrooke|No|Active, not recruiting|November 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|17 Years|45 Years|No|||March 2016|March 7, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543593||13579|
NCT02543606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP-RFH3002-01|Bioequivalence of Two Formulations of Esomeprazole|A Randomized, Two-way Crossover, Single-dose Pharmacokinetic Study to Evaluate the Bioequivalence of Esomelone for Injection/Infusion (Esomeprazole 40mg), Compared to Reference Drug (Nexium 40mg) in Healthy Adult Subjects||Yung Shin Pharm. Ind. Co., Ltd.|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2015|September 4, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02543606||13578|
NCT02541045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI/15/108/03/48|Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis|Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis||Hospital General de Mexico|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541045||13774|
NCT02536820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNIT2015|Psychoneuroimmunology Therapy in Uncontrolled Diabetic Patients: A Quasi-experimental Study||PNIT|Fundación Salutia|Yes|Not yet recruiting|September 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02536820||14097|
NCT02640833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-330|A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor|A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor||AbbVie|No|Not yet recruiting|February 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|174|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02640833||6111|
NCT02542982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFVMA/12/13-15|tDCS and Motor Training and Motor Deficit After Stroke|Effects of Anodal tDCS and Motor Training on Chronic Motor Deficit After Stroke||Military Medical Academy, Belgrade, Serbia|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|40 Years|80 Years|No|||September 2015|September 3, 2015|March 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02542982||13626|
NCT02528435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX Project|Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia|Role of Pharmacogenetic and Psychological Factors in Methotrexate Tolerance: Studies in Children With Chronic Arthritis and Children With Leukemia||University of Aarhus|Yes|Enrolling by invitation|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|150|Samples With DNA|Blood sample to SNP analysis - see project description|Both|9 Years|16 Years|No|Non-Probability Sample|see under project - and group description|April 2015|August 21, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02528435||14740|
NCT02537145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9624|PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women|Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women - Pilot Study|oPTiMuM|TNO|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|Finger-prick-blood for dried blood spots will be performed for oral glucose tolerance tests      (insuline/c-peptide response profile) and determining protein and lipid metabolism as well      as HbA1c.      Finger-prick-blood for measurement of glucose and cholesterol using do-it-yourself devices.      Saliva and fecal samples for determining gut and oral microbiota (bacteria) by DNA      sequencing of bacterial marker genes present in fecal and saliva samples.      Hair sample for determining cortisol concentrations over time.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of 40 women who are between 12 and 15 weeks pregnant at the        time of inclusion in the study. In this study, two groups will be compared: 20 obese        pregnant women (BMI ≥ 30) and 20 lean pregnant women (BMI 18,5 - 25).        All pregnant women will be from Dutch descent (Dutch nationality and culture).|January 2016|January 25, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537145||14072|
NCT02628314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00033891|Reliability of Pupil Response to Acute Pain|Reliability of Pupil Response to Acute Pain||Wake Forest School of Medicine|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Individuals with athritis in the knee or hip with moderate average daily pain score|December 2015|December 8, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02628314||7072|
NCT02530879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22455|Comparison of Voice Therapy and Antireflex Therapy in LPR|Comparison of Voice Therapy and Antireflex Therapy in the Treatment of Laryngopharyngeal Reflux-related Hoarseness: A Prospective Randomized Control Trial||Temple University|No|Not yet recruiting|August 2015|January 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530879||14552|
NCT02535598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sveal1031|Therapy Labs: To Improve Adherence in Internet Based Psychotherapy|Therapy Labs: To Improve Adherence in Internet Based Psychotherapy||Uppsala University|No|Active, not recruiting|May 2014|September 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|169|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02535598||14191|
NCT02532894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/552-31/4|Effects of E-smoke on Levels of Endothelial Progenitor Cells and Microparticles in Healthy Volunteers||ESMOKE|Karolinska Institutet|No|Completed|October 2014|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02532894||14399|
NCT02537392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC81230016|Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease|Primary Prevention of Multi-micronutrient Supplementation During Peri-conception Against Congenital Heart Disease: A Community-based Randomised Controlled Trial in China||Xi’an Jiaotong University College of Medicine|Yes|Recruiting|September 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|9374|||Female|15 Years|49 Years|No|||September 2015|September 3, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537392||14053|
NCT02537405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17018|Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects|Randomized, Non-blinded, Two-way Crossover Study to Establish the Bioequivalence Between a Rivaroxaban Tablet 10 mg and a Rivaroxaban Granule 10 mg in Japanese Healthy Adult Male Subjects||Bayer|No|Completed|February 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537405||14052|
NCT02644161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-421|Can Acupuncture Treat Post-stroke Depression?|A Multisite, Assessor-blinded, Randomized Controlled Trial of Acupuncture for Post-stroke Depression|PSD2|The University of Hong Kong|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|35 Years|80 Years|No|||December 2015|December 28, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02644161||5855|
NCT02540382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liufq_sjt|Comparison of Covered and Bare Stent in TIPS|Comparison of Covered and Bare Stent in TIPS||Beijing Shijitan Hospital|Yes|Completed|January 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02540382||13824|
NCT02540395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELLIMIN|Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation|Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation||Charite University, Berlin, Germany|Yes|Recruiting|March 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|669|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02540395||13823|
NCT02531802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 014|Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh|A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh|ETVAX/dmLT|PATH|Yes|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|13||Anticipated|500|||Both|6 Months|45 Years|Accepts Healthy Volunteers|||August 2015|October 19, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531802||14482|
NCT02531815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7841001|Dose Escalation Study of PF-06741086 In Healthy Subjects|A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects||Pfizer|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|8||Anticipated|56|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02531815||14481|
NCT02541786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaohsiungMUH|Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection|Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection||Kaohsiung Medical University|Yes|Completed|January 2015|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|177|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02541786||13717|
NCT02533817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDM/12/13-7|Fructose and Ethnic Differences Study (FED Study)|Fructose and Ethnic Differences Study|FED|King's College London|No|Completed|December 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02533817||14328|
NCT02528175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273-2011|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer - A Pilot Study||Sunnybrook Health Sciences Centre|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02528175||14760|
NCT02528188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091058|Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee|A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee||Pfizer|Yes|Recruiting|July 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|3000|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528188||14759|
NCT02528201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXA-0508-247|A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis|A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis||Pfizer|No|Completed|September 2002|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|330|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528201||14758|
NCT02528214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13691|Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma|VENTURE|Sanofi|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|12 Years|N/A|No|||March 2016|March 15, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528214||14757|
NCT02538939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0394|Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff|Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff|THIOCAL|Nantes University Hospital|No|Recruiting|December 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538939||13934|
NCT02538952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6294|Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons|Evaluating Performance, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons in Botswana During 2012-2013: The Xpert Package Rollout Evaluation Study (XPRES)|XPRES|Centers for Disease Control and Prevention|No|Active, not recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|18696|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538952||13933|
NCT02530606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNOPF0014|Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer|Transvaginal Ultrasound and Photoacoustic Imaging of the Ovaries and the Fallopian Tubes: A Clinical Feasibility Study||Stanford University|Yes|Not yet recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|80 Years|No|||August 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530606||14573|
NCT02528422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY-1-2014|The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers|The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers - A Randomized, Cross-over, Single-blind, Placebo-controlled Dose-response Study of the Acyl-ghrelin Induced Effects on GFR, Tubular Transport of Sodium and Water in Different Nephron Segments and Central and Peripheral Blood Pressure|DOAG|Regional Hospital Holstebro|Yes|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528422||14741|
NCT02533362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGCN-002|ANF-Rho in the Treatment of Chronic Neutropenia|A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho™ in Patients With Chronic Neutropenia||Prolong Pharmaceuticals|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|N/A|No|||August 2015|August 25, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533362||14363|
NCT02529007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2013/71|Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening|Endo-cuff Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening Patients: A Randomised Controlled Trial. The E-CAP Study|E-CAP|Portsmouth Hospitals NHS Trust|Yes|Recruiting|September 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|534|||Both|60 Years|75 Years|No|||July 2015|August 18, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02529007||14696|
NCT02535533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507716|SLM + Axitinib for Clear Cell RCC|A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)||University of Iowa|Yes|Recruiting|January 2016|||September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535533||14196|
NCT02538107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21386|An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant|Non-interventional, Observational Study to Investigate the Efficiency and Safety of Mircera in Patients With a Kidney Transplant||Hoffmann-La Roche||Completed|September 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|290|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with kidney transplant prescribed methoxy polyethyleneglycol-epoetin beta|October 2015|October 5, 2015|August 24, 2015||No||No|October 5, 2015|https://clinicaltrials.gov/show/NCT02538107||13998|
NCT02540486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNOVATE|Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration|A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension|INNOVATE|LMC Diabetes & Endocrinology Ltd.|No|Completed|December 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|75 Years|No|||September 2015|September 1, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02540486||13816|
NCT02538263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingCYH-TVV-58|Volume-targeted Versus Pressure-limited Noninvasive Ventilation in Patients With Acute Hypercapnic Respiratory Failure|||Beijing Chao Yang Hospital||Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538263||13986|
NCT02538276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2013|Carotid Endarterectomy and Carotid Artery Stenting in Brazil|Study of a Real-word Registry of Carotid Endarterectomy and Carotid Artery Stenting in Brazil. Analysis of Prospective Cases of the Registry of Vascular Diseases at University Hospitals of the State of São Paulo||University of Sao Paulo|Yes|Recruiting|July 2013|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients who underwent to carotid endarterectomy (CEA)or carotida artery stenting(CAS) for        treat carotid stenosis at the any of the five hospitals involved in the study.|August 2015|August 28, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02538276|1 Year|13985|
NCT02544295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBXS 2011-02|Based-virtual Reality Diagnosis for Neuropsychiatric Diseases and Sleep/Wake Disorders|Based-virtual Reality Diagnosis for Neuropsychiatric Diseases and Sleep/Wake Disorders|PHENOVIRTPSY|University of Bordeaux|No|Recruiting|January 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|590|||Both|7 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02544295||13525|
NCT02535793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9410|Characterisation of Occupational Allergy to Drosophila||DROSOALLERG|University Hospital, Montpellier|No|Recruiting|September 2014|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|68 Years|No|||November 2015|November 27, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02535793||14176|
NCT02535806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERCY01|Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults|A Pilot Study of Mitoxantrone-Based Four Drug Reinduction in Combination With Bortezomib for Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Children and Young Adults||Children's Mercy Hospital Kansas City|No|Recruiting|July 2015|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|39 Years|No|||September 2015|September 1, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535806||14175|
NCT02538211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 52510.018.15|The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses|The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses|Rota-biome|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|63|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02538211||13990|
NCT02545062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM- MOCA- 1|MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes|Early Detection of Mild Cognitive Impairment in Young Diabetes Patients Using the MoCa Test||Clalit Health Services|No|Recruiting|May 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|170|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02545062||13466|
NCT02529540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-WEAR 3|The Children's WEAR 3|The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial (Phase 3)||Sun Yat-sen University|No|Enrolling by invitation|September 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|4000|||Both|11 Years|16 Years|No|||August 2015|August 19, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02529540||14655|
NCT02529553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15383|A Study of LY3076226 in Participants With Advanced or Metastatic Cancer|A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Recruiting|September 2015|September 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529553||14654|
NCT02536053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324/13/03/02/2014/2|Outcomes in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage|Functional Outcomes and Health Related Quality of Life in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage: A Prospective Study||Helsinki University Central Hospital|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|10 Years|N/A|No|Non-Probability Sample|Lower extremity sarcoma patient who underwent limb-salvage surgery|August 2015|August 26, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02536053||14156|
NCT02540746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-312|Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth|Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth: A Pilot Randomized Trial||St. Joseph's Healthcare Hamilton|No|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|17 Years|25 Years|No|||September 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02540746||13796|
NCT02534129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProTechSure 001|Topical Use of Difinsa53™ to Prevent Radiation Dermatitis|Topical Use of a Silibin-based Cream, Difinsa53™, to Prevent Radiation Dermatitis in Patients With Breast Cancer: A Prospective Study||ProTechSure Scientific, Inc.|No|Recruiting|August 2015|July 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|26|||Female|N/A|N/A|No|||August 2015|August 26, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534129||14304|
NCT02541682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUTF-GOKAEK 2013/50|Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy|Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy||Mustafa Kemalpasa Government Hospital|No|Completed|March 2013|July 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|252|||Female|16 Years|41 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02541682||13725|
NCT02541695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54064.081.15|Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli|Characterization Of Resistance Against Live-attenuated Diarrhoeagenic E. Coli|CORAL|NIZO Food Research|Yes|Active, not recruiting|September 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541695||13724|
NCT02531906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 262314|Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation|Analysis of Analgesia Regimens During Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study||Roswell Park Cancer Institute|Yes|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531906||14474|
NCT02538471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505016222|LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer|LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer||Weill Medical College of Cornell University|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|90 Years|No|||September 2015|September 1, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538471||13970|
NCT02538484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMS# 15-2100|Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects|A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women With Estrogen Receptor Positive Breast Cancer||The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 31, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02538484||13969|
NCT02544282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZA-ANE-PECS-01|Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery|Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery: Effect on Postoperative Pain and Opioid Consumption||GZA Ziekenhuizen Campus Sint-Augustinus|No|Recruiting|April 2014|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|140|||Female|18 Years|80 Years|No|||October 2015|October 5, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02544282||13526|
NCT02529436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD2015|Overuse of Antidepressant in Patients With Alzheimer Disease|Overuse of Antidepressant in Patients With Alzheimer Disease and Associated Disorders : An Observational Study|OVADAD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|70 Years|N/A|No|Non-Probability Sample|Seniors (age 70 or older) with dementia on antidepressants.|March 2015|August 18, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02529436||14663|
NCT02543866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15587|Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms|Fecal Microbiota Transplantation as a Strategy to Eradicate Intestinal Carriage of Resistant Organisms||Seattle Children's Hospital|Yes|Not yet recruiting|December 2015|September 2022|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|7 Years|21 Years|No|||September 2015|September 4, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543866||13558|
NCT02543879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-HEM-101|Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed/Refractory Acute Leukemia or High-Risk MDS|A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients With Relapsed Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome||Forma Therapeutics, Inc.|No|Recruiting|September 2015|August 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543879||13557|
NCT02543385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/905/D|S Ketamine Use in Total Abdominal Hysterectomy|The Use of S Ketamine Versus Placebo During Target Controlled Intravenous Anaesthesia to Reduce Morphine Consumption and Side-Effects After Abdominal Hysterectomy: A Randomized Control Trial|SKET|KK Women's and Children's Hospital|No|Withdrawn|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|0|||Female|21 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015||No|Change of protocol title|No||https://clinicaltrials.gov/show/NCT02543385||13595|
NCT02541032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00044329|PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke|PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke|PREMIERS|University of South Carolina|Yes|Not yet recruiting|October 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02541032||13775|
NCT02542189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-377-2013|High Sensitivity Cardiac Troponin T in Patients With Atrial Fibrillation Admitted to an Emergency Department (ED)|High Sensitivity Cardiac Troponin T in Patients With Atrial Fibrillation Admitted to an Emergency Department (ED)||University Hospital Heidelberg|No|Completed|June 2009|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|3037|||Both|N/A|N/A|No|Probability Sample|A cohort of approximately 3,500 consecutive patients presenting to the emergency        department of the University Clinic Heidelberg between June 2009 and March 2013.|September 2015|September 2, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02542189||13686|
NCT02529761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-T 002|TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma|Transarterial Chemoembolization (TACE) With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma: a Multicenter Prospective Nonrandomized Study||Fourth Military Medical University|No|Recruiting|August 2015|October 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529761||14638|
NCT02529774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507149-6|Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer|Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Controlled Phase II/III Trial in China||Fudan University|Yes|Not yet recruiting|September 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|432|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529774||14637|
NCT02537184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/17758-6|Impact of Two Recall Intervals on Dental Caries Incidence and Other Outcomes of Preschool Children|Impact of Two Recall Intervals Associated to Oral Health Counseling on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children With High Caries Risk: Randomized Clinical Trial||University of Sao Paulo|Yes|Active, not recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|224|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||August 2015|September 2, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537184||14069|
NCT02537470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHV20200|Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes|A 12-week Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of Biphasic Remogliflozin Etabonate When Administered to Subjects With Type 2 Diabetes Mellitus|BRID|BHV Pharma|No|Recruiting|July 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537470||14047|
NCT02535845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA178414-04|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|May 2017|April 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535845||14172|
NCT02544334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500286|Oral Metagenomic Biomarkers in Rheumatoid Arthritis|Oral Metagenomic Biomarkers in Rheumatoid Arthritis||University of Florida|No|Not yet recruiting|May 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|100|Samples With DNA|Supragingival dental plaque will be pooled from different tooth surfaces using sterile      periodontal curettes. DNA samples will be subjected to deep sequencing.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Rheumatoid Arthritis (RA) adult patients who have not been treated with biologics (naïve        to biologics), RA patients responsive to first line anti-TNF therapy, RA patients who are        resistant to two or more TNF antagonists, and healthy controls from age-matched members of        the same household.|March 2016|March 16, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02544334||13522|
NCT02543476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4193R00002|SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck|SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck|SUPREME-HN|AstraZeneca|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|Samples Without DNA|Archival tumor tissues samples|Both|N/A|N/A|No|Non-Probability Sample|Patients who have progressed on or after first line platinum-based chemotherapy regimen        for recurrent/metastatic SCCHN and started second line therapy for recurrent/metastatic        SCCHN between the 1st January 2010 and the 31st December 2014. Two parallel patient        cohorts will be recruited for this study: patients with available tumor sample for        determination of PD-L1 status at first and/or second line setting (independently of actual        PD-L1 results), and patients without available tumor sample.|February 2016|February 11, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02543476||13588|
NCT02558101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0204|Lung Screen Uptake Trial|Randomised Controlled Trial to Test Novel Invitation Methods and Materials Targeted to Increase Informed Uptake of Lung Cancer Screening in Individuals at High Risk of Lung Cancer|Lung-SCREEN|University College, London|Yes|Recruiting|September 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|2000|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02558101||12464|
NCT02532218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-3037MO-005|Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia|Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia|REASCEND|Arisaph Pharmaceuticals Inc|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||August 2015|October 8, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532218||14451|
NCT02532231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0213|Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse|PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532231||14450|
NCT02559570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-62|A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)|LIN-MD-62|Forest Laboratories|Yes|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|160|||Both|6 Years|17 Years|No|||October 2015|October 30, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559570||12351|
NCT02549118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-TXM|Tenoxicam for Intrapartum Analgesia|Efficacy of Intravenous Tenoxicam as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial||Ain Shams Maternity Hospital|Yes|Not yet recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549118||13154|
NCT02548455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 616|St Jude Medical LV Lead - Quartet 1457Q IDE|A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an Investigational Device Exemption (IDE) Study||St. Jude Medical|No|Not yet recruiting|October 2015|April 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|430|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548455||13205|
NCT02556125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500402|Diaphragm Pacing After Spinal Cord Injury|Intramuscular Pacing to Enhance Voluntary Diaphragm Activation||University of Florida|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Forty adults will be recruited from an acute care hospital setting|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556125||12616|
NCT02540642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKNMC No./Ethics/App/2010/45|Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients|Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients||Smt. Kashibai Navale Medical College and General Hospital|Yes|Completed|October 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|30 Years|70 Years|No|||November 2015|November 16, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02540642||13804|
NCT02540759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-NNHPD-213421|Effect of Dose of Buglossoides Oil on EPA Accrual and on the Inflammatory Response|Study of the Effect of Dose of Buglossoides Arvensis Oil on Eicosapentaenoic Acid Accrual and on the Inflammatory Response||Réseau de Santé Vitalité Health Network|No|Completed|September 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02540759||13795|
NCT02543437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1002|Large Head X3 Study|The Effect of Large Diameter Head to Prevent Dislocation, and of 3 rd Generation Highly Crosslinked Polyethylene to Reduce Wear in Computer Assisted Total Hip Arthroplasty.||Stryker Japan K.K.|No|Active, not recruiting|July 2010|December 2016|Anticipated|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|20 Years|N/A|No|||August 2015|September 4, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543437||13591|
NCT02543528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5201|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2015|||||N/A|N/A|N/A||||||||||||||March 15, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543528||13584|
NCT02543554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409024|ED Lung Protective Ventilation to Reduce Complications|The Effect of Lung Protective Ventilation Initiated in the Emergency Department on the Incidence of Pulmonary Complications and Clinical Outcomes||Washington University School of Medicine|No|Recruiting|October 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|513|||Both|18 Years|N/A|No|Probability Sample|mechanically ventilated patients in the emergency department|December 2015|December 26, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02543554||13582|
NCT02543567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107861|A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants|A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects||Crucell Holland BV|Yes|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|525|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543567||13581|
NCT02528370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI013/02352|Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions|Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions|telEPOC|Hospital Galdakao-Usansolo|No|Completed|May 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|197|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528370||14745|
NCT02535663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YF_immune|Consumption of Dairy Yogurt Enhanced Immune Function|Consumption of Dairy Yogurt With Rhamnogalacturonan in Korean Citrus Hallabong Peel Polysaccharide Enhanced Immune Function and Attenuated Inflammatory Response||Yonsei University|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|30 Years|69 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535663||14186|
NCT02531269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-319|Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period|Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period||Bristol-Myers Squibb|No|Active, not recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The study population was selected from European HCV registries or databases in specific        health-care facilities from Austria, Denmark, Italy, Sweden, Spain, Switzerland, and        United Kingdom (UK)|February 2016|February 8, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02531269||14522|
NCT02632240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNW-1-072/N/3/0|Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions|Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions - Randomized Clinical Trial||Medical University of Silesia|No|Completed|October 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|No|||December 2015|December 16, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632240||6771|
NCT02632253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIIT-GUCH|Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease|Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease (GUCH)|HIIT-GUCH|University Hospital Inselspital, Berne|Yes|Recruiting|January 2016|June 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02632253||6770|
NCT02534064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATWIN2107|Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women|Effect of the Consumption of Yogurt Fortified in Calcium and Vitamin D on the Circulating Levels of 25OHD in Postmenopausal Women||Yoplait France SAS|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|140|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02534064||14309|
NCT02534311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29712|A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)|Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level||Hoffmann-La Roche||Recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Moderate to severe RA participants who are treated with tocilizumab|August 2015|August 27, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534311||14290|
NCT02542436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29965|Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population|An Observational Study to Investigate the Real World Effectiveness of Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in the UK||Hoffmann-La Roche||Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with metastatic colorectal cancer|December 2015|December 1, 2015|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542436||13668|
NCT02541877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU CT004|Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve|A Prospective, Multi-center,Randomized Controled Trial of Sizing-strategy of Bicuspid Aortic Valve Stenosis With Transcatheter Self-expandable Valve|START|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Not yet recruiting|September 2015|September 2023|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|159|||Both|65 Years|N/A|No|||September 2015|September 3, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02541877||13710|
NCT02541890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2279|Effects of Workplace Intervention in Occupational Rehabilitation on Return to Work|Effects of Workplace Intervention in Inpatient Occupational Rehabilitation on Return to Work for Persons With Somatic and/or Common Mental Health Problems. A Randomised Controlled Trial||Norwegian University of Science and Technology|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||March 2016|March 3, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02541890||13709|
NCT02632487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501139|Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults|Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults||University of Florida|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|60 Years|N/A|No|||December 2015|December 14, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02632487||6752|
NCT02532335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCAPUSH|Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers|Study of the Effects of Obeticholic Acid on Farnesoid X Receptor Expression in Jejunum and on Gut Microbiota in Morbidly Obese Patients and Healthy Volunteers|OCAPUSH|Sahlgrenska University Hospital, Sweden|No|Recruiting|August 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532335||14442|
NCT02541461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04-026-002|Body Composition After Laparoscopic Gastrectomy for Gastric Cancer|Evaluation of Changes in Body Composition After Laparoscopic Gastrectomy for Stomach Cancer - Comparison Between Billoth I and Roux-en-Y Anastomosis||Hanyang University Seoul Hospital|No|Recruiting|October 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|30 Years|80 Years|No|||November 2015|November 10, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541461||13742|
NCT02643277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRFARH001|Effectiveness of Automated Mobile Phone Based Text Messaging on the Improvement of Glycaemic Outcomes|A Pilot Study On The Effectiveness Of Using Automated Mobile Phone Text Messaging In Improving Glycaemic Control Among Newly Detected Type 2 Diabetic Patients||India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|Yes|Recruiting|December 2014|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|244|||Both|20 Years|60 Years|No|||December 2015|December 30, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02643277||5923|
NCT02532608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.LS.15.2|Infra-slow Oscillations During Sleep|Infra-slow Oscillations During Sleep, After Acute Sleep Deprivation and in Subjects With Restless Legs Syndrome/Periodic Leg Movements During Sleep (RLS/PLMS): an Explorative, Prospective, Monocentric, Observational Case-control and Interventional Study|SleepD-ISO|Neurocenter of Southern Switzerland|No|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532608||14421|
NCT02532621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterGraft Study|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||August 21, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532621||14420|
NCT02541526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004494b|Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia|Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia||University of Science Malaysia|No|Recruiting|May 2013|May 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|65 Years|No|||September 2015|September 1, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02541526||13737|
NCT02541539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15020059|Effects of Lactobacillus Casei on Respiratory and Gastrointestinal Diseases in Adults|Effects of Lactobacillus Casei in the Prevention of Upper Respiratory and Diarrheal Diseases Among Adults||University of Science Malaysia|Yes|Active, not recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|81 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02541539||13736|
NCT02632695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043451|Physical Activity Interventions for Leg Ulcer Patients|Physical Activity Interventions for Leg Ulcer Patients|FOOTFIT|Medical University of South Carolina|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|55 Years|N/A|No|||December 2015|December 14, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02632695||6736|
NCT02535611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAZUMS|Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome||EMISO|Mazandaran University of Medical Sciences|Yes|Not yet recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02535611||14190|
NCT02539212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|939530|Comparison of Microwave and Radiofrequency Ablation for Liver|A Randomized Controlled Trial of Microwave and Radiofrequency Ablation in the Treatment of Early-stage Hepatocellular Carcinoma Meeting Milan Criteria||Chinese PLA General Hospital|Yes|Completed|October 2008|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02539212||13913|
NCT02537080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508-S22P|The Effect of Nimodipine on the Postoperative Cognitive Dysfunction|The Effect of Nimodipine in the Preoperative Period on the Onset of Postoperative Cognitive Dysfunction in Adults||University Hospital Hradec Kralove|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|No|||November 2015|November 17, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537080||14077|
NCT02541604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29664|A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors|||Hoffmann-La Roche||Recruiting|October 2015|October 2022|Anticipated|October 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|30 Years|No|||December 2015|December 17, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541604||13731|
NCT02541617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150174|Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation|Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation|Hub&Spoke|Vanderbilt University|No|Not yet recruiting|January 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|September 1, 2015|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541617||13730|
NCT02528812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140537-HK|Rolling Massage Decreases Pain Pressure Threshold|Pain Pressure Threshold of a Muscle Tender Spot Increases Following Local and Non-local Rolling Massage||Memorial University of Newfoundland|No|Completed|April 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|5||Actual|150|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02528812||14711|
NCT02629380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rizzoli HA-MEN|Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial|Early Viscosupplementation After Partial Meniscectomy: a Double Blind, Placebo Controlled Randomized Trial|HA-MEN|Istituto Ortopedico Rizzoli|Yes|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|50 Years|No|||November 2015|February 8, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629380||6990|
NCT02528942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1856.cc|Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients|Early Phase Clinical Trial Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients||University of Colorado, Denver|Yes|Not yet recruiting|July 2016|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528942||14701|
NCT02535962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-017|Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA)|Effects of Probiotic Addition to Corticosteroid Treatment for PFAPA|PFAPA|Connecticut Children's Medical Center|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|53|||Both|1 Year|12 Years|No|||August 2015|August 28, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535962||14163|
NCT02530242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-013|Carbon Monoxide Measurement to Screen for Sickle Cell Disease|Point-of-Care End-Tidal Carbon Monoxide Measurement to Screen for Sickle Cell Disease|SCDCO|Children's Hospital & Research Center Oakland|No|Completed|July 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|1 Year|18 Years|No|||December 2015|December 7, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530242||14601|
NCT02537912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS13167|Blood Glucose and Body Fat Regulatory Effect of Peanut Skin Extract|Effects of Peanut Skin Extract on Blood Glucose Regulation and Body Fat Reduction||Chung Shan Medical University|Yes|Completed|December 2013|June 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 30, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02537912||14013|
NCT02537925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaningSPH_2014|The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma|The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma||Nanning Second People's Hospital|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||August 2015|August 28, 2015|May 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537925||14012|
NCT02532868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-002|A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)|A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.|No|Terminated|May 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532868||14401|
NCT02532881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK-93184|Evaluation of a Video-based Internet Intervention as Preparation for Inpatient Psychosomatic Rehabilitation|Evaluation of a Video-based Internet Intervention as Preparation for Inpatient Psychosomatic Rehabilitation: A Randomized Controlled Trial|Reh@:Info|Johannes Gutenberg University Mainz|No|Recruiting|August 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|788|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02532881||14400|
NCT02533128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 15/003|Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery|Biomarkers, Blood Pressure and BIS: Perioperative Risk Stratification and Management Optimization of Patients at Cardiac Risk Undergoing Major Noncardiac Surgery (The BBB Study)|BBB|Cantonal Hospital of St. Gallen|Yes|Recruiting|September 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|458|||Both|45 Years|N/A|No|||October 2015|October 21, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533128||14381|
NCT02535260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0682|Clearblue Advanced Fertility Monitor Consumer Three Cycle at Home Study|Clearblue Advanced Fertility Monitor Consumer Three Cycle at Home Study||SPD Development Company Limited|No|Withdrawn|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Urine samples collected throughout study|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|women wishing to become pregnant|August 2015|August 25, 2015|September 18, 2013||No|Study not started, no longer required|No||https://clinicaltrials.gov/show/NCT02535260||14217|
NCT02540408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2011-119|Detection and Characterization of COPD in Dairy Farmers|COPD in Dairy Farmers: Screening, Characterization and Constitution of a Cohort. The BALISTIC Study|BALISTIC|Centre Hospitalier Universitaire de Besancon|Yes|Completed|November 2011|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|400|Samples Without DNA|Serum for further analyses|Both|40 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|COPD patients will be defined according to the GOLD criteria (post-bronchodilator FEV1/FVC        ratio<70%).        Healthy subjects must have pre-bronchodilator FEV1/FVC ratio >75% and pre-bronchodilator        FEV1 >95% of predicted value.|September 2015|February 5, 2016|August 29, 2013||No||No||https://clinicaltrials.gov/show/NCT02540408||13822|
NCT02536118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micra Registry|Micra Transcatheter Pacing System Post-Approval Registry|Micra Transcatheter Pacing System Post-Approval Registry||Medtronic|No|Recruiting|July 2015|August 2023|Anticipated|August 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1440|||Both|N/A|N/A|No|Non-Probability Sample|Patients intended to be implanted with a Micra system are eligible for enrollment and all        patients must be consented prior to the Micra system implant. As such, only geographies        with regulatory approval for the Micra system are eligible to enroll patients (see        locations section).        All patients enrolled and successfully implanted with a Micra system will be followed for        a minimum of 5 years, unless a patient is exited from the registry due to an unavoidable        reason such as death, physician discretion, or patient withdrawal of consent. If a Micra        system is not successfully implanted, patients will be exited from the registry unless a        Micra System and/or implant procedure related event is identified, for which the patient        will be followed until the event is resolved or no further actions need to be taken.|August 2015|August 26, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536118|5 Years|14151|
NCT02533375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-193|Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)|A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis||AbbVie|No|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|15 Years|75 Years|No|||January 2016|January 25, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533375||14362|
NCT02533700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WXin|CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL|CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)||Shandong Provincial Hospital|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1|||Both|16 Years|70 Years|No|||October 2015|October 14, 2015|July 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02533700||14337|
NCT02542826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CUSM-15-074|Pulmonary Rehab, Dyspnea, Walk and Step Testing in COPD|Constant Rate Shuttle Walking and Stair Stepping Tests to Assess Exertional Dyspnea in COPD: Responsiveness to Pulmonary Rehabilitation and Minimal Clinically Important Difference||McGill University|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|40 Years|80 Years|No|||September 2015|September 3, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02542826||13638|
NCT02540499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15000617|Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy|Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy|INHALE|Rigshospitalet, Denmark|No|Recruiting|May 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02540499||13815|
NCT02541084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17945|Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan|Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) Treatment in Real-life Japanese Settings.||Bayer|No|Recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Information on patients will be collected from all female and male out-patients with a        diagnosis of wAMD who currently receive anti-VEGF therapy with proactive regimen at Kozawa        Eye Hospital (Mito-city, Japan). Of these, patients who are accompanied by his/her        caregiver and the caregiver (a pair of patient-caregiver) who satisfy eligibility listed        below will be recruited for the assessment of primary and secondary objectives.|March 2016|March 7, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02541084||13771|
NCT02529254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgery video coaching 15006|Video Coaching as an Efficient Teaching Method for Surgical Residents|Video Coaching as an Efficient Teaching Method for Surgical Residents A Randomized Control Trial||Maisonneuve-Rosemont Hospital|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 6, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02529254||14677|
NCT02542878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC-SHS-01.15|Effect of Myofascial Release by Foam Rolling on Back Muscles Endurance|Acute Effects of Foam Rolling Self-application on Isometric Back Extension Endurance on Basketball Players. A Pilot Study.|FR-Lumbar|Universidad Miguel Hernandez de Elche|No|Not yet recruiting|October 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02542878||13634|
NCT02542943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204762|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542943||13629|
NCT02540629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-EM-2015-3|Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City||2% Project|Seoul National University Hospital|Yes|Not yet recruiting|January 2016|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8070|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02540629||13805|
NCT02528955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREKHT|De-Intensification Radiotherapy Postoperative Head Neck|De-intensification of Postoperative Radiotherapy in Selected Patients With Head and Neck Cancer|DIREKHT|University of Erlangen-Nürnberg Medical School|No|Recruiting|October 2014|October 2021|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02528955||14700|
NCT02533882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F140821001|Lakeshore Examination of Activity and Disability Exercise Response Study|Dose-Response Effects of Transformative Exercise in Improving Health and Function in Adults With Spinal Cord Injury and Multiple Sclerosis|LEADERS|University of Alabama at Birmingham|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|240|||Both|18 Years|65 Years|No|||February 2016|February 20, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02533882||14323|
NCT02534428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34037 A|Wool Clothing for the Management of Childhood Atopic Dermatitis|The Effects of Superfine Merino Wool in the Management of Childhood Atopic Dermatitis||Murdoch Childrens Research Institute|No|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|N/A|3 Years|No|||August 2015|August 24, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02534428||14281|
NCT02542956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR91333|Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine for Pain Management|Prospective, Randomized, Controlled Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine For Pain Management After Abdominoplasty and TRAM Flap Breast Reconstruction.||Henry Ford Health System|No|Recruiting|October 2014|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542956||13628|
NCT02542969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGL-196-03|Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin|A Single Center, Open-label, Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin in Healthy Subjects||Madrigal Pharmaceuticals, Inc.|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|October 7, 2015|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542969||13627|
NCT02543047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP14-026|The Angioshield Study Feasibility II|THE ANGIOSHIELD STUDY:Feasibility Study to Demonstrate the Safety of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery||Neograft Technologies, Incorporated|Yes|Recruiting|September 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02543047||13621|
NCT02531685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0013|Phase 1 Study of dmLT ID Vaccination in Healthy Adults|A Phase 1 Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Intradermal (ID) Vaccination in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting||December 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|99|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|March 17, 2016|August 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531685||14491|
NCT02531698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971017|A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years|A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years||Pfizer|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|24 Months|10 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531698||14490|
NCT02538874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB007-005|A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body|A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986171 in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|October 2015|February 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|104|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|November 4, 2015|August 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538874||13939|
NCT02544906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTx 7|Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation||Agitation|Mansoura University|Yes|Not yet recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|120|||Both|30 Years|60 Years|No|||September 2015|September 8, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544906||13478|
NCT02529878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECGC-0001|Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer|A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer||The First Affiliated Hospital of Zhejiang Chinese Medical University|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529878||14629|
NCT02536560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL.37233.100.11, R-11.26AM|Intestinal Microbiota Composition After Antibiotic Treatment in Early Life|"Intestinal Microbiota Composition After Antibiotic Treatment in Early Life. The INCA Study"|INCA|Agentschap NL|No|Recruiting|January 2012|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|Samples With DNA|faecal samples|Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Healthy newborns born in the hospital, observed for low probability of neonatal infection        will be compared to newborns exposed to antibiotic therapy in early life (first 1-2 weeks)        by investigating potential differences in intestinal fecal microbiota composition|August 2015|August 28, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02536560||14117|
NCT02540876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0083|Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery|A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment||University of Chicago|Yes|Recruiting|September 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02540876||13786|
NCT02529449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-6001|Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus|Clinical Pharmacological Study of ASP1941 - A Clinical Pharmacological Study of ASP1941 in Subjects With Type 1 Diabetes Mellitus||Astellas Pharma Inc|No|Active, not recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|43|||Both|20 Years|74 Years|No|||March 2016|March 17, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529449||14662|
NCT02529462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-GEN-2013|Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients|Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders||AB Biotics, SA|No|Completed|July 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|521|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529462||14661|
NCT02530138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|563|The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver|||National Nutrition and Food Technology Institute||Recruiting|August 2014|||February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||August 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530138||14609|
NCT02532179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-26|Subcutaneous Immunotherapy for Mouse in Adults|A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)|SCITMO|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|August 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|55 Years|No|||March 2016|March 3, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532179||14453|
NCT02532192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1068|A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma||M.D. Anderson Cancer Center|No|Withdrawn|December 2015|||December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|August 21, 2015|No|Yes|Withdrawal of study support.|No||https://clinicaltrials.gov/show/NCT02532192||14452|
NCT02532283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107746|A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection||Janssen Research & Development, LLC|Yes|Recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||March 2016|March 15, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532283||14446|
NCT02532556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2528|Electrical Stimulation of the Muscle Pumps of the Leg|Electrical Stimulation of the Muscle Pumps of the Leg|Muscle Pump|Imperial College London|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 24, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02532556||14425|
NCT02534610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN010-13|Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty|Is There Any Analgesic Benefit From Preoperative vs. Postoperative Etoricoxib Administration in Total Knee Arthroplasty?||Foisor Orthopedics Clinical Hospital|No|Completed|January 2014|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|165|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02534610||14267|
NCT02539264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEES-OSA|Impact of Smoking, Benzodiazepine (BZD) Use and Obesity on Severe Obstructive Sleep Apnea (sOSA)|Impact of Smoking, BZD and Obesity on Severe Obstructive Sleep Apnea (sOSA)||Astes|No|Completed|January 2014|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|920|||Both|N/A|N/A|No|Non-Probability Sample|All patients registered for an overnight PSG at Clinique Saint-Luc of Bouge|January 2016|January 5, 2016|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02539264||13909|
NCT02541734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50233.091.14|Effect of Gelofusine on GLP1-receptor Imaging|Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney|GLP1-EX-GELO|Radboud University|No|Active, not recruiting|August 2015|March 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02541734||13721|
NCT02541747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG14114|Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors|Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors||Taichung Veterans General Hospital|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02541747||13720|
NCT02543229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-302-1001|Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD|A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD||Opthea Pty Ltd.|Yes|Recruiting|July 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|50|||Both|50 Years|N/A|No|||November 2015|November 25, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543229||13607|
NCT02538796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001179|The Embodied Cognition: Exploratory Study of Automatic and Controlled Processes in Anorexia Nervosa.|The Embodied Cognition: Exploratory Study of Automatic and Controlled Processes in Anorexia Nervosa. A Monocentric Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|176|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538796||13945|
NCT02530073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0874|Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO)|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|FETO|University of Colorado, Denver|Yes|Recruiting|September 2015|February 2023|Anticipated|August 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530073||14614|
NCT02532738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCINRCD|The Efficiency of MSC in Refractory Crohn's Disease|A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease||Sixth Affiliated Hospital, Sun Yat-sen University|No|Not yet recruiting|January 2016|December 2018|Anticipated|November 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02532738||14411|
NCT02552849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29808|Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada|||Hoffmann-La Roche||Recruiting|December 2012|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Idiopathic Pulmonary Fibrosis (IPF)|December 2015|December 1, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552849||12867|
NCT02553122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12-178|The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty|The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty During the Early Perioperative Period||Montefiore Medical Center|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||September 2015|September 15, 2015|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553122||12846|
NCT02557074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-API-01|TREg Activation in the Treatment of the PELADE (Alopecia Areata)|TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2|TreatPelade|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|September 2015|May 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|60 Years|No|||September 2015|September 21, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02557074||12543|
NCT02558231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065A308|The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension|The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study|TRITON|Actelion|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558231||12454|
NCT02558309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070113|Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure|Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure||University of Pittsburgh|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Subjects who are scheduled to undergo gradual, step-wise reduction of Intracranial        Pressure (ICP) will be screened.|September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558309||12448|
NCT02537769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47782-D|Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients|Randomized Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients||University of Washington|Yes|Recruiting|August 2015|March 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537769||14024|
NCT02537782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S538235_v1.2|Myocardial Work and Metabolism in CRT|Investigating Inhomogeneities of Regional Myocardial WORKload and Metabolism in a Cardiac Resynchronisation Therapy Patient Population|WORK-CRT|Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2015|||February 2018|Anticipated|N/A|Interventional|N/A|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02537782||14023|
NCT02531763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1ZIAHL006094-05|Behavioral Economics Framingham Incentive Trial (BE FIT)|Behavioral Economics Framingham Incentive Trial: A Randomized Controlled Trial|BEFIT|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Enrolling by invitation|September 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531763||14485|
NCT02531776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6-2014-042|Patient Experiences With Injection Needles|Patient Experiences With Injection Needles|NEEDLE|University of Copenhagen|No|Completed|December 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|December 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02531776||14484|
NCT02541838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00064233|Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy|High Intensity Muscle Power and Balance Perturbation Training to Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy|DPN|University of Maryland|Yes|Not yet recruiting|October 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541838||13713|
NCT02631993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIM Photochem 2|Photochemotherapy and Graft-versus-leukemia in Acute-leukemia|Photochemotherapy of Acute Graft-versus-host Disease (aGVHD) of the Skin - is Graft-versus-leukemia Preserved in Patients Transplanted for Acute Leukemia?||Karolinska University Hospital|No|Completed|October 2014|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|47|||Both|N/A|N/A|No|Non-Probability Sample|Patients with AML or ALL having received photochemotherapy for aGVHD evoked by HSCT given        at Center for Allogeneic Stem Cell transplantation (CAST) between 1985 - end of 2004.|December 2015|December 11, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02631993||6790|
NCT02632006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-009|Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma|A Clinical Study of Adoptive Cellular Immunotherapy Using Pluripotent Killer T Cells Expressing Antibodies for Programmed Death 1 (PD-1) in Treating Patients With Advanced Hepatocellular Carcinoma||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||September 2015|December 30, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02632006||6789|
NCT02533830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KasrELAini hospital|Gum Chewing And Bowel Motility in Patients Undergoing Cesarean Section. Kasr el Ainy Experience|Gum Chewing And Bowel Motility in Patients Undergoing Cesarean Section. Kasr el Ainy Experience.A Randomized Controlled Trial|RCT|Kasr El Aini Hospital|Yes|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|162|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|January 29, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533830||14327|
NCT02540694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51598.018.15|EBUS vs EUS-B for Diagnosing Sarcoidosis|Endobronchial vs. Esophageal Ultrasound for Diagnosing Sarcoidosis: A Randomized Clinical Trial; - A Standard vs. - ProCore Needle Comparison -||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|May 2015|June 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|350|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02540694||13800|
NCT02536235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF15-20|Applied Topical Heat as an Adjunct for Pain Control in First-Trimester Surgical Abortionl|Applied Topical Heat as an Adjunct for Pain Control in First-Trimester Surgical Abortion: A Randomized Controlled Trial|HAPPE|Planned Parenthood of New York City, Inc.|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|16 Years|51 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02536235||14142|
NCT02538328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/105|Comparison of Harmonic Scalpel and Ligasure Devices in Laparoscopic Morbid Obesity Surgery|Comparison of Harmonic Scalpel and Ligasure Devices in Laparoscopic Morbid Obesity Surgery||Inonu University|Yes|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|90|||Both|18 Years|60 Years|No|||August 2015|September 1, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02538328||13981|
NCT02538341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERVE-UM1|Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)|Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)||University of Alabama at Birmingham|Yes|Not yet recruiting|September 2015|||September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|50 Years|N/A|No|||August 2015|August 30, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538341||13980|
NCT02538354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2014/291|The Effect of Riboflavin in Crohn's Disease|The Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's Disease|RISE-UP|University Medical Center Groningen|No|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|84|||Both|18 Years|65 Years|No|||August 2015|August 30, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02538354||13979|
NCT02536183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU Thermodox|A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors|A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults||Children's Research Institute|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|N/A|30 Years|No|||August 2015|August 27, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536183||14146|
NCT02531867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-HPP-409|Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan|A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Hypophosphatasia (HPP) in Japan||Alexion Pharmaceuticals|No|Active, not recruiting|July 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|N/A|N/A|No|||August 2015|August 24, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02531867||14477|
NCT02536508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT010008|Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease||Pearl Therapeutics, Inc.|Yes|Recruiting|August 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Both|40 Years|80 Years|No|||January 2016|January 6, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536508||14121|
NCT02640027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|The Use of Telemedicine Tool in Supracondylar Humerus Fractures in Children|Telemedicine in Supracondylar Humerus Fractures|T-SCHF|University of California, Los Angeles|No|Not yet recruiting|February 2016|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|10 Years|No|||December 2015|December 21, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02640027||6173|
NCT02535052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-216|Investigating the Immune System in chrONIC Kidney Disease.|Investigating the Immune System in chrONIC Kidney Disease - the SONIC Study.|SONIC|University of Birmingham|No|Recruiting|July 2015|||August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Serum, Plasma, Peripheral Blood Mononuclear Cells, Urine|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|CKD patients - individuals attending local tertiary care nephrology clinics.        Healthy control subjects - individuals accompanying CKD patients to nephrology clinics or        individuals invited to participate from Birmingham 1000 Elders Cohort.|July 2015|August 27, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535052||14233|
NCT02536443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMMIT015|Contemporary Modalities in Treatment of Heart Failure|Contemporary Modalities in Treatment of Heart Failure|COMMIT-HF|Silesian Centre for Heart Diseases|No|Recruiting|January 2009|||December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is formed by all-comer patients hospitalized in cardiology wards and        intensive cardiac care units with a diagnosis of systolic heart failure. For the purpose        of this study heart failure is defined as a set of symptoms resulting from myocardial        systolic function impairment, confirmed in resting transthoracic echocardiography with        left ventricular ejection fraction (LVEF) ≤35%.|August 2015|August 27, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02536443|1 Year|14126|
NCT02528292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB-007275|Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis|Phase 4 Study of Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Patients With Rheumatoid Arthritis Undergoing Treatment With Anti-TNF Therapy||Barts & The London NHS Trust|No|Active, not recruiting|October 2010|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|Samples With DNA|Synovial tissue and blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients within Rheumatology secondary care services with active Rheumatoid Arthritis will        be recruited|August 2011|August 18, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT02528292||14751|
NCT02530658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G4K|Next Generation Sequencing of Tumor and Normal Tissues Prospectively in Pediatric Oncology Patients at St. Jude Children's Research Hospital|Genomes for Kids (G4K)||St. Jude Children's Research Hospital|No|Recruiting|August 2015|October 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Except for patients with retinoblastoma, craniopharyngioma, pontine glioma and optic pathway      tumors, tumor and normal tissue will be analyzed. For patients with retinoblastoma,      craniopharyngioma, pontine glioma and optic pathway tumors, only blood samples will be      collected and studied. Leukemia patients and patients with solid tumors and evidence of bone      marrow infiltration may undergo a skin biopsy procedure to obtain the germline specimen.|Both|N/A|N/A|No|Non-Probability Sample|Participants will be patients at St. Jude Children's Research Hospital (SJCRH) with        diagnoses of hematological, solid or central nervous system tumors who agree to        participate in this study and their parents or legally authorized representatives who        consent to participate.|March 2016|March 21, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530658||14569|
NCT02535338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01411|Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer||National Cancer Institute (NCI)|No|Recruiting|January 2016|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||September 2015|March 21, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535338||14211|
NCT02536716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0448|The Effect of Platform-Matching Versus Platform-Switching Dental Implants on Peri-implant Hard and Soft Tissue Healing|The Effect of Platform-Matching Versus Platform-Switching Using Standard Internal Versus Tapered Internal Plus Dental Implants on Peri-implant Hard and Soft Tissue Healing||University of Louisville|Yes|Not yet recruiting|August 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536716||14105|
NCT02536729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAVAD2015|Evaluation of the Quality of Life of Patients Requiring Intestinal Cleansing Using Oral Medications to Imaging Procedure by Patient Reported Outcome|||Fundación Salutia|No|Not yet recruiting|September 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|600|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults who are in diagnostic centers, which have order for an imaging procedure that        requires intestinal cleansing conducted.|August 2015|August 31, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536729||14104|
NCT02528526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXY1A_2014-0374|Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm|A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia|OXY1A|University of Zurich|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02528526||14733|
NCT02641340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS002-15-050|Fentanyl Sublingual Spray in Opioid Naive Participants|A Phase 1, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fentanyl Sublingual Spray in Opioid Naive Subjects||INSYS Therapeutics Inc|Yes|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|12||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641340||6072|
NCT02539225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15461|A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||Eli Lilly and Company|No|Recruiting|October 2015|February 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539225||13912|
NCT02543840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-289|Hybrid Collaborative Care Randomized Program Evaluation|Hybrid Controlled Trial to Implement Collaborative Care in General Mental Health|BHIP-CCM|VA Boston Healthcare System|No|Not yet recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|675|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543840||13560|
NCT02543541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Y15|A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials|A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials||Case Comprehensive Cancer Center|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543541||13583|
NCT02533206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150487-01H|Pilot Study of The EPIC Trial|Endoscopic Polypectomy Performed In Clinic (EPIC) for Chronic Rhinosinusitis With Polyps: Pilot Study of The EPIC Randomised Controlled Trial||Ottawa Hospital Research Institute|Yes|Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02533206||14375|
NCT02537418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I226|Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens|A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens||Canadian Cancer Trials Group|Yes|Recruiting|August 2015|February 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|March 22, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537418||14051|
NCT02536313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-367-1871|Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen|A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen||Gilead Sciences|No|Active, not recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536313||14136|
NCT02536612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA14-68|Empower, Nudge: Increasing Dual Protection in South Africa|Empower, Nudge: Increasing Dual Protection Among Young Women in South Africa|EN|Brown University|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02536612||14113|
NCT02533115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0314-401|EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML|Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for Patients 60-75 Years of Age With Secondary AML|401|Celator Pharmaceuticals||Available||||||N/A|Expanded Access|N/A|||||||Both|60 Years|75 Years||||March 2016|March 15, 2016|August 24, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02533115||14382|
NCT02533336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL Project in Tanzania|The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania|The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania: Cluster Randomized Trial|DL|National Institute for Medical Research, Tanzania|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4840|||Both|6 Months|11 Years|No|||August 2015|August 25, 2015|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02533336||14365|
NCT02545049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17530|Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.|FIGARO-DKD|Bayer|Yes|Recruiting|September 2015|February 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6400|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545049||13467|
NCT02528500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA 13-02|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels|Early Feasibility Assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels|TAMBE|W.L.Gore & Associates|Yes|Not yet recruiting|September 2015|March 2021|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02528500||14735|
NCT02535000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery|Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery||Serviço de Anestesiologia de Joinville|Yes|Active, not recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02535000||14237|
NCT02530866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5446|Randomized Controlled Clinical Pilot Trial of Intensive Management for Gestational Diabetes|Randomized Controlled Clinical Pilot Trial of Intensive Management for Gestational Diabetes|GDM-MOMS|University of Oklahoma|No|Recruiting|June 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||August 2015|August 19, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02530866||14553|
NCT02537652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184563|Central and Peripheral Blood Pressure in Stroke|Effect of Posture and Fasting State on Central and Peripheral Blood Pressure in Patients With Stroke||Hampshire Hospitals NHS Foundation Trust|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|75|||Both|N/A|N/A|No|Probability Sample|Patients diagnosed with a major stroke, minor stroke or TIA by a stroke consultant at a        local hospital will be eligible to participate.|September 2015|September 1, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537652||14033|
NCT02537665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19990807|Heating Precondition of Epidural Catheter Decrease the Incidence of Injury to Blood Vessel During Epidural Catheter Placement|||Fudan University||Recruiting|June 2015|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|20 Years|40 Years|No|||August 2015|August 31, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537665||14032|
NCT02541383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM 2015-01|A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma|Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma|Cassiopeia|Intergroupe Francophone du Myelome|Yes|Not yet recruiting|September 2015|August 2024|Anticipated|August 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1080|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02541383||13748|
NCT02541396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET009|A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy|A Pilot Study Of The Efficacy Of WafermineTM Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy||iX Biopharma Ltd.|Yes|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|72|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02541396||13747|
NCT02542774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15_108R|Sex Differences in the Risk of Cardiovascular Diseases Associated With Diabetes|Sex Differences in the Risk of Cardiovascular Diseases Associated With Diabetes: an Examination of Variation in Health Service Delivery||University College, London|Yes|Active, not recruiting|August 2015|November 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the CALIBER database who have diabetes, are included in the Clinical Practice        Research Datalink (CPRD) and consented to data linkage.|September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542774||13642|
NCT02543346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEU-BRC-001|Comparability and Standardization of Controlled Allergen Challenge Facilities|Comparability and Standardization of Controlled Allergen Challenge Facilities||Queen's University|No|Active, not recruiting|October 2015|May 2016|Anticipated|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|98|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543346||13598|
NCT02538289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital without dyspnea|Hospital Without Dyspnea. Rationale and Design of a Multidisciplinary Intervention|Hospital Without Dyspnea. Rationale and Design of a Multidisciplinary Intervention||Hospital General Universitario Gregorio Marañon|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538289||13984|
NCT02538432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15XXGCC|Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors|15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS||University of Maryland|Yes|Not yet recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538432||13973|
NCT02539134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-935-1002|TAK-935 Multiple Rising Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects||Takeda|No|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|7||Anticipated|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539134||13919|
NCT02543775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1003-CE|Sentinel Lymph Node Detection in Early Cervical Cancer|Sentinel Lymph Node Detection in Early Cervical Cancer||University Health Network, Toronto|Yes|Recruiting|July 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Female|18 Years|80 Years|No|||September 2015|September 4, 2015|June 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543775||13565|
NCT02543788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.850|CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS|CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?||Hospices Civils de Lyon|No|Recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|June 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02543788||13564|
NCT02528695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44098.091.13|Adipose Tissue Imaging in Type 2 Diabetes|Adipose Tissue Imaging in Patients With Type 2 Diabetes, Pilot Study|ATI-DM2|Radboud University|No|Recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528695||14720|
NCT02534194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15020|Gestational Age Assessment Tool|Gestational Age Assessment Tool for Newborn Babies|GestATion|University of Nottingham|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Newborn babies within 7 days of birth recruited from Nottingham University Hospitals NHS        Trust.|February 2016|February 25, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02534194||14299|
NCT02543918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16202|A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants|Vaccination Response Following Administration of Ixekizumab to Healthy Subjects||Eli Lilly and Company|No|Completed|September 2015|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543918||13554|
NCT02531399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-250315|Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects|Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects||Medical University of Vienna||Recruiting|October 2015|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531399||14512|
NCT02533895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUVAC1|Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood|Monocyte-derived Dendritic Cells Loaded With Tumour Cell Lysates for the Treatment of Refractory Solid Tumours of Childhood||Activartis Biotech|No|Completed|February 2000|October 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|N/A|N/A|No|||December 2015|December 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02533895||14322|
NCT02539524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102838/2014|Effects of Yoga on Clinical Impact and Psychosocial Aspects of COPD|Effects of Yoga Respiratory Exercises on Clinical Impact, and Psychosocial Aspects in Patients With Chronic Obstructive Pulmonary Disease||University of Sao Paulo|No|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|50 Years|90 Years|No|||August 2015|September 2, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539524||13889|
NCT02539537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 29 (UCGI 26)|A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma|A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma|NEOPAN|UNICANCER|Yes|Recruiting|March 2015|March 2020|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02539537||13888|
NCT02541578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0721|Physiological Complexity of Gait Over the First Six Months Post Stroke|Physiological Complexity of Gait Over the First Six Months Post Stroke||University of Indianapolis|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|21 Years|80 Years|No|Non-Probability Sample|A total of 60 adults with acute stroke will be enrolled in this prospective, longitudinal        cohort study.|September 2015|September 9, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541578||13733|
NCT02543957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37346|Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy|A Prospective Study of the Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy||Baylor College of Medicine|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|80 Years|No|Probability Sample|Study participants ages 18-80 will be recruited from patients undergoing an ERCP at the        Baylor St Luke Medical center in Houston or at University of Texas Health Science Center        at San Antonio. Both practices are university based practice and serve as a tertiary        referral center for all complicated EUS and ERCP procedures in eastern Texas.        Choledocholithiasis and its complications requiring ERCP are prevalent and represent a        large share of this ERCP practice.|September 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543957||13551|
NCT02537236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|omega-3-HIV/2009|Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.|Efficacy and Safety of Fish Oil (Omega-3 Fatty Acid) Supplementation With Therapeutic Lifestyle Changes Diet Associated With Lipidic Profile in HIV-positive Patients With Antiretroviral Therapy.||Instituto Mexicano del Seguro Social|Yes|Completed|January 2009|December 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|200|||Both|18 Years|60 Years|No|||August 2015|September 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537236||14065|
NCT02539901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 227 02|Development of a Deaf Child With a Cochlear Implant.|Cognitive and Communicative Development Description of Deaf Child With a Cochlear Implant.|DECCODES|University Hospital, Toulouse|No|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|73|||Both|12 Months|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young patients consulting in the Unit of Pediatric Cochlear Implantation,        Hospital-University Centre of Toulouse.        The normal hearing participants will be recruited by posters, produced in various places        childcare (crèches, schools) or pediatric services Purpan hospital.|August 2015|August 31, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02539901||13861|
NCT02544919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOF_NEURO_1|Lipids and Neurological Complications in Liver Transplantation|Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial>|LNCLT|Mansoura University|No|Recruiting|September 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|60 Years|No|||September 2015|September 12, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544919||13477|
NCT02543060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015062|A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular Dentifrice|A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity When Comparing Two-step Toothpaste to a Regular Dentifrice||Procter and Gamble||Completed|June 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543060||13620|
NCT02543996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150190|Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)|Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|June 2030|Anticipated|June 2030|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|9999|||Both|N/A|100 Years|Accepts Healthy Volunteers|||August 2015|January 6, 2016|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02543996||13548|
NCT02531971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063835|Fentanyl Patch Pharmacokinetics in Healthy Adults|Absolute Bioavailability/ Pharmacokinetic and Residual Drug Analysis of Duragesic ® Transdermal System and Generic Fentanyl Transdermal System in Healthy Adults||University of Maryland|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531971||14469|
NCT02534376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040945|Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal|Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth||Cedars-Sinai Medical Center|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|18 Years|N/A|No|||December 2015|December 5, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534376||14285|
NCT02534896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_15_05|To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis|A Phase III, Randomized, Double-Blind, Double Dummy, Active Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis||Sun Pharma Global FZE|No|Not yet recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|90 Years|No|||August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534896||14245|
NCT02543164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KME68/02/15|Influence of Beta-glucan Enriched Barley Flour in Bread on Glycemic Response|Comparison of the Glycemic Response of Consumption of Bread Enriched With Barley Beta-glucans With White Bread. Controlled Intervention Trial. A Pilot Study||Nutrition Institute, Slovenia|No|Active, not recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02543164||13612|
NCT02537886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015262|Development of Patient Centered Virtual Multimedia Interactive Informed Consent Tool to Improve Patient Comprehension and Consent|Development of Patient Centered Virtual Multimedia Interactive Informed Consent Tool to Improve Patient Comprehension and Consent||Yale University|No|Not yet recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|6|||Both|21 Years|N/A|No|Non-Probability Sample|The target population for this study includes patients from the Yale Center for Asthma and        Airway Disease (YCAAD) clinic. Participants for the VIC study will be recruited from the        large and diverse asthma population that the YCAAD GenEx 2.0 trial accesses for        enrollment.|August 2015|August 28, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02537886||14015|
NCT02539420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-245|A Prospective Trial of BiPAP Administration vs. Non-positive Pressure Therapy for Pediatric Status Asthmaticus|A Prospective, Randomized Trial of Early Versus Delayed BiPAP Administration or Non-positive Pressure Therapy in the Management of Pediatric Status Asthmaticus||Northwell Health|Yes|Not yet recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|147|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539420||13897|
NCT02530515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0830|Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)|Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|Yes|Recruiting|December 2015|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 21, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530515||14580|
NCT02530528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-042|Pilot Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|27|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530528||14579|
NCT02530541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14-015|Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|April 2014|May 2015|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530541||14578|
NCT02542202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1542|Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer|A Pilot Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Renal Cell Carcinoma||University of Chicago|No|Recruiting|May 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542202||13685|
NCT02534831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIN2012-1|Manual Therapy in Chronic Obstructive Pulmonary Disease|The Effect of Soft Tissue Manual Therapy Intervention on Lung Function in Severe Chronic Obstructive Pulmonary Disease: a Proof of Concept Study||University of Chile|Yes|Completed|March 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|50 Years|85 Years|No|||August 2015|August 26, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02534831||14250|
NCT02541240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RARMUoHP063015|Effects of an Intervention to Enhance Resilience in Physical Therapy Students|Effects of an Intervention to Enhance Resilience in Physical Therapy Students||University of Indianapolis|No|Enrolling by invitation|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541240||13759|
NCT02546999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1195|Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?|Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?|BoNT-A-CP|St. Olavs Hospital|Yes|Recruiting|September 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|4 Years|17 Years|No|||December 2015|December 7, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546999||13317|
NCT02547012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS13-CT11-15|Comparison of Two Rescue Therapies for Helicobacter Pylori Infection|Comparison of Two Rescue Therapies for Helicobacter Pylori Infection — A Multicenter Randomized Controlled Trial||Kaohsiung Veterans General Hospital.|Yes|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|90 Years|No|||September 2015|September 9, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02547012||13316|
NCT02536274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-164|"Examination of the Impact of a Dynamic Flexion Orthosis (Dynaflex®Ottobock) or of a Back Bandage (Lumbo Sensa®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Back Pain"|"Examination of the Impact of a Dynamic Flexion Orthosis (Dynaflex®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Low Back Pain" and "Examination of the Impact of a Back Bandage (Lumbo Sensa®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Low Back Pain"||RWTH Aachen University|No|Not yet recruiting|September 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02536274||14139|
NCT02536287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahykdxdefsyy12|Comparison of Total Parathyroidectomy With and Without Autotransplantation|Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial||The Second Hospital of Anhui Medical University|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02536287||14138|
NCT02536300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-313-1580|Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma|Dose Optimization Study of Idelalisib in Follicular Lymphoma or Small Lymphocytic Lymphoma||Gilead Sciences|Yes|Recruiting|October 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536300||14137|
NCT02536573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI 2015-0101|Study of Total Hip Arthroplasty Using Radlink Surgical Positioning Software|Prospective, Randomized Study to Evaluate Total Hip Arthroplasty With and Without Radlink Surgical Positioning Software||Anderson Orthopaedic Research Institute|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536573||14116|
NCT02556554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1006|Pilot Prospective CGM Quality Improvement (QI) Project|A Single-center, Prospective, 'Open-label,' Investigator-initiated Pilot Study Evaluating the Role of Continuous Glucose Monitor (CGM) Use Either Alone or With Remote Monitoring Capabilities||University of Colorado, Denver|No|Recruiting|September 2015|February 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02556554||12583|
NCT02549222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00112|A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components|A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components|PIPER|Cerus Corporation|No|Enrolling by invitation|December 2015|||September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|2932|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hematology-oncology disorders, including those undergoing hematopoietic stem        cell transplant (HSCT), expected to require one or more PC transfusions will be included        in the study.|November 2015|December 9, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549222||13146|
NCT02547259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108067|Influence of Emotion in a Test Run Forgetfulness|Influence of Negative or Painful Emotions in a Directed Forgetting Paradigm in Healthy Subjects and Patients With Schizophrenia||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547259||13297|
NCT02529722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2907|Biomarkers for the Progression of IgA Nephropathy|Histological and Clinical Biomarkers to Predict the Progression of IgA Nephropathy||Istanbul University|No|Completed|January 2012|April 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|120|||Both|16 Years|75 Years|No|Probability Sample|Patients with the diagnosis of biopsy confirmed IgA nephropathy|August 2015|August 19, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02529722|36 Months|14641|
NCT02535676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31063714.1.1001.0068|Schizophrenia TreAtment With electRic Transcranial Stimulation|Treatment of Negative Symptoms of Schizophrenia With Transcranial Direct Current Stimulation (tDCS): A Randomized, Double-blinded, Sham-controlled, Clinical Trial|STARTS|University of Sao Paulo|No|Recruiting|November 2014|||December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|No|||August 2015|August 28, 2015|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535676||14185|
NCT02642705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01482-45|High Intensity Interval Training and Hypoxic Conditioning in Obese Patients|New Treatment Modalities in Obese Patients: High Intensity Interval Training and Hypoxic Conditioning|HYPINT|University Hospital, Grenoble|No|Recruiting|September 2015|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 24, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642705||5967|
NCT02538224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|azadtehran|Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment|Randomized, Double Blind, Placebo Controlled Clinical Trial of Compare With Doxycycline Plus Ketoprofen Gel in Chronic Periodontitis||Islamic Azad University, Tehran|Yes|Completed|July 2013|June 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538224||13989|
NCT02542384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845-CLIN3001|A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of Intravenous CR845 in Patients Undergoing Abdominal Surgery||Cara Therapeutics, Inc.|Yes|Active, not recruiting|September 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|600|||Both|21 Years|N/A|No|||February 2016|February 25, 2016|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542384||13672|
NCT02639754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00024824|Community Intervention for HIV Testing & Care Linkage Among Young MSM in Bulgaria|Community Intervention for HIV Testing & Care Linkage Among Young MSM in Bulgaria||Medical College of Wisconsin|No|Enrolling by invitation|December 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|320|||Male|16 Years|20 Years|No|||February 2016|February 25, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639754||6194|
NCT02639767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-304|Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma|A Phase I Study of Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02639767||6193|
NCT02639780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1043/2015|Biochemical Alterations of Stored Erythrocyte Membranes|Biochemical Alterations of Stored Erythrocyte Membranes||Medical University of Vienna|No|Recruiting|December 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|36|Samples Without DNA|packed red blood cells|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|volunteers who will donate one unit of packed red blood cells|December 2015|December 23, 2015|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02639780||6192|
NCT02540889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0452|Listen in: Developing and Testing a Therapy Application for Patients With Speech Comprehension Deficits After Stroke.|Listen-In: the Development and Testing of a Web-based Therapy Application for Patients With Impaired Speech Comprehension Caused by Stroke|Listen-in|University College, London|Yes|Not yet recruiting|October 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02540889||13785|
NCT02540837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol2_2tdn|Obturator and Femoral Nerve Block in Patients With Hip Fracture|Analgesic Effect of an Obturator Nerve Block Combined With a Femoral Nerve Block Compared With Femoral Nerve Block Alone in Patients With Hip Fracture||University of Aarhus|Yes|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|55 Years|N/A|No|||August 2015|November 3, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02540837||13789|
NCT02536521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1507-039-686|Predictive Variables of the Hemodynamic Effect During the Laparoscopic Surgery in Children|Study on the Predictive Variables Able to Predict the Hemodynamic Effect of Intra-abdominal Pressure in the Children Undergoing Laparoscopic Surgery|Lapa-BP|Seoul National University Hospital|Yes|Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|||Both|N/A|7 Years|No|Non-Probability Sample|Pediatric patients undergoing laparoscopic surgery|August 2015|August 31, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536521||14120|
NCT02642900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DML01|Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers|Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers: a Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|July 2009|July 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||December 2015|December 25, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02642900||5952|
NCT02538822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408061|Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging|Assessment of the Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging - A Monocentric Study||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538822||13943|
NCT02540967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17512|Drug Use Investigation of Gadovist.|Drug Use Investigation of Gadovist||Bayer|No|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3300|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients who planned Gd contrast enhanced MRI in accordance with approved        label. Eligible patients who receive Gadovist will be enrolled and documented in the eCRF|March 2016|March 23, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02540967||13779|
NCT02541110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obgyn. .|Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler|Second Trimester Maternal Serum Homocysteine Level & Uterine Artery Doppler for Prediction of Preeclampsia , Intra-Uterine Growth Retardation (IUGR) & Other Obstetric Complications||Kasr El Aini Hospital|No|Not yet recruiting|September 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Spontaneous pregnancies with no risk factors|August 2015|September 3, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541110||13769|
NCT02532712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-18-101|Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Male Volunteers||Enzychem Lifesciences Corporation|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|64|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532712||14413|
NCT02536833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM04690-OA-02|A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects||Samumed LLC|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|445|||Both|40 Years|80 Years|No|||January 2016|January 12, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536833||14096|
NCT02635555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107445|The Effects of Height and Weight Adjusted Dose of Local Anesthetic.|The Effects of Height and Weight Adjusted Dose of Local Anesthetic Compared to Standard Dose for Spinal Anesthesia in Elective Cesarean Section||Lawson Health Research Institute|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02635555||6517|
NCT02635581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-01|A DEXA Clinical Study to Evaluate the Osteointegrative Potential of Trabecular Titanium™|||Limacorporate S.p.a|No|Completed|December 2008|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02635581||6515|
NCT02635594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS884/15|Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery|Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery From Physical Exertion in Healthy People - a Randomized, Double-blind, Placebo-controlled, Two-way Cross-over Study||Lonza Ltd.|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|36|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02635594||6514|
NCT02535351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 75/15|Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery|Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery|TARIBO|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Not yet recruiting|October 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|75 Years|No|||August 2015|August 27, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02535351||14210|
NCT02539030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03CAR|Comparison of Efficacy and Safety of Microfracture and Modified Microfracture|Random Clinical Trial for Comparison of Efficacy and Safety of Simple Microfracture and Modified Microfracture Using Collagen in the Patients With Knee Cartilage Defects||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|February 2013|June 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539030||13927|
NCT02541123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-12|Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma|A Prospective Evaluation of Uch-l1 and Gfap Biomarker Kinetics After Mild Brain Injury Trauma|VIGILANT|Banyan Biomarkers, Inc|No|Recruiting|January 2016|||November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects eligible for study participation will be over the age of 18 with a standard of        care head CT that has been confirmed to be CT-positive for acute intracranial lesions        based on the local neuroradiologist's review and can undergo blood draw within 6 hours of        head injury. Subjects who will be permitted into the study include those who will meet all        the inclusion criteria and will have none of the exclusion criteria.|January 2016|January 26, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541123||13768|
NCT02543502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP nº 4742. 12|Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction|Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction: Randomized Controlled Trial|TPAMI|Instituto de Cardiologia do Rio Grande do Sul|No|Completed|August 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|54|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02543502||13586|
NCT02532959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study:177|Diagnostic Breath Analysis Study to Detect Sepsis|Pilot Study to Evaluate Diagnostic Breath Analysis for Early Detection of Systemic Inflammatory Response Syndrome (SIRS) and Sepsis||Landon Pediatric Foundation|No|Recruiting|June 2015|September 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Exhaled breath saved for re-test in thirty days|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients enter through Emergency Room, are identified at risk for SIRS|July 2015|August 25, 2015|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532959||14394|
NCT02644122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140904|SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes|A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes||University of California, San Diego|Yes|Not yet recruiting|April 2016|April 2021|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644122||5858|
NCT02543853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990902|The Effect of Two Different Endoscopic Entry Techniques on Postoperative Gastrointestinal Function|The Effect of Two Different Endoscopic Entry Techniques on Postoperative Gastrointestinal Function||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Recruiting|March 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Female|N/A|N/A|No|||September 2015|September 4, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02543853||13559|
NCT02529501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAG|Spinal Versus General Anesthesia for Ambulatory Anesthesia|Factors Influencing the Choice of Anesthesia (Spinal Anesthesia or Short General Anesthesia) in Outpatient Surgery|BAG|Nordic Pharma SAS|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for surgery under spinal anesthesia or short general anesthesia will be        informed about the study and will be asked to participate.|March 2016|March 22, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02529501||14658|
NCT02537431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX023-CL304|Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)|An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)||Ultragenyx Pharmaceutical Inc|Yes|Recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|65 Years|No|||February 2016|February 26, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537431||14050|
NCT02539355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI2P30CA015704|Diet and Metabolic Inflammation|Diet and Metabolic Inflammation||Fred Hutchinson Cancer Research Center|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539355||13902|
NCT02539628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-PJ-14|Adductor Canal Block With Continuous Infusion Versus Intermittent Boluses and Morphine Consumption|Adductor Canal Block With Continuous Infusion Versus Intermittent Boluses and Morphine Consumption: A Randomized, Triple-masked, Controlled Study||Rigshospitalet, Denmark|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02539628||13881|
NCT02537288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-012|A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval|A Phase I Single Centre, Randomized, Double Blind (Except For Moxifloxacin), Placebo And Active Controlled, Four Way Cross Over Study Investigating The Effect Of Single Therapeutic And Supra Therapeutic Doses Of Fedovapagon On The QT/QTC Interval In Healthy Volunteers Using Oral Moxifloxacin To Confirm Assay Sensitivity||Vantia Ltd|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537288||14061|
NCT02533180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN056ST|Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation|Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults (ITN056ST)|OPTIMAL|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2015|October 2021|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533180||14377|
NCT02542332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung Cancer screening|Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?|Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?||Otto Wagner Hospital|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|556|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 4, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02542332||13675|
NCT02542345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00372-39|Comparative Assessment of Coronary MR Angiography Vs Coronary Multislice CT After Coronary Artery Reimplantation in Children and Young Adults.|Comparative Assessment of Coronary MR Angiography Vs Coronary Multislice CT After Coronary Artery Reimplantation in Children and Young Adults.|IRCADO|Centre Chirurgical Marie Lannelongue|Yes|Recruiting|May 2011|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Both|5 Years|30 Years|No|||September 2015|September 4, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542345||13674|
NCT02535858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094.0.237.000-07|Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals|Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals||University of Mogi das Cruzes|Yes|Completed|November 2007|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Male|20 Years|50 Years|No|||August 2015|August 26, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02535858||14171|
NCT02529202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15647|Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia|Dexmedetomidine Use During Therapeutic Hypothermia Treatment for Neonates With Hypoxic-ischemic Encephalopathy: The Cool DEX Study||Seattle Children's Hospital|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|1 Day|No|||August 2015|August 18, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02529202||14681|
NCT02528786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Namilumab-1003|Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study.|A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study||Takeda|No|Not yet recruiting|October 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02528786||14713|
NCT02528799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nexvax2-1004|Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet||ImmusanT, Inc.|Yes|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528799||14712|
NCT02531984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-26|The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis|Open Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study )|AZI-STOP|Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|3 Years|17 Years|No|||August 2015|August 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02531984||14468|
NCT02541448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT DD030316|Pneumoperitoneum Management With SurgiQuest AirSeal at Low vs. Higher Pressure ( PRESSURE )|A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.|PRESSURE|SurgiQuest, Inc.|No|Recruiting|July 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541448||13743|
NCT02633917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI 10/374|Motor Control Exercises vs Standard Exercises in Unspecific Low Back Pain|Motor Control Exercises vs Standard Exercises in Patients With Unspecific Low Back Pain||Universidad Complutense de Madrid|Yes|Completed|June 2011|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02633917||6642|
NCT02531087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7703|Urinary Biomarkers of OI Pathobiology|Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology||Baylor College of Medicine|No|Recruiting|September 2015|September 2025|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Urine samples will be collected|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with OI|November 2015|November 23, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531087||14536|
NCT02531100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BonyPid-201|BonyPid-500TM Bone Graft Substitute Study|PolyPid, Ltd. Pilot Study of the BonyPid-500TM Bone Graft Substitute||PolyPid Ltd.|No|Not yet recruiting|November 2015|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|77|||Both|20 Years|80 Years|No|||August 2015|August 23, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531100||14535|
NCT02533635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HongKongBU|Ganoderma Tea on Eczema Patient|Product Functional Study of Effect A Master Ganoderma Detox Tea on Eczema Patient||Hong Kong Baptist University|No|Recruiting|August 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02533635||14342|
NCT02539316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-03|Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population|Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population|SMOFPILOT|Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|18 Years|No|||August 2015|August 31, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02539316||13905|
NCT02539511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7014|Glutamatergic Modulation of Disordered Alcohol Use|The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use||New York State Psychiatric Institute|Yes|Recruiting|July 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|60 Years|No|||August 2015|August 31, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539511||13890|
NCT02634216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0206|Effects of Capros in Patients With Type-1 Diabetes|Effects of Capros Supplementation on Hyperglycemia in Patients With Type-1 Diabetes|Carpos T1D|Ohio State University|No|Recruiting|January 2015|October 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|10 Years|60 Years|No|||March 2016|March 21, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02634216||6619|
NCT02536937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP13778|A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate|An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function||Sanofi|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536937||14088|
NCT02536950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB34914|An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas|An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas||Stanford University|Yes|Not yet recruiting|August 2015|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|44 Years|No|||August 2015|August 31, 2015|July 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536950||14087|
NCT02536963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44EY025926|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||August 27, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536963||14086|
NCT02538705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoFoot DiabTrial|Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot|Safety and Efficacy Study of Pl-vegf165 to Treat Diabetic Foot Syndrome||Human Stem Cell Institute, Russia|No|Recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02538705||13952|
NCT02541591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58017|Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients|Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients: a Randomized Controlled Trial (the NEUROPROTECT Post-CA Trial)|NEUROPROTECT|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|August 2015|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02541591||13732|
NCT02529566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2013|Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine|Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine||The Foundation for Spinal Research, Education and Humanitarian Care, Inc.|No|Enrolling by invitation|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients between the age of 18-85 years who presents problems of degenerative lumbar disk.|August 2015|August 19, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02529566|2 Years|14653|
NCT02634450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC EID PILOT|Early Infant Diagnosis Point of Care Pilot|Evaluation of Point-Of-Care Testing Assays for Early Infant in Mozambique-Cluster Randomised Trial||Instituto Nacional de Saúde, Mozambique|No|Recruiting|September 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|241|||Both|N/A|18 Months|Accepts Healthy Volunteers|||December 2015|December 18, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02634450||6601|
NCT02528656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408081|Physiological Assessments During Non Operative Treatment on the Chest Wall Deformities|Physiological Assessments During Non Operative Treatment on the Chest Wall Deformities. Pectus Excavatum Pectus-Carinatum. Single-center Study|PECTUS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|10 Years|30 Years|No|||February 2016|February 19, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02528656||14723|
NCT02534389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1818/2013|Fish Oil Supplement in Rectal Cancer|Fish Oil Supplement Combined With Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer||AC Camargo Cancer Center|Yes|Recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02534389||14284|
NCT02533947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaSpo|Cognition in Allogeneic Stem Cell Transplanted Patients and Sports|Effects of Physical Exercise on Cognitive Functions in Patients After Allogeneic Stem Cell Transplantation|CaSpo|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|June 2014|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|March 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02533947||14318|
NCT02534207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29784|A Brain Imaging Study to Assess GABAA Receptor Alpha5 Subunit Occupancy Following a Single Dose of RO5186582 in Japanese Healthy Volunteers.|A Single-Centre, Non-Randomised, Open Label, Positron Emission Tomography Imaging Study to Assess Occupancy of Alpha5-Containing GABAA Receptors by RO5186582 in Healthy Volunteers of Japanese Origin.||Hoffmann-La Roche||Completed|August 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534207||14298|
NCT02634710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25722|Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall|Pilot Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall||Medical College of Wisconsin|Yes|Recruiting|February 2016|December 2025|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02634710||6581|
NCT02537548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4T-14-1|Retroperitoneal Lymph Node Dissection in Treating Patients With Stage I-IIA Testicular Seminoma|Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-2cm)||University of Southern California|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Male|16 Years|N/A|No|||September 2015|September 4, 2015|August 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537548||14041|
NCT02537561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x279|Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors|A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors||Washington University School of Medicine|No|Withdrawn|December 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|August 28, 2015|No|Yes|The pharmaceutical company did not want to follow through with support for the study.|No||https://clinicaltrials.gov/show/NCT02537561||14040|
NCT02539082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01RGS|the Safety and Efficacy of Collagen Injection in Patients With Plantar Fasciitis|A Post-marketing Surveillance to Evaluate the Safety and Efficacy of Collagen Injection in Patients With Plantar Fasciitis||Sewon Cellontech Co., Ltd.|Yes|Recruiting|November 2013|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02539082||13923|
NCT02634944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15090054|The Use of the VOMS Tool With Military Personnel to Track mTBI Recovery and RTD Status|The Use of the VOMS Tool With Military Personnel to Track Mild Traumatic Brain Injury Recovery and Return to Duty Status||University of Pittsburgh|No|Not yet recruiting|May 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|650|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02634944||6563|
NCT02540265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-15-014|Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery|A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy, and Pharmacokinetics of N1539 Following Bunionectomy||Recro Pharma, Inc.|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|75 Years|No|||January 2016|January 15, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540265||13833|
NCT02540278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-149-1-5|Evaluation of the Positive Prevention PLUS Program|Evaluation of the Positive Prevention PLUS Program Teen Pregnancy Prevention Program|PP+|California State University, San Bernardino|No|Completed|August 2013|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|4267|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540278||13832|
NCT02540291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7046-G000-101|Study of E7046 in Subjects With Selected Advanced Malignancies|An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies||Eisai Inc.||Recruiting|July 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|99 Years|No|||December 2015|January 21, 2016|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02540291||13831|
NCT02543359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12060529|A Statewide Trial to Compare Three Training Models for Implementing an Evidence-based Treatment (EBT)|A Statewide Trial to Compare Three Training Models for Implementing an EBT||University of Pittsburgh|Yes|Recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|648|||Both|1 Year|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02543359||13597|
NCT02534909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316X2201|Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria|An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)||Novartis|No|Active, not recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|N/A|N/A|No|||March 2016|March 23, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02534909||14244|
NCT02534922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-OC-001|Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer|Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|ProlantaOC|Oncolix, Inc.|Yes|Recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534922||14243|
NCT02544009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150192|Quantifying the Persistence of Metabolic Adaptation and Weight Regain Following Extreme Weight Loss|Quantifying Weight Regain and the Persistence of Metabolic Adaptation Following Extreme Weight Loss||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|March 2, 2016|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544009||13547|
NCT02532803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4346|Mri IN STaging REctal Polyp Planes|Mri IN STaging REctal Polyp Planes|MINSTREL|Royal Marsden NHS Foundation Trust|Yes|Recruiting|August 2015|August 2022|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02532803||14406|
NCT02539745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tjykdxykyy1|Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma|Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma||Tianjin Medical University Eye Hospital|Yes|Completed|July 2013|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|Samples With DNA|Cdx-2, Fok I, Bsm I and Taq I polymorphisms|Both|55 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|primary open-angle glaucoma patients and randomly age-matched people as controls in the        Han population of Tianjin China|August 2015|August 31, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02539745||13873|
NCT02542215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMP-8811-202|Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer|A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC)||Sucampo Pharma Americas, LLC|Yes|Recruiting|June 2015|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|285|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542215||13684|
NCT02551484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASILLAS Fd. Avenir 2012|Contribution of Near-InfraRed Spectroscopy (NIRS) to the Evaluation of Healing After Amputation of the Leg|Contribution of Near-InfraRed Spectroscopy (NIRS) to the Evaluation of Microcirculation Following Trans-tibial Amputation for Peripheral Artery Disease|NIRS|Centre Hospitalier Universitaire Dijon||Recruiting||||January 2016|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|85 Years||||November 2012|September 14, 2015|August 20, 2015||||No||https://clinicaltrials.gov/show/NCT02551484||12972|
NCT02551497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1014802/102|Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects|Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects||Convergence Pharmaceuticals|No|Active, not recruiting|April 2015|||September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02551497||12971|
NCT02544217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH176-101|A Dose-escalating Clinical Trial With KH176|A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176||Khondrion BV|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02544217||13531|
NCT02544230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTX.01|Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia|Efficacy of Granulocyte Transfusions for the Treatment of Severe Infections in Hematological Patients With Febrile Neutropenia||Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne|No|Completed|January 2004|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|101|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with malignant emopatia who received granulocyte transfusions as adjunctive        therapy in the treatment of severe infection, unresponsive to appropriate antimicrobial        therapy, which was incurred during neutropenia.|September 2015|September 5, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544230||13530|
NCT02545894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0581|An Evaluation of a New Nonverbal Treatment for Global Aphasia|An Investigation Into the Effect of a Novel, Non Verbal, Cognitive Treatment on Functional Communication in Global Aphasia||University College, London||Recruiting|September 2014|September 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|7|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02545894||13402|
NCT02546128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL - 11401|LEICeSter Tendon Extracorporeal Shockwave Studies|LEICSTES = LEICeSter Tendon Extracorporeal Shockwave Studies Assessing the Benefits of the Addition of Extra-Corporeal Shockwave Treatment to a Structured Home-rehabilitation Programme for Patients With Tendinopathy.|LEICSTES|University Hospitals, Leicester|No|Recruiting|July 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02546128||13384|
NCT02535741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-016|Clinical Outcome Study for the Triathlon Cruciate Retaining (CR) Total Knee|Clinical Outcome Study for the Triathlon CR Total Knee|TriathlonCR|Stryker European Operations BV|No|Active, not recruiting|October 2006|May 2016|Anticipated|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|21 Years|80 Years|No|||August 2015|November 3, 2015|August 21, 2015|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT02535741||14180|
NCT02544048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915197|Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults|Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|December 18, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544048||13544|
NCT02544061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-SWI-004|NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds|A Phase IIa Open-label, Randomized Study to Compare the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of NM-IL-12 (rHuIL-12) to Standard of Care in Subjects With Open Surgical Wounds Following Colostomy Takedown Allowed to Heal by Secondary Intention||Neumedicines Inc.|No|Recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|December 29, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544061||13543|
NCT02528331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047168|Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|CBT-TMS|Duke University|Yes|Not yet recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528331||14748|
NCT02534571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC325 Study|To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes|Endoscopic Application of a Hemostatic Powder TC-325 Versus Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes; A Non-inferiority Randomized Trial|TC325|Chinese University of Hong Kong|No|Recruiting|September 2015|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|247|||Both|18 Years|100 Years|No|||January 2016|January 28, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02534571||14270|
NCT02539979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2351-15|A Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve|A Double Blinded Randomized Control Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve||Sheba Medical Center|No|Recruiting|August 2015|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 2, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539979||13855|
NCT02540707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506092MIND|Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes|Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial||National Taiwan University Hospital|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|20 Years|N/A|No|||September 2015|September 21, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02540707||13799|
NCT02530996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMA-006-14F|Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment|Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment|Scleroderma|VA Office of Research and Development|No|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|32|Samples With DNA|1. Plasma BH4 and BH2 levels        2. NO measurements.        3. Two 3 mm punch skin biopsies and skin resistance artery collection.        4. Spin trapping and electron paramagnetic resonance (EPR) spectroscopy in skin resistance           arteries.        5. Oxidant and antioxidant gene expression in skin arterioles and whole blood.        6. Oxidative stress and antioxidant activity in whole blood and plasma.        7. Spin trapping and EPR spectroscopy in whole blood.|Both|18 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|SSc patients will be recruited by Dr. Frech from both the University of Utah SSc Clinic        and VISN 19 to complete Specific Aim 1 then referred to VA for 40212 BH4 consent and        randomization.|January 2016|January 21, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02530996||14543|
NCT02531009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|995SS001|Systemic Sclerosis Clinical and Biomarker Study|A Multicenter, Prospective, Longitudinal Study to Evaluate Gastrointestinal Function and Clinical and Molecular Biomarkers in Subjects With Early and Late Diffuse Cutaneous Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis, and Healthy Volunteers||Biogen|No|Withdrawn|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|RNA (ribonucleic acid) will be extracted for gene expression from the skin biopsies, skin      tape, and blood.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study participants will be recruited at participating locations in a standard clinical        practice setting.|October 2015|October 30, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531009||14542|
NCT02635451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHMostafa|The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes|The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes||Ain Shams Maternity Hospital|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This study will be conducted at the department of Obstetrics and Gynecology recruiting        pregnant women selected from the attendees of antenatal clinic, emergency department and        from inpatient wards of Ain Shams University Maternity Hospital starting from January        2016.        This study will include 40 pregnant women between 28-37 weeks were recruited.|December 2015|December 17, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02635451||6525|
NCT02635464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-CIC/IGDB|Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy|The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (hUC-MSCs) With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy||Chinese Academy of Sciences|No|Recruiting|October 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|35 Years|65 Years|No|||December 2015|December 19, 2015|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02635464||6524|
NCT02540772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conf-01|Neuropsychological Rehabilitation of Spontaneous Confabulation|Study of the Neuroanatomical Circuits, Predictors and Prognostic Factors of Spontaneous Confabulation: Designing an Assessment and Rehabilitation Program||San Rafael University Hospital, Granada, Spain|No|Completed|April 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|86 Years|No|||February 2016|February 9, 2016|August 15, 2015|Yes|Yes||No|September 5, 2015|https://clinicaltrials.gov/show/NCT02540772||13794|
NCT02532062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15020031|The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer|Efficacy of Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer (The Pittsburgh Vitamin D Study)||University of Pittsburgh|Yes|Recruiting|January 2016|September 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|50 Years|85 Years|No|||February 2016|February 1, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02532062||14462|
NCT02541331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPI-1201|Efficacy Of Bacterial Lysate In Asthmatic Children|Influence of Polyvalent Mechanical Bacterial Lysate ISMIGEN® on Clinical Course of Asthma and Related Immunological Parameters in Asthmatic Children (EOLIA Study): Randomised Double-blind Placebo-controlled Multicentre Parallel-group Study|EOLIA|Lallemand Pharma International|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|6 Years|16 Years|No|||September 2015|September 3, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541331||13752|
NCT02541344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/024613|Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects|Double-blind, Randomised, Placebo-controlled, Three-way Crossover Clinical Investigation to Evaluate the Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects||InQpharm Group|No|Completed|June 2014|||October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02541344||13751|
NCT02541357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6459 MBM Colorectal|Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Colorectal Surgery - a Randomized Controlled Trial|MBM_Colo|Universität Duisburg-Essen|Yes|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541357||13750|
NCT02642809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x411|Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers|A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers||Washington University School of Medicine|No|Not yet recruiting|March 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|December 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02642809||5959|
NCT02642822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-EPI-002|The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University|The Epidemiologic Study of Human Cytomegalovirus （CMV）in Female Students of Xiamen University||Xiamen University|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|102|||Female|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 female students aged 18 to 30 years old will be recruited from Xiamen University.|December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642822||5958|
NCT02530346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIM-2015-087|Is Colostomy Closure Without Mechanical Bowel Preparation Safe in Pediatric Patients? Randomized Clinical Trial.|Is Colostomy Closure Without Mechanical Bowel Preparation Safe in Pediatric Patients? Randomized Clinical Trial.||Hospital Infantil de Mexico Federico Gomez|No|Recruiting|October 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|1 Month|18 Years|No|||February 2016|February 18, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530346||14593|
NCT02538640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBE040|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content and GI Consumed Alone.|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content and GI Consumed Alone.||Mondelēz International, Inc.|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538640||13957|
NCT02528448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPE-01-2014|0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis|The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis|KIPA|Regional Hospital Holstebro|Yes|Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|60 Years|N/A|No|||August 2015|August 18, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02528448||14739|
NCT02541409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA02672|Directly Observed Therapy for HCV in Chennai, India|Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India|C-DOT|Johns Hopkins Bloomberg School of Public Health|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541409||13746|
NCT02632019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-006|Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract|A Clinical Study of Adoptive Cellular Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen in Treating Patients With Advanced Malignant Tumor of Biliary Tract||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||September 2015|December 30, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02632019||6788|
NCT02543684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes study|Post-prandial Glucose and Insulin Levels in Type 2 Diabetes Mellitus Patients After Consumption of Ready-to-eat Mixed Meals|Post-prandial Glucose and Insulin Levels in Type 2 Diabetes Mellitus Patients After Consumption of Ready-to-eat Mixed Meals||Harokopio University||Completed|November 2013|||April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|45 Years|75 Years|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543684||13572|
NCT02528734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_JDR5|Prospective Evaluation of Needle Exsufflation for Pneumothorax|Impact of Pneumothorax Duration Before Treatment on the Success of Needle Exsufflation||Hôpital Louis Mourier|No|Recruiting|January 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|adult patients admitted to the ICU with a pneumothorax|February 2016|February 25, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528734||14717|
NCT02528747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22421|A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate|A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)||Hoffmann-La Roche||Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|582|||Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients with metastatic bone disease who are receiving oral ibandronate        will be followed for approximately 1 year.|August 2015|August 18, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528747||14716|
NCT02536846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001140|The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals|The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals||Mclean Hospital|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536846||14095|
NCT02632266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002292|Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants|Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants||University of Kansas Medical Center|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|52|||Both|28 Weeks|34 Weeks|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02632266||6769|
NCT02632500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtocolsCPR|Multicenter internAtional raNdomized Controlled manIkin Study on Different Protocols of CPR (MANI-CPR)|Multicenter internAtional raNdomized Controlled manIkin Study on Different Protocols of CPR (MANI-CPR)|MANI-CPR|Pavia nel Cuore|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02632500||6751|
NCT02543762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-Ceron|Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease|Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease|CE|Hospital Clinic of Barcelona|No|Completed|February 2012|May 2015|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|No|Non-Probability Sample|Prospective, multicenter, multicenter study, coordinated by the Department of        Gastroenterology, Hospital Clínic of Barcelona|September 2015|September 4, 2015|May 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02543762|2 Years|13566|
NCT02528981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2012-165|Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial|Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial||Ryerson University|No|Recruiting|August 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528981||14698|
NCT02529215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048092|Improving Team Training During Mock Code Blue Simulations|Improving the Quality of Team Training and Performance During Interprofessional in Situ Mock Code Blue Simulations: A Randomized Controlled Mixed-methods Study||The Hospital for Sick Children|No|Recruiting|April 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|264|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529215||14680|
NCT02537158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-077|Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection|Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection:a Non-randomized Controlled Trial||Chinese Academy of Medical Sciences|Yes|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||March 2016|March 13, 2016|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02537158||14071|
NCT02629094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160030|Cardiometabolic Effects of Eplerenone in HIV Infection|Cardiometabolic Effects of Eplerenone in HIV Infection||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||November 2015|January 26, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629094||7012|
NCT02532309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJFH-20150203-CAP|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques|A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques||China-Japan Friendship Hospital|Yes|Recruiting|April 2015|||April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|35 Years|80 Years|No|||August 2015|August 26, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02532309||14444|
NCT02533921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0814|Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?|Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?||University of Colorado, Denver|No|Recruiting|October 2015|September 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|N/A|No|||December 2015|December 10, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533921||14320|
NCT02542072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-59 (VISA-406)|Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses|Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses||Coopervision, Inc.|No|Active, not recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|90|||Both|18 Years|50 Years|No|||February 2016|February 1, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542072||13695|
NCT02528890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2015|Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District|Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District|GBS|The Nazareth Hospital, Israel|Yes|Not yet recruiting|October 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|184|||Female|18 Years|40 Years|No|Probability Sample|The study will include 184 participants who meet the inclusion criteria and gave their        informed consent to participate. The sample size enables a confidence level of 95% within        a 5% range of the GBS carrier rate, assuming that the rate is close to 17%. The        investigators assume to identify 23 to 41 carriers, which will allow comparison of        demographic variables between carriers and non-carriers.|August 2015|August 18, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02528890||14705|
NCT02540681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR130357|Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma|Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma (ProFit)|ProFit|Major Extremity Trauma Research Consortium|Yes|Recruiting|January 2015|July 2022|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|60 Years|No|Non-Probability Sample|Participants will be drawn from the TAOS study which enrolls patients with below the knee        amputations from trauma centers participating in the Major Extremity Research Consortium        (METRC).|September 2015|September 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540681||13801|
NCT02537730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVJ-MKTG-1318|BIOCLEAN MPS VII in Combination With Biofinity Lens: A Two Week Crossover Study|BIOCLEAN MPS VII in Combination With Biofinity Lens: A Two Week Crossover Study||Coopervision, Inc.|No|Active, not recruiting|September 2015|February 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537730||14027|
NCT02633410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL-FEM 01|Transtibial Versus Anteromedial Femoral Tunnel Technique in ACL Reconstruction|Prospective Randomized Clinical Study Comparing Anteromedial Portal Versus Transtibial Technique for Femoral Tunnel Positioning in Anterior Cruciate Ligament Reconstruction With Hamstring Autograft||Panam Clinic|No|Completed|July 2007|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|14 Years|50 Years|No|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633410||6681|
NCT02539186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGHIRB No: 1-104-05-108|The Effect of Platelet Rich Plasma for Carpal Tunnel Syndrome|The Effect of Sono-guided Injection With Platelet Rich Plasma for Carpal Tunnel Syndrome||Tri-Service General Hospital|Yes|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||August 2015|September 1, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539186||13915|
NCT02539199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15109M|Vaginally Administered Versus Per Oral Misoprostol in Induction of Labour|Vaginally Administered Versus Per Oral Misoprostol in Induction of Labour: a Randomized Trial||Tampere University Hospital|Yes|Recruiting|September 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|N/A|No|||August 2015|March 2, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02539199||13914|
NCT02533388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA on stress|Effects of Electroacupuncture on Stress Response During Extubation of General Anesthesia in Elderly Patients|Effects of Electro-acupuncture on Stress Response During Extubation of General Anesthesia in Elderly Patients Undergoing Neurosurgery Operation|EAstress|Shengjing Hospital|Yes|Recruiting|May 2015|May 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 22, 2015|June 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02533388||14361|
NCT02533193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sirrrsh20150802-1|Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy|A Randomized Controlled Trial of Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy||Sir Run Run Shaw Hospital|No|Recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 22, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02533193||14376|
NCT02543723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence|A Randomized Longitudinal Intervention Study to Assess the Efficacy and Feasibility of Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence and Health Literacy Among Cancer Patients.||East Carolina University|No|Not yet recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543723||13569|
NCT02543736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treadmill Study|Reliability and Validity of Gait and Postural Balance Parameters|Reliability and Validity of Gait and Postural Balance Parameters Using an Instrumented Treadmill in Patients With Knee Osteoarthritis||Schulthess Klinik||Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|76|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02543736||13568|
NCT02536638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-15|Proteinuria During Acute Pyelonephritis In Pregnancy|Quantitating Proteinuria During Acute Pyelonephritis In Pregnancy||MemorialCare Health System|Yes|Recruiting|July 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|Samples With DNA|urine collection for 24 hour urine protein and creatinine analysis urine sample for      urinalysis with microscopy and culture blood for measurement of serum creatinine|Female|18 Years|N/A|No|Probability Sample|All patients admitted to inpatient management of acute pyelonephritis meeting the        inclusion and exclusion criteria will be enrolled in the study. A 24 hour urine collection        with be performed for evaluation of protein.|August 2015|August 28, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02536638||14111|
NCT02544815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Digoxin - START - AHF|Digoxin Short Term Treatment Assessment Randomized Trial in AHF|Assessment of the Efficacy and Safety of a Short Term Treatment With Digoxin on Patients With Acute Heart Failure Syndromes. A Randomized Controlled Trial.|DIG-START-AHF|University of Monastir|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544815||13485|
NCT02544828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160093|Intravenous Iron Sucrose in Arthroplasty|Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery?||Konkuk University Medical Center|Yes|Not yet recruiting|November 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|19 Years|N/A|No|||September 2015|September 8, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02544828||13484|
NCT02544841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 TP1AH000003-02-00 SSI|Evaluation of Safer Sex Intervention (SSI)|Evaluation of Safer Sex Intervention (SSI)||The Policy & Research Group|No|Active, not recruiting|February 2012|November 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|319|||Female|14 Years|19 Years|No|||September 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544841||13483|
NCT02529020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mou01|Jaw Clenching on Anaerobic Ability and Ventilatory Flows|Acute Effects of Jaw Clenching Using a Customized Mouthguard on Anaerobic Ability and Ventilatory Flows||University Ramon Llull|Yes|Completed|May 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|30|||Male|19 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529020||14695|
NCT02641262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenanICE201501|Henan STEMI Registry|Henan ST-segment Elevation Myocardial Infarction (STEMI) Registry||Henan Institute of Cardiovascular Epidemiology|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|STEMI patients within 30 days of symptom onset|December 2015|December 30, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02641262|1 Year|6078|
NCT02643459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HerlevH01|Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage|Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients|suPAR|Herlev Hospital|Yes|Recruiting|January 2016|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|38000|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02643459||5909|
NCT02536339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29366|Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy|An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)||Genentech, Inc.||Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536339||14134|
NCT02536352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00038838|Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being|Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being||Johns Hopkins University|Yes|Not yet recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|1300|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536352||14133|
NCT02538562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25697|Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea|HER2 Advanced Gastric Epidemiology Study in Korea: An Assessment of HER2 Status in Tumor Tissue Samples of Gastric and Gastro-esophageal (GE) Junction Cancer||Hoffmann-La Roche||Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1695|Samples With DNA|Approximately 2000 tumor tissue samples will be obtained from 17 local laboratories in      Korea. Because the study itself is noninterventional, samples must have been previously      collected in accordance with routine clinical practice.|Both|N/A|N/A|No|Non-Probability Sample|Available tumor samples from patients with gastric or gastroesophageal junction cancer        will be analyzed. No study visits or interventions are planned.|August 2015|August 31, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538562||13963|
NCT02541513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004494a|An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence|An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence||University of Science Malaysia|No|Active, not recruiting|May 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|65 Years|No|||September 2015|September 1, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541513||13738|
NCT02641327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-CLC-2015_Prot_1_BP|Monitoring Changes in Blood Pressure|Protocol for Evaluation of EarlySense: A Contact-less Device for Monitoring Changes in Blood Pressure||EarlySense Ltd.|Yes|Recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from 2 groups will be recruited:          1. Patients hospitalized in Internal Medicine unit with unstable blood pressure that             need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical,             hypotension or Hypertension patients, patients with kidney failure, heart disease,             stroke)          2. Patients hospitalized in intensive care with arterial line that allow continuous             blood pressure measurement|January 2016|January 7, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02641327||6073|
NCT02643537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009|Associated Pathologies Following Luxatio Erecta Humeri: A Retrospective Analysis of 31 Cases and Diagnostic Algorithm|||Medical University of Vienna||Completed|January 1992|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|Included for analysis were thirty-one patients (11 females (average age 68.2 years) and 20        males (average age 48.3 years)) who have been treated for Laxation erecta between 1992 and        2015.|December 2015|December 28, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02643537||5903|
NCT02539654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXE844b-C003|Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)|An Open-Label, Single-Dose, Pharmacokinetic Study of EXE844 Sterile Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery||Alcon Research|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|6 Months|12 Years|No|||March 2016|March 4, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539654||13879|
NCT02539888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404878264|Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy|Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy||Indiana University|No|Not yet recruiting|August 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 2, 2015|April 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02539888||13862|
NCT02544880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140960|PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC|PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial||University of Miami|Yes|Not yet recruiting|December 2015|||December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544880||13480|
NCT02544893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/649|Postoperative Analgesic Effects of Using Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block|Postoperative Analgesic Effects of Using Bupivacaine Alone or Added Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block in Thoracotomy||TC Erciyes University|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|93|||Both|18 Years|65 Years|No|||September 2015|September 10, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544893||13479|
NCT02529579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cellular immunotherapy|Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer|||Changhai Hospital||Recruiting|June 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|187|||Both|18 Years|70 Years|No|||January 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529579||14652|
NCT02641405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/PROG.478|Efficacy of Proprioceptive Focal Stimulation (EQUISTASI) on Gait Parameters in Parkinson. Italian Multicentric Study|Efficacy of Proprioceptive Focal Stimulation (EQUISTASI) on Gait Parameters in Parkinson. Italian Multicentric Study|PAGE|I.R.C.C.S. Fondazione Santa Lucia|No|Recruiting|November 2015|July 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|N/A|N/A|No|||December 2015|December 28, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02641405||6067|
NCT02532816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ind_dompustunting|Nutrient-Dense Complementary Foods on Catch-up Growth and Nutritional Status of Stunting Children|The Effect of Higher Nutrient-Dense Complementary Foods on Catch-up Growth and Nutritional Status of Stunting Children in Dompu District, Indonesia||SEAMEO Regional Centre for Food and Nutrition|Yes|Active, not recruiting|October 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|217|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532816||14405|
NCT02533076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCP13-3302-CYST|The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients|The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients||Universitaire Ziekenhuizen Leuven|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|8 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 21, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02533076||14385|
NCT02538887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0535|Use of a Supplemental Radiofrequency Detection System Subsequent to Manual Counting of Vaginal Textiles Following Vaginal Birth|Use of a Supplemental Radiofrequency Detection System Subsequent to Manual Counting of Vaginal Textiles Following Vaginal Birth: A Prospective Effectiveness and Efficiency Study For Sponge Tracking||The University of Texas Health Science Center, Houston||Not yet recruiting|November 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects will be inpatients at UTHealth/Memorial Hermann Hospital (and affiliates) who        are awaiting vaginal birth. Subjects will be identified upon admittance to Labor and        Delivery triage.|August 2015|August 31, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538887||13938|
NCT02540070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104373|Evaluation of Motor Sparing Knee Block to Infiltration Analgesia for Pain Following Knee Arthroplasty|Ultrasound Guided Motor Sparing Knee Blocks With or Without Dexmedetomidine for Postoperative Analgesia Following Knee Arthroplasty: a Randomized Double Blinded Study||Lawson Health Research Institute|No|Recruiting|August 2014|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|85 Years|No|||August 2015|September 2, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02540070||13848|
NCT02543450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke_Project_15|Physiotherapy in Order to Improve Walking Capacity and Participation in Chronic Stroke Subjects|Two Different Physiotherapy Programs in Order to Improve Walking Capacity and Participation in Chronic Stroke Subjects||University of Valencia|No|Recruiting|September 2014|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543450||13590|
NCT02642328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIG 01|High Intensity Interval Training With Strength/Power Exercises on VO2Max|Effects of Eight Sessions of High Intensity Interval Training (HIIT) With Strength/Power Exercises on VO2Max Gains and Aerobic Performance|Strength|Universidade Federal do Rio de Janeiro|Yes|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 25, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02642328||5996|
NCT02642341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-74|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642341||5995|
NCT02642354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-75|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642354||5994|
NCT02540200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHA-RS/2016-118|Efficacy of BST-CarGel in Treating Chondral Lesions of the Hip|A Pilot Study for Efficacy of BST-CarGel as an Adjunct to Microfracture for the Treatment of Chondral Lesions of the Hip: a Case Control Study||Nova Scotia Health Authority|Yes|Not yet recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02540200||13838|
NCT02540213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21387|Observational Study of MIRCERA in Users of Self-Application and Multidose Systems|||Hoffmann-La Roche||Completed|January 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with chronic kidney disease who received ESA therapy or multidose system        before they changed to MIRCERA|November 2015|November 18, 2015|September 1, 2015||No||No|November 18, 2015|https://clinicaltrials.gov/show/NCT02540213||13837|
NCT02544932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREFER-AF|Pleotropic Effect of New Oral Anticoagulants|Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation||Kyunghee University Medical Center|Yes|Not yet recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544932||13476|
NCT02539784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P121205|Thoracic Spinal Cord Stimulation as a Symptomatic Treatment for Advanced Parkinson's Disease|Thoracic Spinal Cord Stimulation as a Symptomatic Treatment for Advanced Parkinson's Disease: A Phase I Safety and Efficacy Study|SpinalPark|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|45 Years|69 Years|No|||August 2015|August 31, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539784||13870|
NCT02540044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02046|Supporting Patient Care With Electronic Resource (SuPER)|Supporting Patient Care With Electronic Resource (SuPER): Efficacy of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis|SuPER|University of British Columbia|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|148|||Both|19 Years|N/A|No|||January 2016|January 14, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540044||13850|
NCT02530151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201218|Intra-articular Morphine and Clonidine Injections for Pain Management in Hip Arthroscopy|Prospective Assessment of Intraoperative Intra-articular Morphine and Clonidine Injection in Hip Arthroscopy on Postoperative Pain Management||Northwestern University|No|Recruiting|November 2015|January 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530151||14608|
NCT02642406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEN2015-01|Therapy Management With Nab-Paclitaxel in Daily Routine|Safety, Efficacy and Patient Reported Outcomes of Advanced Breast Cancer Patients: Therapy Management With Nab-Paclitaxel in Daily Routine - SERAPHINA|SERAPHINA|University Hospital Tuebingen|Yes|Recruiting|December 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood samples|Female|18 Years|99 Years|No|Non-Probability Sample|1200 patients with locally advanced/metastatic breast cancer for who is curruently or will        be treated with nab-Paclitaxel according to the approval as stated in the Summary of        Product Characteristics.|December 2015|December 23, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02642406||5990|
NCT02529150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 38814|WISER After Ovarian Cancer - Exercise Pilot Study|WISER After Ovarian Cancer - Exercise Pilot Study||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|May 2015|||December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Actual|10|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529150||14685|
NCT02530944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23andMe_SLE001|Web-based Genetic Research on Lupus|||23andMe, Inc.|No|Recruiting|April 2015|January 2020|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Saliva samples are collected for DNA analysis|Both|6 Years|N/A|No|Non-Probability Sample|Community Sample|August 2015|August 31, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530944||14547|
NCT02531178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-439|A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257||AbbVie|No|Completed|July 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|8|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02531178||14529|
NCT02543489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1103|Flex Intramedullary Rod Study|A Prospective, Post-market, Multi-center Comparative Study of the Efficacy of Flex Intramedullary(IM) Rod in Terms of Range of Motion (ROM) Improvement.||Stryker Japan K.K.|No|Recruiting|December 2012|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||January 2016|March 7, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543489||13587|
NCT02544022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150195|Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)|Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|December 2017|Anticipated|October 2016|Anticipated|N/A|Observational|N/A|||Anticipated|414|||Both|5 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 18, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544022||13546|
NCT02537938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGP 555-002|Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)|A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects||NeuroGenetic Pharmaceuticals Inc|Yes|Recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537938||14011|
NCT02537951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49568.078.14|Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study|Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study||Erasmus Medical Center|Yes|Enrolling by invitation|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02537951||14010|
NCT02543372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/175-31/5|RCT of Internet-Delivered CBT Treatments for Pathological Gambling: Comparing the Effects of Added Involvement From CSOs|Internet-Delivered Treatments for Pathological Gambling: a Randomized Controlled Trial Comparing the Effects of Added Involvement By Concerned Significant Others||Karolinska Institutet||Recruiting|August 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543372||13596|
NCT02535494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6723|Risks and Benefits of Naloxone Prescribing|Risks and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users||New York State Psychiatric Institute|No|Recruiting|March 2014|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|700|||Both|21 Years|65 Years|No|||August 2015|August 31, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535494||14199|
NCT02557763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-OT-0-091/57|To Compare Anterior Knee Pain Between Non Severe and Severe Patellofemoral Arthritis After Oxford UKA|Study of Oxford Unicompartmental Knee Arthroplasty to Determine Anterior Knee Pain, Pain Score, Knee Score and Functional Score Between Patients Without Severe Patellofemoral Arthritis and Patients With Severe Patellofemoral Arthritis||Thammasat University|Yes|Completed|January 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|104|||Both|40 Years|N/A|No|||September 2015|September 22, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557763||12490|
NCT02557815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1027|Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence|Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|February 2012|||October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|80|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557815||12486|
NCT02529098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 523 03|Modification in Cortical Activation in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation|Modification in Cortical Activation by Functional Magnetic Resonance Imaging (fMRI) in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation|PlainteIMF|University Hospital, Toulouse|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02529098||14689|
NCT02529111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7415 15|Percutaneous Closure of Atrial Septal Defects in Children: Integration of 3D Echocardiography and Fluoroscopy Imaging.|Integration of Three-dimensional Echocardiography and Fluoroscopy Imaging During the Percutaneous Closure of intAtrial Septal Defects in Children: CIA-3D-navigator.|CIA3DNAVIGATOR|University Hospital, Toulouse|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|N/A|18 Years|No|||December 2015|December 11, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529111||14688|
NCT02550340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muc-M002-15|Munich Study for Beer Related ECG Change Workup|Munich Study for Beer Related ECG Change Workup|Munich BREW|Klinikum der Universitaet Muenchen|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3029|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants of the Munich Octoberfest and similar events|September 2015|September 15, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02550340|1 Day|13060|
NCT02553460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TINI|Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I|Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I||St. Jude Children's Research Hospital|Yes|Recruiting|October 2015|October 2031|Anticipated|February 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|365 Days|No|||January 2016|January 29, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553460||12820|
NCT02553746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14073|Ultrasound for Neuraxial Anesthesia|Study of the Use of Ultrasound Scan for Lumbar Regional Anesthesia||424 General Military Hospital|No|Recruiting|September 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|85 Years|No|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553746||12798|
NCT02541305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JVT001|Effectiveness of an Exercise Proprioceptive Program in Institutionalized Elderly|Effectiveness of an Exercise Proprioceptive Program on Predictors of Risk of Falls in Institutionalized Elderly||Universidad Miguel Hernandez de Elche|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||September 2015|December 2, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541305||13754|
NCT02542293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419AC00003|Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)|NEPTUNE|AstraZeneca|Yes|Recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|130 Years|No|||March 2016|March 9, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542293||13678|
NCT02637830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|036/2011|In Situ Remineralisation Response of Different Artificial Caries-like Enamel Lesions to Home-care and Professional Fluoride Treatments|||University of Sao Paulo||Completed|January 2012|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02637830||6342|
NCT02642588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCaseMC|Effect of a Commercially Available Carbohydrate Rich Gel on Maternal Fatigue: A Randomized Controlled Trial|Effect of a Commercially Available Carbohydrate Rich Gel on Maternal Fatigue: A Randomized Controlled Trial||University Hospital Case Medical Center|Yes|Not yet recruiting|February 2016|January 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|190|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02642588||5976|
NCT02538367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH12852-102|Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation|A Randomized, Double-blind/Open-label, Placebo/Active-controlled, Single/Multiple Dose, Parallel, Phase 1/2a Trial to Evaluate the Safety, Tolerability, PK , PD of YH12852 in Healthy Subjects and Patients With Functional Constipation||Yuhan Corporation|No|Recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|11||Anticipated|80|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||August 2015|September 3, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02538367||13978|
NCT02542995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ 1R18-HSO18160-03|Creating Healthy Work Places (HWP) Study|Creating Healthy Workplaces: Improving Outcomes for Providers and Patients|HWP|Minneapolis Medical Research Foundation|No|Completed|November 2009|January 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1296|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02542995||13625|
NCT02543008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUHSPortoAlegre_II|Effect of Physical Activity Following Thoracic Mobilization on Heart Rate Variability and Pressure Pain Threshold.|Effect of Physical Activity Following Thoracic Mobilization on Heart Rate Variability and Pressure Pain Threshold in Asymptomatic Subjects: a Randomized Clinical Trial.||Federal University of Health Science of Porto Alegre||Recruiting|September 2015|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02543008||13624|
NCT02535988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangPPH|Abscopal Effect for Metastatic Colorectal Cancer|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Colorectal Cancer||Zhejiang Provincial People’s Hospital|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||August 2015|August 28, 2015|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535988||14161|
NCT02631447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SECOMBIT|Sequential Combo Immuno and Target Therapy (SECOMBIT) Study|A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation|SECOMBIT|Fondazione Melanoma Onlus|Yes|Not yet recruiting|February 2016|December 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|230|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02631447||6831|
NCT02631460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010-2015023|S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC|A Randomized Phase II Study of S1 Plus Carboplatin Followed by Maintenance S1versus Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer||Sun Yat-sen University|Yes|Recruiting|December 2015|December 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|470|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02631460||6830|
NCT02530008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 30113|Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer|Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2013|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Probability Sample|women with recurrent breast cancer|January 2016|January 26, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530008||14619|
NCT02535923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1836-W|CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes|CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes|CBT-I|VA Office of Research and Development|No|Not yet recruiting|April 2016|November 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535923||14166|
NCT02544620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVH-SK-TKA-THA-UKA|Out Patient Surgery for Total Knee and Hip Replacement and Unicompartmental Knee Replacement - a Feasibility Study|||Hvidovre University Hospital|Yes|Recruiting|September 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|-  Unselected primary THA/TKA/UKA          -  ASA score I/II          -  Can be operated as #1 or #2          -  No sleep apnea treated with CPAP|September 2015|September 8, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02544620||13500|
NCT02544633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-109|Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET|Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor||Mirati Therapeutics Inc.|Yes|Recruiting|October 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544633||13499|
NCT02635529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_D012_44443|DFDBA and Amniotic Membrane in the Treatment of Periodontal Osseous Defects|A Clinical and Radiographic Evaluation of DFDBA (Demineralised Freeze Dried Bone Allograft) With Amniotic Membrane (AM) in the Treatment of Periodontal Osseous Defects-12 Month Randomized Controlled Clinical Trial||Krishnadevaraya College of Dental Sciences & Hospital|Yes|Recruiting|November 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02635529||6519|
NCT02538653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBE042|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.||Mondelēz International, Inc.|No|Recruiting|September 2015|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538653||13956|
NCT02543645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1127-06|A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer|A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer||Celldex Therapeutics|No|Recruiting|October 2015|June 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543645||13575|
NCT02533154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-280515|Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients|Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients||Medical University of Vienna|No|Not yet recruiting|December 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533154||14379|
NCT02544659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-SAPHO-01|Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome|Unrandomized, Open Label Single-center Study to Assess the Long Term Efficacy of Intravenous Bisphosphonates for Bone Marrow Edema in Patients With SAPHO Syndrome||Peking Union Medical College Hospital||Active, not recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2015|November 8, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02544659||13497|
NCT02641197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-1501|Vascular Reactivity Assessment by the AngioDefender Device -- A Precision Study|Vascular Reactivity Assessment by AngioDefender -- A Repeatability and Reproducibility Study||Everist Genomics, Inc|No|Not yet recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641197||6083|
NCT02531724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUHThoraxLL3|Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery|Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery|LEVOAKI|Sahlgrenska University Hospital, Sweden|No|Recruiting|September 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531724||14488|
NCT02533401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18429|A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Rituximab Plus Fludarabine and Cyclophosphamide (FCR) as First-line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)||Hoffmann-La Roche||Completed|February 2006|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533401||14360|
NCT02533661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412127RINC|Effects of Family-Centered Intervention for Preterm Infants at Preschool Age|Effects of Family-Centered Intervention for Preterm Infants at Preschool Age||National Taiwan University Hospital|No|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|270|||Both|3 Years|4 Years|No|||August 2015|August 31, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02533661||14340|
NCT02541929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00864|Fish Oil Brain Delivery Study|Fish Oil Brain Delivery Study||University of Southern California|No|Recruiting|September 2015|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|N/A|||||||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541929||13706|
NCT02541942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1731-4214|Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial|Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial||Novo Nordisk A/S|No|Enrolling by invitation|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Male|12 Years|N/A|No|||January 2016|February 3, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02541942||13705|
NCT02641275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRM-CMD Parents|Self-management Training for Parents With Chronic Muscular Dystrophia|Self-management Training for Parents With Chronic Muscular Dystrophia|ZRM-CMD-P|University Children's Hospital, Zurich|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|N/A|No|||December 2015|January 18, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02641275||6077|
NCT02531997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00100709|A Mind-body Intervention to Improve Body and/or Self Image|A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial||University of Michigan|Yes|Recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|97|||Female|21 Years|N/A|No|||August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531997||14467|
NCT02532010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMC IST-CTI-MDS|Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML|Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML)|Pacritinib|Weill Medical College of Cornell University|Yes|Active, not recruiting|June 2015|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|65 Years|N/A|No|||February 2016|February 17, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532010||14466|
NCT02533674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM60184-A-003-14|Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors||PharmaMar|No|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02533674||14339|
NCT02538900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00105855|Low InTensity Exercise Intervention in PAD|Low InTensity Exercise Intervention in PAD|LITE|Northwestern University|Yes|Recruiting|June 2015|June 2021|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|305|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538900||13937|
NCT02541994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.002.A|Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension|The Potential Value of Axial Length and Central Corneal Thickness in the Assessment for Risk of Permanent Optic Nerve Damage and Visual Field Loss in Benign Intracranial Hypertension||Ochsner Health System|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02541994||13701|
NCT02536079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeST2014|NeuroAiD Safe Treatment Registry|NeuroAiD Safe Treatment Registry|NeST|CHIMES Society|No|Recruiting|June 2014|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|The NeST Registry is a product-specific and safety outcome registry that includes patients        who are taking NeuroAiD. Participation is entirely voluntary and an agreement will be        obtained before inclusion. The decision on the use of NeuroAiD should be made following a        discussion between participant and physician and only then will the option of        participation in the registry be considered.|August 2015|August 26, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02536079|3 Months|14154|
NCT02536092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-15-HR-03|A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal|A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal||Cutera Inc.|No|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536092||14153|
NCT02539927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52030-295|Validation Study of the SAGIT® Instrument in Acromegaly|International Multicentre Validation Study of SAGIT® Instrument in Acromegaly|SAGIT|Ipsen|No|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from Acromegaly in specialist care clinics and hospital clinics.|February 2016|February 25, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02539927||13859|
NCT02539108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC58|Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children|Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children||Sanofi|No|Active, not recruiting|August 2015|November 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539108||13921|
NCT02533570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-022|Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus|A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus||Seattle Genetics, Inc.|No|Recruiting|July 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533570||14347|
NCT02532595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03261504F|TDN, Manual Therapy and Exercise For the Management of Achilles Tendinopathy|Trigger Point Dry Needling, Manual Therapy and Exercise vs Manual Therapy and Exercise For the Management of Achilles Tendinopathy||Nova Southeastern University|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||August 2015|August 21, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02532595||14422|
NCT02528513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaxiICU|Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients|Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine for Long-Term Sedation in Critically Ill, Mechanically Ventilated Patients: a Prospective, Randomized Study||West China Hospital|Yes|Not yet recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02528513||14734|
NCT02641080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508807749|Evaluating the Need for Pneumatic Compression Devices|Evaluating the Need for Pneumatic Compression Devices: A Randomized-controlled Trial (RCT) of Aspirin Versus Aspirin and Pneumatic Compression Devices||West Virginia University|Yes|Not yet recruiting|January 2016|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02641080||6092|
NCT02537678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH107522-01|Stepped Care for Children After Trauma: Optimizing Treatment|Stepped Care for Children After Trauma: Optimizing Treatment||University of South Florida|Yes|Recruiting|September 2015|April 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537678||14031|
NCT02539147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01617-38|Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis|Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis|CASPASEs|Groupe Hospitalier Paris Saint Joseph|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|N/A||1|Actual|6|None Retained|arterial blood (20ml)|Both|N/A|N/A|No|Probability Sample|Patients with sepsis severe (bacterial infection associated with deterioration of at least        one vital function) defined according to the criteria consensus conference|August 2015|August 31, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02539147||13918|
NCT02633631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410028|Contraceptive Choice Center|The Center for Contraceptive Excellence: an Innovative Health Services Delivery and Payment Model|C3|Washington University School of Medicine|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10025|||Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|We plan to recruit women who are at high risk for unintended pregnancy and birth.|December 2015|December 14, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02633631||6664|
NCT02633644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-250|Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)|The Harmony System for the Treatment of Heart Failure Patients - A Safety and Performance Study||Enopace Biomedical|No|Recruiting|September 2015|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633644||6663|
NCT02536651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343/13/03/02/13/5|Reliability and Validity of the Finnish Visual Analogue Scale Foot and Ankle and the Lower Extremity Functional Scale|Reliability and Validity of the Finnish Versions of the Visual Analogue Scale Foot and Ankle and the Lower Extremity Functional Scale||Helsinki University Central Hospital|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone surgery due to foot and ankle pathology|August 2015|August 27, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02536651||14110|
NCT02536664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22283|Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants|RIM - Rituximab in Maintenance||Hoffmann-La Roche||Completed|September 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|505|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with follicular lymphoma who are to be treated with Rituximab in the        maintenance dosing period as decided by the physician|October 2015|October 7, 2015|August 24, 2015|No|Yes||No|October 7, 2015|https://clinicaltrials.gov/show/NCT02536664||14109|
NCT02529475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC14.428|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)|HYDROPS|University Hospital, Grenoble|Yes|Not yet recruiting|September 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529475||14660|
NCT02529488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILH297-P002|Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00|Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00||Alcon Research|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|22 Years|N/A|No|||February 2016|February 26, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02529488||14659|
NCT02533440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5142-001|Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain|A Prospective, Randomized, Open-Label Study Comparing Postsurgical Analgesia Using EXPAREL® To Standard Of Care For The Full Arch Surgical Therapy (FAST) Dental Implant Surgery Procedure|FAST|Bellaire Facial Surgery Center|No|Enrolling by invitation|August 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533440||14357|
NCT02643472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS-1403-1567|GPS (Giving Parents Support): Parent Navigation After NICU Discharge|GPS (Giving Parents Support): Parent Navigation After NICU Discharge|GPS|Children's Research Institute|No|Recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|N/A|N/A|No|||February 2016|February 14, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02643472||5908|
NCT02643485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10111|Pedobarography After Forefoot Reconstruction|Dynamic Pedobarography With a New Insole After Forefoot Reconstruction|PeFRe|Technische Universität München|No|Recruiting|December 2015|September 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients planned for forefoot surgery|December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643485||5907|
NCT02544867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPP Project #130817|Optimizing Sedentary Behavior Interventions to Affect Acute Physiological Changes|Optimizing Sedentary Behavior Interventions to Affect Acute Physiological||University of California, San Diego|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544867||13481|
NCT02529267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAISE-2|Prospective Abuse and Intimate Partner Violence Surgical Evaluation|Prospective Abuse and Intimate Partner Violence Surgical Evaluation (PRAISE-2) : A Multicentre Pilot Prospective Cohort Study|PRAISE-2|McMaster University|No|Recruiting|August 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Female|16 Years|N/A|No|Non-Probability Sample|Adult women presenting to participating fracture clinics with a fracture or dislocation.|August 2015|August 21, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02529267||14676|
NCT02643550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2201-203|Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Innate Pharma|No|Recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643550||5902|
NCT02528383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-143-3|Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors|Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life||University of Connecticut Health Center|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528383||14744|
NCT02528643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-3021|A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma||Astellas Pharma Inc|Yes|Recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528643||14724|
NCT02530086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504015652|Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement|Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement|NoNGT|Yale University|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02530086||14613|
NCT02539797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22017|Improving Cognition in Schizophrenia Using tDCS|Improving Cognition in Schizophrenia Using Transcranial Direct Current Stimulation|ICDC|University of California, Los Angeles|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|55 Years|No|||March 2016|March 17, 2016|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539797||13869|
NCT02643589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-201304-K1(02)|Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation|Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis||Nanfang Hospital of Southern Medical University|Yes|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|14 Years|65 Years|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02643589||5899|
NCT02537587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-1342|Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact|Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact|Solstice|Glycemic Index Laboratories, Inc|No|Completed|January 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|7||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537587||14038|
NCT02537964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018-15-SZMC|Effectiveness of Chlorhexidine Bathing in the Neonatal Intensive Care Unit|Evaluation of the Effectiveness of Chlorhexidine Bathing in Reducing Nosocomial Infections in the Neonatal Intensive Care Unit||Shaare Zedek Medical Center|Yes|Not yet recruiting|November 2015|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|N/A|N/A|No|||August 2015|August 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537964||14009|
NCT02542644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-013015|Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT|Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following Descemet's Membrane Endothelial Keratoplasty Using Ultra-high Resolution Optical Coherence Tomography||Medical University of Vienna|Yes|Not yet recruiting|September 2015|||September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02542644||13652|
NCT02541981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507087RIND|Natural Course for Renal Function After Heart Transplantation|Natural Course for Renal Function After Heart Transplantation||National Taiwan University Hospital|No|Active, not recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|heart transplantation|September 2015|September 10, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541981||13702|
NCT02630186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-032|A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC|A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)||Clovis Oncology, Inc.|No|Recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|93|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630186||6928|
NCT02630199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-038|Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer|Phase I, Open-Label Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer||Samsung Medical Center|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|19 Years|N/A|No|||December 2015|December 28, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02630199||6927|
NCT02630212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015QLMS37|The Relationship Between ALDH2 and Aortic Dissection|The Relationship Between ALDH2 and Aortic Dissection|RALAD|Qilu Hospital|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|4 ml vein blood samples were collected from aortic dissection or controls in tubes      containing EDTA. The samples would be centrifuged and saved in a -80℃ ultra-low temperature      refrigerator.      1 cm2 of aorta specimen were collected from patients operated on for Type A dissection, and      refrigerated with liquid nitrogen.|Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients diagnosed with aortic dissection in Qilu Hospital.|December 2015|December 23, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630212||6926|
NCT02528916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42679|Nociceptin Concentration in Synovial Fluid and Plasma|Nociceptin Concentration in Synovial Fluid and Plasma in Patients Undergoing Primary Total Knee Arthroplasty: A Prospective Pilot Study||Milton S. Hershey Medical Center|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sequential patients receiving primary unilateral knee arthroplasty by the same surgeon|March 2016|March 17, 2016|July 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02528916||14703|
NCT02530398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-XTCX-05|A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites|Single-arm, Non-randomized, Open, Drug Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion Treatment on Digestive System Cancer Patients With Ascites||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530398||14589|
NCT02530164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP-1483-0152-I|Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression|Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression - A Prospective Multicenter Double Blind Randomized Placebo Controlled Trial (DepressionDC)|DepressionDC|Ludwig-Maximilians - University of Munich||Recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530164||14607|
NCT02530177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-198|Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer|A Prospective, Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|700|Samples With DNA|saliva (baseline only)|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinics|February 2016|February 29, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530177||14606|
NCT02533596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPE-5343-2010|Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange|Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange||Hannover Medical School|No|Completed|September 2010|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|Samples With DNA|-  blood samples        -  plasma samples from TPE waste bag|Both|18 Years|80 Years|No|Probability Sample|Tertiary hospital patients after kidney transplantation with humoral rejection and        patients with other antibody mediated diseases.|February 2015|August 24, 2015|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02533596||14345|
NCT02534844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTS301|Study of 2-hydroxypropyl-β-cyclodextrin (VTS-270) to Treat Niemann-Pick Type C1 (NPC1) Disease|A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of 2-hydroxypropyl-β-cyclodextrin (VTS-270) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease||Vtesse Inc.|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|51|||Both|4 Years|21 Years|No|||March 2016|March 15, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534844||14249|
NCT02535130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NebuPEP|Evaluation of Nebulization and Positive Expiratory Pressure Combination|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|August 2015|September 2015|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|16 Years|55 Years|No|||August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535130||14227|
NCT02542124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-ONC-001|NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)|A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)||Neumedicines Inc.|No|Recruiting|December 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|January 14, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542124||13691|
NCT02635178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Raines02|Brief Anxiety Sensitivity Treatment for Obsessive Compulsive Symptoms|Randomized Control Trial Examining a Brief Anxiety Sensitivity Cognitive Concerns Intervention for Obsessive Compulsive Symptoms||Florida State University||Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02635178||6546|
NCT02540356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391402|Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer|A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects With Refractory Ovarian Cancer With Malignant Ascites||Baxalta US Inc.|No|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540356||13826|
NCT02540421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN1701|Recurrence in High-grade Lesions After Conization|Presence of Positive Resection Margins, Hypooestrogenism and Specimen Volume May Influence Risk of Disease Recurrence in Patients With High-grade Cervical Intra-epithelial Neoplasia Undergoing Large Loop Excision of the Transformation Zone||Faculdade de Medicina do ABC|Yes|Completed|January 2001|December 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|103|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients were included in the study if they had a history of surgery for conization by        LLETZ for the histopathological diagnosis of cervical intraepithelial neoplasia grades II        and III (CIN II and CIN III).|September 2015|September 1, 2015|October 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02540421||13821|
NCT02531191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK27|Bioequivalence Evaluation of a New and Current Tablet of ASP015K|ASP015K Pharmacokinetic Study - Bioequivalence Evaluation of a Small and Current Tablet of ASP015K||Astellas Pharma Inc|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531191||14528|
NCT02531204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0201|A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules|Pharmacodynamic Study of ASP1585 - Verification of Bioequivalence Between ASP1585 Granules and ASP1585 Capsules||Astellas Pharma Inc|No|Completed|August 2014|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531204||14527|
NCT02541630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00069755|Big Mind for Veterans With PTSD|A Pilot Study of Big Mind for Veterans With PTSD||VA Salt Lake City Health Care System|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02541630||13729|
NCT02541643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2022|Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma|Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma||Icahn School of Medicine at Mount Sinai||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||September 2015|September 2, 2015|September 2, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02541643||13728|
NCT02558764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effects of Preventive Negative Pressure Wound Therapy With PICO on Surgical Wounds of Kidney Transplant Patients|Effects of Preventive Negative Pressure Wound Therapy With PICO on Surgical Wounds of Kidney Transplant Patients: A Pilot Trial||Nova Scotia Health Authority|No|Not yet recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|75 Years|No|||September 2015|September 23, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558764||12413|
NCT02550275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 201409|Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging||COSIMH|University Hospital, Angers||Recruiting|January 2015|||February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02550275||13065|
NCT02554422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-MD-0014|Objective Measurement of Ossicular Chain Mobility Using a Palpating Instrument Intraoperatively|Messung Der Beweglichkeit Der Gehörknöchelchenkette während Einer Ohroperation. ("Objective Measurements of Ossicular Chain Mobility Using a Palpating Instrument Intraoperatively")|PalpEar|Sensoptic SA|No|Completed|December 2013|August 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554422||12746|
NCT02554435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0014|TAME Health: Testing Activity Monitors' Effect on Health|TAME Health: Testing Activity Monitors' Effect on Health||The University of Texas Medical Branch, Galveston||Recruiting|January 2016|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|55 Years|74 Years|Accepts Healthy Volunteers|||September 2015|January 5, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02554435||12745|
NCT02558972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-11,388|Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)|Northera Improves Postural Tachycardia Syndrome (POTS) and Postural||New York Medical College|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558972||12397|
NCT02635360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18472|Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer|A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer||University of Virginia|Yes|Not yet recruiting|January 2016|May 2021|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||December 2015|December 15, 2015|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635360||6532|
NCT02543580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijingmazui24|Acupuncture-assisted Anesthsia With Single or Dual Acupoints Affects Analgesics|Efficiency of Acupuncture-assisted Anesthsia With Single or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer: A Single Center, Randomized, Double-blinded, Controlled Clinical Trial||Xijing Hospital|Yes|Recruiting|July 2015|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|204|||Both|18 Years|80 Years|No|||September 2015|September 4, 2015|December 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02543580||13580|
NCT02532634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KJH-2015-01|Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone|Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy|RAPA|Kangdong Sacred Heart Hospital|No|Recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|292|||Both|19 Years|N/A|No|||September 2015|September 3, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02532634||14419|
NCT02532647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS7056-015|Efficacy and Safety of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy|A Study Evaluating the Safety and Efficacy of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy||Paion UK Ltd.||Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532647||14418|
NCT02544568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/801-32|Effects of Standardized Meals on the Metabolic, Hormonal and Inflammatory Responses in Human|Effects of Standardized Meals With Different Compositions of Fat, Protein and Carbohydrate on the Metabolic, Hormonal and Inflammatory Responses in Human||Karolinska University Hospital|Yes|Recruiting|November 2009|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|90|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02544568||13504|
NCT02544581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare|Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare||SoberLink, LLC|Yes|Enrolling by invitation|September 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Alcohol abusers enrolled into an aftercare program following residential treatment for        alcohol abuse|September 2015|September 6, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544581||13503|
NCT02534792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58389|Early Revalvulation After Fallot Repair Improves Clinical Outcome|||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|320|||Both|N/A|N/A|No|Non-Probability Sample|Tetralogy of Fallot patients repaired with transannulaire patch.|February 2016|February 18, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534792||14253|
NCT02540720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhai|The Research of Standard Diagnosis and Treatment for Severe HSP in Children|The Research of Standard Diagnosis and Treatment for Severe Henoch-Schonlein Purpura in Children||Nanjing Children's Hospital|No|Recruiting|August 2015|July 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|2 Years|16 Years|No|||August 2015|September 1, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02540720||13798|
NCT02532140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-5107-101|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime|Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime Administered as Single IV Doses in Healthy Human Volunteers||Wockhardt|No|Active, not recruiting|August 2015|February 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|January 28, 2016|August 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532140||14456|
NCT02532153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001783|The Impact of Ketamine on the Reward Circuitry of Suicidal Patients|The Impact of Ketamine on the Reward Circuitry of Suicidal Patients: An MRI Study||Massachusetts General Hospital|No|Not yet recruiting|November 2018|||October 2020|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532153||14455|
NCT02631733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02125|Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors||National Cancer Institute (NCI)|Yes|Not yet recruiting|May 2016|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|February 15, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02631733||6809|
NCT02537691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB29599|Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers|A Prospective, Single Arm, Longitudinal Cohort Study To Assess Biomarkers In Real World Patients With Severe Asthma||Hoffmann-La Roche||Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1213|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537691||14030|
NCT02538588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akeflow|Comparison of Amikacin Lung Delivery With Two Nebulizers|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|August 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|16 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02538588||13961|
NCT02532439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408063|Bone Microarchitectural Database Constitution From HR-pQCT Device in Clinical Situation Potentially Associated With Bone Loss|Bone Microarchitectural Database Constitution From High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Device in Clinical Situation Potentially Associated With Bone Loss|DMPOs|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|August 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532439||14434|
NCT02644057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-11-MMC|Dobutamaine Versus Milrinone in Cardiorenal Syndrome|Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure|DOMICAS|Maimonides Medical Center|No|Recruiting|March 2016|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|95 Years|No|||March 2016|March 11, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644057||5863|
NCT02535884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-198|Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)|Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD): A Prospective, Randomised, Controlled, International, Multi-centre Study|HD-DBS|Heinrich-Heine University, Duesseldorf|Yes|Recruiting|July 2014|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02535884||14169|
NCT02538731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sdqfs001|Laser Lithotripsy for Difficult Large Bile Duct Stones|Randomized Trial of Spyglass Guided Laser Lithotripsy Versus Dilation-Assisted Stone Extraction for the Endoscopic Removal of Difficult Large Bile Duct Stones||Shandong Provincial Hospital|No|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02538731||13950|
NCT02538744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H36362|Complementary Combination Therapy for Cocaine Dependence|Complementary Combination Therapy for Cocaine Dependence||Baylor College of Medicine|Yes|Recruiting|August 2015|||August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|55 Years|No|||August 2015|September 1, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538744||13949|
NCT02528825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-14-295|Effect-site Concentration of Remifentanil for Smooth Removal of the Double-lumen Endotracheal Tube|||Ajou University School of Medicine||Completed|November 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|25|||Both|19 Years|65 Years|No|||August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528825||14710|
NCT02644096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rehabilitation after THR|Rehabilitation of Patients After THR - Based on Patients´Selfrated Health|Rehabilitation of Patients Aged 65 and Over After Total Hip Replacement - Based on Patients´Health Status|Rehab-THR|University of Aarhus|No|Completed|September 2004|December 2013|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|175|||Both|65 Years|97 Years|No|||December 2015|December 28, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02644096||5860|
NCT02536144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEK-2015-046|The Clinical Application of MCCES in Examination of Human Colon|The Clinical Application of Magnetic-controlled Capsule Endoscopy System in Examination of Human Colon||Nanfang Hospital of Southern Medical University|Yes|Recruiting|August 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536144||14149|
NCT02538913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2284|Exercise Training for Rectal Cancer Patients|Exercise Training for Rectal Cancer Patients. A Randomized Controlled Trial.||Norwegian University of Science and Technology|No|Recruiting|September 2015|August 2023|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02538913||13936|
NCT02544958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 251/2015|Er:YAG Laser for Treatment of Enlarged Pores|The Efficacy and Safety of Erbium:Yttrium Aluminum Garnet Laser for Treatment of Enlarged Pores: A Pilot Study||Mahidol University|Yes|Active, not recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02544958||13474|
NCT02529046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCyrino|Conjugated Linoleic Acid in Obese Women|Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-blinded and Placebo-controlled Trial|CLA|Universidade Estadual de Londrina|No|Completed|March 2007|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02529046||14693|
NCT02529059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT058|SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms|A Phase IV, Open-label, Multi Centre Pilot Study to Assess Changes in Cerebral Function Parameters in Patients Without Perceived Central Nervous System (CNS) Symptoms When Switched From a Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz (Atripla®) to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (Eviplera®)||St Stephens Aids Trust|No|Recruiting|November 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02529059||14692|
NCT02539160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-10953|Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease|Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease||University of Florida|Yes|Recruiting|February 2016|October 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|82|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539160||13917|
NCT02528682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCT19|MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT|Vaccination With PD-L1/L2-silenced Minor Histocompatibility Antigen-loaded Donor DC Vaccines to Boost Graft-versus-tumor Immunity After Allogeneic Stem Cell Transplantation (a Phase I/II Study)|PSCT19|Radboud University|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528682||14721|
NCT02544971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0215-15-TLV|Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual|Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual|NFTIP|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|September 7, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02544971||13473|
NCT02540083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124.03-2015-GES-0001|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-Enrich: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy After Screening Digital Breast Tomosynthesis Exam|ADAPT-ENRICH|GE Healthcare|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Female|30 Years|N/A|No|||December 2015|December 1, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540083||13847|
NCT02537873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54DA038999 Project 1|Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder|Phase I Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder||Virginia Commonwealth University|Yes|Recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|59 Years|No|||February 2016|February 19, 2016|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537873||14016|
NCT02540330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATOS-2015-007|PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy|An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy||Atossa Genetics, Inc.|No|Recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540330||13828|
NCT02537301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150611-4|Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by a Group of Doctors|Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by Trainees After Finishing ERCP Training||Fourth Military Medical University|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Doctors who received and finished their ERCP training in Xijing Hospital of Digestive        Diseases and joined in a chatting group through a mobile social app|January 2016|January 9, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02537301||14060|
NCT02537639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Andreas Bloch|Impact of Simulator-based Training in Transoesophageal Echocardiography|Impact of Simulator-based Training in Transoesophageal Echocardiography|ISITOE|University Hospital Inselspital, Berne|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|45|||Both|25 Years|65 Years|No|Non-Probability Sample|Trainees in critical care|August 2015|August 28, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02537639||14034|
NCT02532946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boston Medical Center|Bedsider.Org in Post-abortion Contraceptive Counseling: A Mixed Methods Study|Bedsider.Org in Post-abortion Contraceptive Counseling: A Mixed Methods Study|Bedsider|Boston Medical Center|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|346|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||August 2015|February 2, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02532946||14395|
NCT02537743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM - 04302|Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma|Open-labeled, Multicenter, Non-interventional, Prospective PRO Registry for Patients With First Line Treatment for Advanced RCC Using a Tablet-technology Based Digital Device|PROKidney|iOMEDICO AG|No|Recruiting|August 2015|January 2021|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with advanced (inoperable or metastatic) renal cell cancer at the start of the        first line antitumoral therapy|March 2016|March 11, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537743||14026|
NCT02643381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022015-023|Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial|Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial|EvK|University of Texas Southwestern Medical Center|Yes|Not yet recruiting|April 2016|April 2021|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|825|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643381||5915|
NCT02543242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InTone|InTone for Urinary Incontinence|Effectiveness of the Intone Pelvic Floor Device for Urinary Incontinence||University Health Network, Toronto|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|70 Years|No|||September 2015|September 4, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543242||13606|
NCT02543255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACDC-RP|Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)|Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated|ACDC-RP|University Health Network, Toronto|Yes|Not yet recruiting|October 2016|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Male|18 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543255||13605|
NCT02543268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107786|A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants|A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN®‐Filo in Healthy Adult Subjects||Crucell Holland BV|Yes|Recruiting|September 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|329|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543268||13604|
NCT02542449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19A301_2013|Effects of Greenselect Phytosome® on Weight Maintenance After Weight Loss in Obese Women|Placebo Controlled, Randomized, Single Blinded Trial on the Effects of Greenselect Phytosome® on Weight Maintenance in Obese Women After a 3-month Weight Loss Intervention||Istituto Auxologico Italiano|No|Completed|April 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||August 2015|September 4, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542449||13667|
NCT02541760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163|Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children|Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children||Hormozgan University of Medical Sciences|Yes|Completed|April 2014|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|143|||Both|2 Years|6 Years|No|||September 2015|September 2, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541760||13719|
NCT02529592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS 2.0 - 2014/1946-31|Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences|Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences: A Randomized, Double-blind Placebo Controlled Study on Healthy Human Volunteers||Karolinska Institutet|No|Completed|February 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02529592||14651|
NCT02641171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00029059|Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort|Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|December 2015|September 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|Samples Without DNA|exhaled air samples blood samples fecal samples|Both|18 Years|65 Years|No|Non-Probability Sample|Our target population will consist of individuals with established diagnosis of Crohn's        Disease (CD). The target population will include male and female between the ages of 18        and 65 years and standard BMI (between 19 and 30). Potential study participants will be        excluded if having any disease compromising immune system (such as HIV positive status or        patients after organ transplantations), diagnosis of any liver disease, active and        untreated tuberculosis and chemotherapy agents. All potential participants must have        scheduled appointment for colonoscopy.|December 2015|December 28, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02641171||6085|
NCT02539914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303891- 47/2013|Feasibility Study of a Virtual Reality Cognitive-motor Task Based on Positive Stimuli for Stroke Rehabilitation|Interactive System for Diagnostics and Rehabilitation of Cognitive-motor Deficits: Controlled Longitudinal Clinical Study With Stroke Patients||Universidade da Madeira|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539914||13860|
NCT02533648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.639|Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients|Involvement of Reactive Oxygen Species Produced by the Xanthine Oxidase in Mitochondrial Alterations in Skeletal Muscle of Type 2 Diabetic Patients|DIAXO|Hospices Civils de Lyon|Yes|Recruiting|September 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|39|||Both|30 Years|60 Years|No|||August 2015|August 24, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02533648||14341|
NCT02539329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408060|Characterization of Anti-FGFR3 Antibodies|Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|465|Samples Without DNA|blood sample for antibodies measure|Both|18 Years|N/A|No|Non-Probability Sample|Patient group : patient with clinically pure sensory peripheral neuropathy and positive        for anti-FGFR3 antibodies Control group :clinically pure sensory peripheral neuropathy and        negative for anti-FGFR3 antibodies|March 2016|March 9, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02539329||13904|
NCT02633670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXNXHEMOPATCH|Hemopatch Versus No Hemopatch (Renal Transplant)|A Prospective Randomized Trial of Hemopatch Versus No Hemopatch For the Intraoperative Hemostasis During Deceased Donor Renal Transplant||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633670||6661|
NCT02539368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOB-INF-1402|Post-marketing Use of Inflectra (Infliximab) for Standard of Care Treatment of Inflammatory Bowel Disease|Post-Marketing Observational Cohort Study of Patients With Inflammatory Bowel Disease (IBD) Treated With Inflectra (Infliximab) in Usual Clinical Practice (CONNECT-IBD)|CONNECT-IBD|Hospira, Inc.|No|Recruiting|April 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3300|||Both|18 Years|N/A|No|Non-Probability Sample|The target study population will include patients with CD or UC, who are being treated, or        initiating treatment, with Inflectra or Remicade at the time of study enrolment. This        would include the following treatment subgroups:          -  Biologic-naïve patients initiating Inflectra (or Remicade);          -  Patients currently being treated with Inflectra (or Remicade);          -  Patients who are considered stable by the Investigator under Remicade therapy for CD             or UC, who switch to Inflectra;          -  Patients switching to Inflectra or Remicade from an alternative biologic therapy             (e.g. adalimumab) due to non-responsiveness to or intolerance;          -  Patients re-initiating Inflectra or Remicade after having successfully completed and             exited a previous course of infliximab therapy in the past.          -  Patients with fistulating disease or stomas and those receiving combination therapy             will be included.|January 2016|January 21, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02539368||13901|
NCT02528149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308016|Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study|Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|Samples With DNA|blood samples and adjacent part and aneurysm of renal aneurysms|Both|15 Years|N/A|No|Probability Sample|Patients with one or more Renal artery aneurysm (RAA), not eligible for endovascular        treatment, have been operated at the Hospital of Saint-Etienne, with tissue (adjacent part        and aneurysm) cryopreserved in liquid nitrogen in renal lab and then sent in genetic lab        in EHGP.|August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528149||14762|
NCT02529787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/12/406|A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg DR Capsules (Takeda Pharmaceuticals America Inc., USA)||Genuine Research Center, Egypt|No|Completed|February 2013|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529787||14636|
NCT02529800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-VICT-102|Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetics Incorporating a Comparison of Fed/Fasted Pharmacokinetics of HIP1402 in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Enrolling by invitation|September 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|September 15, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02529800||14635|
NCT02533713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001535|Effects of Exoskeleton-Assisted Gait Training on Bone Health and Quality of Life|Effects of Exoskeleton-Assisted Gait Training on Bone Health and Quality of Life: A Randomized Clinical Trial||Spaulding Rehabilitation Hospital|No|Not yet recruiting|October 2015|||October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533713||14336|
NCT02539550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7481001|A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects|A Phase 1, Placebo-controlled, Randomized, Subject- And Investigator-blind, Sponsor-open, Crossover Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of Pf-06266047 After Administration Of Single Ascending Doses To Healthy Adult Subjects||Pfizer|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02539550||13887|
NCT02629081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1503015486|Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease|Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial||Yale University|No|Recruiting|March 2015|January 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|||Both|21 Years|75 Years|No|Probability Sample|Controls (participants scheduled for upper endoscopy for anemia, weight loss, diarrhea, or        screening for esophageal varices and who do not have heartburn or other GERD symptoms and        Cases (participants scheduled for upper endoscopy for heartburn or other GERD symptoms.)|December 2015|December 10, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02629081||7013|
NCT02532569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-KD-287-CT-401|Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj|A Multi-center, Open, Phase 4 Clinical Trial to Assess the Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj. and to Conduct an Exploratory Investigation on Vaccine Interchangeability in Korean Children Aged 6 Years Who Received Primary 3 Doses With ENCEVAC® or Japanese Encephalitis Vaccine-GCC® Inj.|BR-JELITE|Boryung Pharmaceutical Co., Ltd|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|188|||Both|6 Years|6 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532569||14424|
NCT02534155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiRiDe|High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Trial Comparing MitraClip® to Surgical Therapy|High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy|HiRiDe|University of Zurich|Yes|Recruiting|April 2015|September 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|294|||Both|75 Years|N/A|No|||August 2015|August 24, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02534155||14302|
NCT02541903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150330009 (UAB 14113)|Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma|A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy||University of Alabama at Birmingham|Yes|Recruiting|October 2015|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Male|18 Years|N/A|No|||November 2015|November 11, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541903||13708|
NCT02541916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tol002|Liver Immune Tolerance Marker Utilization Study|Liver Immune Tolerance Marker Utilization Study|LITMUS|University of Toronto|Yes|Recruiting|April 2015|March 2020|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|102|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541916||13707|
NCT02629640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/SS/0196|Enhanced CJD Surveillance in the Older Population|Enhanced CJD Surveillance in the Older Population||University of Edinburgh|Yes|Recruiting|January 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|-  Blood samples        -  Brain tissue|Both|65 Years|N/A|No|Non-Probability Sample|Patients aged 65+ accessing NHS Lothian neurology/psychogeriatric services with atypical        features of the recognised forms of dementia. Eligible patients will be identified by the        local clinical team by screening their existing patient lists, as they see patients as        they attend their clinic or are visited in the community. The clinic staff are asked to        consult the study team to confirm the patient's eligibility.|January 2016|January 26, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629640||6970|
NCT02540525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-2009|Transobturator Sling Compared With Single-incision Mini-sling for the Treatment of Stress Urinary Incontinence|Transobturator Sling Compared With Single-incision Mini-sling for the Treatment of Stress Urinary Incontinence: A Randomized Controlled Trial||Faculdade de Medicina do ABC|Yes|Completed|January 2013|July 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|February 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02540525||13813|
NCT02540538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBnr01|Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders|Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders||Maastricht University Medical Center|Yes|Active, not recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|34|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2015|December 14, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540538||13812|
NCT02531230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1502|"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes|"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes After Plain Old Balloon Angioplasty (POBA) and/or Drug Coated Balloon (DCB) Treatment in the Infra-inguinal Position With the objectiVE to Implant Multiple Stent Segments|LOCOMOTIVE|B. Braun Melsungen AG|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|The aim of the study is to assess the safety and efficacy of the Multi-LOC® peripheral        stent system to treat de novo and restenotic lesions (no in-stent restenosis (ISR), no        restenosis post drug coated balloon (DCB)) after flow limiting plain old balloon        angioplasty (POBA) and/or DCB dilatations in the superficial femoral artery (SFA) and        popliteal segments (P1, P2 & P3)|December 2015|December 7, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02531230||14525|
NCT02531503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|697/2557(EC3)|Predicting Factors for Asthma Remission in Children|Predicting Factors for Asthma Remission in Children||Mahidol University|Yes|Recruiting|February 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|15 Years|No|Non-Probability Sample|The children who were diagnosed as having asthma at pediatric allergy clinic were        recruited.|August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531503||14504|
NCT02530788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-036|High-dose Selenium Supplementation in Patients With Left Ventricular Assist|Perioperative High-dose Selenium Supplementation in Patients With Left Ventricular Assist Device - a Double Blinded Randomised Controlled Trial|SOS-LVAD|RWTH Aachen University|Yes|Not yet recruiting|August 2015|November 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02530788||14559|
NCT02634463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108047|Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone|Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone||Janssen Research & Development, LLC|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adult participants taking aripiprazole, olanzapine, paliperidone or risperidone will be        included in the study.|March 2016|March 11, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02634463||6600|
NCT02634476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33-1314|Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?|Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?||Turning Point|No|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||December 2015|December 15, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02634476||6599|
NCT02533297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88490|Developing Standards Skill According to the Learning Curves|Developing Standards for Skill Performance Times in Nursing Clinical Education Program According to Learning Curve||Mashhad University of Medical Sciences|Yes|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|57|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02533297||14368|
NCT02533310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIMSE|Virtual Reality Immersive Method for Spider (Phobia) Exposure Therapy (VIMSE)|Single-session Gamified Virtual Reality Exposure Therapy for Spider Phobia vs. Traditional Exposure Therapy: a Randomized Controlled Non-inferiority Trial|VIMSE|Stockholm University|No|Active, not recruiting|August 2015|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533310||14367|
NCT02530710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q203-TB-PI-US001|A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers||Qurient Co., Ltd.|No|Active, not recruiting|August 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02530710||14565|
NCT02534441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4596-A|Epidemiology and Co-Reactivity of Novel Surfactant Allergens|Epidemiology and Co-Reactivity of Novel Surfactant Allergens||Minneapolis Veterans Affairs Medical Center||Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02534441||14280|
NCT02643680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med CU IRB 242/58|Clinical Study of Biocellulose Wound Dressing Containing Silk Sericin and PHMB for STSG Donor Sites|Clinical Efficacy of the Novel Biocellulose Wound Dressing Containing Silk Sericin and Polyhexamethylene Biguanide for Split-thickness Skin Graft Donor Sites||Chulalongkorn University|Yes|Recruiting|December 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02643680||5892|
NCT02643693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3L-PK-02-US|User Acceptability of P3L|User Acceptability of a Nicotine Lactate Delivery System Relative to the VUSE e-Cigarette System and Combustible Cigarette Comparators||Philip Morris Products S.A.|No|Recruiting|December 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|6||Anticipated|24|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02643693||5891|
NCT02538055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS019239|Using CERS to Optimize Quality of Life for Persons With Diabetes and Chronic Pain|Using CERS to Optimize Quality of Life for Persons With Diabetes and Chronic Pain|Living Healthy|Weill Medical College of Cornell University|No|Active, not recruiting|September 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|19 Years|N/A|No|||March 2016|March 9, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02538055||14002|
NCT02540785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005|Early Changes Between Lenticule Extraction and Small-Incision Lenticule Extraction|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction||Sun Yat-sen University|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540785||13793|
NCT02539277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141107-3.0|A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection|A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection: A Double Blind, Double Dummy, Randomized, Controlled Trial||China Academy of Chinese Medical Sciences|Yes|Recruiting|December 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|70 Years|No|||August 2015|September 2, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02539277||13908|
NCT02531282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1030|Effect of a Health Promotion Intervention for People With Chronic Pain at a Healthy Life Centre|Effect of and Experiences With a Health Promotion Intervention for People With Chronic Pain at a Healthy Life Centre - an Open, Pragmatic, Randomized Controlled Trial With a Nested Qualitative Study||Norwegian University of Science and Technology|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02531282||14521|
NCT02642458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEN2015-02|Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients|Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab|PerFECT|University Hospital Tuebingen|Yes|Not yet recruiting|January 2016|||January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|99 Years|No|Non-Probability Sample|The study will be conducted as an open registry, therefore there will be no restriction in        the number of patients to be included.        The assignment of the patient to a particular treatment falls within current practice and        the prescription of the medicine is clearly separated from the decision to include the        patient in the non-interventional study.|December 2015|January 5, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02642458||5986|
NCT02529397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBBS: 15-647|Obesity Treatment Enhanced With Working Memory Training|Obesity Treatment Enhanced With Working Memory Training|Focus|University of Vermont|No|Active, not recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529397||14666|
NCT02535143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUGRP/2014/183.|Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students|The Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students||Riyadh Colleges of Dentistry and Pharmacy|Yes|Completed|September 2014|July 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|21 Years|26 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535143||14226|
NCT02532166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-4072|Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus|Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus. Diagnostic Value of White Light Endoscopy, Narrow Band Imaging and Chromoendoscopy for Detection of Esophageal Manifestation in Patients With Oral Lichen.||Ruhr University of Bochum|No|Recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02532166||14454|
NCT02547792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXA03-001|Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults|Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine||Vaxart|Yes|Recruiting|November 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|54|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547792||13256|
NCT02554136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROMA-105|Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816|An Open-labeled, Randomized Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Single Oral Administration of HGP0918 and HGP0816 in Healthy Adult Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554136||12768|
NCT02554149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ante-001|Radiological Measurement of Femoral Stem Version Using Lateral Decubitus Method: A Prospective Study|||Seoul National University Bundang Hospital|Yes|Recruiting|September 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Probability Sample|patients who underwent THR between October 2015 and December 2015|January 2016|January 11, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554149|1 Year|12767|
NCT02560285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPauloGH1001|High-risk Patients in Cardiac Surgery Procedures: HiriSCORE|An International Multicenter Prospective Study for Identify High-risk Patients in Cardiac Surgery Procedures: HiriSCORE|HiriSCORE|University of Sao Paulo General Hospital|Yes|Recruiting|January 2016|December 2018|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgery procedures|November 2015|February 12, 2016|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02560285|30 Days|12296|
NCT02545218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StockholmSGH|Perineorraphy Versus Pelvic Floor Exercise - a Randomized Trial|Perineorraphy Versus Pelvic Floor Exercise - a Randomized Trial||Stockholm South General Hospital|No|Not yet recruiting|September 2015|May 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||September 2015|September 10, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545218||13454|
NCT02550158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2009-1|A Study Evaluating the Impact of an Educational Program (EDU-MICI) on Patients With Inflammatory Bowel Disease|A Randomized Controlled Study Evaluating the Impact of an Educational Program "EDU-MICI" on Patients With Inflammatory Bowel Disease|ECIPE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|Yes|Completed|June 2011|April 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|263|||Both|18 Years|70 Years|No|||September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550158||13074|
NCT02531581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-11|Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive|Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531581||14498|
NCT02631187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/P/164|Feasibility Study of Balloon Eustachian Tuboplasty (BET)|Feasibility Study of Balloon Eustachian Tuboplasty (BET) for Grade 2 and 3 Pars Tensa Retractions|BET|Plymouth Hospitals NHS Trust|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02631187||6851|
NCT02631434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STSTCOPD|Comparison Between Sit-to-stand Test and Six-minute Walk Test in Chronic Obstructive Pulmonary Disease|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|August 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|20|||Both|45 Years|90 Years|No|||December 2015|December 11, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02631434||6832|
NCT02531139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDOlesen|The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery|The Effect of Blood Pressure on Cerebral Perfusion and Oxygenation During Vascular Surgery||Rigshospitalet, Denmark|Yes|Not yet recruiting|February 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|19 Years|N/A|No|||January 2016|January 14, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02531139||14532|
NCT02537093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|741223-2|﻿﻿Pilot Study of Asynchronous and Synchronous Telepsychiatry for Skilled Nursing Facilities|﻿﻿A Pilot Study Examining Use of Asynchronous and Synchronous Telepsychiatry Consultation for Skilled Nursing Facility Residents||University of California, Davis|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537093||14076|
NCT02531880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150177|Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy|Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy||National Institutes of Health Clinical Center (CC)||Suspended|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|August 22, 2015|August 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531880||14476|
NCT02637843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCESS-I|Randomized Comparison of Sheaths for Radial Access|Randomized Comparison of Coated Slender Versus Un-coated Traditional Sheath|ACCESS-I|Aarhus University Hospital Skejby|No|Recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02637843||6341|
NCT02637856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN30035|A Study of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment|AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE MODIFYING TREATMENT||Genentech, Inc.||Recruiting|February 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02637856||6340|
NCT02538510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9383|Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery|A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies||University of Washington|Yes|Recruiting|September 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538510||13967|
NCT02538523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_LBP_002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||September 30, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538523||13966|
NCT02528240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58015 / B322201525314/ I / U|Endodontic Microsurgery With the Use of L-PRF and an Occlusive Membrane: a Randomized Controlled Clinical Trial|Endodontic Microsurgery With the Use of L-PRF and an Occlusive Membrane: a Randomized Controlled Clinical Trial||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02528240||14755|
NCT02536248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JANU-INF|Sitagliptin Therapy and Kinetics of Inflammatory Markers|EFFECTS OF SITAGLIPTIN THERAPY ON THE KINETICS OF MARKERS OF LOW-GRADE INFLAMMATION AND CELL ADHESION MOLECULES IN PATIENTS WITH TYPE 2 DIABETES||Laval University|Yes|Active, not recruiting|August 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536248||14141|
NCT02640040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN02|The Effect of Combined Surgery in Management of Congenital Pseudarthrosis of Tibia|The Effect of Combined Surgery in Management of Congenital Pseudarthrosis of Tibia||Hunan Children's Hospital|No|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|2 Years|18 Years|No|||December 2015|December 21, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02640040||6172|
NCT02641184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJPPH01|Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction|A Multicenter Prospective Observational Study to Evaluate the Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction (AMI)||Zhejiang Provincial People’s Hospital|No|Enrolling by invitation|December 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Blood specimens for biomarker analysis and storage for future genetic studies|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to an emergency room and diagnosed as acute myocardial infarction|February 2016|February 13, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02641184||6084|
NCT02531412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI/993|Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients|Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients|SPIROCAN|Instituto Nacional de Cancerologia de Mexico|Yes|Recruiting|October 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|80 Years|No|||October 2015|March 1, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531412||14511|
NCT02531425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS-I140|Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC|Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer|TNBC|OncoSec Medical Incorporated|No|Recruiting|September 2015|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531425||14510|
NCT02536534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17926|Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension|(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension|e-MOTION PH|Bayer|No|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Canadian patients are eligible for the study if they have been diagnosed with symptomatic        Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension        (CTEPH) and are stable on optimal medical therapy and who meet the study's eligibility        criteria|March 2016|March 3, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02536534||14119|
NCT02628574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX518-003|Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors|A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults With Advanced Solid Tumors - Part A: Dose-Escalation Part B: Expanded Cohort||GITR, Inc.|No|Recruiting|December 2015|June 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628574||7052|
NCT02539394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-145|Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion|Do Intraoperative Topical Corticosteroids Aid in the Prevention of Postoperative Dysphagia Following Elective Anterior Cervical Discectomy and Fusion? A Randomized, Controlled, Double Blinded Clinical Trial||Hospital for Special Surgery, New York|Yes|Enrolling by invitation|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539394||13899|
NCT02544945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3DBolus|Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy|Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy: A Feasibility Study Measuring Bolus Spatial Accuracy, Dosimetric Accuracy and Treatment Set-up Time||Nova Scotia Health Authority|Yes|Not yet recruiting|September 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Female|18 Years|N/A|No|||September 2015|September 8, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02544945||13475|
NCT02533479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-1|Erythrocytes and Skeletal-muscle Fatty Acids Are Positively Correlated After Caloric Restriction and Exercise|Erythrocytes and Skeletal-muscle Unsaturated and Omega-6 Fatty Acids Are Positively Correlated After Caloric Restriction and Exercise||Centre d'Alt Rendiment|Yes|Completed|January 2010|October 2014|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02533479||14354|
NCT02533492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2933a3|Compare Antimicrobial to Conventional Suture in Patients Receiving Primary Total Knee Replacement|Compare the Results of Antimicrobial to Conventional Suture Materials in Patients Receiving Primary Total Knee Replacement: A Prospective Double-blinded Randomized Controlled Trial|Vicryl-Plus|Chang Gung Memorial Hospital|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Both|N/A|N/A|No|||August 2015|August 24, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533492||14353|
NCT02628821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2015|The Effectiveness of Non-Invasive Ventilation Use in Preterm Infants.|Effectiveness of Synchronized Non-Invasive Ventilation to Prevent Invasive Mechanical Ventilation Use in Preterm Infants.||Hospital General Universitario Gregorio Marañon|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|N/A|3 Months|No|Non-Probability Sample|Prospective observational study of SNIPPV use in preterm infants of less than 32 weeks of        gestation from January 2012 to December of 2014.        SNIPPV is used for:          -  nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria             (FiO2>50%; apnea spells more than 4/h or more than 1 that needs PPV) if they are in a             stable situation. SAP (systemic arterial pressure)> P10 with preserved respiratory             drive (no more than 6 apneas episodes per hour or more than 2 requiring PPI).          -  Electively For extubation:               -  Preterm infants in which nCPAP extubation has previously failed or Prolonged                  mechanical ventilation (more than 15 days) with high respiratory parameters                  (PMAP > 10 cmH2O and FiO2>35%).|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628821||7033|
NCT02539693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082015|Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery|Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery: A Prospective Randomized Trial||Makassed General Hospital|No|Not yet recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||August 2015|September 2, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539693||13877|
NCT02539706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sinan|Menstrual Cycle on Injection Pain of Rocuronium|The Impact of the Menstrual Cycle on Injection Pain of Rocuronium|MENS|Adnan Menderes University|Yes|Recruiting|January 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Female|18 Years|45 Years|No|||September 2015|September 15, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539706||13876|
NCT02531243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000377|Computer-Aided Learning for Managing Stress|A Pilot Study of Computerized Biofeedback Games With Young People Experiencing Psychotic-Spectrum Symptoms|CALMS|Beth Israel Deaconess Medical Center|Yes|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|13 Years|23 Years|No|||February 2016|February 24, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02531243||14524|
NCT02531542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/2014/69|Evaluation of Rapid Emergency Echography for Acute Dyspnoea|Evaluation of Rapid Emergency Echography for Acute Dyspnoea for the Diagnosis of Acute Left-sided Heart Failure in Elderly Subjects Admitted to the Emergency Room (READ Protocol)|READ|Centre Hospitalier Universitaire de Besancon|Yes|Not yet recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|500|||Both|75 Years|N/A|No|||August 2015|August 20, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02531542||14501|
NCT02533752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01816|Canadian WATCHMAN Registry|Canadian WATCHMAN Registry|WATCHMAN|Cardiology Research UBC|No|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing WATCHMAN device Implantation|August 2015|August 24, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533752|24 Months|14333|
NCT02532855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-838|A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838)|A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.|No|Recruiting|October 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|556|||Both|25 Years|N/A|No|||March 2016|March 16, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532855||14402|
NCT02533102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-E044-004|Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers|Evaluation of E7050 Pharmacokinetics After 100 mg Single Oral Doses Under Fed and Fasted Conditions and Characterization of E7050 Pharmacokinetics After 100 mg, 200 mg and 400 mg Single Oral Doses Under Fasted Condition in Healthy Subjects||Eisai Inc.|No|Completed|November 2010|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533102||14383|
NCT02537028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200527-002|MSC2364447C Phase 1b in Systemic Lupus Erythematosus|A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus Erythematosus||EMD Serono|Yes|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537028||14081|
NCT02531555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meseli et al.|Clinical Efficacy Of 810 Nanometer Diode Laser As An Adjunct To Mechanical Periodontal Treatment Of Residual Periodontal Pockets|||Marmara University|No|Completed|January 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02531555||14500|
NCT02542930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhejiang Provincal People's Hp|Abscopal Effect for Metastatic Non-small Cell Lung Cancer.|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Non-small Cell Lung Cancer.||Zhejiang Provincial People’s Hospital|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||October 2015|October 9, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542930||13630|
NCT02540343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Balgrist 2013-0394|Intercultural Adaptation and Validation of the "Orebro Musculoskeletal Pain Questionnaire"|Intercultural Adaptation and Validation of the "Orebro Musculoskeletal Pain Questionnaire"-Translation and Validation of a Questionnaire|Orebro-G|Balgrist University Hospital|No|Recruiting|November 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|N/A||3|Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acute and chronic neck pain patients Healthy volunteers|January 2016|January 11, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02540343||13827|
NCT02530333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404-370|Differential Biomechanical Effects of an ACL Injury Prevention Program in Women's Basketball and Soccer Players|Differential Biomechanical Effects of an ACL Injury Prevention Program in Women's Basketball and Soccer Players||High Point University|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|99|||Female|12 Years|19 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02530333||14594|
NCT02544802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-VGH-201102|Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee|Treatment of Primary Osteoarthritis of the Knee Joint With Autologous Mesenchymal Stem Cells||Steminent Biotherapeutics Inc.|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|70 Years|No|||September 2015|September 6, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02544802||13486|
NCT02541708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCIDA 001-2015|IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania|Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania|Ferinject|Ifakara Health Institute|Yes|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Female|18 Years|49 Years|No|||February 2016|February 9, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541708||13723|
NCT02531711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2321|Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain & Function|Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain & Function|LRPD|University of North Carolina, Chapel Hill|No|Not yet recruiting|August 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02531711||14489|
NCT02530099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-Trial|Simulation-based Training of Operating Assistants: Procedure- Versus Camera Navigation Training|Simulation-based Training of Operating Assistants: Procedure- Versus Camera Navigation Training - a Randomized Controlled Trial Examining Clinical Transfer||Rigshospitalet, Denmark|No|Not yet recruiting|September 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|36|||Both|N/A|N/A|No|||August 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530099||14612|
NCT02530112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17913|Functional Outcome Measures for Head and Neck Patients|Functional Outcome Measures for Head and Neck Patients||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2013|||November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Subjects who have consented to Otorhinolaryngology Research Registry and are undergoing        free flap surgery.|March 2016|March 18, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530112||14611|
NCT02529605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500360|Relative Bioavailability of Two Different Milk Thistle Formulations|Relative Bioavailability of Two Different Milk Thistle Formulations: A Single Dose Randomized Crossover Pharmacokinetic Study||University of Florida|No|Recruiting|September 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02529605||14650|
NCT02533726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33144|Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers|Randomized Control Trial Evaluating Optimal Patient Turning Procedures for Reducing Hospital Acquired Pressure Ulcers|LS-HAPU|Stanford University|No|Terminated|August 2015|August 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1313|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 17, 2015||No|Stopping rule: Low event rate|No||https://clinicaltrials.gov/show/NCT02533726||14335|
NCT02643420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-GCF-301|RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide|RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)|ADVANCE|Spectrum Pharmaceuticals, Inc|No|Recruiting|December 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|580|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643420||5912|
NCT02528669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024875|Patient Ambulation in Post-Op Recovery|Measuring Patient Ambulation in Post-Operative Recovery||Intermountain Health Care, Inc.|No|Recruiting|March 2014|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|3000|||Both|18 Years|N/A|No|||May 2015|August 18, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02528669||14722|
NCT02538445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001156|Can we Forget? Directed Forgetting and Embodied Cognition in Schizophrenia|Can we Forget? Directed Forgetting and Embodied Cognition in Schizophrenia||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|March 22, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538445||13972|
NCT02541812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:077|The Use of Magnetic Brain Stimulation to Treat Obsessive Compulsive Disorder, a Pilot Study|The Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Obsessive Compulsive Disorder (OCD), a Pilot Study||University of Manitoba|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||August 2015|September 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541812||13715|
NCT02642913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-279|Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients|A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642913||5951|
NCT02532296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-3222|Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients|Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients at a Safety Net Hospital: Activating Partnerships Among Patients, Families and Medical Staff||Cambridge Health Alliance|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02532296||14445|
NCT02533908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fentanyl-2015|Combination of Nitrous Oxide 70% With Fentanyl Intranasal for Procedural Analgosedation in Children|Combination of Nitrous Oxide 70% With Fentanyl Intranasal for Procedural Analgosedation in Children: A Prospective, Randomized, Double-blind, Placebo-controlled, Monocentric Study||University Children's Hospital, Zurich|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|402|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533908||14321|
NCT02534142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-20-05-15|Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence|Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence||Meuhedet. Healthcare Organization|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|||Both|51 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|a representative sample of Meuhedet members who adhered / did not adhere to followup of a        positive fecal occult blood test using colonoscopy|August 2015|August 24, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02534142||14303|
NCT02539563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-328|Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?|Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?||Wake Forest School of Medicine|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|240|||Female|18 Years|50 Years|No|||February 2016|February 9, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02539563||13886|
NCT02541851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/03|Chronic Pain After Surgical Intensive Care Admission: Incidence and Risk Factors: the DOLOCHROREA Study|Chronic Pain After Surgical Intensive Care Admission: Incidence and Risk Factors: the DOLOCHROREA Study|DOLOCHROREA|Centre Hospitalier Universitaire de Besancon|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|840|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted in the surgical critical care unit of the Centre Hospitalier        Universitaire de Besançon, France.|September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02541851||13712|
NCT02629367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOVA-D1|Influence of Vorapaxar on Thrombin Generation and Coagulability|||Inova Health Care Services|No|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 11, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02629367||6991|
NCT02537249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0556|Effects of Dexmedetomidine on Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery|||Yonsei University|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|111|||Both|20 Years|85 Years|No|||November 2015|November 9, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02537249||14064|
NCT02537574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALKS-6428-A301|Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)|A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL®||Alkermes, Inc.|No|Recruiting|August 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537574||14039|
NCT02538718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MgSO4 study|Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor|Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor||Seoul National University Hospital||Recruiting|July 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538718||13951|
NCT02530554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15-028|Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|December 5, 2015|August 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530554||14577|
NCT02530567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7318 02|Non-invasive Evaluation of Portal Pressure by MRI|Using MRI for a Non-invasive Evaluation of Portal Pressure|ENIP|University Hospital, Toulouse|Yes|Recruiting|October 2015|December 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530567||14576|
NCT02530580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0261|Effects of GABA Modulator AZD7325 on Cutaneous Sensation|A Phase I Single Site, Single Dose, Randomized, Double-blind, Placebo Controlled, 2-way Cross-over Biomarker Study Investigating the Effect of the GABA Modulator AZD7325 on Cutaneous Sensation in Healthy Volunteers||University College, London|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|February 2, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02530580||14575|
NCT02634229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11010|Predisposition Genes in Monogenic Diabetes (DIAMONO)|Constitution of a Cohort of Families With Monogenic Diabetes to Identify Novel Causes of Non Auto-immune Diabetes Mellitus in Children and Young Adults|DIAMONO|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diabetic family members and healthy relatives|August 2015|February 15, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02634229||6618|
NCT02529735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSFrancilien|Study on Pressure Values Measured on Three Alternative Sites of the Lower Limbs Compared to the Arm|Etude Prospective Observationnelle Multicentrique Sur Volontaires Sains Des VALeurs de Pression Artérielle mesurées Sur Trois Sites alteRnAtIfS Des Membres inférieurs cOmparées au Site de référence|VALPARAISO|Centre Hospitalier Sud Francilien|No|Not yet recruiting|January 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers among fire fighters and nursing student|August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529735||14640|
NCT02535689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150185|Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus|Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|May 2020|Anticipated|May 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|38|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535689||14184|
NCT02535936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0335|Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy|Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy||The University of Texas Health Science Center, Houston|No|Recruiting|August 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|3 Years|18 Years|No|||March 2016|March 2, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535936||14165|
NCT02643563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|456-2014|Analgesic Duration of Long Acting Local Anesthetics for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block|Comparison of the Analgesic Duration of 0.5% Bupivacaine With 1:200,000 Epinephrine Versus 0.5% Ropivicaine Versus 1 % Ropivicaine for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|December 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02643563||5901|
NCT02537977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ1537|CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy|CD19-directed Chimeric Antigen Receptor T Cells Therapy in Relapsed/Refractory B Cell Malignancy||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Recruiting|July 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|12 Years|70 Years|No|||August 2015|August 28, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537977||14008|
NCT02538042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063247|Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)|Strengthening Instrumental Extinction to Prevent Smoking Relapse|VLNCCue|Duke University|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538042||14003|
NCT02534623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHZ trial 001|Postoperative Quality of Recovery After Transurethral Resection of the Bladder|Postoperative Quality of Recovery After Transurethral Resection of the Bladder: Spinal Versus General Anesthesia||General Hospital Zadar|No|Not yet recruiting|September 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02534623||14266|
NCT02543463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1101v2|Navigation With X3 vs Non-Navigation With X3 Study|Comparison X3 Study Between Navi-THA and Non-navi-THA||Stryker Japan K.K.|No|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||January 2016|March 7, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543463||13589|
NCT02630459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120309|A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention||Amgen|Yes|Recruiting|January 2016|December 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|459|||Both|20 Years|65 Years|No|||February 2016|February 26, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630459||6907|
NCT02530359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCGFAA-DRA-PFD|Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney Injury|Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury|AKI|Hospital Civil de Guadalajara|Yes|Not yet recruiting|October 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|85 Years|No|||August 2015|August 19, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530359||14592|
NCT02542787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBX-001|Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis|A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis||Canbex Therapeutics Ltd|Yes|Recruiting|August 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||November 2015|November 26, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02542787||13641|
NCT02531789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011/115491|Procedure Outcome Predictor (POP) Using the Complement Cascade|Procedure Outcome Predictor (POP) Using the Complement Cascade|CPOP|University of Exeter|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|45 patients receiving elective colorectal surgery|August 2015|August 20, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02531789||14483|
NCT02535221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCP12|Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer|Randomized Trial of Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With Estrogen Receptor-Positive HER2 Negative Breast Cancer||Peking University|No|Not yet recruiting|September 2015|December 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Female|35 Years|55 Years|No|||August 2015|August 26, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02535221||14220|
NCT02535234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA011015|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||November 12, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535234||14219|
NCT02643719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01981|Migraine Treatment in ED|Evaluation of a Behavioral Program for Migraineurs in the Emergency Department.||New York University School of Medicine|Yes|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643719||5889|
NCT02643732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170-11-15|Fatigue in Sarcoidosis - Treatment With Methylphenidate|Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate|FaST-MP|University of East Anglia|Yes|Not yet recruiting|May 2016|July 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643732||5888|
NCT02533843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_OASIS|Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation|Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation|OASIS|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|April 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02533843||14326|
NCT02539433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #03-117|Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)|Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)||Northwell Health|No|Completed|December 2003|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|22|||Both|23 Years|81 Years|No|||August 2015|August 31, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02539433||13896|
NCT02539446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201312077RINC|Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease|The Effects of Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease||National Taiwan University Hospital|No|Recruiting|October 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|October 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02539446||13895|
NCT02536261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSIP-1586|Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus|Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus||Ruijin Hospital|Yes|Recruiting|November 2015|||December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Whole blood; urine; tumor specimens (if possible)|Both|15 Years|70 Years|No|Non-Probability Sample|invasive prolactinomas involving the cavernous sinus|January 2016|January 29, 2016|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02536261|2 Years|14140|
NCT02552524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201091|Effect of rTMS in Pathological Gamblers|Study of the Effect of an Active rTMS Session in Pathological Gamblers: Impact on Craving and Severity of These Behaviors||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|December 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02552524||12892|
NCT02556502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01149-40|18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study|18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study|MAF|Central Hospital, Nancy, France|Yes|Recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|November 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556502||12587|
NCT02550171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-094|BioGene Bank Cohort Study for Approved Research Requests|The BioGene Bank Cohort Study is a Collection of Human Blood Samples (DNA and Plasma) Along With De-identified (Coded) Health Information, Questionnaire Responses on Environment and History of Family Disease to be Used for Research|BGB|Northwell Health|No|Completed|March 2009|August 2014|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7056|Samples With DNA|DNA|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anyone receiving care at the NS LIJ Health System and family members.|September 2015|September 14, 2015|October 9, 2013||No||No||https://clinicaltrials.gov/show/NCT02550171|10 Years|13073|
NCT02535754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01079|Interventions to Increase Workplace Wellness|Interventions to Increase Workplace Wellness||University of British Columbia|Yes|Completed|April 2010|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|682|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535754||14179|
NCT02535767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14495|Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali|Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali|PQSAFETY|University of California, San Francisco|Yes|Completed|August 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02535767||14178|
NCT02635607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-IISP-01|Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol|A RCT Study to Evaluate the Safety and Efficacy of the Fixed Day-5 Antagonist Protocol Versus the Flexible Antagonist Protocol for the Controlled Ovarian Stimulation in Chinese Women With Predicted High Ovarian Response|GnRH|Chong Qing Reproducive and Genetic Institute|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|35 Years|No|||December 2015|December 16, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02635607||6513|
NCT02535065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013 Spiral-Z|Zenith® Low Profile AAA Endovascular Graft|Clinical Study Plan for the Zenith® Low Profile AAA Endovascular Graft||Cook||Suspended|August 2014|September 2023|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|November 16, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535065||14232|
NCT02535078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMCgp100-201|Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma|A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma||Immunocore Ltd|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535078||14231|
NCT02543125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guangdongwchhi4|Nasal High Frequency Oscillatory Versus Nasal Intermittent Positive Pressure Ventilation in Neonate After Extubation|Nasal High Frequency Oscillatory Versus Nasal Intermittent Positive Pressure Ventilation in Neonate After Extubation||Guangdong Women and Children's Hospital and Health Institute|Yes|Active, not recruiting|February 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|N/A|3 Months|No|||February 2016|February 22, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02543125||13615|
NCT02536001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-15-ZIV|Prospective Randomized Study to Compare Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes|Prospective Randomized Study to Compare Anatomical, Functional and Sexual Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes While Preserving the Uterus||Ziv Hospital|Yes|Not yet recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|30 Years|85 Years|No|||May 2015|August 26, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02536001||14160|
NCT02543619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZad UMS|Efficacy of Two Injection Techniques on Success Rate of Inferior Alveolar Nerve Anesthesia|Comparative Efficacy of Gow-Gates and Inferior Alveolar Nerve Block Injection Techniques on Success Rate of Anesthesia in Patients With Symptomatic Irreversible Pulpitis||Azad University of Medical Sciences|Yes|Completed|March 2015|August 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543619||13577|
NCT02532907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1794|Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs|Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs||University of Colorado, Denver|No|Recruiting|August 2015|September 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Some of the data, blood and tissue that is taken during the study will be kept and used in      future research to learn more about _Hepatitis C.|Both|18 Years|70 Years|No|Probability Sample|Recruitment of patients will primarily occur through the Hepatology clinic, so        non-veterans will be recruited. A total of 20 HCV-positive patients who will be treated        with FDA-approved treatments as covered by the patient's insurance. Half of the patients        will be treatment-naïve prior to enrollment and half will be treatment-experienced with        either null response or relapse, i.e., persistent viremia. An equal proportion in each        group will be biopsied at 4 versus 12 weeks after first dosing of DAA. Patients will be        subjected to two biopsies during the life of the study.|February 2016|February 22, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02532907||14398|
NCT02541825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingShijitan|Using Covered Stent of Diameter of 7mm in TIPS|Using Covered Stent of Diameter of 7mm in a Prospective, Single Blind, Randomized, Controlled Study of TIPS(Transjugular Intrahepatic Portosystemic Stent Shunt )||Beijing Shijitan Hospital|Yes|Active, not recruiting|August 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02541825||13714|
NCT02643862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients|Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients|MAP-X|Stanford University|Yes|Active, not recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|55 Years|No|||December 2015|December 28, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02643862||5878|
NCT02535624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PELVIC001|Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures|Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures - Quasi-randomized Clinical Trial of 56 Hemodynamically Unstable Patients With Injury Severity Score ≥ 33||Uppsala University|No|Completed|February 2003|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02535624||14189|
NCT02543190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408M52923|System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program|System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program|SWIFT|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543190||13610|
NCT02543281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11299|Adaptive CRT Effect on Electrical Dyssynchrony|Adaptive CRT Effect on Electrical Dyssynchrony|aCRT-ELSYNC|Oregon Health and Science University|Yes|Enrolling by invitation|April 2015|May 2021|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543281||13603|
NCT02541864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS12-CT11-08|Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication|Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial||Kaohsiung Veterans General Hospital.|Yes|Completed|July 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|20 Years|N/A|No|||September 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541864||13711|
NCT02535559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-15-0500|Longitudinal Evaluation of Teens Against Tobacco Use|Longitudinal Evaluation of Teens Against Tobacco Use||The University of Texas Health Science Center, Houston|No|Not yet recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02535559||14194|
NCT02544243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI-05|Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer|Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Vinorelbine Plus Gemcitabine Versus Vinorelbine Plus Cisplatin||Shandong Cancer Hospital and Institute||Not yet recruiting|September 2015|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|70 Years|No|||September 2015|September 5, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02544243||13529|
NCT02530983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009873|Mayo Clinic Conduit Report Card Questionnaires (CONDUIT)|Mayo Clinic Conduit Report Card Questionnaires|CONDUIT|Mayo Clinic|No|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing or having already undergone an esophagectomy or esophageal        reconstruction.|January 2016|January 18, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530983||14544|
NCT02539823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSBI HSM# 087-14|Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans|To Characterize the Acute and Short-term Effects of Cannabidiol (CBD) Administration on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans||Hurd,Yasmin, Ph.D.|Yes|Not yet recruiting|September 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|65 Years|No|||August 2015|September 2, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539823||13867|
NCT02535832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0585-F6A|Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)|Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)||University of Kentucky|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535832||14173|
NCT02528409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1115|Vortioxetine for Binge Eating Disorder|A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder||University of Chicago|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528409||14742|
NCT02535442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-15-0003|Nasal Swab Study to Explore the Nasal Microbia|An Exploratory Study to Evaluate the Microbial Consortia and the Host Inflammatory Factors Present in the Nasal Passages of Patients During Upper Respiratory Symptomology and When Healthy||Kimberly-Clark Corporation|No|Recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|None Retained|microbiota from nasal samples|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of male and female subjects with common cold symptoms.|December 2015|December 11, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02535442||14203|
NCT02535455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A118121|Acceptance and Compassion to Enhance Self-care Pilot|Development and Pilot of Positive Self-Reappraisal Emotion Regulation Intervention to Improve Self-Care Among HIV+ Substance Users|ACES Pilot|University of California, San Francisco|No|Not yet recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02535455||14202|
NCT02542865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204477|A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Immunity Outcomes in School Children|Impact of a Multiple Micronutrient (MMN) Beverage Powder on Immunity Outcomes in School Children (7-10yrs; Inclusive) in India and Bangladesh: a Randomised, Double Blind, Controlled, and Multicenter Trial||GlaxoSmithKline|No|Not yet recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|624|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542865||13635|
NCT02528604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPAPAF-65 V2.0|Electrical Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation|Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation in Over 65s - The CAPAPAF-65 Study|CAPAPAF-65|Eastbourne General Hospital|No|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528604||14727|
NCT02528617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-285|The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease|The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease||Baylor Research Institute|No|Recruiting|July 2015|July 2021|Anticipated|July 2021|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|4 Years|14 Years|No|||August 2015|August 18, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528617||14726|
NCT02528877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14129|Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis|A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis||City of Hope Medical Center|Yes|Active, not recruiting|November 2015|||November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02528877||14706|
NCT02537041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-02|Non-invasive Evaluation of Myocardial Stiffness by Elastography|Non-invasive Evaluation of Myocardial Stiffness by Elastography in the Elderly Suffering From Isolated Diastolic Heart Failure: New Diagnostic Tool?|Elasto-Cardio|French Cardiology Society|No|Recruiting|September 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02537041||14080|
NCT02537054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUG-201202-EyNeP|Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)|Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)|EyNeP|University Hospital, Bonn|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02537054||14079|
NCT02535702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150186|Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction|Development of Neuroimaging Methods to Assess the Neurobiology of Addiction||National Institutes of Health Clinical Center (CC)||Not yet recruiting|August 2015|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|360|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02535702||14183|
NCT02529917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-95|The Benefits of Hemp Protein Supplementation During Resistance Training|The Benefits of Hemp Protein Supplementation During Resistance Training||University of Saskatchewan|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529917||14626|
NCT02535585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1134|Arthroscopic Treatment of Anterior Shoulder Dislocation Using Knotted and Knotless Anchors|Arthroscopic Treatment of Anterior Shoulder Dislocation Using Knotted and Knotless Anchors||University of Sao Paulo|No|Not yet recruiting|November 2015|November 2019|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|N/A|N/A|No|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02535585||14192|
NCT02528968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-MED-13|National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A|UK-PK Study: National Study of the Implementation of a Pharmacokinetic-Focused Educational Package for Patients Living With Severe Haemophilia A|UK-PK|Hampshire Hospitals NHS Foundation Trust|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528968||14699|
NCT02529033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504777|Hemodynamic Survey Cardiac Surgical Scenarios|Comparative Hemodynamic Assessment Between Lidco Rapid and Pulmonary Artery Thermodilution||University of Iowa|Yes|Enrolling by invitation|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiac Fellowship trained Anesthesiologists|August 2015|August 18, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02529033||14694|
NCT02628548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001851|Neural Correlates of Successful Cognitive Aging|Neural and Cognitive Changes Associated With Mental Training in Older Adults||Massachusetts General Hospital|No|Recruiting|November 2015|December 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|200|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02628548||7054|
NCT02628561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tdcstroke|Transcranial Direct Current Stimulation Associate to Constraint Induced Movement Therapy Over Premotor Cortex in Severe Stroke|||Federal University of Paraíba|No|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02628561||7053|
NCT02539680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-145|Intestinal Phosphate Transporter Expression in CKD Patients|Joint Study on Intestinal Phosphate-TRAnsporter Expression in CKD Patients|PeTRA|RWTH Aachen University|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02539680||13878|
NCT02534402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01147|Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression|Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management: COPD Prednisone Sub-Study||University of British Columbia|No|Recruiting|August 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|19 Years|95 Years|No|||August 2015|August 31, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02534402||14283|
NCT02533739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/28MAR/143|Vestibular Disorder and Visuo-spatial Functions|Impact Des déficits Vestibulaires Sur le développement Des Fonctions Visuo-spatiales.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|September 2015|||December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|2 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02533739||14334|
NCT02628808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-33|Susceptibility Genes in Autism Spectrum Disorders|Search of Susceptibility Genes in Autism Spectrum Disorders||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|August 2008|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|DNA from subjects will be stored in the biobank of our study. From some patients with      deleterious mutations in synaptic genes, cells (PBMC, Keratinocytes ou Fibroblasts) will be      sampled from derivation in Induced Pluripotent Stem Cells.|Both|18 Months|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|For all patients included in the study, .|November 2015|December 9, 2015|September 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02628808||7034|
NCT02533323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-NK/T-5010|P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens|Phase 2 Trial of Pegaspargase-Gemox Chemotherapy in Newly Diagnosed, Nasal Type, Extranodal Natural Killer/T-cell Lymphoma||Sun Yat-sen University|Yes|Recruiting|January 2012|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533323||14366|
NCT02542475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001011|Low Field Magnetic Stimulation: Open Label Study.|Low Field Magnetic Stimulation: Open Label Study.||Mclean Hospital|No|Active, not recruiting|September 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542475||13665|
NCT02529891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208090|Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease|Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease|LAVOLEX|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with exacerbation of COPD and Healthy volonteers|November 2015|November 30, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529891||14628|
NCT02644265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONNECT-ME 1.0|CONNECT-ME: Consciousness in Neurocritical Care Cohort Study Using fMRI and EEG|CONNECT-ME: CONsciousness in NEurocritical Care cohorT Study Using fMRI and EEG|CONNECT-ME|Rigshospitalet, Denmark|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood (serum), cerebrospinal fluid|Both|16 Years|N/A|No|Non-Probability Sample|The target population comprises adult non-communicating patients with DoC due to TBI and        non-TBI (age > 15 years). The investigators will apply the classical definition of        consciousness as a "state of full awareness of the self and one's relationship to the        environment". The term DoC includes patients in coma, VS/unresponsive wakefulness state        (UWS), and MCS, as well as those who have emerged - but not completely - from MCS (eMCS).|February 2016|February 11, 2016|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02644265|1 Year|5847|
NCT02536976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04412-15-A|Mirabegron in Parkinson Disease and Impaired Cognition|A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition|MICT-PD|HealthPartners Institute|Yes|Recruiting|December 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|80 Years|No|||August 2015|December 2, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536976||14085|
NCT02536989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96-C009|Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot|Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot||Far Eastern Memorial Hospital|Yes|Completed|March 2009|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||August 2010|February 5, 2016|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT02536989||14084|
NCT02538575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00387-42|6 Minute Walk Test in Cystic Fibrosis|Prognosis Contribution of the 6 Minute Walk Test in Cystic Fibrosis : Prospective Multicenter Study|MUCO-TM6|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|September 2015|March 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|August 31, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538575||13962|
NCT02530190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSER 2015|Investigation of Popular Recovery Techniques for Ultramarathon Recovery|Investigation of Popular Recovery Techniques for Ultramarathon Recovery||Western States Endurance Run Research Foundation|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530190||14605|
NCT02530203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS-PAF|Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation|Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation|SCS-PAF|Medtronic BRC|No|Recruiting|February 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02530203||14604|
NCT02633930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY20151203-2|Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy|Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial||Xijing Hospital of Digestive Diseases|Yes|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|566|||Both|18 Years|70 Years|No|||December 2015|December 18, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633930||6641|
NCT02540434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408015402|Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions|Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (TOP-CLOT)|TOP-CLOT|Weill Medical College of Cornell University|No|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|133|||Both|18 Years|100 Years|No|||October 2015|October 9, 2015|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540434||13820|
NCT02542592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_08_2015a|Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients|Effect of Preoperative Intravenous High Dose Methylprednisolone on Immune Signaling in Patients Scheduled for Total Hip-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Both|55 Years|80 Years|No|||September 2015|September 9, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542592||13656|
NCT02541370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s2015-080-03|Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133|Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies||Chinese PLA General Hospital|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||September 2015|September 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541370||13749|
NCT02643511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STGAF|Hemiablative Focal Brachytherapy Pilot Study|Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer||St George Hospital, Australia|No|Recruiting|September 2015|July 2025|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02643511||5905|
NCT02534090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001806|Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy|Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy|NIRS/NICU2|Brigham and Women's Hospital|No|Not yet recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|28 Days|Accepts Healthy Volunteers|Non-Probability Sample|Premature infants from 32 weeks to 36 weeks 6 days of post menstrual age.|August 2015|August 26, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534090||14307|
NCT02534103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0879|Relationship Between a Combined Index of Diastolic and Systolic Performance and Intraoperative Hemodynamic Changes During Off-pump Coronary Bypass Surgery|||Yonsei University|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|20 Years|N/A|No|Non-Probability Sample|patients with coronary artery obstructive disease planned to have multivessel OPCAB|August 2015|August 24, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534103||14306|
NCT02540993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16244|Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease|FIDELIO-DKD|Bayer|Yes|Recruiting|September 2015|May 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4800|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540993||13778|
NCT02534675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141758|Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers|An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Malignancies and Poor Prognosis|I-PREDICT|University of California, San Diego|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|225|Samples With DNA|Primary tumor tissue or metastases|Both|18 Years|N/A|No|Non-Probability Sample|Patients with incurable malignancies with aggressive biology|August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534675||14262|
NCT02534688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kingchulalongkorn|Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients|Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients||King Chulalongkorn Memorial Hospital||Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534688||14261|
NCT02635373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-093|European Calciphylaxis Registry Network|European Calciphylaxis Registry Network|EuCalNet|RWTH Aachen University|No|Recruiting|December 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosed CUA|January 2016|January 11, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02635373|5 Years|6531|
NCT02540655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB02|Efficacy and Safety Study of Mesenchymal Stem Cells (Stemchymal®) in Polyglutamine Spinocerebellar Ataxia|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia||Steminent Biotherapeutics Inc.|Yes|Recruiting|July 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|70 Years|No|||September 2015|September 1, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02540655||13803|
NCT02539095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01CTZ|Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection|A Double-blind, Randomized, Post-marketing Surveillance to Evaluate the Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|April 2014|December 2015|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02539095||13922|
NCT02542059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51058.091.14|Visualizing Beta Cells After Bariatric Surgery|Visualizing Beta Cells in Patients With Remission of T2DM After Bariatric Surgery|GLP1-bar|Radboud University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|Indiciduals who have undergone RYGB at least 1 year earlier at the Rijnstate Hospital in        Arnhem.|September 2015|September 16, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02542059||13696|
NCT02634723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061501|Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A|Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A||Baxalta US Inc.|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|22|||Both|N/A|N/A|No|Non-Probability Sample|Previously untreated patients (PUPs) in China with moderate to severe hemophilia A.|February 2016|February 22, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02634723||6580|
NCT02536196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFLECT|TriGuard Embolic Deflection Device to Reduced Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation|A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation|REFLECT|Keystone Heart|No|Not yet recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|285|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536196||14145|
NCT02541552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADDCAN05|Effect of Volume of Local Anesthetic for Adductor Canal Block on Quadriceps Muscle Function: A Dose Finding Study|Effect of Volume of Local Anesthetic for Adductor Canal Block on Quadriceps Muscle Function: A Dose Finding Study||Lawson Health Research Institute|No|Recruiting|April 2015|||May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02541552||13735|
NCT02630732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B²asic1|Back School or Brain School for Patients Undergoing Surgery for Lumbar Radiculopathy?|Back School or Brain School for Patients Undergoing Surgery for Lumbar Radiculopathy? A Randomized Controlled Trial With Two-year Follow-up|B²asic|Universitair Ziekenhuis Brussel|No|Not yet recruiting|January 2016|August 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2015|December 24, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02630732||6886|
NCT02538146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKentucky|Effect of Acetyl-L-carnitine on Chronic Pancreatitis|Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis||University of Kentucky|Yes|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|20 Years|90 Years|No|||August 2015|August 28, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02538146||13995|
NCT02542839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500341|rTMS and Botulinum Toxin in Primary Cervical Dystonia|Combined Therapy With rTMS and Botulinum Toxin in Primary Cervical Dystonia||University of Florida|Yes|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|75 Years|No|||November 2015|November 5, 2015|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542839||13637|
NCT02541201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC1430|The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS)|The Effect of the Consumption of Low-Fat Milk Enriched With Plant Sterols on Serum Low-Density Lipoprotein Cholesterol in Healthy Southern Chinese (COME-PASS)|COME-PASS|The University of Hong Kong|Yes|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|221|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02541201||13762|
NCT02559622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457ADE02|Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab|A Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory Evaluation of Surrogate Markers of Cardiovascular Risk in Patients With Active Chronic Plaque-type Psoriasis Treated for up to 52 Weeks With Subcutaneous (s.c.) Secukinumab (300 mg or 150 mg).|CARIMA|Novartis|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02559622||12347|
NCT02547844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EfaRiLipidomics|Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla|Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla®||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02547844||13252|
NCT02546349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140420|Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA|The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide||Taipei Veterans General Hospital, Taiwan|No|Active, not recruiting|July 2014|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|143|||Both|40 Years|90 Years|No|||September 2015|September 9, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02546349||13367|
NCT02546362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50212|CEFALY® Device in the Treatment of Patients With Fibromyalgia|A Single Center, Pilot, Open Trial of the CEFALY® Device in the Treatment of Patients With Fibromyalgia||Cefaly Technology|No|Recruiting|October 2015|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546362||13366|
NCT02546375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871052|A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands|A Retrospective Observational Research Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands||Pfizer|No|Active, not recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|CML out-patient clinics|March 2016|March 11, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02546375||13365|
NCT02554006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150595|Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings|Predischarge Bundle for Patients in Dual Antiplatelet Therapy to Minimize the Negative Impact of Nuisance Bleedings on Quality of Life: a Randomized Controlled Trial.|BATMAN|University Hospital of Ferrara|Yes|Active, not recruiting|September 2015|April 2017|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|448|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554006||12778|
NCT02554019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990|Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus|A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus|BT063 in SLE|Biotest|Yes|Recruiting|August 2015|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554019||12777|
NCT02541721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-01-01|Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses|An Open-label Study to Investigate the Effectiveness in Clinical Symptomatic Control and Tolerability of Medical Device LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses||Health Products Research and Development Lda.|No|Not yet recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||August 2015|September 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541721||13722|
NCT02534272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6110|Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota|Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota||University Hospital, Strasbourg, France|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|320|Samples Without DNA|Stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Symptomatic subjects will be recruited during their visit to hospital for intestinal        symptoms. Asymptomatic subjects will be recruited in the general population.|November 2015|November 6, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02534272||14293|
NCT02534532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18250|Atrial Fibrillation Screening With a Smartphone Device and iECG Application|Atrial Fibrillation Screening With a Smartphone Device and iECG Application|AFScreenCol|Bayer|No|Withdrawn|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|0|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects included in the study are patients 65 years and older reaching programmed primary        care counselling, and who are willingly to participate and do not present any exclusion        criteria for the screening|November 2015|November 24, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02534532||14273|
NCT02538835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46332|The Effect of Group Treatment for Depression: A Study of Metacognitive Therapy, Mindfulness and Support Groups|The Effect of Group Treatment for Depression: A Randomised Controlled Study of Metacognitive Therapy, Mindfulness and Support Groups||University of Southern Denmark||Not yet recruiting|November 2015|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|65 Years|No|||August 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538835||13942|
NCT02538848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4010.PCT001|Study of HTD4010 in Healthy Volunteers and T2DM Patients|A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (T2DM)||HighTide Biopharma Pty Ltd|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|68|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538848||13941|
NCT02530125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 15H08|Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission|Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission||Northwestern University|Yes|Recruiting|September 2015|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530125||14610|
NCT02541773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 10 20 Jan 2016|Novel Vascular Biomarkers Behaviour and Clinical Value in Heart Failure and CRT|The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response|COVERT-HF|University Hospitals Coventry and Warwickshire NHS Trust|No|Active, not recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|58|Samples Without DNA|Participants with have peripheral and coronary sinus samples taken for plasma and serum.|Both|18 Years|N/A|No|Non-Probability Sample|Chronic heart failure patients who have been referred for and meet national criteria for        Cardiac Resynchronization Therapy implants|September 2015|March 8, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541773||13718|
NCT02643836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014D006902|Pulsed Electromagnetic Field (PEMF) Therapy for Post-Concussive Syndrome|Pulsed Electromagnetic Field (PEMF) Therapy for Post-Concussive Syndrome|PEMF|Spaulding Rehabilitation Hospital|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|30 Years|No|||January 2016|January 4, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643836||5880|
NCT02535364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015001|Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)|A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|ROCKET|Juno Therapeutics, Inc.|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535364||14209|
NCT02537327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56046|Incidence of Recurrent Caries Next to Tooth Restorations|Epidemiological Study on the Incidence and Characteristics of Secondary Caries Next to Tooth Restorations||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|Patients visiting the university dental clinic (Department of Oral Health Care) for a        dental check-up|May 2015|August 27, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02537327||14058|
NCT02530437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0966|A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction|A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction||M.D. Anderson Cancer Center|No|Not yet recruiting|February 2016|||February 2022|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530437||14586|
NCT02542670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dr Said Hammad|Whole Exome Sequencing in Colorectal Cancers in Delta Region|Whole Exome Sequencing in Colorectal Cancers in Delta Region||Tanta University|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|50|Samples With DNA|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used      for hybridization capture and NGS using the IlluminaMiSeqDx platform.|Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cancer colon with no distant metastasis Cancer colon with distant metastases control group|September 2015|September 27, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542670||13650|
NCT02628327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-496E|Assessing Patient Satisfaction|Factors Influencing Patient Satisfaction Surveys (FIPSS)|FIPSS|Wills Eye|No|Recruiting|June 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Glaucoma or glaucoma suspect|January 2016|January 8, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02628327||7071|
NCT02539238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-1352|Improving CPR Quality With Longitudinal Practice and Realtime Feedback - RCT With CEA|The Effect of a New Training Program on CPR Quality of Pediatric Healthcare Providers: A Randomized Control Trial With Economic Evaluation||Alberta Children's Hospital|Yes|Recruiting|June 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2015|September 2, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02539238||13911|
NCT02544178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSN_02|Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma|EPIBRAINRAD : Study of Neurological Complication After Radiotherapy for Glioblastoma High Grade|EPIBRAINRAD|Institut de Radioprotection et de Surete Nucleaire|No|Recruiting|April 2015|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|-  protéin S-100B, 8,12-iso-iPF2α-VI level, homocystéine        -  micro RNAs (brain-miR-112, brain-miR-161, hsa-let-7d-3p, hsa-miR-5010-3p,           hsa-miR-26a-5p, hsamiR-1285-5p, hsa-miR-151a-3p, hsamiR-103a-3p, hsa-miR-107,           hsa-miR-532-5p, hsa-miR-26b-5p, hsa-let-7f-5p, …).        -  microparticules|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients treated by radiotherapy and chemotherapy for a glioma stade IV in the        Hospital Pitié Salpetreière or in the Paul Strauss hospital from April 2015 to April 2017        will be included.|September 2015|September 4, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02544178||13534|
NCT02530736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/2247|Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis|Responsiveness of the 4 Metre Gait Speed in Patients With Idiopathic Pulmonary Fibrosis and Determination of the Minimum Important Difference|IPFRESP|Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guideliness        referred for Pulmonary Rehabilitation|August 2015|August 20, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02530736||14563|
NCT02542748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2015-5-5-01|Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients|Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients Undergoing Cesarean Section: a Randomized Double Blinded Controlled Study||Fourth Military Medical University|Yes|Recruiting|May 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||March 2016|March 16, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542748||13644|
NCT02528305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015CM|The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis|A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis||University of Bath|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|59 Years|No|||January 2016|January 7, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02528305||14750|
NCT02538783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823005|The Weigh Forward, Financial Incentives for Maintenance of Weight Loss|A Randomized Trial of Financial Incentives for Maintenance of Weight Loss||University of Pennsylvania|Yes|Not yet recruiting|November 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|190|||Both|30 Years|80 Years|No|||August 2015|September 1, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538783||13946|
NCT02536404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD334-005|Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis|||Arena Pharmaceuticals|Yes|Recruiting|November 2015|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536404||14129|
NCT02536417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2015-048|Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients|Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients: A Randomized Double-blinded Placebo Controlled Pilot Study||Fraser Health||Not yet recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|19 Years|N/A|No|||August 2015|August 27, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02536417||14128|
NCT02535169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403986016|Lifestyle-Related Health Outcomes in Prediabetes and Diabetes|Lifestyle-Related Health Outcomes in Prediabetes and Diabetes||Indiana University|No|Recruiting|May 2014|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|10 Years|21 Years|No|||January 2016|January 20, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535169||14224|
NCT02538965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-AML-002|A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia|A PHASE 2 , MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE (REVLIMID®) IN PEDIATRIC SUBJECTS 1 YEAR TO = 18 YEARS OF AGE WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA||Celgene Corporation|Yes|Recruiting|November 2015|January 2024|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|1 Year|18 Years|No|||March 2016|March 22, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538965||13932|
NCT02538978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST/CLI/143003|Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System|Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients|CLIRST III|Cesca Therapeutics, Inc.|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|40 Years|85 Years|No|||August 2015|August 31, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538978||13931|
NCT02532582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00105002|Assessment of Patient Positioning|Effort to Reduce Postoperative Brachial Neuropraxia Through Nerve Compression||Northwestern University|No|Enrolling by invitation|May 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital        (surgical setup is similar for living liver donor surgery and liver surgery (e.g.        retractors, arterial line for monitoring, surgeons). Investigators will approach both        living liver donors and liver surgery patients for enrollment to receive additional        neuromuscular monitoring.|December 2015|December 23, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02532582||14423|
NCT02543294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0379|REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)|REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2012|||September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543294||13602|
NCT02529631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/07|RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity|Randomized, Double-blind, Clinical Investigation to Compare Orlistat 60 mg and a Customized Polyglucosamine, Two Treatment Methods for the Management of Overweight and Obesity||Certmedica International GmbH|No|Completed|November 2009|August 2013|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02529631||14648|
NCT02529644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-926|Church-based HIV Screening: Taking It to the Pews|Assessing HIV Screening in African American Churches|TIPS|University of Missouri, Kansas City|Yes|Recruiting|July 2015|February 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1540|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02529644||14647|
NCT02533271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT2015-03|Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer|Phase III Study of Short-term Radiotherapy Plus Neoadjuvant Chemotherapy Versus Preoperative Long-term Chemoradiotherapy in Locally Advanced Rectal Cancer|STELLAR|Chinese Academy of Medical Sciences|Yes|Recruiting|August 2015|August 2025|Anticipated|August 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|552|||Both|18 Years|70 Years|No|||August 2015|August 22, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02533271||14370|
NCT02540590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2013|Post-operative Blood Flow Measurements of the Oral Mucosa|Evaluation of Laser Speckle Contrast Imaging for Assessment of Oral Mucosal Blood Flow Following Periodontal Plastic Surgery: an Exploratory Observational Study|LASCAM|Semmelweis University|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caucasians subjects presenting multiple Miller Class I. and II. gingival recessions        (Multiple Adjacent Recession Type Defects, MARTD) were recruited in the Department of        Periodontology in Semmelweis University.|September 2015|September 3, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540590||13808|
NCT02545036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH104-REC1-041|Combined Western and Traditional Chinese Medicine Daycare for CKD Patients|Clinical Study of Combined Western Medicine and Traditional Chinese Medicine Daycare Model for Chronic Kidney Disease Patients||China Medical University Hospital|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||September 2015|September 8, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02545036||13468|
NCT02534714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|632002|Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016|Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016||OSF Healthcare System|No|Recruiting|July 2015|July 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|580|||Both|50 Years|N/A|No|Non-Probability Sample|(Part 1, Retrospective Study) - patients diagnosed with any form of spinal disease who        underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from        November 1, 2012 to October 31, 2014 who had a serum vitamin D level collected as standard        of care prior to surgery.        (Part 2, Prospective Study) - patients diagnosed with any form of spinal disease that        underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel        Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016 who had a serum vitamin        D level and bone marrow density scan collected as standard of care prior to surgery.|August 2015|August 28, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534714||14259|
NCT02534987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI108680-01|Integrated Clinical Prediction Rules: Bringing Evidence to Diverse Primary Care Settings|Integrated Clinical Prediction Rules: Bringing Evidence to Diverse Primary Care Settings|iCPR2|Boston University|No|Not yet recruiting|October 2015|March 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|N/A|70 Years|No|||August 2015|August 27, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02534987||14238|
NCT02539017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renyu-012|The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer|||First Affiliated Hospital Xi'an Jiaotong University||Not yet recruiting|November 2015|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Female|18 Years|70 Years|No|||August 2015|September 1, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02539017||13928|
NCT02533141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-240215|Effect of Simvastatin Withdrawal on Ocular Endothelial Function|Effect of Simvastatin Withdrawal on Ocular Endothelial Function||Medical University of Vienna|No|Not yet recruiting|December 2015|||April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533141||14380|
NCT02533453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5551L00018|A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients|A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus|Bydureon|AstraZeneca|No|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|19 Years|75 Years|No|||February 2016|February 11, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02533453||14356|
NCT02533466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204739|Study to Investigate the Intial Stages of Enamel Erosion in Vivo|Study to Investigate the Intial Stages of Enamel Erosion in Vivo||GlaxoSmithKline|No|Not yet recruiting|October 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533466||14355|
NCT02633202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRNPC15|Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era|Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era||Sun Yat-sen University|Yes|Recruiting|November 2015|November 2020|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02633202||6697|
NCT02642627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-1504|The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area|The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area||Suneva Medical, Inc.|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||December 2015|December 29, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02642627||5973|
NCT02528396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT013|To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus|A Randomized, Monocentric, Double-blind, Multiple Daily Dose, Two-period, 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus||Adocia|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|64 Years|No|||March 2016|March 14, 2016|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02528396||14743|
NCT02539459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-070|Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus|A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy|SAGE|Fox Chase Cancer Center|Yes|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539459||13894|
NCT02539472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K14097|Early Diagnosis of Mycosis Fungoides|Evaluation of a Combination of Blood Biomarkers for the Early Diagnosis of Mycosis Fungoides|DIAPREMYF|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|620|||Both|18 Years|N/A|No|||July 2015|August 31, 2015|July 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539472||13893|
NCT02539342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caphosol Study|Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy|Caphosol Study: A Randomized Controlled Open-Labeled Trial Investigating Topical Caphosol for Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy||Medical College of Wisconsin|Yes|Not yet recruiting|December 2016|October 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Both|N/A|25 Years|No|||March 2016|March 14, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539342||13903|
NCT02633423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFLCCH|Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery|Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery||Ospedale San Raffaele|Yes|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|189|||Both|18 Years|100 Years|No|||February 2016|February 1, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02633423||6680|
NCT02633657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP108|A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome|RLS|XenoPort, Inc.|No|Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|13 Years|17 Years|No|||December 2015|March 2, 2016|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02633657||6662|
NCT02537002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2341003|Single Dose Study of PF-05230907 in Healthy Japanese Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of An Intravenous Bolus Infusion Pf-05230907 In Healthy Japanese Subjects||Pfizer|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537002||14083|
NCT02537015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-005 OLE 2|An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert|An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004|OLE2|ForSight Vision5, Inc.|No|Enrolling by invitation|August 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537015||14082|
NCT02530411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/VCC/0013|Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer|A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy|FURVA|Velindre NHS Trust|Yes|Recruiting|April 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||August 2015|August 19, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02530411||14588|
NCT02530424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-14-B01|"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "|"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "|NA-PHER2|Fondazione Michelangelo|Yes|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|32|||Female|18 Years|N/A|No|||August 2015|August 20, 2015|September 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02530424||14587|
NCT02534220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral-B|Manual Versus Oscillating-rotating Toothbrushes After Root Coverage Procedure|Gingival Margin Stability After Mucogingival Plastic Surgery. The Effect of Manual Versus Powered Toothbrushing: a Randomized Clinical Trial||University of Milan|No|Completed|February 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534220||14297|
NCT02540304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSP23320095624WC|Teen Pregnancy Prevention Replication Study|Teen Pregnancy Prevention Replication Study||Abt Associates|No|Active, not recruiting|September 2012|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|7620|||Both|13 Years|19 Years|No|||September 2015|September 4, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540304||13830|
NCT02540369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17995|To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.|PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada.|PEGASUS|Bayer|No|Recruiting|December 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with wAMD (wet age-related macular degeneration) and DME (Diabetic macular edema)        treated by retina specialist/ophthalmologist in selected Canadian clinical sites|March 2016|March 7, 2016|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02540369||13825|
NCT02542501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-ES-52014-219|Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues|A Prospective Post Marketing Non Interventional Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive LHRH Analogues and to Evaluate the Effect of LHRH Analogues on Lower Urinary Tract Symptoms (ANALUTS Study)|ANALUTS|Ipsen|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|458|||Male|N/A|N/A|No|Non-Probability Sample|Community sample|February 2016|February 29, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02542501||13663|
NCT02542514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLOC|Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma|Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma|iLOC|The Lymphoma Academic Research Organisation|Yes|Recruiting|September 2015|January 2019|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02542514||13662|
NCT02534454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20547|TDCS and Cognitive Retraining to Augment Pharmacotherapy for the Treatment of Nicotine Dependence|Transcranial Direct Current Stimulation (TDCS) and Cognitive Retraining to Augment Pharmacotherapy for the Treatment of Nicotine Dependence|TDCSNIC|The Mind Research Network|No|Recruiting|August 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02534454||14279|
NCT02643433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201518|Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines|Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines|MR+JE|Centers for Disease Control and Prevention, China|No|Recruiting|August 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1056|||Both|8 Months|9 Months|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02643433||5911|
NCT02643498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-109|A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer|A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02643498||5906|
NCT02644278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15-984-001|First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy|An Open-Label, Phase 1, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in Subjects With Advanced Solid Tumors or Lymphomas||Vertex Pharmaceuticals Incorporated||Recruiting|December 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|December 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644278||5846|
NCT02529410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0183|Standard Care Versus Triventricular Pacing in Heart Failure|A Multicentre Randomised Control Trial Comparing Standard Cardiac Resynchronisation Pacing With Triventricular Pacing|STRIVE HF|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|August 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02529410||14665|
NCT02530970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PR-1110|A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope|A Post Market Observational Study to Obtain Additional Information on the Use of Cormatrix® Cangaroo ECM® Envelope|SECURE|CorMatrix|No|Enrolling by invitation|October 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable electronic        device placement.|November 2015|November 5, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530970||14545|
NCT02531217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATYR1940-C-005|Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension|An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)||aTyr Pharma, Inc.|Yes|Enrolling by invitation|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531217||14526|
NCT02542410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00018628|Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study|Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study||Children's Hospital Boston|Yes|Not yet recruiting|December 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Female|18 Years|35 Years|No|||September 2015|September 3, 2015|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542410||13670|
NCT02542423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 15/479|Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.|Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure. The ENDOLUNG Study||Centre Hospitalier Universitaire de Besancon|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542423||13669|
NCT02644317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS15103|The Balance Influence of Shoe Inserts on Motor Development Delayed Children|Chung Shan Medical University Hospital Institutional Review Board||Chung Shan Medical University|No|Enrolling by invitation|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|36 Months|83 Months|No|||December 2015|December 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644317||5843|
NCT02538068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0275|The Psychology of Physical Activity|Meaning and Purpose as Predictors of Physical Activity Maintenance||University of Colorado, Denver|No|Completed|January 2014|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|160|||Both|30 Years|89 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02538068||14001|
NCT02540915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1248|The Children's Spine Foundation and Study Group|The Children's Spine Foundation and Study Group||University of Colorado, Denver|No|Recruiting|November 2013|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|1000|||Both|N/A|12 Years|No|Non-Probability Sample|All patients 12 and under that are being treated at Children's Hospital Colorado        Orthopaedic department for a chest wall deformity, spine deformity and/or spinal disorder.|March 2016|March 3, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02540915|10 Years|13783|
NCT02528760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Cirrhosis-005|To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis|To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study||Institute of Liver and Biliary Sciences, India|No|Recruiting|September 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|162|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528760||14715|
NCT02541422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2015-27|Use of NAC in Alleviation of Hangover Symptoms|Use of NAC in Alleviation of Hangover Symptoms||St. Luke's Hospital and Health Network, Pennsylvania|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541422||13745|
NCT02630745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perio 2|Immediate Verses Delayed Surgical Periodontal Therapy After Endodontic Treatment in Endo Perio Lesion With Communication|Evaluation of the Effect of Immediate and Delayed Surgical Periodontal Therapy After Non-surgical Endodontic Treatment on Periodontal Healing in Concurrent Endodontic Periodontal Lesion With Communication-A Randomized Clinical Trial"||Postgraduate Institute of Dental Sciences Rohtak|Yes|Active, not recruiting|June 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02630745||6885|
NCT02537821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKSF-01-2014|HLA Sensitization in Severely Burned Patients|HLA Sensitization in Severely Burned Patients||University of Zurich||Recruiting|June 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Severely burned patients|August 2015|August 28, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02537821||14020|
NCT02530021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-15|Heart Rate Variability (HRV) Testing Compared With Exercise Stress Test in Hospitalized Patients With Chest Pain|Sixty Minutes Heart Rate Variability Testing Compared With Non-invasive Exercise Stress Test in Hospitalized Patients With Suspected Angina Pectoris||Meir Medical Center|Yes|Recruiting|August 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients with suspected ischemic heart disease requiring further evaluation.|March 2016|March 14, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530021||14618|
NCT02542722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-CTS-5125|Type 2 Diabetes Prevention|Prevention of Type 2 Diabetes Mellitus (Egabro-Pizarra Study)|PIZARRA|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|No|Completed|January 2009|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|390|||Both|40 Years|65 Years|No|||May 2015|September 7, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02542722||13646|
NCT02531516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106935|An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS|ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy||Aragon Pharmaceuticals, Inc.|Yes|Recruiting|November 2015|October 2026|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1500|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531516||14503|
NCT02531022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823025|Evaluating Increasing Physical Activity After Hospitalization for Acute Coronary Syndrome|A Randomized, Controlled Trial Evaluating Methods to Use Physical Activity to Improve Outcomes After Hospitalization for Acute Coronary Syndrome||University of Pennsylvania|No|Enrolling by invitation|February 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531022||14541|
NCT02643602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaBicTheo|Does Bicarbonate in Addition to Theophylline Reduce CIN?|Does Bicarbonate in Addition to Theophylline Reduce Contrast Induced Nephropathy Compared to Sodium Chloride?||Technische Universität München|No|Completed|December 2005|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02643602||5898|
NCT02635477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAIM ASP 2015|Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults|Get Going: Fellow-Led Trial of an Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults Transitioning From a Cardiovascular Hospitalization to Home|AAIMASP|American College of Cardiology||Not yet recruiting|January 2016|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|70 Years|100 Years|No|||January 2016|January 6, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02635477||6523|
NCT02534324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397/57|The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department|The Effect of Pre-discharge Blood Pressure on the Follow-up Outcomes After Managing the Patients With Asymptomatic Severe Hypertension in Emergency Department||Chulalongkorn University|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (≥18 years old) who presented in our ED with systolic BP (SBP) greater or        equal to 180 mmHg and diastolic BP (DBP) ≥ 100 mmHg were consecutively enrolled in this        study.|February 2016|February 16, 2016|August 25, 2015||No||No|February 16, 2016|https://clinicaltrials.gov/show/NCT02534324|7 Days|14289|The results may not be generalizable to other centers with different treatment practices. We still had a considerable percentage of patients who were lost-to-follow-up that may have affected the results. The size of population was relatively small.
NCT02534337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-FOX4/HCC|Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma|Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)||Guangxi Medical University|Yes|Active, not recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534337||14288|
NCT02534350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-218-1797|Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection|A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection||Gilead Sciences|Yes|Recruiting|December 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534350||14287|
NCT02542605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140207|To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients|Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients||Amgen|No|Recruiting|November 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|42|||Both|18 Years|45 Years|No|||January 2016|January 4, 2016|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542605||13655|
NCT02542657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#253|Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma|Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma||University of California, Davis|Yes|Recruiting|October 2015|July 2020|Anticipated|May 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542657||13651|
NCT02542527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBF1504|Evaluation of the Functionality of a Fluid Filled Single Breast Pump|C88- Pilot Study A Prospective Case Series for Evaluation of the Functionality of a Fluid Filled Single Breast Pump Applied on a Lactating Breast|C88|Medela AG|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02542527||13661|
NCT02634957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15120009|Impact of Duration Of Absolute Voice Rest on Voice Outcome After Phonomicrosurgery|Impact of Duration Of Absolute Voice Rest on Voice Outcome After Phonomicrosurgery||University of Pittsburgh|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02634957||6562|
NCT02540902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho 15-06|Study of an All Polyethylene Tibial Component|A Prospective Study of an All Polyethylene Tibial Component Used in Total Knee Arthroplasty Surgery||Golden Jubilee National Hospital|No|Not yet recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|70 Years|N/A|No|||September 2015|September 3, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02540902||13784|
NCT02532075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWU-01|The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease|The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)||University of Portsmouth|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|20|||Both|35 Years|90 Years|No|||February 2016|February 26, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02532075||14461|
NCT02530749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0579|Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients|Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients||University of Colorado, Denver|No|Recruiting|April 2014|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|This study includes patients 18 years and older with a history of brain tumor scheduled        for elective resection of tumor. Patients have to be ambulatory and be able to complete        the examination and obtain a Hopkins Frailty Score.|February 2016|February 22, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02530749||14562|
NCT02530762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-1409|Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber|A Randomized, Double-Blind, Crossover Study to Assess the Acute Gastrointestinal Tolerability Following a Single Serving of Cba-1, a Novel Dietary Fiber, in Healthy Men and Women||Cargill|Yes|Completed|September 2014|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|45|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02530762||14561|
NCT02548065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOUSenese|Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Fibromyalgia Syndrome|Efficacy and Tolerability of Balneotherapy With Mineral Water Named" Debole of Vetriolo" in Patients With Fibromyalgia Syndrome (FS): A Randomized Double Blind Controlled Clinical Trial|VET|Azienda Ospedaliera Universitaria Senese|Yes|Active, not recruiting|April 2015|March 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548065||13235|
NCT02552602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGPHD2015|The Role of Multivitamins in Pediatric HIV Management in Nigeria|The Role of Multivitamins in Pediatric HIV Management in Nigeria: A Randomized Controlled Study||University of the West of Scotland|Yes|Active, not recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|190|||Both|5 Years|12 Years|No|||September 2015|September 16, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02552602||12886|
NCT02550093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU86297|The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold|The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study||Northwestern University|No|Active, not recruiting|April 2015|April 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02550093||13079|
NCT02560649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYRAMID|An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients|A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients||Ruijin Hospital||Active, not recruiting|May 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|324|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02560649||12268|
NCT02560662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhysSurg-B|PhysSurg-B : Physical Exercise in Relation to Surgical Operations - Breast Cancer|PhysSurg-B : Physical Exercise in Relation to Surgical Operations a Prospective Open-label Randomized Controlled Study of the Effect of Physical Exercise on Recovery and Adverse Events After Breast Cancer Surgery|PhysSurg-B|Sahlgrenska University Hospital, Sweden|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Female|N/A|N/A|No|||September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560662||12267|
NCT02538198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-129|Lenalidomide Maintenance in Plasma Cell Myeloma|Lenalidomide Maintenance in Plasma Cell Myeloma||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538198||13991|
NCT02538302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92.121.505|Minirin Versus Oxybutynin for Nocturnal Enuresis in Children|Minirin Versus Oxybutynin for Nocturnal Enuresis in Children||Hormozgan University of Medical Sciences|Yes|Completed|July 2013|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|5 Years|14 Years|No|||August 2015|August 29, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538302||13983|
NCT02531451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004872-47|The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise in Healthy Adults|The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise|NSAID2015|Karolinska Institutet|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531451||14508|
NCT02531737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14041/REFRACT|Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer|Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy|REFRACT|University Hospital, Limoges|Yes|Not yet recruiting|September 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||August 2015|August 23, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02531737||14487|
NCT02534415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YU-351|Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure|Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure||Marmara University|No|Completed|August 2013|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02534415||14282|
NCT02542618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51699.078.15|The Efficacy of Inquiry Based Stress Reduction (IBSR) for Depression, a Clinical Trial|The Efficacy of Inquiry Based Stress Reduction (IBSR) for Depression, a Randomized Clinical Trial||Erasmus Medical Center|No|Recruiting|October 2015|March 2020|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02542618||13654|
NCT02635620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQualLife|Changes in Psychological and Somatic Parameters Associated With Changing From Smoking to E-cigarettes|Changes in Lung Function Parameters, Bronchial Reactivity, State of Health and Smoking Behaviour Associated With Changing From Conventional Smoking to Electronic Cigarettes|EQualLife|Ludwig-Maximilians - University of Munich|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of smokers who want to start using electronic cigarettes.        Control group contains smokers who stop smoking in the framework of a clinical conducted        program.|December 2015|December 16, 2015|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02635620||6512|
NCT02539043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36341214.3.00005345|Effects of Ultrasound Cavitation Focused on Located Adiposity|Effects of Ultrasound Cavitation Focused on Located Adiposity: Pilot Study||Federal University of Health Science of Porto Alegre|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Female|19 Years|49 Years|Accepts Healthy Volunteers|||August 2015|September 1, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02539043||13926|
NCT02539056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08CON|The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte)|This Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) in Patients With Cartilage Defects in Their Knees.||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|July 2012|August 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539056||13925|
NCT02530450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110049H|Continuous Glucose Monitor in Children With Poorly Controlled Diabetes|iPro Continuous Glucose Monitor in Children With Poorly Controlled Diabetes: A 6-Month, Randomized, Interventional Pilot Study||The University of Texas Health Science Center at San Antonio|No|Completed|May 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|7 Years|17 Years|No|||February 2016|February 8, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530450||14585|
NCT02530463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0930|Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Combination of Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530463||14584|
NCT02532985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-1411|Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber|A Randomized, Double-Blind, Crossover Study to Assess Gastrointestinal Tolerability of Cba-1, a Novel Dietary Fiber, Using Three Dose Levels at Multiple Eating Occasions in Healthy Men and Women||Cargill|Yes|Completed|October 2014|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|45|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532985||14392|
NCT02532998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6400C00004|A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects|A Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 Following Single-Dose Administration to Healthy Male Subjects||AstraZeneca|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|8||Anticipated|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02532998||14391|
NCT02537444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-208|ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)|||Acerta Pharma BV||Recruiting|November 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Female|18 Years|N/A|No|||August 2015|November 11, 2015|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537444||14049|
NCT02535299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1|Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 Treatment|The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog Treatment|Par-4；GLP-1|Third Military Medical University|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02535299||14214|
NCT02532322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00006330|Efficacy of Acetaminophen in Posterior Fossa Surgery|Efficacy of Intravenous Acetaminophen as Analgesic Adjuvant Therapy in Children Undergoing Posterior Fossa Surgery||Children's Research Institute|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|2 Years|12 Years|No|||November 2015|November 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532322||14443|
NCT02534883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25065|Cervical Ripening in Postmenopausal Women|Cervical Ripening in Postmenopausal Women: A Randomized, Double Blind, Placebo Controlled Trial||St. Louis University|No|Recruiting|August 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Female|45 Years|85 Years|No|||March 2016|March 16, 2016|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534883||14246|
NCT02533219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCH- LDOPA|Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia|Phase II Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia|[18F]-DOPA|Baylor College of Medicine||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|64 Years||||August 2015|August 25, 2015|August 24, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02533219||14374|
NCT02528357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212|GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1)|A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors||GlaxoSmithKline|No|Recruiting|September 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|264|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02528357||14746|
NCT02539940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4448-06/15|Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment|A Prospective Observational Study Using Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment|Apollo|Jena University Hospital|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The study population comprises patients in Germany who undergo treatment with the ELUTAX        SV-DEB that is applied for treatment of peripheral arterial disease (PAD) in        below-the-knee vessels.|December 2015|December 4, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539940||13858|
NCT02541149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Annexin A2|Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma|Evaluation of Annexin A2 as a Novel Diagnostic Marker for Hepatocellular Carcinoma in Egyptian Patients||Ain Shams University|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult Egyptian patients attending outpatient clinic for HCC , Ain Shams University        Hospitals, Cairo Egypt (Group 1&2)|September 2015|September 3, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541149||13766|
NCT02542800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-30|The Influence of Collective Schemas on Individual Memory|ETUDE D'IMAGERIE PAR RESONANCE MAGNETIQUE FONCTIONNELLE CHEZ LE SUJET SAIN DES RELATIONS ENTRE MEMOIRE COLLECTIVE ET INDIVIDUELLE|MULTIBRAIN_2|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|September 2015|||March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|20 Years|38 Years|Accepts Healthy Volunteers|||August 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02542800||13640|
NCT02542813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201558|Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers|A Single Centre, Single Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers||GlaxoSmithKline|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542813||13639|
NCT02533050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308171|Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP|Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With a Continuous Positive Airway Pressure System (CPAP). Etude CAPCORSAS|CAPCORSAS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|August 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|192|||Both|30 Years|70 Years|No|||March 2016|March 9, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533050||14387|
NCT02532842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105892|Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate|Paliperidone Palmitate in Early Schizophrenia - A Retrospective, Non-interventional Study of Patients With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate Over a 12-Month Period||Janssen Pharmaceutica N.V., Belgium|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|||Both|18 Years|29 Years|No|Non-Probability Sample|Participants with Schizophrenia (according to ICD 10 or DSM IV) who were recently        diagnosed (<= 1 year [y] before start of PP treatment) with >= 18 y and <=29 y of age and        who received PP for at least 12 months prior to study start of the study (retrospective        cohort).|November 2015|November 2, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02532842||14403|
NCT02541656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-879|Dynamic Preload Dependence Indices in Laparoscopic Surgery|Dynamic Preload Dependence Indices in Laparoscopic Surgery||Hospices Civils de Lyon|No|Recruiting|January 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|September 2, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02541656||13727|
NCT02541669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_112|A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Subjects|A Phase 1, Randomized, Open-Label, Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects||Takeda|No|Recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541669||13726|
NCT02534246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY2970|Head to Head Comparison of Two Needles EUS Guided FNB|A Paired Prospective, Single Blinded Study of the Diagnostic Accuracy and Specimen Adequacy of Two Endoscopic Tissue Biopsy Needles for Diagnosis Solid Pancreatic Mass||Milton S. Hershey Medical Center|Yes|Not yet recruiting|January 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|89 Years|No|||March 2016|March 14, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02534246||14295|
NCT02534506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-110|Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors||Bristol-Myers Squibb|No|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534506||14275|
NCT02537834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBT02|Tofogliflozin GLP-1 Analogue Combination Trial|An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus||Kowa Company, Ltd.|No|Recruiting|August 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|20 Years|75 Years|No|||August 2015|October 29, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537834||14019|
NCT02528266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034A01_CIP|Surgical Treatment of Symptomatic Neuroma|Open Non-randomized Clinical Investigation to Evaluate the Safety and Effectiveness of the Nerve Capping Device to Prevent Neuroma Formation After Traumatic Nerve Section|STOP NEUROMA|Polyganics Innovations BV|No|Recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02528266||14753|
NCT02528487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1132 (MP)|Predictors of the Long-term Functional Benefits of a Pulmonary Rehabilitation Program?|Predictors of the Long-term Functional Benefits of a Pulmonary Rehabilitation Program?||Hopital du Sacre-Coeur de Montreal|No|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|270|||Both|40 Years|90 Years|No|Non-Probability Sample|COPD patients will be consecutively recruited at entry in one of five PR programs in the        Montreal area: Hôpital du Sacré-Coeur de Montréal (HSCM), Mount Sinai Hospital, Hôtel-Dieu        de Montréal (CHUM), and Hôpital Charles-LeMoyne, Jewish Rehabilitation Hospital of Laval|August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528487||14736|
NCT02542267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISR 14-04|In-Stent Restenosis Post-Approval Study|Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)||W.L.Gore & Associates|Yes|Enrolling by invitation|September 2015|November 2020|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542267||13680|
NCT02531113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-2201|Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease|A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy||Celgene|Yes|Recruiting|September 2015|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531113||14534|
NCT02531126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-3102|Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis|A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis||Celgene|Yes|Recruiting|August 2015|||September 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531126||14533|
NCT02537314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131032|Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans|Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans||Vanderbilt University|No|Enrolling by invitation|September 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|34|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537314||14059|
NCT02537756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA178414-01|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|August 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|4||Anticipated|168|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537756||14025|
NCT02642718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP 359352|Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy|Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy||Hospital Arquitecto Marcide|No|Completed|April 2001|November 2001|Actual|October 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Female|18 Years|70 Years|No|||January 2016|January 1, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02642718||5966|
NCT02533089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB KT intervention|Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi|Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi||Dignitas International|No|Not yet recruiting||February 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Anticipated|124|||Both|N/A|N/A|No|||August 2015|August 25, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533089||14384|
NCT02545010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY01/05/15|Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer|Phase I Study of Low Dose Whole Abdominal Radiation Therapy (LDWART) in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer With Predominant Non-visceral Abdominal Disease||National University Hospital, Singapore|No|Not yet recruiting|September 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|21 Years|N/A|No|||September 2015|September 7, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545010||13470|
NCT02545023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-15-3|Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy|Supportive Care Needs of Breast Cancer Survivors: A Needs Assessment||University of Southern California|Yes|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|N/A|No|Non-Probability Sample|Latina breast cancer survivors receiving ongoing care, including routine follow-up, at        LAC+USC.|September 2015|September 6, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02545023||13469|
NCT02542228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6119806000|Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease|Construction and Validation of a Health-related Quality of Life (HR-QOL) Instrument for Patients With Primary Antibody Deficiency Disease|HR-QOLPIDD|University of South Florida|No|Active, not recruiting|March 2014|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with primary antibody immune deficiency with x-linked agammaglobulinemia and        common variable immune deficiency|August 2015|September 2, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02542228||13683|
NCT02642835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9/12/14|A Long Term Follow up of Anterior Meshes for Recurrent Prolapse|A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse||Medway NHS Foundation Trust|No|Completed|August 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|||Female|18 Years|100 Years|No|Non-Probability Sample|50 consecutive patients having previously undergone a mesh repair|March 2016|March 20, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02642835||5957|
NCT02540551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC152028|Sentinel Node Detection in Ovarian Cancer|Sentinel Node in Ovarian Cancer: SONAR-2|SONAR-2|Maastricht University Medical Center|No|Recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|52|||Female|18 Years|85 Years|No|||March 2016|March 15, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02540551||13811|
NCT02540564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-2010|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2013|||||N/A|N/A|N/A||||||||||||||September 1, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540564||13810|
NCT02540577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA- 159|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||March 13, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540577||13809|
NCT02534636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM011-002|Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis|Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986165 in Subjects With Moderate to Severe Psoriasis||Bristol-Myers Squibb|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|145|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534636||14265|
NCT02534857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiFMIH|A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment|A Randomized Double Blinded Controlled Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment||Shanghai First Maternity and Infant Hospital|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Female|N/A|42 Years|No|||August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534857||14248|
NCT02539576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204662|Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects|A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects||ViiV Healthcare|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539576||13885|
NCT02539589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 TP1AH000003-02-00 BART|Evaluation of Becoming a Responsible Teen (BART)|Evaluation of Becoming a Responsible Teen (BART)||The Policy & Research Group|No|Active, not recruiting|June 2012|January 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|850|||Both|14 Years|18 Years|No|||August 2015|August 31, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539589||13884|
NCT02629952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0014873|Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes|Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes||Menzies Institute for Medical Research|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02629952||6946|
NCT02629965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.33|Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients|A Randomised, Double-blinded, Active-controlled 2-way Cross Over Trial to Assess the Effects of 6 Weeks Treatment of Once Daily Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Delivered by RESPIMAT Inhaler Compared With Tiotropium Delivered by RESPIMAT Inhaler on Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|180|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|December 1, 2015||||No||https://clinicaltrials.gov/show/NCT02629965||6945|
NCT02528929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16497|Gluten-free Diet in Irritable Bowel Syndrome|Assessing the Clinical Response to a Gluten Free Diet in Patients With Diarrhoea Predominant Irritable Bowel Syndrome, in Whom Overt Coeliac Disease Has Been Excluded||Sheffield Teaching Hospitals NHS Foundation Trust||Active, not recruiting|September 2012|||August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|16 Years|N/A|No|||August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528929||14702|
NCT02530723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27773|Functional Changes and Power Training in Older Women.|The Effects of Low-intensity Power Training on Strength, Power, and Functional Outcomes in Older, Community-dwelling Women.|F-POW|University of Toronto|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|50|||Female|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02530723||14564|
NCT02530957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9543|Non Invasive Ventilation Combined to High Flow Nasal Cannula Oxygen for Preoxygenation of Hypoxemic ICU Patients|Comparison of Two Methods of Preoxygenation Before Oro Tracheal Intubation in the Hypoxemic Patient in Intensive Care Unit : Non Invasive Ventilation (NIV) + High Flow Nasal Cannula Oxygen Versus NIV Alone : a Randomized Controlled Study|OPTINIV|University Hospital, Montpellier|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|August 19, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02530957||14546|
NCT02539810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140914|Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)|Optimum and Stepped Care Standardised Antihypertensive Treatment With or Without Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. ANDORRA TRIAL|ANDORRA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|December 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|40 Years|80 Years|No|||July 2015|February 23, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539810||13868|
NCT02644291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15211|Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors|Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|January 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|1 Year|21 Years|No|||January 2016|January 12, 2016|December 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644291||5845|
NCT02644304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC in PCOS|Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome|Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility||Woman's Health University Hospital, Egypt|Yes|Recruiting|May 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Female|20 Years|40 Years|No|||December 2015|December 28, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02644304||5844|
NCT02533856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15G.242|Trial of Emergency Department Discharge With Enhanced Transitions of Care Compared to Usual Care|Randomized Control Trial of Emergency Department Discharge With Enhanced Transitions of Care Compared to Usual Care|ETOC|Thomas Jefferson University|No|Enrolling by invitation|August 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02533856||14325|
NCT02535416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-1002|A Study of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers|||Arrowhead Research Corporation|No|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|January 19, 2016|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535416||14205|
NCT02535429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV massage|Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|July 2015|December 2015|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|75 Years|No|||August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535429||14204|
NCT02530801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15073|Strategies for Management of Recurrent Pterygium|Management of Recurrent Pterygium to Prevent Visual Impairment|REPEAT|University of Nottingham|No|Not yet recruiting|September 2015|August 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530801||14558|
NCT02531035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-312-T1DM|A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadaquate Glycemic Control With Insulin Therapy Alone|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes|inTandem3|Lexicon Pharmaceuticals|Yes|Recruiting|September 2015|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531035||14540|
NCT02630472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821731|Topical Irrigation Therapy for CRS|Efficacy and Safety of Adjuvant Topical Irrigation in the Treatment of Acute Exacerbation of Chronic Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)|QSIND|University of Pennsylvania|No|Not yet recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630472||6906|
NCT02630485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02964|Graceful Lifestyle Changes Study for PCOS and Infertility|Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility|GLC|University of British Columbia|No|Not yet recruiting|December 2015|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02630485||6905|
NCT02541071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rombold_01|Influence of the Noradrenergic System on the Formation of Intrusive Memories|Influence of the Noradrenergic System on the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm||Charite University, Berlin, Germany|No|Completed|November 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|118|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02541071||13772|
NCT02530047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0032|Mesenchymal Stem Cells (MSC) for Ovarian Cancer|Phase 1 Study to Determine the Effects of Mesenchymal Stem Cells Secreting Interferon Beta in Patients With Advanced Ovarian Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|18 Years|90 Years|No|||November 2015|November 10, 2015|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02530047||14616|
NCT02533167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-323|Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery|Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery||Wake Forest School of Medicine|Yes|Completed|July 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|70|||Female|18 Years|50 Years|No|||February 2016|February 3, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02533167||14378|
NCT02542462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2754|Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study|Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study||Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|4||Anticipated|100|||Both|42 Days|90 Days|Accepts Healthy Volunteers|||November 2015|November 10, 2015|June 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542462||13666|
NCT02531295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CHR 15-17116|Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study|Immunologic Response to Euphorbia Kansui Extract Powder Prepared as Tea in HIV-infected Antiretroviral Therapy (ART)-Suppressed Individuals: a Dose Escalation Study||University of California, San Francisco|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|9|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531295||14520|
NCT02537847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sitafloxacin123|Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli|A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli|SETAP|Mahidol University|No|Recruiting|November 2012|May 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537847||14018|
NCT02538159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CAT-2014-36|Safety and Bacteraemia Between Peripherally Inserted and Central Inserted Catheters.|Randomized, Prospective, Single-center Study to Compare the Effectiveness and Safety in Terms of Catheter Bacteraemia, Between Peripherally Inserted Central Catheters and Non-tunneled Central Venous Catheter in Tertiary Hospital|PYCBAC|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|516|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02538159||13994|
NCT02531529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTx 1|Dexmedetomedine Infusion Versus Fentanyl Infusion for Donor Anlgesia During Living Donor Hepatectomy|||Mansoura University|No|Completed|January 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531529||14502|
NCT02535949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMPITI TRIAL|Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury|Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury (TAMPITI TRIAL)|TAMPITI|Washington University School of Medicine|Yes|Recruiting|February 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535949||14164|
NCT02534935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971035|Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.|A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months.||Pfizer|Yes|Recruiting|August 2015|November 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|396|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534935||14242|
NCT02534948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MABT001|Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety|Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Females With Social Anxiety|MABT|Bahria University|Yes|Recruiting|October 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|28 Years|No|||January 2016|January 13, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02534948||14241|
NCT02635490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-X20-068|Is Prophylactic Antibiotics Necessary In Otherwise Healthy Adult Patients Undergoing Ureteroscopic Procedures for Ureteral Stones?|||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Completed|April 2013|March 2015|Actual|March 2015|Actual|Phase 0|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|52|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Cohort study|December 2015|December 16, 2015|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02635490|1 Month|6522|
NCT02538250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-1422|Acceptability Study on Oral Nutrition Supplement (ONS)|Acceptability Study on Nutricomp Drink Plus in Adult Patients||B. Braun Melsungen AG|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02538250||13987|
NCT02538380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50139.018.14|EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer Patients|EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|March 2015|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|August 31, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538380||13977|
NCT02529228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/01504|Combined Effects of Meal Frequency and Protein Load on Cardiometabolic Risk Factors|||Clinical Nutrition Research Centre, Singapore|No|Completed|December 2014|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|10|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02529228||14679|
NCT02529241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCB01-0371-15-1-01|An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371|An Open-label, Single Dose, Parallel Design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral Dosage Form of LCB01-0371 in Healthy Volunteers||LegoChem Biosciences, Inc|No|Recruiting|July 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02529241||14678|
NCT02531893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150182|Psychological Treatments for Youth With Severe Irritability.|Psychological Treatments for Youth With Severe Irritability.||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|August 2023|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|8 Years|18 Years|No|||July 2015|March 23, 2016|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02531893||14475|
NCT02643797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK104250-01A1|Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings|Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings|MAC|Scripps Whittier Diabetes Institute|Yes|Not yet recruiting|February 2016|June 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02643797||5883|
NCT02530671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011015|Effect of a Multi-directional Power Toothbrush on Recession|Effect of a Multi-directional Power and a Manual Toothbrush in Subjects Susceptible to Gingival Recession: A 12-month Randomized Controlled Clinical Study||University of Schleswig-Holstein|No|Completed|June 2011|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 27, 2015|August 18, 2015||No||No|August 26, 2015|https://clinicaltrials.gov/show/NCT02530671||14568|
NCT02536456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150823|China PEACE Millions Persons Project|China PEACE Millions Persons Project||China National Center for Cardiovascular Diseases|Yes|Recruiting|July 2014|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|4000000|Samples With DNA|For each high-risk subject, a 6mL whole blood sample is collected in an EDTA vacuum tube.A      10mL urine sample is also collected.|Both|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents from the communities or villages in selected sites|August 2015|August 28, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536456||14125|
NCT02536469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR01CD101|HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors|A Phase Ib, Dose Escalation, Multiple Dose Trial With HuMax-IL8 in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors||Cormorant Pharmacuticals AB|No|Recruiting|August 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536469||14124|
NCT02535468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00400|T2Bacteria Panel Pivotal Study||T2Bacteria|T2 Biosystems|No|Recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1850|||Both|18 Years|95 Years|No|Non-Probability Sample|Candidates participating in the prospective arm of the study will come from the hospital        population who have had a blood culture ordered per routine standard of care. The        contrived arm of the study is open to any participants that meet the study enrollment        criteria. The study population for both arms is defined as all subjects who meet the study        eligibility criteria, provide informed consent, and provide the clinical specimens under        this protocol.|December 2015|December 21, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535468||14201|
NCT02552277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA-002-DPN-001|A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.||Celgene|Yes|Recruiting|October 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552277||12911|
NCT02552537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 2015-0380|iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions|Integrated Approaches to Food Allergen and Allergy Risk Management: iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions|iFAAM-PPI|University of Zurich|Yes|Recruiting|September 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02552537||12891|
NCT02554578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-MHE-2014-55|Impact of mHealth in Heart Transplant Management|Effectiveness Improving Medication Adherence in Heart Transplant Management|mHeart|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Not yet recruiting|October 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554578||12734|
NCT02545985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|First-in-man Sirolimus-eluting Prolim® Stent Registry|Novel Sirolimus-eluting Stent Prolim® With a Biodegradable Polymer in the All-comers Population||Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland|No|Completed|January 2013|June 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|204|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02545985||13395|
NCT02542553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bilateral BAL in VAP|Bilateral Bronchoalveolar Lavage in Ventilator-associated Pneumonia|Bilateral Bronchoalveolar Lavage Cultures for Diagnosing Ventilator-associated Pneumonia. Microbiologic Concordance and Impact on the Efficacy of Treatment Decisions.||Catholic University of the Sacred Heart|No|Completed|February 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|79|||Both|18 Years|N/A|No|||August 2015|September 3, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02542553||13659|
NCT02542566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 4 28/08/2014|Protected Versus Early Weight Bearing Post Microfracture Surgery|Randomised Control Trial Comparing Conservative Rehabilitation and Protected Weight Bearing Versus Accelerated Rehabilitation and Early Weight Bearing Post Microfracture Knee Surgery.||Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|16 Years|60 Years|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542566||13658|
NCT02541019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48149215.0.0000.5253|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy||Hospital Federal de Bonsucesso|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Female|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541019||13776|
NCT02535637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15246|Breastfeeding and Obesity on Offspring Body Composition|Impact of Breastfeeding and Obesity on Offspring Body Composition and Growth at Six Months of Age||University of Oklahoma|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|1 Month|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|A total of 37 mothers whom exclusively breast fed to six-months. Participants        (mothers/infant) included offspring from mothers with a singleton-term healthy pregnancy        (37-40 weeks). Both vaginal and cesarean deliveries were included. Infants who are        exclusively breastfed (defined as no formula in the last 20 days) prior to enrollment will        be considered.|August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535637||14188|
NCT02539498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091113|Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism|Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism|MicrOs|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|132|||Female|N/A|81 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539498||13891|
NCT02540018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-15-03-013204|Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis|Multicenter Randomized Controlled Trial to Assess the Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Superficial Femoral and Popliteal Arteries to Prevent Vessel Restenosis or Reocclusion|EffPac|Jena University Hospital|No|Recruiting|September 2015|September 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|80 Years|No|||December 2015|December 4, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02540018||13852|
NCT02532725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1120-6134|Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men|Relationship of Occupational Heat Stress Endurance, Work, and Percentage of Body Fat in Middle Aged Men||Freeman-Sheldon Research Group, Inc.|No|Completed|June 1972|December 1972|Actual|December 1972|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|12|||Male|35 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Lean and obese middle aged men unaccustomed to working in hot industrial conditions|August 2015|August 23, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02532725||14412|
NCT02532972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-054H|Cochlear Implantation for Treatment of Single-sided Deafness|Cochlear Implantation for Treatment of Single-sided Deafness||Massachusetts Eye and Ear Infirmary|No|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532972||14393|
NCT02534740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461052|A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food|A Phase 1, Open-Label, Randomized, Single Dose Study To Estimate The Relative Bioavailability And Food Effect Of PF‑06291826 (Tafamidis) Following Administration Of New Soft Gelatin Capsule Oral Formulations In Healthy Subjects||Pfizer|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 20, 2015|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534740||14257|
NCT02534649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2015-09|Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials|Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials|BIP|Institut Bergonié|No|Recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02534649||14264|
NCT02537457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17017|Bioequivalence Study of Rivaroxaban|Randomized, Non-blinded, Two-way Crossover Study to Establish the Bioequivalence Between a Rivaroxaban Tablet 15 mg and a Rivaroxaban Granule 15 mg in Japanese Healthy Adult Male Subjects||Bayer|No|Completed|January 2014|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537457||14048|
NCT02538601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1605|Enhanced Smoking Cessation Intervention for Smokers Exposed to the World Trade Center (WTC) Disaster|Enhanced Smoking Cessation Intervention for Smokers Exposed to the WTC Disaster||Stony Brook University|No|Completed|February 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02538601||13960|
NCT02536157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12020625|Volar Plate Injury: A Comparison of Two Splinting Methods|A Randomised Controlled Trial Investigating the Effectiveness of Two Splinting Methods in the Non-operative Management of Volar Plate Injuries at the Proximal Interphalangeal Joint||National Health Service, United Kingdom|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|16 Years|N/A|No|||March 2016|March 21, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02536157||14148|
NCT02541006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-21.12|Comparison 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD|A Randomized, Parallel-group, Phase IV Study to Compare the Bronchodilator Efficacy of Tiotropium (18 µg Once Daily [od]) Delivered Via a DISCAIR With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD||Neutec Ar-Ge San ve Tic A.Ş|No|Completed|November 2014|August 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||November 2013|September 3, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541006||13777|
NCT02539602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20040080E|Evaluation of a Need to Know (N2K): A New Sex Education Program for High School Students|Rigorous Evaluation of Need to Know (N2K): A Three-Year Quasi-Experimental Sex Education Program for High School Students in Texas|N2K|The University of Texas Health Science Center at San Antonio|No|Completed|September 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1616|||Both|14 Years|15 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539602||13883|
NCT02539615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCP005|A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old|A Single-arm, Multi-center Trial of the ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years of Age||Atossa Genetics, Inc.|No|Withdrawn|September 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|0|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02539615||13882|
NCT02532790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AiZhang|The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children|The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children||Nanjing Children's Hospital|No|Recruiting|August 2015|July 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|16 Years|No|||August 2015|August 25, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532790||14407|
NCT02544477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFNC after pulmonary lobectomy|High-flow Nasal Cannula Oxygen Versus Conventional Oxygen Therapy After Pulmonary Lobectomy|||Catholic University of the Sacred Heart|No|Recruiting|August 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 5, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02544477||13511|
NCT02541565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9291|Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma|MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-cell Lymphoma||University of Washington|No|Recruiting|November 2015|||September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02541565||13734|
NCT02532673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-531|Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir|Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir||Bristol-Myers Squibb|No|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Commercially insured population (single large health plan)|August 2015|August 23, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02532673||14416|
NCT02529306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0045-15BNZ|The Correlation Between Testosterone and Cortisol Level and Inflammatory Markers Levels in Type 2 Diabetic Men.|The Correlation Between Testosterone and Cortisol Level and Inflammatory Markers Levels in Type 2 Diabetic Men.|BZMC|Bnai Zion Medical Center|No|Not yet recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Male|40 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 2 diabetic men, age 40-55|July 2015|August 19, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02529306||14673|
NCT02537535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRC2014-GOAL Canada Study|Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada|Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada|GOAL|Canadian Heart Research Centre|No|Enrolling by invitation|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Low density lipoprotein cholesterol (LDL-C) management in Canadian patients at high        cardiovascular risk|August 2015|August 28, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537535||14042|
NCT02536690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0183-004|Remifentanil and Midazolam on Propofol for Loss of Consciousness|The Effect of Remifentanil and Midazolam on Propofol for Loss of Consciousness During Induction of Anesthesia||Severance Hospital|Yes|Recruiting|August 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|120|||Female|20 Years|50 Years|No|||August 2015|August 27, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536690||14107|
NCT02532686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC-101-2314-B-039-030-MY3|DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia|DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia||China Medical University Hospital|No|Recruiting|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2015|August 23, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02532686||14415|
NCT02542163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #9648|Pilot Evaluation of the NimbleHeart Harness System in Cardiac Rehabilitation (PEN-CR)|Pilot Evaluation of the NimbleHeart Harness System in Cardiac Rehabilitation (PEN-CR)||NimbleHeart Inc.|No|Recruiting|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac Rehabilitation phase II population|September 2015|September 4, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02542163||13688|
NCT02542176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150888|Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome|Pilot Study: Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome||University of Connecticut|No|Not yet recruiting|October 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Male|30 Years|70 Years|No|||September 2015|September 3, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542176||13687|
NCT02540239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|simethione|Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy|||Changhai Hospital|Yes|Recruiting|January 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|600|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540239||13835|
NCT02540252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSJ-2015|Nutrition and Inflammation Among Patients With Lower Limb Amputation|Nutritional Status, Eating Pattern and Inflammation Among Patients With Amputation of the Lower Limb - a Longitudinal Cohort Study|Amp-Nu|Hvidovre University Hospital|Yes|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Biomarkers within the inflammatory and Metabolic pathways|Both|50 Years|N/A|No|Non-Probability Sample|Patients are included from a cohort of patients who are admitted to the Department of        Ortopedic Surgery.|September 2015|September 10, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540252||13834|
NCT02544490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA/0029/2014|Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis|Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis|miRNA-Sepsis|National University Hospital, Singapore|No|Recruiting|September 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples Without DNA|Whole blood extraction from subjects subsequently separated to plasma and serum that are      stored in the Tissue Repository.|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This research project will be a prospective observational cohort study of controls without        infection and patients along the entire sepsis continuum the Emergency Department (ED).        Admitted patients will be followed-up in the inpatient units including the intensive care        unit (ICU) and general wards. Healthy controls and those with systemic inflammatory        response syndrome (SIRS) but without evidence of infection will also be recruited to        demonstrate differentiation of biomarkers for early diagnosis. The reference standards for        infection and sepsis will be positive cultures (e.g. from blood, urine, endotracheal tube,        sputum) and final discharge diagnoses.|March 2016|March 21, 2016|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02544490||13510|
NCT02544503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081238|Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients|Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients||Emory University|No|Recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544503||13509|
NCT02532933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|779383 2015 Attune Patella|Stereo Radiography of TKA Patella Mechanics|Influence of Patellar Geometry on Kinematics, Quadriceps Function, and Patient Outcome in Subjects With the Attune PS RP||University of Denver|No|Enrolling by invitation|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|No|||August 2015|August 21, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532933||14396|
NCT02543697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2170|Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors|Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors|AVS|Haukeland University Hospital|Yes|Recruiting|February 2015|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02543697||13571|
NCT02633163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC-UCMSC-001|A Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus|A Phase II Sequential Dose-Escalation Study Evaluating the Safety and Feasibility of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (MSC) for the Treatment of Adults With Treatment Refractory Lupus|MscISLE|Medical University of South Carolina|Yes|Not yet recruiting|July 2016|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|65 Years|No|||December 2015|February 8, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02633163||6700|
NCT02535871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-121A-302|A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris||Valeant Pharmaceuticals|No|Not yet recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|9 Years|N/A|No|||September 2015|September 11, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535871||14170|
NCT02536131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1502/2014|Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease|Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease||Medical University of Vienna|No|Active, not recruiting|August 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|89 Years|No|||August 2015|August 26, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02536131||14150|
NCT02542397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-NOS-PAIN-001|LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients|LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Pilot Study of Pain Management in Oncology Outpatients||Carolinas Healthcare System|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02542397||13671|
NCT02542137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhejiang Provincal PH|Abscopal Effect for Metastatic Small Cell Lung Cancer|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Small Cell Lung Cancer||Zhejiang Provincial People’s Hospital|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||September 2015|September 6, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02542137||13690|
NCT02644200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015|Gelatin Tannate as Treatment for Acute Childhood Gastroenteritis|Gelatin Tannate as Treatment for Acute Childhood Gastroenteritis: a Prospective, Randomized, Single-blind Controlled Clinical Trial|GT|University of Roma La Sapienza|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|3 Months|5 Years|No|||December 2015|December 28, 2015|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02644200||5852|
NCT02536677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLEmer201507|The Evaluation and Management of Patients With Acute Chest Pain in China|The Evaluation and Management of Patients With Acute Chest Pain in China||Qilu Hospital|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|In order to create a representative sample of Shandong province, the cooperative hospitals        in our study are selected from eligible grade II and III hospitals with stratified random        sampling design. Eligible hospitals are stratified into 3 strata: rural, grade II-urban        and grade III-urban. We then randomly select 1/15 of all hospitals from each strata using        simple random sampling method. Finally, 22 hospitals are selected including 12 rural        hospitals, 6 grade II and 4 grade III urban hospitals. Qilu hospital,the coordinating        hospital do not participate in the sampling. The study will recruit consecutive patients        between September 2015 and September 2017.|August 2015|August 27, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536677|1 Month|14108|
NCT02532088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDOPP-21100|Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes|Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes|PREDOPP|University of Science Malaysia|Yes|Not yet recruiting|December 2015|September 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|268|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02532088||14460|
NCT02529618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082102|Field Implementation of iDETECT|Implementation of iDETECT for Field Triage of mTBI in Football Players||Emory University|No|Completed|August 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Both|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|iDETECT will be used to assess neuro-functional outcomes known to be impaired after mTBI        in competitive high school athletic teams over a standard season.        Eligible participants include: a) all football athletes at participating high schools; b)        all non-football athletes who sustain a concussion during the Fall 2015 season; c)        interested non-collision sport athletes without a concussion (to serve at controls).|March 2016|March 3, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529618||14649|
NCT02529904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2015/02|ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults|A Phase II, Open Label Study to Describe Immune & Transcriptional Responses to MF59 Adjuvanted Trivalent Influenza Vaccine (ATIV) in Healthy 13-24 Month Children and Adults 18-65 Years||University of Oxford|Yes|Recruiting|August 2015|January 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|13 Months|65 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02529904||14627|
NCT02644226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1407/258-117|Laryngeal Mask Airway (LMA) Complication in Children|Retrospective Investigation of Perioperative Upper Airway Complications After Anesthesia Using Supraglottic Airway Devices in Children: Comparison of Desflurane and Sevoflurane||Seoul National University Bundang Hospital|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|3528|||Both|N/A|15 Years|No|Non-Probability Sample|Children aged less than 15 years who underwent general anesthesia under supraglottic        airways using sevoflurane or desflurane as maintenance agents in Seoul National University        Bundang Hospital between June 2013 and June 2015.|January 2016|January 19, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02644226||5850|
NCT02644252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toco-Pulm|Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer|Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Toco-Pulm|Vejle Hospital|Yes|Recruiting|January 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|190|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02644252||5848|
NCT02529163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032/2015|Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms|Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms|LLS-ICP|Centre for Addiction and Mental Health|No|Recruiting|August 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529163||14684|
NCT02539771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111121|Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events|Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events|DREPASOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2014|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|August 31, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539771||13871|
NCT02539992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-045|ShapeMatch Cutting Guide Functional Outcomes Study|A Prospective, Randomized, Multi-centre Study of the Triathlon Cruciate Retaining Total Knee System Using ShapeMatch Cutting Guides|ShapeMatch|Stryker European Operations BV|No|Terminated|May 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|September 1, 2015|Yes|Yes|Product discontinued in November 2014|No||https://clinicaltrials.gov/show/NCT02539992||13854|
NCT02542306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141100002114025|Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest|Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest|SEFC|Beijing Municipal Science & Technology Commission|Yes|Recruiting|July 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||September 2015|September 4, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02542306||13677|
NCT02533609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-ENDVERSION|Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis|Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis|DIADSORB MAB|Heinrich-Heine University, Duesseldorf|No|Active, not recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Intensive care patients with acute kidney injury requiring continous renal replacement        therapy with citrate-anticoagulation|February 2016|February 11, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533609||14344|
NCT02534870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-769|Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects|Multiple-Dose Pharmacokinetics, Safety and Tolerability of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects||AbbVie|No|Completed|September 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534870||14247|
NCT02535156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM/02/112/01|Schizotypal Personality Disorder Risperidone|||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||Completed|January 2003|January 2015|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02535156||14225|
NCT02544139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC0227|Specificity Study of Diagnostic for Chagas Disease|Determination of Estimated Specificity of Chagas Detect Plus Rapid Tests||InBios International, Inc.||Completed|July 2015|||March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|serum|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The study will enroll male and female subjects between 18 and 70 years of age without        known risk factors for Chagas. Typically Chagas disease is a chronic, asymptomatic        disease.|March 2016|March 22, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544139||13537|
NCT02630225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSD# 48970|Helping Individuals With Firearm Injuries|Helping Individuals With Firearm Injuries: A Cluster Randomized Trial|HIFI|University of Washington|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02630225||6925|
NCT02537600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-TL-MEL-Th|Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis|Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma|CONVERCE|Center Eugene Marquis|Yes|Recruiting|December 2015|June 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|137|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02537600||14037|
NCT02540850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESEPT|CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population|Screening of Colorectal Cancer Using Improved SEPT9 (Septin 9) Gene Methylation Assay in Chinese Population|RESEPT|BioChain (Beijing) Science and Technology, Inc.|Yes|Completed|February 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1031|||Both|17 Years|88 Years|Accepts Healthy Volunteers|Probability Sample|All eligible inpatients, outpatients, and subjects from health examination centers.|January 2016|January 7, 2016|August 12, 2015||No||No|October 13, 2015|https://clinicaltrials.gov/show/NCT02540850||13788|
NCT02528461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV sCD163 Sofosbuvir|Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C|Measuring Inflammation Cells (CD163 and CD206) With the Purpose of Examining Reduction of Fibrosis in the Liver of Chronic Hepatitis C Patients Following Treatment With the Medication Sofosbuvir||University of Aarhus|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02528461||14738|
NCT02534961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-003B|Prophylactic Antibiotics Before RFA for HCC|Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|20 Years|80 Years|No|||August 2015|August 25, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534961||14240|
NCT02534974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00802-45|Impact of the Addition of a Device Providing Continuous Pneumatic Regulation of Tube Cuff Pressure to an Overall Strategy Aimed at Preventing Ventilator-associated Pneumonia in the Severe Trauma Patient. A Multicentre, Randomised, Controlled Study.||AGATE|Poitiers University Hospital||Recruiting|July 2015|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||Anticipated|440|||Both|18 Years|N/A|No|||July 2015|August 27, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02534974||14239|
NCT02537808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-12315|Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma|A Non-interventional Study of Lenalidomide (Revlimid®) in Combination With Dexamethasone as First Line Therapy in Transplant-ineligible Patients With Multiple Myeloma|FIRST-NIS|iOMEDICO AG|No|Recruiting|June 2015|May 2022|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|167|||Both|18 Years|N/A|No|Probability Sample|Transplant-ineligible patients with previously untreated, symptomatic multiple myeloma (as        defined by IMWG criteria) and with an indication for medical treatment as assessed by the        investigator.|March 2016|March 11, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02537808||14021|
NCT02530060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107748|A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants|An Open-Label Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration of a Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine Fixed-Dose Combination Tablet in Healthy Japanese Adult Male Subjects||Janssen Pharmaceutical K.K.|No|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530060||14615|
NCT02537704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPPMEX-077|Translational Study for Obesity Management in Mexican Adults Using the "Group Lifestyle Balance Program"|Translational Study for Overweight and Obesity Management in Adults Using the "Group Lifestyle Balance Program" in Primary Care Clinics and Public Hospitals From Sonora, México|GLBOMEX|Universidad de Sonora|No|Recruiting|September 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537704||14029|
NCT02537717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-55|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||October 13, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537717||14028|
NCT02531308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYM2014-MET-R-CHOP|Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)|A Phase ll Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (RM-CHOP) for Previously Untreated Aggressive Diffuse Large B-cell Lymphoma|DLBCL|Rush University Medical Center|Yes|Recruiting|July 2015|January 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531308||14519|
NCT02535247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-075|Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma|A Phase II Study to Determine Feasibility and Safety of Single Agent MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma||Fox Chase Cancer Center|Yes|Recruiting|December 2015|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535247||14218|
NCT02540473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009196|Fostering Resilience in Physician Moms|Fostering Resilience: An Intervention for Women Physicians at Risk for Burnout||Mayo Clinic|No|Active, not recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Female|25 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02540473||13817|
NCT02543905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4045|The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment|The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment|PROFILE|Institute of Cancer Research, United Kingdom|Yes|Recruiting|April 2015|April 2025|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|Serum, plasma, urine, DNA, RNA|Male|40 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|350 men in each cohort|February 2016|February 22, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02543905||13555|
NCT02541136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rec Ref 2011/45/13|Neural Changes of Exercise: a Functional MRI Study|Neural and Stress Correlates of Resilience in an Exercise-behavioural Programme||University of Dublin, Trinity College|Yes|Completed|October 2011|April 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02541136||13767|
NCT02541474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1707|The PAtient-Centred Team - Effectiveness and Cost-effectiveness Study|Effectiveness and Cost-effectiveness of Interdisciplinary Teamwork in Medical Emergencies: The PAtient-Centred Team (PACT) Service Model. Effect and Cost Effectiveness Evaluation|PACT|University Hospital of North Norway|No|Not yet recruiting|October 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|65 Years|N/A|No|||September 2015|September 3, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02541474||13741|
NCT02541487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fit-Later|Fetal Effects of Pre-Pregnancy Lifestyle Interventions in Unexplained Infertility Patients|Fetal Effects of Pre-Pregnancy Lifestyle Interventions in Unexplained Infertility Patients||University of Oklahoma|No|Not yet recruiting|October 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|A de-identified sample of blood will be collected at the time of the baseline visit.|Female|18 Years|45 Years|No|Probability Sample|Women that are seen in the OU Reproductive Medicine clinic.|September 2015|September 1, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02541487||13740|
NCT02631200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20724-1|Advance Care Planning With Older Patients Who Have End-stage Kidney Disease|Advance Care Planning With Older Patients Who Have End-stage Kidney Disease: Feasibility of a Deferred Entry Randomised Controlled Trial Incorporating a Mixed Methods Process Evaluation|ACREDiT|Queen's University, Belfast|No|Not yet recruiting|February 2016|September 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|65 Years|N/A|No|||December 2015|December 11, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02631200||6850|
NCT02631213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||December 11, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02631213||6849|
NCT02543931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501627690|Curcuma Longa L in Rheumatoid Arthritis|Phase Ib Randomized, Double-Blind, Placebo-Controlled Study of Meriva in Rheumatoid Arthritis|CLaRA|University of Arizona|Yes|Recruiting|November 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543931||13553|
NCT02543944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203970|Improving Treatment Outcomes for Prescription Opioid Dependence|Improving Treatment Outcomes for Prescription Opioid Dependence|GBN|University of Arkansas|Yes|Not yet recruiting|October 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543944||13552|
NCT02533687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-TURP-BM-01|Comparison of Different Energy Sources During TUR-P|Comparison of Two Different Bipolar and A Monopolar Energy Sources During Transurethral Resection of Prostate||Selcuk University|No|Not yet recruiting|August 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Male|40 Years|80 Years|No|||March 2016|March 1, 2016|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02533687||14338|
NCT02536014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0337|Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-|||Yonsei University|No|Completed|August 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Male|N/A|N/A|No|||January 2016|January 27, 2016|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02536014||14159|
NCT02536027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstHospitalchenzhou|Effect of CVVH on NGAL in Septic AKI|Effect of Continuous Venovenous Hemofiltration on the Plasma Level of Neutrophil Gelatinase-associated Lipocalin in Critical Ill Patients With Septic Acute Kidney Injury||First People's Hospital of Chenzhou|Yes|Completed|August 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02536027||14158|
NCT02635542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1016|Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery|Prospective, Randomized Trial Comparing Effect of General Anesthesia With and Without Neuromuscular Blockade on Postoperative Pulmonary Complications in Elective Cardiac Surgical Patients||University of Chicago|Yes|Recruiting|March 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|90 Years|No|||March 2016|March 2, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02635542||6518|
NCT02534584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|Use of Care Bundle in Acute Kidney Injury|Impact of Compliance With a Care Bundle on Acute Kidney Injury Outcomes||Derby Hospitals NHS Foundation Trust|No|Completed|August 2013|July 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|944|||Both|17 Years|N/A|No|Probability Sample|All adults patients with acute kidney injury|August 2015|August 25, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534584||14269|
NCT02538393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18175|Relative Bioavailability of Sorafenib Tablet for Oral Suspension|An Open Label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of Sorafenib Tablet for Oral Suspension Compared to Marketed Tablet and to Investigate the Pharmacokinetics of Sorafenib Tablet for Oral Suspension Including Food Effect and Dose Proportionality||Bayer|No|Active, not recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538393||13976|
NCT02542735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI14/00710|Incidence of Type 2 Diabetes in the di@Bet.es Study|Incidence of Type 2 Diabetes in the di@Bet.es Study: Role of Fatty Acid Transport System Regulated by VEGFB in the Development of Metabolic Diseases.||Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Blood Serum and DNA|Both|18 Years|N/A|No|Probability Sample|The study is based on the di@bet.es study, a cross-sectional study undertaken from        2007-2010 from a random cluster sampling in the Spanish population over 18 years of age        (Soriguer et al. Diabetologia 2012;55(1):88-93).|September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542735||13645|
NCT02541162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00443-44|Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|COUPLE|Groupe Hospitalier Paris Saint Joseph|No|Recruiting|August 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02541162||13765|
NCT02559154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010K059|Modified Bortezomib-based Combination Therapy for Multiple Myeloma|An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||Recruiting|July 2010|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559154||12383|
NCT02555150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063-013|A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD|A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD||Rhodes Pharmaceuticals, L.P.|No|Recruiting|September 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|35 Years|No|||February 2016|February 17, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555150||12690|
NCT02555163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mans17-9-2015|Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor (HoLERBT) Versus Conventional Transurethral Resection Of Bladder Tumors (cTURBT): A Prospective Randomized Controlled Trial|HoLERBT|Mansoura University|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||September 2015|September 18, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02555163||12689|
NCT02558465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17522|Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)|Special Drug Use Investigation of Xarelto for VTE|JPMS-XAR-VTE|Bayer|No|Recruiting|November 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|||Both|N/A|N/A|No|Non-Probability Sample|Female and male patients who start rivaroxaban for VTE （pulmonary embolism, deep vein        thrombosis) anticoagulation therapy|March 2016|March 16, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02558465||12436|
NCT02561507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-215|Perioperative Aspirin Usage Survey|Use of Aspirin in the Perioperative Setting: A Surgeon's Survey||University of New Mexico|No|Not yet recruiting|October 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members of the American College of Surgeons|September 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561507||12202|
NCT02560675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-14-RMB Whiplash_CTIL|Why Does Acute Post Whiplash Injury Pain Transform Into Chronic Pain?|Why Does Acute Post Whiplash Injury Pain Transform Into Chronic Pain? Multi-modal Assessment of Risk Factors and Predictors of Pain Chronification||Rambam Health Care Campus|No|Not yet recruiting|January 2016|October 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|870|Samples With DNA|Blood collection for genetics. Whole blood sample (10cc) will be collected from each subject      and placed in EDTA-coated tubes. Genomic DNA will be isolated using DNA Extraction Kit .      Quality and quantity of the DNA sample will be measured using a NanoDrop Machine.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|750 Subjects with acute post whiplash injury pain. and 120 healthy subjects .|December 2015|December 27, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560675||12266|
NCT02549703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1495|Mitochondrial Dysfunction and Disease Progression|Mitochondrial Dysfunction and Disease Progression||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|Samples With DNA|Blood and CSF samples will be stored indefinitely at the Casaccia lab. Skin samples will be      stored indefinitely at the New York Stem Cell Foundation.|Both|18 Years|N/A|No|Non-Probability Sample|Multiple sclerosis patients willing and able to undergo the assessments required for this        study.|February 2016|February 10, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549703||13109|
NCT02532452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4184|Third Party Anti-Viral Cytotoxic T-Cells|Third Party Anti-viral Cytotoxic T-cells (CTLs) for Treatment of Viral Infections in Immunocompromised Patients||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|August 2015|August 2022|Anticipated|August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||January 2016|January 26, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532452||14433|
NCT02532465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00486|Glottic View Using Supraglottic Devices in Pediatric Patients|Glottic View Using Supraglottic Devices in Pediatric Patients||Nationwide Children's Hospital|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|18 Years|No|||March 2016|March 11, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532465||14432|
NCT02531958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-227|Assessment of Optimal Egg Intake in a Healthy Population|Assessment of Optimal Egg Intake in a Healthy Population||University of Connecticut|No|Active, not recruiting|August 2015|May 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531958||14470|
NCT02532257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0361|Study of Ibrutinib in Combination With Rituximab and Lenalidomide|An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532257||14448|
NCT02539251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.LC.07|Arabic Ages and Stages Questionnaire-III|Adaptation and Validation of the Ages and Stages Questionnaires -3 (ASQ-3) in Arabic||American University of Beirut Medical Center|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|575|||Both|4 Months|3 Years|Accepts Healthy Volunteers|Probability Sample|For adaptation, 75 parents of eligible children between the ages of 4 months and 3 years        will be approached.        For validation of A-ASQ-3, 500 Children (100 per age group) from a random sample of day        care centers and pediatricians' clinics from across the country will be recruited.|August 2015|August 31, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02539251||13910|
NCT02541318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST 103-2410-H-039-011|Study of Effects of Dao-In Exercise on the Perimenopausal Women With Sleep Disturbance|Study of Effects of Dao-In Exercise on the Perimenopausal Women With Sleep Disturbance||China Medical University Hospital|Yes|Recruiting|August 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|45 Years|60 Years|No|||September 2015|September 2, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02541318||13753|
NCT02536859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4227|Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus|A Randomised, Single-centre, Double-blind, Two-period Cross-over, Multiple Dose Trial Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Active, not recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||March 2016|March 11, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536859||14094|
NCT02537171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-G30|Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer|Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Recruiting|July 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02537171||14070|
NCT02538458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01335-42|Efficacy and Safety of 3% Hypertonic Saline Inhalation (24h vs 72h) to Treat Acute Bronchiolitis in Hospitalized Infants|Effects of Reduction of the Length of Treatment by Nebulized 3% Hypertonic Saline From 72 to 24 Hours on Clinical Remission, in Children Younger Than 12 Month Hospitalized for Acute Bronchiolitis. BRONDUSAL|BRONDUSAL|University Hospital, Grenoble|Yes|Recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|12 Months|No|||August 2015|September 1, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02538458||13971|
NCT02544113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-943|A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation|A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection After Liver Transplantation. A Multi-Center Study||The Cleveland Clinic|Yes|Recruiting|December 2015|||September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544113||13539|
NCT02532023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28825|The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients|The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients||Tehran University of Medical Sciences|Yes|Enrolling by invitation|September 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|20 Years|50 Years|No|||August 2015|August 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532023||14465|
NCT02540031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-014-003|The Impact of Additional Oral Preparation on the Quality of Bowel Preparation for Colonoscopy|The Impact of Additional Oral Preparation on the Quality of Bowel Preparation for Colonoscopy in Patients Showing Brown Effluents||Keimyung University Dongsan Medical Center|Yes|Recruiting|September 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|158|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02540031||13851|
NCT02542761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001367|Comparative Performance of Dynamic Elastic Response Feet|Comparative Performance of Dynamic Elastic Response Feet||Mayo Clinic|No|Active, not recruiting|June 2015|April 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||January 2016|January 4, 2016|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542761||13643|
NCT02528123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoVC-004|VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia|VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia||London Vision Clinic|Yes|Not yet recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|187|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02528123||14764|
NCT02539732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 15-214|Prediction of Outcome of Weaning From Mechanical Ventilation Using the Electrical Activity of the Diaphragm|Prediction of Outcome of Weaning From Mechanical Ventilation Using the Electrical Activity of the Diaphragm|OWED|St. Michael's Hospital, Toronto|No|Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated Intensive Care Unit patients who are ready to undergo a        Spontaneous Breathing Trial.|September 2015|September 29, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02539732||13874|
NCT02541500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004494|An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence|An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS)||University of Science Malaysia|No|Recruiting|April 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|65 Years|No|||September 2015|September 1, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541500||13739|
NCT02528838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-Celgene-NETH-001|An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.|A Non-interventional Observational Post Authorization Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide (REVIEW)|REVIEW|Celgene|No|Active, not recruiting|May 2011|December 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|238|||Both|18 Years|N/A|No|Non-Probability Sample|Patients already successfully, i.e. with currently stable disease or meeting the criteria        for complete response, very good partial response or partial response, on-treatment for        maximally up to 6 cycles with lenalidomide at each site will be enrolled into the study.        In all cases, the decision to treat the patient with lenalidomide was already made prior        to the decision to enter the subject into the study.|January 2016|January 19, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02528838||14709|
NCT02529072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065241|Nivolumab With DC Vaccines for Recurrent Brain Tumors|AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors|AVERT|Duke University|Yes|Recruiting|January 2016|August 2019|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529072||14691|
NCT02537223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX-001|Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer|Phase I Trial of BYL719 in Combination With Concurrent Cisplatin-based Chemoradiotherapy in Patients With Locoregionally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN)||University Health Network, Toronto|No|Not yet recruiting|September 2015|March 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537223||14066|
NCT02537522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5730|Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses|||Johnson & Johnson Vision Care, Inc.|Yes|Completed|July 2015|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537522||14043|
NCT02531464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRQS-30740|Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer|Effectiveness of a Multi-faceted Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer||Laval University|No|Recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02531464||14507|
NCT02531477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Intra-carotid Anesthetic Agent Delivery||ICAAD|Mansoura University|No|Recruiting|January 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|10 Weeks|2 Years|No|||August 2015|August 21, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02531477||14506|
NCT02536794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 15B01|MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer|A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer||Northwestern University|Yes|Recruiting|December 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536794||14099|
NCT02536807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42297|Minimally Invasive Volume Augmentation of Papillae Around Implant Restorations With Hyaluronic Acid Injection|Minimally Invasive Volume Augmentation of Papillae Around Implant Restorations With Hyaluronic Acid Injection. A Randomized Controlled Clinical Trial With 6 Months Follow-up||Malmö University|No|Active, not recruiting|August 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536807||14098|
NCT02533999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-13|Peak(R) vs. Electrocautery in Children Undergoing Tonsillectomy With Adenoidectomy|Assessment of 14-Day Outcomes With the Peak® Surgery System Versus the Traditional Electrocautery Method in Children Ages 3 to 18 Years Undergoing Tonsillectomy With Adenoidectomy for Sleep Disordered Breathing||Nemours Children's Clinic|No|Enrolling by invitation|April 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|3 Years|17 Years|No|||August 2015|August 26, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533999||14314|
NCT02534012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182015|Paravertebral Block vs. General Anesthesia for Major Abdominal Surgery|Paravertebral Block Versus General Anesthesia for Major Abdominal Surgery in Elderly: a Prospective Randomized Clinical Trial||Makassed General Hospital|No|Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Both|70 Years|N/A|No|||August 2015|August 24, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02534012||14313|
NCT02540187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108164|Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients|Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2012|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|164|Samples Without DNA|blood specimen|Male|18 Years|65 Years|No|Probability Sample|Haemophilia A and B patients between 18 and 65 years old, whatever the severity of their        disease|March 2016|March 9, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540187||13839|
NCT02540460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCB01-0371-14-1-01|Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371|A Phase I Clinical Study, Multiple Dose of LCB01-0371 in Healthy Male Subjects||LegoChem Biosciences, Inc|No|Completed|June 2014|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|November 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02540460||13818|
NCT02537119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardenal Herrera University|Massage Therapy on Hamstrings in Patients With Nonspecific Low Back Pain|Massage Therapy on Hamstrings in Patients With Nonspecific Low Back Pain||Cardenal Herrera University|Yes|Completed|May 2015|January 2016|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||September 2015|January 26, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02537119||14074|
NCT02537132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG_ALS1H_01|"New Perspectives of Adaptation to NIV in ALS"|"New Perspectives of Adaptation to Non-Invasive Ventilation (NIV) in Amyotrophic Lateral Sclerosis (ALS)"||Fondazione Don Carlo Gnocchi Onlus||Recruiting|January 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537132||14073|
NCT02543658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The first affiliated hospital|Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension|The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension||The First Affiliated Hospital of Nanchang University|No|Not yet recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||September 2015|September 4, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02543658||13574|
NCT02529995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00018|Phase I, Study in Chinese NSCLC Patients|Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent|AURAChinaPK|AstraZeneca|No|Active, not recruiting|August 2015|October 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02529995||14620|
NCT02532049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC062|A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313|A Phase Ia Clinical Trial to Assess the Safety, Immunogenicity and Ex-vivo Efficacy of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 Pfs-IMX313 Alone and With MVA Pfs25-IMX313||University of Oxford||Recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02532049||14463|
NCT02537366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EssaiClinique-VENDETTA|Dexmedetomidine for Non-invasive Ventilation After Chest Trauma|Dexmedetomidine for Non-invasive Ventilation After Chest Trauma (VENDETTA)|VENDETTA|University Hospital, Grenoble|Yes|Recruiting|September 2015|||August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|October 20, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02537366||14055|
NCT02537379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1444 / COPE1501|Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection||Gilead Sciences|No|Recruiting|September 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Adult patients with serogroup 2 (genotype 2) chronic HCV infection with or without        compensated cirrhosis who take SOF+COPE as part of routine clinical care at a        participating clinical site.|February 2016|February 10, 2016|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537379||14054|
NCT02633176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWOG0103|Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma|Phase Ⅲ Randomized Trial of Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel Induction Chemotherapy Followed by Concurrent Chemoradiation in Previously Untreated Patients Metastatic Nasopharyngeal Carcinoma||Sun Yat-sen University||Recruiting|January 2015|||January 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02633176||6699|
NCT02633189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEVERLY|Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer|A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer|BEVERLY|National Cancer Institute, Naples|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||December 2015|December 15, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02633189||6698|
NCT02539381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15NE064|The Stroke Vision App: A Screening Tool for Visual Stroke|Stroke Vision: A Screening Tool for the Assessment of Visual Impairments in Stroke Survivors||NHS Greater Glasgow and Clyde|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|62|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02539381||13900|
NCT02528162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the ELENA study|Evaluation of Education for Gestational Diabetes|Evaluation of Knowledge Regarding Gestational Diabetes and Evaluation of (Group) Education for Gestational Diabetes||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2015|October 2020|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|45 Years|No|Non-Probability Sample|Women diagnosed with GDM based on the IADPSG criteria|August 2015|August 17, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02528162||14761|
NCT02529813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-1018|CD19+ CAR T Cells for Lymphoid Malignancies|CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Recruiting|December 2012|||December 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|80 Years|No|||February 2016|February 11, 2016|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529813||14634|
NCT02529826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0530-14-HMO|Fertility Preservation in Prepubertal Boys: An Experimental Approach|Fertility Preservation in Prepubertal Boys: An Experimental Approach||Hadassah Medical Organization|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Male|3 Months|18 Years|No|||April 2015|August 19, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529826||14633|
NCT02629653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEAC-0613|Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study|Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study||S. Andrea Hospital|No|Completed|December 2013|December 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02629653||6969|
NCT02540447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Purge_LTX|Purge Vs no Purge in Living Donor Liver Transplantation Recipients|Graft Portal Reperfusion Without Purging Graft Preservative Solution In Living Donor Liver Transplantation. A Prospective Randomized Controlled Trial|PNP|Mansoura University|No|Completed|January 2013|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|No|||September 2015|September 21, 2015|August 30, 2015||No||No|September 5, 2015|https://clinicaltrials.gov/show/NCT02540447||13819|
NCT02533349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-007-001|Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease|Randomized Controlled Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease||Samsung Medical Center|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02533349||14364|
NCT02536209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-8554-E03|A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects|||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|4||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02536209||14144|
NCT02536482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1173-4156|Free Amino Acid-based Formula to Treat Children Cow's Milk Protein Allergy|Tolerability to a New Free Amino Acid-based Formula in Children With Cow's Milk Protein Allergy||Edetec Indústria Alimentícia S.A.|Yes|Completed|August 2013|June 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|5 Years|No|||August 2015|August 28, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02536482||14123|
NCT02536768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BostonU|Evaluation of South Africa's National Adherence Strategy|Evaluation of the National Department of Health's National Adherence Guidelines for Chronic Diseases in South Africa Using Routinely Collected Data|ENHANCE|Boston University|Yes|Not yet recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|6680|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 29, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02536768||14101|
NCT02534233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00075654|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium|ColdPlay2|Johns Hopkins University|Yes|Enrolling by invitation|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534233||14296|
NCT02534467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35095A|Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?|Montelukast as Adjunct Treatment in Children With Atopic Dermatitis||Murdoch Childrens Research Institute|No|Not yet recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|6 Years|16 Years|No|||August 2015|August 24, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534467||14278|
NCT02540135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1313|Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma|Fluorescein vs. Intraoperative MRI in the Resection of Malignant High Grade Glioma||University of Colorado, Denver|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540135||13843|
NCT02529176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPA818|Trial of a Best-Practice Alert in the Electronic Medical Record to Reduce Unnecessary Telemetry Monitoring|Randomized Trial of a Best-Practice Alert in the Electronic Medical Record to Reduce Unnecessary Telemetry Monitoring||University of California, San Francisco|Yes|Not yet recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|384|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529176||14683|
NCT02541188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9428|Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea||MediSein|University Hospital, Montpellier|No|Recruiting|October 2014|January 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|460|||Female|18 Years|N/A|No|Probability Sample|Patients have or have had a breast cancer diagnosed before 40 years old in two shores of        the Mediterranean sea (France, lgeria, Marocco, Egypt, Tunisia)|September 2015|September 1, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02541188||13763|
NCT02541253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3110A_C_P3|A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children|An Open-label(Part1), Single Arm(Part1), Randomized(Part2), Double-blind(Part2), Active-controlled(Part2), Phase III Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children||Green Cross Corporation|Yes|Active, not recruiting|September 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|543|||Both|6 Months|19 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02541253||13758|
NCT02530216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039499|Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes|Automated Evaluation of Gastrointestinal Symptoms (AEGIS): A Pragmatic Clinical Trial Evaluating the Impact of AEGIS on Clinical Outcomes|AEGIS|Cedars-Sinai Medical Center||Not yet recruiting|January 2016|||June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|448|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530216||14603|
NCT02530229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/306/14|Arthrocentesis Study|Early Diagnostics of Septic Arthritis and Periprosthetic Joint Infections With Calorimetry and Polymerase Chain Reaction (PCR) of Synovial Aspirate Fluid||Charite University, Berlin, Germany|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|joint aspirates of native joints and joints with suspected periprosthetic joint infection|Both|18 Years|N/A|No|Probability Sample|Any patient with suspicion of septic arthritis or periprosthetic joint infection of the        hip, knee and shoulder being diagnosed or treated in our facility in a clinical routine        scenario willing to participate in this study (written informational consent)|August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530229|3 Months|14602|
NCT02534480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGP 555-001|Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)|A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers||NeuroGenetic Pharmaceuticals Inc|Yes|Completed|March 2015|November 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02534480||14277|
NCT02537197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-2025|The Effect of Regular Naltrexone Dosing on Disordered Gamblers|The Effect of Regular Naltrexone Dosing on Disordered Gamblers: An Examination of Neural Activation, Gambling Urges, and Gambling Behaviour||University of Calgary|Yes|Not yet recruiting|April 2016|August 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537197||14068|
NCT02537210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA withdrawal study|Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis|Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial||Chinese University of Hong Kong|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537210||14067|
NCT02537496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/2015|Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS|Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Enhancement of Dorsolateral Prefrontal Cortex Neuroplasticity: A TMS-EEG Study|rTMS-AD|Centre for Addiction and Mental Health|Yes|Recruiting|August 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|55 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02537496||14045|
NCT02537262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0451|Effect of Preoperative Oral Carbohydrates on Quality of Recovery in Laparoscopic Colorectal Surgery Patients|||Yonsei University|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|85 Years|No|||March 2016|March 11, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537262||14063|
NCT02537275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0024|Effect of the Pigment-free Optical Zone Diameter of Decorative Tinted Soft Contact Lenses on Visual Function|||Yonsei University|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02537275||14062|
NCT02540005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230215-1|Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage|Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage||Tampere University Hospital||Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|32|||Both|18 Years|N/A|No|Non-Probability Sample|Acute aneurysmal subarachnoid haemorrhage patients|January 2016|January 13, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540005||13853|
NCT02530593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoLiCOL|QoLiCOL - Quality of Life in Colon Cancer|QoLiCOL - Quality of Life in Colon Cancer|QoLiCOL|Sahlgrenska University Hospital, Sweden|No|Recruiting|June 2015|June 2020|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients with colon cancer prior to treatment initiation.|August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530593||14574|
NCT02537509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000881-73|PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo|Multicentre, Cross-over, PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter as an add-on Therapy, Coupled With Oral Vitamin D Supplementation vs. Placebo in a Randomised, Parallel-group Trial|PRADA|Rennes University Hospital|No|Recruiting|October 2015|January 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|N/A|No|||November 2015|November 2, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02537509||14044|
NCT02540798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SandwellWBNHS|Do Patient Anxiety Levels Decrease Urodynamic Test Reproducibility?|Do Increased Levels of Anxiety Decrease the Reproducibility of Symptoms During Urodynamic Studies in Women?||Sandwell & West Birmingham Hospitals NHS Trust||Recruiting|July 2015|April 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|Only patients referred for urodynamics for the first time will be asked to consider being        included in the study. Minimum of 30 participants to be included. Recruited via obstetric        and urogynaecology clinics.|September 2015|September 1, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02540798||13792|
NCT02528474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0041|Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents|||Yonsei University|No|Recruiting|August 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|19 Years|N/A|No|||September 2015|September 22, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02528474||14737|
NCT02542150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0933|Effects of Acetate, Alcohol, and Gut Microbiome on Brain Function|Effects of Acetate, Alcohol, and Gut Microbiome on Brain Function||University of Colorado, Denver|No|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542150||13689|
NCT02540317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICBT for stress|Internet-based Cognitive Behavior Therapy for Stress Disorders: a Randomized Trial|||Karolinska Institutet|No|Not yet recruiting|October 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540317||13829|
NCT02534363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZQ2005_nc1Y|Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up|Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year|AZQ2005_nc1Y|Fundación Marques de Valdecilla|No|Completed|October 2005|January 2013|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|136|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534363||14286|
NCT02544347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-116-17/06|Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Vaspin and Omentin-1 in Type 2 Diabetic Patients With Chronic Periodontitis||Bulent Ecevit University|No|Completed|July 2014|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||September 2015|November 2, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544347||13521|
NCT02535507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK1406|Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Pyrotinib as a Single Agent in HER2 Mutation Advanced Non-small Cell Lung Cancer Patients Who Failed to Previous at Least 2nd Line Treatments||Tongji University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02535507||14198|
NCT02542241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00877|Hypertonic Saline Resuscitation in Trauma Patients After Hemorrhage Control|Hypertonic Saline Resuscitation for Early Closure of Open Abdomen in Trauma Patients|CELTA|Fundacion Clinica Valle del Lili|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02542241||13682|
NCT02530645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA032323|Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults|||New York State Psychiatric Institute|No|Not yet recruiting|October 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|21 Years|No|||August 2015|August 21, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530645||14570|
NCT02530372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRD-01F|Feasibility of the UriCap-F for Urine Collection in Hospitalized Women|Feasibility of the UriCap-F for Urine Collection in Hospitalized Women||G.R. Dome Medical Ltd.|No|Enrolling by invitation|September 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02530372||14591|
NCT02528994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014D001170|Short Term Dietary Serine Supplementation and Circulating Serine Levels|A Pilot Study to Test the Effect of Short Term Dietary Serine Supplementation on Circulating Serine Levels||Massachusetts General Hospital|No|Not yet recruiting|July 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|24|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528994||14697|
NCT02542488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPBANGPREG|STOPBANG As A Screening Tool for Obstructive Sleep Apnoea in Pregnancy|Use of the STOPBANG Questionnaire for Predicting Obstructive Sleep Apnoea in Pregnancy||City Hospitals Sunderland NHS Foundation Trust||Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women booked to deliver at Sunderland Royal Hospital who have a body mass index        ≥40 at their first midwife appointment.|September 2015|September 3, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542488||13664|
NCT02537860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08252015|Paravertebral Block for Inguinal Hernia Repair in Elderly|Paravertebral Block for Inguinal Hernia Repair in Elderly: Randomized Double-blinded Clinical Trial||Makassed General Hospital|No|Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|N/A|No|||August 2015|August 28, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02537860||14017|
NCT02537899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATURN2015|Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD|A Case Series of Patients With Spinal Cord Injury Treated With Standard Therapies and NeuroAiD|SATURN|Moleac Pte Ltd.|No|Recruiting|June 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||August 2015|August 28, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02537899||14014|
NCT02530684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271/14|Study of Various Insoles in Patients With Knee Osteoarthritis|||University of Lausanne Hospitals|No|Recruiting|October 2014|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with knee osteoarthritis and control subjects|December 2015|December 1, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02530684||14567|
NCT02538926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9459|Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma||University of Washington|No|Not yet recruiting|November 2015|||July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02538926||13935|
NCT02542540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201174|Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI)|Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI) Is Nintendo Wii an Effective Intervention for Children With Osteogenesis Imperfecta||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|July 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|6 Years|18 Years|No|||September 2015|January 19, 2016|September 3, 2015||No|difficulty to include patients|No||https://clinicaltrials.gov/show/NCT02542540||13660|
NCT02631473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 055|PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers|Pharmacokinetics of Efavirenz and Lopinavir Nano-formulations in HIV Negative Healthy Volunteers: an Adaptive Design Study||St Stephens Aids Trust|Yes|Recruiting|November 2015|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02631473||6829|
NCT02533804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-140128105327-NAEP|A Community Epidemiology Study Evaluating the Factors Influencing Overall Health and Wellness|The Lake Nona Life Project||Johnson & Johnson Consumer and Personal Products Worldwide|No|Recruiting|December 2014|||August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|9000|||Both|18 Years|110 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults ages 18 and older living and/or working in the Lake Nona Community (proper) of        Orlando, Florida.|October 2015|October 9, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02533804||14329|
NCT02538536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBI-4050-ATX-9-03|A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||ProMetic BioSciences Inc.||Recruiting|July 2015|||September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|40 Years|N/A|No|||February 2016|February 16, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02538536||13965|
NCT02543970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLE-001|A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles|A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles||BioPhotas|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Test subjects will be between the ages of 30-75, Type I-IV Fitzpatrick Skin Color, and        willingness and ability to participate and comply with the test protocol and absence of        exclusionary criteria.|September 2015|September 4, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543970||13550|
NCT02543983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150188|Neurobiology of Suicide|The Neurobiology of Suicide||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|July 2021|Anticipated|July 2021|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|170|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|November 14, 2015|September 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543983||13549|
NCT02529514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baclo-Sleep|Usage of Baclofen for Sleep Improvement After Cardiac Surgery|Usage of Baclofen for Sleep Improvement After Cardiac Surgery||University Hospital of Liege|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|N/A|No|||August 2015|August 18, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02529514||14657|
NCT02529527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-001313|Web-based Preconception Health Education Tool|MyFamilyPlan: A Patient-Centered Web-based Preconception Health Education Tool||University of California, Los Angeles|No|Recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|340|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529527||14656|
NCT02529839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105-15-HMO-CTIL|Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)|Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis||Hadassah Medical Organization|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|August 19, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02529839||14632|
NCT02541799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504742|Comprehension of Research Informed Consent When Applied Through a Telemedicine Medium|Comprehension of Research Informed Consent When Applied Through a Telemedicine Medium||University of Iowa|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||October 2015|October 3, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541799||13716|
NCT02560298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2133|Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer|InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease|InterAACT|Eastern Cooperative Oncology Group||Recruiting|January 2016|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560298||12295|
NCT02558556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47718.068.14|FALCON: a Multicenter Randomized Controlled Trial|Near-infrared Fluorescence Cholangiography Assisted Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy (FALCON): a Multicenter Randomized Controlled Trial||Maastricht University Medical Center|Yes|Recruiting|January 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|308|||Both|18 Years|N/A|No|||September 2015|February 5, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558556||12429|
NCT02546908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107351|A Registry of Participants With Prostate Cancer in Asia|A Multicenter, Prospective, Longitudinal Registry of Patients With Prostate Cancer in Asia||Janssen Research & Development, LLC|No|Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3830|||Male|21 Years|N/A|No|Non-Probability Sample|Participants with High-risk localized prostate cancer (PC), Non-metastatic, biochemically        recurrent PC and Metastatic PC will be enrolled in this study.|March 2016|March 2, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546908|5 Years|13324|
NCT02546921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD14/001|This First in Human Study of the New Therapeutic Antibody MOv18 IgE in Patients With Advanced Cancer|A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-alpha, in Patients With Advanced Solid Tumours||Cancer Research UK|No|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|16 Years|N/A|No|||November 2015|November 23, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02546921||13323|
NCT02553486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NantesUH|Internationally Adopted Children Quality of Life|Internationally Adopted Children Quality of Life Study (QUADOP)|QUADOP|Nantes University Hospital|No|Completed|September 2015|March 2016|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|756|||Both|1 Month|25 Years|No|Non-Probability Sample|All international adopted children, who arrived in France between 2008 and 2013, living in        four French districts (Loire-Atlantique, Ille-et-vilaine, Maine et Loire and Finistère)|March 2016|March 24, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553486||12818|
NCT02553499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248-001|Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)|A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.||Merck Sharp & Dohme Corp.|No|Recruiting|November 2015|August 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553499||12817|
NCT02536547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01818-37|Diagnostic Value of Pulmonary Ultrasound in the Diagnosis of Ventilator-associated Pneumoniae|Diagnostic Value of Pulmonary Ultrasound in the Diagnosis of Ventilator-associated Pneumoniae|PAVM|Groupe Hospitalier Paris Saint Joseph|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|None Retained|biochemistry : procalcitonin, leukocytes, neutrophils      microbiology : bronchoalveolar lavage and tracheal aspiration|Both|18 Years|N/A|No|Non-Probability Sample|All patients with suspected VAP will be included in the study (new or extension of a        radiological image in a patient in mechanical ventilation for at least 48 hours associated        with at least two of the following criteria : fever ≥38.5 ° C or <36, 5 ° C, leukocytosis>        10 * 103 / ml or leukopenia <4 * 103 / ml; secretions purulent tracheal; reduction in PaO2        / (FiO2) <300 or PaO2 <60 mmHg)|August 2015|August 27, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02536547||14118|
NCT02542631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-00525|Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents|Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents||Calibra Medical, Inc.|No|Recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|312|||Both|22 Years|75 Years|No|||February 2016|February 17, 2016|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542631||13653|
NCT02536326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-ZX-028|LEPU Renal Denervation System for Resistant Hypertension|LEPU Renal Denervation System for Resistant Hypertension in Chinese Populations|LEPU-RDN|Lepu Medical Technology (Beijing) Co.,Ltd|Yes|Completed|November 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536326||14135|
NCT02539173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONCTION DIAPHRAGMATIQUE|Diagnosis of Diaphragmatic Paralysis After Interscalene Block: Feasibility and Impact Observed|Diagnosis of Diaphragmatic Paralysis After Interscalene Block by Measuring the Inspiratory Diaphragmatic Thickening: Feasibility and Impact Observed|BBDDIAPHRAGM|Groupe Hospitalier Paris Saint Joseph|Yes|Recruiting|June 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02539173||13916|
NCT02544386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701116|Impact of Hemiplegia Due to Stroke on the Microarchitecture of the Bone|Impact of Hemiplegia Due to Stroke on the Microarchitecture of the Bone: Evaluation Using Micro CT 3D High Resolution and by Magnetic Resonance Imaging (MRI)||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|June 2009|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|blood sample|Both|30 Years|N/A|No|Non-Probability Sample|Patient aged at least 30 who have experienced a vascular hemiplegia within 30 days before        enrollment|September 2015|September 8, 2015|September 7, 2015||No|Inclusion rhythm too slow|No||https://clinicaltrials.gov/show/NCT02544386||13518|
NCT02531828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 23402513.9.0000.5208|Study Comparing the Polyurethane Films and Sugarcane Biopolymer Used as Dressings|Expansion of Prospective Randomized Study Comparing the Polyurethane Films and Sugarcane Biopolymer Used as Dressings||Polisa - Biopolímeros para Saúde|Yes|Completed|August 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|1 Year|N/A|No|||August 2015|August 24, 2015|June 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02531828||14480|
NCT02531841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRKS00005503|High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma|High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial|MATRix|University Hospital Freiburg|Yes|Recruiting|July 2014|December 2019|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02531841||14479|
NCT02531854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBP-11-201|A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy|A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy||Advaxis, Inc.|No|Not yet recruiting|January 2016|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|20 Years|N/A|No|||December 2015|December 30, 2015|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531854||14478|
NCT02542696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTH-301|An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease|An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)||Cynapsus Therapeutics Inc|Yes|Recruiting|August 2015|||November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|226|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542696||13648|
NCT02542709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-011|The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder|The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder||Laval University|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02542709||13647|
NCT02541175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/15|Multi-Channel Esophageal ECG Signal Classification|Paroxysmal Atrial Fibrillation Detection and Heart Beat Classification in Multi-Channel Esophageal Long-Term ECG|MC-EECG|University Hospital Inselspital, Berne|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients: Adults, hospitalised at University Hospital Bern, Dept. of Cardiology.        Healthy subjects: Adults without any assumed or known cardiac disease.|November 2015|November 12, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02541175||13764|
NCT02532036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB040|MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection|A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis||University of Oxford|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02532036||14464|
NCT02535897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G26062012 BMS|Protein Ingestion and Muscle Carnitine Uptake|The Effects of an Insulinotropic Protein-carbohydrate Beverage on L- Carnitine Absorption and Muscle Carnitine Uptake||University of Nottingham|No|Completed|July 2013|July 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|7|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535897||14168|
NCT02541435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/583|Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer|Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer - a Prospective Longitudinal Study||St. Olavs Hospital|No|Not yet recruiting|August 2016|December 2033|Anticipated|December 2033|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1600|Samples With DNA|Blood|Female|30 Years|70 Years|No|Non-Probability Sample|women treated for breast cancer with radiotherapy|March 2016|March 6, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02541435||13744|
NCT02532530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLDELIRIUM1|Peri-operative Monitoring of Cerebral Oxygenation and the Onset of Delirium in Patients Undergoing Cardiac Surgery|Peri-operative Monitoring of Regional Cerebral Oxygen Saturation and Onset of Delirium in Cardiac Surgery Patients|ICARUS|Hasselt University|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|70 Years|N/A|No|||September 2015|September 8, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02532530||14427|
NCT02532543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1114|Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials|Prospective, Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials (SYMBIOS CORTICAL-CANCELLOUS GRANULE MIX; SYMBIOS OSTEOGRAF LD-300; OSTEOGRAF/N-300) Following Tooth Extraction||University of North Carolina, Chapel Hill|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532543||14426|
NCT02544451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15-809-110|Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor|A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Enrolling by invitation|August 2015|April 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|256|||Both|6 Years|N/A|No|||September 2015|September 4, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544451||13513|
NCT02532387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000877|Outpatient Treatment of PE and DVT in the Emergency Department|Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis: Impact of a New Protocol on Emergency Department Efficiency and Patient Safety||Massachusetts General Hospital|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|This is a multi-center prospective, observational study of MGH or BWH patients with PE or        DVTwith historical and contemporary controls.|March 2016|March 15, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532387|1 Month|14438|
NCT02532400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1505|Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients|Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial|COMPETE|Ruijin Hospital|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02532400||14437|
NCT02533765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST186.02|Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor|Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor||Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|May 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02533765||14332|
NCT02540148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO001C|Transpalpebral Micro Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration|Transpalpebral Micro Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration||The Eye Machine Canada Inc.||Not yet recruiting||||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A||||September 2015|September 2, 2015|September 1, 2015||Yes||No||https://clinicaltrials.gov/show/NCT02540148||13842|
NCT02540161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063483|Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma|Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma||Duke University|No|Recruiting|October 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|61|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540161||13841|
NCT02528903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29827|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers||Genentech, Inc.||Not yet recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528903||14704|
NCT02536170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076988|Arginine Therapy for Sickle Cell Disease Pain|Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease Pain||Emory University|Yes|Recruiting|February 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|114|||Both|3 Years|21 Years|No|||February 2016|February 9, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536170||14147|
NCT02544763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1521 Blinded Phase|A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Focal Seizures.||GW Research Ltd|Yes|Not yet recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|2 Years|65 Years|No|||September 2015|September 25, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544763||13489|
NCT02544776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|effect of amlodipine in pco|Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients|Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients||Ain Shams Maternity Hospital|Yes|Completed|January 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|35 Years|No|||March 2016|March 24, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544776||13488|
NCT02542111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-GDP|A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL|A Phase II Study of the Efficacy and Safety of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB Diffuse Large B-cell Lymphoma||Ruijin Hospital||Recruiting|May 2015|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|75 Years|No|||September 2015|September 9, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02542111||13692|
NCT02529384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-2015128|Multiple B-value Diffusion-weighted Imaging(DWI) in Evaluation of Breast Lesions|Multiple B-value Diffusion-weighted Imaging in Evaluation of Breast Lesions：Compare Biexponential Model, Stretched Exponential Model, Conventional Monoexponential DWI and Pathological Specimens.||Tang-Du Hospital|Yes|Recruiting|January 2015|December 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|After Surgical operation, specimen of lesion will be collected(Not every patient's specimen      will be collected. We should be approved by patient themselves). For analyze the relation      with biomarker from the MR imaging and pathological/molecular-biological biomarkers.|Female|18 Years|80 Years|No|Non-Probability Sample|Women with brest lesions.|August 2015|August 18, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02529384||14667|
NCT02531750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR_ORTHOMED|Metabolic Complications Following Achilles Tendon Rupture - A Cohort Study|Metabolic Complications Following Achilles Tendon Rupture - A Cohort Study||Hvidovre University Hospital|Yes|Recruiting|June 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blod and urine samples|Both|18 Years|70 Years|No|Non-Probability Sample|Fifty non-diabetic individuals of age 18 to 70 years who should undergo non-operative        treatment of acute Achilles tendon rupture and who are included to the randomized clinical        trial: Non-operative Treatment of Acute Achilles Tendon Rupture: Early Controlled        Mobilization Compared With Immobilization, ClinicalTrials.gov Identifier: NCT02015364 at        the department of orthopaedics, Hvidovre Hospital are recruited as cases for this study.|February 2016|February 28, 2016|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02531750||14486|
NCT02544854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-068|Pharmacokinetic/Pharmacodynamic Model of Propofol in Children|Pharmacokinetic/Pharmacodynamic Model of Propofol in Children||Pontificia Universidad Catolica de Chile|Yes|Recruiting|September 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|40|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|September 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02544854||13482|
NCT02541214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-171|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||January 11, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541214||13761|
NCT02541227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVER-GB-0514|Cerebrolysin REGistry Study in Stroke|Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke|CREGS-S|Ever Neuro Pharma GmbH|No|Recruiting|May 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|All patients receive acute ishemic stroke care according to local treatment standards, not        amended or influenced by the study|September 2015|September 3, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02541227|90 Days|13760|
NCT02632942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2141 125|Criteria for Accessory Vein Obliteration Trial.|Assessing Clinical Utility of the Criteria for Accessory Vein Obliteration for Failing Arteriovenous Fistula.|CAVO|King Faisal Specialist Hospital & Research Center|No|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02632942||6717|
NCT02535325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01408|Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer|A Phase I Study of Methoxyamine Combined With Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|September 2015|||October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|February 5, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02535325||14212|
NCT02536703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU CT005|Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population|LOTUS-CHINA: Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation In Patients With Severe Aortic Stenosis In Chinese Population|LOTUS-CHINA|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Not yet recruiting|September 2015|December 2020|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|65 Years|N/A|No|||August 2015|August 27, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536703||14106|
NCT02537067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04CON|Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle|A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle for 18 Months||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02537067||14078|
NCT02541279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/324|Effectiveness of a Group Intervention for the Treatment of Shoulder Pathologies|Effectiveness of a Group Intervention for the Treatment of Shoulder Pathologies||Universidad Miguel Hernandez de Elche|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||August 2015|September 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02541279||13756|
NCT02541292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15009760|Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD|Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD||Rigshospitalet, Denmark|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Persons in Denmark diagnosed with FSHD is invited to the study.|February 2016|February 18, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541292||13755|
NCT02641002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-90002-AML-001|A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)|A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome||Celgene|No|Recruiting|February 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02641002||6098|
NCT02532829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/H01|Human Intestinal Peptides Evaluation and Research|Effects of Different Metabolic States and Surgical Models on Glucose Metabolism and Secretion of Ileal L-cell Peptides|HIPER|Turkish Metabolic Surgery Foundation|No|Enrolling by invitation|September 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|240|Samples Without DNA|Plasma|Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. GROUP NS-A: Healthy participants, no known disease, no previous surgery, HbA1c<5.7%,             BMI<25 kg/m2.          2. GROUP NS-B: Obese diabetic, type 2 diabetes diagnosis longer than 3 years; BMI>30             kg/m2.          3. GROUP NS-C: Non-obese diabetic, type 2 diabetes diagnosis longer than 3 years; BMI<30             kg/m2.          4. GROUP NS-D: Obese non-diabetics, HbA1c<5.7%, No signs and history of T2D, and BMI>30             kg/m2.          5. Group SG: Participants who underwent sleeve gastrectomy          6. Group MGB: Participants who underwent mini-gastric bypass          7. Group IT: Participants who underwent sleeve gastrectomy with ileal transposition          8. Group TB: Participants who underwent sleeve gastrectomy with transit bipartition|August 2015|August 21, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02532829||14404|
NCT02534168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002488|Post-surgical Pain Assessment in Children: Roles of Skin Conductance and Genomics|Post-surgical Pain Assessment in Children: Roles of Skin Conductance and Genomics||Milton S. Hershey Medical Center|No|Not yet recruiting|September 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|N/A|3 Years|No|||August 2015|August 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534168||14301|
NCT02529280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090165H|Choices for Latinas and Clinical Trials|Choices: Increasing Access of Latinas Into Breast Cancer Clinical Trials||The University of Texas Health Science Center at San Antonio|No|Completed|February 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529280||14675|
NCT02529293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT012|A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers|A Pilot Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product (2 Single Doses of 0.2 U/kg) and U-200 Product (2 Single Doses of 0.2 U/kg) in Healthy Male and Female||Adocia|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529293||14674|
NCT02536898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/334|Norwegian Capture the Fracture Initiative|Norwegian Capture the Fracture Initiative|NoFRACT|Oslo University Hospital|No|Recruiting|May 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|87000|||Both|50 Years|N/A|No|||August 2015|August 31, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02536898||14091|
NCT02536911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP13777|A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate|An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function||Sanofi|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536911||14090|
NCT02537613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-283|A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Dana-Farber Cancer Institute|Yes|Recruiting|December 2015|August 2021|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02537613||14036|
NCT02537626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_AD_001|An Evaluation of the Effects of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease|An Evaluation of the Effect of the Erchonia ALS on Alzheimer's Disease||Erchonia Corporation|No|Not yet recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537626||14035|
NCT02545075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-248|A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine|A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine||Bristol-Myers Squibb|No|Recruiting|October 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02545075||13465|
NCT02544256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507-S16P|Mild Hypothermia During Intracranial Aneurysm Clipping|Mild Hypothermia During Intracranial Aneurysm Clipping: Effect on Brain Microcirculation and Postoperative Vasospasms in Patients With Ruptured Aneurysms||University Hospital Hradec Kralove|No|Not yet recruiting|December 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 15, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02544256||13528|
NCT02541955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acthar in Rheumatoid Arthritis|Use of Acthar in Rheumatoid Arthritis (RA) Related Flares|Use of Acthar in Rheumatoid Arthritis Related Flares||University of California, Los Angeles|No|Not yet recruiting|September 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02541955||13704|
NCT02542007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVERY Combo 2015-01|Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions|RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery|RECOVERY|OrbusNeich|Yes|Recruiting|May 2015|July 2021|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|436|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02542007||13700|
NCT02529371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRD-01M|Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients|Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients||G.R. Dome Medical Ltd.|No|Enrolling by invitation|September 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Male|18 Years|N/A|No|||September 2015|September 17, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02529371||14668|
NCT02533622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QI-2010-05|Holy Name Progressive Mobility in the ICU|A Clinical Study Of The Impact Of Total Care® Bed System Combined With The Liko Lift to Facilitate Early Progressive Mobility Compliance and Associated Clinical and Financial Outcomes.||Hill-Rom|No|Completed|January 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the Medical ICU|August 2015|August 24, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT02533622||14343|
NCT02532361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18473|Proportion of Hysterectomy After Female Sterilization|A Retrospective Analysis to Describe the Proportion of Hysterectomy After Female Sterilization With Hysteroscopic Device or Tubal Ligation Using Intermountain Healthcare Database in the US||Bayer|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|10578|||Female|18 Years|49 Years|No|Non-Probability Sample|Women aged 18 - 49 at index date who underwent hysteroscopic device sterilization        procedure or tubal ligation sterilization procedure.        Index date: Date of sterilization procedure|January 2016|January 19, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532361||14440|
NCT02532374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3L-PK-01-NZ|Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L|A Single-center, Open-label, Ascending Nicotine Levels Study to Investigate the Nicotine Pharmacokinetic and Pharmacodynamics Profiles, Safety and Tolerability of P3L in Smoking Healthy Subjects in Relation to Nicorette® Inhalator||Philip Morris Products S.A.|No|Completed|September 2015|February 2016|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532374||14439|
NCT02534493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS-CTMD-15-001|Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome|Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome||Pressure Profile Systems, Inc.|No|Recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|21 Years|65 Years|No|||August 2015|August 25, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534493||14276|
NCT02542020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32889514.4.0000.5262|Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis|Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis|Prospec-HIV|Oswaldo Cruz Foundation|Yes|Recruiting|June 2015|May 2022|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Patients infected by HIV with or without chronic viral hepatitis|September 2015|September 2, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02542020||13699|
NCT02540174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTAKRA-1405|Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment|Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program|ALTAKRA-1405|Centre Oscar Lambret|No|Recruiting|May 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|242|||Both|18 Years|65 Years|No|||September 2015|September 17, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02540174||13840|
NCT02540668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16008|A Drug Interaction Study of AZD3293 (LY3314814) and Warfarin in Healthy Participants|Effect of AZD3293 on the Pharmacokinetics of Warfarin in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02540668||13802|
NCT02528253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091059|A Phase 3 Study of Tanezumab for Chronic Low Back Pain|A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain|TANGO|Pfizer|Yes|Recruiting|August 2015|May 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|1800|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528253||14754|
NCT02534701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERASER|ERic Acute StrokE Recanalization (ERASER)|ERic Acute StrokE Recanalization (ERASER)|ERASER|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 year with acute ischemic stroke|August 2015|August 27, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534701||14260|
NCT02540226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-210|Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement|The Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Total Knee Replacement|TXA Knee|Hospital for Special Surgery, New York|Yes|Recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||September 2015|December 8, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540226||13836|
NCT02529748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506M73781|Pilot Study to Assess the Quantitative Dermal Transfer Efficiencies of Solids for Multiple Transfer Pathways|Pilot Study to Assess the Quantitative Dermal Transfer Efficiencies of Solids for Multiple Transfer Pathways||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|August 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529748||14639|
NCT02530034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0057|Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies|Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530034||14617|
NCT02532920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|715/2557(EC4)|The Natural History of Atopic Disease in Thai Children and Association With Atopic March|The Natural History of Atopic Disease in Thai Children and Association With Atopic March||Mahidol University|Yes|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|80|||Both|N/A|15 Years|No|Probability Sample|Patient who was diagnosed with atopic dermatitis by physician by searching ICD 10(L20.9,        L20.8)|March 2016|March 15, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532920||14397|
NCT02530307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-3951-201|HT-3951 vs. Placebo in Stroke Rehabilitation|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke|RESTORE|Dart NeuroScience, LLC|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|40 Years|85 Years|No|||February 2016|February 5, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530307||14596|
NCT02530320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEINO 13|Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved|Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved||Grupo Español de Investigación en Neurooncología|No|Recruiting|July 2015|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02530320||14595|
NCT02538419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002326|Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment|Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment||Brigham and Women's Hospital|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|45|||Both|21 Years|N/A|No|||October 2015|October 19, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538419||13974|
NCT02545088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-RCT-Phase III-Study II|New Technology for Individualised, Intensive Training of Gait After Stroke- Study II|New Technology for Individualised, Intensive Training of Gait After Stroke- Phase III Trials, Study II|HAL-RCT-II|Danderyd Hospital|No|Recruiting|October 2015|January 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|162|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02545088||13464|
NCT02529865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMCR-005|Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence|Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence|ADRESU|Nagoya University||Recruiting|July 2015|||December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Male|20 Years|N/A|No|||January 2016|January 14, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529865||14630|
NCT02542254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPL554-009-2015|The Effects of RPL554 on Top of Standard COPD Reliever Medications|A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.||Verona Pharma plc|No|Active, not recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|30|||Both|40 Years|70 Years|No|||November 2015|November 24, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02542254||13681|
NCT02534597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0682|National Evaluation of Quality of Childcare|National Evaluation of Quality of Childcare (ENCCI)|ENCCI|Duke University|No|Not yet recruiting|August 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|10||Anticipated|2520|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534597||14268|
NCT02533414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-RIRS-UAS-04|Effect of Use of Ureteral Access Sheath on Levels of Cystatin C & Netrin-1 in Patients Undergoing RIRS|Effect of Use of Ureteral Access Sheath on Blood and Urine Levels of Cystatin C and Netrin-1 in Patients Undergoing Retrograde Intrarenal Surgery||Selcuk University|No|Not yet recruiting|June 2016|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02533414||14359|
NCT02531594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC 2015-1914|An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients|An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients||Children's Hospital Medical Center, Cincinnati|Yes|Not yet recruiting|April 2016|June 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|N/A|N/A|No|||August 2015|August 21, 2015|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531594||14497|
NCT02540616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-006-01|Transcranial Electrical Stimulation for Mal de Debarquement Syndrome|Transcranial Electrical Stimulation for Mal de Debarquement Syndrome||Laureate Institute for Brain Research, Inc.|No|Recruiting|September 2013|December 2022|Anticipated|December 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02540616||13806|
NCT02534818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G09|Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia|Conventional Fluorescein Sodium Dosage o.1ml/kg Compared With a Lower Fluorescein Sodium Dosage o.02ml/kg for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial||Shandong University|Yes|Recruiting|June 2015|||November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|180|||Both|40 Years|80 Years|No|||August 2015|November 7, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534818||14251|
NCT02535091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP3089C021|Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures|An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures||SK Life Science|No|Not yet recruiting|May 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|490|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535091||14230|
NCT02543892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-040|A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya|Phase 1-2 Safety and Immunogenicity Study of PATH-wSP in Kenyan Adults and Toddlers||PATH|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Anticipated|147|||Both|1 Year|40 Years|Accepts Healthy Volunteers|||August 2015|January 15, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543892||13556|
NCT02530476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0975|Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia|Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia||M.D. Anderson Cancer Center|No|Recruiting|December 2015|||December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530476||14583|
NCT02530489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1043|Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer|Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530489||14582|
NCT02543424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/10FEV/053|Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients|Studies of the Diagnosis, Rehabilitation and Links Between Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|September 2015|||December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|5 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02543424||13592|
NCT02537990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS Database|Management of National MDS Clinical Database and Local Tissue Bank|Management of National MDS Clinical Database and Local Tissue Bank|MDS|Sunnybrook Health Sciences Centre|No|Recruiting|August 2005|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Specimens of bone marrow will be collected by aspiration when bone marrows are done for      clinical purposes only. BM Plasma will be stored in aliquots, Mononuclear cells (MCs) will      be isolated by density gradient centrifugation of buffy coat cells. The remainder of MC      collected in this way will be used for immediate extraction of DNA by standard techniques.|Both|19 Years|N/A|No|Non-Probability Sample|Primary care clinic, referrals from community physicians.|August 2015|August 28, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02537990|6 Years|14007|
NCT02538003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCB01-0371-13-1-03|To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371|A Randomized, Open-label, Single Dose, Crossover, Phase Ⅰ Trial to Evaluate the Effect of Food on the Pharmacokinetics of LCB01-0371 in Healthy Male Subjects||LegoChem Biosciences, Inc|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02538003||14006|
NCT02530905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4045-101|Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping||Sarepta Therapeutics|Yes|Active, not recruiting|October 2015|April 2018|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|12|||Male|7 Years|21 Years|No|||January 2016|January 5, 2016|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02530905||14550|
NCT02533934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12044|Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre or Post Liver Transplant|A Pilot Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir and Ledipasvir for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant|STOP-CO|University of California, San Francisco|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533934||14319|
NCT02530775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15040227|"Is Instrumentation Necessary for "Static" Degenerative Spondylolisthesis"|"Is Instrumentation Necessary for "Static" Degenerative Spondylolisthesis - A Prospective Randomized Clinical Study"||University of Pittsburgh|No|Withdrawn|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 18, 2015||No|The study did not receive IRB approval and was withdrawn|No||https://clinicaltrials.gov/show/NCT02530775||14560|
NCT02548572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMC1TES/RP|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy NSR Device Study - A Multicenter Study|TES/RP|Wills Eye|Yes|Not yet recruiting|March 2016|December 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|22 Years|80 Years|No|||September 2015|September 11, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548572||13196|
NCT02549040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-046|Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)|A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults||Merck Sharp & Dohme Corp.|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549040||13160|
NCT02549053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2011-10|Prevalence of Human Papillomavirus in Barrett Esophagus Compared With Controls|Prevalence of Human Papillomavirus in Barrett Esophagus Compared With Controls|Barrett|University Hospital, Angers|No|Completed|February 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|219|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02549053||13159|
NCT02548364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJD-VITDAMI-14-01|Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI)|Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction|VITDAMI|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|No|Recruiting|October 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|40 Years|85 Years|No|||March 2016|March 21, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548364||13212|
NCT02550626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0365|Exploring the Relationship Between Alpha-synucleinopathy Related Non-motor Symptom and Post-op. Delirium in Elderly Patients With Spine Surgery|||Yonsei University|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|129|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|spine surgery|September 2015|September 14, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02550626||13038|
NCT02550639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hCMV2013-RESPECT|Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant|A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT)|RESPECT|Hospital Universitari de Bellvitge|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|160|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550639||13037|
NCT02561247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro 1463|Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute CRRT in Children|Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children||Baxter Healthcare Corporation|No|Recruiting|November 2015|May 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||August 2015|December 21, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561247||12222|
NCT02542683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP7626|Physical Activity and Cognitive Development in Children|Physical Activity and Cognitive Development in Children||Columbia University|No|Not yet recruiting|October 2015|December 2025|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|400|||Both|30 Months|6 Years|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542683||13649|
NCT02528136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarbeteocinHeart2014|The Clinical Carbetocin Myocardium Trial|The Clinical Carbetocin Myocardium Trial|CMT|Oslo University Hospital|Yes|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|50 Years|No|||August 2015|September 14, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02528136||14763|
NCT02530697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40068714.1.0000.5558|The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil|The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: An Open-label, Randomized Clinical Trial in Brazil||University of Brasilia|No|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02530697||14566|
NCT02530918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS7080-A-U101|Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration|PHASE I DOSE ESCALATION AND EXPANSION STUDY OF DS-7080a IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION||Daiichi Sankyo Inc.|No|Recruiting|July 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|45|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530918||14549|
NCT02535975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0706|The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy|||Yonsei University|No|Recruiting|December 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2015|August 26, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02535975||14162|
NCT02533232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-MAC-001|Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia|Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial||Pakistan Institute of Learning and Living|Yes|Recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533232||14373|
NCT02532270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP 01|Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring|Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring During Spinal Anaesthesia for Cesarean Section:A Prospective,Randomized, Controlled Study||Fudan University|No|Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532270||14447|
NCT02539407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-08|Population Pharmacokinetics of β-Lactams in Critically Ill Children|Population Pharmacokinetics and Rationalization of β-Lactams Administration in Critically Ill Children|OPTIMOME|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|540|||Both|N/A|18 Years|No|Non-Probability Sample|Minor patients requiring the administration of β-lactam antibiotics|September 2015|September 24, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02539407||13898|
NCT02539719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRX003-001|Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer|A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer||Stemcentrx|No|Recruiting|August 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Female|18 Years|N/A|No|||October 2015|October 16, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539719||13875|
NCT02532101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIDOPP-21102|Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|UNIDOPP|University of Science Malaysia|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02532101||14459|
NCT02528539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMH2015.002|Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)|Prevention of Secondary Lymphedema by Utilizing Self-management Education in Conjunction With Acupuncture Among Breast Cancer Patients Who Are at High Risk of Developing Lymphedema||Huntington Memorial Hospital|No|Recruiting|August 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528539||14732|
NCT02528552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-PRC-001|Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO|A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia||Theradome, Inc.|No|Recruiting|August 2015|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528552||14731|
NCT02528565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-BA-01|Gastric Banding After Failed Gastric Bypass|Laparoscopic Adjustable Gastric Banding With the Adhesix Bioring After Failed Gastric Bypass: a Prospective Evaluation in a High-volume Center||be Medical|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with failed RYGB receiving revisional LAGB.|August 2015|August 18, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02528565|2 Years|14730|
NCT02536924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6015290|RCT of RESOLVE: A Waiting Room Intervention for Crisis Clients|Randomized Control Trial of RESOLVE (Relaxation Exercise, SOLving Problem and cognitiVe Errors): A Waiting Room Intervention for Crisis Clients|RESOLVE|Queen's University|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|140|||Both|18 Years|65 Years|No|||August 2015|August 29, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02536924||14089|
NCT02531165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR14-10591|Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|PERSEUS|Centre Hospitalier Universitaire Vaudois|Yes|Not yet recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02531165||14530|
NCT02536495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14152|Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer|An Investigator-Sponsored Phase 1/2 Study of Selinexor (KPT-330) and Docetaxel as Second Line Therapy in Patients With Relapsed Squamous Cell Lung Cancer||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|September 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|August 27, 2015|Yes|Yes|PI decision due to funding support|No||https://clinicaltrials.gov/show/NCT02536495||14122|
NCT02542033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-RCT1-2015|Glycemic Response to Low Sugar Apple Juice|Double-blind, Randomized, Controlled, Cross-over Trial on Glycemic Response to Low Sugar Apple Juice||Clinical Research Center Kiel GmbH|No|Active, not recruiting|May 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Male|18 Years|N/A|No|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02542033||13698|
NCT02529137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-141310|Pivotal Study for Validation of Philips Dx (PDx)|Pivotal Study for Validation of Philips Dx for Diagnosis in Surgical Pathology||Philips Digital Pathology Solutions|No|Active, not recruiting|July 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|2000|||Both|N/A|N/A|No|Non-Probability Sample|Both: surgical pathology slides of both female and male participants are being studied.|December 2015|March 10, 2016|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529137||14686|
NCT02540941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456- HMO-CTIL|Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells|Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells||Hadassah Medical Organization|No|Not yet recruiting|October 2015|||June 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will obtain human single and bulk cells from healthy donors. Volunteers will be sperm        donors who shall designate part or full donation to the proposed research. Egg donors who        shall designate part of the eggs to the proposed research; for women who come to the        clinics of fertility problems. Reaching the donors will be using advertisements in sperm        banks and in women's health centers or asking for student volunteers.|June 2015|September 1, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02540941||13781|
NCT02540954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16598|Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)|An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD)||Bayer|No|Recruiting|September 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|51 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540954||13780|
NCT02541968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD F2F vs ICBT|Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder|Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder - a Randomized Controlled Non-inferiority Trial||Karolinska Institutet||Recruiting|August 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02541968||13703|
NCT02543632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1591|PARACHUTE V PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE.|PARACHUTE V: PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE. A German Trial to Evaluate the Improvement in Quality of Life and Cardiac Output Following Implanting of the Parachute Implant System|P5|CardioKinetix, Inc|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at least 18 years of age with symptoms of heart failure and anteroapical wall        motion abnormality due to myocardial infarction.|September 2015|December 8, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543632|6 Months|13576|
NCT02534766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2015/71|MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD|MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN - COPD - A Comparison of Clinical Outcomes Before and After the MISSION Clinic.|MISSION-COPD|Portsmouth Hospitals NHS Trust|No|Not yet recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be patients who attend MISSION COPD clinics, identified as having        uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the        MISSION clinical team or health care professionals who attend the clinic in a clinical        capacity.|August 2015|August 28, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02534766||14255|
NCT02534779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15-134|Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products|Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products||CONRAD|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|January 28, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534779||14254|
NCT02536430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZadUMS-P/212/D|Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block|Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block in Patients With Irreversible Pulpitis: A Prospective, Randomized, Double-blind Clinical Trial||Azad University of Medical Sciences|Yes|Completed|March 2015|August 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536430||14127|
NCT02542046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16964|Uniformity of Oral Contrast Material in the Bowel|Uniformity of Oral Contrast Material in the Bowel||University of California, San Francisco|No|Recruiting|January 2015|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|750|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542046||13697|
NCT02640924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-1278A3|Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma|Proton Beam Radiotherapy Versus Switching Control Radiofrequency Ablation for Patients With Medium (>3, ≦5 cm) or Large (>5, ≦7cm) Treatment-naive Hepatocellular Carcinoma||Chang Gung Memorial Hospital|No|Recruiting|January 2016|December 2021|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|20 Years|85 Years|No|||March 2016|March 18, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02640924||6104|
NCT02538809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-21|Quantitative Evaluation of Cytokeratin in the Urine of Spinal Cord Individuals With Suspicion of Bladder Cancer|Quantitative Evaluation of a Bladder Cancer Marker (Cytokeratin) in the Urine of Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer|Cytokeratin|Swiss Paraplegic Centre Nottwil|No|Not yet recruiting|September 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|individuals presenting with symptoms or clinical findings suspicious for bladder cancer at        a tertiary urologic referral center|August 2015|September 1, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02538809||13944|
NCT02539004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0117-15|US-NCCT Real-time Fusion for Urinary Stones Follow up|Ultrasound Non-contrasrt Computed Tomography Real-time Fusion for Urinary Stones Follow up||Rambam Health Care Campus|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|patients with proved urolithiasis on NCCT|September 2015|September 6, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02539004||13929|
NCT02544737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HangzhouCH|Apatinib for Metastatic Esophageal Cancer.|A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer.||Hangzhou Cancer Hospital||Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||October 2015|October 10, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02544737||13491|
NCT02544750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1521 Open-Label Extension|An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Focal Seizures.||GW Research Ltd|Yes|Not yet recruiting|June 2016|July 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|144|||Both|2 Years|65 Years|No|||September 2015|September 25, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544750||13490|
NCT02528279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rep001|Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria|Prospective Assessment of Relapse Characteristics of Plasmodium Ovale and Antimalarial Treatment Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria in Gabon|REPLAMO|Albert Schweitzer Hospital|No|Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|1 Year|N/A|No|||August 2015|August 18, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02528279||14752|
NCT02643355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR# 15-4004|Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED|Utility of Olanzapine in the Treatment of Opioid Withdrawal in the Emergency Department||Minneapolis Medical Research Foundation|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02643355||5917|
NCT02632955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2151 054|Drug Eluting Balloon for Early Fistula Failure Trial|Drug Eluting Balloon for Early Fistula Failure Trial|DEBEFF|King Faisal Specialist Hospital & Research Center|No|Recruiting|December 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02632955||6716|
NCT02539290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1146|Preovulatory Uterine Flushing With Saline as a Treatment for Unexplained Infertility|Preovulatory Uterine Flushing With Saline as a Treatment for Unexplained Infertility: A Randomised Controlled Trial Protocol||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Female|18 Years|37 Years|No|||August 2015|August 31, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02539290||13907|
NCT02533960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASUNOA-Prime|Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime|Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime|RASUNOA-Prime|University Hospital Heidelberg|No|Recruiting|June 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|4000|||Both|18 Years|N/A|No|Probability Sample|Acute stroke patients with atrial fibrillation (AF) under different anticoagulation        schemes pre stroke [Non-vitamin K antagonists oral anticoagulants (NOAC, also referred to        as novel or new oral anticoagulants), Vitamin K antagonists (VKA), and no oral        anticoagulation. According to the type of stroke, patients will be enrolled in the        ischemic or hemorrhagic stroke substudy.|August 2015|August 26, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02533960||14317|
NCT02539849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA-FOS|Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease|Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02539849||13865|
NCT02540122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5627|Pilot Clinical Evaluation of Approved Contact Lenses|Imaging of Conjunctival Microvasculature During Contact Lens Wear||Johnson & Johnson Vision Care, Inc.|Yes|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540122||13844|
NCT02540811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRG-A01-01|Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament|A Prospective, Non-comparative Clinical Investigation of a Novel Decellularised Porcine Xenograft (dCELL® ACL Scaffold) for Reconstruction of the Anterior Cruciate Ligament||Tissue Regenix Ltd|No|Not yet recruiting|September 2015|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||September 2015|September 3, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02540811||13791|
NCT02528773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141105|Efficacy of ART to Interrupt HIV Transmission Networks|Efficacy of ART to Interrupt HIV Transmission Networks|ART-NET|University of California, San Diego|No|Recruiting|October 2014|||October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|425|Samples With DNA|Blood Draws: Approximately 2 tablespoons (30 mL) of blood will be taken for blood tests and      storage at each visit. Participants' blood will be tested for:        -  CD4+/CD8+ T-cell Count. This is a measure of the immune system; T-cells help the immune           system fight infections.        -  HIV-1 RNA (Viral Load). This measures the amount of HIV in the blood.        -  HIV pol sequence. This measures the type of HIV in your blood.        -  Blood will be collected for storage for future HIV testing, studies to measure the           amount of residual HIV that remains in people who are doing well on HIV treatment,           genetic testing of the HIV virus and possible HLA genotype testing as determined by the           results of this and future studies.|Both|18 Years|N/A|No|Non-Probability Sample|Persons with newly diagnosed HIV infection|August 2015|August 17, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02528773||14714|
NCT02534051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carepath|A Clinical Care Pathway for Obese Pregnant Women: A Pilot Cluster RCT|A Clinical Care Pathway for Obese Pregnant Women: A Pilot Cluster Randomized Controlled Trial||McMaster University|No|Not yet recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|190|||Female|12 Weeks|20 Weeks|Accepts Healthy Volunteers|||August 2015|August 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02534051||14310|
NCT02538172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STCS FUP # 052|Cell-mediated Immunity for Prevention of CMV Disease|Monitoring of Specific Cytomegalovirus Cell-mediated Immunity (CMV-CMI) for Optimization of Preventive Strategies Against CMV Infection in High-risk Solid-organ Transplant Recipients||University of Lausanne Hospitals|No|Recruiting|October 2015|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02538172||13993|
NCT02536781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE582088|Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment|Khon Kaen University Ethics Committee in Human Research||Khon Kaen University|Yes|Recruiting|August 2015|||May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|25 Years|No|||September 2015|September 3, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02536781||14100|
NCT02543138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEE YOON-JE|The Development and Experimental Application of a New Thoracostomy Trocar|The Development and Experimental Application of a New Thoracostomy Trocar|TDEANTT|Hanyang University|Yes|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|16|||Both|25 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02543138||13614|
NCT02543151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-11|SpyGlass in Post Liver Transplant Biliary Complications.|Prospective Evaluation of SpyGlass Direct Visualization System in Post Liver Transplant Biliary Stricture.||Hospital Israelita Albert Einstein|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543151||13613|
NCT02529696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502M62761|Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers|Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|September 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients receiving care from the neuro ICU at the University of Minnesota will be eligible        for participation.|August 2015|August 18, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02529696||14643|
NCT02529709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasCU|The Effect of Meal Composition on Blood Lipids|The Effect of Meal Composition on Blood Lipid Concentrations||Texas Christian University|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02529709||14642|
NCT02529423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7KKBE20132101|Multi-country Project on the Role of Diet, Food-related Behavior, and Obesity in the Prevention of Depression|Multi-country cOllaborative Project on the rOle of Diet, FOod-related Behaviour, and Obesity in the Prevention of Depression (MoodFOOD)|MoodFOOD|University of the Balearic Islands|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02529423||14664|
NCT02532660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laboratório Catarinense SA|Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode|Fase II/III Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode|LABCATTCJUSS|Laboratório Catarinense SA|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|178|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02532660||14417|
NCT02542085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OuluUH|Comparison of Hybrid and Laparoscopic Incisional Hernia Repair|Comparison of Hybrid and Laparoscopic Incisional Hernia Repair: A Prospective Randomized Multicentre Study||Oulu University Hospital|Yes|Active, not recruiting|November 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||September 2015|September 4, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02542085||13694|
NCT02542098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD4002|Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children|A Phase 2B, Open-label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Effectiveness of Hydrocodone Bitartrate Extended-Release Tablets (HYD) in Children, Aged 12 to 17 Years Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Around-the-Clock Opioid Analgesics||Purdue Pharma LP|Yes|Not yet recruiting|January 2017|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|12 Years|17 Years|No|||December 2015|December 10, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542098||13693|
NCT02529982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1370|Effects of Curcumin Supplementation on Glycemic Control, Oxidative Stress, Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes|Effects of Curcumin Supplementation on Glycemic Control, Oxidative Stress, Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes||National Nutrition and Food Technology Institute|Yes|Recruiting|July 2015|||January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|65 Years|No|||July 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529982||14621|
NCT02530294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM04-HH05|Study of DRM04 in Subjects With Axillary Hyperhidrosis|A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of DRM04 in Subjects With Axillary Hyperhidrosis||Dermira, Inc.|No|Active, not recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|353|||Both|9 Years|N/A|No|||March 2016|March 9, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530294||14597|
NCT02534116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Persing.8.15|A Comparison of Incisional Negative-Pressure Wound Therapy Versus Conventional Dressings Following Abdominal Surgery|A Comparison of Incisional Negative-Pressure Wound Therapy Versus Conventional Dressings Following Abdominal Surgery: A Randomized-Controlled Trial||Yale University|Yes|Not yet recruiting|October 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02534116||14305|
NCT02537340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP796/15|PET/CT for Staging Rectal Cancer Patients With and Without EMVI-MR|The Use of PET/CT for Initial Staging of Rectal Cancer Patients With Extramural Vascular Invasion Detected by MR (EMVI-MR)||Instituto do Cancer do Estado de São Paulo|Yes|Active, not recruiting|August 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|106|||Both|18 Years|N/A|No|Probability Sample|Patients with histologically proven rectal cancer.|August 2015|August 30, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02537340||14057|
NCT02537353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14186713000000068|Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip|Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding||University of Sao Paulo General Hospital|Yes|Not yet recruiting|September 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|N/A|N/A|No|||July 2015|August 31, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537353||14056|
NCT02543203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0005|Essential Oils for Enhancing QOL in ASD|Essential Oils for Enhancing of Quality of Life in Autism Spectrum Disorder (ASD)||Ohio State University|No|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|34|||Both|3 Years|9 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543203||13609|
NCT02543216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FADSDIET|Gene - Diet Interactions in Fatty Acid Desaturase 1 Gene|Gene - Diet Interactions in Fatty Acid Desaturase 1 Gene (FADSDIET)|FADSDIET|University of Eastern Finland||Completed|January 2015|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|59|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543216||13608|
NCT02452164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T91/2015|Family MobilePhone Otoscopy in Diagnostics of Otitis Media|Family MobilePhone Otoscopy in Diagnostics of Otitis Media. (Family mOTO-Study)|FamilymOTO|Turku University Hospital|No|Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||February 2016|February 12, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452164||20597|
NCT02430194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-300-Amendment 1|Lonafarnib With Ritonavir in HDV (LOWR-2)|An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)|LOWR-2|Eiger BioPharmaceuticals|Yes|Recruiting|December 2014|January 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|65 Years|No|||April 2015|April 25, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02430194||22282|
NCT02430207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFSN201407|Incidence of Pulmonary Embolism During Temporary Pacing Via Femoral Versus Subclavian Vein|Study of Incidence of Pulmonary Embolism During Peroperative Period of Temporary Pacing Via Femoral Vein Versus Subclavian Vein in China||The First Affiliated Hospital with Nanjing Medical University|Yes|Not yet recruiting|May 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||April 2015|February 18, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02430207||22281|
NCT02452008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1557|Study of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer|||Sidney Kimmel Comprehensive Cancer Center|No|Not yet recruiting|July 2015|||July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||May 2015|May 21, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452008||20609|
NCT02452021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002155|Pencil Beam Scanning Proton Radiotherapy for Esophageal Cancer|An Observational Study of Pencil Beam Scanning (PBS) Proton Radiotherapy (RT) as a Component of Trimodality Therapy for Esophageal Cancer||Mayo Clinic|Yes|Recruiting|July 2015|March 2019|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with non-metastatic esophageal cancer who are candidates for neoadjuvant        chemoradiotherapy followed by surgery|December 2015|December 31, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452021||20608|
NCT02448849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-013|Autologous BM-MSC Transplantation in Combination With Platelet Lysate (PL) for Nonunion Treatment|Use of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Combination With Platelet Lysate Product for Human Long Bone Nonunion Treatment, A Phase 2-3 Clinical Trial||Royan Institute|Yes|Recruiting|June 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|October 29, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02448849||20852|
NCT02449096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117-15|Comparison of the Results of Complex Ankle Fractures Treated With and Without Ankle Arthroscopy|Operative Treatment of Complex Ankle Fractures: Comparison of the Results With and Without Ankle Arthroscopy-a Randomized Controlled Trial||Ludwig-Maximilians - University of Munich|Yes|Recruiting|July 2015|June 2025|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||October 2015|October 18, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449096||20833|
NCT02448654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504015628|Treatment for Nicotine Addiction in Women|COMT Inhibition as a Novel Treatment for Nicotine Addiction in Women||Yale University|Yes|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||January 2016|January 8, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448654||20867|
NCT02435186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-H20150111|p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer|Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer||Shenzhen SiBiono GeneTech Co.,Ltd|No|Not yet recruiting|June 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02435186||21900|
NCT02455765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00366|Glycemic Response of Co-ingesting Carbohydrate and Amino Acids|Glycemic Response of Co-ingesting Carbohydrate and Amino Acids||Clinical Nutrition Research Centre, Singapore|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|7||Actual|23|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455765||20321|
NCT02449395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39301|Cross-sectional Study of Fibromyalgia|A Cross-sectional Study of Fibromyalgia in Beijing||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|April 2015|November 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients fulfilling 1990 or 2010 ACR criterion for fibromyalgia be seen in the        Fibromyalgia Outpatient Service which belonged to the Department of Rheumatism,        Guang'anmen Hospital, Beijing China.|December 2015|December 17, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02449395||20810|
NCT02449603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10319|Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes|Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study||Xijing Hospital|Yes|Recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02449603||20794|
NCT02685358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-288|An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach|An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach||VA Office of Research and Development|Yes|Not yet recruiting|October 2016|March 2020|Anticipated|August 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|260|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02685358||2695|
NCT02685371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-31-2016-1083|Septal Shift for the Diagnosis of COnstrictive Pericarditis: The Impact of Inspiratory Effort Quantification on Deep Breathing Manoeuvres|Septal Shift for the Diagnosis of COnstrictive Pericarditis: The Impact of Inspiratory Effort Quantification on Deep Breathing Manoeuvres (SCOPED)|SCOPED|Université de Sherbrooke||Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population consists of healthy subjects not know for any cardiovascular disease.|February 2016|February 12, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02685371||2694|
NCT02459522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANHRVB_Dr.Tang|Bayesian Estimation of Diagnostic Performance for Cardiovascular Autonomic Neuropathy|Bayesian Estimation of Diagnostic Performance of Short-term Heart Rate Variability for Cardiovascular Autonomic Neuropathy Without a Gold Standard||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|88|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Individuals with inclusion and exclusion criteria were recruited from healthy examination        centres to assess cardiovascular autonomic function using both the short-term heart rate        variability and Ewing's tests.|June 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02459522||20032|
NCT02441348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15030497|Efficacy of Conversation Training Therapy (CTT)|Efficacy of Conversation Training Therapy (CTT)||University of Pittsburgh|No|Active, not recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|55 Years|No|Non-Probability Sample|Individuals diagnosed with either muscle tension dysphonia (MTD) or vocal fold lesion who        are candidates for voice therapy.|February 2016|February 9, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441348||21427|
NCT02441361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise & Bariatric|Effects of Exercise Training in Bariatric Patients|Effects of Exercise in Bariatric Patients: a Randomized Controlled Trial||University of Sao Paulo|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02441361||21426|
NCT02454491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58|Verapamil vs Heparin in Transradial Procedures|Comparison of VERapamil vs. Heparin Therapy on Procedural sUccess During Transradial Coronary Procedures (VERMUT Study)|VERMUT|University Hospital of Ferrara|Yes|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02454491||20418|
NCT02454504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307.CI|Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy|||Regina Elena Cancer Institute||Recruiting|March 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02454504||20417|
NCT02454309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00892|Cranberry for the Prevention of Urinary Tract Infections|A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women||University of British Columbia|Yes|Not yet recruiting|July 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454309||20432|
NCT02444884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0812|MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors|A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors||Children's Oncology Group|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Both|12 Months|21 Years|No|||February 2016|February 5, 2016|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444884||21156|
NCT02444897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-12-514|The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy|The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy||Keimyung University Dongsan Medical Center|No|Completed|September 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|19 Years|80 Years|No|||May 2015|May 14, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02444897||21155|
NCT02442323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13023|A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients|A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients||Fox Chase Cancer Center|No|Recruiting|August 2013|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02442323||21352|
NCT02454647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-PKPDGN|Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients|Induction Chemotherapy, Chemo-radiotherapy and Surgery in Locally Advanced Gastric Cancer Patients: Long Term Results From a Single Institution.||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|46|Samples With DNA|Surgical specimen with potential for extraction of DNA.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with locally advanced adenocarcinoma of the stomach treated with a neoadjuvant        protocol consisting of induction chemotherapy (ICT), chemoradiotherapy (CRT)and salvage        surgery. Patients must have a medically fit condition to complete the protocol.        Initial staging comprises a thoracic and abdominal computerised tomography scan,        endoscopic ultrasound endoscopy (EUS), biopsy and blood test including blood cell count,        hepatic and renal function.        Radiological and endoscopic evaluations are performed at baseline and at the completion of        ICT and CRT.        Blood tests are acquired at baseline, before each chemotherapy course and concurrently        with evaluations. Blood tests are also obtained during follow-up and at the time        progression.|May 2015|May 27, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454647||20406|
NCT02449590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M197|Onion, Cardiovascular Risk Markers and Gene Expression|The Effects of Onion on Plasma Lipoproteins, Blood Pressure and Gene Expression in Overweight Humans - a Double-blinded, Randomized Cross-over Study|M197|University of Copenhagen|No|Completed|August 2008|April 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|February 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02449590||20795|
NCT02448667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-014|Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies|Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies||Rigshospitalet, Denmark|No|Recruiting|January 2015|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448667||20866|
NCT02436018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20150308|WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy|Safety and Efficacy Evaluation of The Nasopharyngeal Airway Embedded With Jet Ventilation Catheter(WEI NASAL JET) Applied for The Sedation of Outpatient Upper Gastrointestinal Endoscopy||RenJi Hospital|Yes|Recruiting|March 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|1800|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02436018||21836|
NCT02436291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE-01|Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis|Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis||MB Mazor Ltd.|No|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||April 2015|May 5, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02436291||21815|
NCT02456389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-073|Perioperative Risk Study|A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-based, Protocol-driven Management in Patients Undergoing Elective Major Cancer Surgery|PRS|Fox Chase Cancer Center|Yes|Recruiting|July 2014|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1456|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02456389||20273|
NCT02454413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Microbial Evaluation of Denture Cleaning and Overnight Storage|ASSESSMENT OF THE IMPACT OF CLEANING METHODS AND OVERNIGHT DENTURE STORAGE ON BIOFILM FORMATION ON REMOVABLE ACRYLIC DENTURES.||Universitaire Ziekenhuizen Leuven|No|Completed|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|13|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 15, 2013||No||No||https://clinicaltrials.gov/show/NCT02454413||20424|
NCT02454426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TakedaHRV|Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease|An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease||Thomas Jefferson University|No|Not yet recruiting|April 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454426||20423|
NCT02453516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serratus Block|The Effect of the Serratus Block on Pain Control After Breast Surgery|The Effect of The Serratus Block on Analgesia After Breast Surgery A Randomized Controlled Double-Blinded Study||Women's College Hospital|No|Recruiting|October 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|80 Years|No|||December 2015|December 9, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02453516||20493|
NCT02432027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-C-82T-2101|Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test|A Single-Center, Randomized, Observer Blind, Vehicle- and Comparator-controlled Trial to Evaluate the Antipsoriatic Efficacy and Safety of Topical Formulations of C-82 in a Psoriasis Plaque Test||Prism Pharma Co., Ltd.|No|Completed|June 2015|September 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|14|||Male|18 Years|N/A|No|||October 2015|October 19, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02432027||22143|
NCT02456441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 17136213.0.0000.5345|Effects of TENS in Autonomous System in Women With Overactive Bladder|The Effects of Transcutaneous Tibial Nerve Stimulation in Sympathetic and Parasympathetic System in Women With Overactive Bladder: Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|Yes|Active, not recruiting|March 2014|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Female|40 Years|60 Years|No|||May 2015|May 27, 2015|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456441||20269|
NCT02445846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0528|Dual Rapid HIV & Syphilis Tests in Zambia|Field Performance Evaluation of Dual Rapid HIV & Syphilis Tests in Zambia||University of North Carolina, Chapel Hill|No|Recruiting|May 2014|January 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|3765|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women, regardless of HIV status, seeking antenatal care at Chipata, Chawama, or        Kamwala District Health Centres in Lusaka, Zambia.|May 2015|May 14, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445846||21082|
NCT02450409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK_2015_1|A New Technique to Produce Anatomical Alignment Results With Less Midflexion Instability in Total Knee Arthroplasty|||University of Jena||Recruiting|January 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|N/A|N/A|No|||May 2015|May 20, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02450409||20732|
NCT02444637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACE_1.0|Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD|Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease||National Neuroscience Institute|Yes|Recruiting|April 2015|||April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|85 Years|No|||May 2015|May 11, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02444637||21175|
NCT02444650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP2804|Measurement of Pulse Wave Velocity|Photoplethysmogram Measurement of Pulse Wave Velocity||Nonin Medical, Inc|No|Completed|April 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normotensive and hypertensive subjects.|July 2015|July 9, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444650||21174|
NCT02444910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8265426|Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects|Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects||KinDex Pharmaceuticals, Inc.|Yes|Completed|April 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|40 Years|70 Years|No|||July 2015|December 28, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444910||21154|
NCT02432248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00056W9|Effect of DHEA on Patients With Poor Ovarian Responds|Effect of Dehydroepiandrosterone on Live Birth Rate in Subfertile Patients With Poor Ovarian Responds||The Affiliated Hospital of Inner Mongolia Medical University|No|Recruiting|February 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Female|21 Years|42 Years|No|||April 2015|April 28, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02432248||22126|
NCT02448524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiSten01|A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease|A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease|DESSOLVE C|Micell Technologies|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|428|||Both|18 Years|75 Years|No|||July 2015|July 10, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448524||20877|
NCT02448537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-083|A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas|A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas||Massachusetts General Hospital|Yes|Recruiting|August 2015|November 2022|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448537||20876|
NCT02446665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5707-AE|Disease Status in Primary Sclerosing Cholangitis by Elastography|Comprehensive Evaluation of Disease Status in Primary Sclerosing Cholangitis by MRCP and MR Elastography Through Hepatic Fibrosis Estimation With Comparison to FibroScan||University Health Network, Toronto|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|N/A|N/A|No|||December 2015|December 1, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02446665||21019|
NCT02444923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levita|Scleral Versus Corneal RGP Contact Lenses in Irregular Cornea Disorders|A Randomised Controlled Research to Asses the Clinical Performance and Effect on Vision Related Quality of Life of Rigid Gas Permeable Scleral Versus Corneal Contact Lenses for Keratoconus and Other Irregular Cornea Disorders||London South Bank University|Yes|Not yet recruiting|June 2015|October 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02444923||21153|
NCT02433587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-14-29|Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization|Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization||University Hospital Case Medical Center|Yes|Recruiting|April 2015|April 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433587||22023|
NCT02442245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HUS002|The Effect of XSurge Supplementation on Biomarkers and Performance From High Intensity Resistance Exercise|The Effect of XSurgeTM Supplementation on Biomarkers, Oxidative Stress, and Recovery From High Intensity Resistance Exercise||Kemin Foods LC||Active, not recruiting|February 2015|August 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|41|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02442245||21358|
NCT02446028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-250|A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes|A Randomized, Open-label Parallel Group Phase 2b Trial Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes||Biodel|No|Active, not recruiting|May 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446028||21068|
NCT02459028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01_T3P|Positive Psychology Interventions in Individuals With Chronic Pain and Spinal Cord Injury|A Phase II, Community-based, Single-blinded, Randomized Controlled, Parallel-group Trial to Assess the Effects of a Tailored Positive Psychology Intervention on Chronic Pain and Well-being in Individuals With Spinal Cord Injury|T3P|Swiss Paraplegic Research|No|Recruiting|May 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|16 Years|N/A|No|||May 2015|June 9, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02459028||20070|
NCT02442674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-13-207|A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia|A Pilot Phase 3b,Multicenter,Randomized,Double-blind,Placebo-controlled Trial of the Safety,Efficacy,and Pharmacokinetics of Titrated Oral SAMSCA®(Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|8|||Both|4 Years|17 Years|No|||February 2016|February 1, 2016|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442674||21325|
NCT02429401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-1306-03852|Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men|Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men: a Randomized Clinical Trial Among Injured Patients|Project Valor|University of Texas, El Paso|No|Recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02429401||22343|
NCT02446899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3461C00004|Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus||AstraZeneca|Yes|Recruiting|July 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446899||21001|
NCT02446912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3461C00005|Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus||AstraZeneca|Yes|Recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446912||21000|
NCT02461264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-128|Radomized Trial of Two Transfusion Strategies in Patients Hospitalized for Acute Leukemia Induction Chemotherapy or Hematopoietic Stem Cells With Medico-economic Evaluation|Randomized Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization.|1 VERSUS 2 CGR|University Hospital, Caen|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461264||19898|
NCT02458118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11109|Pancreatic Perfusion Using Secretin and MRI|Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis||University of Nottingham|No|Recruiting|June 2012|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458118||20140|
NCT02446145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-DELTA1-063|A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients|A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients ≥65 Years of Age Not Eligible for Intensive Chemotherapy|DELTA|Technische Universität Dresden|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|238|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02446145||21059|
NCT02434120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR_2015_13|MRI Perfusion Curves Typology and Orbital Tumors (PERFORM)|Validation, for Orbital Tumors, of the MRI Perfusion Curves Typology Established for Salivary Tumors|PERFORM|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|November 2015|||November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing a MRI because of an orbital mass|November 2015|November 19, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434120||21982|
NCT02434133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0340|Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients|Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients||University of Wisconsin, Madison|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|110|Samples With DNA|Blood sample to measure antibody concentration|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will consist of individuals with inflammatory bowel disease and        healthy controls.|December 2015|December 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434133||21981|
NCT02454673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUN-GCNMEM|Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer|Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|121|Samples With DNA|Surgical specimen with potential for extraction of DNA.|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with locally advanced adenocarcinoma gastric cancer for a neoadjuvant protocol        consisting of preoperative chemotherapy or induction chemotherapy, chemoradiotherapy and        salvage surgery. Patients must have a medically fit condition to complete the protocol.        Initial staging comprises a thoracic and abdominal computerised tomography scan,        endoscopic ultrasound endoscopy (EUS), biopsy and blood test including blood cell count,        hepatic and renal function.        Radiological and endoscopic evaluations are performed at baseline and at the completion of        chemotherapy and chemoradiotherapy.        Blood tests are acquired at baseline, before each chemotherapy course and concurrently        with evaluations. Blood tests are also obtained during follow-up and at the time        progression.|March 2015|May 26, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454673||20404|
NCT02453191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504731|TVEC and Preop Radiation for Sarcoma|Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas||University of Iowa|Yes|Recruiting|July 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453191||20518|
NCT02453204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC: CSP152114|STAND UP - Sedentary Behaviour in Older Adults: Investigating a New Therapeutic Paradigm|STAND UP - Sedentary Behaviour in Older Adults: Investigating a New Therapeutic Paradigm Work Package 3: Investigating the Effect of Sedentary Time, Reduced Sedentary Time and Increased Light-intensity Physical Activity on Metabolic and Psychological Health in Older Adults|STAND-UP|University of Leicester|Yes|Recruiting|April 2015|April 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|56|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||May 2015|December 1, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02453204||20517|
NCT02457910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1374|Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer|A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|June 2015|||December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457910||20156|
NCT02458885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Pilot Study on ST Elevation Acute Myocardial Infarction|Relevamiento / Encuesta Nacional de Infarto Agudo de Miocardio Con elevación Del ST|ARGEN-IAM-ST|Sociedad Argentina de Cardiología|Yes|Recruiting|April 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with ST elevation Myocardial infarction.|June 2015|June 2, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458885|30 Days|20081|
NCT02431572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-421|A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy|A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy||Massachusetts General Hospital|Yes|Not yet recruiting|May 2015|March 2020|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431572||22178|
NCT02431585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-IBS|Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics.|Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics. (GS-IBS)|GS-IBS|University of Bari|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|4 Years|18 Years|No|||April 2015|April 30, 2015|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02431585||22177|
NCT02448264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX7353-101|First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects||BioCryst Pharmaceuticals|No|Completed|May 2015|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02448264||20897|
NCT02444871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEEP Trial|IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis|Immunoglobulin-M-enriched (IgM-enriched) Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis||Goethe University|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Patients with severe sepsis or septic shock in a surgical, tertiary care ICU|May 2015|May 27, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02444871||21157|
NCT02445352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR207-III-02|Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R207 (Rosuvastatin /Ezetimibe Combination) and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia|ROSE|Alvogen Korea|No|Completed|July 2014|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|379|||Both|19 Years|N/A|No|||May 2015|May 14, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445352||21120|
NCT02432235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCT-301-001|Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma|A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma||ADC Therapeutics SARL|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432235||22127|
NCT02453360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1419|Adductor Canal Block for Total Knee Arthroplasty|Impact of Volume of Local Anesthetic Injected for Adductor Canal Block on Recovery Profile and Block Characteristics Following Total Knee Arthroplasty.||University of Wisconsin, Madison|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02453360||20505|
NCT02452359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0315|Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae|Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae||Venus Concept|Yes|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|24 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452359||20582|
NCT02457468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-2015-01|The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology|The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology||Predicted, Reported and Observed Outcomes Foundation|No|Recruiting|June 2015|June 2023|Anticipated|June 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Cohort will be selected from clinic patients scheduled for surgery with coflex device        after decompression|February 2016|February 5, 2016|May 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457468|5 Years|20190|
NCT02435966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University European of Madrid|Dry Needling in Patients With Chronic Neck Pain|Effectiveness of Dry Needling on the Upper Trapezius and the Levator Scapulae in Patients With Chronic Neck Pain: Randomized Clinical Trial||European University of Madrid|Yes|Completed|May 2013|March 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|55 Years|No|||August 2015|August 8, 2015|March 27, 2015||No||No|August 8, 2015|https://clinicaltrials.gov/show/NCT02435966||21840|
NCT02435979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00251|Proximal Strengthening for the Management of Wrist Pain|Proximal Strengthening for the Management of Wrist Pain: A Randomized Controlled Trial||Nationwide Children's Hospital|No|Recruiting|May 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|8 Years|N/A|No|||November 2015|November 18, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02435979||21839|
NCT02455973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERC|Interdisciplinary Intervention With Motivational Approach in Adolescents With Overweight and Obesity.|Interdisciplinary Intervention Effectiveness on Motivational Approach in Lifestyle Modification in Adolescents With Overweight and Obesity|MERC|Pontificia Universidade Católica do Rio Grande do Sul|Yes|Recruiting|March 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|18 Years|No|||October 2015|October 13, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02455973||20305|
NCT02456558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA44-0114|Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects|A Phase Ib Randomized, Double-blind, Placebo-controlled, Ascending Sequential Dose, Adaptive Design Study to Evaluate the Safety, Antiretroviral Activity, and Pharmacokinetics of Intravenous Deferiprone in Treatment-Naïve HIV-Positive Subjects||ApoPharma|Yes|Active, not recruiting|June 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|No|||February 2016|February 9, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456558||20260|
NCT02456571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063296|CTC Immune Checkpoint|Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells||Duke University|No|Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|40|||Male|18 Years|N/A|No|Non-Probability Sample|Duke Cancer Institute Patients|March 2016|March 7, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02456571||20259|
NCT02449408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058058|Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World|Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World||Duke University||Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators plan to recruit 10 overweight or obese adolescents followed by the Duke        Division of Pediatric Endocrinology and Diabetes. Investigators will review the electronic        medical records of potential participants identified by their primary providers to ensure        they meet the eligibility criteria.        The investigators will also recruit 10 infants hospitalized in the Duke Transitional Care        Nursery and will review the electronic medical records of potential participants        identified by their primary providers to ensure they meet the eligibility criteria.|May 2015|October 26, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449408||20809|
NCT02436265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cuadal_IV Dexamethasone-Shah|Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery|Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery||Indiana University|No|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|94|||Both|3 Months|10 Years|No|||May 2015|May 5, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02436265||21817|
NCT02456272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7312 02|Hearing Aid Versus Surgical Rehabilitation as Treatment of Otosclerosis: Pilot Study|Hearing Aid Versus Surgical Rehabilitation as Treatment of Otosclerosis: Pilot Study|PARCO|University Hospital, Toulouse|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456272||20282|
NCT02456285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03880|Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways|Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways|CoSMIC|Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|April 2015|March 2021|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will comprise patients with colorectal cancer with liver-limited        hepatic metastases referred to the Hepatobiliary Surgical Unit at Manchester Royal        Infirmary - a National Health Service (NHS) regional cancer-network approved        hepato-pancreato-biliary (HPB) centre with a formally constituted and National Cancer        Network peer-review accredited multidisciplinary team (MDT).|May 2015|May 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02456285||20281|
NCT02444780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nWMO 115|Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery|Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery||Medical Centre Leeuwarden|No|Completed|June 2015|November 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Probability Sample|All consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week        period.        We aim to include at least 90 patients.|February 2016|February 16, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444780|30 Days|21164|
NCT02444793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1641004|A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors|A Phase 1b Study Of PF-05082566 In Combination With Mogamulizumab (KW-0761) In Patients With Advanced Solid Tumors||Pfizer|No|Recruiting|May 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02444793||21163|
NCT02454764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HBV-001|'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT|To Study the Efficacy of 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT - A Randomized Control Trial||Institute of Liver and Biliary Sciences, India|No|Recruiting|May 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454764||20397|
NCT02458183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-DTPP-CT-301|Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS|A Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants|Venus|Boryung Pharmaceutical Co., Ltd|Yes|Recruiting|February 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|464|||Both|7 Weeks|10 Weeks|Accepts Healthy Volunteers|||May 2015|May 28, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458183||20135|
NCT02458248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRBCRFG-170415-AS|Sodium Intake in Chronic Kidney Disease (STICK)|Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial|STICK|University College Hospital Galway|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02458248||20130|
NCT02459054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-551|Syncardia 50cc TAH-t as a Bridge to Transplant|SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant||SynCardia Systems. Inc.|Yes|Recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|10 Years|N/A|No|||January 2016|January 18, 2016|December 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459054||20068|
NCT02453932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX09104-203|Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia|A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia||Dongzhimen Hospital, Beijing|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|637|||Both|45 Years|85 Years|No|||August 2015|August 3, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453932||20461|
NCT02456298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH104363|Comparing Behavioral Assessments Using Telehealth for Children With Autism|||University of Iowa|Yes|Recruiting|June 2015|||March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Months|83 Months|No|||November 2015|November 30, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456298||20280|
NCT02445066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00028235|A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults|A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults - An EVIDENCE Sub-Study||Wake Forest School of Medicine|Yes|Enrolling by invitation|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|65 Years|89 Years|No|||May 2015|May 11, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445066||21142|
NCT02446106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/NS/0068|Monosodium L-glutamate (MSG) on Satiety|The Effect of Monosodium L-glutamate (MSG) on Satiety and Energy Intake in Overweight and Obese Women||Ajinomoto Co., Inc.|Yes|Completed|June 2012|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|75|||Female|19 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02446106||21062|
NCT02436746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2014-483|The Cognitive Variability in NF1 and TSC Monozygotic Twins|The Cognitive Variability in Neurofibromatosis Type I and Tuberous Sclerosis Complex Monozygotic Twins|COVANTT|Erasmus Medical Center|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|116|||Both|N/A|N/A|No|Non-Probability Sample|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I or Tuberous        Sclerosis Complex|May 2015|May 4, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02436746||21780|
NCT02445716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP/Evidence|Transdermal Testosterone Nanoemulsion in Women Libido|Transdermal Testosterone Nanoemulsion Effects Emergent Loss of Libido in Women: A Randomized, Double-Blind, Placebo-Controlled Trial|Biolipid/B2|University Potiguar|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|30 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02445716||21092|
NCT02445729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0548|Impact of Timing of Wound Dressing Removal After Cesarean Section|Impact of Timing of Wound Dressing Removal After Cesarean Section: Effect of Dressing Removal at 24 Hours Versus 48 Hours on Wound Healing and Incidence of Surgical Site Infections Following Cesarean Section||The University of Texas Medical Branch, Galveston|Yes|Enrolling by invitation|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02445729||21091|
NCT02444806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/EM/1257|PSG Versus Oxim-capnography to Setup Home NIV|The Clinical Effectiveness of Full Montage Polysomnography Versus Limited Respiratory Polygraphy During Non-invasive Ventilation Set up in Chronic Obstructive Pulmonary (COPD)-Obstructive Sleep Apnoea (OSA) Overlap Syndrome: A Randomised Controlled Trial||Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|January 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444806||21162|
NCT02444819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EMSI-201|Phase II Trial to Evaluate the Efficacy and Safety of HM61713 (BI 1482694) as the 1st-line NSCLC Anticancer Therapy|A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 (BI 1482694) as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation||Hanmi Pharmaceutical Company Limited|No|Active, not recruiting|March 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|19 Years|N/A|No|||February 2016|February 1, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444819||21161|
NCT02460562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67-4326|Caries Prevention Effect of S-PRG Filler Incorporated in Denture Base Resins on Edentulous Elderly People|The Caries Prevention Effect of Surface Pre-reacted Glass-ionomer Filler Incorporated in Denture Base Resins on Edentulous Elderly People||Thammasat University|Yes|Not yet recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||May 2015|June 1, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460562||19952|
NCT02460575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DK105849|Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months|L. Reuteri for Pediatric Diarrhea in Peru: Growth, Enteropathy, and Microbiota|PRIDEC Peru|Tulane University School of Medicine|Yes|Not yet recruiting|October 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Months|24 Months|Accepts Healthy Volunteers|||May 2015|June 1, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460575||19951|
NCT02434952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015NECHR|Safety and Tolerability of Low Dose Primaquine|The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians||Malaria Consortium|Yes|Recruiting|October 2014|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|1 Year|N/A|No|||April 2015|April 30, 2015|September 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02434952||21918|
NCT02455505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-095|Identifying Family Members in Need of Support During Palliative Care and Bereavement|Identifying Family Members in Need of Support During Palliative Care and Bereavement||Memorial Sloan Kettering Cancer Center||Recruiting|May 2015|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|22|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from MSK and Calvary Hospital locations (The Bronx,        Brooklyn, and Manhattan), which provides hospice and bereavement services to patients        suffering from advanced cancer and their families.|November 2015|November 24, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02455505||20341|
NCT02453165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440|Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Closure|Randomized Clinical Trial About Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Suturing||Università degli Studi dell'Insubria|Yes|Recruiting|January 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2800|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|February 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453165||20520|
NCT02452463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 257814|Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy|A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy||Roswell Park Cancer Institute|Yes|Recruiting|June 2015|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|99|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452463||20574|
NCT02442128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-14-1071|Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children|Using Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children: a Randomized Prospective Study||King Saud University|Yes|Not yet recruiting|May 2015|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02442128||21367|
NCT02445027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P001519|Pilot Study for Imaging of the Esophagus Using a Tethered Capsule OCT Endomicroscopy in the Primary Care Setting|Pilot Study for Imaging of the Esophagus Using a Tethered Capsule OCT Endomicroscopy in the Primary Care Setting||Massachusetts General Hospital|No|Recruiting|August 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02445027||21145|
NCT02454595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-006|Registry to Measure the Impact of Adding Genomic Testing|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients at Intermountain Hospitals||Myriad Genetic Laboratories, Inc.|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic      adenocarcinoma biopsies.|Male|55 Years|N/A|No|Non-Probability Sample|Newly diagnosed ( ≤ 6 months), untreated patients with histologically proven        adenocarcinoma of the prostate|February 2016|February 19, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02454595|3 Months|20410|
NCT02564458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1705|Fitness in Allogeneic Stem Cell Transplantation|Fitness in Allogeneic Stem Cell Transplantation|FAST|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|September 2015|June 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564458||11975|
NCT02444624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0295|Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches|Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches|CLOSNEC|Nantes University Hospital|No|Recruiting|May 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Fecal samples|Both|N/A|31 Weeks|No|Non-Probability Sample|Recruitment of CASES (NEC group) will prospectively occure according to the following        schedule:        Following the diagnosis confirmed ECUN (stage II or III Bell) during the stay in        neonatology:          -  stool sample at the earliest          -  In case of surgery, if resection: a collection of intestinal contents and biopsy of             the intestinal mucosa during the act          -  collection of clinical data from birth until hospital discharge or transfer of the             child and then collecting the ASQ 24 months.        Inclusion of control patients should be made within 7 days of the onset of the        corresponding NEC case. Informed parents will previously allow enrollment of their child        to set faeces sampling and data capture from birth to the output of hospitalization or        transfer of the child and then collecting the ASQ 24 months.|September 2015|September 16, 2015|February 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02444624||21176|
NCT02429882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101228|Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis|A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis||Amgen|No|Withdrawn|May 2015|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|April 24, 2015|Yes|Yes|Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab,    study is being cancelled/closed.|No||https://clinicaltrials.gov/show/NCT02429882||22306|
NCT02429895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-198|A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197|A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)||AbbVie|Yes|Enrolling by invitation|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02429895||22305|
NCT02429908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME2013-01S|Post-Market Surveillance Study of the TM Ardis Interbody Fusion System|A Prospective, Multi-Center, Post-Market Surveillance Study to Assess the Clinical Efficacy and Fusion Rates of the Zimmer TM Ardis Interbody Fusion System||Zimmer, Inc.|No|Active, not recruiting|March 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2016|March 15, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02429908||22304|
NCT02457039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW-14206|Acupuncture Prevents Chemobrain in Breast Cancer Patients|An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemobrain in Breast Cancer Patients||The University of Hong Kong|No|Recruiting|August 2015|August 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|168|||Female|18 Years|65 Years|No|||December 2015|December 4, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02457039||20223|
NCT02457052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 558 15|Impact of a Transportable Customizable and Scalable Sitting Positioning Device on Swallowing Disorders|Impact of a Transportable Customizable and Scalable Sitting Positioning Device on Swallowing Disorders|DATP-DEG|University Hospital, Toulouse|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02457052||20222|
NCT02461394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1469-BL|User Performance Evaluation of Contour Plus, Accu-Chek Active, Accu-Chek Performa and OneTouch Select Simple Blood Glucose Monitoring Systems Following ISO 15197:2013|User Performance Evaluation of Contour Plus, Accu-Chek Active, Accu-Chek Performa and OneTouch Select Simple Blood Glucose Monitoring Systems Following ISO 15197:2013||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Completed|May 2015|||December 2015|Actual|N/A|Interventional|N/A|||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461394||19888|
NCT02449174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-14-0020|Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route|A Study of Fecal Microbiota Transplantation (FMT) for the Treatment of Recurrent C. Difficile Associated Diarrhea (RCDAD) Via Retention Enema or Oral Route||The University of Texas Health Science Center, Houston|No|Active, not recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|December 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02449174||20827|
NCT02431013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI-103|Cilostazol-Simvastatin Drug Interaction Study|A Randomized, Open-label, Multiple-dose, Parallel Study to Investigate The Effect of Cilostazol on the Disposition of Simvastatin in Healthy Male Volunteers||Ajou University School of Medicine|No|Recruiting|April 2015|||August 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431013||22221|
NCT02457182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-141|Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome|Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome||University of New Mexico|No|Active, not recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02457182||20212|
NCT02454322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #200388|The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience|The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience||Northwestern University|No|Recruiting|May 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Cerebrospinal fluid and peripheral serum|Female|18 Years|N/A|No|Probability Sample|This project will include 300 women recruited from the obstetrical service at Prentice        Women's Hospital. Women will be included if they are at least 34 weeks gestation, have a        singleton pregnancy, and have been diagnosis with a hypertensive disorder of pregnancy        (either gestational hypertension or preeclampsia).|September 2015|September 24, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02454322||20431|
NCT02452970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-27-01|RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy|A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy|EPIC|EpicentRx, Inc.|No|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452970||20535|
NCT02442505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_13-114|Device-detected Paroxysmal Atrial Fibrillation|Validation of the Modified Microlife Blood Pressure Monitor in Patients With Paroxysmal Atrial Fibrillation||University of Birmingham|No|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients who have an implanted pacemaker for sick sinus syndrome with previously        documented AF with atrial high-rate episodes, with be identified from the pacemaker clinic        register at one NHS Trust. Patients with AF and one of the following pacemakers will be        identified from this register: Medtronic Sensia DR, Medtronic Advisa DR, Sorin Reply DR,        and St. Jude Medical Accent DR and the study population will be randomly drawn from these        patients. Atrial high rate episodes will be defined as atrial rates ≥180 beats per minute        [3-6]. The exclusion criteria will include any patient who's pacemaker has had previously        documented atrial sensing or pacing problem issues and patients with permanent AF.|May 2015|May 8, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02442505||21338|
NCT02445768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503M65644|Functional Connectivity In Relation To Proprioception and Sensorimotor Recovery in Stroke Patients (Feasibility Study)|Functional Connectivity In Relation To Proprioception and Sensorimotor Recovery in Stroke Patients (Feasibility Study)||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445768||21088|
NCT02461186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1501|Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar|An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria||University of Oxford|Yes|Withdrawn|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|May 26, 2015||No|Change of the study site due to the current political climate in Myanmar.|No||https://clinicaltrials.gov/show/NCT02461186||19904|
NCT02457403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0487|Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy: Rotational Thromboelastometry Versus Conventional Therapy||SCARLET|Ohio State University|No|Enrolling by invitation|May 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457403||20195|
NCT02457416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/430|Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut|Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut||Oslo University Hospital|Yes|Recruiting|March 2014|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|15 Years|No|||May 2015|May 26, 2015|May 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02457416||20194|
NCT02436512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2014-001|Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide|A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Response of Inhaled Nitric Oxide as a Predictor of Successful Wean From Parental Prostacyclins in Subjects With Pulmonary Arterial Hypertension|EAGLE|Geno LLC|Yes|Withdrawn|June 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|70 Years|No|||June 2015|September 3, 2015|April 13, 2015|Yes|Yes|Inability meet enrollment in study population.|No||https://clinicaltrials.gov/show/NCT02436512||21798|
NCT02446015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC120-P001|Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye|Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye||Alcon Research|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02446015||21069|
NCT02450656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14AFS|Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Colorectal, Non-small Cell Lung and Pancreatic Cancer|Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Colorectal, Non-small Cell Lung and Pancreatic Cancer|M14AFS|The Netherlands Cancer Institute|No|Recruiting|June 2015|December 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|November 13, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450656||20713|
NCT02450669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9242|Predictors of Airway Extubation/Weaning Failure|Practices and Risk Factors for Weaning and Extubation Airway Failure in Adult Intensive Care Unit: a Multicenter Trial|Free-Rea|University Hospital, Montpellier|No|Recruiting|December 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|All the adult patients extubated in the ICU|May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450669||20712|
NCT02455388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD078636-01A1|d13C Added Sugar Intake Biomarker: Determining Validity in Children|d13C Added Sugar Intake Biomarker: Determining Validity in Children||Virginia Polytechnic Institute and State University|No|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02455388||20350|
NCT02449187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP-1310-P1-FE|Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers||Jeil Pharmaceutical Co., Ltd.|No|Not yet recruiting|May 2015|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Male|19 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 17, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449187||20826|
NCT02436785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03446|Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?|Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening Over the 4 Weeks Using a Randomised Control Trial?||University of British Columbia|No|Recruiting|May 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|85 Years|No|||December 2015|December 2, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02436785||21777|
NCT02438696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333.4|Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects|Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF) Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose) in Healthy Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study at Two Different Dose Strengths)||Boehringer Ingelheim||Completed|May 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|29|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|May 6, 2015||||No||https://clinicaltrials.gov/show/NCT02438696||21630|
NCT02453997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW12-462|Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis|Mycophenolic Acid Pharmacokinetics and Pharmacogenomics - Impact on the Clinical Outcomes of Patients With Severe Lupus Nephritis||The University of Hong Kong|Yes|Recruiting|October 2012|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|EDTA blood samples for pharmacogenomics analysis|Both|18 Years|80 Years|No|Probability Sample|Lupus Nephritis patients (both active or remission)|December 2015|December 2, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453997||20456|
NCT02450396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.381bis|Pregnancy and Medically Assisted Conception in Rare Diseases|Prospective Observational Study About Pregnancy and Medically Assisted Conception in Rare Diseases|EGR2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2014|December 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|serum, cord blood|Female|N/A|N/A|No|Non-Probability Sample|Woman with a rare and/or systemic disease Pregnancy confirmed by a positive beta-HCG assay        or an obstetric ultrasound OR medically assisted conception procedure|December 2015|December 15, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450396||20733|
NCT02449434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ114/N205|Timing of Dietary Acid Intake, Brushing Teeth and Acid Erosion.|Timing of Dietary Acid Intake, Brushing Teeth and Acid Erosion.||King's College London|Yes|Recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred into the Dental institute of King's College London for dental treatment|February 2016|February 25, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449434||20807|
NCT02442258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-600|Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function|Evaluation of the Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function||AbbVie|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|46|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442258||21357|
NCT02443649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10810|Improving Sleep Quality in People With Insomnia|Improving Sleep Quality in People With Insomnia||Oregon Health and Science University|No|Recruiting|January 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|25 Years|85 Years|No|||December 2015|December 15, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02443649||21251|
NCT02450864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 101-1810A3|The Biological Effect of ESWT and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness|The Biological Effect of Extracorporeal Shockwave Technology (ESWT) and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness||Chang Gung Memorial Hospital|Yes|Recruiting|January 2013|December 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|No|||April 2015|May 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02450864||20697|
NCT02450877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-AML-004|A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.|A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 2 STUDY, WITH A SAFETY RUN-IN PART TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF AZACITIDINE COMPARED TO NO ANTICANCER TREATMENT IN CHILDREN AND YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA IN MOLECULAR RELAPSE AFTER FIRST COMPLETE REMISSION||Celgene|Yes|Recruiting|August 2015|May 2024|Anticipated|June 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Months|21 Years|No|||October 2015|October 23, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450877||20696|
NCT02448316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-151|Plantar Fasciitis, Operation or Conservative Treatment|Randomized Clinical Trial Comparing Conventional Conservative Treatment for Plantar Fasciopathia With Endoscopic Surgery With Fascial Release.||Bispebjerg Hospital|No|Active, not recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|65 Years|No|||October 2015|October 13, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02448316||20893|
NCT02445898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK_VL_01_2015|Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients|Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty||Rigshospitalet, Denmark|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Both|55 Years|80 Years|No|||September 2015|September 3, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445898||21078|
NCT02445911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KQ-791-02|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes||Kaneq Bioscience Limited|No|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445911||21077|
NCT02429414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0991|Video Double-Lumen Tube Prospective Randomized Study|Prospective Randomized Study on Video Double-Lumen Tube Versus Double-Lumen Tube||M.D. Anderson Cancer Center|No|Recruiting|September 2015|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429414||22342|
NCT02433834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT001101-00|Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma|A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma||Pearl Therapeutics, Inc.|No|Active, not recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|249|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433834||22004|
NCT02450838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 301|Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)|A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|April 2015|||June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02450838||20699|
NCT02450851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150130|Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network|Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|8000|||Both|1 Month|100 Years|No|||April 2015|January 30, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450851||20698|
NCT02446678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO2|Use of PillCam ESO2 in Triaging Patients Present With Upper GIB|The Use Of PillCam Esophagus In Triaging Patients Presented With Upper Gastrointestinal Bleeding||Chinese University of Hong Kong|No|Active, not recruiting|November 2013|August 2015|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|68|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02446678||21018|
NCT02446470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-026|Sinus Tarsi Versus Extensile Lateral Approach for Calcaneus Fractures|Sinus Tarsi Versus Extensile Lateral Approach for Open Reduction Internal Fixation of Intra-articular Calcaneus Fractures||University of Tennessee|No|Enrolling by invitation|May 2015|May 2022|Anticipated|May 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02446470||21034|
NCT02442687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062677|JKB-121 for the Treatment of Nonalcoholic Steatohepatitis|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)||Duke University|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442687||21324|
NCT02459990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452R00003|Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom|Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom||AstraZeneca|No|Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|22000|||Female|N/A|N/A|No|Non-Probability Sample|Women who may become pregnant ages 18-50 in the UK.|July 2015|July 2, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02459990||19996|
NCT02460003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-Physiotherapy|Physiotherapy Program for Cluster Headache|Effectiveness of Physiotherapy Program in Patients With Cluster Headache|PhyCH|AG Clinic|Yes|Enrolling by invitation|April 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02460003||19995|
NCT02459041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVEUS|Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes|Real-time Semi-quantification of Endoscopic Ultrasound Elastography and Contrast-enhancement Using Strain Histograms (SH) and Contrast-enhancement (CE) for the Differentiation of Focal Pancreatic Masses and the Assessment of Lymph Node Involvement|ADVEUS|University of Medicine and Pharmacy Craiova|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|Samples Without DNA|Pancreas and lymphnode samples (EUS-guided fine needle aspiration)|Both|18 Years|90 Years|No|Non-Probability Sample|All patients with a suspicion of pancreatic masses or lymph nodes should undergo EUS, with        sequential EG-EUS and CE-EUS. Personal data (name, surname, age, admission date, SSN,        diagnosis at admission) will be registered in the study.        EUS and EUS-guided fine needle aspiration are methods used for pancreatic masses and        lymphnodes assessment in daily clinical practice. Contrast enhanced-EUS (CE-EUS) is        aproved in european countries, and this mehode has been accepted for EUS procedures in        daily practice, as well as elastography (EG-EUS). Anyway, signed informed consent for        EG-EUS, CE-EUS and FNA biopsy is required for participation in the study.|May 2015|May 28, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459041||20069|
NCT02458898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29967|Text Message Intervention to Improve Adherence in Adolescents and Young Adults With Celiac Disease|Text Message Intervention to Improve Adherence in Adolescents and Young Adults With Celiac Disease||Stanford University|No|Recruiting|February 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|12 Years|24 Years|No|||May 2015|May 27, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02458898||20080|
NCT02452775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 40814|Autologous OC-L Vaccine and Ovarian Cancer|A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Female|18 Years|N/A|No|||May 2015|May 26, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452775||20550|
NCT02452788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMhem-01|Pharmaceutical Care in Ambulatory Hemodialysis Patients|Effectiveness of Pharmaceutical Care in Ambulatory Hemodialysis Patients: a Randomized Controlled Pilot Study||Hospital Moinhos de Vento||Not yet recruiting|May 2015|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452788||20549|
NCT02453074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002351|Automated System for Gathering and Reporting Clinical Outcomes to Providers|Automated System for Gathering and Reporting Clinical Outcomes to Providers||Harvard Medical School|No|Completed|January 2015|April 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|326|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of two primary clinics at Massachusetts General Hospital, Boston MA|May 2015|May 21, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453074||20527|
NCT02449148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKFZ Study_ID 670|Nutrition and Energy Restriction for Cancer Prevention|Healthy Nutrition and Energy Restriction as Cancer Prevention Strategies: a Randomized Controlled Intervention Trial|HELENA|German Cancer Research Center|No|Recruiting|May 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02449148||20829|
NCT02449161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-31-2015-998|The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates|The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates: a RCT|MPA post AE|Université de Sherbrooke|No|Not yet recruiting|June 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Female|25 Years|N/A|No|||May 2015|May 19, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449161||20828|
NCT02436772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HEOR_05|Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC|Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC||SCRI Development Innovations, LLC|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|100 metastatic breast cancer patients from 1 clinic in Tennessee|February 2016|February 18, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02436772||21778|
NCT02438423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015 TIV-MNP|Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle|A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle||Georgia Institute of Technology|Yes|Active, not recruiting|June 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2015|February 2, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438423||21651|
NCT02441634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-1031|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||December 9, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441634||21405|
NCT02456337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067/2013|Xenogenous Collagen Matrix Graft With or Without Enamel Matrix Proteins Derivative for Root Coverage|Xenogenous Collagen Matrix Graft Associated or Not With Enamel Matrix Derivative Proteins in the Treatment of Gingival Recession Class I and II of Miller: Randomized Controlled Clinical Study||University of Campinas, Brazil|Yes|Recruiting|July 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456337||20277|
NCT02447042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.0156|Minimal Volume for a Fluid Challenge in Septic Patients|Study of Changes on Mean Systemic Filling Pressure (Pmsf) and Microcirculation After a Fluid Challenge in Septic Patients: Looking for the Minimal Volume||St George's, University of London|No|Recruiting|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447042||20990|
NCT02440958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0973|Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial|||Yonsei University|No|Not yet recruiting|May 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|19 Years|75 Years|No|||May 2015|May 7, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440958||21457|
NCT02445001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-163A|Erythrocyte Ghost Mediated Retinal Diagnosis|Erythrocyte Ghost Mediated Retinal Diagnosis|EGMRetinalDx|Northwell Health|No|Withdrawn|October 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 28, 2013||No|Withdrawn before recruitment started.|No||https://clinicaltrials.gov/show/NCT02445001||21147|
NCT02444559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-JH-14|Does Perineural Clonidine Prolong Duration of a Nerve Block?|Does Perineural Clonidine Prolong the Duration of an Adductor Canal Block When Controlling for a Systemic Effect? - A Randomised Paired Trial in Healthy Volunteers.||Koege Sygehus|Yes|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444559||21181|
NCT02449928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUMCH|Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients|Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,||Peking Union Medical College Hospital||Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449928||20769|
NCT02441062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503708|Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors|Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors||University of Iowa|Yes|Recruiting|September 2015|June 2021|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|6 Months|N/A|No|||January 2016|January 15, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441062||21449|
NCT02441075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00028|70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014|70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014|70% EtOH|Nationwide Children's Hospital|No|Completed|May 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|3 Months|30 Years|No|||January 2016|January 28, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02441075||21448|
NCT02445222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTL019A2205B|CD19 CART Long Term Follow Up (LTFU) Study|Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy||Novartis|No|Recruiting|June 2015|March 2036|Anticipated|March 2036|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|N/A|N/A|No|||March 2016|March 23, 2016|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02445222||21130|
NCT02449083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-007|Magnet Resonance Imaging to Evaluate of Dynamic T2 Preparation Puls by Patients With Shunt or Chronic Obstructive Pulmonary Disease|Cardiac Magnet Resonance Imaging to Evaluate of Dynamic T2 Preparation Puls by Patient With Shunt or Patients With Chronic Obstructive Pulmonary Disease (COPD)||Heinrich-Heine University, Duesseldorf|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|80|Samples Without DNA|Blood|Both|18 Years|N/A|No|Probability Sample|Patients with atrial septal defect (ASD) or ventricular septal defect (VSD) and COPD, who        is planned for MRI and angiography|November 2015|November 19, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02449083||20834|
NCT02449356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013L14|Clinical Study of the Endotracheal Tube Used in Prone Position Ventilation Condition|Clinical Study of the Endotracheal Tube Used in Prone Position Ventilation Condition||Central South University|No|Enrolling by invitation|January 2014|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|180|||Both|N/A|N/A|No|||May 2015|May 20, 2015|April 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449356||20813|
NCT02459314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dutchmill 002|Comparison of the Efficacy of Plant Sterol-Enriched Soymilk Versus Plain Soymilk in Volunteers With High LDL-Cholesterol|Comparison of the Efficacy of Plant Sterol-Enriched Soymilk Versus Plain Soymilk in Volunteers With High LDL-Cholesterol|sterols|Chiang Mai University|Yes|Completed|April 2013|April 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459314||20048|
NCT02459067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCB-101-001|ImmuniCell® in Patients With Advanced Cancers|Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial||TC Biopharm|No|Recruiting|December 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|January 26, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02459067||20067|
NCT02445495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDA288|Chart Review of the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis|A Single Centre Retrospective Chart Review Study to Assess the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis||Pacific Dermaesthetics|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 participants at primary clinic|April 2015|May 12, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02445495||21109|
NCT02449369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|521770|Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee|Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee Arthroplasty (TKA). Prospective, Randomized, Open-label Trial to Determine if Switching From Oral to Intravenous Acetaminophen and Orphenadrine for 48 Hours After TKA Improves Outcomes.|IVAM|Florida Hospital|No|Recruiting|April 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449369||20812|
NCT02450435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostatic Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|No|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|60|||Male|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage prostatic cancer come to Fuda Hospital for treatment.|December 2015|December 28, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450435||20730|
NCT02441270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 2015/0204|Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients|Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients||University Hospital, Ghent|Yes|Recruiting|April 2015|||October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Female|18 Years|N/A|No|||May 2015|May 7, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02441270||21433|
NCT02449811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-081|RAS Peptide Profiles in Patients With Arterial Hypertension|Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypertension||University Hospital, Basel, Switzerland|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|80|Samples Without DNA|plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|Community sample|November 2015|November 23, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02449811||20778|
NCT02454075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-010|YF476 and Type II Gastric Carcinoids|A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome||Trio Medicines Ltd.|No|Enrolling by invitation|April 2011|January 2024|Anticipated|January 2024|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454075||20450|
NCT02454088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-2010|A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands|||Goldman, Butterwick, Fitzpatrick and Groff|No|Active, not recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|22 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02454088||20449|
NCT02448589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-119-102|An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel|A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|Yes|Recruiting|September 2014|October 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448589||20872|
NCT02458027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:115-3|A FINEH Protein Trial - Part 2|Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 2 - Are Acute Effects of Hemp Protein on Blood Glucose and Appetite Insulin-dependent?||University of Manitoba|No|Active, not recruiting|July 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458027||20147|
NCT02458079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-AH-01|Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis|||Institute of Liver and Biliary Sciences, India|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|29|||Both|18 Years|70 Years|No|||December 2015|December 29, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02458079||20143|
NCT02458092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14620.b|Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B|Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B||U.S. Army Medical Research and Materiel Command|Yes|Completed|April 2008|June 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458092||20142|
NCT02442050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14-1653|Del Nido Cardioplegia Randomized Trial|The Use of Del Nido Cardioplegia in Adult Cardiac Surgery: A Prospective Randomized Trial||Inova Health Care Services|No|Recruiting|January 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|19 Years|79 Years|No|||May 2015|May 8, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02442050||21373|
NCT02444273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403118|The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital|The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital||Washington University School of Medicine|No|Enrolling by invitation|October 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444273||21203|
NCT02444533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007071|EXPAREL® for Pain After Tonsillectomy|A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients||Mayo Clinic|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444533||21183|
NCT02457117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0098|A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)||Georgetown University|Yes|Recruiting|May 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|200|||Female|50 Years|99 Years|No|Non-Probability Sample|Women receiving breast cancer treatment.|January 2016|January 26, 2016|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457117|5 Years|20217|
NCT02457260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15020481|Oral Nitrite for Older Heart Failure Patients|Study of the Utility of Oral Nitrite Therapy to Improve Skeletal Muscle Bioenergetics and Physical Capacity in Older Heart Failure Patients|ONTx+HF|University of Pittsburgh|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|75 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457260||20206|
NCT02460627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20150006|Topical Lidocaine After Arthroscopy on Knee|Postoperative Pain Management With Topical Lidocaine After Arthroscopy on Knee. A Randomized Double-blind Study||Northern Orthopaedic Division, Denmark|Yes|Not yet recruiting|May 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|50 Years|No|||May 2015|June 1, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02460627||19947|
NCT02460640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tap Block|Treatment of Acute and Chronic Pain in the Minimally Invasive Partial Nephrectomy: Tap Block vs Intravenous Pca|Treatment of Acute and Chronic Pain in the Minimally Invasive Partial Nephrectomy: Transversus Abdominis Plane Block vs Intravenous Patient Controlled Analgesia. Prospective Randomized Trial||Regina Elena Cancer Institute|No|Recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02460640||19946|
NCT02427607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-J000-341|Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects|An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects||Eisai Inc.|No|Active, not recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|12 Years|N/A|No|||February 2016|February 4, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02427607||22481|
NCT02427620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0559|A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma|A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|April 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427620||22480|
NCT02449304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BirminghamWHC|Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device|Evaluation of Feasibility and Effectiveness of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device: a Cohort Study||Birmingham Women's NHS Foundation Trust|No|Active, not recruiting|March 2015|April 2020|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|25 Years|65 Years|No|||May 2015|May 16, 2015|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449304||20817|
NCT02458781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|398092-1|Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth|Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth: A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Ciprofloxacin and Metronidazole||San Antonio Military Medical Center|Yes|Enrolling by invitation|January 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458781||20089|
NCT02568618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409729|Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability|Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability Analysis to Guide Analgesic Treatment: A Randomized, Controlled Pilot Study Using the Pain Medication and Mental Health DNA InsightTM Test.|Genomics|Defense and Veterans Center for Integrative Pain Management|No|Recruiting|July 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02568618||11656|
NCT02568631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-HPNCL-01|Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls|Improving Social Cognition for Adults With Autism Spectrum Disorder by the Serious Game JeStiMulE Versus Classic Video Game Stimulation Not Improving Social Cognition||Fondation Lenval|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|No|||October 2015|October 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02568631||11655|
NCT02448927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRECT Trial|The preDIlatation in tRanscathEter aortiC Valve implanTation Trial|The preDIlatation in tRanscathEter aortiC Valve implanTation Trial|DIRECT|University of Athens|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448927||20846|
NCT02434094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18032|Development of a Comprehensive AP Training Curriculum for Adults|Development of a Comprehensive AP Training Curriculum for Adults||University of Virginia|No|Recruiting|April 2015|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|||Both|18 Years|75 Years|No|Non-Probability Sample|-  clinicians who manage patients on insulin pumps and continuous glucose monitors          -  participants former study participants who have experience operating DiAs.          -  participants who wear an insulin pump and continuous glucose monitor but have no             experience DiAs.|May 2015|May 11, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02434094||21984|
NCT02447471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00992|Agreement of the Nexfin™ Monitor With Non-invasive Blood Pressure Measurement|Agreement of the Nexfin™ Non-invasive Cardiac Output Monitor With Non-invasive Blood Pressure Measurement in Patients Undergoing Cesarean Delivery Under Spinal Anesthesia: a Pilot Observational Study|Nexfin Pilot|University of British Columbia|No|Completed|May 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|BC Women's hospital parturients|January 2016|January 22, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447471||20958|
NCT02445560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400955|The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women|The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function, Wellness and the Potential Mitigating Effects of a Multi-strain Probiotic, Prebiotic, and Synbiotic: a Randomized, Double-blinded Crossover Study in Older Women.||University of Florida|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|29|||Female|65 Years|N/A|No|||January 2016|January 26, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02445560||21104|
NCT02452957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206-T-SIMPLICITI-RM|Safety and Effectiveness of the Tornier Simpliciti™ Shoulder System in Shoulder Arthroplasty|A Prospective Multi-Center Study of the Safety and Effectiveness of the Tornier Simpliciti™ Shoulder System in Shoulder Arthroplasty||Tornier, Inc.|No|Not yet recruiting|December 2015|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Adult subject with clinical indication for total shoulder or hemi replacement due to        primary diagnosis of osteoarthritis.|November 2015|November 3, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02452957||20536|
NCT02461160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-915-1001|Phase 1, TAK-915-1001, Single Rising Dose, Multiple Rising Dose, Drug Interaction Study|A Phase 1 Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-915 in Healthy Subjects||Takeda|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Anticipated|92|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461160||19906|
NCT02435719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAfRI/OBS/001|Alcohol Hand Gel Use in Mbale Regional Referral Hospital: a Cost Effectiveness Evaluation|Effectiveness Evaluation of Alcohol Hand Gel Use in Mbale Regional Referral Hospital, Rural Eastern Uganda|WardGel|Sanyu Africa Research Institute|No|Recruiting|October 2014|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3010|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include in-patients and health care providers on six (6)        selected wards (Labour ward, Postnatal ward, Gynaecological ward, Acute Care unit,        paediatric Ward, and general surgical wards) The sample will be selected by convenience        non-probability sampling method|April 2015|May 2, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02435719||21859|
NCT02435732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0195|CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs|A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%||University of Wisconsin, Madison|Yes|Not yet recruiting|September 2016|December 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|April 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435732||21858|
NCT02447718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalhousieU|Vaccinating Children After Chemotherapy|Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study||Dalhousie University|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447718||20939|
NCT02461147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCK first validation|Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration|Initial Cholecystectomy With Intraoperative Cholangiography for Patients at Intermediate Risk of Common Bile Duct Stone Migration : Prospective Validation and Analysis||University Hospital, Geneva|No|Active, not recruiting|September 2013|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|16 Years|N/A|No|Non-Probability Sample|All patients admitted through the emergency department for an acute gallstone-related        condition.|June 2015|June 3, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02461147||19907|
NCT02457715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063108|Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis|Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis||Duke University|No|Recruiting|July 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|This is a parallel group, single institution, prospective clinical study.|March 2016|March 7, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457715||20171|
NCT02457728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StJohn|Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate|Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate||St John of God Hospital, Vienna|No|Completed|January 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|November 8, 2015|May 17, 2015||No||No|August 16, 2015|https://clinicaltrials.gov/show/NCT02457728||20170|
NCT02428361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15859|Fecal Microbiota Transplant (FMT) for Pouchitis|||University of California, San Francisco|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||January 2016|January 8, 2016|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02428361||22423|
NCT02445573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI24B01-021|Efficacy of Electroacupuncture (EA) for Women With Pure Stress Urinary Incontinence (SUI)|A Pilot Randomized Placebo Controlled Trial of Electroacupuncture for Women With Pure Stress Urinary Incontinence||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Completed|December 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|40 Years|75 Years|No|||May 2015|May 29, 2015|May 13, 2015||No||No|May 15, 2015|https://clinicaltrials.gov/show/NCT02445573||21103|
NCT02444403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA039073|Police Training to Reduce Occupational Needlesticks and HIV Among Substance Users|Proyecto ESCUDO: Police Training to Reduce Occupational Needlesticks and HIV Among Substance Users|ESCUDO|University of California, San Diego|Yes|Recruiting|June 2015|||March 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444403||21193|
NCT02444416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-019|Prospective Registry of Acute Heart Failure|Prospective Registry of Acute Heart Failure||University Hospital, Geneva|No|Recruiting|December 2014|June 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Whole blood|Both|16 Years|100 Years|No|Non-Probability Sample|Patients hospitalized for an acute heart failure|March 2016|March 3, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444416||21192|
NCT02442544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFSDM1|Prebiotic Fiber Supplement in T1DM Children|Effect of Prebiotic Fiber on Gut Microbiota, Intestinal Permeability and Glycemic Control in Children With Type 1 Diabetes: A Pilot Randomized, Double Blind, Placebo Controlled Study||University of Calgary|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|8 Years|17 Years|No|||October 2015|October 21, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02442544||21335|
NCT02450084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUMC 2015-01-024-002|Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery|Postoperative Analgesic Effects of Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery||Ewha Womans University Mokdong Hospital|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|21 Years|60 Years|No|||July 2015|July 4, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02450084||20757|
NCT02455596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-NETs-001|Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors|Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Recruiting|May 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|January 4, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455596||20334|
NCT02453529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-4873-101|Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects|A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects||Wockhardt||Completed|April 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453529||20492|
NCT02442596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABSES|Abdominal SepsiS Study: Epidemiology of Etiology and Outcome|Abdominal SepsiS Study: Epidemiology of Etiology and Outcome|AbSeS|European Society of Intensive Care Medicine|No|Recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive, adult ICU patients diagnosed with IAI- intra-abdominal infection (either        as a primary diagnosis or as a complication during the ICU course) during a 6 months        period and with a maximum of 15 cases per unit.|January 2016|January 4, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02442596||21331|
NCT02456519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15HS03|Quality of Postoperative Recovery in Children and Young People|Quality of Postoperative Recovery in Children and Young People: The Modified QoR-15 Questionnaire||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|10 Years|18 Years|No|Non-Probability Sample|Children/ young people aged between 10 and 18 years undergoing general anaesthesia for        surgery or diagnostic imaging|May 2015|February 9, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02456519||20263|
NCT02454738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHchestradiology-001|Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts|Ultralow Dose Computed Tomography in Close Contacts at High Risk for Developing Multidrug- or Extensively Drug-resistant Tuberculosis: A Pilot Study||Seoul National University Hospital|No|Active, not recruiting|June 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454738||20399|
NCT02453815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008|Do Arterial Catheters Reduce the Risk of Major Perioperative Complications|Do Arterial Catheters Reduce the Risk of Major Perioperative Complications||The Cleveland Clinic|No|Recruiting|June 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|3784|||Both|18 Years|90 Years|No|||August 2015|August 25, 2015|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02453815||20470|
NCT02457975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00024065|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2015|||||N/A|N/A|N/A||||||||||||||May 27, 2015|May 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457975||20151|
NCT02443662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063.09f|Colloid Osmotic Pressure in Patients With Fontan Circulation|Interstitial Colloid Osmotic Pressure in Children With Fontan Circulation After Fontan Surgery||Oslo University Hospital|No|Not yet recruiting|May 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Interstitial fluid. Serum|Both|13 Years|18 Years|No|Probability Sample|Children who will have a cathererization during their routine check up 10 years after        completion of Fontan surgery.|April 2015|May 11, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02443662||21250|
NCT02443675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4 OS-1|Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy|Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy||Cure Cancer Worldwide, LLC|No|Active, not recruiting|May 2015|December 2020|Anticipated|August 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients Receiving Low Dose Chemotherapy|May 2015|May 13, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02443675||21249|
NCT02455102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022/14|Electronic Warning System for Atrial Fibrillation|Electronic Warning System to Improve Stroke Prevention in Atrial Fibrillation - A Quality Improvement Initiative at the University Hospital Bern||University Hospital Inselspital, Berne|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1707|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02455102||20372|
NCT02455115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP after Livertransplantation|Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure|Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure||Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02455115||20371|
NCT02452645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrownMC|Improving Nutrition and Physical Activity Environments in Home-based Child Care|Improving Nutrition and Physical Activity Environments in Home-based Child Care||Brown University|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02452645||20560|
NCT02450474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL14/11224|Mobilising Lower Limb Fluid for Hemodynamic Stability in Haemodialysis|Pilot Evaluation of Intermittent Pneumatic Compression and Neuromuscular Electrical Stimulation for Enhancing Vascular Refilling in Haemodialysis||The Leeds Teaching Hospitals NHS Trust|No|Recruiting|February 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|12|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02450474||20727|
NCT02433847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mosa_GIFx_1.0|Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects|||Seoul National University Hospital||Not yet recruiting|May 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||April 2015|April 29, 2015|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433847||22003|
NCT02442349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00017|Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific|A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene|AURA17|AstraZeneca|No|Active, not recruiting|June 2015|June 2017|Anticipated|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|319|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02442349||21350|
NCT02451475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUH-ANES-2013-10|Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome|Comparative Effectiveness of Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome: A Controlled Randomized Study||Mansoura University|Yes|Completed|February 2013|October 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|70 Years|No|||May 2015|May 21, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02451475||20650|
NCT02451488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005510|Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma|Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma||Mayo Clinic|Yes|Recruiting|May 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451488||20649|
NCT02451501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NebuPostu|Influence of Body Posture on Pulmonary Aerosol Deposition||NebuPostu|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|July 2015|October 2015|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02451501||20648|
NCT02450734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM CEPAR : 2012-014|Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Surgery|Safety and Efficiency of Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Surgery||Institut Mutualiste Montsouris|No|Completed|April 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing carotid endarterectomy|May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450734||20707|
NCT02450747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5692|Performance of a Multifocal Contact Lens - Presbyopia Study|||Johnson & Johnson Vision Care, Inc.|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450747||20706|
NCT02443714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFJI-2015|Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology|Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology||Chongqing Medical University|Yes|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443714||21246|
NCT02446600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00606|Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||National Cancer Institute (NCI)|Yes|Recruiting|February 2016|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|N/A|N/A|No|||February 2016|February 8, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446600||21024|
NCT02446613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204509|Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958|A Single-centre, Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Who Completed Treatment in Study TL7116958 in 2014||GlaxoSmithKline|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446613||21023|
NCT02444611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC/01 ELVIS|A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study|A Randomised, Controlled Trial Investigating the Influence of BCG (Bacillus Calmette-Guérin) and Hepatitis B Immunisation at Birth on Neonatal Immune Responses|ELVIS|Murdoch Childrens Research Institute|Yes|Recruiting|March 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|200|||Both|N/A|3 Days|No|||May 2015|May 11, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02444611||21177|
NCT02435459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_12-054|The Effect of Different Lining Strategies on Amalgam Restorations|The Effect of Different Lining Strategies on Amalgam Restorations||University of Birmingham|No|Recruiting|April 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|640|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02435459||21879|
NCT02455479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12060012440|Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals|Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine||Weill Medical College of Cornell University|Yes|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|21 Years|60 Years|No|||October 2015|December 9, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02455479||20343|
NCT02444507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSP RFH3002-01|A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product|A Randomized, Two-Way Crossover, Single-Dose Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product (Nexium Powder for Injection and Infusion 40 mg) in Healthy Adult Subjects||isRed Pharma & Biotech Research Corporation||Recruiting|April 2015|June 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02444507||21185|
NCT02452060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU14-00472|Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy|Randomized, Double-blind, Placebo Controlled Study on the Effect of a Single Postoperative Administration of Low Dose Ketamine After Gastric Bypass and Gastrectomy Surgeries||New York University School of Medicine|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452060||20605|
NCT02452073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JinlingH|An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis|||Jinling Hospital, China|Yes|Completed|January 2014|April 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients and volunteers who were admitted to our hospital|May 2015|May 21, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02452073||20604|
NCT02454998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-3500C (99-3910A3)|Alveolar Bone Grafting Outcome Between Patient With and Without Orthodontic Treatment|The Difference in the Surgical Outcome of Unilateral Cleft Lip and Palate Between Patients With and Without Pre-Alveolar Bone Graft Orthodontic Treatment||Chang Gung Memorial Hospital|No|Active, not recruiting|February 2011|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|8 Years|12 Years|No|||February 2015|May 26, 2015|February 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02454998||20380|
NCT02457377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136|Laparoscopic Transabdominal Cerclage: New Approach|Laparoscopic Transabdominal Cerclage: A New Ideal Approach||Cairo University|Yes|Recruiting|January 2004|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|41 Years|No|||May 2015|May 27, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02457377||20197|
NCT02441647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLEY HERTZ-003|Clinical Study to Prove Safety in Use (Irritability and Sensitization in Genital Mucosa) of an Intimate Lubricating Gel|Clinical Study to Prove Safety in Use (Irritability and Sensitization in Genital Mucosa) of an Intimate Lubricating Gel|CL STD SAF USE|Kley Hertz S/A|No|Completed|June 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|33|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02441647||21404|
NCT02428855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007|Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma|Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma||Massachusetts General Hospital|Yes|Recruiting|April 2015|September 2022|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428855||22385|
NCT02445508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02061124|Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion|Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion||University Hospital, Gentofte, Copenhagen|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|15|||Both|40 Years|75 Years|No|||November 2015|November 20, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445508||21108|
NCT02456051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3463_2014_D'Angelo|Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients|Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients|PaCANOD|University of Roma La Sapienza|Yes|Recruiting|April 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|440|Samples Without DNA|Serum samples|Both|45 Years|75 Years|No|Non-Probability Sample|Adult patients newly diagnosed of diabetes, according to the criteria established by the        American Diabetes Association (ADA) (fasting glucose greater than or equal to 126 mg/dl,        or random blood glucose greater than or equal to 200 mg/dl, or glycated hemoglobin greater        than or equal to 6.5%)|May 2015|May 27, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456051||20299|
NCT02456064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Equipo Multidisciplinar|Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus|Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus With Poor Control of Their Disease||Equipo Multidisciplinar Sanitario CS Foietes|No|Active, not recruiting|May 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|25 Years|N/A|No|||May 2015|May 27, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02456064||20298|
NCT02456077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2785|Strengthening Physician Communication About HPV Vaccines|Strengthening Physician Communication About HPV Vaccines||University of Colorado, Denver|No|Recruiting|January 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|76000|||Both|9 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456077||20297|
NCT02450955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID006|Does the Addition of Manipulation Provide Added Benefit to Massage Therapy for Tension-type Headache Patients?|Does the Addition of Manipulation Provide Added Benefit to Massage Therapy for Tension-type Headache Patients? A Randomized Controlled Clinical Trial|MANIHDI-II|University of Valencia|No|Completed|February 2014|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|65 Years|No|||May 2015|May 20, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02450955||20690|
NCT02449018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBW251X2201|A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251|A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD||Novartis|No|Recruiting|April 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|March 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449018||20839|
NCT02448836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-OT-0034-CTIL|Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)|Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|50 Years|No|||May 2015|May 14, 2015|May 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448836||20853|
NCT02449070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1407-011-030|Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction|Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction : A Randomized Clinical Trial||Pusan National University Hospital|Yes|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|20 Years|N/A|No|||May 2015|May 15, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02449070||20835|
NCT02455414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301004|Tracking Neurodegeneration in Early Wolfram Syndrome|Tracking Neurodegeneration in Early Wolfram Syndrome|TRACK|Washington University School of Medicine|No|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|150|Samples With DNA|A skin biopsy will be obtained from which the investigator will sequence all the exons and      exon-intron junctions of the WFS1 gene. In some cases, the investigator will also sequence      other genes related to Wolfram syndrome including WFS2, MANF, and Caspase-12. If the      investigator doesn't find mutations in these genes, a whole-exome sequencing may be      performed. The genetic test provided has the potential to create a uniquely-identifiable      fingerprint that could possibly identify a participant.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Age, gender and handedness matched participants between the age of 1 day to no upper        limit.|January 2016|January 13, 2016|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02455414||20348|
NCT02428088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-202|Dasotraline Pediatric ADHD Study|A 6-week, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-group Efficacy and Safety Study of Dasotraline Versus Placebo in Subjects 6 to 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)||Sunovion|Yes|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|6 Years|12 Years|No|||January 2016|January 7, 2016|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428088||22444|
NCT02428322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH-ASTHMA-VIT.D|Trial of Vitamin D3 Supplementation in Paediatric Asthma|Randomized, Double-blind, Placebo Controlled Trial of Vitamin D3 Supplementation on Clinical, and Subjective Symptoms of Paediatric Asthma|NCHVitDAst|University of Dublin, Trinity College|No|Completed|October 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|53|||Both|6 Years|16 Years|No|||December 2015|December 1, 2015|October 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02428322||22426|
NCT02449278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUCC-NHL04 Trial|The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma|The Palliative Benefit of Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center - NHL04 Trial||Wuhan University|Yes|Recruiting|October 2015|October 2025|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449278||20819|
NCT02445872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYTOP1502|Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy|Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy||Zhejiang University|No|Not yet recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2015|December 8, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02445872||21080|
NCT02436473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203161|Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model|Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model||GlaxoSmithKline|No|Withdrawn|December 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|May 4, 2015||No|This study was cancelled. No subjects were enrolled and no data has been collected|No||https://clinicaltrials.gov/show/NCT02436473||21801|
NCT02449538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-117|Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors|||Samsung Medical Center|No|Recruiting|April 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449538||20799|
NCT02452879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z121107001012148|Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study|The Effectiveness, Superiority and Safety of EA on OAB:Multi-center Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|October 2014|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02452879||20542|
NCT02455882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00084633|Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer|Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer||University of Michigan|Yes|Recruiting|January 2015|June 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Tissue with invasive disease, blood, and urine samples will be obtained from patients with      breast cancer before, during, and after systemic treatment for primary breast cancer and at      the time of disease recurrence.|Female|18 Years|N/A|No|Non-Probability Sample|Patients who present with newly diagnosed breast cancer or breast cancer recurrence.|November 2015|November 30, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455882||20312|
NCT02457767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anaest-App|Optimizing of Waiting - Time in the Anesthesia Admissions Ambulance of the Charité - University Medicine Berlin by Support of a Mobile Application - a Pilot Study|Optimization of Waiting - Time in the Anesthesia Admissions Ambulance Department of Anaesthesia and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin by Support of a Mobile Application - a Pilot Study||Charite University, Berlin, Germany|No|Withdrawn|June 2015|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|5 Years|N/A|No|Probability Sample|Male and female patients (aged > 4 years) for elective surgery|July 2015|July 30, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457767||20167|
NCT02428842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2013-02 BIO-RAIDs|Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)|Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)|BIO-RAIDs|Institut Curie|No|Recruiting|July 2013|||July 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|700|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02428842||22386|
NCT02456610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CMV/EBV-CTL|Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China|Adoptive Transfer of Peptide Stimulated CMV/EBV Specific Cytotoxic T Lymphocytes to Prevent and Treat EBV/CMV Infections in Patients Post Allogeneic Stem Cell Transplantation in China||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|May 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||February 2016|February 18, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02456610||20256|
NCT02452892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAL-02-007|Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)||Tal Medical, Inc.|No|Recruiting|September 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452892||20541|
NCT02452905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVID/2014-02|Finding Better Treatment of Bronchiolitis: A Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments|A Phase II Double-blind Randomised, Placebo-controlled Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments||Telethon Kids Institute|Yes|Not yet recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|1 Month|12 Months|No|||May 2015|May 20, 2015|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452905||20540|
NCT02447627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|996SC001|Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease|A Study of Methodologies to Measure Blood Flow and Oxygenation as Potential Biomarkers in Adults With Sickle Cell Disease||Biogen|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|38|Samples Without DNA|Blood samples will be collected for hematology, blood chemistry, and venous blood gas      analysis. Blood samples will also be used for exploratory biomarker development specific to      SCD.|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Participants with mild to severe VOC|January 2016|January 14, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02447627||20946|
NCT02443038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPP2774|Yoga's Effect on Fall Risk Factors in the Rural, Older Adult Population; an Academic/Community Partnership|Yoga's Effect on Fall Risk Factors in the Rural, Older Adult Population; an Academic/Community Partnership|Yoga/Falls|University of Wisconsin, Madison|No|Recruiting|April 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|October 1, 2015|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02443038||21297|
NCT02443051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-180THO|Treatment of Social Anxiety in Youth|Attention Training for Adolescents With Social Anxiety Disorder||Virginia Polytechnic Institute and State University|No|Recruiting|May 2013|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02443051||21296|
NCT02444585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00135|Longjohn Amgen Study - Effect of Denosumab...|Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement|EDRPBLFHR|University of Southern California|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444585||21179|
NCT02458105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/541|Acceptance & Commitment Therapy for Psychotic Inpatients|Acceptance & Commitment Therapy for Psychotic Inpatients||Uppsala University|No|Enrolling by invitation|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458105||20141|
NCT02447861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064133|Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome|Behavioral, Molecular and Genetic Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome||Emory University|No|Recruiting|July 2013|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Study subjects will be recruited by an internet-based registry. The registry website will        be indexed on popular search enginesand potential study subjects can elect to visit the        website as they choose. Study population will be individuals with the 3q29 deletion or        3q29 duplication and their family members, although in most cases the primary caregiver of        the 3q29 deletion or duplication individual will contribute the data. This study aims to        collect data on approximately 200 individuals with the 3q29 deletion and 100 individuals        with the 3q29 duplication. For comparison purposes, the study will assess an equal number        of matched number of unaffected siblings and control individuals without the 3q29 deletion        or duplication.|December 2015|December 10, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02447861|5 Years|20928|
NCT02431845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0577|Pharmacogenetic Study of Obsessive-Compulsive Disorder|Pharmacogenetic Study of Obsessive-Compulsive Disorder||Severance Hospital|Yes|Recruiting|January 2013|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|19 Years|60 Years|No|||November 2015|November 16, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02431845||22157|
NCT02453659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215114|Women Engaging in Quitting Smoking Together|Distress Tolerance Treatment for Weight Concern in Smoking Cessation Among Women|WE QUIT|Rhode Island Hospital|No|Recruiting|January 2015|March 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453659||20482|
NCT02446093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaTK02|Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma|Neoadjuvant GMCI Plus Modified FOLFIRINOX and Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma|PaTK02|Advantagene, Inc.||Recruiting|October 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|76 Years|No|||October 2015|October 21, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446093||21063|
NCT02577302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30-00137|Clinical Study of Chronic Tibial Nerve Stimulation (CTNS) to Demonstrate Non-Inferiority as Compared to Posterior Tibial Nerve Stimulation in the Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology|Multi-center, Prospective, Randomized, Controlled Clinical Trial Study of Chronic Tibial Nerve Stimulation (CTNS) to Demonstrate Non-Inferiority in the Treatment of Urinary Urgency Incontinence Resulting From Refractory Overactive Bladder (OAB) With Wireless Neuromodulation Technology as Compared to Peripheral Tibial Nerve Stimulation (PTNS) - "PROTECT" Study|PROTECT|StimGuard, LLC.|Yes|Not yet recruiting|January 2016|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|22 Years|N/A|No|||October 2015|October 14, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577302||10988|
NCT02452697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057501|Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT|A Randomized Phase II Trial to Evaluate Progression-Free Survival Rates in Patients Receiving NK Cell-Enriched Donor Cell Infusions When Administered Alone or Administered With the TLR9 Agonist, DUK-CPG-001, From a 4-7/8 HLA-Matched Related or 8/8 HLA-Matched Donor Following Non-myeloablative Allogeneic Stem Cell Transplantation|NK-DCI|Duke University|Yes|Not yet recruiting|July 2016|July 2023|Anticipated|July 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452697||20556|
NCT02461108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110002491|Nudging Nutrition With Monetary Incentives Environmental Cues|Nudging Nutrition: Evaluating the Impact of Monetary Incentives and Environmental Cues on Food Choices||Cornell University|No|Completed|May 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|221|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461108||19910|
NCT02440919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11354813.1.0000.5504|Oxygen Supplementation and Ventilator Hyperinflation in the Endotracheal Suction (OSVHES)|Effects of Low Oxygen Supplementation and Ventilator Hyperinflation in the Endotracheal Suction of Mechanically Ventilated Patients|OSVHES|Universidade Federal de Sao Carlos|Yes|Active, not recruiting|June 2013|November 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|95 Years|No|||July 2015|September 22, 2015|March 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440919||21460|
NCT02452567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501010|Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects|Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects|MAL|Washington University School of Medicine|Yes|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02452567||20566|
NCT02449382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVVH-Na-002|Continuous Venovenous Hemofiltration Versus Conventional Treatment for Acute Severe Hypernatremia|To Effect and Safety of Continuous Venovenous Hemofiltration (CVVH) Versus Conventional Treatment for Acute Severe Hypernatremia in Critical Ill Patients: A Randomized Clinical Trial||Fourth Military Medical University|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02449382||20811|
NCT02461173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sub 10|Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility|Comparison Between Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility||Cairo University|Yes|Recruiting|June 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|20 Years|40 Years|No|||January 2016|January 26, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02461173||19905|
NCT02458222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-300|Efficacy of Language Games as Therapy for Post Stroke Aphasia|Efficacy of Language Games as Therapy for Post Stroke Aphasia|AphasiaGame|University of Birmingham|No|Not yet recruiting|July 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02458222||20132|
NCT02442336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11822|A Web-Based Multimedia Intervention for Head and Neck Cancer Patients|A Web-based Multimedia Intervention for Head and Neck Cancer Patients||Fox Chase Cancer Center|No|Recruiting|June 2012|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02442336||21351|
NCT02452814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29710|Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection||Hoffmann-La Roche||Active, not recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|8|||Both|19 Years|N/A|No|Non-Probability Sample|This study will include null responder subjects with Chronic hepatitis C (CHC) genotype 1        virus infection who have participated in Study SPC3649-205.|March 2016|March 1, 2016|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452814||20547|
NCT02452827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0034-15|The Correlation of Myodural Bridges to Biomechanical Parameters in Patients Suffering From Primary Chronic Neck Pain|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from Primary Chronic Neck Pain who have undergone MRI. Healthy        volunteers who have undergone MRI of the cervical spine.|May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02452827||20546|
NCT02445313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDEKMP3|Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device|Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device||Doheny Image Reading Center|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohort A will consist of patients with AMD, recruited by PI when they come in to the        clinic, with whom we will conduct medical record review and imaging procedures, using one        of the research devices.        Cohort B will consist of control subject with no ocular problems, with whom no record        review will be conducted, but imaging will be conducted with study devices.|January 2016|January 20, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445313||21123|
NCT02445157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/2248|Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis|Reliability of the 4 Metre Gait Speed in Patients With Idiopathic Pulmonary Fibrosis|IPFREL|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|February 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|99 Years|No|Probability Sample|Patients diagnosed with IPF according to NICE guidelines|October 2015|October 26, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02445157||21135|
NCT02432547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X14-0157|Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)|A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema|LADAMO|University of Sydney|Yes|Recruiting|June 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432547||22103|
NCT02449824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO15/085|MRI and Early Decision-making in Chemotherapy for Breast Cancer|Characterising Early Response to Neoadjuvant Chemotherapy With Quantitative Breast MRI|CHERNAC|University of Leeds|No|Not yet recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|tumour biopsy samples and blood|Female|18 Years|N/A|No|Non-Probability Sample|Female patients aged over 18 years with invasive carcinoma of the breast who, following        discussion at the breast multidisciplinary team (MDT) meeting, are to be treated in Leeds        using NAC with curative intent will be approached to take part in this study (this        includes HER2+ patients receiving trastuzumab); the sample will thus reflect the general        population of patients receiving NAC.|May 2015|May 29, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02449824||20777|
NCT02450136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-135|Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors|||Samsung Medical Center|No|Not yet recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450136||20753|
NCT02448940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umsu.rec.1393.74|The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements|The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements, Body Composition, Appetite and Serum Lipid Profile in Overweight and Obese Adults||Urmia University of Medical Sciences|Yes|Completed|February 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|May 16, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02448940||20845|
NCT02432794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIL_2013|Trial on Delay Phenomenon Utility in Preventing Anastomotic Leakage After an Esophagectomy|A Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After an Ivor-Lewis Esophagectomy|APIL_2013|Hospital Universitari de Bellvitge|Yes|Recruiting|May 2015|April 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02432794||22084|
NCT02454270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107241|A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64052781, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies||Janssen Research & Development, LLC|No|Recruiting|June 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02454270||20435|
NCT02458976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000196|Pulsed-dye Laser Treatment Prior to Surgical Excision|||Massachusetts General Hospital|Yes|Not yet recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458976||20074|
NCT02457897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150119|Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations|Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in Patients With Insulin Receptor Mutations||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|65 Years|No|||December 2015|January 8, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02457897||20157|
NCT02457962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000136|Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study|Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study||Mayo Clinic|No|Recruiting|April 2015|||April 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients being treated at Mayo Clinic with photon/ proton therapy.|February 2016|February 23, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02457962|100 Years|20152|
NCT02446262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150132|Neural and Psychological Mechanisms of Pain Perception|Neural and Psychological Mechanisms of Pain Perception||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|260|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446262||21050|
NCT02461238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UParis13|Impact of Vouchers and Nutrition Education on the Consumption of Fruits and Vegetables Among Vulnerable Single-parent Families (FLAM)|Etude Fruits et Légumes à la Maison (FLAM)|FLAM|University of Paris 13|No|Recruiting|June 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02461238||19900|
NCT02457988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COORS|The Cirrhosis Outpatient Optimization, Readmission & Safety Study|COORS: The Cirrhosis Outpatient Optimization, Readmission & Safety Study|Vivify|University of California, Los Angeles|No|Recruiting|April 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02457988||20150|
NCT02450201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125518|MRI With C13 Pilot Study Prostate Cancer|A Pilot Study to Evaluate the Reproducibility of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) and Its Ability to Reflect Treatment Effects in Patients With Prostate Cancer||University of California, San Francisco|Yes|Not yet recruiting|October 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450201||20748|
NCT02430766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lymphnode metastases-IRE-01|Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)|Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 26, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430766||22240|
NCT02451930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15568|A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC|A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Recruiting|September 2015|May 2018|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451930||20615|
NCT02460510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ALF-01|Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF|Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF: A Randomized Open -Label Study||Institute of Liver and Biliary Sciences, India|No|Completed|June 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02460510||19956|
NCT02457299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH15-175|Esophagectomy With or Without Prior Ischemic Gastric Preconditioning|A Multicenter, Randomized Trial of Esophagectomy and Cervical Esophagogastrostomy With (Two-stage) or Without (One-stage) Prior Ischemic Gastric Preconditioning by Laparoscopic Ligation of Left Gastric and Short Gastric Arteries||NorthShore University HealthSystem|No|Recruiting|May 2015|May 2022|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02457299||20203|
NCT02457663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0525|Identification and Validation of Biomarkers for Infections in Burns|Identification and Validation of Established and Novel Biomarkers for Infections in Burns||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|April 2015|December 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to participating burn centers who meet inclusion criteria.|May 2015|May 26, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457663||20175|
NCT02443688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX-4430-CF-201|EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis||Celtaxsys, Inc.|Yes|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|195|||Both|18 Years|30 Years|No|||March 2016|March 10, 2016|May 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443688||21248|
NCT02454517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9369|Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer|PALS: Prostate Cancer Active Lifestyle Study|PALS|Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|January 2016|||May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Male|40 Years|75 Years|No|||November 2015|November 16, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454517||20416|
NCT02454530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISTA|Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study|Prophylactic Treatment for Chemo-induced Neutropenia. Use of G-CSF Biosimilar (Nivestim®) According to the Chemotherapy Context: Adjuvant Versus Metastatic|VISTA|Hospira, Inc.|No|Recruiting|October 2014|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with solid tumour treated with cytotoxic chemotherapy and for whom a prophylactic        treatment with G-CSF biosimilar (Nivestim®) is initiated|December 2015|December 31, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454530||20415|
NCT02456792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1|IVF Versus LOD in Women With CC Resistant PCOS|In Vitro Fertilization Versus Laparoscopic Ovarian Drilling in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome||Mansoura University|No|Not yet recruiting|January 2016|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|35 Years|No|||January 2016|January 29, 2016|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02456792||20242|
NCT02456805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH23|Alternate Formula Feedings in Formula Intolerant Infants|Efficacy of Alternate Formula Feedings in Formula Intolerant Infants||Abbott Nutrition|No|Completed|August 1996|June 1997|Actual|June 1997|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|113|||Both|N/A|9 Weeks|No|||May 2015|May 27, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456805||20241|
NCT02457754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIUZ-2014-BIO-08-216-162|Physical Fitness and Bone Structure Evaluation in Preschool Children|Physical Fitness and Bone Structure Evaluation in Preschool Children||Universidad de Zaragoza||Active, not recruiting|January 2015|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|225|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy 3 to 5 year-old children|December 2015|December 1, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457754||20168|
NCT02457832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0870-W|Motor Training in PD|Optimizing Motor Training in Parkinson Disease Through Neural Mechanisms (NEURODEGEN)||VA Office of Research and Development|No|Recruiting|November 2014|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|99|||Both|40 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02457832||20162|
NCT02431299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH096835-01|Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development|Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development|IT IS VALID|Indiana University|No|Completed|September 2012|||July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|299|||Both|18 Years|N/A|No|Non-Probability Sample|Consumers with mental illness, who are participating in the Illness Management and        Recovery intervention in New Jersey and Indiana. This includes consumers from state        hospitals, rehabilitation centers and community mental health centers. Additionally, the        clinicians who are leading the intervention are considered to be participants of the study        as well.|November 2015|November 19, 2015|April 23, 2015||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT02431299||22199|Unable to randomly assign a level of competency in providing IMR. Geographically limited to three states within the United States. Relatively brief observation period (3-months).
NCT02451423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14524|Study of MPDL3280A in Bladder Cancer|A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder||University of California, San Francisco|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451423||20654|
NCT02451436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X140429002|A Sleep and Media Intervention to Improve Adolescents' Metabolic Health and Weight Status|Pilot Study of a Sleep and Media Intervention to Improve Adolescents' Metabolic Health and Weight Status||University of Alabama at Birmingham|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|17 Years|Accepts Healthy Volunteers|||December 2015|February 6, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02451436||20653|
NCT02448914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSM-003|A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients|A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease||LobSor Pharmaceuticals AB|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|30 Years|N/A|No|||August 2015|August 27, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02448914||20847|
NCT02440854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.247|Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings|A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced Non-small Cell Lung Cancer in a Real World Setting in Greece.||Boehringer Ingelheim||Recruiting|February 2016|October 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|NSCLC EGFR mutation|March 2016|March 1, 2016|April 28, 2015||||No||https://clinicaltrials.gov/show/NCT02440854||21465|
NCT02448498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32113|Strength Training Regimen for Normal Weight Diabetics||STRONG-D|Stanford University||Not yet recruiting|February 2016|||March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|282|||Both|30 Years|75 Years|No|||November 2015|November 16, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02448498||20879|
NCT02448511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ozone 1|Local Application of Ozone Gas for Infected Ulcers|Local Application of Ozone Gas for Infected Ulcers: A Double Blinded Randomized Control Trial||St. John's Research Institute|No|Completed|August 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02448511||20878|
NCT02460848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCCII-Nutrition|Effects of Cash Transfers on Severe Acute Malnutrition|Effects of Unconditional Cash Transfers on the Management of Severe Acute Malnutrition (SAM) in the Democratic Republic of Congo: a Cluster Randomized Trial||UNICEF|Yes|Completed|July 2015|January 2016|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1600|||Both|6 Months|59 Months|No|||January 2016|January 4, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460848||19930|
NCT02457390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140154|The Value of CE-LUS During Robot-assisted Surgery for Primary Colorectal Cancer|The Value of Contrast Enhanced Laparoscopic Ultrasound Examination During Robot-assisted Surgery for Primary Colorectal Cancer|CE-LUS|Odense University Hospital|Yes|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 25, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457390||20196|
NCT02429089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 2015-01|Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck|Phase I Study of LEE011plus Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|CETLEE011|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02429089||22367|
NCT02450565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropathic Pain Translation|Translation of the Self Completed-Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale|Translation and Validation of the Traditional Chinese-Cantonese Version of the Self Completed-Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale||The University of Hong Kong|Yes|Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|No|Probability Sample|A total of 200 pain patients will be recruited. One hundred of these patients will be        patients suffering from neuropathic pain, and 100 will be patients with nociceptive pain.        The diagnosis of neuropathic or nociceptive pain will be made by pain specialists based on        a detailed history, physical examination, investigation results and medical records. The        pain specialists' diagnosis will be used for distinguishing between nociceptive and        neuropathic pain. Demographic information including age, sex, pain diagnosis and duration,        education level, co-existing medical problems and employment status will be recorded. The        Cantonese S-LANSS will then be administered to patients to be completed without the help        of staff.|May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450565||20720|
NCT02460874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062845|Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (GCC 1465)|A Pilot Study and Phase II Double Blind Placebo Controlled Randomized Trial Examining the Safety and Efficacy of Glyburide as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases||University of Maryland|Yes|Not yet recruiting|February 2016|October 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460874||19928|
NCT02427815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYULagone|Peer-Enhanced Education to Reduce Sleep Ethnic Disparities|Tailored Peer-Based Sleep Health Education and Social Support Among Blacks With Obstructive Sleep Apnea|PEERS-ED|New York University Langone Medical Center|Yes|Recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|398|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02427815||22465|
NCT02428075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypertension-Nepal|Community-based Management of Hypertension in Nepal|Protocol for Community-based Intervention for Blood Pressure Reduction in Nepal: a Community-based Cluster Randomized Controlled Trial|COBIN|University of Aarhus|No|Recruiting|November 2015|April 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|1638|||Both|25 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 13, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428075||22445|
NCT02453633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-ENT|Theory Based SMS Reminders - Text's Impact on Patient Attendance|Theory Based SMS Reminders - Text's Impact on Patient Attendance||Lovisenberg Diakonale Hospital|No|Not yet recruiting|May 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|N/A|80 Years|No|||May 2015|May 22, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453633||20484|
NCT02456584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702179|Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods|Pharmacodynamics (Suppression of Ovulation) and Pharmacokinetics Following a Single Subcutaneous Administration of Depo Provera® CI 150 mg/mL, Depo Provera® CI 300 mg/2 mL, or During Two Cycles of Depo-subQ Provera 104®||FHI 360|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|48|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456584||20258|
NCT02457520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS157LT|ABSORICA in Patients With Severe Recalcitrant Nodular Acne|An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne||Ranbaxy Inc.|No|Recruiting|January 2015|November 2017|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|12 Years|45 Years|No|||May 2015|May 28, 2015|May 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457520||20186|
NCT02447315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAN-CL-0004|A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects|A Phase 1 Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects||Astellas Pharma Inc|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447315||20969|
NCT02432755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-7164A3|Effects of Home-based Mirror Therapy Combined With Task-oriented Training for Patients With Stroke|Effects of Home-based Mirror Therapy Combined With Task-oriented Training for Patients With Stroke: a Randomized Controlled Trial||Chang Gung Memorial Hospital|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|80 Years|No|||November 2015|March 7, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02432755||22087|
NCT02453945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.E.B. number: 15-144|Use of a Support Bra to Reduce Pain and Improve Surgical Healing in Women Undergoing Sternotomy for Cardiac Surgery|Use of a Support Bra to Reduce Pain and Improve Surgical Healing in Women Undergoing Sternotomy for Cardiac Surgery||St. Michael's Hospital, Toronto|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453945||20460|
NCT02452593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGSDGO|Randomized Trial of Tibial Nerve Stimulation Versus Pelvic Floor Exercises for Treatment of Overactive Bladder|Randomized Trial of Tibial Nerve Stimulation Versus Pelvic Floor Exercises for Treatment of Overactive Bladder, Urge and Mixed Urinary Incontinence||Federal University of Rio Grande do Sul|Yes|Recruiting|January 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452593||20564|
NCT02452606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0241|Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease|Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease||Asan Medical Center|No|Active, not recruiting|March 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|79 Years|No|||May 2015|May 20, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02452606||20563|
NCT02450162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-115|Lateral Rectus Muscle and Anterior Segment Optical Coherence Tomography (AS-OCT) in Two Recession Surgeries|Comparison of the Changes of Lateral Rectus Muscle Insertion Measured With AS-OCT in Two Recession Surgeries|AS-OCT|Samsung Medical Center|No|Not yet recruiting|May 2015|December 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|5 Years|60 Years|No|Non-Probability Sample|60 patients        : 30 for conventional recession surgery 30 for hang-back recession surgery|April 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450162||20751|
NCT02441127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU4|Diode Laser for Harvesting Gingival Graft|Diode Laser For Harvesting Subepithelial Connective Tissue Graft in The Treatment of Gingival Recession Defects: A Novel Approach to Limit Morbidity||Cukurova University|Yes|Completed|October 2012|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|38 Years|No|||May 2015|May 12, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02441127||21444|
NCT02453971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA5-2513DSM213|Trial to Evaluate the Effects of the German eCHECKUP TO GO in Students|German Title: Prävention Substanzbezogener Störungen Bei Studierenden|PsSt|Esslingen University of Applied Sciences|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1465|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|December 11, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02453971||20458|
NCT02453984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPDL3280A-img-042015|MPDL3280A-imaging-IST-UMCG|ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment||University Medical Center Groningen|No|Not yet recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453984||20457|
NCT02456766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1310FT|Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis|A Multicenter Clinical Study on the Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for the Diagnosis of Hepatic Steatosis||Wuxi Hisky Medical Technology Co Ltd||Recruiting|June 2014|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|240|Samples Without DNA|Liver Biospy Specimens|Both|18 Years|65 Years|No|Probability Sample|The subjects with liver diseases who need to have a liver biopsy in hospital and meet all        of the inclusion criteria and none of the exclusion criteria, may participate in this        study. Within two weeks of FibroTouch examination, subjects are required to have qualified        histological specimens of liver biopsy for comparation.|May 2015|May 27, 2015|March 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02456766||20244|
NCT02456948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EE1401F|Adjunct Minocyline in Treatment-resistant Depression|A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD)|Mino-TRD|Charite University, Berlin, Germany|Yes|Recruiting|December 2015|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456948||20230|
NCT02457858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00045961|Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study|Manganese Porphyrin MnTE-2-PyP (BMX - 010) Preservation of Islet Cell Mass and Function for Clinical Islet Transplantation||University of Alberta|Yes|Recruiting|August 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|68 Years|No|||November 2015|November 30, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02457858||20160|
NCT02447848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP302|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Acute Pain|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Acute Pain in Patients in Emergency Room Setting||AcelRx Pharmaceuticals, Inc.|No|Recruiting|October 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447848||20929|
NCT02433288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560C00088|Rosuvastatin Adherence App Study in China|A Randomized, Two-arm, Open, 24-week Study to Evaluate the Effect of a Smart Phone-based Patient Support Tool on Duration of Treatment in Patients Prescribed Rosuvastatin in China|eHELP China|AstraZeneca|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|862|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433288||22046|
NCT02446574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-27/230|Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma|Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma||Chinese Academy of Medical Sciences|Yes|Recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|68 Years|No|||July 2007|December 9, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02446574||21026|
NCT02456974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/172|Antibiotic Dosing in Pediatric Intensive Care|Antibiotic Dosing in Pediatric Intensive Care|ADIC|University Hospital, Ghent|No|Recruiting|May 2012|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|blood samples|Both|N/A|16 Years|No|Non-Probability Sample|children admitted to a neonatal or pediatric intensive care unit|November 2015|November 17, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02456974|3 Days|20228|
NCT02456987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039751|Virtual Reality in Inpatients|The Feasibility, Usability, Acceptability, and Clinical Utility of a Virtual Reality Intervention in the Inpatient Setting||Cedars-Sinai Medical Center|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456987||20227|
NCT02451839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-345|An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)|An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)|VITALITY|AbbVie|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|190|||Both|18 Years|75 Years|No|Probability Sample|Subjects will be males and/or females who are attending a routine clinical visit and meet        all of the inclusion criteria and none of the exclusion criteria.|March 2016|March 1, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451839||20622|
NCT02449031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2407|Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs|A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® Podhaler™ (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs||Novartis|No|Recruiting|May 2015|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|6 Years|N/A|No|Non-Probability Sample|CF patients chronically colonized with P. aeruginosa enrolled in the Cystic Fibrosis        Foundation (CFF) PortCF registry and using TOBI Podhaler (TOBI Podhaler-treated cohort) or        another FDA-approved inhaled antipseudomonal antibiotic (non-TOBI Podhaler-treated        cohort).        Patients must enroll during an on-cycle treatment period. It is anticipated that this        patient population will include a subset of patients with increased P. aeruginosa MICs to        tobramycin at baseline.|February 2016|February 19, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449031|5 Years|20838|
NCT02449044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-03-244|International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia|International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia: Extension to Studies 156-02-235 and 156-03-238 to Assess One-year Safety||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|May 2004|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 14, 2015|No|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT02449044||20837|
NCT02449122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nano drug lung cancer|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma：Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||June 2015|February 23, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449122||20831|
NCT02452177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jinling Hospital|Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease|Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease: Clinical Observation and Experimental Study||Jinling Hospital, China|Yes|Recruiting|May 2015|February 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||May 2015|May 21, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02452177||20596|
NCT02452190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072-AS-30025|Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils|A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils||Teva Pharmaceutical Industries|No|Recruiting|September 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|12 Years|N/A|No|||March 2016|March 1, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452190||20595|
NCT02436304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXE844b-C002|Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2|Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion||Alcon Research|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|6 Months|12 Years|No|||November 2015|November 24, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436304||21814|
NCT02456454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMC#03-12-26|Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder|Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder||Nationwide Children's Hospital|No|Completed|January 2006|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|3 Years|7 Years|No|||November 2015|November 11, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456454||20268|
NCT02450682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005395|Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study|Evaluate the Safety of Apixaban in Patients Who Undergo Cardiovascular Implantable Electronic Device (CIED) Procedure: A Randomized Pilot Study|Apixaban|Mayo Clinic|Yes|Withdrawn|February 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450682||20711|
NCT02574767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondecyt #1150878|Diet and Physical Activity Counseling and n3-long Chain (PUFA) Supplementation in Obese Pregnant Women|Effectiveness on Maternal and Offspring Metabolic Control of a Home-based Dietary and Physical Activity Counseling and n3-long Chain Polyunsaturated Fatty Acids (PUFA) Supplementation in Obese Pregnant Women.|MIGHT|University of Chile|No|Recruiting|August 2015|March 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|1000|||Female|18 Years|40 Years|No|||October 2015|October 9, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574767||11183|
NCT02461121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST vs NST|HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk|Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Completed|May 2004|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|9 Years|59 Years|No|||May 2015|June 2, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02461121||19909|
NCT02442206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ADE05|Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients|A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)|CLAIM|Novartis|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|40 Years|N/A|No|||March 2016|March 20, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02442206||21361|
NCT02456012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NationalCheng-KungU|Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients|Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients|Eso_1y_R6PUB|National Cheng-Kung University Hospital|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|288|||Both|20 Years|95 Years|No|||May 2015|May 25, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456012||20302|
NCT02453711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9536-4153|Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus|Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus||Novo Nordisk A/S|No|Active, not recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|935|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453711||20478|
NCT02448407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMH-PRP-2013|Intraarticular Injections of Platelet-rich Plasma in Pain's Treatment of the Osteoarthritic Knee|Intraarticular Injections of Platelet-rich Plasma in Pain's Treatment of the Osteoarthritic Knee||Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|No|Completed|January 2014|November 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|40 Years|80 Years|No|||February 2015|May 15, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02448407||20886|
NCT02428114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT 14-05|A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)|A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)|React-G|Ottawa Hospital Research Institute|No|Recruiting|April 2015|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|100|||Both|19 Years|N/A|No|Non-Probability Sample|Newly diagnosed breast cancer patients, who will be receiving FEC-D, AC-D, dose dense        AC-T, TC or TAC chemotherapy will be eligible.|August 2015|August 18, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02428114||22442|
NCT02456350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504001|Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Genetically Engineered T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor for Treatment of Patients With B Cell Malignancies||Shenzhen Second People's Hospital|No|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|1 Year|85 Years|No|||May 2015|May 27, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02456350||20276|
NCT02449902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXV13-01|TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy|A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)||TherapeuticsMD|No|Completed|July 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|40 Years|75 Years|No|||November 2015|November 5, 2015|May 18, 2015|Yes|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT02449902||20771|
NCT02449447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-compared|Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet|European Comparative Effectiveness Research on Internet-based Depression in Sweden (E-compared) Treatment). A Randomized Controlled Trial Comparing Blended Internet and Face-to-face CBT Against Treatment as Usual|E-compared|Linkoeping University|Yes|Active, not recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02449447||20806|
NCT02449460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlmazovFCHBE-4|Cardiovascular Epidemiology in Russian Federation|Multicenter Observational Study of Epidemiology of Cardiovascular Diseases and Risk Factors in Different Regions of Russian Federation|ESSE-RF|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|Yes|Recruiting|July 2012|December 2022|Anticipated|March 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|18000|Samples With DNA|whole blood serum plasma urine|Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Random sample population|May 2015|May 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449460||20805|
NCT02438982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pednephro RCT/PM/NRSMCH-54|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome||Nilratan Sircar Medical College|Yes|Active, not recruiting|January 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|3 Years|16 Years|No|||October 2015|October 5, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438982||21608|
NCT02454192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31993|Community Healthcare for Asthma Management and Prevention of Symptoms|A Study of the Feasibility and Effectiveness of Implementing and Diffusing an Evidence-based Childhood Asthma Management Intervention in Community Health Centers|CHAMPS|George Washington University|No|Active, not recruiting|October 2010|March 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|599|||Both|5 Years|12 Years|No|||February 2016|February 8, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02454192||20441|
NCT02454205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NExT-5001|An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis|Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial|NEXT|University of Cape Town|Yes|Recruiting|October 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454205||20440|
NCT02455167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0919|Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis|Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less)||University of Colorado, Denver|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|80 Years|No|||October 2015|October 2, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455167||20367|
NCT02453256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29767|A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) [focuSSced]|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis||Hoffmann-La Roche||Recruiting|August 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453256||20513|
NCT02442063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17110|Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions|An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions||Bayer|No|Active, not recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02442063||21372|
NCT02442076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-5928A3|Skin and Acupuncture Needle Vibration Behaviors Through Observation|Skin and Acupuncture Needle Vibration Behaviors Through Observation||Chang Gung Memorial Hospital||Recruiting|May 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers who is          1. Aged 20~65          2. Without chronic disease          3. Didn't receive surgery in the past 12 months|February 2016|February 19, 2016|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02442076||21371|
NCT02456896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T/IM-NF/Pharm/14/19|Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder|Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder||All India Institute of Medical Sciences, Bhubaneswar|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456896||20234|
NCT02456909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICU_RCT|Patient Controlled Analgesia Pump Cues on Patient Satisfaction|The Effect of Patient Controlled Analgesia Pump Cues on Patient Satisfaction|PCA Cues|Medical College of Wisconsin|No|Recruiting|April 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|7 Years|18 Years|No|||March 2016|March 9, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456909||20233|
NCT02447822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsanMC 2014-1213|Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)|A Prospective Randomized Controlled Study to Evaluate Feasibility and Safety of Early Steroid Withdrawal After 6mg/kg vs 4.5mg/kg Thymoglobulin Induction Therapy in Kidney Transplantation||Asan Medical Center||Not yet recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02447822||20931|
NCT02445638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|693261|HDL Lipidomic, Proteomic and Functional Changes in Women After Eating Eggs|HDL Lipidomic, Proteomic and Functional Changes in Response to Whole Egg Consumption in Overweight and Obese Women||University of California, Davis|No|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445638||21098|
NCT02428621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01629-38|Early Treatment for Class II Division 1 Malocclusion With Twicare® and Herbst Removable Appliances|Prospective Multicentric, Open-label, Randomized Study Assessing the Efficacy of the Removable and Adjustable Preformed Twicare® Appliance Versus Removable Herbst Appliance Treatment in Class II Malocclusion|EffTwicare|FCI System|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|148|||Both|7 Years|12 Years|No|||August 2015|August 4, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428621||22403|
NCT02428868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2015004/AR|IV Iron in Association With Tranexamic Acid for Hip Fracture|Use of Combined Tranexamic Acid and Intravenous Iron for Hip Fracture Surgery in Elderly||Institut Kassab d'Orthopédie|Yes|Not yet recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|150|||Both|60 Years|N/A|No|||April 2015|April 28, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02428868||22384|
NCT02450357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|60|||Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage breast cancer come to Fuda Hospital for treatment.|December 2015|December 28, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450357||20736|
NCT02446080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUUnivates|Drink Milk Consumption Benefits With Culture Probiotic in the Treatment of Constipation|The Drink Milk Consumption Benefits With Culture Probiotic in the Treatment of Constipation Women||Centro Universitário Univates|No|Completed|December 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446080||21064|
NCT02446340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-02|Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers|A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186||Kineta Inc.|Yes|Completed|November 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|April 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446340||21044|
NCT02450214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAIC N 722/15|Intraoperative Ketamine and Magnesium Therapy for Control of Postoperative Pain After a Liposuction and Lipoabdominoplasty|Efficacy of Ketamine and Magnesium Association in the Postoperative Pain After Liposuction and Lipoabdominoplasty: Prospective, Randomized and Blinded Study|KEMPLA|University of Chile||Enrolling by invitation|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|December 19, 2015|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02450214||20747|
NCT02451943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15677|A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma|ANNOUNCE|Eli Lilly and Company|Yes|Recruiting|September 2015|September 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451943||20614|
NCT02452268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-ONC-101|A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers|A Phase 1 Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers||Admune Therapeutics LLC|Yes|Recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452268||20589|
NCT02447523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/17-10-2012|The Impact of Metabolic Syndrome on Patients Undergoing Elective Laparotomy|||University of Ioannina|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|N/A|N/A|No|Non-Probability Sample|Study population: Adult patients are undergoing elective laparotomy of estimated duration        of more than one hour. All operations will be performed under general anesthesia.        Group sample sizes of 42 in group one and 42 in group two achieve 90% power to detect a        difference between the group proportions of 0,2500. The proportion in group one (MetS        group) is assumed to be 0,0500 under the null hypothesis and 0,3000 under the alternative        hypothesis. The proportion in group two (the Non-MetS group) is 0,0500. The test statistic        used is the two-sided Likelihood Ratio test. The significance level of the test was        targeted at 0,0500. The significance level actually achieved by this design is 0,0909.|February 2016|February 18, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02447523||20954|
NCT02447536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCGSTRAIN|Trial of Two Strains of BCG|Evaluating the Effect of Different BCG Strains on Early Life Hospital Admissions in Guinea-Bissau: A Randomised Trial|BCGSTRAIN|Bandim Health Project|Yes|Recruiting|May 2015|December 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02447536||20953|
NCT02457442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRV|Interaction of Sevoflurane Propofol and Remifentanil in Anesthesia for Laparoscopic Surgery|Validation of the Interaction Model of the Anesthetic Potency of Sevoflurane, Propofol and Remifentanil|SPRV|University Hospital Inselspital, Berne|No|Recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02457442||20192|
NCT02457455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antalya TRH 002|Urgent Medical and Surgical Conditions During Flights|Inflight Emergencies During Eurasian Flights||Antalya Training and Research Hospital|No|Completed|October 2014|January 2015|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1312|||Both|N/A|95 Years|No|Probability Sample|All passengers who needs urgent medical support|May 2015|May 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457455||20191|
NCT02457676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014076|Improving Self Regulation in Children With Fetal Alcohol Syndrome Spectrum Disorders: A Neuroplastic Intervention|Improving Self Regulation in Children With Fetal Alcohol Syndrome Spectrum Disorders: A Neuroplastic Intervention||The Hospital for Sick Children|No|Completed|October 2009|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02457676||20174|
NCT02457741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 15-074|Validation of a Simple Approach to Estimate Alveolar Recruitability in ARDS Patients|A Simple Approach to Estimate Alveolar Recruitability in Patients With Acute Respiratory Distress Syndrome: a Validation Study||St. Michael's Hospital, Toronto||Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|17 Years|N/A|No|Non-Probability Sample|Moderate-to-severe ARDS patients as per the Berlin definition|March 2016|March 2, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02457741||20169|
NCT02431039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1503-016-653|Comparison Between NEOSORB Plus and NEOSORB|Comparison of Intraoperative Handling and Wound Healing Between NEOSORB Plus Antibacterial Suture With NEOSORB Suture: Prospective, Single-blind, Randomized Controlled Trial||Seoul National University Hospital|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||August 2015|August 12, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02431039||22219|
NCT02431052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM01B-ACN02|A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris|A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris||Dermira, Inc.|No|Active, not recruiting|April 2015|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431052||22218|
NCT02459925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014610|MOMS Hubs- CT Dept of Social Services Block Grant|MOMS Partnership—Community-Based Hubs for Maternal Mental Health and Workforce Development, New Haven MOMS Partnership- CT Dept of Social Services Block Grant|MOMS-Hubs|Yale University|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02459925||20001|
NCT02459119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150302002 (UAB 1477)|Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)|A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy||University of Alabama at Birmingham|Yes|Recruiting|May 2015|||May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|19 Years|N/A|No|||November 2015|November 11, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459119||20063|
NCT02459132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA.CC-14-0183|High-intensity Aerobic Interval Training in Testicular Cancer Survivors|A Phase II Randomized Trial of High-intensity Aerobic Interval Training and Surrogate Markers of Cardiovascular Disease in a Population-based Sample of Testicular Cancer Survivors|HITTS|University of Alberta|No|Not yet recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|80 Years|No|||May 2015|May 29, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459132||20062|
NCT02458833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011720|Home Plate: A Trial to Improve Home Food Preparation Practices Among Parents of Toddlers|Home Plate: A Randomized Controlled Trial of a Community-Engaged Intervention to Improve Home Food Preparation Practices and Health During Early Childhood||Children's Hospital of Philadelphia|No|Recruiting|June 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458833||20085|
NCT02452541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-679|TBI-Prognosis Multicenter Prospective Study|Early Determination of Neurological Prognosis in ICU Patients With Severe Traumatic Brain Injury: The TBI-Prognosis Multicenter Prospective Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Recruiting|April 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|315|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452541||20568|
NCT02455531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10HL068270-4b|Long-term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type|Long-term Outcomes of Children With HLHS (Hypoplastic Left Heart Syndrome) and the Impact of Norwood Shunt Type (A Study Conducted by the Pediatric Heart Network)|SVRIII|New England Research Institutes|Yes|Enrolling by invitation|June 2015|June 2025|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|264|Samples With DNA|Participants and their parents who have not yet contributed to the SVR Extension      biorepository will be offered the opportunity to provide saliva for extraction and storage      of DNA. If study participants have consented to participate in the biorepository through the      SVR Extension study but not yet contributed a sample, they will be asked to contribute at      the time of the SVR III participation. Families who were not previously approached, or who      declined participation in the biorepository earlier, may be offered the opportunity to      participate at the time of the SVR III participation.|Both|10 Years|12 Years|No|Probability Sample|All SVR study cohort members will be contacted to assess for vital status. Transplant free        survivors will be approached to participate in the in-person assessment.|May 2015|June 4, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02455531||20339|
NCT02455544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD002|The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy|The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy||Ohio State University|Yes|Recruiting|August 2014|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Urine specimens|Female|18 Years|48 Years|No|Non-Probability Sample|This study involves testing of urine specimens that originate from pregnant women (ages        18-48) who are presenting for evaluation, following onset of clinical symptoms of        preeclampsia. Preeclampsia is a pregnancy specific medical complication of pregnancy and        thus selection of specimens only of pregnant women is necessary. The urine specimens from        symptomatic women will be used for the testing of the diagnosis value of the CRD test.|May 2015|May 26, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02455544|10 Months|20338|
NCT02454777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-14-5|High-Intensity Interval Training in Improving Fitness in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy With Trastuzumab|High-Intensity Interval Training (HIT) for Breast Cancer Patients During Trastuzumab Use||University of Southern California|Yes|Not yet recruiting|June 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|30|||Female|30 Years|60 Years|No|||May 2015|May 21, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02454777||20396|
NCT02427581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506113|Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy||Washington University School of Medicine|No|Recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|April 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02427581||22483|
NCT02453100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0022238|Managing Urinary Incontinence in Elderly Village Women in Rural Bangladesh|Managing Urinary Incontinence in Elderly Village Women in Rural Bangladesh: a Cluster Randomized Trial of a Community Exercise-based Intervention||University of Alberta|Yes|Recruiting|June 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Female|60 Years|75 Years|No|||November 2015|November 30, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453100||20525|
NCT02447783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311497-II|Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2|Effect of Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2||University of California, Davis|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|75|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2014|May 18, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02447783||20934|
NCT02446717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-410|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy||AbbVie|No|Active, not recruiting|April 2015|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|130|||Both|18 Years|70 Years|No|||February 2016|February 22, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446717||21015|
NCT02433574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINNEARRE-I|Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection|Phase I Study: Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body Radiotherapy and REsection|LINNEARRE-I|Juravinski Cancer Center|Yes|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 26, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02433574||22024|
NCT02459288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-102-085|Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients|A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome.|APROVE-CKD|National Cheng-Kung University Hospital|No|Recruiting|January 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|No|||May 2015|May 28, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02459288||20050|
NCT02447796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 15/60|Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery|A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery||Baskent University|Yes|Recruiting|May 2015|July 2015|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|70 Years|No|||May 2015|May 18, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447796||20933|
NCT02451748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0117|IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA|IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA||University of Illinois at Chicago|No|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451748||20629|
NCT02456168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET CNS5161|Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus|Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus||Northwell Health||Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|24 lupus subjects will be recruited based on the following Inclusion/Exclusion criteria        and serum anti-NMDAR antibody status. The investigators are not selecting for SLE patients        known to have cognitive or psychiatric disturbances because attribution of these problems        is very difficult given the confounding effects of medications, co-morbid disease,        metabolic disturbances and infections. The investigators are interested in the effects of        the anti-NMDAR Aab and will stratify lupus subject population on this variable. The PET        and MRI imaging studies will be performed only during times of stable disease activity and        medication use to avoid confounding influences of acute changes in disease activity and        steroids/immunosuppressive medications. The 17 healthy control subjects should have no        history of chronic illness and be on no prescribed medications other than oral        contraception. Subjects older than age 55 will also be excluded to avoid confounding        effects of age on cognitive testing.|November 2015|November 25, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02456168||20290|
NCT02456181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031586|Investigation of Instructional Approaches to Elementary Math|Investigation of the Efficacy of the JUMP Program of Mathematics Instruction|JUMP Math|The Hospital for Sick Children|No|Active, not recruiting|March 2012|February 2016|Anticipated|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1156|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456181||20289|
NCT02432521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35583814.1.0000.0068_CAAE|Predictors of Treatment Response of Motor Sequels After a Stroke|Predictors of Treatment Response of Motor Sequels After a Cerebrovascular Accident||University of Sao Paulo General Hospital|Yes|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of hemiplegia ambulatory from the Institute of Physical Medicine and        Rehabilitation (IMREA) from the Clinics Hospital (HC) of the Medical School of the        University of Sao Paulo (USP)|January 2016|January 8, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02432521||22105|
NCT02456376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71002-PHI-14|Balance Control in Children With Cerebral Palsy|Sensor Fusion for Balance Control in Children With Cerebral Palsy||Temple University|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456376||20274|
NCT02445742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOS-IIG-01|CML Treated With Bosutinib After Relapse|Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment|BOSTRO|PETHEMA Foundation|Yes|Recruiting|May 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02445742||21090|
NCT02460900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062925|Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke|||University of Maryland|Yes|Not yet recruiting|December 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|65 Years||||May 2015|June 2, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460900||19926|
NCT02447328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6998L00004|A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer||AstraZeneca|No|Active, not recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Female|N/A|N/A|No|||February 2016|February 25, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02447328||20968|
NCT02438670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-68u|MPC Versus PID for Closed Loop Insulin Delivery|Use of a PID (Proportional-Integral-Derivative) Controller Versus an MPC (Model Predictive Control) Controller Algorithm and Health Monitoring System (HMS) for Closed-Loop Insulin Delivery||William Sansum Diabetes Center|No|Recruiting|May 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|21 Years|65 Years|No|||May 2015|May 7, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02438670||21632|
NCT02438683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.28|BI 409306 Cardiac Safety Trial in Healthy Volunteers|A Randomized, Double-blind, Double Dummy, Placebo-controlled, Three-way Crossover Study to Assess Cardiac Effects After Single Oral Doses of BI409306 Under Resting and Exercise Conditions in Healthy Male Volunteers||Boehringer Ingelheim||Completed|May 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|May 6, 2015||||No||https://clinicaltrials.gov/show/NCT02438683||21631|
NCT02456428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q13-06C|Incretin-based Drugs and the Risk of Heart Failure|Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|1499650|||Both|18 Years|N/A|No|Probability Sample|In each jurisdiction, a base cohort will be assembled including all patients with a        first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is defined        as the date of prescription or dispensation of a first-ever non-insulin anti-diabetic        drug. From this base cohort, a study cohort will be formed consisting of all patients who        initiated a new anti-diabetic drug class during the year in which incretin-based drugs        entered the market in each jurisdiction or any time thereafter. Study cohort entry is        defined by the prescription date of the newly-prescribed drug class. Two separate cohorts        will be created based on the presence or absence of a history of HF prior to and including        study cohort entry.|May 2015|June 16, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456428||20270|
NCT02456662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00056271|Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial|A Randomized Controlled Trial of Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline|SPARED|University of Rochester|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456662||20252|
NCT02455635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135|Lower Abdominal Pain During Office Hysteroscopy Can Assess Tubal Patency in Infertile Women|Lower Abdominal Pain During Office Hysteroscopy As A Guide In The Assessment Of Tubal Patency In Infertile Women||Cairo University|Yes|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Female|20 Years|30 Years|No|||May 2015|May 27, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455635||20331|
NCT02455648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232100-0016_24:2011/517374|Autologous Cell Sheets Transplantation After ESD in the Esophagus|Transplantation of Autologous Cell Sheets After Endoscopic Submucosal Dissection (ESD) for Early Adenocarcinoma of the Esophagus|CellSheet2|Karolinska University Hospital|No|Recruiting|January 2012|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455648||20330|
NCT02428608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evolus - CLIN006|Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006|A Multi-center, Open Label, Single Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines|EV-006|Evolus, Inc.|No|Active, not recruiting|May 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|475|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|August 10, 2015|April 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02428608||22404|
NCT02456506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU5010|Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.|Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.||Sun Yat-sen University|Yes|Not yet recruiting|June 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|May 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456506||20264|
NCT02444572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXACARE_med14|Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer|Comparison of Thromboembolic Events Between EnoXA® and Lovenox® in Patients Undergoing Digestive CAncer and Subjected to Thromboprophylaxis|ENOXACARE|Les Laboratoires des Médicaments Stériles|Yes|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|20 Years|90 Years|No|||November 2015|November 2, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444572||21180|
NCT02448277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990188|Comparison of Different Tools Inserted Nasal Endotracheal Tube|A Comparson Among the Use of Direct Laryngoscope.AirwayScope and GlideScope in General Anesthetized Patients Who Require Nasal Endotracheal Tube Intubation||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|April 2012|December 2015|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||April 2011|May 15, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448277||20896|
NCT02448095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML1214|Retrospective Evaluation of CML Patients in the National Compassionate Program|Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|CML Ph+ patients in the Ponatinib compassionate use program|May 2015|May 19, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448095||20910|
NCT02440737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC REACH 1525|Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Stage I-III Breast, Lung, Prostate, or Colorectal Cancer and Their Caregivers|Navigated Early Survivorship Transition (NEST) Project|NEST|Vanderbilt-Ingram Cancer Center|Yes|Recruiting|May 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02440737||21474|
NCT02440750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYSTERO|Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women|||University of Cagliari|No|Not yet recruiting|June 2016|June 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02440750||21473|
NCT02451683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150069|Corticospinal Function After SCI|Corticospinal Function After Spinal Cord Injury||University of Miami|No|Recruiting|April 2015|April 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|300|||Both|18 Years|85 Years|No|||December 2015|December 15, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451683||20634|
NCT02451982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1568|Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer|A Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With Our Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|February 2016|February 2020|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|100 Years|No|||February 2016|February 19, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451982||20611|
NCT02451995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH2319|Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation|A Prospective Multi-centre Study of Effectiveness of Ripple Mapping for Atrial Tachycardia Ablation|RIPPLE-AT|Imperial College London|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||February 2016|February 22, 2016|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02451995||20610|
NCT02444325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503174|Diabetes Group Prenatal Care|Group Prenatal Care for Women With Diabetes: A Pilot Randomized Control Trial||Washington University School of Medicine|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|50 Years|No|||January 2016|January 4, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02444325||21199|
NCT02444338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version No. 3.3|A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation|A RandomizEd Study of tHe MitrACliP DEvice in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Recruiting|March 2015|||September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444338||21198|
NCT02457429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01843|A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux|A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux||Central Manchester University Hospitals NHS Foundation Trust|No|Active, not recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|1 Year|16 Years|No|||January 2016|January 26, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02457429||20193|
NCT02431546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057493|VIDA Mobile Health Cardiovascular Prevention Program|A Lifestyle-Based Mobile Health Strategy for Cardiovascular Disease Prevention in Graduates From Cardiac Rehabilitation: VIDA Pilot Study||Duke University|Yes|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431546||22180|
NCT02431559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2014-001|A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated|A Phase 1/2 Study of Chemo-immunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) and Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated||Ludwig Institute for Cancer Research|No|Recruiting|November 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|53|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431559||22179|
NCT02453399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB001115|Relief of Migraine Pain Through Electro Stimulation|Relief of Migraine Pain Through Transcutaneous Electro Stimulation||Siano Mobile Silicon|No|Active, not recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453399||20502|
NCT02454439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0233|Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial|Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial||University Hospital, Clermont-Ferrand||Recruiting|May 2015|November 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454439||20422|
NCT02457494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al424-986|Kidney Stone Risk Factors in Patients Infected With HIV|CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV|CALVIH|Association pour le Developpement d'Investigations et de Thérapeutiques en Néphrologie|No|Recruiting|May 2015|March 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adult male or female HIV1 infected patients having experienced a renal stone episode        within the past six months or living with a renal stone|June 2015|June 2, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02457494||20188|
NCT02457507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-B12|Vitamin B12 Supplement to Prevent Cognitive Decline|||Chinese University of Hong Kong||Completed|August 2011|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|271|||Both|70 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02457507||20187|
NCT02443428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBU-N-H-01|Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry|Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry||Eisai Inc.|No|Completed|August 2013|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|18 Years|N/A|No|Probability Sample|Participants with locally advanced or metastatic breast cancer who have progressed after        up to two chemotherapeutic regimens for advanced disease will be prospectively included in        the registry. Prior therapy should have included an anthracycline and a taxanes unless the        patient was not suitable for these treatments.|January 2016|January 11, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443428||21267|
NCT02443454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWV/CP/KTx/2015/05|Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation|Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation|PWV/CP/KTx|Medical University of Warsaw|Yes|Completed|May 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 100 consecutive patients admitted to routine visin in Transplant Centre and 30        healthy subjects were included in this study.|September 2015|September 30, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02443454||21266|
NCT02449057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP1014F01|An Evaluation of JUST Court in Yuma County, AZ|An Evaluation of JUST (Juveniles Under Supervision and Treatment) Court in Yuma County, AZ|JUST|Pepperdine University|No|Recruiting|March 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|13 Years|17 Years|No|||May 2015|May 15, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02449057||20836|
NCT02455401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-024|Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery|Effect of Remifentanil on Postoperative Vomiting in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia||Inje University|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|105|||Both|3 Years|6 Years|No|||December 2015|December 9, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02455401||20349|
NCT02564471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790117|Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.|Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years|MALRAB|State University of New York - Upstate Medical University|No|Not yet recruiting|October 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564471||11974|
NCT02564783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSKENDU-1|The Burden of Pediatric Surgical Conditions in Rural Kenya|The Burden of Pediatric Surgical Conditions in Rural Kenya - a Prospective Cohort Study||Helsinki University Central Hospital|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|800|||Both|6 Months|18 Years|Accepts Healthy Volunteers|Probability Sample|800 children and youth under the age of 18 in a well defined area in rural Western Kenya        (Kabondo city in Homa Bay County).|October 2015|October 26, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02564783||11951|
NCT02458157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFAKI|Forced Fluid Removal in High Risk Acute Kidney Injury|Forced Fluid Removal vs. Usual Intensive Care in High-risk Acute Kidney Injury With Severe Fluid Overload - A Randomized Controlled Trial|FFAKI|Nordsjaellands Hospital|Yes|Recruiting|October 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02458157||20137|
NCT02430740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH1|Tailored Ovarian Stimulation Based on BMI, AMH, AFC|Multicentric Randomized Controlled Study to Determine a Tailored Strategy for Controlled Ovarian Stimulation in IVF Based on AMH, BMI and AFC||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Not yet recruiting|January 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|43 Years|No|||December 2015|December 21, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430740||22242|
NCT02445261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133|Mobile Phone Effects on Umbilical Artery Doppler and Heart Rate Tracing|The Effects of Mobile Phone on Umbilical Artery Doppler and Fetal Cardiotogogrphy in Normal and Gowth Restricted Fetuses||Cairo University|No|Recruiting|June 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|190|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445261||21127|
NCT02461095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00311|Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome|Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome: A Randomized Controlled Trial||Nationwide Children's Hospital|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|58|||Both|12 Years|N/A|No|||January 2016|January 26, 2016|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461095||19911|
NCT02452710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-583|Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors|Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors||Dana-Farber Cancer Institute|No|Recruiting|August 2015|June 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|September 15, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452710||20555|
NCT02432261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN005A|Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men|A Randomized, Two Center, Double-Blind Trial to Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Healthy Men||Health Decisions|Yes|Active, not recruiting|April 2015|September 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|44|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432261||22125|
NCT02445521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00079788|Testing of Four Home Phenylalanine Monitoring Prototype Devices|Testing of Four Home Phenylalanine Monitoring Prototype Devices Using Whole Blood From Normal and PKU Subjects||Emory University|Yes|Completed|May 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|9|Samples Without DNA|Whole blood and plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Control will be recruited by distributing an email to all staff on the Emory Genetics        Clinic listserv to solicit a volunteer to provide 4ml of whole blood only. Respondents who        are within two years of age and the same gender of at least one of the PKU subjects will        be considered eligible. Remaining subjects will be recruited through Emory Genetics Clinic        and possibly through the Emory Metabolic Nutrition Program's Annual Metabolic Camp.|December 2015|December 9, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445521||21107|
NCT02454933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5165C00001|Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours|A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination With MEDI4736 Versus AZD9291 Monotherapy in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)|CAURAL|AstraZeneca|Yes|Active, not recruiting|July 2015|October 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454933||20384|
NCT02455687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400046|Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.|Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose With/Without the Nebulized Budesonide for the Management of the Severe Asthma Exacerbation in the Emergency Room. A Randomized Controlled Trial.||Hamad Medical Corporation|Yes|Recruiting|June 2014|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|2 Years|14 Years|No|||May 2015|June 14, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02455687||20327|
NCT02443571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fluciclovine (18F) - BED - 001|Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)|A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects||Blue Earth Diagnostics|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|714|||Both|18 Years|N/A|No|Non-Probability Sample|All patients (male/female) who underwent PET scanning using fluciclovine (18F) as the        radiotracer for the detection of cancer at a clinical site participating in this study.|June 2015|June 24, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443571||21257|
NCT02429427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/20/01|European Celecoxib Trial in Primary Breast Cancer|A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients|REACT|Imperial College London|Yes|Active, not recruiting|December 2005|November 2022|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2639|||Female|18 Years|N/A|No|||March 2014|April 24, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02429427||22341|
NCT02456740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120296|Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|STRIVE|Amgen|Yes|Recruiting|July 2015|February 2018|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|852|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456740||20246|
NCT02458924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393230|Niacin Skin Flush Response in Patients With Schizophrenia|Niacin Skin Flush Response in Patients With Schizophrenia, Their First Degree Relatives, Bipolar Disorder Patients, and Healthy Controls||Isfahan University of Medical Sciences|No|Completed|January 2014|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458924||20078|
NCT02447263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver Cancer HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||June 2015|February 23, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447263||20973|
NCT02457806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-04|Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers|Phase 2, Randomized, Double-Blind, Placebo-Controlled, 4-Period, Complete Cross-Over Comparison of the Anesthetic Efficacy of Bilateral and Unilateral Application of Kovacaine Mist in Healthy Volunteers||St. Renatus, LLC|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457806||20164|
NCT02457819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-310|Dasotraline Pediatric Extension Study|An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)||Sunovion|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|6 Years|12 Years|No|||December 2015|December 16, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457819||20163|
NCT02443597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFHSRMREC/2015/OB/GYNAE/053|Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment?|Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment?||Benha University|No|Completed|June 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|||Female|20 Years|35 Years|No|Non-Probability Sample|Inclusion criteria will consist of women who have a live, intrauterine, singleton        pregnancy between 11- 14 weeks gestation.|January 2016|January 16, 2016|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02443597||21255|
NCT02443610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMOTHEPP ( RB 13.175)|Haemorrhages and Thromboembolic Venous Disease of the Postpartum|Hémorragies et Maladie Veineuse Thromboembolique du Post-partum : Epidémiologie, Etudes Des déterminants Cliniques et Biologiques|HEMOTHEPP|University Hospital, Brest|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|Blood samples|Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All women admitted for delivery in a maternity Finistère|June 2015|February 1, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02443610||21254|
NCT02445534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECORD|Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy|Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy|RECORD|University Medical Centre Ljubljana|Yes|Recruiting|January 2005|May 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|65 Years|No|Non-Probability Sample|All patients enrolled in clinical trials of stem cell therapy in non-ischemic dilated        cardiomyopathy at UMC Ljubljana from January, 2005 will be enrolled.|December 2015|December 3, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02445534|5 Years|21106|
NCT02452125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-1118|The Effects of Nicotine Chewing Gum in Parkinson's Disease|The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease|PD|New York Institute of Technology|No|Recruiting|May 2015|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2016|January 19, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452125||20600|
NCT02449993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MammaTyper_1.neo-adjuvant st.|Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy|Evaluation of the MammaTyper Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patients With Early Breast Cancer: Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy||Biontech Diagnostics GmbH|No|Completed|June 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|101|||Female|18 Years|70 Years|No|||May 2015|May 20, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02449993||20764|
NCT02433080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0765|Diet and Physical Activity in Uterine Cancer Survivors|Randomised, Controlled, Pilot Clinical Trial to Assess the Feasibility of a Healthy Eating and Physical Activity Program in Endometrial Cancer Survivors|DEUS|University College, London|No|Active, not recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Female|18 Years|N/A|No|||August 2015|February 2, 2016|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02433080||22062|
NCT02454361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBP7072-1-001|Safety, Tolerability and Pharmacokinetics of KBP-7072|A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration||KBP Biosciences|No|Completed|May 2015|December 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|December 28, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454361||20428|
NCT02450929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taperguard|Prospective Clinical Evaluation of the Taperguard Endotracheal Tube|Prospective Clinical Evaluation of the Taperguard Endotracheal Tube||Oregon Health and Science University|No|Active, not recruiting|June 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40000|||Both|N/A|N/A|No|Probability Sample|The study will include data from all surgical patients enrolled in the National Surgical        Quality Improvement Project (NSQIP) (IRB4621) who had surgery at OHSU between June 1, 2011        and May 31, 2014. We anticipate that we will enroll approximately 2500 subjects in each        arm of the study.|May 2015|May 18, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02450929||20692|
NCT02458755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2011-12-053|Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis|Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study)|STAMINA-MRI|Samsung Medical Center|No|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|20 Years|N/A|No|||May 2015|May 29, 2015|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458755||20091|
NCT02458768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-IMHCL001|Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of s.c. Administration of IVF-M HP Inj. Versus Menopur® Inj. in Infertility Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies (ART) Such as in Vitro Fertilization-embryo Transfer (IVF-ET)||LG Life Sciences||Completed|July 2013|||November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Female|20 Years|39 Years|No|||May 2015|January 4, 2016|May 28, 2015||No||No|November 23, 2015|https://clinicaltrials.gov/show/NCT02458768||20090|
NCT02454803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-206|Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice|An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice|ULIS III|Ipsen|No|Recruiting|January 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patient suffering from upper limb spasticity (ULS) seen in clinic, hospital and/or        rehabilitation centers.|February 2016|February 5, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454803||20394|
NCT02451449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CØF 2015|Celiac Disease and Infertility Among Men and Women in Denmark|Celiac Disease and Infertility Among Men and Women in Denmark: Prevalence of Celiac Disease Among Men and Women Treated in Danish Public Fertility Clinics|CØF2015|University of Aarhus|No|Recruiting|January 2015|November 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1200|Samples With DNA|Whole blood Biopsy of small-bowel|Both|18 Years|40 Years|No|Probability Sample|Both female and male participants are being studied|February 2015|December 1, 2015|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02451449||20652|
NCT02451722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-2053-15-SMC|Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear|Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear in Diabetic Patients and in Healthy Subjects|Kyboot|Sheba Medical Center|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451722||20631|
NCT02448355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hanhart1|Ocular Effects of Carotid Endarterectomy|Ocular Effects of Carotid Endarterectomy A Cohort Longitudinal Study||Shaare Zedek Medical Center|No|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|120 Years|No|||November 2015|November 24, 2015|November 28, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02448355||20890|
NCT02448368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA3170-111|RDEA3170 Tablet and Capsule Bioavailability Study|A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170||Ardea Biosciences, Inc.|No|Active, not recruiting|May 2015|January 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448368||20889|
NCT02448628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS3150-A-J206|A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment|A Multi-center, Open Label, Dose Titration, Exploratory Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment.||Daiichi Sankyo Inc.|No|Active, not recruiting|May 2015|June 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|80 Years|No|||January 2016|January 26, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448628||20869|
NCT02458794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_5|Crossover Study of the LMA SupremeTM vs Ambu-Aura GainTM|A Randomized Crossover Study of the LMA SupremeTM Versus Ambu-Aura GainTM in Adult Patients||Schulthess Klinik|No|Not yet recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|19 Years|65 Years|No|||July 2015|July 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02458794||20088|
NCT02458807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2014/22|The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions|The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions|SENSOR|Portsmouth Hospitals NHS Trust|No|Active, not recruiting|August 2014|March 2017|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Daily sputum and urine samples have been collected for study analysis. However we do not      plan to extract DNA.|Both|18 Years|N/A|No|Probability Sample|Patients who are self-managing chronic respiratory conditions (apart from CF), and are        colonised with either PA or HI and are prone to exacerbation.|January 2016|January 6, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458807||20087|
NCT02452281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-41|Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma|Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma||The University of Texas Health Science Center, Houston|No|Withdrawn|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|May 13, 2015|Yes|Yes|PI departure, operational issues|No||https://clinicaltrials.gov/show/NCT02452281||20588|
NCT02446275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID005|Efficacy of Manual Therapy in Migraine|DO SOFT TISSUE TECHNIQUES HAVE A POSITIVE EFFECT ON DISABILITY AND QUALITY OF LIFE IN MIGRAINE SUFFERERS?: A Randomized Controlled Trial|MTHDIQMi|University of Valencia|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||May 2015|May 15, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02446275||21049|
NCT02448329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-127|Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy|||Samsung Medical Center|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|20 Years|No|||December 2015|December 28, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02448329||20892|
NCT02435147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 15 03 003|Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index|Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index||HealthEast Care System|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|90|||Female|40 Years|90 Years|No|Non-Probability Sample|This study will enroll postmenopausal women between the ages of 40 and 90 years who have        completed a minimum of 36 months of denosumab therapy for the treatment of osteoporosis.|February 2016|February 17, 2016|May 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02435147||21903|
NCT02435160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150406|The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis|||Shanghai Jiao Tong University School of Medicine||Not yet recruiting|May 2015|||May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|25 Years|60 Years|No|||April 2015|May 5, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02435160||21902|
NCT02455258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIUGM|Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy (D/MT) Program for Older Adults|Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy Program for Older Adults Through an Empirical Research Approach||Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|No|Active, not recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|75|||Both|60 Years|N/A|No|||December 2015|December 22, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02455258||20360|
NCT02455271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN02T|Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients|Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients (Study LUN02T)||Eisai Inc.|No|Active, not recruiting|October 2012|December 2015|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Participants who have completed Study LUN01S and need to continue eszopiclone|May 2015|May 22, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02455271||20359|
NCT02460614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRR-15|Effects of Rhinopharyngeal Retrograde Clearance in Children With Acute Viral Bronchiolitis|Comparison Between Rhinopharyngeal Retrograde Clearance and Nasopharyngeal Aspiration in Children With Acute Viral Bronchiolitis||Pontificia Universidade Católica do Rio Grande do Sul|No|Completed|March 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|12 Months|No|||June 2015|June 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02460614||19948|
NCT02460289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US 10329|Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia|Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV)||Galderma Laboratories, L.P.|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Male|18 Years|60 Years|No|||January 2016|January 20, 2016|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460289||19973|
NCT02460302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0306-A|Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy|Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial||Mount Sinai Hospital, Canada|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|45 Years|N/A|No|||June 2015|June 1, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02460302||19972|
NCT02432014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH085987|Parent Preferences and Family Engagement in a Conduct Problems Prevention Program|DCISR for Adaptive Intervention Models in Children's Mental Health||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|300|||Both|5 Years|12 Years|No|||April 2015|April 27, 2015|April 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02432014||22144|
NCT02456311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 14.380|Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy|Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy Human Pilot Study||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|November 24, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02456311||20279|
NCT02451462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0122-BMT290|Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients|Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients||Stanford University|No|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02451462||20651|
NCT02441153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4RC North|Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy|T4RC North: Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy; Does a Longer Wait Improve Outcomes?|T4RC|Advanced Medical Research Institute of Canada|No|Not yet recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|80|None Retained|To maximize the utility of this trial, immunohistochemical staining will be performed on      pre-CRT tumor samples to prospectively validate the scoring system proposed by Hur et al.      [28] The question being whether or not expression of these biomarkers can predict which      patients will experience pCR and disease-free survival.|Both|18 Years|N/A|No|Non-Probability Sample|This study will include patients at Health Sciences North who have been referred to a        general or colorectal surgeon for resection of their rectal cancer.|May 2015|May 8, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441153||21442|
NCT02447744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000295|Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment|Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment||Massachusetts General Hospital|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02447744||20937|
NCT02451761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.858|Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability|Molecular Characterization of Apparently Balanced Chromosomal Rearrangements by Next-generation Sequencing in 55 Patients With Intellectual Disability and/or Multiple Congenital Anomalies|ANI|Hospices Civils de Lyon|No|Recruiting|April 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|55|||Both|3 Months|N/A|No|Non-Probability Sample|Patients presenting intellectual disability and/or multiple congenital anomalies|November 2015|November 9, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02451761||20628|
NCT02438436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD/GC-HCC|Simo Decoction and Gum Chewing for Bowel Activity|Influence of Simo Decoction Plus Acupuncture and Gum Chewing on Postoperative Bowel Activity After Resection for Patients With HCC|SD/GC-HCC|Guangxi Medical University|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|August 31, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438436||21650|
NCT02445755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30820|Transcutaneous Bilirubinometry in Neonates With the Bilicare System|Transcutaneous Bilirubinometry in Neonates With the Bilicare System||Stanford University|Yes|Completed|June 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|35 Weeks|N/A|No|Non-Probability Sample|Up to 100 total participants will be enrolled by the study. Since the goal of the study is        to ASSAY SAMPLE FROM BABIES WITH DIVERSE BILIRUBIN LEVELS, the study participants will be        moderate premature and mature infants. In particular, the target population will be        moderate premature infants at >35 weeks postmenstrual age (PMA) and of term PMA.|May 2015|May 20, 2015|May 13, 2015|No|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT02445755||21089|
NCT02452086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D52.2567|Low Level Laser Therapy and Expression of VEGF, NO, VEGFR-2, HIF-1α in Diabetic Foot Ulcers|Effect of Low Level Laser With Ga-As (904 nm) on Expression of Angiogenic Factors (VEGF, VEGF Receptor-2,NO, HIF-1α), Oxygen Saturation of Peripheral Blood and Wound Surface Area in Ischemic Diabetic Foot Ulcers||Tarbiat Modarres University|No|Completed|June 2013|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02452086||20603|
NCT02451267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-0016-15|Clinical Prediction Rules for Identifying Patients With Chronic Neck Pain Who Will Benefit From General Aerobic Exercise|Clinical Prediction Rule for Identifying Patients With Chronic Neck Pain Who Will Benefit From General Aerobic Exercise||Clalit Health Services|No|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02451267||20666|
NCT02441777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001042|Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging|Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging||Massachusetts General Hospital|No|Not yet recruiting|August 2016|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02441777||21394|
NCT02446002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1009|Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects|Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects||US WorldMeds LLC|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446002||21070|
NCT02444312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRiC2015|Trial of Benefit Finding in Caregivers: The Building Resources in Caregivers (BRiC) Study|A Randomised Controlled Trial of Benefit Finding in Caregivers: The Building Resources in Caregivers (BRiC) Study Protocol|BRiC|University of Limerick|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444312||21200|
NCT02457598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-401-1757|Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies|A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies||Gilead Sciences|No|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457598||20180|
NCT02433054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262/ 2014|Bern Venous Stent Registry|Bern Venous Stent Registry||University Hospital Inselspital, Berne||Recruiting|January 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients with symptoms of chronic venous disease and obstruction and/or stenosis of the        iliofemoral veins and/or inferior vena cava.|April 2015|April 28, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02433054|5 Years|22064|
NCT02446249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150129|Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction|Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction||National Institutes of Health Clinical Center (CC)||Not yet recruiting|April 2015|February 2022|Anticipated|February 2022|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|March 11, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446249||21051|
NCT02448290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-126|Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy|Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy||Samsung Medical Center|No|Recruiting|January 2015|October 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448290||20895|
NCT02451813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLukeNY|The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block|The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block||St. Luke's-Roosevelt Hospital Center|Yes|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|65 Years|No|||March 2015|May 19, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02451813||20624|
NCT02451826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|674|A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women|A Randomized Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering a Daily Dose of 2500 μg of Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel 1.5mg Oral Dose on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women||Population Council|No|Not yet recruiting|May 2015|February 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|April 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451826||20623|
NCT02441959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504015767|Full-Endoscopic vs Open Discectomy for the Treatment of Symptomatic Lumbar Herniated Disc|Full-Endoscopic vs Open Discectomy for the Treatment of Symptomatic Lumbar Herniated Disc: A Prospective Multi-Center Randomized Study||Yale University|No|Not yet recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02441959||21380|
NCT02455310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201212784|Extension Connection Evaluation|Extension Connection: Dissemination Effectiveness Evaluation|ExConEval|University of Iowa|No|Active, not recruiting|January 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|60000|||Both|65 Years|N/A|No|Non-Probability Sample|All Iowa Medicare beneficiaries who are nursing home residents or diagnosed with dementia        and meet other eligibility criteria, for each year from 2011 to 2014.|May 2015|May 26, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02455310||20356|
NCT02448862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0098-001|Differences in Incidence of Common Side Effects Between Young Adults and Elderly Patients While Using IV-PCA|Differences in Incidence of Common Side Effects Between Young Adults and Elderly Patients While Using Fentanyl-based IV-PCA||Severance Hospital|No|Recruiting|May 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|10000|||Both|20 Years|N/A|No|Non-Probability Sample|Collected data from the patients who had used IV-PCA for pain control after an elective        surgery under general or spinal anesthesia between Sep. 2010 and March. 2014.|May 2015|May 19, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448862||20851|
NCT02448875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-13-01|Clinical Evaluation of Visco-Assisted CyPass Micro-Stent Implantation in Patients With Open Angle Glaucoma|A Randomized, Prospective Clinical Evaluation of the Safety and Effectiveness of Visco-Assisted CyPass Micro-Stent Implantation in Patients With Open Angle Glaucoma|ViscoPass|Transcend Medical, Inc.|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|N/A|No|||February 2016|February 28, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02448875||20850|
NCT02461004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152BE15016|CKD-391 Pharmacokinetic Study Phase I|Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461004||19918|
NCT02448420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1303|Study of Palbociclib and Trastuzumab With or Without Letrozole in HER2-positive Metastatic Breast Cancer|PATRICIA: A Phase II Clinical Trial of Combined Palbociclib and Trastuzumab, With or Without Letrozole, in Post-menopausal Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer|PATRICIA|SOLTI Breast Cancer Research Group|Yes|Recruiting|July 2015|December 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Female|18 Years|N/A|No|||August 2015|August 5, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02448420||20885|
NCT02436031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2014P001033B|Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B|The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B|DESOSA|Brigham and Women's Hospital|No|Active, not recruiting|April 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|60 Years|No|||November 2015|November 6, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436031||21835|
NCT02456402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|Drug Coated Balloon Compared to Bare Metal Stent for de Novo Coronary Artery Lesions|Randomized Controlled Trial of Drug Coated Balloon Compared to Bare Metal Stent Using FFR-guidance for the Treatment of de Novo Coronary Artery Lesions||Ulsan University Hospital|Yes|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|85 Years|No|||June 2015|June 1, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02456402||20272|
NCT02458729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG8B6181|The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis|The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis||Chang Gung Memorial Hospital|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|294|||Both|50 Years|80 Years|No|||May 2015|May 28, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458729||20093|
NCT02458742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019/2558(EC2)|Spinal Morphine Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland|Spinal Morphine (0.05 mg) Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland- a Randomized Double-blinded Control Trial||Mahidol University|Yes|Not yet recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458742||20092|
NCT02461030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058/2013|Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Periodontal Treatment|An 8-Week Clinical Study to Evaluate the Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Non-surgical Periodontal Treatment: Randomized Clinical Trial||University of Campinas, Brazil|Yes|Completed|August 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|75 Years|No|||May 2015|June 2, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461030||19916|
NCT02428374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPM/UNIFESP|Role of Immune Responses After Acute Myocardial Infarction|Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)|BATTLE-AMI|Federal University of São Paulo|Yes|Recruiting|May 2015|July 2019|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|85 Years|No|||June 2015|June 10, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02428374||22422|
NCT02454218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140231|Effect of Transcranial Direct-current Stimulation in Attentional Performance and Pain in Patients With Fibromyalgia|Effect of Transcranial Direct-current Stimulation in Attentional Performance and Pain in Patients With Fibromyalgia||Hospital de Clinicas de Porto Alegre|No|Recruiting|November 2014|August 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Female|18 Years|65 Years|No|||May 2015|May 21, 2015|January 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454218||20439|
NCT02457234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRS #14-55|Influence of Cultural Immersion on Willingness to Try Fruits and Vegetables Among Children in Guam: the Traditions Study|Examining the Influence of Cultural Immersion on Willingness to Try Fruits and Vegetables Among Children in Guam: the Traditions Study|Traditions|University of Guam|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|104|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457234||20208|
NCT02461277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart Institute InCor|Postoperatory Recovery in Thoracic Surgical Procedure, Fast-track Protocol vs. Conventional Care|Postoperatory Recovery in Thoracic Surgical Procedure, Fast-track Protocol vs. Conventional Care||Instituto do Coracao|Yes|Completed|April 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|80 Years|No|||May 2015|June 1, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461277||19897|
NCT02569359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-104-05-041|Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy|||Tri-Service General Hospital|Yes|Not yet recruiting|January 2016|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||October 2015|October 4, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569359||11599|
NCT02569372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1102B_P1|A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients|A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)||Green Cross Corporation|Yes|Recruiting|October 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|48|||Both|19 Years|65 Years|No|||October 2015|December 7, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569372||11598|
NCT02448108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00085129000|Internet Psychotherapy for Bipolar Disorder in Primary Care|Internet Psychotherapy for Treating Bipolar Disorder in Primary Care||University of Pittsburgh|Yes|Not yet recruiting|July 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02448108||20909|
NCT02435498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106402|Web-based Education Module for Pain Management|A Web-based Education Module Versus Standard of Care for Pain Management Following a Fracture in Children: a Randomized Controlled Trial||Lawson Health Research Institute|No|Recruiting|May 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|230|||Both|N/A|17 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02435498||21876|
NCT02449564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-030|The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors|||Samsung Medical Center|No|Recruiting|April 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449564||20797|
NCT02445092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-158-SDR|The Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome|Double Blind Randomized Controlled Trial on the Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome||McGill University Health Center|Yes|Recruiting|January 2014|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|900|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|January 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02445092||21140|
NCT02457624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503-044-655|Gastric Cancer Screening Quality Improvement System Establishment|A Prospective Cohort Study for Development of Korean Gastric Cancer Prediction Model and Tailored Gastric Cancer Screening Program||Seoul National University Hospital|No|Recruiting|March 2008|December 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who received colonoscopy in Seoul National University Hospital Healthcare System        Gangnam Center from 2008 till 2020.|May 2015|May 26, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02457624|6 Years|20178|
NCT02436798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02338|5-HT3 Antagonists (Antiemetics) and Cardiac Safety|5-HT3 Antagonists (Antiemetics) and Cardiac Safety Using an Active Surveillance Approach||University of British Columbia|No|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|250|Samples With DNA|DNA samples will be retained for genomic analyses.|Both|6 Months|45 Years|No|Probability Sample|Children, women of a reproductive age, and pregnant women receiving ondansetron for        treatment of post-operative or chemotherapy-induced nausea and vomiting or hyperemesis        gravidarum.|November 2015|November 30, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436798||21776|
NCT02454127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANS0001|Effectiveness of Four Popular Diet Strategies for Weight Loss and Cardiac Risk Reduction|Effectiveness of Four Dietary Treatment Strategies for Metabolic Syndrome: a Prospective Randomized Trial||Tufts Medical Center|No|Completed|July 2000|January 2004|Actual|January 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02454127||20446|
NCT02458872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011896|Impact of a Data-driven Monitor Alarm Reduction Strategy Implemented in Safety Huddles|Impact of a Data-driven Monitor Alarm Reduction Strategy Implemented in Safety Huddles||Children's Hospital of Philadelphia|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|61936|||Both|N/A|N/A|No|||December 2015|December 15, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458872||20082|
NCT02447003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-086|Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)|A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)||Merck Sharp & Dohme Corp.|No|Recruiting|June 2015|November 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|245|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447003||20993|
NCT02458599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204676|Efficacy Study of Protein Supplementation in Attenuating the Decline in Performance After Strenuous Concurrent Exercise|A Study to Evaluate the Effects of Protein Supplementation in Attenuating the Decline in Performance Following Strenuous Concurrent Exercise||GlaxoSmithKline|No|Recruiting|June 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458599||20103|
NCT02429440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231/2004|Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides|Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides|UroRCC|University Hospital Tuebingen|No|Active, not recruiting|May 2005|June 2015|Anticipated|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2015|April 23, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02429440||22340|
NCT02445274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015MEKY046|Two Different Cataract Surgical Procedures to Prevent Posterior Capsule Opacification|Effectiveness of Two Different Surgical Procedures to Prevent Posterior Capsule Opacification in Age-related Cataract Patients||Sun Yat-sen University|Yes|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|50 Years|90 Years|No|||May 2015|May 29, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02445274||21126|
NCT02447276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-1227|Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip|A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip||Regeneron Pharmaceuticals|Yes|Active, not recruiting|May 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|375|||Both|40 Years|80 Years|No|||January 2016|January 8, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447276||20972|
NCT02451787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vit D Study part 2 v.1|The 'Hidden' Biological Impact of Vitamin D Deficiency: a Biomarker Study; Part 2|The 'Hidden' Biological Impact of Vitamin D Deficiency: a Biomarker Study||The Hong Kong Polytechnic University|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451787||20626|
NCT02445404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12-011|Study to Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated Peripheral T-cell Lymphoma|Randomized Phase II Study to Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated Peripheral T-cell Lymphoma||Samsung Medical Center|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|19 Years|65 Years|No|||May 2015|May 12, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02445404||21116|
NCT02445417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transition|Brain Activity During Birth for Prediction of Newborns at Risk for Brain Injury|Brain Activity During Birth for Prediction of Newborns at Risk for Brain Injury||Sharp HealthCare|No|Recruiting|May 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|36 Weeks|44 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Term infants at delivery (37-44 weeks gestational age)|October 2015|October 27, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02445417||21115|
NCT02429960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMUPS-012013|Comparison of Different Analgesia-Monitors in Tracing Unconscious Pain Sensations|Investigation of the Clinical Use of Different Analgesia-Monitors for Tracing Unconscious Pain Sensations During General Anesthesia|AMUPS|Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02429960||22300|
NCT02451358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIV06|Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India|Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India||Sanofi|Yes|Recruiting|July 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|6 Months|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451358||20659|
NCT02450370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-201405|Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome|Comparison of Symptom Response Following a Conventional Irritable Bowel Syndrome Dietary Advice Versus Low FODMAP Diet in Hong Kong Chinese Irritable Bowel Syndrome Patients||Hong Kong Sanatorium & Hospital|Yes|Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450370||20735|
NCT02457013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9433|Interest of High Flow Nasal Cannula (HFNC) Versus Non Invasive Ventilation During the Initial Management of Severe Bronchiolitis in Infants|Interest of High Flow Nasal Cannula (HFNC) Versus Non Invasive Ventilation During the Initial Management of Severe Bronchiolitis in Infants|TRAMONTANE|University Hospital, Montpellier|Yes|Recruiting|October 2014|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|N/A|6 Months|No|||May 2015|May 26, 2015|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457013||20225|
NCT02457585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312-079-541|Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis|Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis||Seoul National University Hospital|Yes|Recruiting|March 2015|April 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 26, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02457585||20181|
NCT02457637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHINA-ACLF|A Prospective Multicenter Study of Acute on Chronic Liver Failure in China|||Shanghai Jiao Tong University School of Medicine|No|Enrolling by invitation|January 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|whole blood, serum, urine, stool, liver tissue|Both|15 Years|79 Years|No|Probability Sample|chronic liver disease patients（having liver dysfunction more than 6 months） with acute        liver injury[having ALT(alanine aminotransferase)>3NL(normal level),AST(aspartate        aminotransferase)>3NL or TB(total bilirubin)>2NL within 1 week before enrollment] or acute        decompensation(having ascites, hepatic encephalopathy, bacterial infection or        gastrointestinal bleeding within 1 month before enrollment)|May 2015|May 28, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02457637||20177|
NCT02442141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011407|Peri-operative NIRS Monitoring In Infants|Cerebral Near-infrared Spectroscopy Monitoring in Infants During the Peri-operative Period: a Prospective Observational Cohort Study||Children's Hospital of Philadelphia|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|N/A|6 Months|No|Probability Sample|Children will be identified from the operating room schedules or, for emergency cases the        coordinating anesthetist will contact the study team.|March 2016|March 16, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02442141||21366|
NCT02457078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGC1401|Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory in Infants|Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory and Language in Infants||University of Illinois at Urbana-Champaign|No|Recruiting|February 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02457078||20220|
NCT02455843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongPH Jinan|Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC|A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC||Shandong Provincial Hospital|Yes|Recruiting|June 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 12, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02455843||20315|
NCT02455856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107144|Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants|A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42847922 in Healthy Male Subjects||Janssen Cilag N.V./S.A.|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455856||20314|
NCT02434653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112-14|A Comparison Between Two Strategies for Postpartum Anemia Diagnosis and Follow up After Vaginal Deliveries|A Comparison Between Two Strategies for Postpartum Anemia Diagnosis and Follow up After Vaginal Deliveries - Hemoglobin Screening in High Risk Population Versus by Symptoms||HaEmek Medical Center, Israel|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1680|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02434653||21941|
NCT02440620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140090|Cardiac Toxicity in Medical Treatment of Breast Cancer|Cardiac Toxicity in Medical Treatment of Breast Cancer|CaTOB|Odense University Hospital|Yes|Recruiting|October 2014|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Blood samples will be analyzed for N-terminal proBNP and ultra-sensitive TnT. Targeted      sequencing of a limited number of well-known genes related to heart failure will be      conducted and analysis of potential future biomarkers related to heart failure is possible      from blood samples stored in a biobank.|Both|18 Years|N/A|No|Probability Sample|Patients with HER2 positive breast cancer in adjuvant treatment with trastuzumab.|May 2015|May 7, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02440620||21483|
NCT02457169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMassBoston|Addressing Systemic Health Disparities in Early Identification and Treatment of Autism Spectrum Disorder (ASD): ABCD Project|Addressing Systemic Health Disparities in Early ASD Identification and Treatment||University of Massachusetts, Boston|No|Enrolling by invitation|September 2014|||September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|118|||Both|14 Months|3 Years|No|||June 2015|June 1, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02457169||20213|
NCT02455349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB# 14-13|Improving Negative Symptoms and Community Engagement in Veterans With Schizophrenia|Improving Negative Symptoms and Community Engagement in Veterans With Schizophrenia||VA Maryland Health Care System|Yes|Recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02455349||20353|
NCT02453503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394115|Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on Lichen Planus|Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus||Isfahan University of Medical Sciences|Yes|Completed|January 2014|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453503||20494|
NCT02453776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_354|Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab|Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission|PRECISION|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|90 Years|No|||January 2016|January 15, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453776||20473|
NCT02434926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/2558(EC2)|Anesthetic Management in Fetoscopic Surgery and Incidence of Complications|Anesthetic Management in Fetoscopic Surgery and Incidence of Complications - A Retrospective Review||Mahidol University|Yes|Not yet recruiting|May 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|151|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women who received fetocsopic surgery for any reasons eg. laser ablation of        vessels in twin-twin transfusion syndrome, balloon occlusion in fetal congenital        diaphragmatic hernia, fetal bladder outlet obstruction, intrauterine blood transfusion        etc.|May 2015|May 7, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02434926||21920|
NCT02455024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-14-401|An Observational Study to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig®|A Postmarketing Observational Cohort Study to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig® in Routine Clinical Practice in the United States (US).|OMNI|Ariad Pharmaceuticals|No|Recruiting|May 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Adult patients with CP-CML for whom the decision to initiate treatment with commercially        available Iclusig has already been made|January 2016|January 22, 2016|April 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02455024||20378|
NCT02451124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6214|Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus|Office Based Screening Test for Barrett's Esophagus||Case Comprehensive Cancer Center|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451124||20677|
NCT02452931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOL2581A|Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty|An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty||Tolmar Inc.|Yes|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|9 Years|No|||November 2015|February 26, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452931||20538|
NCT02440802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B403201317385|Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer|Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer|Feel+|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|April 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|One saliva sample (2mL) will be collected once at baseline for single nucleotide      polymorphism analyses.|Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer patients for which reimbursed androgen deprivation therapy with a        gonadoliberin antagonist is indicated, for aperiod of at least 6 months.|July 2015|July 28, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02440802||21469|
NCT02444221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI08890|Rivaroxaban Evaluation in Real Life Settings|Rivaroxaban Evaluation in Real Life Settings|RIVER|Thrombosis Research Institute|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|Males and females aged 18 years and over|May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444221|2 Years|21207|
NCT02444234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00182|Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis|Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis||University of Southern California|No|Not yet recruiting|July 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444234||21206|
NCT02455804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV103-02|NIRTRAKS Post-Market Study (NIRTRAKS)|NIRTRAKS Post-Market Study|NIRTRAKS|Medinol Ltd.|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|131|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455804||20318|
NCT02455817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS- Angina|REWARDS-Angina at Follow up Post Stenting|||Medstar Research Institute|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||6|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients male or female, 18 years or older who have received at least one commercially        available Drug Eluting Stent or Bare Metal Stent: Cypher, Taxus Express, Xience V, Promus        Element, Resolute, or Bare Metal Stents|May 2015|May 26, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455817||20317|
NCT02446418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116492|A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma|A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivered by Dry Powder Inhaler in Subjects With Persistent Asthma||GlaxoSmithKline|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|422|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446418||21038|
NCT02436486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15689A|Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men|Interventional, Randomised, Double-blind, Placebo- and Positive Controlled, Single-dose, Cross-over Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men||H. Lundbeck A/S|Yes|Completed|May 2015|||August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|76|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|May 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02436486||21800|
NCT02436499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:022|Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes.|Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes."||University of Manitoba|No|Recruiting|July 2015|||May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436499||21799|
NCT02436759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVL-1201-201|Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis|A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis||RevitaLid Inc.|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436759||21779|
NCT02445235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFG2015-SOPWS|Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy|Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy|SOPWS|Bracane Company|No|Terminated|April 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|85 Years|No|Non-Probability Sample|Must be receiving therapy for pain, wound care or scar therapy|January 2016|January 18, 2016|May 8, 2015||No|Sponsor discretion determined no clinical benefit|No||https://clinicaltrials.gov/show/NCT02445235||21129|
NCT02445248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTL019C2201|Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|JULIET|Novartis|Yes|Recruiting|July 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445248||21128|
NCT02455570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 721-13|Global Assessment of Endoscopic Ultrasound Performance Skills|Global Assessment of Endoscopic Ultrasound Performance Skills - a New Tool to Measure the Learning Curve and Technical Skills of Endosonografists||Sahlgrenska University Hospital, Sweden||Recruiting|August 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|25 Years|N/A|No|Non-Probability Sample|Endosonographists in traning under experienced supervision at tertiary endoscopy centers.|December 2015|December 8, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02455570||20336|
NCT02455583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6451|An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana|An Assessment of an HIV Prevention Intervention (Project AIM) on Youth Sexual Intentions, Sexual Behaviors and HSV-2 Incidence and Prevalence in Junior Secondary Schools in Eastern Botswana.|AIM|Centers for Disease Control and Prevention|No|Active, not recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4732|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|February 2, 2016|January 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02455583||20335|
NCT02450695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0190|rTMS in Treatment Refractory Obsessive-Compulsive Disorder|A Randomized Crossed-over Trial Examining Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment Refractory Obsessive-Compulsive Disorder.||McMaster University|No|Not yet recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||May 2015|May 19, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450695||20710|
NCT02450708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-059|Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes|Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes||Memorial Sloan Kettering Cancer Center||Recruiting|May 2015|||May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|The trial will recruit potential transplant eligible participants with AML in clinic.|March 2016|March 15, 2016|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02450708||20709|
NCT02442804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150112|Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke|The Effects of Pomegranate Polyphenols on Neuropsychological Functioning Following Ischemic Stroke||Loma Linda University|No|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|89 Years|No|||March 2016|March 1, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442804||21315|
NCT02452034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5592-097|Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)|A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia||Merck Sharp & Dohme Corp.|Yes|Recruiting|September 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|2 Years|17 Years|No|||March 2016|March 23, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452034||20607|
NCT02452047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7655A-013|Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection|RESTORE-IMI 1|Merck Sharp & Dohme Corp.|No|Recruiting|August 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452047||20606|
NCT02455830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000014903-Cytokines|Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy|A Study to Determine if Autologous Umbilical Cord Blood Cell Therapy Alters Serum Levels of Cytokines and Trophic Factors in Neonatal Encephalopathy||Neonatal Encephalopathy Consortium, Japan|Yes|Recruiting|April 2015|February 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|18|||Both|N/A|24 Hours|No|Non-Probability Sample|Infants with encephalopathy who meet the inclusion criteria of therapeutic hypothermia,        either those who receive the cell therapy or those who do not.|May 2015|May 26, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455830||20316|
NCT02457689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14SM2037|The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo|A Randomized Phase I/II Study to Assess the Safety and Immunogenicity of the DNA-GTU Vaccine Administered by Two Novel Routes Compared to Placebo in HIV-infected Patients on Antiretroviral Therapy|CUTHIVTHER001|Imperial College London|Yes|Recruiting|May 2015|February 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|30|||Both|18 Years|45 Years|No|||May 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457689||20173|
NCT02457702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 022015-085|Mitochondrial Function in Patients With Severe Liver Disease|Mitochondrial Function in Patients With Severe Liver Disease|SLDglyc|University of Texas Southwestern Medical Center|No|Recruiting|October 2015|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02457702||20172|
NCT02441712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17909|Rehabilitation With Patterned Electrical Neuromuscular Stimulation for Patients With Patellofemoral Pain|Supervised Rehabilitation With Patterned Electrical Neuromuscular Stimulation for Patients With Patellofemoral Pain|PENS for PFP|University of Virginia|Yes|Recruiting|March 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|15 Years|40 Years|No|||May 2015|May 7, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441712||21399|
NCT02450825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.012|Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration|Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02450825||20700|
NCT02456090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064599|PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care|PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care||University of Pittsburgh|No|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential participants for the PaTH Clinical Data Research Network (CDRN) Study of Healthy        Lifestyles, Body Weight and Health Care will include patients identified through EHRs at        the participating PaTH sites, using the eligibility criteria defined through the PCORnet        Obesity Task Force and described below. We aim to recruit as many patients as possible        from the target population, with one of the recruitment strategies producing a 50%        enrollment rate.|November 2015|November 30, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456090|10 Years|20296|
NCT02456103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-021e-CF|Extension Study of Ataluren for Nonsense Mutation Cystic Fibrosis|A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis||PTC Therapeutics|Yes|Enrolling by invitation|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|6 Years|N/A|No|||May 2015|May 26, 2015|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456103||20295|
NCT02457325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1120-3074|Lower Third Molar Removal With 2% and 4% Articaine|Comparative Analysis Between 2% and Articaine Articaine 4%, Both With 1: 200,000 Epinephrine: Evaluation of Anesthetics Efficacy, Intraoperative Bleeding and Hemodynamic Parameters in Extraction of Lower Third Molars||University of Sao Paulo|Yes|Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457325||20201|
NCT02429388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140274H|High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure|High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|September 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429388||22344|
NCT02451098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152PDL14025|Clinical Trial to Evaluate the Efficacy and Safety of CKD-391|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Factorial Design, Phase III Clinical Trial To Evaluate the Efficacy and Safety of Atorvastatin+Ezetimibe Combination Therapy and Atorvastatin Monotherapy in Patients With Primary Hypercholesterolemia||Chong Kun Dang Pharmaceutical|No|Completed|March 2015|January 2016|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|385|||Both|19 Years|N/A|No|||January 2016|January 26, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451098||20679|
NCT02454842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-601|Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC|A Phase 2 Study of TH-4000 in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor|TH-4000|Threshold Pharmaceuticals|Yes|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454842||20391|
NCT02447614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-OSAHS-002|Follow-up Studies of Primary Snoring(PS) and Obstructive Sleep Apnea Hypopnea Syndrome(OSAHS) in Chinese Children|Follow-up Studies of PS and OSAHS in Chinese Children||Beijing Children's Hospital|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|800|||Both|3 Years|12 Years|No|||May 2015|May 25, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02447614||20947|
NCT02438930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK_UG_K01|Client-Centered Counseling During Routine/Opt-Out HIV-Testing in Uganda|Client-Centered Counseling During Routine/Opt-Out HIV-Testing in Uganda||University of Connecticut Health Center|No|Completed|May 2008|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|333|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438930||21612|
NCT02438943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP218,11/12|An Intervention to Improve Management of Dyslipidemia in Primary Care|A Cluster Randomized Controlled Trial of an Intervention to Improve the Management of Dyslipidemia in Primary Care||The University of The West Indies|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|80 Years|No|||May 2015|May 5, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438943||21611|
NCT02451397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPLA_Dr.Tang|Associations Analysis Between Lifestyle and Osteoporosis|The Associations Analysis Between Lifestyle and Osteoporosis Among Chinese Population||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|3100|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|We performed a risk-factor study for osteoporosis using a random sample of the Chinese        population. Participants were recruited from rural and urban communities in Shanghai.        Survey participants aged 30-90 years were included in this study.|November 2015|November 4, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02451397||20656|
NCT02452619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0030-15-ASF|MRI Brain Changes Induced by Hyperbaric Oxygen Therapy in Brain Injury Patients|Brain Angiogenesis Induced by Hyperbaric Oxygen Therapy Can be Visualized by Perfusion MRI in Brain Injury Patients||Assaf-Harofeh Medical Center|No|Enrolling by invitation|March 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Retrospective analysis of patients suffering from chronic neuro-cognitive damage treated        at Sagol center for hyperbaric medicine and research, Assaf Harofeh Medical Center, Israel        from September 2013 .        Patients included if they had at least two perfusion MRIs + DTI and two neurocognitive        tests, before and after Hyperbaric Oxygen Therapy (HBOT). Treatment was approved by the        institutional review board of the hospital.|May 2015|May 21, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02452619||20562|
NCT02460523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|borderline CBDS|Management of Borderline Common Bile Duct Stone|Management and Outcome of Borderline Common Bile Duct With Stone|CBDS|Mansoura University|No|Completed|April 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|N/A|N/A|No|||April 2012|July 20, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02460523||19955|
NCT02429921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-1211_MOD1|High-selenium Lentils Versus Arsenic Toxicity|Mitigating Arsenic Toxicity in Bangladeshi People by Supplementing Their Diets With High Selenium Lentils||University of Calgary|Yes|Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|14 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02429921||22303|
NCT02429934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-330 SLE Arthritis|Abatacept for SLE Arthritis (IM101-330)|Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)||University of California, Los Angeles|Yes|Not yet recruiting|May 2015|October 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429934||22302|
NCT02459665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETH000828|Rwanda VMB Restoration Study|Preparing for a Clinical Trial of Interventions to Maintain Normal Vaginal Microbiota for Preventing Adverse Reproductive Health Outcomes in Africa|VMB|University of Liverpool|No|Active, not recruiting|June 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|68|||Female|18 Years|45 Years|No|||December 2015|December 1, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459665||20021|
NCT02453724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P002671|Lung Ultrasound Safety in Humans|Lung Ultrasound Safety in Humans||Massachusetts General Hospital|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All emergency department patients greater than 18 years of age|March 2016|March 17, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453724||20477|
NCT02453737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002566|A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca|A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer||Mayo Clinic|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|168|||Female|50 Years|N/A|No|||December 2015|December 4, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453737||20476|
NCT02453269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANS 123|Transdisciplinary Program Against Childhood Obesity|Outcome of a 1-year Transdisciplinary Program Against Childhood Obesity|OTPACO|Fortaleza University|Yes|Completed|May 2013|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02453269||20512|
NCT02453542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202100-2973|Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors|Global Haemostatic Methods to Measure the Treatment Effect Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors||Karolinska Institutet|No|Recruiting|March 2015|||June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|whole blood|Male|7 Years|N/A|No|Probability Sample|Fifteen patients (adults and children) with hereditary haemophilia with inhibitors.        Five patients (adults) with acquired haemophilia|February 2016|February 22, 2016|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02453542|2 Years|20491|
NCT02443246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDBON-302|A Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency|A Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency||Kwang Dong Pharmaceutical co., ltd.|No|Active, not recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|19 Years|65 Years|No|||May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443246||21281|
NCT02428127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203093|Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children|Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children||GlaxoSmithKline|No|Completed|May 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|30|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428127||22441|
NCT02444546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1472|Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Recurrent or Refractory Brain Tumors|Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors||Mayo Clinic|Yes|Suspended|June 2015|||April 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|10 Years|21 Years|No|||February 2016|February 18, 2016|May 1, 2015|Yes|Yes|evaluate the first three Dose Level 1 patients for toxicities|No||https://clinicaltrials.gov/show/NCT02444546||21182|
NCT02445859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB15/130|Continuous Antibiotic Prophylaxis in Colorectal Surgery|Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery|Colo-Pro|University of Leeds|Yes|Recruiting|August 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445859||21081|
NCT02448680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFB-FVIIa-007-14|A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients From ≥6 Months Old to <12 Years Old With Inhibitors to Factor VIII or IX|A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients From ≥6 Months Old to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2|Percept2|rEVO Biologics|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|6 Months|11 Years|No|||November 2015|November 24, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448680||20865|
NCT02450305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|482428 HBO|Hyperbaric Oxygen and Its Effect on Radiation Induced Long Term Side Effects|Hyperbaric Oxygen and Its Effect on Radiation Induced Long Term Side Effects||State University of New York - Upstate Medical University|No|Recruiting|August 2013|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that will be receiving HBO therapy for head and neck cancer related side effects|December 2013|May 19, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450305||20740|
NCT02445794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-002|A First in Human Study of RT001 in Patients With Friedreich's Ataxia|A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia||Retrotope, Inc.|No|Recruiting|August 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|50 Years|No|||November 2015|November 19, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445794||21086|
NCT02445807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFD06-CD-005|A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days||Promius Pharma, LLC|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445807||21085|
NCT02445820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES2015002|HES and Acute Kidney Injury in Adult Cardiac Surgery|The Association Between Hydroxyethyl Starch 130/0.4 and Acute Kidney Injury After Cardiopulmonary Bypass: a Single-center Retrospective Study||University Hospital of Liege|No|Completed|November 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|697|||Both|18 Years|N/A|No|Non-Probability Sample|Adults patients undergoing cardiac surgery|October 2015|October 29, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02445820||21084|
NCT02447029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vaginal Lidocaine|Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial|Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial|SALSA|Stanford University|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02447029||20991|
NCT02574468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91_509|Effect of Topical Dexamethasone on Histologic Response of Human Dental Pulp|Effect of Topical Dexamethasone on Histologic Response of Human Dental Pulp||Isfahan University of Medical Sciences|No|Completed|January 2013|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 10, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02574468||11206|
NCT02452476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05633AA1-02|A Double Blind, Randomized, Single Dose, Controlled Study to Compare CHF 5633 (Synthetic Surfactant) and Poractant Alfa in RDS|||Chiesi Farmaceutici S.p.A.|Yes|Not yet recruiting|October 2015|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|N/A|24 Hours|No|||May 2015|May 20, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452476||20573|
NCT02442219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2472|A Blood Based Diagnostic Test for Coeliac Disease|A Blood Based Diagnostic Test for Coeliac Disease||Oslo University Hospital|No|Active, not recruiting|February 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|150|Samples With DNA|A tetramerbased bloodtest which will bind and identify gluten specific T-cells. 50 ml blood      will be needed for this test, along with characterization of other blood values (eg. Hb,      leukocytes, transferrin binding, B12, biobanking etc).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants are invited through announcement in media. Eligibility is tested through        HLA-test and previous workup with confirmation / exclusion of coeliac disease by reference        method (duodenal biopsy).|March 2016|March 7, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02442219||21360|
NCT02442232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq|Hemodynamic Changes After Anesthesia With Propofol: Study of Biomarkers|||Conselho Nacional de Desenvolvimento Científico e Tecnológico||Completed|March 2013|||April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|191|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients under propofol anesthesia|May 2015|May 8, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442232||21359|
NCT02454049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nitrate_2015-04|Influence of Dietary Nitrate on Time Trial Performance in Swiss Paracycling Athletes|Influence of Dietary Nitrate on Paralympics 2016 Time Trial Performance in Swiss Elite Paracycling Athletes|nitrate_TT|Swiss Paraplegic Centre Nottwil|No|Recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|16|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454049||20452|
NCT02456532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#9384|Safety and Efficacy of Chronic Hypnotic Use 2|Risks for Transition From Therapeutic Hypnotic Use to Abuse|CIS2|Henry Ford Health System|Yes|Recruiting|July 2015|December 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456532||20262|
NCT02449616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-188-04|Evaluation of Repeat Administration of Purified Poloxamer 188|Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis|EPIC-E|Mast Therapeutics, Inc.|Yes|Recruiting|June 2015|||June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|388|||Both|4 Years|65 Years|No|||July 2015|July 10, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449616||20793|
NCT02449889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000191|A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation|FASHION|Ferring Pharmaceuticals|Yes|Not yet recruiting|March 2016|August 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|258|||Female|18 Years|39 Years|No|||February 2016|February 29, 2016|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449889||20772|
NCT02444936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canaday Zostavax|ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors|A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors||Louis Stokes VA Medical Center|No|Not yet recruiting|May 2015|||May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|50 Years|N/A|No|||May 2015|May 14, 2015|May 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444936||21152|
NCT02443532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAB120001|Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes|Quality of Life, Treatment Satisfaction, Fear of Hypoglycemia, Eating Habits, Ang Glucose Control in Patients With Type 1 Diabetes: Effects of Structured Group Education Versus Group Care.||Azienda Ospedaliero-Universitaria Careggi|No|Enrolling by invitation|March 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|15 Years|65 Years|No|||May 2015|May 11, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02443532||21260|
NCT02443545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA38-EXT|Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias|Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias||ApoPharma|Yes|Enrolling by invitation|May 2015|October 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|N/A|No|||February 2016|February 9, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443545||21259|
NCT02456636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE-POWER|Rural Engagement in Primary Care for Optimizing Weight Reduction|Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER)|RE-POWER|University of Kansas Medical Center|Yes|Recruiting|January 2016|December 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1440|||Both|20 Years|75 Years|No|||February 2016|February 8, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456636||20254|
NCT02447016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1462-IL-SMC|Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera|Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence|DeepSwitch|Sheba Medical Center|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02447016||20992|
NCT02451514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_02E2|A Study to Evaluate 4-Year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158).|A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 and V102_02E1||Novartis|No|Completed|June 2015|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|129|||Both|15 Years|23 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02451514||20647|
NCT02433795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY14-09|Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)|A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)||Seoul National University Hospital|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02433795||22007|
NCT02451059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MD007793-01A1|Reducing Socioeconomic Disparities in Health at Pediatric Visits|Reducing Socioeconomic Disparities in Health at Pediatric Visits|WECARE01|Boston Medical Center|No|Recruiting|September 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2050|||Both|N/A|1 Month|No|||January 2016|January 11, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02451059||20682|
NCT02450097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2013/1618-31/3|Metabolic and Hormonal Effects of 5:2 Intermittent Fasting|Metabolic and Hormonal Effects of 5:2 Intermittent Fasting in Patients With Type 2 Diabetes and Subjects With Adiposity||Karolinska University Hospital|Yes|Active, not recruiting|December 2013|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02450097||20756|
NCT02452112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIG13-CN-301|Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain|||Mundipharma (China) Pharmaceutical Co. Ltd|No|Recruiting|November 2014|November 2015|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|85 Years|No|||August 2015|August 17, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452112||20601|
NCT02449694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-LVR-022015|Trial of the TransMedics Organ Care System™ Liver For Preserving and Assessing Donor Livers for Transplantation|Single-arm Prospective Trial to Evaluate The Safety and Performance of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation|REVIVE|TransMedics|Yes|Not yet recruiting|June 2015|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02449694||20787|
NCT02449707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRP/2014/109|Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins|Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Lift Using Ultrasound Activated Resorbable Poly-D-L-lactide Pins in Maxillary Sinus Lift - a Split Mouth Randomized Control Trial||Riyadh Colleges of Dentistry and Pharmacy|No|Recruiting|April 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|45 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 16, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449707||20786|
NCT02451371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501-022-638|Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophrenia|A Pilot Study for the Treatment of Refractory Auditory Verbal Hallucinations With Transcranial Direct Current Stimulation(tDCS) in Patients With Schizophrenia||Seoul National University Hospital|Yes|Not yet recruiting|September 2015|||February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|50 Years|No|||April 2015|August 23, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02451371||20658|
NCT02454686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibroscan|Fibroscan Predicts Complications After Hepatectomy|Role of Fibroscan in Predicting Complications After Hepatectomy|Fibroscan|University of Milan|No|Completed|February 2012|May 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Both|18 Years|N/A|No|Non-Probability Sample|A prospective cohort of patients scheduled for hepatectomy.|May 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454686||20403|
NCT02454699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0092|Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers|A Phase 1 Trial to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of MBX-400 in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|November 2015|December 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|November 19, 2015|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02454699||20402|
NCT02461342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANGEI_Dr.Tang|Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy|Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy in Chinese Population||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2100|Samples With DNA|DNAs were extracted and genetyped by using SNP.|Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The investigators recruited participants from rural and urban communities in Shanghai.        Survey participants with undiagnosed CAN, aged 30-90 years, were included in this study.        Our study invited a total of 3,012 subjects to a screening visit between 2011 and 2012.|June 2015|June 2, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461342||19892|
NCT02458703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS 2015/1|Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction|Hypoxemia, Dyspnea, and Exercise Tolerance in Patients With Pulmonary Arteriovenous Malformations , With and Without Airflow Obstruction|ExercisePAVM2|Imperial College London|No|Not yet recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|16 Years|80 Years|No|||April 2015|May 29, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458703||20095|
NCT02443623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-008|VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV|Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)||Cangene Corporation|Yes|Recruiting|September 2015|January 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|3000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443623||21253|
NCT02443636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100270|The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry|The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry: Reliable Assessment to Enable Research and Improve Clinical Care||Nova Scotia Health Authority|No|Recruiting|May 2015|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population is english and french speaking males and females seeking or receiving help        for mental health related problems in the Maritime provinces of Canada. Participants must        have the capacity to provide informed consent or have an appropriate substitute decision        maker that can provide consent on their behalf. Whilst the recruitment will be targeted to        include individuals suffering with depression and other types of mental illness, no        specific diagnosis is required for participation in the registry.|March 2016|March 8, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02443636|10 Years|21252|
NCT02445781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00064405|Differing Levels of Hypoglycemia|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Differing Levels of Hypoglycemia||University of Maryland|Yes|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445781||21087|
NCT02448069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0327|Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke|ARTSS-IA: A Pilot, Phase IIa, Safety and Feasibility Study of ARgatroban in Combination With Recombinant Tissue Plasminogen Activator Stroke Study - Intra-Arterial|ARTSS-IA|The University of Texas Health Science Center, Houston|Yes|Recruiting|May 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|May 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448069||20912|
NCT02440633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-14-001|A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects|||Otsuka Pharmaceutical Co., Ltd.|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02440633||21482|
NCT02447705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-101-3476A3|Replacement of Lamivudine by Telbivudine to Improve Renal Function|Replacement of Lamivudine by Telbivudine to Improve Renal Function for Post-transplant Hepatitis B Patients - a Randomized Clinical Trial||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|April 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|N/A|Accepts Healthy Volunteers|||March 2013|May 14, 2015|June 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02447705||20940|
NCT02460783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150123|Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function|Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|55 Years|70 Years|No|||December 2015|January 1, 2016|May 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02460783||19935|
NCT02460718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T0808270039|ENCOURAGE: Evaluating Community Peer Advisors and Diabetes Outcomes in Rural Alabama|ENCOURAGE: Evaluating Community Peer Advisors and Diabetes Outcomes in Rural Alabama|ENCOURAGE|Weill Medical College of Cornell University|No|Completed|February 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|424|||Both|19 Years|N/A|No|||March 2016|March 9, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02460718||19940|
NCT02460770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13 150 03|Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device|Pilot Study of Investigation of Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device|MESAD|University Hospital, Toulouse|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|75 Years|No|||May 2015|May 29, 2015|January 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02460770||19936|
NCT02440711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A97186|Evaluation of a Modified Running-specific Prosthetic Foot|Endurance, Energy Expenditure, Perceived Function, and Satisfaction of Persons With Transtibial Limb Loss Using a Running‐Specific Prosthesis Modified for Walking||University of Washington|No|Recruiting|May 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02440711||21476|
NCT02440724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0820|The Usefulness of Self-expandable Metal Stents(SEMS) for Malignant Gastric Outlet Obstruction: a Prospective Study Using New Designed Stents|The Usefulness of Self-expandable Metal Stents(SEMS) for Malignant Gastric Outlet Obstruction: a Prospective Study Using New Designed Stents|SEMS|Asan Medical Center|No|Recruiting|August 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|19 Years|N/A|No|||May 2015|May 7, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02440724||21475|
NCT02457338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631099|Infant Microbiota and Probiotic Intake Study|Infant Supplementation With Probiotic Bifidobacterium Longum Subsp. Infantis Study|IMPRINT|University of California, Davis|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457338||20200|
NCT02455336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1925-P|Fenofibrate Treatment in SCI|An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI||VA Office of Research and Development|No|Recruiting|May 2015|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|69 Years|No|||March 2016|March 15, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02455336||20354|
NCT02458989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thyroid Cosmesis H14-02408|Thyroid Cosmesis Study at St. Paul's Hospital, Vancouver BC|A Randomized Controlled Trial Comparing The Cosmetic Outcome Of Electrocautery Versus Scalpel For Thyroidectomy Incisions||St. Paul's Hospital, Canada|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02458989||20073|
NCT02441764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKI-PMS-1201|Halaven Post-Marketing Surveillance (PMS)|Post-Marketing Surveillance of Halaven Injection in Korean Patients||Eisai Inc.|No|Recruiting|March 2013|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Participants who are prescribed with Halaven per approved prescribing information of        Halaven will be enrolled in the study.|March 2016|March 8, 2016|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441764||21395|
NCT02448212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS121-US103|Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects|A Phase 1 Receptor Occupancy Study Using Positron Emission Tomography to Investigate Novel Ligand [11C]TASP0410699 Alone and Following Single Oral Dose Administrations of TS-121 in Healthy Adult (Male) Subjects||Taisho Pharmaceutical R&D Inc.|No|Completed|May 2015|||January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448212||20901|
NCT02460822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PAF07680|Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management|Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management||University of Michigan|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|October 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02460822||19932|
NCT02455895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-01-14|Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora|A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora||NovaBay Pharmaceuticals, Inc.|No|Recruiting|May 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|6 Years|N/A|No|||May 2015|May 27, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455895||20311|
NCT02441504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1988-CEP/HUPE|Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes|Effects of Low Intensity Aerobic Exercise Training on the Microvascular Endothelial Function of Patients With Type 1 Diabetes: a Non-pharmacological Interventional Study||Instituto Nacional de Cardiologia de Laranjeiras|Yes|Completed|January 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441504||21415|
NCT02441621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-139|Prediction of Volume Responsiveness in Presence of Left Ventricular Diastolic Dysfunction|Prediction of Fluid Responsiveness in Presence of Diastolic Dysfunction||University of Schleswig-Holstein|Yes|Not yet recruiting|June 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02441621||21406|
NCT02450344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alcohol2015HK|Promoting Alcohol-related Attitudinal and Behavioural Change Amongst Adolescents Through Internet Intervention|Promoting Alcohol-related Attitudinal and Behavioural Change Amongst Adolescents Through Internet Intervention: A Cluster Randomised Controlled Trial||The University of Hong Kong|No|Enrolling by invitation|June 2015|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6552|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02450344||20737|
NCT02459691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-10-365|Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)|Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos in Primary Care (E-LITE Latinos)||Palo Alto Medical Foundation|Yes|Recruiting|September 2014|August 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|186|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02459691||20019|
NCT02446132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-303|Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type||Avanir Pharmaceuticals|Yes|Recruiting|December 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|550|||Both|50 Years|95 Years|No|||December 2015|December 18, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446132||21060|
NCT02430506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-012-402|A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB|A Phase I Randomized Placebo-controlled Double-blind Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QuantiFERON®-TB Gold (+) and QuantiFERON®-TB Gold (-) Adults Without Evidence of Tuberculosis.|C-012-402|Aeras|Yes|Completed|September 2008|July 2010|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430506||22259|
NCT02455089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC15.010|Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus|Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus|GADD34-LES|University Hospital, Grenoble|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455089||20373|
NCT02459717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66/INT/2015|Pre-biotics and Probiotics for Constipation in Parkinson's Disease|Double Blind, Placebo-controlled Trial of a Fermented Milk Containing Multiple Probiotics Strains and Prebiotic Fiber for Constipation Associated With Parkinson's Disease||IRCCS Policlinico S. Matteo|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|90 Years|No|||October 2015|October 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02459717||20017|
NCT02459730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GICCHXART|Glass-ionomer Cement Containing Chlorhexidine for ART|Glass-ionomer Cement Containing Chlorhexidine for ART||University of Campinas, Brazil|Yes|Completed|February 2013|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02459730||20016|
NCT02446431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence|Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence: A Multi-Institutional Study|Metronomic|Miller Children's & Women's Hospital Long Beach|No|Recruiting|July 2014|July 2029|Anticipated|July 2024|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|12 Months|31 Years|No|||May 2015|May 13, 2015|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446431||21037|
NCT02446444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZUP1303|Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer|Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD|ENZARAD|University of Sydney|Yes|Recruiting|March 2014|December 2021|Anticipated|September 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446444||21036|
NCT02446457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0539|Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma|Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446457||21035|
NCT02429102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-8554-E01|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects|||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|135|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02429102||22366|
NCT02459756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREC 14/17|Anthocyanin-rich Blackcurrant and Vascular Function|Effects of an Anthocyanin-rich Blackcurrant Beverage on Cardiovascular Function||University of Reading|Yes|Completed|June 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|23|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02459756||20014|
NCT02457780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01OH010524-01|Stress Management Program for World Trade Center (WTC) Responders|Mind-Body Treatment for WTC Responders With Comorbid PTSD and Respiratory Illness||Stony Brook University|No|Recruiting|August 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02457780||20166|
NCT02457793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29653|A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|142|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457793||20165|
NCT02434107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1410112004|Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)|Controlled and Prospective Randomised Study to Compare Complete Lymph Node Dissection Versus Watchful Waiting in Patients With Malignant Melanoma With a Tumour Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node|DeCOG-SLT|University Hospital Tuebingen|No|Active, not recruiting|December 2005|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|558|||Both|18 Years|75 Years|No|||April 2015|July 17, 2015|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02434107||21983|
NCT02441309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_039|A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)|A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma|MEMOS|University of Oxford|Yes|Recruiting|October 2014|July 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|16 Years|65 Years|No|||January 2016|January 18, 2016|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02441309||21430|
NCT02441322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820817|Evaluating Therapeutic Response to Novo-TTF|High Resolution MRI and MRS to Evaluate Therapeutic Response to Novo-TTF in Newly and Recurrent Glioblastomas||University of Pennsylvania|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|September 2, 2015|February 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441322||21429|
NCT02454855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-K13-170|Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients|Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (> = 70 Years) - PHRC-K13-170|MEQAPAG|Centre Jean Perrin|Yes|Recruiting|May 2015|September 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|70 Years|N/A|No|||May 2015|August 7, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02454855||20390|
NCT02448030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0359|Effects of Functional Electrical Stimulation on Metaboreflex Activation in Healthy Individuals|Effects of Functional Electrical Stimulation Compared to Isometric Exercise on Metaboreflex Activation in Healthy Individuals: Randomized Crossover Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02448030||20915|
NCT02448043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200526|Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure|Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure||Northwestern University|Yes|Recruiting|May 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448043||20914|
NCT02451553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9078|Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer|Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers||University of Washington|Yes|Recruiting|November 2015|||November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|19 Years|N/A|No|||November 2015|November 16, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451553||20644|
NCT02441842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5820 / 2006|Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension|Evaluation of Perioperative Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preoperative Hypertension||Milton S. Hershey Medical Center|No|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|85|||Both|18 Years|69 Years|No|||May 2015|May 7, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02441842||21389|
NCT02441894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZL07239|Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer|Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer|PEGAZUS|Sanofi|No|Recruiting|April 2015|December 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|20 Years|N/A|No|||November 2015|November 26, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441894||21385|
NCT02455076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080596|Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes|Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes||Emory University|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|150|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455076||20374|
NCT02456779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPTESTCN|Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD|Assessment of Equivalence of a Non-invasive In-vitro Diagnostic Test (Peptest) in Comparison to Other Routine Clinical Diagnostic Methods for GERD by Testing a Large Number of Clinical Samples|PEPTESTCN|MAAB (Shanghai) Medical Device Limited|No|Recruiting|May 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1020|Samples Without DNA|Saliva samples will be obtained from each subject. Specimens will be disposed of after      testing for presence of pepsin using Peptest.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|GERD patients Erosive Esophagitis (EE) Non-erosive reflux disease (NERD) Heathly controls        with GERD symptoms|January 2016|January 21, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02456779||20243|
NCT02457949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02401|The Impact of Alternative Social Assistance Disbursement on Drug-related Harm|The Impact of Alternative Social Assistance Disbursement on Drug-Related Harm: a Randomized Control Trial|TASA|University of British Columbia|Yes|Recruiting|October 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Anticipated|273|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02457949||20153|
NCT02434679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13024 DAIR3N|Dynamic of the Acquisition of Antibiotic Resistance in Integrons in Neonatology Newborns|Dynamic of the Acquisition of Antibiotic Resistance in Integrons in Neonatology Newborns|DAIR3N|University Hospital, Limoges|No|Recruiting|October 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|255|Samples With DNA|The meconium or the first stool will be sampled at D0. The stool will then be sampled: at      D7, at D21 and every 15 days until the day of discharge.      If the NB has no stool on the given day, a period of 3 more days will be accepted from the      day the sampling was planned. After this period, "no sample" will be stated.      Meconiums and stool must be sampled in sterile jars, labelled and sent with the designation      "DAIR3N protocol" to the bacteriology laboratory of each center. If the local laboratory      cannot seed the samples 7 days a week, stool samples can be kept maximum 48h at +4°C before      management.      In the mother      Vaginal sample will be taken during the delivery according to care practices of each center      if:      it is a preterm vaginal delivery, early membrane rupture happens, there is a threat of very      preterm delivery. About 55% of inclusions should be subject to this type of sampling.      Sampling of mother's stool will be asked at the inclusion.|Both|N/A|1 Day|No|Probability Sample|Mother-child pairs of all the NB, born in the center and hospitalized in the neonatology        units of each center with a predictable stay ≥ 3 weeks in the unit|February 2016|February 23, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434679||21939|
NCT02453126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0594|Fibrostenotic Eosinophilic Esophagitis: Assessment Tools|Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools||University of Colorado, Denver|No|Recruiting|December 2014|||January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|5 Years|18 Years|No|Non-Probability Sample|Children, ages 5 to 18 years, scheduled to undergo a clinical upper endoscopy with biopsy        for suspected or confirmed Eosinophilic Esophagitis.|November 2015|November 4, 2015|September 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02453126||20523|
NCT02458677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX003-CL001|Single Ascending Dose Study of PRX003 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects||Prothena Biosciences Limited|No|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458677||20097|
NCT02458690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411802537|eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients|eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients||Indiana University|Yes|Enrolling by invitation|July 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|216|||Both|50 Years|N/A|No|||August 2015|August 12, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458690||20096|
NCT02458352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-2015-0072|Ultra Low Dose CT for CACS and AC of SPECT|Usefulness of Ultra Low Dose Cardiac CT for Coronary Calcium Scoring and for Attenuation Correction of SPECT||University of Zurich|Yes|Recruiting|November 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|105|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02458352||20122|
NCT02458365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH086129|A Stage-Based Expert System for Teen Dating Violence Prevention|A Stage-Based Expert System for Teen Dating Violence Prevention||Pro-Change Behavior Systems|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3901|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|May 26, 2015||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT02458365||20121|
NCT02458378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMPPC-2015-inpt|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||January 4, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458378||20120|
NCT02450045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044335|Pre-op Femoral Nerve Block for Hip Fracture|Use of Pre-operative Nerve Blocks in Older Patients With Hip Fracture: A Pilot Study||University of Alberta|No|Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|65 Years|N/A|No|||January 2016|January 20, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02450045||20760|
NCT02448810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391401|Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer|A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer||Baxalta US Inc.|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448810||20855|
NCT02448823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI114438|Evaluating Demand Generation (Stylish Man , Stylshs Living) for HIV Prevention/Family Planning Services, Rakai, Uganda|Evaluating Demand Generation (Stylish Man, Stylish Living) for HIV Prevention/Family Planning Services, Rakai, Uganda||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|August 2014|September 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|15000|||Both|18 Years|49 Years|No|||May 2015|May 19, 2015|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02448823||20854|
NCT02450422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colorectal Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage colorectal cancer come to Fuda Hospital for treatment.|December 2015|December 28, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450422||20731|
NCT02453555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.19|Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus|A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.||Boehringer Ingelheim||Recruiting|May 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|273|||Both|20 Years|N/A|No|||March 2016|March 8, 2016|May 21, 2015||||No||https://clinicaltrials.gov/show/NCT02453555||20490|
NCT02453568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TxA|Use of Tranexamic Acid for Prevention of Postpartum Hemorrhage and Routine Blood Loss in Obstetrics|Use of Tranexamic Acid for Prevention of Postpartum Hemorrhage and Routine Blood Loss in Obstetrics||New York University School of Medicine|Yes|Not yet recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Female|14 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 20, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453568||20489|
NCT02454153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093188|Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy|Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy|HYPNOS|Johns Hopkins University|Yes|Recruiting|October 2014|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|21 Years|75 Years|No|||May 2015|May 26, 2015|January 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454153||20444|
NCT02449850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15118|Preventing Atopic Dermatitis and ALLergies in Children|Preventing Atopic Dermatitis and ALLergies in Children|PreventADALL|Oslo University Hospital|No|Recruiting|December 2014|June 2044|Anticipated|June 2044|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|5200|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449850||20775|
NCT02451527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013L02060|The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects|An Open-label，Single-arm，Sequential，Single-center Clinical Trial of the Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection (PEX168) in Healthy Adult Subjects||First Affiliated Hospital Xi'an Jiaotong University|Yes|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02451527||20646|
NCT02451540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2014-134|Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging|Placebo Controlled Study to Assess the Effect of Roflumilast in Hyperinflated COPD Patients in Addition to LABA/LAMA Therapy Using Functional Respiratory Imaging.||FLUIDDA nv|No|Recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|N/A|No|||September 2015|September 22, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02451540||20645|
NCT02561923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107832|A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants|Randomized, Parallel-Group, 2-Part Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding Parameters and Pharmacodynamics After a Punch Biopsy Procedure in Healthy Subjects Treated With Rivaroxaban||Janssen Scientific Affairs, LLC|Yes|Recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|156|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561923||12170|
NCT02457559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-401-1787|Long-term Safety and Efficacy of ONO/GS-4059 in Adults With Relapsed/Refractory B-cell Malignancies|An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies||Gilead Sciences|No|Active, not recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457559||20183|
NCT02457572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2014-07-005|Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition|Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition in the Patients Undergoing Off-pump Coronary Arterial Bypass Grafting||Samsung Medical Center||Completed|October 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|20 Years|80 Years|No|Probability Sample|Adult patients undergoing elective off-pump coroanry arterial bypass grafting|September 2015|September 11, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02457572||20182|
NCT02427841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11256|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer||OHSU Knight Cancer Institute|Yes|Recruiting|January 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|April 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02427841||22463|
NCT02456545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BipoLife-A1|Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders|Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders|BipoLife-A1|Technische Universität Dresden|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1650|||Both|15 Years|35 Years|No|Non-Probability Sample|Risk groups I: help-seeking persons with subthreshold symptoms        Risk group II: in- and outpatients with depressive disorder        Risk group III: in- and outpatients with ADHD        representative population cohort from IMAGEN study|February 2016|February 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02456545||20261|
NCT02454751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA/2014/002|The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial|The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial||St. Boniface General Hospital Research Centre|No|Not yet recruiting|October 2015|January 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454751||20398|
NCT02458820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-011635|Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest|Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest||Children's Hospital of Philadelphia|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|N/A|N/A|No|||November 2015|November 30, 2015|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458820||20086|
NCT02449200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR 14-0917|RCT of Multimodal Physiotherapy for Acute / Sub-acute Cervical Radiculopathy|A Randomised Controlled Trial of Multimodal Physiotherapy for Patients With Acute / Sub-acute Cervical Radiculopathy|PACeR|Royal College of Surgeons, Ireland|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||May 2015|July 20, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02449200||20825|
NCT02429128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lean PCOS & Training|14 Weeks Exercise Training on Lean Women With and Without PCOS|14 Weeks Exercise Training on Lean Women With and Without PCOS||University of Copenhagen|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2015|August 4, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02429128||22364|
NCT02429141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAICE-001|Periarterial Injection Versus Multiple Periveural Injection|The Ultrasound Guided Periarterial Injection Technique To Axilary Brachial Plexus Block Versus Perineural Multiple InjectionTechnique||North American Institute for Continuing Medical Education (NAICE)|No|Recruiting|January 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||September 2015|September 17, 2015|April 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02429141||22363|
NCT02445040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I100738|Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates|A Clinical Study to Evaluate the Safety and Effectiveness of the Infinity Acute Care System Workstation Neonatal Care Babylog VN500 Device in High Frequency Oscillatory Ventilation (HFOV) Mode in Very Low Birth Weight (VLBW) Neonates||Draeger Medical Systems, Inc.|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|23 Weeks|30 Weeks|No|||January 2016|January 25, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445040||21144|
NCT02445053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-770-116|Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)|Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)|VOCAL|Vertex Pharmaceuticals Incorporated|No|Recruiting|April 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|6 Years|N/A|No|Non-Probability Sample|Male and female patients with CF, age 6 years or older, who have 1 of the following CFTR        mutations on at least 1 allele: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or        G1349D|March 2016|March 10, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02445053||21143|
NCT02455869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014J|Comparison of Alendronate With Atorvastatin in Chronic Periodontitis|Comparative Evaluation of Subgingivally Delivered 1% Alendronate Versus 1.2% Atorvastatin Gel in Treatment of Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|July 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|104|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02455869||20313|
NCT02456142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206005358|CAUDAL BUPIVACAINE VERSUS INTRAVENOUS MORPHINE ON TIME TO FIRST ANALGESIC REQUIREMENT|EFFECT OF CAUDAL BUPIVACAINE VERSUS INTRAVENOUS MORPHINE ON TIME TO FIRST ANALGESIC REQUIREMENT IN PEDIATRIC SURGICAL PATIENTS; A RANDOMISED CONTROLLED TRIAL.|CaBuMorph|Makerere University|Yes|Recruiting|July 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|8 Years|No|||August 2015|August 6, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456142||20292|
NCT02440321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC97-2314-B-038-043-MY3|Effects of Parent-child Interactive Intervention in Preventing Children's Environmental Tobacco Smoke Exposure at Home|The Third Year Project of The Associated Factors of Smoking Around School-aged Children and The Intervention Development Using the Theory of Reasoned Action||Taipei Medical University|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|150|||Both|N/A|N/A|No|||May 2015|May 6, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02440321||21506|
NCT02440386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRECREF:849/2014|iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care|iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care|iLink|University of Cape Town|No|Recruiting|April 2015|November 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02440386||21501|
NCT02454335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093759|POEM Anterior Versus Posterior Approach|Comparison of Outcome and Complications of Anterior Versus Posterior Myotomy in Per-oral Endoscopic Myotomy (POEM) Endoscopic Procedure for Treatment of Achalasia: Randomized Single Blinded Clinical Trial||Johns Hopkins University|Yes|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|100 Years|No|||February 2016|February 29, 2016|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02454335||20430|
NCT02454543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-RAMPP_MK-2014|Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases|Multicentric, Prospective, Randomized Controlled Trial Comparing Radical Prostatectomy Plus Neoadjuvant Hormones With Androgen Deprivation Therapy Alone in the Management of Men With Pauci-metastatic Prostate Cancer|g-RAMPP|Martini-Klinik am UKE GmbH|No|Recruiting|May 2015|April 2025|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|452|||Male|18 Years|75 Years|No|||March 2016|March 4, 2016|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02454543||20414|
NCT02456155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-92|A Trial of Bedside Placement of Nasal Jejunal Tube Confirmed by Ultrasound Compared to Placement by Endoscope in Patients With SAP|Study to Compare the Placement Method of Nasal Jejunal Tube in Patients With Severe Acute Pancreatitis: Bedside Placement With Ultrasound Confirmation Versus Placement Endoscopically|SAP|Nanjing University|Yes|Recruiting|January 2014|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02456155||20291|
NCT02455921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBD 712/19-3-15|Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children|Comparative Effect of Neuromuscular Blockade Reversal Agent on Extubation Conditions, Postoperative Cognitive Function and Behaviour of School-aged Children Undergoing Ear Note Throat (ENT) Surgery||Attikon Hospital|No|Enrolling by invitation|May 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|200|||Both|6 Years|12 Years|No|||May 2015|November 30, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455921||20309|
NCT02456220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCMinasGerais|Dentoskeletal Changes Associated With Herbst Appliance Therapy|Three-dimensional Assessment of the Dentoskeletal Changes Associated With Herbst Appliance Therapy: A Controlled Clinical Trial||Pontifícia Universidade Católica de Minas Gerais|No|Completed|March 2013|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|12 Years|16 Years|No|||October 2015|October 24, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456220||20286|
NCT02454452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 2012/068|Comparison of Radiofrequency, Vein Stripping and CHIVA for Venous Insufficency|Comparative Randomized Clinical Study to Evaluate the Efficacy of Radiofrequency vs Surgical Technique of Internal Saphenous Vein Stripping and CHIVA Technique in the Treatment of Chronic Venous Insufficiency.||Corporacion Parc Tauli|No|Active, not recruiting|February 2013|September 2017|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|207|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454452||20421|
NCT02454465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS/PG/NHS/00370|Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions|"Time to ACT": Multi-site Evaluation of an Acceptance and Commitment Therapy Group Intervention for Adjustment Difficulties in Neurological Conditions||University of Hertfordshire|No|Not yet recruiting|July 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|90 Years|No|||May 2015|May 21, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454465||20420|
NCT02460419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015029|Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma|Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.||Sun Yat-sen University|Yes|Recruiting|April 2015|May 2021|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|65 Years|No|||May 2015|May 29, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02460419||19963|
NCT02447835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815905|Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction|The Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction and Muscarinic Mediation of B-Cell Function: A Small Mechanistic, Single-Site Study||Monell Chemical Senses Center|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|October 25, 2012||No||No||https://clinicaltrials.gov/show/NCT02447835||20930|
NCT02434393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-048|Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project|Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project|ADNI-D|University of Southern California|No|Recruiting|February 2015|January 2021|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|blood, urine|Both|65 Years|N/A|No|Probability Sample|120 older adults meeting criteria for Major Depression or Late Life Depression (LLD).|January 2016|January 20, 2016|December 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02434393||21961|
NCT02434406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD/14-15/16|Website-Based Self-Help for Women With Anxiety After Childbirth|Feasibility of a Web-Based Intervention for Women With Postpartum Anxiety: A Randomized Controlled Trial||City University, London|No|Not yet recruiting|July 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||January 2016|February 1, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434406||21960|
NCT02430246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0096-13|The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies|The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies||HaEmek Medical Center, Israel|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|376|||Female|18 Years|N/A|No|||April 2015|April 25, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02430246||22279|
NCT02450604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/23|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain|DOUFABIS|University Hospital, Bordeaux|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|6 Years|80 Years|No|||May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450604||20717|
NCT02452424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-14|A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors|Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors||Plexxikon|No|Recruiting|June 2015|July 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452424||20577|
NCT02457143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-145|Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Clinical Trial|Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Randomized Clinical Trial||St. Michael's Hospital, Toronto|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|7000|||Both|21 Years|74 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457143||20215|
NCT02441608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLEY HERTZ-002|Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|SAF DER ASSESS|Kley Hertz S/A|No|Completed|June 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02441608||21407|
NCT02452294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120ZDE01T|Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)|An Open-label, Uncontrolled, Single Arm Phase II Trial of Buparlisib in Patients With Metastatic Melanoma With Brain Metastases Not Eligible for Surgery or Radiosurgery|BUMPER|University Hospital Tuebingen|No|Recruiting|July 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||May 2015|July 17, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02452294||20587|
NCT02452307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/2003|Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy|Prospective Randomized Trial of Peptide-specific Vaccination in HLA-A*02 Positive Prostate Carcinoma Patients With Biochemical Recurrence After Radical Prostatectomy||University Hospital Tuebingen|No|Active, not recruiting|April 2004|July 2015|Anticipated|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|36|||Male|45 Years|80 Years|No|||April 2015|May 19, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02452307||20586|
NCT02446951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404-061|Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department|Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department||Children's Hospitals and Clinics of Minnesota|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1550|||Both|N/A|7 Days|No|Non-Probability Sample|ED patients presenting with jaundice.|November 2015|November 17, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446951||20997|
NCT02446964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14106|Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia|Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia||City of Hope Medical Center|Yes|Recruiting|June 2015|||June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|60 Years|No|||January 2016|January 25, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446964||20996|
NCT02445885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATE-MI|Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction|Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction|LATE-MI|Rigshospitalet, Denmark|Yes|Recruiting|May 2015|May 2020|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445885||21079|
NCT02441699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9071|Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India|Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India||London School of Hygiene and Tropical Medicine|No|Recruiting|April 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2940|Samples With DNA|Stool samples will be collected and divided into two aliquots. One aliquot will be fixed and      used for assessing the rate and intensity of soil-transmitted helminth (STH) infection and      the second aliquot will be frozen and used to assess biomarkers of environmental enteropathy      and enteric infection|Both|N/A|N/A|No|Probability Sample|Rural householders living in Ganjam district, Orissa, India.|May 2015|May 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02441699||21400|
NCT02441751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK110032015|Intraoperative Volume Management and QT Interval|Intraoperative Repolisarisation - Etiology and Relevance for the Decision Making by Anesthesiologists in the Management of Volume Substitution and Transfusion||Technische Universität Dresden|Yes|Recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients for major surgery in urology and orthopedics|May 2015|May 11, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441751||21396|
NCT02447978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201477|Duration of Protection: GSK DTaP Vaccines|Duration of Protection Following Five Doses of GlaxoSmithKline's (GSK's) DTaP Vaccines in School Age Children||GlaxoSmithKline||Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|N/A||3|Actual|1|||Both|47 Months|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Kaiser Permanente Northern California (KPNC) member who received 5 doses of acellular        pertussis vaccines between ages 1 month and 84 months at KPNC.|October 2015|October 29, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02447978||20919|
NCT02460549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04|Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation|Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation|Nutriprophy|Institut de Cancérologie de la Loire|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Male|18 Years|N/A|No|||May 2015|June 1, 2015|April 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02460549||19953|
NCT02444364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERCK-200379|Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus|Pilot Project Evaluation of the DPP-4 Inhibition With Sitagliptin on Calcium and Bone Metabolism in Patients With Type 2 Diabetes Mellitus||University of Missouri-Columbia|No|Withdrawn|May 2015|||December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|May 11, 2015|Yes|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT02444364||21196|
NCT02431819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408064|Evaluation of the Safety of Compressive Socks to Treat Venous Insufficiency in Patients With Peripheral Arterial Disease|Single Center Prospective Study Evaluating the Safety of Progressive Compressive Stockings for the Treatment of Venous Insufficiency in Patients With Peripheral Arterial Disease||Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|February 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02431819||22159|
NCT02452801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-215|Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment||Alkermes, Inc.|No|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452801||20548|
NCT02455986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StepSmart|The StepSmart Project: A Pedometer Based Phased Intervention to Encourage Physical Activity in Schools|A Randomised Controlled Trial of a Pedometer Based Phased Intervention to Encourage Physical Activity in Schools: A Feasibility Study.||Queen's University, Belfast|No|Active, not recruiting|April 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455986||20304|
NCT02447549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2014/10049|Study of Tumour Focused Radiotherapy for Bladder Cancer|A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder|RAIDER|Institute of Cancer Research, United Kingdom|Yes|Recruiting|September 2015|March 2029|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|16 Years|N/A|No|||February 2016|February 10, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447549||20952|
NCT02447562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECHRONIC|Model for the Integral Assessment of Chronic Disease Management Supported in Information Technology and Communication.|A Randomized Clinical Trial to Investigate the Management for the Integral Assessment Model of Chronic Disease Supported in Information Technology and Communication.||Instituto de Investigacion Sanitaria La Fe|No|Completed|June 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|495|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447562||20951|
NCT02428335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sestamibi 1.0|Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib|Evaluation of Technetium-99m Sestamibi to Determine Muscle Energy Metabolism in RCC (Renal Cell Cancer) Patients Treated With Sunitinib||AHS Cancer Control Alberta|No|Not yet recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Men and women aged 18 years of age or older with a confirmed diagnosis of renal cell        carcinoma. Participants will receive standard of care treatment with sunitinib.        Participants must be willing to undergo exercise testing and diagnostic imaging with        technitium 99m-sestamibi|April 2015|April 28, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02428335||22425|
NCT02428348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/1283(2)|EEG@HOME (Phase 3b of the Project, Interviews)|||University Hospital, Ghent|Yes|Enrolling by invitation|January 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|6 Years|80 Years|No|||December 2015|December 7, 2015|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02428348||22424|
NCT02454179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-006|Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma|A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma|KEYNOTE147|Acerta Pharma BV|No|Recruiting|May 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454179||20442|
NCT02454257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICNARC/02/07/15|Risk Modelling for Quality Improvement in the Critically Ill: Making Best Use of Routinely Available Data|Risk Modelling for Quality Improvement in the Critically Ill: Making Best Use of Routinely Available Data||Intensive Care National Audit & Research Centre|No|Not yet recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|940000|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted to an adult critical care unit or cardiothoracic critical care unit or        experiencing an in-hospital cardiac arrest in an NHS acute hospital in England or Wales.|May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02454257||20436|
NCT02447237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2014-113|Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients|Randomized Controlled Trial About the Effect of Liquid Compared to Solid Food on the Intake of Energy and Protein in Patients With Leukemia, Lymphoma or Other Malignant Hematologic Disease||University of Copenhagen|No|Recruiting|March 2015|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02447237||20975|
NCT02447250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009883|Preterm Infant Inhaled Albuterol Dosing|Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia||Oregon Health and Science University|No|Recruiting|October 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|28 Days|No|||October 2013|May 15, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447250||20974|
NCT02450461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0148|Breath Analysis in Asthma|Exhaled Breath Analysis by Secondary Electrospray Ionization (SESI-MS) in Patients With Asthma||University of Zurich|No|Recruiting|April 2015|September 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from asthma will be included according to the predefined inclusion and        exclusion criteria.        Healthy controls will be recruited from the general population by printed flyers,        newspaper advertisements and personal communication.|December 2015|December 9, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02450461||20728|
NCT02434692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARGOS-02|Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)|A Prospective, Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of the ARGOS-IO System in Patients With Primary Open Angle Glaucoma (POAG)||Implandata Ophthalmic Products GmbH|Yes|Recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|40 Years|85 Years|No|||April 2015|April 30, 2015|September 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02434692||21938|
NCT02460068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBIT-M2|A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis|A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis|NIBIT-M2|Italian Network for Tumor Biotherapy Foundation|Yes|Recruiting|December 2012|January 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|168|||Both|18 Years|N/A|No|||May 2015|June 1, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02460068||19990|
NCT02447575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H36079|Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients|Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients||Baylor College of Medicine|No|Recruiting|February 2015|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|120 subject diagnosed with asthma or chronic obstructive pulmonary disease (COPD) will be        recruited to perform inhaler maneuver using an electronic flowmeter, this will measure how        they are performing their inhaler maneuver. They will then have a short educational        session on how to use the inhaler and then repeat the electronic flowmeter maneuver. The        two sessions will then be compared. Perfoming the inhaler maneuver pre and post will use a        placebo inhaler.|May 2015|May 18, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02447575||20950|
NCT02450721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StPetersburgSPMU|Clinical and Laboratory Biomarkers in Patients With Atherothrombotic Stroke||CLAST|St. Petersburg State Pavlov Medical University|No|Recruiting|January 2011|January 2018|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|97|Samples With DNA|Blood serum|Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|In-hospital patients|May 2015|May 27, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450721||20708|
NCT02433821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP_UNIFESP-0208/11|Pilates to Treat Neck Pain|Effectiveness of Pilates to Treat Mechanical Neck Pain||Federal University of São Paulo|No|Completed|February 2012|May 2014|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||April 2015|April 29, 2015|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02433821||22005|
NCT02454348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204265|NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock|NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock (NOVEL Trial)|NOVEL|University of Arkansas|No|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454348||20429|
NCT02454660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS022336-01A1|Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages|Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages|AIM@BP|University of Michigan|No|Recruiting|May 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02454660||20405|
NCT02447809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Plasma and Platelet microRNAs in Clopidogrel Low Response Patients|The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism|PPRC|The First Affiliated Hospital with Nanjing Medical University|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02447809||20932|
NCT02446730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAUTY-II|Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome|A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent|BEAUTY-II|Chonnam National University Hospital|Yes|Recruiting|September 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02446730||21014|
NCT02446743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_75|Combined Study - Phase 3b MenB Long Term Persistence in Adolescents.|A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of Novartis Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 and V72P10, Compared to Naïve Healthy Controls.||Novartis|Yes|Recruiting|November 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Both|15 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02446743||21013|
NCT02442908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-K002|Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia|A 12-Week, Randomised, Placebo Controlled, Multi-Centre, Parallel Group Study Assessing the Safety and Tolerability of Nutrifriend Cachexia (Non-Complete Dietary Formula) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Smartfish AS|No|Recruiting|May 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||November 2015|November 17, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02442908||21307|
NCT02459483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy|Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy|ETICCO|Institut de Cancérologie de la Loire|Yes|Recruiting|December 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|184|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02459483||20035|
NCT02452372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-AS1-001|A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP)|A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)||Alnylam Pharmaceuticals|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452372||20581|
NCT02460458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABB-11-01|TYPE 3 VON WILLEBRAND INTERNATIONAL REGISTRIES INHIBITOR PROSPECTIVE STUDY|TYPE 3 VON WILLEBRAND INTERNATIONAL REGISTRIES INHIBITOR PROSPECTIVE STUDY|3WINTERS-IPS|Fondazione Angelo Bianchi Bonomi|Yes|Active, not recruiting|December 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|250|Samples With DNA|Venous blood sample, that will be used to obtain both citrated Platelet Poor Plasma for VWF      assays and Cell Pellet for DNA extraction.|Both|N/A|N/A|No|Non-Probability Sample|A large cohort of patients with diagnosis of Type 3 von Willebrand Disease, enrolled in        Europe and in Iran using homogeneous and standardized criteria.|May 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460458||19960|
NCT02460471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11020|Palliative Radiotherapy Protocol in Head and Neck Cancer|Palliative Radiotherapy for Advanced Head and Neck Carcinomas, a Phase II Study||Maisonneuve-Rosemont Hospital|No|Completed|June 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460471||19959|
NCT02429648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF|Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation|Timing of DCC in Patients Undergoing Pulmonary Vein Isolation Ablation (PVI) of Persistent/Permanent Atrial Fibrillation||The Cleveland Clinic|Yes|Completed|June 2009|March 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|176|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT02429648||22324|
NCT02459574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVATAR-AF|Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation|Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation|AVATAR-AF|Imperial College London|Yes|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|80 Years|No|||August 2015|October 27, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02459574||20028|
NCT02458716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081403|Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer|Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed With Metastatic Prostate Cancer||Rutgers, The State University of New Jersey|No|Recruiting|March 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|April 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458716||20094|
NCT02447341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-372|Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)|Multicenter Observational Study to Determine the Profile and Antithrombotic Management of Patients With Nonvalvular Atrial Fibrillation Attending Internal Medicine Departments in Spanish Hospitals (Perfilar Study)||Bristol-Myers Squibb|No|Active, not recruiting|March 2015|June 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with NVAF|March 2016|March 7, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02447341||20967|
NCT02441972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS2011051|Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics|Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics||Wuxi No. 4 People's Hospital|No|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02441972||21379|
NCT02456025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC 124|Topical Tacrolimus in Vernal Keratoconjunctivitis|Topical Tacrolimus in Vernal Keratoconjunctivitis||The Eye Center and The Eye Foundation for Research in Ophthalmology|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Years|18 Years|No|||November 2015|November 22, 2015|August 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02456025||20301|
NCT02456038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPPJEAP-01|Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)|A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Enrolling by invitation|August 2014|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||June 2015|June 2, 2015|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456038||20300|
NCT02445586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29282|Safety Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) in Indian Patients With Breast Cancer|A Phase IV, Multicenter, Open-Label, Single Arm Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) In First Line Treatment of Indian Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer||Hoffmann-La Roche||Recruiting|August 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445586||21102|
NCT02444676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 00269|Heart Failure STratification and OutcomeS|Heart Failure STratification and OutcomeS|HEFESTOS|Jordi Gol i Gurina Foundation|Yes|Recruiting|March 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|45 Years|N/A|No|Non-Probability Sample|Heart Failure patients included in the study will come from primary care setting. We        consider primary care, the health assistance provided in outpatients by a General        practitioner, or out of hours care in primary care setting.|January 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444676||21172|
NCT02454062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-114-102|A Trial of TAS-114 in Combination With S-1|A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors||Taiho Oncology, Inc.|No|Recruiting|March 2013|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02454062||20451|
NCT02454140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140103|Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer|Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer|SBRT|University of California, San Diego|Yes|Recruiting|June 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02454140||20445|
NCT02455180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50578.029.14|Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients|Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients||VU University Medical Center|No|Recruiting|March 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455180||20366|
NCT02444949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTGU1501|A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma|||China Three Gorges University, Yichang, China||Enrolling by invitation|June 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|70 Years|No|||March 2015|May 14, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444949||21151|
NCT02456415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNI-01|The Efficacy and Safety of Magnesium Alloy Screw as a Novel Bioabsorbable Material in Patients Due to Hand Fractures|A Prospective, Single Center, Single Group, Open-label Study to Evaluate the Efficacy and Safety of Magnesium Alloy Screw as a Novel Bioabsorbable Material in Patients Requiring Internal Fixation Due to Hand Fractures||U&I Corporation|Yes|Completed|July 2013|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2015|September 14, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456415||20271|
NCT02453698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020845|Stimulant Effects on Brain Activity|Stimulant Effects on Brain Activity During the Stop Signal Task||The Hospital for Sick Children|No|Completed|January 2011|March 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|19|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453698||20479|
NCT02663466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-005-PS|Off-midline Closure Errors as a Risk Factor for Recurrence Following Limberg Flap in Patients With Pilonidal Sinus|Importance of Erroneous Off-midline Closure as a Recurrence Factor in Limberg Flap Reconstruction in Sacrococcygeal Pilonidal Sinus: a Multicenter, Matched-case-control Study||Medical Park Gaziantep Hospital|Yes|Completed|January 2015|November 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|180|||Both|16 Years|N/A|No|Non-Probability Sample|patients with clinically confirmed recurrence of SPS following LF surgery (recurrent        group, RG) and patients who underwent same surgery from the January 2008 to July 2015 but        have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were        accepted eligible.|January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663466||4372|
NCT02570438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001020|Improving Surgical Safety of Seniors Through Preoperative Cognitive Screening|Improving Surgical Safety of Seniors Through Preoperative Cognitive Screening||Brigham and Women's Hospital|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients 65 years of age or older presenting to Massachusetts General Hospital (MGH) or        Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery        requiring hospital admission. Exclusion criteria will be planned ICU admission        postoperatively; history of stroke or brain tumor; uncorrected vision or hearing        impairment (unable to see pictures or read or hear instructions); limited use of the        dominant hand (limited ability to draw); and/or inability to speak, read or understand        English.|October 2015|October 6, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02570438||11516|
NCT02444429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.848|3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation|Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study|I4BiS|Hospices Civils de Lyon|Yes|Recruiting|August 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|346|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02444429||21191|
NCT02444442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/15|Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension|The Australian SHAM Controlled Clinical Trial of Renal DeNervation in Patients With Resistant Hypertension (AUSHAM-RDN-01)||Baker IDI Heart and Diabetes Institute|No|Not yet recruiting|June 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|85 Years|No|||May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444442||21190|
NCT02444663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109367|Validation of a Stress Device for the Knee|Validation of a Device for Performing Valgus and Varus Stress X-rays of the Knee||Oxford University Hospitals NHS Trust|No|Not yet recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|60|||Both|50 Years|N/A|No|||May 2015|May 11, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02444663||21173|
NCT02432040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS_PGH_2013_002|Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis|Atorvastatin as Adjunctive Therapy for Chronic Plaque Type Psoriasis Versus Betamethasone Valerate Alone:A Randomized, Double-Blind, Placebo-Controlled Trial||Philippine Dermatological Society|Yes|Completed|February 2013|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|65 Years|No|||October 2015|October 21, 2015|April 28, 2015||No||No|May 2, 2015|https://clinicaltrials.gov/show/NCT02432040||22142|
NCT02446366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-14-8|Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer That Was Removed by Surgery|Phase I Dose-Escalation Study of Hypofractionated SBRT for Adjuvant/Salvage Radiotherapy in Prostate Cancer||University of Southern California|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Male|18 Years|N/A|No|||November 2015|November 28, 2015|April 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446366||21042|
NCT02446691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205336|Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations|A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea||GlaxoSmithKline||Active, not recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|128|||Both|2 Months|24 Months|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446691||21017|
NCT02455453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411005|Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography|Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography||Washington University School of Medicine|Yes|Recruiting|June 2015|June 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455453||20345|
NCT02455466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0652|Altered PSA Test Due to Possible Suspected Heterophilic Antibodies|Altered PSA Test Due to Possible Suspected Heterophilic Antibodies||University of Zurich|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood serum of patients|Male|40 Years|90 Years|No|Non-Probability Sample|Male, where a PSA measurement is planned|December 2015|December 2, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02455466||20344|
NCT02450799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILQ245-P001|Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation|Corrected VA With Long-Term Follow-Up After AcrySof® IOL Implantation||Alcon Research|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|90|||Both|N/A|N/A|No|||November 2015|November 25, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450799||20702|
NCT02449837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1408|Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy|Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|210|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing radiation treatments at Lineberger Comprehensive Cancer Center at UNC        Hospitals for one of six cancer types: head and neck, cervical, rectal, lung, prostate,        and oligometastatic cancer with any solid tumor histology.|October 2015|October 9, 2015|April 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02449837||20776|
NCT02461303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15030141|Fertility Assessment in Patients With Klinefelter Syndrome|Non-Invasive Methods to Maximize Fertility in Peri-Pubertal Patients With Klinefelter Syndrome||University of Pittsburgh|Yes|Recruiting|November 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|60|Samples With DNA|Urine and semen samples|Male|12 Years|25 Years|No|Non-Probability Sample|Adolescent and young adults males who are proven to have Klinefelter Syndrome based on        prior chromosome analysis (47,XYY) and present in the Division of Pediatric Endocrinology        at the Children's Hospital of Pittsburgh of UPMC.|December 2015|December 4, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02461303||19895|
NCT02461316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25066|Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia|Open, Non-Interventional, Multicentre Trial of Rituximab in Combination With FC for the First-Line Therapy of Patients With Chronic Lymphocytic Leukaemia||Hoffmann-La Roche||Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Previously untreated patients with Chronic Lymphocytic Leukemia (CLL)|March 2016|March 1, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02461316||19894|
NCT02441452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InCor Heart Institute|Functional Capacity of Exercise and Lung Function in Patients Submitted Early Rehabilitation|Functional Capacity of Exercise and Lung Function in Patients Submitted to Early Rehabilitation Program After Nuss Procedure: a Randomized Controlled Trial||Instituto do Coracao|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|14 Years|30 Years|No|||May 2015|May 7, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02441452||21419|
NCT02441465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28395|Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies|A Phase 1, Open-Label, Absolute Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies||Hoffmann-La Roche||Recruiting|August 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441465||21418|
NCT02456688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARXB00434L|Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency|An Open-label, Single-dose Study to Assess the Pharmacokinetics of Imrecoxib in Subjects With Impaired Hepatic Function||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|January 2015|July 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|May 26, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02456688||20250|
NCT02460393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sss07|A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects|A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects||Shenyang Sunshine Pharmaceutical Co., LTD.|No|Recruiting|May 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|May 29, 2015|January 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460393||19965|
NCT02461329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FN-Brno|Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy|Comparison of the Effects of Gelatine (Gelofusine ® B. Braun) Versus Crystalloid Solution (Ringerfundin ® B. Braun) for Volume Therapy on Coagulation, Thrombocyte Function and Thrombelastometry (ROTEM ®), in Elective Hip Replacement Surgery|Gelaring|Brno University Hospital|Yes|Not yet recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|85 Years|No|||June 2015|June 2, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02461329||19893|
NCT02460588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 140908|Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis|Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial|EXAFIP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02460588||19950|
NCT02456818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTAIN|Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards|A Hospital-based Cohort Study in German Hematological / Oncological Wards to Assess the Effect of Contact Isolation on Nosocomial Colonization With ESBL-producing Escherichia Coli (CONTAIN Study)|CONTAIN|University of Cologne|No|Enrolling by invitation|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2264|Samples With DNA|Rectal swabs or stool samples|Both|N/A|N/A|No|Non-Probability Sample|All admitted patients on participating hematological and oncological wards in hospitals        with a non-outbreak setting for ESBL-EC.|February 2016|February 5, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02456818||20240|
NCT02456831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AE58|Soy Formula Feedings in Healthy, Term Infants|Efficacy of Soy Formula Feedings in Healthy, Term Infants||Abbott Nutrition|No|Completed|December 1992|June 1994|Actual|June 1994|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|115|||Both|N/A|9 Weeks|No|||May 2015|May 28, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456831||20239|
NCT02446938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY-2015-CCM-002|Position of Esophageal Balloon in Patients With Mechanical Ventilation|A Simple Method for Confirming the Optimal Position of Esophageal Balloon in Patients With Mechanical Ventilation||Capital Medical University|Yes|Completed|May 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Probability Sample|Adult patients with mechanical ventilation.|June 2015|October 9, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446938||20998|
NCT02452944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIRB2014-337|Comparison of Nerve Stimulating Approach and Interfascial Injection Approach During Sono-guided Obturator Nerve Block|Comparison of Nerve Stimulating Approach and Interfascial Injection Approach During Sono-guided Obturator Nerve Block in Transurethral Resection of Bladder Tumors Under Spinal Anesthesia||Gachon University Gil Medical Center|No|Completed|December 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|62|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 7, 2015||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT02452944||20537|We checked the success or fail with nerve stimulator only before beginning the surgery. Therefore, the possibility of incomplete anterior or posterior branch block due to the investigator’s miss still remained, which is a limitation of this study.
NCT02461407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTER0503|Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Gastric Cancer(ALTER0503)||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|378|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461407||19887|
NCT02440516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_04_29|Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis|Standardized Comprehensive Two-month Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis: a Randomized-controlled Trial|"MS-Fit"|University Hospital Inselspital, Berne|Yes|Not yet recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|65 Years|No|||May 2015|May 6, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02440516||21491|
NCT02451657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29589|Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome|A Multicenter, Longitudinal, Non-drug Study to Assess the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome||Hoffmann-La Roche||Active, not recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|6 Years|11 Years|No|Non-Probability Sample|Male and female children, 6 to 11 years of age inclusive, with diagnosis of Down syndrome.|March 2016|March 1, 2016|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451657||20636|
NCT02451917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDONEFRO|Glargine Versus NPH in Patients With Chronic Kidney Disease|Subcutaneous Insulin Glargine Versus NPH Insulin in Patients With Chronic Kidney Disease Stages III and IV: Randomized Controlled Trial.||University of Sao Paulo General Hospital|Yes|Recruiting|December 2013|December 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||September 2014|May 25, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02451917||20616|
NCT02454894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150206|Optimization Lumbar Puncture In Children|Optimization Lumbar Puncture In Children|OLPIC|Beijing Children's Hospital|No|Withdrawn|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|0|||Both|1 Month|18 Years|No|||May 2015|October 28, 2015|March 13, 2015||No|Due to the reason that not all participants agree to have anesthesia and postoperative    management at the same time|No||https://clinicaltrials.gov/show/NCT02454894||20387|
NCT02457351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17616|Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study|An Open-label, Non-randomized, Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Roniciclib in Patients With Advanced Solid Tumors||Bayer|No|Recruiting|July 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02457351||20199|
NCT02457364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0372|Non-Op Management of Ventral Hernia Patients|Prospective Observational Trial of Initial Non-operative Management of Ventral Hernia Repair||The University of Texas Health Science Center, Houston|No|Recruiting|July 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|143|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a ventral hernia who are undergoing non-operative management of their        hernia at LBJ General Hospital.|July 2015|July 22, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02457364||20198|
NCT02431260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 54329-101|An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies||Incyte Corporation|No|Recruiting|May 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02431260||22202|
NCT02455492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15_034R|Factors Associated With Perioperative Outcomes in Non-emergency Surgery|An Epidemiological Investigation Into the Association Between Recent Stroke, Acute Coronary Syndrome or Pneumonia and Adverse Perioperative Outcomes Following Elective Non-cardiac and Cardiac Surgery||University of Nottingham|No|Completed|January 2004|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|266436|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients within the Clinical Practice Research Datalink who have undergone a        non-cardiac or cardiac elective procedure between 1/01/2004 and 31/12/2013.|May 2015|May 27, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02455492||20342|
NCT02450630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000004199|Assessing the Effect of Strengthening Referral of Sick Children From the Private Health Sector and Its Impact on Referral Uptake in Uganda.|Strengthening Referral of Sick Children Form the Private Health Sector||Ministry of Health, Uganda|Yes|Not yet recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|8910|||Both|N/A|5 Years|No|||May 2015|May 18, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02450630||20715|
NCT02450643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.24.CLI|Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula|Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula||Nestlé|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|83|||Both|2 Months|4 Years|No|||April 2015|October 6, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02450643||20714|
NCT02450175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOTPCMP|Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls|Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls||Sinai Hospital of Baltimore|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450175||20750|
NCT02431533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-PBI-2012|The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome|The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome: A Randomized, Double-Blind Placebo Controlled Clinical Trial||Pharmabiotix Inc|No|Recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02431533||22181|
NCT02452554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1522|Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma|A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma||Children's Oncology Group|Yes|Recruiting|October 2015|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|12 Months|30 Years|No|||March 2016|March 2, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452554||20567|
NCT02447770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311497-I|Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1|Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1||University of California, Davis|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||July 2014|May 18, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02447770||20935|
NCT02448641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-STR02|Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke|A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke|ACTIsSIMA|SanBio, Inc.|Yes|Recruiting|January 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448641||20868|
NCT02448901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2213|Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography|Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography||LifeBridge Health|No|Recruiting|April 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers (n=20) Heart Failure Patients (n=20)|May 2015|May 15, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02448901||20848|
NCT02436278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0015|The Predictive Ability of 4MGS in IPF|Does 4 Metre Gait Speed (4MGS) Predict Mortality and Non-elective Hospitalisation in Patients With Idiopathic Pulmonary Fibrosis (IPF)?|IPFMORT|Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|||Both|18 Years|99 Years|No|Probability Sample|Patients diagnosed with IPF according to NICE guidelines|October 2015|October 27, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02436278||21816|
NCT02455999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL1001_III|Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain|||Sylentis, S.A.||Recruiting|June 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455999||20303|
NCT02444741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1020|MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|Yes|Recruiting|September 2015|||September 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|104|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444741||21167|
NCT02451176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-1571|Biologic Mesh Versus Synthetic Mesh in Repair of Ventral Hernias|A Prospective Randomized Trial of Biologic Mesh Versus Synthetic Mesh for the Repair of Complex Ventral Hernias|ventral hernia|The Cleveland Clinic|Yes|Enrolling by invitation|April 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|21 Years|N/A|No|||May 2015|February 2, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451176||20673|
NCT02451189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-ESTER STUDY|RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis||PRO-ESTER|Scottish Universities Environmental Research Centre|No|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|23|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451189||20672|
NCT02457650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504002|T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies|Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1||Shenzhen Second People's Hospital|No|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|1 Year|N/A|No|||May 2015|May 27, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02457650||20176|
NCT02445625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBILI-VB-2015-01|BCI (Brain Computer Interface) Intervention in Autism|An Interventional Study to Improve Social Attention in Autistic Spectrum Disorder (ASD): A Brain Computer Interface (BCI) Approach|BCIAUT|University of Coimbra|No|Enrolling by invitation|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|16 Years|30 Years|No|||May 2015|May 14, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02445625||21099|
NCT02433301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2014-076|PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy|PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer||Rikshospitalet University Hospital||Recruiting|April 2015|June 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|None Retained|Four biopsies from each patient harvested from the Gastroesophageal junction cancer|Both|18 Years|N/A|No|Non-Probability Sample|All patients referred to the Department of Surgical Gastroenterology, Rigshospitalet, with        histologically verified adenocarcinoma of the Gastroesophageal junction and assessed as        operable. Informed consent is required from each patient|October 2015|October 27, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02433301||22045|
NCT02433314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-SSE-302|An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus|An Open Label, Expanded Access Protocol to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus||Sage Therapeutics||Available||||||N/A|Expanded Access|N/A|||||||Both|2 Years|N/A||||August 2015|August 11, 2015|April 29, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02433314||22044|
NCT02433327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEWS|Paediatric Early Warning System - A Danish Multi-center Study|Paediatric Early Warning System - A Danish Multi-center Study||Aarhus University Hospital|No|Recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8000|||Both|N/A|15 Years|No|||April 2015|April 29, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02433327||22043|
NCT02457065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00028495|Skin Care Behaviors Among Melanoma Survivors and Their Families|Skin Care Behaviors Among Melanoma Survivors and Their Families||Dartmouth-Hitchcock Medical Center||Recruiting|March 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|May 28, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457065||20221|
NCT02457195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRP-592|Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting|Preoperative Use of Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients With History of Severe PONV - Open Label, Prospective, Pilot Study|GTPPONV|Milton S. Hershey Medical Center|Yes|Not yet recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|89 Years|No|||May 2015|May 26, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457195||20211|
NCT02452099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COI-DMSO-01|Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.|Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells.|DMSOconc3|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452099||20602|
NCT02455674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH003|Using Mean Ages on Clothing Size Labels in Revised Advanced Pediatric Life Support Formulas for Weight Estimation|Weight Estimation of A Child With Unknown Age and Height: Using Mean Ages on Clothing Size Labels in Revised APLS Formulas for Weight Estimation. A Prospective Cross-Sectional Study||Antalya Training and Research Hospital|Yes|Completed|December 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1094|||Both|1 Year|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Data of children, aged between 1 to 12 years, were consecutively collected. Patients were        divided into two groups as under the age of 6 (age <6) and over 6 years of age (age≥6).|May 2015|May 25, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455674||20328|
NCT02442765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-301|Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type||Avanir Pharmaceuticals|Yes|Recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|380|||Both|50 Years|90 Years|No|||December 2015|December 18, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442765||21318|
NCT02446925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surefire-LCC 1.0|Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study|Surefire Catheter Versus Standard End-hole Microcatheter in Yttrium-90 Distribution and Tissue Penetration: A Pilot Study||Wright State University|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446925||20999|
NCT02452385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM082-OPH-101|Phase 1 Study of CM082 in Patients With Wet-AMD|Phase 1 Study of CM082 in Patients With Wet-AMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy||AnewPharma|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|50 Years|N/A|No|||January 2016|January 2, 2016|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02452385||20580|
NCT02452398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0115|Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types VI Using Intense Pulsed Light|Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types V-VI Using Intense Pulsed Light||Venus Concept|Yes|Active, not recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 10, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452398||20579|
NCT02452411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI010|Efficacy of Two Ways of Applying Homework Assignments in the Treatment of Adjustment Disorders|Differential Efficacy of Two Ways of Applying Homework Assignments in the Treatment of Adjustment Disorders: Application Supported by Information and Communication Technologies Versus Traditional Application||Universitat Jaume I|No|Active, not recruiting|January 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452411||20578|
NCT02455908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL-2 off label|IL-2 for Multi Drug Resistant Nephrotic Syndrome|Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome||Istituto Giannina Gaslini|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|18 Years|No|||May 2015|May 27, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02455908||20310|
NCT02441218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-16257-063|Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study||SHIFT|Servier|Yes|Completed|September 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6505|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 5, 2015||No||No|May 12, 2015|https://clinicaltrials.gov/show/NCT02441218||21437|The section Other Adverse Events (Not including serious) has been completed by the sponsor to include only the Non Serious Adverse Events emergent on treatment during the study.
NCT02441231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT 022B|Probiotic Visbiome for Inflammation and Translocation in HIV II|Probiotic Visbiome for Inflammation and Translocation in HIV II (PROOV IT II)|PROOV IT II|University Health Network, Toronto|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Male|19 Years|N/A|No|||March 2016|March 10, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02441231||21436|
NCT02459392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75/EK/15|EuroPainClinics® Study II (Prospective Trial)|EuroPainClinics® Study II (Prospective Randomized Double Blinded Trial)|EPCSII|Europainclinics z.ú.|Yes|Recruiting|May 2015|November 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02459392||20042|
NCT02448004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107301|Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants|A Phase 1, Open-label Study to Characterize the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Subjects||Janssen Cilag N.V./S.A.|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|May 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02448004||20917|
NCT02452632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-2009|A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin|A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin||Astellas Pharma Inc|No|Recruiting|July 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|19 Years|74 Years|No|||September 2015|September 29, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02452632||20561|
NCT02452918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-ORI-14-03|A Study to Evaluate the Safety of a Single IV Dose of Orbactiv (Oritavancin) in Subjects on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)||The Medicines Company|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452918||20539|
NCT02450968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK15-2015|Altitude Related Illness In Patients With Respiratory Disease|Dexamethasone for Prophylaxis of Acute Mountain Sickness in Patients With Chronic Obstructive Pulmonary Disease Travelling to Altitude||University of Zurich|No|Recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|20 Years|75 Years|No|||December 2015|December 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450968||20689|
NCT02431026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEM-C|Temperature Evaluation by MRI Thermometry During Cervical Cooling|Temperature Evaluation by MRI Thermometry During Cervical Cooling|TEM-C|University of Vermont||Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431026||22220|
NCT02448550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-RRC-CE1|Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial|Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina, and Non-ST Segment Elevation Myocardial Infarction|CALIFORNIA|Kaiser Permanente|Yes|Recruiting|May 2015|November 2023|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|5270|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448550||20875|
NCT02448784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART09T|Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).|Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.||Eisai Inc.|No|Recruiting|April 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Naive participants diagnosed as Dementia with Lewy bodies and administrated Aricept        (donepezil hydrochloride)|November 2015|November 4, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448784||20857|
NCT02456675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40093-201|INCB040093 and INCB040093 Combined With INCB039110 in Relapsed/Refractory Hodgkin Lymphoma|A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With INCB039110 in Subjects With Relapsed or Refractory Hodgkin Lymphoma||Incyte Corporation|Yes|Active, not recruiting|June 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456675||20251|
NCT02457884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12131601|Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema|Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema (DMO)- Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Recruiting|May 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|152|||Both|21 Years|70 Years|No|||February 2016|February 17, 2016|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02457884||20158|
NCT02434445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW12342|Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients|Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients||The University of Hong Kong|Yes|Recruiting|July 2012|July 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|patient's serum and urine samples|Both|18 Years|90 Years|No|Probability Sample|Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation|December 2015|December 2, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434445||21957|
NCT02448797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV-61|Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation|Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)|EVIDENCE|Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|May 2015|November 2021|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|70 Years|No|||May 2015|May 21, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448797||20856|
NCT02448303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-007|Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer|A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma|KEYNOTE166|Acerta Pharma BV|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448303||20894|
NCT02451579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT-2015-01|A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy|A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy||Goldman, Butterwick, Fitzpatrick and Groff|No|Recruiting|February 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451579||20642|
NCT02442999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020545|The SNORES Randomized Clinical Trial|Sleep Apnea in Non-ovulating REI Patients: The SNORES Randomized Clinical Trial|SNORES|University of South Florida|No|Recruiting|January 2016|August 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02442999||21300|
NCT02444286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version No. 1.0|The RESHAPE-HF1-FU Study|Observational Study of Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation - Follow Up of the Former Participants in the RESHAPE-HF Trial (Abbott Vascular).||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|42|||Both|18 Years|N/A|No|Non-Probability Sample|The RESHAPE- HF1-FU Study is an observational, multi-center clinical evaluation        (follow-up) of the MitraClip device plus optimal standard of care therapy (subjects with        Device) compared to optimal standard of care therapy alone (other subjects), of former        participants in the RESHAPE-HF Trial (Abbott Vascular).|May 2015|May 13, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444286||21202|
NCT02450149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-002|Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors|||Samsung Medical Center|No|Not yet recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450149||20752|
NCT02438215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRX4204-001|Study of IRX4204 for Treatment of Early Parkinson's Disease|An Open-Label, Single Site Study Using [123I]β-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects||Io Therapeutics|Yes|Completed|August 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|August 7, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02438215||21667|
NCT02456363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS09128|Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis|Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry Project||Chung Shan Medical University|Yes|Recruiting|November 2009|December 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02456363||20275|
NCT02457091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSS IL-0010|Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS|Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS|GetFit|University of Illinois at Urbana-Champaign|Yes|Completed|October 2013|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|54 Years|No|||December 2015|December 1, 2015|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02457091||20219|
NCT02459587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-103|Crisis Line Facilitation|Facilitating Use of the Veterans Crisis Line in High-Risk Patients|CLF|VA Office of Research and Development|No|Not yet recruiting|January 2016|April 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|99 Years|No|||November 2015|November 3, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02459587||20027|
NCT02459600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR026014CTIL|Comparison of Refraction Measurments in Children Under General Anesthesia, With and Without Cycloplegic Drops|Methodes of Meausring Refraction in Children Under General Anesthesia||Soroka University Medical Center|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|1 Year|12 Years|No|||May 2015|June 1, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02459600||20026|
NCT02438410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005723|Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis|Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis||Mayo Clinic|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Stool and blood laboratory data such as CBC with differential, creatinine, TNF levels,      albumin, fecal calprotectin, ESR, CRP, infliximab and antibodies to infliximab levels will      be obtained.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients must be scheduled to receive clinically indicated infliximab at the discretion of        their treating physician during an acute hospitalization with a flare of moderate to        severe UC. These will be inpatients at Mayo Clinic Rochester campus or be admitted in Mayo        Clinic Health Systems. Endoscopic findings will be noted and those deemed to have moderate        to severe disease activity based on the Mayo Scoring System for Assessment of Ulcerative        Colitis Activity will be considered.|January 2016|January 8, 2016|April 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02438410||21652|
NCT02446223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICATO-2013-01|Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%|A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015%||Goldman, Butterwick, Fitzpatrick and Groff||Recruiting|January 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446223||21053|
NCT02446236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 5444|Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)|Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)||Hackensack University Medical Center|Yes|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446236||21052|
NCT02457247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calcichew-4001|Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation|A Randomized, Open-Label, 2-Way Cross-Over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Supplementation||Takeda|No|Completed|June 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|276|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457247||20207|
NCT02575157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBHADH1|Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates|Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates||National Bone Health Alliance|No|Recruiting|June 2015|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|120|||Both|50 Years|N/A|No|||October 2015|October 13, 2015|October 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575157||11153|
NCT02448953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKTRDP-2015BAI12B08-03|Two-field Versus Three-field Lymphadenectomy in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement|Comparison of Lymph Node Dissection Results and Prognosis in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement: Two-field Versus Three-field Lymph Node Dissection||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2015|December 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|786|||Both|18 Years|75 Years|No|||May 2015|May 17, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02448953||20844|
NCT02436525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005OR.|Microbial and Periodontal Changes Associated With Conventional Versus Self Ligating Brackets|Faculty of Dental Medicine, Boys, Cairo Al-Azhar University||Al-Azhar University|No|Recruiting|March 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|45|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||February 2015|May 5, 2015|April 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436525||21797|
NCT02444754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01215|Attitudes and Knowledge Regarding Clinical Trials in Underserved Populations Receiving Care at the Comprehensive Cancer Center of Wake Forest University|Patient Experience Protocol (PEP): A Pilot Study of Underserved Populations at the Comprehensive Cancer Center of Wake Forest University (CCCWFU)||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|January 2016|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|315|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have received a diagnosis of a malignant cancer belonging to one of the        minority/underserved populations.|January 2016|January 21, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444754||21166|
NCT02444767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV5-006|Bimatoprost Ocular Insert Pharmacokinetic Study|A PK Study to Assess the Relative Systemic Exposure to Bimatoprost and Bimatoprost Acid After Administration of a Single 13 mg Bimatoprost Ocular Insert for 1 Week in Medically Stable Adult Subjects With or Without Open-Angle Glaucoma or Ocular Hypertension||ForSight Vision5, Inc.|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02444767||21165|
NCT02451228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0067|Indomethacin PK and PD Therapy in Pregnancy|Pharmacokinetic and Pharmacogenomic Approach to Indomethacin Therapy in Pregnancy||The University of Texas Medical Branch, Galveston|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Maternal Venous Blood for serum Maternal Blood for DNA (for CYP2C9) Maternal Urine Cord      Blood (Umbilical Vein and Artery) for serum|Female|18 Years|N/A|No|Non-Probability Sample|Study participants include 300 pregnant women between 18-32 weeks of gestation admitted to        the Labor and Delivery unit at a single site (UTMB) at risk of PTB (sPTL or shortened        cervix with or without funneling membranes) to whom indomethacin is prescribed.|December 2015|December 1, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451228||20669|
NCT02451241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sleep01|The Role of Acupuncture for the Treatment of Obstructive Sleep Apnea in Patients With Hypertension|The Role of Acupuncture for the Treatment of Obstructive Sleep Apnea in Patients With Hypertension||University of Pernambuco||Recruiting|February 2015|March 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|44|||Both|30 Years|65 Years|No|||August 2015|August 11, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451241||20668|
NCT02458495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DK087894|The Diabetes Medication Adherence Promotion Intervention Trial|Leveraging Patient Portals to Improve Medication Adherence in Type 2 Diabetes|Diabetes MAP|Vanderbilt University|Yes|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458495||20111|
NCT02454374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP0159|Joint Loading vs Normal Physiotherapy Care in Degenerative Knees (V1)|Joint Loading vs Normal Physiotherapy Care in Degenerative Knees (V1)||Leeds Comunity Healthcare NHS Trust|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|45 Years|N/A|No|||May 2015|June 2, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02454374||20427|
NCT02452437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELLHDM-001|Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis|Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease|OCKD|Emerio & Lourdes Linares Research and Education Center|No|Recruiting|May 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452437||20576|
NCT02452450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL1307|Ibuprofen and Paracetamol Pharmacokinetic Study|||Reckitt Benckiser Healthcare (UK) Limited|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|43|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452450||20575|
NCT02430480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150124|Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer|Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Male|18 Years|99 Years|No|||April 2015|March 16, 2016|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02430480||22261|
NCT02446847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA-867|3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption|A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects||Rockefeller University|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446847||21005|
NCT02446860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4151|A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)|A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)|ADAPTeR|Royal Marsden NHS Foundation Trust|Yes|Recruiting|April 2015|May 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02446860||21004|
NCT02446639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0056|Assessment the Dosage of Troponin T Hypersensitive Dosage in a Patient Population Hemodialysis and Peritoneal Dialysis|Assessment the Dosage of Troponin T Hypersensitive Dosage in a Patient Population Hemodialysis and Peritoneal Dialysis (ECHOTnT)|ECHOTnT|Nantes University Hospital|No|Recruiting|June 2014|July 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing haemodialysis or peritoneal dialysis for more than 3 months|May 2015|May 13, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02446639||21021|
NCT02434068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11851|Assessment of Flexible Ureteroscopy Residual Fragments|Assessment of Flexible Ureteroscopy Residual Fragments||University of Sao Paulo General Hospital|No|Enrolling by invitation|March 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|115|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic renal calculi|January 2015|May 4, 2015|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02434068||21986|
NCT02434081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP 6-14 NICOLAS|NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC|A Feasibility Trial Evaluating Anti-PD1 Nivolumab Consolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC|NICOLAS|European Thoracic Oncology Platform|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434081||21985|
NCT02447159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT for PMTCT|Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria|Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria||University of California, San Francisco|No|Recruiting|August 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|550|||Female|15 Years|45 Years|No|||September 2015|September 29, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02447159||20981|
NCT02450890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-2PN012-301|Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD||Orient Pharma Co., Ltd.|Yes|Recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|6 Years|18 Years|No|||December 2015|December 29, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450890||20695|
NCT02450903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A1201|LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.|A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib||Novartis|No|Recruiting|August 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02450903||20694|
NCT02461420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00013300|Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome|Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome||Children's Hospital Boston|Yes|Recruiting|May 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Blood draw for future correlative studies in the PMS Biorepository of the Developmental      Synaptopathies Consortium|Both|3 Years|21 Years|No|Non-Probability Sample|90 subjects with PMS will be enrolled across the 4 sites for this study|February 2016|February 18, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02461420||19886|
NCT02441530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BezmialemVU|Effectiveness of Vitamin D in Primary Dysmenorrhoea|Vitamin D in the Treatment of Primary Dysmenorrhoea: A Prospective Randomised Controlled Trial||Bezmialem Vakif University|No|Completed|November 2012|October 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|143|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441530||21413|
NCT02441543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-01/2015|Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus|Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus||Istituto Clinico Humanitas|No|Recruiting|April 2015|May 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Metastatic tumor patients treated with Everolimus|May 2015|May 7, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02441543||21412|
NCT02454634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2013-0216|Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas|Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)|NOA-16|National Center for Tumor Diseases, Heidelberg|Yes|Recruiting|June 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||May 2015|October 22, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02454634||20407|
NCT02454790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP OES|Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer|Standard Follow-up Program (SFP) for Esophageal Cancer Patients Treated With Radiotherapy or Chemoradiation||University Medical Center Groningen|No|Recruiting|September 2014|January 2028|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with esophageal cancer receiving a radiotherapy dose > 40 Gy|March 2016|March 15, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454790|5 Years|20395|
NCT02460445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI14/00649|Phlebotomy and Polycystic Ovary Syndrome|Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||June 2015|June 1, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460445||19961|
NCT02448082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZeenatMia201001496|The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis|The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis||University of Johannesburg|Yes|Active, not recruiting|October 2014|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02448082||20911|
NCT02448342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-00100-P|Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients|Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study|SMILE™|Sensible Medical Innovations Ltd.|Yes|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|380|||Both|21 Years|N/A|No|||March 2016|March 24, 2016|May 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448342||20891|
NCT02435706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1840|Esthetic Outcomes of Single Immediate Implant Placement|Esthetic Outcomes of Single Immediate Implant Placement With Immediate Restoration Performed With Two Surgical Techniques||Columbia University|No|Active, not recruiting|December 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02435706||21860|
NCT02444260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP342,12/13|A Trial of Local Anaesthesia Versus Local Anaesthesia and Conscious Sedation for Hernioplasty|Improving Patient Outcomes With Inguinal Hernioplasty - a Randomized Controlled Trial of Local Anaesthesia Versus Local Anaesthesia and Conscious Sedation||The University of The West Indies|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||March 2015|May 13, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02444260||21204|
NCT02454920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150332|Measurement of the Distance Between the Limbus and Insertion of Extraocular Muscles Using Anterior Segment Optical Coherence Tomography|Measurement of the Distance Between the Limbus and Insertion of Extraocular Muscles Using Anterior Segment Optical Coherence Tomography||Bascom Palmer Eye Institute|Yes|Completed|May 2015|January 2016|Actual|December 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients age greater then 18 years undergoing a strabismus evaluation at the Bascom        Palmer Eye Institute|January 2016|January 11, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454920|12 Months|20385|
NCT02455219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503M65881|DatScan With Prototype Collimator|Investigating the Use of Siemens Prototype UHRSZ Collimator for Imaging DatScan SPECT/CT Imaging||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|50 Years|75 Years|No|Non-Probability Sample|Patients referred to Nuclear Medicine for a clinically indicated DatScan for the diagnosis        of Parkinson's disease|December 2015|December 3, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02455219||20363|
NCT02435992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-3101|Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis||Celgene|Yes|Recruiting|May 2015|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435992||21838|
NCT02436005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-16|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02436005||21837|
NCT02455739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEYNEP KAMIL|Gum Chewing and Postoperative Intestinal Function After Gynecolgic Operations|Effect of Gum Chewing on Intestinal Functions After Gynecologic Operations||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Recruiting|March 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455739||20323|
NCT02455752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTME-200315|Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.|Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.|LE-TME|Mansoura University|Yes|Completed|March 2015|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||July 2015|July 16, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455752||20322|
NCT02451735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16723|Genetic Counseling for Breast Cancer Survivors (GC for BC)|Genetic Counseling for Breast Cancer Survivors (GC for BC)||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|169|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451735||20630|
NCT02453789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2591|A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection|A Randomized Double-blind, Placebo-controlled Cross-over Study of Inhaled Alginate Oligosaccharide (OligoG) for 28 Days in Subjects With Cystic Fibrosis Using Aztreonam Due to Chronic Colonization With Burkholderia Spp.|SMR-2591|AlgiPharma AS|Yes|Active, not recruiting|February 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02453789||20472|
NCT02460263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|The EvAluation of TaBlo In-CLinic and In-HOme|A Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the Tablo Hemodialysis System In-Center and In-Home by Subjects With End Stage Renal Disease (ESRD) Who Are on Stable Dialysis Regimens|TABLO|Outset Medical||Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2015|June 2, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460263||19975|
NCT02441283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-576|A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530|A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Enrolling by invitation|June 2015|June 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||January 2016|January 23, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441283||21432|
NCT02441296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-152-31M|Carbohydrate and Metabolism: a Pilot Study|Postprandial Serum Responses to Various Infant Formulas and Breast Milk in Infants- a Pilot Study||Umeå University|No|Active, not recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Both|3 Months|3 Months|Accepts Healthy Volunteers|||May 2015|February 12, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02441296||21431|
NCT02445014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-002058|Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule|Pilot Study for Imaging of Barrett's Esophagus Using an Spectrally Encoded Confocal Microscopy Tethered Endoscopic Capsule|SECM|Massachusetts General Hospital|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02445014||21146|
NCT02455375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-14-0063|Diagnostic of Puumala Virus Infection in France|Puumala Hantavirus Infection in France: Evaluation of Commercial Assays for the Detection of Antibodies Against This Virus and the Use of Urine Samples for the Molecular Detection of This Infection|HANTADIAG|Centre Hospitalier de Charleville-Mézières|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Urine Plasma Serum|Both|18 Years|75 Years|No|Non-Probability Sample|Patients hospitalized for suspected PUUV infection|January 2016|January 27, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455375||20351|
NCT02450188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-AOUC-2014-02|Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)|An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)|STEDOV|University of Florence|No|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|N/A|No|||May 2015|May 20, 2015|December 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450188||20749|
NCT02441101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409760|Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)|Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure, a Pilot Clinical Trial (The SPARK Trial)|SPARK|University of Iowa|Yes|Enrolling by invitation|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441101||21446|
NCT02447497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-013509|In Vivo Patient Preoperative Skin Prep Persistence|Assessment of Antimicrobial Persistence of 3M CHG/IPA Preoperative Skin Preparation Against Resident Flora on the Abdominal and Inguinal Regions||3M|No|Completed|March 2015|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447497||20956|
NCT02447731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sound Energy|The Effects of Sound Energy on Pulmonary Gas Exchange|The Effects of Sound Energy on Pulmonary Gas Exchange||Loma Linda University|Yes|Suspended|July 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|21 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young healthy adults of any gender.|February 2016|February 9, 2016|February 2, 2015|Yes|Yes|Need to find qualified study personnel, need to finalize protocol|No||https://clinicaltrials.gov/show/NCT02447731||20938|
NCT02457130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0162|Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)|Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study|TICS-DM|Spanish Society of Cardiology|No|Recruiting|April 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||May 2015|May 27, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457130||20216|
NCT02458235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation|A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation||University of California, San Francisco|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|N/A|29 Years|No|||June 2015|June 23, 2015|January 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458235||20131|
NCT02443792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicirc004|Unicirc vs Open Surgical Circumcision|Adult Male Circumcision With Unicirc Under Topical Anesthetic vs Open Surgical Circumcision: a Randomized Controlled Trial|Unicirc004|Simunye Primary Health Care|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|75|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 13, 2015|April 10, 2015||No||No|October 29, 2015|https://clinicaltrials.gov/show/NCT02443792||21240|
NCT02443805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL75.14|Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis||Stallergenes|Yes|Recruiting|September 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|990|||Both|12 Years|65 Years|No|||December 2015|December 14, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443805||21239|
NCT02447198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0216|Cannabidiol (CBD) and Pediatric Epilepsy|Cannabidiol (CBD) and Pediatric Epilepsy||University of Colorado, Denver|No|Recruiting|June 2015|||July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood samples will be drawn up to 6 times. It will be centrifuged to collect the plasma. The      plasma will be used to obtain concentration of cannabinols and anticonvulsant medications in      order to perform pharmacokinetic calculations.      All urine output for the first 8 hours after initial CBD dose will be collected.|Both|31 Days|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit children and their parents who are currently using or plan to use CBD for        their seizure disorder.|February 2016|February 29, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02447198||20978|
NCT02457286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 13-204|Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study|Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study||Northwell Health|No|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02457286||20204|
NCT02444351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0169|Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis|||Yonsei University|No|Recruiting|April 2015|January 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||May 2015|May 11, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02444351||21197|
NCT02458326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37052114.3.0000.5208|Aerobic Training Effect on the Improvement of Pain Perception in Patients With Fibromyalgia and Migraine|Aerobic Training Effect on the Improvement of Pain Perception in Patients With Fibromyalgia and Migraine: a Randomized Clinical Trial||Universidade Federal de Pernambuco|No|Recruiting|April 2015|September 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|30 Years|55 Years|No|||May 2015|May 27, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458326||20124|
NCT02458339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0035|Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors|Phase I Study of Methotrexate Infusion Into the Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors||The University of Texas Health Science Center, Houston|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|21 Years|No|||December 2015|December 18, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458339||20123|
NCT02442882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00018178|The Acute Effect of Boxing on Balance, Neuropsychological, and Visual Functions|The Acute Effect of Boxing on Balance, Neuropsychological, and Visual Functions||Children's Hospital Boston|No|Not yet recruiting|July 2016|July 2020|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from those who are participating at a boxing tournament.|January 2016|January 26, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02442882||21309|
NCT02448251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC00102014-101|Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer|A Phase I/II, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients With Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)||ACEA Biosciences, Inc.|No|Recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448251||20898|
NCT02459834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|allulose2015|The Fructose and Allulose Catalytic Effects (FACE) Study|An Acute Randomized Dose-finding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Carbohydrate Metabolism: The Fructose and Allulose Catalytic Effects (FACE) Study||University of Toronto||Not yet recruiting|September 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|September 21, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459834||20008|
NCT02456194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL007|Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial|||Nova Scotia Health Authority|No|Recruiting|September 2015|||August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||January 2016|January 26, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456194||20288|
NCT02456207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT400NHL2|A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma|A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma||Sinocelltech Ltd.|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||May 2014|May 27, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02456207||20287|
NCT02435199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMA401-011|Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy|A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy||Spinifex Pharmaceuticals Pty Ltd|No|Withdrawn|June 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435199||21899|
NCT02435212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670F2202|Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload|A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload||Novartis|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|17 Years|No|||October 2015|October 5, 2015|March 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435212||21898|
NCT02452580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vestreviken -1403001|The Norwegian Family Centered Care Study|Impact of Family Centered Care on Preterm Infants and Their Parents||Vestre Viken Hospital Trust|Yes|Recruiting|September 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|28 Weeks|32 Weeks|No|Non-Probability Sample|All infants (gestational age 28-32 weeks) and their parents hopitalized at VVHT and        HUH.The recruited parent-infant dyads will thus be population based, i.e. representing the        county of Buskerud and Hordaland. Patients will be recruited consecutively at admission to        the NICU and included after written informed consent by both parents.|January 2015|May 21, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02452580||20565|
NCT02458664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI12029|BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer|BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer|BASE HSP110|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|597|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, male or female, over 18 years, undergoing curative colorectal resection|November 2015|November 30, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458664||20098|
NCT02447055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508102|Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma|Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol||Washington University School of Medicine|No|Recruiting|December 2015|November 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02447055||20989|
NCT02447068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-001|Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis|A Proof of Concept, Investigator Blinded Study to Evaluate the Efficacy and Safety of a Novel Combination of a Home Narrow Band Ultraviolet B (NBUVB) Lamp With an Occlusive Dressing in Adult Subjects With Mild to Moderate Psoriasis Vulgaris||Illumicure Inc|Yes|Recruiting|May 2015|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447068||20988|
NCT02441907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aflibercept Cytokine DME|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naïve Patients With Diabetic Macular Edema||St. Michael's Hospital, Toronto|No|Recruiting|August 2015|April 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|May 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441907||21384|
NCT02452840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00057705|Photodynamic Therapy for PDA in NV AMD|Adjunctive Photodynamic Therapy for Persistent Disease Activity in Patients With Neovascular Age-Related Macular Degeneration||Duke University|No|Recruiting|October 2014|October 2021|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with NVAMD with evidence of PDA in spite of loading dose intravitreal anti-VEGF        therapy.|December 2015|December 14, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02452840||20545|
NCT02452853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC002|HR Combined With FOLFOX4 for HCC With PVTT|Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus||Sun Yat-sen University|Yes|Active, not recruiting|May 2015|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02452853||20544|
NCT02453477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004860-39 (EudraCT)|Gene Therapy for Transfusion Dependent Beta-thalassemia|A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia|TIGET-BTHAL|IRCCS San Raffaele|Yes|Recruiting|May 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Both|3 Years|64 Years|No|||June 2015|June 9, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02453477||20496|
NCT02459847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00320|Mind-Body Training for Hand Rehabilitation|Effects of Mind-body Interventions on Stress, Anxiety, and Pain in Hand Therapy Patients||University of Southern California|No|Completed|August 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|November 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02459847||20007|
NCT02435745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0144|Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome|Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome|OSA in EDS|University of Zurich|No|Completed|April 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Prospective case-control study including EDS patients and controls matched for age,        gender, height and weight. The following outcomes will be assessed: 1) apnoea-hypopnoea        index, 2) sleep-related questionnaires, 3) medical chart review, and 4) echocardiography|December 2015|December 10, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435745||21857|
NCT02448563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28272|Reducing Obesity in Underserved Postpartum African American Women|Reducing Obesity in Underserved Postpartum African American Women|RENEW|Boston Medical Center|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02448563||20874|
NCT02454972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-B-005-14|Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors|A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors||PharmaMar||Recruiting|August 2015|||July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|N/A|No|||September 2015|February 10, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454972||20381|
NCT02459496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiNA-D|Diabetes Nutrition Algorithms in the German Diabetes Study|Dietary Strategies to Improve Metabolism and Body Weight in Type 2 Diabetes|DiNA-D|German Institute of Human Nutrition|Yes|Recruiting|September 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|79 Years|No|||November 2015|November 17, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02459496||20034|
NCT02443194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0124-15 TLV|The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients||Tel-Aviv Sourasky Medical Center|No|Terminated|May 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|May 3, 2015|Yes|Yes|principle investigator decision due to many adverse events in patients|No||https://clinicaltrials.gov/show/NCT02443194||21285|
NCT02445989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48663-A|Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity|Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity||University of Washington|No|Not yet recruiting|May 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|April 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445989||21071|
NCT02445547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTIT-HBV-M|Telbivudine and Tenofovir in Men of Childbearing Age With Immune-tolerant Chronic Hepatitis B|Telbivudine and Tenofovir Double Therapy in Men of Childbearing Age With Immune-tolerant Chronic Hepatitis B||Fuzhou General Hospital|Yes|Active, not recruiting|October 2014|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Male|18 Years|45 Years|No|||May 2015|May 14, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02445547||21105|
NCT02446704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-121|Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy|Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy||Massachusetts General Hospital|Yes|Recruiting|September 2015|April 2022|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446704||21016|
NCT02429635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/294|My Exercise. A Team-based Workplace Intervention for Increased Exercise|Workplace Health and Wellness Promotion: Investigating the Effects of a Team-based Intervention on Individual Motivation and Enhanced Physical Activity, Health and Work-functioning|Myexercise|Norwegian School of Sport Sciences|Yes|Active, not recruiting|January 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02429635||22325|
NCT02450318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500077|Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease|Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease||University of Florida|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Female|18 Years|89 Years|No|||February 2016|February 2, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450318||20739|
NCT02450331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29636|A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]|A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy||Hoffmann-La Roche||Recruiting|October 2015|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450331||20738|
NCT02445300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMPRG8C0711|Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in MIS TKA|Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in Minimally Invasive Total Knee Arthroplasty：A Prospective, Randomized Controlled Study||Chang Gung Memorial Hospital|Yes|Completed|October 2013|October 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|N/A|N/A|No|||May 2015|May 12, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02445300||21124|
NCT02683941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-US-52030-328|Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors|A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors|SPINET|Ipsen|Yes|Not yet recruiting|February 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683941||2804|
NCT02683954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nesfatin 1|The Association Between Endometriosis, Obesity and nesfatin1|The Association Bet Endometriosis, Obesity and nesfatin1||Ain Shams Maternity Hospital|Yes|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|sixty female patients were admitted to the wards to undergo laparoscopy for various        indications|February 2016|February 16, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02683954||2803|
NCT02684266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR6390-I-101|A Study of SHR6390 in Advanced Solid Tumor Patients|A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Solid Tumor Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Not yet recruiting|February 2016|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02684266||2779|
NCT02566369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18251|Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris||Galderma R&D|No|Recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|9 Years|N/A|No|||February 2016|February 5, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566369||11829|
NCT02453828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-192|Intraoperative Anesthesia Care Transition Checklist|The Effects of Implementing an Anesthesia Information Management System Guided Intraoperative Anesthesia Care Transition Checklist on Postoperative Complications: A Randomized Trial||The Cleveland Clinic|No|Active, not recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|13676|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02453828||20469|
NCT02453841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00723|Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption|Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery or Adenoidectomy||Nationwide Children's Hospital|No|Enrolling by invitation|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|2 Years|18 Years|No|||December 2015|December 16, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02453841||20468|
NCT02443493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.38/onco15.06|Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients|Low-level Laser Therapy as a Tool for the Prevention of Radiodermatitis in Breast Cancer Patients|TRANSDERMIS|Hasselt University|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Female|N/A|N/A|No|||May 2015|May 12, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443493||21263|
NCT02449317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2558/171|Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury|Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast|BELIEVE|Mahidol University|Yes|Recruiting|May 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|90 Years|No|||June 2015|June 3, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02449317||20816|
NCT02449330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M26-43|Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study|Clinical Study for the Effect of Teneligliptin on the Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus|TOPLEVEL|National Cerebral and Cardiovascular Center||Not yet recruiting|June 2015|||June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|936|||Both|20 Years|85 Years|No|||May 2015|May 17, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02449330||20815|
NCT02449343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTER0203|Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)|A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Yes|Recruiting|May 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|318|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|May 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449343||20814|
NCT02455609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210|Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain|Intrathecally Administered Ketamine, Dexmedetomidine, and Their Combination With Bupivacaine for Postoperative Analgesia in Major Abdominal Cancer Surgery||Assiut University|No|Active, not recruiting|March 2015|September 2015|Anticipated|August 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|30 Years|50 Years|No|||May 2015|May 27, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455609||20333|
NCT02455622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-ELA-401|Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age|A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age||Shire||Recruiting|June 2015|August 2022|Anticipated|February 2022|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|N/A|6 Years|No|||January 2016|January 6, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455622||20332|
NCT02433535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522110-3|Trial of Simvastatin for the Treatment of Severe Asthma|Randomized Trial of Simvastatin for the Treatment of Severe Asthma||University of California, Davis|Yes|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||April 2015|May 4, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02433535||22027|
NCT02454231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFlorence|Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)|Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells|SCELTA|University of Florence|Yes|Recruiting|September 2009|October 2015|Anticipated|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|40 Years|N/A|No|||May 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454231||20438|
NCT02460354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077633|Metformin and Congenital Nephrogenic Diabetes Insipidus|Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)||Emory University|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||September 2015|October 11, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460354||19968|
NCT02446301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1001-103|A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers|A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection vs. Bain®. Nalbuphine HCl IM Injection, in Healthy Volunteers||Lumosa Therapeutics Co., Ltd.|No|Completed|January 2015|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|May 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446301||21047|
NCT02446626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150131|Xenodiagnosis After Antibiotic Treatment for Lyme Disease|Xenodiagnosis After Antibiotic Treatment for Lyme Disease - Phase II Study||National Institutes of Health Clinical Center (CC)||Recruiting|May 2015|December 2030|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 9, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446626||21022|
NCT02461368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH injection|Ultrasound-Guided Glenohumeral Steroid Injection|Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial||Chuncheon Sacred Heart Hospital|Yes|Completed|December 2012|February 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|80 Years|No|||June 2015|June 3, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02461368||19890|
NCT02434666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC-001-10|Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07|Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07||Chase Pharmaceuticals Corporation|Yes|Enrolling by invitation|January 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|50 Years|89 Years|No|||July 2015|July 17, 2015|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434666||21940|
NCT02451085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2|The Effect of a Telerehabilitaion Program on Gait and Balance in Patients After Hip Surgery|The Effect of a Telerehabilitaion Program on Gait and Balance in Patients After Hip Surgery.||Reuth Medical Center|No|Recruiting|July 2015|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|85 Years|No|||October 2015|October 26, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451085||20680|
NCT02451384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015-010|According CTC to Compare the Influences of Different Methods to Remove the PDAC|To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells||Shanghai Zhongshan Hospital|Yes|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|80 Years|No|||June 2015|June 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02451384||20657|
NCT02454816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV2.0|Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in Colombia|Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in COLOMBIA||Universidad Nacional de Colombia|Yes|Recruiting|May 2015|||October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|12|||Female|14 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02454816||20393|
NCT02450617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oslo|Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial|Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial|STAB|Modum Bad|No|Recruiting|June 2014|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02450617||20716|
NCT02454569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFHCS|Vicente Ferrer HIV Cohort Study|Vicente Ferrer HIV Cohort Study|VFHCS|Rural Development Trust Hospital|No|Recruiting|September 2009|||September 2039|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|HIV infected patients|May 2015|May 27, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02454569|30 Years|20412|
NCT02447588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504-MAD-021-AR|IUI Schedule in Cases of High Progesterone|Programming IUI With Sperm Donor in Patients With High Progesterone the Day of hCG Administration|IAD-P4|IVI Madrid|No|Not yet recruiting|July 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02447588||20949|
NCT02447601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEX168-Ik|Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|March 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|January 24, 2016|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02447601||20948|
NCT02452658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14-582 Study 2|Fast Food Photo Study 2|Detecting Changes on Fast Food Menu||Carnegie Mellon University|No|Completed|May 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|311|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452658||20559|
NCT02440451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBILI-VB-2015-02|Rt-fMRI NF Intervention Study in ASD|Improving Facial Expression Identification in ASD: a Real-time fMRI Neurofeedback Approach|NF-ASD|University of Coimbra|No|Enrolling by invitation|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|16 Years|30 Years|No|||May 2015|May 6, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02440451||21496|
NCT02451670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13-154|Reducing Cardiovascular Risk in Adults With Serious Mental Illness|Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support|SMIWizard|HealthPartners Institute|Yes|Not yet recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2250|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451670||20635|
NCT02454907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00083614|The Use of Technology to Improve MS Clinical Trials and Patient Care|The Use of Technology to Improve MS Clinical Trials and Patient Care||Johns Hopkins University|Yes|Not yet recruiting|June 2015|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454907||20386|
NCT02445378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14182|Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy|The Effect of Aromatherapy on Insomnia and Other Common Cancer Patient Symptoms||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2014|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|N/A|No|||February 2016|February 22, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445378||21118|
NCT02431000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02277-XP|Male Fertility and Sperm Cryopreservation|Male Fertility Pre- and Post- Radiation and Chemotherapy, and Sperm Preservation||University of Tennessee|No|Recruiting|May 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Subject who express the desire to have pre-treatment sperm cryopreservation. These subjects      will undergo an informed consent process. If the five years of storage are up before      subjects are ready to claim it, it will be their responsibility to keep the account open by      paying a fee of about $300.00 per any additional year in storage. If they withdraw from the      study before the five years are up, they will be free to claim the sperm from storage or to      leave it there until the five years are up. Afterwards, they will be responsible for the      annual fees.      Long term Semen Freezing :      After freezing, sperm samples will be sent to FairFax Cryobank in Austin, Texas for      long-term storage. A storage agreement plan has been pre-arranged with FairFax and UTMG.|Male|13 Years|N/A|No|Probability Sample|Subject Recruitment and Screening Subjects will be recruited by referral from the Memphis        area cancer centers and physicians whose patients express the desire to have pre-treatment        sperm cryopreservation. Minors will be recruited by referral from the SJCRH and        Methodist-Le Bonheur physicians|May 2015|September 17, 2015|April 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02431000||22222|
NCT02457026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063930|Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD|Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in Patients With Neovascular Age-Related Macular Degeneration||Duke University|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|55 Years|N/A|No|||December 2015|December 9, 2015|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457026||20224|
NCT02447211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900|Topical Doxepin for Radiation-induced Dermatitis|Topical Doxepin for Prevention and Management of Radiation-induced Dermatitis||Isfahan University of Medical Sciences|Yes|Recruiting|May 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|February 24, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447211||20977|
NCT02453217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIP1214-V1|The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial|The Potential Efficacy and Acceptability of the Chinese Health Improvement Profile (CHIP) in Improving the Physical Health of People With Severe Mental Illness - A Pilot Clustered Randomised Controlled Trial|CHIP|The Hong Kong Polytechnic University|No|Enrolling by invitation|August 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|144|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453217||20516|
NCT02427594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058905|Acid-Base Compensation in Chronic Kidney Disease|Acid-Base Compensation in Chronic Kidney Disease: Measurement and Physiologic Impact|ABC|Duke University|No|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|16|||Both|22 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 23, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02427594||22482|
NCT02448771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-060|A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer|A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2015|April 2022|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448771||20858|
NCT02449291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10018|Study of APD421 as PONV Treatment (no Prior Prophylaxis)|Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis||Acacia Pharma Ltd|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|580|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449291||20818|
NCT02461251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETL R15054|Thromboelastometry-guided Treatment Protocol Versus Standard Care of Major Haemorrhage in Obstetric Patients|Thromboelastometry-guided Treatment Protocol Versus Standard Care of Major Haemorrhage in Obstetric Patients|ROTEM-PPH|Tampere University Hospital|No|Not yet recruiting|September 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|60 Years|No|||May 2015|June 1, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02461251||19899|
NCT02446353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ESCL001|Pharmacokinetics and Safety Study of Apetrol ES|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers|Apetrol|LG Life Sciences|No|Completed|April 2010|October 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|79|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02446353||21043|
NCT02457611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1612|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection|Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection||Gilead Sciences|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457611||20179|
NCT02444520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR130202 (Primary)|Persistent Physical Symptoms Reduction INtervention: a System Change & Evaluation in Primary Care|Persistent Physical Symptoms Reduction INtervention: a System Change & Evaluation in Primary Care|PRINCE Primary|King's College London|Yes|Not yet recruiting|May 2015|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|240|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02444520||21184|
NCT02455557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 259614|SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma||Roswell Park Cancer Institute|Yes|Recruiting|May 2015|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455557||20337|
NCT02460276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG-MCL6|A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma|PHILEMON|Lund University Hospital|No|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460276||19974|
NCT02446119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21560|Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip|Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip|PyloEndoFlip|Temple University|No|Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inclusion criteria:          1. Subjects will be of either sex, 18 to 70 years of age.          2. Two groups will be recruited. 2a. First, patients with an established diagnosis of             gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects             will have delayed gastric emptying on gastric scintigraphy defined as greater than             60% retention at 2 hours and/or greater than 10% retention at 4 hours.        2b. Second, control subjects will be nondiabetic patients without gastroparesis or        gastroesophageal reflux symptoms undergoing upper endoscopy.|May 2015|May 14, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02446119||21061|
NCT02446405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZUP 1304|Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer|Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET|ENZAMET|University of Sydney|Yes|Recruiting|March 2014|December 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446405||21039|
NCT02428101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|master(No.38)|Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer|Relation of Genetic Polymorphism of ABCG2 Gene And Occurrence of Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer||Ain Shams University|Yes|Enrolling by invitation|December 2014|May 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Gastrointestinal tract (GIT) Cancer|January 2016|January 13, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02428101||22443|
NCT02450071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAST-01|Pre-Hospital Advanced Airway Management in the Nordic Countries|Pre-Hospital Advanced Airway Management in the Nordic Countries - A Prospective Multicentre Observational Study|PHAST|Karolinska Institutet|No|Recruiting|May 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|N/A|N/A|No|Probability Sample|All patients requiring prehospital advanced airway management (PHAAM) by the Helicopter        Emergency Medical Services (EMS) and Ground EMS (GEMS) units in the study. PHAAM includes        endotracheal intubation, supraglottic airway and percutaneous/surgical airway.|February 2016|February 25, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02450071||20758|
NCT02459678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-3884|ART Readiness in HIV-infected Pregnant Women|ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial||University of North Carolina, Chapel Hill|No|Not yet recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|526|||Both|18 Years|N/A|No|||May 2015|June 1, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02459678||20020|
NCT02442752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_108|Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months|A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11 Months With Acid-Related Diseases||Takeda|No|Suspended|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|1 Month|11 Months|No|||March 2016|March 7, 2016|May 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442752||21319|
NCT02442791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-TTMPharma-001|GLP-1 Analogs for Neuroprotection After Cardiac Arrest|GLP-1 Analogs for Neuroprotection After Out-of-hospital Cardiac Arrest, a Randomized Clinical Trail|GLIP1|Rigshospitalet, Denmark|Yes|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442791||21316|
NCT02451410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intervention1|An Intervention to Improve Nutrition and Physical Activity in Preschoolers in Cuenca, Ecuador|Impact of an Intervention to Improve Nutrition and Physical Activity in Preschoolers in Cuenca, Ecuador||Universidad de Cuenca|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02451410||20655|
NCT02459236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin301-203|A Study of Intermittent Doses of CERC-301 in MDD|A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment||Cerecor Inc|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|104|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459236||20054|
NCT02459301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I221|A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies|A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies||Canadian Cancer Trials Group|Yes|Recruiting|April 2015|December 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|38|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02459301||20049|
NCT02446756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH20150430|Clinical Observation and MRI Influence of Acupuncture on Knee Osteoarthritis|Clinical Observation and MRI Influence of Acupuncture on Knee Osteoarthritis||Peking Union Medical College Hospital|Yes|Completed|January 2010|February 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|80 Years|No|||May 2015|May 13, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02446756||21012|
NCT02431858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-011|Catheter Over Needle vs Catheter Through Needle|Catheter Over Needle Technique Causes Less Leakage and Secondary Failure Than Catheter Through Needle Technique for Continuous Femoral Nerve Block||Sir Charles Gairdner Hospital|No|Recruiting|May 2015|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02431858||22156|
NCT02444598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KISOS001|Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds|A Prospective, Randomized, Controlled Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds (VACoCREW Trial)|VACoCREW|Karolinska Institutet|Yes|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||September 2015|September 27, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444598||21178|
NCT02447081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10053|Amplatzer™Amulet™ Post-Market Study|Amplatzer™Amulet™ Observational Post-Market Study|Amulet™PMS|St. Jude Medical|No|Recruiting|April 2015|December 2018|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation|November 2015|November 18, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447081|2 Years|20987|
NCT02430753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lung fuction insuf-IRE-01|Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency|Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 26, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430753||22241|
NCT02452333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70904504|Oncoplastic Approach to Excisional Breast Biopsies|Oncoplastic Approach to Excisional Breast Biopsies: A Prospective Randomized Controlled Trial||Akdeniz University|Yes|Recruiting|May 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02452333||20584|
NCT02444858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-IVY-SC-004|Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Paraquat Poisoning Induced Lung Injury|UCMSC-PQLI|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|60 Years|No|||April 2015|May 12, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444858||21158|
NCT02458482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150070|Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children|Randomized Control Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children||Vanderbilt University|Yes|Not yet recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|17 Years|No|||May 2015|May 29, 2015|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02458482||20112|
NCT02443064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYH-88|Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin|Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus（MRSA） Blood Stream Infection (Septicemia) and Endocarditis in Chinese Patients||Zhejiang University|Yes|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|November 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02443064||21295|
NCT02455518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4156|Comparative Efficacy of 4 Oral Analgesics|Comparative Efficacy of 4 Oral Analgesics for the Initial Management of Acute Musculoskeletal Extremity Pain||Montefiore Medical Center|Yes|Not yet recruiting|May 2015|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|400|||Both|21 Years|65 Years|No|||May 2015|May 26, 2015|May 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455518||20340|
NCT02448056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504020RINC|MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma|MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma||National Taiwan University Hospital|No|Not yet recruiting|June 2015|May 2025|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|serum; tissue: tumor/ non-tumor part.|Both|20 Years|N/A|No|Non-Probability Sample|HCC receive surgery, RFA, TACE or Sorafenib tx.|May 2015|May 14, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02448056|5 Years|20913|
NCT02451280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-1621A3|Unilateral vs. Bilateral Approaches to Hybrid Stroke Rehabilitation|Unilateral vs. Bilateral Approaches to Hybrid Stroke Rehabilitation||Chang Gung Memorial Hospital|No|Enrolling by invitation|June 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Both|20 Years|80 Years|No|||April 2015|June 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451280||20665|
NCT02451566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0017|TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR (Endovascular Aneurysm Repair)|TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR With the Ovation Prime™ Abdominal Stent Graft System||TriVascular, Inc.|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll male and female subjects 18 years of age and older that have an AAA        and meet all other inclusion/exclusion criteria.|November 2015|November 24, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02451566|1 Month|20643|
NCT02442947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1853-YH-CTIL|Examination of Textile Solutions for Reducing Physiological Stress|Physiological Examination of Textile Solutions for Stress Reduction When Dressed in Protective Garment and Work Clothes and Under Physical and Heat Stress Conditions||Sheba Medical Center|No|Completed|June 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02442947||21304|
NCT02442960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30934|Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis|An Open-Label, Dose-Escalation Phase Ib Study Evaluating the Safety and Preliminary Efficacy of Oral SA100 in the Treatment of Patients With Mild-to-Moderate Ulcerative Colitis||Stanford University|No|Recruiting|September 2014|||September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||May 2015|May 9, 2015|April 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442960||21303|
NCT02455778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cinnamon 2010|Effect of Oral Cinnamon Intervention in Metabolic Syndrome|Effect of Intervention With Oral Cinnamon on Metabolic Profile and Body Composition of Asian Indians With Metabolic Syndrome in North India: A 16 Week Double Blind Placebo Control Trial||Diabetes Foundation, India|Yes|Completed|August 2011|April 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|103|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02455778||20320|
NCT02459938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2014-004|Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia|A Randomized Open-label Crossover Study to Compare the Safety and Efficacy of ZP-Glucagon to Injectable Glucagon in the Treatment of Insulin-induced Hypoglycemia in Subjects With Type-1 Diabetes||Zosano Pharma Inc.|No|Active, not recruiting|January 2015|August 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|16|||Both|18 Years|60 Years|No|||July 2015|July 14, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02459938||20000|
NCT02459951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4729FBD|Improving Holding Function of the Hemiplegic Hand|Improving Holding Function of the Hemiplegic Hand With Chemodenervation||Albert Einstein Healthcare Network|No|Enrolling by invitation|July 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|9|||Both|35 Years|80 Years|No|Non-Probability Sample|patients who are clinically appropriate for Botox A injection to treat upper limb        spasticity due to stroke|May 2015|May 29, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02459951||19999|
NCT02460978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-230|Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two|Depict 2|Bristol-Myers Squibb|Yes|Recruiting|June 2015|January 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|768|||Both|18 Years|75 Years|No|||November 2015|February 25, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460978||19920|
NCT02443207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq 471-790.2011/7|Impact of Dental Pain on the Quality of Life|Perceived Impact of Dental Pain on the Quality of Life of Preschool Children and Their Families||Universidade Estadual da Paraiba|No|Completed|January 2013|May 2014|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|843|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Probability Sample|A school-based, cross-sectional study was carried out involving male and female children        aged three to five years enrolled at private and public preschools in the city of Campina        Grande, Brazil. Campina Grande is an industrialized city in northeastern Brazil with a        population of 386,000 inhabitants and is divided into six administrative districts. The        city has considerable cultural, social and economic disparities, with a mean monthly        income per capita equal to US$ 110 and a Human Development Index of 0.72 [11]. The        participants were selected from a total population of 12,705 children in this age group        and corresponded to 6.41% of the entire population and therefore representative of        preschool children in Campina Grande.|May 2015|May 12, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02443207|1 Day|21284|
NCT02453672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB8-G11-NHV|Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects|A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects||Samsung Bioepis Co., Ltd.|No|Completed|April 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|119|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453672||20481|
NCT02453685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-4157|A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients|A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy||Novo Nordisk A/S|No|Active, not recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453685||20480|
NCT02459509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-105|A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children|A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial||The University of Hong Kong||Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459509||20033|
NCT02446379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-005|Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery|Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery|CLIO|Lightpoint Medical Limited|No|Not yet recruiting|October 2016|December 2017|Anticipated|November 2017|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|30 Years|N/A|No|Non-Probability Sample|Female or male patients aged ≥ 30 years diagnosed with gastric, pancreatic, bile duct or        duodenal cancer, whose treatment is to be tumour excision surgery.|March 2016|March 11, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02446379||21041|
NCT02429076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000566|EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia|Electroencephalogram Studies of Intravenous Methylphenidate-Induced Emergence From General Anesthesia||Massachusetts General Hospital|No|Not yet recruiting|June 2016|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|74|||Both|18 Years|36 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|April 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429076||22368|
NCT02429375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-232|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma|Phase IB/II Study of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center||Recruiting|April 2015|||April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02429375||22345|
NCT02450058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMI96.018|Adjuvant FEC Versus EP in Breast Cancer (MIG5)|Fluorouracil, Epirubicin and Cyclophosphamide Versus Concurrent Epirubicin and Paclitaxel in Node Positive Early Breast Cancer Patients: a Randomized, Phase III Trial of Gruppo Oncologico Nord-Ovest - Mammella Intergruppo Group|MIG5|National Institute for Cancer Research, Italy||Completed|November 1996|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1055|||Female|18 Years|70 Years|No|||May 2015|May 18, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450058||20759|
NCT02433808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH15-089|Neostigmine Reversal And Neuromuscular Recovery|Neostigmine Reversal And Neuromuscular Recovery||NorthShore University HealthSystem Research Institute|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02433808||22006|
NCT02454244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI15/0049|Efficacy of Amygdala Retraining With Mindfulness (ART+MF) vs Compassion Therapy (CT) for the Treatment of Patients With Fibromyalgia|Efficacy of Amygdala Retraining With Mindfulness (ART+MF) vs Compassion Therapy (CT) for the Treatment of Patients With Fibromyalgia: A Three-arm Randomized, Controlled Trial.||Hospital Miguel Servet|No|Active, not recruiting|June 2015|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02454244||20437|
NCT02449109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nano drug liver cancer|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma：Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||June 2015|February 23, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449109||20832|
NCT02688205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140107R|Correlation Between Cyriax's Functional Examination and Ultrasound Examination in Patients With Shoulder Pain|Correlation Between Cyriax's Functional Examination and Ultrasound Examination in Patients With Shoulder Pain||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|March 2014|December 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|206|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with or without shoulder pain|February 2016|February 22, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02688205||2476|
NCT02570724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5204|HES Patch Versus Blood Patch|Clinical Effect and Cerebral Vasoconstriction Induced After Epidural Blood Patch Versus Epidural Hydroxyethyl Starch Patch in Patients With Headache Due to Intracranial Hypotension||University Hospital, Strasbourg, France|Yes|Recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||September 2015|October 6, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02570724||11494|
NCT02428634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHE-002-SI|The Program SI! for Cardiovascular Health Promotion at Elementary School|The Program SI! for Cardiovascular Health Promotion for Elementary Students Aged 6 to 11: a Cluster Randomized Trial|PSIE|Foundation for Science, Health and Education, Spain|No|Active, not recruiting|September 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|2238|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02428634||22402|
NCT02454283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGN-VN-003|Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|RESTORE SR|Laguna Pharmaceuticals, Inc.|Yes|Terminated|September 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|May 20, 2015|Yes|Yes|Cardiac safety finding|No||https://clinicaltrials.gov/show/NCT02454283||20434|
NCT02454296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22702|Paracervical Block for Pain Associated With Laminaria Insertion|Paracervical Block for Pain Associated With Laminaria Insertion||University of Hawaii|No|Recruiting|May 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02454296||20433|
NCT02461290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21526|Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1|Open, Noninterventional, Multicentre Trial of Rituximab in Combination With Chemotherapy (CVP, CHOP or FCM) Chemotherapy in Patients With Follicular Lymphoma||Hoffmann-La Roche||Completed|April 2008|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|99|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with follicular lymphoma|August 2015|August 31, 2015|May 29, 2015|No|Yes||No|August 31, 2015|https://clinicaltrials.gov/show/NCT02461290||19896|
NCT02447289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041530|Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment|Efficacy, Safety and Cost-effectiveness of Intranasal Sedation With Ketamine and Midazolam in Pediatric Dentistry: a Randomized Clinical Trial|NASO|Universidade Federal de Goias|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02447289||20971|
NCT02438917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0548|Biomarkers of Liver Fibrosis|Biomarkers of Liver Fibrosis||Icahn School of Medicine at Mount Sinai|No|Recruiting|June 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Whole blood, Urine, Saliva|Both|18 Years|N/A|No|Non-Probability Sample|Patients with the hepatitis C virus (HCV) who are about to begin HCV treatment.|December 2015|December 23, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438917||21613|
NCT02456597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15000927|A Novel Concept for Continuous Peripheral Nerve Block - Sciatic Nerve|A Novel Concept for Continuous Peripheral Nerve Block - Popliteal Region||Hillerod Hospital, Denmark|Yes|Completed|April 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02456597||20257|
NCT02450383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO1|Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness|Comparison of Two Different Surgical Approaches to Increase Peri-Implant Mucosa Thickness: A Randomized Controlled Clinical Trial||University of Iowa|No|Recruiting|January 2015|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02450383||20734|
NCT02449421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB: 2014-345|Sustaining and Improving Clinicians' Use of Evidence-Based Psychotherapy (EBP) for PTSD|A Comparison of the Effects of Internet-Based Strategies to Support Mental Health Clinicians' Use of an Effective Psychotherapy for Post Traumatic Stress Disorder (PTSD)||Ryerson University|Yes|Enrolling by invitation|December 2014|October 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02449421||20808|
NCT02454829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYOFONOV01|Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation|Follow-up of Ovarian Function in Young Girls and Women Who Underwent Ovarian Cortex Cryopreservation for Fertility Preservation at the Cliniques Universitaires Saint-Luc||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Enrolling by invitation|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|546|||Female|N/A|N/A|No|Non-Probability Sample|All women who underwent ovarian cortex cryopreservation in our institution between 1997        and 2013|May 2015|May 26, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454829||20392|
NCT02454712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF614-101|Study of PF614 Compared to OxyContin® in Healthy Volunteers|Phase 1, Single-Center, Dose-Escalation and Fixed-Dose Crossover Food Effect Cohort Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®|SAD|Signature Therapeutics|No|Not yet recruiting|August 2015|May 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454712||20401|
NCT02454725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00020837|Regular HIV Testing Among At-Risk Latino Men|Regular HIV Testing Among At-Risk Latino Men||Medical College of Wisconsin|No|Enrolling by invitation|June 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Male|18 Years|N/A|No|||May 2015|May 26, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02454725||20400|
NCT02452671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-0156|Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device|Observational Plan Designed to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device for the Fixation of Osteotomies and Reconstruction of the Lesser Toes Following Correction Procedures||Cartiva, Inc.|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Subjects who are candidates for hammer toe surgery.|January 2016|January 5, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452671||20558|
NCT02452684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN01S|Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients|Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients (Study LUN01S)||Eisai Inc.|No|Active, not recruiting|October 2012|August 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3300|||Both|N/A|N/A|No|Non-Probability Sample|Insomnia participants who did not take eszopiclone before assessment|May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02452684||20557|
NCT02441491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1520|Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )|High-dose Cyclophosphamide for the Treatment of ROHHAD (Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation) Syndrome||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2015|March 2023|Anticipated|March 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|12 Months|22 Years|No|||June 2015|June 18, 2015|April 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441491||21416|
NCT02455037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087641|Evaluation of a Neck Strengthening Program to Reduce the Risk of Sport-related Concussion|Evaluation of a Neck Strengthening Program as a Potential Intervention to Reduce the Risk of Sport-related Concussion||University of Michigan|No|Active, not recruiting|May 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02455037||20377|
NCT02455050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11193X-002|A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief|||Allergan|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|93|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|January 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455050||20376|
NCT02455063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMPPC-2015-hotel|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2015|||||N/A|N/A|N/A||||||||||||||January 4, 2016|May 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455063||20375|
NCT02446314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-001|An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults|A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults||University of Reading||Recruiting|May 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|120|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02446314||21046|
NCT02446327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00097-36|The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure Study|The Metabolic Road to Diastolic Heart Failure : Diastolic Heart Failure Study (MEDIA-DHF)|MEDIA-DHF|Central Hospital, Nancy, France|No|Completed|January 2012|March 2015|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|47|||Both|18 Years|N/A|No|||April 2015|May 13, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446327||21045|
NCT02435472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135512|Active Surveillance Exercise Clinical Trial|A Randomized Clinical Trial of Supervised Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer|ASExerciseRCT|University of California, San Francisco|No|Recruiting|April 2015|April 2025|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Male|18 Years|N/A|No|||May 2015|May 5, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02435472||21878|
NCT02435485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D0911|The Rehabilitation Outcome of Patients With Lumbar Spondylolisthesis. A Prospective Randomized Study|The Rehabilitation Outcome of Patients With Lumbar Spondylolisthesis. A Prospective Randomized Study||Chang Gung Memorial Hospital|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|90|||Both|50 Years|80 Years|No|||May 2015|May 7, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02435485||21877|
NCT02447458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN3126_102|MLN3126 Single Rising Dose Study|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects||Takeda|No|Terminated|September 2013|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|May 14, 2015|No|Yes|Site non-compliance to GCP (No safety concerns. See detailed description)|No|July 7, 2015|https://clinicaltrials.gov/show/NCT02447458||20959|
NCT02451137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14347|A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)|A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus||Sanofi|No|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3270|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451137||20676|
NCT02451150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536/CPH-103|A Phase 3 Pharmacokinetic Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension|An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics of a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension||Takeda|No|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|6 Years|16 Years|No|||January 2016|January 6, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451150||20675|
NCT02460679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI589-15-001|Safety and Biomarker Study of EPI-589 in Subjects With ALS|A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis|EPI-589|Edison Pharmaceuticals Inc|No|Recruiting|December 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|70 Years|No|||January 2016|January 29, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02460679||19943|
NCT02460692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA038634-01A1|Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain|A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain||University of California, San Diego|Yes|Not yet recruiting|June 2016|May 2020|Anticipated|May 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|May 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460692||19942|
NCT02432534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-01|Atorvastatin in Active Vitiligo|Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial||Centre Hospitalier Universitaire de Nice|No|Recruiting|May 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02432534||22104|
NCT02456623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DK097444-01|Obesity Intervention for Low-Income African American Preschoolers|Parent Focused Obesity Intervention for Low-Income African American Preschoolers||Eastern Michigan University|Yes|Recruiting|September 2013|August 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02456623||20255|
NCT02451202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51815|Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures|A Comparison of Surgical Conditions Between Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures.||Chulalongkorn University|No|Not yet recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||May 2015|May 20, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451202||20671|
NCT02451215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504-044|Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors|LITT for the Treatment of Newly Diagnosed Central Nervous System Tumors Located in Difficult to Surgically Access Regions of the Brain and Recurrent/Resistant Pediatric Central Nervous System Tumors Located Anywhere Within the Brain||Children's Hospitals and Clinics of Minnesota|Yes|Recruiting|April 2015|||April 2025|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|22 Years|No|||May 2015|May 19, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02451215||20670|
NCT02445144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3574|Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease|Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|November 2014|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Blood samples for evaluation of inflammatory markers|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|18-55 year old male and female patients with sickle cell anemia who are asymptomatic of        previous CNS disease|December 2015|December 28, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02445144||21136|
NCT02441205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00055208|Interval Training, Inflammation and Immune Function|The Impact of High Intensity Interval Training on Inflammatory State and Immune Function in Elderly Individuals||Duke University|No|Recruiting|April 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||February 2016|March 7, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02441205||21438|
NCT02449551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-07-167|Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment|||Samsung Medical Center|No|Recruiting|February 2015|December 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449551||20798|
NCT02460796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UnBrasilia|Hippotherapy and Parkinson's Disease|Hippotherapy on Functional Capacity and Quality of Life in Parkinson's Disease: a Prospective Study||University of Brasilia|Yes|Completed|June 2013|October 2013|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|||Both|65 Years|83 Years|No|Non-Probability Sample|18 volunteers with Parkinson's desease.|June 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460796|8 Weeks|19934|
NCT02450448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Cancer CTC 001|The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment||Fuda Cancer Hospital, Guangzhou|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ⅱ,Ⅲ,Ⅳ stage renal cancer come to Fuda Hospital for treatment.|December 2015|December 28, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450448||20729|
NCT02433067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFranche-Comte|Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer|Impact of Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer, During Treatment With Trastuzumab in Adjuvant|CARDAPAC|University of Franche-Comté|No|Recruiting|April 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|117|||Female|18 Years|65 Years|No|||April 2015|April 28, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02433067||22063|
NCT02454101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|delayed cord clamping in term|Milking Versus Delayed Cord Clamping in Full Term Neonates|Milking Versus Delayed Cord Clamping in Full Term Neonates Delivered by Elective Cesarean Section A Randomized Controlled Trial|MDCCT|Ain Shams University|No|Completed|August 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|300|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|March 7, 2016|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02454101||20448|
NCT02454114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/NW/0731|HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections|HOME FIRST (HOME Followed - up With Infection Respiratory Support Team)|HOMEFIRST|Royal Liverpool and Broadgreen University Hospitals NHS Trust|No|Completed|October 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||October 2012|May 26, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02454114||20447|
NCT02446977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCS-CBG-2014-01|Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke|Randomized Clinical Trial to Investigate Whether Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke Causes a Reduction of Glutamate-mediated Excitotoxicity||Castillo, José, M.D.|No|Active, not recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02446977||20995|
NCT02446990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-16257-083|Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure|Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease|SIGNIFY|Servier|Yes|Completed|September 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19102|||Both|55 Years|N/A|No|||June 2015|June 26, 2015|May 5, 2015||No||No|May 20, 2015|https://clinicaltrials.gov/show/NCT02446990||20994|
NCT02455427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225014|Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke|Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke|NEUROSTIM|Hospital Israelita Albert Einstein|Yes|Not yet recruiting|May 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||May 2015|May 29, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455427||20347|
NCT02455440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeorgePH|Esmolol Infusion in Patients Undergoing Craniotomy|Esmolol Reduces Anesthetic Requirements Thereby Facilitating Early Extubation; a Prospective Controlled Study in Patients Undergoing Intracranial Surgery||George Papanicolaou Hospital|No|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||July 2015|July 7, 2015|May 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02455440||20346|
NCT02430233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-13|Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor|Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor - Randomized Double Blind Placebo Controlled Trial||HaEmek Medical Center, Israel|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||April 2015|April 29, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02430233||22280|
NCT02454868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBrasilia|Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade|Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade||Brasilia University Hospital|No|Not yet recruiting|May 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|1||Anticipated|30|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02454868||20389|
NCT02454881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T97/2015|Dose Response Study of Dexmedetomidine in Orthopaedic Spine Surgery Patients|Dose Response Study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in Orthopaedic Spine Surgery Patients|DoserespDex|Turku University Hospital|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|75 Years|No|||February 2016|February 5, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02454881||20388|
NCT02451293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTM-01|The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome|The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome|MEDACIS|Roskilde County Hospital|Yes|Recruiting|January 2016|November 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|February 24, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02451293||20664|
NCT02453087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29687|A Study of Escalating Doses of DCDS0780A in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|An Open-label, Multicenter, Phase 1/1B Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma||Hoffmann-La Roche||Recruiting|May 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453087||20526|
NCT02453334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT14039|Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®|IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection)|IRON CLAD|Luitpold Pharmaceuticals|No|Recruiting|July 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|March 22, 2016|May 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453334||20507|
NCT02453347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-352H|Cranial Electrotherapy Stimulation (CES) Therapy|Cranial Electrotherapy Stimulation (CES) Therapy for PTSD and Anxiety in OEF/OIF Veterans With Mild TBI|CES|The University of Texas Health Science Center at San Antonio|No|Recruiting|October 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 10, 2015|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453347||20506|
NCT02451696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-00245|A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD|A PILOT STUDY TO EVALUATE THE EFFECTS OF EVEROLIMUS ON BRAIN mTOR ACTIVITY AND CORTICAL HYPEREXCITABILITY IN TUBEROUS SCLEROSIS COMPLEX (TSC) AND FOCAL CORTICAL DYSPLASIA (FCD)||New York University School of Medicine|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|40 Years|No|||December 2015|December 7, 2015|October 8, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02451696||20633|
NCT02451709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/13/041|STudy of Asthma Adherence Reminders|Can Electronic Adherence Monitors With Feedback and Daily Reminders Improve Adherence and Health Outcomes in Children With Asthma?|STAAR|Sheffield Children's NHS Foundation Trust|No|Completed|October 2013|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|90|||Both|6 Years|16 Years|No|||May 2015|November 20, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02451709||20632|
NCT02448888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDLEF1|Prevention and Treatment of Back Pain Through an Adapted Exercise Program|Prevention and Treatment of Back Pain Through an Adapted Exercise Program Tailored to the Job on an Assembly Line Training Versus General Exercise Recommendations: Randomized Clinical Trial||Universidad San Jorge|Yes|Active, not recruiting|January 2015|December 2015|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02448888||20849|
NCT02451592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEIFEM 2015|Fungemia in Hematologic Malignancies|SEIFEM 2015: Fungemia in Hematologic Malignancies||Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne|No|Recruiting|January 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|80 Years|No|Probability Sample|Consecutive adult and pediatric patients affected by hematologic malignancies and eligible        to chemotherapy that develop fungemia|May 2015|May 21, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02451592||20641|
NCT02451605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000677-39|Regional Anesthesia for Knee Prothesis Surgery|Regional Blockade for Knee Prothesis Surgery: Comparison Between Femoral, Sciatic and Adductor Canal Block||University Hospital of Liege|No|Not yet recruiting|June 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02451605||20640|
NCT02434965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-554|Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy|A Safety and Feasibility Study of Autologous Cord Blood (CB) and Human Placental Derived Stem Cells (HPDSC) in Neonates With Severe Hypoxic-Ischemic Encephalopathy (HIE)|HPDSC+HIE|New York Medical College|No|Not yet recruiting|January 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|6 Hours|No|||November 2015|November 18, 2015|April 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434965||21917|
NCT02455323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID004|The Influence of Manual Therapy in the Quality of Life in Tension-Type Headache|Influence of Spinal Manipulation and Suboccipipital Inhibition as a Complementary Therapy for Tension Headache in Quality of Life: A Randomized Controlled Trial|MTheadacheQL|University of Valencia|No|Completed|March 2013|December 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02455323||20355|
NCT02449135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nano drug pancreatic cancer|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||June 2015|February 23, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02449135||20830|
NCT02447367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLP-1207-P1-FE|Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers|Randomized, Open-label, Single Dose, Two-way Crossover, Clinical Trial to Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 After Oral Administration in Healthy Male Volunteers||Jeil Pharmaceutical Co., Ltd.|No|Not yet recruiting|July 2015|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447367||20966|
NCT02451852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5160C00021|AZD9291 US Expanded Access Program|A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients With Advanced/Metastatic EGFR T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy||AstraZeneca||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|130 Years|No|||January 2016|January 20, 2016|May 20, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02451852||20621|
NCT02460211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040458|Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D|Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D|ASSESS-D|Intermountain Health Care, Inc.|Yes|Recruiting|June 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02460211||19979|
NCT02453178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG048170-01A1|Effects of a Bicycling Intervention on Cognitive Skills and Cardiovascular Health|Effects of a Bicycling Intervention on Cognitive Skills and Cardiovascular Health|BIKE|University of Iowa|Yes|Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|48|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|April 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02453178||20519|
NCT02453464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM129-mCRC-01|A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer|A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|August 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|74 Years|No|||September 2015|October 13, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453464||20497|
NCT02459808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBSTransitTimeAarhus|Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome|Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome||University of Aarhus|Yes|Recruiting|May 2015|||May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|79 Years|No|Non-Probability Sample|Patients at Aarhus University Hospital, admitted with Guillain-Barré syndrome.|April 2015|May 28, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02459808||20010|
NCT02459821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEO-SM2012JP|Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects|The Effects of an Innovative Gait Robot for the Repetitive Practice of Floor Walking and Stair Climbing up and Down in Patients Suffered From Multiple Sclerosis: a Randomized Control Trial||Universita di Verona|Yes|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02459821||20009|
NCT02431286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP297/12|Palonosetron Associated to Aprepitant in Prophylaxis of PONV|Evaluation of Palonosetron and Palonosetron/Aprepitant in Post Operative Nausea and Vomiting Incidence in Oncological Patients|PONV|Instituto do Cancer do Estado de São Paulo|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|90|||Female|18 Years|70 Years|No|||April 2015|April 30, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02431286||22200|
NCT02460250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12033 FIBROSCAME|Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death|Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death|FIBROSCAME|University Hospital, Limoges|No|Recruiting|February 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|707|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02460250||19976|
NCT02445326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-14-007|Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model||Ocular Therapeutix, Inc.|No|Not yet recruiting|November 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445326||21122|
NCT02445339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00928|Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users|Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life||New York University School of Medicine|Yes|Recruiting|July 2015|January 2023|Anticipated|January 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02445339||21121|
NCT02448121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 25000039812/2005-99|Autologous Bone Marrow Stem Cell Transplantation for Hip Osteonecrosis in Sickle Cell Disease|Treatment for Hip Osteonecrosis With Autologous Mononuclear Cells Transplantation in People With Sickle Cell Disease||Federal University of Bahia|No|Enrolling by invitation|August 2006|August 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448121||20908|
NCT02448134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA021726|A Community-Based Strategy for Preventing Underage Drinking|A Community-Based Strategy for Preventing Underage Drinking||Oregon Research Institute|No|Recruiting|September 2014|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10848|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02448134||20907|
NCT02427854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1727|Palestinian Perineum and Birth Complication Study|Can Perineal Tears and Obstetric Anal Sphincter Injuries in Palestine be Prevented? A Study of Two Different Interventions|PPS|Oslo University Hospital|No|Not yet recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|70000|||Both|N/A|N/A|No|||April 2015|April 27, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02427854||22462|
NCT02456935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_301|Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|A Double-blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis||CJ HealthCare Corporation|No|Recruiting|May 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|20 Years|70 Years|No|||May 2015|May 27, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02456935||20231|
NCT02446392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM-ICU|The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients|The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients|TDM-ICU|Linkoeping University|No|Completed|October 2014|March 2016|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|Plasma samples at three consecutive days for measurement of plasma drug concentrations|Both|18 Years|N/A|No|Non-Probability Sample|Intensive care unit patients treated with beta-lactam antibiotics|March 2016|March 1, 2016|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02446392||21040|
NCT02433548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318/14|Fascia Iliaca Block in the Emergency Department for Analgesia After Femoral Neck Fracture|Fascia Iliaca Block in the Emergency Department for Analgesia After Femoral Neck Fracture||Centre Hospitalier Universitaire Vaudois|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02433548||22026|
NCT02433561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUVaudois|Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block|Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block: Respiratory-related and Pain-related Outcomes||Centre Hospitalier Universitaire Vaudois|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02433561||22025|
NCT02454166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-2081B|The Analysis of Chinese Medical Syndromes Differentiation on Acute Ischemic Stroke|The Study of Chinese Medical Syndromes on Common Diseases: The Analysis of Chinese Medical Syndromes Differentiation on Acute Ischemic Stroke||Chang Gung Memorial Hospital|No|Not yet recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Acute ischemic stroke patients from Stroke Center at Linkou Chang Gung Memorial Hospital.        The onset of stroke is set Within 7 days.|April 2015|May 26, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454166||20443|
NCT02449577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M212|Identification of Biomarkers for Acute Intake of Beer and Alcohol and Acute Effects on Plasma and Insulin Response|Metabolomics in Beer Research: Identification of Biomarkers for Acute Intake of Beer and Alcohol in Individuals With a High or Low Habitual Intake, and Acute Effects on Plasma Glucose and Insulin Response Compared to Regular Soda|METABEER|University of Copenhagen|Yes|Completed|May 2013|June 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|11||Actual|19|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 28, 2013||No||No||https://clinicaltrials.gov/show/NCT02449577||20796|
NCT02453438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001346|Mood Patient Powered Research Network (MoodNetwork)|Mood Patient Powered Research Network (MoodNetwork)||Massachusetts General Hospital|Yes|Recruiting|March 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|50000|||Both|18 Years|N/A|No|Non-Probability Sample|English speaking individuals over 18 years of age who self-identify as having a mood        disorder.|January 2016|January 19, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02453438|3 Years|20499|
NCT02450942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM08|18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|March 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02450942||20691|
NCT02451254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-EC-0142-15-CTIL|Coagulation Activity and Thrombogenesis in Patients With Atrial Fibrillation|Coagulation Activity and Thrombogenesis in Patients With Atrial Fibrillation||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451254||20667|
NCT02440867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00839-38|Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy|Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study|PilotTMS-COG|University Hospital, Caen|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 9, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02440867||21464|
NCT02456844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM006-003|Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients|Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456844||20238|
NCT02456857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0087|Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy|Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy||M.D. Anderson Cancer Center|No|Recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456857||20237|
NCT02453451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-016|The Effect of the Hole in the Cardiac Septum Developed by the MitraClip Procedure on the Blood Flow Mechanics|The Effect of the Iatrogenic Atrial Septal Defect After MitraClip Procedure on the Hemodynamic Outcome|MitraClipASD|RWTH Aachen University|Yes|Not yet recruiting|May 2015|April 2017|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02453451||20498|
NCT02690688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-2016-Monitoring|Intra-abdominal Pressure and Dynamic Preload Variables|The Influence of Pneumoperitoneum and Open Abdominal Surgery on Dynamic Preload Variables||University of Luebeck|No|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with the need of an abdominal operation. According operation technique patients        gets assigned to one of the groups.        In- and exculsion criteria are given below.|February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02690688||2286|
NCT02690701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AUS02|Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|VIP-S|Novartis|No|Not yet recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02690701||2285|
NCT02575651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-FZPL-I-AST-TOL/PK|A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|April 2015|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575651||11115|
NCT02458417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49720.018.14|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation||Netherlands Institute for Pigment Disorders|No|Enrolling by invitation|May 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458417||20117|
NCT02458430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00093414|Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease|Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Clin Core/Proj#2|UDALL|University of Michigan|No|Recruiting|January 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Saliva and Blood|Both|50 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ago 50 and over|December 2015|December 8, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02458430||20116|
NCT02450526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-158|Dysport in the Treatment of Glabellar Lines in Chinese Subjects|A Phase III, Randomised, Double Blind and Open Label Phase, Multicentre, Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Dysport Including a Comparison to Botox in the Treatment of Moderate to Severe Glabellar Lines, and to Assess the Long Term Efficacy and Safety of Dysport Following Repeated Treatments in This Indication||Ipsen|No|Recruiting|April 2015|October 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|65 Years|No|||December 2015|December 21, 2015|May 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02450526||20723|
NCT02450539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15806|A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer|A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy||Eli Lilly and Company|No|Recruiting|August 2015|November 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450539||20722|
NCT02460315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|timing of cholecystectomy|Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones|Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones by Endoscopic Retrograde Cholangiopancreatography|ERCP|Mansoura University|No|Completed|May 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||May 2013|June 1, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02460315||19971|
NCT02447302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD334-003|Safety and Efficacy of APD334 in Patients With Ulcerative Colitis|||Arena Pharmaceuticals|Yes|Recruiting|July 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447302||20970|
NCT02452138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503015RINB|Endotoxin Activity Assay and Microcirculation in Severe Sepsis|Endotoxin Activity Assay and Microcirculation Examination in Patients With Severe Sepsis||National Taiwan University Hospital|No|Not yet recruiting|January 2016|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with severe sepsis|December 2015|December 17, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452138||20599|
NCT02441400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS500|EndoStim Patient Registry|EndoStim Patient Registry-LES Stimulation System for the Treatment of GERD|RESTORE|EndoStim Inc.|Yes|Recruiting|May 2013|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects with a diagnosis of GERD who are not contraindicated to implantation of the        EndoStim LES Stimulation System.|January 2016|January 25, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02441400|5 Years|21423|
NCT02441413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2014-103_BE|Transplant Optimization Using Functional Imaging (TROFI)|Transplant Optimization Using Functional Imaging (TROFI)|TROFI_BE|FLUIDDA nv|No|Active, not recruiting|September 2015|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02441413||21422|
NCT02454387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4474-01|A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers|A Double-blind, Single and Multiple Ascending Dose, Randomised, Placebo-controlled Study, in Healthy Adult and Elderly Subjects Exploring Safety, Tolerability, Pharmacokinetics of ONO-4474 and Pharmacology of ONO-4474 in NGF-hyperalgesia||Ono Pharmaceutical Co. Ltd|No|Recruiting|May 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Anticipated|176|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02454387||20426|
NCT02454400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prepare|Pre-surgery Physiotherapy for Patients With Specific Low Back Pain|Pre-surgery Physiotherapy for Patients With Specific Low Back Pain , RCT|PREPARE|Linkoeping University|No|Active, not recruiting|September 2012|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|25 Years|80 Years|No|||April 2015|August 31, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02454400||20425|
NCT02454556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMFOL001|A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART|||Gema Biotech S.A.|No|Recruiting|April 2015|March 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|37 Years|No|||May 2015|October 27, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454556||20413|
NCT02453230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17227|The Effect of Light on the Fetal Biophysical Profile|The Effect of Light on the Fetal Biophysical Profile||St. Louis University|No|Recruiting|January 2015|January 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Female|14 Years|60 Years|No|||December 2015|December 9, 2015|January 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02453230||20515|
NCT02453243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H000007010|Emergency Department Safety Assessment and Follow-up Evaluation 2|Emergency Department Safety Assessment and Follow-up Evaluation 2|ED-SAFE-2|University of Massachusetts, Worcester|Yes|Enrolling by invitation|December 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|15000|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02453243||20514|
NCT02440997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 15010015|A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache|A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache||Children's Mercy Hospital Kansas City|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|46|||Both|7 Years|17 Years|No|||May 2015|May 7, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02440997||21454|
NCT02441010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI37B04-05|Application of Monitoring and Intervention Technologies in Suboptimal Health Status|Application of Monitoring and Intervention Technologies in Suboptimal Health Status in a General Population in China||Chinese PLA General Hospital|Yes|Completed|May 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|2014|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02441010||21453|
NCT02458469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURC-062-12S|Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI|Pathogenesis of Sleep Disordered Breathing in Spinal Cord Injury Patients|REST-SCI|VA Office of Research and Development|Yes|Recruiting|May 2015|April 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458469||20113|
NCT02460705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16617|Fecal Microbiota Transplant for Inflammatory Bowel Disease|||University of California, San Francisco|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02460705||19941|
NCT02460731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSP-YP-001|Young Plasma Transfusions for Progressive Supranuclear Palsy|A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy||University of California, San Francisco|No|Recruiting|May 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|85 Years|No|||December 2015|December 2, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460731||19939|
NCT02461381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCANHRVB_Dr.Tang|Bayesian Estimation of Diagnostic Performance of Diabetic Cardiovascular Autonomic Neuropathy Without a Gold Standard|Bayesian Estimation of Diagnostic Performance of Short-term Heart Rate Variability for Diabetic Cardiovascular Autonomic Neuropathy in the Absence of a Gold Standard||Shanghai Tongji Hospital, Tongji University School of Medicine|Yes|Recruiting|January 2013|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Diabetic patients with inclusion and exclusion criteria were recruited from healthy        examination centres to assess cardiovascular autonomic function using both the short-term        heart rate variability and Ewing's tests.|December 2015|December 3, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461381||19889|
NCT02430701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esophageal Neoplasms -IRE-01|Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms: Phase I and Phase II Clinical Trial|IRE|Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|April 29, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02430701||22244|
NCT02430714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEN01T|Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)|Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)||Eisai Inc.|No|Recruiting|May 2015|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|All participants with unresectable thyroid cancer and administrated Lenvatinib in Japan|November 2015|November 5, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430714||22243|
NCT02458560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03|Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve|Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve|CENTERA-EU|Edwards Lifesciences|Yes|Recruiting|March 2015|April 2021|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||January 2016|January 25, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458560||20106|
NCT02458573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0157|Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy|||Yonsei University|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|86|||Both|20 Years|70 Years|No|||May 2015|May 27, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02458573||20105|
NCT02450123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-076|Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors|||Samsung Medical Center|No|Not yet recruiting|May 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|20 Years|N/A|No|||May 2015|May 20, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02450123||20754|
NCT02449655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-122|Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy|||Samsung Medical Center|No|Recruiting|February 2015|December 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|20 Years|N/A|No|||December 2015|December 28, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449655||20790|
NCT02449668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10952-1095|Acupuncture Treatment of Shoulder Impingement Syndrome|Acupuncture Treatment of Shoulder Impingement Syndrome: a Randomized Controlled Trial||Rueda, Juan Carlos, M.D., Ph.D.|No|Completed|March 2012|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||May 2015|May 19, 2015|May 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02449668||20789|
NCT02449941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0341|Helicobacter Pylori and Proton Pump Inhibitor|Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor||Asan Medical Center|No|Active, not recruiting|March 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|19 Years|65 Years|No|Non-Probability Sample|Sample size will be determined based on the analysis the distribution rate of HP at first        30 patients.|May 2015|May 18, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02449941||20768|
NCT02441140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-029|Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis|Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis||Dana-Farber Cancer Institute|Yes|Recruiting|May 2015|April 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|April 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02441140||21443|
NCT02451956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-04-128|Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy|||Samsung Medical Center|No|Recruiting|January 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||May 2015|May 19, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02451956||20613|
NCT02451969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PPV-3001|Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly|Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly||Sinovac Biotech Co., Ltd|No|Active, not recruiting|April 2015|February 2017|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1760|||Both|2 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02451969||20612|
NCT02455128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACM 2015|Therapeutic Listening in Patients With Colorectal Cancer|The Influence of Therapeutic Listening on Anxiety and Fear Related to Surgery in Patients Preoperatively of Colorectal Surgery: a Randomized Clinical Trial||University of Sao Paulo|No|Enrolling by invitation|August 2014|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02455128||20370|
NCT02455141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1501|Adjuvant Treatment of EC Followed by wP and wPCb in Triple-Negative Breast Cancer|Epirubicin-Cyclophosphamide Followed by Weekly Paclitaxel or Weekly Paclitaxel Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial|TPPC|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|July 2015|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|970|||Female|18 Years|70 Years|No|||March 2016|March 10, 2016|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02455141||20369|
NCT02445612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT MA09-hRPE 001(SMD)LTFU|Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients|Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)||Ocata Therapeutics|Yes|Enrolling by invitation|July 2012|December 2030|Anticipated|December 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|13|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is by invitation only for previous participants in the core protocol.|May 2015|May 14, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445612||21100|
NCT02438709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81170805，2008ZX09312-016|Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy|Application of COX-2 Inhibitor for Treatment of Primary Hypertrophic Osteoarthropathy|EOSCITPHO|Peking Union Medical College Hospital|No|Recruiting|December 2012|July 2016|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||April 2015|May 5, 2015|January 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02438709||21629|
NCT02442622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-01059|Effectiveness of Astym Treatment For de Quervain's Tenosynovitis|Effectiveness of Astym Treatment For de Quervain's Tenosynovitis||New York University School of Medicine|No|Recruiting|January 2015|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02442622||21329|
NCT02446587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELECT|Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke|Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT)|SELECT|The University of Texas Health Science Center, Houston|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Eligible patients will be adults (≥18 with the final diagnosis of an acute ischemic        infarction and large artery occlusion in anterior circulation strokes). Given the        observational design of the study there will be no stringent exclusion based on stroke        severity or IV tPA treatment|February 2016|February 9, 2016|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02446587||21025|
NCT02456116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP13067BGMPOA|Efficiency Study About the Effect of Acupuncture on Postoperative Pain After Total Knee Arthroplasty|Efficiency Study About the Effect of Acupunctur on Postoperative Pain After Total Knee Arthroplastry|APOPKA|Medical University of Vienna|No|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|N/A|No|||May 2015|May 27, 2015|May 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02456116||20294|
NCT02456129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15250|Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan|An Open-label Study to Evaluate the Effect of Repeated Oral Administration of 200 mg Itraconazole(ITZ) Given Once Daily Over 14 Days on the Single Oral Dose Pharmacokinetics of Vilaprisan (BAY1002670) as Well as Assessment of Absolute Bioavailability Using a Single Intravenous Microtracer Dose of [14C]Vilaprisan in Healthy Postmenopausal Women||Bayer|No|Completed|July 2015|February 2016|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456129||20293|
NCT02449681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-602|Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS|A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin||Threshold Pharmaceuticals|Yes|Recruiting|August 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|January 4, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449681||20788|
NCT02427828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-0216-OTH|VRES Study in Two Phases to Monitor Cardiac Surgical Patients Following Discharge From ICU|Continuous, Ambulatory, Non Invasive, Vital Sign Monitoring Using VRES of Cardiac Surgical Patients Following Discharge From Intensive Care. Impact on Detection of Physiological Deterioration|VRES|OBS Medical Ltd|No|Completed|March 2013|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|208|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|November 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02427828||22464|
NCT02432768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8-2014-006|The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)|The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)||Rigshospitalet, Denmark|Yes|Recruiting|April 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|November 4, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432768||22086|
NCT02447224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK102048|Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis|A Pilot Study for a Randomized Trial of Antibiotics Versus Surgery for Treatment of Patients With Acute Uncomplicated Appendicitis||Olive View-UCLA Education & Research Institute|No|Active, not recruiting|October 2014|June 2016|Anticipated|October 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|N/A|No|||October 2015|October 13, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447224||20976|
NCT02455661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-560N-MA|Femoral Closure Versus Radial Compression Devices Related to Percutaneous Coronary Interventions Study||FERARI|Universitätsmedizin Mannheim|No|Recruiting|February 2014|||May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 24, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02455661||20329|
NCT02441023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-C01-181015|Nutritional Therapy and Education With Multimedia Application in Patients With Type 2 Diabetes|Nutritional Therapy and Education With a Multimedia Application in the Metabolic Control of Patients With Type 2 Diabetes. Randomized Clinical Trial||Coordinación de Investigación en Salud, Mexico|Yes|Completed|March 2013|December 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Both|30 Years|70 Years|No|||May 2015|February 6, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02441023||21452|
NCT02456870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2411|Expandability of Aging Adipose Tissue|Aging Subcutaneous Adipose Tissue Response to Overfeeding|EAT|University of Colorado, Denver|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|25 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02456870||20236|
NCT02456883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0105|Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456883||20235|
NCT02451774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IICIA -PTX02|Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction|SAFETY AND EFFICACY OF PENTOXIFYLLINE VERSUS PLACEBO ADMINISTERED AS APOPTOSIS INDUCTOR DURING REMISSION INDUCTION PHASE OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA|PTX-II|University of Guadalajara|No|Recruiting|January 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|1 Year|18 Years|No|||December 2015|December 1, 2015|February 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02451774||20627|
NCT02458170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130026|Examination of Biopsies From Healthy Knee Joints|Examination of Biopsies From Healthy Knee Joints for the Use of Research Activities in Inflammatory Joint Diseases||Northern Orthopaedic Division, Denmark|No|Terminated|August 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|43|Samples With DNA|Biopsies from synovial tissue.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Cohorts will be selected from primary care clinic.|May 2015|May 29, 2015|September 12, 2014||No|Shutdown of The Department of Inflammatory Diseases at Novo Nordisk.|No||https://clinicaltrials.gov/show/NCT02458170||20136|
NCT02434458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC15DISI0040|Sudoscan in Patients With Autoimmune Disorders|Investigation of Sudoscan in the Evaluation of Small Fiber Dysfunction in Korean Patients With Autoimmune Disorders||The Catholic University of Korea|Yes|Completed|May 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|85|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients who meet the following diagnostic criteria for either 1. Fibromyalgia or 2.        Rheumatoid arthritis|September 2015|September 12, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02434458||21956|
NCT02434471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00061735|Single Breath Hold Abdominal MRI|Single Breath Hold Abdominal MRI||Duke University||Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02434471||21955|
NCT02460029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoonCat Study|MRI Imaging of Retromuscular Hernia Repair With CICAT Visible®|Prospective MRI Follow-up After Retromuscular Incisional Hernia Repair Using the Dynamesh CICAT Visible® Mesh||Algemeen Ziekenhuis Maria Middelares|No|Recruiting|May 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients scheduled for an open retromusculare repair of an incisional hernia.|January 2016|January 4, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460029||19993|
NCT02455791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1039|Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery|Pilot Study for Identification of Breast Cancer Patients for Potential Avoidance of Surgery: Accuracy of Image Guided Percutaneous Sampling Compared With Surgery to Evaluate Eradication of Breast Cancer After Preoperative Chemotherapy||M.D. Anderson Cancer Center|No|Recruiting|June 2015|||June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02455791||20319|
NCT02448602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangchunUCM|Different Acupoints Compatibility Difference of the Effect of Treatment of the Primary Insomnia|Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect||Changchun University of Chinese Medicine|Yes|Recruiting|January 2015|August 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|333|||Both|18 Years|60 Years|No|||May 2015|May 20, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448602||20871|
NCT02448615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000047574|Birth Cohort in Coast Province, Kenya|A Longitudinal Birth Cohort Study in Coast Province, Kenya||The Hospital for Sick Children|No|Not yet recruiting|July 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|1 Year|No|Probability Sample|All pregnant women (and their unborn newborns) who consent to participate in the control        arm of the previously approved trial "An integrated toolkit to save newborn lives and        brains in Kenya" (NCT02208960) will be eligible for enrollment in this study. At the time        of consent, participants will be informed that they are free to consent to the neonatal        kit trial without consenting to the birth cohort study.|May 2015|May 20, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448615||20870|
NCT02457923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_MSAKHI|Mobile -Solutions Aiding Knowledge for Health Improvement|Mobile Health Solutions to Help Community Providers Promote Maternal & Infant Nutrition & Health - A Community-based Cluster RCT in Rural India to Evaluate M-SAKHI for Use by ASHAs to Reduce Malnutrition in Infants up to 24 Months|M-SAKHI|Lata Medical Research Foundation, Nagpur|Yes|Not yet recruiting|May 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|2728|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02457923||20155|
NCT02458001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 11/111/02|Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer|Developing a Stepped Approach to Improving Sexual Function After Gynaecological Cancer- a Feasibility Study and Randomized Controlled Trial|SAFFRON|University College, London|Yes|Not yet recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||May 2015|May 28, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02458001||20149|
NCT02455713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000047473|Positive Pressure Ventilation and Sternal Closure in HLHS|Effect of Positive Pressure Ventilation on Hemodynamics Around Delayed Sternal Closure Following Stage 1 Palliation of the Single Ventricle||The Hospital for Sick Children|No|Recruiting|February 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|1 Month|No|||May 2015|May 23, 2015|April 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02455713||20325|
NCT02455726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601 gluta-aos|Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease|Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial||Azienda Ospedaliera Spedali Civili di Brescia|No|Not yet recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 25, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02455726||20324|
NCT02456467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17923:|HemoSonics-UVA HemoSonics-UVA Cardiac Surgery Clinical Study Protocol|HemoSonics-UVA Cardiac Surgery Clinical Study Protocol||University of Virginia|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Participants for this study will be recruited at UVA. The subject population will be        representative of the local racial and ethnic population.|May 2015|May 27, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456467||20267|
NCT02453750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000028032|Airway Inflammation in Congenital Diaphragmatic Hernia Patients|Investigation of Airway Inflammation in Congenital Diaphragmatic Hernia Patients||The Hospital for Sick Children|No|Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|6 Years|18 Years|No|||May 2015|May 21, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453750||20475|
NCT02453763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-2012|In Vivo Imaging of Therapeutic Electric Current Flow|In Vivo Imaging of Therapeutic Electric Current Flow|tDCS|University of Florida|Yes|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|24 normal adult subjects will be assessed.|September 2015|September 28, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02453763||20474|
NCT02458053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3193|Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men|Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men|TEAM|University of North Carolina, Chapel Hill|No|Recruiting|February 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458053||20145|
NCT02442817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LING-1|Linagliptin and Mesenchymal Stem Cells: A Pilot Study|Linagliptin and Mesenchymal Stem Cells: A Pilot Study||University of Nevada, Reno|No|Recruiting|April 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|21 Years|45 Years|No|||November 2015|November 30, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02442817||21314|
NCT02432053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0894|A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India|An Open Label, Multi-centre, Prospective Study to Demonstrate Safety and Efficacy of Once Daily Advagraf in Patients Undergoing Kidney or Liver Transplantation in India||Astellas Pharma Inc|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02432053||22141|
NCT02460146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-10-202|PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects|A Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects||Complexa, Inc.|Yes|Recruiting|April 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|June 1, 2015|May 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02460146||19984|
NCT02460159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653C-384|A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)|A Phase III, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Atorvastatin Calcium Monotherapy||Merck Sharp & Dohme Corp.|No|Active, not recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|20 Years|80 Years|No|||March 2016|March 10, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02460159||19983|
NCT02454608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-009H|Trial of Verapamil in Chronic Rhinosinusitis|Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis||Massachusetts Eye and Ear Infirmary|No|Recruiting|May 2015|May 2019|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|80 Years|No|||May 2015|October 29, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454608||20409|
NCT02454621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN-CA-01|Trial of the Smoking Cessation Volitional Help Sheet in Primary Care|Randomized Controlled Trial of the Smoking Cessation Volitional Help Sheet in Primary Care||University of Manchester|No|Withdrawn|May 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 19, 2015||No|The researcher quit the study|No||https://clinicaltrials.gov/show/NCT02454621||20408|
NCT02452203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|float-fMRI-1|Examining the Effects of Reduced Environmental Stimulation on the Brain|Examining the Effects of Reduced Environmental Stimulation on the Brain||Laureate Institute for Brain Research, Inc.|No|Recruiting|May 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02452203||20594|
NCT02443818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLIVIER-FAIVRE Sirolimus|Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA|Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth|PROMISE|Centre Hospitalier Universitaire Dijon||Recruiting|May 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|3 Years|65 Years|No|||March 2015|January 18, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02443818||21238|
NCT02443831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 14/0529|CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies|Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies||University College, London|Yes|Not yet recruiting|March 2016|December 2022|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|24 Years|No|||December 2015|December 1, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02443831||21237|
NCT02443844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16.02.2015 20/03|Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression|||Diskapi Teaching and Research Hospital|No|Recruiting|February 2015|February 2020|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|80 Years|No|||May 2015|May 11, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02443844||21236|
NCT02443857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChARMin|Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin|Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin: A Monocentric Interventional Study||University Children's Hospital, Zurich|Yes|Recruiting|June 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|430|||Both|5 Years|21 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02443857||21235|
NCT02447757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDAR Sokolov|Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth|Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth: Retrospective Observational Study||Brno University Hospital|Yes|Active, not recruiting|January 2010|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parturients during the delivery|May 2015|May 19, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02447757||20936|
NCT02459886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228HV101|Single-Ascending Dose Study of BIIB054 in Healthy Participants|A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects||Biogen|No|Recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|40|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02459886||20004|
NCT02458586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFOP-2|Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)|Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)|UFOP-2|German Institute of Human Nutrition|No|Not yet recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458586||20104|
NCT02435511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG047869-01|Study the Impact of the CommunityRx Program on Health, Self-care and Cost|Evaluating CommunityRx, a Self-Care Innovation for Older Adults, Using Agent-Based Modeling: Collecting and Analyzing Data to Build the Agent Based Model||University of Chicago|No|Recruiting|December 2015|September 2019|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|400|||Both|45 Years|74 Years|No|||March 2016|March 22, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02435511||21875|
NCT02443116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0105|Study of NGM282 in Patients With Nonalcoholic Steatohepatitis|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis||NGM Biopharmaceuticals, Inc|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||November 2015|November 14, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02443116||21291|
NCT02448017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1858|Effects of Herbst Appliance Therapy to Improve Airway Dimension|Effects of Herbst Appliance Therapy to Improve Airway Dimension||The University of Hong Kong|Yes|Active, not recruiting|July 2012|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|11 Years|17 Years|No|||December 2015|December 1, 2015|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02448017||20916|
NCT02449915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-079|Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse|Does Liposomal Bupivacaine Improve Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse? A Randomized Placebo Controlled Trial||TriHealth Inc.|No|Recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|64|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449915||20770|
NCT02452983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36160|Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome|SS1: Pilot Study of Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (MDS)|SS1|Baylor College of Medicine|Yes|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|January 14, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02452983||20534|
NCT02452996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNC-001bis|Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers|A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers||GeNeuro Innovation SAS|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|21|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02452996||20533|
NCT02449798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPW-STP-00007|Prospective Feasibility Trial of AccuCath 2.25" BC Placed in Difficult Access Patients in the Emergency Department|A Prospective Feasibility Trial of AccuCath 2.25" BC Intravascular Catheter System With Retractable Coiled Tip Guidewire Placed in Difficult Access Patients in the Emergency Department||Vascular Pathways, Inc.|No|Recruiting|March 2015|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02449798||20779|
NCT02445287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6M3388|Clinical Evaluation of CARESTREAM Cone Beam Computed Tomography (CBCT)|Clinical Evaluation of CARESTREAM Cone Beam Computed Tomography (CBCT)||Carestream Health, Inc.|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer healthy subjects|May 2015|November 20, 2015|May 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445287||21125|
NCT02457156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL000732|Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy|PANasta Trial Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy - a Double Blinded Multi Centred Trial|PANasta|University of Liverpool|No|Recruiting|April 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|506|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02457156||20214|
NCT02440815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROI MH101472|Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression|Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression||University of California, San Francisco|Yes|Not yet recruiting|November 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|110|||Both|65 Years|N/A|No|||October 2015|October 23, 2015|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02440815||21468|
NCT02456701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN3379-CL-003|Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379|Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in||Kolltan Pharmaceuticals, Inc.|No|Recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456701||20249|
NCT02456714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|volgt|Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma|Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma|4CC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|March 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456714||20248|
NCT02457104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2046|The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43|The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43||University of Colorado, Denver|No|Recruiting|June 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|Samples Without DNA|Stool aspirate will be frozen (temporarily "banked") until a sufficient number of samples is      available to analyze the microbiome in a cost-effective manner. The samples will not be      saved after this microbiome analysis for any future analysis. The colonic and small      intestinal mucosal tissue will be frozen. The colonic and small instestinal samples will be      used for RNA isolation as a part of this study. The remainder of the sample will be banked      for possible future use.|Both|40 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will select four groups of patients presenting for colonoscopy to participate in this        study: normal weight individuals not taking PPI, normal weight individuals taking PPI,        obese individuals not taking PPI, and obese individuals taking PPI.|December 2015|December 21, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02457104||20218|
NCT02457312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-077|The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues|The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues||The University of Hong Kong|No|Completed|March 2013|December 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|May 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457312||20202|
NCT02442115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00212|Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress|The MET Signaling System, Autism and Gastrointestinal Dysfunction||Children's Hospital Los Angeles|No|Recruiting|September 2009|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Urine sample collection. Saliva sample collection for DNA extraction.|Both|5 Years|17 Years|No|Probability Sample|Children with Autism Spectrum Disorders with and without functional constipation|September 2015|September 18, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02442115||21368|
NCT02447172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-TOP-005|Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers|A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer|COACT-2|Innocoll|No|Recruiting|June 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|May 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447172||20980|
NCT02457273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1Z14|Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients|An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinomas||National Health Research Institutes, Taiwan|Yes|Not yet recruiting|June 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|20 Years|N/A|No|||May 2015|May 26, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02457273||20205|
NCT02680795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-BEL-106|To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes|An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes||Spectrum Pharmaceuticals, Inc|No|Not yet recruiting|February 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680795||3046|
NCT02562729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zsfdu-obgyn-003|Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer|A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study||Shanghai Gynecologic Oncology Group|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Female|18 Years|70 Years|No|||September 2015|September 28, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02562729||12108|
NCT02445170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/13/03/02/2014/8|Heath-related Quality of Life of Diabetic Transmetatarsal Amputees and Below-knee Prosthetic Users|Heath-related Quality of Life of Diabetic Transmetatarsal Amputees and Below-knee Prosthetic Users||Helsinki University Central Hospital|No|Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic patients who underwent transmetatarsal amputaion or below-knee prosthetic users        in a time frame of 2-5 years from the amputation.|May 2015|May 12, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02445170||21134|
NCT02438657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013|Ultrasound-guided Nerve Block: Determination of the Minimal Effective Volume of Local Anesthetic|Ultrasound-guided Median Nerve Block With Dextrose 5% Hydrodissection: Determination of the Minimal Effective Volume of Local Anesthetic|VMAL|Hopital Foch|No|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||April 2015|May 7, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438657||21633|
NCT02456480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-008|Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis|A Randomized, Double-blind, Placebo Controlled Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Omiganan in Patients With Mild to Moderate Atopic Dermatitis||Cutanea Life Sciences, Inc.|No|Completed|May 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02456480||20266|
NCT02456493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0254|The Effect of Carotid IMT (Intima Media Thickness) on Postoperative Cognitive Dysfunction in Patients Undergoing Off-Pump Coronary Artery Bypass Graft Surgery|||Yonsei University|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|274|||Both|20 Years|79 Years|No|Non-Probability Sample|patients who are schedued to undergo OPCAB, patients who have coronary artery occlusive        disease (non-surgical group)|June 2015|June 23, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456493||20265|
NCT02446041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BR00034|ICS/LABA Adherence and COPD Exacerbation|Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy||AstraZeneca||Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10000|||Both|40 Years|99 Years|No|Non-Probability Sample|ICS/LABA patients with administrative claims data from health plans in the Northeast,        Midwest, South and West United States.|October 2015|October 29, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02446041||21067|
NCT02446288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMJ-1003|TMJ NextGen Pilot Study to Treat Subjects With Bruxism|A Pilot Study of the TMJ NextGeneration Compared to the DSG Relaxer for Reduction in Nocturnal Bruxism Episodes in Subjects Diagnosed With Sleep Bruxism||Cardiox Corporation|No|Not yet recruiting|June 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02446288||21048|
NCT02452151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMILAR|"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"|Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission.|SIMILAR|Onze Lieve Vrouwe Gasthuis|No|Not yet recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452151||20598|
NCT02459613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13-38|Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis|Evaluation de la rhAnnexine V-128 radiomarquée Dans le Diagnostic de l'Endocardite Infectieuse, du Thrombus Atrial et de Leurs Complications Emboliques associées|AnnIE|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Not yet recruiting|September 2015|||February 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|August 27, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02459613||20025|
NCT02430181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-300|Lonafarnib With and Without Ritonavir in HDV (LOWR-1)|An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)|LOWR-1|Eiger BioPharmaceuticals|Yes|Completed|November 2014|November 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|21|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02430181||22283|
NCT02446548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/Aliskiren/KTx|Influence of Aliskiren on Albuminuria After Kidney Transplantation|Influence of Aliskiren on Albuminuria After Kidney Transplantation||Medical University of Gdansk|No|Completed|March 2013|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02446548||21028|
NCT02446561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMX1509|A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication|||Mundipharma Research Limited|No|Active, not recruiting|April 2015|March 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02446561||21027|
NCT02461433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00030337|Surgical Application of Vac Dressings In Obese Patients to Reduce Wound Complications|The SAVIOR Trial: Surgical Application of Vac Dressings In Obese Patients to Reduce Wound Complications|SAVIOR|Johns Hopkins University|No|Recruiting|June 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461433||19885|
NCT02461199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02KOHAM|Stool Transplantation to Reduce Antibiotic Resistance Transmission|Prospective Observational Study of Fecal Microbiota Transplantation Used to Eradicate Gut-colonizing Multidrug-resistant Bacteria in Patients With Blood Disorders|START|Medical University of Warsaw|No|Recruiting|February 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Stool samples collected before and after the procedure.|Both|18 Years|N/A|No|Probability Sample|Patients with blood disorders treated in the Department of Hematology, Oncology and        Internal Diseases, with positive gut colonization status with MDR bacteria, who consent        for fecal microbiota transplantation.|June 2015|June 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02461199||19903|
NCT02442414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5209-CPK-1001|A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors|||Sihuan Pharmaceutical Holdings Group Ltd.|No|Recruiting|April 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|May 8, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02442414||21345|
NCT02447991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-001549|Rizatriptan for Episodic Dizziness in Vestibular Migraine|A Phase II/III Trial on Rizatriptan for Vestibular Migraine||University of California, Los Angeles|Yes|Recruiting|December 2014|June 2019|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447991||20918|
NCT02446054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013CMP-V2|A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease|A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease||Celio Technology Inc.|No|Completed|February 2014|December 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|30 Years|60 Years|No|||May 2015|January 27, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02446054||21066|
NCT02446067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRanchi|Cerebral Hemodynamics With rTMS in Alcohol Dependence|Cerebral Hemodynamics With rTMS in Alcohol Dependence: A Randomized, Sham Controlled Study||Central Institute of Psychiatry, Ranchi, India|No|Completed|March 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02446067||21065|
NCT02434939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/HD07/606U|Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers|Low-dose Ketamine Versus Morphine for Severe Painful Sickle Cell Crises in Children at Mulago Hospital: A Randomised Controlled Trial|KEM-VOC|Makerere University|Yes|Completed|June 2015|February 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|7 Years|18 Years|No|||July 2015|February 12, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02434939||21919|
NCT02435173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCDZ173X2201|Study of Efficacy of CDZ173 in Patients With APDS/PASLI|An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Double-blind Placebo Controlled Study With Extension to Assess the Safety and Efficacy of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)||Novartis|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|16 Years|75 Years|No|||March 2016|March 17, 2016|February 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02435173||21901|
NCT02448225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 1524|18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules|PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|June 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|40 Years|80 Years|No|||January 2016|January 4, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448225||20900|
NCT02448238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUHIV001|Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Chronic Immune Activation in HIV-infected Malian Women|A Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Microbial Translocation and Chronic Immune Activation in HIV-infected Malian Women||Virginia Commonwealth University|No|Recruiting|May 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448238||20899|
NCT02454582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Number: 1264/2014|Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation|Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation||Medical University of Vienna||Completed|January 2015|March 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454582||20411|
NCT02453802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D1051|Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty|Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty||Chang Gung Memorial Hospital|Yes|Not yet recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|50 Years|80 Years|No|||May 2015|May 26, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02453802||20471|
NCT02455284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANR 14 - CD / FIBRATLAS|In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III|In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III|FIBRATLAS|University Hospital, Tours|No|Recruiting|October 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|184|||Both|82 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02455284||20358|
NCT02455297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17120|Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib||Bayer|No|Recruiting|August 2015|September 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02455297||20357|
NCT02449954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43|Effect of Morphine, Tramadol, and Ketorolac on Postoperative Stress and Immune Responses|Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy||Assiut University|No|Active, not recruiting|June 2014|June 2015|Anticipated|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|60|||Female|20 Years|60 Years|No|||May 2015|May 18, 2015|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02449954||20767|
NCT02455011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R477-201|Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus|A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus||REMD Biotherapeutics, Inc.|Yes|Recruiting|September 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|72|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|May 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455011||20379|
NCT02442635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-15691|Yoga During Chemotherapy Study|Developing a Yoga Intervention During Cancer Chemotherapy||University of California, San Francisco|Yes|Recruiting|May 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02442635||21328|
NCT02450578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_DSM265_14_01|DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria|Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge||Medicines for Malaria Venture|Yes|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|March 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450578||20719|
NCT02450591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-067|Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations|Pilot Study of Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations||Memorial Sloan Kettering Cancer Center||Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02450591||20718|
NCT02455232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00444-45|Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients|Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients|FLEXELBOW|Centre d'Investigation Clinique et Technologique 805|No|Recruiting|May 2015|October 2015|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|75 Years|No|||June 2015|June 20, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02455232||20362|
NCT02455245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGG 14C03|A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma|A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|March 2015|||April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|21 Years|No|||January 2016|January 27, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02455245||20361|
NCT02432781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0151|Oral Carbohydrate in DM Patients Undergoing Total Knee Arthroplasty|Effect of Preoperative Oral Carbohydrates on Postoperative Nausea and Vomiting and Quality of Recovery in DM Patients Undergoing Total Knee Arthroplasty||Severance Hospital|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|82|||Both|19 Years|N/A|No|||January 2016|January 29, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02432781||22085|
NCT02454023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116-2015|SLEep APnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke|SLEep APnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke (SLEAP SMART): A Randomized Controlled Trial|SLEAP SMART|Sunnybrook Health Sciences Centre|No|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|238|||Both|N/A|N/A|No|||September 2015|September 9, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02454023||20454|
NCT02454036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-GYN-02-MCC|Biobehavioral Intervention in Gynecologic Oncology Patients|Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation||University of Kentucky|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|21 Years|80 Years|No|||January 2016|January 12, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02454036||20453|
NCT02450916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406016RINC|An Interview Study With Injured Workers Concerning Their Experiences With the Social Systems and Psychosocial Health Consequences|An Interview Study With Injured Workers Concerning Their Experiences With the Social||National Taiwan University Hospital|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|51|||Both|15 Years|N/A|No|Non-Probability Sample|Subjects who had ever experienced work-related injuries or diseases over the past 3 years        are invited.        Inclusion Criteria:          1. work-related injuries          2. work-related diseases        Exclusion Criteria:        1.transportation-related injuries on the way to work or on duty at work|May 2015|May 18, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02450916||20693|
NCT02451163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fib-CC-2014|DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly|A Randomized, Controlled Clinical Study on the Effect of Polysaccharides From Wheat on Common Cold Infections in Elderly|Fib-CC-2014|Clinical Research Center Kiel GmbH|No|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|380|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451163||20674|
NCT02445391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1131|Platinum Based Chemotherapy or Observation in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy|A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy||Eastern Cooperative Oncology Group|Yes|Recruiting|April 2015|||May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|558|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02445391||21117|
NCT02442713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVD002|The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia|A Baseline Controlled Study With Fluvoxamine to Evaluate the Effect on Polysonogram in Depressed Patients With Insomnia||Guang Dong Provincial Mental Health Institute|No|Recruiting|November 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 9, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02442713||21322|
NCT02447185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDR-RAN-RCT-LSY|25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial|25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial|aiRTo-PDR|The First People's Hospital of Xuzhou|No|Recruiting|June 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447185||20979|
NCT02447484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA039071|Texting Intervention to Sustain HIV Prevention in Women in High-drug-use Contexts|Texting Intervention to Sustain HIV Prevention in Women in High-drug-use Contexts||University of California, San Diego|Yes|Not yet recruiting|January 2016|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02447484||20957|
NCT02457000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-14-23|Sleep, Circadian Rhythm & Skin Health|Sleep, Circadian Rhythm & Skin Health||University Hospital Case Medical Center|Yes|Recruiting|March 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|50|Samples Without DNA|Skin, blood, urine, saliva and hair follicle samples may be collected from volunteers to      look at various markers related to sleep, the circadian rhythm and skin disease.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults from Northeast Ohio who are either healthy, normal volunteers or have skin        pathology including but not limited to eczema, psoriasis, acne, and other inflammatory        dermatoses|December 2015|December 3, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02457000||20226|
NCT02446483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201527|A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults|Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt)and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions||GlaxoSmithKline|No|Completed|March 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02446483||21033|
NCT02442726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2014-002|Activation of A-delta-fibres and C-fibres in a First Degree Thermal Injury in Volunteers|Activation of A-delta-fibres and C-fibres in a First Degree Thermal Injury in Volunteers|BI-Laser|University of Copenhagen|No|Completed|May 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02442726||21321|
NCT02460666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT008383-01A1|Brain Connectivity and Response to Tai Chi in Geriatric Depression|||University of California, Los Angeles|Yes|Not yet recruiting|July 2015|||March 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|60 Years|N/A|No|||May 2015|May 29, 2015|March 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02460666||19944|
NCT02453490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCLM-01|Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis|The Second Affiliated Hospital of Zhejiang University||Zhejiang University|No|Not yet recruiting|May 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|May 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02453490||20495|
NCT02435693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pc|Pharmaceutical Care Program for Type 2 Diabetes Mellitus|Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule|pcp|R. C. Patel Institute of Pharmaceutical Education & Research|No|Completed|July 2012|November 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Both|35 Years|N/A|No|||November 2015|November 3, 2015|February 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02435693||21861|
NCT02444728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTAR001|Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE|Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus|CHORUS|Chinese SLE Treatment And Research Group|No|Recruiting|July 2015|December 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|70 Years|No|||July 2015|December 15, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444728||21168|
NCT02444299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908-T-RESURF-RM|Aequalis Resurfacing Head Study|An Observational Cohort Study Evaluating the Safety and Performance of Aequalis Resurfacing Head Implant in a Consecutive Series of Patients With Shoulder Arthroplasty||Tornier, Inc.|No|Active, not recruiting|April 2011|April 2021|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from 6 centers in Europe where shoulder arthroplasty with        Aequalis® Resurfacing Head is performed.        The first 100 patients treated in the centers will be included then followed-up, until the        10 years follow-up visit.|May 2015|May 18, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444299||21201|
NCT02459197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1001-02|A Proof of Concept Study to Investigate the Effect of a New Treatment in Patient With Chronic Pain|A Proof of Concept Study to Investigate the Effect of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain or Osteoarthritic Pain of Knee or Hip||Tools4Patient|No|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|132|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459197||20057|
NCT02445365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140133|Remote Ischemic Conditioning in Patients With Ulcerative Colitis|Effect of Remote Ischemic Conditioning (RIC) on Inflammation and Remodelling of Extracellular Matrix Proteins in Patients With Inflammatory Bowel Diseases||Odense University Hospital|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|38|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 12, 2015||||No||https://clinicaltrials.gov/show/NCT02445365||21119|
NCT02432274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-207|Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies|Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies||Eisai Inc.|No|Recruiting|December 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|99|||Both|2 Years|18 Years|No|||February 2016|February 19, 2016|April 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432274||22124|
NCT02447510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams Universty|Growth Factors Release of PRF and PRGF|Crevicular Fluid Growth Factors Release Profile Following the Use of Platelets Rich Fibrin (PRF) and Plasma Rich Growth Factors (PRGF) in Treating Periodontal Intrabony Defects (Randomized Clinical Trial)||Al-Azhar University|No|Completed|September 2014|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02447510||20955|
NCT02459249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206-6941 CI:1198|Metabolic Syndrome Diagnosis and Treatment for Adults of Low Socioeconomic Status Communities|Treatment of Metabolic Alterations in Adults Living in Communities With Low Socioeconomic Status|PrEVEnTYCM|Mexican National Institute of Public Health|Yes|Recruiting|April 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|55 Years|No|||February 2016|February 23, 2016|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02459249||20053|
NCT02458131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0901|Community-based Adolescent Diabetes Prevention Program|TEEN HEED: An Adolescent Peer Led Diabetes Prevention Intervention||Icahn School of Medicine at Mount Sinai|No|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02458131||20139|
NCT02432560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDAS|Safety and Durability of Sirolimus for Treatment of LAM|Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)|MIDAS|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|March 2015|April 2020|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Rare Lung Disease Clinical Network Consortium Clinics|April 2015|May 1, 2015|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02432560||22102|
NCT02453139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202370|Exercise, Prostate Cancer and Circulating Tumour Cells|Evasion of Immune Editing by Circulating Tumour Cells in an Exercise Modifiable Mechanism Underlying Aggressive Behaviour in Obese Men With Prostate Cancer|ExPeCT|University of Dublin, Trinity College|No|Recruiting|October 2014|September 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02453139||20522|
NCT02445105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH104423|Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services|Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services||Florida State University|Yes|Enrolling by invitation|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|72474|||Both|N/A|N/A|No|||December 2015|December 16, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02445105||21139|
NCT02447874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077736|Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease|Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell Disease|R34 pK/PD|Emory University|No|Enrolling by invitation|May 2015|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|7 Years|21 Years|No|||May 2015|May 15, 2015|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02447874||20927|
NCT02443129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/14|Swept Source Enhanced Depth Imaging Optical Coherence Tomography|Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease||Shaare Zedek Medical Center|No|Not yet recruiting|May 2016|August 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|9||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|March 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443129||21290|
NCT02443922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Cell - Protocol 2|Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM|Dynamic Responsiveness of Insulin Secretory Parameters to Sitagliptin and Glimeperide Administration in Subjects With Type 2 Diabetes Mellitus: An Open Label Study||Foundation for the National Institutes of Health|No|Not yet recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|100|||Both|30 Years|65 Years|No|||May 2015|May 11, 2015|May 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02443922||21230|
NCT02453412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT12.01|Preoperative Arteriovenous Fistula Simulation Study|Randomized-controlled Clinical Trial for the Evaluation of the Efficacy of Computational Simulation for the Planning of Vascular Access Surgery in Hemodialysis Patients|3S|Maastricht University Medical Center|No|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|372|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02453412||20501|
NCT02454946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERDL-27|Blood Types and Erectile Dysfunction|The Relation Between ABO Blood Types and Erectile Dysfunction||T.C. ORDU ÜNİVERSİTESİ|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|102|||Male|N/A|N/A|No|Probability Sample|Administered to urology polyclinic between April 2013 and April 2014. Sexually active 102        patients whose blood types were known were included in this study.|May 2015|May 27, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454946||20383|
NCT02454959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003013|Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD|A Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects With Moderate to Severe COPD With and Without a Valved Holding Chamber||Pearl Therapeutics, Inc.|No|Recruiting|May 2015|September 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||February 2016|February 17, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454959||20382|
NCT02458261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-6119|Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy|Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy||University of Cincinnati|No|Enrolling by invitation|March 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Samples that are being collected are as follows: serum, continuous renal replacement therapy      effluent, and urine (if patient is making urine during sample collection). Drug assays will      be performed for each sample and samples will be disposed of after the final analysis is      complete. The assays are not interventional and patient care does not change as a result of      study enrollment.|Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients on continuous renal replacement therapy who are being initiated on        cefepime 2000 mg IV every 8 hours with a four-hour infusion|December 2015|December 3, 2015|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02458261||20129|
NCT02453958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC_mTBI_001|Mild Traumatic Brain Injury Discrimination|Non-Invasive Assay to Discriminate Mild Traumatic Brain Injury|MTBID|Empirical Technologies Corporation|No|Completed|June 2011|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02453958||20459|
NCT02454010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF21101US101|A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer|A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer||Fujifilm Pharmaceuticals U.S.A., Inc.|Yes|Recruiting|January 2016|December 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02454010||20455|
NCT02453152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500379|Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)|Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)||University of Florida|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Male|N/A|14 Years|No|Non-Probability Sample|Males with geneticially confirmed XLMTM|October 2015|October 29, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02453152||20521|
NCT02453425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sepsis-studien|The Effects of Blood Pressure on Renal Function and Oxygenation in Septic Shock|Goal Directed Therapy in Septic Shock - the Effects of Mean Arterial Pressure Levels, Adjusted With Norepinephrine, on Renal Perfusion, Function and Oxygenation.||Sahlgrenska University Hospital, Sweden|No|Recruiting|May 2011|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|8|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02453425||20500|
NCT02457871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144-PRJ94IR|Promoting Self-Management in Low Income African Americans Living With Hypertension|Promoting Self-Management in Low Income African Americans Living With Hypertension|ENCM|University of Wisconsin, Milwaukee|Yes|Recruiting|July 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|65 Years|No|||June 2015|June 23, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02457871||20159|
NCT02442037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-IVY-SC-002|Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Active Ulcerative Colitis.|UCMSC-UC|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|May 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2015|May 14, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02442037||21374|
NCT02446873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201409108|Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador|Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador||Washington University School of Medicine|No|Active, not recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|6 Months|9 Months|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02446873||21003|
NCT02446886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1405015090|Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS|Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS||Weill Medical College of Cornell University|Yes|Not yet recruiting|April 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|May 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02446886||21002|
NCT02445079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001928|Ugandan Non-Communicable Diseases and Aging Cohort|Epidemiology of Atherosclerosis Among Older-Age People in Southwestern Uganda|UGANDAC|Massachusetts General Hospital|No|Recruiting|December 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|Annual collection of serum, plasma, and stool.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study recruits two sub-groups of participants:        Study Group 1:        -HIV infected persons aged 40 and older, in care at the Immune Suppression Syndrome HIV        Clinic at Mbarara Regional Referral Hospital        Study Group 2:        -Community-based, HIV uninfected persons recruited from the catchment area of the Mbarara        Regional Referral Hospital (greater Mbarara), and age and gender-matched to Group 1        participants|March 2016|March 14, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02445079||21141|
NCT02444377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1026|High-intensity Interval Training in Overweight/Obese|Impact of Varying High-intensity Interval Protocols on Cardiometabolic Risk Factors in Overweight/Obese||University of North Carolina, Chapel Hill|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444377||21195|
NCT02430493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130R00026|Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients|A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients|YingLong|AstraZeneca|No|Recruiting|May 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one        tablet from the department of cardiology in the around 20 tier-2 or 3 hospitals.|March 2016|March 2, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02430493|1 Year|22260|
NCT02452320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503016056|Prospective, Double Blind, Placebo Control, Bariatric IV Ace|Prospective, Double Blind, Placebo Control, Study of Acetaminophen iv on Hospital Length of Stay in Morbidly Obese Individuals Undergoing Elective Laparoscopic Sleeve Gastrectomy|Bariatricace|Weill Medical College of Cornell University|No|Recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452320||20585|
NCT02444832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeurovascCDI001|Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy|Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy|MACAARET|Hospital Clinic of Barcelona|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Communicating Artery Aneurysm treated with endovascular coiling.|May 2015|May 14, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444832||21160|
NCT02444845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27762|Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan|Prevalence of Anaemia Secondary to Early Stage Chronic Kidney Disease in High Risk Diabetic and/or Hypertensive Population||Hoffmann-La Roche||Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|246|None Retained|Samples will be collected to determine glomerular filtration rate (eGFR) as well as anemia      profile.|Both|40 Years|N/A|No|Non-Probability Sample|The study will enroll high-risk hypertensive and/or diabetic patients in Pakistan who meet        eligibility criteria for observation.|May 2015|May 14, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02444845||21159|
NCT02451800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411008|Exercise: Improving Compliance and Long-term Weight Loss|Exercise: Improving Compliance and Long-term Weight Loss With Sanford Profile Program||South Dakota State University|No|Recruiting|February 2015|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02451800||20625|
NCT02438904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0295|Miltenyi Device for CD34 Selection|Miltenyi Device for CD34+ Cell Selection||M.D. Anderson Cancer Center|No|Recruiting|May 2015|||May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||December 2015|December 30, 2015|May 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02438904||21614|
NCT02450552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014D002776|Clinical Trial of Ezogabine (Retigabine) in ALS Subjects|A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis||Massachusetts General Hospital|Yes|Recruiting|June 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|192|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02450552||20721|
NCT02454478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-112|Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)|Phase 1 Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic RCC||Eisai Inc.|No|Active, not recruiting|July 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|N/A|No|||December 2015|January 19, 2016|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02454478||20419|
NCT02450110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID-HELP|A Pilot Study of Spinal Cord Stimulation in Heart Failure Patients With Depressed Left Ventricular Function||RAPID-HELP|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health||Recruiting|February 2015|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02450110||20755|
NCT02461355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1700|Transcranial Direct Current Stimulation for Post-Stroke Aphasia|Enhancing Aphasia Therapy With Anodal Transcranial Direct Current Stimulation in Chronic Stroke Patients||Columbia University|No|Recruiting|June 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|21 Years|N/A|No|||June 2015|June 2, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02461355||19891|
NCT02434419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURJC2015-02|Effect of Pectoral Electrostimulation on Reduction of Mammary Ptosis|Effect of Pectoral Electrostimulation on Reduction of Mammary Ptosis After Bariatric Surgery||Hospital General Universitario Elche|Yes|Completed|January 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|45|||Female|N/A|N/A|No|||April 2015|May 4, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02434419||21959|
NCT02434432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUR.LB.02|Music Therapy for Pain Management in the NICU Setting|Music Therapy as a Method of Non-Pharmacological Pain Management in the NICU Setting|MTP|American University of Beirut Medical Center|No|Completed|January 2014|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|40|||Both|28 Weeks|36 Weeks|No|||April 2015|April 30, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02434432||21958|
NCT02450812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18043|Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany|URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra- 223 Dichloride (Xofigo) Treated Chemotherapy naïve mCRPC Patients in a Real Life Setting in Germany|URANIS|Bayer|No|Recruiting|May 2015|January 2020|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|N/A|No|Non-Probability Sample|The study population will consist of chemotherapy-naive mCRPC patients with symptomatic        bone metastases without known visceral metastases for whom the attending physician decided        according to his/her medical practice to treat the patient with Radium-223 dichloride.|March 2016|March 16, 2016|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450812||20701|
NCT02451072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSDPUK-126|The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers|The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers||Psychiatric University Hospital, Zurich|Yes|Completed|March 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|25|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02451072||20681|
NCT02445833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vivir mejor|On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive Patients|Design, Development And Validation Of A On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive And Risk For Diabetes Mellitus People With Overweight And Type I Obesity|VIVIR-MEJOR|Universitat Jaume I|No|Active, not recruiting|September 2014|March 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02445833||21083|
NCT02458313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0650|Nicotinic Agonist Effects on BMI and Neuronal Response|Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults||University of Colorado, Denver|Yes|Recruiting|November 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|100|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02458313||20125|
NCT02444390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1403|Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor|Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women|SAFIR-TOR|UNICANCER|No|Recruiting|April 2015|July 2020|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02444390||21194|
NCT02431273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARV-IVR 01|Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women|Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women||Auritec Pharmaceuticals|No|Recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|6|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|August 4, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02431273||22201|
NCT02431832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILI_Elderly|Exploration of microRNA and Metabolomics Biomarkers Predicting Drug Induced Liver Injury in Elderly People|||Seoul National University Hospital||Recruiting|February 2015|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Male|65 Years|84 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02431832||22158|
NCT02453113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2015-1840|Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment|Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment||University of California, Irvine|Yes|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02453113||20524|
NCT02453373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRS-01-13-01|Helping Stroke Patients With ThermoSuit Cooling|Helping Stroke Patients With ThermoSuit Cooling|SISCO|Life Recovery Systems|Yes|Recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453373||20504|
NCT02449863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-07-15|Lung Ultrasound as a Predictor of Mechanical Ventilation in Neonates Older Than 32 Weeks|Lung Ultrasound as a Predictor of Mechanical Ventilation in Neonates Older Than 32 Weeks||Hospital Sant Joan de Deu|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|32 Weeks|N/A|No|Non-Probability Sample|Patients older than 32 weeks admitted to the neonatal intensive care unit with respiratory        distress who were not on invasive mechanical ventilation (MV) were eligible for        recruitment.|May 2015|May 19, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449863|2 Days|20774|
NCT02449876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNE 123|The Feasibility of Using Neuroscience Education in Adults Over 65 Years Old With Chronic Low Back and/or Lower Extremity Pain|The Feasibility of Using Neuroscience Education in Adults Over 65 Years Old With Chronic Low Back and/or Lower Extremity Pain||State University of New York - Upstate Medical University|No|Not yet recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|65 Years|N/A|No|||May 2015|May 19, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449876||20773|
NCT02445118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTF 184N|Allograft Adipose Matrix (AAM) in Subcutaneous Dorsal Wrist|Local Skin and Volume Changes With the Use of Allograft Adipose Matrix (AAM) in the Subcutaneous Human Dorsal Wrist, a Pilot Study||Musculoskeletal Transplant Foundation|No|Recruiting|May 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-smoking females between 45 and 65 years of age with a BMI <30, with well controlled        blood pressure, no active infections, collagen disorders,vascular diseases, history of        lymphedema, mastectomy, lymph node dissection, end stage organ failure such as COPD, CRF,        or CHF, and who have not undergone deep chemical peels, laser, Ultherapy, Thermage or        other light or energy based procedures to the dorsum of the hands within the past year.|May 2015|May 20, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02445118||21138|
NCT02445131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2-BCG|Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)|Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients|CLL2-BCG|German CLL Study Group|No|Recruiting|May 2015|May 2020|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02445131||21137|
NCT02441088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412770|Theranostics: 68GaDOTATOC and 90YDOTATOC|Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET|PRRT|University of Iowa|Yes|Recruiting|May 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|6 Months|N/A|No|||August 2015|August 3, 2015|May 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02441088||21447|
NCT02453386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOZ-CL05|Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)|TOZ-PD|Biotie Therapies Inc.|Yes|Recruiting|July 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|30 Years|80 Years|No|||March 2016|March 9, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453386||20503|
NCT02453646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR 0147|Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter|Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter||Marvao Medical|Yes|Recruiting|April 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|80 Years|No|||September 2015|December 2, 2015|May 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02453646||20483|
NCT02461212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078470|Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth|Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth||Emory University|No|Recruiting|May 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|75|||Both|7 Years|18 Years|No|||December 2015|December 8, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02461212||19902|
NCT02461225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_DPN|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||February 3, 2016|June 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02461225||19901|
NCT02457481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFFR-OEC-2015|An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro|An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro||National Foundation for Fertility Research|No|Active, not recruiting|May 2015|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457481||20189|
NCT02442453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHANASHREE786|Effect of Scaling and Root Planing Along With Topical Application of Commercially Available Curcuma Longa Gel on Superoxide Dismutase and Malondialdehyde Levels in Saliva of Chronic Periodontitis Patients|||Tatyasaheb Kore Dental College||Completed|January 2014|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|April 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02442453||21342|
NCT02442466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MelCure|Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma|||MelCure SA||Terminated|May 2011|||May 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|April 26, 2015||No|Difficulties to recruit on time the required patient population.|No||https://clinicaltrials.gov/show/NCT02442466||21341|
NCT02458651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO29443|Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China|An Observational Study of Patients With Newly Diagnosed Unresectable Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) in China||Hoffmann-La Roche||Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1585|||Both|N/A|N/A|No|Non-Probability Sample|Participants with newly diagnosed, unresectable Stage IIIB or IV non-small cell lung        cancer (NSCLC)|March 2016|March 1, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458651||20099|
NCT02444247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC400|Motivation to Exercise|Motivation to Exercise|Motiv2Ex|USDA Grand Forks Human Nutrition Research Center|No|Recruiting|May 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02444247||21205|
NCT02460744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHRT|2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer|A Phase II Study of 2-weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiotherapy in Patients With Breast Cancer||Postgraduate Institute of Medical Education and Research|No|Completed|June 2013|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|85 Years|No|||May 2015|June 1, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02460744||19938|
NCT02460757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLKEssenVC|Glottic Width and Respiratory Flow in Patients With Various Lung Diseases|Glottic Width and Respiratory Flow in Patients With Various Lung Diseases||University Hospital, Essen|No|Completed|February 2014|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with various lung diseases in a primary care clinic|December 2015|December 8, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02460757||19937|
NCT02446652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(014/037/ICI)(CEI/941/14)|Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer|Phase III Clinical Trial: "Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer||National Institute of Cancerología|Yes|Not yet recruiting|July 2015|August 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Female|18 Years|N/A|No|||May 2015|May 13, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02446652||21020|
NCT02457533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM1|Case Management - Active Telephone Support to Patients With COLD|Active Support to Patient With COLD||Region Sjælland|No|Recruiting|April 2015|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02457533||20185|
NCT02457546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-14-002|The EVICEL® Neurosurgery Phase III Study|A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair||Ethicon, Inc.|No|Recruiting|July 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|230|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|May 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02457546||20184|
NCT02429115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR-1310-07055|Peer-mentoring, Quality of Life and Caregiver Burden in Patients With Chronic Kidney Disease and Their Caregivers|Improving Patient Quality of Life and Caregiver Burden by a Peer-Led Mentoring Program for Patients With Chronic Kidney Disease and Their Caregivers||Milton S. Hershey Medical Center|No|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|216|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02429115||22365|
NCT02433340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-965|Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study|Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)||AbbVie|Yes|Active, not recruiting|April 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|163|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|April 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02433340||22042|
NCT02457208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1407|PK Study of Anti-TB Drugs|Studying the Blood Levels of First-line Anti-tuberculosis Drugs in Relation to Treatment Outcomes Among Newly Diagnosed Adults With Pulmonary Tuberculosis on the Thai-Myanmar Border||University of Oxford|No|Not yet recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02457208||20210|
NCT02457221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0912|A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis|A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis||Astellas Pharma Inc|No|Recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|60 Years|No|||February 2016|February 26, 2016|May 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457221||20209|
NCT02459015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG-001|Performance Study of an Artificial Nerve Guide (Reaxon® Nerve Guide) to Treat Digital Nerve Lesions|A Controlled, Randomized, Comparison, Blind Evaluation of Repair of Digital Nerve Lesions in Man Using an Implanted Reaxon® Nerve Guide||Medovent GmbH||Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459015||20071|
NCT02458040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BENEBIO01|Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs|Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs||Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|This is a systematic review. No patient will be directly included in this study, but the        investigators will include clinical trials.|May 2015|May 28, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02458040||20146|
NCT02438956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500236|Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo|Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo|GSH|University of Florida|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|120|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02438956||21610|
NCT02438969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150127|Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence|(Epi)Genetic Modulators of Fear Extinction in Alcohol Dependence||National Institutes of Health Clinical Center (CC)||Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|120|||Both|21 Years|65 Years|No|||February 2016|March 3, 2016|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02438969||21609|
NCT02456727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4192|Acupuncture Approaches for Chronic Pain|Acupuncture Approaches to Decrease Disparities in Outcomes of Pain Treatment - A Two Arm Comparative Effectiveness Trial|AADDOPT-2|Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|May 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|March 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02456727||20247|
NCT02455154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1502|Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy|Traditional Chinese Medicine as Preventive Method for Osteoporosis in Early Breast Cancer Patients Receiving Adjuvant Endocrine Therapy|COAT|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|May 2015|September 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Female|18 Years|N/A|No|||December 2015|December 29, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02455154||20368|
NCT02455362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022/13 V.3.2.3|Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease|A Multi-site, Double-blind, Parallel Arm, Block Randomised, Placebo Controlled, Factorial Phase III Study of Opioids for Chronic Refractory Breathlessness in People With Chronic Obstructive Pulmonary Disease.||Flinders University|Yes|Withdrawn|May 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 20, 2015||No|'Recruitment not possible given changes to trial criteria|No||https://clinicaltrials.gov/show/NCT02455362||20352|
NCT02449967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatic Cancer HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Withdrawn|May 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02449967||20766|
NCT02449980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-32402|Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax|Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax: A Randomized Controlled Trial||Baylor College of Medicine|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|5 Years|18 Years|No|||January 2016|January 25, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02449980||20765|
NCT02429661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-GF-IN-2013|Girls First - India (2013-2015)|Girls First - India Evaluation (2013-2015)||CorStone|No|Completed|May 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|4592|||Both|9 Years|20 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02429661||22323|
NCT02429947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC6606|An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients|An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients||University of South Florida|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|411|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CMT, 18 years or older, who have joined the Inherited Neuropathies        Consortium RDCRN Contact Registry.|April 2015|April 28, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02429947||22301|
NCT02451111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 35/14|Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma|Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.||Swiss Group for Clinical Cancer Research|Yes|Recruiting|October 2015|December 2029|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|85 Years|No|||December 2015|December 14, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02451111||20678|
NCT02459184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH2015|addressInG iNcome securITy in Primary carE|IGNITE (addressInG iNcome securITy in Primary carE) Study: A Pragmatic Randomized Controlled Trial|IGNITE|St. Michael's Hospital, Toronto|No|Not yet recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459184||20058|
NCT02450981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-021-1|Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration|Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration||Biocad|No|Not yet recruiting||||September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|50 Years|N/A|No|||May 2015|May 22, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02450981||20688|
NCT02457845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1472|HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors|Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors||University of Alabama at Birmingham|Yes|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|3 Years|18 Years|No|||November 2015|November 30, 2015|May 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02457845||20161|
NCT02443753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1|EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects|A Pilot Safety and Tolerability Study of the Use of the EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects||GI Dynamics|No|Terminated|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02443753||21243|
NCT02443779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.060|Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease|Relationship Between Symptom Severity, Retinal Morphology, and the Nigrostriatal Dopamine System in the Brain in Parkinson's Disease||Thomas Jefferson University|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|12|||Both|50 Years|80 Years|No|Non-Probability Sample|The study population will be Parkinson's disease patients (Hoehn and Yahr stage 1 - 3).        One study group will be subjects (N = 6) with early PD who will be within 3 years from        diagnosis and not requiring dopaminergic therapy. These subjects will need to have Unified        Parkinson's Disease Rating Scale motor scores of 10 - 15. The second study group will be        subjects (N = 6) with more advanced PD and will have had PD for at least 5 years and will        need to have Unified Parkinson's Disease Rating Scale motor scores of > 20.|September 2015|September 29, 2015|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02443779||21241|
NCT02459145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS0001|Assessing the Effects of a Clinical Exercise Protocol on Children With Post-concussion Syndrome|Assessing the Effects of a Clinical Exercise Protocol on Children With Post-concussion Syndrome||University of Arizona|No|Withdrawn|June 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|13 Years|18 Years|No|||January 2016|January 25, 2016|May 19, 2015||No|PI Left Insitution - study no RCT|No||https://clinicaltrials.gov/show/NCT02459145||20061|
NCT02459158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1100-CL-103|A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia|A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of ME1100 Inhalation Solution Plus Best Available Therapy Versus Best Available Therapy Alone in the Treatment of Mechanically Ventilated Patients With Bacterial Pneumonia||Meiji Seika Pharma Co., Ltd.|No|Recruiting|September 2015|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02459158||20060|
NCT02440906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168-2012|Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project|Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project|WIN|University of Florida|No|Active, not recruiting|June 2012|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1663|||Both|21 Years|55 Years|No|||February 2016|February 18, 2016|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02440906||21461|
NCT02448745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiberiaDL|Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL)|||The Mentor Initiative||Enrolling by invitation|January 2014|April 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1900|||Both|2 Months|59 Months|Accepts Healthy Volunteers|||May 2015|May 15, 2015|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02448745||20860|
NCT02448758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB(NPC)²-1209|Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)|Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais|CB(NPC)²|Centre Oscar Lambret|No|Recruiting|September 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|785|||Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer with mutation of the Nord Pas de Calais|May 2015|May 15, 2015|March 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02448758||20859|
NCT02448576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-5010-TNBC-PCI|PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy|A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy||Sun Yat-sen University|Yes|Recruiting|May 2015|May 2023|Anticipated|May 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|326|||Female|18 Years|65 Years|No|||May 2015|May 14, 2015|May 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02448576||20873|
NCT02455193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1282|Neuronal Effects of Exercise in Schizophrenia|Neuronal Effects of Exercise in Schizophrenia||University of Colorado, Denver|No|Recruiting|August 2014|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|140|||Both|21 Years|70 Years|No|||December 2015|December 29, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455193||20365|
NCT02455206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0179|Counseling During Pulmonary Rehabilitation|Effect of Counseling During Pulmonary Rehabilitation on Self-determined Motivation Towards Physical Activity in Patients With Chronic Obstructive Pulmonary Disease||Zurich University of Applied Sciences||Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|40 Years|90 Years|No|||January 2016|January 4, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02455206||20364|
NCT02458937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONFUNC|Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis|Functional Outcomes for Children, Adolescents, and Young Adults With Osteonecrosis Following Hip Core Decompression||St. Jude Children's Research Hospital|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|8 Years|29 Years|No|Non-Probability Sample|Participants will be patients with osteonecrosis at St. Jude Children's Research Hospital        who receive hip core decompression surgery as part of their standard care.|November 2015|November 16, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02458937||20077|
NCT02458950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si501/2014|Characteristics and Clinical Outcomes of Anorexia Nervosa : Siriraj Hospital Experience|Characteristics and Clinical Outcomes of Anorexia Nervosa : Siriraj Hospital Experience||Mahidol University|Yes|Recruiting|December 2014|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|13|||Both|10 Years|18 Years|No|Non-Probability Sample|Patients of Siriraj Hospital|May 2015|May 28, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02458950||20076|
NCT02453620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-00741|Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer|A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|November 2015|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|May 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02453620||20485|
NCT02452346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409015482|Study of Clinical Efficacy and Safety of Tosedostat in MDS|A Two-arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-based Therapy|IST-CTI-MDS|Weill Medical College of Cornell University|No|Recruiting|February 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|January 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452346||20583|
NCT02452866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM-1219-350|Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole|A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis||Symbiomix Therapeutics|No|Completed|June 2015|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|325|||Female|12 Years|N/A|No|||October 2015|October 20, 2015|May 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02452866||20543|
NCT02445599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEOEC RKEB/IKEB 4044-2013|Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain|Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain, as Well as the Changes of the Postoperative Breathing Function Values, a Randomized, Controlled, Prospective Trial||University of Debrecen|Yes|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3|||Both|18 Years|80 Years|No|||December 2015|December 15, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02445599||21101|
NCT02459002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0405|Thoracic Pilot Project|Prospective Study to Determine Impact of Early Palliative Care Consult on QOL, Cancer Related Symptoms In Advanced Lung Cancer Patients||M.D. Anderson Cancer Center|No|Recruiting|July 2012|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|MD Anderson Cancer Center Non-small cell lung cancer (NSCLC) patients|December 2015|December 2, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02459002||20072|
NCT02453919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVIH|Register of Cardiovascular Complications Among People Living With HIV|Register of Cardiovascular Complications Among People Living With HIV|RECOVIH|Saint Antoine University Hospital|No|Recruiting|February 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Adults living with HIV in Paris, France who have a minimum of one additional        cardiovascular risk factor and underwent complete cardiac examination at the Cardiac        Center of the Saint Antoine University Hospital.|May 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02453919|10 Years|20462|
NCT02456649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMH2015.001|Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe|A Phase II Study of the Outcomes of Intraoperative Margin Assessment With Adjunctive Use of MarginProbe in Addition to Standard|MarginProbe|Huntington Memorial Hospital|No|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|N/A|N/A|No|||May 2015|May 26, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02456649||20253|
NCT02449629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 130|Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care|Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care||Westat|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|187|||Both|16 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|The three population groups are:          1. TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit             (AMTU) site or elsewhere.          2. TGMY (16-24 years of age) not currently in care who are living with HIV, not living             with HIV, or those who are unaware of their HIV status.          3. Health care and social service providers who work with TGMY at AMTU sites or             elsewhere that serve TGMY within the AMTU cities.|March 2016|March 1, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02449629||20792|
NCT02449642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol1|LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation|LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation||Rambam Health Care Campus|Yes|Completed|July 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|Samples Without DNA|frequent blood tests for luteinizing hormone, estradil and progesterone levels|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|women aged 18-42 years old BMI < 32 kg/M2|August 2015|August 16, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02449642||20791|
NCT02452489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangchunUCM02|Different Acupoints Compatibility Difference of the Effect of Treatment of the Diabetic Gastroparesis|Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect||Changchun University of Chinese Medicine|Yes|Recruiting|January 2015|August 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|65 Years|No|||May 2015|May 21, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02452489||20572|
NCT02452723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISC-hpNSC|A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease|A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease||Cyto Therapeutics Pty Limited|Yes|Recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|30 Years|70 Years|No|||February 2016|March 10, 2016|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02452723||20554|
NCT02432807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUR-1301-101|Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis|A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis||Kurobe LLC|No|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|1 Year|N/A|No|||March 2016|March 1, 2016|April 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02432807||22083|
NCT02456753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0024|Assesment by Ultrasonography of the Perineal-cephalic Distance|Assesment by Ultrasonography of the Perineal-cephalic Distance in Consistence With the Notion of Clinical Fetal Head Engagement|ECHOTRANS|Lille Catholic University|No|Recruiting|December 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|411|||Female|18 Years|N/A|No|Non-Probability Sample|Patients included are women about to give birth, they undergo a clinical examination done        by midwives. Followed by a trans-perineal ultrasonography examination done by a technical        operator in order to measure the perineal-cephalic distance.        These examination are done the day of enrollment, they last for a few minutes and no        further tests will be done afterwards.|August 2015|August 4, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02456753||20245|
NCT02456922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP301|A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics|A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics|Harmony 1|Medtronic Diabetes|No|Not yet recruiting|April 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|2 Years|75 Years|No|||January 2016|January 28, 2016|May 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02456922||20232|
NCT02459405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0724/13|Decreasing Leak Rate in Colorectal Surgery Using Near Infra-red (NIR) Imaging|Decreasing Leak Rate in Colorectal Surgery Using Near Infra-red (NIR) Imaging: a Multicentric Prospective Phase II Study||University Hospital, Geneva|No|Recruiting|March 2013|September 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|260|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02459405||20041|
NCT02444455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-IVY-SC-003|Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury|Safety and Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stem Cell Transplantation in Acute Lung Injury|UCMSC-ALI|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Recruiting|May 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|35 Years|70 Years|No|||May 2015|May 11, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02444455||21189|
NCT02456324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0777|A Prospective European Post-Market Clinical Evaluation of the CuraSeal Percutaneous Intraluminal Closure System for Anorectal Fistulas|A Prospective European Post-Market Clinical Evaluation of the CuraSeal Percutaneous Intraluminal Closure System for Anorectal Fistulas||Curaseal Inc.|No|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02456324||20278|
NCT02456961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCXL-ionto|Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin|Comparative Study of Results of Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin: a Randomized Control Trial||Ufa Eye Research Institute|Yes|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02456961||20229|
NCT02448381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-CTCL-01|FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma||Soligenix||Recruiting|December 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02448381||20888|
NCT02448394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH105290-01|Assessment of a Community Support Worker Intervention for PLWH in Rural Ethiopia|Assessment of a Community Support Worker Intervention for PLWH in Rural Ethiopia||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|October 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2640|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02448394||20887|
NCT02548949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061143|Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ|Korean Post Marketing Surveillance To Observe Effectiveness And Safety Of Pristiq (Registered) In Patients With Major Depressive Disorder.|PMS|Pfizer|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|N/A|No|Non-Probability Sample|Adults 19 years of age or older, who have been received at least one dose of PRISTIQ® for        the treatment of Major depressive disorder (MDD). The study population would be enrolled        in multi-center in which subjects are administered PRISTIQ as part of routine practice at        Korean health care centers by accredited psychiatrists.|March 2016|March 7, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02548949||13167|
NCT02547818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZT-001|Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease|A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease||AZTherapies, Inc.|Yes|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|55 Years|79 Years|No|||March 2016|March 24, 2016|September 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547818||13254|
NCT02555176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.365|Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)|A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling||Thomas Jefferson University|Yes|Recruiting|August 2015|||September 2020|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555176||12688|
NCT02561273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511-14|Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma|A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma||University of Nebraska|Yes|Not yet recruiting|November 2015|||March 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561273||12220|
NCT02561286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806708|Being Responsible for Ourselves HIV Risk Reduction for Black MSM|Help Us, Save Us! HIV/STI Risk Reduction for Black Men Who Have Sex With Men|BRO|University of Pennsylvania|No|Completed|April 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|595|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561286||12219|
NCT02561299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-0007-P|Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study|Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study|OPTIMIZE BTK|Cardiovascular Systems Inc|No|Recruiting|September 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02561299||12218|
NCT02555696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMPS-Celgene-AUT-002|Abraxane in Treatment of Metastatic Breast Cancer|Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting||Celgene|No|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic breast cancer|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555696||12649|
NCT02555709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTP-43742-002|An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients|A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients||Vitae Pharmaceuticals, Inc.|No|Active, not recruiting|August 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|13||Actual|74|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555709||12648|
NCT02555722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC150625|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555722||12647|
NCT02548312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COI-RCT|The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles|Randomised Controlled Trial to Measure the Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles||The BMJ|No|Not yet recruiting|September 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|8||Anticipated|1020|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548312||13216|
NCT02548624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPO0520|An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position|An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position||Medtronic - MITG|No|Suspended|November 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The laboratory observation will consist of one non-patient subject (N=1). The hospital        observation will consist of 18 patients (N=18) hospitalized at the Columbia University        Medical Center on the general care floor at-risk for hospital-acquired pressure ulcers.        The hospitalized subjects will be stratified into three groups. Six subjects with normal        BMI classification (18.5 -24.9), six with overweight BMI classification (25.0-29.9), and        six with overweight BMI classification (30.0-39.9) will comprise the study sample.|February 2016|February 25, 2016|September 1, 2015|No|Yes|Protocol is being reevaluated by sponsor|No||https://clinicaltrials.gov/show/NCT02548624||13192|
NCT02550431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1215|Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth|Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth||University of Colorado, Denver|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Blood|Both|9 Years|21 Years|No|Non-Probability Sample|Transgender youth ages 9 to 21 years of age who have been on a GnRH agonist or cross-sex        hormones for at least three months|March 2016|March 18, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550431||13053|
NCT02619357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202373|Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma|A Method Validation, Single-period, Open-label Evaluation Study to Explore the Sensitivity of a Novel Biosensor Device (SenseWear Armband Gecko) for Measuring Physical Activity in Subjects With COPD & Asthma||GlaxoSmithKline|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02619357||7761|
NCT02625441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBCG-01-2015|Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer|A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer|BOLD-1|Helsinki University Central Hospital|No|Recruiting|December 2015|June 2023|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1366|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02625441||7293|
NCT02621996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44943415.5.0000.5208|Hammock Positioning's Influence on the Electromyographic Activity in the Flexor Muscles in Newborn Preterm|Hammock Positioning's Influence on the Electromyographic Activity in the Flexor Muscles in Newborn Preterm||Universidade Federal de Pernambuco|Yes|Not yet recruiting|December 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|1 Week|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02621996||7558|
NCT02612896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYSTISTOP_2.1_22092015|Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?|Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?|CYSTISTOP|Institute of Tropical Medicine, Belgium|No|Not yet recruiting|March 2016|November 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|2900|||Both|5 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612896||8257|
NCT02613169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50301-J|Infant TB Infection Prevention Study|Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants|iTIPS|University of Washington|Yes|Not yet recruiting|February 2016|September 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||November 2015|November 19, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02613169||8236|
NCT02627365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASP4FSW|Motivation Matters Study|Motivation Matters! Randomized Clinical Trial of Theory Based SMS to Support Treatment as Prevention in High-Risk Women|MM|Women's Health Project Mombasa|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|210|||Female|18 Years|N/A|No|||December 2015|December 10, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627365||7145|
NCT02627378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-00190|Saudi Outcomes of ECMO-treated MERS-CoV Patients|Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure||Dammam University|Yes|Completed|September 2012|October 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627378||7144|
NCT02557828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505705|Target Sign vs Palpation for Radial Arterial Line Placement|Dynamic Need Tip Positioning With Ultrasound Versus Palpation Technique for Radial Artery Cannulation: A Prospective Randomized Controlled Trial||University of Iowa|No|Recruiting|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557828||12485|
NCT02558803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 21|HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3|HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3||Regenstrief Institute, Inc.|No|Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|3500|||Both|11 Years|17 Years|No|||September 2015|February 22, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558803||12410|
NCT02554175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTWang|The Effective Effect-Site Propofol Concentration for Induction and Intubation for Schnider Model in Parturients|The Effective Effect-Site Propofol Concentration for Induction and Intubation for Schnider Model in Parturients||Fudan University|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554175||12765|
NCT02560311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr.2015-0050|Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis|Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis||University of Zurich||Recruiting|December 2014|February 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|Female patients with a human epidermal growth factor receptor (HER) 2+ breast cancer in        metastatic stage (M1)|September 2015|September 24, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02560311||12294|
NCT02553759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ObActions|Observed Actions in Chronic Neck Pain|Influence of the Actions Observed on Cervical Motion in Patients With Chronic Neck Pain. Randomized Controlled Trial|ObACNPain|AG Clinic|Yes|Completed|October 2013|May 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|No|||September 2015|September 17, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553759||12797|
NCT02557893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR008131|Effects of Resistance Exercise During Pregnancy|Effects of Exercise on Back Pain in Pregnancy||University of Georgia|No|Completed|April 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|134|||Female|18 Years|38 Years|No|||September 2015|September 22, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02557893||12480|
NCT02550860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-786|Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function|Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function|Tewlip|Hospices Civils de Lyon|No|Recruiting|January 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|September 14, 2015|August 31, 2015||||No||https://clinicaltrials.gov/show/NCT02550860||13020|
NCT02559128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G 15-06-02|The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes|The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes|CARMET2|Institute for Clinical and Experimental Medicine|Yes|Recruiting|December 2013|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|100|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|100 subjects in total, divided into four groups will be included: 40 patients with type 2        diabetes or prediabetes and chronic heart failure (HF+T2D+), 20 subjects with HF without        T2D (HF+T2D-), 20 subjects with T2D alone (HF-T2D+) and 20 healthy control volunteers        (HF-T2D-).|September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559128||12385|
NCT02558933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/5553|Epigallocatechin Gallate (EGCG) to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children|Epigallocatechin Gallate (EGCG) as Therapeutic Tool to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children|Neuro-SAF|Parc de Salut Mar|No|Recruiting|June 2015|April 2017|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|14 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558933||12400|
NCT02544516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308139|Upside Down, Give me the Handle|Study on the Links Between Perception and Action in Schizophrenia, "Upside Down, Give me the Handle"||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544516||13508|
NCT02551120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110074-2|Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism|Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism||University of Aarhus|No|Recruiting|June 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples (whole blood, serum and plasma), urine collection (24h) and bone biopsies|Both|N/A|N/A|No|Non-Probability Sample|All patients with non-surgical hypoPT and pseudohypoparathyroidism in Denmark|October 2015|October 23, 2015|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02551120||13000|
NCT02559193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADAR|Pharmacogenomic Testing for Medication Management.|Pharmacogenomic Testing for Medication Management.||First Vitals Health and Wellness, Inc.|Yes|Recruiting|September 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|200000|||Both|18 Years|N/A|No|Probability Sample|The Study will include male or female patients 18 years of or older who are receiving at        least one medication with metabolism known to depend on genetic variation and have the PGx        test already performed. The patient must also meet the inclusion/ exclusion criteria        established by the protocol.|September 2015|November 15, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559193|90 Days|12380|
NCT02558985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503944048|Pulmonary Compliance Changes During Manipulation of Early Onset Scoliosis and Cast Application|Pulmonary Compliance Changes During Manipulation of Early Onset Scoliosis and Cast||Indiana University|No|Recruiting|September 2015|June 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|6 Months|9 Years|No|Non-Probability Sample|Any patients 6 months to 9 years of age with progressive Early Onset Scoliosis who present        for serial thoracolumbar casting and spine manipulation at Riley Hospital for Children        will be invited to participate.|September 2015|September 22, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02558985||12396|
NCT02548754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRCH135160|Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation|TRanscutaneous Electrical vAgus Nerve sTimulation to Suppress Atrial Fibrillation|TREAT-AF|University of Oklahoma|Yes|Recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|21 Years|90 Years|No|||September 2015|September 11, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548754||13182|
NCT02554357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAICE-002|Quality of Analgesia After Interscalene Block After Arthroscopic Shoulder Surgery|Quality of Analgesia After Interscalene Block With Bupivacaine and Exparel® vs. Bupivacaine Alone After Arthroscopic Shoulder Surgery||North American Institute for Continuing Medical Education (NAICE)|No|Recruiting|July 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||September 2015|September 16, 2015|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02554357||12751|
NCT02556840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00261-48|Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes|Impact of Two Standardized Clinical Care Protocols on Pregnancy Outcomes in Women With Monogenic Diabetes MODY2|MODY2|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|October 2015|October 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02556840||12561|
NCT02555007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-53|Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM|Phase IA/IB of Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With Non Small Cell Lung Cancer or Malignant Pleural Mesothelioma|NVB Metro|Assistance Publique Hopitaux De Marseille|No|Recruiting|August 2015|||August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02555007||12701|
NCT02555020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0158|Effect of Preoperative Oral Carbohydrates on Quality of Recovery|Effect of Preoperative Oral Carbohydrates on Quality of Recovery: Randomized Controlled Trial|laparoscopy|Yonsei University|Yes|Enrolling by invitation|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|153|||Both|20 Years|70 Years|No|||September 2015|September 18, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02555020||12700|
NCT02546427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15551|Hypofractionated Whole Pelvic Radiotherapy of the Prostate|Phase I Feasibility Study of Accelerated Hypofractionated Whole Pelvic Radiotherapy for Patients With Intermediate-High Risk Prostate Cancer||University of California, San Francisco|Yes|Not yet recruiting|September 2015|June 2022|Anticipated|June 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|18 Years|N/A|No|||September 2015|September 8, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02546427||13361|
NCT02553837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3101B_P3|Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult|Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult||Green Cross Corporation|Yes|Active, not recruiting|November 2015|July 2022|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|317|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2015|January 31, 2016|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02553837||12791|
NCT02549079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK104/08|Soluble Factors in the Serum of Severely Burned Patients|Soluble Factors in the Serum of Severely Burned Patients||RWTH Aachen University|Yes|Completed|January 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|Samples With DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with burn injuries treated in the burn intensive care unit|September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549079||13157|
NCT02549092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-927|A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)|An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study||AbbVie|No|Enrolling by invitation|September 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|30 Years|99 Years|No|||January 2016|January 12, 2016|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549092||13156|
NCT02560831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 02993812.3.0000.5208|Effects of Therapeutic Exercises in Elderly Women With Knee Osteoarthritis|Assessment of the Effects of Therapeutic Exercises Associated With Pompage Technique on Pain, Muscle Strength and Postural Balance in Older Women With Knee Osteoarthritis: a Randomized Clinical Trial|TherExercOA|Universidade Federal de Pernambuco|Yes|Completed|March 2013|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|60 Years|80 Years|No|||September 2015|September 24, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02560831||12254|
NCT02547233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1193|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up||LEO Pharma|No|Recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547233||13299|
NCT02549768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-095|Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery|Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors||Pontificia Universidad Catolica de Chile|Yes|Not yet recruiting|September 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|September 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549768||13104|
NCT02546089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL - 11334|ABI v Dry Needling for Plantar Fasciitis|Investigating the Effects of Ultrasound Guided Autologous Blood Injection for Chronic Plantar Fasciitis Versus Ultrasound Guided Dry-needling Alone, a Randomised Controlled Trial||University Hospitals, Leicester|Yes|Recruiting|September 2014|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02546089||13387|
NCT02546102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-107-301|Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma|A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy||ImmunoCellular Therapeutics, Ltd.|Yes|Recruiting|December 2015|December 2021|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|414|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546102||13386|
NCT02560857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8133|Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients|Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients|QTF-Monitor|University Health Network, Toronto|No|Recruiting|September 2014|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Whole blood samples (plasma will be extracted to perform Quantiferon-Monitor test)|Both|18 Years|N/A|No|Probability Sample|Adult SOT recipients on at least one immunosuppressive medication.|September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560857||12252|
NCT02551198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0210|Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation|Comparative Evaluation the Efficacy of 2L Polyethylene Glycol With Ascorbic Acid (PEG-Asc) and Oral Sulfate Solution (OSS) in Split Method for Bowel Preparation (The Phase III Prospective Randomized Clinical Trial)||National Cancer Center, Korea|Yes|Recruiting|November 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|184|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551198||12994|
NCT02551042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0417|CSL Behring Sclero XIII|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis||University College, London|No|Not yet recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|December 17, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551042||13006|
NCT02550327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-198|Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer|A Pilot Study of Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Resectable or Potentially Resectable Pancreatic Adenocarcinoma (PDAC)||Baylor Research Institute|Yes|Recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550327||13061|
NCT02558738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOS_PPL-084|Non Interventional Clinical Investigation of Ectoin Ear Spray in Skin Treatment of Outer Ear Canal Irritations|Non Interventional Study (NIS): Clinical Investigation for Evaluation of the Safety and Efficacy of Ectoin Ear Spray and Normison Ear Spray in Skin Treatment of Outer Ear Canal Irritations: A Mulitcenter Non Interventional Study||Bitop AG|Yes|Completed|June 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|primary care ENT units study the therapeutic process in this observational trial in total        of 60 patients in three centres with dermatological irritations of the outer ear canal and        pruritus|September 2015|September 23, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02558738||12415|
NCT02558751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-AG045973|Pneumonia Vaccine in Aging HIV Positive Individuals|Immune Response to Pneumococcal Vaccination in Aging HIV Positive Individuals||University of Toledo Health Science Campus|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|51|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02558751||12414|
NCT02545257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153/13/03/00/2015|Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care|Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care||Helsinki University|No|Active, not recruiting|September 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|191|||Both|65 Years|N/A|No|||January 2016|January 13, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02545257||13451|
NCT02543177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-088|Optimised Procedure in Patients With NSTEMI and CKD|Optimised Procedure in Patients With an Acute Non-ST-segment Elevation Myocardial Infarction and Acute or Chronic Kidney Disease|NSTEMI-CKD|RWTH Aachen University|No|Recruiting|September 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543177||13611|
NCT02554825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSI R&T #13-012|Healthy Futures Evaluation|Healthy Futures Longitudinal School-Cluster Randomized Controlled Trial||JSI Research & Training Institute, Inc.||Completed|August 2011|May 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Actual|1344|||Both|10 Years|15 Years||||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554825||12715|
NCT02558777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MID-Nurse-P|Pilot Study of a Multicomponent Nurse Intervention to Reduce Delirium in Hospitalized Older Adults|Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P|MID-Nurse-P|Complejo Hospitalario Universitario de Albacete|No|Completed|October 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|65 Years|N/A|No|||September 2015|September 23, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02558777||12412|
NCT02558790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-000528|MMFS-201-301 in ADHD|MMFS-201-301 in ADHD: An Open-label Pilot Study of Cognitive and Functional Effects||Massachusetts General Hospital||Not yet recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|55 Years|No|||December 2015|December 23, 2015|September 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558790||12411|
NCT02545569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0459|Evaluation of New Custom Made Hearing Product Technology and Shell Modification|Evaluation of New Custom Made Hearing Product Technology and Shell Modification|CPS|Phonak AG, Switzerland|No|Recruiting|January 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|25|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||September 2015|October 28, 2015|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02545569||13427|
NCT02534727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150187|Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance|Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|99 Years|No|||July 2015|October 16, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02534727||14258|
NCT02559999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308172|Objective Markers of Pain Perception in Humans|Objective Markers of Pain Perception in Humans: a Study in Healthy Subjects||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|June 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|44|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02559999||12318|
NCT02560025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-334|Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML|A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia||Massachusetts General Hospital|Yes|Not yet recruiting|October 2015|September 2024|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560025||12316|
NCT02551679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 12-01/HS-01-2015|Blood Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)|A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)|ACP-CLI|Hemostemix|Yes|Recruiting|August 2014|August 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551679||12957|
NCT02544685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients|Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose|FENSY|S&D Pharma SK s.r.o.|No|Recruiting|July 2010|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|6 Months|19 Years|No|||September 2015|September 8, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02544685||13495|
NCT02560038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-13-102|Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer|Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer||The University of Texas Health Science Center, Houston|Yes|Recruiting|October 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560038||12315|
NCT02556073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140218|ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control|The Use of ﬂuticasone Propionate/Salmeterol Inhaler With Integrated Dose Counter and Smartphone Self Management to Improve Airway Inflammation and Asthma Control||Taipei Veterans General Hospital, Taiwan|No|Enrolling by invitation|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|20 Years|70 Years|No|||September 2015|September 20, 2015|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02556073||12620|
NCT02546492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063872|Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar|Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar|TGActhar|University of Maryland|Yes|Not yet recruiting|December 2015|September 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|April 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02546492||13356|
NCT02546505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EREN-BVA|Impact of Front-of-pack Nutrition Labelling on Consumer Purchases|Impact of Front-of-pack Nutrition Labelling on Consumer Purchases - Controlled Trial in Shopper Laboratory Stores||University of Paris 13|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02546505||13355|
NCT02532777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZhang|The Research of Standard Diagnosis and Treatment for HSPN in Children|The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children||Nanjing Children's Hospital|No|Recruiting|August 2015|July 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Both|2 Years|16 Years|No|||August 2015|August 23, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532777||14408|
NCT02553135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150371|Choroideremia Gene Therapy Clinical Trial|An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)||University of Miami|Yes|Recruiting|September 2015|January 2021|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|18 Years|N/A|No|||October 2015|October 6, 2015|June 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553135||12845|
NCT02552173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ante-002|The Relationship Between Operative and Radiologic Stem Version|The Relationship Between Operative and Radiologic Stem Version : Which Factors Influence Resultant Stem Version in Primary Total Hip Arthroplasty||Seoul National University Bundang Hospital|Yes|Recruiting|October 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Between October 2015 and December 2015, 40 consecutive patients who underwent primary        cementless total hip arthroplasty agreed to undergo a postoperative computed tomography        scan.|January 2016|January 11, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552173||12919|
NCT02552186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67521|Non-invasive Clinical Pectus Index as a Measurement of Severity in Pectus|Non-invasive Clinical Pectus Index as a Measurement of Severity in Pectus||All Children’s Hospital Johns Hopkins Medicine|No|Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|230|||Both|11 Years|21 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552186||12918|
NCT02558582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0231|Effect of Exercise Training in Patients With Pulmonary Hypertension|Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries||University of Zurich|No|Recruiting|September 2015|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02558582||12427|
NCT02553317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0681-C301|Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura|A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura|HERCULES|Ablynx|Yes|Recruiting|September 2015|||October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553317||12831|
NCT02553330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-204|A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)|An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata||Incyte Corporation|No|Recruiting|October 2015|January 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553330||12830|
NCT02556788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18252|Double-Blind Efficacy and Safety of CD5789 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris||Galderma R&D|No|Recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|9 Years|N/A|No|||March 2016|March 7, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556788||12565|
NCT02556801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/0047|SUBLIVAC Phleum Study|A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense (SP) Compared to Placebo in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis||HAL Allergy|Yes|Active, not recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02556801||12564|
NCT02548702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTU2290|Community-based Sport Programme and Type 2 Diabetes|Effect of a Community-based Sport Programme on Disease Symptoms and Quality of Life in Men and Women With Type 2 Diabetes|Fit4Life|Nottingham Trent University|No|Not yet recruiting|October 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4032|||Both|35 Years|64 Years|No|||September 2015|September 10, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02548702||13186|
NCT02548936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-sleas|Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE|Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial||Peking Union Medical College Hospital|Yes|Enrolling by invitation|April 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|65 Years|No|||August 2015|September 11, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02548936||13168|
NCT02547285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208136|Analysis of the Biomechanics of Walking|Analysis of the Biomechanics of Walking in the Senior Under the Terms of Footwear||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|50 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Elderly people|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547285||13295|
NCT02551562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NuD-SD-01|A Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments|A Post-market, Randomized Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments||DeNova Research|No|Not yet recruiting|September 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02551562||12966|
NCT02551809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V203-AD|Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients|A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease||United Neuroscience Ltd.||Recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|60 Years|N/A|No|||December 2015|December 15, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02551809||12947|
NCT02546180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 14-000084|Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist|Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist||Mayo Clinic|No|Completed|February 2014|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 8, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546180||13380|
NCT02561182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002284|Bone Health in Patients With Overgrowth|Bone Health in Patients With Overgrowth||Mayo Clinic|No|Active, not recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|whole blood|Both|5 Years|N/A|No|Non-Probability Sample|Patients aged 5 years old and over with a known clinical diagnosis of an overgrowth        syndrome such as Klippel-Trenaunay Syndrome, CLOVE syndrome, Proteus syndrome, diffuse        capillary malformation with overgrowth, or other unspecified OGS.|September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561182||12227|
NCT02552563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01247|Engaging Caregivers in Dementia Care|Engaging Caregivers in the Care of Veterans With Dementia||Philadelphia Veterans Affairs Medical Center|No|Completed|February 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 15, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02552563||12889|
NCT02559414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-02104|Antiplatelet Therapy in HIV|Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV||New York University School of Medicine|No|Recruiting|February 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|50|||Both|21 Years|80 Years|No|||September 2015|September 22, 2015|March 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559414||12363|
NCT02547701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM Ped-004|Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population|Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis||Polichem S.A.|No|Recruiting|August 2014|April 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|2 Years|17 Years|No|||September 2015|September 15, 2015|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547701||13263|
NCT02547922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3461C00007|Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis|TULIP-LN1|AstraZeneca|Yes|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547922||13246|
NCT02558023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5866|The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine|The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial|Uranic|University Hospital, Strasbourg, France|Yes|Not yet recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|366|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02558023||12470|
NCT02552797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0340|The Development and Piloting of 'Power Up': A Tool for Young People With Internalising/Emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS)|The Development and Piloting of 'Power Up': A Tool for Young People With Internalising/Emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS)|Power Up|University College, London|No|Not yet recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|105|||Both|11 Years|N/A|No|||September 2015|September 16, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02552797||12871|
NCT02552628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0448|WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)|DEEP BRAIN STIMULATION FOR SEVERE DYSTONIA ASSOCIATED WITH WILSON'S DISEASE. A Prospective Multicenter Meta-analysis of Nof1 Trials|WILSTIM DBS|Hospices Civils de Lyon|Yes|Not yet recruiting|October 2015|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5|||Both|18 Years|60 Years|No|||September 2015|September 17, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02552628||12884|
NCT02556931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15165|Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies|Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||November 2015|November 5, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556931||12554|
NCT02625610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 100070-007|Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)|A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction||EMD Serono|Yes|Recruiting|December 2015|November 2023|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|666|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625610||7280|
NCT02625623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 100070-008|Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)|A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||EMD Serono|Yes|Recruiting|December 2015|January 2023|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625623||7279|
NCT02614937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-004|Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion|Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)||Ohr Pharmaceutical Inc.|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|40 Years|N/A|No|||November 2015|November 24, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614937||8100|
NCT02612597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0453|The Effect of Blood Volume Changes on the Glucose Tolerance|The Effect of Blood Volume Changes After Bed Rest and Aerobic Exercise Training on the Glucose Tolerance|BV-GT|Zurich Center for Integrative Human Physiology||Recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02612597||8280|
NCT02617238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K110102|Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness|Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness|SPARTE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2013|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|55 Years|75 Years|No|||November 2015|November 27, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02617238||7923|
NCT02612220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-03|Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection|Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection - A Randomized Controlled Trial|BioFoam|Technische Universität Dresden|No|Recruiting|December 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02612220||8309|
NCT02558816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0048|A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients|A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients|OAsIs|Nantes University Hospital|Yes|Recruiting|October 2015|October 2022|Anticipated|October 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|16 Years|80 Years|No|||September 2015|November 2, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02558816||12409|
NCT02556567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204310|Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices|Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices||Arkansas Children's Hospital Research Institute|No|Recruiting|August 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556567||12582|
NCT02546622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATHN 2|ATHN 2: Factor Switching Study|A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Products||American Thrombosis and Hemostasis Network|No|Recruiting|September 2015|January 2022|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|600|None Retained|Plasma drawn at baseline, after 10 Exposure Days, after 50 Exposure Days, and at study end      (1 year). If inhibitor suspected, sample will be drawn and tested locally, and within 2      weeks of first positive inhibitor, a confirmatory sample will be drawn and sent to CDC.      Patients may be co-enrolled in other ATHN studies such as My Life Our Future, will performs      genotype Samples may be linked in patient who have authorized|Both|2 Years|N/A|No|Non-Probability Sample|The study will enroll approximately 600 patients with hemophilia who meet the eligibility        criteria and are receiving care from one of the ATHN-affiliated Hemophilia Treatment        Centers (HTC). There will be 2 arms:        Arm A (Prospective) will include patients who are switching factor replacement products        and will be followed prospectively for up to 1 year.        Arm B (Retrospective) will include patients who have switched factor replacement products        previously (within the past 50 weeks at the time of enrollment). These patients will be        assessed retrospectively and/or followed prospectively for up to 1 year.|November 2015|November 4, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546622||13346|
NCT02559037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYS2015-02|Acupuncture and Moxibustion Treatment for Crohn's Disease|Study on the Mechanism of Moxibustion Effect on Maintaining Crohn's Disease Intestinal Homeostasis Via Intestinal Microbiota and Intestinal Mucosal Immunity||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Recruiting|April 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02559037||12392|
NCT02559050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-AR-01|Nasal Reconstruction Using a Customized 3D-printed Nasal Stent for Congenital Arhinia|Nasal Reconstruction Using a Customized 3D-printed Nasal Stent for Congenital Arhinia||Seoul St. Mary's Hospital|No|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Male|N/A|N/A|No|Non-Probability Sample|A 7-year-old male patient with congenital arhinia with no history of previous treatment.|September 2015|September 23, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02559050||12391|
NCT02558868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYMedOncoPAC02|Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer|Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer||Zhejiang University|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||November 2015|November 29, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02558868||12405|
NCT02558881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-757|Colon Capsule Versus Virtual Colonoscopy for Colorectal Cancer Screening|Evaluation of a Complementary Action of Recruitment of Patients With a Positive Screening Test and Not Realizing Optical Colonoscopy as Part of Organized Colorectal Cancer Screening|COCAGI|Hospices Civils de Lyon|No|Completed|June 2014|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|664|||Both|50 Years|N/A|No|Probability Sample|Patients with a positive FOBT at screening organized colorectal cancer, patients who have        not achieved optical colonoscopy and who received the usual procedure and complete        recovery.|September 2015|September 23, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558881||12404|
NCT02550522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI and Tetraplegia|Brain Computer Interface: Neuroprosthetic Control of a Motorized Exoskeleton|Brain Computer Interface: Neuroprosthetic Control of a Motorized Exoskeleton|BCI|University Hospital, Grenoble|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|40 Years|No|||September 2015|October 5, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550522||13046|
NCT02550808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-MTB-001|Metabolic Changes in Patients With Chronic Cardiopulmonary Disease|Metabolic and Histological Changes in Skeletal Muscle and Fat Tissue in Patients With Chronic Cardiopulmonary Disease||General and Teaching Hospital Celje|No|Recruiting|March 2012|December 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|400|Samples With DNA|Serum; plasma; Skeletal muscle; fat tissue; urine; full blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with chronic disease (Heart failure, COPD, malignancy, CKD) and healthy controls|September 2015|September 15, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550808||13024|
NCT02554682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011732|The P4 Intervention Study to Improve Adolescent Health|A Pilot Efficacy and Implementation Study of the Patients, Parents and Professionals Partnering to Improve Adolescent Health (P4) Intervention||Children's Hospital of Philadelphia|No|Not yet recruiting|December 2015|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|750|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554682||12726|
NCT02545751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hangzhou CH|SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer|A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer||Hangzhou Cancer Hospital|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||October 2015|October 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545751||13413|
NCT02548546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004151|Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques|Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques||Mayo Clinic|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02548546||13198|
NCT02529969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|615|Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes|Curcumin Supplementation and Type 2 Diabetes||National Nutrition and Food Technology Institute||Recruiting|July 2015|||January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|65 Years|No|||July 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529969||14622|
NCT02554838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140702|How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling|How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling|PACTE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2015|February 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|70 Years|N/A|No|||September 2015|January 14, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554838||12714|
NCT02554851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN002/2015|Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.|Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study.||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|No|Not yet recruiting|May 2016|||October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02554851||12713|
NCT02545972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OneTAC|Once-a-day Tacrolimus Conversion Study: The OneTAC Trial|A Prospective Non-randomized Trial of Conversion From Twice a Day Tacrolimus to Once Daily Modified Release Tacrolimus|OneTAC|Newark Beth Israel Medical Center|No|Recruiting|February 2016|February 2019|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545972||13396|
NCT02546219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000816|a4b7 Integrin in Eosinophilic Esophagitis|Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis||Massachusetts General Hospital|No|Recruiting|March 2016|March 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Peripheral blood and esophageal eosinophils will be analyzed and may be stored for future      studies.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with active eosinophilic esophagitis|March 2016|March 15, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546219||13377|
NCT02548767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499106|Adverse Metabolic Effects of Dietary Sugar|Adverse Metabolic Effects of Dietary Sugar: Ad Libitum vs Energy-balanced Diets||University of California, Davis|No|Not yet recruiting|January 2016|June 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02548767||13181|
NCT02553538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000473|Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation|Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation as Part of a Population-Based Health IT System: A Randomized Control Trial||Massachusetts General Hospital|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1612|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553538||12814|
NCT02556853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14074|Ultrasound for Double Lumen Endotracheal Tube|Comparison Between Ultrasound and Clinical Assessment of the Correct Positioning of Left Double Lumen Endotracheal Tube||424 General Military Hospital|No|Recruiting|September 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|80 Years|No|||September 2015|September 22, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02556853||12560|
NCT02560402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-2014.563|The Relation Between the Renal Resistive Index and Glomerular Hyper Filtration|Relation Between Renal Resistive Index, Glomerular Hyperfiltration and Hyperdynamic Circulation in Critically Ill Patients With Trauma or Sepsis.||VU University Medical Center|No|Recruiting|August 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|N/A|No|Probability Sample|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma|September 2015|September 24, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02560402||12287|
NCT02551185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-201|ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors||Acetylon Pharmaceuticals Incorporated||Not yet recruiting|November 2015|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551185||12995|
NCT02551432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP MK3475|Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer|Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer|MISP-MK3475|Seoul National University Hospital|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|20 Years|N/A|No|||September 2015|September 15, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02551432||12976|
NCT02558829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-130-052|Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency|Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)||AEterna Zentaris|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558829||12408|
NCT02558842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0192|Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance|Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance in a Region With High Prevalence of the Disease: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|March 2013|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558842||12407|
NCT02553889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 416858 CS4|A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis|A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis||Ionis Pharmaceuticals, Inc.|No|Recruiting|October 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|53|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553889||12787|
NCT02548182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2-1-002-12|Enhancing Physical Activity and Weight Reduction Through Smartcare and Financial Incentives|Enhancing Physical Activity and Weight Reduction Through Smartcare and Financial Incentives: A Pilot Randomized Controlled Trial|EPAWROSFI|Seoul National University Hospital|No|Active, not recruiting|March 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Male|19 Years|45 Years|No|||August 2015|September 11, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02548182||13226|
NCT02551900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPSC-4|A Comparison of the Effect of Warm and Cold Water Exercise Training on Vascular Function in Type 2 Diabetic Patients|A Comparison of the Effect of Warm and Cold Water Exercise Training on Vascular Function in Type 2 Diabetic Patients||Chulalongkorn University||Enrolling by invitation|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|60 Years|75 Years|No|||August 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551900||12940|
NCT02550951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-1408-124-607|Utility of MR Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy|Utility of Magnetic Resonance Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy||Seoul National University Hospital|Yes|Enrolling by invitation|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|7|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550951||13013|
NCT02553850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20416|An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)|A SURVEY TO STUDY THE CORRELATION BETWEEN THE SERUM LEVELS OF BONE TURNOVER MARKERS AND THE CLINICAL PICTURE IN PATIENTS WITH BREAST CANCER AND BONE METASTASES RECEIVING IBRADONIC ACID TREATMENT||Hoffmann-La Roche||Completed|April 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|442|||Both|18 Years|N/A|No|Probability Sample|Patients with breast cancer and bone metastases who have been prescribed ibandronate        (Bondronat) will be evaluated in the routine oncological setting for 12 months.|November 2015|November 2, 2015|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553850||12790|
NCT02554071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013:459|Manitoba Pharmacist Initiated Smoking Cessation Pilot Project|Manitoba Pharmacist Initiated Smoking Cessation Pilot Project||University of Manitoba|No|Completed|January 2014|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554071||12773|
NCT02550301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8707|Does Mean Platelet Volume Change With Clopidogrel|Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?||University Health Network, Toronto|No|Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Whole blood in EDTA collection tubes to measure Mean Platelet Volume|Both|19 Years|N/A|No|Non-Probability Sample|Consecutive patients who are clopidogrel naïve, electively listed for coronary angiography        and Percutaneous Intervention (PCI) at PMCC, Toronto General Hospital (TGH), will be        prospectively enrolled in this pilot study|September 2015|September 17, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550301||13063|
NCT02548442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMP-01|Children's Autism Metabolome Project|Children's Autism Metabolome Project (CAMP): Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood|CAMP-01|Stemina Biomarker Discovery, Inc.|No|Recruiting|August 2015|August 2020|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1500|Samples With DNA|Blood plasma for metabolite analysis and blood samples for DNA and RNA expression analysis      will be collected from all children as part of the study protocol. In addition, a urine      sample for metabolite analysis will also be obtained from children capable of providing the      sample while at the clinical site.|Both|18 Months|48 Months|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be identified as autism spectrum disorder (ASD) or developmentally delayed        (DD) subjects by standard behavioral techniques; Typically developing (TD) subjects will        be recruited from the communities in which the autism research centers are situated. The        ADOS-2 (research reliable), the Mullen Scales of Early Learning (MSEL), as well as an        evaluation based on the DSM-V checklist will be administered to each subject enrolled in        the study suspected to have a developmental delay or autism. Typically developing children        enrolled in the study will be given an MSEL evaluation to document that they are neither        ASD nor DD subjects.|September 2015|September 25, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02548442||13206|
NCT02555904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000986|VoIce Changes and Heart Failure|Do VoIce Changes Predict Heart Failure||Massachusetts General Hospital|No|Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|Patients with acute heart failure syndromes admitted for inpatient management meeting        inclusion and exclusion criteria will be asked to consent for the study.|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555904||12633|
NCT02559557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15297|Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects|Adaptation and Pilot-Testing a Parenting Intervention for Spanish-Speaking Parents of Children at Risk for Neurocognitive Late Effects||City of Hope Medical Center|Yes|Recruiting|October 2015|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559557||12352|
NCT02554643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise on Type 2 Diabetes|Soccer and Health: Diet and Exercise on Type 2 Diabetes Mellitus|Soccer and Health: Impact of Nutritional Intervention and Recreational Soccer Training in Patients With Type 2 Diabetes Mellitus||University of Sao Paulo General Hospital|Yes|Completed|November 2012|July 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554643||12729|
NCT02554656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501100|Vfend Special Investigation For Pediatric|Vfend Special Investigation For Pediatric||Pfizer|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|15 Years|No|Probability Sample|The subjects who have been treated with voriconazole for severe mycosis|March 2016|March 23, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554656||12728|
NCT02554669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|papa vs pppa|Acute Effects of Postabsorptive and Postprandial Physical Activity|Acute Effects of Postabsorptive and Postprandial Physical Activity on Glycemia and Inflammation||Lillehammer University College|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|12|||Both|N/A|N/A|No|||September 2015|September 17, 2015|May 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02554669||12727|
NCT02546414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJLIJINHUI-2015|Platelet Count（PC）/Spleen Diameter(SD) Ratio to Predict the Variceal Haemorrhage in HBV Cirrhotic Patients in China|||RenJi Hospital|Yes|Completed|January 2013|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|150|||Both|45 Years|85 Years|No|Non-Probability Sample|HBV cirrhotic patients in China|September 2015|September 8, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02546414||13362|
NCT02546674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ADE20|Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.|A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID|NILOdeepR|Novartis|No|Recruiting|February 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|171|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546674||13342|
NCT02549274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008155|Effectiveness of a Self-rehabilitation Program|Effectiveness of Active Home Exercises for Patients With Chronic Neck Pain: a Prospective Comparative Randomized Clinical Trial||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549274||13142|
NCT02544646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040411|Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG|Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG or PEX||Medical University of Vienna||Recruiting|October 2011|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|February 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02544646||13498|
NCT02559947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISR-2014-100702|The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder|Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-label, Flexible-dose Vortioxetine||Psychiatric Medicine Associates, L.L.C.|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|September 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559947||12322|
NCT02546960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107946|A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860|Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860||Janssen Research & Development, LLC|Yes|Recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|835|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546960||13320|
NCT02547194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167861|The Health-related Quality of Life of Patients Who Underwent Coronary Artery Bypass Surgery With the No-touch Technique.|The Health-related Quality of Life of Patients Who Underwent Coronary Artery Bypass Surgery With the No-touch Vein Harvesting Technique.||Örebro County Council|No|Recruiting||||February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|350|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients included in the study have been operated on at the department of        Cardiothoracic and Vascular Surgery, Orebro University Hospital, Orebro, Sweden.|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547194||13302|
NCT02549521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nycomed 06.09.05|Mg Induced Changes From Day 0 to Day 28 on Serum and Urine Bone Metabolic Parameters in 70 y Old Females (no 50).|Magnesium Supplementation in Elderly Females|parathormon|Oslo University Hospital|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|50|||Female|70 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|November 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02549521||13123|
NCT02543333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-T3D-002/2|Validation of Structured Light Plethysmography: Asthma|Validation of Structured Light Plethysmography: Pre- and Post- Bronchodilator Challenge|SLPBD|Pneumacare Ltd|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|2 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 participants between the ages of 2 and 80 with stable asthma who are undergoing        routine clinical investigation of broncho-reversibilty.        100 participants between the ages of 2 and 80 with acute asthma who are undergoing routine        clinical investigation of broncho-reversibilty.        100 participants between the ages of 2 and 80 with no history of respiratory disease        ('Normal'). These participants will not undergo a bronchodilator challenge.|September 2015|September 3, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02543333||13599|
NCT02548637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-JOINT001|Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain|Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain||John Wayne Cancer Institute|No|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02548637||13191|
NCT02555878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107047|A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants|Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism||Janssen Research & Development, LLC|Yes|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555878||12635|
NCT02554045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA 801|Daily Tadalafil on Body Fat and Lean Mass|Effects of Daily Tadalafil on Body Composition in Men With Sexual Distress|TADBODY|University of Roma La Sapienza|Yes|Completed|January 2015|September 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|65 Years|No|||September 2015|September 17, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02554045||12775|
NCT02532504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREATOR001|Change Your Life With Seven Sheets of Paper|Change Your Life With Seven Sheets of Paper: A Pilot Randomized Controlled Trial for Postnatal Depression: A Pilot Randomized Controlled Trial for Postnatal Depression|CREATOR|Pakistan Institute of Learning and Living|Yes|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|36|||Female|18 Years|45 Years|No|||August 2015|August 22, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02532504||14429|
NCT02532517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-IDE-1001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||February 8, 2016|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532517||14428|
NCT02552862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-VSL-2014-49|Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)|Study of the Effect of Adjunctive Vivomixx® in Addition to Antibiotics on Systemic and Cerebral Inflammatory Response in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02552862||12866|
NCT02561351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si237/2013|Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation|Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation||Mahidol University|No|Completed|September 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|7 Years|20 Years|No|Non-Probability Sample|atopic asthmatic patients in Department of Pediatrics, Siriraj hospital (tertiary care)|September 2015|September 24, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02561351||12214|
NCT02550483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS51|Novel Metabolites of Beta-Carotene and Lycopene|||USDA Beltsville Human Nutrition Research Center|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|36|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2015|December 11, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02550483||13049|
NCT02550496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01491-46|Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis|Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis. Prospective, Multicenter Study (ETDT)|ETDT|Centre Hospitalier Universitaire, Amiens|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||September 2015|September 23, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550496||13048|
NCT02553070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500799|Health Professions Students and Faculty Perceptions of Poisoning Severity|Health Professions Students and Facutly Perceptions of Poisoning Severity||University of Florida|No|Completed|September 2015|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pharmacy students in their 1st or 2nd year of pharmacy school.|November 2015|November 12, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553070||12850|
NCT02556697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/093/HP|In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients|In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients|MiPECSE|University Hospital, Rouen|No|Recruiting|December 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02556697||12572|
NCT02556294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH100627-01A1|Fostering Resilience to Psychosocial and HIV Risk in Indian MSM|Fostering Resilience to Psychosocial and HIV Risk in Indian MSM||Massachusetts General Hospital|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|608|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02556294||12603|
NCT02546752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck - 20|Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine|Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine||Regenstrief Institute, Inc.|No|Not yet recruiting|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|598|||Both|11 Years|17 Years|No|||September 2015|September 17, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546752||13336|
NCT02550756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-MN-201|Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|An Open Label, Ascending Dose Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)||Centrexion Therapeutics||Completed|February 2014|||November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550756||13028|
NCT02555969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11829|Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis|Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis||Tufts Medical Center|No|Recruiting|August 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|This study will enroll AL amyloidosis patients at Tufts Medical Center who have baseline        bone marrow cells available from the time of diagnosis, or from a time of therapy prior to        achieving a response, and then subsequently achieve a CR or VGPR with first-line therapy.        Up to 30 patients diagnosed with AL amyloidosis will be evaluated on this protocol.|September 2015|September 24, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02555969||12628|
NCT02545699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-EYE 15507|Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy|Prospective Randomized Trial to Compare the Adenoma Detection Rate of G-EYE™ Colonoscopy With Standard Colonoscopy||Smart Medical Systems Ltd.|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|350|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02545699||13417|
NCT02551757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43428-A|Stroke and CPAP Outcome Study: A Sham-controlled Trial of CPAP Among Stroke Rehabilitation Patients|Randomized Trial of Continuous Positive Airway Pressure in Patients Undergoing Intensive Inpatient Rehabilitation After Acute Stroke|SCOUTS|University of Washington|No|Completed|June 2013|July 2015|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551757||12951|
NCT02554773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-AT3SC-002|An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B|An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With ALN-AT3SC||Alnylam Pharmaceuticals|No|Recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|70 Years|No|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554773||12719|
NCT02554786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVM149B2301|A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma|A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma||Novartis|Yes|Not yet recruiting|November 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|2800|||Both|12 Years|75 Years|No|||September 2015|September 17, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02554786||12718|
NCT02550106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EFR02|Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment|A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment|SUNRISE|Novartis|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|75 Years|No|||March 2016|March 20, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02550106||13078|
NCT02558296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1442-C-476|Bexagliflozin Efficacy and Safety Trial (BEST)|A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events|BEST|Theracos|Yes|Recruiting|October 2015|April 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1650|||Both|40 Years|N/A|No|||March 2016|March 11, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558296||12449|
NCT02560506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Model Systems|Development of Low Cost Devices to Increase Access to Treadmill Training|Development of Low Cost Devices to Increase Access to Treadmill Training||Rehabilitation Institute of Chicago|No|Active, not recruiting|January 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02560506||12279|
NCT02548377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC-HNC|Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial|Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial|RIPC-HNC|Aarhus University Hospital Skejby|No|Enrolling by invitation|September 2015|||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548377||13211|
NCT02548390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXDX-107-01|Study of Intravenous RXDX-107 in Patients With Solid Tumors|A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer||Ignyta, Inc.|No|Recruiting|September 2015|June 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2015|October 29, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548390||13210|
NCT02552160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6570R00001|DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy|Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners.|DETECT|AstraZeneca|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||3|Anticipated|6600|||Both|40 Years|N/A|No|Probability Sample|Patients who have been diagnosed with COPD (Chronic obstructive pulmonary disease), who        have been changed over within the last 3 months to one of the 3 listed fixed-dose        combinations (FDC) or for whom such a changeover is intended, and whose lung function        parameters and CAT (COPD Assessment Test™) score from the time prior to the changeover are        available (within the last 6 months) or are determined at the time of the 1st visit, if        this is planned as part of the routine treatment.|March 2016|March 17, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02552160|12 Months|12920|
NCT02550990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-4892A3|Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition in Stroke Patients With Cognitive Decline|Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition, Physiological Markers, Daily Function and Quality of Life in Stroke Patients With Cognitive Decline||Chang Gung Memorial Hospital|No|Recruiting|September 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|20 Years|90 Years|No|||August 2015|September 14, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02550990||13010|
NCT02551224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2405|Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Open-label, Cross-over Study Comparing the Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): The Advantage Study|Advantage|Novartis|No|Not yet recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|100|||Both|40 Years|N/A|No|||August 2015|September 14, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02551224||12992|
NCT02551237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 42 GERICO12/UCGI|Neoadjuvant Treatment for Advanced Rectal Carcinoma|A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma|NACRE|UNICANCER|Yes|Recruiting|December 2015|March 2030|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|75 Years|N/A|No|||March 2016|March 17, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02551237||12991|
NCT02560545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-LD-0001-15-CTIL|Cannabinoids Effects on the Pain Modulation System|Cannabinoids Effects on the Pain Modulation System||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2015|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|25 Years|65 Years|No|||September 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560545||12276|
NCT02556229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0201|Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.|ALINEA|Hospices Civils de Lyon|Yes|Not yet recruiting|February 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|No|||December 2015|December 9, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556229||12608|
NCT02559336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duke-NUS-KP/2015/0019|Pilot Study of the SPaRK (Supportive and Palliative Care Review Kit) Model of Care for Advanced Cancer Patients Who Have an Unplanned Admission to Singapore General Hospital|Pilot Study of the SPaRK (Supportive and Palliative Care Review Kit) Model of Care for Advanced Cancer Patients Who Have an Unplanned Admission to Singapore General Hospital|SPaRK|National Cancer Centre, Singapore|No|Not yet recruiting|October 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|21 Years|N/A|No|||September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559336||12369|
NCT02616926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015012|Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma|Hepatic Resection Versus Transarterial Chemoembolization Plus Radiofrequency Ablation for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|December 2015|July 2021|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|538|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616926||7947|
NCT02616939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-14-0127-CTIL|Clinical In-hospital Evaluation of the Usefulness of a New Multi-detector Computed Tomography Scanner From Arineta Ltd|Clinical In-hospital Evaluation of the Usefulness of a New Multi-detector Computed Tomography Scanner From Arineta Ltd|Arineta|Carmel Medical Center|Yes|Recruiting|January 2016|November 2022|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients with a clinical indication for cardiac CT|March 2016|March 23, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02616939||7946|
NCT02621879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mansourau27|Bilateral Gluteal Fascio-myo-cutaneous Flap in Treatment of Recurrent Pilonidal Disease|Bilateral Gluteal Fascio-myo-cutaneous Advancement Flap in Treatment of Recurrent Sacrococcygeal Pilonidal Disease||Mansoura University|Yes|Completed|March 2012|January 2016|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|16 Years|70 Years|No|||March 2016|March 14, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621879||7567|
NCT02612207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-24465|Point-of-Care System for Determination of Bilirubin Capacity in Neonates|||Stanford University|Yes|Recruiting|August 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|14 Days|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of preterm (≥ 28 wks GA, BW≥1000g) as well as sick or        unstable late-term newborns (infants ≥ 35 wks GA, BW≥2500g).|November 2015|November 19, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02612207||8310|
NCT02619942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELARC|Investigate the Radical Extent of Lymphadenectomy of LAparoscopic Right Colectomy for Colon Cancer(RELARC).|A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Radical Extent of Lymphadenectomy: D2 Dissection vs. Complete Mesocolic Excision, of LAparoscopic Right Colectomy for Right-sided Colon Cancer.|RELARC|Peking Union Medical College Hospital|Yes|Recruiting|December 2015|January 2021|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1072|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02619942||7716|
NCT02620735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6157-DE|Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol|Innovative Smart-phone-enabled Health Coaching Intervention (iMOVE) to Promote Long-term Maintenance of Physical Activity Behavior in Breast Cancer Survivors: Study Protocol for a Feasibility Pilot Randomized Controlled Trial|iMOVE|University Health Network, Toronto|No|Recruiting|December 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|107|||Female|18 Years|75 Years|No|||November 2015|November 30, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02620735||7655|
NCT02622061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-051|NIOX VERO Nasal Application in Primary Ciliary Dyskinesia|A Clinical Investigation Determining the Discriminative Ability of the NIOX VERO NASAL to Differentiate Subjects With Primary Ciliary Dyskinesia From Healthy Controls||Aerocrine AB|No|Not yet recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a multi-center, single visit clinical investigation involving patients with known        PCD [Cohort 1] vs. age matched healthy volunteers [Cohort 2].|December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622061||7553|
NCT02622074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-173|Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)|A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)||Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02622074||7552|
NCT02616731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXAvsDiosmin-IUDmenorrhagia|Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD|Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial||Ain Shams University|Yes|Recruiting|September 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02616731||7962|
NCT02617030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS 2013-NI 14003|Developing a Program for Transition to Adult Care for Youth With Chronic Conditions : a Mixed Method Study|Developing a Program for Transition to Adult Care for Youth With Chronic Conditions : a Mixed Method Study|TRANSAD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|390|||Both|N/A|N/A|No|Non-Probability Sample|Youth with chronic diseases after transfer to adult care|November 2015|November 25, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02617030||7939|
NCT02548039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/RM/001|To Study The Influence Of Genomic Factors On Metabolism And Effects Of Clomiphene In Asian Normogonadotrophic Anovulatory Patients.|To Study The Influence Of Pharmacogenomics Factors On Pharmacokinetics And Pharmacodynamics Of Clomiphene In Asian Normogonadotrophic Anovulatory Patients.||KK Women's and Children's Hospital|No|Recruiting|January 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Plasma, serum and Genomic DNA.|Female|21 Years|43 Years|No|Non-Probability Sample|Asian Normogonadotrophic Anovulatory Women|September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548039||13237|
NCT02548104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMCPro00034213|Analgesic Efficacy of Anterior Femoral, Genicular and Adductor Canal Nerve Block|Department of Anesthesiology of Cedars Sinai Medical Center||Cedars-Sinai Medical Center|No|Not yet recruiting|March 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|90 Years|No|||February 2016|February 2, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548104||13232|
NCT02550353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-002|Changes Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis||Sun Yat-sen University|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550353||13059|
NCT02545504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-296-1080|GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma||Gilead Sciences|Yes|Recruiting|October 2015|December 2023|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545504||13432|
NCT02545517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v49_23E1|A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.|A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine.||Novartis||Active, not recruiting|October 2015|December 2022|Anticipated|December 2022|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|578|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02545517||13431|
NCT02548273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/SC/2012/4/159|Corneal Changes in Diabetics After Phacoemulsification|Corneal Changes in Diabetics After Phacoemulsification||Jawaharlal Institute of Postgraduate Medical Education & Research|Yes|Completed|January 2013|June 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|160|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending the Ophthalmology OPD, JIPMER|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548273||13219|
NCT02548286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144BE15015|Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs|A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers(B)||Chong Kun Dang Pharmaceutical|No|Completed|August 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02548286||13218|
NCT02554227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Köln_11_2014|Cytokine Profiles in Spondylodiscitis|Verification and Progress of Cytokine Profiles for the Discrimination of Infectious and Non-infectious, Degenerative Diseases of the Spine||University of Cologne|No|Not yet recruiting|October 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Bio-Plex Pro Human Cytokine Group I 27-plex Assay (IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6,      IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, Eotaxin, G-CSF,      GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF)|Both|40 Years|80 Years|No|Probability Sample|Patients with spondylodiscitis, erosive osteochondrosis|September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554227||12761|
NCT02560337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaTo-ROC|Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.|Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase 2 Randomized, Open-label Study|CaTo-ROC|Vejle Hospital|Yes|Recruiting|September 2015|September 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560337||12292|
NCT02560363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6400C00003|A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects|An Open-label, Randomized, Cross Over Single Oral Dose Study Comparing the Pharmacokinetics of Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects||AstraZeneca|No|Withdrawn|November 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|September 24, 2015||No|Has been terminated before FSFV.|No||https://clinicaltrials.gov/show/NCT02560363||12290|
NCT02550678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASN-002-001|A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma|A Phase 1/2a Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma|ASN-002-001|Ascend Biopharmaceuticals Ltd|No|Recruiting|September 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02550678||13034|
NCT02550691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/092/HP|Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene|Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene Aiming at Improving the Genetic Counseling in Spinal Muscular Atrophy Families|BADGES|University Hospital, Rouen|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|311|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550691||13033|
NCT02553278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF18521|VelaShape and Contour I V3 Devices for Abdominal Fat Reduction vs. Control|Clinical Study to Evaluate the Performances of VelaShape and the Performance of Contour I V3 Devices for Abdominal Fat Reduction vs. Control||Syneron Medical|No|Not yet recruiting|December 2015|December 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|October 7, 2015|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553278||12834|
NCT02551055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C032-6001 (MLN1117-1003)|MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma|An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma||Millennium Pharmaceuticals, Inc.|No|Recruiting|October 2015|July 2020|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|178|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02551055||13005|
NCT02560376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM12|68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis|68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis||Peking Union Medical College Hospital|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|6 Years|70 Years|No|||May 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560376||12289|
NCT02550938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-300307-00|Primer Aligner Study|Primer Aligner Study||Align Technology, Inc.|No|Recruiting|May 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 14, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550938||13014|
NCT02555462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR.2015-0099|Real-Ear Measurement (REM) and Test Box System Integration Into Fitting Software|||Phonak AG, Switzerland||Active, not recruiting|September 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|205|||Both|16 Years|67 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02555462||12667|
NCT02558595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002827|Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)|Randomized, Controlled Pilot Study of Niacinamide in Polycystic Kidney Disease||University of Kansas Medical Center|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|60 Years|No|||October 2015|October 1, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558595||12426|
NCT02548806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX2015/28/02|Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers|Randomised Single Dose 3 Way Crossover Single Blind Study to Evaluate the Pharmacokinetic Dose Proportionality, Compare the Bioavailability and Safety of Clonidine Mucoadhesive Buccal Tablets (MBT) With Catapres in Normal Healthy Volunteers||Onxeo|No|Recruiting|September 2015|April 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548806||13178|
NCT02547415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408152|Chronic Pain in Children and Adolescents.|Study of Characteristics of Medically Unexplained Chronic Pain in Children and Adolescents.|PEDOUL|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|7 Years|17 Years|No|Non-Probability Sample|Children and adolescent with chronic pain|March 2016|March 22, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547415||13285|
NCT02547428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-EB-1020-202|Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Euthymics BioScience, Inc.|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|February 25, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547428||13284|
NCT02555670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICUBIACT|Relation Between Bioelectrical Impedance Analysis and CT-scan Analysis in the ICU|Relation Between Bioelectrical Impedance-derived Muscle Mass and CT-derived Muscle Area in Critically Ill Patients||VU University Medical Center|No|Completed|May 2014|August 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|222|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Adult Intensive Care Unit|September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555670||12651|
NCT02545296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-IMPH-BABY-01|HIV Point-of-Care Test Evaluation in Infants|HIV Point-of-Care Tests in Babies Study (BABY) - Operational Evaluation of HIV Point-of-Care Tests for Very Early Infant HIV Diagnostics in Infants Born to HIV Infected Mothers in Mbeya, Tanzania|BABY|Ludwig-Maximilians - University of Munich|Yes|Recruiting|July 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||March 2016|March 2, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545296||13448|
NCT02556203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17938|Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes|Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes|GALILEO|Bayer|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1520|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|September 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556203||12610|
NCT02556047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC332|Evaluation of the Safety & Performance of 2 Intradermal Safety Devices|A Clinical Investigation to Evaluate the Safety and Performance of Two Star Intradermal Safety Device (IDSD) Syringes in Healthy Adult Volunteers||University of Surrey|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02556047||12622|
NCT02555683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2307|Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.||Novartis|Yes|Recruiting|December 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|846|||Both|12 Years|N/A|No|||March 2016|March 10, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555683||12650|
NCT02559635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-06-2015|Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus?|Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus? A Multicenter Randomized Controlled Trial||Jewish General Hospital|No|Not yet recruiting|December 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|N/A|No|||July 2015|September 23, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02559635||12346|
NCT02545829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-POVI-101|Evaluating the Bioequivalence of HIP1302, HGP1406|A Randomized, Open, 2-way Cross-over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HIP1302 and HGP1406 (Tenofovir) in Healthy Korean Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Active, not recruiting|August 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||August 2015|September 8, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02545829||13407|
NCT02554201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYY201501|Efficacy of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction|Efficacy of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2015|September 29, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02554201||12763|
NCT02554214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007|Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device|||Rheon Medical SA||Recruiting|September 2015|||September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02554214||12762|
NCT02552147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015384|Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism|Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism||Yale University|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|40 Years|No|||February 2016|February 17, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552147||12921|
NCT02547766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00075500|Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices|Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices||University of Utah|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547766||13258|
NCT02529930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB C-01|An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)|An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)||Vaccibody AS|Yes|Recruiting|August 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||November 2015|November 27, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529930||14625|
NCT02529943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norton15_05|Changes in Motor Latency During Spinal Decompression: Relationship to Outcomes|||University of Saskatchewan|No|Not yet recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with central spinal stenosis scheduled for surgical decompression.|August 2015|August 19, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02529943||14624|
NCT02529956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0008|A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis|A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis||UCB Pharma|No|Completed|November 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|70 Years|No|||August 2015|August 19, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02529956||14623|
NCT02557321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-MM-1201|PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma|A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma||Provectus Pharmaceuticals|No|Recruiting|October 2015|November 2023|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557321||12524|
NCT02550925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSG-15-020-01|Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors|A Novel Acceptance-Based Intervention for Anxious Cancer Survivors||University of Colorado, Boulder|No|Recruiting|September 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02550925||13015|
NCT02551172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROMA-301|Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD|An Efficacy and Safety Study of HCP1105 Capsule in Combined Hyperlipidemic Patients With High Risk for Coronary Heart Disease (CHD): A Randomized,Double-blind, Multicenter, Phase 3 Study||Hanmi Pharmaceutical Company Limited|No|Recruiting|October 2014|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|270|||Both|19 Years|N/A|No|||September 2015|September 15, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551172||12996|
NCT02553525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500432|Effects of Stimulation Patterns of Deep Brain Stimulation|Effects of Stimulation Patterns of Deep Brain Stimulation||University of Florida|No|Not yet recruiting|February 2016|February 2021|Anticipated|February 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553525||12815|
NCT02553824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31390|FDA Approved Medication to Reduce Binge Eating and/or Purging|Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder||Stanford University|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||September 2015|September 16, 2015|August 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553824||12792|
NCT02531646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9J8068|Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis|Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis||Carestream Health, Inc.|No|Enrolling by invitation|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Enrollment will include patients scheduled to have a chest CT exam.|August 2015|February 19, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531646||14493|
NCT02531945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7419 15|Evaluation of the Surface Topography for Monitoring Scoliosis Patients Aged 10-13 Years|Scoliosis Patients Aged 10-13 Years: Monitoring of Scoliosis by the Surface Topography|SCOBIOMOD|University Hospital, Toulouse|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|125|||Both|10 Years|13 Years|No|||October 2015|October 13, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02531945||14471|
NCT02548403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korea University Prep1|Effect of Simethicone on Bowel Preparation for Colonoscopy|Use of Simethicone to Improve the Bowel Cleansing Effects of Polyethylene Glycol With Ascorbic Acid for Colonoscopy||Korea University Anam Hospital|Yes|Completed|July 2014|November 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|260|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548403||13209|
NCT02551406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcCO2-VAD|Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients|Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients|TcCO2-VAD|Centre d'Investigation Clinique et Technologique 805|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Ventilated neuromuscular disease patients followed at the Franch national reference center        of Garches.|February 2016|February 25, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551406||12978|
NCT02551419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-509|Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET|Effect of a Ketogenic Supplement on Brain Energy Metabolism Measured by Neuroimaging in Mild Cognitive Impairment|BENEFIC|Université de Sherbrooke|No|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|55 Years|N/A|No|||July 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551419||12977|
NCT02558244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Image-defined RF NB|Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study|Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study||Assiut University|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients, those diagnosed with Neuroblastoma, in the period from 2001        January till 2015 December, and received treatment at the pediatric oncology department,        their medical records will be retrospectively reviewed for data collection.|March 2016|March 8, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558244||12453|
NCT02544672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-260|Function Benefits of a Myoelectric Elbow-Wrist-Hand Orthosis|Function Benefits of a Myoelectric Elbow-Wrist-Hand Orthosis||Myomo||Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02544672||13496|
NCT02552641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMESO|Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole|Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole||EMS|Yes|Recruiting|September 2015|September 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|363|||Both|18 Years|50 Years|No|||September 2015|September 16, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02552641||12883|
NCT02552654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rombold_02|Cortisol and the Formation of Intrusive Memories|Cortisol and the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm||Charite University, Berlin, Germany|No|Not yet recruiting|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552654||12882|
NCT02561338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMM0201|A Multi-center 12-week Study of HMS5552 in T2DM|A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects||Hua Medicine Limited|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|300|||Both|40 Years|75 Years|No|||September 2015|February 16, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561338||12215|
NCT02558387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-120133|Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck|Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study||Samsung Medical Center|No|Active, not recruiting|November 2014|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558387||12442|
NCT02552810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UValencia_001_Plasma|Plasma of Argon Cleaning on Implant Abutments: 5-year Results of a RCT|Effect of Plasma of Argon Cleaning on Implant Abutments in Patients With a History of Periodontal Disease and Thin Biotype: Five Years Post-loading Results of a Randomized Controlled Trial||University of Valencia|Yes|Completed|January 2010|September 2015|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02552810||12870|
NCT02555514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBBM-CKJ|Identification of Biochemical and Biomechanical Markers for Cartilage Degeneration in the Knee Joint (IBBM-CKJ)|Identification of Biochemical and Biomechanical Markers for Cartilage Degeneration in the Knee Joint (IBBM-CKJ)|IBBM-CKJ|University of Cologne|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|In order to investigate cartilage degeneration/turnover (COMP, collagen II, GAGs), miRNA and      cytokine profiles 4 blood draws will be carried out|Both|18 Years|N/A|No|Non-Probability Sample|End stage medial, bi- or tricompartimental OA with indication to total knee replacement        with failure of conservative treatment|September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02555514||12663|
NCT02556632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC14079|Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer or Breast Cancer In Situ|Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis||University of Rochester|Yes|Recruiting|October 2015|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|180|||Female|21 Years|N/A|No|||March 2016|March 16, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556632||12577|
NCT02548221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTE and LVPE|Impact of Large-Volume Pleural Effusions on Heart Function|The Assessment of Heart Function Using Transthoracic Echocardiogram (TTE) Following Thoracentesis on Large-volume Pleural Effusions|TTE|Beijing Chao Yang Hospital|No|Recruiting|September 2015|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|14 Years|75 Years|No|Probability Sample|The patients with unilateral or bilateral pleural effusion, with at least 500ml amount of        effusion are enrolled in this study. Study population include malignant pleural effusion,        tuberculosis pleural effusion, parapneumonic effusion, and a variety of causes for        transudative pleural effusion.|September 2015|September 11, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02548221||13223|
NCT02557997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6074|Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation|Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation||University Hospital, Strasbourg, France|No|Recruiting|April 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|202|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients visiting an HIV Infection care center at a university hospital will be selected|September 2015|September 22, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02557997||12472|
NCT02555748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 URO 06|Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma|Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma|SUP-R|Institut Claudius Regaud|Yes|Recruiting|October 2015|April 2020|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|214|||Both|18 Years|N/A|No|||September 2015|December 1, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02555748||12645|
NCT02555761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229666-007|Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea|||Allergan|No|Recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|2 Years|N/A|No|Probability Sample|Patients with itching associated with Allergic Conjunctivitis prescribed Lastacaft® as        standard of care in clinical practice.|December 2015|December 8, 2015|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555761||12644|
NCT02561364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-03853-XP|Biophysical Profile in Preterm Pregnancies|Pattern of Human Fetal Biophysical Profile Scoring in Relationship to Gestational Age.|BPP|University of Tennessee|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant patients that meet the all of the inclusion criteria and do not meet the        exclusion criteria, will be approached during their routine prenatal care regarding their        interest in participation. Women must be between 20 weeks to 36 weeks of their pregnancy.|September 2015|September 28, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561364|4 Weeks|12213|
NCT02548481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14004|Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke|Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke|BESTA-AVC|University Hospital, Limoges|No|Not yet recruiting|October 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|395|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Administration of BESTA scale (test to assess) within 3 days after stroke and at 3 months        and 1 year after stroke. This scale will be compared to standard scales.|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548481||13203|
NCT02551250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150160|Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis|Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging as a Surveillance Test for Hepatocellular Carcinoma in Patients With Liver Cirrhosis|MAGNUS-HCC|Seoul St. Mary's Hospital|No|Recruiting|September 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|211|||Both|40 Years|70 Years|No|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551250||12990|
NCT02546076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KELOID|Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars|Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars|KELOID|University Hospital Inselspital, Berne|No|Not yet recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02546076||13388|
NCT02546323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3565C00003|A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis|A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects||AstraZeneca|No|Recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|506|||Both|45 Years|69 Years|No|||March 2016|March 3, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02546323||13369|
NCT02549404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-011|Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)||Kyowa Hakko Kirin Company, Limited|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549404||13132|
NCT02553200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU|The Efficacy of Breathing Exercise With BreatheMAX Device on Airway Secretion Clearance and Lung Function|Study of Breathing Exercise With Oscillated Inspiratory Loading (OIS) and Oscillated Positive Expiratory Pressure (OPEP) for Airway Secretion Clearance and Lung Function in Intubated Patients, Both With and Without Mechanical Ventilation Dependence|BMACPF|Khon Kaen University|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|N/A|No|||September 2015|February 15, 2016|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02553200||12840|
NCT02559596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0311|Reactivation of Varicella Zoster Virus and Risk of Vascular Disease|Reactivation of Varicella Zoster Virus and Risk of Vascular Disease in the Health Survey for England: a Nested Case Control Study||University College, London|No|Active, not recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|2000|||Both|16 Years|N/A|No|Non-Probability Sample|The study population will be drawn from adults who have already participated in the Health        Survey for England between 2009 and 2013 and who have a stored serum sample available for        analysis. No new participants will be recruited.|September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559596||12349|
NCT02559609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-041-2|Interventions for Unemployed Hazardous Drinkers|||University of Connecticut Health Center|Yes|Recruiting|January 2016|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02559609||12348|
NCT02558543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003321-17|Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis|Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment|scleradec2|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|September 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02558543||12430|
NCT02557152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-10|The GentleWave Registry|The GentleWave Post-Market Registry||Sonendo, Inc.|No|Recruiting|September 2015|||August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Up to 500 subjects that have been treated with the Sonendo GentleWave System.|September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557152|24 Months|12537|
NCT02547623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-01|Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery|A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery||ICON Bioscience Inc|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547623||13269|
NCT02554591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509030|Genomic Landscape of Ceritinib|Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib||Washington University School of Medicine|No|Recruiting|September 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from the Washington University School of Medicine and        Barnes-Jewish healthcare system who previously consented to study HRPO (Human Research        Protection Office)# 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and        Collection of Health Information from Patients with Thoracic Malignancies, Suspected        Thoracic Malignancies, or Mesothelioma").|September 2015|September 17, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02554591||12733|
NCT02549716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBSTUDY00002767|Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH|Clinical, Pharmacological and Molecular Effects of Intravenous and Oral Acetaminophen in Adults With Aneurysmal Sub-Arachnoid Hemorrhage|aSAH|Milton S. Hershey Medical Center|Yes|Not yet recruiting|November 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02549716||13108|
NCT02531620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015A1|Prehabilitation in Elective Colorectal Resection: A Pilot Study (Prehab)|Prehabilitation Interventions in Elective Colorectal Resections: A Randomized Pilot Study (Prehab)|Prehab|McMaster University|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02531620||14495|
NCT02531633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201677|Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis||GlaxoSmithKline|Yes|Recruiting|October 2015|May 2020|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|204|||Both|50 Years|N/A|No|||February 2016|March 17, 2016|July 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531633||14494|
NCT02552368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201021771|Treatment of Chronic Stroke With IpsiHand|A Brain Computer Interface and Brain-Controlled Stroke Rehabilitation Method Utilizing Electroencephalography in Hemiparetic and Hemiplegic Stroke Patients to Achieve Thought Control of Machines and a Better Understanding of Brain Function||Washington University School of Medicine|Yes|Recruiting|August 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02552368||12904|
NCT02559232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17961|An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers|An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers|BRONCE-AP|Bayer|No|Active, not recruiting|September 2015|April 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|patients at risk of stroke or systemic embolism on anticoagulant therapy, who have changed        their therapeutic regimen according to their doctor's decision, due to any clinical        situation and based on routine clinical practice, and who at the time of enrolment in the        study have been receiving treatment with a DOAC for at least three months|January 2016|January 18, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02559232||12377|
NCT02557620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4215|Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly|A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly||Novo Nordisk A/S|No|Active, not recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557620||12501|
NCT02557698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-SP-ABC-13|Effectiveness of Using an Oil Bath Additive|Prospective, Randomized Study on the Skin Functional Parameters to Assess Skin Barrier Improvement After the Use of a Commercially Available Oil Bath Containing 84.75% Soybean Oil Compared to no Bath Additive||Charite University, Berlin, Germany|No|Completed|November 2014|September 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|6 Months|85 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557698||12495|
NCT02531919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300000483|Extended Use of Sodium Bicarbonate in Patients With Cancer|Chronic Oral Bicarbonate Feasibility Study||University of Arizona|Yes|Completed|August 2013|May 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|August 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531919||14473|
NCT02531932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1075|Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer|A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531932||14472|
NCT02545686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2364-YL-CTIL|Effect of CPAP on Breath Hold and Chest Movement in Normal Volunteers|Use of the Real-time Position Management (RPM) to Measure the Effects of Continuous Positive Airway Pressure (CPAP) on Duration of Breath Hold and Diaphragm Motion in Normal Volunteers|CPAP_normal|Sheba Medical Center|No|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545686||13418|
NCT02548923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTMCKTRAUMA1|Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients|Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients||University of Tennessee Graduate School of Medicine|No|Completed|November 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548923||13169|
NCT02621892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-01-301|A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Ardelyx|No|Recruiting|October 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621892||7566|
NCT02617017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130909|Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease|Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial|BUSPARK|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|35 Years|80 Years|No|||November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02617017||7940|
NCT02617316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20130302|The Different Running Speeds of Strike Patterns|Analysis of the Different Running Speeds of Strike Patterns: The Efficiency of Shoes||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|December 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||December 2014|November 27, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02617316||7917|
NCT02625584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETH000849|Reading Together: How to Promote Children's Language Development Using Family-based Shared Book Reading|Reading Together: How to Promote Children's Language Development Using Family-based Shared Book Reading||University of Liverpool|No|Not yet recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|30 Months|36 Months|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02625584||7282|
NCT02623036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHUMC 2015.10.01|The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors|The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension||Memorial Health University Medical Center|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623036||7478|
NCT02627391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 140460|Early Surgery for Patients With Asymptomatic Aortic Stenosis|Early Surgery for Patients With Asymptomatic Aortic Stenosis|ESTIMATE|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|January 2016|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|360|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02627391||7143|
NCT02621970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-098-Dept. of RT|Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma|Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy||Sun Yat-sen University|No|Not yet recruiting|January 2016|January 2024|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|534|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621970||7560|
NCT02552771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-162|The Canadian Mitral Research Alliance (CAMRA-1) Trial|A Randomized Trial of Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The Canadian Mitral Research Alliance (CAMRA-1) Trial|CAMRA-1|St. Michael's Hospital, Toronto|Yes|Not yet recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02552771||12873|
NCT02552823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H29|Effects of Peas on Blood Glucose Control|A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas on Post-prandial Glucose Response in Healthy Adults||St. Boniface General Hospital Research Centre|No|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02552823||12869|
NCT02554695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002313|Osteoclast Inhibition and Bone Formation|Effects of Age and Osteoclast Inhibition on Bone Formation||Mayo Clinic|No|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Female|25 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02554695||12725|
NCT02550405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingNormalU|The Behavioral and Brain Mechanism of IGD|The Behavioral and Brain Mechanism of Internet Gaming Disorder||Beijing Normal University|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|204|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02550405||13055|
NCT02553031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201403082MIND|Application of MR-PET in Colorectal Cancer|Application of MR-PET in Colorectal Cancer||National Taiwan University Hospital|No|Recruiting|July 2014|May 2016|Anticipated|December 2015|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|90 Years|No|Non-Probability Sample|This is a prospective cohort study. Patients with 50 newly diagnosed colorectal cancers        and 50 patients with suspicious recurrent colorectal cancers will be enrolled.|September 2015|September 16, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02553031||12853|
NCT02556645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-1-0008|A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel|||University of Pennsylvania||Not yet recruiting|November 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||September 2015|September 18, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02556645||12576|
NCT02546895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-132|Prospective Registration of Head and Neck Cancer|Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection||Samsung Medical Center|No|Recruiting|September 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|1. Serum        2. Tissue specimen|Both|19 Years|N/A|No|Probability Sample|Pathologically proven head and neck cancer patients, who are referred to Samsung Medical        Center|November 2015|November 17, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02546895||13325|
NCT02555280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAS003|Post-Approval 'Real Conditions of Use' Study|A 2 and 5 Year Comparative Evaluation of Clinical Outcomes in the Treatment of Degenerative Spinal Stenosis With Concomitant Low Back Pain by Decompression With and Without Additional Stabilization Using the Coflex® Interlaminar Technology for FDA Real Conditions of Use Study|PAS003|Paradigm Spine|No|Not yet recruiting|December 2015|June 2022|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|345|||Both|40 Years|N/A|No|||September 2015|September 18, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555280||12680|
NCT02558530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atkins|Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease|Rapid Resolution of Human Fatty Liver Disease, the Key to Obesity-related Morbidity and Mortality||Helsinki University Central Hospital|No|Active, not recruiting|January 2015|April 2017|Anticipated|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558530||12431|
NCT02554292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-A-1507|Post Market Surveillance of SeQuent Please Neo With Scoring Balloon|Post MArket Surveillance of SeQuent Please Neo With ScORing Balloon Lesion Preparation in Real WorlD Patients|PASSWORD|B. Braun Melsungen AG|No|Recruiting|October 2015|February 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients with coronary artery disease, specifically with in-stent restenosis|February 2016|February 26, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554292|9 Months|12756|
NCT02547155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 15-019|Does Spinal Anesthesia for Prolapse Surgery With Lead to Urinary Retention?|Does Spinal Anesthesia for Prolapse Surgery With Concomitant Sling Procedures Lead to an Increase in Urinary Retention Compared to General Anesthesia?||Cleveland Clinic Florida|No|Recruiting|March 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|68|||Female|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02547155||13305|
NCT02550873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRM-151-202|A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||Promedior, Inc.|Yes|Recruiting|August 2015|March 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|117|||Both|40 Years|80 Years|No|||September 2015|March 17, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550873||13019|
NCT02555475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/15/SVHM/41|The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital|The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital: a Randomised Trial||Macfarlane Burnet Institute for Medical Research and Public Health Ltd|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555475||12666|
NCT02559804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB with SCI|Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)|Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)|NB-SCI|Associazione Italiana Ematologia Oncologia Pediatrica|No|Recruiting|May 2014|April 2017|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|18 Years|No|Probability Sample|Patients in the age range 0-18 years diagnosed with peripheral neuroblastic tumour and SCI        in the period from May 2014 to April 2017|September 2015|September 23, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02559804|5 Years|12333|
NCT02559817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-63|A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, A Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (ie, Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation|LIN-MD-63|Forest Laboratories|Yes|Recruiting|October 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|260|||Both|7 Years|17 Years|No|||October 2015|October 30, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559817||12332|
NCT02553603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0086|The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment|The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment||The University of Texas Medical Branch, Galveston|No|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02553603||12809|
NCT02551367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8691|Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )|Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome|LVCCFOROI|Ain Shams Maternity Hospital|Yes|Not yet recruiting|October 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551367||12981|
NCT02560246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822218|Maternal Gut Microbiome (MGM) Study of Diet, the Gut Microbiome and Preterm Birth|Maternal Gut Microbiome (MGM) Study of Diet, the Gut Microbiome and Preterm Birth|MGM|University of Pennsylvania|No|Recruiting|April 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|1. Collect stool, maternal blood, cord blood, and placenta from women with preterm and term      labor in order to investigate whether diet and gut microbiome play a role in preterm birth.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women will be recruited from three locations: Penn ObGyn Associates, Helen O.        Dickens Clinic, and Maternal Fetal Medicine at 2000 Courtyard. Potential subjects will be        identified from clinical schedules and will be pre-screened in EPIC for eligibility. They        may be approached during a clinical visit, or the research team may call them prior to or        after a scheduled visit to introduce the study. Women can be enrolled anytime between the        confirmation of pregnancy and 24 weeks/0 days gestation. For convenience, research visits        can be conducted at the time of a scheduled clinical visit, or at a separate time.|September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560246||12299|
NCT02560259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/157(REK)|The Role of Referred Pain From the Retro Trochanteric Region in Patients With Knee Pain|The Role of Referred Pain From the Retro Trochanteric Region in Patients With Knee Pain. Prevalence, Interpretation and Management: A Randomized Controlled Study||University Hospital of North Norway|No|Not yet recruiting|October 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02560259||12298|
NCT02549547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID: H15-01932|Jump Step - A Participatory Approach to Physical Activity & Mental Wellness|Jump Step - A Participatory Approach to Physical Activity & Mental Wellness|JumpStep|University of British Columbia|No|Recruiting|August 2015|June 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02549547||13121|
NCT02545868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN29739|A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis|||Hoffmann-La Roche||Recruiting|October 2015|October 2022|Anticipated|October 2022|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545868||13404|
NCT02549599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chat/Text Program|Evaluating a Digital Health Information Tool|Chat/Text Program: Digital Health Information Efficacy Trial|Chat/Text|New York University|No|Completed|February 2015|March 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|5220|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549599||13117|
NCT02558673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSP 72118|Trimethylamine-N-oxide Production and Metabolism|Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans||Cornell University|No|Active, not recruiting|May 2014|July 2016|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02558673||12420|
NCT02557867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-253|The Effect of Obesity in Dexmedetomidine Metabolic Clearance|The Effect of Obesity in Dexmedetomidine Metabolic Clearance||Pontificia Universidad Catolica de Chile|Yes|Recruiting|August 2015|December 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557867||12482|
NCT02550782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mengücek gazi|Infraclavicular Perineural Dexmedetomidine|Does Patient-Controlled Infraclavicular Perineural Dexmedetomidine Improve Postoperative Analgesia Deadline?||Cukurova University|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|December 26, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550782||13026|
NCT02550795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast PONV|Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer|Effects of Single Dose Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer||Gachon University Gil Medical Center|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Female|20 Years|65 Years|No|||September 2015|September 14, 2015|August 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550795||13025|
NCT02556593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1009|IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases|IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases||Sun Yat-sen University|No|Recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02556593||12580|
NCT02556606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-001-14F|Ketamine for Treatment Resistant Late-Life Depression|Ketamine for Treatment Resistant Late-Life Depression||VA Office of Research and Development|Yes|Not yet recruiting|October 2015|September 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|72|||Both|55 Years|N/A|No|||September 2015|September 24, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02556606||12579|
NCT02556268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17957|Interaction With HIV Antiretroviral Agents|Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients||Bayer|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556268||12605|
NCT02551991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-398-07-02-03|Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma||Merrimack Pharmaceuticals|Yes|Recruiting|September 2015|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|168|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551991||12933|
NCT02534259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002137|Mobile Monitoring of Fracture Healing|Mobile Monitoring of Fracture Healing||Milton S. Hershey Medical Center||Recruiting|August 2015|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing treatment for severe tibia fracture and/or defect using a circular        external fixator.|March 2016|March 14, 2016|August 21, 2015||Yes||No||https://clinicaltrials.gov/show/NCT02534259||14294|
NCT02548143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFB-FVIIa-008-14|A Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) LR769 for the Prevention of Excessive Bleeding in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX Undergoing Elective Surgery or Other Invasive Procedure|A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX Undergoing Elective Surgery or Other Invasive Procedures (PERSEPT 3)|LR769|rEVO Biologics|Yes|Not yet recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|6 Months|75 Years|No|||November 2015|November 24, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548143||13229|
NCT02555449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15566|A Study of [¹⁴C]-LY3202626 in Healthy Male Participants|Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects||Eli Lilly and Company|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555449||12668|
NCT02558166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-2015.025|Renal Resistive Index in Patients With Shock|Relation Between the Renal Resistive Index and Markers of the Systemic Circulation, the Microcirculation, Fluid Status and of Renal Function.||VU University Medical Center|No|Recruiting|August 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Adult patients, admitted tot the Intensive Care Unit (ICU)        Variables will be measured in a population of 80 adult patients admitted tot the Intensive        Care Unit. This group consists of two groups of 40 patients. The first group consists of        40 patients with cardiogenic or septic shock, the second group will be the control group        being intensive care patients without shock. The patients with shock are at increased risk        for developing Acute Kidney Injury (AKI).|September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558166||12459|
NCT02552329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chiang Mai University|Effects of Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With MCI|A Randomized Controlled Trial of Mind-body Exercise: Effects of a 6-month Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With Mild Cognitive Impairment (MCI)|MCI-TaiChi|Chiang Mai University|No|Active, not recruiting|December 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|55 Years|85 Years|No|||September 2015|September 30, 2015|January 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02552329||12907|
NCT02554942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17912|A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors|An Open-Label Study of the Safety Of NeoRecormon in Patients With Solid Tumors Being Treated With Platinum Capable of Inducing Anemia||Hoffmann-La Roche||Completed|June 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554942||12706|
NCT02552381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICT 2015-A00501-48|Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH|Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH|FICT|Diagnostica Stago R&D|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Frozen citrated Poor Platelets Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients from Internal Medicine Department, in a French Hospital|September 2015|November 18, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02552381||12903|
NCT02552394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015998|J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts|Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts||Weill Medical College of Cornell University|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||September 2015|September 16, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552394||12902|
NCT02555657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-119|Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)|A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)||Merck Sharp & Dohme Corp.|Yes|Recruiting|October 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555657||12652|
NCT02546024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178116/813302/14/153|Predictors of Treatment Response in Late-onset Major Depressive Disorder|Predictors of Treatment Response in Late-onset Major Depressive Disorder||King's College London|No|Not yet recruiting|September 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|60 Years|N/A|No|Non-Probability Sample|40 participants with major depressive disorder will be recruited from Community Mental        Health Services, Home Treatment Service, and Inpatient services of the Mental Health of        Older Adults and Dementia Clinical Academic Group in the South London and Maudsley NHS        Foundation Mental Health Thrust.|September 2015|September 8, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546024||13392|
NCT02532244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|764456|Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases|Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases||Nemours Children's Clinic|No|Recruiting|June 2015|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|serum, lymphoblastoid cell lines derived from peripheral blood mononuclear cells, saliva,      buccal cells|Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll children diagnosed with a motor neuron or neuromuscular disease as        well as their parents and/or siblings.|August 2015|August 24, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02532244||14449|
NCT02556021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_302|Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease|A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease||CJ HealthCare Corporation|No|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|324|||Both|20 Years|75 Years|No|||September 2015|September 21, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02556021||12624|
NCT02556242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIDZC8610|Targeted Indoor Residual Spraying Against Malaria|From Malaria Control to Sustainable Elimination: Cluster Randomised Trial Comparing Targeted Versus Generalised Vector Control in South Africa|TIRS|London School of Hygiene and Tropical Medicine|Yes|Enrolling by invitation|October 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02556242||12607|
NCT02547961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Cancer CAR-T 001|Chimeric Antigen Receptor-Modified T Cells for Breast Cancer|Chimeric Antigen Receptor-Modified T Cells for HER-2 Positive Recurrent and Metastatic Breast Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|September 2015|March 2020|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||September 2015|September 10, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02547961||13243|
NCT02547974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201281|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.||GlaxoSmithKline||Active, not recruiting|August 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547974||13242|
NCT02547987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BaylorBCC|Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer|CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery|CADENCE|Baylor Breast Care Center|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547987||13241|
NCT02546271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 194226|A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men|A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men|GPS|Ryerson University|No|Completed|March 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|82|||Male|18 Years|N/A|No|||November 2015|November 18, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02546271||13373|
NCT02555527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063824|Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment|Cost-effectiveness and Financial Impact of Contrast Echocardiography for the Assessment of Left Ventricular Thrombus||Duke University|No|Active, not recruiting|September 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dilated or ischemic cardiomyopathy and an ejection fraction (EF) ≤35%        referred for clinically indicated, resting transthoracic echocardiography.|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555527||12662|
NCT02548858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-108|Perineorrhaphy Outcomes Related to Body Imagery|Perineorrhaphy Outcomes Related to Body Imagery (POETRY)|POETRY|University of New Mexico|No|Recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|46|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548858||13174|
NCT02548871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP1AH000066|Evaluation of the Teen Outreach Program in Chicago Public Schools|Evaluation of the Teen Outreach Program in Chicago Public Schools: Replication of an Evidence-Based Teen Pregnancy Prevention Program||Chapin Hall Center for Children|No|Completed|September 2010|August 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12253|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548871||13173|
NCT02552719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEQ2015|Validation of the German Version of the Injustice Experience Questionnaire|Validation of the German Version of the Injustice Experience Questionnaire (IEQ) in 6 Pain Centers|GIEVA|University of Zurich|No|Enrolling by invitation|July 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|210|||Both|18 Years|N/A|No|Non-Probability Sample|pain patients|September 2015|September 21, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02552719||12877|
NCT02559206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-204|Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation||Ironwood Pharmaceuticals, Inc.|No|Recruiting|October 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|520|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559206||12379|
NCT02545855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIRES1507|High-flow Nasal Cannula Therapy for Stable Chronic Obstructive Pulmonary Disease (COPD)|Long-term High-flow Nasal Cannula Therapy in Patients With Stable COPD: a Prospective, Randomized Crossover Study||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|N/A|No|||September 2015|September 7, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02545855||13405|
NCT02545413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC/2015/protocol/24|Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome|Randomized,Double-blind, Placebo Controlled Trial to Study the Efficacy and Safety of Probiotics in Adult Patients With Irritable Bowel Syndrome-diarrhea Predominant (IBS-D)||Next Gen Pharma India Pvt. Ltd.|No|Withdrawn|May 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|65 Years|No|||March 2016|March 21, 2016|August 31, 2015||No|Investigator (Dr Amit) not interested to carry out the study|No||https://clinicaltrials.gov/show/NCT02545413||13439|
NCT02545426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myocardial stunning - Calcium|Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration|Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration||University of Sao Paulo General Hospital|No|Recruiting|July 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|17 Years|70 Years|No|||September 2015|September 9, 2015|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02545426||13438|
NCT02558062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC ONE|Microdosing of BAC ONE to the Distal Lung|Exploratory Clinical Study of Intrapulmonary Microdosing of the BACterial Detection Probe (BAC ONE) in Ventilator Associated Pneumonia|BAC ONE|University of Edinburgh|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|12|||Both|16 Years|N/A|No|||September 2015|September 22, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02558062||12467|
NCT02551315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-117|Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes|Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes: the DiabOS Study|DiabOS|University Hospital, Basel, Switzerland|Yes|Not yet recruiting|April 2016|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|440|Samples Without DNA|Bone trunover markers, parameters re calcium metabolism, HbA1c, Insulin, pentosidine,      markers of inflammation|Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Female and male diabetics (aged between 50 and 75 years; BMI between 18 and 37 kg/m2) Age-        and sex-matched non-diabetic controls|September 2015|September 24, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02551315||12985|
NCT02553434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506936985|Comparing 14 F Pigtail Catheter to Traditional 28-32F Chest Tube in the Management of Traumatic Hemothorax and Hemopneumothorax|Prospective and Randomized Study Comparing 14 F Pigtail Catheter to Traditional 32-36F Chest Tube in the Management of Traumatic Hemothorax and Hemopneumothorax||University of Arizona|No|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02553434||12822|
NCT02557841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cerebellar_tDCS_MotorLearning|Cerebellar tDCS on Motor Learning of Healthy Individuals|Effects of Cerebellar Transcranial Direct Current Stimulation (ctDCS) on Motor Learning of Healthy Individuals||Universidade Federal de Pernambuco|Yes|Recruiting|September 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02557841||12484|
NCT02557854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW-HIFU-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||September 22, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557854||12483|
NCT02560155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-11-F|Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial|Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial (DECO-SSI Trial)|DECO-SSI|Lindenhof AG|Yes|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|2670|||Both|16 Years|N/A|No|||November 2015|November 9, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02560155||12306|
NCT02551822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-133|Cycling Versus Continuous Mode in Neuromodulator Programming|Cycling Versus Continuous Mode in Neuromodulator Programming||University of New Mexico|No|Recruiting|July 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|23|||Female|21 Years|N/A|No|||September 2015|September 15, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02551822||12946|
NCT02561260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1-1101-2|Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China|||Beijing Tongren Hospital||Active, not recruiting|May 2015|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|400|||Both|6 Months|N/A|No|Non-Probability Sample|The unidentified encephalitis patients who meeting the inclusion criteria and exclusion        criteria and signed a written informed consent.|September 2015|September 27, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561260||12221|
NCT02555501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCF-060264-AM|Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy|Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial|OMLTPT|Universidade Ceuma|Yes|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|3 Years|18 Years|No|||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555501||12664|
NCT02557971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-US-OAB-0403|Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder|||Allergan|No|Active, not recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Both|18 Years|N/A|No|Probability Sample|Patients prescribed BOTOX® for the treatment of idiopathic OAB in clinical practice.|March 2016|March 8, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557971||12474|
NCT02536066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPPA99|Daily Physical Activity After Meals -Long Term Effects on Blood Glucose|Daily Physical Activity After Meals -Long Term Effects on Blood Glucose||Lillehammer University College|No|Completed|September 2010|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|N/A|N/A|No|||August 2015|August 26, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02536066||14155|
NCT02556008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH001|Cannabidiol for Pediatric Epilepsy (Compassionate Use)|Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol)||University of California, Los Angeles||Available||||||N/A|Expanded Access|N/A|||||||Both|1 Year|17 Years||||December 2015|December 1, 2015|September 18, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02556008||12625|
NCT02548689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00103009|PAI-1 Expression in Non-scarring Hair Loss|Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.||Northwestern University|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|55|Samples With DNA|Skin tissue will be formalin-fixed overnight at room temperature, processed and paraffin      embedded. Six micron thick sections will be prepared. Tissue blocks and slides will be      stored at room temperature. All samples will be de-identified.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|All hair loss subjects will be recruited from patients seen at Northwestern Memorial        Hospital or Northwestern Medical Faculty Foundation physicians offices. Age-matched        control subjects will be recruited by either 1) the use of flyers displayed in the        hospital and surrounding community, or 2) will be identified during a clinic visit at        Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician        offices.|March 2016|March 21, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02548689||13187|
NCT02558725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015057|Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women|Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women||Assuta Hospital Systems|No|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|42 Years|No|||December 2015|December 28, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558725||12416|
NCT02544152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMP-0211-201|Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome|A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U)||Sucampo Pharma Americas, LLC|No|Recruiting|February 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544152||13536|
NCT02544165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0925-0586|Non Invasive Measurement of the Haemodynamic Parameters and of the Advanced Glycation End Products (AGEs) Levels|Non Invasive Measurement of the Haemodynamic Parameters and of the Advanced Glycation End Products (AGEs) Levels in Students Smokers and in Students Who Intake Caffeine (NONINVASHAEMOAGES)|NONINVASHEMO|Technological Education Institute of Sterea Ellada|Yes|Completed|November 2012|June 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|178|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02544165||13535|
NCT02550080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDPIDV-DDS-001|Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome|A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome||Shandong Provincial Institute of Dermatology and Venereology|No|Recruiting|July 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|3130|||Both|18 Years|65 Years|No|||September 2015|September 13, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02550080||13080|
NCT02558920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASN-SUGARS 2015|Meta-analyses of the Relation of Fructose-Containing Sugars and Their Food Sources With Risk of Obesity|Relation of Fructose-Containing Sugars and Important Food Sources of These Sugars With Markers of Adiposity and Risk of Obesity: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials and Prospective Cohort Studies||University of Toronto|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|May 2015|October 30, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02558920||12401|
NCT02627352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-439|How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?|Prospective Evaluation of the New Micropulse Transscleral Cyclophotocoagulation|TSCPC|Wills Eye|Yes|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|85 Years|No|||December 2015|December 9, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627352||7146|
NCT02621632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2013-091|SocknLeg - a User Friendly Medical Compression Study of a Modified Application of a Medical Device|SocknLeg - a User Friendly Medical Compression Study of a Modified Application of a Medical Device|Socknleg|University of Zurich|Yes|Completed|March 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02621632||7586|
NCT02613039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDRO-AOUC-2015-2|Oral Contraceptive Therapy and Sexuality|Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health|COSEX|University of Florence|No|Recruiting|October 2015|September 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 20, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613039||8246|
NCT02612350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway Gennomics 004|Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease|Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease|H1000|Pathway Genomics|No|Recruiting|November 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood will be obtained, the plasma sample separated for the isolation of cell-free      DNA, and the sample that may be stored will be excess plasma as well as potentially DNA from      the buffy coat.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who are at increased risk for the development of cancer due to age over 50        years, a strong family history of cancer, known carrier of a pathogenic variant in a gene        indicating an increased risk of cancer, for example a hereditary cancer syndrome, or due        to exposure to environmental toxins, carcinogens, or mutagens, including tobacco. The        individuals have to have the legal authority to provide consent, and therefore be 18 years        of age or older.|November 2015|November 19, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02612350||8299|
NCT02614274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1213242|Nutramax Joint Health Formulation Biochemical Response Study|Pilot Assessment of the Biochemical Response of a Novel Nutraceutical Joint Health Formulation Using a Multiplexed Biomarker Approach||University of Missouri-Columbia|No|Completed|November 2014|January 2016|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|40 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614274||8151|
NCT02624232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140017|Long-term Outcome in Patients With Anorectal Malformations|Long-term Outcome in Patients Operated for Congenital Anorectal Malformations|LOPAM|Odense University Hospital|Yes|Not yet recruiting|January 2016|October 2020|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|10 Years|31 Years|No|Non-Probability Sample|Participants are born with anorectal malformations and subjected to surgery at the Odense        University Hospital during the period 1985 - 2004.|December 2015|December 4, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02624232||7386|
NCT02624245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|: PL004|The Movement Control Training Associated With Conventional Physical Therapy is More Effective Than Conventional Physical Therapy Alone in Pain and Functional Performance?||MCTACPTMECPTA|University of Nove de Julho|Yes|Completed|May 2013|October 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|35 Years|No|||December 2015|December 3, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02624245||7385|
NCT02624258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14BT055|Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma|Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Hodgkin Lymphoma||University of Pennsylvania|Yes|Recruiting|November 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|24 Years|No|||December 2015|December 7, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624258||7384|
NCT02558322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVHH-KVSH-2015/1|Regional Variation in the Primary Medical Care of Northern Germany|Regional Variation of Patient Population and Reasons for Consultation in the Primary Medical Care of Northern Germany|AVFN|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study is located in Northern Germany. We included all districts and cities        ("Landkreise" and "Kreisfreie Städte") which have at least 20% of their area within a        maximum linear distance of 100kms from our study centre in Hamburg. We assigned all        districts and cities to three region types: "urban area", "environs" and "rural area". In        each region type 80 GPs will be recruited and stratified by district. The prospected        sample size in each district unit corresponds to its population size in relation to the        total population in the respective region type. In each GP practice 15 patients will be        selected at random (using random number tables) and invited to participate in the study.        From our experience with similar studies we anticipate a response rate of 33%.|September 2015|September 21, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02558322||12447|
NCT02555332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#12-054|Maternal Thyroid Function in Early Pregnancy and Their Relationship With Gestational Diabetes Mellitus|Maternal TSH Level and TPOAb Status in Early Pregnancy and Their Relationship to the Risk of Gestational Diabetes Mellitus||Shanghai First Maternity and Infant Hospital|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7729|||Female|18 Years|40 Years|No|Probability Sample|All the pregnant women who were receiving antenatal care at Shanghai First Maternity and        Infant Hospital, Tongji University School of Medicine were invited to participate in the        study.Informed consents were obtained from all subjects.|September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555332||12676|
NCT02555540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioVacSafe - Boostrix|Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses|Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults||University Hospital, Ghent|No|Active, not recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|16||Actual|240|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02555540||12661|
NCT02560688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1040-A-E106|Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects|A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects||Daiichi Sankyo Inc.|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560688||12265|
NCT02560714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1099|SI Joint Fusion and Decortication Using the SImmetry System|SI Joint Fusion and Decortication Using the SImmetry System||Zyga Technology, Inc.|No|Recruiting|August 2015|November 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the Investigator's standard patient population diagnosed        with SIJ pain and representing candidates' for SIJ fusion.|September 2015|September 23, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560714||12263|
NCT02555124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107878|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Subjects||Janssen Pharmaceutical K.K.|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555124||12692|
NCT02555137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54450.058.15|Early Non-invasive Detection of CTEPH After Pulmonary Embolism|Early Non-invasive Detection of CTEPH After Pulmonary Embolism - The InShape-2 Study|InShape2|Leiden University Medical Center|No|Not yet recruiting|January 2016|December 2019|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|336|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients treated for objectivated symptomatic acute PE|September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02555137|2 Years|12691|
NCT02558400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG324-CS301|Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Aerie Pharmaceuticals||Recruiting|September 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|690|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558400||12441|
NCT02548338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34358414.9.0000.5505|Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer|Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer||Federal University of São Paulo|Yes|Completed|September 2014|April 2015|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|85 Years|No|||August 2015|September 11, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02548338||13214|
NCT02548351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-303|Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment|A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis|REGENERATE|Intercept Pharmaceuticals|Yes|Recruiting|September 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2000|||Both|18 Years|85 Years|No|||February 2016|February 25, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548351||13213|
NCT02550600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXO_1|Extracorporeal Lung Assist Device in Acute Lung Impairment|EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study|EXODUS|Technische Universität München|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02550600||13040|
NCT02550613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201401081MIND|Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma|Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma||National Taiwan University Hospital|No|Recruiting|May 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|90 Years|No|Non-Probability Sample|We will enroll 100 HCC patients who are admitted for curative or non-curative treatments,        including operation, radiofrequency ablation, TACE, target therapy, chemotherapy, or        radiotherapy.|September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550613||13039|
NCT02560727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TET-CN-121002|To Evaluate the Feasibility, Safety, and Efficacy of TET for FMT Via Colonic Approach|Feasibility, Safety, and Efficacy of Transendoscopic Enteral Tubing in Fecal Microbiota Transplantation|TET|The Second Hospital of Nanjing Medical University|Yes|Recruiting|October 2014|October 2016|Anticipated|September 2015|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|10 Years|70 Years|No|Probability Sample|A prospective study was conducted at the Digestive Medicine Center of the Second        Affiliated Hospital of Nanjing Medical University from October 2014 to June 2016. All        recruited cases met the including criteria: aged 10-70 yr, suitable for endoscopy, and        agreed to undergo FMT and TET|September 2015|September 24, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560727||12262|
NCT02546440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Number: 2014-000924-11|Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)|Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)|DMF-CTCL|Universitätsmedizin Mannheim|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02546440||13360|
NCT02559739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014/15|Sleep Deficiency and Stroke Outcome|Sleep Deficiency and Sleep Fragmentation and Their Impact on the Short- and Long-term Outcome of Ischemic Stroke and Transient Ischemic Attacks - a Two-center Prospective Observational Cohort Study||University Hospital Inselspital, Berne|No|Recruiting|July 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|520|||Both|18 Years|85 Years|No|Probability Sample|Patients suffering from ischemic stroke or transient ischemic attack (TIA) will be        recruited at the Stroke Unit and the ward of the Department of Neurology, Inselspital        Bern, and the Stroke Unit and ward of the Neurocenter of Southern Switzerland, Lugano, and        followed-up for (at least) 2 (maximum 4) years. They will be evaluated for pre-existing        and new-onset sleep disturbances that result in sleep deficiency (< 6h sleep /night and/or        post-stroke reduction of average sleep time/night ≥ 2h) or sleep fragmentation (insomnia,        sleep-disordered breathing, restless legs syndrome).|September 2015|September 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559739||12338|
NCT02556723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RetinaCLINIC|Intravitreal Injections of Ziv-aflibercept for Macular Diseases|Intravitreal Injections of Ziv-aflibercept for Macular Diseases: Diabetic Macular Edema, Wet AMD and Macular Edema Secondary to Vein Occlusons||Retina Clinic, Sao Paulo, Brazil|No|Active, not recruiting|September 2014|September 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556723||12570|
NCT02551133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208|Comparison of Dexamethasone Doses on Persistent Postmastectomy Pain|Comparison of the Two Different Doses of Dexamethasone on Persistent Mastectomy Pain||Mustafa Kemal University|No|Active, not recruiting|November 2014|||November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Female|18 Years|70 Years|No|||September 2015|September 15, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551133||12999|
NCT02560779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105HCC101|Trial of TRC105 and Sorafenib in Patients With HCC|An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)||Tracon Pharmaceuticals Inc.|No|Recruiting|January 2016|July 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02560779||12258|
NCT02549014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1064-001|A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)|A Single Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064||Merck Sharp & Dohme Corp.|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 11, 2015|No|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT02549014||13162|
NCT02549027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1064-003|A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)|A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)||Merck Sharp & Dohme Corp.|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|September 11, 2015|No|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT02549027||13161|
NCT02555982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0245|Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor|Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study|Btx-HT|University Hospital, Clermont-Ferrand||Not yet recruiting|September 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02555982||12627|
NCT02555228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-QIPSMJ|Small Volume Simethicone Before Gastroscopy: Any Benefit?|Benefits of Premedication With Small Volume Simethicone Solution Before Diagnostic Gastroscopy: A Randomized Endoscopist-blinded Prospective Study||Changi General Hospital|Yes|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|54|||Both|21 Years|N/A|No|||February 2016|February 15, 2016|September 13, 2015||No||No|February 15, 2016|https://clinicaltrials.gov/show/NCT02555228||12684|
NCT02546986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-486-NSCL-001|Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer||Celgene Corporation|Yes|Recruiting|October 2015|June 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546986||13318|
NCT02553551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seoul-06|Effect of Vitamin C on Postoperative Pain After Laparoscopic Cholecystectomy|Effect of Vitamin C on Postoperative Pain After Laparoscopic Cholecystectomy; a A Prospective Randomized Controlled Trial||Seoul St. Mary's Hospital|Yes|Recruiting|July 2015|September 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553551||12813|
NCT02553902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52032.029.15|Economic Evaluation of Treatment Modalities for Position Dependent Obstructive Sleep Apnea|||Onze Lieve Vrouwe Gasthuis|No|Recruiting|September 2015|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02553902||12786|
NCT02549651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00023|MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023)|A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma||MedImmune LLC|No|Not yet recruiting|April 2016|April 2021|Anticipated|April 2021|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549651||13113|
NCT02554734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3112003|Pharmacokinetic Study in Healthy Volunteers|Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females|NOCOFPK2|Orion Corporation, Orion Pharma|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02554734||12722|
NCT02547519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808040017|Pre-POINT-Early Study|Pilot Study Using Oral Insulin at Early Age for Immune Efficacy in Primary Prevention of Type 1 Diabetes||Technische Universität München|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|44|||Both|6 Months|2 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02547519||13277|
NCT02559466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08|Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Clinical Study Coupled With Positon Emission Tomography (PET)|Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Randomized Clinical Study Coupled With Positon Emission Tomography (PET)||Assistance Publique Hopitaux De Marseille|No|Recruiting|September 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559466||12359|
NCT02546115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL - 11335|RCT - Assessing the Benefits of the Use of a Tension Night Splint in Patients With Plantar Fasciitis|Assessing the Benefits of the Use of a Tension Night Splint in Patients With Plantar Fasciitis, a Single-blinded Randomised Controlled Trial||University Hospitals, Leicester||Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02546115||13385|
NCT02545465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17983|A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice|Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas|CAPTURE|Bayer|No|Recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|N/A|N/A|No|Probability Sample|Source population of the study are patients with Pulmonary arterial hypertension(PAH) and        Chronic thromboembolic pulmonary hypertension (CTEPH). Patients with this rare condition        are mostly diagnosed and managed at specialist centers. This includes initiation or any        change of Pulmonary Hypertension (PH) therapy. The participation of these specialized        centers in the study is going to ensure the representativeness of the study population. In        order to reduce selection bias physicians will be asked to include all eligible patients.|March 2016|March 16, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545465||13435|
NCT02545478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000116|Biomarkers in Infection|Early Detection of Inflammatory Biomarkers in Infection||Beth Israel Deaconess Medical Center|Yes|Recruiting|April 2006|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|Samples With DNA|whole blood, serum and plasma|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to the Emergency Department with suspected infection as well as a        non-infected control population.|September 2015|November 13, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545478||13434|
NCT02561091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-111-CL-13-01|AM-111 in the Treatment of Acute Inner Ear Hearing Loss|Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss|HEALOS|Auris Medical, Inc.|No|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561091||12234|
NCT02543073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-ILD-2015|MSC for Treatment of Interstitial Lung Disease After Allo-HSCT|Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|September 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02543073||13619|
NCT02543086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKAE609A2109|Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos|A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual &Sexual Blood-stage P. Falciparum Following Inoculation in Healthy Volunteers & Subsequent Infectivity to Mosquitoes||Novartis|No|Terminated|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02543086||13618|
NCT02552108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQuebecOutaouais|A Single-Component CBT for GAD|Behavioural Experiments for Intolerance of Uncertainty: A Single-Component Treatment for Generalized Anxiety Disorder||Universite du Quebec en Outaouais|No|Not yet recruiting|October 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 19, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552108||12924|
NCT02552121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN702|HuMax®-TF-ADC Safety Study in Patients With Solid Tumors|Dose-escalating Safety Trial of Tissue Factor Specific Antibody Drug Conjugate (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor||Genmab|Yes|Recruiting|October 2015|September 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552121||12923|
NCT02559492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39110-106|INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors|A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors||Incyte Corporation|No|Recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559492||12357|
NCT02547207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-13-004-EU-HF|MultiPoint Pacing Mapping Study|MultiPoint Pacing Mapping Study||St. Jude Medical|No|Recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients meeting specific eligibility criteria|December 2015|December 21, 2015|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02547207||13301|
NCT02558179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAGE-001|Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method|Prospective Multicenter Cross Sectional Study of the American International Biotechnology (AIBiotech) Gynecologene Test for the Evaluation of Bacterial Vaginosis/Vaginitis in Symptomatic Women|SAGE|American International Biotechnology|No|Recruiting|September 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Extracted DNA from vaginal swab(s) will be maintained after evaluation for a time period up      to 1 year.|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women at least 18 years of age will be eligible for this study when diagnosed with        bacterial vaginosis or vaginitis confirmed using the CDC (Centers for Disease Control)        diagnostic gold standard of Nugent score; Amsel criteria will also be recorded.|September 2015|October 28, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558179|6 Weeks|12458|
NCT02554955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17910|A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants|Pilot, Single-arm, Non-comparative, Open-label Study of Daclizumab in Combination With Mycophenolate Mofetil and Sirolimus in the Prevention of Acute Rejection in Cardiac Allografts Recipients in Risk of Deteriorated Renal Function||Hoffmann-La Roche||Completed|February 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554955||12705|
NCT02545101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-303-00034|An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH|A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH.|SAMPLE|Otsuka Pharmaceutical Europe Ltd|No|Enrolling by invitation|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Eligible patients are ≥ 18 years old and have been treated with at least 2 doses of        tolvaptan for one occurrence of hyponatraemia secondary to SIADH during 2014. If the        number of patients treated with tolvaptan in 2014 in the participating centres is not        sufficient to reach the intended sample size, this retrospective enrolment period could be        extended to include patients treated in 2013.        A mix of centres and treating departments (e.g. endocrinology, nephrology, etc.), will be        selected within each participating country in order to provide a sufficiently        representative sample of patients treated with tolvaptan for hyponatraemia secondary to        SIADH.|March 2016|March 18, 2016|September 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02545101||13463|
NCT02555826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-012|Study of the Efficacy and Safety Of Apremilast (CC-10004), in Subjects With Moderate Plaque Psoriasis|A PHASE 4, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004), IN SUBJECTS WITH MODERATE PLAQUE PSORIASIS||Sadick Research Group|No|Recruiting|March 2015|||November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555826||12639|
NCT02559583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR105066|Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America|Hemato-Oncology Latin America Observational Registry in CLL, Multiple Myeloma, Non-Hodgkin Lymphoma|HOLA|Janssen-Cilag Ltd.|No|Recruiting|July 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|8100|||Both|18 Years|N/A|No|Probability Sample|Participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and        non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America|March 2016|March 11, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559583||12350|
NCT02549976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4|Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis|Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis|DESTIN|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Not yet recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|101|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549976||13088|
NCT02549989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-079|Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer|Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549989||13087|
NCT02552576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-12-83|Study of Voncento® in Subjects With Von Willebrand Disease|An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects With Von Willebrand Disease||CSL Behring|No|Recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||March 2016|March 8, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552576||12888|
NCT02545166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI163115|Validation of a Purine Biosensor in Detecting Acute Cerebral Ischaemia: Carotid Endarterectomy Model in SMARTChip|Validation of a Purine Biosensor in Detecting Acute Cerebral Ischaemia: Carotid Endarterectomy Model in SMARTChip|CEMS|University Hospitals Coventry and Warwickshire NHS Trust|No|Not yet recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|40 male or female patients, aged 18 years or over, scheduled for carotid endarterectomy        and 80 age and sex-matched control patients scheduled for day surgery.|September 2015|September 10, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545166||13458|
NCT02552472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA-CC|A Study of Inhaler Use in the Community|Haphazard and Careless Use of Inhalers, an Observational Study||Beaumont Hospital|No|Completed|August 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be a random sample of patients with a known history of        respiratory illness and already prescribed a salmeterol/fluticosone Diskus inhaler.        Patients will be identified in both community pharmacy centres and general practice        clinics within Ireland.|January 2016|January 11, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552472||12896|
NCT02557399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201884|DUAC® Early Onset Efficacy Study in Japanese Subjects|Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects||GlaxoSmithKline|No|Active, not recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|351|||Both|12 Years|45 Years|No|||December 2015|January 4, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02557399||12518|
NCT02550236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFE child study Leipzig|LIFE Leipzig Research Centre for Civilization Diseases|Prospective Population-based Childhood Cohort Study in the Leipzig Area Investigating Genetic, Environmental, and Metabolic Factors and Their Association With the Development of Civilization Diseases|LIFE-Child|University of Leipzig|Yes|Recruiting|October 2010|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|12000|Samples With DNA|-  blood samples for mRNA and DNA analysis        -  serum samples        -  plasma samples        -  serum samples from oral glucose tolerance testing        -  urine samples        -  hair samples        -  mother's milk|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The LIFE Child study is a prospective longitudinal population-based cohort study. All        children with their families and pregnant women of the area of Leipzig are eligible to        participate in the LIFE Child study. This sample is supposed to represent the population        of the city.|September 2015|September 11, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02550236||13068|
NCT02545647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0624|Banded Versus Non-banded Roux-en-y Gastric Bypass|Banded Versus Non-banded Roux-en-y Gastric Bypass, a Randomised Controlled Trial|Bandolera|Rijnstate Hospital|No|Recruiting|September 2015|September 2019|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|60 Years|No|||September 2015|September 7, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02545647||13421|
NCT02552875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-101-0114|Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults|Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults|STSTS|University of Regensburg|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|1 Month|21 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|July 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02552875||12865|
NCT02552888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TulaneU|Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial|Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial|NICE|Tulane University|Yes|Recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|74 Years|No|||March 2016|March 21, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552888||12864|
NCT02557711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8D0951|The Findings' Corration Between Two Different Examination in Strokes With Elbow Flexor Spasticity|The Correlation Between Clinical Examination and Ultrasound Elastography Acoustic Radiation Force Impulse Findings in Hemiplegic Patients With Elbow Flexor Spasticity After Stroke||Chang Gung Memorial Hospital|No|Not yet recruiting|June 2016|September 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|refer from physiatrists in Kaohsiung Chang Gung Memorial Hospital|September 2015|September 22, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02557711||12494|
NCT02546765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000413|Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery|Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery in Adult Patients 60 Years of Age and Older|Delirium|Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|60 Years|N/A|No|||October 2015|October 27, 2015|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02546765||13335|
NCT02550821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 15/313|Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects|Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects||Hacettepe University|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02550821||13023|
NCT02549144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL-DIET|Effects of a Large Increase in Dietary Fats and Cholesterol on HDL Composition and Function in Healthy Subjects|Effects of a Large Increase in Dietary Fats and Cholesterol on HDL Composition and Function in Healthy Subjects||Azienda Ospedaliero, Universitaria Pisana|No|Not yet recruiting|December 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02549144||13152|
NCT02549157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS project ID: 130775|Treatments for Urogynaecological Problems and Patient Selfreports|Relationship Between Treatments for Urogynecological Problems and Patient Reported Values, Psychological States, and Quality of Life||Swansea University|No|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Consecutive patients referred for treatments (physiotherapy, surgery) for        uro-gynaecological problems (pelvic floor dysfunction, cancer) will be asked if they would        like to participate in this evaluative study. The initial approach will be made through a        letter sent out with their appointment details, which will give information about the        study. This will make clear that their treatment will not depend on their participation in        the study. The patients also will be given the chance to discuss their participation with        the specialist nurse at the time of their pre-treatment assessment, and will give their        consent (by completing and signing a Consent Form) on the day of their taking part in the        research study, after they have had time to think about their participation and ask any        questions that they may have.|September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549157||13151|
NCT02559505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00058437|Influenza Immunity in Children|Understanding How the Initial Encounter With Influenza Virus Poises Children for Protective Immunity||University of Rochester|No|Recruiting|October 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|105|||Both|3 Months|35 Months|Accepts Healthy Volunteers|||December 2015|December 18, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559505||12356|
NCT02559284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0013|RESPIMER® Netiflow® vs. Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy (Nasal Polyposis)|A Comparative, Multicenter and Randomized Study Evaluating the Safety and Efficacy of RESPIMER® Netiflow® Versus Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy in the Treatment of Nasal Polyposis.|NETIFLOW|Laboratoire de la Mer|No|Recruiting|April 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|65 Years|No|||September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559284||12373|
NCT02554617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555/2552(EC2)|Measurements of Exhaled Nitric Oxide in Healthy Subjects in Thailand|Measurements of Exhaled Nitric Oxide in Healthy Subjects in Thailand|FeNO_nor|Mahidol University|No|Completed|October 2010|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|September 2015|September 17, 2015|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT02554617||12731|
NCT02554760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA15-004|Flank Study With Crown Cooling Insert|CoolSculpting the Flank Using an Applicator With a Crown Cooling Insert|CCI|Zeltiq Aesthetics|No|Active, not recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||September 2015|January 11, 2016|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554760||12720|
NCT02557048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped Head Neck Malig|Head and Neck Cancer in Children: A Retrospective Study|Malignant Head and Neck Tumors in Children: A Retrospective Study||Assiut University|No|Not yet recruiting|May 2016|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|N/A|18 Years|No|Non-Probability Sample|A hospital-based study, involving Pediatric cancer patients, those diagnosed with        malignant tumors of the head & neck, in the period from 2001 January till 2015 December,        and received treatment at the pediatric oncology department, their medical reports will be        retrospectively reviewed for data collection.|March 2016|March 8, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557048||12545|
NCT02548715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043413|Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery|Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial|LSHT|University of Alberta|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||September 2015|September 11, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548715||13185|
NCT02547571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V2015-001|The Bowel CLEAnsing: A National Initiative|The Bowel CLEAnsing: A National Initiative|B-CLEAN|McGill University Health Center|No|Not yet recruiting|October 2015|January 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|12||Anticipated|3500|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547571||13273|
NCT02547584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_AWARE|Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation|Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation|AWARE|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|152|||Female|18 Years|80 Years|No|Probability Sample|Women with diagnosis of paroxysmal or persistent AF|September 2015|September 9, 2015|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547584||13272|
NCT02554981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-RES-015-001|Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®||EMPOWER|Allergan|No|Active, not recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|55 Years|No|||January 2016|January 27, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554981||12703|
NCT02559310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB-BC-3781-3101|Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia|LEAP|Nabriva Therapeutics AG|Yes|Recruiting|September 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|738|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559310||12371|
NCT02547467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49RC14_0223|TOADS Study: TO Assess Death From Septic Shock.|Epidemiological Survey of Death Modalities in Patients With Septic Shock Referred to French Intensive Care Units: TOADS Study.|TOADS|University Hospital, Angers|Yes|Not yet recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients who had died of septic shock|September 2015|September 9, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02547467||13281|
NCT02547480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T126E2|LifePearl-Iri Pharmacokinetic Study|Pharmacokinetic Study In Patients With Liver Predominant Unresectable mCRC Receiving Treatment With LifePearl Microspheres Loaded With Irinotecan||Terumo Europe N.V.|Yes|Not yet recruiting|September 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02547480||13280|
NCT02546739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doing-002|Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies||Beijing Doing Biomedical Co., Ltd.|No|Not yet recruiting|January 2016|October 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|70 Years|No|||September 2015|January 12, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546739||13337|
NCT02544074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0039|Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)|Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)|eSAGE|Ohio State University|No|Recruiting|January 2015|||December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||13|Anticipated|72|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited from a wide variety of community events including senior        centers, health fairs, educational talks to lay public, independent and assisted living        facilities, and free memory screens as well as from ambulatory Geriatric or Memory        Disorders Clinics. The SAGE cognitive screening tool will be given to all subjects willing        to take the test.Participants who complete the SAGE test and meet inclusion and exclusion        criteria will be divided into groups based on their initial SAGE scores. Each group will        be composed of subjects with the same score. Individuals will be randomly selected from        each group and asked to further participate in a one-time clinical evaluation.|September 2015|September 4, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02544074||13542|
NCT02545153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|glue 55 galla|Fibrin Sealant for Cholangiotomy Closure Study|Randomised Controlled Trial of Fibrin Sealant to Prevent Bile Leakage After Cholangiotomy||Lasarettet i Enköping|No|Recruiting|January 2009|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||September 2015|September 8, 2015|October 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02545153||13459|
NCT02552953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC065-01|A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers|A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers||Cyclacel Pharmaceuticals, Inc.|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552953||12859|
NCT02547545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AF2012LSK-021|Breast Cancer Chemotherapy Risk Prediction Mathematical Model|Macro-microscopic Syndrome Differentiation and Combination，Based on the "Chinese Medicine Clinical Phenotype" to Construct Breast Cancer Chemotherapy Risk Prediction Mathematical Model|BCCRPMM|First Affiliated Hospital Xi'an Jiaotong University||Not yet recruiting|September 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|795|||Female|18 Years|80 Years|No|Non-Probability Sample|breast cancer patients|September 2015|September 9, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02547545||13275|
NCT02528864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-7316A3|MRI and Metabolomics Biomarkers for Uterine Malignancy|Multiparametric Magnetic Resonance Imaging and Metabolomics Approaches to Study Biomarkers for Uterine Malignancy|EMCAMRS|Chang Gung Memorial Hospital|No|Not yet recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|1. Plasma sample preparation for global metabolites analysis and lipidomic analysis:        2. Urine samples will be diluted with distilled water. Samples are centrifuged at 14,000 g           for 5 min, and the supernatants will be collected for LC-MS analysis.        3. Cellular metabolites extraction: Extraction method will be carried out by the method           modified by Munger and Patterson. The medium will be aspirated from culture plates           containing cells and 80% methanol (at -80°C) will immediately be added.|Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients in a tertiary referral center.|August 2015|August 18, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02528864||14707|
NCT02554344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-074|Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)|Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)||Baylor Research Institute|Yes|Recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Female|21 Years|N/A|No|||March 2016|March 16, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554344||12752|
NCT02613988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsanMCHSKim_01|Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas|Early Response Assessment Using on 3T Advanced MR Imaging as Predictor of Long-term Treatment Response in Newly Diagnosed Glioblastomas||Asan Medical Center||Recruiting|December 2015|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02613988||8173|
NCT02627326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|perio1|Chlorhexidine Intracanal Medicament in Periodontal Healing in Concomitant Endo Perio Lesion With Communication|Evaluation of Effectiveness of Chlorhexidine Intracanal Medicament on Periodontal Healing in Concomitant Endodontic and Periodontal Disease With Communication : A Randomized Controlled Clinical Trial||Postgraduate Institute of Dental Sciences Rohtak|Yes|Completed|May 2014|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02627326||7148|
NCT02617108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FuXingH2|Foley Balloon Therapy for Preventing Post-operative Adhesion Following Transection of Uterine Septum|A Prospective and Randomized Trial on the Effect of Foley Balloon Therapy for Preventing Post-operative Adhesion Following Transection of Uterine Septum||Fu Xing Hospital, Capital Medical University|Yes|Not yet recruiting|January 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|210|||Female|25 Years|40 Years|No|||November 2015|November 28, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617108||7933|
NCT02617186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFCRS-RP-003-1508-31|Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer|Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: A Randomized Controlled Trial||St. Joseph's Healthcare Hamilton|No|Recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02617186||7927|
NCT02617758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108059|Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants|An Open-Label, Randomized, Single Application, Two-Period Crossover, Pivotal Bioequivalence Study to Evaluate the Bioequivalence of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects||Janssen Research & Development, LLC|No|Recruiting|November 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02617758||7883|
NCT02558335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09313|CTCs for High Grade Glioma|Circulating Tumor Markers for High Grade Glioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|22 cc of blood|Both|18 Years|N/A|No|Probability Sample|1. Patients with grade III and IV glioma|September 2015|September 22, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02558335||12446|
NCT02558621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQrate01/2015|New Robotic Assistance System for Spinal Fusion Surgery|Clinical Trial on Performance and Acceptance of a New Robotic Assistance System During Spinal Fusion Surgery|AQrate|KB Medical SA|No|Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|85 Years|No|||February 2016|February 23, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02558621||12424|
NCT02547168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_Lung_AF|Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection|Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection|Lung-AF|McMaster University|No|Recruiting|March 2016|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547168||13304|
NCT02560701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS-1408-20393|High Deductible Health Plans and Bipolar Disorder|Impact of High Deductible Health Plans on Patients With Bipolar Disorder||Harvard Pilgrim Health Care|Yes|Active, not recruiting|September 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|109000|||Both|12 Years|63 Years|Accepts Healthy Volunteers|Non-Probability Sample|Investigators will include health plan members aged 12 to 63 years at the beginning of the        baseline period. Consistent with prior research,89-91 we will use medical claims data and        a validated algorithm to identify members who had at least two ambulatory encounters or        one hospital encounter with a diagnosis of bipolar disorder. Intervention cohorts will        include traditional plan members with bipolar illness who experience an employer-mandated        switch to HSA-eligible HDHPs with full drug cost-sharing or to HSA-ineligible HDHPs that        subject medications only to copayments as in traditional health plans.|September 2015|October 15, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560701||12264|
NCT02548559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000959|Sublingual Cannabidiol for Anxiety|Sublingual Cannabidiol for Anxiety||Mclean Hospital|No|Not yet recruiting|September 2015|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548559||13197|
NCT02553083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0380-15-RMC|High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection|High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection|HDDT|Rabin Medical Center|No|Not yet recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|July 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553083||12849|
NCT02553096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49741 .091.14|Exacerbation Self-management in COPD: The ACCESS Study|Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): A Randomized Controlled Trial|ACCESS|Radboud University|Yes|Recruiting|June 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|86|||Both|40 Years|N/A|No|||September 2015|September 16, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02553096||12848|
NCT02554864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0046-B|Location of Injection of Local Anesthetics in the Adductor Canal Block|Location of Injection of Local Anesthetics in the Adductor Canal Block: A Randomized Controlled Trial of the Effect on Postoperative Analgesia and Motor Power|LILAC|Women's College Hospital|No|Not yet recruiting|January 2016|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|50 Years|No|||December 2015|December 11, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02554864||12712|
NCT02546453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2014-01|Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids|Use of Specific Genetic Alteration s of Tumoral Cells Identified by NGS to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor -|NGSKids|Institut Curie|No|Recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|18 Years|No|||September 2015|September 8, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02546453||13359|
NCT02559752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509033|Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy|Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy||Washington University School of Medicine|No|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|4 Years|21 Years|No|||October 2015|October 22, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02559752||12337|
NCT02548598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14945|Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma|Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma|AIMS|University of California, San Francisco|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|160|Samples Without DNA|Mucus collected from the airway, induced sputum, brushings from the airway epithelium, mucus      collected from the nasal passages, and blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients of the UCSF Sinus Center practice of Drs. Andrew Goldberg and Steven Pletcher.|September 2015|September 10, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02548598||13194|
NCT02555033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFPS1415|Effects of Simultaneous Balance and Resistance Training in Older Adults|Effects of Simultaneous Balance and Resistance Training on Strength, Power and Balance in Older Adults: A Stratified and Randomised Trial||University of Kassel|No|Completed|February 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02555033||12699|
NCT02546713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-AA-14-075|Abutment Macro Design and Peri-implant Tissues|The Influence of Abutment Macro-design on Peri-implant Tissue Dimensions for Guided Placed and Restored Implants||Nova Southeastern University|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|28|||Both|21 Years|N/A|No|||September 2015|January 14, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546713||13339|
NCT02553291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaseWestern|A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults|||Case Western Reserve University|Yes|Recruiting|November 2014|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|March 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02553291||12833|
NCT02545660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4984|The Use of Quantitative Light Induced Fluorescence Digital as an Oral Hygiene Evaluation Tool in Orthodontics|The Use of QLF-D (Quantitative Light-induced Fluorescence-DigitalTM) as an Oral Hygiene Evaluation Tool to Assess Plaque Accumulation and Enamel Demineralisation in Orthodontics||Royal Liverpool and Broadgreen University Hospitals NHS Trust|Yes|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|11 Years|N/A|Accepts Healthy Volunteers|||September 2015|November 19, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545660||13420|
NCT02560805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082400|Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV|Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II|ANG-P|Emory University|No|Active, not recruiting|October 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|134|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560805||12256|
NCT02550704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/079/HP|Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients|Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in Patients Suffering From Irritable Bowel Syndrome With Diarrhoea|SIIMPA|University Hospital, Rouen|No|Not yet recruiting|October 2015|December 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|68|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550704||13032|
NCT02559544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 20114|[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer|[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02559544||12353|
NCT02556528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID: 11437|Feasibility of Health Coaching in Cancer Patients|A Study to Assess the Feasibility of Using Health Coaching Sessions in Cancer Patients||Oxford University Hospitals NHS Trust|No|Not yet recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02556528||12585|
NCT02556541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-94-15|Ultrasound-guided Peripheral Vascular Access in Children|Ultrasound-guided Peripheral Vascular Access in Children - a Single- Blind, Randomized, Cross-over Trial||University of Aarhus||Recruiting|September 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Supportive Care|||Anticipated|50|||Both|N/A|3 Years||||April 2015|March 4, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02556541||12584|
NCT02554903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-205|Macitentan in Pulmonary hypertenSiOn Post-left ventRiculAr Assist Device implaNtatiOn|A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation|Soprano|Actelion|Yes|Not yet recruiting|December 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02554903||12709|
NCT02559973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-13-0006|Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder|A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine (RBP-6000) Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) in Comparison to Intermediate Molecular Weight (Reference Treatment) in Treatment-Seeking Subjects With Opioid Use Disorder||Indivior Inc.|No|Recruiting|September 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|September 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559973||12320|
NCT02551718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9226|High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia|Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data||University of Washington|Yes|Recruiting|September 2015|||July 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|3 Years|N/A|No|||March 2016|March 3, 2016|August 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02551718||12954|
NCT02529657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12288113.1.0000.5511|Low Level Laser Therapy to Reduce Comorbidity in Spinal Surgery|Analysis of Effect of Low Level Laser Therapy in Spinal Surgery|LASPINE|University of Nove de Julho|Yes|Active, not recruiting|February 2013|August 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|10 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 22, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02529657||14646|
NCT02549885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECCR2015|Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief|Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief in Women With Migraine|PNF|Universidade Federal de Pernambuco|No|Not yet recruiting|September 2015|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|30|||Female|20 Years|40 Years|No|||September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549885||13095|
NCT02548975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456789|Risk Factors for Delirium Following Cardiac Surgery|Risk Factors for Delirium Following Cardiac Surgery||Vanderbilt University|No|Enrolling by invitation|November 2009|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|8000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cardiac surgery patients over 18 years old at Vanderbilt University Medical Center|November 2015|November 13, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548975||13165|
NCT02548988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056711/2015|Selective Neuromuscular Electrical Stimulation on VMO|Immediate Effect of Selective Neuromuscular Electrical Stimulation of Vastus Medialis Obliquus in Women With Patellofemoral Pain Syndrome||Universidade Federal do Rio Grande do Norte|No|Enrolling by invitation|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|28 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548988||13164|
NCT02544594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MucM001-15|Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction|Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction|ECLS-SHOCK|Klinikum der Universitaet Muenchen|No|Recruiting|November 2015|September 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|75 Years|No|||November 2015|November 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02544594||13502|
NCT02544607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001912|Ketamine for Depression: An MRI Study|Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression||Massachusetts General Hospital|Yes|Not yet recruiting|March 2016|||January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02544607||13501|
NCT02555592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56 study|Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level|Treatment Strategy of Surgical Resection With Sequential Adjuvant Chemotherapy and Radiotherapy for Patients With Stage IIIA Non-small Cell Lung Cancer and N2 Disease Only in the Subaortic or Paraaortic Level, or Both||Pusan National University Hospital|No|Recruiting|October 2015|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stage IIIA non-small cell lung cancer and N2 disease only in the subaortic        or paraaortic level, or both|October 2015|October 5, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555592||12657|
NCT02547220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP616-302|A Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant|A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients||Shire|Yes|Recruiting|October 2015|February 2022|Anticipated|February 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547220||13300|
NCT02551952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interventional Study Design|Digital Game: A Scale to Evaluate the Perioperative Cognitive Function|Digital Game MentalPlus®: A Scale to Evaluate on Perioperative Cognitive Function: Content Analysis, Internal Consistency, Convergent Validity and Clinical Validation of the Diagnostic Test|MentalPlus®|University of Sao Paulo|Yes|Not yet recruiting|November 2015|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02551952||12936|
NCT02545803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDR4_ZOL1|The Effect of High Frequency Percussive Ventilation on Cerebral Tissue Oxygenation|The Effect of High Frequency Percussive Ventilation on Cerebral Tissue Oxygenation||Hasselt University|No|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02545803||13409|
NCT02549807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408031|Measurement by 2D Ultrasound of the Pennation Angle and Elasticity of Gastrocnemius Muscle|Evaluation of the Reproducibility of the Measurement by 2D Ultrasound and Sonoelastometry of the Pennation Angle and Elasticity of the Medial Gastrocnemius Muscle in Children/Adolescent/Adult Cerebral Hemiplegia After Stroke||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|July 2014|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|5 Years|75 Years|No|Non-Probability Sample|Hemiplegic adults/children/adolescent after stroke ,|September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549807||13101|
NCT02560636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4255|Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer|Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer|PLUMMB|Royal Marsden NHS Foundation Trust|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|January 6, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560636||12269|
NCT02547740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO8502|Macular Damage in Glaucoma|Structural and Functional Progression of Glaucomatous Damage to the Macula||Columbia University|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|375|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients seen in Columbia eye clinics and enrolled in cross-sectional database; Columbia        University Medical Center Eye Institute and New York Eye & Ear Infirmary of Mount Sinai        staff and relatives.|January 2016|January 21, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02547740||13260|
NCT02556359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTC13005|Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes|Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes|IMMUNEREP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2015|September 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples will be obtained as a source of DNA and viable lymphocytes for functional      studies. Blood will be sent to the laboratory of Dr JP de Villartay, INSERM UMR1163, Genome      Dynamics in the Immune System, Université Paris Descartes - Sorbonne Paris Cité, Institut      Imagine, 24 boulevard du Montparnasse, 75015 PARIS. Functional studies will be performed      immediately.      A portion of the blood sample taken as part of the research will be included in a biological      collection: B-EBV cell lines will be derived from patients and their parents. EBV-B cell      lines will be established by Centre de Ressource Biologique (CRB, Hôpital Necker - Enfants      Malades, Bâtiment IMAGINE 1er étage, 149, rue de Sèvres - 75 743 PARIS CEDEX 15, under the      supervision of Dr Marie-Alexandra Alyanakian & Anne Esling & Christine Gouarin). Skin      biopsies will be obtained from patients to derive fibroblast lines at CRB.|Both|N/A|N/A|No|Non-Probability Sample|Any patient presenting clinical immune deficiency and at least one associated feature        hinting at a possible DNA repair defect, such as microcephaly, growth retardation starting        in utero, distinctive facial appearance ("bird-like face"), developmental delay,        cerebellar degeneration, UV light sensitivity, premature aging, dystrophic nails, dental        abnormalities, hair anomalies, pancytopenia and/or bone marrow failure|September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556359||12598|
NCT02555319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPV-001|A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV)|A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Implantation of Transcatheter Pulmonary Valve (TPV) for the Treatment of Congenital Heart Disease With Pulmonary Valve Disease||Seoul National University Hospital|Yes|Recruiting|September 2015|July 2021|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||September 2015|February 25, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02555319||12677|
NCT02548650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS 53377|Vorapaxar as an Add-On Antiplatelet Therapy in Post Myocardial Infarction Patients With and Without Diabetes Mellitus|Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Post Myocardial Infarction Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study|OPTIMUS-5|University of Florida|No|Recruiting|March 2016|October 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548650||13190|
NCT02557412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINML01|Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea|Long-term Effect of Nasal Continuous Positive Airway Pressure on Lipid Profile in Patients With Dyslipidaemia and Mild-moderate Obstructive Sleep Apnea||Hospital Universitario La Paz|No|Recruiting|May 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|114|||Both|35 Years|75 Years|No|||September 2015|September 21, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02557412||12517|
NCT02557945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7165R|Gabapentin in Patients at Clinical Risk for Psychosis|Gabapentin in Patients at Clinical Risk for Psychosis||New York State Psychiatric Institute|No|Recruiting|August 2015|May 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|48|||Both|18 Years|30 Years|No|||August 2015|September 24, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557945||12476|
NCT02550535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-00272-CT2014002|Study of Gene Modified WT1 (Wilms' Tumor 1)TCR Therapy in MDS and AML Patients|A Single Arm Phase I/II Study of the Safety and Efficacy of Gene Modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukaemia With Low Blast Counts Failing to Achieve an International Working Group (IWG) Defined Response Following Azacitidine Therapy||Cell Therapy Catapult|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02550535||13045|
NCT02556814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Caffeic acid + HD-DXM|Caffeic Acid Combining High-dose Dexamethasone in Management of ITP|A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556814||12563|
NCT02548234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH104-REC3-052|Effect of Mirror Therapy Versus Bilateral Arm Training for Rehabilitation After Chronic Stroke|Effect of Mirror Therapy Versus Bilateral Arm Training for Rehabilitation After Chronic Stroke: a Pilot Randomized-controlled Trial||China Medical University Hospital|Yes|Enrolling by invitation|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||September 2015|September 16, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548234||13222|
NCT02554500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-266-5|Bone Microcirculation After Remote Ischemic Preconditioning|Effects of Remote Ischemic Preconditioning in Bone Microcirculation||University of Schleswig-Holstein|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554500||12740|
NCT02553148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Estimating the Global Need for Palliative Care for Children|Estimating the Global Need for Palliative Care for Children: A Cross Sectional Analysis||International Children's Palliative Care Network|No|Completed|June 2014|October 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Retrospective||23|Actual|18837613|||Both|N/A|19 Years|Accepts Healthy Volunteers|Probability Sample|All children in sample countries with the following diagnoses included: all cancers        (except non-malignant skin); HIV/AIDS; cardiovascular diseases; cirrhosis of liver;        congenital anomalies; endocrine, blood, & immune disorders; meningitis; kidney diseases;        protein energy malnutrition; neurological conditions; neonatal conditions; drug-resistant        tuberculosis. Cases with sequela not associated with need for palliative care were        removed.|February 2016|February 22, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02553148||12844|
NCT02553161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelBello/Singh AIM|Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth|Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth||University of Cincinnati|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02553161||12843|
NCT02557776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2009/659|Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer|BRCAsearch: A Population Based Prospective Study on Screening for BRCA1 and BRCA2 Germline Mutations in Patients With Newly Diagnosed Breast Cancer Treated in Southern Sweden.|BRCAsearch|Lund University|No|Recruiting|February 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02557776||12489|
NCT02547038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS15-CT2-10|Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy|Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication||Kaohsiung Veterans General Hospital.|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|20 Years|90 Years|No|||September 2015|September 9, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02547038||13314|
NCT02547051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2001AA|Dietary Factors and Stuttering: A Look Into Food Allergies and Other Environmental Triggers Associated With Variations in Severity of Persistent Developmental Stuttering|Dietary Factors and Stuttering: A Look Into Causes and Variations in Severity of Persistent Developmental Stuttering||The R2 Institute|No|Not yet recruiting|September 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02547051||13313|
NCT02556970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU/2014/4744|A Study Investigating Pain Following Single-port or Multi-port Video Assisted Thoracoscopic Surgery|A Randomised Multi-centre Feasibility Study Investigating Post-operative Pain Following Single-port or Multi-port Video Assisted Thoracoscopic Surgical (VATS) Procedures|SiMuPort|University Hospitals Bristol NHS Foundation Trust|No|Not yet recruiting|November 2015|November 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02556970||12551|
NCT02556983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-02-2015-030|CT Dose Simulation Study for Appendicitis|Optimizing the Radiation Dose for CT Imaging With Iterative Reconstruction in Diagnosing Acute Appendicitis: Dose Simulation Study||Seoul National University Bundang Hospital|No|Recruiting|August 2015|September 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|15 Years|44 Years|No|Non-Probability Sample|Emergency department visit with suspected symptoms and signs of acute appendicitis.|September 2015|September 21, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556983||12550|
NCT02545920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0310|To Assess Ear Blood Flow During Dialysis|Pilot Study to Assess the Effects of Haemodialysis Treatments on Blood Flow to the Ear||University College, London|No|Not yet recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with chronic kidney failure attending for regular dialysis treatment|September 2015|September 7, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545920||13400|
NCT02549872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15_138|Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries|Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries: a Cohort Study in Linked Electronic Health Records||University College, London|Yes|Active, not recruiting|September 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|51000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients registered in English general practices contributing with data to the CALIBER        research platform from 1997 onward.|September 2015|September 11, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02549872||13096|
NCT02552732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA138|Nasal High Flow Therapy 30 Day Readmission Study|Nasal High Flow (NHF) Therapy Use Following Hospitalization for an Exacerbation of COPD: A Feasibility Study|N3ADS|Fisher and Paykel Healthcare|Yes|Recruiting|November 2015|||March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552732||12876|
NCT02560610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/019/15|Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma|The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial||Atopix Therapeutics, Ltd.|Yes|Not yet recruiting|October 2015|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|September 24, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02560610||12271|
NCT02552290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303-4412|Immediate Effects Cervicothoracic Manipulation Versus Passive Upper Trapezius Stretch|Effects of Cervicothoracic Manipulation and Passive Stretching to the Upper Trapezius Muscle on Pressure Pain Thresholds and Cervical Range of Motion on Healthy Individuals||University of Nevada, Las Vegas|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02552290||12910|
NCT02552303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817800|The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia|The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia||University of Pennsylvania|No|Active, not recruiting|August 2013|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|72|||Both|21 Years|65 Years|No|||March 2015|September 15, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552303||12909|
NCT02559323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04910|LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey|LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|May 2010|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Subject with cancer diagnosis|September 2015|September 23, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02559323||12370|
NCT02547870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107976|A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long‐Acting Nanosuspension of Rilpivirine on Pharmacokinetics|A Phase 1 Open‐Label, Randomized, Parallel‐Group Study in Healthy Subjects to Investigate the Effect of Different Storage Conditions of a Long‐Acting Nanosuspension of Rilpivirine on the Single‐Dose Plasma Pharmacokinetics of Rilpivirine After Intramuscular Injection||Janssen Infectious Diseases BVBA|No|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02547870||13250|
NCT02551913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS398|A Theory-based Sleep Intervention in Improving Sleep Quality in Adolescents|Effectiveness of Theory-based Sleep Hygiene Intervention in Improving Sleep Quality in Adolescents: a Cluster Randomized Controlled Trial||Qazvin University Of Medical Sciences|Yes|Recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2715|||Both|N/A|18 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551913||12939|
NCT02551926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS25|Health Education Using Text Messaging Prevents Hypertension in High Risk People|Health Education Using Text Messaging Prevents Hypertension in High Risk People: a Comparison Between Effectiveness of Electronic Text Messaging and Printed Material||Qazvin University Of Medical Sciences||Recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02551926||12938|
NCT02550730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33788|Best Beginnings for Babies Birth Sister Program Evaluation|Birth Sisters Best Beginnings Evaluation|BBB|Boston Medical Center|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|594|||Female|18 Years|64 Years|No|||September 2015|September 14, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02550730||13030|
NCT02550743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 302|BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study|BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study||Brown University|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550743||13029|
NCT02528344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064057|High Intensity Interval Training and Rheumatoid Arthritis|The Effects of High-Intensity Interval Training on Inflammation in Adults With Rheumatoid Arthritis||Duke University|No|Not yet recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|60 Years|80 Years|No|||August 2015|August 17, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528344||14747|
NCT02549846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000021032|AdminiStration of Statin On Acute Ischemic stRoke patienT Trial|Randomized Controlled Trial of Early Versus Late Statin Therapy in Patients With Ischemic Stroke|ASSORT|Hyogo College of Medicine|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||September 2015|September 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549846||13098|
NCT02557386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001|Optimal Volume of Bupivacaine in Adductor Canal Nerve Block|Optimal Volume of Bupivacaine in Adductor Canal Nerve Block in Patients Undergoing Unilateral Cruciate Ligament Reconstruction Surgery||Pontificia Universidad Catolica de Chile|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557386||12519|
NCT02552264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHA REB ROMEO File #: 1019748|Testing a Training Program to Enhance Emotional Management Skills and Professional Resiliency in Healthcare Providers|Implementing and Evaluating an Empirically Supported Training Program to Enhance Emotional Management Skills and Professional Resiliency in Healthcare Providers||Nova Scotia Health Authority|No|Not yet recruiting|November 2015|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|240|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552264||12912|
NCT02533791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT020-2|A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization|Safety and Immunogenicity of a Booster Dose of the Recombinant Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults After Primary Immunization||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|July 2015|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|110|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 11, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02533791||14330|
NCT02557334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE STRAW II|Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk|Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk||Penn State University|No|Recruiting|October 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|50|||Both|35 Years|60 Years|No|||December 2015|December 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02557334||12523|
NCT02557438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000360|Effects of Weight Loss Surgery on Bone Health in Adolescents|Bone Metabolism in Adolescents Undergoing Bariatric Surgery||Massachusetts General Hospital|Yes|Recruiting|June 2015|December 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|240|Samples With DNA|Blood samples, fecal samples|Both|14 Years|21 Years|No|Non-Probability Sample|Obese adolescents and young adults 14-21 years old undergoing RYGB or VSG and non-surgical        controls.|September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557438||12515|
NCT02557490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014YJZ16|Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases|A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases||Beijing Cancer Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557490||12511|
NCT02557503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014KT71|Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE|An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE||Beijing Cancer Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|80 Years|No|||July 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557503||12510|
NCT02611973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140933|Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia|French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study|FAST|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|November 2015|November 2022|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2250|||Both|18 Years|N/A|No|||September 2015|November 19, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02611973||8328|
NCT02620683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1741|Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine|Comparison of Buffered vs. Non-Buffered Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes|BUFFL|University of North Carolina, Chapel Hill|No|Recruiting|December 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620683||7659|
NCT02611804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM 2015-01|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp||Teva Pharmaceuticals USA|No|Recruiting|October 2015|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|475|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611804||8341|
NCT02620930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot. n. 2013/00 21553|Diagnosis And Treatment of Sleep Apnea in Patient With Heart Failure|Diagnosis And Treatment of Sleep Apnea in Patient With Heart Failure DASAP-HF Study|DASAP-HF|University of Florence||Recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|N/A|No|Probability Sample|Patients implanted with an ICD or CRT-D endowed with the APNEA Scan algorithm that meet        all inclusion/exclusion criteria.will be enrolled after signing of an informed consent        form and an authorization to use and disclose health information.|November 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620930||7640|
NCT02621723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMedicalcenter|Capturing Readmission Internationally to Prevent Readmission by Safer@Home Group|Capturing Readmission Internationally to Prevent Readmission by Safer@Home|CURIOS@|VU University Medical Center|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|All patients readmitted for at least one night for a medical specialism after any type of        admission at any ward in the previous 30 days, with an overnight stay. This could be from        any ward, for any procedure (elective/non-elective)|December 2015|December 1, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02621723|6 Months|7579|
NCT02612727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108M03601_Phase 2|Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates|Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates|FSPT|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|N/A|14 Days|Accepts Healthy Volunteers|||November 2015|November 23, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612727||8270|
NCT02612987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/326|iCBT for Adolescents With Co-morbid Insomnia|Internet-delivered Cognitive Behaviour Therapy for Adolescents With Co-morbid Insomnia Attending Children and Youth Psychiatry: An Open Trial||Uppsala University Hospital|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|13 Years|18 Years|No|||November 2015|November 19, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02612987||8250|
NCT02559726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/06|Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing Response|Identification and Quantification of a Mechanical Hyper-synchronicity State in Hypertrophic Cardiomyopathy (HCM) With Left Outflow-tract Obstruction and Description of Its Electrical and Electro-mechanical Characteristics Thanks to an Innovative Multi-imaging Approach to Predict a Positive Response to Dual Chamber Pacing. The Hsync Study.|HSYNC|University Hospital, Bordeaux|No|Recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02559726||12339|
NCT02548611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE MucT001-14|Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention|Intensified Loading With Prasugrel Versus Standard Loading With Clopidogrel in Invasive-treated Patients With Biomarker-Negative Angina Pectoris|SASSICAIA|Klinikum der Universitaet Muenchen|Yes|Recruiting|September 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2240|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548611||13193|
NCT02550886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-395|Anticipated Versus Actual Patient and Caregiver Burden Following Ambulatory Orthopedic Surgery|Anticipated Versus Actual Patient and Caregiver Burden Following Ambulatory Orthopedic Surgery|Work Burden|Hospital for Special Surgery, New York|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing outpatient arthroscopic knee debridement or meniscectomy surgery at        Hospital for Special Surgery|March 2016|March 1, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02550886||13018|
NCT02546232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-BCT-1|Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting|Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting: A Phase 2 Clinical Trial Protocol Studying Biological Rationale for the Optimal Selection of Treatment Regimens||Oslo University Hospital|No|Recruiting|March 2015|April 2028|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02546232||13376|
NCT02552784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-38|Quality of Life of Patients and Theirs Parents With Inherited Metabolic Diseases With Restricted Diet|Determinants of Health Status and Quality of Life of Patients and Their Parents With Inherited Metabolic Diseases Diagnosed During Childhood and Requiring Restrictive and Specific Diet|MHMRS Qol|Assistance Publique Hopitaux De Marseille|No|Recruiting|June 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|763|||Both|N/A|17 Years|No|||July 2015|September 15, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02552784||12872|
NCT02555553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1335|Noom Monitor for Binge Eating|Noom Monitor for Binge Eating||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|No|||December 2015|December 29, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555553||12660|
NCT02560740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POQ 00001|A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy|A Randomised, Double-blinded, Placebo Controlled Study to Assess the Efficacy and Safety of PerOx Quench or Placebo for 35 Days on the Prevention of Oxaliplatin Treatment Induced Sensory Neuropathy||SMR Biotech Co., Ltd.|No|Not yet recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2015|September 23, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02560740||12261|
NCT02560753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3D959-201|Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease|Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease||T3D Therapeutics, Inc.|No|Recruiting|July 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|36|||Both|50 Years|90 Years|No|||November 2015|November 17, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560753||12260|
NCT02560766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP109|An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome|RLS|XenoPort, Inc.|No|Recruiting|January 2016|October 2023|Anticipated|October 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|132|||Both|13 Years|17 Years|No|||March 2016|March 2, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560766||12259|
NCT02550184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150090|Ultrasonography in the Emergency Department|Ultrasonography in the Emergency Department. A Randomised Controlled Multicenter Study.||Odense University Hospital|Yes|Not yet recruiting|October 2015|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|288|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02550184||13072|
NCT02548780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T125E2|LifePearl-Doxo Pharmacokinetic (PK) Study|Pharmacokinetic Study in Patients With Unresectable Hepatocellular Carcinoma (HCC) Receiving Treatment With LifePearl Microspheres Loaded With Doxorubicin||Terumo Europe N.V.|Yes|Not yet recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02548780||13180|
NCT02553343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QHD01|A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older|Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older||Sanofi|No|Active, not recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|792|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553343||12829|
NCT02553356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT2385-102|PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2385 Tablets||Peloton Therapeutics, Inc.|No|Completed|September 2015|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553356||12828|
NCT02560792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31MH079636|Tailored Activity Goals - an Exercise Prescription Study||TAG|University of Colorado, Boulder|No|Completed|September 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|101|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02560792||12257|
NCT02550418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUX-3/UCA|Budesonide 9 mg Capsules in Active UC|Open-label, Multi-centre, Proof of Concept Phase IIa Clinical Trial on the Efficacy and Tolerability of an 8 Week Oral Treatment With Once Daily 9 mg Budesonide in Patients With Active Ulcerative Colitis|TOPICAL-1|Dr. Falk Pharma GmbH|No|Recruiting|October 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 22, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550418||13054|
NCT02559453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121012014|Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds|A Randomized Trial Comparing the Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds Requiring Hospitalization||Georgetown University|No|Enrolling by invitation|September 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|90 Years|No|||September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559453||12360|
NCT02549352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1196|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up||LEO Pharma|No|Recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549352||13136|
NCT02549365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2801|Efficacy & Safety of Nasal Influenza Immunisation in Children|Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 Study|SNIFFLE-3|Imperial College London|Yes|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||July 2015|October 21, 2015|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549365||13135|
NCT02547909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2146-15-SMC|The Application of Probe-based Confocal Laser Endomicroscopy in the Diagnosis of Deep Endometriosis|The Application of Probe-based Confocal Laser Endomicroscopy in the Diagnosis of Deep Endometriosis||Sheba Medical Center|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|75 Years|No|||September 2015|September 10, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547909||13247|
NCT02555488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shahid beheshti university|Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy|Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy in Reducing the Microbial Flora of the Canal While Root Retreatment in Patients With Periradicular Lesions||Shahid Beheshti University|No|Recruiting|January 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555488||12665|
NCT02545309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-569 ex 13/14|Secondary Sclerosing Cholangitis in Critically Ill Patients|Secondary Sclerosing Cholangitis in Critically Ill Patients (SSC-CIP): A Pilot Study on the Possible Genetic Basis of the Disease|SSC-CIP|Medical University of Graz|No|Recruiting|January 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|140|Samples With DNA|Serum Stool Urine DNA|Both|18 Years|99 Years|No|Probability Sample|Patients with no liver disease in the past, who develop secondary sclerosing cholangitis        during/after a critical illness|October 2015|October 2, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545309||13447|
NCT02545322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BART 1.1|Image Guided Adaptive Radiotherapy in the Head-and-neck Region|Image Guided Adaptive Radiotherapy Based on Elastic Image Registration for Improved Tumor Coverage and Reduction of Side Effect in Normal Tissues|BART|Medical University of Graz|No|Completed|February 2012|August 2013|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|80 Years|No|||September 2015|September 7, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545322||13446|
NCT02545881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turku UH|Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness|Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness|PROAG|Turku University Hospital||Recruiting|July 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Fixed tissue|Male|30 Years|85 Years|No|Probability Sample|Patients with histologically diagnosed prostate cancer who are scheduled for radical        prostatectomy in a university hospital|September 2015|September 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02545881||13403|
NCT02558647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR:239985|Overcoming Insomnia. From Genes to Long-term Impact on Health and Work.|Overcoming Insomnia. From Genes to Long-term Impact on Health and Work. A Large RCT of Online Cognitive-behavioral Therapy for Insomnia.|HUNT-SHUTi|Norwegian Institute of Public Health|No|Not yet recruiting|January 2016|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1500|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02558647||12422|
NCT02557477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381-09|Omega 3/6 Fatty Acids for Reading in Children|Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden||Göteborg University|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|9 Years|10 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02557477||12512|
NCT02533778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140041|ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization|ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization|ARISE|Abington Memorial Hospital|Yes|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533778||14331|
NCT02534025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2015|Remote Ischemic Preconditioning in Liver Transplantation||RIRI|Mansoura University|No|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|30 Years|60 Years|No|||March 2016|March 14, 2016|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02534025||14312|
NCT02550054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU4|Erythropoietin in Premature Infants to Prevent Encephalopathy|Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China||Children's Hospital of Fudan University|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|312|||Both|N/A|48 Hours|No|||March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02550054||13082|
NCT02550067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523201|The Evidence for Contraceptive Options and HIV Outcomes Trial|A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs)|ECHO|FHI 360|Yes|Recruiting|November 2015|June 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|7800|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|September 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02550067||13081|
NCT02550314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIENT1328|A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18|A Phase III Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18-multicenter,Investigator Initiated Clinical Trial||Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Active, not recruiting|March 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|80 Years|No|||January 2016|January 28, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550314||13062|
NCT02554916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 443-2009|Locomotor Adaptation Training to Prevent Mobility Disability|Locomotor Adaptation Training to Prevent Mobility Disability||University of Florida|Yes|Recruiting|July 2010|December 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|48|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554916||12708|
NCT02558686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 2015-12|Exercise and Post-dry Needling Soreness|Effects of Eccentric Exercise, Sham or Placebo on Post-Needling Soreness by Dry Needling on Active Trigger Points||Universidad Rey Juan Carlos|Yes|Completed|October 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558686||12419|
NCT02553265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3731|Carbidopa for the Treatment of Excessive Blood Pressure Variability|Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13|CarbiFD|New York University School of Medicine|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|12 Years|60 Years|No|||September 2015|September 15, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553265||12835|
NCT02531074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-13-0608|Swipe Out Stroke (SOS): Feasibility of Using a Consumer Based Electronic Application to Improve Compliance With Weight Loss in Obese Minority Stroke Patients|Swipe Out Stroke (SOS): Feasibility of Using a Consumer Based Electronic Application to Improve Compliance With Weight Loss in Obese Minority Stroke Patients|SOS|The University of Texas Health Science Center, Houston||Recruiting|January 2015|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|18 Years|85 Years||||August 2015|August 20, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531074||14537|
NCT02531360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-815|Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies|Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies||Molecular NeuroImaging|No|Recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|June 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531360||14515|
NCT02531373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-005|A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)|A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|September 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|9||Anticipated|330|||Both|2 Months|49 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531373||14514|
NCT02560571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0142-15-MMC|Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients|||Meir Medical Center||Not yet recruiting|October 2015|||October 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560571||12274|
NCT02560584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B308/13|A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting|A Prospective, Open, Comparative, Within Patient Controlled Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients With Bladder Cancer||Photocure|No|Recruiting|September 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560584||12273|
NCT02556307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22263|A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients|||Hoffmann-La Roche||Completed|March 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|270|||Both|18 Years|N/A|No|Non-Probability Sample|Slovenian patients with chronic hepatitis C (CHC) treated with Peginterferon alfa-2a and        ribavirin.|January 2016|January 18, 2016|September 21, 2015||No||No|January 18, 2016|https://clinicaltrials.gov/show/NCT02556307||12602|
NCT02557516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2201-202|Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia|Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Innate Pharma|No|Recruiting|November 2015|June 2019|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557516||12509|
NCT02549755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0543|11C-acetate for Treatment Response After Radiotherapy for HCC|Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma||Indiana University|Yes|Not yet recruiting|September 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549755||13105|
NCT02554253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007148|The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction|The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction in Patients 75 Years of Age or Older and Undergoing Cardiac Surgery||Mayo Clinic|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|75 Years|N/A|No|||September 2015|September 17, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554253||12759|
NCT02548416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2015/338|Peroperative Use of Positive End-expiratory Pressure Prevents Formation of Atelectasis as Studied by Computerised Tomography at End of Surgery|Peroperative Use of Positive End-expiratory Pressure Prevents Formation of Atelectasis as Studied by Computerised Tomography at End of Surgery||Landstinget Västmanland|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|40 Years|75 Years|No|||November 2015|November 9, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02548416||13208|
NCT02548429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-P-001047|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||September 11, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548429||13207|
NCT02552199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-4000-EM-101|A Non-Interventional Study To Assess Sweating|A Non-Interventional Study To Assess Sweating, As Measured By Gravimetry, In Subjects With Primary Hyperhidrosis And In Healthy Individuals||Brickell Biotech, Inc.|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with palmar hyperhidrosis and healthy subjects|October 2015|October 23, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552199||12917|
NCT02559076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14NT05|The Eat Right Emirates Healthy Lifestyle Study|Preschool Obesity in the United Arab Emirates: Determinants and the Effectiveness of the 10-step Healthy Lifestyle Tool for Toddlers- Eat Right Emirates|ERERCT|Great Ormond Street Hospital for Children NHS Foundation Trust|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02559076||12389|
NCT02559089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1-1101-1|Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China|||Beijing Tongren Hospital||Active, not recruiting|May 2015|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|400|||Both|6 Months|N/A|No|Non-Probability Sample|the unidentified encephalitis patients who meeting the inclusion criteria and exclusion        criteria and signing the written informed consent form。|September 2015|September 27, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559089||12388|
NCT02545348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLucGsendo1|Use of the Sentinel Node Biopsy for Early Endometrial Cancer.|Evaluation (Good Medical Practice Evaluation) of the Use of the Sentinel Node Biopsy in Early Stage Endometrial Cancer and Its Implication on the Adjuvant Treatement and on the Outcomes of the Cancer|SNE|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|August 2015|September 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|All the patient with early stage endometrial cancer, whith or without indication of        complete lymphadenectomy|November 2015|November 16, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02545348||13444|
NCT02545361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAHR002|Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients|A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patients Who Express Both B7 and FasR||Kahr Medical|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|September 6, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02545361||13443|
NCT02552667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MOLZ-302|Efficacy and Safety of HCP1102 Capsule|Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial||Hanmi Pharmaceutical Company Limited|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|228|||Both|15 Years|N/A|No|||September 2015|September 16, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02552667||12881|
NCT02557633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL102|A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL|A Pre-season, Single Site, Single-blind, Parallel Group, Randomized Study to Determine the Tolerability and Safety of Two New Cumulative Doses of Modified Grass Allergens Adsorbed to L-tyrosine With Monophosphoryl Lipid A Adjuvant (Corixa), Phenol Preserved (Grass MATA MPL); Allergy Therapeutics, (UK) Ltd., Compared With Placebo in Patients With Seasonal Allergic Rhinoconjunctivitis Due to Grass Pollen Allergy.||Allergy Therapeutics|Yes|Active, not recruiting|August 2015|October 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|50 Years|No|||March 2016|March 18, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557633||12500|
NCT02559141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ B260/11|Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study|||University of Schleswig-Holstein|No|Completed|March 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559141||12384|
NCT02554370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-A00230-51|Psychoeducational Programme for PD Patients With STN-DBS|Psychoeducational Programme for Patients With Parkinson's Disease Undergoing Subthalamic Deep Brain Stimulation|PSYCHE|Groupe Hospitalier Pitie-Salpetriere|No|Completed|February 2008|June 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|19|||Both|18 Years|70 Years|No|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554370||12750|
NCT02545439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-A109|A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study to Evaluate the Impact of CYP3A4 Induction on the Single Dose Pharmacokinetics of ALKS 5461||Alkermes, Inc.|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545439||13437|
NCT02545452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16997|Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring|A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Anastrozole and Levonorgestrel Released From an Intra-vaginal Ring in Healthy Young Women||Bayer|No|Active, not recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|47|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545452||13436|
NCT02552212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS0006|Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS|Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation|C-axSpAnd|UCB Pharma|No|Recruiting|September 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552212||12916|
NCT02551003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU1|Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy|A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China||Children's Hospital of Fudan University|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|24 Hours|No|||March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02551003||13009|
NCT02551016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14_149SK|Heart Failure Recorded in Primary Care, Hospital Admissions and National Mortality Registry|Capture and Concordance of Heart Failure Recorded in Primary Care, Hospital Admissions and National Mortality Registry: A Cohort Study In 2.1 Million People||University College, London|Yes|Active, not recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|From 1 January 1997, all patients aged ≥18 years old, registered in CPRD practices in        England consenting to data linkage, with at least one year of up-to-standard pre-study        follow-up are potentially eligible.|July 2015|September 14, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551016||13008|
NCT02551029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 152048|fMRI and Visceral Perception Upon Capsaicin Infusion|Brain and Brainstem Activation Following Duodenal Nociceptive Stimulation With Capsaicin, an Exploratory High-resolution fMRI Study in Healthy Volunteers||Maastricht University Medical Center|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|21|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02551029||13007|
NCT02556866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120122|Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis|Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Rituximab in Combination With Corticosteroids to Corticosteroids Plus Placebo in the Treatment of Non-infectious Active Mixed Cryoglobulinemia Vasculitis|ESBAM|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||July 2015|September 21, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02556866||12559|
NCT02556918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082180|Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery|Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery|SITA-CABGDM|Emory University|Yes|Recruiting|January 2016|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556918||12555|
NCT02548494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-Lantus|Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric New-onset Type 1 Diabetes|Early Administration of Long-acting Insulin Glargine for the Treatment of Diabetic Ketoacidosis in Pediatric New-onset Type 1 Diabetes: A Randomized Double Blind Trial||Chattanooga-Hamilton County Hospital Authority|No|Not yet recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|1 Year|21 Years|No|||September 2015|September 11, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548494||13202|
NCT02551523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0288|Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection|A Prospective, Randomised, Controlled, Open-label, Non-inferiority Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Under Suppressive Early Standard of Care Antiretroviral Therapy||University of Zurich|No|Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551523||12969|
NCT02553967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMASCO-1503|Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)|Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)|REMASCO|Centre Oscar Lambret|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02553967||12781|
NCT02558205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14100902|Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry|Establishing a Correlation Between Pre-treatment CT Perfusion Parameter Values and Post-treatment PET/CT Dosimetry to Aid in Tumor-specific Y-90 Radioembolization Treatment Planning for Hepatocellular Carcinoma||Rush University Medical Center|No|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients identified for Y-90 transarterial radioembolization of liver tumors with        hepatocellular carcinoma|September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558205||12456|
NCT02558218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBCat|Postoperative Discomfort and Ocular Redness Following Phacoemulsification Surgery|Postoperative Discomfort and Ocular Redness Following Phacoemulsification and Intraocular Lens Implantation||Democritus University of Thrace|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|55 Years|65 Years|No|||September 2015|September 22, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02558218||12455|
NCT02560467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15158|Perfusion Imaging With Myocardial Contrast Echocardiography in HCM|||Oregon Health and Science University|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|19 Years|80 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02560467||12282|
NCT02548130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Centre CHUM|Impact of MELD Score for 700 Consecutive Liver Transplantations|Impact of the Introduction of the MELD Score to Prioritize the Waiting List on Survival, Blood Losses, And Transfusion Requirement for 700 Consecutive Liver Transplantations, Observational Study||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|October 2002|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|700|||Both|17 Years|70 Years|No|Non-Probability Sample|All patients for a liver transplantation|September 2015|September 10, 2015|September 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548130||13230|
NCT02556281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/066/HP|Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III|PROGNOSTIC VALUE OF CIRCULATING TUMORAL FREE DNA Versus CIRCULATING TUMORAL CELLS IN PATIENTS WITH COLORECTAL CANCER STAGE II-III|CTC|University Hospital, Rouen|No|Recruiting|October 2012|September 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|293|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556281||12604|
NCT02556346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3724_CLL_SLL_001|Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Molecular Templates, Inc.|Yes|Withdrawn|November 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 16, 2015|Yes|Yes|The patient population (CLL & SLL) was included in another ongoing study involving NHL    patients.|No||https://clinicaltrials.gov/show/NCT02556346||12599|
NCT02533557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBIRB2015-45|Comparison 1 Plane-2 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block|A Randomized Comparison Between 1 Plane-2 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCBPB) in Upper Extremity Surgery|US-SCBPB|Gachon University Gil Medical Center|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02533557||14348|
NCT02553941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#256|Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome|Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy||University of California, Davis|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553941||12783|
NCT02549482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-110-SPV|Detecting a Volume Deficit During Spontaneous Breathing|Detecting a Central Volume Deficit in Spontaneous Breathing Healthy Volunteers by Systolic Blood Pressure Variation||Aalborg Universitetshospital|No|Completed|August 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 12, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549482||13126|
NCT02549690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_ 06_2015|Testosterone Gel in Poor Responders Undergoing IVF|Effectiveness of Testosterone Gel Pretreatment in Poor Responders Undergoing IVF Treatment: a Randomized Controlled Trial||Vietnam National University|No|Not yet recruiting|September 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|42 Years|No|||September 2015|September 14, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02549690||13110|
NCT02558257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0578|Perception of Palliative Care Encounter|Perception of the Palliative Care Encounter by Patients Who Are Referred to Outpatient Supportive/ Palliative Care||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Participants who have undergone a consultation with a supportive Care doctor in the        Supportive Care Center at The University of Texas MD Anderson Cancer Center in Houston,        Texas.|January 2016|January 22, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558257||12452|
NCT02554123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRJC15-22|Reduction of Postoperative Pain After Milligan-Morgan Haemorrhoidectomy With Application of Vitamin E Ointment|Reduction of Postoperative Pain and Improvement of Patients´Comfort After Milligan-Morgan Haemorrhoidectomy With Application of Vitamin E Ointment||Hospital General Universitario Elche|Yes|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|N/A|N/A|No|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554123||12769|
NCT02549859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-0539|Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS|Long-term Effect of Low Frequency 60Hz Stimulation on Aspiration, Freezing of Gait and Other Axial and Motor Symptoms in PD Patients With Bilateral STN DBS||University of Chicago|No|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|45 Years|75 Years|No|||September 2015|September 11, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549859||13097|
NCT02549924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERVGDM2|Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus|Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus Inadequately Controlled With Metfomin||University of Guadalajara|No|Recruiting|September 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|30 Years|60 Years|No|||November 2015|November 30, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549924||13092|
NCT02617511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2015:020|Omega-3 Supplementation and Resistance Training|Omega-3 Fatty Acid Supplementation and Resistance Training on Inflammation and Body Composition in Older Men||University of Manitoba|No|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617511||7902|
NCT02617524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLICL 01446|Dedicated Sheath Feasibility Study|A Prospective, Open-label Study to Evaluate the Feasibility and Safety of the Valve Medical Dedicated Sheath During Balloon Aortic Valvuloplasty|BAV|Valve Medical|No|Not yet recruiting|January 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617524||7901|
NCT02616458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0270|The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population|The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population||University of Colorado, Denver|No|Completed|November 2010|August 2015|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|310|||Both|12 Months|15 Months|No|||November 2015|November 30, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02616458||7983|
NCT02616718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008340|Incisional Hernia Progression Over Time|Incisional Hernia Progression Over Time|INPRO|Bispebjerg Hospital|Yes|Recruiting|September 2015|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02616718||7963|
NCT02611817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002SC-3031|Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy||Takeda|Yes|Recruiting|January 2016|September 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|824|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611817||8340|
NCT02623504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-EQP-001|DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder|A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder||Validus Pharmaceuticals|Yes|Recruiting|January 2016|January 2022|Anticipated|January 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|10 Years|17 Years|No|||January 2016|January 6, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623504||7442|
NCT02614573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/CS-01|International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly|International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly: a Pilot Study|INR-Cap pilote|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|No|||February 2016|February 18, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614573||8128|
NCT02617056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1932-P|Objective Assessment of Behavioral Associations of Patients With Dementia|Objective Assessment of Behavioral Associations of Patients With Dementia||VA Office of Research and Development|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients in dementia unit have advanced dementia; a small number of young adult controls        will be studied to validate electrodermal measurements|February 2016|February 5, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02617056||7937|
NCT02617069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTPAF-01|Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Randomized Study||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|September 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|80 Years|No|||November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02617069||7936|
NCT02548299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1607|Cooking and Nutrition Education for Health Among Adults With Diabetes|Cooking and Nutrition Education for Health Among Adults With Diabetes||The Cleveland Clinic|No|Active, not recruiting|May 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548299||13217|
NCT02552836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Montfort Hospital|Efficacy of Psychotherapy for Depressed Parkinson`s Disease Patients|Evaluation of Two Psychotherapies for Depressed Patients With Parkinson`s Disease||Hopital Montfort|No|Not yet recruiting|November 2015|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552836||12868|
NCT02555241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080641|Emergence of Generative Language|Instructional Programming to Promote the Emergence of Generative Language in Children With Autism Spectrum Disorder||Emory University|No|Enrolling by invitation|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|6|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555241||12683|
NCT02559674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-803-01-15|ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel|Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer||Altor Bioscience Corporation|Yes|Not yet recruiting|April 2016|April 2022|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559674||12343|
NCT02549937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-012-00US1|A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics of Sulfatinib in Advanced Solid Tumors||Hutchison Medipharma Limited|No|Recruiting|October 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549937||13091|
NCT02559297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-58-23|Effects of Sevoflurane and Desflurane on Treg|Effects of Sevoflurane and Desflurane Anesthesia on Regulatory T Cells in Patients Undergoing Living Donor Kidney Transplantation||Mahidol University|No|Recruiting|August 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559297||12372|
NCT02545114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002103|Tolvaptan for Patients With Acute Neurological Injuries|Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries||University of Pittsburgh|No|Recruiting|August 2015|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545114||13462|
NCT02545127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000050|Trial Exploring the Efficacy and Safety of FE 202767|A Randomised, Double-blind, Placebo-controlled, Multicentre Trial Exploring the Efficacy and Safety of Intra-nasal Administration of FE 202767 in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production|Mermaid|Ferring Pharmaceuticals|Yes|Not yet recruiting|December 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|44 Years|No|||October 2015|October 22, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545127||13461|
NCT02547441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-004|Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle|A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension||Cutanea Life Sciences, Inc.|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547441||13283|
NCT02547454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22069|An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)|Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA||Hoffmann-La Roche||Completed|December 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|393|||Both|19 Years|N/A|No|Non-Probability Sample|Participants with CKD who do not require dialysis and are appropriate for treatment with        Mircera according to European Best Practice Guidelines (EBPG) and Kidney Disease Outcomes        Quality Initiative (K/DOQI) guidelines.|October 2015|October 21, 2015|September 9, 2015||No||No|October 21, 2015|https://clinicaltrials.gov/show/NCT02547454||13282|
NCT02554032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-071|The Aortic Surgery Cerebral Protection Evaluation (ACE) Randomized Trial|A Randomized Controlled Trial of Axillary vs. Innominate Artery Cannulation for Antegrade Cerebral Protection in Aortic Surgery: The ACE Randomized Trial||St. Michael's Hospital, Toronto|No|Recruiting|June 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02554032||12776|
NCT02553044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18850|Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women|Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|October 2015|October 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|112|||Female|55 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553044||12852|
NCT02555774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YJeongHong|Efficacy of Cognitive Training in Subjective Memory Impairment|One Center, Randomized Trial to Assess Efficacy of Cognitive Training in Subjective Memory Impairment||Asan Medical Center|No|Recruiting|May 2014|January 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|55 Years|75 Years|No|||December 2015|December 30, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555774||12643|
NCT02547675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-031|Rociletinib (CO-1686) USA Expanded Access Program|An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation||Clovis Oncology, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2016|March 17, 2016|September 10, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02547675||13265|
NCT02547688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046727|Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep|Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep||Johns Hopkins University|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547688||13264|
NCT02555293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 13-129|Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection|Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection|ARROW|RWTH Aachen University||Recruiting|February 2016|||April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02555293||12679|
NCT02555306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36-001|A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration|A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration||Santen Inc.|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|50 Years|N/A|No|||October 2015|October 6, 2015|September 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555306||12678|
NCT02560441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-LYM-005|Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|A Multicenter Phase II Trial to Evaluate the Safety and Efficacy of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type||Chinese Academy of Medical Sciences|No|Active, not recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02560441||12284|
NCT02553629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52829.058.15|Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients|Effect of Depth of Neuromuscular Block on Intraoperative Surgical Conditions as Determined by the Leiden Surgical Rating Scale in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery|BLISS3|Leiden University Medical Center||Recruiting|September 2015|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02553629||12807|
NCT02553642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-126|Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)|A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553642||12806|
NCT02551653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204746|Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients|A Microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Using Positron Emission Tomography (PET)||GlaxoSmithKline|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551653||12959|
NCT02551887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck - 14|HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts|HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts||Regenstrief Institute, Inc.|No|Completed|February 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|3||Actual|647|||Both|11 Years|14 Years|No|||February 2016|February 9, 2016|September 15, 2015||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT02551887||12941|
NCT02557789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB-BC-3781-1107|Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects|A Study to Assess the Bioavailability and Pharmacokinetics of an Immediate Release Tablet Formulation of Lefamulin When Administered to Fed and Fasted Healthy Subjects in Comparison to an Intravenous Formulation and a Capsule Formulation||Nabriva Therapeutics AG|Yes|Completed|June 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557789||12488|
NCT02550015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/563|High Intensity Interval Training After Stroke|The Effect of High Intensity Interval Training on Maximal Oxygen Uptake and Risk Factors for Recurrent Stroke||Norwegian University of Science and Technology|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02550015||13085|
NCT02554409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QID02|Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry|Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry Protocol||Sanofi|No|Recruiting|January 2010|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Intradermal Influenza Vaccine (QIV        ID)|March 2016|March 21, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554409||12747|
NCT02561065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TANSNIP CNIC-VUMC-SANTANDER|Long-term Impact Evaluation of a Worksite-based Lifestyle Intervention to Reduce Cardiovascular Risk in Office Workers|Long-term Impact Evaluation of a Worksite-based Lifestyle Intervention to Reduce Cardiovascular Risk in Office Workers|TANSNIP|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Yes|Enrolling by invitation|May 2015|May 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1000|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02561065||12236|
NCT02540109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI092144-P2|Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study|Targeted Transcranial Electrotherapy for Stroke Rehabilitation - Exploratory Trial on Aphasia||Soterix Medical|Yes|Recruiting|July 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|25 Years|75 Years|No|||November 2015|November 2, 2015|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540109||13845|
NCT02554526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J150100036|Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors|Basic Study on Novel Therapeutic Strategy With Bypassing Agent Therapy in Hemophilia A Patients With Inhibitors||Nara Medical University|No|Not yet recruiting|September 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|10|||Male|N/A|N/A|No|Non-Probability Sample|We guess that there are approximately 200-300 hemophilia A patients with inhibitors in our        country. We have approximately 20 out-patients in our hospital. Based on this information,        we set up the patients subjects (n=10).|September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554526||12738|
NCT02554539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34225|Transciptomic Modification Induced by miRNAs in Endometrial Fluid|Human Embryonic Transciptomic Modification Induced by miRNAs Secreted by Human Endometrium to Endometrial Fluid|miRNA_EF|Stanford University|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02554539||12737|
NCT02558699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0646|Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation||CUVIA-AF II|Yonsei University|No|Not yet recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|19 Years|80 Years|No|||September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02558699||12418|
NCT02545582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05|VITARIA Registry Study|VITARIA Registry Study||Cyberonics, Inc.|No|Recruiting|August 2015|December 2017|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic heart failure, NYHA class II/III with LVEF≤40%|March 2016|March 11, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545582|12 Months|13426|
NCT02552056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 1874|The Effect of Integrating CAMH Into PHC and Traditional Healers' Practice in Uganda: a Randomized Controlled Trial|The Effect of Integrating Child and Adolescent Mental Health Into Primary Health Care and Traditional Healers' Practice: a Randomized Controlled Trial in Eastern Uganda||University of Bergen|No|Not yet recruiting|October 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02552056||12928|
NCT02552316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821876|Psoriasis Microbiome and Phototherapy|The Cutaneous Microbiota of Psoriasis: Lesional Variation and a Phase IV, Interventional Study of Its Response to Phototherapy||University of Pennsylvania|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|34|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552316||12908|
NCT02548169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-119|Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer|A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer|PancVax|Baylor Research Institute|Yes|Recruiting|August 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548169||13227|
NCT02556164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UArizona|Electro-acupuncture for Gait and Balance in Parkinson's Disease|Objective Assessment of Electro-acupuncture Efficacy for Gait and Balance in Patients With Parkinson's Disease||University of Arizona|Yes|Active, not recruiting|May 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||September 2015|September 21, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02556164||12613|
NCT02556515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276-08457c|Joint Replacement or Interpositional Arthroplasty for CMC1 Arthritis, a Prospective Trial|Total Joint Replacement or Interpositional Arthroplasty for the Treatment of Arthritis in the Carpometacarpal Joint of the Thumb||Oslo University Hospital|Yes|Active, not recruiting|November 2008|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02556515||12586|
NCT02552420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRD|The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism|The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism||The First Affiliated Hospital of Guangzhou Medical University|No|Completed|September 2007|July 2015|Actual|July 2012|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort||1|Actual|128|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|DVT patients included in this study had been definitively diagnosed as having DVT with        CPUS and/or angiography. Included non-DVT volunteers were confirmed to be without DVT with        CPUS. The healthy volunteer group matched the DVT group in number, age, and gender.|September 2015|September 15, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02552420||12900|
NCT02557269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSSS2015|4"S" - Seasonal Symptoms Suppression Study|Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on "Seal" to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis|4"S"|Association Asthma, Bulgaria|Yes|Active, not recruiting|May 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|55 Years|No|||September 2015|September 21, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02557269||12528|
NCT02546284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB003-05|Study of KB003 in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)|A Phase 1 Study of KB003 in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)||KaloBios Pharmaceuticals|No|Enrolling by invitation|November 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||November 2015|December 21, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02546284||13372|
NCT02550041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9582|Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis Patients|||University Hospital, Montpellier|No|Recruiting|August 2015|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|15 Years|N/A|No|||September 2015|September 11, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02550041||13083|
NCT02550288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653C-383|A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)|A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Active, not recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|297|||Both|20 Years|80 Years|No|||March 2016|March 3, 2016|September 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02550288||13064|
NCT02556255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-PAD-01|Safety and Effectiveness Study of Eximo's CathiTM Atherectomy Device for PAD Treatment|Safety and Effectiveness Evaluation of Eximo's CathiTM, a Hybrid Atherectomy Device, in Subjects Affected With PAD||Eximo Medical Ltd.|No|Not yet recruiting|October 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02556255||12606|
NCT02556710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-003-B|Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampion™ In Adults With Pain With Osteoarthritis Of The Knee|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluated the Efficacy and Safety of an Intra-Articular Injection of AMPION™ in Adults With Pain Due to Osteoarthritis of the Knee||Ampio Pharmaceuticals. Inc.|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|484|||Both|40 Years|85 Years|No|||February 2016|March 20, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556710||12571|
NCT02548000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150257|Diabetes Resistance Training Adaptations in Elderly|Muscle and Vascular Adaptations Induced by Resistance Training in Elderly Diabetic Type 2|DRTAE|Hospital de Clinicas de Porto Alegre|No|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|42|||Both|60 Years|N/A|No|||February 2016|February 22, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02548000||13240|
NCT02546518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Non-Surgical Treatment of SOM|A Comparison of Surgical and a New Non-Surgical Treatment Methods for Secretory Otitis Media in Children|A Comparison of Surgical and a New Non-Surgical Treatment Methods for Secretory Otitis Media in Children- Hearing and Socioeconomic Aspects||Vastra Gotaland Region|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Months|7 Years|No|||March 2016|March 14, 2016|September 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546518||13354|
NCT02546531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510157|Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer|Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer||Washington University School of Medicine|Yes|Recruiting|January 2016|July 2020|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02546531||13353|
NCT02556658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01243-44|Predicted Level of General Anaesthesia in Hip Fracture Surgery|Predicted Level of General Anaesthesia in Hip Fracture Surgery|NAPfem|University Hospital, Angers||Recruiting|February 2015|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|90 Years|No|||September 2015|September 18, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556658||12575|
NCT02556736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RST-001-CP-0001|RST-001 Phase I/II Trial for Retinitis Pigmentosa|Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in Patients With Retinitis Pigmentosa (RP)||RetroSense Therapeutics|Yes|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|January 10, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556736||12569|
NCT02549417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-012|Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis)||Kyowa Hakko Kirin Company, Limited|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549417||13131|
NCT02560415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB2014-A-00170-47 - P120914|Gaming Open Library for Intervention in Autism at Home (GOLIAH /MICHELANGELO)|Patient-centric Model for Remote Management, Treatment and Rehabilitation of Children With Autism - Michelangelo / GOLIAH (Gaming Open Library for Intervention in Autism at Home) Project|MICHELANGELO|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|5 Years|8 Years|No|||September 2015|September 24, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560415||12286|
NCT02558348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL3818-US-001|A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)|A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)|AL3818|Advenchen Laboratories, LLC|Yes|Recruiting|November 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|September 26, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558348||12445|
NCT02551328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|452/2014|Preconditioning With Sevoflurane and Propofol in Patients Undergoing Minimally Invasive Mitral Valve Surgery|A Single-center Observational Study Investigating the Effect of Volatile Conditioning (VC) With Sevoflurane on Myocardial Biomarkers and Platelets Function in Patients Having Minimally Invasive Mitral Valve Surgery (MIMV)|MINI-SEVO|Fondazione Toscana Gabriele Monasterio|No|Recruiting|June 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|N/A|No|Probability Sample|Age>=18 Pt undergoing elective (or urgent) first-time minimal invasive mitral valve        surgery Pt will have to sign informed consent|September 2015|September 15, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02551328||12984|
NCT02545712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-KSV-01|Safe Excipient Exposure in Neonates and Small ChildreN|Safe Excipient Exposure in Neonates and Small ChildreN - a Retrospective, Descriptive Study Off the Amount of Ethanol, Propylene Glycol, Benzyl Alcohol, Benzoates, Acesulfam k, Aspartame, Glycerol and Sorbitol Exposed to Pediatric Patients|SEEN|Bispebjerg Hospital|Yes|Enrolling by invitation|January 2016|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|N/A|5 Years|No|Non-Probability Sample|Neonatal patients and pediatric patients (≤ 5 years) who, at one point, have been/are        being treated at the "Neonatalklinikken" (units 5021, 5023, 5024) or "BørneUngeklinikken"        (units 5061, 5062, 5054, 4144) of Rigshospitalet, Denmark. To be included in the study,        the patients must receive 5 or more different drugs one week after their hospitalisation.|January 2016|January 28, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02545712||13416|
NCT02552485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56867|Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions|Prospective, Monocentric Study for the Evaluation of Latent Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions Lost to Follow-up.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|93|||Both|18 Years|N/A|No|Probability Sample|Patients who underwent congenital heart defect closure before the age of 18 years and who        are lost to follow-up. Lost to follow-up is defined as latest clinical control ≥ 5 years.|December 2015|December 30, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02552485||12895|
NCT02558413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA585-001|Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers|A Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers||Biota Scientific Management Pty Ltd|No|Completed|August 2015|||December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558413||12440|
NCT02558426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER.ALL.2013.31|Estrogen Receptors and Chronic Venous Disease|Molecular Analysis of Estrogen Receptors in Patients With Chronic Venous Disease|ERCVD|University of Cantanzaro|Yes|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Chronic Venous Disease and varicose veins eligible to receive open venous        surgery procedure.|September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558426||12439|
NCT02547337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISLET-PET|Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes|Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes Using Positron Emission Tomography and Diffusion Weighted Imaging|ISLET-PET|Turku University Hospital|No|Not yet recruiting|September 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|Samples Without DNA|Plasma, serum, faeces|Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects recruited via newspaper advertisements. Subjects with Type 1 diabetes        recruited at the policlinics of endocrinology and internal medicine in the district of        Turku University Hospital.|September 2015|September 9, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02547337||13291|
NCT02547350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-UTUC|Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas|||Peking University First Hospital||Not yet recruiting|September 2015|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|N/A|N/A|No|||September 2015|September 9, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02547350||13290|
NCT02547363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1195|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up||LEO Pharma|No|Recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547363||13289|
NCT02561234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB1102-100B|A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors|A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors||Aeglea Biotherapeutics|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561234||12223|
NCT02549508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA 134|Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD|Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD||Fisher and Paykel Healthcare|Yes|Recruiting|September 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549508||13124|
NCT02552095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1302|Triathlon PKR Study in Japan|A Prospective, Single Arm, Multi Center Study on the Compatibility of Triathlon PKR and the Motion Analysis for Japanese||Stryker Japan K.K.|No|Recruiting|June 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|79 Years|No|||March 2016|March 15, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552095||12925|
NCT02559180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwapTwo Study|Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab|Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab|SwapTwo|The Cleveland Clinic|Yes|Recruiting|October 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559180||12381|
NCT02553876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMS-01-2015|Dorsal Root Ganglion Stimulation for Hand and Upper Limb Pain|An Observational Cohort Study to Assess the Long Term Effectiveness of Dorsal Root Ganglion Stimulation for Chronic Pain in the Upper Limb(s)||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2015|June 2022|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|75 Years|No|Probability Sample|Twenty (20) subjects of either gender, minimum of 18 years of age, maximum of 75 years of        age, suffering from chronic, refractory upper limb pain for at least 6 months, who have        been or will be routinely scheduled to receive the commercially available DRG        Neurostimulator System.|September 2015|September 17, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02553876||12788|
NCT02557035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-15-17|An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting|A Phase 3, Single-dose, Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron 0.25 mg Administered as a 30-minute IV Infusion Compared to Palonosetron 0.25 mg Administered as a 30-second IV Bolus for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy.||Helsinn Healthcare SA|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557035||12546|
NCT02557204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH 007|Comparison of Different Methods of Nasogastric Tube Insertion in Anesthetized and Intubated Patients|Comparison of Different Methods of Nasogastric Tube Insertion in Anesthetized and Intubated Patients: A Prospective Randomized Controlled Trial||Antalya Training and Research Hospital|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|200|||Both|18 Years|70 Years|No|||December 2015|December 6, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02557204||12533|
NCT02553473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001481-25|Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis|Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial||Sorlandet Hospital HF||Enrolling by invitation|October 2015|October 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553473||12819|
NCT02559518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cerebellum_MotorLearning|Non-invasive Cerebellar Stimulation on Motor Learning|Effects of Non-invasive Cerebellar Stimulation on Motor Learning and Cortical Electrical Activity of Healthy Individuals||Universidade Federal de Pernambuco|Yes|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|March 5, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02559518||12355|
NCT02559531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCER 15-083|Reliability of the Swiss Emergency Triage Scale (SETS®) Used by Emergency Medical Service (EMS) Providers|Reliability of the Swiss Emergency Triage Scale (SETS®) Used by Emergency Medical Service (EMS) Providers||University Hospital, Geneva|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559531||12354|
NCT02556411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADENOMYOSIS|Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)|||University of Cagliari|No|Not yet recruiting|June 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02556411||12594|
NCT02556437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-2015-200|Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)|Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy||Rigshospitalet, Denmark|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556437||12592|
NCT02554448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-1|Detection of CTCs in Stage III Colorectal Cancer Patients Undergoing Neoadjuvant Chemotherapy|Detection of CTCs in Stage III Colorectal Cancer Patients Undergoing Neoadjuvant Chemotherapy||Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 17, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554448||12744|
NCT02554461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56955|Optimization of Movement Patterns in Elite Volleyball Players|Optimaliseren Van Lichaams- en Bewegingsspecifieke Kenmerken Bij Volleybalspelers Met Het Oog op Het Reduceren Van Blessures||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female national team volleyball players|September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554461||12743|
NCT02553772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11182X-001|A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.|||Allergan|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|242|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553772||12796|
NCT02553785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-0056|Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy|Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy|ReviventTC1|BioVentrix|Yes|Recruiting|June 2015|March 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553785||12795|
NCT02621580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103197|Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients|A 24-Month Cohort Study Assessing the Nature and the Time Course of Structural and Functional Changes to the Retina Following PASCAL Photocoagulation in Proliferative Diabetic Retinopathy Patients||Lawson Health Research Institute|No|Active, not recruiting|September 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621580||7590|
NCT02621788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000234|Evaluation of Mind-body Educational Program to Enhance Resiliency and Reduce Burnout in First Year Residents|Evaluation of Mind-body Educational Program to Enhance Resiliency and Reduce Burnout in First Year Residents||Massachusetts General Hospital|Yes|Completed|April 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02621788||7574|
NCT02615990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erigo 15-0519|Impact of the Erigo Machine on Functional Recovery in ICU Patients|Impact of the Erigo Machine on Functional Recovery in ICU|Mobility|University of Kentucky|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|November 23, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02615990||8019|
NCT02612870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baden201512|Sienna+® Injection Time Study 4 Arms|Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy|Sentimag02|Kantonsspital Baden|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Female|18 Years|85 Years|No|||November 2015|November 23, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02612870||8259|
NCT02613143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXX-WZ|Zonulo-hyaloido-vitrectomy for Malignant Glaucoma|||Wenzhou Medical University||Recruiting||||December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|N/A|No|Probability Sample|This study was consisted of patients who underwent the zonulo-hyaloido-vitrectomy for        malignant glaucoma through an anterior approach. The Office of Research Ethics,Eye        Hospital of Wenzhou Medical University approved the study protocol, and all patients        provided their informed consent.|November 2015|November 20, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02613143||8238|
NCT02619851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-BI-201|A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects|A Phase II Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects: Controlled, Parallel, Multicenter||Anterogen Co., Ltd.|No|Not yet recruiting|December 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619851||7723|
NCT02622412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GY1331|Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease|Randomised Controlled Trial Testing the Effectiveness of a New Multi-professional Breathlessness sErvice for Patients With Any Advanced diSease Against Usual Care (BreathEase)|BreathEase|Ludwig-Maximilians - University of Munich|No|Recruiting|March 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02622412||7526|
NCT02622425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153001|The Effect of PD01 on Cardiovascular Health and Microbial Environment|The Effect of the Carotenoid-producing Bacillus Strain PD01 on Cardiovascular Health and Microbial Environment||Maastricht University Medical Center|Yes|Active, not recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622425||7525|
NCT02552550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208112|Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx|Analysis of Swallowing, Speech and Quality of Life of Patients With Stage T3-T4 Squamous Cell Carcinoma of the Oropharynx Before and After Multimodal Treatment With Curative Intent||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|July 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|Patietn with T3 or T4 stage squamous cell cancer of the oropharynx|September 2015|September 16, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02552550||12890|
NCT02559219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 36914|Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction|Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|15 Years|N/A|No|Probability Sample|any person who has received a cancer diagnosis of acute lymphoblastic leukemia (ALL) or        Hodgkins lymphoma (HL) before the age of 21 and now is 15 years or older and is now off        therapy (considered in remission).|September 2015|September 23, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559219||12378|
NCT02555787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-MA-1002|Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients|Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)|CHORUS|Astellas Pharma Inc|No|Recruiting|March 2015|March 2023|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Probability Sample|Kidney transplant recipients|December 2015|December 16, 2015|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555787||12642|
NCT02555800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INER|Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis|Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial||Centro de Investigación en. Enfermedades Infecciosas, Mexico|No|Recruiting|December 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|36|||Both|N/A|N/A|No|||September 2015|September 19, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02555800||12641|
NCT02559687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-180|Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)|A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180)||Merck Sharp & Dohme Corp.|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559687||12342|
NCT02548676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT - 110414|Optical Angiography in Glaucoma|Optical Angiography in Glaucoma||Medical University of Vienna||Recruiting|April 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|30 open angle glaucoma patients 30 healthy age- and sex matched controls|September 2015|September 10, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548676||13188|
NCT02553798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM04-HH06|Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis|An Open-label Study Assessing Long-term Safety of DRM04 in Subjects With Primary Axillary Hyperhidrosis||Dermira, Inc.|No|Recruiting|August 2015|||May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|660|||Both|9 Years|N/A|No|||January 2016|January 21, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553798||12794|
NCT02557464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-04|Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.|Identification of Early Semantic Markers of Alzheimer's Disease by Using Eye Tracking in Reading Neutral and Predictable Sentences|ADAL|Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|48|||Both|60 Years|N/A|No|||March 2016|March 17, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02557464||12513|
NCT02560350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFEC-2015-090|Small Intestinal Submucosa Scaffold Combined With Adipose-derived Stem Cells to Form an Adipocyte-containing Hypodermis|Implantation of a Small Intestinal Submucosa Scaffold Combined With Adipose-derived Stem Cells to Evaluate Its Potential to Form an Adipocyte-containing Hypodermis||Nanfang Hospital of Southern Medical University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5|||Both|28 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|healthy people with normal adipose tissue|September 2015|September 24, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02560350||12291|
NCT02548819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORG0000351|University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices|University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices|CDMR|University Health Care System, Augusta, Georgia|No|Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who require MR imaging in the presence of a pacemaker or ICD|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548819|6 Months|13177|
NCT02551146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-217|Influence of Implants and Locators for Improved Retention|Influence of Implants and Locators for Improved Retention of Mandibular Full Dentures on Patient's Quality of Life and Oral Function. A Controlled, Randomized and Prospective Study|GC|Philipps University Marburg Medical Center|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|45 Years|80 Years|No|||September 2015|September 15, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02551146||12998|
NCT02557646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22453|An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C|||Hoffmann-La Roche||Completed|May 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|697|||Both|18 Years|N/A|No|Non-Probability Sample|Treatment naive participants with confirmed chronic hepatitis C who are started on        combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and        whose treatment has been approved by the Interferon Committee.|January 2016|January 12, 2016|September 22, 2015||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT02557646||12499|
NCT02557659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013 CA|Zenith® Low Profile AAA Endovascular Graft|Clinical Investigation Plan for the Zenith® Low Profile AAA Endovascular Graft||Cook||Active, not recruiting|March 2011|September 2019|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557659||12498|
NCT02559388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR.SUMS.REC.1394.32|Montelukast for Treatment of Uremic Pruritus|Assessment of Montelukast Efficacy in the Treatment of Refractive Uremic Pruritus||Shiraz University of Medical Sciences|Yes|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|N/A|N/A|No|||September 2015|September 23, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559388||12365|
NCT02545374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9250|Medico-economic Evaluation of a Project of Wounds by a Remote Network|Medico-economic Evaluation of the DOMOPLAIES Project by the CICAT-LR Network|DOMOPLAIES|University Hospital, Montpellier|No|Recruiting|May 2014|March 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545374||13442|
NCT02551380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000955-25|Folinic Acid in Children With Autism Spectrum Disorders|Evaluation of the Efficiency of Folinic Acid in Children With Autism Spectrum Disorders: a Pilot Study "EFFET"|EFFET|Central Hospital, Nancy, France|Yes|Not yet recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|10 Years|No|||September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551380||12980|
NCT02557724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140000266|Mobilization of Mesenchymal Stem Cells During Liver Transplantation|Mobilization of Mesenchymal Stem Cells During Liver Transplantation||Rutgers, The State University of New Jersey|No|Recruiting|September 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing liver transplant or liver resection|September 2015|September 23, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02557724||12493|
NCT02557737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8B0222|Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities|Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities||Chang Gung Memorial Hospital|No|Recruiting|September 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|40|||Both|N/A|N/A|No|||September 2015|October 12, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02557737||12492|
NCT02549781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308093|Environmental Influence on Gambling Behavior|Influence of Sensorimotor Environment on Gambling Behavior in Pathological Gambling.||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549781||13103|
NCT02556476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCUS-2435/11|Cost Effectiveness Analysis of Critical Care in Resource Limited Setting|Cost Effectiveness of Intensive Care in a Low Resource Setting: Prospective Cohort of Medical Critically Ill Patients|CEACCLR|University of Sarajevo|No|Completed|June 2011|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|N/A|N/A|No|Non-Probability Sample|consecutive critically ill patients treated during one year in a recently established        medical ICU at the Sarajevo University Clinical Center.|September 2015|September 21, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556476||12589|
NCT02556489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-23|Transcriptomics Signature of Anti Vaccinia Memory B Cells|Transcriptomics Signature of Anti Vaccinia Memory B Cells in Healthy Individuals at a Short Time After Vaccination||Institut National de la Santé Et de la Recherche Médicale, France|No|Enrolling by invitation|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy donnors vaccinated against smallpox|May 2015|September 29, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556489||12588|
NCT02555852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNODES_DEMO-2|Proton Pump Inhibitors and Risk of Community-acquired Pneumonia|Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|4238504|||Both|40 Years|N/A|No|Probability Sample|In each jurisdiction, the investigators will assemble a study cohort that includes all        patients with a new prescription for an oral NSAID between January 1, 1997 and March 31,        2010. The date of study cohort entry is defined by the prescription date of the        newly-prescribed NSAID.|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555852||12637|
NCT02547246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108053|Transcranial Magnetic Stimulation and Bulimic Craving|Transcranial Magnetic Stimulation, Embodied Cognition and Bulimic Craving||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Female|18 Years|40 Years|No|||March 2016|March 22, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547246||13298|
NCT02559401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 42313|Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation|Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|June 2014|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Probability Sample|patients with brain lesions near eloquent cortex|June 2015|September 23, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02559401||12364|
NCT02529319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00076945|Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation|Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation: The DECAAF II Study|DECAAFII|University of Utah|Yes|Not yet recruiting|September 2016|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|888|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02529319||14672|
NCT02557022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-GL BW2014|Meta Analysis of the Effect of a Low Glycemic Index Diet and Glycemic Load on Body Weight|The Effect of a Low Glycemic Index Diet and Glycemic Load on Body Weight: A Systematic Review and Meta-analyses of Randomized Controlled Trials||University of Toronto|No|Active, not recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Varied|November 2014|November 5, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557022||12547|
NCT02545933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS 53376|Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor|Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study|VORA-PRATIC|University of Florida|No|Recruiting|February 2016|June 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545933||13399|
NCT02545946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00033369|Trial of Abscess Drainage Techniques|Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Control Trial.||Wake Forest Baptist Health|No|Not yet recruiting|October 2015|January 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|N/A|18 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545946||13398|
NCT02545959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPAU2014/01|Intrathecal Rituximab in Progressive Multiple Sclerosis|Intrathecal Rituximab in Progressive Multiple Sclerosis|EFFRITE|Centre Hospitalier de PAU|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|45 Years|N/A|No|||October 2015|October 1, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545959||13397|
NCT02548741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506912530|Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes|Evaluation of the Metformin Scavenging Mechanism on Methylglyoxal in Patients With Type 2 Diabetes Mellitus|MET|University of Arizona||Not yet recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|September 10, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548741||13183|
NCT02544555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCENARIO-FP|Efficacy of Subintimal vs Intraluminal Approach for Atherosclerotic Chronic Occlusive Femoropopliteal Arterial Disease|Safety and Efficacy of Subintimal Versus Intraluminal Approach for Atherosclerotic Chronic Occlusive Femoro-Popliteal Arterial Disease: Prospective, Multicenter, Randomized, Controlled Trial (SCENARIO-FP)|SCENARIO-FP|Korea University Guro Hospital|Yes|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02544555||13505|
NCT02557178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HL114162-02A1|Home-Based Health Management of COPD Patients|Home-Based Health Management of COPD Patients||Minnesota HealthSolutions|Yes|Not yet recruiting|July 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|115|||Both|40 Years|N/A|No|||March 2016|March 14, 2016|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02557178||12535|
NCT02557191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4484|Biomarkers, Neurodevelopment and Preterm Infants|Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants||Montefiore Medical Center|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Cord blood, buccal swab and urine samples will be collected from enrolled patients.|Both|N/A|2 Days|No|Probability Sample|Preterm infants <32 weeks GA|September 2015|September 21, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02557191|2 Years|12534|
NCT02546206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAR-2011-10-11/14|Probiotic Yoghurt Effect on Experimental Gingivitis|Influence of Probiotics on Clinical Parameters and GCF Levels of Interleukin-1β in Experimental Gingivitis: a Randomized Controlled Clinical Trial||Marmara University|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|16 Years|26 Years|Accepts Healthy Volunteers|||August 2015|September 8, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02546206||13378|
NCT02549534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502603664|Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer|Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer||Indiana University|Yes|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult women with breast cancer (WBC) and healthy female controls (HCs)|March 2016|March 15, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549534||13122|
NCT02549742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH1222|Electrochemotherapy on Head and Neck Cancer|Electrochemotherapy on Head and Neck Cancer||Rigshospitalet, Denmark|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549742||13106|
NCT02554747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDUSF-2015-21-(129)|Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa|Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa|ADDENDUM|Odense University Hospital|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|99 Years|No|||December 2015|December 3, 2015|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554747||12721|
NCT02552134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPU HEPA|Standardised Regional Sport-club Based Exercise Programmes|HEPA Steiermark: Standardised Regional Sport-club Based Exercise Programmes|SRS|Sportunion Österreich|No|Recruiting|October 2016|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|194|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||September 2015|October 23, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552134||12922|
NCT02552407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThrombectomyMetaAnalysis|Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis|Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis||Population Health Research Institute|No|Active, not recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|18000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with STEMI undergoing emergency PCI|September 2015|September 15, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02552407||12901|
NCT02547506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0726|Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise|Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise||University of Indianapolis|No|Not yet recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 45 individuals will be enrolled in this cross-sectional study. Three groups        will each consist of 15 individuals (individuals with Parkinson Disease that participate        in boxing, individuals with Parkinson disease that participate in group exercise other        than boxing, and individuals without disability that participate in group exercise other        than boxing).|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547506||13278|
NCT02551458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bedenne PHRC N 2013|Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy|SYSTEMATIC SURGERY VERSUS SURVEILLANCE AND RESCUE SURGERY IN OPERABLE CANCER OF THE OESOPHAGUS WITH A COMPLETE CLINICAL RESPONSE TO RADIOCHEMOTHERAPY|Esostrate|Centre Hospitalier Universitaire Dijon||Recruiting||||March 2023|Anticipated|Phase 2/Phase 3|Interventional|N/A|2||||||Both|18 Years|75 Years||||March 2015|September 14, 2015|August 20, 2015||||No||https://clinicaltrials.gov/show/NCT02551458||12974|
NCT02558998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 34514|Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care|Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2015|||March 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02558998||12395|
NCT02559011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_09_21|Assessment of Arrhythmias in Patients Undergoing Transcatheter Aortic Valve Implantation Using a Small Insertable Cardiac Monitoring Device|Assessment of Arrhythmias in Patients Undergoing Transcatheter Aortic Valve Implantation Using a Small Insertable Cardiac Monitoring Device|Reveal|University Hospital Inselspital, Berne|No|Recruiting|March 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with severe, symptomatic aortic valve stenosis undergoing TAVI at the        institution irrespective selected bioprosthesis will be included in the study. Final        decision on eligibility will be made by the local Heart Team.|March 2016|March 10, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559011||12394|
NCT02556034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTO148ART4009|Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.|Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)|APRAN|Centre de Rhumatologie de l'Est du Québec|No|Recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The target population will be subjects with active Rheumatoid Arthritis or Psoriatic        Arthritis.|October 2015|October 9, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02556034||12623|
NCT02557555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150001531|Patient Education on Labor Analgesia Options|Effects of Antenatal and Perinatal Education of Labor Analgesia Options on Maternal Anxiety, Labor Analgesia and Maternal Satisfaction With Labor Analgesia||Rutgers, The State University of New Jersey|No|Recruiting|September 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|40 Years|No|Probability Sample|pregnant females in prenatal clinic and labor suite|September 2015|September 22, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02557555||12506|
NCT02557568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108059|Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne|Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne|ScreenStaph|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2011|February 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|160|||Both|25 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557568||12505|
NCT02550769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES-LRAB_TAU-2015|Study of NOTES-TME Versus L-LAR in Rectal Cancer|Multicenter Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Low Anterior Resection in Rectal Cancer|NOTESvsL-LAR|Corporacion Parc Tauli|No|Recruiting|April 2015|April 2019|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02550769||13027|
NCT02554305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033-15-HMO|The Fusion Versus The Affinity Oxygenation Systems|The Fusion Versus The Affinity Oxygenation Systems - A Prospective Randomized Trial In Patients Undergoing Coronary Artery Bypass Grafting (CABG)||Hadassah Medical Organization|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 17, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02554305||12755|
NCT02545179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR.USWR.REC.1394.111|Web-based Daily Care Training of Children With Cerebral Palsy|Ethics Committee of the University of Social Welfare and Rehabilitation Science||University of Social Welfare and Rehabilitation Science|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|N/A|N/A|No|||September 2015|September 9, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545179||13457|
NCT02551965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6116|Nursing Follow up in Geriatric Oncology : Tracking Time of Caregiver Exhaustion Risk|Nursing Follow up in Geriatric Oncology : Tracking Time of Caregiver Exhaustion Risk|TANGO|University Hospital, Strasbourg, France|Yes|Not yet recruiting|September 2015|September 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02551965||12935|
NCT02551978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOP_1|Kids Obesity Prevention Program - Study (KOP)|Kids Obesity Prevention Program - Study (KOP). A Serious Game to Address Barriers to Prevention and Treatment of Obesity in Primary School Children|KOP|University Hospital Tuebingen|No|Completed|September 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||September 2015|November 26, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551978||12934|
NCT02558270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOETHE_V2|Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism|Acute Effects of Sodium GlucOse Co-Transporter 2 (SGLT2) Inhibition on Hepatic Glucose and Energy Metabolism||Medical University of Vienna|Yes|Recruiting|March 2016|November 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558270||12451|
NCT02558283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLIFT-002|A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults|||Allergan|No|Recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|175|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558283||12450|
NCT02547116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047491|Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis|Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis||Johns Hopkins University|No|Not yet recruiting|November 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|12 Years|N/A|No|||September 2015|September 10, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547116||13308|
NCT02553447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|556-15|Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency|A Phase II Study of Vitamin D Replacement in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Low Vitamin D Levels||University of Nebraska|Yes|Recruiting|October 2015|||August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|19 Years|N/A|No|||March 2016|March 13, 2016|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553447||12821|
NCT02558075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00097120|Mood Lifters: A Self Help Program|Mood Lifters: A Self Help Program to Improve One's Psychological and Behavioral Well Being||University of Michigan|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558075||12466|
NCT02558088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WADA2013sal|Pharmacological Properties of Salmeterol|Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males||University of Copenhagen|Yes|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02558088||12465|
NCT02560051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-13-101|Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer|Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer||The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2015|November 2023|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|224|||Male|18 Years|N/A|No|||November 2015|November 11, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560051||12314|
NCT02560064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/114|Length of Small Bowel. How Can Standardise Measurement and Why?|Length of Small Bowel. How Can Standardise Measurement and Why?||İnonu University|No|Not yet recruiting|November 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Power analyse was done. Study include at least 44 patients.|September 2015|October 2, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02560064||12313|
NCT02554630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500447|Novel Mechanisms and Approaches to Treat Neonatal Sepsis|Novel Mechanisms and Approaches to Treat Neonatal Sepsis: Adjuvant Therapies, Host Microbiome, and Genomic Expression and Functional Capacity of Innate Immune Cells||University of Florida|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|Samples With DNA|Blood Sample Meconium Sample|Both|N/A|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Preterm neonates 0-72 hours old Term Neonates 0-72 hours old Healthy Adult Controls 18-55        years old|September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554630||12730|
NCT02549638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000548|Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma|Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma||Mayo Clinic|No|Recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples|Both|18 Years|N/A|No|Non-Probability Sample|Mayo Clinic Thoracic Surgery Patients|January 2016|January 8, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549638||13114|
NCT02560493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-037|Gaming Technology to Encourage Healthy Weight and Activity in Youth|Gaming Technology to Encourage Healthy Weight and Activity in Youth|GameSquad|Pennington Biomedical Research Center|No|Active, not recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|46|||Both|10 Years|12 Years|No|||March 2016|March 17, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02560493||12280|
NCT02560597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC2015/0083|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy - Case Study in Patients With Epilepsia Partialis Continua (EPC) and Refractory Status Epilepticus (SE)||University Hospital, Ghent|Yes|Enrolling by invitation|February 2015|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02560597||12272|
NCT02560116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-283|The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals|The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals to Assess Pulmonary Artery Systolic Pressures. Correlation With Invasive Measurements Obtained by Right Heart Catheterization||Northwell Health|Yes|Withdrawn|June 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|After obtaining informed written consent, investigators will enroll all consecutive        patients (age ≥ 18 years old) undergoing right heart catheterization in the        catheterization laboratory for various clinical indications as part of routine medical        care.        This will be a prospective and multicenter study. The participating institutions are:        North Shore University Hospital (Manhasset, NY), Long Island Jewish Medical Center (New        Hyde Park, NY), and Mt Sinai Medical Center (NY, NY).|January 2016|January 20, 2016|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560116||12309|
NCT02551575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BAI02B06|Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis|Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|November 2014|December 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|468|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02551575||12965|
NCT02547181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-2014|Comparing Short-term Function and Pain After No Treatment or Splinting for Boxer's Fracture|Comparing Short-term Function and Pain After No Treatment or Splinting for Boxer's Fracture||Sunnybrook Health Sciences Centre|No|Recruiting|September 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|March 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02547181||13303|
NCT02553811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244468|Diagnosis of Carpal Tunnel Syndrome: Effectiveness of Diagnostic Tests. Clinical Trial of Accuracy|Effectiveness of Clinical Examination, Ultrasound and Electromyography in the Diagnosis of Carpal Tunnel Syndrome: Study Protocol for a Clinical Trial of Accuracy|DCTS|Federal University of São Paulo|Yes|Active, not recruiting|April 2013|December 2016|Anticipated|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|145|||Female|40 Years|80 Years|No|||October 2015|October 20, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02553811||12793|
NCT02531321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00112|Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics|Effects of Protease Inhibitor Use on Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics in HIV-positive Women||University of Southern California|No|Recruiting|August 2015|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||August 2015|August 20, 2015|August 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531321||14518|
NCT02531334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-278|Effects of TA-65, a Telomerase Activator on Metabolic Syndrome|Effects of TA-65, a Telomerase Activator on Metabolic Syndrome||University of Connecticut|No|Recruiting|August 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|32 Years|70 Years|No|||October 2015|October 28, 2015|August 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531334||14517|
NCT02531347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110013|Comparison of Telemedical and Conventional Treatment of Hypertension|Treatment of Hypertension Using Telemedical Home Blood Pressure Measurements||Regional Hospital Holstebro|No|Completed|March 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|375|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531347||14516|
NCT02555813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-006|Treatment of Pancreatic Cancer With Abraxane|Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients||Celgene Corporation|No|Recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Metastatic pancreatic cancer|March 2016|March 24, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555813||12640|
NCT02548468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.237|Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma|A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma||Thomas Jefferson University|Yes|Not yet recruiting||||September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548468||13204|
NCT02560532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-054-203|Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage|A Prospective, Multi-center, Open-label, Single-arm, Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated by Surgical Clipping or Endovascular Coiling|REVERSE|Actelion|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02560532||12277|
NCT02558660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00076630|Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients|Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients||University of Michigan|No|Completed|August 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|177|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 24, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02558660||12421|
NCT02558712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080630|Technology-based Eye Care Services (TECS) Compare|Prospective Comparison of Technology-based Eye Care Services (TECS) Assessment Versus Standard Face to Face Ophthalmologic Exam||Emory University|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558712||12417|
NCT02556398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-07|Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control|Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control||Joslin Diabetes Center|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|25 Years|75 Years|No|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556398||12595|
NCT02546154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monofer-NIS-07|Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)|A Non-interventional Study of the Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With the Intravenous Iron Monofer® (10% Iron Isomaltoside 1000)||Pharmacosmos A/S|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients ≥18 years of age diagnosed with iron deficiency anaemia as a consequence of CKD        or IBD.|February 2016|March 1, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546154||13382|
NCT02546167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14415|CART-BCMA Cells for Multiple Myeloma|Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|March 18, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546167||13381|
NCT02561416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14/00087|Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome|Cost-utility and Biological Underpinnings of Mindfulness-Based Stress Reduction (MBSR) in Fibromyalgia Syndrome: A Three-arm Randomized, Controlled Trial (EUDAIMON Project)|EUDAIMON|Fundació Sant Joan de Déu|No|Not yet recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561416||12209|
NCT02561468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nefo_breast cancer|The Preemptive Analgesic Efficacy of Nefopam|||Seoul National University Bundang Hospital||Recruiting|April 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|94|||Female|20 Years|80 Years|No|||August 2015|September 24, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02561468||12205|
NCT02547805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000713|Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones||Allena Pharmaceuticals|No|Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547805||13255|
NCT02548052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201465|Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis|A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test||GlaxoSmithKline|No|Completed|October 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548052||13236|
NCT02547610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402050MINC|MR/PET in the Evaluation of Patients With Esophageal Cancer|MR/PET in the Evaluation of Patients With Esophageal Cancer||National Taiwan University Hospital|No|Recruiting|May 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|20 Years|90 Years|No|Non-Probability Sample|In this prospective study, we will recruit newly diagnosed esophageal cancer patients and        perform MR/PET before and after chemoradiation therapy.Total 80 patients will be recruited        and followed after treatment complete for at least two years.|September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02547610||13270|
NCT02561429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si645/2012|Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Skin Prick Test Positive Control|Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Positive Control of Skin Prick Test||Mahidol University|Yes|Completed|July 2013|August 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|180|||Both|7 Years|60 Years|No|||September 2015|September 25, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02561429||12208|
NCT02561442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scP-02-001|Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration|A Single-Dose, Randomized, Three-way, Partially Blinded Crossover Study to Compare the Pharmacokinetics and Bioavailability of Ceftriaxone Administered as a 1 Gram Intravenous Infusion, a 1 Gram Subcutaneous Infusion and a 2 Gram Subcutaneous Infusion in Healthy Adult Subjects||scPharmaceuticals, Inc.|No|Not yet recruiting|October 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561442||12207|
NCT02561455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0109|Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial|A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial||Astellas Pharma Inc|No|Recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561455||12206|
NCT02561481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H00007832|Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)|Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)||University of Massachusetts, Worcester|Yes|Recruiting|December 2015|March 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|12 Years|No|||December 2015|December 29, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561481||12204|
NCT02561494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nefo_stomach op|Postoperative Analgesic Effect of Nefopam|||Seoul National University Bundang Hospital||Recruiting|June 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|78|||Both|20 Years|70 Years|No|||December 2015|December 30, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02561494||12203|
NCT02627846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1788|Laser Ablation Versus Mechanochemical Ablation Trial|A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency|LAMA|University of Hull|Yes|Recruiting|June 2015|September 2030|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627846||7108|
NCT02627859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13DUR502|26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle|A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle||Bioventus LLC|No|Active, not recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|19 Years|85 Years|No|||February 2016|February 9, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627859||7107|
NCT02624167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-3509A/002/II/2015|A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia|A Phase IIa, 4 Week, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability and Efficacy of Dose Range of NW-3509A (15 to 25mg BID) in Patients With Chronic Schizophrenia as Add on to Aripiprazole or Risperidone||Newron|Yes|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624167||7391|
NCT02620241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VrijeUB|Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR).|Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR) in Infants||Vrije Universiteit Brussel||Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|365 Days|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02620241||7693|
NCT02620475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02683|A Randomized Split Scar Study of Suture Safe Treatment of Surgical Wounds to Minimize Scaring|A Randomized Split Scar Study of Suture Safe (South Medic) Treatment of Surgical Wounds to Minimize Scaring||University of British Columbia|No|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02620475||7675|
NCT02617719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|b2xrypzt|Comprehensive Geriatric Assessment in Primary Care: The Fit for Late Life Project|Comprehensive Geriatric Assessment in Primary Care: The Fit for Late Life||University of Southampton|Yes|Enrolling by invitation|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Staff: Primary care staff who are involved in the care of patients aged 75 years and older        from a single United Kingdom primary care practice.        Patients: Patients aged 75 years and older from a single United Kingdom primary care        practice.        Carers: Carers of patients aged 75 years and older from a single United Kingdom primary        care practice.|March 2016|March 1, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02617719||7886|
NCT02623725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD64|Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America||Sanofi|No|Not yet recruiting|March 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|372|||Both|13 Years|22 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623725||7425|
NCT02624726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/14.01|Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment|A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial|MINOAS|Hellenic Oncology Research Group|No|Recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02624726||7348|
NCT02624739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGH-11-15-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||January 14, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624739||7347|
NCT02560324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823286|Effect of Ramelteon on Smoking Abstinence|Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation|RAP|University of Pennsylvania|No|Not yet recruiting|September 2015|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560324||12293|
NCT02559661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49238|Virtual Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance|Virtual Vitreoretinal Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance||Odense University Hospital|No|Enrolling by invitation|October 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Substudy A:          1. Group with trained vitreoretinal surgeons (n = 5).          2. Group with future ophthalmologists in training (n = 10).          3. Group of medicine students with limited knowledge of the anatomy and pathology (n =             20).        Substudy B:        Based on the constructed program in substudy A, five subjects goes through an intensive        training program, which terminated when they achieve the same target score as Group 1 in        substudy A.|September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559661||12344|
NCT02557581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD|cAMP Signaling and Muscle Adaptations|||University of Copenhagen|No|Recruiting|July 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|72|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02557581||12504|
NCT02557594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA2802_BE_I|Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers|A Randomized, Open-label, Two-way Crossover Study to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg After a Single Oral Dose in Healthy Male Volunteers||Dong-A ST Co., Ltd.|Yes|Not yet recruiting|October 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557594||12503|
NCT02553109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-001|Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study|The Risk of Rupture or Growth in Patients With Small Unruptured Paraclinoid Aneurysm: Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study|PANDORA|Seoul National University Hospital|Yes|Recruiting|January 2015|June 2022|Anticipated|June 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|645|||Both|20 Years|N/A|No|Non-Probability Sample|Invastigators defined the cohort population as adults( more than 20 years old) with newly        diagnosed small (less than 5mm) unruptured paraclinoid aneurysm who agree to participate.|February 2016|February 17, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02553109|5 Years|12847|
NCT02555410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.01P|Seizure Detection and Warning System in Epilepsy Patients|A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients||Brain Sentinel|No|Recruiting|January 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|2 Years|99 Years|No|||September 2015|October 14, 2015|February 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555410||12670|
NCT02559700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|188008|Online Brain Training Intervention for Over 50s|Optimising Engagement in an Online Brain Training Intervention for Adults Over 50||King's College London|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10000|||Both|50 Years|110 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559700||12341|
NCT02546245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015556|Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children|Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children||Yale University|No|Recruiting|September 2015|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546245||13375|
NCT02550964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0826|Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy|Incidence and Risk Factor Evaluation for Toxic Maculopathy Associated With Hydroxychloroquine and Chloroquine||Asan Medical Center|No|Recruiting|January 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|124|||Both|19 Years|N/A|No|Non-Probability Sample|The purpose of this cohort study is to evaluate the incidence and risk factor. We will        recruit a total of 124 participants considering the study budget.|September 2015|September 17, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550964||13012|
NCT02560389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204583|Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)|Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)||University of Arkansas|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|105|||Female|25 Years|50 Years|No|||September 2015|September 24, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02560389||12288|
NCT02560428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11482|Evaluating System Change to Advance Learning and Take Evidence to Scale (ESCALATES)|Evaluating System Change to Advance Learning and Take Evidence to Scale (ESCALATES)|ESCALATES|Oregon Health and Science University|No|Active, not recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|7|||Both|18 Years|89 Years|No|Non-Probability Sample|This study will include all R18 grantees|March 2016|March 24, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560428||12285|
NCT02549105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams MH|Lidocaine-Prilocaine Cream (EMLA) Topical Application Versus Wound Infiltration With Lidocaine After Cesarean Section|A Comparison Between Lidocaine-Prilocaine Cream (EMLA) Application And Wound Infiltration With Lidocaine For Post Caesarean Section Pain Relief : A Randomized Controlled Trial||Ain Shams Maternity Hospital|Yes|Recruiting|October 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02549105||13155|
NCT02555631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3604|PowerUp for Health: A Diabetes Prevention Program for Men|Translating the Diabetes Prevention Program to Engage Men From Disadvantaged Areas||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555631||12654|
NCT02559765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200140102|Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.|Current Access to, Use and Perceived Efficacy of Physiotherapy and Rehabilitation Services by People With Progressive Multiple Sclerosis: a Survey of People With Progressive Multiple Sclerosis Via the UK MS Register.||University of Glasgow|No|Recruiting|August 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|People with progressive multiple sclerosis and registered on the UK MS Register|September 2015|September 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559765||12336|
NCT02546466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045641/2015|Effects of Functional Taping on Static Postural Control in Patients With Non-specific Chronic Low Back Pain|Effects of Functional Taping Compared to Sham and Minimal Intervention Strategy on Pain Intensity and Static Postural Control in Patients With Non-specific Chronic Low Back Pain: a Protocol for a Randomized Sham-controlled Trial||University of Sao Paulo|No|Active, not recruiting|September 2015|November 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|50 Years|No|||March 2016|March 24, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546466||13358|
NCT02546726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB15229|Heat & Aerobic Training (HEAT) Study|Heat & Aerobic Training (HEAT) for Pre-Hypertensive Middle-Aged Adults|HEAT|University of Illinois at Urbana-Champaign|No|Recruiting|August 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|64 Years|No|||September 2015|September 9, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02546726||13338|
NCT02556385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1507-308-006|Effects of rTMS Based on Brain Activation During Language Performance in Stroke Patients With Non-fluent Aphasia|Effects of Repetitive Transcranial Magnetic Stimulation Based on Brain Activation During Language Performance in Stroke Patients With Non-fluent Aphasia: A Pilot Study||Seoul National University Bundang Hospital|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4|||Both|18 Years|80 Years|No|||February 2016|February 15, 2016|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02556385||12596|
NCT02545673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UG2015_01|Enhanced Linkage to HIV Care Following Home-Based HIV Testing in Rural Uganda|Enhanced Linkage to HIV Care Following Home-Based HIV Testing in Rural Uganda||San Diego State University|No|Not yet recruiting|November 2015|June 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|566|||Both|18 Years|59 Years|No|||September 2015|September 7, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02545673||13419|
NCT02558634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02535|Thalamic DBS for Laryngeal Dystonia (Spasmodic Dysphonia)- DEBUSSY Trial|Thalamic Deep Brain Stimulation for Laryngeal Dystonia (Spasmodic Dysphonia): A Prospective, Randomized, Double-Blinded, Sham-Controlled Trial||University of British Columbia|Yes|Recruiting|January 2016|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|75 Years|No|||February 2016|February 21, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558634||12423|
NCT02551471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/37|Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer||PELVICARE|University Hospital, Bordeaux|No|Recruiting|October 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from primitive locally-advanced non-metastatic rectal cancer (T4bNxM0),        operated and non-operated.        Patients suffering from non-metastatic recurrence of rectal cancer, operated and        non-operated|September 2015|March 7, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02551471|12 Months|12973|
NCT02529332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00076285|Omega-3 Supplementation for Smell Dysfunction|Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Pituitary Tumor Resection||Emory University|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02529332||14671|
NCT02533531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-F010|Proof of Concept Study for 1 Lead Patch Technology|Proof of Concept Study for 1 Lead Patch Technology||LifeWatch Services, Inc.|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02533531||14350|
NCT02547649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-006|A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older||Merck Sharp & Dohme Corp.|Yes|Completed|October 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|690|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547649||13267|
NCT02550392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15079|Psychoeducation for Transient Ischaemic Attack and Minor Stroke|Optimising Psychoeducation for Transient Ischaemic Attack and Minor Stroke Management (OPTIMISM)|OPTIMISM|University of Nottingham|No|Not yet recruiting|October 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02550392||13056|
NCT02553005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Coimbra|Evaluation of the Effect of Acupuncture on Hand Pain, Functional Deficits and Health Related Quality of Life in Patients With Rheumatoid Arthritis|Evaluation of the Effect of Acupuncture on Hand Pain, Functional Deficits and Health Related Quality of Life in Patients With Rheumatoid Arthritis - A Multicenter, Double-blinded, Randomised Clinical Trial||University of Coimbra|No|Recruiting|May 2015|June 2017|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02553005||12855|
NCT02553018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-112014|Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe|A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.|Self-i|GECEM|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|290|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553018||12854|
NCT02530840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0025-14-COM|Improving Adherence and Commitment to Treatment in Diabetic Patients|Impact:Improving Adherence and Commitment to Treatment||Clalit Health Services|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|210|||Both|30 Years|70 Years|No|||August 2015|August 20, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02530840||14555|
NCT02547883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/41|Statins In The Elderly|Mortality and Economic Impact of Stopping Statins in People Aged of 75 and Over: a Pragmatic Clinical Trial|SITE|University Hospital, Bordeaux|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2430|||Both|75 Years|N/A|No|||October 2015|October 5, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02547883||13249|
NCT02550665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHongLee|Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg|A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg|ODESA|Asan Medical Center|No|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|45 Years|90 Years|No|||September 2015|September 14, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02550665||13035|
NCT02555956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Macular Grid Laser|Grid Laser for Diffuse Diabetic Maculopathy|Subthreshold Double Frequency Nd. YAG Grid Laser for Diffuse Diabetic Maculopathy|MMG|Dow University of Health Sciences|Yes|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|20 Years|80 Years|No|Non-Probability Sample|Diabetic patients having diffuse diabetic macular edema.|September 2015|September 20, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02555956||12629|
NCT02557282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9J8421|CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol|CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol|CTP|Carestream Health, Inc.|No|Completed|September 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Thirty retrospective CT perfusion (CTP) cases that include the collection of CTP original        data, perfusion maps and 2 non-contrast head CTs.|September 2015|September 22, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557282||12527|
NCT02555839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-017|Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice|Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)||Celgene|No|Recruiting|March 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Relapsed and/or Refractory Multiple Myeloma|September 2015|September 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555839||12638|
NCT02556112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20150017H|Effectiveness of a Group Lifestyle Balance Class in a Military Population|Effectiveness of a Group Lifestyle Balance Class in a Military Population||David Grant U.S. Air Force Medical Center||Enrolling by invitation|August 2015|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|107|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02556112||12617|
NCT02546037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC: 08/H0724/11|Clotting With Different Dialyzer Membranes|Pilot Study to Determine the Effect of Different Dialyzer Membranes on Clotting During Haemodiafiltration Treatments in Patients With Chronic Kidney Disease|TAGPSOLACEA|University College, London|No|Not yet recruiting|September 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|attending RFH kidney care centre for routine outpatient HDF treatments for chronic kidney        disease|September 2015|September 9, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02546037||13391|
NCT02546570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015347|Oxytocin and Affect Processing in Posttraumatic Stress Disorder|Posttraumatic Stress Disorder and Affective Functioning: A Test of the Potentially Normalizing Effects of Oxytocin||Yale University|No|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|June 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02546570||13350|
NCT02546583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505015805|Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure|Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure||Yale University|Yes|Recruiting|August 2015|||July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02546583||13349|
NCT02547753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 45413015.0.0000.0075|Evaluation of Alveolar Wound Repair After Dental Extraction in Kidney Transplanted Recipients|Evaluation of Alveolar Wound Repair After Dental Extraction in Kidney Transplanted Recipients||University of Sao Paulo|Yes|Recruiting|October 2015|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|blood and saliva - laboratorial tests|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|kidney transplanted individuals requiring extraction of erupetd teeth|October 2015|October 29, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547753||13259|
NCT02556372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKB-122AIH|Liver Test Study of Using JKB-122 in AIH Patients|A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies|JKB-122AIH|TaiwanJ Pharmaceuticals Co., Ltd|No|Not yet recruiting|September 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|September 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556372||12597|
NCT02556580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Albumin April 2015|Volume Kinetics for 20% Albumin in Different Clinical Situations|Volume Kinetics for 20% Albumin in Conscious and Anesthetized Humans With and Without Inflammation|Albumin|Sodertalje Hospital|No|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|May 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02556580||12581|
NCT02549170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161403|Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP|A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)||Baxalta US Inc.|Yes|Recruiting|December 2015|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|232|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549170||13150|
NCT02549183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B726|Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes|Evaluation of Stimulation Pulse Rate on Clinical Outcomes in Patients Whose Pain is Controlled by 10KHz Frequency - a Feasibility Study|PROCO|Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|June 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02549183||13149|
NCT02557425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506994146|Prophylaxis Again Malaria to Enhance Child developmenT (PROTECT Study)|Prophylaxis Again Malaria to Enhance Child Development|PROTECT|Indiana University|No|Not yet recruiting|October 2015|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|300|||Both|10 Months|38 Months|No|Non-Probability Sample|300 Ugandan Children already enrolled in PROMOTE II study|September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557425||12516|
NCT02560012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-14-102|Personalized Targeted Inhibitors Treatment in Renal Cell Cancer|Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations||The University of Texas Health Science Center, Houston|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560012||12317|
NCT02557360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/02/A/NZ5/00321|Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis|Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis||Pomeranian Medical University Szczecin|No|Not yet recruiting|October 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557360||12521|
NCT02548962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1138-CA|Study of Ibrutinib in Combination With Pomalidomide (Pomalyst™) and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide (Pomalyst™) and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma||Pharmacyclics|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|231|||Both|18 Years|100 Years|No|||October 2015|October 21, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548962||13166|
NCT02547064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlideMStylet|Effect of Modified Stylet Angulation on the Intubation With GlideScope®|Effect of Modified Stylet Angulation on the Intubation With GlideScope®|GlideMStylet|Keimyung University Dongsan Medical Center|Yes|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|80 Years|No|||September 2015|September 9, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02547064||13312|
NCT02547077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|774875|Use of 2-octylcyanoacrylate (Dermabond) Versus 5-0 Fast Absorbing Gut During Cutaneous Wound Closure|Use of 2-octylcyanoacrylate (Dermabond) Versus 5-0 Fast Absorbing Gut During Cutaneous Wound Closure: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial||University of California, Davis|No|Active, not recruiting|July 2015|July 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547077||13311|
NCT02557165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT114804|Impact of COPD on Muscle Regeneration|Impact of Chronic Obstructive Pulmonary Disease on Peripheral and Respiratory Muscle Regeneration||Laval University|No|Active, not recruiting|January 2011|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|27|Samples Without DNA|Muscle biopsies from the quadriceps and diaphragm muscles|Both|40 Years|80 Years|No|Non-Probability Sample|Patient with a scheduled thoracic surgery|September 2015|September 21, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02557165||12536|
NCT02553720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArizonaCC|Aqua Therapy in Deep Venous Thrombosis and Insufficiency|Aqua Therapy to Lower Adverse and Negative Effects of Deep Vein ThrombosIs and Post Thrombotic Syndrome|ATLANTIS|Arizona Cardiovascular Consultants|No|Recruiting|September 2015|December 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02553720||12800|
NCT02558140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29773|A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors||Hoffmann-La Roche||Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558140||12461|
NCT02558153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL44059.058.13|RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula|A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula|APERTO|Groene Hart Ziekenhuis|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|90 Years|No|||September 2015|September 22, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02558153||12460|
NCT02547298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25534|Interstitial Cystitis (IC)-Like Findings With Hydrodistension|Correlation Between Urinary Symptoms and Interstitial Cystitis (IC)-Like Findings on Cystoscopy With Hydrodistension||St. Louis University|No|Recruiting|June 2015|August 2020|Anticipated|August 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|990|||Female|18 Years|90 Years|No|||March 2016|March 16, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02547298||13294|
NCT02547311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2015PG-T1D080|Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes|||University of Colorado Denver School of Medicine Barbara Davis Center|No|Recruiting|July 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|320|||Both|11 Years|17 Years|No|||September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547311||13293|
NCT02554799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_ MMV390048_15_01|A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers|A Phase 1 Exploratory Study to Evaluate the Pharmacokinetics of Selected Oral Formulations of MMV390048 Administered in the Fasted State to Healthy Volunteers||Medicines for Malaria Venture|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02554799||12717|
NCT02554812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991004|A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)|A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies||Pfizer|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|317|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554812||12716|
NCT02551666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasAMU|Balance Recovery Training for Fall Prevention in Retirement Communities|Balance Recovery Training for Fall Prevention in Retirement Communities||Texas A&M University||Not yet recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02551666||12958|
NCT02557880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002530|Sleep Application Diary and Sleep Hygiene in Adolescents|Does the Utilization of a Sleep Application Diary Improve Sleep Hygiene in Adolescents?||Milton S. Hershey Medical Center|No|Not yet recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|17 Years|No|||August 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557880||12481|
NCT02557919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0683|Families Reduce Exposure to Smoke at Home|Evaluation of the Smoking Cessation and Tobacco Use Exposure Patterns of Head Start Parents in Boston|FRESH|Harvard School of Public Health|No|Completed|September 2013|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02557919||12478|
NCT02535819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-CHRMT|Endothelial Cell Loss After Phacoemulsification Intra and Supracapsular|Endothelial Cell Loss After Phacoemulsification Intra and Supracapsular|PERCEPOLIS|Centre Hospitalier Régional Metz-Thionville|No|Recruiting|June 2015|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|294|||Both|18 Years|N/A|No|||June 2015|November 17, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02535819||14174|
NCT02560233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRNP_2013S1A2A2035364_1|Modulating Stress-Reactivity by Real-Time Multimodal Functional Neuroimaging Based Neurofeedback|Modulating Stress-Reactivity by Real-Time Multimodal Functional Neuroimaging Based Neurofeedback||University Hospital, Basel, Switzerland|No|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02560233||12300|
NCT02552706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL2014006|The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis|The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding||Shenzhen Bao'an Maternal and Child Health Hospital|Yes|Recruiting|September 2014|September 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|270|||Both|N/A|3 Days|No|||September 2015|September 17, 2015|September 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552706||12878|
NCT02547272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208087|Epidemiological Study of Intestinal Colonization With Staphylococcus Aureus|Epidemiological Study of Intestinal Colonization With Staphylococcus Aureus in a Cohort of Adult Patients Hospitalized in Intensive Care at the University Hospital of St Etienne.|DigeSTAPH|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2013|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|bacterial samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized in intensive care|March 2016|March 22, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547272||13296|
NCT02547103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThOR-PD Group|Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection|Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Pilot Study, Double- Blind, Stratified Randomized Controlled Trial|COSMO-PD|Chiang Mai University|Yes|Not yet recruiting|November 2015|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02547103||13309|
NCT02545530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLD2015.0203|Transdermal Clonidine in Chronic Hemodialysis Patients|Transdermal Clonidine on Blood Pressure of Chronic Hemodialysis Patients: A Randomized Crossover Clinical Trial||Peking University People's Hospital|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|80 Years|No|||September 2015|September 7, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545530||13430|
NCT02552342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-836|Corticosteroid Therapy for Severe Community-Acquired Pneumonia|Efficacy of Methylprednisolone in Severe Community-acquired Pneumonia，A Multi-center Randomized Controlled Trial||Peking Union Medical College Hospital|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|610|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02552342||12906|
NCT02552589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR012015|Effect of Toothpaste on the Reduction of Plaque and Inflammation|Clinical Evaluation of the Effect of an Experimental Toothpaste on the Reduction of Dental Plaque and Gingival Inflammation||Technische Universität Dresden|Yes|Completed|September 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02552589||12887|
NCT02558439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-OA-502|Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 24-Week Study to Evaluate the Safety and Efficacy of a Single Injection of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain||Centrexion Therapeutics||Recruiting|September 2015|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|172|||Both|45 Years|80 Years|No|||February 2016|February 24, 2016|September 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558439||12438|
NCT02546635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX-024.HCl-1.02|Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects|A Safety, Tolerability, and Pharmacokinetic Clinical Trial of AX-024.HCl to Evaluate A) Potential Food Effect and B) Multi-dosing in Healthy Male Subjects||Artax Biopharma Inc|No|Completed|August 2015|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02546635||13345|
NCT02545764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS13-009|Training Induced Reduction of Lower-limb Joint Loads During Locomotion in Obese Children|The Effects of a Strength and Neuromuscular Exercise Programme for the Lower Extremity on Knee Load, Pain and Function in Obese Children and Adolescents: a Randomised, Single-blinded Controlled Trial||St. Pölten University of Applied Sciences||Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|10 Years|18 Years|No|||December 2015|December 3, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02545764||13412|
NCT02614014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-EII-09|Stress and Personality Profiles in IBD|Effect of the Stress and Personality Profiles in the Development, Evolution and Treatment of Inflammatory Bowel Disease.||Asociación Española de Gastroenterología||Recruiting|June 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|85 Years|No|||December 2015|December 1, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02614014||8171|
NCT02614287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15770|A Safety Study of LY2951742 in Participants With Migraine, With or Without Aura|A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine||Eli Lilly and Company|Yes|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614287||8150|
NCT02616744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONADIUV|Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors|A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial|BONADIUV|Azienda Ospedaliero-Universitaria Careggi|No|Recruiting|January 2011|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|190|||Female|18 Years|75 Years|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616744||7961|
NCT02627508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-34762|Pilot Trial of Pregnenolone in Autism|Randomized Controlled Pilot Trial of Pregnenolone in Autism||Stanford University|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Years|21 Years|No|||December 2015|December 10, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627508||7134|
NCT02621398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031507|Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer|Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer||Rutgers, The State University of New Jersey|Yes|Not yet recruiting|January 2016|September 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|January 25, 2016|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621398||7604|
NCT02611414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50793815900005304|Effectiveness of tDCS for the Treatment of Functional Dyspepsia|Effectiveness of Transcranial Direct Current Stimulation for the Treatment of Functional Dyspepsia: a Randomized Controlled Trial||Hospital Ernesto Dornelles|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02611414||8371|
NCT02613819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 15.03|Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney|Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)|FASTACK II|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Not yet recruiting|April 2016|March 2021|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|February 7, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02613819||8186|
NCT02553564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nephrology - 06032015|30 Day Rehospitalization Risk in Hemodialysis Patients|A Randomized Controlled Trial of a Checklist Intervention to Reduce 30 Day Rehospitalization Risk in Hemodialysis Patients||Northwell Health|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553564||12812|
NCT02549378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308031|Study of the Impact of Changes in Carbonemia on Microcirculation in Patients Achieving a Test Hypercapnia|Study of the Impact of Changes in Carbonemia on Microcirculation in Patients - A Monocentric Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|N/A|No|||September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549378||13134|
NCT02552680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG100432|Preventive Program for Work-Related Musculoskeletal Disorders|Influence of a Preventive Program (Educational and Gymnastics) for Work-Related Musculoskeletal Disorders in Surgeons||Hospital de Clinicas de Porto Alegre|No|Completed|October 2010|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02552680||12880|
NCT02545998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2535|Conducting Annual Asthma Reviews Using Telehealthcare: Comparison With Standard Care (Face-to-face Consultations)|Conducting Annual Asthma Reviews Using Telehealthcare: Comparison With Standard Care (Face-to-face Consultations)||Imperial College London|No|Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02545998||13394|
NCT02549300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU|The Effects of Connective Tissue Massage and Lifestyle Modifications in Adolescents Tension Type Headache|Konnektif Doku Masajı ve Yaşam Stili Modifikasyonlarının Adölesanlarda Gerilim Tipi Baş Ağrısına Etkisi||Hacettepe University|No|Recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|19 Years|No|||September 2015|September 11, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02549300||13140|
NCT02549313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108183|Effect of the Position of the Patient's Head|Study of the Effect of the Position of the Patient's Head With Brain Lesions on Cerebral Blood Flow||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Patient with brain lesion|November 2015|November 2, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549313||13139|
NCT02555995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0316|Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)|Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)||University of Bern|Yes|Completed|November 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555995||12626|
NCT02559713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vedolizumab-4001|Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease|An Open-Label, Multicenter, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically||Takeda|No|Not yet recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559713||12340|
NCT02550977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16119|Russia/Ukraine Suppression of Ovarian Activity Study|Multicenter, Open-label, Uncontrolled Study to Investigate Suppression of Ovarian Activity of a Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in 80 Young Female Volunteers Over 3 Treatment Cycles||Bayer|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02550977||13011|
NCT02549560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transcranial Stimulation|Effects of the Transcranial Stimulation on Prevention of Cognitive Dysfunction in Cardiac Surgery|Effects of the Transcranial Direct Current Stimulation on Prevention of Cognitive Dysfunction in Elderly Patients Submitted to Cardiac Surgeries: Prospective, Randomized and Double-blind Study|tDCS|University of Sao Paulo|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|138|||Both|18 Years|80 Years|No|||September 2015|September 12, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02549560||13120|
NCT02553369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/B/18|Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection|Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection|ChikVIH|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|February 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|392|||Both|18 Years|N/A|No|Probability Sample|patient followed for HIV infection at the 2 investigator centers.|September 2015|September 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02553369||12827|
NCT02553616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD083576-01A1|An Intervention to Promote Healthy Behaviors in Homeless Youth|An Intervention to Promote Healthy Behaviors in Homeless Youth||University of Texas at Austin|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Both|18 Years|23 Years|Accepts Healthy Volunteers|||December 2015|December 5, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553616||12808|
NCT02559778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC012|Pediatric Precision Laboratory Advanced Neuroblastoma Therapy|PEDS-PLAN - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy- A Pilot Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by Maintenance With DFMO for Subjects With Newly Diagnosed High-Risk Neuroblastoma|PEDS-PLAN|Spectrum Health Hospitals|Yes|Recruiting|September 2015|September 2025|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Months|21 Years|No|||February 2016|February 16, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559778||12335|
NCT02549196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC-001-12|A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type|A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type|CPC-12|Chase Pharmaceuticals Corporation|No|Recruiting|October 2015|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|89 Years|No|||January 2016|January 30, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549196||13148|
NCT02549209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCRC GYN15-013|Pembro/Carbo/Taxol in Endometrial Cancer|Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma||Big Ten Cancer Research Consortium|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|No|||September 2015|September 14, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549209||13147|
NCT02553187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLT201401|A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia|A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia||Zhejiang Kanglaite Pharmaceutical Co.Ltd|Yes|Recruiting|September 2015|April 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||September 2015|September 16, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02553187||12841|
NCT02551211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/080/HP|Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer|Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer|LYMPHOLUNG|University Hospital, Rouen|No|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|58|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551211||12993|
NCT02529085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 359 03|PWS European Blood Bank for Infants and Controls From 0 to 48 Months|Study of Early Endocrine Profile in Infants With Prader-Willi Syndrome (PWS) in Order to Unravel the Switch From Early Feeding Difficulties to Obesity and Hyperphagia.||University Hospital, Toulouse|No|Recruiting|March 2013|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|500|||Both|N/A|18 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|April 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02529085||14690|
NCT02549430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREnd|To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy|Phase 2,Open-label,Multicenter,Randomized Study of PD0332991 (Oral CDK4/6 Inhibitor) Monotherapy and in Combination With the HT to Which the pt Has Progressed in the Previous Line for ER+,Her2- Post-menopausal Advanced Breast Cancer Pts|TREnd|Fondazione Sandro Pitigliani|No|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02549430||13130|
NCT02559856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRRA|Comparison of Bleeding Risk Between Rivaroxaban and Apixaban|Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study|COBRRA|Ottawa Hospital Research Institute|Yes|Recruiting|January 2016|April 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559856||12329|
NCT02533544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-174-1805|Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B|Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea||The Catholic University of Korea|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|||Both|19 Years|N/A|No|Probability Sample|Secondary and Tertiary hospital|October 2015|October 15, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02533544||14349|
NCT02537795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58187|Psychiatric Neurosurgery (PNS) for Obsessive Compulsive Disorder (OCD): A Qualitative Analysis of Patient and Family Member Experiences|Psychiatric Neurosurgery (PNS) for Obsessive Compulsive Disorder (OCD): A Qualitative Analysis of Patient and Family Member Experiences||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In the University Hospital of Leuven, more than thirty patients suffering from severe OCD        have been treated with DBS. The investigators will ask patients who are currently being        treated with DBS whether they are willing to participate in this study. The investigators        will also ask whether one of their family members might participate, preferentially their        partner or another close family member. The aim is to include at least ten patients and        their family members. OCD patients, who have been treated with anterior capsulotomy, and        their family members will also be asked for participation in this study. The aim is to        also include ten patients and family members in this group.|August 2015|January 26, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02537795||14022|
NCT02551601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE561056|Subfoveal Choroidal Thickness in Thai Population|Subfoveal Choroidal Thickness in Thai Population||Khon Kaen University|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers, age 18 years or above, no ocular diseases|February 2016|February 23, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551601||12963|
NCT02555111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11077 - P 110150|Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.|Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.|RIPORT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|80 Years|No|||September 2015|September 24, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02555111||12693|
NCT02558114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACHE|Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.|Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|December 2015|October 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558114||12463|
NCT02551796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|Early Changes Among FLEx, LASIK and FS-LASIK|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis||Sun Yat-sen University|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|31 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551796||12948|
NCT02551848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104584|Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment|Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment||Western University, Canada|No|Recruiting|August 2014|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551848||12944|
NCT02551861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-377|A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3|A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3||Bristol-Myers Squibb|No|Withdrawn|December 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551861||12943|
NCT02555267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERIAD|Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma|Multi-center, Prospective Cohort Study to Investigate the Impact of Comprehensive Geriatric Assessments on Survival and Toxicities in Elderly Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP||Chonbuk National University Hospital|No|Recruiting|September 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|148|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients (≥ 65 years) with DLBCL treated with R-CHOP|February 2016|February 5, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555267||12681|
NCT02558946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501440753|Physical Therapy for Men Undergoing Prostatectomy|Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy||Indiana University|No|Recruiting|May 2015|January 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Male|18 Years|N/A|No|||September 2015|September 22, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558946||12399|
NCT02549586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tol 001|Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance|Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance|ASCOTT|University of Toronto|Yes|Recruiting|December 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02549586||13118|
NCT02548663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME_E_SLA|Sport Therapy and Osteopathy Manipulative Treatment in ALS|Sport Therapy for Contrasting the Deterioration of Muscle Oxidative Metabolism in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) - Project ME_E_SLA|ME_E_SLA|University of Milano Bicocca|No|Completed|June 2014|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02548663||13189|
NCT02550509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301141|Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle|Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle - A Monocentric Study||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|November 2013|September 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550509||13047|
NCT02556177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2015-GES-0017|Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2|Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2|mTBI-phase2|GE Healthcare|No|Recruiting|November 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|525|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|August 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556177||12612|
NCT02550834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44408|Wheelchair Indoors Curling With SCI patients_RCT|The Effects of Indoors Curling Exercise in Persons With Chronic Spinal Cord Injury on Control Capabilities of Trunk Movements: a Randomized-controlled Trial.|SCI-RCT|HES-SO Valais-Wallis|No|Completed|August 2015|February 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02550834||13022|
NCT02560870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487|Compare the Efficacy of Aloe Vera Mouthwash With Non- Alcoholic Chlorhexidine Mouthwash on Periodontal Diseases|Randomized, Clinical Trial to Evaluate the Effects of Aloe Vera Mouthwash in Comparison With Non-alcoholic Chlorhexidine on Periodontal Disease||Islamic Azad University, Tehran|Yes|Completed|March 2014|May 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560870||12251|
NCT02560883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-12194|Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes|Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|January 2013|||December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be a multi-institutional, international project that will collate clinical        information from patients with Hairy Cell Leukemia from participating institutions in the        Hairy Cell Leukemia Foundation.Initially, this study will be launched at three        institutions (The Ohio State University in Columbus Ohio, M.D. Anderson Hospital in        Houston Texas, and the Royal Marsden Hospital in London in the United Kingdom). Patients        with HCL, who live in remote areas, without access to a HCLFCenter of Excellence, may        voluntarily submit their name and contact information, through the Hairy Cell Leukemia        Foundation website.|October 2015|October 22, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02560883||12250|
NCT02548884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Difficult cannulation|Pancreatic Sphincterotomy Versus Double Wire Technique in Difficult Cannulation|||Helsinki University Central Hospital|No|Recruiting|September 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1300|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02548884||13172|
NCT02551705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58457|Functional Imaging of Social Cognition in Premanifest Huntington's Disease|Functional Imaging of Social Cognition in Premanifest Huntington's Disease|FISCIP|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02551705||12955|
NCT02559986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111007501|Follow up of Mothers Suspected of Postpartum Depression|Follow-up of Postpartum Depression After Referral From Pediatric Clinics||Indiana University|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|73|||Female|18 Years|N/A|No|Non-Probability Sample|Mothers whose children received care at one of 4 community general pediatrics clinic with        the Child Health Improvement through Computer Automation (CHICA) system who had a positive        PD screen and brought the child to the majority of the child's visits to the study clinic|September 2015|September 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559986||12319|
NCT02546843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDAR FN Brno|Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population|Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction|PedLapBlock|Brno University Hospital|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|18 Years|No|||September 2015|September 9, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02546843||13329|
NCT02546856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI14/01208|Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients|Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients|ETIFIC|Hospital Galdakao-Usansolo|No|Recruiting|March 2015|July 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|628|||Both|N/A|N/A|No|||September 2015|September 15, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02546856||13328|
NCT02553174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003086|AKI in Thoracic and Abdominal Surgery|Acute Kidney Injury and Nonsteroidal Anti-inflammatory Drugs in Patients Undergoing High-risk Abdominal or Thoracic Surgery||Milton S. Hershey Medical Center|No|Not yet recruiting|November 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|Urine|Both|21 Years|N/A|No|Non-Probability Sample|Subjects will be identified by surgeon and by length of procedure. Patients presenting to        the Anesthesia Preoperative Clinic who are scheduled to have surgery lasting longer than 4        hours by certain surgeons, and who are anticipated to recover postoperatively in the        Surgical Intensive Care Unit will be given a recruitment/consent form explaining the        study. The study will then be explained to potential patients by a member of the research        team to determine recruitment eligibility and willingness to participate.|November 2015|November 19, 2015|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02553174||12842|
NCT02558010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW-Methadone-001|Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients|Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients||Medical College of Wisconsin|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|10 Years|17 Years|No|||September 2015|September 22, 2015|February 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558010||12471|
NCT02546778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23686013.9.0000.5345|Effects of Radiofrequency on Located Adiposity|Effects of Radiofrequency on Located Adiposity: A Pilot Study||Federal University of Health Science of Porto Alegre|Yes|Completed|May 2014|August 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02546778||13334|
NCT02546791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-556|Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study|Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study|PASS|Bristol-Myers Squibb|No|Active, not recruiting|January 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|15 Years|N/A|No|Non-Probability Sample|Public centers in the Mexican Republic|March 2016|March 2, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546791||13333|
NCT02551068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01200|High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib|High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study|HOPE-IPF|University of British Columbia|No|Recruiting|December 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|19 Years|N/A|No|||December 2015|December 17, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02551068||13004|
NCT02551081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU2|Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units|Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units||Children's Hospital of Fudan University|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|28 Days|No|Non-Probability Sample|The study population will be recruited from Hospital inpatient population, primarily the        neonatal intensive care unit who has some anomaly or abnormal laboratory testing        suggestive of a genetic disease.|March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02551081||13003|
NCT02546661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2615C00001|Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer|An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)|BISCAY|AstraZeneca|No|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|130 Years|No|||February 2016|February 19, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546661||13343|
NCT02546934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2015-18 CBCSG018|ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)|A Phase II, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|TNBC|Fudan University|No|Not yet recruiting|April 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|254|||Female|18 Years|70 Years|No|||March 2016|March 13, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02546934||13322|
NCT02552992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFCHR14-14148|Yoga for Chronic Low Back Pain and Its Mechanism of Action: Impact of Strength and Stretch (YoMA II)|Yoga for Chronic Low Back Pain and Its Mechanism of Action: Impact of Strength and Stretch (YoMA II)||University of California, San Francisco|No|Active, not recruiting|January 2015|December 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02552992||12856|
NCT02553252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106851|SKY Versus WLC in PTSD|Sudarshan Kriya Yoga (SKY) Versus Wait List Control (WLC) in Post Traumatic Stress Disorder: A Randomised Controlled Study||Lawson Health Research Institute|No|Active, not recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||March 2016|March 6, 2016|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02553252||12836|
NCT02551770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/15|Emdogain Minimally Invasive Surgical Technique|Straumann® Emdogain® Application In Conjunction With Minimally Invasive Surgical Technique For Periodontal Disease Treatment: A Split-Mouth Design Study||Institut Straumann AG|No|Recruiting|October 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551770||12950|
NCT02551783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dorsal vs Ventral|Dorsal vs. Ventral Buccal Graft Dorsal vs. Ventral Buccal Graft|A Randomized Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|DoVeBuG|University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|September 2015|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|85 Years|No|||September 2015|September 15, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02551783||12949|
NCT02547389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nmp/22181|Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy|Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy: Randomized Controlled Trial||NMP Medical Research Institute|Yes|Completed|January 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|144|||Both|18 Years|60 Years|No|||September 2015|September 9, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02547389||13287|
NCT02561169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oseltamivir - 2015|A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza|A Randomized Controlled Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza||McMaster University|No|Not yet recruiting|November 2015|December 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|940|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561169||12228|
NCT02549261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-NI-LC-2|Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer|Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer||Biotech Pharmaceutical Co., Ltd.|No|Active, not recruiting|March 2011|December 2015|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||September 2015|September 11, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02549261||13143|
NCT02552043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMadrid|Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients|Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients||Universidad Autonoma de Madrid|Yes|Recruiting|July 2015|July 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|41|||Both|7 Years|18 Years|No|||July 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552043||12929|
NCT02557308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 4.4|An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis|An Observational, Prospective, Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis||Celltrion|Yes|Recruiting|August 2014|June 2026|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Blood samples for immunogenicity should be retained at the central laboratory up to the End      of the Study, in case additional analysis is required. If additional analysis is not      required during the study or after the End of the Study, blood samples will be stored in a      CELLTRION, Inc. or designated biobank for a further 5 years (from the date the sample is      transferred to the CELLTRION, Inc. or biobank) unless a specific authorization is given by      CELLTRION, Inc.|Both|18 Years|N/A|No|Probability Sample|Approximately 1000 male or female patients with confirmed diagnosis of AS.|September 2015|February 15, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02557308|5 Years|12525|
NCT02556060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-102309|Lamotrigine for Ketamine Dependence Trial|Lamotrigine for Ketamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial||Taipei City Hospital|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||November 2015|November 23, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02556060||12621|
NCT02546479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915194|Follow-Up Study of People Treated for Scoliosis|Breast and Other Cancers Following X-Rays for Scoliosis||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|5573|||Female|50 Years|95 Years|No|||August 2015|October 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546479||13357|
NCT02550457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056666/2015|Kinesio Taping on Chronic Nonspecific Low Back Pain|Effects of Kinesio Taping on Chronic Nonspecific Low Back Pain: a Randomized Controlled Trial||Universidade Federal do Rio Grande do Norte|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Female|18 Years|50 Years|No|||September 2015|September 11, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550457||13051|
NCT02543827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV140-SLG-003|Evaluation of the Efficacy and Safety of MV140|Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact|MV140|Inmunotek S.L.|No|Recruiting|November 2015|January 2019|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|240|||Female|18 Years|75 Years|No|||December 2015|December 22, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02543827||13561|
NCT02549391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7580-010|Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)||Kyowa Hakko Kirin Company, Limited|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|20 Years|N/A|No|||March 2016|March 23, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02549391||13133|
NCT02557256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped Pelvi-abd Malig|Malignant Pediatric Pelvic Tumors: A Retrospective Study|Malignant Pediatric Pelvi-abdominal Tumors: A Retrospective Study||Assiut University|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|90|||Both|N/A|18 Years|No|Non-Probability Sample|A hospital-based study, involving Pediatric cancer patients, those diagnosed with        malignant tumors of the pelvis, or arising from the pelvic organs, in the period from 2001        January till 2015 December, and received treatment at the pediatric oncology department,        their medical reports will be retrospectively reviewed for data collection.|March 2016|March 8, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557256||12529|
NCT02551744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS12-CT7-08|Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers|Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users — a Double-blind Randomized Controlled Trial||Kaohsiung Veterans General Hospital.|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|334|||Both|20 Years|90 Years|No|||September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551744||12952|
NCT02552069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1505|Tritanium® Study in Japan|The Verification Study on the Early Fixation/ Stability of Tritanium Cup||Stryker Japan K.K.|No|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552069||12927|
NCT02549625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-006427|Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells|Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells for Systemic, Single Right Ventricular Failure Due to Congenital Heart Disease||Mayo Clinic|Yes|Recruiting|August 2015|December 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|30 Years|No|||March 2016|March 11, 2016|September 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549625||13115|
NCT02549248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008122|Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology|Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology. A Monocentric Study|NANOPI|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|December 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|Samples Without DNA|Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood      and urine|Both|18 Years|N/A|No|Probability Sample|-  " Test group ": patients suffering from idiopathic interstitial lung diseases             including sarcoidosis and idiopathic pulmonary fibrosis.          -  " Control group ": patients suffering from interstitial lung diseases of known             aetiologies, such as hypersensibility pneumonitis, infectious or cancerous             interstitial diseases and interstitial diseases caused by drug reactions.|September 2015|September 11, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549248||13144|
NCT02552017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039/2014|Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|ADENOMA|South Tyneside NHS Foundation Trust|Yes|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1772|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02552017||12931|
NCT02552030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-287|iPhone App Compared to Standard RR-measurement|iPhone App Compared to Standard RR-measurement - iPARR Trial|iPARR|University Hospital, Basel, Switzerland|Yes|Recruiting|October 2015|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02552030||12930|
NCT02558452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENIOR|SENIOR Transplant Registry - European Transplant Registry of Senior Renal Transplant Recipients (Above the Age of 65 Years) on Tacrolimus Once Daily (Advagraf) Based Triple Therapy|SENIOR Transplant Registry - European Transplant Registry of Senior Renal Transplant Recipients (Above the Age of 65 Years) Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids||Charite University, Berlin, Germany|No|Not yet recruiting|October 2015|January 2028|Anticipated|January 2027|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|HLA antibodies, Non HLA antibodies|Both|65 Years|N/A|No|Probability Sample|The study population will consist of a representative group of approximately 1000 senior        (≥65 years) kidney transplant patients, who receive a renal allograft and an initial        standard triple immunosuppression (tacrolimus once daily (Advagraf), mycophenolate (either        ≥1.0g/day Mycophenolate Mofetil (MMF) or ≥720mg/d enteric-coated Mycophenolate Sodium        (EC-MPS)) and steroids. The patients will be recruited from approximately 42 transplant        centers in Europe.|September 2015|September 22, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02558452|10 Years|12437|
NCT02550366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMR_CE_WH_AccMRI|Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI|Novel Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MR for Non-Invasive Evaluation of Coronary Artery Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult population with no contraindication to magnetic resonance imaging|September 2015|September 11, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02550366||13058|
NCT02549495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000711|Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico|Evaluation of a Community Health Worker Intervention on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico||Brigham and Women's Hospital|No|Active, not recruiting|March 2013|August 2016|Anticipated|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with Diabetes Mellitus, Type 2, or Hypertension, taking daily therapy,        living in one of four study communities in rural Chiapas, Mexico.|February 2016|February 4, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02549495||13125|
NCT02619565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM09236 - P081246|Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes|Prognostic Value of Recurrent Mutations in a Prospective Cohort of Myelodysplasia and Secondary Acute Myeloid Leukemias|MDS04|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|April 2010|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|323|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02619565||7745|
NCT02622178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-125E|How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?|Sensitivity and Specificity of the NOVA-DN VEP Protocol and a Novel Analysis of Optical Coherence Tomography Images for Glaucoma Diagnosis||Wills Eye|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02622178||7544|
NCT02612584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0015|Clinical Efficacy of the Pinhole Soft Contact Lenses for Correcting Presbyopia|||Yonsei University|No|Recruiting|November 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|45 Years|65 Years|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02612584||8281|
NCT02623842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1166-4522|Radiofrequency Non-ablation in the Treatment of Women With Urinary Stress Incontinence: Study Pilot|||Centro de Atenção ao Assoalho Pélvico|No|Completed|July 2013|May 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Female|18 Years|65 Years|No|||November 2015|December 7, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623842||7416|
NCT02619578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-30323|The Effect of TEAS on the Quality of Early Recovery|The Effect of Transcutaneous Electric Acupoint Stimulation on the Quality of Early Recovery in Patients Undergoing Gynecological Laparoscopic Surgery: a Prospective, Randomized, Placebo-controlled Trial||Guizhou Provincial People's Hospital|No|Completed|November 2013|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Female|29 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 28, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02619578||7744|
NCT02618590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-029-内科|A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure|Which Treatment Strategy is Best in Non-small Cell Lung Cancer Patients Harboring EGFR Mutant Type After First/Second Line EGFR-TKI Failure, a Retrospective Study||Sun Yat-sen University|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|75 Years|No|Probability Sample|Patients who were diagnosed with stage IV non-small cell lung cancer (NSCLC) harboring        EGFR mutant type (19 and/or 21 exon mutation), and took EGFR-TKI as first/second line        therapy.|March 2016|March 15, 2016|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02618590||7820|
NCT02624570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412AUS56X|Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.|An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy|AMLFLT3|Novartis||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 6, 2016|December 3, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02624570||7360|
NCT02560818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASOHAR|Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer|Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer|CASOHAR|Centre Francois Baclesse|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560818||12255|
NCT02553382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-111|Fibre Grain Herb Trial in Type 2 Diabetes|Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus|FIGHT|St. Michael's Hospital, Toronto||Recruiting|November 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|40 Years|75 Years|No|||November 2015|November 11, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02553382||12826|
NCT02553395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-40|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||October 13, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553395||12825|
NCT02552693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EG0137|The TracTOR (Tracking and Tracing Operations Research) Study -- Zimbabwe|Enhancing Retention in Care for HIV-positive Mothers and Their Infants by Improving Facility Tracking and Community Health Worker Tracing in Zimbabwe|TracTOR|Elizabeth Glaser Pediatric AIDS Foundation|No|Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|N/A|N/A|No|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552693||12879|
NCT02550717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18116|Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)|A Pharmacoepidemiologitcal Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK|EPISAT|Bayer|No|Recruiting|September 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|200000|||Both|40 Years|84 Years|No|Non-Probability Sample|THIN is a computerized medical research database that contains systematically recorded        data on more than 3 million UK primary care patients. It is representative of this        population with regard to age, sex, and geographic distribution, and has been validated        for use in pharmacoepidemiological and epidemiological research in multiple studies 13.        Participating Primary Care Physicians (PCPs) record prospectively data as part of their        routine patient care, including demographics and life style factors (e.g. alcohol use,        body mass index (BMI) and smoking status), consultation rates, referrals, hospital        admissions, laboratory test results, diagnoses, prescriptions ordered by the PCPs, and a        free text section, and send their data anonymously to THIN for use in research projects.|March 2016|March 7, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550717||13031|
NCT02553863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12131801|The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy|A Randomised Controlled Trial to Assess the Effectiveness and Cost-effectiveness of Acupuncture in the Management of Chemotherapy-induced Peripheral Neuropathy||The Hong Kong Polytechnic University|No|Not yet recruiting|September 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|N/A|N/A|No|||September 2015|September 16, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02553863||12789|
NCT02545140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173431|Prevention Strategies for Adolescents at Risk of Diabetes|Prevention Strategies for Adolescents at Risk of Diabetes - Validation of a Risk Tool for Young People Aged 12 - 14 Years|PRE-STARt|University Hospitals, Leicester|No|Not yet recruiting|October 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|12 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Boys and girls who are between 12 and 14 years of age who do not have an existing        diagnosis of type 1 or type 2 diabetes.|October 2015|October 23, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02545140||13460|
NCT02548910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3588|Phlebotomy to Prevent Blood Loss in Major Hepatic Resections|The PRICE Trial: Phlebotomy Resulting in Controlled Hypovolemia to Prevent Blood Loss in Major Hepatic Resections|PRICE|Ottawa Hospital Research Institute|Yes|Not yet recruiting|February 2016|||February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|62|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02548910||13170|
NCT02559791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-38072|Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma|Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma||McMaster University|No|Enrolling by invitation|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559791||12334|
NCT02554097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFH-SBSM-001|Optimization and Cost-effective Analysis of Secondary Biliary Stones' Managements|Optimization and Cost-effective Analysis of Secondary Biliary Stones' Managements - A Multicenter, Prospective Cohort Study Based on Case Register System||Beijing Friendship Hospital|Yes|Recruiting|August 2015|||December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2700|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients are diagnosed with gallstones and common bile duct stones.|September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554097|3 Years|12771|
NCT02554110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-003533|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||January 19, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554110||12770|
NCT02556216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S 061-10.027|Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)|Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)|BoneX|Hannover Medical School|No|Recruiting|February 2015|July 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|blood; urine, bone tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease (including kidney transplanted patients) with mineral        and bone disease|September 2015|September 18, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02556216||12609|
NCT02559843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611|Effects of Pomegranate Juice on Oxidative Stress in Patients With type2 Diabetes|Effects of Pomegranate Juice Consumption on Glycemic Control, Lipid Profile, Oxidative Stress and Blood Pressure in Patients With Type 2 Diabetes||National Nutrition and Food Technology Institute|Yes|Completed|November 2014|February 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|65 Years|No|||September 2015|September 23, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02559843||12330|
NCT02559882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2015_0045|How to Test Success of a Renal Denervation|Testing Effectiveness of Renal Denervation in Patients With Therapy-resistant Hypertension||University of Zurich|No|Recruiting|August 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Probability Sample|Patient with therapy resistant hypertension and clinical indication for renal nerve        ablation|August 2015|September 24, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02559882||12327|
NCT02559830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-OPC-15005802|Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy|A Phase I/II Clinical Trial of Lentiviral Hematopoietic Stem Cell Gene Therapy for Treatment of Developed Metachromatic Leukodystrophy and Adrenoleukodystrophy||Shenzhen Second People's Hospital|Yes|Recruiting|January 2015|October 2025|Anticipated|October 2025|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|45 Years|No|||September 2015|September 23, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02559830||12331|
NCT02533245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THES1|Transplantoux Health Evaluation Study|Effect of an Exercise Training Intervention on Health-related Quality of Life and Psychosocial and Behavioral Variables in Adult Solid Organ Transplant Recipients: a Quasi-experimental Study Design|THES|Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|500|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02533245||14372|
NCT02549820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011714|Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|CHOP_FETO|Children's Hospital of Philadelphia|Yes|Recruiting|July 2015|June 2022|Anticipated|June 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|50 Years|No|||March 2016|March 16, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549820||13100|
NCT02549833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17078|Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma|Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma||University of California, San Francisco|Yes|Not yet recruiting|October 2015|September 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|September 11, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549833||13099|
NCT02553733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003242|Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD|Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease|HeartBeet|Penn State University|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|85 Years|No|||December 2015|December 22, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553733||12799|
NCT02561026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150215-01H|Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)|Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)|TOPPIT|Ottawa Hospital Research Institute|Yes|Not yet recruiting|January 2016|February 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02561026||12239|
NCT02548520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2007-0255|Maternal and Infant Vitamin Status During the First Nine Months of Infant Life|Vitamin D Status in the First 9 Months of Life||University of Aarhus|No|Completed|October 2008|March 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Female|24 Years|41 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant Caucasian women with a normal pregnancy|September 2015|September 11, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548520||13200|
NCT02544542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X3348|Clinical Trial of a New Rectum Cooling System on Patients of Hypoxic-ischemic Brain Damage|A Comparative Clinical Trial of a New Rectum Cooling System Versus Temperature-adjusting Blanket on Patients of Hypoxic-ischemic Brain Damage||Children's Hospital of Chongqing Medical University|No|Recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||January 2016|January 5, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544542||13506|
NCT02555215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS311|Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|10 Years|17 Years|No|||September 2015|September 17, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555215||12685|
NCT02559349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15415|Gut Microbiota And Radiotherapy|Gut Microbiota And Radiotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Stool Sample|Both|18 Years|N/A|No|Probability Sample|patients receiving SBRT to a lung tumor|September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559349||12368|
NCT02559362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23114|Study on Breast Cancer Patient Perspectives of Exercise|Study on Breast Cancer Patient Perspectives of Exercise||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Female|18 Years|N/A|No|Probability Sample|Breast cancer subjects|September 2015|September 23, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02559362||12367|
NCT02545283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29519|A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Hoffmann-La Roche||Recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02545283||13449|
NCT02554604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0122-15|Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies|Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies and Volatile Organic Compounds in Maternal Saliva Characteristic of Preeclampsia||Meir Medical Center|No|Not yet recruiting|September 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant woman followed in Community Obstetric Clinics and in the High Risk Obstetric        Clinic at Meir Medical Center who agree to participate in the study.        Woman will be recruited based on the presence of one or more risk factors for the        development of preeclampsia including: first pregnancy, overweight at the beginning of        pregnancy or significant weight gain during pregnancy , previous history of preeclampsia        and a first degree family member with a history of preeclampsia|September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554604||12732|
NCT02555371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201810|Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients|A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)||GlaxoSmithKline|No|Recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|N/A|No|||March 2016|March 10, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555371||12673|
NCT02559427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THERMA SAS|SPA Therapy in the Treatment of Sleep Apnea Syndrome|Impact of 3-week SPA Therapy on Sleep Apnea in Patients With Obstructive Sleep Apnea Syndrome and Chronic Venous Insufficiency: A Randomized, Controlled Study|THERMA-SAS|Association Francaise pour la Recherche Thermale|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02559427||12362|
NCT02545816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BISZOL1|Comparing Simplified EEG Monitoring Tool With Standard EEG Monitoring in Patients With Acute Neurological Insult|A Validation Study to Compare Bispectral Index EEG Monitoring With Full EEG in Patients With an Acute Neurological Insult||Hasselt University|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02545816||13408|
NCT02554188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00527|Fasting-mimicking Diet and Immunosenescence|Effect of Fasting-mimicking Diet on Immunosenescence and Vaccination (in the Elderly): a Randomized Clinical Trial||University of Southern California|No|Not yet recruiting|November 2015|June 2020|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|300|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554188||12764|
NCT02554240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA5202_KOA_II|Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee|Active-controlled, Dose-Response, Randomized, Double-blind, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee||Dong-A ST Co., Ltd.|No|Recruiting|December 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|80 Years|No|||September 2015|September 17, 2015|April 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02554240||12760|
NCT02552433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15.035|Complications in Body Contouring Surgery|Complications in Post-bariatric Body Contouring Surgery; Prevalence With hands-on Treatment Regimen|CONTOUR|St. Antonius Hospital|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|Bloodsamples, asessing:        -  albumin        -  hemoglobin        -  vitamin D (25-hydroxy vitamin D)        -  ferritin        -  folic acid        -  vitamin B12|Both|18 Years|N/A|No|Non-Probability Sample|All post-bariatric patients with a stable weight and complaints of skin surplus can be        referred to the department of Plastic and Reconstructive Surgery by the department of        Bariatric Surgery or the general practitioner. After reference the treating plastic        surgeon will decide whether there is an indication for BCS; the type and timing of the BCS        will be at the discretion of the treating plastic surgeon. If a patient is eligible for        BCS and meets the inclusion criteria the treating plastic surgeon or one of the physicians        or a trained staff nurse of the plastic surgery department will explain the study and hand        out patient information letter. In the second preoperative consultation informed consent        will be performed.|September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552433|30 Days|12899|
NCT02552901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFT-0002|Cardiox Liver Function Test Pivotal Trial|A Pivotal, Within Subject, Comparison of the LFT™ Dye Monitor System to the Indocyanine Green Dye (ICG) Serial Blood Plasma Disappearance Rate in Patients With Impaired and Non-Impaired Hepatic Function|LFT-0002|Cardiox Corporation|No|Withdrawn|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552901||12863|
NCT02557906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153962|Evaluating Outcomes of Immediate Breast Reconstruction (POBRAD-M)|Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue|POBRAD-M|King's College London|No|Recruiting|July 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|259|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02557906||12479|
NCT02559921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cycdc2015-3|Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.|||Beijing Chaoyang District Centre for Disease Control and Prevention||Completed|December 2014|December 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|300|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|January 19, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559921||12324|
NCT02559934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTAKD|Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis|An Open-label, Multiple-dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis||G&E Herbal Biotechnology Co., LTD|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|No|||September 2015|September 24, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02559934||12323|
NCT02554318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGHE 626/E4.4/K/2011|Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia|The Effect of Fermented Soybean Supplementation on the Body Weight and Physical Function of Tuberculosis Patients With Standard Therapy in Indonesia|FSS|University of Giessen|No|Completed|October 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|55 Years|No|||September 2015|September 17, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02554318||12754|
NCT02548897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500458|Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease|Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease||University of Florida|Yes|Enrolling by invitation|October 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Both|30 Years|75 Years|No|||September 2015|September 11, 2015|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548897||13171|
NCT02552914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027/15|Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs|Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of Several Sexual Transmitted Infections, Including Reproducibility of the Test Results and Acceptability by MSM Participating in a PrEP Study|Colli-Pee|Institute of Tropical Medicine, Belgium|No|Recruiting|September 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|First-void urine|Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Only participants participating in the Be-PrEP-ared study (EudraCT number: 2015-000054-37)        can be enrolled. These are men having sex with men who are at high risk acquiring HIV.|October 2015|October 5, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02552914||12862|
NCT02556320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/075/HP|Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs|Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs|VIRIDAE|University Hospital, Rouen|No|Completed|May 2013|December 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556320||12601|
NCT02546544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_038|Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma|Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma|LINES|University of Oxford|Yes|Recruiting|March 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||January 2016|January 18, 2016|August 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02546544||13352|
NCT02554383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15030187|Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?|Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?||University of Pittsburgh|Yes|Recruiting|February 2016|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|688|||Both|2 Years|11 Years|No|||February 2016|February 10, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554383||12749|
NCT02554396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX100.FDAII|Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia|A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia||Presbyopia Therapies, LLC||Completed|September 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|45 Years|59 Years|No|||February 2016|February 18, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554396||12748|
NCT02557230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped GU Tumors|Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience|Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience||Assiut University|No|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients, those diagnosed with any of genitourinary neoplasms, in the        period from 2001 January till 2015 December, and received treatment at the pediatric        oncology department, their medical records will be retrospectively reviewed for data        collection.|March 2016|March 8, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557230||12531|
NCT02548728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3041|Oxytocin Treatment of Opioid Dependence|Oxytocin Treatment of Opioid Dependence||University of North Carolina, Chapel Hill|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|21 Years|45 Years|No|||September 2015|September 11, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548728||13184|
NCT02551536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/425-26/13|Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis|Comparison of Efficacy, Safety and Cost Effectiveness of Montelukast and Levocetirizine Versus Montelukast and Fexofenadine in Patients of Allergic Rhinitis: a Randomized, Double-blind Clinical Trial||Indira Gandhi Medical College|Yes|Completed|April 2014|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551536||12968|
NCT02554513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2068-P|Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)|Apraxia of Speech: A Comparison of EPG Treatment & Sound Production Treatment|EPG&SPT|VA Office of Research and Development|No|Not yet recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|21 Years|75 Years|No|||October 2015|October 29, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02554513||12739|
NCT02551159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419LC00001|Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer|A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer (SCCHN) Patients|KESTREL|AstraZeneca|Yes|Recruiting|October 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|628|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551159||12997|
NCT02557750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Comb Mod Hepatoblastoma SECI|Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience|Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience||Assiut University|No|Recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|35|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients, those diagnosed with hepatoblastoma, in the period from 2002        January till 2016 January, and received treatment at the pediatric oncology department,        their medical records will be retrospectively reviewed for data collection.|March 2016|March 8, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02557750||12491|
NCT02560168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-0726|Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease|Multidimensional Wavelet Analysis of Surface Electrocardiogram for Identifying Subclinical Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease||Icahn School of Medicine at Mount Sinai|No|Recruiting|October 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560168||12305|
NCT02551588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081112|Valvular Aortic Stenosis: Study of Myocardiac Fibrosis by Magnetic Resonance Imagery|Calcified Aortic Valve Stenosis (AVS). Markers of Fibrosis Using Cardiac Magnetic Resonance|RACINE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|70|Samples Without DNA|Plasma and serum|Both|18 Years|90 Years|No|Non-Probability Sample|Valvular Aortic Stenosis with or without surgery (symptomatic patients) or controls|January 2016|January 22, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02551588||12964|
NCT02546947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00067-38|Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents (NMBA) Used for Acute Respiratory Distress Syndrome (ARDS) After Cardiothoracic Surgery|Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents (NMBA) Used for Acute Respiratory Distress Syndrome (ARDS) After Cardiothoracic Surgery|CURAREA|Centre Chirurgical Marie Lannelongue|Yes|Recruiting|September 2014|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|82|||Both|18 Years|N/A|No|||August 2015|September 10, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02546947||13321|
NCT02553512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-HELIUS|Helius in Hypertension-I: The UK Hypertension Registry|Helius in Hypertension-I: The UK Hypertension Registry||Proteus Digital Health, Inc.|No|Completed|September 2013|May 2015|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having blood pressure (measured in mm Hg) ≥150 systolic or ≥90 diastolic during        chronic treatment with 2 or more anti-hypertensive drugs, and age ≥80 years; or blood        pressure ≥140 systolic or ≥90 diastolic during chronic treatment with 2 or more        anti-hypertensive, and <80 years|September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02553512|2 Weeks|12816|
NCT02560220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOL-1|MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients|A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1 Study)|TOL-1|Heidelberg University|Yes|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02560220||12301|
NCT02560454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140706|Cognitive Training in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Cognitive Training in Children With Attention Deficit Hyperactivity Disorder (ADHD)|TDAHEC2|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|8 Years|12 Years|No|||September 2015|December 15, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02560454||12283|
NCT02547636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-SDY-020450|Prospective Clinical Evaluation of the FilmArray® NGDS Warrior Panel|Prospective Clinical Evaluation of the FilmArray® NGDS Warrior Panel||BioFire Diagnostics, LLC|No|Recruiting|December 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Residual specimens may be stored for use as negative clinical matrix in contrived testing      studies.|Both|N/A|N/A|No|Non-Probability Sample|Subjects with fever will be prospectively enrolled, and whole blood will be collected.        Additional residual specimens left-over from standard of care laboratory testing will also        be enrolled.|February 2016|February 10, 2016|September 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547636||13268|
NCT02551835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODIN 8.3|Vitamin D Supplements on Markers for Cardiovascular Disease and Diabetes: an Individual Participant Data Meta-analysis|The Effect of Vitamin D Supplementation on Markers for Cardiovascular Disease and Diabetes: an Individual Participant Data Meta-analysis of Randomized Controlled Trials||VU University Medical Center|No|Active, not recruiting|April 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||12|Actual|2945|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The participating RCTs are the Tromso IGT, Tromso OBESITY, Tromso BMD, Tromso CLAMP,        Tromso DEPRESSION, Styrian Vitamin D Hypertension Trial, Paravit, Oosterwerff, Chel,        Wicherts, UCC1, and UCC2 trials.|March 2016|March 1, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02551835||12945|
NCT02559115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-146|68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer|A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||November 2015|November 30, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559115||12386|
NCT02559167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.183|Cannabidiol and Cocaine Craving/Dependence|Cannabidiol as a New Treatment for Cocaine Addiction|CBD|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559167||12382|
NCT02550470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO20140001012|Evaluation of Micropore"s SpiraLith Absorbents|Evaluation of Micropore's SpiraLith TM Absorbents Into Anesthesia Breathing Circuits||Rutgers, The State University of New Jersey|No|Enrolling by invitation|July 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|100|||Both|N/A|N/A|No|||December 2015|December 1, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550470||13050|
NCT02556151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK104127-01|Neuromodulation Therapy for Fecal Incontinence|Neuromodulation Therapy for Fecal Incontinence||Georgia Regents University|Yes|Recruiting|April 2015|November 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|90 Years|No|||September 2015|September 18, 2015|September 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556151||12614|
NCT02544789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-3-C01|Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia|Phase II, Multi-center, and Pharmacokinetic Study of Efficacy, Safety and Pharmacokinetic of Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia||Betta Pharmaceuticals Co.,Ltd.|Yes|Completed|June 2009|May 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|1 Year|21 Years|No|||September 2015|September 8, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544789||13487|
NCT02553681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-002-001|Clinical Evaluation of HPT Treated Rigid Contact Lenses Made From Roflufocon D|Clinical Evaluation of Hydra-PEG (Polyethylene Glycol) Treatment (HPT) Treated Rigid Contact Lenses Made From Roflufocon D||Contamac Ltd|No|Recruiting|July 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02553681||12803|
NCT02561390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si521/2013|Comparison Between spIgE and Skin Prick Test of Local and Imported Aeroallergens|In-vivo Potency Evaluation of American Cockroach, Dog, Cat, Dust Mites and Mold Allergen Extracts Produced by Siriraj Hospital Comparing With Imported Extracts by Using Skin Prick Test.||Mahidol University|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|84|||Both|10 Years|60 Years|No|||June 2013|September 25, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02561390||12211|
NCT02558192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN001|Administration of a Lactobacillus GG and Vitamins Containing Mixture is Effective in Preventing Nosocomial Infection in Children|||Federico II University|No|Completed|January 2014|June 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|90|||Both|3 Months|5 Years|No|||September 2015|September 22, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02558192||12457|
NCT02554968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005266|Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer|Reliability and Validity of Five Shoulder-Specific Patient Reported Outcome Measures for Use in Patients With Head and Neck Cancer||Mayo Clinic|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients reporting shoulder discomfort, stiffness or weakness following a neck dissection        procedure for management of head and neck cancer.|September 2015|September 17, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554968||12704|
NCT02553954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SkinAge-1306|Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).|Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues Collected for Two Age Groups.||Centre Oscar Lambret|No|Recruiting|October 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02553954||12782|
NCT02559102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHF/CTG055/2014|Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants|Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery on Peri-operative Outcomes and Neurocognitive Development in Infants: A Randomized Controlled Trial|DEGA|KK Women's and Children's Hospital|Yes|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|34 Weeks|54 Weeks|Accepts Healthy Volunteers|||August 2015|September 22, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02559102||12387|
NCT02548117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-15-40-10|H-36731: Finasteride in Management of Elevated Red Blood Cells|H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis||Baylor College of Medicine|No|Not yet recruiting|October 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|788|||Male|18 Years|N/A|No|||September 2015|September 10, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02548117||13231|
NCT02554877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4801010|A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin|A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554877||12711|
NCT02554890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696BUS01|comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode|A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).|PIONEER-HF|Novartis|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|736|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554890||12710|
NCT02553226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01102015|Continued Versus Discontinued Oxytocin Stimulation of Labour|Continued Versus Discontinued Oxytocin Stimulation of Labour in a Double-blind Randomised Controlled Trial||University of Aarhus|Yes|Not yet recruiting|March 2016|October 2020|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Female|18 Years|99 Years|No|||February 2016|February 2, 2016|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02553226||12838|
NCT02553239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoolLoop PAF|CoolLoop Paroxysmal Atrial Fibrillation|CoolLoop Paroxysmal Atrial Fibrillation|CoolLoop PAF|AFreeze GmbH|No|Recruiting|July 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|70 Years|No|||September 2015|September 18, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02553239||12837|
NCT02623569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A130901CSPF01|To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina|Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study||Xintong Pharmacy Company|Yes|Recruiting|October 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02623569||7437|
NCT02623582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04415|CD123 Redirected Autologous T Cells for AML|Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623582||7436|
NCT02624622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM HRRC 14-356|Chlorhexidine Cord Care for Newborn Infants in Kenya|A Comparison Between Mothers and Community Health Workers on Use of Chlorhexidine for Umbilical Cord Care: A Randomized Noninferiority Trial||University of New Mexico|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624622||7356|
NCT02567214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-10-2016-2572|Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD|Indacaterol 110µg/ Glycopyrronium 50µg (Ultibro®) Versus Tiotropium (Spiriva®) Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD|RED|Laval University|No|Not yet recruiting|December 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|51 Years|N/A|No|||October 2015|October 6, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02567214||11764|
NCT02613403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682-021|Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects With Chronic HCV GT1 or GT3 Infection Who Have Failed a Direct Acting Antiviral Regimen||Merck Sharp & Dohme Corp.|No|Recruiting|December 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613403||8218|
NCT02613416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706513|Denosumab and Breast Imaging|Phase II Correlative Study of Denosumab Effects on Tissue and Imaging Breast Biomarkers|Dmab|Stony Brook University|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|N/A|75 Years|No|||November 2015|November 23, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613416||8217|
NCT02625688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2013|The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion|The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion: A Randomized-blinded Controlled Trial||Princess Anna Mazowiecka Hospital, Warsaw, Poland|No|Recruiting|August 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|37 Weeks|42 Weeks|No|||December 2015|December 8, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02625688||7274|
NCT02625506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/15.05.67|Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block|Efficacy of Adding Tramadol as Adjunctive Analgesic With Levobupivacaine in Modified Pectoral Nerve Block for Modified Radical Mastectomy Surgery||Mansoura University|Yes|Enrolling by invitation|June 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|20 Years|60 Years|No|||December 2015|December 5, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02625506||7288|
NCT02532491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROAC2014_1Y|Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up|Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up|ROAC2014_1Y|Fundación Marques de Valdecilla|No|Recruiting|May 2014|January 2020|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02532491||14430|
NCT02536586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15838|A Study of LY3023414 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies||Eli Lilly and Company|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|August 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02536586||14115|
NCT02556619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0559|Randomized Control Trial (RCT) of Early Palliative Care for HCC|Early Symptom Control and Palliative Care Referral for Advanced Hepatocellular Carcinoma; a Randomized Control Trial||The University of Texas Health Science Center, Houston|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02556619||12578|
NCT02557243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped Malig Extremities|Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study|Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study||Assiut University|No|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|260|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients, those diagnosed with bone & soft tissue neoplasms involving the        extremities, in the period from 2000 January till 2015 December, and received treatment at        the pediatric oncology department, their medical records will be retrospectively reviewed        for data collection.|March 2016|March 8, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557243||12530|
NCT02556333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150201|Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection|Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|14 Years|N/A|No|||September 2015|September 22, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556333||12600|
NCT02528578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208141|Modulation of Painful Perception|Modulation of Painful Perception|MODOU|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|June 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528578||14729|
NCT02528591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208159|Prospective Single-center Study Evaluating the Central Blood Pressure in Renal Transplantation|Prospective Single-center Study Evaluating the Central Blood Pressure in Renal Transplantation|PACT|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|89|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528591||14728|
NCT02549612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hearing improvement after AOM|The Effect of Early Non-Surgical Treatment of Children With Middle Ear Effusion on the Hearing|The Effect of Early Non-Surgical Treatment of Children With Middle Ear Effusion on the Hearing Level and the Health Economics||Vastra Gotaland Region|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Months|7 Years|No|||March 2016|March 14, 2016|April 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549612||13116|
NCT02552927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55472|Chest Shielding in Premature Infants During Phototherapy|Effect of Chest Shielding on the Incidence of Patent Ductus Arteriosus in Premature Infants Undergoing Phototherapy|SLIGHT|University of Rochester|Yes|Recruiting|August 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|23 Weeks|33 Weeks|No|||September 2015|September 16, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02552927||12861|
NCT02552940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29691|An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice|A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE||Hoffmann-La Roche||Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Participant with a diagnosis of moderate to severe RA defined as DAS28 more than or equal        to (>=) 3.7, naïve to TCZ and in whom the treating physician has made the decision to        commence TCZ SC in accordance with the label and reimbursement criteria|March 2016|March 1, 2016|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02552940||12860|
NCT02558478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5885|Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing|Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing|GEN-NEUROSENS|University Hospital, Strasbourg, France|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|39|Samples With DNA|DNA Fibroblasts|Both|2 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This project focuses on families with unsual phenotypes who have sensorineural disease        with retinal degeneration AND/OR deafness. Our first hypothesis is that these clinical        entities are associated with new genes not described to date. However, it is impossible to        exclude at this stage an allelic variability (mutations in genes already known but with an        unusual phenotype) or mutations in genes implicated in neurosensory diseases but not        detected by prior exploration. These situations illustrate the problem of genetic        complexity and difficulty of the phenotype correlations - genotype.|March 2016|March 10, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02558478||12435|
NCT02558491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18348|Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM Using an Insulin Pump|Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM Using an Insulin Pump||University of Virginia|No|Recruiting|September 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|21 Years|65 Years|No|||September 2015|September 29, 2015|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558491||12434|
NCT02528851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-PAP|Cardiorespiratory Effects of "Higher" Versus "Equivalent" CPAP Upon Extubation From High EAP in Preterm Infants|Cardiorespiratory Effects of "Higher" Versus "Equivalent" CPAP Upon Extubation From High Endotracheal Airway Pressures in Preterm Infants: A Randomized Cross-Over Trial|CO-PAP|McMaster University|Yes|Not yet recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|N/A|6 Months|No|||August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02528851||14708|
NCT02545387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-KM|Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells|Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells||Medical University of Graz|No|Active, not recruiting|January 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|45|Samples Without DNA|serum liver tissue bone marrow|Both|18 Years|99 Years|No|Probability Sample|cells and tissue from patients with chronic hepatitis C virus infection|November 2015|November 24, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545387||13441|
NCT02545400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-side effects|Quantification of Side Effects During Hepatitis C Therapy|Quantification of Side Effects During Dual or Triple Therapy for Chronic Hepatitis C||Medical University of Graz|No|Completed|November 2013|June 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|108|||Both|18 Years|99 Years|No|Probability Sample|Patients with chronic hepatitis C undergoing therapy with pegylated interferon and        ribavirin +/- a firstgeneration protease inhibitor|October 2015|October 2, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545400||13440|
NCT02545738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-004502-15|Antiproteinuric Effects of Liraglutide Treatment|Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial|LIRALBU|Steno Diabetes Center|Yes|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02545738||13414|
NCT02549898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15005669|Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI|Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI||Danish Headache Center|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|42|||Female|18 Years|40 Years|No|||September 2015|September 14, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02549898||13094|
NCT02558569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359/2558(EC3|The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block|The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial||Mahidol University|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558569||12428|
NCT02561013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-013293|A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers|A Randomized, Controlled, Clinical Study to Assess a New Adjustable Compression Device in Patients With Venous Leg Ulcers||3M|No|Withdrawn|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|N/A|No|||November 2015|November 23, 2015|September 23, 2015|No|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT02561013||12240|
NCT02537483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-120A-201|A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris||Valeant Pharmaceuticals|No|Not yet recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|350|||Both|9 Years|N/A|No|||September 2015|September 11, 2015|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02537483||14046|
NCT02554279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000205|MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population|A Randomized, Assessor-blind Trial Comparing MENOPUR® (Menotropins for Injection) and Recombinant FSH (Follicle Stimulating Hormone) in a GnRH Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population|MEGASET HR|Ferring Pharmaceuticals|No|Recruiting|August 2015|September 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Female|21 Years|35 Years|No|||January 2016|January 12, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02554279||12757|
NCT02554331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9183|Gait and REM Sleep Behavior Disorder|Recherche et Mesure d'Anomalies précoces de la Marche au Cours Des Troubles du Comportement en Sommeil Paradoxal Idiopathiques|RBD-M2H|University Hospital, Montpellier|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|63|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02554331||12753|
NCT02559895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD403-CLIN-006|A Multicenter Assessment of ALD403 in Frequent Episodic Migraine|A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines||Alder Biopharmaceuticals, Inc.|Yes|Recruiting|September 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|600|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559895||12326|
NCT02559908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V25L-001|A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creation of Facial Volume in the Chin and Jaw|A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of VYC-25L Hyaluronic Acid Injectable Gel for Restoration and Creation of Facial Volume in the Chin and Jaw||Allergan|No|Active, not recruiting|February 2015|April 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559908||12325|
NCT02559960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dengzhan-V1.0|Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study|Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study||China Academy of Chinese Medical Sciences|Yes|Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|Patients who use Breviscapine Powder-Injection in the monitoring departments of centain        hospitals|October 2015|October 7, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02559960||12321|
NCT02548533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49394.018.14|Fractional Laser Assisted Topical Anesthesia|Fractional CO2 Laser Assisted Topical Articaine Anesthesia vs. Topical EMLA Administration: a Randomized Controlled Study||Netherlands Institute for Pigment Disorders|No|Recruiting|June 2015|November 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|11|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548533||13199|
NCT02552758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-25|The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism|The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism||Shanghai Mental Health Center|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||September 2015|September 16, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02552758||12874|
NCT02530632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504089RIND|The Effects of General Anesthesia on Microcirculation of Central and Peripheral Soft Tissue: a Comparison of Inhalational and Intravenous Anesthetics|The Effects of General Anesthesia on Microcirculation of Central and Peripheral Soft Tissue: a Comparison of Inhalational and Intravenous Anesthetics||National Taiwan University Hospital|No|Not yet recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Female|20 Years|65 Years|No|||August 2015|August 19, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02530632||14571|
NCT02560480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241/2015|Groin Injuries in Finnish Contact Sports|Groin Injuries in Finnish Contact Sports: Prospective 2-year Clinical and Magnetic Resonance Imaging Study|Finngroin|Kuopio University Hospital|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Male|16 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|three contact sport teams (male ice-hockey, soccer, bandy)|September 2015|October 14, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560480||12281|
NCT02546687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0251-15-RMC|Prediction of Anastomotic Leak/Stricture After Esophagectomy With Gastric Pull-up by Venous Blood Gas|Prediction of Anastomotic Leak/Stricture After Esophagectomy With Gastric Pull-up by Venous Blood Gas||Rabin Medical Center|Yes|Enrolling by invitation|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Venous blood gas mesurment|Both|18 Years|N/A|No|Probability Sample|Patients who scheduled to undergo elective esophagectomy with gastric pull-up        reconstruction in Beilinson hospital and are willing and able to give inform consent.|September 2015|September 9, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546687||13341|
NCT02546700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB29804|A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)|||Hoffmann-La Roche||Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|75 Years|No|||March 2016|March 1, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546700||13340|
NCT02549287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1409-21178|Comparative Effectiveness Trail to Reduce Child Maltreatment, Improve Client Outcomes and Examine Client Burden|Comparative Effectiveness Trail to Reduce Child Maltreatment, Improve Client Outcomes and Examine Client Burden||Georgia State University|No|Enrolling by invitation|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|960|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02549287||13141|
NCT02557113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cavuplasty|Creation of a Small Cavity Reduces the Rate of Cement Leakage During Vertebral Body Augmentation|Creation of a Small Cavity in Vertebral Body Reduces the Rate of Cement Leakage During Vertebral Body Augmentation: A Prospective Randomized Controlled Study||Johann Wolfgang Goethe University Hospitals|No|Completed|January 2011|January 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02557113||12540|
NCT02557126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC103KR|Study of URC102 to Assess the Safety and Efficacy in Gout Patients|A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients||JW Pharmaceutical||Not yet recruiting|October 2015|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Male|20 Years|69 Years|No|||September 2015|September 22, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02557126||12539|
NCT02557139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD025-106|Bioavailability of KD025 in Healthy Male Subjects Completed in the UK|A Three Way Crossover, Randomised, Open-Label Study in Healthy Subjects, Designed to Compare the Bioavailability of a KD025 Tablet Formulation Administered in the Fed and Fasted States and to Assess the Relative Bioavailability of a Tablet and Capsule Formulation in the Fed State||Kadmon Corporation, LLC|No|Completed|September 2015|December 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|January 13, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557139||12538|
NCT02560519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA1|Albumin in Cardiac Surgery|Albumin vs Ringer Solution for Cardiac Surgery|ALBICS|Helsinki University Central Hospital|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1300|||Both|18 Years|90 Years|No|||September 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560519||12278|
NCT02560558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082511|Bela 8 Week Dosing|Belatacept Immunosuppression Therapy in Post-Transplant Kidney Recipients: Comparison of 4-Week and 8-Week Dosing Intervals||Emory University|Yes|Recruiting|September 2015|September 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02560558||12275|
NCT02546973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANCA|Quality of Life in Patients With Anal Cancer|ANCA - A Registry Based Study of Clinical Results and Health Related Quality of Life in Patients After Treatment for Anal Cancer|ANCA|Sahlgrenska University Hospital, Sweden|No|Recruiting|September 2015|September 2022|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Patients with anal cancer diagnosed 2011-2013|September 2015|September 30, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02546973||13319|
NCT02550002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOLERANT|Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen|Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen (TOLERANT Study)||University Hospital Inselspital, Berne|Yes|Recruiting|December 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|175|None Retained|blood|Both|50 Years|N/A|No|Non-Probability Sample|A total of 150 patients will be recruited to this study, with approximately 75 randomised        to each study arm (relaxed and strict retinal fluid treatment regimen). Assuming an        approximate 20% screen failure rate, approximately 188 patients will need to be screened        to have 150 patients found eligible and commencing treatment in the trial.|January 2016|January 5, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02550002||13086|
NCT02550249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neo-nivo|Neoadjuvant Nivolumab in Glioblastoma|Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme|Neo-nivo|Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|1 Year|N/A|No|||July 2015|September 11, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02550249||13067|
NCT02556450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Homage|Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure|Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) "HOMAGE" Programme " Heart OMics in AGing "|Homage|ACS Biomarker|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|800|||Both|65 Years|N/A|No|||September 2015|September 21, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02556450||12591|
NCT02556463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6410C00001|A Study of MEDI9197 Administered in Subjects With a Solid Tumor Cancer|A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects With a Solid Tumor Cancer||MedImmune LLC|No|Recruiting|November 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|99 Years|No|||March 2016|March 22, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556463||12590|
NCT02556827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71306642-050.01.04|Demodex Density, Immune Response and Oxidative Stress in Rosacea Patients|Investigation of Relation Between Demodex Density With Immune Response and Oxidative Stress in Rosacea Patients||Istanbul Training and Research Hospital|No|Recruiting|July 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rosacea patients who are between the ages of 18-70, who having no systemic illness and who        were not smoking and who were not using any topical and systemic treatment for a month        attended to the study. As a control group it was planned that healthy volunteers who were        compatible in terms of age, sex and skin phenotype, who were not smoking, with no systemic        illness to be taken.|September 2015|September 22, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556827||12562|
NCT02548013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ain Shams MS PPROM|Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management|Is Outpatient Management of PPROM Equivalent to Hospital Management||Ain Shams Maternity Hospital|Yes|Recruiting|August 2014|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|560|||Female|18 Years|40 Years|No|||September 2015|September 11, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02548013||13239|
NCT02548247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS528_10|Effect of Consumption of Orafti® Inulin on Bowel Motor Function in Subjects With Constipation|Effect of Consumption of Inulin on Bowel Motor Function in Subjects With Constipation||Beneo GmbH|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02548247||13221|
NCT02546297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150717|Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis|The Comparisons of the Efficacy and Safety of Inhaled LAMA or ICS+LABA for Patients in COPD C Group With Bronchiectasis||Shanghai Pulmonary Hospital, Shanghai, China|Yes|Recruiting|January 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02546297||13371|
NCT02556749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE CRAN|Effects of Cranberry Juice on Cardiovascular Risk Factors|Effects of Cranberry Juice on Cardiovascular Risk Factors in a Placebo-controlled Crossover Trial||Penn State University|No|Recruiting|October 2015|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|65 Years|No|||December 2015|December 18, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556749||12568|
NCT02557061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/118/HP|Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers|Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers|TIL|University Hospital, Rouen|No|Active, not recruiting|April 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557061||12544|
NCT02557958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0769|Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study|Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study||New York University School of Medicine|No|Active, not recruiting|January 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|50 Years|N/A|No|||March 2016|March 4, 2016|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557958||12475|
NCT02551263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBC1505|Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer|Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer|E-SPEC|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Recruiting|July 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Female|20 Years|75 Years|No|Non-Probability Sample|Female patients with HER2-negative hormone-resistant inoperable or recurrent metastatic        breast cancer, who are scheduled to receive the first or second line chemotherapy in        clinical practice in Japan.|October 2015|October 25, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551263||12989|
NCT02556879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140315|Immunization Anti HLA in the Liver Transplant Recipients (DSATH)|Immunization Anti HLA in the Liver Transplant Recipients (DSATH)|DSATH|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|September 21, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02556879||12558|
NCT02556996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRRB A-7965|Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children|Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children||U.S. Army Medical Research and Materiel Command|Yes|Completed|October 1998|April 2002|Actual|March 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|356|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||October 2015|October 7, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556996||12549|
NCT02546401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 15-027|Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump|Comparison of Injection of an Analogue Bolus of Insulin Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump.|BOLUS|University Hospital, Brest|No|Recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546401||13363|
NCT02546648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POISE3034|PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study|PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study (POISE-3)|POISE-3|McMaster University|No|Recruiting|February 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|45 Years|N/A|No|||September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02546648||13344|
NCT02552745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012137|Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization|Sun Yat-sen University Cancer Center||Sun Yat-sen University|No|Completed|October 2014|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|65 Years|No|Non-Probability Sample|diagnosed with HCC according to the "primary liver cancer diagnosis and treatment        practices" published by the Ministry of Health in 2011 China.|January 2016|January 2, 2016|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552745||12875|
NCT02560129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00031295|MICU Recovery Clinic|Evaluation of Outcomes Following Critical Illness Through a MICU Recovery Clinic||Wake Forest School of Medicine|No|Recruiting|July 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Wake Forest MICU Survivors|September 2015|September 24, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560129||12308|
NCT02557009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044000EP|Changes in Hemodynamic Values With Posture|Changes in Hemodynamic Values With Posture||Milton S. Hershey Medical Center|No|Recruiting|October 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients at Hershey Medical Center having CABG and aortic valve surgery|September 2015|September 28, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557009||12548|
NCT02555644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16016|A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer|A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer||Eli Lilly and Company|No|Recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555644||12653|
NCT02546011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24511|The Monica Fetal Heart Monitor|The Monica External Fetal Heart Rate Monitor Compared to the Standard Fetal Heart Rate Monitor||St. Louis University|No|Recruiting|January 2014|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|13 Years|55 Years|No|Non-Probability Sample|The potential participants will be on the antepartum service so we will be providing them        with antepartum and obstetrical care clinically.|September 2015|September 9, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546011|1 Week|13393|
NCT02531061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208092|Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy|Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2013|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02531061||14538|
NCT02555358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alien Craft 0004|Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study|Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Multicenter, Open, Randomized, Controlled Clinical Study||Hebei Medical University|Yes|Recruiting|November 2014|December 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|60 Years|No|||September 2015|September 18, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02555358||12674|
NCT02551393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX-15-115(88-14)|Enhance Drug Compliance in Response to Home Blood Pressure(BP) Monitoring in Older People|Enhance Drug Compliance in Response to Home Blood Pressure(BP) Monitoring in Older People With Uncontrolled Hypertension: a Randomized Controlled Trial||The University of Hong Kong|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02551393||12979|
NCT02557802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC306C|T-cell Diversity Following Intranasal and Intramuscular Vaccines|Breadth of T-cell Responses After Heterologous Route Immunological Prime-boost Using Influenza Antigens as a Model System||University of Surrey|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557802||12487|
NCT02535546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeamontH|Seasonal Trends in Pneumococcal Carriage in COPD Patients|Characterisation of Isolates of Streptococcus Pneumoniae in Patients With Chronic Obstructive Pulmonary Disease|Helios|Beaumont Hospital|No|Active, not recruiting|July 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|Sputum|Both|18 Years|N/A|No|Non-Probability Sample|A combination of COPD inpatients and outpatients from Beaumont Hospital, Dublin, Ireland.|August 2015|August 26, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535546||14195|
NCT02555579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451-15-EP|Simplified Diet Approach in Phenylketonuria|Use of Dietary Protein and Free Fruits and Vegetables to Improve Metabolic Control Among Teens and Adults With Phenylketonuria: A Mixed Methods Approach||University of Nebraska|No|Not yet recruiting|September 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|65 Years|No|||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555579||12658|
NCT02548208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESWT_DOMS|Single Focused Shock Wave in the Release od Delayed Onset Muscle Soreness (DOMS)|Effect of a Single Administration of Focused Extracorporeal Shock Wave in the Relief of Delayed-Onset Muscle Soreness||Goethe University|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548208||13224|
NCT02547025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS13-CT12-17|Personalized Treatment for Refractory H Pylori Infection|Personalized Treatment for Refractory H Pylori Infection||Kaohsiung Veterans General Hospital.|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|90 Years|No|||September 2015|September 9, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02547025||13315|
NCT02533258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061076|Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice|Post-Marketing Surveillance Study To Observe Inlyta (Registered) Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice||Pfizer|No|Active, not recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1|||Both|18 Years|N/A|No|Non-Probability Sample|advanced renal cell carinoma with disease progression on sunitinib or interferon|March 2016|March 10, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02533258||14371|
NCT02556905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-RV-KR-001|A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea|REVLIMID® Drug Use Examination||Celgene|No|Recruiting|March 2011|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|All Korean patients who are intended to be treated with REVLIMID® and must be registered        in risk management program according to the approved package insert.|September 2015|September 21, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556905||12556|
NCT02549235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-183/2015|Morphological Characteristics Of Uteri With Three-dimensional Ultrasound At The Time Of Embryo Transfer|Morphological Characteristics Of Uteri With Three-dimensional Ultrasound At The Time Of Embryo Transfer and Correlation to Clinical Outcomes||Chinese University of Hong Kong|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|530|||Female|18 Years|42 Years|Accepts Healthy Volunteers|Probability Sample|Women with infertility undergoing IVF/ICSI and embryo transfer will be recruited from the        Assisted Reproductive Technology Unit of the department of Obstetrics and Gynaecological,        Prince of Wales Hospital|September 2015|September 15, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549235||13145|
NCT02549469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12656|Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily|A Pilot Four-Way Crossover Bioequivalence Trial of Sustained Release Forms of Naproxen Versus Aleve Tablets in Healthy Adult Subjects in a Fasted State||Bayer|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02549469||13127|
NCT02559440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81500772|Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy|Combination Therapy With Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy Concomitant With Allergic Rhinitis||Guangzhou Women and Children's Medical Center|Yes|Completed|February 2014|August 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|240|||Both|5 Years|11 Years|No|||September 2015|September 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559440||12361|
NCT02557295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 4.2|An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA|An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis||Celltrion|Yes|Recruiting|December 2013|June 2026|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|950|Samples Without DNA|Blood samples for immunogenicity should be retained at the central laboratory up to the End      of the Study, in case additional analysis is required. If additional analysis is not      required during the study or after the End of the Study, blood samples will be stored in a      CELLTRION, Inc. or designated biobank for a further 5 years (from the date the sample is      transferred to the CELLTRION, Inc. or biobank) unless a specific authorization is given by      CELLTRION, Inc.|Both|18 Years|N/A|No|Probability Sample|The study population will consist of at least 950 male and female patients with Rheumatoid        Arthritis|September 2015|February 15, 2016|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02557295|5 Years|12526|
NCT02557347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FO_in_PD|Fluid Overload in Peritoneal Dialysis|The Efficacy of Managing Fluid Overload in Peritoneal Dialysis Patient by a Structured Nurse-lead Intervention Protocol||Chinese University of Hong Kong|No|Active, not recruiting|June 2013|June 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557347||12522|
NCT02552966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201370|Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin|Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study||Northwestern University|No|Enrolling by invitation|September 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|90 Years|No|||September 2015|September 16, 2015|September 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552966||12858|
NCT02552979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si524/2011|Atopy Patch Test in Children With Atopic Dermatitis|Atopy Patch Test in Children With Atopic Dermatitis||Mahidol University|No|Completed|January 2012|September 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|56|||Both|1 Month|18 Years|No|Non-Probability Sample|children with atopic dermatitis|September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02552979||12857|
NCT02552355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8573H|Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin|Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin||Colorado State University|No|Recruiting|August 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|60|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552355||12905|
NCT02561312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-084|Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell|Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell||Chattanooga-Hamilton County Hospital Authority|No|Recruiting|August 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|8|||Both|3 Years|25 Years|No|Probability Sample|8 chronically exchanged transfused participants at T.C. Thompson Children's Infusion        Clinic with sickle cell disease (Hemoglobin SS or SBeta thalassemia) currently receiving        rapid manual partial exchange transfusion.|September 2015|September 24, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561312||12217|
NCT02547935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00023|A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabestes and CKD3|An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD3 Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB||AstraZeneca|No|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|74 Years|No|||March 2016|March 10, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547935||13245|
NCT02625857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107668|Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer|An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Metastatic Castration-resistant Prostate Cancer||Janssen Research & Development, LLC|No|Recruiting|December 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625857||7261|
NCT02613572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822310|Alpha Lipoic Acid in Geographic Atrophy|Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).|ALA|University of Pennsylvania|Yes|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|65|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613572||8205|
NCT02570763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508M77345|Combining Non-Invasive Brain Stimulation With Cognitive Behavioral Intervention in Substance Use Disorder|||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570763||11491|
NCT02617732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-TCM-TQGV-01|Effects of Tianqi Capsule on Glucose Variability in Patients With Type 2 Diabetes.|||Peking Union Medical College Hospital|No|Not yet recruiting|January 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||November 2015|November 25, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02617732||7885|
NCT02612714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-2005C|Statin Lowering Testosterone and Sexual Function|Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes||Chang Gung Memorial Hospital|No|Completed|July 2013|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|151|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02612714||8271|
NCT02615210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23154|Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures|Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures|SOCABS|Temple University|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|90 Years|No|||November 2015|November 23, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615210||8079|
NCT02536599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doc Inf FN Ped Onc|Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia|Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia||Assiut University|No|Recruiting|October 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients who have episodes of fever & neutropenia|March 2016|March 8, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536599||14114|
NCT02546141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53912.081.15|Postprandial Plasma Amino Acid Concentrations After Dairy Consumption|Postprandial Plasma Amino Acid Concentrations After Dairy Consumption|PARROT|NIZO Food Research|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|8||Actual|10|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546141||13383|
NCT02546609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-0200-01|The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease|A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients||NuSirt Biopharma|No|Recruiting|November 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546609||13347|
NCT02558361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00023672|Treatment With Apremilast in Patients With Psoriatic Arthritis|A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis||University of South Florida|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558361||12444|
NCT02558374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS304|Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension|||Aerie Pharmaceuticals||Recruiting|September 2015|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02558374||12443|
NCT02532751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204/13/03/02/15/1|Effects of Body Contouring Surgery in Obese Patients|Effects of Body Contouring Surgery in Obese Patients: a Prospective Study||Helsinki University Central Hospital|No|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 patients who underwent body contour surgery|August 2015|August 23, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02532751||14410|
NCT02553655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150648|Remote Ischemic Limb Preconditioning In Healthy Volunteers|Does Remote Ischemic Limb Preconditioning Improve Cerebral Vasomotor Reactivity in Healthy Volunteers?||University of Miami|No|Not yet recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02553655||12805|
NCT02553668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-109|Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression|Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression||University Hospital of Cologne|No|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02553668||12804|
NCT02557373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-5744H|Pilot Feasibility of Rice Bran Supplementation in Children|Pilot Feasibility of Rice Bran Supplementation for Diarrheal Disease Prevention in Malian Children||Colorado State University|No|Recruiting|August 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|50|||Both|4 Months|10 Months|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02557373||12520|
NCT02548026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7439|Meals and Grazing Study|Meals and Grazing Study|MAGS|Fred Hutchinson Cancer Research Center|No|Completed|January 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02548026||13238|
NCT02533024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ulnar-Neuropathy-ULE|Preoperative Prevalence of Ulnar Neuropathy and Changes in Ulnar Nerve Latency During Surgery|Preoperative Prevalence of Ulnar Neuropathy and Changes in Ulnar Nerve Latency During Surgery||University of Toledo Health Science Campus|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|50 Years|N/A|No|||August 2015|August 21, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02533024||14389|
NCT02553915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT008857-01|Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach|Omega-3 Fatty Acids for MDD With High Inflammation: A Personalized Approach||Massachusetts General Hospital|Yes|Not yet recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553915||12785|
NCT02553928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14603A|Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18|Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18||H. Lundbeck A/S|Yes|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||October 2015|October 23, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553928||12784|
NCT02549911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISA|HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis|Hyperthermic Intraperitoneal Chemotherapy, Intravenous Chemotherapy Combined With Surgery for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis||Zhejiang Cancer Hospital|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||September 2015|September 14, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02549911||13093|
NCT02548260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301/15|Treatment of Proximal Interphalangeal Joint Injuries. Clinical Efficiency of Syndactyly Treatment and Digital Compression|Treatment of Proximal Interphalangeal Joint Injuries. Comparative Study of the Clinical Efficiency and Cost of Syndactyly Treatment Versus Immobilization and Compression Versus no Compression||Centre Hospitalier Universitaire Vaudois|Yes|Not yet recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02548260||13220|
NCT02544529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPS 001|Echothiophate Iodide for the Prevention of Progression of Myopia|Echothiophate Iodide for the Prevention of Progression of Myopia||Danbury Eye Physicians & Surgeons, PC|No|Not yet recruiting|June 2016|October 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|33|||Both|9 Years|15 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544529||13507|
NCT02556892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107620|A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Janssen Pharmaceutical K.K.|No|Active, not recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||March 2016|March 8, 2016|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556892||12557|
NCT02550145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29010|Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery|The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery||Stanford University|Yes|Recruiting|February 2014|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550145||13075|
NCT02558036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178075|Optimal Head and Neck Position During Videolaryngoscopy|Optimal Head and Neck Position for Intubation During Videolaryngoscopy: Comparison Between "Sniffing" and Neutral Position Using Channelled and Non-channelled Videolaryngoscopes||University Hospitals Coventry and Warwickshire NHS Trust|No|Recruiting|January 2016|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|85 Years|No|||March 2016|March 9, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558036||12469|
NCT02558049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4393|Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid|Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid||University of Ottawa|No|Active, not recruiting|November 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|54|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02558049||12468|
NCT02551549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD101.IV.1.02|An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects||Cidara Therapeutics Inc.|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02551549||12967|
NCT02547662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1487|Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia|Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia||Mayo Clinic|Yes|Recruiting|December 2015|||December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547662||13266|
NCT02551445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIEF-2011-299232|A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders.|A fMRI Pilot Study of the Effects of Cognitive Behavioural Therapy (Meal-support) in Eating Disorders.|ET4AN|King's College London|No|Completed|September 2011|September 2014|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|19 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551445||12975|
NCT02554058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bannatyne2010:157|Combined Tactile and Proprioception Training After Spinal Cord Injury|Phase 1 Effects of Training With a Novel Rehabilitation Bike on the Functional Recovery and Corticospinal Plasticity in Individuals With Incomplete Spinal Cord Injuries||University of Manitoba|Yes|Recruiting|May 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02554058||12774|
NCT02549339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1194|Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up|Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up||LEO Pharma|No|Recruiting|November 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549339||13137|
NCT02547896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30880914.1.0000.5417|Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction.|Effectiveness of Non-steroidal Anti-inflammatory Diclofenac and Its Association to the Opioid Codeine for Pain, Swelling and Trismus in the Bilateral Mandibular Third Molar Extraction With a High Degree of Difficulty Model.||University of Sao Paulo|Yes|Completed|September 2014|September 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02547896||13248|
NCT02548156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204777|Intra Oral Kinetics of Fluoride Containing Dentifrices in a Modified Saliva Clearance Study|Intra-oral Kinetics of Fluoride Containing Dentifrices in a Modified Saliva Clearance Study||GlaxoSmithKline|No|Not yet recruiting|September 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548156||13228|
NCT02551692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063505|Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)|Effects of Smoking Environments on Craving and Smoking||Duke University|No|Not yet recruiting|September 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551692||12956|
NCT02556086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-378|A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)|A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)||Bristol-Myers Squibb|No|Withdrawn|December 2015|July 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|January 19, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556086||12619|
NCT02554084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52165|Optical Coherence Tomography of Tear Film Dynamics In-Vivo|Optical Coherence Tomography of Tear Film Dynamics In-Vivo||University of Rochester|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02554084||12772|
NCT02550548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065698|Incretin Action in Physiology and Diabetes|Incretin Action in Physiology and Diabetes||Duke University|Yes|Not yet recruiting|March 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|February 10, 2016|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02550548||13044|
NCT02545725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57073|Quality of Life in Colorectal (ex-)Cancer Patients, Based on the Belgian Cancer Registry.|Quality of Life in (ex-)Cancer Patients, Based on the Belgian Cancer Registry. Pilot Study: Quality of Life in Colorectal (ex-)Cancer Patients.|QOLColorect|Belgian Cancer Registry|No|Completed|April 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1220|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients of colorectal cancer (ICD-10: C18-C19-C20) with incidence in 2008-2010 were        selected for this study. Patients are at least 18 years old at diagnosis and maximal 90        years old when completing the questionnaire.        Patients are living in Flanders, speak Dutch and are followed in 1 of the 7 participating        hospitals.        The patients are able to complete the questionnaire themselves: patients with cognitive        problems are excluded.|September 2015|September 8, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02545725||13415|
NCT02552225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 34438|Treatment of Chronic Laryngitis With Amitriptyline|Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline||Boston Medical Center|Yes|Not yet recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|64 Years|No|||September 2015|September 15, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552225||12915|
NCT02552238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-142|Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142|A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease||Bracco Diagnostics, Inc|No|Recruiting|October 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|175|||Both|18 Years|N/A|No|||July 2015|November 2, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552238||12914|
NCT02559648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EL-THOS-001|Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis|Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial||Laikon General District Hospital, Athens|No|Recruiting|September 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|N/A|No|||September 2015|September 24, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559648||12345|
NCT02546193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008988|Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction|Outpatient Foley Catheter Compared to Usual Inpatient Care for Cervical Ripening: A Randomized Controlled Trial||Mayo Clinic|No|Enrolling by invitation|September 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|N/A|N/A|No|||September 2015|September 8, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546193||13379|
NCT02550652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29748|A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN)|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis||Hoffmann-La Roche||Recruiting|November 2015|April 2019|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550652||13036|
NCT02548507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMI|Nocturnal Leg Cramps in Geneva : an Observational Study|Prevalence, Main Features and Treatment of Nocturnal Leg Cramps in Geneva: A Primary Care Prospective Observational Study|CNMI|University of Geneva, Switzerland|No|Recruiting|March 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|50 Years|N/A|No|Non-Probability Sample|Patients of 50 years old or more, consulting primary care physicians in Geneva|September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02548507|3 Weeks|13201|
NCT02551276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL-STYRKE|Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy|Role of 11 Weeks of Beta2-adrenergic Signaling and Resistance Training for Cardiac and Skeletal Muscle Hypertrophy in Men||University of Copenhagen|No|Completed|November 2013|November 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|42|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02551276||12988|
NCT02546869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB29906|A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting|||Hoffmann-La Roche||Suspended|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546869||13327|
NCT02550912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD(NO.18)|A Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children|A Pilot Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children||Ain Shams University|Yes|Recruiting|August 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|15 Years|No|||September 2015|September 14, 2015|September 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02550912||13016|
NCT02555423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179669|The Effects of Serratus Plane Block Performed Under Direct Vision on Post-operative Pain in Breast Surgery|||Kingston Hospital NHS Trust||Not yet recruiting|October 2015|||April 2017|Anticipated|N/A|Interventional|Primary Purpose: Supportive Care|||||||Female|18 Years|N/A||||September 2015|September 18, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555423||12669|
NCT02557672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009579|PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding|Prothrombin Complex Concentrate Compared to Fresh Frozen Plasma for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.||Mayo Clinic|No|Not yet recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557672||12497|
NCT02557685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16216|Gut Microbiota Changes After Fecal Microbiota Transplantation|Alterations in Gut Microbiota and Metabolism Following FMT for Recurrent C. Difficile Infection||The Miriam Hospital|Yes|Recruiting|June 2015|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557685||12496|
NCT02530827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 01848612.1.0000.5440|Energy Expenditure of People Living With HIV/AIDS|Influence of Lipid-lowering Drugs in Patients Seropositive for HIV With Lipodystrophy in Resting Energy Expenditure and Total Energy Expenditure||University of Sao Paulo General Hospital|Yes|Completed|March 2013|November 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|45|Samples With DNA|urine.|Male|18 Years|60 Years|No|Probability Sample|Men previously diagnosed with HIV infection, on antiretroviral therapy.|August 2015|August 20, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02530827||14556|
NCT02535013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507-062-687|Intraoperative Lung Ultrasound in Pediatric Patients|Benefit of Intraoperative Lung Ultrasound in Pediatric Patients Undergoing Cardiac Surgery|LUS|Seoul National University Hospital|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|122|||Both|N/A|5 Years|No|||September 2015|September 29, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535013||14236|
NCT02547129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003291|Static vs. Articulating Antibiotic Spacer for PJI in TKA|A Randomized Clinical Trial of Static Versus Articulating Antibiotic Spacer for Treatment of Periprosthetic Joint Infection in Total Knee Arthroplasty||Mayo Clinic|No|Enrolling by invitation|September 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02547129||13307|
NCT02547376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 11353|Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas|Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas||University Hospitals, Leicester|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Soft tissue sarcoma tissue Blood (Plasma and Buffy coat) Saliva|Both|18 Years|N/A|No|Non-Probability Sample|Patient managed by East Midland Sarcoma Service with Soft Tissue Sarcoma undergoing        attempted curative resection|September 2015|September 11, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02547376||13288|
NCT02558907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoCA|Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology|Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology|MoCA|Centre Francois Baclesse|No|Recruiting|September 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|66|||Both|71 Years|N/A|No|Probability Sample|aged patients with 1st line treatment of their cancer will be received an examination        oncogériatric|September 2015|September 23, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02558907||12402|
NCT02558959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYMedOncoBIL01|Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer|Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study||Zhejiang University||Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|75 Years|No|||November 2015|November 29, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02558959||12398|
NCT02549963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCI 201501|Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban|A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation||Guangdong General Hospital|Yes|Not yet recruiting|October 2015|||October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02549963||13089|
NCT02535273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tangdu-dex-loc|The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia|The Effect of Dexmedetomidine Subsidiary Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia：A Randomized, Double Blind Controlled Trial||Tang-Du Hospital|No|Not yet recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|212|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02535273||14216|
NCT02535286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-UPCC-108|Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL|Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL)||TG Therapeutics, Inc.|No|Recruiting|September 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535286||14215|
NCT02560090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038334|Bamberg Diabetes Transitional Care Pilot Study|Transforming Patient-Centered Medical Homes Into Medical Communities for Underserved Rural Patients||Medical University of South Carolina|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|65|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02560090||12311|
NCT02560103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPN-VEC-162-0101|An Observational Study to Investigate the Effects of Rapid Transmeridian Travel|An Observational Study to Investigate the Effects of Rapid Travel||Vanda Pharmaceuticals|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|October 2015|October 9, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02560103||12310|
NCT02555865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHlung002|Aetiology of Children With Bronchiectasis in China|Aetiology of Children With Bronchiectasis in China--A Multicenter Retrospective Study||Beijing Children's Hospital|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|Children who was confirmed diagnosis as bronchiectasis at the certain hospitals (sponsor        and collaborators)|November 2015|November 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02555865||12636|
NCT02546258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPD810|Evaluation of the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis|A Prospective, Open Label, Non-comparative Clinical Investigation to Evaluate the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis||Reckitt Benckiser Healthcare (UK) Limited|No|Recruiting|November 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02546258||13374|
NCT02543749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ADE60|DC Vaccination in CML|Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia||Charite University, Berlin, Germany|No|Recruiting|July 2014|January 2019|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02543749||13567|
NCT02543801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2022|A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty|A Prospective, Randomized Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty||Kootenai Health|No|Enrolling by invitation|January 2016|January 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|30 Years|85 Years|No|||January 2016|January 22, 2016|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543801||13563|
NCT02543814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-US-01-DIMESOL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||January 20, 2016|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02543814||13562|
NCT02560142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29791|A Non-interventional Functional Magnetic Resonance Imaging Study and Behavioral Assessment in Healthy Participants|||Hoffmann-La Roche||Active, not recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|Whole blood for DNA extraction|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female participants 18 to 45 years old (inclusive).|December 2015|December 18, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02560142||12307|
NCT02552459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstSunYetSen-jn2015|Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery|Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02552459||12897|
NCT02557087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-HBB|Hyoscine ButylBromide for Intrapartum Analgesia|Efficacy of Intravenous Hyoscine ButylBromide as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial||Ain Shams Maternity Hospital|Yes|Not yet recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|104|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557087||12542|
NCT02551510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4164-07/14|Comparison of Skin Adhesive to Subcuticular Suture Wound Closure After Port Placement|Open, Randomized, Controlled Non-inferiority Trial to Compare Synthetic Tissue Adhesive and Skin Suture After Port Catheter Implantation With Reference to Cosmetic Result and Economy of Time at Equal Risk for Wound Infection|PWC|Jena University Hospital|No|Recruiting|August 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02551510||12970|
NCT02553577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA040694-01|Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes|The Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes in Appalachia||University of Kentucky|Yes|Not yet recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|360|Samples With DNA|Serum cytokines: interleukin (IL) IL-1α, IL1β, IL-6, IL-8, IL-10, CRP, TNFα and MMP-8      Urinary Cotinine Urinary ( NNAL) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and      its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol Expired Carbon Monoxide|Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant and postpartum women, age 18-44 who use tobacco products (traditional cigarettes,        ENDS, electronic cigarettes)|September 2015|September 16, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02553577||12811|
NCT02553590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF 2B/Titra/2014/D|Tolerability of SLIT With LAIS® 2-Tree Allergoid Tablets|Non-Interventional Study (NIS) on the Tolerability of Sublingual Immunotherapy With LAIS® 2-Tree Tablets in Consideration of the Chosen Titration Schedule in Everyday Practice||University Hospital of Cologne|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|160|||Both|5 Years|N/A|No|Non-Probability Sample|Patients aged 5 years or older can be enrolled in the NIS if sublingual specific        immunotherapy has been indicated due to allergic rhinoconjunctivitis or allergic bronchial        asthma induced by the allergens to be investigated (birch and/or alder).|November 2015|November 10, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02553590||12810|
NCT02545907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/0786|A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis|A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis|CATALYST|University College, London|No|Not yet recruiting|October 2015|April 2018|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02545907||13401|
NCT02553213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studie_ECODO|Early Changes of Diabetes Parameters After Obesity Therapy|Early Changes of Diabetes Parameters After Obesity Therapy|ECODO|University of Hohenheim|No|Recruiting|July 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02553213||12839|
NCT02547558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IndaEPOC|Pulmonary Gas Exchange Response to Indacaterol in COPD|Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients||Hospital Clinic of Barcelona|No|Not yet recruiting|October 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|80 Years|No|||September 2015|September 10, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02547558||13274|
NCT02547857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 14-3918|Transvaginal Pelvic Ultrasound in the ED|Transvaginal Pelvic Ultrasound in the ED||Minneapolis Medical Research Foundation|No|Recruiting|September 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Female|18 Years|N/A|No|Probability Sample|Adult women for whom bedside transvaginal US is planned by their treating physician will        be assessed for eligibility.|March 2016|March 14, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02547857||13251|
NCT02546388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001421|Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis|Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis||Brigham and Women's Hospital|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|90 Years|No|||September 2015|September 9, 2015|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546388||13364|
NCT02550119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-06-1|Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy|A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU.||University of Southern California|Yes|Terminated|April 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|19|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 13, 2015||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT02550119||13077|
NCT02545244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDCH/2015-16/1107|Effectiveness of Black Tea Mouthwash on Plaque Formation|"Effectiveness of Black Tea Mouthwash on Plaque Formation:A Randomized Controlled Clinical Trial"|Blacktea|Sri Hasanamba Dental College and Hospital|Yes|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545244||13452|
NCT02545543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-QIV-13-02|A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population Aged 5 Through to 17 Years of Age|A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a bioCSL Quadrivalent Inactivated Influenza Virus Vaccine (bioCSL QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age||bioCSL PTY LTD|Yes|Active, not recruiting|September 2015|July 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2278|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02545543||13429|
NCT02560181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clinicaltrials_hchu_180-2014|Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer|Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer||Sunnybrook Health Sciences Centre|Yes|Recruiting|August 2014|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|N/A|N/A|No|||September 2015|September 24, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02560181||12304|
NCT02560194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ON22|Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland|Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland - A Random Evaluation||University of Dundee|No|Recruiting|June 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|59 Years|61 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02560194||12303|
NCT02555345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RZ-689|Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis|Difference in Gene Expression Profile in Peripheral Blood Mononuclear Cells and Inflammation Profile in Patients With Classic Asthma, Cough Variant Asthma, and Eosinophilic Bronchitis Compared With Healthy Controls||State Key Laboratory of Respiratory Disease|No|Recruiting|October 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|250|Samples With DNA|Blood sample collection for future analysis (including genetic tests on DNA) on the      pathobiology of diseases.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All of subjects with classic asthma, CVA, eosinophilic bronchitis, and healthy volunteers        are recruited from respiratory outpatient clinics and from staff at the First Affiliated        Hospital of Guangzhou Medical College between October 25, 2014 and January 20,2016.|September 2015|September 17, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02555345||12675|
NCT02548195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gemoxicc|Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma|Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma||Shanghai Zhongshan Hospital|No|Recruiting|July 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|286|||Both|18 Years|70 Years|No|||September 2015|September 11, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02548195||13225|
NCT02561221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-052|Promoting Successful Weight Loss in Primary Care in Louisiana|Promoting Successful Weight Loss in Primary Care in Louisiana|PROPEL|Pennington Biomedical Research Center|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1080|||Both|20 Years|75 Years|No|||February 2016|February 4, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561221||12224|
NCT02618343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-859H|EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron|A Randomized Control Equivalence Study of Emergency Medical Services Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron for Treatment of Pre-hospital Nausea||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|March 2016|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|99 Years|No|||December 2015|December 2, 2015|November 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618343||7839|
NCT02573155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6640C00001|Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects|A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects||AstraZeneca|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|18||Anticipated|56|||Both|18 Years|130 Years|No|||March 2016|March 7, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573155||11307|
NCT02573168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCITE-013304-ARX1010.PTL|Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Schizophrenia/Schizoaffective Disorder|A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Patients Suffering From Schizophrenia/Schizoaffective Disorder||St. Joseph's Healthcare Hamilton|Yes|Recruiting|November 2015|September 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|531|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573168||11306|
NCT02621268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820766|Minimally Invasive Imagery With Indocyanine Green|A Pilot & Feasibility Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Minimally Invasive Thoracic Surgery Presenting With Thoracic Nodules|ICG|University of Pennsylvania|Yes|Recruiting|November 2014|February 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621268||7614|
NCT02626806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZL9281|Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease|Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease|EUROCAD|Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Blood samples|Both|18 Years|99 Years|No|Non-Probability Sample|To compare hs-TnT levels after a cardiac stress test in patients with vs. patients without        CAD|December 2015|December 8, 2015|April 1, 2014||No||No||https://clinicaltrials.gov/show/NCT02626806||7188|
NCT02617329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20140137|Extracorporeal Therapy on Shoulder and Neck Pain|Effects of Extracorporeal Shock Wave Therapy on Shoulder and Neck Pain||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|20 Years|45 Years|No|||August 2015|November 25, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02617329||7916|
NCT02620449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150728005|Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults|Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults (Phosphate and Fibroblast Growth Factor 23 [FGF23]: Dietary and Molecular Mediators of Health and Disparities in Cardiovascular and Kidney Diseases)||University of Alabama at Birmingham|No|Recruiting|August 2015|December 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02620449||7677|
NCT02547532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fsalvatoremaugeri|Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency|Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency|AATD|Fondazione Salvatore Maugeri|No|Not yet recruiting|September 2015|October 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Normal volunterrs Patients with COPD without AATD Patients with COPD and with AATD|September 2015|September 9, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547532||13276|
NCT02544399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801092|Bone Microarchitecture in Women Practicing Golf|Is Golf a Sport Suited to the Female Skeleton After 60 Years? Pilot Study Evaluating the Microarchitecture 3D Carriers and Noncarriers Bones||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|67|Samples Without DNA|Blood sample|Female|60 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject practicing foot walk or golf or sedentary|September 2015|September 8, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02544399||13517|
NCT02544412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1263|A Well-being Training for Preservice Teachers|A Well-being Training for Preservice Teachers|PST|University of Wisconsin, Madison|No|Active, not recruiting|September 2015|September 2020|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02544412||13516|
NCT02550574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|773443|Use of 2-octylcyanoacrylate With Full-thickness Skin Grafts|Use of 2-octylcyanoacrylate (Dermabond) During Cutaneous Wound Closure With Full-thickness Skin Grafts: a Randomized Split Wound Comparative Effectiveness Trial||University of California, Davis|No|Active, not recruiting|August 2015|August 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02550574||13042|
NCT02550587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erzincan Mengücek Gazi|Patient Satisfaction With Anesthesia Care|Satisfaction Rate of Patients Receiving Anesthesia in the First Half of 2015, in Erzincan||Cukurova University|No|Active, not recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|8000|||Both|18 Years|65 Years|No|Probability Sample|Patients undergoing anesthesia in Erzincan|February 2016|February 29, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02550587||13041|
NCT02545192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001621|A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments|A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments|LFMS in PTSD|Mclean Hospital|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|65 Years|No|||September 2015|September 8, 2015|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02545192||13456|
NCT02545205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-RCT-Phase III-Study I|New Technology for Individualised, Intensive Training of Gait After Stroke|New Technology for Individualised, Intensive Training of Gait After Stroke- Phase III Trials, Study I|HAL-RCT-I|Danderyd Hospital|No|Not yet recruiting|August 2016|January 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02545205||13455|
NCT02547779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 141349|Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)|Isotonic Solutions and Major Adverse Renal Events Trial in Non-Medical Intensive Care Units|SMART-SURG|Vanderbilt University|Yes|Recruiting|October 2015|July 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5000|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547779||13257|
NCT02544438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BST-PHASE1-01|Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|a Phase i/Iia, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BSR-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease|BSTPHASE1-01|BioSight Ltd.|Yes|Recruiting|September 2015|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 27, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02544438||13514|
NCT02544464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KonkukUMC|Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?|Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?||Konkuk University Medical Center|Yes|Not yet recruiting|November 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|19 Years|N/A|No|||October 2015|October 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02544464||13512|
NCT02556684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSGILAB001|Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|A Prospective Study to Evaluate Dynamic Breast-Specific Gamma Imaging in Monitoring Tumor Responses in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|BSGILAB|Zhejiang University|Yes|Recruiting|September 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|70 Years|No|Probability Sample|Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|January 2016|January 12, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02556684||12573|
NCT02545491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.DS.03|Implementation and Adoption of Care for Child Development in Day Care Centers|Implementation of Care for Child Development and Implications on Early Childhood Development: A Pilot Study in Lebanon||American University of Beirut Medical Center|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|456|||Both|N/A|3 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02545491||13433|
NCT02552251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-059|COrticosteroid in Congenital Adrenal Hyperplasia|Comparative Study of the Use of Glucocorticoids in the Treatment of Congenital Adrenal Hyperplasia in Its Classical Form|COCA|University Hospital, Caen|No|Recruiting|August 2012|||December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|40|||Female|18 Years|55 Years|No|||September 2015|September 15, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02552251||12913|
NCT02556762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-EC-002|Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer|Phase III Randomized Controlled Trial of Definite Chemoradiotherapy in Patients With Esophageal Cancer: Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy|SUMC-EC-002|Shantou University Medical College|No|Recruiting|August 2015|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|202|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02556762||12567|
NCT02556775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161301|Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia (Immune Globulin (Human) 10% With rHuPH20)|Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia (Immune Globulin (Human) 10% With rHuPH20)||Baxalta US Inc.|No|Recruiting|December 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood samples (plasma) for antibodies against recombinant human hyaluronidase (rHuPH20) that      remain after study testing is done may be stored and used for additional testing (eg,      further evaluation of an abnormal test or an adverse event). Samples will be stored in a      coded form for a maximum of 2 years after the final study report has been completed and,      subsequently, will be destroyed.|Female|N/A|N/A|No|Non-Probability Sample|Women who became pregnant after ever treated with HYQVIA, and their infant children|March 2016|March 22, 2016|June 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02556775|33 Months|12566|
NCT02552511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU6|Epidemiology Study on Neonatal Seizure|A Multi-Centre Epidemiology Study on Neonatal Seizure in China||Children's Hospital of Fudan University|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1400|||Both|N/A|28 Days|No|Probability Sample|All inpatients and Outpatients of neonates|March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02552511||12893|
NCT02530268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corrona-SPA-400|The Corrona, LLC Spondyloarthritis and Psoriatic Arthritis (SpA/PsA) Registry|Spondyloarthritis and Psoriatic Arthritis (SpA/PsA) Registry||The Consortium of Rheumatology Researchers of North America, Inc.|No|Enrolling by invitation|March 2013|December 2100|Anticipated|December 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are enrolled in the Spondyloarthritis and Psoriatic Arthritis Registry during        regularly-scheduled office visits. Selected rheumatologists are invited to participate as        investigators in the Registry. Physicians are selected carefully in an effort to ensure        enrollment of subjects that represent a reasonable representation of a cross-section of        the population throughout the country with rheumatic diseases. All potential sites are        screened for clinical research experience and adherence to GCP (Good Clinical Practice)        guidelines.|August 2015|August 19, 2015|May 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02530268|8 Years|14599|
NCT02530281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM04-HH04|Study of DRM04 in Axillary Hyperhydrosis|A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects With Axillary Hyperhydrosis||Dermira, Inc.|No|Active, not recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|344|||Both|9 Years|N/A|No|||March 2016|March 9, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530281||14598|
NCT02547402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA-10-203|A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males|An Open-label Exploratory Study of the Pharmacokinetic Interaction of CXA-10 Administered to Steady State With Pravastatin and Vytorin® (Simvastatin and Ezetimibe) in Healthy Males|DDI|Complexa, Inc.|No|Enrolling by invitation|September 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|19 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547402||13286|
NCT02554929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000050447|Treatment of Social Anxiety Disorder and Selective Mutism|Efficacy of a Group Cognitive Behavioral Therapy Program in the Treatment of Young Children With Social Anxiety Disorder and/or Selective Mutism: A Randomized Controlled Trial|SAD & SM TRMT|The Hospital for Sick Children|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|4 Years|7 Years|No|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554929||12707|
NCT02559063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR015452|Vision-based Speed of Processing Cognitive Training and Mild Cognitive Impairment|Neurophysiological Aspects of Vision-based Speed of Processing Cognitive Training in Older Adults With Mild Cognitive Impairment||University of Rochester|Yes|Not yet recruiting|October 2015|August 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559063||12390|
NCT02545270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vallap01|Validation of a Subjective Rating Scale for Assessment of the Surgical Workspace in Laparoscopy|Validation of a Subjective Rating Scale for Assessment of the Surgical Workspace in Laparoscopy||Herlev Hospital|Yes|Not yet recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02545270||13450|
NCT02554474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01843|OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis|Effective of Online Physical Activity Monitoring in Inflammatory Arthritis (OPAM-IA): A New Model of Care||University of British Columbia||Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|19 Years|N/A|No|||September 2015|September 29, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554474||12742|
NCT02554487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016/15|Early Sleep Apnea Treatment in Stroke|Early Sleep Apnea Treatment in Stroke: A Randomized, Rater-Blinded, Clinical Trial of Adaptive Servo-Ventilation|eSATIS|University Hospital Inselspital, Berne|No|Recruiting|August 2015|July 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|80 Years|No|||September 2015|September 16, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02554487||12741|
NCT02551614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201463|Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease|Measurement of Neutrophil Retention in the Lung in Vivo, Using Autologous Labelled Neutrophils, in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|46|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551614||12962|
NCT02551627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204476|A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children|Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children (7-10yrs; Inclusive) in Bangladesh: a Randomised, Double Blind Controlled Trial||GlaxoSmithKline|No|Not yet recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|396|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551627||12961|
NCT02551640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000765|Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients|Improving Physical Activity Behavior in Patients With High Cardio-metabolic Risk Using a Multi-modal mHealth Intervention: a 2-arm Randomized Controlled Trial||Massachusetts General Hospital|No|Enrolling by invitation|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02551640||12960|
NCT02555891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287245-HPM-BRUY-46830|The PIP-STOPP Study|Assessing Potentially Inappropriate Prescribing (PIP) and Predicting Patient Outcomes in Ontario's Elderly Population Using the Modified STOPP Criteria in Large Administrative Health Databases (the PIP-STOPP Study)|PIP-STOPP|Bruyere Research Institute|No|Active, not recruiting|September 2014|||March 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2000000|||Both|66 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients included in the study will be all OHIP (Ontario Health Insurance Plan) eligible        patients, 66 years of age or older and receiving at least one prescription medication        during study accrual period.|September 2015|September 21, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555891||12634|
NCT02558894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4198C00001|Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma|A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma||AstraZeneca|No|Recruiting|November 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558894||12403|
NCT02545595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBRITI|Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients|||Poitiers University Hospital||Completed|May 2012|||December 2013|Actual|Phase 2|Interventional|N/A|3||||||Both|18 Years|80 Years|No|||September 2015|September 9, 2015|March 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02545595||13425|
NCT02554162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chewy|Chewy Satiety - the Interplay Between Food Structure, Oral Processing and Satiety|Chewy Satiety - the Interplay Between Food Structure, Oral Processing and Satiety||VTT Technical Research Centre of Finland||Active, not recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|20|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554162||12766|
NCT02551874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-369|A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy|A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy||Bristol-Myers Squibb|No|Recruiting|October 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|598|||Both|18 Years|N/A|No|||October 2015|February 25, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551874||12942|
NCT02556099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2875 EXTEND|EXTEND EXpanding Treatment for Existing Neurological Disease|EXpanding Treatment for Existing Neurological Disease (EXTEND)||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|August 2014|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|2 Years|17 Years|No|||September 2015|September 18, 2015|May 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02556099||12618|
NCT02559869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000140|Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis|Imaging and BioFluid Biomarkers in Amytrophic Lateral Sclerosis|TRACK-ALS|Massachusetts General Hospital|No|Recruiting|November 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|iPSC Line Generation, DNA, Inflammatory Markers, Plasma, CSF|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 200 subjects will be screened and approximately 100 subjects will be        enrolled. Fifty (50) subjects will be diagnosed with possible, probable, probable-lab        supported, or definite ALS, fifty (50) subjects will have no known neurological disease.|December 2015|December 30, 2015|September 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02559869||12328|
NCT02554266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0024-01|Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries|A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) Catheter for Treatment of Below-the-Knee (BTK) Arteries|BTKRegistry|C. R. Bard|No|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 4|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll patients presenting with claudication, or critical limb ischemia        (Rutherford Category 3- 5) and an angiographically significant (≥ 70%) native artery        lesion appropriate for angioplasty that is below the knee.|November 2015|November 2, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02554266|24 Months|12758|
NCT02550132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQTR-2013-SMTrate|The Role of the Rate of Force Application in Responses to Spinal Manipulation Therapy|Neuromechanical Response to Spinal Manipulation Therapy: Effects of a Constant Rate of Force Application||Université du Québec à Trois-Rivières|No|Completed|June 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|September 8, 2015||No||No|December 2, 2015|https://clinicaltrials.gov/show/NCT02550132||13076|
NCT02550379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-41-Fitzgerald|Emotion Recognition Training for Young People|Emotion Recognition Training for Socially Anxious Adolescents: A Randomized Controlled Trial||University College Dublin|No|Enrolling by invitation|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550379||13057|
NCT02530255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-003-AD|Telomerase Activator and Retinal Amyloid|Evaluation of an Oral Telomerase Activator on Retinal Amyloid||Chippewa Valley Eye Clinic|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02530255||14600|
NCT02546336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP RFD|Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation|Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation: A Prospective Pilot Study||Women's College Hospital|No|Recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||December 2015|December 11, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02546336||13368|
NCT02546596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YURO-H1|The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer|The Effect of Electro-hyperthermia in Preoperative Radiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer: Phase II Single Institutional Study||Yonsei Hyperthermia Study Group|Yes|Recruiting|April 2014|February 2022|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|19 Years|85 Years|No|||September 2015|September 8, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02546596||13348|
NCT02550899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIDS|Polyacrylamide Hydrogel Injection Treatment for Anal Incontinence|Polyacrylamide Hydrogel Injection Treatment for Anal Incontinence||Karolinska Institutet|No|Completed|January 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Female|18 Years|N/A|No|||January 2016|January 9, 2016|September 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02550899||13017|
NCT02552498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/2013|Post Occlusive Reactive Hyperemia on Gingiva Assessed by Laser Speckle Contrast Imaging|||Semmelweis University|No|Not yet recruiting|October 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552498||12894|
NCT02560077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 531319|Effect of Cashew Apple Juice on the Physiological and Psychological Fitness in the Middle Aged and Elderly Volunteers|Study the Effect of Cashew Apple Juice on the Physiological and Psychological Fitness in the Middle Aged and Elderly Volunteers||Khon Kaen University|Yes|Completed|December 2010|December 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02560077||12312|
NCT02550847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407052MINC|Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer|Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer||National Taiwan University Hospital|No|Recruiting|August 2014|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|90 Years|No|Non-Probability Sample|This study will include 100 consecutive patients (around 100 newly diagnosed patients per        year at NTUH) presenting with suspect pancreatic cancer for treatment.|September 2015|September 15, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02550847||13021|
NCT02551094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIPS-003|Colchicine Cardiovascular Outcomes Trial (COLCOT)|Colchicine Cardiovascular Outcomes Trial|COLCOT|Montreal Heart Institute|Yes|Recruiting|September 2015|September 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4500|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551094||13002|
NCT02558855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01151512|The Effects of Thrust Joint Manipulation on the Resting and Contracting Thickness of Transversus Abdominis in Subjects With Low Back Pain|The Effects of Thrust Joint Manipulation on the Resting and Contracting Thickness of Transversus Abdominis in Subjects With Low Back Pain||Nova Southeastern University|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558855||12406|
NCT02545790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0635|Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions|Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions|LVOTO|University of Colorado, Denver|No|Recruiting|August 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|Samples With DNA|Plasma and tissue samples from patients will be stored for the duration of the study.      Patients may choose to consent to have these samples stores beyond the completion of primary      analysis for testing in future studies.|Both|N/A|18 Years|No|Non-Probability Sample|Potential subjects will be identified from the cardiac surgical and clinic schedules at        Children's Hospital Colorado (CHCO).|March 2016|March 18, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545790||13410|
NCT02535026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25371|An Observational Study on HER2 Status of Breast Invasive Carcinoma in Latin American Participants|Epidemiological, Prospective and Observational Study on the HER2 Status in Breast Invasive Carcinomas Assessed by Immunohistochemistry (IHC) and Silver In-situ Hybridization (SISH) in a Sample of Latin-American Patients||Hoffmann-La Roche||Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|580|||Female|18 Years|N/A|No|Non-Probability Sample|Breast tissue samples from female participants with a breast cancer diagnosis that undergo        an anatomopathological examination of surgical specimens and/or core needle biopsies when        surgery is not possible.|March 2016|March 1, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02535026||14235|
NCT02551107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-LR-01|Infant Nasal Nitric Oxide Levels in Congenital Heart Disease|Nasal Nitric Oxide Levels in Infants With and Without Congenital Heart Disease||University of Alberta|No|Recruiting|September 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|N/A|1 Year|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02551107||13001|
NCT02551341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEEP-1|Lung Protective Ventilation During Robotic Assisted Prostatectomy|Randomized Study To Study the Effect of Lung Protective Ventilation (PEEP) Compared With Normal Ventilation (ZEEP) on Lung Function, Kidney Treatment of Sodium and Water, Vasoactive Hormones, Biomarkers of Nephrotoxicity and Haemodynamics in Patients Undergoing Robot-assisted Radical Prostatectomy||Aarhus University Hospital|Yes|Recruiting|September 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|N/A|No|||September 2015|September 15, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02551341||12983|
NCT02547714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AJP01|Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A|A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A||Novartis|No|Recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02547714||13262|
NCT02547727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|495/2015|Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults|Humoral and Cell-mediated Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in Previously Rabies Immunized HIV-infected Adults||Queen Saovabha Memorial Institute|No|Not yet recruiting|October 2015|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||September 2015|September 10, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02547727||13261|
NCT02555735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRL-003|Exceptional Responders With Pancreatic Cancer to Chemotherapy|Evaluation of Exceptional Responders With Pancreatic Cancer to Standard of Care Chemotherapy||Adera Labs, LLC|No|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with metastatic pancreatic cancer|October 2015|October 17, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02555735||12646|
NCT02555930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1574|Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study|Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study|HIV-POGO|Imperial College London|No|Recruiting|December 2014|January 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Individuals over the age of 18 of any gender with HIV|July 2015|September 21, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02555930||12631|
NCT02543710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/548|Biomarker Guided Treatment in Gynaecological Cancer|Biomarker Guided Treatment in Gynaecological Cancer|MoMaTEC2|Haukeland University Hospital|No|Recruiting|October 2015|December 2033|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1300|||Female|18 Years|95 Years|No|||January 2016|January 13, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02543710||13570|
NCT02544698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cycdc2015-2|Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older|||Beijing Chaoyang District Centre for Disease Control and Prevention||Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|120|||Both|2 Months|N/A|Accepts Healthy Volunteers|||August 2015|September 6, 2015|September 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544698||13494|
NCT02559024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-102A|Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer|Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer||Providence Health & Services|No|Recruiting|September 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|44|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559024||12393|
NCT02550210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15120|A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers|A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|99 Years|No|||December 2015|December 7, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02550210||13070|
NCT02550223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Refa 5|Ultrasound Guided Radial Artery Catheterization|Ultrasound Guided Radial Artery Cathetrization, A Novel Technique.|US radial|Mansoura University|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|90|||Both|20 Years|50 Years|No|||September 2015|September 14, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550223||13069|
NCT02544724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-ONC-002|NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy|Single-Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy||Neumedicines Inc.|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|January 14, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02544724||13492|
NCT02549131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cesarean Closure|Cesarean Wound Closure in Women With BMI 40 or Greater|Cesarean Wound Closure in Women With BMI 40 or Greater: A Randomized Controlled Trial Comparing Subcuticular Suture to Surgical Staples||Mednax Center for Research, Education and Quality|Yes|Not yet recruiting|September 2015|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|420|||Female|18 Years|50 Years|No|||September 2015|September 14, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02549131||13153|
NCT02557100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-567|Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis|A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs||Bristol-Myers Squibb|No|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02557100||12541|
NCT02558127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-CFT-2014-68|Asthma With Hypersecretion-associated Gene for Cystic Fibrosis|Asthma With Hypersecretion-associated Gene for Cystic Fibrosis Clinical, Inflammatory and Genetics Characterization|CF-asthma|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|May 2015|May 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|From peripheral blood samples, the DNA extraction following the protocol saline method. From      the DNA samples obtained CFTR gene analysis to detect genetic variants by sequencing or mass      Next Generation Sequencing (NGS) in Miseq team Illumina platform (available in the Hospital      de la Santa Creu i Sant be held Pau).|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|A total of 100 asthmatic patients of both sexes, aged between 18 and 80 years will be        included in the study. They have not a respiratory infection in the last month. Of the 100        patients, 50 will be hypersecretory asthmatic patients and 50 non- hypersecretory        asthmatic patients. Both groups have an even distribution regarding sex, age, level and        disease control. Asthma patients were defined according to the criteria of the GEMA 2015        -GINA 2014|February 2016|February 19, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02558127||12462|
NCT02556190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-6446-2013|Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis|Colistin Pharmacokinetics in Critically Ill Patients With Acute Kidney Injury AKIN III During Extended Dialysis Using the GENIUS Dialysis System||Hannover Medical School|No|Recruiting|June 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|-  blood samples        -  dialysate samples|Both|18 Years|N/A|No|Probability Sample|Critically ill patients in a tertiary hospital with acute kidney injury AKIN III with need        for renal replacement and colistin therapy.|September 2015|September 18, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02556190||12611|
NCT02546817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-440|Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS|Eliquis (Apixaban) Regulatory Postmarketing Surveillance In Real World Practice (rPMS) For Venous Thromboembolism (VTE) Treatment And Prevention Of Recurrent VTE||Bristol-Myers Squibb|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|265|||Both|19 Years|N/A|No|Non-Probability Sample|Adult (≥19 years of age) patients who are initiating treatment with Eliquis for the        treatment of VTE or prevention of recurrent VTE for the first time|January 2016|January 22, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02546817|2 Years|13331|
NCT02553694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-0198|Sleep Apnea Video Education for CPAP (SAVE-CPAP)|Impact of a Short Educational Video on OSA Patient Satisfaction, Knowledge and Outcomes|SAVE-CPAP|University of Chicago|No|Recruiting|July 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|208|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|August 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02553694||12802|
NCT02553707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20268|A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer|Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment||Hoffmann-La Roche||Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|182|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553707||12801|
NCT02561403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14955|Brain Aging in Veterans (BRAVE) Training: A Cognitive Training Pilot Trial in Older Veterans With Traumatic Brain Injury|Cognitive Reserve and Training in Older Veterans With Traumatic Brain Injury: Study 2||San Francisco Veterans Administration Medical Center||Recruiting|March 2016|December 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|90|||Both|60 Years|85 Years|No|||March 2016|March 15, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561403||12210|
NCT02558608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPL001|Effect of Dissecting of The Inferior Pulmonary Ligament on Postoperative Pulmonary Reexpansion and Recurrence|Effect of Dissecting of The Inferior Pulmonary Ligament on Postoperative Pulmonary Reexpansion and Recurrence After Operation by Video-assisted Thoracic Surgery in the Treatment of Primary Spontaneous Pneumothorax(PSP)||Chinese Medical Association|Yes|Recruiting|June 2015|April 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|10 Years|50 Years|No|||October 2015|October 14, 2015|September 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02558608||12425|
NCT02552082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCR-OR-1501|Scorpio Non Restricted Geometry (NRG) Study in Japan|The Verification Study on the Effectiveness of Rotational Tolerance of Scorpio NRG Study in TKA||Stryker Japan K.K.|No|Recruiting|June 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02552082||12926|
NCT02554708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTW/PV201505-21|pCONus Treatment of Wide Neck Intracranial Aneurysms|pToWin pCONus Treatment of Wide Neck Intracranial Aneurysms|pToWin|Phenox GmbH|Yes|Recruiting|August 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients harbouring an unruptured or ruptured bifurcation aneurysm, in which pCONus        assisted coiling was judged to be the most appropriate treatment|March 2016|March 23, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02554708||12724|
NCT02554721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-13-102|Pharmacodynamic Study of Cilostazol in Healthy Volunteers|Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers|CiloMecT|Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|68|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554721||12723|
NCT02549950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13/261/R|Efficiency of Piezo-Corticision in Accelerating Orthodontic Tooth Movement|Efficiency and Efficacy of Peizo-Coticision in Reducing Orthodontic Treatment Time: Randomized Clinical Trial||King Abdullah International Medical Research Center|Yes|Recruiting|September 2015|July 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|15 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02549950||13090|
NCT02560207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/468|Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.|Does Continuous Cefotaxime Administration Improve Time to Attainment and Maintenance of Target Drug Levels in Critically Ill Patients?||University Medical Center Groningen|No|Not yet recruiting|September 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02560207||12302|
NCT02548078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202090|A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children|Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa||GlaxoSmithKline||Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||November 2015|January 21, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02548078||13234|
NCT02559479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEICA;PI/15/0183|A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes|A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes||Instituto Aragones de Ciencias de la Salud|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02559479||12358|
NCT02552446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE:14-070|Energy Expenditure in ICU Patients Using Predictive Formulas and Various Body Weights Versus Indirect Calorimetry|Indirect Calorimetry an Essential Tool in the Intensive Care: Comparison of the Energy Expenditure Calculated With Different Body Weights Used in Several Predictive Equations and Indirect Calorimetry Measurements||University Hospital, Geneva|No|Completed|April 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Probability Sample|ICU ventilated patients of a tertiary mixed ICU population|September 2015|September 16, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02552446||12898|
NCT02545556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver hepaSphere cryosurgery|Liver Cancer HepaSphere Combined With Cryosurgery|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）Combined With Cryosurgery for Liver Cancer: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|August 2015|September 2020|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02545556||13428|
NCT02550197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GQM07|Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years|Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 18 to 60 Years in the Republic of Korea||Sanofi|No|Active, not recruiting|September 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02550197||13071|
NCT02615119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-004|Anatomical Substrates of Interoception|Anatomical and Psychophysiological Substrates of Interoception||Laureate Institute for Brain Research, Inc.|Yes|Recruiting|October 2015|December 2027|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|310|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02615119||8086|
NCT02619032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATT968|Remifentanil and Fentanyl in Dental Surgery (REFEDS)|Remifentanil vs Fentanyl During Day Case Dental Surgery in Persons With Special Needs: a Comparative Study of Their Effect on Stress Response and Postoperative Pain|REFEDS|Attikon Hospital|No|Completed|October 2005|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|45 Years|No|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02619032||7786|
NCT02624518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0074|68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer|68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans||Stanford University|Yes|Recruiting|November 2015|November 2020|Anticipated|November 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|18 Years|N/A|No|||December 2015|December 4, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624518||7364|
NCT02563522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMNHU-003|Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers|A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Asses the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)||ViroMed Co., Ltd. dba VM BioPharma|Yes|Not yet recruiting|November 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563522||12047|
NCT02563808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817436|Impact of Anticipated Regret Incorporation Into Patient Decision Aids|Impact of Anticipated Regret on Decision-Making in Preference Sensitive Care for Breast and Prostate Cancer||University of Pennsylvania|No|Completed|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|189|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563808||12025|
NCT02626819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP 12-252|Improving Weight Management at the VA|Improving Weight Management at VA: Enhancing the MOVE!23 for Primary Care (CDA 10-206)||VA Office of Research and Development|No|Recruiting|August 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02626819||7187|
NCT02621775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_36|Effectiveness of Two Stress Management Programs in Adaptation Disorder With Anxiety (ADA)|Effectiveness of Two Stress Management Programs in the Adaptation Disorder With Anxiety (ADA) : Computer-based or Face- to -Face to Face Versus Control Group.Open Multicenter Prospective Randomized Controlled Therapeutic 3 Parallel Groups|Seren@ctif|University Hospital, Lille|No|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02621775||7575|
NCT02551731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS011-15-054|Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms|A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms||INSYS Therapeutics Inc|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|36 Months|No|||March 2016|March 4, 2016|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02551731||12953|
NCT02529345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-130919|Clear-Road Trial, Investigating the Efficacy of the RoadSaver Stent|CLEAR-ROAD; a Physician-initiated Carotid Trial Investigating the Efficacy of Endovascular Treatment of Carotid Arterial Disease With the Multi-layer RoadSaver Stent||Flanders Medical Research Program|Yes|Active, not recruiting|April 2015|May 2017|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02529345||14670|
NCT02529358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-MI|Text Message Based Maintenance Intervention|Evaluation of a Transdiagnostic Text Message Based Maintenance Intervention After Inpatient Cognitive Behavioural Therapy||Friedrich-Alexander-Universität Erlange-Nürnberg|Yes|Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|180|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|March 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02529358||14669|
NCT02554552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YY_YY1201_001/2a|Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee||Yooyoung Pharmaceutical Co.,Ltd.|Yes|Recruiting|September 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02554552||12736|
NCT02554565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2013-06|Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards the Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV : Human PapillomaVirus)||PAIR HPV|Institut Curie|No|Recruiting|July 2014|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02554565||12735|
NCT02549443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-383-SDR|The Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG|The Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG||McGill University Health Center|Yes|Completed|August 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|30|||Both|18 Years|90 Years|No|||September 2015|September 14, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02549443||13129|
NCT02549456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD/148|Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer|Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer|NOTES|Mansoura University|Yes|Recruiting|December 2015|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||March 2016|March 15, 2016|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02549456||13128|
NCT02552004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001|Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study|Assessment of the Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery - a Pilot Study|Pilot pCLE|IHU Strasbourg|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|February 26, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02552004||12932|
NCT02529670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53123716.3.0000.5511|Low Level Laser Therapy in the Dorsal Root Ganglion in the Treatment of Chronic Low Back Pain|Study of the Effect of Low Level Laser Therapy in the Dorsal Root Ganglion in the Diagnosis and Treatment of Chronic Low Back Pain||University of Nove de Julho|Yes|Recruiting|March 2014|November 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|31|||Both|20 Years|90 Years|No|||March 2016|March 14, 2016|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529670||14645|
NCT02529683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-6518|Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya|Clinical Trial of Acceptability, Adherence and Immune/Microbiologic Effects of a Vaginal Contraceptive Ring Among HIV-negative Women in Western Kenya||Centers for Disease Control and Prevention|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02529683||14644|
NCT02546882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI11B03|The Improving Effect of Autologous Stromal Vascular Fraction (SVF) in Adipose Tissue on Skin Grafting|Phase 1/2 Study of Autologous Stromal Vascular Fraction in Adipose Tissue Transplantation in Improving Skin Grafting||Shanghai Jiao Tong University School of Medicine|No|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|3 Years|70 Years|No|||September 2015|September 9, 2015|January 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02546882||13326|
NCT02549664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411014982|Exercise in Genetic Cardiovascular Conditions|Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy "LIVE-HCM"/Lifestyle and Exercise in the Long QT Syndrome "LIVE-LQTS"|LIVE-HCM/LQT|Yale University|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4286|||Both|8 Years|50 Years|No|Non-Probability Sample|Individuals with Hypertrophic Cardiomyopathy or Long QT Syndrome between the ages of 8-50.|September 2015|September 14, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02549664|3 Years|13112|
NCT02549677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJBC1506|Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer|Comparison the Safety and Efficacy of Epirubicin Plus Cyclophosphamide (EC)Versus Docetaxel Plus Cyclophosphamide (TC) in Lymph Node Negative, ER Positive, Her2 Negative Breast Cancer Patients as Adjuvant Chemotherapy|ELEGANT|Ruijin Hospital|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Female|18 Years|70 Years|No|||September 2015|September 13, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02549677||13111|
NCT02557932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0207|Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication|Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial||National Cancer Center, Korea|No|Not yet recruiting|September 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02557932||12477|
NCT02536872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/06/2015|A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder|An Observational Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder||Medway NHS Foundation Trust|No|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|100 Years|No|Non-Probability Sample|women with overactive bladder syndrome|December 2015|December 27, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02536872||14093|
NCT02536885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508-S21P|The Effect of Blood Pressure on the Postoperative Cognitive Dysfunction|The Effect of the Perioperative Blood Pressure on the Onset of Postoperative Cognitive Dysfunction in Adults||University Hospital Hradec Kralove|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||September 2015|September 2, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02536885||14092|
NCT02547142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHH_EarlyPalliativeCare_EDAP|Early Integration of Palliative Care in Esophageal Cancer Patients|Evaluation of the Implementation of an Early Integrated Palliative Care Program in the Esophageal Cancer Population||McMaster University|No|Recruiting|March 2016|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|N/A|No|||March 2016|March 15, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02547142||13306|
NCT02553980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPF14ICF14|Virtual Trainer System (3rd Version) for Physical Activity Promotion in Middle-aged Hong Kong Adults|Development and Dissemination of an Online Exercise and Health Promotion Program for Hong Kong Middle-aged Chinese: The Virtual Trainer System 3rd Version||Chinese University of Hong Kong|No|Recruiting|October 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|February 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02553980||12780|
NCT02553993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG8C0261|Comparing the Cognitive Effects of Two Exergame Training and Traditional Training in Patients With Chronic Stroke|Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke||Chang Gung Memorial Hospital|Yes|Completed|September 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|January 6, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02553993||12779|
NCT02557984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS_Study_01|Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity|Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers||University of Zurich|No|Completed|February 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|121|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02557984||12473|
NCT02551289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14MP002|MAgnetic Resonance Imaging in COeliac Disease|MRI Assessment in Newly Diagnosed Coeliac Disease and Following Gluten-free Diet Treatment|MARCO|University of Nottingham|No|Recruiting|September 2015|||September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|72|Samples Without DNA|Stool sample|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|36 newly diagnosed coeliac disease patients.        A parallel group of 36 healthy subjects, frequency matched for age (in 20 years bands) and        gender.|September 2015|September 15, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02551289||12987|
NCT02551302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho-6-2015|"Efficacy of Hybrid Systems ("Topping Off") Versus Rigid Spinal Fusion in Lumbar Fusion Surgery: A Dual-center, Prospective, Randomized Pilot Study ("CD Horizon BalanC")"||BalanC|University of Cologne|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|N/A|No|||September 2015|September 15, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02551302||12986|
NCT02551354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208078|Estimation of Pain During Epidural Analgesia During Labor|Estimation of Pain During Epidural Analgesia During Labor - a Monocentric Study|PERIDANS|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Female|18 Years|45 Years|No|||September 2015|September 15, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02551354||12982|
NCT02559245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|makan.pourmasoumi@gmail.com|Comparison and Assessment of Effects of Flixweed and Fig on Irritable Bowel Syndrome With Predominant Constipation and Gastrointestinal Function: Single Blind Randomized Parallel Trial|||Isfahan University of Medical Sciences||Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02559245||12376|
NCT02559258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUN001-101|Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Epsi- Gam in Healthy, Cat-, Dust Mite-, or Bermuda Grass-Allergic Subjects||Tunitas Therapeutics, Inc.|No|Active, not recruiting|August 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02559258||12375|
NCT02559271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aug/25/2015|Pediatric Refraction With SVOne Autorefractor|Pediatric Refraction With SVOne Autorefractor||Smart Vision Labs||Recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|5 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|pediatric population, between 5 and 16 years of age|September 2015|September 22, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02559271||12374|
NCT02549001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1331|Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis|A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis||Polichem S.A.|No|Recruiting|August 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|980|||Both|12 Years|80 Years|No|||September 2015|September 10, 2015|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549001||13163|
NCT02556944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-001-009|Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power|Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power||Samsung Medical Center|No|Enrolling by invitation|April 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02556944||12553|
NCT02556957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062089|CHWs, mHealth, and Combination HIV Prevention|CHWs, mHealth, and Combination HIV Prevention: An Implementation Science Cluster-Randomized Trial (mLAKE)|mLAKE|Johns Hopkins University|Yes|Recruiting|September 2015|August 2020|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|2500|||Both|15 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02556957||12552|
NCT02555384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ2015-264|AMblyopia Treatment Through PErceptual Training in Children (AMPEL)|Improving Visual Functions in Young Children With Amblyopia Through Perceptual Learning|AMPEL|University of Basel|No|Not yet recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|8 Years|No|||September 2015|September 17, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02555384||12672|
NCT02555397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate Cancer (9829)|Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer|Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer After Definitive Radiotherapy||Henry Ford Health System|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||September 2015|September 17, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555397||12671|
NCT02560272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014L00216|Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried|A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age||Beijing Minhai Biotechnology Co., Ltd|No|Recruiting|September 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1560|||Both|2 Months|5 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02560272||12297|
NCT02545608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43CH1406|Safety and Efficacy of Restylane Vital for Skin Rejuvenation of Dorsal Hands|A Randomised, Multi-centre, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects||Q-Med AB|No|Recruiting|October 2015|February 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|109|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02545608||13424|
NCT02556424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 15_0056|Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema|Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema|TRIOZ|Nantes University Hospital|Yes|Recruiting|January 2016|February 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02556424||12593|
NCT02555605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXMRI20|Dexmedetomidine Sedation in Children With Respiratory Morbidities|Feasibility of Dexmedetomidine in Children With Respiratory Morbidities Undergoing Deep Sedation for Magnetic Resonance Imaging||Universitair Ziekenhuis Brussel|No|Completed|November 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Both|1 Month|16 Years|No|Probability Sample|Children up to the age of 16 years with at least 3 characteristics of respiratory        morbidities were identified as having increased risk for adverse respiratory events and        they were eligible for participation in this evaluation.|September 2015|September 17, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555605||12656|
NCT02555618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-850/CPH-003|A Phase 2 Study of Trivalent Inactivated Influenza Vaccine (TIV), TAK-850 (Cell-culture Derived) Compared to TIV (Egg-derived) in Adults|A Phase 2 Randomized Double Blind Parallel-Group Comparative Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of Trivalent Inactivated Influenza Virus Vaccine (TIV), TAK-850 (Cell-culture Derived) to TIV (Egg-derived) in Healthy Adults Aged 20-49 Years||Takeda||Not yet recruiting|September 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02555618||12655|
NCT02557451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRON PHRC I 2013|Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications|Subretinal Haematoma in AMD: Randomized Controlled Study of 2 Therapeutic Approaches in the Antiangiogenic Era|STAR|Centre Hospitalier Universitaire Dijon||Not yet recruiting||||January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|18 Years|N/A||||August 2015|September 22, 2015|September 16, 2015||||No||https://clinicaltrials.gov/show/NCT02557451||12514|
NCT02546050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNF-CBMR 2015-000199-86|The Effect of Metformin on Composition of Human Gut Bacteria|Effects of Metformin on Human Gut Microbiota||University of Copenhagen|Yes|Completed|June 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02546050||13390|
NCT02556671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYatsenU2H|Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI|Platelet Reactivity Over Time After Receiving Clopidogrel Among Moderate CKD Patients Undergoing Percutaneous Coronary Intervention||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|April 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|Dual antiplatelet therapy (DAPT) with standard doses of aspirin and clopidogrel has long        been the cornerstone in patients undergoing percutaneous coronary intervention (PCI).        However, inhibition of platelet activation and aggregation after In these studies,        platelet function was only assessed by a single measurement and a single method early        after the start of antiplatelet treatment. To test the stability of platelet reactivity        measurements over time among patients undergoing PCI, we use 3 methods (VerifyNow P2Y12        assay, Flow cytometric assessment of the phosphorylation status of VASP, light        transmittance aggregometry) for platelet function testing in 2 periods (~14days), with        maintenance doses of clopidogrel.|September 2015|September 19, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02556671||12574|
NCT02555072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN 005/2014|Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)|Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic Area||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Not yet recruiting|March 2016|December 2026|Anticipated|December 2026|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|4761|||Both|9 Months|50 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|April 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02555072||12696|
NCT02555085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234HV101|Single Ascending Doses of BIIB063 in Healthy Volunteers|Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers||Biogen|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02555085||12695|
NCT02555098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-15|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||February 24, 2016|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555098||12694|
NCT02557529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 31|Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy|Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy - The DAHANCA 31 Study||Herlev Hospital|No|Recruiting|August 2015|May 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02557529||12508|
NCT02557542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/1295|Pilot RCT Evaluating a One Stop Vein Clinic|Pilot Randomised Controlled Trial Evaluating the Potential Benefit of a One Stop Vein Clinic (OSVeC)|OSVeC|Imperial College London|Yes|Recruiting|October 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|416|||Both|18 Years|N/A|No|||July 2015|November 18, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02557542||12507|
NCT02534519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0408|Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+.|Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+|Blood Genome|Blood Donation Service Zurich, SRC|No|Recruiting|July 2015|June 2018|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|8|Samples With DNA|Two times 10 mL EDTA-anticoagulated whole blood and genomic DNA resulting from this amount.|Both|1 Year|70 Years|Accepts Healthy Volunteers|Probability Sample|Genomic DNA of 2 U- samples were both provided as blinded reference material from New York        and Vienna blood centres, respectively. Both donors are lost for follow up, and although        there is no documented evidence for refusal of the respective donors to use their material        in research projects, samples still lack informed consent. Additional reference samples (n        max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich        blood donors with informed consent, only|August 2015|August 24, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02534519|1 Day|14274|
NCT02550561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2010|Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS|Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome||University of California, Irvine|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02550561||13043|
NCT02555254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD2015ISOCRATE|Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia|Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia. A Randomized Controlled Pilot Study|ISOCRATE|Centre Hospitalier Departemental Vendee|No|Recruiting|January 2016|November 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02555254||12682|
NCT02557607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P 2013-06|Quantification of Cerebral Blood Flow by Arterial Spin Labeling in Vasospasm in Subarachnoid Haemorrhage|Quantification of Cerebral Blood Flow by Arterial Spin Labeling in the Screening and Monitoring of Vasospasm in Subarachnoid Haemorrhage|ASL-HSA|University Hospital, Angers|No|Recruiting|December 2014|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02557607||12502|
NCT02530619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 15H10|Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia|A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase A, in Adult Patients With Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)||Northwestern University|Yes|Recruiting|October 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02530619||14572|
NCT02554994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0706|Multifactorial Intervention on Frailty in Vulnerable Older Adults|The Effect of Multifactorial Intervention on Frailty in Vulnerable Older Adults Living in Rural Communities: A Designed Delay Trial|ASPRA-IS|Asan Medical Center|No|Recruiting|August 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|65 Years|N/A|No|||September 2015|September 25, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02554994||12702|
NCT02547493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9419|Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients|Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept|VACINA|University Hospital, Montpellier|Yes|Recruiting|September 2015|September 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|85 Years|No|||September 2015|September 9, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02547493||13279|
NCT02549729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.076.422|Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy|Effect of the Pelvic Floor Training on Pelvic Floor Muscle Strength in Postmenopausal Women With or Without Hormonal Therapy: A Randomized Controlled Trial||University of Sao Paulo|Yes|Recruiting|September 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2015|November 24, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02549729||13107|
NCT02543671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|613977|Investigation of Vitamin D3 Enriched, Reduced-fat Yellow Cheese Efficacy to Prevent Vitamin D Deficiency|Investigation of Vitamin D3 Enriched, Reduced-fat Yellow Cheese Efficacy to Prevent Vitamin D Deficiency||Harokopio University||Completed|October 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|80|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02543671||13573|
NCT02555189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15G.322|Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression|Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression||Thomas Jefferson University|Yes|Recruiting|December 2015|||September 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Male|18 Years|N/A|No|||December 2015|December 1, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555189||12687|
NCT02555202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCADL (RB 15.037)|Validation of French Version of LCADL and Dyspnea-12|Validation of the French Version of the London Chest Activity of Daily Living Scale (LCADL) and the Dyspnea-12 Questionnaire|LCADL|University Hospital, Brest|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|copd patients stage 3 and 4|September 2015|September 18, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02555202||12686|
NCT02551939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201352|Breast Fat Grafting Augmentation in Chinese Women|Magnetic Resonance Imaging and Breast-Q Evaluation After Breast Autologous Fat Grafting Augmentation in Chinese Women||Nanjing Medical University|Yes|Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|38|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02551939||12937|
NCT02558504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-687|Radiofrequency in the Treatment of Barrett's Oesophagus|Clinical and Medico-economic Evaluation of Radiofrequency Ablation Versus Oesophagectomy in the Treatment of High Grade Dysplasia in Barrett's Oesophagus|HARMONI|Hospices Civils de Lyon|Yes|Recruiting|January 2013|November 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02558504||12433|
NCT02558517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|medint002|Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus|Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic Lupus|CORTICOLUP|Groupe Hospitalier Pitie-Salpetriere|No|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02558517||12432|
NCT02544711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0097|Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment|Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment|MARGIC|Nantes University Hospital|Yes|Recruiting|December 2015|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02544711||13493|
NCT02532764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQ-010-001|Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients|Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis||ProQR Therapeutics|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|60 Years|No|||February 2016|February 5, 2016|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02532764||14409|
NCT02548832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EABYBL|Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Dyslipidemia|Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Mixed Dyslipidemia||University of Guadalajara|No|Recruiting|April 2013|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|60 Years|No|||September 2015|September 10, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02548832||13176|
NCT02548845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-303-00043|An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain|An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA)|ALGA|Otsuka Pharmaceutical Europe Ltd|No|Enrolling by invitation|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Eligible patients are oncology patients ≥ 18 years old who had been diagnosed with at        least one occurrence of hyponatraemia secondary to the SIADH and who had been managed ein        one of the Spanish centres who have implemented the SEOM algorithm.|March 2016|March 18, 2016|September 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02548845||13175|
NCT02547948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD19-targeting CAR T|CD19-targeting CAR T Cells for B Cell Lymphoma|CD19-targeting CAR T Cells for Refractory B Cell Lymphoma||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|September 2015|March 2020|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02547948||13244|
NCT02555943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_DASCO|DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)|Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients|DASCO|Humanity & Healthy GI and Liver Centre|Yes|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||February 2016|February 26, 2016|September 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02555943||12630|
NCT02556138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003183|Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates|Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates||Mayo Clinic|No|Enrolling by invitation|September 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02556138||12615|
NCT02533037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16992|Effects Of Rehabilitation Incorporating Gait Training On Clinical Measures Associated With Chronic Ankle Instability|Effects Of Rehabilitation Incorporating Gait Training On Clinical Measures Associated With Chronic Ankle Instability||University of Virginia|No|Completed|August 2013|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|40 Years|No|||August 2015|August 21, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02533037||14388|
NCT02553408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canada-IIS_ADC-OUS-IIS-14-07|Patients and Care Providers Perspectives and Experience With Decision Aid Tool for Self-monitoring of Blood Glucose|Patients and Care Providers Perspectives and Experience With Decision Aid Tool for Self-monitoring of Blood Glucose||Lawson Health Research Institute|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02553408||12824|
NCT02553421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVW-CLR-CS09-400|Optical Detection of Intravenous Infiltration:A Pilot Study|||ivWatch, LLC|No|Recruiting|August 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|340|||Both|N/A|17 Years|No|||September 2015|September 16, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02553421||12823|
NCT02561377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81370923|Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)|Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)||Nanjing University of Traditional Chinese Medicine|No|Recruiting|September 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|276|||Both|45 Years|75 Years|No|||September 2015|September 28, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561377||12212|
NCT02559375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 26914|PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals|PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|September 2014|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|466|||Both|18 Years|N/A|No|Probability Sample|Cancer Patients|February 2016|February 23, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02559375||12366|
NCT02546830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB14-060|Automatic Oxygen Administration After Major Abdominal and Thoracic Surgery|Automatic Oxygen Administration in Early and Late Postoperative Hypoxaemia Prevention After Major Abdominal and Thoracic Surgery|FreeO2-Post-Op|University Hospital, Brest|Yes|Recruiting|January 2016|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02546830||13330|
NCT02557217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP202-002|NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction|A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults Who Have Left Ventricular Systolic Dysfunction Following Myocardial Infarction||Armaron Bio Pty Ltd|Yes|Recruiting|October 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02557217||12532|
NCT02545231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pitavastatin|Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis|Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis, Endothelial Function, Circulating microRNAs, and Cardiovascular Events in Patients With Coronary Artery Disease Requiring Stent Implantation: OCT and NIRS Comparison|ELEVATE|Korea University Anam Hospital|Yes|Recruiting|February 2013|August 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|30 Years|79 Years|No|||September 2015|September 8, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02545231||13453|
NCT02676544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803676|Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)|Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)||Rhode Island Hospital|Yes|Recruiting|December 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|50 Years|N/A|No|||February 2016|February 4, 2016|January 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676544||3372|
NCT02676557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASIK-LC study|The Lamina Cribrosa (LC) Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)|The Lamina Cribrosa (LC) Morphologic Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)||Samsung Medical Center|No|Completed|April 2014|March 2015|Actual|August 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|No|Non-Probability Sample|The myopic patients who were supposed to undergo LASIK surgery|February 2016|February 5, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02676557|6 Months|3371|
NCT02664402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160056|Tool to Assess Psycho-Social-Spiritual Healing: Cognitive Interviewing|Analysis of a Tool to Assess Psycho Social Spiritual Healing: Cognitive Interviewing||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|30|||Both|18 Years|100 Years|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02664402||4300|
NCT02690571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184-31M|Pulmonary Effects of 100% Biodiesel Exhaust|Pulmonary Effects of 100% Biodiesel Exhaust|BD100Broncho|Umeå University|No|Completed|October 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02690571||2295|
NCT02690584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1456|Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury|Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury||Norwegian University of Science and Technology|No|Recruiting|March 2016|April 2023|Anticipated|April 2023|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|65 Years|No|||March 2016|March 3, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02690584||2294|
NCT02661633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-Ahead|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization in High School Athletes|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization in High School Athletes|AheadCAS - HS|BrainScope Company, Inc.|No|Recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|13 Years|19 Years|No|Non-Probability Sample|Approximately 150 male and female student-athletes from participating high schools will be        invited to participate.|January 2016|January 19, 2016|January 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661633||4513|
NCT02678234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205638|Russian Market Potential of Theraflu Day Powder for Oral Solution for Cold and Flu.|An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection||GlaxoSmithKline|No|Not yet recruiting|March 2016|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678234||3242|
NCT02661776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0987|The Change of NK Cell Activity After Head and Neck Cancer Surgery|||Yonsei University|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|blood obtained from enrolled patients before and after surgery|Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing head and neck surgery|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661776||4502|
NCT02671617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eHIITCa|Preoperative HIIT in Elderly Cancer Patients|A Randomised Control Trial to Assess Efficacy of Preoperative High Intensity Interval Training in Elderly Patients Scheduled for Oncological Abdominal Surgery|eHIITCa|University of Nottingham|No|Not yet recruiting|March 2016|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|48|||Both|65 Years|N/A|No|||January 2016|January 28, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02671617||3749|
NCT02512341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCG Analysis|Automatic Differentiation of Innocent and Pathologic Murmurs in Pediatrics|Automatic Differentiation of Innocent and Pathologic Murmurs in Pediatrics||CSD Labs GmbH|No|Completed|November 2013|June 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|106|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients with and without heart defects showing pathological heart murmurs, innocent        heart murmurs and heart sounds without murmurs at the cardiology department.|July 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512341|1 Day|15975|
NCT02515370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Musoke-R01-080476-Option B+|Friends for Life Circles for Option B Plus|Using Enhanced Peer Group Strategies to Support Prevention of Mother to Child HIV Transmission (PMTCT) Option B+ in Uganda|FLCs|MU-JHU CARE|No|Not yet recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|540|||Female|18 Years|55 Years|No|||July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515370||15744|
NCT02515630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-352-1672|Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)||Gilead Sciences|No|Recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515630||15724|
NCT02673541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D16030|Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents|Randomized, Multi-Center, Comparative and Cost Effectiveness Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents in the Management of Walled Off Pancreatic Necrosis||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|February 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02673541||3603|
NCT02664623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/ET-02|Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients|Effectiveness of Personalized Nutrition Advice Delivered Via Dietary Consultations for Optimizing Dietary Calcium Intake in Patients With Multiple Sclerosis (MS) and Monitored as Outpatients: a Randomized, Single-blind, Bicentric Study|CalciCoach|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|February 2017|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|182|||Both|18 Years|69 Years|No|||March 2016|March 4, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664623||4283|
NCT02666404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-401|Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock|Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock: Evaluating the Combination of Intraabdominal Pressure and Renal Resistive Index With Hemodynamic Parameters for Guidance of Shock Therapy - A Multicenter International Clinical Trial|VoluKid|University Hospital, Basel, Switzerland|Yes|Recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02666404||4147|
NCT02666417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeGOS_KP|Iron Absorption From a Micronutrient Powder Containing Galacto-oligosaccharides (GOS)|Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa|FeGOS|Swiss Federal Institute of Technology|Yes|Recruiting|January 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Both|6 Months|10 Months|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02666417||4146|
NCT02685644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07|Association Between Laparoscopic Removal of Endometriomas and Anti-mullerian Hormone Levels|Effects of Laparoscopic Endometrioma Removal on Anti-mullerian Hormone Levels||Ankara University|No|Not yet recruiting|April 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|102|Samples Without DNA|Blood serum samples|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will recruit healthy women besides having endometrioma cysts who will undergo        laparoscopic removal of such lesions.|February 2016|February 15, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02685644||2673|
NCT02685657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10735|Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer|A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer||Russian Academy of Medical Sciences|No|Not yet recruiting|September 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02685657||2672|
NCT02673853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/00055|Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion|Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion||National University Hospital, Singapore|No|Not yet recruiting|February 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|21 Years|99 Years|No|Non-Probability Sample|The study population will be picked from all patients who are going surgery at National        University Hospital (NUH) during the period of data collection, and who are receiving        supraglottic airway for their procedure. They must fulfil the inclusion and exclusion        criteria.|February 2016|February 1, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02673853||3579|
NCT02674776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013003P3A03|Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout|A Clinical Trial About the Efficacy and Safety of HuZhen Capsule in Treating Patients With Acute Gout: A 72 Hours, Multi-center, Randomized, Double-blind, Parallel Placebo Compared Clinical Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|65 Years|No|||September 2015|February 2, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674776||3508|
NCT02664649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141102|Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis|Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events After Trans-Aortic Valve Implantation for Aortic Stenosis|ATLANTIS|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|February 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1509|||Both|18 Years|N/A|No|||December 2015|January 22, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02664649||4281|
NCT02677077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEL-TYS-14-10727|Clinical Disease Activity With Long Term Natalizumab Treatment|MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab||Biogen|No|Recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Both|18 Years|65 Years|No|Probability Sample|Participants who have been receiving treatment with natalizumab for ≥24 months.|February 2016|February 19, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02677077||3331|
NCT02686671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L16-047|The Pull Test To Determine Responders To Subacromial Injection In Patients With Shoulder Impingement|A New Diagnostic Clinical Test To Determine Responders To Subacromial Injection In Patients With Shoulder Impingement: A Case Series||Texas Tech University Health Sciences Center|No|Not yet recruiting|February 2016|August 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Probability Sample|A consecutive sample of convenience of subjects treated by physicians from Advanced Pain        Centers of Alaska for musculoskeletal shoulder pain and scheduled for a subacromial CSI as        part of their care will be asked to participate in the study. The study will end when a        minimum of 30 subjects qualify for the research study.|February 2016|February 16, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02686671||2594|
NCT02662465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1174-3413|Oral Manifestations in Children With Cancer|Oral Manifestations of Leukemia and Anticancer Treatment in Childhood||Universidade Federal do Rio Grande do Norte|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|1 Year|25 Years|No|||January 2016|January 20, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662465||4449|
NCT02662725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_48|Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases|A Multicenter Phase II Study of Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases|IPI+RTS|University Hospital, Lille|Yes|Completed|September 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662725||4429|
NCT02675244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-0010|Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery|Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|April 2016|April 2021|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675244||3472|
NCT02675257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 82DZD01101|Depression and Diabetes Control Trial|Depression and Diabetes Control Trial|DDCT|Forschungsinstitut der Diabetes Akademie Mergentheim|Yes|Recruiting|July 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|70 Years|No|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02675257||3471|
NCT02664220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-1000|Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis|A Randomized Pilot Trial of Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|17 Years|No|||January 2016|January 21, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664220||4314|
NCT02688348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000496|Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer|Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer||Jonsson Comprehensive Cancer Center|No|Not yet recruiting|June 2016|||January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02688348||2465|
NCT02666781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9507|Postoperative Rostral Fluid Shift and Obstructive Sleep Apnea|The Contribution of Rostral Shift of Fluid to Postoperative Worsening of Obstructive Sleep Apnea Severity in Surgical Patients - A Prospective Cohort Study||University Health Network, Toronto|No|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical patients attending the preoperative assessment clinic in Toronto Western Hospital        (UHN) who will be undergoing elective non-cardiac surgery, requiring general anesthesia,        lasting for 1-2 hours or more and requiring same day admission for a minimum of 2 days        postoperatively.|February 2016|February 8, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02666781||4118|
NCT02674867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP 59 CLEAC|CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)|ANRS EP59 CLEAC : Physiopathological Study of Immunovirological Evolution of Perinatally HIV-1 Infected Children Depending on Early (Before 6 Months) or Late (After 2 Years) Antiretroviral Therapy Introduction.|CLEAC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|5 Years|18 Years|No|||February 2016|February 2, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02674867||3501|
NCT02668042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIH-PLAGH-ST-006|The Activity of Tissue Engineering Skin Substitutes|Living Tissue Engineering Skin Substitutes Safety and Efficacy Studies for the Treatment of Difficult to Heal Wounds|MSCs|Chinese PLA General Hospital|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02668042||4021|
NCT02688322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SULBAC552011411|Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections|Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections||Prince of Songkla University|No|Active, not recruiting|September 2014|||August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688322||2467|
NCT02688335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052615|Home-Based Usability and Effectiveness of Cloud 9|Home-Based Usability and Effectiveness of Cloud 9|Cloud9|Johns Hopkins University|No|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688335||2466|
NCT02671669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01809|Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology|Empowering Individuals Post-Cardiopulmonary Outpatient Rehabilitation to Continue to Live a Heart Healthy Lifestyle: Utilizing Mobile Health Technology||New York University School of Medicine|No|Recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02671669||3745|
NCT02671799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VenTouch CT004|Evaluation of the Minimally Invasive VenTouch System in the Treatment of Functional Mitral Regurgitation (FMR)|Evaluation of the Minimally Invasive VenTouch System in the Treatment of Functional Mitral Regurgitation (FMR) a First-in Man Continuation Study||Mardil Medical|No|Recruiting|January 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2016|January 29, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02671799||3735|
NCT02662075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02083|Effect of Electronic Cigarettes on Platelets, Endothelium and Inflammation|Acute Effects of Electronic Cigarettes on Platelet, Vascular Endothelial Function, and Inflammation in Healthy Active Smokers||New York University School of Medicine|No|Not yet recruiting|March 2016|March 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662075||4479|
NCT02664714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5015537|Individual Pelvic Floor Muscle Training Versus Individual With Group Versus Group for Stress Urinary Incontinence|The Effects of Individual Pelvic Floor Muscle Training Versus Individual Treatment With Progression to Group Versus Group Training for Women With Stress Urinary Incontinence: Protocol for a Randomized Controlled Trial||Universidade Federal de Sao Carlos|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02664714||4276|
NCT02688998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160006-01H|REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab|Simple, Prospective and Randomized Trial to Obtain Answers to Questions of Standard of Care: Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab: A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Her2 Negative).|OTT 15-07|Ottawa Hospital Research Institute|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Female|19 Years|N/A|No|||March 2016|March 16, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688998||2415|
NCT02689011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU / UriKANE / 2013|Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)|Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)|UriKANE|Aga Khan University|Yes|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|30 Years|70 Years|No|||February 2016|February 25, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02689011||2414|
NCT02671942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTQ-01459-IIA|A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients|||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Not yet recruiting|February 2016|August 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|40 Years|N/A|No|||January 2016|February 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02671942||3724|
NCT02671955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108083|A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer|An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer||Janssen Research & Development, LLC|No|Recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02671955||3723|
NCT02674594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-405|Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US|An Early Evaluation of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin in the US||Bristol-Myers Squibb|No|Completed|October 2014|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|30000|||Both|18 Years|N/A|No|Non-Probability Sample|Premier Hospital database is the source of all data|February 2016|February 2, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02674594||3522|
NCT02674607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2132/10/13|the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children|the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children||Tanta University|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674607||3521|
NCT02676102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02109|RCT Comparing Tailored Versus Targeted Organ Donation Video Education|Community Based Research to Improve Organ Donor Registration Among Black Men - Aim 2 Randomized Trial Comparing Tailored Versus Targeted Videos.||New York University School of Medicine|No|Recruiting|February 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|1338|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676102||3406|
NCT02676115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00048|Medipore Tape Study|The Use of Wound Taping Protocol to Improve Cosmetic Scar After Anterior Cruciate Ligament (ACL) Reconstruction||New York University School of Medicine|No|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|95 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02676115||3405|
NCT02689817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00093653|Monitoring Physiologic Data in the Development of Pressure Ulcers|Monitoring Physiologic Data in the Development of Pressure Ulcers||Johns Hopkins University|No|Not yet recruiting|March 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689817||2352|
NCT02672267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIO 1/2|A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction|A PHASE III, SINGLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH MYOCARDIAL INFARCTION||Altaco XXI, LLP|Yes|Recruiting|July 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02672267||3699|
NCT02678195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITIP2|3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi|Double-blind Randomized Controlled Clinical Trial of 3 Days Versus 5 Days Amoxicillin Dispersible Tablets for Chest-indrawing Childhood Pneumonia Among Children 2-59 Months of Age Presenting to Kamuzu Central Hospital in Lilongwe, Malawi||Save the Children||Not yet recruiting||||August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|2 Months|59 Months||||February 2016|February 4, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02678195||3245|
NCT02662101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Engage-453139_2013|Impact of Oxidized Silver Wound Dressings on Wound Bacteria|Molecular Microbial Ecology as a Diagnostic Tool to Identify Mode of Action and New Targets for Oxidized Silver Wound Dressings||Exciton Technologies Inc.|No|Completed|January 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|17 Years|70 Years|No|||January 2016|January 20, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662101||4477|
NCT02662322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC15_9868|Effect of Language and Confusion on Pain During Peripheral Intravenous Catheterization (KTHYPE)|Effect of Language and Confusion on Pain During Peripheral Intravenous|KTHYPE|Rennes University Hospital|No|Recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02662322||4460|
NCT02689167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2015/254|Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma|Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma||Centre Hospitalier Universitaire de Besancon|No|Recruiting|February 2016|February 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689167||2402|
NCT02677181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81370666|Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT|Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT||Chinese PLA General Hospital|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|40 Years|70 Years|No|||February 2016|February 4, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02677181||3323|
NCT02675894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-2013-2283|Radiofrequency Ablation Using Cooled-Wet Electrode|Switching Bipolar Radiofrequency Ablation Using Cooled-Wet Electrode for Treatment of Hepatocellular Carcinoma: A Preliminary Study||Seoul National University Hospital|Yes|Active, not recruiting|November 2013|November 2017|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|20 Years|75 Years|No|||February 2016|February 16, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02675894||3422|
NCT02675907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-15-016|Evaluation of N1539 Following Bunionectomy Surgery|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Bunionectomy||Recro Pharma, Inc.|No|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675907||3421|
NCT02662556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP303|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain||AcelRx Pharmaceuticals, Inc.|No|Recruiting|March 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|40 Years|N/A|No|||March 2016|March 3, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662556||4442|
NCT02686411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1074|Palliative Care Consult Service vs Palliative Care Unit|A Prospective Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants and their caregiver seen by a palliative care doctor for a consult and        transferred to the palliative care unit (PCU) at MD Anderson Cancer Center in Houston,        Texas|February 2016|February 18, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02686411||2614|
NCT02686424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCO-RD 010 CRT (114824)|Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT)|Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy|ONCO-RD010CRT|Seoul National University Hospital|No|Suspended|March 2010|||January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Gastric carcinoma patients who received ghastrectomy|February 2016|February 20, 2016|February 15, 2016||No|paperwork delay|No||https://clinicaltrials.gov/show/NCT02686424||2613|
NCT02677207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNJ-DEP|The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive|The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial|JNJ-DEP|CliniRx Tangent Research|No|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|50 Years|No|||March 2016|March 2, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02677207||3321|
NCT02677220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM5631|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||February 4, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677220||3320|
NCT02666573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-221-000-044-597|Photodynamic Therapy During Supportive Periodontal Therapy|Effects of Photodynamic Therapy on Clinical and Immunological Parameters in a Group of Periodontal Patients Undergoing Supportive Periodontal Therapy||National University, Singapore||Completed|June 2013|||December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666573||4134|
NCT02665156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1034/15|Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy|Phase 2 Clinical Trial to Assess Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy||Regina Elena Cancer Institute|No|Recruiting|January 2016|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|N/A|N/A|No|||January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02665156||4242|
NCT02672085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPT PRP|In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study|In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study|PRP Randomized|La Tour Hospital|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02672085||3713|
NCT02677623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP3450|Evaluation of Ureteral Patency in the Post-indigo Carmine Era|Evaluation of Ureteral Patency in the Post-indigo Carmine Era||Columbia University|No|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|137|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02677623||3289|
NCT02670382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2845|Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids|Role of EPA and DHA in Fish Oil on Inflammation and Lipoprotein Metabolism||Tufts University|No|Not yet recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02670382||3844|
NCT02682420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0018|everlinQ endoAVF Europe (EU) Study|everlinQ endoAVF EU Study||TVA Medical Inc.|No|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02682420||2921|
NCT02674828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509016461|Physical Activity and Glycemic Control in Adolescents|Physical Activity and Glycemic Control in Adolescents||Yale University|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|13 Years|24 Years|No|||February 2016|February 1, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02674828||3504|
NCT02674841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20150070|Live Feedback to Increase Adherence in Adolescents With Patellofemoral Pain|Efficacy of Live Feedback to Increase Objectively Monitored Adherence to Prescribed, Home-based, Exercise Therapy-dosage in 15 to 19 Year Old Adolescents With Patellofemoral Pain. A Randomized Controlled Superiority Trial||Aalborg University|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|19 Years|No|||February 2016|February 9, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02674841||3503|
NCT02676596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-312-1.02US|Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects|||Kowa Research Institute, Inc.|Yes|Completed|April 2014|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02676596||3368|
NCT02683187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00067061|DPP4 Inhibition & Beta Cell Function|Role of Alpha-cell GLP-1 in the Beta-cell Response to DPP-4 Inhibition||Duke University|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|70|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02683187||2862|
NCT02669342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-03435|Sharklet Catheter Study|Randomized Controlled Trial for the Early Clinical Experience and Evaluation of the Radiance Clear Sharklet Silicone Foley Catheter||University of British Columbia|No|Not yet recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|19 Years|N/A|No|||March 2016|March 14, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02669342||3924|
NCT02673866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-U202|Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)|A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)||Daiichi Sankyo Inc.|No|Not yet recruiting|February 2016|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|310|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673866||3578|
NCT02674880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.1(15PT).15 ComEt-CBM|Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance|Use of High-molecular Weight Hyaluronan in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Diseases Treated With Non-invasive Ventilation: Feasibility and Outcomes|HAEC-DONA|Campus Bio-Medico University|No|Not yet recruiting|March 2016|May 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674880||3500|
NCT02666703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRS-RPROJ-2014-191|Extracorporeal Cytokine Adsorption in Cardiac Surgery|Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery|IMEECCACS|University Medical Centre Ljubljana|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666703||4124|
NCT02678949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIMFG1|Changes in the Lung Clearance Index in Pediatric Patients With Asthma|Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator||Hospital Infantil de Mexico Federico Gomez|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|105|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02678949||3187|
NCT02666547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220/12|68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis|Value of PET/ CT in the 68Ga-NODAGA-RGD for the Evaluation of the Tumoral Neoangiogenesis||University of Lausanne Hospitals|No|Recruiting|December 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666547||4136|
NCT02675140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChengduWCCH|Effect of Hookworm Elimination and Vitamin A Intervention on Iron Status of Preschool Children in Sichuan, China|Chengdu Women's and Children's Central Hospital||Chengdu Maternal and Children's Health Care Hospital|Yes|Completed|March 2012|March 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|209|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02675140||3480|
NCT02677766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO_EFFI15_14|Occupational Therapy in Complex Patients: a Pilot Study|Occupational Therapy in Complex Patients: a Pilot Study|TO_EFFI15_14|University of Modena and Reggio Emilia|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02677766||3278|
NCT02667574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_36|Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)|Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)|VISMONEO|University Hospital, Lille|Yes|Active, not recruiting|November 2014|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667574||4057|
NCT02667587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-548|Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).|A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548|CheckMate548|Bristol-Myers Squibb|Yes|Not yet recruiting|March 2016|September 2020|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667587||4056|
NCT02675595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD thesis|5D Versus Conventional 2D Fetal Echocardiography During Second Trimester of Pregnancy|Prospective Evaluation of Fetal Intelligent Navigation Echocardiography (FINE)(5D) Versus Conventional 2D Echocardiography in Comprehensive Fetal Cardiac Imaging in the Second Trimester of Pregnancy||Ain Shams University|No|Recruiting|January 2016|May 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|80|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Second trimester pregnant women|January 2016|February 4, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675595|1 Day|3445|
NCT02668510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16/03|RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort|A Randomized Controlled Pilot Trial Comparing Extracorporeal Shock Wave Therapy With Platelet Rich Plasma Versus Extracorporeal Shock Wave Therapy in a High Demand Cohort With Resistant Plantar Fasciitis||William Beaumont Army Medical Center|No|Not yet recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668510||3985|
NCT02668523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-0010|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||February 10, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668523||3984|
NCT02668861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstTianjunMU|Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels|Influence of Oral Vitamin D3 on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis and Lower Vitamin D Levels||The First Affiliated Hospital of Shanxi Medical University||Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||January 2016|January 29, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668861||3959|
NCT02688075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107542|An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada|Prospective, Observational, 12-month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CANadian CAnagliflozin REgistry: CanCARE)|CanCARE|Janssen Inc.|No|Recruiting|November 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|535|||Both|18 Years|N/A|No|Non-Probability Sample|The registry population will include Canadian sodium-glucose co-transporter 2 (SGLT2)        naive type 2 diabetes mellitus (T2DM) participants, initiating canagliflozin as part of        their optimal treatment approach, based on the independent clinical judgment of their        treating physicians.|March 2016|March 9, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688075||2486|
NCT02665507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0630-15-HMO|Light Therapy for the Treatment of Back Pain in Pilots (LLL&Pilots)|Evaluation of the Efficacy of Light Therapy for the Treatment of Back Pain in Pilots|LLL&Pilots|Hebrew University of Jerusalem|No|Not yet recruiting|March 2016|August 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|January 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665507||4215|
NCT02668458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLORALI 2|Comparison of Pre-oxygenation of NIV and HFNC Therapy for Intubation of ICU Patients With Acute Respiratory Failure|Comparison of Pre-oxygenation by Non-invasive Ventilation With High-flow Nasal Oxygen Therapy for Intubation of Intensive Care Patients in Cases of Acute Respiratory Failure: A Prospective, Randomized, Controlled Study (FLORALI 2)|FLORALI2|Poitiers University Hospital|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02668458||3989|
NCT02668471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-09-58-14|U/S Guided vs. Traditional Palpation for Radial Artery Cannulation|Ultrasound-guided Compared With Traditional Palpation Radial Artery Cannulation in Critically Ill Children||Ramathibodi Hospital|Yes|Recruiting|August 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|1 Month|18 Years|No|||January 2016|January 26, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668471||3988|
NCT02669199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-007|MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound|Between Umbilical Cord Mesenchymal Stem Cells Sources Sweat Gland Samples of Large Area Skin Wound Injury Patients Before and After the Transplant Center, Open, Random, Own More Controlled Clinical Trials|MSCs|Chinese PLA General Hospital|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02669199||3934|
NCT02669472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI|Fresh to You: Multilevel Approaches in Low Income Housing to Increase F&V Intake|Fresh to You: Multilevel Approaches in Low Income Housing to Increase F&V Intake|LWVB|Brown University|No|Completed|April 2009|June 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1598|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02669472||3914|
NCT02680470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WS/0004|Virtual Observed Therapy for Patients With Tuberculosis|Virtual Observed Therapy for Patients With Tuberculosis||University of Edinburgh|No|Recruiting|August 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02680470||3071|
NCT02680483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JoAFR-JCCG|Atrial Fibrillation Registry in Jordan|Atrial Fibrillation Registry in Jordan|JoAFR|Jordan Collaborating Cardiology Group|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|100 Years|No|Non-Probability Sample|All new admissions with atrial fibrillation above the age of 18 or those who develop        atrial fibrillation during hospitalization for non AF reason.|February 2016|February 17, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680483|1 Year|3070|
NCT02665793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2445 vs4.1 27.12.2015|Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study|Mechanisms Underlying the Change in Threshold or Severity of Peanut-allergic Reactions in TRACE Peanut Study Participants - Extension Study|TRACEextension|Imperial College London|Yes|Not yet recruiting|May 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|45 Years|No|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665793||4193|
NCT02666183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6Y15|Online Information and Support for Distance Caregivers|Online Information and Support for Distance Caregivers||Case Comprehensive Cancer Center|No|Not yet recruiting|June 2016|June 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|613|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666183||4164|
NCT02674100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-326|AHPBA Pancreatic Irreversible Electroporation (IRE) Registry|AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer||University of Louisville|No|Recruiting|January 2016|January 2030|Anticipated|January 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Each participating center will need to describe its own mechanism for patient        identification and eligibility screening.|February 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674100|2 Years|3560|
NCT02674113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211908|Regional Anesthesia in Hip Arthroscopy|Use of Regional Anesthesia in Hip Arthroscopy||University of Missouri-Columbia|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02674113||3559|
NCT02516410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-107|A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|August 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|N/A|No|||October 2015|October 28, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516410||15665|
NCT02688517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001209|Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer|Targeted Genomic Analysis of Human Cancers||Rutgers, The State University of New Jersey|No|Recruiting|February 2013|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1100|||Both|1 Year|N/A|No|||February 2016|February 17, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688517||2452|
NCT02661919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00042423|Assessment of the Emfit Mattress Sensor for Detection and Alarm of Night-time Generalized Tonic-clonic Seizures.|Assessment of the Emfit Mattress Sensor (L-4060SLC) and Monitor (DVM-GPRS-V2) and Their Acoustic and Cloud Interface Notification Capabilities as a Nocturnal Detection System for Movements Associated With Generalized Tonic-clonic Seizures.||Emfit, Corp.|No|Enrolling by invitation|February 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|89 Years|No|||January 2016|January 20, 2016|March 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02661919||4491|
NCT02669121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-211|Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults|Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years||Takeda|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3400|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669121||3940|
NCT02671071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACOG 0215/EVA 001|Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study|Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study||Latin American Cooperative Oncology Group|Yes|Not yet recruiting|February 2016|November 2019|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Female|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with cervical cancer in 1-year period (recently diagnosed IB to IIA        high risk or IIB-IVB or recurrent disease - FIGO stages) at the participating sites will        be included in the study.|January 2016|February 25, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02671071|3 Years|3791|
NCT02688634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500667|The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair|The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair|Cleft Palate|University of Florida|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|60 Years|No|||February 2016|February 22, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688634||2443|
NCT02688647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD025-207|A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis|A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||Kadmon Corporation, LLC|No|Not yet recruiting|March 2016|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688647||2442|
NCT02662231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlobalSurg-II|Determining the Worldwide Epidemiology of Surgical Site Infections After Gastrointestinal Surgery|Determining the Worldwide Epidemiology of Surgical Site Infections After Gastrointestinal Surgery|GlobalSurgII|University of Birmingham|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|Consecutive patients undergoing emergency, or elective gastrointestinal resection,        cholecystectomy and appendectomy.|January 2016|January 19, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02662231||4467|
NCT02669147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1517|A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC|A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC|DELC|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Enrolling by invitation|November 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|20 Years|N/A|No|Non-Probability Sample|CRPC patients who are observed PSA or disease progression after anti-androgen therapy and        decided to administrate Enzalutamide|January 2016|February 3, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669147||3938|
NCT02669160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0032|Tolerance of a Motorized Orthosis Reproducing Walking Movement vs Conventional Standing-up Devices in Child With CP|Tolerance of a Motorized Orthosis Reproducing Walking Movement Versus Conventional Passive Standing-up Devices in Children With Cerebral Palsy : A Non-inferiority, Randomised, Multicenter, Controlled Trial|EOMEC/CP|Lille Catholic University|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|36|||Both|6 Years|16 Years|No|||January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669160||3937|
NCT02663960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-950|Compare Efficacy and Simplicity of Regional Citrate Anticoagulation With Fixed Dose Versus Adjusted Citrate Program|Is Regional Citrate Anticoagulation With Fixed Citrate Blood Concentration More Effective and Easy-to-handle Than Adjusted-dose Protocol in Adult Critically Ill Patients? A Cohort Study||Peking Union Medical College Hospital|Yes|Recruiting|August 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02663960||4334|
NCT02668055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-005|Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds|Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitutes Treatment of Difficult to Heal Wounds Single-center Randomized Parallel Controlled Clinical Studies|TB4|Chinese PLA General Hospital|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|17 Years|78 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02668055||4020|
NCT02688179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160032|Neuroinflammation and Postoperative Delirium in Cardiac Surgery|||Vanderbilt University|Yes|Recruiting|January 2016|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients over the age of 18 undergoing open heart surgery|February 2016|February 22, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02688179||2478|
NCT02678104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRP/2016/23|The Influence of Intra-alveolar Application of Honey on Healing Following Extraction|The Influence of Intra-alveolar Application of Honey on Healing Following Molar Teeth Extraction: A Randomized Clinical Trial||Riyadh Colleges of Dentistry and Pharmacy|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02678104||3252|
NCT02668315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM0128171|Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant|A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor||Maisonneuve-Rosemont Hospital|Yes|Recruiting|January 2016|January 2021|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|3 Years|60 Years|No|||January 2016|January 28, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02668315||4000|
NCT02688452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00230|Water Oxygenation and Brain Activity|Water Oxygenation and Brain Activity: A Magnetoencephalographic (MEG) Pilot Study||New York University School of Medicine|No|Active, not recruiting|December 2012|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02688452||2457|
NCT02665351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peramivir in adult influenza_1|Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections|A Phase 2, Pilot, Open-label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects With Confirmed Influenza Infection||Chinese University of Hong Kong|No|Completed|February 2011|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02665351||4227|
NCT02675517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.42|Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice|Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice||Boehringer Ingelheim||Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|40 Years|N/A|No|Probability Sample|COPD patients|March 2016|March 16, 2016|January 29, 2016||||No||https://clinicaltrials.gov/show/NCT02675517||3451|
NCT02675530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612002073|Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism|Parallel Effects of Ketamine and Schizophrenia on Neurocognitive Function||Yale University|No|Completed|December 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT02675530||3450|
NCT02688543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF knee 001|Radiofrequency Ablation of Genicular Nerves for Advanced Osteoarthrosis of the Knee Joint 1 Year Follow-up.|Analgesic Effect and Functional Improvement Caused by Radiofrequency Ablation of Genicular Nerves in Patients With Advanced Osteoarthrosis of the Knee Joint Until 1 Year Following Treatment||Hospital General de Jerez de la Frontera|No|Completed|March 2013|January 2016|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688543||2450|
NCT02678143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201602019|Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease|A Pilot Study of Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease||Washington University School of Medicine|No|Not yet recruiting|March 2016|May 2020|Anticipated|May 2020|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||March 2016|March 19, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678143||3249|
NCT02678156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1403|Assessment of the Performance of LYoplant® ONlay for Duraplasty|Assessment of the Performance of LYoplant® ONlay for Duraplasty. A Non-interventional, Multi-centre Post Market Clinical Follow-up (PMCF) Study.|LYON|Aesculap AG|No|Not yet recruiting|February 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients|February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678156||3248|
NCT02665624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNEAH-2015/KK/04|Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation|Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation||Camlıca Erdem Hospital|Yes|Completed|April 2015|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02665624||4206|
NCT02665637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P6 1.5|Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin|A Randomized, Double-blind, Two-arm, Parallel-group, Single Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Two Formulations of Trastuzumab (CT-P6 and US-licensed Herceptin) in Healthy Subjects||Celltrion|Yes|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|70|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|February 10, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665637||4205|
NCT02677090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.10.NRC|Fiber Tolerability in Children Aged 3-7 Year|Fiber Tolerability In Children Aged 3-7 Year|Fiber - TIC|Nestlé|No|Completed|January 2016|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|36|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||January 2016|March 9, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02677090||3330|
NCT02665494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-CAUSE|Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors|Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors||Fondazione del Piemonte per l'Oncologia|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|patients with diagnosis of all-stages cholangiocarcinoma, including rare and crossing-over        histological types, and excluding gallbladder cancer and ampullary carcinoma|January 2016|January 26, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02665494||4216|
NCT02678169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 9508|European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke|A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke|PROMISE|Penumbra Inc.|Yes|Recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|N/A|No|Probability Sample|Present with symptoms consistent with an acute ischemic stroke within 6 hours of stroke        symptom onset. Arterial occlusion of the distal intracranial carotid artery (ICA and ICA        terminus) or middle cerebral artery (M1/M2)|February 2016|March 14, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02678169||3247|
NCT02678182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3804|Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial|Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial|PLATFORM|Royal Marsden NHS Foundation Trust|Yes|Recruiting|February 2015|February 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|616|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02678182||3246|
NCT02662296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2561.00|Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant|A Phase II, Non-randomized , Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, to Treat Patients With Persistent or Relapsed B-Cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|February 2016|||February 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662296||4462|
NCT02664948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-TOP-2015|Early Geriatric Follow-up in Older Acute Medical Patients|Early Geriatric Follow-up After Hospital Discharge in Older Acute Medical Patients - a Quasi Randomized Controlled Trial||University of Aarhus|No|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|75 Years|N/A|No|||December 2015|January 22, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02664948||4258|
NCT02664961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105GTN201|Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)|A Phase 2A Study of TRC105 (With Option to Add Standard Dose Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)||Tracon Pharmaceuticals Inc.|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|99 Years|No|||January 2016|January 22, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664961||4257|
NCT02690402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-12|Fragility and Adapted Physical Activity|Fragility Multidisciplinary Evaluation and Adapted Physical Activity||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|April 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|970|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02690402||2308|
NCT02678208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBBH|The Effect of Tranexamic Acid on Uterine Blood Flow After Vaginal Delivery|||Assiut University|No|Completed|February 2015|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|40 Years|No|||February 2016|February 27, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678208||3244|
NCT02666625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00555-34|Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank|Study of Iatrogenic Effects of Treatment for Childhood Cancer - Constitution of a Biological Samples Bank as Part of a Cohort of Patients (Cohort FCCSS)|BIO-F|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|December 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Probability Sample|Patients treated for a paediatric malignancies before the year 2000 having survived two        years after treatment of solid tumor diagnosed before 18 years old|January 2016|January 25, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02666625|7 Years|4130|
NCT02666638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01932|Technical Development of up to 7T Magnetic Field Strength|Technical Development of up to 7T Magnetic Field Strength||New York University School of Medicine|No|Recruiting|July 2015|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666638||4129|
NCT02678676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-4833/EC445|An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications|An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.||Takeda|No|Completed|November 2004|November 2011|Actual|November 2011|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3599|||Both|36 Years|75 Years|No|Probability Sample|High-risk T2DM participants previously treated with pioglitazone and placebo in PROactive        study (NCT00174993) were included in this study.|February 2016|February 7, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02678676|10 Years|3208|
NCT02678923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-APO-15-01|MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial|A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Treatment on Plaque Burden as Determined by Intravascular Ultrasound and to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of MDCO-216 Given as Multiple Weekly Infusions in Subjects With a Recent Acute Coronary Syndrome|PILOT|The Medicines Company|Yes|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678923||3189|
NCT02663830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIOO|The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene|The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial.||Ain Shams University|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|210|||Female|21 Years|35 Years|No|||January 2016|January 21, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663830||4344|
NCT02662010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2029|The Relationship Between Advanced Glycation Endproducts and Diabetes|The Relationship of Advanced Glycation Endproducts in the Anterior Lens Capsule to Glycemic Status and Diabetic Retinopathy: A Cross Sectional Study of Patients With and Without Type 2 Diabetes Mellitus Undergoing Cataract Surgery||University of Colorado, Denver|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|Samples With DNA|Buffy Coat|Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The Investigators propose recruiting 80 subjects (40 with no diabetes, 20 with diabetes        and no diabetic retinopathy and 20 with diabetes and diabetic retinopathy).        Within the 40 control patients without a clinical diagnosis of T2DM, 20 will have an        abnormal HbA1C at the time of surgery. It is important to enroll the patients with an        abnormal HbA1C in order to see if there are early manifestations of an abnormal glucose        level as detected by AGEs in the anterior lens capsule.|January 2016|January 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662010||4484|
NCT02666859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016934|Virtual Reality Prosthetic Training and Rehabilitation|The Use of Virtual Reality to Enhance Upper Limb Prosthetic Training and Rehabilitation||University of South Florida|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666859||4112|
NCT02689375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM13/10904|A Prospective, Open Label, Pilot Study of Patient OutcoMes Following Successful TriAl of High Frequency SpInal CorD Stimulation at 10kHz (HF10™) Leading to Permanent Implant Compared to Trial Failure and Standard CarE for the TreatmeNt of Persistent Low BACK Pain of Neuropathic Origin|Rospective, Open Label, Pilot Study of Patient OutcoMes Following Successful TriAl of High Frequency SpInal CorD Stimulation at 10kHz (HF10™) Leading to Permanent Implant Compared to Trial Failure and Standard CarE for the TreatmeNt of Persistent Low BACK Pain of Neuropathic Origin|Maiden Back|The Leeds Teaching Hospitals NHS Trust|No|Recruiting|February 2015|||August 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|100 Years|No|||February 2016|February 18, 2016|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02689375||2386|
NCT02664064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB20152184|Evaluation of Prevent in Underserved Populations|Evaluation of an Online Diabetes Prevention Program Adapted for Safety Net Users|PUP|Omada Health, Inc.|No|Recruiting|January 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02664064||4326|
NCT02670798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506098|Thromboelastography Transfusion Protocol for Pediatric Neuromuscular Scoliosis Surgery|Implementation of a Thromboelastography Guided Transfusion Protocol in Pediatric Neuromuscular Scoliosis Surgery||Washington University School of Medicine|Yes|Recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|12 Years|18 Years|No|||January 2016|January 28, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670798||3812|
NCT02670096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00756|A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing|A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing||New York University School of Medicine|No|Recruiting|January 2016|March 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02670096||3866|
NCT02679456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCY-078-203|Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis|A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis||Scynexis, Inc.|No|Recruiting|November 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 6, 2016|January 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679456||3148|
NCT02679469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339-102-00003|A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects|||Otsuka Pharmaceutical Co., Ltd.|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02679469||3147|
NCT02677662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-69-31M|Longitudinal Acute Air Pollution Systemic Effects|Longitudinal Acute Air Pollution Systemic Effects (LAPSE)|LAPSE|Umeå University|No|Recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02677662||3286|
NCT02664311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000419|A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation|A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation||Beth Israel Deaconess Medical Center|Yes|Terminated|February 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|85 Years|No|||January 2016|January 22, 2016|September 24, 2014||No|under enrollment|No||https://clinicaltrials.gov/show/NCT02664311||4307|
NCT02663037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRI 2016/0001|Simple Segmentation Tool to Understand Elderly Health Status and Needs|Developing A Simple Segmentation Tool to Understand Elderly Health Status and Needs in Singapore||National University, Singapore|No|Not yet recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|204|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from a pool of elderly patients who present to the Emergency        Department.|January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663037||4405|
NCT02676505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KasrELAini maternity hospital|Effect of the Length of Second Stage of Labor in Primigravidae on Maternal & Neonatal Outcomes|Effect of the Length of Second Stage of Labor in Primigravidae on Maternal & Neonatal Outcomes|RCT|Kasr El Aini Hospital|Yes|Active, not recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|434|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|The study was conducted on 434 primigravidae women admitted to Kasr El Ainy teaching        Maternity Hospital for labor. The study will be done in the period between October 2015        and April 2016. The study will include 434 women with the diagnosis of the first stage of        labor with at least cervical dilatation 4cm.|February 2016|February 4, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02676505|6 Months|3375|
NCT02691169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNMP-01|Integrated 18F-labelled PSMA Project|Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Subjects With Castration-Resistant Prostate Cancer||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|18 Years|N/A|No|||March 2016|March 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02691169||2250|
NCT02676687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurosurg02|Supratotal Resection for Gliomas Within Noneloquent Areas|Supratotal Resection for Gliomas Within Noneloquent Areas: A Single Center Prospective Randomized Controlled Clinical Trial||Southwest Hospital, China|Yes|Recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02676687||3361|
NCT02663375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-04|ACURATE TA™ Valve Implantation Registry: SAVI 2|Symetis ACURATE TA™ Valve Implantation Using TransApical Access:SAVI2 Registry|TA-SAVI2|Symetis SA|No|Completed|November 2013|January 2016|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|||Both|N/A|N/A|No|Non-Probability Sample|ACURATE TA™ is approved for use to treat patients with severe aortic stenosis, the        inclusion criteria are broad in order to allow the device to be used in an all-comers        population and following the Instructions For Use.|February 2016|February 12, 2016|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02663375|1 Year|4379|
NCT02663388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01175-44|Epigenetic Mechanisms and Severe Obesity (Biological Tissue Collection)|Influence of Vitamins Status on Severe Obesity Related Complications|OBESEPI|University of Lorraine||Recruiting|January 2016|||January 2026|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|blood, liver, fat tissue (subcutaneous, visceral, mesenteric), small bowell, feces|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who undergo bariatric surgery following french national guidelines (HAS 2009)|January 2016|January 20, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02663388|10 Years|4378|
NCT02662361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-REV-2014027|Evaluation of the Prevalence and Risk Factors for Patients With Peri-implant Disease：a Retrospective Study|The Prevalence and Risk Factors for Patients With Peri-implant Disease：a Retrospective Study||Fourth Military Medical University|Yes|Recruiting|October 2014|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|131|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients restored with implant-supported fixed partial dentures and single crowns at the        Department of Prosthodontics, School of Stomatology of the Fourth Military Medical        University between January 2011 to May 2014.|January 2016|January 20, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662361||4457|
NCT02683460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patella resurfacing|Patellar Resurfacing Under Subvastus Approach in Total Knee Arthroplasty|Comparison of Clinical Results of Patella Resurfacing Versus Patellar Retention Under Subvastus Approach in Total Knee Arthroplasty: A Randomized, Controlled, Double-Blind Trial||The Catholic University of Korea|No|Not yet recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||February 2016|February 16, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02683460||2841|
NCT02673879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC REF No. 370/2015|IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion|A Trial of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults With Large Pericardial Effusion Due to Tuberculous and Non-tuberculous Pericarditis|IMPI-2|University of Cape Town|Yes|Recruiting|February 2016|January 2020|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2176|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673879||3577|
NCT02663648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell cycle regulatory gene-MPD|Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders|Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders||Shandong University|Yes|Not yet recruiting|June 2016|June 2020|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis        (MF) or chronic myeloid leukemia (CML) as defined by the World Health Organization (WHO)        diagnostic criteria|January 2016|January 21, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02663648||4358|
NCT02671110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300066-10|A Trial Comparing Two Approaches to Weight Loss|A Randomized Trial Comparing Two Approaches to Weight Loss||Bowling Green State University|No|Completed|August 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02671110||3788|
NCT02680496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOKOMAT-I|Energy Consumption and Cardiorespiratory Load During Walking With and Without Robot-Assistance|||Vrije Universiteit Brussel||Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02680496||3069|
NCT02671812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OF13122003|Outcome After Dental Implant Treatment|Longterm Outcome After Dental Implant Treatment||Folktandvården Stockholms län AB|No|Enrolling by invitation|April 2015|June 2018|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|Saliva and gingival fluid|Both|20 Years|N/A|No|Probability Sample|All patients treated with dental implants at the Specialist Clinic Skanstull, Stockholm,        Sweden, between 1999-2005|February 2016|February 4, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02671812||3734|
NCT02663921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02039|Visible Light Study|Determination of the Minimal Dose of Visible Light Required to Achieve Immediate Pigment Darkening, Persistent Pigment Darkening, and Delayed Tanning for Fitzpatrick Skin Types IV-VI Utilizing Two Visible Light Sources.||New York University School of Medicine|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663921||4337|
NCT02662621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01638-39|Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors|Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for Early Diagnosis of Malgnant Solid Tumors|EXODIAG|Centre Georges Francois Leclerc|No|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|March 11, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662621||4437|
NCT02672202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614-15-RMB Hernia_CTIL|Shifting Pain Modulation From Pro-to Anti-nociceptive|Shifting Pain Modulation From Pro-to Anti-nociceptive: Individualized Prevention of Post Operative Pain||Rambam Health Care Campus|No|Not yet recruiting|February 2016|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02672202||3704|
NCT02676960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204890|Feasibility Study: MRI on 6 Months, 1 Year, and 2 Years Old Children Without Sedation|Feasibility Study: MRI on 6 Months, 1 Year, and 2 Years Old Children Without Sedation||Arkansas Children's Hospital Research Institute|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|45|||Both|6 Months|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Up to 15 healthy term infants age ~6 months, up to 15 healthy term infants age ~1 year and        another up to 15 healthy toddlers at age 2 years.|February 2016|February 4, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02676960||3340|
NCT02674919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHE-2016-LI|Nordic Hamstring and Repeated-sprint Ability in Football (Soccer) Players|The Efficacy of a 10-week Intervention, Using the Nordic Hamstring Exercise, on Repeated-sprint Ability in Football (Soccer) Players - a Randomized Controlled Trial||Hvidovre University Hospital|No|Active, not recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|35|||Male|17 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674919||3497|
NCT02690480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2014-12|Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease|A Randomized, Double-blind, Parallel-group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FaslodexTM) 500mg With Placebo and Fulvestrant (FaslodexTM) 500mg in Combination With PD-0332991 (Palbociclib) as First Line Treatment for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer, Who Have Completed at Least 5 Years of Adjuvant Endocrine Therapy and Remained Disease Free for More Than 12 Months Following Its Completion or Have "de Novo" Metastatic Disease. "The FLIPPER Study"|FLIPPER|Spanish Breast Cancer Research Group|No|Recruiting|February 2016|December 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690480||2302|
NCT02669615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO0|Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation||Medical College of Wisconsin|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669615||3903|
NCT02674971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTKIRB-15-02609|Lowering Caloric Density of the Diet||Lower CD|University of Tennessee||Recruiting|December 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02674971||3493|
NCT02688426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLT-CABG-2016/1|Effects of the Low-level Laser Therapy on Functional Capacity of the Patients With Coronary Artery Bypass Surgery|Effects Acute of the Low-level Laser Therapy on Functional Capacity on Patients With Coronary Artery Bypass Surgery : A Randomized, Controlled Clinical Trail||Federal University of Health Science of Porto Alegre|No|Recruiting|March 2015|June 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|40 Years|75 Years|No|||March 2016|March 21, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688426||2459|
NCT02670226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO15-HB-METABOMU|Muscular Biomarkers in Amyotrophic Lateral Sclerosis|Metabolomics and Transcriptomics Approaches to Identify Muscular Biomarkers in Amyotrophic Lateral Sclerosis|METABOMU|University Hospital, Tours|No|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02670226||3856|
NCT02663869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aging with HIV|Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles|Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles|Aging_in_HIV|University of Modena and Reggio Emilia|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|1600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected and not infected people|January 2016|January 27, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02663869||4341|
NCT02664363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00069444|EGFRvIII CAR T Cells for Newly-Diagnosed GBM|EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia|ExCeL|Duke University|No|Not yet recruiting|March 2016|August 2023|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02664363||4303|
NCT02670863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.15.INF|Safety and Efficacy Study|Safety and Efficacy of a New Term Infant Formula Supplemented With A Prebiotic: a Doubleblind, Randomized, Controlled Trial||Nestlé|No|Recruiting|January 2016|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|260|||Both|N/A|26 Days|Accepts Healthy Volunteers|||January 2016|February 3, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02670863||3807|
NCT02664272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL MIA rasp 15-4567-03|Intraoperative Case Series Study: Trial Rasp Position Versus SL-PLUS™ MIA Ti/HA Femoral Hip Stem Position|Intraoperative Case Series Study: Trial Rasp Position Versus SL-PLUS™ MIA Ti/HA Femoral||Smith & Nephew, Inc.|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|21 Years|N/A|No|Non-Probability Sample|Patients enrolled in this multicenter clinical observation will have at least one of the        indications listed below and meet all of the inclusion criteria. Patients meeting any of        the exclusion criteria are not eligible for this study.        Indications:          -  Advanced hip joint wear due to degenerative, post-traumatic or rheumatoid arthritis          -  Fracture or avascular necrosis of the femoral head          -  Follow-on conditions after previous surgery such as osteosynthesis, joint             reconstruction, arthrodesis, hemiarthroplasty or total hip replacement.|January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664272||4310|
NCT02521298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15002993|Treatment of Lateral Elbow Tendinopathy|Lateral Elbow Tendinopathy: A Randomized Controlled Trial Examining The Treatment Effect Of Strength Training Combined With Cortico-Steroid Injection, Dry-Needling Or Placebo||Bispebjerg Hospital|No|Not yet recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||August 2015|August 9, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02521298||15289|
NCT02521311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17428|Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)|A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis|ReCOVER|University of California, San Francisco|No|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||August 2015|August 10, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521311||15288|
NCT02691000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151558|The Light Heart Study: Daily Light Box Use for Depressive Symptoms in Patients With Stage B Heart Failure|The Light Heart Study: Daily Light Box Use for Depressive Symptoms in Patients With Stage B Heart Failure|Light-Heart|University of California, San Diego|No|Recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02691000||2262|
NCT02666053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-071|A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects|A Study to Assess the Effect of a High-fat Meal and Increased Gastric pH on the Bioavailability of an Extended-release Formulation of BMS-663068 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2016|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666053||4174|
NCT02666066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-43-05/08-intern|Radiomics for Prediction of Survival in GBM|Radiomics for the Prediction of Survival in GBM After Radiotherapy With/Without Temozolomide|Radiomics|Maastricht Radiation Oncology|No|Recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Histologically proven glioblastoma, diagnosed with a biopsy only, and treated with        curative intent|January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666066||4173|
NCT02672943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG8D6031|Parkinson Disease Before and After Medication and Rehabilitation Treatment|The Role of Noradrenergic Network, and Its Association With Autonomous Dysfunction,Cerebral Autoregulation and microRNA in Parkinson Disease Before and After Medication and Rehabilitation Treatment||Chang Gung Memorial Hospital|No|Active, not recruiting|January 2016|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02672943||3648|
NCT02675868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53411.091.015|Effects of Vasopressors on Immune Response|The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study||Radboud University|No|Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02675868||3424|
NCT02662595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMI-01|mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau|Mimi - mHealth to Increase Measles Immunization. A Randomized Controlled Trial.|mimi|Bandim Health Project|No|Not yet recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Health Services Research|3||Anticipated|1050|||Both|N/A|3 Months|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662595||4439|
NCT02683161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071969|Pre to Postoperative Smoking Cessation|Pre to Postoperative Smoking Cessation||Johns Hopkins University|No|Recruiting|October 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 10, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02683161||2864|
NCT02683174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0225|Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)|Diagnostic Yield of an Ambulatory Patch Monitor in Emergency Department Syncope Patients Unexplained After Emergency Department Evaluation: A Pilot Study (PATCH-ED)|PATCH-ED|NHS Lothian|No|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|16 Years|N/A|No|||February 2016|February 16, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02683174||2863|
NCT02683447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140-2015|Ageing and Acute Care Physicians' Performance|Impact of Acute Care Physician's Age on Crisis Management Performance and Learning After Simulation-based Education||Sunnybrook Health Sciences Centre|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683447||2842|
NCT02666534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUderma-05|Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma|A Randomised Trial Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: Results From a 24-month Follow-up||Dong-A University|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|65 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666534||4137|
NCT02678026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/888|Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth|Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth||Federico II University|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|50 Years|No|||February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678026||3258|
NCT02668068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-SH/NCH/IGDB|A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells|A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis||Chinese Academy of Sciences|No|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02668068||4019|
NCT02687555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32-12/14|The Role of Computerized Training in Post-Traumatic Stress Disorder|The Role of Computerized Training in Post-Traumatic Stress Disorder||Ruhr University of Bochum|No|Recruiting|February 2016|February 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||March 2016|March 2, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02687555||2526|
NCT02687568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4439-12|Values of Enhanced Monitoring by EEG Recording (Narcotrend) for Sedation in Colonoscopy|Values of Enhanced Monitoring by EEG Recording ( Narcotrend ) as an Adjunct to Standard Monitoring for Sedation in Colonoscopy||Ruhr University of Bochum|No|Recruiting|May 2014|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Included are patients which is a , diagnostic or interventional colonoscopy under sedation        with propofol.|February 2016|March 5, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02687568||2525|
NCT02662985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2354|Study of Application of Power Doppler Ultrasonography (PDUS) to Measure Response to Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)|A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis|PDUS|Novartis|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662985||4409|
NCT02663284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/67|Evaluation of the Physiodoloris Pain Monitor in Patients With Complex Regional Pain Syndrome|Evaluation of Non-invasive Monitor of Physiodoloris Pain in Patients With Complex Regional Pain Syndrome Treated by Nerve Block (Prospective Monocenter Study)|ANI-ALGO|Hopital Foch|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02663284||4386|
NCT02665117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092015-058|Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate|Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665117||4245|
NCT02669173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7315|Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma|Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma||Case Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669173||3936|
NCT02669186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039201-1|Effects of Anesthetic Technique on NK Cells|Effects of Anesthetic Technique on Natural Killer Cell Population and Cytotoxicity||Cedars-Sinai Medical Center|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669186||3935|
NCT02677012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0006|Comparison of Time Associated With Techniques to Process Autologous Fat Grafts|A Randomized, Prospective Comparison of Time Associated With Techniques to Process Autologous Fat Grafts||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02677012||3336|
NCT02665026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2015-276|Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Surgery for Rectal Cancer|A Single Center, Open, Randomized Clinical Trials, Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Total Mesorectal Excision for Middle and Low Rectal Cancer||Huashan Hospital|Yes|Recruiting|January 2016|||December 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|70 Years|No|||January 2016|January 23, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02665026||4252|
NCT02671552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12P.615|Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery|Contrast-Enhanced Ultrasound for the Evaluation of Renal Cell Carcinoma Cryoablation||Thomas Jefferson University|No|Recruiting|January 2013|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671552||3754|
NCT02671565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204982-01|Comparative Effectiveness of Hyaluronic Acid Injections for Management of Knee Osteoarthritis|Comparative Effectiveness of Hyaluronic Acid Injections to Prevent/Delay Knee Surgical Interventions Among Patients With Knee Osteoarthritis||University of Arkansas|No|Not yet recruiting|February 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|20000|||Both|40 Years|100 Years|No|Non-Probability Sample|Patients with a moderate to severe knee OA identified by using a specialist visit along        with recent history of pain medication use (proxy for moderate to severe pain)|February 2016|February 3, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02671565||3753|
NCT02670018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DMCL005|BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/2000 mg(25/1000 mg x 2 Tablets) in Comparison to Each Component Gemigliptin 50 mg and Metformin HCl Extended Release 2000 mg(1000 mg x 2 Tablets) Administered in Healthy Male Volunteers||LG Life Sciences|No|Enrolling by invitation|August 2015|March 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02670018||3872|
NCT02677194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-AOI-12|HeaLED: Pilot Study of Skin Healing Under LED Exposure|Stimulation of Cutaneous Healing Processes With LED: a Controlled Comparative Study to Identify Optimal Settings|HeaLed|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|February 2016|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 4, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02677194||3322|
NCT02677233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vid-20|Association Between Vitamin D Deficiency and Preeclampsia: A Case Control Study|||Ain Shams Maternity Hospital|Yes|Completed|June 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|90|Samples Without DNA|serum|Female|18 Years|35 Years|No|Non-Probability Sample|This study will be carried out on 90 pregnant women recruited at pre labour room at Ain        Shams University Maternity Hospital. They will be divided into preeclamptic group and non        preeclamptic group, 45 cases in each one|February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677233||3319|
NCT02688673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-DC/CIK-SCLC|DC Vaccine Combined With CIK Cells in Patients With SCLC|Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Extensive-Stage Small- Cell Lung Cancer: a Phase I/II Study||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|August 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||October 2015|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688673||2440|
NCT02688816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0399|Comparison of Cervical Cancer Screening Tests in HIV-infected Women in Lusaka, Zambia|Z 1313 - Comparison of Point-of-care Molecular Tests and Visual Inspection With Acetic Acid for Cervical Cancer Screening in HIV-infected Women in Lusaka, Zambia||University of North Carolina, Chapel Hill|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|200|||Female|18 Years|N/A|No|Non-Probability Sample|HIV-infected women undergoing cervical cancer screening in Lusaka, Zambia|February 2016|February 17, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688816||2429|
NCT02663856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MySAwH|My Smart Age With HIV: Smartphone Self-assessment of Frailty|My Smart Age With HIV (MySAwH): Smartphone Self-assessment of Frailty and Information - Communication Technology to Promote Healthy Ageing in HIV.|MySAwH|University of Modena and Reggio Emilia|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|50 Years|N/A|No|Non-Probability Sample|In a prospective 24 months study, 300 consecutive HIV positive patients aged>50 years (100        per centre)will be enrolled to assess primary objective.|January 2016|January 27, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663856||4342|
NCT02674542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCPM 21416|Family Planning Intentions and Practices Among Women With Poor Obstetric Outcome|Family Planning Intentions and Practices Among Women Who Have Experienced a Poor Obstetric Outcome: a Qualitative Study||University of North Carolina, Chapel Hill|No|Active, not recruiting|February 2015|June 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|60 women who have experienced a stillbirth or early neonatal death. Study participants        will be recruited from the postnatal wards at Bwaila Maternity Hospital in Lilongwe,        Malawi.|February 2016|February 1, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02674542||3526|
NCT02677922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-221-AML-005|A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy||Celgene|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677922||3266|
NCT02677935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nmp/22182|Impact of Peer Education Program on Headache Disorders|Impact of Peer Education Program on Headache Disorders in Rural Communities, India: a Quasi-experimental Study||NMP Medical Research Institute|Yes|Completed|January 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|360|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677935||3265|
NCT02664103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPCYR07568|Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer|A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer|METRO-ABC|Sanofi|Yes|Recruiting|January 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Female|18 Years|65 Years|No|||March 2016|March 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02664103||4323|
NCT02669082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramelteon-4002|The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy|The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy||Takeda|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|64 Years|No|||February 2016|February 3, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669082||3943|
NCT02665884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0085-15-HYMC|Diurnal Fluctuations of Intraocular Pressure in EX-Press Valve Blebs in Glaucoma Patients|||Hillel Yaffe Medical Center|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|30 Years|80 Years|No|Probability Sample|The study will include 20 open-angle glaucoma (OAG) patients underwent Ex-Press filtration        surgery, and 20 OAG patients treated with medications alone.|November 2015|January 24, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02665884||4186|
NCT02665897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET|Pre-eclampsia and Biochemical Markers|Correlation Between Complications of Pre-eclampsia and Detection of Novel Biochemical Markers|PET|Assiut University|Yes|Recruiting|December 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|96|||Female|20 Years|40 Years|No|Probability Sample|Pregnant women after 20 weeks|January 2016|January 25, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665897||4185|
NCT02690441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971427272T1|Physical Exercise Augmented CBT for GAD|Physical Exercise Augmented Cognitive Behaviour Therapy for Older Adults With Generalised Anxiety Disorder|PEXACOG|Solli Distriktspsykiatriske Senter|No|Not yet recruiting|March 2016|December 2021|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|60 Years|75 Years|No|||February 2016|February 18, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690441||2305|
NCT02690454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUMK202E|Which Platelet Function Test Best Reflects the In Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite?|Which Platelet Function Test Provides the Best Reflection of the in Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite? A Pharmacokinetic and Pharmacodynamic Study Including Patients With Myocardial Infarction.|HARMONIC|Collegium Medicum w Bydgoszczy|No|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|80 Years|No|Probability Sample|Patients with myocardial infarction|February 2016|February 19, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02690454||2304|
NCT02664337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00067150|Conjoint Analysis of Patient Preferences in Joint Interventions|Conjoint Analysis of Patient Preferences in Joint Interventions||Duke University|No|Not yet recruiting|February 2016|February 2021|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2310|||Both|18 Years|85 Years|No|||January 2016|February 2, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664337||4305|
NCT02664571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/DM-01|Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis|Evaluation of Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis|FBB ACC|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|January 2017|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|32|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664571||4287|
NCT02672579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081076|Study of Kids Itch Severity (SKIS)|Study of Kids Itch Severity (SKIS): "Validation and Mobilization of Pediatric Pruritus Outcome Instruments"|SKIS|Emory University|No|Enrolling by invitation|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|235|||Both|4 Years|17 Years|No|Non-Probability Sample|Children between the ages of 4 and 17 who have chronic pruritus (for 6 weeks or longer).        The information detailed below is reflective of the pediatric population which is the        primary focus of this study though the parents and clinicians will also complete surveys.|January 2016|January 29, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02672579||3676|
NCT02672774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN-II-RU-TE-2014-4-2289|Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers|Study of Minimally Invasive Endoscopic IMaging Methods for the Evaluation of neoANGiogenesis in Gastrointestinal Cancers|IM-ANG|University of Medicine and Pharmacy Craiova|Yes|Recruiting|October 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|90 Years|No|||January 2016|January 31, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02672774||3661|
NCT02682888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESTC-neuSCAN_20|Trait Anxiety and Defensive Networks|||University of Electronic Science and Technology of China||Recruiting|December 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|130|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682888||2885|
NCT02687516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1300/REK Vest|Treatment of Severely Obese Children and Adolescents Employing "Family-based Behavioral Social Facilitation Treatment"|Treatment of Severely Obese Children and Adolescents in Common Health Care Settings: An Effectiveness Study Employing "Family-based Behavioral Social Facilitation Treatment"||University of Bergen|No|Recruiting|February 2014|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|8 Years|16 Years|No|||February 2016|February 19, 2016|February 21, 2014||No||No||https://clinicaltrials.gov/show/NCT02687516||2529|
NCT02667899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shwuxuehai|The Consciousness Variation of Deep Brain and Transcranial Magnetic Stimulation for Disorders of Consciousness Patients|The Consciousness Variation of Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS) for Disorders of Consciousness(DOC) Patients in a Large Scale Randomised Trial||Huashan Hospital|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|14 Years|65 Years|No|||January 2016|January 28, 2016|December 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667899||4032|
NCT02672982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACFInternational|Follow Up of Severely Malnourished Children (FUSAM)|Follow Up of Severely Malnourished Children (FUSAM): Effectiveness of a Combined Nutrition Psychosocial Intervention on Health and Development.|FUSAM|Action Contre la Faim|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|6 Months|24 Months|No|||February 2016|February 15, 2016|January 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02672982||3645|
NCT02678936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aurora|Anal Fistula Repair With Platelet-rich Plasma|Anal fistUla Repair With Platelet-Rich plasmA (AURoRA)|Aurora|University Hospital, Basel, Switzerland|No|Withdrawn|November 2015|||November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|99 Years|No|||February 2016|February 5, 2016|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02678936||3188|
NCT02668159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONITO 2015-090|Pilot Study on Metabolic Effects of Fish Peptides and Vitamin D|Cardiometabolic Health Effects and Mechanisms of Action of Fish Nutrients|BONITO|Laval University|No|Recruiting|August 2015|December 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02668159||4012|
NCT02668172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49517.078.14|Pasireotide LAR and Pegvisomant Study in Acromegaly|Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant|PAPE|Erasmus Medical Center|Yes|Recruiting|August 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|January 26, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02668172||4011|
NCT02677584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R / 15.06.75|Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity|Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity||Mansoura University Children Hospital|Yes|Recruiting|March 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|12 Weeks|No|||February 2016|February 8, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02677584||3292|
NCT02677597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISPEC study|Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma|An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma||Fudan University|No|Recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|70 Years|No|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677597||3291|
NCT02676414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHL-HEP1|Validation of a Hypertension Education Program|Validation of the Hypertension Education Program of the German Hypertension League (DHL©) "My Blood Pressure - OK!"||Charite University, Berlin, Germany||Recruiting|August 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|134|||Both|22 Years|N/A|No|||February 2016|February 5, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02676414||3382|
NCT02661802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13473813.1.0000.5505|Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome|Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome||Federal University of São Paulo|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661802||4500|
NCT02679716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAO|Reconstruction of Pathological Changes of the Ophthalmic Artery in Patients With Retinal Artery Occlusion|Hemodynamic Computer-assisted Reconstruction of Pathological Changes at the Origin of the Ophthalmic Artery in Patients With Retinal Artery Occlusion||Vienna Institute for Research in Ocular Surgery|No|Recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|10|||Both|21 Years|N/A|No|||February 2016|February 7, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02679716||3129|
NCT02664324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|888MS003|MSPT Device Usability Study|The Multiple Sclerosis Performance Test (MSPT) Device for Functional Assessment of Multiple Sclerosis (MS) Patients|MSPT|Biogen|No|Recruiting|March 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Multiple sclerosis patients or patients with related conditions in a clinical care        setting.|March 2016|March 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02664324||4306|
NCT02666586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:110|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control||University of Manitoba||Recruiting|January 2016|August 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|5||Anticipated|60|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||November 2015|February 23, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02666586||4133|
NCT02662140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01854|Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Mobile Health Solutions for Behavioral Skill Implementation Through Homework||New York University School of Medicine|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|16|||Both|7 Years|11 Years|No|||February 2016|February 24, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02662140||4474|
NCT02666755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15229491635|Novel Detection System for Lung Cancer Curative Effect Monitoring|Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer||Fourth Military Medical University|Yes|Not yet recruiting|January 2016|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|Each specimen was collected into one 10mL EDTA-containing vacutainer and was spun into      plasma within 4 hours of collection. cfDNA was extracted from 2 mL of plasma, and the final      DNA eluent was frozen at- 20℃ until genotyping|Both|18 Years|85 Years|No|Probability Sample|patients diagnosed with NSCLC|January 2016|January 28, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02666755||4120|
NCT02665819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508057|Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.|SALTO-BIO (Long Term Follow up in Oncology) - PanCareLIFE. Long Term Support for Pediatric Cancer Survivors in Rhône-Alpes. Evaluation of Women Fertility.|SALTO-BIO|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|84|Samples With DNA|25 ml of blood for each patient will be necessary to measure the AMH and FSH hormones rates.|Female|18 Years|N/A|No|Probability Sample|The population studied belongs to a cohort composed of women treated for a cancer in their        childhood (diagnosed between 1987 and 1999 in Rhône-Alpes Region) before 15 years old.|March 2016|March 21, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665819||4191|
NCT02667145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPernambuco2015|Assistive Device for Hand Osteoarthritis|Self-care Program Evaluation With Focus on Assistive Devices for Individuals With Hand Osteoarthritis||Universidade Federal de Pernambuco|Yes|Completed|November 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|90 Years|No|||January 2016|January 25, 2016|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02667145||4090|
NCT02666209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-002|Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma|Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma||Dana-Farber Cancer Institute||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2016|January 26, 2016|January 22, 2016|Yes|Yes||||https://clinicaltrials.gov/show/NCT02666209||4162|
NCT02683720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLxxxx|Evaluating the Efficacy of a Novel Oral Supplement in Tackling Malnutrition in the Elderly|Evaluating the Efficacy of a Novel Oral Supplement in Tackling Malnutrition in the Elderly|ProMO|Wageningen University|No|Not yet recruiting|September 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02683720||2821|
NCT02676713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAMHospital|Traditional Chinese Medicine Sequential Treatment for Endometriosis Associated Infertility|Activating Blood, Dredging Liver and Nourishing Kidney Sequential Treatment for Endometriosis Associated Infertility - a Randomized Double-blind Placebo Controlled Study||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|December 2014|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Female|20 Years|35 Years|No|||February 2016|February 17, 2016|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02676713||3359|
NCT02667431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823303-1|Cancer of the Uterus and Treatment of Stress Urinary Incontinence|Cancer of the Uterus and Treatment of Stress Urinary Incontinence|CUTI|Women and Infants Hospital of Rhode Island|No|Recruiting|January 2016|June 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|556|||Female|18 Years|100 Years|No|Non-Probability Sample|Patients with newly diagnosed complex atypical hyperplasia or clinical stage 1 or 2        endometrial cancer based on physical exam and/or imaging will be approached.|February 2016|February 4, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02667431||4068|
NCT02677740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601M83405|Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity|Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Male|21 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677740||3280|
NCT02667262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 3B|An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims Data|An Observational Study to Develop Computable Algorithms for Identifying Opioid Abuse and Addiction Based on Administrative Claims Data||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||January 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|4000|||Both|18 Years|N/A||Probability Sample|Patients with at least two years continuous enrollment in Group Health integrated group        practice (IGP) receiving ER/LA opioid analgesics|January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02667262||4081|
NCT02676856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microtransplantation-AML-2016|Hematopoietic Stem Cell Microtransplantation for in AML|Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|14 Years|65 Years|No|||February 2016|February 3, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02676856||3348|
NCT02676869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP321-P012|Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma|A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab|TACTI-mel|Prima BioMed Australia Pty. Ltd.|No|Recruiting|February 2016|March 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02676869||3347|
NCT02675582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1509|Investigation of the Acute Calming Effects of Drinks Containing Herbal Extracts in Healthy Adults|Investigation of the Acute Calming Effects of Drinks Containing Herbal Extracts in Healthy Adults||PepsiCo Global R&D|No|Recruiting|June 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|72|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02675582||3446|
NCT02668276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1294|Engaging Newly Diagnosed Men About Cancer Treatment Options|The Impact of a Gene Expression Profile on Treatment Choice and Outcome Among Minority Men Newly Diagnosed With Prostate Cancer: A Randomized Trial|ENACT|University of Illinois at Chicago|No|Not yet recruiting|March 2016|August 2022|Anticipated|August 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Male|N/A|76 Years|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668276||4003|
NCT02666716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF14.06|Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients|Pharmacokinetics of Fluconazole Given Intravenously as Prophylaxis or Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit (PACIFIC)|PACIFIC|Radboud University|Yes|Recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Plasma samples for determination of fluconazole and free fluconazole|Both|18 Years|N/A|No|Non-Probability Sample|All patients receiving fluconazole as prophylaxis or therapy for an (invasive) fungal        infection at the ICU will be included.|January 2016|January 25, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02666716||4123|
NCT02676973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27P01|Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design|Three Arm Apical Suspension Trial for Post-Hysterectomy Vault Prolapse: Prospective Randomized Trial Involving Sacral Colpopexy, Transvaginal Mesh and Native Tissue Apical Repair|ASPIRe|NICHD Pelvic Floor Disorders Network|Yes|Recruiting|March 2016|February 2021|Anticipated|February 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|363|||Female|21 Years|N/A|No|||March 2016|March 24, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02676973||3339|
NCT02676986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARB|Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer|Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer|ARB|Queen Mary University of London|No|Recruiting|August 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|235|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676986||3338|
NCT02665273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4754|Greater Occipital Nerve Block With Bupivacaine for Acute Migraine|A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine||Montefiore Medical Center|Yes|Recruiting|July 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665273||4233|
NCT02662751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2014/FM-01|Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA|The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial|VASCU|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|May 2021|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|260|||Both|18 Years|89 Years|No|||November 2015|January 20, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02662751||4427|
NCT02662764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP312|Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg|A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg||AcelRx Pharmaceuticals, Inc.|No|Not yet recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|315|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662764||4426|
NCT02662998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZGS2015133|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS|UHEAR-BIS|General Hospital Groeninge||Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|70 Years|N/A|No|Probability Sample|This trial will recruit older patients with a minimum age of 70 years old who have been        diagnosed with a solid tumour or hematologic malignancy, who are eligible for an        oncogeriatric evaluation.|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662998||4408|
NCT02675920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-2013-2284|A Study of HCC High Risk Group Using Two Surveillance Tools|A Prospective Cohort Study to Compare Contrast Enhanced Liver CT and Ultrasonography for Hepatocellular Carcinoma Surveillance in High-risk Group of HCC: Preliminary Study||Seoul National University Hospital|Yes|Recruiting|November 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|138|||Both|20 Years|N/A|No|Probability Sample|Patients at high risk of HCC AND High Risk Index (>=2.33)        Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or        older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of        anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).|February 2016|February 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02675920||3420|
NCT02675933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-15-162|Satisfaction Rates Among Parents of Children With Autism in the ED|What Factors Effect Parental Satisfaction During Their Visit to a Pediatric Emergency Department Among Parents of Children With Autism?|ASD|Seton Healthcare Family|Yes|Not yet recruiting|February 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|116|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02675933||3419|
NCT02680210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00996-43|Self-defining Memories in Patients With a TBI|Self-defining Memories in Patients With a TBI and Their Relationships With Cognitive, Emotional and Behavioural Dimensions|IDENTITY|Centre d'Investigation Clinique et Technologique 805|Yes|Recruiting|January 2016|July 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02680210||3091|
NCT02680223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA_2015|Efficacy of Coloured Overlays and Lenses for Reading Difficulty|Efficacy of Coloured Overlays and Lenses for Adults With Reading Difficulty||City University, London|No|Recruiting|January 2016|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680223||3090|
NCT02672878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIBS VI|Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)|Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis|RIBS VI|Spanish Society of Cardiology|No|Recruiting|April 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|130|||Both|20 Years|85 Years|No|||January 2016|February 2, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02672878||3653|
NCT02672501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genechem|A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia|Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia||Shanghai GeneChem Co., Ltd.|No|Recruiting|January 2016|December 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|70 Years|No|||February 2016|February 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02672501||3682|
NCT02676011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087133|Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery|Prevention of Brad Arrhythmia Induced by Repeated Succinylcholine by Atropine Sulfate During Gynecological Laparoscopic Surgery: a Randomized Controlled Trial||Assiut University|Yes|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|120|||Female|18 Years|50 Years|No|||February 2016|February 4, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676011||3413|
NCT02676024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150075-01H|Consolidating Tools for Outcomes in Resuscitation|Consolidating Tools for Outcomes in Resuscitation (CONTOUR)|CONTOUR|Ottawa Hospital Research Institute|Yes|Not yet recruiting|April 2016|February 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|456|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02676024||3412|
NCT02690857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.533|Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)|Efficacy of Docosahexanoic Acid on Lipid Peroxidation in Subjects With Cystic Fibrosis|OMEGAMUCO|Hospices Civils de Lyon||Completed|May 2010|||May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Male|6 Years|30 Years|No|||February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02690857||2273|
NCT02673632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU2016|The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS|The Influence of Anti-Müllerian Hormone on Ovarian Responsiveness to Ovulation Induction With Gonadotrophins in Women With Polycystic Ovarian Syndrome||Ain Shams Maternity Hospital|Yes|Not yet recruiting|February 2016|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|35 Years|No|Probability Sample|The study population comprises women with PCOS, fulfilling the inclusion criteria,        attending to Ain Shams University Maternity Hospital, assisted reproductive technology        (ART) Unit, during the study period, who are planning for Intracytoplasmic sperm injection        (ICSI).|February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02673632||3596|
NCT02668809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFOH|Oral Hygiene Intervention Pilot Study|Iowa Nursing Facility Oral Hygiene Intervention: A Pilot Study||University of Iowa|No|Recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|390|||Both|21 Years|120 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668809||3963|
NCT02668822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8342B-060|Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women With Moderate to Severe Primary Dysmenorrhea||Merck Sharp & Dohme Corp.|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Female|N/A|50 Years|No|||March 2016|March 23, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668822||3962|
NCT02675803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAY736X2101|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients|A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients||Novartis|No|Recruiting|December 2010|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02675803||3429|
NCT02521558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34203|Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease|Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease|CTAD|Boston University|No|Not yet recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|50 Years|90 Years|No|||August 2015|August 10, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02521558||15269|
NCT02527915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANWF-15-8012|Mental Health eConsults|The Effects of Mental Health eConsults: A Clinic-level Randomized Trial||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|August 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|900000|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527915||14780|
NCT02527928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|teva|Cost-Effectiveness of Amphotericin B|Cost-Effectiveness of Different Formulation of Amphotericin B in Private and Public Hospitals in Southern Brazil||Hospital Universitario Evangelico de Curitiba|No|Not yet recruiting|September 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|This is a study of pharmacoeconomics. Patients who used amphotericin B e total cost of        hospitalization.|August 2015|August 17, 2015|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02527928||14779|
NCT02682901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-06-FB-0119|Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects|Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects||Eastern Virginia Medical School|No|Recruiting|June 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||February 2016|February 10, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682901||2884|
NCT02673710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29985|A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Survivors Treated With Chemotherapy Combined With Bevacizumab|A MULTICENTER NON-INTERVENTIONAL STUDY EXPLORING THE IMPACT OF SARCOPENIA ON THE OUTCOMES OF COLORECTAL CANCER SURVIVORS TREATED WITH A CHEMOTHERAPY COMBINED WITH BEVACIZUMAB||Hoffmann-La Roche||Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab        and chemotherapy for whom it is decided to continue the administration of bevacizumab        beyond progression while changing chemotherapy regimen (CTR) will be included in this        study|March 2016|March 1, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673710||3590|
NCT02673840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EID-DF-02|Ketotifen as a Treatment for Vascular Leakage During Dengue Fever|Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)|KETODEN|National University Hospital, Singapore|Yes|Recruiting|March 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|21 Years|60 Years|No|||February 2016|February 3, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02673840||3580|
NCT02674711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2015.048d|Impact of Pre-operative Pain Education Video on Spinal Post-operative Opioid Medication Use|The Effect of a Brief Pre-operative Pain Medication Educational Video Before Lumbar Surgery on Post-operative Use of Opioid Medication. A Randomized Controlled Trial||Brooke Army Medical Center|No|Recruiting|August 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674711||3513|
NCT02662842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-15SCARL15|BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study|BD FlowSmart™ User Claims Study||Becton, Dickinson and Company|Yes|Active, not recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|75|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662842||4420|
NCT02683980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-SBU-VP-15-02|Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH|Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH||Lumenis Ltd.||Not yet recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||February 2016|February 11, 2016|January 31, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683980||2801|
NCT02670993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508071|Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease|Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease. Multicenter Study LACME|LACME|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|February 2016|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|60 Years|N/A|No|||January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02670993||3797|
NCT02668848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG6e0401|The Fluid Therapy Strategy of the Non-dehydrated Patients With Acute Ischemic Stroke.|The Fluid Therapy Strategy of the Patients With Acute Ischemic Stroke and a Bun/Cr Ratio Less Than 15.||Chang Gung Memorial Hospital|Yes|Recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|N/A|N/A|No|||January 2016|January 27, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668848||3960|
NCT02676609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9665|Impact of Food Carbohydrate and Insulin Dose Computing by on Smart Phone on Glucose Control in Patients With Diabetes|Assessment of the Impact of Food Carbohydrate and Insulin Dose Computing by an Application on Smart Phone on Glucose Control in Patients With Type 1 Diabetes|GLUCAL|University Hospital, Montpellier|No|Recruiting|February 2016|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|March 14, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676609||3367|
NCT02676622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1100448|Autologous Stem Cell Transplant for Refractory Crohn's Disease|A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-Transplant Ultra Low-Dose IL-2 for Refractory Crohn's Disease||Nationwide Children's Hospital|Yes|Terminated|April 2013|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|12 Years|29 Years|No|||February 2016|February 3, 2016|April 21, 2013||No|PI moved to a different institution.|No||https://clinicaltrials.gov/show/NCT02676622||3366|
NCT02687815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12020541|Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)|Vitamin D to Prevent Severe Asthma Exacerbations||University of Pittsburgh|Yes|Recruiting|February 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|6 Years|14 Years|No|||February 2016|February 29, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687815||2506|
NCT02668211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14LJH002|Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components|Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components|TOPAZ|MicroPort Orthopedics Inc.|No|Not yet recruiting|February 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|21 Years|76 Years|No|||January 2016|January 26, 2016|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02668211||4008|
NCT02674503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1995-R|Impact of a Mobility Program|Impact of a Hospital Mobility Program on Function After Discharge||VA Office of Research and Development|Yes|Not yet recruiting|April 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|226|||Both|50 Years|N/A|No|||February 2016|February 3, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02674503||3529|
NCT02677857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTKIRB-15-02602-FB|Developing a Healthy Lifestyle in Breast Cancer Survivors|Developing a Healthy Lifestyle in Breast Cancer Survivors||University of Tennessee||Recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02677857||3271|
NCT02669602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN|Dynamic Mediterranean Prospective Cohort: the SUN Project|Dynamic Mediterranean Prospective Cohort: the SUN Project||Clinica Universidad de Navarra, Universidad de Navarra|No|Enrolling by invitation|December 1999|December 2075|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22500|Samples With DNA|Saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Spanish university graduates|January 2016|February 1, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02669602||3904|
NCT02678130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-011|A Prospective Study of the InterFuse T(tm),|A Prospective Study of the InterFuse T(tm)||Vertebral Technologies, Inc.|No|Recruiting|January 2015|January 2019|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|No|||February 2016|February 8, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678130||3250|
NCT02663297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC-1524-ATL|Administration of T Lymphocytes for Prevention of Relapse of Lymphomas|Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|February 2016|April 2034|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|3 Years|N/A|No|||February 2016|February 10, 2016|January 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663297||4385|
NCT02678117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI,IRB 2010014053.3|Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain|Analgesic Potentials of Preoperative Oral Pregabalin,Intravenous Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain.(Randomized,Double-Blind Study)||National Cancer Institute, Egypt|No|Recruiting|July 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|65 Years|No|||February 2016|February 6, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678117||3251|
NCT02664441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK104936-01A1|Energy Balance in Craniopharyngioma-related Hypothalamic Obesity|Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity|ECHO|Seattle Children's Hospital|Yes|Not yet recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|10 Years|25 Years|No|||January 2016|February 16, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664441||4297|
NCT02688829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Firehawk_FIM|The First-In-Man Pilot Study of Firehawk|The Initial Small-Scale Clinical Study of Rapamycin-Eluting Coronary Stent System of Microport (Firehawk)||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Completed|December 2009|January 2015|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688829||2428|
NCT02688842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Firehawk_LS|Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease|The Safety and Effectiveness Evaluation of New Specifications (38mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.|Firehawk_38|Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Recruiting|October 2014|December 2020|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|80 Years|No|||January 2015|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688842||2427|
NCT02689024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54580.018.15|Delirium in Elderly Patients With Trauma of the Hip|A Multicenter Randomized Controlled Trial in Elderly Patients With Hip Fractures Comparing Continuous Fascia Iliaca Compartment Block to Systemic Opioids and Its Effect on Delirium Occurrence|DEPTHip|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Not yet recruiting|April 2016|January 2019|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|340|||Both|55 Years|N/A|No|||February 2016|February 18, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02689024||2413|
NCT02668757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartHab-001|HeartHab, Can a Patient-tailored Application Support Coronary Artery Disease Patients During Rehabilitation?|Pilot Study, How the HeartHab Application Can Support Coronary Artery Disease Patients in Their Rehabilitation Program?|HeartHab|Hasselt University|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 31, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668757||3967|
NCT02668770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0135|Phase I Study of Ipilimumab and MGN1703|A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668770||3966|
NCT02674555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8273-CL-0104|A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors Harboring Epidermal Growth Factor Receptor (EGFR) Mutations||Astellas Pharma Inc|No|Not yet recruiting|February 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674555||3525|
NCT02674568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRX001-002|Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)|An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)||Stemcentrx|Yes|Recruiting|January 2016|January 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|154|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674568||3524|
NCT02677896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0335|A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)|A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)||Astellas Pharma Inc|Yes|Not yet recruiting|February 2016|December 2023|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Male|18 Years|N/A|No|||February 2016|February 5, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677896||3268|
NCT02664727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UThessaly|Effects of Acute Exercise on Various Parameters in Individuals With Alcohol Use Disorders|Effects of Acute Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Individuals With Alcohol Use Disorders||University of Thessaly|No|Completed|January 2014|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02664727||4275|
NCT02669888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST 104-2325-B-182A-005|Indigo Naturalis in Treating Atopic Dermatitis Topically|Efficacy and Safety of Topical Indigo Naturalis in Treating Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial||Chang Gung Memorial Hospital|No|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|12 Years|40 Years|No|||August 2015|January 29, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02669888||3882|
NCT02669901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-616|Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder|Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder||University of New Mexico|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669901||3881|
NCT02669095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5796|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||January 28, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669095||3942|
NCT02669355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/2015/RP/17|Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting|Observational Study to Determine the Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting||Columbia Asia|Yes|Completed|October 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|123|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged above 18 years who come to consult in Rheumatalogy OPD in all three Columbia        Asia Hospitals situated in Bangalore are taken into study.|January 2016|January 27, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02669355||3923|
NCT02669706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1000|Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia|Assessment of the Safety and Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia in Patients With Hematologic Malignancies and Stem Cell Transplant Recipients.||University of Illinois at Chicago|No|Recruiting|March 2015|November 2016|Anticipated|March 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be comprised of adult patients with hematologic malignancies        and/or hematopoietic stem cell transplant recipients who have an indication for PJP        prophylaxis with pentamidine. Further details are outlined in the inclusion/exclusion        criteria.|January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02669706||3896|
NCT02669238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/CHU/03|Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis|Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis|END-IMPACT|Centre Hospitalier Universitaire de la Réunion|Yes|Not yet recruiting|June 2016|February 2019|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|45 Years|No|||February 2016|February 3, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02669238||3932|
NCT02690610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30613/11/15|Value of Rapid on Site Evaluation During EBUS-guided TBNA in the Diagnosis of Mediastinal Lesions|Value of Rapid on Site Evaluation During Endobronchial Ultrasound Guided Trans-bronchial Needle Aspiration (EBUS-TBNA) in the Diagnosis of Mediastinal Lesions||Tanta University|Yes|Recruiting|November 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02690610||2292|
NCT02669368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01MgRo|Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy|Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy||Assiut University||Active, not recruiting|March 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669368||3922|
NCT02669654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-14066|Effectiveness Trial of Day-care vs. Usual Care of Severe Pneumonia & Malnutrition in Children|Effectiveness Trial of Day-care Versus Usual Care Management of Severe Pneumonia With or Without Malnutrition in Children Using the Existing Health System of Bangladesh|Day-care|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4000|||Both|2 Months|5 Years|No|||November 2015|January 27, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02669654||3900|
NCT02677454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Libre|Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes|Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes||Vastra Gotaland Region|No|Completed|June 2015|||December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|74 Years|No|||January 2016|February 3, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02677454||3302|
NCT02675608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-727936|Vaccine Efficacy in Diabetic and Elderly Patients|||Tulane University School of Medicine|No|Recruiting|August 2015|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||5|Anticipated|110|Samples Without DNA|plasma, serum, PBMCs, urine, saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were recruited from the New Orleans metropolitan area through flyers, radio ads,        internet ads, social media, and doctor referrals.|February 2016|February 2, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675608||3444|
NCT02687529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST001_USA7|Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection|Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection||QIAGEN Gaithersburg, Inc|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|565|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who have either a low risk or known risk for TB exposure.|February 2016|February 19, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687529||2528|
NCT02690077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-16|Family-Centered Cesarean Delivery|Family-Centered Cesarean: A Randomized Controlled Trial||Aurora Health Care|No|Not yet recruiting|June 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|508|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02690077||2332|
NCT02666339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508192|Mélisses Garden: Effect on Anxious State in Adult Patients Hospitalized in Psychiatry|Mélisses Garden: Effect of the Mediation by Care-garden on Anxious State in Adult Patients Hospitalized in Psychiatry (Prospective, Monocentric, Controlled, Randomized, Open in Two Parallel Groups Study)|JDM|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|May 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|190|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02666339||4152|
NCT02666352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682-029|A Study of the Pharmacokinetics of MK-3682 and MK-8408 in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)|A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682 and MK-8408 When Coadministered to Subjects With Moderate and Severe Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666352||4151|
NCT02675621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1517|Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults|Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults||PepsiCo Global R&D|No|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|46|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02675621||3443|
NCT02683135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1501952|Lifestyle Control of Postprandial Hyperglycemia|Low-carbohydrate Diet, With or Without Exercise, for Improving Postprandial Glucose Control and Vascular Function in Type 2 Diabetes and Prediabetes.||University of British Columbia|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|15|||Both|40 Years|75 Years|No|||February 2016|February 22, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683135||2866|
NCT02683148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x402|DHEA in Synovial Sarcoma Patients|A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients||Washington University School of Medicine|No|Not yet recruiting|April 2016|April 2025|Anticipated|April 2025|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|47|||Both|16 Years|N/A|No|||February 2016|February 11, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683148||2865|
NCT02671916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL_2015_HIRS|Health and Quality of Life One Year After Discharge From the Intensive Care Unit (ICU)|Health and Quality of Life One Year After Discharge From the ICU: in Time Not Limited Quality Control After Intensive Medical Treatment|QoL_ICU|Klinik Hirslanden, Zurich|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|all patients with conditions that lead to an ICU stay|February 2016|February 12, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02671916|1 Year|3726|
NCT02671929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK-91809|Translation and Development of an Online Self-help Intervention With Subsequent Feasibility Study|Translation and Development of an Online Self-help Intervention With Subsequent Feasibility Study as an After Care After Inpatient Psychosomatic Treatment|KEN|Johannes Gutenberg University Mainz|No|Recruiting|September 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02671929||3725|
NCT02662790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXA|Dexamethasone on Fetal and Uteroplacental Doppler|Effects of Antenatal Dexamethasone Administration on Fetal and Uteroplacental Doppler Waveforms in Women at Risk for Preterm Birth||Assiut University||Completed|February 2014|January 2015|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|N/A|N/A|No|||January 2016|January 21, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02662790||4424|
NCT02666365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003845|Continuous v Bolus Infusion of Cefazolin During Whipple Procedure|Pharmacokinetic Comparison of Cefazolin Redosing Strategy for Surgical Prophylaxis. Bolus Dose vs Continuous Infusion||Milton S. Hershey Medical Center|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666365||4150|
NCT02661815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-483|A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer|A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|January 2016|January 2022|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661815||4499|
NCT02668419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13132413.0.0000.5505|Electrical Stimulation Improves Exercise Tolerance in Patients With Advanced Heart Failure on Continuous Dobutamine Use|Neuromuscular Electrical Stimulation Improves Exercise Tolerance in Patients With Advanced Heart Failure on Continuous Dobutamine Use - A Randomized Controlled Trial||Federal University of São Paulo|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|49|||Both|N/A|N/A|No|||January 2016|January 28, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02668419||3992|
NCT02668744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL123865-01A1|A School-based Gardening Obesity Intervention for Low-income Minority Children|Texas Sprouts: A School-based Gardening Obesity Intervention for Low-income Minority Children||University of Texas at Austin|Yes|Active, not recruiting|April 2015|March 2020|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4800|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02668744||3968|
NCT02672553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12|EDWARDS INTUITY Valve System CADENCE-MIS Study|A Randomized Comparison of the EDWARDS INTUITY Valve Sys-tem anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve Replacement Using Minimally Inva-Sive Techniques|CADENCE-MIS|Edwards Lifesciences|No|Completed|May 2012|August 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02672553||3678|
NCT02665975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARU-0116|Internet-based Versus Face-to-face Clinical Care for Tinnitus|Internet-based Versus Face-to-face Clinical Care for Tinnitus: A Multi-study Randomised Control Trial||Anglia Ruskin University|Yes|Not yet recruiting|October 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665975||4180|
NCT02671500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-342-1518|Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV||Gilead Sciences|No|Not yet recruiting|March 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671500||3758|
NCT02671513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR6390-I-102|A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients|A Tolerability and Pharmacokinetics Phase 1 Study of SHR6390 in Advanced Melanoma Patients||Jiangsu HengRui Medicine Co., Ltd.|No|Not yet recruiting|January 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|February 1, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02671513||3757|
NCT02670759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.291|Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery|Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery (VATS): Analgesic Effectiveness and Role in Fast-track Surgery||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02670759||3815|
NCT02670772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRHI001|Dose Optimisation of Stavudine for the Treatment of HIV Infection|A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1|D4T|University of Witwatersrand, South Africa|Yes|Completed|July 2012|December 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1077|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02670772||3814|
NCT02672345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4617|Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB|Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB||Instituto Dante Pazzanese de Cardiologia|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Will be selected 100 patients who underwent ascending thoracic aortic aneurysm repair        surgery electively in Dante Pazzanese Institute of Cardiology (IDPC).|January 2016|February 2, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672345|1 Year|3693|
NCT02670655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUderma-06|Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis|Efficacy of Iontophoresis-assisted Ablative Fractional Laser Photodynamic Therapy With Short Incubation Time for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial||Dong-A University|No|Completed|June 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|65 Years|84 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670655||3823|
NCT02670889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC 7230, U54-HD061221|Urease Inhibitor Drug Treatment for Urea Cycle Disorders|Manipulating the Gut Microbiome in Urea Cycle Disorders||Children's Research Institute|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670889||3805|
NCT02671097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17723|Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate|A Phase 1, Open Label, Fixed-sequence Study to Evaluate the Effect of BAY1841788 (ODM-201) on Drug Transporters Using Rosuvastatin as Probe Substrate and to Assess Pharmacokinetics and Safety of BAY1841788 in Female and Male Volunteers||Bayer|No|Recruiting|February 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671097||3789|
NCT02691325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201544|Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects|A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects||GlaxoSmithKline|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|30|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691325||2238|
NCT02666326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AROMI-1|Accelerated Rule Out of Myocardial Infarction|Accelerated Rule-Out of Acute Myocardial Infarction, Using Copeptin and High Sensitive Troponin T - the AROMI Trial|AROMI|Aarhus University Hospital Skejby|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|4772|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666326||4153|
NCT02672566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508175|Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction|Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction. Randomized Multicenter Trial|GROWTH|Centre Hospitalier Universitaire de Saint Etienne|Yes|Not yet recruiting|June 2016|September 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02672566||3677|
NCT02662374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RiyadhCDP|Oral Hygiene Regimen in Patients on HCT|Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial||Riyadh Colleges of Dentistry and Pharmacy|Yes|Enrolling by invitation|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|45|||Both|3 Years|16 Years|No|||January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662374||4456|
NCT02671890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1512|Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer|Phase 1 Trial and Randomized, Double-Blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients||Mayo Clinic|Yes|Recruiting|February 2016|||May 2021|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671890||3728|
NCT02676908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJH-01-VV|Optimum Duration of Compression Stockings After Endovenous Varicose Vein Surgery|A Randomised Controlled Trial Comparing Duration of Compression Hosiery After Endovenous Ablation of Varicose Veins||St. James's Hospital, Ireland|No|Not yet recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02676908||3344|
NCT02687776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-275|Perioperative Copeptin: Predictive Value and Risk Stratification in Patients Undergoing Major Surgery|Perioperative Copeptin: Predictive Value and Risk Stratification in Patients Undergoing Major Surgery||University Hospital, Basel, Switzerland|No|Recruiting|February 2016|August 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients >18 years undergoing major vascular surgery will be invited to        participate. Specifically, patients undergoing abdominal aortic aneurysm repair,        suprainguinal and infrainguinal vascular surgery, as well as carotid surgery will be        included. After the first 30 patients, the population is to be expanded to elevated-risk        surgeries in general.|February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02687776||2509|
NCT02688062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-SDSCI/IGDB|NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells Transplantation vs. Intradural Decompression and Adhesiolysis in SCI|NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells Transplantation vs. Intradural Decompression and Adhesiolysis in Patients With Chronic Spinal Cord Injury||Chinese Academy of Sciences|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|60 Years|No|||February 2016|February 17, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02688062||2487|
NCT02665286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5903|Orphenadrine and Methocarbamol for LBP|Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study||Montefiore Medical Center|Yes|Not yet recruiting|February 2016|April 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|69 Years|No|||January 2016|January 22, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665286||4232|
NCT02666807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TehranUMS|Effects of Ginger Supplementation on NF-KB in Peripheral Blood Mononuclear Cells in Type 2 Diabetes Mellitus|Effects of Oral Ginger Supplementation on NF-KB (Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells) in Peripheral Blood Mononuclear Cells (PBMC) and Glycemic and Lipid Profiles in Patients With Type 2 Diabetes Mellitus||Tehran University of Medical Sciences|Yes|Completed|June 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|50|||Both|30 Years|60 Years|No|||January 2016|January 25, 2016|January 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666807||4116|
NCT02665416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29889|Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors|An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody) in Patients With Metastatic Solid Tumors||Hoffmann-La Roche||Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02665416||4222|
NCT02665663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-18|Tongue Strength in Amyotrophic Lateral Sclerosis (ALS)|Measure of the Strength of the Tongue in Patients With Amyotrophic Lateral Sclerosis and Relation With Swallowing Disorders||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|February 2016|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665663||4203|
NCT02685072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1504015618|Progesterone Augmentation of Nicotine Replacement Therapy Study||PANS|Yale University|Yes|Recruiting|February 2016|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|No|||February 2016|February 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685072||2717|
NCT02677519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-BP-EF004|A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD|A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)|EF004|Rhodes Pharmaceuticals, L.P.|Yes|Not yet recruiting|February 2016|September 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|120|||Both|4 Years|6 Years|No|||February 2016|February 8, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677519||3297|
NCT02677532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APERIVIP|Epidural Versus Wound Infusion Plus Morphine Bolus in Open Abdominal Aortic Aneurysm Repair|Analgesia Postoperatoria Mediante Catetere Perdurare e Analgesia Postoperatoria Mediante Infusione Continua Periferia Nell'Intervento Chirurgico Per Riparazione Chirurgica di Aneurismi Dell'Aorta Addominale: Tecniche a Confronto|APERIVIP|University of Genova|No|Completed|December 2011|January 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02677532||3296|
NCT02672514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rölig Studie|Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?|Does Minimal Extracorporeal Circulation Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?||Herzzentrum Coswig|No|Completed|February 2010|June 2015|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02672514||3681|
NCT02672527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-003176-23|Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma|A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma|TSAR|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02672527||3680|
NCT02665923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP6304|Gastric Emptying in Children|Gastric Emptying in Pediatric Patients||Columbia University|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|110|||Both|N/A|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|This dual-purpose study will have two wings. The first involves recruitment of fasted        patients presenting for elective procedures. These patients will undergo one ultrasound        prior to their elective procedure after induction of general anesthesia. Any outpatient        presenting for elective surgery will be eligible The second wing involves serial        ultrasounds over several visits of healthy newborns, initially recruited from the        well-baby nursery. Any child in the well-baby nursery is eligible. Our initial pilot        period will study a total of 30 healthy newborns.|February 2016|February 5, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665923||4183|
NCT02665936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wahdan|Effect of Epidural Dexamethasone on Labor Analgesia|Epidural Levobupivacaine Versus A Combination of Levobupivacaine and Dexamethasone in Parturients Receiving Epidural for Vaginal Delivery Analgesia: A Comparative, Dose Ranging and Safety Evaluation Study||Kasr El Aini Hospital||Active, not recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|40 Years|No|||January 2016|January 27, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02665936||4182|
NCT02688192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131323|Mobile Health Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors|TLC FIT: A Novel Mobile Health Fitness Program for Adolescent and Young Adult (AYA) Childhood Cancer Survivors|TLC FIT|Rutgers, The State University of New Jersey|No|Recruiting|January 2014|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|108|||Both|13 Years|25 Years|No|||February 2016|February 17, 2016|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688192||2477|
NCT02661646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010|Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced PCD|Assessment of Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device at Home||Tactile Medical|No|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Primary or secondary, unilateral or bilateral lower extremity lymphedema patients using        the Flexitouch system during a 12 week study period.|January 2016|January 20, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661646||4512|
NCT02672722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18220|Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound|Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound||University of Virginia|No|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|19|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672722||3665|
NCT02662348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-SR-116.F1|T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System|T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System||The First Affiliated Hospital with Nanjing Medical University|Yes|Enrolling by invitation|February 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662348||4458|
NCT02526004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC-CFMATTERS|Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified|Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified|CFMATTERS|University College Cork|Yes|Recruiting|January 2015|October 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|252|||Both|16 Years|80 Years|No|||August 2015|August 17, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526004||14927|
NCT02526017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPA008-003|Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers|A Phase 1a/1b Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers|FPA008-003|Five Prime Therapeutics, Inc.|Yes|Recruiting|August 2015|August 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526017||14926|
NCT02513615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14CECPDNA1006|Epigenetic Determinants of Peritoneal Fibrosis|Epigenetic Determinants of Peritoneal Fibrosis||McMaster University|No|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|A 15ml sample of PD fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients with end stage renal disease recently started on peritoneal dialysis. Patients        will be over the age of 18.|August 2015|August 5, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513615||15877|
NCT02683707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00089755|The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)|The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial|PACIFY|Johns Hopkins University|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683707||2822|
NCT02661932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-POF 2012|Fertility Preservation in Breast Cancer Patients|Efficiency and Safety Study of Ovarian Stimulation With Letrozole for Fertility Preservation in Breast Cancer Patients|Brovale|Erasme University Hospital|No|Recruiting|November 2012|December 2021|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|54|||Female|18 Years|40 Years|No|||January 2016|January 20, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02661932||4490|
NCT02664636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/JF-02|Cortical Reorganization Models for Motor Areas and Inter-hemispheric Equilibrium Post-stroke: a Pilot Study|Pilot Study on the Development of Cortical Reorganization Models for Motor Areas and Inter-hemispheric Equilibrium in the Post-stroke Early Recovery Phase Evaluated by Functional Near-infrared Spectroscopy (fNIRS)|ERASM|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|75 Years|No|||February 2016|February 18, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664636||4282|
NCT02667184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507E75043|The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Healthy Human Subjects|The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Health Human Subjects||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|May 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02667184||4087|
NCT02685397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS IX|Management of Castration-Resistant Prostate Cancer With Oligometastases|The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.|PCS IX|Sir Mortimer B. Davis - Jewish General Hospital|No|Not yet recruiting|April 2016|||April 2025|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02685397||2692|
NCT02678065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-120524|In.Pact Flexion, Investigating the Performance of the In.Pact Admiral DEB for Popliteal Lesions|In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions|INPCTFLEXION|Flanders Medical Research Program|Yes|Recruiting|April 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678065||3255|
NCT02678078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0671-15-RMB|Characterization of Cancer Tissue Using 3D Biosynthetic Material|Characterization of Cancer Tissue Using 3D Biosynthetic Material||Technion, Israel Institute of Technology|No|Not yet recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|we will collect a liver biopsy and blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|every man or women 18 years old or older, with a liver tumor.|February 2016|February 15, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678078||3254|
NCT02676778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7777-J081-205|Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma|A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma||Eisai Inc.|No|Not yet recruiting|March 2016|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|20 Years|N/A|No|||January 2016|February 5, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02676778||3354|
NCT02677831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0970608|Healthy Aging Longitudinal Study in Taiwan|Healthy Aging Longitudinal Study in Taiwan (HALST)|HALST|National Health Research Institutes, Taiwan|No|Active, not recruiting|July 2008|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5664|Samples With DNA|whole blood, serum, urine.|Both|55 Years|104 Years|Accepts Healthy Volunteers|Probability Sample|Investigators plan to conduct a longitudinal study on a cohort of 5,000+ men and women        ages 55 years or older to address issues related to healthy aging. The study population        consists community-based middle to old aged men and women in the catchment area of 7        hospitals (2 in the north, 2 in the middle, 2 in the south and 1 in the east, about half        urban half rural). In this proposed study, investigators will recruit the subjects in the        catchment area of the above 7 hospitals and expand data collection to include more        interviewer-administered data, physical examinations and blood and urine specimens.|February 2016|February 15, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02677831||3273|
NCT02664766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UThessaly 2|Effects of Long-term Exercise on Various Parameters in Heavy Drinkers|Effects of Long-term Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Heavy Drinkers||University of Thessaly|No|Completed|January 2014|June 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02664766||4272|
NCT02672696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fluoromap Gamma 3 nail|Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail|Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail|INOPEG|Hôpital du Valais|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02672696||3667|
NCT02677844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16080|A Study of Abemaciclib in Healthy Participants|A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects||Eli Lilly and Company|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02677844||3272|
NCT02664233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SN-14-1027|Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care|Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care||The University of Texas Health Science Center, Houston|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02664233||4313|
NCT02684799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-123|Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination|A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)||Tobira Therapeutics, Inc.|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684799||2738|
NCT02673463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-150|Spironolactone in Atrial Fibrillation|Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation|IMPRESS-AF|University of Birmingham|Yes|Recruiting|January 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|50 Years|N/A|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673463||3609|
NCT02663570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melatonina15|Effects of Melatonin in PCOS Women|Effects of 6 Months of Melatonin Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS||Catholic University of the Sacred Heart||Recruiting|June 2015|||January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|35 Years|No|||January 2016|January 21, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663570||4364|
NCT02663583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA15-0744|Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell|Observational Parallel Cohort Study of Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell Carcinoma||M.D. Anderson Cancer Center|No|Recruiting|January 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|Participants having treatment with either proton therapy (called Intensity-Modulated        Proton Therapy or IMPT) or robotic surgery (called TransOral Robotic Surgery or TORS) at        MD Anderson Cancer Center in Houston, Texas.|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663583||4363|
NCT02661737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HAOS005|Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Volumes|||LG Life Sciences||Active, not recruiting|January 2015|May 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|503|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject who receive hyaluronic acid filler into the nasolabial folds|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661737||4505|
NCT02661750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0004-02|Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy|Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy||Gastroenterology Services, Ltd.|Yes|Recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in our practice who are undergoing a routine colonoscopy who had an inadequate        preparation for colonoscopy in the past|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661750||4504|
NCT02668575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: PRO14110168|Integrating Supportive Care in Cystic Fibrosis|Integrating Supportive Care in Cystic Fibrosis: A Pilot Study||University of Pittsburgh|No|Not yet recruiting|February 2016|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02668575||3980|
NCT02668588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-PB/14/05|Extended-release of Octreotide (LF-PB) for the Treatment of Seroma|A Multicentre, Double Blind, Randomized Placebo Controlled Trial to Assess the Effect of LF-PB on Seroma Formation in Women With Breast Cancer Undergoing Axillary Lymph Node Dissection||Chemi S.p.A.|No|Recruiting|October 2015|January 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668588||3979|
NCT02689206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204836|Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent|A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent||GlaxoSmithKline|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689206||2399|
NCT02665247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00847|Impact of Sleep Workshops in College Students|Impact of Sleep Workshops in College Students||New York University School of Medicine|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665247||4235|
NCT02676141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-00068|Responsiveness of the German Version of the Neck Disability Index (NDI-G)|Responsiveness of the German Version of the Neck Disability Index (NDI-G)||Balgrist University Hospital|No|Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic neck pain.|February 2016|February 5, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02676141||3403|
NCT02677909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2016|Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in ICU Patients|Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in ICU Patients||Cedars-Sinai Medical Center|No|Not yet recruiting|March 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical intensive care patients|February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677909|1 Month|3267|
NCT02685631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1523|Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Registry|Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Registry|RESIN|Vanderbilt-Ingram Cancer Center|No|Recruiting|July 2015|August 2021|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary and secondary liver cancer receiving SIR Spheres® microspheres (Y90        resin microspheres) treatment as part of their overall oncologic management|February 2016|February 18, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02685631||2674|
NCT02673593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS102A-01|Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects|A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS102 in Healthy Subjects||DS Biopharma|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|57|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 3, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02673593||3599|
NCT02669719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILU02|Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC|A Randomized Phase II Study to Evaluate Efficacy and Safety of DCVAC/LuCa Added to Chemotherapy With Carboplatin and Pemetrexed vs Chemotherapy Alone in Patients With Stage IV Non-small Cell Lung Cancer||Shanghai Chest Hospital|No|Recruiting|January 2016|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02669719||3895|
NCT02669732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8500-A-J205|An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp|A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus.||Daiichi Sankyo Inc.|No|Recruiting|January 2016|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669732||3894|
NCT02677337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065849|NCCN Renal Cell Registry|Novel Educational Interventions for Community Oncologists & Patients: Optimizing Renal Cell Carcinoma Outcomes Through Engagement||Duke University|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02677337||3311|
NCT02677389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15059|Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin|Active Living After Cancer: Building a Physical Activity Intervention Into Clinical Care for Breast and Colorectal Cancer Survivors in Wisconsin||University of Wisconsin, Madison|Yes|Recruiting|December 2015|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02677389||3307|
NCT02665767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hanyang University|Telementoring for Identifying the Appendix Using Telesonography|A Feasibility Study of Telementoring for Identifying the Appendix Using Smartphone-based Telesonography|TIAT|Hanyang University|Yes|Completed|March 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|30|||Both|25 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665767||4195|
NCT02673892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9735-AE|Patient Oriented Discharge Summary Impact Study|The Impact of a Patient-Centered Discharge Summary (PODS) on Patient Experience and Health Outcomes Following Discharge: A Multicenter Randomized Controlled Trial|PODS|University Health Network, Toronto|No|Recruiting|February 2016|March 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|760|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673892||3576|
NCT02663674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0053|Early Fluconazole Treatment for Coccidiodomycosis Pneumonia|A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|December 2015|January 2021|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|99 Years|No|||January 2016|March 24, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663674||4356|
NCT02668289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Periodontal biotype|Periodontal Phenotype Study|Periodontal Phenotype and Supracrestal Soft Tissue Dimentions - Clinical Correlations and Their Impact on Post-extraction Volumetric Changes||University of Iowa|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668289||4002|
NCT02690506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05-027|The Effect of Pregabalin on the Spinal Anesthesia|The Effect of Pregabalin on the Spinal Anesthesia: Randomized Controlled Placebo Study||Kyungpook National University||Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|36|||Both|19 Years|70 Years|No|||February 2016|February 24, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690506||2300|
NCT02671773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14016|Characterising the Microbiota in Asthma|Characterising the Microbiota in Asthma|MIA|University of Nottingham|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|72|Samples With DNA|Sputum samples to be retained containing bacterial DNA|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult asthmatic patients on Step 2 or Step 4 of the British Thoracic Society Asthma        stepwise management protocol for asthma whose details are stored on the Nottingham        Respiratory Research Patient Database or who attend respiratory clinics at the Nottingham        City Hospital|January 2016|February 1, 2016|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02671773||3737|
NCT02671786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-2 SAMMAN|Community Based Management of Severe Malnutrition in Tribal Area of Melghat- Cluster Randomized Control Field Trial|Community Based Management of Severe Malnutrition in Under 5 Children in Tribal Area of Melghat, Maharashtra- Cluster Randomized Control Field Trial|SAMMAN|MAHAN Trust||Completed|May 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|824|||Both|6 Months|60 Months|No|||January 2016|January 29, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02671786||3736|
NCT02663934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508002|Exercise Training to Improve Brain Health in Older HIV+ Individuals|Exercise Training to Improve Brain Health in Older HIV+ Individuals|Ex/HIV|Washington University School of Medicine|Yes|Not yet recruiting|February 2016|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|50 Years|N/A|No|||February 2016|February 2, 2016|January 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02663934||4336|
NCT02687789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOAF-11/2012|Safety, Tolerability and Efficacy of Vaginal Suppository WO3191 in the Post-treatment of Bacterial Vaginosis|A Prospective Parallel-design, Double-blind, Randomised, Controlled Investigation to Gain Clinical Experience and Further Knowledge About the Certified Medical Device Vaginal Suppository WO 3191 With Respect to Safety, Tolerability and Efficacy in the Post-Treatment of Bacterial Vaginosis||Dr. August Wolff GmbH & Co. KG Arzneimittel|No|Completed|April 2014|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|43|||Female|18 Years|50 Years|No|||February 2016|February 16, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02687789||2508|
NCT02690337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1123-A-J101|Study of DS-1123a in Advanced Solid Tumours|Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Recruiting|January 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||February 2016|February 18, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02690337||2312|
NCT02677636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M169981002|Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older|A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis|MSRD-100|Merz Pharmaceuticals, LLC|No|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|370|||Both|3 Months|N/A|No|||February 2016|February 8, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677636||3288|
NCT02672332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC301|P3 Study in Acne Comparing Once Daily SB204 and Vehicle|A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris||Novan, Inc.|No|Recruiting|February 2016|October 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1300|||Both|9 Years|99 Years|No|||February 2016|February 22, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672332||3694|
NCT02672540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGSC-002|A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients|A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE™ Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)||Prolong Pharmaceuticals|No|Not yet recruiting|April 2016|September 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672540||3679|
NCT02665689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORO001|Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab|Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab|DORO|Charite University, Berlin, Germany|No|Recruiting|January 2016|June 2021|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665689||4201|
NCT02679950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0540|Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse|Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse||Indiana University|No|Recruiting|November 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|6|Samples With DNA|Tumor tissue Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of        the initial diagnosis or a late relapsed GCT.|February 2016|February 8, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02679950||3111|
NCT02679963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005586-75|Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer|A Randomized Double-blind Phase II Trial Evaluating Maintenance Olaparib Versus Placebo in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer|PIPSeN|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|January 2016|January 2021|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02679963||3110|
NCT02679976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5728|Marketed Contact Lens Real World Through Focus Curve|||Johnson & Johnson Vision Care, Inc.||Completed|July 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679976||3109|
NCT02679989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Met-IER2016|The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity|A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity|Met-IER|King's College London|No|Not yet recruiting|February 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|46|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02679989||3108|
NCT02672904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0057-11-KMC|KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma|Comparison Between the Use of KTP Laser vs. CO2 Laser for Endoscopic Surgical Removal of Malignant Neoplasms of the Vocal Cords||Kaplan Medical Center|Yes|Recruiting|January 2013|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02672904||3651|
NCT02663050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mustafa|The Effect of Kinesio Taping Application for Dysmenorrhea|The Effect of Kinesio Taping Application for Dysmenorrhea: A Randomized Controlled Clinical Trial||Gulhane Military Medical Academy|No|Not yet recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|40 Years|No|||February 2016|February 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663050||4404|
NCT02670395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108105|A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants|A Double Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Subjects||Janssen Research & Development, LLC|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02670395||3843|
NCT02674334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409418786|Prospective Evaluation of Cognitive Outcomes After Anesthesia on Patients in the Beach Chair Position|Prospective Evaluation of Cognitive Outcomes After Anesthesia on Patients in the Beach Chair Position|BCP|West Virginia University|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02674334||3542|
NCT02676765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20006291|Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy|Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy||Virginia Commonwealth University|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676765||3355|
NCT02674958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150432|Mobilization of Endothelial Progenitor Cells and Aspirin|Mobilization of Endothelial Progenitor Cells Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Randomized Controlled Trial of Aspirin|TROPHIC 3|Ottawa Heart Institute Research Corporation|Yes|Not yet recruiting|March 2016|September 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02674958||3494|
NCT02677714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-Annexin-05|99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer|99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy||Advanced Accelerator Applications|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02677714||3282|
NCT02678689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-203|A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Patients With CLN2 Disease|A Phase 2 Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Patients With CLN2 Disease||BioMarin Pharmaceutical|No|Enrolling by invitation|January 2015|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|N/A|No|||February 2016|February 5, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678689||3207|
NCT02666989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yehuda04|Open-Label Placebo for the Treatment of Depression|||Shalvata Mental Health Center|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666989||4102|
NCT02671682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAPEMS|Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis|Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome||University of Ulm|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Eluate (Immunadsorption) and Plasma (Plasmapheresis)|Both|12 Years|80 Years|No|Probability Sample|patients with relapse of Multiple Sclerosis or Clinically Isolated Syndrome who do not        fully recover after high doses of intravenous corticosteroids|February 2016|February 9, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02671682||3744|
NCT02671695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/03/15|Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia|Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia||Tanta University|Yes|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|18 Years|No|||January 2016|January 30, 2016|January 30, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671695||3743|
NCT02675010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1|Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study|Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Multicenter Study||Mansoura University|No|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|March 14, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02675010||3490|
NCT02675023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911501|Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects|A Randomized, Open-label, Two-arm, Parallel Group, Single Dose Study to Assess the Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects||Baxalta US Inc.||Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|156|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675023||3489|
NCT02676921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18840|The Osteogenic Potential of Human Maxillary Sinus Shneiderian Membrane|Phase 1: Study of the Osteogenic Potential of Human Maxillary Sinus Shneiderian Membrane|HMSSM|Lebanese University|Yes|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|N/A||1|Actual|10|Samples With DNA|Human sinus membrane|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The present study investigates whether human sinus Shneiderian membrane (hMSSM) contain an        osteogenic progenitor cell population capable of forming bone by utilizing in vitro        assays.|February 2016|February 8, 2016|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02676921|4 Weeks|3343|
NCT02666092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_43|Anisakis Blastocystis Cryptosporidium Fish Serology|Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Role of Anisakidae and/or Fish Flesh Antigens in Fish Allergies.|ABCFish2|University Hospital, Lille|No|Recruiting|February 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|102|Samples Without DNA|Serum samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The recruited population will include:          -  51 patients with fish allergy          -  51 matched control subjects (sex, age +/- 5 years)|January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666092||4171|
NCT02666105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LS095|Exemestane in Post-Menopausal Women With NSCLC|Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer||Masonic Cancer Center, University of Minnesota|Yes|Not yet recruiting|April 2016|February 2020|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|N/A|N/A|No|||January 2016|January 25, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666105||4170|
NCT02666560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141A22|Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?|Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?||Institute of Child Health|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|5 Years|11 Years|No|||January 2016|January 25, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02666560||4135|
NCT02674802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Affiliated Hospital of NCU|Reinfection After Eradication of Helicobacter Pylori Infection|Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study|RAEHPI|The First Affiliated Hospital of Nanchang University|No|Recruiting|December 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|3500|||Both|18 Years|70 Years|No|Non-Probability Sample|In the retrospective study,people who has infected helicobacter pylori and successfully        eradicated it more than six months detected helicobacter pylori by the C-urea breath test        in order to evaluate the reinfection In the prospective study,people who has infected        helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6        months detected helicobacter pylori by the C-urea breath test in order to prospect the        reinfection|February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674802||3506|
NCT02674815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFSJ0086|Preoperative High Intensity Interval Training: The PHITT Trial|High Intensity Interval Training in Patients Scheduled for Colorectal and Thoracic Surgery: A Feasibility Study|PHITT|University of Dublin, Trinity College||Not yet recruiting|February 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02674815||3505|
NCT02690376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH19107|An Observer Blinded Comparison of MACE and Conventional Upper Gastrointestinal Endoscopy in Upper GI Bleeding|An Observer Blinded Comparison of Magnetically Assisted Capsule Endoscopy and Conventional Upper Gastrointestinal Endoscopy in Upper GI Bleeding|MACE|Sheffield Teaching Hospitals NHS Foundation Trust|No|Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02690376||2310|
NCT02669303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUR.MA.134|Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome|Comparing Subacromial Injection of Platelet-rich Plasma Versus Methylprednisolone in the Treatment of Shoulder Subacromial Impingement Syndrome|ShIP|American University of Beirut Medical Center|No|Recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02669303||3927|
NCT02671981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1205|Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma|Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma||Radiation Therapy Oncology Group|Yes|Recruiting|December 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671981||3721|
NCT02670369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 K23 HL119352-1|Investigating Sedentary Time in Aging: New Directions|Investigating Sedentary Time in Aging: New Directions|ISTAND|Group Health Cooperative|Yes|Completed|July 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|60 Years|89 Years|No|||January 2016|January 28, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02670369||3845|
NCT02688309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045274|Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases|Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases|P3F2|Johns Hopkins University|No|Recruiting|January 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02688309||2468|
NCT02665520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elaj stem cells 1|Penile Intracavernosal Stem Cells Therapy for Erectile Dysfunction|Phase 1 Study of the Use of Autologous Penile Stem Cells in Men With Erectile Dysfunction||Elaj medical centers|Yes|Recruiting|October 2015|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|40 Years|70 Years|No|||January 2016|January 26, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02665520||4214|
NCT02665533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.354.720|Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery|Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery||Federal University of the Valleys of Jequitinhonha and Mucuri|Yes|Recruiting|January 2016|July 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|35 Years|No|||January 2016|January 26, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665533||4213|
NCT02674581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-070|A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction|An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End‑Stage Renal Dysfunction (ESRD)||Bristol-Myers Squibb|No|Not yet recruiting|February 2016|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674581||3523|
NCT02670616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04-027|Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma|Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)||Samsung Medical Center|Yes|Not yet recruiting|February 2016|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|19 Years|N/A|No|||January 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670616||3826|
NCT02678416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNK14504055|A Study Comparing Reduction in Pain Intensity Following IV or Oral Acetaminophen|A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study to Compare the Reduction in Pain Intensity After Single-Dose Administration of IV or Oral Acetaminophen and IV Morphine by Using UVB or IDC Pain Models||Mallinckrodt|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|62|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678416||3228|
NCT02678429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160155|Atlas Predicted DBS Settings in Essential Tremor|Atlas Predicted DBS Settings in Essential Tremor||Vanderbilt University|No|Not yet recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678429||3227|
NCT02666079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPM-007|Randomised Trial of LightPath Imaging in Breast Cancer Surgery|A Randomised, Controlled, Multi-centre Clinical Study to Evaluate the Outcomes Following the Intra-operative Use of the LightPathTM Imaging System Compared to Standard Practice in Wide Local Excision (WLE) for Breast Cancer||Lightpoint Medical Limited|No|Not yet recruiting|June 2016|December 2022|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666079||4172|
NCT02674646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSETTA|RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial|RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial|ROSETTA|Technische Universität München|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02674646||3518|
NCT02519894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramathibodi Hospital|Effect of Intensive Low Sodium Restriction on Glomerular Infiltration Rate in Chronic Kidney Disease|Effect of Intensive Low Sodium Restriction on Glomerular Infiltration Rate in Chronic Kidney Disease||Ramathibodi Hospital||Enrolling by invitation|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 9, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02519894||15397|
NCT02519907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-602547-2|Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|EPIONE|Indiana University|No|Recruiting|September 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02519907||15396|
NCT02514967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SLE3343|CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis||Anthera Pharmaceuticals|Yes|Not yet recruiting|June 2016|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514967||15775|
NCT02515227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18174|Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab|A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade|Mel64;PATHVACS|University of Virginia|Yes|Recruiting|November 2015|August 2021|Anticipated|August 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515227||15755|
NCT02518061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1418|11C-Methionine PET as Prognostic Marker of Gliomas|RUOLO DELLA 11C-METIONINA PET NELLA CARATTERIZZAZIONE MOLECOLARE E PROGNOSTICA DEI GLIOMI CEREBRALI CANDIDATI A CHIRURGIA.||Istituto Clinico Humanitas|No|Recruiting|July 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|145|Samples Without DNA|Tumor surgical specimen|Both|18 Years|N/A|No|Non-Probability Sample|We will recruit a maximum number of 145 patients with glioma operated in our institution        during 2011-2015, of which are available clinical and instrumental data and surgical tumor        specimen.|August 2015|August 5, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02518061||15538|
NCT02666313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEBPASS|WEB-Based Physiotherapy for People With Axial Spondyloarthritis|WEB-Based Physiotherapy for People With Axial Spondyloarthritis: A Cohort Study||University of Glasgow|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02666313||4154|
NCT02668835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-15-6628|GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson's Disease Trial|GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson's Disease Trial|GADGET-PD|Scripps Translational Science Institute|No|Enrolling by invitation|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|96|||Both|18 Years|N/A|No|Non-Probability Sample|Study population is limited to individuals presenting in Scripps Health clinics with        diagnosis of Parkinson's disease or essential tremor.|January 2016|January 28, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02668835||3961|
NCT02675296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3|Regional and Long Term Outcomes of Acute Kidney Injury in England From 2000 to 2015 - A National Database Study|Regional and Long Term Outcomes of Acute Kidney Injury in England From 2000 to 2015 - A National Database Study||Derby Hospitals NHS Foundation Trust|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|54680|||Both|N/A|120 Years|No|Non-Probability Sample|The 2000 to 2015 data was extracted from the Hospital Episode Statistics (HES), a data        warehouse containing details of all admissions, outpatient appointments and A&E        attendances at NHS hospitals in England. HES collects a detailed record for each 'episode'        of admitted patient care delivered in England, either by NHS hospitals, primary care        trusts, mental health trusts or delivered in the independent sector but commissioned by        the NHS. These data are collected during a patient's time in hospital and stored as a        large collection of separate records, one for each period of care, in a secure data        warehouse.|February 2016|February 4, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675296||3468|
NCT02675309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-8554-E05|A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects|||Mitsubishi Tanabe Pharma Corporation|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02675309||3467|
NCT02688153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11|EDWARDS INTUITY Valve System CADENCE Study|A Randomized Comparison of the EDWARDS INTUITY Valve System anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve replacEment|CADENCE|Edwards Lifesciences|No|Active, not recruiting|October 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02688153||2480|
NCT02662478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-006-ST|Laparoscopic Resection of Large Gastric Stromal Tumors|Accuracy and Feasibility of a Morpho-anatomical Classification Oriented Laparoscopic Resection of Gastric Stromal Tumors in Advanced Laparoscopic Surgery Center: a Prospective Cohort Study||Medical Park Gaziantep Hospital|Yes|Completed|June 2008|February 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|Samples Without DNA|gastric resection material|Both|18 Years|N/A|No|Probability Sample|Using the Turkish national procedural classification code number for laparoscopic stomach        surgeries, a search was made in the Medical Park Gaziantep Hospital database which        identified 124 patients underwent laparoscopic gastric resection for tumor. Then an        additional similar search was performed to obtain primary gastric GIST subgroup according        to the histopathological results and a total of 23 patients in whom LRS were performed,        were identified.|February 2016|February 3, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02662478||4448|
NCT02675465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATB200-02|First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221|An Open-Label, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusions of ATB200 Alone and ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease Who Were Previously Treated With Alglucosidase Alfa||Amicus Therapeutics|No|Recruiting|January 2016|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|January 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675465||3455|
NCT02663973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBECAM 0115|Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III|Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III||Latin American Cooperative Oncology Group|No|Recruiting|January 2016|January 2021|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Female|18 Years|N/A|No|Non-Probability Sample|Woman ≥ 18 years old with recent diagnosis of breast cancer|February 2016|February 11, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663973||4333|
NCT02669290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04791|Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy|Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy (MUGA-CRT)|MUGA CRT|University of California, San Francisco|No|Recruiting|January 2007|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669290||3928|
NCT02675972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DongguanPeoplesH|Which Parameters of Short-term Blood Pressure Variability Best Predict Early Outcomes in Acute Ischemic Stroke|Association of 24-hour Blood Pressure Variability With Early Outcomes in Patients With Acute Non Cardiogenic Ischemic Stroke|BPV|Dongguan People's Hospital|Yes|Recruiting|January 2014|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|fasting glucose, creatine, BNP, CRP,BUN,cholesterol, LDL,HDL|Both|18 Years|80 Years|No|Non-Probability Sample|acute ischemic stroke patients with 72 hour after onset|February 2016|February 3, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02675972||3416|
NCT02665377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SahlgrenskaUHMT01|ANPtransplantation|||Sahlgrenska University Hospital, Sweden|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665377||4225|
NCT02665390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201601|Percutaneous Cryoablation Peripheral Lung Cancer|Percutaneous Cryoablation for the Treatment of Medically Inoperable Peripheral Lung Cancer|PCPLC|Shanghai Chest Hospital|No|Not yet recruiting|February 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665390||4224|
NCT02685046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-TT-IMA-14|Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy|Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.|ImPACCT|UMC Utrecht|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02685046||2719|
NCT02661620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDAPT 15-4538-02|REDAPT Retrospective-Prospective Modular Stem Study|A Retrospective-Prospective Study of REDAPT™ Revision Femoral System Modular Stem||Smith & Nephew, Inc.|No|Recruiting|February 2016|August 2026|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|132|||Both|N/A|N/A|No|Probability Sample|Subject has undergone revision hip arthroplasty with the REDAPT™ Revision Femoral System        modular stem with implantation from 2012 to the date of Institutional Review Board        (IRB)/Ethics Committee (EC) approval of this protocol at the study site.|March 2016|March 2, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661620||4514|
NCT02668432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150864H|Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock|||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668432||3991|
NCT02665364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN-K-002|Study of IFN-K in Systemic Lupus Erythematosus|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus||Neovacs|Yes|Recruiting|September 2015|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|65 Years|No|||January 2016|January 22, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02665364||4226|
NCT02677051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro20120001884|Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism|Sulforaphane in Autism: A Treatment Trial to Confirm Phenotypic Improvement With Sulforaphane Treatment in a New Jersey (NJ) Population of Individuals With Autism||Rutgers, The State University of New Jersey|Yes|Recruiting|February 2016|January 2022|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|13 Years|30 Years|No|||March 2016|March 23, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677051||3333|
NCT02665260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01-004|Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum|Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum||Montefiore Medical Center|No|Completed|July 2012|January 2016|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02665260||4234|
NCT02664844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0255|Physical Activity and Food Intake Interaction: Effect of Weight Loss in Obese Adolescent|Physical Activity and Food Intake Interaction: Effect of Weight Loss in Obese Adolescent||University Hospital, Clermont-Ferrand||Completed|September 2013|December 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|12 Years|18 Years|No|||January 2016|January 22, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02664844||4266|
NCT02665910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR0302-102|Multiple Doses Escalation Study of SHR0302 in RA Patients|A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA||Jiangsu HengRui Medicine Co., Ltd.|No|Not yet recruiting|February 2016|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02665910||4184|
NCT02666170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alpha-Lipoic Acid 2016|Effects of Alpha-acid Lipoic in PCOS Women|Effects of 6 Months of Alpha-Lipoic Acid Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS||Catholic University of the Sacred Heart||Not yet recruiting|January 2016|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|35 Years|No|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666170||4165|
NCT02688777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2004-R|A Novel Strategy to Decrease Fall Incidence Post-Stroke|A Novel Strategy to Decrease Fall Incidence Post-Stroke||VA Office of Research and Development|No|Not yet recruiting|June 2016|May 2020|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|85 Years|No|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688777||2432|
NCT02662205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKState|Group Yoga Therapy at a College Counseling Center|A Controlled Trial of Group Yoga Therapy at a College Counseling Center||Oklahoma State University|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02662205||4469|
NCT02662439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-BCM-15-1|Bioimpedance Analysis in Chronic Heart Failure|Role of the Bioimpedance Analysis in Guiding the Diuretic Therapy in Chronic Heart Failure - A Randomized Controlled Trial||Semmelweis University||Recruiting|February 2016|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662439||4451|
NCT02673125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.111b|Prospective Paired Study on the Effectiveness of MitoGrade|Prospective Paired Study on the Effectiveness of MitoGrade||Reprogenetics|No|Recruiting|December 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673125||3634|
NCT02673138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508016333|Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion|Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion||Yale University|No|Recruiting|January 2016|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|No|||February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673138||3633|
NCT02674620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:020|Trial of Aerobic Treadmill Exercise Treatment for Concussion|Randomized Controlled Trial of Aerobic Treadmill Exercise Treatment for Concussion||Panam Clinic|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|13 Years|19 Years|No|||January 2016|February 2, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02674620||3520|
NCT02677948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.131|Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)||University of Michigan Cancer Center|Yes|Not yet recruiting|February 2016|||October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|79 Years|No|||February 2016|February 8, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677948||3264|
NCT02677961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-14242|An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry|An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry||Ohio State University Comprehensive Cancer Center|No|Recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a diagnosis of bone or soft-tissue tumor as defined by the WHO        classification of tumors of soft tissue and bone (4th ed.)|February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677961|5 Years|3263|
NCT02670187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 2274|Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers|Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers||GeneOne Life Science, Inc.|Yes|Recruiting|January 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670187||3859|
NCT02670460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR-0046|Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial|Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial||Lungpacer Medical Inc.|No|Completed|October 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02670460||3838|
NCT02670473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-55 (CV-15-09)|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||February 2, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670473||3837|
NCT02675049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA10|Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia|Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia||Tianjin Medical University Cancer Institute and Hospital|Yes|Completed|January 2016|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|20 Years|60 Years|No|||February 2016|February 29, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675049||3487|
NCT02690740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ_001_CPT|Titrated Quantitative Conjunctival Provocation Test (tqCPT)|Titrated Quantitative Conjunctival Provocation Test (tqCPT): Standardization and Validation of a New Clinical Endpoint|tqCPT|Zentrums für Rhinologie und Allergologie Wiesbaden|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|67 Years|No|||February 2016|February 23, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02690740||2282|
NCT02677610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M169981001|Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older|A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis|MSRD-100|Merz Pharmaceuticals, LLC|No|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|370|||Both|3 Months|N/A|No|||February 2016|February 8, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677610||3290|
NCT02670525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-384|Matched Targeted Therapy For High-Risk Leukemias|Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias||Dana-Farber Cancer Institute|No|Not yet recruiting|February 2016|November 2020|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|DNA isolated from leukemia samples obtained from patients|Both|N/A|30 Years|No|Non-Probability Sample|Pediatric and young adult participants with high risk or relapsed/refractory leukemia|January 2016|January 29, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670525||3833|
NCT02670538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-53|Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Patients With Bipolar I Disorder|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression||Forest Laboratories|No|Not yet recruiting|March 2016|June 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670538||3832|
NCT02670551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-54|Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Patients With Bipolar I Depression|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression||Forest Laboratories||Not yet recruiting|March 2016|June 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670551||3831|
NCT02668536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512016909|A Sunscreen Based on Bioadhesive Nanoparticles|Assessing the Safety and Efficacy of Multifunctional Skin-adhesive Nanoparticles for UV Protection in Humans||Yale University|Yes|Not yet recruiting|February 2016|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668536||3983|
NCT02690350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31784-A-E101|An Open Study Assessing the Safety and Tolerability of U3-1784|A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours||Daiichi Sankyo Inc.|No|Recruiting|January 2016|April 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02690350||2311|
NCT02693340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P150702|Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease|Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease|IBDOT|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|March 2020|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|• Sampling period(s):        -  Blood: W0, W6, W14, W30 and W52 and relapse.        -  Biopsies and fecal: W0, W14 and M52 and relapse.|Both|18 Years|N/A|No|Non-Probability Sample|Crohn's Disease Diagnosis (CD) or ulcerative colitis (UC)|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693340||2083|
NCT02664077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-13|A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer|A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer|ARGO|NSABP Foundation Inc|Yes|Not yet recruiting|February 2016|October 2024|Anticipated|August 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1118|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664077||4325|
NCT02664090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-139-DM-88|Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in ARDS Patients|Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in Patients With Acute Respiratory Distress Syndrome (ARDS)||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|All critically ill adult patients with diagnosis of ARDS whose hemodynamic monitoring is        being done by trans-esophageal doppler (TED), and planned for prone ventilation by        treating physician's decision, will be screened for inclusion in this study.|January 2016|January 26, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02664090||4324|
NCT02674789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54333.081.15|Ionized Magnesium in Athletes|Ionized Magnesium Concentration in Athletes and Exercise Induced Changes in Ionized Magnesium||Wageningen University|No|Active, not recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02674789||3507|
NCT02670109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCMNSZ REF 1239|Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients|High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients Without Complete Pathological Response to Neoadjuvant Chemotherapy||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|60 Years|No|||February 2016|February 12, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670109||3865|
NCT02680834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6010|VLU Non-inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-layer Bandaging|Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-inferiority Study||Tactile Medical|Yes|Recruiting|February 2016|March 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680834||3043|
NCT02680847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531015|Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain|An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia||Pfizer|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|7 Years|17 Years|No|||March 2016|March 17, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680847||3042|
NCT02665078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-7111|Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules|Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules Using Resected Human Lungs||University Health Network, Toronto|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Any patients scheduled for lobectomy of anatomical segmental resection for malignant lung        tumors.|January 2016|January 22, 2016|May 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02665078||4248|
NCT02666846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM52|Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model|A Randomised, Double Blind, Cross Over Clinical Study in Healthy Human Volunteers to Assess the Efficacy and Safety of Three Different Topical Analgesics (DCF100, TIB200 And SPR300) Versus Placebo and Active Control(s) in a Model of UV-Induced Inflammatory Pain||Futura Medical Developments Ltd.|No|Completed|March 2015|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02666846||4113|
NCT02677688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/10/06-X|Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)|Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment|LUPUS CTL EBV|Nantes University Hospital|No|Active, not recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02677688||3284|
NCT02664051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56881|Mast Cells in Acid-induced Intestinal Permeability|The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers||Universitaire Ziekenhuizen Leuven|No|Recruiting|August 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|January 21, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02664051||4327|
NCT02664285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ceserean section|Closure Versus Non Closure of Subcutaneous Tissue After Cesarean Section in Diabetic Patients|Closure Versus Non Closure of Subcutaneous Tissue After Cesarean Section in Diabetic Patients||Ain Shams University|Yes|Active, not recruiting|January 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|136|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02664285||4309|
NCT02662257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[869]-1|Impact of Anesthesia Maintenance Methods on Incidence of Postoperative Delirium|Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Incidence of Postoperative Delirium in Elderly Patients After Cancer Surgery: An Open-label, Randomized Controlled Trial||Peking University First Hospital|Yes|Recruiting|April 2015|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|65 Years|90 Years|No|||January 2016|January 22, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02662257||4465|
NCT02663401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROUS_NICE|Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus Cafeterias|Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus Cafeterias|5-C CROUS|University of Paris 13|No|Recruiting|March 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663401||4377|
NCT02663414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-102359|European Post-Market Study for Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction|European Post-Market, Prospective, Multi-Center, Single-Arm Study to Evaluate Symptom Relief in Subjects With Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction|Atlas-PMCF|Moximed|No|Not yet recruiting|March 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|25 Years|N/A|No|||January 2016|January 26, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02663414||4376|
NCT02662153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 1B|Incidence and Predictors of Opioid Overdose and Death in ER/LA Opioid Users as Measured by Diagnoses and Death Records|Incidence and Predictors of Opioid Overdose and Death Among ER/LA Opioid Analgesics Users as Measured by Diagnoses and Death Records - a Retrospective Database Study||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A||Non-Probability Sample|The source populations will be those members of the selected health plans and insurance        programs identified for which full demographic, provider, facility and pharmacy data are        available, and in which protected health information (PHI) can be linked to death        certificate information.        The four large healthcare systems that have established electronic databases for studying        coded terminology outcomes selected for this study are: Kaiser Permanente Northwest        (KPNW); Group Health Cooperative (GHC); Optum with access to the Optum Research Database        (ORD), containing United Healthcare commercial insurance data; and Vanderbilt University        with access to Medicaid data for the State of Tennessee (TennCare)"|November 2015|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662153||4473|
NCT02671630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 101-2314-B-570-001|Computerized Cognitive Training Program for Older Persons With Mild Dementia|||Far Eastern Memorial Hospital|Yes|Completed|June 2013|||October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|30|||Both|65 Years|N/A|No|||January 2016|January 29, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02671630||3748|
NCT02671760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-A-02|Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia|A Randomized, Double-Blind, Single-Dose Study to Assess the Pharmacodynamic Effects of SM-1 Versus Comparator and Placebo in a 5 Hour Phase Advance Model of Insomnia in Adults Who Suffer From Short-Term Insomnia||Sequential Medicine Ltd|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|39|||Both|25 Years|64 Years|No|||January 2016|January 29, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671760||3738|
NCT02676804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18664|Exercise Dosing Trial for Individuals With Parkinson's Disease|Exercise Dosing Trial for Individuals With Parkinson's Disease|PDEX|University of Virginia|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|45 Years|N/A|No|||February 2016|February 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676804||3352|
NCT02663661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18568|Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index|Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index||University of Virginia|Yes|Not yet recruiting|February 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|63|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02663661||4357|
NCT02666443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-1350|Low Dose Dexamethasone in Supraclavicular Blocks|Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Randomized, Double Blinded, Control Study||University of Calgary|No|Not yet recruiting|February 2016|February 2021|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|306|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666443||4144|
NCT02666456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOLORisk WP4|The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain|DOLORisk: Understanding Risk Factors and Determinants for Neuropathic Pain - The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain||University of Kiel|No|Not yet recruiting|April 2016|||March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Painless patients and patients with chronic peripheral neuropathic pain.|January 2016|January 25, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02666456||4143|
NCT02665039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUCOG I|A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function|A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function.|VINGEM|Karolinska University Hospital|Yes|Recruiting|April 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665039||4251|
NCT02671838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-01-2016|A Musculoskeletal Ultrasound Program to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis|Developing a Musculoskeletal Ultrasound Program as an Intervention to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis: A Randomized Controlled Trial||Singapore General Hospital|No|Not yet recruiting|February 2016|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|132|||Both|21 Years|75 Years|No|||January 2016|January 29, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671838||3732|
NCT02675855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 350|GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers|A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers||Osiris Therapeutics|No|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675855||3425|
NCT02665143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507016193|A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia|A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia||Yale University|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665143||4243|
NCT02672657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00317-40|Determinants of Quality Of Life in AGEd Cancer Patients|Assessing the Evolution and Determinants of Quality of Life in Elderly Cancer Patients and Their Caregivers: a Prospective Multicenter Observational Cohort Study.|DEQOLAGE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|December 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|70 Years|N/A|No|Non-Probability Sample|All patients presenting at the participating hospitals with newly diagnosed colorectal or        prostate cancer and referred by an oncologist, surgeon, radiotherapist, or other        specialist to the hospital geriatric oncology clinics for a multidimensional geriatric        assessment before the initiation of cancer treatment will be eligible for inclusion,        regardless of stage at diagnosis and plans for treatment|December 2015|January 29, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02672657||3670|
NCT02676375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024|Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment|Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment||Brentwood Biomedical Research Institute|No|Active, not recruiting|January 2014|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676375||3385|
NCT02676466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500895|The ENRGISE Pilot Study|The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study|ENRGISE|University of Florida|Yes|Recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|300|||Both|70 Years|N/A|No|||March 2016|March 2, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676466||3378|
NCT02675504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14006|Validation of a Scale of Self-assessment of Fear Faces in Children 4 to 12 Years|Validation of a Scale of Self-assessment of Fear Faces in Children 4 to 12 Years: Scary Scale|TROUILLOMETRE|University Hospital, Limoges|No|Not yet recruiting|March 2016|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|483|||Both|4 Years|12 Years|No|Probability Sample|Participating in the study of children aged 4 to 12 years. In this study, participation of        school children and hospitalized children|October 2015|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02675504||3452|
NCT02690727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP6530-1501|To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers|An Open Label, Randomized, Single Dose, Cross Over Study to Evaluate Food Effects on Relative Bioavailability of RP6530 Administered in Fasting and Fed Conditions in Healthy Volunteers||Rhizen Pharmaceuticals SA|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690727||2283|
NCT02669940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-743|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study|HCV RWE|AbbVie|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|158|||Both|18 Years|99 Years|No|Non-Probability Sample|Treatment-naïve or -experienced adult male or female patients with confirmed chronic        hepatitis C genotype 1, receiving combination therapy with the interferon-free ABBVIE        REGIMEN ± RBV according to standard of care and in line with the current local label|January 2016|January 28, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669940||3878|
NCT02670213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1841-4211|A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan|A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan||Novo Nordisk A/S|No|Recruiting|March 2016|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|N/A|N/A|No|Non-Probability Sample|Male or female patients, regardless of age, requiring treatment with NovoThirteenR at the        discretion of the treating physician|March 2016|March 18, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02670213||3857|
NCT02675725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nWMO 128|Kinetics of the Sublingual Microcirculation During Fluid Bolus|Kinetics of the Sublingual Microcirculation During the Treatment of a Postoperative Shock||Medical Centre Leeuwarden|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Postoperative cardiac surgery patients|February 2016|February 2, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02675725||3435|
NCT02675738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCP-1|Reliability of the Preoperative Work-up in Patients Submitted to Surgery for Cystic Neoplasms of the Pancreas|Reliability of the Preoperative Work-up in a Prospective Series of Patients Submitted to Surgery for Cystic Neoplasms of the Pancreas|NCP-1|Universita di Verona||Recruiting|December 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from pancreatic cystic neoplasms candidate to surgery|February 2016|February 4, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02675738||3434|
NCT02675751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-115-MIPS|Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-guided PRK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and the Star S4 IR™ Excimer Laser System||Abbott Medical Optics|No|Recruiting|January 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|334|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675751||3433|
NCT02680236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4218|Art Therapy for Pain Relief in Breast Cancer Patients|Can Art Therapy Improve Breast Cancer Patients' Perception of Persistent Post Treatment Pain and Functioning? A Mixed Methods Pilot Study||Royal Marsden NHS Foundation Trust|No|Recruiting|June 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|85 Years|No|Non-Probability Sample|Patient with breast cancer as assessed by the RM pain team.|February 2016|February 8, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02680236||3089|
NCT02670499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF2015-01|Study Comparing GAP-Flex to CPM Therapy in Treatment of TKR|A Randomized Controlled Multicenter Study Comparing GAP-FLEX to Continuous Passive Motion (CPM) Therapy in Combination With Standard of Care Physical Therapy in Subjects With Total Knee Replacement (TKR)|GAP-Flex|Xeras Medical Technologies|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|52|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02670499||3835|
NCT02664376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-sarcopenia|Prevalence of Sarcopenia and Its Geriatric Features|Prevalence of Sarcopenia and Its Geriatric Features||Brugmann University Hospital|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|65 Years|N/A|No|Non-Probability Sample|Each patient over 65 years admitted to the unit 83 of the Geriatric Department, CHU        Brugmann Hospital, from 10/01/2016 till 20/05/2016 undergoes a comprehensive geriatric        assessment at the end of its hospitalisation stay. The screening for sarcopenia is part of        this geriatric assessment.|January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664376||4302|
NCT02527551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-06|Efficacy of Deep Haptic Massage in Fibromyalgia : Preliminary Study|Efficacy of Deep Haptic Massage in Fibromyalgia : Preliminary Study|FEM|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|September 2015|November 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|65 Years|No|||July 2015|August 17, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02527551||14808|
NCT02519465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luciana doutorado 02|Evaluation of Lung Deposition of Aerosol Via HFNC in Healthy Adults|Evaluation of Lung Deposition of Aerosol Via HFNC in Healthy Adults||Universidade Federal de Pernambuco|Yes|Recruiting|July 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519465||15430|
NCT02519478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNH-02-5779-01|Prevention of Head Impacts in Football: The HuTT Technique|Prevention of Head Impacts in Football: The HuTT Technique|HuTT|University of New Hampshire|No|Active, not recruiting|August 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|170|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02519478||15429|
NCT02521987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207726|Port Size and Post-Operative Pain Perception by Patients|Port Size and Post-Operative Pain Perception by Patients||Loyola University|Yes|Recruiting|July 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|N/A|N/A|No|||March 2016|March 1, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02521987||15236|
NCT02522000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC142070|Functional Dyspepsia and Symptom Perception|Symptom Perception in Patients With Functional Dyspepsia: Involvement of the TRPV-1 Neuropeptide Pathway||Maastricht University Medical Center|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|50 patients with functional dyspepsia and 20 healthy controls will be included|July 2015|August 12, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02522000||15235|
NCT02684305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|686-15- TLV|Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction|Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02684305||2776|
NCT02684318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLA/ACOG1401|Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors|Phase Ib/II Study to Evaluate the Efficacy and Tolerability of PM01183 in Combination With Olaparib in Patients With Advanced Solid Tumors||Poveda, Andrés, M.D.|No|Recruiting|July 2015|July 2018|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02684318||2775|
NCT02670746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-008|A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer|Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)|TRUST|Celgene Corporation|No|Recruiting|October 2015|April 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Two-hundred adult patients treated with the combination nab-paclitaxel and gemcitabine        (AG) for metastatic pancreatic adenocarcinoma will be recruited from approximately 25        oncology sites in the Netherlands. In all cases, the decision to treat the patient with AG        was already made prior to the decision to enter the subject into the study. Treatment will        be according to routine clinical practice and based on recommendations as per SmPC.|March 2016|March 23, 2016|August 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02670746||3816|
NCT02677493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY_IFEZ_Q301|Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' After Intramuscular Administration in Healthy Adult Subjects||Il-Yang Pharm. Co., Ltd.|No|Active, not recruiting|October 2015|June 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1794|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02677493||3299|
NCT02676999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0369|Clinical and Radiographical Analysis of the Distal Radioulnar Joint Following Implantation of a Scheker Total Distal Radioulnar Joint Prosthesis|Clinical and Radiographical Analysis of the Distal Radioulnar Joint Following Implantation of a Scheker Total Distal Radioulnar Joint Prosthesis||University of Zurich||Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Patient treated with a Scheker total distal radioulnar joint prosthesis and with a        follow-up time between 12 and 60 months after primary implantation, who were willing and        able to give written informed consent to participate in the study.|February 2016|February 8, 2016|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02676999|12 Months|3337|
NCT02677038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0503|Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer|Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677038||3334|
NCT02685943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2014/465|A Randomized Trial for Suicidal Patients|"Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial||Vestre Viken Hospital Trust|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Months|N/A|No|||February 2016|February 15, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02685943||2650|
NCT02686190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081119|Effects of Light-therapy in Alzheimer's Disease|Effects of Bright Light to Improve Agitation and Sleep Disorders in Patients With Alzheimer's Disease|ALZ-Light|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2012|December 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|60 Years|N/A|No|||February 2016|March 16, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686190||2631|
NCT02667951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 97-2420-H-182-002-MY3|A Home-based Training Program for Elderly Patients With Dementia|||Chang Gung Memorial Hospital|Yes|Completed|June 2009|March 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|129|||Both|N/A|N/A|No|||January 2016|January 28, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02667951||4028|
NCT02665130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BCN01T|Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants|State Key Laboratory of Respiratory Disease||State Key Laboratory of Respiratory Disease|Yes|Recruiting|December 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||January 2016|January 22, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02665130||4244|
NCT02684552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016|Non Invasive Ventilation During Physical Training in Cystic Fibrosis|Physiotherapist in Charge of the Study||Karolinska University Hospital|No|Not yet recruiting|February 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|90 Years|No|||February 2016|February 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02684552||2757|
NCT02684786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-000928|A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension|A Phase I Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension||Mayo Clinic|No|Not yet recruiting|March 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|100 Years|No|||February 2016|February 17, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684786||2739|
NCT02673086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH 010|Retroclavicular Versus Infraclavicular Brachial Plexus Block|Could the Retroclavicular Block Alternative for Ultrasound-guided Infraclavicular Block: A Prospective Randomized Controlled Trial||Antalya Training and Research Hospital|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2015|February 2, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02673086||3637|
NCT02664350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500780|Precision Medicine Guided Treatment for Cancer Pain|Precision Medicine Guided Treatment for Cancer Pain||University of Florida|Yes|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|120 Years|No|||January 2016|January 22, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664350||4304|
NCT02670356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11787|Study Comparing Fish Oil and Krill Oil|Study Comparing Fish Oil and Krill Oil||Tufts University|No|Recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02670356||3846|
NCT02688504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2012/33|Health and Road Safety: Influence of Drugs Use and Health Status|CESIR-U2 : Influence of Drugs Use and Health Status|CESIR-U2|University Hospital, Bordeaux|No|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|This study is a multicentre observational study that will include 2 populations: drivers        involved in serious road accidents (hospitalization > 24 hours) and non-serious road        accidents (hospitalization < 24 hours). The drivers involved in road accidents and        admitted in an emergency department will be identified during daily visits (except on week        end) by Clinical Research Associates (CRA) of the different centres. As soon as possible,        a structured validated interview will done by a trained CRA.|February 2016|February 17, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02688504||2453|
NCT02666768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21549-01|ACTIMMUNE in Intermediate Osteopetrosis|Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis||Los Angeles Biomedical Research Institute|No|Recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|N/A|No|||March 2016|March 9, 2016|June 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666768||4119|
NCT02672917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-0715-CP-001.01|Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies|Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies||MabVax Therapeutics, Inc.|No|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672917||3650|
NCT02669446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/EHT/NIS|Ectoin® Lozenges in the Treatment of Acute Viral Pharyngitis|Non Interventional Clinical Investigation of Ectoin® Lozenges in the Treatment of Acute Viral Pharyngitis||Bitop AG|Yes|Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with viral pharyngitis|January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02669446||3916|
NCT02669459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 53792.078.15|Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol|A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment|TopIC-2|Erasmus Medical Center|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|433|||Female|18 Years|N/A|No|||October 2015|January 27, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669459||3915|
NCT02677883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 1593|Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis|Manometry- Versus Symptom-Guided Large Volume Thoracentesis: a Randomized Controlled Study||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|19 Years|N/A|No|||February 2016|February 9, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677883||3269|
NCT02673528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-007-LAA|Laparoscopic Assisted or Total Laparoscopic Appendectomy|Laparoscopic Assisted or Total Laparoscopic Appendectomy in Patients With Uncomplicated Acute Appendicitis: a Matched Case-control, Cost-utility Study||Medical Park Gaziantep Hospital|Yes|Completed|January 2015|January 2016|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|451|Samples Without DNA|appendectomy material|Both|16 Years|99 Years|No|Probability Sample|The control group (Group 1) comprised 108 matched-cases of uncomplicated appendicitis        operated with total laparoscopic appendectomy within the period January 2008 through July        2011.        The study group (Group 2) is represented by 108 consecutive patients diagnosed with        uncomplicated acute appendicitis, operated with lap assisted appendectomy.        Group 3 consisted of 211 patients with uncomplicated appendicitis, in whom Lap assisted ap        were unsuccessful because of several reasons, were underwent to Total Lap App within the        same period|February 2016|February 1, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02673528||3604|
NCT02668783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8342B-059|Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women With Moderate to Severe Primary Dysmenorrhea (With Optional Extension)||Merck Sharp & Dohme Corp.|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Female|N/A|50 Years|No|||March 2016|March 23, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668783||3965|
NCT02668796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLK-1502|To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.|A Phase III Investigator-Blind, Randomized, Parallel-Group, Placebo- Controlled, Multicentre Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk Inc.) Administered for 14 Days and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause.||Glenmark Pharmaceuticals Ltd. India|No|Recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Female|30 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668796||3964|
NCT02670850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC102-2314-B-182-051-MY3|Intervention Program for Patients With Mild Cognitive Impairment|||Chang Gung Memorial Hospital|Yes|Recruiting|October 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|65 Years|N/A|No|||January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02670850||3808|
NCT02691494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-817|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)|A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women||AbbVie|Yes|Recruiting|February 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Female|18 Years|51 Years|No|||February 2016|February 22, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691494||2225|
NCT02667288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-303|An Open-Label Safety Study of A-101 Solution|An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.||Aclaris Therapeutics, Inc.|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667288||4079|
NCT02667600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35648|Blood Loss Measurement During Cesarean Delivery|Study Assessing Blood Loss Measurement During Cesarean Delivery With Triton Device||Stanford University|No|Not yet recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|50 Years|No|Non-Probability Sample|Healthy female patients undergoing uncomplicated Cesarean delivery|January 2016|February 29, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667600||4055|
NCT02665091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nmp/22189|Peer Education Program for HIV/AIDS Related Sexual Behaviors of Secondary School Students|Impact of Peer Education Program on HIV/AIDS Related Sexual Behaviors of Secondary School Students in Rural Communities, India: a Quasi-experimental Study.||NMP Medical Research Institute|Yes|Completed|February 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|560|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665091||4247|
NCT02661763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNZABREC 002-10-13|Rheumatic Heart Disease Study in Lusaka|Prevalence of Rheumatic Heart Disease in Zambian Schoolchildren: an Echocardiographic Screening Study Involving Task-shifting to General Radiographers||University of Zambia|Yes|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1024|||Both|10 Years|21 Years|No|Non-Probability Sample|A population of approximately 1,024 schoolchildren drawn from 15 primary and secondary        schools in Lusaka, Zambia, to be screened for RHD in order to determine prevalence of the        disease.|January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661763||4503|
NCT02662088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLOSTUDY-1|Laparoscopic-lavage Observational Study|Laparoscopic-lavage Observational Study|LLOS|University of Turin, Italy|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Each patient is required to meet all of the inclusion criteria and none of the exclusion        criteria|February 2016|February 5, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662088|5 Years|4478|
NCT02664974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEN|Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer|Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|December 2008|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|79|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02664974||4256|
NCT02665182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP12-1|Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis|Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis - a Randomized Controlled Trial|EleScro|Medical University of Warsaw|No|Recruiting|July 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665182||4240|
NCT02673684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390805|Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use|Double Blind, Randomized, Sham-Controlled Study on the Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use in Pain Patients|NSS|Defense and Veterans Center for Integrative Pain Management||Not yet recruiting|February 2016|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673684||3592|
NCT02676193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA190347|Effect of Packaging on Smoking Perceptions and Behavior|Effect of Packaging on Smoking Perceptions and Behavior: A Randomized Trial|CASA|University of California, San Diego|No|Not yet recruiting|February 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|450|||Both|21 Years|65 Years|No|||February 2016|February 3, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02676193||3399|
NCT02676206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-540|Music Therapy in Procedural Sedation in the Emergency Department|Music Therapy in Procedural Sedation in the Emergency Department||University of New Mexico|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02676206||3398|
NCT02676310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-085|Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)|Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men||Allergan|Yes|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|90|||Male|18 Years|49 Years|No|||March 2016|March 15, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676310||3390|
NCT02676388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Freeze-dried FMT-STC|Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation|Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation: a Randomized Controlled Study||Jinling Hospital, China|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676388||3384|
NCT02690870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160220|Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF|Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Not yet recruiting|January 2017|March 2019|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Female|37 Years|42 Years|No|||February 2016|February 23, 2016|February 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690870||2272|
NCT02663843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601LSFOI|Low Skill Fibreoptic Intubation I-gel vs Air-Q|Comparison of 'Low Skill Fibreoptic Tracheal Intubation' Via I-gel® and Air-Q® Supraglottic Airway Devices in Patients With Simulated Difficult Airways.||Singapore General Hospital|No|Not yet recruiting|April 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|80 Years|No|||January 2016|January 21, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663843||4343|
NCT02677545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00171|Ticagrelor Versus Clopidogrel in Carotid Artery Stenting|Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI)|PRECISE-MRI|University Hospital, Basel, Switzerland|Yes|Not yet recruiting|April 2016|July 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|40 Years|N/A|No|||February 2016|February 4, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677545||3295|
NCT02677558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021/2016|The Impact of Obesity on Cardiac Function in Pregnancy|The Impact of Obesity on Cardiac Function in Pregnancy|CFOP|University of Cape Town|Yes|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|80|||Female|18 Years|N/A|No|Probability Sample|Healthy obese pregnant, non-labouring women at term who fulfil the inclusion criteria will        be recruited into the study group. As controls, healthy non-obese non-labouring term        pregnant women will be recruited. Controls will be matched for age and ethnicity.|February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02677558||3294|
NCT02675101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160096|Nuts and Olestra for Persistent Organic Pollutant Reduction (NO-POPs) Trial|Nuts and Olestra for Persistent Organic Pollutant Reduction (NO-POPs) Trial: A Pilot Investigation|NO-POPs|University of California, San Diego|No|Recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675101||3483|
NCT02693353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150420|Epiretinal Membrane and Pseudophakic Cystoid Macular Edema|Association of Cystoid Macular Edema After Cataract Surgery in Patients With and Without Epiretinal Membrane||Loma Linda University|Yes|Recruiting|February 2016|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All patients over 18 who are undergoing cataract surgery at Loma Linda University Eye        Institute|March 2016|March 8, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02693353||2082|
NCT02693574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1|Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori|Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population||Damascus Hospital|Yes|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||February 2016|February 28, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02693574||2065|
NCT02668185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15HH2867|Neuropeptide Treatment for Hot Flushes During the Menopause|Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes|NK3R|Imperial College London|Yes|Recruiting|January 2016|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||October 2015|February 8, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668185||4010|
NCT02668198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007241|Assessing a Endoscopic Mucosal Resection Site Using Different Endoscopic Imaging Methods|Diagnostic Accuracy of Using Colonoscope With Near Focus Capability in Detecting Residual Colorectal Neoplastic Tissue After EMR: a Prospective Study||Mayo Clinic|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668198||4009|
NCT02662803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/217/15|Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)|Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)|GAD_exercise|Charite University, Berlin, Germany|No|Enrolling by invitation|December 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02662803||4423|
NCT02677506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101723|Infraclavicular or Supraclavicular Brachial Plexus Blocks for Elbow Surgery|A Randomized Comparison of Infraclavicular and Supraclavicular Brachial Plexus Blocks for Elbow Surgery||Lawson Health Research Institute|No|Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02677506||3298|
NCT02670512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Connect1.8|Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis: A Multicentre Randomized Controlled Trial|Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis (CONNECT Trial): A Multicentre Randomized Controlled Trial|CONNECT|Lawson Health Research Institute|Yes|Not yet recruiting|April 2016|March 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02670512||3834|
NCT02671045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COTA 14001|Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer|A Prospective Observational Study of Comprehensive Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer||Cota Inc.|No|Recruiting|April 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|1100|||Both|18 Years|N/A|No|Probability Sample|All (consecutive) adult patients with untreated metastatic non-small cell lung cancer        treated at a COTA center will be considered enrolled on the trial starting with enrollment        of the index subject and continuing until study enrollment is completed.|January 2016|January 28, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02671045||3793|
NCT02661828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00084849|Tapering Off Antidepressants|A Comparison of Two Antidepressant Tapering Regimens||Emory University|No|Recruiting|January 2016|October 2025|Anticipated|October 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661828||4498|
NCT02661841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0086-15 HYMC|Effectiveness of Lung Impedance Guided Preemptive Therapy of Chronic Heart Failure Patients With Preserved Ejection Fraction (LVEF ≥ 45%) in Our Hospital's Outpatient Clinic|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2016|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661841||4497|
NCT02668393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.224|Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma|An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy||Boehringer Ingelheim||Recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 27, 2016||||No||https://clinicaltrials.gov/show/NCT02668393||3994|
NCT02668666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCRC BRE15-016|Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer|A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016||Big Ten Cancer Research Consortium|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668666||3973|
NCT02668679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068-15-EMC|The Effect of Dream Doctors in Children Undergoing Digestive Endoscopic Procedures|The Effect of Dream Doctors in Children Undergoing Digestive Endoscopic Procedures: Physiological and Biological Assessment of Emotional and Cognitive Consequences||HaEmek Medical Center, Israel|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|1 Year|18 Years|No|||February 2016|February 1, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02668679||3972|
NCT02665832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1351002|Study of DWJ1351 in Healthy Male Volunteers|A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers||Daewoong Pharmaceutical Co. LTD.|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|58|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665832||4190|
NCT02667756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro1532|Predicting Osteoarthritis Risk Following Knee Injury.|Identification of Prognostic Biomarkers for Osteoarthritis Risk Following Knee Injury: the Knee Injury Cohort @ the Kennedy Study|KICK|University of Oxford|No|Active, not recruiting|June 2010|February 2020|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|Samples include blood (plasma, serum, whole blood RNA, and where consent given, DNA), urine      and where undergoing a relevant clinical procedure to allow sampling, synovial fluid.|Both|16 Years|50 Years|No|Non-Probability Sample|This is a non-intervention cohort study of subjects who have recently sustained a        structural knee injury. Individuals are identified from the practice of a collaborating        surgeon (AW) at a number of London sites, several of which are within private practice.        Because of the practice of the surgeon investigator, a large number will be sporting        professionals, or playing amateur sport at a high level.|February 2016|February 12, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667756||4043|
NCT02687217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/ECHR/2014/326|Effect of Peri-operative Supplemental Oxygen in Wound Infection After Appendectomy|Role of Perioperative Hyperoxygenation in Wound Infection Following Surgery for Acute Appendicitis: A Randomised Controlled Trial.||Lady Hardinge Medical College|Yes|Completed|November 2011|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|15 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687217||2552|
NCT02676830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-312-1.03US|Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312|||Kowa Research Institute, Inc.||Completed|August 2014|April 2015|Actual|February 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02676830||3350|
NCT02676843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP4551|Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations|Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations||Columbia University|No|Enrolling by invitation|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676843||3349|
NCT02662491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/05|Effects of Vitamin D and Calcium Supplementation on Health and Well-being of Vitamin D Deficient UAE Citizens|Effects of Vitamin D and Calcium Supplementation on Health of UAE Citizens||United Arab Emirates University|Yes|Recruiting|January 2016|June 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|432|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662491||4447|
NCT02668016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2947|Self-Assessment Method for Statin Side-effects Or Nocebo|Self-Assessment Method for Statin Side-effects Or Nocebo|SAMSON|Imperial College London|Yes|Not yet recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|January 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02668016||4023|
NCT02687503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0884|Impact of Probiotic Use on Immune Cell Function in Children|Impact of Probiotic Use on Immune Cell Function in Children||University of Wisconsin, Madison|No|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|12 Months|36 Months|No|||February 2016|February 16, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687503||2530|
NCT02669017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCT-402-101|Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)|A Phase 1 Adaptive Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)||ADC Therapeutics SARL|No|Recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669017||3948|
NCT02676297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-07-000027|Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products|Phase I Randomised, Three-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Two Test Products With Spiriva Respimat Comparator Product||3M|Yes|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02676297||3391|
NCT02665403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR-12-020|Play Interventions to Reduce Anxiety and Negative Emotions in Hospitalized Children|Play Interventions to Reduce Anxiety and Negative Emotions in Hospitalized Children||The University of Hong Kong|Yes|Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|304|||Both|3 Years|12 Years|No|||January 2016|January 22, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02665403||4223|
NCT02679924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-2015-01|A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek|A Single Center, Prospective, Randomized, Sham Controlled, Double Blind, Split Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek||Goldman, Butterwick, Fitzpatrick and Groff|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02679924||3113|
NCT02679937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F172NC-S1|Prevention of Obesity in Military Communities - Fit4Duty|Prevention of Obesity in Military Communities - Fit4Duty: Phase 2|POMC-Fit4Duty|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Active, not recruiting|June 2014|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679937||3112|
NCT02677480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662-08|The Effect of Probiotic Streptococci and pH-rising Components on the Oral Microbial Flora|The Effect of Probiotic Streptococci and pH-rising Components on the Oral Microbial Flora in Subjects With Reduced Salivary Secretion Rate||Göteborg University|No|Completed|November 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02677480||3300|
NCT02663622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.181|A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant|A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant||University of Michigan Cancer Center|Yes|Not yet recruiting|February 2016|||June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663622||4360|
NCT02667977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-15901|Reexamining Hypotonic Intravenous Fluid Use|Reexamining Hypotonic Intravenous Fluid Use in Pediatric Patients With Gastroenteritis.||Ann & Robert H Lurie Children's Hospital of Chicago|No|Withdrawn|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|0|||Both|6 Months|16 Years|No|||January 2016|January 26, 2016|October 13, 2014||No|Difficulty getting labs in this setting. After pilot study, this study was not continued.|No||https://clinicaltrials.gov/show/NCT02667977||4026|
NCT02661789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GnRHa|Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression|Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression|GnRHa|Rigshospitalet, Denmark|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|63|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661789||4501|
NCT02687009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066964|A Study of Niclosamide in Patients With Resectable Colon Cancer|A Phase I Study of Niclosamide in Patients With Resectable Colon Cancer||Duke University|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|99 Years|No|||February 2016|February 16, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687009||2568|
NCT02673112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000023|Study of an Exercise Program (STEP) for Youth With Concussion|Study of an Exercise Program (STEP) for Youth With Concussion|STEP|Seattle Children's Hospital|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|11 Years|18 Years|No|||February 2016|February 1, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02673112||3635|
NCT02664129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9545|Video as a Tool to Improve Insight in Schizophrenia|Video Self-observation as a Therapeutic Tool for Improving the Insight of Patients With Schizophrenia Disorders|VideoInsight|University Hospital, Montpellier|No|Recruiting|December 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02664129||4321|
NCT02664142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KARIM-3|BIS Monitoring of the Depth of Anaesthesia in Children|Monitoring the Depth of Anaesthesia in Children in the Course of a Surgical Procedure Using the BIS Monitor - Prospective Randomized Study||University Hospital Ostrava|No|Recruiting|June 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|15 Years|No|||January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02664142||4320|
NCT02662127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198127|Effect of Standing, Lying and Stockings on Blood Bio-markers (v.1)|Local Endogenous Biomarkers in the Later Stages of Chronic Venous Disease Versus Controls During Gravitational Stress, Prolonged Elevation Recovery and Compression||London North West Healthcare NHS Trust|No|Not yet recruiting|April 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02662127||4475|
NCT02681367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#001008|Management of Recurrent Implantation Failure|The First Study to Compare the Effect of Freeze All Policy Versus Fresh Embryo Transfer After ICSI in Patients With Recurrent Implantation Failure|RIF|TopLab Company for ART Laboratories Consultation and Training|Yes|Completed|February 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|39 Years|No|||February 2016|February 9, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02681367||3002|
NCT02681380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01004|Impact of a Relation Training on Empathy of Medical Student|Impact of a Relation Training, Balint-like, on Empathy of Medical Student in the 4th Year.|EMPATHIE|University of Paris 5 - Rene Descartes|No|Active, not recruiting|September 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681380||3001|
NCT02674373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-GC-DNAc|Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer Treatment|Prognostic and Predictive Impact of Circulating Tumor DNA in Advanced and Localized Gastric Cancer Treatment|PLAGAST|Association des Gastroentérologues Oncologues|No|Recruiting|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|circulating tumor DNA|Both|18 Years|N/A|No|Non-Probability Sample|All patients treated for a histologically proven, localized or advanced adenocarcinoma of        gastric or gastro-oesophageal junction, will be enrolled in this prospective cohort study        after receiving and signed a specific consent information form.|February 2016|February 2, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02674373||3539|
NCT02668484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMucS001-15|REpositionable Versus BallOOn-expandable Prosthesis for Trans-catheter Aortic Valve Implantation|Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation|REBOOT|Klinikum der Universitaet Muenchen|Yes|Recruiting|January 2016|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668484||3987|
NCT02512783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302-019|Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation|Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation||Children's Hospitals and Clinics of Minnesota|No|Terminated|May 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|175|||Both|2 Months|17 Years|No|||July 2015|July 29, 2015|August 15, 2013|Yes|Yes|Interim analysis indicated treatment was effective and statistically significant|No||https://clinicaltrials.gov/show/NCT02512783||15941|
NCT02522416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFO_2015_30|A Comparison of Two Devices for Measuring the Central Thickness of the Cornea Before and After Surgery (CECOT)||CECOT|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|November 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients for whom a LASIK refractive surgery at the Adolphe de Rothschild ophthalmologic        foundation is planned|November 2015|November 17, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02522416||15203|
NCT02525393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI 339|Transcranial Stimulation in Motor Stroke Rehabilitation|Safety and Efficacy of Non Invasive Transcranial Brain Stimulation in Motor Stroke Rehabilitation||University of Turin, Italy|No|Completed|March 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|70 Years|No|||August 2015|August 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525393||14974|
NCT02525406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgical-Cancellation-Study|Models for Improving Operating Room Productivity: Delays, Cancellations and Pre-admission Testing|Models for Improving Operating Room Productivity: Delays, Cancellations and Pre-admission Testing||University of Toledo Health Science Campus|No|Active, not recruiting|July 2015|June 2016|Anticipated|October 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|9240|||Both|N/A|N/A|No|Probability Sample|All patients scheduled for surgery at UTMC from Jan 01,2010 to December 31, 2014|July 2015|March 4, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02525406||14973|
NCT02685098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505714405|A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation|A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation|CHAMP|Indiana University|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|16|||Both|40 Years|80 Years|No|||February 2016|February 12, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685098||2715|
NCT02685384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U18DP006116|Post ACA Reform: Evaluation of Community Health Center Care of Diabetes (PREVENT D)|Post ACA Reform: Evaluation of Community Health Center Care of Diabetes|PREVENTD|Oregon Health and Science University|No|Active, not recruiting|January 2012|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2073222|||Both|20 Years|64 Years|No|Non-Probability Sample|Study eligible patients within electronic health record data from the ADVANCE clinical        data research network (CDRN) of PCORnet|February 2016|February 12, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02685384||2693|
NCT02686450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShenzhenCH|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2014|||||N/A|N/A|N/A||||||||||||||February 15, 2016|January 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686450||2611|
NCT02678013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC 004|RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC|Radiofrequency Ablation Combined With Highly-purified CTL vs. Radiofrequency Ablation Alone for Recurrent HCC||Sun Yat-sen University|Yes|Active, not recruiting|February 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||February 2016|February 20, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678013||3259|
NCT02675192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508145|Biological Aging of Skeletal Muscles in Humans|Biological Aging of Skeletal Muscles in Humans, a Monocentric, Prospective Study|BioAge|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Urinary and blood samples will be taken, and a muscle biopsy will be performed.|Both|80 Years|83 Years|Accepts Healthy Volunteers|Probability Sample|Patients are recruited in the Proof cohort (Barthélemy et al., 2007).|March 2016|March 21, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02675192||3476|
NCT02663700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0001|Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso|Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso.||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting||October 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|112|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||December 2015|March 10, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663700||4354|
NCT02663713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C05274|A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction|A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction|ALTIC|University of Patras|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|N/A|No|||January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663713||4353|
NCT02664493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-017-002|The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes|The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes: An Open-Label, Randomized Clinical Trial||Samsung Medical Center|Yes|Not yet recruiting|January 2016|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|19 Years|70 Years|No|||January 2016|January 26, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02664493||4293|
NCT02672488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METSOR|Metformin Plus Sorafenib for Advanced HCC|Safety and Efficacy of Metformin Plus Sorafenib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma(BCLC-C): A Phase 2 Randomized Study||Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02672488||3683|
NCT02675829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-335|Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers|A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675829||3427|
NCT02670044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH29914|A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy|A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy||Hoffmann-La Roche||Not yet recruiting|February 2016|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|140|||Both|60 Years|N/A|No|||January 2016|January 28, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02670044||3870|
NCT02670057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00619|Sphenopalatine Ganglion Block to Treat Shoulder Pain During and/or After Cesarean|Sphenopalatine Ganglion Block to Treat Shoulder Pain During and/or After Cesarean||New York University School of Medicine|No|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02670057||3869|
NCT02688413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MindMaze-2016-RCT01|Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation|Randomized Parallel-group Study Evaluating the Effectiveness and Cost-effectiveness of the Co-administration of MindMotionPRO Plus Standard Practice Versus Standard Practice in Early Post-stroke Upper-limb Rehabilitation|MOVE-Rehab|Mindmaze SA|No|Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02688413||2460|
NCT02668224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408208|Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties.|Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties : Pilot Study, Interventional, Prospective, Longitudinal.|NEUROVIB|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|February 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668224||4007|
NCT02675218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508203|Bone MicroArchitecture Abatacept (BMA2)|Bone MicroArchitecture Abatacept in Rheumatoid Arthritis Patients (BMA2)|BMA2|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Blood samples will be performed to determine the predictive value of joint inflammation.|Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients diagnosed according to ACR/EULAR 2010 criteria, and        Abatacept therapy sub-cutaneous required according EULAR recommendation.|February 2016|February 2, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02675218||3474|
NCT02691156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-31187|Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants|Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants||Stanford University|Yes|Recruiting|December 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|24 Weeks|34 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Inpatient premature infants|February 2016|February 19, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02691156||2251|
NCT02671344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406-BIO-036-FQ|Determining the Genetic Profile in Semen Donors With Pregnancy, Donor Versus no Pregnancy Obtained in TRA|Determination of Gene Profiling in Semen Donors With Pregnancy Versus no Donor Gestation, Obtained in Assisted Reproduction Treatments||IVI Bilbao|No|Recruiting|April 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Anticipated|30|Samples With DNA|Determination of gene profiles characterizing the set of mRNA from donor seminal samples|Male|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Open retrospective study of 30 semen donors. Comparisons were made of gene expression        profile between the IAD, IVF and ICSI groups according to the clinical outcomes of        pregnancy.          -  The donor recruitment will be made according to standard protocols rather Bilbao IVI             centers will no visit, checking out additional analytical donation program to the             donor is attached.          -  By SIVIS data base, the results of different gestation is collected reproductive             treatments that allow the allocation to the comparison groups gene profile.|January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02671344||3770|
NCT02676063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC1416|Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy With Hypothermia Treatment|Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy in the Era of Neuroprotective Treatment With Hypothermia|LyTONEPAL|University Hospital, Grenoble|No|Recruiting|September 2015|February 2021|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|This study will be performed on all moderate or severe cases of hypoxic ischemic        encephalopathyhie, occurring between 34 and 42 completed weeks gestation in newborns        admitted to a neonatal intensive care unit of the participating French regions. Children        will be followed-up until the age of 3 years.|February 2016|February 2, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02676063||3409|
NCT02676128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH108431|Mobile Health Application to Improve HIV Medication Adherence|Mobile Health Application to Improve HIV Medication Adherence||Rhode Island Hospital|Yes|Not yet recruiting|February 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676128||3404|
NCT02677870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCMC IRB#|The Effectiveness of Kuvan in Amish PKU Patients|The Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or "Kuvan") in Amish PKU Patients||University Hospital Case Medical Center|No|Not yet recruiting|May 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Both|2 Years|60 Years|No|||February 2016|February 4, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677870||3270|
NCT02664454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140707|Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care|Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care: A Pragmatic Three-arm Cluster Randomized Controlled Trial|CEPIA|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|750|||Both|70 Years|N/A|No|||December 2015|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664454||4296|
NCT02661906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA 2014-028|Effect of SKY on Psychosocial Parameters of Type 2 Diabetic Patients After a 12 Week Intervention|Effect of SKY on Anxiety, Depression and Quality of Life of Type 2 Diabetic Patients After a 12 Week Intervention in a Randomized Controlled Trial||Dasman Diabetes Institute|No|Not yet recruiting|July 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|30 Years|65 Years|No|||January 2016|January 20, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02661906||4492|
NCT02674230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0250A3|OCEAN Registry: Obesity and Clock for Elegant Aging Registry|OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫|OCEAN|Chang Gung Memorial Hospital|Yes|Recruiting|July 2011|June 2026|Anticipated|June 2026|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|A. Serum. B. White blood cells. C. Adipose tissue. (If receiving liposuction, plastic      surgery, bariatric surgery, dermatological procedure, intra-abdominal operation, and      cardiovascular surgery)|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general population including healthcare facility and        non-health care settings. Healthcare facility includes university based hospital and        primary care clinics. Non-health care settings include schools, subjects families, and        employment agencies.|February 2016|February 2, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02674230|10 Years|3550|
NCT02675413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511112|Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS|Mechanisms of Action of Dimethyl Fumarate in Relapsing MS||Washington University School of Medicine|No|Recruiting|February 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675413||3459|
NCT02682108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si237/2014|Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis|Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis in Patients With Chronic Viral Hepatitis||Mahidol University|No|Recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|138|||Both|18 Years|80 Years|No|||February 2016|February 12, 2016|February 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682108||2945|
NCT02669108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01636|PET-MRI for Functional Imaging of the Testis: A Feasibility Study|PET-MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male||New York University School of Medicine|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669108||3941|
NCT02666391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-2|Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)|||South China Research Center for Stem Cell and Regenerative Medicine|Yes|Not yet recruiting|May 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||January 2016|January 24, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666391||4148|
NCT02685904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHEN1502|A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis||TSH Biopharm Corporation Limited|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|N/A|No|||February 2016|February 15, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02685904||2653|
NCT02662699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-29|Clinical Signs and Symptoms of Anemia in Patients Over 75 Years|Clinical Signs and Symptoms of Anemia in Patients Over 75 Years||University Hospital, Strasbourg, France|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Both|75 Years|N/A|No|Non-Probability Sample|Anemic patients|January 2016|January 20, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02662699||4431|
NCT02662946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Angio-Co-Re|Evaluation of Intestinal Vascolarization With Indocianine Green Angiography During Rectal Resection or Left Colectomy|Evaluation of Intestinal Vascolarization by Intraoperative Angiography With Indocianine Green During Laparoscopi Rectal Resection or Left Colectomy: Predictive Value on Anastomotic Leak.||Scientific Institute San Raffaele|No|Recruiting|January 2016|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|208|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02662946||4412|
NCT02669381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02558|Phenylalanine Requirements in Healthy Pregnant Women|Dietary Phenylalanine Requirements During Different Stages of Gestation in Healthy Pregnant Women||University of British Columbia||Not yet recruiting|January 2016|November 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02669381||3921|
NCT02669394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00972|Reshaping the Path of Vascular Cognitive Impairment (VCI)|Reshaping the Path of Vascular Cognitive Impairment With Resistance Training||University of British Columbia|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Both|55 Years|N/A|No|||January 2016|January 27, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02669394||3920|
NCT02664701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2014/MA-01|Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts|Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts: a Multicentre, Assessor-blinded, 2-parallel-group, Randomised, Superiority Trial|G-PACTS|Centre Hospitalier Universitaire de Nīmes|Yes|Not yet recruiting|January 2017|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664701||4277|
NCT02691013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151294|The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery|The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery||University of California, San Diego|No|Not yet recruiting|February 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|100 Years|No|||February 2016|February 23, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02691013||2261|
NCT02667912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022|Distal Renal Denervation|Anatomically Optimized Distal Renal Denervation for Treatment of Resistant Hypertension||Federal State Budgetary Scientific Institution, Research Institute of Cardiology|No|Active, not recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|80 Years|No|||January 2016|January 29, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667912||4031|
NCT02667925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-004103-12|Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin|Study of the Isotopic Distribution of Intraperitoneal Postoperative Locoregional Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin|ISOTOVE|Centre Jean Perrin|No|Recruiting|March 2016|March 2023|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|70 Years|No|||March 2016|March 3, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667925||4030|
NCT02662530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105515|Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia|Comparison of Clinical and Kinematic Assessment in the Determination of Botox® Injection Parameters in Cervical Dystonia Patients||Western University, Canada|No|Not yet recruiting|February 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02662530||4444|
NCT02676401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-J06|An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy|||Mitsubishi Tanabe Pharma Corporation|No|Recruiting|February 2016|||April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|280|||Both|20 Years|75 Years|No|||February 2016|February 3, 2016|February 1, 2016||||No||https://clinicaltrials.gov/show/NCT02676401||3383|
NCT02664935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-072|National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer|National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer||University of Birmingham|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|620|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02664935||4259|
NCT02693678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studi FM|Real and Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS)Effect on Knee Proprioception|Real or Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS) in Skiers, Effect on Knee Joint Proprioception||Studi Fisioterapici di Montagna|Yes|Not yet recruiting|April 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Male|18 Years|60 Years|No|||February 2016|February 26, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02693678||2057|
NCT02693691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10105|CardioMEMS European Monitoring Study for Heart Failure|CardioMEMS European Monitoring Study for Heart Failure|MEMS-HF|St. Jude Medical|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02693691||2056|
NCT02672683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 14086|Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs|Non Invasive Detection of Acute Rejection by Circulating microRNAs in Cardiac Transplantation: a Multicenter Prospective Study|MIRRACLE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|September 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a cardiac transplant|January 2016|January 29, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02672683||3668|
NCT02666599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363/11|Per-operating Use of a Probe for Detection of β+|Per-operating Use of a Probe for Detection of β+||University of Lausanne Hospitals|No|Recruiting|February 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666599||4132|
NCT02666612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00585-50|Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells in Adult Patients With Metastatic Cancer|Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells in Adult Patients With Metastatic Cancer|CEC-CTC|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|August 2008|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02666612||4131|
NCT02678039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#23226|Fluoroscopy-guided Versus Traditional Placement of Epidural Catheters|Fluoroscopy-guided Versus Traditional Placement of Epidural Catheters||Dartmouth-Hitchcock Medical Center|No|Completed|August 2012|May 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02678039||3257|
NCT02678052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vedolizumab-5001|OTIS Vedolizumab Pregnancy Exposure Registry|Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry||Takeda|No|Recruiting|December 2015|March 2021|Anticipated|March 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant woman with or without UC or CD with exposure to Entyvio or any other biological        agent (only for women with UC or CD) during pregnancy will be observed in this study.|February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678052||3256|
NCT02666482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24RT-0027|Using Technology to Help Low-income and Latino Smokers Quit|Using Technology to Help Low-income and Latino Smokers Quit||i4Health|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666482||4141|
NCT02666495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0228|Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series|Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series||NHS Lothian|No|Enrolling by invitation|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|February 15, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666495||4140|
NCT02674386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091064|Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement|A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement||Pfizer|Yes|Not yet recruiting|December 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment|1||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02674386||3538|
NCT02674399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-OAP2-US01|A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis|A Phase 2, Double-Blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Treatment of Osteoarthritis||Nature Cell Co. Ltd.|No|Recruiting|January 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|22 Years|60 Years|No|||February 2016|February 3, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674399||3537|
NCT02674893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRINDISI 2013|Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes|Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes|GLP1 et Goût|Centre Hospitalier Universitaire Dijon||Recruiting|February 2014|November 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Intervention Model: Parallel Assignment|3||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674893||3499|
NCT02674906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECICS|Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)|Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes. Heparin vs Citrate in Cellsaver (HECICS).|HECICS|Ziekenhuis Oost-Limburg|No|Not yet recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02674906||3498|
NCT02666222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204 PAS|The Esteem® Hearing Implant Post Approval Study|To Evaluate the Long-term Safety and Efficacy of the Esteem® Hearing Implant in Subjects Suffering From Moderate to Severe Hearing Loss||Envoy Medical Corporation|Yes|Completed|March 2011|January 2016|Actual|February 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons suffering from moderate to severe hearing loss that is sensorineural in origin|January 2016|January 26, 2016|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666222||4161|
NCT02686944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-no: 2015-002689-22|A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors|A Phase I Open-label Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax in Patients With Progressing Gastrointestinal Stromal Tumors (GIST) During Ongoing Second-Line Treatment With Sunitinib. A Prospective Single Armed, Open Label Phase I Safety and Efficacy Study|GIST|Immunicum AB|No|Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|February 16, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02686944||2573|
NCT02676154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02364|Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)|A Phase II, Open-Label Exploratory Study Investigating the Efficacy of Toviaz for Treatment of Adult Patients With Spinal Cord Injury With Neurogenic Detrusor Overactivity for Amelioration of Autonomic Dysreflexia(PIIR-AK-TOVIAZ-AD)||University of British Columbia|Yes|Recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||February 2016|February 25, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02676154||3402|
NCT02674763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN779 0601|Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia|A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia||ImmunoGen, Inc.|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|124|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674763||3509|
NCT02690298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMI UVU 2015-0052|Evaluation of ExSpiron™ Measurements Derived Without Patient Specific Calibration|Evaluation of ExSpiron™ Non-Invasive Respiratory Volume Monitor Measurements Derived Without Patient Specific Calibration|RMI UVU|Respiratory Motion, Inc.|Yes|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Respiratory measurements will be acquired from up to 100 subjects from a wide        cross-section of the adult population. Potential subjects will be screened based on the        following inclusion/exclusion criteria to determine eligibility.|February 2016|February 18, 2016|September 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02690298||2315|
NCT02664506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21987|Theory-Driven Treatment of Language and Cognitive Processes in Aphasia|Theory-Driven Treatment of Language and Cognitive Processes in Aphasia||Temple University||Recruiting|March 2014|||February 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02664506||4292|
NCT02664779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS1|Determination and Comparison of Short-term Effectiveness of Three Methods Used for Recognition of Arrhythmias in People With Different Degrees of Medical Training (Advanced Life Support Workshop Participants-ALS): Randomized Controlled Educational Experiment.|||Universidad Nacional de Colombia|Yes|Recruiting|January 2016|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|84|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664779||4271|
NCT02671006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508109|Monitoring Chronic Urticaria Basophil Irritability by Cytometry|Monitoring Chronic Urticaria Basophil Irritability by Cytometry (Monocentric Study)|CUBIC|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Blood sample will be collected during a venipuncture required for the medical follow up and      should not interfere with the usual treatment.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patient analysis will be performed on          -  30 patients with an active CU according to the EAACI criteria.          -  30 volunteers with no history of immediate allergy (patients under medical follow up             for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched).             Controls should have no history of atopy, urticaria or immediate allergy declared             (rhinitis, urticaria, asthma) at the time of the test. Blood sample will be collected             during a venipuncture required for the medical follow up and should not interfere             with the usual treatment.|January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02671006||3796|
NCT02675790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141077|Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa|Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa|SPRINT|Vanderbilt University|Yes|Not yet recruiting|July 2016|December 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|1 Year|18 Years|No|||February 2016|February 4, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02675790||3430|
NCT02690311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-08-072|A Study on the Changes of the Biological Rhythm by Display Image Modulation|||Samsung Medical Center||Completed|August 2013|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|22|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2013|February 18, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02690311||2314|
NCT02690324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-07-151|The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders|||Samsung Medical Center||Recruiting|November 2015|||February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2015|February 18, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02690324||2313|
NCT02672449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO 98|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer||European Institute of Oncology|Yes|Active, not recruiting|May 2015|January 2020|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Male|18 Years|N/A|No|||January 2016|February 1, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02672449||3686|
NCT02663336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WaidBP16|Prevalence of Masked Hypertension in Nephrological Patients|Prevalence of Masked Hypertension in Nephrological Patients||Waid City Hospital, Zurich|No|Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|90 Years|No|Probability Sample|Patients with chronic kidney disease of the nephrological outpatient clinic of Waidspital        with normal office blood pressure in the context of diagnosed arterial hypertension with        or without antihypertensive medication|December 2015|January 21, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663336||4382|
NCT02663609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1073-450|Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome|Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome|RE-KLAIM|Corcept Therapeutics|No|Enrolling by invitation|October 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|ACTH Independent Cushing's Syndrome patients treated with Korlym® mifepristone) as        standard of care in clinical practice.|January 2016|January 29, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02663609||4361|
NCT02670070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GSCL003|BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers||LG Life Sciences|No|Not yet recruiting|March 2016|August 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02670070||3868|
NCT02670083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN29552|CREAD Study" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease||Hoffmann-La Roche||Recruiting|January 2016|July 2021|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|750|||Both|50 Years|85 Years|No|||March 2016|March 1, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670083||3867|
NCT02684812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000343-26|Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.|Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study.|ULTRA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|July 2012|January 2020|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|950|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684812||2737|
NCT02665299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway Genomics 005|Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy|Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy||Pathway Genomics|No|Recruiting|January 2016|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood is drawn and DNA is purified from the plasma. The DNA is analyzed for circulating      tumor DNA. The DNA will be stored for up to 10 years.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals 18 years of age or older without a prior diagnosis of cancer who are scheduled        to undergo a screening or diagnostic colonoscopy by Dr. Phillip Fleshner.|January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665299||4231|
NCT02674529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00111326|Study of Neural Responses Induced by Antidepressant Effects||SONRISA|University of Michigan|No|Not yet recruiting|April 2016|||April 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674529||3527|
NCT02666430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-1501D-3003|Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus Patients|An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study||Mylan Inc.|No|Enrolling by invitation|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666430||4145|
NCT02666677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVITE|INVITE Study: Invasive Instrumentation in Trauma Patients in the Shock Room|Invasive Instrumentation in Trauma Patients in the Shock Room: A Online-survey for Anaesthesia Departments in Germany|INVITE|Universitätsklinikum Köln|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Traumatized patiennts in the emergency department|January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666677||4126|
NCT02666690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01527-32|Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast|Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast|VARIA-DCE-US|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|July 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02666690||4125|
NCT02687269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAN|Ranolazine a Potential New Therapeutic Application|Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial||Policlinico Universitario Agostino Gemelli|No|Not yet recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02687269||2548|
NCT02692729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIP|Transverse Supraumbilical Versus Pfannenstiel Incision for Cesarean Section in Morbidly Obese Women|Transverse Supraumbilical Versus Pfannenstiel Incision For Cesarean Section in Morbid Obese Patients" A Single Blinded Randomized Controlled Trial"||Ain Shams University|Yes|Recruiting|March 2016|September 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|40 Years|No|||March 2016|March 19, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692729||2130|
NCT02677779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPE 15.161|CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers|A Randomised, Open Label, Controlled Clinical Study to Evaluate the Efficacy and Safety of CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers|DULCIS|Azienda Ospedaliero-Universitaria Careggi|No|Enrolling by invitation|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02677779||3277|
NCT02665806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR.TUMS.REC.1394.1586|Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis|Ciclesonide vs Fluticasone Propionate Nasal Sprays in Patients With Nasal Poplyposis; a Randomized Clinical Trial||Tehran University of Medical Sciences|Yes|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|16 Years|N/A|No|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665806||4192|
NCT02666885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPM_Demonstrator_HNC|Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer|Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer and Development of a Multi-parametric Decision Support System for Personalised Medicine in Radiation Oncology||University Hospital Tuebingen|No|Recruiting|July 2015|||June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||December 2015|January 25, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02666885||4110|
NCT02666898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICLL07GAI|Phase II Trial GA101 Inbrutinib B CLL|Phase II, Multicenter, Trial, Exploring "Chemo-free" Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup|ICLL07GAI|French Innovative Leukemia Organisation|Yes|Recruiting|October 2015|April 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666898||4109|
NCT02682121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo|Metabolic Alterations in Platelet Study II|MAP-2|University of Utah||Recruiting|April 2012|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02682121||2944|
NCT02682134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAlJabari|Sore Throat Prevention Following Intubation|Comparison Between Xylocaine Gel as Endotracheal Cuff Lubricant Versus Dexamethasone 8 mg Intravenously or Both for Sore Throat Prevention Following Intubation: Interventional Study||University of Jordan|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|300|||Both|15 Years|70 Years|No|||February 2016|February 10, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02682134||2943|
NCT02661945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFNBI|Usefulness of Near-focus With Narrow-band Imaging|Usefulness of Near-focus With Narrow-band Imaging for Determining Gastric Tumor Margin||Kyunghee University Medical Center|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|19 Years|N/A|No|||January 2016|January 24, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661945||4489|
NCT02661958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT-65-02|Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris|A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks||Sol-Gel Technologies, Ltd.|No|Not yet recruiting|March 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|660|||Both|9 Years|N/A|No|||January 2016|January 20, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661958||4488|
NCT02661971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMSES/FLOT7|FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)|Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO|RAMSES/FLOT7|Krankenhaus Nordwest|Yes|Not yet recruiting|April 2016|||April 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|908|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661971||4487|
NCT02677441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 15-235|Conservative or Surgical Management of Rockwood Type III to V Acromioclavicular Dislocations|Conservative or Surgical Management of Rockwood Type III to V Acromioclavicular Dislocations: A Non-inferiority Randomized Study|AC Cons Chir|La Tour Hospital|Yes|Not yet recruiting|February 2016|May 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677441||3303|
NCT02516865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00117|Practical Approaches to Exercise in Moms|Practical Approaches to Exercise in Moms|PE Moms|Nationwide Children's Hospital|No|Recruiting|April 2015|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02516865||15630|
NCT02516878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcupBWC001|Acupuncture for Body Weight Control|Acupuncture for Body Weight Control: A Pilot Randomized Controlled Trial||Hong Kong Baptist University|No|Not yet recruiting|August 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|No|||July 2015|August 5, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516878||15629|
NCT02526810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130319c|Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes|Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes|COGFOST|Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|July 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|25 Years|70 Years|No|||August 2015|August 19, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526810||14865|
NCT02513628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MelunH|Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest|The Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest: a Pilot Prospective Study|ONSD-CA|Hopital of Melun|No|Completed|November 2011|January 2014|Actual|September 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Probability Sample|All unconscious (Glasgow Coma Scale ≤6) patients ≥18 years old, admitted in ICU after        successful resuscitation from CA, and treated with TH targeted to 33°C were screened.        Exclusion criteria were as follows: unavailable ONSD measurement within 24 hours after        return of spontaneous circulation (unavailable investigator, early death, or major        hemodynamic instability), traumatic or neurological origin of CA, previous cerebrovascular        disease, facial trauma affecting the orbits and/or eyeballs, and previous history of        ocular pathology such as exophthalmia, glaucoma or cataract.|July 2015|July 30, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02513628|3 Months|15876|
NCT02686463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QYang_001|Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy|Diagnosis and Treatment of Laparoscopy for Malignant Ovarian Cancer: an Open-label, Parallel, Randomized, Controlled Clinical Trial of Efficacy and Safety||Shengjing Hospital|No|Not yet recruiting|April 2016|June 2023|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|65 Years|No|||February 2016|February 18, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02686463||2610|
NCT02662244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160062|Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma|Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma||University of California, San Diego|No|Recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662244||4466|
NCT02664883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4K-14-4|Myeloid Derived Suppressor Cells Clinical Assay in Finding and Monitoring Kidney Cancer|MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma||University of Southern California|Yes|Recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|63|Samples With DNA|Blood and urine samples|Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with renal cell carcinoma and their accompanying partners who are seen at the        Urologic Oncology and Medical Oncology Clinics of the Keck Medical Center of University        Southern California (USC), Norris Cancer Center, and USC-Los Angeles County Hospital will        be recruited for this trial.|January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664883||4263|
NCT02667795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNE 2447|Improving Physical Fitness Prior to Colorectal Surgery: A Pilot Study|||York Teaching Hospitals NHS Foundation Trust|No|Not yet recruiting|October 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02667795||4040|
NCT02668978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEALLS|SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial Using HEMOPATCH|Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection With Hemopatch™ Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial||Quirón Madrid University Hospital|No|Not yet recruiting|March 2016|April 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668978||3951|
NCT02668991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106701|Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort|A Study to Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder and in a Normally Developing Cohort||Janssen Research & Development, LLC|No|Recruiting|July 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children and Adult participants with history of Autism Spectrum Disorder (ASD) will be        observed.|March 2016|March 15, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668991||3950|
NCT02675881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-2013-1441|Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)|Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®) for Treatment of Focal Liver Malignancies: A Preliminary Study||Seoul National University Hospital|Yes|Active, not recruiting|July 2013|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|75 Years|No|||February 2016|February 4, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02675881||3423|
NCT02675166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508056|Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes|SALTO -2 ( Long Term Monitoring In Oncology ) : Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes, Multicentric Study|SALTO-2|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|October 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|544|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is composed of 544 patients registered in the ARCERRA documùent. They        survived at a pediatric cancer, diagnosed in Rhône-Alpes between January the 1st 1993 and        December the 31st 1999. They were less than 15 years old during this period.|March 2016|March 21, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02675166||3478|
NCT02690987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/1041|Gut Hormones in Obesity, Nicotine and Alcohol Dependence|Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?|GHADD|Imperial College London|Yes|Recruiting|August 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|95|||Both|18 Years|60 Years|No|||October 2015|February 19, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02690987||2263|
NCT02677142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014297|Evaluating the Efficacy of a Group Social Skills Intervention|A Randomized Control Trial to Evaluate the Efficacy of a Group Social Skills Intervention for Childhood Survivors of Brain Tumours||The Hospital for Sick Children|No|Completed|April 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|8 Years|16 Years|No|||February 2016|February 3, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02677142||3326|
NCT02673151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0076|68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment|68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA and Non-Contributory Bone Scintigraphy, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)||Stanford University||Not yet recruiting|February 2016|||February 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Male|N/A|N/A|No|||February 2016|February 1, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673151||3632|
NCT02662569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120119|A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia|A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of AMG 145 in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia||Amgen|Yes|Not yet recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|900|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662569||4441|
NCT02662582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3318-CL-3002|A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Two Period, Crossover Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease||Astellas Pharma Inc|No|Not yet recruiting|March 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|75 Years|No|||January 2016|January 20, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662582||4440|
NCT02681614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE10814|Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning|Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning||Case Comprehensive Cancer Center|Yes|Not yet recruiting|April 2016|May 2018|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Male|18 Years|N/A|No|||March 2016|March 18, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681614||2983|
NCT02673827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618.841/2014|Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis|Effect of Progressive Muscle Relaxation as a Nursing Intervention on Sleep Quality, Depression and Stress in People With Multiple Sclerosis||Federal University of Espirito Santo|No|Completed|April 2014|July 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673827||3581|
NCT02664610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO13884|Community Study to Reduce High Blood Pressure Through Text Messaging (REACH OUT)|REACH OUT: to Reduce High Blood Pressure|REACH OUT|University of Michigan|No|Active, not recruiting|February 2014|March 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||October 2015|January 22, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02664610||4284|
NCT02665650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFM13-103|Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)||Affimed GmbH|Yes|Not yet recruiting|March 2016|August 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02665650||4204|
NCT02685059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG89|Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer|A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)|GeparNuevo|German Breast Group|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|174|||Female|18 Years|N/A|No|||January 2016|February 12, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685059||2718|
NCT02667002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162|Comparison of Anatomic Results Between Bilateral and Conventional Abdominal Sacral Hysteropexy|Randomized Single Blind Controlled Trial of Comparison of Anatomic and Sexual Outcomes Between Conventional and Bilateral Sacral Hysteropexy||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Active, not recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667002||4101|
NCT02667275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-302|A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.|SK|Aclaris Therapeutics, Inc.|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667275||4080|
NCT02674464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UH2HL130688|Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities|Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities||Johns Hopkins University|Yes|Not yet recruiting|September 2016|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1890|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02674464||3532|
NCT02663076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XARENO-Registry|Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry|FACTOR XA - INHIBITION IN RENAL PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION OBSERVATIONAL REGISTRY|XARENO|GWT-TUD GmbH|No|Not yet recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Patients with CKD (eGFR15-49 mL/min per 1.73 m2) and NVAF are in the focus of the XARENO        registry|January 2016|January 21, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02663076|18 Months|4402|
NCT02686970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CorporationPT|Spanish Adaptation and Study of Reliability of the European Quality Questionnaire (EuroQ2)|Spanish Adaptation and Study of Reliability of the European Quality Questionnaire (EuroQ2)||Corporacion Parc Tauli|No|Not yet recruiting|March 2016|November 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Family member or person responsible for patient decision making in the ICU|January 2016|February 16, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02686970||2571|
NCT02686983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-GON-1|GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study|Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study|DHC-GON-1|Danish Headache Center|Yes|Not yet recruiting|March 2016|July 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|34|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|February 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02686983||2570|
NCT02671409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 44079115.1.1001.5511|Translational Study of the Effects of Neural Mobilization in Patients With Lomboisquiatalgia|Translational Study of the Effects of Neural Mobilization in Patients With Lomboisquiatalgia||University of Sao Paulo|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|35 Years|No|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671409||3765|
NCT02671422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.223|LUME BioNIS: a Biomarker Study in Patients With NSCLC|A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.||Boehringer Ingelheim||Recruiting|March 2016|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|FPE tumour tissue and one blood sample. A buccal swab may replace the blood sample if not      available.|Both|18 Years|N/A|No|Probability Sample|NSCLC patients under Vargatef® treatment according to label|March 2016|March 21, 2016|January 29, 2016||||No||https://clinicaltrials.gov/show/NCT02671422||3764|
NCT02674412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-544|Buspirone for Functional Dysphagia|Placebo-controlled, Randomized, Double-blind, Cross-over Style Trial of Buspirone in Functional Dysphagia||The Cleveland Clinic|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674412||3536|
NCT02671058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC-2015-BA|Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories|Randomized, Open Label, Crossover Study Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Administered as a Suppository With the Sephure® Rectal Suppository Applicator Compared With Cortenema in Healthy Subjects||Cristcot LLC|No|Not yet recruiting|March 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671058||3792|
NCT02675478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC220-A-J101|Phase 1 Study of Quizartinib|A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia||Daiichi Sankyo Inc.|No|Not yet recruiting|February 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675478||3454|
NCT02688959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0807|Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)|A Feasibility/Pilot Trial of a Motor Attention Training Intervention for College Students With ADHD||University of Wisconsin, Madison|No|Recruiting|February 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|125|||Both|18 Years|23 Years|No|||February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688959||2418|
NCT02667613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B403201316810b|Changes in Everydaylife Activity of Children With CP During HABIT-ILE|Effet de la réadaptation Sur Les déficiences, Limitations d'activité et Restriction de la Participation Des Enfants présentant Des lésions Neurologiques Non-évolutives. Part IIb|change_CP|Université Catholique de Louvain|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|18 Years|No|||January 2016|January 28, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02667613||4054|
NCT02667873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-801-0115|A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors|A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors||Stemline Therapeutics, Inc.|No|Recruiting|February 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667873||4034|
NCT02675842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7221|Investigation of Cannabis for Pain and Inflammation in Lung Cancer|Investigation of Cannabis for Pain and Inflammation in Lung Cancer||New York State Psychiatric Institute|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|December 2021|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|60 Years|No|||January 2016|February 4, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675842||3426|
NCT02668900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-06|Decision Support for Adults Facing Implantable Cardioverter-Defibrillator Pulse Generator Replacement|Evaluation of Decision Support for Adults Facing Implantable Cardioverter-Defibrillator Pulse Generator Replacement: A Feasibility Study||Ottawa Heart Institute Research Corporation|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02668900||3956|
NCT02669511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQR309-005|PQR309 in Patients With Relapsed or Refractory Primary CNS Lymphoma|Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary CNS Lymphoma||PIQUR Therapeutics AG|No|Recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02669511||3911|
NCT02691182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P304|Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)|||Supernus Pharmaceuticals, Inc.||Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|6 Years|12 Years|No|||February 2016|February 19, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691182||2249|
NCT02672475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1557|Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer|A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Not yet recruiting|February 2016|||January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672475||3684|
NCT02669797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Berge Intervention|Family Matters Intervention: Targeting Family Meals Using Technology to Reduce Childhood Obesity|Using State-of-the-Art Intervention Methods During Family Mealtimes and Partnerships With Primary Care to Reduce Childhood Obesity||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|September 2017|August 2022|Anticipated|June 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02669797||3889|
NCT02693795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-PREMIER trial|Baduanjin Exercise Prevents Post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER Trial)|Baduanjin Exercise Prevents Post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER Trial)||Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02693795||2048|
NCT02676674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24415|Vitamin D Levels Following Topical Application of Vitamin D Ointment|Vitamin D Levels in Subjects With Vitamin D Deficiency Following Topical Application of Three Doses of Vitamin D Ointment - A Proof of Concept Study|VITD-001|University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676674||3362|
NCT02670577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACt|Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry|Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry|IMPACt|Agendia|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|481|||Both|18 Years|N/A|No|Non-Probability Sample|Stage I or II HR-positive, HER2-negative breast cancer patients AND T1a/b, N0/N1 (up to 1        node) Triple Negative, or HER2-positive breast cancer patients|January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02670577|2 Months|3829|
NCT02670837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LS154|Study of Cellutome System for Treatment of Individual Lesions in EB Pts|Study of Epidermal Grafting Using the CelluTome Epidermal Harvesting System for the Treatment of Individual Lesions in Persons With Epidermolysis Bullosa [MT2015-36]||Masonic Cancer Center, University of Minnesota|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670837||3809|
NCT02665715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-REAKTIV-15|Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?|Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?||Bispebjerg Hospital|No|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665715||4199|
NCT02665728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI400-201|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects||Braintree Laboratories|No|Recruiting|December 2015|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|17 Years|No|||January 2016|January 25, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665728||4198|
NCT02671331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO25874|Loop Duodenal Switch Surgery in Morbidly Obese Patients|The Effect of Loop Duodenal Switch Surgery in Morbidly Obese Patients on Weight Loss at One Year||Medical College of Wisconsin|No|Recruiting|January 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|53|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients who are candidates for bariatric surgery and meet inclusion criteria for the Loop        duodenal swith surgery with be approached for study consent.|March 2016|March 4, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02671331||3771|
NCT02661984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-052|Measurement of FeNO in Young Children With the NIOX VERO|A Randomized, Multi-Center, Single-Visit, Clinical Investigation to Assess the Degree of Agreement and Feasibility of Measuring Exhaled Nitric Oxide in Children, Aged 4-6 Years Old, With the NIOX VERO Using the 6 Second Exhalation Mode as Compared With the 10 Second Exhalation Mode||Aerocrine AB|No|Not yet recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and Asthmatic 4 - 6 year old children.|January 2016|January 20, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02661984||4486|
NCT02663063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-005A|The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan|The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan-The Second and Third Year Project.||Taipei Veterans General Hospital, Taiwan|Yes|Enrolling by invitation|December 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|494|||Both|20 Years|90 Years|No|||January 2016|January 30, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663063||4403|
NCT02667444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC302|P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne|A Phase 3 Multi-Center, Randomized, Dboule-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris||Novan, Inc.|No|Recruiting|February 2016|October 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1300|||Both|9 Years|99 Years|No|||February 2016|February 22, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667444||4067|
NCT02686957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM948/14|Recurrence and Pregnancy Post-repair of Obstetric Fistula in Guinea|Risk Factors of Fistula Recurrence and Pregnancy Outcomes Following Fistula Repair in Guinea||Centre National de Formation et de Recherche en Sante Rurale|No|Recruiting|July 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|364|||Female|18 Years|65 Years|No|Probability Sample|The study population is composed of women who underwent repair for obstetric fistula in        three fistula repair hospitals in Guinea from 1 January 2012 to 30 June 2015.|February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02686957||2572|
NCT02672059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0706/035|Pain In Neuropathy Study|Pain In Neuropathy Study|PINS|King's College London|No|Recruiting|February 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|700|Samples With DNA|1. We will collect blood samples (30mls) from each subject, which will be stored at -800C           in a locked freezer. All samples will eventually be transported to King's College for           storage in compliance with The Human Tissues Act. DNA will be taken for studies in           genetics polymorphisms or mutations within genes which may modify the risk of a person           developing a neuropathic pain and/or the severity of neuropathic pain, if and only if           patients agree. Genetic analysis will be strictly restricted to the neuropathic pain           field, and data will be anonymised after blood has been taken from patients. If blood           chemistry and HbA1c is not available from primary care, these will also be checked. We           will also assess new potential metabolic biomarkers in the serum of patients that can           shed a light into mechanisms for the development of neuropathy and pain.        2. IENFD assessed via one 3mm skin punch biopsies performed 10 cm above lateral malleolus.|Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with peripheral neuropathies associated with diabetes, carpal tunnel syndrome or        others.|January 2016|January 29, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02672059||3715|
NCT02672072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04|Simulation-based Education for Managing Stress in ICU Nurses|Simulation-based Education for Managing Stress in ICU Nurses|SISTRESSREA|Assistance Publique Hopitaux De Marseille||Not yet recruiting|January 2016|March 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|ICU nurses from adult ICUs with a professional experience in the actual ICU of at least 6        months and no decision to leave the ICU at the time of enrollment|January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02672072||3714|
NCT02662777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1317|Eso-Sponge Registry|International, Prospective, Multicenter Registry Designed to Collect Clinical Evidence for Endoscopic Vacuum Treatment Using Eso-SPONGE® for Anastomotic Leakage After Esophageal Resection or Iatrogenic or Spontaneous Esophageal Perforation.||Aesculap AG|No|Recruiting|January 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with anastomotic leakages after esophageal resection or gastrectomy and        spontaneous or iatrogenic esophageal perforations.|February 2016|February 3, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662777|2 Weeks|4425|
NCT02675712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S15/02/022|Effect of African Drumming in Mood Disorders|The Effect of African Drumming on on Mental Well-being Among Adults With Acute Mood Disorder||University of Stellenbosch|No|Completed|April 2015|August 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|13 adults diagnosed with a mood disorder (by their own physician), aged 33 to 69 years (M        = 45.38, SD = 11.48). The population included both women (n = 10) and men (n = 3). Almost        half the participants were of Mixed Ethnicity (n = 6), while the remaining participants        were White (n = 7).|February 2016|February 4, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02675712||3436|
NCT02668692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-1128|LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis|Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris||LEO Pharma|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668692||3971|
NCT02669004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scoliosis|Intermittent Epidural Bolus Versus Epidural Infusion for Posterior Spinal Fusion After Adolescent Idiopathic Scoliosis|Patient-controlled Intermittent Epidural Bolus Versus Epidural Infusion for Posterior Spinal Fusion After Adolescent Idiopathic Scoliosis||Inonu University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|8 Years|17 Years|No|||January 2016|January 29, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669004||3949|
NCT02671825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0012P|A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects|A Phase 1 Single Center, Single Group, 7-way Crossover Pilot Pharmacokinetic Study to Evaluate the Disposition of Active Component Following Single Inhaled Doses of Five Formulations of PUR0200 Compared to Reference Product in Healthy Adult Subjects||Pulmatrix Inc.|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02671825||3733|
NCT02676219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-IST-2190|Pilot Study Utilising an Impression Technique to Capture in Vivo Images of Teeth|Pilot Study to Investigate the Reparative Effect of a Two Phase Oral Care Product Containing Containing Sodium Monofluorophosphate and Sodium Fluoride on Enamel Against a Dietary Acid Exposure Utilising an Impression Technique to Capture in Vivo Images of Teeth||Unilever R&D|No|Completed|July 2015|||October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02676219||3397|
NCT02664909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-058-2|Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty|Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty||University of Connecticut Health Center|Yes|Recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|55 Years|N/A|No|||January 2016|January 22, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664909||4261|
NCT02664922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anes Tech 11-003514|Anesthetic Techniques in EP Patients|Anesthetic Techniques and the Effect on Cardiac Electrophysiology Procedures||University of California, Los Angeles|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|4||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664922||4260|
NCT02683967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE1303|The Impact of Acupuncture on the Success Rates of IVF (In Vitro Fertilisation) Treatments|The Impact of Acupuncture on the Success Rate of IVF Treatments||Homerton University Hospital NHS Foundation Trust|No|Completed|November 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Female|18 Years|43 Years|No|||February 2016|February 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683967||2802|
NCT02677415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QML20150508|Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment|Impact of General vs Local Anesthesia on Neurological Function in Patients With Acute Ischemic Stroke Undergoing Endovascular Treatment||Beijing Tiantan Hospital|No|Not yet recruiting|March 2016|July 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|640|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677415||3305|
NCT02677428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1319-R|Remotely-Delivered Benefits Counseling for Service Connection Applicants|Remotely-Delivered Benefits Counseling for Service Connection Applicants||VA Office of Research and Development|Yes|Recruiting|December 2015|May 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|64 Years|No|||February 2016|February 3, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02677428||3304|
NCT02667691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01974-43|Evaluation of SODB® in Metabolic Adaptations in Overweight Women|Evaluation of SODB®, Associated With a Caloric Restriction, in Metabolic Adaptations in Overweight Women: Randomized Double-blind Study Versus Placebo|SORESCAL|Bionov|No|Not yet recruiting|February 2016|January 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02667691||4048|
NCT02667704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.239|Influence of Bosentan on the Pharmacokinetics of Nintedanib|Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects||Boehringer Ingelheim||Completed|February 2016|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 21, 2016||||No||https://clinicaltrials.gov/show/NCT02667704||4047|
NCT02672319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS Glue Study|EUS-guided Glue Injection for Varices Study|Endoscopic Ultrasound (EUS) Guided Cyanoacrylate Injection for Variceal Obturation as Secondary Prophylaxis for Patients at High Risk for Recurrent Gastroesophageal Variceal Bleeding||Chinese University of Hong Kong|No|Recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|85 Years|No|||January 2016|February 2, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02672319||3695|
NCT02675426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-549|A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs|SELECT-NEXT|AbbVie|Yes|Recruiting|November 2015|August 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|99 Years|No|||February 2016|February 3, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675426||3458|
NCT02688218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15452|Exercise Detection Study|Testing and Tuning a Multiparameter Exercise Detection Algorithm||Oregon Health and Science University|No|Recruiting|February 2016|February 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688218||2475|
NCT02690597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 560 07|Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management|Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management by Mobile Acute Pain Team|ANXYDOL|University Hospital, Toulouse|No|Recruiting|February 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690597||2293|
NCT02669628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR314/15|Antimullerian Hormone in Endometriomas|Anti-mullerian Hormone in Ovarian Reserve Evaluation After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery. A Pilot Study.||Hospital Universitari de Bellvitge|No|Not yet recruiting|February 2016|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|No|||January 2016|January 27, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02669628||3902|
NCT02677298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPH-301-201030|Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I|Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study|BLESSI|Croma-Pharma GmbH|No|Not yet recruiting|February 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677298||3314|
NCT02673021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001758|MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)|MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)|MARK 1A|Mayo Clinic|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02673021||3642|
NCT02692742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-MT001-2-2015-1|Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer|MyeloConcept|Myelo Therapeutics GmbH|Yes|Recruiting|February 2016|September 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692742||2129|
NCT02670239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI-178|Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)|||University of Turin, Italy||Recruiting|May 2014|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|lungs from brain dead donors that were considered at high-risk for transplantation and        underwent EVLP|January 2016|January 27, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02670239||3855|
NCT02670252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCY vs TBICY-ALL-2016|BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT|Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|14 Years|65 Years|No|||January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670252||3854|
NCT02668237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508188|Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP|Impact on Anti-infectious Treatments of the Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Community-acquired Pneumonia of Children at Pediatric Emergencies|OptiPAC|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|3 Months|18 Years|No|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668237||4006|
NCT02668250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508190|Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality|The OPTI-AGED Study : Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality in Elderly Patients. A Randomized, Multicentre, Prospective Controlled Study|OPTI-AGED|Centre Hospitalier Universitaire de Saint Etienne|Yes|Not yet recruiting|May 2016|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2500|||Both|80 Years|N/A|No|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668250||4005|
NCT02673268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00745-44|Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate Reconstruction by Prothesis|Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate Reconstruction by Prothesis|MARCI|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|70 Years|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673268||3624|
NCT02673281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000343|Activation of Brain Centers by Short-term Walnut Consumption in Obesity|Activation of Brain Centers Responsible for Decreasing Appetite and Improvement of the Cardiometabolic Profile by Short-term Walnut Consumption in Obesity: A Pilot Study||Beth Israel Deaconess Medical Center|No|Recruiting|January 2016|February 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02673281||3623|
NCT02667340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10009797|Superstarch and Physical/Cognitive Performance Following a Simulated Soccer Game|Effects of Starch Produced From Heat-treated Corn (Superstarch) Supplementation on Skills, Cognitive Function and Physical Performance During/Following a Simulated Soccer Game||University of Western Ontario, Canada|Yes|Not yet recruiting|February 2016|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|15|||Both|15 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667340||4075|
NCT02667353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53144|Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression|Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy||Universitaire Ziekenhuizen Leuven|Yes|Completed|June 2011|December 2015|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|110|||Both|55 Years|N/A|No|||January 2016|January 27, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02667353||4074|
NCT02675114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08|The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis|A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement Who Have Severe, Calcific, Symptomatic Aortic Stenosis|PARTNER 3|Edwards Lifesciences|No|Not yet recruiting|April 2016|March 2027|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1228|||Both|65 Years|N/A|No|||February 2016|February 2, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675114||3482|
NCT02675127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/15/588|Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.||Genuine Research Center, Egypt|No|Completed|December 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675127||3481|
NCT02671123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-02|Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?|Evaluation of Effect of Co-registration Between Optical Coherence Tomography (OCT) and Coronary Angiography Onto OCT Guided Percutaneous Coronary Intervention (PCI)||St. Francis Hospital, New York|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671123||3787|
NCT02673034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CirProg|Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.|Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.||Regionshospitalet Viborg, Skive|Yes|Recruiting||March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Serum|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Women undergoing IVF-treatment using either GnRHa long protocol or GnRH antagoinst        co-treatment.|February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673034||3641|
NCT02673047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/OAB/006|Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder||BOREAL|Allergan|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|473|||Both|18 Years|N/A|No|Probability Sample|Adult patients treated with Botox® for urinary incontinence associated with NDO or IOAB in        clinical practice.|January 2016|February 1, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673047||3640|
NCT02514980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718/ ref. no.103|Infra-orbital Nerve Block for Post Operative Analgesia in Children Undergoing Cleft Lip Surgery.|Infra-orbital Nerve Block for Post Operative Analgesia in Young Children Undergoing Pediatric Cleft Lip Surgery.|IFONB|Assiut University|Yes|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Months|2 Years|No|||February 2016|February 21, 2016|August 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514980||15774|
NCT02518581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBDM-03|Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus|Estimating Free-living Human Energy Expenditure - Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus|DLW|Profil Institut für Stoffwechselforschung GmbH|No|Recruiting|August 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|64 Years|No|||February 2016|February 23, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518581||15498|
NCT02687802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/19122-4|Respiratory Mechanics and Patient-ventilator Asynchrony Index in Patients With Invasive Mechanical Ventilation|Respiratory Mechanics and Patient-ventilator Asynchrony Index in Patients With Invasive Mechanical Ventilation|EpiSync|University of Sao Paulo General Hospital|No|Not yet recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients intubated and under invasive mechanical ventilation in a University hospital ICU|January 2016|February 16, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02687802||2507|
NCT02667665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAD1412|Verification Study and Reactivity Study for the Validity of QuQu Scale|Verification Study and Reactivity Study for the Validity of a Novel Dementia Rating Scale "QUick QUestion Scale" for Alzheimer's Disease Dementia|QuQu|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Not yet recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|240|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Alzheimer's Disease Dementia and Mild Cognitive Impairment|February 2016|February 23, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667665||4050|
NCT02667938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TASU-301|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules|A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules||Hanmi Pharmaceutical Company Limited|No|Active, not recruiting|March 2015|May 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|510|||Male|50 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667938||4029|
NCT02668497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107433|Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy|||Western University, Canada|No|Recruiting|January 2016|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668497||3986|
NCT02676518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057/2015|AMH, Glucose Intolerance and Metabolic Syndrome in PCOS|Anti-Müllerian Hormone and Its Association With Glucose Intolerance and Metabolic Syndrome in Women With Polycystic Ovary Syndrome||Chulalongkorn University|Yes|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|70|Samples Without DNA|-  Serum anti-mullerian hormone level        -  Blood test for 2-hours 75 gram glucose tolerance test        -  Blood tests for total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Thai women with PCOS diagnosed by Rotterdam criteria 2003 who visit at Gynecological        Department, King Chulalongkorn Memorial Hospital, Bangkok,Thailand|February 2016|February 3, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02676518||3374|
NCT02672865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150301|Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer|Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer||Loma Linda University|No|Recruiting|December 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672865||3654|
NCT02664116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-002|IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine|IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine||Scripps Health|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664116||4322|
NCT02662335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9363|Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors|Computerized Cognitive Retraining in Breast Cancer Survivors||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662335||4459|
NCT02681341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015-236|Vascular Post Market Review|Vascular Post Market Review||Baylor Research Institute|No|Not yet recruiting|February 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing a carotid endarterectomy with patch arterioplasty|February 2016|February 11, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681341||3004|
NCT02681354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-PFE-JSP-01|Dual Task Training in Elderly Using the BioRescue|What is the Influence of Dualtask-training With the BioRescue (Analyses and Rehabilitation of Mobility) on Static Balance, Dynamic Balance During Gait and Cognitive-motor Dual Tasks During Gait: A Randomized Controlled Trial||Hasselt University|No|Recruiting|November 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|40|||Both|65 Years|N/A|No|||February 2016|February 11, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02681354||3003|
NCT02678299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREBEN|Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study|Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study||University of Aarhus|No|Recruiting|February 2016|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|85 Years|No|||February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678299||3237|
NCT02665104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE RKEB/IKEB:4364/2015|Middle Cerebral Artery Velocity and Oxygen Saturation of the Brain During Carotid Endarterectomy|Investigation of Blood Flow Velocity in the MCA and Oxygen Saturation of the Brain During Carotid Endarterectomy in Local Anesthesia in Patients With and Without Neurological Symptoms Using Transcranial Doppler (TCD) and INVOS Monitor||University of Debrecen|Yes|Recruiting|April 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|100 patients awaiting carotid artery endarterectomy carried out in regional anesthesia.          -  Age: patients over 18 years.          -  Gender: both female and male patients are included in the study.|January 2016|January 22, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02665104||4246|
NCT02666872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-074|Evaluation of an Intervention PROMOting VAccination in Maternity in Quebec|Evaluation of a New Educational Strategy Promoting Vaccination in Maternity in Quebec Based on Motivational Interviewing Techniques: PROMOVAQ Study|PROMOVAQ|Université de Sherbrooke|Yes|Active, not recruiting|June 2013|June 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2719|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02666872||4111|
NCT02672995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511005MINB|Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial|Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial||National Taiwan University Hospital|Yes|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|N/A|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02672995||3644|
NCT02686164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-109|Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors|An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors||Eisai Inc.||Recruiting|January 2016|May 2018|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686164||2633|
NCT02688985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29966|To Explore the Mechanism of Action of Ocrelizumab and B-cell Biology in Patients With Relapsing Multiple Sclerosis (RMS).|An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis||Genentech, Inc.||Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Both|18 Years|55 Years|No|||March 2016|March 7, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688985||2416|
NCT02662712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108092|A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)|A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Subjects (Part I), and After Multiple Dose Regimens in Subjects With Chronic Hepatitis B (Part II)||Janssen Sciences Ireland UC||Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|78|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02662712||4430|
NCT02668445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54408.081.15|Molecular Response After Concurrent Exercise With Low Glycogen|The Effects of Glycogen Availability on the Skeletal Muscle Molecular Response After Concurrent Exercise|Glyconcurrent|Wageningen University|No|Active, not recruiting|November 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|March 4, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668445||3990|
NCT02670590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOVE|NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life|NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life|ct-NAFLD|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|No|Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|21 Years|70 Years|No|||January 2016|February 1, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02670590||3828|
NCT02670603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04-018-002|A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis|A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy||Samsung Medical Center|Yes|Recruiting|August 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670603||3827|
NCT02688621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS 15-259|Internet Assisted Obesity Treatment Enhanced With Financial Incentives|Internet Assisted Obesity Treatment Enhanced With Financial Incentives|iREACH3|University of Vermont|No|Recruiting|December 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02688621||2444|
NCT02673983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFAT-001|Safety and Efficacy Study of the FTRD System for Obtaining Full-thickness Intestinal Biopsies|Endoscopic Full-thickness Biopsy of the Intestine||Region Skane|No|Not yet recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02673983||3569|
NCT02665598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BoGao|Prognostic Observation of Posterior Reversible Encephalopathy Syndrome|Prognostic Observation of Posterior Reversible Encephalopathy Syndrome|POPRES|Yantai Yuhuangding Hospital|Yes|Not yet recruiting|February 2016|January 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|The patients with complete inpatient clinical records who meet the inclusion criteria from        January 2016 to July 2015 will be included in this research.|February 2016|February 1, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02665598||4208|
NCT02667457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-Annexin-04|99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis|99mTc-rhAnnexin V-128 SPECT Imaging of Apoptosis in Asymptomatic Patients With Carotid Atherosclerotic Plaque||Advanced Accelerator Applications|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667457||4066|
NCT02689609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0|Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma|Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma||The University of Hong Kong|No|Active, not recruiting|January 2008|December 2016|Anticipated|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|149|||Both|18 Years|80 Years|No|Non-Probability Sample|Eligible patients included those with previously untreated non-metastatic nasopharyngeal        carcinoma (NPC) who received only one course of radical IMRT with or without adjunct        chemotherapy for their NPC as curative treatment.|February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02689609|5 Years|2368|
NCT02689622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7429 07|PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.|Best PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.|PREDICTOR|University Hospital, Toulouse|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|450|||Both|70 Years|N/A|No|||February 2016|February 18, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02689622||2367|
NCT02674139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-MD-IUD|Comparison Between Intrauterine Contraceptive Device Insertion During Cesarean Section Vs Conventional Application|Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application||Beni-Suef University|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02674139||3557|
NCT02674152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1336.1|Dose Finding Study of BI 836880 in Patients With Solid Tumors|A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.||Boehringer Ingelheim||Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 4, 2016||||No||https://clinicaltrials.gov/show/NCT02674152||3556|
NCT02674516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823967|The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior|The Effect of Repeated Transcranial Direct Current Stimulation of the Prefrontal Cortex on Antisocial and Aggressive Behavior||University of Pennsylvania|No|Not yet recruiting|February 2016|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02674516||3528|
NCT02675491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS6051-A-J102|Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors|Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene||Daiichi Sankyo Inc.||Recruiting|February 2016|March 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|N/A|No|||February 2016|February 29, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675491||3453|
NCT02678403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7386 08|Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI|Efficacy of Transcutaneous Electrical Nerve Stimulation in the Improvement of Walking Distance in Patients With Peripheral Artery Disease With Intermittent Claudication|TENS-PAD|University Hospital, Toulouse|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||January 2016|February 4, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02678403||3229|
NCT02671526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC-1005-14|Cognitive Remediation for HIV-associated Neurocognitive Dysfunction|Plasticity-based Adaptive Cognitive Remediation (PACR) for HIV-associated Neurocognitive Dysfunction|HAND|Posit Science Corporation|Yes|Recruiting|December 2015|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|25 Years|60 Years|No|||January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02671526||3756|
NCT02671539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THOR-TUE-01|THOR - Tübingen Choroideremia Gene Therapy Trial|THOR - Tübingen Choroideremia Gene Therapy Trial Open Label Phase 2 Clinical Trial Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|THOR|STZ eyetrial|Yes|Enrolling by invitation|January 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02671539||3755|
NCT02661711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICM1014|Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study|Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)|AMOUR|Moorfields Eye Hospital NHS Foundation Trust|Yes|Recruiting|March 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||March 2016|March 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661711||4507|
NCT02661997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-004-15S|Novel Interventions for Gulf War Veterans' Illnesses|Novel Interventions for Gulf War Veterans' Illnesses|NIGWVI|VA Office of Research and Development|No|Not yet recruiting|January 2017|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|N/A|No|||January 2016|January 20, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02661997||4485|
NCT02676245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00060088|Parent Education and Choice About Newborn Screening and Bloodspot Retention|Parent Education and Choice About Newborn Screening and Bloodspot Retention||University of Utah|No|Completed|September 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|664|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02676245||3395|
NCT02676258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030313M|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2015|||||N/A|N/A|N/A||||||||||||||February 3, 2016|January 30, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676258||3394|
NCT02691338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0459-15-Rambam-CTIL|Monitoring Neurological Deterioration in Anaesthetised Patients With Electroencephalogram (EEG)|Monitoring Neurological Deterioration in Anaesthetised Patients With Electroencephalogram (EEG): Demonstration With Patients Undergoing Neurovascular Intervention After Cerebrovascular Attack (CVA).||Rambam Health Care Campus|No|Not yet recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CVA undergoing percutaneous thrombectomy under general anesthesia|February 2016|February 21, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02691338||2237|
NCT02678221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIUGR|Sildenafil Citrate for the Management of Asymmetrical Intrauterine Growth Restriction|||Assiut University|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|No|||February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678221||3243|
NCT02676661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jhchen|Evaluation of the Prevalence and Risk Factors for Patients With Peri-implant Disease|The Prevalence and Risk Factors for Patients With Peri-implant Disease： A Prospective Study||Fourth Military Medical University|Yes|Recruiting|October 2014|December 2022|Anticipated|October 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|350|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Partially edentulous patients implant dental implants and will be restored with        implant-supported fixed partial dentures and single crowns at the Department of        Prosthodontics, School of Stomatology of the Fourth Military Medical University|January 2016|February 5, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02676661|5 Years|3363|
NCT02664584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08NIR03/113|The Trinity, Ulster and Department of Agriculture Cohort Study||TUDA|University of Ulster|No|Active, not recruiting|December 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|5186|Samples With DNA|Blood samples Buccal swabs Buffy coats|Both|60 Years|N/A|No|Non-Probability Sample|Patients aged 60 and above|January 2016|January 26, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02664584||4286|
NCT02666118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0486|Efficacy of Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Intervention|Randomized Prospective Comparison of Analgesic Efficacy of Peripheral Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Shoulder Repair||Children's Hospital Medical Center, Cincinnati||Enrolling by invitation|February 2013|January 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|10 Years|21 Years|No|||October 2015|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02666118||4169|
NCT02666131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-DFU-302|A Study of Granexin Gel to Treat Diabetic Foot Ulcer|A Phase 3, Randomized, Double-blind, Parallel-group, Multicenter Study Investigating the Safety and Efficacy of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 2)||FirstString Research, Inc.|Yes|Recruiting|July 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|368|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666131||4168|
NCT02666144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2015-6|Comparison of Optic Nerve Head and Retinal Nerve Fiber Layer Parameters Derived From Two Different Methods of Scan Alignment|||Heidelberg Engineering GmbH|No|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 eyes of 20 normal healthy subjects and 20 eyes of 20 glaucoma patients, both genders        approx. equally.|January 2016|January 27, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666144||4167|
NCT02676323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANAML|Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome||St. Jude Children's Research Hospital|No|Recruiting|February 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|24 Years|No|||March 2016|March 23, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676323||3389|
NCT02678442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007801|Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle|Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling||Mayo Clinic|No|Enrolling by invitation|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|25|||Both|18 Years|100 Years|No|||February 2016|February 10, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678442||3226|
NCT02664831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS1|Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest|Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest|PCAS|Maine Medical Center|No|Recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Whole blood will be assayed for cellular components, neuregulin, ERBB receptors, and lipids|Both|18 Years|N/A|No|Non-Probability Sample|Cardiac arrest survivors with encephalopathy undergoing targeted temperature management|January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664831||4267|
NCT02669979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarolinskaACT|Domiciliary Professional Oral Care for Dependent Elderly|Domiciliary Professional Oral Care for Dependent Elderly - Access to Improved Oral and General Health?||Karolinska Institutet|No|Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|366|||Both|80 Years|95 Years|No|||February 2016|February 1, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02669979||3875|
NCT02674854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG324-CS302|Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension|||Aerie Pharmaceuticals||Not yet recruiting|February 2016|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|690|||Both|18 Years|99 Years|No|||February 2016|February 2, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674854||3502|
NCT02686658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH2003|A Phase 2/3 Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration|A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration||Ophthotech Corporation|Yes|Recruiting|January 2016|||December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|50 Years|N/A|No|||March 2016|March 16, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686658||2595|
NCT02674126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087350|The Efficacy of Maternal Sound for Pediatric Patients Undergoing Cardiac Surgery|When Are Parents Helpful? A Randomized Clinical Trial of the Efficacy of Maternal Sound for Pediatric Patients Undergoing Cardiac Surgery||Assiut University|Yes|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|4 Years|8 Years|No|||February 2016|February 2, 2016|January 31, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674126||3558|
NCT02674698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEC-15-465|Disseminating a Dashboard for VA Purchased Community Nursing Homes|Disseminating a Dashboard for VA Purchased Community Nursing Homes|CNHDashboard|Providence VA Medical Center|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|18|||Both|N/A|N/A|No|||February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674698||3514|
NCT02690064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-AOX|Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF|Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF|CF-AOX|Georgia Regents University|Yes|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|7 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690064||2333|
NCT02677285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R150095|Bioimpedance Based Monitoring of Operation Wound and Skin Graft Healing|Bioimpedance Based Monitoring of Operation Wound and Skin Graft Healing||Tampere University Hospital|Yes|Enrolling by invitation|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Plastic surgery and KEI2 wards at Tampere University Hospital|January 2016|February 3, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02677285||3315|
NCT02667093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Persimmune Sample Collection|Samples From Leukemia Patients and Their Donors to Identify Specific Antigens|Bone Marrow and Peripheral Blood (PB) Samples From Patients With Leukemia and PB From Their BM Donors (BMD) to Identify Leukemia-Specific Antigens (LSA) and Graft Versus Host Disease Antigens (GVHDA) for Use in Cellular Immunotherapy||University of California, San Diego|No|Recruiting|January 2013|December 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Samples will be shipped to Persimmune for processing and storage with results shared with      Dr. Ball and his lab at UCSD.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with leukemia and their potential bone marrow donors.|January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02667093||4094|
NCT02667106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015016|Phase I Pharmacokinetic Study of RX0041-2|Systemic Pharmacokinetics of Acute, Topical, Intranasal Administration of RX0041-002 in Healthy Male and Female Subjects||Pharmaceutical Project Solutions, Inc.|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02667106||4093|
NCT02664688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/15|Lumbar Stabilization Exercises vs Flexor Exercises in Degenerative Spondylolisthesis|Lumbar Stabilization Exercises vs Flexor Exercises in Patients With Chronic Low Back Pain and Degenerative Spondylolisthesis||National Institute of Rehabilitation, Mexico|No|Recruiting|July 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|50 Years|N/A|No|||January 2016|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02664688||4278|
NCT02679443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/2376/DM/913|Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy|Optimum Duration of Vitamin B12 and Folate Supplementation in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Undergoing Pemetrexed Containing Chemotherapy: a Randomized Controlled Trial|PEMVITASTART|Postgraduate Institute of Medical Education and Research||Recruiting|July 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679443||3149|
NCT02679690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110506|Assessing Knowledge of Dietary Sodium Content and Implementation of Color-Coded Cue Cards and Dietary Sodium|Assessing Knowledge of Dietary Sodium Content and Implementation of Color-Coded Cue Cards to Aid in Improving Adherence to Low Sodium Diets in Patients With Heart Failure.||University of Pittsburgh||Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02679690||3131|
NCT02672215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2012/320|RCT Computer-tailored Intervention on Workplace Sitting|The Effectiveness of a Web-based Computer-tailored Intervention on Workplace Sitting: a Randomized Controlled Trial|StartToStand|University Ghent|No|Active, not recruiting|September 2014|October 2017|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|1061|||Both|18 Years|70 Years|No|||January 2016|January 31, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02672215||3703|
NCT02672228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1430|Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)|Feasibility of the Vapor Nanobubble Technology (MalariSense) for Malaria Diagnostics|MalariaSense|Medical Research Council Unit, The Gambia|No|Recruiting|October 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|1 Year|N/A|No|||January 2016|January 28, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02672228||3702|
NCT02663024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1111B_P2|Study of Idursulfase-beta (GC1111) in Hunter Syndrome|Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Idursulfase-beta (GC1111) in Hunter Syndrome (Mucopolysaccharidosis II) Patients||Green Cross Corporation|No|Not yet recruiting|December 2016|June 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Male|5 Years|35 Years|No|||January 2016|January 21, 2016|January 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663024||4406|
NCT02663323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER/EX|Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions|MeRes-1 Extend|Meril Life Sciences Pvt. Ltd.|Yes|Not yet recruiting|December 2015|||December 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02663323||4383|
NCT02669771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-MA-1018|Long-Term Specified Drug Use-Results Survey for Xtandi Capsule|Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey||Astellas Pharma Inc|No|Recruiting|January 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Male|N/A|N/A|No|Non-Probability Sample|Patients with castration-resistant prostate cancer|January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02669771||3891|
NCT02669784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3932|CTA Volume Dose Reduction Study|Does Reduction in Contrast Administration Dose in Computed Tomography Arteriograms Degrade Image Quality? A Single Institutional Review of an Ultra-low Contrast Dose Protocol||Milton S. Hershey Medical Center|No|Not yet recruiting|February 2016|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669784||3890|
NCT02665052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1828-R|Translating Intensive Arm Rehabilitation in Stroke to a Telerehabilitation Format|Translating Intensive Arm Rehabilitation in Stroke to a Telerehabilitation Format|TeleBATRAC|VA Office of Research and Development|Yes|Not yet recruiting|July 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|78|||Both|18 Years|90 Years|No|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665052||4250|
NCT02677168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOM-015|cNEP for the Treatment of Sleep Apnea in Patients Who Cannot Use CPAP|Continuous Negative External Pressure (cNEP) for the Treatment of Obstructive Sleep Apnea (OSA) in Patients Who Cannot Use Continuous Positive Airway Pressure (CPAP)|cNEP|Sommetrics, Inc.|No|Not yet recruiting|February 2016|||July 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677168||3324|
NCT02674477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00079236|Treatment Engagement With Technology-assisted Treatment|Treatment Engagement With Technology-assisted Treatment|TETAT|Johns Hopkins University||Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674477||3531|
NCT02676739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012443|A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS|||London Health Sciences Centre|No|Not yet recruiting|April 2016|December 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|59 Years|No|||February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676739||3357|
NCT02690714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002C011G|A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia|A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia||ProMetic BioTherapeutics, Inc|Yes|Not yet recruiting|March 2016|August 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|2 Years|80 Years|No|||February 2016|February 19, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690714||2284|
NCT02685111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2015-1143|Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)||Asan Medical Center|No|Not yet recruiting|February 2016|March 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|162|||Female|19 Years|70 Years|No|||February 2016|February 13, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02685111||2714|
NCT02672891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MenoufiaOGG|Intrauterine Balloon Tamponade in the Management of Postpartum Hemorrhage|Intrauterine Balloon Tamponade in the Management of Postpartum Hemorrhage in a Low Resource Setting||Menoufia Obstetrics and Gynecology Group|Yes|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|45 Years|No|||January 2016|January 31, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02672891||3652|
NCT02674997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001501|GAS-Hem Feasibility Study|A New Patient-centric Outcome Measure for Patients With Hemophilia: Testing the Feasibility of GAS-Hem in Pediatric, Adolescent and Adult Hemophilia A Patients||Baxalta US Inc.|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|5 Years|65 Years|No|Non-Probability Sample|Patients with moderate to severe hemophilia A in the United States or Canada.|February 2016|February 2, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02674997||3491|
NCT02676882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016P000275|EnBrace HR for MDD Relapse Prevention in Women Trying to Conceive and Early Pregnancy|EnBrace HR for MDD Relapse Prevention in Women Trying to Conceive and Early Pregnancy||Massachusetts General Hospital|No|Not yet recruiting|June 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676882||3346|
NCT02676895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03_04TP|A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults|A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis||GSK Vaccines Institute For Global Health S.r.l.|Yes|Not yet recruiting|April 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676895||3345|
NCT02679703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8639|Polarity Action in Electrical Stimulation Transcutaneous Donors for Treatment Areas Burned Patients|Polarity Action in Electrical Stimulation Transcutaneous for Treatment of Graft Donor Areas in Patients Autogenous Burned: Blind Randomized Clinical Trial||University of Sao Paulo|Yes|Not yet recruiting|February 2016|December 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|59 Years|No|||February 2016|February 9, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02679703||3130|
NCT02677363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208531|Functional Outcomes of Stay Strong Stay Healthy Program|Functional Outcomes of Stay Strong, Stay Healthy Program||University of Missouri-Columbia|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677363||3309|
NCT02677376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15052|Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC|Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide||University of Wisconsin, Madison|Yes|Not yet recruiting|March 2016|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Male|18 Years|N/A|No|Non-Probability Sample|Men ≥18 years with progressive, bone-metastatic castrate-resistant prostate cancer who        will be treated with enzalutamide will be enrolled.|February 2016|February 10, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02677376||3308|
NCT02676934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-ETCNTRL|End Tidal Control of Sevoflurane||EtCntrl|Mansoura University|Yes|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|45 Years|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676934||3342|
NCT02676947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO2060|A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension|A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension|TRANSFORM-UK|Papworth Hospital NHS Foundation Trust|No|Recruiting|January 2016|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|70 Years|No|||January 2016|February 8, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02676947||3341|
NCT02682667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160061|Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols|Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|December 2027|Anticipated|December 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|99 Years|No|||January 2016|February 11, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682667||2902|
NCT02664662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medical University Hospital|The Validation of Tailored Rehabilitated Education in Breast Cancer Survivors After Surgery|||Taipei Medical University|Yes|Recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Female|20 Years|80 Years|Accepts Healthy Volunteers|||September 2015|January 22, 2016|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02664662||4280|
NCT02662634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-003-024|A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer|A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer||GU Research Network, LLC|No|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|19 Years|N/A|No|||March 2016|March 24, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662634||4436|
NCT02662647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaNGH-H001|Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML|||Chinese PLA General Hospital|No|Recruiting|April 2015|December 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|75 Years|No|||January 2016|January 23, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662647||4435|
NCT02518984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFGen Long Term|Atrial Fibrillation General Registry|Atrial Fibrillation General Long Term Registry|AFGenLT|European Society of Cardiology|No|Recruiting|October 2013|December 2018|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Out patients with AF and patients with acute pre-existing or new onset AF|February 2016|February 10, 2016|April 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02518984|3 Years|15467|
NCT02522754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB 004 IDB 005|Development of an Intranasal Proteosome Influenza Vaccine|Study to Determine if Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine is Safe, Immunogenic and Efficacious in the Influenza Human Viral Challenge Model||Hvivo|Yes|Completed|January 2002|January 2004|Actual|January 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|174|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02522754||15177|
NCT02688660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0185|MRI Markers of Outcome After Severe Pediatric TBI|MRI Markers of Outcome After Severe Pediatric Traumatic Brain Injury (TBI)||University of Wisconsin, Madison|No|Not yet recruiting|April 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|N/A||3|Anticipated|950|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients who have experienced TBI and had an acute MRI scan and those who        participate in the prospective phase and obtain a follow-up MRI. Healthy controls will        also be enrolled.|February 2016|February 22, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02688660||2441|
NCT02672280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-3|Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects||SEESCMMSCTSD|South China Research Center for Stem Cell and Regenerative Medicine||Not yet recruiting|May 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 31, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02672280||3698|
NCT02675777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ-R18-HS023173|Sustaining Patient-centered Alcohol-related Care|Sustained Implementation of Patient-Centered Care for Alcohol Misuse|SPARC|Group Health Cooperative|No|Not yet recruiting|February 2016|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|381550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675777||3431|
NCT02676752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 15135|Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis|Assessing Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors||Vanderbilt-Ingram Cancer Center|Yes|Not yet recruiting|February 2016|||December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|22 Years|N/A|No|||February 2016|February 3, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02676752||3356|
NCT02677818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-YXB-001|The Relationship Between Clotting Factor VIII and Bleeding Adverse Reactions in Patients Under the Therapies of Thrombolysis, Anticoagulation and Anti-platelet|||Zhujiang Hospital|No|Not yet recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|||Both|30 Years|65 Years|No|Probability Sample|The stroke patient using Anti-thrombotic drugs diagnosed by Zhujiang Hospital.|October 2015|February 18, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677818||3274|
NCT02670720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4161-303|Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema|OPuS-4: An Open-label Study to Evaluate the Long-term Safety of Avoralstat in Subjects With Hereditary Angioedema|OPuS-4|BioCryst Pharmaceuticals|Yes|Terminated|December 2015|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 20, 2016|Yes|Yes|preceding efficacy study of avoralstat in its current formulation was not significant and does    not support continued development|No||https://clinicaltrials.gov/show/NCT02670720||3818|
NCT02667964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGF-Exercise|FGF-21 and Exercise in Relation to Insulin Secretion|FGF-21 During Physical Exercise in Patients With Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Healthy Controls||Charite University, Berlin, Germany|No|Recruiting|November 2015|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02667964||4027|
NCT02666651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00115|Regional Tolvaptan Registry|Regional Tolvaptan Registry|Tolvaptan|Cardiology Research UBC|No|Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|19 Years|N/A|No|||January 2016|January 25, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02666651||4128|
NCT02666664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-040|Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk|A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy||Esperion Therapeutics|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||January 2016|March 10, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666664||4127|
NCT02685917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Collagen augmentation|Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy|Effects of Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy: A Randomized, Controlled, Double-Blind Trial||The Catholic University of Korea|No|Not yet recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|65 Years|No|||February 2016|February 14, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02685917||2652|
NCT02666274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N354|Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread|Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|stool samples|Both|18 Years|N/A|No|Non-Probability Sample|Any adult hospitalized patient at Guy's and St Thomas' Foundation Trust who carries        resistant gram negative bacteria on a screening or clinical sample|January 2016|January 26, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02666274||4157|
NCT02666287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201958|GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)|An Open Label, Six-period Cross-over, Single and Repeat Dose Study to Determine the Pharmacokinetics of Fluticasone Furoate and GSK961081 When Administered Alone, in Combination, or Concurrently Via the ELLIPTA||GlaxoSmithKline|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666287||4156|
NCT02669420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220|Misoprostol for Second Trimester Pregnancy Termination|Intra Uterine Extra Amniotic (200 μg ) Versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination: Randomized Controlled Trial|MIS|Assiut University|Yes|Completed|January 2015|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Female|N/A|N/A|No|||January 2016|January 27, 2016|January 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669420||3918|
NCT02674243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03315|Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion|Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion: a Randomized Controlled Trial Study||Chiang Mai University|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674243||3549|
NCT02673008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRD-directed DLI-2016|MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT|Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|14 Years|65 Years|No|||January 2016|January 30, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02673008||3643|
NCT02689180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-240|Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients|Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure|ReBIC-1|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|May 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|90 Years|No|||February 2016|February 22, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02689180||2401|
NCT02674035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1175-1484|Plication of the Rectus Abdominis in Two Planes and in One Continuous Suture Plan|Plication of the Rectus Abdominis in Two Planes and in One Continuous Suture Plan||Federal University of São Paulo|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Female|25 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02674035||3565|
NCT02675335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SitaDFU_v1.0|Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin|Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin|SitaDFU|Medical University Innsbruck|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 8, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02675335||3465|
NCT02675348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fES-uREC-15-1 3 02|Beef Protein Supplementation in Endurance Athletes|Effects of Meat Protein Administration on Body Composition, Strength, Muscle Structure, Immunological and Haematological Markers in Endurance Athletes|Beef|University of Greenwich|Yes|Recruiting|January 2016|June 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675348||3464|
NCT02691312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501086|Pediatric Type 1 Diabetes and Retinopathy|Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera||University of Florida|No|Not yet recruiting|April 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|9 Years|26 Years|No|||February 2016|February 22, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691312||2239|
NCT02662959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med Onc-G 01|Irinotecan as 3rd Line Therapy in Gastric Cancer|A Phase II Study of Irinotecan as Single Agent in the Third Line Treatment of Unresectable or Metastatic Gastric Cancer.||Fudan University|No|Recruiting|April 2015|||May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|70 Years|No|||November 2015|January 21, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02662959||4411|
NCT02670005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160010|Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction|||Nanjing Medical University|No|Not yet recruiting|February 2016|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|patients with ST-segment elevation myocardial infarction received selective percutaneous        coronary intervention|January 2016|January 27, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02670005||3873|
NCT02674932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00107976|Character Strengths Intervention Among Psychiatrically Hospitalized Youth|Assessment of a Character Strengths Intervention in Improving Treatment Outcomes Among Psychiatrically Hospitalized Youth||University of Michigan|No|Enrolling by invitation|February 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|210|||Both|12 Years|17 Years|No|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674932||3496|
NCT02687542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7601003|Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations|A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease||Pfizer|Yes|Recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|198|||Both|45 Years|85 Years|No|||March 2016|March 21, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687542||2527|
NCT02663245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/129|INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control|INTEGRA Study: Intervention in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control on Primary Health Care.||Jordi Gol i Gurina Foundation|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|864|||Both|30 Years|80 Years|No|||January 2016|January 25, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02663245||4389|
NCT02663258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4254|A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)|An Explorative Phase II Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)|ADAPTeM|Royal Marsden NHS Foundation Trust|Yes|Recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02663258||4388|
NCT02665845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508090|Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).|Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.|COMBOMESA|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|February 2016|January 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665845||4189|
NCT02663427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z201501|Serological Screening of Gastric Cancer in Wuxi Region|Serological Screening of Gastric Cancer in Wuxi Region||Wuxi People's Hospital|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|5000|||Both|40 Years|70 Years|No|||January 2016|January 25, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02663427||4375|
NCT02682381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-C14-006|A Study of Teduglutide in Children With Short Bowel Syndrome Who Are Dependent on IV Fluids or Nutrition|A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support||Shire|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|28|||Both|N/A|17 Years|No|||February 2016|February 29, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682381||2924|
NCT02682394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR0216-15CTIL|Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas|Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer||Soroka University Medical Center|No|Recruiting|September 2015|October 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Cell-free DNA, CFD|Both|18 Years|N/A|No|Non-Probability Sample|30 patients diagnosed with any pancreatic cancer, in any stage, before treatment.|September 2015|February 12, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02682394||2923|
NCT02674347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-5107-102|MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous Zidebactam in Healthy Adult Human Subjects||Wockhardt|No|Not yet recruiting|February 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674347||3541|
NCT02678377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201249|The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence|The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence||Northwestern University|No|Not yet recruiting|February 2016|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|February 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678377||3231|
NCT02662283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usix-IgAN-002|Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy|Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial||Sun Yat-sen University|No|Not yet recruiting|May 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|14 Years|70 Years|No|||February 2016|February 1, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662283||4463|
NCT02677272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7464 06|Factors Predisposing to Inappropriate Transfers of Nursing Home Residents to Emergency Departments|Factors Predisposing to Inappropriate Transfers of Nursing Home Residents to Emergency Departments|FINE|University Hospital, Toulouse|Yes|Recruiting|January 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1004|||Both|N/A|N/A|No|Non-Probability Sample|All patients living in Nursing Home admitted in Emergency Department of the hospitals        participating in the study during the inclusion period will be included in the study.|February 2016|February 4, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02677272||3316|
NCT02693470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-0312A3|The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)|The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab)||Chang Gung Memorial Hospital|No|Recruiting|August 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693470||2073|
NCT02693483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|povidone iodine|Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis|Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis||Ain Shams Maternity Hospital|Yes|Recruiting|April 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|306|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02693483||2072|
NCT02664597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 140911|ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses|ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses|ASCORDIA01|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|606|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664597||4285|
NCT02664818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BA111B02|Study of China Heart Failure Registry to Investigate Characteristics of Patients in China|China Heart Failure Registry Study: A Multicenter, Prospective Investigation of Clinical Characteristics, Treatment, and Outcome of Patients Hospitalized With Heart Failure|China-HF|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized with primary discharge diagnosis of heart failure|January 2016|January 22, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02664818|1 Year|4268|
NCT02669667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4361C00002|Safety and Tolerability of MEDI19314 as Single Ascending Dose in Healthy Subjects|A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects||MedImmune LLC|No|Recruiting|February 2016|May 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669667||3899|
NCT02671032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D748893|CHANGE Feasibility Study|Characterisation of Audiological Outcomes With the Nucleus CI532 Cochlear Implant in Adult Subjects.|CLTD5626|Cochlear|No|Recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02671032||3794|
NCT02672150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJ-TRIALS|Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System|Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System: Multi-site Implementation Study|(JJ-TRAILS)|Chestnut Health Systems|No|Enrolling by invitation|April 2015|June 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|360|||Both|N/A|N/A|No|||January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02672150||3708|
NCT02677311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0596-F2L|GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient|Gonadotropin Releasing Hormone Agonist (GnRHa) Therapy and Ovarian Preservation in Pediatric and Adolescent Subject Receiving Chemoradiation Therap||University of Kentucky|No|Active, not recruiting|September 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|40|||Female|8 Years|19 Years|No|||February 2016|February 3, 2016|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02677311||3313|
NCT02677324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-491|Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia|Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Not yet recruiting|April 2016|February 2023|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677324||3312|
NCT02678702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109566|Cognitive Behavioral Therapy for Treatment of Insomnia in Patients With Major Depression|Treatment of Insomnia in Patients With Major Depression Disorder Using Cognitive Behavioral Therapy, Sleep Restriction and Stimulus Control Therapy. A Randomized, Controlled 8 Week Study||University of Aarhus|Yes|Recruiting|August 2015|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|67 Years|No|||October 2015|February 5, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02678702||3206|
NCT02670265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB61/12|Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions|Early Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions (NUPAN), a Prospective Randomized Interventional Trial|NUPAN|University Medicine Greifswald|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670265||3853|
NCT02662816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0253|Non-invasive Quantification of Muscle and Liver Glutathione GSH-MRS|Feasibility Study of the Quantification of Glutathione Concentrations in Muscle and Liver Using in Vivo Proton Magnetic Resonance Spectroscopy (1H MRS)in Human||University Hospital, Clermont-Ferrand||Not yet recruiting|January 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|N/A|35 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02662816||4422|
NCT02689596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-REST14|Oxytocin and Resting State fMRI|Intranasal Oxytocin and Resting State fMRI in Healthy Volunteers||University Hospital Heidelberg||Completed|October 2014|||October 2015|Actual|N/A|Interventional|Primary Purpose: Basic Science|2||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02689596||2369|
NCT02689791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IowaSU|Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults|Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults||Iowa State University|No|Completed|January 2012|August 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|31|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02689791||2354|
NCT02663817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130751|DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy|DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy||University of Miami|No|Recruiting|November 2013|||May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663817||4345|
NCT02665559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPOGONADISME|Study of the Prevalence and Associated Factors With Hypogonadism in HIV + Men|Transversal Study, Prospective, to Evaluate the Prevalence and Factors Associated With Hypogonadism in HIV + Men|HYPOG|Tourcoing Hospital|Yes|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|HIV-DNA quantification on PBMCs sample|Male|18 Years|50 Years|No|Non-Probability Sample|HIV-infected men, treated by cART and presenting an undetectable viral load|January 2016|January 27, 2016|June 5, 2013||No||No||https://clinicaltrials.gov/show/NCT02665559||4211|
NCT02665572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zahran MH3182015|Outcome of Renal Transplant on a Defunctionalized Bladder|Outcome of Renal Transplant on a Defunctionalized Bladder. A Randomized Controlled Trial||Mansoura University|Yes|Recruiting|August 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02665572||4210|
NCT02665585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3PCAS|Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS)|Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS) Randomized Controlled Trial|3PCAS|University of Roma La Sapienza|Yes|Recruiting|November 2014|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|55 Years|100 Years|No|||February 2016|February 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02665585||4209|
NCT02688127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|r22wa2xt|Efficacy of Tranexamic Acid In Reducing Blood Loss During Cesarean Section Because Of Placenta Previa|Efficacy of Tranexamic Acid In Reducing Blood Loss Among Pregnant Women During Cesarean Section Because Of Placenta Previa||Medical Research Council|Yes|Completed|August 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Female|18 Years|38 Years|No|||February 2016|February 17, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688127||2482|
NCT02688140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-APOLLO-064|Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia|A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia|TUD-APOLLO-064|Technische Universität Dresden|Yes|Not yet recruiting|April 2016|January 2022|Anticipated|November 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02688140||2481|
NCT02664519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092015-005|Mechanisms of Muscle Blood Flow Dysregulation and Exercise Intolerance in Chronic Kidney Disease|Mechanisms of Muscle Blood Flow Dysregulation and Exercise Intolerance in Chronic Kidney Disease||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02664519||4291|
NCT02671994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOAT|Geriatric and Oncologic Assessment Before Treatment|Significance of Geriatric Assessment for Optimal Treatment of Older Cancer Patients|GOAT|Odense University Hospital|Yes|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|70 Years|N/A|No|||February 2016|February 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02671994||3720|
NCT02672007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMES-16-001|Methods for the Measurement of Respiratory Rate|Methods for the Measurement of Respiratory Rate||Herlev Hospital|No|Completed|January 2016|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02672007||3719|
NCT02669498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057/12|Consequences of Changing Current Standards: Endocrine Status After Routine Fallopian Tube Removal|Consequences of Changing Current Standards: Endocrine Status After Routine Fallopian Tube Removal||University Hospital Inselspital, Berne|Yes|Recruiting|November 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 30, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02669498||3912|
NCT02677350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150965|AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PEri-fistula iNjEctions (GALENE)|A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.|GALENE|University of Miami|Yes|Not yet recruiting|March 2016|||March 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677350||3310|
NCT02667392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2051-P|Biofeedback to Increase Propulsion During Walking After Stroke|Biofeedback to Increase Propulsion During Walking After Stroke||VA Office of Research and Development|No|Not yet recruiting|April 2016|July 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667392||4071|
NCT02675361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEPSTONES-ConHD|Effectiveness of a Transition Program for Adolescents With Congenital Heart Disease in the Transition to Adulthood|Effectiveness of a Transition Program to Empower Adolescents With Congenital Heart Disease in the Transition to Adulthood: the STEPSTONES Project||Göteborg University|No|Not yet recruiting|May 2016|January 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|240|||Both|16 Years|16 Years|No|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02675361||3463|
NCT02688166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00068503|Cardiac MRI Biomarker Testing (GCC 1618)|Cardiac Magnetic Resonance Imaging and Biomarker Testing for Evaluating Cardiac Injury Resulting From Radiation Therapy in Lung and Breast Cancer: A Pilot Study||University of Maryland|Yes|Not yet recruiting|April 2016|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Investigators hypothesize that CMR and biomarker examinations before and after        radiotherapy for lung and breast cancers will demonstrate evidence of cardiac strain and        dysfunction proportional to the extent of cardiac exposure during the course of radiation.        Investigators intention is to conduct a pilot study of 10 patients receiving moderate        doses of radiation exposure to the heart (5 lung cancer patients and 5 breast cancer        patients) when treated by our current institutional standards with the idea that this        could lead to a grant if early signs of cardiac injury can be measured. These patients'        treatment plans would include contours to measure dose received by multiple structures        within the heart (coronary vessels and all cardiac chambers) as well as the        heart/pericardium itself. Investigators would obtain biomarkers by bloodwork before,        during, and after radiotherapy for correlation with clinical outcomes and Cardiac MRs        obtained prior to and 1 year after completion of radiotherapy.|March 2016|March 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02688166||2479|
NCT02690493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|935.288|The Efficacy of an Acupuncture Protocol and Use of Taping in the Treatment of Spastic Upper Limb After Stroke|The Efficacy of an Acupuncture Protocol and Use of Taping in the Treatment of Spastic Upper Limb After Stroke||Federal University of Health Science of Porto Alegre|No|Completed|January 2015|December 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02690493||2301|
NCT02669316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIONAFLD|Echocardiography, Adherence to Mediterranean Diet (AMDS) and Physical Exercise in Fatty Liver|Adherence to Mediterranean Diet and Physical Exercise Profile in NAFLD: Relationship With Echocardiography Measures in Non-diabetic Subjects.|CARDIONAFLD|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|No|Completed|January 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|660|||Both|18 Years|65 Years|No|Non-Probability Sample|subjects withour acute or chronic disease checked by US imaging of the liver during        routine work-up for dietary and physical exercise counseling|March 2016|March 1, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02669316||3926|
NCT02669329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA15-005|CoolSculpting the Upper Arm Study|CoolSculpting the Upper Arm Using a Vacuum Applicator|ARM|Zeltiq Aesthetics|No|Recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 18, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02669329||3925|
NCT02663882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5479|Self-Control and Adult Cigarette Smokers|Self-Control and Adult Cigarette Smokers||Yeshiva University|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663882||4340|
NCT02666196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAA-I|A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects|A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects|DAA-I|National University Hospital, Singapore|Yes|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|18|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|December 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02666196||4163|
NCT02685410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301011336|Formative Research for an HIV Videogame for Young Black Women|Formative Research for an HIV Videogame for Young Black Women||Yale University|No|Active, not recruiting|July 2013|July 2016|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02685410||2691|
NCT02677753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0034|InterStim Implantation Rates Following Percutaneous Nerve Evaluation With Fluoroscopy Versus Without|InterStim Implantation Rates Following Percutaneous Nerve Evaluation With Fluoroscopy Versus Without||University of Louisville|No|Enrolling by invitation|August 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02677753||3279|
NCT02664155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508189|Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants|VENOUS THROMBOEMBOLISM IN RENALLY IMPAIRED PATIENTS AND DIRECT ORAL ANTICOAGULANTS: The VERDICT Study|VERDICT|Centre Hospitalier Universitaire de Saint Etienne|Yes|Not yet recruiting|June 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664155||4319|
NCT02663102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204687|Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.|Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.||GlaxoSmithKline||Not yet recruiting|November 2016|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|720|||Both|36 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects aged 3 years and above who were vaccinated with Fluarix Tetra or eligible        to receive Fluarix Tetra in Korea according to the locally approved PI.|January 2016|January 21, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663102||4400|
NCT02681107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA.CC-16-0006|APBI: 27Gy in 5 Fractions for Early Breast Cancer|Accelerated Partial Breast Irradiation Using Five Daily Fractions: A Single Arm, Phase II, Prospective Cohort Study to Examine Cosmetic Outcomes and Toxicity (The ACCEL Trial)|ACCEL|AHS Cancer Control Alberta|Yes|Not yet recruiting|May 2016|July 2020|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|274|||Female|50 Years|N/A|No|||January 2015|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681107||3022|
NCT02674165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H30298|Evaluation of Haitian American Responsible Teens|Evaluation of Haitian American Responsible Teens|HART|Boston Medical Center|No|Completed|April 2012|September 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|637|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02674165||3555|
NCT02674178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145|FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women|FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women||Cairo University|Yes|Completed|June 2012|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|235|||Female|20 Years|40 Years|No|||February 2016|February 2, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02674178||3554|
NCT02674191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jan 2016. Version 1|Posterior Segment Intrusion Using Miniplates|Evaluation of Posterior Segment Intrusion Using Miniplates in Skeletal ClassII Hyperdivergent Adolescence: A Randomized Control Trial||Cairo University|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674191||3553|
NCT02675062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M150323|Habitual Physical Activity and Sedentary Behavior Following Total Knee Arthroplasty|The Effect of Total Knee Arthroplasty on Habitual Physical Activity, Sedentary Behaviour and Health Outcomes in Patients With Osteoarthritis||University of Witwatersrand, South Africa|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|||Both|55 Years|80 Years|No|Non-Probability Sample|The study population will include all knee osteoarthritis patients receiving care at the        Charlotte Maxeke Johannesburg Academic Hospital. Patients will be recruited from the        Orthopaedic Division of the hospital. The participants for this study will be knee        osteoarthritis patients scheduled (on surgical waiting list) for a single primary total        knee arthroplasty. Knee osteoarthritis will be diagnosed based on clinical criteria as        defined by the American Rheumatism Association. The grade of knee osteoarthritis will be        graded using the Kellgren and Lawrence classification of severity.|February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02675062||3486|
NCT02663453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-PE-1-033/56|Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition|Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition: A Two-Center, Double-Blind Randomized Clinical Trial||Thammasat University|Yes|Completed|December 2013|January 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|24 Weeks|30 Weeks|No|||January 2016|January 21, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02663453||4373|
NCT02668380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-G202|An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer|An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer|AHEAD-G202|Peking Union Medical College Hospital|Yes|Recruiting|September 2015|May 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced Metastatic Gastric Cancer|January 2016|January 28, 2016|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02668380||3995|
NCT02672098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150302|Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer||Loma Linda University|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||January 2016|January 29, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672098||3712|
NCT02672111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-499|Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder|An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder||Braeburn Pharmaceuticals|No|Recruiting|November 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672111||3711|
NCT02668263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NorthTeesNHS|Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy|Randomised Clinical Trial Investigating the Use of Drains and Quilting Sutures on Seroma Formation Following Mastectomy - A Pilot Study||North Tees and Hartlepool NHS Foundation Trust|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02668263||4004|
NCT02666469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8834-D|HBOT Global Functioning After Stroke|Hyperbaric Oxygen and Focused Rehabilitation Program: A Feasibility Study in Improving Global Functioning After Stroke||University Health Network, Toronto|No|Recruiting|October 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02666469||4142|
NCT02522689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-PCNL-UMMP-02|Comparison of Ultra-mini PCNL and Micro PCNL|Comparison of Success Rates, Complication Rates and Injury to Kidneys of Ultra-mini PCNL and Micro PCNL in the Treatment of Kidney Stones||Selcuk University|No|Not yet recruiting|July 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02522689||15182|
NCT02523976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHBDH-IIT2015001|Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia||Institute of Hematology & Blood Diseases Hospital|No|Not yet recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||August 2015|August 13, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02523976||15083|
NCT02524041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308046|Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism|Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524041||15078|
NCT02668640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-776|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China||AbbVie|No|Not yet recruiting|February 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|99 Years|No|Probability Sample|Participants receiving Adalimumab with Rheumatoid Arthritis (RA) in China|January 2016|January 27, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668640||3975|
NCT02668653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC220-A-U302|Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML|A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia|QuANTUM-First|Daiichi Sankyo Inc.|Yes|Not yet recruiting|March 2016|||January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|536|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668653||3974|
NCT02675816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|Inspire® Upper Airway Stimulation System|Inspire® Upper Airway Stimulation System: Randomized Control Trial / European Post-Market Study|RCT|Inspire Medical Systems, Inc.|No|Recruiting|August 2015|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675816||3428|
NCT02675400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS_FathersToo|Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)|Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)||Seattle Children's Hospital|Yes|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02675400||3460|
NCT02663726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLSGT180116|Adapted Yoga for Inactive Older Adults|A Pilot Randomised Controlled Trial Investigating the Effects of a 10-week Yoga Intervention on Physical Function and Health-related Quality of Life in Physically-inactive Older Adults||Northumbria University|No|Recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663726||4352|
NCT02663739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-12|Zenith® TXD Post-market Surveillance in Japan|Zenith TXD Dissection Stent Graft System Usage Results Surveillance in Japan for Treating Acute Complicated Stanford Type B Aortic Dissection||Cook||Active, not recruiting|March 2015|November 2022|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Both|N/A|N/A|No|Non-Probability Sample|All patients in Japan treated with TXD at investigational sites.|January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02663739||4351|
NCT02684279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-322|Dasotraline Binge Eating Disorder Extension Study|An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder||Sunovion|Yes|Recruiting|February 2016|January 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|56 Years|No|||February 2016|February 11, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684279||2778|
NCT02673606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000496|Impact of Estrogen on Fear Extinction|The Influence of Estrogen on the Fear Extinction Network in Humans||Massachusetts General Hospital||Recruiting|January 2013|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|150|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673606||3598|
NCT02673619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201484|A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects|A Phase 2a Study to Evaluate the Clinical Effect, Pharmacokinetics, Safety and Tolerability of Topically Applied Umeclidinium in Subjects With Primary Palmar Hyperhidrosis||GlaxoSmithKline|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673619||3597|
NCT02672930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230|How Much Reliable iv Calcium for the Treatment of Hyperkalemia?|How Much Reliable iv Calcium for the Treatment of Hyperkalemia?||Haseki Training and Research Hospital|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|Blood potassium levels above 6.5 and all patients with ECG changes due hyperpotassemia        were included in the study.|January 2016|January 29, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02672930|1 Day|3649|
NCT02672787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151384|A ED-based Intervention to Improve Antihypertensive Adherence|A Randomized, ED-based Intervention to Improve Antihypertensive Adherence||Vanderbilt University|Yes|Not yet recruiting|February 2016|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|21 Years|85 Years|No|||January 2016|February 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02672787||3660|
NCT02688790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL-PK-02|Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With Known or Suspected Bacterial Infection|Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection||Durata Therapeutics Inc., an affiliate of Allergan plc|No|Not yet recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|N/A|28 Days|No|||February 2016|February 18, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688790||2431|
NCT02688972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|861.084|The Accumulative Effect of Cold Water Immersion in Football Athletes|||Universidade Federal do Rio Grande do Norte|Yes|Completed|July 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Male|17 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688972||2417|
NCT02670954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jinling37ICU|Evaluation of the Effect of Appropriate Sedation for Patients After Abdominal Surgeries : A Prospective Randomised Controlled Study|||Chinese Medical Association|No|Completed|October 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|16 Years|85 Years|No|||January 2016|January 28, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02670954||3800|
NCT02670967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIberBPMeta|Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials|Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials||St. Michael's Hospital, Toronto|No|Active, not recruiting|September 2014|||September 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy, hypertensive, hypercholesterolaemic, diabetic|August 2015|February 1, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02670967||3799|
NCT02674256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56177|The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers|The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers: A Randomized, Single-blind, Placebo-controlled Study|CRH|Universitaire Ziekenhuizen Leuven|No|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|February 3, 2016|March 25, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674256||3548|
NCT02676037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015OS06|Diagnosis of Hallux Valgus by Using a Foot Pressure Platform as an Alternative to Radiological Images|||University of Dundee||Not yet recruiting|February 2016|May 2018|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will come from an existing list of patients referred to the Foot Pressure        Analysis Clinic and will include any patients who are diagnosed with HV. They will be        recruited with the knowledge of the consultant orthopedic surgeons who are the direct care        providers for these patients. The surgeons will write to eligible participants and include        a Patient Information sheet about the project (which does not require to record data        beyond what is normally performed as part of the Foot Pressure Analysis Clinic) If the        participant is interested in taking part he/she will contact the department.|February 2016|February 2, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02676037|9 Months|3411|
NCT02684825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APUmbertoI|Detection of Silent Atrial Fibrillation aFter Ischemic StrOke|Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network)|SAFFO|Azienda Policlinico Umberto I|Yes|Recruiting|October 2015|June 2019|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|424|||Both|65 Years|N/A|No|||February 2016|February 12, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02684825||2736|
NCT02685085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM0702116|Combined Method for Induction of Labor|||Woman's Health University Hospital, Egypt|Yes|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685085||2716|
NCT02666508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0620|Trial of Toothpaste to Reduce Plaque and Inflammation|A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation||University of Illinois at Chicago|No|Recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666508||4139|
NCT02666521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204|Hypoglycaemia in People With Type 2 Diabetes in Primary Care|Study to Determine the Frequency and Associated Predictors of Hypoglycaemia in People With Type 2 Diabetes Mellitus Managed in Primary Care||University of Leicester|No|Enrolling by invitation|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|2422|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with Type 2 diabetes managed in primary care|January 2016|January 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02666521||4138|
NCT02678312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2319|Single Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure|Multicenter, Open-label, Single Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to < 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction||Novartis|Yes|Not yet recruiting|June 2016|September 2020|Anticipated|September 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|360|||Both|1 Month|17 Years|No|||February 2016|February 4, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678312||3236|
NCT02662829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN7358|Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)|Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)||Columbia University|No|Active, not recruiting|December 2015|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1160|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02662829||4421|
NCT02681848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/49/94|What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?|||University of Bristol|Yes|Active, not recruiting|July 2015|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180000|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators will use the CPRD to conduct a cohort study of all patients prescribed        varenicline or nicotine replacement products. The study type is "Hypothesis testing".        Exposure will be defined as the first prescription of either varenicline or nicotine        replacement therapy.        Setting/Context:        Prescriptions of smoking cessation medications issued in primary care.        Target population:        All smokers aged over 18 prescribed smoking cessation treatment in eligible primary care        centres contributing to the CPRD after the 1st of September 2006.        Sampling method:        The investigators will sample all individuals prescribed smoking cessation medication at        any point after 1st of September 2006 to the most recent release of the CPRD data.        Study population:        The investigators will use patients prescribed other smoking cessation products such as        nicotine patches as controls for patients prescribed varenicline.|February 2016|February 11, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02681848||2965|
NCT02667015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126253|Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity|Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity|SUD/Anx|Hartford Hospital|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 5, 2014||No||No||https://clinicaltrials.gov/show/NCT02667015||4100|
NCT02678325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-00041|The Basel Enteral High Protein Study|Tolerance of Early High Protein Nutrition of the Critically Ill: Comparison of a Protein-rich Enteral Formula With a Standardized High Carbohydrate Product on Total Calorie and Protein Intake||University Hospital, Basel, Switzerland|No|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678325||3235|
NCT02678338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0038|CAMELLIA: Anti-CD47 Antibody Therapy in Relapsed/Refractory Acute Myeloid Leukaemia|A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia (CAMELLIA)||Stanford University|Yes|Recruiting|November 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678338||3234|
NCT02676167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0327|Public Health Targeting of PrEP at HIV Positives' Bridging Networks|Public Health Targeting of PrEP at HIV Positives' Bridging Networks|SOPHOCLES|University of Chicago|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|250|||Male|18 Years|39 Years|No|||February 2016|February 3, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02676167||3401|
NCT02676180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0883|Detecting Bladder Cancer Using the UroMark Test.|A Prospective Observational Study to Determine the Negative Predictive Value of UroMark to Rule Out the Presence of Bladder Cancer in Patients With Haematuria.|DETECT I|University College, London|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|889|Samples With DNA|Urine will be collected for analysis using UroMark assay.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with visible and non-visible haematuria (blood in urine) will be enrolled. About        10% of cases with haematuria will be found to have bladder cancer. For the majority of        cases (60.5%), no cause is found. Other causes include stone disease (3.6%), benign        prostate conditions (20-30%), renal disease (9.8%) infection (13%) and renal/prostate        cancer (1%). The DETECT I study will determine if the UroMark test can be used to rule out        bladder cancer in cases referred for investigation of haematuria.|December 2015|February 3, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02676180|1 Month|3400|
NCT02688439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01327|Ultrasound Guided Sciatic Nerve Block|Effect of Leg Positioning and Tourniquet Inflation on Onset and Duration of Ultrasound Guided Sciatic Nerve Block After Injection of Local Anesthetic||New York University School of Medicine|No|Recruiting|March 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|81|||Both|21 Years|70 Years|No|||February 2016|February 24, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02688439||2458|
NCT02667301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETDA-1|Eustachian Tube Dysfunction Assessment|Investigation of Activities of Paratubal Muscles for Opening Eustachian Tube as Assessed by Simultaneous Electromyography and Tubomanometric Observations|ETDA|Stratejik Yenilikci Girisimler Ltd.|No|Completed|January 2014|January 2016|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02667301||4078|
NCT02670291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL 525/4-1|Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation|Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation||University Hospital Tuebingen|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|55 Years|No|||January 2016|February 1, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02670291||3851|
NCT02667769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZBL-2014-2|Comparison of Two Protocols on the Implementation of a Fasting Day in Type 1 Diabetes|Comparison of Two Protocols on the Implementation of a Fasting Day to Check the Basal Insulin Replacement in Type 1 Diabetes: Complete Fasting Compared to the Permission for Carbohydrate- and Calorie-free Food||Diabeteszentrum Bad Lauterberg im Harz|No|Active, not recruiting|August 2014|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|N/A|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667769||4042|
NCT02668029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalkO2|Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis|Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis Normoxemic at Rest Who Desaturate on Exercise||University of Siena|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|85 Years|No|||January 2016|January 28, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668029||4022|
NCT02687230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-0815-CP-001.01|Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1|Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies||MabVax Therapeutics, Inc.|Yes|Not yet recruiting|April 2016|June 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687230||2551|
NCT02663531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-180515|Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease|Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease||Medical University of Vienna|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02663531||4367|
NCT02663544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI2395|The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)|The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)||Fred Hutchinson Cancer Research Center|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|72|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663544||4366|
NCT02670811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAGB 001|Antihypertensive Effect of Fermented Milk With Lactococcus Lactis on Prehypertensive Subjects|Randomized Double-blind Controlled Clinical Study of the Antihypertensive Effect of Fermented Milk With Lactococcus Lactis NRRL-B50571||Centro de Investigación en Alimentación y Desarrollo A.C.||Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|25 Years|55 Years|No|||February 2016|February 2, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02670811||3811|
NCT02670824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-105-01|Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage|Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects||CereNova, LLC|Yes|Recruiting|December 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670824||3810|
NCT02665169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5203083|Kuopio Fall Prevention Study.|Randomized Fall Prevention Trial For Aging Females by Providing Supervised Exercises and Free Use of Municipal Recreation Facilities.|KFPS|Kuopio University Hospital|No|Not yet recruiting|March 2016|October 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1078|||Female|75 Years|84 Years|No|||January 2016|January 22, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02665169||4241|
NCT02666014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHF/FG581S/2013|Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery|Comparison of Sugammadex Versus Neostigmine in Women at High Risk of Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery: A Randomized Controlled Trial||KK Women's and Children's Hospital|Yes|Recruiting|June 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Female|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02666014||4177|
NCT02669966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500543|Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR|Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR||University of Florida|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669966||3876|
NCT02674724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Department of Neurology|The Effect of Resistance Training in Parkinson Disease: A Pilot Study|The Effect of Resistance Training on Balance in Patients With Parkinson Disease: A Pilot Study||University of Sao Paulo General Hospital|Yes|Recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|63|||Both|50 Years|75 Years|No|||January 2016|February 5, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02674724||3512|
NCT02665442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511016760|Retracting the Esophagus During AF Ablation|Esophageal Stylet as a Strategy to Minimize the Risk of Esophageal Injury During the Atrial Fibrillation Catheter Ablation Procedure.|EsoSure|Northeast Scientific, Inc.|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 23, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02665442||4220|
NCT02679261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BICATOR|Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve|Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)|BICATOR|Hospital Universitari Vall d'Hebron Research Institute|No|Not yet recruiting|February 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02679261||3163|
NCT02674204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-12-Goodman-STOP|STOP Heart Disease in Breast Cancer Survivors Trial|Statin Therapy Operates to Prevent (STOP) Heart Disease in Breast Cancer Survivors Trial|STOP|Cedars-Sinai Medical Center|Yes|Recruiting|February 2016|October 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674204||3552|
NCT02674217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentroHMI|Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells|Outpatient Hematopoietic Grafting in Patients With Multiple Sclerosis Employing Autologous Non-cryopreserved Peripheral Blood Stem Cells: A Feasibility Study||Centro de Hematología y Medicina Interna|Yes|Enrolling by invitation|May 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||February 2016|February 2, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02674217||3551|
NCT02667158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 4B|A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion||Member Companies of the Opioid PMR Consortium||Enrolling by invitation||||December 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||4|Anticipated|842|||Both|18 Years|N/A||Probability Sample|Patients (18 years of age or older) identified from the HealthCore Integrated Research        Database (HIRD) with at least two pharmacy claims for any IR or ER/LA opioid analgesic in        the most recent 18 months of claims data|November 2015|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667158||4089|
NCT02673242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E16260|Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disorder|||Sykehuset Innlandet HF||Recruiting|November 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673242||3626|
NCT02679222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-541|Comparing the Ketogenic Effect of Coconut Oil and Different MCTs|Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides|Coco-MCT|Université de Sherbrooke|No|Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 5, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679222||3166|
NCT02683395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX122-01|A Study of PLX51107 in Advanced Malignancies|A Phase 1b Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Malignancies||Plexxikon|No|Recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683395||2846|
NCT02668120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_18|Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic||IHC|University Hospital, Lille|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|54|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient pregnant following at the Lille University Hospital. The case group will be        composed of patients who experienced chronic histiocytic intervillositis. Two control        groups will be prospectively: The first will include patients whose pregnancy is low risk.        The second will consist of pathological pregnancies (IUGR, Preeclampsia and Death In        Utero).|January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668120||4015|
NCT02670785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVC-MD-01|A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy|A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate Safety and Efficacy of Three Doses of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy||Warner Chilcott|No|Recruiting|February 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Female|35 Years|N/A|No|||March 2016|March 3, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670785||3813|
NCT02675660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Homoarginine-UKE-KP2012-01|Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects|Study to Evaluate the Safety, Tolerability, Kinetics, and Dynamics of Single and Multiple Doses of an Oral Formulation of L-Homoarginine||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2014|January 2016|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02675660||3440|
NCT02675686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 138 01|Amniotic Biomarkers in the Prediction of Postpartum Renal Function.|Amniotic Biomarkers Research for Prediction of Postnatal Renal Function in Fetus With a Bilateral Abnormal Renal Development: National, Multicenter, Prospective and Non-interventional Study of Diagnostic Validation.|BIOMAN|University Hospital, Toulouse|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|358|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02675686||3438|
NCT02680249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP656.1003|Food Effect Study of CTP-656 in Healthy Male Volunteers|A Phase 1 Single Center, Open-Label, Randomized, Three-Way Crossover Study of the Relative Bioavailability of a Single Dose of CTP-656 in a Fasted, Fed Low-Fat and Fed Moderate-Fat Condition in Healthy Male Subjects||Concert Pharmaceuticals|No|Recruiting|February 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02680249||3088|
NCT02668705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA158219-CA|Agent-Enhanced Document Explanation|Research Ethics and Safety Promoted by Embodied Conversational Technology||Boston Medical Center|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|524|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668705||3970|
NCT02668718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-FINROG-0301|Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer|Adjuvant Radiation Therapy vs. Watchful Waiting in Prostate Cancer Patients With Positive Margins or Capsular Penetration After Radical Prostatectomy||Helsinki University Central Hospital|No|Active, not recruiting|March 2004|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Male|N/A|N/A|No|||February 2016|February 1, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668718||3969|
NCT02677649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2870|Microbiota Diversity and Composition and Polyphenol Bioavailability|Microbiota Diversity and Composition and Polyphenol Bioavailability: a Controlled Feeding Trial With a Plant Free Diet Containing Whole Cranberry Powder||Tufts University|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02677649||3287|
NCT02683681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009557|HF Tissue Registry|Heart Failure Intraoperative Tissue Sample Acquisition Registry||Intermountain Health Care, Inc.|No|Enrolling by invitation|June 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|-  Tissue samples will be obtained at the time of LVAD implantation by keeping the part of           the left ventricular apex that the surgeon is removing in order to place the inflow           cannula of the LVAD. No extra tissue sample other than the tissue that has to be           removed as a part of a standard LVAD operation needs to be obtained.        -  Tissue samples will be acquired from the failing heart at the time of heart           transplantation, after it has been excised and a donor heart has been implanted in its           place.        -  Control tissue samples will be acquired intraoperatively during cardiac surgery wherein           any amount of excised tissue is routinely discarded.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are seen at participating facilities for left ventricular assist device        (LVAD) implantation and/or heart transplantation will be screened for this registry study.|January 2016|February 11, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683681|50 Years|2824|
NCT02683694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOC|Characteristics and Limitations of Intraoperative OCT Supported Membrane Peeling in Macular Diseases|Characteristics and Limitations of Intraoperative OCT Supported Membrane Peeling in Macular Diseases||Vienna Institute for Research in Ocular Surgery|Yes|Recruiting|February 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|21 Years|N/A|No|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02683694||2823|
NCT02664792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACOG 0114|Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer|Use of [18]F-FDG - PET/CT in Brazil Unified Health System (SUS) as an Alternative Non-invasive Method for Staging of Lung Cancer||Latin American Cooperative Oncology Group|No|Recruiting|August 2014|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2014|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664792||4270|
NCT02672137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_L_04201|Knowledge Translation for Patients With Acute Coronary Syndromes|Knowledge Translation to Promote Evidence-based Medical Therapy in Acute Coronary Syndromes|AMI-OPTIMA|Montreal General Hospital|No|Completed|January 2010|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4604|||Both|N/A|N/A|No|||January 2016|February 2, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02672137||3709|
NCT02672306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-1|Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease|Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease|SEESUPAD|South China Research Center for Stem Cell and Regenerative Medicine|Yes|Not yet recruiting|May 2016|October 2019|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|85 Years|No|||January 2016|January 29, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02672306||3696|
NCT02676700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2013-125|Pelvic Floor Muscle Training and Kaatsu Training for Women With Stress Urinary Incontinence|The Effect of Pelvic Floor Muscle Training With or Without Kaatsu Training for Women With Stress Urinary Incontinence||Herlev Hospital|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02676700||3360|
NCT02683993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-SBU-VP-15-01|Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings|Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings||Lumenis Ltd.||Not yet recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683993||2800|
NCT02684006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991003|A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)|A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (MSB0010718C) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma||Pfizer|Yes|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|583|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684006||2799|
NCT02672670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20151219002|Effects of a Coping-oriented Supportive Programme (COSP) for People With Spinal Cord Injury During Inpatient Rehabilitation|||The Hong Kong Polytechnic University|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 30, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02672670||3669|
NCT02667418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|596|Optimal Treatment for Recurrent Clostridium Difficile|CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection|OpTION|VA Office of Research and Development|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|546|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667418||4069|
NCT02667990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47798|Maximal Plantar Pressure and Comfort Evaluation of Orthopedic Stilettos|Maximal Plantar Pressure and Comfort Evaluation During Normal Every Day Use of an "Orthopedic" Stiletto, a Normal Stiletto and a Control Trainer Shoe||Copenhagen University Hospital, Hvidovre|Yes|Completed|August 2015|January 2016|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Female|18 Years|67 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02667990||4025|
NCT02671084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090106/2015|Sevoflurane and Percutaneous Coronary Intervention by Stent|Use of Sevoflurane in Patients Submitted a Percutaneous Coronary Intervention by Stent||Instituto Dante Pazzanese de Cardiologia|Yes|Recruiting|February 2016|February 2019|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1254|||Both|N/A|80 Years|No|||January 2016|March 13, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671084||3790|
NCT02685683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GED-0301-CD-005|Pharmacodynamic Study of Mongersen in Patients With Crohn's Disease|A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease||Celgene|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685683||2670|
NCT02665546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4275/15/102|Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis|Evaluation of Exercise Capacity and Mechanisms of Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis||InCor Heart Institute|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with diagnosis of pulmonary Langerhans cell histiocytosis and current or ex        smokers followed at the outpatient clinic of the Pulmonary Division of the Hospital das        Clinicas of the University of Sao Paulo|January 2016|January 26, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02665546||4212|
NCT02667197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 3A|Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose in Databases Used for PMR Study 1B|Study to Validate Coded Medical Terminologies Used to Identify Opioid-Related Overdose in the Postmarketing Databases Employed in PMR Study 1B||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|800000|||Both|N/A|N/A|No|Probability Sample|Members of the KPNW integrated healthcare system located in Oregon and Washington        prescribed opioid analgesics.|January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02667197||4086|
NCT02667496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT14019|Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease|A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease||Sanofi|Yes|Recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||March 2016|March 23, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667496||4063|
NCT02676336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16VBHB|A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness|||BioPharmX, Inc.||Recruiting|February 2016|||January 2017|Anticipated|Phase 4|Interventional|N/A|3||||||Female|18 Years|N/A||||February 2016|February 5, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676336||3388|
NCT02681861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6294-CL-0001|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects|A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects||Astellas Pharma Inc|Yes|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02681861||2964|
NCT02661659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1519|A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy|A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy||University of Chicago|No|Not yet recruiting|February 2016|||February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661659||4511|
NCT02664389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/160/HP|Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation|Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation|PANEL|University Hospital, Rouen|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|120|||Both|N/A|N/A|No|||January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664389||4301|
NCT02667509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2016-China2|The Evolutionary Model of Mild-to-moderate Myopia in China|The Evolutionary Model of Mild-to-moderate Myopia in China||Sun Yat-sen University|Yes|Completed|January 2005|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|852441|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects from all the province of China who undergoing the examination of Refractive error        from 2005 to 2015 year.|January 2016|January 26, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02667509||4062|
NCT02677064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-024|Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia|Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|75 Years|No|Non-Probability Sample|All patients with acute leukemia (AML or ALL) who are admitted to the Leukemia Service for        induction or re-induction therapy.|February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02677064||3332|
NCT02677103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120801R|Comparison of the Effect of Radial Shock Wave, Ultrasound-guided Needle Puncture, and Combination of Both in the Treatment of Calcific Tendinitis of the Shoulder|Comparison of the Effect of Radial Shock Wave, Ultrasound-guided Needle Puncture, and Combination of Both in the Treatment of Calcific Tendinitis of the Shoulder||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|April 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|20 Years|75 Years|No|||March 2016|March 24, 2016|September 2, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677103||3329|
NCT02675699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG.AUHE.102510|The Optimising Family Engagement in HENRY (OFTEN) Study|Effectiveness of an Implementation Optimisation Intervention Aimed at Increasing Parent Engagement in HENRY, a Childhood Obesity Prevention Programme: a Cluster Randomised Controlled Trial|OFTEN|University of Leeds|No|Recruiting|October 2015|August 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|864|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675699||3437|
NCT02675764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO42759|Sensory Stimulation to Enhance Hand Function Post Stroke|Sensory Stimulation to Enhance Hand Function Post Stroke||Medical University of South Carolina|No|Recruiting|January 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02675764||3432|
NCT02676726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/1817|STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer|STELLA 2 Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes, Evaluating Complications|STELLA-2|Hospital Universitari Vall d'Hebron Research Institute|Yes|Recruiting|July 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Female|18 Years|85 Years|No|||February 2016|February 3, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02676726||3358|
NCT02670915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-4101|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes|onset®7|Novo Nordisk A/S|No|Not yet recruiting|May 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|833|||Both|1 Year|17 Years|No|||March 2016|March 10, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670915||3803|
NCT02527278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18477|Retrospective Claims Analysis of Hysterectomy After Sterilization|A Retrospective Claims Analysis to Calculate the Proportion of Women Undergoing Hysterectomy, Salpingectomy, Salpingostomy, Hysteroscopy or Who Had a Diagnosis of Pelvic Pain After Hysteroscopic Sterilization or Laparoscopic Tubal Ligation||Bayer|No|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|19317|||Female|18 Years|49 Years|No|Non-Probability Sample|Women aged 18 - 49 at the time of the sterilization procedure from an administrative        claims database|October 2015|October 13, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527278||14829|
NCT02514811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Philliber10-15ppgnw|Replication of the Teen Outreach Program in the Pacific Northwest|Northwest Coalition for Adolescent Health (NWCAH) Teen Outreach Program Replication Study||Philliber Research & Evaluation|No|Active, not recruiting|September 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8686|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2015|August 3, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02514811||15787|
NCT02514824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-223|MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma|MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Recruiting|October 2015|July 2020|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514824||15786|
NCT02519322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0041|Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma|Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma||M.D. Anderson Cancer Center|Yes|Recruiting|February 2016|||February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519322||15441|
NCT02672631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENMG and MRI on Median Nerve|Evaluation of Complete Median Nerve Transection With Clinical, Electroneuromyographic and Diffusion Tensor Imaging|Evaluation of Primary Repaired Wrist Level Complete Median Nerve Transection With Clinical, Electroneuromyographic (ENMG) and Diffusion Tensor Imaging (DTI) Methods||TC Erciyes University|No|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|40 Years|No|Non-Probability Sample|Ten patients who were operated for median nerve injuries in 2014 will be enrolled. In the        sample, correlations between Tinnel Test, motor strength assessment (Medical Research        Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW)        monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test, EMG with the        DTI results will be assessed.|January 2016|January 29, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02672631||3672|
NCT02663596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 1510004004|Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution|A Prospective, Open-Label Study of the Safety and Therapeutic Drug Monitoring of Continuous Infusion Vancomycin Through the Addition of the Vancomycin Into the Continuous Renal Replacement Therapy Solution||Drexel University|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2016|January 25, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663596||4362|
NCT02664896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1188|Pain Phenotypes in Knee Osteoarthritis|Determination of Pain Phenotypes in Older Adults With Knee Osteoarthritis||University of Colorado, Denver|No|Recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|240|None Retained|1mL of whole blood will be taken for analysis of inflammatory factors including IL-1beta,      IL-6, IL-8, TNF, and C-Reactive Protein. Samples will be stored at University of Colorado      Hospital until analysis is complete. Samples will then be destroyed.|Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subject population will include 50-85 year olds who experience knee pain and have        been diagnosed with knee osteoarthritis by a physician. Additionally, a healthy control        cohort will be recruited. This cohort will also be 50-85 years old but will deny having        any pain and will not be diagnosed with knee osteoarthritis.|January 2016|January 22, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02664896||4262|
NCT02684292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-204|Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)|A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma||Merck Sharp & Dohme Corp.|Yes|Not yet recruiting|March 2016|August 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|February 12, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684292||2777|
NCT02684539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF1|Autonomous Syncope Onset Prediction and Prevention|Autonomous Syncope Onset Prediction and Prevention An Open-label, One-centre Pilot Study on Healthy Subjects With the Erigo Tilt Table||Swiss Federal Institute of Technology|No|Withdrawn|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 27, 2015|Yes|Yes|project weill not be realized for organisational reasons|No||https://clinicaltrials.gov/show/NCT02684539||2758|
NCT02662218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1348|Observational Study of Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound Dressing|Prospective, Multicenter, Observational Study to Evaluate the Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound Dressing||BSN Medical GmbH|No|Not yet recruiting|March 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with superficial wounds of any etiology, that are treated at outpatients' clinic|January 2016|January 22, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02662218||4468|
NCT02678260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDR001X1101|Phase I Study of PDR001 in Patients With Advanced Malignancies.|A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies||Novartis|No|Not yet recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02678260||3240|
NCT02678273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH_OIC_ICOC Version 1.0|Developing an Integrated Community of Care in Singapore|Developing an Integrated Community of Care for a Socioeconomically Disadvantaged Population in Singapore||Singapore General Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|60 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678273||3239|
NCT02678286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-15-015|Evaluation of N1539 Following Abdominoplasty Surgery|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery||Recro Pharma, Inc.|No|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678286||3238|
NCT02675946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGX1321-101|Study of CGX1321 in Subjects With Advanced Solid Tumors|A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors||Curegenix Inc.|No|Recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675946||3418|
NCT02675959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC 571|Myeloablative Conditioning and Haplo AlloSCT for Patients With Sickle Cell Disease|Safety and Efficacy of Prophylactic Defibrotide in Patients With Sickle Cell Disease Following Myeloablative Conditioning and Haploidentical Stem Cell Transplantation|NYMC-571|New York Medical College|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|2 Years|34 Years|No|||February 2016|February 2, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675959||3417|
NCT02673697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPS003|Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement|Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease|PERSIST-AVR|LivaNova|Yes|Not yet recruiting|February 2016|January 2023|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1234|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02673697||3591|
NCT02664870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066468|Evaluation of Biomarkers in Human Synovial Fluid|Prospective Biological and Clinical Databank for the Evaluation of Biomarkers in Human Synovial Fluid||Duke University|No|Not yet recruiting|January 2016|January 2026|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|Biospecimen retention would include the collection and storage of synovial fluid samples      from the hip, shoulder, and knee.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited at the Sports Medicine and Adult Reconstruction Clinics at Duke        University Medical Center.|January 2016|January 22, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02664870||4264|
NCT02663687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP623-100|Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects||Shire|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02663687||4355|
NCT02685930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509075|Pneumonia in the Intensive Care Unit (ICU) Setting|Pneumonia in the Intensive Care Unit (ICU) Setting||Washington University School of Medicine|No|Recruiting|January 2016|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Microbiological: tracheal aspirate, bronchialalveolar lavage, blood cultures, viral PCR      multiplex from respiratory specimen Bronchialalveolar lavage: Cell count and differential|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the 8300 and 8400 medical intensive care units at Barnes-Jewish Hospital with        respiratory failure from pneumonia requiring invasive mechanical ventilation.|February 2016|February 18, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02685930||2651|
NCT02670980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP1|Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy|Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy|IRIS 2|Pixium Vision SA|No|Recruiting|January 2016|April 2022|Anticipated|April 2022|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|N/A|No|||March 2016|March 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02670980||3798|
NCT02665338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032649|TMS-fMRI for Neural Pathway in Smokers|Repetitive TMS Modulates Dorsal Lateral Prefrontal-Ventral Medial Prefrontal Pathway to Decrease Craving in Smokers||Medical University of South Carolina||Recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02665338||4228|
NCT02667171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12910 01-01-01|COPD Online Rehabilitation (CORe)|COPD Online Rehabilitation (CORe) - a Randomized, Multicenter Telemedicine Intervention Study|CORe|University Hospital Bispebjerg and Frederiksberg|Yes|Recruiting|March 2016|December 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02667171||4088|
NCT02686437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR06|Tension of THERABAND® Kinesiology Tape on Shoulder Pain|Tension of THERABAND® Kinesiology Tape on Shoulder Pain|ShoulderTBKT|Sport and Spine Rehab Clinical Research Foundation|No|Recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686437||2612|
NCT02671435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419NC00001|A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors|A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects With Select Advanced Solid Tumors||MedImmune LLC|No|Not yet recruiting|February 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|208|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671435||3763|
NCT02661724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054201|Take Charge of Burn Pain|Take Charge of Burn Pain: A Randomized Controlled Trial of a Web-based Self-Management Intervention to Improve Burn Pain Outcomes||Johns Hopkins University|Yes|Recruiting|April 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661724||4506|
NCT02664207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0795|Extended Criteria For Fetal Myelomeningocele Repair|Extended Criteria For Fetal Myelomeningocele Repair: A Pilot Study||The University of Texas Health Science Center, Houston|Yes|Recruiting|December 2015|||January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|16 Years|45 Years|No|||January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664207||4315|
NCT02686203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD-IP-101|Evaluate the Effectiveness of Low Level Laser Therapy (LLT) Combined With Acupuncture|A Feasibility Study to Evaluate the Effectiveness of Low Level Laser Therapy Combined With Acupuncture as Palliative Treatment of Patients With Various Solid Malignancies Who Are no Longer Candidates for Active Oncological Therapies||Erika Carmel ltd|No|Not yet recruiting|March 2016|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02686203||2630|
NCT02671656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC1501|Study of the Reliability of a Device (HumanSens Plus) Allowing Immediate Measurement Uric Acid in the Blood Obtained by Finger Tip Puncture.|Reliability Assessment of the HumaSens Plus Measurement of Uricemia in Capillary Blood|URICA|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Diabetes|January 2016|January 29, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671656||3746|
NCT02678351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0075|68Ga-PSMA PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery|68Ga-PSMA PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer||Stanford University|Yes|Not yet recruiting|March 2016|||February 2021|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Male|18 Years|N/A|No|||February 2016|February 4, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678351||3233|
NCT02674984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0751|Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder|Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|November 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674984||3492|
NCT02689804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP1857|EC PK in Women With Normal and Obese BMI|Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index||Columbia University|Yes|Enrolling by invitation|July 2015|June 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02689804||2353|
NCT02667626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140863|Reproductive Health Survivorship Care Plan|Intervening on Reproductive Health in Young Breast Cancer Survivors|SCPR|University of California, San Diego|No|Recruiting|November 2015|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Female|18 Years|45 Years|No|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667626||4053|
NCT02674659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUHK-2016|The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 Level After Coronary Bypass Surgery|The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 (PCSK-9) Level in Patients After Coronary Bypass Surgery||National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Not yet recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|70 Years|No|||February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674659||3517|
NCT02662309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010463QM|Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder|A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)|ABACUS|Queen Mary University of London|Yes|Recruiting|February 2016|March 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02662309||4461|
NCT02669524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15007312|Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes|Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes - the Role of Glucagon||University Hospital, Gentofte, Copenhagen|No|Enrolling by invitation|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|12||Anticipated|20|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||December 2015|January 27, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02669524||3910|
NCT02670707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37718 TXCH LCH0115|Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)|Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)||Baylor College of Medicine|Yes|Not yet recruiting|January 2016|||January 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|N/A|21 Years|No|||January 2016|January 28, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670707||3819|
NCT02673801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63 00001|Optimized Referral of Knee Patients to the Orthopedic Outpatient Clinic|OPtimeret Kirurgisk Visitation af Knæartrose Patienter (OPKVIK)||Central Jutland Regional Hospital|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|226|||Both|18 Years|N/A|No|Probability Sample|Patients with a new referral to the orthopedic outpatient clinic with suspected knee        osteoarthritis|August 2015|February 3, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02673801||3583|
NCT02674022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006909|Screening for Metabolic Problems in Mothers of Children With Autism and Typically Developing Children|Screening for Metabolic Problems in Women, and Possible Treatment With Vitamin/Mineral Supplement||Mayo Clinic|No|Not yet recruiting|February 2016|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674022||3566|
NCT02662543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224/T-3|The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines|The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children Aged < 18 Years After Introduction of Rotavirus Vaccines|ERVS|University of Tartu|Yes|Recruiting|February 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Fecal samples|Both|N/A|18 Years|No|Non-Probability Sample|All children less than 18-years-old hospitalized due to acute gastroenteritis to seven        Estonian hospitals participating in this study from 02.2015-09.2016|January 2016|January 20, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662543||4443|
NCT02669810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2014-001476-63|EXpanded CELL ENdocardiac Transplantation (EXCELLENT)|A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand® Automated Process, and Injected in Patients With an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% After PTCA and Stent(s) Implantation Versus Standard of Care.|EXCELLENT|CellProthera|Yes|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|75 Years|No|||February 2016|March 15, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669810||3888|
NCT02669823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALUBAC|Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region||PALUBAC|Sysmex Europe GmbH||Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|1250|||Both|3 Months|N/A|No|Non-Probability Sample|Patients referred to Clinical research Unit Nanaro with suspicion of infectious disease|January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02669823||3887|
NCT02670941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB57258|Aromatherapy for Chemotherapy-induced Symptoms|Aromatherapy for Management of Chemotherapy-induced Symptoms||University of Rochester|Yes|Recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|21 Years|89 Years|No|||February 2016|February 1, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670941||3801|
NCT02661672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 16-0028|INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo in Patients With Brain Hemorrhage|INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo in Patients With Brain Hemorrhage: A Prospective Multicenter Registry||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|22 Years|N/A|No|||January 2016|January 20, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661672||4510|
NCT02661685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKDC-001|Safety Study of Adoptive Transfer of Autologous IKDC-like Cells|An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial||National Defense Medical Center, Taiwan|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|21 Years|75 Years|No|||January 2016|January 19, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661685||4509|
NCT02661698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44N2|Plasma Diurnal Variation in and Absorption of EPA and DHA|Diurnal Variation of Plasma Concentration of EPA and DHA and Absorption of Doses Taken at Hora Somni||Northumbria University|No|Not yet recruiting|February 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|24|||Both|25 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02661698||4508|
NCT02674633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akili-001R|Software Therapy for Actively Reducing Severity of ADHD|A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)|STARS-ADHD|Akili Interactive Labs, Inc.|No|Not yet recruiting|March 2016|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|8 Years|12 Years|No|||February 2016|February 11, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674633||3519|
NCT02683408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVR-02|Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon|Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon||Primus Pharmaceuticals|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02683408||2845|
NCT02683421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV3-23|Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging|Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging||Navidea Biopharmaceuticals|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|18|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683421||2844|
NCT02683434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA15/386|Effects of Kinesio Taping on Postural Stability in Young Soccer Players|Effects of Kinesio Taping on Postural Stability in Young Soccer Players||Baskent University|No|Recruiting|January 2016|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|62|||Male|12 Years|16 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02683434||2843|
NCT02668133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1420|Zinc Absorption From SQ-LNS With and Without Phytase|Efficacy of Exogenous Phytase Added to Small Quantity Lipid Nutrient Supplements (SQ-LNS) on the Fractional and Total Absorption of Zinc Among Young Children in the Gambia: A Double-blind Randomized Controlled Trial With a Cross-over Design||Medical Research Council Unit, The Gambia|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|18 Months|23 Months|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02668133||4014|
NCT02668146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042|An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor|A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor||VA Greater Los Angeles Healthcare System|Yes|Recruiting|October 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668146||4013|
NCT02676076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AB1-03|TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA|A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 100/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN PATIENTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG ACTING ß2 AGONISTS|TRIMARAN|Chiesi Farmaceutici S.p.A.|Yes|Not yet recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1148|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676076||3408|
NCT02662504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_01|Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma|Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma|MesoPDT|University Hospital, Lille|Yes|Recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662504||4446|
NCT02664415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 397|Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|50 Years|No|||March 2016|March 8, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664415||4299|
NCT02681393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA Maintenance in Stroke|Physical Activity Maintenance in Stroke|The Effectiveness of an Educational Brochure on Exercise and a Motivational Telephone Support in Physical Activity Maintenance for Stroke Survivors||McMaster University|No|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02681393||3000|
NCT02681406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819881|Smartphone Based Continuing Care for Alcohol|Impact of Enhancements to Smartphone Based Continuing Care for Alcohol Dependence||University of Pennsylvania|No|Recruiting|September 2014|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681406||2999|
NCT02672241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sanghaixinhua-002|Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children|Phase 2 Study of Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|February 2013|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Years|12 Years|No|||January 2016|February 2, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02672241||3701|
NCT02663349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4612-A|Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness|Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness||Minneapolis Veterans Affairs Medical Center|No|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663349||4381|
NCT02663362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMD FH 306624|Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications|Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications|MRS VALIDATION|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Recruiting|February 2012|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|12 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|A healthy individual, who is willing and able to undergo MR imaging and spectroscopy for        up to two hours at a time|January 2016|January 20, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02663362||4380|
NCT02675283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH19172|Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting|Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting: A Feasibility Study||Sheffield Teaching Hospitals NHS Foundation Trust|No|Not yet recruiting|February 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02675283||3469|
NCT02669030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVX-IIT2016-001|A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia|A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia||Institute for Advanced Medical Research, Alpharetta, GA|No|Not yet recruiting|February 2016|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669030||3947|
NCT02677155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lymvac-2|Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma|Open Label, Phase II, Study: Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Patients With Stage III/IV Untreated and Relapsed Follicular Lymphoma|Lymvac-2|Oslo University Hospital|Yes|Recruiting|January 2016|January 2024|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677155||3325|
NCT02665962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09815|Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer|Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|||Anticipated|20|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02665962||4181|
NCT02684331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-490|CMR in Type 2 Diabetes Mellitus Patients|Cardiac Magnetic Resonance Imaging in Type 2 Diabetes Mellitus: The Mechanisms of Cardiac Function and Perfusion Dysfunction||Slagelse Hospital|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|EDTA-plasma Heparin-plasma Serum urine|Both|18 Years|80 Years|No|Non-Probability Sample|300 T2DM patients, with or without known cardiovascular disease, will be recruited from        the diabetes outpatient clinic, Slagelse Hospital.        The patients will be divided into groups depending on their diabetes complication status.        Individual groups of patients with fx. +/- retinopathy, +/- autonomous neuropathy, +/-        hypertension, normo-/mikro-/makroalbuminuria will be compared.|February 2016|February 24, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02684331||2774|
NCT02677727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0502|Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor|A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor||Indiana University|No|Recruiting|December 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|DNA to use for future planned evaluations to predict patients at higher risks of developing      neuropathy|Male|15 Years|N/A|No|Non-Probability Sample|Patients who are beign treated with cisplatin-based chemotherapy for testicular germ cell        tumor|February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02677727||3281|
NCT02674438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Comparison of Outcomes and Access to Care for Heart Failure Trial|Comparison of Outcomes and Access to Care for Heart Failure Trial|COACH|Institute for Clinical Evaluative Sciences|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674438||3534|
NCT02676817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00990-47|Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis|Probe-based Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Score|ENHANCE|European Georges Pompidou Hospital|Yes|Recruiting|April 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Colonic biopsies wre taken during colonoscopy in order to assess the histological      inflammation and to correlate the result with pCLE description.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with UC who need control coloscopy|February 2016|February 3, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02676817||3351|
NCT02692651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck Fidaxo|A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections|A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections||Kaye, Keith, M.D., M.P.H.|No|Not yet recruiting|April 2016|April 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692651||2136|
NCT02669953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHTH-010915 (Ex-Oct)|Aflibercept in Recurrent or Persistent CNV|Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration|OPHTH-010915|Medical University of Vienna||Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|50 Years|N/A|No|Non-Probability Sample|20 Patients with nAMD|January 2016|January 27, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02669953||3877|
NCT02675634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP266|Investigation of Two New 1-piece Ostomy Products in People With an Ileostomy or Colostomy|Investigation of Two New 1-piece Ostomy Products in People With an Ileostomy or Colostomy||Coloplast A/S|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02675634||3442|
NCT02667717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508193|Efficacy and Safety of a Learning Program of Self- Rehabilitation Exercises by Mirror Therapy|Efficacy and Safety of a Learning Program of Self- Rehabilitation Exercises by Mirror Therapy in the Complex Regional Pain Syndrome of the Upper Limb : a Multicentric Randomized Open Study.|AlgoMIR|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|May 2016|August 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667717||4046|
NCT02667730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-12-126-004-0001|Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries|Correlation Between Acute Analgesia and Long-Term Function Following Ankle|CALF|Canadian Department of National Defense|No|Recruiting|June 2015|March 2018|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|17 Years|60 Years|No|||January 2016|January 26, 2016|July 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02667730||4045|
NCT02667743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-03-2015|Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC|||Shanghai Yizhong Biotechnology Co., Ltd.||Recruiting|March 2015|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|468|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667743||4044|
NCT02676349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005681-29|Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)|Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma||Institut de Cancérologie de Lorraine|Yes|Not yet recruiting|February 2016|January 2023|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||November 2015|February 3, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02676349||3387|
NCT02682407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS721-GNP-001|OMS721 Treatment of Steroid-Dependent Glomerulopathies|A Phase 2 Uncontrolled Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With Steroid-Dependent IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease||Omeros Corporation|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682407||2922|
NCT02667041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015014|NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial|NeuroQore Repetitive Transcranial Magnetic Monophasic vs. Biphasic Stimulation For Major Depressive Disorder: A Randomized Controlled Trial||University of Ottawa||Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|75 Years|No|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02667041||4098|
NCT02667054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013011|Topical Anesthetic for Procedures Through the Nose|A Phase III Investigation Of Topical Application Of RX0041-002 On Safety And Efficacy In Local (Topical) Anesthesia For Diagnostic Procedures And Surgeries On Or Through The Accessible Mucous Membranes Of The Nasal Cavities||Pharmaceutical Project Solutions, Inc.|No|Completed|September 2014|January 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|648|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667054||4097|
NCT02668003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/004/14|The Maintaining Musculoskeletal Health Study|The MAintaining MusculOskeleTal Health (MAmMOTH) Study|MAmMOTH|University of Aberdeen|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|946|||Both|25 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02668003||4024|
NCT02673216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-116-14|Infection and Adverse Pregnancy Outcome|Infection and Adverse Pregnancy Outcome||Statens Serum Institut|No|Recruiting|March 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|Serum Vaginal Swabs|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women attending for antenatal care or with spontaneous miscarriage|February 2016|February 1, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02673216||3628|
NCT02676427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530/15 S-IV|Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination|Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination - "FRIEND Study"|FRIEND|Charles University, Czech Republic|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|18 Years and older, mechanically ventilated ICU patients in septic shock|February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676427||3381|
NCT02665780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02159|Assessing the Effect of Periodontal Debridement, Tongue Cleaning and Mouth Rinsing for the Treatment of Oral Malodour|||University of British Columbia|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665780||4194|
NCT02666027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHA REB ROMEO File#: 1019905|The Use of the Fluid IV Alert Monitor to Decrease the Incidence of Undetected Empty IV Bag in Dimmed Operating Rooms|The Use of the Fluid IV Alert (FIVA) Monitor to Decrease the Incidence of Undetected Empty Intravenous Bag in Dimmed Operating Rooms|FIVA|Nova Scotia Health Authority|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|90|||Both|N/A|N/A|No|||January 2016|January 26, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02666027||4176|
NCT02663310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KunmingTH_HZ_001|Treatment for Chronic Spinal Cord Injury: Surgery With Rehabilitation vs Rehabilitation|Surgical Decompression/Untethering Combined With Weight Bearing Rehabilitation in Chronic Spinal Cord Injury Subjects||Kunming Tongren Hospital|No|Recruiting|July 2015|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||January 2016|February 3, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02663310||4384|
NCT02675322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangdongPHTCM|Danlou Tablets to Prevent Left Ventricular Remodeling|Effects of Danlou Tablets to Prevent Left Ventricular Remodeling After Myocardial Infarction: A Double-blind, Randomized, Placebo Controlled, Pilot Study||Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Completed|January 2012|December 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02675322||3466|
NCT02673437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Rivaroxaban ACS Specialist Cohort Event Monitoring Study|An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales|ROSE ACS|Drug Safety Research Unit, Southampton, UK|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2386|||Both|18 Years|N/A|No|Non-Probability Sample|Patients newly prescribed rivaroxaban in any combination with standard oral antiplatelet        therapy or current standard antiplatelet combination therapy (at least dual therapy, but        not monotherapy) for secondary prevention in patients after ACS|February 2016|February 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02673437||3611|
NCT02516111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014M|Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment|Comparative Evaluation of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Treatment of 2/3-walled Intrabony Defects in Chronic Periodontitis Subjects: a Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|September 2014|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516111||15688|
NCT02519335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCH-001|Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation|Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation||Medical City Children's Hospital|Yes|Recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|6 Months|No|||May 2015|August 5, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02519335||15440|
NCT02672644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10346|Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep|A Single-Center, Non-Comparative Study to Evaluate Subject Recovery Following Correction of Bilateral Nasolabial Folds Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine||Galderma Laboratories, L.P.|No|Not yet recruiting|April 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672644||3671|
NCT02677116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15841|A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer|A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors||Eli Lilly and Company|No|Not yet recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|70|||Both|N/A|17 Years|No|||February 2016|February 22, 2016|January 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02677116||3328|
NCT02667678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508032|5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients|5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.|HIVOL2|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|February 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|235|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667678||4049|
NCT02669745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-0125|The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients|The Study of Molecular Risk Panels in Chinese Breast Cancer Patient Using Mammaprint, TargetPrint, BluePrint and Research Gene Panel Assays.||Agendia|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|70 Years|No|Non-Probability Sample|Women of Chinese Descent with Stage I or Stage II Breast Cancer|January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02669745||3893|
NCT02669758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK3831-A306|A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia|A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia||Alkermes, Inc.|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|390|||Both|18 Years|70 Years|No|||February 2016|February 26, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669758||3892|
NCT02688296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB-001|Effectiveness Of The Fibulock Intramedullary Nail|The Use Of A Fibular Intramedullary Nail For Fixation For Unstable Fibula Fractures|Fibulock|Sonoma Orthopedic Products, Inc.|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who received the Fibulock Intramedullary Nailand are at least 12 weeks post        implant, but less than 31 weeks post implant.|February 2016|February 22, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688296||2469|
NCT02666300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|post2015taper|To Compare the Incidence of POST Between a TaperGuard ETT and Cylindrical-shaped ETT Under High Cuff Pressure|To Compare the Incidence of Postoperative Sore Throat Between a TaperGuardEndotracheal Tube(ETT)and a Cylindrical-shaped ETT Under Highcuffpressure:A Randomized,Double-blindTrial.||The Second Affiliated Hospital of Dalian Medical University|Yes|Recruiting|December 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02666300||4155|
NCT02664857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D|Vitamin D Supplementations and Postoperative Pain|Effect of Vitamin D Supplementation on Postoperative Pain and Sedation-agitation||Cukurova University|No|Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|17 Years|No|||January 2016|January 27, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664857||4265|
NCT02663089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003|A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects|An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK961081, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose||GlaxoSmithKline|No|Active, not recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663089||4401|
NCT02663440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJZLYY-HN-2016-01|Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme|||Zhejiang Cancer Hospital||Recruiting|January 2016|||December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663440||4374|
NCT02684565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-001928|Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects|Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects|BCAA|University of California, Los Angeles|No|Not yet recruiting|February 2016|March 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|20 Years|50 Years|No|||February 2016|February 11, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684565||2756|
NCT02684578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-18258|Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD|METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration|METforMIN|University of California, San Francisco|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|N/A|No|||March 2016|March 1, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684578||2755|
NCT02662452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG2222-CL-101|First-in-Human Single and Multiple Dose of GLPG2222|Randomized, Double-blind, Placebo-controlled, First-in-Human Study of GLPG2222 in Healthy Male Subjects||Galapagos NV|No|Recruiting|January 2016|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662452||4450|
NCT02669433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVT-101-2001|Study Evaluating RVT-101 in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study|A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)||Axovant Sciences Ltd.|Yes|Recruiting|January 2016|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|50 Years|85 Years|No|||March 2016|March 11, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669433||3917|
NCT02667782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-ZVG9|Feasibility Study on the Use of Mindfulness-based Intervention for Family Carers of PWD|Use of a Mindfulness-based Intervention for Family Carers of People With Dementia in the Community: A Feasibility Study||The Hong Kong Polytechnic University|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667782||4041|
NCT02686996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16061A|The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk|The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk: a Double-blind, Placebo-controlled Trial||Monash University|Yes|Not yet recruiting|July 2016|June 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02686996||2569|
NCT02674360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKH109956, DKH110010|RCT Regarding SDM Online Training and Face-to-face SDM Training|Randomized Controlled Trial Regarding (RCT) Innovative Dissemination Strategies for a Brief Shared Decision Making (SDM) Intervention for Oncologists: Web-based SDM Online Training and Individualized, Context-based Face-to-face SDM Training||University Hospital Heidelberg|No|Not yet recruiting|May 2016|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02674360||3540|
NCT02669693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 12-037a|Effect of Olives on Glycaemic Response in Vivo|Effect of Olives on Glycaemic Response in Vivo||University of Leeds||Recruiting|December 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02669693||3897|
NCT02673255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-0115|Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program|Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program||Biomat USA, Inc.|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673255||3625|
NCT02689388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHB_6925|Comparing Regional Anaesthesia to Systemic Analgesia to Decrease Post-Operative Delirium in Acute Hip Fracture Surgery|The Use of Post-operative Regional Analgesia Rather Than Systemic Analgesia to Decrease the Incidence of Post-operative Delirium After Acute Hip Fracture Surgery? A Prospective Randomised-controlled Double-blinded Pilot Study.|RASAPOD|Auckland City Hospital|Yes|Not yet recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|65 Years|N/A|No|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02689388||2385|
NCT02678364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM 4 (y) 07/10/14|Effect of Vitamin D-biofortified Eggs on Wintertime Serum 25-hydroxyvitamin D in Adults: Randomized Controlled Trial|A Dietary Intervention Study Examining the Effect of Consumption of Vitamin D-enhanced Eggs on Winter-time Vitamin D Status in Adults|EnhanceDeggs|University College Cork|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|55|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678364||3232|
NCT02665611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2124-15-SMC|Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence|The Effect of Remote Monitoring and Support for Patients Suffering From Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence to Treatment||Assuta Hospital Systems|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||January 2016|February 7, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02665611||4207|
NCT02668302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2015-09|The PIO II Study of In-office Placement of a Steroid-eluting Sinus Implant|The PIO II Study: A Randomized Controlled Blinded Trial to Evaluate the Safety and Efficacy of In-office Placement of a Steroid-eluting Sinus Implant Post-ethmoidectomy||Collin County Ear Nose & Throat|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668302||4001|
NCT02668549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 4A|Cross-Sectional Study to Define and Validate "Doctor/Pharmacy Shopping" as Outcomes Suggestive of Abuse and/or Addiction|Cross-Sectional Study to Define and Validate "Doctor/Pharmacy Shopping" as Outcomes Suggestive of Abuse and/or Addiction||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|164000|||Both|18 Years|N/A||Non-Probability Sample|Adult patients (18 years of age or older) with data in both IMS LRx and PharMetrics Plus,        who also have a minimum of two dispensings for IR or ER/LA opioids or two or more diuretic        dispensings. The first of these dispensings will have occurred in 2012 and an additional        dispensing within 18 months after the first. Dispensings will be determined from the IMS        LRx database.|November 2015|January 26, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02668549||3982|
NCT02686476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMELIFT01|Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes|Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study|E-LIFT|Medanta, The Medicity, India|Yes|Not yet recruiting|March 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||February 2016|February 18, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02686476||2609|
NCT02686489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16010603|Humidity Therapy for Spontaneously Breathing Tracheostomy Patients|Large Volume Nebulizers Versus Heated Humidity in Spontaneously Breathing Tracheostomy Patients||Rush University Medical Center|No|Not yet recruiting|March 2016|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02686489||2608|
NCT02678390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-508|Physical Exercise and Ketone Production in Women With or Without Prediabetes|Stimulating the Production of Ketones Through the Combined Use of Physical Exercise and Dietary a Medium Chain Triglycerides (MCT) Supplement|Exercise-MCT|Université de Sherbrooke|No|Recruiting|September 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Female|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678390||3230|
NCT02662023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP Basal vs. Bolus|Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses|Continuous Transversus Abdominis Plane Nerve Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses (A Randomized, Double-Masked, Active-Control, Split-Body, Crossover Study)||University of California, San Diego|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662023||4483|
NCT02662036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201601064|Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction|A Prospective Trial to Assess Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction||Washington University School of Medicine|No|Recruiting|March 2016|May 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|156|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662036||4482|
NCT02662049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETE001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2014|||||N/A|N/A|N/A||||||||||||||January 20, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662049||4481|
NCT02676232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R464E|DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.|DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.||Universitat Oberta de Catalunya|No|Recruiting|September 2014|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|9 Years|15 Years|No|||February 2016|February 3, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02676232||3396|
NCT02688530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-853|Intravenous Dexamethasone for Prolongation of Analgesia Following Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy: A Randomized, Controlled, Phase IV Dose-Response Study|Intravenous Dexamethasone for Prolongation of Analgesia Following Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy: A Randomized, Controlled, Phase IV Dose-Response Study|SCB and IV Dex|Hospital for Special Surgery, New York||Not yet recruiting|March 2016|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|140|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688530||2451|
NCT02677571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20995/2014ps|PVB vs PECS Block in Breast Surgery|Thoracic Paravertebral Block Versus Pectoral Nerves Block (Modified PECS) Block in Breast Surgery|PVBvsPECS|Istituti Ospitalieri di Cremona|No|Recruiting|December 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Female|18 Years|N/A|No|||December 2015|February 4, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02677571||3293|
NCT02666157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BR-104-049|Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation|Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)|DARING-AF|National Cheng-Kung University Hospital|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3672|||Both|20 Years|N/A|No|||February 2016|February 14, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666157||4166|
NCT02677402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2O|Effects of Various Modalities Water Immersion on Veins|Effects of Thermo Neutral Water Immersion, Cold-water Immersion and Contrast Water Therapy on Lower Limb Veins Calibres||University of Franche-Comté|No|Recruiting|December 2012|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02677402||3306|
NCT02677974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study|On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study||On-X Life Technologies, Inc.|No|Recruiting|November 2015|November 2021|Anticipated|November 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|510|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with On-X aortic heart valve replacements implanted within the prior year.|February 2016|February 8, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677974|5 Years|3262|
NCT02673814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1501|Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer|An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer||Peregrine Pharmaceuticals|Yes|Not yet recruiting|February 2016|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|198|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673814||3582|
NCT02663219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 078|Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States|Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex With Men (MSM) in the United States||HIV Prevention Trials Network|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|356|||Male|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02663219||4391|
NCT02676284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DURE04|Durolane SJ for Treatment of Rhizarthrosis|Study of the Clinical and Biomechanical Effectiveness of Durolane SJ in Rhizarthrosis||Zambon SAU|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|No|||January 2016|February 3, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02676284||3392|
NCT02666378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-017|Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer|Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer||Dana-Farber Cancer Institute|No|Not yet recruiting|March 2016|July 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|190|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02666378||4149|
NCT02677467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gurivengers|Correlation Between Epistaxis and Cardiovascular Disease|Epistaxis Correlate With Cardiovascular Disease?|CBECD|Hanyang University|Yes|Not yet recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Blood sample for evaluating about cardiovasular risk.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group A : A participant enroll if their age is over 18 with spontaneous epistaxis and        their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs        immediately treatment for hypertensive urgency. And, they don't want to participate in        this investigation.        Group B : A participant enroll if their age is over 18 with bleeding of wound and their        cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds'        condition is serious or their pain is much severe. And, they don't want to participate in        this investigation.|February 2016|February 8, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02677467|3 Months|3301|
NCT02673970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-BN-001|Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma|Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma|ICIT|Universitair Ziekenhuis Brussel|No|Recruiting|October 2014|January 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Cllection of cell free DNA for mutational analysis|Both|18 Years|N/A|No|Probability Sample|All patient with an unresectable stage III or stage IV melanoma treated with pembrolizumab|February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673970||3570|
NCT02669992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/321-31/1|Loop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site?|Loop Ileostomy Closure.Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site in the Abdominal Wall. A Prospective Randomised Multicenter Trial.|LISTO|Karolinska University Hospital|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|400|||Both|N/A|N/A|No|||January 2016|January 27, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02669992||3874|
NCT02670278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24300409|Evolutionary and Sociocultural Aspects of Human Milk Composition||INSPIRE|Washington State University|No|Recruiting|May 2014|||August 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||11|Anticipated|960|Samples With DNA|milk, feces, saliva|Both|1 Month|N/A|No|Non-Probability Sample|Healthy breastfeeding women and their infants|January 2016|January 27, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02670278||3852|
NCT02664181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2516|Oral THU-Decitabine + Nivolumab for Advanced Non-Small Cell Lung Cancer|Combination of Oral THU-Decitabine With Nivolumab for Treatment of Patients With Advanced Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Not yet recruiting|July 2016|January 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664181||4317|
NCT02664194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16568|Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|COOL-MI InCor|University of Sao Paulo General Hospital|Yes|Recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||January 2016|January 25, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664194||4316|
NCT02688088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15537|A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body|Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients||Eli Lilly and Company|No|Recruiting|February 2016|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688088||2485|
NCT02688101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD-2015-001|Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors|A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors||Collaborative Medicinal Development Pty Limited|Yes|Not yet recruiting|February 2016|June 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|February 17, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02688101||2484|
NCT02677246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJ001|Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children|Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children||St. Justine's Hospital|Yes|Not yet recruiting|April 2016|March 2022|Anticipated|March 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|2 Years|21 Years|No|||February 2016|February 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677246||3318|
NCT02662517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCologne|Growth Hormones and Cells in Human Milk Depending on Gestational Age|Growth Hormones and Cells in Human Milk Depending on Gestational Age and Lactation Phase|BMProfile|University Hospital of Cologne|No|Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|human breast milk, umbilical chord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breastfeeding mothers|January 2016|January 20, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02662517||4445|
NCT02669225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160059|Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People|Characterization of Brain Amyloid- & Amp; lt;= (A & Amp; lt;=) Retention During Wakefulness And Following Emergence From Sleep In Healthy Subjects||National Institutes of Health Clinical Center (CC)||Not yet recruiting|January 2016|December 2022|Anticipated|December 2022|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|January 29, 2016|January 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669225||3933|
NCT02681653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI/IMP/IEC/56/19.08.2011|Study the Impact of Statins in Septic Shock|Prospective Randomized Study to Assess Impact of Statins in Septic Shock||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Completed|January 2012|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|February 11, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02681653||2980|
NCT02677675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPM/TNCPI/RMC/1.4.18.1 (JKEUPM|Effectiveness of Mobile Phone Technology on Adherence and Treatment Outcomes Among HIV Positive Patients on ART|Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia||Universiti Putra Malaysia|Yes|Completed|January 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|242|||Both|15 Years|65 Years|No|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677675||3285|
NCT02664532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR/JHTMH/09242A|Miller Straight Blade vs Macintosh Blade|Miller Straight Blade With Paraglossal Technique Compared to the Macintosh Blade in Respect to Visualization of Larynx and Ease of Intubation||Tata Main Hospital|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|January 10, 2016||No||No|February 12, 2016|https://clinicaltrials.gov/show/NCT02664532||4290|Blinding of laryngoscope to the laryngoscopist was not possible. The study was conducted in predicted non-difficult airways and cannot be extrapolated in difficult airway situations.
NCT02664545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAR II TRIAL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||January 22, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664545||4289|
NCT02666833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002339|Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers|Polarization Enhanced Wide Field Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers|PERFIS|Massachusetts General Hospital|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who receive their dermatologic care at the Massachusetts General Hospital        Dermatologic Surgery Unit, who have at least one biopsy-proven nonmelanoma skin cancer,        scheduled to be treated by Mohs micrographic surgery.|January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02666833||4114|
NCT02667119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-101-2|Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults|Treating Co-Occurring PTSD and Substance Abuse in High-Risk Transition Age Youth||University of Connecticut Health Center|No|Not yet recruiting|February 2016|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|25 Years|No|||January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667119||4092|
NCT02676583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLFACT-TONSIL-01|Effectiveness of Tonsil Fossa Closure in Pain Relief After Tonsillectomy in Children|Effectiveness of Tonsil Fossa Closure in Pain Relief After Tonsillectomy in Children: Randomized Clinical Trial, Double-blind, Controlled Study||Clinica Olfact||Not yet recruiting|February 2016|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|200|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02676583||3369|
NCT02690415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROD-SIU-14-197-CIRCUS|Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses|Effect of Antibiotics on Community-Associated Staphylococcus Aureus Colonization and Recurrent Infection in Patients With Uncomplicated S. Aureus Skin Abscesses|CIRCUS|Southern Illinois University|No|Enrolling by invitation|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|colonization swabs from the nose, axilla, inguinal folds and wound isolate|Both|6 Months|18 Years|No|Probability Sample|Pediatric patients presenting in the Emergency Department or Express Cares and Primary        Care Clinics with skin abscesses who do and do not receive antibiotic therapy at two time        points.|February 2016|February 18, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02690415||2307|
NCT02690428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-2014-003|Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers|To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)||Clinical Laserthermia Systems AB|No|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02690428||2306|
NCT02672462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-CT-20150301|Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study|The Safety and Efficacy of a Renal Denervation System in Treating Patients With Hypertension: A Pilot Study||Shanghai Golden Leaf MedTec Co. Ltd||Recruiting|December 2015|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02672462||3685|
NCT02663635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1550599|Simulated Clinical Use Testing on Safe'N'Sound 1ML Stalked Passive Delivery System With Add-On Extended Finger Flanges|Simulated Clinical Use Testing on Safe'n'Sound 1mL Staked Passive Delivery System With add-on Extended Finger Flanges||Nemera La Verpilliere|No|Completed|January 2016|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663635||4359|
NCT02667132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GranulomatousMWG|Granulomatous Mastitis Current Approach and Treatment|Granulomatous Mastitis Current Approach and Treatment (Multicentric Study) Granulomatous Mastitis Working Group||Granulomatous Mastitis Working Group|Yes|Active, not recruiting|December 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|400|||Female|18 Years|90 Years|No|Probability Sample|from 18 to 90 years womens with Granulomatous Mastitis|January 2016|January 25, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02667132||4091|
NCT02670876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0720152106|Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators|Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators: Using Tools Measuring Brain Function and Structure, Cognition and Behavior.||Seoul National University Childrens Hospital||Completed|January 2014|June 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|12 Years|17 Years|No|||January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02670876||3806|
NCT02684591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRIVE|Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy|Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial|ARRIVE|University of California, San Diego|No|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684591||2754|
NCT02665312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CheckPoint|Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine|CHEmotherapy-induced Cardiotoxicity and Study of risK Factor Correlation in Patients With Colorectal Cancer Receiving Oral or INfusional Fluoropyrimidine Treatment - CHECKPOINT||Fondazione del Piemonte per l'Oncologia|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with colorectal cancer receiving Oral or INfusional fluoropyrimidine Treatment|January 2016|January 23, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02665312||4230|
NCT02669641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SteatoSPC|Complex Imaging Assessment of Steatosis|Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline|SteatoSPC|University of Medicine and Pharmacy Craiova|Yes|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02669641||3901|
NCT02674945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406M51644|Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase|Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|75|||Both|18 Years|99 Years|No|||February 2016|February 2, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02674945||3495|
NCT02663895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36140|A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis|A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis||Stanford University|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663895||4339|
NCT02662855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPT-125|Efficacy of Favipiravir Against Severe Ebola Virus Disease|Efficacy of Favipiravir Against Severe Ebola Virus Disease||Beijing Institute of Pharmacology and Toxicology|Yes|Completed|November 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|13 Years|75 Years|No|||January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662855||4419|
NCT02679235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-617|Brain Energy and Aging With Triheptanoin|Brain Energy and Aging With Triheptanoin: The BEAT7 Study|BEAT7|Université de Sherbrooke|No|Not yet recruiting|February 2016|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 5, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679235||3165|
NCT02675647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6124|Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients|Heparin Management for Cardiopulmonary Bypass in Cardiac Surgery: A Prospective, Comparative and Randomized Study Evaluating a Dosage Based on the Ideal Body Weight in Obese Patients|HEPOIRINE|University Hospital, Strasbourg, France|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02675647||3441|
NCT02672969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248/2558 (EC1)|The Evaluation of Pre-Post Smoke Evacuation Uses on Surgical Smoke and Bio-Aerosols in Operating Rooms|The Evaluation of Pre-Post Smoke Evacuation Uses on Surgical Smoke and Bio-Aerosols in Operating Rooms at a University Hospital, Thailand||Mahidol University|No|Recruiting|August 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Both|N/A|N/A|No|||January 2016|January 30, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672969||3646|
NCT02677792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2015-0155|Wellness and Weight Family Group Project|Wellness and Weight Family Group Project||University of Mississippi Medical Center|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|17 Years|No|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677792||3276|
NCT02667847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030220|Preoperative Anxiety Evaluation: a New Visual Smileys Scale|Preoperative Anxiety Evaluation: a New Visual Smileys Scale||Cedars-Sinai Medical Center|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|80 Years|No|Probability Sample|200 patients undergoing surgery at Cedars Sinai Medical Center|February 2016|February 2, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02667847||4036|
NCT02667860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-AIE-2015-01|Intra-corporeal vs Extra-corporeal Anastomosis in Laparoscopically Assisted Right Hemicolectomy|Intra-corporeal vs Extra-corporeal Anastomosis in Laparoscopically Assisted Right Hemicolectomy||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|March 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|99 Years|No|||January 2016|January 26, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02667860||4035|
NCT02675673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0393-CE|Feeding Tube in Cancer Patients|A Randomized Comparison of Enteral Feeding for Head and Neck (HNC) Cancer Patients||University Health Network, Toronto|Yes|Withdrawn|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02675673||3439|
NCT02673229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13663|Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns|Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns||University of Kansas Medical Center|No|Recruiting|January 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|75 Years|No|||February 2016|February 2, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673229||3627|
NCT02677805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPH-302-201030|Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II|Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study|BLESSII|Croma-Pharma GmbH|No|Not yet recruiting|February 2016|April 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677805||3275|
NCT02663128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16001|A Study of AZD3293 (LY3314814) in Healthy Participants|A Bioequivalence and Food Effect Study in Healthy Subjects Administered 2 Different Tablet Formulations of AZD3293||Eli Lilly and Company|No|Not yet recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|18|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663128||4398|
NCT02669914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-x001|MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors|A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors||Washington University School of Medicine|No|Not yet recruiting|April 2016|October 2021|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|136|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669914||3880|
NCT02669927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/17DEC/539|Frailty and Postoperative Shock|||Université Catholique de Louvain||Completed|January 2013|||January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|45 Years|N/A|No|Non-Probability Sample|53 patients (age = 82 ans [56-98]) hospitalized in St-Luc Hospital (Belgium) for hip        surgery between 2013 and 2015|January 2016|January 29, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669927||3879|
NCT02667366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-0417|Effectiveness and Cost-effectiveness of Telephone-delivered Psychotherapy for Depression in Primary Care|Improving Access to Evidence-based Treatment for Depression: Effectiveness and Cost-effectiveness of Telephone-delivered Cognitive Behavioral Therapy (CBT) in Primary Care||University of Zurich|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02667366||4073|
NCT02667379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-HypoCat-001|Skin Tests in Cat Allergic Patients With Cat Dander Samples Obtained Before and After Vaccinating the Cat|Evaluation of Skin Prick Tests in Cat Allergic Patients With Cat Dander Samples Obtained Before and After Vaccinating the Cat||University of Zurich|No|Enrolling by invitation|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667379||4072|
NCT02664675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-2013-003|Cellular and Molecular Inflammatory Mechanisms Leading to Bone Resorption in Peri-implantitis Vs Periodontitis|Comparison of Cytokines Production and Cellular Recruitment in Gingival Crevicular Fluid (GCF) and Granulation Tissue From Periodontitis, Peri-implantitis and Healthy Patients Leading to Activation of Osteoclasts and Bone Resorption|DUOROPA|University of Paris 5 - Rene Descartes|No|Completed|April 2014|January 2016|Actual|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|33|Samples Without DNA|Gingiva samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated in periodontology department of Hospital Rotschild or Charles Foix|January 2016|January 27, 2016|April 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02664675|1 Day|4279|
NCT02662907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0238|Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy|Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2026|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662907||4415|
NCT02662920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22410|Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)|Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Completed|August 2010|November 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|209|||Both|60 Years|N/A|No|Non-Probability Sample|Adults age ≥60 who received treatment while hospitalized for AML|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662920||4414|
NCT02520219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endostar-PTLC-001|Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study|The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study.||Nanjing NingQi Medicine Science and Technology Co., Ltd.|Yes|Recruiting|December 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02520219||15372|
NCT02526212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3580|Buprenorphine Group Medical Visits in Primary Care|Buprenorphine Group Medical Visits for Drug Users at Risk for HIV|G-BMT|Montefiore Medical Center|No|Not yet recruiting|June 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02526212||14911|
NCT02526225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412-Z-YXET-ZS-RE|A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.|A Randomized,Double Blind,Placebo Parallel Controlled,Multicenter Clinical Sthdy of Ginkgo Diterpene Lactone Meglumine Injection for Acute Ischemic Stroke Efficacy Safety.||Ministry of Science and Technology of the People´s Republic of China|Yes|Enrolling by invitation|June 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|3452|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02526225||14910|
NCT02666040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-v035|Study on Ultrapro vs Polypropylene: Early Results From a Multicentric Experience in Surgery for Hernia|A Multicenter Prospective Randomized Study Of Comparison Between Semi-Absorbable Prosthesis And Totally Nonabsorbable Prosthesis In Inguinal Hernia Surgery|SUPERMESH|Istituto Clinico Humanitas|No|Active, not recruiting|November 2009|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|1200|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02666040||4175|
NCT02672709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15-128|Apixaban in Hemodialysis|Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis||Jewish General Hospital|No|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|19 Years|79 Years|No|||January 2016|January 30, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02672709||3666|
NCT02675088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-045/1|Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer|Randomized Phase III Study Comparing Different Thoracic Radiotherapy Regimens in Patients With Extensive Stage Small Cell Lung Cancer Who Respond to Chemotherapy||Chinese Academy of Medical Sciences|No|Not yet recruiting|March 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02675088||3484|
NCT02690831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidad Autonoma de Madrid|Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma|Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma||Universidad Autonoma de Madrid||Recruiting|December 2015|January 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02690831||2275|
NCT02690844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182108|Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome|Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome||University of Alberta|No|Not yet recruiting|April 2016|July 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690844||2274|
NCT02669134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147-2015-PL|CRT Improved Clinical Response UK Trial|CRT Improved Clinical Response UK Trial: A Multi-centre, Prospective, Randomized, Cross-over, Double Blind Study|CRICKET|Aston University|Yes|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02669134||3939|
NCT02669407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066528|Splanchnic Nerve Anesthesia in Heart Failure|Splanchnic Nerve Block for Acute Heart Failure||Duke University|Yes|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02669407||3919|
NCT02667470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATH-002|Reproducibility Study of OABSS and Its Response to Treatment|Overactive Bladder Symptom Scores (OABSS) Responsiveness Before and After Anticholinergic Treatment in Women With Overactive Bladder (OAB)|RESORT part 2|Astellas Pharma Inc|No|Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667470||4065|
NCT02667483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5141-A-J101|Study of DS-5141b in Patients With Duchenne Muscular Dystrophy|Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy||Daiichi Sankyo Inc.||Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|5 Years|10 Years|No|||February 2016|February 19, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667483||4064|
NCT02685670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHHUTCM20160106|Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma|A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma||The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|70 Years|No|||February 2016|February 14, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685670||2671|
NCT02670733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2015-023-01|Effect of Increased Positive End-expiratory Pressure on Intracranial Pressure in Different Respiratory Mechanic in Acute Respiratory Distress Syndrome|||Capital Medical University||Not yet recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Severe brain injured patients with ARDS|January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02670733||3817|
NCT02678091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR_2015_40|Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)|Contribution of the Quantitative Analysis of the Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)|PUCE|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|February 2016|October 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678091||3253|
NCT02675439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADU-CL-07|Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas|A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas||Aduro Biotech, Inc.||Not yet recruiting|March 2016|||March 2020|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675439||3457|
NCT02688231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58587|Task-oriented Upper Limb Training in MS|Intensity Dependent Clinical Effects of a Task-oriented Upper Limb Training in Multiple Sclerosis||Hasselt University|No|Recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|90 Years|No|||February 2016|February 17, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02688231||2474|
NCT02688244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAC-2015-HCUVA|Irrigation Versus Suction in Complicated Acute Appendicitis|Randomized Trial Comparing Irrigation Versus Suction in Laparoscopic Appendectomy for Complicated Acute Appendicitis in Adults|ISAAC|Hospital Universitario Virgen de la Arrixaca|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02688244||2473|
NCT02662738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-NAA-1650|The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product|The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product||Unilever R&D|No|Not yet recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02662738||4428|
NCT02674425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL001185|Wearable Dark-adaptometer in Normal Adult Healthy Volunteers|Evaluation of a Novel Wearable Light-emitting System for Measuring Dark-adaptation Thresholds in Normal Adult Healthy Volunteers||University of Liverpool||Not yet recruiting|March 2016|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers with no prior/current eye problems or family history of genetic        eye diseases and good general health.|February 2016|February 1, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02674425||3535|
NCT02676570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC15SISI0338|Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method|Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method - Retrospective Study Using Residual Storage Tissue Specimen||Seoul St. Mary's Hospital|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|Samples Without DNA|Study specimen : Tissue Study content analysis: To determine fungal species and genetic      mutations associated with drug resistance by extracting fungal DNA, but not patients'      genetic information|Both|N/A|N/A|No|Non-Probability Sample|Patients who were diagnosed with invasive fungal disease based on the biopsy from June        2009 to May 2014|February 2016|February 6, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02676570||3370|
NCT02676089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AB2-02|TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)|A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS|TRIGGER|Chiesi Farmaceutici S.p.A.|Yes|Not yet recruiting|March 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1435|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676089||3407|
NCT02686177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140710|Effect of GLP-1 on Angiogenesis|Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1|ANGIOSAFE 1|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686177||2632|
NCT02662972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTATN2015|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.||Norwegian University of Science and Technology|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02662972||4410|
NCT02670304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28843020|Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS|The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment||First Affiliated Hospital, Sun Yat-Sen University|No|Completed|January 2012|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|45 Years|No|||January 2016|January 28, 2016|August 7, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670304||3850|
NCT02670317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL-GALILEO|Multicenter Phase II Study About the Combination of CHOP-21 With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma Patients.|Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.|FIL-GALILEO|Fondazione Italiana Linfomi ONLUS|No|Not yet recruiting|February 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02670317||3849|
NCT02676050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUAL|Visualising c-MET and Activated Neutrophils in Lung Cancer|Exploratory Study to Optically Visualise Activated Neutrophils and the Proto-oncogene, c-MET, in Lung Cancer Using DUAL Colour Fibre-based Endomicroscopy|DUAL|University of Edinburgh|Yes|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|16 Years|N/A|No|||February 2016|March 21, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02676050||3410|
NCT02686684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-DTI|Tecfidera Diffusion Tensor Imaging|An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis|DTI|University at Buffalo|No|Enrolling by invitation|November 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Seventy-five (75) consecutive relapsing MS patients who started treatment with dimethyl        fumarate and 40 healthy controls will be recruited in the study.|February 2016|February 16, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02686684||2593|
NCT02686697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1119|Carnosine and Cognitive Training in Schizophrenia|A Double-blind, Placebo-controlled Study on the Effects of Combined L-Carnosine and Cognitive Training on Cognition in Schizophrenia|CACTIS|Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|February 16, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686697||2592|
NCT02663271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201600074|TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma|A Phase 2, Multi-center, Single Arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-refractory Recurrent Glioblastoma||University of Florida|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|22 Years|N/A|No|||January 2016|January 21, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663271||4387|
NCT02665858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-15-HYMC|OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|5 Years|18 Years|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02665858||4188|
NCT02665871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cycdc2015-4|Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older|||Beijing Chaoyang District Centre for Disease Control and Prevention||Not yet recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Both|3 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665871||4187|
NCT02664428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreBIOil 2|Measuring the Impact of Dietary Supplementation With a New Baking Product on Gut Microbiota and Cholesterol Metabolism|Measuring the Impact of Dietary Supplementation With New Baking Product PreBIOil on Gut Microbiota and Cholesterol Metabolism||Fondazione Edmund Mach|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|64|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02664428||4298|
NCT02689193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDIS|IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres|IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres|IDIS|Institute of Tropical Medicine, Belgium|No|Recruiting|September 2014|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|2500|Samples Without DNA|Whole blood, plasma, serum and urine.|Both|2 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults presenting with (a history of) fever and healthy volunteers.|February 2016|February 18, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02689193||2400|
NCT02663557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008105150027|The Influence of Circadian and Long-term Blood Pressure Variation on the Recurrent Stroke|Evaluating the Influence of Circadian and Long-term Blood Pressure Variation on Secondary Cardiovascular Events Prevention in Patients With Prior Stroke.|IVBPRS|Dongguan People's Hospital|Yes|Recruiting|July 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|800|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with prior ischemic stroke, which should be verified by define radiological        evidences and acute onset of clinical manifestations.|January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663557||4365|
NCT02670031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2603|REMODEL: Hypertensive Heart Disease|Response of the Myocardium to Hypertrophic Conditions in the Adult Population||National Heart Centre Singapore|Yes|Recruiting|January 2016|May 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|Blood samples will be collected from all participants.|Both|21 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from primary care clinic and outpatient clinics from the        National Heart Centre Singapore. In addition, they will be recruited through posters and        advertisements.|January 2016|January 27, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02670031||3871|
NCT02665195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-017|Prospective Registry of Multiplex Testing (PROMPT)|Prospective Registry of Multiplex Testing (PROMPT): Phase II||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|saliva specimen|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be conducted as a multi-center study with the involvement of attendings,        genetic counselors, and research study staff at the participating institutions.|March 2016|March 11, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665195|60 Days|4239|
NCT02663232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML30089|Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma|Epidemiological Study of V600 BRAF Mutation in Spanish Patients Diagnosed With Metastatic Melanoma: ABSOLUT-BRAF Study||Hoffmann-La Roche||Completed|June 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|285|||Both|18 Years|N/A|No|Non-Probability Sample|Participants diagnosed with metastatic melanoma who have valid samples for BRAF mutation        testing and give their informed consent will be included in this trial.|February 2016|February 1, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02663232||4390|
NCT02667886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X4P-001-RCCA|Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma|A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma||X4 Pharmaceuticals||Recruiting|January 2016|||March 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|83|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667886||4033|
NCT02670330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-006|Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa|An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa||Scioderm, Inc.|No|Active, not recruiting|May 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|1 Month|N/A|No|||February 2016|February 4, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670330||3848|
NCT02670343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-15013|Phlebotomy Study of Testosterone Undecanoate|Evaluation of Blood Collection Methodology Following Administration of a Single-Dose of an Oral Testosterone Undecanoate Formulation In Hypogonadal Men||Clarus Therapeutics, Inc.|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|65 Years|No|||February 2016|February 1, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670343||3847|
NCT02677987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201700|The "Light for the Brain" Study|Treating Cognitive Impairments in Cancer Patients Via Systematic Light Exposure||Northwestern University|No|Not yet recruiting|February 2016|April 2021|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|No|||February 2016|February 8, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02677987||3261|
NCT02678000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHW090X2102|Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function|A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers|LHW090|Novartis|No|Not yet recruiting|March 2017|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||March 2016|March 3, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678000||3260|
NCT02663518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTI-621-01|A Trial of TTI-621 for Patients With Hematologic Malignancies|A Phase 1a/1b Dose Escalation and Expansion Trial of Single-agent TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies||Trillium Therapeutics Inc.|No|Recruiting|January 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|18 Years|N/A|No|||September 2015|February 26, 2016|January 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663518||4368|
NCT02663804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2014/0023|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2014|||||N/A|N/A|N/A||||||||||||||January 21, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663804||4346|
NCT02675985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0829|Early Intensive Physical Therapy in Subarachnoid Hemorrhage|Effects of Early Intensive Physical Therapy for Patients With Subarachnoid Hemorrhage in a Neurological ICU||University of Colorado, Denver|No|Not yet recruiting|February 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02675985||3415|
NCT02675998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-02-201|An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)|An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)||Ardelyx|No|Recruiting|January 2016|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675998||3414|
NCT02668874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sealant Study|A Clinical Trial Comparing Isolite® vs. Cotton Roll Isolation in the Placement of Dental Sealants|A Clinical Trial Comparing Isolite® vs Cotton Roll Isolation in the Placement of Dental Sealants||University of Iowa|No|Recruiting|February 2015|September 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02668874||3958|
NCT02668887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hornheide-Derm-001|Employment and Quality of Life in Patients With Malignant Melanoma|A Prospective Cohort Study on Employment and Quality of Life in Patients With Malignant Melanoma||Fachklinik Hornheide an der Universität Münster|No|Not yet recruiting|January 2016|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|14 Years|65 Years|No|Non-Probability Sample|Patients with malignant melanoma|January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668887||3957|
NCT02690389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SiChuanCHRI001|Electro-acupuncture and Flumazenil's Effect on Sedation|The Sedation Effect of Electro-acupuncture on Bilateral Zusanli (ST 36) and Neiguan (PC 6) in General Anesthesia May Not be Mediated by the Benzodiazepines- GABA Pathway|EA&FLUM|Sichuan Cancer Hospital and Research Institute|Yes|Completed|January 2015|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|80|||Both|30 Years|60 Years|No|||February 2016|February 18, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02690389||2309|
NCT02664298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201525497|Prospective Registry of Immediate/Delayed Loading of Implants in the Cranial Bone-grafted Severely Atrophic Jaw||ILICRAN|AZ Sint-Jan AV|No|Recruiting|January 2007|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|all consenting patients that require fixed prosthetic rehabilitation in a cranial        bone-grafted severely atrophic jaw|January 2016|January 22, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02664298|36 Months|4308|
NCT02666820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53-170-14-3-2|Endoscopic Papillary Large Balloon Dilatation Versus Mechanical Lithotripsy for Large Stones|Endoscopic Papillary Large Balloon Dilatation Versus Sphincterotomy +/- Mechanical Lithotripsy for Removal of Bile Duct Stones With a Mean Stone > 20 mm : A Randomized Controlled Study||Prince of Songkla University|Yes|Completed|December 2010|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02666820||4115|
NCT02681874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-37460|Smart and Secure Children Program for Preschool Obesity|Feasibility Study of the Modified-Smart and Secure Children Program in Primary Care|SSC|Baylor College of Medicine|No|Recruiting|December 2015|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|2 Years|5 Years|No|||January 2016|February 10, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02681874||2963|
NCT02664558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-UBX-001|A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)|A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)|LIBERTY|Eiger BioPharmaceuticals||Not yet recruiting|March 2016|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02664558||4288|
NCT02669043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002397|Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects|||Massachusetts General Hospital|Yes|Not yet recruiting|April 2016|March 2021|Anticipated|March 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|64 Years|No|||March 2016|March 21, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669043||3946|
NCT02669056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-35|Brainstem and Prematurity|Brainstem Assesment in a Cohort of Very Preterm Babies (Less Than 28 Weeks)||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|January 2016|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|34|||Both|N/A|28 Weeks|No|||January 2016|January 27, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02669056||3945|
NCT02672735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.389|Influence of a Corrective Exercise Training Program on Measures of Functional Movement Among Active-Duty Firefighters|Influence of a Corrective Exercise Training Program on Measures of Functional Movement Among Active-Duty Firefighters||University of Wisconsin, Milwaukee|No|Recruiting|July 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 2, 2016|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02672735||3664|
NCT02672956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129|Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results|Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|105|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02672956||3647|
NCT02665676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped Embryonal Tumors SECI|Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience|Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience||Assiut University|No|Not yet recruiting|August 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|420|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients, those diagnosed with any of embryonal neoplasms, in the period        from 2001 January till 2015 December, and received treatment at the pediatric oncology        department, their medical records will be retrospectively reviewed for data collection.|March 2016|March 8, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665676||4202|
NCT02682680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOAL RCT|Randomized Trial Comparing Colesevelam vs. Ezetimibe|Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial|GOAL-RCT|LMC Diabetes & Endocrinology Ltd.|No|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682680||2901|
NCT02677701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEACH-IP-15|Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF|TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin|TEACH|National Jewish Health|Yes|Not yet recruiting|April 2016|June 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|12 Years|N/A|No|||February 2016|February 4, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677701||3283|
NCT02667405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6712|The Short Term Effect of Hot Packs and Whirlpool for Increasing Total Active Motion at the Wrist|The Short Term Effect of Hot Packs and Whirlpool for Increasing Total Active Motion at the Wrist||Western University, Canada|No|Completed|December 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02667405||4070|
NCT02676791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-07|Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection|Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection - a Randomized Controlled Trial|LOCARE|Technische Universität Dresden|Yes|Recruiting|February 2016|April 2022|Anticipated|February 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02676791||3353|
NCT02684838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR22-001|Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry|Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice|VIGILANT|Arbor Pharmaceuticals, Inc.|No|Not yet recruiting|February 2016|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Available biomarker data will be collected (e.g., MGMT, EGFR, and IDH 1&2) and exploratory      patient survival analysis will be conducted based upon biomarker status.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been prescribed Gliadel Wafer by the physician as part of usual care|February 2016|February 12, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684838||2735|
NCT02674009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29670|Observational Study to Determine the Effectiveness and Safety of Vismodegib in Patients With Locally Advanced Basal Cell Carcinoma (laBCC)|Non-Interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions (NIELS)||Hoffmann-La Roche||Recruiting|September 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving/having received Vismodegib for treatment for laBCC according to the        German label and in line with the current summary of product characteristics (SmPC) and        who have no contraindication to Vismodegib therapy as per the local label are eligible for        this non interventional study if written informed consent is provided.|March 2016|March 1, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674009||3567|
NCT02663908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000108|A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease|A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)|PRONOUNCE|Ferring Pharmaceuticals|Yes|Recruiting|February 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Male|N/A|N/A|No|||March 2016|March 2, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02663908||4338|
NCT02672748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL126666-01A1|Growing Resilience in Wind River Indian Reservation|Growing Resilience: an RCT on the Health Impact of Gardens With Wind River Indian Reservation|GR|University of Wyoming|Yes|Recruiting|November 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|5 Years|80 Years|Accepts Healthy Volunteers|||January 2016|February 2, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02672748||3663|
NCT02666911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008487|Assessing the Comparability of 2D and 4D Ultrasound Measurements|Assessing the Comparability of 2D and 4D Ultrasound Measurements of Human Carpal Tunnel Synovium, Median Nerve and Tendon Displacement||Mayo Clinic|No|Not yet recruiting|January 2017|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666911||4108|
NCT02680808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F901318.01.04.15|Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe|An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe||F2G Ltd.|No|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02680808||3045|
NCT02680821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish EC - 1107232415|Reconstruction of the Anterolateral Ligament (ALL) With Revision Anterior Cruciate Ligament (ACL) Surgery|Effect of Reconstruction of the Anterolateral Ligament (ALL) in Combination With Revision Anterior Cruciate Ligament (ACL) Surgery. A Clinical Randomized Trial||Aarhus University Hospital|Yes|Recruiting|February 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|102|||Both|18 Years|50 Years|No|||February 2016|February 11, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680821||3044|
NCT02666794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45992815000000068|Trial on the Impact of Technical Anesthetic in Pregnancies With Intrauterine Growth Restriction|Comparative Clinical Trial on the Impact of Technical Anesthetic in Uterine Tone and Fetal Heart Rate in Pregnancies With Intrauterine Growth Restriction||University of Sao Paulo General Hospital|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|N/A|No|||January 2016|January 24, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02666794||4117|
NCT02675153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPA-CN-160122|To Evaluate the Efficacy and Safety of Sirolimus for Crohn's Disease With Stenosis|Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis||The Second Hospital of Nanjing Medical University|Yes|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2016|February 2, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02675153||3479|
NCT02675205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGR_2014-33|Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm|Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm|TIC-TAC|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|December 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02675205||3475|
NCT02662868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACOG 0312|Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments|Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments||Latin American Cooperative Oncology Group|No|Recruiting|June 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1500|||Female|18 Years|N/A|No|Non-Probability Sample|Women >18 years old, patients diagnosed with metastatic breast cancer in the year of 2012        in Brazil|January 2016|January 20, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02662868||4418|
NCT02663115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1178-1176|Influence of Severe Heart Failure to Function and Molecular Biological Parameters of Catabolism in the Human Diaphragm and Peripheral Skeletal Muscle||LIPAMUS-HF|Heartcenter Leipzig GmbH|No|Recruiting|January 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|75|||Both|40 Years|70 Years|No|Non-Probability Sample|Patients with severe therapy-refractory heart failure|January 2016|January 27, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02663115||4399|
NCT02672423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16169|A Study of Abemaciclib in Healthy Participants|A Bioequivalence Study Comparing Abemaciclib Capsule and Tablet Formulations and Effect of Food on Abemaciclib Tablet Pharmacokinetics in Healthy Subjects||Eli Lilly and Company|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672423||3688|
NCT02672436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENERGI-F703-01|ENERGI-F703 for Diabetic Foot Ulcers Phase II Study|A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers||Energenesis Biomedical Co., Ltd.|No|Not yet recruiting|June 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|20 Years|N/A|No|||January 2016|February 1, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672436||3687|
NCT02663011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N201508007|Language Error Type Evaluation in Developmental Delay Preschool Children by PLS-C|||Taipei Medical University Hospital||Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||5|Actual|54|||Male|3 Years|5 Years|No|Probability Sample|This is a retrospective chart study enrolled 55 children aged 3, 4 and 5 in department of        rehabilitation in Taipei Medical University Hospital from 2011 Jan to 2014 Dec whose        average PLS-C score was at least 1.5 SD below normal. Those normal or PLS-C score was less        than 1.5SD below normal were excluded.|January 2016|January 21, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663011||4407|
NCT02667067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140154|Investigation of the Simplify™ Cervical Artificial Disc|Clinical Study Protocol for the Investigation Of The Simplify™ Cervical Artificial Disc||Simplify Medical Inc.|No|Recruiting|November 2015|January 2023|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667067||4096|
NCT02675270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC011317|Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia|||Georgetown University||Recruiting|August 2011|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|40 Years|N/A|No|||February 2016|February 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675270||3470|
NCT02688114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-076|Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus|Healing of the Esophageal Mucosa After Radiofrequency Ablation of Barrett's Esophagus||Dallas VA Medical Center|No|Enrolling by invitation|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02688114||2483|
NCT02673099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0082-13|The Benefit of Оn-Line High Convection Volume Hemodiafiltration Treatment Versus High Flow Dialysis on Reduction of Oxidative Stress and Health Related Quality of Life in Dialysis Patients|The Benefit of Оn-Line High Convection Volume Hemodiafiltration Treatment Versus High Flow Dialysis on Reduction of Oxidative Stress and Health Related Quality of Life in Dialysis Patients||Western Galilee Hospital-Nahariya|No|Active, not recruiting|August 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02673099||3636|
NCT02672293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holden/White|Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate|Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate||Queen's University|No|Recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|January 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02672293||3697|
NCT02669485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 16027|The Impact of Indocyanine Green-enhanced Fluorescence Imaging on Bowel Transection in Left-sided Colorectal Resection|A Prospective Study to Investigate the Impact of Using Indocyanine Green-enhanced Fluorescence Imaging on the Location of Bowel Transection in Patients Undergoing Left-sided Colorectal Resection||The University of Hong Kong|Yes|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||January 2016|January 29, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02669485||3913|
NCT02675036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/623/REK|Interceptive Study of Ectopic Eruption of Permanent Maxillary Canine Teeth|Interceptive Study of Ectopic Eruption of Permanent Maxillary Canine Teeth||University of Tromso|No|Recruiting|September 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02675036||3488|
NCT02667561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 060/15|Phase I Clinical Trial of PK, PD and Safety Evaluations of Testosterone Gel 1% for 28 Days in Post-menopausal Women.|Phase I Clinical Trial of Pharmacokinetics, Pharmacodynamic and Safety Evaluations of Testosterone Gel 1% for Topical Use, After Administration of Three Different Dosages or Placebo for 28 Days in Post-menopausal Women.||Biolab Sanus Farmaceutica|No|Not yet recruiting|July 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|64|||Female|42 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667561||4058|
NCT02523547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-CAV-401|Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude|PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab||Hanmi Pharmaceutical Company Limited|No|Recruiting|January 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|19 Years|N/A|No|||August 2015|August 13, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02523547||15116|
NCT02524366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elliott TC vs ST AUS|A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement|A Randomized Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|September 2015|August 2022|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|394|||Male|18 Years|85 Years|No|||August 2015|August 13, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524366||15053|
NCT02670200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-2016-001|Internet-delivered Psycho-oncological Support|MAC-CBT Used as Internet-delivered Psycho-oncological Support|ICBT_MAC|Neuropsychiatrischen Zentrums Hamburg-Altona|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02670200||3858|
NCT02678247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-15-1-0708|Functional Performance Evaluation of NU-FlexSIV Socket|Functional Performance Evaluation of the Northwestern University Flexible Sub-Ischial Vacuum (NU-FlexSIV) Socket for Persons With Transfemoral Amputation||Northwestern University|No|Not yet recruiting|April 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||March 2016|March 15, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678247||3241|
NCT02662114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4240|Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus|A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus|EU-TREAT|Novo Nordisk A/S|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2644|||Both|18 Years|N/A|No|Non-Probability Sample|T1DM (Type 1 diabetes mellitus) and T2DM (Type 2 diabetes mellitus) patient sample treated        with Tresiba® under conditions of routine care.|January 2016|January 21, 2016|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02662114||4476|
NCT02681081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400913|Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness|Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness|OPTIMIZE|University of Florida|Yes|Recruiting|February 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02681081||3024|
NCT02681094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1683C00005|A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone||AstraZeneca|No|Recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681094||3023|
NCT02670486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0034|Audiovisual Stimulus During Urodynamics|Audiovisual Stimulus During Urodynamics to Provoke Detrusor Overactivity|AVUDE|Women and Infants Hospital of Rhode Island|No|Active, not recruiting|August 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|218|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02670486||3836|
NCT02673164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIENCE|Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease|Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease - SCIENCE A European Multi-Centre Trial|SCIENCE|Rigshospitalet, Denmark|Yes|Not yet recruiting|April 2016|April 2020|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|30 Years|80 Years|No|||February 2016|February 2, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673164||3631|
NCT02673177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015(43)|Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer|A Randomized, Prospective Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer in Urinary, Erectile Function and Anal Function|TRVL|Southwest Hospital, China|Yes|Not yet recruiting|February 2016|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02673177||3630|
NCT02675374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/13|Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation||HIPPIE|University Hospital, Bordeaux|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02675374||3462|
NCT02673996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15-2434|POTS Adrenergic Ab (CIHR Aims #1&2)|The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)||University of Calgary|No|Recruiting|January 2016|December 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|125|Samples Without DNA|Serum for antibody assay; plasma for cytokine assessment; plasma for catecholamines|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with POstural Tachycardia Syndrome (POTS)|February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673996||3568|
NCT02677129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPM2015-003|FAGOTT Study - Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy|FAGOTT Study - Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy|FAGOTT|Goethe University|Yes|Recruiting|August 2014|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|44|||Both|50 Years|N/A|No|||February 2016|February 4, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02677129||3327|
NCT02688257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0806/50 CCR3372|Assessing Treatment Response in Breast Cancer With Functional Imaging|Assessing Treatment Response of Breast Cancer Using Multimodal Functional Imaging||Institute of Cancer Research, United Kingdom|No|Active, not recruiting|September 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients with breast cancer who are due for neoadjuvant chemotherapy|February 2016|February 17, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02688257||2472|
NCT02688270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-014-001|Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon|A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease||Covis Pharma S.à.r.l.|No|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688270||2471|
NCT02663947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1091|Comparison of Optic Nerve Sheath Diameter Measured by Ultrasonography Before and After Ventriculoperitoneal Shunt Surgery in Adult Patients With Hydrocephalus|||Yonsei University|No|Not yet recruiting|January 2016|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|90 Years|No|Non-Probability Sample|Patients who are scheduled for elective ventriculoperitoneal shunt surgery under general        anesthesia|January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663947||4335|
NCT02687243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1220|StoryTelling Medicine Application Using a Virtual Reality Intervention|Assessing the Effects of an Interactive Virtual Reality Intervention in Reducing Preoperative Anxiety in Children Undergoing Elective Surgery: A Randomized Controlled Trial Study Protocol|STM|McMaster University|No|Not yet recruiting|March 2016|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|8 Years|13 Years|No|||February 2016|February 16, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02687243||2550|
NCT02687256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 36142|Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set|Evaluation of Extended Infusion Set Wear Using the Medtronic Extended Wear Sof-set Infusion Set||Stanford University|Yes|Recruiting|March 2016|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||March 2016|March 22, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687256||2549|
NCT02667028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016PS04K01|Retrospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital|Retrospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital of China Medical University|R-PUSH|Shengjing Hospital|No|Recruiting|October 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|patients receiving PCI in department of Cardiology,Shengjing Hospital of China Medical        University from January 1, 2010 to October 31, 2014|January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667028||4099|
NCT02667314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klipsy_044_PACE|The Effect of Solving Jigsaw Puzzles on Visuospatial Cognition in Older Adults: Jigsaw Puzzles As Cognitive Enrichment|Jigsaw Puzzles As Cognitive Enrichment|PACE|University of Ulm|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|50 Years|N/A|No|||February 2016|February 1, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667314||4077|
NCT02674490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00089018|Effects of Transcranial Direct Current Stimulation Plus Language Therapy for Naming in Subacute Left Hemisphere Stroke|Effects of Transcranial Direct Current Stimulation (tDCS) Plus Language Therapy for Naming in Subacute Left Hemisphere Stroke|tDCSLCVA|Johns Hopkins University|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|100 Years|No|||January 2016|February 2, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674490||3530|
NCT02662062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZUP 1502|Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer|Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer|PCR-MIB|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Yes|Not yet recruiting|February 2016|January 2024|Anticipated|September 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02662062||4480|
NCT02677259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0564|Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles|Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: a Randomized, Controlled Study||One Fertility|No|Not yet recruiting|May 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|506|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02677259||3317|
NCT02688803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160078-01H|Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)|Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04|OTT 15-04|Ottawa Hospital Research Institute|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|200|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688803||2430|
NCT02667327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-DFU-301|A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer|A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)||FirstString Research, Inc.|Yes|Recruiting|July 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|552|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667327||4076|
NCT02667639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPH104FIH01|First in Human Study for RPH-104|A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose (4, 20, 80, 160 and 320 mg) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects||TRPHARM|Yes|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|35|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|February 2, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02667639||4052|
NCT02670564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZH 2014-0535|ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)|Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study)||Swiss Pediatric Oncology Group|Yes|Recruiting|April 2013|April 2023|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|1000|||Both|N/A|18 Years|No|||January 2016|January 27, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02670564||3830|
NCT02668562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150656|Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor|Reassessment of Anti-Platelet Therapy Using InDividualized Strategies -Ticagrelor in Patients With Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery - A Pharmacodynamic and Clinical Study to Decrease Bleeding Risks and Ischemic Complications - The RAPID-TITRATE CABG Study|RAPID CABG|Ottawa Heart Institute Research Corporation|Yes|Recruiting|February 2016|June 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|143|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02668562||3981|
NCT02689401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-419|MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer|MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|February 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689401||2384|
NCT02689414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16004|A Study of Remote Ischaemic Preconditioning in Patients With Atherosclerosis Undergoing Vascular Surgery|||Tartu University Hospital||Recruiting|January 2016|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02689414||2383|
NCT02667652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|776117|The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes|The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes:a Randomized Controlled Trials||Third Military Medical University|Yes|Active, not recruiting|January 2016|January 2018|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|65 Years|No|||February 2016|February 22, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667652||4051|
NCT02672254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPT-2016.11|New Strategies Against Cutaneous Squamous Cell Carcinoma|Investigation "in Vitro" of New Strategies Alternative to Surgery Against Cutaneous Squamous Cell Carcinoma: Topical Chemotherapy Followed by Superficial Radiotherapy.||Corporacion Parc Tauli|Yes|Completed|January 2016|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|3|Samples With DNA|A431NS cell cultures from ATCC of human cutaneous squamous carcinoma.|Female|N/A|N/A|No|Non-Probability Sample|A431NS human squamous cutaneous carcinoma cell line was obtained from the American Type        Culture Collection. A431NS cells were cultured in flasks of 25 cm2 with Dulbecco's        Modified Eagle's Medium (DMEM) supplemented with 1% penicillin/streptomycin, and with 10%        fetal calf serum to reach confluence. Two hundred thousand cells were seeded per well in        24-well plates, and incubated for 24 hours at 37ºC and 5% CO2.|January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02672254||3700|
NCT02674672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1419|A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System|A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System||B.Braun Médical - CoE Chasseneuil|No|Recruiting|September 2015|||September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02674672||3516|
NCT02674685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501106|Vfend Special Investigation For Prophylaxis|Vfend Special Investigation For Prophylaxis||Pfizer|No|Active, not recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|The subjects who have been treated with voriconazole for prophylaxis of invasive fungal        infections in patients undergoing HSCT (Hematopoietic Stem Cell Transplantation)|March 2016|March 23, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02674685||3515|
NCT02686151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bhsu|The Letrozole Administration During Luteal Phase|The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome||The Affiliated Hospital of Inner Mongolia Medical University|No|Not yet recruiting|April 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|20 Years|40 Years|No|||February 2016|February 15, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02686151||2634|
NCT02671643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1532|To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma|To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma Followed at a Subspecialty Clinic|ACT AA|University of North Carolina, Chapel Hill|No|Recruiting|October 2014|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|12 Years|18 Years|No|Non-Probability Sample|80 African-American adolescents ages 12-18 with a physician diagnosis of persistent        asthma. These adolescents are followed at the UNC Asthma Clinic seen by either pediatric        pulmonologists or allergists.|January 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02671643||3747|
NCT02665325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHInnerMongolia-Thyroid-01|Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma|Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma||The Affiliated Hospital of Inner Mongolia Medical University|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients aged 18-65 years; newly diagnosed differentiated thyroid carcinoma and undergone        thyroidectomy according to the China thyroid association guidelines for the Management of        thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.|January 2016|January 26, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02665325||4229|
NCT02669680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAFT|Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure|Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure: A Multicentre Randomized Trial||University of Leipzig|Yes|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02669680||3898|
NCT02674737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jinling37ICUCMH|Evaluation of the Effect of Appropriate Sedation for Patients After Gastrectomy: A Prospective Randomised Controlled Study|||Chinese Medical Association|Yes|Recruiting|January 2016|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||January 2016|February 3, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02674737||3511|
NCT02674750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-907-201|Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL|Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell Lymphoma||Curis, Inc.|Yes|Recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674750||3510|
NCT02665455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-UK-VAL-15026|FreeStyle Libre in Pregnancy Study|Evaluation of the Accuracy of the FreeStyle Libre Flash Glucose Monitoring System - Use in Pregnancy|FLIPS|Abbott Diabetes Care|No|Recruiting|January 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02665455||4219|
NCT02665702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-SH-001|Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas|Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study||Fudan University|No|Recruiting|January 2016|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|75 Years|No|||January 2016|January 24, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02665702||4200|
NCT02671903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15HH2828|The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).|AV Optimisation Delivered With Direct His Bundle Pacing, in Patients With Heart Failure, Long PR Without Left Bundle Branch Block: Randomised Multi-centre Clinical Outcome Study.|HOPE-HF|Imperial College London|Yes|Recruiting|January 2016|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|February 8, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671903||3727|
NCT02662270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibromyalgia and TDCs|QEEG and Qualitative EEG for the Identidification of Abnormal Patterns in Fibromyalgia Patients|Quantitative and Qualitative EEG From Fibromyalgia Patients for the Identification of Abnormal Patterns on Closed Eyes EEG|QEEGFP|Spanish Foundation for Neurometrics Development|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women between 20 and 70 years old divided in two groups, one consisting in 50        subjects diagnosed with fibromyalgia acording to the current criteria of the American        College of Rheumatology and a control group matched by age and gender without fibromyalgia|January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662270||4464|
NCT02675179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508108|EOS® Versus Spiral CT Technique for Achieving a Pelvimetry in Suites of Obstructed Labor.|EOS® Versus Spiral CT Technique for Achieving a Pelvimetry in Suites of Obstructed Labor: Comparative Single-center Prospective Study - PELVIC-EOS.|PELVI-EOS|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|February 2016|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|64|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02675179||3477|
NCT02675231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15804|A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer|monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer|monarcHER|Eli Lilly and Company|No|Not yet recruiting|April 2016|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675231||3473|
NCT02678962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIOLs2016|Comparison of Outcomes With Multifocal Intraocular Lenses|Comparison of Outcomes With Multifocal Intraocular Lenses|COMIL|Wenzhou Medical University|Yes|Recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|90|||Both|40 Years|80 Years|No|||February 2016|February 20, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02678962||3186|
NCT02679248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15NBHN|A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults|A Double Blind, Placebo Controlled Parallel Study to Investigate the Effect of a Nitric Oxide Supplementation Product on Pre- and Mildly Hypertensive Adults.|15NBHN|KGK Synergize Inc.|No|Recruiting|January 2016|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02679248||3164|
NCT02668406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melioidosis|Study to Obtain Blood Samples to Improve the Diagnosis of Melioidosis|Establishment of a Reference Clinical Sample Panel Allowing for the Development and Proof-of-concept Validation of an In-vitro Diagnostic Test for the Diagnosis of Melioidosis||Institute of Tropical Medicine, Belgium|No|Recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|3600|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients presenting with systemic inflammatory response syndrome.|February 2016|February 11, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668406||3993|
NCT02671019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1758-31/2|Effectiveness and Costs of Internet-based Treatment for Harmful Alcohol Use and Face-to-face Treatment in Addiction Care|Comparing Effectiveness and Costs of Internet-based Treatment for Problematic Alcohol Use and Face-to-face Treatment in Addiction Care: A Randomized Controlled Trial||Karolinska Institutet|No|Recruiting|November 2015|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02671019||3795|
NCT02676479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016|Uterine Irrigation Method in Infertility Patients Who Require PGD|The Histological and Genetic Investigation of Cells, Fluid and Tissue in the Uterine Cavity, Using the Uterine Irrigation Method, in Patients Who Suffer From Unexplained Infertility and Hereditary Genetic Disease, and Who Require PGD Scans.||Istanbul University|No|Enrolling by invitation|February 2016|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|21 Years|39 Years|No|||February 2016|February 29, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02676479||3377|
NCT02676492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-15/16-2278|A Naturalistic Study Investigating Sleep and Cognitive Learning in Children With and Without Tic Disorders|A Naturalistic Study Investigating Sleep and Cognitive Learning in Children With and Without Tic Disorders||King's College London|No|Not yet recruiting|March 2016|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Male|11 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Students at mainsteam secondary schools, patients of the Tic and Neurodevelopmental        (TANDeM) service at the Evelina Children's Hospital.|February 2016|February 3, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676492||3376|
NCT02665429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H00009241|A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department|A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department||University of Massachusetts, Worcester|No|Enrolling by invitation|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|110|||Both|N/A|N/A|No|||February 2016|February 13, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665429||4221|
NCT02682147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508782|Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema|Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema||University of Iowa|Yes|Not yet recruiting|March 2016|December 2023|Anticipated|February 2023|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|80|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02682147||2942|
NCT02682160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7310 02|Pilot Study to Evaluate Daily Protein's Intake Following Bariatric Surgery by Using the Software Protein Assistant|Pilot Study to Evaluate the Evolution of Daily Protein Intake in Obese Patients With Recent Bariatric Surgery, Using the Software Protein Assistant.||University Hospital, Toulouse|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|38|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02682160||2941|
NCT02669069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuromoddevices|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2016|||||N/A|N/A|N/A||||||||||||||January 28, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669069||3944|
NCT02673723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstHAnhuiMU|The Application of Docozine Combined With Sufentanil for Awake Tracheal Intubation|The Application of Docozine Combined With Sufentanil for Awake Tracheal Intubation—a Multiple Center, Randomized, Controlled，Double Blinded Clinical Trial||The First Affiliated Hospital of Anhui Medical University|Yes|Recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02673723||3589|
NCT02673736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX123-01|A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)||Plexxikon|No|Recruiting|February 2016|||February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673736||3588|
NCT02670629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR14-011|Management of Distal Radius Fractures in Children Younger Than 11 Years Old.|Management of Distal Radius Fractures in Children Younger Than 11 Years Old. Comparison Between Two Groups||Universidad Autonoma de Nuevo Leon|Yes|Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|11 Years|No|||January 2016|January 27, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02670629||3825|
NCT02670642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612C00004|Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD|On Demand vs Continuous Treatment of Endoscopy Negative Subjects With Gastroesophageal Reflux Disease (GERD) With Esomeprazole 20-mg Once Daily Over a 6 Months Long Term Treatment Phase. An Open, Randomised, Multicenter Study. NEED.|NEED|AstraZeneca|No|Completed|August 2001|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|877|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02670642||3824|
NCT02682914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYUH 2013-10-018|Stroke in Korean Young Adults Study||SKY|Hanyang University|Yes|Recruiting|December 2013|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|470|||Both|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|Patients who had their first-ever ischemic stroke symptoms within the previous month and        visited one of the 8 participating tertiary medical centers in the Republic of Korea.|February 2016|February 10, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02682914|3 Years|2883|
NCT02682927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX008-1501|A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCL) in Children and Young Adults With Dravet Syndrome|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome||Zogenix, Inc.|Yes|Recruiting|January 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|2 Years|18 Years|No|||March 2016|March 8, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682927||2882|
NCT02664805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0133-1180|Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema|A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema||LEO Pharma|No|Recruiting|February 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664805||4269|
NCT02665065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iomab-01|Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML|A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia|SIERRA|Actinium Pharmaceuticals|Yes|Not yet recruiting|June 2016|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|55 Years|N/A|No|||January 2016|January 28, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665065||4249|
NCT02673203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015469|Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects|Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects||Yale University|No|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673203||3629|
NCT02662608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIND15-0074|Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)|NOTCH 1 Inhibitor Brontictuzumab for Adenoid Cystic Carcinoma Bearing Two Activating NOTCH1 Mutations||M.D. Anderson Cancer Center|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02662608||4438|
NCT02692560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG043853|I-STAND R21: Reducing Sedentary Time in Obese Older Adults|Take Active Breaks From Sitting (TABS): Reducing Sedentary Time in Obese Older Adults||Group Health Cooperative|Yes|Recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|60 Years|89 Years|No|||February 2016|February 25, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02692560||2143|
NCT02675569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-1670|ACCESS HD: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis|ACCESS HD Pilot: A Randomized Trial Comparing Catheters to Fistulas in Elderly patientS Starting HemoDialysis|ACCESS HD|University of Calgary|No|Not yet recruiting|March 2016|September 2021|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||December 2015|February 3, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02675569||3447|
NCT02672761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR-Diako-MA-2015|Effect of 8 Weeks of MBSR Training on Neuroplasticity and Improvement of Attention, Memory and Well-Being|MBSR Improves Memory and Attention Due to a Stress Reduction as Opposed to Specific Memory Training|MBSR2015|Universitätsmedizin Mannheim|Yes|Recruiting|January 2016|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02672761||3662|
NCT02675075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1902-P|DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS|DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS||VA Office of Research and Development|No|Active, not recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|A Cohort of Veteran diagnosed with ALS seen at the Tampa VA|February 2016|February 2, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02675075||3485|
NCT02673294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNISA2016-01|Chronicity Dependence of a Balance Training in Adults Post-stroke|Chronicity Dependence of a Balance Training in Adults Post-stroke||Hospitales Nisa||Completed|February 2014|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Both|50 Years|65 Years|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673294||3622|
NCT02673307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-A00009-42|Chewing Gum and Gastric Emptying of Water|||Hôpital Edouard Herriot||Recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673307||3621|
NCT02681627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rego2015 1630|Sim (Scratch in Miscarriage) Study|Pilot Randomised Controlled Trial of the Effect of Endometrial Scratch in Recurrent Miscarriage on Pregnancy Outcomes|SiM|University Hospitals Coventry and Warwickshire NHS Trust|No|Recruiting|November 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|40 Years|No|||February 2016|February 11, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02681627||2982|
NCT02681640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-2015-1|uPAR PET/CT for Preoperative Staging of Breast Cancer Patients|Phase II Trial: uPAR PET/CT for Preoperative Staging of Breast Cancer Patients||Rigshospitalet, Denmark|No|Recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|85 Years|No|||March 2016|March 9, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02681640||2981|
NCT02671968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1510-SI / HypoDE|Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)|Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)||Science Consulting in Diabetes||Recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|March 17, 2016|January 25, 2016||||No||https://clinicaltrials.gov/show/NCT02671968||3722|
NCT02664168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016Jpar01|A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)|A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)||Rothman Institute Orthopaedics||Not yet recruiting|January 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664168||4318|
NCT02666924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCH RGH CCDS 1.0|The Effects of Culturally Specific Cooking Classes on Diabetes Control in Chinese Canadian Persons|The Effects of Attending Language and Culturally Appropriate Cooking Classes on Glycemic Control, Diabetes Knowledge and Self-management in Chinese-Canadian Patients Living With Diabetes Mellitus Type Two: A Pilot Study|CCDS|Vancouver General Hospital|No|Not yet recruiting|January 2016|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666924||4107|
NCT02677025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032061|Young Women's Health CoOp (Cooperative) in Cape Town|Seek, Test, Treat, & Retain Pilot for Out of School Teens at Risk in Cape Town|YWHC|RTI International|Yes|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|16 Years|21 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02677025||3335|
NCT02667080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20140023|Sperm Quality in Consecutive Sperm Samples After 4-7 Days and 2 Hours of Sexual Abstinence|Parameters of Sperm Quality in Consecutive Sperm Samples From Males Partners of Couples Seeking Treatment for Infertility||Aalborg University|No|Active, not recruiting|April 2014|December 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02667080||4095|
NCT02672124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEW MICRO SWIM-UP PROCEDURE|A New Micro Swim-up Procedure for Sperm Preparation in ICSI Treatment|||Cervesi Hospital, Cattolica, Italy||Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|This study included couples submitted to in vitro fertilization treatment at the Unit of        Physiopathology of Reproduction (Cervesi Hospital, Cattolica, RN, Italy).|January 2016|January 29, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02672124||3710|
NCT02563132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 08|Carbon Dioxide Insufflation Colonoscopy in IBD Patients|Carbon Dioxide Insufflation Colonoscopy in Inflammatory Bowel Disease Patients||Vitkovice Hospital|No|Recruiting|October 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563132||12077|
NCT02565836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15092404|Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed|Reversal of Warfarin-associated Major Hemorrhage: a Multicenter, Retrospective Cohort Study of Fixed-dose Activated (FEIBA VH) Versus Variable-dose Inactivated (Kcentra) Prothrombin Complex Concentrate||Rush University Medical Center|No|Enrolling by invitation|October 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|564|||Both|18 Years|N/A|No|Non-Probability Sample|Patients administered a prothrombin complex concentrate as part of routine care for INR        normalization due to a major bleed will be assessed for inclusion.|March 2016|March 22, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02565836||11870|
NCT02567981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-08|Comparison of Two Nutrition Interventions in Young Children in El Salvador|Impact of the Consumption of an M+ Fortified Premix (Chapuditos®) in 4 Rural Municipalities in the Department of La Libertad, El Salvador in Children From 6 to 59 Months.||The Mathile Institute for the Advancement of Human Nutrition|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4000|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567981||11705|
NCT02573909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH2014-004313-82|The Safety and Efficacy of Epidural Oxycodone|The Safety and Efficacy of Epidural Oxycodone|epioksipanu|Kuopio University Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|75 Years|No|||October 2015|October 12, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573909||11249|
NCT02573922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH24-02-2012|Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery|Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery|oksineukir|Kuopio University Hospital|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02573922||11248|
NCT02574312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|ATTUNE Single-Use Instrumentation vs. ATTUNE Reusable Instrumentation in Primary Total Knee Arthroplasty|Comparison of Alignment Achieved Using Single-Use Versus Reusable Instrumentation in Total Knee Arthroplasty (TKA): A Prospective, Non-Randomized Multi-center Investigation|SOLO|DePuy Orthopaedics|No|Recruiting|October 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|22 Years|80 Years|No|||October 2015|October 9, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574312||11218|
NCT02574325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-3037MO-006|A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis|||Arisaph Pharmaceuticals Inc|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574325||11217|
NCT02566928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1402-10800|Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence|Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence|CAMP-2|Clinical Directors Network|Yes|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|278|||Both|7 Years|70 Years|No|||February 2016|February 24, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566928||11786|
NCT02567175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010908|Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders|Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders||Children's Hospital of Philadelphia||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Years|N/A||||October 2015|October 1, 2015|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567175||11767|
NCT02573467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338B2203E1|An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203|Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis||Novartis|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|240|||Both|36 Years|N/A|No|||November 2015|November 16, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573467||11283|
NCT02562339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000956|Resiliency Training for Adolescents With Craniofacial Conditions and Their Caregivers|Examining the Psychosocial Effects of Resiliency Training for Adolescents With Craniofacial Conditions and Their Caregivers||Massachusetts General Hospital|No|Recruiting|May 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|14 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02562339||12138|
NCT02566512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:068|Assessment of Cough Strength in Patients With Tracheostomies|Assessment of Cough Strength in Patients With Tracheostomies||University of Manitoba|No|Recruiting|September 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|The study group will include all adult patients in the IICU, on prolonged mechanical        ventilation who are having spontaneous breathing trials as part of their weaning protocol.|June 2015|September 30, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02566512||11818|
NCT02574364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wxinhai|Abdomen CT and Open Appendicectomy：New Diagnostic and Surgical Procedures|Abdomen CT and Open Appendicectomy：New Diagnostic and Surgical Procedures|ACAOA|Ningbo Municipal No.4 Hospital|Yes|Completed|July 2013|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|730|||Both|15 Years|N/A|No|||October 2015|October 9, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02574364||11214|
NCT02533063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0480|Semi-Recumbent Vibration Therapy in Older Adults|Semi-Recumbent Vibration Therapy in Older Adults||University of Wisconsin, Madison|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02533063||14386|
NCT02543398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20130470H|Evaluation of Healing at Molar Extraction Sites With and Without Ridge Preservation|Evaluation of Healing at Molar Extraction Sites With and Without Ridge Preservation||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|October 2013|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 4, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02543398||13594|
NCT02543411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0933|Use of Lidocaine in Endoscopic Submucosal Dissection|Effect of Intravenous Lidocaine During Endoscopic Submucosal Dissection for Gastric Neoplasm||Severance Hospital|No|Completed|September 2015|||November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|20 Years|80 Years|No|||December 2015|December 14, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02543411||13593|
NCT02575105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGraz|BIS Monitoring of Patients With Hydrocephalus|Bispectral Index Monitoring of Propofol Anesthesia in Patients With Hydrocephalus. A Prospective Observational Study|BIS1|Medical University of Graz|No|Completed|May 2008|May 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|60|||Both|1 Month|65 Years|No|Non-Probability Sample|. In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control        patients at approximately the same age group will be included in the study.        In the second study 15 post cerebral hemorrhage adult patients undergoing        ventriculo-peritoneal shunt placements and 15 adult control patients will be included in        the study.|October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02575105||11157|
NCT02564614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29700|A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)|A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)||Hoffmann-La Roche||Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564614||11964|
NCT02568761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0637|Injection Snoreplasty and Oropharyngeal Exercises|Injection Snoreplasty and Oropharyngeal Exercises: Two Therapeutic Options in the Management of Snoring and Obstructive Sleep Apnea Syndrome.||Hospital de Clinicas de Porto Alegre|No|Recruiting|August 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02568761||11645|
NCT02578147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140697|JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls|JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls||University of Miami|No|Recruiting|September 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Female|11 Years|14 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578147||10923|
NCT02562859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1837-CL-103|Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food|An Open-label Study to Compare the Oral Bioavailability of an Oral Tablet of GLPG1837 Relative to an Oral Suspension After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Oral Tablet||Galapagos NV|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02562859||12098|
NCT02569658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rush TXA TSA|Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty|Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty||Rush University Medical Center|No|Recruiting|September 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569658||11576|
NCT02563223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-118|The Effect of Gravity on the Muscular Control of Landing From a Jump|The Effect of Gravity on the Muscular Control of Landing From a Jump|SLS-JUMP|University Hospital, Caen|No|Recruiting|November 2011|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02563223||12070|
NCT02566733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remifentanil_CPB|Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass|Performance of the Minto Model in Effect Site Mode for Target Controlled Infusion of Remifentanil During Cardiopulmonary Bypass||Seoul National University Hospital|Yes|Not yet recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|80 Years|No|||September 2015|October 1, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02566733||11801|
NCT02566746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0041|Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment||ConstiCAPE|Nantes University Hospital|No|Not yet recruiting|January 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|December 17, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02566746||11800|
NCT02578160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBEMATECH|Effectiveness of Tell-Show-Do Behavior-Management Technique During Local Anesthesia in Preschool Children|Effectiveness of Tell-Show-Do Behavior-Management Technique in Anxiety, Pain and Behavior Levels During an Inferior Alveolar and Lingual Nerve Block Procedure in Preschool Children: A Randomized Clinical Trial||University of Sao Paulo|No|Recruiting|October 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|36 Months|71 Months|No|||October 2015|October 17, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578160||10922|
NCT02565316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9470-7440|Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial|Efficacy of Nepeta Menthoides Boiss & Bohse Freeze Dried Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial||Shiraz University of Medical Sciences|Yes|Completed|November 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565316||11910|
NCT02565784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1315|Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population|An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population||Q-Med AB|No|Recruiting|December 2015|||December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565784||11874|
NCT02567942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160089|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer||Konkuk University Medical Center|No|Recruiting|July 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|300|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02567942||11708|
NCT02567955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV 2355|Immunogenicity and Safety of Gardasil-9 and Cervarix|Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule||Laval University|No|Recruiting|September 2015|November 2018|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|370|||Both|9 Years|10 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567955||11707|
NCT02568072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0035|Training-induced Increased Left Ventricular Trabeculation|Increased Left Ventricular Trabeculation in Athletes - a Marker of Left Ventricular Non-compaction or a Physiological Epiphenomenon of Increased Cardiac Preload?|MARATHON|St George's, University of London|No|Active, not recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|Blood samples. Urine samples.|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants running first marathon event in Virgin London marathon 2016.|November 2015|November 19, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02568072||11698|
NCT02570152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200274|A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia|A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia||GlaxoSmithKline||Not yet recruiting|January 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5000|||Both|6 Months|50 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570152||11538|
NCT02577952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009092|Lipodystrophy Connect Patient Registry|Lipodystrophy Connect Patient Registry||PatientCrossroads|No|Recruiting|January 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People with known or suspected lipodystrophy and their family members.|October 2015|October 14, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02577952|5 Years|10938|
NCT02567500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-HPNCL-02|The Physalis Child : Identification of Cognitive and Emotional Factors|Identification of Cognitive and Emotional Factors in Relation to Auditory Hallucinations in Non-psychotic Children||Fondation Lenval|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|6 Years|18 Years|No|||October 2015|October 2, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02567500||11742|
NCT02568358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuTx_Mibi-DNA-1|DNA-based Testing in BAL of Lung Transplant Recipients With Suspected Non-viral Lower Respiratory Tract Infection|DNA-based Testing in BAL of Lung Transplant Recipients With Suspected Non-viral Lower Respiratory Tract Infection||Hannover Medical School|No|Not yet recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|Samples With DNA|Bronchoalveolar lavage|Both|18 Years|N/A|No|Probability Sample|Lung transplant recipients with suspected non-viral lower respiratory tract infection|October 2015|October 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568358||11676|
NCT02565888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 14.12|A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat|A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers|DATE-4|Radboud University|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565888||11866|
NCT02565901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9388|Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP (RID))||University of Washington|No|Not yet recruiting|April 2016|||August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565901||11865|
NCT02565914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-661-110|A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation|A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|August 2015|December 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1375|||Both|12 Years|N/A|No|||September 2015|September 29, 2015|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565914||11864|
NCT02563860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-05-117|Pharmacological Treatment of Rett Syndrome With Statins|Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)|Statins|Montefiore Medical Center|No|Recruiting|July 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|3 Years|N/A|No|||September 2015|September 28, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563860||12021|
NCT02564991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150203|Study of Structural Imaging|Cross-Sectional and Longitudinal Study of Structural Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||August 2015|March 1, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02564991||11935|
NCT02567409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01642|Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer|A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma||National Cancer Institute (NCI)|Yes|Not yet recruiting|August 2016|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567409||11749|
NCT02566174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915206|Family Caregiving Role Adjustment and Dyadic Mutuality|Family Caregiving Role Adjustment and Dyadic Mutuality: A Mixed Methods Study||National Institutes of Health Clinical Center (CC)||Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|240|||Both|18 Years|100 Years|No|||September 2015|October 20, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02566174||11844|
NCT02566187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FAVC-CT-101|A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet|||Boryung Pharmaceutical Co., Ltd|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566187||11843|
NCT02571296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310|The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth|The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth||Ghamra Military Hospital|No|Recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|212|||Female|20 Years|40 Years|No|||October 2015|October 7, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02571296||11450|
NCT02573662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-ORTHOMET-01|Metabolic Complications Following Knee Injury in Young and Middle Aged Patients|Metabolic Complications Following Knee Injury in Young and Middle Aged Patients|OrthoMetKnee|Haugaard, Steen Bendix, M.D., DMSc|Yes|Recruiting|April 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|16|Samples With DNA|Blood and Urine sampling|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sixteen physical active non-diabetic individuals of age 18 to 50 years who are undergoing        knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are        recruited as cases for this case-control study.        Ten non-diabetic individuals matched for age, gender and physical activity are recruited        as control subjects.        The pre-surgical physical activity level is expected to be lower than their habitual        physical activity, however more than that which would be expected from individuals with a        sedentary life-style.        At least 6 of the control subjects will be examined another two times, that is, after 6        weeks and after 16 weeks for the purpose of time controls.|November 2015|November 8, 2015|March 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02573662||11268|
NCT02563743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2544/2014|Common Mental Disorders in the Workplace: Evaluation of an Intervention Conducted at the Occupational Health Services|Facilitating Return to Work Among Employees on Sick Leave Due to Common Mental Disorders (CMDs): a Cluster Randomized Controlled Trial of an Intervention Conducted at the Occupational Health Services||Karolinska Institutet||Enrolling by invitation|September 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02563743||12030|
NCT02587273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENTANYL06. Version 8|The Pharmacokinetics of Fentanyl in Intensive Care Patients|The Pharmacokinetics of Fentanyl in Intensive Care Patients|FENTANYL06|Oslo University Hospital|Yes|Recruiting|October 2015|November 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|June 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587273||10222|
NCT02589522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01779|VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer|Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Not yet recruiting|August 2016|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589522||10050|
NCT02571933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-04|Face Validity and Cross-Cultural Acceptability of the FPS-R in Cameroon|Face Validity and Cross-Cultural Acceptability of the FPS-R in Cameroon|FPS-RCam|Cameroon Baptist Convention Health|No|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|60|||Both|4 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population encompasses the four primary language-defined cultural groups that        present to Mbingo Baptist Hospital. Goal of 12-15 pediatric patients per cohort (Grammar        English, Pidgin English, French, and Fulfulde speaking), who have pain as part of their        presenting complaint.|January 2016|January 26, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02571933||11401|
NCT02577406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-221-AML-004|An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation|A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation|IDHENTIFY|Celgene|Yes|Recruiting|December 2015|February 2020|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|60 Years|N/A|No|||March 2016|March 10, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577406||10980|
NCT02578290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPAL-3872|Clinical Decision Support (CDS) for Outpatient Radiology Imaging|The Impact of Clinical Decision Support (CDS) for Outpatient Radiology Imaging: A Randomized Control Trial||Abdul Latif Jameel Poverty Action Lab|No|Enrolling by invitation|October 2015|October 2020|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2038|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578290||10912|
NCT02578316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-E044-104|A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.|An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.||Eisai Inc.|No|Completed|June 2009|October 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2015|December 10, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578316||10910|
NCT02564835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00096913|Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer|Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer||University of Michigan|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Both|21 Years|N/A|No|||September 2015|September 29, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02564835||11947|
NCT02565121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/427|Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital|Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital: Prevalence and Treatment||St. Olavs Hospital|No|Completed|June 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02565121||11925|
NCT02561754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1857|Weight Management for Adolescents With IDD|Weight Management for Adolescents With IDD|IDDAdol|University of Kansas Medical Center|No|Recruiting|March 2015|February 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|123|||Both|11 Years|21 Years|No|||September 2015|September 25, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561754||12183|
NCT02568345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191.837|Sugammadex ED90 Dose in the Obese Patients|Sugammadex ED90 Dose to Reverse the Rocuronium Blockade in the Obese Patients||Faculdade de Ciências Médicas da Santa Casa de São Paulo|No|Completed|January 2013|January 2014|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|60 Years|No|||January 2016|January 22, 2016|October 2, 2015||No||No|October 6, 2015|https://clinicaltrials.gov/show/NCT02568345||11677|
NCT02566096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229|Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively|Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine in Patients Undergoing Major Abdominal Cancer Surgery||Assiut University|Yes|Completed|September 2015|March 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|March 18, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566096||11850|
NCT02566213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-084|Human Fine-motor-skills in Weightlessness: Comparison of a Laboratory and an Everyday-like Context|Human Fine-motor-skills in Weightlessness: Comparison of a Laboratory and an Everyday-like Context|FINESKILL|University Hospital, Caen|No|Recruiting|October 2010|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02566213||11841|
NCT02573545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5261|Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case|Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case|IFE|University Hospital, Strasbourg, France|No|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|148|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02573545||11277|
NCT02566330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51074.068.14|The EndoBarrier Device: A 3-year Follow up Study|The Effect of the EndoBarrier Device: A 3-year Follow up of a Randomized Clinical Trial||Maastricht University Medical Center|Yes|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|29|||Both|18 Years|N/A|No|Non-Probability Sample|In this observational follow-up study of a randomized clinical trial a maximum of 29        participants may be included who were previously enrolled in the EndoBarrier device study        at the MUMC or the Atrium Medical Centre Heerlen.|October 2015|October 12, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02566330||11832|
NCT02566603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100-203|Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia|A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia||Protalex, Inc.|Yes|Recruiting|November 2015|November 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566603||11811|
NCT02576093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR1-14/2013|Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients|First-in-human, Single Center, Combined SAD/MAD, Double-blind, Placebo-controlled, Half-side Comparison Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of 0.1%, 0.3% and 1% WOL071-007-containing Formulations in Atopic Dermatitis Patients||Dr. August Wolff GmbH & Co. KG Arzneimittel|Yes|Completed|March 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|58|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02576093||11081|
NCT02566447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-01-2015|"Solana™ Trichomonas Assay Field Study"|"Solana™ Trichomonas Assay Field Study"||Quidel Corporation|No|Not yet recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Trichomonas vaginalis in vaginal swabs and urine samples|Female|N/A|N/A|No|Probability Sample|Female subjects symptomatic for Trichomonas vaginalis infection.|September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566447||11823|
NCT02565251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00022929|Volemic Resuscitation in Severe Sepsis and Septic Shock|Volemic Resuscitation in Severe Sepsis and Septic Shock||Iuliu Hatieganu University of Medicine and Pharmacy|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02565251||11915|
NCT02566876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02122013|Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders|A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders||Federico II University|Yes|Completed|December 2013|September 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|4 Years|18 Years|No|||September 2015|October 1, 2015|February 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02566876||11790|
NCT02572011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTU127818|Transtibial Amputee Balance Training: A Randomised Controlled Trial|A Games-console Based Balance Training Intervention for Transtibial Amputees: A Randomised Controlled Trial||Nottingham Trent University|No|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572011||11395|
NCT02569970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-562|Efficacy of Fluoxetine Against Seizure-induced Central Apneas|Efficacy of Fluoxetine Against Seizure-induced Central Apneas : a Randomized Placebo-controled Double-blind Trial.|FLUOXETINE|Hospices Civils de Lyon|Yes|Recruiting|November 2010|May 2017|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02569970||11552|
NCT02569983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_WM_040|The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research|A Multi-centre Prospective Pilot Observational Cohort Study to Assess Quality of Life and Survival After Surgery for Advanced Ovarian Cancer|SOCQER-2|University of Birmingham|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Female|18 Years|N/A|No|Non-Probability Sample|Ovarian cancer patients|October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569983||11551|
NCT02562794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15860|Addressing Mental Health Disparities in Refugee Children: A Community-based Participatory Research (CBPR) Collaboration|Addressing Mental Health Disparities in Refugee Children: A CBPR Collaboration||Harvard School of Public Health|No|Not yet recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 27, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02562794||12103|
NCT02569580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022-14-LND|Effectiveness of "No More" Anti-lice Medical Device to Kill Lice and Lice Eggs|Clinical Trial of Anti-Lice Treatment Using the Medical Device "No More" Which is Designed to Kill Lice and Lice Eggs on the Head.||Pharmayeda|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02569580||11582|
NCT02569853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFN-11-CD-004|DFN-11 Injection in Episodic Migraine With or Without Aura||RESTOR|Dr. Reddy's Laboratories Limited|No|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569853||11561|
NCT02563158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFJZYY-GD-15-01|Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC|Short- and Long-term Outcomes of Liver Resection With Versus Without Hepatic Inflow Occlusion for the Hepatitis B Virus-related Hepatocellular Carcinoma: a Prospective Randomized Controlled Trial|OHx-NOHx|Chinese PLA General Hospital|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|65 Years|No|||November 2015|November 29, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563158||12075|
NCT02570750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801392|The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis|Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis||Pfizer|No|Active, not recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with severe plaque psoriasis and starting an anti-TNF treatment with        etanercept|March 2016|March 1, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570750||11492|
NCT02572323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG048650|Tesamorelin for Cognition in HIV|Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons||University of California, San Diego|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|115|||Both|40 Years|70 Years|No|||February 2016|February 4, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572323||11371|
NCT02572336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01462|A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA|Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18||D-Pharm Ltd.|No|Recruiting|October 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2015|November 16, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02572336||11370|
NCT02562885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW2015|Effect of Auditory Stimulation on Spike Waves in Sleep|Effect of Closed-loop Auditory Stimulation on Spike Waves During Slow Wave Sleep, an Open Label Pilot Study|ECLASS|University Children's Hospital, Zurich|No|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|4 Years|12 Years|No|||August 2015|October 6, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02562885||12096|
NCT02566551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTM-02|Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment.|Prospective Controlled Randomized Study of Prostatic Arteries Embolization (PAE) vs Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia (BPH) Treatment.||Group of Research in Minimally Invasive Techniques|Yes|Recruiting|October 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|40 Years|N/A|No|||October 2015|October 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02566551||11815|
NCT02574858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00099903|Study of the Safety of QRH-882260 Heptapeptide||QRH-882260|University of Michigan|Yes|Enrolling by invitation|November 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02574858||11176|
NCT02587741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Third SunYetSan|Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens|Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens: a Multicentre Randomized Parallel-group Clinical Trial|CORRECT|Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|July 2015|July 2025|Anticipated|July 2023|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|30 Years|65 Years|No|||October 2015|October 25, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02587741||10187|
NCT02587754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Acupuncture in the Treatment of Fatigue in Parkinson's Disease|Acupuncture in the Treatment of Fatigue in Parkinson's Disease: a Pilot Randomized Controlled Study||Tan Tock Seng Hospital|Yes|Recruiting|May 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|85 Years|No|||October 2015|October 25, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02587754||10186|
NCT02561559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1393|SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma|Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma||Istituto Clinico Humanitas|Yes|Recruiting|April 2015|April 2020|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients affected by soft-tissue sarcomas with lung metastases unsuitable for surgery|September 2015|February 26, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561559||12198|
NCT02575521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM-IRB-14-08-2015|Effect of Propofol-Dexmedetomidine on Cerebral Oxygenation and Metabolism During Brain Tumor Resection|Effect of Propofol-Dexmedetomidine Total Intravenous Anaesthesia on Cerebral Oxygenation and Metabolism During Brain Tumor Resection Compared to Sevoflurane Anaesthesia||Mansoura University|Yes|Enrolling by invitation|August 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|60 Years|No|||October 2015|October 11, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02575521||11125|
NCT02590211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00639-40|Poker, Skills and Associated Problems|Poker, Skills and Associated Problems (PERHAPS). Controlled Experimental Single Centre Study of Poker Players: Study of the Cognitive Mechanisms Underlying Poker Skills and of the Specificity of Poker-related Problems|PERHAPS|Nantes University Hospital|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02590211||9997|
NCT02590328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSSCID|Neonatal Screening of Severe Combined Immunodeficiencies|Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs||Children's Hospital of Fudan University|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200000|Samples With DNA|Some drops of blood stored on the neonatal screening card (Guthrie card) as a source of DNA      to screening. Samples is performed after parents' information and consent. The card drawn      for the protocol will follow the usual network except that the test for quantifying TRECs      will be realized to determine the presence of SCID.|Both|N/A|28 Days|No|Non-Probability Sample|Screening newborns will be selected from all cooperative hospitals of Neonatal Screening        Programme in Shanghai who was born from 2016 to 2020.|October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590328||9988|
NCT02573623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12293 PROMISE-TB|Evaluation of an Innovative Tuberculosis Diagnostic Test|Evaluation, of Innovative Tuberculosis Diagnostic Tests - Promoting Infant Health and Nutrition in Sub-Saharian Africa (PROMISE Consortium)|PROMISE-TB|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|July 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||6|Anticipated|300|Samples Without DNA|Urine Serum Cell culture supernatant|Both|N/A|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 0 to 15 years with a definite diagnosis of tuberculosis infection,        HIV-infected or uninfected.        They will be matched on age and HIV status, to an equivalent number of children without        any evidence of tuberculosis infection.|October 2015|October 9, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02573623||11271|
NCT02567838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-022|Lidocaine Gel During Transrectal Sonography|Effect of Lidocaine Gel on the Pain Relief During Transrectal Sonography||Kangbuk Samsung Hospital|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|80|||Female|19 Years|80 Years|No|||October 2015|October 2, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567838||11716|
NCT02567851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_11-225|A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity|BREVITY: A Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity|BREVITY|University of Birmingham|No|Recruiting|February 2014|February 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||October 2015|October 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567851||11715|
NCT02570178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/01677|Effectiveness of an Intervention to Improve Balance and Decrease Falls in the Elderly (EWii)|Randomized Clinical Trial Evaluating the Effectiveness of a Primary Care Intervention Using the NintendoTM Wii Console to Improve Balance and Decrease Falls in the Elderly (EWii)|EWii|Jordi Gol i Gurina Foundation|Yes|Recruiting|September 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|760|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570178||11536|
NCT02571062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiHATFEX008|Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation|A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition||Drugs for Neglected Diseases|No|Completed|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|October 7, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02571062||11468|
NCT02571140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT-02-2013|A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects|A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects||Entera Bio Ltd.|Yes|Enrolling by invitation|October 2013|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571140||11462|
NCT02573350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-07-208|A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683|A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID With Optional Titration to 200 mg BID for up to Six Months Exposure in Patients With Pulmonary Multi-drug Resistant Tuberculosis||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|March 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|213|||Both|18 Years|64 Years|No|||October 2015|October 13, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573350||11292|
NCT02562079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/37|Vasculopathy, Inflammation and Systemic Sclerosis|Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation|VISS|University Hospital, Bordeaux|No|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|270|||Both|18 Years|75 Years|No|||September 2015|September 25, 2015|December 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02562079||12158|
NCT02562092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080817|The Georgia Latino AIDS/HIV Diagnosis and Linkage in Youth (GLADLY) Project|The Georgia Latino AIDS/HIV Diagnosis and Linkage in Youth (GLADLY) Project|GLADLY|Emory University|No|Recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|460|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02562092||12157|
NCT02564237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE1201|A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults|A Phase I, Randomized, Observer-blind, Comparator-controlled, Study of the Safety and Immunogenicity of StreptAnova™ Vaccine in Healthy Adults Age ≥ 18 - 50 Years||Dalhousie University|Yes|Recruiting|August 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564237||11992|
NCT02573025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YV29573|A Bioequivalence Study of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys®) Following Subcutaneous Administration|An Open-label, Randomized, Multi-center, Single Dose, Two-period, Two Sequence Crossover Study to Investigate the Bioequivalence of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol-free Formulation Versus the Reference Market Formulation Following Subcutaneous Administration Via Prefilled Syringe in Healthy Chinese Subjects||Hoffmann-La Roche||Active, not recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|273|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573025||11317|
NCT02575092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lu 20143440|The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment|Department of Geriatrics|CONTRAST-CADT|Fuling Central Hospital of Chongqing City|Yes|Recruiting|November 2015|June 2018|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|4000|||Both|40 Years|85 Years|No|||February 2016|February 1, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575092||11158|
NCT02564081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpM2015-001|Remote Effects of Lower Limb Stretching|||Goethe University||Completed|August 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564081||12004|
NCT02566525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery|CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery|REFRESH|CytoSorbents, Inc|Yes|Recruiting|November 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566525||11817|
NCT02543320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1102|LORETA (Low Resolution Electromagnetic Tomography) Neurofeedback|Neurofeedback for Acute Radiotherapy-Induced Pain in Head and Neck Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2014|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02543320||13600|
NCT02538029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1000|The Effects of Dual Task Training in Individuals With Parkinson's Disease|The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease||The Cleveland Clinic|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|N/A|N/A|No|||January 2016|January 27, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02538029||14004|
NCT02538120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A010008-35|Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients|Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1|NEURODIAB1|University Hospital, Angers|Yes|Completed|May 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|February 11, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02538120||13997|
NCT02531490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC152017|Early Vascular Adjustments During Hypertensive Pregnancy|Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial|EVA|Maastricht University Medical Center|No|Recruiting|December 2015|April 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|368|||Female|18 Years|50 Years|No|||February 2016|February 4, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531490||14505|
NCT02576821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14-P010|Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease|Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease|ShaTau7|Centre Hospitalier St Anne|No|Recruiting|January 2016|October 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576821||11025|
NCT02572817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC-005|Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A|A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||March 2016|March 8, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572817||11333|
NCT02562872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_DSM265_14_03|DSM265 Prophylaxis of Plasmodium Falciparum Malaria|Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum||Medicines for Malaria Venture|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562872||12097|
NCT02574546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1585|Markers for Predicting Risk of Breast Cancer in Women of Different Races|Molecular Markers for Predicting Risk of Developing Breast Cancer in Different Ethnicities||Sidney Kimmel Comprehensive Cancer Center|No|Not yet recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood and breast tissue (normal and tumor cells) samples will be collected.|Female|18 Years|N/A|No|Non-Probability Sample|Women with a newly diagnosed breast cancer planning bilateral mastectomy.|October 2015|October 9, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02574546||11200|
NCT02567708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201543|A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Crossover Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma||GlaxoSmithKline|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|March 10, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02567708||11726|
NCT02570542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-193|Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)|A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)||Memorial Sloan Kettering Cancer Center||Recruiting|October 2015|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570542||11508|
NCT02563106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-2-004-005|A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI|A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection||Synthetic Biologics Inc.|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|372|||Both|50 Years|N/A|No|||November 2015|November 16, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563106||12079|
NCT02569931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0068|The Unstable Kneecap - the Impact of Anatomy on Function|Surgery for Patellofemoral Instability, is There Normal Gait|SPRING|St George's, University of London|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569931||11555|
NCT02574598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/014/033/ICI|MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients|A Randomized Crossover, Phase II Clinical Trial of MK-3475 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Treated.||Instituto Nacional de Cancerologia de Mexico|No|Not yet recruiting|January 2016|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||October 2015|October 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574598||11196|
NCT02577055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140311|Fertility After Poly-myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids|Fertility After Poly-myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids|Lune2|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|April 2016|April 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|294|||Female|18 Years|40 Years|No|||February 2016|February 23, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02577055||11007|
NCT02577068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0746|Combination Effect of Nefopam With Propacetamol for Postoperative Pain After Thyroidectomy|||Yonsei University|No|Not yet recruiting|October 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|84|||Both|20 Years|70 Years|No|||October 2015|October 13, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02577068||11006|
NCT02562001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43450715.7.0000.0068_CAAE|Association Between tDCS and Lokomat Training in Patients With Incomplete Spinal Cord Injury|Association of Transcranial Direct Current Stimulation (tDCS) With Gait Training With Partial Body Weight Support on the Robotic Device (Lokomat) for Treatment of Patients With Incomplete Spinal Cord Injury||University of Sao Paulo General Hospital|No|Not yet recruiting|November 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02562001||12164|
NCT02562014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #27112|Role of Colonic Short Chain Fatty Acids in Obesity|Effect of Inulin and Resistant Starch on Postprandial Short Chain Fatty Acid, Glucose, Insulin and Gut Hormone Responses in Lean and Overweight Subjects.||University of Toronto|No|Completed|February 2012|January 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562014||12163|
NCT02562027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509035|SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer|Objective Treatment Allocation With SBRT vs. Surgery in High Risk Patients With Early Stage Lung Cancer Within an Accountable Care Collaborative Effort Between Surgery and Radiation Oncology||Washington University School of Medicine|No|Not yet recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Participants from Washington University School of Medicine and the Barnes Jewish medical        system.|September 2015|September 24, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02562027||12162|
NCT02572167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-025|A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma|A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy||Seattle Genetics, Inc.|No|Recruiting|October 2015|May 2020|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572167||11383|
NCT02572414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813202|Men Together Making a Difference: Health Promotion for Black Men|Health Promotion for HIV Positives: A Randomized Trial With HIV Positive Black Men||University of Pennsylvania|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|384|||Male|40 Years|N/A|No|||September 2015|October 7, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02572414||11364|
NCT02574715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18096|An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method|A Cross-sectional, Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess® as Their Contraceptive Method - The JULIA Study|JULIA|Bayer|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1200|||Female|18 Years|29 Years|No|Non-Probability Sample|A total of 1,200 women aged 18 to 29 will be consecutively included in this study as they        present at private gynecology clinics. Subjects must have been using the Jaydess        intrauterine delivery system as their contraceptive of choice for a period of 6 (±1)        months.        The study population may be stratified into subsets to assess and identify differences in        the subjects' quality of life, social and demographic characteristics, contraception        characteristics, satisfaction, perceived benefits of Jaydess and bleeding pattern        features.|March 2016|March 1, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02574715||11187|
NCT02565576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFZ533X2204|Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis||Novartis|Yes|Recruiting|September 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|85 Years|No|||March 2016|March 3, 2016|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565576||11890|
NCT02565589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK_ICU_healthy|Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients|Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients||Yonsei University|No|Completed|April 2014|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|From April 2014 to July 2015, 24 critically ill patients were enrolled in this study after        admission to the ICU at Yonsei University Severance Hospital. For validation of the        experimental findings, age-, sex- and BMI-matched healthy subjects were enrolled as        controls among individuals seen at a health evaluation center during the same period.|September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565589||11889|
NCT02570984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00019640|Controlling and Preventing Asthma Progression and Severity in Kids|Controlling and Preventing Asthma Progression and Severity in Kids|CASK|Children's Hospital Boston|Yes|Not yet recruiting|September 2016|September 2024|Anticipated|September 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|24 Months|47 Months|No|||October 2015|October 21, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570984||11474|
NCT02570997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cog 0101|Ascending Dose Study of CT1812 in Healthy Volunteers|A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers||Cognition Therapeutics|Yes|Recruiting|September 2015|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|114|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02570997||11473|
NCT02572661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N14SUS|Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT)|Mapping of Sentinel Lymph Node Drainage Using SPECT to Tailor Highly‐Selective Elective Nodal Irradiation in Node‐Negative Neck of Patients With Head and Neck Cancer (SUSPECT)|SUSPECT|The Netherlands Cancer Institute|Yes|Recruiting|July 2015|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|October 8, 2015|December 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02572661||11345|
NCT02572674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071245|Study of Predictor of Mood Relapse in Bipolar Disorders|Study of Predictor of Mood Relapse in Bipolar Disorders : Prospective, Clinical, Neuropsychological, Biological and Genetic Study|RechuteBP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|274|||Both|18 Years|55 Years|No|||July 2015|October 8, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02572674||11344|
NCT02562924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 15-010|The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery|An Open-label, Prospective, Randomized, Pilot Clinical Study to Study the Efficacy of MEDIHONEY® Rinses Compared to Intranasal Corticosteroid Rinses in Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery||University of Vermont Medical Center|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 26, 2015|April 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02562924||12093|
NCT02562937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECotten|Reducing Sedentary Behaviour in University Students Using Text Messages|Reducing Sedentary Behaviour In University Students Using A Text Message-Based Intervention||Western University, Canada|Yes|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562937||12092|
NCT02586753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MianyangCH001|Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus|A Phase II Study to Compare Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus||Mianyang Central Hospital|Yes|Not yet recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02586753||10262|
NCT02568033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-130|Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer|Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001)||The Cooper Health System|No|Recruiting|October 2013|||October 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568033||11701|
NCT02569060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A125548|Feeding America Intervention Trial for Health--Diabetes Mellitus|Feeding America Intervention Trial for Health--Diabetes Mellitus|FAITH-DM|University of California, San Francisco|No|Recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569060||11622|
NCT02572960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-LSB|Physiologic Interactions Between the Adrenal- and the Parathyroid Glands|Physiologic Interactions Between the Adrenal- and the Parathyroid Glands|AldOst|University of Aarhus|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Female|60 Years|80 Years|No|||September 2015|October 8, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572960||11322|
NCT02572973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014928|Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders|Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders: A Pilot Study|ANM|Weill Medical College of Cornell University|No|Recruiting|July 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02572973||11321|
NCT02586974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0052588|Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response|Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response: Head-to-head Randomized Comparison Versus Standard Insufflation During Robot Assisted Radical Prostatectomy||Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Recruiting|September 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|64|||Male|40 Years|80 Years|No|||October 2015|October 23, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02586974||10245|
NCT02586987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1345C00003|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 in Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|130 Years|No|||March 2016|March 11, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586987||10244|
NCT02576782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS2015-1|Dexamethasone & Bupivacaine vs Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Perioperative Analgesia in Patients Undergoing Lower Limb Surgeries|Combination of Dexamethasone and Bupivacaine Versus Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Intraoperative and Postoperative Analgesia in Patients Undergoing Lower Limb Vascular Surgeries||Cairo University|No|Completed|June 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|63|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02576782||11028|
NCT02576119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-044|A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects|A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|76|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576119||11079|
NCT02567656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP6530-1401|Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma|A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma||Rhizen Pharmaceuticals SA|Yes|Recruiting|September 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567656||11730|
NCT02567669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008778|Muscle Loss and Fatigue as a Consequence of Radiotherapy|Muscle Loss and Fatigue as a Consequence of Radiotherapy|MUSFAT|Essentia Health|No|Not yet recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with nonmetastatic breast cancer with indications for postoperative radiotherapy|October 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567669||11729|
NCT02579629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00073292|Use of On-Q Pump for Pain Post C-Section|Multimodal Post-Cesarean Analgesia With Spinal Morphine and Continuous Wound Infiltration of Ropivacaine Using the OnQ® Elastomeric Pump: A Dose-Ranging Study Using a High-Volume, Low-Dose Protocol||Emory University|No|Enrolling by invitation|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|August 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579629||10810|
NCT02577419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048134|Optimizing Growth in Infants Receiving Modified Fat Breast Milk for the Treatment of Chylothorax|Optimizing Growth in Infants Receiving Modified Fat Breast Milk for the Treatment of Chylothorax Following Cardiothoracic Surgery||The Hospital for Sick Children|No|Recruiting|October 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|21|||Both|N/A|12 Months|No|||October 2015|October 13, 2015|October 1, 2015||||No||https://clinicaltrials.gov/show/NCT02577419||10979|
NCT02561637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICAM2015|The Effect of Spouses' Involvement Through Case Management in Older Patients' Fast-track Program|The SICAM-trial: Studying the Effect of Spouses' Involvement Through Case Management in Older Patients' Fast-track Program During and After Total Hip Replacement - A Quasi-experimental Study With a Complex Intervention|SICAM|University of Aarhus|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02561637||12192|
NCT02569424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0246|Effect of PEEP and Trendelenburg on Ultrasound Size of Internal Jugular and Subclavian Veins|Effect of PEEP and Trendelenburg on Ultrasound Size of Internal Jugular and Subclavian Veins: A Cross-over Randomized Controlled Study|PEEPUS|University Hospital, Clermont-Ferrand||Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02569424||11594|
NCT02565940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-35|Study by Metagenomics and Culturomicsapproaches of Bacterial and Viral Flora of Diabetic Foot Infection|||Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2014|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||150|||Both|18 Years|N/A|No|Probability Sample|diabetic patient with foot infection|September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565940||11862|
NCT02572882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823162|Gut Microbiome and p-Inulin in Hemodialysis|A Multi-center Study to Characterize the Gut Microbiome of Individuals With End-stage Renal Disease Treated With Maintenance Hemodialysis, and to Explore Effects of P-inulin on the Gut Microbiome||University of Pennsylvania|Yes|Not yet recruiting|October 2015|June 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|85 Years|No|||August 2015|October 7, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02572882||11328|
NCT02570659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erics Whiplash RCT|Investigating the Effect of an Information Video for Neck Injuries in a Emergency Department Setting|A Randomized Controlled Trial Evaluating the Effect of an Information Video in a Acute Whiplash Population||Karolinska Institutet|No|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02570659||11499|
NCT02570672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-237H|Metformin for Preventing Frailty in High-risk Older Adults|||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|65 Years|90 Years|No|||October 2015|October 6, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02570672||11498|
NCT02576015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZK-07|The Effect of Continuous Femoral Nerve Block With Modulation of Depth of Anesthesia on Prognosis of Patients Receiving Total Knee Arthroplasty|The Effect of Continuous Femoral Nerve Block With Modulation of Depth of Anesthesia on Prognosis of Patients Receiving Total Knee Arthroplasty||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|80 Years|No|||October 2015|October 14, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02576015||11087|
NCT02576028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1173-0402|Fascial Manipulation® Associated With Standard Care Versus Standard Post-surgical Care for Total Hip Arthroplasty|Fascial Manipulation® Associated With Standard Care Versus Standard Post-surgical Care for Total Hip Arthroplasty: a Randomized Controlled Trial.||Azienda Ospedaliera Bolognini di Seriate Bergamo|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02576028||11086|
NCT02576041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIN/14/Bil-ARU/001|Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria||F1|Menarini International Operations Luxembourg SA||Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Both|21 Years|55 Years|No|||January 2016|January 22, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576041||11085|
NCT02571166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49596-J|HSV529 Vaccine in HSV-2 Seropositive Adults|Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571166||11460|
NCT02571179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH12_04_2010|Intranasal Fentanyl in Treatment of Labour Pain|Intranasal Fentanyl in Treatment of Labour Pain - Efficacy and Safety|fentaobs|Kuopio University Hospital|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|45 Years|No|||March 2016|March 9, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571179||11459|
NCT02575469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0323-14- RMB-CTIL|Exercise Capacity in Diseases and Health|Exercise Capacity in Diseases and Health||Rambam Health Care Campus|No|Not yet recruiting|October 2016|January 2036|Anticipated|October 2035|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|6 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and        healthy volunteers evaluated as controls.|September 2015|October 12, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575469||11129|
NCT02571842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWC-006|Rituximab in Recurrent IgA Nephropathy|A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology||Chulalongkorn University|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571842||11408|
NCT02577276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006308|Evaluation of a Tele-Rehabilitation Service Program|Joint Gertner ReAbility Online and Mayo Clinic Feasibility Study: Evaluation of a Tele-Rehabilitation Service Program||Mayo Clinic|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|80 Years|No|||October 2015|October 26, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577276||10990|
NCT02571283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.1276|Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel|A Randomized, Prospective Trial Comparing Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel||University of Louisville|Yes|Not yet recruiting|October 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|October 6, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02571283||11451|
NCT02569281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 08-2015|US-guided Percutaneous Electrolysis (EPE®) in Shoulder Pain|Effectiveness of the Inclusion of US-guided Percutaneous Electrolysis (EPE®) in Subacromial Pain Syndrome||Universidad Rey Juan Carlos|Yes|Active, not recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||February 2016|February 25, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569281||11605|
NCT02572024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BATstudy|The Effect of Baroreflex Activation Therapy (BAT) on Blood Pressure and Sympathetic Function in Patients With Resistant Hypertension (The Nordic BAT Study)||The Nordic BAT|Helsinki University Central Hospital||Recruiting|November 2015|||November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572024||11394|
NCT02576171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoFT Pilot|Group Therapy Supported Internet-based CBT for Adolescents With Social Anxiety Disorder - A Feasibility Trial|Group Therapy Supported Internet-based Cognitive Behavioral Therapy for Adolescents With Social Anxiety Disorder - A Feasibility Trial|SoFT|Karolinska Institutet|No|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|17 Years|No|||October 2015|October 20, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576171||11075|
NCT02566720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0452|Amantadine and Functional Improvement Following ABI Measured by MRI Tractography; A Pilot Study|Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study||Hamilton Health Sciences Corporation|No|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566720||11802|
NCT02573779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36828|Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk|Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk||Baylor College of Medicine|No|Enrolling by invitation|August 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|125|||Both|N/A|3 Days|No|Non-Probability Sample|Newborn infants less than 1500 g birth weight who are fed primarily either mother's own        milk or donor human milk.|October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573779||11259|
NCT02561598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2884|A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia|A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|350|Samples With DNA|Samples from other approved projects will be used from both malignant hyperthermia cases and      controls.|Both|N/A|N/A|No|Non-Probability Sample|Cases are selected from the medical records at Cincinnati Children's Hospital Medical        Center who have a current malignant hyperthermia diagnosis. Control cases are selected        based on previous participation in pharmacogenetic research and had exposure to agents        known to trigger malignant hyperthermic episodes.|September 2015|September 25, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02561598||12195|
NCT02568137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NS094033|Phone-based Intervention Under Nurse Guidance After Stroke|Phone-based Intervention Under Nurse Guidance After Stroke|PINGS|Medical University of South Carolina|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|October 1, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02568137||11693|
NCT02577796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-09-19|Radial Artery Spasm Leading to Occlusion in Patients Undergoing Coronary Angiogram Via Radial Access|Association of Radial Artery Spasm With Development of Radial Arterial Occlusion in Patients Undergoing Diagnostic Angiogram and/or Percutaneous Coronary Intervention (PCI) Via Radial Access||Maimonides Medical Center|Yes|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with an informed consent undergoing successful and atraumatic transradial        cannulation for either diagnostic angiography/percutaneous coronary intervention ( PCI)        over 18 years of age|October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577796|30 Days|10950|
NCT02577120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0116|Wound Healing Endpoint and Recurrence|Wound Healing Endpoint and Recurrence||Ohio State University|Yes|Recruiting|May 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Anticipated|265|Samples With DNA|Tissue|Both|18 Years|N/A|No|Probability Sample|265 clinically diagnosed infected burn or chronic wound patients|October 2015|October 13, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02577120||11002|
NCT02566564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-071-P01|Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain|An Open Label, Single Dose, Dose-escalating Phase I/IIa Study to Determine the Safety and Clinical Effects of Intra-articular Injections of Lopain (MTX-071) in Patients With Chronic Osteoarthritic Knee Joint Pain||Mestex AG|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|23|||Both|40 Years|70 Years|No|||October 2015|October 2, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02566564||11814|
NCT02571504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-367 BMD|Cognitive Training for the Remediation of Functional Brain Health in HIV|Brain Imaging to Understand HIV-associated Neurocognitive Disorder and Predict Response to Cognitive Training||McGill University|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|35 Years|N/A|No|||October 2015|October 7, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02571504||11434|
NCT02575859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/13|Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients|Pilot Study of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Colorectal Cancer at High Risk for the Development of Metachronous Peritoneal Metastases||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|January 2006|December 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||September 2015|October 13, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02575859||11099|
NCT02561689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCopenhagen|SEALANT-DK: Longevity and Efficacy of 6 Resin Sealants Used for Sealing Permanent Teeth in Children and Adolescents|SEALANT-DK: Longevity and Efficacy of 6 Resin Sealants Used for Sealing Permanent Teeth in Children and Adolescents|SEALANT-DK|University of Copenhagen|Yes|Recruiting|January 2014|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|December 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02561689||12188|
NCT02590133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015-031-01|A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC|A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|July 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590133||10003|
NCT02566252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUL-042-003|Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)|A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodium or Albuterol Sulfate||Pulmotect, Inc.|No|Recruiting|July 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566252||11838|
NCT02566473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50HS018910|FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry|Improving Orthopedic Outcomes Through a National TJR Registry|FORCE-TJR|University of Massachusetts, Worcester|No|Recruiting|April 2011|April 2031|Anticipated|April 2031|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women older than age 18, who schedule elective primary or revision arthroplasty        (total joint replacement; hip resurfacing; uni-compartmental knee procedures|September 2015|September 30, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02566473|20 Years|11821|
NCT02563119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBeglinger|Intestinal Microbiota in Patients Before and After Bariatric Surgery and Healthy Controls|Characterization of Intestinal Microbiota in Healthy Subjects and Patients Before and After Bariatric Surgery Using Next Generation Sequencing Methods||University Hospital, Basel, Switzerland|No|Completed|October 2013|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563119||12078|
NCT02565524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-HPNCL08|Exploration and Characterization of Genetic and Phenotypic Profile of the"Schizotiste"|Exploration and Characterization of Genetic and Phenotypic Profile of the "Early Dissociative Disorder" Associated With Autism Spectrum Disorder: a Pilot Study|GenAuDiss|Fondation Lenval|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|7 Years|18 Years|No|||September 2015|September 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565524||11894|
NCT02569671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/14|Bone Level Tapered Multi-Center Study|Immediate Placement of the Straumann® Bone Level Tapered Implant With Early Loading in Single Tooth Gaps in the Maxilla and Mandible Compared to Delayed Placement||Institut Straumann AG|No|Recruiting|October 2015|May 2022|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569671||11575|
NCT02581618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trakya-Kardiyo-2015-1|Remote Ischemic Preconditioning in Elective Percutaneous Interventions|Effect of One Cycle Remote Ischemic Preconditioning on Myocardial Injury After Percutaneous Coronary Interventions in Patients With Stable Coronary Artery Disease||Trakya University|No|Completed|May 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581618||10657|
NCT02562586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1055|Is Drainage Necessary After Total Hip Replacement?|Is Drainage Necessary After Total Hip Replacement? A Randomized Controlled Trial||University of Sao Paulo|No|Completed|May 2014|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02562586||12119|
NCT02571998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-009|A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris|A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel Versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects With Moderate to Severe Acne Vulgaris||Cutanea Life Sciences, Inc.|No|Recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Female|12 Years|N/A|No|||February 2016|February 29, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571998||11396|
NCT02575417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003004|Development of a Community Engagement Activity for Advance Care Planning|Development of a Community Engagement Activity for Advance Care Planning|CERC|Milton S. Hershey Medical Center|Yes|Recruiting|August 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575417||11133|
NCT02573363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0412|Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia|Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)||University of Chicago|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|N/A|N/A|No|||January 2016|January 5, 2016|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573363||11291|
NCT02566278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD151355|Determination of Upper Airway Collapsibility During Routine CPAP Titration|Determination of Upper Airway Collapsibility During Routine CPAP Titration||University of California, San Diego|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|79 Years|No|||September 2015|September 30, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02566278||11836|
NCT02568423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16172|A Study of LY3074828 in Healthy Participants|A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects||Eli Lilly and Company|No|Active, not recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|42|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568423||11671|
NCT02576756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULINT|Retrospective Study in Patients Who Have Had a Difficult Intubation.|Retrospective Study of the Risk of Aspiration and Postoperative Pulmonary Problems in Patients Who Have Had a Difficult Intubation.||Universitair Ziekenhuis Brussel|No|Active, not recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Every patients who had an intubation where another device than a laryngoscope was        necessary|October 2015|October 15, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576756||11030|
NCT02576769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC1|The Role of Melanocyte in Basal Cell Carcinoma|Melanocyte Features and Its Influence in Pigmentation in Basal Cell Carcinoma in the Mexican Population||Universidad Autonoma de San Luis Potosí|No|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with histologic diagnosis of basal cell carcinoma|October 2015|October 13, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576769||11029|
NCT02568280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3922|Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|A Randomised Trial Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|64 Years|No|||October 2015|October 8, 2015|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568280||11682|
NCT02568514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823096|Study of the Effect on Clinical Outcomes Using Secure Text Messaging|Study of the Effect on Clinical Outcomes Using Secure Text Messaging||University of Pennsylvania|No|Not yet recruiting|September 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 15, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568514||11664|
NCT02571244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022.420.000-11|Text Messaging for Supporting Quit Attempts|Telephone Counseling and Text Messaging for Supporting Post-discharge Quit Attempts Among Hospitalized Smokers in Brazil||Federal University of Juiz de Fora|No|Recruiting|June 2015|February 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02571244||11454|
NCT02637557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-3718-202|A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD|A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors||Ironwood Pharmaceuticals, Inc.|No|Not yet recruiting|February 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02637557||6363|
NCT02637570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394423|Effect of Hibiscus Tea and Green Tea Supplements on Athletic Performance, Blood Pressure, Muscle Damage Indices and Oxidative Stress in Male Athletes 18-35 Years Old and Cardiovascular Disease Prevention Approach|||Isfahan University of Medical Sciences||Recruiting|October 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|60|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02637570||6362|
NCT02540512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15063|Acupuncture for Pain in the Emergency Department|Auricular Acupuncture for the Acute Management of Pain in the Emergency Department||Loma Linda University|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|16 Years|89 Years|No|||September 2015|September 1, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02540512||13814|
NCT02535403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chilled Out DK|Internet-based Cognitive Behavioral Therapy (CBT) for Adolescents With Anxiety Disorders|||University of Aarhus||Recruiting|August 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|13 Years|17 Years|No|||August 2015|August 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02535403||14206|
NCT02562976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxhnk3062|OLGA Stage is More Appropriate in Predicting Early Gastric Cancer|OLGA Stage is More Appropriate in Predicting Early Gastric Cancer Than Endoscopic Gastric Atrophy Classification and OLGIM Stage: A Prospective Study||Shanghai Jiao Tong University School of Medicine|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|227|||Both|40 Years|80 Years|No|Non-Probability Sample|The study involved consecutive patients from 40-80 years who undergoing        esophagogastroduodenoscopy|September 2015|September 27, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02562976||12089|
NCT02561767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCs-KTx-DCD-150924|Effect of BM-MSCs in DCD Kidney Transplantation|The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561767||12182|
NCT02567578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH12852-201|A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia|A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia||Yuhan Corporation|No|Suspended|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|420|||Both|19 Years|N/A|No|||January 2016|January 3, 2016|October 1, 2015||No|due to dose re-selection|No||https://clinicaltrials.gov/show/NCT02567578||11736|
NCT02562183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLK-4002|The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein|The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein||Techpool Bio-Pharma Co., Ltd.|No|Enrolling by invitation|August 2015|March 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2186|||Both|18 Years|80 Years|No|||December 2015|December 24, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02562183||12150|
NCT02577003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431J-843|Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy||Merck Sharp & Dohme Corp.|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|138|||Both|20 Years|N/A|No|||March 2016|March 16, 2016|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02577003||11011|
NCT02577016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431J-842|Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin Monotherapy in Addition to Diet and Exercise Therapy||Merck Sharp & Dohme Corp.|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|138|||Both|20 Years|N/A|No|||March 2016|March 18, 2016|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02577016||11010|
NCT02573493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510013|Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Phase II Non-Randomized Two Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arm 1) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".|APA|Washington University School of Medicine|No|Not yet recruiting|January 2016|July 2028|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573493||11281|
NCT02573610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-108|Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery|A Randomized, Double-masked, Parallel Group Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery (Levofloxacin 0.5% Ophthalmic Solution as a Comparator) - Phase III, Confirmatory Study of Perioperative Bacteria Eradication -||Santen Pharmaceutical Co., Ltd.|No|Recruiting|September 2015|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|430|||Both|19 Years|N/A|No|||November 2015|November 11, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573610||11272|
NCT02567812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-04-009|Database of Pelvic Inflammatory Disease|Prospective Data Collection of Patients With Pelvic Inflammatory Disease||Kangbuk Samsung Hospital|No|Recruiting|October 2015|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|19 Years|80 Years|No|Probability Sample|Pelvic inflammatory disease or pelvic inflammatory disorder (PID) is an infection of the        upper part of the female reproductive system namely the uterus, fallopian tubes, or the        ovaries. Often there may be no symptoms. Signs and symptoms, when present may include        lower abdominal pain, vaginal discharge, fever, burning with urination, pain with sex, or        irregular menstruation. Untreated PID can result in long term complications including        infertility, ectopic pregnancy, chronic pelvic pain, and cancer.|October 2015|October 2, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567812|1 Year|11718|
NCT02574650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLPR-010|Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation|SCOUT|Mitralign, Inc.|Yes|Recruiting|November 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574650||11192|
NCT02577939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1311|Evaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation|Evaluation of Cardiorespiratory Performance After Interval Exercise Training (IET) Prior to Hematopoietic Cell Transplantation||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|June 2013|June 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||October 2015|October 13, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02577939||10939|
NCT02567279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9531|Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa|Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa|DIBLAN|University Hospital, Montpellier|Yes|Not yet recruiting|December 2015|October 2020|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|40 Years|No|||September 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567279||11759|
NCT02567292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080481|Breast Milk and Congenital Gastrointestinal Disorders|Effects of an All Breast Milk Diet on Enteral Feeding Outcomes of Neonates With Congenital Gastrointestinal Disorders||Emory University|No|Recruiting|May 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|N/A|N/A|No|||October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567292||11758|
NCT02575911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTJ121-P001|Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study|Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study||Alcon Research|No|Active, not recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|21 Years|N/A|No|||January 2016|January 14, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575911||11095|
NCT02575963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-01|Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients|A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia||Actinium Pharmaceuticals|No|Recruiting|October 2012|May 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|60 Years|N/A|No|||October 2015|October 25, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575963||11091|
NCT02566902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-15-047|Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma|Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma||Seton Healthcare Family|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|213|||Both|6 Years|17 Years|No|||September 2015|September 30, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02566902||11788|
NCT02572492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG#20/13|Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support|Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT|CARFI|Aalborg Universitetshospital|Yes|Recruiting|January 2015|April 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572492||11358|
NCT02586506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201594|Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma|An Open-label Study of the Ease of Use and Correct Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Asthma||GlaxoSmithKline|No|Completed|October 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|259|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586506||10281|
NCT02586519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINUP|Pressure-Sensing Insoles in the Neuropathic Ulcer Treatment Pathway|Pressure-Sensing Insoles in the Neuropathic Ulcer Treatment Pathway (PINUP): A Randomized Controlled Clinical Trial|PINUP|University of Calgary|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|100 Years|No|||October 2015|October 23, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586519||10280|
NCT02573870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201546|Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease|201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD||GlaxoSmithKline|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||February 2016|March 10, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573870||11252|
NCT02574039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGRAIN1|Oat Phenolics Bioavailability|Absorption, Metabolism and Excretion of Oat Phenolic Acids in Healthy Men.||University of Reading|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02574039||11239|
NCT02575976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-898235|Effects of Cardiac Rehabilitation on Functional Capacity and Cardiovascular Risk Factors|Effects of Cardiac Rehabilitation on Functional Capacity and Cardiovascular Risk Factors in Brazilian Patients Assisted by Public Health Care: A Randomized Controlled Trial||Federal University of Minas Gerais|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575976||11090|
NCT02567136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130126|Imaging Biomarkers in ALS|A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|September 2015|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|21 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll ALS patients seeking care at the University of Minnesota and        age-matched healthy control volunteers.|September 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567136||11770|
NCT02588859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680R00019|Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients|A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)|ONTARGET-INDIA|AstraZeneca|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetes patients|March 2016|March 24, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02588859||10101|
NCT02571569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16144|A Single Escalating Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors|A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors||Bayer|Yes|Recruiting|October 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Male|18 Years|65 Years|No|||March 2016|March 7, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571569||11429|
NCT02573961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRCEgypt|Laser Acupuncture Versus High Protein/Low Carbohydrate Diet on Endothelial Markers in Obese Females|Laser Acupuncture Versus High Protein/Low Carbohydrate Diet on Endothelial Markers in Obese Females. A Randomized Controlled Trial||National Research Center, Egypt|Yes|Not yet recruiting|October 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573961||11245|
NCT02575534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010486|Acute Mechanical Response to Anti-arrhythmic Drug Therapy|Acute Mechanical Response to Anti-arrhythmic Drug Therapy|AAD and CRT|University of Pittsburgh|Yes|Not yet recruiting|October 2015|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02575534||11124|
NCT02589288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC09|Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus|Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus For Postoperative Analgesia After Day-Case Anterior Cruciate Ligament Reconstruction||ASST Gaetano Pini-CTO|No|Recruiting|November 2015|October 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|February 9, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589288||10068|
NCT02589301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF143|Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations|A Single-center, Open-label, Parallel Study With Single Subcutaneous Injection for Pharmacokinetics and Pharmacodynamics Comparison of Two Pegfilgrastim Formulations in Both Male and Female Healthy Volunteers, Test Formulation is an Injectable Solution Containing 6 mg of Pegfilgrastim, Manufactured by Eurofarma Laboratórios S/A, and Reference Formulation (Neulastim® Injectable Solution Containing 6 mg) Marketed by Produtos Roche Químicos e Farmacêuticos S/A||Eurofarma Laboratorios S.A.|No|Recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 18, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02589301||10067|
NCT02564380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-TRK-0115|Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)|PRIMUS|AIO-Studien-gGmbH|Yes|Not yet recruiting|January 2016|September 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02564380||11981|
NCT02564913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111106|Integrated Clinical Evaluation of Traditional Chinese Medicine (TCM) and Conventional Medicine on Diabetic Patients|||Changhua Christian Hospital||Completed|December 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|250|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The investigators recruited the control group , the pre-DM group, and the DM group.|September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564913||11941|
NCT02565277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRIC Dr.Atoui|The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial|The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial||Advanced Medical Research Institute of Canada|No|Not yet recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565277||11913|
NCT02574416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM MED 1215|An Evaluation of the Determinants of Lifestyle and Health Behaviors in Later Life|An Evaluation of the Determinants of Lifestyle and Health Behaviours in Later Life, and to Investigate Their Relationship With Health Outcomes|LiLL|National Health Service, United Kingdom|No|Recruiting|February 2015|June 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|60 Years|110 Years|No|Non-Probability Sample|Users of the Medicine for Older People Services in Southampton|October 2015|October 9, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02574416||11210|
NCT02574429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTDBT-1|CPT Group for DBT Clients With Co-Occurring Borderline Personality Disorder and PTSD|Pilot Study Examining the Impact of a Cognitive Processing Therapy (CPT) Group for Patients With Co-Occurring Borderline Personality Disorder and Posttraumatic Stress Disorder|CPTDBT|St. Joseph's Healthcare Hamilton|Yes|Not yet recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|17 Years|65 Years|No|||September 2015|October 13, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02574429||11209|
NCT02583919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 449884-CS4|Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes|Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin||Ionis Pharmaceuticals, Inc.|No|Recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583919||10480|
NCT02583932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-JGH-15-100|Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer|Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In People Newly Diagnosed With Advanced Cancer: Full Trial||Jewish General Hospital|No|Recruiting|October 2015|October 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|471|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02583932||10479|
NCT02569034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400639|Dissociating Components of Anhedonia: A Pilot fMRI Study|Dissociating Components of Anhedonia: Pilot Behavioral and fMRI Data for the Effort Expenditure for Rewards Task||University of Florida|No|Not yet recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569034||11624|
NCT02577224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZRD1024|An RCT of a Patient-initiated Treatment Service for BEB and HFS|A Randomised Controlled Trial to Explore the Effectiveness and Cost-effectiveness of a Patient-initiated Botulinum Toxin Treatment Model for Blepharospasm and Hemifacial Spasm Compared to Treatment as Usual||Moorfields Eye Hospital NHS Foundation Trust|Yes|Recruiting|August 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|266|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02577224||10994|
NCT02571075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381600|Battlefield Auricular Acupuncture During Adult Tonsillectomies and Effect of Post op Pain and Nausea|A Randomized, Single-blind, Prospective Trial of Auricular Acupuncture for the Reduction of Post-operative Tonsillectomy Pain in Adults|BFA|Defense and Veterans Center for Integrative Pain Management|No|Recruiting|November 2013|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02571075||11467|
NCT02576613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/200/15|Modified Psychodynamic Psychotherapy for Patients With Schizophrenia|Modified Psychodynamic Psychotherapy for Patients With Schizophrenia - a Randomized Controlled Trial|MPP-S|Charite University, Berlin, Germany|No|Recruiting|October 2015|December 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02576613||11041|
NCT02576626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL5250604215|Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD|The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD|ULT01|Groningen Research Institute for Asthma and COPD|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||December 2015|December 2, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02576626||11040|
NCT02574338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSFC-2015-CT|Cervical Ripening: A Comparison Between Intravaginal Misoprostol Tablet and Intracervical Foley's Catheter in a Low Resource Setting|||Federal Teaching Hospital Abakaliki|Yes|Recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574338||11216|
NCT02577250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4555-B|Ketamine Infusions for PTSD and Treatment-Resistant Depression|Efficacy and Safety of Repeated Intravenous Subanesthetic Ketamine Infusions Among Veterans With Treatment Resistant Depression Comorbid With Chronic Post-Traumatic Stress Disorder: A Proof-of-concept Study||Minneapolis Veterans Affairs Medical Center|Yes|Recruiting|May 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02577250||10992|
NCT02573857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP15C11|A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection|A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection|DSMOZ-2|Medicines for Malaria Venture|No|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02573857||11253|
NCT02563847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 2014/072|Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans|Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Normal Weight and Obese Subjects||University Hospital, Basel, Switzerland|No|Completed|May 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563847||12022|
NCT02565264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012|Effect of Plasma Derived Exosomes on Cutaneous Wound Healing|Effect of Plasma Derived Exosomes on Intractable Cutaneous Wound Healing: Prospective Trial||Kumamoto University|No|Not yet recruiting|October 2015|March 2018|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||September 2015|September 30, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565264||11914|
NCT02574377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49528.000.14|myDC/pDC in Stage III Melanoma Patients|Myeloid and Plasmacytoid Blood Dendritic Cells for Immunotherapy of Stage III Melanoma Patients||Radboud University||Recruiting|September 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 25, 2016|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02574377||11213|
NCT02574390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082277|Answer ALS: Individualized Initiative for ALS Discovery|Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS|AnswerALS|Johns Hopkins University|No|Recruiting|December 2015|July 2019|Anticipated|January 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|plasma, serum, DNA, Cerebrospinal fluid, induced pluripotent stem cells,|Both|18 Years|100 Years|No|Non-Probability Sample|patients with ALS|January 2016|January 27, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574390|1 Year|11212|
NCT02565563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173479|Recording Heart Rate Variability During Eye Movement Desensitisation Reprocessing With or Without Eye Movement|Digitally Recording Heart Rate Variability Via the Patient's Finger: Is There a Difference Between Eye Movements and no Eye Movements During Eye Movement Desensitisation Reprocessing Treatment for Post Traumatic Stress Disorder?|EMDR;PTSD|University of Edinburgh|No|Not yet recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02565563||11891|
NCT02574026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00421-38|Tapfinger Psychomotor Target|MagnetoEncephaloGraphy Study of Cerebral Activations Induced by Psychomotor Tasks for Target Localisation in View of BCI Clinical Trial|TAPFINGER|University Hospital, Grenoble|No|Recruiting|August 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|October 12, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02574026||11240|
NCT02564107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18044|A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease|An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease||Hoffmann-La Roche||Completed|November 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564107||12002|
NCT02573649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIRECS|The Tilt Test-Induced REsponse in Closed-loop Stimulation (TIRECS) Study|Effects of Closed-loop Stimulation vs. DDD Pacing on Prevalence and Timing of Haemodynamic Variations and Clinical Prodromes Induced by Head-up Tilt Test in Patients With Refractory Cardioinhibitory Vasovagal Syncope. The TIRECS Study|TIRECS|Azienda Ospedaliera Cardinale G. Panico|No|Recruiting|April 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|October 9, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02573649||11269|
NCT02573766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0399|Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy|Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy||M.D. Anderson Cancer Center|Yes|Recruiting|October 2015|||October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|90|||Female|18 Years|N/A|No|||March 2016|March 10, 2016|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573766||11260|
NCT02574455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-132-05|Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer|Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer||Immunomedics, Inc.|Yes|Not yet recruiting|July 2016|June 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02574455||11207|
NCT02574520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C803-028|Trial of Extended Release Bupivacaine for Pain Relief After Surgery|A Placebo-controlled Trial of SABER® Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy|PERSIST|Durect|No|Recruiting|October 2015|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574520||11202|
NCT02577315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.27|Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions|An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Two Fixed Dose Combination Tablets of Empagliflozin 12.5 mg and Metformin 500 mg Compared With the Free Combination of Empagliflozin 25 mg and Metformin 1000 mg Tablets Under Fed Conditions||Boehringer Ingelheim||Completed|September 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 8, 2015||||No||https://clinicaltrials.gov/show/NCT02577315||10987|
NCT02577328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0138-14-BNZ|Pain Management in Internal Medicine Department|Pain Management in Internal Medicine Department||Bnai Zion Medical Center|Yes|Not yet recruiting|November 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients in the ward with mild pain and above|June 2015|October 14, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02577328||10986|
NCT02571413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[Si 9091/2552(EC2)]|Evaluation of the Animated Cartoon-aided Teaching of Intranasal Corticosteroid Allergic Rhinitis|Evaluation of the Animated Cartoon-aided Teaching of Intranasal Corticosteroid Administration Technique Among Thai Children With Allergic Rhinitis||Mahidol University|No|Completed|May 2009|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|5 Years|16 Years|Accepts Healthy Volunteers|||March 2009|October 6, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT02571413||11441|
NCT02561832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D081EC00001|A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer|A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations||AstraZeneca|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|130 Years|No|||February 2016|February 16, 2016|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561832||12177|
NCT02566031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149AKR01|A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients|A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients||Novartis||Not yet recruiting|October 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|404|||Both|40 Years|40 Years|No|||September 2015|September 30, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02566031||11855|
NCT02576639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNP520X2102|Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects||Novartis||Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|125|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576639||11039|
NCT02576652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140259|Bone Histomorphometry in Subjects Undergoing Total Hip Replacement|Bone Histomorphometry of the Proximal Femur in Denosumab-treated Subjects Undergoing Total Hip Replacement||Amgen|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|50 Years|100 Years|No|||February 2016|February 4, 2016|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576652||11038|
NCT02576678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PPSO-001|A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis|A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis||Celgene|Yes|Recruiting|October 2015|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|6 Years|17 Years|No|||February 2016|February 16, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576678||11036|
NCT02562989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6240-001|[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)|A Study to Qualify [18F]MK-6240 Positron Emission Tomography (PET) for Use as a Biomarker of Neurofibrillary Tangle Pathology in Alzheimer's Disease||Merck Sharp & Dohme Corp.|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562989||12088|
NCT02563002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-177|Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)|A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)||Merck Sharp & Dohme Corp.|Yes|Recruiting|November 2015|September 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563002||12087|
NCT02565966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S14-01069|Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues|Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues||New York University School of Medicine||Recruiting|June 2014|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565966||11860|
NCT02576067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1382|Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study|Cardiovascular Inflammation Reduction Trial (CIRT) - Inflammation Imaging Study|CIRT|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|December 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576067||11083|
NCT02565095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-128|Interaction of Otolith Stimulation and Carotid Baroreflex in Humans|Interaction of Otolith Stimulation and Carotid Baroreflex in Humans|OTOBAR|University Hospital, Caen|No|Recruiting|March 2009|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|54|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02565095||11927|
NCT02565108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1428 Blinded Phase|A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)||GW Research Ltd|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||January 2016|January 28, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565108||11926|
NCT02581371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMRIS-ARM-C|Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm|Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke||Clinical Institute of the Brain, Russia|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|75 Years|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581371||10676|
NCT02570295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFT_82/15|Swiss Army Physical Fitness Training|Swiss Army Physical Fitness Training - An Intervention Study Investigating the Influence of the Swiss Armed Forces' New Sport Concept on Physical and Psychological Parameters of the Recruits|SAFT|Swiss Federal Institute of Sport Magglingen|No|Enrolling by invitation|July 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|25 Years|No|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570295||11527|
NCT02570308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMCgp100-102|A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma|A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma||Immunocore Ltd|No|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570308||11526|
NCT02566837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 425 03|Use of Ultrasound in Injections of Botulinum Toxin|Ultrasound Guidance to Alleviate the Pain Associated With Intramuscular Injections of Botulinum Toxin in Spastic Patients|TOXINECHO|University Hospital, Toulouse|No|Completed|February 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02566837||11793|
NCT02566850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13098|Investigational Study of the Ekso Bionics Powered Exoskeleton for High-Dosage Use by Individuals With SCI in a Non-Clinical Environment|Investigational Study of the Ekso Bionics Powered Exoskeleton for High-Dosage Use by Individuals With Spinal Cord Injury in a Non-Clinical Environment||Ekso Bionics|No|Enrolling by invitation|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566850||11792|
NCT02569684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180 REK|Effects of Prebiotics on GLP-1 in Type 2 Diabetes|Effects of Prebiotics on GLP-1 in Type 2 Diabetes||Oslo University Hospital||Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||August 2015|October 5, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02569684||11574|
NCT02574936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74059997.050.01.04/77|Reduction Dead Space Volume With Karydakis Modification|Effects of Reduction Dead Space Volume With Karydakis Modification||Siverek Devlet Hastanesi|Yes|Completed|January 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|49 Years|No|||October 2015|October 13, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574936||11170|
NCT02585713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU221501I|Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism|A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism||Academic and Community Cancer Research United|Yes|Recruiting|November 2015|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|315|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585713||10342|
NCT02588664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS-1403-14532|Comprehensive Post-Acute Stroke Services|Early Supported Discharge for Improving Functional Outcomes After Stroke|COMPASS|Wake Forest Baptist Health|Yes|Not yet recruiting|April 2016|September 2020|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|6000|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588664||10116|
NCT02566499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:73|Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection|Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection||University of Manitoba|No|Not yet recruiting|October 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Female|40 Years|85 Years|No|||July 2015|October 1, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02566499||11819|
NCT02566772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-TAS3681-101|Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer|A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer||Taiho Oncology, Inc.|No|Not yet recruiting|March 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566772||11798|
NCT02574234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7313 02|Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies (APOCOGNIT)|Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies|APOCOGNIT|University Hospital, Toulouse|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|105|||Both|75 Years|N/A|No|||October 2015|October 9, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02574234||11224|
NCT02562209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACER_2015|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER) and Weight Loss|To Determine the Effect of PACER Diet (High Protein Atkin's Complete VEgetaRian Diet) in Obese Subjects|PACER|Diabetes Foundation, India|Yes|Completed|January 2012|November 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|25 Years|60 Years|No|||September 2015|September 28, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02562209||12148|
NCT02563821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14032 (PCEA-IMG)|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG)|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study.|PCEA-IMG|University Hospital, Limoges|No|Recruiting|November 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02563821||12024|
NCT02570594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5506|Autobiographical Memory Organization in Schizophrenia|Autobiographical Memory Organization in Schizophrenia|AMOrSchiz|University Hospital, Strasbourg, France|No|Recruiting|January 2014|||January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|October 5, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02570594||11504|
NCT02574169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7604 03|Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation|Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation|M'RHICO|University Hospital, Toulouse|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02574169||11229|
NCT02562742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1879|Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection||Gilead Sciences|No|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Adult patients with serogroup 2 (genotype 2) chronic HCV infection with or without        compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating        clinical site.|February 2016|February 5, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562742||12107|
NCT02562755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-HEP024|Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone|A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy|PHOCUS|SillaJen, Inc.|Yes|Recruiting|October 2015|October 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562755||12106|
NCT02572310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR HVC|Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty|A Prospective Radiostereometric Analysis (RSA) Study of Implant Stability and Clinical Evaluation of Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty||Nova Scotia Health Authority|No|Not yet recruiting|November 2015|December 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|21 Years|80 Years|No|||October 2015|October 7, 2015|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02572310||11372|
NCT02572570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3097|Clinical Investigation of a New Bulk Fill Composite Resin in the Restoration of Posterior Teeth|Clinical Investigation of a New Bulk Fill Composite Resin in the Restoration of Posterior Teeth||University of North Carolina, Chapel Hill|No|Recruiting|December 2015|June 2021|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572570||11352|
NCT02578108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201206|Diagnostic Genicular Nerve Block Prior to Radiofrequency Ablation for Knee Osteoarthritis Pain|A Prospective Trial of Zero Versus One Diagnostic Genicular Nerve Blocks to Determine Clinical Outcomes After Radiofrequency Ablation for the Treatment of Chronic Painful Knee Osteoarthritis||Northwestern University|Yes|Recruiting|October 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|30 Years|80 Years|No|||February 2016|February 17, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578108||10926|
NCT02642523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151768|Natriuretic Peptides and Metabolic Risk in Obesity|Natriuretic Peptides and Metabolic Risk in Obesity||Vanderbilt University|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02642523||5981|
NCT02534077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB Study# 1155515|Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants|Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants||Mednax Center for Research, Education and Quality||Recruiting|August 2015|||December 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|2 Years|No|||August 2015|August 24, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534077||14308|
NCT02539758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tjykdxykyy2|The Effect of Ocular Massage on the Management of Elevated Intraocular Pressure After Acute Angle Closure|The Effect of Ocular Massage on the Management of Elevated Intraocular Pressure After Acute Angle Closure||Tianjin Medical University Eye Hospital|Yes|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|45 Years|75 Years|No|||August 2015|August 31, 2015|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02539758||13872|
NCT02567448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD130851|Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA|Pathophysiology of the Upper Airway in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Concomitant Obstructive Sleep Apnea (OSA)||University of California, San Diego|No|Recruiting|July 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02567448||11746|
NCT02566460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-S616|The Effect of Lactate Clearance Oriented Haemodynamic Therapy on the Outcome of Patients With Septic Shock|||Peking Union Medical College Hospital||Completed|January 2013|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02566460||11822|
NCT02575742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReDA-010366 QM|Colonic Motility in Constipation and Ageing|Colonic Motility And Gut Microbiota Composition In Constipation And Ageing||Queen Mary University of London||Recruiting|October 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|60|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 women aged 18-40 years (15 non-constipated women, 15 with chronic constipation) and 30        women aged between 70-90 years (15 non-constipated women, 15 with chronic constipation)        will be recruited, via advertisement in the community.|October 2015|October 26, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02575742||11108|
NCT02566343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4743|Preoperative Diagnostic Tests for Pulmonary Risk Assessment in COPD|Preoperative Diagnostic Tests for Pulmonary Risk Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Undergoing Major Surgery|PredicT|Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|355|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for major surgery, who present in the pre-assessment clinic of the        University Medical Center Hamburg-Eppendorf during the study recruitment period, will be        screened for eligibility. Patients with typical clinical signs and a positive COPD        Assessment Test (CAT™) qualify for spirometry. After informed consent 80 patients with        disproved COPD (FEV1/FVC ratio ≥ 0.70) and 240 patients with confirmed COPD (FEV1/FVC        ratio < 0.70) will consecutively be included.|October 2015|October 1, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02566343||11831|
NCT02577926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-181|The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia|Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial|Ruxo-BEAT|RWTH Aachen University|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||October 2015|November 5, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02577926||10940|
NCT02564861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1971-A-E106|DS-1971a Multiple Dose Study|A Phase I, Double-Blind, Randomised, Placebo Controlled, Multiple-Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male and Female Subjects||Daiichi Sankyo Inc.|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564861||11945|
NCT02562820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-627|An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome|Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial||The Cleveland Clinic|Yes|Active, not recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|5 Years|25 Years|No|||February 2016|February 23, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562820||12101|
NCT02562456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECART|Cost-efficacy Between ART and Composite Resin Restorations in Primary Molars|Difference of Cost-efficacy Between Atraumatic Restoration Treatment (ART) and Composite Resin Restorations in Primary Molars: A Randomized Clinical Trial||University of Sao Paulo|No|Recruiting|October 2015|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|428|||Both|3 Years|6 Years|No|||November 2015|November 23, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02562456||12129|
NCT02565407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505M72302|Robot-aided Proprioceptive Rehabilitation Training|Robot-aided Proprioceptive Rehabilitation Training With Additional Vibro-tactile Feedback||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|October 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|75 Years|Accepts Healthy Volunteers|||September 2015|November 9, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02565407||11903|
NCT02570906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPO0517|Performance Assessment of a Remote Patient Monitoring Device|A Performance Assessment of a Remote Patient Monitoring Device in Measuring Heart Rate, Respiration Rate, Posture, and Activity Level||Medtronic - MITG|No|Completed|December 2015|February 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers, Adults 18 to 50 years old|February 2016|February 25, 2016|September 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570906||11480|
NCT02564705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-14-001|Comparative Study of Anterior vs. Posterior Surgical Treatment for Lumbar Isthmic Spondylolisthesis|A Multi-Center, Prospective, Comparative Study of Anterior vs. Posterior Surgical Treatment for Lumbar Isthmic Spondylolisthesis|I-Spondy|AOSpine North America Research Network|No|Recruiting|February 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|180|||Both|18 Years|55 Years|No|Non-Probability Sample|Patients with Isthmic spondylolisthesis (IS)|March 2016|March 8, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564705||11957|
NCT02564718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17618|Rivaroxaban for Treatment in Venous or Arterial Catheter Related Thrombosis in Neonates|7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Catheter-related Arterial or Venous Thrombosis.|Einstein Jr|Bayer|Yes|Recruiting|November 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|N/A|6 Months|No|||February 2016|February 25, 2016|September 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564718||11956|
NCT02572505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2002937|Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples|Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples|PrEP-HIVD|University of Missouri-Columbia|No|Not yet recruiting|November 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572505||11357|
NCT02588651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1415|A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)|A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)||Case Comprehensive Cancer Center|Yes|Not yet recruiting|May 2016|June 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588651||10117|
NCT02563301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008AN01|Videolaryngoscopy in Patients With Cervical Spine Immobilisation|A Randomised Crossover Trial Comparing the McGrath Series 5 Videolaryngoscope With the Macintosh Laryngoscope in Patients With Cervical Spine Immobilisation||NHS Tayside|No|Completed|August 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|49|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02563301||12064|
NCT02563314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408025|Comparison of Two Oxygen Setting During Non-invasive Mechanical Ventilation of Chronic Obstructive Pulmonary Disease|Comparison of Two Oxygen Setting During Non-invasive Mechanical Ventilation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial|OXYSET|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|January 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|88|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02563314||12063|
NCT02568592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERN_15-0012|Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake|Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake in Women||University of Birmingham|No|Recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|May 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02568592||11658|
NCT02572739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Wu-002|Cardiac Output Measurement With NICCOMO and PiCCO Devices at Different PEEP Levels|Assessment of Reliability of Cardiac Output Measurement Based on Impedance (NICCOMO) - Method of Noninvasive Cardiac Output Measurement, Compared to Transthoracic Thermodilution (PiCCO) at Different PEEP Levels||Medical University of Gdansk|No|Recruiting|May 2014|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients treated in intensive therapy unit, mechanically ventilated, haemodynamics        monitored with PiCCO technique|February 2016|February 7, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02572739||11339|
NCT02572752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.237|Relative Bioavailability of 2 Oral Formulations of Nintedanib|Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects||Boehringer Ingelheim||Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|70|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|October 8, 2015||||No||https://clinicaltrials.gov/show/NCT02572752||11338|
NCT02579122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE_2015_REVI_PM|REVIparin-BRIDging-in a General Practice Setting in GErmany|REVIparin-BRIDging-in a General Practice Setting in GErmany (REVIBRIDGE). Non-interventional Study to Evaluate Reviparin for Prevention of Thrombosis and Thromboembolism in General and Orthopedic Surgery (Here: for Perioperative Bridging of Oral Anticoagulation in Interventional Procedures) in General Practices|REVIBRIDGE|Mylan Inc.|No|Recruiting|October 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Probability Sample|patients under oral anticoagulation with phenprocoumon in general practices|January 2016|January 28, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02579122||10848|
NCT02577263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019892|Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer|Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer||Pontificia Universidad Catolica de Chile|No|Recruiting|April 2015|June 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histological diagnosis of gastric adenocarcinoma who were treated with        surgery|October 2015|October 13, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02577263||10991|
NCT02578238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-619|Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"|Post-Marketing Surveillance of Humira in Korean Pediatric CD Patients Under the "New-Drug Re-examination"||AbbVie|No|Recruiting|September 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|6 Years|17 Years|No|Probability Sample|Pediatric CD patients who have been prescribed Humira® by the treating physician|January 2016|January 27, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578238||10916|
NCT02578251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-PCM|Paracetamol for Intrapartum Analgesia|Efficacy of Intravenous Paracetamol as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial||Ain Shams Maternity Hospital||Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|104|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578251||10915|
NCT02579369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-EB-101|Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa|A Phase 1 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa||Anterogen Co., Ltd.|No|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|10 Years|60 Years|No|||October 2015|October 16, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579369||10829|
NCT02579382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-283-1062|A Study of the Safety, Tolerability, and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment||Gilead Sciences|Yes|Recruiting|November 2015|October 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|175|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579382||10828|
NCT02568319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-202-CL-21|Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging in a Defined Special Population - Obese Subjects (BMI > or Equal to 30 kg/m2)||Neothetics, Inc|No|Completed|September 2015|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|December 23, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568319||11679|
NCT02571725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1419|PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer|A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer||New Mexico Cancer Care Alliance|Yes|Recruiting|February 2016|February 2022|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571725||11417|
NCT02569606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZH 2015 - 0309|Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm|Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm||University of Zurich|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1800|||Both|18 Years|N/A|No|Probability Sample|All trauma patients with an injury severity score (ISS) >15 treated in University Hospital        Zurich or Lucerne hospital during 2005 to 2007 and 2012 to 2014|January 2016|January 13, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569606||11580|
NCT02569619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAF-1|Evaluation of an Intervention to Promote Physical Activity in Outpatients With Mental Disorders|Evaluation of an Intervention to Promote Physical Activity in Outpatients With Mental Disorders: Motivational Determinants of Adherence, Effect on Cognitive Determinants of Physical Activity, Physical Activity, Sitting Time and Clinical Symptoms|GAF|Charite University, Berlin, Germany|No|Completed|April 2014|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569619||11579|
NCT02575560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCH200501|Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)|High Dose Weekly Use First-generation EGFR-TKI Instead of Daily Regular Dose in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)||Qingdao Central Hospital|Yes|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Probability Sample|histological confirmed local advanced or metastatic lung adenocarcinoma with EGFR mutation        diagnosed by 2nd generation sequence system.|October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575560||11122|
NCT02575573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDEED|Resuscitation Decisions in the Emergency Department (ED)|Influencing Factors on Resuscitation Decisions in the ED|REDEED|University Hospital, Basel, Switzerland|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50000|||Both|18 Years|N/A|No|Non-Probability Sample|Admitted patients from the Emergency Department of the University Hospital of Basel        between the 1st of January 2010 and the 31st of December 2014.|January 2016|January 19, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575573||11121|
NCT02587676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC13-006|Deterioration of Resilient Denture Liners and Patient Characteristics|Changes in the Hardness of Resilient Denture Liners Embedded in Maxillary Complete Dentures and Their Association With Patient Characteristics||Nihon University|No|Active, not recruiting|June 2013|December 2018|Anticipated|July 2015|Actual|N/A|Observational|N/A||1|Actual|100|||Both|40 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient of wearing complete maxillary dentures who visited the Department of Removable        Prosthodontics at our institute were recruited for this study.        The volunteers were enrolled only after they provided written informed consent.|October 2015|October 30, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587676||10192|
NCT02587689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-021-001|Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor|Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor||PersonGen Biomedicine (Suzhou) Co., Ltd.|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02587689||10191|
NCT02587702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDM2012002|Influence of Improved Formula on Fatty Acids and Mineral Metabolism in Infants|||Beingmate Baby & Child Food Co Ltd .|No|Recruiting|June 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|90|||Both|N/A|7 Days|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02587702||10190|
NCT02572375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGU510|Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study|An Open-Label, Randomized, Multiple-Dose, 2-Way Crossover Comparative Bioavailability Steady State Study of Codeine Phosphate/Guaifenesin Extended-Release Tablet in Healthy Subjects|COGUSS|Nexgen Pharma, Inc|Yes|Completed|October 2014|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|April 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572375||11367|
NCT02572609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.509|Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride|Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride||Boehringer Ingelheim||Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|October 5, 2015||||No|November 26, 2015|https://clinicaltrials.gov/show/NCT02572609||11349|
NCT02565745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277865740699|Impact of the Use of Dressings Versus Lubrication of Skin With Cream to Prevent Pressure Ulcers: Clinical Trial|Assessing the Impact of the Use of Dressings Versus Conventional Lubricated Skin With Cream in Preventing Pressure Ulcers in Patients at High and Very High Risk Entering All Services of Medical and Surgical Care: Multicenter Clinical Trial|PENFUP|Fundación Cardioinfantil Instituto de Cardiología|Yes|Not yet recruiting|October 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|90 Years|No|||September 2015|September 30, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565745||11877|
NCT02565758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-394|ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors|A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors||AbbVie|No|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|192|||Both|18 Years|99 Years|No|||March 2016|March 4, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565758||11876|
NCT02565771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208137|Evaluation of the Improvement of Autonomic Nervous System by a Physical Rehabilitation Program Adapted to Adulthood After Chemotherapy or Radiotherapy in Childhood|Evaluation of the Improvement of Autonomic Nervous System by a Physical Rehabilitation Program Adapted to Adulthood After Chemotherapy or Radiotherapy in Childhood|SALTO_GyV|Centre Hospitalier Universitaire de Saint Etienne|No|Enrolling by invitation|March 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992        with deregulation ANS or autonomic imbalance.|October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565771||11875|
NCT02565134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1_PII-02|A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus|Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients||Amorepacific Corporation|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|294|||Both|19 Years|70 Years|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565134||11924|
NCT02565147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCO-BIV-12-02|Bivalirudin Infusion for Ventricular Infarction Limitation|Bivalirudin Infusion for Ventricular Infarction Limitation|BIVAL|The Medicines Company|No|Recruiting|November 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|September 30, 2015|December 5, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565147||11923|
NCT02573701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II3/02/0811|Guideline vs Usual Treatment in Schizophrenic Adolescents|Comparative Study of Recommended Treatment for Schizophrenia Guideline Treatment vs Treatment as Usual in Child Psychiatric Hospital: Effect on Adherence, Efficacy on Symptoms, and Global Function|ACER|Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico|Yes|Completed|October 2011|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|12 Years|17 Years|No|||February 2016|February 17, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573701||11265|
NCT02564692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR-001|GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype|Alzheimer's Prevention Registry GeneMatch Program||Banner Health|No|Recruiting|November 2015|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500000|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This large research study will ultimately enroll 500,000 adults. We will recruit subjects        from all over the United States, as everything is done via email, mail, or/and phone.|December 2015|December 9, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564692|15 Years|11958|
NCT02562157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-32|Endoscopic Gastroenteric Anastomosis With New Tissue Apposing Stent in the Management of Antro-pyloroduodenal Obstruction : Evaluation of Feasibility, Efficacy and Tolerance.|Gastroenteric Anastomosis With Natural Orifice Translumenal Endoscopic Surgery (NOTES) Using the New Fashionned Tissue Apposing Stent Axios® for the Treatment of Antro-pyloric or Duodenal Obstructions : Prospective Evaluation of Feasibility, Efficacy and Tolerance.||Assistance Publique Hopitaux De Marseille||Not yet recruiting|November 2015|||September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02562157||12152|
NCT02562170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401/2013|Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study|Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study||Medical University of Vienna|No|Completed|July 2013|May 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Female|18 Years|75 Years|No|||September 2015|September 26, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02562170||12151|
NCT02565394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-006129|Microbreaks in the OR to Mitigate High Physical and Mental Demands|OR-STRETCH: Microbreaks in the Operating Room With the Incorporation of Stretches to Mitigate High Physical and Mental Demands While Enhancing Performance During Surgical Procedures|OR-STRETCH|Mayo Clinic|No|Not yet recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|22 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02565394||11904|
NCT02564094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18043|A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies|Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly||Hoffmann-La Roche||Completed|February 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564094||12003|
NCT02562443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-30|Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA|A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent|INSPIRE|Onconova Therapeutics, Inc.|Yes|Recruiting|October 2015|September 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|79 Years|No|||March 2016|March 24, 2016|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562443||12130|
NCT02570230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI2558|Ketamine Combination With Spinal Morphine for Post Thoracic Surgery Pain : A Randomized Control Study|Low Dose Intraoperative Intravenous Ketamine Combination With Spinal Morphine for Post Thoracic Surgery Pain : A Randomized Control Study||Mahidol University|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570230||11532|
NCT02564354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQ-010-002|Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation|Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation||ProQR Therapeutics|Yes|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564354||11983|
NCT02575508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 265214|Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer|A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients||Roswell Park Cancer Institute|Yes|Not yet recruiting|March 2016|||May 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575508||11126|
NCT02562677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS for Elderly|TNS for Treating Major Depressive Disorder in the Elderly|Effect of TNS for Major Depressive Disorder in the Elderly: a Phase II Randomized Controlled Trial||Santa Casa Medical School|No|Not yet recruiting|October 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|65 Years|99 Years|No|||September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562677||12112|
NCT02565862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 14.11|A Drug-drug Interaction Study Between Daclatasvir and Metformin|A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers|DATE-3|Radboud University|No|Not yet recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|October 9, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565862||11868|
NCT02565875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150727-01H|Standardizing Language in Laparoscopic Surgery|Does Standardizing Language in Laparoscopic Surgery Improve Efficiency? A Randomized Controlled Trial|SLL|Ottawa Hospital Research Institute|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565875||11867|
NCT02576106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET15-001|Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy|Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy|CRYOSE01|Centre Leon Berard|No|Not yet recruiting|November 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|55 Years|N/A|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576106||11080|
NCT02569879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201521|Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.|Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.||GlaxoSmithKline||Active, not recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|1|||Both|N/A|12 Months|No|Probability Sample|-  All infants ≤12 months of age in Bogota, reported with pertussis disease in the             national databases of Bogota, between January 2005 and December 2014.          -  All infants ≤12 months of age in Bogota, deceased between January 2005 and December             2014 due to pertussis disease (primary diagnosis), based on death certificate             information.          -  All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and             December 2014.          -  All infants ≤12 months who have received primary pertussis vaccination in Bogota,             between January 2005 and December 2014.          -  All pregnant women who have received Boostrix as a part of the UMV program in Bogota,             between March 2013 and December 2014.|December 2015|December 10, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569879||11559|
NCT02576795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMN270-201|Gene Therapy Study in Severe Haemophilia A Patients|A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A||BioMarin Pharmaceutical||Recruiting|August 2015|||June 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02576795||11027|
NCT02575365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DTR05|Effect of Fingolimod on Neurodegeneration|Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients||Novartis|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575365||11137|
NCT02575378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZHYY-ZYYZX-rjzl|Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer|||Ruijin Hospital|Yes|Active, not recruiting|September 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|159|||Both|18 Years|75 Years|No|||October 2015|October 13, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02575378||11136|
NCT02584452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151095|Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction|Randomized Controlled Trial Evaluating Postoperative Analgesia and Muscle Strength Among Multiple Regional Anesthesia Techniques for Ambulatory ACL Reconstruction||Vanderbilt University|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|14 Years|N/A|No|||October 2015|October 21, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584452||10439|
NCT02570061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2013 FSP-044|Recruiting to Clinical Trials on the Telephone|Recruiting to Clinical Trials on the Telephone||Rigshospitalet, Denmark|No|Completed|July 2013|February 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|125|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570061||11545|
NCT02562651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202|Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Primary Anterior STEMI|Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Acute Primary Anterior STEMI (ST Segment Elevation Myocardial Infarction)|MASTARD|Russian Academy of Medical Sciences|Yes|Recruiting|February 2014|October 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||September 2015|September 25, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02562651||12114|
NCT02569398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107373|An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia|A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia||Janssen Research & Development, LLC|Yes|Recruiting|October 2015|May 2023|Anticipated|April 2023|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1650|||Both|60 Years|85 Years|No|||March 2016|March 23, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569398||11596|
NCT02569411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-240c|Contacting Authors to Retrieve Individual Patient Data|Contacting Authors to Retrieve Individual Patient Data: Protocol for a Randomized Controlled Trial||St. Michael's Hospital, Toronto||Enrolling by invitation|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|116|||Both|N/A|N/A|No|||October 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569411||11595|
NCT02569697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15-135|Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms|Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms||CONRAD|No|Recruiting|October 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02569697||11573|
NCT02585492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neonatologia-2014-02|Effects of Mother Position in Skin-to-skin Contact Newborn on Oxygen Saturation Levels.|Episodes of Decreased Oxygen Saturation in Newborns in Skin-to-skin Contact: Role of Maternal Position After Delivery. A Randomized Clinical Study.||Red Salud Materno Infantil y del Desarrollo|No|Not yet recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5866|||Both|259 Days|293 Days|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585492||10359|
NCT02573402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0806|The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury|The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury||The University of Texas Health Science Center, Houston||Not yet recruiting|November 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||October 2015|October 8, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573402||11288|
NCT02573415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 14-085|Uterine Transplantation for the Treatment of Uterine Factor Infertility|Uterine Transplantation for the Treatment of Uterine Factor Infertility||The Cleveland Clinic|Yes|Recruiting|October 2015|October 2021|Anticipated|October 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|45 Years|No|||October 2015|October 28, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573415||11287|
NCT02571621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/10|Serial Usage of Combitube in Anesthesiology|Evaluation of Serial Usage of Combitube in Anesthesiology|Combitube|Medical University of Vienna|No|Completed|January 1989|December 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|745|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients undergoing general anesthesia physical status ASA class I and II|October 2015|October 6, 2015|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571621||11425|
NCT02576132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vola-ICU|Pupillometry for Pain Assessment in Critically Ill Patients|Pupillometry for Pain Assessment in Critically Ill Patients||Charite University, Berlin, Germany|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients, aged 18 years or older with an expected intensive care unit        length of stay of of at least 48 hours.|October 2015|October 13, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02576132||11078|
NCT02561936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107783|Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet|A Phase 1, Open-label, Randomized, 2-panel, 4-way Crossover Study in Healthy Adult Subjects to Assess the Rilpivirine Relative Bioavailability Compared to the 25-mg Oral Tablet and the Food Effect Following Single Dose Administration of Oral Pediatric Formulation Candidates||Janssen Sciences Ireland UC|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02561936||12169|
NCT02588677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB10015|The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib||AB Science|Yes|Recruiting|April 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|381|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588677||10115|
NCT02570581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-003461-34|MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers|MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers|MELA|Centre Hospitalier Universitaire de Nice|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|24||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02570581||11505|
NCT02573740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-730|Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment|A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease||AbbVie|No|Recruiting|December 2015|June 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|85 Years|No|||January 2016|January 12, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573740||11262|
NCT02563964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51875.068.14 / METC 152007|Vulnerable Plaque Imaging in NSTEMI|Characterizing Vulnerable Plaques in Non-ST-Elevation Myocardial Infarction Using 18F-NaF Positron Emission Tomography - Cardiac Magnetic Resonance Imaging: A Feasibility Study|CULPRIT|Maastricht University Medical Center|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|33|Samples Without DNA|Biomarkers|Both|18 Years|85 Years|No|Probability Sample|Thirty-three patients, 18-85 years old and admitted with non-ST elevation myocardial        infarction (NSTEMI). After informed consent, patients wil receive standard,        guideline-based clinical care that includes invasive coronary angiography. Plasma biomaker        will be sampled serially, and a comprehensive Sodium 18F-Fluoride Positron Emission        Tomography/Cardiac Magnetic Resonance imaging (18F-NaF PET/CMR) will be performed at        baseline (<72 hours) and at 6 months, or earlier when patients suffer recurrent myocardial        infarction < 6months. Patients will be followed for one year during regular outpatient        clinic visits.|September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02563964|1 Year|12013|
NCT02566668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15050456|Immune Interactions in Severe Asthma|Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma||University of Pittsburgh|No|Recruiting|September 2015|March 2021|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood - total and specific Immunoglobulin E (IgE); complete blood count; plasma and serum;      Deoxyribonucleic Acid (DNA); peripheral blood mononuclear cells (PBMC) Endobronchial biopsy      Endobronchial brushings Pulmonary Lavage Exhaled Breath Condensate (EBC)|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected using a Research Registry and clinic patients of the        Investigators.|September 2015|September 30, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02566668||11806|
NCT02568007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|798217|Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders|Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders||Medical College of Wisconsin|No|Not yet recruiting|December 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568007||11703|
NCT02568267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXDX-101-02|Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)|An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements|STARTRK-2|Ignyta, Inc.|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568267||11683|
NCT02578069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA-001|First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent|A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the NOVA Sirolimus Eluting Stent Versus the Apollo Stent||Sino Medical Sciences Technology Inc.|Yes|Active, not recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|75 Years|No|||October 2015|October 14, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02578069||10929|
NCT02574754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17226|Assessment of 2012 Bioequivalence Standards for Warfarin|Assessment of 2012 Bioequivalence Standards for Narrow Therapeutic Index Drugs: a Study With Warfarin||University of California, San Francisco|Yes|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574754||11184|
NCT02567201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0216|Electrophysiological Evaluation of Voluntary Attention||EVA|Hospices Civils de Lyon|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|360|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02567201||11765|
NCT02561546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p53-DB-001|p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma|A Phase II Study to Investigate Preliminary Efficacy Using p53 Gene Therapy for Treatment of Diabetes Concurrent With Hepatocellular Carcinoma||Shenzhen SiBiono GeneTech Co.,Ltd|No|Not yet recruiting|December 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||July 2015|September 25, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02561546||12199|
NCT02566226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 265/15|Impact of Intrathecal Morphine on Sleep Apnea Syndrome|Impact of Intrathecal Morphine on Sleep Apnea Syndrome After Hip Arthroplasty Performed Under Spinal Anaesthesia||Centre Hospitalier Universitaire Vaudois|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|18 Years|99 Years|No|||November 2015|November 25, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02566226||11840|
NCT02635282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-04113-FB|IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D|Intranasal Ketamine Versus Intranasal Midazolam Plus Fentanyl in Treating Pain Associated With Incision and Drainage of Abscesses in the Pediatric Emergency Department: A Randomized Controlled Trial||University of Tennessee Health Science Center|No|Not yet recruiting|April 2016|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02635282||6538|
NCT02538237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|subgingival irrigation|the Effect of Sub-gingival Irrigation With Ibuprofen 2% Mouthwash in Treatment of Periodontal Diseases.|A Randomized, Double-Blind, Split-mouth, Placebo-controlled, Clinical Trial of the Effect of Sub-gingival Irrigation With Ibuprofen Mouthwash in Treatment of Periodontal Diseases|ibuprofen|Islamic Azad University, Tehran|Yes|Completed|November 2013|February 2015|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02538237||13988|
NCT02542891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-16|European Comparative Effectiveness Research on Internet-based Depression Treatment|E-Compared: Comparative Effectiveness Research on Internet Based Depression Treatment- French Trial|E-COMPARED|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 6, 2016|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02542891||13633|
NCT02542904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EME vs. LME|Extensive Mesenteric Excision (EME) Versus Local Mesenteric Excision (LME) for Crohn's Disease|||Jinling Hospital, China||Recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02542904||13632|
NCT02576925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOA_2015-7|A Predictive Score for the Ischemic Etiology of a Transient Diplopia (VASCO-DIP)|Development and Validation of a Predictive Score for the Ischemic Etiology of a Transient Diplopia|VASCO-DIP|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|October 2015|April 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|175|||Both|18 Years|N/A|No|Non-Probability Sample|Adults having had a transient diplopia during the last 8 days and seen at the fondation        ophtalmologique Adolphe de Rothschild|October 2015|October 13, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576925||11017|
NCT02576938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16284|A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis||Eli Lilly and Company|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576938||11016|
NCT02570282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-6007-02-01|Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder|A Phase 2A, Single-Dose, Double-Blind Placebo-Controlled, 2-Way Crossover Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder||Strategic Science & Technologies, LLC|No|Recruiting|October 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|21 Years|60 Years|No|||October 2015|October 6, 2015|October 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570282||11528|
NCT02564211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431J-849|Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)|A Phase III, Multicenter, Open-label Long-term Treatment Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy||Merck Sharp & Dohme Corp.|No|Active, not recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|20 Years|N/A|No|||March 2016|March 10, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564211||11994|
NCT02567825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060148|Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media|Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media||University of Pittsburgh|Yes|Recruiting|November 2015|February 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|6 Months|35 Months|No|||February 2016|February 2, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567825||11717|
NCT02566356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09654|Adult Study Oxytocin - fMRI|Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - fMRI|ASO-fMRI|University of California, San Francisco|Yes|Recruiting|September 2012|||August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566356||11830|
NCT02565160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0388|Analysis of Human Knee Joint Fluid Using Metabonomic, Genomic and Tribology Techniques|LOOKING FOR BIOMARKERS IN HUMAN JOINT FLUID USING METABONOMIC AND MICROBIOMIC ANALYSIS||Imperial College London|No|Not yet recruiting|October 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|Blood, Urine and Joint Fluid|Both|16 Years|80 Years|No|Non-Probability Sample|In summary we expect to recruit 150 subjects and sample three body fluid types. In some        cases control and multiple time points will be collected.|April 2015|September 30, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02565160||11922|
NCT02567305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4991 & PV5063|Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)|Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|September 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|50ul Blood during routine blood sampling|Both|N/A|18 Years|No|Probability Sample|All children with suspected sepsis|October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567305||11757|
NCT02571959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA 046|Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults|Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)|PHACO|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02571959||11399|
NCT02566629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G11|Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase|Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase||Shandong University|Yes|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|extract 16S rDNA from fecal microflora|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients who fulfil the Rome III criteria of irritable bowel syndrome in Qilu Hospital        outpatient|September 2015|October 1, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566629||11809|
NCT02566642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013003284|Understanding the Role of the Anesthesiologist|Patients Preoperative Understanding of the Role of the Anesthesiologist||Rutgers, The State University of New Jersey|No|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients coming to the Pre Admission Testing (PAT) at an urban hospital in anticipation of        surgery|January 2016|January 28, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02566642||11808|
NCT02586207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH MISP|Pembrolizumab in Combination With CRT for LA-SCCHN|Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Sanford Health|Yes|Recruiting|November 2015|September 2021|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586207||10304|
NCT02573714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-07|Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises|Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Pain Crises in Resource-Limited Settings||Cameroon Baptist Convention Health|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|4 Years|16 Years|No|||January 2016|January 26, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573714||11264|
NCT02568371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2015/07|Biobank Based on the i-Share Student Cohort|Biobank Based on the i-Share Student Cohort|bio-Share|University Hospital, Bordeaux|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|buffy coat ; plasma ; serum ; whole blood ; red blood cells ; DNA ; RNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The bio-Share study is a biological repository embedded within the i-Share study, aiming        at collecting blood samples from a subset of 2000 i-Share participants volunteering for        this ancillary project.|October 2015|November 5, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568371||11675|
NCT02568384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCA-2014-006-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||January 29, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568384||11674|
NCT02577445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVNS03|The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice|The remedē® System (Respiratory Rhythm Management™ Device) for the Treatment of Central Sleep Apnea in Daily Practice|TREAT-CSA|LivaNova|Yes|Not yet recruiting|December 2015|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with central sleep apnea|October 2015|October 13, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02577445||10977|
NCT02578862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.131.A|Total Intravenous Anesthesia in Sinus Surgery|Total Intravenous Versus Inhaled Anesthesia in Endoscopic Sinus Surgery for Advanced Paranasal Disease||Ochsner Health System|Yes|Recruiting|July 2015|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578862||10868|
NCT02567773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204699|Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078|A Randomized Double-blind (Sponsor Unblind) Placebo Controlled Study in Healthy Subjects to Evaluate: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Repeat Doses of GSK2881078, the Selective Androgen Receptor Modulator With an Open Label Dosing Arm to Evaluate the Effect of CYP3A4 Inhibition on Pharmacokinetics of GSK2881078||GlaxoSmithKline|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567773||11721|
NCT02573805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPTR in 2015-09-24|the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males|the Evaluation of Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males|NPTR|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|No|Recruiting|September 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|None Retained|Rigiscan parameters analyzed by Rigiscan plus software|Male|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chinese males ≥20 years|October 2015|October 10, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573805|12 Months|11257|
NCT02575495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_580278|A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation|A Pilot Randomized Control Study of Shortening Antibiotic Treatment Duration For Asymptomatic Bacteriuria Within A Month After Kidney Transplantation||Mahidol University|No|Completed|February 2015|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|N/A|No|||March 2016|March 15, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575495||11127|
NCT02587585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiECRCT-20150034|The Effect of Activity Feedback Enabled by Smart Watches During In-patient Stroke Rehabilitation|An International Randomized Clinical Trial of Activity Feedback During In-patient Stroke Rehabilitation Enabled by Smart Watches||The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Yes|Recruiting|September 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02587585||10199|
NCT02564120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-10-1483|North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)|||UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|January 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1656|||Male|35 Years|80 Years|No|Non-Probability Sample|Newly-diagnosed, early stage (localized, non-metastatic) prostate cancer patients|September 2015|September 29, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02564120||12001|
NCT02565004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150204|Clinical and Laboratory Analysis of Familial Cancer|Clinical and Laboratory Analysis of Familial Cancer||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|20|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565004||11934|
NCT02563431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/17|Multi-disciplinary Prevention Program|Early Phase of Multi-disciplinary Prevention Program of Shoulder Pain Post-stroke|4P-ED|University Hospital, Bordeaux|No|Recruiting|July 2012|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02563431||12054|
NCT02563444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00413-44|Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology|Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology|ECHOFUSION|University Hospital, Strasbourg, France|No|Completed|June 2014|September 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|100 Years|No|||May 2014|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563444||12053|
NCT02571738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osiris Protocol 303|Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers|A Multicenter, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers|*OTI-15-01|Osiris Therapeutics|Yes|Recruiting|October 2015|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571738||11416|
NCT02577289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|open_sinus_augmentation|Open Sinus Lift Technique With Simultaneous Implantation Using Platelet Rich Fibrin (PRF) Versus Nano-crystalline Hydroxyapatite|Evaluation of Bone Quantity in Open Sinus Lift Technique With Simultaneous Implantation Using Platelet Rich Fibrin (PRF) Versus Nano-crystalline Hydroxyapatite as Sole Grafting Material in Patients With Atrophied Posterior Maxillary Ridge||Cairo University|Yes|Recruiting|July 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577289||10989|
NCT02574130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-IM-2-046/57|Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria|Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria||Thammasat University|Yes|Recruiting|July 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574130||11232|
NCT02563756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNITKAstudien2015|Unicondylar- or Total Knee Replacement? Patient Satisfaction, Function and Muscle Mass|Unicondylar - or Total Knee Replacement in Medial Gonarthritis? A Randomized Study of Patient Related Outcome Measures, Function and Muscle Mass|UKA or TKA?|Karolinska Institutet|No|Recruiting|September 2015|April 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|80 Years|No|||September 2015|September 28, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02563756||12029|
NCT02565927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL032.0|A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction|A Novel Tracheal Radioactive Stent Loaded With 125I Seeds for the Malignant Airway Obstruction Versus a Conventional Stent: A Prospective Randomized Controlled Trial||Zhongda Hospital|No|Recruiting|May 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02565927||11863|
NCT02577666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014B0348|Evaluation of EBT With Young, Substance Abusing Homeless Mothers|Evaluation of EBT With Young, Substance Abusing Homeless Mothers||Ohio State University|No|Recruiting|February 2015|November 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02577666||10960|
NCT02577679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503116RINA|Associations Between Periodontitis and Autoimmune Antibodies in Rheumatoid Arthritis Disease|Associations Between Periodontitis and Autoimmune Antibodies in Rheumatoid Arthritis Disease||National Taiwan University Hospital|No|Active, not recruiting|June 2015|November 2015|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|47|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Physically healthy persons, especially free of any autoimmune diseases, DM, CVD. No        history of periodontal treatment.|October 2015|October 14, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02577679||10959|
NCT02570399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1388|High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients|Feasibility Study of High Dose Stereotactic Body Radiation Therapy (SBRT) for Lymph Nodal Lesions in Oligometastatic Patients for Genito-urinary, Gastro-intestinal and Gynaecological Cancer||Istituto Clinico Humanitas|Yes|Recruiting|April 2015|April 2022|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02570399||11519|
NCT02570412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aldox Compassionate Use|Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy|Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy||CytRx||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2015|October 21, 2015|October 6, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02570412||11518|
NCT02569736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29237|Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation|Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation|Tocihelper|Association Aquitaine de Recherche Clinique en Rhumatologie|No|Recruiting|September 2014|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be performed as a prospective observational open-labeled study        (non-interventional) to evaluate the impact of TCZ treatment on the evolution of        circulating Tfh cells levels. The administration of treatments (TCZ and MTX) will be done        according to current practice, and will not be motivated by the inclusion in this study.        TCZ will be administered in association with a conventional DMARD, or in monotherapy,        according to clinical recommendations. The objective of this study is to analyze the        impact of new therapy set-up, and patients included in the TCZ group would be under MTX        treatment for at least 3 months. The immunological analysis will be performed with        drop-off of blood samples used in the recommended follow-up of patients treated by MTX or        TCZ. For the healthy controls, the immunological analysis will be performed with drop-off        of blood samples used in the recommended follow-up of patients treated for osteoporosis or        osteoarthritis.|October 2015|October 7, 2015|October 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569736||11570|
NCT02563561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-EOQ-13-305|A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT|A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT||Spectrum Pharmaceuticals, Inc|Yes|Recruiting|September 2015|March 2021|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1869|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563561||12044|
NCT02563834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10100002643|A Novel PET Approach to Measuring Myocardial Metabolism|A Novel PET Approach to Measuring Myocardial Metabolism||Indiana University|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02563834||12023|
NCT02573948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12299 DRIVE IN|Feasibility of Interventions on People Who Inject Drugs in Vietnam|Feasibility of an Interventional Project to Reduce HIV Incidence Among People Who Inject Drugs in Haiphong, Viet Nam|DRIVE-IN|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Active, not recruiting|September 2014|June 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People who inject drugs living in Haiphong, Vietnam. The longitudinal phase will be        restricted to those not followed by health care services, i.e. not taking methadone nor        antiretroviral therapy|October 2015|October 9, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02573948||11246|
NCT02567396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01641|Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction|A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction||National Cancer Institute (NCI)||Not yet recruiting|July 2016|||October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567396||11750|
NCT02569996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18167|A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma|A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen||Hoffmann-La Roche||Completed|July 2005|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 23, 2015|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT02569996||11550|
NCT02570217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHHFNC vs NCPAP 2012|HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity|HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP (Nasal Continuous Positive Airway Pressure) in Preterm Infants With Mild to Moderate Respiratory Distress Syndrome (RDS): a Randomized Clinical Trial.||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|January 2012|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Both|29 Weeks|36 Weeks|No|||October 2015|October 6, 2015|October 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570217||11533|
NCT02568774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcupPSOAB|Acupuncture on Post-Stroke Overactive Bladder|Acupuncture on Post-Stroke Overactive Bladder: A Randomized Controlled Trial||The University of Hong Kong|No|Recruiting|August 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|June 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02568774||11644|
NCT02569047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALLART|ART and Hall Technique for Management of Occlusal-proximal Caries in Primary Molars|ART and Hall Technique for the Management of Occlusal-proximal Caries in Primary Molars: A Randomized Clinical Trial||University of Sao Paulo|No|Not yet recruiting|October 2015|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|8 Years|No|||October 2015|October 5, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02569047||11623|
NCT02569294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-HYP-CBT-037|Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being|Feasibility and Impact of Yoga, Self-hypnosis and Cognitive-behavioral Group Interventions in Improving Well-being of Breast Cancer Patients|GIBC|University Hospital of Liege|No|Active, not recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|114|||Female|18 Years|75 Years|No|||October 2015|October 3, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569294||11604|
NCT02567630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00547|Early Childhood Constraint Therapy in Cerebral Palsy|Early Childhood Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy||Nationwide Children's Hospital|Yes|Recruiting|October 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|216|||Both|10 Months|24 Months|Accepts Healthy Volunteers|||October 2015|October 8, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02567630||11732|
NCT02567643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-032|Stereotactic Radiosurgery (SRS) for Multiple CNS Mets|Stereotactic Radiosurgery for Multiple (5+) CNS Metastases||The Cooper Health System|No|Recruiting|May 2013|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|N/A|N/A|No|||October 2015|October 2, 2015|April 3, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02567643||11731|
NCT02577744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38032414.3.0000.5208|Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function and Lung Regional Ventilation on Bariatric Surgery|Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function, Regional Lung Ventilation and Respiratory Mechanics on Patients Submitted Bariatric Surgery Evaluated by Spirometry and Electric Impedance Tomography: A Clinical Trial Controlled Randomized||Universidade Federal de Pernambuco||Recruiting|October 2015|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|50 Years|No|||October 2015|October 13, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577744||10954|
NCT02571920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A14-D64-VOL.23|Hemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA)|Hemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA Study)|EMOA|University Hospital, Caen|No|Recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving elective cardiac surgery during the study period|November 2015|November 3, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571920||11402|
NCT02565693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47761.041.14|Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation|Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation: A Randomised Phase II Clinical Trial|APACHE-AF|UMC Utrecht|Yes|Recruiting|September 2014|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|August 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02565693||11881|
NCT02565706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIC NEI-12-TX|Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption|Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption||William Paterson University of New Jersey|No|Active, not recruiting|July 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|744|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565706||11880|
NCT02567877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2155|Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?|Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?||University of Colorado, Denver|No|Not yet recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|190|Samples With DNA|blood samples|Both|18 Years|65 Years|No|Non-Probability Sample|Patients undergoing thyroidectomy for nodular thyroid disease|October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567877||11713|
NCT02570490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE06-301|Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections||Cempra Inc|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|712|||Both|12 Years|N/A|No|||March 2016|March 21, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570490||11512|
NCT02564367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMBH-STO-0114|Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction|Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction|S-1 adjuvant|AIO-Studien-gGmbH|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02564367||11982|
NCT02576808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-TM-4-077/57|Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis|Comparative Study of Efficacy and Adverse Effects of Ginger Extract and Loratadine for Treatment of Allergic Rhinitis Patients (Clinical Trial Phase II)||Thai Traditional Medical Knowledge Fund|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|60 Years|No|||October 2015|October 13, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576808||11026|
NCT02565329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LacClearance|Serum Lactate Trend in Liver Resection|Serum Lactate Trend in Liver Resection With Intermittent Pringle Maneuver: The "Square-Root" Shape||University of Milan|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|133|||Both|34 Years|85 Years|No|Non-Probability Sample|133 consecutive patients scheduled for liver resection for primary and secondary tumors|September 2015|September 29, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565329||11909|
NCT02565342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 317/15|Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery|Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery||Centre Hospitalier Universitaire Vaudois|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||September 2015|September 30, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02565342||11908|
NCT02590029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00085446|Psychosocial Support for Acute Hospital Pain and Distress|Psychosocial Support for Acute Hospital Pain and Distress||University of Utah||Recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1002|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02590029||10011|
NCT02573311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.85|Actual Use Study of Tamsulosin in Men|A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men||Boehringer Ingelheim||Active, not recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Male|18 Years|N/A|No|||February 2016|February 23, 2016|October 1, 2015||||No||https://clinicaltrials.gov/show/NCT02573311||11295|
NCT02567370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130100|Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study With a Food-Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects and Subjects With Schizophrenia|FIH|Amgen|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567370||11752|
NCT02588469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2015/250|Exercise and Venous Compression on Upper Airway Resistance in Obese Teenagers With OSA|Effects of Exercise and Venous Compression on Upper Airway Resistance in Obese Teenagers With Obstructive Sleep Apnea Syndrome|OBESOMAC|Centre Hospitalier Universitaire de Besancon|No|Recruiting|August 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|12 Years|17 Years|No|||October 2015|October 26, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02588469||10131|
NCT02562326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT014|A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus|A Randomised, Monocentric, Double-blind, Multiple Daily Dose, Two-period 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualised Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus||Adocia|No|Recruiting|September 2015|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562326||12139|
NCT02562898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144525|Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma|144525|University of California, San Francisco|Yes|Recruiting|October 2015|March 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562898||12095|
NCT02565537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34288|High Resolution Wavefront-guided vs. Wavefront Optimized LASIK|A Prospective Randomized Comparison of the AMO CustomVue to the Alcon Wavelight in Patients Undergoing LASIK||Stanford University|No|Recruiting|October 2015|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02565537||11893|
NCT02567734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-PLAGH-YY-001|Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors|Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors：The Safety and Efficacy Assessment||Chinese PLA General Hospital|No|Active, not recruiting|October 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||October 2015|December 24, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02567734||11724|
NCT02573753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002092|The Effects of Sleep on Human Microbiota: Implications for Health and Disease|The Effects of Sleep on Human Microbiota: Implications for Health and Disease||Mayo Clinic|No|Enrolling by invitation|October 2015|June 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573753||11261|
NCT02567864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20140089|Development and Evaluation of the Healthy Beat Accupunch (HBA) Exercise Program for the Community Older Adults|Development and Evaluation of an Evidence-based Intervention Guideline of the Healthy Beat Accupunch (HBA) Exercise Program for the Community Older Adults|HBA|Kaohsiung Medical University|No|Recruiting|August 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|65 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567864||11714|
NCT02568124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-213|Tranexamic Acid in Chronic Subdural Hematomas|Tranexamic Acid in Chronic Subdural Hematomas|TRACS|Centre Hospitalier Universitaire de Sherbrooke|No|Recruiting|November 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568124||11694|
NCT02572778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO2015-02|Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer|Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.|UCL-Xenog|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|September 2015|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Biopsies of the tumor of the patients with squamous cell carcinoma of the head and neck|Both|18 Years|N/A|No|Probability Sample|All patients with a primary advanced or recurrent head and neck tumor.          -  Inclusion preoperatively or before biopsy          -  Written informed consent prior to surgery or biopsy|October 2015|October 8, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02572778||11336|
NCT02573012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA29585|Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants|Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients||Hoffmann-La Roche||Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573012||11318|
NCT02572089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Naloxone-Phase1a-002|Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers|Phase 1, Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers||National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572089||11389|
NCT02572102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-119|Impact of Energy Drinks and Panax Ginseng on Heart Rhythm|Impact of Energy Drinks and Panax Ginseng on Heart Rhythm in Healthy Volunteers||University of the Pacific|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572102||11388|
NCT02567071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-70|Natural Microbiota Restoration After C-section Birth|Retablissement Du Microbiote Naturel Apres Naissance Par Cesarienne|RESTORE|Institut National de la Santé Et de la Recherche Médicale, France|No|Not yet recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|225|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02567071||11775|
NCT02564250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2015/1017|Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women|Healthy Mother - Lifelong Health: A Longitudinal Study on Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women||Vestre Viken Hospital Trust|No|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|N/A|N/A|No|Probability Sample|Pregnant women with prepregnancy BMI > 35|September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564250||11991|
NCT02576496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDO-S101-1001|Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies|A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies||Mundipharma-EDO GmbH|Yes|Not yet recruiting|October 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576496||11050|
NCT02566239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU9944|Ambient Independence Measures for Guiding Care Transitions|Ambient Independence Measures for Guiding Care Transitions|AIMs|Oregon Health and Science University|No|Recruiting|March 2014|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02566239||11839|
NCT02562599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiotherapy center-001|Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin|Study Of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Raltitrexed-Cisplatin for Patients With Locally Advanced Nasopharyngeal Carcinoma||Hubei Cancer Hospital|No|Recruiting|August 2015|August 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|September 28, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02562599||12118|
NCT02562612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-88-001|Pharmacokinetics Study of SM-88 Oral Administration in Healthy Male Adult Subjects|Single Ascending Dose Clinical Trial to Assess the Pharmacokinetics of SM-88 Oral Administration in Healthy Male Adult Subjects||Synergy Research Inc.|No|Not yet recruiting|January 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562612||12117|
NCT02562625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4251|Trial of Pembrolizumab and Radiotherapy in Melanoma|Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma|PERM|Royal Marsden NHS Foundation Trust|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|N/A|No|||September 2015|January 6, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02562625||12116|
NCT02630979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cure and more1|Oncologists Satisfaction With Outcomes of Some Cytotoxic Agents|Prospective Observational Questionnaire Based Study Measuring Oncology Physicians Knowledge and Satisfaction With the Outcomes of Expensive Cytotoxic Agents||Ain Shams University|Yes|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|No biospecimen|Both|N/A|N/A|No|Non-Probability Sample|Medical or clinical oncology doctors|January 2016|January 1, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02630979||6867|
NCT02541058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD202|Non-Invasive Chromosomal Evaluation of 22q11.2|Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma|22Q|Ariosa Diagnostics, Inc|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Retained samples included extracted DNA and plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women carrying a fetus at risk or a confirmed fetus with 22q11.2        deletion/duplication. A person confirmed to have 22q11.2 deletion/duplication or a        biologically related parent of a child that has chromosomal deletion/duplication in the        region of 22q11.2.|September 2015|September 2, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02541058||13773|
NCT02532348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108080|Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection|Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection|PLAQUETTE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|August 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|133|Samples Without DNA|blood specimen|Both|18 Years|N/A|No|Probability Sample|Study populations:          -  HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors)             and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load             under 40 cp/ml.          -  Untreated HIV patients|August 2015|August 21, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02532348||14441|
NCT02577900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QEH-O&T-001|Diabetic Foot Ulcer Study on Topical Interventions|Randomized, Controlled Study of Nanocrystalline Silver, Manuka Honey and Conventional Dressing in Healing Diabetic Foot Ulcer|DFU|Queen Elizabeth Hospital, Hong Kong|No|Completed|February 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Both|40 Years|85 Years|No|||October 2015|October 15, 2015|October 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577900||10942|
NCT02573389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPSC IRB 10705|Pancreatic Duct Stenting to Prevent Postoperative Pancreatic Fistula (POPF) After Distal Pancreatectomy|A Pilot Study on the Effect of Transampullary Pancreatic Duct Stenting on Postoperative Pancreatic Fistula Rate After Distal Pancreatectomy||Kaiser Permanente|Yes|Not yet recruiting|September 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2015|October 7, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573389||11289|
NCT02572180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAD_BluHud_524|A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD)|A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD): Differential Effects of Training in a 2D or 3D Environment||University Hospital Tuebingen|No|Recruiting|September 2015|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|6 Years|10 Years|No|||March 2016|March 21, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572180||11382|
NCT02570711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-004|Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer|||Acerta Pharma BV||Recruiting|October 2015|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570711||11495|
NCT02585947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TenoCore|A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy|||Seoul National University Hospital|No|Not yet recruiting|November 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|19 Years|81 Years|No|||October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585947||10324|
NCT02585960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261303|BAX 855 PK-Guided Dosing|Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A||Baxalta US Inc.|No|Recruiting|November 2015|November 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|116|||Both|12 Years|65 Years|No|||November 2015|November 25, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585960||10323|
NCT02575794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC-1401|Terameprocol in Treating Patients With Recurrent High Grade Glioma|Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma||Sidney Kimmel Comprehensive Cancer Center|Yes|Suspended|February 2016|||December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 9, 2015|No|Yes|Drug production issues|No||https://clinicaltrials.gov/show/NCT02575794||11104|
NCT02575807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADU-CL-11|Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer|A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer||Aduro Biotech, Inc.|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|126|||Female|18 Years|N/A|No|||February 2016|March 24, 2016|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575807||11103|
NCT02572232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1805/2015|Supraglottic Airway Devices in Pediatric Difficult Airway Situations|Comparison of Three Different Supraglottic Airway Devices and Endotracheal Intubation in Pediatric Difficult Airway Situations in a Manikin||Medical University of Vienna|Yes|Not yet recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572232||11378|
NCT02572245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5381005|A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Pharmacokinetics Of Pf-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects|B538-05|Pfizer|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|164|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|September 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572245||11377|
NCT02588443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 20214|Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma|Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|February 8, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588443||10133|
NCT02588456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 31415|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|November 13, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588456||10132|
NCT02563067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2314|Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.||Novartis|Yes|Recruiting|December 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|846|||Both|12 Years|N/A|No|||March 2016|March 10, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563067||12082|
NCT02572908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wheat-IBS|Effects of Wheat Breads on Symptoms of IBS, a Pilot Study|Effects of Wheat Breads on Symptoms of IBS, a Pilot Study|Wheat-IBS|Oy Karl Fazer Ab||Active, not recruiting|August 2015|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|26|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02572908||11326|
NCT02572921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USalzburg|Comparison of Positive Psychotherapy and Cognitive-Behavioral Psychotherapy for Depression|Evaluation of the Positive Psychotherapy to Reduce Symptoms and to Promote Happiness With Depressive Patients Compared to Cognitive-Behavioral Psychotherapy||University of Salzburg|Yes|Active, not recruiting|May 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2015|October 8, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02572921||11325|
NCT02563184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flu Vaccine Quad vs Tri|Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease|Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease||Banner Health|No|Recruiting|September 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563184||12073|
NCT02583386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3516|Comprehensive Fall Prevention and Detection in Multiple Sclerosis|Comprehensive Fall Prevention and Detection in Multiple Sclerosis|FFF|Portland VA Medical Center|No|Not yet recruiting|December 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|94|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583386||10521|
NCT02571439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2014-08-05|Comparative Study of Two Different Techniques to Perform TAP-blocks|A Randomized Controlled Trial of Surgical TAP-block After Cesarean Delivery: a Cost-effective Alternative to the Conventional TAP-block|Surgical-TAP|Maimonides Medical Center|No|Recruiting|October 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|40 Years|No|||October 2015|October 6, 2015|August 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02571439||11439|
NCT02567422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01643|VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma|A Phase I Study of VX-970 in Combination With Cisplatin and XRT in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)||National Cancer Institute (NCI)||Not yet recruiting|August 2016|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567422||11748|
NCT02565173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-01-2015|Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma|Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma|MATrX-1|Inotek Pharmaceuticals Corporation|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|335|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565173||11921|
NCT02565420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-858|Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial|Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial||The Cleveland Clinic|No|Not yet recruiting|September 2015|September 2022|Anticipated|September 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|8548|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565420||11902|
NCT02564133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/35|Hip Fracture and Patent Foramen Ovale|Are Postoperative Complications More Frequent When Patients Having a Hip Fracture Have a Patent Foramen Ovale ?|COL-FOP|Hopital Foch|No|Recruiting|June 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564133||12000|
NCT02564146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-PAK-0114|First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine|Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study|ALPACA|AIO-Studien-gGmbH|Yes|Not yet recruiting|April 2016|June 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|325|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564146||11999|
NCT02576431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOXO-TRK-15002|Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors|A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-Positive Tumors||Loxo Oncology, Inc.|No|Recruiting|October 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|151|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576431||11055|
NCT02576444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508016363|OLAParib COmbinations|A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors|OLAPCO|Yale University|Yes|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576444||11054|
NCT02567682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBT440-003|Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of GBT440 on the Pharmacokinetics of Probe Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 in Healthy Subjects||Global Blood Therapeutics|No|Recruiting|September 2015|February 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567682||11728|
NCT02583672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDN6722|Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)|Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|September 2015|July 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583672||10499|
NCT02583685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_SWITCH-1|Switching Regimen in Treating Cirrhotic HCV GT1b Subjects|Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)|SWITCH-1|Humanity & Healthy GI and Liver Centre|Yes|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|160|||Both|18 Years|70 Years|No|||October 2015|October 20, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583685||10498|
NCT02583698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-005|Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices|Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices||Institute of Liver and Biliary Sciences, India|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02583698||10497|
NCT02577354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950057|ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain|ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain (ReActiv8-B)|ReActiv8-B|Mainstay Medical|Yes|Not yet recruiting|June 2016|April 2022|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|22 Years|65 Years|No|||March 2016|March 23, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577354||10984|
NCT02564393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO09-PD / MucoNETs|Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis|Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose|MucoNETs|University Hospital, Tours|No|Completed|May 2011|||May 2013|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pathophysiological study comparing a " Cystic fibrosis " group to a control group (adults)|September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564393||11980|
NCT02574208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPICAB|Acceptability/Feasibility of HIV Testing by ELISA or Rapid Test to Adult Patients in Paris, France|Acceptability and Feasibility of HIV Testing by ELISA or Rapid Test to Adult Patients Consulting Their General Practitioner in Paris, France: A Multi-center Prospective Randomized Study||Hopital Lariboisière|No|Not yet recruiting|October 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|260|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02574208||11226|
NCT02574221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015049|A Pilot Study to Evaluate a Molecular Method for Plaque|A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity||Procter and Gamble||Completed|August 2015|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02574221||11225|
NCT02567903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49117.058.14|Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System|Tourniquet Study: Is the High Thrombosis Risk After Knee Arthroscopy Caused by Limb-tourniquet Application? A Randomized Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System||Groene Hart Ziekenhuis|No|Recruiting|September 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567903||11711|
NCT02570022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB-TSA|Liposomal Bupivacaine in Total Shoulder Arthroplasty|Liposomal Bupivacaine Versus Interscalene Nerve Block for Pain Control After Shoulder Arthroplasty: A Prospective Randomized Trial|EXP-TSA|Henry Ford Health System|Yes|Recruiting|October 2014|September 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 20, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570022||11548|
NCT02570035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE0003|Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease|Protocol for Specified Drug Use-results Survey of Betanis Tablets (for Patients With Coexisting Cardiovascular Disease)||Astellas Pharma Inc|No|Completed|December 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|316|||Both|N/A|N/A|No|Non-Probability Sample|Overactive bladder patients with current or a history of cardiovascular disease and        treated with mirabegron|October 2015|October 6, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570035||11547|
NCT02564406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3785|Extracorporeal CO2 Removal in Hypercapnic Patients|Extracorporeal CO2 Removal in Hypercapnic Patients Who Failed Noninvasive Ventilation and Refuse Endotracheal Intubation: a Case Series||University of Roma La Sapienza|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02564406||11979|
NCT02574247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1137|Role of the Auditory Efferent System in Auditory Perceptual Learning|Role of the Auditory Efferent System in Auditory Perceptual Learning||VA Loma Linda Health Care System|No|Not yet recruiting|October 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|50 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574247||11223|
NCT02574260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/03-E|An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)|Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma||BioVex Limited|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|September 18, 2015|Yes|Yes||No|November 13, 2015|https://clinicaltrials.gov/show/NCT02574260||11222|
NCT02577523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612H-006|A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease||NeuroDerm Ltd.|Yes|Recruiting|December 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|30 Years|80 Years|No|||November 2015|January 14, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577523||10971|
NCT02568527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVPEI-2012-11|Biodegradable Synthetic Scaffold as a Substitute for hAM in Limbal Epithelial Cells Transplant in LSCD Patients|Study to Evaluate Safety & Efficacy of PLGA Scaffold to Regenerate Limbal Epithelial Cells Using Autologous Limbal Grafts by SLET (Simple Limbal Epithelial Transplant) Procedure in Patients Having Total Unilateral LSCD||L.V. Prasad Eye Institute|No|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||October 2015|October 3, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02568527||11663|
NCT02561858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-07|Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation|Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Male|18 Years|70 Years|No|||September 2015|September 25, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02561858||12175|
NCT02572466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271/57|Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis|Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis||Chulalongkorn University|No|Completed|February 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|207|Samples Without DNA|blood sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ESRD group End-stage renal disease patients receiving regular hemodialysis at King        Chulalongkorn memorial hospital, Bhumirajanagarindra kidney institute hospital.        Control group Patients who come to OPD at King Chulalongkorn memorial hospital for their        follow up blood check.|January 2016|January 27, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572466||11360|
NCT02572479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_15|Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)|Observational Study for Evaluating the Potential of Diet and Food Components as Disease Modifiers in Amyotrophic Lateral Sclerosis (JERN_ALS)|JERN_ALS|University of Jena|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood sampling every six months (1x 9mL Sarstedt monovette)|Both|18 Years|90 Years|No|Non-Probability Sample|ALS patients diagnosed according to El Escorial / Awaji criteria for ALS|September 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572479||11359|
NCT02577692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eN-2015-1.0|Inspired Oxygen on Oxidative Stress and Breath Volatile Organic Compound Composition in Healthy Volunteers|Impact of Inspired Oxygen on Oxidative Stress and Breath Volatile Organic Compound Composition in Healthy Volunteers: A Randomized Controlled Cross-over Trial||Klinikum der Universitaet Muenchen, Grosshadern|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02577692||10958|
NCT02577705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1041002551|Building Wealth and Health Network: A Microfinance/TANF Demonstration Project|Building Wealth and Health Network: A Microfinance/TANF Demonstration Project||Center for Hunger-Free Communities|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|145|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02577705||10957|
NCT02571699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH|Minimum Effective Volume of Lidocaine-Bupivacaine for Subgluteal Block|Minimum Effective Volume of Lidocaine-Bupivacaine for Ultrasound-Guided Subgluteal Sciatic Nerve Block||McGill University Health Center|No|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571699||11419|
NCT02571712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-094|Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension|||Allergan|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|750|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571712||11418|
NCT02574117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corticotomy_CBCT|Cone Beam Computed Tomography for Evaluating Corticotomy-assisted Maxillary Expansion|Cone Beam Computed Tomography for Evaluating Corticotomy-assisted Maxillary Expansion With Bone Allograft||Cairo University|No|Completed|April 2010|December 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|22 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574117||11233|
NCT02572726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0106-15_CTIL|An Exploration of the Neuroplasticity of Endogenous Analgesia in Health and Chronic Pain|Integration of Neuroimaging and Transcranial Magnetic Stimulation: an Exploration of the Neuroplasticity of Endogenous Analgesia in Health and Chronic Pain||Rambam Health Care Campus|No|Not yet recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|100|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572726||11340|
NCT02562508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-006|A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls|Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years||Xiamen University|No|Active, not recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|979|||Female|9 Years|26 Years|Accepts Healthy Volunteers|||September 2015|December 29, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02562508||12125|
NCT02577029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heparc-2008|Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV|A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH)|Monarch|Arrowhead Research Corporation|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|75 Years|No|||September 2015|January 22, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577029||11009|
NCT02569593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAS15|Evaluation of the Absorption Rate From Different Oral Fe-supplements in Obese Volunteers Pre- and Post-RYGB|Evaluation of the Absorption Rate From Different Oral Fe-supplements in Obese Volunteers Pre- and Post-RYGB: an Interventional Study||Katholieke Universiteit Leuven|No|Recruiting|October 2015|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569593||11581|
NCT02572947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRD-13-2015-I|A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients|An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors|MONODO|University Hospital, Geneva|No|Not yet recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572947||11323|
NCT02577770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014TD0018|The Effect of Caffeine on Acupuncture Analgesia With the Human Pain Model|A Single Center, Double Blind, Randomized, Parallel-group Study to Assess the Effect of 200mg Caffeine,400mg Caffeine and Decaffeinated on Acupuncture Analgesia With the Human Pain Model||Chengdu University of Traditional Chinese Medicine|No|Recruiting|May 2015|May 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|200|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|September 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577770||10952|
NCT02562638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8178-A|Pre-Procedural Fasting in Cardiac Intervention|Do Patients Need Pre-Procedural Fasting for Coronary Artery Procedures?||University Health Network, Toronto|Yes|Not yet recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02562638||12115|
NCT02569112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0915|Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction and Laxity of the Flanks|Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With MP2 Technology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks||Venus Concept|Yes|Active, not recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569112||11618|
NCT02569125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CDE40T|Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome|Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome|EPASOS|University Hospital Freiburg|No|Withdrawn|January 2016|||January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|N/A|No|||February 2016|February 24, 2016|March 18, 2015||No|Change in supply of study medication|No||https://clinicaltrials.gov/show/NCT02569125||11617|
NCT02581150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0044|Cost-utility Analysis of the Outpatient Versus Conventional Hospitalization in Treatment of Occlusive Arterial Disease|Cost-utility Analysis of the Outpatient Hospitalization Versus Conventional Hospitalization in Endovascular Treatment of Occlusive Arterial Disease|AMBUVASC|Nantes University Hospital|Yes|Recruiting|February 2016|May 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|100 Years|No|||March 2016|March 2, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581150||10693|
NCT02562053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS 2|Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?|Does Adding Combined Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? A Double Blind Placebo Controlled Study.||Cairo University|Yes|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|20 Years|40 Years|No|||October 2015|October 3, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562053||12160|
NCT02562066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS-001|Amifampridine Phosphate for the Treatment of Pediatric Congenital Myasthenic Syndromes|A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS)||Catalyst Pharmaceuticals, Inc.|No|Recruiting|January 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|2 Years|17 Years|No|||March 2016|March 23, 2016|September 24, 2015|No|Yes||Yes||https://clinicaltrials.gov/show/NCT02562066||12159|
NCT02571634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404457|Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints|Open Label Feasibility Pilot Study to Assess the Efficacy and Safety of the Use of Lazanda for Anxiolysis During Radiofrequency Nerve Ablation of Lumbar Facet Joints|RFA|Defense and Veterans Center for Integrative Pain Management|No|Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02571634||11424|
NCT02575209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015534|Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects|Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects||Corporacion Parc Tauli||Recruiting|September 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females and males with and without schizophrenia of recent diagnosis.|October 2015|October 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575209||11149|
NCT02575222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15179|Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma|Phase I Study of Neoadjuvant Nivolumab in Patients With Non-metastatic High-risk Clear Cell Renal Cell Carcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575222||11148|
NCT02567474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-327|Effect of Self Management Program on Clinical Status of COPD Patients|Effect of Self Management Program Based on 5A Model on Clinical Status of Chronic Obstructive Pulmonary Disease||Ahvaz Jundishapur University of Medical Sciences|No|Completed|November 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02567474||11744|
NCT02566265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507016111|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)|SHIVERING 2|Yale University|No|Recruiting|September 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566265||11837|
NCT02567604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B15/31|Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective|Development of Core Outcomes for Age-related Macular Degeneration (AMD)||Queen's University, Belfast|No|Not yet recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|caregivers/ carers such as family members, unpaid friends or volunteers taking active part        in providing help and support for AMD patients|October 2015|October 1, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02567604||11734|
NCT02569710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-335-604|A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir|A Randomized, Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C||Alios Biopharma Inc.|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569710||11572|
NCT02575300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18141|Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2015|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575300||11142|
NCT02570932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-LEM3|Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries|Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries||Puerta de Hierro University Hospital|No|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||November 2015|November 12, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570932||11478|
NCT02570945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-965|Trial of a Pharmacist-physician Intervention Model to Reduce High-risk Drug Use by Hospitalised Elderly Patients|Randomized Controlled Trial of a Pharmacist-physician Intervention Model to Reduce High-risk Drug Use by Elderly Inpatients||Centre Hospitalier Universitaire de Sherbrooke|No|Active, not recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|65 Years|N/A|No|||October 2015|October 6, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02570945||11477|
NCT02561819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00014026|Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure Patients|Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure Patients||Children's Hospital Boston|No|Not yet recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Urine samples|Both|2 Years|17 Years|No|Non-Probability Sample|Patients with intestinal failure between 2-17 years of age inclusive will be recruited        through the Center for Advanced Intestinal Rehabilitation (CAIR) program at Boston        Children's Hospital.|September 2015|September 25, 2015|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561819||12178|
NCT02572934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53126.042.15|Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)|Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)|STANDBY|University Medical Center Groningen|No|Recruiting|August 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|280|||Male|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Potential participating TC survivors will be identified by the TC registry of the        uro-oncology tumor working group of the UMCG. The investigators will randomly select (with        an SPSS-query) 70 potential participants from the CT-group and search for age-matched        controls in the RT-, SU- and CO-group. A margin of three years will be accepted. If no        matching RT-patients, SU-patients or healthy volunteers are available, age-matching        criteria will be relaxed by allowing the difference to increase with one year at each        step, to a maximum of six years. Vital status will be checked with help of information        from the municipal population registry (GBA:'gemeentelijke basisadministratie'). Healthy        volunteers are recruited via advertisements in local door-to-door papers and by flyers        exposed in the UMCG.|October 2015|October 8, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02572934||11324|
NCT02576730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34131.068.10/ MEC 10-3-072|Functional Outcome Assessment After (Calcaneal) Trauma Surgey|Functional Outcome Assessment After (Calcaneal) Trauma Surgey|FACTS|Maastricht University Medical Center|No|Completed|October 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|healthy subjects and patients after foot and ankle trauma fracture surgery|December 2010|October 13, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02576730||11032|
NCT02576509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-459|A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma|A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)||Bristol-Myers Squibb|Yes|Recruiting|November 2015|June 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|726|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576509||11049|
NCT02576522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408|Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor|Tumor Bed Hypofractionated IMRT (VMAT-RA) After Surgical Resection for Patients With Single, Large (≥2.1 cm) Brain Metastases From Solid Tumor||Istituto Clinico Humanitas|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02576522||11048|
NCT02571491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSJD-ESCOKETA-2010|Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery|Assessment of the Analgesic Efficacy and Tolerability of the Perioperative Association of the Ketamine With Opiates After Posterior Vertebral Fusion Surgery in Children With Idiopathic Scoliosis||Fundació Sant Joan de Déu|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|8 Years|18 Years|No|||October 2015|October 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02571491||11435|
NCT02569099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZimbabwe|Effects of Training Caregivers on the Outcomes of Stroke Survivors and Caregivers in Zimbabwe|A Randomised Controlled Study to Compare the Effects of Standardised Care Plus Conventional Care Versus Conventional Care Only on the Outcomes of Stroke Survivors (HIV+ and HIV-) and Their Family Caregivers in Harare and Chitungwiza||University of Zimbabwe|Yes|Recruiting|October 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|188|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02569099||11619|
NCT02577861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-GPLSCD01-03|Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency|Multinational, Multicentre, Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency Due to Ocular Burns (HOLOCORE)|HOLOCORE|Chiesi Farmaceutici S.p.A.|No|Recruiting|October 2015|June 2020|Anticipated|May 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|2 Years|N/A|No|||February 2016|February 26, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02577861||10945|
NCT02567344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047358|Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving|A Double Blind, Sham Controlled Trial of Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving and Impulsive Decision Making in Cannabis Use Disordered Participants.||Medical University of South Carolina|No|Not yet recruiting|September 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|60 Years|No|||August 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567344||11754|
NCT02635191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-HP-001|Tailored Therapy for Helicobacter Pylori in Children|Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial||Beijing Children's Hospital|Yes|Recruiting|March 2014|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|4 Years|18 Years|No|||November 2015|December 16, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02635191||6545|
NCT02530892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31948|Effect of Embryo Mechanical Properties on Clinical Pregnancy After In Vitro Fertilization|Measuring the Relationship Between Embryo Mechanical Properties and Embryo Development After In Vitro Fertilization|EMECH|Stanford University|No|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing in vitro fertilization at the Stanford IVF clinic between August        2015 and April 2016.|August 2015|August 19, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02530892||14551|
NCT02536742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 53-14 / BIG 14-04|Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer|A Phase II Study of Palbociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer|PYTHIA|International Breast Cancer Study Group|Yes|Not yet recruiting|March 2016|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02536742||14103|
NCT02536755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13781|Skeletal Response to Eliglustat in Patients With Gaucher Disease|Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies|EXOSKEL|Sanofi|No|Recruiting|October 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||February 2016|February 23, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536755||14102|
NCT02564575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 305|Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults|Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564575||11967|
NCT02564588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-221|Dasotraline Binge Eating Disorder Study|A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder||Sunovion|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|55 Years|No|||January 2016|January 12, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564588||11966|
NCT02562560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00910-53|Neuropsycholgy and Neuroimaging in Transient Global Amnesia|Neuropsycholgy and Neuroimaging in Transient Global Amnesia|2NIA|University Hospital, Caen||Terminated|September 2008|||July 2015|Actual|N/A|Interventional|Primary Purpose: Diagnostic|2||Actual|60|||Both|30 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562560||12121|
NCT02562573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBI4050-ATX-9-04|Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome|A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome||ProMetic BioSciences Inc.|Yes|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562573||12120|
NCT02578199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104008-01|Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care|Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care||Yale University|Yes|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578199||10919|
NCT02575287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-JUN-17-2015|Minimal Injuries From Esophagus Detected by Optical Enhancement System™ Associated to Optical Magnification HD Scopes|Mucosal and Minimal Injuries Detected Through Digital Chromoendoscopy Using Optical Enhancement System™ Associated to High Definition Plus Optical Magnification in Non Erosive Gastroesophageal Reflux Disease||Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Completed|September 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|Samples Without DNA|histological biopsies from esophagus|Both|18 Years|N/A|No|Non-Probability Sample|Patients that had reflux symptoms (heartburn and regurgitation) and 8 or more points at        the Spanish version of GERD questionnaire validated by Zavala-González et al. underwent an        upper videoendoscopy using initially high definition white light and then digital        chromoendoscopy (I-Scan™) in the three different image algorithms. If the esophagus was        normal and no changes were seen by these two techniques, they were considered as NERD        patients and a pH-impedanciometry was performed as gold standard study, in order to        diagnosis reflux disease. We considered a GERD diagnosis with more than 73 episodes of        reflux in 24 hours or acid exposure time abnormal with ph<4 measured in more than 4,2%of        the time over 24 hours.|January 2016|January 7, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02575287||11143|
NCT02588274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015S102|Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndromes|Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndromes: Study Protocol for a Randomized, Placebo-controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|November 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Male|18 Years|50 Years|No|||October 2015|October 26, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02588274||10146|
NCT02571205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-003195-68|Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy|Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|November 2015|March 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Samples to be collected as part of Biobank|Male|12 Years|17 Years|No|Probability Sample|This is a single-centre, prospective, observational, study on clinical outcomes of        testosterone replacement therapy in adolescents with DMD and delayed puberty. Being an        observational study of routine care, there will be no specified end point. We will aim to        recruit any adolescent with DMD and delayed puberty who is reviewed by the muscle team at        the John Walton Muscular Dystrophy Research Centre from the study approval date.|February 2016|February 25, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02571205||11457|
NCT02571309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medituner-001|Asthmatuner a Self-management App for Asthma: A Randomized Controlled Multicentre Trial|Asthmatuner a Self-management App for Asthma|Asthmatuner|Karolinska Institutet|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|43|||Both|6 Years|N/A|No|||October 2015|October 6, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02571309||11449|
NCT02564432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1544-I|Microbiome and Metagenome in Percutaneous Osseointegrated Prostheses (MMPOP)|Microbiome and Innate Immunity With Percutaneous Osseointegrated Prostheses|MMPOP|VA Office of Research and Development|No|Not yet recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Stomal and skin swab samples for bacterial 16S ribosomal RNA and fungal 18S ribosomal RNA.      Blood samples to detect mRNA of genes regulating production of immune proteins. Serous      drainage from the stoma to determine wound healing cytokine expression.|Both|18 Years|80 Years|No|Non-Probability Sample|10 transfemoral amputees selected from Veteran and active military populations|November 2015|November 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564432||11977|
NCT02575391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-107B|The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer|The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy||Providence Health & Services|No|Terminated|October 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 25, 2015||No|Lack of participant recruitment.|No||https://clinicaltrials.gov/show/NCT02575391||11135|
NCT02575404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-166|GR-MD-02 Plus Pembrolizumab in Melanoma Patients|Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma||Providence Health & Services|No|Not yet recruiting|October 2015|October 2021|Anticipated|October 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575404||11134|
NCT02578589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280981PM|Medial Plica Syndrome of the Knee: Conservative Treatment Versus Arthroscopic Plica Resection - a Randomized Controlled Multicenter Trial|||Regionshospitalet Silkeborg|No|Recruiting|September 2014|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02578589||10889|
NCT02567513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090948|Cost-Effectiveness of Weight Loss Prevention in Nursing Homes: A Controlled Trial|Cost-Effectiveness of Weight Loss Prevention in Nursing Homes: A Controlled Trial||Vanderbilt University|No|Completed|October 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|154|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567513||11741|
NCT02567526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111645|Cost Effectiveness of Nutrition Intervention in Long Term Care|Cost Effectiveness of Nutrition Intervention in Long Term Care||Vanderbilt University|No|Active, not recruiting|August 2011|January 2016|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|148|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567526||11740|
NCT02564445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823326|Using Social Incentives and Gamification for Weight Loss Promotion|Using Social Incentives and Gamification for Weight Loss Promotion||University of Pennsylvania|No|Enrolling by invitation|January 2016|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564445||11976|
NCT02567149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0|Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.|Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|17 Years|No|||September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567149||11769|
NCT02567162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150655H|Multinational Survey of Epidemiology, Morbidity, and Outcomes in Intracerebral Hemorrhage|Multinational Survey of Epidemiology, Morbidity, and Outcomes in Intracerebral Hemorrhage (MNEMONICH)|MNEMONICH|The University of Texas Health Science Center at San Antonio|No|Enrolling by invitation|November 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized for ICH will be asked to provide their permission for the use of        this information for retrospective research studies directed at ICH; such research to be        conducted by the MNEMONICH investigators.|October 2015|October 5, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567162|90 Days|11768|
NCT02587286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gather mHealth 1|Gather mHealth India RCT for Behavior and Health Outcomes|Investigation of the Gather mHealth Platform on Diabetics' Behavior and Health Outcomes.||Gather Health India|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|91|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587286||10221|
NCT02577237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2315|Building Caregiver Skills Using a Simulation-based Intervention for Care of Head and Neck Cancer|Building Family Caregiver Skills Using a Simulation-based Intervention for Care of Patients With Head and Neck Cancer||Case Comprehensive Cancer Center|No|Recruiting|August 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577237||10993|
NCT02578225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288-AU/003|Acute and Chronic Heart Failure in Real Life in Turkey|Acute and Chronic Heart Failure in Real Life in Turkey: National, Multi-center, Epidemiological, Observational and Ad-Hoc Cross-sectional Study|SELFIE-HF|Cumhuriyet University|No|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|930|||Both|18 Years|N/A|No|Probability Sample|In 23 designated sites, for a month on a day which will be determined by the site itself,        patients who have been admitted to the clinic or hospitalized with Heart Failure (Acute        and Chronic) diagnosis will be enrolled into the study. Target population of the study is        the acute and chronic heart failure patients who will consult to the hospital on the        related day of the week for a month which is determined by sites.|December 2015|December 29, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02578225||10917|
NCT02564731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHlung003|Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study|Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study||Beijing Children's Hospital|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|Children who was confirmed diagnosis as bronchiectasis at the certain hospitals (sponsor        and collaborators)|November 2015|November 16, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02564731||11955|
NCT02574741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000726|Combination Treatment for Augmenting Language in Children With ASD|Augmenting Language Interventions in ASD: A Translational Approach (ACE Project 3)|PIII|University of California, Los Angeles|Yes|Recruiting|June 2012|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|72|||Both|5 Years|11 Years|No|||October 2015|October 9, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02574741||11185|
NCT02569502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18634|A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection|Open Label, Nonrandomized Clinical Trial of Safety and Tolerability of Enfuviritide (Fuzeon®, HIV Fusion Inhibitor) in Patients With Advanced HIV1 Infection||Hoffmann-La Roche||Completed|April 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569502||11588|
NCT02569515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18101|A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia|An Open-Label Study of the Tolerability and Flexibility of Multi-Dose NeoRecormon Administered by Reco-Pen in Pre-Dialysis Patients With Chronic Renal Anemia.||Hoffmann-La Roche||Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569515||11587|
NCT02568553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01640|Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma|A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)||National Cancer Institute (NCI)||Not yet recruiting|June 2016|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568553||11661|
NCT02574806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBNPRNS01|Normal Values of Brain Natriuretic Peptide in Healthy Newborn|Normal Values of Brain Natriuretic Peptide in Healthy Newborn||Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud||Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|167|||Both|N/A|1 Minute|Accepts Healthy Volunteers|Non-Probability Sample|Healthy term newborn obtained by vaginal delivery and/or cesarean section.|October 2015|October 10, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02574806||11180|
NCT02574871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28201014.2.0000.5497|Data Collection for Stress Identification|Data Collection for Identification of the Chronic Stress Presence in Healthy Adult Subjects||University of Mogi das Cruzes|Yes|Completed|August 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|undergraduate students|October 2015|October 13, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574871||11175|
NCT02587611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastric emptying|Randomized Comparison of Elemental Liquid Diet and Standard Semi-solid Diet on Gastric Emptying|Randomized Comparison of Elemental Liquid Diet and Standard Semi-solid Diet on Gastric Emptying in Healthy Subjects and Bedridden Gastrostomy-fed Patients||Showa Inan General Hospital|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 31, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587611||10197|
NCT02587624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMUN-DB-002-MAGNA-AF|Remote MAGNetic Catheter Ablation for Atrial Fibrillation|Safety, Radiation Exposure and Efficacy of Remote MAGNetic Catheter Ablation for Atrial Fibrillation|MAGNA-AF|Paracelsus Medical University|No|Recruiting|March 2011|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with class I or class IIa indication for catheter ablation for        symptomatic atrial fibrillation according to the current guidelines [Camm AJ et al. 2012        focused update of the ESC guidelines for the management of atrial fibrillation. European        Heart Journal (2012) 33, 2719-2747].|October 2015|October 25, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02587624|12 Months|10196|
NCT02568800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0392|Prolonged Infusion Cefepime and Nosocomial Infections|Prolonged Infusion Cefepime and Nosocomial Infections|PICNIC|Hospital de Clinicas de Porto Alegre|No|Recruiting|October 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|80 Years|No|||October 2015|October 15, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568800||11642|
NCT02565290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP4989/2014|Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arteriosus: a Randomized Clinical Trial.|Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arteriosus: a Randomized Clinical Trial.||Instituto de Cardiologia do Rio Grande do Sul|No|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|74|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565290||11912|
NCT02574884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORT10-DB / VINTAGE VHC|Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins||VINTAGE VHC|University Hospital, Tours|No|Completed|August 2011|July 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02574884||11174|
NCT02576145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA16215|A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)|Immune Response to Neoantigen and Recall Antigen in Pediatric Renal Transplant Recipients Treated With the IL-2R Alfa Monoclonal Antibody, Daclizumab (Zenapax®)||Hoffmann-La Roche|Yes|Completed|April 2003|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|2 Years|19 Years|No|||December 2015|December 9, 2015|October 5, 2015|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT02576145||11077|
NCT02572297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.582|National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies|National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies|REPOMSE|Hospices Civils de Lyon|No|Completed|May 2010|August 2015|Actual|February 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1072|||Both|15 Years|N/A|No|Non-Probability Sample|Patients suffering from drud-resistant partial epilepsy whom a video-EEG monitoring of        their seizures was scheduled as part of a pre-surgical assessment|September 2015|October 7, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02572297|10 Years|11373|
NCT02572544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUHeye|Comparison of Objective and Subjective Changes Induced by Multiple Pinhole Glasses and Single Pinhole Glasses|||Chung-Ang University Hospital|No|Recruiting|October 2015|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572544||11354|
NCT02568059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-TM-1-179/57|The Clinical Safety of Alcoholic Extract Sahastara Remedy of Extract Capsule in Healthy Volunteers|The Clinical Safety of Alcoholic Extract Sahastara Remedy of Extract Capsule in Healthy Volunteers (Clinical Trial Phase I)||Thammasat University|Yes|Recruiting|December 2015|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568059||11699|
NCT02572648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083607|A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls|A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls (MIND-HF)|MIND-HF|Emory University|Yes|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women with heart failure and men and women without heart failure to serve as        healthy age-matched controls.|December 2015|December 3, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572648||11346|
NCT02561910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HerniaCR|Effectivity of Laparoscopic Inguinal Hernia Repair (TAPP) in Daily Clinical Practice - Early and Long-term Results|Effectivity of Laparoscopic Inguinal Hernia Repair (TAPP) in Daily Clinical Practice - Early and Long-term Results||Hernia Center Rottenburg|No|Completed|January 2000|August 2015|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|952|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients admitted for hernia surgery during a one year period (n=928) were operated        exclusively in TAPP technique and were assigned to follow-up.|September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561910||12171|
NCT02561975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9375|Adaptation of Alveolar-capillary Diffusion at Effort of Subjects Suffering From Complex Congenital Heart Disease||CAR-DIFF|University Hospital, Montpellier|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|56|||Both|8 Years|N/A|No|||September 2015|September 24, 2015|January 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02561975||12166|
NCT02571556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-008|OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)|OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)||Eyegate Pharmaceuticals, Inc.|No|Recruiting|November 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||October 2015|January 19, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571556||11430|
NCT02575040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMMA-Fecal Tx-1|Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease|Efficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel Disease||Gulhane Military Medical Academy|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575040||11162|
NCT02564263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-181|Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)|A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)||Merck Sharp & Dohme Corp.|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564263||11990|
NCT02562248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508683196|Improving Anxiety Detection in Pediatrics Using Health Information Technology|Improving Anxiety Detection in Pediatrics Using Health Information Technology||Indiana University|Yes|Enrolling by invitation|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562248||12145|
NCT02576964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18269|A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer|An Open-Label Phase II Study of Capecitabine in Combination With Pegylated Interferon Alfa-2a in Patients With Advanced Hepatocellular Carcinoma||Hoffmann-La Roche||Completed|January 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576964||11014|
NCT02562118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR01/04/15|Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer|Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor||National University Hospital, Singapore|No|Not yet recruiting|September 2015|June 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02562118||12155|
NCT02562365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSCC-OC1501|Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer|A Phase II,Randomized Study of Adjuvant Chemotherapy of Three-step Regimens (ACTS) in Stage IIIc and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)|ACTS|Fudan University|No|Recruiting|November 2015|November 2023|Anticipated|November 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|70 Years|No|||December 2015|December 13, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02562365||12136|
NCT02575131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9619|Breakfast Test Products and Acute Satiety Scores|The Effect of Breakfast Test Products on Acute Satiety Scores in Different Test Conditions||TNO|No|Active, not recruiting|October 2015|July 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Actual|32|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 10, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575131||11155|
NCT02575144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-CLARIDEX|GEM-CLARIDEX: Ld vs BiRd|GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma|GEM-CLARIDEX|PETHEMA Foundation|Yes|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|338|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575144||11154|
NCT02583906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S55742|Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment|Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment||Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02583906||10481|
NCT02576743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SDG25850002|Pushing Spatiotemporal Limits for 4D Flow MRI and Dynamic MRA in the Brain at Ultra-High Field|Pushing Spatiotemporal Limits for 4D Flow MRI and Dynamic MRA in the Brain at Ultra-High Field||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|November 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients, age 18-75 years;          -  Patients with previously un-ruptured AVMs, who have had a catheter-guided DSA for             evaluation of the AVM; any Spetzler-Martin grade; patients with one or more             un-ruptured AVMs regardless of symptoms          -  Patients with non-symptomatic patients; one or more un-ruptured conservatively             managed aneurysms, all aneurysm sizes and shapes (fusiform, saccular, sessile).        Subjects:        - healthy subjects between 18 and 75 years.|October 2015|October 13, 2015|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576743||11031|
NCT02575196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1105|Non Invasive Neuromonitoring After Cardiac Arrest|Phase 2 Prospective, Observational, Pilot Study of Noninvasive Monitoring of Regional Cerebral Blood Flow for the Evaluation of Brain Tissue Perfusion During and After Resuscitation for Cardiac Arrest|NINCA|Icahn School of Medicine at Mount Sinai|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Comatose survivors of cardiac arrest|October 2015|October 14, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575196||11150|
NCT02575274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT peri-implantitis|Peri-Implantitis Surgical Treatment an RCT Study|Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial||Federal University of Minas Gerais|No|Enrolling by invitation|September 2013|July 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|January 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02575274||11144|
NCT02562768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15512|A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease|Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease||Eli Lilly and Company|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562768||12105|
NCT02568995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA2014|Pain Management Following Total Hip Arthroplasty|Postoperative Pain Management Following Total Hip Arthroplasty. A Comparison Between Local Infiltration Analgesia and Ultrasound Guided 3-in-1 Block|FEMORALIA|Örebro University, Sweden|No|Recruiting|May 2014|||December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||February 2016|February 14, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568995||11627|
NCT02569008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0116|Minimal Volume for Fluid Challenge in Post-operative Patients|Study of Changes on Mean Systemic Filling Pressure (Pmsf) in Post-surgical Patients After a Fluid Challenge: Looking for the Minimal Dose of Fluids||St George's, University of London|No|Completed|January 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|80|||Both|N/A|N/A|No|||October 2015|October 8, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569008||11626|
NCT02569242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-24/CA209-473|Study of ONO-4538 in Unresectable Advanced or Recurrent Esophageal Cancer|ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer||Ono Pharmaceutical Co. Ltd|Yes|Recruiting|December 2015|||September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|20 Years|N/A|No|||March 2016|March 10, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569242||11608|
NCT02566304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.323|Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies||Thomas Jefferson University|Yes|Recruiting|November 2015|||September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566304||11834|
NCT02574793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2015-152|Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects|Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects||Huashan Hospital|Yes|Recruiting|December 2014|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome|October 2015|October 10, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574793||11181|
NCT02585232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1824-W|Optimizing Dementia Care Through Collaborative Recovery Interventions|Optimizing Dementia Care Through Collaborative Recovery Interventions|ODeC|VA Office of Research and Development|Yes|Not yet recruiting|January 2016|October 2020|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|19 Years|N/A|No|||November 2015|November 6, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02585232||10379|
NCT02565979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-3-037|Long-term Resveratrol and Metabolism|Effects of Long-term Resveratrol Supplementation on Metabolic Health||Maastricht University Medical Center|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|70 Years|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565979||11859|
NCT02565992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA-011|Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma|Phase I Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma|CAPRA|Viralytics||Recruiting|October 2015|January 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565992||11858|
NCT02577133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-04|Prevention of Colic With the Probiotic Lactobacillus Reuteri|Prevention of Colic With the Probiotic Lactobacillus Reuteri in Mexican Infants: Randomized, Double-blind Study||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Not yet recruiting|October 2015|October 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|478|||Both|N/A|1 Week|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577133||11001|
NCT02576665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-15-02|A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors|A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors|Toca6|Tocagen Inc.|No|Not yet recruiting|February 2016|November 2019|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|90 Years|No|||January 2016|January 20, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576665||11037|
NCT02570321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14918|Cross-linking for Corneal Ulcers Treatment Trial|Cross-linking for Corneal Ulcers Treatment Trial|CLAIR|University of California, San Francisco|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|266|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570321||11525|
NCT02571816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215-CL-0106|A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215|A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215||Astellas Pharma Inc|No|Completed|October 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571816||11410|
NCT02571829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011-HMO-CTIL|A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma|A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma||Hadassah Medical Organization|No|Not yet recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571829||11409|
NCT02571985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-625 CA-P1|PRESERVE-Zenith® Iliac Branch System Clinical Extended Study|Clinical Study to Evaluate the Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation With the ConnectSX™||Cook||Active, not recruiting|May 2012|October 2017|Anticipated|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571985||11397|
NCT02575313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-173B|The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer|The Effects of Whole Food Intervention on Mucositis in Patients Being Treated for Head and Neck Cancer With Radiation With or Without Chemotherapy||Providence Health & Services|No|Terminated|October 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 25, 2015||No|Lack of participant recruitment.|No||https://clinicaltrials.gov/show/NCT02575313||11141|
NCT02561702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00057653|Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease|Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease||University of Rochester|No|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561702||12187|
NCT02573259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B8011001|A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCHNC), Ovarian, Sarcoma, Hodgkin Lymphoma|A Phase 1, Open-Label, Dose Escalation And Expansion Study Of PF-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Or Relapsed Or Refractory Classic Hodgkin Lymphoma||Pfizer|No|Recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573259||11299|
NCT02573272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-ESL-2105-01|Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors|Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|June 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|204|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with focal epilepsy on stable treatment for the last two years|September 2015|October 8, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02573272||11298|
NCT02566005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0032|A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor|A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor||St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|188|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566005||11857|
NCT02566018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-310|Treatment of Proximal Humerus Fractures in the Elderly|Treatment Options for Proximal Humerus Fractures in the Elderly and Their Implication on Personal Independence|prox_hum|University Hospital, Basel, Switzerland|No|Recruiting|May 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|166|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients fulfilling all of the following inclusion criteria|September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566018||11856|
NCT02574702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILEOS-ISS_2013|Trial to Reduce Wound Infection With Contralateral Drainage in Loop Ileostomy Closure|Prospective Randomized Controlled Trial to Reduce the Superficial Surgical Site Infection Due to a Contralateral Drainage Application in Loop Ileostomy Closure||Corporacion Parc Tauli|No|Recruiting|February 2013|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|78|||Both|18 Years|90 Years|No|||September 2015|October 12, 2015|March 18, 2013||No||No||https://clinicaltrials.gov/show/NCT02574702||11188|
NCT02562235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15681|Riociguat in Children With Pulmonary Arterial Hypertension (PAH)|Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)|PATENT-CHILD|Bayer|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|17 Years|No|||February 2016|February 26, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562235||12146|
NCT02562495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508123|Ultrasound to Evaluate the Quadriceps Muscle Wasting|Interest of the Ultrasound to Evaluate the Quadriceps Muscle Wasting in Critical Ill Patients.|ECHOSCAN|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|January 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|42|||Both|18 Years|100 Years|No|||September 2015|January 29, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562495||12126|
NCT02565641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16832|A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer|An Open-label, Phase II Study of Capecitabine Plus Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Hoffmann-La Roche||Completed|March 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565641||11885|
NCT02565953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISBAL|Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon||FISBAL|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|October 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565953||11861|
NCT02575625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO2011-FP/TRANSTEATOSE|Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis|Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis|TRANSTEATOSE|University Hospital, Tours|No|Recruiting|April 2013|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02575625||11117|
NCT02574403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000678-37|Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS|Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)|STOPECU|Nantes University Hospital|Yes|Recruiting|November 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|N/A|No|||March 2016|March 17, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02574403||11211|
NCT02564055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203121|A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)|Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis||GlaxoSmithKline|Yes|Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|270|||Both|12 Years|65 Years|No|||February 2016|February 4, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564055||12006|
NCT02570048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tinnitus pilotV1|1 Tinnitus Alleviation Via Sensory Substitution|Tinnitus Alleviation Via Sensory Substitution (Modulation of Tinnitus Through Simultaneous Auditory and Transcutaneous Tactile Stimulation of the Tongue).||MuteButton|No|Completed|June 2012|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|65 Years|No|Non-Probability Sample|The study population will be persons who are diagnosed as having tinitus by an        audiologists that are at least 18 years of age. It is expected that the user age        distribution will be skewed towards an older deomographic due to the increased prevalence        of hearing loss-related tinnitus in the elderly.|October 2015|October 6, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02570048||11546|
NCT02571608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-152|Continuation of Metformin to Improve And Keep Peri-operative Glycemic Control|ContinuAtioN of meTformin to Improve And KEep Peri-operative Glycemic Control: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.|CANTAKE|McMaster University|No|Not yet recruiting|February 2016|August 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571608||11426|
NCT02643823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-Rheumatoid Arthritis|Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis|Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02643823||5881|
NCT02534805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20003950|Patient Buddy App for the Prevention of Readmission in Cirrhosis|Patient Buddy App for the Prevention of Readmission in Cirrhosis||Virginia Commonwealth University|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|21 Years|N/A|No|Non-Probability Sample|Cirrhotic subjects who are hospitalized for non-elective reasons|August 2015|August 25, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02534805||14252|
NCT02542852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dolatav Study|A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia|A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)|Dolatav|Ospedale San Raffaele|No|Recruiting|September 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02542852||13636|
NCT02542917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WA/0518|Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study|Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study||King's College Hospital NHS Trust|No|Enrolling by invitation|September 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Unselected patients with any form of inflammatory bowel disease on any treatment and at        any stage of disease activity (diagnosed more than 6 months prior to study entry)|May 2015|September 4, 2015|May 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542917||13631|
NCT02529852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0069|A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma|A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02529852||14631|
NCT02585479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-C/Ahcc|Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma|Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)||Guangxi Medical University|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|75 Years|No|||October 2015|October 22, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585479||10360|
NCT02585700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORLAK-100|A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split, Inactivated Influenza Vaccine Produced by Torlak in Healthy Adult Volunteers in Serbia||Institute of Virology, Vaccines and Sera, Torlak|No|Active, not recruiting|November 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|February 4, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02585700||10343|
NCT02563938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK001-001|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001|A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease||Allakos, Inc.|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02563938||12015|
NCT02563951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNS-CL001|Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers|A Phase I Pharmacokinetic Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers||Maxinase Life Sciences Ltd.|Yes|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02563951||12014|
NCT02578355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The OPeRA study|National Plaque Registry and Database|National Plaque Registry and Database|OPeRA|Semmelweis University Heart and Vascular Center|No|Not yet recruiting|September 2016|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|90 Years|No|Probability Sample|Patients who underwent clinically indicated coronary CTA are involved in the sudy.|February 2016|February 22, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578355|5 Years|10907|
NCT02577172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK - 2014/1169|Testicular Cancer and Aerobic and Strength Training|Testicular Cancer and Aerobic and Strength Training - a Randomized Controlled National Phase II Study|TAST|Oslo University Hospital|No|Recruiting|November 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|94|||Male|18 Years|60 Years|No|||September 2015|December 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02577172||10998|
NCT02568085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arista for Thyroids|Trial Evaluating Use of Arista in Total Thyroidectomy|Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Total Thyroidectomy With and Without Neck Dissections||University of California, San Francisco|No|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568085||11697|
NCT02568098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1501|Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects|Open-Label Study to Evaluate Safety, Tolerability, Potential Pharmacokinetic Interactions and Mosquito-Lethal Effects of Orally Administered Ivermectin, Primaquine, Dihydroartemisinin-Piperaquine, and Albendazole in Healthy Adult Subjects||University of Oxford|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568098||11696|
NCT02562950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1837-CL-102|A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects|A Phase I, Open Interaction Study Between Oral Doses of GLPG1837 and Single Doses of Midazolam in Healthy Male Subjects||Galapagos NV|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02562950||12091|
NCT02583165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6150C00001|A Study in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors||MedImmune LLC|No|Recruiting|November 2015|August 2020|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583165||10538|
NCT02571322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150524|Whole Body Vibration Training on Body Composition|The Effect of Whole Body Vibration Training on Body Composition, Physical Fitness, and Quality of Life||University of Miami|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02571322||11448|
NCT02571335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBansi|Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS|Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial||Klinik Valens|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02571335||11447|
NCT02572999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C22/15/028/01|Incidence and Risk Factors for Hospitalization-Associated Disability|Incidence and Risk Factors for Hospitalization-Associated Disability (HAD) and Its Association With Hospital and Care Processes in Patients With Valvular Heart Disease||Universitaire Ziekenhuizen Leuven||Recruiting|October 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged 70 years and older admitted for elective heart valve surgery (replacement,        repair or combined with CABG) or if admitted for elective transcatheter aortic valve        implantation, or if a patient presents with symptomatic moderate to severe valvular heart        disease on hospital admission.|September 2015|December 23, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02572999||11319|
NCT02564601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19415|The Impact of Piano Training on Cognitive Performance and Psychosocial Well-Being in Older Adults|The Impact of Piano Training on Cognitive Performance and Psychosocial Well-Being in Older Adults||University of South Florida|Yes|Recruiting|June 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|90|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02564601||11965|
NCT02568332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACHI-02|A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals|A Phase I Study to Assess the Safety and Immunogenicity of Prime-boost Immunisations With Vaccine Candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 Seropositive HCV-uninfected Adults on Antiretroviral Therapy (ART)||University of Oxford|Yes|Recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|60 Years|No|||October 2015|October 1, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02568332||11678|
NCT02564744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0302|IMGN529 in Combination With Rituximab in Patients With RR DLBCL and Other Forms of NHL|A Phase 2 Study to Evaluate the Efficacy and Tolerability of IMGN529 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma||ImmunoGen, Inc.|No|Not yet recruiting|December 2015|December 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564744||11954|
NCT02575937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXYZM3|Low Glycemic Diet Intervention and Community Diabetic Patients|The Efficiency of Nutrition Education-based Low Glycemic Diet Intervention on Community Diabetic Patients||Sun Yat-sen University|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1000|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02575937||11093|
NCT02571868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Acute and Cronic Evaluation of AV/PV and VV Delay IEGM Based Optimisation Algorithm-QuickSept Study|Acute and Cronic Evaluation of AV/PV and VV Delay IEGM Based Optimisation Algorithm (QuickOpt™) Compared With Echocardiographic Method for Cardiac Resincronization Therapy in CRT Implants With Right Interventricular Basal-Mid Septum Placement of Leads (QuickSept Study)|QuickSept|Maria Vittoria Hospital|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CRT-D|October 2015|October 7, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571868||11406|
NCT02571881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH01-07-2012|Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section|Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section|oksisektio|Kuopio University Hospital|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|45 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571881||11405|
NCT02571946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-053|Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Feasibility of High Dose Proton Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: Prospective Phase II Trial|PTHP|Samsung Medical Center|No|Not yet recruiting|December 2015|September 2022|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|20 Years|N/A|No|||September 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571946||11400|
NCT02574611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-15-026|Use of High Resolution Colonic Manometry in Studying Motility|Safety and Efficacy of High Resolution Manometry in Studying Colonic Motility and Iontophoretic Administration of Prokinetic Agents||James J. Peters Veterans Affairs Medical Center|No|Recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Anticipated|16|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574611||11195|
NCT02574624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISIA|Vitreous Surgery With Intraocular Assistance|Vitreous Surgery With Intraocular Assistance (VISIA)|VISIA|Johns Hopkins University|No|Not yet recruiting|October 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|100 Years|No|||October 2015|October 9, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02574624||11194|
NCT02576080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-31|Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index|Efficacy of Adjuvant Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index. Multicenter, Prospective, Randomized Study. Etude Multicentrique, Prospective, randomisée|GIGIST|Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|October 2015|October 2020|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|80 Years|No|||October 2015|October 14, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02576080||11082|
NCT02565602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/01000|Comparison of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism|A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans||National University, Singapore|Yes|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02565602||11888|
NCT02572141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU10|FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)|A Phase III Study to Evaluate the 3-year Disease-free Survival in Patients With Locally Advanced Colon Cancer Receiving Either Perioperative or Postoperative Chemotherapy With FOLFOX or CAPOX Regimens|OPTICAL|Sun Yat-sen University|No|Recruiting|October 2015|October 2022|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|738|||Both|18 Years|70 Years|No|||October 2015|December 29, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02572141||11385|
NCT02576158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-01|HPV Integration Testing for Cervical Cancer Screening|HPV（Human Papillomavirus） Integration Testing for Cervical Cancer Screening||Huazhong University of Science and Technology||Recruiting|April 2015|April 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|12000|||Female|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy women between the ages of 30 and 65 years|September 2015|October 12, 2015|September 22, 2015||||No||https://clinicaltrials.gov/show/NCT02576158||11076|
NCT02564536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510166|Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)|A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes||Washington University School of Medicine|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564536||11970|
NCT02561533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIHCDBMTC1|Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma|Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC||University of Aarhus|Yes|Recruiting|December 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02561533||12200|
NCT02565615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581197|Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting|Atorvastatin Effectiveness And Safety In Cardiology Patients In Real World Setting: A Registry Study In China|ATTENTION|Pfizer|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Chinese cardiology patients|March 2016|March 24, 2016|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02565615|12 Weeks|11887|
NCT02576574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 100070-005|Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)|A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer||EMD Serono|Yes|Recruiting|October 2015|June 2023|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576574||11044|
NCT02567123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM-17714|Running Study for Runners With Chronic Knee Pain|The Effects of Gait Retraining in Runners With Patellofemoral Pain: A Randomized Trial||University of New Mexico||Completed|November 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|44 Years|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567123||11771|
NCT02566694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNOH LIRC|Analysis of Specimens From Patients With Orthopaedic Implants|Analysis of Specimens From Patients With Orthopaedic Implants||Royal National Orthopaedic Hospital NHS Trust|No|Recruiting|March 2015|March 2020|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|Samples Without DNA|Periprosthetic tissue samples|Both|11 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be both male and female, aged between 11-70 years.|September 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566694||11804|
NCT02576886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-15-CARD-001|Combined Supine/Prone Acquisitions in Stress-First/Stress-Only Myocardial Perfusion Imaging to Reduce Equivocal Results|Combined Supine/Prone Acquisitions in Stress-First/Stress-Only Myocardial Perfusion Imaging to Reduce Equivocal Results in Patients Undergoing Testing in a Tertiary Care Facility|SFSO-MPI|Hamilton Health Sciences Corporation|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|490|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576886||11020|
NCT02576951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16084|A Study of LY2951742 in Healthy Participants|Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation||Eli Lilly and Company|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|178|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576951||11015|
NCT02565498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCREB # 15-070|Preoperative vs Postoperative IMRT for Extremity/Truncal STS|Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma||Mount Sinai Hospital, Canada|No|Not yet recruiting|November 2015|December 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02565498||11896|
NCT02565719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP 401|REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection|An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® or Zadaxin® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B||Replicor Inc.|No|Recruiting|September 2015|December 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|55 Years|No|||September 2015|November 4, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565719||11879|
NCT02568150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWP450004|Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines|Single Arm, Open, Single Institute, Domestic Phase 4 Clinical Study to Evaluate the Onset Time of Improvement of Glabellar Frown Lines and Safety of DWP450-004 Injection for Adults With Worse Than Moderate Glabellar Frown Lines||Daewoong Pharmaceutical Co. LTD.|No|Completed|February 2014|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568150||11692|
NCT02568163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5502|Influence of Stress on Non Surgical Periodontal Treatment|Influence of Stress on Non Surgical Periodontal Treatment||University Hospital, Strasbourg, France|No|Recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|June 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02568163||11691|
NCT02566954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-HPNCL-03|3 Dimensional Study of Lower Limbs and Feet of Children in Standing Position|3 Dimensional Study of Lower Limbs and Feet of Children in Standing Position|MI3DEOS|Fondation Lenval|No|Recruiting|May 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02566954||11784|
NCT02569021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501030|Battery-preserving Stimulation Patterns for Deep Brain Stimulation|Battery-preserving Stimulation Patterns to Improve Symptoms in Parkinson's Disease and Essential Tremor||University of Florida|Yes|Recruiting|May 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569021||11625|
NCT02565732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL045|Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis|||Revance Therapeutics, Inc.||Completed|September 2015|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565732||11878|
NCT02564796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO 619|Erythropoietin to Prevent Unnecessary Transfusions In The Patients With Congenital Cyanotic Heart Disease - A Prospective Control Trial|Erythropoietin to Prevent Unnecessary Transfusions In The Patients With Congenital Cyanotic Heart Disease - A Prospective Randomized Control Trial||University of California, San Diego||Not yet recruiting|September 2015|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|4 Weeks|No|||September 2015|September 30, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564796||11950|
NCT02587598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 53914-101|Study of INCB053914 in Subjects With Advanced Malignancies|A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies||Incyte Corporation|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587598||10198|
NCT02565446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003148|Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram|Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram||Mayo Clinic|No|Recruiting|September 2015|December 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02565446||11900|
NCT02565459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Third-party MSC-Tx tolerance A|MSC and Kidney Transplant Tolerance (Phase A)|Third-party Bone Marrow-derived Mesenchymal Stromal Cells to Induce Tolerance in Recipients of Kidney Transplants From Deceased Donors (Phase A)||A.O. Ospedale Papa Giovanni XXIII|No|Recruiting|September 2015|December 2021|Anticipated|September 2021|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02565459||11899|
NCT02562378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medopp038|T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer|Phase I Multicenter Clinical Trial Evaluating the Combination of Trastuzumab Emtansine (T-DM1) and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer||MedSIR|No|Recruiting|October 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|November 24, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02562378||12135|
NCT02562391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9872TLAA|Effect of Left Atrial Appendage Excision on Procedure Outcome in Patients With Persistent and Long-standing Persistent Atrial Fibrillation Undergoing Surgical Ablation|||Meshalkin Research Institute of Pathology of Circulation|Yes|Active, not recruiting|May 2011|May 2017|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02562391||12134|
NCT02565069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIND-EU - CF163|Identification for the Treatment of Complex Arrhythmias|Identification for the Treatment of Complex Arrhythmias (CartoFinder™ Algorithm Trial: "CF163 EU")||Biosense Webster, Inc.|No|Recruiting|July 2015|April 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565069||11929|
NCT02565082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Drepanocytose-Hemostatic|Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients|Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients||Brugmann University Hospital|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02565082||11928|
NCT02584192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2014|Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction|Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction||Guangzhou General Hospital of Guangzhou Military Command|Yes|Completed|October 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584192||10459|
NCT02572115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFME001|Differentiated Access to Out-of-hours Primary Care Through Emergency Access|Differentiated Access to Out-of-hours Primary Care Through Emergency Access|Akutknappen|University of Aarhus|Yes|Not yet recruiting|August 2016|August 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Anticipated|6000|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|January 15, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02572115||11387|
NCT02577081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0163-15-MMC|Assessment of the Risk of Contralateral Non Simultaneous Neck of Femur Fracture in the Elderly.|Assessment of the Risk of Contralateral Non Simultaneous Neck of Femur Fracture in the Elderly. CT Based Study.||Meir Medical Center|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|70 Years|90 Years|No|||October 2015|October 17, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02577081||11005|
NCT02570620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI09-JP/ECOLDIA|Contribution of Ultrasonography in the Evaluation of Cervical Induction-delivery Time|Apport de l'échographie du Col Dans l'évaluation du Délai Induction Accouchement (DIA) Chez Des Patientes à Score de Bishop défavorable après déclenchement Par Dinoprostone Intravaginal|ECOLDIA|University Hospital, Tours|No|Completed|September 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|342|||Female|18 Years|50 Years|No|||October 2015|October 5, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570620||11502|
NCT02570633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 28236814.3.0000.5149|Ginger Capsules for the Prophylactic Treatment of Migraine|Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment||Federal University of Minas Gerais|Yes|Recruiting|July 2014|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|60 Years|No|||March 2016|March 24, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570633||11501|
NCT02575768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-014|Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease|Reduced Myocardial Flow Reserve in Exertional Angina With Severe Aortic Stenosis and Normal Coronary Arteries: Insight From Prospective Observational Adenosine-stress Cardiac Magnetic Resonance Imaging Study||Samsung Medical Center|Yes|Completed|June 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects who had severe AS and normal LV ejection fraction (EF ≥ 50%) in transthoracic        echocardiography were included in the investigators' prospective study. Severe AS was        defined as aortic valve area index less than 0.6 cm2/m2 as previously published.|June 2012|October 14, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02575768||11106|
NCT02575846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056976|Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair|Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair||Duke University||Recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||September 2015|October 13, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575846||11100|
NCT02588287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0123|Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir|Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir||University of Colorado, Denver|No|Recruiting|November 2015|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|60 Years|No|||February 2016|February 2, 2016|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02588287||10145|
NCT02588300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5782/13|Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy|Evaluation of the Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy According to the Munich Sleep Video Protocol||Technische Universität München|No|Active, not recruiting|July 2013|November 2015|Anticipated|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|75 Years|No|||October 2015|October 25, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02588300||10144|
NCT02570074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066102|PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults|Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants|PROOF|Duke University|Yes|Recruiting|December 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570074||11544|
NCT02563405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-3-UA|The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients|The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|September 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2015|December 13, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563405||12056|
NCT02566148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS PARCOURS|Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France|Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France|PARCOURS|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|February 2012|May 2013|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|2468|||Both|18 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|Migrants from Sub-Saharan Africa living in Ile-de-France (Paris area) and visiting health        care facilities: people living with HIV/AIDS (HIV group), people with chronic hepatitis B        (hepatitis B group), and people who have neither of these conditions and consult within        primary health care facilities in Ile-de-France (reference group).|September 2015|September 30, 2015|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02566148||11846|
NCT02566382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 12.172 DESEP|Preliminary Study of Feasibility of Arthrodesis Scapula-humeral Under Arthroscopy|Arthrodesis Gleno Humeral Under Arthroscopy in the Sequelae of Plexus Brachial Evaluation of the Technical Feasibility|DESEP|University Hospital, Brest|No|Recruiting|September 2015|June 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02566382||11828|
NCT02570867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstJinanU|Functional Brain Changes of Primary Open-angle Glaucoma Patients|Study on the Changes of Brain Function in Primary Open-angle Glaucoma Patients With fMRI||First Affiliated Hospital of Jinan University|No|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|POAG group :20 cases normal control group:20 cases|October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570867||11483|
NCT02570880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLOWBREAD-15-1|Effect of Dough Fermentation Time of Bread on the Glycaemic Index|Effect of Dough Fermentation Time of Bread on the Glycaemic Index|SLOWBREAD|Zurich University of Applied Sciences|No|Enrolling by invitation|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570880||11482|
NCT02573636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS VIII|The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy|The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy||Sir Mortimer B. Davis - Jewish General Hospital|No|Not yet recruiting|January 2016|||January 2030|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|208|Samples With DNA|Areas of prostate tumor will be identified by the pathologist of the study. This will then      be excised from the paraffin block using a tissue microarray punch. Two punches will be      acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted      using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the      isolation of nucleic acids will be used differing only in the time of protease digestion      such that RNA is isolated after a short incubation (30 minutes), while DNA is isolated after      a longer incubation (overnight). DNA will be used to assess copy number variation at the      PTEN locus (10q23) using quantitative PCR and appropriate Taqman chemistry.|Male|18 Years|N/A|No|Non-Probability Sample|The original slides of 208 patients with informed consent will be reviewed. Patients with        and without markers under the investigation will be accrued into this study. The        investigators at the treating institutions will submit paraffin-embedded tissue blocks        from the original pre-treatment diagnostic prostatic biopsy, which will be reviewed to        confirm the Gleason score and to record other histopathologic features, such as the extent        of tumor in the biopsies, the number of positive biopsies, and mitotic index.|October 2015|October 29, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02573636||11270|
NCT02577146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506127|The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic|The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic||Washington University School of Medicine|No|Not yet recruiting|October 2015|January 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577146||11000|
NCT02577159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPHNIS|Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)|Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)|DAPHNIS|Osaka University|Yes|Recruiting|July 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|65 Years|No|||August 2015|October 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02577159||10999|
NCT02566395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-551|Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies||Northwell Health|No|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|21 Years|No|||September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566395||11827|
NCT02570737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardioneumology|Latin American Pulmonary Hypertension Registry|Latin American Pulmonary Hypertension Registry|RELAHP|Asociacion Latinoamericana de Torax|No|Enrolling by invitation|April 2014|April 2019|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Latin American Patients of any age, with diagnosis of Pulmonary Hypertension from groups        I-V confirmed by Right Heart Catheterization|October 2015|October 13, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570737|5 Years|11493|
NCT02563548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-107-101|Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab|A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors||Halozyme Therapeutics|No|Recruiting|October 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563548||12045|
NCT02567747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203127|Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age|Impact of Vaccination Against Pneumococcal Disease on the Morbidity of Acute Otitis Media in Colombian Children < 5 Years of Age||GlaxoSmithKline||Not yet recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1|||Both|N/A|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|All eligible subjects (aggregated) captured by the selected national databases in        Columbia.|October 2015|October 15, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567747||11723|
NCT02570334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12322 PediacamDEV|A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)|A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)|PediacamDEV|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Not yet recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|400|||Both|4 Years|7 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570334||11524|
NCT02578004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU Farhat Hached|Risk Factors for Pressure Ulcers|Case Control Study of the Risk Factors for Pressure Ulcers in Tunisian Patients||Centre Hôpital Universitaire Farhat Hached|Yes|Completed|January 2013|June 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|313|||Both|19 Years|88 Years|Accepts Healthy Volunteers|Probability Sample|This prospective study consisted of 100 patients were having at least one wound of        pressure ulcer that met the following inclusion criteria. Who followed in many departments        (emergency, orthopedic, physical medicine) of three University Regional hospitals of        Tunisia (Farhat Hached and Sahloul Sousse, Fattouma Bourguiba Monastir) were evaluated        prospectively.|October 2015|October 14, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578004||10934|
NCT02563977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KATønseth|Changes To The Abdominal Wall After DIEP Flap Breast Reconstruction|Structural Changes In The Abdominal Wall After Deep Inferior Epigastric Perforator Flap Breast Reconstruction||Oslo University Hospital||Recruiting|July 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|||Female|N/A|N/A|No|Non-Probability Sample|15 women consecutively undergoing secondary, unilateral breast reconstruction with a DIEP        flap were identified and recruited to participate in the study. The patients were informed        about of risks and benefits and gave written consent prior to participation. All smokers        stopped smoking 4 weeks prior to surgery|September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02563977||12012|
NCT02566941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-SNM001|Neuromuscular Electrical Stimulation in the Critically Ill|Neuromuscular Electrical Stimulation in the Critically Ill||Brugmann University Hospital|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02566941||11785|
NCT02573220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0081|Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer|A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients||University of Chicago|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573220||11302|
NCT02563639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-404|Apixaban in Atrial Fibrillation Registry|APAF Apixaban in Atrial Fibrillation Registry|APAF|IHF GmbH - Institut für Herzinfarktforschung|No|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation (newly diagnosed, paroxysmal, permanent or        persistent)|September 2015|September 28, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02563639|12 Months|12038|
NCT02563652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/641|Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?|Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery? A Prospective Observational Study||St. Olavs Hospital|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Full blood, serum, plasma and urine will be stored in cryotubes at -81 degrees celcius for      later analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients eligible for major abdominal surgery in St Olavs Hospital, Trondheim, Norway|October 2015|October 14, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02563652||12037|
NCT02561676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-860-14|Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education|Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education||Kessler Foundation|No|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02561676||12189|
NCT02566122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5423|Establishment of Normal Muscle Strength for French Population|Establishment of Normal Muscle Strength Measured by Hand-held Dynamometer and Muscle Mass Assessed by Ultrasonography for French Population||University Hospital, Strasbourg, France|No|Recruiting|January 2014|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|320|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|male and female volunteers aged 18-90 years|September 2015|October 1, 2015|February 12, 2013|No|Yes||No||https://clinicaltrials.gov/show/NCT02566122||11848|
NCT02573298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2012/148|Cryotherapy and Doppler in Inflammatory Rheumatic Diseases|Cryotherapy and Doppler in Inflammatory Rheumatic Diseases|CDRI|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|February 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|85 Years|No|||October 2015|October 8, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573298||11296|
NCT02575664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH2011-000692-14|Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty|Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty|lonkkalaasta|Kuopio University Hospital|No|Completed|August 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|75 Years|No|||December 2015|December 25, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02575664||11114|
NCT02575677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH26062012|Oxycodone in Treatment of Early Labour Pain Efficacy and Safety|Oxycodone in Treatment of Early Labour Pain Efficacy and Safety|oksisynnytys|Kuopio University Hospital|No|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|venous blood for the analysis of oxycodone|Female|18 Years|65 Years|No|Probability Sample|Parturients who are in early labor and need some pain medication.|March 2016|March 9, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575677||11113|
NCT02635568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1639|Duration of Marijuana Concentration in Breast Milk- A Pilot Study|Duration of Marijuana Concentration in Breast Milk- A Pilot Study||University of Colorado, Denver|No|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Maternal breast milk, maternal urine, infant urine|Female|18 Years|N/A|No|Non-Probability Sample|1. Patients who test positive for THC on a urine toxicology screening who intend to             breastfeed will be recruited within 72 hours of delivery.          2. Using direct-to-patient advertising, the investigators plan to advertise the study in             the UCH prenatal clinics, postpartum unit, and in the UCH and CHCO NICUs with an IRB             approved flyer. Patients who volunteer will submit a confidential urine sample to the             research staff when they present for delivery at UCH, or within 72 hours after             delivery.|December 2015|December 18, 2015|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02635568||6516|
NCT02538666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-451|A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy|A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)|CheckMate 451|Bristol-Myers Squibb|Yes|Recruiting|September 2015|June 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|810|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|August 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538666||13955|
NCT02538679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037604|A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques|A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Technique Versus Laparoscopic Transversus Abdominis Plane Nerve Block Technique Versus No Block on Postoperative Opioid Consumption After Major Colorectal Surgery||Cedars-Sinai Medical Center||Not yet recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|252|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02538679||13954|
NCT02534181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.015.415|Refeeding Syndrome in Cancer Patients|Refeeding Syndrome in Cancer Patients Admitted to Adult Intensive Care Unit|RESCUE|University of Sao Paulo|No|Active, not recruiting|July 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02534181||14300|
NCT02588131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBIT-MESO-1|A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)|A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1||Italian Network for Tumor Biotherapy Foundation|Yes|Recruiting|October 2015|March 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588131||10157|
NCT02590835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2013-3|Efficiency of Piezocision-assisted Orthodontic Treatment in Adult Patients|Efficiency of Piezocision-assisted Orthodontic Treatment in Adult Patients||University Hospital of Liege|No|Completed|February 2013|October 2015|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02590835||9949|
NCT02567019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00882-47|Immunoregulation of Periodontal Diseases|Immunoregulation of Periodontal Diseases||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02567019||11779|
NCT02567032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02262|Adult Study Oxytocin - Behavioral|Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - Behavioral|ASO-Behavioral|University of California, San Francisco|Yes|Recruiting|October 2010|||July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567032||11778|
NCT02568605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-REB14-2464|Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease|Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease||University of Calgary|No|Recruiting|May 2015|May 2019|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568605||11657|
NCT02562690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD2014-134|Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome|Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome||University of Hertfordshire|Yes|Recruiting|March 2015|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Probability Sample|Acute Coronary Syndrome (ACS) Patients. ACS patients will comprise of patients admitted to        hospital with suspected cardiac chest pain and at least 2 of the following 3 criteria of        (1) chest pain, (2) ischaemic ECG changes (3) a cardiac troponin measurement exceeding the        99th percentile of a normal reference population (upper reference limit).|October 2015|October 4, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02562690||12111|
NCT02562703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tVNS|tVNS for Depression|Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: a Phase II, Randomized, Double-blind Clinical Trial||Santa Casa Medical School|No|Not yet recruiting|November 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|59 Years|No|||September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562703||12110|
NCT02582931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510101|MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer|Pilot Study of MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer||Washington University School of Medicine|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582931||10556|
NCT02572427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202043|Resident Training Enhanced by New Innovations: Teleintubation|Video Laryngoscopy for Enhancing and Maintaining Intubation Skills||University of Arkansas|No|Completed|September 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|82|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 6, 2015||No||No|October 9, 2015|https://clinicaltrials.gov/show/NCT02572427||11363|
NCT02572687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16116|A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies|An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies||Eli Lilly and Company|No|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572687||11343|
NCT02566915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0067|Effects of Exhalation Valve on the Lack of Air and Exercise Tolerance in Patients With COPD|Effects of Expiratory Positive Airway Pressure on Dyspnea and Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease||Hospital de Clinicas de Porto Alegre|No|Enrolling by invitation|August 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|19|||Both|50 Years|90 Years|No|||February 2016|February 22, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02566915||11787|
NCT02587000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141201|Adenomyosis and Ulipristal Acetate|Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis|FRA-IIT-UPA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2015|November 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Female|35 Years|50 Years|No|||May 2015|October 23, 2015|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02587000||10243|
NCT02587013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151019|Comparison of Uterine Repair Methods for Cesarean Delivery|Randomized Controlled Trial of Uterine Exteriorization Versus in Situ Repair for Elective Cesarean Delivery||Maisonneuve-Rosemont Hospital|No|Recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|180|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02587013||10242|
NCT02577211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnrct2|Hypocaloric Enteral Nutrition in the Critically Ill Patient|Randomized Controlled Trial of Hypocaloric Hyperproteic Enteral Nutrition in the Critically Ill Patient|hipoentnut|Lafrancol S.A.|Yes|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|120 Years|No|||November 2015|November 7, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02577211||10995|
NCT02568839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDIX HER2|Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer|PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|PREDIX HER2|Karolinska University Hospital|No|Recruiting|November 2014|December 2022|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568839||11639|
NCT02568852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lutfiyeETD|Comparison of Coagulation Factors During Laparoscopic Cholecystectomy|Comparison of Coagulation Factors During Laparoscopic Cholecystectomy With General Anesthesia and Spinal-epidural Anesthesia:Prospective Randomized Trials||Lütfiye Nuri Burat Government Hospital|No|Recruiting|October 2015|February 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 1, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568852||11638|
NCT02575872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2167|Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors|The Effectiveness of a Comprehensive Physical Activity Behavioral Intervention on Underserved Diverse Obese Endometrial Cancer Survivors||Albert Einstein College of Medicine of Yeshiva University|No|Active, not recruiting|October 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Female|18 Years|90 Years|No|||October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02575872||11098|
NCT02569216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i15-00553|Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth|Electrical Inhibition (EI): A Preliminary Study To Prevent The Uterine Contractions Of Human Preterm Labor And Preterm Birth|EI|New York University Langone Medical Center|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569216||11610|
NCT02571751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Approval No. 534|Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Cohesive Silicone Gel-Filled Breast Implants UNIGEL®|||Sewoon Medical Co., Ltd||Recruiting|August 2015|||May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|166|||Female|22 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571751||11415|
NCT02569073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22894|Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain|Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain|ICAMP|Temple University|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||October 2015|October 5, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569073||11621|
NCT02564016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033454|Efficacy of Labor Epidurals for Postpartum Tubal Ligation|Efficacy of Labor Epidurals for Postpartum Tubal Ligation: Effect of Postpartum Epidural Saline Infusion on the Reactivation of Labor Epidurals for Postpartum Tubal Ligation Following Vaginal Delivery||Medical University of South Carolina|Yes|Recruiting|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02564016||12009|
NCT02575261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-T for malignant glioma|CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 13, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02575261||11145|
NCT02577627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTI-006|Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC|Multi-Centre, Multi-Indication, Two-Stage, Oncological Study to Retrospectively Assess and Prospectively Validate the Predictive Accuracy of PrediCare - a Standalone, Treatment Decision Support Software Device for Predicting Time-to-Progression in Individual Patients Under Standard of Care Treatments||Optimata Ltd.|No|Recruiting|September 2015|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|5000|||Both|18 Years|120 Years|No|Probability Sample|Data from up to about 1000 NSCLC patients' files will be collected. Data from up to about        1000 SCLC patients' files will be collected. Data from up to about 1000 Colon cancer        patients' files will be collected. Data from up to about 1000 Breast cancer patients'        files will be collected. Data from up to about 1000 Prostate cancer patients' files will        be collected.|October 2015|November 2, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577627||10963|
NCT02564289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/70-31|Cardiovascular Effects of Chronic Snus Use|Cardiovascular Effects of Chronic Snus Use|CHROS|Umeå University|No|Completed|September 2015|March 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|Samples With DNA|Blood samples, Urine samples|Male|30 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|25 healthy non-smoking males with regular snus consumption and 25 healthy non-smoking and        non-snus using. Healthy volunteers were recruited in Umeå and surrounding communities.|March 2016|March 18, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564289||11988|
NCT02569762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:069|Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism|Assessment of the Effect of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism||University of Manitoba|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|22|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||January 2016|February 22, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02569762||11568|
NCT02577653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-20150818005|Posturographic Characteristics of Eccentric, Isometric and Concentric Movements|Posturographic Characteristics of Eccentric, Isometric and Concentric Movements||Carrick Institute for Graduate Studies|No|Recruiting|October 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02577653||10961|
NCT02569307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-NAYAB-001|Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States|A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States|NAYAB|Pakistan Institute of Learning and Living|Yes|Recruiting|October 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|16 Years|35 Years|No|||March 2016|March 9, 2016|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02569307||11603|
NCT02569320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15004|HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma|A Phase 1b Trial of AR-42 With Pomalidomide in Relapsed Multiple Myeloma||Ohio State University Comprehensive Cancer Center|Yes|Not yet recruiting|December 2015|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569320||11602|
NCT02569164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kasrelaini Obgyn..|Cardiovascular Risks and Urinary Albumin Excretion(UAE) in Polycystic Ovarian Syndrome (PCO)|Urinary Albumin Excretion in Women With Polycyclic Ovary Syndrome and it's Relation to Cardiovascular Risk Factors||Kasr El Aini Hospital|No|Not yet recruiting|October 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|20 Years|50 Years|No|Probability Sample|PCO patients|October 2015|October 5, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02569164||11614|
NCT02570958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFCRS-RP-002-1504-29|Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors|Robotic ICG Guided Surgery (RIGGS): A Novel Technique for Targeting Small Lung Tumors|RIGGS|St. Joseph's Healthcare Hamilton|No|Not yet recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570958||11476|
NCT02570971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITX-2015|Mannitol Versus Supportive Care in Ciguatera Fish Poisoning|Mannitol Versus Supportive Care in Ciguatera Fish Poisoning: A Randomized Control Trial||University of South Florida||Not yet recruiting|October 2015|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|100 Years|No|||October 2015|October 6, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570971||11475|
NCT02564419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150244|Brain Machine Interface (BMI) in Subjects Living With Quadriplegia|Early Feasibility Study of a Medtronic Activa PC+S System for Persons Living With Spinal Cord Injury|BMI|University of Miami|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|3|||Both|22 Years|50 Years|No|||November 2015|November 23, 2015|August 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564419||11978|
NCT02572219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMB04|Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients|Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients||Neuromed IRCCS||Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|40 Years|65 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572219||11379|
NCT02587546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-thulium|Thulium Contact Laser of Laryngotracheal Stenosis|Thulium Contact Laser in the Treatment of Tumorous and Non-tumorous Laryngotracheal Stenosis||University Hospital Ostrava|No|Recruiting|October 2015|September 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|70 Years|No|||October 2015|October 25, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587546||10202|
NCT02565212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55|Comparison of the Effects of Nasal Steroids and Montelukast on Olfactory Functions in Patients With Allergic Rhinitis|Istanbul Gaziosmanpasa Taksim Research and Training Hospital,||Istanbul Training and Research Hospital|No|Completed|May 2014|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|June 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565212||11918|
NCT02565225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiDEAR|Mobile Medically Supervised Patient Management in Rheumatoid Arthritis|Mobile Medically Supervised Patient Management in Rheumatoid Arthritis Patients Using DocuMed.rh and RheumaLive App|MiDEAR|Heinrich-Heine University, Duesseldorf||Active, not recruiting|November 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Probability Sample|RA patients|September 2015|September 30, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02565225||11917|
NCT02575755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAC10.53|A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women|A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant Papua New Guinean Women||Papua New Guinea Institute of Medical Research|No|Recruiting|October 2012|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575755||11107|
NCT02574559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074454|CBCT for Parents of Children With Autism|Cognitively Based Compassion Training for Parents of Children With Autism Spectrum Disorders||Emory University|No|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574559||11199|
NCT02587559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042015-091|Effectiveness of Manual Therapy and Exercise in Shoulder OA|Effectiveness of Manual Therapy and Exercise in the Management of Glenohumeral Osteoarthritis: A Randomized Controlled Trial||University of Texas Southwestern Medical Center|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|90 Years|No|||November 2015|November 2, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02587559||10201|
NCT02587572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0000-02|Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial|A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.|SIRONA|Longeveron LLC|Yes|Not yet recruiting|December 2015|March 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|45 Years|85 Years|No|||October 2015|October 23, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587572||10200|
NCT02572349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-1701-101|Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects||Ironwood Pharmaceuticals, Inc.|No|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572349||11369|
NCT02572362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2014-0255|Secondary Cancer Risk After Radiation Therapy for Rectal Cancer|Estimation of Second Cancer Risk in Patients Planned With Different Radiotherapy Regimes for Rectal Cancer - A Planning Study and Model-based Analysis||Kantonsspital Graubuenden|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|25|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients having had radiation therapy for rectal cancer. Estimation of second cancer risk        using data from planning CTs comparing dose Distribution using different Radiation therapy        techniques (3DCRT vs VMAT).|October 2015|October 7, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02572362||11368|
NCT02568449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-010|Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent|A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma||Barbara Ann Karmanos Cancer Institute|Yes|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2015|October 2, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568449||11669|
NCT02568670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15849513.2.0000.5487|Removal Peripheral Intravenous Catheters According to Clinical Signs or Every 96 Hours: A Non Inferiority Study|Removal Peripheral Intravenous Catheters According to Clinical Signs or Every 96 Hours: A Non Inferiority Study (ResPeCt)|ResPeCt|Federal University of São Paulo|Yes|Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1305|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02568670||11652|
NCT02589847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection|An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection||Rebiotix Inc.|No|Recruiting|October 2015|February 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589847||10025|
NCT02569554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7461008|PPI And Food Effect Study For PF-06463922 In Healthy Volunteers|A Phase 1, Randomized, Crossover, Open-Label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet Formulation Of PF-06463922||Pfizer|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569554||11584|
NCT02566044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBW276X2201|Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Inhaled QBW276 in Patients With Cystic Fibrosis||Novartis|Yes|Withdrawn|January 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566044||11854|
NCT02566057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-587B|Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis|Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis||Northwell Health|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|64 Years|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566057||11853|
NCT02568683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-1562|Safety and Efficacy of Entospletinib (GS-9973) Combined With Vincristine (VCR) and VCR-based Combination Chemotherapy in Adult Participants With Non-Hodgkin Lymphoma (NHL)|A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) Combined With Vincristine (VCR) and VCR-based Combination Chemotherapy in Adult Subjects With Non-Hodgkin Lymphoma (NHL)||Gilead Sciences|No|Recruiting|November 2015|June 2023|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|124|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568683||11651|
NCT02568904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alcohol01|Alcohol Consumption With or Without a Multispecies Probiotic|Effect of Alcohol Consumption With or Without a Multispecies Probiotic on Gut Permeability, Bacterial Translocation Neutrophil Function and Hangover Symptoms||Medical University of Graz|No|Not yet recruiting|January 2016|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Both|19 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02568904||11634|
NCT02587663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-05-5|Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI|Sonography Compared With MRI in Pre-Operative Evaluation of Patients With Breast Cancer to Determine Extent of Breast Disease||University of Southern California|Yes|Active, not recruiting|November 2005|November 2016|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|300|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02587663||10193|
NCT02565654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0717-201506|Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome|Efficacy of Rifaximin for Diarrhea-predominant Irritable Bowel Syndrome With Positive Lactulose Hydrogen Breath Test||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Faeces|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 40 cases of LHBT positive and 20 cases of LHBT negative IBS-D patients will be        included in this study. The estimate of the LHBT positive rate was 40%, so we need to        screen about 100 IBS-D patients. We are going to recruit 120 IBS-D patients in our center        with respect to patients lost to follow up.|June 2015|September 30, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565654||11884|
NCT02575989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131204|Prevention of HYPOthermia in TRAUMa Patients|Prevention of HYPOthermia Before Admission in TRAUMa Patients - Hypotraum 2 Study|HYPOTRAUM 2|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|October 2015|October 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02575989||11089|
NCT02576002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18515|Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)|Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US||Bayer|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2691|||Both|N/A|18 Years|No|Non-Probability Sample|The study population will be all patients who were born after 1991 and thus under the age        of 18 during the years 2010 to 2013 in the MarketScan data. The larger population of        patients under age 18 will comprise the general population from which population-based        prevalence rates will be derived.|February 2016|February 25, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576002||11088|
NCT02564809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02438|Cognitive Brain Training in Older Adults|The Effect of Fit Brains Training on Cognitive Performance in Older Adults||University of British Columbia|Yes|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02564809||11949|
NCT02564822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisualStimulation_Migraine|Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura|Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura||Universidade Federal de Pernambuco|Yes|Recruiting|July 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and healthy volunteers will be recruited via advertisements on the university.        Patients should have migraine diagnosis according to the International Classification of        Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.        For control subjects the individuals should not have migraine diagnosis assessed according        to IHCD-III criteria.|September 2015|September 29, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02564822||11948|
NCT02567227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4752|Cognitive Remediation to Improve Mobility in Sedentary Seniors|Cognitive Intervention to Improve Simple and Complex Walking|CREM|Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|February 2016|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|420|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02567227||11763|
NCT02567240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040035|Carbon Monoxide-Saturated Medium for Islet Isolation|A Novel Approach to Harvest Islets for Autologous Islet Transplantation||Medical University of South Carolina|Yes|Recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|69 Years|No|||September 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567240||11762|
NCT02567383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150205D|Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer|A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer||Shin Kong Wu Ho-Su Memorial Hospital|No|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|85 Years|No|||October 2015|October 2, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567383||11751|
NCT02570477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMT-CDI-RCT|FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment|Fecal Microbiota Transplantation (FMT) for Moderate to Severe Clostridium Difficile Infection (CDI): A Randomised Study With Concurrent Stool Microbiota Assessment (FMT-CDI-RCT Study)||Chinese University of Hong Kong|Yes|Recruiting|September 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570477||11513|
NCT02573194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHSC|The Effect of Breakfasts Varying in Protein Source on Appetite and Energy Intake|The Acute Effect of Breakfasts Varying in Protein Source Content on Subjective Appetite Ratings and Voluntary Energy Intake in Healthy Subjects||Lund University|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573194||11304|
NCT02561585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1222|LEO 124249 Ointment in the Treatment of Alopecia Areata|Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata||LEO Pharma|No|Recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561585||12196|
NCT02563691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185-2014|Stereotactic Radiotherapy for Oligometastatic Prostate Cancer|Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer: A Phase I/II Study|CROP|Sunnybrook Health Sciences Centre|No|Recruiting|November 2014|November 2018|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||September 2015|September 28, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02563691||12034|
NCT02563704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UYaounde1|A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon|A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon||University of Yaounde 1|No|Completed|September 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|238|||Both|3 Months|15 Years|No|||September 2015|September 30, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02563704||12033|
NCT02576483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34287|An Evaluation of LASIK Surgery in Physicians|An Evaluation of Quality of Vision and Quality of Life With LASIK Surgery in Physicians||Stanford University|No|Recruiting|July 2015|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|21 Years|62 Years|Accepts Healthy Volunteers|Non-Probability Sample|Physicians with refractive errors|October 2015|October 13, 2015|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576483||11051|
NCT02567994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP_C303|Tenelia Triple Combination Study|Efficacy and Safety of Teneligliptin Versus Sitagliptin as add-on Therapy to Metformin Plus Glimepiride in T2DM Patinets With Inadequate Glycemic Control|TETRIS|Handok Pharmaceuticals Co., Ltd.|No|Recruiting|January 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|19 Years|N/A|No|||October 2015|October 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02567994||11704|
NCT02571894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBC|The Cardio-Oncology Breast Cancer Study|Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)|COBC|Karolinska University Hospital|Yes|Recruiting|July 2014|February 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Female|18 Years|N/A|No|||October 2015|October 7, 2015|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02571894||11404|
NCT02578056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUOc|Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence|Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence. A Multicenter, Randomized, Double-blind, Controlled Study||University of Sao Paulo General Hospital|No|Enrolling by invitation|February 2014|September 2024|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|374|||Female|18 Years|100 Years|No|||October 2015|October 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02578056||10930|
NCT02568891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-255 ex 13/14|Modulation of Gut Microbiota in End-stage Renal Disease|Modulation of Gut Microbiota in End-stage Renal Disease: A Pilot Study|MGM-dialysis|Medical University of Graz|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02568891||11635|
NCT02576275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-22|A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)|A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma||Infinity Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|May 2024|Anticipated|June 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576275||11067|
NCT02576392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA BAA HHSF223201400146C|FDA: Lowering Orthopedic Opioid Dosing (FLOOD)|Reducing the Use of Opioid Therapy Following Orthopedic Surgery: A Randomized Controlled Trial|FLOOD|Kaiser Permanente|No|Enrolling by invitation|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|21 Years|N/A|No|||October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576392||11058|
NCT02562040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U011HL125307-O1A1|Pediatric Adenotonsillectomy for Snoring|Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health|PATS|Brigham and Women's Hospital|Yes|Not yet recruiting|January 2016|October 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|3 Years|10 Years|No|||October 2015|October 15, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562040||12161|
NCT02567357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2149PSY|Parents Resources for Decreasing the Incidence of Change Triggered Temper Outbursts|PREDICTORS (Parents Resources for Decreasing the Incidence of Change Triggered Temper Outbursts)|PREDICTORS|Queen's University, Belfast|No|Recruiting|January 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|7 Years|16 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02567357||11753|
NCT02570165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012|Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD||GlaxoSmithKline|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|320|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570165||11537|
NCT02585219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50485.042.14|Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas|Pilot Feasibility of 11C-MET-PET as a Post-surgery Baseline Scan in the Follow-up of High-grade Gliomas for the Detection of Tumor Recurrence.||University Medical Center Groningen|No|Not yet recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy        (surgical resection followed by chemoradiotherapy).        Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the        brain are excluded. Patients with only a biopsy be excluded.        The group will consist of 10 patients. This number may be adjusted for patients who are        found to have a different diagnosis after histological examination or fall out. For a        pilot feasibility study our experience that a number of 10 patients is sufficient for PET        examination.|October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585219||10380|
NCT02585466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGraz4|BIS and Entropy Nociception Monitoring|Precise Quantification of Surrogate Nociception Measures "Bispectral Index (sBIS)-Electromyography (sEMG) Variabilities" and "Response Entropy-State Entropy (RE-SE) Difference". A Practice Alignment Study.|BIS4|Medical University of Graz|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Fifty patients, aged 18-65 years, undergoing general surgery on the lower limb were        randomly allocated to the BIS 25 or BIS 50 groups|October 2015|October 23, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02585466||10361|
NCT02562313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT015|A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®|A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®||Adocia|No|Recruiting|September 2015|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|64 Years|No|||September 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562313||12140|
NCT02563925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-038|Brain Irradiation and Tremelimumab in Metastatic Breast Cancer|A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02563925||12016|
NCT02564198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15542|A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors|A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors||Eli Lilly and Company|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|12 Months|21 Years|No|||February 2016|February 19, 2016|September 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564198||11995|
NCT02534038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AVP-786-203|Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of AVP-786 for the Treatment of Disinhibition in Patients With Neurodegenerative Disorders||Avanir Pharmaceuticals|No|Not yet recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|50 Years|90 Years|No|||August 2015|August 25, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02534038||14311|
NCT02544035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915196|Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission|Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|July 2025|Anticipated|July 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|12||Anticipated|720|||Both|6 Months|N/A|Accepts Healthy Volunteers|||August 2015|September 18, 2015|September 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02544035||13545|
NCT02531152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR13459|28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension|A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension||Sanofi|No|Active, not recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02531152||14531|
NCT02539303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001279|Delivery of Yamani-15/5 Chemical Solution for PAD|In-vivo Demineralization of Calcific Peripheral Arterial Disease (PAD) Using Local Delivery of Yamani-15/5 Chemical Solution||Mayo Clinic|No|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|85 Years|No|||December 2015|December 31, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02539303||13906|
NCT02539485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15381538|Heating Precondition of Streamlined Liner of the Pharynx Airway Decrease the Incidence of Sore Throat|||Fudan University||Recruiting|June 2015|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|120|||Female|18 Years|60 Years|No|||August 2015|September 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539485||13892|
NCT02590848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14/00108|Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development|Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development: A Dietary Intervention|WALNUTs|Centre for Research in Environmental Epidemiology, Spain|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590848||9948|
NCT02582632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-684|A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults|An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)||AbbVie|No|Active, not recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|100 Years|No|||March 2016|March 22, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582632||10579|
NCT02582645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001_IMPACTED_CANINES|Closed Window vs. Open Window Technique in Management of Palatally Impacted Canines|Closed Window Technique Versus Open Window Technique in Management of Palatally Impacted Canines. A Randomized Clinical Trial||University Hospital Olomouc|No|Recruiting|October 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|11 Years|17 Years|No|||October 2015|October 20, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02582645||10578|
NCT02574065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0090|Effects on Crying Time in Colicky Infants With the Supplementation of Lactobacillus Reuteri DSM 17938|Effects on Crying Time in Colicky Infants With the Supplementation of Lactobacillus Reuteri DSM 17938: A Randomized, Double Blind, Placebo-controlled Study||Shanghai Children's Hospital||Not yet recruiting|August 2015|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Both|N/A|4 Months|No|||October 2015|October 9, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02574065||11237|
NCT02572700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15009080|Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis|Pain Mechanisms and Ultrasonographic Inflammatory Changes as Prognostic Factors in Patients With Psoriatic Arthritis: a Prospective, Exploratory Cohort Study||Frederiksberg University Hospital|Yes|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|100 Years|No|Non-Probability Sample|> 18 years of age with PsA according to the CASPAR criteria who initiate or switch        anti-rheumatic treatment (biologics and/or conventional synthetic DMARDs) due to active        PsA in routine care.|October 2015|October 8, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02572700||11342|
NCT02566655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/OP/2011|Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis|Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures|CSM/OP/2011|Red de Terapia Celular|Yes|Recruiting|September 2015|September 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|50 Years|70 Years|No|||January 2016|January 12, 2016|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566655||11807|
NCT02586766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01CE001957-05|University of Michigan Youth Violence Prevention Emergency Department Brief Intervention (Project Sync)|University of Michigan Youth Violence Prevention Emergency Department Brief Intervention||University of Michigan|No|Completed|October 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|409|||Both|14 Years|20 Years|No|||October 2015|October 22, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02586766||10261|
NCT02563574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500625|ARCH II Study (Alcohol Research Center on HIV Study II)|Alcohol and HIV: Biobehavioral Interactions and Intervention||University of Florida|Yes|Not yet recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|140|||Both|35 Years|70 Years|No|||November 2015|November 4, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563574||12043|
NCT02563587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-02|Efficacy of Spontaneous Laughter in the Postoperative Treatment of Children|Efficacy of the Spontaneous Laughter on Postoperative Pain and Anxiety in Children. A Randomized Controlled Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Recruiting|September 2015|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|210|||Both|6 Years|14 Years|No|||September 2015|September 28, 2015|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02563587||12042|
NCT02578212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-396|Trust Game and Placebo Response|Trust Game and Placebo Response||University Hospital, Basel, Switzerland|No|Recruiting|January 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|105|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578212||10918|
NCT02564224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCCZ-S01|Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients|Randomized Clinical Trial of Stoma Reversal Comparing Pursestring Wound Closure vs Conventional Closure to Eliminate the VSS Score of the Scar for Colorectal Cancer Patients|PURSE|Zhejiang University||Not yet recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564224||11993|
NCT02572765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMB05|Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension|Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension||Neuromed IRCCS||Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Total blood and serum|Both|30 Years|85 Years|No|Probability Sample|Subjects will be selected from patients who will undergo FDG-PET/CT imaging of chest and        abdomen in the Department of Nuclear Medicine of IRCCS Neuromed, accordingly to the        following inclusion/exclusion criteria. All the enrolled patients must have an indication        for FDG-PET/CT. Approximately 120 hypertensive and normotensive subjects of both genders        (at least 45 per group, in order to have the appropriate statistical power) will be        included in the study.|November 2015|November 17, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572765||11337|
NCT02572986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL-USG02-P/2015|A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies|A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in the Treatment of Scabies||Dr. Reddy's Laboratories Limited|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|2 Years|N/A|No|||October 2015|October 30, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572986||11320|
NCT02563873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/YH/0097|Bowditch Revisited: Defining the Optimum Heart Rate Range in Chronic Heart Failure|Bowditch Revisited: Defining the Optimum Heart Rate Range in Chronic Heart Failure||University of Leeds|No|Not yet recruiting|October 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02563873||12020|
NCT02574143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGNOSIS|The PROspective German NOn-CF bronchiectaSIS Patient Registry|The PROspective German NOn-CF bronchiectaSIS Patient Registry|PROGNOSIS|Hannover Medical School|No|Recruiting|July 2015|July 2018|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-CF bronchiectasis|October 2015|October 9, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02574143|3 Years|11231|
NCT02574156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC|Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial|Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial|CHyCS|University of Sao Paulo|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574156||11230|
NCT02563769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23222|Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study|Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Clavulanic Acid||Temple University|Yes|Recruiting|February 2016|||February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|45 Years|No|||March 2016|March 22, 2016|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02563769||12028|
NCT02571660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE 05|Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma|Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma in the Hospital General Naval de Alta Especialidad||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Not yet recruiting|November 2015|July 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|15 Years|No|||November 2015|November 24, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571660||11422|
NCT02577601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 11784|Impact of Combined Hormonal Contraceptives on UPA|Determining the Impact of Combined Hormonal Contraceptives on Ulipristal Acetate||Oregon Health and Science University|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577601||10965|
NCT02576327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-2015YJZ25|A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation|A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation||Peking University|No|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576327||11063|
NCT02576340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ob002|Spasmolytic in Upper Gastrointestinal Endoscopy|Spasmolytic (Otilonium Bromide) Use in Upper Gastrointestinal Endoscopy: Randomized Prospective Trial||Konya Training and Research Hospital|No|Completed|January 2013|June 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|400|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576340||11062|
NCT02568709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08411|Oxytocin MEG Study|Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia|MEG|University of California, San Francisco|Yes|Active, not recruiting|February 2012|||March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568709||11649|
NCT02565186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-305|An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine|An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)|GLADIATOR|CoLucid Pharmaceuticals|No|Enrolling by invitation|October 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2580|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565186||11920|
NCT02563886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAMT-346/15|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) for Upper Limb Stroke Rehabilitation|EAMT|Swiss Federal Institute of Technology|No|Active, not recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02563886||12019|
NCT02567565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0225|Evaluation of Tear Film Lipid Layer Thickness Change After Cataract Surgery|Evaluation of Tear Film Lipid Layer Thickness Change After Cataract Surgery||Yonsei University|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|19 Years|80 Years|No|Probability Sample|Cataract patients with lens opacities classification higher than grade III|October 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567565|3 Months|11737|
NCT02565511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPI015A2201J|A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.|Generation|Novartis|Yes|Recruiting|November 2015|August 2023|Anticipated|August 2023|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1340|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565511||11895|
NCT02569918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-602547-4|Use of Hand Prosthesis With Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|EPIONE|University of Lausanne Hospitals|No|Recruiting|February 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02569918||11556|
NCT02568930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200851|SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?|SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?|SUSTAIN-IT|Northwestern University|No|Recruiting|July 2015|March 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|800|||Both|60 Years|80 Years|No|Non-Probability Sample|The study population includes advanced heart failure patients (60-80 years of age)        scheduled for DT MCS and their caregivers and advanced heart failure patients (60-80 years        of age) listed for HT and their caregivers.|October 2015|January 21, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568930||11632|
NCT02575885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 257514|Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers|Nicotine Delivery From Novel Non-tobacco Electronic Systems (ENDS)|ENDS|Roswell Park Cancer Institute|No|Recruiting|March 2016|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575885||11097|
NCT02572076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL00035|Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System|Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System||Motus GI Medical Technologies Ltd||Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572076||11390|
NCT02572284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18201|Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer|A Phase I Dose Escalation Study of Preoperative Stereotactic Body Radiation Therapy (SBRT) for High Risk Prostate Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2015|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572284||11374|
NCT02564159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0424|Malnutrition Screening by Muscle Ultrasound in Patients Requiring Mechanical Ventilation in Intensive Care Unit|Ultrasound Measurement of the Quadriceps Muscle Diameter for the Detection and the Follow-up of Malnutrition in Patients Receiving Mechanical Ventilation in Intensive Care Unit|MALICUS|Nantes University Hospital|No|Recruiting|October 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|226|||Both|18 Years|N/A|No|||September 2015|January 20, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564159||11998|
NCT02578264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6616|Molecular Stethoscope|Molecular Stethoscope for Colon Cancer Detection||Scripps Translational Science Institute|No|Enrolling by invitation|June 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients with colorectal cancer that will be receiving surgical removal of their cancer as        part of their care.|October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578264||10914|
NCT02578277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-063|Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates|Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|November 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578277||10913|
NCT02575950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1223|Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne|Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne||LEO Pharma|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|35 Years|No|||February 2016|February 10, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575950||11092|
NCT02573597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34734|PIEB vs CEI for Labor Analgesia: An MLAC Study|Programmed Intermittent Epidural Bolus (PIEB) Compared to Continuous Epidural Infusion (CEI) Relative Efficacy and Mechanism of Efficacy For Labor Anlagesia: A Minimal Local Analgesic Concentration (MLAC) Study||Stanford University|Yes|Recruiting|October 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|160|||Female|18 Years|45 Years|No|||November 2015|November 10, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02573597||11273|
NCT02568826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XIL02/15|Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain|Tolerability, Safety and Activity of IDN5243, 4 mg Bid Intramuscularly in the Treatment of Low Back Pain. A Prospective, Open Label, Single-center, Uncontrolled Study|IDN5243inLBP|Indena S.p.A|No|Not yet recruiting|October 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568826||11640|
NCT02574988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/15|Severe Cutaneous Adverse Reactions in Thailand|The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand|ThaiSCAR|Chulalongkorn University|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|cryopreserved peripheral blood mononuclear cells, buffy coat, serum|Both|15 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),        drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized        exanthematous pustulosis (AGEP), or generalized bullous fixed drug eruption (GBFDE) from 6        tertiary medical centers in Thailand with be recruited into this registry|October 2015|October 29, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02574988|1 Year|11166|
NCT02589795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUTHIVAC002|Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers|A Phase I Clinical Trial to Assess the Safety and Immunogenicity of HIV DNA-C CN54ENV Immunisations Administered Via the Intramuscular and Intradermal Methods With and Without Electroporation Followed by Boosting With Recombinant HIV CN54gp140 in Healthy Male and Female Volunteers||Imperial College London|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 2, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02589795||10029|
NCT02568787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150512|The Effect of an RBAC Supplement (BRM4) on NAFLD|The Effect of an Enhanced Rice Bran Nutritional Supplement on Non-Alcoholic Fatty Liver Disease (NAFLD)||University of Miami|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568787||11643|
NCT02589808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/YH/0333|Preoperative Pocket Echocardiography Trial|Preoperative Pocket Echocardiography Trial|POPPET|Imperial College London|No|Completed|July 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|76|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02589808||10028|
NCT02577536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PregSource|PregSource: Crowdsourcing to Understand Pregnancy|PregSource: Crowdsourcing to Understand Pregnancy, Observations of Daily Living From Pregnant Women|PregSource|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|All pregnancy women 18 years of age or older.|August 2015|December 28, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02577536|3 Years|10970|
NCT02570100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RepriM-1407|Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM)|Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells||Centre Oscar Lambret|No|Recruiting|April 2015|September 2020|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02570100||11542|
NCT02570113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0001|The Peregrine Post-Market Study for the Treatment of Hypertension|A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter||Ablative Solutions, Inc.|Yes|Recruiting|November 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|80 Years|No|||December 2015|December 31, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570113||11541|
NCT02574663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGR-1202-102 (RM-404)|TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors|A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors||TG Therapeutics, Inc.|Yes|Recruiting|October 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574663||11191|
NCT02574676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-083252|Quality of Life (QOL) Registry for Patients With AL Amyloidosis|Prospective Observational Study Measuring the Short-Form36 ( SF-36v2) and Other QOL Tools in an AL Amyloidosis Population||Prothena Therapeutics Ltd.|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with Al Amyloidosis|October 2015|October 9, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02574676|12 Months|11190|
NCT02580656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL001166|An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer|An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer (OMAC Study)||University of Liverpool|No|Not yet recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02580656||10731|
NCT02572596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-TPO-01|Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients|A Prospective Control Study of Comparing Intermediate-dose Cyclophosphamide(ID-CTX) and G-CSF Plus or Not Recombinant Human Thrombopoietin (rhTPO) for PBSC Mobilization in Patients With Multiple Myeloma||Beijing Chao Yang Hospital|Yes|Active, not recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|10 Years|70 Years|No|||October 2015|October 8, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02572596||11350|
NCT02570360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0710|Exercise and Treatment-as-usual in Substance Use Treatment Outcomes|Comparative Effects of Exercise and Treatment-as-usual on Abstinence, Craving, and the Endocannabinoid System in Substance Users||University of Wisconsin, Madison|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|55 Years|No|||January 2016|January 26, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02570360||11522|
NCT02574728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082488|Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors|AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors||Emory University|Yes|Recruiting|June 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Months|30 Years|No|||October 2015|October 12, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574728||11186|
NCT02575716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU-561330812|Comparison of Intubating Condition of the Mcgrath Videolaryngoscope With and Without Muscle Relaxant|Comparison of Intubating Condition of the Mcgrath Videolaryngoscope With and Without Muscle Relaxant||Prince of Songkla University|No|Completed|March 2013|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02575716||11110|
NCT02589899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|impedance monitoring 1/2015|Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring|Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring||Oslo University Hospital||Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|October 2015|October 27, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02589899||10021|
NCT02589912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-113H|Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients|Compassionate Use Arm - ABI541 Auditory Brainstem Implant for Neurofibromatosis Type 2 Patients With Deafness||Massachusetts Eye and Ear Infirmary||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Years|80 Years||||October 2015|January 6, 2016|October 27, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02589912||10020|
NCT02569801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29689|A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy (HydranGea)|A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2 - Breast Cancer Resistant to Aromatase Inhibitor Therapy||Genentech, Inc.||Recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569801||11565|
NCT02569814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FARC-CT-102|A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin|||Boryung Pharmaceutical Co., Ltd|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569814||11564|
NCT02562404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1025037|Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation|Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation (Vagus Nerve Study)||Intermountain Health Care, Inc.|No|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Atrial fibrillation patients at the Intermountain Medical Center Heart Rhythm Clinic who        are candidates for Radiofrequency Catheter Ablation (RFCA) will be screened for        participation in this study.|September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562404||12133|
NCT02562417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 478/14|Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex|Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex||Centre Hospitalier Universitaire Vaudois|No|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562417||12132|
NCT02569138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM_FFP|Balance-Enhancing Effects of Insole Hardness and Thickness for Older Adult Footwear|Investigating Long Term Balance-Enhancing Effects of Insole Hardness and Thickness for Older Adult Footwear||Wilfrid Laurier University|No|Not yet recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569138||11616|
NCT02569151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9-Kamoi|20 Years Results by HBP and DBP in Patients With Type 2 Diabetes Mellitus After Following-up|USEFULNESS OF MORNING HOME BLOOD PRESSURE MEASUREMENTS IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: RESULTS OF A 20-YEARS, PROSPECTIVE, LONGITUDINAL STUDY||Nagaoka Red Cross Hospital|No|Not yet recruiting|April 2016|April 2027|Anticipated|March 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|20 Years|100 Years|No|Probability Sample|600 patients with type 2 diabetes mellitus|October 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569151||11615|
NCT02573129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PurdueU|The Lean Meats Mediterranean Diet Study|Effects of Incorporating Red Meat Into a Mediterranean-style Dietary Pattern on Cardiometabolic and Emotional Well-being||Purdue University|No|Recruiting|May 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|45|||Both|30 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02573129||11309|
NCT02573181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-007|A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine||Merck Sharp & Dohme Corp.|Yes|Completed|October 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|253|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573181||11305|
NCT02573506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1011|Study of Consolidation Chemotherapy For Bulky Local Advanced None-small Cell Lung Cancer|A Prospective, Randomized, Phase Ⅱ Study of Consolidation Chemotherapy or Observation After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer||Sun Yat-sen University|No|Recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|75 Years|No|||October 2015|October 14, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02573506||11280|
NCT02573519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-54-15|Gastrointestinal Motility Among Diabetic Patients|Gastrointestinal Motility Among Diabetic Patients||University of Aarhus|Yes|Recruiting|October 2015|August 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|December 11, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573519||11279|
NCT02572453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01681|AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma|Phase 2 Study of AT13387 in ALK+ ALCL, MCL, and BCL-6+ DLBCL||National Cancer Institute (NCI)||Not yet recruiting|January 2016|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|January 11, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572453||11361|
NCT02576379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALH3-KF-2015|The Impact of a Helicopter Emergency Medical System on Prognosis in Stroke Patients|The Impact of a Helicopter Emergency Medical System on Prognosis in Stroke Patients||Rigshospitalet, Denmark|Yes|Active, not recruiting|January 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|All patients arriving at the regional stroke unit at Copenhagen University Hospital,        Roskilde, suspected of an acute vascular condition within the geographical area covered by        both HEMS and GEMS in a 40-month period from January 1st 2010 until April 30th 2013.        The geographical catchment area is defined as the area from where HEMS transported        patients the first year of implementation.        We compare stroke patients transported by HEMS with stroke patients transported by GEMS.|October 2015|October 13, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576379|2 Years|11059|
NCT02563275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-002|The Operation of Control Devices During Parabolic Flights: Influence of Weightlessness, Stress and Motivation|The Operation of Control Devices During Parabolic Flights: Influence of Weightlessness, Stress and Motivation|Grafism|University Hospital, Caen|No|Recruiting|March 2013|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02563275||12066|
NCT02563535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo015|Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia||ACOART-BTK|Ospedale San Donato|No|Recruiting|September 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02563535||12046|
NCT02567617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4547/12|Polyphenols Supplementation on Prostaglandin E2 in Women - Randomized Clinical Trial|Polyphenol Supplementation Inhibits Physiological Increase of Prostaglandin E2 During Reproductive Period - A Randomized Clinical Trial||Instituto de Cardiologia do Rio Grande do Sul|Yes|Completed|May 2014|March 2015|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Female|25 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567617||11733|
NCT02571907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-625 P2|PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study|Clinical Study to Evaluate the Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation||Cook||Active, not recruiting|April 2015|March 2020|Anticipated|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571907||11403|
NCT02562352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPER-001-19-Aug-15|Team Approach to Polypharmacy Evaluation and Reduction|Team Approach to Polypharmacy Evaluation and Reduction: Feasibility Study|TAPER|McMaster University|No|Not yet recruiting|October 2015|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|75|||Both|70 Years|N/A|No|||September 2015|September 25, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02562352||12137|
NCT02574351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-076B|Study of T-Regulatory Cells in Asthma|Study of T-Regulatory Cells in Asthma||Northwell Health|No|Completed|May 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|66|Samples Without DNA|T regulatory cells are isolated in the blood specimens|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females in good health between the ages of 18-50, with or without asthma.|January 2016|January 28, 2016|November 1, 2013||No||No||https://clinicaltrials.gov/show/NCT02574351||11215|
NCT02577835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASOTENS REGISTRY|International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring|International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring|VASOTENS|Italian Institute of Telemedicine|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Suspected hypertensive patients referred to routine diagnostic evaluation for their        condition (hypertension) or established hypertensive subjects|February 2016|February 25, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02577835|2 Years|10947|
NCT02566759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-831-1001|A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects||Takeda|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|8||Anticipated|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02566759||11799|
NCT02575053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.107/anesth15.02|Safety of a Powder-free Latex Allergy Protocol in the Operating Theatre: A Prospective, Observational Cohort Study|Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study||Jessa Hospital|No|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Every patient with (suspected) latex allergy who will undergo surgery will be approached        to participate in this study. There are no restrictions regarding type of surgery (both        inpatient and outpatient surgery)|October 2015|October 27, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575053||11161|
NCT02588014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018-15-SHA|The Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia|Examining the Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia Using Magnetoencephalography||Shalvata Mental Health Center|Yes|Not yet recruiting|November 2015|December 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals diagnosed with schizophrenia|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588014||10166|
NCT02571101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-PED-CDFR0812_P2|A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation|A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation||CTC Bio, Inc.|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|297|||Male|19 Years|65 Years|No|||December 2015|December 16, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571101||11465|
NCT02567591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I15017 FAPA|Adapted Physical Activity Effect on Aerobic Function and in Patients in Pre Liver Transplantation|Adapted Physical Activity Effect on Aerobic Function and in Patients in Pre Liver Transplantation|FAPA|University Hospital, Limoges|No|Not yet recruiting|November 2015|May 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|70 Years|No|||September 2015|October 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567591||11735|
NCT02538081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-008-14S|Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia||VA Office of Research and Development|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02538081||14000|
NCT02538185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIC-NANO-001|Intradermal Rabies Immunization Using NanoJect: A Comparative Study|Intradermal Rabies Immunization Using NanoJect: A Comparative Study||University of Lausanne Hospitals|No|Completed|August 2013|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02538185||13992|
NCT02531438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTK0796-CABP-1200|Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)|A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia||Paratek Pharmaceuticals Inc|Yes|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02531438||14509|
NCT02541266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 LO 1189|Imaging in Clinical Trials - a Questionnaire Study to Assess Impact of Imaging Regimes on Patient Participation|Imaging in Clinical Trials - a Questionnaire Study to Assess Impact of Imaging Regimes on Patient Participation|ASK|Institute of Cancer Research, United Kingdom|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Group 1: Patients recruited to studies with imaging Group 2: Patients who have previously        participated in studies with imaging Group 3: Patients attending for scans as part of        their clinical pathway|December 2015|December 18, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02541266||13757|
NCT02586532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916007|Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China|Copy of Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barrr Virus (EBV)-Based NPC Screening Project in China||National Institutes of Health Clinical Center (CC)||Not yet recruiting|October 2015|December 2021|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|30 Years|59 Years|No|||October 2015|March 24, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586532||10279|
NCT02567539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1394|Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma|Phase II Study of Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma||Istituto Clinico Humanitas|Yes|Recruiting|April 2015|April 2021|Anticipated|April 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|February 26, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02567539||11739|
NCT02574442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCR - H15-01726|Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer|Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia|Confocal|British Columbia Cancer Agency|No|Not yet recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Cervical biopsies|Female|18 Years|N/A|No|Probability Sample|Be scheduled for colposcopy & biopsy at the VGH Women's Clinic|September 2015|October 9, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02574442||11208|
NCT02572518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN 003/2013|Immunity After Two Doses of Yellow Fever Vaccine|Duration of Immunity After Two Doses of Vaccine Against Yellow Fever in Adults|IATDYFV|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Completed|May 2014|July 2015|Actual|July 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|440|Samples With DNA|whole blood, serum|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The target study population will consist of 440 adult who have previously received at        least one dose of yellow fever 17DD vaccine. The volunteers who received two doses of        vaccine will be distributed in subgroups 1-5 and 6 years old or more, relative to the date        of the last dose received. Volunteers with just one dose and who have received the same        for at least 10 years, constitute the reference group (control) for serological and        immunological studies. These volunteers will be guided and directed to revaccination in        rooms vaccine immunization program and 30 to 45 days after revaccination shall be        subjected to serological testing.|October 2015|October 9, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02572518|45 Days|11356|
NCT02568748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIK Tanta university|Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC|Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma||Tanta University|Yes|Recruiting|October 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|N/A|N/A|No|||October 2015|October 6, 2015|October 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568748||11646|
NCT02567786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plasma versus Plasmalyte|Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children|Comparison of Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children Undergoing Open-heart Surgery: A Double-blind Randomized Controlled Study||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|October 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Months|55 Months|No|||December 2015|December 31, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567786||11720|
NCT02571452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1539-I|Brief Behavioral Insomnia Treatment Study|Telephone-Facilitated Insomnia Treatment in Primary Care for OEF/OIF/OND Veterans|BBTI|VA Office of Research and Development|No|Not yet recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02571452||11438|
NCT02573974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO14-TL/METERMUCADIG|Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer|Study of Alterations in Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer|METERMUCADIG|University Hospital, Tours|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|45|||Both|18 Years|80 Years|No|||February 2016|February 1, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573974||11244|
NCT02575781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED14147|A Study of SAR428926 in Patients With Advanced Solid Tumors|A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors||Sanofi|No|Recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|93|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575781||11105|
NCT02564315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1041 LongTermQuitting|The Long-Term Quitting (Smoking Cessation) Study|The Long-Term Quitting Study: Testing Relapse Recovery Intervention Components||University of Wisconsin, Madison|Yes|Recruiting|October 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|1000|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564315||11986|
NCT02564328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201400000003-2|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke||Southern Medical University, China|Yes|Recruiting|November 2014|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564328||11985|
NCT02568046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sym004-09|Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients|An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy||Symphogen A/S|No|Recruiting|March 2016|June 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568046||11700|
NCT02574572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-003|Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury|Evaluation of the Safety and Potential Effectiveness of Autologous Mesenchymal Stem Cells Transplantation in Subjects With Cervical Chronic and Complete Spinal Cord Injury||Hospital Sao Rafael|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02574572||11198|
NCT02568475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343268|Involving Nursing Home Residents and Their Families in Acute Care Transfer Decisions|Involving Nursing Home Residents and Their Families in Acute Transfer Decisions: Pilot Test of a New Decision Aid||Florida Atlantic University|No|Completed|October 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|191|||Both|21 Years|N/A|No|||October 2015|October 5, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568475||11667|
NCT02574013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49877.100.14|Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery|The Impact of Use of a Retractor Sponge on Duration of Hospital Stay and Perioperative Complications in Patients With Colorectal Cancer Undergoing Laparoscopic Colorectal Surgery: the SPONGE Trial|SPONGE|St. Antonius Hospital|No|Recruiting|November 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02574013||11241|
NCT02563600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwanseaU|Effect of Brief-tele Support on Attendance at Physiotherapy Sessions|Effect of Brief-tele Support on Attendance at Physiotherapy Sessions for Pelvic Floor Dysfunctions||Swansea University|No|Recruiting|September 2015|August 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|500|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563600||12041|
NCT02569645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-064|Rosuvastatin in the Treatment of Rectal Cancer|Phase 2 Trial of Rosuvastatin (Crestor®) Combined With Standard Chemoradiation Therapy in the Treatment of High-Risk Locally Advanced Rectal Cancer||AHS Cancer Control Alberta|No|Not yet recruiting|November 2015|May 2021|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02569645||11577|
NCT02575430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET NAT 01|Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT|Retrospective, Uncontrolled, Multicenter, Case History Study to Determine the Natural History of Visual Function in Subjects With Inherited Retinal Disease (IRD) Caused by Inherited Mutation of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)||QLT Inc.|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|60|||Both|8 Years|N/A|No|Non-Probability Sample|Subjects with IRD phenotypically diagnosed as LCA or RP caused by autosomal recessive        mutation in RPE65 or LRAT.|March 2016|March 1, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02575430||11132|
NCT02575443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMS NMD depth|Neuromuscular Block and Anesthetic Depth Monitoring|||Seoul National University Bundang Hospital||Recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|20 Years|80 Years|No|||October 2015|October 9, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02575443||11131|
NCT02570854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSJ137X2201|A Single-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients|A First-in-human, Two-part (Open Label, and Randomized/Double Blind/Placebo Controlled), Single-dose Study of CSJ137 in Erythropoietin-treated Chronic Hemodialysis Patients With Functional Iron-deficiency Anemia||Novartis|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570854||11484|
NCT02572154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 198 08|Sperm DNA Fragmentation in Recurrent Pregnancy Loss|Male Factor in Early Recurrent Pregnancy Loss : Study of Sperm DNA Fragmentation in Patients With Unexplained Recurrent Pregnancy Loss.|PARTHOM|University Hospital, Toulouse|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572154||11384|
NCT02572388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC053|A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1|Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers||University of Oxford||Recruiting|September 2015|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02572388||11366|
NCT02578082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0135|Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment|The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208||Theravance Biopharma R & D, Inc.|No|Recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578082||10928|
NCT02578095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VK5211-201|Acute Hip Fracture Study in Patients 65 Years or Greater|A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture||Viking Therapeutics, Inc.|Yes|Recruiting|October 2015|March 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|65 Years|N/A|No|||December 2015|February 17, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578095||10927|
NCT02575898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15113|Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study|Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|October 2015|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|N/A|N/A|No|||October 2015|October 12, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575898||11096|
NCT02575352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-NI-INJ|Calcium Phosphate Cement Registry (CPC Registry)|Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.|CPC|Graftys SA|No|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients eligible and planned for bone defect treatment who meet predefined criteria        in Instructions For Use (IFU) of GRAFTYS®HBS/ GRAFTYS®Quickset.|October 2015|October 12, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575352|24 Months|11138|
NCT02575456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT024|A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine|A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone||Jiangsu Province Centers for Disease Control and Prevention|Yes|Active, not recruiting|October 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|500|||Both|8 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02575456||11130|
NCT02567799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0101-01|BIO 300 Non-Small Cell Lung Cancer Study|A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)|NSCLC|Humanetics Corporation|No|Recruiting|November 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567799||11719|
NCT02574689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X130405004|Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South|Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South|HIPP|University of Alabama at Birmingham|No|Recruiting|September 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|50 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02574689||11189|
NCT02570139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-012990|Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing|Multi-Center, Randomized Trial Comparing the Efficacy of 3M™ Cavilon™ Advanced Barrier Film for the Treatment of Incontinence-associated Dermatitis to a Commercially Available Moisture Barrier||3M|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|N/A|N/A|No|||February 2016|February 15, 2016|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570139||11539|
NCT02577185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXP-1187|An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A|An Exploratory Psoriasis Plaque Test Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A as Tool Compound||LEO Pharma|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02577185||10997|
NCT02577198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41J11000110008|Computerized Decision Support System Linked to Electronic Health Records to Improve Patient Care in a General Hospital|Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Patient Care in a General Hospital|CODES|Istituto Ortopedico Galeazzi|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|6800|||Both|N/A|N/A|No|||October 2015|December 2, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577198||10996|
NCT02563288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeorgePapanikolaouHospital|Esmolol Versus Dexmedetomidine During Intracranial Procedures|Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures||George Papanicolaou Hospital|No|Recruiting|January 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 28, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02563288||12065|
NCT02573792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDS_2015_21|Optical Coherence Tomography and Optic Neuritis (OCTON)|Optical Coherence Tomography for the Etiological Diagnosis of Inflammatory Optic Neuritis|OCTON|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|October 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen at the Adolphe de Rothschild ophthalmological foundation for the first onset        of an optical neuritis|October 2015|October 9, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02573792||11258|
NCT02563990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150583|Injection Pressure & Adductor Canal Block|The Impact of Injection Pressure During Adductor Canal Nerve Block||University of Miami||Not yet recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02563990||12011|
NCT02579876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010148|Milk Patch for Eosinophilic Esophagitis|A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children|SMILEE|Children's Hospital of Philadelphia|Yes|Recruiting|October 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Years|17 Years|No|||November 2015|November 6, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579876||10791|
NCT02580136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015C0066|Esthesioneuroblastoma: Outcomes After Treatment|Esthesioneuroblastoma: Outcomes After Treatment|ENB|Ohio State University|No|Recruiting|September 2015|September 2026|Anticipated|September 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|10 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with esthesioneuroblastoma (ENB)|October 2015|October 19, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02580136|120 Months|10771|
NCT02572128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rice_FeZnEC|Mineral Absorption From Fortified Rice Produced With Different Fortification Techniques|Comparative Evaluations of Micronutrient Absorption From Mineral Fortified Rice Produced With Different Fortification Techniques: An Evaluation of Hot and Cold Extrusion (Study 1) and Coating Technologies (Study 2)||Swiss Federal Institute of Technology|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|44|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02572128||11386|
NCT02574273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503015990|Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)|Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) for Youth With Anxiety, ADHD, or Autistic Disorder||Weill Medical College of Cornell University|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|8 Years|12 Years|No|||October 2015|October 26, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574273||11221|
NCT02575586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83|Effectiveness of Deep Dry Needling on Muscle Tone in Healthy Subjects|Effectiveness of Deep Dry Needling on Muscle Tone in Healthy Subjects||University of Castilla-La Mancha|Yes|Completed|October 2015|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|February 29, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02575586||11120|
NCT02575599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIW 221065|Web-based Guided Self-Determination Intervention for Adults With Type 2 Diabetes in General Practice|Assessment of a Web-based Guided Self-Determination Intervention for Adults With Type 2 Diabetes in General Practice|DiaWeb|University of Stavanger|Yes|Not yet recruiting|August 2016|January 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|172|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02575599||11119|
NCT02580409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000393|REACH Pilot Study (Rehabilitation Enhancing Aging Through Connected Health)|Maintaining Physical Independence in Older Adults|REACH|Spaulding Rehabilitation Hospital|No|Recruiting|January 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580409||10750|
NCT02584465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-OV235|REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression|A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression|REGOVAR|ARCAGY/ GINECO GROUP|Yes|Recruiting|September 2015|May 2020|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Female|18 Years|N/A|No|||July 2015|October 21, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584465||10438|
NCT02564952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1428 Open-Label Extension|An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)||GW Research Ltd|No|Not yet recruiting|January 2016|July 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||September 2015|September 29, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564952||11938|
NCT02564965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001390|Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis|Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis: A Prospective, Randomized Noninferiority Trial.||Mayo Clinic|No|Enrolling by invitation|May 2014|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|60 Years|No|||September 2015|September 30, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564965||11937|
NCT02575820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1510/318-112|Old Blood and Postoperative Complications|The Effects of Old Red Blood Cell Transfusion on Morbidity in Patients Undergoing Revision Total Hip Arthroplasty: Retrospective Study||Seoul National University Hospital|No|Not yet recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent revision total hip replacement|October 2015|October 14, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02575820||11102|
NCT02575833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140254|Treadmill CV Safety Study|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina||Amgen|Yes|Recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||January 2016|January 13, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575833||11101|
NCT02575638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ48-01|Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)|Phase I Clinical Trial of Camptothecin-20-O-Propionate Hydrate (CZ48)||Cao Pharmaceuticals Inc.|Yes|Enrolling by invitation|July 2008|August 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575638||11116|
NCT02575703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15697|A Study of [¹⁴C]-LY3023414 in Healthy Participants|Disposition of [¹⁴C]-LY3023414 Following Oral Administration in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575703||11111|
NCT02584738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-03|Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation|Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Recruiting|September 2015|January 2018|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|2 Years|15 Years|No|||October 2015|November 30, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02584738||10417|
NCT02587923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1707/2015|Endoscopic Unroofing for Small Gastric SETs|A Retrospective Study on Safety, Diagnostic Yield and Therapeutic Effects of Endoscopic Unroofing for Small Gastric Subepithelial Tumors||Medical University of Vienna||Not yet recruiting|October 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|100 Years|No|Non-Probability Sample|Retrospective series of patients treated at a tertiary university based center.|October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587923||10173|
NCT02561572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH19048|The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail|The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|16 Years|N/A|No|||September 2015|November 16, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561572||12197|
NCT02575924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGM13|Influence of Culture Media on Clinical Outcomes in Poor Responders or Severe Male Infertility|Employing a Single Step Media Can Improve the Clinical Outcomes in Those Patient Who Usually Show an High Cycle Cancellation Rate?||European Hospital|Yes|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|24|||Both|18 Years|50 Years|No|||January 2016|January 14, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575924||11094|
NCT02564484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJLPSC|iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy|Collection of PBMC's From Patients With Unusually Severe Vincristine-Induced Neuropathy for the Creation of Neuronal-Like Cells||St. Jude Children's Research Hospital|No|Recruiting|November 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Blood samples will be obtained from each cohort.|Both|18 Years|N/A|No|Non-Probability Sample|Cases and controls for this study will be recruited from among the acute lymphocytic        leukemia (ALL) survivor members of the St. Jude Lifetime Cohort study (SJLIFE). Cases will        be matched for gender, tumor type, estimated cumulative vincristine dose at which toxicity        occurred, intended vincristine chemotherapy regimen, age (within 5 years) and race with        existing controls.|November 2015|November 17, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564484||11973|
NCT02580890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0498|Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)||Hospital de Clinicas de Porto Alegre|No|Completed|September 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|No|||February 2016|February 24, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580890||10713|
NCT02572843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 16/14|Anti-PD-L1 in Stage IIIA(N2) NSCLC|Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.||Swiss Group for Clinical Cancer Research|No|Not yet recruiting|March 2016|December 2021|Anticipated|March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02572843||11331|
NCT02567097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15428|Evaluating Specific Plans to Increase Smoking Quit Attempts in Prison|The Role of Self-Incentives in Smoking Cessation: A Randomised Controlled Trial Within a Local Prison||University of Manchester|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|159|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567097||11773|
NCT02576587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-594|Influence of Sleep Apnea on Risk of Atrial Fibrillation|Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation|Safebeat|The Cleveland Clinic|Yes|Recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|PAXgene RNA, Serum, Citrate, Citrate Plasma, EDTA, EDTA Plasma, SCAT- 1, Plain urine, Urine      in Acetic Acid|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Cases. Patients with PAF who present to Electrophysiology (EP) Clinic at University        HospitalsCase Medical Center (UHCMC) and the Cleveland Clinic Foundation (CCF) will be        approached for recruitment in the study.        Controls. Patients without AF will be recruited from the UHCMC and CCF General Cardiology        and Internal Medicine clinics (geographically similar to controls). Selection bias will be        minimized as there are a broad range of reasons for patients to present to these clinics.|January 2016|January 26, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02576587||11043|
NCT02576600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesthesie Trousseau 001|Pupillometry Guided Remifentanil Administration and Total Opioid Consumption During Propofol - Remifentanil TCI|Pupillometry Guided Versus Standard Practice Remifentanil Administration and Total Opioid Consumption||Hôpital Armand Trousseau|Yes|Completed|October 2010|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|60 Years|No|||October 2015|October 16, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576600||11042|
NCT02563028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-272|A Novel Method for Capturing the Visual Evoked Potential During Microdiscectomy Under Total Intravenous Anesthesia|A Novel Method for Capturing the Visual Evoked Potential (VEP) During Microdiscectomy Under Total Intravenous Anesthesia (TIVA)|VEP|Hospital for Special Surgery, New York|No|Recruiting|October 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|December 8, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563028||12085|
NCT02563041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCPel|Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis Catheters|Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial)|CITRIM|Catholic University of Pelotas|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|179|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02563041||12084|
NCT02577783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ5202|PDD vs PAD to Treat Initially Diagnosed MM|Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study||The First Affiliated Hospital of Soochow University|No|Recruiting|October 2015|December 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577783||10951|
NCT02574585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-005|Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury|Randomized Clinical Trial for the Evaluation of Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury||Hospital Sao Rafael|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|April 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02574585||11197|
NCT02566408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5115|Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity|Attitudes, Beliefs and Preferences of Older Breast Cancer Survivors Towards Physical Activity||Case Comprehensive Cancer Center|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Female|65 Years|N/A|No|||March 2016|March 23, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02566408||11826|
NCT02567266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150187|Community Study of Outcome Monitoring for Emotional Disorders in Teens|Community Study of Outcome Monitoring for Emotional Disorders in Teens|COMET|University of Miami|Yes|Recruiting|January 2016|||April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|222|||Both|12 Years|18 Years|No|||February 2016|February 1, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567266||11760|
NCT02567487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931893045140401|TAP Block With Two Different Doses of Levobupivacaine|Comparison of TAP Block With Two Different Doses of Levobupivacaine for Postoperative Pain Management in Pediatric Patients||Ankara University|No|Active, not recruiting|July 2015|July 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|2 Years|12 Years|No|||October 2015|October 2, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02567487||11743|
NCT02565667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FudanKOL|A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler|A Prospective Randomized Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler||Fudan University|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 24, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02565667||11883|
NCT02565680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 221 02|Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency|Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency|CAHISU|University Hospital, Toulouse|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02565680||11882|
NCT02572713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S4-001|Systemic Synuclein Sampling Study (S4)|Systemic Synuclein Sampling Study (S4)|S4|Michael J. Fox Foundation for Parkinson's Research|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|Biofluid samplings [blood, saliva, and cerebrospinal fluid (CSF)] Tissue samplings (skin,      colon, submandibular gland)|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited through patient care clinics, physician referrals, and by        reaching out to the community (e.g. PD-affiliated groups).|October 2015|March 24, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572713||11341|
NCT02561949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603-04|Adapting Mental Health Interventions for War-Affected Youth Through Employment Programs|Adapting Mental Health Interventions for War-Affected Youth Through Employment Programs in Sierra Leone||Harvard School of Public Health|Yes|Not yet recruiting|December 2015|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|15 Years|24 Years|No|||September 2015|September 25, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561949||12168|
NCT02561962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130314|A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma||Amgen|No|Recruiting|November 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561962||12167|
NCT02562222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optimizing_tDCS_Migraine|Optimized tDCS for the Treatment of Migraine|Optimizing the Effect of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Migraine||Universidade Federal de Pernambuco|Yes|Not yet recruiting|November 2015|April 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|14|||Both|18 Years|55 Years|No|||September 2015|September 28, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02562222||12147|
NCT02576405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG|Psychiatric Disorder and Postoperative Morbidity in Hip and Knee Artroplasty|Characterization of Preoperative Psychiatric Disorder in Relation to Postoperative Morbidity in Elective Fast-Track Total Hip and Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Not yet recruiting|October 2015|March 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Danish population sample (N=2000) of hip and knee arthroplasty patients in an elective        fast-track setting.|September 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576405||11057|
NCT02566824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-05-055|Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder|A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder||McGill University Health Center|No|Recruiting|October 2010|October 2020|Anticipated|August 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|216|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566824||11794|
NCT02577913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2014_03|European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception|European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception|EURAS-CORA|Center for Epidemiology and Health Research, Germany|Yes|Recruiting|November 2015|April 2022|Anticipated|November 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|101000|||Female|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using combined hormonal contraceptives|January 2016|January 27, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02577913||10941|
NCT02563795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANK-42479|Low Dose Spinal Anesthesia in Cesarean Surgery|Does the Reduction of Local Anesthetic Dose Provide Surgical Anesthesia While Avoiding Maternal Hypotension in Obese Pregnant for C/S by Single Shot Spinal Anesthesia?||Ankara University|No|Completed|May 2015|February 2016|Actual|January 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|100|||Female|18 Years|40 Years|No|Probability Sample|Patients undergoing cesarean section under spinal anesthesia in obstetric clinic|March 2016|March 14, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02563795|1 Day|12026|
NCT02571010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14RBD-RESISTAL|Evaluation of the Efficacy of Somatosensory Rehabilitation of Pain by Vibrotactile Stimulation on Static Mechanical Allodynia|Pilot Study to Evaluate the Effectiveness of Somatosensory Rehabilitation of Pain by Vibrotactile Stimulation on Static Mechanical Allodynia of Less Than Three Months Duration|RESISTAL|CRRF La Châtaigneraie|No|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02571010||11472|
NCT02571790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-23|Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation|Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation|Relax-TAG|Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|58|||Both|18 Years|65 Years|No|||October 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571790||11412|
NCT02571803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.15/III/15|Dietary Intervention to Stop COronary Atherosclerosis in Computed Tomography|The Effect of Strict Dietary Intervention on Atherosclerotic Lesions in Patients Diagnosed With Coronary Artery Disease, Assessed by Coronary Computed Tomography Angiography (CCTA).|DISCO-CT|Institute of Cardiology, Warsaw, Poland|Yes|Recruiting|October 2015|October 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571803||11411|
NCT02562469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIVATE|ACTIVATE: A Computerized Training Program for Children With ADHD|ACTIVATE: A Computerized Training Program for Children With ADHD||New York University|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|11 Years|No|||September 2015|September 25, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02562469||12128|
NCT02590484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUH14367|The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta|The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta: a Prospective Study||Minia University||Recruiting|June 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|40 Years||||October 2015|October 28, 2015|October 27, 2015||||No||https://clinicaltrials.gov/show/NCT02590484||9976|
NCT02573883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-154|Clobetasol Proprionate Versus Radiofrequency CO2 Laser for the Treatment of Lichen|A Randomized Trial of Clobetasol Proprionate Versus Radiofrequency CO2 Laser|CuRLS|Medstar Research Institute|Yes|Recruiting|October 2015|April 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Female|18 Years|N/A|No|||October 2015|October 9, 2015|October 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573883||11251|
NCT02573896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANT 2013-01|Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells|Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide||New Approaches to Neuroblastoma Therapy Consortium|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Month|30 Years|No|||December 2015|December 11, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573896||11250|
NCT02571972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#14-435|Dorzolamide-timolol Eye Drops Given With Eye Injections to Treat Age-related Macular Degeneration|Effect of Topical Dorzolamide-timolol in Non-responders Receiving Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration||Wills Eye|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571972||11398|
NCT02540863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-427|Miofascial Release and Exercises Therapy in the Treatment of Temporomandibular Disorders|Effectiveness of Myofascial Release and Exercises Therapy in the Treatment of Temporomandibular Disorders: a Randomized Clinical Trial||Universidad de Almeria|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|30 Years|70 Years|No|||September 2015|September 15, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02540863||13787|
NCT02535377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406-ALC-048-ES|Human Sperm Markers of Cryodamage Resistance|Molecular Diagnostic of Sperm Cryoresistance of Semen Donors and Clinical Outcomes After Artificial Insemination. Optimization of Sperm Bank||Instituto Valenciano de Infertilidad, IVI Alicante|Yes|Recruiting|February 2015|July 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men from 18-35 years, included in the donation program of IVI Alicante. Any transmisible        clinical pathology, viral infection or genetic disease should be ruled out by family        history records.        In addition, seminal samples from donors must meet the seminal criteria considered by our        laboratory:          -  sperm concentration> 40 million sperm / ml;          -  percentage of progressive motility> 50%          -  percentage of normal forms> 4%.        For pregnancy rates after IUI, only women< 40 years without tubal pathologies and IUI        indications will be included.|August 2015|September 4, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02535377||14208|
NCT02531256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/709/D|An Investigation of a New Laryngeal Mask Airway LMA Protector|An Investigation of a New Laryngeal Mask Airway LMA Protector|LMA|KK Women's and Children's Hospital|No|Completed|January 2014|December 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|21 Years|70 Years|No|||August 2015|February 28, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02531256||14523|
NCT02531568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-E10|Drug Interaction Study of Warfarin and MT-3995|A Phase I, Open-label, Single-Centre, Drug-Drug Interaction Study to Evaluate the Influence of MT-3995 on Pharmacokinetics(PK) and Pharmacodynamics of Warfarin in Healthy Subjects||Mitsubishi Tanabe Pharma Corporation||Completed|June 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02531568||14499|
NCT02571348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF CD1412/0089(P)|Optimum Micro-osteoperforations Accelerated Tooth Movement Interval|Optimum Micro-osteoperforations Accelerated Tooth Movement Interval, Related Pain Perception and Impact to Daily Functions - A Randomized Controlled Trial||University of Malaya|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571348||11446|
NCT02564757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eoma2|Does Pregnancy Increase Risk of Ventral Hernia Recurrence?|Does Pregnancy Increase Risk of Ventral Hernia Recurrence?||Bispebjerg Hospital|No|Active, not recruiting|September 2015|February 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3600|||Female|12 Years|45 Years|No|Non-Probability Sample|Fertile female patients who have undergone ventral hernia repair|January 2016|January 11, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564757||11953|
NCT02564770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28321|A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia|A Retrospective Chart Review of the Use of MabThera (Rituximab) for the Treatment of Rheumatoid Arthritis (RA) in Australian Rheumatology Practice||Hoffmann-La Roche||Completed|January 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|167|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid arthritis (RA) participants who have been treated with rituximab|March 2016|March 1, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02564770||11952|
NCT02575729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG8A0051|Sonography-guided Steroid Injection for Carpal Tunnel Syndrome|Sonography-guided Steroid Injection for Carpal Tunnel Syndrome||Chang Gung Memorial Hospital|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||September 2015|October 12, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02575729||11109|
NCT02571400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNDAustralia|Can we Predict Patients at Risk of Long-term Opioid Use After Surgery?|||University of Notre Dame Australia|No|Recruiting|October 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Pre-Admission Clinic, St Vincent's Private Hospital (pre-operative assessment unit) Day        Surgery Unit, St Vincent's Private Hospital|October 2015|October 7, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571400||11442|
NCT02571465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFA10-3|Assessment of Fluid Responsiveness in Patients After Cardiac Surgery|Assessment of Fluid Responsiveness in Patients After Cardiac Surgery Comparison of Different Functional Hemodynamic Parameters and Tests|POP|Triemli Hospital|No|Recruiting|April 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing elective off-pump CABG|October 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571465||11437|
NCT02574494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040747|Does Breastfeeding Lower Blood Pressure in Postpartum Hypertensive Patients?|||Cedars-Sinai Medical Center|No|Recruiting|October 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|N/A|N/A|No|Non-Probability Sample|The study population will include breastfeeding mothers that have met criteria for        hypertension.|October 2015|October 18, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02574494||11204|
NCT02574507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063328|Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners|Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners||Duke University|Yes|Recruiting|October 2015|September 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|80 Years|No|||August 2015|January 4, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02574507||11203|
NCT02563470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNS01|Bleeding, Cardio- and Cerebrovascular Complications in Head and Neck Surgery|A Retrospective Registry of Bleeding, Cardio- and Cerebrovascular Complications in Patients Treated for Head and Neck Cancer||University of Turku|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|456|||Both|18 Years|N/A|No|Non-Probability Sample|head and neck cancer patients|September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563470||12051|
NCT02568982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120132|Cushing's Disease Complications|Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease|COMPLICUSHING|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|September 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|blood Urinary salivary|Both|18 Years|N/A|No|Non-Probability Sample|Cushing 's disease|October 2015|October 13, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02568982||11628|
NCT02571582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study of Advanced Lung Disease|Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy|Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy||Federal University of Uberlandia|No|Completed|January 2009|October 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|553|||Both|15 Years|N/A|No|Non-Probability Sample|All Patients with established diagnosis of advanced lung disease that makes / made long        home Oxygen use which were accompanied or followed at Oxygen Therapy Clinic of the Federal        University of Uberlândia (UFU) by the Home Care Program (PAD), from 2009 to 2015. The        sampling is for convenience.|October 2015|October 6, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571582||11428|
NCT02565303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-35-(1)|Minimum Effective Dose of Ropivacaine for Spinal Anesthesia in Cesarean Section|Minimum Effective Dose of Ropivacaine for Different Intervertebral Space of Spinal Anesthesia in Cesarean Section||Shanghai 6th People's Hospital|No|Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02565303||11911|
NCT02575326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8298|Teen Asthma Control Encouraging a Healthier Lifestyle|Developing Patient-Centered Approaches to Asthma Management in Obese Adolescents|TAC|Henry Ford Health System|No|Recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|166|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575326||11140|
NCT02575339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCRC GI13-002|MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma|An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002||Big Ten Cancer Research Consortium|Yes|Not yet recruiting|December 2015|June 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|118|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575339||11139|
NCT02576977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-183|Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)|A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM). (KEYNOTE 183)||Merck Sharp & Dohme Corp.|Yes|Recruiting|October 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576977||11013|
NCT02567318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-MSH-2015|Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?|Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? - A Study of Healthy Volunteers||Rigshospitalet, Denmark|Yes|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|120|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02567318||11756|
NCT02578017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH14-00163|ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease|ENHANCE Study (ElectroNic Hydroxyurea AdhereNCE): A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease|ENHANCE|Nationwide Children's Hospital|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|72|||Both|N/A|19 Years|No|||October 2015|October 14, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02578017||10933|
NCT02577042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALATOR|Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 60 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen|Study of the Effect of Atorvastatin for Reducing "Inflamaging" (Aging-related Complication) in HIV-infected Patients Older Than 60 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen||Fundacio Lluita Contra la SIDA|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|99 Years|No|||February 2016|February 26, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02577042||11008|
NCT02573376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0809|Antiviral Pharmacology and Adherence in Drug Users|Antiviral Pharmacology and Adherence in Drug Users||University of Colorado, Denver|No|Recruiting|November 2015|March 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 2, 2016|June 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573376||11290|
NCT02576535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8844|Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations|Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations||New York University School of Medicine|No|Completed|February 2000|||June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 12, 2015|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT02576535||11047|
NCT02575118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2014/1529|Bisphenol A in Saliva and Urine Related to Placement of Dental Composites|Concentration of Bisphenol A in Saliva and Urine Before and After Treatment With Polymer-based Dental Filling Materials||Uni Research|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Saliva Urine|Both|16 Years|30 Years|No|Non-Probability Sample|Patients scheduled for regular dental examination at the public dental clinic, Bergen        Downtown District, who are in need for treatment with dental polymer-based filling        materials, are suitable for study (inclusion / exclusion criteria) and have given their        written informed consent.|October 2015|October 12, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02575118||11156|
NCT02577094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0429|Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia||EPRALLO|Nantes University Hospital|No|Not yet recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02577094||11004|
NCT02565433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAMECE-1302|Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)|Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases|PRAMECE-1302|Centre Oscar Lambret|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|130|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|May 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02565433||11901|
NCT02572401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810971|Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men|Reducing the Risk of HIV/STD Infection Among African American Men|STAND|University of Pennsylvania|No|Completed|October 2011|June 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|391|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|October 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02572401||11365|
NCT02572635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPV-001|A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax|A Randomised, Placebo Controlled, Double-blind, Dose Escalation, Single Centre Trial to Evaluate the Safety and Immunogenicity of PnuBioVax Administered on Three Occasions 28 Days Apart at Three Dose Levels in Healthy Adult Subjects.||ImmunoBiology Limited|No|Active, not recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572635||11347|
NCT02578121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0203974|UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination|A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients||University of Arkansas|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578121||10925|
NCT02578134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 09-2015|US-guided Percutaneous Electrolysis (EPE®) in Plantar Fasciosis|Effectiveness of US-guided Percutaneous Electrolysis (EPE®) Versus Placebo in Individuals With Plantar Fasciosis||Universidad Rey Juan Carlos|Yes|Withdrawn|October 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578134||10924|
NCT02564848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-06-Chung-SNBO|IIT2015-06-Chung: Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 70|IIT2015-06-Chung: Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 70|SNBO >70|Cedars-Sinai Medical Center|No|Recruiting|November 2015|January 2022|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|70 Years|N/A|No|||November 2015|November 12, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02564848||11946|
NCT02568293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-1601|Angioplasty + SBCV vs. Angioplasty Alone for Femoropopliteal Artery Stenosis|A Multicenter, Parallel, Blinded, Randomized Comparison of the Safety and Efficacy of Balloon Angioplasty Plus Intraluminal SBCV To Balloon Angioplasty Alone for Treatment of Stenosis or Occlusion Within the Femoropopliteal Artery|SHIELD|Symic Vascular|No|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|40 Years|N/A|No|||October 2015|October 13, 2015|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568293||11681|
NCT02568306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9747-4194|A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects|A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects||Novo Nordisk A/S|No|Recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568306||11680|
NCT02561611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-024|Multi-component Workplace Energy Balance Intervention|Multi-component Workplace Energy Balance Intervention|WorkACTIVE-P|Pennington Biomedical Research Center|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|64 Years|No|||January 2016|January 15, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02561611||12194|
NCT02567890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-0838:1|Swedish Body Project for Prevention of Eating Disorders|An Interactive Internet-based Program for Prevention of Eating Disorders on a Broad Basis|sBodyProject|Karolinska Institutet|No|Recruiting|September 2015|December 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|400|||Female|15 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567890||11712|
NCT02584205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36660314.8.0000.5208|Does Inspiratory Muscle Training Improve Functional Capacity in Subjects With Obstructive Sleep Apnea?|Does Inspiratory Muscle Training Improve Functional Capacity in Subjects With Obstructive Sleep Apnea? Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Recruiting|April 2015|February 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|40 Years|65 Years|No|||October 2015|October 20, 2015|April 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02584205||10458|
NCT02577484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US100|Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement|Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study|ACIST-FFR|Acist Medical Systems|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects 18 years of age or older, with single or multi-vessel CAD for whom FFR        measurement is indicated to guide percutaneous coronary intervention strategy.|February 2016|February 22, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577484||10974|
NCT02574286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-GCB-402|This Study is to Evaluate the Effect of Velaglucerase Alfa (VPRIV®) on Patients With Type 1 Gaucher Disease Through the IV Administration of VPRIV® Over 2 Years|An Open-label, Multi-center, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa a on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease||Shire|No|Not yet recruiting|March 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|65 Years|No|||October 2015|October 16, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574286||11220|
NCT02574299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-796|Characterization of Auditory Processing Involved in the Encoding of Speech Sounds|Characterization of Ascending and Descending Auditory Processing Involved in the Encoding of Speech Sounds in Adult and Children: Variability Related to Changes in Sensory Input or a Neurodevelopmental Disorder or Targeted Remediation|PRODIPRICIDE|Hospices Civils de Lyon|No|Recruiting|October 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|165|||Both|6 Years|70 Years|Accepts Healthy Volunteers|||August 2015|October 9, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02574299||11219|
NCT02564276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 15.114|Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer|Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer||Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|114|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564276||11989|
NCT02584478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL3818-US-002|A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 to Standard Platinum-Based Chemotherapy (AL3818-US-002)|A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)|AL3818|Advenchen Laboratories, LLC|Yes|Recruiting|December 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|August 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584478||10437|
NCT02561624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1712-14|Hati Salama (Secure Voucher)|Expanding the Successful E-voucher System to Improve Malaria Prevention and Fight New Global Health Threats Through Innovative Health Partnerships and Mobile Phone Technology in Tanzania||Queen's University|No|Recruiting|July 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|5000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02561624||12193|
NCT02561871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107705|A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers|Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers||Crucell Holland BV|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561871||12174|
NCT02568696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnro/64/13/03/02/2015|Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function|Activation of Coagulation Pathways in Clinical Renal Allotransplantation and Delayed Graft Function and Acute Rejection of the Graft|KTX|Helsinki University Central Hospital|No|Recruiting|June 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Three 4.5 ml citrated blood samples are taken during kidney transplantation surgery.      Sample 1: taken after induction of anesthesia but before beginning of surgery from central      venous catheter or by peripheral venous puncture.      Sample 2 and 3: taken at 2 minutes after start of the reperfusion from the blood going into      the transplant and the blood coming out of the transplant (iliac artery and renal vein      respectively) by vessel puncture with a 24G needle. These samples are drawn into 5-ml      syringes and transferred immediately into pyrogen free citrated vacuum tubes.      Samples are centrifuged, plasma separated and divided into aliquots and stored at -80C.|Both|18 Years|N/A|No|Non-Probability Sample|In Finland all adult kidney transplantation surgeries are performed at investigators        institution. Study population consists of all adult patients fulfilling inclusion criteria        admitted to the hospital for cadaveric renal transplantation.|October 2015|October 4, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02568696||11650|
NCT02587936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4UH3DK104655-02|Improving Chronic Disease Management With Pieces|Improving Chronic Disease Management With Pieces (ICD-Pieces)|ICD-Pieces|University of Texas Southwestern Medical Center|Yes|Not yet recruiting|January 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|11956|||Both|18 Years|85 Years|No|||October 2015|October 26, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02587936||10172|
NCT02566707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 14.08|Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen|Pharmacokinetics, Safety and Efficacy of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen in Patients With Intolerance and/or Resistance to NRTIs, NNRTIs and RTV: A Pilot Study|PRADAII|Radboud University|No|Recruiting|August 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02566707||11803|
NCT02570789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 2012-09|Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy|A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma|METASUN|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02570789||11489|
NCT02565238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA105|BIO.MASTER.BioMonitor 2 Study|Master Study of the Insertable Cardiac Monitor BioMonitor 2.||Biotronik SE & Co. KG|No|Enrolling by invitation|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|87|||Both|18 Years|99 Years|No|Non-Probability Sample|The patient collective consists mainly of patients with indications of an insertable        cardiac monitor or who are planned for loop recorded guided AF-therapy management. The        investigator will select patients who are appropriate for particiation from his general        patient population.|September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565238||11916|
NCT02561884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1276006|A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers|||Daewoong Pharmaceutical Co. LTD.|No|Enrolling by invitation|October 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|58|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561884||12173|
NCT02562131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/163-4|PET-MR-PSA Prostate Cancer Recidive Study|18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment|PET-MR-PSA|Norwegian University of Science and Technology|No|Recruiting|September 2015|December 2027|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Male|18 Years|N/A|No|Non-Probability Sample|The aim in 2 years is 80 prostate cancer patients with biochemical relapse following        radical treatment, or patients with persistently elevated PSA levels after radical        prostatectomy.|September 2015|September 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562131||12154|
NCT02564497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-349|A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C|A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Subjects||Bristol-Myers Squibb|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|146|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564497||11972|
NCT02564523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107249|Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults|A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Three Age Strata in Africa||Crucell Holland BV|Yes|Recruiting|November 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1188|||Both|1 Year|70 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564523||11971|
NCT02584998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 14-369-2 -- 01522|Reducing Colorectal Cancer Death Through Mailed Outreach Screening|Reducing Colorectal Cancer Death Through Mailed Outreach Screening||Philadelphia Veterans Affairs Medical Center|No|Active, not recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|783|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584998||10397|
NCT02561793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEA 2|DHEA Versus Placebo in Women With Poor Ovarian Response|Does DHEA Improve Pregnancy Rate in Women Undergoing IVF/Intracytoplasmatic Sperm Injection(ICSI) With Expected Poor Ovarian Response According to the Bologna Criteria? A Double Blind Randomized Placebo Controlled Study|DHEA|Cairo University|Yes|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Female|20 Years|43 Years|No|||January 2016|January 26, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02561793||12180|
NCT02561806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16012|A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis|A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis|IXORA-S|Eli Lilly and Company|No|Active, not recruiting|October 2015|August 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561806||12179|
NCT02570646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-155-E|QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings|QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings|QA-DDS|University of Kentucky|Yes|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02570646||11500|
NCT02565849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAF-8421|Study of Ventilatory Mechanics in Patients With Sickle Cell Anemia|Early Detection of Changes in Ventilatory Mechanics in Patients With Sickle Cell Anemia|SCA|Rio de Janeiro State University|Yes|Completed|February 2013|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with sickle cell anemia, type of hemoglobin SS, above 18 years of age,        accompanied by the Hematology Clinic at the University Pedro Ernesto hospital and no        contraindications for study participation|September 2015|September 30, 2015|August 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02565849||11869|
NCT02567006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2170|SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala|SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala|SMSVaxGuate|University of Colorado, Denver|No|Recruiting|March 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|720|||Both|6 Weeks|6 Months|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567006||11780|
NCT02567253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO/2015/002|Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer|Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial|OvIP1|University Hospital, Ghent|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Female|18 Years|N/A|No|||September 2015|October 1, 2015|September 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567253||11761|
NCT02569866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESG180402|Antibiotics After Breast Reduction:Clinical Trial With Randomization|Antibiotics After Breast Reduction:Clinical Trial With Randomization||Federal University of São Paulo|No|Recruiting|November 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02569866||11560|
NCT02563418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2013 - 11|Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study|Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study|VOG-HD|University Hospital, Angers||Recruiting|May 2014|||May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02563418||12055|
NCT02563717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/927-31/4|Comparison Of Respiratory Support After Delivery on Infants Born Before 28 Weeks Gestational Age|A Randomised Controlled Trial of Delivery Room Intubation Rates Comparing a New System and T-piece Resuscitation System for Initial Stabilisation of Infants Born <28 Weeks|CORSAD28|Karolinska Institutet|Yes|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|N/A|N/A|No|||March 2016|March 3, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02563717||12032|
NCT02573038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.878|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients.|ASTRID|Hospices Civils de Lyon|Yes|Not yet recruiting|February 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|No|||December 2015|December 9, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573038||11316|
NCT02573051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANP|Termination Of Anembryonic Pregnancy|Misoprostol Plus Isosorbide Mononitrate Versus Misoprostol For Termination Of Anembryonic Pregnancy||Assiut University|No|Recruiting|June 2015|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|108|||Female|20 Years|40 Years|No|||October 2015|October 8, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573051||11315|
NCT02571673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-245|Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)|Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)||Memorial Sloan Kettering Cancer Center||Recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Clinics|January 2016|January 13, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571673||11421|
NCT02571686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139253|Accuracy of Pulse Oximeters With Profound Hypoxia|Accuracy of Pulse Oximeters With Profound Hypoxia||Mortara Instrument|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|10-12 healthy volunteers|December 2015|December 22, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571686||11420|
NCT02570087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTOHFrEF|Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)|Benefits of Chronic Total Coronary Occlusion Percutaneous Intervention in Patients With Chronic Heart Failure and Reduced Ejection Fraction.|CTOHFrEF|Hospital Clinic of Barcelona|No|Completed|July 2011|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|80 Years|No|||October 2015|October 5, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02570087||11543|
NCT02574637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5170C00002|Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease|A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy||MedImmune LLC|Yes|Recruiting|January 2016|May 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|342|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574637||11193|
NCT02566681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC/ONM|Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis|Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM)|MSC/ONM|Red de Terapia Celular|Yes|Recruiting|September 2015|April 2018|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||September 2015|September 30, 2015|January 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566681||11805|
NCT02565199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081901|Premotor Cortex: A New Target for Stroke Motor Rehabilitation|Premotor Cortex: A New Target for Stroke Motor Rehabilitation Using Transcranial Magnetic Stimulation||Emory University|No|Recruiting|September 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02565199||11919|
NCT02565628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7821002|PF-06669571 In Subjects With Idiopathic Parkinson's Disease|A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.||Pfizer|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|19|||Both|45 Years|85 Years|No|||March 2016|March 18, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565628||11886|
NCT02571374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|symbioticcolorectalcancer|Symbiotics to Prevent Postoperative Infection in Colorectal Cancer|Change in Incidence of Surgical Site Infection After Resection of Colorectal Cancer Between Patients Receiving a Symbiotic Compound and Patients Receiving a Placebo.||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|October 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|92|||Both|18 Years|85 Years|No|||October 2015|October 7, 2015|April 11, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571374||11444|
NCT02565823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS2015-11|The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue|Investigation of Exercise-Induced Myokines and Adipokines||Joslin Diabetes Center|No|Recruiting|October 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565823||11871|
NCT02587910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAUMCRH.RC3.23/Sep/2015|Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease|Melanole, a Nigella Sativa (Black Seed) Extract for the Treatment of Gastroesophageal Reflux Disease|GERDMeDS|Lebanese American University|Yes|Recruiting|October 2015|September 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|60 Years|No|||October 2015|October 26, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02587910||10174|
NCT02573727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-004|To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure|''To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure'||Institute of Liver and Biliary Sciences, India|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||October 2015|January 17, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02573727||11263|
NCT02576314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_HCV G3 Study|Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients|Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection||Humanity & Healthy GI and Liver Centre|Yes|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576314||11064|
NCT02566135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR/85/Inst/GJ/2013|I-gel Versus C-LMA as a Conduit for Tracheal Intubation Using Ventilating Bougie|I-gel Versus C-LMA as a Conduit for Tracheal Intubation Using Ventilating Bougie||Medical College Baroda|No|Completed|March 2014|February 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02566135||11847|
NCT02582203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111010324|Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA|Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus||Wayne State University||Recruiting|February 2012|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582203||10612|
NCT02563080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exocrine insufficiency|Pancreatic Exocrine Insufficiency in Acute Pancreatitis|Development of Pancreatic Exocrine Insufficiency After Moderately Severe or Severe Acute Pancreatitis|APPEI|Helsinki University Central Hospital|No|Recruiting|September 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|None Retained|Fecal samples.|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with first attack of moderately severe or severe acute pancreatitis treated in        Helsinki University Hospital.|January 2016|January 5, 2016|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02563080|5 Years|12081|
NCT02563327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-6719|Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis|TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling|S31PK/PD|Centers for Disease Control and Prevention|No|Not yet recruiting|October 2015|March 2020|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563327||12062|
NCT02576418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_08_2015|PartoSure to Predict Spontaneous Preterm Delivery in Pregnancies After Assisted Reproductive Technology (ART)|Evaluation of the PartoSure Time to Delivery (TTD) Test to Predict Spontaneous Preterm Delivery in Pregnancies After Assisted Reproductive Technology (ART)||Vietnam National University|No|Not yet recruiting|October 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|50 Years|No|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576418||11056|
NCT02531672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-117|Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography|Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography: An Expanded Access Study||Memorial Sloan Kettering Cancer Center||Available|August 2015|||August 2019|Anticipated|N/A|Expanded Access|N/A|||||||Male|18 Years|N/A|No|||February 2016|February 22, 2016|August 20, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02531672||14492|
NCT02539069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09CON|The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy|A Post-marketing Surveillance to Evaluate the Efficacy and Safety of CHONDRON (Autologous Cultured Chondrocyte) Through Arthroscopy in Patients With Knee Cartilage Defects||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02539069||13924|
NCT02544360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040890|A Photoaging Mobile App Promoting Poster Campaign for Preventing Smoking in Secondary Schools|Smokerface: A Photoaging Mobile App Promoting Poster Campaign for Preventing Smoking in Secondary Schools: Randomized Controlled Trial|Smokerface|University of Giessen|Yes|Active, not recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12000|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02544360||13520|
NCT02535715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20140476H|A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)|A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02535715||14182|
NCT02535728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53243.100.15|Anesthesia Geriatric Evaluation and Quality of Life After Cardiac Surgery|Anesthesia Geriatric Evaluation and the Prediction of Quality of Life in Elderly Cardiac Surgery Patients|AGE|St. Antonius Hospital|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|560|Samples Without DNA|Blood samples are taken directly after induction of anesthaesia.|Both|70 Years|N/A|No|Probability Sample|All patients planned for elective cardiac surgery and aged 70 years or older.|August 2015|August 26, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535728||14181|
NCT02589067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30529|Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization|Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization.||Los Angeles Biomedical Research Institute|Yes|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|5 Years|18 Years|No|||March 2016|March 9, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589067||10085|
NCT02578303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB / N° 2014-A01617-40|Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations|Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations|VAAPS|Central Hospital Saint Quentin|No|Recruiting|May 2015|May 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|139|||Both|75 Years|120 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02578303||10911|
NCT02568865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001913|Noninvasive Physiologic Sensors to Assess Depression|||Massachusetts General Hospital||Not yet recruiting|December 2015|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Adult outpatients with a current major depressive episode (n=40) and healthy adult        controls (n=10).|October 2015|October 2, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02568865||11637|
NCT02568878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Creatine for Depressed Male and Female Methamphetamine Users|An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users||Montana State University|No|Recruiting|November 2015|May 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|59 Years|No|||December 2015|December 10, 2015|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568878||11636|
NCT02563210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC 36 (RB 15.181)|Airway Resistance Measurement in Children 3 to 6 Years of Age|Interrupter Technique and Plethysmography Airway Resistance Measurement: Comparison of These Two Techniques for the Diagnosis of Airway Obstruction Diagnosis and Bronchodilation Response in Children 3 to 6 Years of Age|ARC36|University Hospital, Brest|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|3 Years|6 Years|No|||July 2015|October 20, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02563210||12071|
NCT02563457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 031 08|Efficacy of Periodontal Treatment on Glycaemic Control in Diabetic Patients|Efficacy of Periodontal Treatment on Glycaemic Control in Diabetic Patients|DIAPERIO|University Hospital, Toulouse|No|Recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||October 2015|October 4, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02563457||12052|
NCT02573688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIDM-2014-GEO|Interdisciplinary Intervention in Patients With Obesity and Other Metabolic Diseases|Interdisciplinary Intervention Project - Promotion and Rehabilitation in Patients With Obesity and Other Metabolic Diseases||Federal University of São Paulo|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|30 Years|50 Years|No|||October 2015|October 8, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02573688||11266|
NCT02578342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410.000.055|Brain Activity in Adults With ADHD During Neuropsychological Tasks|Brain Activity and Functional Connectivity in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) During Tasks of Motor Inhibition and Cognitive Switching||Kantonsspital Aarau|Yes|Recruiting|August 2015|August 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three groups:          1. healthy volunteers          2. ADHD subjects receiving medications          3. medication-naive ADHD subjects|October 2015|October 15, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02578342||10908|
NCT02565017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-226|Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System|Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|81|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|December 2015|December 28, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565017||11933|
NCT02567929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160086|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer||Konkuk University Medical Center|No|Recruiting|July 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|300|||Female|20 Years|N/A|No|||February 2016|February 26, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02567929||11709|
NCT02568202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAEM-4268|Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)|Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)||Novo Nordisk A/S|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|449|||Both|18 Years|N/A|No|Probability Sample|This study will investigate adult patients at least 18 years of age with mild-severe        hemophilia B and caregivers of children (current age below 18 years) with hemophilia B.|January 2016|January 11, 2016|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568202||11688|
NCT02571530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-312|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer|Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer||Northwell Health|No|Recruiting|September 2015|||September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|September 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571530||11432|
NCT02577575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01508|Adult Oxytocin Study|The Effects of Oxytocin on Social Cognition in Patients With Schizophrenia|OT|University of California, San Francisco|Yes|Active, not recruiting|August 2010|||September 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02577575||10967|
NCT02569333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbvie-PATIENT-UC|Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis|Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis: PATIENT-UC|PATIENT-UC|Mount Sinai Hospital, Canada|No|Not yet recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02569333||11601|
NCT02569346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 15.02|Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet|Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (SCRUM)|SCRUM|Radboud University|No|Not yet recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569346||11600|
NCT02576990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-170|Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170)|A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)||Merck Sharp & Dohme Corp.|No|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576990||11012|
NCT02564874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505M71543|Effect on Dietary Compensation and Weight Gain in Adults by Savory Solid and Sugary Liquid Discretionary Food Sources|Effect on Dietary Compensation and Weight Gain in Adults by Savory Solid and Sugary Liquid Discretionary Food Sources||University of Minnesota - Clinical and Translational Science Institute||Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564874||11944|
NCT02564887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15080566|Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy|Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy||University of Pittsburgh|No|Not yet recruiting|February 2016|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564887||11943|
NCT02567331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18017|A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer|An Open-label Study of the Safety, Tolerability, and Response Rate of Xeloda in Treatment-naïve Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|October 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567331||11755|
NCT02567552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412-BCN-087-AB|Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone|Randomized Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone (Prolutex) 25 mg/Day Versus Intramuscular Progesterone (Prontogest) 50 mg/Day||IVI Barcelona|Yes|Recruiting|May 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02567552||11738|
NCT02575027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-001086|Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme|4π Radiotherapy for Recurrent Glioblastoma Multiforme: A Feasibility Trial||Jonsson Comprehensive Cancer Center|Yes|Recruiting|November 2014|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575027||11163|
NCT02564042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203120|A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis|Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis||GlaxoSmithKline|Yes|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|270|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564042||12007|
NCT02564302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NERG-03|Effects of Mindfulness on Atrial Fibrillation|Effects of Monitored Mindfulness Training on Quality-of-life, Anxiety, and Depression in Patients Awaiting Ablation of Atrial Fibrillation||Newmarket Electrophysiology Research Group Inc|No|Recruiting|August 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564302||11987|
NCT02562547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH-SR-S-01|Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice|Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice||Desert Perinatal Associates|No|Completed|April 2015|September 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|799|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Participants will be all women who present for vaginal delivery at Dignity Health - St.        Rose, Siena Campus during the 3 month study period. The main focus of this study is to see        whether the Hem-Avert® reduces Cesarean delivery among women undergoing labor and        delivery. To be included in this study, by definition, the participant must be a pregnant        woman.|September 2015|September 27, 2015|September 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562547||12122|
NCT02563899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202093|Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis|A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis||GlaxoSmithKline|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563899||12018|
NCT02563912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resuscitaion book|Pre-calculated Doses of Medication for Pediatric Resuscitation, a Simulation Experimental Trial|Pre-calculated Doses of Medication for Pediatric Resuscitation, a Simulation Cross-over Randomized Experimental Trial||St. Justine's Hospital|No|Recruiting|September 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||September 2015|September 29, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02563912||12017|
NCT02566616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0646|Electrical Nerve Stimulation of the Ulnar Nerve|Electrical Nerve Stimulation of the Ulnar Nerve During Cubital Tunnel Decompression Surgery: Does it Improve Long Term Functional Outcomes?|ESTIM|University of Chicago|Yes|Not yet recruiting|November 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566616||11810|
NCT02564549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10633|MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca|Multiparametric MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Cancer (MAVERICK)||Virginia Commonwealth University|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|192|||Male|40 Years|N/A|No|||November 2015|November 19, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564549||11969|
NCT02564562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7461004|A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers|A Phase 1 Open-Label, Radiolabeled, Single-Dose Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers||Pfizer|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564562||11968|
NCT02570893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTOG-1401|A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma|A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma||Zhejiang Cancer Hospital|Yes|Recruiting|May 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|366|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02570893||11481|
NCT02576548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5760C00001|A Phase 1 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.|A Phase I Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors|MEDI4276|MedImmune LLC||Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576548||11046|
NCT02561650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15010196|Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions|An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions||Mallinckrodt|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561650||12191|
NCT02561663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWT-03 Pivotal 2|NWT03 and Arterial Stiffness|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Determine the Effect of 5g Egg Protein Hydrolysate (NWT-03) on Arterial Stiffness, Microcirculation and Blood Pressure in Otherwise Healthy Subjects With Metabolic Syndrome||Newtricious R&D BV|No|Recruiting|September 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02561663||12190|
NCT02569437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-0462|Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps|The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569437||11593|
NCT02569450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0282|Evaluation of Control Chart Impact on Surgical Outcomes|The Impact of Surgical Outcomes Monitoring Using Control Chart on Surgical Performance: A Cluster Randomized Trial|SHEWHART|Hospices Civils de Lyon|No|Not yet recruiting|October 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients operated in participating French public and private hospitals (cluster)|September 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569450||11592|
NCT02571426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC52320142569-1|Renal Function During Pediatric Anesthesia|The Influence of Propofol and Sevoflurane Anesthesia on Water and Sodium Retention in Children||Uppsala University|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|32|||Male|1 Year|12 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571426||11440|
NCT02569892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-33991|Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration|Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration||Stanford University|No|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|60 Years|N/A|No|||October 2015|October 6, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569892||11558|
NCT02574481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2063|ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent|A Randomized Trial Comparing the ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries|IMPERIAL|Boston Scientific Corporation|Yes|Recruiting|December 2015|January 2022|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|485|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574481||11205|
NCT02564003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-11|Oxycodone Pharmacokinetics in Preterm Infants|Oxycodone Pharmacokinetics in Preterms, Infants and Children|oksineoinfa|Kuopio University Hospital|Yes|Completed|June 2012|August 2013|Actual|August 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|79|Samples Without DNA|Plasma and urine samples for oxycodone concentration measurement|Both|N/A|2 Years|No|Non-Probability Sample|Children age from 23 gestational weeks to two years|September 2015|September 29, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02564003||12010|
NCT02587767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577MPLACS|577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy|Prospective Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy||Sun Yat-sen University|Yes|Active, not recruiting|October 2015|February 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|55 Years|No|||October 2015|October 26, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02587767||10185|
NCT02566317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA198971|Stand & Move at Work|Stand & Move at Work: A Group Randomized Trial||Arizona State University|Yes|Not yet recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02566317||11833|
NCT02568462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0182(C)|Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent|Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II|RENASCENT II|Amaranth Medical Inc.|Yes|Not yet recruiting|November 2015|July 2021|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|84 Years|No|||October 2015|October 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568462||11668|
NCT02575014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOT 529762|Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy|Preoperative Hyperbaric Oxygen Therapy (HBOT) vs. Non Preoperative HBOT in Patients Undergoing Pancreaticoduodenectomy for Premalignant, and Malignant Tumors of the Common Bile Duct, Periampullary and Duodenum|HBOT|Florida Hospital Tampa Bay Division|Yes|Recruiting|October 2013|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02575014||11164|
NCT02587845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-129|Use of Transexamic Acid in Hip Replacement|Use of Tranexamic Acid(TNA) in Preventing Blood Loss During and After Total Hip Arthroplasty||Samsung Medical Center|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|150|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|April 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02587845||10179|
NCT02569268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hongyu Wang|Beijing Vascular Disease Patients Evaluation STudy|Early Vascular Disease Detection System for High Risk Patients in Beijing|BEST|Peking University Shougang Hospital|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood sample for DNA examination|Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects such as patient or inpatient patients , aged 45-75 years ,in high-risk vascular        events groups ,and from Dongcheng District, Shijingshan Shougang community and Mentougou        District.|October 2015|October 7, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569268|3 Years|11606|
NCT02572856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50690|Continuous Glucose Monitoring During and After Surgery|Continuous Glucose Monitoring During and After Surgery|CGM|University of Washington|No|Recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02572856||11330|
NCT02566577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00064523|Physiologic Effects of RBC Transfusion|Physiologic Effects of RBC Storage in Chronic Transfusion Recipients: Vasoreactivity, Exercise Capacity, and Oxygen Consumption||Emory University|No|Enrolling by invitation|July 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|80 Years|No|||October 2015|October 1, 2015|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02566577||11813|
NCT02566590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72083|Preventing the Loss of Muscle and Function in Hospitalized Older Adults|Preventing the Loss of Muscle and Function in Hospitalized Older Adults||University of Utah|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|70 Years|85 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02566590||11812|
NCT02575079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080344|Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT|Parafilm Application to Prevent Central Line Associated Bloodstream Infections in Pediatric Patients Undergoing Hematopoietic Cell Transplantation||Emory University|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|N/A|21 Years|No|||October 2015|October 13, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575079||11159|
NCT02576457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI471-049|Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis|A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis||Bristol-Myers Squibb|Yes|Recruiting|December 2015|October 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576457||11053|
NCT02570802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nerve US Children 01|Ultrasonographic Reference Values for Peripheral Nerves in Children|Ultrasonographic Reference Values for Peripheral Nerves and Nerve Roots in the Normal Population of Children and Adolescents||University Hospital, Basel, Switzerland|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|255|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02570802||11488|
NCT02570815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFCRS-RP-001-1504-29|Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer|Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer: Analysis of Accuracy and Added Value||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|January 2016|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02570815||11487|
NCT02569567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART15|Comparison of Smart-Shear Wave Elastography and Transient Elastography|Applicability, Reliability and Accuracy for Staging Hepatic Fibrosis: Comparison of Smart-Shear Wave Elastography and Transient Elastography|SMART|Asan Medical Center|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|20 Years|80 Years|No|Non-Probability Sample|A total of 105 participants will be enrolled. Participants are patients with liver disease        who are planning to undergo liver surgery, and potential liver donors for living related        liver transplantation.        Study population size was calculated by considering a power of 80%(1-sided alpha of 25%),        and an expected dropout rate of 10%.|October 2015|November 14, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569567||11583|
NCT02573428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-620|Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder|Evaluating the Validity of an Eye Gaze Tracking Assessment Tool in Identifying Autism Spectrum Disorder|EYE|The Cleveland Clinic|Yes|Recruiting|June 2015|February 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|200|||Both|18 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|ASD and Non-ASD participants will be recruited following their evaluations in the Center        for Autism diagnostic clinics as well as from the Social Practice and Instruction Enhances        Socialization (SPIES) program both of which are part of the Cleveland Clinic Center for        Autism.|December 2015|December 21, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573428||11286|
NCT02566863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Wu-003|Haemodynamic Effect of Dexmedetomidine|Haemodynamic Effect of Dexmedetomidine in Relation to Autonomic System Activity||Medical University of Gdansk|No|Recruiting|June 2015|October 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|20 Years|65 Years|No|||February 2016|February 7, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566863||11791|
NCT02568917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFART|Effectiveness of ART and Conventional Treatment - Practice-based Clinical Trial|Effectiveness of Atraumatic Restorative Treatment and Conventional Restorations in Primary and Permanent Dentition: A Practice-based Clinical Trial||University of Sao Paulo|No|Recruiting|January 2016|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|6 Years|14 Years|No|||March 2016|March 16, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02568917||11633|
NCT02588027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16665|Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder|Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder||University of California, San Francisco|No|Recruiting|October 2015|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588027||10165|
NCT02565472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508M77407|Effects of Juice on Gastrointestinal Tolerance and Breath Hydrogen Response in Human Subjects|Effect of a White Grape Juice Compared to Apple Juice on Gastrointestinal Tolerance and Breath Hydrogen Response in Human Subjects||University of Minnesota - Clinical and Translational Science Institute||Completed|October 2015|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02565472||11898|
NCT02577640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0226|Dietary Soy Isoflavones In Chronic Pancreatitis|Dietary Soy Isoflavones In Chronic Pancreatitis||Ohio State University|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02577640||10962|
NCT02570191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18092|A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)|An Open-label, Multicenter, National, Not-randomized Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (PEGASYS) in Patients With HBeAg-negative Chronic Hepatitis B||Hoffmann-La Roche||Completed|November 2004|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570191||11535|
NCT02570204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033|Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests|Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests||Gynuity Health Projects|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|236|||Female|11 Years|56 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570204||11534|
NCT02571543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015/15|Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?|Investigation of Ibuprofen in the Delay of Ovulation in NC-IVF (Natural Cycle in Vitro Fertilisation) Therapy With the Objective of Reducing Premature Ovulation and Thus Improving Effectivity (Off Label Use)|Ibudelay|University Hospital Inselspital, Berne|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02571543||11431|
NCT02573935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSG 03/14|Clarithromycin in Multiple Myeloma Induction Therapy|A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma|CLAIM|Aalborg Universitetshospital|Yes|Recruiting|January 2015|July 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573935||11247|
NCT02568436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-Ortho-02-2015|Effect of Low Level Laser Therapy in Accelerating Tooth Movement For Dental Crowding Cases|Evaluation of Low-Level Laser Therapy (LLLT) on Accelerating Orthodontic Tooth Movement When Leveling and Aligning Upper Crowded Incisors: A Clinical Randomized Controlled Trail||Damascus University|Yes|Recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|16 Years|24 Years|No|||October 2015|October 2, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02568436||11670|
NCT02577809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M141181|Intrathecal Opioid Study|An Investigation of the Influence of Different Intrathecal Opioids on the Post-operative Pain Experiences of Woman at Rahima Moosa Mother and Child Hospital||University of Witwatersrand, South Africa|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02577809||10949|
NCT02576288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00345|Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity|Effects of Sitagliptin on Arterial Vasoreactivity and Proatherogenic Mediators in Obesity|SAVORO|University of Southern California|No|Not yet recruiting|January 2016|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576288||11066|
NCT02576301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX1222|Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS|Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS|AML|OXiGENE|No|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|105|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576301||11065|
NCT02574104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|792397-1|Generalizing TESTPILOT to New Single Family Room NICUs|Generalizing TESTPILOT-NICU: Transportable Enhanced Simulation Technologies for Pre-Implementation Limited Operations Testing in Neonatal Intensive Care Units|TESTPILOT|Women and Infants Hospital of Rhode Island|Yes|Recruiting|September 2014|March 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||15|Anticipated|1200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Institutions building a new single family room or hybrid Neonatal Intensive Care Unit        (NICU)|October 2015|October 8, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02574104||11234|
NCT02577991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00085674|Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)|A Prospective, Randomized Controlled Trial on the Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)||Northwestern University|No|Recruiting|February 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577991||10935|
NCT02563730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO-VATS|Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease|Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease||University Hospital Tuebingen|No|Recruiting|November 2014|||November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||September 2015|September 28, 2015|May 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02563730||12031|
NCT02568644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 21057913.9.0000.5135|Ginger Capsules for the Acute Treatment of Migraine Attacks|Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition to Ketoprofen for the Acute Treatment of Migraine Attacks||Federal University of Minas Gerais|Yes|Completed|July 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||October 2015|October 2, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568644||11654|
NCT02576184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140312|Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery|Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery: A Randomized-controlled Trial|MEMBO|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|381|||Both|18 Years|N/A|No|||September 2015|October 14, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02576184||11074|
NCT02576262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-02|HPV Integration Testing for Human Papillomavirus-Positive Women|||Huazhong University of Science and Technology||Recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1200|||Female|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|participants who visited the gynecologic clinic of hospital for various gynecologic        disorders and underwent primary HPV testing were prospectively recruited|September 2015|October 12, 2015|September 22, 2015||||No||https://clinicaltrials.gov/show/NCT02576262||11068|
NCT02569788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHIC-TR-HNCNS-2015-01|Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma|Phase I/II Trail Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma||Shanghai Proton and Heavy Ion Center|Yes|Recruiting|September 2015|March 2020|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569788||11566|
NCT02575547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-034-Nutrition and NPC|Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients|Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemo-radiotherapy on Nutritional Status in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: Prospective Observational Study||Sun Yat-sen University|Yes|Recruiting|May 2015|June 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|186|||Both|18 Years|65 Years|No|Non-Probability Sample|III-IVb(Union for International Cancer Control,UICC 7th) NPC patients with histologic        diagnosis of World Health Organization(WHO) II|February 2016|February 20, 2016|September 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02575547||11123|
NCT02569944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDHURH-001|Feasibility of Bladder Stimulation in Infants|Evaluation of Feasibility of Urine Collection Using Perineal Bag Versus Bladder Stimulation in Infants Less Than 12 Months Old||Hospital del Río Hortega|No|Completed|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|58|||Both|N/A|12 Months|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569944||11554|
NCT02569957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15P.404|Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma||Thomas Jefferson University|Yes|Recruiting|October 2015|||October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||October 2015|October 28, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569957||11553|
NCT02590341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYKKE Registry|Myocarditis Registry for Children and Adolescents - MYKKE|Myocarditis Registry for Children and Adolescents - MYKKE|MYKKE|German Heart Institute|No|Recruiting|June 2014|May 2024|Anticipated|May 2024|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|17 Years|No|Probability Sample|Patients admitted to pediatric heart centers or pediatric cardiology departments|October 2015|October 27, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02590341|10 Years|9987|
NCT02581917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22A15|Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia|A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients||Comprehensive Cancer Center of Wake Forest University|No|Not yet recruiting|October 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with Acute Myeloid Leukemia (AML)|September 2015|October 19, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02581917||10634|
NCT02562833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLENO-FMH-1|The PLE²NO Self-management and Exercise Program for Knee Osteoarthritis|The PLE²NO Self-management and Exercise Program for Knee Osteoarthritis||Technical University of Lisbon|No|Completed|February 2015|October 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02562833||12100|
NCT02563392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-129|Does Preventive Uterine Artery Occlusion During Laparoscopic Myomectomy Impact on Ovarian Reserve Markers?|Does Preventive Uterine Artery Occlusion During Laparoscopic Myomectomy Impact on Ovarian Reserve Markers? A Randomized Control Trial|ORAM|University Hospital, Geneva|No|Recruiting|April 2015|December 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||October 2015|October 1, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02563392||12057|
NCT02570451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001214B|Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older|Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older: Feasibility of Routine Screening and Utility for Predicting Morbidity||Brigham and Women's Hospital|No|Active, not recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|711|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 65 years or older in the Weiner Center for Preoperative Evaluation presenting for        elective joint replacement surgery|October 2015|October 6, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570451||11515|
NCT02570464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/147/HP|Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning|Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning|CLARIS|University Hospital, Rouen|No|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|68|||Both|30 Years|85 Years|No|||October 2015|October 5, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570464||11514|
NCT02586220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2015-003-2|Iodine Nutrition During Pregnancy and Related Neonatal Physical Development|Iodine Nutrition During Pregnancy and Related Neonatal Physical Development||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|spot urine sample of pregnant women|Female|22 Years|35 Years|No|Probability Sample|250 pregnant women recruited from antenatal outpatient clinics in Xinhua Hospital        Affiliated to Shanghai Jiaotong University School of Medicine, China.|October 2015|October 22, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586220||10303|
NCT02586233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1040-A-U103|Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke|A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke|ASSENT|Daiichi Sankyo Inc.|No|Recruiting|September 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586233||10302|
NCT02567045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colorectal cancer screening|Uptake to Colorectal Cancer Screening in Familial-risk Population|Uptake to Colorectal Cancer Screening in Familiar-risk Population: A Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Test With Colonoscopy||Hospital Universitario de Canarias|No|Not yet recruiting|October 2015|March 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1076|||Both|18 Years|40 Years|No|||October 2015|October 1, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567045||11777|
NCT02563665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-HCKD/001/SOFO/2015|Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy|A Prospective Study on Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy||Institute of Liver and Biliary Sciences, India|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients        with Hepatitis C infection attending nephrology and Hepatology OPD (Out Patient        Department) or getting outpatient dialysis at the dialysis unit of Institute of Liver and        Biliary Sciences.|September 2015|October 7, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563665||12036|
NCT02563678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040229|Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines|Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines: a Pilot Study|O2B|Intermountain Health Care, Inc.|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|9||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563678||12035|
NCT02536105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001113|PK/PD Pediatric ADHD Classroom Study|Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital|Yes|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|6 Years|12 Years|No|||February 2016|February 1, 2016|August 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02536105||14152|
NCT02544373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00098738|CPAP to Treat Cognitive Dysfunction in MS|A Randomized Trial of Positive Airway Pressure Therapy to Treat Cognitive Dysfunction in MS Patients With Obstructive Sleep Apnea||University of Michigan|No|Recruiting|September 2015|August 2025|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|175|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02544373||13519|
NCT02530385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P001632|Fecal Microbiota Transplant for Obesity and Metabolism|Placebo Controlled Study of Fecal Microbiota Transplant (FMT) to Impact Body Weight and Glycemic Control in Adults Using a Frozen Encapsulated Inoculum||Massachusetts General Hospital||Not yet recruiting|April 2016|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|25 Years|60 Years|No|||February 2016|February 12, 2016|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02530385||14590|
NCT02535481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0079|Epidermal Grafting in Wound Healing|A Multi-centre Randomised Controlled Trial to Compare Epidermal Grafting With Split Skin Grafting for Wound Healing|EPIGRAAFT|University College, London|Yes|Recruiting|September 2015|September 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02535481||14200|
NCT02568501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012160|Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults|Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults||University of Pennsylvania|No|Enrolling by invitation|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568501||11665|
NCT02562846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201524466|PRediction Of Treatment Response to ECT in Depression and Cognitive Side effecTs|Prediction of ECT Treatment Response in Depression and Early Detection of ECT-related Memory Problems|PROTECT|Universiteit Antwerpen|No|Recruiting|June 2015|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Whole blood|Both|18 Years|85 Years|No|Probability Sample|The investigators include a severely depressed patient population that has to be evaluated        regularly. For that reason, the investigators choose residential patients. They are        recruited at the psychiatric hospital in Duffel.        Treating psychiatrists consider a candidate eligible for ECT and start pre-ECT        investigations. The investigators screen all depressive ECT patients for inclusion in the        study and ask for their informed consent (IC). The treating psychiatrist decides when ECT        is stopped considering clinical evolution and side effects.|September 2015|September 25, 2015|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02562846|9 Months|12099|
NCT02577367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-02|Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding|The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding||Maimonides Medical Center|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|100 Years|No|||October 2015|October 14, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577367||10983|
NCT02567695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBT440-004|A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects|A Phase 1, Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of GBT440 300 mg Administered as Capsule Formulations in Healthy Subjects||Global Blood Therapeutics|No|Recruiting|September 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567695||11727|
NCT02567916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-08-026-001|A Comparison of Injection Pain of Propofol During Endoscopy : LCT Propofol vs MCT/LCT Propofol|A Comparison of Injection Pain of Propofol During Endoscopy : LCT Propofol vs MCT/LCT Propofol||Keimyung University Dongsan Medical Center||Completed|April 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|129|||Both|15 Years|N/A|No|||March 2016|March 5, 2016|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02567916||11710|
NCT02564627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC15-02|PENS T6 With Ambulatory Self-applied Patch vs Conventional Procedure|Percutaneous Electrical Neurostimulation (PENS) of Dermatome T6 With an Ambulatory Self-applied Patch vs PENS of Dermatome T6 With Conventional Procedure: Effect on Appetite and Weight Loss in Moderately Obese Patients||Abdel Kadar Clinic|Yes|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02564627||11963|
NCT02563093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC57|Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2015-2016 Formulations||Sanofi|No|Active, not recruiting|September 2015|August 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563093||12080|
NCT02569086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIP/TAZO-INTERMEDIATE|Piperacillin PK Analysis in Severe Sepsis Patients|Population Pharmacokinetics of Piperacillin in the Early Phase of Severe Sepsis - Does Standard Dosing Result in Therapeutic Plasma Concentrations?||University of Aarhus|No|Recruiting|October 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Patients with severe sepsis treated empirically with Piperacillin/Tazobactam|October 2015|October 5, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02569086||11620|
NCT02575235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHRM-CPC2|Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia|Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia|CPC2|Seoul National University Hospital|No|Not yet recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|60 Years|N/A|No|||October 2015|October 13, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575235||11147|
NCT02575248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fwa000017585|Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest|Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest||Ain Shams University|Yes|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Female|20 Years|40 Years|No|||February 2016|February 12, 2016|September 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575248||11146|
NCT02573844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geophyt|Pain Relief In Irritable Bowel Syndrome|Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo|PRITON|Geophyt S.r.l.s.|Yes|Recruiting|January 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573844||11254|
NCT02563340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-KTx-cAMR-150926|Effect of BM-MSCs on Chronic AMR After Kidney Transplantation|Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study||First Affiliated Hospital, Sun Yat-Sen University||Not yet recruiting|November 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563340||12061|
NCT02577510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2014-005-|Comparing Ways to Freeze the Nerve That Provides Thigh Sensation|A Comparison Between Ultrasound- and Neurostimulation-Guided Lateral Femoral Cutaneous Nerve Block||Canadian Forces Health Services Centre Ottawa|No|Enrolling by invitation|November 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|November 10, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577510||10972|
NCT02574962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002770|Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy|Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy||University of Kansas Medical Center|Yes|Not yet recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|August 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574962||11168|
NCT02563782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA09-hRPE AMD 02 PORTRAY|Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD|Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD|PORTRAY|Ocata Therapeutics|Yes|Recruiting|August 2015|May 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||September 2015|September 29, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563782||12027|
NCT02564029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7431005|PF-06372865 in Subjects With Photosensitive Epilepsy|A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control||Pfizer|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|8|||Both|18 Years|60 Years|No|||March 2016|March 23, 2016|September 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564029||12008|
NCT02570269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_6|Prospective Comparison of Oral Intubation Via - Ambu® Aura Gain™ vs Slotted Guedel Tubus|Prospective Randomized Comparison Between a Flexible Fiberoptic Intubation Via the Ambu® Aura Gain™ Airway and the Slotted Guedel Tubus in Terms of Time to a Completed Airway Management and Patient Safety.||Schulthess Klinik|No|Recruiting|December 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|January 5, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02570269||11529|
NCT02570529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0679|Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy|||Yonsei University|No|Not yet recruiting|October 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|20 Years|80 Years|No|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570529||11509|
NCT02571764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1409|Supplementary Food for Moderate Acute Malnutrition in Children|The Effect of Supplementary Food on Recovery From Moderate Acute Malnutrition in Pre-school Children in Rural Mexico||PepsiCo Global R&D|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|248|||Both|2 Years|5 Years|No|||October 2015|October 7, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02571764||11414|
NCT02571777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVM149B2302|Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma|A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma||Novartis|Yes|Not yet recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|3155|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571777||11413|
NCT02566109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF 01115|Community Hospital Identification of High CV Risk Patients During Cancer Treatment|Community Hospital Identification of High CV Risk Patients During Cancer|CHI|Wake Forest NCORP Research Base|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|21 Years|N/A|No|||September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02566109||11849|
NCT02568943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589D2001X|An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma|An Open-label, Multi-center, Expanded Treatment Protocol of Oral Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed, and Relapsed and Refractory Multiple Myeloma||Novartis||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568943||11631|
NCT02567760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 571329|Development and Evaluation of a Cognitive Enhancement Product Made From Selected Thai Herbs for Menopausal Women|Development and Evaluation of a Cognitive Enhancement Product Made From Selected Thai Herbs for Menopausal Women||Khon Kaen University|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|30|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02567760||11722|
NCT02572895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACCANN_2015|Cranberry Extract and Urinary Infection Prevention: a Clinical Trial|Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins: A Double-blind Clinical Trial|PACCANN|Laval University|No|Recruiting|August 2015|December 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02572895||11327|
NCT02570698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-15-0001|BM Collection From NICU Infants for Composition|Collection and Characterization of Premature Infants Feces for Identification of Factors Contributing to Skin Irritation||Kimberly-Clark Corporation|No|Recruiting|October 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|30 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Infants who are equal or less than a gestational age of 30 weeks + 4 days|February 2016|February 17, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02570698||11496|
NCT02574832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU0020134|Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery|Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery||Northwestern University|No|Recruiting|October 2015|September 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|75|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574832||11178|
NCT02569177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL46363.041.14|Biomarkers for Postoperative Myocardial Infarction in Cardiac Surgery.|Evaluation of the Association Between Heart Type Fatty-acid Binding Proteins and High Sensitive Troponin and Postoperative Myocardial Infarction in Patients Undergoing Cardiac Surgery.||UMC Utrecht|No|Withdrawn|November 2015|||November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood samples will be drawn before incision (baseline), during cardiopulmonary bypass and      after release of the aortic cross clamp. Subsequently, blood samples will be drawn on      arrival at the intensive care unit and three and six hours after arrival. On post-operative      day 1 and 2 blood samples will be drawn on the ICU or the medium care. All samples will be      stored according the hospital blood banking protocol and analyzed at once at the end of the      study. Left over material will be discarded after all necessary analysis has been conducted.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing cardiac surgery.|November 2015|November 24, 2015|September 28, 2015||No|Due to lack of funding|No||https://clinicaltrials.gov/show/NCT02569177||11613|
NCT02573480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2015:311|Optimization Study of the Wraparound Care for Youth Injured by Violence Program|Optimization Study of the Wraparound Care for Youth Injured by Violence Program||University of Manitoba|Yes|Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|24 Years|No|||November 2015|November 5, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573480||11282|
NCT02564172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0075|Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia|Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia: a Randomized, Open, Controlled, Multicenter Trial.|STIMCONE|Nantes University Hospital|Yes|Recruiting|September 2015|October 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||September 2015|January 5, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02564172||11997|
NCT02564185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/51|Prospective, Randomized Study of the Impact of a Education Program for Patients Suffering From Low Back Pain|Prospective, Randomized Study of the Impact of a Education Program for Patients Suffering From Low Back Pain|TENS|Hopital Foch|No|Completed|September 2010|January 2016|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||January 2016|January 18, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564185||11996|
NCT02566889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108044|An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease|A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease|ADAPT|Janssen Scientific Affairs, LLC|Yes|Recruiting|November 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|6 Years|16 Years|No|||March 2016|March 16, 2016|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566889||11789|
NCT02577458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM082-CA-I-103|Study of the Combination of CM082 With Everolimus in Patients With mRCC|Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy||AnewPharma|No|Recruiting|September 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577458||10976|
NCT02577471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH01062012|The Function of Gastrointestinal Tract During Pregnancy|The Function of Gastrointestinal Tract During Pregnancy and After Delivery|umpiraskaus|Kuopio University Hospital|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|400 pregnant ladies, 400 ladies who had delivered within three weeks and 200 control        ladies who were not pregnant|October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02577471||10975|
NCT02576834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014B0532|Suicide Prevention Among Substance Abusing Homeless Youth|Suicide Prevention Among Substance Abusing Homeless Youth||Ohio State University|Yes|Recruiting|April 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02576834||11024|
NCT02576847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-006|Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel|A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea||Cutanea Life Sciences, Inc.|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576847||11023|
NCT02575690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599/12|Spirulina Supplementation and Cardiovascular Risk in Obese Caucasians With Treated Hypertension|Effect of Spirulina Maxima Supplementation on Cardiovascular Risk in Obese Caucasians With Treated Hypertension:a Randomized Double-blind Placebo-controlled Study||Poznan University of Medical Sciences|No|Active, not recruiting|January 2013|October 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|25 Years|60 Years|No|||October 2015|October 14, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02575690||11112|
NCT02568176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108043|Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants|An Open-Label Study to Evaluate the Pharmacokinetics of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|October 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568176||11690|
NCT02568189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1599|Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration|Randomized Controlled Trial of Inferior Vena Cava Ultrasonography in the Management and Disposition of Pediatric Patients Undergoing Evaluation for Sepsis and Dehydration||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|564|||Both|N/A|21 Years|No|||January 2016|January 11, 2016|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568189||11689|
NCT02566200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15597|French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015|French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015|FASTMI2015|French Cardiology Society|No|Active, not recruiting|October 2015|October 2027|Anticipated|May 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5000|Samples With DNA|-  blood samples for genotyping and serum banking        -  faeces samples for genetic analysis of microbiota|Both|18 Years|N/A|No|Probability Sample|Patient hospitalized in an intensive care unit in France for an acute myocardial        infarction|February 2016|February 23, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566200|10 Years|11842|
NCT02564653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01422|Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam Public Health System|Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam Public Health System:a Rural Model||New York University School of Medicine|No|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||September 2015|September 30, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02564653||11961|
NCT02564666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0815|The Effect of Telephone Counseling on the Compliance and Satisfaction for Advanced HCC Patients Receiving Sorafenib|The Effect of Telephone Counseling on the Compliance and the Level of Satisfaction for Patients Receiving Sorafenib Due to Advanced Hepatocellular Carcinoma|SORATEL|Asan Medical Center|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Both|20 Years|90 Years|No|||September 2015|September 29, 2015|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02564666||11960|
NCT02564939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0073|Ramelteon Prevention of Delirium - RCT|Randomized, Double Blind, Placebo-Controlled Clinical Trial Evaluating Ramelteon in the Prevention of Delirium||Hartford Hospital|No|Not yet recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|65 Years|N/A|No|||September 2015|September 29, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02564939||11939|
NCT02569905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014032605|Effect of Parecoxib Sodium and Flurbiprofen Injection on Postoperative Shivering|Tumor Hospital of Guangxi Medical University, China||Guangxi Medical University|Yes|Completed|April 2014|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|166|||Both|21 Years|62 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569905||11557|
NCT02575066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15PAS|Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients|Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)|PASART-2|The Netherlands Cancer Institute|Yes|Not yet recruiting|January 2016|April 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|October 12, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02575066||11160|
NCT02576353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS002-15-049|Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects|A Phase 1, Open-label, Randomized, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects||INSYS Therapeutics Inc|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576353||11061|
NCT02566434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0800|Methionine Tolerance in Healthy Human Adults|Methionine Tolerance in Healthy Human Adults|Met|Texas A&M University|No|Recruiting|July 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|40 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02566434||11824|
NCT02572869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-244|Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps|Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps||Memorial Sloan Kettering Cancer Center||Recruiting|September 2015|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|61|||Both|25 Years|80 Years|No|Non-Probability Sample|All eligible patients will be identified from the institutional databases. Preliminary        queries indicate that approximately 61 patients are eligible and currently alive.|October 2015|October 29, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02572869||11329|
NCT02570126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200147|A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.|Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.||GlaxoSmithKline||Recruiting|November 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1220|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||March 2016|March 10, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570126||11540|
NCT02570373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107879|A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants|Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects||Janssen Research & Development, LLC|No|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|September 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02570373||11521|
NCT02576470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500742|Motor Learning in Dysphagia Rehabilitation|Applying Motor Learning Principles to Dysphagia Rehabilitation||University of Florida|No|Not yet recruiting|November 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|12||Anticipated|114|||Both|21 Years|100 Years|No|||October 2015|October 13, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02576470||11052|
NCT02573441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000043747|KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer|KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer||The Hospital for Sick Children|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|6 Years|17 Years|No|||October 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573441||11285|
NCT02570386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-001|Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer|A Randomized Controlled Trial of Clinical Effectiveness of Freezing All Embryos Followed by Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer, in Women Undergoing In-vitro Fertilization Treatment||The University of Hong Kong|Yes|Recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|42 Years|No|||October 2015|October 14, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02570386||11520|
NCT02575170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599/068/069|Amino Acid Infusion in Mothers Before and During Cesarean Delivery|Intravenous Amino Acid Infusion in Mothers Before and During Cesarean Delivery: Effects on Maternal and Neonatal Temperature||B.P. Koirala Institute of Health Sciences|No|Recruiting|June 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|76|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02575170||11152|
NCT02566980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-458M|Biological Triggers of Depression in Pregnancy|The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality||Michigan State University|Yes|Enrolling by invitation|August 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Adult Blood Cord Blood Placenta|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant females age 18 and older, psychiatrically healthy or depressed; post-partum        females experiencing perinatal depression with and without suicide ideation.|October 2015|October 1, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02566980||11782|
NCT02566993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-C-003-14|Clinical Trial of Lurbinectedin (PM01183) Plus Doxorubicin (DOX) Versus Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line|Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Plus Doxorubicin (DOX) Versus Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)|ATLANTIS|PharmaMar||Not yet recruiting|December 2015|||November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566993||11781|
NCT02569827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cel01|Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore|A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore||Singapore General Hospital|Yes|Not yet recruiting|July 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|72|||Both|21 Years|65 Years|No|||October 2015|October 7, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569827||11563|
NCT02569840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ002|Amino Acid Feed Children's Study|An Evaluation of the Tolerance and Acceptability of Neocate Junior an Amino Acid Based Formula for Children||Nutricia UK Ltd|No|Not yet recruiting|November 2015|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|1 Year|10 Years|No|||October 2015|October 6, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02569840||11562|
NCT02562911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 485 03|Puberty in Girls Followed for Cystic Fibrosis|Epidemiological Study of the Progress of Puberty in Girls Followed for Cystic Fibrosis|EPIMUCO|University Hospital, Toulouse|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|8 Years|N/A|No|Non-Probability Sample|Girl aged 8 years of age, adolescents and young adults, had period or not, visit the        Reference and Competence Center of Cystic Fibrosis.|October 2015|October 4, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02562911||12094|
NCT02563145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Health-F2-2013-603016|Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents|Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents (Part of EU-MATRICS: Multidisciplinary Approaches to Translational Research)||Central Institute of Mental Health, Mannheim|Yes|Not yet recruiting|October 2015|April 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||June 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563145||12076|
NCT02576249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003120|Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis|Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections||Mayo Clinic|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576249||11069|
NCT02576197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO/PRO 2|Trial to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients|Phase IV, Unicentric, Randomized, Double Blind Clinical Trial to Evaluate Efficiency and Safety of a Treatment With a Probiotic in Adult Patients Diagnosed With Mild to Moderate Plaque Psoriasis, Controlled With Topic Treatment||Biopolis S.L.|No|Recruiting|May 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576197||11073|
NCT02576210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111207-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||October 14, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576210||11072|
NCT02561845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560R00019|Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients|Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in Percutaneous Coronary Intervention Patients||AstraZeneca|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|3500|Samples Without DNA|whole blood|Both|N/A|N/A|No|Probability Sample|PCI Patients initiating statin therapy|October 2015|October 8, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02561845||12176|
NCT02576691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yuanli2015|Effects of Percutaneous Coronary Intervention in Patients With Cardiac Arrest After Acute Myocardial Infarction: a 2-Year Study|||Wenzhou Medical University||Completed|January 2005|April 2015|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2363|||Both|N/A|N/A|No|Probability Sample|20 million residents of the South of Zhejiang Province|October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576691||11035|
NCT02563236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-022|Evaluation of 3D Selection Tasks in Parabolic Flight Conditions: Pointing Task in Augmented Reality User Interfaces|Evaluation of 3D Selection Tasks in Parabolic Flight Conditions: Pointing Task in Augmented Reality User Interfaces|3DPICK|University Hospital, Caen|No|Completed|March 2012|December 2014|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02563236||12069|
NCT02563249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-026|Influence of Gravity on Dexterity, Hand-eye Coordination and Perception of Orientation and Distances||DEXTER0g|University Hospital, Caen|No|Recruiting|May 2012|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02563249||12068|
NCT02564900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8201-A-J101|Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors|Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors||Daiichi Sankyo Inc.|No|Recruiting|August 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564900||11942|
NCT02562105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.05.42|Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation|In a Developing Country; What is the Fate of Hematologic Cancer Patients Requiring Mechanical Ventilation for More Than One Day? A Prospective Cohort Study||Mansoura University|Yes|Completed|January 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Hematological cancer patients admitted to ICU of oncology center, Mansoura University|September 2015|September 27, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02562105||12156|
NCT02568657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celox|Uterine Tamponade for Treatment of Primary Postpartum Hemorrhage|Comparison Between Celox Versus Bakri Balloon for Treatment of Primary Atonic Postpartum Hemorrhage||Assiut University|No|Completed|February 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|20 Years|40 Years|No|||February 2015|October 4, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02568657||11653|
NCT02577822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00082654|The Viability of Short Stems in Total Hip Arthroplasty|The Viability of Short Stems in Total Hip Arthroplasty||Northwestern University|No|Completed|October 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|85 Years|No|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02577822||10948|
NCT02563496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113577|A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria|An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria||GlaxoSmithKline|No|Not yet recruiting|September 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|6 Months|15 Years|No|||January 2016|January 25, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02563496||12049|
NCT02572830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-86401-09-01|Reconsolidation and EMDR|Blocking Memory Reconsolidation by Eye Movement Desensitization and Reprocessing (EMDR)||University of Zurich|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02572830||11332|
NCT02563379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBPS-0915-EA|Association of Dipping Pattern or Early Morning Surge of BP With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Subjects With Hypertension (DIMOSPAF)|Association Between Circadian Blood Pressure Patterns With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Hypertensive Subjects|DIMOSPAF|Evangelismos Hospital|No|Not yet recruiting|September 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|200|||Both|18 Years|85 Years|No|Probability Sample|We will evaluate all adult patients referred by their family physicians to the        "Hypertension and Cardiovascular Prevention" Outpatient Clinic at Evangelismos General        Hospital in Athens, from June 2015 to present.        All patients with an average office systolic BP ≥140 mmHg and/or an average diastolic BP        ≥90 mmHg on three consecutive visits are considered as having essential HTN. Furthermore,        individuals under treatment with one or more antihypertensive drug are also enrolled in        the study.|September 2015|September 30, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563379|12 Months|12058|
NCT02575001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attachment2015|The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes|The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes||University of Ljubljana, Faculty of Medicine|No|Recruiting|July 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|200|Samples With DNA|The genes with expected influence to stress reactivity and mental disorders will be tested.|Both|8 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children of 8 to 15 years of age with type 1 diabetes with their parents; Children of 8 to        15 years of age with Hashimoto thyroiditis with their parents; Healthy primary school        pupils of 8 to 15 years of age with their parents|October 2015|October 13, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02575001||11165|
NCT02581930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01744|Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma|A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance||National Cancer Institute (NCI)||Not yet recruiting|May 2016|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581930||10633|
NCT02585973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1430|Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC|Phase Ib Trial of Dose-escalating AZD1775 in Combination With Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|November 2015|November 2021|Anticipated|November 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02585973||10322|
NCT02566785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|677-15-FB|Balance Training for Elders With Heart Failure|Balance Activities and Strengthening to Improve Condition [BASIC]: Training for Elders With Heart Failure|BASIC|University of Nebraska|No|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|No|||March 2016|March 8, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02566785||11797|
NCT02568111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLD-PEG-14-10784|Brimonidine Tartrate for the Treatment of Injection Related Erythema|Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)|BRITE|Biogen||Not yet recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568111||11695|
NCT02575612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer|Can a Pathological Complete Response in the Breast be Diagnosed by Vacuum-assisted, Ultrasound Guided Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients? A Proof of Concept From a Prospective Cohort Study||Heidelberg University|No|Completed|July 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Female|18 Years|N/A|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02575612||11118|
NCT02568241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10|Interferon-α After DLI for the Prevention of Relapse|Interferon α After Prophylactic Donor Lymphocyte Infusion for the Relapse Prevention After Hematopoietic Stem Cell Transplantation|IDPR-HSCT|Peking University People's Hospital|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|42|||Both|2 Years|60 Years|No|||October 2015|October 4, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568241||11685|
NCT02568254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5735|Clinical Evaluation of Investigational Contact Lenses|||Johnson & Johnson Vision Care, Inc.|Yes|Completed|September 2015|January 2016|Actual|January 2016|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|78|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568254||11684|
NCT02571218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_785|AF Substrate Mapping and Guided Ablation|Substrate-Targeted Catheter Ablation to Treat Persistent Atrial Fibrillation||St. Jude Medical|No|Active, not recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|85 Years|No|||March 2016|March 23, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02571218||11456|
NCT02571231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsloUH_bogland|High Flow Ventilation With Volume Guarantee|Pilot Study: High Flow Ventilation With Volume Guarantee||Oslo University Hospital|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|N/A|3 Months|No|||September 2015|October 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02571231||11455|
NCT02568397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15997|A Drug-drug Interaction Study of AZD3293 (LY3314814) in Healthy Participants|Effect of AZD3293 on the Pharmacokinetics of Dabigatran in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02568397||11673|
NCT02568410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064249|Platelets as Regulators of Inflammation in Cardiac Surgery|Platelets as Regulators of Inflammation and Tissue Injury After Cardiac Surgery|PRICS|Duke University|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Plasma, DNA, Platelet RNA|Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing elective coronary artery bypass grafting|September 2015|October 6, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568410||11672|
NCT02538991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/13/03/03/2015|TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence|TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence - Patient Satisfaction and Complications of the Treatment||Helsinki University Central Hospital||Recruiting|September 2015|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Female|18 Years|90 Years|No|||February 2016|February 2, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02538991||13930|
NCT02535117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC 003|Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC|Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Initial Partial Hepatectomy: A Multicenter Experience||Sun Yat-sen University|Yes|Active, not recruiting|June 2015|July 2020|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|N/A|N/A|No|||August 2015|August 25, 2015|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02535117||14228|
NCT02562963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT-THU2015|Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor|Phase 1/2 Study of Natural Killer T Cell Infusion in Patients With Advanced Solid Tumor||Tsinghua University|Yes|Recruiting|November 2015|December 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||November 2015|November 3, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02562963||12090|
NCT02563197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17607|Inhalation Flow Rate-study|An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler||Bayer|No|Active, not recruiting|November 2015|April 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02563197||12072|
NCT02571270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEPJMF-001|12-Week-Combined Physical Training In Heart Failure Patients|Impact Of Supervised 12-Week-Combined Physical Training In Heart Failure Patients: A Randomized Trial||Universidade Estadual Paulista Júlio de Mesquita Filho||Completed|March 2015|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|75 Years|No|||October 2015|October 6, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571270||11452|
NCT02566798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0173|Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive|Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive|OléograpeSEED|Nantes University Hospital|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|50 Years|N/A|No|||September 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566798||11796|
NCT02566811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0630|Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)|A Randomised Trial of Non-selective Versus Selective Adjuvant Therapy in High Risk Apparent Stage 1 Endometrial Cancer|STATEC|University College, London|Yes|Not yet recruiting|June 2016|||June 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Female|16 Years|N/A|No|||February 2016|February 19, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02566811||11795|
NCT02574819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTQ-MNTX|Study of Methylnaltrexone in Opioid-Induced Constipation Patients|Methylnaltrexone (MNTX) for Treatment of Opioid-induced Constipation in Advanced Illness Patients : a Multicenter, Randomized, Double-blind , Placebo-controlled Trail||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Recruiting|April 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|80 Years|No|||October 2015|October 10, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574819||11179|
NCT02575183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI195422|Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation|Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation||American University of Beirut Medical Center|No|Not yet recruiting|October 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||September 2015|October 13, 2015|March 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02575183||11151|
NCT02569229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-143|Glucose Tolerance in Children With Cystic Fibrosis|Glucose Tolerance and Its Clinical Impact in Children and Adolescents With Cystic Fibrosis|GluTolCF|University Hospital, Basel, Switzerland|Yes|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Glucose, C-Peptide, Insulin, HbA1c in blood specimen.|Both|10 Years|20 Years|No|Non-Probability Sample|Patients with genetically determined cystic fibrosis.|October 2015|October 2, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02569229||11609|
NCT02567058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORT 2011-FP / MEDUSAA|Biomechanical and Ultrasonic Assessment of the Achilles Tendon in Vivo (MEDUSAA)|Biomechanical and Ultrasonic Assessment of the Achilles Tendon in Vivo (MEDUSAA)|MEDUSAA|University Hospital, Tours|No|Completed|December 2012|August 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|62|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567058||11776|
NCT02577432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/REC/2013|Two Syringe Spinal Anesthesia Technique for Cesarean Section: A Simple Way to Achieve More Satisfactory Block and Less Hypotension|Two Syringe Spinal Anesthesia Technique for Cesarean Section: A Controlled Randomized Study of a Simple Way to Achieve More Satisfactory Block and Less Hypotension||Dr. Soliman Fakeeh Hospital|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Female|N/A|N/A|No|||October 2015|October 19, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02577432||10978|
NCT02577497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18422|Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma|Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma|EXPAND|University of Virginia|Yes|Recruiting|March 2016|February 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|17 Years|No|||March 2016|March 14, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577497||10973|
NCT02576899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1756-P|Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence|Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence|ACT-PT|VA Office of Research and Development|No|Recruiting|September 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02576899||11019|
NCT02576912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015242|Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone|Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone|THC-Preg|Yale University|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576912||11018|
NCT02569528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059115|ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1|ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1|INFORM-AF|Duke University|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will include 100 patients and 10 physicians, who are caring for those patients in        the outpatient setting.|February 2016|February 22, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02569528||11586|
NCT02569775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBG 001|Outcomes of Stem Cells for Cerebral Palsy|Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial||Vinmec International Hospital|No|Completed|April 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|1 Year|15 Years|No|||October 2015|October 15, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569775||11567|
NCT02571595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-368-BMB|A Sleep Program to Improve Sleep Quality in People With HIV|Efficacy Potential of an Internet-based Sleep Program to Improve Sleep Quality in People With HIV||McGill University|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|35 Years|N/A|No|||October 2015|October 6, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02571595||11427|
NCT02578173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150682H|Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0|Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|October 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cardiovascular disease who are undergoing clinically indicated coronary or        peripheral angiography|October 2015|October 15, 2015|October 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578173||10921|
NCT02574975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhujiangH|Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics|Comparison of Different Methodologies Assessing Airway Responsiveness and Investigation of Treatment Efficacy of Budesonide /Formoterol in Asthmatics||Zhujiang Hospital|Yes|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|80|||Both|14 Years|65 Years|No|||October 2015|October 15, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574975||11167|
NCT02568215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 703/HPTN 081|Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women|A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1500|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568215||11687|
NCT02573285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1188|Spontaneous Pneumothorax in Children|Simple Aspiration for Initial Management of Primary Spontaneous Pneumothorax in Children: A Multi-Center Pilot Study||University of Wisconsin, Madison|Yes|Recruiting|September 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02573285||11297|
NCT02578186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013063|Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness|Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness||Procter and Gamble|No|Completed|November 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578186||10920|
NCT02570425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR00114|Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices|THE HCP ELIOT STUDY: Comparing Maintenance of Device Mastery With TURBOHALER© vs. SPIROMAX© in Healthcare Professionals naïve to Both Devices (The Easy Low Instruction Over Time [ELIOT] Study)|HCP-ELIOT|Research in Real-Life Ltd|Yes|Completed|July 2014|June 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|462|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02570425||11517|
NCT02570685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GratitudeJournal2015|Psychosocial Benefits of Gratitude Journals|Psychosocial Benefits of Gratitude Journals: A Randomized Controlled Intervention Trial||University of Limerick|No|Completed|October 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570685||11497|
NCT02577341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-FXY-061|Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer|A Prospective, Double-blinded, Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer||Sun Yat-sen University|No|Recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577341||10985|
NCT02571088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408030|Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients|Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients: Benefits on Physical Ability and Skeletal Muscle. An Interventional Pilot, Multicentric, Prospective, Longitudinal Study|EXDRE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02571088||11466|
NCT02571192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP626-102|A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose|A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects||Shire|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571192||11458|
NCT02576054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-200|Safety and Tolerability Study of V501 in Japanese Boys (V501-200)|A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys||Merck Sharp & Dohme Corp.|No|Active, not recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Male|9 Years|15 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576054||11084|
NCT02574845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2094|DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)|The Effect of Different Doses of Metformin or Furosemide on Rosuvastatin Pharmacokinetics Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-way Crossover Study)||Boehringer Ingelheim||Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 12, 2015||||No||https://clinicaltrials.gov/show/NCT02574845||11177|
NCT02577380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council # 640|Addressing Gender Based Violence in HIV Testing and Counseling|Addressing Gender Based Violence in HIV Testing and Counseling||Population Council|No|Completed|June 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02577380||10982|
NCT02577393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTEEC-2015|Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy|||Shandong Cancer Hospital and Institute|No|Enrolling by invitation|June 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02577393||10981|
NCT02562807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10060040|A Study of TAS-303 in Female Patients With Stress Urinary Incontinence|A Phase I Study of TAS-303 in Female Patients With Stress Urinary Incontinence||Taiho Pharmaceutical Co., Ltd.|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|32|||Female|20 Years|64 Years|No|||February 2016|February 23, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02562807||12102|
NCT02563054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17032|A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer|An Open-Label Randomized International Multi-Center Phase III Study of Capecitabine (Xeloda) in Combination With Cisplatin Versus FU/Cisplatin in Patients With Advanced and/or Metastatic Gastric Cancer||Hoffmann-La Roche||Completed|April 2003|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02563054||12083|
NCT02572037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL2014001|Research and Clinical Value of New Classification for Premature Ejaculation|Research and Clinical Value of New Classification for Premature Ejaculation||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Not yet recruiting|October 2015|April 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Male|18 Years|60 Years|No|Probability Sample|Adult males with sympton of premature ejaculation, excepting for other diseases.|October 2015|October 7, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02572037||11393|
NCT02572050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0191|Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection|Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer|AaRon|National Cancer Center, Korea|Yes|Not yet recruiting|October 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|19 Years|N/A|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572050||11392|
NCT02561728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1748|Hanger Helmet Study|Prospective Study to Evaluate Effectiveness of the Hanger Helmet vs the P Pod Helmet in Improving the Head and Face Symmetry||Children's Hospital Medical Center, Cincinnati|No|Not yet recruiting|November 2015|October 2023|Anticipated|October 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|10 Months|No|||November 2015|November 10, 2015|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02561728||12185|
NCT02564926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690L00067|Foxiga Korea Local Phase 4 Study|Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin|BEYOND|AstraZeneca|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|19 Years|75 Years|No|||March 2016|March 21, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02564926||11940|
NCT02566070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150311|COntinuous vs BOlus Nasogastric Feeding in Mechanically Ventilated Pediatric Patients 2|COntinuous vs BOlus Nasogastric Feeding in Mechanically Ventilated Pediatric Patients 2|COBO2|Akron Children's Hospital|Yes|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|860|||Both|1 Month|12 Years|No|||January 2016|January 20, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02566070||11852|
NCT02566083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIOL-202-TPAS|Post-Approval Study of the Tecnis® Toric IOL|Post-Approval Study of the Tecnis® Toric IOL, Models ZCT300 and ZCT400||Abbott Medical Optics|No|Recruiting|October 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|435|||Both|22 Years|N/A|No|||October 2015|October 29, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566083||11851|
NCT02574949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-8832-AE|Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Dose|Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Radiation Dose and Impact on Image Quality During Cardiac Catheterization||University Health Network, Toronto|No|Not yet recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|600|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02574949||11169|
NCT02570256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RehabilitationIC|Deficit Fields for Stroke Recovery|Error-enhanced Learning & Recovery in 2 & 3 Dimensions||Rehabilitation Institute of Chicago||Recruiting|May 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02570256||11530|
NCT02572622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HacettepeUN|Comparison of Different Treatment Methods in Lumbal Disc Herniation Treatment|Lumbal Disk Herniasyonunda Farklı Tedavi Yöntemlerinin Karşılaştırılması||Hacettepe University|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02572622||11348|
NCT02577718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NiCE|Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution|Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients||Novel Anti-Infective Technologies, LLC||Enrolling by invitation|November 2015|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02577718||10956|
NCT02578329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R194/14 - CCM203|An Intervention Study to Assess the Effect of the Mediterranean Diet on the Plasma Fatty Acid Profile|A Randomized Intervention Study to Assess the Effect of the Mediterranean Diet on the Plasma Fatty Acid Profile|RISMED|Centro Cardiologico Monzino|No|Recruiting|July 2015|February 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|30 Years|75 Years|No|||October 2015|October 15, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02578329||10909|
NCT02577549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01AR068658-01|Weight Loss and Exercise for Communities With Arthritis in North Carolina|Weight Loss and Exercise for Communities With Arthritis in North Carolina|WE-CAN|Wake Forest School of Medicine|Yes|Not yet recruiting|January 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|820|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02577549||10969|
NCT02576366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TacDDI151010|Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus|Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|June 2016|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02576366||11060|
NCT02570516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140108|NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome|Comparison of Colonoscopy With Virtual Chromoendoscopy Using 3rd Generation NBI System to Chromoendoscopy With Indigo Carmine in Lynch Patients.|LYNCH-CHROMO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02570516||11510|
NCT02564978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150202|Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration|Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Recruiting|September 2015|March 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|55 Years|N/A|No|||September 2015|October 27, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02564978||11936|
NCT02577562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-541 CA|Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study|Zenith® Fenestrated AAA Endovascular Graft Clinical Study||Cook||Active, not recruiting|May 2010|April 2017|Anticipated|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02577562||10968|
NCT02577588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2009-11-03-1055|Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer|Phase I Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer|ATACC|National Center for Tumor Diseases, Heidelberg|Yes|Not yet recruiting|April 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02577588||10966|
NCT02572791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3177 60559|Staph Household Intervention for Eradication (SHINE)|Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection|SHINE|Washington University School of Medicine|Yes|Recruiting|October 2015|July 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|207|||Both|N/A|18 Years|No|||October 2015|October 19, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02572791||11335|
NCT02572804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V15-02041|Comparing Rectus Sheath Catheter to Epidural Post Cystectomy|A Randomised Controlled Trial of Thoracic Epidural Analgesia Versus Surgically Placed Rectus Sheath Catheters for Open Radical Cystectomy: Is There a Difference in Patient Outcomes?||Vancouver Coastal Health|No|Recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|19 Years|N/A|No|||October 2015|October 8, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572804||11334|
NCT02577614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11975|FEIBA and Use of Blood Products in Cardiac Surgery|Factor VIII Inhibitor Bypass Activity (FEIBA) for the Reduction of Transfusion in Cardiac Surgery: A Randomized Double Blind Placebo Controlled Pilot Trial|FEIBA|Oregon Health and Science University|Yes|Not yet recruiting|February 2016|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|100 Years|No|||February 2016|February 3, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02577614||10964|
NCT02576561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX 02-01|Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL|Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL||THEVAX Genetics Vaccine|Yes|Recruiting|November 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|9||Anticipated|51|||Female|21 Years|50 Years|No|||March 2016|March 23, 2016|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576561||11045|
NCT02565550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G10|Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome|Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome||Shandong University|Yes|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565550||11892|
NCT02570841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA738B0401|Pain Thresholds Under High-dose Topical Capsaicin|Heat-, Cold-, and Mechanical Pain Thresholds Under Exposition of High Dose Topical Capsaicin||Medical University of Vienna|No|Completed|February 2015|September 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02570841||11485|
NCT02577757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-Promoteur 2012-04|Establishing the Language Network With Independent Component Analysis of Resting State MRI||ICA Langage|University Hospital, Angers|No|Recruiting|November 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|7 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02577757||10953|
NCT02567110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083464|Magnetic Resonance Spectroscopy (MRS) in Midlife Depression|Inflammation-Induced Central Nervous System (CNS) Glutamate as a Function of Depression in Middle Age||Emory University|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|160|Samples With DNA|inflammatory gene expression studies, APOE4 genotyping|Both|50 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients who have a diagnosis of depression or bipolar depression and men        and women without a diagnosis of depression or bipolar depression in the control group|January 2016|January 22, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02567110||11772|
NCT02561715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_14-096|Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study for People With Parkinson's|Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study to Examine the Effects of Anosognosia on Self-Reported Quality of Life for People With Parkinson's||University of Birmingham|No|Recruiting|August 2015|November 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Parkinson's due for deep brain surgery|September 2015|September 25, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02561715||12186|
NCT02564640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AntalyaTRH 008|Comparison of Hemodynamic Changes by Using the Videolaryngoscope and the Macintosh Laryngoscope|Comparison of Hemodynamic Changes After Endotracheal Intubation by Using the Videolaryngoscope and the Macintosh Direct Laryngoscope in Elderly Hypertensive Patients||Antalya Training and Research Hospital|No|Completed|June 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|65 Years|90 Years|No|||June 2015|December 8, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564640||11962|
NCT02566291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGA 2014|Observational Study With Investigation of Two Second Generation Laryngeal Masks|Supraglottic Airways LMA Supreme and Ambu AuraGain in Clinical Practice: a Prospective Observational Study|OSSGA|Johannes Gutenberg University Mainz|No|Completed|January 2015|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|364|||Both|18 Years|N/A|No|Probability Sample|Inclusion criteria:        Age > 18 Years informed consent elective surgery undergoing general anesthesia        non-pregnant|September 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566291||11835|
NCT02570347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIP/IEC/2015/17/649|Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite|Routine vs. Clinically-Directed Antibiotic Treatment in Snake Bite With Local Envenomation: a Randomised Controlled Trial|RADIANS|Jawaharlal Institute of Postgraduate Medical Education & Research|No|Not yet recruiting|November 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570347||11523|
NCT02577848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1-301xnk|GLP-1 on Non-ST-Segment Elevation Myocardial Infarction|Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction||Chinese PLA General Hospital|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02577848||10946|
NCT02584725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAM9601|Tranexamic Acid Dosing for Total Joint Arthroplasty|Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty||Columbia University|No|Completed|December 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584725||10418|
NCT02569541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE06-302|Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated|An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated||Cempra Inc|No|Recruiting|December 2015|December 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|N/A|No|||February 2016|February 2, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569541||11585|
NCT02566538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 400 03|Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging (MonaLisaPredor)|Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging|MLP|University Hospital, Toulouse|No|Recruiting|May 2013|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|Blood|Both|42 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|The design is a prospective cohort study carried out among 1500 men and women from the        general population, aged 42-89 years,and living in South-western France. Except for        participants aged 80-89 years, all participants have been previously assessed in        2005-2007, as regard to their psychometric and cognitive performances and level of        cardiovascular risk, as part of the Mona Lisa study.|September 2015|September 30, 2015|May 24, 2013||No||No||https://clinicaltrials.gov/show/NCT02566538||11816|
NCT02576704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-30|Prognostic Value of Myocardial Perfusion Heterogeneity in Normal SPECT Studies|Prognostic Value of Myocardial Perfusion Heterogeneity in Normal Dual Isotope High Speed Myocardial Perfusion Imaging With a Semi Conductor Gamma Camera.|PROMETHE|University Hospital, Grenoble|Yes|Recruiting|August 2014|September 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|18 Years|N/A|No|Non-Probability Sample|Study cohort Patient referred to the Nuclear Cardiology Laboratory of the University        Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis        evaluation of suspected or know coronary artery disease, whose myocardial stress imaging        was normal or with Summed stress score (SSS) < or = 4.|December 2015|December 28, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576704||11034|
NCT02576717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-3001|A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis|A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis||Celgene|Yes|Active, not recruiting|October 2015|||June 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2350|||Both|N/A|N/A|No|||March 2016|March 3, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576717||11033|
NCT02584985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAP-GRECCAR 11-IPC 2015-005|Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer|A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11)|ETAP|Institut Paoli-Calmettes|Yes|Not yet recruiting|January 2016|January 2022|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Female|18 Years|N/A|No|||October 2015|January 14, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02584985||10398|
NCT02561780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010011|Impact of a Mental Health Curriculum for High School Students on Knowledge and Stigma|Youth Mental Health Awareness Study and Early Intervention Research Project||University of Ottawa|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|534|||Both|14 Years|19 Years|No|||September 2015|September 24, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02561780||12181|
NCT02566486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-27194235-03|Postoperative Pain Intensity After Using Different Instrumentation Techniques: a Randomized Clinical Study|Postoperative Pain Intensity After Using Different Instrumentation Techniques: a Randomized Clinical Study||Bulent Ecevit University|Yes|Completed|November 2013|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Both|21 Years|65 Years|No|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02566486||11820|
NCT02567084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POZNAN-UMS-JK1|Complete Twelve Month Bone Remodeling With a Bi-phasic Injectable Bone Substitute in Benign Bone Tumors|A Prospective, Longitudinal Patient Study on CERAMENT™/BONE VOID FILLER in Benign Bone Tumors|BRBBT|Poznan University of Medical Sciences|Yes|Completed|February 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|7 Years|75 Years|No|||October 2015|October 1, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02567084||11774|
NCT02562196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect_tDCS_Migraine|tDCS for the Treatment of Migraine|Effect of Transcranial Direct Current Stimulation (tDCS) Optimized Protocol for the Treatment of Migraine||Universidade Federal de Pernambuco|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|55 Years|No|||September 2015|September 28, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02562196||12149|
NCT02588872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012103-AM02|Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis|Hyaluronic Acid vs Platelet Rich Plasma: Prospective Double-blind Randomized Controlled Trial Comparing Clinical Outcomes and the Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis|HA vs PRP|Rush University Medical Center|No|Completed|August 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02588872||10100|
NCT02571114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014:121|Glycemic and Metabolic Responses of Frozen Yogurt Containing Saskatoon Berry Powder in Healthy Males and Females|A Randomized, Controlled Study to Examine the Glycemic and Metabolic Responses of Frozen Yogurt Containing Saskatoon Berry Powder in Healthy Males and Females||University of Manitoba|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571114||11464|
NCT02572193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H1|To Assess the Feasibility of Same Day Discharge Following a POEM Procedure|To Assess the Feasibility of Same Day Discharge Following a POEM Procedure|POEM2|McMaster University|No|Not yet recruiting|October 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02572193||11381|
NCT02562482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRC 704|Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults|Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562482||12127|
NCT02562716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1505|S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Randomized Phase II Study of Perioperative mFolfironix Versus Gemcitabine/Nab-paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma||Southwest Oncology Group|Yes|Recruiting|October 2015|||October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562716||12109|
NCT02571153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCSP 057539/2015|Low Doses of Ketamine and Postoperative Quality of Recovery|Effects of Low Doses of Ketamine on Postoperative Quality of Recovery After Total Intravenous Anesthesia||Pontificia Universidade Catolica de Sao Paulo|No|Recruiting|September 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|60 Years|No|||October 2015|October 6, 2015|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571153||11461|
NCT02574078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-370|A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370)|A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)||Bristol-Myers Squibb|Yes|Recruiting|November 2015|April 2022|Anticipated|April 2022|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|1953|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574078||11236|
NCT02574091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-ICC-NZ-I01|Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients|A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Healthy Adult Participants, Followed by Patients With Mild to Moderate Psoriasis||Betta Pharmaceuticals Co.,Ltd.|No|Not yet recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|October 8, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02574091||11235|
NCT02572440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z13110700213134|Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation|Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University||Beijing Anzhen Hospital||Temporarily not available|October 2014|||June 2015|Actual|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02572440||11362|
NCT02542280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abahaa050301|Does Endometrial Injury Improve Intrauterine Insemination Outcome?|Endometrial Injury May Increase the Pregnancy Rate in Patients Undergoing Intrauterine Insemination||Ain Shams Maternity Hospital|Yes|Completed|July 2013|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|360|||Female|18 Years|38 Years|No|||November 2015|December 3, 2015|September 3, 2015||No||No|October 2, 2015|https://clinicaltrials.gov/show/NCT02542280||13679|
NCT02542371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001832|Use of 99mTc Tilmanocept for Imaging Arterial Inflammation|Use of 99mTc Tilmanocept for Imaging Arterial Inflammation||Massachusetts General Hospital||Enrolling by invitation|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|18|Samples Without DNA|whole blood, plasma and serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected subjects and HIV non-infected subjects|March 2016|March 22, 2016|August 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02542371||13673|
NCT02539953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH1002|Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy|||King's College Hospital NHS Trust|Yes|Not yet recruiting|April 2015|||September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2015|September 2, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539953||13857|
NCT02539966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT6200|Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold|Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold|FANTOM II|REVA Medical, Inc.|Yes|Active, not recruiting|March 2015|October 2020|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02539966||13856|
NCT02567188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22439|A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis|||Hoffmann-La Roche||Completed|April 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|144|||Both|18 Years|N/A|No|Non-Probability Sample|Adult participants with CKD Stage 3-4 treated with MIRCERA|January 2016|January 14, 2016|September 28, 2015|No|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT02567188||11766|
NCT02567435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01644|Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma|A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)||National Cancer Institute (NCI)||Not yet recruiting|June 2016|||November 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|465|||Both|N/A|40 Years|No|||October 2015|March 7, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567435||11747|
NCT02573584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500864|Vascular Fingerprint Validation Study|Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study||University Medical Center Groningen|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|178|||Male|18 Years|50 Years|No|Probability Sample|Newly diagnosed testicular cancer patients before start of chemotherapy.|October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573584||11274|
NCT02564341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA037768-A|Targeting Effective Analgesia in Clinics for HIV - Intervention|Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Intervention Component|TEACH|Boston Medical Center|No|Active, not recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02564341||11984|
NCT02571361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-KHT-2015 - v2|PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial|PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial|PANSAID|Naestved Hospital|No|Recruiting|November 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|556|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571361||11445|
NCT02565030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18804|Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome|Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|September 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|Patients referred to Sheffield Pulmonary Vascular Disease Unit from the Midlands , North        of England & Wales.|October 2015|October 1, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02565030||11932|
NCT02565043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT13/01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2015|||||N/A|N/A|N/A||||||||||||||September 29, 2015|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02565043||11931|
NCT02565056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156756|Feasibility RCT of ACT Self-help for Depression in Haemodialysis|Acceptance and Commitment Therapy Self-help Intervention for Depression in Haemodialysis Patients: A Feasibility Randomised Controlled Trial||University of Lincoln|No|Recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565056||11930|
NCT02576860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS001-CO-PR-005|Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle|A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period||Cutanea Life Sciences, Inc.|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02576860||11022|
NCT02576873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|455/56|Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration|Long-term Outcome of End-stage Renal Disease Patients Treated With High-efficiency Hemodiafiltration: a Historical Cohort of a Single-center in South East Asia||Chulalongkorn University|No|Recruiting|March 2014|November 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|66|||Both|18 Years|N/A|No|Non-Probability Sample|End-stage renal disease patients who had been received long-term hemodiafiltration at King        Chulalongkorn Memorial hospital during 2001-2013|October 2015|October 13, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576873||11021|
NCT02573142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066366|Integrated Child Obesity Treatment Study: Bull City Healthy and Fit|A Novel Healthcare-Community Partnership for Childhood Obesity Treatment: A Randomized Pilot Study|BCHF|Duke University|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|11 Years|No|||October 2015|October 8, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02573142||11308|
NCT02571478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20150096H|Evaluation of a Brief Marriage Intervention for Internal Behavioral Health Consultants in Military Primary Care|Evaluation of a Brief Marriage Intervention for Internal Behavioral Health Consultants in Military Primary Care||Wright State University|No|Not yet recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02571478||11436|
NCT02574897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1404|The Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Chemotherapy|Evaluating the Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Intensive Chemotherapy||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|July 2014|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02574897||11173|
NCT02563483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yoga caregivers|Yoga for Family Caregivers of Alzheimers Disease Patient|A Yoga and Compassion Meditation Program Improve Quality of Life and Self-compassion in Family Caregivers of Alzheimer's Disease Patients: a Randomized Controlled Trial||Federal University of São Paulo|No|Completed|September 2007|November 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563483||12050|
NCT02573207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Recovery of Hibernating Myocardium in End Stage Heart Failure||RHIMES-HF|Intermountain Health Care, Inc.|No|Not yet recruiting|December 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|94|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (>= 18 years old) with end stage ischemic cardiomyopathy receiving a LVAD        at the U.T.A.H. Cardiac Transplant Program. We will exclude subjects with acute forms of        heart failure and patients with left ventricular ejection fraction (LVEF) < 40% and        non-obstructive coronary artery disease.|September 2015|October 7, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573207||11303|
NCT02563353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150121|PTH and Vibration in OSteoporosis Study|PTH and Vibration in OSteoporosis (PaVOS) Study|PaVOS|Odense University Hospital|Yes|Recruiting|November 2015|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Female|50 Years|N/A|No|||December 2015|December 3, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02563353||12060|
NCT02563366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCs-KTx-DCD-150925|Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.|Effect of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Recovery of Poor Early Graft Function Post Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University||Not yet recruiting|November 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563366||12059|
NCT02565797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOS-2015-CT01-1|Comparative Prevention-effectiveness Trial of DabirAIR Overlay System|A Point-of-care, Pragmatic Comparative Prevention-effectiveness Trial of DabirAIR Alternating Pressure Overlay System to Reduce Hospital-acquired Pressure Ulcers in the Peri-operative Setting.||Dabir Surfaces Inc|No|Recruiting|November 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|800|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02565797||11873|
NCT02565810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB5-G21-RA|An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis|An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis||Samsung Bioepis Co., Ltd.|No|Active, not recruiting|September 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|55 Years|No|||September 2015|December 2, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565810||11872|
NCT02577107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ACN07|Head to Head Study of Anti-VEGF Treatment.|An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD|RELIANCE|Novartis|No|Not yet recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|N/A|N/A|No|||October 2015|October 13, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02577107||11003|
NCT02562287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32356214200005327|Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder|A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02562287||12142|
NCT02562300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Utrotonics during CS|Uterotonics Using to Reduce Bleeding at Cesarean Section|Comparative Study of Sublingual Misoprostol Versus Oxytocin in Reducing Bleeding at Cesarean Section||Assiut University|No|Completed|January 2014|April 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Female|20 Years|40 Years|No|||January 2014|September 27, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02562300||12141|
NCT02563613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFKM|Happy Family Kitchen Movement Project|Happy Family Kitchen Movement, A Community-based Research to Enhance Family Health, Happiness and Harmony in Hong Kong: A Cluster Randomized Controlled Trial|HFKM|The University of Hong Kong|No|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|4000|||Both|12 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02563613||12040|
NCT02563626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAR|Coronary Artery Aneurysm Registry|Coronary Artery Aneurysms: Incidence, Management and Long Term Prognosis|CAAR|St Carlos Hospital, Madrid, Spain|No|Recruiting|September 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a coronary aneurysm diagnosis.|September 2015|January 31, 2016|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02563626|12 Months|12039|
NCT02574780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA,801|Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy|Lymphedema Treatment of Post-surgical Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy|LTP|Federal University of São Paulo|Yes|Active, not recruiting|April 2014|September 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574780||11182|
NCT02577965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/01/2011-2|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial|OCTAVIA|A.O. Ospedale Papa Giovanni XXIII|Yes|Completed|March 2011|September 2014|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02577965||10937|
NCT02577978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00090745|Stability of the Medial Pivot Total Knee Prosthesis|Stability of the Medial Pivot Total Knee Prosthesis||Northwestern University|No|Completed|April 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02577978||10936|
NCT02578030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP465-111|Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD|A Phase 1, Open-label Study of the Pharmacokinetics of d- and L-amphetamine After a Single Dose of SHP465 12.5 mg or 25 mg Administered to Children and Adolescents Aged 6 to17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|6 Years|17 Years|No|||November 2015|November 17, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578030||10932|
NCT02574052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEC-C-2014-094|Medical College Students' Responds to Menu Labeling|Medical College Students' Responds to Menu Labeling With or Without Nutrition||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Completed|October 2014|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02574052||11238|
NCT02563171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-115-17/06|Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Vaspin and Omentin-1 in Obese Patients With Chronic Periodontitis||Bulent Ecevit University|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|30 Years|49 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563171||12074|
NCT02578043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBG 1508|A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris|A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|April 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|844|||Both|12 Years|40 Years|No|||October 2015|October 15, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578043||10931|
NCT02568020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Keto-019-IP3|LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD|Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|No|Not yet recruiting|December 2015|May 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2015|September 30, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568020||11702|
NCT02568566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01645|Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants|A Prospective, Single-Arm, Open-Label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls||National Cancer Institute (NCI)|Yes|Not yet recruiting|April 2016|||August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|143|||Female|9 Years|11 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568566||11660|
NCT02568579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050219|Infant Immunity Comparison of Breastfed and Bottlefed Infants|Effects of Breastfeeing in Immunologic Priming in Young Infants||Duke University|No|Recruiting|January 2015|August 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Four 2.6 ml ACD tubes will be collected . All blood will be processed for pyrosequencing,      TBNK, CBC and differential, platelets, sera plasman and PBMC's. Stool samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|-  Pregnant women 18 years of age or older.          -  Vaginal delivery          -  Healthy, full-term babies.          -  Willing to primarily (> 75%) breastfeed or exclusively formula feed for at least the             first 4 months of life.          -  Willing to follow the American Academy of Pediatrics' Immunizations guidelines.|August 2015|October 2, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02568579||11659|
NCT02574910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112014-087|Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1|A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|2 Years|9 Years|No|||October 2015|October 9, 2015|April 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574910||11172|
NCT02574923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBG 002|Outcomes of Stem Cells for Cerebral Palsy|Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial||Vinmec International Hospital|No|Recruiting|November 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|15 Years|No|||December 2015|December 4, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02574923||11171|
NCT02566421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU # 01615|Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery|Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02566421||11825|
NCT02568540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00018023|C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study|preSmartphone App for Monitoring and Reporting of Hepatitis C Related Health Information: C Tracker Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study|CTracker|Children's Hospital Boston|No|Recruiting|October 2015|September 2020|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who have been diagnosed with Hepatitis C.|October 2015|October 9, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02568540||11662|
NCT02569632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrensHRCOakland|Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)|Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure||Children's Hospital & Research Center Oakland|No|Recruiting|January 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569632||11578|
NCT02576236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140928|Therapeutic Trial Comparing Empiric Sequential Treatment vs Sequential Treatment Guided by the Determination of the Resistance to Clarithromycin by PCR vs. Quadruple Bismuth Therapy for Helicobacter Pylori Infection|Comparison of the Efficacy of Sequential Treatment Guided by the PCR Detection of Clarithromycin Resistance and Quadruple Bismuth Therapy With Empirical Sequential Treatment for Helicobacter Pylori Infection: A Randomised Multicentre Trial|Hepysé|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|October 2015|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|950|||Both|18 Years|N/A|No|||August 2015|October 14, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02576236||11070|
NCT02572557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TruFreeze cryotherapy|TruFreeze Cryotherapy Central Airway Disease|A Prospective Evaluation of Spray Cryotherapy in Patients With Malignant and Benign Central Airway Disease||University Medical Center Groningen|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||October 2015|October 7, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02572557||11353|
NCT02564679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSG_metabolic profile|Sleeve Gastrectomy in Adolescents With Complicated Morbid Obesity and NAFLD|Effects of Sleeve Gastrectomy on Hepatic and Metabolic Abnormalities in Adolescents With Complicated Morbid Obesity and NAFLD||Bambino Gesù Hospital and Research Institute|No|Completed|July 2014|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|13 Years|17 Years|No|||September 2015|September 29, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02564679||11959|
NCT02561897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPRF2015-01|EdoxabaN or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-Valvular Atrial Fibrillation|A Phase 4, Randomized, Open Label, Multicenter, Prospective Comparative Study to Evaluate the Efficacy and Safety of Edoxaban or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-valvular Atrial Fibrillation|ENTICED-AF|Electrophysiology Research Foundation|Yes|Recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02561897||12172|
NCT02569723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#255|Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy|Pilot Study of a Carbon 14 Oxaliplatin Microdosing Assay to Predict Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer||University of California, Davis|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569723||11571|
NCT02562274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 571373|Evaluation of Consumption Safety and Effect of Mulberry Leaves and Vietnamese Coriander Based Instant Polyherbal Porridge on Working Memory and Bone Formation Markers|Evaluation of Consumption Safety and Effect of Mulberry Leaves and Vietnamese Coriander Based Instant Polyherbal Porridge on Working Memory and Bone Formation Markers||Khon Kaen University|Yes|Completed|September 2014|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02562274||12143|
NCT02568813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-834|Epilepsy and Mood Regulation Disorder in Children|Epilepsy and Mood Regulation Disorders: a Prospective and Longitudinal Study in Children With Newly Diagnosed Epilepsy|EPILETRE|Hospices Civils de Lyon|No|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|300|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||September 2015|October 2, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568813||11641|
NCT02573532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL-PMI|Incidence, Patient Characteristics, Pathophysiology, and Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery|Basel Incidence, Patient Characteristics, Outcome and Possible Strategies to Improve Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery: 1-Year Follow-up|BASEL-PMI|University Hospital, Basel, Switzerland|No|Recruiting|October 2015|February 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|45 Years|N/A|No|Probability Sample|Consecutive patients that underwent a systematic approach to PMI detection at University        Hospital Basel, a tertiary care center, will be included.        The screening consists of a pre-operative "baseline" measurement of hs-cTnT within 30 days        prior to surgery, and two post-operative measurements taken on the first and second day        after surgery. Screening is done in patients requiring hospitalization >24 hours after        surgery AND (aged ≥ 65 years OR history of coronary artery disease OR peripheral artery        occlusive disease OR cerebrovascular disease). Patients are seen by a cardiologist in case        of detection of a PMI.|October 2015|October 8, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02573532||11278|
NCT02562144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Isala|A Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults|A Randomized Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults|Xylocaine|Isala|No|Not yet recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 26, 2015|September 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562144||12153|
NCT02565355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106580|Targeted Food Elimination for Treatment of Functional Gastrointestinal Diseases in Children|Randomized Controlled Trial of Food Elimination Based on IgG Antibodies for Treatment of Functional Gastrointestinal Diseases (FGIDs) in Children|FGID|Lawson Health Research Institute|No|Not yet recruiting|September 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02565355||11907|
NCT02565368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158BE15008|A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|19 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02565368||11906|
NCT02565381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001300|A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers|The QUIT Smoking Study: A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care to Help Homeless Smokers Quit Smoking|QUIT|Massachusetts General Hospital|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02565381||11905|
NCT02562534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A01406-37|Creation of an ECG Database in 3T MRI With Healthy Heart and Several Kind of Cardiac Disease.|Use of a New ElectroCardioGraph to Create an ECG Database in 3T MRI With Healthy Heart and Several Kind of Cardiac Disease in Order to Let go of Artifacts.|DB-ECG-3T|Central Hospital, Nancy, France|No|Recruiting|January 2014|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562534||12123|
NCT02577731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 106-2013|Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury|Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury||University of Florida|No|Recruiting|January 2014|October 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|110|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02577731||10955|
NCT02562430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P000889|Neurobiological Underpinnings of Placebo Response in Depression|Neurobiological Underpinnings of Placebo Response in Depression||Massachusetts General Hospital|Yes|Not yet recruiting|September 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||September 2015|September 25, 2015|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02562430||12131|
NCT02562664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPCOS|Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients|Insulin Sensitizing Agent (Metformin) Improves Clinical Pregnancy Rate and Insulin Parameters in Polycystic Ovarian Syndrome Patients With Acanthosis Nigricans||Assiut University||Completed|January 2014|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Female|20 Years|40 Years|No|||January 2014|September 29, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02562664||12113|
NCT02573090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCopenhagen1|Sealing Manifest Occlusal Caries Lesions in the Permanent Dentition|SEAL-DK: Sealing Manifest Occlusal Caries Lesions in the Permanent Dentition in Children and Adolescents. RCT|SEAL-DK|University of Copenhagen|Yes|Active, not recruiting|November 2006|December 2019|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|521|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573090||11312|
NCT02573103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHuang|Air Pollution and Lipids Metabolic Disorder|Air Pollution and Lipids Metabolic Disorder||Peking University|Yes|Active, not recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples Without DNA|plasma and urine|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will maintain enrollment criteria of the in-progress study being 50 healthy adults        without CV disease or risk factors|October 2015|October 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02573103||11311|
NCT02565485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 15-00366|Pulse Pressure and Post-epidural Fetal Heart Rate Changes|Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial||MetroHealth Medical Center|No|Recruiting|September 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|276|||Female|18 Years|50 Years|No|||September 2015|September 30, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02565485||11897|
NCT02572206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7107|PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations|Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers||New York State Psychiatric Institute|Yes|Enrolling by invitation|September 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||December 2015|March 17, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02572206||11380|
NCT02574533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL-123|Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma|A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma Refractory or Recurrent to Checkpoint Inhibitor Therapy||Gradalis, Inc.|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02574533||11201|
NCT02566161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999915199|Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)|Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)||National Institutes of Health Clinical Center (CC)||Not yet recruiting|September 2015|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1500|||Both|18 Years|70 Years|No|||September 2015|October 1, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02566161||11845|
NCT02569255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAC and PVI 2015|Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation|Safe Use of New Oral Anticoagulants in Patients Treated by Catheter Ablation for Atrial Fibrillation||Private Hospital Heart Center Varde|No|Completed|November 2011|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|234|||Both|N/A|N/A|No|Non-Probability Sample|Patients with paroxysmal or persistent atrial fibrillation and symptomatic despite        pharmacological treatment.|October 2015|October 2, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02569255||11607|
NCT02575482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP140105HT4|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-D4010 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects||Suven Life Sciences Limited|Yes|Recruiting|July 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02575482||11128|
NCT02569385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 15-034|Examination of Cardiovascular Function/ Cardio Respiratory Interaction on Spontaneous Breathing Trials in Patients in the Prolonged Weaning|Examination of Cardiovascular Function/ Cardio Respiratory Interaction on Spontaneous Breathing Trials in Patients in the Prolonged Weaning|Weaning TTE|RWTH Aachen University|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in prolonged weaning (Group 3 by Boles) with NYHA I-II, who come to the        Department of Intensive Care Medicine RTWH Aachen University, will be recruited in the        study. Recruitment will be performed in accordance to the inculsion and exclusion        criteria.|August 2015|October 2, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02569385||11597|
NCT02572583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013BAI13B021|A Clinical Study of Treating Influenza With Liugan Shuangjie Heji|||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|No|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||April 2015|October 8, 2015|April 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02572583||11351|
NCT02570607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-10|Preoperative BNP as Biomarker of Postoperative Cardiovascular Complications|Relevance of Preoperative BNP as a Biomarker of Postoperative Cardiovascular Complications in Major Non-cardiac Adult Surgery|BNP|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|November 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|100 Years|No|Non-Probability Sample|patient Who have to undergoing moderate or high cardiovascular risk non-ambulatory        scheduled surgery with the exception of cardiac surgery|October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570607||11503|
NCT02577874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chinese European study 2015|A Comparison of European and Chinese Blood Sugar Responses|A Comparison of European and Chinese Blood Sugar Responses||Small Changes|Yes|Recruiting|June 2015|January 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|19 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|Health adults, male and female between the ages of 19 and 59|October 2015|October 15, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02577874||10944|
NCT02577887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10073|Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II|Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II|BRADYCARE II|St. Jude Medical|No|Recruiting|July 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2016|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a standard bradycardia pacing indication and implanted with a St. Jude        Medical pacemaker|October 2015|October 15, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02577887|1 Year|10943|
NCT02587832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081110|High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome|Randomized Control Trial: Heated Humidity High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome in Extreme Low Birth Infants in Immediate Post Extubation Period||Sidra Medical and Research Center|No|Completed|July 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||October 2015|October 25, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02587832||10180|
NCT02570555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5503|Strabismus Surgery and Driving Ability|Strabismus Surgery and Driving Ability||University Hospital, Strasbourg, France|No|Recruiting|April 2013|||April 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with strabismus tested before and after the eye surgery Control patients.|September 2015|October 6, 2015|February 12, 2013||No||No||https://clinicaltrials.gov/show/NCT02570555||11507|
NCT02570568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00152|Pen Torch Transillumination: Shedding Light on Difficult Venepuncture|Pen Torch Transillumination: Shedding Light on Difficult Venepuncture||National University Hospital, Singapore|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|21 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570568||11506|
NCT02576223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008712|Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery|Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery - a Randomized, Blinded, Placebo Controlled Study||Hillerod Hospital, Denmark|Yes|Not yet recruiting|October 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02576223||11071|
NCT02527525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6270|First STEPS- Study of Type 1 in Early Childhood and Parenting Support|A Stepped Care Behavioral Intervention Trial for Young Children With T1D||Children's Research Institute|Yes|Not yet recruiting|April 2016|June 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|22 Years|N/A|No|||August 2015|August 17, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02527525||14810|
NCT02512497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0047|Romidepsin Maintenance After Allogeneic Stem Cell Transplantation|Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 7, 2016|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512497||15963|
NCT02514720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/2014|Nicotine Metabolizers and [11C]-(+)-PHNO|Impact of Nicotine Metabolism on Brain Dopamine Transmission|MET|Centre for Addiction and Mental Health|No|Recruiting|June 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514720||15794|
NCT02517762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XC90-ALBP|Acute Low Back Pain: Causes, Mechanisms, Treatment and Followup|Labour Triggered Acute Low Back Pain: Origin, Mechanisms, Causes of Pain, Evaluation of Treatment and Followup|ALBP|Göteborg University|Yes|Completed|March 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517762||15561|
NCT02521870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV3-MEL-01|A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma|A Phase 1b, Open-label, Multicenter, Dose Escalation Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma||Dynavax Technologies Corporation|Yes|Recruiting|September 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|September 9, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521870||15245|
NCT02521883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T248/2014|Transcranial Direct Current Stimulation (tDCS) as an add-on Therapy for Treatment of Major Depressive Disorder. (DEPTDCS2014)|||Turku University Hospital|Yes|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||February 2016|February 19, 2016|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521883||15244|
NCT02646475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151699|Metabolic Effects of Angiotensin-(1-7)|Metabolic Effects of Angiotensin-(1-7)||Vanderbilt University|Yes|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|19|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646475||5677|
NCT02714881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016P000219|Lipids, Inflammation, and CV Risk in RA|Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis||Brigham and Women's Hospital||Not yet recruiting|April 2016|March 2021|Anticipated|April 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|75|||Both|35 Years|90 Years|No|||March 2016|March 21, 2016|March 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714881||429|
NCT02715128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|493-14|Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex|Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex: fMRI Study in Major Depression||Ludwig-Maximilians - University of Munich||Not yet recruiting|March 2016|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715128||410|
NCT02719249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14-9733|Fabry Disease Screening in ESRD Patients in West of France|Fabry Disease Prevalence in End-stage Renal Disease (ESRD) Patients on Dialysis or Transplant in West of France|SNOUFY|Rennes University Hospital|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|70 Years|No|Non-Probability Sample|End-stage renal disease patients|March 2016|March 24, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719249||93|
NCT02649205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Keto-023-CNI|Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet|Characterisation of Patient Profile and Contemporary Treatment of Pre-dialytic Chronic Kidney Disease (CKD) in Patients Receiving a Restricted Protein Diet Supplemented With Ketosteril® - a Drug Utilisation Study (DUS)||Fresenius Kabi|No|Recruiting|February 2016|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|Pre-dialytic chronic kidney disease patients treated at nephrology units of selected        hospitals in Czech Republic, Hungary and Romania.|March 2016|March 18, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02649205||5467|
NCT02649504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015858|Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia|The Study of Immunotherapy With Rituximab and Pulse Dexamethasone Followed by With Mycophenolate Mofetil or Placebo in Adult Patients With Persistent and Chronic Immune Thrombocytopenia||Weill Medical College of Cornell University|Yes|Not yet recruiting|June 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649504||5444|
NCT02655991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH=08-2-0096|Homecoming Line: Telephone Support for Veterans|Homecoming Line: Telephone Support for Veterans|HCL|VA Palo Alto Health Care System|No|Completed|March 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|358|||Both|18 Years|100 Years|No|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655991||4947|
NCT02656004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSaoFrancisco2|Essential Oil of Eucalyptus Effect on Cardiovascular Responses|Essential Oil of Eucalyptus Effect on Cardiovascular Responses During Recovery of Elderly and Isometric Resistance Exercise||Universidade Federal do vale do São Francisco|Yes|Completed|August 2013|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656004||4946|
NCT02647866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4083-002|Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction & Long-term Extension Therapy) of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active Ulcerative Colitis||Kyowa Hakko Kirin Pharma, Inc.|No|Recruiting|December 2015|September 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|January 28, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647866||5570|
NCT02518191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTU-6H-20150731001|Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity|Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China||Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Yes|Not yet recruiting|August 2015|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Female|18 Years|49 Years|No|||August 2015|August 5, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518191||15528|
NCT02518204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL001|Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults|Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults||Lumos Labs, Inc.|No|Recruiting|July 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|280|||Both|70 Years|89 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518204||15527|
NCT02671734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121426|Improving the Informed Consent Process for Youth Undergoing Pediatric Endoscopy and Their Parents|Using Media to Improve the Informed Consent Process for Youth Undergoing Pediatric Endoscopy and Their Parents||Huang, Jeannie, M.D.|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|77|||Both|7 Years|17 Years|No|||January 2016|January 29, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02671734||3740|
NCT02671747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0942|Pilot: Mind Over Matter: Healthy Bowels, Healthy Bladder|Pilot Testing for Mind Over Matter: Healthy Bowels, Healthy Bladder||University of Wisconsin, Madison|No|Active, not recruiting|August 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Female|50 Years|N/A|No|||February 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671747||3739|
NCT02512640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-102-0112A3|Comparison of Oxidative Stress Changes in Different Ventilation Strategies During Gynecologic Laparoscopic Surgery|Comparison of Oxidative Stress Changes in Different Ventilation Strategies During Gynecologic Laparoscopic Surgery||Chang Gung Memorial Hospital|Yes|Completed|May 2013|July 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|52|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02512640||15952|
NCT02512874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001230|Does Pulmonary Rehabilitation Improve Frailty?|Does Pulmonary Rehabilitation Improve Frailty in Chronic Lung Disease?||Mayo Clinic|No|Enrolling by invitation|July 2015|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02512874||15934|
NCT02517294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15-17|, "Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"|"Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"||Nemours Children's Clinic|No|Recruiting|June 2015|June 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|3 Years|11 Years|No|||August 2015|August 4, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02517294||15597|
NCT02527590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008057|Development of Stimulator Pneumatic for Realization of Evoked Potential Allodynic/Somatosensory|Development of Stimulator Pneumatic for Realization of Evoked Potential Allodynic/Somatosensory|STIMEA|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02527590||14805|
NCT02519959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253-2015|Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer (FAITH)|Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen|FAITH|Sunnybrook Health Sciences Centre|No|Not yet recruiting|December 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519959||15392|
NCT02514512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/15/HAWKE/55|Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking|Phase I Feasibility Study of Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation and Radiofrequency Tracking|LIGHTSABR|Royal North Shore Hospital|Yes|Recruiting|September 2015|September 2022|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514512||15810|
NCT02514525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0011|Multi-center Clinical Study to Evaluate the Coldplay Focal Ablation System|Multi-center Clinical Study to Evaluate the Coldplay Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium|ColdPlay3|C2 Therapeutics, Inc.|No|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514525||15809|
NCT02513433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65/IEC/01/12-13|Comparison of Levobupivacaine, Ropivacaine and Bupivacaine in Epidural Anaesthesia|Comparative Evaluation of Newer Congeners i.e. Levobupivacaine and Ropivacaine With Bupivacaine, in Lumbar Epidural Anaesthesia for Hip Surgeries||Government Medical College, Haldwani|No|Completed|December 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|3||Actual|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513433||15891|
NCT02513446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.20|Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects|Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)||Boehringer Ingelheim||Completed|September 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|July 30, 2015||||No||https://clinicaltrials.gov/show/NCT02513446||15890|
NCT02513511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169/14|Hypnosis to Perform Awake Intubation|Hypnosis as a Sole Agent to Perform Awake Intubation|Hypnotube|University of Lausanne Hospitals|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513511||15885|
NCT02515799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/14|Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis|A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis|Tacho-COPD|bene-Arzneimittel GmbH|No|Completed|August 2014|July 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|27|||Both|40 Years|85 Years|No|||August 2015|August 2, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02515799||15711|
NCT02516085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD01|Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin|||University Hospital, Basel, Switzerland|Yes|Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|7 Years|10 Years|No|||August 2015|August 5, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516085||15690|
NCT02514798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11570|Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing|Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing in Severe COPD Patients||Tufts Medical Center|No|Recruiting|July 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|August 3, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514798||15788|
NCT02524405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221-2013|BEAM: Brain-Eye Amyloid Memory Study|The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration|BEAM|Sunnybrook Health Sciences Centre|No|Not yet recruiting|November 2015|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|320|Samples With DNA|Blood samples for genetic testing including apoliprotein E4 status, as well as for      proteomic, lipidomic and other fluid biomarkers of neurodegeneration and vascular disease,      will be collected for each participant. All samples should be taken after a 10 hour fast; if      not possible, the participant should have a light meal only. Samples should be collected      between 8am and 10am, in order to minimize circadian variations in biomarker levels.|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three hundred and twenty (320) subjects will be enrolled: 60 normal elders (20 aged 50-64        and 40 aged 65-90), 65 with MCI, 65 with AD, 65 with LBD spectrum, and 65 with subcortical        VCI.        All patients will receive a standardized work up for dementia including brain imaging and        a blood work screen to rule out secondary causes of dementia as part of their clinical        work-up prior to study enrollment. Memory clinic patients will undergo a detailed        neurocognitive assessment (Behavioural Neurology Assessment-Revised), and the clinical        history and examination will use a standardized common elements approach.|August 2015|August 14, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524405||15050|
NCT02511769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-032|Web-MAP Intervention for Youth With Sickle Cell Disease|WEB MAP Intervention for Youth With Sickle Cell Disease|Web-MAP|Connecticut Children's Medical Center|Yes|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|11 Years|18 Years|No|||July 2015|July 28, 2015|September 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02511769||16019|
NCT02516098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.850|Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.|A Single Center, Single-dose, Double-blind, Randomized, Two Period Crossover, Two Stage Design to Determine Bioequivalence of Two Formulations Containing Hyoscine Butylbromide 10mg Sugar Coated Tablets, Under Fasting Conditions||Boehringer Ingelheim||Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|August 3, 2015||||No||https://clinicaltrials.gov/show/NCT02516098||15689|
NCT02511847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201408024MIPC|Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib|An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Negative Breast Cancer and Research of Biomarkers of Activity and Efficacy of Afatinib||National Taiwan University Hospital|Yes|Not yet recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|20 Years|N/A|No|||July 2015|July 27, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02511847||16013|
NCT02511860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000001|Burdock and Blood Pressure in African-American Women|Burdock and Blood Pressure in African-American Women: A Randomized Controlled Trial||Proactive Health Labs|Yes|Not yet recruiting|August 2015|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02511860||16012|
NCT02525315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-137|Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations||TMS HALLU|University Hospital, Caen|No|Completed|June 2007|December 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|No|||August 2015|August 14, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525315||14980|
NCT02663986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02090|Organizational Skill Training (OST) in Schools|A School-Based Program to Improve Children's Organizational Skills||New York University School of Medicine|No|Recruiting|February 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|32|||Both|8 Years|11 Years|No|||March 2016|March 15, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663986||4332|
NCT02520206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF11093|Adenosylmethionine Metabolism in Human Inflammation|Translational Study on the Regulation of Adenosylmethionine Synthesis During Chronic Inflammation||National Chung Hsing University|Yes|Enrolling by invitation|January 2011|August 2015|Anticipated|July 2014|Actual|N/A|Observational|N/A||2|Anticipated|250|Samples With DNA|plasma, RBC, PBMC|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients with arthritis or healthy adults|August 2015|August 6, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02520206||15373|
NCT02519790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54HD085601-01|Optimizing Medication Management for Mothers With Depression|Optimizing Medication Management for Mothers With Depression|OPTI-MOM|Northwestern University|Yes|Recruiting|August 2015|June 2021|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood, Cerebrospinal Fluid|Female|18 Years|45 Years|No|Non-Probability Sample|Community sample of women taking sertraline (Zoloft), fluoxetine (Prozac), citalopram        (Celexa), or escitalopram (Lexapro) in pregnancy and planning to deliver at Prentice        Women's Hospital in Chicago|August 2015|August 7, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519790||15405|
NCT02519803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHIRST-SA|A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa|A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa|PHIRST-SA|National Institute for Communicable Diseases, South Africa|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|two community based sites, one site is rural and the other is an urban setting. all        household in these 2 districts are eligible. Household will be randomly selected on a        cluster sampling method|August 2015|August 6, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519803||15404|
NCT02514317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-058|Percutaneous Treatment of Carpal Tunnel Syndrome With Scan|Ultrasound-assisted Percutaneous Release of Carpal Tunnel Syndrome|ECHOCARPE|University Hospital, Caen|Yes|Completed|January 2012|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02514317||15825|
NCT02667821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162001|Vertebral Artery and Cerebral Hemodynamics After Various Head Positions & Manipulation in Patients With Neck Pain|Changes in Vertebral Artery and Cerebral Hemodynamics Following Various Head Positions & Cervical Manipulation in Patients With Chronic/Recurrent Neck Pain||Canadian Memorial Chiropractic College|No|Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02667821||4038|
NCT02512861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311-105|Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery|Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery: A Prospective: Double-Blind, Randomized Controlled Trial||Children's Hospitals and Clinics of Minnesota|Yes|Active, not recruiting|April 2014|May 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|N/A|17 Years|No|||March 2016|March 22, 2016|June 6, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512861||15935|
NCT02516462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFFR-IVM-2015|In Vitro Maturation of Human Eggs|In Vitro Maturation of Human Eggs|IVM|National Foundation for Fertility Research|No|Recruiting|July 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|35 Years|45 Years|No|||August 2015|August 3, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516462||15661|
NCT02524925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87|Postoperative Stress Response in Patients Following Fast Track vs Conventional Protocol After Hepatectomy or Pancreatectomy|Postoperative Stress Response in Patients Following Fast Track Versus Conventional Protocol After Hepatectomy or Pancreatectomy||National and Kapodistrian University of Athens|Yes|Completed|April 2012|July 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|231|||Both|30 Years|82 Years|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524925||15010|
NCT02674282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOT983|Maximum Oxygen Uptake in ACL-injured Professional Soccer Players|Maximum Oxygen Uptake in ACL-injured Professional Soccer Players||University of Sao Paulo|No|Active, not recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02674282||3546|
NCT02674295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108107|A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants|An Open-label, Single-dose Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Subjects||Janssen Research & Development, LLC|No|Not yet recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674295||3545|
NCT02518022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEER2015|How to be Safe With Alcoholic Drinks in Diabetes|A Monocentric, Controlled, Randomized, Open-label Cross-over Study to Explore the Possible Insulin Treatment of Beverages Containing Alcohol and Carbohydrates in Adolescents and Young Adults With Type 1 Diabetes|BEER|Kinderkrankenhaus auf der Bult|No|Recruiting|September 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|16 Years|21 Years|No|||December 2015|December 15, 2015|May 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02518022||15541|
NCT02521675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00709-40|Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions|Multicentre Randomized Cross-over Study Assessing in Type 1 Diabetic Patients With Pump Insulin the Non-inferiority of Glycemic Control Obtained With the Algorithms Tested in DIABRASPORT Versus the Rest Period Without Physical Activity|Diabrasport2|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02521675||15260|
NCT02519634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(45)2015|SMP vs RIRS for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial|Super-Mini Percutaneous Nephrolithotomy (SMP) Versus Retrograde Intrarenal Surgery (RIRS) for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||August 2015|August 6, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02519634||15417|
NCT02671864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P150601|Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy|Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2|ANGIOSAFE 2|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|March 2022|Anticipated|March 2022|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|7200|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671864||3730|
NCT02513888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENT_WIN_RURAL|Prevention of Type 2 Diabetes With Vitamin D Supplementation|Prevention of Type 2 Diabetes in Women With Prediabetes Using Vitamin D Supplementation and Lifestyle Intervention in North India (PREVENT-WIN Study)|PREVENT-WIN|Diabetes Foundation, India|Yes|Recruiting|February 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513888||15857|
NCT02517541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP259|A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products|A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products||Coloplast A/S|No|Active, not recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517541||15578|
NCT02526485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150433|Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2|||Vanderbilt University|No|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples With DNA|Whole blood will be stored in freezers at minus 80 degrees.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from a hospital setting and identified based on laboratory        testing for heparin-induced thrombocytopenia.|August 2015|August 16, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02526485||14890|
NCT02526537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSCI001|Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients|The Postoperative Adjuvant Therapy of Gefitinib for High Risk Stage Ib NSCLC Patients With EGFR Sensitive Mutation, an Open, Paired, Non-interventional, Multi-center Clinical Study||West China Hospital|Yes|Recruiting|August 2015|September 2022|Anticipated|August 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|78 Years|No|Probability Sample|NSCLC patients received complete resection at stage Ib with deletion of exon 19 or        mutation of L858R at exon 21 in EGFR|August 2015|August 17, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02526537||14886|
NCT02673073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWARE-HF|Self-Awareness of Symptoms, Signs and Medical Compliance Using a Patient Diary in Heart Failure Management|Self-Awareness of Symptoms, Signs and Medical Compliance Using a Patient Diary in Heart Failure Management (AWARE-HF)|AWARE-HF|Seoul National University Bundang Hospital|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1220|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673073||3638|
NCT02662413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1804|To Determine the Validity of the ACT in an Adolescent Population With Persistent Asthma|To Determine the Measurement Properties of the ACT in an Adolescent Population With Persistent Asthma Followed at a Subspecialty Clinic.|ACT2|University of North Carolina, Chapel Hill|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|12 Years|18 Years|No|Non-Probability Sample|Children ages 12-18 with a physician diagnosis of persistent asthma living in a defined        geographical area|January 2016|January 25, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02662413||4453|
NCT02514473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX14-809-109|A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation|A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|6 Years|11 Years|No|||July 2015|September 1, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514473||15813|
NCT02517801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anthocyanins|Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women|Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women|Anthocyanins|Heinrich-Heine University, Duesseldorf|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Female|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02517801||15558|
NCT02517814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-2015-06|Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517814||15557|
NCT02520609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150174|Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease|Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|February 6, 2016|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02520609||15342|
NCT02673398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15342|Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer|Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer||City of Hope Medical Center|Yes|Not yet recruiting|June 2016|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||February 2016|February 1, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673398||3614|
NCT02523703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-063|Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study||EXCEED|University Hospital, Caen|No|Completed|September 2007|||February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523703||15104|
NCT02524626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56309|Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve|Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve: A Potential New Therapeutical Intervention for Shortening Postoperative Ileus||Katholieke Universiteit Leuven|No|Recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02524626||15033|
NCT02524691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-002-RP|Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus|Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus||Clinical Innovations, LLC|No|Enrolling by invitation|August 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|306|||Female|18 Years|N/A|No|Probability Sample|Pregnant women undergoing an evaluation for suspected ROM.|August 2015|August 13, 2015|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524691||15028|
NCT02518425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ_02_02_2015|Improvement in Acoustic Voice Characteristics in Functional Dysphonia After Therapy|Which Instrumental Acoustic Voice Parameters Indicate Vocal Improvement After Voice Therapy in Patients With Functional Dysphonia||University of Zurich|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|20 Years|70 Years|No|Probability Sample|Patients with functional voice disorders|August 2015|August 4, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02518425||15510|
NCT02518438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190|The Analgesic Efficacy of Wound Infiltration With Tramadol|A Randomized Trial of the Analgesic Efficacy of Wound Infiltration With Tramadol After Cesarean Delivery Under General Anesthesia||Yeditepe University Hospital|No|Completed|May 2012|May 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02518438||15509|
NCT02523352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRIOBESE|Magnetic Resonance Imaging Study in Obese Volunteers|Magnetic Resonance Imaging Study in Obese Volunteers to Evaluate the Effects of Recruitment Maneuver and Titrated Positive End-expiratory Pressure Ventilation on Lung's and Heart's Function and Heart-lung Interaction.||Massachusetts General Hospital|No|Not yet recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523352||15131|
NCT02523872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00064591|Description of Fluid Balance in Patients With Acute Respiratory Failure|Description of Fluid Balance in Patients With Acute Respiratory Failure||Smiths Medical, ASD, Inc.|No|Enrolling by invitation|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with acute respiratory failure who might benefit from a strategy designed to        limit fluid administration|August 2015|August 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523872||15091|
NCT02515656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX 401-11|Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis|Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis International, Multicentre, Randomised, Double-blind, Parallel Group Study, Comparative Versus Miconazole|PRISM|Laboratoire Innotech International|Yes|Recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|650|||Female|18 Years|64 Years|No|||March 2016|March 18, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515656||15722|
NCT02527226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004441|Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors|Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors||Mayo Clinic|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527226||14833|
NCT02518503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q12-02|High Potency Statins and the Risk of Diabetes|Higher Potency Statins and the Risk of New Diabetes: Multicentre, Observational Study of Administrative Databases|Statins-DM|Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|136966|||Both|40 Years|N/A|No|Probability Sample|In each jurisdiction, the investigators will assemble a study cohort that includes all        patients with a new prescription for a statin, including simvastatin, lovastatin,        pravastatin, fluvastatin, atorvastatin, and rosuvastatin between 1 January 1998 (or one        year after the beginning of data availability) and 31 March 2011. The date of study cohort        entry is defined by the prescription date of the newly-prescribed statin after hospital        discharge.|August 2015|March 11, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518503||15504|
NCT02516995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00440-39|Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer|Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer|FIBROP|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|August 2010|July 2014|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|18 Years|70 Years|No|||February 2016|February 9, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516995||15620|
NCT02521740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1318184|CAREGIVER2, Caregiver's Health Assessment : Clinical and Biological Markers|Soutien Des Soins Informels Aux Personnes âgées Fragiles : Accompagnement Des Aidants Sur Base d'Une évaluation Clinique et Biologique de la Charge de Soins.||Centre Hospitalier Universitaire Dinant Godinne - UCL Namur|No|Recruiting|March 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Blood samples taken between 8 and 11 am. Blood parameters including cell counts and assays      of acute phase proteins (C-reactive protein (CRP), albumin, pre-albumin) are determined      according to the routine of the hospital.      PBMC are isolated by centrifugation in a Lympho-Ficoll gradient by the biobank of CHU Dinant      Godinne.      Collected plasma is stored at −80 °C until analysis. The amounts of insulin-like growth      factor-1 (IGF-1), interleukin-6 (IL-6) are essayed by enzyme-linked immunosorbent assay      (ELISA).      PBMC are sent to Liege (GIGAI3) and Namur (URBC) for respectively ADN and ARN analyses.      ADN analyses concerned the immunity markers and ARN analyses concerned the transcriptomics      and epigenetic markers.      The biobank of the CHU Dinant-Godinne meets the requirements of the quality book developed      by the biobanks of Walonnie-Bruxelles (BWB).|Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  caregivers of a community dwelling dependent elderly (≥70years)          -  controls : poeple who lives with a healthy elderly (≥70years)|August 2015|August 10, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02521740||15255|
NCT02512926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POE14-01|Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children|Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias|POE14-01|Phoenix Children's Hospital|Yes|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Months|29 Years|No|||July 2015|July 28, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512926||15930|
NCT02522325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0553|Reinforcing Effects of Cocaine During Phendimetrazine Maintenance|Behavioral Effects of Drugs (Inpatient): 31 (Cocaine and Phendimetrazine)|BED IN 31|University of Kentucky|No|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522325||15210|
NCT02522338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008078|Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance|Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance|HIVOL|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|300|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02522338||15209|
NCT02514434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0029|Usefulness of Ultrasonography Versus Non-contrast Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma (MIRACLE-HCC)|Usefulness of Ultrasonography Versus Non-contrast Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma (MIRACLE-HCC): a Prospective Randomized Trial||Yonsei University|No|Recruiting|March 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|412|||Both|20 Years|70 Years|No|||July 2015|July 30, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02514434||15816|
NCT02518074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-070|Hearing and Vestibular Interactions in the Collection of Own Body and Sense of Self||AUDIOSELF|University Hospital, Caen|No|Recruiting|October 2013|||November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02518074||15537|
NCT02518087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRAKI 02-2015|Increased Adsorption Membranes During Cardiopulmonary Bypass|Increased Adsorption Membranes During Cardiopulmonary Bypass. A Randomized Controlled Trial to Evaluate Impact in Postsurgical Acute Kidney Injury||Hospital Universitari de Bellvitge|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02518087||15536|
NCT02512419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activo R21|Developing a Text-Message Enhanced Physical Activity Intervention for Latino Men|Developing a Text-Message Enhanced Physical Activity Intervention for Latino Men||University of California, San Diego|Yes|Recruiting|July 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512419||15969|
NCT02512510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0127|Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|COPD|Theravance Biopharma R & D, Inc.|No|Recruiting|September 2015|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|618|||Both|40 Years|N/A|No|||September 2015|September 22, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512510||15962|
NCT02512523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD_TEN_PH42014|Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)|A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment||Handok Pharmaceuticals Co., Ltd.|No|Recruiting|August 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||October 2015|October 5, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512523||15961|
NCT02516592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A3405|Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Switching From Salmeterol/Fluticasone to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic COPD Patients|FLASH|Novartis|No|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|492|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516592||15651|
NCT02519244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0278|Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis|Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis||The University of Texas Health Science Center, Houston||Recruiting|May 2015|||March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|65 Years|No|||August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02519244||15447|
NCT02521805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B316 SAPO 2B|Enhanced Satiety With Pork Products Containing Dietary Fibre|Enhanced Satiety With Pork Products Containing Dietary Fibre|SAPO|University of Copenhagen|No|Not yet recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02521805||15250|
NCT02524574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-089|Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure||TEP-READ|University Hospital, Caen|No|Completed|September 2010|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524574||15037|
NCT02651493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003506.|Digital Dysmorphology Project|Down Syndrome Detection From Facial Photographs Using Machine Learning Techniques||Children's Research Institute|No|Recruiting|February 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|750|||Both|N/A|18 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02651493||5291|
NCT02651506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFCRS-RP-007-1512-17|Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules|Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules: Comparison of Outcomes and Costs in a Public Healthcare System||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|April 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651506||5290|
NCT02719509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR # 15-4092|Emergency Department Cardiac Ultrasound|Prospective Evaluation of the Utility of Bedside Cardiac Ultrasound for Undifferentiated Chest Pain and Shortness of Breath in the Emergency Department||Minneapolis Medical Research Foundation|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with undifferentiated chest pain or shortness of breath who have a cardiac        ultrasound ordered by the emergency provider as part of the diagnostic workup|March 2016|March 21, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02719509||73|
NCT02653781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR222015|Implementation of Realistic Simulation as Patient Safety Improvement Method|Implementation of Realistic Simulation as Patient Safety Improvement Method: Controlled Trial||University of Brasilia|Yes|Enrolling by invitation|March 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02653781||5117|
NCT02659176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mansoura31|Trans-perineal Repair With or Without Limited Internal Sphincterotomy for Treatment of Type I Anterior Rectocele|Comparative Study Between Trans-perineal Repair With or Without Limited Internal Sphincterotomy in Treatment of Type I Anterior Rectocele: A Randomized Controlled Trial||Mansoura University|Yes|Completed|January 2011|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|80 Years|No|||March 2016|March 14, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659176||4702|
NCT02659267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAMOS Beagá|Evaluation of a Strategy Designed to Promote Physical and Healthy Eating|Evaluation of a Strategy Designed to Promote Physical and Healthy Eating Between Users of the Health Academy Program in Belo Horizonte, Minas Gerais - "VAMOS BEAGÁ"|VAMOS|Universidade Federal de Santa Catarina|No|Active, not recruiting|October 2014|March 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|256|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02659267||4695|
NCT02519582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCC-mCRC-01|Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy|Phase II Trial to Investigate the Safety and Efficacy of Orally Applied Niclosamide in Patients With Metachronous or Synchronous Metastases of a Colorectal Cancer Progressing After Therapy|Nikolo|Charite University, Berlin, Germany|No|Not yet recruiting|August 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02519582||15421|
NCT02519829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6757 (REB # 16747)|A Clinical Trial Comparing Monocryl and Dermabond Closure Versus Staple Closure in Total Hip Arthroplasty|A Randomized Clinical Trial Comparing Monocryl and Dermabond Closure Versus Staple Closure in Total Hip Arthroplasty||Lawson Health Research Institute|No|Completed|January 2010|December 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02519829||15402|
NCT02525640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108402|Hearing Handicap in Patients With Single Sided Deafness|Hearing Handicap in Patients With Single Sided Deafness||Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|September 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02525640||14955|
NCT02674308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-0002_401|Entyvio (Vedolizumab) Long Term Safety Study|Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease|Entyvio PASS|Takeda|No|Recruiting|March 2015|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|Participants with ulcerative colitis (UC) or Crohn's disease (CD) who are initiating        Entyvio or another biologic agent. Participants may be biologic-naive or have prior use of        a biologic agent|February 2016|February 2, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02674308||3544|
NCT02674321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-809-C-17|A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)|A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome||Teva Pharmaceutical Industries|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|12 Years|18 Years|No|||February 2016|February 3, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02674321||3543|
NCT02516696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411015662|BiRd vs. Rd as Initial Therapy in Multiple Myeloma|Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma|BiRd vs Rd|Weill Medical College of Cornell University|Yes|Active, not recruiting|August 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|65 Years|N/A|No|||August 2015|August 5, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516696||15643|
NCT02516709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT003|Linear Source Registry for Prostate Cancer|CivaString Registry for Prostate Cancer|CaRe PC|CivaTech Oncology|No|Not yet recruiting|August 2015|December 2021|Anticipated|August 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood, serum|Male|18 Years|N/A|No|Non-Probability Sample|Patients currently indicated for brachytherapy, implanted with the linear LDR source for        prostate cancer with a life expectancy greater than 5 years|August 2015|August 5, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516709|5 Years|15642|
NCT02522559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spiceinschool01|Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches|Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches||Penn State University|No|Recruiting|April 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|170|||Both|11 Years|19 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|April 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02522559||15192|
NCT02522572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mozobil Sanofi|Quantitating the Impact of Plerixafor|Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels||University of Cincinnati|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522572||15191|
NCT02513277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0341|Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study|Screening for Glucose Intolerance and Development of a Lifestyle Education Programme for Prevention of Type 2 Diabetes in a Population With Learning Disabilities||University of Leicester|No|Completed|February 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|930|Samples With DNA|whole blood|Both|18 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with a learning (intellectual) disability who are live in Leicester, Leicestershire        or Rutland, UK;|July 2015|January 20, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513277||15903|
NCT02523001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uAQP2/01|Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)|Urinary AQP2 Excretion in Hypercholesterolemic Patients as a Measure of Effect of Statin Therapy|uAQP2/01|University of Bari|Yes|Completed|October 2013|July 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|37|Samples Without DNA|Blood analyses (serum lipids, creatininemia, glucose, bilirubin) Urines (creatininuria,      urinary AQP2)|Both|40 Years|75 Years|No|Probability Sample|Behavioral: diet Drug: statins, as required according to the ACC/AHA guidelines        Diagnostic: anthropometric data, abdominal and carotid ultrasonography, serum (lipids,        renal function) and urinary (AQP2, osmolality) dosages at enrollment and during a 3-months        follow up (week 0, 1, 4, 12)|August 2015|August 11, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523001||15158|
NCT02523053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-01-011|Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients|A Randomized Controlled Study on the Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Anti-tumor Recurrence in Hepatocellular Carcinoma Patients With High Risk of Microvascular Invasion Presence||Eastern Hepatobiliary Surgery Hospital|Yes|Not yet recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||August 2015|August 12, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523053||15154|
NCT02519049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1287|11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)|Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis||Istituto Clinico Humanitas|No|Recruiting|September 2014|November 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Biopsy specimen|Both|18 Years|N/A|No|Non-Probability Sample|All patients affected by MPM and referred to our Institution for therapeutic pleurodesis        and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. A minimum        number of 20 patients will be considered for the analysis.|August 2015|August 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02519049||15462|
NCT02523742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-097|Study of the Hemispheric Specialization for Language in Subjects With Neuropsychiatric Disorders Compared to Control Subjects||BIP|University Hospital, Caen|No|Completed|November 2005|||November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|152|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523742||15101|
NCT02518646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC_2015-1782|DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models|DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models|DECISION|Radboud University|No|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients aged ≥ 18 years (surgical, medical, neurology/neurosurgical, or trauma        patients) a from the participating multinational ICUs. These ICU patients are at risk of        developing the outcome of interest, delirium.|December 2015|December 2, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02518646||15493|
NCT02667808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051780|Exploring the Impact of HIV and ART on Knowledge, Attitudes and Practices in Reproductive Health in Lilongwe, Malawi|Exploring the Impact of HIV and ART on Knowledge, Attitudes and Practices in Reproductive Health in Lilongwe, Malawi|HIV KAP|Emory University|No|Active, not recruiting|August 2011|||December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|562|||Both|18 Years|55 Years|No|Non-Probability Sample|Persons living with HIV in Lilongwe, Malawi recruited from The Lighthouse Trust Clinic|January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667808||4039|
NCT02519751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202600|New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass|Total Body Skeletal Muscle Mass Estimation by Creatine (Methyl-d3) Dilution in Athletes||GlaxoSmithKline|No|Completed|October 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02519751||15408|
NCT02523248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/755-31/2|Comparison Between UPPP and Tonsillectomy in Adult OSA|Randomized Control Study Between Uvulopalatopharyngoplasty and Tonsillectomy in Adult Sleep Apnea Patients||Karolinska University Hospital|No|Recruiting|January 2016|January 2022|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|65 Years|No|||February 2016|February 25, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02523248||15139|
NCT02519309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUH_01|Dietary Intervention in Type-2 Diabetes and Pre-Diabetes|Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake||Virta Health|No|Active, not recruiting|August 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|21 Years|65 Years|No|||February 2016|February 22, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02519309||15442|
NCT02525289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141372|Impact of Three Body Positioning Strategies in the Drainage Fluids After Coronary Artery Bypass Surgery|Study of Impact of Three Body Positioning Strategies in the Drainage Fluids in the Immediate Postoperative Period in Patients After Coronary Artery Bypass Surgery|positioning|University of Sao Paulo General Hospital|Yes|Completed|November 2012|June 2015|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02525289||14982|
NCT02667210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 4C|Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review|Retrospective Cohort Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Diversion, Abuse and/or Addiction by Medical Record Review||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||June 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||4|Anticipated|590|||Both|18 Years|N/A||Probability Sample|Patients identified from the HealthCore Integrated Research Database|November 2015|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667210||4085|
NCT02667223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481051|Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase|A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (pf 04950615) Alone And In Co Mixture With Recombinant Human Hyaluronidase (rhuph20, Pf 06744547) In Healthy And Hypercholesterolemic Adult Subjects||Pfizer|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02667223||4084|
NCT02667236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-SEBK-301|A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.||Aclaris Therapeutics, Inc.|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02667236||4083|
NCT02519972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH96-TD-G-111-016|Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer|Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer||Taichung Veterans General Hospital|Yes|Completed|August 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1102|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02519972||15391|
NCT02515903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFYY-NSD-001|Comparison Between Stereotactic Aspiration and Intra-endoscopic Surgery to Treat Intracerebral Hemorrhage|Comparison Between Stereotactic Aspiration and Intra-endoscopic Surgery to Treat Intracerebral Hemorrhage|EndoSurofICH|Nanfang Hospital of Southern Medical University|Yes|Recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 2, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02515903||15703|
NCT02515916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301013407|Fertility Preservation- Oncology Treatment Effects and Psychological Impact|Fertility Preservation- Oncology Treatment Effects and Psychological Impact||Weill Medical College of Cornell University|No|Not yet recruiting|October 2015|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|45 Years|No|Non-Probability Sample|Women scheduled to undergo chemotherpay/radiotherapy and are seeking fertility        preservation at WCMC|August 2015|August 3, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02515916||15702|
NCT02513992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58243|Ictal SPECT With Intra-arterial Injection|Early Ictal SPECT With Intra-arterial Injection to Localize the Ictal Onset Zone in Refractory Focal Epilepsy.||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1|||Both|18 Years|60 Years|No|||July 2015|July 30, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02513992||15849|
NCT02667535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDN 001/16|PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure|Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers.||Biolab Sanus Farmaceutica|No|Not yet recruiting|July 2016|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02667535||4060|
NCT02667548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016PS04K02|Prospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital|Prospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital of China Medical University|P-PUSH|Shengjing Hospital|No|Not yet recruiting|January 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7000|Samples With DNA|A venous blood sample of 10mL will be collected before discharge for biomarker analysis and      storage for future genetic studies.|Both|18 Years|N/A|No|Non-Probability Sample|In department of Cardiology,Shengjing Hospital of China Medical University, 7000        hospitalized patients undergoing Percutaneous Coronary Intervention will be enrolled        consecutively.|January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02667548||4059|
NCT02523534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200809|Utilizing a Novel Method to Map Sources of Atrial Fibrillation|Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns||Northwestern University|No|Enrolling by invitation|August 2015|August 2021|Anticipated|August 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|21 Years|N/A|No|||August 2015|August 12, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02523534||15117|
NCT02512627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-6651A3|Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment|Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment: An Efficacy Study||Chang Gung Memorial Hospital|No|Recruiting|March 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2015|December 28, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02512627||15953|
NCT02525679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1368.1|Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers|Single-blind, Partially Randomised, Placebo-controlled Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 655130 in Healthy Male Volunteers||Boehringer Ingelheim||Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|August 14, 2015||||No||https://clinicaltrials.gov/show/NCT02525679||14952|
NCT02525692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005|Oral ONC201 in Adult Recurrent Glioblastoma|Oral ONC201 in Adult Recurrent Glioblastoma||Oncoceutics, Inc.||Recruiting|January 2016|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525692||14951|
NCT02519140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-05-06|Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections|Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections||Maimonides Medical Center|No|Recruiting|August 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|No|||February 2016|February 21, 2016|August 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02519140||15455|
NCT02671474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perceval thrombosis|Valve Leaflet Motion in Sutureless Bioprosthetic Aortic Valves|||Karolinska University Hospital||Recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|55|||Both|18 Years|N/A||||January 2016|January 31, 2016|January 24, 2016||||No||https://clinicaltrials.gov/show/NCT02671474||3760|
NCT02671604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK9|Rhabdomyolysis and Robot-assisted Radical Prostatectomy|Is Rhabdomyolysis an Anesthetic Complication in Patients Undergoing Robot-assisted Radical Prostatectomy?||Umraniye Education and Research Hospital|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|52|||Male|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients scheduled for an elective Robot assisted radical prostatectomy were enrolled to        the study.|January 2016|January 31, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02671604|2 Months|3750|
NCT02517723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET_BPS+PTBS|Narrative Exposure Therapy in Women With Borderline Personality Disorder and Posttraumatic Stress Disorder|A Randomized Controlled Clinical Trial (RCCT) to Test the Effectiveness of Narrative Exposure Therapy (NET) Versus Dialectical-Behavioral Therapy in Reducing Trauma Related Symptoms in Women Suffering From Borderline Personality Disorder (BPD) and Posttraumatic Stress Disorder (PTSD)||Evangelisches Krankenhaus Bielefeld gGmbH||Recruiting|April 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||August 2015|August 4, 2015|January 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02517723||15564|
NCT02517736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-067|Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination||O-Mel-Sora|University Hospital, Caen|Yes|Active, not recruiting|February 2012|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517736||15563|
NCT02521493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML1531|Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome|Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome||Children's Oncology Group||Recruiting|November 2015|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|91 Days|3 Years|No|||January 2016|January 26, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521493||15274|
NCT02521506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOVIQ|Clinical Efficacy of OneTouch® Verio™IQ Meter|Clinical Efficacy of OneTouch® Verio™IQ Meter|ECOVIQ|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02521506||15273|
NCT02526394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multiboost|Pertussis and Meningitis C Concomitant Vaccination in Adolescents|A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™)|Mutliboost|Public Health England|No|Recruiting|September 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|800|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2015|October 20, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02526394||14897|
NCT02664753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2015/PR-01|L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury|L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial|CarniSave|Centre Hospitalier Universitaire de Nīmes|Yes|Not yet recruiting|January 2017|January 2020|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|272|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664753||4273|
NCT02665013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD079457-01|Reducing Delay of Vaccination in Children Study|Reducing Delay of Vaccination in Children Study|REDIVAC|Kaiser Permanente|No|Not yet recruiting|February 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|500|||Female|18 Years|N/A|No|||January 2016|January 22, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02665013||4253|
NCT02521415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK-2015|IN Sub-Dissociative Ketamine vs IN Fentanyl|Randomized Controlled Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children With Suspected Forearm Fractures in the Pediatric Emergency Department||Carolinas Healthcare System|Yes|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|17 Years|No|||December 2015|December 21, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521415||15280|
NCT02521428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOLD_T|End-of-Life Decisions in Surgical Intensive Care Medicine - The Relevance of Treatment Withholding|End-of-Life Decisions in Surgical Intensive Care Medicine - The Relevance of Treatment Withholding||Charite University, Berlin, Germany|No|Completed|August 2008|August 2015|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|226|||Both|N/A|N/A|No|Probability Sample|All Surgical Intensive Care Department patients will be enrolled in the study|August 2015|August 11, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02521428||15279|
NCT02527395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-MSH-2014|Association Between Heat Pain Detection Threshold and Area of Secondary Hyperalgesia|To Determine the Degree of Association Between Heat Pain Detection Threshold and Area of Secondary Hyperalgesia Following Brief Thermal Sensitization in Healthy Male Volunteers||Rigshospitalet, Denmark|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|120|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527395||14820|
NCT02524990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024|Simplified Medical Abortion Follow-Up|Simplified Medical Abortion Follow-Up Study||Gynuity Health Projects|No|Terminated|April 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|53|||Female|11 Years|56 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|August 11, 2015||No|Integrated into another study|No||https://clinicaltrials.gov/show/NCT02524990||15005|
NCT02525068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR‐CTSU/2012/10037|A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC|A Randomised Phase II Study of Enzalutamide (MDV3100) in Combination With AZD5363 in Patients With Metastatic Castration‐Resistant Prostate Cancer (RE‐AKT)|RE-AKT|Institute of Cancer Research, United Kingdom|Yes|Recruiting|December 2014|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|136|||Male|18 Years|N/A|No|||August 2015|August 13, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02525068||14999|
NCT02525081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACIM|Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction|Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease||Bispebjerg Hospital|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|86 Years|No|||August 2015|August 17, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02525081||14998|
NCT02675387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPGRP/43535001/163|Efficacy of External Cold and a Vibrating Device in Reducing Discomfort of Dental Injections in Children|Efficacy of External Cold and a Vibrating Device in Reducing Discomfort of Dental Injections in Children - A Split Mouth Randomized Clinical Trial||Riyadh Colleges of Dentistry and Pharmacy|Yes|Recruiting|October 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|7 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02675387||3461|
NCT02518295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.33. MET|β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion|β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion: Probiotic and Lactose Intolerance||Nestlé|Yes|Recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|32|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02518295||15520|
NCT02522780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000175|Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis||Ferring Pharmaceuticals|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||October 2015|October 14, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522780||15175|
NCT02662426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFLDCRct|Lingdancao Granules in the Treatment of Seasonal Influenza|Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza||The First Affiliated Hospital of Guangzhou Medical University|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|318|||Both|14 Years|65 Years|No|||February 2016|February 14, 2016|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02662426||4452|
NCT02519283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150654|Get With the Guidelines in ED Patients With Heart Failure|Get With the Guidelines in ED Patients With Heart Failure|GUIDED-HF|Vanderbilt University|Yes|Recruiting|October 2015|September 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|700|||Both|21 Years|N/A|No|||October 2015|October 19, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02519283||15444|
NCT02523924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1545|Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy|Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||August 2015|August 12, 2015|May 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523924||15087|
NCT02523937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSET 2014-A00588-39|Evaluation of Soluble Fibrin in Thrombosis Exclusion|Evaluation of Performances of Soluble Fibrin Assay in Exclusion of Pulmonary Embolism and Deep Venous Thrombosis|FSET|Diagnostica Stago R&D|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Frozen heparinized and citrated Poor Platelets Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients from Emergency or Internal Medicine Units, in a French Hospital.|November 2015|November 18, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523937||15086|
NCT02526550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC26-EXT|Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX|Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children||Siriraj Hospital|No|Completed|June 2014|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02526550||14885|
NCT02526589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15042|Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy|Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy||Tampere University Hospital|No|Recruiting|August 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|201|||Male|18 Years|90 Years|No|Probability Sample|Robotic assisted laparoscopic radical prostatectomy patients. Catheter removal visit.|August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526589||14882|
NCT02662686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506-IGX-042-AD|Study for the Evaluation of "MitoScore" Marker in the Diagnosis of Embryo Viability in Euploids Embryos|Randomized Multi-centric Prospective Study for the Evaluation of "MitoScore" Marker in the Diagnosis of Embryo Viability in Euploids Embryos.|MitoScore|Igenomix|No|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|1718|||Female|18 Years|50 Years|No|||January 2016|January 27, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662686||4432|
NCT02511808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-413|Adaptive Interventions for Problem Drinkers|Adaptive Interventions for Problem Drinkers||Northwell Health|Yes|Recruiting|March 2015|||February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|75 Years|No|||February 2016|February 12, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02511808||16016|
NCT02515396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMI-0100 RCT205|Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide|A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Inhaled Dosing With MMI-0100 on Airway Inflammation as Assessed in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS)|LPS|Moerae Matrix, Inc.|No|Recruiting|July 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515396||15742|
NCT02519595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1-2013-88|Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children|Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children||Children's Hospital of Michigan|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|3 Years|18 Years|No|||August 2015|August 10, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519595||15420|
NCT02527096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 167 Lamidol|A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)|A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir®) and Dolutegravir(Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Active, not recruiting|September 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02527096||14843|
NCT02527109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 110|The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure|||RDD Pharma Ltd|No|Not yet recruiting|October 2015|||October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527109||14842|
NCT02527122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM09-STD-011|Determine Minimum Amount of Allergen From D. Pteronyssinus and D. Farinae Extract That Produces Positive Skin Reaction|Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract. Determination of the Allergenic Potency in Vivo Histamine Equivalent Units (HEP)|MM09|Inmunotek S.L.|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|64 Years|No|||December 2015|December 21, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527122||14841|
NCT02513550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15988|A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis|IXORA-P|Eli Lilly and Company|No|Active, not recruiting|August 2015|September 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1227|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513550||15882|
NCT02513563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18304|AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer|A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|September 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513563||15881|
NCT02512094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236/2557(EC3)|Validity and Reliability of Thai Version of Barthel Index for Hip Fracture Patients|Validity and Reliability of Thai Version of Barthel Index for Hip Fracture Patients||Mahidol University|Yes|Recruiting|June 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|50 Years|N/A|No|Non-Probability Sample|Hip fractured patients|September 2015|September 21, 2015|July 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512094||15994|
NCT02519842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-044|Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondandsetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)|A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Subjects Receiving Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.|No|Recruiting|September 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|N/A|17 Years|No|||February 2016|February 24, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519842||15401|
NCT02511444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MemorialCareHS|Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor|Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor||MemorialCare Health System|No|Recruiting|July 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|356|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511444||16044|
NCT02521324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2361-15-SMC|Effect of Device Guided Breathing on Sleeplessness (2BRT01)|The Effect of Device-Guided Breathing on Healthy Subjects With Sleeplessness Using a Sensor and Mobile App|2BRT01|Afeka, The Tel-Aviv Academic College of Engineering|No|Not yet recruiting|March 2016|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521324||15287|
NCT02525159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDEI.PTID.05.3(CM)|Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio|Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio in Premenopausal Mexican Women With Risk of Breast Cancer|EDIMI216OHE1|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|No|Completed|August 2006|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Female|35 Years|52 Years|No|||August 2015|August 13, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02525159||14992|
NCT02522065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.05.796-GHM|neuroQWERTY: a Transparent Patient-centered Outcome Method to Quantify Parkinsonian Motor Signs for Drug Trials|Motor Response to Dopaminergic Therapy in a Population of de Novo Parkinson's Disease Cases Quantified Via Typing Analyses - -neuroQWERTY|neuroQWERTY|Fundación de investigación HM|No|Recruiting|May 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|A group of early Parkinson's disease participants who are going to be prescribed        dopaminergic agents and a group of healthy volunteers will be recruited at the different        collaborating institutions.|August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02522065||15230|
NCT02522078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0115|Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion|Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion - A Clinical Trial|MisoWet|Hospital de Clinicas de Porto Alegre|No|Completed|August 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Female|14 Years|50 Years|No|||March 2016|March 24, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02522078||15229|
NCT02522091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002|Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI||IMPRO|University Hospital, Caen|No|Recruiting|November 2010|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|178|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02522091||15228|
NCT02516033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2014/239|Hybrid Atrail Fibrillation Ablation Registry|Identification of a Risk Profile Associated With Failure of the Hybrid Ablation of Atrial Fibrillation.||University Medical Center Groningen|Yes|Enrolling by invitation|January 2015|January 2025|Anticipated|January 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Full blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients who have agreed to undergo the hybrid ablation procedure because of atrial        fibrillation.|August 2015|August 7, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516033|5 Years|15694|
NCT02516306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-C-002|A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia|A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution (Lipoic Acid Choline Ester, 1.5%), in Improving Distance Corrected Near Vision in Subjects With Presbyopia||Encore Vision, Inc.|No|Active, not recruiting|September 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|45 Years|55 Years|No|||December 2015|December 21, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516306||15673|
NCT02514109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908074|Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies|Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|blood sample for antibodies measure|Both|18 Years|N/A|No|Non-Probability Sample|Patient group : patient with sensitive neuronopathy Control group :patient without        sensitive neuronopathy|March 2016|March 9, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514109||15841|
NCT02517775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-012|Effects of Cranberry Consumption in Vascular Function in Healthy Individuals|Intake and Time-dependent Effects of Cranberry (Poly)Phenol Consumption in Vascular Function in Healthy Individuals|Cranberry|Heinrich-Heine University, Duesseldorf|No|Completed|October 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02517775||15560|
NCT02512198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREC15066|Electronic Prescription Data to Improve Primary Care Prescribing|Electronic Prescription Data to Improve Primary Care Prescribing|EPIPP|University of Dundee|No|Active, not recruiting|July 2015|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|236|||Both|N/A|N/A|No|||December 2015|December 7, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02512198||15986|
NCT02665988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36721|Adjunctive Transcranial Direct Current Stimulation|A Single-Blind, Randomized Control Trial of Adjunctive Transcranial Direct Current Stimulation (tDCS) for Chronic Pain Among Patients Receiving Specialized, Inpatient Multi-Modal Pain Management|tDCS|Baylor College of Medicine|No|Recruiting|January 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665988||4179|
NCT02670421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-000081|Stress Management Intervention in Women's Heart Clinic, Heart SMART Program|Stress Management Intervention in Women's Heart Clinic, Heart SMART Program||Mayo Clinic|No|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|25 Years|75 Years|No|||January 2016|January 29, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670421||3841|
NCT02518516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNODES_Demo_1|High Potency Statins and Acute Kidney Injury|Use of High Potency Statins and Rates of Admission for Acute Kidney Injury: Multicenter, Retrospective Observational Analysis of Administrative Databases||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2067639|||Both|40 Years|N/A|No|Probability Sample|In each jurisdiction, the investigators will assemble a study cohort that includes all        patients with a new prescription for a statin, including simvastatin, lovastatin,        pravastatin, fluvastatin, atorvastatin, and rosuvastatin between 1 January 1997 (or one        year after the beginning of data availability) and 30 April 2008. The date of study cohort        entry is defined by the prescription date of the newly-prescribed statin. Two separate        cohorts will be created based on the presence or absence of a history of chronic kidney        disease.|August 2015|March 11, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518516||15503|
NCT02518529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC12|Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients|An Open, Multi-centre Study to Determine the Tolerability, Safety and Antibody Response Resulting From G17DT at 250mcg at Weeks 0, 2 and 6 With a Booster of 125mcg or 250mcg Given to Patients With Stage I - III Gastric Cancer||Cancer Advances Inc.||Completed|February 2001|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02518529||15502|
NCT02522260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YWengstrom|OptiTrain - Optimal Training Women With Breast Cancer|OptiTrain - Optimal Training for Women With Breast Cancer During Chemotherapy Treatment|OptiTrain|Karolinska Institutet|Yes|Recruiting|August 2013|December 2021|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|240|||Female|18 Years|70 Years|No|||August 2015|August 11, 2015|June 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02522260||15215|
NCT02517567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLT978-P001|DAILIES TOTAL1® - Comparative Assessment of Tear Film Evaporation|Pilot Study on the Effect of Daily Disposable Silicone Hydrogel Contact Lenses on Tear Film Lipids||Alcon Research|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517567||15576|
NCT02517580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK7-002|Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population|Vitamin K2 Supplementation and Effect on Arterial Stiffness Progression in the Renal Transplant Population||Lebanese American University|Yes|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517580||15575|
NCT02516605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJN452X2201|A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of LJN452 in PBC Patients|A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Biliary Cirrhosis||Novartis|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||March 2016|March 18, 2016|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516605||15650|
NCT02516618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-1516|Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Fasinumab in Healthy Japanese and Caucasian Subjects||Regeneron Pharmaceuticals|Yes|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|72|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516618||15649|
NCT02522143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310M45125|College Students Who Self-Harm|College Students Who Self-Harm: An Intervention Study||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|February 2014|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|27 Years|No|||August 2015|August 12, 2015|February 7, 2014||No|No funding|No||https://clinicaltrials.gov/show/NCT02522143||15224|
NCT02522403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR15-010|Acupuncture in Distal Radius Fracture Patients|Application of Laser Acupuncture in Rehabilitating Patients With Distal Radius Fracture||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02522403||15204|
NCT02525341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212M25141|Yoga Versus Exercises for Managing OA|Yoga Versus Aerobic and Strengthening Exercises for Managing Knee Osteoarthritis|YEMO|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|96|||Both|60 Years|N/A|No|||August 2015|August 13, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02525341||14978|
NCT02512731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 11-0055-A|Intraoperative Fluid Therapy for Deceased Donor Renal Transplantation|Intraoperative Fluid Therapy for Deceased Donor Renal Transplantation|EDM|University Health Network, Toronto|No|Active, not recruiting|June 2012|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02512731||15945|
NCT02659969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916052|PregSource: Crowdsourcing to Understand Pregnancy Observations of Daily Living From Pregnant Women|PregSource: Crowdsourcing to Understand Pregnancy Observations of Daily Living From Pregnant Women||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|100000|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|March 11, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02659969||4641|
NCT02660008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP4207-15126|Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon|A Randomized, Double-blind Trial of Single Doses of ZP4207 Administered s.c. to Hypoglycemic Type 1 Diabetic Patients to Describe the Pharmacokinetics and Pharmacodynamics of ZP4207 as Compared to Marketed Glucagon||Zealand Pharma|No|Recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|50 Years|No|||January 2016|January 27, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02660008||4638|
NCT02715986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7733 02|Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy|Structural-functional Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy: an Exploratory Study|ECT-IM|University Hospital, Toulouse|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|50 Years|70 Years|No|||March 2016|March 16, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02715986||344|
NCT02656628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-TRA-T-08-198-03|Observational Patient Registry of the Dynamic Locking Screws|A Multi-Center Prospective, Observational Patient Registry of the Dynamic Locking Screws in Metaphyseal and Diaphyseal Shaft Fractures of the Humerus, Femur and Tibia|DLS|Synthes GmbH|No|Withdrawn|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who meet the in- and exclusion criteria and have signed an informed patient        consent prior to surgery will be included.|January 2016|January 20, 2016|July 4, 2014|Yes|Yes|Due to the voluntary recall of the study device (DLS 3.7mm and DLS 5.0mm)|No||https://clinicaltrials.gov/show/NCT02656628|6 Months|4898|
NCT02656641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35156|Using the PHQ-9 and GAD-7 as Feedback Instruments in Brief Psychotherapy|Using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7-Item Scale (GAD-7) as Feedback Instruments in Brief Psychotherapy||Christiana Care Health Services|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|64 Years|No|||January 2016|January 13, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02656641||4897|
NCT02648308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058323|Extension of the 5As Team Study for Improved Provider Obesity Management to Physicians and Medical Trainees (Part 2)|Extension of the 5As Team Study for Improved Provider Obesity Management to Physicians and Medical Trainees (Part 2)|5AsT-MD2|University of Alberta|No|Recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|First year medical residents who are training in family medicine at the University of        Alberta.|January 2016|January 5, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648308||5536|
NCT02527863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFA-2-2014|Effect of the Aquaretic Tolvaptan on Nitric Oxide System|The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney Disease|TOPO|Regional Hospital Holstebro|Yes|Recruiting|February 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02527863||14784|
NCT02526914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hadassah Medical Organization|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making||Hadassah Medical Organization|No|Not yet recruiting|October 2015|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Anticipated|432|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 16, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526914||14857|
NCT02526940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308020|Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men|Impact of Pre- Antiretroviral Therapy (ART) Blood Cluster of Differentiation (CD)4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men|VIRECT|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|blood specimen and rectal biopsies|Male|18 Years|N/A|No|Probability Sample|3 groups of men elaborated on the basis of their blood CD4+ T cells count at the time of        cART initiation: >350; 350-200; <200, respectively.|October 2015|October 30, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526940||14855|
NCT02518737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRD|Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity|Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide||University of Copenhagen|No|Enrolling by invitation|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|The groups will be recruited from the Helbred2006 cohort, Glostrup Hospital, Denmark.|August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02518737||15486|
NCT02521441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-CDR-1-1302|A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.|A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiveing Myelotoxic Chemotherapy.||Generon (Shanghai) Corporation Ltd.|No|Recruiting|May 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|70 Years|No|||August 2015|August 11, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521441||15278|
NCT02521454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT008854-01|A Pilot Trial of Mindfulness-Based Resilience Training Among Police Officers|||Pacific University|Yes|Recruiting|August 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02521454||15277|
NCT02524704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColoradoSU|Electrical Impedance Imaging of Patients With Cystic Fibrosis|Electrical Impedance Tomography (EIT): A Non-radiating Functional Imaging for Cystic Fibrosis||Colorado State University|Yes|Enrolling by invitation|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|80|||Both|2 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|There are three groups in this study. Group 1 consists of healthy controls between the        ages of 2 and 21. Group 2 consists of persons with cystic fibrosis between the ages of 2        and 21 who are either clinically indicated for a pulmonary CT scan or will receive one as        part of their routine care. Group 3 consists of persons with cystic fibrosis between the        ages of 8 and 21 who are being started on IV antibiotics for a clinically diagnosed        pulmonary exacerbation.        Sampling is by convenience or invitation to volunteer.|August 2015|August 13, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02524704||15027|
NCT02667522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 MH108766-01A1|Shaping Neural Activity Through Parenting|Targeting Biomarkers of Risk for Depression and Anxiety Through a Parenting Intervention|SNAP|Stony Brook University|Yes|Not yet recruiting|April 2016|May 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|6 Years|7 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02667522||4061|
NCT02511496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP-COI-1-2014|Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia|Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia||Maimónides Biomedical Research Institute of Córdoba|No|Not yet recruiting|September 2015|December 2020|Anticipated|November 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|2800|||Both|18 Years|N/A|No|Non-Probability Sample|The sample consists of all HIV-infected patients co-infected with an active chronic HCV.|July 2015|July 30, 2015|March 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02511496|5 Years|16040|
NCT02515526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EtOH_CYP_2013_KPUK|Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein|Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein||University of Cologne|Yes|Active, not recruiting|June 2015|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02515526||15732|
NCT02523898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SemnanUMS1|Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant|Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial||Semnan University of Medical Sciences|Yes|Enrolling by invitation|November 2015|August 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|388|||Female|20 Years|36 Years|No|||July 2015|August 12, 2015|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523898||15089|
NCT02524340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCATS for JIA|Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference|Patient Centered Adaptive Treatment Strategies for Juvenile Idiopathic Arthritis Using Bayesian Causal Inference||Children's Hospital Medical Center, Cincinnati|No|Not yet recruiting|September 2015|May 2019|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1144|||Both|2 Years|19 Years|No|Non-Probability Sample|Children less than 19 years of age that have been diagnosed with JIA and that have a study        visit recorded in the electronic health record within 1 year of diagnosis.|August 2015|August 13, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524340|1 Year|15055|
NCT02524353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFEV01|Follow-up Study of Patients Undergoing Cardiac Surgery|Follow-up Study of Functional Capacity and Respiratory Muscle Strength in Patients Undergoing Cardiac Surgery|Follow-up01|Centro Universitário de Votuporanga|No|Not yet recruiting|August 2015|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||August 2015|August 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02524353||15054|
NCT02671201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-412|Training Concepts in Emergency Ultrasonography|Training Concepts in Emergency Ultrasonography for Medical Students||University of Cologne|No|Recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Undergraduate medical students|January 2016|February 1, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02671201||3781|
NCT02523261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPN_2015_22|Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke||ASTER|Fondation Ophtalmologique Adolphe de Rothschild|Yes|Recruiting|October 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|322|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523261||15138|
NCT02525497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-PD-2014|Safety, Effectiveness and Manipulability Evaluation of a Domestic PD Machine|A Randomized, Multicenter, Crossover Study Comparing the Domestic FM Peritoneal Dialysis Machine With Baxter HOMECHOICE||Chinese PLA General Hospital|Yes|Active, not recruiting|July 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 25, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02525497||14966|
NCT02513771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5346|Sitagliptin for Reducing Inflammation and Immune Activation|A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)||AIDS Clinical Trials Group|Yes|Recruiting|September 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513771||15866|
NCT02671292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS-72-3248|Preventing Obesity in Military Communities-Adolescents|Preventing Obesity in Military Communities-Adolescents|POMC-A|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Recruiting|July 2015|May 2021|Anticipated|May 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02671292||3774|
NCT02671305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152-2014|Delivery Room Assistance With the Placental Circulation Intact|Delivery Room Assistance With the Placental Circulation Intact: Effects on Early Postnatal Adaptation and Outcome of Preterm Babies. Study Protocol for a Randomized Control Trial (the PCI-trial)|PCI-T|University of Florence|No|Not yet recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|23 Weeks|29 Weeks|No|||January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671305||3773|
NCT02523378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0284|Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion|Edmonton Symptom Assessment Scale: Time Duration of Self-Completion Versus Assisted-Completion in Advanced Cancer Patient: a Randomized Controlled Trial||M.D. Anderson Cancer Center|No|Recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02523378||15129|
NCT02520037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Aarhus|Fluid Responsiveness Prediction Using Extra Systoles|Fluid Responsiveness Prediction Using Extra Systoles in Critically Ill Patients||University of Aarhus|No|Recruiting|June 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients admitted to a University Hospital intensive care unit|July 2015|August 6, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02520037||15386|
NCT02518880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-178|Dynamics of Stroke Volume and Cardiac Output During Parabolic Flight, and Its Relationship to Intravascular Volume||DYMCO|University Hospital, Caen|No|Completed|March 2010|||February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518880||15475|
NCT02524743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.04.2014/48|The Prevention of Pain Associated With Rocuronium Injection|The Prevention of Pain Associated With Rocuronium Injection: Effect of Pretreatment With Acetaminophen and Lidocaine||Suleyman Demirel University|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02524743||15024|
NCT02671383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRHI052|Evaluation of Low-dose Darunavir in a Switch Study|A Randomised, Open Label Switch Study Comparing Darunavir/Ritonavir 400mg/100mg Daily With Lopinavir/Ritonavir 800mg/200mg Daily, in HIV-positive Participants|DRV|University of Witwatersrand, South Africa|Yes|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02671383||3767|
NCT02517463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW10-392|Ulipristal Emergency Contraception Used Before or After Ovulation|Observational Study on the Clinical Efficacy of Ulipristal for Emergency Contraception When Administered Before or After Ovulation||The University of Hong Kong|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|700|||Female|18 Years|N/A|No|Probability Sample|A total of 700 women attending the Family Planning Association of Hong Kong for emergency        contraception who fulfilled the inclusion criteria and not meeting the exclusion criteria        were recruited.|August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02517463||15584|
NCT02512133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|MIGS VS SLT Comparison in Glaucoma Patients|MIGS VS SLT in Glaucoma Patients: Prospective Study||University of Turin, Italy|No|Active, not recruiting|February 2012|July 2017|Anticipated|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|50 Years|80 Years|No|||July 2015|July 29, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02512133||15991|
NCT02524873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC01|Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension|Assessment of the Relationship Between Genes That Encode Proteins Important in Blood Pressure Regulation and Blood Pressure Therapy in Patients With Hypertension||Geneticure, LLC|No|Completed|April 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|99|||Both|30 Years|70 Years|No|Non-Probability Sample|Patients with hypertension|August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524873||15014|
NCT02674074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 120/11|Evaluation of Corneal Temperature by Infrared Thermography in Glaucoma Patients|Evaluation of Corneal Temperature by Infrared Thermography in Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02674074||3562|
NCT02674087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I1 029|Prospective Monitoring of Children Born in Haute Vienne From Uterine Life to Adulthood||NEHAVI|University Hospital, Limoges|No|Recruiting|April 2014|April 2019|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Expectant mother|January 2016|February 3, 2016|April 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02674087|3 Years|3561|
NCT02521285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01265|Acetylsalicylic Acid in Preventing Disease Recurrence in Patients With Barrett's Esophagus After Successful Elimination by Radiofrequency Ablation|Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation||National Cancer Institute (NCI)|Yes|Recruiting|January 2016|||April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|118|||Both|18 Years|75 Years|No|||January 2016|February 4, 2016|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521285||15290|
NCT02527369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1-713/2/2014|Effect of the XP1100RF Therapy on Thighs Circumference Reduction|Effect of the XP1100RF Therapy on Thighs Circumference Reduction||BTL Industries Ltd.|No|Active, not recruiting|December 2014|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|22 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02527369||14822|
NCT02669576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-6578-BO|Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy|Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy: A Randomized Controlled Trial.|ENDOTK|Universität Duisburg-Essen|No|Recruiting|January 2016|January 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Female|18 Years|75 Years|No|||February 2016|February 15, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02669576||3906|
NCT02669589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM 14_0066|Investigating Different Anticoagulants for Renal Replacement Therapy|Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury|RICH|University Hospital Muenster|Yes|Recruiting|March 2016|March 2021|Anticipated|February 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1450|||Both|18 Years|90 Years|No|||March 2016|March 23, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02669589||3905|
NCT02527382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23937|Peritoneal Bacterial Contamination Following Resection With Closed or Open Rectal Stump for Left-sided Cancer|Peritoneal Bacterial Contamination With Closed or Open Rectal Stump||Bucharest Emergency Hospital|Yes|Completed|January 2014|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|26|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02527382||14821|
NCT02512705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patterson-1|Medical Monitoring for Agitated Patients Pilot RCT - Medical Monitoring|A Pilot Randomized Control Trial: The Ability to Medically Monitor With Use of Physical and Chemical Restraints or Seclusion of Acutely Agitated or Violent Patients Who Present to the Psychiatric Emergency Services||St. Joseph's Healthcare Hamilton|Yes|Not yet recruiting|September 2015|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02512705||15947|
NCT02512952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224/2013-14|Treatment of Periodontal Intrabony Defects Using Autologous Platelet Rich Fibrin vs Titanium Platelet Rich Fibrin|Treatment of Periodontal Intrabony Defects Using Autologous Platelet Rich Fibrin and Titanium Platelet Rich Fibrin: A Randomized Clinical Comparative Study||Government Dental College and Research Institute, Bangalore|No|Completed|June 2014|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|38|||Both|20 Years|55 Years|No|||July 2015|July 29, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02512952||15928|
NCT02511392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS-OCD|Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive Compulsive Disorders|Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive-Compulsive Disorders: Double Blind Randomized Clinical Trial|rTMS-OCD|Assiut University|No|Completed|January 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|20 Years|50 Years|No|||July 2015|July 29, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511392||16048|
NCT02511405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-111-215|A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)|A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma|GLOBE|Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Recruiting|August 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511405||16047|
NCT02511418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475-01|Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure|Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure||Mayo Clinic||Completed||||January 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02511418||16046|
NCT02665234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIM-726|A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease|A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease||Mimetogen Pharmaceuticals USA, Inc.|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665234||4236|
NCT02521610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29772|A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Healthy Subjects||Hoffmann-La Roche||Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521610||15265|
NCT02524483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|467-14-EP|Influence of High-Dosage Physical Therapy on the Balance and Mobility of Individuals With Multiple Sclerosis|||University of Nebraska||Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|30 Years|70 Years|No|||August 2015|August 12, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02524483||15044|
NCT02524496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009012025|Limited Access Protocol for the Use of Oral Cisapride|Limited Access, Open-label, Compassionate Use of Cisapride in the Treatment of Gastroparesis||Yale University|No|Completed|March 2001|March 2011|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects of the study were diagonosed with gastroparesis that was not being adequately        treated.|August 2015|August 13, 2015|December 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT02524496||15043|
NCT02512757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ajinomoto 2015-01|A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology|The AminoIndex™ Study - A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology||Innovis LLC|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|Subjects will consent to archiving and future analysis of their blood samples for up to      twenty (20) years.|Both|55 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Study will enroll sufficient subjects to yield a minimum of 60 subjects in Study Group 1,        30 subjects in Study Group 2 and 60 subjects in Study Group 3 - a total of 150 evaluable        study subjects who meet all inclusion and exclusion criteria. Eligible subjects will be        men and women age 55 - 79, inclusive, who meet NLST guidelines of being at high risk for        lung cancer: greater than or equal to a 30 pack year smoking history (equivalent of 1 pack        per day for 30 or more years) and a current smoker or quit less than 15 years ago.|July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512757||15943|
NCT02512770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270718|Hemodynamic and Respiratory Effects of Esophageal Dilation in Children|Esaphageal Balloon Dilatation in Children: Hemodynamic , Ventilatory Changes and Complications||Istanbul University|Yes|Completed|January 2015|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|N/A|16 Years|No|||July 2015|July 30, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02512770||15942|
NCT02520726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUtahIRB0062412|PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims|A Randomized, Double-blind, Placebo-controlled Pilot Study of Sertraline for the Prevention of PTSD in Burn Victims||University of Utah|No|Recruiting|September 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|April 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520726||15333|
NCT02523560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATEGME1/233547/13/NCBR/2015|Applying Telemedicine in a Model of Implementing Cardiac Rehabilitation in Heart Failure Patients|Applying Telemedicine Technologies in a Novel Model of Organizing and Implementing Comprehensive Cardiac Rehabilitation in Heart Failure Patients - TELEREH-HF|TELEREH-HF|Institute of Cardiology, Warsaw, Poland|Yes|Recruiting|June 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|850|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02523560||15115|
NCT02524561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002326|KEEPS Mammographic Density And Breast Health Ancillary Study|KEEPS Mammographic Density And Breast Health Ancillary Study|KEEPS MDBHAS|Brigham and Women's Hospital|Yes|Completed|September 2005|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|727|||Female|42 Years|58 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524561||15038|
NCT02513030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2033-MG-CTIL|Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing|Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing|SIMPLER|Sheba Medical Center|No|Not yet recruiting|August 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an ICD or CRT-D undergoing pocket generator replacement.|July 2015|July 28, 2015|March 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02513030||15922|
NCT02513043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1031|Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine|Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine||Gynuity Health Projects|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|11 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women seeking abortion|March 2016|March 8, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513043||15921|
NCT02520765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|obesity index in ICSI|Obesity Index That Better Predict Ovarian Response|Obesity Index That Better Predict Ovarian Response: Body Mass Index, Waist Circumference, Waist Hip Ratio, or Waist Height Ratio in Women Undergoing ICSI||Ain Shams University|Yes|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|20 Years|35 Years|No|Non-Probability Sample|200 patients who are admitted to the IVF center at Ain Shmas University hospital and        scheduled for ICSI|February 2016|February 17, 2016|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02520765||15330|
NCT02516423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A061402|Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone|Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy||Alliance for Clinical Trials in Oncology|Yes|Recruiting|December 2015|||September 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516423||15664|
NCT02516436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNX-302|The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects|A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA®) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects||BioDelivery Sciences International|No|Not yet recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||August 2015|August 4, 2015|August 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516436||15663|
NCT02519608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150497|ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts|Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI|NATHAN-NEVER|University Hospital of Ferrara|Yes|Recruiting|September 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02519608||15419|
NCT02527798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1978|Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)|Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia||University of North Carolina, Chapel Hill|Yes|Recruiting|August 2015|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|120|||Both|N/A|28 Days|No|||October 2015|October 30, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527798||14789|
NCT02518269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GH33|A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty|A Prospective 3-Arm Randomized Controlled Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty||Biomet, Inc.|No|Recruiting|May 2015|December 2026|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02518269||15522|
NCT02516722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNS01-001|TReatment Of Pulmonary HYpertension 1 Study|Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension|TROPHY|SoniVie Ltd.|Yes|Not yet recruiting|November 2015|April 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02516722||15641|
NCT02521207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXP001-003|Pilot Study of OXP001(2) and Brufen in Healthy Subjects|A Two-Part, Randomised, Open-Label, Evaluator-Blinded, Multiple-Dose, Phase I Pilot Study With OXP001 Ibuprofen 400 mg Tablets and Brufen® 400 mg Tablets to Assess the Comparative Bioavailability (Part 1) and Effects on Gastroduodenal Irritation (Part 2) in Healthy Human Subjects||Oxford Pharmascience Ltd|No|Completed|July 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|53|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02521207||15296|
NCT02524327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-28|Frail Status of Elderly Patients After Repair and Anesthesia Guided by the bispectraL Index|Influence of the Modality of General Anesthesia Guided by the Bispectral Index (Manual or Automated) on the Occurrence of a Loss of Capability in Elderly Patients (> 70 Yrs): a Randomized Multicenter Study|FRAIL|Hopital Foch|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|430|||Both|70 Years|N/A|No|||February 2016|February 19, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524327||15056|
NCT02670122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJD-TAN-14-01|Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC|Prospective, Multicenter, Non Randomized, Single Arm Study to Evaluate Safety of Transarterial Chemoembolization (TACE) With Doxorubicin Eluting 100 µ Microspheres in Patients With Non Resectable Hepatocellular Carcinoma||Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|No|Recruiting|March 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|90 Years|No|Non-Probability Sample|Target population includes:          -  Patients with stage B HCC carcinoma according to Barcelona Clinic Liver Cancer             classification (BCLC).          -  Patients with stage A HCC according to BCLC if they are not candidates or not willing             to go through surgery or radiofrecuency.|January 2016|January 30, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670122||3864|
NCT02670135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2014-09-CT-ISR-DB|Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers|Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers||Colgate Palmolive|No|Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|January 29, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670135||3863|
NCT02521389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWT-143|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects||MEI Pharma, Inc.|No|Active, not recruiting|June 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|35|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02521389||15282|
NCT02525172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504036MIPB|Immune Modulation Therapy for Pompe Disease|Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients||National Taiwan University Hospital|Yes|Recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|N/A|N/A|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02525172||14991|
NCT02670408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATAGC 002|Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation|Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation, a Multicenter Study (INTERHEART)||University of Alberta|No|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Biopsy extract containing RNA|Both|18 Years|N/A|No|Non-Probability Sample|This study aims to recruit 300 biopsies from heart transplant patients for clinical        indications and the standard of care biopsies.|January 2016|January 27, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02670408||3842|
NCT02518282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 15-223 CINV 15-01|High-sensitivity Troponin T in Acute Myocardial Infarction After Cardiac Valvular Surgery|High-sensitivity Troponin T in Acute Myocardial Infarction in Patients Undergoing Cardiac Valvular Surgery||University of Valladolid|Yes|Recruiting|January 2014|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|Adult patients (over 18 years old) undergoing heart valvular surgery with CPB.|August 2015|August 14, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518282||15521|
NCT02522013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHZZU-166|Aminophylline for Patients With Post-Dural Puncture Headache|Aminophylline for Patients With Post-Dural Puncture Headache: a Prospective, Multi-center, Randomized Controlled Trial||The First Affiliated Hospital of Zhengzhou University|Yes|Recruiting|October 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02522013||15234|
NCT02516826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01-055|The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease|The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial||Samsung Medical Center|No|Not yet recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|504|||Both|19 Years|70 Years|No|||August 2015|August 4, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516826||15633|
NCT02670434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-CR-3.01US|Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia|||Kowa Research Institute, Inc.||Recruiting|January 2016|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02670434||3840|
NCT02522169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000076-25|TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease|Verbessertes Therapiemanagement für pädiatrische CED-Patienten Mit Chronisch-entzündlicher Darmerkrankung: Eine Randomisierte Multizentrische Studie, Welche Die Effektivität Einer Talspiegel-gesteuerten Infliximab-Erhaltungsphase Mit Dem herkömmlichen Dosierungsregime Vergleicht Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Randomized Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease|TOPIT|Klinikum Westbrandenburg GmbH|No|Not yet recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|17 Years|No|||August 2015|August 12, 2015|May 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02522169||15222|
NCT02528006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges|Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges||Kumamoto University|Yes|Active, not recruiting|August 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2015|February 23, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02528006||14773|
NCT02522585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN-II p16 NK|p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management|Predictive Value of p16 and Ki-67 Immunohistochemical Staining and NK Cells in Expectant Management of Cervical Intraepithelial Neoplasia Grade 2||Parc de Salut Mar|Yes|Active, not recruiting|December 2011|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Citologies and biopsies of the cervix. Blood cells.|Female|18 Years|N/A|No|Non-Probability Sample|Adult females with CIN-II lesion on cervical biopsy that agree to a conservative        management during a period not more than 24 months, referred to the low genital tract        diseases clinic of Hospital del Mar.|August 2015|August 11, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02522585||15190|
NCT02670902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DA035330|Intervention for Persons Leaving Residential Substance Abuse Treatment|Intervention for Persons With Co-Occurring Disorders Leaving Residential Tx||New York University|No|Not yet recruiting|June 2016|February 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02670902||3804|
NCT02526771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHLND-2015-8-10|Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma|A Randomized Controlled Study of Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526771||14868|
NCT02513381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/YH/1125|Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome|The Effect of Colecalciferol (Vitamin D) on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Double Blind Randomised Placebo-controlled Study||University of Hull|Yes|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|40|||Female|18 Years|45 Years|No|||October 2015|October 19, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02513381||15895|
NCT02517853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETP-01-2014|Efficiency of Neurostimulation of Tibial Nerve in the Treatment of Low Anterior Resection Syndrome|Prospective and Randomized Study to Evaluate the Efficiency of Percutaneous Neurostimulation of Posterior Tibial Nerve in the Treatment of Low Anterior Resection Syndrome (LARS)||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|February 2016|July 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|42|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02517853||15554|
NCT02517866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI-P4-002|Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia|A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia||Takeda|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|494|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02517866||15553|
NCT02658552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-486|A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules|A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules||The University of Hong Kong|Yes|Recruiting|November 2015|July 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02658552||4750|
NCT02658565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-GYN-150-MCC|Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation|Surgical Staging for the Treatment of Endometrial Cancer Based on IOC||University of Kentucky|Yes|Not yet recruiting|January 2016|December 2024|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|100 Years|No|||January 2016|January 14, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658565||4749|
NCT02720354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK-DMDPA-001|A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"|||Synektik S.A.|Yes|Not yet recruiting|April 2016|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02720354||8|
NCT02720367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-200-102|Safety and Tolerability of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Bladder Cancer|A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder||Taris Biomedical LLC||Not yet recruiting|May 2016|||August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02720367||7|
NCT02716285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL56000.068.16; METC162009|Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery|Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery|PERSUADE|Maastricht University Medical Center|No|Not yet recruiting|May 2016|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|178|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02716285||321|
NCT02646358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-188-10|Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer|A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function||Mast Therapeutics, Inc.|No|Recruiting|January 2016|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|January 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646358||5686|
NCT02653339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-958|Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.|||Peking Union Medical College Hospital|No|Not yet recruiting|February 2016|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02653339||5150|
NCT02653352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500404/2003-8|Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas|School Randomised Trial on Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas||Rio de Janeiro State University|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1140|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||November 2015|January 8, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02653352||5149|
NCT02512718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00016641|Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation|Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation||Children's Hospital Boston|Yes|Not yet recruiting|July 2015|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|1 Month|35 Years|No|||July 2015|July 29, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512718||15946|
NCT02515448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENTAERO|A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia||GENTAERO|Poitiers University Hospital||Active, not recruiting||||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2015|August 3, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02515448||15738|
NCT02520115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-024|Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer|Study of Serum Measured Folate Receptor and Its Induction as a Biomarker in the Diagnosis and Surveillance of Ovarian Carcinoma||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02520115||15380|
NCT02521727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NonAA|To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas|A Prospective Colonoscopic Study to Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas (NonAA Study)|NonAA|Chinese University of Hong Kong|Yes|Not yet recruiting|August 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|828|Samples With DNA|stool, colonic mucosa|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|siblings of Hong Kong Chinese patients with advanced neoplasm compared with a sex and        age-matched control population|August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02521727||15256|
NCT02527941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTorontoBV|Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology|Effect of Bacterial Vaginosis and Its Treatment on HIV Susceptibility and Female Genital Immunology||University of Toronto|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527941||14778|
NCT02513914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15BN045|Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial|Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP)|OPEN-UP|St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513914||15855|
NCT02513225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14020838|Trial of an Adapted STD Screening and Risk Reduction Intervention|Randomized Controlled Trial of an Adapted STD Screening and Risk Reduction Intervention||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02513225||15907|
NCT02671162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT2015080110410N2|Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus|Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial||Shiraz University of Medical Sciences|Yes|Completed|July 2015|January 2016|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||January 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671162||3784|
NCT02519491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150116-01H|Utility of a Smart Phone Application in Assessing Radial Artery Patency - the CAPITAL iRADIAL Study|Utility of a Smart Phone Application in Assessing Radial Artery Patency - the CAPITAL iRADIAL Study||Ottawa Heart Institute Research Corporation|No|Recruiting|July 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|438|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02519491||15428|
NCT02511301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH001|Circadian Thermal Sensing to Detect Breast Disease|Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System||Cyrcadia Health|Yes|Recruiting|June 2015|February 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|173|||Female|21 Years|N/A|No|||June 2015|July 28, 2015|June 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511301||16055|
NCT02525250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS-AML-NK / IPC-2012-007|Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide|Pilot Study Immunomonitoring NK Cells in Patients With Myeloid Malignancies||Institut Paoli-Calmettes|No|Completed|December 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|August 13, 2015|April 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02525250||14985|
NCT02525263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTX-CL001|Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)|A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease|RMTX-CL001|RegenMedTX LLC|Yes|Not yet recruiting|August 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|70 Years|No|||August 2015|August 13, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525263||14984|
NCT02673372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-14|Geriatric Ketamine for Pain Management Study|Low-Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department Geriatric Population: A Prospective, Randomized, Double-Blind Study.||Maimonides Medical Center|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|65 Years|120 Years|No|||February 2016|February 11, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673372||3616|
NCT02511782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0212|Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD|Use of a Transdermal Patch to Noninvasively Monitor Inflammatory Biomarkers of Acute and Chronic Skin GVHD||Children's Hospital Medical Center, Cincinnati|No|Completed|February 2012|October 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|57|||Both|3 Months|30 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02511782||16018|
NCT02511587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV_FSME_1.2|Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®|Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®||Medical University of Vienna|No|Completed|October 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511587||16033|
NCT02518659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL nr.: 47262.091.13|Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors|Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia|Privet|Radboud University|No|Completed|February 2014|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02518659||15492|
NCT02673762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeriRx003|Salivary Transcriptome Biomarkers for Early Diabetes Detection|Salivary Transcriptome Biomarkers for Early Diabetes Detection||PeriRx|No|Recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|180|Samples With DNA|Salivary mRNA and cDNA|Both|18 Years|N/A|No|Non-Probability Sample|Adults with undiagnosed abnormal glucose metabolism undergoing clinically driven screening        for pre-diabetes and type II diabetes.|December 2015|February 1, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02673762||3586|
NCT02512068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472-3003|A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 25 mg Once Weekly to Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure||Takeda|No|Recruiting|August 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|20 Years|N/A|No|||January 2016|January 28, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02512068||15996|
NCT02512328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERICLES-I-APP|Improvement of Colonoscopy Preparation by New Media (APP)|First Experiences With an Offline App (SPA; Smartphone Application) for Colonoscopy Preparation- PERICLES-I APP; Prospective Evaluations of Improvement of Colonocopy Preparation by Optimized Visualization (PERICLES)|PERICLESAPPI|Technische Universität München|No|Recruiting|March 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02512328||15976|
NCT02527291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-0231-15-CTIL|Cytomegalovirus Reactivation in Non Immunocompromised Patients Undergoing Cardiac Surgery|Cytomegalovirus Reactivation in Non Immunocompromised Patients Undergoing Cardiac Surgery||Soroka University Medical Center|Yes|Recruiting|November 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|Blood work: Cytomegalovirus Ab (CMV Ab), Cytomegalovirus Polymerase Chain Reaction (CMV PCR)      and Interleukin (IL28).|Both|18 Years|N/A|No|Non-Probability Sample|The study population will be screened at the cardiothorathic surgery ward Soroka Medical        Center.|March 2016|March 15, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527291||14828|
NCT02524795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LES-001-O3|Omega 3 Fatty Acids and Systemic Lupus Erythematosus|Omega 3 Fatty Acids, Inflammatory Status and Biochemical Markers of Patients With Systemic Lupus Erythematosus: a Pilot Study|OM3LES|Federal University of Minas Gerais|No|Completed|March 2009|March 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|60 Years|No|||August 2015|August 13, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02524795||15020|
NCT02673918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCH-UBC 01|The Breast Cancer Online Rehabilitation Program|The Breast Cancer Online Rehabilitation Program: A Feasibility Study of Individually Tailored Online Rehabilitation After Breast Cancer Surgery The Copenhagen BRECOR Program|BRECOR|University of British Columbia|No|Not yet recruiting|February 2016|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02673918||3574|
NCT02673931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJE-PHARMA-001|GLP-1 and Hyperoxia for Organ Protection in Heart Surgery|Efficacy of Glucagon-like-peptide-1 Agonists and Restrictive vs. Liberal FiO2 in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study|GLORIOUS|Rigshospitalet, Denmark|Yes|Recruiting|February 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1080|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673931||3573|
NCT02521168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164/H2.F1/ETIK/2013|Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia|Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia|OTICC|National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Completed|July 2013|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|N/A|36 Months|No|||February 2016|February 16, 2016|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02521168||15299|
NCT02521181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK099877-B|The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)|The BASE Study: Bicarbonate Administration to Stabilize eGFR|BASE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|October 2015|June 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|192|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02521181||15298|
NCT02516189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEFMM|Strength Training for Elderlies and Their Effects on Muscle Fatigue and Microcirculation - Randomized Clinical Trial|Strength Training for Elderlies and Their Effects on Muscle Fatigue and Microcirculation - Randomized Clinical Trial||Professor Fernando Figueira Integral Medicine Institute|No|Not yet recruiting|August 2015|November 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|2||Anticipated|80|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516189||15682|
NCT02664480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gulhane School of Medicine|Assesment of Salivary Alpha-amylase Levels Before and After Ovulation|Assesment of Salivary Alpha-amylase Levels Before and After Ovulation: A Randomized Controlled Trial||Gulhane Military Medical Academy|No|Enrolling by invitation|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|Samples Without DNA|salivary amylase|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Pcos women will included the study population. Because ovulation don't happen.|January 2016|January 22, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02664480||4294|
NCT02527330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-2770A3|Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging|Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging|CHFIRONMR|Chang Gung Memorial Hospital|No|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acute HF episode with hospitalization treatment within 12 months were        enrolled.|August 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527330||14825|
NCT02527343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS17|The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Partial Lipodystrophy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Partial Lipodystrophy||Ionis Pharmaceuticals, Inc.|Yes|Recruiting|October 2015|||September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527343||14824|
NCT02527356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST-104-2314-B-182-023-MY3|Advancing Mobility and Socialization in Toddlers With Disabilities: a Trial to Assess the Effects of Modified Toy Cars Training With Different Postures|||Chang Gung Memorial Hospital|No|Enrolling by invitation|August 2015|July 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|12 Months|36 Months|No|||July 2015|August 18, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527356||14823|
NCT02512393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500357-2|Transcranial Direct Current Stimulation in Older Persons With Knee Pain (Knee Pain and tDCS): Randomized Pilot Study|Transcranial Direct Current Stimulation in Older Persons With Knee Pain: Randomized Pilot Study||University of Florida|Yes|Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|85 Years|No|||December 2015|December 8, 2015|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512393||15971|
NCT02515422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/99|Subcutaneous Wound Infiltration of Ketamine or Bupivacaine Pain Perception After Cesarean Section|Subcutaneous Wound Infiltration of Ketamine is Superior to Bupivacaine in Terms of Pain Perception and Opioid Consumption After Cesarean Section: a Double-blinded Randomized Placebo Controlled Clinical Trial.||Kayseri Education and Research Hospital||Completed|June 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515422||15740|
NCT02515435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK1405|The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced Non-squamous Non-small Cell Lung Cancer Patients Who Failed to Previous at Least 3rd Line Treatments.||Tongji University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515435||15739|
NCT02515695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 92/05|Phase I BP Interferon (IFN) Beta-001|Bioavailability, Pharmacokinetic and Pharmacodynamic Profile of Interferon Beta-1a (Bioferon®) Administered i.v. and s.c. as Single Doses to Healthy Subjects||Centre Hospitalier Universitaire Vaudois|Yes|Completed|May 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02515695||15719|
NCT02672384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-ICU STUDY (RB 15.108)|Chronic Periodontitis in Critically Ill Patients: Diagnosis and Epidemiology||CP-ICU|University Hospital, Brest|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02672384||3690|
NCT02672397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010975|The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia|The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia in Hispanic and Caucasian Parturients: A Randomized Controlled Trial||Oregon Health and Science University|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|4||Anticipated|176|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02672397||3689|
NCT02513901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015TD-Chidamide|Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir|Safety and Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir(CHARTER)|CHARTER|Tang-Du Hospital|Yes|Recruiting|July 2015|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||August 2015|August 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513901||15856|
NCT02517268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.050|Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer|A Prospective Randomized Controlled Trial Evaluating an Accelerated 5 Day Pathway for Discharge Following Pancreaticoduodenectomy (PD): Whipple Accelerated Recovery Pathway (WARP Trial)|WARP|Thomas Jefferson University|Yes|Not yet recruiting||||August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02517268||15599|
NCT02515994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5726|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2015|||||N/A|N/A|N/A||||||||||||||November 19, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515994||15696|
NCT02516020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_ 05_2015|Effectiveness of Single Step Culture Media and Sequential Culture Media on Blastulation Rate|Effectiveness of Single Step Culture Media and Sequential Culture Media on Blastulation Rate: a Randomized Controlled Trial.||Vietnam National University|No|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|448|||Female|18 Years|42 Years|No|||August 2015|August 10, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516020||15695|
NCT02670174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/0816|Influence of Kinetic Chain Training on the Treatment Outcome of Overhead Athletes With Impingement|Influence of Kinetic Chain Training on the Treatment Outcome of Overhead Athletes With Shoulder Impingement Syndrome||University Ghent|No|Recruiting|September 2015|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2016|January 29, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02670174||3860|
NCT02527408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1818-15|Wearable Technology for Hospital Inpatients|Wearable Technology for Hospital Inpatients|WEARIT-IN|Queen's University|No|Recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult intensive care unit patients|August 2015|August 17, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02527408||14819|
NCT02514850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT018|A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes|A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes||Adocia|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|64 Years|No|||November 2015|November 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514850||15784|
NCT02517905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-329|Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Local Administration of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction||Pacira Pharmaceuticals, Inc|No|Completed|August 2015|February 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517905||15550|
NCT02517918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2014-01|Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma|Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group|METZOLIMOS|Institut Bergonié|Yes|Recruiting|February 2015|August 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|13 Years|N/A|No|||March 2016|March 3, 2016|February 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02517918||15549|
NCT02523118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2311|OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages|A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)|OMEGA|Children's Hospital Medical Center, Cincinnati|No|Recruiting|July 2015|January 2051|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|1050|Samples With DNA|Biopsies from the gastrointestinal (GI) tract may be collected and used to learn more about      eosinophilic gastrointestinal disorders. Genetic analysis may be performed on some of these      samples.|Both|3 Years|65 Years|No|Non-Probability Sample|Males and females between the ages of 3-65 years with EoE, EG, or EC|August 2015|August 12, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02523118||15149|
NCT02523131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCam11|Home Testing of Day and Night Closed Loop With Pump Suspend Feature|An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions|APCam11|University of Cambridge|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|6 Years|N/A|No|||November 2015|November 14, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02523131||15148|
NCT02511535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBE_1.1|TBE Vaccination in Allergic Patients|TBE Vaccination in Allergic Patients||Medical University of Vienna|Yes|Recruiting|September 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|156|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511535||16037|
NCT02511548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCUptake|Increasing Medical Male Circumcision Uptake|Increasing Medical Male Circumcision Uptake in Orange Farm (South Africa): An Operational Study of Demand Creation||Progressus|No|Not yet recruiting|August 2015|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|140|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511548||16036|
NCT02515084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 10-03|Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma|Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT|THYRIRMTEP|Centre Henri Becquerel|No|Active, not recruiting|March 2011|December 2015|Anticipated|July 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|August 3, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02515084||15766|
NCT02515383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0271|Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)|Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|13 Years|17 Years|No|Non-Probability Sample|Adolescent patients at The University of Texas MD Anderson Cancer Center in Houston, Texas|February 2016|February 1, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02515383||15743|
NCT02518217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShapeUpEmpower2015|ShapeUp Empower Study|||The Miriam Hospital|No|Recruiting|August 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||January 2016|February 11, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518217||15526|
NCT02523222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36132|Dextrose Gel for Newborn Hypoglycemia|Dextrose Gel for Newborn Hypoglycemia||Baylor University|Yes|Not yet recruiting|September 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1032|||Both|N/A|48 Hours|No|||August 2015|August 12, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523222||15141|
NCT02520518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-5531H|Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?|Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?||Colorado State University|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|92|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520518||15349|
NCT02524249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506014098|Early Versus Late Caffeine for ELBW Newborns|A Randomized Double Blind Controlled Trial of Early Versus Late Caffeine for Extremely Low Birth Weight Newborns||Wayne State University|Yes|Recruiting|September 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|4 Weeks|No|||November 2015|November 19, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524249||15062|
NCT02515721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G06|PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma|Probe-based Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia,Intraepithelial Neoplasia,and Carcinoma:A Multicenter,Randomized,Controlled Trial|PCLE|Shandong University|Yes|Recruiting|July 2014|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|242|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515721||15717|
NCT02515734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO CC-13|A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab|A Randomized Phase II Study to Investigate the Deepness of Response of FOLFOXIRI Plus Cetuximab (Erbitux) Versus FOLFOXIRI Plus Bevacizumab as the First-line Therapy in Metastatic Colorectal Cancer Patients With RAS Wild-type Tumors: DEEPER|DEEPER|Japan Clinical Cancer Research Organization|Yes|Not yet recruiting|August 2015|June 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|20 Years|N/A|No|||August 2015|August 4, 2015|July 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515734||15716|
NCT02526615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TurkuUH-ROSI|Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes|Comparison of Effects of Rosiglitazone and Metformin on Myocardial, Skeletal Muscle, Liver and Adipose Tissue Insulin Stimulated Glucose Uptake in Patients With Type 2 Diabetes Mellitus|ROSI|Turku University Hospital|No|Completed|October 2000|December 2001|Actual|December 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|40 Years|75 Years|No|||August 2015|August 14, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526615||14880|
NCT02526511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081407|Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors|Pilot Study of Renal Neoplasms With Perfusion Magnetic Resonance Imaging||Rutgers, The State University of New Jersey|No|Recruiting|April 2015|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526511||14888|
NCT02526524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCRM112|Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM|Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus||Elcelyx Therapeutics, Inc.|No|Recruiting|September 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|552|||Both|25 Years|N/A|No|||March 2016|March 2, 2016|August 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526524||14887|
NCT02511912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELIEVE-HF I|REducing Lung Congestion Symptoms Using thE V-wavE Shunt in Advanced Heart Failure|REducing Lung Congestion Symptoms Using thE V-wavE Shunt in Advanced Heart Failure|RELIEVE-HF|V-Wave Ltd|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02511912||16008|
NCT02672163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180/13/03/02/2013|Autologous Atrial Appendage Derived Cells in the Treatment of Heart Failure|Epicardial Delivery of Autologous Atrial Appendage Micrografts During Coronary Artery Bypass Surgery - Safety and Feasibility Study||Helsinki University Central Hospital|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|75 Years|No|||January 2016|February 9, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02672163||3707|
NCT02521571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00568|The Resilience Alliance|The Resilience Alliance||New York University School of Medicine||Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|357|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02521571||15268|
NCT02521584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adel/2015|Ischemia Time and Graft Survival|||Mansoura University|Yes|Recruiting|January 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|25 Years|60 Years|No|Probability Sample|recipients of living donor liver transplantation|August 2015|August 11, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02521584||15267|
NCT02512666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-070|Non Invasive Optical Imaging of WBC Count|Non Invasive Optical Imaging of Capillaries Through the Nailfold for White Blood Cell Enumeration in Patients With Hematologic Malignancies||Massachusetts General Hospital|No|Active, not recruiting|September 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02512666||15950|
NCT02517242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0485|Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control|Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic controlCONTROL||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|May 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|60 Years|N/A|No|||August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02517242||15601|
NCT02524899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-0109|CRT-Guanfacine for SPD|Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524899||15012|
NCT02524912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRITaiwan|Methadone Maintenance Outcome Study in Taiwan: 5-year Follow-up|Methadone Maintenance Outcome Study in Taiwan: 5-year Follow-up||National Health Research Institutes, Taiwan||Active, not recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|1200|||Both|20 Years|N/A|No|Non-Probability Sample|We included participants in this current study from those who attended our three studies        before (IRB approved ID: EC0980203, EC0980209, EC1010102).|September 2015|November 18, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524912|1 Year|15011|
NCT02672358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRB436E1201|Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC|A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer||Novartis|No|Not yet recruiting|July 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02672358||3692|
NCT02521948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD-051|Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device|Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device||Essential Medical, Inc.|No|Active, not recruiting|July 2015|March 2016|Anticipated|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02521948||15239|
NCT02522156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|American_University|Looming Vulnerability and Smoking Cessation Attempts|Looming Vulnerability and Smoking Cessation Attempts||American University|No|Recruiting|February 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02522156||15223|
NCT02527980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0575|E-Cigarettes: Dynamic Patterns of Use and Health Effects|E-Cigarettes: Dynamic Patterns of Use and Health Effects||University of Wisconsin, Madison|No|Recruiting|September 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|450|Samples Without DNA|urine samples retained for additional analyses|Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|2 groups: regular users of electronic cigarettes and commercial cigarettes and regular        exclusive users of commercial cigarettes|November 2015|November 12, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527980||14775|
NCT02522351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.21. NRC|Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia|Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke)||Nestlé|No|Recruiting|June 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|47|||Both|18 Years|85 Years|No|||February 2016|February 22, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02522351||15208|
NCT02673359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR2|Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Short Cervix and History of PTL and/or MTM|Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Sonographic Short Cervix and History of Preterm Labor and/or Midtrimester Miscarriage||Mansoura University|No|Recruiting|February 2016|February 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Female|20 Years|35 Years|No|||February 2016|February 9, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673359||3617|
NCT02527135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49533-EJ|Text Messaging to Improve HIV Testing Among Young Women in Kenya|Evaluating Feasibility and Potential Impact of Text Messages on HIV Awareness Among Young Women in Rural Kenya: a Pilot Study|T2T|University of Washington|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527135||14840|
NCT02514239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1351.1|Phase I Dose Escalation of i.v. and s.c. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients|An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients||Boehringer Ingelheim||Recruiting|July 2015|December 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|100 Years|No|||March 2016|March 7, 2016|May 21, 2015||||No||https://clinicaltrials.gov/show/NCT02514239||15831|
NCT02518594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-PROSPECT|A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix|A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix|PROSPECT|The George Washington University Biostatistics Center|Yes|Recruiting|October 2015|June 2019|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|600|||Female|N/A|N/A|No|||February 2016|February 18, 2016|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518594||15497|
NCT02672800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-313|A Psychosocial Intervention for Bereaved Spousal Caregivers of Persons With Dementia|A Psychosocial Intervention for Bereaved Spousal Caregivers of Persons With Dementia: Adapting the "Finding Balance" Tool||University of Saskatchewan||Not yet recruiting|March 2016|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|60 Years|N/A|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02672800||3659|
NCT02672813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC/521/015|Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery|Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery: A Randomized Single Blinded Control Trial||B.P. Koirala Institute of Health Sciences|Yes|Recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02672813||3658|
NCT02514733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200153|Association of Donor Age With Recipient Outcomes in Kidney Transplant|Association of Donor Age With Recipient Outcomes in Kidney Transplant||Northwestern University|No|Not yet recruiting|August 2016|July 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|80|||Both|60 Years|N/A|No|Non-Probability Sample|All older kidney transplant recipients, age >=60 at transplant who underwent the procedure        at Northwestern University during specified time frame ( see below)|February 2016|March 7, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02514733||15793|
NCT02518321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16-15-022|Can Technology-Assisted Toilets Improve Hygiene and Independence in Geriatric Rehabilitation? A Cohort Study|Can Technology-Assisted Toilets Improve Hygiene and Independence in Geriatric Rehabilitation? A Cohort Study||Bruyere Research Institute|No|Not yet recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|65 Years|N/A|No|||July 2015|August 5, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518321||15518|
NCT02522806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408062|Endometrial Local Injury Before First IVF : Evaluation of Pregnancy Rate|Endometrial Local Injury Before First IVF : Evaluation of Pregnancy Rate|BEONE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|428|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02522806||15173|
NCT02647307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS1040-A-E108|Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b|A Phase I, Open Label, Parallel Group Study to Evaluate the Effect of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of a DS 1040b IV Infusion Administered to Healthy Male Subjects||Daiichi Sankyo Inc.|No|Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02647307||5613|
NCT02647320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8500-A-U202|12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin|A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin||Daiichi Sankyo Inc.|No|Recruiting|January 2016|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|260|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647320||5612|
NCT02647567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVERSO-03|Caffeine Intake and Additive Effects on Cognition|Can Caffeine Intake Combined With Aerobic Exercise Leads to Cognitive Improvement and Psychomotor Performance in Trained Individuals?|Caffeine|Universidade Federal do Rio de Janeiro|Yes|Completed|May 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647567||5593|
NCT02716298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-64|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||March 17, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716298||320|
NCT02650557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECS-sysu|Prediction Value of Ecg on Coronary Slow-flow|Prediction Value of Ecg on Coronary Slow-flow (PECS) Study|PECS|Sun Yat-sen University|No|Completed|January 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|998|||Both|18 Years|N/A|No|Non-Probability Sample|All of the subjects had chest pain and were referred to our catheterization laboratory for        coronary angiography. Diagnosis of CSF was based on thrombolysis in myocardial infarction        (TIMI) frame count (TFC).|January 2016|January 6, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02650557||5363|
NCT02659293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-1286|Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma|Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma||University of Chicago|Yes|Not yet recruiting|March 2016|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659293||4693|
NCT02659306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNPT027|Metformin Immunotherapy in HIV Infection|The Effect of Metformin on HIV Reservoir Size in Non-diabetic Antiretroviral Therapy (ART) Treated Participants: the Lilac Study||McGill University Health Center|Yes|Not yet recruiting|March 2016|October 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659306||4692|
NCT02517060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SozPrime|Neural Mechanisms of Tactile Priming on Social Perceptions - Pilot Study|Neural Mechanisms of Tactile Priming on Social Perceptions - Pilot Study||Charite University, Berlin, Germany|No|Recruiting|August 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adult male and female subjects|January 2016|January 27, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02517060||15615|
NCT02517281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01052-37|Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies|Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies|SKINTARGET|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|700|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02517281||15598|
NCT02520128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/13/0376|A Study of IMRT in Primary Bone and Soft Tissue Sarcoma|A Phase II Study of Intensity Modulated Radiotherapy (IMRT) for Patients With Primary Bone and Soft Tissue Sarcoma|IMRiS|University College, London|No|Recruiting|March 2016|March 2021|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|143|||Both|16 Years|N/A|No|||March 2016|March 18, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02520128||15379|
NCT02526069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-SS-0064|An ACT Based Application for Young People With Type 1 Diabetes|An ACT Based Application for Young People With Type 1 Diabetes|ACT|University of Edinburgh||Terminated|May 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|13 Years|22 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|August 13, 2015||No|No uptake from potential participants|No||https://clinicaltrials.gov/show/NCT02526069||14922|
NCT02514161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEU La Salle|Respiratory Exercises Versus Manual Therapy and Respiratory Exercises in Moderate Smokers|Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Moderate Smokers||Universidad Autonoma de Madrid|Yes|Completed|June 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|November 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514161||15837|
NCT02522234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-CDR-1-1301|A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of F-627 as Prophylaxis Therapy to TAC Chemotherapy in Women With Breast Cancer||Generon (Shanghai) Corporation Ltd.|No|Recruiting|March 2014|December 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Female|18 Years|75 Years|No|||August 2015|August 10, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522234||15217|
NCT02518386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpiTox|Epidemiology of Acute Self-poisoning in Emergency Services in France|Evaluation of the Epidemiology and the Take Load of Voluntary Drug Intoxications by the Emergency Structures in France|EpiTox|University Hospital, Grenoble|Yes|Active, not recruiting|March 2015|December 2015|Anticipated|April 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|||Both|N/A|N/A|No|Non-Probability Sample|Patients dispatched of admitted for acute self poisoning in emergency medical services        and/or emergency departments|August 2015|August 4, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02518386|1 Month|15513|
NCT02673346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-007166|Employee Wellness Survey|Assessing Tobacco Use and Treatment Preferences Among Alaska Yukon-Kuskokwim Health Corporation Employees|Wellness|Mayo Clinic|No|Active, not recruiting|January 2015|December 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|467|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Employees at a health corporation in Western Alaska|February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673346||3618|
NCT02523170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0572|A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas|A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas|CONCYST|University College, London|No|Recruiting|July 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|June 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523170||15145|
NCT02515357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46|Mediterranean Lifestyle Intervention in Patients With Obstructive Sleep Apnea|The Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Obstructive Sleep Apnea: a Randomized, Controlled, Single-Blind Clinical Trial||Harokopio University|No|Recruiting|June 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515357||15745|
NCT02515604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104-15-WOMC|Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure|Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial||Wolfson Medical Center|No|Recruiting|August 2015|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A||||November 2015|November 17, 2015|August 2, 2015||Yes||No||https://clinicaltrials.gov/show/NCT02515604||15726|
NCT02513472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-M001-218|Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)|An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)||Eisai Inc.|No|Recruiting|August 2015|January 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513472||15888|
NCT02513758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201078|Penetration and Compartimentation of HIV|Penetration and Compartimentation of HIV in Genital Mucosa||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2002|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|blood, saliva, sperm and cervicovaginal secretions|Both|18 Years|N/A|No|Non-Probability Sample|HIV patients|March 2016|March 22, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513758||15867|
NCT02663479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TruCardia-002|Nutraceutical Supplement in the Management of Hypertension|Proprietary Lipid-Lowering Nutraceutical Supplement in the Management of Hypertension||Thorne Research Inc.||Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663479||4371|
NCT02663752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ABE04|A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.|A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bone Marrow.|EXPHAR|Novartis|Yes|Not yet recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663752||4350|
NCT02516969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-151|Surgery With or Without Adjuvant Stereotactic Body Radiotherapy|A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer||University of Pittsburgh|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516969||15622|
NCT02515617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 045-14|Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)|Drainage of Subglottic Secretions and Prevention of Ventilator-associated Pneumonia in Intensive carE Units: Medico-Economic Study With a Randomized clusTer and crossovER Design: DEMETER Study|DEMETER|Centre Hospitalier Departemental Vendee|No|Recruiting|November 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2553|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02515617||15725|
NCT02524665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114553|8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne|U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne||GlaxoSmithKline|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|29 Years|No|||August 2015|August 20, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524665||15030|
NCT02524678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URC004KR|Phase 1 Study(Additional) of URC102 in Healthy Subjects|A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males||JW Pharmaceutical|No|Not yet recruiting|August 2015|December 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|49 Years|Accepts Healthy Volunteers|||July 2015|August 14, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02524678||15029|
NCT02663999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZNS-PK-1034|A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers|A Two-Period, Randomized, Open-Label, Crossover Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers||Acorda Therapeutics|No|Recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663999||4331|
NCT02664012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSD1501|Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Menthol Electronic Cigarettes vs Combustible Menthol Cigarettes and Nicotine Gum|A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Menthol Electronic Cigarettes||R.J. Reynolds Vapor Company|No|Recruiting|January 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Anticipated|65|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02664012||4330|
NCT02517203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-062|Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight|Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight|SpaceInVision|University Hospital, Caen|No|Recruiting|June 2014|||October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02517203||15604|
NCT02511873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYCOMPA|Fycompa in Subjects With Small Fiber Neuropathy (SFN)|Randomized Crossover Trial of Fycompa in the Treatment of Pain Associated With Small Fiber Neuropathy (SFN)||PNA Center for Neurological Research|No|Active, not recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 26, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511873||16011|
NCT02515123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPEL (ICU-02)|Promotion of Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in ICU Patients.|Promotion of Regular Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in Long-stay ICU Patients. A Multicenter, Phase II, Sham-controlled, Randomized Trial. The PROPEL Study|PROPEL|E-Motion Medical Ltd.|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|85 Years|No|||November 2015|November 3, 2015|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515123||15763|
NCT02515136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBL_2014-29|Stimulus-response and Parkinson's Disease (SRlearning)|Stimulus-response Associations in Parkinson's Disease Patients|SRlearning|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515136||15762|
NCT02664259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHE201602|UTB-VBN-EBUS With or Without Fluoroscopy for the Diagnosis of PPLs|Ultrathin Bronchoscopy With Virtual Bronchoscopic Navigation and Endobronchial Ultrasound for the Diagnosis of Peripheral Pulmonary Lesions Without Fluoroscopy: a Randomized Controlled Trial||Shanghai Chest Hospital|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664259||4311|
NCT02527304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4957|Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery|Adaptive Staged SBRT for Spinal Metastases||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527304||14827|
NCT02520284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-326-1100|Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis|A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis||Gilead Sciences|Yes|Recruiting|September 2015|February 2019|Anticipated|February 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1600|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520284||15367|
NCT02520544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-S-038|ATX Register Accolade Stem & Trident/Tritanium Cup With X3 Insert|THE ATX REGISTRY ATX Register Accolade Stem & Trident/Tritanium Cup With X3 Insert International Multicentre Surveillance Register|ATX|Stryker European Operations BV|No|Active, not recruiting|January 2012|February 2025|Anticipated|February 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|497|||Both|18 Years|75 Years|No|||August 2015|August 7, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520544||15347|
NCT02526303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVT-AT-1|Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis|Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis: a Single Center Prospective Randomized Controlled Trial||Fourth Military Medical University|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||August 2015|August 15, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526303||14904|
NCT02526316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICORYX-2|Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers|Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer|VICORYX-2|Oryx GmbH & Co. KG|Yes|Recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526316||14903|
NCT02526342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBogenhausen_04|Impact of Negative Pressure Wound Therapy on Free Muscle Flaps|Impact of Negative Pressure Wound Therapy on Free Muscle Flaps||Klinik Bogenhausen|Yes|Not yet recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 15, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02526342||14901|
NCT02669277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMASU R30/2015|Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP|Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP: A Prospective Randomized Study||Ain Shams University|No|Recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|12 Months|16 Years|No|||January 2016|January 27, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669277||3929|
NCT02513602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITR|Osseointegrated Dental Implants in Kidney Transplanted Patients|Peri-Implant Bone Assessment in Transplanted Patients: A Case Control Study||University of Trieste|Yes|Recruiting|May 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|26|Samples With DNA|bone specimen harvested during implant site preparation in order to obtain usefull samples      for hystomorphometrical analysis|Both|18 Years|N/A|No|Probability Sample|The minimal number of the participants of this study is 26 per group: this results from        the measure of a 0,8 effect size. If the effect size is less than 1 (minimal value), it        represents the situation where the medium difference of standard deviations of the        variable "bone density" is equivalent to the difference of the value between the two        groups of the study.        Subject of test group will be enrolled an a kidney transplanted patients, while Subjects        of control group will be enrolled retrospectively in healthy patients|July 2015|July 30, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02513602||15878|
NCT02517047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00018778|Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma|Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma||Children's Hospital Boston|No|Recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|26|||Both|6 Years|17 Years|No|||March 2016|March 22, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02517047||15616|
NCT02519660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 6/13|Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children|Lidocaine/Tetracaine Patch (Ralydan) vs Lidocaine/Prilocaine Cream (EMLA) for Needle Related Procedures in Children: a Multicenter, Randomized Controlled Trial||IRCCS Burlo Garofolo|No|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|320|||Both|3 Years|10 Years|No|||August 2015|August 10, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519660||15415|
NCT02519881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04CAR|the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle|This Clinical Trial Evaluated the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Patients With Cartilage Defects in Their Ankles.||Sewon Cellontech Co., Ltd.|Yes|Recruiting|February 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519881||15398|
NCT02661893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108077|A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922|An Open-Label Drug Interaction Study to Assess the Pharmacokinetics of JNJ-42847922 When Administered Alone and in Combination With Rifampin in Healthy Male and Female Subjects||Janssen Research & Development, LLC|No|Recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661893||4493|
NCT02518789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tangdu-Eto-myo|Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus|Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period||Tang-Du Hospital|No|Not yet recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|55 Years|No|||August 2015|August 7, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518789||15482|
NCT02519010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC/1/10/01 CAREPALST|A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)||Genuine Research Center, Egypt|No|Completed|March 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519010||15465|
NCT02522546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIN|A Study to Assess the Carriage of Pneumococci in Children Aged 1-5 Years, and Their Household Contacts|A Study to Assess the Carriage of Pneumococci in Children Aged 1-5 Years, and Their Household Contacts|PIN|Public Health England|No|Recruiting|July 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Nasal swabs|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 1-5 years and their household contacts|July 2015|August 12, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02522546||15193|
NCT02520102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS13932|Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia|A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia||Sanofi|No|Not yet recruiting|June 2016|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|55 Years|70 Years|No|||February 2016|February 2, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520102||15381|
NCT02672839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L6972-03|A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation|A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects||Ligand Pharmaceuticals|No|Recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|8|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02672839||3656|
NCT02672852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.4|BI655066 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment|BI 655066 Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)||Boehringer Ingelheim||Recruiting|February 2016|October 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 1, 2016||||No||https://clinicaltrials.gov/show/NCT02672852||3655|
NCT02514135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternUCanada|Intra-abdominal Hypertension in Critically Ill Patients|Intra-abdominal Hypertension in Critically Ill Patients||Western University, Canada|Yes|Recruiting|September 2015|May 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|All adults (>18 years of age) admitted to the intensive care unit at Victoria Hospital,        London, Ontario who have a Foley catheter in-situ|March 2016|March 1, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514135||15839|
NCT02514148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEULS-PI-002/2013|Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients|Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients||Universidad Autonoma de Madrid|Yes|Not yet recruiting|September 2015|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|86|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|May 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02514148||15838|
NCT02519088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KrankenhausBBT|A New Approach to a Personalized Patient Blood Management Program (pPBM) in Total Hip Arthroplasty (THA)|A New Approach to a Personalized Patient Blood Management Program in Total Hip Arthroplasty||Krankenhaus der Barmherzigen Brüder Trier|Yes|Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|477|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who electively underwent primary THA in 2013 and 2014|October 2015|October 8, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02519088||15459|
NCT02519101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290-15|Effects of Continuous Noninvasive Arterial Pressure Measurement on Anaesthesia|Impact of Continuous Noninvasive Arterial Blood Pressure Monitoring on Blood Pressure Stability During General Anaesthesia in Orthopedic Patients|ANIKOB|Ludwig-Maximilians - University of Munich|No|Recruiting|June 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02519101||15458|
NCT02526758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SACOPD2015|Small Airways Evaluation and Treatment|Evaluation and Treatment of Small Airways in COPD||Zhujiang Hospital|No|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|85 Years|No|||August 2015|August 17, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526758||14869|
NCT02526797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEH-2015-058|Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance|Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance||Herlev Hospital|Yes|Enrolling by invitation|January 2013|December 2017|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Male|18 Years|75 Years|No|Non-Probability Sample|Men with newly diagnosed low-risk prostate cancer enrolled in active surveillance at Dept.        of Urology, Herlev University Hospital, from Januar 2013 to June 2015, who have had an        mp-MRI of the prostate in their diagnostic follow-up.|August 2015|January 19, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526797||14866|
NCT02512835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU|Understanding the Value of Community Vital Signs in Primary Care|Understanding the Value of Community Vital Signs in Primary Care||Virginia Commonwealth University|No|Not yet recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||2|Anticipated|170000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Aims 1a and 1b: The participants include all unique patients seen at the 12 study        practices (approximately 170,000 patients over the past two years). Aims 2 and 3: The        clinicians in this analysis will include 15 participants recruited from the approximately        100 clinicians at the 12 practices - ideally 1-2 clinicians from each office. Because the        study will characterize the upper bounds, or ideal outcomes, in the use of community vital        signs, clinicians who are willing to participate and provide feedback will be selectively        recruited.|July 2015|July 31, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02512835||15937|
NCT02516137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00077095|Hamstring Tightness|Clinical Effects of Dry Needling Among Asymptomatic Individuals With Hamstring Tightness||Emory University|No|Active, not recruiting|July 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|28|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516137||15686|
NCT02516150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001323|Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon|Effect of Ethanol Intoxication on the Anti-hypoglycemic Action of Glucagon||Massachusetts General Hospital|Yes|Recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|21 Years|80 Years|No|||March 2016|March 15, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516150||15685|
NCT02519361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0148-15-MMC|Involvement of the Translation Initiation Factors in Resolution of Inflammation in the Elderly Population|The Involvement of the Translation Initiation Factors eIF4E and eIF4G in Resolution of Inflammation in the Elderly Population||Meir Medical Center|Yes|Not yet recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|N/A|No|Probability Sample|patients admitted to internal department due to acute infection|August 2015|August 5, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02519361||15438|
NCT02527057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89000--0000|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer|Diffusion-weighted Magnetic Resonance Imaging(DW-MRI) for Early Response Assessment of Neoadjuvant Chemoradiation Therapy(Neo-CRT) in Patients With Esophageal Squamous Cell Carcinoma(ESCC)||Hunan Province Tumor Hospital|No|Recruiting|October 2014|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|75 Years|No|Probability Sample|Eligible participants will have histologically confirmed esophageal squamous cell        carcinoma with no contraindications for receiving neoadjvuant chemoradiation followed by        surgery. All participants will be required to give informed consent to participate in the        protocol, which has been approved by the review boards of the participating institutions.|August 2015|August 18, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527057||14846|
NCT02527733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2129|Retinal Sensitivity in BRVO After Anti-VEGF Therapy|Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy||Fukushima Medical University||Recruiting|June 2015|||September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02527733||14794|
NCT02513095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGL-4104-C-1502|Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)|Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)||Eagle Pharmaceuticals, Inc.|No|Completed|September 2015|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|No|||September 2015|October 1, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513095||15917|
NCT02511626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo_QOL|Quality of Life in Endometriosis - a Case Control Study|Quality of Life in Endometriosis - a Case Control Study Using Internationally Validated Questionnaires||University of Zurich|Yes|Recruiting|January 2010|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female Age >18        Case group: women with endometriosis Healthy volunteers in control group|March 2016|March 10, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02511626||16030|
NCT02516228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGI-001|Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges|Geodesic Transcranial Electrical Neuromodulation(GTEN100) Device|GTEN|Electrical Geodesics, Inc.|No|Not yet recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|12 Years|N/A|No|||August 2015|August 26, 2015|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516228||15679|
NCT02669836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI275|Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia|Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia||Washington University School of Medicine|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|N/A|21 Years|No|||January 2016|January 27, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02669836||3886|
NCT02669849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15-210-101|Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury|A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury||Vertex Pharmaceuticals Incorporated|Yes|Not yet recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|14 Years|75 Years|No|||February 2016|February 4, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669849||3885|
NCT02513316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0116|Clinical Relevance of Microbleeds In Stroke|Microbleeds and Genetic Risk Factors to Predict the Risk of Intracranial Haemorrhage in Patients Treated With Anticoagulation Following Cardioembolic Stroke Due to Atrial Fibrillation|CROMIS-2|University College, London|No|Recruiting|October 2010|September 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Study I: CROMIS-2 (AF) Prospective cohort study of patients anticoagulated after        cardioembolic stroke Study I (AF): The investigators will recruit a total of 1425 patients        from UK centres. All eligible patients with first or recurrent ischaemic stroke and TIA in        whom it is decided that best practice oral anticoagulant treatment is to be commenced will        be invited to participate from acute stroke units and outpatient stroke clinics.        Study II (ICH): The investigators will recruit 600 patients treated at participating        hospitals with ICH. Of these patients, 300 ICH cases will be related to anticoagulant use.        The investigators will also recruit at least 300 ICH cases not related to anticoagulant        use during the study period. Patients seen in outpatient clinics or from existing        databases may also be recruited, at centres where these are available.|July 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513316||15900|
NCT02512367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENIS PHRC I 2014|Evaluate the Efficacy of a Global Dental Health Promotion Program on Dental Hygiene in Patients With Schizophrenia.|Efficacy of a Dental Health Promotion Program in Patients With Schizophrenia|EBENE|Centre Hospitalier Universitaire Dijon||Not yet recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|230|||Both|18 Years|N/A||||June 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512367||15973|
NCT02516514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-033|The Only Blood Culture for Diagnosis of Bacteremia - Comparative Study of Practice|The Only Blood Culture for Diagnosis of Bacteremia - Comparative Study of Practice|HEMU|University Hospital, Caen|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|302|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02516514||15657|
NCT02661568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-368|Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)|Anticoagulation Treatment Patterns and Persistence After Acute Venous Thromboembolism in the UK in Routine Clinical Practice: A Retrospective Database Study of the Clinical Practice Research Datalink and the Hospital Episode Statistics Dataset||Bristol-Myers Squibb|No|Completed|September 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|38409|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, community sample and residents of a community|January 2016|January 19, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661568||4518|
NCT02661854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM09-SIT-013|Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy|Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract|MM09|Inmunotek S.L.|No|Not yet recruiting|March 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|9||Anticipated|180|||Both|12 Years|65 Years|No|||December 2015|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661854||4496|
NCT02526654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-340|Heidelberg Edge Perimetery Compared to Octopus Visual Field Testing and Investigation of New Ocular Imaging Parameters|Validation and Reproducibility of the Heidelberg Edge Perimeter in the Detection of Visual Field Defects in Glaucomatous Patients and Investigation of Novel Ocular Imaging Parameters|HEP/OCT|Wills Eye|No|Completed|July 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|140|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02526654||14877|
NCT02521818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00066092|Dietary Treatments for Cognitive Impairment in Older Adults|Feasibility and Efficacy of Dietary Interventions for Cognitive Impairment in Older Adults||Johns Hopkins University|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|No|||August 2015|August 10, 2015|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521818||15249|
NCT02511925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013IC004B|Electronic Hand Hygiene Monitoring and ICU Infection Rates|A Pragmatic Crossover Cluster Randomised Study of Electronic Compliance Monitoring of Staff Hand Sanitisation in Critical Care (HANDS Study)|HANDS|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|November 2013|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|1065|||Both|N/A|N/A|No|Non-Probability Sample|All patients admitted to the ICU during the study period.|July 2015|July 27, 2015|November 26, 2013||No||No||https://clinicaltrials.gov/show/NCT02511925||16007|
NCT02661867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plure|Pelvic Floor Function Evaluation of Singleton Primiparae After Vaginal Delivery and Cesarean Section|Pelvic Floor Function Evaluation of Singleton Primiparae After Vaginal Delivery and Cesarean Section: Seven to Twelve-Year Long Observational Cohort Study||Brno University Hospital|No|Completed|January 2002|December 2014|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|865|||Female|N/A|N/A|No|Probability Sample|Primiparae delivered vaginally (VD group) or by cesarean section (CS group) during the        years 2002-2007 in university-based large perinatology center|January 2016|January 22, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02661867||4495|
NCT02670148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0159|Assessment of Chiropractic Treatment: Strength and Balance|Assessment of Chiropractic Treatment: Strength and Balance|ACT3|RAND|Yes|Not yet recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02670148||3862|
NCT02527070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2080-15-SMC|Evaluating the State of Microvessels by Minimum Rise Time (MRT01)|Evaluating an Optical Index (Minimum Rise Time) as a Measure for the State of Microvessels|MRT01|Afeka, The Tel-Aviv Academic College of Engineering|No|Recruiting|September 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527070||14845|
NCT02527993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypoGB2015|Treatment of Hypoglycemia Following Gastric Bypass Surgery|Treatment of Hypoglycemia Following Gastric Bypass Surgery||Koege Sygehus|Yes|Enrolling by invitation|October 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|16|||Female|25 Years|60 Years|No|||February 2016|February 2, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02527993||14774|
NCT02525705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_42/1004|Dumping Syndrome After Operation of Esophageal Atresia Type III|Frequency of Occurrence of Dumping Syndrome After Operation of Esophageal Atresia Type III|DUMPING|University Hospital, Lille|Yes|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|N/A|14 Weeks|No|||August 2015|August 14, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02525705||14950|
NCT02662400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNCs IN Diabetes|Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies|Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM||Postgraduate Institute of Medical Education and Research|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|30 Years|65 Years|No|||January 2016|January 22, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02662400||4454|
NCT02515539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-3103-01|Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)|Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)||CardiAQ Valve Technologies, Inc.|Yes|Recruiting|August 2015|July 2021|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515539||15731|
NCT02523911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2015-31|Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening|Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate Bowel Preparation With and Without Simethicone for Routine Colonoscopy: A Double-blinded Randomized Controlled Trial||Mercy Medical Center, Des Moines, Iowa|Yes|Recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523911||15088|
NCT02524964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2014-011-01|Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction|Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention||Guangdong Provincial Hospital of Traditional Chinese Medicine|Yes|Not yet recruiting|December 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524964||15007|
NCT02524977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0017|Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation|Impact of a Quality Improvement And Education Initiative on 'Appropriate' Use of Anticoagulant Therapy in Patients With Atrial Fibrillation||University of Cincinnati|No|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|70|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524977||15006|
NCT02662387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150128|External Nasal Dilator and Oxygen Therapy in Respiratory Failure|Use of External Nasal Dilator as an Adjuvant to High-Flow Nasal Cannula Oxygen Therapy in Children With Acute Respiratory Failure: A Prospective Randomized Controlled Trial|HFNC|Loma Linda University|Yes|Recruiting|July 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|17 Years|No|||January 2016|January 21, 2016|September 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662387||4455|
NCT02518763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-090|Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice||VITAD|University Hospital, Caen|No|Active, not recruiting|June 2011|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|50 Years|N/A|No|||August 2015|August 6, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518763||15484|
NCT02522507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 15-590|A Peer E-mentoring Intervention to Improve Employment|A Peer E-mentoring Intervention to Improve Transition to Employment for Youth With Physical Disabilities||Holland Bloorview Kids Rehabilitation Hospital|No|Recruiting|January 2016|December 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|15 Years|25 Years|No|||January 2016|January 11, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02522507||15196|
NCT02525055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVL-003|The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model|Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model||Hvivo|Yes|Completed|January 2014|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02525055||15000|
NCT02651519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015110302|Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation|Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation||China Medical University, China|Yes|Recruiting|January 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|50 Years|No|||January 2016|March 1, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02651519||5289|
NCT02657993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1344|Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence|Hypnosis to Reduce Aromatase Inhibitor (AI) Associated Musculoskeletal Pain and to Improve AI Adherence: An RCT to Explore Efficacy and Cost Effects||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657993||4793|
NCT02712255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/15/B/HS6/00923_PPD|Effects of Individual, Dyadic, and Collaborative Plans on Physical Activity in Patient-Partner Dyads|Physical Activity, and Health-Related Quality of Life: Dyadic Research in the Context of Forming Individual, Dyadic, and Collaborative Plans (Trial 2: Patient-Partner Dyads)||University of Social Sciences and Humanities, Warsaw|No|Not yet recruiting|March 2016|||March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|400|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02712255||631|
NCT02717026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-262ex14/15|Multimodal Imaging of Retinal Vessels|Retinal Vessel Morphology in Multimodal Imaging|MIR|Medical University of Graz|No|Recruiting|July 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|adult patients scheduled for routine retinal assessment|March 2016|March 17, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02717026||264|
NCT02654652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 24375713.0.0000.5149|Impact of Symbiotic Administration on Intestinal Function of Head and Neck Patients Surgically Treated|Intestinal Function of Patients With Uper Air and Digestive Neoplasia Submitted to Surgical Treatment: Symbiotic Use Impact||Federal University of Minas Gerais|Yes|Recruiting|October 2014|July 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654652||5050|
NCT02654665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-LiNASH|Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults|Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults|CGH-LiNASH|Changi General Hospital|No|Recruiting|March 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654665||5049|
NCT02645006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SomamfycCTNF|Workshop for Primary Prevention of Falls. CHANGING TO NEVER FALL. CTNF|Effectiveness of an Intervention by a Health Education Workshop Compared With the Usual Advice to Reduce the Incidence of Falls in Independent 65 Years and Older Not Institutionalized. Primary Prevention.CHANGING TO NEVER FALL. CTNF|CTNF|Sociedad Madrileña de Medicina de Familia y Comunitaria|Yes|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|316|||Both|65 Years|N/A|No|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645006||5790|
NCT02522312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-00864|A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients|A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients||Hazleton Eye Specialists|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|102|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|March 2016|March 1, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02522312||15211|
NCT02527577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908127|Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.|Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection|BLOC-TAP|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|April 2010|February 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||July 2015|August 17, 2015|August 14, 2015||No|difficulties to recruit patients|No||https://clinicaltrials.gov/show/NCT02527577||14806|
NCT02515240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV PPV23|Immune Response to Pneumococcal Vaccination in HIV Infected Individuals|Immune Response to Pneumococcal Vaccination in HIV Infected Individuals||University of Toledo Health Science Campus|No|Completed|July 2010|March 2015|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|124|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|July 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02515240||15754|
NCT02515500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial|Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial||University of California, San Francisco|No|Not yet recruiting|September 2015|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515500||15734|
NCT02522247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/755-31/2B|RCT Between UPP and Controls in Adult OSA|Randomized Control Trial Between Uvulopalatoplasty and Delayed Surgery (Controls)||Karolinska University Hospital|No|Suspended||||February 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|65 Years|No|||February 2016|February 26, 2016|August 10, 2015||No|No patients have been enrolled, maybe in the future the study will start up again|No||https://clinicaltrials.gov/show/NCT02522247||15216|
NCT02524262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|620070-SWE-2012|L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde|Slow-release L-cysteine Capsule Prevents Carcinogenic Gastric Acetaldehyde Exposure in Helicobacter-associated Atrophic Gastritis||Uppsala University|No|Completed|December 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524262||15061|
NCT02663141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9111257006|Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema|||Tehran University of Medical Sciences|No|Recruiting|June 2015|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||January 2016|January 27, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663141||4397|
NCT02663154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1016941|Aromatherapy for Postoperative Nausea and Vomiting in Children|Aromatherapy for Postoperative Nausea and Vomiting in Children: A Single Blind Randomized Clinical Trial||IWK Health Centre|No|Completed|July 2014|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|39|||Both|4 Years|16 Years|No|||January 2016|January 25, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02663154||4396|
NCT02511509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/535/10/KB|Bifrontal and Bitemporal Electroconvulsive Therapy (ECT) in Treatment of Patients With Schizophrenia|Comparison of the Efficacy and Safety of the Bifrontal Electroconvulsive Therapy (ECT) and the Standard Bitemporal ECT in the Treatment of Patients With Schizophrenia|ESBECT|Medical Universtity of Lodz|No|Not yet recruiting|July 2015|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|64 Years|No|||July 2015|July 27, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02511509||16039|
NCT02518399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09272013.025|Chronic Heat Therapy for Improving Vascular Health|Chronic Heat Therapy for Improving Biomarkers of Vascular Health in Young, Healthy, Humans|CHT|University of Oregon|No|Active, not recruiting|April 2013|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02518399||15512|
NCT02671214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020V|The Effect of Selected Fibres and Flours in Flat Bread on Post-prandial Blood Glucose Responses|The Effect of Selected Fibres and Flours in Flat Bread on Post-prandial Blood Glucose Responses||Unilever R&D|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|12||Actual|42|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02671214||3780|
NCT02671227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intrathecal Mg in gyne. lap.|Intrathecal Mg in Gynecologic Laparoscopic Surgeries.|Effects of Addition of Magnesium Sulfate in Spinal Anesthesia on Surgeon Satisfaction and Postoperative Pain in Gynecologic Laparoscopic Surgeries.||Assiut University|Yes|Recruiting|May 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671227||3779|
NCT02519816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTRP 1401|Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD|Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD|CARE|Maisonneuve-Rosemont Hospital|Yes|Recruiting|March 2016|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|19 Years|N/A|No|||March 2016|March 14, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02519816||15403|
NCT02528084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB2015|The Effects of Yoga on Patients With Rotator Cuff Injuries|The Effects of Yoga on Patients With Rotator Cuff Injuries||Lawson Health Research Institute|No|Not yet recruiting|September 2015|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02528084||14767|
NCT02526238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-15-0035|Effectiveness of Theta Burst Stimulation (TBS) and Voluntary Trunk Rotation for Neglect|The Treatment Effectiveness of Theta Burst Stimulation and Voluntary Trunk Rotation for Patients With Unilateral Neglect in Stroke||Kowloon Hospital, Hong Kong|No|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||August 2015|August 17, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526238||14909|
NCT02668627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2013-12-088|MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)|MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)||Samsung Medical Center|No|Recruiting|December 2013|May 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|20 Years|N/A|No|Non-Probability Sample|Acute ischemic stroke, eligible for endovascular treatment within 12 hours of symptom        onset|January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02668627||3976|
NCT02521038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK Registry|Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry|The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry||Seoul National University Hospital|Yes|Recruiting|July 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Blood samples for laboratory tests including tests such as, CBC, electrolyte, liver function      test, BUN, creatinine, Uric Acid, CRP, Cholesterol panel, etc.      Urine samples for Urine Analysis.|Both|N/A|N/A|No|Non-Probability Sample|ACS pateints who use Brilinta as a anti-platelet agent|August 2015|August 8, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02521038|18 Months|15309|
NCT02521051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-055|Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer|A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer||Massachusetts General Hospital|Yes|Recruiting|October 2015|June 2022|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521051||15308|
NCT02516475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055570|Effects of Zinc Supplementation on Anthropometric Factors, Apelin and Inflammatory Markers in Obese Individuals|Effects of Zinc Supplementation on Weight, Body Mass Index (BMI), Waist Circumference, Fat Mass and Lean Mass, Apelin and Inflammatory Markers in Obese Individuals||National Nutrition and Food Technology Institute|Yes|Completed|October 2014|June 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516475||15660|
NCT02521844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3-002|A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours|A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours||D3 (Drug Product and Development), Biomedical Sciences Institute|No|Recruiting|October 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521844||15247|
NCT02519153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MThar87|Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones|Role of Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) in Management of Distal Ureteral Stone||Mansoura University|Yes|Active, not recruiting|July 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|October 16, 2015|June 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519153||15454|
NCT02668965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si701/2015|The Effects of Intrauterine Infusion of hCG at the Time of Embryo Transfer|The Effects of Intrauterine Infusion of Human Chorionic Gonadotropin at the Time of Embryo Transfer on IVF/ICSI Outcomes: Randomized, Double-blind Controlled Study||Mahidol University|Yes|Recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|200|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668965||3952|
NCT02527317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1010|Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer|An Observational Study of Dose Dense Chemotherapy With Lipegfilgrastim Support||Beaumont Hospital|No|Recruiting|January 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Planned chemotherapy with Dose Dense Doxorubicin-Cyclophosphamide (AC) for early breast        cancer|August 2015|August 17, 2015|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02527317||14826|
NCT02519400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGAM-001|A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects|A Single Dose, Double-blind, Genotype-based Stratification Study to Explore the Pharmacokinetics and Pharmacodynamics of Amitriptyline According to CYP2D6 and CYP2C19 Polymorphisms in Healthy Korean Male Adult Subjects||Asan Medical Center|No|Not yet recruiting|August 2015|||October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 9, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02519400||15435|
NCT02519647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267/15|Comparison of Intubation Conditions Between the Gliderite and the S-Guide|Comparison of Intubation Conditions Between the Gliderite and the S-Guide in Patients With Simulated Difficult Airways|S-Guide|University of Lausanne Hospitals|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02519647||15416|
NCT02672189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI 2014-6788 / NL53182.031.15|Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms|A Randomized Controlled Trial of Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms||The Netherlands Cancer Institute|No|Recruiting|February 2015|February 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|265|||Female|18 Years|55 Years|No|||January 2016|January 29, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02672189||3705|
NCT02676648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00102827|Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes|Randomized Trial of Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes||University of Michigan|No|Recruiting|February 2016|October 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|64|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02676648||3364|
NCT02518048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0053-1227|A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris|A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LEO 90100 Aerosol Foam Compared to Betesil® Medicated Plaster in the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|August 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02518048||15539|
NCT02518555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15012|Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2015|||November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518555||15500|
NCT02522286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37930708|Creating a Zone of Openness to Increase Patient-Centered Care|Creating a Zone of Openness to Increase Patient-Centered Care||Palo Alto Medical Foundation|No|Completed|June 2014|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|October 19, 2015|May 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02522286||15213|
NCT02522299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201928|A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 for 12 Weeks in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|40 Years|80 Years|No|||February 2016|March 3, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02522299||15212|
NCT02526134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDUCOR-IPC 2013-008|Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum|Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum|FIDUCOR|Institut Paoli-Calmettes|No|Active, not recruiting|April 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02526134||14917|
NCT02520180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-IC-001|Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)|A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk™ Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk™ Stent System) for the Treatment of Atherosclerotic Lesion(s)||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Recruiting|December 2015|June 2022|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1656|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02520180||15375|
NCT02522728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-015 Triathlon RSA _2|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon CR vs. PS|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon CR vs. PS|TriathlonRSA|Stryker European Operations BV|No|Active, not recruiting|January 2007|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||August 2015|August 11, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522728||15179|
NCT02523300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-AD-2015-07|Glucocorticoid on the Prognosis of TEVAR|Prognostic Value of Single-dose Glucocorticoid After Endovascular Repair for Aortic Dissection||Changhai Hospital|Yes|Not yet recruiting|October 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02523300||15135|
NCT02524431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-430E|The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma|The Changes of Mitochondrial Dynamics and the Molecular Mechanisms in the Trabecular Meshwork of Patients With Glaucoma||Wills Eye|No|Recruiting|November 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|7|||Both|21 Years|80 Years|No|||August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524431||15048|
NCT02526251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49341|Does the Microbiome in IBD Change Alongside Special Treatment Scenarios?|Does the Microbiome in IBD Change Alongside Special Treatment Scenarios?||Nordsjaellands Hospital|Yes|Recruiting|August 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Fecal samples|Both|18 Years|N/A|No|Non-Probability Sample|IBD patients in remission or mild to moderate active|March 2016|March 1, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02526251||14908|
NCT02662192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02319|Fitness, Hearing and Quality of Life in Older Adults With Hearing Loss. Walk, Talk and Listen for Your Life|Targeting Functional Fitness, Hearing and Health-Related Quality of Life in Older Adults With Hearing Loss. Walk, Talk and Listen for Your Life, A Randomized Controlled Trial|WTL|University of British Columbia|No|Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02662192||4470|
NCT02519023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7152222222|TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy|Transversus Abdominis Plane (TAP) Infiltration vs. Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Assisted Hysterectomy||University of Minnesota - Clinical and Translational Science Institute||Not yet recruiting|September 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 5, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519023||15464|
NCT02524210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208088|Effect of Inhibitors of the Proton Pump on Intestinal Transporters|Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study|BIPP|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2014|December 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524210||15065|
NCT02527720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AA022213-01A1|Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking|Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking|BBMT|University of Maryland|No|Recruiting|June 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02527720||14795|
NCT02517411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0058UG|Physiotherapy in Patients With Stable Chronic Obstructive Pulmonary Disease|Effects of a Physiotherapy Program in Patients With Stable Chronic Obstructive Pulmonary Disease||Universidad de Granada|Yes|Active, not recruiting|April 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||December 2015|December 3, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02517411||15588|
NCT02517424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMJP-1|Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder|Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)||Tilray||Not yet recruiting|January 2016|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02517424||15587|
NCT02511353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.002|Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study|Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL)|IVERMAL|Liverpool School of Tropical Medicine|Yes|Recruiting|July 2015|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|141|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02511353||16051|
NCT02527746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-F-627-CH1|Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase I, Single Center, Open-label, Dose Escalation Study of Recombinant Human Granulocyte Colony-stimulating Factor Fc Fusion Protein (F-627) in Breast Cancer Patient Receiving Adjuvant Chemotherapy||Generon (Shanghai) Corporation Ltd.|No|Completed|December 2012|February 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Female|18 Years|75 Years|No|||August 2015|August 17, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527746||14793|
NCT02517996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034476|Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)|Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial||Johns Hopkins University|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|February 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517996||15543|
NCT02526446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-367|Self-administered Acupressure for Symptom Management of Caregiver Stress|A Randomized, Wait-list Controlled Trial of Self-administered Acupressure for Symptom Management Among Chinese Family Caregivers With Caregiver Stress||The University of Hong Kong|Yes|Not yet recruiting|April 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 16, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526446||14893|
NCT02526459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-15-31|The Effect of Birth Plans on Obstetrical Outcomes|The Effect of Birth Plans on Obstetrical Outcomes: a Randomized Control Trial||Regina Qu'Appelle Health Region|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|N/A|No|||August 2015|August 14, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02526459||14892|
NCT02526472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDR-2-2015|Transabdominal US-guided (UGET) vs. Modified Transvaginal US-guided (mTVET) Embryo Transfer in Human IVF|A Large Prospective Randomized Trial Comparing Trans-abdominal Ultrasound-guided Embryo Transfer (UGET) With a Novel, Modified Trans-vaginal Ultrasound-guided Embryo Transfer Technique (mTVET) Based on Previous Uterine Length Measurement||University of Turin, Italy|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1648|||Female|18 Years|43 Years|No|||August 2015|August 16, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526472||14891|
NCT02516241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419BC00001|Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Bladder Cancer|A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Bladder Cancer||AstraZeneca|Yes|Recruiting|November 2015|September 2019|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|525|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|July 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516241||15678|
NCT02672020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14028|Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card|The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card|COMETETACTIC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Both|15 Years|N/A|No|||January 2016|January 29, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02672020||3718|
NCT02513576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51770|Physiotherapy Exercises in Patients With Sternal Instability After Cardiovascular Surgery|A Randomized, Controlled Study of Physiotherapy Exercises in Patients With Sternal Instability Due to Mediastinitis After Cardiovascular Surgery||University of Sao Paulo General Hospital|No|Completed|October 2011|March 2015|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513576||15880|
NCT02517008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|The Impact of Non-monetary Incentives on Facility Delivery in Rural Zambia|Measuring the Impact of Non-monetary Incentives on Facility Delivery in Rural Zambia: A Clustered Randomized Controlled Trial||IDinsight|No|Completed|June 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2159|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02517008||15619|
NCT02517021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPA-15-18|A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting|A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles in Patients Receiving Highly Emetogenic Chemotherapy||Helsinn Healthcare SA|Yes|Recruiting|November 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517021||15618|
NCT02511639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JIT36T|Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients|MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy|MAIN-A|Istituto Oncologico Veneto IRCCS|No|Recruiting|July 2014|December 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|253|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02511639||16029|
NCT02511652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBarcelona|Ambu AuraGain vs LMA Supreme in Laparoscopic Surgery|Comparison of the Ambu AuraGain vs. LMA Supreme in Paralysed Patients Undergoing Gynecologic Laparoscopic Surgery in the Trendelemburg Position||Hospital Clinic of Barcelona|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|80 Years|No|||February 2016|February 19, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511652||16028|
NCT02665741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|797109-3|Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments|Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments||University of California, Davis|Yes|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|126|||Both|50 Years|N/A|No|||February 2016|February 23, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02665741||4197|
NCT02669862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-WART-201|A Study of A-101 Solution in Subjects With Common Warts.|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts.||Aclaris Therapeutics, Inc.||Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669862||3884|
NCT02513862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-zx011|Prospective Trial of Autologous Platelet Rich Plasma in Aortic Surgery|Prospective Randomized Trial of Autologous Platelet Rich Plasma in Reducing Allogeneic Transfusions During Aortic Surgery Under Deep Hypothermic Circulatory Arrest||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|70 Years|No|||July 2015|July 30, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02513862||15859|
NCT02513875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENT-WIN 2012|Prevention of Type 2 Diabetes With Vitamin D|Prevention of Type 2 Diabetes in Women With Prediabetes Using Vitamin D Supplementation and Lifestyle Intervention in North India (PREVENT-WIN Study)|PREVENT-WIN|Diabetes Foundation, India|Yes|Recruiting|February 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513875||15858|
NCT02518100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSP-F004|Vital Signs Patch: Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|Vital Signs Patch: Early Feasibility and Usability Study - Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|VSP|LifeWatch Services, Inc.|Yes|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518100||15535|
NCT02516527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-247|A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors||Bristol-Myers Squibb|No|Recruiting|October 2015|November 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516527||15656|
NCT02670161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH14-355|Quality Improvement and Practice Based Research in Neurology Using the EMR|Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record||NorthShore University HealthSystem Research Institute|No|Not yet recruiting|May 2016|April 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3300|||Both|18 Years|100 Years|No|||January 2016|January 29, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02670161||3861|
NCT02515266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20121|Additional Protein Fortification in Extremely Low Birth Weight Infants|Evaluation of Additional Protein Fortification in Extremely Low Birth Weight Infants Fed Human Milk: PROTSUP Study|PROTSUP|Hôpital de la Croix-Rousse|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|152|||Both|N/A|4 Months|No|Non-Probability Sample|Premature infants weighing <1250 g at birth, who were exclusively fed with fortified HM        and received additional proteinfortification for >12 consecutive days.|July 2015|July 31, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02515266||15752|
NCT02513251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-013|Chinese-Cantonese Version of Short Form McGill Pain Questionnaire Validation|Validation of the Traditional Chinese-Cantonese Version of Short Form McGill Pain Questionnaire (C-SF-MPQ-2)||The University of Hong Kong|Yes|Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|220|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic pain patients from the Pain Clinic in Queen Mary Hospital|July 2015|July 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513251||15905|
NCT02666976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0110|The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker|||Yonsei University|No|Completed|July 2014|January 2016|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|80 Years|No|||January 2016|January 24, 2016|January 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02666976||4103|
NCT02519764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/OM-01|Evaluation of the Impact of a Hydration Protocol "at Thirst" on Natremia of the Ultra Trail du Mont-Blanc, 2015 Runners|Evaluation of the Impact of a Hydration Protocol "at Thirst" on Natremia of the Ultra Trail du Mont-Blanc, 2015 Runners|NATRITRAIL|Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|198|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 1, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519764||15407|
NCT02512432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150826|INTACS (Intrastromal Corneal Ring Segments) For Corneal Ectasia|INTACS (Intrastromal Corneal Ring Segments) For Corneal Ectasia|INTACS|University of California, San Diego|Yes|Not yet recruiting|July 2015|June 2025|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512432||15968|
NCT02512445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09054|Trauma Informed Guilt Reduction Therapy|Trauma Informed Guilt Reduction Therapy|TrIGR|Veterans Medical Research Foundation|No|Not yet recruiting|October 2015|September 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512445||15967|
NCT02666235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/CARD/03|Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR)|A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.|RIC-COR|NHS National Waiting Times Centre Board|No|Enrolling by invitation|July 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02666235||4160|
NCT02522429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441488-MM-58041|Thalamic Low Intensity Focused Ultrasound in Acute Brain Injury|Thalamic Low Intensity Focused Ultrasound Stimulation in Disorders of Consciousness Following Acute Severe Brain Injury|LIFUP|University of California, Los Angeles|Yes|Recruiting|July 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522429||15202|
NCT02522442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABF-2007-MCT-03|Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP)|Phase IV Study of Bi-Level Positive Positive Airway Pressure (BiPAP)Compared to Nasal Continuous Positive Airway Pressure (CPAP) Therapy|BiPAPRescue|Philips Respironics|No|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|51|||Both|21 Years|75 Years|No|||August 2015|August 12, 2015|July 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT02522442||15201|
NCT02528019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anti-athero|Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors|Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus.||Kurume University||Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|30 Years|90 Years|No|||August 2015|August 18, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02528019||14772|
NCT02523963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10427|Effects of Family Work Shop for Children With Developmental Delays|Effects of Family Work Shop for Children With Developmental Delays||Taipei Medical University|No|Not yet recruiting|August 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Months|36 Months|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02523963||15084|
NCT02512744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/7/2015 n67|Reducing Decannulation Time: Limitation of Decannulation Capping Trials (REDECAP)|Reducing Decannulation Time in Critically-ill Tracheostomized Patients: Decannulation Capping Trial Protocol vs Frequency Aspiration Protocol (REDECAP)|REDECAP|Hospital Virgen de la Salud|Yes|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512744||15944|
NCT02658006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1903|Evaluation of Monitoring TECHNOlogies in the PERI-OPerative Care of Cardiac Surgical Patients|Evaluation of Multimodal Monitoring Technologies in the Peri-operative Care of Cardiac Surgical Patients|TechnoPeriOp|Montreal Heart Institute|No|Recruiting|November 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|176|||Both|18 Years|N/A|No|Probability Sample|Adult patients having any cardiac surgery at the Montreal Heart Institute.|January 2016|January 21, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658006||4792|
NCT02653989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV9300-01|Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An International, Phase 2, Open-Label, Efficacy and Safety Study of MDV9300 in Patients With an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B-Cell Lymphoma||Medivation, Inc.|Yes|Not yet recruiting|March 2016|August 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653989||5101|
NCT02657343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-530|An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.|An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.||Dana-Farber Cancer Institute|Yes|Not yet recruiting|February 2016|February 2023|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657343||4843|
NCT02649322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.099.08|Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy|Randomized, Controlled Trial of Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy.||Orlando Health, Inc.|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|11 Years|17 Years|No|||January 2016|January 6, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02649322||5458|
NCT02524639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-011973|Sirolimus for the Treatment of Hyperinsulinism|Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism.||Children's Hospital of Philadelphia|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|N/A|12 Months|No|||March 2016|March 20, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524639||15032|
NCT02513056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821487|Study Evaluating the Use of MRI on CMS Patients|Prospective Observational Study Evaluating the Use of MRI on CMS Beneficiaries With Non-Conditional Pacemakers and/or Implantable Cardioverter Defibrillators|PM/ICD|University of Pennsylvania|No|Recruiting|August 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pacemakers and/or implantable cardioverter defibrillators (ICD) referred for        an outpatient Magnetic Resonance Imaging (MRI) procedure.|July 2015|October 8, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02513056|6 Weeks|15920|
NCT02519738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00077762|Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion|Granulation Tissue at G Tube Site: Treatment With Kenalog vs Chemical Cauterization With Silver Nitrate vs Soap Washcloth Abrasion||University of Michigan|No|Recruiting|January 2015|June 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|N/A|17 Years|Accepts Healthy Volunteers|||August 2015|August 8, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02519738||15409|
NCT02525471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNS60-01|A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)|||Massachusetts General Hospital|No|Recruiting|October 2015|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525471||14968|
NCT02525484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29830|A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants|A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers||Hoffmann-La Roche||Not yet recruiting|August 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02525484||14967|
NCT02525185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1022|Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy||CRID-CRT|Oslo University Hospital|No|Recruiting|September 2015|||February 2018|Anticipated|N/A|Interventional|N/A||||200|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525185||14990|
NCT02525198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21647|The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial|A Randomised Controlled Trial in 'At Risk' Humans Investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action: The COGNITIVE AGING NUTRITION and NEUROGENESIS (CANN) Trial|CANN|University of East Anglia|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|55 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525198||14989|
NCT02666950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1488|WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome||Mayo Clinic|Yes|Not yet recruiting|April 2016|||April 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666950||4105|
NCT02666963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 901-C-1503|A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults|A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults||Reata Pharmaceuticals, Inc.|No|Not yet recruiting|October 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666963||4104|
NCT02516683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0242|The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study|The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study||Yonsei University|Yes|Completed|December 2001|July 2015|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|229|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|a Shigellosis outbreak took place at Gangnam Severance Hospital in Seoul, Korea, due to        the consumption of contaminated food in the hospital cafeteria for employees. The        causative pathogen was Shigella sonnei, and a total of 181 patients were diagnosed and        treated for Shigellosis. After the termination of Shigellosis outbreak, we could establish        a cohort of the Shigella-exposed group for serial surveys. The initially established        Shigella-exposed cohort was comprised of 143 subjects, and we also could recruited the        control group as age- and sex-matched healthy volunteers who were also hospital employees        at same period and had not been infected, nor exposed to causal food.|August 2015|August 5, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516683||15644|
NCT02519543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO-BD-100|Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder|Treating Insulin Resistance to Improve Outcome in Refractory Bipolar Disorder: a Randomized, Double-blind, Placebo-control Study of the Efficacy of Metformin in Patients With Insulin Resistance and Non-remitting Bipolar Illness|TRIO-BD|Nova Scotia Health Authority|Yes|Recruiting|September 2015|September 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519543||15424|
NCT02519556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProbioticsAD2015|Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children|Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children up to 6 Months||Casa Espirita Terra de Ismael|Yes|Not yet recruiting|August 2015|December 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Months|19 Years|No|||August 2015|August 6, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02519556||15423|
NCT02524613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4653|Prospective Bone Marrow Biopsy Safety and Efficacy Study|||Jacobi Medical Center|Yes|Active, not recruiting|July 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|40 Years|N/A|No|Non-Probability Sample|All adult hematology patients who have just completed an elective bone marrow biopsy will        be considered eligible for enrollment.|August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524613||15034|
NCT02673658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4100068712 Project 1|Project for Cognitive Advancement in Infants With Neuromotor Disorders|Project for Cognitive Advancement in Infants With Neuromotor DisOrders:The CAN-DO Project|CAN-Do|Duquesne University|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|7 Months|36 Months|No|||January 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02673658||3594|
NCT02520908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 14018|Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis|Prospective, Controlled, Multicenter Cohort Study Evaluating the Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis|CUTALLO|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|September 2015|December 2023|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|78|Samples Without DNA|During the blood samples usually performed in routine patient management, 30 ml of      peripheral blood will be collected at inclusion and one year after inclusion and sent to the      investigator's central collection laboratory (INSERM UMRS 976, Saint-Louis Hospital, Paris,      France).|Both|18 Years|65 Years|No|Non-Probability Sample|Advanced-stage epidermotropic T-cell lymphomas (ETCL), i.e. mycosis fungoides (MF) and its        leukemic variant, Sézary syndrome|July 2015|August 7, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02520908||15319|
NCT02520921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141005|Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome|Aspirin With a Novel Twice-a-day Administration in Diabetic Patients With Acute Coronary Syndrome to Minimize Recurrence of Acute Ischemic Events or New Urgent Revascularization|ANDAMAN|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2574|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02520921||15318|
NCT02520934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503076MIPD|Miglustat on Gaucher Disease Type IIIB|Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB||National Taiwan University Hospital|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|6 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520934||15317|
NCT02528097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00743|A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis|A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis||New York University School of Medicine|Yes|Completed|September 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|April 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02528097||14766|
NCT02514902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0166-F6A|Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)|Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)|STABILISER-I|University of Kentucky|No|Recruiting|July 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|72|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514902||15780|
NCT02528110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WuhanU_HIPEC|Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer|A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy||Wuhan University|Yes|Not yet recruiting|August 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02528110||14765|
NCT02521857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-A110|A Water Consumption Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study to Evaluate the Impact of Water Consumption on the Pharmacokinetics of Sublingually Administered ALKS 5461||Alkermes, Inc.|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521857||15246|
NCT02525952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-01-012|Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System|A Randomized Controlled Trial to Compare the Outcomes Between Hepatectomy and Transarterial Chemoembolization for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System||Eastern Hepatobiliary Surgery Hospital|Yes|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|70 Years|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02525952||14931|
NCT02525965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHLRM-2015-8-10|The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma|The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma After Hepatectomy: a Randomized Controlled Trial||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|70 Years|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02525965||14930|
NCT02672046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6300002|Optimized Referral of Knee Patients at the Clinic of Sports Injuries|Danish Title: Optimeret Visitation af Midaldrende knæpatienter Med Symptomer Muligvis Relateret Til Meniskskade||Central Jutland Regional Hospital|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|35 Years|N/A|No|Probability Sample|Middle aged patients with knee symptoms referred to the Clinic of Sports Injuries|January 2016|January 29, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02672046||3716|
NCT02513329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200390|Stellate Ganglion Block (SGB) For Women for Breast Cancer|Effects of Stellate Ganglion Block (SGB) on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast Cancer||Northwestern University|No|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|30|||Female|30 Years|70 Years|No|||February 2016|February 16, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02513329||15899|
NCT02513342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSLCG-001|Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma|Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study||Nanjing NingQi Medicine Science and Technology Co., Ltd.|No|Recruiting|March 2015|April 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||March 2015|July 30, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02513342||15898|
NCT02513355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS-ENDO-001|Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research|||Nanjing NingQi Medicine Science and Technology Co., Ltd.|Yes|Recruiting|February 2015|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||February 2015|July 31, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02513355||15897|
NCT02512146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G03|The Expression of the Ionotropic Glutamate Receptors in Colon of IBS|The Expression of the Ionotropic Glutamate Receptors in Colon of IBS||Shandong University|Yes|Recruiting|June 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Taken biopsies during Colonoscopy|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients underwent colonoscopy in Qilu Hospital outpatient and inpatient department.|July 2015|July 27, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02512146||15990|
NCT02526043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huashan 002|Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma|A Prospective Randomized Control Trail of Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma||Fudan University|No|Recruiting|August 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 14, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02526043||14924|
NCT02661607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/3/14|Point of Care Echocardiography Versus Chest Radiography for the Assessment of Central Venous Catheter Placement|A Prospective Study to Compare Point of Care Echocardiography Versus Chest Radiography for the Assessment of Central Venous Catheter Placement in Critical Care Environments||University of Göttingen|No|Recruiting|October 2014|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02661607||4515|
NCT02519946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15GRNT25680030|On-Line Intervention to Lower Cardiovascular Risk in Pediatric Heart Transplant Patients|||Stanford University|No|Not yet recruiting|August 2015|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|9 Years|19 Years|No|||August 2015|August 6, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02519946||15393|
NCT02522468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-BRE-BCS-RSL-001|A Trial of RSL Versus WL for Malignant Breast Disease|A Randomized Single-Center Superiority Trial of Radioactive Seed Localization Versus Needle Localization for Malignant Breast Disease|BCS-RSL-001|Carolinas Healthcare System|Yes|Recruiting|July 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|20 Years|85 Years|No|||February 2016|February 5, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02522468||15199|
NCT02524379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0335|Glyburide Opportunity for Spinal Cord Injury Protection|Glyburide Opportunity for Spinal Cord Injury Protection; Pilot Study: An Open-label Prospective Evaluation of Safety, Pharmacokinetics, and Preliminary Efficacy of RP-1127 in Patients With Acute Traumatic Cervical SCI|GOSCIP|Ohio State University|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||September 2015|October 9, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524379||15052|
NCT02512484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB A&E study|Improving the Detection of Active Tuberculosis in Accident and Emergency Departments|Improving the Detection of Active Tuberculosis in Accident and Emergency (A&E) Departments|ACE|Public Health England|No|Not yet recruiting|May 2016|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Retention of residual blood samples after inital testing, with appropriate consent to do so      from individuals and ethics committee.|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals at high risk of TB|March 2016|March 15, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512484||15964|
NCT02522988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X150506002|The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors|The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors|OLPI|University of Alabama at Birmingham|No|Recruiting|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|19 Years|70 Years|No|||February 2016|February 19, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02522988||15159|
NCT02525211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOLOSEIN / IPC 2011-005|Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment|Double-blind Randomized Prospective Phase III Study of a Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment of the Postoperative Pain From Hospital to Home||Institut Paoli-Calmettes|No|Recruiting|October 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|November 16, 2012||No||No||https://clinicaltrials.gov/show/NCT02525211||14988|
NCT02514577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-122A-301|122-301 Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Not yet recruiting|October 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514577||15805|
NCT02517619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-006|Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis|EGP-437-006|Eyegate Pharmaceuticals, Inc.|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|12 Years|85 Years|No|||August 2015|August 5, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517619||15572|
NCT02520453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-166|Adjuvant MEDI4736 for Esophageal Cancer|Randomised, Double-blind, Phase II Trial of Adjuvant MEDI4736 or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy||Samsung Medical Center|No|Not yet recruiting|December 2015|December 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|19 Years|N/A|No|||August 2015|August 7, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520453||15354|
NCT02523417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Cancer HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA for Breast Cancer: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Completed|May 2015|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||October 2015|February 23, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523417||15126|
NCT02527681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPR-PIP-001|Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics|An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic Antibiotics||Basilea Pharmaceutica|No|Recruiting|August 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|3 Months|No|||August 2015|August 17, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02527681||14798|
NCT02515162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONE-2|Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization|Fischer Cone Biopsy Excisor Versus Loop Excision Procedure. A Randomized Trial of Two Operation Techniques in Women Undergoing Conization for Cervical Dysplasia||Zydolab - Institute of Cytology and Immune Cytochemistry|No|Recruiting|July 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||February 2016|February 28, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515162||15760|
NCT02521142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAA|Non-invasive Optical Angiography in Age-related Macular Degeneration|||Medical University of Vienna||Recruiting|October 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|72|||Both|N/A|N/A|No|Non-Probability Sample|patients with CNV due to AMD both, treatment naive and active CNV being treated|January 2016|January 18, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02521142||15301|
NCT02520232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2013/22|Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition|Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition (VIAGECO)|VIAGECO|University Hospital, Bordeaux|No|Recruiting|June 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|360|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02520232||15371|
NCT02520245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2810-ONC-1425|Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study|||Regeneron Pharmaceuticals||Not yet recruiting|August 2015|November 2023|Anticipated|November 2023|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520245||15370|
NCT02511834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0113|VEST III PMS Clinical Protocol||VEST III|Vascular Graft Solutions Ltd.|No|Recruiting|October 2015|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|December 20, 2015|July 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511834||16014|
NCT02515409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-KA-0263-15-TLV-CTIL|Heated Humidified High Flow Nasal Cannula for Children With Obstructive Sleep Apnea|Heated Humidified High Flow Nasal Cannula for Children With Obstructive Sleep Apnea||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|16 Years|No|Non-Probability Sample|Children ages 0-16 years with obstractive sleep apnea, referred for treatment with non        invasive ventilation.|June 2015|August 2, 2015|June 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515409|6 Months|15741|
NCT02515669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN001-006|Study of BMS-986089 in Ambulatory Boys With DMD|A Multi-site, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy||Bristol-Myers Squibb|Yes|Recruiting|December 2015|November 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Male|5 Years|10 Years|No|||January 2016|March 11, 2016|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02515669||15721|
NCT02515968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0509|Comparison of Desflurane and Propofol on Quality of Recovery in Patients Undergoing Robotic or Laparoscopic Gastrectomy|||Yonsei University|No|Not yet recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|20 Years|N/A|No|||August 2015|August 3, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515968||15698|
NCT02515461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_LEST_KIDNEY|Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease|Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease||Odense University Hospital|Yes|Recruiting|July 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|July 31, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02515461||15737|
NCT02521259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1503-289-004|Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery|The Correlation Between Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery||Seoul National University Bundang Hospital|No|Recruiting|April 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|68|||Both|3 Years|5 Years|No|Non-Probability Sample|Patients, aged between 3 and 5 years, scheduled for strabismus surgery|November 2015|November 26, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521259||15292|
NCT02526563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14110169|Serum Ropivacaine Concentrations in Pediatric Patients Receiving Continuous Wound Catheter Analgesia|Serum Ropivacaine Concentrations in Pediatric Patients Receiving Continuous Wound Catheter Analgesia||University of Pittsburgh|Yes|Recruiting|August 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|5 Years|18 Years|No|Non-Probability Sample|Pediatric patients that require an iliac crest bone harvest that requires an iliac crest        wound catheter|August 2015|August 24, 2015|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526563||14884|
NCT02512120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Autoflow46|Volume Controlled Ventilation vs Autoflow-volume Controlled Ventilation|Comparison of Volume Controlled Ventilation(VCV) vs Autoflow-volume Controlled Ventilation(Autoflow-VCV) During Robot-assisted Laparoscopic Radical Prostatectomy|VCVAFVCV|Korea University Anam Hospital|Yes|Not yet recruiting|August 2015|December 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|46|||Male|19 Years|80 Years|No|||August 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512120||15992|
NCT02520583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509-009-1502|The Effects of Probiotic Supplementation on Markers of Muscle Damage and Performance Following Exercise Induced Muscle Damage|The Effects of Probiotic Supplementation on Markers of Muscle Damage and Performance Following Exercise Induced Muscle Damage|PRO001|Texas Christian University||Recruiting|February 2015|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02520583||15344|
NCT02674451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00036762|Remote Ischemic Preconditioning to Prevent Contrast Nephropathy|Remote Ischemic Preconditioning to Prevent Contrast-induced Nephropathy in Patients With Stable and Unstable Coronary Disease Undergoing Coronary Angiography.|RIPC-CIN|Johns Hopkins University|No|Recruiting|August 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|N/A|N/A|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02674451||3533|
NCT02521662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1172-9632|The Use of Nicotine Patches Together With E-cigarettes (With and Without Nicotine) for Smoking Cessation|A Randomised-controlled Clinical Trial to Evaluate the Effectiveness and Safety of Combining Nicotine Patches With E-cigarettes (With and Without Nicotine) Plus Behavioural Support, on Smoking Abstinence|ASCEND-II|University of Auckland, New Zealand|No|Not yet recruiting|November 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1809|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02521662||15261|
NCT02516254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054-574|Assessment of the Efficacy of Vitamin D-fortified Bread in Healthy Adults|Comparison of the Efficacy of Vitamin D-fortified Bread Versus Vitamin D Supplement in Healthy Adults: a Randomized Controlled Clinical Trial||National Nutrition and Food Technology Institute|Yes|Completed|January 2015|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|60|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516254||15677|
NCT02669875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPP|Serelaxin To Lower Portal Pressure|Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension|STOPP|University of Edinburgh|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|February 2, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669875||3883|
NCT02518009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI GETS|GEnder Dysphoria Treatment in Sweden|Phenotype Modulations Following Treatment With Contrary Sex Hormones|GETS|Karolinska Institutet|No|Recruiting|April 2015|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Tissue samples from blood, skin, muslce and fat|Both|20 Years|40 Years|No|Probability Sample|Subjects that are under investigation for gender dysphoria that have been accepted but not        yet started their treatment with contrary sex hormones are asked if they want to        participate.|February 2016|February 25, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02518009||15542|
NCT02522767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000174|Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis||Ferring Pharmaceuticals|No|Recruiting|October 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|75 Years|No|||March 2016|March 18, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522767||15176|
NCT02520596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDR-002|Absorption and Metabolism of Dietary Phenolics From Raspberries|Bioavailability of Anthocyanins in Humans Following the Ingestion of Berries and Grapes||University of Parma|No|Completed|November 2013|June 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02520596||15343|
NCT02525601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-015 Triathlon RSA _5|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Cruciate Retaining - Cemented vs. Uncemented|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Cruciate Retaining (CR) - Cemented vs. Uncemented|TriathlonRSA|Stryker European Operations BV|No|Active, not recruiting|March 2009|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||August 2015|August 13, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525601||14958|
NCT02673060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-MBC-01|A Trial of MBC-11 in Patients With CIBD|A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)||Osteros Biomedica Ltd|Yes|Completed|July 2014|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02673060||3639|
NCT02519504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081271|Intervention and Outcomes in Duarte Galactosemia|Intervention and Outcomes in Duarte Galactosemia||Emory University|No|Recruiting|July 2015|July 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1200|Samples With DNA|DNA isolated from saliva samples|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Study participants will be recruited in multiple collaborating states from records of        infants born in that state who were diagnosed with Duarte Galactosemia detected by newborn        screening (NBS). The current list of collaborating states includes: AL, CA, GA, IL, MI,        NC, NJ, OR, SC, TX, WA, and WI but this list may change.|January 2016|January 5, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519504||15427|
NCT02513927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-2|The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese|The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese: a Randomized Crossover Study||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|August 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02513927||15854|
NCT02514226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44769315.0.0000.5511|Evaluation of Periodontal Treatment in Patients With Bronchiectasis|Evaluation of Periodontal Treatment in Patients With Bronchiectasis: a Randomized, Single-center, Three-month, Parallel Group, Non-inferiority Clinical Study||University of Nove de Julho|Yes|Not yet recruiting|August 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|35 Years|N/A|No|||July 2015|July 30, 2015|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514226||15832|
NCT02524886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS for TD|Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia|Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Effects||GGZ Centraal|Yes|Recruiting|June 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524886||15013|
NCT02524938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15DI242|Dietary Polyphenols and Glycation in Renal Insufficiency|PoGlyDRI - Impact of Dietary Polyphenols on Protein Glycation in Type 2 Diabetes Mellitus Subjects With Chronic Renal Insufficiency|PoGlyDRI|NHS Greater Glasgow and Clyde|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|40 Years|80 Years|No|||September 2015|September 10, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02524938||15009|
NCT02671318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43102815.0.0000.5505|Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence|Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus)|StopCMV|Hospital do Rim e Hipertensão|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671318||3772|
NCT02523274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500598|Resveratrol and Exercise to Treat Functional Limitations in Late Life|Resveratrol and Exercise to Treat Functional Limitations in Late Life||University of Florida|Yes|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|65 Years|N/A|No|||February 2016|February 18, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523274||15137|
NCT02523287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioVacSafe - Fluad|Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses|Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Fluad Seasonal Influenza Vaccine or Placebo in Healthy Adults||University Hospital, Ghent|No|Active, not recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|240|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02523287||15136|
NCT02524184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wze20150088|Sildenafil Activates Brown Adipose and Promotes Browning of White Adipose|Sildenafil Activates Brown Adipose and Promotes Browning of White Adipose in Human Adults||Wuhan General Hospital of Guangzhou Military Command|Yes|Recruiting|August 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|15|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02524184||15067|
NCT02524236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 Urology|Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.|Studying the Dose Response of 50 and 100 IU of Botox A Toxin Injection in the Prostates of BPH Patients.||Beni-Suef University|No|Recruiting|August 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Male|50 Years|N/A|No|||January 2016|January 28, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524236||15063|
NCT02517086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-FMRP nº 810616/2014|Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer|Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer||University of Sao Paulo|Yes|Not yet recruiting|August 2015|July 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Anticipated|3|||Female|45 Years|60 Years|No|||August 2015|August 3, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02517086||15613|
NCT02670681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602/14|Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects|Effects of Different Intensities of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects||Federal University of Paraíba|No|Recruiting|November 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|40 Years|70 Years|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670681||3821|
NCT02527239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LF006B|Prevalence of Pompe's Disease in Respiratory Clinics|Prevalence of Pompe's Disease Amongst Patients With Unexplained Respiratory Muscle Weakness or Respiratory Failure|PURF|Royal Brompton & Harefield NHS Foundation Trust|No|Not yet recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adults aged over 18 presenting to respiratory clinics with respiratory muscle weakness of        an unknown cause.|August 2015|August 17, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527239||14832|
NCT02514538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJG-PAR-2010|EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL.|EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL.|Paracetamol|Jordi Gol i Gurina Foundation|Yes|Active, not recruiting|February 2012|||July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514538||15808|
NCT02517320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3995-J05|Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy|A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy||Mitsubishi Tanabe Pharma Corporation|No|Recruiting|July 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|20 Years|75 Years|No|||February 2016|February 9, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02517320||15595|
NCT02659137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152042|HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients|HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients|HESITATE|Maastricht University Medical Center|Yes|Recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients undergoing implantation of a TAVI device in the Maastricht University Medical        Center.|January 2016|January 14, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02659137||4705|
NCT02656433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRNS23062015|tES With Random Noise Stimulation Applied to Children With Brain Injury|Transcranial Noninvasive Brain Stimulation With Random Noise for Children With Congenital or Acquired Brain Injury|BrainInjury|Spanish Foundation for Neurometrics Development|Yes|Active, not recruiting|June 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|3 Years|7 Years|No|||January 2016|January 12, 2016|November 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656433||4913|
NCT02646813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035615|Comparison of Intra and Extraluminal Bronchial Blocker in Adults|A Comparison of Intraluminal and Extraluminal Placement of the Arndt Bronchial Blockers for Adult Thoracic Surgery||Wake Forest School of Medicine|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02646813||5651|
NCT02646046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CallplusCPR|Combining Performance of Call EMS and Simultaneous Chest Compressions in a Lone Rescuer CPR|A Study of Evaluation of Effectiveness on the Combining Performance of Call Emergency Medical System (EMS) and Simultaneous Chest Compressions With One Hand in a Lone Rescuer CPR: a Simulation Study Using the Manikin||Konkuk University Medical Center|Yes|Recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02646046||5710|
NCT02646059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangzhouBC1|The Effective Ways of Recruiting Lapsed Blood Donors: a Stratified Randomized Pilot Study|||Guangzhou Blood Center|No|Active, not recruiting|November 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|1188|||Both|18 Years|50 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646059||5709|
NCT02653612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-009-14F|Intraoperative Imaging of Pulmonary Adenocarcinoma|Intraoperative Imaging of Pulmonary Adenocarcinoma||VA Office of Research and Development|No|Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|99 Years|No|||January 2016|January 11, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02653612||5129|
NCT02653625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-205|PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis|PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis||Tobira Therapeutics, Inc.|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653625||5128|
NCT02512991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALH2-KF-2015|Follow-up of Patients Bound for PCI After Implementation of a Helicopter Emergency Medical System|Helicopter Versus Ground Emergency Medical Systems and the Effect on Mortality and Labour Market Affiliation of Patients Bound for Percutaneous Coronary Intervention||Rigshospitalet, Denmark|Yes|Active, not recruiting|January 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1350|||Both|N/A|N/A|No|Probability Sample|All STEMI patients having acute coronary angiography performed at the PCI centre at        Copenhagen University Hospital, Rigshospitalet in a 40-month period from January 1st 2010        until April 30th 2013; and who were diagnosed with STEMI within the geographical area        covered by both HEMS and GEMS.        Patients are divided into two groups: 1) "field triaged" (ECG recorded out-of-hospital)        and 2) inter-hospital transfers (ECG recorded in-hospital).|October 2015|October 13, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512991||15925|
NCT02666937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.524 (A2015.361)|The Correlation Between SpO2 and PaO2 in the ICU.|The Correlation Between SpO2 and PaO2 in the ICU.||VU University Medical Center|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients on the Intensive Care Unit who require mechanical ventilation and have an        arterial line|January 2016|January 25, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02666937||4106|
NCT02522676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-PCNL-LPRPS-01|Evaluation of Different Treatment Modalities for Lower Pole and Renal Pelvis Stones|Comparison of Success Rates, Complication Rates and Injury to Kidneys of Conventional PCNL, Mini PCNL, Ultra-mini PCNL, Micro PCNL, RIRS and ESWL in the Treatment of Lower Pole and Renal Pelvis Stone(s)||Selcuk University|No|Not yet recruiting|August 2016|November 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|300|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02522676||15183|
NCT02514200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL2|Treatment of Keratoconus With Advanced CXL-II|Treatment of Keratoconus With Advanced Corneal Crosslinking-II||Umeå University|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|12 Years|N/A|No|||August 2015|August 1, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514200||15834|
NCT02514213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCa-001|Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer|Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer||Inovio Pharmaceuticals|No|Recruiting|July 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Male|18 Years|90 Years|No|||February 2016|March 24, 2016|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514213||15833|
NCT02513238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406653|Stemcells for Radiation Induced Xerostomia|Mesenchymal Stem Cells for Radiation-induced Xerostomia (MESRIX) in Previous HPV-positive Oropharyngeal Head and Neck Cancer Patients - A Safety and Feasibility Study|MESRIX|Rigshospitalet, Denmark|Yes|Enrolling by invitation|June 2015|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02513238||15906|
NCT02513459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.20|A Long Term Extension Trial of BI 655066 in Patients With Moderately to Severely Active Crohn's Disease|An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066, in Patients With Moderately to Severely Active Crohn's Disease||Boehringer Ingelheim||Recruiting|September 2015|June 2026|Anticipated|June 2026|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|640|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|July 30, 2015||||No||https://clinicaltrials.gov/show/NCT02513459||15889|
NCT02671175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.034|Post-discharge Malaria Chemoprevention(PMC) Study|Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial|PMC|Liverpool School of Tropical Medicine|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2212|||Both|N/A|60 Months|No|||January 2016|January 28, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671175||3783|
NCT02523859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS7056-011|Study Evaluating the Efficacy and Safety of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery|A Randomized, Single-blind, Propofol-controlled Phase III Study Evaluating the Efficacy and Safety of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the Post-anesthesia Care Unit/Intensive Care Unit||Paion UK Ltd.|No|Terminated|July 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 11, 2015||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT02523859||15092|
NCT02663778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14080080|Task Specific Timing and Coordination Exercise to Improve Mobility in Older Adults: Program to Improve Mobility in Aging|Task Specific Timing and Coordination Exercise to Improve Mobility in Older Adults|PRIMA|University of Pittsburgh|Yes|Not yet recruiting|March 2016|July 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|248|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663778||4348|
NCT02528071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308188|Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis|Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis : Impact and Prognosis. Single-center Prospective Pilot Study|SLA|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|165|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ALS Healthly volonteers|February 2016|February 19, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02528071||14768|
NCT02511600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0958|Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication|A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies||M.D. Anderson Cancer Center|Yes|Withdrawn|December 2015|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511600||16032|
NCT02518893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48058-ED|Health Research Participation: Experiences and Decisions of Military Members|Health Research Participation: Experiences and Decisions of Military Members||University of Washington|No|Recruiting|April 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Current United States military service members (active duty, reserve, or guard) of any        service branch who have participated in military or civilian health care research within        the past three years or who have declined research participation.|August 2015|August 6, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518893||15474|
NCT02672033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000487|Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma|Neoadjuvant Accelerated Hypofractionated Radiation Therapy Immediately Prior to Radical Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Pilot Study||Jonsson Comprehensive Cancer Center|Yes|Recruiting|September 2015|||January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|November 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02672033||3717|
NCT02676440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-GUM-2101|A Study to Measure the Effect of a Toothpaste and Serum or a Standard Fluoride Toothpaste on Gingival Health Over a Six Month Period.|A Study to Measure the Effect of a Toothpaste Containing Zinc Citrate Trihydrate Used in Combination With a Serum Containing Zinc Sulphate Heptahydrate and a Standard Fluoride Toothpaste on Gingival Health Over a Six Month Period.||Unilever R&D|No|Active, not recruiting|July 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02676440||3380|
NCT02517476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-001|Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial|Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial|EFFORT|University Hospital, Basel, Switzerland|No|Recruiting|April 2014|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02517476||15583|
NCT02524197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845-CLIN2001-PO|A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee|A Single-Blind, Multiple Ascending-Dose Pilot Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee||Cara Therapeutics, Inc.|No|Completed|August 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|81|||Both|25 Years|N/A|No|||November 2015|February 3, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524197||15066|
NCT02511704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIMFTCL/CIG-E/1|Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette|Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine Administered by Electronic Cigarette and Cigarette||Parc de Salut Mar|Yes|Completed|October 2014|December 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|July 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511704||16024|
NCT02511964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGF 01|High Intensity Interval Training in 1% or 10% Slope|Effect of Six Running Sessions of High Intensity Interval Training in Different Slopes on Aerobic Performance: a Randomized Controlled Trial|Slope|Universidade Federal do Rio de Janeiro|Yes|Completed|January 2013|December 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02511964||16004|
NCT02676531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPSC-5|Walking Meditation Exercise in Breast Cancer Patients|Effects of Walking Meditation on Vascular Function in Breast Cancer Patients Receiving Anthracyclines Chemotherapy||Chulalongkorn University|Yes|Enrolling by invitation|November 2015|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|36|||Female|35 Years|70 Years|No|||February 2016|February 5, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02676531||3373|
NCT02676635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2U60OH009762-06|Safety Voice for Ergonomics as a Preventive Approach for Work-related Musculoskeletal Disorders in Masonry Apprentices|National Center for Construction Safety and Health Research and Translation: Safety Voice for Ergonomics|SAVE|Eastern Washington University|No|Not yet recruiting|February 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02676635||3365|
NCT02517749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ115/N175|Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management|Randomised Controlled Trial Comparing Outpatient Management of Malignant Pleural Effusion Via an Indwelling Pleural Catheter and Talc Pleurodesis Versus Standard Inpatient Management in Improving Health Related Quality of Life|OPTIMUM|Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|August 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||June 2015|August 7, 2015|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02517749||15562|
NCT02518035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-2849B|Silicone Gel to Improve Scar in Microtia Patients|Use of Silicone Gel to Improve Retroauricular Scar in Microtia Patients||Chang Gung Memorial Hospital|Yes|Recruiting|July 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|9 Years|20 Years|No|||July 2015|August 6, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518035||15540|
NCT02516761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID011|Effect of Low-impact Aerobic Exercise and Music Therapy in Fibromyalgia|Effect of Low-impact Aerobic Exercise Combined With Music Therapy in Patients With Fibromyalgia|EffMusFibro|University of Valencia|No|Completed|July 2015|March 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516761||15638|
NCT02516774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002618-22|A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers|A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers|TAM-RT|Gustave Roussy, Cancer Campus, Grand Paris|No|Withdrawn|December 2014|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 29, 2015||No|No patients enrolled|No||https://clinicaltrials.gov/show/NCT02516774||15637|
NCT02512224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHLW H26-Policy-011|Comparison of Outcomes Between Parenteral and Enteral Nutrition|Comparison of Short-term Mortality and Morbidity Between Parenteral and Enteral Nutrition for Adults Without Cancer: a Propensity-matched Analysis Using a National Inpatient Database||Tokyo University|No|Completed|April 2012|December 2014|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|5824|||Both|20 Years|N/A|No|Non-Probability Sample|For this study, the investigators used the Japanese Diagnosis Procedure Combination        database, the details of which have been described elsewhere. The database includes        administrative claims and discharge abstract data. In 2012, these data were collected for        about seven million inpatients from 1,057 participating hospitals across Japan, which        amounted to about half of the acute-care hospitalizations in the country.|September 2015|September 10, 2015|July 28, 2015||No||No|August 5, 2015|https://clinicaltrials.gov/show/NCT02512224||15984|
NCT02522949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZY-001|Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold|Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers. A Double-blind, Randomized, Placebo-controlled Study|COLDPREV|Enzymatica AB|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02522949||15162|
NCT02525133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-016|Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty|MATRIX-2|Innocoll|No|Recruiting|August 2015|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02525133||14994|
NCT02525146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F130522004|Birmingham Access to Care Study||BA2C|University of Alabama at Birmingham|No|Active, not recruiting|September 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|19 Years|N/A|No|||August 2015|August 13, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02525146||14993|
NCT02514278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/33|Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy|Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy|GRECCAR 12|University Hospital, Bordeaux|Yes|Recruiting|January 2016|March 2022|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|218|||Both|18 Years|N/A|No|||July 2015|March 7, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02514278||15828|
NCT02517346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPAR2015|Efficacy of Telemonitoring on CPAP Treatment Compliance in Obstructive Sleep Apnea (OSA) Patients|Efficacy of Telemonitoring on CPAP Treatment Compliance in Obstructive Sleep Apnea (OSA) Patients||Sociedad Española de Neumología y Cirugía Torácica|No|Active, not recruiting|January 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02517346||15593|
NCT02517359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFT001|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.||Respivert Ltd|No|Terminated|July 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|July 28, 2015||No|Preset pharmacokinetic stopping criteria met at lower doses than expected.|No||https://clinicaltrials.gov/show/NCT02517359||15592|
NCT02512302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN101-105|Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).|A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|GOLDEN7|Sunovion Respiratory Development Inc.|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|40 Years|70 Years|No|||February 2016|February 2, 2016|July 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512302||15978|
NCT02515565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0057UG|Physiotherapy in Patients Hospitalized Due to Pneumonia.|Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia||Universidad de Granada|Yes|Recruiting|May 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|N/A|No|||December 2015|December 3, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02515565||15729|
NCT02515851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-086|A Randomized, Double-blind Controlled Trial of Bupivacaine Extended-release Liposome Injection for Postsurgical Analgesia in Patients Undergoing Open-reduction Internal Fixation of the Distal Radius|A Randomized, Double-blind Controlled Trial of Bupivacaine Extended-release Liposome Injection for Postsurgical Analgesia in Patients Undergoing Open-reduction Internal Fixation of the Distal Radius||University of Louisville|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515851||15707|
NCT02518633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAadipose|Obstructive Sleep Apnoea and Adipose Tissue Dysfunction|Assessment of Hypoxia in Adipose Tissue of Subjects With Obstructive Sleep Apnoea||Royal Devon and Exeter NHS Foundation Trust|Yes|Completed|March 2010|June 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|Samples Without DNA|adipose tissue and blood samples|Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with newly diagnosed obstructive sleep apnoea and controls|August 2015|August 5, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02518633||15494|
NCT02518854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-1970A3|Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome|Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome||Chang Gung Memorial Hospital|No|Recruiting|June 2015|June 2017|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples Without DNA|Plasma|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 6-18 years visit pediatric nephrology clinic during study period|August 2015|August 5, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518854||15477|
NCT02526641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV sCD163 AbbVie|Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C|New AbbVie Direct Acting Antiviral (DAA) Treatment of Chronic Hepatitis C Infection - Effects on the Macrophage Activation Marker Soluble CD163, Portal Hypertension, and Metabolic Liver Function||University of Aarhus|Yes|Recruiting|August 2015|September 2022|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|70 Years|No|||August 2015|August 14, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526641||14878|
NCT02526745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cycdc2015-1|Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older|||Beijing Chaoyang District Centre for Disease Control and Prevention||Enrolling by invitation|December 2015|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Anticipated|440|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||August 2015|January 19, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526745||14870|
NCT02523040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-197|A Study of Lenalidomide for Adult Histiocyte Disorders|A Phase II Study of Lenalidomide for Adult Histiocyte Disorders||Dana-Farber Cancer Institute|Yes|Recruiting|August 2015|August 2022|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523040||15155|
NCT02512575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6470C00001|A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.|A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.||AstraZeneca|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02512575||15957|
NCT02511275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308142|Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a Microdialysis Technique|Assessment of Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a Microdialysis Technique: NECPAR Study|NECPAR|Centre Hospitalier Universitaire de Saint Etienne|Yes|Recruiting|February 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02511275||16057|
NCT02515097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-122A-302|122-302 Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis||Valeant Pharmaceuticals International, Inc.|No|Not yet recruiting|October 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515097||15765|
NCT02669251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160060|AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase 1b/2 Study of AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|September 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|99 Years|No|||January 2016|January 29, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669251||3931|
NCT02669537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GoPro|Utility of the GoPro Hero 3 Camera as an Educational Tool For Vaginal Surgical Skills|Utility of the GoPro Hero 3 Camera as an Educational Tool For Vaginal Surgical Skills||University Hospital Case Medical Center|No|Not yet recruiting|May 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Anticipated|70|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02669537||3909|
NCT02526498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041404|Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery|TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial)|TRIUMPH-T|Rutgers, The State University of New Jersey|No|Recruiting|June 2015|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|45 Years|N/A|No|||March 2016|March 4, 2016|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526498||14889|
NCT02512107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560061|Impact of JuicePlus+ on the Health Status of an Overweight Stressed Population|The Effect of Juice Plus+ on the Microbiome, Intestinal Permeability and Inflammatory Status of Psychologically Stressed Individuals With High Body Mass Indices||University of Memphis|No|Recruiting|January 2015|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02512107||15993|
NCT02516449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 20858|Assessment of Shared Decision Making Aids in Asthma|Utility of Two Patients Decision Aids About Asthma Inhaled Controller Medication Use in Adult Patients With Asthma||Laval University|No|Completed|March 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|51|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02516449||15662|
NCT02669550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Comparison of Disposcope Endoscope and Fiberoptic Bronchoscope|A Comparison of Disposcope Endoscope and Fiberoptic Bronchoscope During Awake Orotracheal Intubation in Obese Patients With Anticipated Difficult Airway : A Prospective, Randomised and Controlled Clinical Trial||The First Hospital of Qinhuangdao|Yes|Completed|July 2012|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02669550||3908|
NCT02526576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSVF0002|Adipose Derived Stem Cells in Facial Fat Grafting|A Phase II Double-blind, Randomized, Study to Assess the Efficacy of Facial Fat Grafts Supplemented With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)|SVF|Antria|No|Recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|70 Years|No|||October 2015|October 16, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526576||14883|
NCT02516735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G07|I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia|I-scan With Magnification Targeted Biopsies Compared With a Standard Biopsy Protocol for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial||Shandong University|Yes|Recruiting|May 2015|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|164|||Both|40 Years|80 Years|No|||August 2015|August 3, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516735||15640|
NCT02524860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150330, version 2.0|Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device|Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device in Patients With an Elevated PSA and a Positive Multiparametric MRI||Focal Healthcare Inc.|No|Not yet recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|80 Years|No|||August 2015|August 14, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524860||15015|
NCT02665468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLP 11-002|eHealth Partnered Evaluation Initiative|eHealth Partnered Evaluation Initiative|eHealth PEI|VA Office of Research and Development|No|Not yet recruiting|February 2016|September 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|900|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02665468||4218|
NCT02517697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15050540|Oral Nitrite Trial for Hypertension and Metabolic Syndrome|Nitrite Modulation of Hypertension, Platelet Activation, and Endothelial and Mitochondrial Function|ONPC|University of Pittsburgh|No|Recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517697||15566|
NCT02517710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECH/TCMC101|Study to Compare Suture Material in Closure of Uterine Incision in Cesarian Section|Single-blinded Prospective Trial Comparing Quantitive Blood Loss, Operative Time, and Post Operative Pain Using Stratafix Barbed Suture in Cesarian Section to the Use of Traditional Suture Material|Stratafix|Evangelical Community Hospital, Lewisburg, PA|No|Recruiting|April 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|October 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02517710||15565|
NCT02527967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JagiellonianU-02|ERAS in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery|Enhanced Recovery After Surgery Protocol in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery||Jagiellonian University|No|Completed|January 2013|February 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|143|||Both|18 Years|N/A|No|Non-Probability Sample|The analysis included prospectively collected data from consecutive patients electively        operated for colorectal cancer in the years 2013-2014. All patients were operated using        laparoscopic surgery, and the perioperative care was based on pre-established ERAS        protocol consisting of 13 items|August 2015|August 17, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02527967||14776|
NCT02672826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 067 08|Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women|Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women|ADIPENDO|University Hospital, Toulouse|No|Recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Female|25 Years|65 Years|No|||January 2016|January 31, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02672826||3657|
NCT02521597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOTO study|Mobile Otoscopy - Efficacy of Residents to Diagnose Acute Otitis Media Using a Smartphone Otoscope Attachment|Mobile Otoscopy - Efficacy of Residents to Diagnose Acute Otitis Media Using a Smartphone Otoscope Attachment: A Randomized Controlled Trials|MOTO|St. Justine's Hospital|No|Recruiting|August 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|1 Year|4 Years|No|||September 2015|September 28, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02521597||15266|
NCT02521753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2014-785-056|Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients|Effect Polyunsaturated Fatty Acids or Magnesium in Metabolic, Hormonal, and Inflammatory Profile in Obese Women With Polycystic Ovary Syndrome. A Randomized Clinical Trial|OMgObPCOS|Coordinación de Investigación en Salud, Mexico|No|Not yet recruiting|August 2015|December 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|123|||Female|18 Years|38 Years|No|||August 2015|August 12, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02521753||15254|
NCT02521766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00001 Rev.02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2015|||||N/A|N/A|N/A||||||||||||||August 10, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521766||15253|
NCT02524145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTexasSouthwestern|Chronotropic Incompetence in Patients With HFpEF|Determinants of Chronotropic Incompetence in Patients With Heart Failure and a Preserved Ejection Fraction (HFpEF)||University of Texas Southwestern Medical Center|Yes|Recruiting|March 2013|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524145||15070|
NCT02525614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-015 Triathlon RSA _4|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Standard vs. Short Keel|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Standard vs. Short Keel|TriathlonRSA|Stryker European Operations BV|No|Active, not recruiting|February 2008|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|85 Years|No|||August 2015|August 13, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525614||14957|
NCT02525627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-S-045|A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads|A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads With Highly Cross Linked (X3) Acetabular Polyethylene Insert in the Hemispherical Trident Cup|X3largeheads|Stryker European Operations BV|No|Active, not recruiting|October 2010|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||August 2015|August 13, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525627||14956|
NCT02662179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Fried|Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?|Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?||Brugmann University Hospital|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|70 Years|N/A|No|Non-Probability Sample|Elderly patients with solid tumors|January 2016|January 22, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02662179||4471|
NCT02522702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COACH|Computer Assisted Optical Assessment of Small Colorectal Polyps|||Technische Universität München|No|Recruiting|August 2015|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Colonic Polyps|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing routine colonoscopy|August 2015|August 11, 2015|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02522702||15181|
NCT02522715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011227|Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer|A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer||OHSU Knight Cancer Institute|Yes|Recruiting|June 2015|||June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Male|18 Years|N/A|No|||February 2016|February 17, 2016|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522715||15180|
NCT02518334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wine and GC|Wine Consumption and Glycemic Control||WGC|University of Missouri-Columbia|No|Withdrawn|March 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|21 Years|65 Years|No|||August 2015|August 4, 2015|February 8, 2012||No|The project was never initiated.|No||https://clinicaltrials.gov/show/NCT02518334||15517|
NCT02526719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN14-7891|Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT|Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT||University Health Network, Toronto|No|Withdrawn|September 2015|January 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|August 14, 2015||No|Study design changed, no longer a randomized trial design|No||https://clinicaltrials.gov/show/NCT02526719||14872|
NCT02526732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_04_001_HELP|Hepatic Inflammation and Physical Performance in Patients With NASH|Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis|HELP|Johannes Gutenberg University Mainz|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|45|||Both|18 Years|70 Years|No|||November 2015|November 3, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526732||14871|
NCT02673775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro20140001089|Air Pollution Study: The Effect of Ozone on the Lung|Activated Macrophages and Ozone Toxicity||Rutgers, The State University of New Jersey|No|Recruiting|January 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|58|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02673775||3585|
NCT02673788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09-102|Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Intraventricular Hemorrhage|||Samsung Medical Center|No|Recruiting|January 2016|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|9|||Both|6 Months|2 Years|No|Non-Probability Sample|Paitents who enrolled in the previous phase 1 clinical trial of Pneumostem transplantation        for IVH.|February 2016|February 1, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02673788||3584|
NCT02511262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-DHF-309-004.001|Detection of Mycoplasma Pneumoniae|Clinical Trial Protocol for the Illumigene® Mycoplasma Direct Assay||Meridian Bioscience, Inc.||Completed|August 2015|||January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|471|Samples With DNA|Dual throat swabs.|Both|N/A|N/A|No|Non-Probability Sample|Prospective patients with symptoms of upper respiratory infections which may be        attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma        pneumoniae.|February 2016|February 5, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511262||16058|
NCT02511522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE1|Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases|Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases||Canadian Cancer Trials Group|Yes|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511522||16038|
NCT02514551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15541|A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer|Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma||Eli Lilly and Company|No|Recruiting|October 2015|October 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514551||15807|
NCT02514564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faperj-E-26/101.575|The Effects of Aerobic Exercise in Microvascular Endothelium Function in Patients With Cardiovascular Diseases|The Effects of Aerobic Exercise Training in Patients With Cardiovascular Diseases Related to Microvascular Endothelium Function, Angiogenesis, Oxidative Stress and Aerobic Capacity||Instituto Nacional de Cardiologia de Laranjeiras|Yes|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|115|Samples Without DNA|Blood samples for nitrite/nitrate quantification.|Both|40 Years|80 Years|No|Non-Probability Sample|Patients treated in the hospital in which the exercise will be performed.|February 2016|February 25, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514564||15806|
NCT02514837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTM 2015|Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer|Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer|RTM|University of Edinburgh|Yes|Not yet recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Female|18 Years|N/A|No|||July 2015|July 31, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02514837||15785|
NCT02522598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-VVZ149-04|Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Laparoscopic-assisted Gastrectomy in Early Gastric Cancer Patients||Vivozon, Inc.|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|70 Years|No|||February 2016|February 4, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02522598||15189|
NCT02673385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I12022|Study of the Impact of Administering t the Scale of Brazelton on the Mother's Confidence in Her Newborn Born Premature at the Approach of Returning Home|Study of the Impact of Administering t the Scale of Brazelton on the Mother's Confidence in Her Newborn Born Premature at the Approach of Returning Home|BRAZMAMAN|University Hospital, Limoges|No|Not yet recruiting|March 2016|November 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Male|N/A|36 Weeks|No|Probability Sample|Mother-child dyads whose infants were born before 36 S.A.|February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673385||3615|
NCT02515812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-075|Comparative Study of Cardiac Adrenergic Function Explored by I-123-MIBG and CZT Camera (D-SPECT) Versus Anger Camera in Patients With Heart Failure||ADRECARD|University Hospital, Caen|No|Completed|October 2012|||March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515812||15710|
NCT02518828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiLo-HF Pilot Trial|High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|HiLo|University of Alberta|No|Not yet recruiting|June 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518828||15479|
NCT02519062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1332|Role of FDG PET, Immune and Hypoxic Marker in NSCLC|FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale||Istituto Clinico Humanitas|No|Recruiting|December 2014|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|130|Samples Without DNA|Tumor surgical specimen|Both|18 Years|N/A|No|Non-Probability Sample|We will recruit a maximum number of 130 NSCLC patients operated radically (stage I-III) at        our institution during 2010-2014, of which are available clinical and instrumental data        and surgical tumor specimen.|August 2015|August 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02519062||15461|
NCT02522819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108101|Feasibility Evaluation of CPAP in the Treatment of Obstructive Sleep Apnea Synchrone in the Acute Phase of Stroke|Feasibility Evaluation of Continuous Positive Airway Pressure (CPAP) in the Treatment of Obstructive Sleep Apnea Synchrone in the Acute Phase of Stroke||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2011|November 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02522819||15172|
NCT02649140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(52)2015|Effect of Vinegar Consumption on 24-hour Urinary Risk Factors Associated With Stone Formation|The Effect of Vinegar Consumption on 24-hour Urinary Risk Factors Associated With Calcium Oxalate Urinary Stone Formation: a Randomised Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02649140||5472|
NCT02659007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-4894H|Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga|Less Neuropathy After Yoga|LeNY|Colorado State University|No|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659007||4715|
NCT02646826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-Paxerol-002|Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial|Paxerol™ (a Novel Formulation of Acetaminophen and Ibuprofen) for Treatment of Nocturia - A Phase II Placebo-Controlled Trial||Wellesley Pharmaceuticals, LLC|No|Not yet recruiting|January 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|January 4, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646826||5650|
NCT02650570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0056|Mitochondrial Respiratory Function in Mammalian Skeletal Muscle|Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights Into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals||The University of Texas Medical Branch, Galveston|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Plasma will be collected and retained in the PI lab.|Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6        months) or recurrent head and neck squamous cell carcinoma (HNSCC) (n=10).        Healthy Controls (n=10).|December 2015|January 6, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02650570||5362|
NCT02660827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 302|Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes|Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes||Medtronic Diabetes|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|7 Years|13 Years|No|||March 2016|March 15, 2016|January 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660827||4575|
NCT02660866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xlpadtrace|Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)|Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)|XLPADTRACE|North Texas Veterans Healthcare System|Yes|Not yet recruiting|May 2016|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|90 Years|No|||March 2016|March 23, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02660866||4572|
NCT02518152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014N|Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis|Efficacy Of Platelet Rich Fibrin With 1% Alendronate For Treatment Of Intrabony Defects In Chronic Periodontitis: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518152||15531|
NCT02671136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150307|Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes|Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes||Loma Linda University|No|Recruiting|October 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|35 Years|80 Years|No|||January 2016|January 28, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02671136||3786|
NCT02511210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|erzincan university|Regional Anesthesia / Peripheral Nerve Block and General Anesthesia on Preoperative Anxiety|Comparison of the Effects of Regional Anesthesia / Peripheral Nerve Block and General Anesthesia on Preoperative Anxiety||Cukurova University|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|80 Years|No|||September 2015|December 26, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02511210||16062|
NCT02511223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-2358-TG-CTIL|Efficacy and Safety of PARPi to Treat Pancreatic Cancer|PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER||Sheba Medical Center|No|Not yet recruiting|September 2015|October 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02511223||16061|
NCT02511236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150356|Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention|Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention||University of Miami|No|Recruiting|August 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02511236||16060|
NCT02518815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550-1304-Mis-213|Preoperative Warming Prevents Postoperative Hypothermia in Laparoscopic Gynecologic Surgery. A Randomized Control Trial|Preoperative Active Warming Prevents Postoperative Hypothermia in Patients Undergoing Laparoscopic Gynecologic Surgery. A Randomized Control Trial||Toronto East General Hospital|No|Completed|May 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Female|16 Years|N/A|No|||August 2015|August 5, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02518815||15480|
NCT02518178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109440|Khushi Baby (KB): Novel Mobile Health Solution for Vaccination Record Keeping in India|Khushi Baby (KB): Efficacy and Impact Assessment of Novel Mobile Health Solution for Vaccination Record Keeping in Rural Udaipur, Rajasthan, India||Khushi Baby Inc.|No|Enrolling by invitation|August 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Both|42 Days|6 Months|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02518178||15529|
NCT02673567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV48125-PK-10078|To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration of TEV-48125 (Single Ascending Doses and Single Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects||Teva Pharmaceutical Industries|No|Not yet recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673567||3601|
NCT02512887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASH|Caudal vs Local Anesthesia in Hypospadias|Caudal vs Local Anesthesia in Hypospadias: The CLASH Study|CLASH|McMaster University|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Male|6 Months|48 Months|No|||March 2016|March 21, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512887||15933|
NCT02516982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2687|mHealth for Antenatal Mental Health|Tablet Computers for Implementing NICE Antenatal Mental Health Guidelines - Feasibility Study|AMHS|Imperial College London|No|Recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women who are 18 years old or older.|July 2015|November 4, 2015|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02516982||15621|
NCT02528032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14-9767|Revisit the Value of Imaging in Best Using CArdiac Resynchronization Therapy|Revisit the Value of Imaging in Best Using CArdiac Resynchronization Therapy|RICART|Rennes University Hospital|No|Recruiting|August 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02528032||14771|
NCT02528045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye017|Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy|Efficacy of Surgical Treatment of Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy||Kyorin University|No|Completed|June 2012|June 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|||Both|20 Years|90 Years|No|Non-Probability Sample|The patients who underwent vitrectomy with scleral shortening for macular hole retinal        detachment or myopic traction maculopathy|August 2015|August 18, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02528045||14770|
NCT02528058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye018|Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy|Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy||Kyorin University|No|Completed|June 2010|July 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|7|Samples Without DNA|Excised internal limiting membrane during the surgical treatment for myopic traction      maculopathy|Both|20 Years|90 Years|No|Non-Probability Sample|The patients who underwent vitrectomy with internal limiting membrane peeling for myopic        traction maculopathy|August 2015|August 17, 2015|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02528058||14769|
NCT02526030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZQ2005_3Y|Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up|Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up|AZQ2005_3Y|Fundación Marques de Valdecilla|No|Completed|October 2008|June 2015|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|203|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526030||14925|
NCT02526121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEICA;PI10/099|Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia|Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia.||Instituto Aragones de Ciencias de la Salud|No|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||March 2015|August 17, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02526121||14918|
NCT02668367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA585-002|Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers|A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers||Biota Scientific Management Pty Ltd|No|Completed|November 2015|||February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02668367||3996|
NCT02513134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC3|Intraocular Lens Power Calculation Using Pre- and Intra-operative Measurements|Intraocular Lens Power Calculation Using Pre- and Intra-operative||Vienna Institute for Research in Ocular Surgery|No|Completed|June 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|||Both|21 Years|N/A|No|Non-Probability Sample|The participants will be recruited by the clinical investigators in the Hanusch Hospital.        Each subject has to meet the inclusion and exclusion criteria and to sign informed        consent.|July 2015|July 28, 2015|June 2, 2014||No||No||https://clinicaltrials.gov/show/NCT02513134||15914|
NCT02513147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDOOR|HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen|HIV Reservoir Dynamics After Switching to Dolutegravir in Patients With Two NRTI and a Protease Inhibitor Based Regimen. A Phase IV Open Randomized Trial||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513147||15913|
NCT02516202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MsFLASH-05|The Vaginal Health Trial|The Vaginal Health Trial - Effects of Vaginal Estradiol Tablet and Moisturizing Gel on Postmenopausal Vaginal Symptoms||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|April 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|45 Years|70 Years|No|||October 2015|October 20, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516202||15681|
NCT02525874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS310|Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).|An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen|No|Recruiting|August 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||August 2015|September 17, 2015|July 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525874||14937|
NCT02676453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VarmlandBL|Dental Hygienist Support Promotes Good Oral Health in Nursing Homes|Dental Hygienist Support Promotes Good Oral Health in Nursing Homes||Public Dental Health, Varmland|No|Completed|September 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|31|||Both|N/A|N/A|No|||February 2016|February 5, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676453||3379|
NCT02521974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2-ABMG|A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants|M2-ABMG|Fidec Corporation|Yes|Not yet recruiting|October 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|164|||Both|6 Weeks|5 Years|Accepts Healthy Volunteers|||July 2015|August 12, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02521974||15237|
NCT02522208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR06.009|Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets|Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure||Arbor Pharmaceuticals, Inc.|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522208||15219|
NCT02513693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA_LF_2015_012|Deep Neuromuscular Blockade During Robotic Radical Prostatectomy|Effect of Deep Neuromuscular Blockade on Surgical Conditions and Recovery After Robotic Radical Prostatectomy: a Prospective Randomized Study||Palacky University|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Male|19 Years|N/A|No|||July 2015|July 30, 2015|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513693||15871|
NCT02513719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-303|XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)|XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance||Abbott Vascular|Yes|Active, not recruiting|March 2013|December 2019|Anticipated|March 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|20 Years|N/A|No|Non-Probability Sample|General patient population with ischemic heart disease in Japan who are eligible for        treatment with XIENCE PRIME SV Everolimus Eluting Stent will be included in the study.|July 2015|July 30, 2015|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513719||15870|
NCT02516852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402004456|Assessing the Effect of Sustainable Small-scale Egg Production on Maternal and Child Nutrition in Rural Zambia|Assessing the Effect of Sustainable Small-scale Egg Production on Maternal and Child Nutrition in Rural Zambia||Cornell University|No|Enrolling by invitation|June 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516852||15631|
NCT02519712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-141|Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors|Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|60 Years|N/A|No|||October 2015|October 14, 2015|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519712||15411|
NCT02519725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHPStJoseph|Impact of an ICU Diary on the Well-being of Patients and Families. A Prospective Multicenter Mixed Study|ICU Diaries Impact of an ICU Diary on the Psychological Well-being of the Patients and Their Relatives. Mixed Multicenter Randomized Study With Blind Evaluation|ICU-diary|Groupe Hospitalier Paris Saint Joseph|Yes|Recruiting|September 2015|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|520|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02519725||15410|
NCT02522221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-511|Tecarfarin Anti-Coagulation Trial (TACT)|A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation|TACT|Armetheon Inc|Yes|Not yet recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|18 Years|85 Years|No|||August 2015|August 12, 2015|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522221||15218|
NCT02522039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlostrupUH|Pupillary Response After Glaucoma Medication|Effect of Topical Anti-glaucoma Medications on Late Pupillary Light Reflex, as Evaluated by Pupillometry|pupil|Glostrup University Hospital, Copenhagen|No|Completed|May 2014|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|November 14, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522039||15232|
NCT02522052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GotenburgU|Mussels, Inflammation and Rheumatoid Arthritis (MIRA)|Mussels, Inflammation and Rheumatoid Arthritis (MIRA)|MIRA|Göteborg University|No|Active, not recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|25 Years|65 Years|No|||October 2015|October 26, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02522052||15231|
NCT02517112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-126|3D Ballistocardiography in Microgravity||B3D|University Hospital, Caen|No|Recruiting|December 2011|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517112||15611|
NCT02512042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAT/BNZL/2014|Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes|A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories, Inc., In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes||Actavis Inc.|No|Active, not recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|1100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02512042||15998|
NCT02515318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0056UG|Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Effects of a Physiotherapy Program in Acute Exacerbation of Chronic Obstructive Pulmonary Disease||Universidad de Granada|Yes|Active, not recruiting|May 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||December 2015|December 3, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02515318||15748|
NCT02515331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHW090X2202|Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients|A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension||Novartis|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|85 Years|No|||February 2016|February 23, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515331||15747|
NCT02518360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversidadMHE|Osteopathic Treatment in Patients With Low Back Pain: Stabilometry|Effect of Osteopathic Treatment in Patients With Nonspecific Low Back Pain: Stabilometry|Osteop-COP|Universidad Miguel Hernandez de Elche|No|Not yet recruiting|September 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02518360||15515|
NCT02518373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC5|Effect of G17DT in Patients With Stage II/III Colorectal Cancer|An Open-label Volunteer Study of the Effect of G17DT on the Elevation of Plasma Gastrin Levels After Therapy With a Proton Pump Inhibitor (Omeperazole) in Patients With Treated Stage II/III Colorectal Cancer|CC5|Cancer Advances Inc.|No|Completed|April 2000|February 2001|Actual|February 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02518373||15514|
NCT02526264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STELLA|Evaluation of Quality of Life and Period of Hospitalization by Education|Clinical Trial to Evaluate Quality of Life, Period of Hospitalization and Complication Rates in Patients With Stoma Receiving Specific Preoperative Education vs. Standard Preoperative Education|STELLA|Krankenhaus Nordwest|No|Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|138|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526264||14907|
NCT02516930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1522|A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China|Crowdsourcing Versus Social Marketing Video Campaigns to Promote Condom Use: A Noninferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China||University of North Carolina, Chapel Hill|No|Active, not recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1168|||Male|16 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 9, 2015|July 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02516930||15625|
NCT02516943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 723/2557(EC4)|The Effects of Using Pathological- Based Guidelines for Arterial Blood Gas Analysis in Patients Aftercardiac Surgery|The Effects of Using Pathological- Based Guidelines for Arterial Blood Gas Analysis in Patients Aftercardiac Surgery||Mahidol University|No|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516943||15624|
NCT02520011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-ALV-201|Alvocidib Biomarker-driven Phase 2 AML Study|A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Tolero Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|79|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520011||15388|
NCT02524132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812015|Physical Activity Intervention in Preschool Children|Physical Activity Intervention in Preschool Children||Mayo Clinic|No|Completed|September 2011|August 2015|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524132||15071|
NCT02524171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-081|Justice-Involved Veterans and Moral Reconation Therapy|Improving Treatment Engagement and Outcomes Among Justice-Involved Veterans|MRT|VA Office of Research and Development|Yes|Not yet recruiting|May 2016|December 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|365|||Both|N/A|N/A|No|||January 2016|January 28, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02524171||15068|
NCT02527707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-LNF-002|Titrating-Dose of Lonafarnib in Combination With Ritonavir|A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib in Combination With Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus|LOWR 4|Eiger BioPharmaceuticals|Yes|Not yet recruiting|September 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527707||14796|
NCT02512588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTD-001 IH201|A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2|A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2||Balance Therapeutics|Yes|Recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512588||15956|
NCT02515864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYU-981-007|Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)|A Crossover Study to Assess the Effects of FYU-981 on the QT/QTc Interval in Healthy Male and Female Volunteers||Fuji Yakuhin Co., Ltd.|No|Active, not recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|48|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515864||15706|
NCT02515877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005505-21|Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers|Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers|HPV-RX|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|January 2008|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|70 Years|No|||August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515877||15705|
NCT02526420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15VR7|Versartis International Trial in Adults With Long-Acting Growth Hormone|An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)|VITAL|Versartis Inc.|No|Recruiting|July 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|23 Years|70 Years|No|||March 2016|March 15, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526420||14895|
NCT02524717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107774|A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function||Janssen Research & Development, LLC|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524717||15026|
NCT02524730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLCRG-001-2007 / K-S-002|Scorpio NRG (Re-"Energize") Cruciate Retaining (CR) Post-market International Outcome Study|Scorpio NRG Prospective, Open-label, Post-market International Multicentre Outcome Study|ScorpioNRG|Stryker European Operations BV|No|Active, not recruiting|May 2009|December 2023|Anticipated|December 2023|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|40 Years|75 Years|No|||August 2015|August 14, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524730||15025|
NCT02671708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDA+BUCY vs BUCY-AML-2016|IDA+BUCY vs BUCY Conditioning Regimen for Low-risk and Intermediate-risk AML Undergoing Auto-HSCT|Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Low-risk and Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|14 Years|65 Years|No|||January 2016|January 30, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02671708||3742|
NCT02513108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS2015NIBO01|Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study)|Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study)|SPEEDY|Helse Stavanger HF|No|Not yet recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|151|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02513108||15916|
NCT02521337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pre Term MiRNA-HMO-CTIL|PreTerm RNA in Maternal Serum|||Hadassah Medical Organization|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy pregnant women|July 2015|August 9, 2015|July 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02521337||15286|
NCT02520063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150701004 (UAB 1514)|Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer|A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer||University of Alabama at Birmingham|Yes|Recruiting|February 2016|||February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|35|||Female|19 Years|N/A|No|||February 2016|February 20, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520063||15384|
NCT02520076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00047923|Aralast NP in Islet Transplant|Improving Single Donor Success Rate in Clinical Islet Transplantation Using Alpha-1 Antitrypsin (Aralast NP)||University of Alberta|Yes|Recruiting|August 2015|March 2018|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|68 Years|No|||August 2015|August 11, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520076||15383|
NCT02671851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/83|Ultrasound-Guided Thoracic Paravertebral Blocks in Patients Undergoing Reduction Mammoplasty|Ultrasound-Guided Bilateral Thoracic Paravertebral Blocks as an Adjunct to General Anaesthesia in Patients Undergoing Reduction Mammoplasty: A Historical Cohort Study||Istanbul University|No|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|64|||Female|18 Years|70 Years|No|Probability Sample|Female patients undergoing bilateral reduction mammoplasty|February 2016|February 9, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671851||3731|
NCT02521272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VentRes-2015-01-KR|Hypercapnia and Gas Exchange Under the Avalanche Snow Model (HyperAvaSM)|Hypercapnia and Gas Exchange Under the Simulated Avalanche Snow|HyperAvaSM|Czech Technical University in Prague|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521272||15291|
NCT02521480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0615.11f|Determination of Analgesic Effect From One Transcranial Magnetic Stimulation(TMS)Treatment Following Vaginal Reconstructive Surgery.|Determination of the Analgesic Effects of One Session of Postoperative Left Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation (TMS) Following Vaginal Reconstructive Surgery.|TMS|East Tennessee State University|Yes|Withdrawn|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|N/A|N/A|No|||March 2016|March 7, 2016|August 10, 2015|Yes|Yes|Study not feasible or convenient for the subject|No||https://clinicaltrials.gov/show/NCT02521480||15275|
NCT02511366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50301.068.14|Repetitive Brake Activation|The Effect of Repetitive Ileal Brake Activation on Food Intake, Satiety, Gastrointestinal Peptide Release, Gastric Emptying and Gallbladder Volume||Maastricht University Medical Center|Yes|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|November 2, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02511366||16050|
NCT02511379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXJ821-P001 (C-13-039)|Clinical Evaluation of Systane® Balance in Dry Eye Subjects|Clinical Evaluation of Systane® Balance on Corneal Staining in Indian Subjects With Dry Eye||Alcon Research|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511379||16049|
NCT02669563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00105110|An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients|An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients||University of Michigan|No|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02669563||3907|
NCT02521402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Golla-01-Keloid|Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance Following Keloid Scar Revision Surgery|Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery||Golla Center for Plastic Surgery|No|Not yet recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|80 Years|No|||August 2015|August 11, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521402||15281|
NCT02513654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114536|Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects|An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects||GlaxoSmithKline|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513654||15874|
NCT02513667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042015-076|Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma|Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation in ALK-rearranged Metastatic Lung Adenocarcinoma||University of Texas Southwestern Medical Center|Yes|Recruiting|November 2015|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|33|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513667||15873|
NCT02520349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01DA037950-02|Lab to Real World Assessment of E-cigarette Abuse Liability and Appeal|Lab to Real World Assessment of E-cigarette Abuse Liability and Appeal||Truth Initiative|Yes|Not yet recruiting|August 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Plasma nicotine: Investigators will examine change in plasma nicotine concentration before      and after 5 minutes of directed product use (10 total puffs). At the start of the session, a      phlebotomist will draw 7mL of blood via venipuncture (no catheter). Participants will then      be directed to take a puff of their own brand/assigned e-cigarette device every 30 seconds      for 5 minutes. At the end of the directed use session, the phlebotomist will draw another      7mL of blood via venipuncture. Blood samples will be processed at the Center for Study of      Tobacco Products lab, frozen, and walked across the street to the Bioanalytical Mass      Spectrometry Core Laboratory at VCU for cotinine/3-OH analysis using previously developed      assays. Blood samples will not be retained for additional analyses.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 30 community volunteers who currently use 10 or more cigarettes per day and        have no immediate plans to quit smoking will be enrolled. Investigators will attempt to        recruit an equal number of men and women of diverse racial/ethnic backgrounds. This        preliminary study is not intended to address gender or race/ethnic differences.|August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520349||15362|
NCT02520362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090522|Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases|Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases||Amgen|No|Active, not recruiting|May 2010|May 2023|Anticipated|May 2023|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|575462|||Both|55 Years|99 Years|No|Non-Probability Sample|Three study populations will be identified based on the following inclusion and exclusion        criteria. Patients in Medicare and United HealthCare will need to have appropriate plan        coverage to be included in any of the following populations. Appropriate plan coverage for        the United HealthCare database refers to both pharmacy and medical plan coverage.        Appropriate plan coverage for the US Medicare database refers to enrollment in traditional        fee-for-service Medicare (Medicare Parts A and B coverage and not in a Medicare Advantage        plan), plus Part D. The requirement of 12-months of continuous enrollment is not relevant        for Scandinavian national registries because all citizens are enrolled in the universal        health coverage from birth to death unless they move out of the country.|February 2016|February 11, 2016|May 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02520362||15361|
NCT02661880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Music in Palliative Care|The Role of Music in Palliative Care: A Proposal for a Rural Based Initiative in Music Based Interventions|The Role of Music in Palliative Care: A Proposal for a Rural Based Initiative in Music Based Interventions||Nova Scotia Health Authority|No|Not yet recruiting|April 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661880||4494|
NCT02526992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701104|Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.|Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|May 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|65 Years|No|||July 2015|August 17, 2015|August 17, 2015||No|recruitment difficulties|No||https://clinicaltrials.gov/show/NCT02526992||14851|
NCT02527005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIbadan|A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients|A Comparative Study of Azithromycin and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant HIV Positive Patients||University of Ibadan|Yes|Not yet recruiting|September 2015|February 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527005||14850|
NCT02513940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507526854|Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes|Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes||Indiana University|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|15|||Male|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513940||15853|
NCT02513017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR - 101411|Insomnia and Cardiovascular Diseases: Influence of Behavioral Treatments and Preferences|Insomnia and Cardiovascular Diseases: Influence of Behavioral Treatments and Preferences||Ryerson University|No|Completed|February 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|204|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02513017||15923|
NCT02666742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003241|Safety and Efficacy of Post Ablation Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation|Safety and Efficacy of Post Ablation Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation|STROKE-VT|University of Kansas Medical Center|Yes|Not yet recruiting|July 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666742||4121|
NCT02671240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6246|Prognosis of Behavioral Addiction in Parkinson's Disease||PROBA-PD|University Hospital, Strasbourg, France|No|Not yet recruiting|February 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Both|30 Years|N/A|No|Non-Probability Sample|Patients with Parkinson's disease who developed or not a behavioral addiction|January 2016|January 28, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02671240||3778|
NCT02527564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53208|Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder|A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder||Stanford University|No|Not yet recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527564||14807|
NCT02523755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT|Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia|Evaluation of Regional Distribution of Ventilation in Spontaneous Breathing Patients During Labor With or Without Epidural Analgesia Using EIT (Electrical Impedance Tomography)||Universitair Ziekenhuis Brussel|No|Recruiting|September 2015|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523755||15100|
NCT02514343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR15-009|Magnesium Sulfate and Bupivacaine for Rehabilitation After Distal Radius Fractures|Intra-articular Infiltration With Magnesium Sulphate and Bupivacaine in Distal Radius Fractures. Randomized, Double-blind Study||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|July 2015|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514343||15823|
NCT02514356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH107218-01|SMS as an Incentive To Adhere (SITA) - An Intervention Communicating Social Norms by SMS to Improve ARV Adherence|A Small Randomized Controlled Trial Providing Weekly Information by SMS About Own and Group-level ARV Adherence to Patients in Two Clinics in Uganda|SITA|RAND|No|Not yet recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|15 Years|24 Years|No|||July 2015|July 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514356||15822|
NCT02663791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Whitehall II - Alcohol PWV 01|Alcohol Consumption and Arterial Stiffness: A Longitudinal Study of Pulse Wave Velocity in the Whitehall II Cohort|||University College, London|Yes|Active, not recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10308|||Both|34 Years|N/A|No|Non-Probability Sample|Data will be drawn from the Whitehall II cohort study database. This incorporates        longitudinal assessments of 6,895 male (67%) and 3,413 female British civil servants,        originally recruited between 1985 and 1988. The overall age range was 34 to 56 years.        Assessments were repeated at 4-to-5 year intervals. PWV measurement was introduced to the        protocol at phase 9, with assessments taking place during 2008 and 2009. 4,347        participants had a successful PWV assessment during this time. This sample comprised 3,237        males (74%) and 1,110 females. Follow-up testing took place at phase 11, during 2012 and        2013. Of the participants who underwent a PWV assessment at phase 9, 3,484 also had a        successful PWV assessment at phase 11. This group included 2,644 males (76%) and 840        females.|January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02663791||4347|
NCT02515825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1217-001|Angiographic Comparison in an Observational Study of CADence (The AMBIENCE Study)|Angiographic Comparison in an Observational Study of CADence (The AMBIENCE Study)|AMBIENCE|AUM Cardiovascular, Inc.|No|Recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|41 Years|N/A|No|Non-Probability Sample|Subjects already scheduled for coronary angiography who meet study inclusion and exclusion        criteria.|September 2015|September 24, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515825||15709|
NCT02515838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVOC01|Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD|A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Explore Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD)||Dilaforette AB|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|77|||Both|12 Years|40 Years|No|||February 2016|February 15, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02515838||15708|
NCT02519075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1386|11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE|Diagnostic and Prognostic Role of 11C-Choline PET/CT and DWI MRI for Response Assessment in Patients Affected by Hepatocellular Carcinoma (HCC) and Candidate to TARE||Istituto Clinico Humanitas|Yes|Recruiting|April 2015|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|None Retained|Biopsy specimen|Both|18 Years|N/A|No|Non-Probability Sample|All patients affected by HCC and referred to our Institution for TARE will be enrolled.|August 2015|August 7, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02519075||15460|
NCT02525796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107407|Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism|Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism||Brigham and Women's Hospital|No|Recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525796||14943|
NCT02662660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUE 16-03|Analgesia iv vs Epidural Analgesia vs Port-sites Infiltration After Laparoscopic Sleeve Gastrectomy|Postoperative Pain After Laparoscopic Sleeve Gastrectomy: Comparison of Isolated Intravenous Analgesia, Epidural Analgesia Associated With Analgesia iv and Port-sites Infiltration With Bupivacaine Associated With Analgesia iv||Hospital General Universitario Elche|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|147|||Both|N/A|N/A|No|||January 2016|January 20, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02662660||4434|
NCT02662673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-817|Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device|Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device|IDITOP-3|Hospices Civils de Lyon|No|Active, not recruiting|January 2014|February 2017|Anticipated|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|50 Years|80 Years|No|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02662673||4433|
NCT02519985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoVC-005|Repeatability and Reproducibility of the ArcScan Insight 100 VHF Digital Ultrasound|Repeatability and Reproducibility of Corneal and Anterior Segment Measurements by ArcScan Insight 100 Very High-frequency Digital Ultrasound||London Vision Clinic|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519985||15390|
NCT02526095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_33|The French EsoGastricTumours Data Base|National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base|FREGAT|University Hospital, Lille|Yes|Recruiting|June 2014|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|90 Years|No|Probability Sample|All patients with gastroesophageal cancer diagnosed and treatment-naïve, if not receiving        neoadjuvant treatment in a participating center will be included after acceptance and        signature of consent, whether operated or not, whatever histologic type, tumor stage, and        the therapeutic strategy.|February 2016|February 10, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526095|3 Years|14920|
NCT02526108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002608|Energy Expenditure of High Intensity Functional Training|Energy Expenditure of High Intensity Functional Training||University of Kansas Medical Center|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02526108||14919|
NCT02525848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008718/ reference no. 104|Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries|Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries|PONV|Assiut University|Yes|Completed|August 2015|March 2016|Actual|March 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Female|18 Years|45 Years|No|||March 2016|March 22, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525848||14939|
NCT02525861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471101|Ph 3/4 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study|A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following GLASSIA Therapy in A1PI-Deficient Subjects||Baxalta US Inc.|No|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525861||14938|
NCT02659020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15839|A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma|A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma||Eli Lilly and Company|Yes|Recruiting|March 2016|March 2020|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|196|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659020||4714|
NCT02659033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC13-179 / P140904|Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.|Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.|CEREMI|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2016|March 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|March 16, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02659033||4713|
NCT02645617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVP-I Varnish|Safety Evaluation of Advantage Anti-Caries Varnish|Phase 1 Safety Evaluation of Advantage Anti-Caries Varnish||Advantage Dental Services, LLC|No|Not yet recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|36 Months|60 Months|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02645617||5743|
NCT02650778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-06-0007|Automated Breast Ultrasound Screening|Automated Breast Ultrasound Screening in Women With Dense Breasts (BIRADS 3 or 4) and BIRADS Category 1 or 2 Mammogram Assigning BIRADS 3 Lesions to Yearly Follow-up|ABUS|Northeastern Ohio Radiology Research and Education Fund|No|Enrolling by invitation|October 2014|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women age >18 scheduled for routine screening mammogram. Women with Density 3 or 4 and        BIRADS category 1 or mammogram are asked to participate in study|January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650778||5346|
NCT02651051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-13-131017b|Metabolic and Appetite Parameters Following Addition of Whey Protein to a Fat-based Breakfast|The Influence of Whey Protein Addition to a Fat-based Breakfast on Metabolic and Appetite Parameters Following a Second Meal||Northumbria University|No|Completed|April 2014|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651051||5325|
NCT02654808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ6474|AirSeal®Insufflation Trocar/CO2 Absorption Study|A Comparison of CO2 Absorption During Gynecologic Laparoscopy Using the AirSeal® Valveless Trocar System Versus Standard Insufflation Trocars at Intra-abdominal Pressures of 10 mmHg and 15 mmHg - a Randomized Controlled Trial||Columbia University|No|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654808||5038|
NCT02654821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11TCR|Study With T-cel Receptor Gene Therapy in Metastatic Melanoma|Multicenter Phase I/IIa Study Using T-cell Receptor Gene Therapy in Metastatic Melanoma|TCR|The Netherlands Cancer Institute|Yes|Recruiting|March 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02654821||5037|
NCT02645812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 14.062 - EAMG|Validation of the French Version of the Fatigue Score "Brief Fatigue Inventory ( BFI)".|Validation de la Version française du Score de Fatigue " Brief Fatigue Inventory (BFI)|EAMG|University Hospital, Brest|No|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with fatigue symptom consulting a general practitioner|November 2015|March 3, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02645812||5728|
NCT02645825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 14.077 - EGAS|Predictive Character Analysis of Ganglionic Echography for the Diagnostic of Benin or Malignant Superficial Adenopathy|Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle|EGAS|University Hospital, Brest|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patient from ambulatory medicine consultation with superficial adenopathy|November 2015|January 13, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02645825||5727|
NCT02524223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108144|Prevalence of HPV Transmission During Medically Assisted Procreation Procedures|Prevalence of HPV Transmission During Medically Assisted Procreation Procedures|AMPAMAVIR|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|915|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524223||15064|
NCT02673320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0040|Prospective Study for Delay in Surgical Treatment of Traumatic Cervical Central Cord Injury in Canal Stenosis|Prospective Study for Delay in Surgical Treatment of Traumatic Cervical Central Cord Injury in Canal Stenosis|DS3CS|Nantes University Hospital|No|Not yet recruiting|March 2016|March 2021|Anticipated|March 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673320||3620|
NCT02673333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-286|Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma|A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673333||3619|
NCT02515253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-01|A Breast Support Intervention for Women With Breast Pain|A Randomised Control Trial of an Individual Bra Prescription Versus Standard Care for Women With Larger Breasts and Breast Pain||University of Portsmouth|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Female|18 Years|55 Years|No|||December 2015|March 15, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02515253||15753|
NCT02523586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11231|Comparison of Pharyngeal Oxygen Delivery by Different Oxygen Masks|Comparison of Pharyngeal Oxygen Delivery by Different Oxygen Masks||Oregon Health and Science University|No|Recruiting|May 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523586||15113|
NCT02523729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH102-REC3-053|Effects of Anke Malz on Women During Lactation|Effects of Anke Malz on Women During Lactation||China Medical University Hospital|Yes|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|38|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02523729||15102|
NCT02524535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-088|Alliance With Therapeutic Entourage in Support of Young Suicidal||IPSI2|University Hospital, Caen|No|Completed|April 2007|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|292|||Both|13 Years|40 Years|No|||August 2015|August 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524535||15040|
NCT02524548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB 2014/01316|SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors|Improving Medication Adherence With Adjuvant Aromatase Inhibitor in Women With Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder||National University, Singapore|No|Recruiting|May 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|280|||Female|21 Years|80 Years|No|||March 2016|March 21, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02524548||15039|
NCT02663492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAS_001|Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients|Transcutaneous Electrical Acupoint Stimulation Ameliorates Chemotherapy-Induced Bone Marrow Suppression in Lung Cancer Patients||Tongji University|Yes|Recruiting|August 2014|December 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|75 Years|No|||January 2016|January 21, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02663492||4370|
NCT02521623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48607|SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial|SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial||Aarhus University Hospital|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||December 2015|December 29, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521623||15264|
NCT02511314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC-NH-1205|A Trial of effectIveness of a Smart Sensor for Continence Care: the ARCTICC Study|A Randomised, Controlled Trial of effectIveness of a Smart Sensor for Continence Care: the ARCTICC Study|ARCTICC|University of Alberta|No|Not yet recruiting|June 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|86|||Both|65 Years|N/A|No|||March 2016|March 9, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02511314||16054|
NCT02511327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT02408926|Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants|Pertussis Immunization During Pregnancy: Assessment of the Role of Maternal Antibodies on Immune Responses in Term and Preterm Infants: the MAMA Study|MAMA|Universiteit Antwerpen|No|Recruiting|January 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|300|Samples Without DNA|Blood samples and breast milk samples|Both|N/A|40 Years|Accepts Healthy Volunteers|Probability Sample|Four cohorts of women-infant pairs will be recruited before or directly after delivery.        A cohort of preterm born infants will be compared to term born infants, and both will be        compared within groups of vaccinated women (adult acellular pertussis containing vaccine)        or unvaccinated women.|July 2015|July 29, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02511327||16053|
NCT02514616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESE-001|Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter (GERD)|Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter: a Multicenter, Randomized, Double-blind, Sham-controlled Parallel-group Trial Evaluating Short Term Efficacy of EndoStim Device on GERD|EST-SHAM-EUR|Erasme University Hospital|No|Terminated|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|70 Years|No|||November 2015|November 19, 2015|July 24, 2015||No|Early termination due to a suspension of financial support|No||https://clinicaltrials.gov/show/NCT02514616||15802|
NCT02514629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCS240281|Testosterone, Metformin, or Both, for Hypogonadism in Obese Males|Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism||Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|No|Active, not recruiting|July 2013|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|107|||Male|18 Years|50 Years|No|||November 2015|November 6, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02514629||15801|
NCT02676362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/05|Methodological Evaluation of Gingival Crevicular Fluid Volume and Elastase Level|Methodological Evaluation of Gingival Crevicular Fluid Volume and Elastase Levels: Sequential Sampling, Length of Sampling Time And Two Different Sampling Methods||Baskent University|Yes|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|20|||Both|31 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02676362||3386|
NCT02517216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-004|Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods||BrainDTI|University Hospital, Caen|No|Recruiting|February 2014|||April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|27|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02517216||15603|
NCT02521688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDASU-RECD 1214402|Inflammatory Cytokines in GCF and Placental Tissues in Chronic Periodontitis Patients With Preterm Delivery|Inflammatory Cytokines in Gingival Crevicular Fluid and Placental Tissues in Chronic Periodontitis Patients With Preterm Delivery||Ain Shams University|Yes|Completed|August 2013|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|40|Samples Without DNA|Placental tissue Gingival clevicular fluid from deepest pocket|Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Fourty Mothers participating in this study recruited from Maternal-Fetal medicine clinic,        Faculty of Medicine, Ain Shams University that must undergo delivery without induction,        i.e. delivery following labour pains not pre-scheduled caesarian sections|August 2015|August 11, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02521688||15259|
NCT02511431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150170|Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir|Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|December 2030|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|December 12, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511431||16045|
NCT02511691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK ZH 2014-0441|PET/MRI Imaging of Glutamate Release in the Brain|PET/MRI Imaging of Glutamate Release in the Brain of Healthy Controls||University of Zurich|No|Recruiting|July 2015|September 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511691||16025|
NCT02519452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107838|A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma|An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma||Janssen Research & Development, LLC|No|Recruiting|October 2015|June 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|128|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519452||15431|
NCT02526329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT267|Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant|A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation||Stanford University||Suspended|August 2015|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|August 14, 2015|No|Yes|Insufficient resources|No||https://clinicaltrials.gov/show/NCT02526329||14902|
NCT02518126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0176-15-RMB CTIL|Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction Neonates|Comparison of LIF (Leukemia Inhibitory Factor) Level Between Neonates Who Are IUGR (Intra Uterine Growth Restriction) and Those Who Are AGA (Average for Gestational Age)||Rambam Health Care Campus||Not yet recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Cord blood and a small peace of the placenta|Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with fetuses who are AGA and those with fetuses that are IUGR|August 2015|August 6, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518126||15533|
NCT02525991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-Loxapine-2015-01|Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting|A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting||Ferrer Internacional S.A.|No|Not yet recruiting|November 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525991||14928|
NCT02526056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 15/064|Usability and Acceptance of Exergames Among Elderly People and Physiotherapists - a Mixed Method Approach|Usability and Acceptance of Exergames Among Elderly People and Physiotherapists - a Mixed Method Approach||Klinik Valens|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02526056||14923|
NCT02522650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0496|A Crossover Pilot Study of the Effect of Amiloride on Proteinuria|A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease||Georgetown University|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522650||15185|
NCT02522663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVRre|The Impact of 24/7-phone Support on Readmission After Aortic Valve Replacement, a Randomized Clinical Trial|The Impact of 24/7-phone Support on Readmission After Aortic Valve Replacement, a Randomized Clinical Trial|AVRre|Oslo University Hospital|No|Recruiting|April 2015|January 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 27, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02522663||15184|
NCT02526355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TechMotherCare001|Development and Assessment of a Mobile Phone Based Intervention to Reduce Postnatal Depression and Improve Child Health|Development and Assessment of a Mobile Phone Based Intervention to Reduce Postnatal Depression and Improve Child Health|TechMother|Pakistan Institute of Learning and Living|No|Recruiting|January 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|36|||Female|18 Years|44 Years|No|||August 2015|August 15, 2015|November 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02526355||14900|
NCT02524301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908019|Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study|Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study||Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2009|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|45|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524301||15058|
NCT02524314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-03-EUHUM-01 Germany|Safety and Efficacy Study of the Treatment of Humerus Fractures - Germany|CE Marking Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Humerus Fractures||IlluminOss Medical, Inc.||Recruiting|August 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|61 Years|N/A|No|||March 2016|March 9, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524314||15057|
NCT02526147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6119-001|WFP Cash, Food, and Voucher Study in Ecuador|||International Food Policy Research Institute|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|2580|||Both|N/A|N/A|No|||August 2015|August 24, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02526147||14916|
NCT02526160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX023-CL303|Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)||Ultragenyx Pharmaceutical Inc|Yes|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526160||14915|
NCT02516657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437619-6|Liraglutide in Adolescents With Type 1 Diabetes|Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus||University at Buffalo|No|Recruiting|May 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Observational|Observational Model: Case-Only||1|Anticipated|11|Samples Without DNA|Serum|Both|15 Years|21 Years|No|Non-Probability Sample|Individuals age 15-21 years with Type 1 diabetes diagnoses greater than 1 year who manage        their diabetes with CSII and CGM. Both male and female subjects are eligible.|August 2015|August 5, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516657||15646|
NCT02519530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 TP1AH000017-04-00|Multi-site Evaluation of an Evidence-based Positive Youth Development Program|Multi-site Evaluation of an Evidence-based Positive Youth Development Program: a School-level, Longitudinal, Randomized Controlled Trial||University of South Florida|No|Completed|August 2012|June 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|8161|||Both|13 Years|22 Years|Accepts Healthy Volunteers|||July 2015|August 6, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02519530||15425|
NCT02524028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00044089|Relationship Between Autonomic Central Nervous System Activation and Atrial Fibrillation Using Functional MRI (fMRI)|Relationship Between Autonomic Central Nervous System Activation and Atrial Fibrillation: A Prospective Functional MRI Study (fMRI)|fMRI|University of Utah|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential participants for the fMRI Study will be recruited from the        Cardiology/Electrophysiology (EP) clinic during normally scheduled clinic visits. Control        participants will be recruited from other hospital clinics.|August 2015|August 13, 2015|September 17, 2013||No||No||https://clinicaltrials.gov/show/NCT02524028||15079|
NCT02524119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052015-073|LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma|A Phase II Study of LEE011 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma|LEE001|University of Texas Southwestern Medical Center|Yes|Not yet recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524119||15072|
NCT02527694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-EM-2015-2P|Comparison of Quality of Cardiopulmonary Resuscitation Between Flexible Stretcher and Standard Stretcher in Out-of-Hospital Cardiac Arrest|Comparison of Quality of Cardiopulmonary Resuscitation Between Flexible Stretcher and Standard Stretcher in Out-of-Hospital Cardiac Arrest: Ambulance Stretcher Innovation of Asian CPR (ASIA-CPR) Trial|ASIA-CPR|Seoul National University Hospital|Yes|Not yet recruiting|August 2015|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02527694||14797|
NCT02520895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.548|Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia|Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia, Biomedical Research on Medical Devices Human ImmunTracker and Human Immun'IgH|RIPAL|Hospices Civils de Lyon|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|patients with lymphoma or chronic lymphocytic leukemia|July 2015|August 7, 2015|September 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02520895||15320|
NCT02523885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_JDR3|Use of Non Steroidal Antiinflammatory Drugs in Patients With Community Acquired Pneumonia|Descriptive Analysis of Non Steroidal Antiinflammatory Drugs Use in Patients Diagnosed With Community Acquired Pneumonia|ALPAJ|Hôpital Louis Mourier|Yes|Completed|November 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|181|||Both|18 Years|65 Years|No|Probability Sample|all adult patient presenting either to the emergency department or admitted directly to        the ICU or the pneumology ward with a suspicion of CAP will be screened|February 2016|February 25, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523885||15090|
NCT02527655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP-MOTM|The Men on the Move Study|Shape the Path: Targeting the Health and Mobility of Older Men Through Key Community Partnerships -- The Men on the Move Study||Simon Fraser University|No|Recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|65 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02527655||14800|
NCT02514928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI003|Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas|Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas||Fudan University|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02514928||15778|
NCT02517177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008|Alterations in Autonomic Cardiovascular Control Induced at Partial G Forces||AUTOCARD|University Hospital, Caen|No|Completed|June 2011|||December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517177||15606|
NCT02511574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470.095|Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth|Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth in Pregnant Women With a Uterine Cervix Measuring 25 mm or Less in Length||University of Sao Paulo|No|Recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02511574||16034|
NCT02511821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15051|Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery|Electronic Monitoring of Patient-Reported Outcomes and Function in GI Cancer Surgery: A Feasibility Study||City of Hope Medical Center|Yes|Recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|21 Years|N/A|No|||November 2015|November 13, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02511821||16015|
NCT02525510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029669|Deceased Organ Donor Interventions to Protect Kidney Graft Function|Mild Hypothermia Versus Pulsatile Perfusion in Deceased Donors and Kidney Graft Function||University of California, San Francisco|Yes|Not yet recruiting|November 2015|March 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02525510||14965|
NCT02673905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NosetoKnee2|Clinical Trial for the Regeneration of Cartilage Lesions in the Knee|Randomized, Multi-center Phase II Clinical Trial for the Regeneration of Cartilage Lesions in the Knee Using Nasal Chondrocyte-based Tissue (N-TEC) or Nasal Chondrocyte-based Cell (N-CAM)-Therapies|NosetoKnee2|University Hospital, Basel, Switzerland|No|Not yet recruiting|August 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673905||3575|
NCT02674048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.104956|Metvix Daylight PDT in Actinic Keratosis|Observational Study to Evaluate Clinical Practice and Satisfaction With Metvix® Daylight Photodynamic Therapy (PDT) in the Treatment of Mild and/or Moderate Actinic Keratosis of the Face and/or the Scalp|SESAME|Galderma|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|540|||Both|18 Years|N/A|No|Non-Probability Sample|patients with mild to moderate Actinic Keratosis on the face or scalpe|March 2016|March 1, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02674048||3564|
NCT02674061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-100|Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)|A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)||Merck Sharp & Dohme Corp.|No|Recruiting|February 2016|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|325|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02674061||3563|
NCT02517437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-8557-A|Suprascapular and Axillary Blocks Versus Interscalene Block for Shoulder Surgery|Novel Combination of Suprascapular & Axillary Nerve Blocks Versus Conventional Interscalene Brachial Plexus Block for Pain Relief Following Shoulder Surgery: A Multi-centre Randomized, Patient & Assessor Blinded, Non-inferiority Trial|PASS|University Health Network, Toronto|Yes|Not yet recruiting|August 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517437||15586|
NCT02517450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 12-237|Effectiveness of an Adventure-based Training Programme|Effectiveness of an Adventure-based Training Programme in Promoting the Psychological Well-being of Primary School Children||The University of Hong Kong|Yes|Completed|April 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|120|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02517450||15585|
NCT02526082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS Group|Long-term Follow-up of the Helsinki Businessmen Study|Long-term Follow-up of the Helsinki Businessmen Study Cohort of Men Born in 1919-1934|HBS|Helsinki University Central Hospital|No|Active, not recruiting|January 1964|December 2040|Anticipated|December 2040|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|3490|Samples With DNA|APOE, telomeres, DNA collected for future use|Male|31 Years|46 Years|Accepts Healthy Volunteers|Non-Probability Sample|Originally a convenient cohort of male executives and businessmen (born 1919-1934,        n=3490), who participated in health check-ups during 1964-1973, but since the beginning of        1970s it has developed into a clinic-epidemiological longitudinal study.|August 2015|August 14, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526082||14921|
NCT02524782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6240C00001|A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes|A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)||MedImmune LLC|No|Recruiting|February 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524782||15021|
NCT02674269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-OAB-03-P|Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")|A Randomized Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botulinum Toxin (Botox®) Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")|INTIMO2|UroGen Pharma Ltd.|No|Not yet recruiting|February 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Female|18 Years|75 Years|No|||February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02674269||3547|
NCT02526927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408082|Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period.|Monocentric Study Evaluating Bone Microarchitecture by High Resolution Quantitative Computerized Tomography (HR-pQCT) in Young Adults and Adolescents Who Developed Anorexia Nervosa (AN) in Peri or Prepubertal Period.|AMOS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|50|||Both|10 Years|30 Years|No|||March 2016|March 9, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526927||14856|
NCT02526186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20150072H|Battlefield Auricular Acupuncture for Control of Post-partum Pain|Battlefield Auricular Acupuncture for Control of Post-partum Pain||Mike O'Callaghan Federal Hospital|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526186||14913|
NCT02526199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005383-14|Protracted Mixture of Local Anesthetics for Major Foot and Ankle Surgery|Protracted Mixture of Local Anesthetics for Major Foot and Ankle Surgery. A Randomized Double-blind, Controlled Study Comparing Bupivacaine-Epinephrine 0.5% Versus Bupivacaine-Epinephrine 0.5% With Dexamethasone||Kolding Sygehus|No|Enrolling by invitation|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526199||14912|
NCT02515981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23336|New Hampshire Medicaid Wellness Incentive Program|New Hampshire Medicaid Wellness Incentive Program|NHWIP|Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|May 2012|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2800|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515981||15697|
NCT02672618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHuang|Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology|Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|November 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|200|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Heart failure patients included in this study had been definitively diagnosed as having        with Echocardiography. The healthy volunteer group matched the HF group in number, age,        and gender.|February 2016|February 2, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02672618||3673|
NCT02526953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAC-001|Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients|Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer||Blokhin's Russian Cancer Research Center|No|Not yet recruiting|October 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|August 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526953||14854|
NCT02525523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH UCP-301|Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects With Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis||Atlantic Pharmaceuticals Ltd||Recruiting|November 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525523||14964|
NCT02666248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11315|Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies|Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies||Abramson Cancer Center of the University of Pennsylvania|Yes|Enrolling by invitation|January 2016|||January 2031|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|N/A|No|Probability Sample|Subjects who have participated in a lentiviral vector study and have received        CART-EGFRvIII cells.|February 2016|February 3, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02666248||4159|
NCT02666261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29763|A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany|A Non-interventional Study on the Epidemiology and Testing of HER2 in Breast Cancer in Germany||Hoffmann-La Roche||Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer tissue samples from participants in Germany|March 2016|March 1, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02666261||4158|
NCT02514993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2004-2013|The Unstable Thoracic Cage Injury|The Unstable Thoracic Cage Injury: The Concomitant Sternal Fracture Indicates a Severe Thoracic Spine Fracture||BG Unfallklinik|Yes|Completed|January 2003|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|130|||Both|18 Years|49 Years|No|Non-Probability Sample|Patients suffering a thoracic spine fracture and a concomitant sternal fracture|July 2015|August 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514993||15773|
NCT02518607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-019|Safety, Blood Levels and Effects of MGB-BP-3|A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3||MGB Biopharma Limited|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|18||Actual|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02518607||15496|
NCT02518620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX0061-C203|An Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Rheumatoid Arthritis|A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX 0061||Ablynx|Yes|Recruiting|July 2015|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|501|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518620||15495|
NCT02517333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140844|Exploring the Impact and Feasibility of a Pathway to Sport and Long-term Participation in Young People|Exploring the Impact and Feasibility of a Pathway to Sport and Long-term Participation in Young People|EPIC|Oxford Brookes University|No|Recruiting|March 2014|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|90|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02517333||15594|
NCT02671253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24/13703/03/2015|Myomectomies:Tumor Characteristics and Clinical Implications|Myomectomies:Tumor Characteristics and Clinical Implications||Helsinki University Central Hospital|No|Recruiting|October 2015|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|45 Years|No|Non-Probability Sample|Women at age under 46 years undergoing myomectomy.|January 2016|January 31, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02671253||3777|
NCT02515552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM Wellness Project|Web-Based Program for Symptom Management in Fibromyalgia|Web-Based Program for Symptom Management in Fibromyalgia||Collinge and Associates, Inc.|No|Completed|September 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|883|||Both|21 Years|N/A|No|||July 2015|August 3, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515552||15730|
NCT02514252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0264|Sublingual Fentanyl for the Management of Breakthrough Pain|A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514252||15830|
NCT02514265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822352|Trans-MAPP Symptom Patterns Study (SPS)|MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS)|MAPP II SPS|University of Pennsylvania|No|Recruiting|July 2015|June 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|640|Samples With DNA|DNA Blood Urine Vaginal Swabs Rectal Swab|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Trans-MAPP SPS study will include adults 18 years and older with urological pelvic        pain syndromes. Approximately one-half of the participants will be male, and one-half will        be enriched to meet the body map pain location criteria of Pelvis pain only.|October 2015|October 27, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514265||15829|
NCT02519166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02|Characterisation of Biofilm of the Chronic Wounds||Biofilm Plaie|Institut Curie|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|130|||Both|18 Years|N/A|No|||July 2015|August 6, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02519166||15453|
NCT02519179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000|Influence of Bottle-Type of Infant Feeding Behavior||OBS-II|California Polytechnic State University-San Luis Obispo|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02519179||15452|
NCT02521116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUGEN-061014|Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap|Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap|DVA-Oxymap|Medical University of Vienna||Recruiting|February 2016|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02521116||15303|
NCT02521129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-048-003|A New Track Ablation Device for Liver Biopsy: A Feasibility Study|A New Track Ablation Device for Liver Biopsy: A Feasibility Study||Samsung Medical Center|Yes|Not yet recruiting|September 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|80 Years|No|||August 2015|August 9, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02521129||15302|
NCT02521064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McmasterCH - 15-365|Effects of Exclusive Enteral Nutrition on the Microbiome in Pediatric Inflammatory Bowel Disease|The Role of Exclusive Enteral Nutrition in the Pediatric Inflammatory Bowel Disease Microbiome: a Pilot Study||McMaster Children's Hospital|No|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|None Retained|Bl|Both|5 Years|18 Years|No|Non-Probability Sample|Pediatric patients (<18yo) being followed and managed through the McMaster Children's        Hospital's Division of Pediatric Gastroenterology. Patients are diagnosed with Crohn's        Disease, Ulcerative Colitis, or Inflammatory Bowel Disease-Unclassified.|August 2015|August 7, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02521064||15307|
NCT02527785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-1401|Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer|Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Gastric Cancer||Hallym University Medical Center|No|Recruiting|February 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||February 2016|February 18, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527785||14790|
NCT02513485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081486|Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa|Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa||Emory University|Yes|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|13|||Both|21 Years|65 Years|No|||October 2015|October 29, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513485||15887|
NCT02667249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP 001|Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods|Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods||University Hospital Tuebingen|No|Completed|August 2011|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|241|||Both|18 Years|99 Years|No|Probability Sample|patients undergoing elective laparoscopic cholecystectomy|November 2015|January 25, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02667249||4082|
NCT02523391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-8995-08|Bioequivalence Study of Capsule and Tablet Formulations of TA-8995|A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects||Xention Ltd|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523391||15128|
NCT02523404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung Cancer HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Cancer: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|May 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523404||15127|
NCT02524275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|762-14*|Docetaxel and Capecitabine in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck||University of Nebraska|Yes|Recruiting|March 2015|||April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524275||15060|
NCT02524288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8342B-061|Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)|A Phase 3, Single Arm, Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring in Healthy Women 18 Years of Age and Older, At Risk for Pregnancy||Merck Sharp & Dohme Corp.|No|Recruiting|August 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524288||15059|
NCT02513784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP4553|Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome|Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome|Mouthwash|Columbia University|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513784||15865|
NCT02513797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-011|aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation|LEFT ATRIAL APPENDAGE LIGATION WITH THE LARIAT+® SUTURE DELIVERY SYSTEM AS ADJUNCTIVE THERAPY TO PULMONARY VEIN ISOLATION FOR PERSISTENT OR LONGSTANDING PERSISTENT ATRIAL FIBRILLATION|aMAZE|SentreHEART, Inc.|Yes|Recruiting|September 2015|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513797||15864|
NCT02645903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP|Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy|Ultrasound-guided Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy: Randomized Controlled Double-blinded Trial||Inonu University|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645903||5721|
NCT02645916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISEE_2015_DSGOST|Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet|Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet||Gachon University Gil Oriental Medical Hospital|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Female|19 Years|59 Years|No|||January 2016|January 20, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645916||5720|
NCT02650713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP29945|A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors|AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS||Hoffmann-La Roche||Recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650713||5351|
NCT02654431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-ER/PR-IHC|Identification and Semi -Quantification of ER/PR Proteins Expression|Identification and Semi -Quantification of ER/PR Proteins Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Tissue||Applied Spectral Imaging Ltd.|No|Completed|May 2013|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|350|||Female|20 Years|80 Years|No|Probability Sample|Breast cancer patients|January 2016|January 12, 2016|June 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02654431||5067|
NCT02661516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-338|Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists|Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-Valvular Atrial Fibrillation Treated With Vitamin K Antagonists||Bristol-Myers Squibb|No|Completed|July 2014|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|16513|||Both|18 Years|100 Years|No|Non-Probability Sample|Retrospective cohort with study period from January 1, 2003 to December 31, 2013 using the        Clinical Practice Research Datalink (CPRD). The study will identify AF patients treated        with VKA during the study period and will follow them from the first record of VKA use        (index date). until the first of end of study period, leaving the database, VKA        discontinuation/switch, or death. It will use person-time denominators to handle the        varying length of follow-up of patients|January 2016|January 19, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661516||4522|
NCT02527174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230-37|A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia|A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)|VIAC|University of Alberta|Yes|Not yet recruiting|June 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 24, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02527174||14837|
NCT02527187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T502-SSP-007|Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa|Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation|T502|Inmunotek S.L.|No|Recruiting|March 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|198|||Both|5 Years|70 Years|No|||February 2016|February 24, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527187||14836|
NCT02527200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-4179|Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome|Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.||Novo Nordisk A/S|No|Recruiting|November 2015|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|18 Years|No|||November 2015|November 11, 2015|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527200||14835|
NCT02662881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIO.CR.BIOAVN.002.15|Treatment of Avascular Necrosis of the Femoral Head With Core Decompression Using the PerFuse Instrument and BioCUE|Post-Market Data Collection for Treatment of Avascular Necrosis (AVN) of the Femoral Head With Core Decompression Using the PerFuse Instrument and BioCUE|REGP-44-00|Biomet, Inc.|No|Not yet recruiting|March 2016|March 2023|Anticipated|March 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Subjects with unilateral or bilateral avascular necrosis (or osteonecrosis) of the femoral        head will be prospectively enrolled in the study.|January 2016|January 21, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02662881|5 Years|4417|
NCT02662894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS0815|Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.|Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.||EMS|No|Not yet recruiting|August 2016|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|334|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02662894||4416|
NCT02519257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96091|The Relationship of Adiponectin in Adipose Tissue, Thy-1 in Plaques, and Inflammatory Mediators With Cardiac Diseases|The Relationship of Adiponectin in Adipose Tissue, Thy-1 in Plaques, and Inflammatory||Far Eastern Memorial Hospital|No|Completed|August 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|96|||Both|N/A|N/A|No|||August 2015|August 6, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02519257||15446|
NCT02524054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000027|Aerosol Inhalation Treatment for Dyspnea - Patients|Aerosol Inhalation Treatment for Dyspnea||Beth Israel Deaconess Medical Center|No|Recruiting|November 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524054||15077|
NCT02514330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGF 02|Running Slopes and Power Performance|Concurrent Effect of Running in Different Slopes on Power Performance||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514330||15824|
NCT02668107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 43874915.0.0000.5201|Electromyographic Activity of Preterm Newborns Submitted to Hammock Positioning : a Randomized Clinical Trial|Electromyographic Activity of Preterm Newborns Submitted to Hammock Positioning : a Randomized Clinical Trial||Instituto Materno Infantil Prof. Fernando Figueira|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|78|||Both|N/A|20 Days|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668107||4016|
NCT02527954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412-ALC-086-PH|Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions|Impact of Y-chromosome Microdeletions From Infertile Men on the Chromosomal Constitution of Their Spermatozoa and Embryos. Combined IntraCytoplasmatic Sperm Injection (ICSI) and Preimplantation Genetic Screening (PGS) as Treatment Strategy.||Instituto Valenciano de Infertilidad, IVI Alicante|No|Not yet recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Whole blood, ejaculated semen or testicular biopsy, blastomere|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Couples undergoing "In vitro" Fertilization (IVF) treatment whose man has non-obstructive        azoospermia or severe oligozoospermia (≤ 5x1000000 spermatozoa/ml) and consent the genetic        analysis of semen samples, as well as the embryo cohort generated by ICSI.|August 2015|August 17, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02527954|12 Months|14777|
NCT02514174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.209|Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older|A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations||Boehringer Ingelheim||Recruiting|August 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|No|||March 2016|March 21, 2016|July 17, 2015||||No||https://clinicaltrials.gov/show/NCT02514174||15836|
NCT02515929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USeville|Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs|Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With an Oligomeric Proanthocyanidins Nutritional Supplement||University of Seville|Yes|Completed|September 2013|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515929||15701|
NCT02518672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-108|Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)|Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.|PREMDIC|SCF Pharma|Yes|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518672||15491|
NCT02518685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTC006|ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss|Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study||BaroNova, Inc.|Yes|Recruiting|September 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|22 Years|60 Years|No|||December 2015|December 10, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518685||15490|
NCT02519231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49582-A|Copper IUD Treatment Observation Study|A Multi-Center, Double-Blinded, Randomized, Phase IV 6-Month Pilot Study to Compare Bleeding Patterns, Satisfaction and Quality of Life Among New Copper 380A IUD Users Treated With Naproxen Sodium (440mg Twice Daily) Versus Placebo|CITROS|University of Washington|No|Not yet recruiting|August 2015|August 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|June 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519231||15448|
NCT02521792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVO-1A-203|In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects|A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)||Clementia Pharmaceuticals Inc.|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|65 Years|No|||January 2016|January 7, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521792||15251|
NCT02524158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O7768-R|Yoga for Veterans With CLBP|Yoga Therapy to Improve Function Among Veterans With Chronic Low Back Pain||VA Office of Research and Development|No|Active, not recruiting|April 2013|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524158||15069|
NCT02516553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1367.1|BI 894999 First in Human Dose Finding Study in Advanced Solid Tumours|An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Recruiting|July 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 27, 2015||||No||https://clinicaltrials.gov/show/NCT02516553||15654|
NCT02516566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsanMC|Effects of PEEP on Optic Nerve Sheath Diameter During Robot-Assisted Laparoscopic Prostatectomy|Effects of Positive End-Expiratory Pressure Ventilation on Optic Nerve Sheath Diameter in Patients Undergoing Robot-Assisted Laparoscopic Prostatectomy||Asan Medical Center|No|Completed|September 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|38|||Male|20 Years|N/A|No|||November 2015|November 30, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516566||15653|
NCT02522390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9616|The Nutrition Researcher Cohort 2014 Study|The Nutrition Researcher Cohort 2014 Study; New Standardized Self-quantification Methodologies Serving Both Research and Personal Health Maintenance|NRC250|TNO|No|Recruiting|January 2015|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|"do-it-yourself", at-home measurements of blood glucose and blood cholesterol.      In addition, the plasma metabolome and selected biomarkers (from dried blood spot), urinary      metabolome (from collected urine), DNA damage (from dried blood spots, telomere length and      mitochondrial DNA deletions, DNA base damage/oxidation, gamma H2AX DNA strand break assay),      micronutrient analysis (from dried blood spot or capillary blood collection) and microbiome      (sequencing metagenomics/Fecal Swabs) will be offered to participants as additional      measurements, if funding or in-kind sponsoring is available.      Funding is already available for:        -  Dried blood spot collection for analysis of biomarkers (including fatty acids,           vitamins, amino acids) and metabolomics;        -  Faecal collection (swab) for metagenome analysis        -  Capillary blood collection for CRP, HbA1c and other parameters        -  OGTT sampling kit for analysis of insulin and c-peptide;|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The NRC cohort will be composed of employees and students in the area of life sciences.        This allows optimal involvement of participants in shaping all aspects of the cohort and        the ownership of data. We aim to recruit about 250 male and female scientists for the        entire cohort. For each participating country it is aimed to recruit about 25        participants, taking drop-out and varying submission and/or starting dates between the 15        participating countries into account. Besides, a higher number of participants will        increase the chance of being able to compare the data with other countries.|August 2015|August 10, 2015|March 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02522390||15205|
NCT02514785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB34487|Zone-Model Predictive Control on the Diabetes Assistant (DiAs) Platform Efficacy|Use of Zone-Model Predictive Control (MPC) Controller on the Diabetes Assistant (DiAs) Platform With Fault Detection in Adolescents With Type 1 Diabetes in the Outpatient Setting (UCSB Study)||Stanford University|Yes|Not yet recruiting|July 2015|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|10 Years|19 Years|No|||July 2015|July 31, 2015|July 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514785||15789|
NCT02526407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATB2015|Singing Away the Blues: the Impact of Singing on Symptoms of Postnatal Depression|Singing Away the Blues: the Impact of Singing on Symptoms of Postnatal Depression|SATB|Royal College of Music|No|Recruiting|October 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526407||14896|
NCT02527642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411015635|Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media|Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media: A Randomized Controlled Trial by Time-Lapse System- Single Step vs Sequential Media||Weill Medical College of Cornell University|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02527642||14801|
NCT02511483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-169-MUHC|Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain|Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy|PRO_GENE_POP|McGill University Health Center|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|July 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02511483||16041|
NCT02512029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A12|18F-AV-1451 PET Imaging in TBI|18F-AV-1451 PET Imaging in Subjects With Subacute Traumatic Brain Injury||Avid Radiopharmaceuticals|No|Withdrawn|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512029||15999|
NCT02515032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-C002|Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia|A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed With Non Small Cell Lung Cancer (NSCLC) With Involuntary Weight Loss||Smartfish AS|No|Recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||July 2015|July 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515032||15770|
NCT02515305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-15-003|Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris|||Perrigo Company|No|Recruiting|July 2015|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|889|||Both|12 Years|40 Years|No|||July 2015|August 3, 2015|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515305||15749|
NCT02513953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endometriosis|Case Report of Endometrioma in Layers of Broad Ligament.|Endometrioma in Layers of Brot ad Ligament in Left Adnexa|mesosalpinx|Ruby Hall IVF and Endoscopy Centre|Yes|Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513953||15852|
NCT02513966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58228|Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.|Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|July 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Actual|7835|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing cardiac surgery from 2010 untill 2014 in the University Hospitals        of Leuven.|July 2015|July 31, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02513966||15851|
NCT02518139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0128|A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 52-week, Randomized, Active−Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease||Theravance Biopharma R & D, Inc.|No|Recruiting|September 2015|||March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1050|||Both|40 Years|N/A|No|||September 2015|September 24, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518139||15532|
NCT02527668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-11-25-HyD-O|To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia|To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia: a Double-blind Randomized Placebo-controlled Trial||DSM Nutritional Products, Inc.|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|150|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527668||14799|
NCT02520830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blueberries|Effects of Blueberry-polyphenols on Endothelial Function, Absorption and Metabolism|Sustained Effects of Blueberry Polyphenols on Vascular Function in Healthy Individuals||Heinrich-Heine University, Duesseldorf|No|Completed|March 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|45|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02520830||15325|
NCT02523716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_02_33|Effect of Short-term Simulated Altitude Exposure on Cardiopulmonary Functional Capacity|Effect of Short-term Simulated Altitude Exposure on Cardiopulmonary Functional Capacity||University of Limerick|No|Active, not recruiting|May 2015|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|June 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02523716||15103|
NCT02527629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015- 01, 20.07.2015|Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance")|Aortic Replacement Using Individualised Regenerative Allografts: Bridging the Therapeutic Gap - ARISE (the "Surveillance")|ARISE|corlife|Yes|Recruiting|September 2015|March 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe aortic valve disease and the indication for aortic valve replacement|September 2015|September 24, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02527629||14802|
NCT02514655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111113|Simple Mechanical Device to Control Pressure in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia|Role of a Simple Mechanical Device of Pressure Control in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia|PAV-PROTECT|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02514655||15799|
NCT02523651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapitalMedicalU-1|Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy|Study of Local Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Allogeneic Human Dental Pulp Stem Cells Injection Therapy||Capital Medical University|No|Recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||August 2015|August 13, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523651||15108|
NCT02511288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET15000076|LIquid BIopsies in Lung Cancer (LIBIL)|Blood Collection for Patients With Advanced Non-small Cell Lung Cancer|LIBIL|Centre Leon Berard|No|Recruiting|July 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced NSCLC, treated at the Centre Leon Berard|July 2015|October 26, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02511288||16056|
NCT02511561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201506|OTO-201 for the Treatment of Otitis Externa|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa||Otonomy, Inc.|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|6 Months|80 Years|No|||January 2016|January 21, 2016|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02511561||16035|
NCT02514876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXT-001|Foresight Intracardiac Echocardiography (ICE) System|Visualization of Human Cardiovascular Anatomy With Foresight Intracardiac Echocardiography (ICE) System||Colibri Technologies, Inc||Recruiting|September 2015|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02514876||15782|
NCT02520986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONDYLOMA-1|Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma|Carbon Dioxide Laser Ablation Versus Electrocoagulation - a Prospective, Randomized Multicenter Trial Comparing Two Surgical Treatments in Women Undergoing Therapy for Condyloma Acuminata||Zydolab - Institute of Cytology and Immune Cytochemistry|No|Not yet recruiting|April 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|114|||Female|18 Years|N/A|No|||February 2016|February 28, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520986||15313|
NCT02520999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP300|The Effect of Various External Pressure on Blood|Comparison of the Effect of Various External Pressure on Blood During Rapid Infusion|EPB|Korea University Anam Hospital|Yes|Completed|August 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|25|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520999||15312|
NCT02516176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU000200161|Sideways Treadmill Training to Improve Paretic Leg Stepping in Persons Post-Stroke|The Feasibility and Efficacy of Induced Lateral Step Treadmill Training to Improve Paretic Limb Stepping Post-Stroke||Northwestern University|No|Recruiting|February 2015|June 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02516176||15683|
NCT02515110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15-10994|Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer|Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta||Virginia Commonwealth University|Yes|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Female|50 Years|N/A|No|||January 2016|January 29, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02515110||15764|
NCT02664987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPD14-AP-401|Analgesic Treatment for Cancer Pain in South East Asia|A Cross-sectional Study to Investigate the Pain Control Status in Cancer Patients in South East Asian Countries|ACE|Mundipharma Pte Ltd.|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|464|||Both|18 Years|N/A|No|Probability Sample|Subjects were selected from government and private hospitals that see cancer patients.|January 2016|January 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664987||4255|
NCT02665000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB/2015/00944|Evaluating the Effects of a Structured Training Program on the Learning Curve of Residents in Laparoscopic Surgery|A Randomised Controlled Trial Evaluating the Effects of a Structured Training Program on the Learning Curve of Residents in the Field of Laparoscopic Surgery (STAR Trial)||National University Hospital, Singapore|Yes|Recruiting|August 2014|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|24 Years|35 Years|No|||March 2016|March 21, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02665000||4254|
NCT02521155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-071-CERES-D|"Safeguard Your Smile" an Oral Health Literacy Intervention Promoting Positive Oral Hygiene Self-care Behavior|"Safeguard Your Smile" an Oral Health Literacy Intervention Promoting Positive Oral Hygiene Self-care Behavior Among Punjabi Immigrants: A Randomized Controlled Trial||Université de Montréal|No|Completed|July 2015|February 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|March 1, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02521155||15300|
NCT02513186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD13983|SAR650984 Combined to CyBorD in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant|A Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study, of SAR650984 Administered Intravenously in Combination With Bortezomib, Cyclophosphamide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplantation|CyBorDSAR|Sanofi|No|Recruiting|September 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513186||15910|
NCT02525575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1911-P|Suicide Safety Planning Group Treatment: "Project Life Force"|Suicide Safety Planning Group Treatment - "Project Life Force"|PLF|VA Office of Research and Development|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02525575||14960|
NCT02525588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-039|Polyethylene Wear Study on the Triathlon Total Knee Prosthesis|Polyethylene Wear Study on the Triathlon Total Knee Prosthesis A Prospective Randomized Single Centre RSA Study|X3vsN2Vac|Stryker European Operations BV|No|Active, not recruiting|September 2011|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525588||14959|
NCT02665208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01654|A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients|Mobile Phone Messaging to Support Smoking Cessation Among Office-based Buprenorphine and Inpatient Detoxification Patients: a Pilot Study||New York University School of Medicine|No|Active, not recruiting|March 2015|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|203|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02665208||4238|
NCT02665221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00173|Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY|Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.||New York University School of Medicine|No|Recruiting|July 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02665221||4237|
NCT02514447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1T28-03|Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy|Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy||G1 Therapeutics, Inc.|No|Recruiting|July 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514447||15815|
NCT02514460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z141107002514063|Clinical Study of Stent Versus Direct Atherectomy to Treat Diabetic Lower Limb Ischemia|||Xuanwu Hospital, Beijing||Enrolling by invitation|January 2014|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2014|September 14, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514460||15814|
NCT02513394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-05|PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer|PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer|PALLAS|Alliance Foundation Trials, LLC.|Yes|Recruiting|August 2015|September 2025|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4600|||Both|18 Years|N/A|No|||July 2015|December 10, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513394||15894|
NCT02513641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-018|Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes|Effect of 2-Week Nightly Moderate Hypoxia on Oral Glucose Tolerance in Individuals With Type 2 Diabetes|SLEEPDM|Pennington Biomedical Research Center|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513641||15875|
NCT02525458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QAMS-2015|Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin|Antimicrobial Activity of a Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin: A Randomized Clinical Trial||Kimmerling Holdings Group, LLC|Yes|Recruiting|July 2015|January 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525458||14969|
NCT02661581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H13-02163-A002|Peer-led, Empowerment-based, Approach to Self-management Efforts in Diabetes|Peer-led, Empowerment-based, Approach to Self-management Efforts in Diabetes: A Randomized Controlled Trial (The PLEASED Trial)|PLEASED|University of British Columbia|No|Recruiting|November 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|21 Years|N/A|No|||February 2016|February 10, 2016|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02661581||4517|
NCT02661594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10013|Thorough QT Study of Intravenous Amisulpride|A Randomised, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous APD421 on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects||Acacia Pharma Ltd|No|Completed|November 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|40|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661594||4516|
NCT02514746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV07 - PR-15036|Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose|Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose||PATH|Yes|Not yet recruiting|July 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|818|||Both|43 Months|51 Months|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02514746||15792|
NCT02514759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Philliber10-15TWC|Replication of the Teen Outreach Program in Kansas City|The Women's Clinic of Kansas City Teen Outreach Program Replication Study||Philliber Research & Evaluation|No|Active, not recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1885|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02514759||15791|
NCT02517502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002415|Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy|Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy||University of Kansas Medical Center|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|65 Years|No|||August 2015|August 4, 2015|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517502||15581|
NCT02517515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-767|ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection||AbbVie|Yes|Active, not recruiting|July 2015|June 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02517515||15580|
NCT02517528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14-491|ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT -333 Co-administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis|An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis||AbbVie|Yes|Active, not recruiting|July 2015|March 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02517528||15579|
NCT02512471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-64-2|The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block|The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block||Huazhong University of Science and Technology|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|July 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02512471||15965|
NCT02671188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200928|A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis|A Multi-centre, Randomised, Double-blind (Sponsor Open), Placebo-controlled, Repeat Dose, Proof of Mechanism Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis||GlaxoSmithKline|No|Not yet recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02671188||3782|
NCT02519270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGN002-101|Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)|NHL|Valor Biotherapeutics, LLC|No|Recruiting|December 2015|December 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519270||15445|
NCT02527161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriShapeMatch-10_SubStudyB|Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study B|A Prospective, Non-randomized, Longitudinal Study of the Clinical Outcomes of Participants That Receive the Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study B||Stryker South Pacific|No|Active, not recruiting|June 2011|||November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|50 Years|90 Years|No|||January 2016|January 19, 2016|August 3, 2015|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT02527161||14838|
NCT02511340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHGV678-204|A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients|Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients||Jiangsu Hansoh Pharmaceutical Co., Ltd.|No|Active, not recruiting|January 2013|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|167|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02511340||16052|
NCT02524808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10537|Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer|Multicentric Project for the Prospective Identification and Validation of Molecular Alterations That Define the "BRCANess" Profile in Ovarian Epithelial Cancer and Its Application as a Response Predictor to Platinum and Antitarget Therapies in the Clinical Practice. The Finding BRCANess Project|FindBRCANess|Fundación de investigación HM|No|Not yet recruiting|August 2015|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|230|||Female|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with advanced epithelial ovarian cancer (stage 1c or higher) since 2008|August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524808|6 Months|15019|
NCT02524821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-100-005|The Effect of Gelesis100 on the Pharmacokinetics of Clopidogrel and Metformin|Randomized, Open-label, 4-Way Crossover Study Assessing the Effect of Gelesis100 on the Pharmacokinetics of Metformin, Administered Under Fasting and Fed Conditions||Gelesis, Inc.|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02524821||15018|
NCT02526667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15-029|Preoperative CHG Cloth|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation||Medline Industries|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|325|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|December 5, 2015|August 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526667||14876|
NCT02673671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2014-001|G-Tech Feasibility Study for Early Detection of a Post-op Ileus|Measurement Of GI Myoelectric Activity In Patients At Risk For Or Who Have A Post-Operative Ileus (POI) - Monitoring/ Recording GI Myoelectric Activity For Early Detection of A POI|GTECHPOI|G-Tech Corporation|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02673671||3593|
NCT02520505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-149|SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis|Determining the Fertility Benefit of Immediate SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis||The Cleveland Clinic|No|Recruiting|April 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|35 Years|No|||February 2016|February 15, 2016|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02520505||15350|
NCT02518841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01870|A Comparison of ThermaWedge™ Device and Achilles Tendon Stretching for the Treatment of Plantar Fasciopathy|A Comparison of ThermaWedge™ Device and Achilles Tendon Stretching for the Treatment of Plantar Fasciopathy||University of British Columbia|No|Not yet recruiting|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02518841||15478|
NCT02527486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AW_registry|Seoul National University Airway Registry|Airway Registry for Chronic Airway Diseases||Seoul National University Hospital|Yes|Recruiting|September 2011|December 2031|Anticipated|December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Blood (whole blood, serum, plasma, buffy coat) Urine|Both|20 Years|90 Years|No|Non-Probability Sample|COPD Asthma ACOS Bronchiectasis TB-destroyed lung Other chronic airway diseases|August 2015|August 17, 2015|December 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02527486|10 Years|14813|
NCT02527499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPD3E0311|The Effects of Combining Modified ride-on Cars With Bimanual Training on Enhancing Mobility, Socialization, Motor Function and Participation in Toddlers With Disabilities|||Chang Gung Memorial Hospital|No|Recruiting|February 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|12 Months|36 Months|No|||July 2015|August 17, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02527499||14812|
NCT02523794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.1.1.H1|Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis|A Double Blind, Placebo-controlled Study Evaluating an Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis||Revalesio Corporation|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|16 Years|49 Years|No|||August 2015|August 12, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02523794||15097|
NCT02523807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0486-14-RMB|Tremor Monitoring Device|Tremor Monitoring Device||Rambam Health Care Campus|No|Not yet recruiting|September 2015|||August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with tremor due to Parkinson's disease or Essential tremor will be included|September 2015|September 1, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523807||15096|
NCT02527850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-15|Effect of Low Level Laser Irradiation on Muscle Performance and Recovery|Effect of Low Level Laser Irradiation on Muscle Performance and Recovery||Hillel Yaffe Medical Center|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02527850||14785|
NCT02527876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505m70321|Exercise, Activity and Smoking in Young Adults|Exercise to Promote Quit Attempts in Young Adults|EASY-A|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02527876||14783|
NCT02511886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-14-0001|A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder||Indivior Inc.|Yes|Active, not recruiting|September 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511886||16010|
NCT02511899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS850/15|Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function|Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function||Vital Solutions Swiss AG|No|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02511899||16009|
NCT02671396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13MMHIS120|Effects of Virtual Reality Based Training on Posture Stability in Parkinson's Disease|Effects of Virtual Reality Based Training on Posture Stability in Individuals With Parkinson's Disease||National Yang Ming University|Yes|Completed|August 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|N/A|No|||January 2016|January 28, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671396||3766|
NCT02671487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-CMBM-002|Mind-Body Skills Groups for Behavioral and Emotional Problems in War-Traumatized Male Adolescents in Gaza|Mind-Body Skills Groups for Behavioral and Emotional Problems in War-Traumatized Male Adolescents in Gaza||The Center for Mind-Body Medicine|No|Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Male|14 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671487||3759|
NCT02511795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6010C00005|AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors|A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours||AstraZeneca|No|Recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|130 Years|No|||November 2015|November 10, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511795||16017|
NCT02512081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOS-2307-CR|"The Lived Experience of Investigations for Sciatica"|"The Lived Experience of Investigations in Sciatica"||University of Southampton|Yes|Enrolling by invitation|September 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (aged over 18 years) with a clinical diagnosis of 'Sciatica of likely nerve root        origin' who have undergone investigations as part of their conservative management and        received results in the past 6 weeks.|July 2015|November 18, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512081||15995|
NCT02515071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic NO3- in OSAS|A 2 Week, Crossover Trial of Dietary Nitrate in Obstructive Sleep Apnoea Syndrome (OSAS).|Dietary Nitrate for OSAS: a Randomized, Placebo-controlled, Crossover Trial.||Royal College of Surgeons, Ireland|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|85 Years|No|||August 2015|October 22, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02515071||15767|
NCT02517892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01147-40|A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents|A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents|MATCH-R|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|December 2014|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02517892||15551|
NCT02650726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXYZM-4|Purified Anthocyanins Supplementation and High-Density Lipoprotein (HDL) Function|Effect of Purification Anthocyanins on HDL and Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial||Sun Yat-sen University|Yes|Completed|November 2014|November 2015|Actual|September 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|40 Years|60 Years|No|||January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650726||5350|
NCT02656589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC201512|microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin|A Perspective Study of the Predictive Value of microRNA in Patients With HER2 Positive Advanced Stage Breast Cancer Who Were Treated With Herceptin||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|advanced breast cancer patients first diagnosis in Sun Yat-sen Memorial Hospital, Sun        Yat-sen University. Informed consent must be obtained for all of the included patients.|January 2016|January 12, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02656589||4901|
NCT02645734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93210|The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema|The Comparison Between the Therapeutic Effect of Intravitreal Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema||hahid Beheshti University of Medical Sciences|Yes|Recruiting||||February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|133|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|January 4, 2016|January 2, 2016||Yes||No||https://clinicaltrials.gov/show/NCT02645734||5734|
NCT02645747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18586|Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion|RETRO CRVO: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion|RETRO CRVO|Bayer|No|Active, not recruiting|January 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The source population of this study is patients who suffer from visual impairment due to        macular edema secondary to central retinal vein occlusion.|March 2016|March 3, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02645747||5733|
NCT02655510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003249|Use of F-652 in Patients With Alcoholic Hepatitis|An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis|TREAT 008|Mayo Clinic|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|21 Years|N/A|No|||January 2016|January 12, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655510||4984|
NCT02655809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-07|Physica KR Fluoroscopy Study|Physica KR: In Vivo Kinematic Analysis of a Novel Total Knee Replacement Implant||Limacorporate S.p.a||Recruiting|May 2015|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|23|||Both|22 Years|80 Years|No|||January 2016|January 12, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655809||4961|
NCT02513004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-ZX46|Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel|Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|June 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|June 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513004||15924|
NCT02666729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003285|Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins|Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins|FORMIDIBLE|University of Kansas Medical Center|No|Not yet recruiting|July 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|112|||Both|18 Years|80 Years|No|Non-Probability Sample|People who are undergoing an intial AF ablation procedure.|January 2016|January 27, 2016|January 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666729||4122|
NCT02523079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34627|Cognitive Behavioral Therapy for Insomnia Among Different Types of Shift Workers|Cognitive Behavioral Therapy for Insomnia Among Different Types of Shift Workers|CBT-INSOMNIA|Finnish Institute of Occupational Health|No|Recruiting|January 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|60 Years|No|||August 2015|August 13, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02523079||15152|
NCT02515058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0552H|Ridge Preservation Following Tooth Extraction Using Two Mineralized Cancellous Bone Allografts|Ridge Preservation Following Tooth Extraction Using Mineralized Freeze-Dried Bone Allograft Compared to PUROS Mineralized Bone Allograft||The University of Texas Health Science Center at San Antonio|No|Recruiting|September 2015|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|July 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02515058||15768|
NCT02518412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1890(REK)|Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease|Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease|tDCS|University of Tromso|No|Recruiting|May 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|85 Years|No|||August 2015|August 10, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02518412||15511|
NCT02671877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/ INT /2015|Preoperative Fibroscopy as a Predictor of the Difficulty of Laryngoscopy and Intubation|Preoperative Fibroscopy as a Predictor of the Difficulty of Laryngoscopy and Intubation|TubeDiff|IRCCS San Raffaele|No|Recruiting|January 2016|July 2016|Anticipated|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients candidate to elective Ear-Nose-Throat (ENT) surgery under general anesthesia|January 2016|January 29, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02671877||3729|
NCT02514187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01132|A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients|A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients||British Columbia Cancer Agency|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|19 Years|N/A|No|||October 2015|October 20, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02514187||15835|
NCT02520297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-2004|A Pilot Study of TRV130 for the Treatment of Fracture Pain|A Phase 2, Open-label Pilot Study of TRV130 for the Treatment of Moderate to Severe Acute Pain Associated With Long Bone Fracture||Trevena Inc.|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520297||15366|
NCT02520310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVJ-514|AVJ-514 Japan Trial|A Prospective, Multi-Center, Single-Arm Clinical Evaluation of the AVJ-514 System for the Treatment of Symptomatic Chronic Severe Mitral Regurgitation||Abbott Vascular|Yes|Recruiting|August 2015|April 2021|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||January 2016|January 11, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02520310||15365|
NCT02525809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-114|Incidence of Dual Mobility Polyethylene Wear in Total Hip Prosthesis. Randomised Study Versus Fixed Insert by Radiostereometric Analysis.||DOUMOB|University Hospital, Caen|No|Completed|March 2010|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|82|||Both|60 Years|75 Years|No|||August 2015|August 14, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525809||14942|
NCT02522130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ob/gyn4|Different Analgesics Prior to Intrauterine Device (IUD) Insertion: Is There Any Evidence?|Different Analgesics Prior to IUD Insertion: Is There Any Evidence?||Al Hayat National Hospital|Yes|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 13, 2015|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522130||15225|
NCT02526290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUN-010|Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator|Single-Arm, Multicenter, Open-Label Study to Evaluate the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Participants With Aqueous Tear Deficient Dry Eye||Oculeve, Inc.|Yes|Active, not recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|97|||Both|22 Years|N/A|No|||January 2016|January 25, 2016|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526290||14905|
NCT02513420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2014-3504-56|Levator Ani Muscle Avulsion at First Birth of Mexican Women: Randomized Control Trial|Perineal Muscle Training Versus Usual Prenatal Care in the Incidence of Avulsion of the Levator Ani Muscle at First Birth of Mexican Women: Randomized Control Trial||Coordinación de Investigación en Salud, Mexico|Yes|Recruiting|July 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|228|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513420||15892|
NCT02522845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0181|Compression Therapy Following Endothermal Ablation|Multicentre Randomised Controlled Trial of Compression Therapy Following Endothermal Ablation (COMETA)|COMETA|Imperial College London||Recruiting|May 2015|||April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||May 2015|September 8, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522845||15170|
NCT02525978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00082047|Heart Rate Variability in Depression|Relationship Between Heart Rate Variability and Emotional Experience in Healthy and Depressed Adults||Emory University|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02525978||14929|
NCT02511197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM10|68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis|Safety and Diagnostic Performance of 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis||Peking Union Medical College Hospital|Yes|Recruiting|May 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511197||16063|
NCT02519036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 443139-CS1|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease||Ionis Pharmaceuticals, Inc.|Yes|Recruiting|August 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|25 Years|65 Years|No|||March 2016|March 2, 2016|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02519036||15463|
NCT02514044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0354|Dextroamphetamine and tDCS to Improve the Fluency|Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase||The University of Texas Health Science Center, Houston|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|58|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514044||15845|
NCT02668328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYUmed|CGV in Newly Diagnosed Type 2 Diabetes Patients: Effect of Dietary Interventions in the Human Microbiome|Continuous Glucose Variability in Newly Diagnosed Type 2 Diabetes Patients: Assessing the Effect of Dietary Interventions in the Human Microbiome||New York University School of Medicine|Yes|Not yet recruiting|September 2016|September 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|129|||Both|40 Years|N/A|No|||January 2016|January 26, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02668328||3999|
NCT02516371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC15OISI0093|Lymphocytes Subpopulation in Cancer Patients|Lymphocytes Subpopulation and Its Relevance With Tumor Grade and Prognosis in Cancer Patients|CaLym|The Catholic University of Korea|No|Recruiting|August 2015|December 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|20 Years|80 Years|No|||August 2015|August 25, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02516371||15668|
NCT02519296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE-PTSD-Klinik Syd|A fMRI Study of the Treatment of Danish Veterans With PTSD With Prolonged Exposure Therapy|A fMRI Study of the Treatment of Danish Veterans With Post-Traumatic Stress Disorder With Prolonged Exposure Therapy: Study Protocol for a Case-control Trial||Aalborg Universitetshospital|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02519296||15443|
NCT02526433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATB2015b|Singing Away the Blues: Assessing the Wellbeing of Mothers|Singing Away the Blues: Assessing the Wellbeing of Mothers, Their Use of Music and Its Impact on Symptoms of Postnatal Depression|SATBB|Royal College of Music|Yes|Recruiting|August 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women in the final 3 months of pregnancy or the first 6 months post-birth|October 2015|October 26, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526433||14894|
NCT02514369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARVLB01|Pharmacogenomics of New Antiretrovirals|Pharmacogenetics of New Antiretroviral Drugs||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|November 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|HIV1-positive patients|July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514369||15821|
NCT02523521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-140-15|Impact of an Exercise Program for Children Aged 4 to 6 Years With Bronchopulmonary Dysplasia|Impacte d'un Programa d'Exercici Per Nens d'Entre 4 a 6 Anys Amb Displàsia Broncopulmonar||Hospital de Nens de Barcelona|No|Recruiting|August 2015|November 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|52|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523521||15118|
NCT02525900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204411|Comparing the Efficacy of Transversus Abdominis Plane Block, Both Single Injection and Continuous Block Technique, to Wound Infiltration for Total Abdominal Hysterectomy|Comparing the Efficacy of Transversus Abdominis Plane Block, Both Single Injection and Continuous Block Technique, to Wound Infiltration for Total Abdominal Hysterectomy: A Prospective Randomized Study||University of Arkansas|No|Not yet recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 2, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02525900||14935|
NCT02525913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204538|Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue|Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue||University of Arkansas|No|Withdrawn|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Female|18 Years|N/A|No|||October 2015|October 7, 2015|August 13, 2015|No|Yes|Study was withdrawn from the IRB and never opened. No subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT02525913||14934|
NCT02514590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30-00113|Wireless High Frequency Spinal Cord Stimulation for Chronic Pain|Multi-center, Prospective, Randomized, Controlled Clinical Trial of Wireless High Frequency Spinal Cord Stimulation to Demonstrate Non-Inferiority in the Treatment of Chronic Pain as Compared to Traditional Stimulation||Stimwave Technologies|Yes|Not yet recruiting|March 2016|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|February 8, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514590||15804|
NCT02514863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-MA-electrodes|Electrode Placement in Electrical Velocimetry|Influence of Electrode Placement on Electrical Velocimetry Cardiac Output Measurements||Universitätsmedizin Mannheim|Yes|Completed|December 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing CMR|July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514863||15783|
NCT02671448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-022|Pilot Trial of Homebound Stem Cell Transplantation|Pilot Trial of Homebound Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prior to study enrollment, MSK attending physicians and transplant coordinators will        review the eligibility of new patients.|January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02671448||3762|
NCT02671461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV006-004|Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"|A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack||Bristol-Myers Squibb|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1312|||Both|18 Years|N/A|No|||January 2016|March 21, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02671461||3761|
NCT02512601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SULODEXIDE_PTS/01/13|Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide|Prospective Evaluation of the Quality of Life of Patients With Post-thrombotic Syndrome Who Receive Compression Therapy and Sulodexide — SQUARES Study|SQUARES|Bama GeVe, S.L.U.|No|Recruiting|September 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512601||15955|
NCT02512614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-6102|Evaluation of Novel Antimicrobial Hand Towels|Evaluation of Novel Antimicrobial Hand Towels||Centers for Disease Control and Prevention|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|449|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|June 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02512614||15954|
NCT02515890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14050609|Memory Modulation by Pain During Sedation|Modulation of Long-term Memory by the Experience of Pain During Sedation With Midazolam and Dexmedetomidine||University of Pittsburgh|No|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515890||15704|
NCT02516163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriShapeMatch-10_Substudy A|Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using Shapematch Cutting Guides:Sub-Study A|A Prospective, Non-randomized,Study of the Clinical Outcomes of Participants That Receive the Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study A||Stryker South Pacific|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|50 Years|90 Years|No|||September 2015|December 7, 2015|August 3, 2015|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT02516163||15684|
NCT02519855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-062|Study to Evaluate Immunogenicity, Safety, and Tolerability of Zostavax™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants >=50 Years of Age (V211-062)|A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)||Merck Sharp & Dohme Corp.|No|Completed|September 2015|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|882|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519855||15400|
NCT02668913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO15/302|LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer|LCC-CARIS-01: A Pilot Feasibility Study to Assess the Use of Molecular Profiling to Determine Choice of Treatment for Patients With Gynecological Cancer||University of Leeds|No|Recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02668913||3955|
NCT02668926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-00015|Endocrine and Emotional Effects of Lisdexamfetamine and D-amphetamine: a Placebo-controlled Study in Healthy Subjects|Endocrine and Emotional Effects of Lisdexamfetamine and d- Amphetamine: a Placebo-controlled Study in Healthy Subjects (LisDexStudy)|LisDex|University Hospital, Basel, Switzerland|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02668926||3954|
NCT02523820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID10-57-18|Nebulized Corticosteroid for Post Extubation Stridor in Children|Nebulized Corticosteroid for Post Extubation Stridor in Children: A Randomized Double Blind Controlled Trial||Ramathibodi Hospital|Yes|Recruiting|January 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|144|||Both|1 Month|18 Years|No|||August 2015|August 12, 2015|August 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523820||15095|
NCT02523833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 3966/13/091|Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis|Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation||University of Sao Paulo General Hospital|No|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|28|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|August 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523833||15094|
NCT02520531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100506 /K-S-006|Scorpio Posterior Stabilised (PS) vs Scorpio NRG ("Energize") PS - Total Knee Arthroplasty|Scorpio PS vs Scorpio NRG PS - Total Knee Arthroplasty Comparative Investigation of Function|ScorpioNRGPS|Stryker European Operations BV|No|Active, not recruiting|September 2010|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520531||15348|
NCT02519868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 227-15|Chemical Block and Electrical Stimulation of the Carotid Body to Treat Refractory Hypertension|Chemical Block and Electrical Stimulation of the Carotid Body to Treat Refractory Hypertension||Centre Hospitalier Universitaire Vaudois|No|Recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||August 2015|August 10, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519868||15399|
NCT02668614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 107218|Early Detection of Skin Cancer With Sensor Technology|Early Detection of Skin Cancer Using Millimetre-Wave Waveguide Reflectometers||Lawson Health Research Institute|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02668614||3977|
NCT02668952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-572|Fluid Chloride and AKI in Cardiopulmonary Bypass|The Impact of Low Chloride Containing Fluids on Acute Kidney Injury After Cardiopulmonary Bypass as Assayed by Urinary [TIMP2*IGFBP7]||University of New Mexico|No|Not yet recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02668952||3953|
NCT02526901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011Y2-00025|The Born in Guangzhou Cohort Study (BIGCS)|The Born in Guangzhou Cohort Study (BIGCS)|BIGCS|Guangzhou Women and Children's Medical Center|Yes|Recruiting|February 2012|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|During pregnancy: maternal blood, urine and stool. At delivery: cord, cord blood and      placenta. During infancy: dry blood spot, stool and blood. Druing childhood: blood, buccal      swab and stool.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women attending their first routine antenatal examinations (usually around week        16) and their partners and offsrping|August 2015|August 16, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526901||14858|
NCT02517255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|518.844|Salvage of Myocardial Infarction Documented by MRI in Patients Undergoing Rescue Percutaneous Coronary Intervention|Salvage of Myocardial Infarction Documented by Magnetic Resonance Imaging in Patients Undergoing Rescue Percutaneous Coronary Intervention|SAVEME|Federal University of São Paulo|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|72|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02517255||15600|
NCT02515682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471213|Equol Supplementation on Blood Pressure and Vascular Function|Effect of Natural S-equol on Blood Pressure and Vascular funtion-a Six-month Randomized, Double-blind and Placebo-controlled Trial Among Equol Non-producers of Postmenopausal Women With Prehypertension or Untreated Stage 1 Hypertension||Chinese University of Hong Kong|No|Not yet recruiting|October 2015|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|207|||Female|48 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02515682||15720|
NCT02669264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCT-402-102|Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)|A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)||ADC Therapeutics SARL|No|Recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Years|N/A|No|||March 2016|March 22, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02669264||3930|
NCT02518776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-016|Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS||ITEMS|University Hospital, Caen|No|Recruiting|June 2010|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518776||15483|
NCT02522273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3493|Evaluation of the 'SensPoint' Lactate Meter in the Estimation of Foetal Scalp Blood and Umbilical Cord Blood Lactate|Evaluation of the 'SensPoint' Lactate Meter Validation of a Hand-Held Lactate Measuring System 'SensPoint' in the Estimation of Foetal Scalp Blood and Umbilical Cord Blood Lactate||North Bristol NHS Trust|No|Not yet recruiting|October 2015|||March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Female|18 Years|45 Years|No|Non-Probability Sample|Women who have a fetal blood sample or umbilical cord blood sample taken for the        measurement of lactate as part of their care during childbirth.|August 2015|August 10, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02522273||15214|
NCT02522520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRE-15|Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy|Pedometer Intervention, Health Counseling, Symptom Management for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy.Two-armed Randomized Phase II Trial||Rigshospitalet, Denmark|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02522520||15195|
NCT02512211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALIDATION|Validation of Questionnaires HAL and HEP|Spanish Validation of "Haemophilia Activities List" (HAL) and "Specific Sport Scale" (HEP-Test-Q) Questionnaires|VALIDATION|Universidad Católica San Antonio de Murcia|No|Recruiting|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|8 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with haemophilia and parents of children with hemophilia around the country that        will participate in study.|September 2015|October 7, 2015|July 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02512211||15985|
NCT02512458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 9A/14|Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer|A Study of Cabazitaxel Treatment in Castration Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Microenvironment|CABA-BONE|Hellenic Cooperative Oncology Group|No|Recruiting|July 2015|February 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||October 2015|October 29, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02512458||15966|
NCT02666001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-068|A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Suboxone (Buprenorphine/Naloxone)|A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Suboxone and BMS-663068||Bristol-Myers Squibb|No|Not yet recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|32|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02666001||4178|
NCT02518997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1464|Effects of Reading to Preterm Infants on Baby and Parents' Well Being|Effects of Reading to Preterm Infants on Baby and Parents' Well Being||Georgetown University|No|Enrolling by invitation|October 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|N/A|40 Weeks|No|||August 2015|August 5, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02518997||15466|
NCT02517788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 93/06|Phase I BP Interferon (IFN) Beta-004|Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects||Centre Hospitalier Universitaire Vaudois|Yes|Completed|May 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517788||15559|
NCT02522533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0192|Intervention for Pre-Frailty and Frailty in Thoracic Surgery Patients|Intervention for Pre-Frailty and Frailty in Thoracic Surgery Patients||University of Chicago|No|Recruiting|July 2015|||April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Both|60 Years|N/A|No|||August 2015|August 10, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02522533||15194|
NCT02517099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165460|Preschool Wheeze: Inflammation/Infection Guided Management|Use of Pathological Phenotype to Determine Optimal Management for Moderate to Severe Preschool Wheeze|PrIGMa|Imperial College London|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|1 Year|5 Years|No|||February 2016|February 24, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02517099||15612|
NCT02673515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2014-03|The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy|The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy|InterFast|Medical University of Graz|Yes|Recruiting|April 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02673515||3605|
NCT02673580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELEPRO|Tele-patient-reported Outcomes (telePRO) in Clinical Practice - Effect of Patient-initiated Versus Fixed Interval telePRO Based Outpatient Follow-up|||University of Aarhus||Recruiting|January 2016|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Both|15 Years|N/A|No|||January 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673580||3600|
NCT02522455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04003|Flow-cycled Ventilation in Preterm Infants|Flow-cycled Ventilation in Preterm Infants (FLIPI): A Pilot Study Looking at the Tolerance of Flow-cycled Ventilation by Preterm Infants With Respiratory Distress Syndrome|FLIPI|Central Manchester University Hospitals NHS Foundation Trust|Yes|Recruiting|September 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|24 Hours|No|||January 2016|January 26, 2016|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02522455||15200|
NCT02515942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLG561-2201|CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)|A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy||Alcon Research|No|Recruiting|September 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|114|||Both|50 Years|N/A|No|||February 2016|February 23, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515942||15700|
NCT02515955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107762|A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants|A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects||Janssen-Cilag International NV|No|Recruiting|August 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|76|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515955||15699|
NCT02526680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-396|Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?|The Impact of a Novel Artificial Vision Device (OrCam) on the Quality of Life of Patients With Advanced Glaucoma||Wills Eye|No|Completed|May 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02526680||14875|
NCT02663505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU-Risk-Score|Development Of An ICU Risk Score|I See You Risk Your ICU Capacity - Development Of An ICU Risk Score Discriminating Reasonable and Non-Reasonable ICU Admissions||University of Schleswig-Holstein|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8000|||Both|N/A|N/A|No|Probability Sample|All patients receiving elective or emergency surgery during phase 1 (2 months) and phase 3        (2 months) of the study, approximately 8000 in total.|February 2016|February 10, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02663505||4369|
NCT02527811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDTP-CDMA-201402|Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery|A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases||Techpool Bio-Pharma Co., Ltd.|Yes|Enrolling by invitation|April 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|N/A|4 Years|No|||December 2015|December 21, 2015|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02527811||14788|
NCT02527837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR-1-2014|The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects|The Effect of Sodium Nitrite Infusion on Renal Variables, Peripheral and Central Blood Pressure in Hypertensive Versus Normotensive Subjects in a Randomised, Placebo Controlled, Cross Over, Case-control Study|HYCA|Regional Hospital Holstebro|No|Recruiting|May 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2015|August 17, 2015|February 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02527837||14786|
NCT02527252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAL-472|Craniosacral Therapy in Patients With Chronic Low Back Pain|Benefits of Craniosacral Therapy in Patients With Chronic Low Back Pain: A Randomized Controlled Trial||Universidad de Almeria|No|Completed|July 2015|November 2015|Actual|October 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527252||14831|
NCT02512237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMC-ARX788-101|A Dose-escalation Study of ARX788, IV Administered in Subjects With Breast Cancer With HER2 Expression|A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Breast Cancer With Multiple Levels of HER2 Expression||Zhejiang Medicine Co., Ltd.|Yes|Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02512237||15983|
NCT02512250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0667|Swiss Hemophilia Registry|||Swiss Hemophilia Network|No|Recruiting|May 2015|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hemophilia and other severe bleeding disorders|July 2015|July 30, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02512250|10 Years|15982|
NCT02512263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBTPCoCa|Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients|Assessment of Adherence and Efficiency of a Home-based Training Program on the Muscular Strength, the Endurance and the Quality of Life for Colon Cancer Patients Treated by Chemotherapy||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|July 2015|July 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512263||15981|
NCT02514421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0701|Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514421||15817|
NCT02512913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01TW009654|Family Smoking Cessation in Romania Using Pregnancy as a Window of Opportunity|Family Smoking Cessation in Romania Using Pregnancy as a Window of Opportunity|PERSIST|Michigan State University|No|Recruiting|August 2015|November 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|430|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02512913||15931|
NCT02513160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDB-AS-30039|Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Active, not recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|426|||Both|12 Years|N/A|No|||March 2016|March 1, 2016|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513160||15912|
NCT02516488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014C0205|Comparison of Confocal Laser Endomicroscopic in Vivo Diagnosis and ex Vivo Examination (INDEX Study) Against Surgical Histopathology of Cystic Pancreatic Lesions||INDEX|Ohio State University|No|Recruiting|May 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|None Retained|Fluid from cyst in pancreas|Both|18 Years|N/A|No|Probability Sample|Patients with Cystic Pancreatic Lesions|August 2015|August 3, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516488||15659|
NCT02516501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15025|Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition|Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial|KETOCOMP|MVZ Leopoldina GmbH|No|Recruiting|June 2015|||June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|85|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02516501||15658|
NCT02517593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006204|Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake|Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake: A Pilot Study to Determine if a Polygenic Risk Score Influences the Decision to Accept Breast Cancer Preventive Medications (Tamoxifen, Raloxifene, or Exemestane) Amongst Non-BRCA Women at Risk|GENRE|Mayo Clinic|No|Not yet recruiting|November 2015|June 2021|Anticipated|November 2020|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Female|35 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02517593||15574|
NCT02517606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUBahia LBP|Hip Posterolateral Complex Strengthening in Patients With Chronic Nonspecific Low Back Pain: a Randomized Clinical Trial|Hip Posterolateral Complex Strengthening in Patients With Chronic Nonspecific Low Back Pain: a Randomized Clinical Trial||Federal University of Bahia|Yes|Not yet recruiting|July 2016|December 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|February 4, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517606||15573|
NCT02673944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLUS-PVES-01|Portable Pves Study|An Accuracy Study to Assess the Performance of the Peritron+ in Measuring Vesical Pressure in Patients in Comparison With Standard Urodynamic Measurements||Laborie Medical Technologies Inc.|No|Enrolling by invitation|January 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02673944||3572|
NCT02673957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE15-280|Analysis of Local and Circulating Compounds Released Following Blood Pressure Cuff Inflation|Analysis of Local and Circulating Compounds Released Following Hypoxia Induced by Blood Pressure Cuff Inflation||University of New England|Yes|Recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|Samples With DNA|Peripheral venous blood samples, which are processed by centrifuge. The plasma will be      extracted and retained for analysis, with the rest of the sample discarded.|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants|February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673957||3571|
NCT02516124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT022664405|EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients|Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT|NISSC|European Group for Blood and Marrow Transplantation|No|Recruiting|December 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients treated with autologous HSCT for severe systemic sclerosis|August 2015|August 7, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516124||15687|
NCT02519348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4190C00022|A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma|A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma||MedImmune LLC|No|Recruiting|October 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519348||15439|
NCT02519569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/388(REK)|Internet-based Intervention for Complicated Grief: A Pilot Study|Internet-based Intervention for Complicated Grief: A Pilot Study||University of Tromso|No|Not yet recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02519569||15422|
NCT02525094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5240C00001|Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis|A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis|ALLEVIAD|MedImmune LLC|No|Recruiting|August 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2015|October 5, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525094||14997|
NCT02713191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renu1|Dexmedetomidine vs. Midazolam Sedation for Endobronchial Ultrasound|Efficacy and Safety of Dexmedetomidine vs. Midazolam Sedation in Patients Undergoing Convex-probe Endobronchial Ultrasound: a Randomized Double Blind Trial||Postgraduate Institute of Medical Education and Research|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|99 Years|No|||March 2016|March 14, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02713191||559|
NCT02646852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15-11073|A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors|A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors||Delta-Fly Pharma, Inc.||Recruiting|March 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02646852||5648|
NCT02651584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-421|Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence|A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Treatment of Adult Outpatients With Opioid Use Disorder||Braeburn Pharmaceuticals|No|Recruiting|December 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651584||5284|
NCT02651870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144HT14020|Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy||Chong Kun Dang Pharmaceutical|No|Recruiting|March 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|19 Years|N/A|No|||March 2015|January 8, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02651870||5262|
NCT02650583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9480|Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children|Enhancing Connections Program in Palliative Care: Taking Care of the Children||University of Washington|No|Recruiting|December 2015|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|48|||Both|25 Years|65 Years|No|||February 2016|February 12, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02650583||5361|
NCT02657915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215ON203|Long-Term Assessment of Remyelinating Therapy|A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201|RENEWed|Biogen|No|Enrolling by invitation|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|82|||Both|18 Years|N/A|No|Non-Probability Sample|Subject previously enrolled in the 215ON201 study|February 2016|February 12, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02657915||4799|
NCT02517879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Community Point Distribution of Insecticide Treated Bed Nets|Measuring Attendance of Community Point Distribution of Insecticide-treated Bed Nets and the Impact of Community Health Worker Hang-up in Rural Zambia: A Randomized Controlled Trial and Cost Analysis||IDinsight|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|560|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02517879||15552|
NCT02518165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HUS003|The Effects of A Proprietary Spearmint Extract on Cognitive Performance|A Randomized, Double-Blind, Placebo-Controlled, Parallel Trial to Assess the Effects of A Proprietary Spearmint Extract on Cognitive Performance, Mood, and Sleep in Men and Women||Kemin Foods LC|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|134|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02518165||15530|
NCT02671149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD01|The Effect of Small Changes in Hydration on Cognition|How do Small Changes in Hydration Influence Cognition: A Mechanistic Investigation||Swansea University|No|Active, not recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|February 1, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02671149||3785|
NCT02511249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008026|Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke|Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke (AVCnn7 Years Study)||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|7 Years|7 Years|No|Non-Probability Sample|Children who have had an ischemic arterial stroke between November 2003 and October 2006,        in France, who was included in "AVCnn cohort" and who accept an psychological and physical        examination at 7 years|July 2015|July 29, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02511249||16059|
NCT02524418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-2006|Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS|Prospective Evaluation of the Clinical Utility of Endoscopic Retrograde Cholangiopancreatography (ERCP) Guided Cholangiopancreatoscopy With the SpyGlass DS.|SPYDS|University of Florida|No|Recruiting|August 2015|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02524418||15049|
NCT02525718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200903|Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction|Does Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction Reduce Postoperative Pain and Opioid Requirement?: A Prospective Double-Blinded Randomized Controlled Trial||Northwestern University|No|Recruiting|June 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Female|18 Years|79 Years|No|||August 2015|August 14, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02525718||14949|
NCT02525731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA037768-B|Targeting Effective Analgesia in Clinics for HIV - Patient Cohort|Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Patient Cohort Component|TEACH|Boston Medical Center|No|Active, not recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected COT patients from the HIV clinics at Boston Medical Center and Grady Memorial        Hospital|February 2016|February 3, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02525731||14948|
NCT02676271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-15|The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease|The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease||Assaf-Harofeh Medical Center||Completed|March 2015|October 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|35|||Both|N/A|N/A|No|Probability Sample|Forty patients (43 hips) who had undergone VDRO for LCPD who participated in a long term        follow-up study a decade ago. All patients were treated in our institution during 1959 to        1983 with proximal VDRO.|February 2016|February 5, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02676271||3393|
NCT02524093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PosMT1.0|The Impact of Positive Mental Training in Multiple Sclerosis|The Efficacy of Positive Mental Training in Patients With Multiple Sclerosis Experiencing Psychological Distress: A Pilot Randomised Controlled Trial|PosMTMS|University of Edinburgh|No|Not yet recruiting|September 2015|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|December 2, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02524093||15074|
NCT02524106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI204426|Bococizumab HIV Evaluation (B-HIVE) Study|Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects|B-HIVE|University of California, San Francisco|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|N/A|No|||November 2015|November 30, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524106||15073|
NCT02527044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4385|Impact of Preoperative FFR on Arterial Bypass Graft Functionality|Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm|FFR|Ottawa Heart Institute Research Corporation|Yes|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02527044||14847|
NCT02526277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0107|A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome|A Randomized Prospective Study on the Efficacy of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome||Ohio State University|No|Recruiting|July 2015|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|July 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526277||14906|
NCT02514486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13114|Assessment of Cancer Concerns at the End of Treatment (ACE)|Assessment of Cancer Concerns at the End of Treatment (ACE)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|N/A|No|Probability Sample|Breast cancer survivors|March 2016|March 18, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514486||15812|
NCT02514499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07914|Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study|Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2014|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||350|||Both|18 Years|80 Years|No|Probability Sample|BRCA1/2 negative patients|March 2016|March 18, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514499||15811|
NCT02517827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHZ_RASA_PESTO_1.0|Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions|Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions A Prospective, Multi-centre, Randomised Study|PESTO-AFC|Herz-Zentrums Bad Krozingen|Yes|Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|21 Years|85 Years|No|||August 2015|August 6, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02517827||15556|
NCT02517840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/199 ESTUDIO|Revascularization in Nonagenarian Patients With Critical Lower Limb Ischaemia|Revascularization Results in Nonagenarian Patients With Critical Lower Limb Ischaemia|NONA-CLI|Hospital Universitario Getafe|No|Completed|January 2002|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|90 Years|N/A|No|Non-Probability Sample|Patients suffering from Critical Limb Ischemia aged 90 year-old or above|August 2015|August 4, 2015|July 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02517840||15555|
NCT02527616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAS-001-FFR|An Investigation to Evaluate an Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR)|A Randomised, Crossover Investigation to Evaluate and Compare the Effectiveness, Safety and Feasibility of a Novel Dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR) Using Intra-coronary Non-weight Adjusted Adenosine Infusion With the Standard Intra-venous Administration of Adenosine, in Subjects With Intermediate Coronary Artery Stenosis.||Diasolve Ltd|No|Not yet recruiting|October 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|44|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02527616||14803|
NCT02513823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11089|Effectiveness of Vitamin D Supplementation|Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure and Improving Endothelial Function of Pre-menopausal African American Women||Texas Woman's University|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513823||15862|
NCT02516072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-RIPC|Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy|The Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Diagnostic or Therapeutic Peripheral Angiography: a Pilot Randomised Controlled Trial||Changi General Hospital|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|99 Years|No|||February 2016|February 16, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516072||15691|
NCT02523430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|May 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523430||15125|
NCT02523443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-148|Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection|A Prospective Randomized Controlled Clinical Trial of Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Open Liver Resection||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523443||15124|
NCT02524834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIDE:Thoracoabdominal Lesions|Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis|Proposed Single Center Investigational Device Exemption: Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis||Los Angeles Biomedical Research Institute|No|Recruiting|July 2015|July 2025|Anticipated|July 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|21 Years|90 Years|No|||March 2016|March 1, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524834||15017|
NCT02524847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKS-2014-001|UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease|Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)||Therakos|Yes|Not yet recruiting|September 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|1 Year|21 Years|No|||August 2015|August 14, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524847||15016|
NCT02668341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVDP-405-14|PsoBarrierEU - Barrier Analysis of Guideline-Compliant Healthcare for Psoriasis in Europe|PsoBarrierEU - Barrier Analysis of Guideline-Compliant Healthcare for Psoriasis in Europe|PsoBarrier|Universitätsklinikum Hamburg-Eppendorf|Yes|Enrolling by invitation|October 2015|March 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||5|Anticipated|2500|||Both|N/A|N/A|No|Probability Sample|adult patients with diagnosed psoriasis vulgaris|February 2016|February 5, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02668341||3998|
NCT02520778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01270|EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor||National Cancer Institute (NCI)||Not yet recruiting|April 2016|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520778||15329|
NCT02523573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_JDR4|Study of High Flow Nasal Cannula Oxygen for Bronchoscopy With Bronchoalveolar Lavage in ICU Patients|High Flow Nasal Oxygen for Bronchoscopy With Bronchoalveolar Lavage in Acute Respiratory Failure Patients: the OptiBAL Study.|Optibal|Hôpital Louis Mourier|No|Completed|November 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Adult patients admitted to the Intensive Care Unit, with acute hypoxemic respiratory        failure requiring bronchoalveolar lavage|February 2016|February 25, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523573||15114|
NCT02525042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI09031|Genetic Susceptibility to Ankylosing Spondylitis (AS) by Functional Genomics Approach|Study of the Genetic Susceptibility to Ankylosing Spondylitis by Functional Genomics Approach|GENOSPA|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2011|||January 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||3|Actual|97|Samples With DNA|RNA is extracted from cells obtained from blood samples (leukocytes).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Ankylosing Spondylitis (AS) and matched family controls from families having        a LOD score ≥ 0.15.|June 2015|August 13, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02525042||15001|
NCT02514304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERBLEED-Hamilton Ontario|Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding|Study of Risk Factors for Gastrointestinal Bleeding and of the Determinants of Non-fatal and Fatal Cardiovascular Events After Gastrointestinal Bleeding in Patients Receiving Antithrombotic Therapy for Cardiovascular Prevention||Population Health Research Institute|No|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Residents of Hamilton, ON: The community, inpatient/outpatient clinics (endoscopy clinics,        stroke prevention clinics, cardiac/vascular clinics), emergency rooms|October 2015|October 19, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514304||15826|
NCT02668601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00465|Maternal GDM in Hispanic Youth: Risk for Obesity|Maternal Gestational Diabetes in Hispanic Youth: Obesity and Insulin Resistance||University of Southern California|Yes|Active, not recruiting|August 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|80|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|GDM exposed and non-exposed Hispanic offspring of singleton pregnancies between the ages        of 4 to 18 years old. Offspring are the children of women with a history of GDM or with        normal glucose levels during pregnancy who participated in the BetaGene Study. Normal        glucose levels during pregnancy are defined as 1-hour 50g glucose challenge test <120        mg/dl. GDM diagnosis is defined as two or more abnormal values on 3-h 100-g diagnostic        OGTT. GDM defined by American Diabetes Association Criteria in place from 2003-2008.|January 2016|January 28, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02668601||3978|
NCT02512315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACT4-NPC-5010|A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma|4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial||Sun Yat-sen University|Yes|Not yet recruiting|August 2015|December 2024|Anticipated|December 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|N/A|70 Years|No|||July 2015|July 27, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02512315||15977|
NCT02515578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0403|Southwest Health Extension Partnership to Enhance Research Dissemination|Southwest Health Extension Partnership to Enhance Research Dissemination||University of Colorado, Denver|No|Recruiting|October 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|10000|||Both|18 Years|89 Years|No|||February 2016|February 1, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02515578||15728|
NCT02515591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/NW/0019|Validating the Use of Disposable Bronchoscopes for Research Bronchoalveolar Lavage|Validating the Use of Disposable Flexible Intubation Bronchoscopes for Research Bronchoalveolar Lavage|BALval|Royal Liverpool and Broadgreen University Hospitals NHS Trust|No|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Bronchoalveolar lavage cells Bronchoalveolar lavage supernatent|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers, male and Non pregnant female, aged between 18-55 years old.|August 2015|August 4, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02515591||15727|
NCT02519621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032015-099|To Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing|A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing|Cardinal PRO|University of Texas Southwestern Medical Center|No|Not yet recruiting|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|89 Years|No|||December 2015|December 3, 2015|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519621||15418|
NCT02673645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBS IRB15-0711|Remediating Academic Skill Deficits Among Disadvantaged Youth|||University of Chicago|Yes|Active, not recruiting|August 2015|June 2019|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1848|||Both|N/A|N/A|No|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673645||3595|
NCT02516956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRNN-014|Impact of Different Breakfast Meals on Food Choices, Eating Behaviors and Brain Activation|Impact of Different Breakfast Meals on Food Choices, Eating Behaviors and Brain Activation||University of Parma|No|Active, not recruiting|June 2014|December 2015|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|15|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02516956||15623|
NCT02520271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVO1114|Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders|ODS is a Naturalistic, Open Label, Non-randomized Follow-up Study on Depression and Related Substance Use Disorders (SUD). Study Targets: Efficacy of Psychosocial Treatment, Pharmacogenetics, Inflammation Related Biomarkers|ODS|Seinajoki Central Hospital|No|Completed|October 2009|June 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|242|||Both|17 Years|65 Years|No|||August 2015|August 11, 2015|June 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02520271||15368|
NCT02524652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 193-15|Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction|Postoperative Analgesic Efficacy of Local Infiltration Analgesia Versus Adductor Canal Block After Anterior Cruciate Ligament Reconstruction: A Randomised Controlled Double-blinded Trial||Centre Hospitalier Universitaire Vaudois|No|Recruiting|September 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|50 Years|No|||November 2015|November 25, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524652||15031|
NCT02671578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS-01FOP|Bispectral Index and Clinical Parameters Evaluation in Dental Procedures|Bispectral Index and Clinical Parameters Evaluation in Different Dental Procedures With Nitrous Oxide and Oxygen Sedation|BIS-01|University of Campinas, Brazil|No|Completed|November 2006|November 2008|Actual|November 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02671578||3752|
NCT02671591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-10|A Pilot Study of PrEP Acceptance Among Young Black MSM|A Pilot Study of PrEP Acceptance Among Young Black MSM|MI-PrEP|University of Kentucky|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02671591||3751|
NCT02512848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AHCR2014-007|The Feasibility Study of the Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period|The Feasibility Study of Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period||First Affiliated Hospital Xi'an Jiaotong University||Recruiting|April 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|100|Samples Without DNA|endometrial sampling|Female|40 Years|80 Years|No|Non-Probability Sample|participants with risks of endometrial cancer in the postmenopausal period|July 2015|July 30, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02512848||15936|
NCT02525926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-APN-02|Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension|Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension|DENERV'AP|Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|January 2016|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02525926||14933|
NCT02525328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908129|Genome Study in Constitutional Thinness|Genome Study in Constitutional Thinness|GENOSCANN|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|350|Samples With DNA|blood or saliva specimen in families including at least one well phenotyped CT index case      (grade 2 or 3 of thinness according WHO classification). Family's members are : CT subjects      and subjects without CT.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Fifty families including at least 2 well phenotyped CT index case (grade 2 or 3 of        thinness according WHO classification) and members without CT.|March 2016|March 9, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525328||14979|
NCT02672176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820612|Improving Health in Diabetes Project|Patient and Provider Engagement and Empowerment Through Technology (P2E2T2) Program to Improve Health in Diabetes|P2E2T2|University of California, Davis|No|Not yet recruiting|February 2016|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02672176||3706|
NCT02514122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio# 14-193|Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda: a Randomized Control Trial|Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda: a Randomized Control Trial||University of Saskatchewan|Yes|Recruiting|June 2015|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|60 Years|No|||July 2015|July 31, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514122||15840|
NCT02522026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01 RIBO II|Follow-up-study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers|Follow-up-study of Participants (COPD Patients and Healthy Control Subjects) From the Cross-sectional Study "11-03 Ribolution" for the Evaluation of Predictive Biomarkers Based on Non-coding RNA|Ribo2|Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Enrolling by invitation|August 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|Samples With DNA|blood, sputum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All 150 patients of study "11-03 Ribolution" will be contacted and re-invited for the        current follow-up study as completely as possible|August 2015|August 12, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02522026||15233|
NCT02520089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR14-010|Humeral Shaft Pseudoarthrosis Treated With Bone Autograft Versus Platelet Rich Plasma|Comparison of Treatment of Humeral Shaft Pseudoarthrosis Between Bone Autograft Versus Platelet Rich Plasma. Randomized, Blinded Study||Universidad Autonoma de Nuevo Leon|Yes|Active, not recruiting|November 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02520089||15382|
NCT02525367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWO/15-10E|Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy|Clinical Pilot Study in the Feasibility and Effect of Online Cognitive Training on Cognitive Functions in Patients With Parkinson's Disease, Multiple Sclerosis and Depressive Patients Treated With Electroconvulsive Therapy||VU University Medical Center|No|Not yet recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|30 Years|70 Years|No|||August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02525367||14976|
NCT02525380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCbead_PVTT|Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma|Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC||Seoul National University Hospital|Yes|Recruiting|September 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||October 2015|October 22, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02525380||14975|
NCT02672371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002574|The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults|The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults||Spaulding Rehabilitation Hospital|No|Not yet recruiting|February 2016|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02672371||3691|
NCT02521961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9425|Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors|Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors||Fred Hutchinson Cancer Research Center|No|Recruiting|February 2016|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02521961||15238|
NCT02523989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-TMU-100-06|The Relationship Between Arsenic Methylation Capability and Blood Metals in Children With Developmental Delays|The Relationship Between Genetic Polymorphism of Arsenic Methylation Enzymes, Arsenic Methylation Capability and Blood Metals, and Developmental Delays in Preschool Children||Taipei Medical University|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|137|Samples With DNA|Blood and urine samples of participants were collected and urine used for the analysis of      the arsenic species using high performance liquid chromatography linked hydride generator      and atomic absorption spectrometry. Buffy coat were separated from plasma and extract DNA to      analyze the genetic polymorphism of arsenic methylation related enzymes using polymerase      chain reaction and restriction fragment length polymorphism. 2 ml blood were digested for      the determination of mercury, lead and arsenic.|Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|children with developmental delays and children with normal development|August 2015|August 13, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02523989|3 Months|15082|
NCT02524067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS project|Modified Environment for Agitation in Patients With TBI|Modified Environment for Agitation in Patients With Traumatic Brain Injury: a Controlled Multicenter|ABS|University of Aarhus|Yes|Recruiting|October 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|42|||Both|18 Years|N/A|No|||July 2015|October 19, 2015|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02524067||15076|
NCT02516839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151110|PACIFIC: Providing Adults Collaborative Interventions For Ideal Changes|Treatment of Obesity Targeting Appetite and Cue Reactivity|ROC|University of California, San Diego|Yes|Recruiting|September 2015|March 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02516839||15632|
NCT02670928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ARU05|Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.|Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.||Novartis|No|Recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02670928||3802|
NCT02522182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E35E09000880002|ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)|ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome. The ALLEPRE Trial: a Fully Nurse-led Intensive Intervention Programme|ALLEPRE|Azienda Ospedaliero-Universitaria di Parma|No|Recruiting|November 2013|November 2020|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2060|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02522182||15221|
NCT02522195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUUberlandia|Meal Distribution Across the Day in Female Nurses Working Shifts|Meal Distribution Across the Day in Female Nurses Working Shifts and Their Relationship With Nutritional Status||Federal University of Uberlandia|Yes|Completed|November 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|221|||Female|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Woman who were part of Nursing Staff of University Hospital, and agreed to participate in        the study. Each volunteer provided a full, written informed consent.|August 2015|August 10, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02522195||15220|
NCT02524080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBoras|Healthcare at Optimal Care Level for Patients Who Needs Primary Care|Healthcare at Optimal Care Level for Patients Who Needs Primary Care - Collaboration Between Care Providers From The Emergency Medical Services' Perspective||University of Boras|Yes|Active, not recruiting|September 2011|June 2017|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02524080||15075|
NCT02522832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVL-CS-002|Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge|Discovering New Treatments for Asthma and COPD. The Use of the Human Viral Challenge Model With a Newly Manufactured and Characterised GMP Wild-Type Human Rhinovirus||Hvivo|Yes|Completed|January 2013|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|17|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02522832||15171|
NCT02663193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108103|Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability|A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)|REAAcT|Janssen Scientific Affairs, LLC|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Male|18 Years|N/A|No|Non-Probability Sample|Participants who have a confirmed metastatic adenocarcinoma of the prostate will receive        either enzalutamide or abiraterone acetate with prednisone for the treatment at the        discretion of their treatment physician and in accordance with clinical practice.|March 2016|March 11, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663193||4393|
NCT02663206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049663|Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders|Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in the Treatment of Medical Refractory Spastic Esophageal Disorders: A Randomized Trial||Johns Hopkins University|Yes|Recruiting|January 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 25, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02663206||4392|
NCT02527538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2013209(1169)|Prediction of Hypotension During Beach Chair Position Using Pleth Variability Index|Pleth Variability Index Predicts Hypotension in Beach Chair Position in Mechanically Ventilated Adults During General Anesthesia||Chung-Ang University Hospital|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|57|||Both|20 Years|70 Years|No|Non-Probability Sample|age between 20 and 70 years who is planning to undergoing elective shoulder surgery under        general anesthesia|August 2015|January 26, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02527538||14809|
NCT02520323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00095799|The Lung Microbiome in Sarcoidosis|The Lung Microbiome in Sarcoidosis||University of Michigan|No|Recruiting|June 2015|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects will be patients with sarcoidosis (involving any organ system), with        non-sarcoid interstitial lung disease, and healthy controls.|August 2015|August 11, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02520323||15364|
NCT02520336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7797|Postpartum Diabetes Screening in Women With Gestational Diabetes|Active Management of Postpartum Diabetes Screening After Gestational Diabetes: a Randomized Controlled Trial||Thomas Jefferson University||Recruiting|July 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|78|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02520336||15363|
NCT02514018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAVI-VZV-001|Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine|A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.|KAVI-VZV-001|University of Toronto|Yes|Recruiting|September 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|44|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514018||15847|
NCT02520973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00039194|Screening for TB in Pregnancy. on HIV-Infected Pregnant Women|Screening for TB in Pregnancy A Supplement to: The Effect of Tuberculosis and Its Treatment on HIV-Infected Pregnant Women and Their Infants||Johns Hopkins University|No|Recruiting|May 2015|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2000|||Female|18 Years|N/A|No|||August 2015|August 7, 2015|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02520973||15314|
NCT02512653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608-PR-PRI-199|Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)|Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)||Laboratorios Leti, S.L.|No|Active, not recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|60 Years|No|||July 2015|December 15, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512653||15951|
NCT02512900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5180C00002|A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma||MedImmune LLC|No|Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|22|||Both|12 Years|17 Years|No|||October 2015|October 16, 2015|July 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512900||15932|
NCT02511613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-1501|Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration|A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration||Ohr Pharmaceutical Inc.|No|Recruiting|July 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|N/A|No|||July 2015|July 28, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511613||16031|
NCT02516319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFA-0001|Liver Function Assessment - Feasibility and Dosing Study|A Feasibility Study to Determine an Adequate Dose of ICG for the Liver Function Assessment System in Healthy Volunteers||Cardiox Corporation|No|Terminated|September 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|57|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 21, 2015|No|Yes|Business decision to discontinue product development.|No||https://clinicaltrials.gov/show/NCT02516319||15672|
NCT02516579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCORT-HU|European Sickle Cell Disease Cohort - Hydroxyurea|ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea|ESCORT-HU|ADDMEDICA SASA|Yes|Recruiting|January 2009|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|2 Years|N/A|No|Non-Probability Sample|Patient with sickle-cell disease|November 2015|November 9, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02516579||15652|
NCT02518971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00087825|Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients||University of Michigan|No|Recruiting|August 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|228|||Male|35 Years|N/A|No|||January 2016|January 25, 2016|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518971||15468|
NCT02517489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN14-PFD/CAPE COD|Community-Acquired Pneumonia : Evaluation of Corticosteroids|Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia|CAPE_COD|University Hospital, Tours|Yes|Not yet recruiting|September 2015|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02517489||15582|
NCT02525003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HelsinkiUni|The BreaD Study - Bio-availability of D2 Vitamin Present in Bread|Work Package 5: The Potential Advantages and Limitations of Use of Novel Food-based Solutions for Prevention of Vitamin D Deficiency. Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN)|BreaD_ODIN|Helsinki University|No|Completed|January 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|41|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02525003||15004|
NCT02664025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VE|Simulation in Teaching Vaginal Examination|The Benefits of Simulation in Teaching Vaginal Examination for Women During Labor: a Randomized Controlled Study|VE|Assiut University|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|N/A|N/A|No|||January 2016|March 10, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664025||4329|
NCT02664038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2017-R|Cognitive Training in the Treatment of AUD|Cognitive Training in the Treatment of Alcohol Use Disorders in Older Veterans||VA Office of Research and Development|No|Recruiting|January 2016|January 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|90 Years|No|||January 2016|January 27, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02664038||4328|
NCT02521194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0350|Occupational Therapy in Palliative Care|Is Inpatient Occupational Therapy Perceived to be Beneficial by the Palliative Patient and Caregiver?||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521194||15297|
NCT02527824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-1501|Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer|Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer||Hallym University Medical Center|No|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|19 Years|N/A|No|||February 2016|February 18, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527824||14787|
NCT02526888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-078-103|Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects|A Single-center, Open-label, Randomized, Two-way Crossover Study to Investigate the Effect of Multiple-dose Diltiazem on the Pharmacokinetics of a Single Dose of 25 mg ACT 541468 in Healthy Male Subjects||Actelion|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526888||14859|
NCT02514915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-150|Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases|Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases||University of Pittsburgh|Yes|Recruiting|February 2016|July 2020|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514915||15779|
NCT02718027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP 07-2015|Biomarker for Patient With Alport Disease or Highly Suspected for Alport Disease|Biomarker for Alport Disease - an International Epidemiological Protocol|BioAlport|University of Rostock|Yes|Recruiting|November 2015|November 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml      EDTA blood and a dry blood spot filter card are taken. To proof the correct Alport diagnosis      in those patients where up to the enrollment in the study no genetic testing has been done,      sequencing of Alport disease will be done.      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany|Both|2 Months|N/A|No|Probability Sample|All patients with Alport disease or patients with high-grade suspicion for Alport disease        submitted to the participating centers should be included into the study|March 2016|March 18, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02718027||187|
NCT02718040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10345|Emervel for the Correction of Lower Face Wrinkles & Folds|A Multi-Center Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine||Galderma Laboratories, L.P.|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718040||186|
NCT02651883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3042|Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3|Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3|MBMT-3|University of North Carolina, Chapel Hill|No|Not yet recruiting|January 2016|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|510|||Female|25 Years|64 Years|Accepts Healthy Volunteers|||December 2015|January 7, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02651883||5261|
NCT02655393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.02.AMZ|A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects|A Single (Part A) and Multiple (Part B) Dose Study of AMAZ-02, a Food Derived Ingredient to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile in Healthy Elderly Subjects||Amazentis SA|No|Recruiting|January 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|9||Anticipated|60|||Both|61 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655393||4993|
NCT02655107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 119/14|Non-invasive Measurement of Hemoglobin in Infants and Neonates|Non-invasive Measurement of Hemoglobin in Infants and Neonates: Comparison With CO-oximetrie and Point-of-care Devices.||University of Schleswig-Holstein|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|1 Month|2 Years|No|Non-Probability Sample|Infants and neonates undergoing congenital heart surgery weighing between 3kg and 20kg|January 2016|January 12, 2016|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02655107||5015|
NCT02655276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Classroom FR03|Sublingual Glycine vs. Placebo on Attentional Difficulties and Hyperactivity in Prepuberal Children|Effects of Sublingual Microencapsulated Glycine on Attentional Difficulties and Hyperactivity in Prepuberal Children - A Placebo-controlled, Double-blind, Randomized, Cross-over Study||University Hospital Freiburg|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655276||5002|
NCT02646735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10982|Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients|A Randomized, Open Label, Multi-Centre Study to Compare the Efficacy and Tolerability of Fulvestrant 500mg With Exemestane for Postmenopausal Advanced Breast Cancer Patients||Chinese Academy of Medical Sciences|No|Active, not recruiting|December 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|N/A|N/A|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646735||5657|
NCT02524470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSP-F001v1.0|Vital Signs Patch Early Feasibility and Usability Study v1.0|Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting v1.0|VSP|LifeWatch Services, Inc.|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524470||15045|
NCT02673502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-162-MUHC|Pre-operative Carbohydrate Drink to Preserve Peri-operative Insulin Sensitivity|Impact of Pre-operative Carbohydrate Drink Provision on Attenuating Peri-operative Insulin Resistant in Major Abdominal Surgery||McGill University Health Center|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673502||3606|
NCT02516397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID : 2014 -A01889-38|OMNIA Efficacy on Body Fat Mass Reduction|Randomised Controlled Trial, Double-blind, to Measure Efficiency and Tolerance of a New Food Supplement OMNIA on Body Fat Mass Reduction in Overweight Subjects|PEPOLUS|Vivatech|No|Not yet recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02516397||15666|
NCT02515643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)219/2014|Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients|Estimating the Contribution of Renal Function to Endothelial Dysfunction by a Two-cohort Study: Living Kidney Donors and Their Transplant Recipients|CONFUCIUS|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|75 Years|No|Non-Probability Sample|Cohort 1        Healthy subjects who will undergo a nephrectomy as part of the living donor program at        each participating center.        Cohort 2        Renal transplant recipients from cohort 1|August 2015|August 4, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02515643||15723|
NCT02520050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS#: 2014-40|The Effect of 3 Different Models of MNT on DM Control in Overweight Patients With T2DM|The Effect of Three Different Models of Medical Nutrition Therapy (MNT) on Diabetes Control in Overweight and Obese Patients With Type 2 Diabetes: A Randomized Comparative Study. (Nutrition Path Study)||Joslin Diabetes Center|No|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|30 Years|80 Years|No|||August 2015|August 6, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520050||15385|
NCT02526966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108060|Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy|Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy|NIGA-RA|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526966||14853|
NCT02526979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-203|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 5 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)|A Multicentre, Open-Label, Single Dose, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 5 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)||Astellas Pharma Inc|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|5 Years|11 Years|No|||February 2016|February 18, 2016|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526979||14852|
NCT02518958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-14-02|A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab|A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)|PRIMETIME|EpicentRx, Inc.|No|Recruiting|July 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2015|October 29, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518958||15469|
NCT02518308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15000|Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer|Mindfulness-Based Interventions in Patients Treated for Gynecologic Cancer - Impact on Patient Reported Outcomes and Immunologic Correlates||University of Wisconsin, Madison||Recruiting|October 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|38|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518308||15519|
NCT02518568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00355 CP 1 02|Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia|Study of the Pharmacokinetics of Serum Iron After a Single Oral Administration of Ferrous Sulphate Supplement Synthetic Formula in Women With Iron Deficiency Anaemia.||Pierre Fabre Medicament||Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|45 Years|No|||November 2015|November 9, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518568||15499|
NCT02513212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015059|A Clinical Study to Determine the Safety and Effectiveness of Dentinal Hypersensitivity Treatment With Two Different Toothbrushes|||Procter and Gamble||Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513212||15908|
NCT02517554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09115|A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services|A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2015|||August 2018|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Candidate for genetic testing for BRCA or colon cancer related genes|February 2016|February 15, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517554||15577|
NCT02516293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0055.0.009.000-11|Cardiac Rehabilitation in Chagas Heart Failure|Cardiac Rehabilitation Program in Patients With Chagas Heart Failure: a Pilot Study||Evandro Chagas National Institute of Infectious Disease|No|Completed|May 2013|December 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02516293||15674|
NCT02515786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 041/13|Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula|Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula on Nasal Mucociliary Clearance, Mucus Properties, Inflammation and Airway Symptoms in Patients||University of Sao Paulo|No|Active, not recruiting|January 2013|December 2015|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|19|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02515786||15712|
NCT02518802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-TONG002|Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma|Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma||Tang-Du Hospital|Yes|Recruiting|January 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|70 Years|No|||April 2015|August 5, 2015|May 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518802||15481|
NCT02526368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15557|A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer|A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer|pyruvate|University of California, San Francisco|Yes|Not yet recruiting|November 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02526368||14899|
NCT02526381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB542902|Clinical Study On The Relation Among Prescription, Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease|Study on the Relation Between Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease and Its Biological Basis||Tianjin University of Traditional Chinese Medicine|Yes|Recruiting|July 2015|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526381||14898|
NCT02514031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052015-024|ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer|A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514031||15846|
NCT02668081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS15-CT7-13|Comparing the Effects of EST and EPBD in Patients With Acute Biliary Pancreatitis|Prospective Randomized Study Comparing the Effects of Endoscopic Sphincterotomy (EST) and Endoscopic Papillary Balloon Dilation (EPBD) in Patients With Acute Biliary Pancreatitis (ABP)||Kaohsiung Veterans General Hospital.|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|39|||Both|20 Years|100 Years|No|||January 2016|January 26, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02668081||4018|
NCT02520466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2012-0201|Cocoa Flavanol and Coronary Vasomotion Vascular Function in Patients With Coronary Artery Disease|Effect of Cocoa Flavanol-containing Drink on Coronary Vascular Function in Patients With Coronary Artery Disease||University of Zurich|No|Recruiting|July 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|42|||Both|20 Years|80 Years|No|||August 2015|August 7, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02520466||15353|
NCT02525744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15989|A Study of a New LY900014 Formulation in Healthy Participants|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel LY900014 Formulation||Eli Lilly and Company|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|August 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02525744||14947|
NCT02525757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0722|MPDL3280A With Chemoradiation for Lung Cancer|DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A||M.D. Anderson Cancer Center|No|Recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525757||14946|
NCT02513979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHSTSA-102|Postoperative Pain and Angiotensin II Receptor Antagonists|The Effect of Angiotensin II Receptor Antagonists on Acute and Chronic Postoperative Pain in Patients Treated for Hypertension.|PP&ARA|University of Athens|No|Recruiting|August 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|35 Years|79 Years|No|||July 2015|October 7, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513979||15850|
NCT02514291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412211RINA|Sleep Intervention for Pediatric Epilepsy|Evaluation of a Clinic-based Sleep Intervention for Pediatric Epilepsy||National Taiwan University Hospital|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Years|6 Years|No|||July 2015|July 31, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02514291||15827|
NCT02523365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cervical Carcinoma HepaSphere|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|May 2015|June 2020|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523365||15130|
NCT02525822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-123A-201|Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris||Valeant Pharmaceuticals|No|Not yet recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|210|||Both|12 Years|N/A|No|||September 2015|September 11, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525822||14941|
NCT02519374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.29. NRC|Fiber Tolerability in Children|Fiber Tolerability in Children|FITIC|Nestlé|No|Completed|June 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|40|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||July 2015|February 4, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02519374||15437|
NCT02671357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERAMIP-IsoRY trial|Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy; Roux-en-Y vs Iso-peristaltic Gastro-enterostomy|Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy With Stented Pancreaticogastrostomy; Randomized Controlled Trial on Roux-en-y Gastro-enterostomy Versus In-line Iso-peristaltic. The ERAMIP-IsoRY Trial|ERAMIP-IsoRY|University Hospital, Gasthuisberg|No|Not yet recruiting|February 2016|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|85 Years|No|||February 2016|February 1, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02671357||3769|
NCT02671370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-00049|Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study|Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study||Balgrist University Hospital|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Participants with neck pain of any duration|January 2016|February 1, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02671370||3768|
NCT02516670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15106|Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer|A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|69|||Male|18 Years|N/A|No|||August 2015|August 4, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516670||15645|
NCT02520024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13304|Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living|||Temple University Collaborative on Community Inclusion|Yes|Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02520024||15387|
NCT02520258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THU-0887|Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption|Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption||Rockefeller University|No|Recruiting|August 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02520258||15369|
NCT02524587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-113|Study of the Wear of a Highly Cross-linked Polyethylene Acetabular Doped With Vitamin E and Coated With Titanium in Total Hip Replacement||POLYTITAN|University Hospital, Caen|No|Recruiting|January 2010|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02524587||15036|
NCT02524600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-030|Technical Performance of a New Cardiac Technology "IQ-SPECT" Applied to SCINTI-CT Myocardial Imaging With 99mTc-Sestamibi in Coronary Patients||IQSCINTIMYOC|University Hospital, Caen|No|Completed|January 2012|||June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|103|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02524600||15035|
NCT02664467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORLugano|Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project|Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project||Ospedale Regionale di Lugano|No|Not yet recruiting|March 2016|November 2019|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02664467||4295|
NCT02520843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002602-31|An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF|An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and Stromal Vascular Fraction||Assistance Publique Hopitaux De Marseille|Yes|Recruiting|October 2015|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02520843||15324|
NCT02525835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150713|Tissue Sodium in Autoimmune Disease|Tissue Sodium in Autoimmune Disease||Vanderbilt University|No|Not yet recruiting|October 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525835||14940|
NCT02673749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G28-003|Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance|A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance||Ritter Pharmaceuticals, Inc.|No|Recruiting|February 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|372|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673749||3587|
NCT02517190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-024|Effects of Repeated Short-term Microgravity During Parabolic Flight Conditions on Neuro-endocrine, Immune and Metabolic Changes||COSI@PFC|University Hospital, Caen|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517190||15605|
NCT02512939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Next gen|Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection|Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection|Next Gen|Public Health England|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02512939||15929|
NCT02511665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METAL|Metformin And Longevity|METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer|METAL|Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|185|||Male|18 Years|N/A|No|||July 2015|July 29, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02511665||16027|
NCT02511678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGC15-BNE098|Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases|Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases|MOTION|Galil Medical|No|Recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511678||16026|
NCT02675452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150161|AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.|A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma||Amgen|No|Not yet recruiting|April 2016|March 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|85|||Both|18 Years|85 Years|No|||February 2016|February 26, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02675452||3456|
NCT02518542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POETA|Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia|Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) as Additional Endoscopic Treatment Options for Achalasia and Other Esophageal Motility Disorders|POETA|Medical University of Vienna|No|Recruiting|June 2014|June 2027|Anticipated|June 2024|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|December 8, 2014||No||No||https://clinicaltrials.gov/show/NCT02518542||15501|
NCT02525445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU 2013/80-31|Effects of Genuine vs Sham Acupuncture and Communication Type on Relaxation|Effects of Genuine vs Sham Acupuncture and Communication Type on Relaxation|ACU|Karolinska Institutet|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|243|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525445||14970|
NCT02511938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD071324|Kids' Choice Restaurant Program|Introducing Child Menus in Restaurants to Improve Access to Healthier Foods|KCRP|San Diego State University|No|Completed|December 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|N/A|N/A|No|||January 2016|January 4, 2016|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02511938||16006|
NCT02675543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitreo002|Vitreous Inflammation in Standard and Heavy Silicone Oil|||Università degli Studi di Brescia|No|Completed|June 2015|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02675543||3449|
NCT02675556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140917|Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression|A Phase I, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Treatment Resistant Depression.|ANU|University of Miami|Yes|Not yet recruiting|August 2016|||March 2022|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02675556||3448|
NCT02527460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150183|Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection|Anakinra, a Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection||National Institutes of Health Clinical Center (CC)||Not yet recruiting|August 2015|May 2019|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|61 Years|No|||August 2015|August 22, 2015|August 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02527460||14815|
NCT02513407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15160|Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities|Reducing Cancer and Chronic Disease Risk in Medically Vulnerable Communities: A Feasibility Study Measuring Behavioral and Biological Outcomes of the Eat Move Live Intervention||City of Hope Medical Center|Yes|Recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513407||15893|
NCT02522611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150175|Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain|A Multicenter, Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-Induced Bone Pain||National Institutes of Health Clinical Center (CC)||Suspended|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|August 12, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522611||15188|
NCT02673450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE 2-16|PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.|PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit. A Prospective Cohort Study.||Roskilde County Hospital|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|21 ml of blood from each patient is kept in a biobank for 10 years|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the ICU at Køge Hospital in the study period|February 2016|February 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673450||3610|
NCT02527473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-EM-2014-2498|Improving Bystander CPR Quality Through Dispatcher-assisted Basic Life Support Education Program|Improving Bystander CPR Quality Through Dispatcher-assisted Basic Life Support Education Program||Seoul National University Hospital||Completed|November 2014|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|24|||Both|35 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02527473||14814|
NCT02527512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00015085|Bacterial Contamination: Iodine vs Saline Irrigation in Pediatric Spine Surgery|Bacterial Wound Contamination Prior to Closure: Povidone-Iodine Versus Saline Irrigation in Pediatric Spine Fusion Surgery||Children's Hospital Boston|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02527512||14811|
NCT02513680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36980514.0.0000.5345|Effects of Application LED Therapy and Laser Therapy in Facial Rejuvenation|Effects of Application LED Therapy and Laser Therapy in Facial Rejuvenation: Pilot Study||Federal University of Health Science of Porto Alegre|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513680||15872|
NCT02526628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_KS_TESTOSTERONE|Thrombosis and Neurocognition in Klinefelter Syndrome|The Haemostatic Balance and Neurocognitive Phenotype in Klinefelter Syndrome - The Effect of Testosterone Treatment||University of Aarhus|Yes|Not yet recruiting|September 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|120|Samples With DNA|Bloodsamples|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men with Klinefelter syndrome identified through clinics for fertility, endocrinology and        genetics. Healthy controls from the general population living in Central Denmark Region.|August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526628||14879|
NCT02520882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM11|68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas|Safety and Diagnostic Performance of 68Gallium-labeled NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas||Peking Union Medical College Hospital|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||March 2015|August 11, 2015|August 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02520882||15321|
NCT02515292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142 /181/ 20.05.2014|Evaluation of Infants With Intrauterine Growth Restriction|Multidimensional Modeling in Evaluation of Infants With Intrauterine Growth Restriction|ModeInfIUGR|Iuliu Hatieganu University of Medicine and Pharmacy||Recruiting|June 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|24 Hours|No|Non-Probability Sample|Population with IUGR from a 3rd level maternity from Nord-West of Romania|August 2015|August 4, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515292||15750|
NCT02519998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14D.611|Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development|Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development||Thomas Jefferson University|Yes|Recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Urine Blood Saliva|Both|10 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals ages 10 or older. If the patient has experienced a suspected concussion, must        be a patient at the Jefferson Comprehensive Concussion Center.|August 2015|August 6, 2015|March 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02519998||15389|
NCT02524392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniResearch|Effect Evaluation of Independent Medical Evaluation (IME) in Norway|Effect Evaluation of Independent Medical Evaluation (IME) After Six Months Sick Leave: A Randomized Controlled Trial of Independent Medical Evaluation (IME) Versus Treatment as Usual in Norway|NIME|Uni Research|No|Recruiting|September 2015|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3784|||Both|18 Years|66 Years|No|||December 2015|December 2, 2015|June 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02524392||15051|
NCT02518906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAST|Evaluation of AIT Study|Process-Outcome Study on Psychotherapeutic Interventions in Adolescents With Personality Disorders||University Hospital, Basel, Switzerland|Yes|Recruiting|September 2015|||September 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|13 Years|19 Years|No|||March 2016|March 16, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02518906||15473|
NCT02523638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN-PV|Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients|An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients|PEN-PV|AOP Orphan Pharmaceuticals AG|Yes|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|99 Years|No|||February 2016|February 16, 2016|June 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02523638||15109|
NCT02517229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-084|The Effect of Altered Gravity Condition on Postural Control||POSTURGRAV|University Hospital, Caen|No|Recruiting|September 2012|||October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|18|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517229||15602|
NCT02516215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505008RINA|Sublingual Microcirculation Data of Patients With Systemic Diseases|Population Research of Sublingual Microcirculation Data of Patients With Systemic Diseases||National Taiwan University Hospital|No|Not yet recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||8|Anticipated|360|||Both|20 Years|79 Years|No|Probability Sample|Patients with diagnosed hypertension, diabetes mellitus, both hypertension and diabetes        mellitus, end stage renal disease with hemodialysis, peripheral arterial occlusive        disease, coronary artery disease, liver cirrhosis, or anemia.|August 2015|August 3, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516215||15680|
NCT02670668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10562|Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer|Single Centre，Exploratory，Parallel and Retrospective Study to Analysis the Mutation and Expression of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer||Fudan University|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|N/A|N/A|No|||January 2016|January 28, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670668||3822|
NCT02521935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1811|Conventionally vs. Digitally Fabricated Complete Dentures: Clinical Treatment Outcome Differences|Conventionally vs. Digitally Fabricated Complete Dentures: Clinical Treatment Outcome Differences||University of North Carolina, Chapel Hill|No|Not yet recruiting|August 2015|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521935||15240|
NCT02521636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-038|Clinical Trial Assessing the Value of an Antibiotic Protocol Guided by Serum Procalcitonin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care||BPCTréa|University Hospital, Caen|No|Recruiting|October 2010|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02521636||15263|
NCT02521649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC2|Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer|An Open, Dose-ranging, Multicenter Study to Determine the Antibody Response to G17DT and Its Safety and Tolerability in the Treatment of Patients With Gastric Cancer||Cancer Advances Inc.||Completed|September 1998|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|52|||Both|N/A|N/A|No|||August 2015|August 10, 2015|May 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521649||15262|
NCT02520557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP093-452|An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate|An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate||Sunovion|No|Recruiting|November 2015|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|Samples With DNA|Blood or Saliva|Both|N/A|N/A|No|Probability Sample|Males and Females with a history of seizure disorders who may or may not develop severe        skin reactions while using Eslicarbazepine|November 2015|November 12, 2015|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520557||15346|
NCT02520570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/20140709|Post-market Safety Reassessment of Ulinastatin for Injection|Post-market Safety Reassessment of Ulinastatin for Injection||Techpool Bio-Pharma Co., Ltd.|Yes|Recruiting|August 2014|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|patients with ulinastatin treated|December 2015|December 24, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02520570||15345|
NCT02526784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000184|A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer|A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer||Ferring Pharmaceuticals|No|Recruiting|December 2015|June 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|August 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02526784||14867|
NCT02526875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330HT14009|Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled|A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled||Chong Kun Dang Pharmaceutical|No|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|20 Years|N/A|No|||August 2015|August 17, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02526875||14860|
NCT02521246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACEMS0315|Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control||EMS|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|282|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521246||15293|
NCT02527889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCRL-1|The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL)|||The Hong Kong Polytechnic University|Yes|Recruiting|July 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|70 Years|No|||August 2015|August 19, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02527889||14782|
NCT02527902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008123|Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy|Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|12|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02527902||14781|
NCT02512159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2301-12|Skin Ulcers Treatment With an Handicraft Topical Device|Effectiveness of Topical Negative Handicraft Device for Versus Traditional Conservative Treatment in Skin Ulcers Management in Lower Limb||Coordinación de Investigación en Salud, Mexico|Yes|Completed|March 2014|January 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|80 Years|No|||February 2014|July 29, 2015|March 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02512159||15989|
NCT02512172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1538|A Pilot Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer|A Pilot Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|June 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512172||15988|
NCT02515149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC - NCHHSTP - 6382|Impact on Linkage to HIV Care With Point of Care CD4 Testing and Home-based HIV Testing in Kenya|Randomized Controlled Trial to Assess Accuracy, Feasibility, Acceptability, Cost Effectiveness and Impact of Point of Care CD4 Testing on HIV Diagnosis, Linkage to Care and Time to Antiretroviral Therapy Initiation Among HIV Infected Patients in Rural Western Kenya|CD4-POC|Centers for Disease Control and Prevention|No|Completed|July 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|770|||Both|N/A|N/A|No|||August 2015|August 3, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515149||15761|
NCT02519673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFO_2015_26|Comparison of Corneal Stromal Tissue Consumption (LATAC)|Comparison of Corneal Stromal Tissue Consumption Values Estimated When Programming the Intervention Versus the Values Measured by Pre and Postoperative Topography|LATAC|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|November 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a refractive disorder and for whom a refractive surgery by LASIK is        programmed.|November 2015|November 17, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02519673||15414|
NCT02714283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-1503-29191|Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis|Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis||Oregon Health and Science University|No|Active, not recruiting|January 2016|July 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|55000|||Both|65 Years|N/A|No|Non-Probability Sample|Patients within Medicare with a diagnosis of bronchiectasis|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02714283||475|
NCT02655406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/NE/0314|COMpression Following Endovenous TreatmenT of Incompetent Varicose Veins (COMFETTI)|COMpression Following Endovenous TreatmenT of Incompetent Varicose Veins (COMFETTI)|COMFETTI|Imperial College London|No|Not yet recruiting|January 2016|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||December 2015|January 18, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655406||4992|
NCT02659761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAISTR_2016|Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs|A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART|TAISTR|University College Dublin|Yes|Not yet recruiting|January 2016|March 2019|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02659761||4657|
NCT02659878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBR/052/00436-2/2015|Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage|Incidence, Influencing Factors and Outcome of Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage||University of Debrecen|Yes|Recruiting|February 2015|August 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study intends to include all patients over 18 years of age who were admitted to our        clinic within 48 hours after the bleeding regardless of gender, neurological status or        age.|January 2016|January 15, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02659878||4648|
NCT02651753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146BE15025|A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337|A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers.||Chong Kun Dang Pharmaceutical|No|Active, not recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 22, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02651753||5271|
NCT02651766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3987-BO|The Effects of Cupping Massage in Patients With Chronic Neck Pain - A Randomized Controlled Trial|Randomised Controlled Trial on the Influence of Cupping Massage on Pain Intensity and Sensory Mechanical and Pain Thresholds in Patients With Chronic Non Specific Neck Pain|SKM|Universität Duisburg-Essen|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||January 2016|January 8, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651766||5270|
NCT02525939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL-301|Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS|A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial|dal-GenE|DalCor Pharmaceuticals|Yes|Not yet recruiting|March 2016|August 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5000|||Both|45 Years|N/A|No|||February 2016|February 15, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525939||14932|
NCT02663167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPN 2015/470-31|Internet-based Cognitive-behavior Therapy for Children With Obsessive-compulsive Disorder|Internet-based Cognitive-behavior Therapy for Children With Obsessive-compulsive Disorder: a Pilot Trial||Karolinska Institutet||Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|7 Years|11 Years|No|||February 2016|February 4, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02663167||4395|
NCT02663180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1179-1857|Effects of an Educational Program on Depression Literacy and Stigma Among Secondary School Students in Jazan City|Effects of an Educational Program on Depression Literacy and Stigma Among Students of Secondary Schools in Jazan City||University of Jazan|Yes|Recruiting|January 2016|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02663180||4394|
NCT02520492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01568-39|Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma|Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma|GMaPIC|Centre Jean Perrin|No|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|February 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02520492||15351|
NCT02524002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22375|A Randomizzed Control Trial of Enhanced vs. Routine Clear Liquid Intake in Labor|Clear Liquids vs Enhanced Clear Liquids; Effect on Labor Performance||Temple University|No|Recruiting|August 2014|May 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|August 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02524002||15081|
NCT02524015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150231|Novel Treatment For Pusher Syndrome Using Physical Therapy|||Loma Linda University|No|Enrolling by invitation|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|89 Years|No|||January 2016|January 29, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02524015||15080|
NCT02515708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-549|Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation|A Phase I Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation||The Cleveland Clinic|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515708||15718|
NCT02521922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSP-F001v1.2|Vital Signs Patch Early Feasibility and Usability Study|Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|VSP|LifeWatch Services, Inc.|No|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|March 15, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521922||15241|
NCT02522481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-141|Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141|A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease||Bracco Diagnostics, Inc|No|Recruiting|September 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|175|||Both|18 Years|N/A|No|||July 2015|October 8, 2015|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522481||15198|
NCT02522494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 12-282|Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits|Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits|TELEHEALTH|VA Office of Research and Development|No|Not yet recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|470|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02522494||15197|
NCT02522793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00058440|Optical Spectroscopy for Cutaneous Cancer|Non-Invasive Optical Spectroscopy for Identification of Cutaneous Cancer||Duke University|No|Not yet recruiting|August 2015|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Patients who present to the Duke or VA Dermatology or Otolaryngology clinics with a        suspicious skin lesion that is in need of a biopsy.|July 2015|August 12, 2015|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02522793||15174|
NCT02520622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821426|Digital vs. Printed Photographs: Impact on Skin Self-Examinations|Evaluation of the Impact of Using Digital Photographs on a Mobile Device Versus Printed Photographs on Patient Conducted Skin Exams||University of Pennsylvania|Yes|Recruiting|February 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02520622||15341|
NCT02520635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0008|Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients|A Clinical Study of Supra-early Post-Surgery Chemotherapy Plus Standard TEMODAL® Regimen Versus Standard TEMODAL® Regimen in the Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme||Beijing Tiantan Hospital|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||August 2015|August 9, 2015|June 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520635||15340|
NCT02520193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP 2014-01|Impact of Early Mobilization on Mechanical Ventilation Duration in Intubated Critically Ill Patients|Prospective, Randomized, Multi-center Trial to Assess the Impact of Early Mobilization on Mechanical Ventilation Duration in Intubated Critically Ill Patients|EarlyMob|University Hospital, Angers|No|Recruiting|December 2015|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|772|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02520193||15374|
NCT02522741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00175|Safe Mothers, Safe Children Initiative|Safe Mothers, Safe Children Initiative||New York University School of Medicine|No|Suspended|November 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|August 7, 2015||No|Recruitment temporarily halted|No||https://clinicaltrials.gov/show/NCT02522741||15178|
NCT02513732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-306|XIENCE Xpedition Everolimus-Eluting Coronary Stent Post Marketing Surveillance (XIENCE Xpedition SV PMS)|XIENCE Xpedition Everolimus-Eluting Coronary Stent Post Marketing Surveillance||Abbott Vascular|Yes|Active, not recruiting|July 2014|March 2021|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|20 Years|N/A|No|Non-Probability Sample|General patient population with ischemic heart disease in Japan who are eligible for        treatment with XIENCE Xpedition 2.25 mm stent will be included in the study.|January 2016|January 11, 2016|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513732||15869|
NCT02513745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 2014-003|Conventional Surgery vs. Verion/VerifEye|Refractive Outcomes Evaluation of the Verion Image Guided System + ORA System With VerifEye||Carolina Eyecare Physicians, LLC|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||July 2015|July 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513745||15868|
NCT02673411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-2016-0065|Ultrasonography SWE for Hepatic Fibrosis Evaluation|Diagnostic Performance of Shear Wave Elastography for Fibrosis Evaluation: Preliminary Study||Seoul National University Hospital|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|158|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are scheduled to undergo liver resection or liver biopsy (n=138). Volunteers        who agree to undergo US shear wave elastography (n=20) to determine inter-observer        agreement.|February 2016|February 1, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673411||3613|
NCT02673424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT16453285|Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis|Comparison of Clinical Outcomes Between Imaging and Physiology-guided Intervention Strategy in Patients With Intermediate Stenosis: Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis (FLAVOUR)|FLAVOUR|Seoul National University Hospital|Yes|Not yet recruiting|April 2016|January 2022|Anticipated|December 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1860|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02673424||3612|
NCT02673476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8176-510|A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus|A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness||Alios Biopharma Inc.|Yes|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||February 2016|February 1, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673476||3608|
NCT02523235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prox-Distal Catheter Insertion|Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks|Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks||University of California, San Diego|No|Recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|August 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523235||15140|
NCT02515045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 14-002|Dropless vs. Standard Drops Contralateral Eye Study|Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen||Carolina Eyecare Physicians, LLC|No|Recruiting|January 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|66|||Both|50 Years|80 Years|No|||July 2015|July 31, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02515045||15769|
NCT02519114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL49476.000|Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma|Natural Killer Cel Alloreactive Bone Marrow Transplantation for Multiple Myeloma||Maastricht University Medical Center|Yes|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|60 Years|No|||August 2015|August 5, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02519114||15457|
NCT02519127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52245.068.15/METC153004|Metflex: The Effectiveness of a Dietary Intervention|Employing Dynamic Kinetic Responses to Demonstrate the Effectiveness of Dietary Intervention: A Challenge-based Study Using a Low-glycaemic Load Diet||Maastricht University Medical Center|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02519127||15456|
NCT02671266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001777|Oxytocin Administration in BDD and OCD|Effect of Intranasal Oxytocin on Social Cognition||Massachusetts General Hospital|Yes|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 2, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02671266||3776|
NCT02671279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/361|Low Calorie Diet in Morbidly Obese Patients|Effect of 6 Days Low Calorie Diet Before Bariatric Surgery|PreBar|Haukeland University Hospital|No|Recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|14|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02671279||3775|
NCT02512055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA09/247|Ketamine Tolerance in Children After Repeated Administrations During Radiotherapy Sessions|Ketamine Tolerance in Children After Repeated Administrations During Radiotherapy Sessions||Baskent University|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|33|||Both|1 Year|14 Years|No|||July 2015|July 28, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02512055||15997|
NCT02515344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0497|Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer|Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer: Randomised Study Measuring the Impact on Participation|IDLN|Nantes University Hospital|Yes|Not yet recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1300|||Both|25 Years|74 Years|No|||July 2015|August 3, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02515344||15746|
NCT02524522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEAN-IPI|Perioperative Mechanical Ventilation and Postoperative Monitoring of IPI|Perioperative Pulmonary Recruitment and Postoperative Monitoring of Integrated Pulmonary Index in Off-pump Coronary Bypass Grafting|WEAN-IPI|Northern State Medical University|No|Completed|August 2015|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02524522||15041|
NCT02673554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP and Tachyphylaxis|The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP|The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of Glucose-dependent Insulinotropic Polypeptide (GIP) in Patients With Type 2 Diabetes is Not Caused by Rapid Tachyphylaxis||Diabeteszentrum Bad Lauterberg im Harz|No|Completed|May 2004|||December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02673554||3602|
NCT02520479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-SYSUCC|"Sandwich" Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL|Phase 2 Trial of "Sandwich" Pegaspargase-CHOP Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, Nasal Type, Extranodal Natural Killer/T-cell Lymphoma||Sun Yat-sen University|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|69 Years|No|||February 2016|March 7, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520479||15352|
NCT02525770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-018|Comparative Study of the Wear of Uncemented Acetabular Conventional Polyethylene and X3 in Total Hip Replacement, for Stereo-radiographic Analysis||COCYCOX|University Hospital, Caen|No|Active, not recruiting|June 2010|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|112|||Both|18 Years|70 Years|No|||August 2015|August 14, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02525770||14945|
NCT02525783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15A-T-PYC-R|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||March 10, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525783||14944|
NCT02514603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16018|A Study of LY2606368 in Japanese Participants With Advanced Cancers|A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors||Eli Lilly and Company|Yes|Recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|July 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514603||15803|
NCT02668094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03-037-001|The Effect of Pregabalin on Pain of Propofol Injection|The Effect of Pregabalin on Pain of Propofol Injection||Kyungpook National University|Yes|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|20 Years|60 Years|No|||February 2016|February 4, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02668094||4017|
NCT02523846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20790|Patient Re-education vs. Background Morphine to IV-PCA in Patient With Unsatisfactory Analgesia Post Laparotomy|Comparing Effectiveness of Post-operative Analgesia Between Patient Re-education and the Additional of a Basal Morphine Infusion to IV-PCA Morphine in Patients With Unsatisfactory Analgesia After Laparotomy||Clinical Research Centre, Malaysia|Yes|Recruiting|August 2015|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|70 Years|No|||August 2015|August 14, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523846||15093|
NCT02512679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-06-00177|Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells|Protocol for Related Donor Hematopoietic Stem Cell Transplantation (HSCT) for Treatment of Symptomatic Genetic Lymphohematological Diseases||Children's Hospital Los Angeles|Yes|Completed|February 2007|February 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|3 Months|21 Years|No|||July 2015|July 29, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02512679||15949|
NCT02512692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102254|90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma|A Traditional Feasibility Study of Gemcitabine, Cisplatin, and 90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma||Medical University of South Carolina|Yes|Recruiting|July 2015|||August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512692||15948|
NCT02525419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307-347|Intermittent Fasting, Caloric Restriction and Body Composition in Obese Men and Women|Effects of Intermittent Fasting and Caloric Restriction on Total and Regional Body Composition, Cardiometabolic, Oxidative Stress & Plasma Toxin Biomarkers, and Energy Metabolism in Overweight/Obese Men and Women||Skidmore College|Yes|Completed|August 2013|March 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02525419||14972|
NCT02525432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-16-XXXX|Autologous Stem Cell Study for Adult TBI (Phase 2b)|Treatment of Adult Severe Traumatic Brain Injury Using Autologous Bone Marrow Mononuclear Cells||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|May 2016|December 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|55 Years|No|||March 2016|March 9, 2016|March 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525432||14971|
NCT02664740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2015/AS-01|Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus|Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial|PhagoPied|Centre Hospitalier Universitaire de Nīmes|Yes|Not yet recruiting|January 2017|August 2018|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02664740||4274|
NCT02521012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DepFuDKUH5703453|Follow-up Study With Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)|Follow-up Study With Randomized Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)|DepFuD|Kuopio University Hospital|No|Not yet recruiting|October 2015|October 2025|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3028|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02521012||15311|
NCT02521025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 15-3-035|Bedrest, Feeding Pattern, and Insulin Sensitivity|The Impact of Continuous Versus Intermittent Feeding on Changes in Insulin Sensitivity During Bed-rest||Maastricht University Medical Center|Yes|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|35|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02521025||15310|
NCT02517034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15161|Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer|Advancing Screening and Treatment for Older Patients With Cancer||City of Hope Medical Center|Yes|Recruiting|August 2015|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Both|65 Years|N/A|No|||February 2016|February 25, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02517034||15617|
NCT02516267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multiplate CABG|Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.|The Importance of Evaluation of Platelet Aggregability in the Release of Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome With Dual Antiplatelet Therapy.||University of Sao Paulo General Hospital|Yes|Recruiting|July 2015|July 2020|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|246|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516267||15676|
NCT02516280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHV2012-01|Effects of Gaseous Cryotherapy on Knee ROM After TKA: A Feasibility Study|Effects of Hyperbaric Gaseous Cryotherapy on Knee Flexion Range of Motion in the First Two Days After Total Knee Arthroplasty: A Feasibility Randomized Controlled Trial||Centre Hospitalier de Verdun|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|35 Years|79 Years|No|||August 2015|August 4, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02516280||15675|
NCT02665481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410093|Mindfulness-Based Stress Reduction, Health Education and Exercise|Remediating Age Related Cognitive Decline: Mindfulness-Based Stress Reduction and Exercise|MEDEX|Washington University School of Medicine|Yes|Recruiting|April 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|580|||Both|65 Years|84 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02665481||4217|
NCT02521779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-020|The Role of Dietary Fat on Postprandial Endotoxemia in Healthy Adults|Dietary Fat Affects Postprandial Serum Endotoxin Concentration in Healthy Adults||Iowa State University|No|Completed|April 2014|April 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02521779||15252|
NCT02527421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFD01-CD-013|DFD01 Spray vs. Comp01 Lotion HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis|||Promius Pharma, LLC|No|Recruiting|July 2015|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|12 Years|16 Years|No|||February 2016|February 24, 2016|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527421||14818|
NCT02526823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongPH01|Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma|Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma||Shandong Provincial Hospital||Recruiting|August 2015|February 2019|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|80 Years|No|||August 2015|September 1, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02526823||14864|
NCT02526836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Complete Mesocolic Excision|Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer|Complete Mesocolic Excision (CME) With Central Supplying Vessel Ligation (CVL) Compared With Conventional Surgery for Colon Cancer: a Double-blinded Randomized Study||Mansoura University|No|Recruiting|September 2014|January 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02526836||14863|
NCT02511951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahykdxdefsyy11|One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy|A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy||The Second Hospital of Anhui Medical University|Yes|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|80 Years|No|||August 2015|August 16, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02511951||16005|
NCT02665754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBIRB2016-002|Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis|The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen|ILIT-T|Gachon University Gil Medical Center|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||January 2016|January 24, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02665754||4196|
NCT02514772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP13-302|GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®|A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®|ASSIST-RT|Sandoz||Recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514772||15790|
NCT02515006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adwin/chr/1121|Impact of Homeopathy for Persistent Insomnia in Patients With Cancer|Randomized Controlled Trial of Homeopathy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer||Adwin Life Care|Yes|Completed|September 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|160|||Both|18 Years|45 Years|No|||August 2015|August 2, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515006||15772|
NCT02518113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14548|A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL|A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients||Eli Lilly and Company|No|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|92|||Both|2 Years|N/A|No|||February 2016|February 22, 2016|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518113||15534|
NCT02526602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15043|Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.|Preservation of Endopelvic Fascia During Radical Prostatectomy: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.||Tampere University Hospital|No|Recruiting|August 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Male|18 Years|80 Years|No|||August 2015|August 14, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526602||14881|
NCT02513264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-25|Registry for Asthma Characterization and Recruitment 2|Registry for Asthma Characterization and Recruitment 2 (ICAC-25)|RACR2|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|June 2015|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4100|Samples With DNA|Blood samples|Both|1 Year|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who reside within the metropolitan statistical area of the clinical site and have        clinician-diagnosed asthma, current symptoms of asthma, or risk factors for development of        asthma. The population may at times include participants without asthma, atopy, and        rhinitis.|March 2016|March 9, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02513264|7 Years|15904|
NCT02662933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22A08|Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)|Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|January 2009|||April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|82|||Both|60 Years|N/A|No|||January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02662933||4413|
NCT02515019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sevo_2_2014|Bispectral Index Guided Sevoflurane Titration|Bispectral Index Guided Titration of Sevoflurane in On-pump Cardiac Surgery Reduces Plasma Sevoflurane Concentration and Vasopressor Requirements||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2011|January 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515019||15771|
NCT02515279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22273|An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria|A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months||Hoffmann-La Roche||Completed|November 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|463|||Both|N/A|N/A|No|Non-Probability Sample|The study will enroll Austrian participants receiving peginterferon alfa-2a and ribavirin        for HCV infection according to routine practice.|January 2016|January 12, 2016|July 29, 2015|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT02515279||15751|The sustained viral response that had to be filled out 6 months (or later) after the end of treatment was documented poorly due to reasons such as participants that were lost to follow-up or the study closure was before the visit date for the SVR.
NCT02518347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE1517|Strawberries and Knee Osteoarthritis (OA)|Effects of Freeze-dried Strawberries on Systemic Markers of Inflammation and Knee Function in Participants With Osteoarthritis (OA)||Oklahoma State University|No|Recruiting|March 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02518347||15516|
NCT02527083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00000878|Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain|Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain||VA Pittsburgh Healthcare System|No|Enrolling by invitation|January 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|48|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|January 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527083||14844|
NCT02513810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0040|A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation|||Yonsei University|No|Recruiting|July 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3020|||Both|19 Years|N/A|No|||December 2015|December 9, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02513810||15863|
NCT02523495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC003-TTMCRC|The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer|||Huazhong University of Science and Technology||Recruiting|June 2012|||July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Whole blood|Both|N/A|N/A|No|Probability Sample|Metastasis colorectal cancer patients in Chinese Han population|February 2016|February 17, 2016|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523495|5 Years|15120|
NCT02523508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20150310003|Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function|Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function||The Hong Kong Polytechnic University|No|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02523508||15119|
NCT02527759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0336|Patient Self Monitoring to Evaluate 30 Day Post Discharge Heart Failure Outcomes|Patient Self Monitoring to Evaluate 30 Day Post Discharge Heart Failure Outcomes||Georgetown University|No|Not yet recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|65 Years|N/A|No|Non-Probability Sample|Patients with heart failure|April 2015|August 21, 2015|April 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02527759||14792|
NCT02527772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD-FOX4/HCC|Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma|Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)|LD-FOX4/HCC|Guangxi Medical University|Yes|Active, not recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02527772||14791|
NCT02512185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9075|Towards Optimal Prescription of Chemotherapy in Prostate Cancer|TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)|TOPCOP|University Health Network, Toronto|No|Recruiting|July 2015|February 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|332|||Male|65 Years|N/A|No|Probability Sample|Men 65 and older starting first line chemotherapy, or Abiraterone, or Enzalutamide for        mCRPC|March 2016|March 4, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02512185||15987|
NCT02527265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR14323|Afrezza Safety and Pharmacokinetics Study in Pediatric Patients|Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza® in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus||Sanofi|Yes|Suspended|October 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|4 Years|17 Years|No|||March 2016|March 14, 2016|August 17, 2015|No|Yes|Due to transfer of ownership of Afrezza IND & NDA back to MannKind Corporation, enrollment    into the TDR14323 study was suspended|No||https://clinicaltrials.gov/show/NCT02527265||14830|
NCT02527447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150176|Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)|A Pilot Study of Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in Patients With Relapsed Orrefractory Acute Myeloid Leukemia||National Institutes of Health Clinical Center (CC)||Recruiting|August 2015|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|36|||Both|18 Years|70 Years|No|||July 2015|March 11, 2016|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02527447||14816|
NCT02514083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150172|A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|July 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|99 Years|No|||July 2015|February 27, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514083||15842|
NCT02521467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doaa Adel|Adjunctive Role of PRF After Free Gingival Graft Harvesting - Case Series|Adjunctive Role of Platelets Rich Fibrin in Palatal Wound Healing After Free Gingival Graft Harvesting - Case Series||Ain Shams University|Yes|Completed|January 2014|||January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|45 Years|No|||August 2015|August 10, 2015|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521467||15276|
NCT02525224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PHX-0001|Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults|Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults||Pharmanex|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2015|September 17, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02525224||14987|
NCT02524444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients|A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients||University of Ibadan|Yes|Not yet recruiting|September 2015|February 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524444||15047|
NCT02672592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-376|Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome|Effects of IL-1 Beta on the Hypothalamic-pituitary-gonadal (HPG) Axis in Men With Obesity and Metabolic Syndrome - The TestIL Trial|TestIL|University Hospital, Basel, Switzerland|No|Recruiting|January 2016|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|75 Years|No|||January 2016|January 29, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02672592||3675|
NCT02672605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823273|Measurement of Individual Level of Abortion Stigma Study|Measurement of Individual-Level Abortion Stigma Resulting From Pennsylvania State-Mandated Abortion Consent Language: A Pilot Randomized Controlled Trial||University of Pennsylvania|No|Recruiting|November 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02672605||3674|
NCT02525302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-DMD-03|HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02|HT-100 Long-term Safety and Pharmacodynamics in Patients With DMD Who Have Completed Protocols HALO-DMD-01 and HALO-DMD-02||Akashi Therapeutics|Yes|Enrolling by invitation|May 2015|August 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Male|6 Years|20 Years|No|||February 2016|February 3, 2016|July 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525302||14981|
NCT02524509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CON|the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee|An Inverstigational Clinical Trial for the Safety and Efficacy Evaluation of Chondron(Autologous Cultured Chondrocyte)Compared With Mircrofracture Surgery in Subjects With Cartilage Defects of the Knee Joint||Sewon Cellontech Co., Ltd.|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Total 50 patients. Patients who received autologous chondrocyte implantation using        CHONDRON (autologous cultured chondrocyte) for knee osteoarthritis or patients underwent        microfracture. There are total 28 patients who get CHONDRON grafting until now.        Considering dropout rate, the selected number of investigational group is total 25, and 25        of equivalent control group is planned.|August 2015|August 28, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02524509||15042|
NCT02514642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAD-201523|Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease|Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial||First Affiliated Hospital of Harbin Medical University|Yes|Recruiting|July 2015|November 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||July 2015|September 28, 2015|July 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514642||15800|
NCT02525887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFG201502-PGX|Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways|A Clinical Trial to Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways 2C19, 2C9, 2D6, 3A4, 3A5, Factor II, Factor V, MTHFR and VKORC1||Bracane Company|No|Recruiting|July 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Data from a total of approximately 10,000 adult male or female patients age 18 or older        who are prescribed at least one medication within any of the metabolic pathways being        assessed will be collected for the study.|August 2015|August 14, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525887||14936|
NCT02513368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSIR|Peri Implant Soft Tissue Healing in Single Implant Restoration Using Two Different Techniques|Peri Implant Soft Tissue Healing in Single Implant Restoration Using the Guided Bone Regeneration Technique Ore a Connective Tissue Graft||University of Firenze and Siena, Napoli, Italy|No|Completed|January 2011|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02513368||15896|
NCT02516787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-082|Coherence Between Brain Cortical Function and Neurocognitive Performance During Changed Gravity Conditions||CORTICOG|University Hospital, Caen|No|Completed|November 2010|||November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02516787||15636|
NCT02516800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-SLC-2014-01|Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD|Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD||University of Aarhus|Yes|Recruiting|May 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|600|Samples With DNA|Full blood Aortic Valve|Both|N/A|65 Years|No|Non-Probability Sample|Patients with premature aortic valve stenosis in Denmark and Sweden.|July 2015|August 3, 2015|February 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02516800||15635|
NCT02657837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000051399|Measures of Respiratory Health (MRH)|Measures of Respiratory Health|MRH|The Hospital for Sick Children|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|30 Months|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who meet all of the inclusion and none of the exclusion criteria will be        eligible for participation in this study. Participants will include individuals with CF,        individuals with other respiratory disease and healthy individuals.|January 2016|January 13, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02657837||4805|
NCT02718898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16010|A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis|A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis|IXORA-Q|Eli Lilly and Company|No|Not yet recruiting|April 2016|July 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718898||120|
NCT02718911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16348|A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors|A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Not yet recruiting|May 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|178|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02718911||119|
NCT02659774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSTWPLACE2015|Smoking Cessation in Workplaces in Hong Kong|Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong||The University of Hong Kong|Yes|Recruiting|January 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02659774||4656|
NCT02652195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00086964|Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II|Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II||University of Utah|No|Not yet recruiting|January 2016|||January 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|44|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652195||5237|
NCT02660021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201627035|Prospective Registry of 3-dimensional Virtual Treatment Planning of Orthognathic Surgery||3D-VIRTOG|AZ Sint-Jan AV|No|Recruiting|July 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All consenting patients, eligible for orthognathic surgery, performed at the General        Hospital Saint-John Bruges, from July 1st 2010 onwards.|January 2016|January 18, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660021|12 Months|4637|
NCT02647580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M229|Appetite Regulation in Children With Failure to Thrive|Appetite-regulating Hormones, the Gut Microbiome and the Metabolome in Children With Failure to Thrive||University of Copenhagen|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples With DNA|Plasma, serum, feces, urine|Both|12 Months|36 Months|No|Non-Probability Sample|Children with failure to thrive|January 2016|January 4, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02647580||5592|
NCT02514005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID007|Manual Therapy and Dry Needling in Patellofemoral Syndrome|Effectiveness of Manual Therapy and Dry Needling in Nonspecific Patellofemoral Syndrome.|MTPSSFP|University of Valencia|No|Recruiting|July 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|December 5, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02514005||15848|
NCT02667834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00072-45|Efficiency of the French Translation Social Cognition and Interactive Training (SCIT)Program|Efficiency of the French Translation Program:Social Cognition and Interactive Training (SCIT) of Negative Symptoms in Schizophrenia|SCIT-VF|Hôpital le Vinatier|Yes|Recruiting|October 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|50 Years|No|||January 2016|January 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02667834||4037|
NCT02523677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC_IRB_15666|Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment|Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment|ReFLECT|University of Illinois at Urbana-Champaign|No|Active, not recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|451|||Female|21 Years|N/A|No|Non-Probability Sample|Female breast cancer patients and survivors aged 21 years or older and who have access to        an iPad (iOS 6.2 or later) and the Internet.|February 2016|February 11, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523677||15106|
NCT02523690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072940|Evaluating Muscle Weakness Improvement With Lorcaserin in ICU|Evaluating Lorcaserin Drug Therapy For ICU-Acquired Weakness: A Pilot Randomized Trial|EMILI|Johns Hopkins University|No|Enrolling by invitation|September 2015|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523690||15105|
NCT02512978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z15110700400000|Reverse the HYpoTHyroid Status in Acute Myocardial InfarCtion (RHYTHMIC)|Reverse the HYpoTHyroid Status in Acute Myocardial InfarCtion (RHYTHMIC)|RHYTHMIC|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|August 2015|||September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||August 2015|January 27, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512978||15926|
NCT02520388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLD200-108|A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting|A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Evening-dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post-waking, Early Morning Function in Children Aged 6 to 12 With Attention Deficit Hyperactivity Disorder (ADHD)||Ironshore Pharmaceuticals and Development, Inc|No|Recruiting|August 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|6 Years|12 Years|No|||August 2015|March 16, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520388||15359|
NCT02520401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s57668|The Use of a Probiotic Lozenge in the Treatment of Peri-implantitis|The Use of a Probiotic Lozenge in the Treatment of Peri-implantitis||Universitaire Ziekenhuizen Leuven||Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||May 2015|October 12, 2015|May 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520401||15358|
NCT02526173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFRLP003|DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)|A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RALP) - Effect on Potency Outcomes||MiMedx Group, Inc.|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|230|||Male|40 Years|70 Years|No|||March 2016|March 1, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02526173||14914|
NCT02515513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500239|The Role of Muscle Cachexia in Pancreatic Cancer|The Role of Muscle Cachexia in Pancreatic Cancer||University of Florida|No|Recruiting|March 2016|December 2025|Anticipated|December 2025|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|225|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|June 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02515513||15733|
NCT02525536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060212|A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors|A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386) in Adult Japanese Patients With Advanced Solid Tumors||Takeda|No|Completed|June 2009|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|20 Years|74 Years|No|||August 2015|August 19, 2015|July 26, 2015||No||No|August 19, 2015|https://clinicaltrials.gov/show/NCT02525536||14963|
NCT02525549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-817|Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris|||Perrigo Company|No|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|903|||Both|12 Years|40 Years|No|||August 2015|August 17, 2015|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525549||14962|
NCT02525653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-054|Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers|A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers||Memorial Sloan Kettering Cancer Center||Recruiting|August 2015|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525653||14954|
NCT02524769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207152|The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides|The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides||Loyola University|Yes|Recruiting|December 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|55 Years|N/A|No|||March 2016|March 1, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02524769||15022|
NCT02527603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPTCOT201501|Spaso Versus Self-assisted Maneuver for Anterior Shoulder Dislocation|Randomized Clinical Trial Comparing the Spaso Maneuver Versus the Self-assisted Boss-Holzach-Matter for Anterior Shoulder Dislocations||Corporacion Parc Tauli|Yes|Recruiting|August 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02527603||14804|
NCT02523066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Magna Ease CN001|Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients|||Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.|Yes|Recruiting|September 2014|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|The patients who had the heart valves (Type: 7300TFX and 3300TFX), and are willing to        participate in the study.|August 2015|August 13, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02523066||15153|
NCT02523144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMCIRB-K2014057|Dexmedetomidine in Children Having Transthoracic Echocardiography|A Qualitative Comparison of Oral Chloral Hydrate vs 2.0 or 3.0 mcg/kg Nasal Dexmedetomidine in Children Undergoing Transthoracic Echocardiography||Children's Hospital Medical Center, Cincinnati|No|Recruiting|September 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|3 Months|36 Months|No|||February 2016|February 4, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02523144||15147|
NCT02523157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CityULondon|Wellbeing in Pregnancy: Evaluating an Intervention to Improve Women's Emotional Wellbeing in Pregnancy|Wellbeing in Pregnancy: Evaluating an Intervention to Improve Women's Emotional Wellbeing in Pregnancy|WiP|City University, London|No|Completed|August 2015|February 2016|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|March 3, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02523157||15146|
NCT02525666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BigWig Study|Bilateral Laparoscopic Repair of Groin Hernias With One Large Self-fixating Mesh (ProGripTM)|Evaluation of Bilateral Laparoscopic Repair of Groin Hernias With One Large Self-fixating Mesh (ProGripTM) in a Prospective Cohort Study|BigWig|Algemeen Ziekenhuis Maria Middelares|No|Recruiting|August 2015|April 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|80 Years|No|Non-Probability Sample|100 adult patients, men only, ages between 18 and 80 years with a primary bilateral        inguinal hernias will be included based on clinical examination and/or ultrasonography.|January 2016|January 4, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02525666||14953|
NCT02518867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0118A|Motor Disability of Children With Cerebral Palsy Using Motor Transcranial Magnetic Stimulation|Modulating and Managing the Motor Disability of Children With Cerebral Palsy Using Motor Transcranial Magnetic Stimulation||Chang Gung Memorial Hospital|Yes|Recruiting|March 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|7 Years|20 Years|No|||July 2015|August 5, 2015|February 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02518867||15476|
NCT02663765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANC|Lack of Antenatal Care in Primiparas|Impact of Lack of Antenatal Care in Primiparas on Maternal and Perinatal Outcomes|ANC|Assiut University|Yes|Recruiting|January 2016|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|600|||Female|18 Years|40 Years|No|Probability Sample|primiparas who will be delivered in Assiut Women Health Hospital|January 2016|January 22, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02663765||4349|
NCT02525562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-044|Stryker NTX Registry Scorpio NRG (Re-"Energize"), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert|Stryker NTX Registry Scorpio NRG Triathlon Total Knee, Triathlon PKR With X3 Insert International Multicentre Outcomes Register|NTX|Stryker European Operations BV|No|Active, not recruiting|June 2012|March 2024|Anticipated|March 2024|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|224|||Both|N/A|N/A|No|||August 2015|August 13, 2015|June 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525562||14961|
NCT02524457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-096|How Menopause Affects Lipid Metabolism in the Visceral Fat Depots|How Menopause Affects Lipid Metabolism in the Visceral Fat Depots||Rigshospitalet, Denmark|Yes|Not yet recruiting|September 2015|September 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|Samples With DNA|blood and fat biopsies|Female|45 Years|55 Years|No|Probability Sample|Women from 45-55 years of age undergoing gynecological surgery for benign reasons.|August 2015|August 13, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02524457||15046|
NCT02673489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-379|A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection|A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection||Bristol-Myers Squibb|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02673489||3607|
NCT02516384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404014982|Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)|Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)||Weill Medical College of Cornell University|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516384||15667|
NCT02525354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNH-01-2536-01|Dietary Arachidonic Acid, Obesity and Atopic Respiratory Disease|Obesity and Atopic-related Respiratory Disease: Possible Role of Dietary Omega 6 and 3 Fatty Acids||University of New Hampshire|No|Completed|October 2001|May 2003|Actual|May 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples Without DNA|plasma samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects were recruited from the University and surrounding local communities,        using posted flyers, website announcements, personal announcements in classes, referrals        from local physicians, and word of mouth. Prospective subjects were interviewed initially        by telephone.|July 2015|August 13, 2015|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02525354||14977|
NCT02664246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16qqy|Contrast-induced Nephropathy: Incidence,Risk Factors,Effective Prevention and Management Method|Chinese People's Liberation Army General Hospital||Chinese PLA General Hospital|Yes|Completed|January 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10000|||Both|18 Years|80 Years|No|Probability Sample|patients undergoing percutaneous coronary intervention (PCI) from 2010 to 2015|January 2016|January 26, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02664246||4312|
NCT02523664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI-3396-2|Neural Correlates of Stress Hormones|Why Does Cortisol Enhance Memory Retrieval in Patients With Borderline Personality Disorder and Posttraumatic Stress Disorder? Investigating the Neuronal Correlates of Cortisol Administration and the Effects of Stress Exposure|Cort-fMRI|Charite University, Berlin, Germany|No|Recruiting|January 2014|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|75|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02523664||15107|
NCT02512380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-069|Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer|Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|July 2015|July 2021|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|70 Years|No|||July 2015|August 6, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02512380||15972|
NCT02519387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP11-MY-401|Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity|Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia||Mundipharma Pharmaceuticals Sdn. Bhd.|No|Completed|July 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|40 Years|N/A|No|||August 2015|August 11, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02519387||15436|
NCT02671721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001613|Intraoperative Protective Ventilation and Postoperative Pulmonary Complications|Intraoperative Protective Ventilation and Postoperative Pulmonary Complications||Massachusetts General Hospital|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|100 Years|No|||February 2016|February 3, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02671721||3741|
NCT02513121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4405|Dietary Treatment Study of Pediatric NAFLD|Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD|DTS|University of California, San Diego|No|Recruiting|July 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|11 Years|16 Years|No|||July 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513121||15915|
NCT02513589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2014/17|Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke|Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke|PLAQINSTEP|University Hospital, Bordeaux|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|18 Years|N/A|No|||July 2015|July 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02513589||15879|
NCT02516748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1505-019-670|Real-time Diagnosis of Colorectal Polyps Using Narrow-Band Imaging|Prospective Study of Real-time Diagnosis of Colorectal Polyps Using Narrow-Band Imaging: Gangnam-ReaDi Study||Seoul National University Hospital|Yes|Not yet recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Customers who received colonoscopy in Seoul National University Hospital Healthcare System        Gangnam Center from August 2015 to August 2016.|August 2015|August 3, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02516748||15639|
NCT02514889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCORI-1306-01150|Is MyPlate Approach to Helping Overweight Patients Lose Weight More Patient-centered?|Is MyPlate.Gov Approach to Helping Overweight Patients Lose Weight More Patient-centered?||University of California, Los Angeles|No|Recruiting|July 2015|April 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02514889||15781|
NCT02668354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer in Infants SECI|Cancer in Infants: South Egypt Cancer Institute Experience|Cancer in Infants: South Egypt Cancer Institute Experience||Assiut University|No|Not yet recruiting|October 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|1 Year|No|Non-Probability Sample|Infants, those diagnosed with any of malignant neoplasms, in the period from 2001 January        till 2015 December, and received treatment at the pediatric oncology department, their        medical records will be retrospectively reviewed for data collection.|March 2016|March 8, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02668354||3997|
NCT02526849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-FMT-STC-2015|Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation|A Randomized Controlled Study of Efficacy, Safety and Durability of Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation||Jinling Hospital, China|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|February 3, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02526849||14862|
NCT02526862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPPVMNI_200910|Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation|Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial|PUPPVMNI|B. Braun Medical SA|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|152|||Both|18 Years|N/A|No|||August 2015|August 15, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02526862||14861|
NCT02521831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00125|Neuroinflammatory and Neurocognitive Effects of Spinal vs. Inhalational Anesthesia for Elective Surgery in Infants|Neuroinflammatory and Neurocognitive Effects of Spinal vs. Inhalational Anesthesia for Elective Surgery in Infants: A Randomized, Controlled, Double-Blinded Study||Nationwide Children's Hospital|No|Enrolling by invitation|October 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|1 Year|No|||September 2015|September 24, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521831||15248|
NCT02512965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC24|Feasibility Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative RT in Spinal Metastases|A Phase II Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases||Canadian Cancer Trials Group|Yes|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|March 16, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512965||15927|
NCT02520375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58074|Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy|Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy||Universitaire Ziekenhuizen Leuven||Not yet recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|36 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 10, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02520375||15360|
NCT02670447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508174|Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies|Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies: A Multicentric Study|PEPsy|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|June 2016|November 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Blood samples will be taken for every patient to make toxicological tests.|Both|18 Years|35 Years|No|Probability Sample|Patients suffering of schizophrenia will be included in this study. They do not have ever        taken anti-psychotic treatment.|January 2016|January 29, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02670447||3839|
NCT02527434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4884C00001|Study of Tremelimumab in Patients With Advanced Solid Tumors|A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors||AstraZeneca|No|Recruiting|November 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02527434||14817|
NCT02513199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1671|Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma|Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|17|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513199||15909|
NCT02516540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBRE-2-20150626|Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers|Prospective Randomized Multicenter Trial to Assess the Efficacy of a Structured Physical Exercise Training and Mediterranean Diet in Women With BRCA1/2 Mutations|LIBRE-2|Technische Universität München|No|Recruiting|March 2015|October 2021|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|N/A|No|||November 2015|November 8, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02516540||15655|
NCT02670694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26535|Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW|Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi|RDCRN|Baylor College of Medicine|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|804|||Both|1 Year|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|This research study will investigate sleep behavior in the rare neurological disorders        Angelman Syndrome (AS), Rett Syndrome (RTT) and Prader-Willi Syndrome (PWS).|January 2016|February 1, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02670694||3820|
NCT02519517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acute permissive hypercapnia|Permissive Hypercapnia During One Lung Ventilation: Impact on Right Ventricular Systolic and Diastolic Functions During Lung Resection|Acute Permissive Hypercapnia During One Lung Ventilation: Impact on Right Ventricular Systolic and Diastolic Functions During Lung Resection||Cairo University|No|Completed|November 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|15|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|June 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02519517||15426|
NCT02527018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1232|A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study|A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study||University of California, Irvine|Yes|Recruiting|November 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|66|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|August 17, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02527018||14849|
NCT02527031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HParis|A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (ACPAR2)|A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest|ACPAR2|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|September 2015|March 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|65 Years|No|||August 2015|August 24, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02527031||14848|
NCT02513498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9292|Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease|Ixazomib for Treatment of Chronic Graft vs. Host Disease||Fred Hutchinson Cancer Research Center||Recruiting|December 2015|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02513498||15886|
NCT02520817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasser hamed ahmed Mousa|Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study|Professor of Tropical Medicine||Mansoura University||Completed|January 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|58|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients (truck drivers) with liver cirrhosis were screened for MHE. The        patients attended the Tropical and Neurology Outpatient clinics in Mansoura university        Hospital, Mansoura|August 2015|August 9, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02520817||15326|
NCT02519777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5324|Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)|A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|March 2016|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519777||15406|
NCT02527148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShapeNZRCT-10|A Trial of Mechanical Axis vs Kinematic Alignment in Total Knee Replacement|A Prospective, Randomized, Controlled Trial of Mechanical Axis vs Kinematic Alignment in TKR - With a Follow-up, Longitudinal Study of the Clinical and Radiographic Outcomes||Stryker South Pacific|No|Active, not recruiting|August 2011|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|80 Years|No|||September 2015|December 7, 2015|August 3, 2015|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT02527148||14839|
NCT02524756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNS-RH|Feasibility and Functional Outcome of Laparoscopic Nerve Sparing Radical Hysterectomy|Feasibility and Functional Outcome of Laparoscopic Nerve Sparing Radical Hysterectomy||Mansoura University|Yes|Enrolling by invitation|October 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||August 2015|August 13, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02524756||15023|
NCT02518698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18273|Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population|Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases||Bayer|No|Active, not recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1163|||Male|65 Years|88 Years|No|Non-Probability Sample|Castrated resistant prostate cancer patients with bone metastases|March 2016|March 10, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02518698||15489|
NCT02527213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1STS12001|Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate (STS) for the Treatment Pain With Calcific Uremic Arteriolopathy a Single Armed Extension Phase Prospectively Observe Lesion Progression in the Presence of STS|A Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy Followed by a Single Armed Extension Phase to Prospectively Observe Lesion Progression in the Presence of Sodium Thiosulfate Treatment||Luitpold Pharmaceuticals|No|Terminated|January 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 17, 2015|Yes|Yes|Company decision|No||https://clinicaltrials.gov/show/NCT02527213||14834|
NCT02513849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15021|Tamoxifen in Patients With Oesophageal Cancer|A Pilot Study of Tamoxifen in Oesophageal Cancer||University of Nottingham|No|Not yet recruiting|August 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|95 Years|No|||July 2015|July 30, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02513849||15860|
NCT02512354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THEVENON PHRC I 2014|Contribution of High-throughput Exome Sequencing in the Diagnosis of the Cause Fetal Polymalformation Syndromes|Contribution of High-throughput Exome Sequencing in Fetopathology|FOETEX|Centre Hospitalier Universitaire Dijon|No|Recruiting|March 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|N/A|2||Anticipated|100|||Both|N/A|N/A||||February 2015|July 29, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512354||15974|
NCT02516813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100036-002|Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy|An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors||EMD Serono|Yes|Recruiting|September 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516813||15634|
NCT02517073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2015-008|Practice of Mechanical Ventilation in Patients With Severe Brain Injury in China|A Survey on the Practice of Mechanical Ventilation Among Patients With Severe Brain Injury in China: a Prospective Observational Study||Capital Medical University|Yes|Completed|August 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanical ventilated patients with severe brain injury|January 2016|January 26, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02517073||15614|
NCT02511717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106903|A Trial of Transcutaneous Nerve Stimulation for OAB|A Randomized Trial of Transcutaneous Nerve Stimulation for Overactive Bladder Patients||Lawson Health Research Institute|No|Enrolling by invitation|January 2016|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511717||16023|
NCT02511730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2013-004E|Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer||Fujifilm Medical Systems USA, Inc.|No|Completed|June 2015|August 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|July 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511730||16022|
NCT02518750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSALV|Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma|A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma||St. Jude Children's Research Hospital|No|Recruiting|December 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|21 Years|No|||February 2016|February 23, 2016|July 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518750||15485|
NCT02525237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-G316|Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer|Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma||Qingdao Municipal Hospital||Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02525237||14986|
NCT02525276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008066|Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause|Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause||Rigshospitalet, Denmark|No|Not yet recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Female|18 Years|55 Years|No|||August 2015|August 14, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02525276||14983|
NCT02517307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU11258|Fatty Acid Oxidation Defects and Insulin Sensitivity|Role of Fatty Acid Oxidation Defects in Insulin Sensitivity||Oregon Health and Science University|No|Recruiting|February 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02517307||15596|
NCT02662166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6/1801/2014|MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer|Magnetic Resonance Imaging of Bladder Cancer|MIB|Turku University Hospital|No|Recruiting|July 2014|||July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|85 Years|No|||January 2016|January 19, 2016|January 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02662166||4472|
NCT02526693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-400E|Is the RAPDx Pupillograph Able to Distinguish Between Glaucoma Subjects and Healthy Subjects?|RAPDx Pupillography for Early Detection of Glaucoma||Wills Eye|No|Completed|June 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02526693||14874|
NCT02526706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-494|Using a Type of Blue Dye to Observe Bleb Function During Cataract Surgery|VisionBlue for the Assessment of Filtering Bleb Functioning During Cataract Surgery||Wills Eye|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|21 Years|N/A|No|||January 2016|January 12, 2016|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02526706||14873|
NCT02513173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWU17581|Effects of Different Verbal Instructions in Healthy Adults and Patients With Low Back Pain|Effects of Different Verbal Instructions on Lumbar Multifidus Muscle Activation in Healthy and Patients With Low Back Pain||Texas Woman's University|No|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible participants are English-speaking adults 18 years of age or older, with or        without low back pain.|July 2015|July 30, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02513173||15911|
NCT02512406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400293|Sensory Processing in Tourette Syndrome|Sensory Processing in Tourette Syndrome||University of Florida|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|35|||Both|6 Years|18 Years|No|Non-Probability Sample|Targeted study population includes patients 6-18 diagnosed with Tourette Syndrome who are        a patient of University of Florida Movement Disorders Center.|January 2016|January 21, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512406||15970|
NCT02519413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS419|Tecfidera Lymphocyte Chart Review|A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)|REALIZE|Biogen|No|Recruiting|July 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in patients with relapsing forms of multiple sclerosis (MS)        who initiated Tecfidera treatment for the first time (treatment naïve) under routine        clinical care. For inclusion in the study, patients' charts must have a baseline        measurement for absolute lymphocyte count (ALC) and absolute CD4+ or CD8+ count within 6        months prior to Tecfidera initiation, and at least 1 measurement for ALC and absolute CD4+        or CD8+ count while on Tecfidera treatment for at least 6 months. For patients who        discontinue Tecfidera, data will be collected for up to 6 months following Tecfidera        discontinuation.|August 2015|August 7, 2015|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02519413||15434|
NCT02716753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dno 2015/387-31|Effects of Seminal Plasma on Pregnancy Rate With IVF|The Effects of Male Factors on the Success Rate of in Vitro Fertilization. Will Deposition of Seminal Plasma Around the External Cervical os Increase Pregnancy Rate?|SENAVA|Ostergotland County Council, Sweden|No|Not yet recruiting|August 2016|March 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|350|||Both|20 Years|40 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716753||285|
NCT02645708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRER(54)2015|External Physical Vibration Lithecbole(EPVL) Versus Traditional Row of Stone After Retrograde Intrarenal Surgery(RIRS)|External Physical Vibration Lithecbole(EPVL) Contrast With the Traditional Row of Stone Effect After Retrograde Intrarenal Surgery(RIRS): A Multi-center Prospective Randomized Controlled Trial||The First Affiliated Hospital of Guangzhou Medical University|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||August 2015|January 1, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02645708||5736|
NCT02646033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RajivGCIRC|Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position|Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position||Rajiv Gandhi Cancer Institute & Research Center, India|No|Recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|60 Years|No|Non-Probability Sample|Patients undergoing robotic surgeries in steep trendelenburg position|January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646033||5711|
NCT02648061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1807|Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest|Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest||Norwegian University of Science and Technology|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients who are admitted to either the Intensive Care Unit (ICU) or the        Coronary Care Unit (CCU) at St. Olav's University Hospital, Trondheim, Norway, after        out-of-hospital cardiac arrest will be considered for inclusion.(catchment population of        700,000)|January 2016|January 4, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02648061||5555|
NCT02660164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMC-1501|A Study to Assess the Effectiveness of the Nautilus BrainPulse™ as an Aid in the Diagnosis of Concussion|A Study to Assess the Effectiveness of the Nautilus BrainPulse™ as an Aid in the Diagnosis of Concussion||Jan Medical, Inc.|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|700|||Both|10 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort A: High-Risk of Concussion Middle school, high school and college athletes of        either gender participating in sports where high-risk of concussion is anticipated:        football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby,        cheerleading, boxing, and gymnastics.        Cohort B: Low-Risk of Concussion Middle school, high school and college athletes of either        gender participating in sports where low-risk of concussion is anticipated: swimming,        track, volleyball, baseball, softball and golf.|January 2016|January 18, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660164||4626|
NCT02647372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2012/12|Deep Brain Stimulation for Parkinson's Disease: the Globus Pallidus Internus Versus Subthalamic Nucleus|Deep Brain Stimulation for the Treatment of Parkinson's Disease: Comparative Analysis of Clinical Effect of Stimulation of the Globus Pallidus Internus and Subthalamic Nucleus||Hospital Sirio-Libanes|Yes|Active, not recruiting|June 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02647372||5608|
NCT02652624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-380-1961|Safety and Efficacy of Switching to a FDC of GS-9883/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women|A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women||Gilead Sciences|Yes|Recruiting|February 2016|June 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652624||5204|
NCT02652923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15P.487|Contrast Ultrasound Detection of Sentinel Lymph Nodes|Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients||Thomas Jefferson University|Yes|Enrolling by invitation|January 2016|January 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|112|||Female|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652923||5181|
NCT02660697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSD-Semmelweis-Perio|3D Radiographic Evaluation of a Novel Implant Site Development Technique|3D Radiographic Evaluation of Post-extraction Healing Following Treatment With a Novel Implant Site Development Technique||Semmelweis University|No|Completed|December 2007|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660697||4585|
NCT02653456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMS-102|Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease|A Prospective, Multi Center Pilot Study Evaluating Plaque Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Infrainguinal Lower Extremity Vascular Disease||Ra Medical Systems|No|Not yet recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653456||5141|
NCT02653469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2015-06-015|Augmented Pulse Pressure Variation to Predict Fluid Responsiveness in Open Laparotomy|Pulse Pressure Variation With Augmented Ventilation to Predict Fluid Responsiveness in the Patients Undergoing Open Laparotomy Surgery||Samsung Medical Center|No|Completed|September 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|20 Years|80 Years|No|Probability Sample|Adult patients undergoing elective open laparotomy surgery.|March 2016|March 2, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02653469||5140|
NCT02645110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602-15-HMO|Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations|Openly, Controlled Interventional Trial for Evaluating the Effectiveness of Whole-natural Hand-wash Formulations in Bacterial Removal and Openly Randomized Trial for Estimating the Relative Mildness of the Formulations||Mother's Choice Ltd|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02645110||5782|
NCT02716259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/120-E_BS|Periodontal and Cardiovascular Diseases Project|Impact of Basic Periodontal Therapy in the Levels of Porphyromonas Gingivalis and Aggregatibacter Actinomycetemcomitans Subgingival and Its Association With Vascular Function||Complutense University|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716259||323|
NCT02654028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT/HCC|Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection|Association Between Autologous Transfusion and Tumor Recurrence Among Patients With Hepatocellular Carcinoma After Resection|AT/HCC|Guangxi Medical University|Yes|Recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02654028||5098|
NCT02654041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MusliGBM002|Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients|Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients||Musli Thyropeutics Ltd.|No|Not yet recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654041||5097|
NCT02652494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-014|Observational Study of Apremilast in Patients With Psoriasis in The Netherlands|Observational Study of Apremilast Use and Effectiveness Over a One Year Treatment Period in Patients With Psoriasis in The Netherlands|APRIL|Celgene|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Two hundred adult patients treated with apremilast for psoriasis in clinical practice. In        all cases, the decision to treat the patient with apremilast will be made prior to the        decision to enter the subject into the study.|January 2016|January 8, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02652494||5214|
NCT02652026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBarcelona|Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients|Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients||University of Barcelona|No|Completed|June 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02652026||5250|
NCT02719496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0396|Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease|Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease|PHYTOPARK|Nantes University Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|30 Years|80 Years|No|||March 2016|March 21, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02719496||74|
NCT02650011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-KACLiF|Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease|The Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease: Multicenter, Prospective Cohort Study||Chuncheon Sacred Heart Hospital|No|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1520|||Both|19 Years|N/A|No|Non-Probability Sample|Patients who have chronic liver disease and admitted for acute deterioration of liver        function (ACLF)|January 2016|January 7, 2016|July 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02650011||5405|
NCT02659345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Z15|Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients|Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients Undergoing Chemotherapy Treatment||Case Comprehensive Cancer Center|Yes|Recruiting|May 2015|January 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659345||4689|
NCT02648373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00072901|Patient Education for Patients With Back Pain Referred to Physical Therapy|Effect of a Patient Education Intervention for Patients With Low Back Pain Referred to Physical Therapy||University of Utah|No|Completed|October 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02648373||5531|
NCT02648620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUR15-001|Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon|A Prospective, Multi-Center, Single-Arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects With De Novo Lesions of the Femoropopliteal Artery|PREVEIL|SurModics, Inc.|No|Not yet recruiting|February 2016|May 2019|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02648620||5512|
NCT02717013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2016-CS01|The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism|The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism||Metabolic Technologies Inc.|No|Recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02717013||265|
NCT02654392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10010467|Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance|Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance||University of Western Ontario, Canada|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|18|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02654392||5070|
NCT02654457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-Ki-67-IHC|Identification and Semi-Quantification of Ki-67 Protein Expression Status|Identification and Semi-Quantification of Ki-67 Protein Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Breast Tissue||Applied Spectral Imaging Ltd.|No|Completed|December 2013|January 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|3|||Female|21 Years|89 Years|No|Probability Sample|Women having breast cancer aged 21 and up|January 2016|January 12, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02654457||5065|
NCT02653092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1052|Reprometabolic Syndrome Mediates Subfertility in Obesity|Reprometabolic Syndrome Mediates Subfertility in Obesity||University of Colorado, Denver|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02653092||5169|
NCT02661087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Monobisy|Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility|MONOBISY: Randomized Controlled Trial Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility||Brugmann University Hospital|No|Active, not recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|118|||Female|18 Years|42 Years|No|||March 2016|March 8, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661087||4555|
NCT02661100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Y16|A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients|A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients||Case Comprehensive Cancer Center|Yes|Not yet recruiting|July 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661100||4554|
NCT02713243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJN452X2202|To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.|A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).||Novartis|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713243||555|
NCT02713256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFZ533X2205|A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease|An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease||Novartis|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713256||554|
NCT02659605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0633|Cord Clamping Level Above or Below Mother's Perineum|Cord Clamping Level Above or Below Mother's Perineum|CLAMP|The University of Texas Health Science Center, Houston|No|Not yet recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659605||4669|
NCT02658318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201525560|Postoperative Complications After Cleft Palate Closure in Patients With Pierre Robin Sequence: Operative Considerations|||AZ Sint-Jan AV|No|Completed|January 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|92|||Both|N/A|N/A|No|Non-Probability Sample|All cleft patients consecutively treated with a modified Furlow palatoplasty between        01/01/2011 and 31/08/2015 in the Department of Oral and Maxillofacial Surgery of the        General Hospital Saint-John Bruges (Bruges, Belgium) or the Department of Pediatrics of        the Semmelweis University (Budapest, Hungary)|January 2016|January 15, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02658318||4768|
NCT02658331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EbolaFire|Evaluation of the FilmArray BioThreat-E Test|Clinical Evaluation of the BioFire FilmArray® BioThreat-E Test for the Diagnosis of Ebola Virus Disease in West Africa||BioMérieux|No|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|156|Samples With DNA|Whole blood Urine Saliva|Both|18 Years|N/A|No|Probability Sample|All patients, male and female, older than 18, sent to Conakry or Coyah Ebola Treatment        Centers for a suspicion of Ebola Virus Disease according to WHO criteria, and considered        as eligible for Ebola routine diagnosis.|January 2016|January 14, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02658331||4767|
NCT02713776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_880|Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment|Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study|SOMILEO|Hospices Civils de Lyon||Not yet recruiting|April 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|March 15, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02713776||514|
NCT02713789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ION04-ED|Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED|A Double-blind, Placebo-controlled, Parallel Design, Randomized, Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene Transfer in Males With Erectile Dysfunction||Ion Channel Innovations|No|Recruiting|April 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|35|||Male|18 Years|80 Years|No|||March 2016|March 15, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713789||513|
NCT02651909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15050224|Utilization of TEG to Monitor Rivaroxaban Activity|Utilization of Thromboelastography to Monitor Rivaroxaban Activity in Trauma and Emergency Surgery Patients||University of Pittsburgh|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients that have taken the drug Rivaroxaban with-in the past 48hours that arrive in the        ED with traumatic injury or with illness requiring emergent surgery|January 2016|January 8, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02651909||5259|
NCT02649582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG14-001|Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients|Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma|ADDIT-GLIO|University Hospital, Antwerp|No|Recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02649582||5438|
NCT02658409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC3106_AD_P3|A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)||Green Cross Corporation|Yes|Active, not recruiting|November 2015|||November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1630|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 25, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02658409||4761|
NCT02658422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201681|Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions|An Open-label Balanced, Randomised, Single Dose, Two-way Crossover Study to Determine the Bioequivalence of GW483100 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) Relative to Reference Montelukast Sodium 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) in Healthy Male and Female Volunteers Under Fasting Conditions||GlaxoSmithKline|No|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02658422||4760|
NCT02658513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14OncN0013|Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer|Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer||Royal Surrey County Hospital NHS Foundation Trust|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with thyroid cancer receiving radioiodine therapy after total thyroidectomy|January 2016|January 14, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02658513||4753|
NCT02651285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH2016/01|Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF|G-CSF Supplemented Medium for IVF Embryo Culture in Patients Undergoing IVF||Centre for Endocrinology and Reproductive Medicine, Italy|Yes|Recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Female|20 Years|38 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651285||5307|
NCT02651298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-section|CO2-laser Treatment for Caesarean Section Scars|Fractional CO2-laser Treatment of Caesarean Section Scars - A Randomized Controlled Split-scar Trial With Long Term Follow-up Assessment||Bispebjerg Hospital|Yes|Completed|January 2014|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Female|22 Years|55 Years|No|||January 2016|January 7, 2016|January 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651298||5306|
NCT02660892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02691|Determination of Threonine Requirements and the Metabolic Availability of Threonine From Food Sources in Healthy School-aged Children|Determination of Threonine Requirements and the Metabolic Availability of Threonine From Food Sources in Healthy School-aged Children||University of British Columbia|No|Not yet recruiting|February 2016|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|6|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660892||4570|
NCT02660671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822504|Behavioral Economic Approaches to Increase Colorectal Cancer Screening|Behavioral Economic Approaches to Increase Colorectal Cancer Screening||University of Pennsylvania|No|Not yet recruiting|January 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|2250|||Both|50 Years|64 Years|No|||January 2016|January 20, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02660671||4587|
NCT02660736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201287|Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects|A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects||GlaxoSmithKline|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02660736||4582|
NCT02712463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107059|A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics|A Retrospective, Observational Study to Assess the Rate of Hospitalization in Patients With Schizophrenia Treated One Year Before With Oral Antipsychotics and One Year After With Long Acting Injectable Atypical Antipsychotics - REALAI Study|REALAI|Janssen-Cilag Ltd.|No|Recruiting|July 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Time Perspective: Retrospective||1|Anticipated|312|||Both|18 Years|55 Years|No|Non-Probability Sample|Participants (both gender and 18 to 55 years of age) with schizophrenia treated with oral        anti-psychotics then switched to long acting Injectable anti-psychotics.|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02712463||615|
NCT02653768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-091|STepped Exercise Program for Knee OsteoArthritis|STepped Exercise Program for Knee OsteoArthritis (STEP-KOA)|STEP-KOA|VA Office of Research and Development|No|Not yet recruiting|April 2016|March 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|345|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653768||5118|
NCT02655952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-3164|Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients|Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer||WntResearch AB|No|Not yet recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02655952||4950|
NCT02661243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL47808.029.14|Implantology and Sjögren's Syndrome|Implantology and Sjögren's Syndrome: a Multicenter Prospective Cohort Study||VU University Medical Center|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661243||4543|
NCT02712216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0298|Evaluation of Abdominal Wall Thickness at Possible Trocar Sites Based on Body Mass Index|Evaluation of Abdominal Wall Thickness at Possible Trocar Sites Based on Body Mass Index||University of Mississippi Medical Center|No|Recruiting|February 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712216||634|
NCT02712437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.168|Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer|Prospective Study Evaluating the Use of PROSPECT, a Cognitive Behavioral Therapy-based Internet Module, to Reduce Insomnia in Patients With Early Stage Breast Cancer||University of Michigan Cancer Center|Yes|Recruiting|March 2016|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02712437||617|
NCT02649192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVIT|FluMist® Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children|A Double-Blind, Randomized, Placebo-Controlled Study of IgA Induction by Vitamin Supplementation at the Time of FluMist® Vaccinations in Children||St. Jude Children's Research Hospital|No|Recruiting|January 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649192||5468|
NCT02653079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMO-LDRT01|Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving LDRT|Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving Local Low Dose Radiation Therapy (LDRT)|IMMO-LDRT01|University of Erlangen-Nürnberg Medical School|No|Not yet recruiting|February 2016|February 2022|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Serum, Plasma, Blood cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from chronic inflammatory diseases of the joints, namely painful        shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome        (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia.        Patients were attributed to our clinic and the study protocol was explained in detail. The        patients have to give their informed consent before starting with the LDRT. The        treatment-plan of the underlying disease remained unchanged. This treatment scheme is        conducted with 2 irradiations within 7 days for total treatment duration of 3 weeks. The        single dose is 0.5 Gy and the complete dose of one round of LDRT is 3 Gy.|January 2016|January 8, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653079||5170|
NCT02658487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HEM 1553|Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia|Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML|VITAL|Vanderbilt-Ingram Cancer Center|Yes|Recruiting|March 2016|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658487||4755|
NCT02712957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO6860-OA-01|A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain|A Proof-of-Concept, Randomized, Double Blind, Placebo and Active Control, 3-Period, Crossover Design Study Assessing NEO6860 in Patients With Pain Associated With Osteoarthritis of the Knee||Neomed Institute|No|Recruiting|March 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|40 Years|80 Years|No|||March 2016|March 24, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712957||577|
NCT02656888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS0615|Comparison of EMS Association to Transpulmin®, Alivium® and Claritin® to Treat Flu Symptoms|Phase III, National, Multicenter, Randomized, Open Trial, to Assess the EMS Association Superiority Compared to Transpulmin®, Alivium® and Claritin® to Treat Flu Symptoms||EMS|Yes|Not yet recruiting|July 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|2 Years|12 Years|No|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656888||4878|
NCT02646098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAAL-trial|CD34+ Selected ASCT for Aggressive Lymphomas|CD34+ Selected Versus Unselected Autologous Stem Cell Transplantation in Advanced Stage Mantle Cell and Diffuse Large B-cell Lymphoma Patients, a Randomized Phase II Study|SAAL|University Hospital Inselspital, Berne|No|Recruiting|November 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02646098||5706|
NCT02646397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZKI-CKD-001|Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension|Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial|BEAHIT|Shanghai Changzheng Hospital|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|508|||Both|18 Years|80 Years|No|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02646397||5683|
NCT02649114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/836-1|Eating Disorders With and Without Childhood Trauma|Treatment of Eating Disorders With and Without Childhood Trauma: A Randomized Controlled Trial||Modum Bad|No|Recruiting|August 2015|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02649114||5474|
NCT02649361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-11-II|Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||January 2016|January 6, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02649361||5455|
NCT02712710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140714R|Does Addition of a Functional Knee Brace Improve Rehabilitation Outcome in Subjects With Osteoarthritis of the Knee?|Does Addition of a Functional Knee Brace Improve Rehabilitation Outcome in Subjects With Osteoarthritis of the Knee?||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|October 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||March 2016|March 17, 2016|November 24, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712710||596|
NCT02654509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-14-06|Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus|Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus||U.S. Army Medical Research and Materiel Command|No|Not yet recruiting|March 2016|February 2022|Anticipated|February 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654509||5061|
NCT02656992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 13/292|Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis|Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis||Hacettepe University|No|Recruiting|September 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02656992||4870|
NCT02650596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301nlxnk|Effects of GLP-1 on Chronic Heart Failure|Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes||Chinese PLA General Hospital|Yes|Recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02650596||5360|
NCT02649374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0263-15-RMC|Gut Microbiome and Gestational Diabetes Mellitus|Gut Microbiome and Gestational Diabetes Mellitus||Rabin Medical Center|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|400|||Female|18 Years|45 Years|No|||January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02649374||5454|
NCT02649621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Eye-002|The Improvement of Limbal Stem Cell Deficiency (LSCD) in Unilateral Stem Cell Damage by Amniotic Membrane Extract Eye Drop (AMEED)|The Effect of in Vivo Cultured Limbal Stem Cells in the Treatment of Unilateral Corneal Stem Cell Damage||Royan Institute|Yes|Completed|August 2011|August 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|No|||January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649621||5435|
NCT02649634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFREB#5297|Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?|Adding Motivational Interviewing to a Behavioral Weight Loss Treatment for Obesity: A Randomized Controlled Trial|BWLP+MI|University of Calgary|No|Completed|September 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649634||5434|
NCT02715791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0744|TAPESTRY With Health Connnectors for Diabetes Management|Teams Advancing Patient Experience: Strengthening Quality for People Through Health Connectors for Diabetes Management (TAPESTRY-HC-DM): A Feasibility RCT|TAP-HC-DM|McMaster University|No|Recruiting|February 2016|November 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02715791||359|
NCT02648984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S56272|Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With Closed Ventricular Septal Defect|Ad Hoc Analysis for the Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With a Closed Ventricular Septal Defect||Universitaire Ziekenhuizen Leuven||Recruiting|September 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02648984||5484|
NCT02648997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-490|A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma|A Single Arm, Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma||Dana-Farber Cancer Institute|Yes|Recruiting|March 2016|July 2023|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648997||5483|
NCT02649010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP309|A Performance Evaluation of the Enlite 3 Sensor|A Performance Evaluation of the Enlite 3 Sensor||Medtronic Diabetes|No|Not yet recruiting|January 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|75 Years|No|||January 2016|January 5, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649010||5482|
NCT02651714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VLY-686-2102|Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis||Vanda Pharmaceuticals|No|Recruiting|January 2016|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651714||5274|
NCT02714569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16417|A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328||Eli Lilly and Company|No|Recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|58|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714569||453|
NCT02714582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA/RP/2015/086/EC|Feasibility, Appropriateness, Meaningfulness and Effectiveness of Bedside Shift Reporting|Patient Participation at the Bedside: Feasibility, Appropriateness, Meaningfulness and Effectiveness of Bedside Shift Reporting. A Matched Controlled Trial||University Hospital, Ghent|No|Not yet recruiting|March 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02714582||452|
NCT02714595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1424R2131|Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens|A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens||Shionogi Inc.|No|Not yet recruiting|March 2016|May 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714595||451|
NCT02647723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0392|Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation|Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation: A Randomized Controlled Study in African American Women Living in Low-income Urban Environments|NAPS|University of Chicago|Yes|Recruiting|January 2016|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|162|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647723||5581|
NCT02646969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.13.INF|Growth and Metabolic Biomarkers of Healthy Term Infants Fed Formulas With Staged Protein Concentrations Over the First Year of Life|Growth and Metabolic Biomarkers of Healthy Term Infants Fed Formulas With Staged Protein Concentrations Over the First Year of Life||Nestlé|Yes|Recruiting|October 2015|June 2022|Anticipated|June 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|690|||Both|N/A|7 Days|Accepts Healthy Volunteers|||October 2015|January 4, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02646969||5639|
NCT02647242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 9193-4|Proof of Concept BeatPark|Pilot Study on Feasibility and Safety of a Gait Auto-rehabilitation Program by Rhythmic Auditory Cueing Delivered by BeatHealth in Patients With Parkinson's Disease.|BEAT PARK 2|University Hospital, Montpellier|No|Not yet recruiting|February 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02647242||5618|
NCT02658929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRB-401|Study of bb2121 in Multiple Myeloma|A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma||bluebird bio|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658929||4721|
NCT02716311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1503|Study Evaluating the Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer|Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer|ACE|Intergroupe Francophone de Cancerologie Thoracique|No|Not yet recruiting|April 2016|January 2020|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02716311||319|
NCT02656810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF708-101|A Comparison Study of PF708 and Forteo in Healthy Subjects|A Double-Masked, Randomized, Two-Treatment Cross-over Study Comparing the Pharmacokinetics of PF708 and Forteo Administered by Subcutaneous Injection in Healthy Adult Subjects||Pfenex, Inc|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656810||4884|
NCT02645214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062781|Antiseptic Scrub Contamination and Transmission Trial|Antiseptic Scrub Contamination and Transmission Trial: A Randomized Controlled Trial to Evaluate the Impact of Antiseptic Scrubs on Bacterial Contamination.|ASCOT|Duke University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645214||5774|
NCT02657551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-350|A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer|A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|January 2016|October 2022|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657551||4827|
NCT02657811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0169-15-SZMC|Time-Lapse Incubation for Embryo Culture - Morphokinetics and Environmental Stability|Time-Lapse Incubation for Embryo Culture - The Impact of Morphokinetics and Environmental Stability on Reproductive Outcomes||Shaare Zedek Medical Center|Yes|Not yet recruiting|January 2016|August 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|372|||Female|18 Years|39 Years|No|||January 2016|January 13, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02657811||4807|
NCT02715778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001326|Translational Investigation of Gestational Environment on Neurobehavioral Function in Children|Translational Investigation of Gestational Environment on Neurobehavioral Function in Children||Massachusetts General Hospital|No|Enrolling by invitation|February 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|6 Years|N/A|No|Non-Probability Sample|This study will be composed of two components: a maternal assessment based at        Massachusetts General Hospital (MGH) and a child evaluation based at Boston Children's        Hospital. Mother and child pairs may elect to complete both components of the study. If        either participant does not want the child to take part in the research, the maternal        component may be completed alone. Similarly, the child may enroll in the research study        without the enrollment of the mother with parental consent.        Women who are interested and eligible for the study may choose to complete the study        in-person at MGH or to be evaluated remotely by a phone interview and set of online        surveys. All child subjects must participate in an in-person visit at Boston Children's        Hospital.|March 2016|March 22, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02715778||360|
NCT02650024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-US-337-1786|Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes|Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes||University of California, San Diego|Yes|Not yet recruiting|January 2016|July 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650024||5404|
NCT02647801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-JGU-psychEK-011|Investigating Self-control and Mindfulness With Ambulatory Assessed Network Systems in Health-related Domains|The SMASH Study: Investigating Self-control and Mindfulness With Ambulatory Assessed Network System in Health-related Domains|SMASH|Johannes Gutenberg University Mainz|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02647801||5575|
NCT02657863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J14106|Cancer DNA in Blood and Urine|Non-invasive Detection of Cancer DNA in Blood and Urine||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2014|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|Urine and Blood|Male|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and men with prostate cancer|January 2016|January 13, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657863||4803|
NCT02653742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3943|Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children|Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children||Albany Medical College|No|Recruiting|May 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|8 Months|7 Years|No|||January 2016|January 10, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653742||5120|
NCT02656407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-66|Intraoperative Functional Ultrasound|Doppler Ultrasonore Ultrasensible Peropératoire du Cerveau - Vers Une Aide Temps Reel à la Cartographie Corticale Fonctionnelle|FUSIMAGINE|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02656407||4915|
NCT02650297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAUKazeroun|The Effect of Combined Decongestive Therapy and Pneumatic Compression Pump on Body Image in Patients With Lymphedema|The Effect of Combined Decongestive Therapy and Pneumatic Compression Pump on Body Image in Patients With Lymphedema Secondary to Breast Cancer Treatment||Islamic Azad University, Kazeroun|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Female|35 Years|70 Years|No|||January 2016|January 7, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650297||5383|
NCT02652819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-808|FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis||FibroGen|Yes|Recruiting|December 2015|April 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||January 2016|January 8, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02652819||5189|
NCT02653105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-A-2014-05|Women at Risk of Breast Cancer and OLFM4|Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging||Institut Cancerologie de l'Ouest|No|Not yet recruiting|February 2016|February 2026|Anticipated|February 2026|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|300|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653105||5168|
NCT02646540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080051|AiDing Diuresis wIth Tolvaptan (ADD-IT)|AiDing Diuresis wIth Tolvaptan (ADD-IT)|ADD-IT|Emory University|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646540||5672|
NCT02646787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50416 EB|Virtual Reality Water Friendly Wound Care|Water Friendly Virtual Reality for Burns|H2OWC|University of Washington|No|Recruiting|October 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|200|||Both|8 Years|N/A|No|||December 2015|January 4, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02646787||5653|
NCT02651818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20132|Changes in Quality of Life Following Surgical Treatment of Benign Non-toxic Goiter|The Impact of Surgical Treatment of Benign Non-toxic Goiter on Quality of Life|SOLOIST|University of Southern Denmark|No|Recruiting|October 2014|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|104|||Both|20 Years|80 Years|No|Non-Probability Sample|All patients undergoing hemi- or total thyroidectomy at Odense University Hospital for        benign symptomatic non-toxic goiter|January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651818||5266|
NCT02652091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17942|Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction|Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction||Bayer|No|Recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|144|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated        syndrome (CIS)|February 2016|February 29, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02652091||5245|
NCT02660606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 2A (Qual)|A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire|A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|POMAQ|Member Companies of the Opioid PMR Consortium||Completed||||November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|54|||Both|18 Years|N/A||Non-Probability Sample|Patients with chronic pain recruited from primary care or chronic pain clinics|January 2016|January 18, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660606||4592|
NCT02644824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000032246|Biventricular Pacing in Children With Congenital Heart Disease|Biventricular Pacing in Children With Wide QRS After Surgery for Congenital Heart Disease||The Hospital for Sick Children|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|72|||Both|N/A|1 Year|No|||January 2016|January 4, 2016|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02644824||5804|
NCT02660918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35179|Decreasing Postoperative Pain Following Endometrial Ablation|Decreasing Postoperative Pain Following Endometrial Ablation: A Randomized Controlled Trial||Christiana Care Health Services|No|Not yet recruiting|February 2016|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|134|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02660918||4568|
NCT02660957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A&E|Smoking Cessation Among People Attending A&E|Effectiveness of a Brief, Self-determination Intervention for Smoking Cessation (Immediate or Progressive) Among People Attending Emergency Departments: a Randomised Controlled Trial||The University of Hong Kong|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1566|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660957||4565|
NCT02652039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STMP - 03|Interactionality of Music Preference and Individual Variables in Pain Perception and Management|Interactionality of State-Trait Music Preference, Individual Variability, and Music Characteristics as a Multi-Axis Paradigm for Context-Specific Pain Perception and Management||University of Iowa|Yes|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|35|||Both|40 Years|70 Years|No|Non-Probability Sample|Cancer patients|January 2016|January 24, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652039||5249|
NCT02652052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004683|Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)|Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)|HTSS|Mayo Clinic|No|Recruiting|March 2016|June 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652052||5248|
NCT02712489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS T-003 EF-UP|A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial|A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP)|ISST-003EF-UP|Istituto Superiore di Sanità|No|Active, not recruiting|January 2015|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|179|Samples With DNA|Blood samples|Both|18 Years|45 Years|No|Non-Probability Sample|HAART-treated patients who participated to the therapeutic phase II trial of the Tat        vaccine "ISS T-003"|March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712489||613|
NCT02656719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1|Comparison Between Bronchoscopy and Real- Time Ultrasound Guided Percutaneous Tracheostomy|Comparison Between Bronchoscopy and Real- Time Ultrasound Guided Percutaneous Dilatational Tracheostomy for Safety, Complications and Efficiency in Critically Ill Patient||Tepecik Training and Research Hospital|No|Active, not recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02656719||4891|
NCT02656797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor017715ctil|Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis|Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis||Soroka University Medical Center|Yes|Not yet recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||November 2015|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656797||4885|
NCT02656238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTEPH Registry|New International CTEPH Database|New International CTEPH Database||International CTEPH Association|No|Recruiting|February 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|Patients recently diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH),        meeting the registry's inclusion criteria, are eligible for inclusion into the New        International CTEPH Database.        Only newly diagnosed, i.e. incident patients are eligible for inclusion. A patient is        considered an incident patient if a diagnostic heart catheterization was performed within        1 year prior to the initial inclusion visit (for the first patient included) at the site        participating in the New International CTEPH Database.|January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656238|3 Years|4928|
NCT02657590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v.01_07.09.2015|Documentation of Cardiac Arrhythmias After Open Heart Surgery|Documentation of Cardiac Arrhythmias After Open Heart Surgery||Rambam Health Care Campus|No|Not yet recruiting|March 2016|November 2019|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|All patients aged 18 and over who underwent open-heart surgery.|March 2016|March 16, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657590||4824|
NCT02715739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mattias-attergrim-201603131327|Is There a Difference in the Mortality Prediction Performance of Two ICISS Approaches for Trauma Patients Admitted to Hospitals in Urban India?|||Karolinska Institutet||Active, not recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3921|||Both|N/A|N/A|No|Non-Probability Sample|Trauma patients admitted to participating centres.|March 2016|March 21, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02715739||363|
NCT02715752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022015|Clinical Study of Gene-Eden-VIR/Novirin|Retrospective Chart Review of Gene-Eden-VIR/Novirin||The Center for the Biology of Chronic Disease|No|Completed|January 2016|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Men and women ages greater than 18 years old|March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715752||362|
NCT02656901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43/CE/2014|Early Postoperative Cognitive Dysfunction After Closed Loop Anesthesia vs Inhalational Anesthesia or TIVA|Incidence of Early Postoperative Cognitive Dysfunction After Closed Loop Anesthesia vs Inhalational Anesthesia or TIVA||University of Foggia||Recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|4||Anticipated|84|||Both|18 Years|N/A|No|||January 2016|February 16, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656901||4877|
NCT02648802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBCS1|Cavity Shaving in Breast Conserving Surgery for Breast Cancer Patients|Cavity Shaving in Breast Conserving Surgery With Intraoperative Cavity Margin Assessment: A Single Center,Randomized,Controlled Trial||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|No|Recruiting|January 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|178|||Female|18 Years|65 Years|No|||January 2016|January 17, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02648802||5498|
NCT02652559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201600008|Initiation of Long-term Non-invasive Ventilation in COPD|Treatment of Chronic Respiratory Failure in COPD Patients With Non-invasive Ventilation: Starting at Home and Selecting the Right Patient|RECONSIDER|University Medical Center Groningen|Yes|Not yet recruiting|May 2016|August 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652559||5209|
NCT02652572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLU-PK-300|Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers|Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Venous Leg Ulcers||FirstString Research, Inc.|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652572||5208|
NCT02713269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0223|Thermal Ablation and Stereotactic Spine Radiosurgery (SSRS)|A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement||M.D. Anderson Cancer Center|No|Not yet recruiting|July 2016|||July 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713269||553|
NCT02713282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108121|A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation|A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation||Janssen-Cilag International NV|No|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|50 Years|No|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713282||552|
NCT02657005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK216-01|TK216 in Patients With Relapsed or Refractory Ewing Sarcoma|A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma||Tokalas, Inc.|No|Not yet recruiting|March 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|12 Years|N/A|No|||January 2016|January 13, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657005||4869|
NCT02657161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV001-I|Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant|Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant||Yisheng Biopharma (Singapore) Pte. Ltd.|Yes|Completed|February 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|37|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657161||4857|
NCT02657070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 53/2013|Counteracting Learned Non-use Through Augmented Visuomotor Feedback in Virtual Reality (RGS)|Desaprendiendo la parálisis Aprendida Con RGS en Pacientes Afectos de Ictus||Universitat Pompeu Fabra||Completed|March 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|25 Years|75 Years|No|||January 2016|January 14, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657070||4864|
NCT02648867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-002-PC|Evaluation of Maternal Feedback to Shorten Pushing Efforts During Labor|Evaluation of Continuous Maternal Feedback to Shorten Second Stage Labor||Clinical Innovations, LLC|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|145|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648867||5493|
NCT02717286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFParana|Restorative Treatment in First Molars Affected by Molar-Incisor Hypomineralization|||Universidade Federal do Paraná|Yes|Completed|January 2013|October 2015|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717286||244|
NCT02647151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALvsALA|Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel|Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel||Fundación Instituto Valenciano de Oncología|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02647151||5625|
NCT02646137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Combined TACE and RF|Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma|Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study||Tanta University|Yes|Recruiting|January 2015|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|January 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646137||5703|
NCT02645604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916033|Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali|Artemether-Lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2015|May 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|4100|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||December 2015|January 1, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02645604||5744|
NCT02651038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mica_HDF|Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration|Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration|Mica-HDF|Medical University of Vienna|Yes|Completed|May 2012|January 2016|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|79 Years|No|||January 2016|January 7, 2016|July 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02651038||5326|
NCT02655445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZB-CSDH-1|Randomized Controlled Trial Investigating Optimal Treatment for Chronic Subdural Hematoma|Compact Trial - A Randomized Controlled Trial Investigating Optimal Treatment for Chronic Subdural Hematoma||Universitair Ziekenhuis Brussel|No|Recruiting|January 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 11, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02655445||4989|
NCT02655133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgGAM-CLRZ-2014|Effects on Microcirculation of IgGAM in Severe Septic/Septic Shock Patients.|Effects on Sublingual Microcirculation of IgGAM Immunoglobulins (Pentaglobin®) in Severe Septic/Septic Shock Patients: a Randomized Controller Trial.||Università Politecnica delle Marche|Yes|Recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02655133||5013|
NCT02645877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH-DTO-201501|Trends of the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Retrospective Analysis|Ten-year Trends in the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Multicenter, Retrospective, Observational Study||Peking University People's Hospital|No|Completed|January 2005|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3909746|||Both|N/A|N/A|No|Non-Probability Sample|All pre-hospital service data from the Beijing Emergency Medical Center and Beijing Red        Cross Emergency Center were collected from January 2005 to December 2014.|January 2016|January 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645877||5723|
NCT02645890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150BPH15022|Study to Compare the Safety and Pharmacokinetics of CKD-397|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects|CKD-397|Chong Kun Dang Pharmaceutical|No|Completed|November 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02645890||5722|
NCT02654587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSE2101C301|Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC|A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-based Chemotherapy Failure or as 3rd Line After Platinum-failure and Checkpoint Inhibitor-failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic Non-Small-Cell Lung Cancer|ATALANTE 1|Orphan Synergy Europe - Pharma|Yes|Recruiting|January 2016|March 2020|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654587||5055|
NCT02647463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCNY-73312|Evaluating the Efficacy of ABC for High-Risk Parent and Infants|Evaluating the Efficacy of ABC for High-Risk Parent and Infants||Stony Brook University|No|Not yet recruiting|January 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|6 Months|20 Months|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647463||5601|
NCT02658292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M902001001|Safety and Efficacy of NAFT900 in Children With Tinea Capitis|A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years||Merz Pharmaceuticals, LLC|No|Not yet recruiting|February 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|12 Years|No|||January 2016|January 14, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658292||4770|
NCT02660905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150881-01H|HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal|CTN289|Ottawa Hospital Research Institute|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02660905||4569|
NCT02658357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-PK-103|Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant|Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant||Braeburn Pharmaceuticals|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||January 2016|January 15, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658357||4765|
NCT02658370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/189/10|An Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis|A Prospective Pilot Study to Evaluate an Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis||Charite University, Berlin, Germany|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|75 Years|No|||January 2016|January 15, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02658370||4764|
NCT02712723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011XUS10T|Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer|Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|February 2016|April 2023|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712723||595|
NCT02654015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 16-0027|INVEST: Minimally Invasive Endoscopic Surgery vs. Medical Management in Supratentorial Intraparenchymal Hemorrhage|INVEST: A Phase II, Randomized, Controlled Trial of Minimally Invasive Endoscopic Surgical (MIES) Treatment With Apollo Versus Medical Management for Supratentorial Intracerebral Hemorrhage (ICH)||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654015||5099|
NCT02657213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC15.110|Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia|Study of Minimed 640G Insulin Pump With SmartGuard in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia|ALPPHY|University Hospital, Grenoble|No|Active, not recruiting|December 2015|December 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|65 Years|No|||August 2015|January 12, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02657213||4853|
NCT02657226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14120283|Intensive Monitoring of Renal Function|Association Between Intensive Monitoring of Renal Function and Outcomes in Critically Ill Patients||University of Pittsburgh|No|Active, not recruiting|January 2015|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|65800|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to any of eight ICUs at the University of Pittsburgh Medical        Center.|March 2016|March 2, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02657226||4852|
NCT02648841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015 YL-02|A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.|||Chinese Academy of Medical Sciences|No|Recruiting|July 2015|June 2022|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|588|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02648841||5495|
NCT02648854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158BE15007|Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|October 2015|November 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648854||5494|
NCT02717260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01554-45|Inhibition Transcranial Random Noise Stimulation|Inhibition Control Modulation by Transcranial Random Noise Stimulation (tRNS ) on the Prefrontal Cortex Measured by Change in Go no Test|inhibistim|Hôpital le Vinatier|Yes|Recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02717260||246|
NCT02646618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK103944-01A1|Get Social: Randomized Trial of a Social Network Delivered Lifestyle Intervention|Get Social: Randomized Trial of a Social Network Delivered Lifestyle Intervention||University of Massachusetts, Worcester|Yes|Not yet recruiting|February 2016|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646618||5666|
NCT02650336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIN-sysu|Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial|Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial|ACTIN|Sun Yat-sen University|No|Completed|October 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|592|Samples Without DNA|Morning blood samples were received from all volunteers after an 8-h overnight fast. The      investigators obtained the blood samples used to measure preoperative serum uric acid,      baseline serum creatinine (SCr) (prior to the pre-procedural hydration), blood urea nitrogen      (BUN), fasting blood glucose, random blood glucose, electrolytes before PCI, serum lipids,      albumin, hemoglobin, and other standard clinical parameters. Blood samples were left to clot      for one hour and then centrifuged at 1500 ×g for 10 min. Plasma samples were accumulated and      stored at −80 °C until analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 years or older undergoing planed PCI at the institution of first        affiliated hospital of SYSU were prospectively recruited between May 2014 and July 2015.        The exclusion criteria were pregnancy, lactation, sepsis, the intravascular administration        of a contrast medium within the past 7 days, nephroprotective drug treatment (e.g.,        N-acetylcysteine, theophylline, sodium bicarbonate, prostaglandin E1), nephrotoxic drug        intake (e.g., non-steroidal anti-inflammatory drugs, metformin, aminoglycosides,        cisplatin) within the past 7 days, a history of serious allergic to contrast media, renal        transplantation, end-stage renal disease necessitating dialysis, and severe concomitant        disease of other systems.|January 2016|January 6, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02650336||5380|
NCT02654171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK0529-1003|Viral Inhibition in Children for Treatment of RSV|A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection|VICTOR|Ark Biosciences Inc.|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|1 Month|24 Months|No|||January 2016|January 12, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02654171||5087|
NCT02716961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-SR-193|Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer|Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer||The First Affiliated Hospital with Nanjing Medical University||Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|70 Years|No|||November 2015|March 22, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02716961||269|
NCT02646865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBB-CLINPSY-2016-1|Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety (SCE-CBT)|A Randomized Controlled Trial on the Efficacy of Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety|SCE-CBT|Babes-Bolyai University|No|Recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02646865||5647|
NCT02646878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP310|A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics|A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics||Medtronic Diabetes|No|Not yet recruiting|May 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|14 Years|75 Years|No|||January 2016|March 14, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02646878||5646|
NCT02655120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0503|Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult|Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult|BMP7|University Hospital, Lille|No|Recruiting|March 2005|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||January 2016|January 11, 2016|November 12, 2014||No||No||https://clinicaltrials.gov/show/NCT02655120||5014|
NCT02658175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS7|The Approach Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome|ISIS 304801-CS7 The APPROACH Open Label Extension Study Volanesorsen (ISIS 304801) An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)||Ionis Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658175||4779|
NCT02658188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0005|Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients|Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients||Astellas Pharma Inc|No|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|182|||Both|20 Years|80 Years|No|||February 2016|February 3, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02658188||4778|
NCT02652377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP-494-001|EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients|A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)||Enanta Pharmaceuticals|No|Not yet recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652377||5223|
NCT02652637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYKS-MOBILE|MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.|MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.||Helsinki University Central Hospital||Recruiting|February 2016|||January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|415|||Both|18 Years|95 Years|No|||February 2016|February 17, 2016|January 8, 2016||||No||https://clinicaltrials.gov/show/NCT02652637||5203|
NCT02653534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1486/REK vest|Impact of Promoting Kangaroo Mother Care (KMC) for Low Birth Weight Infants|Impact of Promoting Kangaroo Mother Care (KMC) for Low Birth Weight Infants|KMC-LBW|Society for Applied Studies|Yes|Recruiting|November 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Anticipated|10500|||Both|N/A|3 Days|Accepts Healthy Volunteers|||December 2015|January 12, 2016|December 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02653534||5135|
NCT02656251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URio Grande|Efficacy of Two Chlorhexidine Solutions to Control the Initial Subgingival Biofilm Formation|Efficacy of Two Clorhexidine Formulations to Control the Initial Subgingival Biofilm Formation||Federal University of Rio Grande do Sul|No|Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|35|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02656251||4927|
NCT02650427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15-41|A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection|A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection|HCC-DPPIV|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|February 2016|July 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02650427||5373|
NCT02719262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-F105002|Reduced of Ambient Melamine Exposure by Melamine Workplace Intervention|Workplace Intervention and Reduced Ambient Melamine Exposure and Renal Damage in Melamine Tableware Manufacturing Workers||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02719262||92|
NCT02652689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP023|Diagnosis of Pulmonary Embolism by Doppler Signals|Transthoracic Parametric Doppler Assessment of Lung Doppler Signals in Acute Pulmonary Embolism||Echosense Ltd.|No|Not yet recruiting|April 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02652689||5199|
NCT02655926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0226|Deep Brain Stimulation for Severe Obsessive Compulsive Disorder|Deep Brain Stimulation for Severe Obsessive Compulsive Disorder: Efficacy and Mechanisms of Ventral Striatum and Subthalamic Nucleus Targets||University College, London|No|Active, not recruiting|September 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|20 Years|N/A|No|||July 2015|January 12, 2016|July 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02655926||4952|
NCT02651961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6262|Cost-effectiveness Evaluation of One Stage Versus Two Stage Exchange for Chronically Infected Total Hip and Total Knee Prostheses|Cost-effectiveness Evaluation of One Stage Versus Two Stage Exchange for Chronically Infected Total Hip and Total Knee Prostheses|IPRO|University Hospital, Strasbourg, France|Yes|Not yet recruiting|January 2016|||June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02651961||5255|
NCT02651974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082012-086 Sub-study|Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study|Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study||University of Texas Southwestern Medical Center|No|Enrolling by invitation|September 2015|August 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Anticipated|2124|||Both|50 Years|64 Years|No|||January 2016|January 19, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02651974||5254|
NCT02647879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-15-003|Treatment as Prevention for Hepatitis C in Iceland|Treatment as Prevention for Hepatitis C in Iceland. A Nationwide Campaign for Reducing Disease Burden Using Combination Antiviral Treatment|TraPHepC|Landspitali University Hospital|No|Recruiting|January 2016|May 2031|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients diagnosed with chronic HCV infection in Iceland|January 2016|February 18, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02647879||5569|
NCT02647892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787-15|Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia|Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia||University of Nebraska|No|Recruiting|January 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|19 Years|100 Years|No|||January 2016|January 11, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647892||5568|
NCT02653209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1603221|TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.|TriMaster: Randomised Double-Blind Crossover Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes Who Have Suboptimal Glycaemic Control on Dual Therapy With Metformin and a Sulphonylurea|TriMaster|NIHR Exeter Clinical Research Facility|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|July 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|600|||Both|30 Years|80 Years|No|||January 2016|January 12, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02653209||5160|
NCT02648321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 13-482|Motivational Intervention for Physical Activity in Psychosis|Motivational Intervention of Exercise in Patients With Psychosis||The University of Hong Kong|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|64 Years|No|||January 2016|January 5, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02648321||5535|
NCT02658994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THPPPlusChild001|Thinking Healthy Program Peer Delivered Plus|Thinking Healthy Program - Peer Delivered in Pakistan - Child-Focused|THPP+|Human Development Research Foundation, Pakistan|Yes|Recruiting|October 2014|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02658994||4716|
NCT02720380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562.554|Buteyko Method for Children With Asthma|||Universidade Federal do Rio Grande do Norte||Recruiting|July 2015|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|7 Years|12 Years|No|||March 2016|March 21, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02720380||6|
NCT02720393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1255|Impact of No-carrageenan Diet on Glucose Tolerance in Prediabetes|Impact of no Carrageenan Diet on Glucose Tolerance in Prediabetes||University of Illinois at Chicago|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02720393||5|
NCT02654470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLXibility|Watchman FLX Left Atrial Appendage Closure Device Post Approval Study|Watchman FLX Left Atrial Appendage Closure Device Post Approval Study||Boston Scientific Corporation|No|Not yet recruiting|February 2016|July 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Any subject who meets all the inclusion criteria, does not meet any of the exclusion        criteria, and who provides written informed consent, may be enrolled in the study. The        subjects selected for participation will be from the investigator's general patient        population.|November 2015|January 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654470||5064|
NCT02652507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-0106|Dexmedetomidine and Ketamine in MRI|Effect of a Combination of Dexmedetomidine and Ketamine Anesthesia on Upper Airway Morphology in Children||Children's Hospital Medical Center, Cincinnati|No|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|22|||Both|1 Year|18 Years|No|||January 2016|January 26, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652507||5213|
NCT02652806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-806|FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease|A Phase 3, Randomized, Open-Label, Active-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease on Dialysis||FibroGen|Yes|Recruiting|December 2015|April 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||January 2016|January 8, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02652806||5190|
NCT02659085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001520-37|Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder|A Randomized Controlled Non-inferiority Trial Comparing Ketamine With ECT in Patients With Major Depressive Disorder||Region Skane|Yes|Recruiting|February 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||January 2016|January 15, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659085||4709|
NCT02656420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006734|Broccoli Sprout Dose Response|Broccoli Sprout Dose Response||Johns Hopkins Bloomberg School of Public Health|No|Enrolling by invitation|January 2016|January 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|170|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656420||4914|
NCT02654548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE1302|Sebum Excretion in Neonates of Women With Polycystic Ovary Syndrome (PCOS)|Sebum Excretion in Neonates of Women With Polycystic Ovary Syndrome (PCOS): Does Increased Skin Greasiness in the First Week of Life Predict Subsequent Development of the Syndrome? A Cohort Study||Homerton University Hospital NHS Foundation Trust|No|Recruiting|June 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654548||5058|
NCT02659189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2677|Hospitalary Chronic Obstructive Pulmonary Disease Registry|Hospitalary Chronic Obstructive Pulmonary Disease Registry||Hospital Italiano de Buenos Aires|No|Not yet recruiting|March 2016|January 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|40 Years|85 Years|No|Non-Probability Sample|Patients older than 40 years with a chronic obstructive pulmonary disease diagnosis        according to global initiative for chronic obstructive lung disease criteria.|January 2016|January 19, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02659189|3 Years|4701|
NCT02659202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002521|Spinal Stimulation During Exercise in Heart Failure|Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure||Mayo Clinic|No|Recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659202||4700|
NCT02651025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:44426115.0.0000.5147|Effects of Resistance Training on Physical Activity in Daily Life and Functional Capacity in Hemodialysis Patients|Effects of Resistance Training on Physical Activity in Daily Life, Muscle Function and Functional Capacity in Patients With End Stage Renal Disease on Hemodialysis: a Randomised Controlled Trial||Federal University of Juiz de Fora|No|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|29|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651025||5327|
NCT02660320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-09|Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin|Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin|Dermabrasion|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|February 2016|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02660320||4614|
NCT02661217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2401|Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event|A Multicenter, Randomized, Open Label, Parallel Group Study Comparing Pre-discharge and posT-discharge tReatment Initiation With LCZ696 in heArt Failure patieNtS With Reduced ejectIon-fracTion hospItalized for an Acute decOmpensation eveNt (ADHF)|TRANSITION|Novartis|Yes|Recruiting|February 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661217||4545|
NCT02645396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-EPI-001|A Cohort Study of Cytomegalovirus（CMV） Infection Among Pregnant Women and Their Newborns in China|A Cohort Study of Cytomegalovirus（CMV） Infection Among Pregnant Women and Their Newborns in China||Xiamen University|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|blood/urine samples of the pregnant women; saliva /urine samples of the newborns|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This study will enroll ~8000 pregnant women aged 18 years and above at MCHHs. Pregnant        women who meet the inclusion/exclusion criteria will be enrolled. All inclusion and        exclusion criteria will be reviewed by investigators or qualified designees to ensure that        each subject is qualified for the study. In general, those whose newborns (including early        birth, any congenital anomaly) are successfully followed up remain in the study        population. However, those with adverse pregnancy outcomes captured in the MCHHs, such as        abortion and still birth, etc., will also be the investigators' subjects even though we        cannot have newborns' urine/saliva samples.|June 2015|December 31, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645396||5760|
NCT02658058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.SS.13|Pre-procedural Ultrasound Techniques Versus Conventional Landmark Technique of Spinal Anesthesia in Elderly Patients|A Randomized Controlled Trial of Pre-procedural Ultrasound Techniques Versus the Conventional Landmark Technique of Spinal Anesthesia in Elderly Patients||American University of Beirut Medical Center|No|Recruiting|November 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|180|||Both|60 Years|N/A|No|||January 2016|January 15, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02658058||4788|
NCT02716493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20994|Feasibility of a 8-week Telerehabilitation Program for Patients With Thoracic Neoplasia Receiving Chemotherapy|Feasibility of an Eight-week Telerehabilitation Program for Patients With Unresectable Thoracic Neoplasia Receiving Chemotherapy|TELErp|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||Active, not recruiting|November 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|40 Years|80 Years|No|||March 2016|March 17, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02716493||305|
NCT02646631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01386|Behavioral and Educational Tools to Improve Epilepsy Care|Behavioral and Educational Tools to Improve Epilepsy Care||New York University School of Medicine||Not yet recruiting|April 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646631||5665|
NCT02659280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MinneapolisMRF|Using "Store and Forward" Tele-health as an Adjunct to Traditional Outpatient or Home Health Physical Therapy|Using "Store and Forward" Tele-health as an Adjunct to Traditional Outpatient or Home Health Physical Therapy|TELE|Minneapolis Medical Research Foundation|No|Not yet recruiting|February 2016|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659280||4694|
NCT02719990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15VR8|Open-label Extension Study to Evaluate the Safety of Long-term Monthly Administration of Somavaratan in Adults With GHD|An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)||Versartis Inc.|No|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|75 Years|No|||March 2016|March 24, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719990||36|
NCT02646891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC-041|Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants|Phase I/II Double-blind, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study of the Safety, and Immunogenicity of the Trivalent P2-VP8 Subunit Rotavirus Vaccine in Healthy South African Adults, Toddlers and Infants||PATH|Yes|Not yet recruiting|February 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|18||Anticipated|660|||Both|6 Weeks|45 Years|Accepts Healthy Volunteers|||December 2015|January 5, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646891||5645|
NCT02653872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6190C00003|A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects|An Open-label, Non-randomized, Fixed Sequence Study Assessing the Pharmacokinetics of AZD7986 When Administered Alone and With Multiple Doses of Verapamil and Itraconazole or Diltiazem in Healthy Subjects||AstraZeneca|No|Active, not recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02653872||5110|
NCT02653885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YIH|Haematologic Predictors and Clinical Outcome in Cardiac Surgery|Haematologic Predictors and Clinical Outcome in Cardiac Surgery||Ankara University|No|Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|1500|||Both|18 Years|80 Years|No|Non-Probability Sample|cardiac patients needed cardiac surgery|January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02653885||5109|
NCT02658201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/12/026|Ultrafast MRI Imaging to Exclude Constipation|Use Of Ultrafast MRI Imaging (FIESTA) In Diagnosis Of Suspected Constipation In Haematological Malignancy and Immunocompromised Patients|FIESTA|Sheffield Children's NHS Foundation Trust|No|Active, not recruiting|September 2012|May 2016|Anticipated|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Years|18 Years|No|||January 2016|January 14, 2016|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02658201||4777|
NCT02650479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA-650-CLP-114|Study of the Effects of Intravenous Exenatide on Cardiac Repolarization|Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers||Intarcia Therapeutics|No|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650479||5369|
NCT02650492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-2015-004|Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma|Exploratory Study on Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma||Clinical Laserthermia Systems AB|No|Recruiting|October 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||December 2015|January 7, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02650492||5368|
NCT02651363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN003-001|Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain|Incidence of Adverse Events, Risk Factors, and Drug Utilization Factors Related to Treatment With Diclofenac 25 MG/Paracetamol 500 MG and Diclofenac 50 MG/Paracetamol 500 MG in Patients From Metropolitan Lima||Bristol-Myers Squibb|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|375|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years of age or and older from 6 medical centers from Metropolitan Lima, Peru        who received at least one dose of Dolocordralan Extra 25 or Dolocordralan Extra Forte        according to product label indications will be included in this study|February 2016|February 17, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02651363||5301|
NCT02651610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1401|Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer|An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer||Peregrine Pharmaceuticals|Yes|Suspended|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651610||5282|
NCT02659397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-035|A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg|A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients||Esperion Therapeutics|No|Recruiting|December 2015|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|March 17, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659397||4685|
NCT02659488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2882|Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects|Effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder||Lindner Center of HOPE|No|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659488||4678|
NCT02652884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2627|Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy|Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy|Corthyroid|Hospital Italiano de Buenos Aires|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02652884||5184|
NCT02713529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150195|Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer|A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors||Amgen|No|Not yet recruiting|April 2016|January 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|197|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713529||533|
NCT02647164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC2015-01|The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring|The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring||GenoSaber|Yes|Not yet recruiting|January 2016|||September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|360|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with NSCLC(stage Ⅰ/Ⅱ/ⅢA), who will receive operation.|September 2015|January 5, 2016|December 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647164||5624|
NCT02651623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501104|Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects|A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline (Zoloft (Registered)) On The Cardiac Repolarization In Healthy Subjects|Zoloft|Pfizer|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02651623||5281|
NCT02650440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robotics in Stroke|Locomotor Training With Robotic Gait in Stroke|Study of the Gait Speed With Robotic Orthosis Training in Stroke: a Randomized Clinical Trial||University of Sao Paulo|Yes|Recruiting|November 2013|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650440||5372|
NCT02654483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34182|Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients|A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients||Stanford University|No|Not yet recruiting|April 2016|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|13 Years|N/A|No|||March 2016|March 17, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654483||5063|
NCT02654574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-867|Comparison of Two Modes of Administration of the IADL Questionnaire, Assessing the Level of Functional Autonomy of Patients to Carry Out the Tasks of Daily Living: Randomized Controlled Trial Among Patients of a Memory Clinic|Comparison of Two Modes of Administration of the IADL Questionnaire|IADL|Hospices Civils de Lyon|No|Recruiting|June 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|394|||Both|50 Years|N/A|No|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654574||5056|
NCT02659670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00036221|Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea|Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea||Wake Forest School of Medicine|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659670||4664|
NCT02659683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-10-179|Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Esomeprazole Mg DR Capsule 40 mg [Torrent,India] Versus Nexium 40 mg DR Capsule [ AastraZeneca LP, USA] in Healthy Subjects-Fasted Condition.||Torrent Pharmaceuticals Limited|Yes|Completed|May 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|February 2, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02659683||4663|
NCT02650700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XQonc-002|Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC|Spleen Radiotherapy Decreases Severe Chemotherapy Induced Thrombocytopenia (CIT) for the Multi-center Randomized Controlled Study in Advanced NSCLC(SPLEENIR)|SPLEENIR|Xinqiao Hospital of Chongqing|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650700||5352|
NCT02657109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/2014|Influence of a Rehabilitation in Valve Replacement on Heart Rate Variability and Oxidative Stress|Influence of Early Mobilization Protocol in Heart Valve Replacement on Heart Rate Variability and Oxidative Stress||Universidade Metodista de Piracicaba|Yes|Recruiting|September 2014|July 2017|Anticipated|January 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657109||4861|
NCT02652481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1734|Expanding MRI Access for Patients With New and Existing ICDs and CRT-Ds ( ENABLE MRI)||ENABLE MRI|Boston Scientific Corporation|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||January 2016|March 2, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652481||5215|
NCT02652741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-602295-02|Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease|Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease|LENA-WP09|Ethicare GmbH|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|5 Years|No|||January 2016|January 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02652741||5195|
NCT02648360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151048|Text Messaging for Physical Activity & Healthy Eating|Evaluation of a Text Messaging Program for Physical Activity and Healthy Eating for Underserved Hispanic Patients||University of Miami|No|Not yet recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648360||5532|
NCT02653404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGRAManPed2014|IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection|Observational Study to Compare IGRA and Mantoux Test in Children With Suspected Latent or Active TB Infection|TBTubercolar|University of Siena|No|Recruiting|April 2015|December 2020|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|50|||Both|1 Month|17 Years|Accepts Healthy Volunteers|Probability Sample|The study will be performed on children hospitalized at Policlinico Santa Maria alle        Scotte (Infectious Dieseases and Pediatrics wards), at Pediatric Clinic of Grosseto USL9,        and from the ambulatories of the above mentioned hospitals.|January 2016|January 11, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02653404||5145|
NCT02716701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4607-B|Exercise in Multiple Sclerosis|Effects of Exercise on Brain Structure and Function in Multiple Sclerosis||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|100 Years|No|||March 2016|March 24, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02716701||289|
NCT02716714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSCLK2014-01|Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis|A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT)||Korea University|Yes|Recruiting|March 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||February 2016|March 17, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02716714||288|
NCT02656680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K24HL124366-01A1|Mentoring in mHealth and Social Networking Interventions for CVD Risk Reduction|||University of Massachusetts, Worcester|Yes|Not yet recruiting|January 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02656680||4894|
NCT02656693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002372|Integrating Online Weight Management With Primary Care Support|Integrating Online Weight Management With Primary Care Support: Patient-Centered Strategies for Addressing Overweight and Obesity in Primary Care|PROPS|Brigham and Women's Hospital|No|Not yet recruiting|February 2016|August 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|840|||Both|20 Years|70 Years|No|||January 2016|January 13, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02656693||4893|
NCT02656706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 324|BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial|||Brown University|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656706||4892|
NCT02647775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-104-7159A3|Hemodynamic and Inflammatory Responses in Thoracic Surgery|Hemodynamic and Inflammatory Responses in Thoracic Surgery: Hemodynamic and Inflammatory Responses Following Video-assisted Thoracoscopic Surgery||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||December 2015|January 6, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02647775||5577|
NCT02648607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGP-LC15|Management of Chronic Post-Partum Pelvic Girdle Pain Study|Management of Chronic Post-Partum Pelvic Girdle Pain Study: Evaluating Effectiveness of Combined Physiotherapy and a Dynamic Elastomeric Fabric Orthoses|MOPS|University of Plymouth|Yes|Recruiting|January 2016|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02648607||5513|
NCT02716974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1618|A Study of Definitive Therapy to Treat Prostate Cancer|A Pilot Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer|oligo-mets|Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Male|18 Years|80 Years|No|||March 2016|March 23, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716974||268|
NCT02716987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-831-1003|Study to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration|A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration||Takeda|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|22|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716987||267|
NCT02656784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESPI|The Efficacy of TBCT Compared to ERP in the Treatment of OCD Patients, by the Assessment of Magnetic Resonance.|The Resonance Assessment in Magnetic Measurement of the Effect of Psychotherapy in Obsessive-compulsive Disorder in a Randomized Clinical Trial||Universidade Estadual do PiauÍ|Yes|Recruiting|February 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656784||4886|
NCT02645760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU-571H106|Effectiveness of Core Stabilization Exercise in Patients With Subacute Non-Specific Low Back Pain|Comparison of Core Stabilization Exercise and Physical Therapy Treatment in Patients With Subacute Non-specific Low Back Pain|CSENSLBP|Khon Kaen University|Yes|Active, not recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|60 Years|No|||December 2015|January 13, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645760||5732|
NCT02645773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Early intevention|Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring|Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring||Bispebjerg Hospital|Yes|Completed|September 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645773||5731|
NCT02653924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HadassahMC|The Comparison of Microbial Adherence to Various Sutures in Patients Undergoing Oral Surgery|The Comparison of Microbial Adherence to Various Sutures in Patients Undergoing Oral Surgery||Hadassah Medical Organization|No|Not yet recruiting|January 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02653924||5106|
NCT02713503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-167|Evaluating Electronic Devices in a Driving Simulator|HFCV Mobile Device Vehicle Integration Assessment||Clemson University|No|Completed|September 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy drivers|March 2016|March 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02713503||535|
NCT02713737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenanICE|The Correlation Between Sleep Quality and Atrial Fibrillation Undergoing High-flow Nasal Cannula Oxygen (HFNC)|Impact of High-flow Nasal Cannula Oxygen (HFNC) Versus Noninvasive Ventilation Associated With Sleep Quality on Atrial Fibrillation in Hypoxemic Patients After Coronary Surgery||Henan Institute of Cardiovascular Epidemiology|No|Not yet recruiting|April 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713737||517|
NCT02713750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 176|RH and Adolescents|Optimization of Reproductive Health Care for Female Adolescents Living With HIV (Reproductive Health in HIV-infected Female Adolescents)||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|March 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|Samples With DNA|Blood|Female|12 Years|24 Years|No|Non-Probability Sample|100 sexually active, HIV-infected female adolescents, 12-24 years old. All subjects should        know their HIV status.|March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713750||516|
NCT02651896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2015-64|Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer|Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer: a Prospective Cohort.||Hospital Sirio-Libanes|Yes|Recruiting|December 2015|December 2019|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Male|18 Years|N/A|No|Non-Probability Sample|Men with localized histologically confirmed T1B-T4 N0 and M0 prostate cancer.|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651896||5260|
NCT02650349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRATCHY1|StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation|StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study|SCRATCHY|Universitair Ziekenhuis Brussel|No|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02650349||5379|
NCT02658110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLSDA020415|Metabolic and Appetite Responses to Altered Timing of Whey Protein Ingestion|Acute Metabolic and Appetite Responses to Altered Timing of Whey Protein Ingestion in Overweight and Obese Males||Northumbria University|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|14|||Male|18 Years|55 Years|No|||January 2016|January 14, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658110||4784|
NCT02713217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-310|Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics|Adapting and Implementing the Blended Collaborative Care Model in CBOCs|BlendedCCM|VA Office of Research and Development|No|Not yet recruiting|July 2016|December 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|588|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be Veterans receiving care at 6 Community-Based Outpatient Clinics (primary        care clinics) affiliated with the Central Arkansas Veterans Healthcare System, the        Veterans Health Care System of the Ozarks, and the VA Southeast Louisiana Health Care        System.|March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02713217||557|
NCT02652143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCVd20H|Does in Vivo Culture of Pre-cleavage Stage Embryo Reduce the Incidence of Aneuploidy?|Does in Vivo Culture of Pre-cleavage Stage Embryo Reduce the Incidence of Aneuploidy? A Sibling Oocyte, Prospective, Multi-centric, Randomized, Open Study, Clinical Study in Subjects With Subfertility Undergoing Assisted Reproductive Medical Treatment||Anecova SA|Yes|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652143||5241|
NCT02658851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808076|Cold Plasma for the Reduction of Lymphoceles Following PLND|Application of Cold Plasma Energy for Reduction of Lymphoceles Following Pelvic Lymph Node Dissection During Robot-Assisted Radical Prostatectomy||Bovie Medical Corporation|No|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Male|18 Years|80 Years|No|||January 2016|January 15, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658851||4727|
NCT02645851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRO-2015-02|RApid Fluid Volume EXpansion in Patients in Shock After the Initial Phase of Resuscitation.|RApid Fluid Volume EXpansion (RVE) in Critically Ill Patients With Acute Circulatory Failure After the Initial Phase of Resuscitation. A Single-center, Open-label, Randomized Study Comparing 3 Strategies of RVE in Orléans, France.|RAVEXO|Centre Hospitalier Régional d'Orléans|No|Recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02645851||5725|
NCT02645864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-HBE001|Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma|Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study||Peking University|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02645864||5724|
NCT02645136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820.529|The Effects of Pilates in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence|The Effects of Pilates Method in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence: : a Randomized Control Trial||Universidade Estadual de Londrina|No|Completed|January 2014|July 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|115|||Male|50 Years|75 Years|No|||December 2015|December 30, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02645136||5780|
NCT02645409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0546|Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma|Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma||Indiana University|Yes|Recruiting|December 2015|||April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02645409||5759|
NCT02656654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARGE 2014|COrporeal Compression at the ONset of Severe Sepsis and Septic Shock|Pilot Study to Evaluate the Efficacy of and the Tolerance to a Body Bandage to Maintain Fluid Balance in Patients With Severe Sepsis or in Septic Shock in an ICU|COCOON|Centre Hospitalier Universitaire Dijon|No|Recruiting|April 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|47|||Both|18 Years|N/A|No|||April 2015|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656654||4896|
NCT02661438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18253|Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo|Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo||Bayer|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|40 Years|N/A|No|||February 2016|February 25, 2016|December 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02661438||4528|
NCT02661451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVR Unload|Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)|Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure: A Randomized Trial (TAVR UNLOAD)||Cardiovascular Research Foundation, New York|Yes|Not yet recruiting|March 2016|May 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661451||4527|
NCT02656316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-NIR-710-CTIL|The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease|The Effects of Multi-focal Transcranial Direct Current Stimulation (tDCS) on Motor-cognitive Dysfunctions and Freezing of Gait in Patients With Parkinson's Disease: A Randomized Controlled Trial||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|85|||Both|25 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656316||4922|
NCT02656329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-122-020|International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device|AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 30%≤LVEF≤35%|ADMIRE-ICD|GE Healthcare|Yes|Recruiting|January 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2216|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656329||4921|
NCT02656160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2014P001033C|Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults|The Effect of Dalfampridine (4-aminopyridine) on Genioglossus Muscle Activity During Wakefulness and Sleep in Healthy Control Subjects|APIGLOSS|Brigham and Women's Hospital|No|Recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656160||4934|
NCT02644902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC-THP-TACTS-2015|Technology Assisted Cascade Training and Supervision of Community Health Workers for Thinking Healthy Programme|Effectiveness of Technology Assisted Cascade Training and Supervision of Community Health Workers in Delivering Thinking Healthy Program for Perinatal Depression in a Post-conflict Area of Pakistan- Protocol of a Randomized Controlled Trial|THP-TACTS|Human Development Research Foundation, Pakistan|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|N/A|N/A|No|||February 2016|February 8, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644902||5798|
NCT02657083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-MC-01|Prevention of Hypoglycemia After Exercise Using Closed Loop System in Children and Adolescents With Type 1 Diabetes|Prevention of Hypoglycemia After Exercise Using DreaMed Substance Administration Device in Children and Adolescents With Type 1 Diabetes (The PHYSI-DREAM Study)|PHYSI-DREAM|University of Ljubljana, Faculty of Medicine|No|Enrolling by invitation|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|10 Years|17 Years|No|||February 2016|February 22, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02657083||4863|
NCT02657096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|918-10|Decontaminant Agent in the Treatment of Chronic Periodontitis|Effectiveness of an Oral Decontaminant Agent in Addition to Non-surgical Therapy of Chronic Periodontitis: A Split Mouth Study||University of Messina|Yes|Completed|January 2014|September 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657096||4862|
NCT02652585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-TEMANX-065|Validation of a Test System for Development of Medications for Alcoholism|Validation of a Test System for Development of Medications for Alcoholism|TEMANX|Technische Universität Dresden|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652585||5207|
NCT02652598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805704|Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With TBI and MCI|A Proof of Concept Open-label Study to Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With Traumatic Brain Injury (TBI) and Mild Cognitive Impairment (MCI)||Sheppard Pratt Health System|Yes|Enrolling by invitation|November 2015|||January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||January 2016|January 8, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652598||5206|
NCT02655861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504015620|A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis|Prospective Evaluation of Infants and Children With Congenital Ichthyosis||Yale University|No|Recruiting|June 2015|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Saliva or blood|Both|N/A|3 Years|No|Probability Sample|Newborns who present at or within 2 months of birth with a clinical diagnosis of        ichthyosis, except for infants with a family history of ichthyosis vulgaris and infants        with X-linked ichthyosis.|February 2016|February 24, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02655861||4957|
NCT02655874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/01047|Tropical Influenza Control Strategies for the Elderly|A Multi-centre, Randomised, Observer-blind, Active Comparator-controlled, Superiority Trial of the Immune Response to Six-monthly Versus Annual Standard Dose Inactivated Trivalent Influenza Vaccination in the Elderly|TROPICS1|Tan Tock Seng Hospital|No|Not yet recruiting|April 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655874||4956|
NCT02649517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1801|Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction|Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated Heart Failure With Ischemic Systolic Dysfunction|FHID|Russian Academy of Medical Sciences|Yes|Recruiting|January 2016|October 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649517||5443|
NCT02649530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2015.157|An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma|An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma||University of Michigan Cancer Center|Yes|Not yet recruiting|February 2016|||July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|January 5, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649530||5442|
NCT02649543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACAB-01|Comparison of Surgical Site Infection Rate Between Primary, Delayed Primary and Vacuum Assisted Closures.|Comparison of Surgical Site Infection Rate Between Primary, Delayed Primary and Vacuum Assisted Closures. A Prospective Randomized Study.||Tecnologico de Monterrey|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|81|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02649543||5441|
NCT02652832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR B04|Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels|Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels|Plasti-Stim|Hôpital le Vinatier|Yes|Recruiting|December 2010|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|8||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|January 8, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02652832||5188|
NCT02648139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eugenia Dentifrice|A Randomized, Controlled, Double-blind Clinical Trial of Surinam Cherry Dentifrice With Anti-gingivitis Properties|A Randomized, Controlled, Double-blind Clinical Trial of a Eugenia Uniflora Linn. (Surinam Cherry) Dentifrice With Anti-gingivitis Properties||Federal University of Paraíba|Yes|Completed|December 2008|November 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|10 Years|12 Years|No|||January 2016|January 5, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648139||5549|
NCT02648386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-ED-IGDB|Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery|Bone Marrow Mononuclear Cells or Human Umbilical Cord-derived Mesenchymal Stem Cells Combined With NeuroRegen Scaffold™ Transplantation for the Improvement of Erectile Function in Men After Rectal Cancer Surgery||Chinese Academy of Sciences|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|34|||Male|20 Years|65 Years|No|||December 2015|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648386||5530|
NCT02716506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Finpop 2015|FINPOP 2015: Incidence, Methods, Complications and Quality of Life of Pelvic Organ Prolapse Operations in Finland 2015|Finnish Pelvic Organ Prolapse Surgery Survey 2015: Incidence, Methods, Complications and Effect on Quality of Life of Pelvic Organ Prolapse Operations in Finland in 2015||Society for Gynecological Surgery in Finland|No|Active, not recruiting|January 2015|June 2016|Anticipated|December 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3200|||Female|18 Years|120 Years|Accepts Healthy Volunteers|Probability Sample|Women with a symptomatic pelvic organ prolapse (POP) operated in year 2015 in Finland|March 2016|March 17, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02716506|5 Years|304|
NCT02656914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS1115|Comparison of EMS Association to References: Transpulmin®, Alivium® and Claritin® to Treat Flu Symptoms|Phase III, National, Multicenter, Randomized, Open Trial, to Assess the EMS Association Superiority Compared to References: Transpulmin®, Alivium® and Claritin® to Treat Flu Symptoms||EMS|Yes|Not yet recruiting|July 2016|May 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|12 Years|60 Years|No|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656914||4876|
NCT02659124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmnioFix Laser Study|Comparison of AmnioFix Laser and Standard of Care Treatment|Comparison of AmnioFix Laser and Standard of Care in Patients Seeking Laser Facial Treatment||University of California, San Francisco|No|Not yet recruiting|April 2016|January 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02659124||4706|
NCT02648633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18574|Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma|A Pilot Study to Evaluate the Feasibility of the Combined Use of Stereotactic Radiosurgery With Nivolumab and Concurrent Valproate in Patients With Recurrent Glioblastoma||University of Virginia|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02648633||5511|
NCT02646579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00084277|Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only|Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only Among Individuals With Chronic Lower Extremity Conditions||Emory University|No|Recruiting|November 2015|June 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||December 2015|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646579||5669|
NCT02646592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI Alfentanil|Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index|Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index||Hôpital Armand Trousseau||Recruiting|January 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|2 Years|18 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646592||5668|
NCT02657174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.100.869|Evaluation of Low-level Laser at Auriculotherapy Points to Reduce Postoperative Pain in Inferior Third Molar Surgery|Effectiveness of Low Level Laser at the Auriculotherapy Points, in Reducing Postoperative Pain in Third Molar Surgery||University of Nove de Julho|Yes|Recruiting|August 2015|August 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657174||4856|
NCT02644720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China12|Neural Compensation, Visual Function and Visual Quality After Monofocal or Multifocal Intraocular Lens Implantation|Neural Compensation, Visual Function and Visual Quality in Senile Cataract Patients After Monofocal or Multifocal Intraocular Lens Implantation||Sun Yat-sen University|Yes|Recruiting|January 2014|January 2019||January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|75 Years|No|||December 2015|December 31, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02644720||5812|
NCT02660203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP-14/EC/KPDP|Impact of Forced Expiration On Pleural Drainage Duration (KPDP)|Impact of Ipsilateral Decubitus Forced Expiration On Duration of Pleural Drainage After Pulmonary Surgery in Children : Randomized Trial|KPDP|University Hospital, Tours|No|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|N/A|48 Weeks|No|||January 2016|January 18, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02660203||4623|
NCT02648451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AY:SJ1|Acceptability and Tolerance Study of New Oral Nutritional Supplement|Tolerance and Acceptability of AYMES ROME||Aymes International Limited|No|Completed|January 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|100 Years|No|||January 2016|January 5, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02648451||5525|
NCT02648672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPN14770-CNS-101|BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects|A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects||Tetra Discovery Partners|No|Recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648672||5508|
NCT02649439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160035|Prostvac in Patients With Biochemically Recurrent Prostate Cancer|Prostvac in Patients With Biochemically Recurrent Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|100 Years|No|||November 2015|February 5, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02649439||5449|
NCT02649452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/SERC/84/2015|Acute Effects of Vibration on Shoulder Flexibility - Experimental Controlled Trial|||Universiti Tunku Abdul Rahman||Recruiting|November 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|19 Years|27 Years|Accepts Healthy Volunteers|||February 2016|February 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649452||5448|
NCT02649699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA CC 14-0163|Multi-Parametric Brain Cancer MRI|Quantitative and Multi-Parametric 3D Magnetic Resonance Imaging of Primary Brain Tumors||AHS Cancer Control Alberta|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02649699||5429|
NCT02650219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-RCB 2010-A00315-3|Auto-antibodies Prevalence and CD1 Role in Gaucher Disease|Prevalence of Autoantibodies in the Gaucher Disease and the Role of CD1 Molecules in Immune Manifestations of This Disease||Hospital St. Joseph, Marseille, France|No|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|40 GD1 patients and 20 healthy volunteers (control group) were included in the study.|February 2016|February 23, 2016|January 5, 2016||No||No|January 7, 2016|https://clinicaltrials.gov/show/NCT02650219||5389|
NCT02659215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyalofast 15-01|HyaloFAST Trial for Repair of Articular Cartilage in the Knee|A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control|FastTRACK|Anika Therapeutics, Inc.|Yes|Recruiting|December 2015|June 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659215||4699|
NCT02712502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL_RUS/MD/2014/PMS/Levolet|Levofloxacin in Bacterial Rhinosinussitis|Open-label Comparative Safety and Efficacy Study of Levofloxacin and Amoxicillin Clavulanic Acid in Patients With Acute ,Bacterial Rhinosinusitis|Levolet|Dr. Reddy's Laboratories Limited|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|60 Years|No|Non-Probability Sample|100 Subjects with chronic bacterial rhinosinusitis were included in study. 50 subjects        with acute and aggravated chronic bacterial rhinosinusitis in the main group (subjects        receiving levofloxacin (Levolet® R)        50 subjects with acute and aggravated chronic bacterial rhinosinusitis in the control        group (subjects receiving levoflamoxicillin clavulanate)|November 2014|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712502||612|
NCT02650830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0503|Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress|||Yonsei University|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|serum (blood), whole blood|Both|19 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from either patients who visit out-patient clinics (Diabetes center        in Severance hospital) or healthy volunteers.|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650830||5342|
NCT02648581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140302|Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease|A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease|STELABEC|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|January 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648581||5515|
NCT02658630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00062868|Neurophysiological and Kinematic Predictors of Response in Chronic Stroke|Neurophysiological and Kinematic Predictors of Response in Chronic Stroke|SRT4|VA Maryland Health Care System|Yes|Not yet recruiting|January 2016|April 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02658630||4744|
NCT02658643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-06|Analysis of Biliodigestive Anastomosis Techniques (BDA)|Randomized Controlled Study to Determine the Difference in Time and Complication Rate for Biliodigestive Anastomosis by Continuous Versus Interrupted Suture Technique||Technische Universität Dresden|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02658643||4743|
NCT02716480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY GOODLIFE|Health-connected Devices and Physical Activity Recovery in Bariatric Surgery Patients|Impact of the Use of Health-connected Devices on Recovery of Physical Activity in Obese Patients After Bariatric Surgery.|MYGOODTRIP|My Goodlife SAS|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716480||306|
NCT02651116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6531002|Dextromethorphan Pediatric Acute Cough Study|A Placebo-controlled, Double-blind, Randomized, Parallel Group Pilot Study To Evaluate The Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population|CHPA DXM|Pfizer|No|Not yet recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|6 Years|11 Years|No|||February 2016|February 15, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02651116||5320|
NCT02659410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-140-CERES-P|Impact of Thermal Stress on Pulmonary Absorption and Toxicokinetics of 3 Organic Solvents|Studying the Impact of Thermal Stress (Heat) Representative of Occupational Settings on Pulmonary Absorption and Toxicokinetics of 3 Organic Solvents||Université de Montréal|No|Recruiting|November 2015|June 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659410||4684|
NCT02659423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-CE-15-003|Multi-College Bystander Efficacy Evaluation|Growing Researcher and College Communities Supporting Violence Prevention Research||University of Kentucky|No|Enrolling by invitation|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|24|||Both|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Public universities with junior faculty to be mentored in violence prevention Note:        sampling unit for primary analyses is the college: answers to questions below refer to        students clustered at each institution|March 2016|March 7, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02659423||4683|
NCT02645071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-743|Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise|FAMILY Project: Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise||The University of Hong Kong|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645071||5785|
NCT02649881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2015-03|Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging|Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging : A Comparative Study With Coronary Artery of the Transplanted or Autopsy Heart|OCT pathology|Asan Medical Center|No|Recruiting|May 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|This study is targeted at the isolated heart voluntarily donated from adult patients who        receive heart transplantation|January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649881||5415|
NCT02649894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-IP-VH-14-009|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||January 6, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649894||5414|
NCT02654366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA040507-01|Community Supported Risk Reduction for Syringe Exchange Participants|Social Network Intervention for Syringe Exchange Registrants||Johns Hopkins University|No|Not yet recruiting|February 2016|July 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|183|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02654366||5072|
NCT02655055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00026241|Bone Density in Voluntary Apheresis Blood Donors|Randomized Longitudinal Study of Apheresis Voluntary Blood Donors' Bone Density|ALTRUYST|Blood Center of Wisconsin|No|Not yet recruiting|May 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|45|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655055||5019|
NCT02649075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH6112|To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study Evaluating Serum-Derived Bovine Immunoglobulin / Protein Isolate in the Dietary Management of Mild to Moderate Crohn's Disease||Entera Health, Inc|No|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02649075||5477|
NCT02658266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUCHUmU02|Effect of Resistance Training in Adults With Complex Congenital Heart Disease|Effect of Resistance Training in Adults With Complex Congenital Heart Disease||Umeå University|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2015|January 18, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02658266||4772|
NCT02650765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15045|S100 Biomarker in the Acute Management of Mild Head Injuries|S100 Biomarker in the Acute Management of Mild Head Injuries|S100|Tampere University Hospital|No|Recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Emergency department:      - S-S100B      Storage, -70 degrees celsius freezer:        -  Serum 50 microlitres divided into 8 vials (Eppendorf)        -  Plasma divided into 3 vials (Eppendorf)        -  Whole blood (EDTA)|Both|18 Years|N/A|No|Probability Sample|A consecutive sample of adult patients with an acute head injury whom are treated at the        emergency department of the Tampere University Hospital, Tampere, Finland|January 2016|January 7, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02650765||5347|
NCT02655224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385-3008|A Placebo-Controlled, Phase 3 Study of TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids||Takeda|No|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|20 Years|N/A|No|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655224||5006|
NCT02655237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385/CCT-002|A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids|A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids||Takeda|No|Recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|288|||Female|20 Years|N/A|No|||March 2016|March 15, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655237||5005|
NCT02650102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81571319|The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment|The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment||Shanxi Medical University|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650102||5398|
NCT02650115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD020-15|Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples (MICRONACH)|Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples|MICRONACH|Centre Hospitalier Departemental Vendee|No|Not yet recruiting|April 2016|May 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Non-Probability Sample|Participants in this study will be selected by the investigators of each center among        patients for whom a liver biopsy is provided in the clinical management in their center.|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650115||5397|
NCT02650128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0257|Shockwave Coronary Rx Lithoplasty ® Study|Prospective Multi-Center, Single Arm Study of the Shockwave Coronary Rx Lithoplasty® System in Coronary Arteries|Disrupt CAD|Shockwave Medical, Inc.|No|Recruiting|December 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02650128||5396|
NCT02656082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR15/114|Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus|A Single Arm, Simon's 2-stage Minimax Design, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus|TARGET-DLE|University of Leeds|Yes|Recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656082||4940|
NCT02656342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-002574-49|Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients?|Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study||Haukeland University Hospital|No|Recruiting|November 2015|December 2023|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656342||4920|
NCT02656966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB 158/15|Auricular Acupuncture for Treatment of Preoperative Anxiety|Auricular Acupuncture vs. Standard Therapy for Treatment of Preoperative Anxiety in Patients Scheduled for Ambulatory Gynaecological Surgery - a Pilot Non-randomized Controlled Trial|AcuAnx|University Medicine Greifswald|No|Recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|19 Years|55 Years|No|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656966||4872|
NCT02660515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54377.101.15|Operative Treatment of Intra-Articular Distal Radius Fractures With Versus Without Wrist Arthroscopy|Operative Treatment of Intra-Articular Distal Radius Fractures With Versus Without Wrist Arthroscopy, a Randomized Controlled Trial|RADAR|Maasstad Hospital|No|Recruiting|January 2016|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02660515||4599|
NCT02660528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001263|Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder|Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial||Brigham and Women's Hospital|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|30 Years|60 Years|No|||January 2016|January 20, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660528||4598|
NCT02660541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTF15-KR-401|Burn Wound Management of Betafoam® and Allevyn® Ag Dressing|A Pilot Study to Compare Efficacy of Allevyn® Silver Dressing and Betafoam® in Patients With Wound of Acute Burn Injury||Mundipharma Korea Ltd|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||January 2016|January 20, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02660541||4597|
NCT02646436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEPJMF|Peritoneal Dialysis as an Option of Unplanned Initiation of Chronic Dialysis|Peritoneal Dialysis as an Option of Unplanned Initiation of Chronic Dialysis||Universidade Estadual Paulista Júlio de Mesquita Filho|Yes|Active, not recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02646436||5680|
NCT02656355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-5361B|Gait Initiation Difficulty and Anticipatory Postural Adjustment (APA) Impairment in People With PD - Evaluation and Training|||Chang Gung University|Yes|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|90|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656355||4919|
NCT02658071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGGERFISH (RB 15.063)|Measurement of Ocular Tensional Fluctuation by Triggerfish Lens Before and After Cataract Surgery in Patients With Exfoliative Glaucoma||TRIGGERFISH|University Hospital, Brest|No|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with exfoliative glaucoma and cataract|March 2016|March 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658071||4787|
NCT02658084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151055|Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer|A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer||University of Miami|Yes|Not yet recruiting|March 2016|||March 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658084||4786|
NCT02648191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508013|Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery|Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery. A Randomized, Controlled, Double-blind Trial|OBESITE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648191||5545|
NCT02648204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-4216|Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1196|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648204||5544|
NCT02656940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|778/10 Parecer CEP|Dietary Lipids, Energy Expenditure and Obesity Biomarkers|Effects of Dietary Lipid Modulation in Energy Expenditure, Body Composition, Obesity-related Biomarkers and Gene Expression of Peroxisome Proliferator-Activated Receptors Alpha and Gamma 2 in Adipose Tissue of Obese Women||Universidade Federal do Rio de Janeiro|No|Completed|February 2013|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|32|||Female|20 Years|39 Years|No|||January 2016|January 12, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02656940||4874|
NCT02653417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMRAD1901-203|Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms||Radius Health, Inc.|No|Recruiting|December 2015|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Female|40 Years|65 Years|No|||January 2016|January 11, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653417||5144|
NCT02657928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1561|Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer|A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas and Endometrial Cancers.||Mayo Clinic|Yes|Not yet recruiting|June 2016|||June 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657928||4798|
NCT02712970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TrabzonNTRH|Staging System for Chronic Symptomatic Pilonidal Sinus Disease|A Proposed Staging System for Chronic Symptomatic Pilonidal Sinus Disease and Results in Patients Treated With Stage-based Approach||Trabzon Numune Training and Research Hospital|No|Completed|January 2011|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||5|Actual|367|||Both|18 Years|N/A|No|Probability Sample|Patients that were operated because of chronic symptomatic pilonidal sinus disease|March 2016|March 14, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02712970||576|
NCT02646020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPE001|Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment|Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial|EGFR-TKIs|Sun Yat-sen University|Yes|Active, not recruiting|December 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 2, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02646020||5712|
NCT02652754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFU-PK-300|Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers|Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Diabetic Foot Ulcers||FirstString Research, Inc.|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652754||5194|
NCT02652767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-LHON-CLIN-03A|Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation|A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene|RESCUE|GenSight Biologics|Yes|Recruiting|January 2016|February 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652767||5193|
NCT02652780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-LHON-CLIN-03B|Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation|Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene|REVERSE|GenSight Biologics|Yes|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652780||5192|
NCT02653651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTuniselmanar|Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy|A Comparison Between the Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy: A Prospective, Double-blind, Randomized, Placebo Controlled Study||University Tunis El Manar|No|Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02653651||5126|
NCT02713230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-327|Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair||Pacira Pharmaceuticals, Inc|No|Recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713230||556|
NCT02713490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-331|Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty||Pacira Pharmaceuticals, Inc|No|Not yet recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Male|18 Years|N/A|No|||March 2016|March 17, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713490||536|
NCT02646332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS15-CT7-15|Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy|Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication||Kaohsiung Veterans General Hospital.|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|438|||Both|20 Years|90 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646332||5688|
NCT02646345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-218|Surgical Checklist Success in Latin America|WHO Surgical Safety Checklist Implementation and Its Impact in Perioperative Morbidity and Mortality in an Academic Medical Center in Chile||Pontificia Universidad Catolica de Chile|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|70639|||Both|15 Years|N/A|No|Probability Sample|All surgical patients age 15 and above|December 2015|December 31, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02646345||5687|
NCT02654847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-02|Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study|Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02654847||5035|
NCT02658045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172-15MMC|A Clinical Evaluation of the Oxitone Non-invasive Oximeter|A Clinical Evaluation of the Oxitone Non-invasive Oximeter. Method Comparison Study vs. a Standard Clinical Pulse-oximeter Monitor. A Prospective Open Study|CPOM|Meir Medical Center|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 30 subjects will be recruited. Participants will be screened for        inclusion/exclusion criteria at enrolment and will be asked to sign an informed consent        form. Only those who give written informed consent will be included in the study. Basic        clinical, demographic including skin type (Fitzpatrick scale) information and past medical        history (CRF) will be recorded.        Patient selection: Adult patients over the age of 18 of both genders will be recruited.        Patients will be either outpatients in the pulmonary department, or ambulatory patients        undergoing rehabilitation.        Normal Healthy volunteers will be recruited from hospital personnel or medical students.        There will be no known additional risk for the subjects.|November 2015|January 14, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02658045||4789|
NCT02718391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST172.04|Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients: a Phase II Randomized Trial|Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients: a Phase II Randomized Trial (ACDC Adjuvant Trial)|ACDC|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02718391||159|
NCT02718404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST198.01|3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors|3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) in the Treatment of Pain From Bone Metastases of Solid Tumors|HIFU-Bone|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02718404||158|
NCT02655211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0735|Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial|Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial: The Sequential Multiple Assignment Randomized Trial (SMART) Approach to Treatment of Hypertrophic Burn Scars|LIBERTI|University of North Carolina, Chapel Hill|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|180|||Both|6 Months|99 Years|No|||January 2016|January 13, 2016|November 12, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655211||5007|
NCT02654951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01485-A004|Reaching in Stroke|Reducing Compensatory Movements in Stroke Therapy Through the Use of Robotic Devices and Augmented Feedback||University of British Columbia|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|19 Years|N/A|No|||January 2016|January 18, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02654951||5027|
NCT02654964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTS Drug Screening Study|Cancer Stem Cell High-Throughput Drug Screening Study|A Phase 0/1 Study of Combination Drug Therapy For Glioblastoma Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS)||Swedish Medical Center|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02654964||5026|
NCT02645578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renjineuro|Asia Coma Electrical Stimulation (the ACES Trial)|Asia Coma Electrical Stimulation Trial: an Asian Multicenter Randomized Controlled Trial to Assess the Efficacy and Safety of Right Median Nerve Stimulation for Traumatic Coma|ACES|RenJi Hospital|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02645578||5746|
NCT02717494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD P1091|Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women|Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women||Westat|Yes|Recruiting|March 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|345|||Female|N/A|N/A|No|||March 2016|March 22, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717494||228|
NCT02717767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0081|Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in ICU|Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in Intensive Care Units|BIONAGA|Nantes University Hospital|No|Not yet recruiting|March 2016|July 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|350|Samples Without DNA|tracheal aspirate and bronchoalveolar lavages|Both|18 Years|99 Years|No|Non-Probability Sample|Patients in intensive care units|March 2016|March 18, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02717767||207|
NCT02655419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4910C00009|Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults|A Phase IIa Prospective, Open-label, Multicenter Study to Determine the Pharmacokinetics (PK) and Safety and Tolerability of Astreonam-avibactam (ATM-AVI) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) in Hospitalized Adults|REJUVENATE|AstraZeneca|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||January 2016|February 1, 2016|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655419||4991|
NCT02655432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160130|Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population|Évaluation de l'Utilisation d'un Photoscreener Comme méthode de dépistage Des problèmes Ophtalmologiques pédiatriques en Haïti|POPH|Université de Montréal|No|Not yet recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Anticipated|621|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655432||4990|
NCT02646410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-61|Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery|Optimal Delivery of Seasonal Malaria Chemoprevention and Its Effects on the Acquisition of Malaria Immunity|SMC|University of Bamako|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|10000|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02646410||5682|
NCT02646423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD078748|Effect of a Patient-Centered Decision App on TOLAC|Effect of a Patient-Centered Decision App on TOLAC: An RCT|PROCEED|University of California, San Francisco|No|Not yet recruiting|January 2016|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1320|||Female|18 Years|N/A|No|||December 2015|December 31, 2015|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02646423||5681|
NCT02656069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSGP-301|Safety and Efficacy of G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics|G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety||Xeris Pharmaceuticals|No|Not yet recruiting|March 2016|August 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656069||4941|
NCT02644629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-15-0019|Intra-nasal vs. Intra-venous Ketamine Administration|Intra-nasal vs. Intra-venous Ketamine Administration as an add-on to Antidepressant Therapy||Shalvata Mental Health Center|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644629||5819|
NCT02644642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-DEO-15-391|Utility of Disconnection Technique for One Lung Ventilation|Utility of Disconnection Technique for One Lung Ventilation: a Comparison of a Double Lumen Endobronchial Tube With a Bronchial Blocker||Ajou University School of Medicine|No|Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|38|||Both|20 Years|60 Years|No|||December 2015|December 30, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02644642||5818|
NCT02647814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075868|Salud al Día: Engaging Latino Parents in Pediatric Primary Care|Salud al Día: Engaging Latino Parents in Pediatric Primary Care||Johns Hopkins University|No|Not yet recruiting|January 2016|February 2020|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02647814||5574|
NCT02658890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA017-003|Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers|A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors||Bristol-Myers Squibb|No|Recruiting|February 2016|October 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|100 Years|No|||February 2016|February 25, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658890||4724|
NCT02715141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15MOC|Molecular Stool Testing for Colorectal Cancer Surveillance|Molecular Stool Testing for Colorectal Cancer Surveillance|MOCCAS|The Netherlands Cancer Institute|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Stool samples will be collected. The stool samples will be used to test for the presence of      molecular stool markers.|Both|50 Years|75 Years|No|Non-Probability Sample|The intended population of this study consists all subjects in the participating centres        that are elected for colonoscopy surveillance.|March 2016|March 16, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715141||409|
NCT02715154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPH-A-1|Dexmedetomidine for Cesarean Section|Effect and Placental Transfer of Dexmedetomidine During Caesarean Section Under Epidural Anaesthesia||The First Affiliated Hospital with Nanjing Medical University|No|Completed|June 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|23 Years|41 Years|No|||March 2016|March 21, 2016|March 2, 2016||||No||https://clinicaltrials.gov/show/NCT02715154||408|
NCT02649218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031C2201E1|A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients|An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201||Novartis|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649218||5466|
NCT02649231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0253.|Ketamine for Reduction of Alcoholic Relapse|Reducing Relapse in Severe Alcohol Use Disorder With the NMDA Receptor Antagonist Ketamine|KARE|University College, London|Yes|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|60 Years|No|||October 2015|January 12, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649231||5465|
NCT02661464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108112|Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo|A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo||Crucell Holland BV|No|Not yet recruiting|January 2016|May 2023|Anticipated|May 2023|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5500|||Both|N/A|71 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661464||4526|
NCT02658669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1512-W|CBT-I for Veterans With TBI|Cognitive Behavioral Therapy for Insomnia for Veterans With History of TBI||VA Office of Research and Development|No|Not yet recruiting|April 2016|September 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02658669||4741|
NCT02645981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDH3|Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma|Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Yes|Not yet recruiting|February 2016|August 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|January 4, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645981||5715|
NCT02645994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1723/MD/11719-20|Anesthetic Depth Control Using CLADS vs. TCI in Patients With LVSDF|Comparison of the Efficiency of Anesthetic Depth Control Using Closed Loop Anesthesia Delivery System vs. Manual Control Using Target Controlled Infusion in Patients With Moderate to Severe Left Ventricular Systolic Dysfunction||Postgraduate Institute of Medical Education and Research|No|Completed|July 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02645994||5714|
NCT02654080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 112|Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy HIV-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|March 2016|||July 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02654080||5094|
NCT02654093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR213-I-02|A Drug-drug Interaction Study of DP-R213|A Randomized, Open-label, Single-dose, 3-period, 6-sequence Crossover Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of Raloxifene, Cholecalciferol in Healthy Korean Male Subjects||Alvogen Korea|No|Completed|January 2016|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|24|||Male|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|March 10, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02654093||5093|
NCT02661477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T51/2015|Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial|Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial|Hypogamma Int1|Turku University Hospital|No|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661477||4525|
NCT02661490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-204|Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population|A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults||Takeda|Yes|Recruiting|February 2016|April 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|325|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661490||4524|
NCT02652897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS PI15 / 00512|Hemostasis Alterations in Neurosurgical Patients|Prospective Study on Hemostasis Alterations in Patients Undergoing Neuro Surgical Glioma Resection||Hospitales Universitarios Virgen del Rocío|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing elective glioma (study group) and colon (control group)        surgeries.|January 2016|January 8, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02652897||5183|
NCT02653482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00032|Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure|Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure|DEFINE-HF|Saint Luke's Health System|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|19 Years|74 Years|No|||January 2016|January 9, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653482||5139|
NCT02645461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3314|Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS|Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS|AchALS|University of Roma La Sapienza|No|Completed|January 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02645461||5755|
NCT02657603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15016829|Continuous Adductor Canal Block With a New Catheter - Primary Placement and Secondary Repositioning|Continuous Adductor Canal Block With a New Catheter - Primary Placement and Secondary Repositioning||Hillerod Hospital, Denmark|No|Recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 16, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657603||4823|
NCT02653170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135457|Michigan Stroke Transitions Trial|The Michigan Stroke Transitions Trial (MISTT): Improving Care Transitions for Acute Stroke Patients Through a Patient-centered Home Based Case Management Program|MISTT|Michigan State University|No|Recruiting|January 2016|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|480|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02653170||5163|
NCT02658942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62120|Flexible Ureteroscopy Versus ESWL in the Management of Lower Calyceal Stones|Flexible Ureteroscopy Versus ESWL in the Management of Lower Calyceal Stones: A Prospective Randomized Study||Cairo University|Yes|Completed|May 2010|May 2015|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|12 Years|N/A|No|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658942||4720|
NCT02650505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0084-1230|A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of LEO 43204 Gel and Gel Vehicle in Healthy Volunteers Using a Repeat Insult Patch Test Design||LEO Pharma|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02650505||5367|
NCT02645721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2014-31|Internet Based Cognitive Behavior Treatment for Alcohol Use Disorders|Internet Based Cognitive Behavior Treatment for Alcohol Use Disorders - a Randomized Controlled Trial|ICBT-AUD|Karolinska Institutet|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|169|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02645721||5735|
NCT02649088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212639|Sublingual Microcirculation Monitoring in ICU|Sublingual Microcirculation Monitoring in ICU|MICRODAIMON|Università Politecnica delle Marche|No|Completed|April 2013|April 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients admitted in intensive care unit|January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02649088||5476|
NCT02661152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 30|DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.|DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.|DAHANCA30|Danish Head and Neck Cancer Group|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|1262|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02661152||4550|
NCT02651532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENE12016|Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome|Confocal Endomicroscopy Utility for Diagnosing Mucosa Microinflammation in Patients With Irritable Bowel Syndrome||Instituto Ecuatoriano de Enfermedades Digestivas|Yes|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples Without DNA|Histological biopsies of the colonic mucosal|Both|18 Years|80 Years|No|Non-Probability Sample|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent        abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms        begin at least 6 months before diagnosis, associated with 2 or more of: 1) Improvement        with defecation, 2) Start associated with changes in the bowel frequency, 3) Start        associated with changes in stool consistency. In the absence of alarm symptoms. It will be        measured in all patients serology for celiac disease, serum thyroid-stimulating hormone        (TSH) and parasitological test. It will be done, in high suspicion patients, stool        culture, breath test for lactose intolerance and breath test for bacterial overgrowth.|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651532||5288|
NCT02648893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 1508005752|Effect Of A Biofortified Food Basket On Micronutrient Status And Immune And Cognitive Function Among Infants In India|Effect Of A Biofortified Food Basket On Micronutrient Status And Immune And Cognitive Function In The First 1000 Days Of Life In India||Cornell University|Yes|Not yet recruiting|October 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|6 Months|18 Months|No|||January 2016|January 5, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02648893||5491|
NCT02648906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWB_GTM001|A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients|||Daewoong Pharmaceutical Co. LTD.|Yes|Recruiting|July 2015|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|128|||Both|56 Years|85 Years|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648906||5490|
NCT02648919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUANG-2015-1|Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer|Phase II Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer||University of Hawaii|Yes|Recruiting|December 2015|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|60 Years|N/A|No|||January 2016|January 6, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648919||5489|
NCT02648932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0866|The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients|The Rapid Study: Randomized (RA) Phase (P) II Study To Expedite Allogeneic Transplant With Immediate (I) Haploidentical Plus Unrelated Cord Donor (D) Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients||University of Chicago|No|Recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648932||5488|
NCT02652611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00063838|Sacroiliac (SI) Screws: The Effect of SI Screw Removal on Patient-Reported Pain and Functional Outcomes|The Effect of Sacroiliac (SI) Screw Removal on Patient-Reported Pain and Functional Outcomes After Open or Closed Reduction and Internal Fixation of Pelvic Fractures|SIS|University of Maryland|Yes|Recruiting|September 2015|September 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652611||5205|
NCT02653183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxB Po 02|Prospective, Randomized Clinical Investigation of Two Different Postoperative Wound Dressings|A Prospective, Randomized, Controlled Clinical Investigation, Copmparing Two Postoperative Wound Dressings Used After Elective Hip and Knee Replacement|MxBPo02|Molnlycke Health Care AB|No|Recruiting|December 2015|October 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02653183||5162|
NCT02649400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15218913.6.0000.5505|Assessment of Functional Capacity and Inflammatory Markers in Women With Heart Failure With Preserved Ejection Fraction|Assessment of Functional Capacity, Inflammatory Markers and Autonomic Function in Women With Heart Failure With Preserved Ejection Fraction and Previous Coronary Artery Disease||Federal University of São Paulo|No|Active, not recruiting|August 2013|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|Samples With DNA|Venous blood and plasma.|Female|35 Years|70 Years|No|Non-Probability Sample|Women with coronary artery disease diagnosed through angiography and heart failure with        preserved ejection fraction diagnosed via ecocardiography.|January 2016|January 8, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02649400||5452|
NCT02717299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-053|Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial|Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial||TriHealth Inc.|No|Recruiting|November 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717299||243|
NCT02654795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501-1-10-14-13|Assessment of Left Atrial Appendage Morphology in Patients After Ischemic Stroke|AssesSment of the Left Atrial Appendage morphoLogy in Patients aAfter ischeMic Stroke|ASSAM|Medical Centre of Postgraduate Education, Poland|No|Recruiting|August 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02654795||5039|
NCT02653586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|telhaicolege|Prevention Program Promoting Self Resilience,Positive Self-Image and Body Image Among Adolescence Aged 15-17|"In Favor of Resilience Self" Prevention Program Promoting Positive Self-Image and Body Image Among Adolescence Aged 15-17||Tel Hai College|Yes|Completed|May 2013|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|209|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02653586||5131|
NCT02653599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP273-201|A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin||vTv Therapeutics|No|Recruiting|December 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02653599||5130|
NCT02648113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140705|Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia.|Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia. The REALITY (REstrictive And LIberal Transfusion Strategies in Patients With Acute mYocardial Infarction) Randomized Trial.|REALITY|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|February 2016|August 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|630|||Both|18 Years|N/A|No|||December 2015|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648113||5551|
NCT02648126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCLIN 004/2014|Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa|Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz)||The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|No|Enrolling by invitation|November 2015|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|531|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648126||5550|
NCT02712749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE|"Binaural Beats" as Non-drug Premedication in Elderly for Major Surgery.|"Binaural Beats" as Non-drug Premedication for Anxiety Reduction in Elderly Submitted to Major Surgery. A Randomized Controlled Trial.||L'Azienda USL Nord Ovest|No|Not yet recruiting|October 2016|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|90 Years|No|||March 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712749||593|
NCT02712762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1312/118/2015|Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients|Dry Eye and Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients||Singapore National Eye Centre|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|21 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a cross-sectional study involving 30 consecutive suitable GVHD patients. Suitable        patients will be identified by haematologists from the SGH transplantation Centre (Block        7, level 1).        Study duration: One visit        Recruitment duration: 1 Year|March 2016|March 18, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02712762||592|
NCT02654912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH-WIRB-1155095|Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration|Community-led Responses for Elimination (CoRE): A Cluster Randomized Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration in Malaria Elimination Areas in Southern Province Zambia|CORE Zambia|PATH|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4800|||Both|3 Months|N/A|Accepts Healthy Volunteers|||November 2015|January 11, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02654912||5030|
NCT02645526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUAMMcap|Is a Woolen Cap Effective in Maintaining Normothermia in Preterm Infants During Kangaroo Mother Care?|Is a Woolen Cap Effective in Maintaining Normothermia in Preterm Infants During Kangaroo Mother Care?||University Hospital Padova|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|3 Days|No|||December 2015|December 31, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645526||5750|
NCT02645539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPCVFIH_V1.R2|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2016|||||N/A|N/A|N/A||||||||||||||March 21, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645539||5749|
NCT02649907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/143/15|Effects of Weight Loss on Nutritional Mediated Hormone Secretion|Analysis of the Variability of Appetite and Energy Regulating Hormones to an Acute Nutritive Stimulation by Different Combinations of Macronutrients|RepDiet|Charite University, Berlin, Germany|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02649907||5413|
NCT02656758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z151100004015103|Intensive Executive Function Training|A Randomized Controlled Study on the Effect of Intensive Functional Training on Children With Attention Deficit Hyperactivity Disorder||Peking University|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656758||4888|
NCT02656849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-380|BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors|A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors||Dana-Farber Cancer Institute|Yes|Not yet recruiting|February 2016|May 2023|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656849||4881|
NCT02660502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT017|An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects|A Double-blind, Comparator-controlled, Randomised, Three-period Crossover Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects||Adocia|No|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|15|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660502||4600|
NCT02654132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-125|Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma|An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Not yet recruiting|March 2016|November 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|121|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654132||5090|
NCT02645344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20130720002|Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sensory Cueing on Unilateral Neglect in Subacute Patients With Right Hemispheric Stroke|Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Sensory Cueing (SC) on Unilateral Neglect in Subacute Patients With Right Hemispheric Stroke: A Randomized Controlled Study||The Hong Kong Polytechnic University|No|Completed|June 2013|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02645344||5764|
NCT02645591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0633|Randomized AmnioFix Study During Radical Prostatectomy|Neurovascular Bundle Protection With an Amnion/Chorion Membrane Allograft to Improve Postoperative Functional Recovery: A Randomized Comparison to Standard Techniques||M.D. Anderson Cancer Center|Yes|Not yet recruiting|January 2016|||January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Male|35 Years|75 Years|No|||January 2016|January 4, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645591||5745|
NCT02654405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809383|Sodium Butyrate For Improving Cognitive Function In Schizophrenia|Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia||Nathan Kline Institute for Psychiatric Research|No|Not yet recruiting|April 2016|December 2019|Anticipated|November 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02654405||5069|
NCT02647450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4447|GI Consequences Economic Evaluation|An Exploratory Assessment of the Cost Impact of Managing GI Consequences of Cancer Treatment Outside of a Specialist Clinic|GICEE|Royal Marsden NHS Foundation Trust|No|Recruiting|January 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|18 Years|85 Years|No|Non-Probability Sample|All patients cured of cancer and are experiencing GI symptoms due to radio or chemotherapy        during the last one year.|January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02647450||5602|
NCT02655627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1977|Internet Based Exercise Training in Type 2 Diabetes|Can Internet Based Exercise Training Be an Alternative to Supervised Group Exercise Training in Patients With Type 2 Diabetes?||Biruni University||Recruiting|April 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|61|||Both|35 Years|65 Years|No|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655627||4975|
NCT02659436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0986|Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol|Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659436||4682|
NCT02647970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239948|Stearoyl-CoA Desaturase and Energy Metabolism in Humans|Stearoyl-CoA Desaturase and Energy Metabolism in Humans|SEM|University of Oslo|Yes|Not yet recruiting|February 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02647970||5562|
NCT02647762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-301RA|CF101 Therapy for Active Rheumatoid Arthritis|A Phase 3 Trial to Evaluate the Efficacy and Safety of CF101 in Combination With Conventional Therapy in the Treatment of Rheumatoid Arthritis||Can-Fite BioPharma|No|Not yet recruiting|June 2016|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647762||5578|
NCT02651922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199A14PF|Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®|Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®||Pascoe Pharmazeutische Praeparate GmbH|No|Completed|September 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|154|||Both|18 Years|N/A|No|Probability Sample|Patients had to suffer from nervous restlessness in order to be eligible for study        documentation.|January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651922||5258|
NCT02650388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56174-1/2015/EKU(0470/15)|Frailty and Cognitive Function Assessment of TAVI Patients|Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study||Hungarian Institute of Cardiology|No|Recruiting|November 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||December 2015|January 6, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02650388||5376|
NCT02650401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXDX-101-03|Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors|A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors||Ignyta, Inc.|No|Recruiting|December 2015|March 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|2 Years|22 Years|No|||January 2016|January 7, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650401||5375|
NCT02659527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The RAPID study|PET/MRI in Patients With Suspected Prostate Cancer|Randomized Assessment of Patients With Clinically Suspected Prostate Cancer After Multiparametric Metabolic Hybrid Imaging to Evaluate Its Potential Clinical Domain: A Prospective, Randomized, Multi-arm, Multi-treatment Clinical Trial||Medical University of Vienna|No|Not yet recruiting|January 2016|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|220|||Male|N/A|N/A|No|||January 2016|January 19, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659527||4675|
NCT02659540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2015-006|A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma|A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma||Ludwig Institute for Cancer Research|No|Not yet recruiting|January 2016|January 2021|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659540||4674|
NCT02652390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM_CTS_2|Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome|Extended Follow-up of a Randomized Placebo-controlled Trial of Local Steroid Injection in Carpal Tunnel Syndrome||Region Skane|Yes|Enrolling by invitation|February 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|111|||Both|18 Years|70 Years|No|||February 2016|February 21, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02652390||5222|
NCT02645253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3741C00005|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men|A Phase I, Randomized, Single-blind, Placebo-controlled, Sequential-group, Single-center Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AZD7594 Given Once Daily as Inhaled Formulation in Healthy Japanese Men||AstraZeneca|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02645253||5771|
NCT02649790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-8602-801|Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma|Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma||Karyopharm Therapeutics, Inc|No|Recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649790||5422|
NCT02650076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO001A|A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects|||Sanwa Kagaku Kenkyusho Co., Ltd.||Recruiting|January 2016|||March 2016|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||||||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650076||5400|
NCT02644759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA-DM1|Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus|Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus||Stem Cells Arabia|No|Active, not recruiting|February 2014|January 2019|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|8 Years|55 Years|No|||December 2015|December 30, 2015|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644759||5809|
NCT02717793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC231013|Comparison Between Isotonic 1 Repetition Maximum Measurement With Isometric Muscle Strength Testing In Healthy Females|Comparison Between Isotonic 1 Repetition Maximum Measurement With Isometric Muscle Strength Testing In Healthy Females||Universiti Tunku Abdul Rahman|Yes|Completed|October 2013|||December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|30|||Female|19 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02717793||205|
NCT02657044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-610/D|EMR Versus ESD for Resection of Large Distal Non-pedunculated Colorectal Adenomas|Multicenter, Randomised Controlled Trial Comparing Endoscopic Mucosal Resection (EMR) And Endoscopic Submucosal dissecTIon (ESD) for Resection of Large Distal Non-pedunculated Colorectal Adenomas (MATILDA-trial)|MATILDA|UMC Utrecht|No|Not yet recruiting|April 2016|December 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02657044||4866|
NCT02657967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy|Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy (NICM-Registry)|NICMR|Winthrop University Hospital|No|Recruiting|May 2015|July 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1950|Samples With DNA|Whole blood specimens obtained with subject permission, will be retained for the purpose of      future genetic research.|Both|18 Years|N/A|No|Probability Sample|Patients with non-ischemic cardiomyopathy and an ejection fraction of ≤40%.|January 2016|January 13, 2016|May 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02657967|3 Years|4795|
NCT02657980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUL003MDD|The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder|The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder||Ybrain Inc.|Yes|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|19 Years|65 Years|No|||February 2016|February 19, 2016|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02657980||4794|
NCT02718079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ALF-03|High-Volume Plasma Exchange Versus Fractional Plasma Separation and Adsorption (Prometheus) in Patients With Acute Liver Failure|High-Volume Plasma Exchange Versus Fractional Plasma Separation and Adsorption (Prometheus) in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial||Institute of Liver and Biliary Sciences, India|No|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|75 Years|No|||February 2016|March 22, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02718079||183|
NCT02718092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512035809|Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of WON|Randomized Trial Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of Walled -Off Necrosis (WON)|WON|Indiana University|Yes|Not yet recruiting|March 2016|March 2022|Anticipated|March 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718092||182|
NCT02651597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:142|A Study of the Effect of Oats on Post Prandial Glucose Response|A Randomized, Controlled, Cross-over Study of the Effect of Oats on Post Prandial Glucose Response||University of Manitoba|No|Not yet recruiting|January 2016|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651597||5283|
NCT02645786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-19|Thyrotropin Over-suppression and Heart|Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer||Chuncheon Sacred Heart Hospital|No|Completed|September 2009|April 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|31|Samples Without DNA|serum and plasma|Female|32 Years|51 Years|Accepts Healthy Volunteers|Non-Probability Sample|female differentiated thyroid cancer patients who received total- or near-total        thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD)        of Chuncheon Sacred Heart Hospital. Finally, 14 DTC patients were enrolled and studied        from September 2009 to March 2010. As each patient was enrolled, control subjects were        selected from patients who visited endocrinology department for thyroid nodule work-up.        All subjects who met the enrollment criteria took an electrocardiogram to rule out        arrhythmias.|December 2015|December 31, 2015|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02645786||5730|
NCT02645331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20130214003|"Remind to Move" Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy|"Remind to Move" Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy: A Randomized Controlled Trial||The Hong Kong Polytechnic University|No|Completed|February 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|73|||Both|5 Years|16 Years|No|||December 2015|December 31, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02645331||5765|
NCT02714608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM0319|A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)|A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)||Tasly Pharmaceuticals, Inc.|Yes|Not yet recruiting|May 2016|December 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02714608||450|
NCT02660333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSC|Effect of Prebiotic or Synbiotic on Inflammatory Response and Indicators of Nutritional Status in Obesity|Effect of Prebiotic or Synbiotic Supplementation on Inflammatory Response and Indicators of Nutritional Status in Individuals With Morbid Obesity: A Randomized Clinical Trial, Placebo-controlled and Triple Blind||Universidade Federal de Santa Catarina|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|60 Years|No|||January 2016|January 18, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660333||4613|
NCT02714023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201672|Water And Saline Head-to-head In The Blinded Evaluation Study Trial|Water And Saline Head-to-head In The Blinded Evaluation Study Trial|WASH IT BEST|University of Missouri-Columbia|No|Completed|April 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|6 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02714023||495|
NCT02714036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-166-ALS-1202|A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)|A Single-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)||MediciNova|No|Not yet recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714036||494|
NCT02660398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50608--D|Incidence and Severity of Residual Neuromuscular Blockade|Incidence and Severity of Residual Neuromuscular Blockade With Application of a Protocol for Paralysis and Neostigmine Reversal of Rocuronium||University of Washington|No|Recruiting|January 2016|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02660398||4608|
NCT02644603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ERAS-MRCT-1511|Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer|Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer: a Multicenter, Randomized, Controlled Clinical Study||Shanghai Zhongshan Hospital|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|70 Years|No|||March 2016|March 14, 2016|December 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644603||5821|
NCT02651428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCK-IT-100|Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection|Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease||CorMedix|Yes|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|632|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651428||5296|
NCT02658864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHXH-lafutidine|Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets|Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets in Healthy Chinese Subjects||Wuhan Union Hospital, China|Yes|Completed|April 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|19 Years|27 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658864||4726|
NCT02649179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-ESR-14-10228|Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients|Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Placebo Controlled, Double-blind Trial||Fourth Military Medical University|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649179||5469|
NCT02649465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-033|SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD|Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver||Kanazawa University|Yes|Recruiting|January 2016|September 2020|Anticipated|September 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||November 2015|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649465||5447|
NCT02649244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12181423Exp|The Family Caregiver Training Program for Caregivers of People With Dementia|The Family Caregiver Training Program for Caregivers of People With Dementia: A Randomized Control Trial||Nova Southeastern University|No|Completed|January 2015|July 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649244||5464|
NCT02652221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0478|Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound|Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|June 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|55|||Both|N/A|25 Years|No|||January 2016|January 26, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652221||5235|
NCT02652234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-ED-201504|Study of Endostar Subcutaneous Injection in NSCLC|A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|August 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|70 Years|No|||December 2015|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652234||5234|
NCT02647593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2012-0165|The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis|The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis Showing the High Level of Aminotransferase and the Establishment of New Nomenclature ; Gallstone Hepatitis||Gangnam Severance Hospital|No|Enrolling by invitation|June 2006|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|20 Years|90 Years|No|Non-Probability Sample|"Patients have been diagnosed as CBD stone under endoscopic retrograde        cholangiopancreatography (ERCP). Among patients, patients who displayed above 400 IU/L of        aminotransferase without cholangitis (gallstone hepatitis group) and patients who showed        the normal value of aminotransferase (control group) were enrolled in this study. We        estimated two groups by comparing clinical features, lab finding, radiologic images, and        findings under ERCP such as CBD diameter, CBD stone diameter, CBD stone number,        periampullary diverticulum.|January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647593||5591|
NCT02647606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-DE1-15-334|Comparison of the Videolaryngoscopes With Manual In-line Stabilization|Comparison of the McGrath Videolaryngoscope and the Pentax-AWS With the Macintosh Laryngoscope for Nasotracheal Intubation in Patients With Manual In-line Stabilization||Ajou University School of Medicine|No|Not yet recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|120|||Both|19 Years|60 Years|No|||January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02647606||5590|
NCT02719782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTCR-HCC-I-2|TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation|Phase I Study T Cell Receptor-Redirected T Cells Infusions to Treat Patients With Recurrent HBV-Related Hepatocellular Carcinoma Post Liver Transplantation||Lion TCR Pte. Ltd.|No|Recruiting|December 2015|November 2020|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719782||52|
NCT02653794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2016-China1|The Variations of Macular Thickness in Juvenile Subjects|The Variations of Macular Thickness in Juvenile Subjects With Mild-to-Moderate Refractive Error||Sun Yat-sen University|Yes|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|364|||Both|4 Years|17 Years|No|Probability Sample|Subjects consisted of Zhongshan Ophthalmic Center (ZOC) and Hualong Primary School (HPS)),        who came from ZOC group were mild-to-moderate refraction error while who come from HPS        group had no visual complaints.|January 2016|January 10, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02653794||5116|
NCT02653807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREC/CARS-UCL-Hidalgo|Comparison of Two Manual Therapy Techniques on Ankle Dorsiflexion|The Immediate Effects of Two Manual Therapy Techniques on Ankle Musculoarticular Stiffness and Dorsiflexion Range of Motion in People With Chronic Ankle Rigidity: A Randomized Clinical Trial||Université Catholique de Louvain|No|Completed|September 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02653807||5115|
NCT02648074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-010/2014|Eosinophil Induced Remodelling in Asthma|Eosinophil Induced Airway Smooth Muscle Remodelling in Asthma|ERA|Lithuanian University of Health Sciences|No|Recruiting|March 2014|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648074||5554|
NCT02649985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002329|Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease|Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease||Brigham and Women's Hospital|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649985||5407|
NCT02645032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVI T001|Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine|A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children||International Vaccine Institute|No|Not yet recruiting|April 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|144|||Both|2 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02645032||5788|
NCT02658747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML30033|Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK|A Retrospective Chart Review to Describe the Rate of Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK||Hoffmann-La Roche||Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung        cancer (NSCLC)|March 2016|March 1, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658747||4735|
NCT02658760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hums.Rec.1394.74|Dexmedetomidine and Bupivacaine With Bupivacaine in Ultrasonography Guided Fascia Iliaca Compartment Block in Adults|Comparison of Dexmedetomidine and Bupivacaine With Bupivacaine Alone on the Quality of Ultrasonography Guided Fascia Iliaca Compartment Block in Adults Undergoing Femur Fracture Fixation Surgery||Hormozgan University of Medical Sciences|Yes|Recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|N/A|No|||January 2016|January 15, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658760||4734|
NCT02656108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCO|Omission of Controlled Cord Traction During Active Management of Third Stage of Labor|Omission of Controlled Cord Traction During Active Management of Third Stage of Labor. A Single Blinded Randomized Controlled Trial||Ain Shams University|Yes|Not yet recruiting|February 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|February 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656108||4938|
NCT02656121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO|Does Vitamin D Break the Vicious Circle of Polycystic Ovarian Syndrome of Insuline Resistance ?|Advances in Pathogenesis and Management of Polycystic Ovarian Syndrome in Arab Girls and Women: Role of Vitamin D Status, Adipokines, Follistatin, and Vitamin D Supplementation Therapy|PCOSD|Ain Shams University|Yes|Recruiting|February 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656121||4937|
NCT02649764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0665|LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)|Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02649764||5424|
NCT02650037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AirTest|The Air Test: A New Simple, Non-invasive Method to Diagnose Anesthesia-induced Atelectasis|Estudio de validación de la pulsioximetría Como método diagnóstico no Invasivo de Atelectasia Pulmonar y de la Efectividad de la Maniobra de Capacidad Vital Para la reversión de la Atelectasia Durante el Postoperatorio||Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|November 2014|November 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|181|||Both|18 Years|N/A|No|Non-Probability Sample|The study included all patients with ASA status I-III scheduled for elective surgery.|January 2016|January 7, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02650037||5403|
NCT02648815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UClinicalCenterTuzla|Management of Pancreatitis: the Role of Supportive and Drainage Treatment|Management of Moderate and Severe Forms of Acute Pancreatitis||University Clinical Center Tuzla|Yes|Active, not recruiting|January 2010|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||January 2016|January 5, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02648815||5497|
NCT02658955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMar|Changing Technique of Abdominal Wall Closure (PHACPA)|Changing Technique of Abdominal Wall Closure According to European Hernia Society (EHS) Guidelines in a General Hospital|PHACPA|Hospital del Mar|No|Not yet recruiting|March 2016|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658955||4719|
NCT02658968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2015-001933-26|Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-05)|A Phase 1 Dose Finding Study of 177Lu-DOTA-HH1 (Betalutin®) in Patients With Relapsed, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant||Nordic Nanovector|No|Not yet recruiting|January 2016|September 2019|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02658968||4718|
NCT02645097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 39025|Ideal Anatomic Location for Saphenous Nerve Blocks: A Prospective Clinical Evaluation|Ideal Anatomic Location for Saphenous Nerve Blocks: A Prospective Clinical Evaluation||Milton S. Hershey Medical Center|No|Enrolling by invitation|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02645097||5783|
NCT02654379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA28478|Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe|MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach||Hoffmann-La Roche||Recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in the center to receive an infusion for rituximab for a non-oncology        indication during the study period.|March 2016|March 1, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02654379||5071|
NCT02654418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-17-04/01|Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm|A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm||Cosmo Technologies Ltd|No|Recruiting|February 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02654418||5068|
NCT02650310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Instituto Bernabeu Group|New Device to Maintain the Embryo Temperature During Transfer|A New System for Preventing Thermal Stress During Embryo Transfer|EmbryoTemp|Instituto Bernabeu|No|Recruiting|April 2015|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|352|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02650310||5382|
NCT02650323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216_2105|Observational Registry on Acute Coronary Syndromes in Campania|Registro Campano Delle Sindromi Coronariche Acute|Campania RESCA|Federico II University|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|110 Years|No|Probability Sample|Patints hospitalized for Acute Coronary Syndromes|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02650323|1 Year|5381|
NCT02653365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingCYH-ICU-002|Predictors of Non-invasive Ventilation Failure in Patients With Acute Cardiogenic Pulmonary Edema|||Beijing Chao Yang Hospital||Completed|March 2012|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|118|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ACPE|January 2016|January 12, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02653365||5148|
NCT02647957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|489/2015|A Study of the Efficacy of the Code Stroke in Spain|Indicators for Quality Assessment of Hospitalized Ischemic Stroke Patients. A Study of the Efficacy of the Code Stroke in Spain|QICS|Universidad Miguel Hernandez de Elche|No|Not yet recruiting|January 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|240|||Both|18 Years|100 Years|No|||January 2016|January 6, 2016|December 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02647957||5563|
NCT02651233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSerbia|Factors That Influence Adipose Derived Regenerative Cells' Yield and Viability|Factors That May Influence Yield and Viability of Extracted Adipose Derived Regenerative Cells' Per Gram of Fat Tissue||Clinical Centre of Serbia|No|Completed|March 2014|April 2015|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|46|||Both|N/A|N/A|No|Non-Probability Sample|All patients were healthy individuals, both genders with request for subcutaneous        transplantation of autologous cell enriched adipose tissue for different indications|January 2016|January 7, 2016|January 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02651233||5311|
NCT02658682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR-229135|Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure|Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure||University of Oslo|No|Recruiting|January 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|350|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02658682||4740|
NCT02658773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPIUD|Lidocaine-prilocaine Cream on IUD Insertion Pain|Effect of Cervical Lidocaine-prilocaine Cream on IUD Insertion Pain: A Randomized Controlled Trial||Assiut University|No|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|150|||Female|20 Years|40 Years|No|||March 2016|March 10, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658773||4733|
NCT02652078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shockwave 1|Shockwave Therapy in Lower Limb Intermittent Calf Claudication|Extracorporeal Shockwave Therapy in the Treatment of Intermittent Claudication Symptoms in Peripheral Vascular Disease|SLICC|University of Hull|No|Recruiting|June 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|October 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02652078||5246|
NCT02659449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00381-41.V1.2|Assessing the Impact of Different Compression of the Hand Versus Free Hand on the Implementation of the Precision Grip|Assessing the Impact of Different Compression of the Hand (Made to Measure Gloves / Compression Bandaging) Versus Free Hand on the Implementation of the Precision Grip|EvICoMaB|Hôpital Léon Bérard|No|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with burned hands|January 2016|January 15, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02659449||4681|
NCT02659553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28/9/2014|Impact of Graft Steatosis on Post-operative Complications After Liver Transplantation|Impact of Graft Steatosis on Post-operative Complications After Liver Transplantation||Sohag University|Yes|Recruiting|January 2015|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|400|||Both|18 Years|70 Years|No|Probability Sample|All adult patients candidate for liver transplantation are included in this study|January 2016|January 15, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02659553||4673|
NCT02659631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7831001|PF-06671008 Dose Escalation Study in Advanced Solid Tumors|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06671008 In Patients With Advanced Solid Tumors||Pfizer|No|Not yet recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659631||4667|
NCT02660593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SanGrow Decoction for diabetes|Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes|SanGrow Decoction in Patients With Diabetes- Single Center, Open, and Non-randomized Study||Shidaihuajing Institute for Diabetic Research|No|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02660593||4593|
NCT02654262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD74565|Soft Tissue and Bone Development in Young Girls|Obesity and Bone Development in Young Girls|STAR|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|serum, saliva|Female|9 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Girls across obese (n=150; BMI ≥95th age and gender-specific percentile), overweight        (n=150; BMI> 85th percentile and <95th percentile), and normal weight (n=150; BMI< 85th        percentile) categories.|October 2015|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654262||5080|
NCT02654275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-15-HYMC|Effect of Proprioceptive Intervention Training on Power Capacity, Proprioceptive Ability and Technique of Young Swimmers|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|10 Years|20 Years|No|||January 2016|January 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654275||5079|
NCT02660450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIG 02|Relationship Between Aerobic Prescription Methods|Relationship Between Methods of Aerobic Prescription: Heart Rate vs. VO2 Load vs. Self Selected||Universidade Federal do Rio de Janeiro|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02660450||4604|
NCT02659358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2015-10-Shinde-Biosens|Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer|The Biosensor Study: Exploratory Study Evaluating the Use of Wearable Biosensors and Patient Reported Outcomes (PROs) to Assess Performance Status and Distress in Patients With Cancer||Cedars-Sinai Medical Center|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659358||4688|
NCT02652286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 15.270|Pulmonary Artery Harmonic Ace+7 Energy Sealing in VATS Lobectomy|Pulmonary Artery Harmonic Ace+7 Energy Sealing in VATS Lobectomy||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|January 19, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02652286||5230|
NCT02716740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7649 03|Study of Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.|Pilot Study of Branched Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.|MUSCAADE|University Hospital, Toulouse|No|Recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02716740||286|
NCT02660476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIRB: 14-0032. MRC: #14461/14|Qatar Universal Diabetes Outcomes (QUDOS) Study|Qatar Universal Diabetes Outcomes (QUDOS) Study|QUDOS|Weill Cornell Medical College in Qatar|Yes|Recruiting|October 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1700|Samples With DNA|Blood, urine, saliva and stool samples|Both|18 Years|70 Years|No|Probability Sample|Adult patients 18-70 years old with diabetes, who are a resident in Qatar or born in one        of the MENA countries with family originating from MENA countries, will be recruited from        one of the following sites:          -  Primary health care centers          -  Hamad General Hospital          -  Al-Wakra Hospital          -  Al-Khor Hospital|January 2016|January 17, 2016|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02660476||4602|
NCT02649816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Effectiveness of Resin Sealants: Retrospective Cohort Study|A Retrospective Cohort Study on Clinical Success of Resin Sealants||University of Campinas, Brazil|Yes|Completed|March 2011|December 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|88|||Both|5 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated at Piracicaba Dental School - Brazil|January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02649816||5420|
NCT02649829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG13-002|Autologous Dendritic Cell Vaccination in Mesothelioma|First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Resectable Malignant Pleural Mesothelioma|MESODEC|University Hospital, Antwerp|No|Recruiting|October 2015|November 2020|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02649829||5419|
NCT02654210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HelmholtzCIfectionsRes|LoewenKIDS - Infections and the Development of the Immune System||LoewenKIDS|Helmholtz Centre for Infection Research|No|Recruiting|February 2015|December 2022|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Nasal swabs nasal: Microbiome Nasal swabs: Virus detection Stool sample: Microbiome Stool      sample. Pathogen Detection Blood sample|Both|N/A|100 Days|No|Non-Probability Sample|Healthy Newborns in the Studyregions: Braunschweig, Hannover, Bremen, München, Halle        (Saale), Germany|January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654210||5084|
NCT02646917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bellmed001|SkinPen Efficacy on Acne Scars on the Face and/or Back|A Single-Center Trial to Evaluate the Efficacy and Tolerability of SkinPen on Male and Female Subjects' Acne Scars on the Face and/or Back||Bellus Medical, LLC|No|Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646917||5643|
NCT02659514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-POZ-201|Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer|A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC||Spectrum Pharmaceuticals, Inc|No|Not yet recruiting|February 2016|April 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659514||4676|
NCT02650180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPROT 2015-001|Usability Study for SOBERLINK System|Usability Study for SOBERLINK System||Soberlink Healthcare LLC|No|Completed|December 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650180||5392|
NCT02656862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESFANDI|Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo|Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo|RESFANDI|Institute of Tropical Medicine, Belgium|No|Recruiting|October 2015|||May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1520|||Both|2 Years|N/A|No|Probability Sample|The study will take place in the Lisungi Health centre, Pumbu. Pumbu is a health area of        about 14 000 inhabitants, belonging to the municipality of peri-urban Mont Ngafula 1, at        the southern side of Kinshasa. The Lisungi health centre is the only public health        facility in the health area, with on average 250 consultations/week. About 70% of        attending patients have fever as reason for consultation.|January 2016|January 14, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02656862|1 Day|4880|
NCT02647684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163356/15EM/0101|Triple P for Parents of Children With a Diagnosis of Cancer|Triple P for Parents of Children With a Diagnosis of Cancer||University of Manchester|Yes|Recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|100 Years|No|||January 2016|January 10, 2016|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02647684||5584|
NCT02651636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000102014|Combined Therapy With Myo-inositol and Alpha-Lipoic Acid in PCOS Women|Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome||Catholic University of the Sacred Heart||Completed|June 2014|||July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|35 Years|No|||January 2016|January 7, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02651636||5280|
NCT02651649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0411/15/HMO|Pregnancy, Sleep Disordered Breathing and Peripartum Complications|Is Sleep Disordered Breathing During Pregnancy a Modifiable Risk Factor for Fetal Growth Restriction?||Hadassah Medical Organization|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|January 7, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02651649||5279|
NCT02657564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEH-2016-1|Renal Safety of Bowel Preparation With Polyethylene Glycol|The Renal Safety of Bowel Preparation With Polyethylene Glycol for Colonoscopy: A Prospective Cohort Study||Evergreen General Hospital, Taiwan|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1152|||Both|40 Years|N/A|No|||January 2016|January 13, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02657564||4826|
NCT02647359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-028 ANI|Study of Ataluren in Patients With Aniridia|STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia|STAR|PTC Therapeutics|Yes|Recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|2 Years|N/A|No|||February 2016|February 8, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647359||5609|
NCT02652117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PedCard-001|Regional Anesthesia in Cardiac Pediatric Patients Less Than 5 Years Old|Retrospective Review of Regional Anesthesia in Cardiac Pediatric Patients||University of Iowa|Yes|Completed|July 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|545|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiac Pediatric Patients less than 5 years old|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652117||5243|
NCT02655575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/921|Assessment and Treatment of Patients With Long-term Dizziness in Primary Care|Assessment and Treatment of Patients With Long-term Dizziness in Primary Care|LODIP|Bergen University College|No|Recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02655575||4979|
NCT02655796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAK|A Device for Screening of Fall Risk in the Elderly|Evaluation of Screening Accuracy of a Device for Fall Risk Assessment in the Elderly: a Cross-sectional Study With a Futility Design||Istituto Ortopedico Galeazzi|Yes|Recruiting|November 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655796||4962|
NCT02647619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2639063|Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF|A Randomized Controlled Trial (RCT) Comparing Clostridium Histolyticum With Needle Aponeurotomy.||University Hospital, Akershus|Yes|Recruiting|October 2013|June 2021|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02647619||5589|
NCT02658695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahmed Khairy Makled|Evaluation of the Relationship Between Air Bubbles Depth and Pregnancy Rate in ICSI Cycles|Evaluation of the Relationship Between Air Bubbles Depth and Pregnancy Rate in ICSI Cycles||Ain Shams Maternity Hospital|Yes|Recruiting|April 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|82|||Female|18 Years|38 Years|Accepts Healthy Volunteers|Probability Sample|Eighty two women who will undergo ICSI in assisted reproductive technology unit of Ain        Shams University Hospital will be enrolled in and a written informed consent will be        obtained from all participants.|January 2016|January 21, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02658695|8 Weeks|4739|
NCT02653859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC2015-02|Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules|Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells(CTC) in Benign and Malignant Lung Nodules||GenoSaber|Yes|Not yet recruiting|January 2016|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|New Solitary Pulmonary Nodule|October 2015|January 10, 2016|January 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653859||5111|
NCT02649647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERN2015019|Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy|Multicenter Randomized Trial of Sphincter-Preserving Surgery With Proximally Extended Resection Margin on Bowel Function and Anastomotic Complication for Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy|PERN|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|February 2016|February 2026|Anticipated|February 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|75 Years|No|||January 2016|February 17, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649647||5433|
NCT02714049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDSM-2015-03|Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy|Two Arm Open Label Pilot Study of Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy||San Diego Sexual Medicine|No|Not yet recruiting|April 2016|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714049||493|
NCT02714062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-402|A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents|||VIVUS, Inc.|No|Recruiting|March 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|12 Years|17 Years|No|||March 2016|March 15, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714062||492|
NCT02651337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000009795|Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters|Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters||Alcyone Lifesciences, Inc.|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|35 Years|No|||January 2016|January 7, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651337||5303|
NCT02651350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ302-FGRXGB-001|Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI|A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury||Beijing 302 Hospital|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|55 Years|No|||December 2015|January 7, 2016|December 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651350||5302|
NCT02645500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-478|Training Program and Mobile Health Message on Promoting Family Holistic Health|The Efficacy of Training Programme and Mobile Health Message on Promoting Family Holistic Health||The University of Hong Kong|Yes|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645500||5752|
NCT02645058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016589|RIRS Versus ESWL for the Treatment of Renal Stones|Retrograde Intrarenal Surgery (RIRS) Versus Extracorporeal Shock Waves Lithotripsy (ESWL) for the Treatment of Renal Stones Measuring 6-20 mm: A Prospective Randomized Study||University of Turin, Italy|Yes|Recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645058||5786|
NCT02714335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114764|The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients|An Observational Study to Determine the Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients in Taiwan||National Taiwan University|No|Completed|December 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|20 Years|N/A|No|Probability Sample|Site will retrieve tissue samples of around 200 cases of NSCLC patients with informed        consent including about 100 cases of adenocarcinoma (AC) and 100 cases of squamous cell        carcinoma (SCC), with stages of IB, IIA, IIB and IIIA.|March 2016|March 21, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02714335||471|
NCT02655042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-01-002-2015|Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|ReaCT-X|RepliCel Life Sciences, Inc.|No|Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|28|||Both|18 Years|66 Years|No|Non-Probability Sample|Individuals who have completed participation in a clinical trial to evaluate the safety        and efficacy of injections of RCT-01.|January 2016|January 11, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02655042||5020|
NCT02650609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000927-96|Treatment of Chronic Subdural Hematoma by Corticosteroids|Treatment of Chronic Subdural Hematoma by Corticosteroids|SUCRE|Rennes University Hospital|No|Not yet recruiting|March 2016|March 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|202|||Both|18 Years|N/A|No|||December 2015|January 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02650609||5359|
NCT02650895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD24Fc-001|Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects||OncoImmune, Inc.||Completed|February 2014|||January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650895||5337|
NCT02655653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-291|Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery|A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery||Montefiore Medical Center|No|Completed|October 2008|October 2015|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02655653||4973|
NCT02718664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N16URA|Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity|Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity||The Netherlands Cancer Institute|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02718664||138|
NCT02718976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-TFB-SR-ULMR|Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block|Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block||University of Aarhus|Yes|Not yet recruiting|March 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|March 18, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02718976||114|
NCT02648737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11169|Cognitive Behavioural Therapy for Anxiety Disorders in PD|Cognitive Behavioural Therapy for Anxiety Disorders in Patients With Parkinson's Disease: a Randomized, Controlled Trial of the Clinical Effectiveness and Changes in Cerebral Connectivity||Maastricht University Medical Center|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|80 Years|No|||January 2016|January 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648737||5503|
NCT02658799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/071|Effects of a Cyclic NSAID Regimen on Levels of GCF PGE-E2 and IL-1beta|A Cyclic Regimen of Diclofenac Potassium May be Efficacious in the Management of Chronic Periodontitis in Adults||Baskent University|Yes|Completed|January 2000|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|32 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658799||4731|
NCT02658812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0034|Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence|A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658812||4730|
NCT02650154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB1000033567|The Effects of the Anesthetic Ketamine in Young Children Undergoing Procedural Sedation|The Effects of the Anesthetic Ketamine in Young Children Undergoing Procedural Sedation||The Hospital for Sick Children|No|Recruiting|August 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|Blood and plasma samples|Both|3 Months|48 Months|No|Probability Sample|All children between the ages of 3 and 48 months who receive intravenous ketamine for        procedural sedation in the ED during study enrolment hours will be eligible for        recruitment.|January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650154||5394|
NCT02650167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-AOI-02|Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea||COLOSTRUM|Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|116|||Both|N/A|N/A|No|||November 2015|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650167||5393|
NCT02718651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1881-2|Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer|Identification of Response to ALK-targeted Treatment in Lung Cancer Patients by Monitoring Tumor DNA in Blood Samples||University of Aarhus|Yes|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Blood samples - plasma|Both|18 Years|N/A|No|Probability Sample|Patients with ALK-translocated lung cancer|March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02718651||139|
NCT02718950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|i-LAB|Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans|Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans|i-LAB|University of Campinas, Brazil|Yes|Not yet recruiting|June 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|March 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718950||116|
NCT02653261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Tunis El Manar|Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology|Safety and Efficacy of Intravenous Tranexamic Acid in Reducing Blood Transfusion After Endoscopic Transurethral Resections in Urology: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study||University Tunis El Manar|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|90 Years|No|||January 2016|January 12, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02653261||5156|
NCT02656017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060422|Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease|Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease|TAME|University of Pittsburgh|Yes|Not yet recruiting|April 2016|September 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|60 Years|No|||February 2016|February 25, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656017||4945|
NCT02647333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2336|Intervention With Omega Fatty Acids in High-risk Patients|Intervention With Omega Fatty Acids in High-risk Patients With Hypertriglyceridemic Waist||Haukeland University Hospital|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|42|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02647333||5611|
NCT02654002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-402-1851|Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics|A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics||Gilead Sciences|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02654002||5100|
NCT02653547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dur-freq-rTMS-tin|Influence of Treatment Duration and Stimulation Frequency on rTMS in Chronic Tinnitus|Influence of Treatment Duration and Stimulation Frequency on Repetitive Transcranial Magnetic Stimulation in Chronic Tinnitus||University of Regensburg|Yes|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653547||5134|
NCT02659696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-037|Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis|An Observational Study to Evaluate the Efficacy of Nalfurafine Hydrochloride in Patients With Primary Biliary Cholangitis||Teikyo University|No|Recruiting|September 2015|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|Patients with PBC, who complained of moderate or severe pruritus, and decided by physician        to be administered nalfurafine hydrochloride|January 2016|January 15, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02659696||4662|
NCT02652312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesthesia 110T|Dexmedetomidine and Desflurane Consumption|Impact of Dexmedetomidine Infusion on Desflurane Consumption and Hemodynamics During Laparoscopic Cholecystectomy: Randomized Controlled Study||Theodor Bilharz Research Institute|No|Not yet recruiting|February 2016|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|50 Years|No|||January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652312||5228|
NCT02716012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNA-3521-011|First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer|A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer|OUTREACH|Mina Alpha Limited|No|Recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|16 Years|N/A|No|||March 2016|March 21, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02716012||342|
NCT02656732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC_SCTG|Amnion Chorion Membrane in Comparison to Subepithelial Connective Tissue Graft in Gingival Recession Coverage|Clinical Evaluation of Amnion Chorion Membrane in Comparison to Subepithelial Connective Tissue Graft in Gingival Recession Coverage: A Randomized Controlled Clinical Trial.||Cairo University|No|Completed|June 2014|October 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|54 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656732||4890|
NCT02652520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYOP (RB 14.208)|Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)|Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation||University Hospital, Brest|Yes|Recruiting|January 2016|February 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02652520||5212|
NCT02659956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160055|Pathological Basis of MRI Signal Changes in Multiple Sclerosis|The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|August 2041|Anticipated|February 2041|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|January 20, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02659956||4642|
NCT02644785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/10|Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions|Investigation of Anaphylactic Reaction in Cases Undergoing Cardiac By-Pass Surgery||Mustafa Kemal University|Yes|Recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|19 Years|N/A|No|Probability Sample|elective cardiac By-Pass surgery cases|February 2016|February 4, 2016|December 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02644785||5807|
NCT02657018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-424|Mobile Exergaming in Type 2 Diabetes|Mobile Exergaming in Type 2 Diabetes - Effects of an Innovative, Serious Game Application on Physical Activity and Exercise Adherence in Type 2 Diabetes Mellitus (Randomized Controlled Trial)|MOBIGAME|University of Basel|No|Not yet recruiting|February 2016|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|45 Years|70 Years|No|||January 2016|January 13, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657018||4868|
NCT02657031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM 2015.13|The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine|The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.||University Medical Center of Southern Nevada|No|Not yet recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657031||4867|
NCT02649608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16779A|An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients|Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Pro-drug Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of the Pro-drug Lu AE04621 to Patients With Parkinson's Disease||H. Lundbeck A/S|Yes|Recruiting|January 2016|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|45 Years|75 Years|No|||January 2016|January 20, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649608||5436|
NCT02644798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL014.0|Gene Polymorphism in ARDS|The Role of Polymorphism in Prognosis of Acute Respiratory Distress Syndrome (ARDS)and Phenotype Patients to Guide Therapy||Southeast University, China|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Peripheral blood|Both|18 Years|N/A|No|Probability Sample|Patients with ARDS risk factors and ARDS patients|December 2015|December 31, 2015|April 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02644798||5806|
NCT02645084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14_301#14.17.0363|Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool|Identifying the Risk of Hereditary and Familial Colorectal Cancer in Colorectal Cancer Patients by Using an Online Risk Tool: An Evaluation Based on a Stepped Wedge Design|FR-QUENT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Enrolling by invitation|February 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|104|||Both|N/A|N/A|No|||January 2016|January 3, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645084||5784|
NCT02646306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3826/2015|A New Shoulder Proprioceptive Rehabilitative Tool (SRPT) for the Evaluation of the Role of the Shoulder During Reaching|A New Neurocognitive Interpretation of the Shoulder Position Sense During Reaching|SRPT-Iphase|University of Roma La Sapienza|Yes|Completed|July 2015|January 2016|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|44|||Both|55 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects affected by shoulder impingement syndrome and healthy subjects.|January 2016|March 22, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646306||5690|
NCT02654561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNCCC-B01-2014|Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation|Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC||China Medical University, China|No|Not yet recruiting|May 2016|June 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||August 2015|January 12, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02654561||5057|
NCT02653118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-021|Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)|A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women||Merck Sharp & Dohme Corp.|No|Active, not recruiting|January 2016|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4453|||Female|16 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the V503-021 long-term follow-up study received either the selected dose        formulation of V503 or GARDASIL in the V503-001 (NCT00543543) base study|February 2016|February 9, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02653118||5167|
NCT02661503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1762|HD21 for Advanced Stages|HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD||University of Cologne|Yes|Not yet recruiting|April 2016|September 2025|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661503||4523|
NCT02645357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST100.23|Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients|Effect on Professional Practice and Health Care Outcomes of Computerized Evidence-based Information System and Clinical Decision Support: A Randomized Controlled Trial in Orthopaedics (GR-2009-1606736)|ONCO-CODES|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|No|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2046|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645357||5763|
NCT02650193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIN-130-1504|A Study of the Safety and Effects of One or More Doses of HSP-130 Injected Under the Skin in Women With Breast Cancer That Has Not Spread to Distant Sites in the Body.|A Phase 1-2 Ascending Dose Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of HSP-130 in Subjects With Non- Metastatic Breast Cancer Following Single Dose and Multiple Dose Administration by Subcutaneous Injection||Hospira, Inc.|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|48|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650193||5391|
NCT02656524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18686|Stivarga Real Life Evidence in Hungary|Effectiveness of Stivarga (Regorafenib) for Patients With Metastatic Colorectal Cancer in the Hungarian Real World Setting||Bayer|No|Not yet recruiting|April 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|The study population will be all patients who met the criteria within the SmPC. Using the        National Health Insurance Database, patients will be included in this retrospective data        analysis if they had at least one dose of regorafenib treatment cycle.|March 2016|March 16, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02656524||4906|
NCT02654678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-602295-03|Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril|Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril|LENA-WP10|Ethicare GmbH|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|8 Weeks|12 Years|No|||January 2016|January 12, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02654678||5048|
NCT02654691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPN-2015|Chronic Neuropathy Following Chemotherapy|Chronic Neuropathy Following Chemotherapy||Danish Pain Research Center|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|174|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Patients who underwent chemotherapy for a high-risk mamma-cancer and a high-risk        colon-cancer from the period of 2011-2012 and who participated in a prospective        questionnaire study (Ventzel et al. 2015).|January 2016|January 11, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02654691||5047|
NCT02661542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-10502-01|Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas|A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas||Fujifilm Pharmaceuticals U.S.A., Inc.|No|Recruiting|January 2016|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|84|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661542||4520|
NCT02660801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQTR-2016-STIF|Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain|Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain||Université du Québec à Trois-Rivières|No|Recruiting|March 2016|February 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660801||4577|
NCT02651246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 31915|Optional Sub-study to Intraoperative Imaging With ICG Registry|Optional Sub-study to Intraoperative Imaging With ICG Registry||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2015|||December 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|cancer patients who undergo surgery and intraoperative imaging|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651246|10 Years|5310|
NCT02660242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1DX Mini-dose Exercise|The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes|The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes||T1D Exchange Clinic Network Coordinating Center|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|16|||Both|18 Years|64 Years|No|||March 2016|March 24, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660242||4620|
NCT02647632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC34 REVENGE|Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir|Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||Not yet recruiting|January 2016|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02647632||5588|
NCT02659332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URU05|Laser Treatment of Bladder Tumors in the Outpatient Department|Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department||Bispebjerg Hospital|Yes|Enrolling by invitation|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659332||4690|
NCT02660489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORCA2015|Effect of OC459 on the Response to Rhinovirus Challenge in Asthma|Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma||Imperial College London|Yes|Recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|55 Years|No|||January 2016|January 20, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02660489||4601|
NCT02649166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501021|Responsive Deep Brain Stimulator for Essential Tremor|Closing the Loop on Tremor: A Responsive Deep Brain Stimulator for the Treatment of Essential Tremor||University of Florida|Yes|Not yet recruiting|May 2016|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||January 2016|January 6, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02649166||5470|
NCT02653430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD026|Efficacy and Mechanism Study of Bariatric Surgery to Treat Moderate to Severe Obesity in Han Chinese Population|Efficacy and Mechanism Study of Bariatric Surgery to Treat Moderate to Severe Obesity in Han Chinese Population||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|February 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02653430||5143|
NCT02653443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 00116|A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study|A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study to Assess the Recovery and Lifespan of Radiolabeled Autologous INTERCEPT Treated Apheresis Platelet Components Suspended in Nominal 35% Plasma and 65% InterSol Stored for 6 or 7 Days||Cerus Corporation|No|Recruiting|December 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653443||5142|
NCT02653677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bo11/14|Glycemic and Hormone Responses After the Intake of Four Types of Bread.|Glycemic and Hormone Responses and Satiety After the Intake of Four Types of Bread.||University of Turin, Italy|No|Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|16|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 10, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02653677||5124|
NCT02656511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-236-1354|Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection|Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection|DGVTRU|University of California, San Francisco|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656511||4907|
NCT02656576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 153 02|Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy|Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy|HPV-BIOFRO|University Hospital, Toulouse|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02656576||4902|
NCT02646371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2A-2B|Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a|Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a||LimmaTech Biologics AG|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646371||5685|
NCT02650843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T12/2014|Non-motor Symptoms and Brain Dopamine Transporter Binding|Non-motor Symptoms and Brain Dopamine Transporter Binding: An Observational Study in Parkinsonism|NMDAT|Turku University Hospital|No|Enrolling by invitation|January 2015|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients with parkinsonism|January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650843||5341|
NCT02645292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/SERC/83/2015|Comparison Between Stair Climbing and One Mile Walking in Relation to Cardiorespiratory Fitness|Comparison Between Stair Climbing and One Mile Walking in Relation to Cardiorespiratory Fitness||Universiti Tunku Abdul Rahman|No|Completed|October 2015|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02645292||5768|
NCT02658123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201601014|Reducing Readmissions in High-Risk Ostomates|Reducing Readmissions in High-Risk Ostomates||Washington University School of Medicine|No|Not yet recruiting|February 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658123||4783|
NCT02712996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI 56592|Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children|Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits|TBIC|Vanderbilt University|No|Not yet recruiting|March 2016|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02712996||574|
NCT02713009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 15/NI/0068|Impact of Maternal Body Weight on Vitamin D Status During Pregnancy|Investigation of the Impact of Maternal Body Weight on Vitamin D Status During Pregnancy: a Randomised Supplementation Study|MO-VITD|University of Ulster|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02713009||573|
NCT02646644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501247|Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis|Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis|HET-NET|University Medical Center Groningen|No|Not yet recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|45|||Both|18 Years|N/A|No|Probability Sample|We will select the 18F- DOPA-PET scans conducted in the UMCG of adult patients with a        metastasized intestinal NET between February 2014 until November 2015. Only patients of        whose clinical data are available within the UMCG are included.|January 2016|January 2, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02646644||5664|
NCT02646904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9-2015|Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis|Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis||Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|No|Not yet recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|6 Years|16 Years|No|||January 2016|January 5, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02646904||5644|
NCT02655146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ferring-IIT-01|the Effects of GnRHa Add up to Routine Luteal Phase Support on Frozen Embryo Implantation in Frozen Embryo Transfer .|Implantation in Frozen Embryo Transfer||Chong Qing Reproducive and Genetic Institute|Yes|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Female|20 Years|37 Years|No|||December 2015|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655146||5012|
NCT02659228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-784|Assessing Covert Consciousness in Unresponsive Patients|Assessing the Potential for 'Covert Consciousness' in Unresponsive Patients||University of Michigan||Not yet recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|50 Years|No|||January 2016|January 14, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659228||4698|
NCT02647385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2015-90|Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation|Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation||Hospital Sirio-Libanes|Yes|Recruiting|December 2015|August 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|65 Years|No|||January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02647385||5607|
NCT02651558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLOOD PRESSURE|Optical System to Continuously Measure Arterial Blood Pressure|Comparison of an Optical System to Continuously Measure Arterial Blood Pressure Against a Gold-standard Arterial Catheter|BP|Centre Suisse d'Electronique et Microtechnique SA|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02651558||5286|
NCT02651376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302H-2|Safety and Efficacy of Allogenic Adoptive Cell Therpy for Immunodeficiency in Chronic HIV-1 Infected Patients|Safety and Efficacy of Allogenic Adoptive Cell Therpy for Immunodeficiency in Chronic HIV-1 Infected Patients||Beijing 302 Hospital|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||September 2015|January 7, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02651376||5300|
NCT02645799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-II-02|BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY|Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention|BLADE|BIOrest Ltd.|Yes|Not yet recruiting|April 2016|November 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|270|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645799||5729|
NCT02646124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4639|Diazepam for Acute LBP|Adding Diazepam to Standard Management of Acute, Non-radicular Low Back Pain. An Emergency Department Based Randomized Comparative Effectiveness Study||Montefiore Medical Center|Yes|Recruiting|June 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|21 Years|69 Years|No|||December 2015|December 31, 2015|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646124||5704|
NCT02655848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO 10.087|Tenotomy or Tenodesis of Long Head Biceps in Arthroscopic Rotator Cuff Repair|Long Head Biceps Tenodesis or Tenotomy in Arthroscopic Rotator Cuff Repair: An International Multicenter Prospective Randomized Clinical Trial|BITE|Onze Lieve Vrouwe Gasthuis|No|Recruiting|July 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|98|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02655848||4958|
NCT02651844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIDC-2012-0084|Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.|Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy.|MIPRA|Hospital Provincial Magdalena V. de Martínez|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|50 Years|N/A|No|||January 2016|January 7, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02651844||5264|
NCT02651857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exploratory study|Exploratory Study of Upper and Lower Endoscopic Fuse System|||EndoChoice Inc.|No|Active, not recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|75 Years|No|||January 2016|January 8, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651857||5263|
NCT02655458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1275|Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma|Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655458||4988|
NCT02647268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-01|Effect of Magnesium Sulphate Pre-exposure on Oxytocin-induced Contractility in Desensitized Human Myometrium - an in Vitro Study|Effect of Magnesium Sulphate Pre-exposure on Oxytocin-induced Contractility in Desensitized Human Myometrium - an in Vitro Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647268||5616|
NCT02718872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRUITFUL GB-13520139|Tobacco Cessation Training Program in Spanish-speaking Countries|Development and Dissemination of a Tobacco Cessation Training Program for Healthcare Professionals in Spanish-speaking Countries|FRUITFUL|Institut Català d'Oncologia|No|Active, not recruiting|January 2015|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|March 19, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02718872||122|
NCT02655003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150333|Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropscyhiatric Symptoms|TIME - Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropscyhiatric Symptoms|TIME|Sykehuset Innlandet HF|No|Recruiting|January 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|N/A|N/A|No|||January 2016|February 15, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02655003||5023|
NCT02660840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15969A|Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations|Interventional, Open-label, Randomised, Crossover, Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations - Film Coated Tablet (Test Treatment) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) and Coated Tablet (Fluanxol®) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) in Healthy Volunteers||H. Lundbeck A/S|No|Recruiting|January 2016|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|84|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02660840||4574|
NCT02660853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1198|Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers|Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers||Imperial College London|No|Enrolling by invitation|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Sputum cells|Both|16 Years|70 Years|No|Probability Sample|Patients with severe asthma living in the UK|June 2015|January 20, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02660853||4573|
NCT02657616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAC001|Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA|Stroke Prophylaxis of Patients With Atrial Fibrillation: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to Vitamin-k-antagonists Based on an Analysis of German Claims Data||Institut für Pharmakoökonomie und Arzneimittellogistik e.V.||Completed|December 2015|||December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|204464|||Both|18 Years|N/A|No|Non-Probability Sample|The analysis is based on a data set of patients with atrial fibrillation (01/01/2010 -        30/06/2014) insured by the AOK PLUS, AOK Bayern or AOK Baden-Württemberg.|January 2016|January 13, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657616||4822|
NCT02719197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-083-101|First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders|Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects||Actelion|No|Recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02719197||97|
NCT02648698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FuXingH|RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis|A Prospective, Randomized, Placebo-controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis||Fu Xing Hospital, Capital Medical University|No|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Female|18 Years|50 Years|No|||January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02648698||5506|
NCT02648711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX101-102|Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors|Evaluation of an Alternative Schedule for CRLX101 Alone and in Combination With Bevacizumab in Subjects With Advanced Solid Tumor Malignancies||Cerulean Pharma Inc.|No|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02648711||5505|
NCT02659982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-H-003-2013|Evaluation of EarlySense Home Care Tele-monitoring Device -For Early Detection of Deterioration For Cardiac Patients at Home|Study Protocol for Evaluation of EarlySense Home Care Tele-monitoring Device - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion For Early Detection of Deterioration For Cardiac Patients at Home||EarlySense Ltd.|Yes|Recruiting|April 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|21 Years|N/A|No|Non-Probability Sample|Post Cardiac Surgery|January 2016|January 16, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02659982||4640|
NCT02659995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLINF001|Relationship Between Blood Glucose Levels and Variability and Infections Development in Critically Ill Patient|Relationship Between Blood Glucose Levels and Variability and Infections Development in Critically Ill Patient||Università Politecnica delle Marche|No|Recruiting|February 2016|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3300|||Both|18 Years|N/A|No|Non-Probability Sample|patients consecutively admitted in the participating ICUs.|February 2016|February 1, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659995||4639|
NCT02653937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Effect of Shigyakusan Used for IBS and MUPS Diagnosed by Abdominal N Line Tenderness|The Effect of Shigyakusan Used for Irritable Bowel Syndrome and Medically Unexplained Physical Symptoms Diagnosed by Abdominal N Line Tenderness||Nakatani Clinic|No|Completed|March 2013|March 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||January 2016|January 10, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02653937||5105|
NCT02718105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512-MAD-067-JG|Maternal and Fetal Compatibility in ART-oocyte Donor Influences Live Birth Rate|Maternal KIR and Fetal HLA-C Compatibility in ART-oocyte Donor Influences Live Birth Rate a Prospective Controlled Cohort Study||IVI Madrid|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Genomic DNA will be obtained and will be studied in Professor Moffet laboratory in Cambridge      (department of Pathologí, University of Cambridge) KIR typing including copi number and      HLA-C loci will be performed as previously described (Hiby 2010, Jiang 2012). KIR haplotype      regions will be defined by the presence of the following KIR genes: Cen-A/2DL3; Tel-A/3DL1      and 2DS4; Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be      divided into 2 groups: HLA-C1 and HLA-C2.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing an assisted reproductive treatment|March 2016|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718105||181|
NCT02654899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0281001|Single Dose Study of PF-06815345 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06815345, As Well As Characterize The Pharmacokinetics Of Two Formulations And Effect Of Food On Pharmacokinetics Of One Formulation Of Pf‑06815345 Administered To Healthy Adult Subjects||Pfizer|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|5||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02654899||5031|
NCT02650089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSaoFrancisco1|Resistance Exercise Modify Cardiovascular Responses of Professors During Teaching and Sleep|Resistance Exercise Modify Cardiovascular Responses of Professors During Teaching and Sleep||Universidade Federal do vale do São Francisco|Yes|Completed|July 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|10|||Male|30 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02650089||5399|
NCT02649868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160049|LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation|A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|100 Years|No|||December 2015|January 13, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649868||5416|
NCT02718417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991010|Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)|A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100)||Pfizer|Yes|Not yet recruiting|April 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|951|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718417||157|
NCT02660281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBMT 15056|URMC Related Haplo-identical Donor BMT|Haploidentical Donor Hematopoietic Stem Cell Transplantation|HaploOnly|University of Rochester|Yes|Recruiting|October 2015|October 2026|Anticipated|October 2025|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|6 Months|75 Years|No|||January 2016|January 15, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02660281||4617|
NCT02660294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-IVF|Intrauterine Autologous PRP Infusion Compared to HRT for Enhancing Endometrial Thickness in Patients Undergoing ICSI|Intrauterine Autologous Platelet -Enriched Plasma Infusion Compared to Hormonal Replacement Therapy for Enhancing Endometrial Thickness in Patients Undergoing ICSI||Ain Shams University|Yes|Recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02660294||4616|
NCT02655614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN29823|A Single-Ascending-Dose Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Patients With Amyotrophic Lateral Sclerosis|A PHASE I, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, SINGLE ASCENDING-DOSE STUDY TO DETERMINE INITIAL SAFETY, TOLERABILITY, AND PHARMACOKINETIC PARAMETERS OF GDC 0134 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS||Genentech, Inc.||Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02655614||4976|
NCT02660684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-07-11-KOR|Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor|A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor||Astellas Pharma Inc|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660684||4586|
NCT02714933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P150909|Thoracic MRI Imaging in Children|Thoracic Imaging in Children With Neither Irradiation Nor Injection, by a New MRI Protocol Including Advanced Zero Time Echo (ZTE)|ImagINI-CHEST|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|June 2016|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|6 Years|16 Years|No|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714933||425|
NCT02715167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeNOTX|Predictive Factors in Response to Inhaled Corticoids in Chronic Cough||FeNOTX|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Not yet recruiting|March 2016|December 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02715167||407|
NCT02653027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001811|Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del|A Study of the Effect of Combination Lumacaftor and Ivacaftor on Glucose Tolerance in Persons With Cystic Fibrosis Who Are Homozygous for the Phe508del Cystic Fibrosis Transmembrane Conductance Regulator Mutation.|LIGHT-CF|Massachusetts General Hospital|No|Not yet recruiting|January 2016|August 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02653027||5173|
NCT02653040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLIGHT|Light as an Aid for Recovery in Psychiatric Inpatients|Light as an Aid for Recovery in Psychiatric Inpatients: A Pragmatic Randomized Controlled Pilot Trial||University of Aarhus|Yes|Recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|68 Years|No|||November 2015|January 15, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02653040||5172|
NCT02646111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-OS-503-CTIL|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures|An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02646111||5705|
NCT02655835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10939|Internet Mindfulness Meditation Intervention|Internet Mindfulness Meditation Intervention|IMMI|Oregon Health and Science University|No|Active, not recruiting|September 2014|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|52|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02655835||4959|
NCT02714920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0188|DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD)|DNA Repair Enzyme Signature Associated With Response to Chemo- and Radio-therapy in Head and Neck Cancer: ChemRadAssay|CHEMRAD|Hospices Civils de Lyon|No|Recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714920||426|
NCT02656186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO_elderly|Supplementation With Nutrients Modulating IGF-1 and Cytokines in Elderly People at Risk of Undernutrition|Supplementation With Nutrients Modulating IGF-1 Negatively Correlated With Changes in the Levels of Proinflammatory Cytokines in Community-dwelling Elderly People at Risk of Undernutrition||Yonsei University|Yes|Completed|May 2015|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Both|65 Years|86 Years|No|||January 2016|January 15, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656186||4932|
NCT02656199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4541|Change In Diaphragmatic Thickness Predicts Extubation Success|Can the Diaphragm Predict the Course of Mechanical Ventilation? A Prospective Study Evaluating Several M-Mode Ultrasound Measured Diaphragmatic Parameters and Their Effects on Weaning From Mechanical Ventilation||Albert Einstein Healthcare Network|No|Recruiting|January 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on mechanical ventilation in the intensive care unit|January 2016|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656199||4931|
NCT02661425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH MA 1010|Retrospective Study of IBS-D Patients Previously Receiving SBI|Retrospective Study of Irritable Bowel Syndrome With Diarrhea (IBS-D) Patients Previously Receiving Serum-derived Bovine Serum Immunoglobulin (SBI)||Entera Health, Inc|No|Recruiting|December 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have failed on Standard of Care and then taken EnteraGam for management of        their IBS-D for at least eight weeks.|January 2016|January 25, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661425||4529|
NCT02652065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0425|Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis|Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis|MicroPso|Hospices Civils de Lyon|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|22|||Both|20 Years|40 Years|No|||December 2015|January 11, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652065||5247|
NCT02652299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140062|Fibrocytes in Early and Longstanding Rheumatoid Arthritis|Fibrocytes in Early and Longstanding Rheumatoid Arthritis||Odense University Hospital|No|Recruiting|March 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Peripheral blood, Synovial tissue biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Following informed written consent, RA patients will be enrolled from Odense University        Hospital (OUH) during a 12 month period.|March 2016|March 12, 2016|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02652299||5229|
NCT02655887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-14-007|BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease|The BARD® VENOVO™ Venous Stent Study - A Prospective, Non-Randomized, Multi-Center, Single-Arm Study of the Treatment of Iliofemoral Occlusive Disease - an Assessment for Effectiveness and Safety (VERNACULAR)|VERNACULAR|C. R. Bard|Yes|Not yet recruiting|January 2016|March 2020|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655887||4955|
NCT02656134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Small bowel profile in FAP|Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)|Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis||University of Sao Paulo|Yes|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|Small bowel biopsies and blood samples|Both|15 Years|65 Years|No|Non-Probability Sample|Patients with Familial Adenomatous Polyposis with colectomy, or scheduled for surgery.|January 2016|January 12, 2016|January 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02656134|2 Years|4936|
NCT02656927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-REB#15-9413-D|Evaluation of a Specialized Yoga Program for Persons With Spinal Cord Injury (SCI)|Evaluation of a Specialized Yoga Program for Persons With Spinal Cord Injury: A Randomized Controlled Trial|SCI|University Health Network, Toronto|No|Not yet recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656927||4875|
NCT02658019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151049|Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma|Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)||University of Miami|Yes|Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658019||4791|
NCT02652650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108093|A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone|A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone||Janssen Research & Development, LLC|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652650||5202|
NCT02652949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10219498DOC|Valiant Evo US Clinical Trial|Valiant Evo US Clinical Trial|VEVO|Medtronic Endovascular|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|March 9, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652949||5179|
NCT02652962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-200-001|Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters|A Randomized, Double-blind, Placebo-Controlled, 4-Period Study Assessing the Safety, Tolerability and Glycemic and Appetite Effects of Gelesis200 Using Two Different Timings of Administration in Overweight and Obese Subjects|STAGE|Gelesis, Inc.|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|24|||Male|22 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|December 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02652962||5178|
NCT02644915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zxy|Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients|Effect of Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients: A Single-Center, Double-Blinded, Randomised Controlled Trial|I/R|Xijing Hospital|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|55 Years|No|||December 2015|December 30, 2015|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644915||5797|
NCT02653820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-15 HYMC|Complementary Effect of Reflexology on Chemotherapy-Induced Nausea and Vomiting|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|N/A|N/A|No|||January 2016|January 10, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02653820||5114|
NCT02659813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015DE11|Firewire: Investigation of the Clinical Efficiency of a Novel Orthodontic Archwire|Firewire: Investigation of the Clinical Efficiency of a Novel Orthodontic Archwire - A Randomised Clinical Trial|FIREWIRE|University of Dundee|Yes|Not yet recruiting|February 2016|May 2018|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|12 Years|N/A|No|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659813||4653|
NCT02649413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|695 RMC -AJSNS|Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome|Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome|AJSNS|Rabin Medical Center|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|1 Year|18 Years|No|||December 2015|January 11, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02649413||5451|
NCT02649426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 0777|A Study of the ReCor Medical Paradise System in Clinical Hypertension|The "RADIANCE-HTN" Study. A Study of the ReCor Medical Paradise System in Clinical Hypertension|RADIANCE-HTN|ReCor Medical, Inc.|Yes|Recruiting|March 2016|July 2020|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649426||5450|
NCT02654288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81272573|Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy|Dynamic Changes of the Serum Level of Immunoglobulin G4(IgG4) and Interleukin-10(IL-10) in the Patients of Pancreatic Cancer After Gemcitabine-based Chemotherapy||Peking Union Medical College Hospital|Yes|Recruiting|January 2016|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|The IgG4 in serum from peripheral blood will be detected.(4ml/test)|Both|18 Years|75 Years|No|Probability Sample|Pancreatic cancer patients without history of chemotherapy will be recruited. After        evulation of the physical status, the patients will receive gemcitabine-based        chemotherapy.The peripheral blood will be collected and the sera IgG4 and IL-10 will be        detected during chemotherapy. Then the correlation of the dynamic changes of IgG4 and        IL-10 with the response of chemotherapy and the overall survival will be analyzed.|December 2015|January 24, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654288||5078|
NCT02654301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xylose_2015|Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia|Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia in Subjects With Normal Glucose Level and Impaired Fasting Glucose||Yonsei University|No|Completed|June 2014|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2015|January 12, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02654301||5077|
NCT02644928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDOC-BAROBE-2015-01|Weight Loss in Obese Kidney Disease Patients After Bariatric Surgery|Effects of Weight Loss on Renal Function in Obese Patients With Chronic Kidney Disease Undergoing Bariatric Surgery||Hospital Universitario 12 de Octubre|No|Recruiting|March 2016|December 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|22|Samples Without DNA|In this study, blood and urine samples will be collected to determine the effect of weight      loss in proteinuria and renal function.|Both|18 Years|65 Years|No|Probability Sample|Obese subjects with renal pathology (decrease in glomerular filtration and/or        albuminuria/proteinuria) who are candidates to bariatric surgery.|March 2016|March 11, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02644928||5796|
NCT02644941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PRO-V006|Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis|An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)||Humacyte, Inc.|Yes|Not yet recruiting|March 2016|July 2021|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644941||5795|
NCT02644954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1842/Res/1096|Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis|Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study||Postgraduate Institute of Medical Education and Research|Yes|Not yet recruiting|January 2016|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644954||5794|
NCT02649920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD019-15|Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)|Pilot, Comparative, Not Randomized, Two Centers Study Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)|BALLODINO|Centre Hospitalier Departemental Vendee|No|Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649920||5412|
NCT02650245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-59|Breath and Blood Ammonia Response to an Oral Protein Challenge|Breath and Blood Ammonia Response to an Oral Protein Challenge||St. Luke's Hospital and Health Network, Pennsylvania|No|Recruiting|September 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02650245||5387|
NCT02657187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inbody2|The Neuromuscular Effect of Rocuronium in Patient|The Neuromuscular Effect of Rocuronium in Patient Measuring Muscle Mass by Bioelectrical Impedance Analysis||Korea University Anam Hospital|Yes|Recruiting|February 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657187||4855|
NCT02657200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2015/0589 AND EC/2015/0590|Knowledge, Attitude and Practices of Flemish Midwifes Regarding Spontaneous Abortion|Knowledge, Attitude and Practices of Flemish Midwifes Regarding Spontaneous Abortion|KAP-abortion|University Ghent|No|Recruiting|September 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|3000|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02657200||4854|
NCT02661529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004591|Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts|Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts||Mayo Clinic|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|105 Years|No|||January 2016|January 21, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02661529||4521|
NCT02650453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-VE-01|Ongoing Registry of Deep Venous Reconstructions|Ongoing Registry of Deep Venous Reconstructions||Maastricht University Medical Center|No|Recruiting|September 2009|September 2029|Anticipated|September 2019|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patiënts undergoing deep venous reconstuctive interventions in cases of deep venous        obstructive disease; such as (but not limited to) post-thrombotic syndrome and May-Thurner        syndrome|December 2015|January 7, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02650453||5371|
NCT02646605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2158|Depression Amongst HIV Positive Patients in Lilongwe|Prevalence of Depression Amongst HIV Positive Patients Attending ART Clinic at Lighthouse Clinic, Lilongwe||University of North Carolina, Chapel Hill|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|206|||Both|18 Years|N/A|No|Probability Sample|Men and women accessing HIV care at Lighthouse clinic, Lilongwe, Malawi will be invited to        participate.|January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646605||5667|
NCT02646839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBMTC ONC1401|KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children|The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children With ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation||Children's Hospital Los Angeles|Yes|Recruiting|October 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|21 Years|No|||December 2015|January 4, 2016|December 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02646839||5649|
NCT02657356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-1504|Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST|A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension||Reata Pharmaceuticals, Inc.|Yes|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657356||4842|
NCT02657369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-M000-213|A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)|An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)||Eisai Inc.|No|Not yet recruiting|February 2016|May 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657369||4841|
NCT02645552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA4TBI|Pre-hospital Administration of Tranexamic Acid for Moderate and Severe Traumatic Brain Injury|Pre-hospital Administration of Tranexamic Acid for Adults With Moderate and Severe Traumatic Brain Injury: a Randomized, Double-blinded, Placebo-controlled Trial||RenJi Hospital|No|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02645552||5748|
NCT02658539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/55|Impact of Physiological, Lifestyle and Genetic Factors on Body Composition|Impact of Physiological, Lifestyle and Genetic Factors on Body Composition|BODYCON|University of Reading|No|Recruiting|February 2016|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1196|Samples With DNA|A fasting blood sample will be taken at the end of the study visit for the measurement of      fasting lipids (total and high density lipoprotein-cholesterol, triacylglycerol and      non−esterified fatty acids), glucose, insulin, C-reactive protein and for vitamin D status.      The buffy coat (consisting of white blood cells) will be isolated from the blood sample for      genotyping analysis.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Men and women living in and around Reading, Berkshire, United Kingdom|February 2016|February 29, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02658539||4751|
NCT02647645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203142F|Cognitive Training With and Without tDCS to Improve Cognition in HIV|Cognitive Training With and Without tDCS to Improve Cognition in HIV||Nova Southeastern University|No|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02647645||5587|
NCT02660346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL-10 MRSaB|IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB|A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia||Sharp HealthCare|No|Recruiting|November 2015|||May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02660346||4612|
NCT02660359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-FR-52120-223|Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2|A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis|CONTENT2|Ipsen|Yes|Not yet recruiting|March 2016|December 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|408|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660359||4611|
NCT02648438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3741C00004|A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects|An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)||AstraZeneca|No|Active, not recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|December 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02648438||5526|
NCT02653729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abdulsattar|Cbt for Psychosis and Affect on Psychosis Symptoms|Cognitive Behaviour Therapy for Psychosis in First Episode Patient and the Outcome of Cognitive Behaviour Therapy on Psychotic Symptoms|cbtpaps|Bahauddin Zakariya University|Yes|Completed|September 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|35 Years|No|||January 2016|January 12, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02653729||5121|
NCT02659098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106814|A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy|A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration|PRELUDE|Janssen Research & Development, LLC|Yes|Not yet recruiting|March 2016|March 2022|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|255|||Both|55 Years|90 Years|No|||March 2016|March 18, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659098||4708|
NCT02659150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29520|Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis|A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis||Massachusetts General Hospital|No|Not yet recruiting|January 2016|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|50 Years|75 Years|No|||January 2016|January 14, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659150||4704|
NCT02647125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-Shanghai3|A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC|A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma||Fudan University|Yes|Recruiting|October 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02647125||5627|
NCT02650856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR15-007|Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma|Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial||Universidad Autonoma de Nuevo Leon|Yes|Recruiting|September 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02650856||5340|
NCT02649595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15000708|Bridge Copenhagen - Respite Care for Homeless People|Bridge Copenhagen - Respite Care for Homeless People|BC|Hvidovre University Hospital|Yes|Active, not recruiting|April 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649595||5437|
NCT02644772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA-R-ACE|Preventing Repeat Hospitalisations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Risk Factors for Re-exacerbation After a Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|INCA R-ACE|Beaumont Hospital|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|35 Years|N/A|No|Non-Probability Sample|Patients admitted to hospital with an acute exacerbation of COPD|December 2015|December 30, 2015|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02644772||5808|
NCT02650232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-A01215-44|Pilot Study to Evaluate the Somnotouch Device to Quantify Spontaneous Baroreflex Sensitivity|Pilot Study to Evaluate the Somnotouch Device to Quantify Spontaneous Baroreflex Sensitivity in Healthy Subjects and in Patients With Heart Failure|SOMNO-BRS|University Hospital, Angers|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02650232||5388|
NCT02651129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-03259|BC Women's Hospital Noise Pilot|Assessment of Noise in BC Women's Hospital Operating Rooms||University of British Columbia|No|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Operating room staff|January 2016|January 22, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02651129||5319|
NCT02655068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 12-057|Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer|Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance||University of Pittsburgh|Yes|Terminated|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|38|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 1, 2015||No|due to non-feasibility|No||https://clinicaltrials.gov/show/NCT02655068||5018|
NCT02660411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[869]-2|Impact of Anesthesia Maintenance Methods on Long-term Survival Rate|Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial||Peking University First Hospital|Yes|Recruiting|April 2015|May 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|65 Years|90 Years|No|||January 2016|January 17, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02660411||4607|
NCT02660424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15-150-101|A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee||Vertex Pharmaceuticals Incorporated||Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|40 Years|80 Years|No|||January 2016|January 20, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660424||4606|
NCT02646774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-MA-MYC-IA-2012|Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis|A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment)||Astellas Pharma Inc|No|Terminated|March 2014|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 16, 2015||No|Due to administrative reasons|No||https://clinicaltrials.gov/show/NCT02646774||5654|
NCT02651571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-25|Survival Rates of Patients Wearing Total Knee Prosthesis With Mobile Plate for the Past 10 Years|||University Hospital, Strasbourg, France|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients wearing total knee prosthesis with mobile plate for over 10 years|January 2016|January 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02651571||5285|
NCT02655250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|758632-1|Neonatal Microbiome Validity Study|The Neonatal Microbiome Study: Validity of Biologic Sample Collection Methods||State University of New York at Buffalo|No|Active, not recruiting|September 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples With DNA|Stool and breast milk samples will be collected. Bacterial DNA will be isolated and stored.      Human DNA will not be retained in these samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of men/women willing to provide a stool sample and/or breast milk        sample.|December 2015|January 11, 2016|June 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02655250||5004|
NCT02655263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketone8000|Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion|Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion||University of Aarhus|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|March 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02655263||5003|
NCT02655315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_22|Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease|Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"|FAIRPARKII|University Hospital, Lille|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|338|||Both|N/A|80 Years|No|||January 2016|January 11, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02655315||4999|
NCT02655328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 301 03|Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping|Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping|SALBEXO|University Hospital, Toulouse|No|Completed|March 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|40 Years|No|||January 2016|January 11, 2016|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02655328||4998|
NCT02659319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIFA/USDA Agreement No. 05545|Families and Schools for Health|Intervening in Family and Peer Contexts to Decrease Child Overweight|FiSH|Oklahoma State University|No|Completed|May 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|541|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02659319||4691|
NCT02659371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.C02.2014|Weight Loss Prior Mamma Reduction - A Pilot Study|Weight Loss by Low Energy Diet as Treatment Prior Mamma Reduction in Overweight Women - A Pilot Study|MAMMARED|Copenhagen University Hospital at Herlev|No|Active, not recruiting|January 2015|June 2016|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|65 Years|No|||January 2016|January 15, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02659371||4687|
NCT02654873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sislietfal|Is Routine Use of Histopathological Examination Necessary After Cholecystectomy ?|||Sisli Etfal Training & Research Hospital|No|Recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|1000|Samples Without DNA|cholecystectomy specimens|Both|18 Years|80 Years|No|Probability Sample|1000 patients who is operated with non inflamated cholelithiasis will be included to this        study.|January 2016|January 11, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02654873||5033|
NCT02660814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-115-17/06.|Chemerin and Interleukin-6 Levels of Gingival Crevicular Fluid in Obese Individuals Following Periodontal Treatment|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Chemerin in Obese Patients With Chronic Periodontitis||Bulent Ecevit University|No|Completed|July 2014|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|32 Years|53 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660814||4576|
NCT02651467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204763|A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|Yes|Not yet recruiting|January 2016|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651467||5293|
NCT02651480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM MPD|A Nutritional Intervention in Police Officers|A Nutritional Intervention in Police Officers||Physicians Committee for Responsible Medicine|Yes|Not yet recruiting|February 2016|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651480||5292|
NCT02714530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThoRaT|Thoracal Radiotherapy and Tarceva|Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer|ThoRaT|Oslo University Hospital|Yes|Recruiting|October 2014|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02714530||456|
NCT02657291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LawsonHRI|Costoclavicular vs Paracoracoid Approach to Infraclavicular Brachial Plexus Block: a Feasibility Study|Costoclavicular vs Paracoracoid Approach to Infraclavicular Brachial Plexus Block: a Feasibility Study|CPI|Lawson Health Research Institute|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|70|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02657291||4847|
NCT02647177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-14-0980|A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions|A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions||The University of Texas Health Science Center, Houston|No|Recruiting|May 2015|December 2025|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|Cyst aspirate|Both|18 Years|100 Years|No|Non-Probability Sample|Patients presenting to Memorial Hermann Hospital for care with the primary and        subinvestigator(s) of the study will be identified, prescreened for eligibility and listed        for informed consent and subsequent enrollment.|January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647177|1 Year|5623|
NCT02647515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XShen|Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma|||Ruijin Hospital|No|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2013|January 4, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647515||5597|
NCT02647528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chromogenex Acne|A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|Chromogenix|Sadick Research Group|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647528||5596|
NCT02714855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-345|Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France|Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study||Bristol-Myers Squibb|No|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Cardiologists in france caring AF patients|March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714855||431|
NCT02653508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|obesity1uth|Evaluating the Efficacy of the Feeding Exercise Trial in Adolescents (FETA Project) in Central Greece|Evaluating the Efficacy of the Feeding Exercise Trial in Adolescents (FETA Project) in Central Greece|FETA|University of Thessaly|No|Completed|September 2011|September 2014|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|181|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02653508||5137|
NCT02645682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-I-H 1503|The Effects of Anti-infective Central Venous Catheter on Catheter-related Infection in Critically Patients|The Effects of Anti-infective Central Venous Catheter(CVC) on Catheter-related Bloodstream Infection(CRBSI) in Critical Care Patients: a Multiple-center, Randomized, Control Study||West China Hospital||Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1818|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645682||5738|
NCT02645266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC-RD-SOP-038|Mean Visual Acuity Changes Following Five Injections of Aflibercept|Mean Visual Acuity Changes Following Five Injections of Aflibercept and the Relationship Between Ocular and Serum Cytokine Levels and Mean Visual Acuity Gains in DME Patients||McMaster University||Not yet recruiting|March 2016|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645266||5770|
NCT02645279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA15/19|Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates|Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates||Baskent University|No|Active, not recruiting|January 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|112|||Both|N/A|30 Days|No|||December 2015|December 31, 2015|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645279||5769|
NCT02658526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-086/2014|Cognitive Changes in Childs After Anesthesia / Surgery|Role of Anesthesia / Surgery on Cognitive Function in Child||Heidelberg University|No|Recruiting|December 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|9 Months|3 Years|Accepts Healthy Volunteers|Probability Sample|Cohort study - children <3 years|January 2016|January 14, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02658526||4752|
NCT02658656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003|CSP #2003, "Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life"|CSP #2003, "Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life"||VA Office of Research and Development|No|Not yet recruiting|October 2016|August 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02658656||4742|
NCT02714348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HelmVacc_II|Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants|Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants||Centre de Recherche Médicale de Lambaréné||Active, not recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|323|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and their infants from Lambaréné and surroundings (Gabon)|March 2016|March 18, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714348||470|
NCT02660216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO49201525495|A Modified Minimally Invasive Approach Towards Le Fort I Osteotomy: a Prospective Study||MILF-I|AZ Sint-Jan AV|No|Active, not recruiting|November 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|All consenting patients requiring a bimaxillary orthognathic procedure as part of their        orthodontic-surgical treatment plan, and satisfying the inclusion and exclusion criteria.|January 2016|January 18, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660216||4622|
NCT02654119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318-15|Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery|A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients||University of Nebraska|Yes|Not yet recruiting|December 2015|||November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|19 Years|N/A|No|||January 2016|January 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654119||5091|
NCT02660112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006845|(+) Epicatechin to Treat Friedreich's Ataxia|A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia||Mayo Clinic|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|10 Years|50 Years|No|||January 2016|January 18, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660112||4630|
NCT02654184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087118|Right Lateral Positioning and Its Effect on Induction of General Anesthesia for Children|Right Lateral Positioning and Its Effect on Induction of General Anesthesia for Children||Assiut University|Yes|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|8 Years|No|||January 2016|January 12, 2016|January 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654184||5086|
NCT02654197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0093-15|Potential Adverse Developmental and Nutritional Consequences of Helicobacter Pylori Infection in Israeli Children|Potential Adverse Developmental and Nutritional Consequences of Helicobacter Pylori Infection in Israeli Children||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Blood samples will be taken for analysis and will be retained for later investigation.|Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Healthy children aged 6-12 years residing in the catchment areas of primary care clinics        in the Hadera sub-district of Israel.|December 2015|January 11, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02654197||5085|
NCT02714621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WM/0470 CCR4360|MR-HIFU for Gynae Metastases|Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU): A Feasibility Study for Treating Recurrent Gynaecological Malignancies|HIFU-Gynae|Institute of Cancer Research, United Kingdom||Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02714621||449|
NCT02714634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6020|Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate|Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate|BIO 3|University Hospital, Strasbourg, France|No|Not yet recruiting|March 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|286|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02714634||448|
NCT02648516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-010|Safety and Efficacy of Allogenic Adoptive Cell Therpy for Immune Reconstitution in Chronic HIV-1 Infected Patients|Safety and Efficacy of Allogenic Adoptive Cell Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients||Beijing 302 Hospital|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||September 2015|January 5, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02648516||5520|
NCT02646761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060281|interACTION: A Portable Joint Function Monitoring and Training System for Remote Rehabilitation Following TKA|interACTION: A Portable Joint Function Monitoring and Training System for Remote Rehabilitation Following Total Knee Arthroplasty||University of Pittsburgh|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||January 2016|January 4, 2016|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02646761||5655|
NCT02647034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905040R|Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension|Using the Stress Ventricular Function Assessment to Evaluate the Long-term Prognosis and Treatment Outcome in Patients With Pulmonary Hypertension||National Taiwan University Hospital|No|Recruiting|July 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients suspicious for pulmonary hypertension|January 2016|January 4, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02647034|5 Years|5634|
NCT02651831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACT-ICI|Development and Validation of a Health-related Quality of Life Instrument|Development and Validation of a Health-related Quality of Life Instrument: Functional Assessment of Cancer Therapy - Immune Checkpoint Modulators, an Investigator Initiated Study (FACT-ICI)|FACT-ICI|University Health Network, Toronto|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be patients who are receiving treatment that modulates immune        checkpoints and clinicians with expertise in this area.|January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02651831||5265|
NCT02655939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZ/150603/RFX+/OA|Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis|Double Blind, Randomized, Multicentre, Placebo Controlled Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis||Vedic Lifesciences Pvt. Ltd.|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|274|||Both|50 Years|70 Years|No|||January 2016|January 11, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02655939||4951|
NCT02650908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-28|Avivement of Suturing Area in Meniscus Lesion|Does the Avivement of Suturing Area is Essential for Healing a Meniscus Lesion ?||University Hospital, Strasbourg, France|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent meniscal suturing with or without avivement|January 2016|January 7, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02650908||5336|
NCT02650921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43USH1501|Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand|A Randomized, Evaluator Blinded, Split-hand Study to Evaluate the Effectiveness and Safety of Restylane Lyft With Lidocaine Compared to no Treatment for Injection in the Dorsal Hand to Correct Volume Deficit||Q-Med AB|No|Recruiting|December 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 10, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650921||5335|
NCT02658825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108108|A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants|A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Subjects||Janssen Research & Development, LLC|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658825||4729|
NCT02719275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H16-00524|Social Media Markers of Adolescents' Suicide Hazard|Social Media Markers of Adolescents' Suicide Hazard|SMMASH|British Columbia Children's Hospital|Yes|Not yet recruiting|April 2016|||April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|200|||Both|12 Years|17 Years|No|Probability Sample|We aim to recruit a total of 200 subjects in the four different arms of the study. First        arm: 50 adolescents admitted to CAPE because of potentially lethal suicidal behavior. This        group consists of patients whose suicidal behavior could have ended their lives or        significantly compromised their health in the absence of timely interception or        intervention. We use this cohort as a proxy for "would be" completers. Second arm: 50        adolescents admitted to CAPE because of non-lethal suicidal behavior. This group includes        patients who are admitted because of suicidal ideation without any attempt, or suicidal        behaviors that would not have ended their lives or caused significant compromise in their        health. Third arm: 50 adolescents admitted to CAPE due to mental health crises other than        suicidal behavior. Fourth arm: 50 adolescents admitted to BCCH for reasons not related to        mental health.|March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719275||91|
NCT02660762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-ALL-5010|Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL|A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults||Sun Yat-sen University|Yes|Recruiting|January 2010|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|35 Years|No|||January 2016|January 16, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02660762||4580|
NCT02647502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065806|A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis|A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis||Johns Hopkins University|Yes|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|50 Years|No|||January 2016|January 19, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02647502||5598|
NCT02659930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160047|Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma|A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|November 2021|Anticipated|November 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|99 Years|No|||December 2015|January 20, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659930||4644|
NCT02645422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCH43/2015|Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity|Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity|PeLi|Helsinki University Central Hospital|No|Enrolling by invitation|December 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|Whole blood, serum|Both|10 Years|18 Years|No|Non-Probability Sample|The study subjects include children and adolescent with severe, early-onset childhood        obesity. Early-onset obesity is defined as height-adjusted weight >60 % (corresponding to        severe obesity) before the age of 7 years.|December 2015|December 31, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02645422||5758|
NCT02661022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STML-401-0414|SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma|A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma||Stemline Therapeutics, Inc.|Yes|Recruiting|January 2016|March 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661022||4560|
NCT02661035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LS152|Allo HSCT Using RIC for Hematological Diseases|Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]||Masonic Cancer Center, University of Minnesota|Yes|Not yet recruiting|March 2016|March 2025|Anticipated|June 2022|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|N/A|75 Years|No|||January 2016|January 20, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661035||4559|
NCT02649101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZCHBC-007|Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer|Thalidomide Plus Chemotherapy Versus Chemotherapy Alone: A Phase II Study in Advanced Breast Cancer||Zhejiang Cancer Hospital|No|Recruiting|October 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||January 2016|January 5, 2016|December 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02649101||5475|
NCT02658578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0546/2011|Peripheral Nerve Stimulation and Motor Training in Stroke|Peripheral Nerve Stimulation and Motor Training to Enhance Hand Function After Stroke||University of Sao Paulo General Hospital|Yes|Recruiting|February 2015|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658578||4748|
NCT02658591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPG_UofT_FabaBean|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control||University of Toronto|Yes|Recruiting|January 2016|April 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02658591||4747|
NCT02658604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20836|Home Medication Reviews by Pharmacists in Ontario, Canada|Home Medication Review Services for Non-homebound Community Pharmacy Patients: Evaluation of Medication Management Issues in Non-homebound Patients and Characterization of Ideal Target Population for Home-based Medication Reviews.||University of Waterloo|No|Not yet recruiting|January 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|65 Years|N/A|No|Non-Probability Sample|Current patients of participating pharmacies who are aged 65 and older, live at home, and        are on 5 or more medications.|January 2016|January 14, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02658604||4746|
NCT02653833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041688|The Study of Skeletal Muscle Blood Flow in Response to the Medication Ranolazine at Rest and With Exercise|Ranolazine and Skeletal Muscle Perfusion||Cedars-Sinai Medical Center|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|19|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02653833||5113|
NCT02644733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ghada22|Effect of Different Body Position on Intraabdominal Pressure in Mechanically Ventilated Patients|Lecturer in Critical Care Nursing Department|Ghada|Assiut University|Yes|Enrolling by invitation|December 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|60 Years|No|||December 2015|December 30, 2015|December 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644733||5811|
NCT02645019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-01074|The Effect of EGD Probe Insertion on the Intracuff Pressure of the Laryngeal Mask Airway or Cuffed Endotracheal Tube in Children|The Effect of EGD Probe Insertion on the Intracuff Pressure of the Laryngeal Mask Airway or Cuffed Endotracheal Tube in Children||Nationwide Children's Hospital|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Probability Sample|Patients from 0-18 years old having EGD procedure with LMA or cuffed ETT.|December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645019||5789|
NCT02716948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15214|Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine|A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2016|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716948||270|
NCT02717221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14400|In Vivo EGFR Molecular Classification|An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy Using Molecular Imaging||Harbin Medical University|Yes|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|6||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02717221||249|
NCT02646007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-014|Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease|Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation for Human Avascular Necrosis of the Lunate Bone of the Wrist (Kienbock`s Disease)||Royan Institute|Yes|Recruiting|November 2015|December 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|January 3, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02646007||5713|
NCT02649556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRHR-ERS-09-EXT-US|A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2|A 26-week Extension Study to Determine the Biological and Functional Changes in Healthy Smokers Who Switched From Conventional Cigarettes (CC) to Tobacco Heating System 2.2 (THS 2.2) Compared to Those Who Continued to Smoke CC in the ZRHR-ERS-09-US Study||Philip Morris Products S.A.|No|Recruiting|September 2015|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|700|||Both|30 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649556||5440|
NCT02653898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR2211|Malaria Elimination Pilot Study in Military Forces in Cambodia|Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations||Armed Forces Research Institute of Medical Sciences, Thailand|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1200|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653898||5108|
NCT02653911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015EC115|Electroacupuncture on Hormonal and Glycometabolic Profiles in Women With Polycystic Ovary Syndrome: Study Protocol|Efficacy of Electroacupuncture on Hormonal and Glycometabolic Profiles in Women With Polycystic Ovary Syndrome: a Randomized, Sham-controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|40 Years|No|||February 2016|February 12, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02653911||5107|
NCT02654340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSC 06-2015|Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex|Epidemiological Study of the Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex|TuScCom|University of Rostock|Yes|Recruiting|March 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry one dry      blood spot filter card are taken. To proof the correct diagnosis in those patients where up      to the enrollment in the study no genetic testing has been done, sequencing will be done.      The analyses are done in the Centogene AG, Schillingallee 68, 18057 Rostock, Germany|Both|2 Years|N/A|No|Probability Sample|Patients of both genders older than 2 years with tuberous sclerosis complex or high-grade        suspicion for tuberous sclerosis complex|January 2016|January 12, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02654340||5074|
NCT02645227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/12/2013-14V|Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment|Platelet-rich Fibrin With 1.2% Rosuvastatin for the Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 1, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02645227||5773|
NCT02645305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2555/QD-BYT|Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease|Evaluation of Safety and Efficacy of Autologous Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease||University of Science Ho Chi Minh City|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|80 Years|No|||December 2015|December 30, 2015|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645305||5767|
NCT02712905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 59872-101|An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies||Incyte Corporation|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|108|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712905||581|
NCT02712918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BATD_16674|Brief Behavioral Activation Treatment for Depression With Inpatients|An Evaluation of Brief Behavioral Activation Treatment for Depression With Moderate to Severely Depressed Inpatients - A Small Randomized Controlled Trial||Lovisenberg Diakonale Hospital|No|Completed|January 2014|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02712918||580|
NCT02712931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU101|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2015|||||N/A|N/A|N/A||||||||||||||March 17, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712931||579|
NCT02651077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC13_0380|Endometriosis and Brominated Flame Retardant (ENDOTOX Study)|Looking for a Link Between Endometriosis and Exposure to Lipophilic Environmental Chemicals Like Brominated Flame Retardant (ENDOTOX Study)|ENDOTOX|Nantes University Hospital|No|Completed|November 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|76|Samples Without DNA|omental adipose tissue|Female|18 Years|45 Years|No|Probability Sample|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at        Nantes University Hospital for surgical indication of endometriosis lesions ablation.        And 38 women aged 18 to 45 years old without suggestive signs of endometriosis|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651077||5323|
NCT02651090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SONA1|Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI|Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced Computed Tomography and/or Magnetic Resonance Imaging Using Sonazoid||Northeastern Ohio Radiology Research and Education Fund|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|100 Years|No|||January 2016|January 7, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651090||5322|
NCT02645474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECS|Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery?|Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery? A Randomized, Case-control Study||Ospedale Regionale Bellinzona e Valli|No|Not yet recruiting|January 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 10, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645474||5754|
NCT02645487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 022015-106|Stereotactic Radiosurgery (SRS) for Brain Metastasis|A Phase I Dose-Escalation Study of Stereotactic Radiosurgery (SRS) for Brain Metastasis Without Whole Brain Radiation (WBRT)|SRS|University of Texas Southwestern Medical Center|Yes|Recruiting|December 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|99 Years|No|||December 2015|December 30, 2015|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645487||5753|
NCT02650414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012219|CD22 Redirected Autologous T Cells for ALL|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia||University of Pennsylvania|Yes|Recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|1 Year|24 Years|No|||January 2016|January 7, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650414||5374|
NCT02647073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02986|The Mobile Monitoring of Vital Signs in Opioid Users|A Pilot Study to Evaluate the Feasibility of Mobile Monitoring of Vital Signs in Opioid Users|MOVE|University of British Columbia|No|Not yet recruiting|January 2016|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02647073||5631|
NCT02652351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-hepatic cirrhosis|Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis|Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652351||5225|
NCT02652364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2423|Strong Ion Gap as Prognostic Indicator for Adult Patients Admitted With Shock to the Intensive Care Units|Strong Ion Gap as Prognostic Indicator for Adult Patients Admitted With Shock to the Intensive Care Units||Singapore General Hospital|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|112|||Both|21 Years|99 Years|No|Non-Probability Sample|Patient with any form of shock on admission to ICU defined by those who require        vasopressors or inotropes to maintain MAP > 65mmHg on admission|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652364||5224|
NCT02648165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSØ-2015056|Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure|Secondary Prevention of Depression Through Group-based Acceptance and Commitment Therapy Preceded by an Experimental Attentional Bias Modification Procedure||Sorlandet Hospital HF|No|Recruiting|April 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648165||5547|
NCT02660749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-PMS-41|The Effect Of Tramadol, Metamizol and Dexketoprofen Combination On Chronic Pain Development After Heart Surgery|The Effect Of Tramadol, Metamizol and Dexketoprofen Combination On Chronic Pain Development After Heart Surgery||Tobb University of Economics and Technology|Yes|Active, not recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Female and male are being participant.|December 2015|January 20, 2016|January 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02660749||4581|
NCT02660983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-K082-418|A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease||Eisai Inc.|No|Recruiting|August 2013|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|324|||Both|40 Years|99 Years|No|||January 2016|January 25, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660983||4563|
NCT02645643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEI001|Medical Education Intervention for Medical Students|Intervention to Promote Medical Students Empathy, Well-being and Study emotion-a Randomized Clinical Trial.||Sun Yat-sen University|No|Active, not recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02645643||5741|
NCT02646254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/1840/DM/16940|Myocardial Protection and Clinical Outcome in Patients Undergoing Tetralogy of Fallot Repair : A Randomized Study of Two Different Cardioplegia Technique|MYOCARDIAL PROTECTION AND CLINICAL OUTCOME IN PATIENTS UNDERGOING TETRALOGY OF FALLOT REPAIR: A RANDOMIZED STUDY OF TWO CARDIOPLEGIC TECHNIQUES|TOF|Postgraduate Institute of Medical Education and Research|Yes|Completed|June 2014|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|56|||Both|1 Year|50 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02646254||5694|
NCT02646267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEL102|The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients|The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation||The First Affiliated Hospital with Nanjing Medical University|Yes|Enrolling by invitation|March 2016|August 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|60 Years|N/A|No|||January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646267||5693|
NCT02651064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP|USDA Healthy Incentives Pilot|USDA Healthy Incentives Pilot (HIP)|HIP|Abt Associates|No|Completed|June 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|55095|||Both|16 Years|N/A|No|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02651064||5324|
NCT02654925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1779|Myeloid to Adipocyte Transdifferentiation in Human Cells|Myeloid to Adipocyte Transdifferentiation in Human Cells|MYTH|University of Colorado, Denver|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|50|||Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2016|January 11, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02654925||5029|
NCT02654145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204471|Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients|A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)||GlaxoSmithKline|No|Not yet recruiting|March 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|12 Years|N/A|No|||February 2016|March 17, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654145||5089|
NCT02649660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FabryPlatelets|Lipidomics and Functional Analyses of Platelets in Fabry Disease|Lipidomics and Functional Analyses of Platelets in Fabry Disease||Spital Linth|No|Recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|32|Samples Without DNA|Blood plasma, serum and platelet isolates|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Fabry Disease and healthy volunteers|January 2016|January 5, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02649660||5432|
NCT02654314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601017038|Prevention of Delirium in Inpatients Utilizing Melatonin|Prevention of Delirium in Inpatients Utilizing Melatonin|PODIUM|Yale University|No|Not yet recruiting|March 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|650|||Both|65 Years|N/A|No|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654314||5076|
NCT02654327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15084DMcA-AS|pRotective vEntilation With Veno-venouS Lung assisT in Respiratory Failure|pRotective vEntilation With Veno-venouS Lung assisT in Respiratory Failure|REST|Belfast Health and Social Care Trust|Yes|Not yet recruiting|March 2016|April 2021|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1120|||Both|16 Years|N/A|No|||January 2016|January 11, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02654327||5075|
NCT02655081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO13060027|Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy|Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy|IMPACT|University of Pittsburgh|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|90 Years|No|||January 2016|January 11, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02655081||5017|
NCT02646449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA022863-01A1|Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial|Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial|YAAD-P|University of Pittsburgh|No|Recruiting|June 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646449||5679|
NCT02646462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24|Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer|Systematic Lymph Node Sampling and Analysis in Patients Undergoing Radical Resection for Pancreatic Cancer. A National Danish Study||Odense University Hospital|Yes|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Bioptic verified pancreatic adenocarcinoma or periampullary adenocarcinoma (within 20mm of        the papilla) referred for pancreas resection|January 2016|January 6, 2016|June 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02646462||5678|
NCT02718313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2016-0005|Echocardiographic Findings and 30-days Outcomes for Intraventricular Conduction Delay in Patients Undergoing Elective Surgeries|||Yonsei University|No|Not yet recruiting|April 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Adults patients who are planning surgery under general anesthesia and whose preoperative        electrocardiography reading is intraventricular conduction delay|March 2016|March 23, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02718313||165|
NCT02713971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2009-1604984-GAMEPAD|Biofeedback Rehabilitation in Parkinson's Disease|Wearable Sensor-based Biofeedback Training for Balance and Gait in Parkinson's Disease: a Pilot Randomized Controlled Trial.|GAMEPAD_PD|Fondazione Don Carlo Gnocchi Onlus||Completed|January 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02713971||499|
NCT02654743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF15-17002|Open Label of Clinical Trial of Sulforaphane in Children With Autism|An Examination of Changes in Urinary Metabolites With Use of an Antioxidant Supplement, Sulforaphane, in School-aged Children With Autism||University of California, San Francisco|No|Enrolling by invitation|January 2016|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|5 Years|22 Years|No|||January 2016|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654743||5043|
NCT02660437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPIRE2-8465|pCO2 Oscillations During Exercise: Relation to Cerebral Blood Flow and to Cognitive Dysfunction in COPD|Carbon Dioxide Partial Pressure Oscillations During Exercise: Relation to Cerebral Blood Flow Regulation and and to the Prevalence of Cognitive Dysfunction in COPD||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Recruiting|March 2016|March 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|160|||Both|40 Years|80 Years|No|||March 2016|March 23, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02660437||4605|
NCT02647060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511029RINA|The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH|The Exercise Capacity and Quality of Life in the Patients With Idiopathic Pulmonary Arterial Hypertension and Secondary Pulmonary Hypertension||National Taiwan University Hospital|No|Not yet recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|20 Years|80 Years|No|Non-Probability Sample|pulmonary hypertension, clinical stable, able to walk and can perform cardiopulmonary        exercise testing by bicycle|January 2016|January 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02647060||5632|
NCT02647346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-04|In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers|In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers||Podimetrics, Inc.|No|Completed|November 2013|||July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|132|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647346||5610|
NCT02657122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0140|SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects|A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|72|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02657122||4860|
NCT02651662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1979-ONC-1504|Study of REGN2810 in Patients With Lymphoma|||Regeneron Pharmaceuticals|Yes|Recruiting|November 2015|June 2020|Anticipated|June 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02651662||5278|
NCT02660580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200588-002|MSB11022 in Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis|AURIEL-PsO|EMD Serono|No|Recruiting|February 2016|September 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|406|||Both|18 Years|N/A|No|||February 2016|March 23, 2016|January 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660580||4594|
NCT02719717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 15.302|Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy|Prospective, Multi-Center, International Phase 2 Trial of the Use of Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy|VATS PA-ACE|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|May 2016|February 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 28, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719717||57|
NCT02648477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15295|Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer|MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer||City of Hope Medical Center|Yes|Recruiting|March 2016|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648477||5523|
NCT02648490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLX07FIH|An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers|A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.||Henlix, Inc|No|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648490||5522|
NCT02647190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-107|Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older|A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|60 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02647190||5622|
NCT02647203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-RC PIEI-ES|Non-invasive Treatment of Root Caries in Older Adults|Non-invasive Therapy With Fluoridated Toothpastes for Root Caries in Independently-living Older Adults|MIT-RCTalca|University of Talca|No|Active, not recruiting|July 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|316|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647203||5621|
NCT02651740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SXZ-WSD01-2015|Gut Microbiota Reconstruction for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome|Gut Microbiota Reconstruction for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome||Shanghai Zhongshan Hospital|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651740||5272|
NCT02719951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIA 14 FBB / TANGAU|Glutaminergic Transmission in Autism : Molecular Imaging Exploration|Glutaminergic Transmission in Autism : Molecular Imaging Exploration|TANGAU|University Hospital, Tours|Yes|Not yet recruiting|April 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02719951||39|
NCT02645695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|erzincan university|What is the Effective Pulmonary Physiotherapy Method in Critically Care Patients?|Can High Frequency Chest Wall Oscillation Accelerate the Discharged of Intubated Intensive Care Patients?||Erzincan University|No|Completed|February 2014|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645695||5737|
NCT02649803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-10989|Pediatric Asthma Control Under Community Management Model in China|Pediatric Asthma Control Under Community Management Model in China||Shanghai Children's Medical Center|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|800|||Both|1 Month|18 Years|No|||January 2016|January 6, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02649803||5421|
NCT02646228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-12-154|Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer|Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer||Samsung Medical Center|No|Not yet recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|inclusion criteria are as follows: age ≥ 18 years; pathologically confirmed solid cancer;        presence of metastatic lesion(s) not amenable to surgical treatment and having malignant        effusion in the body cavity which needed to be drained by percutaneous methods for        therapeutic purpose.|January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646228||5696|
NCT02646241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1033|Biopsy Protocol of Upper Gastrointestinal Subepithelial Tumors:Diagnostic Accuracy of EUS-FNB Versus Unroofing Biopsy|||Yonsei University|No|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|125|||Both|19 Years|80 Years|No|||January 2016|January 6, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02646241||5695|
NCT02654730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFEPRIM-II|Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia|Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia|SAFEPRIM-II|London School of Hygiene and Tropical Medicine|Yes|Recruiting|December 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|70|||Male|10 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02654730||5044|
NCT02648243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qatar U|Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar: a Randomized Controlled Trial|Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar: a Randomized Controlled Trial||Qatar University|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|375|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02648243||5541|
NCT02660125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144|Endometrial Injury and Implantation Rates Before First ICSI Cycle|Does Local Endometrial Injury Improve Implantation Rates in Women Undergoing Their First ICSI Cycle.||Cairo University|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|40 Years|No|||January 2016|January 20, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02660125||4629|
NCT02658721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVRA|Effects of Systemic or Adjunct Tramadol Addition to Lidocaine Used for IVRA in Patients Undergoing Hand Surgery|Effects of Addition of Systemic Tramadol or Adjunct Tramadol to Lidocaine Used for Intravenous Regional Anesthesia in Patients Undergoing Hand Surgery||Bagcilar Training and Research Hospital|No|Completed|January 2013|August 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|December 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658721||4737|
NCT02658734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29662|A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane|A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane||Hoffmann-La Roche||Not yet recruiting|October 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658734||4736|
NCT02652702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCCZ-D01|Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients|Randomized Clinical Trial Comparing the Safety and Efficiency of Circular Stapler-assisted Colostomy With Hand-stitching Colostomy for Colorectal Cancer Patients|STAPLER|Zhejiang University|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|January 9, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02652702||5198|
NCT02661386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15466|Esophageal Manometry During Recovery From Anesthesia: Pilot Study|Esophageal Manometry During Recovery From Anesthesia: Pilot Study|EMAP|University of California, San Francisco|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2016|January 20, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661386||4532|
NCT02661399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24834|Peripheral Blood Biomarkers Associated With CIPN|Investigation of Peripheral Blood Biomarkers Associated With CIPN||St. Louis University|No|Enrolling by invitation|November 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|N/A||1|Actual|100|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have diagnoses which might be treated with CIPN causing therapy, and/or who        have CIPN symptoms without potential confounding neuropathies (antecedent diabetic or        anatomical peripheral neuropathies).|January 2016|January 21, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02661399||4531|
NCT02658279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-227|Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype|A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658279||4771|
NCT02658344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jointstem2b3|Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis|Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ⅱb/Ⅲ Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis||Biostar|Yes|Active, not recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02658344||4766|
NCT02654990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589D2222|Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma|A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents|PANORAMA_3|Novartis|No|Not yet recruiting|March 2016|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654990||5024|
NCT02660710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1335|Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma|LCCC 1335: A Single-Arm Phase I/II Clinical Trial of Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma in Malawi||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|February 2016|December 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02660710||4584|
NCT02660723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-07|Impact of Aging on Cytokine Production by Innate Immune Cells|To Investigate the Impact of Aging on Cytokine and Chemokine Production by Peripheral Blood Immune Cells|Cytokinage|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|February 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02660723||4583|
NCT02655783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-143|Use of Normal Saline With or Without Dextrose During Induction of Labor in Nulliparous|Utilisation parentérale de Normal Salin Avec ou Sans Dextrose Durant l'Induction du Travail Chez Les Nullipares|DEXTRONS|Université de Sherbrooke|No|Recruiting|January 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|March 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02655783||4963|
NCT02647047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-LIVER|Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery|Spinal Analgesia Versus Epidural Analgesia in Minor Laparotomic Liver Surgery in an Enhanced Recovery Programme: A Randomized Controlled Trial||Ospedale San Raffaele|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02647047||5633|
NCT02715180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hear_position_01|Optimum Hand Position During Cardiopulmonary Resuscitation|Optimum Hand Position During Cardiopulmonary Resuscitation: Comparing Expiration and Inspiration View of the Scout Film of the Low Dose Chest Computed Tomography||Seoul National University Bundang Hospital|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02715180||406|
NCT02715479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI468-052|A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176|A Two-way Drug Interaction Study to Evaluate the Effect of BMS-955176 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176||Bristol-Myers Squibb|No|Not yet recruiting|April 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715479||383|
NCT02649023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-05|Deep Venous Thrombosis After Hepatobiliopancreatic Surgery|Pre- and Early Postoperative Deep Venous Thrombosis in Patients Undergoing Oncological Hepatic or Panreatic Resection|POPLITEA|Technische Universität Dresden|Yes|Recruiting|January 2016|June 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Circulating tumor cells evaluation|Both|18 Years|N/A|No|Probability Sample|Patients scheduled for elective oncological liver or pancreatic resection|January 2016|January 15, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02649023||5481|
NCT02651987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52030-326|Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg|Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days|CLARINET FORTE|Ipsen|Yes|Recruiting|November 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02651987||5253|
NCT02652000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0573|Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy|Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer||Kantonsspital Graubuenden|No|Recruiting|October 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|50|||Male|48 Years|80 Years|No|Non-Probability Sample|Patients having had idodine seed brachytherapy for localized prostate cancer between 2009        and 2014|January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652000||5252|
NCT02712203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200783|MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.|Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|July 2004|December 2016|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|5808|||Both|11 Months|22 Months|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged 11 to 22 months selected to participate in clinical trials to assess the        safety and immunogenicity of the GSK biological Priorix-Tetra™ in Germany, Austria,        Finland, Greece, Poland, Czech Republic, Italy, Lithuania, Norway, Romania, Russian        Federation, Slovakia, Sweden, United States and Puerto Rico.|March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712203||635|
NCT02649998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE.2015.592-T|Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF|Comparison of Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in Patients With Acute Decompensated Heart Failure: A Randomized Controlled Trial||Chinese University of Hong Kong|No|Not yet recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|174|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649998||5406|
NCT02649036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS-2015-TPM-02|Social Inequalities in Emergency Call and Emergency Response Patterns|Social Inequalities in Emergency Call and Emergency Response Patterns||Emergency Medical Services, Capital Region, Denmark|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|90000|||Both|18 Years|N/A|No|Probability Sample|In study part I the study population consists of all adult individuals with residence in        the Capital Region of Denmark identified in a two-year period (December 2011-November        2013). In stydy part II the study population will be limited to individuals from the        Capital Region of Denmark for whom a medical emergency call has been made in the study        period.|January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649036||5480|
NCT02653638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0331|Blood Brain Flow and Exercise|Cerebral Vasodilator Responses in Sedentary and Exercise Trained Humans||University of Wisconsin, Madison|No|Not yet recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02653638||5127|
NCT02655523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200460|A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks|A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial||Northwestern University|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655523||4983|
NCT02655666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP303|Qingdao: Insulin Pump Follow-Up Program|Qingdao: Insulin Pump Follow-up Program||Medtronic Diabetes|No|Recruiting|April 2015|June 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|A total of approximately 100 subjects (age<18 years) will be enrolled by up to 10        investigational centers to complete 13 scheduled study visits in the study.|January 2016|January 12, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02655666||4972|
NCT02644655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-02-007|Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia|A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia||Second Military Medical University||Recruiting|September 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|December 31, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02644655||5817|
NCT02649335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBB in cirrhotic ascites|To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites|To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites|NSBB|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02649335||5457|
NCT02649348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81270449|Effects of Preoperative Exercise in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome|Effects of Preoperative Exercise in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome: A Multicenter Prospective Randomised Controlled Trial||Qingdao University|Yes|Recruiting|December 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|54|||Both|18 Years|80 Years|No|||January 2016|February 15, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649348||5456|
NCT02713464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN1|Does Maternal Instruction Prevent Kernicterus in Nigeria?|Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria||Bilimetrix s.r.l.|Yes|Completed|January 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1765|||Both|N/A|21 Days|No|||March 2016|March 17, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02713464||538|
NCT02650518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00589|Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections|Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)|CARCUTI|National University Hospital, Singapore|Yes|Recruiting|December 2015|October 2018|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|21 Years|N/A|No|||January 2016|January 7, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650518||5366|
NCT02650531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/171/REK nord|Norwegian COgnitive Impairment After STroke (NorCOAST) Study|Norwegian COgnitive Impairment After STroke (NorCOAST) Study|Nor-Coast|Norwegian University of Science and Technology|No|Recruiting|May 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with acute stroke|January 2016|January 7, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02650531||5365|
NCT02654704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1029F|Vaccination Responses in Young and Older Adults|Vaccination Responses in Young and Older Adults||Michigan State University|No|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||6|Anticipated|60|Samples With DNA|If the volunteers agree,tissue is stored for usage in future research without identifiers.      This includes cells from blood and saliva and extracted DNA, RNA and protein. The cells may      be used to grow a new cell line that may be maintained in the laboratory.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The initial target enrollment is 60+ individuals in three group classifications [healthy,        asthmatic, immune-compromised (e.g. Leukemia patients)], with each group further        subdivided into two age groups [Young adults (aged 18-25) or Older adults (aged 55+)],        without gender or ethnicity restrictions.|January 2016|January 12, 2016|January 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02654704||5046|
NCT02654717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFD-07-CD-001|Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp|||Promius Pharma, LLC|No|Recruiting|November 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654717||5045|
NCT02712684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0473|Cancer Diagnosis by Multiparametric UltraSound of the Prostate|Multi-parametric Ultrasound Targeted Biopsies Compared to Multi-parametric MRI Targeted Biopsies in the Diagnosis of Clinically Significant Prostate Cancer|CADMUS|University College, London|Yes|Recruiting|July 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Male|18 Years|N/A|No|Probability Sample|Men, referred to the participating centres, who have had a previous prostate biopsy, who        have a persistent indication for harbouring prostate cancer or who require further        accurate risk stratification. Referrals will be screened and potential participants        contacted by telephone, post or email. These men will be given the patient information        sheet at least 24 hours before their clinic visit, allowing adequate time to consider        their desire for involvement|January 2016|March 18, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712684||598|
NCT02712697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZY3- CCCX-2-1002|Integrative Medicine of IgA Nephropathy|Treatment of Shentong Granules Plus Prednisone on Patients With Severe IgA Nephropathy(Ying-deficiency of the Liver and Kidney Pattern): a Randomized, Double-blind,Placebo-controlled Multicentre Clinical Trial||Shanghai University of Traditional Chinese Medicine|No|Not yet recruiting|June 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||November 2015|March 17, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02712697||597|
NCT02649777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2091|Normal Values of Oxidative Stress, Taurine, and Related Markers|Normal Values of Oxidative Stress, Taurine, and Related Markers||University of Colorado, Denver|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|8 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Individuals older than 8 years and less than 50 years|January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649777||5423|
NCT02649842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIOL-204-EPAS|Post-Approval Study of the TECNIS® Toric Extended Cylinder Range Intraocular Lens (IOL)|Post-Approval Study of the TECNIS® Toric IOL Extended Cylinder Range (ECR), Models ZCT450, ZCT525 and ZCT600||Abbott Medical Optics|No|Recruiting|January 2016|November 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|90|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649842||5418|
NCT02650141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO.12401905505|Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty|Efficacy of Experienced Chinese Herbal Formulas for the Treatment of Different Types of Precocious Puberty: A Single-blinded Randomized Controlled Trial||Children's Hospital of Fudan University|No|Recruiting|August 2013|April 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|138|||Female|N/A|8 Years|No|||February 2016|February 21, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650141||5395|
NCT02717715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VG 023-15|SunRISe Study - Stroke Rehabilitation In Suriname|The Effect of a Tele-supervised Home Based Rehabilitation Program on Physical Fitness, Quality of Gait, Upper Limb Disability and Quality of Life in People After Chronic Stroke in a Urban Setting in Suriname. Randomised Controlled Trial.|SunRISe|Katholieke Universiteit Leuven|Yes|Recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||March 2016|March 18, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02717715||211|
NCT02717728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00021561|Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy|Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy Pain Management: A Randomized Double-blind, Placebo Controlled Study||Children's Hospital Boston|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|12 Years|35 Years|No|||March 2016|March 18, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717728||210|
NCT02655185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016003|Novel Risk Factors of Atrial Fibrillation in Patients With Chronic Heart Failure|Study to Evaluate Association of Blood Lipid Levels With Atrial Fibrillation Incidence in Patients With Chronic Heart Failure||Yangzhou No.1 People's Hospital|Yes|Not yet recruiting|February 2016|July 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|40 Years|90 Years|No|Non-Probability Sample|In-hospital patients with a diagnosis of chronic heart failure will be recruited at        Yangzhou No.1 people's hospital, China.|January 2016|January 11, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02655185||5009|
NCT02655198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58545|Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy|Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy|FFA-LGS|Katholieke Universiteit Leuven|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|18 Years|No|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655198||5008|
NCT02650050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO_2015_28|Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).|Micropulsed Laser in Association With Intravitreal Injections of Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).|LAMED|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02650050||5402|
NCT02650063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01171502|A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -|A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -||Santen Pharmaceutical Co., Ltd.|No|Recruiting|December 2015|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|14|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02650063||5401|
NCT02655341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD-AMI001|Hydration Status Assessment Through Body Composition Monitoring in Patients With Acute Myocardial Infarction|Hydration Status Assessment Through Body Composition Monitoring And Renal Artery Stenosis Evaluation in Patients With Acute Myocardial Infarction Referred For Primary PCI|HYD-AMI|Grigore T. Popa University of Medicine and Pharmacy|No|Recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Inclusion criteria: study population consists of consecutive patients admitted with acute        myocardial infarction (<12h) diagnostic confirmed;          -  included in the Romanian National Programme of Primary Percutaneous Revascularisation             (for who the Guidelines recommend primary PCI);          -  have read and signed standard informed consent for angiography in AMI;|January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655341||4997|
NCT02651259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT 2001|Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection|A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02651259||5309|
NCT02651272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33165|Macitentan in Pulmonary Hypertension of Sickle Cell Disease|The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease|MENSCH|Boston University|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651272||5308|
NCT02660372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-150121160547-DHCT|Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia|A Multi-center, Randomized, Observer-blind, Parallel Group, 8-weeks Non-inferiority Clinical Trial to Compare the Efficacy and Safety of Two Brands of Simeticone for Symptomatic Treatment of Functional Dyspepsia in Adults||Johnson & Johnson Consumer and Personal Products Worldwide|No|Recruiting|February 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660372||4610|
NCT02660385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR016191|Insomnia Self-Management in Heart Failure|Cognitive Behavioral Therapy for Insomnia: A Self-Management Strategy for Chronic Illness in Heart Failure|HSS|Yale University|Yes|Recruiting|October 2015|June 2020|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660385||4609|
NCT02652936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF130-001|A Pharmacokinetics Study of AF-130 in Healthy Subjects|A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects||Afferent Pharmaceuticals, Inc.|No|Recruiting|December 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|109|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652936||5180|
NCT02660645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLCCR-001|Blue Light Cystoscopy With Cysview® Registry|Blue Light Cystoscopy With Cysview® Registry|BLCCR|Photocure|No|Recruiting|April 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients indicated for transurethral resection of the bladder.|January 2016|January 18, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02660645|2 Years|4589|
NCT02645123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|721α/11-10-2011|Gait in Low Back Pain Patients After Spinal Mobilization|Gait Analysis of Chronic Low Back Pain Patients Before and After the Application of Spinal Mobilization|SpinMob|University of Ioannina|No|Completed|December 2011|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Both|21 Years|78 Years|No|||December 2015|December 31, 2015|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02645123||5781|
NCT02653716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14CO183|Effectiveness and Cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health|BeST?- The Best Services Trial (BeST?): Effectiveness and Cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health|BeST?-|University of Glasgow|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|462|||Both|N/A|60 Months|No|||January 2016|January 13, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02653716||5122|
NCT02659735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108109|A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation|A Phase 1, Open-label, 2-panel, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 600-mg Dose of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation, Under Fed and Fasted Conditions||Janssen Research & Development, LLC|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659735||4659|
NCT02717702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056764|Stress-Delta Biomarkers for Acute Coronary Syndrome Risk Stratification|Abbott Stress-Delta Biomarkers for ACS Risk Stratification||Duke University||Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|333|||Both|40 Years|N/A|No|Non-Probability Sample|Potential participants are patients presenting to the Emergency Department for evaluation        of ACS.|March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717702||212|
NCT02654496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-201509-061|Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery|The Gut Microbiota in Patients Post Roux-en-Y Gastric Bypass Surgery||North Dakota State University|Yes|Recruiting|January 2016|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|18||Fecal Samples and Plasma/Serum Samples|Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|3-5 years post gastric bypass patients and control subjects|January 2016|January 29, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02654496||5062|
NCT02661555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brain health in MS|Aerobic Exercise and Brain Health in Multiple Sclerosis|Effects of Aerobic Exercise on Brain Health in People With Multiple Sclerosis||University of Aarhus|No|Recruiting|January 2016|September 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02661555||4519|
NCT02660879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00087922|The Effect of Video Education on Inhaler Use Technique|The Effect of Video Education on Improving Inhaler Use Technique|InhalerEdu|Northwestern University|No|Completed|December 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 18, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660879||4571|
NCT02646150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2015-10|Clinical Use of Magnetic Resonance Perfusion Imaging to Qualitatively Assess Adequate Distal Perfusion After Endovascular Revascularization in Critical Limb Ischemia|Clinical Use of Magnetic Resonance Perfusion Imaging to Qualitatively Assess Adequate Distal Perfusion After Endovascular Revascularization in Critical Limb Ischemia|MR CLI|Asan Medical Center|No|Recruiting|December 2015|October 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lower extremity ischemia|January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646150||5702|
NCT02653703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20130005|L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain|High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde||Aalborg University|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653703||5123|
NCT02653950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0576-15-RMB|Traditional Septoplasty Vs Endoscopic Septoplasty for Treating Deviated Nasal Septum|Traditional Septoplasty Vs Endoscopic Septoplasty for Treating Deviated Nasal Septum: A Prospective, Randomized Controlled Trial||Rambam Health Care Campus||Not yet recruiting|February 2016|||February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02653950||5104|
NCT02656667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESNM (RB 15.058)|Effect of Neuromuscular Electrical Stimulation Versus Cycle Ergometer Training in a Pulmonary Rehabilitation Program|Effect of Neuromuscular Electrical Stimulation Versus Cycle Ergometer Training in a Pulmonary Rehabilitation Program|ESNM|University Hospital, Brest|No|Not yet recruiting|February 2016|August 2018|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02656667||4895|
NCT02651311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-DRU-15-002|Ultrasound Guided Intermediate Cervical Plexus Block for Congenital Muscular Torticollis|Randomized Controlled Trial of the Postoperative Analgesic Efficacy of Ultrasound Guided Intermediate Cervical Plexus Block for Unipolar Sternocleidomastoid Release in Patient With Congenital Muscular Torticollis||Ajou University School of Medicine||Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|1 Year|7 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651311||5305|
NCT02646384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-010037|Ovarian Tissue Cryopreservation in Children|Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University||Mayo Clinic|No|Not yet recruiting|January 2016|||January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|N/A|17 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646384||5684|
NCT02650947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-58-16|Sucralose Effects on Glucose Metabolism and Gut Microbiota|Effects of Sucralose Consumption on Glucose Metabolism, Incretin and Gut Microbiota in Healthy Adult||Ramathibodi Hospital|Yes|Recruiting|January 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02650947||5333|
NCT02718885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16035|Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients|Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients||University of Illinois at Urbana-Champaign|No|Not yet recruiting|April 2016|August 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|20 Years|65 Years|No|||March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02718885||121|
NCT02719210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ALF-02|High Volume Plasma Exchange in Children With Acute Liver Failure|High Volume Plasma Exchange in Children With Acute Liver Failure-A Prospective Randomized Controlled Trial.||Institute of Liver and Biliary Sciences, India|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|18 Years|No|||February 2016|March 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02719210||96|
NCT02656979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmeaU|Blood Flow of Ophthalmic Artery and Glaucoma|Blood Flow of Ophthalmic Artery and Its Relationship to Structural Properties of the Optic Nerve and Intraocular Pressure in Glaucoma||Umeå University|No|Recruiting|December 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|125|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||November 2015|January 13, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02656979||4871|
NCT02647697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP0027|Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers|A Single Oral Dose Study of the Safety, Tolerability, and Pharmacokinetic Profile of Radiprodil in Adult Healthy Volunteers||UCB Pharma|No|Completed|January 2016|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647697||5583|
NCT02660775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00580-49|Social Cognitive Assessment in Autism and Schizophrenia|Social Cognitive Assessment in Psychiatry - Validation of a New Battery: ClaCoS|(ClaCoS)|Hôpital le Vinatier|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|440|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|January 18, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02660775||4579|
NCT02646722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-OBS-15-169|Relation Between Withdrawal Movement for Rocuronium and Emergence Agitation|Relation Between Withdrawal Movement on Rocuronium Injection and Emergence Agitation and Pain in Preschool Ages: Observational Study||Ajou University School of Medicine|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|40|||Both|1 Year|5 Years|No|Non-Probability Sample|patients scheduled for inguinal hernioplasty in university hospital|January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02646722||5658|
NCT02646995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.18.CLI|Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients|||Nestlé|No|Recruiting|January 2016|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|28|||Both|5 Years|18 Years|No|||February 2016|February 8, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02646995||5637|
NCT02718573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-2222|Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood|Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood||Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|January 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Patients will be identified by their health care providers, including the        co-investigators, who will describe the study to potential participants and inform the        research team of patients who are interested in participating.|March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02718573||145|
NCT02647983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-2014|Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection|Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection||Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Male|50 Years|80 Years|No|||January 2016|January 4, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02647983||5561|
NCT02648217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-4243|Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan||Novo Nordisk A/S|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648217||5543|
NCT02656225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-1|Effect of Chinese Herbal Medicine Bazhen Capsule in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome|Effect of Chinese Herbal Medicine Bazhen Capsule in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome: Study Protocol of a Randomized, Placebo-controlled, Double-blind Trial||The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|Yes|Recruiting|March 2015|August 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02656225||4929|
NCT02658149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-422|Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study|||William Beaumont Hospitals|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658149||4781|
NCT02658162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGTP-003|A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients|A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant||Prolong Pharmaceuticals|No|Not yet recruiting|June 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658162||4780|
NCT02715726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13889|Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia|A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy|ODYSSEY EAST|Sanofi|Yes|Not yet recruiting|July 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715726||364|
NCT02653235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14NE490|Impact of Immune Challenge on Triple Network Connectivity in Humans|Exploring the Impact of Peripheral Immune Challenge on the "Triple Network" and "Dorsal Nexus" Functional Connectivity in Humans||NHS Greater Glasgow and Clyde|No|Not yet recruiting|January 2016|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02653235||5158|
NCT02651935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGHCEAH-ICU-3|Intellivent ASV in COPD Patients|A Randomized Controlled Trial Comparing a Fully Closed Loop Ventilation Mode (Intellivent ASV) With Pressure Controlled + Pressure Support Ventilation in COPD Patients||Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital|No|Recruiting|August 2015|April 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|February 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02651935||5257|
NCT02652182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160006|Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction|Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction||Nanjing Medical University|No|Recruiting|January 2016|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who        received emergent percutaneous coronary intervention|January 2016|January 26, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652182||5238|
NCT02660632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R ∕ 15.12.48|Epidural Block vs. Rectus Sheath Block on Postoperative Pulmonary Function|Effect of Thoracic Epidural Analgesia vs Rectus Sheath Catheters on Postoperative Pulmonary Function After Midline Laparotomy: A Prospective Randomized Controlled Study||Mansoura University|Yes|Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 16, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02660632||4590|
NCT02715960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016 AW/CSU/PS|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules||Central South University|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|70 Years|No|||December 2015|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715960||346|
NCT02654782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000858|Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients|Lactated Ringer's Versus 5% Human Albumin: A Double-Blinded, Randomized, Prospective Study in Cardiac Surgical Patients||Mayo Clinic|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|99 Years|No|||January 2016|January 11, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654782||5040|
NCT02655302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_76|Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD|Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD|COPD1722|University Hospital, Lille|No|Not yet recruiting|January 2016|December 2022|Anticipated|December 2022|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|40 Years|N/A|No|||January 2016|January 11, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02655302||5000|
NCT02659787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0170|Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology|Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology|BED|University of Chicago|No|Not yet recruiting|June 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659787||4655|
NCT02650986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 258514|Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1|A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies||Roswell Park Cancer Institute|Yes|Not yet recruiting|March 2016|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650986||5330|
NCT02657278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|825/15|Cardiopulmonary Exercise Test in Peripheral Arterial Disease|The Influence of Peripheral Arterial Disease (PAD) on the Onset of Lactate Threshold (LT) in Patients Undergoing Cardiopulmonary Exercise Test (CPET)||Aintree University Hospitals NHS Foundation Trust|Yes|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657278||4848|
NCT02652442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2058-P|Vestibular Rehabilitation and Otolith Dysfunction|Vestibular Rehabilitation and Otolith Dysfunction||VA Office of Research and Development|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02652442||5218|
NCT02645513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6550|Text Message Reminders to Health Workers on Malaria, Pneumonia, and Diarrhea Case Management in Malawi|The Effect of Mobile Phone Text Message Reminders on Health Workers' Adherence to Malaria and Other Disease Case Management Guidelines in Malawi||Centers for Disease Control and Prevention|No|Active, not recruiting|January 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Actual|182|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645513||5751|
NCT02646501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0743|Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia|||Yonsei University|No|Recruiting|September 2015|September 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|85 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646501||5675|
NCT02651545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1116240|Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis|Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.||State University of New York at Buffalo|No|Recruiting|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll 30 relapsing MS patients new to teriflunomide therapy. We will also sample        30 healthy control volunteers, matched on demographics with the treated group.|November 2015|January 7, 2016|May 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02651545||5287|
NCT02655718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2411|Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis|Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis|NOCA|Russian Academy of Medical Sciences|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02655718||4968|
NCT02646982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00084574|Candesartan's Effects on Alzheimer's Disease And Related Biomarkers|Candesartan's Effects on Alzheimer's Disease And Related Biomarkers|CEDAR|Emory University|Yes|Not yet recruiting|May 2016|September 2021|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|50 Years|N/A|No|||February 2016|February 18, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646982||5638|
NCT02659826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS_CNSexcitability|Non-invasive Stimulation on Central Nervous System Excitability|Effects of Non-invasive Stimulation on Central Nervous System Excitability of Healthy Volunteers||Universidade Federal de Pernambuco|Yes|Recruiting|October 2015|March 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02659826||4652|
NCT02648399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wzhao|Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma|||Fujian Medical University|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|15 Years|60 Years|No|||January 2016|January 6, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02648399||5529|
NCT02644551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELEXT07-01|The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis|The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study||9305-9954 Quebec Inc|No|Not yet recruiting|April 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02644551||5825|
NCT02648750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177976|Stroke Self-Management Delivered by Rehabilitation Assistants Within an Early Supported Discharge Service|A Stroke Self-Management Programme Delivered by Rehabilitation Assistants Within an Early Supported Discharge Service: A Feasibility Randomised Controlled Trial||University of Plymouth|No|Completed|June 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02648750||5502|
NCT02648763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007647|Staging Procedures to Diagnose Malignant Pleural Mesothelioma|Staging Procedures to Diagnose Malignant Pleural Mesothelioma||Mayo Clinic|No|Recruiting|November 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment at the Mayo Clinic Rochester that are scheduled to undergo        staging procedures to diagnose malignant pleural mesothelioma (including pleuroscopy,        bronchoscopy, endobronchial ultrasound and laparoscopy) as part of their standard of care.|January 2016|January 6, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02648763||5501|
NCT02661412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201627038|Immediate Loading of Implants in the Partially or Completely Edentulous Jaw||IMLOAD|AZ Sint-Jan AV|No|Active, not recruiting|January 2001|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|Patients of all ages with loss of all or almost all teeth due to terminal periodontal        disease and/or untreatable endodontic problems, that requested treatment according to the        IL protocol between 01/01/2001 and 31/12/2015. Patients should have adequate bone volume        to predominantly receive an implant of ≥13x3.5mm anteriorly and an implant of ≥9 x 3.5mm        posteriorly. All patients, with or without a pre-prosthetic sinus floor augmentation, are        included in de study.|January 2016|January 19, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02661412||4530|
NCT02652104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helsinki University Hospital|Deep Brain Stimulation in HUCH Region Between 2006 and 2014|A Review of the Clinical Outcome of Deep Brain Stimulation in the Patients With Advanced Parkinson's Disease in Helsinki and Uusimaa Hospital Between 2006 to 2014||Hospital District of Helsinki and Uusimaa|Yes|Completed|January 2006|July 2015|Actual|December 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Actual|140|||Both|18 Years|80 Years|No|Probability Sample|The study population consist of the patients who have received deep brain stimulation        treatment. The patient selection for deep brain stimulation has been done according to a        clinical protocol.|January 2016|January 8, 2016|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02652104|2 Years|5244|
NCT02653274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F14072015 SoM SPMIC BMedSci|Assessment of Millet, Oat and Rye Porridge Breakfasts Glucose and Gastric Emptying|Gastrointestinal and Blood Glucose Responses to Breakfast Porridges Made From Different Grains: A Magnetic Resonance Imaging Pilot Study in Healthy Volunteers|AMORE|University of Nottingham|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02653274||5155|
NCT02657460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v1.4|Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion|Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion||Wuhan Union Hospital, China|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657460||4834|
NCT02716207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChanghaiH001|Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife|Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife||Changhai Hospital|No|Not yet recruiting|March 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02716207||327|
NCT02716220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1502|Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)|BIOTRONIKS - Acute Performance Of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients With de Novo Lesions in NatiVE Coronary Arteries: BIOSOLVE-III|BIOSOLVE-III|Biotronik AG|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716220||326|
NCT02654522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH101|The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers|The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.||Steve Yoelin M.D. Medical Associates, Inc.|No|Not yet recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02654522||5060|
NCT02654626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBP7072-1-002|A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects|A Randomized, Single-blind, Placebo-controlled, Sequential Parallel-Group and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 in Healthy Subjects||KBP Biosciences|Yes|Recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654626||5052|
NCT02653846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBD-IG-LS/SSvsHVPG|Correlation of Liver and Spleen Stiffness by RT-2D-SWE and Severity of Portal Hypertension by HVPG|Correlation of Liver and Spleen Stifness as Assesed by Real Time 2-Dimensional Shear Wave Elastography With Severity of Portal Hypertension and Clinical Outcomes in Patients With Compensated Advanced Chronic Liver Disease||University Hospital Dubrava|No|Recruiting|June 2015|June 2022|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients and inpatients in a tertiary care hospital 1) with suspicion of having        compensated advanced chronic liver disease (cACLD) as assessed by transabdominal        ultrasound, laboratory findings, FIB-4 and/or APRI score, and/or LS measurements by TE; 2)        patients with chronic liver disease in whom any extrahepatic surgical procedure is planned        and in whom it was not possible to exclude cACLD and/or portal hypertension based on        non-invasive procedures only; 3) patients with HCC or other liver tumors on the ground of        presumed liver cirrhosis who are under consideration for surgical resection, in whom HVPG        is performed in order to reliably exclude clinically significant portal hypertension|January 2016|January 9, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02653846||5112|
NCT02657629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0781|Comparison of Feeding Strategies for Hypoplastic Left Heart Syndrome Infants|Comparison of Feeding Strategies After Stage 1 Procedures for Hypoplastic Left Heart Syndrome Infants: A Randomized Controlled Trial||Columbia University|No|Completed|December 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|N/A|3 Months|No|||January 2016|January 19, 2016|January 14, 2016||No||No|January 19, 2016|https://clinicaltrials.gov/show/NCT02657629||4821|
NCT02648880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2266|Preoperative Exercise in Pancreatic Cancer|The Effects of a Preoperative Exercise Intervention During Neoadjuvant Therapy in Patients With Pancreatic Cancer||University of Colorado, Denver|No|Not yet recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|21 Years|70 Years|No|||January 2016|January 6, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02648880||5492|
NCT02649153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/GC-HCC|Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection|Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection|SP/GC-HCC|Guangxi Medical University|Yes|Recruiting|January 2016|June 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02649153||5471|
NCT02645656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVSIDS/OMR/EX1/2013|Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF)|Topical Application of Curcumin Incorporated in Orabase in OSMF Patients||SVS Institute of Dental Sciences|Yes|Active, not recruiting|December 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|22 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645656||5740|
NCT02649257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-Nr.: 1435/2014|Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)|Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)||Medical University of Vienna||Completed|July 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|40 Years|90 Years|No|||January 2016|January 11, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02649257||5463|
NCT02649270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-T1h-PSO-1|Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis|Single and Multiple Dose -Based Tolerability, Safety and Pharmacokinetic Phase 1 Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Patients With Psoriasis||Biotech Pharmaceutical Co., Ltd.|Yes|Recruiting|January 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|55 Years|No|||January 2016|January 10, 2016|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02649270||5462|
NCT02645565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIP/IEC/SC/2013/5/435|Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis|Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis||Jawaharlal Institute of Postgraduate Medical Education & Research|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|N/A|No|||December 2015|January 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645565||5747|
NCT02717741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingYoko|A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor|A Phase I Study to Determine the Safety and Pharmacokinetic Study of Tafetinib in Patients With Advanced Solid Tumors||Nanjing Yoko Biomedical Co., Ltd.|No|Recruiting|May 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02717741||209|
NCT02717754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25140|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Volunteers|A Multiple-Center, Randomized, Double-blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO0640796 (Oseltamivir) and Its Carboxylate Metabolite, RO0640802, Following Intravenous Administrations in Healthy Subjects||Hoffmann-La Roche||Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|99|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 20, 2016|March 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717754||208|
NCT02654886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2013-9365|Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.|Safety and Effectiveness of Resistance Exercise Training in Patients With Late Onset Pompe Disease- A Pilot Study|ExercisPompe|University of California, Irvine|Yes|Recruiting|October 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|75 Years|No|||January 2016|January 11, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02654886||5032|
NCT02661334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20150021H|Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise|Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise (MUSSCLE)|MUSSCLE|David Grant U.S. Air Force Medical Center|Yes|Recruiting|August 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|180|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02661334||4536|
NCT02661347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 15-0701|Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia|Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia||Northwell Health|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|40 Years|No|||January 2016|January 21, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661347||4535|
NCT02657668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IslamicAUN|Emotion Focused Therapy in Irritable Bowel Syndrome Patients|Pilot Study of Efficacy of Emotion Focused Therapy on Stress, Resiliency and Coping Strategies in Irritable Bowel Syndrome Patients||Islamic Azad University, Najafabad Branch|No|Completed|September 2013|October 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02657668||4818|
NCT02657681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJFOX-9205|Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)|Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)||Fundación de investigación HM||Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657681||4817|
NCT02717234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.31.US.CLI|Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement|Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement||Nestlé|No|Active, not recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02717234||248|
NCT02717468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01895-44|Comparative Noninvasive Continuous Cardiac Output by the Clearsight With Invasive Monitoring by Pulsioflex in Abdominal Surgery|Comparative Noninvasive Continuous Cardiac Output by the Clearsight With Invasive Monitoring by Pulsioflex in Abdominal Surgery|CLEARSIGHT|Poitiers University Hospital||Recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|March 17, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717468||230|
NCT02656459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-35447|Longitudinal Gene Expression Profiling in Adults After Traumatic Injury|Longitudinal Gene Expression Profiling in Adults After Traumatic Injury||Stanford University|No|Recruiting|January 2016|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood RNA specimens will be retained up to 3 years after study end.|Both|18 Years|N/A|No|Non-Probability Sample|No patients will be enrolled at Stanford. All enrollment will be done at        Universitätsmedizin Göttingen. ICU admissions will be reviewed by the local research team;        all patients admitted for blunt trauma will then be screened by chart review for matching        inclusion/exclusion criteria.|January 2016|January 29, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656459||4911|
NCT02656472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5900283|A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery|A Pilot Study Comparing Anti-Inflammatory Effects Of Tranexamic Acid Versus Epsilon Aminocaproic Acid In Pediatric Congenital Heart Surgery|TXAEACA|Advocate Health Care|Yes|Recruiting|December 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|3 Months|17 Years|No|||January 2016|January 14, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656472||4910|
NCT02654834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00098|Oxidative Stress in OR Personnel|Oxidative Stress Status During Anesthesia in Pediatric Surgical Room Staff Versus Non-operating Room Personnel: Pilot Study||Nationwide Children's Hospital|No|Recruiting|May 2014|January 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|Two 5 mL blood samples collected at the start of a work week and at the end of a work week.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Twenty operating room staff and twenty intensive care unit staff (40 Total Participants)|February 2016|February 10, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654834||5036|
NCT02654158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013Pro234.EKZY|Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection|Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection||Guangzhou Yipinhong Pharmaceutical CO.,LTD|Yes|Recruiting|August 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|1800|||Both|1 Year|12 Years|No|Probability Sample|Children aged 1 to 12 years old with acute upper respiratory infection|January 2016|February 14, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654158||5088|
NCT02713984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU-BTC-005|A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer|A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer||Southwest Hospital, China|No|Recruiting|March 2016|September 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02713984||498|
NCT02713997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-DK109914|Anti-inflammatory Therapy to Improve Outcomes After TPIAT|Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet Autotransplantation||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|August 2016|January 2022|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713997||497|
NCT02654938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNC-M-VM3-01|Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer|Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer||Panacela Labs LLC|No|Active, not recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Male|45 Years|75 Years|No|||January 2016|January 11, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02654938||5028|
NCT02655094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-MIC-01|Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery|Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery: a Retrospective Single Center Observation||University of Schleswig-Holstein|No|Not yet recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|280|||Both|18 Years|99 Years|No|Non-Probability Sample|Collective of patients with relevant mitral valve disease scheduled for minimal-invasive        mitral valve repair or replacement|January 2016|January 11, 2016|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02655094||5016|
NCT02658474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1880REK|Multidisciplinary Group Based Treatment of Patients With Chronic Pain|Multidisciplinary Group Based Treatment of Patients With Chronic Pain. A Randomized Controlled Trial Comparing Acceptance Commitment Therapy and Treatment in a Primary Care Setting||University of Tromso|No|Not yet recruiting|February 2016|June 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658474||4756|
NCT02660138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-FR-52120-222|Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1|A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis|CONTENT1|Ipsen|Yes|Not yet recruiting|March 2016|December 2021|Anticipated|October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|408|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660138||4628|
NCT02660255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719-15-FB|Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy|Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy|CBD|University of Nebraska||Temporarily not available|February 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|1 Year|60 Years|No|||December 2015|January 15, 2016|December 21, 2015|No|Yes||||https://clinicaltrials.gov/show/NCT02660255||4619|
NCT02660268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC14.455|Contribution of a Clinical Pathway for the Treatment of Hip Prosthesis Infections|Evaluation of the Implementation of a Clinical Pathway for Improving the Performance of Medical and Surgical Management of Hip Prosthesis Infections|OSCAR-PH|University Hospital, Grenoble|No|Not yet recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|192|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02660268||4618|
NCT02661256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14018|Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates|Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates||Winthrop University Hospital|Yes|Completed|June 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7|||Both|34 Weeks|45 Weeks|No|||January 2016|January 18, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02661256||4542|
NCT02652325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016JPAR|Nasal Swab studyComparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA|Comparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA||Rothman Institute Orthopaedics||Active, not recruiting||||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||||||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652325||5227|
NCT02649959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00104/Open Label-Autism|An Open Label Study of CM-AT for the Treatment of Children With Autism|An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin||Curemark|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|3 Years|8 Years|No|||January 2016|January 6, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649959||5409|
NCT02649972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-216|Single-agent Cobimetinib for Adults With Histiocytic Disorders|Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649972||5408|
NCT02644811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFUG-479851|Miniscrews as Anchorage Device for Orthodontic Treatment|Miniscrews as Anchorage Device for Orthodontic Treatment - Randomized Controlled Trials on Anchorage Capacity, Cost Efficiency and Patient Acceptance||Region Gävleborg|No|Active, not recruiting|November 2009|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02644811||5805|
NCT02713451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/2015/52|Liberal Oxygenation Versus Conservative Oxygenation in ARDS|Liberal Oxygenation Versus Conservative Oxygenation in Patients With Acute Respiratory Distress Syndrome : Impact on Mortality (LOCO2 Study)|LOCO2|Centre Hospitalier Universitaire de Besancon|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713451||539|
NCT02656771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA1-KD-14|Evaluation of Stability of Two Uncemented Hip Implants Used for Total Hip Arthroplasty|Evaluation of Uncemented Echo Bi-Metric Full Proximal Profile THA Stem Versus Uncemented Bi-Metric Porous Primary THA Stem in a Randomized Controlled Trial Using RSA and DXA||Rigshospitalet, Denmark||Recruiting|January 2016|February 2021|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|75 Years|No|||January 2016|January 14, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656771||4887|
NCT02646072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20148-494|Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients|The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery||University of Malaya|No|Completed|August 2014|June 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646072||5708|
NCT02646085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001579|Multiparametric Imaging in Multiple Myeloma|Multiparametric Imaging in Multiple Myeloma||Massachusetts General Hospital|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|40 Years|75 Years|No|||December 2015|December 31, 2015|December 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02646085||5707|
NCT02646163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP 101|Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients|Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients||Replicor Inc.|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646163||5701|
NCT02659163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HS024001|An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease|An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease|STRIVE|Massachusetts General Hospital|No|Not yet recruiting|January 2016|July 2017|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|68|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02659163||4703|
NCT02651324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3497|Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis|A Prospective, Randomized, Double-Blind, Controlled Trial Evaluating the Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis||Albany Medical College|No|Recruiting|May 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 7, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651324||5304|
NCT02654600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-37816002/2014-A00702-45|Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications|Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications|COMPLI|Centre Chirurgical Marie Lannelongue|No|Completed|June 2014|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Every ASA 2 or 3 patient eligible for non-complex and non-urgent cardiac surgery|January 2016|January 12, 2016|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02654600||5054|
NCT02651142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT003|A Randomized, Controlled Trial of Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer|||Shandong University|No|Recruiting|January 2015|January 2025|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|75 Years|No|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651142||5318|
NCT02656277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066738|Efficacy of First Time Anterior Shoulder Decision Tool|Efficacy of First Time Anterior Shoulder Decision Tool in a Randomized Control Trial||Duke University|No|Not yet recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656277||4925|
NCT02715115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-RETT-002|A Safety Study of NNZ-2566 in Pediatric Rett Syndrome|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome||Neuren Pharmaceuticals Limited|Yes|Not yet recruiting|March 2016|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|5 Years|15 Years|No|||March 2016|March 16, 2016|February 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715115||411|
NCT02647710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD005861|PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice|PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice|PHAT Life|University of Illinois at Chicago|Yes|Recruiting|June 2010|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02647710||5582|
NCT02660788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-02832|A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue Women|A Randomised Study of Screening Mammography Return Rates in Overdue Women Due to Standard Screening Mammography Program of British Columbia (Smpbc) Reminders Versus Reminder Letters Signed by Women's Family Physicians||British Columbia Cancer Agency|No|Completed|February 2013|December 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|5638|||Female|51 Years|73 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660788||4578|
NCT02646657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-100756|An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis|An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)|LOVE-UC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|July 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646657||5663|
NCT02651181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC076215ctil|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes The DREMED Trail|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREMED Trail||Rabin Medical Center|No|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|30 Years|No|||December 2015|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651181||5315|
NCT02714257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-3576|Seniors Avoiding Falls Through Exercise Study|Integrating Patient-Centered Exercise Coaching Into Primary Care to Reduce Fragility Fracture|SAFE|Milton S. Hershey Medical Center|No|Not yet recruiting|March 2016|August 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2280|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02714257||477|
NCT02714270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHOP-PP|Paperless Partograph for Management of Low Risk Labor|A Randomized Clinical Trial of Paperless Versus Modified World Health Organization Partograph in Management of First Stage of Labour||Assiut University|Yes|Not yet recruiting|April 2016|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|370|||Female|18 Years|40 Years|No|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714270||476|
NCT02652988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0471|Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients|Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients. Phase II, Randomized, Double-blind, Single-center Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|65 Years|No|||January 2016|January 11, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02652988||5176|
NCT02644681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMAS/32/OSR|Neurophysiological Intraoperative Monitoring During Aortic Surgery|Neurophysiological Intraoperative Monitoring During Aortic Surgery|NIMAS|Scientific Institute San Raffaele|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of all consecutive patients with thoracoabdominal aortic        aneurysms who will be subjected to neuromonitoring-guided open repair of the aortic        aneurysm at the Department of Vascular Surgery of San Raffaele Hospital.|February 2016|February 18, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02644681|2 Years|5815|
NCT02644967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2125-204|A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma|A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma||Idera Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644967||5793|
NCT02647840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185519|The Effects of Voice Therapy Based on the Estill Voice Model: a Feasibility Study|The Effects of Voice Therapy Based on the Estill Voice Model: a Feasibility Study||Royal Devon and Exeter NHS Foundation Trust|No|Not yet recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|N/A|No|||January 2016|January 4, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02647840||5572|
NCT02647853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAT4 A1|Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers|A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel||Topokine Therapeutics, Inc.|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02647853||5571|
NCT02652858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0400|Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass|Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass|CAPD-CPB|Hospices Civils de Lyon|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652858||5186|
NCT02720328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|v6|Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants|Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants|ADR-OAC|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|July 2015|||January 2016|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02720328||10|
NCT02656602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L013-011|Computer-assisted Instruction Before Colonoscopy is as Effective as Nurse Counselling, a Controlled Trial|Computer-assisted Instruction Before Colonoscopy is as Effective as Nurse Counselling, a Controlled Trial (PAVO-E-EDUC)|PAVO-E-EDUC|Medical Center Alkmaar|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|385|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656602||4900|
NCT02656615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU 14/020|Abiraterone-Rechallenge Study for CRPC Patients|An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA|ABI-RE|Cantonal Hospital of St. Gallen|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|100 Years|No|||January 2016|January 18, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02656615||4899|
NCT02656836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 15/EM/0217|Home Tonometry With the I-care Tonometer for Glaucoma|Home Tonometry for Monitoring Glaucoma:a Pilot Study of the Icare Home Tonometer||Queen's University, Belfast|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with glaucoma attending clinic|January 2016|January 15, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656836||4882|
NCT02658240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 122015-022|Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration|Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration for Pain Management After Total Hip Arthroplasty: A Randomized Controlled Trial||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02658240||4774|
NCT02648100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 13021|Basal Like Bladder Cancer : Signature and Therapeutic|Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)|DIATRIBBE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2014|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|911|Samples With DNA|Tumor tissue : frozen (n=120), FFPE (n=911)|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Bladder Cancer from 4 cohorts          -  2 observational cohorts of patients with muscle invasive bladder cancer (all stages)             from two Henri Mondor (Créteil) and Foch (Suresnes) hospitals          -  1 multicentric observational cohort of patients with locally advanced muscle invasive             bladder cancer trated by adjuvantchemotherapy after cystectomy          -  1 clinical trial GETUG 19 (MVAC + panitumumab)|December 2015|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648100||5552|
NCT02712229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15120154|A Primary Palliative Care Intervention for Patients With Advanced Cancer|A Cluster Randomized Trial of a Primary Palliative Care Intervention (CONNECT) for Patients With Advanced Cancer|CONNECT|University of Pittsburgh|No|Not yet recruiting|April 2016|March 2021|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1486|||Both|21 Years|N/A|No|||March 2016|March 14, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02712229||633|
NCT02660151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECL00030|Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema|Prospective, Randomized Crossover Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema||Eye-yon Medical|No|Not yet recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660151||4627|
NCT02659800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC 1403|IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas|The Effect of IL-7 (CYT107) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia After Concurrent Radiation and Temozolomide||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2015|April 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|5||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659800||4654|
NCT02646696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Barpak-01-EDA|Reliability Study Using Electrodermal Activity to Measure Sensory Processing in Children With and Without Autism Spectrum Disorder|Reliability of Electrodermal Activity: Quantifying Sensory Processing in Children With Autism Spectrum Disorder||Barpak Geriatric Health Services, Inc. d/b/a Barpak Occupational Therapy|No|Completed|January 2013|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Male|4 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of boys between the ages of 4 - 11 years with and without a diagnosis        of Autism Spectrum Disorder were recruited from private and public New Jersey Schools,        Barpak Occupational Therapy clinic, Bergenfield, New Jersey and Seton Hall University        campus.|January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646696||5660|
NCT02658136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51347|Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices|Computed Tomography Estimated Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices||Rigshospitalet, Denmark|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|100 Years|No|||January 2016|January 15, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02658136||4782|
NCT02648464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000233-73|Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events (OXI)|Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events||Helsinki University Central Hospital|No|Recruiting|February 2016|October 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02648464||5524|
NCT02650362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACTIC1|STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation|STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study|TACTIC|Universitair Ziekenhuis Brussel|No|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02650362||5378|
NCT02650375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-128-I-02|Study of Metatinib Tromethamine Tablet|A Phase Ib Study to Assess the Safety, Tolerability and Preliminary Efficacy of Metatinib Tromethamine Tablet in Chinese Patients With Advanced or Metastatic Gastric or Liver Cancer||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|October 2015|February 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|No|||November 2015|January 7, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02650375||5377|
NCT02651220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71491705|Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris|||Actavis Inc.|No|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1000|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651220||5312|
NCT02654860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR.3/02-2015|Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia|Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia in Patients Scheduled for Hip Replacement Surgery||Sintetica SA|Yes|Not yet recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02654860||5034|
NCT02660658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R ∕ 16.01.15|Optimal Single Dose Intrathecal Dexmedetomidine for Postoperative Analgesia|Optimal Single-dose Intrathecal Dexmedetomidine for Postoperative Analgesia After Lower Limb Surgery||Mansoura University|Yes|Recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|65 Years|No|||January 2016|January 16, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02660658||4588|
NCT02648412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pupillo ketamine|Pupillary Dilation After Incremental Tetanic Stimulations Under Ketamine Sedation|Pupillary Diameter Variation After Standardized Tetanic Stimulations of Incremental Intensities in Patients Under Ketamine Sedation||Hôpital Armand Trousseau|Yes|Completed|April 2012|April 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|2 Years|18 Years|No|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02648412||5528|
NCT02648945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/SERC/86/2015|Effects of Low and High Intensity Exercise in Improving Working Memory Among Students With Anxiety Symptoms|A Comparative Study Between Effects of Low and High Intensity Exercise in Improving Working Memory Among Students With Anxiety Symptoms||Universiti Tunku Abdul Rahman|No|Recruiting|November 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02648945||5487|
NCT02648958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0794|Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations|Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial||Yonsei University|No|Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|68|||Both|20 Years|80 Years|No|||January 2016|January 5, 2016|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02648958||5486|
NCT02653066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1282|HealtheRx Survey for Pulmonary Research Registry Recruitment|HealtheRx Survey for Pulmonary Research Registry Recruitment||University of Chicago|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653066||5171|
NCT02647255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCUE|Trial of Plasma Exchange for Severe Crescentic IgA NEphropathy|Randomized Controlled Trial on Plasma Exchange as Adjunctive Therapy for Severe Crescentic IgA NEphropathy (RESCUE Study)|RESCUE|Peking University First Hospital|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|14 Years|65 Years|No|||January 2016|January 4, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02647255||5617|
NCT02651779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51544.018.14|Internal Plate Fixation vs. Plaster in Complete Articular Distal Radial Fractures|Internal Plate Fixation vs. Plaster in Complete Articular Distal Radial Fractures|VIPAR|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|June 2015|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02651779||5269|
NCT02651792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ketfol versus pethidine|Ketamine- Propofol Versus Pethidine- Propofol in ERCP|Ketamine-propofol Versus Pethidine-propofol for Sedating Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP)||Assiut University||Recruiting|January 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|November 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651792||5268|
NCT02655354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH3MH106338-02|A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity||TSOS6|University of Washington|No|Recruiting|October 2015|June 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|960|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02655354||4996|
NCT02656823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-AN-14-001|Implant-fixed Restorations With ANKYLOS 6.6 mm Implants in the Edentulous Maxilla - A 5-year Follow-up Study|Implant-fixed Restorations With Short Implants in the Edentulous Maxilla - A Clinical Investigation Over a 5-year Follow-up Period||Dentsply Implants||Recruiting|December 2015|||June 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02656823||4883|
NCT02712944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L16-079|Testosterone Replacement in Renal Failure|Effect of Testosterone Replacement on Erythropoietin Stimulating Agent Use in End Stage Renal Disease Patients||Texas Tech University Health Sciences Center|No|Recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Male|18 Years|80 Years|No|||March 2016|March 18, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712944||578|
NCT02657135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-2-0002|Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury|Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury|TEAM-TBI|University of Pittsburgh|Yes|Recruiting|January 2014|June 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|120|||Both|18 Years|60 Years|No|||January 2016|January 25, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02657135||4859|
NCT02657148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070357|Immediate Postpartum Nexplanon Placement in Opioid Dependent Women|A Randomized Clinical Trial to Compare the Effect of Immediate Postpartum Nexplanon Placement Versus Standard Postpartum Contraceptive Care on Consistent Contraceptive Use and Rapid Repeat Pregnancy in Opioid Dependent Women.||University of Pittsburgh|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657148||4858|
NCT02661269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nWMO 127|Relation Between the Increase of Peripheral Edema by Fluid Therapy and the Decrease in Microcirculatory Vesseldensity|Relation Between the Increase of Peripheral Edema by Fluid Therapy and the Decrease in Microcirculatory Vesseldensity||Medical Centre Leeuwarden|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|ICU population|January 2016|January 19, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02661269||4541|
NCT02661282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0899|Phase II Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients|A Phase I/II Clinical Trial of Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661282||4540|
NCT02645318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTHO1501|Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer|A Prospective Study of Circulating Tumor DNA Detection by Targeted Sequencing in Surgical Non-Small Cell Lung Cancer Patients||Peking University People's Hospital|Yes|Completed|May 2015|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|95|Samples With DNA|Fresh tumor tissue, peripheral blood cells, and plasma samples were collected from each      patient.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive cases who were suspected of non-small cell lung cancer and underwent        curative-intent resection.|December 2015|December 30, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645318||5766|
NCT02712424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29001|DAR-901 TB Booster Vaccine to Prevent TB in Adolescents|A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG|DAR-PIA|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|March 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|650|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712424||618|
NCT02649712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xzxy20160106|Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction|Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction||Xuzhou Central Hospital|Yes|Recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|85 Years|No|||January 2016|January 19, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649712||5428|
NCT02654106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-H&N-003|Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases|Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial|SRTRBM|Chinese Academy of Medical Sciences|No|Completed|October 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02654106||5092|
NCT02650661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHYun|Efficacy of a Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively|A Randomized Controlled Trial of Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively in Cancer Survivors||Seoul National University Hospital|Yes|Recruiting|December 2015|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|485|||Both|19 Years|N/A|No|||January 2016|January 7, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02650661||5355|
NCT02650674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBE043|Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products|Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products||Mondelēz International, Inc.|No|Recruiting|October 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02650674||5354|
NCT02714010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1014|EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC|Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis||Sun Yat-sen University|Yes|Recruiting|August 2015|December 2022|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|601|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|November 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714010||496|
NCT02659462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0124-15-RMB CTIL|Cardio Pulmonary Exercise Testing in Patients Post the Fontan Palliation in Comparison With Patients With Repaired Congenital Heart Disease and Healthy Volunteers.|Cardio Pulmonary Exercise Testing in Patients Post the Fontan Palliation in Comparison With Patients With Repaired Congenital Heart Disease and Healthy Volunteers.||Rambam Health Care Campus|No|Enrolling by invitation|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|8 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. 15 patients post the Fontal palliation for single ventricular heart          2. 15 subjects post surgical correction of congenital heart disease.          3. 15 healthy subjects.|January 2016|January 19, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02659462||4680|
NCT02659475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2630|Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)|Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia®) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)||Lindner Center of HOPE|No|Recruiting|September 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659475||4679|
NCT02647476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBET/91/L/2004|Postoperative Enteral Immunonutrition in Gastric Cancer|The Impact of Postoperative Enteral Immunonutrition on Postoperative Complications and Survival in Gastric Cancer Patients||Jagiellonian University|Yes|Completed|November 2004|October 2015|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02647476||5600|
NCT02645838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUGP|Motivational Interviewing for Smoking Cessation|Motivational Interviewing Versus Brief Advice for Smoking Cessation in General Practice||Capital Medical University|No|Not yet recruiting|April 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02645838||5726|
NCT02713711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUCM/1261/N822c/2014|Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis|Comparison of the Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis: A Randomized, Controlled Trial||Universidad Católica del Maule|Yes|Completed|December 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|55 Years|No|||March 2016|March 17, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02713711||519|
NCT02718053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spasticity01|Reliability of Spasticity Measurement With Lokomat|||Ospedale Generale Di Zona Moriggia-Pelascini||Recruiting|July 2015|||April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects are selected from patients hospitalized in our neurorehabilitation unit|March 2016|March 19, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718053||185|
NCT02646319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1313|Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations|A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers|RAPID|Mayo Clinic|Yes|Recruiting|January 2016|||May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646319||5689|
NCT02661360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00493|Effects of Swaddling on Infants During Feeding|Effects of Swaddling During Bottle Feeding on Infants Born Preterm||New York University School of Medicine|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02661360||4534|
NCT02657785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NavyGHB-001|Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy|Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy||Navy General Hospital, Beijing|No|Recruiting|September 2010|December 2024|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|April 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02657785||4809|
NCT02646176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OhioU|Comparative Effectiveness of Rehabilitation Interventions for Traumatic Brain Injury|Comparative Effectiveness of Rehabilitation Interventions for Traumatic Brain Injury|TBI-CER|Ohio State University|No|Completed|October 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2130|||Both|14 Years|N/A|No|Probability Sample|The study sample was drawn from the population of persons who received inpatient        rehabilitation for TBI in North America.|December 2015|December 31, 2015|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02646176||5700|
NCT02718612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104079|Prevalence and Determinants of Sarcopenic Obesity in Taiwanese Dialysis Patients|Association Between Sarcopenia and Sarcopenic Obesity With Metabolic and Cardiovascular Risk Factors in Taiwanese Dialysis Patients||Tungs’ Taichung Metroharbour Hospital|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|20 Years|100 Years|No|Non-Probability Sample|hemodialysis (HD) patients|March 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02718612||142|
NCT02718625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-036|Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers|A Randomized Controlled Trial of Enzymatic Debridement of Pressure Ulcers With Clostridial Collagenase Ointment (SANTYL®) or Hydrogel (SoloSite®)||Smith & Nephew, Inc.|No|Not yet recruiting|April 2016|September 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02718625||141|
NCT02659579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES/M003752/1|Evaluating the Effectiveness of the Reader Organisation's Get Into Reading Intervention|Evaluating the Effectiveness of the Reader Organisation's Get Into Reading Intervention||University of Liverpool|No|Not yet recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|100|||Both|36 Months|59 Months|Accepts Healthy Volunteers|||January 2016|January 15, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02659579||4671|
NCT02659592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3026-DM-CTIL|Transplantation of Frozen Thawed Ovarian Tissue High Reproductive Performance|Transplantation of Frozen Thawed Ovarian Tissue Demonstrates High Reproductive Performance and the Need to Revise Restrictive Criteria||Sheba Medical Center|No|Completed|January 2004|December 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|20 Years|40 Years|No|||January 2016|January 19, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02659592||4670|
NCT02659657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016PHB006-01|Prophylaxis Roles of IL-2 Treatment on Acute GVHD After Transplantation|Prophylaxis Roles of Low Dose of IL-2 Treatment on Acute GVHD After Haploidentical Transplantation||Peking University People's Hospital|Yes|Not yet recruiting|January 2016|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|70|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02659657||4665|
NCT02661373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUZZOFF|First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor|Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4||St. Jude Children's Research Hospital|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|January 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661373||4533|
NCT02646280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3791/2015|Myofascial Massage in the Treatment of Chronic Low Back Pain|The Myofascial Massage in the Treatment of Chronic Non-specific Low Back Pain: the Experience of Contact||University of Roma La Sapienza|Yes|Completed|July 2015|January 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|50 Years|No|||March 2016|March 22, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646280||5692|
NCT02646527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-2015-0416|Dignity Therapy+: A Brief Psychological and Existential Intervention for Dying Patients and Their Families.|Dignity Therapy+: a Brief Psychological and Existential Intervention for Dying Patients and Their Families. A Randomized Controlled Trial|DT-plus|University of Zurich|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646527||5673|
NCT02661178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDI-EMO-001|First in Man Clinical Trial of Emodepside (BAY 44-4400)|A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects||Drugs for Neglected Diseases||Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02661178||4548|
NCT02661191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTHMAVITD|Vitamin D Deficiency and Asthma Exacerbation|Effect of Vitamin D Repletion on Asthma Exacerbation|AVD|University of Turin, Italy|No|Completed|October 2012|March 2014|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|12 Years|80 Years|No|||January 2016|January 18, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02661191||4547|
NCT02661204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEC 2015-00011|Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)|Diagnostic Performance of an Automated Breast Ultrasound System (ABUS): a Single Centre Study||University of Zurich||Not yet recruiting|January 2016|||January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|250|||Female|18 Years|N/A|No|Non-Probability Sample|Population A: women in the age range of 20 to 40 years, with a strong family history of        breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2. A total of 100        patients should be enrolled.        Population B: women with new breast cancer diagnosis undergoing pre-operative local cancer        staging.A total of 50 patients will be enrolled.        Population C: women with lesions classified BI-RADS 3 or 4 in a routine breast imaging        examination. A total of 50 patients will be enrolled.        Population D: women undergoing breast-MRI for the evaluation of breast implants integrity.        A total of 50 patients will be enrolled.|January 2016|January 18, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661204||4546|
NCT02652338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNC-01|Dietary Supplement on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia|Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia||Trommsdorff GmbH & Co. KG|No|Completed|April 2014|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02652338||5226|
NCT02652910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151117|Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma|A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy|MeCAR|Xinqiao Hospital of Chongqing|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02652910||5182|
NCT02653976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-02L02|A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)||Solasia Pharma K.K.|No|Recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|20 Years|N/A|No|||March 2016|March 1, 2016|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02653976||5102|
NCT02718326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-OD-1411|Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)|A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy|PANORAMA|Regeneron Pharmaceuticals|Yes|Not yet recruiting|April 2016|January 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718326||164|
NCT02718339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-169-15 CTIL|In-patient Asthma Counseling by Pulmonologist and Hospital Re-admission Rate|||Soroka University Medical Center|Yes|Not yet recruiting|April 2016|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|March 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02718339||163|
NCT02647138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015935|The Effect of White Noise In High Noise Environment|The Effect of White Noise In High Noise Environment||Weill Medical College of Cornell University|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|100 Years|No|||March 2016|March 17, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02647138||5626|
NCT02650869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SylhetMAG|Role of Probiotics for Prevention of NEC in Preterm VLBW Infants|Role of Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double Blind Randomized Controlled Trial|Probiotics|Sylhet M.A.G.Osmani Medical College|Yes|Completed|July 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|33 Weeks|Accepts Healthy Volunteers|||January 2016|January 7, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650869||5339|
NCT02650622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112014-001|Genetic and Metabolic Disease in Children|Genetic Regulators of Metabolism and Development in Children||University of Texas Southwestern Medical Center|No|Recruiting|June 2015|February 2020|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1550|Samples With DNA|There are 3 cohorts in this study:      Cohort 1: healthy newborns Cohort 2: healthy children aged 0-18 years old Cohort 3: Children      with genetic/metabolic disorders and their families      Blood samples will be collected from all the three cohorts for isolation of plasma for      metabolomic analysis.      In addition, DNA will be extracted from the blood samples of cohort 3 patients for genomic      sequencing, and skin fibroblast cells will be collected from the proband patients in cohort      3.|Both|N/A|N/A|No|Non-Probability Sample|Two populations will be enrolled in this study, control and diseased. Healthy newborns and        older children will be recruited into the control population from Parkland Postpartum        units and Children's Medical Center (CMC), respectively. The diseased population will be        recruited from the clinics of the Pediatric Genetics and Metabolism Division in the        Department of Pediatrics of CMC.|January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650622||5358|
NCT02646514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0053|Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study|||Yonsei University|No|Recruiting|September 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|19 Years|N/A|No|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646514||5674|
NCT02654613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP013|Scaling up TB and HIV Treatment Integration|Addressing Challenges in Scaling up TB and HIV Treatment Integration in Public Health Settings in South Africa|SUTHI|Centre for the AIDS Programme of Research in South Africa|Yes|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|8000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654613||5053|
NCT02656875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-3003|A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain|A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted|ATHENA-1|Trevena Inc.|No|Recruiting|December 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656875||4879|
NCT02655744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-5392B|Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute|||Chang Gung Memorial Hospital||Recruiting|November 2015|||December 2018|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|84 Years|No|Non-Probability Sample|newly-diagnosed patients with primary CNS lymphoma|November 2015|January 12, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02655744||4966|
NCT02655757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301_xnk|Effect of Sitagliptin on Progression of Coronary Intermediate Lesion|Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes||Chinese PLA General Hospital|No|Recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02655757||4965|
NCT02658032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cartmel11.15|Personalized Prevention: Smoking Cessation in Patients With a Lung Nodule|Personalized Prevention: Smoking Cessation in Patients With a Lung Nodule||Yale University|Yes|Not yet recruiting|January 2016|January 2024|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|276|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658032||4790|
NCT02719730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-064|Upgrade the Grains Study: Increasing Whole Grain Consumption in Low-income Children With Obesity|The Metabolic Impact of Concurrent Food Insecurity and Obesity||Children's Hospital & Research Center Oakland|No|Enrolling by invitation|March 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02719730||56|
NCT02652676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150418|Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life|Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life||Loma Linda University|No|Not yet recruiting|January 2016|||December 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|4 Years|No|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652676||5200|
NCT02646930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00067725|Chronic Endometritis and IVF|The Impact of Chronic Endometritis on IVF Pregnancy and Pregnancy Loss Rates|CEIVF|Duke University|No|Recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|60|||Female|21 Years|35 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646930||5642|
NCT02657473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54939|Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis|Effects of Long Term ToBrAmycin InhalaTion SoluTion (TIS) Once daiLy on Exacerbation Rate in Patients With Non-cystic Fibrosis Bronchiectasis. A Double Blind, Randomized, Placebo and TIS Twice Daily (Open Label) Controlled Trial. The BATTLE Study.|BATTLE|Medical Center Alkmaar||Not yet recruiting|July 2016|July 2021|Anticipated|July 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|78|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657473||4833|
NCT02657486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-090|BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder|Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657486||4832|
NCT02657499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQHR01HS024270|Post Affordable Care Act Evaluation|Post Affordable Care Act: Evaluation of Community Health Centers|PACE|Oregon Health and Science University|No|Enrolling by invitation|January 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|555901|||Both|20 Years|64 Years|No|Non-Probability Sample|Study eligible patients within electronic health record data from the OCHIN community        health information network|February 2016|February 4, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657499||4831|
NCT02719223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002-16|The Effect of On-Line Hemodiafiltration Versus High Flux Hemodialysis on Hemodynamic Parameters in Patients With Intra-Dialytic Hypotension|The Effect of On-Line Hemodiafiltration Versus High Flux Hemodialysis on Hemodynamic Parameters in Patients With Intra-Dialytic Hypotension||Western Galilee Hospital-Nahariya|No|Not yet recruiting|March 2016|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02719223||95|
NCT02719483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20141030|Radial Extracorporeal Shock Wave Therapy for Spastic Plantar Flexor Muscles in Young Children With Cerebral Palsy|Applied Research in Children With Spastic Cerebral Palsy in the Extracorporeal Shock Wave Therapy||First Hospital of Jilin University|No|Completed|April 2014|March 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|12 Months|60 Months|No|||March 2016|March 21, 2016|March 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719483||75|
NCT02656485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVB244-001|A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris|A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray||AOBiome LLC|No|Recruiting|August 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|36|||Both|18 Years|45 Years|No|||January 2016|January 13, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656485||4909|
NCT02656498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THK-15002|[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease|An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases||Asan Medical Center|No|Recruiting|January 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|180|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656498||4908|
NCT02649062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0107|Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals|Study of the Pharmacodynamics of NGM282 on Colonic Transit, Bile Acid Homeostasis, and Fecal Fat in Subjects With Functional Constipation and Healthy Individuals||NGM Biopharmaceuticals, Inc|No|Recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649062||5478|
NCT02649283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX CL03|Performance of OrbiSymm in Subjects Referred to Contra Lateral Breast Symmetrisation|Phase IV, Multicenter, Open Label, Non Randomized Comparative Group Study to Assess the Safety and Performance of the OrbiSymm in Subjects Referred to Contra Lateral Breast Symmetrisation Following Breast Reconstruction Post Mastectomy||Orbix Medical Ltd.|No|Not yet recruiting|February 2016|March 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||December 2015|January 5, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02649283||5461|
NCT02649296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skanlab|Effect of Skanlab Regarding Knee Arthrosis|Effect of Skanlab Regarding Knee Arthrosis||Oslo and Akershus University College of Applied Sciences|No|Recruiting|October 2015|December 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|16|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02649296||5460|
NCT02652871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0436|A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652871||5185|
NCT02716467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EERP/USP|Effect of Intercessory Prayer in Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial|Effect of Intercessory Prayer on the Levels of Psychological Variables, Spiritual and Biological of Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial||University of Sao Paulo|Yes|Recruiting|April 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02716467||307|
NCT02645435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AObolognini1|Consequence of the Learning Curve in Direct Anterior Approach for Total Hip Replacement|Consequence of the Learning Curve in Direct Anterior Approach for Total Hip Replacement||Azienda Ospedaliera Bolognini di Seriate Bergamo|No|Completed|December 2015|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|N/A|N/A|No|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645435||5757|
NCT02644980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJZH20140722|Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery|Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study||Xijing Hospital|No|Not yet recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|August 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02644980||5792|
NCT02645240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mansoura30|Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia|Predictive Factors of Intestinal Infraction in Patients With Acute Mesenteric Ischemia||Mansoura University|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|16 Years|85 Years|No|||December 2015|December 31, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645240||5772|
NCT02653144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5628|the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block|Double Blinded Randomized Controlled Study Evaluating the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block in Patients Undergoing Ambulatory Shoulder Surgery||Montefiore Medical Center|Yes|Recruiting|March 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653144||5165|
NCT02712736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00069683|Quality of Life in Patients With PSC|Quality of Life in Primary Sclerosing Cholangitis|QOL in PSC|Duke University|No|Not yet recruiting|March 2016|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02712736||594|
NCT02647749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/01|Non-invasive Mapping of Rhythm Disorders||CARRY|University Hospital, Bordeaux|No|Recruiting|May 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|1200|||Both|15 Years|N/A|No|||January 2016|January 4, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02647749||5579|
NCT02650934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114S309|Predictors of Heart Failure After ST-segment Elevation Myocardial Infarction (HF-EXPRESS)||HF-EXPRESS|Dr. Nafiz Korez Sincan State Hospital|Yes|Recruiting|June 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|312|Samples With DNA|Peripheral Blood specimen|Both|18 Years|80 Years|No|Probability Sample|18-80 years old patients with myocardial infarction in the first 12 hours|June 2015|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02650934||5334|
NCT02659618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29345|Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma|Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma||Rush University Medical Center|No|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Venous blood and serum will be drawn and shipped to Genentech for analysis.|Both|12 Years|65 Years|No|Non-Probability Sample|Thirty prospective subjects will be screened to identify 20 subjects with severe        persistent asthma. These subjects will be recruited from the Allergy/Immunology outpatient        clinic at Rush University Medical Center along with self-referral through advertising        posted on campus.|January 2016|January 19, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02659618||4668|
NCT02652663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1045|Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents|||Yonsei University|No|Active, not recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|||Both|20 Years|90 Years|No|Non-Probability Sample|Patients with newly diagnosed colorectal cancer between January 2005 and December 2010|January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652663||5201|
NCT02655562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing Chao Yang Hospital|Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough|Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial||Beijing Chao Yang Hospital|Yes|Not yet recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02655562||4980|
NCT02655497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#15-29|Maintaining Independence in Everyday Life Among Seniors With Subjective Cognitive Complaints|Maintaining Independence in Everyday Life Among Seniors With Subjective Cognitive Complaints||Baycrest|Yes|Recruiting|September 2015|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02655497||4985|
NCT02646709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-15-153|The Effect of Different Dose of Ketamine With Low Dose Rocuronium in Children|The Effect of Different Doses of Ketamine on Tracheal Intubating Conditions Using Low Dose Rocuronium in Children||Ajou University School of Medicine|No|Not yet recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|2 Years|12 Years|No|||January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02646709||5659|
NCT02658214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D419SC00001|Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors|A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors||AstraZeneca|No|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|80|||Both|18 Years|99 Years|No|||January 2016|January 14, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658214||4776|
NCT02658227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-029/ IPM 039|Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women|Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women||International Partnership for Microbicides, Inc.|Yes|Not yet recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|16|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658227||4775|
NCT02657512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508030|Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects|Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects : RICHAR Study|RICHAR|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657512||4830|
NCT02657525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-88|Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study|Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study|AECOPD-IRS|China-Japan Friendship Hospital|Yes|Active, not recruiting|January 2016|January 2020|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7600|||Both|18 Years|N/A|No|Probability Sample|AECOPD-IRS plans to enroll 7600 hospitalized patients (≥ 18 years old with main diagnosis        as AECOPD). Sample size estimation is based on estimated mortality of AECOPD hospitalized        patients (~5%). Study patients will be recruited from 40-60 hospitals across China,each        hospital will recruit 152-190 patients. Hospital selection follows a multi-stage sampling        strategy.|February 2016|February 3, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657525|3 Years|4829|
NCT02648529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-700|Brain Maturation in Children With Localization Related Epilepsy|Dynamic Regional Brain Maturation in Children With Localization Related Epilepsy|DYNAMAT|Hospices Civils de Lyon|No|Active, not recruiting|September 2008|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|101|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||October 2015|January 6, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02648529||5519|
NCT02651168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol B SMH Aflibercept|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study||St. Michael's Hospital, Toronto|No|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651168||5316|
NCT02651441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-NSCLC|D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)|Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined With Chemotherapy for Non-Small Cell Lung Cancer||Shenzhen Hornetcorn Bio-technology Company, LTD|Yes|Not yet recruiting|February 2016|August 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02651441||5295|
NCT02651454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISEE_2015_OBESITY|A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -|A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -||Gachon University Gil Oriental Medical Hospital|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|65 Years|No|||January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02651454||5294|
NCT02719938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1708|Triggered Palliative Care for Advanced Dementia|Triggered Palliative Care for Advanced Dementia||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|65 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719938||40|
NCT02653495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAN-0891|Impact of Metabolic Syndrome on Flu Vaccine Efficacy|Impact of Metabolic Syndrome on Flu Vaccine Efficacy||Rockefeller University|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653495||5138|
NCT02656745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20152568|Clinical Trial of Mobile-Based Intervention for Smoking Cessation (Clickotine® Study)|Clinical Trial of Mobile-Based Intervention for Smoking Cessation (Clickotine® Study)||Click Therapeutics, Inc.|Yes|Not yet recruiting|February 2016|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656745||4889|
NCT02651727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-4718-103|Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects|A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer||Verastem, Inc.|No|Recruiting|September 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651727||5273|
NCT02658435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201807|Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)|A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers||GlaxoSmithKline|Yes|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658435||4759|
NCT02658448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G201001|GTx-024 as a Treatment for Stress Urinary Incontinence in Women|GTx-024 as a Treatment for Stress Urinary Incontinence in Women: A Proof of Concept Study||GTx|No|Recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|80 Years|No|||January 2016|January 14, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658448||4758|
NCT02644837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015AN07|AuraGain and iGel Crossover Comparison|Randomised Crossover Comparison of the Ambu AuraGain and the iGel in Anaesthetised Adults||NHS Tayside|Yes|Not yet recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02644837||5803|
NCT02644850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508081RINA|Comparison of Gated Blood-pool SPECT and Echocardiogram for Ventricular Function|Comparison of Gated Blood-pool SPECT Using CZT Camera and Echocardiogram for Ventricular Ejection Fraction Estimation||National Taiwan University Hospital|No|Recruiting|October 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|85 Years|No|Probability Sample|Patients underwent transthoracic echocardiogram and resting cardiac function within        interval of 90 days of each other|December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02644850|3 Years|5802|
NCT02660996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5857|Effectiveness of the Advocate Lutheran General Survivorship Center Programs|Assessing the Effectiveness of the Advocate Lutheran General Survivorship Center Programs on Patients' Quality of Life, Distress Level, and Satisfaction||Advocate Health Care|Yes|Recruiting|July 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed cancer patients who see one of the oncologists at The Advocate Lutheran        General Hospital Center of for Advanced Care. Patients who older than 18 years of age,        male or female, and any race are eligible. Patients who are new to the Survivorship Center        or only visited once are eligible.|March 2016|March 2, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660996||4562|
NCT02657941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00142-47|Early and Short Psycho-educational Lifestyle Intervention|Early and Short Psycho-educational Lifestyle Intervention to Prevent Weight Gain Induced by Psychotropic Drugs in Adults With Severe Mental Illness: a Randomized Controlled Trial|HYVIE|Hôpital le Vinatier|Yes|Active, not recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|45 Years|No|||March 2016|March 11, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657941||4797|
NCT02717247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00028-41|Transcranial Random Noise Stimulation in Food Addiction Treatment|Effect of Transcranial Random Noise Stimulation of Prefrontal Cortex on Craving Supply Subject Suffering From Obesity|tRNS-FA|Hôpital le Vinatier|Yes|Recruiting|February 2016|September 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02717247||247|
NCT02647411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARVO R1 2016 1|Increased Prevalence of Myopia in a Ophthalmologic Hospital in Goiânia - Goiás|Increased Prevalence of Myopia in a Ophthalmologic Hospital in Goiânia - Goiás||Instituto de Olhos de Goiania|Yes|Completed|August 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|16971|||Both|2 Years|40 Years|No|Non-Probability Sample|16.806 students from municipal schools of Goiânia during the period October 1995 to        December 2000 In the second study there were selected 165 children from 2 to 14 years old        who were referred to the Institute of Goiânia eyes, look at Brazil project within the        school environment. The Look Brazil project aims to identify vision problems related to        refraction.|January 2016|January 5, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02647411||5605|
NCT02647424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-VL-LCC|A Comparison of Letrozole and Clomifene Citrate|A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women||The University of Hong Kong|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|39 Years|No|||January 2016|January 5, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647424||5604|
NCT02646943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2111129|Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)|Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)|SaMi-Trop|University of Sao Paulo|Yes|Completed|July 2013|August 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1959|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected based on the ECG results performed in 2011-12 by the Telehealth        Network. Since the TeleHealth System is currently acting in support of the Primary Care        system, these patients are under the care of primary care physicians of the Health Family        Strategy, a public primary care program that has a high coverage in the state of Minas        Gerais.|January 2016|January 5, 2016|December 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02646943||5641|
NCT02649855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160048|Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer|Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Male|18 Years|100 Years|No|||December 2015|March 11, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02649855||5417|
NCT02716688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangPPH02|S-1 and Radiotherapy for Elderly Esophageal Cancer Patients|A Phase Ⅱ Study of S-1 With Concurrent Radiotherapy in Elderly Esophageal Cancer Patients||Zhejiang Provincial People’s Hospital|No|Recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|70 Years|N/A|No|||March 2016|March 22, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02716688||290|
NCT02656446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35846|Accuracy of Depth and Landmark Assessment Using Neuraxial Ultrasound Devices|Accuracy of Depth and Landmark Assessment Using Neuraxial Ultrasound Devices||Stanford University|No|Not yet recruiting|January 2016|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|50 Years|No|Non-Probability Sample|50 parturients who decide they want epidural analgesia in labor|January 2016|January 12, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02656446||4912|
NCT02661308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sagsnr. 1-10-72-286-15|Reducing Cancer Side-effects With Systematic Light Exposure|Reducing Cancer Side-effects With Systematic Light Exposure|LYS|Aarhus University Hospital||Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02661308||4538|
NCT02655822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-444-001|Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers|A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers||Corvus Pharmaceuticals, Inc.|Yes|Recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|534|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02655822||4960|
NCT02718365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSCI002|Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC|A Multi-center, Prospective, Randomized Controlled Clinical Trial: Comparison Between Wedge Resection and Segmentectomy in the Surgical Treatment of Ground Glass Opacity-dominant Stage IA Non-small Cell Lung Cancer||West China Hospital|Yes|Not yet recruiting|April 2016|April 2023|Anticipated|April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|688|||Both|18 Years|80 Years|No|||February 2016|March 18, 2016|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02718365||161|
NCT02718378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3107|Evaluation of Safety and Efficacy of Estetrol in Healthy Men|A Phase I, Double-blind, Randomised, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Two Dosages of Estetrol in Healthy Men||Pantarhei Oncology B.V.||Recruiting|March 2016|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02718378||160|
NCT02647996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01873-44|Functional Connectivity Measurement After Severe Traumatic Brain Injury|Functional Connectivity Measurement After Severe Traumatic Brain Injury|Connectivite|University Hospital, Grenoble|No|Recruiting|March 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|34|||Both|18 Years|N/A|No|Non-Probability Sample|severe TBI admitted in ICU and ready to be discharged to rehabilitation with or without        DOC|January 2016|January 4, 2016|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02647996||5560|
NCT02651415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02424|Phase II Study of Perindopril and Regorafenib in mCRC|A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)|PARICCA|British Columbia Cancer Agency|No|Not yet recruiting|March 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02651415||5297|
NCT02651675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHGT002|A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)|A Phase 1/2a, Single Ascending IV Dose Clinical Trial Investigating Human Low Density Lipoprotein Receptor (LDLR) Gene Therapy in Subjects With Homozygous Familial Hypercholesterolemia (HoFH).||University of Pennsylvania|Yes|Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651675||5277|
NCT02650960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58670|Life Balance and Bimanual Activities After Stroke|Life Balance and Bimanual Activities After Stroke||Universitaire Ziekenhuizen Leuven||Not yet recruiting|February 2016|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a first-ever stroke (n=120) will be recruited consecutively by admission in        three rehabilitation centers in Belgium.|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02650960||5332|
NCT02718352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16010 17074|A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence|A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence||Yale University|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|16 Years|25 Years|No|Probability Sample|Fifty16 to 25 year old opioid treatment-seeking individuals enrolled in the APT Adolescent        and Young Adult Suboxone Program.|March 2016|March 23, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02718352||162|
NCT02650791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150629-01H|Platelet Transfusion Requirements in Hematopoietic Transplantation|Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot)|PATH|Ottawa Hospital Research Institute|Yes|Not yet recruiting|February 2016|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|90 Years|No|||February 2016|February 25, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650791||5345|
NCT02650804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP31510IV-05|Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients|A Phase 2 Study of Gemcitabine Plus BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously as 2nd Line Therapy in Advanced Pancreatic Cancer Patients||Berg, LLC|No|Recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650804||5344|
NCT02647788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACH-2015|Acetaminophen/Codeine vs Acetaminophen/Ibuprofen for Pain Control and Patient Satisfaction After Hand Surgery|Pilot Study, Blinded Randomized Control Trial, Single Center Study to Compare Acetaminophen & Codeine Versus Ibuprofen/Acetaminophen for Pain Control and Patient Satisfaction After Ambulatory Hand Surgery||University of Pennsylvania|No|Recruiting|December 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647788||5576|
NCT02646189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP 102|Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients|Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients||Replicor Inc.|No|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02646189||5699|
NCT02651194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-462|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection|A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)|EXPEDITION-4|AbbVie|Yes|Recruiting|December 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|99 Years|No|||January 2016|January 7, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651194||5314|
NCT02714556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIRCA-2016|Changes in Ventilation Inhomogeneity and Respiratory Function Following Elective Caesarean Section Under Regional Anaesthesia|Changes in Ventilation Inhomogeneity and Respiratory Function Following Elective Caesarean Section Under Regional Anaesthesia: a Prospective Observational Study|VIRCA|University Hospital, Geneva|No|Not yet recruiting|May 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women scheduled for elective caesarean section in gestational weeks 37-40|March 2016|March 15, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02714556||454|
NCT02648503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8616-138|Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy|||Ho Chi Minh City University of Medicine and Pharmacy|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02648503||5521|
NCT02648724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sym015-01|Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies|An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies||Symphogen A/S|No|Recruiting|March 2016|September 2019|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02648724||5504|
NCT02648035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29855|EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis|Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.||Hoffmann-La Roche||Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with rheumatoid arthritis for whom the physician has made the decision to        start subcutaneous Tocilizumab treatment.|March 2016|March 1, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02648035||5557|
NCT02648048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB29764|A Safety and Tolerability Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis|A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis||Hoffmann-La Roche||Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|80 Years|No|||March 2016|March 1, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02648048||5556|
NCT02650739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye0021|Optical Coherence Tomography-based Positioning for Macular Hole Surgery|Duration of Prone Positioning After Macular Hole Surgery Determined by Swept Source Optical Coherence Tomography||Kyorin University|No|Completed|May 2013|October 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|125|||Both|20 Years|90 Years|No|Non-Probability Sample|The efficacy of macular hole (MH) surgery with the halting of prone positioning by        monitoring the MH closure in the swept source optical coherence tomographic (SS-OCT)        images in 60 eyes was compared with the 69 eyes with same surgical procedure but the prone        position determined by the surgeon's decision.|January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02650739||5349|
NCT02650752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-278|Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases|Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650752||5348|
NCT02648178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D15154|Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers|Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648178||5546|
NCT02651805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIE-Palliative|Mechanical Insufflator-exsufflator to Control Mucus Hypersecretion in Patients in Palliative Care - A Feasibility Study|Mechanical Insufflator-exsufflator to Manage Respiratory Secretion in Patients in Palliative Care - A Feasibility Study||Universidade Federal de Sao Carlos|No|Recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02651805||5267|
NCT02659384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1508|Anti-programmed Cell Death-1 Ligand 1 (PDL-1) Antibody Atezolizumab, Bevacizumab and Acetyl Salicylic Acid in Recurrent Platinum Resistant Ovarian Cancer|A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetyl Salicylic Acid to Investigate Safety, Efficacy, Biological Activity and Immunological Mechanisms of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|May 2016|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|160|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659384||4686|
NCT02659566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916051|Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Don(SqrRoot)(Copyright)gu(SqrRoot)(Copyright)Bougou, Mali|Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|700|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|March 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659566||4672|
NCT02661009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGFR2015-01|Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)|Human EGFR(Epidermal Growth Factor Receptor) Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)||GenoSaber|Yes|Not yet recruiting|January 2016|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|Non Small Cell Lung Cancer(stage Ⅲ-Ⅳ)|December 2015|January 20, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661009||4561|
NCT02714543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxfordDC|Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study|||The Oxford Dental College, Hospital and Research Center, Bangalore, India|No|Completed|November 2013|November 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|17 Years|60 Years|No|||March 2016|March 15, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02714543||455|
NCT02652130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-GVHD002|Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD||Mesoblast, Ltd.|Yes|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|2 Months|17 Years|No|Non-Probability Sample|In-patients in selected hospitals from MSB GVHD001|January 2016|January 7, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652130||5242|
NCT02655471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65384|Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection|Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study||Universidad Peruana Cayetano Heredia|No|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02655471||4987|
NCT02650635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1245|TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors|Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors||Mayo Clinic|Yes|Recruiting|February 2016|||May 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|February 9, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650635||5357|
NCT02650648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-272|Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|January 2016|||January 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02650648||5356|
NCT02718014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMVIDSRC|Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis|Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis|EPRNPPMP|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Yes|Completed|January 2015|August 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718014||188|
NCT02718300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 50465-201|A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis|A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis||Incyte Corporation|No|Not yet recruiting|June 2016|September 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718300||166|
NCT02647398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-UEM-04|Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue|Randomized Study Comparing Two Strategies of Physical Activity in Long-term Breast and Colon Cancer Survivors and Their Impact on Fatigue||Puerta de Hierro University Hospital|No|Not yet recruiting|January 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|32|||Both|18 Years|65 Years|No|||January 2016|January 5, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02647398||5606|
NCT02659943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160054|T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies|T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|January 2016|December 2021|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|73 Years|No|||January 2016|February 2, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659943||4643|
NCT02647281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202007|First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects|A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects||GlaxoSmithKline|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|14||Anticipated|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02647281||5615|
NCT02647294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-28745A|Polyunsaturated Fatty Acids in Patients With NAFLD.|Nutrition-based Therapy of Liver Disease of Different Origin: Effect of n-3 Polyunsaturated Fatty Acid in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome.||General University Hospital, Prague|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647294||5614|
NCT02715973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-CLD-Nutrition-01|Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease|Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease||Institute of Liver and Biliary Sciences, India|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Months|3 Years|No|||February 2016|March 16, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715973||345|
NCT02656147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doing-004|Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of γδT Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies||Beijing Doing Biomedical Co., Ltd.|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656147||4935|
NCT02651389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 15.087 - ESPPADON|Evaluation of Tests Performance on a New Digital Orthoptic Platform|Evaluation de la Performance d'Une Nouvelle Plateforme de Tests de dépistage Orthoptique numériques|ESPPADON|University Hospital, Brest|No|Recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|96|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People performing an orthoptic exam at ophthalmology department of Brest University        Hospital.|December 2015|March 3, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02651389||5299|
NCT02658097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1516|A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC|A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC||Case Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658097||4785|
NCT02715414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH106771|Family Groups for Urban Youth With Disruptive Behavior|Family Groups for Urban Youth With Disruptive Behavior||NYU Silver School of Social Work|No|Recruiting|June 2015|December 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2956|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02715414||388|
NCT02645175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW1025-2014|Evaluate the Safety Profile and Ability of TW1025(LinEase®) Oral Solution to Decrease Fatigue|A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety Profile and Ability of TW1025(LinEase®) to Decrease Fatigue||Meriyana Bio Inc.|Yes|Enrolling by invitation|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|80 Years|No|||January 2016|February 2, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02645175||5777|
NCT02645188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007140|Effect of Cueing on Gluteus Maximus Recruitment|Effects of Cueing on Gluteus Maximus and Hamstring Recruitment During the Bridging Exercise||Mayo Clinic|No|Completed|December 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645188||5776|
NCT02653313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ParvOryx02|Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer|A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer|ParvOryx02|Oryx GmbH & Co. KG|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02653313||5152|
NCT02653326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC093-15|Technological Platforms and Telerehabilitation in Heart Surgery|Integrative Technological Platforms for Telerehabilitation for Patients With Heart Surgery: A Pilot Randomised Trial||Universidad de Valparaiso|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02653326||5151|
NCT02657798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0860|RESIST: Understanding the Role of Depression in Heart Disease|Resist: What Are the Mechanisms Involved in Depression and Antidepressant Resistance That Increase Cardiovascular Risk?||University College, London|No|Not yet recruiting|February 2016|September 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|90|Samples With DNA|Saliva, peripheral blood mononuclear cells, blood serum, blood plasma, RNA|Both|18 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|Depressed patients will be recruited from the PANDA trial. Healthy controls will be        recruited from primary care.|January 2016|January 14, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657798||4808|
NCT02712476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cerrahpasa Neuroanesthesia|Brain Relaxation With Mannitol and Furosemide|Comparison of Mannitol Alone Versus Different Doses of Mannitol in Combination With Furosemide on Brain Relaxation in Supratentorial Mass Resection Surgery||Istanbul University|No|Completed|July 2013|November 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|20 Years|70 Years|No|||March 2016|March 14, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02712476||614|
NCT02650817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD1901-106|A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer|A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging||Radius Health, Inc.|No|Recruiting|December 2015|||May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650817||5343|
NCT02651103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-01073|Changes in Cerebral Oxygenation Based on Intraoperative Ventilation Strategy|Changes in Cerebral Oxygenation Based on Intraoperative Ventilation Strategy||Nationwide Children's Hospital|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing posterior spinal fusion|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651103||5321|
NCT02649569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-4873|Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer|Continuous Activity Monitoring During Fractionated Radiotherapy: A Pilot Study||Albert Einstein College of Medicine of Yeshiva University|No|Active, not recruiting|June 2015|July 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Planned treatment with fractionated (>= 15 treatments) external beam radiotherapy with        concurrent chemotherapy with curative intent|January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649569||5439|
NCT02657850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00074509|Head and Neck Cancer Treatment Related Dysphagia|Multi-Institution Longitudinal Evaluation of Head and Neck Cancer Treatment - Related Dysphagia||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|March 2018|||March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Both|18 Years|100 Years|No|Probability Sample|head and neck cancer|January 2016|January 13, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657850||4804|
NCT02717507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE1621|Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors|Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial||Children's Oncology Group|Yes|Not yet recruiting|May 2016|||April 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|16 Years|N/A|No|||March 2016|March 17, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717507||227|
NCT02652156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ2014035|TAP Block for Postoperative Pain Control|Transversus Abdominis Plane (TAP) Block Study for Postoperative Pain Control||Midwestern Regional Medical Center|No|Active, not recruiting|November 2015|October 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652156||5240|
NCT02656030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSuvarnnato|Effects of Specific Training for Deep Neck Muscle|Effects of Specific Training of Deep Cervical Muscles in Chronic Mechanical Neck Pain||Khon Kaen University|Yes|Recruiting|November 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|59 Years|No|||February 2016|February 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02656030||4944|
NCT02647905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0023|Evaluation of the Accuracy of an Implanted Glucose Sensor|A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor, PRECISE II|PRECISEII|Senseonics, Inc.|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|February 19, 2016|December 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647905||5567|
NCT02647918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-121-REN|Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function|A Phase 1, Open-label, Parallel-group Study to Evaluate Sotagliflozin Safety and Pharmacokinetics in Subjects With Varying Degrees of Renal Function||Lexicon Pharmaceuticals|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|44|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|December 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647918||5566|
NCT02655159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-CMM-2015-01|Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice|Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice|AMBER|Celgene|No|Not yet recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|330|||Female|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with HER2-negative MBC who have started treatment with        nab-paclitaxel monotherapy no further than third-line chemotherapy for metastatic disease        between 2012 and 2014 will be enrolled consecutively. In addition, patients must meet the        selection criteria established in this protocol.|January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655159||5011|
NCT02660619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 2B|Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication|Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication||Member Companies of the Opioid PMR Consortium||Active, not recruiting||||May 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|600|||Both|18 Years|N/A||Non-Probability Sample|Patients will be recruited from low-risk and high-risk treatment settings in the greater        New York City metropolitan area, which includes the five boroughs of the city and Long        Island. Thus, the population will be a mix of urban and suburban participants.|January 2016|January 18, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660619||4591|
NCT02656264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-KAEK-28028|The Chronic Pain Incidence After Elective and Urgent Cesarean Sections|The Chronic Pain Incidence After Elective and Urgent Cesarean Sections||Tokat Gaziosmanpasa University|Yes|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|45 Years|No|Probability Sample|-  Female          -  18 - 45 years of age          -  underwent elective or urgent cesarean section|January 2016|January 12, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02656264||4926|
NCT02659709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-413E|Electronic Applications for Patients With Glaucoma|A Smartphone- and Tablet-Based Application for Patients With Glaucoma|GlaucomaApp|Wills Eye|No|Active, not recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02659709||4661|
NCT02659722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-012|InterFuse® S and T for the Treatment of Scoliosis, Spondylolisthesis and DDD|A Multi-Center Prospective Study of VTI InterFuse® S and InterFuse® T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease.||Vertebral Technologies, Inc.|Yes|Recruiting|January 2014|January 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|The protocol includes skeletally mature patients both male and female, 18 to 89 years old,        with degenerative disc disease (DDD) and/or scoliosis and a planned fusion of at least        five levels.. DDD is defined as discogenic back pain with degeneration of the disc        confirmed by patient history and radiographic studies.|January 2016|January 15, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659722||4660|
NCT02648685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanofi-023|The Study to Investigate the Contribution of Fasting and Post-prandial Blood Glucose to Overall Glycaemia in Subjects With Normal Glycaemic Metabolism and T2DM|The Study to Investigate the Contribution of Fasting and Post-prandial Blood Glucose to Overall Glycaemia in Subjects With Normal Glycaemic Metabolism and Type 2 Diabetes||West China Hospital|No|Recruiting|November 2015|June 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|-  Age 18-75 years old, male or female          -  Normal glycaemic and normal weight subjects:               -  Normal results of routine blood and urine tests               -  Normal kidney and liver function               -  BMI >=18.5 and <=24.9 Kg/m2               -  Normal blood lipid profile               -  Normal blood pressure               -  Normal OGTT (according WHO 1999 criteria)          -  T2DM subjects:               -  Diagnosed according WHO 1999 criteria               -  Duration of T2DM diabetes>=6 months               -  Treated with stable regimen of OADs >=3 months          -  The subjects didn't receive any drug with potential impact on glycemic metabolism in             the last one month          -  Will sign the consent form|January 2016|January 6, 2016|December 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02648685||5507|
NCT02652728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-602295-01|Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy|Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy|LENA-WP08|Ethicare GmbH|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Month|11 Years|No|||January 2016|January 8, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02652728||5196|
NCT02657876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C9T12015|ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers|An Open-Label, Prospective, Multicenter, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers||Stratatech|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|January 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657876||4802|
NCT02657889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-PN162-01-001|Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)|Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer||Tesaro, Inc.|No|Recruiting|March 2016|February 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657889||4801|
NCT02657902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1960/2015|Does an Additional Antirotation U-Blade (RC) Lagscrew Improve Treatment of AO/OTA (Orthopaedic Trauma Association) 31 A1-3 Fractures With Gamma 3 Nail?|Does an Additional Antirotation U-Blade (RC) Lagscrew Improve Treatment of AO/OTA (Orthopaedic Trauma Association) 31 A1-3 Classified Fractures With Gamma 3 Nail?||Medical University of Vienna||Completed|January 2009|||January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with OTA/AO 31A1-3 fractures treated with Gamma 3® Nail (Stryker Trauma Germany)        and either with standard lagscrews or with the Gamma3 ® RC Lag Screw (Stryker Trauma        Germany)|January 2016|January 15, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02657902||4800|
NCT02715713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L16-059|Autonomic Manifestations of Testosterone Deficiency in Men|Autonomic Manifestations of Testosterone Deficiency in Men||Texas Tech University Health Sciences Center|No|Recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Male|40 Years|80 Years|No|Non-Probability Sample|Two groups will be recruited with 20 men in each group:        Group 1 will include 20 men between the ages of 40 to 80-years-old with symptoms and        biochemical parameters of low testosterone.        Group 2 will include 20 men between the ages of 40 to 80-years-old with prostate cancer        and normal serum testosterone that will be treated with surgical or pharmacological        castration, as following standard of care at Urology Division, resulting in testosterone        deficiency.|March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715713||365|
NCT02655536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510073MIPB|Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial|A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases|BRILLIANT|National Taiwan University Hospital|No|Not yet recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|109|||Both|20 Years|99 Years|No|||January 2016|January 12, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02655536||4982|
NCT02660970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-322|Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea|Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea - a Randomized Clinical Trial With Sham-conditions||University Hospital, Basel, Switzerland|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|6 Years|18 Years|No|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660970||4564|
NCT02659904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/103|The Quantitative Changes in Palatal Donor Sites Thickness After Free Gingival Graft Harvesting|The Quantitative Changes in Palatal Donor Sites Thickness After Free Gingival Graft Harvesting||Ondokuz Mayıs University|Yes|Completed|February 2015|January 2016|Actual|December 2015|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|35 Years|No|||January 2016|January 16, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02659904||4646|
NCT02653755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-255|The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer|The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|March 2016|June 2023|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1380|||Female|50 Years|75 Years|No|||February 2016|February 1, 2016|January 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653755||5119|
NCT02648776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB1-083|Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly|Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly; A Prospective Cohort Study at a Taiwanese Academic Medical Center|RABA-HASDE|China Medical University Hospital|No|Enrolling by invitation|January 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|1400|Samples With DNA|A single set of blood and urine samples taken in cohorts taking sedative-hypnotic      medications, used to evaluate pharmacokinetic and pharmcogenetic parameters.|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Longitudinal prospective observational cohort study        Elderly patients receiving regular outpatient services at China Medical University        Hospital|January 2016|January 7, 2016|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02648776||5500|
NCT02713477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14115|Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus|A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus||Sanofi|No|Not yet recruiting|May 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|20 Years|75 Years|No|||March 2016|March 15, 2016|March 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713477||537|
NCT02652416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.23|Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1026706 in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Trial)||Boehringer Ingelheim||Not yet recruiting|March 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Anticipated|72|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 8, 2016||||No||https://clinicaltrials.gov/show/NCT02652416||5220|
NCT02652429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULSE-PAH-006|Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH|An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH||Bellerophon|Yes|Enrolling by invitation|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|N/A|N/A|No|||March 2016|March 23, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652429||5219|
NCT02650882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62/13|Effect of Inspiratory Muscle Training on the Performance of Handball Athletes|Effect of Inspiratory Muscle Training on the Performance of Handball Athletes||Universidade Metodista de Piracicaba|Yes|Completed|April 2013|March 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02650882||5338|
NCT02713204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R910-3-AMD-1517|Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection|A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration|ONYX|Regeneron Pharmaceuticals||Recruiting|February 2016|November 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|50 Years|N/A|No|||March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713204||558|
NCT02645669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVSIDS/PERIO/2/2014|Effect of a Locally Delivered Probiotic in Periodontitis|Effect of a Locally Delivered Probiotic as an Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis||SVS Institute of Dental Sciences|Yes|Completed|February 2014|August 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||December 2015|January 4, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02645669||5739|
NCT02647216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01138|Mindfulness for Breast Cancer|Mindfulness Training to Improve Well-being in Post-Treatment Breast Cancer Patients||New York University School of Medicine|No|Recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02647216||5620|
NCT02647229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01351|Colonic Irrigation for Colonoscopy Preparation|Measuring the Effectiveness and Utility of Colonic Irrigation for Bowel Preparation in Patients Undergoing Screening or Surveillance Colonoscopy||New York University School of Medicine|No|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647229||5619|
NCT02658305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201525558|Transoral Versus Transbuccal Placement of Bicortical Screws During Orthognathic Surgery|||AZ Sint-Jan AV|No|Completed|October 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|509|||Both|N/A|N/A|No|Non-Probability Sample|All orthognathic patients operated in the lower jaw between January 2010 and December 2012        at the Department of Oral and Maxillofacial Surgery, General Hospital Saint-John Bruges,        Belgium|January 2016|January 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02658305||4769|
NCT02658383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00ES022269|Community-Engaged Research: A Tool to Advance Cookstove Interventions|Community-Based Participatory Research: A Tool to Advance Cookstove Interventions||Colorado State University|Yes|Recruiting|August 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02658383||4763|
NCT02714894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-2015|Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study|Glutamatergic System and Response to Clozapine in Patients With Treatment-Resistant Schizophrenia: a Prospective Proton Magnetic Resonance Spectroscopy Study||Centre for Addiction and Mental Health|No|Not yet recruiting|April 2016|March 2022|Anticipated|March 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|108|Samples With DNA|Blood sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with schizophrenia who fail to respond to optimal treatment with at least two        different non-clozapine antipsychotics (i.e. treatment-resistant schizophrenia [TRS]) and        are starting clozapine will be recruited. A sample of healthy controls will also be        recruited.|March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02714894||428|
NCT02714907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15006113|Clinical Data Validation of Novel Wireless Cortrium C3 Monitor for Continuous Electrocardiogram Measurements|Clinical Data Validation of Novel Wireless Cortrium C3 Monitor for Continuous Electrocardiogram Measurements||Cortrium|Yes|Recruiting|March 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02714907||427|
NCT02653001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR01/2015|The IFR Colon Model|Stool Sample Collection for Research Using the In-vitro IFR Colon Model||Institute of Food Research|No|Enrolling by invitation|January 2016|January 2026|Anticipated|January 2026|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02653001||5175|
NCT02653014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBP5074-1-002|Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment|An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment||KBP Biosciences|Yes|Recruiting|July 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|January 8, 2016|December 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653014||5174|
NCT02658981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC 1501|Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma|A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|68|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658981||4717|
NCT02659046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15158|Severe Traumatic Brain Injury|The Effect of Different Emergency Medical Systems on the Prognosis of Traumatic Brain Injury||Tampere University Hospital|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|December 2015|January 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659046||4712|
NCT02656056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507016139|Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome|Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome||Yale University|No|Recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02656056||4942|
NCT02714296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutricia-001|Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical Nutrition|Phase IV Prospective Sinle Center Randomised Three-arm Controlled Study Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical Nutrition||Nutricia Advanced|No|Not yet recruiting|March 2016|March 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|75 Years|No|||March 2016|March 21, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714296||474|
NCT02655016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-30-5017-C|A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy||Tesaro, Inc.|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|305|||Female|18 Years|N/A|No|||November 2015|February 19, 2016|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02655016||5022|
NCT02655029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC4-06593-21-GRC|Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination|Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension|CONTROL-3|Servier Hellas Pharmaceuticals Ltd.|No|Recruiting|November 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|||Both|18 Years|N/A|No|Probability Sample|Greek patients with arterial hypertension who receive treatment with        Perindopril/Indapamide/Amlodipine fixed dose combination.|January 2016|January 13, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02655029|4 Months|5021|
NCT02651688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-205|A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene|A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene||Repros Therapeutics Inc.|No|Recruiting|January 2016|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Male|18 Years|60 Years|No|||January 2016|January 8, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651688||5276|
NCT02656290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03|COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement|Prospective, Non‐Randomized, Single Arm, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement|COMMENCE-P|Edwards Lifesciences|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|5 Years|N/A|No|||January 2016|January 12, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656290||4924|
NCT02656303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTX-TGR-204|An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304|A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304||TG Therapeutics, Inc.|No|Recruiting|January 2016|December 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656303||4923|
NCT02718924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ch23031401|Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery|Thromboelastometry (ROTEM) For Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery: An Observational Study||Corniche Hospital|No|Recruiting|November 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|45 Years|No|Non-Probability Sample|Term pregnant women presenting for elective cesarean section under spinal anaesthesia|January 2016|March 23, 2016|January 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02718924||118|
NCT02718937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA585-003|Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study|A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model||Biota Scientific Management Pty Ltd|No|Not yet recruiting|March 2016|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02718937||117|
NCT02653521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M201505|The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer|The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer||Sun Yat-sen University|No|Recruiting|December 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||January 2016|January 9, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02653521||5136|
NCT02651948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6253|Transperineal, MRI-guided, Prostate Biopsy|Transperineal, MRI-guided, Prostate Biopsy: First Step to Focal Treatment of Prostate Cancer||University Hospital, Strasbourg, France|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|90|||Male|40 Years|80 Years|No|||January 2016|January 8, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02651948||5256|
NCT02659852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1072|A Prospective Randomized Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction|||Yonsei University|No|Not yet recruiting|January 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02659852||4650|
NCT02658617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUK09|Functional Neuroanatomy and Regional Metabolism Before and After Treatment With Duloxetine|Functional Neuroanatomy and Regional Metabolism Before and After Treatment With Duloxetine: A Combined fMRI and MRS Study in Major Depression||University of Zurich|No|Completed|March 2010|September 2015|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with an acute depressive episode (n = 20; 10 females; mean age ± SD age, 32.2 ±        10.3 years; number of episodes 2.7 ± 1.9; age of onset 26.7 ± 9.1 years) were recruited        from the inpatient department of psychiatry at the University of Zurich. All patients were        either medication naïve or not on any psychotropic medication for at least 6 weeks prior        to study enrollment. Participants were entered into the study after a full explanation of        the purpose of the study and the study procedures and after written consent was obtained        as approved by the University of Zurich's institutional review board.|January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02658617||4745|
NCT02659241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0519|A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer|A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659241||4697|
NCT02659254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicroPort_BRS_FIM|Evaluation of Bioresorbable Rapamycin-Eluting Coronary Stent System (First-in-Man)|The Feasibility and Safety Evaluation of Bioresorbable Rapamycin-Eluting Coronary Stent System for the Treatment of Coronary Heart Disease in Humans for the First Time: a Prospective, Single Arm Clinical Trial.||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Recruiting|January 2016|July 2021|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659254||4696|
NCT02660463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTEPH-2016|Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany|Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany||Kerckhoff Klinik|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Any patient with confirmed CTEPH during the year 2016 or not diagnosis confirmation not        more than 6 months ago|January 2016|January 20, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02660463|30 Days|4603|
NCT02660554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00202148|PCR to Guide Antibiotic Therapy for Pneumonia|A Randomized Clinical Trial to Compare Early Pneumonia Diagnosis Using Polymerase Chain Reaction to Usual Care in Critically Ill Adults||Northwestern University|Yes|Not yet recruiting|January 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|44|||Both|18 Years|100 Years|No|||January 2016|January 18, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02660554||4596|
NCT02645955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHD-01|Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients||MHD HEV|Xiamen University|Yes|Active, not recruiting|June 2014|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|436|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|200 each for the MHD patient group and the control group|December 2015|January 3, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02645955|3 Months|5717|
NCT02645968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILD Patient Registry|Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING|Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING|EXCITING|Heidelberg University|No|Recruiting|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|ILD patients from all forms of health care|January 2016|January 3, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02645968|5 Years|5716|
NCT02719236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517/17.12.2015|Direct Anterior Approach Versus Direct Lateral Approach in Total Hip Arthroplasty|Direct Anterior Approach Versus Direct Lateral Approach in Cementless Total Hip Arthroplasty|DAAvsDLA|Iuliu Hatieganu University of Medicine and Pharmacy|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|35 Years|85 Years|No|||March 2016|March 21, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02719236||94|
NCT02655549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF563-101|A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects|A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers||Pfenex, Inc|No|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02655549||4981|
NCT02655692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLE-003-14W|CAP-Ketamine for Antidepressant Resistant PTSD|CAP-Ketamine for Antidepressant Resistant PTSD||VA Office of Research and Development|Yes|Not yet recruiting|January 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|198|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02655692||4970|
NCT02659891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|IVIg to Treat BK Viremia in Kidney Transplant Recipients|Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients||Massachusetts General Hospital||Not yet recruiting|May 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2016|January 16, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659891||4647|
NCT02659917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Performance of Glass-ionomer Cements: 2-year Follow-up|Performance of Glass-ionomer Cements in the Pit and Fissure Sealing and Atraumatic Restorative Treatment: a Randomized 2-year Clinical Trial||University of Campinas, Brazil|Yes|Completed|August 2008|August 2010|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|147|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02659917||4645|
NCT02656043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-005-101|A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel|A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris||Xenon Pharmaceuticals Inc.|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656043||4943|
NCT02713685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294/GMC/IEC/2016|Comparison of Combined Sciatic(Winnie's) Femoral Nerve Block, and Subarachnoid Block Anesthesia for Lower Limb Surgery|Comparison of Combined Sciatic(Winnie's) Femoral Nerve Block, and Subarachnoid Block Anesthesia for Lower Limb Surgery||Government Medical College, Haldwani|Yes|Recruiting|June 2015|March 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713685||521|
NCT02713698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.221(183-DEFI/165-CES)|Propofol Pharmacokinetics and Pharmacodynamics Modelling|Modelling Propofol Pharmacokinetics and Pharmacodynamics During an Intravenous Anaesthesia Guided by the Bispectral Index (BIS)||Centro Hospitalar do Porto||Not yet recruiting|March 2016|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Arterial blood samples will be collected in serum tubes and centrifuged at 2000 rpm for 15      minutes in order to obtain serum. Serum will be preserved at -80ºC until analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Inpatient care at Centro Hospitalar do Porto|March 2016|March 15, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02713698||520|
NCT02652403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simplified versus conventional|Simplified Versus Conventional Technique for Complete Denture Fabrication.|Quality of Life, Patient Satisfaction, Quality of Dentures, Masticatory Efficiency, Presence of Temporomandibular Dysfunction and Costs Analysis of Simplified and Conventional Techniques for Complete Denture Fabrication||Universidade Federal do Rio Grande do Norte|No|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|35 Years|95 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02652403||5221|
NCT02648568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130603|Does Hypnosis Improve Severe Sleepwalking ?|Does Hypnosis Improve Severe Sleepwalking ?|HYPNOSOM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2015|January 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|15 Years|N/A|No|||December 2015|January 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02648568||5516|
NCT02652273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN13RH410|Inhibition of Co-Stimulation in Rheumatoid Arthritis|Inhibition of Co-Stimulation in Rheumatoid Arthritis|ICoSRA|NHS Greater Glasgow and Clyde|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02652273||5231|
NCT02720341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-ARMin|VIT-ARMin Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin|Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin|VIT-ARMin|Swiss Federal Institute of Technology|Yes|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720341||9|
NCT02644876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001052-11048|Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications|Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications in High-risk Patients: a Randomized, Double-blind, and Placebo Controlled Study||Peking University First Hospital|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|864|||Both|50 Years|N/A|No|||January 2016|January 1, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02644876||5800|
NCT02655965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB-SUR-DESIGN-2015|Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption|A Randomised, Double-blind, Placebo-controlled Study to Assess the effectIveness of Pectoral Nerves Block (PECS) After Breast Surgery on Piritramide Consumption|DESIGN|Jules Bordet Institute|No|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|N/A|No|||January 2016|January 18, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655965||4949|
NCT02655978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-15-35|Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder Type I|Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder Type I||University Hospital Case Medical Center|Yes|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants from all three groups will be made up of those who respond to IRB approved        advertisements or are referred by a provider within the UHCMC Department of Psychiatry or        other provider referral.|January 2016|January 12, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02655978||4948|
NCT02647541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSantos|Preoperative Nutritional Intervention and Outcomes of Children Submitted to Heart Surgery for Congenital Heart Diseases|Preoperative Nutritional Intervention and Outcomes Postoperative of Children Submitted to Heart Surgery for Congenital Heart Diseases||University of Sao Paulo|Yes|Completed|February 2011|November 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|11|||Both|N/A|5 Years|No|||January 2016|January 5, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02647541||5595|
NCT02647554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI-S001|Ulinastatin Treatment in Adult Patients With Severe Sepsis and Septic Shock in China|A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Severe Sepsis and Septic Shock in China||Peking Union Medical College Hospital|Yes|Not yet recruiting|January 2016|April 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02647554||5594|
NCT02719964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2015.0049|Rehabilitation of Visual Attention Following mTBI|Rehabilitation of Visual Attention Following mTBI||United States Naval Medical Center, San Diego|No|Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719964||38|
NCT02719977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I231|A Phase I/II Study of CX5461|A Phase I/II Study of CX5461||Canadian Cancer Trials Group|Yes|Not yet recruiting|May 2016|April 2019|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719977||37|
NCT02650544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDES20150107|Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression|Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients||Sun Yat-sen University|Yes|Active, not recruiting|December 2015|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02650544||5364|
NCT02657239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U48DP005001-01|Mobility & Vitality Lifestyle Program|Health Promotion and Disease Prevention Research Center|MOVE UP|University of Pittsburgh|Yes|Recruiting|May 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02657239||4851|
NCT02657408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1320.17|A Study to Determine BI 1026706 Effects on Lipopolysaccharide-induced Inflammatory Response in Healthy Male Smokers.|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706||Boehringer Ingelheim||Recruiting|March 2016|October 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 14, 2016||||No||https://clinicaltrials.gov/show/NCT02657408||4838|
NCT02661139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B049201525496|Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction||O-BRIDGE|AZ Sint-Jan AV|No|Recruiting|June 2013|December 2023|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|||Both|N/A|N/A|No|Non-Probability Sample|All consenting patients with a histologically confirmed oncology diagnosis that requires        major ablative surgery of the oral cavity, including segmental or total jaw resection, due        to head and neck cancer, ORN or MRONJ|January 2016|January 19, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02661139|36 Months|4551|
NCT02717273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-HSR#14971|A Study of Incidence of Surgical Site Infections in Liver Transplant Patients on an Extended Course of Peri-operative Antibiotics (Three Days) as Compared to Standard of Care Consisting of a Single Dose Pre-operatively and Intra-operative Re-dosing|A Randomized, Prospective Study of Incidence of Surgical Site Infections in Liver Transplant Patients on an Extended Course of Peri-operative Antibiotics (Three Days) as Compared to Standard of Care Consisting of a Single Dose Pre-operatively and Intra-operative Re-dosing||National Institute of General Medical Sciences (NIGMS)|No|Completed|March 2009|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02717273||245|
NCT02654639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0959|Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer|An Open-Label, Multi-center, Phase 2 Study of Switch Maintenance With TAS-102 Plus Bevacizumab Following Oxaliplatin or Irinotecan-Based Fluoropyrimidine-Containing Induction Chemotherapy in Patients With Metastatic Colorectal Cancer|ALEXANDRIA|Georgetown University|Yes|Recruiting|February 2016|February 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|February 15, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654639||5051|
NCT02653573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1297|Young Adult Hypertension Feasibility Study|myHEART (My Hypertension Education and Reaching Target) Program: a Feasibility Study of a Young Adult Hypertension Intervention|myHEART|University of Wisconsin, Madison|No|Active, not recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|39 Years|No|||January 2016|January 11, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02653573||5132|
NCT02661165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USouthampton|How Does the Spirituality of Patients With Type 2 Diabetes Influence Their Self-management?|Exploratory Study: How Does the Spirituality of a Group of British People With Type 2 Diabetes Impact Their Coping and Self-management of Their Condition?||University of Southampton|No|Not yet recruiting|April 2016|September 2020|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with T2D from a community or primary care clinic|January 2016|January 19, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02661165||4549|
NCT02713763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE-2016-01|Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib|Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.|RESUNET|Grupo Espanol de Tumores Neuroendocrinos|No|Not yet recruiting|April 2016|July 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02713763||515|
NCT02660567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15127|Amr's Maneuver and Postpartum Hemorrhage|The Impacts of Using Amr's Maneuver (Cervical Traction) on Atonic Postpartum Hemorrhage; Multi-centre Randomized Controlled Study||ClinAmygate|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|4866|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02660567||4595|
NCT02657746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/N006178/1|Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka|Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka|COBRA-BPS|Duke-NUS Graduate Medical School|Yes|Not yet recruiting|March 2016|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|2550|||Both|40 Years|N/A|No|||February 2016|February 17, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657746||4812|
NCT02657759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPlantes|EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA|EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA|CARDICHOL 1|Direct Plantes|No|Recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657759||4811|
NCT02657772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00055046|Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms|Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms|ULTRA|University of Maryland|No|Recruiting|November 2013|||June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be between 18 and 80 years of age (inclusive)and have a documented untreated        intracranial aneurysm, less than or equal to 5 mm, ruptured or unruptured, for which        Ultra® coils are treatment options, and for which primary coiling treatment is planned to        be completed during a single procedure (i.e., no "staged" treatment). Preliminary        intracranial stent placement and/or use of an intracranial endoluminal balloon device as        adjunctive therapy is allowed.|December 2015|January 15, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657772|18 Months|4810|
NCT02719470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cognition and reahb in PD|Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?|Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?||Ospedale Generale Di Zona Moriggia-Pelascini|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|438|||Both|60 Years|80 Years|No|||March 2016|March 24, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02719470||76|
NCT02655172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508205|Have a Good Grasp of the Worldthe World|Study on the Links Between Action and Perception in Schizophrenia, " Have a Good Grasp of the World "|GRASP|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655172||5010|
NCT02657824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06072015|Rapid and Easy Evaluation of Cardiac Systolic Function by Means of Mitral Valve Movements in the Emergency Department|Rapid and Easy Evaluation of Cardiac Systolic Function by Means of Mitral Valve Movements in the Emergency Department||Bozyaka Training and Research Hospital|No|Completed|August 2015|October 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|an acutely dyspneic patients with receiving echocardigraphy by the chief physicians in the        emergency department|January 2016|February 7, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02657824|2 Months|4806|
NCT02648152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D10070|Polarstem Cementless Hip Stem|Multicenter Clinical Observation Using the Cementless Version of the POLARSTEM|Polarstem I|Smith & Nephew, Inc.|Yes|Active, not recruiting|March 2009|April 2021|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|225|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients enrolled in this multicenter clinical observation will have at least one of the        indications listed below and meet all of the inclusion criteria. Patients meeting any of        the exclusion criteria are not eligible for this study.        Indications          -  Primary or secondary coxarthrosis          -  Rheumatoid arthritis          -  Developmental dysplasia of the hip (Crowe type I and II)          -  Fracture or avascular necrosis of the femoral head|February 2016|February 16, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648152||5548|
NCT02652975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCDE_AUH|Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium|Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium|ABCDE|University of Aarhus|No|Recruiting|September 2015|September 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Female|18 Years|99 Years|Accepts Healthy Volunteers|||September 2015|January 11, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02652975||5177|
NCT02653222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC15.182|Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension|Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension|SCRATCH|University Hospital, Grenoble|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02653222||5159|
NCT02656212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08847002|Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)|Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)|Epicatechin|Veterans Medical Research Foundation|Yes|Recruiting|September 2015|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|21 Years|75 Years|No|||January 2016|January 12, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656212||4930|
NCT02648347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0014|Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)||Akebia Therapeutics|Yes|Recruiting|December 2015|November 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648347||5533|
NCT02712450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0449|Tools Development for Geriatric Emergency Regulation|Tools Development for Geriatric Emergency Regulation at the Emergency Service Centre, in the Rhône Area|REGESA|Hospices Civils de Lyon|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1920|||Both|75 Years|N/A|No|Probability Sample|Elderly patients calling SAMU|February 2016|March 14, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02712450||616|
NCT02644863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYK-esophageal cancer|Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer|Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection||Shenzhen Hornetcorn Bio-technology Company, LTD|No|Recruiting|December 2015|May 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 31, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644863||5801|
NCT02648542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASTDCS001|The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception|The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception||Soterix Medical|Yes|Completed|March 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02648542||5518|
NCT02648555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol W+D|A Lifestyle Intervention to Improve in Vitro Fertilization Results|A Lifestyle Intervention to Improve in Vitro Fertilization Results|W+D|Hospital dos Servidores do Estado do Rio de Janeiro|Yes|Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|240|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02648555||5517|
NCT02657252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPECLIN|Polidocanol Versus Glucose to Treatment Telangiectasis|Randomized, Triple Blind, Clinical Trial Comparing Polidocanol Versus Hypertonic Glucose to Treatment of Telangiectasis in Lower Limb|PG3T|UPECLIN HC FM Botucatu Unesp|Yes|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|115|||Female|18 Years|65 Years|No|||January 2016|January 12, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02657252||4850|
NCT02657265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU2014-09|SpineJack® Versus Conservative Treatment Study|Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack® System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification||Vexim SA|No|Recruiting|January 2016|May 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||January 2016|January 18, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02657265||4849|
NCT02653131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1|The Use of DPP-4 Inhibitors in Short Bowel Syndrome|The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome|DPP-4|Stanley Dudrick's Memorial Hospital|No|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 10, 2016|January 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02653131||5166|
NCT02648646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1448|Falls Prevention Program for Adults With Osteoarthritis|Falls Prevention Program for Adults With Osteoarthritis||University of North Carolina, Chapel Hill|No|Enrolling by invitation|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02648646||5510|
NCT02655679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTP-38543-001|An Ascending Multiple Dose Study of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis|A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis||Vitae Pharmaceuticals, Inc.|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655679||4971|
NCT02653560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072012-001|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension||University of Texas Southwestern Medical Center|Yes|Completed|September 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|21 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653560||5133|
NCT02648594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00958-41|Efficacy Assessment of CT-guided Hook Wire Localization of Lung Nodes Before Thoracoscopy|Efficacy Assessment of CT-guided Hook Wire Localization of Lung Nodes With Medical Device " Fil d'Ariane " Laurane médical Before Thoracoscopy- HARNO Trial|HARNO|Centre Jean Perrin|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02648594||5514|
NCT02648828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15040582|Understanding Physician Signout Risk Perception|Understanding Physician Signout Risk Perception|UPS|University of Pittsburgh|No|Recruiting|July 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohorts will be selected from the teaching teams of the University of Pittsburgh's General        Internal Medicine wards.|January 2016|January 5, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02648828||5496|
NCT02717780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 192/15|Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome|Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome|DESAT|Centre Hospitalier Universitaire Vaudois|No|Recruiting|February 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02717780||206|
NCT02714309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLSDA190116|Metabolic and Appetite Responses to a Whey Protein Preload Following Prior Exercise in Overweight Males|Acute Metabolic and Second Meal Appetite Responses to a Whey Protein Preload Following Prior Moderate Intensity Exercise in Overweight and Obese Males||Northumbria University|No|Recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|13|||Male|18 Years|55 Years|No|||March 2016|March 19, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714309||473|
NCT02655705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oPASI1403|Comparison Study of Psoriasis Severity Assessment Tools|Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment||Seoul National University Hospital|Yes|Active, not recruiting|August 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02655705||4969|
NCT02655289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRKS00007990|Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients|Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients - A Randomized, Double-blind, Placebo-controlled Cross-over Pilot Study||University Hospital Freiburg|No|Recruiting|February 2016|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655289||5001|
NCT02655640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58458|The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis|The Impact of Illness Perceptions and Their Determinants on Health Related Outcomes in Patients With Systemic Lupus Erythematosus and Systemic Sclerosis||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|100 Years|No|Non-Probability Sample|Firstly a list will be created of all patients with lupus and systemic sclerosis who are        in follow-up at the reumatology department in UZ Leuven. Afterwards all patients who        fulfill the inclusion criteria will be selected. The patients who are included will be        informed by mail and they will be asked to participate. When they agree for participating        then they will be asked to complete an informed consent form.        Hereafter the general practitioner and rheumatologist will be contacted to complete the        IPQ-R HP (an illness perception questionnaire for Healthcare professionals)|September 2015|January 11, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02655640||4974|
NCT02717481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0551-15 RMB CTIL|Using US to Evaluate Aortic Aneurysm Size Based on 3D Co-registration to Previous CT Scan|Using Ultrasound to Evaluate Aortic Aneurysm Size Based on 3D Co-registration to Previous Computerized Tomography||Rambam Health Care Campus|No|Not yet recruiting|April 2016|September 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with abdominal aortic aneurysm diagnosis in clinical follow-up or after an        invasive procedure to fix it|March 2016|March 17, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02717481||229|
NCT02650258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG049024|Cadence and Intensity Across the Adult Lifespan|Cadence and Intensity Across the Adult Lifespan|CADENCE-Adults|University of Massachusetts, Amherst|No|Recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|260|||Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample from the surrounding community of male and females 21-85 years will        be recruited as participants. Specifically, 10 men and 10 women for each 5-year age-group        category (21-25, 26-30, 31-35, etc.) will be collected.|January 2016|January 6, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02650258||5386|
NCT02651155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lubiprostone-3001|Lubiprostone for the Treatment of Chronic Idiopathic Constipation|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation||Takeda|No|Recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02651155||5317|
NCT02651402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012311|A Hybrid Effectiveness-Implementation Trial of Group CBT in Urban Schools|A Hybrid Effectiveness-Implementation Trial of Group Cognitive Behavior Therapy (CBT) in Urban Schools||Children's Hospital of Philadelphia|No|Not yet recruiting|February 2016|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|534|||Both|8 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651402||5298|
NCT02646488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-02042|Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease|Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease||New York University School of Medicine|No|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|250|||Both|18 Years|85 Years|No|||March 2016|March 15, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02646488||5676|
NCT02719522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PED-10|Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy|Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy of Treated Intra Cranial Aneurysms (SHIELD)|SHIELD|Medtronic Neurovascular Clinical Affairs|Yes|Not yet recruiting|March 2016|August 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have an intracranial aneurysm. The Pipeline™ Flex Embolization Device with        Shield Technology™ will be used according to its Instructions for Use and its intended use        during the treatment regimen.|March 2016|March 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02719522||72|
NCT02656173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-MA-3016|A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)|A Phase 4, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With OAB Symptoms, While Taking the Alpha Blocker,Tamsulosin, for BPH||Astellas Pharma Inc|No|Recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|550|||Male|40 Years|N/A|No|||February 2016|February 1, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656173||4933|
NCT02645201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastrus01|The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children|Effect of a Probiotic Combination (Gastrus®) on Adverse Effects of Therapy and on Eradication Rate of Helicobacter Pylori Infection in Children|Gastrus|University Medical Centre Ljubljana|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|118|||Both|5 Years|18 Years|No|||December 2015|December 30, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02645201||5775|
NCT02647489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMVAC1_15|Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted|Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Adjuvanted With Alhydrogel, GLA-SE or GLA-LSQ in Healthy Malaria-Naïve Adults and Healthy, Lifelong Malaria-Exposed, Nulligravid Adult Women|PAMVAC|University Hospital Tuebingen|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|11||Anticipated|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|January 12, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647489||5599|
NCT02658396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-363|GO-203-2C + Bortezomib For Relapsed Or Refractory MM|A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Not yet recruiting|February 2016|January 2022|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658396||4762|
NCT02718638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeniseMafra2|Effects of Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients|Effects of a Program of Strength Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients|Hemodialysis|Universidade Federal Fluminense|No|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02718638||140|
NCT02648230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ1712|PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements|PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of cORonary Fractional Flow Reserve Measurements|PERFORM|Columbia University|No|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648230||5542|
NCT02658500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14110000481400|Short and Long Term Effect of Early Infant Feeding and Nutritional Status on the Children's Health|||Beijing Sanyuan Foods Co Ltd|Yes|Recruiting|January 2014|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|N/A|42 Days|Accepts Healthy Volunteers|||January 2016|January 14, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658500||4754|
NCT02715765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512M81581|The Use of Transcranial Electrical Stimulation for Hallucinations|The Use of Transcranial Electrical Stimulation for Hallucinations||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|April 2016|October 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|64 Years|No|||March 2016|March 22, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715765||361|
NCT02655770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000410-22|Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients|Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial||Rigshospitalet, Denmark|Yes|Not yet recruiting|February 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655770||4964|
NCT02661113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0318 Phase II|Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma: Phase II|Phase II Portion of Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma||M.D. Anderson Cancer Center|No|Withdrawn|May 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|January 19, 2016|Yes|Yes|Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)|No||https://clinicaltrials.gov/show/NCT02661113||4553|
NCT02661126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3682B-030|Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency|A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B (MK-3682/MK-5172/MK-8408 Fixed Dose Combination) When Administered to Subjects With Moderate and Severe Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02661126||4552|
NCT02647658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS-1402-10867|Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients|Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients: A Multi-Site Pragmatic RCT|TARGET|University of Pittsburgh|No|Not yet recruiting|April 2016|September 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02647658||5586|
NCT02660307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGRESS|A Stress Reduction Program for Companies|A Randomized Controlled Trial With a Follow-up Evaluation of a Stress Reduction Program for Companies - PROGRESS||Centro de estudos em Atenção Plena|Yes|Completed|February 2014|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 23, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02660307||4615|
NCT02648425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aslan001-002|Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin With Capecitabine|Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine||Aslan Pharmaceuticals|Yes|Recruiting|August 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|N/A|No|||January 2016|January 5, 2016|June 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648425||5527|
NCT02648659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUMC-JSW-ILA01|The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients|The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients||Kyungpook National University|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|20 Years|80 Years|No|||January 2016|January 6, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648659||5509|
NCT02653963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShaheedBMU-9467|Triamcinolone for Ahmed Glaucoma Valve|Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation||hahid Beheshti University of Medical Sciences|No|Recruiting|September 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|December 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02653963||5103|
NCT02654223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG56-SIT-012|Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy|Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy|MG56|Inmunotek S.L.|No|Not yet recruiting|January 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|9||Anticipated|180|||Both|14 Years|65 Years|No|||December 2015|January 11, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02654223||5083|
NCT02715427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01806-43|Enhanced Recovery After Hepatic Surgery (MultiPAS).|Enhanced Recovery After Hepatic Surgery Versus Conventional Care : a Controlled Randomized Monocentric Trial (MultiPAS).|MultiPAS|University Hospital, Angers||Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02715427||387|
NCT02659865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16263|A Study of LY3039478 in Healthy Participants|A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects||Eli Lilly and Company|No|Active, not recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|January 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02659865||4649|
NCT02644577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWang-BD1|Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients|||China Medical University, China|Yes|Completed|June 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|45 Years|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02644577||5823|
NCT02657954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1972-I|Cognitive Rehabilitation for Homeless OEF/OIF/OND Veterans|Cognitive Rehabilitation for Homeless OEF/OIF/OND Veterans||VA Office of Research and Development|No|Not yet recruiting|July 2016|March 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|55 Years|No|||January 2016|January 13, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02657954||4796|
NCT02718586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104074|Serum Level of Myokines and Protein Energy Wasting, Inflammation and Atherosclerosis in Hemodialysis Patients|Association of Serum Myokines and Protein Energy Wasting, Inflammation and Atherosclerotic Vascular Disease in Hemodialysis Patients||Tungs’ Taichung Metroharbour Hospital|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|20 Years|70 Years|No|Non-Probability Sample|hemodialysis (HD) patients|March 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02718586||144|
NCT02718599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-123-DE|Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery|Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery||Assiut University|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718599||143|
NCT02655900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/0232|Use of 3D Ultrasound to Predict Anal Sphincter Defects|Use of 3D Ultrasound to Predict Anal Sphincter Defects||Croydon University Hospital|Yes|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women sustained anal sphincter injury during childbirth being followed up ante or        postpartum|January 2016|January 12, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02655900||4954|
NCT02655913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHVCONSCLC1842|Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer|Phase I/II Study of Vitamin C Infusion in Combination With Local mEHT on Non Small Cell Lung Cancer Patients|VCONSCLC|Clifford Hospital, Guangzhou, China|Yes|Active, not recruiting|December 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02655913||4953|
NCT02652793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-002720-27|Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia|Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia|Osteosimply014|Hospital Clinic of Barcelona|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02652793||5191|
NCT02657642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-086|The OMAGE (Optimization of Medication in AGEd) Transitional Care-Pathway: Impact on Readmissions|The OMAGE (Optimization of Medication in AGEd) Transitional Care-Pathway: Impact on Readmissions|OMAGE-P|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|January 2016|January 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|484|||Both|75 Years|N/A|No|Non-Probability Sample|non demented older people aged 75 years and over admitted in emergency in medical units        living in community|January 2016|January 15, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657642||4820|
NCT02657655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLNT-K360-1|Kinesia 360 Parkinson's Monitoring Study|Kinesia 360 Multi-Center Parkinson's Monitoring Study||Great Lakes NeuroTechnologies Inc.|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02657655||4819|
NCT02716727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1787|Comparison of Two Gingival Displacement Procedures|Comparison of Two Gingival Displacement Procedures; a Randomized Clinical Trial||University of North Carolina, Chapel Hill|No|Not yet recruiting|May 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716727||287|
NCT02650271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEVT-HCC|Adjuvant Entecavir for Postoperative HBV-HCC|Adjuvant Entecavir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection||Guangxi Medical University|Yes|Recruiting|July 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02650271||5385|
NCT02650284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAKORCT-15|A Trial Evaluating TKR Compared to BKR Performed Using Stryker's Mako Robot|A Prospective, Randomised Controlled Trial Evaluating Total Knee Replacement With the Stryker Triathlon Primary Total Knee System, Compared to Bicompartmental Knee Replacement With Restoris MCK Multicompartmental Knee System Performed Using Stryker's Robotic-arm Assisted Surgery System, Mako||Stryker South Pacific|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650284||5384|
NCT02658838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLPCI|The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI|The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI||Beijing Anzhen Hospital|Yes|Active, not recruiting|April 2015|September 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||August 2015|January 19, 2016|January 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02658838||4728|
NCT02644668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 5021|A Study of CK-2127107 in Patients With Spinal Muscular Atrophy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy (SMA)||Cytokinetics|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|72|||Both|12 Years|N/A|No|||March 2016|March 24, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644668||5816|
NCT02652546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160044|CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)|A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2015|October 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|February 6, 2016|January 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652546||5210|
NCT02716246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS IIIA|Phase I/II Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA|Phase I/II Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH||Nationwide Children's Hospital|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9|||Both|2 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02716246||324|
NCT02712242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU8|PRF for Accelerating Palatal Healing|The Effects of Platelet-Rich Fibrin on Palatal Wound Healing After Free Gingival Graft Harvesting: A Comparative Randomized Controlled Clinical Trial||Cukurova University|No|Completed|November 2013|September 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|125|||Both|21 Years|48 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712242||632|
NCT02654535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nuts 2015|Systematic Reviews and Meta-analyses of Nuts and Obesity|Nuts in Relation to Markers of Adiposity, Overweight, and Obesity: A Series of Systematic Reviews and Meta-Analyses of Randomized Controlled Trials and Prospective Cohort Studies||University of Toronto|No|Active, not recruiting|October 2015|September 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|September 2015|January 12, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654535||5059|
NCT02659501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150012|Liposomal Bupivacaine in Implant Based Breast Reconstruction|Liposomal Bupivacaine in Implant Based Breast Reconstruction||Loma Linda University|No|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|99 Years|No|||January 2016|January 15, 2016|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659501||4677|
NCT02644694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-010|PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy|A Prospective, Single-Center, Single-Dose, Phase 1 Clinical Trial Designed to Evaluate the Pharmacokinetics of Dexamethasone Phosphate Ophthalmic Solution Delivered Via the EyeGate® II Drug Delivery System in Patients Undergoing Vitrectomy for Macular Hole Repair or Epiretinal Membrane Peeling||Eyegate Pharmaceuticals, Inc.|No|Not yet recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||November 2015|January 4, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02644694||5814|
NCT02649127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20100372H|The Role of Exercise in the Treatment of PTSD Symptoms|The Role of Exercise in the Treatment of PTSD||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|February 2011|October 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02649127||5473|
NCT02713516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008235|Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and OCD|Low-Cost, Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and Obsessive Compulsive Disorders||Mayo Clinic|No|Not yet recruiting|January 2017|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713516||534|
NCT02660099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiP-ASD/OCD|Internet Delivered CBT for OCD in Adolescents With ASD - A Clinical Case Series|Internet Delivered Cognitive Behavior Therapy for Obsessive-compulsive Disorder in Adolescents With Autism Spectrum Disorder - A Clinical Case Series||Karolinska Institutet|No|Recruiting|July 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02660099||4631|
NCT02657421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-05|OLIF25™ /OLIF51™ Study|A Multi-Center, Prospective, Observational Study to Assess Outcomes for Patients Treated for Lumbar Spinal Conditions Using an OLIF25™ and/or OLIF51™Approach||Medtronic Spinal and Biologics|Yes|Recruiting|November 2015|November 2020|Anticipated|November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have surgery from L2-L5 for OLIF25™ and/or from L5-S1 for OLIF51™ for        degenerative disc disease or degenerative scoliosis.|March 2016|March 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02657421|24 Months|4837|
NCT02657434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29438|A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer [IMpower 132]|A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer||Hoffmann-La Roche||Recruiting|December 2015|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|680|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657434||4836|
NCT02649387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1481|Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy|Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy|MERIT|Mayo Clinic|Yes|Recruiting|February 2016|||May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649387||5453|
NCT02717806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S59023|Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness|Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness|PATHway|Katholieke Universiteit Leuven|Yes|Not yet recruiting|January 2017|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|40 Years|80 Years|No|||March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717806||204|
NCT02652169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRF-TAT|PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4|Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group|PRF-TAT|Medical University of Vienna|Yes|Recruiting|June 2014|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652169||5239|
NCT02652455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18377|Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma|A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|March 2016|||August 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02652455||5217|
NCT02647827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2015-004250-18|Acupuncture or Metformin for Insulin Resistance in Women With PCOS|Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial|PIAII|Karolinska Institutet|Yes|Recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|303|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02647827||5573|
NCT02715102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway Genomics - 006|Circulating Tumor DNA in Patients at High Risk for Lung Cancer|Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Lung Cancer in Patients Undergoing Diagnostic or Therapeutic Bronchoscopy or Thoracotomy||Pathway Genomics|No|Recruiting|March 2016|February 2021|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|DNA will be extracted and run in the ctDNA assay. Patients will be asked to either consent      or not to consent to having their DNA extracted from the original specimen and their      clinical information kept for optional anonymized medical research in the future.|Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled to undergo a diagnostic or therapeutic bronchoscopy or thoracotomy        by Dr. Robert McKenna.|March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02715102||412|
NCT02720315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34835|Intensive Cryotherapy in the Emergency Department for Acute Musculoskeletal Injuries|Intensive Cryotherapy in the Emergency Department (ICED) Versus Conventional Treatment for Acute Musculoskeletal Injuries: The ICED Randomized Controlled Trial||Stanford University|Yes|Enrolling by invitation|February 2016|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02720315||11|
NCT02658786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-cohort-001|Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease|Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease: A Hospital Based Retrospective Followed by Prospective Cohort Study||Institute of Liver and Biliary Sciences, India|No|Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3000|||Both|18 Years|60 Years|No|Probability Sample|Cases with Hepatitis B or Hepatitis C infection and Cases with non alcoholic fatty liver        disease attending OPD or admitted in ward at ILBS, New Delhi|January 2016|February 12, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02658786||4732|
NCT02648009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332-2014|Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection|Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection||Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02648009||5559|
NCT02648256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00408-41|Pneumocystis Pneumonia Diagnosis in HIV- Patients|Pneumocystis Pneumonia Diagnosis in HIV- Patients: Assessment of the Real Time Polymerase Chain Reaction Quantification on Oropharyngeal Rinse|PNEUMOQUANT|Rennes University Hospital|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1250|||Both|18 Years|N/A|No|||December 2015|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648256||5540|
NCT02648087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015 -A00395 - 44|Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer|Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer|NEOSAS|University Hospital, Angers|No|Not yet recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1200|||Both|18 Years|75 Years|No|||December 2015|January 5, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02648087||5553|
NCT02648334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2015-08|Randomized Comparison of Drug-Coated Balloons for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease|Randomized Comparison of Drug-Coated Balloons for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: Prospective, Multicenter, Randomized, Controlled Trial|DCB-SFA|Asan Medical Center|Yes|Not yet recruiting|June 2016|June 2021|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02648334||5534|
NCT02719704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXA-SE|School-based Multicomponent Intervention on Physical Fitness Related to Health and Body Image|Effect of a Multicomponent Intervention Program on Physical Fitness Related to Health and Body Image: School-based Study With Adolescents of Florianópolis, Santa Catarina, Brazil||Santa Catarina Federal University|Yes|Completed|March 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|568|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02719704||58|
NCT02655367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR08/2014|The Effect of Oat Processing on Gastric Emptying and Satiety Induced After Consuming Porridge|The Effect of Oat Processing on Gastric Emptying and Satiety Induced After Consuming Porridge|Oatmet|Institute of Food Research|No|Enrolling by invitation|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|8|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02655367||4995|
NCT02655380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-DRU-15-354|Remifentanil Requirement for Acceptable Intubating Condition|Remifentanil Requirement for Acceptable Intubating Condition With Two Dose Ketamine Without Neuromuscular Blocking Agent in Children||Ajou University School of Medicine||Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|3 Years|12 Years|No|||January 2016|January 13, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02655380||4994|
NCT02660931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130558|Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research|Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research|PAR4|Vanderbilt University|No|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Anticipated|10000|||Both|N/A|21 Years|No|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660931||4567|
NCT02660944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132-03|A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)||Resolve Therapeutics|No|Recruiting|January 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|January 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660944||4566|
NCT02652845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R24MD008128|Wellness Engagement Project, Petersburg|Wellness Engagement Project, Petersburg|WE|Virginia Commonwealth University|No|Terminated|March 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 5, 2015||No|Study Design was changed - no longer prospectively assigning participants|No||https://clinicaltrials.gov/show/NCT02652845||5187|
NCT02649478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLSA-P100/50-PVCL-1|Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate|A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma||Roxane Laboratories|No|Completed|August 2014|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1430|||Both|12 Years|N/A|No|||January 2016|January 13, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649478||5446|
NCT02649491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4201|Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy|Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy|PREDICT|Royal Marsden NHS Foundation Trust|No|Recruiting|November 2015|March 2019|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Patients will be asked to provide stool and urine samples and complete symptom assessment      questionnaires at 6 time points: baseline (before treatment), 2 and 6 weeks after starting      radiotherapy, 6 months after completion of radiotherapy and 12 and 24 months after      completion of treatment. In addition, patients will be asked to provide a rectal swab and a      saliva sample, which will be stored and potentially used at a later stage to characterize      any differences in the microbial populations present. (Funding will be sought elsewhere to      analyse these samples).|Female|18 Years|90 Years|No|Non-Probability Sample|Over 2 years we will recruit 120 patients undergoing radical radiotherapy for a new,        histologically proven, gynaecological malignancy at the Royal Marsden Hospital. Patients        will be followed up for 2 years after completion of radiotherapy.|January 2016|January 5, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02649491||5445|
NCT02653287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFT Study|Lupus Intervention for Fatigue Trial|Lupus Intervention for Fatigue Trial|LIFT|Northwestern University|Yes|Not yet recruiting|December 2016|December 2022|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02653287||5154|
NCT02653300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-H-001|A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)|An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)||Oramed, Ltd.|No|Not yet recruiting|May 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|January 8, 2016|December 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653300||5153|
NCT02661321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA HSR&D PPO 10-299|Location and Timing of Inhaler Use, Exacerbations and Physical Activity in Chronic Obstructive Pulmonary Disease|Location and Timing of Inhaler Use, Exacerbations and Physical Activity in Chronic Obstructive Pulmonary Disease||VA Puget Sound Health Care System|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic obstructive pulmonary disease at VA Puget Sound Health Care System        in Seattle, WA|January 2016|January 19, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661321||4537|
NCT02720302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/141|Treatment of Overweight in Children on Distance|Treatment of Overweight in Children on Distance. A Comparison Between Consultations on the Hospital With Video-Consultations on Distance|TeleSOFT|Skåne University Hospital|No|Recruiting|March 2016|June 2021|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|9 Years|12 Years|No|||March 2016|March 21, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02720302||12|
NCT02645149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIA2015/174|Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma|Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma|MatchMel|Melanoma Institute Australia|Yes|Not yet recruiting|June 2016|June 2021|Anticipated|June 2021|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|18 Years|100 Years|No|||March 2016|March 22, 2016|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02645149||5779|
NCT02645162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3450-PED-ERC-15|Youth Leaders for Early Childhood Assuring Children Are Prepared for School|A Cluster Randomized Control Trial to Evaluate the Efficacy and Feasibility of a Community-based Preschool Programme and Community Engagement Strategy Led by Community Youth Leaders in Rural Pakistan|LEAPS|Aga Khan University|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|42 Months|66 Months|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02645162||5778|
NCT02661230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRICU-Study|Virtual Reality Exercise on the Intensive Care Unit in Heart Patients|Design of a Cognitive Motor Intervention Using a Video Game to Enhance Brain Activity: A Feasibility Study Including Healthy Participants and Heart Patients on the Intensive Care Unit|VRICUGAMING|University of Zurich|No|Active, not recruiting|March 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02661230||4544|
NCT02653378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-09-03|The Effects of Acute Caloric Deprivation on Odour Identification and Food Reward|The Effects of Acute Caloric Deprivation on Odour Identification and Food Reward|DEXDER|University of Ottawa|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02653378||5147|
NCT02653391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIFD-101|A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)|A Prospective, Randomized, Double-Masked, Vehicle Controlled, Paired-Eye Phase 1/2 Clinical Study To Evaluate The Safety, Tolerability And Efficacy of MTP-131 Topical Ophthalmic Solution (OcuviaTM) In Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild To Moderate Corneal Edema||Stealth BioTherapeutics Inc.|No|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|December 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653391||5146|
NCT02714322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYL-1041A-3001|MYL-1401A Efficacy and Safety Comparability Study to Humira®|Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis||Mylan Inc.|No|Active, not recruiting|June 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02714322||472|
NCT02718963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1507/306-002|Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device|Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device||Seoul National University Hospital|Yes|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02718963||115|
NCT02644616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-ZOC-1401|The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement|||Shanghai Chest Hospital|No|Recruiting|November 2014|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02644616||5820|
NCT02644889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGFR2015-02|EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment|Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment||GenoSaber|No|Not yet recruiting|January 2016|||November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with stage Ⅲ-Ⅳ NSCLC with EGFR mutations and who began a treatment by TKI .|November 2015|January 6, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644889||5799|
NCT02658877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01160|Sputum-derived Cellular Targets After Xolair (Omalizumab)|In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab).||New York University School of Medicine|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|December 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658877||4725|
NCT02646683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-100757|A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study|An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)|LOVE-CD|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|July 2015|December 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646683||5661|
NCT02658253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14-60|Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults|Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE|PRIMALVAC|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|January 2016|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|10||Anticipated|68|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|March 23, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02658253||4773|
NCT02713724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GoteborgU_SSv|Effects of Personalized Training Program on Coronary Flow Reserve in Healthy Voluenteers|Effects of a Personalized Training Program on Trans-thorcic Adenosine-assisted Coronary Flow Reserve in Healthy Voluenteers||Göteborg University|Yes|Active, not recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02713724||518|
NCT02654756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13311|Risk of Chronic Kidney Disease Progression|Risk of Chronic Kidney Disease Progression||Winthrop University Hospital|No|Active, not recruiting|May 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|623|||Both|18 Years|N/A|No|Non-Probability Sample|Nephrology outpatient clinic|January 2016|January 18, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02654756||5042|
NCT02654769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-8151-301|A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis|Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities||Actavis Inc.|No|Completed|February 2015|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|441|||Both|18 Years|95 Years|No|||January 2016|January 12, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654769||5041|
NCT02655484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009CB522112|Carbon Dioxide Rebreathing During Exercise Assisted by Non-invasive Ventilation|Evaluation of Carbon Dioxide Rebreathing During Exercise Assisted by Non-invasive Ventilation||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|January 2016|||March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02655484||4986|
NCT02650687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1692|Optimizing Postoperative Cognition the Elderly|Optimizing Postoperative Cognition the Elderly||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2015|August 2020|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|175|||Both|65 Years|N/A|No|Probability Sample|Eligible patients will be identified through the computerized scheduling system at the        Icahn School of Medicine at Mount Sinai.|January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02650687||5353|
NCT02715453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/00837|Intervention in Frailty Versus Usual Care in Frail Patients After an Acute Myocardial Infarction|Randomized Comparison Between a Strategy of Intervention in Frailty Versus the Usual Care in Frail Patients After an Acute Myocardial Infarction|FRAMIP|University of Valencia|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|70 Years|N/A|No|||March 2016|March 16, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02715453||385|
NCT02715466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-1209|Gelatin in ICU and Sepsis|Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis|GENIUS|B. Braun Melsungen AG||Not yet recruiting|March 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|608|||Both|18 Years|85 Years|No|||March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715466||384|
NCT02649751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 15.098 (ROSCO CF)|Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Causing Mutations With at Least One F508del-CFTR Mutation and Chronically Infected With Pseudomonas Aeruginosa, a Study Involving 36 CF Patients (24 Treated, 12 Controls). ROSCO-CF.|ROSCO-CF|University Hospital, Brest|Yes|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649751||5425|
NCT02652208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002292|Comparative Effectiveness of Decision Aids for Stable Chest Discomfort|Randomized Trial Comparing Effectiveness of Two Patient Decision Aids for Stable Chest Discomfort||Massachusetts General Hospital|No|Enrolling by invitation|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02652208||5236|
NCT02657447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2013-003908-39|Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)|A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of 177Lu-DOTA-HH1 (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma||Nordic Nanovector|No|Not yet recruiting|January 2016|June 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02657447||4835|
NCT02646748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39110-107|Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors|A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors||Incyte Corporation|No|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646748||5656|
NCT02715440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081245|Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions|Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions: Feasibility and Impact on Sleep and Behavior|BenzoFree|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2012|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|70 Years|N/A|No|||February 2016|March 16, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02715440||386|
NCT02653248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-128B|SBRT for Organ Confined Prostate Cancer|Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Organ Confined Prostate Cancer||Northwell Health|Yes|Recruiting|August 2010|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Male|18 Years|N/A|No|||January 2016|January 8, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02653248||5157|
NCT02655588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-000384|A Computerized Intervention for Depression|A Computerized Intervention for Depression||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|September 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02655588||4978|
NCT02655601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMX-HGG-001|Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001|A Phase 1/2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001|BMX-HGG|BioMimetix JV, LLC|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02655601||4977|
NCT02647021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREBA.CC.15-0167|Therapeutic, Aerobic and Resistance Group Exercise Training for Head & Neck Cancer Survivors|Evaluating Outcomes From a Combined Supervised Therapeutic and Physical Exercise Program for Post-surgical Head and Neck Cancer Survivors: A Randomized Controlled Trial|TARGET|University of Alberta|No|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02647021||5635|
NCT02720003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC1401PV|A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries|A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)||C. R. Bard|No|Not yet recruiting|March 2016|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|147|||Both|18 Years|85 Years|No|||February 2016|March 21, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720003||35|
NCT02720016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2093-R|Cognitive-Behavioral Conjoint Therapy (CBCT) Project|An Integrative Technology Approach to Home-based Conjoint Therapy for PTSD|CBCT|VA Office of Research and Development|No|Not yet recruiting|July 2016|March 2020|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02720016||34|
NCT02656537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD772|EnSite™ HD Grid Catheter AF/AT Mapping Study|EnSite™ HD Grid Catheter Mapping System for Advanced High Density Three-Dimensional Mapping in Non-Paroxysmal Atrial Fibrillation and Atrial Tachycardia||St. Jude Medical|No|Recruiting|August 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02656537||4905|
NCT02656550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Number 015-158|Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility|Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Factor Infertility||Baylor Research Institute|Yes|Recruiting|February 2016|January 2026|Anticipated|January 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|20 Years|35 Years|No|||February 2016|February 29, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02656550||4904|
NCT02656563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURC-004|Radium 223 Following Intermittent ADT|Phase II, Randomized, Open Label to Evaluate Efficacy,Safety of Radium 223 in Prolonging the Off Treatment Interval in Men With Rising PSA Post-rad, or Post-prostatectomy Without Bone Mets on Intermittent Androgen Ablation Therapy|RAND|Canadian Urology Research Consortium|Yes|Recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Male|45 Years|85 Years|No|||December 2015|January 13, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02656563||4903|
NCT02659111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 205/250-31|Effects of Physical Training in iNPH|Effects of Physical Training in Shunt-operated Patients With Idiopathic Normal Pressure Hydrocephalus|iNPhys|Linkoeping University|No|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02659111||4707|
NCT02647671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00076276|Aquamin and Prevention of Colon Cancer|The Effects of Calcium in Conjunction With Multi-mineral Supplementation (Aquamin) on Gut Microbes and Microbially-derived Metabolites in Subjects at Risk for Colon Cancer in a Randomized Controlled Trial||University of Michigan|Yes|Recruiting|February 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 15, 2016|November 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647671||5585|
NCT02650999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 46415|Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas|Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2016|||January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650999||5329|
NCT02651012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC1401|Study to Evaluate the Efficacy and Safety of 1.5 mg/kg/Day of Sarecycline vs Placebo in the Treatment of Acne Vulgaris|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris|SC1401|Sadick Research Group|No|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|9 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|September 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02651012||5328|
NCT02660177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-00020|Pharmacokinetics of Intravenous Metamizole in Children Less Than 6 Years Old|Single Center, Open-label, Prospective Study to Characterize the Pharmacokinetics of Metamizole and Its Metabolites Following Intravenous Administration in Children Less Than 6 Years Old|PPMS|University Children's Hospital Basel|Yes|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|39|||Both|3 Months|72 Months|Accepts Healthy Volunteers|||January 2016|January 18, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660177||4625|
NCT02660190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no.: 2015-000|Photodynamic Diagnosis (PDD) in Flexible Cystoscopy|Photodynamic Diagnosis (PDD) in Flexible Cystoscopy - DaBlaCa-11|DaBlaCa-11|Aarhus University Hospital|Yes|Recruiting|February 2016|June 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|696|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660190||4624|
NCT02660229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXI15-KR-401|An Interventional Study for Patients With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through IV Continuous Infusion|A 5-day, Multicentre, Randomized, Open-label, Parallel Group, Active Control Pilot Study to Evaluate the Efficacy and Safety of OxyNorm® (Oxycodone Hydrochloride Injection) in Comparison With Morphine Sulfate Through the IV Continuous Infusion Regimen in Patients With Cancer Pain|SWITCH|Mundipharma Korea Ltd|Yes|Recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|19 Years|N/A|No|||January 2016|January 20, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660229||4621|
NCT02647931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006933|The Role of Therapy for Muscle Tension Dysphagia|Muscle Tension Dysphagia Treatment Efficacy||Mayo Clinic|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02647931||5565|
NCT02647944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001783|Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity|Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity||Mayo Clinic|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647944||5564|
NCT02653196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3856|A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors|A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors||Montefiore Medical Center|Yes|Recruiting|September 2015|July 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|30 Years|No|||January 2016|January 8, 2016|January 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02653196||5161|
NCT02659839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101015|Mortality in Cancer Patients Admitted to the Intensive Care Unit in a Resource-limited Setting|Mortality in Cancer Patients Admitted to the Intensive Care Unit in a Resource-limited Setting: A Prospective Cohort Study||Pontificia Universidad Catolica de Chile|No|Recruiting|July 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with histological diagnosis or high clinical suspicious of cancer, admitted to the        intensive care unit|March 2016|March 7, 2016|January 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02659839||4651|
NCT02719743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116938|A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age|An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age||GlaxoSmithKline||Not yet recruiting|May 2016|November 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|185|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719743||55|
NCT02719756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-11023|Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2|Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2||Research Clinical Centre of the Russian Railways, JSC|No|Not yet recruiting|April 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|74 Years|No|||March 2016|March 24, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02719756||54|
NCT02649738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEI-Tissue-Inlay|Corneal Tissue Inlay for Keratoconus|Use of Preserved Corneal Tissue Inlay to Treat Keratoconus||Cornea and Laser Eye Institute|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649738||5426|
NCT02648269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEL-212/101|Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels|A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid||Selecta Biosciences, Inc.|No|Recruiting|December 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|53|||Both|21 Years|70 Years|No|||January 2016|January 6, 2016|January 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02648269||5539|
NCT02648282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15237|Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer|A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|July 2016|||July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|100 Years|No|||January 2016|January 6, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648282||5538|
NCT02648295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509851949|Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty|Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty||West Virginia University|Yes|Active, not recruiting|December 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults undergoing primary total hip and knee arthroplasty|January 2016|January 4, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02648295||5537|
NCT02647008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVERSITY CARDENAL HERRERA-2|Pain Relief During Unsedated Office Hysteroscopy by Applying TENS|Pain Relief During Unsedated Office Hysteroscopy by Applying Transcutaneous Electrical Nerve Stimulation (TENS): A Randomized Double-blind Placebo-controlled Trial||Cardenal Herrera University|No|Recruiting|May 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|138|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02647008||5636|
NCT02714868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G120091|Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)|Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications) - Effectiveness, Social Validity and Feasibility|ProjectTEAM|Boston University|No|Active, not recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|198|||Both|14 Years|21 Years|No|||March 2016|March 16, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02714868||430|
NCT02644590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311080|The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1|The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1||Sheba Medical Center|No|Not yet recruiting|February 2016|February 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|21 Years|No|||December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644590||5822|
NCT02656953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150115|The Impact of Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Neck Complaints|The Impact of Wearing VDU Lenses Versus Progressive Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Work Related Neck Complaints: A Randomized Controlled Trial||University Ghent|No|Active, not recruiting|March 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|45 Years|65 Years|No|||January 2016|January 14, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02656953||4873|
NCT02657057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT46681770|Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB|Effects of Transcutaneous and Percutaneous Posterior Tibial Nerve Stimulation on Idiopathic Overactive Bladder Syndrome: Randomized Clinical Trial||Instituto Médico Tecnológico SL|No|Recruiting|November 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02657057||4865|
NCT02658708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201503075|Bright Light on Fatigue in Women Being Treated for Breast Cancer|Bright Light on Fatigue in Women Being Treated for Breast Cancer: A Pilot Study||Washington University School of Medicine|No|Recruiting|May 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|21 Years|N/A|No|||January 2016|January 14, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02658708||4738|
NCT02712983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100G2202|Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection|A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection||Novartis|Yes|Not yet recruiting|June 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02712983||575|
NCT02648789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-009AC|Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Validation of DNA Methylation Biomarkers for Oral Cancer Detection||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|May 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|oral swab, non-cancerous matched tissue and tumor tissue|Both|20 Years|75 Years|No|Non-Probability Sample|Investigators plan to retrieve the tissue from the biobank in Taipei Veterans General        Hospital or recruit oral cancer patients in this study over six months. The total patient        number are 40-50. Specimen types include non-cancerous matched tissues, cancer tissues,        and the oral swab. DNA methylation for several genes will be tested by using standardized        reagents and instruments.|January 2016|January 5, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02648789||5499|
NCT02649049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|565|Dietary Determinants in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|Assessment of Dietary Intakes of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)||National Nutrition and Food Technology Institute||Recruiting|January 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with NAFLD diagnosed using Fibroscan without any other chronic disorders.|January 2016|January 5, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02649049||5479|
NCT02657694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDEMPTION|Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods|Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods|REDEMPTION|FixHepC|Yes|Enrolling by invitation|July 2015|||June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|82 Years|No|Non-Probability Sample|Worldwide, Hepatitis C Genotypes 1-6|January 2016|January 18, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657694|1 Year|4816|
NCT02657707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL11003|Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis|Pivotal Study of the MicroVention, Inc. Carotid Artery Stent System Used in Conjunction With the Nanoparasol® Embolic Protection System for the Treatment of Carotid Artery Stenosis in Patients at Elevated Risk for Adverse Events From Carotid Endarterectomy.(CONFIDENCE Trial)||Microvention-Terumo, Inc.|Yes|Not yet recruiting|March 2016|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|295|||Both|21 Years|80 Years|No|||February 2016|February 3, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02657707||4815|
NCT02717000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-T-167|NASH: Non-invasive Diagnostic Markers and Imaging|Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Patients With Non-alcoholic Fatty Liver Disease Using Markers and Imaging Techniques||Maastricht University Medical Center||Not yet recruiting|April 2016|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|110|Samples Without DNA|Blood, exhaled air, feces|Both|18 Years|65 Years|No|Probability Sample|Subjects with proven NAFLD by histology or NAFLD proven by imaging, who are undergoing        surgery (i.e. bariatric surgery or cholecystectomy) will be asked to participate in this        study. Furthermore, all subjects have to be between 18 and 65 years old.|March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02717000||266|
NCT02657317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT008422-01|Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in Post-9/11 Veterans|Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in a Combat-Injured Veterans Population||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|January 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|72 Years|No|||February 2016|February 1, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02657317||4845|
NCT02657330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SBP-101-01|Study of SBP-101 in Pancreatic Cancer|A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma||Sun BioPharma Inc|Yes|Recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02657330||4844|
NCT02649309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-SCRIP|Single-cycle Remote Ischemic Preconditioning and Postconditioning (SCRIP) Trial|Effect of Single-cycle Remote Ischemic Preconditioning and Postconditioning on Myocardial Injury in Patients Undergoing Emergency and Elective Percutaneous Intervention in Phramongkutklao Hospital and Thammasat University|SCRIP|Phramongkutklao College of Medicine and Hospital|No|Recruiting|October 2015|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|370|||Both|18 Years|N/A|No|||December 2015|January 6, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02649309||5459|
NCT02654977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00093399|CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy|CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy||University of Michigan|No|Recruiting|April 2015|February 2025|Anticipated|February 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|5 Years|N/A|No|||January 2016|January 11, 2016|January 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654977||5025|
NCT02653157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1505|Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn|IGHID 11519 - Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn||University of North Carolina, Chapel Hill|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Gram-negative bacterial isolates|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (18 years of age or older) hospitalized in the NC Jaycee Burn Center who        require intubation at or less than 24 hours prior to admission as well as those with 20%        or more total body surface area burn, with the anticipation that these patients will        subsequently require intubation.|January 2016|January 8, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02653157||5164|
NCT02717520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-PA-26-7/2015|Long Term Clinical Evaluation of a Posterior Glass Hybrid System vs. Composite Resin|Long Term Clinical Evaluation of a Posterior Glass Hybrid System vs. Composite Resin: a Controlled Clinical MultiCenter Study||University of Zagreb|Yes|Recruiting|September 2015|June 2022|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02717520||226|
NCT02647437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1495|Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia|Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia||University of Colorado, Denver|No|Recruiting|June 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647437||5603|
NCT02647736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoNorm|Copeptin in Normal- to Hyperosmolar States|Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study||University Hospital, Basel, Switzerland|Yes|Recruiting|September 2012|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02647736||5580|
NCT02644707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARISTOTLE UNIVERSITY|Selenium Supplementation in Youths With Autoimmune Thyroiditis|L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial|THYROSEL|Aristotle University Of Thessaloniki|No|Recruiting|March 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|18 Years|No|||December 2015|December 30, 2015|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02644707||5813|
NCT02644993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-111|Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy|||Samsung Medical Center|No|Recruiting|November 2015|||November 2025|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|N/A|18 Years|No|||December 2015|December 31, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02644993||5791|
NCT02653664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49799-B|Chronic Pain Skills Study|Hypnosis and Meditation for Pain Management in Veterans: Efficacy and Mechanisms|CPSS|University of Washington|Yes|Enrolling by invitation|September 2014|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|343|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02653664||5125|
NCT02714075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM_Rice|Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA|Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Different Zinc Compounds, Citric Acid/Trisodium Citrate and Sodium EDTA|MM_Rice|Swiss Federal Institute of Technology|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|6 Years|8 Years|No|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714075||491|
NCT02655731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF117/2015|HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate|HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate|HEURECA|Cardioangiologisches Centrum Bethanien|Yes|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02655731||4967|
NCT02652013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00624-45|Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis|Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis|COGNISEP|Pôle Saint Hélier|No|Recruiting|December 2015|December 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02652013||5251|
NCT02652247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151194|Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients|Serial, Non-invasive Molecular Analysis of Exhaled Breath Condensate to Define the Pulmonary Flora in Critically Injured, Ventilated Adults: The Clinical Trial||Vanderbilt University|No|Recruiting|January 2016|December 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|350|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02652247||5233|
NCT02716233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10205|A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents|A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents|CAALL-F01|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|April 2016|April 2026|Anticipated|April 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1578|||Both|12 Months|18 Years|No|||January 2016|March 17, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02716233||325|
NCT02648971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB30774 (Z61894)|Controlled Trial to Compare Single Versus Two Portal Knee Arthroscopy Techniques|A Randomized Controlled Trial to Compare Single Portal Versus Two Portal Knee Arthroscopy Techniques in Patients With Meniscal Injuries and Articular Cartilage Pathology||Wake Forest School of Medicine|No|Enrolling by invitation|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|21 Years|60 Years|No|||January 2016|January 5, 2016|December 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02648971||5485|
NCT02652468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW14113|TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma|A Pilot Study to Assess Engraftment Using CliniMACS TCR-α/β and CD19 Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Progenitor Cell Transplantation in Patients With Relapsed Lymphoma||University of Wisconsin, Madison|Yes|Recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652468||5216|
NCT02652715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS1581|Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma|A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma||Mayo Clinic|Yes|Recruiting|January 2016|||May 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652715||5197|
NCT02652260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439A-028|Effects of Switching From ATRIPLA^TM (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)|Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.||Merck Sharp & Dohme Corp.|No|Recruiting|March 2016|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652260||5232|
NCT02652533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-7320|Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia|Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia||Children's Hospital Medical Center, Cincinnati|No|Not yet recruiting|March 2016|March 2024|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|3 Months|No|Non-Probability Sample|neonatal cholestasis with concern for BA vs. other liver disease direct bilirubin >20% of        total or ≥2 mg/dL age <3 months|January 2016|January 8, 2016|December 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02652533||5211|
NCT02715401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TASU-103|PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers|A Randomized, Open-Label, Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1303 Capsule and Co-administration of HGP1201 Tablet, HIP1402 Capsule Under Fed Condition in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|October 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02715401||389|
NCT02644564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/195|Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries|Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries||Oslo University Hospital||Recruiting|September 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|40 Years|N/A|No|Probability Sample|All patients living in the municipality of Oslo that visit Section for Orthopaedic        Emergency (Oslo skadelegevakt), Oslo University Hospital with an acute shoulder injury.|January 2016|January 6, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02644564||5824|
NCT02648022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-101-A|Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment|Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorders With Chronic Hepatitis C Receiving Direct Acting Antiviral Treatment||VA Office of Research and Development|No|Completed|January 2012|February 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|79|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02648022||5558|
NCT02661295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|756275-1|A Study of Ferric Citrate to Improve Inflammation and Lipid Levels|The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis||Winthrop University Hospital|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661295||4539|
NCT02716454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDchirCZ-01|Early Surgery Versus Conservative Treatment in Patients With Ileocoecal Crohn's Disease|Early Surgery Versus Conservative Treatment in Patients With Ileocoecal Crohn's Disease - Prospective Randomized Study||Czech Surgical Society|No|Not yet recruiting|May 2016|December 2021|Anticipated|May 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716454||308|
NCT02654353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PersAF-Abl2014|A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach|A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach||Johannes Gutenberg University Mainz|No|Completed|February 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||January 2016|January 12, 2016|January 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02654353||5073|
NCT02657382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083616|Mental Stress Ischemia: Biofeedback Study|Effects of Biofeedback on Myocardial Blood Flow Changes During Mental Stress in Patients With Coronary Artery Disease|MIBS|Emory University|No|Recruiting|September 2015|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|34|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657382||4840|
NCT02657395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006568|Root Coverage Using a Xenograph for Treatment of Gingival Recession|PriMatrix Utilization to Achieve Dental Root Coverage||Mayo Clinic|No|Recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02657395||4839|
NCT02644746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015EC114|Efficacy and Safety of Acupuncture for Degenerative Lumbar Spinal Stenosis|Efficacy and Safety of Acupuncture for Degenerative Lumbar Spinal Stenosis: Protocol for a Randomized Placebo-controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|80 Years|No|||December 2015|December 31, 2015|December 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02644746||5810|
NCT02715947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016 MTX/CSU/PS|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate||Central South University|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|70 Years|No|||December 2015|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715947||347|
NCT02649725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cure and more2|Patients Satisfaction With the Outcomes of Expensive Cytotoxic Agents|Prospective Questionnaire Based Observational Study Measuring the Degree of Patient's Satisfaction With the Outcomes of Expensive Cytotoxic Agents.||Ain Shams University|No|Recruiting|January 2016|January 2019|Anticipated|November 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1800|||Both|17 Years|70 Years|No|Non-Probability Sample|Cancer patients who are willing to answer the questionnaire voluntarily.|January 2016|January 22, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649725|3 Months|5427|
NCT02654444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-HER2-IHC|Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue|Concordance Study of Her2 Expression Level in Breast Cancer Tissues||Applied Spectral Imaging Ltd.|No|Completed|May 2013|January 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|3|||Female|21 Years|N/A|No|Probability Sample|Women having breast cancer|January 2016|January 12, 2016|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02654444||5066|
NCT02646670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARVO R2 2016|Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema|Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema||Instituto de Olhos de Goiania|Yes|Completed|July 2015|November 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|N/A|N/A|No|||January 2016|January 3, 2016|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02646670||5662|
NCT02657577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2014-048|REseArCH INteGration in Women, Infants, and Children|REseArCH INteGration in Women, Infants, and Children: REACHING WIC||Pennington Biomedical Research Center|No|Enrolling by invitation|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||1|Anticipated|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 550 individuals will be identified at WIC clinics in Louisiana. Participants must be        at least 18 years of age.|March 2016|March 24, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02657577||4825|
NCT02645045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1009|Evaluation of Factors Affecting the Tear-film Lipid Layer Thickness|||Yonsei University|Yes|Recruiting|December 2015|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|350|||Both|19 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|age over 19 years old, Patients with dry eye syndrome and normal subjects|December 2015|December 30, 2015|December 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02645045||5787|
NCT02719535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-Q46G|Corneal Biomechanics and Corneal Reshaping Therapy|Corneal Stiffness and Tangent Modulus to Predict the Rate of Corneal Curvature Change in Corneal Reshaping Therapy||The Hong Kong Polytechnic University|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|March 21, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02719535||71|
NCT02646956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH DC011287|Taste Preferences for Nutritive and Non Nutritive Sweeteners Among Children and Adults|Taste Preferences for Nutritive and Non Nutritive Sweeteners Among Children and Adults|TNNS|Monell Chemical Senses Center|No|Completed|May 2014|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|82|Samples With DNA|Salivary samples obtained for genotyping of taste receptor genes|Both|7 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children and adults living in the Philadelphia area|December 2015|January 4, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02646956||5640|
NCT02651701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRPET-CRC|Rectal Cancer Staging Using Whole Body MR-PET|Preoperative Imaging for Rectal Cancer Staging Using Whole Body MR-PET||Seoul National University Hospital|Yes|Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|71|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients newly diagnosed with rectal cancer.|January 2016|January 7, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02651701||5275|
NCT02646202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scleroligation|Scleroligation for Eradication of Gastroesophageal Varices.|Scleroligation is a Safe and Effective New Technique for Eradication of Gastroesophageal Varices.||Tanta University|Yes|Recruiting|January 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||January 2016|January 1, 2016|January 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646202||5698|
NCT02646215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDS-IMT|Inspiratory Muscle Training in Ehlers Danlos Patients|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646215||5697|
NCT02718066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBI-8000-302|Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer|A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Patients With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)||HUYA Bioscience International|No|Not yet recruiting|September 2016|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718066||184|
NCT02657304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508146|Effect of Early Education on the Observance of CPAP Treatment|Effect of Early Education and Information of Sleep Apnea on the Observance of CPAP Treatment|Coach SAS|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02657304||4846|
NCT02658903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxys-01|Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter|Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter||Oxys Medical AG|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02658903||4723|
NCT02658916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN002-004|Extension Study of BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in CN002003|A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003||Bristol-Myers Squibb|No|Enrolling by invitation|February 2016|May 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|41 Years|86 Years|No|||February 2016|February 17, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02658916||4722|
NCT02657720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10141352|Comparison Between Different Technologies That Measure Respiratory Rate|Comparison Between Different Technologies That Measure Respiratory Rate||Oridion|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|February 7, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02657720||4814|
NCT02657733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10144939|Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)|Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)||Oridion|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|February 7, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02657733||4813|
NCT02720029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141751|Detection of Silent Aspiration Events Utilizing pH/Impedance Probes in Hospitalized Patients|Detection of Silent Aspiration Events Utilizing pH/Impedance Probes in Hospitalized Patients||Vanderbilt University|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720029||33|
NCT02720042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE-016|A Prospective, Multi-Center, Single-Arm Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair|A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair||C. R. Bard|Yes|Not yet recruiting|March 2016|September 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720042||32|
NCT02654054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-815|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women||AbbVie|Yes|Recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Female|18 Years|51 Years|No|||January 2016|January 11, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654054||5096|
NCT02654067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pregnancy Airway Study|Evaluation of Mallampati Score Changes in Pregnancy|Evaluation of Mallampati Score Changes in Pregnancy||Brigham and Women's Hospital|No|Not yet recruiting|January 2016|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients|January 2016|January 11, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02654067||5095|
NCT02659072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14013|Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV)|Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV)|PREEV|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women who will have an examination of endo-vaginal ultrasound|December 2015|March 16, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02659072||4710|
NCT02657538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110/13|Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection|Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection: A Clinical Controlled Trial||University of Bern|No|Active, not recruiting|July 2014|March 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|35|||Both|15 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02657538||4828|
NCT02650973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-1701-05|Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta|A Randomized, Single-Blind, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects||Coherus Biosciences, Inc.|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|256|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650973||5331|
NCT02719769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP000004|Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture|Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing||Accelerate Diagnostics, Inc.|No|Enrolling by invitation|January 2016|||April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|Samples Without DNA|Frozen positive blood cultures and bacterial and yeast isolates|Both|N/A|N/A|No|Non-Probability Sample|Clinical specimens that are indicated as positive by blood culture monitoring systems        utilized by clinical microbiology laboratories.|March 2016|March 24, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719769||53|
NCT02645448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSaoFrancisco|Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise|Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise of Different Intensities||Universidade Federal do vale do São Francisco|Yes|Completed|November 2014|September 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|12|||Female|40 Years|60 Years|No|||December 2015|December 30, 2015|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02645448||5756|
NCT02659059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-568|Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer|An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab as First Line-therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)|CheckMate568|Bristol-Myers Squibb|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02659059||4711|
NCT02651207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015OB09|Study Looking at Acceptability of Using Ethyl Chloride Spray Versus Subcutaneous Lidocaine Anaesthetic Prior to Contraceptive Implant Insertion|Study Looking at Acceptability of Using Ethyl Chloride Spray Versus Subcutaneous Lidocaine Anaesthetic Prior to Contraceptive Implant Insertion||Tayside Medical Science Centre|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|128|||Female|13 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patient who choose to use the contraceptive implant as a method of contraception and who        are deemed medically eligible for the method with no medical contrainidications|January 2016|January 7, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02651207||5313|
NCT02715999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02/2016|Transversus Abdominis Plane Versus Quadratus Lumborum Block for Pediatrics|Transversus Abdominis Plane Versus Quadratus Lumborum Block for Pediatrics||Kahramanmaras Sutcu Imam University|No|Recruiting|February 2016|January 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|7 Years|No|||March 2016|March 21, 2016|March 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715999||343|
NCT02716272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1501|Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients|A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients|MAPS2|Intergroupe Francophone de Cancerologie Thoracique|No|Not yet recruiting|April 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02716272||322|
NCT02620956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|669.576.484-00|Aerosol Deposition in Asthmatic Obese Women Using Heliox|Aerosol Deposition in Asthmatic Obese Women Using Heliox: A Randomized, Crossover, Controlled Clinical Trial Study||Universidade Federal de Pernambuco|Yes|Recruiting|November 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620956||7638|
NCT02625493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevas-v2|Patient Preference for Radial Versus Femoral Vascular Access|Patient Preferences for Radial Versus Femoral Vascular Access Options by Coronary Angiography and Intervention|PREVAS|Thorax Centrum Twente|No|Completed|June 2014|October 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|||Both|18 Years|N/A|No|Non-Probability Sample|A consecutive series of patients, who between June and August 2014, underwent elective        coronary procedures at Thoraxcentrum Twente in Enschede.|December 2015|December 4, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02625493||7289|
NCT02625363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutrifood|Water Intake and Glycemic Response : Preliminary Study|Water Intake and Glycemic Response : Preliminary Study||Nutrifood Research Center, Jakarta, Indonesia|No|Recruiting|November 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02625363||7299|
NCT02625376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGED/EudraCT : 2015-001577-41|Resveratrol for Exudative Age-Related Macular Degeneration|Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.|AGED|Poitiers University Hospital|No|Active, not recruiting|August 2015|August 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|489|||Both|55 Years|N/A|No|||November 2015|December 4, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02625376||7298|
NCT02573077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPEL/2014/067|An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy|A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy|ASSERT|Otsuka Pharmaceutical Europe Ltd|No|Recruiting|October 2015|April 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|This non-interventional study will include cancer patients who need a treatment for        hyponatremia secondary to SIADH in one of the hospitals participating in the study.|February 2016|February 9, 2016|October 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573077||11313|
NCT02617212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.310.562|Implant Abutment Dis-/Reconnection and Peri-Implant Marginal Bone Loss.|Impact of Implant Abutment Dis-/Reconnection on Peri-Implant Marginal Bone Loss - Randomized Clinical Trial.||Fortaleza University|Yes|Recruiting|November 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617212||7925|
NCT02617225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/06/UNICEF01|Effect of a Pilot Group Hand-washing Program on Handwashing Behaviors Among Elementary School Children in Assam|Evaluation of DHaAL Intervention of Group Handwashing With Soap Before Mid-day Meals in Rural Elementary School of Assam||Network for Engineering and Economics Research and Management|No|Recruiting|November 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|900|||Both|8 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Elementary schools (Class 1-5) from five education blocks in Kamrup district. The        respondents/participants include school teachers (Interview/observations), Class 1-5        students (distant observation), Class 3-5 students (Interview/observations) and their        parents/other household members (Interview/observations).|November 2015|November 27, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02617225||7924|
NCT02616705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004819|Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis|Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis||Mayo Clinic|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|None Retained|Bile|Both|18 Years|N/A|No|Non-Probability Sample|Cases with biliary stricture(s) of any cause|November 2015|November 27, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02616705||7964|
NCT02620605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C123|The Influence of Timing of Cabergoline Initiation on Prevention of OHSS|The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection .|OHSS|Cairo University|Yes|Recruiting|December 2015|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|75|||Female|19 Years|35 Years|No|||December 2015|December 6, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620605||7665|
NCT02619682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9266|Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma|Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma||Fred Hutchinson Cancer Research Center|No|Recruiting|December 2015|||December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02619682||7736|
NCT02612077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21696|Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)|A Cohort Survey of Patients With Metastatic Colorectal Cancer Starting a Chemotherapy in Combination With Avastin®|CONCERT|Hoffmann-La Roche||Completed|May 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|765|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cancer (mCRC) starting chemotherapy combined with        bevacizumab.|February 2016|February 12, 2016|November 19, 2015||No||No|January 15, 2016|https://clinicaltrials.gov/show/NCT02612077||8320|
NCT02612090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-058|The Cholesterol Lowering Effects of Strawberry|The Cholesterol Lowering Effects of Strawberry: A Randomized Controlled Trial Establishing Strawberry's Role in Cardiovascular Health|STR4|Institute for Food Safety and Health, United States|No|Recruiting|January 2016|May 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|40 Years|69 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612090||8319|
NCT02612337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-201506|Study of OTO-104 in Subjects With Unilateral Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease||Otonomy, Inc.|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|85 Years|No|||November 2015|November 19, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612337||8300|
NCT02612662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5590C00001|A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects|A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects||AstraZeneca|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Anticipated|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612662||8275|
NCT02612675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.10.US.HCN|Glycemic Response to Oral Nutrition Supplements|Plasma Glucose and Insulin Response to Two Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus||Nestlé|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|13|||Both|20 Years|75 Years|No|||November 2015|November 20, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02612675||8274|
NCT02598765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16075|Micro vs. Standard Trabeculectomy Study|Micro vs. Standard Trabeculectomy Study||Francis I. Proctor Foundation|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|N/A|No|||November 2015|November 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598765||9339|
NCT02603107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-380-1878|Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults|A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults||Gilead Sciences|Yes|Recruiting|November 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603107||9006|
NCT02602925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONDOR|Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity|Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity: A Randomized Pragmatic Trial||Radboud University|No|Not yet recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02602925||9020|
NCT02603172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201664|A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis|A Three-part Open-label, Non-randomised, Dose-escalation Study to Investigate the Safety and Tolerability of GSK3039294 Administered as a Single Dose to Healthy Volunteers, and as Repeat Dose to Healthy Volunteers and Patients With Systemic Amyloidosis||GlaxoSmithKline|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02603172||9001|
NCT02607527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-003|Annular Reshaping of the Mitral Valve for MR Using the Millipede IRIS System|Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System||Millipede Inc.|No|Not yet recruiting|March 2016|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|85 Years|No|||November 2015|November 17, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02607527||8669|
NCT02619747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA1218|Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients|A Multi-centre, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Oral Suspension Sachets or Placebo Sachets||Reckitt Benckiser Healthcare (UK) Limited|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619747||7731|
NCT02619760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1114|ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study|ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study|STOPDAPT-2|Kyoto University, Graduate School of Medicine|Yes|Recruiting|December 2015|December 2023|Anticipated|December 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|N/A|N/A|No|||December 2015|December 25, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02619760||7730|
NCT02606500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-01|Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success|Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success||University Medical Centre Ljubljana|No|Not yet recruiting|January 2016|October 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|38 Years|No|||November 2015|November 16, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02606500||8746|
NCT02608801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/2260REK OS|Prediction and Secondary Prevention of Fractures|Prediction and Secondary Preventing of Fractures in a Norwegian Population. A Substudy of Norwegian Capture the Fracture Initiative|NOFRACTsub|Oslo University Hospital||Recruiting|April 2015|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|50 Years|N/A|No|Probability Sample|Patients already enrolled in NoFRACT main-study. Some patients will be asked to        participate in this consent based sub-study, and must be able to answer questionairies,        undergo DXA scan and bloodtests at baseline and follow-up.|November 2015|December 22, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608801||8571|
NCT02607579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-045|Comparing Exparel & Ropivacaine for Pain Relief in Total Knee Arthroplasty|A Randomized, Blinded Study to Compare Exparel and Ropivacaine for Pain Relief Following Total Knee Arthroplasty||Monmouth Medical Center||Recruiting|January 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607579||8665|
NCT02564068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041333|Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Heart Rate|||George Washington University|No|Recruiting|March 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02564068||12005|
NCT02613182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOD001-OLE001|Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|OLE|Prothena Therapeutics Ltd.|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 20, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613182||8235|
NCT02613429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seventh floor 15/1|Identification of Airway Structures Necessary for Airway Access Via the Skin|Identification of Airway Structures Necessary for Airway Access Via the Skin to be Used in Case of Failure to Maintain Oxygenation With Non-invasive Methods||Rigshospitalet, Denmark|No|Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 3, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02613429||8216|
NCT02625753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE : 37084214.3.0000.0068|Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain|A Randomized Study of Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain||University of Sao Paulo General Hospital|Yes|Completed|November 2014|October 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||December 2015|December 9, 2015|November 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625753||7269|
NCT02625805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD5|Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD|Evaluation of the Ability for Monitoring Dynamics in ADD/ADHD With an Easy to Use EEG||Brainmarc Ltd.|No|Not yet recruiting|April 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625805||7265|
NCT02622451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA037888|Differential Sensitivity Markers in Youth Drug Abuse Prevention|Differential Sensitivity Markers in Youth Drug Abuse Prevention||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|December 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|12 Years|17 Years|No|||December 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622451||7523|
NCT02620813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|725019|De Novo Lipogenesis of Sebaceous Glands in Acne|||University of California, Davis||Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620813||7649|
NCT02620826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00077025|Prospective Comparison of Indirect Pulp Therapy and Mineral Trioxide Aggregate Pulpotomy in Decayed Primary Molars|Prospective Comparison of Indirect Pulp Therapy and Mineral Trioxide Aggregate Pulpotomy in Decayed Primary Molars||University of Michigan|No|Active, not recruiting|December 2013|December 2023|Anticipated|December 2023|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02620826||7648|
NCT02626897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3-27.11.2015|A Comparison of Accelerometers for Measuring Daily Activity in Sarcoid|A Comparison of Two Wrist-worn Accelerometer Devices for the Measurement of Activity in Sarcoidosis Patients||University of East Anglia|No|Not yet recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02626897||7181|
NCT02617797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1162-0945|Radiofrequency in the Female Stress Urinary Incontinence|Radiofrequency in the Female Stress Urinary Incontinence: A Randomized Clinical Trial||Centro de Atenção ao Assoalho Pélvico|No|Recruiting|September 2015|July 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Female|18 Years|59 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02617797||7880|
NCT02625766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00060038|Pelvis RCT: Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures|Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures: a Prospective Trial||University of Maryland|Yes|Recruiting|December 2014|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02625766||7268|
NCT02622698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356154|Oral Protein Supplementation Following Non-bariatric Surgery|A Randomized Trial of Oral Protein Supplementation Following Non-bariatric Abdominal Surgery||Eisenhower Army Medical Center||Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622698||7504|
NCT02622919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP2015061050|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||December 4, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622919||7487|
NCT02613741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.20.8840|Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease|Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease||Nemours Children's Clinic|No|Active, not recruiting|January 2001|January 2017|Anticipated|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02613741||8192|
NCT02624011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERN_15-1238|Influence of Sedentary Time on Skeletal Muscle Protein Metabolism|Influence of Increased Sedentary Time on Long-term Rates of Skeletal Muscle Protein Synthesis in Young Adults||University of Birmingham|No|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|March 21, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02624011||7403|
NCT02617901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/14/010|Developing a COMputerised Bone Age Tool|COMBAT 1: COMputerised Bone Age Tool (Phase 1: Feasibility of Using Dual Energy X-ray Absorptiometry for Bone Age Assessment in Children)|COMBAT1|Sheffield Children's NHS Foundation Trust|No|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|1 Year|16 Years|No|||November 2015|November 26, 2015|April 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617901||7873|
NCT02618174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBirmingham-SNS1|Enhanced Broccoli Consumption After a Liking Norm and Vegetable Variety Message: Effects After a 24 Hour Delay.|Enhanced Broccoli Consumption After a Liking Norm and Vegetable Variety Message: Effects After a 24 Hour Delay.||University of Birmingham|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Actual|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02618174||7852|
NCT02618187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERES-101|A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis|A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis||Seres Therapeutics, Inc.|Yes|Recruiting|December 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|55|||Both|18 Years|75 Years|No|||November 2015|December 4, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618187||7851|
NCT02616159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1519|Effect of Oatmeal Varieties on Glycemic and Insulinemic Responses in Healthy Individuals|A Randomized, Controlled, Double-Blind Crossover Trial to Assess Effect of Oatmeal Varieties on Glycemic and Insulinemic Responses in Healthy Individuals||PepsiCo Global R&D|No|Recruiting|November 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616159||8006|
NCT02616406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001248|Objective Measure of Recovery After Outpatient Surgery|Assessment of Physical Activity to Determine When Patients Return to Baseline Levels of Activity Following Outpatient Inguinal Hernia Surgery||Mayo Clinic|No|Recruiting|November 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults with inguinal hernia who are to have hernia repair|January 2016|January 5, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616406||7987|
NCT02626390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7938|Information Provision During Early Gait Training Post Stroke|How do Different Styles of Information Provision Affect Learning During Early Gait Training Post Stroke? A Feasibility Study||University of Southampton|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626390||7220|
NCT02614157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pLNR-201501|Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer|Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Control Trial||West China Hospital|Yes|Recruiting|July 2015|June 2020|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|75 Years|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614157||8160|
NCT02622269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183781|Patient-driven Compression in Urography|Patient-driven Compression in Urography||Örebro University, Sweden|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622269||7537|
NCT02621320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD_2015-11|Vitamin D Supplementation in Wheelchair Indoor Athletes|Effect of Vitamin D3 Supplementation on Exercise Performance in Wheelchair Athletes.|VitD_SCI|Swiss Paraplegic Centre Nottwil|No|Recruiting|November 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|28|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02621320||7610|
NCT02614079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atallah SCS DSSEP|Evaluation of the Percutaneous SCS Trial Using the DSSEP Collision Testing|Evaluation of the Percutaneous Spinal Cord Stimulation Trial Using the Dermatomal Somatosensory Evoked Potentials Collision Testing||University of Toledo Health Science Campus|No|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|November 24, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614079||8166|
NCT02613338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R011373566|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2||The University of Tennessee Knoxville|No|Recruiting|November 2015|December 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|30 Years|80 Years|No|Non-Probability Sample|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee        system at least three months post-operative.|February 2016|February 10, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613338||8223|
NCT02618694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2380|Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study|Posterior Retroperitoneoscopic Approach Versus Transperitoneal Laparoscopic Approach in Management of Adrenal Tumors: A Randomized Comparative Study|PostLapAdrnl|Suez Canal University|No|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||November 2015|November 28, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02618694||7812|
NCT02615600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-tRNS02|Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Tinnitus (tRNS2-tin)|Effectiveness of Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Patients With Chronic Tinnitus||University of Regensburg|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615600||8049|
NCT02627001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402438-1|Nu-Mask Intraoral Airway Device Versus Conventional Bag Valve Mask Ventilation Crossover Trial|Comparison of Air Leak During Ventilation With Nu-Mask Intraoral Airway Device Versus Conventional Bag Valve Mask in a Cadaver Model: A Randomized Crossover Trial||Brooke Army Medical Center|No|Completed|September 2014|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627001||7173|
NCT02627014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM_TMD_1|Effect of Treatment of Temporomandibular Joint in Patients With Chronic Migraine and Temporomandibular Disorders|Effect of Treatment of Temporomandibular Joint in Patients With Chronic Migraine and Temporomandibular Disorders||Cardenal Herrera University|Yes|Recruiting|July 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627014||7172|
NCT02626637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412M57161|KAM: Kids Are Moving|KAM: Kids Are Moving; An Exercise Program for Children With Cancer|KAM|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|November 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|6 Years|18 Years|No|||December 2015|December 9, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02626637||7201|
NCT02626156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043450|Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence|Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence|MUSTCOOL|Medical University of South Carolina|Yes|Recruiting|June 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|50 Years|N/A|No|||December 2015|December 7, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02626156||7238|
NCT02612935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL009 - MS ACHIEVEMENT STUDY|An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis|An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis||Lumos Labs, Inc.|No|Enrolling by invitation|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 50 current members of the Mercy MS Achievement Center will be provided with        12-month premium access Lumosity accounts. Study participants must be ≥18 years of age,        and currently members of the Achievement Center participating in the cognitive wellness        program.|November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612935||8254|
NCT02615704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00161|"Me and My Heart" Study|Evaluation of an Electronic Device Based Support Tool for ACS Patients: Brilique (Ticagrelor) Treatment Adherence (eMocial)|eMocial|AstraZeneca|No|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|N/A||4|Anticipated|920|||Both|18 Years|N/A|No|Non-Probability Sample|The target population are acute coronary syndrome (ACS) patients 18 years or older with        access to an electronic device (compatible with the patient support tool), diagnosed with        ST elevation myocardial infarction, non-ST elevation myocardial infarction or unstable        angina pectoris treated with twice daily Brilique (ticagrelor) co administered with low        dose acetylsalicylic acid according to the prescription recommendation, within 14 days        following the diagnosis of the ACS event.|February 2016|February 16, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02615704||8041|
NCT02615717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNebraskaLincoln|Using Attentional Bias Modification to Address Trauma Symptoms|Using Attentional Bias Modification to Address Trauma Symptoms||University of Nebraska Lincoln|No|Recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|19 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615717||8040|
NCT02625389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUF-55-001|Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization|Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization|In-Live|Guerbet|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients scheduled for endovascular embolization using Lipiodol® Ultra Fluid in        association with surgical glues, for treatment of single or multiple lesions (AVMs,        hemangioma etc.)|December 2015|December 9, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02625389||7297|
NCT02625428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-009240|IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?|Does Contrast-Enhanced Ultrasound Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?||Mayo Clinic|No|Recruiting|November 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625428||7294|
NCT02624180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070892|Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV|Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV||Johns Hopkins University|Yes|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|102|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624180||7390|
NCT02624193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00093335|Health Improvement for Baltimore Youth|Improving Treatment Adherence in HIV-Positive Youth Through Mindfulness Training||Johns Hopkins University|Yes|Enrolling by invitation|April 2013|September 2019|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|13 Years|24 Years|No|||October 2015|December 3, 2015|June 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02624193||7389|
NCT02615262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex01|Intraoperative Dexamethasone in Pediatric Cardiac Surgery|Intraoperative Dexamethasone in Pediatric Cardiac Surgery: a Prospective Double-blind Randomised Clinical Trial||Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|December 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|384|||Both|N/A|12 Months|No|||December 2015|December 17, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615262||8075|
NCT02568956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-2|Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)|||Academy Military Medical Science, China|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02568956||11630|
NCT02611635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18377|AF Patient Preference Study|AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study|PRiSMA-AF|Bayer|No|Recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients in primary care / internal medicine specialist practices or cardiology outpatient        clinics in Sweden.|March 2016|March 21, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611635||8354|
NCT02625480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTE-C19-104|A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)|ZUMA-4|Kite Pharma, Inc.||Recruiting|December 2015|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|2 Years|21 Years|No|||February 2016|March 1, 2016|December 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625480||7290|
NCT02616237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131213002|A Facebook-based Weight Loss Programme for Obese Adults in Hong Kong|Effects of a Facebook-based Weight Loss Programme for Obese Adults in Hong Kong||The Hong Kong Polytechnic University|No|Recruiting|April 2014|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616237||8000|
NCT02615496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16526|Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept|Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study||Bayer|No|Recruiting|December 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Physicians eligible to participate will be ophthalmologists who have administered        aflibercept in the past 6 months.        Patients eligible to participate will be those who have already received at least one        aflibercept injection and are returning for a subsequent visit. Patients will be aged 18        years or older, and will be able to understand the native language of the country in which        the study is conducted.|March 2016|March 10, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02615496||8057|
NCT02615509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9RWH8K|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||January 25, 2016|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615509||8056|
NCT02615782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150FDI15031|A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 After a Single Oral Dose in Healthy Male Subjects||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Male|19 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615782||8035|
NCT02615821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02120|Mental Contrasting Physical Activity Study|Mental Contrasting Physical Activity Study||University of British Columbia||Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|105|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615821||8032|
NCT02615834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060292|Chest Pressure for Intubated Peds Patients|Testing the Ability of Gentle Chest Pressure to Maintain Peripheral Oxygenation in Intubated Pediatric Patients||University of Alberta|No|Not yet recruiting|May 2016|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|80|||Both|1 Year|18 Years|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615834||8031|
NCT02622815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRC5xmille - 12237|Hypercoagulation Screening in Cancer|Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer|HYPERCAN|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|16000|Samples With DNA|whole blood, plasma, serum and tissue|Both|N/A|N/A|No|Non-Probability Sample|Blood donors (age range 35-65 years), who agree to participate, fulfill a specific        questionnaire on their lifestyle and donate venous blood samples at the enrolment into the        study, and after 6-12 months.        The parental cohort of the Moli-sani project included 24,325 subjects (>35 years) from the        Molise region. Blood samples have been collected and stored in the Moli-sani biobank        available to this project.        Cancer patients of both genders (>18 years) with new diagnosis of non small cell lung        cancer, gastrointestinal tumors, and breast cancer are enrolled at different recruiting        sites. Blood samples are collected at the enrollment and at specific time points during        follow-up without interfering with clinical management.|December 2015|December 4, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02622815||7495|
NCT02623595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHX-65|A Study of SBRT in Combination With GM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy|A Prospective Single-arm Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT in Combination With GM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy||Wuhan University|Yes|Not yet recruiting|December 2015|November 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02623595||7435|
NCT02618109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00621-48|Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia|Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia|LABMI|University Hospital, Angers|No|Not yet recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|1 Year|18 Years|No|||November 2015|November 26, 2015|April 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02618109||7857|
NCT02615522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-02-BPK-S Integration|Prospective Post Market Clinical Follow-Up of the Primary Knee Endoprosthesis BPK-S Integration|Prospektive, Klinische Verlaufsuntersuchung (Post Market Follow-Up) Der primären Knieendoprothese BPK-S Integration||Peter Brehm GmbH|No|Not yet recruiting|March 2016|January 2028|Anticipated|August 2027|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing primary total knee endoprosthesis with BPK-S Integration of age 18 and        older|November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615522||8055|
NCT02616107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407014318|Improving Cancer Family Caregivers' Knowledge and Communication About Care Options|Improving Cancer Family Caregivers' Knowledge and Communication About Care Options||Yale University|No|Recruiting|July 2014|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|110 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02616107||8010|
NCT02625168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC|Efficacy and Safety of Afatinib in Patients With EGFR-mutated Metastatic Non-small-cell Lung Cancer Previously Responsive to First-generation Tyrosine-kinase Inhibitors and Chemotherapy||The University of Hong Kong|No|Completed|January 2013|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|N/A|N/A|No|||December 2015|December 6, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625168||7314|
NCT02625181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151750|Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis|Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis||Vanderbilt University|No|Not yet recruiting|December 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|32000|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02625181||7313|
NCT02623608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-JT-Ac.Ch|Effects of Functional Ingredients in an Acute Metabolic Challenge Context|Acute Metabolic Challenge for the Assessment of Cardiometabolic Protective Effects of Foods||Lund University|No|Active, not recruiting|August 2015|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|15|||Both|50 Years|73 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623608||7434|
NCT02616354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Two-step Dosing Of Imipenem|Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin|Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin|PROTDOI|Southeast University, China|Yes|Recruiting|January 2015|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||November 2015|November 24, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616354||7991|
NCT02614586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-058-1003|Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia|A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of TAK-058 and Ondansetron on P50 Auditory Gating in Subjects With Stable Schizophrenia||Takeda|No|Recruiting|December 2015|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614586||8127|
NCT02614846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-TPO- Ie-ITP|Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura||Jiangsu HengRui Medicine Co., Ltd.||Recruiting|August 2015|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|65 Years|No|||November 2015|November 22, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614846||8107|
NCT02612740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2187P|Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal|Deproteinized Bovine Bone for the Treatment of Alveolar Bone Critical Size Defect in Humans: A Randomized Clinical Pilot Study||University of Padova, School of Dental Medicine|Yes|Active, not recruiting|April 2010|October 2016|Anticipated|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|September 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612740||8269|
NCT02573064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCO-COL-2015-01|Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical|||Maimónides Biomedical Research Institute of Córdoba|No|Completed|January 2010|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|113|||Both|16 Years|N/A|No|Non-Probability Sample|Critical patients with monomicrobial bloodstream infections due to monoclonal antibodies        were studied; specific criteria were applied for analysis of empirical therapy and        targeted therapy (113 patients).|October 2015|October 8, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02573064||11314|
NCT02623530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.274.735|Critical Thinking in Nursing Students|The Teaching of Critical Thinking for Nursing Students: A Randomized Controlled Pilot Study||University of Sao Paulo|Yes|Completed|October 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|102|||Both|17 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 5, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623530||7440|
NCT02611713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14-494|Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease|DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)|DUOGLOBE|AbbVie|No|Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|30 Years|N/A|No|Non-Probability Sample|Advanced Parkinson's disease|January 2016|January 25, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611713||8348|
NCT02614417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Sleep-disordered Breathing in Eisenmenger Syndrome|Sleep-disordered Breathing in Eisenmenger Syndrome||Rigshospitalet, Denmark|No|Completed|June 2013|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients with Eisenmenger syndrome|November 2015|November 23, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02614417||8140|
NCT02619110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20130288|The Effect of Backward Walking Treadmill Training on Balance in Patient With Chronic Stroke|The Purpose of This Study Was to Discuss on the Effects of Backward Walking Treadmill Training on Balance Ability, Speed of Walking and Cardiopulmonary Fitness for Patient With Chronic Stroke||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|February 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|60 Years|65 Years|No|||February 2015|November 29, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02619110||7780|
NCT02563015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-15-01|Can Correction of Low Vitamin D Status in Infancy Program for a Leaner Body Composition?|Novel Functional Outcomes of Vitamin D in Infancy; Can Correction of Low Vitamin D Status Program for a Leaner Body Composition Phenotype?||McGill University|No|Recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|222|||Both|N/A|1 Week|Accepts Healthy Volunteers|||February 2016|February 25, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02563015||12086|
NCT02621034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRH-1|Comparative Evaluation of Post-endodontic Pain Using Two Rotary Instrumentation Systems|Comparative Evaluation of Post-endodontic Pain Using Two Rotary Instrumentation Systems: Reciproc & One Shape||Zahedan University of Medical Sciences|Yes|Completed|June 2015|March 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2015|March 11, 2016|November 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621034||7632|
NCT02621047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP29783|The Study of Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib|The Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib: A Multi-center, Open-label Study Following Single Oral Dosing of Alectinib to Subjects With Hepatic Impairment and Matched Healthy Subjects With Normal Hepatic Function.||Hoffmann-La Roche||Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621047||7631|
NCT02620618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intravitreal Infliximab|Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study|Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study||Cairo University|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||December 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02620618||7664|
NCT02627274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29842|A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors|||Hoffmann-La Roche||Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02627274||7152|
NCT02625519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER-FSH-2015-01|Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial)|Prospective, Randomized Open Trial to Evaluate the Efficacy of Highly Purified Urinary FSH Versus Recombinant FSH in Oocyte Donors Undergoing Controlled Ovarian Stimulation Based on Receptor N680S FSH Gene Polymorphism. Genodon Trial|GENODON|Instituto Bernabeu|Yes|Recruiting|December 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 13, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02625519||7287|
NCT02616575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502062RINB|The Application of Smart Health Management System on Home-Care for Elderly Patients|The Application of Smart Health Management System on Home-Care for Elderly Patients||National Taiwan University Hospital|No|Not yet recruiting|December 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|60 Years|N/A|No|Non-Probability Sample|aged 60 or older, living alone or with a companion (not children), taking at least one        chronic medications, having the capability to understand the study and complete the study,        willing to participate into the study with telephone follow ups.|November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616575||7974|
NCT02545335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-neutrophil|Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C|Neutrophil Function During Combination Therapy With Protease Inhibitors in Chronic Hepatitis C||Medical University of Graz|No|Recruiting|November 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Serum Plasma|Both|18 Years|99 Years|No|Probability Sample|patients with chronic hepatitis C undergoing antiviral therapy|February 2016|February 25, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02545335||13445|
NCT02603120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-380-1844|Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to GS-9883/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed||Gilead Sciences|Yes|Recruiting|November 2015|April 2019|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603120||9005|
NCT02603185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemay007 Australian 001|PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Hemay007||Hemay Pharmaceutical PTY. LTD.|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02603185||9000|
NCT02608749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201402022RINB|Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area|Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area||National Taiwan University Hospital|Yes|Completed|May 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|151|||Both|50 Years|N/A|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608749||8575|
NCT02610309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00000105|Family-based Crisis Intervention With Suicidal Adolescents in the ED|Family-based Crisis Intervention With Suicidal Adolescents in the Emergency Department: A Randomized Clinical Trial|FBCI|Children's Hospital Boston|Yes|Completed|January 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|143|||Both|13 Years|18 Years|No|||November 2015|November 18, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610309||8455|
NCT02549573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-AP1-4002|Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®|Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an "On" Versus "End-of-Dose-Off" Motor State|PERFORM|US WorldMeds LLC|No|Recruiting|November 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|78 Years|No|||March 2016|March 3, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02549573||13119|
NCT02603796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D Imaging in neonates|3D Imaging of Neonatal Faces|3D Imaging of Neonatal Subjects||Sharp HealthCare|No|Recruiting|October 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|24 Weeks|42 Weeks|No|Non-Probability Sample|Infants between 24 and 42 weeks corrected gestational age and admitted to Sharp Mary Birch        NICU.|November 2015|November 12, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02603796||8954|
NCT02595294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE0072015-2|Hypoalgesic Effect of Neural Mobilization|Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group||Universidad Europea de Madrid|Yes|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|45 Years|No|||November 2015|November 2, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02595294||9606|
NCT02594826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-804|Cervical Cancer Screening Intervention Among Korean American Women|Facilitating Cervical Cancer Screening Among Underserved Korean American Women||Fox Chase Cancer Center|No|Completed|February 2009|December 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|744|||Female|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594826||9642|
NCT02608567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EACVI-001|Prognostic Impact of Myocardial Longitudinal Strain in Asymptomatic Aortic Stenosis: a Meta-Analysis|Prognostic Impact of Myocardial Longitudinal Strain in Asymptomatic Aortic Stenosis: a Meta-Analysis||European Association of Cardiovascular Imaging|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Asymptomatic patients with at least moderate aortic stenosis (mean pressure gradient        >25mmHg or aortic valve area <1.5cm²) and left ventricular ejection fraction >50%.|November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02608567||8589|
NCT02622204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-224|The Effect of High Tibial Osteotomy on in Vivo Cartilage Mechanobiology in Patients With Knee Osteoarthritis|The Effect of High Tibial Osteotomy on in Vivo Cartilage Mechanobiology in Patients With Knee Osteoarthritis: Cross-sectional Observational Single-centre Study|Osteotomy|University Hospital, Basel, Switzerland|No|Recruiting|December 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|serum, synovium biopsies|Both|18 Years|70 Years|No|Non-Probability Sample|patients with knee osteoarthritis scheduled for high tibial osteotomy|December 2015|December 10, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622204||7542|
NCT02617745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 15.02|Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid|Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma|GLIOPLAK|Centre Henri Becquerel|No|Recruiting|November 2015|May 2020|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02617745||7884|
NCT02612948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3709|Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients|Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients||University of Tennessee Graduate School of Medicine|No|Completed|November 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 21, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612948||8253|
NCT02625701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGeneve - NAC09-022|Perioperative Fluid Management: Goal-directed Versus Restrictive Strategy|Perioperative Fluid Management: Goal-Directed Therapy vs. Restrictive Approach, a Randomized Controlled Trial||University Hospital, Geneva|No|Recruiting|January 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT02625701||7273|
NCT02623153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zswy003|Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer|Phase 2 Study of Comparison Between XELOX (Capecitabine and Oxaliplatin) and Docetaxel, Oxaliplatin and S1 Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer||Shanghai Zhongshan Hospital|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623153||7469|
NCT02613442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 749-15-FB|Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis|Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis||University of Nebraska|No|Not yet recruiting|April 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|19 Years|90 Years|No|Non-Probability Sample|Prospective subjects will be identified from the patient population pool in the Uveitis        Clinic at the Truhlsen Eye Institute, University of Nebraska Medical Center, Department of        Ophthalmology and Visual Sciences.|February 2016|February 25, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02613442||8215|
NCT02617979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511067|Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement|Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement||Washington University School of Medicine|No|Not yet recruiting|January 2016|June 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|225|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02617979||7867|
NCT02626793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PPSO-002|A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions|Long-term Documentation of the Utilization of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)||Celgene|No|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 500 patients with moderate to severe plaque psoriasis are planned to be        enrolled in this NIS. In- and exclusion criteria are derived from the Summary of product        characteristics (SmPC) of Apremilast.|January 2016|January 19, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02626793||7189|
NCT02613845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PODCAS|Predictors for Postoperative Delirium After Cardiac Surgery With Extracorporeal Circulation in Adults: a One-year, Single Center, Observational Cohort Study|Predictors for Postoperative Delirium After Cardiac Surgery With Extracorporeal Circulation in Adults: a One-year, Single Center, Observational Cohort Study|PODCAS|University Hospital, Basel, Switzerland|No|Active, not recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Both|16 Years|N/A|No|Probability Sample|Study subjects are all patients that underwent cardiac surgery with extracorporeal        circulation at the University Hospital Basel during the year 2013. Patients are identified        by screening of the list of operative procedures this year, made available by the        Department of Cardiac Surgery at the University Hospital Basel.|November 2015|November 22, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613845||8184|
NCT02613858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIDI038|Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan||Preempt|Abbott|No|Not yet recruiting|April 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|18 Years|65 Years|No|Non-Probability Sample|Primary Care Clinic/Private Clinic|March 2016|March 22, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02613858||8183|
NCT02613364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC14040|Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors|A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors|YOCAS-II|University of Rochester|Yes|Not yet recruiting|May 2016|June 2021|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|630|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613364||8221|
NCT02618486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101269-1|The Effects of Obesity on Non Surgical Periodontal Therapy|The Effects of Obesity on Non Surgical Periodontal Therapy|EONSPT|University of Malaya|Yes|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02618486||7828|
NCT02618967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140322|Single Ascending Dose Study of AMG 570 in Healthy Subjects|A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects||Amgen|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618967||7791|
NCT02612961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054395|Normal Saline Use With Suctioning|Normal Saline Use With Suctioning: A Randomized-Controlled Trial - Pilot Study||Johns Hopkins University|Yes|Recruiting|January 2016|December 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|100 Years|No|||February 2016|February 19, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612961||8252|
NCT02612974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/AD/JH/058|Clinical Evaluation of Leech Therapy in the Treatment of Knee Osteoarthritis|Randomized Controlled Clinical Evaluation of Leech Therapy in the Treatment of Knee Osteoarthritis|Leech Therapy|Hamdard University|No|Completed|January 2010|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|70 Years|No|||November 2015|November 23, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612974||8251|
NCT02624869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120124|Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).|Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)|HAUSER-OLE|Amgen|Yes|Not yet recruiting|June 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|10 Years|17 Years|No|||February 2016|February 29, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624869||7337|
NCT02621372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|non invasive diagnosis of EV|Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis|Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis||Tanta University|Yes|Recruiting|January 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|A total of 110 cirrhotic patients were included|November 2015|December 1, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02621372||7606|
NCT02621385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VLY-686-1102|Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects|An Open-label, Single-sequence Study to Assess the Effect of Multiple Doses of Tradipitant on Cytochrome P450 3A4 Using Midazolam as a Substrate in Healthy Subjects.||Vanda Pharmaceuticals|No|Recruiting|November 2015|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621385||7605|
NCT02625051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR15-17595|Quality of Life in Kidney Stone Patients Undergoing Surgery|Randomized Controlled Clinical Trial Comparing Ureteroscopic to Percutaneous Removal for the 1-2 cm Calculus Measuring Quality of Life as the Primary Outcome||University of California, San Francisco|No|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625051||7323|
NCT02625064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151030|Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome|Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome|ARDS|Xiangya Hospital of Central South University|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|Samples With DNA|blood|Both|18 Years|N/A|No|Probability Sample|patients at High risk for Extra-pulmonary ARDS and pulmonary ARDS; patients who have ARDS|December 2015|December 5, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02625064||7322|
NCT02571127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hidra 1|Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.|Ph IV , Longitudinal, Prospective, Open Label, Non-comparative, to Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.||Farmoquimica S.A.|Yes|Not yet recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|40 Years|N/A|No|||September 2015|October 6, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02571127||11463|
NCT02626676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USAoPaulo EPIC|Educational Programme Impact on Serum Phosphate Control|Nutrition Educational Programme Impact on Serum Phosphate Control|EPIC|University of Sao Paulo|Yes|Recruiting|November 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|180|||Both|18 Years|100 Years|No|||December 2015|December 9, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02626676||7198|
NCT02625259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1117-1002|A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Participants|A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects||Millennium Pharmaceuticals, Inc.|No|Not yet recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625259||7307|
NCT02618577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAH - AFNET 6|Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes|Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET|NOAH|German Atrial Fibrillation Network|Yes|Not yet recruiting|February 2016|September 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|3400|||Both|65 Years|N/A|No|||November 2015|November 27, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618577||7821|
NCT02617654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1166-6923|Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes|A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients||Uppsala University Hospital|No|Recruiting|November 2015|||September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|30 Years|No|||November 2015|November 25, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02617654||7891|
NCT02621671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501028|Communicating Multiple Disease Risks|Communicating Multiple Disease Risks: A Translation of Risk Prediction Science||Washington University School of Medicine|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1171|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02621671||7583|
NCT02618993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9560|Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy|Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study||University Hospital, Montpellier|No|Not yet recruiting|December 2015|June 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|70 Years|No|||November 2015|December 2, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02618993||7789|
NCT02619305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096620-S5|Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda|Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda: Randomized Controlled Trial||Massachusetts General Hospital|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02619305||7765|
NCT02624609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEEC 12-037 (amended)|Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo|Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo||University of Leeds|Yes|Recruiting|November 2015|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624609||7357|
NCT02624674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-249c|Multi-spectral Imaging to Assess Wounds in Peripheral Vascular Disease Patients|Multi-spectral Imaging to Assess Wounds in Peripheral Vascular Disease Patients||St. Michael's Hospital, Toronto|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624674||7352|
NCT02613624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1913/REK vest|Formative Research to Develop an Intervention Package to Promote Practice of Kangaroo Mother Care for Low Birth Weight and Preterm Infants in a Community (CKMC)|Formative Research to Develop an Intervention Package for Promotion of Kangaroo Mother Care for Low Birth Weight and Preterm Infants in a Community: In Preparation for a Randomized Controlled Trial to Examine Impact of Community Kangaroo Mother Care on Neonatal and Early Infant Mortality|CKMC|Society for Applied Studies|No|Completed|April 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|28|||Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Rural and semi urban population of two primary health centre areas in two districts of the        state of Haryana, India.|January 2016|January 11, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02613624||8201|
NCT02617914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-122|Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients|Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients|ENCODE|RWTH Aachen University|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients referred to our ICU (Criitical Care Unit) for treatment of ARDS of any        cause with a P/F ratio < 150 and indication for continued maximum critical care therapy.        Patients of childbearing age with ARDS will be included.|November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617914||7872|
NCT02614755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL004|An Observational Study of Lumosity in Seniors|An Observational Study of Lumosity in Seniors||Lumos Labs, Inc.|No|Recruiting|November 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants must be cognitively stable older adult volunteers(over 55 years of age)|November 2015|November 23, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02614755||8114|
NCT02620657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11224|Evaluate EGFR Mutation Status and Impact Factors in North China|A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China||Guangdong Association of Clinical Trials|No|Active, not recruiting|December 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|3000 advanced NSCLC patients|December 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620657||7661|
NCT02568722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARRT-AKI: Principal Trial|Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)|STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)||St. Michael's Hospital, Toronto|Yes|Recruiting|October 2015|December 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2866|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02568722||11648|
NCT02568735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH30062008|Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty|The Central Nervous Penetration of Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Reaction in Patients Undergoing Hip Arthroplasty|etoketo|Kuopio University Hospital|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|75 Years|No|||September 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02568735||11647|
NCT02615548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01772|Exercise for Adults With Parkinson Disease|Investigating the Effect of Specific, Long- Term, Community-based Exercises on Walking, Balance, and Quality of Life in Adults With Parkinson Disease.||University of British Columbia|Yes|Not yet recruiting|January 2016|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|45 Years|80 Years|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615548||8053|
NCT02613234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128EEG|Efficacy of 128-channel EEG Combined With BESA Dipole Localization and Intervention on Brain Waves for Epilepsy|Efficacy of 128-channel Electroencephalograph Combined With BESA Dipole Localization Method and Intervention on Brain Waves for Epilepsy: A Single-blinded Randomized Controlled and Open-label Extension Trial||Shanghai Zhongshan Hospital|No|Recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02613234||8231|
NCT02611479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49612-A|Understanding Non-Response in Spine Fusion Surgery|Understanding Non-Response in Spine Fusion Surgery||University of Washington|No|Not yet recruiting|July 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (18 and over) undergoing spine fusion surgery in Washington State.|November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611479||8366|
NCT02611492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM12629_1|A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults|A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)|GRAAPH2014|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|December 2025|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|265|||Both|18 Years|59 Years|No|||November 2015|November 25, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611492||8365|
NCT02611752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-478|A Multiple Dose Opioid Challenge Study|A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder||Braeburn Pharmaceuticals|No|Enrolling by invitation|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|48|||Both|18 Years|55 Years|No|||March 2016|March 9, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611752||8345|
NCT02568969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-1|Lactate in High-risk Cardiac Surgery|Continuous Monitoring of Lactate in High-risk Cardiac Surgery|CLM-CARD|Northern State Medical University|No|Completed|March 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02568969||11629|
NCT02619812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006205|Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT|A Randomized, Placebo-Controlled, Pilot Study of Colesevelam and Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Diarrhea in Patients With Multiple Myeloma Receiving Conditioning Chemotherapy for Autologous Stem Cell Transplantation (SCT)||Mayo Clinic|No|Not yet recruiting|December 2015|August 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02619812||7726|
NCT02613481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YDA-001|The Emotional and Functional Benefits of Poly-L-Lactic Acid|The Emotional and Functional Benefits of Poly-L-Lactic Acid||Yardley Dermatology Associates|No|Not yet recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613481||8212|
NCT02622438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9371|Routine Health Care of Patients With FSHD|Course and Follow up of Patients Affected by Facioscapulohumeral Dystrophy|FSHD|University Hospital, Montpellier|No|Recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|7 Years|N/A|No|||December 2015|December 2, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622438||7524|
NCT02622646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUF-OCT-2015-01|Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients|Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients||Hospital Universitario La Fe|No|Not yet recruiting|May 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|FVIII is measured by the one-stage assay in a central laboratory in complete blood samples|Both|12 Years|N/A|No|Probability Sample|Haemophilia A severe (FVIII < 1 IU/dL) or moderate (FVIII 1 ≤5 IU/dL) in adult or        adolescent patients in prophylactic treatment with Advate®.|December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622646||7508|
NCT02569190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-008-002|Effect of Robot-assisted Gait Training on Brain Reorganization in Hemiplegic Patients|Effect of Robot-assisted Gait Training on Brain Reorganization in Hemiplegic Patients||Veterans Health Service Medical Center, Seoul, Korea|Yes|Recruiting|June 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||October 2015|October 4, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02569190||11612|
NCT02569203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT_ICU_immune|Effect of Immune-enhancing Enteral Nutrition on Immunomodulation in Critically Ill Patients|Effects of Enteral Formula Including Immune-modulating Nutrients on Clinical Course and Immune Function in Critically Ill Patients||Yonsei University|No|Completed|April 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|30|||Both|N/A|N/A|No|||October 2015|October 5, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02569203||11611|
NCT02620046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002SC-3030|Vedolizumab Subcutaneous Long-Term Open-Label Extension Study|A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease||Takeda|Yes|Not yet recruiting|April 2016|February 2022|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|692|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620046||7708|
NCT02623998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMIT-Sita|Remission Evaluation of Metabolic Interventions in Type 2 Diabetes With Sitagliptin (REMIT-Sita)|An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes||Population Health Research Institute|No|Not yet recruiting|December 2015|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|80 Years|No|||December 2015|December 4, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02623998||7404|
NCT02625103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-MEAS|The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.|The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring||Psychiatric Centre Rigshospitalet|Yes|Completed|September 2015|February 2016|Actual|December 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|48|||Both|18 Years|64 Years|No|||February 2016|February 24, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02625103||7319|
NCT02619500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033-16|Thrust Manipulation vs. Non-thrust Mobilizations for Mechanical Neck Pain|A Pragmatically Applied Cervical and Thoracic Non-thrust Mobilizations Versus Thrust Manipulation for Patients With Mechanical Neck Pain: A Multicenter Randomized Clinical Trial||Youngstown State University|No|Recruiting|February 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02619500||7750|
NCT02621164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP607-QIV_FluC_III_2014|Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children and Adolescents Aged 6 Months ~ 18 Years||SK Chemicals Co.,Ltd.|Yes|Completed|September 2014|June 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|454|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02621164||7622|
NCT02626169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33860|The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation|The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation||Baylor College of Medicine|No|Recruiting|December 2015|July 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 9, 2015|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626169||7237|
NCT02626182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NationalJewishHealth|Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF|Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease||National Jewish Health|Yes|Recruiting|December 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626182||7236|
NCT02612025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mucki01|Effects of Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase|Effects of Combined Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase|MUCKI|Johannes Gutenberg University Mainz||Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|4 Years|18 Years|No|||February 2016|February 26, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612025||8324|
NCT02615795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAarhusFA|Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease|Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease. A Clinical, Randomized, Controlled Study for Evaluation of Clinical and Economic Consequences of Monitoring Service||University of Aarhus|Yes|Recruiting|March 2011|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|40 Years|N/A|No|||October 2010|November 23, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02615795||8034|
NCT02620553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1043|Primary Intervention With Mucosal Insulin|Primary Intervention With Mucosal Insulin for Prevention of Type 1 Diabetes in Infants at High Genetic Risk to Develop Diabetes POINT (Primary Oral Insulin Trial) A Dose Finding and Safety Study ( Pre-POINT )|Pre-POINT|University of Colorado, Denver|Yes|Completed|September 2007|January 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|25|||Both|2 Years|7 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620553||7669|
NCT02618031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS Trial|The Capillary Index Score Trial|The Capillary Index Score Trial: Phase I||Akron General Medical Center|Yes|Enrolling by invitation|March 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|54|||Both|18 Years|N/A|No|Non-Probability Sample|The population for the study will consist of patients from multiple stroke centers across        the United States, who have anterior circulation acute ischemic stroke due to blockage of        the intracranial internal carotid artery or middle cerebral artery (M1) within 8 hours of        onset of symptoms.|March 2016|March 14, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02618031||7863|
NCT02617368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304/23/11/2015|Fourier Transform of Videokeratography Data: Clinical Usefulness in Moderate and Frome Fruste Keratoconus|Fourier Transform of Videokeratography Data: Clinical Usefulness in Moderate and Frome Fruste Keratoconus|FFTKC|Democritus University of Thrace||Completed|November 2014|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|185|||Both|8 Years|N/A|No|Non-Probability Sample|All participants were recruited from the Outpatients Cornea service, in a consecutive if        eligible basis|November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617368||7913|
NCT02562781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ÖrebroU|Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?|Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery|HYPEROXIA|Örebro University, Sweden|Yes|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|184|||Both|65 Years|N/A|No|||September 2015|September 28, 2015|November 15, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02562781||12104|
NCT02612155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066647|A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy|A Phase II Multi-site Study of Autologous Cord Blood Cells for Hypoxic (HIE)|(HIE)|Duke University|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|6 Hours|No|||November 2015|November 20, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612155||8314|
NCT02616445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACW0001|Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects|A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects||Actinogen Medical|No|Completed|February 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02616445||7984|
NCT02619123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2009-1493239|Tailored Screening for Breast Cancer in Premenopausal Women|Tailored Screening for Breast Cancer in Premenopausal Women. A Translational, Randomized Population-based Trial|TBST|Cancer Prevention and Research Institute, Italy|No|Recruiting|January 2013|January 2022|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|33200|||Female|44 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02619123||7779|
NCT02621645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58224|Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence|Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy|TRAPIST|Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|January 2016|June 2022|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|N/A|No|||October 2015|December 23, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02621645||7585|
NCT02623673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retina CLINIC|Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema|Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema||Retina Clinic, Sao Paulo, Brazil|Yes|Completed|September 2015|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with macular edema|February 2016|February 14, 2016|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623673||7429|
NCT02627300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCGAM-03|Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial|Clinical Phase III Study to Monitor the Safety, Tolerability and Efficacy of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial||Octapharma|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||December 2015|December 8, 2015|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627300||7150|
NCT02612779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-142|A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide|A Phase 2 Single Arm Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide||Bristol-Myers Squibb|No|Recruiting|November 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612779||8266|
NCT02620514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075262|Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)|Assessment of Health Literacy, Medication Adherence, and a Pilot Multi-component Intervention to Improve Medication Adherence in Patients With Inflammatory Bowel Disease||Emory University|No|Recruiting|June 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|155|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620514||7672|
NCT02549326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295/13/03/03/2012|Vitamin D Intervention in Young Adults With Severe Childhood-onset Obesity|Vitamin D Intervention in Young Adults With Severe Childhood-onset Obesity||Helsinki University Central Hospital|No|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|42|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 9, 2015||||No||https://clinicaltrials.gov/show/NCT02549326||13138|
NCT02607319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmericanUBMCRIF|Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure|Effect of Low Molecular Weight Heparin (Bemiparin) on Implantation Rate in Patients With Recurrent Implantation Failure Undergoing IVF/ICSI - A Prospective Randomized Clinical Trial|BRIF|American University of Beirut Medical Center|No|Recruiting|November 2015|July 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|38 Years|No|||November 2015|November 16, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02607319||8685|
NCT02596763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_45|Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder|Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study|BACLOPHONE|University Hospital, Lille|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|792|||Both|18 Years|80 Years|No|||November 2015|November 3, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596763||9493|
NCT02603809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-080A201|Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension|Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)||Actelion|Yes|Recruiting|December 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|540|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603809||8953|
NCT02606006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-95|Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs|Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs||Aurora Health Care|No|Recruiting|November 2015|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606006||8784|
NCT02600338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Legumes & BP 2014|Meta-analyses of the Effect of Legumes on Blood Pressure|Effect of Legumes on Blood Pressure in Humans: A Systematic Review and Meta-analysis of Randomized Controlled Trials||University of Toronto|No|Active, not recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|Varied|November 2015|November 6, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02600338||9218|
NCT02598843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS ID 89061|Standard Non Operative Treatment Versus Accelerated Rehabilitation of Achilles Tendon Ruptures|Functional Outcomes After Conservative Management of the Acutely Ruptured Achilles Tendon in the Under 60 Age Group. A Randomised Controlled Trial Comparing Standard Conservative Management With Accelerated Rehabilitation Using a Moon Boot||NHS Lothian|Yes|Recruiting|November 2013|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|16 Years|60 Years|No|||November 2015|November 4, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02598843||9333|
NCT02620670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAFVG|Evaluation of the Effect of Moderate-intensity Physical Activity on Glycemic Variability|Evaluation of the Effect of Moderate-intensity Physical Activity on Glycemic Variability in Individuals With Visceral Obesity and Normal Weight Without Changes in Glucose Tolerance||University of Guadalajara|No|Recruiting|April 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|22|||Both|30 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02620670||7660|
NCT02612818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDHY|Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year|Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year|ENDHY|Nordic Pharma SAS|No|Recruiting|October 2015|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|N/A|No|Non-Probability Sample|Subsequent patients of procreation age having undergone a cœlioscopy for endometriosis,        for whom a spontaneous pregnancy is possible, whether or not they wish to become pregnant        immediately, and meeting all of the selection criteria will be included in the study.|October 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02612818||8263|
NCT02622308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1318|The Effects of Intermittent Negative Pressure on Peripheral Circulation in Dialysis Patients and Patients With Lower Limb Ischemia and Leg Ulcers|||Oslo University Hospital||Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|96 Years|No|||March 2016|March 3, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622308||7534|
NCT02622321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH29884|A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients With Inhibitors|||Hoffmann-La Roche||Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|12 Years|N/A|No|||March 2016|March 1, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622321||7533|
NCT02617563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-01|A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|MASTERS-D2|Medtronic Spinal and Biologics|No|Recruiting|December 2015|November 2022|Anticipated|August 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|560|||Both|18 Years|N/A|No|Probability Sample|Approximately 560 patients suffering from lumbar degenerative disc disease (DDD) will be        enrolled over a period of 12 to 18 months in (not limited to) 38 sites located in Europe,        Middle East, Canada, Latin America and Asia Pacific|February 2016|February 3, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02617563|5 Years|7898|
NCT02613598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2014.066|Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma|Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma||University of Michigan Cancer Center|Yes|Not yet recruiting|December 2015|||October 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613598||8203|
NCT02613611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obgyn.. .. ..|HPV Screening (Human Papilloma Virus)|Screening for Human Papilloma Virus in Urine and Pap Smear.A Comparative Study.|HPV|Kasr El Aini Hospital|No|Not yet recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|45 Years|No|Probability Sample|500 females attending colposcopy kasrelaini unit aging 18_45 years|November 2015|November 21, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02613611||8202|
NCT02612831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14APN01|Bariatric Surgery for Obese Patients With Chronic Renal Insufficiency|Bariatric Surgery for Obese Patients With Chronic Renal Insufficiency|BOKID|Centre Hospitalier Universitaire de Nice|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|84|||Both|18 Years|75 Years|No|||November 2015|November 23, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612831||8262|
NCT02612844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1406-4209|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|55 Years|No|||November 2015|November 30, 2015|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612844||8261|
NCT02618239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)296/2013|Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms|Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|November 2013|May 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02618239||7847|
NCT02617680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201404515P|Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia|Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia||University Hospital Hradec Kralove|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|78 Years|No|||November 2015|November 26, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02617680||7889|
NCT02622776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-10795|Advanced Methods for Cancer Detection by Vaginal Screening|Advanced Methods for Cancer Detection by Vaginal Screening (ADVISE): A Pilot Study of Using Vaginal Cell Sampling for Ovarian or Endometrial Cancer Detection|ADVISE|British Columbia Cancer Agency|No|Not yet recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|120|||Female|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622776||7498|
NCT02617589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-498|Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)|A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)|CheckMate 498|Bristol-Myers Squibb|Yes|Recruiting|February 2016|October 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617589||7896|
NCT02617810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108066|A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants|An Open-Label Drug Interaction Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on the Single-Dose Pharmacokinetics of Midazolam and the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02617810||7879|
NCT02626520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC-1|Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla|Phase 2 Evaluation of a Community-Based Multi-modality Management Algorithm for Clinically Non-metastatic Ductal Adenocarcinoma of the Exocrine Pancreas or Ampulla||Essentia Health|No|Recruiting|January 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|37|||Both|18 Years|85 Years|No|||January 2016|January 20, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626520||7210|
NCT02625844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25720|Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia|Croatian Time and Motion Survey for Anaemia Management With Erythropoietin Stimulating Agents in Haemodialysis Units||Hoffmann-La Roche||Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Health care personnel providing care for patients with renal anemia on monopegylated        epoetin beta or other erythropoiesis stimulating agents (ESAs)|February 2016|February 4, 2016|December 7, 2015|No|Yes||No|February 4, 2016|https://clinicaltrials.gov/show/NCT02625844||7262|
NCT02613936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM HRRC #15-124|Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury|Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury||University of New Mexico|Yes|Recruiting|September 2015|September 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|No|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613936||8177|
NCT02620579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500556|Biopsychosocial Influence on Shoulder Pain|Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial|BISP|University of Florida|No|Not yet recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|448|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620579||7667|
NCT02626481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015_29|Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma|A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib and Lenalidomide and Pomalidomide - an IFM 2014-04 Study|IFM2014-04|University Hospital, Lille|Yes|Recruiting|December 2015|January 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02626481||7213|
NCT02614911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIS2014-01|Characterization of Phenotype and Genotype of Early Onset Enteropathies|Host-Microbiota Interactions Across the Gut Immune System: Characterization of Phenotype and Genotype of Early Onset Enteropathies|IMMUNOBIOTA|Imagine Institute|No|Recruiting|June 2014|June 2029|Anticipated|June 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|346|Samples With DNA|Collection of:        -  blood samples        -  feces        -  biopsies (intestine / skin)        -  saliva        -  urina|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Inclusion of patients with chronic severe entheropathy and of their healthy relatives|November 2015|December 1, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02614911||8102|
NCT02614924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD098211|Comparison of Flexible Fibreoptic Scope With Pentax AWS Videolaryngoscope for Ease of Intubation During Awake Intubation|Comparison of Flexible Fibreoptic Scope With Pentax AWS Videolaryngoscope for Ease of Intubation During Awake Intubation||University Hospitals Coventry and Warwickshire NHS Trust|No|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02614924||8101|
NCT02573818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SED-14-001|Sedasys Post Approval Study Users Response to System Alarms|Open-Label Post Approval Study of the SEDASYS System User Response to System Alarms||Ethicon Endo-Surgery||Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|866|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female subjects 18 years or older scheduled for colonoscopy or EGD|October 2015|October 9, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573818||11256|
NCT02573831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH12012015|The Effect of Oxycodone to the Placental Circulation at Early Labour|The Effect of Oxycodone to the Placental Circulation at Early Labour|oksisynnII|Kuopio University Hospital|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|65 Years|No|||October 2015|October 12, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573831||11255|
NCT02614768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIDIMAN_01|Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions|Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions||Medical University of Graz|No|Completed|July 2015|September 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02614768||8113|
NCT02626416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China10|Monitoring of Visual Axis Opacification Under Non-clinical Settings|Self-monitoring of Visual Axis Opacification (VAO) Under Non-clinical Settings in China||Sun Yat-sen University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|N/A|18 Years|No|||December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626416||7218|
NCT02626130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0539|Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)|A Pilot Study of Presurgical Tremelimumab With or Without Tissue Cryoablation in Patients With Metastatic Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626130||7240|
NCT02626143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6029|Effect of Feeding Mode on Infant Growth and Cognitive Function|Effect of Feeding Mode on Infant Growth and Cognitive Function||Mead Johnson Nutrition|No|Not yet recruiting|December 2015|August 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|540|||Both|N/A|120 Days|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626143||7239|
NCT02626065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.884|Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies|Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies|PAIR|Hospices Civils de Lyon|No|Recruiting|March 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626065||7245|
NCT02623309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPLOMUDELDERLY-IPC 2015-004|Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients|||Institut Paoli-Calmettes|Yes|Recruiting|February 2016|February 2021|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|55 Years|70 Years|No|||February 2016|March 4, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623309||7457|
NCT02623322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29893|A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults||Genentech, Inc.||Not yet recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|141|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623322||7456|
NCT02614378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-20151104001|Abortive Effect of an Ear Insufflator on Migraine|Abortive Effect of an Ear Insufflator on Migraine||Carrick Institute for Graduate Studies|No|Recruiting|November 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 18, 2016|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02614378||8143|
NCT02614391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 38/12|Tablet Distraction for Pain Control During Venipuncture|Randomized Controlled Trial to Evaluate Tablet Distraction for Pain Control in Children Underwent Venipuncture||IRCCS Burlo Garofolo|No|Completed|March 2013|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|4 Years|13 Years|No|||November 2015|November 27, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614391||8142|
NCT02626221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EVE01|A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)|A Prospective Non-interventional Study to Collect Real Life Clinical Data on the Impact of Therapy, the Diagnosis and Management of Chronic Urticaria in Patients Refractory to at Least One Course of H1 Antihistamine Therapy|AWARE-LACan|Novartis|No|Recruiting|December 2014|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible Latin American Chronic Urticaria adult patients, males and females, with at least        one course of H1 antihistamines and is shown to be refractory to this treatment|December 2015|December 15, 2015|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02626221|24 Months|7233|
NCT02619799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rangaraya medical college|A Comparative Study of Intrathecal Magnesium Sulphate & Midazolam With Epidural Ropivacaine for Caesarean Patients|A Comparative Study Between Intrathecal Magnesium Sulphate Versus Midazolam Along With Epidural 0.75% Ropivacaine in Combined Spinal Epidural Technique for Preeclampsia Parturients Undergiong Elective Caesarean Section||Rangaraya Medical College|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|28 Years|Accepts Healthy Volunteers|||November 2015|February 12, 2016|November 19, 2015|Yes|Yes||No|January 8, 2016|https://clinicaltrials.gov/show/NCT02619799||7727|
NCT02616679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00706|Cognitive Detection of Preclinical AD: Validation Using Biomarkers|Cognitive Detection of Preclinical AD: Validation Using Biomarkers||New York University School of Medicine|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|Samples With DNA|Any remaining blood specimens will be retained indefinitely for future use by the Center for      Cognitive Neurology (CCN) at NYU Langone Medical Center. Some samples may also be sent to      Janssen Research & Development, LLC for potential future research use. Potential future      research use by study investigators or collaborators will include possible discovery of      novel biomarkers associated with increased AD risk, and study of validity of the use of such      markers in preclinical AD. True genetic testing will not be done on these samples.      Subjects may decline to have their samples stored for future use by checking the applicable      box on the informed consent form. Subjects who agreed to have their samples stored for      future use may revoke this permission.|Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be elderly individuals who are participating in ongoing clinical        research at the NYU CCN, including at the ADC and the Center for Brain Health (CBH).        Participants may also be recruited through community outreach or referrals from other        centers. Cognitively normal (CN) participants and participants with amnestic mild        cognitive impairment (aMCI) will be enrolled.|January 2016|January 22, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616679||7966|
NCT02616692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18234|HCC Patient Preferences in Japan|Patient Preferences for Treatments for Hepatocellular Cancer (HCC) in Japan||Bayer|No|Not yet recruiting|May 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with hepatocellular cancer (HCC)|March 2016|March 9, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02616692||7965|
NCT02624973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/8463|PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial|PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial|PETREMAC|Haukeland University Hospital|Yes|Not yet recruiting|January 2016|June 2030|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624973||7329|
NCT02571647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0219|Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory|Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory|EVAM|Nantes University Hospital|No|Recruiting|January 2016|July 2017|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|65 Years|N/A|No|Non-Probability Sample|Patients eligible for the study will be all patients 65 and older, in consultation from        memory or day hospital Clinical Gerontology ambulatory center at Nantes University        Hospital.        Geriatrician who will see the patient Clinical Gerontology ambulatory center be informed        of the study and gather written consent and that of his legal representative, if        applicable.|March 2016|March 22, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02571647||11423|
NCT02615561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17534|Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product|Multicenter, Two-phase Exploratory Clinical Trial to Examine Efficacy and Safety After Open-label Topical Administration of a Medical Device (Bepanthen Itch Relief Cream) for Treatment of Acute Flare-ups Followed by Topical Administration of a New Cosmetic Bepanthen Product or a Cosmetic Comparator in a Parallel-group, Randomized, Investigator-blinded Care Phase for Skin Care in the Remission Phase in Infants With Mild Atopic Dermatitis||Bayer|No|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|1 Month|4 Years|No|||March 2016|March 1, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615561||8052|
NCT02616991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-002741-64|Computed Tomography CT Venography During Postpartum Venous Thromboembolism|Contribution of CT Venography for Diagnosing Venous Thromboembolism During Postpartum|CTVENPOSTPART|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Female|18 Years|N/A|No|||November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616991||7942|
NCT02617004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM12629_3|Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults|Multicenter Trial Treatment of Philadelphia Chromosome Negative (Ph-) B-lineage Acute Lymphoblastic Leukemia (ALL) of Young Adults (18-59 Years).|GRAALL-2014/B|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|leukemic cells, nucleic acids, serum|Both|18 Years|59 Years|No|Non-Probability Sample|Young Adults (age 18-59) with Philadelphia Chromosome Negative B-cell Acute Lymphoblastic        Leukemia|November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02617004||7941|
NCT02615964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1128|Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.|'Defining the Gold Standard in Diagnosis and Stratification of Raynaud's Disorder', Nova Cold Hands Raynaud's Disorder. Raynaud's Disease is a Vascular Disorder Which Results in Decreased Blood Flow to the Hands and Feet.||University of Illinois at Chicago|No|Enrolling by invitation|May 2015|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to UIC rheumatology clinic with Raynaud's disorder and scleroderma        will be asked to participate.|November 2015|November 23, 2015|July 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02615964||8021|
NCT02571855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-078-102|A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects|Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-541468: Part A: Multiple-ascending Doses in Healthy Young Adults After Morning Administration Part B: Single-ascending Doses in Healthy Elderly Subjects After Morning Administration Part C: Repeated Doses in Both Healthy Young Adults and Elderly Subjects After Evening Administration||Actelion|No|Completed|October 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|84|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02571855||11407|
NCT02623127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-15-01|A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma|A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma|KOSMIC|Seoul National University Hospital|No|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||December 2015|December 2, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02623127||7471|
NCT02617303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14/099|Prevention of Falls and Its Consequences in Elderly People|Effectiveness of an Intervention Through Physical Exercise for the Prevention of Falls and Its Consequences in Elderly People (75-89 Years) Performed in Primary Care: Study Protocol for a Randomized Controlled Trial|PRECIOSA|Jordi Gol i Gurina Foundation|Yes|Recruiting|September 2015|June 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|402|||Both|75 Years|89 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02617303||7918|
NCT02625155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens|Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE|SPHERE|InSource Diagnostics|No|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|14000|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02625155||7315|
NCT02572063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.02.NIHS|Omics4Aging: Stratification of Frailty Population|Omics4Aging: Stratification of Frailty Population Based on Nutrients Profiling and Metabolic Profiling at Baseline|ProAge|Nestlé|No|Not yet recruiting|October 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood and urine samples and feces|Both|65 Years|79 Years|No|Non-Probability Sample|50 frail elderly free living healthy individuals, males and females, age 65-79.|October 2015|October 7, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02572063||11391|
NCT02561988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLU-285-2101|Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies|A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies||Blueprint Medicines Corporation|No|Recruiting|December 2015|May 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561988||12165|
NCT02623192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 15-098|Respiratory Mechanics Registry for ARDS Patients|Respiratory Mechanics in Acute Respiratory Distress Syndrome: A Quality Improvement-based Registry||St. Michael's Hospital, Toronto|Yes|Recruiting|August 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|All patients who have performed the ARDS pulmonary function test will be eligible for the        registry. The clinical team discuss on a case-by-case basis to determine whether an ARDS        patient is appropriate to received the ARDS pulmonary function test (systematic assessment        of respiratory mechanics in the QI portion)|December 2015|December 2, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623192|3 Months|7466|
NCT02615132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150784-01H|TeleRehab for Stroke Patients Using Mobile Technology|TeleRehab for Patients With Post-Stroke Communication Deficits Using Mobile Technology||Ottawa Hospital Research Institute|No|Not yet recruiting|December 2015|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02615132||8085|
NCT02611778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYB201-C2015-01-P3|Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration|Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration|COLUMBUS-AMD|Bioeq GmbH||Recruiting|February 2016|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|50 Years|N/A|No|||March 2016|March 6, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611778||8343|
NCT02611791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1148-8313|Radiofrequency Female External Genital Region: a Clinical Trial|||Centro de Atenção ao Assoalho Pélvico|No|Completed|October 2012|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02611791||8342|
NCT02622217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UParis5|Impact of Sleep Deprivation on Anesthesiology Residents' Non-technical Skills: a Simulation Based Randomised Study.|Impact of Sleep Deprivation on Anesthesiology Residents' Non-technical Skills: a Simulation Based Randomised Study.||University of Paris 5 - Rene Descartes|No|Completed|January 2015|||November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02622217||7541|
NCT02622230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XinjiangUP-WY-201501|Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics of Mianhuahua Flavonoids Tablets After Oral Administration In Healthy Adult Subjects||Xinjiang Uygur Pharmaceutical Co., Ltd.|Yes|Not yet recruiting|December 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02622230||7540|
NCT02619773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-15-10-001|Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery|The Use of Mupirocin Dressings and Its Effect on Surgical Site Infections in Elective Colorectal Surgery: A Prospective, Randomized Controlled Trial||Gundersen Lutheran Medical Foundation|No|Enrolling by invitation|November 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619773||7729|
NCT02622477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML30016|Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)|Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF||Hoffmann-La Roche||Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients with diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF), who        had previously not yet been treated with Pirfenidone|December 2015|December 2, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622477||7521|
NCT02623413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTROL|Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci|Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci|CONTROL|University of Cologne|No|Enrolling by invitation|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|950|Samples Without DNA|Cultured VRE strains from rectal swabs, stool samples and infection sites.|Both|N/A|N/A|No|Non-Probability Sample|Patients treated on one of the participating wards|December 2015|December 4, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02623413||7449|
NCT02623426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119247|Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial|Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial|MERIT|JHSPH Center for Clinical Trials|Yes|Not yet recruiting|April 2016|July 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|December 4, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623426||7448|
NCT02623933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARS 222-2015|MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients|MRI Assisted Focal Boost Integrated With HDR Monotherapy Study in Low and Intermediate Risk Prostate Cancer Patients (MARS)|MARS|Sunnybrook Health Sciences Centre|No|Recruiting|September 2015|March 2021|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 3, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623933||7409|
NCT02624206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1669|Specificity of Flavor-Nutrient Learning: An fMRI Experiment|Specificity of Flavor-Nutrient Learning: An fMRI Experiment||University of North Carolina, Chapel Hill|No|Completed|August 2014|July 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|23|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||November 2015|December 7, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02624206||7388|
NCT02621502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUINOA|Quinoa Effects on Glycemic Index and Satiety|Pilot Study to Evaluate the Glycemic Index, and the Satiating Effect Using Different Quinoa Varieties in a Group of Healthy Overweight Subjects||Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|September 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02621502||7596|
NCT02616653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.251|Identification of the L3-L4 Intervertebral Space in Obese Parturients|Identification of the L3-L4 Intervertebral Space in Obese Parturients at Term in the Sitting and Lateral Positions: Manual Palpation (Tuffier's Line Method) Versus Ultrasound Imaging||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Anticipated|120|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616653||7968|
NCT02620384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.03.26.F2|MELT Heart Failure|Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.||Aultman Health Foundation|No|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620384||7682|
NCT02625454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09-06 RUMC|Reduction of Intrapartum Fever With Intravenous Acetaminophen|Randomized Control Trial of Intravenous Acetaminophen (OFIRMEV) for the Reduction of Intrapartum Maternal Fever and Fetal Tachycardia|RIFIVA|Richmond University Medical Center|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625454||7292|
NCT02611310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29618|A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)|Saudi Arabia - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer||Hoffmann-La Roche||Not yet recruiting|December 2015|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with HER2-positive unresectable LA/mBC|February 2016|February 1, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611310||8379|
NCT02611323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO29833|A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma||Hoffmann-La Roche||Recruiting|December 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611323||8378|
NCT02612389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28572|Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants|Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants|MMforFA|Dartmouth-Hitchcock Medical Center|No|Recruiting|March 2015|June 2020|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612389||8296|
NCT02611726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BnaiZionIVF|Acupuncture for Symptom Control During Assisted Reproductive Treatments Procedures|Effectiveness of Acupuncture Added to Standard Care Vs Standard Care Alone During In-Vitro-Fertilization: A Randomized Controlled Trial||Bnai Zion Medical Center|Yes|Not yet recruiting|December 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|400|||Female|20 Years|44 Years|Accepts Healthy Volunteers|||November 2015|November 22, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02611726||8347|
NCT02616809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306009298|Effects of Standing and Light-intensity Activity on Ambulatory Blood Pressure and Blood Glucose|Effects of Standing and Light-intensity Activity on Ambulatory Blood Pressure and Blood Glucose||Arizona State University|No|Completed|July 2014|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616809||7956|
NCT02622984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R42AA02203503|Remote Brief Intervention and Referrals to Treatment Service for Alcohol|Remote Brief Intervention and Referrals to Treatment Service for Alcohol|RBIRT|Polaris Health Directions|No|Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|356|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02622984||7482|
NCT02603302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Radiation Dose Escalation in Locally Advanced Rectal Cancer|Phase II Study of Neoadjuvant Radiotherapy Dose Escalation in Association With Chemotherapy for the Treatment of Locally Advanced Rectal Cancer|RaDE|University of Brasilia|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02603302||8991|
NCT02603575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingCYHRICU01|Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients|||Beijing Chao Yang Hospital||Recruiting|November 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|16 Years|N/A|No|||November 2015|November 10, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02603575||8971|
NCT02606032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 0163|Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis|Randomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative Colitis|FMT|Hamilton Health Sciences Corporation|Yes|Not yet recruiting|December 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02606032||8782|
NCT02606422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDCD R01DC014475|tDCS Intervention in Primary Progressive Aphasia|Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA)||Johns Hopkins University|Yes|Recruiting|April 2013|May 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02606422||8752|
NCT02598622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011003177|A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL|A Phase II Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL|ALC|Indiana University|Yes|Terminated|September 2009|January 2016|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|5 Years|18 Years|No|||November 2015|November 5, 2015|August 25, 2015|Yes|Yes|Drug availability|No||https://clinicaltrials.gov/show/NCT02598622||9350|
NCT02601209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01929|Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma|A Phase I/ Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma||National Cancer Institute (NCI)|Yes|Recruiting|November 2015|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||January 2016|March 21, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601209||9151|
NCT02596048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-122|A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA)|A Phase IV Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA) of the Thoraco-Abdominal Aorta, and the Carotid, Pulmonary, and Peripheral Arteries|Iomeron®-400|Bracco Diagnostics, Inc|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|November 2, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02596048||9548|
NCT02604524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18529|Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp|Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp||University of Virginia|No|Recruiting|January 2016|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|25 Years|No|||January 2016|January 5, 2016|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02604524||8898|
NCT02605109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERSKORKUH|Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)|Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea|MKU|Konkuk University Medical Center|Yes|Completed|June 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|pesons who had the risk of MERS transmission from the case-patient|November 2015|November 12, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02605109||8853|
NCT02625649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11092015|Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients|Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients: Register-based and Clinical Follow-up Studies||University of Aarhus|No|Recruiting|January 2016|August 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples Without DNA|blood samples urine samples stool samples|Both|18 Years|60 Years|No|Non-Probability Sample|Cases: Type 2 diabetes mellitus patients living in Central Denmark region that have        undergone Roux-en-Y gastric bapass between 2006-2011.        Controls: Type 2 diabetes mellitus patients living in Central Denmark region,        non-RYGB-operated|September 2015|January 4, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02625649||7277|
NCT02627404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111002|Study of the Genetic and Environmental Factors of Vulnerability in Bipolar Disorders|Study of the Genetic and Environmental Factors of Vulnerability in Bipolar Disorders|GAN|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2013|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 8, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02627404||7142|
NCT02621957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29825|Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential|A Phase 1, Open-Label Study to Evaluate the Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential||Genentech, Inc.||Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621957||7561|
NCT02626429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAO-YF|Protein Requirements In Active Female Populations|Evaluation of Protein Requirements in Active, Young Adult Females||University of Toronto|No|Active, not recruiting|May 2015|June 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|7|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626429||7217|
NCT02617693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4186|Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes|Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes|Jom Mama|Novo Nordisk A/S|No|Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|660|||Female|20 Years|39 Years|No|||November 2015|November 25, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02617693||7888|
NCT02617706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPF-615|Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Colon and Rectal Resections|A Prospective, Randomized, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Standard of Care to Assess Postoperative Wound Infection Rate in Colon and Rectal Resections||Ogenix Corporation|Yes|Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02617706||7887|
NCT02622555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSABHT13|Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists|Phase 4 Study of Cardiovascular Morbidity and Safety in Women Treated With Mirabegron for Overactive Bladder||Karolinska Institutet|No|Completed|August 2013|November 2015|Actual|November 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|221|||Female|N/A|N/A|No|Non-Probability Sample|General population of women with overactive bladder syndrome without strict exclusion        criteria|December 2015|December 3, 2015|June 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02622555||7515|
NCT02612480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tica-lps|Ticagrelor in Human Endotoxemia Response to Human Endotoxemia|The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia||Radboud University|Yes|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612480||8289|
NCT02612493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF 120/2015|Obesity and Metabolic Surgery in Patients With Type I Diabetes|Obesity and Metabolic Surgery in Patients With Type I Diabetes||Sana Klinikum Offenbach|No|Completed|January 2006|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|||Both|18 Years|65 Years|No|Non-Probability Sample|All obeses patients with type I diabetes who underwent weight loss surgery in our        department.|November 2015|November 20, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612493||8288|
NCT02617641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1887|A Web-Based Tailored Nursing Intervention to Increase Walking in Patients After an Acute Coronary Syndrome|Evaluation of a Web-Based Tailored Nursing Intervention (TAVIEenM@RCHE) Aimed at Increasing Walking in Patients After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial||Montreal Heart Institute|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|148|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617641||7892|
NCT02620904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5689|Mifepristone Induction for Fetal Demise|Mifepristone Induction for Fetal Demise, a Randomized Control Trial|MIFD|Montefiore Medical Center|No|Not yet recruiting|February 2016|||September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Female|14 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620904||7642|
NCT02620917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3506/AO/15|Continuos Subcutaneous Insulin Infusion in Italy|Survey on Continuos Subcutaneous Insulin Infusion in Italy|IMITA2|University of Padova|No|Recruiting|November 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|we will evaluate allItalian patients treated with insulin pump|November 2015|March 17, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02620917||7641|
NCT02627469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarolinskaII|Oral Hygiene Care and Microflora in Elderly Residents|Effect of Weekly Professional Oral Care, During 12 Months, on the Composition of the Oral Flora and Related Variables in Dependent Elderly Residents||Karolinska Institutet|No|Completed|August 2007|June 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|68|||Both|65 Years|N/A|No|||February 2016|February 22, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627469||7137|
NCT02615093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valeant 302|A Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis||Sadick Research Group|No|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615093||8088|
NCT02622620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014JZ2-007|Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques|||Tang-Du Hospital|No|Not yet recruiting|December 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|86|||Both|N/A|N/A|No|Probability Sample|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who        receive concurrent chemoradiation (CCRT) with temozolomide|December 2015|December 2, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02622620||7510|
NCT02612792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014U|Platelet Rich Fibrin+1.2% Atorvastatin in Treatment of Mandibular Degree II Furcation Defects|Platelet Rich Fibrin Combined With 1.2% Atorvastatin Gel in Treatment of Mandibular Degree II Furcation Defects: a Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|No|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|82|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02612792||8265|
NCT02614209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-120|Blood Collection of Patient Presenting in the ED and Prescribed a BNP|A Blood Collection From Patients Presenting in the Emergency Department and Prescribed a Brain Natriuretic Peptide (BNP) Laboratory Test|BNP|Fujirebio Diagnostics, Inc.|No|Recruiting|May 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Blood sample|Both|21 Years|N/A|No|Non-Probability Sample|Patients presenting to ED and prescribed a BNP with or without HF|November 2015|November 24, 2015|November 6, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614209||8156|
NCT02618928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-405|The Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in France|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in France|OPALE|AbbVie|No|Recruiting|December 2015|October 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|99 Years|No|Non-Probability Sample|Participants with chronic hepatitis C (CHC) virus, genotype 1 or 4|February 2016|February 7, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02618928||7794|
NCT02618941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFFiRiS 008AA|Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)|Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program||Affiris AG|Yes|Active, not recruiting|December 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|40 Years|68 Years|No|||March 2016|March 2, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618941||7793|
NCT02626494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoGlu_PUK_ZH_2014_0010|Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction|Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction: The Role of Glutamate|CoGlu|Psychiatric University Hospital, Zurich|Yes|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02626494||7212|
NCT02626507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL- Gedatolisib-001|Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer|Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer||Eastchester Center for Cancer Care|No|Not yet recruiting|January 2016|March 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626507||7211|
NCT02619669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D14012|Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer|Phase 1b Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Female|18 Years|N/A|No|||October 2015|November 30, 2015|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02619669||7737|
NCT02619929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE2015026|Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany|Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany (StepUp)|StepUp|Pierre Fabre Pharma GmbH|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Palliative patients with advanced non-small-cell lung cancer (NSCLC, stage III and IV) or        anthracycline/taxane-resistant metastatic breast cancer (MBC, stage IV)|December 2015|March 18, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619929||7717|
NCT02620722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02048|A New Technique for Determining Limb Occlusion Pressure|A New Technique for Determining Limb Occlusion Pressure||University of British Columbia|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|16 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620722||7656|
NCT02618720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0250|Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery|Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial|COMBINE|University Hospital, Clermont-Ferrand||Not yet recruiting|January 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|920|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02618720||7810|
NCT02612441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture_neurology_CTIL|The Efficacy of Acupuncture on Patients With First Acute Ischemic Stroke, With Signs of Hemiplegia and Hemiparesis|The Efficacy of Acupuncture on Patients With First Acute Ischemic Stroke, With Signs of Hemiplegia and Hemiparesis||Rambam Health Care Campus|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02612441||8292|
NCT02612454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1434|A Study to Assess the Long-term Safety of Dupilumab (REGN668/SAR231893) Administered in Patients 6 to <18 Year of Age With Atopic Dermatitis (AD)|An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 to <18 Years of Age With Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Enrolling by invitation|October 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|18 Years|No|||November 2015|November 19, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612454||8291|
NCT02612467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140205|Low Back Pain - What's Next? Stratified Care Compared to Current Practice|The Effectiveness of a Stratified Care Model for Non-specific Low Back Pain in Danish Primary Care Compared to Current Practice in a Randomised Controlled Trial||Region of Southern Denmark|Yes|Recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02612467||8290|
NCT02625142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-1277|Family-Centered Rounds Checklist Implementation|Engaging Families in Bedside Rounds to Promote Pediatric Patient Safety||University of Wisconsin, Madison|No|Completed|February 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|340|||Both|N/A|17 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02625142||7316|
NCT02627625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-07-000025|Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products|Phase I Randomised, Five-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Three Test Products With Two Reference Products||3M|Yes|Recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627625||7125|
NCT02614521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IIS-GR-AF|Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation|A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.||Elpen Pharmaceutical Co. Inc.|No|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with paroxysmal atrial fibrillation|November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614521||8132|
NCT02625246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150627|Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis|A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis|CELEB|University of Miami|Yes|Recruiting|December 2015|December 2020|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|30 Years|87 Years|No|||December 2015|December 4, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625246||7308|
NCT02616978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50214|Retrospective Study on the Use of CEFALY® Device During Migraine Attacks|Retrospective Study on the Use of CEFALY® Device During Migraine Attacks||Cefaly Technology|No|Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|807|||Both|N/A|N/A|No|Non-Probability Sample|French speaking patients in Belgium, Switzerland and France, having ordered new electrodes        during the last year will be identified as regular users.|January 2016|January 13, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02616978||7943|
NCT02618824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01201508011|Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery|Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery||National Cardiovascular Center Harapan Kita Hospital Indonesia|Yes|Recruiting|December 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|N/A|5 Years|No|||December 2015|February 17, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618824||7802|
NCT02627664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_21|Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's Disease|Prospective Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's Disease|ProdDiGYPark|University Hospital, Lille|Yes|Recruiting|March 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|64|||Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease (PD) with early idiopathic ( ≤ 5 years of evolution )|January 2016|January 18, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02627664||7122|
NCT02627677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-15-303|A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia|A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib|OPTIC-2L|Ariad Pharmaceuticals|Yes|Recruiting|December 2015|December 2022|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627677||7121|
NCT02622737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE # 41228415.5.0000.5662|Study of the Effects of Three Exercise Programs in Parkinson's Disease|Comparison of the Effects of Exercise by Functional Training, Stationary Bicycle and Exergame in Parkinson Disease|STEP|Federal University of Bahia|No|Recruiting|November 2015|December 2019|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|60 Years|N/A|No|||December 2015|December 3, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02622737||7501|
NCT02621762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293_15|Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum|Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum|BicMag|University Hospital Inselspital, Berne|No|Not yet recruiting|December 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|111 Years|No|||December 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02621762||7576|
NCT02612753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01773-44|Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient|Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient|Taph|Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|November 2015|October 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02612753||8268|
NCT02561520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070211|Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD|Safety and Efficacy of Autologous Platelet Rich Plasma and Platelet Poor Plasma Eye Drops in the Treatment of Ocular Graft-Versus-Host Disease||University of Pittsburgh|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02561520||12201|
NCT02619539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAPIM-1|Shock Index To DEtect Low Plasma Fibrinogen In Trauma (SIDE)|Shock Index To DEtect Low Plasma Fibrinogen In Trauma (SIDE)|SIDE|Masaryk Hospital Krajská zdravotní a.s.|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|Patient having / suspected to have severe trauma admitted to participating centres.|March 2016|March 21, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619539|1 Day|7747|
NCT02621944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500886|Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia|Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia||University of Florida|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|6 Hours|No|||December 2015|December 1, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621944||7562|
NCT02622191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-229|Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye|Segmental Analysis of Retinal Layers and Measurement of Lamina Cribrosa Thickness in Patients With Asymmetric Primary Open-Angle Glaucoma||Wills Eye|No|Completed|July 2012|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02622191||7543|
NCT02561741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15010370|Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions|An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of 3 Tablets of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions||Mallinckrodt|No|Completed|December 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02561741||12184|
NCT02622373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002323|Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition|Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition||University of Kansas Medical Center|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|23 Weeks|42 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|The study group involves premature infants born between 23 to 32 weeks gestation, while        babies born at 34 weeks, 36 weeks and ≥37 and ≤ 42 weeks gestational age will serve as        control groups.|December 2015|December 2, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02622373||7529|
NCT02622594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV Microneedling/PDT 002|Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times|A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times||Dermatology, Laser & Vein Specialists of the Carolinas|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02622594||7512|
NCT02613299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007644|Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma|Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma||Mayo Clinic|No|Recruiting|November 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment at the Mayo Clinic Rochester that have been diagnosed with        mesothelioma and will undergo radiation therapy followed by surgical resection as their        standard of care.|November 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613299||8226|
NCT02613312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007645|Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma|Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma||Mayo Clinic|No|Recruiting|November 2015|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment at the Mayo Clinic Rochester that have been diagnosed with        mesothelioma and will undergo chemotherapy followed by surgery and then IMRT as their        standard of care.|November 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613312||8225|
NCT02621086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA3624|Cellodextrin Tolerability Study|A Pilot Study to Assess the Tolerability of a Single, Ascending Dose of a Non-digestible Carbohydrate in Healthy Volunteers|CELLDEX|University of Nottingham|No|Not yet recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621086||7628|
NCT02623335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 2015-1375|PCORI-1502-27462 Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment|Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment||University of Wisconsin, Madison|Yes|Not yet recruiting|June 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|480|||Both|65 Years|N/A|No|||January 2016|January 21, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02623335||7455|
NCT02627248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT002|Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery|||Shandong University|No|Recruiting|October 2015|October 2025|Anticipated|October 2025|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627248||7154|
NCT02611375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS-668|Conditioning Neural Circuits to Improve Upper Extremity Function|Conditioning Neural Circuits to Improve Upper Extremity Function||Shepherd Center, Atlanta GA|Yes|Enrolling by invitation|January 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|N/A|No|||December 2015|December 17, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611375||8374|
NCT02619591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Umass|Comparison Of Chest Ultrasound Techniques To Identify Clinically Significant Pneumothorax|Comparison Of Chest Ultrasound Techniques To Identify Clinically Significant Pneumothorax||University of Massachusetts, Worcester|No|Completed|September 2011|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|236|||Both|N/A|N/A|No|||November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619591||7743|
NCT02619604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063975|A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia|A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia|Med-IQ CLL|Duke University|No|Not yet recruiting|January 2016|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619604||7742|
NCT02619695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/08|Comparison of Ketoprofen Gel to Placebo in Mechanical Low Back Pain|Comparison of Ketoprofen Gel to Placebo in Patients Presented With Mechanical Low Back Pain to the Emergency Department: A Randomized Placebo Controlled Trial||Akdeniz University|No|Recruiting|June 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619695||7735|
NCT02619708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00028900|Preoperative Immersive Patient Quality Experience|Preoperative Immersive Patient Quality Experience||Dartmouth-Hitchcock Medical Center|No|Recruiting|December 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02619708||7734|
NCT02615535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002184|Neurofeedback-enhanced Mindfulness Meditation in Traumatic Brain Injury|Neurofeedback-enhanced Mindfulness Meditation for the Treatment of Affective and Attentional Disturbances in Patients With Traumatic Brain Injury||Spaulding Rehabilitation Hospital|No|Not yet recruiting|December 2015|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615535||8054|
NCT02627976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53275.041.15|Breast Edema Compression Vest|The Effect of Wearing a Compression Vest on Patient Reported Pain, Quality of Life and Degree of Breast Edema.||UMC Utrecht|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627976||7098|
NCT02627989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18690|An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids|An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids|Ointment TS-AD|Bayer|No|Recruiting|December 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|Patients will be recruited by the investigator who will also be the treating physician. As        an observational study, only patients who the investigator plans on switching to the        ointment (W/O emulsion) from fatty ointment formulation will be eligible to participate.        Patients will be recruited for each seasonal phase and same patients may not necessarily        be observed between the two seasonal phases.|March 2016|March 1, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627989||7097|
NCT02628002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-5363|Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging|Comparison of Anti-gravity Treadmill Exercise and Regadenoson Tc-99m Tetrofosmin Single-photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging||University of Cincinnati|Yes|Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|March 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02628002||7096|
NCT02624401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC-2016|The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)|The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)||University of Turku|No|Recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|160|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02624401||7373|
NCT02624453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12312 PreCASA|Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screeining in AIDS|Implementation and Evaluation of a Screening Strategy to Reduce Morbidity and Mortality Due to Cryptoccocal Meningo-encephalitis in ART Naive AIDS Patients With <100 CD4 Count at the Day Hospital of the Yaounde Central Hospital, Cameroon|PreCASA|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|July 2015|August 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624453||7369|
NCT02615977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE2597/142;ZI1119/32;WI709/102|Learning and Relapse Risk in Alcohol Dependence (FP2)|Learning and Decision Making as Predictors of Treatment Outcome in Alcohol Use Disorder (Funding Period 2)|LeAD_FP2|Technische Universität Dresden|No|Recruiting|April 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615977||8020|
NCT02622490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIT2|Acute Effects of Different Macronutrient Compositions and Meal Distributions of the Food|Diet-induced Thermogenesis 2|DIT2|University Hospital, Linkoeping|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622490||7520|
NCT02611895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9503|Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy|Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy ( RALNOVO )|RALNOVO|University Hospital, Montpellier|No|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|March 22, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611895||8334|
NCT02611427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-142|Increasing Long-Term Physical Activity After Lumbar Spine Surgery|Increasing Long-Term Physical Activity After Lumbar Spine Surgery||Hospital for Special Surgery, New York|Yes|Recruiting|November 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|350|||Both|18 Years|80 Years|No|||November 2015|November 19, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02611427||8370|
NCT02625311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC04-105|Comparing Minimal Invasive Surgery en Conventional Total Knee Arthroplasty|A Prospective Comparative Randomized International Multicenter Study Comparing MIS Computer Navigated Total Knee Arthroplasty vs Conventional Computer Navigated Total Knee Arthroplasty|MIS|Maastricht University Medical Center|No|Completed|December 2004|January 2015|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|45 Years|75 Years|No|||November 2015|December 8, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02625311||7303|
NCT02625324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10219493DOC|Valiant Evo International Clinical Trial|Valiant Evo International Clinical Trial||Medtronic Endovascular|Yes|Not yet recruiting|April 2016|September 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02625324||7302|
NCT02623790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fromage-INAF|Study of the Impact of Cheese Matrix on Postprandial Lipemia: a Clinical Study|Study of the Impact of Cheese Matrix on Postprandial Lipemia: a Clinical Study|FROMAGE|Laval University|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02623790||7420|
NCT02623803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003955|Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies|Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies||Mayo Clinic|No|Recruiting|January 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623803||7419|
NCT02623985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539-2558-EC1|Evaluation of Accuracy of Rapid Tests for Group A Beta Hemolytic Streptococci in Out-patients With Sore Throat|Evaluation of Accuracy of Rapid Tests for Group A Beta Hemolytic Streptococci in Out-patients With Sore Throat From Acute Pharyngitis at Siriraj Hospital||Mahidol University|No|Not yet recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|400|||Both|7 Years|N/A|No|||December 2015|December 3, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02623985||7405|
NCT02621437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0456|Impact of Osteopathy on Pain After Breast Cancer Surgery|Study of the Impact of Osteopathic Care, Complementary Therapy to Standard Care, on Pain in Patients With Breast Cancer Surgery|IPOD|Hospices Civils de Lyon|No|Recruiting|February 2016|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|170|||Female|18 Years|N/A|No|||November 2015|March 24, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02621437||7601|
NCT02628015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ToM-2016-2018|Theory of Mind in Preschool Children, School Children, Youths and Adults Born Preterm or Full-term|Theory of Mind Bei Ehemals früh- Und Reifgeborenen Vorschulkindern, Schulkindern, Jugendlichen Und Erwachsenen||University of Bonn|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Anticipated|480|||Both|4 Years|N/A|Accepts Healthy Volunteers|Probability Sample|preterms were born in the University Hospital of Cologne|March 2016|March 11, 2016|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02628015||7095|
NCT02628028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16173|A Study of LY3337641 in Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of LY3337641 in Adult Subjects With Moderate to Severe Rheumatoid Arthritis: The RAjuvenate Study|RAjuvenate|Eli Lilly and Company|No|Not yet recruiting|July 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02628028||7094|
NCT02627261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0316|Multiple Myeloma Minimal Residual Disease|Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma|MMRD|Hospices Civils de Lyon|No|Recruiting|October 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|a gene sequencing technology will be used on bone marrow samples to detect residual disease|Both|18 Years|N/A|No|Non-Probability Sample|This study will focus on adult patients with multiple myeloma and who will receive a        treatment with high-dose melphalan and autologous bone marrow transplantation|December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627261||7153|
NCT02612558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-053|A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)|A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia|AIHA|Rigel Pharmaceuticals|No|Not yet recruiting|February 2016|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612558||8283|
NCT02612766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCA2-111/2012|Safety and Tolerability of Oat Containing Gluten-free Diet|SAFETY AND TOLERABILITY OF OAT CONTAINING GLUTEN-FREE DIET|SafeOatDiet|Alfred Rusescu Institute for Mother and Child Care||Recruiting|November 2015|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|4 Years|N/A|No|||November 2015|December 4, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02612766||8267|
NCT02616302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_204|A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years|A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease||Takeda|No|Suspended|November 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|1 Year|11 Years|No|||March 2016|March 10, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616302||7995|
NCT02621567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-125|Bright Light Therapy Efficacy for Depressive Symptoms Following Cardiac Surgery: Pilot Trial|Bright Light Therapy Efficacy for Depressive Symptoms Following Cardiac Surgery: Pilot Trial (BEAM-P)|BEAM-P|McGill University|No|Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02621567||7591|
NCT02621710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053161|Goal Achievement and Patient Satisfaction in Benign Hysterectomy|Goal Achievement and Patient Satisfaction in Benign Hysterectomy||University Hospital Case Medical Center||Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing benign hysterectomy for benign indications in a scheduled manner|December 2015|December 1, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02621710||7580|
NCT02616198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10.1/6|6-year Clinical Evaluation of Glass Ionomer Cements (GIS) With Resin Coating on Posterior Teeth|A Prospective 6-year Clinical Study Evaluating Reinforced Glass Ionomer Cements With Resin Coating on Posterior Teeth|GIS|Ege University|Yes|Completed|January 2009|September 2015|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|54|||Both|17 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616198||8003|
NCT02620462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501657972|Wearable Sensor-based Balance Training for Patients With Knee Osteoarthritis|Explore the Effectiveness of a Sensor-based Interactive Exercise Training on Functional Performance in Patients With Knee Osteoarthritis||University of Arizona|No|Active, not recruiting|February 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|90 Years|No|||November 2015|November 30, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02620462||7676|
NCT02612103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150107|Biomarkers in Inflammatory Bowel Diseases|Evaluation of Markers of the Extracellular Matrix Turnover as Biomarkers in Inflammatory Bowel Diseases and Establishment of an Inflammatory Bowel Diseases (IBD) Biobank||Odense University Hospital|No|Recruiting|November 2015|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|IBD and IBS patients at The Department of Medical Gastroenterology, Odense University        Hospital will be asked to participate when they contact the department due to progression        in disease activity or at their regular consultations in the out-patient clinic.        Healthy controls will be recruited by advertising in local news paper and advertising in        public places.|December 2015|December 14, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612103|1 Year|8318|
NCT02605746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX15BN068|Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis|A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration||St. Joseph's Hospital and Medical Center, Phoenix|No|Not yet recruiting|November 2015|September 2017|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|48|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605746||8804|
NCT02595008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 1502|Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.||Taro Pharmaceuticals USA|No|Recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|2 Years|N/A|No|||November 2015|November 8, 2015|November 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595008||9628|
NCT02600065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIO-CMV-01|Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy|Analysis of CMV Infections in Patients Suffering From Brain Tumors and Brain Metastases During and After Radio(Chemo)Therapy|GLIO-CMV-01|University of Erlangen-Nürnberg Medical School|No|Recruiting|November 2014|November 2019|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|blood for CMV status analysis blood for immunophenotyping serum plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with brain tumours (glioblastoma or anaplastic astrocytoma Patients with brain        metastases from diagnosed primary tumours|November 2015|November 5, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02600065||9239|
NCT02604953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-358|Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and "Normal" Patients|1-Year Prospective Study: SD-tVEP and PERG for Early Detection of Retinal Ganglion Cell Dysfunction in Ocular Hypertension Patients||Wills Eye|No|Completed|July 2014|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|90|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604953||8865|
NCT02607839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5569-B|Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans|Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans||University Health Network, Toronto|No|Completed|February 2013|September 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02607839||8645|
NCT02604563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511019|Aging, Geriatric Syndromes and Clonal Hematopoiesis|Aging, Geriatric Syndromes and Clonal Hematopoiesis||Washington University School of Medicine|No|Recruiting|March 2016|November 2025|Anticipated|November 2025|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|175|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604563||8895|
NCT02604576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRDEMS1011|Efficacy of Bromopride and Simethicone Versus Bromopride in Funcional Dyspepsia|Efficacy of Fixed-dose Combination of Bromopride and Simethicone Versus Isolated Bromopride in Participants With Funcional Dyspepsia.||EMS|No|Not yet recruiting|August 2016|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|70 Years|No|||November 2015|November 12, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604576||8894|
NCT02610023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 14222|Food Frequency Questionnaires in Estimating Food Nutrient Intake in Healthy Young Adults|Comparative Assessment of Food Frequency Questionnaires||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|January 2015|||June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the Ohio State University Campus, Wexner Medical        Center Hospitals, and surrounding greater Columbus area.|November 2015|November 18, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610023||8477|
NCT02613325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410125|fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth|Pilot Study to Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth||Washington University School of Medicine|No|Recruiting|June 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613325||8224|
NCT02617394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060267|Novel vs. Traditional US Diaphragm Scanning|Comparing Two Ultrasound-based Methods to Assess Diaphragm Movement||University of Alberta|No|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617394||7911|
NCT02616874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCN02-Romi|Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals|An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi)||IrsiCaixa|No|Recruiting|February 2016|October 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|99 Years|No|||February 2016|February 24, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02616874||7951|
NCT02616887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1460|Study of Image-Guided SBRT for Vertebral Metastases|Phase II Study of Image-Guided Single Fraction SBRT With VMAT-FFF Technique for Vertebral Metastases||Istituto Clinico Humanitas|Yes|Recruiting|November 2015|November 2023|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|59|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with spine metastases|November 2015|November 27, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616887||7950|
NCT02614560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN33A-003|A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients|A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)||Seattle Genetics, Inc.|Yes|Recruiting|November 2015|March 2023|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614560||8129|
NCT02626780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIDAA-01|Adipose-derived SVF for Treatment of Alopecia|Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia||The GID Group|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626780||7190|
NCT02612298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSPC-ALM-1401|Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate|Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension|ESAHOM|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|No|Recruiting|August 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||November 2015|November 20, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02612298||8303|
NCT02621112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-209|HBV Vaccine in Renal Failure Patients|Efficacy of Intradermal Hepatitis B Vaccine in Renal Failure Patients||The University of Hong Kong|Yes|Recruiting|January 2016|||December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|21 Years|N/A|No|||March 2016|March 9, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621112||7626|
NCT02627430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02063|Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer|A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer||National Cancer Institute (NCI)||Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627430||7140|
NCT02617342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00067744|Robot-Mediated Intervention for Children With Autism Spectrum Disorders|Robot-Mediated Social Skills Intervention for Children With Autism Spectrum Disorders||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|November 2015|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Years|8 Years|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617342||7915|
NCT02617576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507M76622|Flavoring Oral Contrast for MR Enterography|Flavoring Oral Contrast for MR Enterography||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients undergoing MR enterography examinations|December 2015|December 7, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617576||7897|
NCT02613104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-2811|Emotion Recognition Modification for Bipolar Disorder|Emotion Recognition Modification for Bipolar Disorder||Yeshiva University|No|Recruiting|October 2014|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|80|||Both|16 Years|25 Years|No|||November 2015|November 20, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02613104||8241|
NCT02613117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014067|Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity|||Procter and Gamble||Not yet recruiting|November 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613117||8240|
NCT02613130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015110|A Study to Evaluate Oral Malodor and Other Outcomes Following The Use of Two-Step Toothpaste Oral Hygiene|||Procter and Gamble||Completed|November 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613130||8239|
NCT02615106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SanghaiXinhua-001|Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma|Phase 2 Study of Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||November 2015|November 23, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02615106||8087|
NCT02618499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Funda05|Delayed Cord Clamping and Use of Oxytocin|Is Placental Transfusion Influenced by the Early Administration of Oxytocin?||Fundacion para la Salud Materno Infantil|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|550|||Both|N/A|N/A|No|||November 2015|November 27, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02618499||7827|
NCT02624414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.214|Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin|A Prospective Study of the Feasibility of Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin||Melbourne Health|No|Recruiting|February 2015|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|34|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624414||7372|
NCT02617121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HallymUMC|The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery|Comparison of the Prophylactic Anti-emetic Efficacy of Gabapentin and Ramosetron in Patients Undergoing Laparoscopic Gynecological Surgery|PONV|Hallym University Medical Center|No|Not yet recruiting|November 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02617121||7932|
NCT02617134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-021-002|CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor|Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor||PersonGen Biomedicine (Suzhou) Co., Ltd.|Yes|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 26, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02617134||7931|
NCT02622035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160026|New Technology and Child Health|New Technology and Child Health (nTech)||National Institutes of Health Clinical Center (CC)||Recruiting|November 2015|October 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|670|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|February 26, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02622035||7555|
NCT02616172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|695389|Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss|Safety of Infusion of Autologous Human Bone Marrow Mononuclear Fraction in Children With Sensorineural Hearing Loss||Florida Hospital|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|6 Years|No|||November 2015|November 25, 2015|August 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616172||8005|
NCT02624752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG2014F-08B|Oral Nutrition Supplementation in Hospitalized Patients|Nutrition Supplementation in Hospitalized Patients (NutriSup Oral)|NutriSup Oral|Lawson Health Research Institute|No|Not yet recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|N/A|No|||December 2015|December 4, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624752||7346|
NCT02624765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000039945|FAST Therapy Trial of Fetal Tachyarrhythmia|Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial||The Hospital for Sick Children|Yes|Enrolling by invitation|December 2015|||November 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|600|||Female|N/A|N/A|No|||March 2016|March 21, 2016|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624765||7345|
NCT02622945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00078932|Effects of Transcranial Direct Current Stimulation in Post-stroke Aphasia|Transcranial Direct Current Stimulation in Acute and Chronic Post-stroke Aphasia||Johns Hopkins University|Yes|Recruiting|February 2014|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||December 2015|December 2, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02622945||7485|
NCT02622048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15209: 15/NW/0532|Understanding and Helping Families: Parents With Psychosis|STAGE 1: Investigating Attributions and Expressed Emotion in Parents With and Without Psychosis STAGE 2: Investigating the Use of a Self-directed Parenting Programme With Parents Experiencing Psychosis||University of Manchester|No|Recruiting|September 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02622048||7554|
NCT02616432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2014b|Tomosynthesis Mammography Imaging Screening Trial|Tomosynthesis Mammography Imaging Screening Trial Lead-in|TMISTLead-in|Sunnybrook Health Sciences Centre|No|Recruiting|October 2014|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2118|||Female|40 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616432||7985|
NCT02621476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-14-1947|Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities|Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities||Kaiser Permanente|Yes|Not yet recruiting|September 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|80000|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02621476||7598|
NCT02615197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49013 - EG|Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients|Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients||University of Washington|No|Recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|12 Years|N/A|No|||March 2016|March 2, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615197||8080|
NCT02614456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-084|Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors|Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study||Fox Chase Cancer Center|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614456||8137|
NCT02614469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-PD-P3-2015-FE|A Food-Drug Interaction Study of Serum Urate After Oral Inosine|A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects||Massachusetts General Hospital|No|Not yet recruiting|December 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614469||8136|
NCT02619526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-174|Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients|Comparative Effects of Nebivolol and Carvedilol on Diastolic Function of the Left Ventricle in the Elderly Heart Failure Patients With Preserved Ejection Fraction: Study Protocol for a Randomized Controlled Trial||Dong-A University|Yes|Active, not recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|70 Years|N/A|No|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02619526||7748|
NCT02621463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00074281|Electric Blower Based Ventilator Used During Procedural Sedation|Electric Blower Based Ventilator Used During Procedural Sedation||University of Utah|No|Enrolling by invitation|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621463||7599|
NCT02624050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003830|Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs|Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System.||Milton S. Hershey Medical Center||Not yet recruiting|April 2016|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624050||7400|
NCT02614703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000001|"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance|"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance is Superior to the Standardized Random Biopsy Protocol in Detecting Neoplasia: A Prospective Randomized Study"||Doctors Hospital at Renaissance|No|Not yet recruiting|January 2016|August 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|185|||Both|40 Years|80 Years|No|||December 2015|December 1, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02614703||8118|
NCT02626767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEES-008/11|Effect of Novel High-intensity Interval Training on Health and Fitness Outcomes in English Adolescents|Effect of Novel High-intensity Interval Training on Cardiometabolic Health and Physical Activity Levels in English Adolescents: A School-based Exploratory Controlled Before-and-after Trial||Teesside University|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626767||7191|
NCT02627911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01294-45|Diabeloop WP6.2 : Crossover Evaluation of Glycemic Control|DIABELOOP WP6.2 : Crossover Evaluation of Glycemic Control Provided for Three Days by the Artificial Pancreas Diabeloop Compared to Conventional Treatment by External Insulin Pump in Patients With Type 1 Diabetes in Sedentary Position, Outstanding Meals and Physical Activity .|WP6-2|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02627911||7103|
NCT02617381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K140901|Pre-operative Haemorrhagic Risk Screening, Using a Standardized Questionnaire Before Scheduled Surgeries|Pre-operative Haemorrhagic Risk Screening, Using a Standardized Questionnaire Before Scheduled Surgeries.|HEMORISQ|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1500|||Both|18 Years|N/A|No|||November 2015|January 16, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617381||7912|
NCT02624843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTHP01|Bioequivalence Study for Benzyl Alcohol Lotion 5%.|Bioequivalence Study for Benzyl Alcohol Lotion 5% (Hi-Tech Pharmacal Co. LTD) and Ulesfia (Benzyl Alcohol Lotion 5%) (Shionogi Inc.) in the Treatment of Head Lice and Their Ova.||Akorn, Inc.|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|6 Months|60 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624843||7339|
NCT02620878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3486/AO/15|Artificial Pancreas in Pediatric Patients (PEDarPAN)|Use of Artificial Pancreas in Pediatric Patients. Feasibility , Safety and Efficacy Study of an Automatic Control of Blood Glucose 24/24 at a Diabetes Camp|PEDarPAN|University of Padova|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|6 Years|18 Years|No|||December 2015|December 3, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02620878||7644|
NCT02620891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJuan|Helium Oxygen Mixture in the Treatment of Meconium Aspiration Syndrome|Study on the Effect of Helium Oxygen Mixture in the Treatment of Meconium Aspiration Syndrome Parallel Synchronized Intermittent Mandatory Ventilation; Synchronous Maudatory Ventilation||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Recruiting|February 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02620891||7643|
NCT02622750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLW2015AD2|Triple-branch Stent Graft Placement and Total-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection|Triple-branch Stent Graft Placement and Total-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection: A Prospective, Multi-center, Randomized, Open-label, Parallel-group, Non-inferiority Clinical Trial|TBSGPATART|Fujian Medical University|Yes|Not yet recruiting|November 2016|March 2019|Anticipated|November 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02622750||7500|
NCT02622763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TolDec-CD-intra|Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment|Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease|TolDecCDintra|Fundacion Clinic per a la Recerca Biomédica|No|Active, not recruiting|November 2015|March 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622763||7499|
NCT02627924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-777|Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab|Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (ROCKA Study)|ROCKA|AbbVie|No|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|99 Years|No|Probability Sample|Subjects receiving Adalimumab with Rheumatoid Arthritis (RA) in Korea|January 2016|January 27, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627924||7102|
NCT02625077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI-UPPERGI-VANTAGE|Valvuloplasty as Alternative to Toupet Fundoplication for GERD|Valvuloplasty as Alternative to Toupet Fundoplication for the Minimal Invasive Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Trial|VANTAGE|Meander Medical Center|No|Not yet recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02625077||7321|
NCT02625090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0073|An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy|An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy||UCB Pharma|Yes|Recruiting|September 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625090||7320|
NCT02620969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGent_UToPaed_2|Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Kinetic Analysis|Part 2 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|UToPaed_2|University Hospital, Ghent|No|Recruiting|October 2015|September 2019|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|N/A|18 Years|No|Non-Probability Sample|CKD patients treated with haemodialysis|December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620969||7637|
NCT02621073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003641|VeraFlo With Prontosan® and Wound and Fracture Healing.|Does VeraFlo With Prontosan® Decrease Time to Wound and Fracture Healing in Patients With Infected Lower Extremity Fractures With Indwelling Hardware?||University of Missouri-Columbia|No|Recruiting|November 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621073||7629|
NCT02627183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150742|Circulating BDNF in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training|Circulating Brain-derived Neurotrophic Factor (BDNF) in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training: A Pilot Study (NEURO-AF)|NEURO-AF|Ottawa Heart Institute Research Corporation|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood samples.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with paroxysmal atrial fibrillation that will undergo catheter ablation and        subjects with permanent or persistent atrial fibrillation undergoing exercise training two        times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study        (NCT02602457).|December 2015|January 4, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627183||7159|
NCT02627196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360043|Barostim Therapy for Heart Failure|Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure|BeAT-HF|CVRx, Inc.|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|21 Years|N/A|No|||December 2015|December 8, 2015|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627196||7158|
NCT02627235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X131203002|The Deep South IVR-based Active Lifestyle Study|The Deep South IVR-based Active Lifestyle (DIAL) Study|DIAL|University of Alabama at Birmingham|No|Recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627235||7155|
NCT02627937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH IRB NO. 104-3716B|Clinical Predictors of Pediatric OSAHS|Clinical Predictors of Pediatric Obstructive Sleep Apnea/Hypopnea Syndrome|PEDOSA|Chang Gung Memorial Hospital|Yes|Recruiting|June 2015|December 2015|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|88|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|children with chief complaints of snoring|October 2015|December 9, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02627937||7101|
NCT02623348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02719|Use of Pedometers to Measure and Increase Walking Among Patients With ESRD|Use of Pedometers to Measure and Increase Walking Among Patients With ESRD|PED|University of California, San Francisco|No|Not yet recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623348||7454|
NCT02615275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA15-0600|Multifrequency Bioelectrical Impedance Analysis to Estimate Body Composition|Validation of Eight-Electrode Multifrequency Bioelectrical Impedance Analysis to Estimate Body Composition in a Head and Neck Cancer Population Undergoing Radiation Therapy||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02615275||8074|
NCT02615574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-023|A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer|A Phase 2 Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer||University of Pittsburgh|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615574||8051|
NCT02615587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18313|Burden of Illness in Atrial Fibrillation|Burden of Illness in Atrial Fibrillation in Denmark||Bayer|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|107532|||Both|18 Years|90 Years|No|Non-Probability Sample|The base population of AF patients will be identified in the National Patient Registry.        For a given period of time (2000-2013, both years inclusive) all patients with a hospital        contact (admission, outpatient visit or ER visit) and for whom AF was the primary or        secondary diagnosis code will be identified.|February 2016|February 4, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02615587||8050|
NCT02615405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC101-2628-B-039-001-MY3|Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour|||National Science Council, Taiwan|Yes|Completed|August 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|65 Years|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615405||8064|
NCT02625779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD_Bipolar|Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression|A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression||Ewha Womans University Mokdong Hospital|Yes|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|19 Years|65 Years|No|||January 2016|January 24, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625779||7267|
NCT02626871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T39/2015|Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation|Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation|FIN-bioAVR|University of Turku|No|Completed|January 2002|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|850|||Both|18 Years|99 Years|No|Non-Probability Sample|All-comers design of patients undergoing aortic valve bioprosthesis implantation|December 2015|December 8, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02626871||7183|
NCT02620020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-1524|A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain|A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain||Regeneron Pharmaceuticals|Yes|Not yet recruiting|November 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|800|||Both|35 Years|N/A|No|||October 2015|November 30, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620020||7710|
NCT02612909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVACFLU-A/H5N1-0203|A Safety and Immunogenicity Study of IVACFLU-A/H5N1|A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC||Institute of Vaccines and Medical Biologicals, Vietnam|Yes|Not yet recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1800|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|November 20, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02612909||8256|
NCT02619903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-279|The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens|The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens||Malmö University|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02619903||7719|
NCT02619955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35RC14_9841|Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity|Hepcicor Cohort : Clinical, Biological, Genetic and Fonctional charactérization of Rare Iron Overlaod phénotypes Associated With Hepcidin Deficiency Excluding C282Y Homozygosity|HEPCICOR|Rennes University Hospital|No|Not yet recruiting|February 2016|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting a rare iron overloads with hepcidin deficiency|November 2015|February 23, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02619955||7715|
NCT02616367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503M66201|Comparison of Comparison of Ropivacaine and Liposomal Bupivacaine for Total Knee Arthroplasty|Comparison Between Ropivacaine and Liposomal Bupivacaine Periarticular Injections for Pain Relief After Total Knee Arthroplasty||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616367||7990|
NCT02616185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7791001|A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)|A Phase I Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)||Pfizer|No|Recruiting|December 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Male|18 Years|N/A|No|||March 2016|March 9, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02616185||8004|
NCT02614105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3342|Urinary Incontinence Amongst Women With Chronic Obstructive Pulmonary Disease|UriCO - Effect of Pelvic Floor Muscle Training and Cough-suppression Therapy on Urinary Incontinence Amongst Women With Chronic Obstructive Pulmonary Disease; a Randomised Controlled Trial|UriCO|Ostfold Hospital Trust|Yes|Recruiting|November 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|96|||Female|18 Years|N/A|No|||November 2015|November 24, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02614105||8164|
NCT02616016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000040604|MRI Guided HIFU for Palliation of Painful Skeletal Metastases in Children|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases in Children - A Pilot Study||The Hospital for Sick Children|Yes|Recruiting|April 2014|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|17 Years|No|||November 2015|November 24, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02616016||8017|
NCT02616029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1824|Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I|A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I||Gilead Sciences|Yes|Recruiting|December 2015|November 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616029||8016|
NCT02627287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4208|A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®|A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen||Novo Nordisk A/S|No|Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|150|||Both|18 Years|74 Years|No|||March 2016|March 1, 2016|November 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627287||7151|
NCT02611440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014.859|Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic Stroke|Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic Stroke (ADMED-AVC)|ADMED-AVC|Hospices Civils de Lyon|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|182|||Both|18 Years|N/A|No|||September 2015|November 18, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02611440||8369|
NCT02616510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-010|Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile|Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile|POPCORn|UMC Utrecht|Yes|Recruiting|July 2013|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|125|Samples Without DNA|plasma, serum, urine|Female|45 Years|N/A|No|Probability Sample|women with PCOS according to rotterdam criteria (2 or more of these criteria)          -  oligo/anovulation          -  polycystic ovarian morphology          -  hyperandrogenism        Women with POI amenorrhea of at least 4 months prior to age 40 years with FSH levels above        40 IU/L|November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616510||7979|
NCT02620267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-050587|Target Engagement of the Early Auditory Processing Network by Transcranial Direct Current Stimulation (tDCS)|Target Engagement of the Early Auditory Processing Network by Transcranial Direct Current Stimulation (tDCS): A Pilot Study||VA Greater Los Angeles Healthcare System|No|Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02620267||7691|
NCT02627313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT-15-02|Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)|Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)||Ottawa Hospital Research Institute|Yes|Not yet recruiting|May 2016|||May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|50 Years|No|||December 2015|December 8, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02627313||7149|
NCT02627339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-234E|Building a Database of Results From People Without Eye Problems|A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)|SPARCS|Wills Eye|No|Completed|August 2012|August 2015|Actual|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|208|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls with no eye diseases|December 2015|December 9, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627339|1 Day|7147|
NCT02620631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200362|Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients|Prospective, Randomized, Double-blinded, Placebo-controlled Study to Examine Pain Relief and the Need for Supplementary Analgesics With Intra-thecal Morphine Sulfate (0.2 mg) in Patients Undergoing Total Knee Arthroplasty (TKA)||Stony Brook University|No|Active, not recruiting|March 2011|January 2017|Anticipated|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|54|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620631||7663|
NCT02626117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_D012_36651|Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study|Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study||Krishnadevaraya College of Dental Sciences & Hospital|Yes|Recruiting|July 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|57 Years|Accepts Healthy Volunteers|||September 2015|December 7, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626117||7241|
NCT02616900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00014027|eSight Eyewear Quality of Life and Efficacy Study|eQUEST -- ESIGHT QUALITY OF LIFE AND EFFICACY STUDY A Multi-center, Prospective Cohort Study to Assess the Impact of eSight Eyewear on Functional Vision Improvement and Quality of Life in a Low Vision Population|eQUEST|eSight Corporation|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|13 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616900||7949|
NCT02595775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|477-2014|A Trial of an Audit and Feedback Report to Improve Colonoscopy Performance|A Randomized Controlled Trial of an Audit and Feedback Report to Improve Colonoscopy Performance||Sunnybrook Health Sciences Centre|No|Enrolling by invitation|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 2, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02595775||9569|
NCT02604420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403014892|Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants|Identification of the Pathogenesis of Thrombotic Microangiopathy in the Allo Stem Cell Transplant Setting in Adults||Weill Medical College of Cornell University|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Peripheral blood mononuclear cells Plasma Bone marrow core biopsies|Both|18 Years|65 Years|No|Non-Probability Sample|Adults (age 18-65) undergoing an allogeneic hematopoietic stem cell transplant|November 2015|November 12, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02604420||8906|
NCT02604433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-536-B-THAL-001|An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia|A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia|BELIEVE|Celgene|Yes|Not yet recruiting|January 2016|April 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02604433||8905|
NCT02609191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/VB-01|Assessment of Body Composition Via Dual-energy X-ray Absorptiometry Bone Densitometry|Assessment of Body Composition Via Dual-energy X-ray Absorptiometry Bone Densitometry: Cross Calibration and Reproducibility Between the "Stratos DR" and "Discovery A" Bone Densitometers|STRATOS|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609191||8541|
NCT02607072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APREMEC-01|Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial|Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial|APREMEC|The Fourth Affiliated Hospital of Anhui Medical University|Yes|Recruiting|October 2015|October 2022|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|3000|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607072||8704|
NCT02607124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011XUS17T|Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)|A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)||Children's Hospital Medical Center, Cincinnati|Yes|Not yet recruiting|December 2015|January 2020|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|12 Months|30 Years|No|||November 2015|November 16, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607124||8700|
NCT02596113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|galanopoulosm|Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer|Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer||Evangelismos Hospital|Yes|Recruiting|July 2015|May 2019|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|whole blood serum and colonic polyps tissue samples|Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals in normal risk for developing CRC aged 50-75 years who undergo preventive        colonoscopy for polyps and CRC detection|November 2015|November 3, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02596113||9543|
NCT02596711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0585|Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers|Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02596711||9497|
NCT02596971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO29563|A Phase 1b Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma|A Phase IB/II Study Evaluating the Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma||Hoffmann-La Roche||Recruiting|December 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02596971||9477|
NCT02617407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-18147|Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients|Pilot Study -- Oral Microbiome and Dental Plaque Control With Livionex(R) in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)||University of California, San Francisco|No|Not yet recruiting|January 2016|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|4 Years|21 Years|No|||November 2015|November 25, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02617407||7910|
NCT02620761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015AKI|Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants|Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants|Fenaki|University of Iowa|Yes|Not yet recruiting|June 2016|December 2018|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|14 Days|No|||November 2015|November 30, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620761||7653|
NCT02617992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2013/8/6.5 (3796)|Systematic Wide-Field EMR Scar Assessment and Therapy Audit|Systematic Wide-Field EMR Scar Assessment and Therapy Audit|SANT|Western Sydney Local Health District|Yes|Recruiting|September 2013|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had endoscopic mucosal resection of colonic polyps that are undergoing        surveillance colonoscopy.|December 2015|December 15, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02617992||7866|
NCT02617043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-BC001|Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery|Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery|HF-WBI-SIB|Fudan University|Yes|Recruiting|April 2015|December 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|60 Years|No|||November 2015|November 27, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617043||7938|
NCT02622152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0000871200|Right Lateral Positioning of Postoperative Pediatric Cardiac Surgery|Right Lateral Positioning of Postoperative Pediatric Cardiac Surgery: Effect on Arterial Oxygenation, Respiratory Mechanics, Hemodynamics, and Adverse Events||Assiut University|Yes|Recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|1 Year|10 Years|No|||January 2016|January 10, 2016|November 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622152||7546|
NCT02616523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/07/14|Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection|Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection||University Medical Centre Ljubljana|No|Active, not recruiting|July 2014|December 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Both|35 Years|85 Years|No|||November 2015|November 27, 2015|November 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02616523||7978|
NCT02616536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniversitiTAR|Comparison Between Teaching Methods on Knowledge Gain of Physiotherapy Students|Comparison Between Traditional Classroom Teaching Verses Flipped Classroom Teaching on Knowledge Gain of Physiotherapy Students||Universiti Tunku Abdul Rahman|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|54|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02616536||7977|
NCT02614807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504516|Protein Supplementation in Thiazide-induced Hyponatremia|Thiazide Diuretic-caused Hyponatremia in the Elderly Hypertensive: Will a Bottle of Nepro a Day Keep Hyponatremia and the Doctor Away? A Proof-of-Concept Trial||Ottawa Hospital Research Institute|No|Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|65 Years|N/A|No|||November 2015|November 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02614807||8110|
NCT02622399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-33938|Mobilizing Community Networks to Optimize Child Well-being|Mobilizing Community Networks to Optimize Child Well-being|NOW|Boston Medical Center|Yes|Recruiting|August 2015|August 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02622399||7527|
NCT02622893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1501|Surgical Approach Affect on Post-operative Analgesic Requirement Following Laparoscopic Nephrectomy|Can Surgical Approach Affect Post-operative Analgesic Requirements Following Laparoscopic Nephrectomy: Transperitoneal Versus Retroperitoneal? A Prospective Clinical Study||Istanbul University|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622893||7489|
NCT02617953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-199-08-14|Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus|Variable Changes in Continuous Resting EEG(Electroencephalography) and Auditory ERP(Event-related Potential) Before and After Transcranial Magnetic Stimulation Treatment; Double Blind Randomized Controll Trails||Seoul National University Hospital|Yes|Enrolling by invitation|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|70 Years|No|||September 2015|November 25, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02617953||7869|
NCT02622334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP30002|A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).|A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION||Hoffmann-La Roche||Recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622334||7532|
NCT02622347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rFSH Spiking Experiment|Spiking-and-Recovery Experiment DOREMI Study|Spiking-and-Recovery Experiment DOREMI Study||UMC Utrecht|No|Active, not recruiting|August 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|30|Samples Without DNA|Bloodserum|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bloodserum samples of 30 women with basal FSH concentration varying between 0-14 IU/L.|December 2015|December 4, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02622347|1 Day|7531|
NCT02618070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|633/2015BO2|Cognitive Modulation of Dyspeptic Symptom During Food Ingestion in Functional Dyspepsia Patients Cognitive Modulation|||University Hospital Tuebingen||Not yet recruiting|January 2016|||November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02618070||7860|
NCT02625935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-10140|Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients|A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing||NanoString Technologies, Inc.|No|Recruiting|December 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|FFPE breast tumor tissue samples|Female|N/A|N/A|No|Probability Sample|Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative        early-stage breast cancer.|February 2016|February 2, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625935||7255|
NCT02626611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28942|Multi Immunotherapy to Test Tolerance and Xolair|A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study|M-TAX|Stanford University|Yes|Active, not recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|70|||Both|4 Years|55 Years|No|||December 2015|December 7, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626611||7203|
NCT02620592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYDPLA1 1001|Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYDPLA1, a Novel DPP- IV Inhibitor, Following Oral Administration in Healthy Volunteers||Cadila Healthcare Limited|Yes|Completed|October 2014|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|December 1, 2015|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620592||7666|
NCT02612012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-BC002|Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes|Phase II Study of Axillary Level I-II Areas Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes||Fudan University|Yes|Recruiting|October 2015|||October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|475|||Female|18 Years|70 Years|No|Probability Sample|Early stage breast cancer patients with 1~2 positive sentinel lymph nodes|November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612012||8325|
NCT02613897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150742H|ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study|A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy||The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|177|||Both|18 Years|70 Years|No|||November 2015|November 20, 2015|November 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613897||8180|
NCT02613910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117059|Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris|OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris||GlaxoSmithKline|Yes|Recruiting|December 2015|May 2022|Anticipated|May 2022|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|N/A|N/A|No|||February 2016|February 11, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613910||8179|
NCT02614261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15769|Evaluation of LY2951742 in the Prevention of Chronic Migraine|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study|REGAIN|Eli Lilly and Company|Yes|Recruiting|November 2015|April 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|825|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614261||8152|
NCT02621489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY2015|Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects|Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects|Rebuild|Karolinska Institutet|No|Recruiting|December 2015|April 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02621489||7597|
NCT02620189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009745|Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα|A Study to Investigate the Role of IL-17 and Th17 Pathway Activation in RA Patients With Inadequate Response to Anti-TNFα Therapies|THERAPIST|Queen Mary University of London|Yes|Recruiting|March 2015|March 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|-  Synovial tissue        -  RNA extraction on peripheral blood mononuclear cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who fulfil the NICE guidelines for biologic anti-TNF therapy as their first line        treatment following failure of standard disease modifying anti-rheumatic therapy will be        recruited from various secondary care settings at a number of centres throughout the UK.|November 2015|November 30, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02620189||7697|
NCT02624817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167.06|Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes|Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to KCNJ11 (KIR6.2) Mutations|SuResponsKIR|Haukeland University Hospital|No|Enrolling by invitation|November 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|9 Years|N/A|No|||December 2015|December 7, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624817||7341|
NCT02622516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viviane-Unopar|Exercise Protocol of Multisensory Rehabilitation in Treatment of the Complaints Vestibular: Clinical Trial Random|Effectiveness of the Exercise Protocol of Multisensory Rehabilitation in Treatment of Patient With Complaints Vestibular: Clinical Trial Random||Universidade Norte do Paraná|Yes|Not yet recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||August 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622516||7518|
NCT02625298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-12|Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Teeth|Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Permanent Teeth With Necrotic Pulps and Chronic Periapical Lesions||Association of Paediatric and Preventive Dentists of Serbia|Yes|Active, not recruiting|September 2010|May 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 5, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625298||7304|
NCT02625337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N15IMP|Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients|Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation|IMPemBra|The Netherlands Cancer Institute|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625337||7301|
NCT02627586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIIT-EARLY|High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction|High Intensity Interval Training & Early Adverse Remodelling After Left Ventricular mYocardial Infarction (HIIT-EARLY): A Randomized Controlled Exercise Intervention Study|HIIT-EARLY|University Hospital Inselspital, Berne|Yes|Enrolling by invitation|June 2015|May 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02627586||7128|
NCT02627612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-225|Evaluation of ProVetus/Sponsorship Initiative|Evaluation of ProVetus/Sponsorship Initiative||Teachers College, Columbia University|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627612||7126|
NCT02571517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSJD-GLUCOBR-2010|Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis|Impact of the Administration of Systemic Glucocorticoids on Inflammatory Response and Clinical Evolution of Patients Diagnosed With Moderate- Severe Bronchiolitis||Fundació Sant Joan de Déu|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|N/A|12 Months|No|||October 2015|October 7, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02571517||11433|
NCT02619253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0551|Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma|A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma||Indiana University|Yes|Not yet recruiting|December 2016|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02619253||7769|
NCT02619266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014YLC32|The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers|The Traditional Chinese Medicine Department of Xin Qiao Hospital||Xinqiao Hospital of Chongqing|Yes|Recruiting|December 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619266||7768|
NCT02614326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MemFlex to prevent relapse|MemFlex to Prevent Depressive Relapse|A Randomised Controlled Trial of the Efficacy of Autobiographical Memory Flexibility (MemFlex) Training in Preventing Relapse of Recurrent Depression||Medical Research Council Cognition and Brain Sciences Unit|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614326||8147|
NCT02624856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4059|Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty|Prospective, Randomized, Double-Blinded, Allocation Concealed Study Comparing the Efficacy of Liposomal Bupivacaine Over Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Primary Total Knee Arthroplasty||Albany Medical College|No|Recruiting|November 2015|||November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|70 Years|No|||December 2015|December 4, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624856||7338|
NCT02623075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201741|Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients|Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients||Northwestern University|Yes|Enrolling by invitation|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623075||7475|
NCT02620319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT 14146-3/2013|Biodegradable Stents in the Management of Stenoses of the Large Airways|Biodegradable Stents in the Management of Stenoses of the Large Airways||Thomayerova Teaching Hospital|Yes|Active, not recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02620319||7687|
NCT02614599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrainProteins|Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|BrainProtein|Spanish Foundation for Neurometrics Development|Yes|Completed|June 2015|November 2015|Actual|November 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|7 Years|13 Years|Accepts Healthy Volunteers|||November 2015|November 21, 2015|April 22, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614599||8126|
NCT02613026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT2009|Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer|Comparative Analysis of the Efficacies of AT and AC-T Regimens in Neoadjuvant Chemotherapy of Breast Cancer||307 Hospital of PLA|No|Completed|July 2009|February 2015|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|70 Years|No|||November 2015|November 22, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02613026||8247|
NCT02623140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORT OUT IX|BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX|Randomized Comparison of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients Treated With Percutaneous Coronary Intervention|SORT OUT IX|Odense University Hospital|Yes|Not yet recruiting|December 2015|October 2021|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3150|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623140||7470|
NCT02614872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2-LUNG-IV-IL-014|Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation|A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation||Kamada, Ltd.|No|Not yet recruiting|January 2016|December 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02614872||8105|
NCT02617875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-069|Telemedical Support for Prehospital Emergency Medical Service|Telemedical Support for Prehospital Emergency Medical Service - a Prospective Randomized Controlled Trial|TEMS|RWTH Aachen University|Yes|Not yet recruiting|June 2016|October 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3010|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617875||7875|
NCT02617888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|362425|The HEART BREAK Study|Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells||Walter Reed National Military Medical Center|No|Completed|March 2011|||September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|228|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617888||7874|
NCT02619188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/894|Nutritional Markers in Normal and Hyperemesis Pregnancies|Pregnancy Unique Questionnaire of Emesis (PUQE) Methode Evaluation; Relation Between Rate of Nausea/Vomiting in Pregnancy (PUQE-score), Self-reported Nutritional Intake and Biochemical Nutritional Markers|PUQE-M|Haukeland University Hospital|No|Recruiting|September 2015|March 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Women admitted to hospital due to Hyperemesis gravidarum          -  Healthy pregnant women (without hyperemesis gravidarum)|November 2015|November 30, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02619188||7774|
NCT02621060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-ACG-271281-LYZ|Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance|Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance||University of Guadalajara|Yes|Recruiting|September 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|60 Years|No|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621060||7630|
NCT02619617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230Y2201|Safety and Efficacy Study of SOM230 s.c. in Cluster Headache|A Two Part Multicenter, Placebo-Controlled, Active-Comparator Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 s.c.||Novartis|No|Not yet recruiting|February 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|150|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02619617||7741|
NCT02619630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM12629_2|Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)|Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients|GRAALL-2014/T|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|December 2025|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|275|||Both|18 Years|59 Years|No|||November 2015|December 1, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02619630||7740|
NCT02626884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1776|Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)|Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)|IRENO|University of Cologne|Yes|Not yet recruiting|March 2016|||September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|99 Years|No|||December 2015|December 7, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02626884||7182|
NCT02623010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0356-15-RMC|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma|Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment||Rabin Medical Center|No|Not yet recruiting|December 2015|June 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|85 Years|No|||October 2015|December 2, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02623010||7480|
NCT02611609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B04-01|A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome|A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome|MUST-ARDS|Athersys, Inc|Yes|Recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|90 Years|No|||February 2016|February 4, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611609||8356|
NCT02616666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00009|A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)|A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)|DECIDE|AstraZeneca|No|Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|872|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02616666||7967|
NCT02627794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039737|Rates of Middle Meatus Synechiae Formation Post Endoscopic Sinus Surgery|Rates of Middle Meatus (MM) Synechiae Formation Post Endoscopic Sinus Surgery (ESS): A Double-blind Randomized Controlled Study Comparing Silastic and Restora™ Steroid Eluting MM Spacer||Cedars-Sinai Medical Center|No|Recruiting|December 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|75 Years|No|||December 2015|March 24, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627794||7112|
NCT02625831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1841851v0|Anti-ficolin-3 Autoantibodies in Lupus Nephritis|Association Between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients With Systemic Lupus Erythematosus|ficolupus|University Hospital, Grenoble|Yes|Completed|November 2012|May 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|213|Samples Without DNA|one serum sample per patient.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|SLE patients were studied from medical data files of the Departments of Internal Medicine        (Grenoble University Hospital, France) and Nephrology (Conception University Hospital,        Marseille, France). For SLE patients, clinical and biological manifestations as well as        treatments received and disease activity evaluated using the SLE Disease Activity Index        (SLEDAI) at the time of sampling were recorded. SLE patients were divided into subgroups        as described in group section.|December 2015|December 7, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02625831||7263|
NCT02611583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Back1|TENS Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the ED|Double-blind, Randomized, Placebo Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the Emergency Department||Albert Einstein Healthcare Network|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611583||8358|
NCT02611596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409189|Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics|Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial||Walter Reed National Military Medical Center|No|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|80|||Both|30 Years|85 Years|No|||November 2015|November 20, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611596||8357|
NCT02621281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT-G-1501|Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients|Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients|CIHMP|First Affiliated Hospital Xi'an Jiaotong University|Yes|Recruiting|December 2015|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|400|||Both|16 Years|N/A|No|||December 2015|January 26, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02621281||7613|
NCT02620124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T5/2013|GnRH Agonist as Luteal Support in FET Cycles|GnRH Anonist as Luteal Support in Frozen-thawed Embryo Transfer Cycles||Turku University Hospital||Completed|May 2013|||April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|100|||Female|20 Years|45 Years|No|||March 2016|March 24, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02620124||7702|
NCT02620137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURJC15-15|Maintenance of Multivitamin Supplements After Sleeve Gastrectomy|Maintenance of Multivitamin Supplements After Sleeve Gastrectomy||Hospital General Universitario Elche|Yes|Completed|January 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|N/A|N/A|No|||November 2015|November 28, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02620137||7701|
NCT02618850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETRA2 - CRC|PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment|Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of First-line Therapy in Patients With Advanced Colorectal Cancer (CRC)|PETRA2 - CRC|National Cancer Institute, Naples|No|Recruiting|April 2014|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|260|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02618850||7800|
NCT02619994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDR-END|Treatment Shortening of MDR-TB Using Existing and New Drugs|Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2, Multicenter, Randomized, Open-label, Clinical Trial|MDR-END|Seoul National University Hospital|Yes|Not yet recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|19 Years|85 Years|No|||January 2016|January 15, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02619994||7712|
NCT02620007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140503|Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease|Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease|TEOREM|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|April 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|80 Years|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02620007||7711|
NCT02613455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405072-2|Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis|Prospective Randomize Trial Comparing Corticosteroid Injection to High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis||Walter Reed National Military Medical Center|No|Recruiting|July 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613455||8214|
NCT02615925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9417|Descriptive Study of Mental Activity|Descriptive Study of Mental Activity in the Emergency Department of the Centre Hospitalier de Mayotte|URGPSYMAY|University Hospital, Montpellier|No|Recruiting|November 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615925||8024|
NCT02622958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH94B CL028|Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)|A Feasibility Study for a Phase 3, Randomized, Four-Week, Double-Blind, Placebo-Controlled, Crossover Trial of the Efficacy and Safety of PH94B Nasal Spray in the Acute Treatment of Social Anxiety Disorder (SAD)||Pherin Pharmaceuticals, Inc.|No|Completed|March 2014|March 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|March 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622958||7484|
NCT02613754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRC 2015-020|Adding Contingency Management to Treatment as Usual for Disordered Gambling.|The Impact of Adding Contingency Management to Treatment as Usual for Disordered Gambling||University of Lethbridge|No|Recruiting|March 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02613754||8191|
NCT02624102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 44663315.4.0000.5662|Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression|Efficacy of Trial-based Cognitive Therapy and Behavioral Activation in Treatment of Depression: a Randomized Clinical Trial||Hemanny, Curt, M.D.|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|60 Years|No|||December 2015|December 15, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02624102||7396|
NCT02611544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0563|Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors|Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors: A Randomized Clinical Pilot Trial||Indiana University|Yes|Recruiting|December 2015|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|78|||Female|18 Years|99 Years|No|||December 2015|December 9, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611544||8361|
NCT02611557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donahue_Lymphedema|Lymphedema Progression Screening Using MRI|Imaging Noninvasively With Functional-MRI for Onset, Response and Management of Lymphatic Impairment|INFORM|Vanderbilt University|No|Recruiting|February 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611557||8360|
NCT02620839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159516|Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies|A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies||University of California, San Francisco|Yes|Not yet recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|41|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620839||7647|
NCT02600520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014X|Comparison of Rosuvastatin With Atorvastatin in Chronic Periodontitis|1.2% Rosuvastatin Versus 1.2% Atorvastatin Local Drug Delivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|Yes|Completed|November 2014|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02600520||9204|
NCT02595879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01907|Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer|Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer||National Cancer Institute (NCI)||Not yet recruiting|December 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|No|||November 2015|January 11, 2016|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02595879||9561|
NCT02610010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-066-Dept. of RT|Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma|Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma: a Phase 3 Non-inferior Multicenter Randomized Controlled Trial||Sun Yat-sen University|No|Recruiting|November 2015|November 2025|Anticipated|November 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02610010||8478|
NCT02596438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388325|Thousand Asian American Study|Thousand Asian American Study (TAAS)|TAAS|University of California, Davis|Yes|Recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Asian Americans residing in Sacramento, CA who are 18 years of age and older.|November 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02596438|6 Months|9518|
NCT02597348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130922|Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy|Curative Potential of Liver Transplantation in Patients With Definitively Unresectable Colorectal Liver Metastases (CLM) Treated by Chemotherapy: a Prospective Multicentric Randomized Trial|TRANSMET|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2015|October 2023|Anticipated|October 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||October 2015|November 5, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02597348||9448|
NCT02597933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.214|A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis|A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)||Boehringer Ingelheim||Recruiting|November 2015|May 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 8, 2015||||No||https://clinicaltrials.gov/show/NCT02597933||9403|
NCT02596373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC-HE1506/PRO/Ⅰ|A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer|A Randomized, Open-label, Positive-controlled, Single-institutional, Phase Ⅱ of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|No|Recruiting|June 2015|December 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|75 Years|No|||November 2015|November 2, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02596373||9523|
NCT02600403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-058|Are There Changes in the Nerve Fiber Layer (NFL) After Lowering of Eye Pressure?|Reversible Structural and Functional Changes After Intraocular Pressure Reduction in Patients With Glaucoma||Wills Eye|No|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|140|||Both|18 Years|90 Years|No|||November 2015|November 5, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02600403||9213|
NCT02622685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_P10292002P|A Multiple Dose Study of DWP10292 and UDCA in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects||Daewoong Pharmaceutical Co. LTD.|Yes|Active, not recruiting|May 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|60|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||November 2015|January 26, 2016|April 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622685||7505|
NCT02623088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC14.422|CPAP Effect on Vascular Function in Obstructive Sleep Apnea|Long Term Effects of Positive Airway Pressure Therapies on Vascular Function in Obstructive Sleep Apnea|VNI-SOH2|University Hospital, Grenoble|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|211|Samples Without DNA|Serum Bank|Both|20 Years|75 Years|No|Non-Probability Sample|Patients with sleep apnea syndrome treated by CPAP after diagnosis and followed 5-7 years,        as part of a clinical research.|December 2015|December 2, 2015|March 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02623088||7474|
NCT02621905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPG010|Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg|Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions||Mayne Pharma International Pty Ltd|No|Recruiting|November 2015|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621905||7565|
NCT02622165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBO-120054|Rewarding Healthy Food Choices: a Mobile Serious Game Intervention in Adolescents|Rewarding Healthy Food Choices: a Mobile Serious Game Intervention Targeting Snacking Behaviours in Adolescents|REWARD|University Ghent|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02622165||7545|
NCT02624310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-01774|A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis|A Phase II, Randomized, Double Blind, Cross-over, Placebo-controlled Study on Norepinephrine Replenishment Therapy Using L-DOPS in Congenital Insensitivity to Pain With Anhidrosis Patients||New York University School of Medicine|No|Withdrawn|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|15 Years|N/A|No|||March 2016|March 7, 2016|September 30, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624310||7380|
NCT02620696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-013|Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin|Effect of Netazepide, a Gastrin/CCK2 Receptor Antagonist, on Esomeprazole-induced Increases in Circulating Gastrin and Chromogranin A, and on Esomeprazole Withdrawal in Healthy Subjects||Trio Medicines Ltd.|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620696||7658|
NCT02623621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRCUS|Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer|A Single-arm Phase II Study of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) as Predictor of Benefit From Bevacizumab (Bev) Beyond Progression in Metastatic Colorectal Cancer (mCRC) - the CIRCUS Study|CIRCUS|Azienda Ospedaliero, Universitaria Pisana|No|Recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|97|Samples With DNA|Paired plasma and blood samples will be collected at baseline, at the time of every disease      assessment and at the time of disease progression|Both|18 Years|N/A|No|Non-Probability Sample|Patients with mCRC progressed on or after a 1st-line bevacizumab-containing regimen and        candidate to continue bevacizumab beyond progression, in combination with a 2nd-line        chemotherapy regimen.|December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623621||7433|
NCT02623634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bei Jing Chao Yang Hospital|The Association Between Factors and the Results of the Cuff Leak Test|The Association Between Factors and the Results of the Cuff Leak Test:a Cohort Study||Beijing Chao Yang Hospital|Yes|Recruiting|October 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|90 Years|No|Probability Sample|patients in RICU of Beijing chaoyang hospital with tracheal intubation|December 2015|December 3, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02623634|2 Years|7432|
NCT02623647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eHYPO|A Phase I-II Study on Stereotactic Body Radiotherapy in 3 Fractions for Low/Int Risk Prostate Cancer|A Phase I-II Study on the Tolerance and Efficacy of SBRT in 3 Fractions for Low/Int Risk Prostate Cancer|eHYPO|Regina Elena Cancer Institute|No|Recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Male|18 Years|N/A|No|||December 2015|December 3, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623647||7431|
NCT02618252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00065438|Ultrasound vs Veinviewer in Patients With Difficulty IV Access|Preventing Delay of Care in Patient With Difficult IV Access: A Randomized Trial of ED Intervention||University of Maryland|No|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02618252||7846|
NCT02622087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MQ13002|The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women|Sex Hormones and Fear Inhibition: a Novel Exploration of Why Women Are so Vulnerable to Anxiety Disorders||The University of New South Wales|No|Recruiting|November 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|35 Years|No|||December 2015|December 1, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622087||7551|
NCT02624362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57940|The Effect of Odors on Asthma Symptoms|The Effect of Suggestion of Harmful/Beneficial Effects of Odors on Asthma Symptoms||Universitaire Ziekenhuizen Leuven|No|Enrolling by invitation|August 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|65 Years|No|||November 2015|December 7, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02624362||7376|
NCT02624375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44564|Immune Response to Shingles Vaccination|Immune Response to Shingles Vaccination||University of Washington|Yes|Recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624375||7375|
NCT02626455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17833|Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)|A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)|CHRONOS-4|Bayer|Yes|Recruiting|January 2016|July 2024|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|724|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626455||7215|
NCT02621242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49167-J|Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals|Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals||University of Washington|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02621242||7616|
NCT02626260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP265_01b|A Pilot Evaluation of Adhesives and How They Are Impacted by Output|A Pilot Evaluation of Adhesives and How They Are Impacted by Output||Coloplast A/S|No|Recruiting|November 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Both|18 Years|N/A|No|||November 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626260||7230|
NCT02626351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuropeAid/134286/L/ACT/ZA|Management and Optimization of Nutrition, Antenatal, Reproductive, Child Health & HIV Care|Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa|MONARCH|University of KwaZulu|Yes|Recruiting|July 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|6000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02626351||7223|
NCT02624947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-M-301|A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization|A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants||Novavax|Yes|Recruiting|December 2015|June 2020|Anticipated|May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|8255|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624947||7331|
NCT02627573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/15-n|Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT|Randomized Trial of GVHD Prophylasxis With Post-transplantation Cyclophocphomide (PTCy) or Thymoglobulin in Unrelated SCT Recepients With Chronic Myeloproliferative Neoplasms and Myelodisplatic Syndrome||St. Petersburg State Pavlov Medical University|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627573||7129|
NCT02614534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCO-HIP-2015-01|Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma|Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma||Maimónides Biomedical Research Institute of Córdoba|No|Recruiting|November 2015|||October 2020|Anticipated|Phase 3|Interventional|N/A|||||||Both|18 Years|75 Years||||November 2015|November 24, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02614534||8131|
NCT02626078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0433|Assessment of Food Practices by Residents in Nursing Homes|Assessment of Food Practices by Residents in Nursing Homes, Study of Relationship Between Food Intake and Nutritional Status.|ARC2|Hospices Civils de Lyon|No|Recruiting|April 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The protocol will include 110 subjects recruited in nursing home in which they reside|November 2015|December 7, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02626078||7244|
NCT02624583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/2015|Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk|Effects of Ramadan Fasting on Clopidogrel Resistance in Patients at High Cardiovascular Risk. An Observational Study|RFeCloR|University of Monastir|No|Active, not recruiting|June 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|Samples Without DNA|Venous blood samples were collected from the enrolled participants. Blood samples were      analyzed for hemoglobin, hematocrit, platelet cell count, Prothrombin time, activated      partial thromboplastin time, and clopidogrel effect on P2Y12 receptor by optical      turbidimetry (expressed as P2Y12 reaction units (PRU)).|Both|40 Years|N/A|No|Non-Probability Sample|Patients were screened in outpatient clinics (cardiology, endocrinology, internal        medicine, family medicine) when they presented for scheduled follow-up.|December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624583||7359|
NCT02619292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMP-001|Mindful Movement for Breast Cancer Survivors|Mindful Movement for Breast Cancer Survivors||John Wayne Cancer Institute|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|50 Years|N/A|No|||November 2015|November 30, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02619292||7766|
NCT02624830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167.06b|Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)|Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations|SuResponsSUR|Haukeland University Hospital|No|Enrolling by invitation|November 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|9 Years|N/A|No|||December 2015|December 7, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624830||7340|
NCT02568488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138|The Effect of Metformin on Different Hormones in PCOS Patients|The Effect of Metformin on Serum Insulin, Androgens and AMH in PCOS Patients||Cairo University|Yes|Completed|March 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|33 Years|No|||October 2015|October 2, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02568488||11666|
NCT02571257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027-018|Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy|An 8-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study in Hypercholesterolemic Patients to Determine the Efficacy and Safety of Combination Therapy With CI-1027 and a Statin||Gemphire Therapeutics, Inc.|No|Completed|August 2000|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|65 Years|No|||October 2015|October 10, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571257||11453|
NCT02626728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123-TAMIS|A Prospective Feasibility Study for TAMIS|A Prospective Quality Assurance Feasibility Study of Laparoscopic Assisted Transanal Minimally Invasive Surgery (TAMIS) for Rectal Cancer|TAMIS|Hvidovre University Hospital|Yes|Recruiting|September 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|99 Years|No|Non-Probability Sample|Consecutive patients with a solitary rectal cancer, who is eligible for surgery. Patients        with rectal cancer (T1-3 stages verified by MRI), regardless regional lymph-node status        and distant metastasis, will be offered the operative procedure with TAMIS technique.|December 2015|December 11, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02626728||7194|
NCT02612701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041957|E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion|E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion||Cedars-Sinai Medical Center|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612701||8272|
NCT02615444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueenMUsz|The Effects of Beta-glucan Enriched Oatcake Consumption on Metabolic Disease Risk Factors|An Investigation of the Effects of Consuming Oatcakes Containing 4g of Oat Beta-glucan on Physiological Parameters in Individuals at Risk of Developing Metabolic Syndrome||Queen Margaret University|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02615444||8061|
NCT02574182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU PROMOTEUR 2014/32|Study of Motor Representations in Healthy Subjects and Amnestic MCI|Walking, Brain and Functional Magnetic Resonance Imaging Study of Motor Representations in Healthy Subjects and Amnestic MCI|IRMARCHE|University Hospital, Angers|No|Recruiting|February 2015|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|-  Healthy volunteers over 18 and under 40.          -  Healthy volunteers over 60 years.          -  MCI patient over 60 years|September 2015|October 8, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02574182||11228|
NCT02574195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR1410209|Evolution of Effectiveness of Diabetes Medical Care in Russia|Evolution of Effectiveness of Diabetes Medical Care in Russia||Endocrinology Research Centre, Moscow|No|Active, not recruiting|August 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 1 or type 2 Diabetes Mellitus|March 2016|March 11, 2016|December 18, 2014||No||No||https://clinicaltrials.gov/show/NCT02574195||11227|
NCT02622529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 15/157|Patients' Conscious Experience and Psychological Consequences of Awake Surgery for Intracerebral Lesions|Patients' Conscious Experience and Psychological Consequences of Awake Surgery for Intracerebral Lesions||Cantonal Hospital of St. Gallen|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Consecutive ongoing recruitment through investigator(s) in daily clinical practice        (consultations). The subjects will receive the consent form with an address and phone        number indicated where further questions regarding the study can be discussed directly        with the project leader. This will take place at least one week before the        hospitalisation.|December 2015|December 3, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622529||7517|
NCT02622542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTVS-KC03|ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy|A Randomized Controlled Comparative Study on Effectiveness of Endovascular Repair Versus Best Medical Therapy for Acute Uncomplicated Type B Aortic Dissection|ACUTE-B|The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|July 2016|December 2025|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|436|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622542||7516|
NCT02627131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBG 003|Autologous Bone Marrow Stem Cell Therapy for Autism|Autologous Bone Marrow Stem Cell Therapy for Autism: An Open Label Uncontrolled Clinical Trial||Vinmec International Hospital|No|Completed|April 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|3 Years|16 Years|No|||December 2015|December 8, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02627131||7163|
NCT02618798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVPG_Platelets_Version_4.0|Hepatic Venous Pressure Gradient and Platelet Activation in Chronic Liver Disease|Association of Hepatic Venous Pressure Gradient With Platelet Activation in Chronic Liver Disease||Medical University of Vienna|No|Recruiting|January 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Serum Plasma Platelet pellet|Both|19 Years|90 Years|No|Probability Sample|Patients suffering from chronic liver disease scheduled for routine measurement of the        hepatic venous pressure gradient (HVPG).|November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618798||7804|
NCT02623764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-15-002|EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors|EEG-cholinergic Index and Its Validation of Clinical Response to Treatment With Cholinesterase Inhibitors|Cholindex|Landspitali University Hospital|Yes|Not yet recruiting|December 2015|November 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|200|||Both|55 Years|85 Years|No|Non-Probability Sample|Individuals diagnosed at a Memory Clinic with Mild Cognitive Impairment or mild dementia        due to Alzheimer´s disease or with dementia due to Lewy body disease|December 2015|December 3, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02623764||7422|
NCT02626299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003455|Assessment of DHA On Reducing Early Preterm Birth|Assessment of DHA On Reducing Early Preterm Birth (ADORE Trial)|ADORE|University of Kansas Medical Center|Yes|Not yet recruiting|April 2016|February 2021|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|March 3, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626299||7227|
NCT02626312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0052|Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function|Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2022|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626312||7226|
NCT02614729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039674|The Consumption of Beef on Appetite and Cognitive Function|A Randomized Controlled Feeding, Crossover Trial to Assess the Appetitive and Cognitive Effects of Daily Beef Consumption in Healthy, Overweight Women||University of Missouri-Columbia|No|Completed|January 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|35|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614729||8116|
NCT02623686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4308|The Effect of an Aromatherapy Intervention on Sleep in the ICU|What is the Effect of an Aromatherapy Intervention on Sleep in the ICU? An Exploratory Study||Royal Marsden NHS Foundation Trust|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623686||7428|
NCT02623699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233AS101|Single and Multiple Dose Study of BIIB067 (Isis-SOD1Rx) in Adults With Amyotrophic Lateral Sclerosis (ALS)|A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis||Biogen|Yes|Recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623699||7427|
NCT02619045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 GENE 07|Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment|Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment, in Their Quality of Life and Medico-economic Analysis of This Follow-up Program Device|EVAL'COACH|Institut Claudius Regaud|No|Recruiting|November 2015|November 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619045||7785|
NCT02624921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHENOTYPE_WP4BCN|PHENOTYPE. Therapeutic Study in Barcelona|Positive Health Effects of the Natural Outdoor Environment in Typical Populations in Different Regions in Europe. Work Package 4: Therapeutic Study in Barcelona||Centre for Research in Environmental Epidemiology, Spain||Completed|October 2013|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|75 Years|No|Non-Probability Sample|All the participants (n=26) were individuals that had previously participated in a survey        of 1000 people in Barcelona city as part of the PHENOTYPE project. As part of the survey,        they had answered the Mental Health Inventory (MHI-5) subscale from the SF-36 health        questionnaire. The investigators purposively selected those individuals MHI-5 scored in        the lower 50th percentile.|December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02624921||7333|
NCT02615015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1947/2014|SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls|Single Nucleotide Polymorphisms in the Deoxyribonuclease 1 Gene Impair Its Activity and Are Increased in a ST-elevation Acute Coronary Syndrome Patient Cohort Compared to Healthy Controls||Medical University of Vienna|No|Enrolling by invitation|September 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|800|Samples With DNA|Whole blood draw, DNA isolation, plasma isolation|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|ST elevation myocardial infarction patients, who have been hospitalized in the General        Hospital of Vienna since 2006 for ST-elevation acute coronary syndrome undergoing primary        percutaneous coronary intervention (pPCI) with TIMI 0-1.|November 2015|November 23, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02615015||8094|
NCT02615028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20120807|Development of Novel Designed Force Plate for Measuring the Balance Ability for the Elders|Kaohsiung Medical University Chung-Ho Memorial Hospital Institutional Review Board||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|December 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02615028||8093|
NCT02615067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-1404-3301|Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer|A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)|proSPECT-AS|Molecular Insight Pharmaceuticals, Inc.|Yes|Recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Male|18 Years|N/A|No|||December 2015|December 22, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615067||8090|
NCT02615080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSPR-008|Safety and Efficacy of CRD007 in Adult Asthma Subjects|A Double-Blind, Randomised, Placebo-controlled, Parallel Group, International, Multi-centre Phase 2 Trial Investigating the Safety and Efficacy of CRD007 in Adult Subjects With Asthma||RSPR Pharma AB|No|Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02615080||8089|
NCT02619370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002634|Evaluation of an Advance Care Planning Activity: Feasibility Testing for a Randomized Controlled Trial|Evaluation of an Advance Care Planning Activity: Feasibility Testing for a Randomized Controlled Trial||Milton S. Hershey Medical Center|Yes|Not yet recruiting|January 2016|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619370||7760|
NCT02624986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH29812|A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma||Hoffmann-La Roche||Recruiting|December 2015|May 2022|Anticipated|May 2022|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624986||7328|
NCT02622009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10451|Viral Infections in BAL and Bronchial Biopsies of Stable COPD Patients|Human Rhinovirus and Respiratory Syncytial Virus From Bronchoalveolar Lavage and Bronchial Biopsies of Selected Patients With Stable Chronic Obstructive Pulmonary Disease.||University of Athens|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|53|Samples With DNA|BAL and bronchial biopsies|Both|51 Years|76 Years|Accepts Healthy Volunteers|Probability Sample|We enrolled 31 patients with COPD and 22 control subjects. The most common symptoms were        dyspnea (32%), cough (19%) and hemoptysis (13%). Whereas 47% of participants did not        mention any symptom, but referred to our department in order to investigate        bronchoscopically abnormal radiographic findings revealed in chest computed tomography.        The commonest comorbidities of COPD patients were arterial hypertension (47%),        hyperlipidemia (20.7%) and coronary artery disease (17%), and of control subjects arterial        hypertension (50%), hyperlipidemia (22,7%) and diabetes mellitus type 2 (13,6%).|December 2015|December 4, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622009||7557|
NCT02612402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0090-14-RMB|Effect of Smartphone App on Activity|The Effect of a Smartphone Application for Encouraging Physical Activity on the Amount of Activity Performed by Patients With Diabetes or Hematological Malignancies||Rambam Health Care Campus|No|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|270|||Both|18 Years|90 Years|No|||November 2015|November 20, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612402||8295|
NCT02612415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HC30|FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study|FIRST-ABC Feasibility Study: Feasibility Study for a Randomised Trial of High Flow Nasal Cannula (HFNC) Versus Continuous Positive Airway Pressure (CPAP) for Non-invasive Respiratory Support in Critically Ill Children|FIRST-ABC|Great Ormond Street Hospital for Children NHS Foundation Trust|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|36 Weeks|15 Years|No|||November 2015|November 20, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02612415||8294|
NCT02612428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTL-308|Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD|A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)||Vital Therapies, Inc.|Yes|Recruiting|January 2016|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|49 Years|No|||February 2016|February 9, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612428||8293|
NCT02627755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-GLI-2015-02|GlideScope® vs GlideScope® + aScope® for Managing Difficult Airways.|GlideScope® vs GlideScope® + aScope® for Managing Difficult Airways. Assessment of a New Procedure for Endotracheal Intubation in Patients With Suspected Difficult Airways||Hospital de Manises|No|Not yet recruiting|January 2016|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02627755||7115|
NCT02614690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC118|Is Univalving or Bivalving of Long Arm Casts for Forearm Fractures Necessary?|Is Univalving or Bivalving of Long Arm Casts for Forearm Fractures Necessary?||Connecticut Children's Medical Center|No|Recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|3 Years|12 Years|No|||November 2015|November 23, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02614690||8119|
NCT02611622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201301163|LumaENT and Patient Satisfaction|Impact of Multimedia-based Patient Education on Patient Satisfaction Scores in an Otolaryngology Practice Setting||Washington University School of Medicine|No|Recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611622||8355|
NCT02620332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MultiPep001|Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)|Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)|MultiPepT1De|King's College London|Yes|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|45 Years|No|||December 2015|December 1, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02620332||7686|
NCT02611739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000049494|Medi-Port Pilot Randomized Controlled Trial|Using a Humanoid Robot to Reduce Procedural Pain and Distress in Children With Cancer: A Pilot Randomized Controlled Trial||The Hospital for Sick Children|Yes|Not yet recruiting|November 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Years|9 Years|No|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611739||8346|
NCT02626910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-12-11-4567|Understanding Disparities in Healthcare and Primary Care Provider Quality|Patient Centered Outcomes Research Institute: Mrs. A and Mr. B||University of Pennsylvania|No|Recruiting|August 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Both: both female and male participants are being studied|December 2015|December 7, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02626910||7180|
NCT02626923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759-TBC|Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients|Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects||Southwest Infectious Disease Clinical Research, Inc.|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|51|||Both|21 Years|65 Years|No|Non-Probability Sample|HIV impacted individual on therapy with once daily Maraviroc|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626923||7179|
NCT02616042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI09001|The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis|The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis: a Randomized Clinical Trial||LG Household & Health Care Ltd.|Yes|Completed|March 2009|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616042||8015|
NCT02628041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-20-2016-2570|HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer|A Phase II Randomized Trial Evaluating Acute and Late Toxicity of High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer|HDRvsLDR|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02628041||7093|
NCT02627950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10498|Impact of Morphine Treatment on Platelet Inhibition in ST-Elevation Myocardial Infarction|Impact of Morphine Treatment on Platelet Inhibition in ST-Elevation Myocardial Infarction (MoSTEMI)|MoSTEMI|University of Luebeck|No|Recruiting|December 2015|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627950||7100|
NCT02627963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-15-303|A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC|A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma||AVEO Pharmaceuticals, Inc.|No|Not yet recruiting|January 2016|June 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|322|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627963||7099|
NCT02625415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-PPEHP-89|The Topical Application of Vitamin B6 in Palmar-Plantar Erythrodysesthesia|A Double Blind Placebo Control Randomised Trial to Test the Effectiveness of Vitamin B6 in Hand Foot Syndrome|HFSB6|Cyprus University of Technology|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02625415||7295|
NCT02622711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuropeanIO|Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer|Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer: A Four-arm Randomized Trial|InForma|European Institute of Oncology|No|Recruiting|November 2015|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|260|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02622711||7503|
NCT02617264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaplanMC|Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery|Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery||Kaplan Medical Center|No|Not yet recruiting|January 2016|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|80 Years|No|||December 2015|December 1, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02617264||7921|
NCT02621294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Measuring Protein Requirement Using Amino Acid Oxidation in Strength and Endurance Athletes|Measuring Protein Requirement Using the Indicator Amino Acid Oxidation Method in Healthy Young Strength and Endurance Exercise Trained Individuals||University of Western Ontario, Canada|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02621294||7612|
NCT02620397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP7001_5ACS|Clinical Study to Validate the Use of a New Point of Care Troponin I Test|Clinical Study to Validate the Use of a New Point of Care Troponin I Test as an Aid in the Diagnosis of Myocardial Infarction and Prognosis of Subjects Presenting With Symptoms of Acute Coronary Syndrome||Trinity Biotech|No|Active, not recruiting|March 2015|November 2016|Anticipated|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|EDTA Whole Blood|Both|21 Years|N/A|No|Non-Probability Sample|Approximately 1000 to 1500 adult subjects presenting to emergency departments (ED) with        symptoms suggestive of acute coronary sydrome (ACS) and/or myocardial ischemia|December 2015|December 14, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02620397||7681|
NCT02620410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-0010|Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System|Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System: RELAX-OAB|RELAX-OAB|Axonics Modulation Technologies, Inc.|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620410||7680|
NCT02620202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1365|Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain|Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain (WESTCOR Study)|WESTCOR|Haukeland University Hospital|No|Recruiting|September 2015|December 2036|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|3000|Samples With DNA|Full blood, Serum samples, EDTA plasma, Urine|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Emergency Department at Haukeland University Hospital or        Stavanger University Hospital with symptoms indicative of acute coronary syndrome|December 2015|December 4, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02620202||7696|
NCT02620215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/2730|Cervical Ripening Balloon in Induction of Labour at Term|Cervical Ripening Balloon in Induction of Labour at Term (CRBII) - A Prospective Randomized Controlled Trial|CRBII|KK Women's and Children's Hospital|No|Not yet recruiting|November 2015|July 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Female|21 Years|40 Years|No|||November 2015|November 30, 2015|November 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620215||7695|
NCT02621450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-51|Low Sodium Dialysate and Ambulatory Blood Pressure Measurement Parameters|The Effect of Low Sodium Dialysate on Ambulatory Blood Pressure Measurement Parameters in Patients Undergoing Hemodialysis||Yuzuncu Yıl University|No|Enrolling by invitation|December 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|December 8, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02621450||7600|
NCT02612506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L47-Ia-01|Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers|A Randomized, Double-Blinded, Safety and Pharmacokinetic Study of Escalating Single Doses of Hepalatide in Healthy Volunteers||Shanghai HEP Pharmaceatical Co., Ltd.|Yes|Recruiting|October 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|November 19, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02612506||8287|
NCT02615756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/180/2013|Molecular and Functional Neurobiology of Physical Exercise|Molecular and Functional Neurobiology of Physical Exercise|EXEBRAIN|Turku University Hospital|No|Recruiting|April 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|September 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02615756||8037|
NCT02615769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPP-Lung|Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks|Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks - a Randomized Controlled Trial in Primary Health Care||University of Aarhus|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4356|||Both|30 Years|49 Years|No|||November 2015|December 1, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615769||8036|
NCT02623374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOW-RG1701|MENOS@Work Trial: A Self-help CBT Intervention for Working Women|Menopause at Work: Improving the Experience of Menopause for Working Women||King's College London|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02623374||7452|
NCT02604459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212915|Can Optimized General Anesthesia Care Reduce Postoperative Delirium?|Does Optimized General Anesthesia Care Reduce Postoperative Delirium In Older Patients Undergoing Hip Fracture Repair?|OPCare|University of Missouri-Columbia|No|Recruiting|June 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|65 Years|N/A|No|||November 2015|November 16, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02604459||8903|
NCT02599857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-126481|The Effects of a CONCOR Smartphone Application|The Effects of a CONCOR Smartphone Application on Arrhythmia, Heart Failure Events and Quality of Life in Patients With Congenital Heart Disease: a Randomized Controlled Trial||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Not yet recruiting|May 2016|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02599857||9255|
NCT02603900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.490|Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty|A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty||Thomas Jefferson University|Yes|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|110|||Both|40 Years|85 Years|No|||November 2015|November 25, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603900||8946|
NCT02600156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-005500|Focal Laser Ablation of Prostate Cancer Tumors|A Pilot Study to Evaluate Magnetic Resonance Thermal Image-Guided Focal Laser Ablation of Prostate Cancer Tumors||Mayo Clinic|No|Recruiting|September 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|45 Years|N/A|No|||November 2015|November 5, 2015|September 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02600156||9232|
NCT02602015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHDehong_NNICU3|Levetiracetam Treatment of Neonatal Seizures|Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China||The People's Hospital of Dehong Autonomous Prefecture|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||November 2015|November 9, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602015||9089|
NCT02602288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA188813|Babies Living Safe and Smokefree|Multilevel Tobacco Intervention in Community Clinics for Underserved Families|BLiSS|Temple University|Yes|Recruiting|February 2016|April 2020|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|372|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02602288||9068|
NCT02601586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7440 01|Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease|Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial|OXYDOPA|University Hospital, Toulouse|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|40 Years|75 Years|No|||November 2015|November 9, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02601586||9122|
NCT02600078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02093|The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure|The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure||University of British Columbia|No|Recruiting|November 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600078||9238|
NCT02604758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7321|Tidal Model's Effect on Coping and Self-Esteem|The Effect of the Psychiatric Nursing Approach Based on the Tidal Model on Coping and Self-esteem in People With Alcohol Dependency: A Randomized Trial||Ege University|No|Completed|October 2013|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|30 Years|50 Years|No|||November 2015|November 12, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604758||8880|
NCT02612610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-012|A 12-Week Study in Subjects With Refractory Chronic Cough|A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough||Afferent Pharmaceuticals, Inc.|No|Recruiting|December 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612610||8279|
NCT02613273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17132|CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer|CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer|CHAMP|University of California, San Francisco|Yes|Not yet recruiting|December 2015|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Male|18 Years|N/A|No|||November 2015|November 20, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613273||8228|
NCT02622100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2015-11|Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRIS BVS|Asan Medical Center|Yes|Recruiting|February 2016|June 2023|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|19 Years|N/A|No|Non-Probability Sample|patients with Bioresorbable Vascular Scaffold|February 2016|February 25, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02622100||7550|
NCT02626247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults|Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults|NUTRIMEMO|Nutrimemo Consortium|Yes|Recruiting|September 2013|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02626247||7231|
NCT02613546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-11754978|THE INFLUENCE OF COGNITIVE BEHAVIORAL THERAPY IN SEXUAL DYSFUNCTION FEMALE: Randomized Clinical Trial|||Centro de Atenção ao Assoalho Pélvico|No|Recruiting|September 2015|November 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|59 Years|Accepts Healthy Volunteers|||November 2015|December 1, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02613546||8207|
NCT02613559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tmab-TK001-AMD-01|Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration|A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration||Jiangsu T-Mab Biopharma Co.,Ltd||Recruiting|November 2015|November 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|27|||Both|45 Years|80 Years|No|||November 2015|November 21, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02613559||8206|
NCT02612571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-495|Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players|Comparing Rates of Glaucomatous Optic Neuropathy in Professional Wind Versus Non-wind Instrument Players in the Philadelphia Orchestra||Wills Eye|Yes|Recruiting|July 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|100 current of retired members of the Philadelphia Orchestra who play or played wind and        non-wind instruments for an average of 1 hour per day for a minimum of 5 years.|November 2015|November 23, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02612571||8282|
NCT02623829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1093|Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)|Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring: A Double Blinded, Randomized Controlled Trial||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02623829||7417|
NCT02615873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 11 004 OLE|A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004|An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004||Intec Pharma Ltd.|Yes|Not yet recruiting|July 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|460|||Both|35 Years|85 Years|No|||October 2015|December 14, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615873||8028|
NCT02624960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4432|Safety and Performance of the Accucinch System|Safety and Performance of the GDS Accucinch Ventriculoplasty System||Guided Delivery Systems Inc.|No|Not yet recruiting|March 2016|March 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02624960||7330|
NCT02614638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/GL-01|Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy|Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy in the Hepato-Gastroenterology Department of the Nîmes University Hospital|OPTI-PP|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|November 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614638||8123|
NCT02613884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128487|Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis|Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis||All Children’s Hospital Johns Hopkins Medicine|Yes|Not yet recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|36 Months|18 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613884||8181|
NCT02618460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal NCE-MRI in volunteers|Renal NCE-MRI in Healthy Volunteers|Non-contrast Enhanced MR Imaging of the Kidney in Healthy Volunteers||Mario Negri Institute for Pharmacological Research|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02618460||7830|
NCT02618473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Snapshot Freeze|Effect of Snapshot Freeze on Cardiac CT Image Quality|Impact of a Motion Correction Algorithm on Image Quality and Diagnostic Utility in Patients Undergoing CT Angiography: A Randomized Controlled Trial||Odense University Hospital|No|Completed|January 2013|August 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|140|||Both|18 Years|N/A|No|||November 2015|December 3, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02618473||7829|
NCT02622386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00105691 /Derm 677|The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis|The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis||University of Michigan|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622386||7528|
NCT02625909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1401|Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.|A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection.|REACT|Kirby Institute|Yes|Not yet recruiting|January 2016|August 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625909||7257|
NCT02626000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130232|Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase 1b/3 Multicenter, Randomized, Open-Label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|MASTERKEY232|Amgen|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626000||7250|
NCT02617927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|szmc 2015-001|The Safety Assessment of Vedolizumab During Pregnancy in IBD Patient|The Safety Assessment of Vedolizumab During Pregnancy in IBD Patient||Shaare Zedek Medical Center|No|Recruiting|October 2015|December 2021|Anticipated|March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|Blood, Stool, Urine & Spit|Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The source population is women attending the IBD MON clinic at Shaare Zedek Medical Center        in Jerusalem, Israel.|November 2015|November 26, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617927|1 Year|7871|
NCT02617940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaoLeopoldoMandic|Efficacy of Sealants in Cavitated Enamel Lesions on Occlusal Surfaces in Children|Effectiveness of Sealants in Cavitated Enamel Lesions on Occlusal Surfaces of Primary and Permanent Molars in Children|SLM1661|Faculty Sao Leopoldo Mandic Campinas|No|Recruiting|May 2015|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|546|||Both|4 Years|9 Years|No|||November 2015|November 25, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02617940||7870|
NCT02623296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1205-CL-103|A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects|A Phase I, Drug-drug Interaction Study Between Oral Doses of GLPG1205 and a Cocktail of CYP2C9, CYP2C19 and CYP1A2 Substrates in Healthy Male Subjects||Galapagos NV|No|Completed|October 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 21, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623296||7458|
NCT02613780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150570-01H|Refractive Treatment of Early Keratoconus|iDesign Aberrometer for the Refractive Treatment of Early Keratoconus||Ottawa Hospital Research Institute|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|60 Years|No|||December 2015|December 11, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613780||8189|
NCT02612272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2015-40|Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections|A Double-blind, Randomized, Controlled, Equivalence Study Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections||St. Luke's Hospital, Pennsylvania|No|Not yet recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|448|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|September 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612272||8305|
NCT02571387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4057-mindob|MindOb: A 12-month Computerized Mindfulness-based Intervention for Obese Individuals|Study of the Effects of Mindfulness on Impulsive Eating, Motivation Toward Exercise, and Weight Loss in Obese Patients: Randomized Controlled Trial|MindOb|University of Paris 5 - Rene Descartes|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 12, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02571387||11443|
NCT02573987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A121414-31|MEOPA Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling.|MEOPA (Equimolar Mix of Oxygen and Nitrogen Monoxide) Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling.|MELIBIO|Hospital St. Joseph, Marseille, France|No|Active, not recruiting|March 2013|December 2015|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Female|18 Years|N/A|No|||October 2015|October 9, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02573987||11243|
NCT02615314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnadoluMC|Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine|Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine||Anadolu Medical Center|No|Completed|January 2015|July 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|232|||Both|10 Years|84 Years|No|Non-Probability Sample|BPPV patients only confirmed by VNG|November 2015|November 25, 2015|November 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02615314||8071|
NCT02615327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2015-104|Effect of Fiber on Glycemic Index|Verifying Fibers Meet Regulatory Definitions for Nutrition Facts Labeling: A Randomized, Controlled Trial Evaluating Polydextrose|Fiber2|Institute for Food Safety and Health, United States|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|40|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615327||8070|
NCT02621619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5369|IV Acetaminophen as an Analgesic Adjunct|Randomized Clinical Trial of IV Acetaminophen as an Analgesic Adjunct to IV Hydromorphone in the Treatment of Acute Severe Pain in Elderly ED Patients||Montefiore Medical Center|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|65 Years|N/A|No|||December 2015|December 2, 2015|November 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621619||7587|
NCT02620436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H34526|Maternity Homes Access in Zambia|Increasing Equitable Access to Safe Deliveries in Zambia|MAHMAZ|Boston University|No|Not yet recruiting|January 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|4900|||Female|15 Years|N/A|No|||December 2015|December 2, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02620436||7678|
NCT02620787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nicolau-53466|Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis|Comparative Assessment of Tedizolid Tissue Penetration and Pharmacokinetic Profile Between Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis||Hartford Hospital|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620787||7651|
NCT02620800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-007-PANC-009|Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer|An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.|FABLOx|Celgene Corporation|Yes|Recruiting|January 2016|May 2020|Anticipated|May 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|65 Years|No|||March 2016|March 24, 2016|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620800||7650|
NCT02627144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21519|Avastin in Metastatic Renal Cancer|AVASTIN® First Line in Metastatic Renal Cancer||Hoffmann-La Roche||Completed|January 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|369|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with advanced and/or metastatic renal cell cancer|December 2015|December 8, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627144||7162|
NCT02614781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RYMMA|Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea|Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea||Nordic Pharma SAS|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|||Female|18 Years|N/A|No|Non-Probability Sample|women asking for medical abortion|March 2016|March 22, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02614781||8112|
NCT02623777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s57413|Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome|Evaluation of the Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome and the Contribution of Short-chain Fatty Acids Production||Katholieke Universiteit Leuven|No|Completed|March 2015|November 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02623777||7421|
NCT02614365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-MED-41E|Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach|Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach|GEMSII|Howard University|Yes|Recruiting|July 2014|December 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|March 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02614365||8144|
NCT02615223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-IR-005|Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer|A Prospective Multi-center Study to Compare the QOL and Efficacy of Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer.|CRYO-PCA-IV|Tianjin Medical University Cancer Institute and Hospital|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|80 Years|No|||November 2015|November 23, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02615223||8078|
NCT02618681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JQi|Earlobe Creases Predict Prognosis in Chinese Patients With Acute Myocardial Infarction|Earlobe Creases Predict Prognosis in Chinese Patients With Acute Myocardial Infarction|ELC-CHN|Liaoning University of Traditional Chinese Medicine|No|Recruiting|June 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|902|||Both|N/A|N/A|No|Probability Sample|acute myocardial infarction|December 2015|December 7, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618681||7813|
NCT02611908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151231|Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.|A Phase 1 Clinical Trial to Evaluate Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.||University of California, San Diego|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611908||8333|
NCT02623946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNO-004|Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients|Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients||Clinique Neuro-Outaouais|No|Recruiting|November 2015|February 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with MacDonald criteria (2005) multiple sclerosis presently being treated with        Alemtuzumab.|December 2015|December 3, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623946||7408|
NCT02626364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-015|Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification|Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification||Arog Pharmaceuticals, Inc.|No|Not yet recruiting|December 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626364||7222|
NCT02626377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2014/231|Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté|Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté. ICE Cohort (Informal Caregivers of Elderly)|ICE|Centre Hospitalier Universitaire de Besancon|No|Recruiting|October 2015|October 2025|Anticipated|October 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|7604|||Both|60 Years|N/A|No|||December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02626377||7221|
NCT02618902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG15-001|A "Negative"Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial|A "Negative"Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial|MS tolDC|University Hospital, Antwerp|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|60 Years|No|||November 2015|December 1, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02618902||7796|
NCT02620566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCTOARICED1|Caudal Block vs Local Wound Infiltration for Hernia Repair in Children|Evaluation of Anesthesia Profile in Pediatric Patients After Inguinal Hernia Repair With Caudal Block or Local Wound Infiltration|CBvsLWI|University Clinic for Anesthesia Reanimation and Intensive Care Mother Theresa|Yes|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|6 Months|7 Years|No|||January 2016|January 3, 2016|September 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02620566||7668|
NCT02626091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005|Perfusion Evaluation by Real-time Fluorescence-based Enhanced Reality of Anastomosis|Perfusion Evaluation by Real-time Fluorescence-based Enhanced Reality of Anastomosis|PERFECT|IHU Strasbourg|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626091||7243|
NCT02611518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108091|A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants|A Phase 1, 2-Panel, Open-Label, Fixed-Sequence Study in Healthy Adult Subjects to Investigate the Pharmacokinetic Interaction Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin||Janssen Research & Development, LLC|No|Not yet recruiting|April 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611518||8363|
NCT02611531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1844|Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)|Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)||University of Chicago|No|Recruiting|November 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|142|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611531||8362|
NCT02625207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001110|THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC|A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers||ViiV Healthcare|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625207||7311|
NCT02625220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5769|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||December 4, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625220||7310|
NCT02625233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5788|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||March 2, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625233||7309|
NCT02616380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-778|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan||AbbVie|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|99 Years|No|Probability Sample|Subjects receiving Adalimumab with Rheumatoid Arthritis (RA) in Taiwan|January 2016|January 27, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616380||7989|
NCT02616393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD019-206|Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases|A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases||Kadmon Corporation, LLC|Yes|Recruiting|November 2015|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616393||7988|
NCT02611453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18285|Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP|CO2 Cholangiography as an Alternative to Iodinated Contrast in Endoscopic Retrograde Cholangiopancreatography||University of Virginia|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611453||8368|
NCT02611466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7962-CL-0022|A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee|A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee|OAK|Astellas Pharma Inc|Yes|Recruiting|February 2016|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|410|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611466||8367|
NCT02618876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 000087145|Effect of Caudal Nalbuphine on Postoperative Analgesia in Children|Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Inguinal Hernia Repair||Assiut University|Yes|Recruiting|November 2015|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|2 Years|6 Years|No|||February 2016|February 4, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618876||7798|
NCT02619149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVAC|Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis|Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis|AVAC|Karolinska Institutet|No|Recruiting|March 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02619149||7777|
NCT02627742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-RR2015-001|Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications|Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications||Hill-Rom|No|Not yet recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627742||7116|
NCT02615678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VINJ007|Acupuncture for CIPN in Breast Cancer Patients|Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series||Southern California University of Health Sciences|No|Recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||November 2015|November 24, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02615678||8043|
NCT02615691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261203|BAX 855 Previously Untreated Patient (PUP)|Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity, and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)||Baxalta US Inc.|Yes|Recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|N/A|5 Years|No|||November 2015|November 24, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615691||8042|
NCT02614976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB157|Incidences of Cuff-related Trauma After Noninvasive Blood Pressure Measurement Between With and Without Padding|Incidences of Cuff-related Trauma After Noninvasive Blood Pressure Measurement Between With and Without Padding||Siriraj Hospital|Yes|Recruiting|April 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614976||8097|
NCT02615236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUS-OASIS|Prospective Evaluation of Perineal Ultrasound in Thr Delivery Room to Improve the Diagnosis of OASIS|Prospective Evaluation of Perineal Ultrasound in Thr Delivery Room to Improve the Diagnosis of OASIS||Ain Shams University|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|300|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615236||8077|
NCT02620280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-14-B02|Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1|Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin|NeoTRIPaPDL1|Fondazione Michelangelo|Yes|Not yet recruiting|January 2016|June 2022|Anticipated|January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|272|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02620280||7690|
NCT02613195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20151020|Clinical Trial of Hydrogen-Rich Celsior Solution Applied in Aging DBD Liver/Kidney Transplantation|Hydrogen-Rich Celsior Solution Improve the Quality of Aging DBD Grafts in Liver/Kidney Transplantation: Prospective, Randomized Clinical Trial|HRCSDBD|RenJi Hospital|Yes|Not yet recruiting|January 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|60 Years|80 Years|No|||October 2015|November 20, 2015|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02613195||8234|
NCT02613208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29756|A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic Her 2- Negative and Aggressive Disease Criteria|Observational, Prospective and Post Authorization Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER2-negative and Aggressive Disease Criteria||Hoffmann-La Roche||Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with HER2-negative aggressive metastatic breast cancer treated with standard        first line chemotherapy with paclitaxel-bevacizumab.|November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613208||8233|
NCT02624466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGent_UToPaed_1|Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Observational Study|Part 1 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|UToPaed_1|University Hospital, Ghent|No|Recruiting|October 2015|September 2019|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|N/A|18 Years|No|Non-Probability Sample|CKD patients|December 2015|December 7, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02624466||7368|
NCT02612285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-5422-CLN2-010|Study of SNX-5422 in TP53 Null Cancers|A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers||Esanex Inc.|No|Recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612285||8304|
NCT02616315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaltrexBuprop-4004|Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery|A Randomized, Double-Blind, Phase 4 Study to Evaluate the Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Patients Post Bariatric Surgery||Takeda|No|Not yet recruiting|February 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616315||7994|
NCT02616328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29936|A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice|A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating the Efficacy and Safety of Using Tocilizumab (TCZ) for Confirmed Rheumatoid Arthritis (RA) Patients In Clinical Practice||Hoffmann-La Roche||Not yet recruiting|January 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|413|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with confirmed rheumatoid arthritis|March 2016|March 1, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616328||7993|
NCT02621307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUSEED|Effect of Salba & Flax on Postprandial Glycemia and Subjective Satiety|The Effect of Salba (Salvia Hispanica L) Versus Flax on Postprandial Blood Glucose Response and Subjective Appetite in Healthy Individuals||St. Michael's Hospital, Toronto|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|December 1, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02621307||7611|
NCT02624037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1475|Precision IFX: Using a Dashboard to Individualize Infliximab Dosage|Precision IFX: Using a Pharmacokinetic Dashboard to Optimize and Individualize Infliximab Dosage for Pediatric Inflammatory Bowel Disease Patients||Icahn School of Medicine at Mount Sinai|No|Recruiting|January 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Years|22 Years|No|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624037||7401|
NCT02626039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOMHGUGM092013|Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients|Characterization and Comparison of Drugable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells and Cell-Free Circulating DNA in Metastatic Breast Cancer Patients|MIRROR|Hospital General Universitario Gregorio Marañon||Recruiting|November 2013|||February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|Samples With DNA|Primary and Metastatic tumoral tissue (FFPE samples) and Blood samples|Female|18 Years|N/A|No|Non-Probability Sample|Women with metastatic breast cancer in which FFPE samples from the primary tumors are        available and in whom a biopsy of the metastatic relapse is clinically indicated.        Investigators will offer enrollment to consecutively seen women who meet the entry        criteria. Target enrollment is 40 patients|December 2015|December 7, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02626039||7247|
NCT02627027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158BE15004|A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|19 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627027||7171|
NCT02611843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487|Peer Supported Web-based CBT for OEF/OIF Veterans With PTSD and Substance Misuse|Peer Supported Web-based CBT for OEF/OIF Veterans With PTSD and Substance Misuse||Syracuse VA Medical Center|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611843||8338|
NCT02611856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC05069|Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome|STT Study : Pediatric Follow-up of Children's From Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome|STT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2008|July 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|Samples Without DNA|sera, urine|Both|4 Years|8 Years|No|Non-Probability Sample|Children aged 4 years to 8 years|November 2015|November 19, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02611856||8337|
NCT02627833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRosewich|Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO|Lungfunction, Lung Clearance Index, Bronchial Inflammation and Epigenetics of Patients With Bronchiolitis Obliterans|FRABO-03|Johann Wolfgang Goethe University Hospitals|No|Recruiting|October 2015|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Cells of induced Sputum, blood sample|Both|6 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with the assured diagnose of Bronchiolitis Obliterans and controls without this        disease.|December 2015|December 9, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627833||7109|
NCT02616471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B306|Effect of High Cheese Consumption on Metabolic Syndrome Risk Factors|Effect of High Cheese Consumption on Metabolic Syndrome Risk Factors in a Metabolically Vulnerable Population|Osterix|University of Copenhagen|No|Completed|March 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|168|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|January 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02616471||7982|
NCT02619968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07587234403|Physical Exercise With Flow Restriction of the Forearm in Chronic Kidney Disease|Effectiveness of Physical Exercise With Flow Restriction on the Diameter and the Flow of the Blood Vessels of the Forearm in Chronic Kidney Disease: a Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Not yet recruiting|January 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619968||7714|
NCT02620228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INJ-LIVERB-01|Identification of Liver Tumours Using BIP - Biopsy System|INJ-LIVERB-01 Identification of Liver Tumours Using BIP - Biopsy System||Injeq Ltd||Not yet recruiting|April 2016|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02620228||7694|
NCT02612623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-021|An 8-Week Refractory Chronic Cough Study|A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough||Afferent Pharmaceuticals, Inc.|No|Recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02612623||8278|
NCT02612857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8400-211|Trial of IMO-8400 in Adult Patients With Dermatomyositis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis|8400-211|Idera Pharmaceuticals, Inc.|Yes|Recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612857||8260|
NCT02606929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN1-2015|Use of Well Known Drugs for New Destination - MS Improvement (MSNT)|Expanded Access Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Multiple Sclerosis Not Responding With Commonly Used Treatments|MSNT|Università Popolare Homo & Natura|No|Temporarily not available|January 2015|November 2015|Actual|September 2015|Actual|Phase 0|Expanded Access|N/A|||||||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02606929||8714|
NCT02604537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15060|Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis|Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02604537||8897|
NCT02610933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/065|Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients|The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial||Onze Lieve Vrouw Hospital||Recruiting|November 2015|December 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|117|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610933||8407|
NCT02609100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507101|Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy|Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy: A Randomized Controlled Trial||Washington University School of Medicine|No|Recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|360|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02609100||8548|
NCT02604849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCO-NEE-2015-01|Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin|||Maimónides Biomedical Research Institute of Córdoba|No|Completed|July 2012|November 2015||July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|The sample consists of all patients who received therapy desconolizacion against        Klebsiella Pneumoniae versus those not receiving such therapy.|November 2015|November 12, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02604849||8873|
NCT02609113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-MAG-22|Static Magnetic Therapy for Carpal Tunnel Syndrome|A Double Blinded, Prospective, Randomized Trial of Static Magnetic Therapy for Carpal Tunnel Syndrome (CTS)|ATTRACT|Wake Forest Baptist Health|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02609113||8547|
NCT02604927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-Alanine Paraplegic Athletes|Beta-alanine Supplementation and Its Effects on Performance, Muscle Carnosine Content and Safety in Athletes With Spinal-cord Injury|||University of Sao Paulo|No|Not yet recruiting|February 2016|September 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02604927||8867|
NCT02611063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064227|Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant|A Phase I Trial of Fostamatinib and Chronic Graft vs. Host Disease Development After Allogeneic Stem Cell Transplantation||Duke University|No|Recruiting|January 2016|January 2021|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611063||8398|
NCT02603692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMIS-QOL|Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS|Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS|PROMIS-QOL|Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20|||Both|5 Years|35 Years|No|Non-Probability Sample|Patients ages 5-35 with a diagnosis of a Central Nervous System (CNS) tumor (newly        diagnosed, relapsed, refractory, or progressed) and scheduled to receive a new therapy        including surgery, chemotherapy and/or radiation therapy.|November 2015|November 12, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02603692||8962|
NCT02603705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-EG-303|Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain|An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain||Egalet Ltd|No|Recruiting|January 2016|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02603705||8961|
NCT02603718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3|An Applicative On-line EEG Tool for Enhancing Treatment Efficacy|An Applicative On-line EEG Tool for Enhancing Treatment Efficacy||Reuth Medical Center|Yes|Recruiting|March 2014|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02603718||8960|
NCT02626195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-13-676|Preoperative Nutritional Support in Malnutritional Cancer Patients|Prospective Study of Preoperative Nutritional Support in Malnutritional Pancreatobiliary Cancer Patients||National Cancer Center, Korea|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||December 2015|December 7, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02626195||7235|
NCT02626208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN 012A|Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone|A Dose Finding Study to Evaluate Serum Estradiol Levels With Use of Contraceptive Vaginal Rings Releasing Nestorone® and Escalating Doses of Estradiol in Normal Cycling Women||Health Decisions|No|Recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|51|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626208||7234|
NCT02617472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT001KSUS|Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)|Assessment of the Effectiveness of a Pelvic Exercise Device in Strengthening Pelvic Floor Muscles and Treating Urinary Incontinence||Lelo Inc.|No|Recruiting|November 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|20 Years|69 Years|No|||November 2015|November 25, 2015|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617472||7905|
NCT02627872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/959-31/1|Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease|Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease|COSMIC|Karolinska Institutet|No|Active, not recruiting|March 2007|December 2020|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|120|Samples With DNA|Bronchoalveolar lavage (BAL) cells, BAL fluid, bronchial biopsies, airway epithelial      brushings, serum, plasma, and blood cells have been collected.|Both|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants from all groups are recruited from the general population through        advertisements.|December 2015|December 10, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627872||7106|
NCT02627885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1938-31/4|Internet-CBT for Parkinsons Disease|Internet-based Cognitive Behavioral Therapy to Increase Function and Quality of Life for Patients With Parkinsons Disease|Patrik|Karolinska Institutet|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627885||7105|
NCT02617355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11061|Interference Between Surgical Magnetic Drapes and Pacemakers|Interference Between Surgical Magnetic Drapes and Pacemakers: An Observational Study Comparing Commercially Available Devices and a New Magnetically Isolated Drape||Maisonneuve-Rosemont Hospital|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|47|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617355||7914|
NCT02617602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDT1.0|Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children|Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children: a Prospective Randomised Trial||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|December 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|3 Years|No|||December 2015|December 17, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617602||7895|
NCT02627534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFOSJC|Effects of Adjunct Photodynamic Therapy in the Treatment of Type 2 Diabetic Patients With Chronic Periodontitis|Local Effects of Adjunct Photodynamic Therapy in the Treatment of Type 2 Diabetic Patients With Chronic Periodontitis: Split-mouth Randomized Triple-blind Clinical Trial||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|April 2014|October 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|N/A|No|||December 2015|December 10, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02627534||7132|
NCT02627547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200120075|Impact of Training Status on Bioavailability of Flavanones|Impact of Training Status of Endurance Athletes on Bioavailability of Flavanones||University of Glasgow|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02627547||7131|
NCT02613377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-MP-21-2016-1070|Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children|Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children|TRALI|St. Justine's Hospital|No|Not yet recruiting|December 2015|December 2018|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1476|Samples With DNA|Blood samples will be collected from patients with suspected TRALI in order to generate some      hypotheses regarding underlying mechanisms associated with the different types of TRALI      (objective #2.e), the plasma level of IL-1beta, IL-6, IL8, and IL-10 will be measured.|Both|N/A|18 Years|No|Non-Probability Sample|All children admitted to a participating PICU will be considered eligible for inclusion.|November 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613377|28 Days|8220|
NCT02613390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0481|Safety Evaluation of Intra-Operative MRI-Based Guidance for Laser Ablation of Epidural Metastasis|A Pilot Study to Evaluate Safety of Intraoperative MRI-Based Image Guidance for Laser Ablation of Epidural Metastasis||M.D. Anderson Cancer Center|No|Recruiting|December 2015|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613390||8219|
NCT02615613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUT.AO.11|The Effect of Food Hedonics on Appetite Hormones Levels|Effect of Food Acceptability on Appetite Hormones' Response in Normal Weight Male Subjects||American University of Beirut Medical Center|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|11|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 26, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02615613||8048|
NCT02617615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB110CLCT01|A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients||Microbio Co Ltd|No|Not yet recruiting|July 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617615||7894|
NCT02617849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-3475-269|Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma|A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma||Jewish General Hospital|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02617849||7877|
NCT02617862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sickkids|PCI Imaging System in Pediatric Ophthalmology|The Use of the PCI Wide Field Imaging System for Pediatric Ophthalmic Photography of the Posterior and Peripheral Retina||The Hospital for Sick Children|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A||||December 2015|December 3, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02617862||7876|
NCT02616822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resv2013|Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients|Acute Effects Of Trans-Resveratrol in Endothelial Function in Treated Hypertensive Patients||Hospital Universitario Pedro Ernesto|Yes|Completed|January 2013|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|45 Years|65 Years|No|||November 2015|November 27, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616822||7955|
NCT02613702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT|Efficacy of a Modified Technique of Free Gingival Graft in Volumetric Changes of the Graft: Randomized Clinical Trial|Efficacy of a Modified Technique of Free Gingival Graft in Volumetric Changes of the Graft: Randomized Clinical Trial|EFFECT|University of Sao Paulo|Yes|Not yet recruiting|December 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02613702||8195|
NCT02626442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BaltimoreVAMC|Exercise and Brain Health|Exercise and Brain Health|EBH|Baltimore VA Medical Center|Yes|Recruiting|July 2013|January 2025|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02626442||7216|
NCT02619422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|másPORmenos|More Intensive Cardiac Rehabilitation Programs in Less Time|Multicenter, Prospective, Randomized, Open, Blinded for the End Point Evaluator to Compare Compliance to Secondary Prevention Measures After Acute Coronary Syndrome and Intensive Cardiac Rehabilitation Program vs Standard Program|másPORmenos|Spanish Society of Cardiology|No|Active, not recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02619422||7756|
NCT02619656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55102|A Trial of Supplemental CO2 Versus Room Air in Percutaneous Endoscopic Gastrostomy|Insufflation With Carbon Dioxide Reduces Pneumoperitoneum After Percutaneous Endoscopic Gastrostomy (PEG): A Randomized Controlled Trial||University of Utah|No|Completed|April 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02619656||7738|
NCT02568228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/706/REK sør-øst C|Health Beneficial Effects of Krill Oil and Lean and Fatty Fish|Health Beneficial Effects of Krill Oil and Lean and Fatty Fish||Oslo and Akershus University College of Applied Sciences|No|Enrolling by invitation|August 2015|December 2025|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|96|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02568228||11686|
NCT02621866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG/15/23/31362|A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors|A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors||University of Edinburgh|No|Not yet recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|No|||July 2015|December 1, 2015|June 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02621866||7568|
NCT02624076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AURIS2015|Acupuncture for Unexplained Subfertiliy|A Randomized Controlled Trial of Acupuncture Versus Expectant Management in Women With Unexplained Infertility|AURIS|Heilongjiang University of Chinese Medicine|No|Not yet recruiting|December 2015|||January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1423|||Female|18 Years|40 Years|No|||December 2015|December 17, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02624076||7398|
NCT02624089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-120-PED|Nebulized Analgesia for Laparoscopic Appendectomy Trial|Evaluation of the Effect of Intraperitoneal Nebulized Ropivacaine on Morphine Consumption After Laparoscopic Appendectomy in Children. A Prospective, Randomized Double Blind Clinical Trial|NALA|McGill University Health Center|Yes|Recruiting|January 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|7 Years|18 Years|No|||March 2016|March 21, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624089||7397|
NCT02614430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-2015|Recover Working Life - Back on the Job After Acute Illness|Recover Working Life - Back on the Job After Acute Illness. A Study of the Effect on Functional Capacity and Self-rated Health and Working Capacity of a Vocational Training Course After Discharge From an Acute Hospitalisation||Hvidovre University Hospital|Yes|Recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|60 Years|No|||November 2015|November 24, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02614430||8139|
NCT02621099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15096|Hybrid Gamma Camera in Breast Surgery|First Use of a Hybrid Gamma Camera for Sentinel Lymph Node Localisation in Patients Undergoing Surgery for Primary Breast Cancer|HICAM|University of Nottingham|No|Not yet recruiting|March 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|58|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients scheduled for a sentinel lymph node biopsy (SLNB) procedure for breast        cancer|December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621099||7627|
NCT02621229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-33865|Refeeding Syndrome in Anorexia Nervosa|Multi Site Randomized Controlled Trial on Refeeding Syndrome in Anorexia Nervosa||Stanford University|Yes|Recruiting|December 2015|||December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|24 Years|No|||March 2016|March 23, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02621229||7617|
NCT02627521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#13-287|Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor|Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist|CABG-TIME|St. Michael's Hospital, Toronto|Yes|Recruiting|July 2015|August 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627521||7133|
NCT02574000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0216|Observational Study of Hemiplegic Shoulder Pain After Recent Stroke|Observational Study to Investigate Proportion of Patients With Hemiplegic Shoulder Pain Within 72 Hours Post-stroke and at Follow-up 8-10 Weeks Later.|SPARS|St George's, University of London|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adults within 72 hours of stroke|October 2015|November 19, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02574000||11242|
NCT02618954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9186|Role of Ultrasound for Evaluating Rheumatoid Arthritis in Remission|Value of Ultrasound for Evaluating Rheumatoid Arthritis in Remission: Longitudinal Study|SONORE|University Hospital, Montpellier|No|Recruiting|October 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02618954||7792|
NCT02624908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28431754DIA4008|Canagliflozin-Mealtime Insulin Rescue|Canagliflozin-Mealtime Insulin Rescue||Atlanta Research and Education Foundation|Yes|Not yet recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|70 Years|No|||December 2015|December 4, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624908||7334|
NCT02623023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAVE-001|Prophylaxis for Anti-VEGF-induced IOP Elevation|Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor||McMaster University|Yes|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|107|||Both|65 Years|N/A|No|||December 2015|December 4, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02623023||7479|
NCT02614794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-380-206|Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer|Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma||Oncothyreon Inc.|Yes|Recruiting|December 2015|April 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614794||8111|
NCT02620059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR.TUMS.REC.1394.485|A Lifestyle Program on Healthy Weight in Postpartum Period|Development and Evaluation of a Lifestyle Intervention Program for Women' Weight Reduction After Childbirth||Tehran University of Medical Sciences|No|Not yet recruiting|March 2016|March 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02620059||7707|
NCT02614612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-108|Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute GVHD|A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease||Incyte Corporation|Yes|Recruiting|December 2015|July 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614612||8125|
NCT02618863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH7|The Cricoid Force Necessary to Occlude the Esophageal Entrance: Is There a Gender Difference?|The Cricoid Force Necessary to Occlude the Esophageal Entrance: Is There a Gender Difference?||Procare Riaya Hospital|No|Enrolling by invitation|December 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618863||7799|
NCT02621658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bowel Prep Protocol|Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy|Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy||San Antonio Military Medical Center|No|Not yet recruiting|January 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02621658||7584|
NCT02615470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP53380|Enhancing a Sustainable Pharmacy-based Immunization Program in Two States|Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States||Auburn University|No|Recruiting|November 2015|October 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615470||8059|
NCT02621814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJEBP-01|Clinical Trial of Friso Formula-fed With Low Glycation and Aggregation Protein About Infant's Growth Rate|A Randomized Controlled Clinical Trial of Friso Formula-fed With Low Glycation and Aggregation Protein About Infant's Growth Rate||Children's Hospital of Fudan University|Yes|Not yet recruiting|March 2016|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621814||7572|
NCT02623881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKH/CGRH_10_2015|Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies|The Effectiveness of Cervical Pessary Versus Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies: a Randomized Controlled Trial.||Vietnam National University|No|Not yet recruiting|December 2015|December 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Female|18 Years|N/A|No|||November 2015|December 3, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623881||7413|
NCT02624349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000037024|Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients|Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients||The Hospital for Sick Children|No|Active, not recruiting|October 2013|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Female|12 Years|19 Years|No|||December 2015|December 7, 2015|October 7, 2013||No||No||https://clinicaltrials.gov/show/NCT02624349||7377|
NCT02615743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-012092|Asthma Controller Adherence After Hospitalization|Automated Adherence Feedback for High Risk Children With Asthma||Children's Hospital of Philadelphia|No|Not yet recruiting|December 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|4 Years|11 Years|No|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615743||8038|
NCT02615288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-038|High Dose Vitamin D3 in Crohn's Disease|Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohn's Disease in Remission: A Randomized Double-blind Controlled Study||McMaster University|No|Completed|January 2014|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615288||8073|
NCT02620072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808040019|Fr1da Insulin Intervention|Mechanistic Study Using Oral Insulin for Immune Efficacy in Secondary Prevention of Type 1 Diabetes||Technische Universität München|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|62|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 29, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02620072||7706|
NCT02615418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBS-Sour-1|Non Invasive Brain Stimulation Treatment for CLBP|A Novel Non Invasive Brain Stimulation,tDCS Based Treatment for Chronic Low Back Pain (CLBP)-Sourasky Medical Center-Tel Aviv|NIBSTCLBP|NIBS NeuroScience Technologies|No|Not yet recruiting|January 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 26, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615418||8063|
NCT02615431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-060|The Influence of MitraClip on Apnoea Asleep|the Influence of MitraClip on Apnoea Asleep|MiClAS|RWTH Aachen University|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|34|||Both|18 Years|N/A|No|Non-Probability Sample|male and female patients is planned an interventional MitraClip examination|November 2015|November 24, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615431||8062|
NCT02627118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-156-3|Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H|Clinical Study To Elucidate The Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR When Compared to a Non-BPA Containing Dialyzer, the Nipro ELISIO-15H|bisphenol-A|University of Connecticut Health Center|No|Enrolling by invitation|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627118||7164|
NCT02615808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4293|Developing and Evaluating User-Designed Data Displays|Developing and Evaluating User-Designed Data Displays||Children's Hospital Medical Center, Cincinnati|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|292|||Both|N/A|12 Months|No|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615808||8033|
NCT02616055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD019-207|Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101|Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease||Kadmon Corporation, LLC|Yes|Active, not recruiting|December 2015|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|55 Years|No|||January 2016|January 22, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616055||8014|
NCT02616068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS600-A-L301 - Loxonin Tape|Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma|A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin® (60 mg Tablet) for the Treatment of Acute Traumatic Injuries||Daiichi Sankyo Brasil Farmacêutica LTDA|No|Recruiting|October 2015|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616068||8013|
NCT02618512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGLU-CL01-T|A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously|A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously|CL01-T|Alexion Pharmaceuticals|Yes|Active, not recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||November 2015|November 30, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618512||7826|
NCT02620163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH22162-301|Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment|A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment||Yuhan Corporation|No|Recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|378|||Both|19 Years|N/A|No|||January 2016|January 6, 2016|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02620163||7699|
NCT02620176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Farmer-2|The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity|The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity in Healthy Volunteers||Wingate Institute of Neurogastroenterology|No|Recruiting|December 2014|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 28, 2015|December 15, 2014||No||No||https://clinicaltrials.gov/show/NCT02620176||7698|
NCT02619162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIO-BR-007|Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics|Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics||Centro Nacional de Investigaciones Oncologicas CARLOS III|No|Recruiting|July 2015|March 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Female|18 Years|N/A|No|||October 2015|November 30, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02619162||7776|
NCT02623049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0590-15|Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation|Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation||Rabin Medical Center||Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|120|Samples Without DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|Candidate for the study will be patients older than 80 years (octogenarians) and those ≤70        years who are 1) admitted to the Internal Medicine division in Rabin Medical Center who        are on treatment of DOAC prior to their hospitalization, 2) hospitalized patients in whom        DOAC will be initiated during hospitalization and 3) referred ambulatory patients on        DOACs. Each potential patient will be screened for age and other risk factors for bleeding        (specifically those that requires dose adjustment such as renal failure, weight,        potentially interacting drugs) under DOAC treatment.|December 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02623049||7477|
NCT02616952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014S292|A Chinese Herbal Decoction for Stress Urinary Incontinence|Effect of Yiqi Suoquan Tang, a Chinese Herbal Decoction, on Stress Urinary Incontinence||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|21 Years|65 Years|No|||December 2015|December 4, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616952||7945|
NCT02617251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS -14-0530|Impact of Deprivation on Hospital Care Efficiency in Paediatrics|Impact of Deprivation on Hospital Care Efficiency in Paediatrics|PRECAPED|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|3500000|||Both|N/A|N/A|No|Non-Probability Sample|hospitalization in neonatology and pediatrics|November 2015|November 25, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02617251||7922|
NCT02616263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK107809|Metatarsal Phalangeal Joint Deformity Progression - R01|Muscle, Joint and Movement Deterioration Contributing to Neuropathic Forefoot Deformity||Washington University School of Medicine|Yes|Not yet recruiting|March 2016|February 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|62|||Both|40 Years|70 Years|No|||November 2015|November 30, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02616263||7998|
NCT02620527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMI-CTDNA-15|Concordance Between ctDNA Assay and FoundationOne|Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations||Foundation Medicine|No|Recruiting|November 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with cancer and who have had a solid tumor biopsy isolated for analysis        by FoundationOne|March 2016|March 9, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620527||7671|
NCT02627807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012011|Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma|Prospective Non-inferiority Randomized Trial Comparing Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation and Traditional Clinical Target Volume in Radiotherapy for Nasopharyngeal Carcinoma||Sun Yat-sen University|No|Recruiting|December 2015|December 2022|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|378|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627807||7111|
NCT02612233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0126|Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin|Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin|DUPRO|St George's, University of London|Yes|Recruiting|September 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612233||8308|
NCT02627040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00023144|Intertrochanteric Femoral Fracture Fixation Trial|A Prospective Randomized Trial of Intertrochanteric Femoral Fractures Treated With a Single Screw Versus a Two-integrated Screw Cephalo-medullary Nail.||Florida Orthopaedic Institute|No|Recruiting|November 2015|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Both|60 Years|N/A|No|||December 2015|December 9, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02627040||7170|
NCT02616588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2137|Vets Helping Vets Pilot Study|Vets Helping Vets Pilot Study|VHV|VA Eastern Colorado Health Care System|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Years|108 Years|No|||November 2015|December 7, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616588||7973|
NCT02613767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15161|Muscle Protein Synthesis Rates After Protein Consumption in Lean, Overweight, and Obese Adults|Muscle Protein Synthesis Rates After Protein Consumption in Lean, Overweight, and Obese Adults||University of Illinois at Urbana-Champaign|No|Active, not recruiting|December 2014|December 2015|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|32|Samples Without DNA|Plasma samples and Skeletal muscle tissue|Both|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|We recruited 32 healthy, sedentary adult subjects (20-45 y) for this investigation. There        are three groups being studied, which will be stratified by body mass index. Because        randomization is not possible, groups were balanced by age and sex. No races or ethnic        groups will be specifically recruited or excluded.|November 2015|November 20, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02613767||8190|
NCT02614001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3663A3|Inspiratory Muscle Training in Stroke Patients With Stable Congestive Heart Failure: a Prospective RCT.|Inspiratory Muscle Training in Stroke Patients With Stable Congestive Heart Failure: a Prospective Randomized Controlled Trial.||Chang Gung Memorial Hospital|Yes|Completed|May 2011|July 2015|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|20 Years|85 Years|No|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614001||8172|
NCT02621983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1897-P|Aerobic Exercise for Cognition in Schizophrenia|Aerobic Exercise for Cognition in Schizophrenia||VA Office of Research and Development|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621983||7559|
NCT02627482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18636|Ambulatory Fetal Heart Rate Monitoring in Small Babies|The Feasibility of Employing Ambulatory Fetal Heart Rate Monitoring in Small for Gestational Age Fetuses at Risk of Stillbirth.||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|September 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|No|Probability Sample|The Investigators will recruit 30 women with a singleton pregnancy (no congenital        abnormality) and a customised birth weight ratio of less than 10th centile on ultrasound        from the small baby clinic, which is provided at the Fetomaternal Unit (FMU) at the Jessop        Wing (JW) Hospital, Sheffield. Each participant will be studied on 2 occasions, 2 to        4weeks apart at their routine hospital visit for serial ultrasound scans.|September 2015|December 8, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02627482||7136|
NCT02617485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MabionCD20-002NHL|MabionCD20® Compared to MabThera® in Lymphoma Patients|Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma||Mabion SA|Yes|Not yet recruiting|December 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|64 Years|No|||November 2015|December 2, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02617485||7904|
NCT02597660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00107019|A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy|A Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy||University of Michigan|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|50 Years|No|||November 2015|November 4, 2015|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597660||9424|
NCT02611050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00028467|Treatment Decisions for Multi-vessel CAD|Treatment Decisions for Multi-vessel Coronary Artery Disease Patients||Dartmouth-Hitchcock Medical Center|No|Enrolling by invitation|December 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02611050||8399|
NCT02595398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS1001-301|Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis|A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis|PEACHTREE|Clearside Biomedical, Inc.|No|Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02595398||9598|
NCT02610140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15743|Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)|A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy||Bayer|Yes|Recruiting|December 2015|July 2019|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02610140||8468|
NCT02609126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-104IAR-101|Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis|A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee|STEP UP|Eupraxia Pharmaceuticals Inc.|No|Not yet recruiting|April 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|40 Years|80 Years|No|||March 2016|March 1, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609126||8546|
NCT02597946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.222|Afatinib in NSCLC With HER2 Mutation|A Phase II Study of Afatinib in Patients With Advanced NSCLC Harboring HER2 Mutations, Previously Treated With Chemotherapy||Boehringer Ingelheim||Not yet recruiting|March 2016|May 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 2, 2015||||No||https://clinicaltrials.gov/show/NCT02597946||9402|
NCT02611076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18231|Smoking-cessation: A Spanish-Language Clinical Trial|Expanding the Reach of a Validated Smoking-Cessation Intervention: A Spanish-Language Clinical Trial||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|October 2015|||May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611076||8397|
NCT02610985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2D/3D hysterectomy|2-D and 3-D Laparoscopic Hysterectomy|3-dimensional Versus Conventional Laparoscopy in Patients Undergoing Total Hysterectomy for Benign Disease - A Randomised Clinical Trial||University Hospital Roskilde|Yes|Not yet recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||November 2015|February 4, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02610985||8403|
NCT02611037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18094|Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma|A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611037||8400|
NCT02612038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000957E|Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation|Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation|ExpFLOSA|Brigham and Women's Hospital|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|70 Years|No|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612038||8323|
NCT02620995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 17663813.4.0000.5272|Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction|Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction||National Institute of Cardiology, Laranjeiras, Brazil|Yes|Recruiting|October 2014|December 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620995||7635|
NCT02621008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss|A Self-Administered Mobile Phone-based Holistic Intervention for Promoting Healthy Habits and Weight Loss in People Who Are Overweight or Obese||Eco Fusion|No|Recruiting|November 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02621008||7634|
NCT02614820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JZheng|The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD|||General Hospital of Chinese Armed Police Forces||Recruiting|November 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Male|2 Years|6 Years|No|||November 2015|November 22, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02614820||8109|
NCT02614833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP321 P011|IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma|AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel||Immutep S.A.|Yes|Recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|211|||Female|18 Years|N/A|No|||February 2016|February 19, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02614833||8108|
NCT02622633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40803214.2.0000.0033|Epidural Stimulation for Resistant Depression Treatment|Epidural Stimulation for Resistant Depression Treatment: A Randomized Double Blind Clinical Trial||University of Brasilia|No|Not yet recruiting|January 2016|||June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|December 3, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02622633||7509|
NCT02613065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F141121006|The Role of Protein in Regulating Ad Libitum Energy Intake in Humans|The Role of Protein in Regulating Ad Libitum Energy Intake in Humans||University of Alabama at Birmingham|No|Recruiting|May 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613065||8244|
NCT02613351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPHC-RG-1Lscoot20151201|Muscle Activity and Sensation During Upright Partitioned Leg Exercise in COPD|Leg Muscle Activity and Sensation During Upright Partitioned Exercise Compared to Walking: Propulsion of a 3-wheeled Scooter by Patients With Chronic Obstructive Pulmonary Disease|MAPLE|West Park Healthcare Centre|No|Not yet recruiting|December 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613351||8222|
NCT02618447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201406079|4D Phase Contrast MR: Hypertrophy in Liver Cancer|4D Phase Contrast MR: Validation and Evaluation of Hypertrophy in Liver Cancer||Washington University School of Medicine|No|Recruiting|August 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618447||7831|
NCT02620345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dydrogesterone Multivitamin|Fibroids in Women of Reproductive Age and Women Pregnancy|Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy|Fibroids|Triệu, Nguyễn Thị, M.D.|Yes|Completed|January 2010|November 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620345||7685|
NCT02620358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 15/82|Two Opposite Strategies of Weaning From Mechanical Ventilation|Two Opposite Strategies of Weaning From Mechanical Ventilation: High Work of Breathing Versus Low Work of Breathing||Althaia Xarxa Assistencial Universitària de Manresa|No|Not yet recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02620358||7684|
NCT02622867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactobacillus plantarum 3547|Lactobacillus Plantarum 3547 Effects Over Inflammatory and Immunologic Markers|Nutritional Intervention Clinical Trial to Evaluate the Lactobacillus Plantarum 3547 Probiotic Effects Over Different Inflammation and Immune System Markers in a Group of Healthy Middle-aged People||Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|February 2013|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02622867||7491|
NCT02626338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-011|Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML|Pilot Study of Crenolanib Combined With High-dose Cytarabine and Mitoxantrone in Subjects With Relapsed/Refractory Acute Myeloid Leukemia||Arog Pharmaceuticals, Inc.|No|Recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626338||7224|
NCT02622906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002579-40|Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure|Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure|ANGIOPAS|Hospital Avicenne|No|Completed|March 2012|October 2015|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02622906||7488|
NCT02618707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0000871120|Lactate Levels During Cardiopulmonary Bypass in Pediatric Patients|Changes of Lactate Levels During Cardiopulmonary Bypass in Pediatric Undergoing Cardiac Surgery: Possible Early Marker of Morbidity and Mortality||Assiut University|Yes|Completed|December 2015|March 2016|Actual|March 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|12 Months|12 Years|No|Probability Sample|cardiac surgery for children with congenital heart defects|March 2016|March 4, 2016|November 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618707|4 Days|7811|
NCT02612194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-GU-URO-CRI-001|LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer|LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer||Carolinas Healthcare System|Yes|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|46|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612194||8311|
NCT02571036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCC-2618-01-001|A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies|A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies||Deciphera Pharmaceuticals LLC|No|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02571036||11470|
NCT02571049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFN-11-CD-006|Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine|Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine||Dr. Reddy's Laboratories Limited|No|Recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02571049||11469|
NCT02573571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL01|Personalized Needs in Clostridium Difficile Infections|Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy|SPECIFY|University of Athens|Yes|Recruiting|October 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Whole blood for human DNA extraction and human stool for whole bacterial DNA extraction.      Sampling is done on the first day and on disease recurrence|Both|18 Years|N/A|No|Probability Sample|Patients with Clostridium difficile-associated diarrhea|October 2015|October 11, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573571||11275|
NCT02626988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOHTDIET2015JR|The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study|The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study||Bioversity International|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|12 Months|55 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626988||7174|
NCT02613260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-14861|Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System|Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System||University of California, San Francisco|No|Recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|9500|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613260||8229|
NCT02618122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GEN-TRA-001|A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece|A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and the Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in Advanced Soft Tissue Sarcomas in a Real World Setting in Greece. The 'beYOND-STS' Study|beYOND-STS|Genesis Pharma S.A.|No|Not yet recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Adult patients with a histologically confirmed diagnosis of advanced (locally advanced or        metastatic) soft tissue sarcoma who have failed treatment with anthracyclines and        ifosfamide or who are unsuited to receive these drugs|November 2015|November 26, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618122||7856|
NCT02623361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICB for hip athroscopy|A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy|A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy||University of California, San Francisco|Yes|Recruiting|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|99 Years|No|||December 2015|December 2, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623361||7453|
NCT02618278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18420|Physiotherapy for Sciatica; Is Earlier Better?|Physiotherapy Management of Lumbar Radicular Syndrome; Does Early Intervention Improve Outcomes?|POLAR|Sheffield Teaching Hospitals NHS Foundation Trust|No|Not yet recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618278||7844|
NCT02618291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32003B_159863/1|Efficacy of an Active Geriatric Evaluation for Geriatric Syndromes to Prevent Functional Decline in Family Medicine|Efficacy of a an Active Geriatric Evaluation (AGE Tool) for Geriatric Syndromes to Prevent Functional Decline in Elderly Patients in Family Medicine: a Pragmatic Cluster Randomized Trial|AGE3|University of Lausanne|No|Not yet recruiting|February 2016|March 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|792|||Both|75 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 27, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02618291||7843|
NCT02618304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0012|Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction|||Yonsei University|No|Recruiting|November 2015|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|19 Years|N/A|No|||November 2015|November 27, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02618304||7842|
NCT02616484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500698|Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:|Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:|DCA/PDCD|University of Florida|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|24|||Both|6 Months|17 Years|No|||November 2015|November 24, 2015|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616484||7981|
NCT02616497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asp-Trifl-1|ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)|Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events|ASTERIAS|University of Ioannina|No|Recruiting|September 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1100|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616497||7980|
NCT02620748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091454|Use of Intravenous Tranexamic Acid During Myomectomy|Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial|TA|George Washington University|No|Recruiting|March 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620748||7654|
NCT02622282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003190|Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease|Text Messaging to Promote Walking Among Latino Adults at Risk for PAD||University of Kansas Medical Center|No|Not yet recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622282||7536|
NCT02622295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412709|Musculoskeletal Plasticity After Spinal Cord Injury|Musculoskeletal Plasticity After Spinal Cord Injury||University of Iowa|No|Recruiting|May 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|21 Years|60 Years|No|||December 2015|December 3, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622295||7535|
NCT02627898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUCS-INTEC-MV-TEVE-001|Effect of Green Tea Extract on Arterial Stiffness in Type 2 Diabetes Mellitus|Effect of Green Tea Extract Administration on Arterial Stiffness in Patients With Type 2 Diabetes Mellitus||Centro Universitario de Ciencias de la Salud, Mexico|No|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|35 Years|65 Years|No|||December 2015|December 10, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627898||7104|
NCT02612545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916023|Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine in Patients With Uncomplicated Falciparum Malaria in Cambodia|A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine in Patients With Uncomplicated Falciparum Malaria in Cambodia||National Institutes of Health Clinical Center (CC)||Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|432|||Both|2 Years|65 Years|No|||November 2015|December 2, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02612545||8284|
NCT02614495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-012-00CH2|Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma|A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)||Hutchison Medipharma Limited|No|Recruiting|February 2016|December 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02614495||8134|
NCT02614716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16149|A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome||Eli Lilly and Company|No|Recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614716||8117|
NCT02623543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OK-ICO|Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum|Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum||Illinois College of Optometry|Yes|Recruiting|November 2013|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623543||7439|
NCT02618811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JagiellonianU-03|ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes|Enhanced Recovery After Surgery Protocol (ERAS) in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes||Jagiellonian University|No|Completed|January 2014|November 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|171|||Both|18 Years|N/A|No|Non-Probability Sample|The analysis included prospectively collected data from consecutive patients electively        operated for colorectal cancer in the years 2014-2015. All patients were operated using        laparoscopic surgery, and the perioperative care was based on pre-established ERAS        protocol consisting of 13 items|November 2015|November 28, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02618811||7803|
NCT02625194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0218|The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation|The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation||Yonsei University|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|36|||Both|20 Years|60 Years|No|||December 2015|December 6, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02625194||7312|
NCT02626689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-536-B-THAL-003|To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care|Burden of Beta-Thalassemia - Quality of Life and Health Care Resource Utilization- A Prospective Observational Study||Celgene|No|Not yet recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|β-thalassemia subjects who are transfusion dependent (TD) and non-transfusion dependent        (NTD)|December 2015|December 8, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02626689||7197|
NCT02625038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-MD-0016|Evaluation of the Intraoperative Accuracy of 3D-planned and Guided Osteotomies of the Hand and Forearm|CT-based Evaluation of the Intraoperative Implementation Accuracy of 3D-planned Osteotomies of the Hand and Forearm Performed With Patient-specific Instruments|CARDFOREARM|Balgrist University Hospital|Yes|Enrolling by invitation|September 2014|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|December 6, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02625038||7324|
NCT02615847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HbSS-MemSID|Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients|A Phase II, Open Label, Single Center Trial to Study the Safety and Tolerability of Memantin Mepha® as Supportive Long Term Treatment in Symptomatic Sickle Cell Disease|MemSID|University of Zurich|No|Recruiting|August 2015|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||September 2015|November 24, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02615847||8030|
NCT02615860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KG1425|Efficacy and Safety of TCA vs. ECA for the Treatment of AIN in HIV-positive Patients|Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial|TECAIN|University Hospital, Essen|Yes|Recruiting|November 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615860||8029|
NCT02624284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823413|tDCS Effects on Resisting Smoking: Dose Ranging Study|tDCS Effects on Resisting Smoking: Dose Ranging Study|RDR|University of Pennsylvania|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02624284||7382|
NCT02624297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD-2015/01|Chemoreflex Control of Sympathetic Activity in Patients With Coronary Artery Disease|Effect of Exercise Training on Chemoreflex Control of Sympathetic Activity in Patients With Coronary Artery Disease and Obstructive Sleep Apnea||University of Sao Paulo General Hospital|Yes|Recruiting|January 2014|January 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02624297||7381|
NCT02619136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-10-2016-2619|Myocardial Ischemia and Transfusion|Myocardial Ischemia and Transfusion: A Pilot, Multi-centre, Open-label Randomized Controlled Trial of Two Commonly Used Transfusion Strategies in Patients With Myocardial Infarction.|MINT|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619136||7778|
NCT02625129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21080|Effectiveness of and Satisfaction With a Pharmacist-managed Travel Medicine Clinic|Determining the Clinical Effectiveness and Patient Satisfaction of a Pharmacist-managed Travel Medicine Clinic Under an Expanded Scope of Practice||University of Waterloo|No|Not yet recruiting|February 2016|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of individuals presenting for travel consultations at        the Travel Health Network. No restrictions will be placed related to patient demographics,        destinations, or travel itineraries; however, travellers with an expected return date        after September 1, 2016 will be excluded, to ensure complete follow-up and data analysis        within the proposed project time frame. A convenience sample of 100 patients will be        consecutively enrolled .|December 2015|December 8, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02625129||7317|
NCT02612168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-001-4ev|Melanoma Image Analysis Algorithm (MIAA) Validation Study|Effectiveness of an Image Analysing Algorithm to Diagnose Melanoma Compared to Gold Standard Histological Determination||Skin Analytics Limited|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1250|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02612168||8313|
NCT02615145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-398|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)|LIFE-C|AbbVie|No|Recruiting|December 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1000|||Both|18 Years|99 Years|No|Non-Probability Sample|Chronic Hepatitis C (CHC)|February 2016|February 7, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02615145||8084|
NCT02615158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27980|Toddler Overweight Prevention Study Among Low-Income Families|Toddler Overweight Prevention: Comparison of Maternal and Toddler Intervention|TOPS|University of Maryland|Yes|Completed|April 2006|May 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|277|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|February 11, 2013||No||No||https://clinicaltrials.gov/show/NCT02615158||8083|
NCT02619448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|665895|Concurrent Chemotherapy and Accelerated Hypofractionated Radiation in Medically Inoperable Non-small Cell Lung Cancer|Pilot Study of the Safety and Feasibility of Administering Concurrent Systemic Chemotherapy With Accelerated Hypofractionated Radiation Therapy in the Treatment of Medically Inoperable T1b and T2 Non-Small Cell Lung Cancer||State University of New York - Upstate Medical University|No|Recruiting|December 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|November 30, 2015|March 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02619448||7754|
NCT02619786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512-2558-EC4|Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin|Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin||Mahidol University|No|Not yet recruiting|December 2015|December 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02619786||7728|
NCT02622724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCLI002|Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)|A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human IFN Beta-1a) and Placebo in the Treatment of Patients With Moderate or Severe Acute Respiratory Distress Syndrome|INTEREST|Faron Pharmaceuticals Ltd|Yes|Recruiting|November 2015|April 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02622724||7502|
NCT02623894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS 1193/B/15|Influence of Different Risk Factors in Vascular Accelerated Aging (EVA Study)|Influence of Different Risk Factors in Vascular Accelerated Aging. A Cross-sectional, Descriptive Observational Study (EVA Study)||Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|October 2015|December 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples Without DNA|Fasting plasma glucose, creatinine, uric acid, Ca, P, serum total cholesterol, high-density      lipoprotein cholesterol and triglyceride levels will be measured using standard enzymatic      automated methods. Low-density lipoprotein cholesterol will be estimated by the Friedewald      equation when the direct parameter is not available. Glycated haemoglobin will be measured      with an immune-turbidimetric assay. Cytokines concentrations in plasma will be determined by      ELISA using commercial kits and following the manufacturer's recommendations. Oxidative      stress will be determined by measuring lipid peroxides and nucleic acid derivatives by ELISA      using commercial kits and following the manufacturer's recommendations.|Both|35 Years|75 Years|No|Probability Sample|Study population It will be the urban population attached to the Health Center of        Salamanca. Using a random sampling stratified by age groups (35, 45, 55, 65 and 75 years)        and gender, 100 subjects will be selected in each group (50 males and 50 females), aged 35        to 75 years.|November 2015|December 7, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02623894|1 Year|7412|
NCT02619916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-214|MBCT and CBT for Depression in Patients After Cancer: a Randomized Controlled Trial|Individual Mindfulness-Based Cognitive Therapy (MBCT) and Individual Cognitive Behavioral Therapy (CBT) for Depression in Patients After Cancer: a Randomized Controlled Trial||University Medical Center Groningen|No|Recruiting|May 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|192|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619916||7718|
NCT02627768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR106450|A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis|Assessment of STELARA® (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort|PsaBio|Janssen Pharmaceutica N.V., Belgium|No|Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1400|||Both|18 Years|N/A|No|Non-Probability Sample|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting        STELARA or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third        line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.|March 2016|March 15, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627768||7114|
NCT02620852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS-1402-10749|Women Informed to Screen Depending on Measures of Risk|Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer|WISDOM|University of California, San Francisco|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100000|||Female|40 Years|74 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620852||7646|
NCT02620865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-100|Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF||Barbara Ann Karmanos Cancer Institute|No|Suspended|December 2015|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 1, 2015|Yes|Yes|Pending administrative documentation|No||https://clinicaltrials.gov/show/NCT02620865||7645|
NCT02622360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study|Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study|SMeDy|Helsinki University|No|Recruiting|July 2015|December 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|Samples With DNA|extraction of DNA from whole blood samples or saliva|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|200 Finnish healthy adult subjects aged 18-45 will be tested, around half of who have a        developmental dyslexia. Prior to the study, subjects are given "Written investigation        information" after which the subjects may participate in the study by signing the "Written        informed consent".        Participants in the dyslexia group are required to have a prior diagnosis of dyslexia as        an inclusion criterion. Groups will be matched for gender, age and educational level. The        participation to the experiment is on voluntary basis after announcement through different        channels, e.g. via email lists. All experiments will be carried out according to the        Declaration of Helsinki.|December 2015|December 2, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02622360||7530|
NCT02624388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17588|Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)|A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy|UVA-Gen001|University of Virginia|Yes|Not yet recruiting|January 2016|November 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|1 Year|21 Years|No|||December 2015|December 3, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624388||7374|
NCT02627222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASSAVITA II|The Efficacy of Pro-vitamin A Biofortified Cassava on Vitamin A Status in Nigerian Preschool Children|The Efficacy of Pro-vitamin A Biofortified Cassava on Vitamin A Status in Nigerian Preschool Children|CASSAVITA II|Wageningen University|Yes|Recruiting|December 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|36 Months|59 Months|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627222||7156|
NCT02611869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CryoLAEF|Effect of Cryoballoon and RF Ablation on Left Atrial Function|Effect of Cryoballoon Versus Radiofrequency Ablation for Pulmonary Vein Isolation on Left Atrial Function in Patients With Non-valvular Paroxysmal Atrial Fibrillation|CryoLAEF|G.Gennimatas General Hospital|No|Recruiting|October 2015|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||November 2015|November 19, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611869||8336|
NCT02621177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP607_FluC_III_2013|Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607(Trivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Healthy Children and Adolescents Aged 6 Month ~ 18 Years)||SK Chemicals Co.,Ltd.|No|Completed|November 2013|July 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|385|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02621177||7621|
NCT02621190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL55865.078.15|Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs|Non-randomized Phase 2 Open-label Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs): CARVE|CARVE|Erasmus Medical Center|No|Not yet recruiting|February 2016|June 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621190||7620|
NCT02615639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYatSenIDD|A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB|A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in Chronic Hepatitis B|CTHBVACADCHB|Third Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|450|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02615639||8046|
NCT02615652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Konstanz|The Impact of Lifestyle on Mental Health Among Young Men in the Gilgel Gibe Field Research Center, Ethiopia: Pilot Study|||University of Konstanz|No|Not yet recruiting|December 2015|July 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|865|Samples Without DNA|Immunoassay test for the screening of khat alkaloids in urine.|Male|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Young adult male inhabitants of the Gilgel Gibe field research center.|November 2015|November 24, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02615652||8045|
NCT02615665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKTCellsInCLM|Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases|Role of CD3+ and NKp46+ Cells in Resected Colorectal Liver Metastases.||University of Milan|No|Completed|January 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|121|Samples Without DNA|We use the surgical specimens.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with colorectal liver metastases scheduled for surgery at our Unit.|November 2015|November 24, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02615665||8044|
NCT02625922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2211|Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care|RELAX-Cardio|Novartis|Yes|Recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02625922||7256|
NCT02626026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-407-1833|Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)|A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)||Gilead Sciences|No|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626026||7248|
NCT02623101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCM-onco ZonMw-1|Reflectance Confocal Microscopy in Basal Cell Carcinoma|In Vivo Reflectance Confocal Microscopy, a Novel Non-invasive Tool for Diagnosing Skin Cancer - A Randomized Controlled Trial||Radboud University|Yes|Recruiting|January 2016|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|329|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02623101||7473|
NCT02613468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OndokusMu|Periodontal Condition in Pregnancy and Low Birth Delivery Incidence|A Comparative Evaluation in Pregnant Women of the Periodontal Condition and Low Birth Delivery Incidence||Ondokuz Mayıs University|Yes|Completed|January 2004|August 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|269|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02613468||8213|
NCT02616211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-002084|An Integrated Approach to Treating Recurrent Lung Adenocarcinomas Resistant to Tyrosine Kinase Inhibitors|An Integrated Approach to Treating Recurrent Lung Adenocarcinomas Resistant to Tyrosine Kinase Inhibitors||Mayo Clinic|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|At the time of recurrence, a minimum of two (2) and a maximum of four (4) tissue cores will      be taken through interventional biopsy, ultra sound guided biopsy, surgical resection, or      bronchoscopy. Investigators may also collect waste pleural fluid in patients who have a      pleurx catheter in place. These biopsies will be collected and individually processed for      pathology, gene mutation screening, transcriptome profiling and tumor xenografts.|Both|18 Years|N/A|No|Non-Probability Sample|Patients seen at the Mayo Clinic Rochester|November 2015|November 24, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02616211||8002|
NCT02616224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29019|A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|||Hoffmann-La Roche||Not yet recruiting|December 2015|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|81|||Both|18 Years|N/A|No|Non-Probability Sample|Participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months        prior to registry enrolment.|November 2015|November 25, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02616224||8001|
NCT02615483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654902|Lumbar Spinal Fusion - Web-based Platform Targeting Anxiety and Depression|Lumbar Spinal Fusion - Web-based Platform Targeting Anxiety and Depression||Central Jutland Regional Hospital|Yes|Recruiting|November 2015|June 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|114|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02615483||8058|
NCT02619721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINS-016|Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)|||Beijing Pins Medical Co., Ltd||Recruiting|October 2015|February 2018|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|16 Years|N/A|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619721||7733|
NCT02620774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nicolau-53433|Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections|||Hartford Hospital|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620774||7652|
NCT02619331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL-DI|Evaluation of High Speed Laser Doppler Imaging Technology|Evaluation of High Speed Laser Doppler Imaging Technology to Quantify Skin Prick Tests in Allergic Volunteers|HSL-DI|Centre Hospitalier Universitaire Vaudois|No|Completed|February 2008|September 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 28, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619331||7763|
NCT02619344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endothelium|Endothelial Dysfunction and Selenium Status in Children With Acute Systemic Inflammatory Response|Endothelial Dysfunction and Selenium Status in Children With Acute Systemic Inflammatory||Federal University of São Paulo|No|Recruiting|August 2014|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|108|Samples Without DNA|blood|Both|1 Month|18 Years|No|Non-Probability Sample|children admitted to an intensive care unit (ICU) with systemic inflammatory response.|November 2015|November 28, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02619344||7762|
NCT02624557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719A2105|Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.|A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.||Novartis|No|Recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624557||7361|
NCT02612311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTX-TGR-304|Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia|A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)|UNITY-CLL|TG Therapeutics, Inc.|Yes|Recruiting|January 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612311||8302|
NCT02612324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2AH000017|An Evaluation of Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program|||University of Hawaii|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1783|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||September 2015|November 20, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02612324||8301|
NCT02621255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fracture Healing|Effect of Anesthesia in Fracture Healing|Effect of General and Regional Anesthesia on Fracture Healing||Cukurova University|No|Recruiting|November 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||October 2015|December 8, 2015|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621255||7615|
NCT02601326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mansourau24|Laparoscopic Ventral Mesh Rectopexy Versus Delorme's Operation in Management of Complete Rectal Prolapse|Laparoscopic Ventral Mesh Rectopexy Versus Delorme's Operation in Management of Complete Rectal Prolapse||Mansoura University|Yes|Completed|January 2012|December 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|70 Years|No|||November 2015|March 14, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02601326||9142|
NCT02604706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use.|RCT of Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use and Use of Addiction Treatment Services. A Randomized Controlled Study||Örebro Läns Landsting|No|Completed|October 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|65 Years|No|||November 2015|November 13, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604706||8884|
NCT02596919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC302|Fast Infrared Meibography (Photography)|Fast Infrared Meibography (Photography)||Queen Victoria Hospital NHS Foundation Trust|No|Not yet recruiting|October 2015|||October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02596919||9481|
NCT02599922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGTC_CNGB3-001|Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene||Applied Genetic Technologies Corp|Yes|Not yet recruiting|February 2016|December 2022|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|6 Years|N/A|No|||February 2016|February 4, 2016|November 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599922||9250|
NCT02597959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002833|Reducing Musculoskeletal Stresses and Work-related Injuries Among Allied Health Professionals in Surgical Care|Exposure Assessment and Intervention for Reducing Musculoskeletal Stresses and Work-related Injuries Among Allied Health Professionals in Surgical Care||Mayo Clinic|No|Recruiting|September 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Surgical Assistants, Circulating Nurses, and Scrub Nurses (Surgical Technicians) employed        at Mayo Clinic Rochester, MN, are the subjects for Aims 1 and 2. The subject population        for the future Aim 3 includes surgical assistant anatomy laboratory students enrolled        through the Mayo School of Health Sciences Surgical First Assistant Program, fall 2015.|November 2015|November 3, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02597959||9401|
NCT02597972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004148|Reverse Total Shoulder Arthroplasty Versus Open Reduction Internal Fixation of 3&4 Part Proximal Humerus Fractures|Reverse Total Shoulder Arthroplasty Versus Open Reduction Internal Fixation of 3 &Amp; 4-Part Proximal Humerus Fractures: A Randomized Prospective Study||Mayo Clinic|Yes|Recruiting|September 2015|January 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|70 Years|N/A|No|||November 2015|November 3, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02597972||9400|
NCT02597231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-15-6639|Melatonin and Sleep in Preventing Delirium in the Hospital|Melatonin and Sleep in Preventing Delirium in the Hospital: A Randomized Placebo-controlled Trial|MELO|Scripps Health|No|Not yet recruiting|November 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|75|||Both|65 Years|100 Years|No|||October 2015|November 3, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02597231||9457|
NCT02595671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57538|B-slim, a Multi-source Digital Super Coach for Sustainable Weight Loss|B-slim, a Multi-source Digital Super Coach for Sustainable Weight Loss||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|September 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02595671||9577|
NCT02616276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS 1192/B/15|Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance (BGI Study)|Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance, a Crossover Clinical Trial (BGI Study)|BGI|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02616276||7997|
NCT02618200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0100|Creation of an Image Database for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer|Creation of a Multimodality Image Database (MRI + Ultrasound) for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer|Echo-CAD|Hospices Civils de Lyon|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||November 2015|February 26, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618200||7850|
NCT02620085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107013RC|Thyroid Disease and Personality Study|Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status|TPS|National Taiwan University Hospital|No|Recruiting|July 2011|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Whole blood|Both|20 Years|85 Years|No|Non-Probability Sample|All patients were aged between 20 and 85 years and fulfilled the criteria for euthyroid        GD. GD is defined by a history of hyperthyroidism, thyroid eye disease or pretibial        myxedema with abnormal high thyroglobulin binding immunoglobulin (TBII) level and        autoimmune characteristics on thyroid echography. Euthyroidism is defined by normal free        thyroxine (fT4) and thyrotropin (TSH) level.|November 2015|December 1, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02620085||7705|
NCT02620098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hand01|Effectiveness of a Handwriting Intervention|Effectiveness of a Handwriting Intervention With At-Risk Kindergarteners||Temple University|No|Completed|September 2014|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02620098||7704|
NCT02624804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro 6262|A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes|A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes||Hackensack University Medical Center|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624804||7342|
NCT02567721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202055|Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)|European Medicines Agency (EMA) Post-authorisation Safety Study of Influenza Vaccine||GlaxoSmithKline||Completed|October 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|N/A||1|Actual|11530|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Registered patients in 9 GP practices in England and who are immunized against seasonal        influenza between 1 September 2015 and 30 November 2015|February 2016|February 11, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02567721||11725|
NCT02570828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001500|Thermal Imaging in Neonates: A Feasibility Study in Healthy Babies and Babies With Suspected TTN|Thermal Imaging in Neonates: a Feasibility Study in Healthy Babies and Babies With Suspected Transient Tachypnea of the Newborn (TTN)||Massachusetts General Hospital|No|Enrolling by invitation|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|3 Days|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02570828||11486|
NCT02621684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410072|Physical Activity Intervention in African American Men After Radical Prostatectomy|A Pilot Study of Physical Activity Intervention in African American Men After Radical Prostatectomy||Washington University School of Medicine|No|Withdrawn|November 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|0|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|November 25, 2015||No|Not able to enroll any participants due to disinterest|No||https://clinicaltrials.gov/show/NCT02621684||7582|
NCT02626403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/280|Fronto-parietal tDCS in Severely Brain Injured Patients With Disorders of Consciousness|Effect of Fronto-parietal Transcranial Direct Stimulation on the Level of Consciousness in Patients With Disorders of Consciousness||University Hospital of Liege||Recruiting|January 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|75 Years|No|||December 2015|December 9, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02626403||7219|
NCT02624895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140383|ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX -1st Line|ProSpective multIcenter observationaL Study on the Quality of Life of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX as 1st Line of Treatment|SILQ|Amgen|No|Recruiting|November 2015|October 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|None Retained|not collected|Both|18 Years|N/A|No|Non-Probability Sample|Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to        receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per        clinical practice. Willingness and ability to comply with the protocol. Written informed        consent to study procedures.|March 2016|March 16, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02624895||7335|
NCT02627560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1722|The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy|The Effect of Topical Administration of Tranexamic Acid on Postoperative Bleeding and Seroma Formation in Patients Undergoing Mastectomy: A Prospective Placebo-controlled Double Blinded Randomized Study||St. Olavs Hospital|Yes|Not yet recruiting|December 2015|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02627560||7130|
NCT02621840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 14-414|A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation|A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation||Wills Eye|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|442|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02621840||7570|
NCT02621853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Clinical Validation of a Raman Spectroscope to Determine Hepatic Fat Content|Clinical Validation of High Throughput Raman Fiber Optic Probe to Determine Hepatic Fat Content||Nova Scotia Health Authority|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621853||7569|
NCT02615886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-5233H|Pilot Feasibility of Rice Bran Supplementation in Nicaraguan Children|Pilot Feasibility of Dietary Heat-Stabilized Rice Bran Supplementation for Diarrheal Disease Prevention in Nicaraguan Children||Colorado State University|No|Active, not recruiting|November 2014|||October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|49|||Both|4 Months|13 Months|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615886||8027|
NCT02620371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226|Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain|Efficacy and Safety of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain in Patients Undergoing Modified Radical Mastectomy||Assiut University|Yes|Recruiting|September 2015|December 2015|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Female|18 Years|60 Years|No|||September 2015|December 1, 2015|November 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620371||7683|
NCT02624687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060576|Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study|Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study|StandBack|University of Pittsburgh|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02624687||7351|
NCT02573675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDKOREA-1|An Assessment on Current Outcomes of Peritoneal Dialysis in Korea|An Assessment on Current Outcomes of Peritoneal Dialysis in Korea|PDKOREA|Ewha Womans University|No|Not yet recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|All incident dialysis patients who started chronic dialysis therapy between January 1,        2009 and December 31, 2014 in Korea|October 2015|October 8, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573675||11267|
NCT02620709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaHOLO Project|The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians|The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians|KaHOLO|University of Hawaii|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02620709||7657|
NCT02613975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC 2013.689|A Cross Over Case Control Study of a Vibration Positional Device for Treatment of OSA|A Cross Over Case Control Study Using a Vibration Positional Device for Treatment of Position Dependent Obstructive Sleep Apnea||Chinese University of Hong Kong|No|Active, not recruiting|April 2015|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||February 2016|February 26, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613975||8174|
NCT02617823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSAN-KK|Influence of Maternal Postioning on Spread of Local Anesthetic After Epidural Analgesia|Influence of Maternal Postioning on Spread of Local Anesthetic After Epidural Analgesia||Region Skane|No|Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02617823||7878|
NCT02618057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_P01|Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia|Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia With Lobar Consolidation or Pleural Effusion in Children||Seoul National University Hospital|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|18 Years|No|||November 2015|December 7, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02618057||7861|
NCT02624934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2023|Podocan and Wnt Pathway in Left Ventricular Remodeling of Aortic Stenosis|Clinical Predictive Value of Podocan and Wnt Pathway Regulatory Molecules on Maladaptive Left Ventricular Response in Aortic Stenosis||Bassett Healthcare|No|Recruiting|October 2015|||October 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with know severe aortic stenosis who are scheduled for cardiac MRI|December 2015|December 4, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624934||7332|
NCT02613923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6114|A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer|A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer||Case Comprehensive Cancer Center|No|Recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|75|||Female|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613923||8178|
NCT02615340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4000145150|Melatonin for Prevention of Delirium in Critically Ill Patients|Efficacy and Safety of Melatonin for Prevention of Delirium in Critically Ill Patients: A Multi-centre, Randomized, Triple-blind, Placebo-controlled Feasibility Study|MELLOW-1|Mount Sinai Hospital, Canada|No|Not yet recruiting|April 2016|February 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|69|||Both|18 Years|N/A|No|||November 2015|March 15, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615340||8069|
NCT02615353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK107579-01|Preventing Diabetes in Latino Youth|Preventing Diabetes in Latino Youth||Arizona State University|Yes|Not yet recruiting|January 2016|December 2021|Anticipated|October 2020|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|12 Years|16 Years|No|||November 2015|November 25, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02615353||8068|
NCT02622607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOL|Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV NSCLC|Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Non-small Cell Lung Cancer (NSCLC)||Tang-Du Hospital|Yes|Recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|70 Years|No|||December 2015|December 2, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622607||7511|
NCT02624648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 43373915.3.0000.5479|Effects of Lepidium Meyenii Walp on Sexual Function in Postmenopausal Women|Effects of Lepidium Meyenii Walp (Peruvian Maca) on Sexual Function in Postmenopausal|maca|Universidade do Vale do Sapucai|Yes|Recruiting|October 2015|December 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02624648||7354|
NCT02624661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1192|Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique|Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique||Norwegian University of Science and Technology|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02624661||7353|
NCT02622971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 470.174|Phototherapy and Cryotherapy in Post-exercise Skeletal Muscle Recovery|Isolated and Combined Effects of Phototherapy and Cryotherapy in Post-exercise Skeletal Muscle Recovery||University of Nove de Julho|Yes|Completed|June 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02622971||7483|
NCT02614040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151769|Saline Against Lactated Ringers or Plasmalyte in the Emergency Department|Saline Against Lactated Ringers or Plasmalyte in the Emergency Department (SaLt-ED)|SaLt-ED|Vanderbilt University|Yes|Recruiting|January 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10000|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02614040||8169|
NCT02614053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mp3|Plethysmography Variability Index Monitoring for Parturients With Antepartum Hemorrhage|Continuous Non Invasive Monitoring of Both Plethysmography Variability Index and Total Hemoglobin During Cesarean Section for Antepartum Hemorrhage As a Method For Early Detection of Bleeding||Kasr El Aini Hospital|No|Active, not recruiting|March 2015|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Female|18 Years|40 Years|No|Non-Probability Sample|parturients with antepartum hemorrhage admitted for cesarean section|November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614053||8168|
NCT02616796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31648|Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome|Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome||Stanford University|No|Recruiting|April 2015|||December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Male|8 Years|15 Years|No|||November 2015|November 29, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616796||7957|
NCT02617095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2762-PIV-11/13|Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome|Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome||Laboratoires Thea|No|Recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02617095||7934|
NCT02618421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-MA-1006|A Cross-sectional Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS)|A Cross-sectional Population Representative Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS) in China, Taiwan and South Korea||Stratycon Business Solutions Pvt Ltd|No|Active, not recruiting|June 2015|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|8000|||Both|40 Years|N/A|No|Probability Sample|Population aged 40 years or over, in China, Taiwan and South Korea|April 2015|December 9, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02618421||7833|
NCT02611661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201511087|Local Ablative Strategies After Endovascular Radioembolization (LASER)|Local Ablative Strategies After Endovascular Radioembolization (LASER)||Washington University School of Medicine|No|Recruiting|January 2016|July 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611661||8352|
NCT02627092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822418|IMPACT STUDY: Investigating Microbial Pathogen Activity of Copper Textiles|An Innovative Approach to Understanding and Controlling Transmission of HAIs|IMPACT|University of Pennsylvania|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|424|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02627092||7166|
NCT02627105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0989|The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy|The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy||University of Colorado, Denver|No|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|50 Years|No|||December 2015|December 8, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627105||7165|
NCT02626702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502015953|Immune Modulators and IVF|Immune Modulators in Women Undergoing IVF----a Prospective Study||Weill Medical College of Cornell University|No|Not yet recruiting|August 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|44 Years|No|Non-Probability Sample|Subjects undergoing In Vitro Fertilization.|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626702||7196|
NCT02613871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1655|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection|A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection||Gilead Sciences|No|Recruiting|December 2015|November 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613871||8182|
NCT02614742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVG001SAH|SFX01 After Subarachnoid Haemorrhage|SFX-01 After Subarachnoid Haemorrhage|SAS|Evgen Pharma|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02614742||8115|
NCT02614885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue|Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue||Innoblative Designs, Inc.|No|Not yet recruiting|January 2016|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Female|18 Years|N/A|No|Non-Probability Sample|Patients presenting for prophylactic mastectomy.|November 2015|November 23, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02614885||8104|
NCT02625662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53213.091.15|Facioscapulohumeral Dystrophy in Children|Facioscapulohumeral Dystrophy in Children: a Prospective, Observational Study on the Natural History, Predictors and Clinical Impact (iFocus)|iFocus|University Medical Center Nijmegen|Yes|Recruiting|November 2015|September 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|DNA and RNA samples|Both|N/A|17 Years|No|Probability Sample|All children aged 0-17 years with genetically confirmed FSHD|December 2015|December 4, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02625662||7276|
NCT02625714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SID142_BE_I_2015|Safety/Tolerability and Pharmacokinetic Study of SID142|A Randomized, Open-label, Oral Multiple Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Profiles of SID142 in Healthy Volunteers||SK Chemicals Co.,Ltd.|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625714||7272|
NCT02615041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-13/2545|The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia|The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia||Prince of Songkla University|No|Completed|January 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|9|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615041||8092|
NCT02616120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECPJ-BDY-2014-27|Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease|Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms With Parkinson's Disease Patients|ESNMS|Dongzhimen Hospital, Beijing|No|Recruiting|May 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02616120||8009|
NCT02616133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064108|HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program|HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program|CECity|Duke University|No|Recruiting|January 2016|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Female|N/A|N/A|No|Non-Probability Sample|Identified patient with breast cancer|February 2016|March 21, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02616133||8008|
NCT02619383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42/13|HBOT Application in Erectile Dysfunction|Hyperbaric Oxygen Can Improve Erectile Dysfunction and Induce Penile Angiogenesis|HBOTED|Assaf-Harofeh Medical Center|No|Completed|June 2013|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02619383||7759|
NCT02625727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST104-2314-B-341-001|Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis|Comparison of Therapeutic Effects of Hyaluronic Acid vs. Hyaluronic Acid Combined Corticosteroid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial||Taipei Medical University|No|Active, not recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625727||7271|
NCT02622997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10575|Predictors of CIN Study Series 5.0:Stability Study in Vaginal Self-samples|A Study Comparing the Stability for Human Papillomavirus Testing of Three Dry Vaginal Self-samples Taken by Women Attending a Colposcopy Clinic|Predictors 5•0|Queen Mary University of London|No|Active, not recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02622997||7481|
NCT02611921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2494|Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder|Intranasal Ketamine Use in Autism Spectrum Disorder: A Placebo-Controlled Crossover Pilot Study||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|12 Years|30 Years|No|||February 2016|February 24, 2016|November 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611921||8332|
NCT02612181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL016.1|Dex on Microcirculation in SS—A Double-blinded Study|The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study||Southeast University, China|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612181||8312|
NCT02624323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AxillaryJugularUSG-RCT|Ultrasound Guided Axillary Versus Jugular Central Venous Catheterization|Real-time Ultrasound-guided Axillary and Jugular Vein Catheterization: A Prospective Comparison in Mechanically Ventilated Critically Ill Patients. A Randomized Study||Publiczny Samodzielny Zaklad Opieki Zdrowotnej Wojewodzkie Centrum Medyczne|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02624323||7379|
NCT02616003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF 121/2015|Preoperative Condition in Giant Obese Patients|A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric Restriction||Sana Klinikum Offenbach|No|Recruiting|August 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 24, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02616003||8018|
NCT02611882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17570|Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients|Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients|PSMA PET|University of California, San Francisco|No|Recruiting|September 2015|December 2020|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|225|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|September 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611882||8335|
NCT02625597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409069|Assessment of the Effects of Different Implant Abutment Occluding Materials on Dental Implant Health Parameters and Microbiology|An In Vivo Assessment of the Effects of Using Different Implant Abutment Occluding Materials on Implant Microleakage and the Peri-Implant Microbiome||Stony Brook University|No|Completed|November 2013|June 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02625597||7281|
NCT02614300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulmRehab_NCFBE|The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis|||Hospital Clinic of Barcelona|Yes|Not yet recruiting|November 2015|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|120|||Both|50 Years|80 Years|No|||November 2015|November 23, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02614300||8149|
NCT02612519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agua-Trial|Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites|Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites. A Multicentre Randomised Controlled Study||University of Leipzig|Yes|Not yet recruiting|November 2015|November 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02612519||8286|
NCT02612532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuCID-2|Lung Cancer Indicator Detection|Lung Cancer Indicator Detection|LuCID|Owlstone Ltd|No|Recruiting|October 2015|August 2018|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|520|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02612532||8285|
NCT02611570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHW103-TDU-212-114008|LDCT Screening in Non-smokers in Taiwan|Low Dose Computed Tomography Screening Study in Non-smokers With Risk Factors for Lung Cancer in Taiwan||Academia Sinica, Taiwan|Yes|Recruiting|October 2014|December 2021|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12000|Samples With DNA|blood samples Urine samples|Both|N/A|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|High risk population for lung cancer|November 2015|November 19, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02611570||8359|
NCT02616341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005-008|Development of a Behavioral Team Intervention for Obsessive Compulsive Disorder|Development of a Behavioral Team Intervention for Obsessive Compulsive Disorder||Butler Hospital|Yes|Active, not recruiting|November 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2015|November 25, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02616341||7992|
NCT02616601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-8251-301|Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis|Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Fluorouracil 0.5% Cream to Carac Cream in Subjects With Actinic Keratoses||Actavis Inc.|No|Completed|February 2015|October 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|410|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616601||7972|
NCT02627781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/15|Diagnostic Algorithm for Appendizitis (DIALAPP)|Evaluation of Diagnostic Algorithm for Suspected Acute Appendicitis|DIALAPP|Goethe University|Yes|Recruiting|November 2015|May 2018|Anticipated|November 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to our University department with suspected appendicitis and/or lower        right abdominal pain.|December 2015|December 9, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02627781|6 Months|7113|
NCT02620150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823405|SSRI Effects on Depression and Immunity in HIV/AIDS|SSRI Effects on Depression and Immunity in HIV/AIDS||University of Pennsylvania|Yes|Not yet recruiting|January 2016|January 2022|Anticipated|January 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|64 Years|No|||November 2015|December 1, 2015|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620150||7700|
NCT02626962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-1402|Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma|Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma|GEM1402|Grupo Español Multidisciplinar de Melanoma|Yes|Not yet recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|99 Years|No|||December 2015|December 9, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02626962||7176|
NCT02626975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_50|MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4|MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4|MRI-DT4|University Hospital, Lille|No|Recruiting|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|patients with an hamstring ACL ligamentoplasty with a follow up of at least 1 year|December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626975||7175|
NCT02612116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUMK202D|Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study|The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study||Collegium Medicum w Bydgoszczy|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612116||8317|
NCT02612129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-ORZY-NPC-002|Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C|Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C||Orphazyme|Yes|Not yet recruiting|April 2016|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|2 Years|18 Years|No|||November 2015|November 25, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02612129||8316|
NCT02619006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU1112-086|Infant Brain Study Follow-Up at 3 and 4 Years of Age|Effects of Placental Transfusion on Early Brain Development in Infants Born at Term: Follow-Up at 3 & 4 Years of Age||University of Rhode Island|No|Enrolling by invitation|November 2015|October 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|30 Months|48 Months|No|Non-Probability Sample|The eligible population includes 106 children who randomized in the controlled trial known        as the "Effects of Placental Transfusion on Early Brain Development" (Infant Brain Study)        (NCT01620008). The children were randomized to either immediate cord clamping or delayed        cord clamping (or cord milking as a proxy for delayed clamping). The study population also        includes a parallel preference group that self-selected cord clamping timing.|November 2015|November 27, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619006||7788|
NCT02620644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retinal GCC in Diabetics|Retinal Ganglion Cell Complex Changes by Optical Coherence Tomography in Diabetic Patients Without Retinopathy|Retinal Ganglion Cell Complex Changes Using Spectral Domain Optical Coherence Tomography in Diabetic Patients Without Retinopathy|RGCC|Cairo University|Yes|Completed|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|35|||Both|N/A|N/A|No|||December 2015|December 1, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02620644||7662|
NCT02619734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11738|Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease|Efficacy and Safety of Autologous Bone Marrow Stem Cells Infusion for Treatment of Chronic Leg Ulcer in Sickle Cell Disease Patients||Federal University of Bahia|No|Enrolling by invitation|August 2006|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619734||7732|
NCT02627443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-02064|Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer||National Cancer Institute (NCI)||Not yet recruiting|August 2016|||May 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|December 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627443||7139|
NCT02623166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/517094-0|Treatment of Pneumonia, Diarrhoea and Fever in Children by Community Health Workers|To Operationalise the Policy of Treating Uncomplicated Pneumonia, Diarrhoea and Fever in Children Aged 2-59 Months by Community Health Workers(CHW)||Society for Applied Studies|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|24000|||Both|2 Months|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted in 2 primary health centres. These include 6 sub centres in        Rasoolpur PHC (population ~57000) and 7 sub centres in Mandkola PHC (population ~57000).|July 2015|December 4, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02623166||7468|
NCT02623465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15628|A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy||Eli Lilly and Company|No|Not yet recruiting|January 2017|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|36|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623465||7445|
NCT02613286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 42981715.7.0000.5205|LESs Surgical Radicality for EaRly Stage Cervical Cancer|A Proof of Concept Phase II Non-inferiority Trial Evaluating the Safety and Efficacy of Extrafascial Hysterectomy Plus Pelvic Lymph-node Dissection in Patients With Stage IA2-IB1 Cervical Cancer ≤ 2cm|LESSER|Hospital de Câncer de Pernambuco|Yes|Enrolling by invitation|May 2015|June 2018|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|70 Years|No|||November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613286||8227|
NCT02566967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-012015|An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective|An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target||Arthritis & Rheumatic Disease Specialties Research|No|Recruiting|May 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02566967||11783|
NCT02623660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-001|Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery|Accelerated Reduction of Post-operative Edema and Early Return to Function Following Total Knee Arthroplasty (TKA)||Bioelectric Research Corporation|Yes|Enrolling by invitation|January 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623660||7430|
NCT02607085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-007|REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study|REal World EVidence for TrEAtment of HyperkaLemia in the Emergency Department (REVEAL - ED): a Multicenter, Prospective, Observational Study|REVEAL-ED|ZS Pharma, Inc.|No|Recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with moderate to severe hyperkalemia [a Standard of Care (SOC) potassium value ≥        5.5 mmol/L] admitted to the ED will be enrolled in the study.|November 2015|November 13, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02607085||8703|
NCT02601404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-07-163|REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)|REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)||Samsung Medical Center|No|Not yet recruiting|November 2015|December 2022|Anticipated|December 2022|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1000|||Both|19 Years|70 Years|No|Non-Probability Sample|A total of 1,000 patients derived from a population of Korean patients receiving PCI for        coronary artery disease will be enrolled in the present registry. It is recommended that        each enrolling investigator review the most recent instructions for use (IFU) of Absorb™        and assess the contraindications, warnings, and precaution sections for treating potential        patients.|November 2015|November 8, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02601404|5 Years|9136|
NCT02605291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERN_15-0963|Dietary Macronutrient Manipulation and Substrate Oxidation During Exercise|The Effect of Dietary Macronutrient Manipulation and Glycogen Depleting Exercise on Substrate Oxidation at Rest and During Exercise||University of Birmingham|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02605291||8839|
NCT02598908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS 194310|An EQA Scheme for TPMT Activity and Thiopurine Metabolites|Collection of Blood Samples for Use in an External Quality Assurance (EQA) Scheme for Thiopurine S-methyl Transferase (TPMT) Activity and Thiopurine Metabolites, 6-thioguanine Nucleotides (6TGN) and 6-methyl Mercaptopurine Nucleotides (6MMPN).||Sandwell & West Birmingham Hospitals NHS Trust|No|Not yet recruiting|April 2016|||March 2021|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|40|Samples Without DNA|Up to 60 mL of EDTA blood will be collected from each of the selected volunteers by trained      phlebotomy staff at Sandwell or City hospitals and virology tested just prior to the sample      distribution.      Surplus blood from routine specimens analysed for 6TGN and 6MMPN will be selected on the      basis of thiopurine metabolite concentrations of interest and volume of blood remaining.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Interested staff working within the Pathology Department at SWBH NHS Trust        A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer        system. Those with a TPMT activity of interest, measured in the past five years, will be        contacted with the agreement of their hospital consultant.|November 2015|November 5, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02598908||9328|
NCT02598921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF|Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF|Determining an Accurate and Cost-effective Strategy for Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF||Assiut University|No|Completed|July 2014|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Female|20 Years|40 Years|No|||October 2013|December 16, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02598921||9327|
NCT02602080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-397|Patient Recovery After Orthopedic Surgery Under Nerve Blocks With Sedation vs. Nerve Block With Either Sedation or General Anesthesia|Patient Recovery After Orthopedic Surgery Under Nerve Blocks With Sedation in Foot and Ankle Patients (FA) and Nerve Block With Either Sedation or General Anesthesia (GA) in Total Shoulder Arthroplasty (TSA) Patients. A Pilot Study||Hospital for Special Surgery, New York|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing elective orthopedic surgery for foot and ankle or total shoulder        replacement that are within the age limit and meet eligibility criteria.|February 2016|February 25, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02602080||9084|
NCT02601677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-DBS|Deep Brain Stimulation of NAc/ALIC to Prevent Treatment-Refractory Obsessive Compulsive Disorder|Deep Brain Stimulation of Nucleus Accumbens/Anterior Limb of Internal Capsule to Prevent Treatment-Refractory Obsessive Compulsive Disorder||Tang-Du Hospital|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|November 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02601677||9115|
NCT02600169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150907|Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab|Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab||University Medical Center Groningen|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients in this study have received treatment with pembrolizumab for the indication        of an advanced melanoma.|November 2015|November 6, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02600169||9231|
NCT02620488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000420|A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease|A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease||University of California, Los Angeles||Recruiting|September 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|13 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02620488||7674|
NCT02621541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-NETPET|Nonfunctional Pancreatic NET and PET Imaging|Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT||Turku University Hospital|Yes|Recruiting|December 2015|February 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02621541||7593|
NCT02623907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIVAS2015|China Valve Registry Study-1|Registry Study of Aortic Valve Diseases in Chinese Elderly|CHIVAS-1|Shanghai Zhongshan Hospital|Yes|Not yet recruiting|May 2016|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|60 Years|N/A|No|Probability Sample|Patients aging more than 60 years diagnosed with severe AS or AR by echocardiography will        be collected from multiple institutions.|December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623907|3 Years|7411|
NCT02623920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507953455|Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)|S-BR|University of Arizona|Yes|Recruiting|December 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||October 2015|February 23, 2016|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623920||7410|
NCT02614092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1884-P|Water-based Activity to Enhance Recall in Veterans|Water-based Activities to Enhance Recall in Veterans (WATER-VET)|WATER-VET|VA Office of Research and Development|No|Not yet recruiting|January 2016|December 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614092||8165|
NCT02618837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUBIUS - 0015746|Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers|Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive Indication|DUBIUS|University of Padova||Recruiting|December 2015|November 2018|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2520|||Both|18 Years|84 Years|No|||January 2016|January 18, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618837||7801|
NCT02573324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-813|A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification|A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)|Intellance 1|AbbVie|Yes|Recruiting|December 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|September 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02573324||11294|
NCT02573337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05DF1502|Perception of Facial Expressions Following Correction of Wrinkles and Folds|A Multi-center, Non-comparative Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face Using Emervel Classic Lidocaine and Emervel Deep Lidocaine||Q-Med AB|No|Active, not recruiting|October 2015|January 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573337||11293|
NCT02626533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-361|Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis|Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis|Pain+Stiffness|Hospital for Special Surgery, New York|No|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|165|Samples With DNA|Whole blood, serum, and joint fluid aspirate samples will be collected and stored for      analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Hospital for Special Surgery patients scheduled to undergo unilateral total knee        arthroplasty under regional anesthesia.|February 2016|February 11, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02626533||7209|
NCT02611934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUMK202C|Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With PCI|Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With Percutaneous Coronary Intervention|UNICORN|Collegium Medicum w Bydgoszczy|No|Not yet recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611934||8331|
NCT02614404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuLow-201605|Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria|Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria|MIM|HuLow|No|Recruiting|November 2015|February 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|No|||November 2015|November 23, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02614404||8141|
NCT02613637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuCa BiO|Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project|Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project||University of Ulm|No|Recruiting|May 2014|||December 2024|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|-  Tumor tissue        -  20-40 mL of peripheral blood in a heparinized (1:10) tube        -  10 ml EDTA-anticoagulated blood sample|Both|18 Years|N/A|No|Probability Sample|All patients with newly diagnosed or existent lung cancer of all LuCa BiO centers in        Germany are intended to be registered with in the LuCa BiO Registry.|November 2015|November 23, 2015|June 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02613637|15 Years|8200|
NCT02613650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI87144|A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers|A Phase 1b Trial of a Combination of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers||University of Utah|Yes|Not yet recruiting|March 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613650||8199|
NCT02626559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00082660|Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee|Serum Bupivacaine Concentration Levels After Injection of the Knee Joint With a Mixture of Liposomal Bupivacaine and Free Bupivacaine During Total Knee Arthroplasty||University of Utah|No|Recruiting|November 2015|||November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults of at least 18 years of age having a primary, unilateral total knee arthroplasty        with a surgical plan to have an intra-articular injection of a mixture of 266 mg of        Exparel, 125 mg of bupivacaine, 1:300,000 epinephrine, and 0.9% saline to make a total        volume of 100 ml.|December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626559||7207|
NCT02626572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-47445-011|Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms|Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.||Servier|Yes|Recruiting|February 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|500|||Both|55 Years|85 Years|No|||December 2015|December 7, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02626572||7206|
NCT02625961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-057|Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)|A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy||Merck Sharp & Dohme Corp.|Yes|Recruiting|February 2016|June 2020|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|260|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625961||7253|
NCT02625974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16027|Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease|Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease|CHICO|Bayer|Yes|Recruiting|January 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|390|||Both|N/A|17 Years|No|||March 2016|March 10, 2016|December 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625974||7252|
NCT02625987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2301-6|Appendicectomy Skin Closure Technique: Changing Paradigms (ASC)|Comparison Between Intradermic vs Habitual Skin Closure Technique in Open Appendicectomy.|ASC|Coordinación de Investigación en Salud, Mexico|Yes|Completed|April 2015|September 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|200|||Both|1 Year|60 Years|No|||December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625987||7251|
NCT02611765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22816|Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study|Syphilis Response to Higher Penicillin Dosage in HIV Co-Infected Patients||Baylor College of Medicine|No|Completed|September 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611765||8344|
NCT02622932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-I-R|Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02622932||7486|
NCT02613663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAdam|Immediate Implant Using "Nanobone" Versus "Autogenous Bone" for Treatment of Patients With Unrestorable Single Tooth.|Evaluation of Surgical Time, Post-operative Pain and Marginal Bone Loss in Immediate Implant Using "Nanobone" Versus "Autogenous Bone" for Treatment of Patients With Unrestorable Single Tooth: Randomized Controlled Trials.||Cairo University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613663||8198|
NCT02618980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-103062-F|Early Endoscopy for Acute Upper Gastrointestinal Bleeding in Acute Coronary Syndrome Patients|Management of Acute Upper Gastrointestinal Bleeding in Recent Acute Coronary Syndrome Patients by Early Endoscopy and Non-Endoscopy Treatment: A Randomized Controlled Trial to Evaluate Efficacy and Safety||Far Eastern Memorial Hospital|Yes|Recruiting|July 2014|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||November 2015|November 29, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02618980||7790|
NCT02619279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096620-S4|A Livelihood Intervention for Impoverished Women and Children in Rural Uganda|A Livelihood Intervention for Impoverished Women and Children in Rural Uganda: Randomized Controlled Trial||Massachusetts General Hospital|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|N/A|18 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02619279||7767|
NCT02622841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51405.041.15|Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases|Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases: First-in-Man Study According to the IDEAL Recommendations|BLEND|UMC Utrecht|Yes|Recruiting|June 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02622841||7493|
NCT02622854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiperlipPankr|Plasma Exchange vs Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis|Comparison of Plasma Exchange and Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis With Mildly Elevated Triglycerides||University Medical Centre Ljubljana|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02622854||7492|
NCT02626546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1128-31/4|Predictors, Risk Factors and Outcome Following Major Surgery|Predictors, Risk Factors and Outcome Following Major Surgery|PROFS|Karolinska Institutet|No|Recruiting|November 2015|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive adult patients who are operated for major surgical procedures during the study        period in tertiary hospitals in Sweden.|December 2015|December 8, 2015|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02626546||7208|
NCT02618434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P302|Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)|||Supernus Pharmaceuticals, Inc.|No|Recruiting|March 2015|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|291|||Both|6 Years|12 Years|No|||February 2016|February 11, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618434||7832|
NCT02624141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18054|A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment||Hoffmann-La Roche||Terminated|April 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 2, 2015||No|The study was terminated due to low recruitment|No||https://clinicaltrials.gov/show/NCT02624141||7393|
NCT02624154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU 211|Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival|Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival||First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2|||Both|10 Years|80 Years|No|Probability Sample|Investigators selected the patient who underwent pancreatectomy during the time from 2010        to 2013 at the First Affiliated Hospital of Sun Yat-sen University.|November 2015|December 4, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02624154||7392|
NCT02626013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS-GENESIS-ONCO-GRC-001|A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With MBC in Greece|A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel (ABRAXANE®) Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With Metastatic Breast Cancer in Greece. The 'ABReast' Study.|ABReast|Genesis Pharma S.A.|No|Not yet recruiting|December 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|245|||Female|18 Years|N/A|No|Probability Sample|Adult patients with a histologically or cytologically confirmed diagnosis of MBC who have        failed first-line treatment for metastatic disease and for whom standard, anthracycline        containing therapy is not indicated|November 2015|December 7, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02626013||7249|
NCT02626104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLAAD|Bovine Lactoferrin and Antibiotic-associated Diarrhoea.|Bovine Lactoferrin in the Prevention of Antibiotic-associated Diarrhoea in Children - a Randomized Clinical Trial.|BLAAD|Medical University of Warsaw|No|Recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|156|||Both|1 Year|18 Years|No|||November 2015|December 9, 2015|June 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626104||7242|
NCT02614170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-115|A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals|A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals||Fujirebio Diagnostics, Inc.|No|Recruiting|March 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Serum, Plasma, Random Urine and 24 hour Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A minimum of 250 subjects will be enrolled in this study. Healthy women and men greater        than or equal to 18 years of age having donated a single blood draw, a random urine        specimen, and a 24-hour urine collection specimen will be eligible.        Each site will evaluate and select patients for enrollment using the inclusion and        exclusion criteria listed below. Study subjects should be selected from all available        patients at the site. Each patient may be entered into the study only once.|November 2015|November 24, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02614170||8159|
NCT02614482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-2574|Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.|Efficacy and Tolerability of Fesoterodine for Overactive Bladder Syndrome in Children: an Extension Study.|FOXY2015|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|October 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|5 Years|14 Years|No|||January 2016|January 27, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02614482||8135|
NCT02627053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIVASVT-100|Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study|Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study||Università degli Studi dell'Insubria|Yes|Recruiting|December 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|100 Years|No|||March 2016|March 13, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02627053||7169|
NCT02627066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14072|Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise|Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise|VCE|University of Illinois at Urbana-Champaign|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|90 Years|No|||December 2015|December 9, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627066||7168|
NCT02618538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progetto IG 2014 Id.15374|The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.|Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.||Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte|No|Enrolling by invitation|July 2015|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|22000|Samples With DNA|whole blood|Both|46 Years|67 Years|No|Non-Probability Sample|All women aged 46-67 years and resident in Turin, Vercelli, and Biella (the three        screening centres involved in the study) and invited to perform a screening mammography.|November 2015|November 27, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618538|2 Years|7824|
NCT02618785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562441242|Antispasmodic Drug for Pain Relief During Hysterosalpingography|Effectiveness of Antispasmodic Drug for Pain Relief During Hysterosalpingography in Infertile Women: A Randomized Double-blind Controlled Trial||Mahidol University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Female|19 Years|42 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618785||7805|
NCT02624700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10790|Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer|Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer||Virginia Commonwealth University|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624700||7350|
NCT02624778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16233|A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD|A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease||Eli Lilly and Company|No|Recruiting|December 2015|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|10||Anticipated|150|||Both|50 Years|N/A|No|||March 2016|March 14, 2016|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624778||7344|
NCT02621515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500776|Nivolumab in Symptomatic Brain Metastases|An Open-label, Single-arm, Phase II, Multicenter Study to Evaluate the Efficacy of Nivolumab in Metastatic Melanoma Patients With Symptomatic Brain Metastases|CA209-322|University Medical Center Groningen|Yes|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621515||7595|
NCT02619318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEL (ViB)|Balancing Everyday Life - A Lifestyle Intervention for People With Psychiatric Disorders|Balancing Everyday Life - A Lifestyle Intervention for People With Psychiatric Disorders||Lund University||Recruiting|November 2013|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02619318||7764|
NCT02623452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15627|A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy||Eli Lilly and Company|No|Not yet recruiting|January 2017|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|36|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623452||7446|
NCT02624713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|telhaicollege|Development of Eating Disorders Symptoms Among Children|Development of Eating Disorders Symptoms Among Children Who Took Part in Family-based Obesity Treatment and Among Their Siblings||Tel Hai College|Yes|Enrolling by invitation|November 2015|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02624713||7349|
NCT02614131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15491|A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)|Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease||Eli Lilly and Company|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|130|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|November 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614131||8162|
NCT02619201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-10|Antiemetic Efficacy of Ondansetron Versus Metoclopramide|Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Not yet recruiting|November 2015|November 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|1 Year|5 Years|No|||October 2015|November 30, 2015|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02619201||7773|
NCT02619214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-OXI-2013-62|Oxidative Stress Related to 2 Different Oxygen Concentrations During General Anesthesia. Clinical Trial.|Oxidative Stress Related to 2 Different Oxygen Concentrations During General Anesthesia. Clinical Trial.|OSGA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|May 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02619214||7772|
NCT02619552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00050472|Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease|Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease||University of Maryland|No|Recruiting|August 2011|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators are planning a study with 60 experimental participants and 30 control        participants. The investigators will recruit participants from multiple referral centers        for IBD with an existing population of nearly 5,000 patients.|September 2015|November 30, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02619552||7746|
NCT02619058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCH-MM-150620|A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients|An Open Label, Dose Escalation, Phase I Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients||Beijing Cancer Hospital|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|70 Years|No|||December 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02619058||7784|
NCT02626741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|647-2557-EC4|Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome|Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome : A Randomized Controlled Trial|SlimWell|Mahidol University|No|Recruiting|February 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02626741||7193|
NCT02619513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexmedetomidine TPVB|Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks|Effects of Dexmedetomidine as an Adjunctive Analgesic Used in Continuous Thoracic Paravertebral Blocks for Post-thoracotomy Pain Syndrome||Guangzhou General Hospital of Guangzhou Military Command|No|Completed|December 2014|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|60|||Both|19 Years|76 Years|No|||November 2015|November 28, 2015|September 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02619513||7749|
NCT02619838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059296|Prospective Subtalar, Double, or Triple Arthrodesis Study With CCS Screws|Prospective Subtalar, Double, or Triple Arthrodesis Study With CCS Screws||Duke University|No|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients will be identified in the clinic by an attending orthopaedic foot and ankle        surgeon or his physician assistant based on clinical exam and radiographic findings.        Patients of all racial, religious, and cultural backgrounds will be included in this        study.|November 2015|March 7, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02619838||7724|
NCT02627209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGH-070|The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis|Non-infectious and Infectious Uveitis Diagnosis|uveitis|Dünyagöz Hospital|Yes|Recruiting|June 2014|January 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|280|||Both|9 Years|86 Years|No|||December 2015|December 9, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02627209||7157|
NCT02626832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910005875|Regulation of Arginine-vasopressin (AVP)|Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders|REGAVP|Yale University|No|Completed|February 2010|December 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02626832||7186|
NCT02618265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH2013144|Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research|Mobile Terminal Based Management and Platelet Reactivity Modified Drug Regulation of Stroke Secondary Prevention||Peking University Third Hospital|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|400|||Both|N/A|N/A|No|||November 2015|November 27, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02618265||7845|
NCT02612246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1972-CL-101|First-in-Human Single and Multiple Dose of GLPG1972|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1972 in Healthy Male Subjects||Galapagos NV|No|Recruiting|November 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612246||8307|
NCT02612259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJD-OB-TRP|A Phase II, Randomized, Double-blind, Placebo-controlled, in Parallel Groups Clinical Trial to Assess the Safety and Efficacy of Dietary Supplementation With Tryptophan to Achieve Weight Loss, and Its Neuropsychological Effects in Adolescents With Obesity|A Phase II, Randomized, Double-blind, Placebo-controlled, in Parallel Groups Clinical Trial to Assess the Safety and Efficacy of Dietary Supplementation With Tryptophan to Achieve Weight Loss, and Its Neuropsychological Effects in Adolescent Patients Age 12 to 17 Years With Obesity||Fundació Sant Joan de Déu|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|12 Years|17 Years|No|||November 2015|November 19, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02612259||8306|
NCT02569463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL2-MAS|Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）|Safety and Efficiency Study of Low-dose IL-2 Treatment in Macrophage Activation Syndrome||Peking University People's Hospital|Yes|Recruiting|June 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|16 Years|65 Years|No|||October 2015|October 4, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02569463||11591|
NCT02569476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-3111_GA101_Study_001|BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies|A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies||BeiGene|Yes|Recruiting|December 2015|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|September 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02569476||11590|
NCT02569489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBI-8000-106|Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer|Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer||HUYA Bioscience International|No|Not yet recruiting|December 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02569489||11589|
NCT02612142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPSMM-2011|Physical EXercise as an Adjunct Treatment for Depression|Efficacy of Exercise as an Adjunct Treatment for Clinically Depressed Inpatients During the Initial Stages of Antidepressant Therapy.|PEXAT|Université de Reims Champagne-Ardenne|No|Completed|June 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||November 2015|November 21, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612142||8315|
NCT02614313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGRG FBT-PLA|Fructose Breath-testing in Irritable Bowel Syndrome (IBS)|Assessment of Psychological and Metabolic Responses During Fructose Intolerance Breath Tests in Patients With Functional GI Disorders: Placebo-controlled Breath Testing||Brain-Gut Research Group|No|Not yet recruiting|April 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02614313||8148|
NCT02617784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP16472|A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)|A Single Center, Open Label, Multiple-Dose Oral Oseltamivir Suspension Study in End-Stage-Renal Disease (ESRD) Patients on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)||Hoffmann-La Roche||Completed|October 2001|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|November 27, 2015|No|Yes||No|January 17, 2016|https://clinicaltrials.gov/show/NCT02617784||7881|
NCT02617082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-BC004|Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery|Phase II Study of Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery||Fudan University|Yes|Recruiting|October 2015|||October 2019|Anticipated|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|828|Samples Without DNA|blood|Female|18 Years|65 Years|No|Probability Sample|DCIS breast cancer patients|November 2015|November 27, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02617082|5 Years|7935|
NCT02616289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-15101|Emollient Therapy for Severe Acute Malnutrition|Topical Emollient Therapy in the Management of Severe Acute Malnutrition: A Randomized Controlled Clinical Trial in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Not yet recruiting|December 2015|February 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|2 Months|24 Months|No|||November 2015|November 25, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02616289||7996|
NCT02620943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAUT|Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in Ethiopia|Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in a Prospective Cohort Study of Rural Ethiopia||Dilla University|No|Completed|August 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|374|||Female|15 Years|49 Years|No|Probability Sample|Pregnant women in rural Ethiopia|November 2015|December 2, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02620943||7639|
NCT02627820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P001574|The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart|An 18 Month Open Label Study Of The Tolerability And Efficacy Of An Antisense Oligonucleotide In Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (Senile Systemic Amyloidosis)||Brigham and Women's Hospital||Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|90 Years|No|||January 2016|January 6, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02627820||7110|
NCT02624024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-059975|Clinical Performance Evaluation of AQT90 FLEX TnI and TnT|AQT90 FLEX TnI and TnT - Clinical Sensitivity and Specificity Study||Radiometer Medical ApS||Recruiting|January 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1400|Samples Without DNA|Frozen plasma samples are retained for this study and possible future studies.|Both|21 Years|N/A|No|Probability Sample|Subjects 21 years of age or older presenting to the emergency department (ED) with acute        chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or        acute myocardial infarction (MI).|March 2016|March 9, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624024||7402|
NCT02615249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP148MP201|Clinical Evaluation of Metal Panel Allergens: Dose Response Study|Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study||Allerderm|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615249||8076|
NCT02619461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT_Exercise_Appetite_001|The Acute Effect of Exercise on Appetite Appetite-regulating Hormones and Inflammation in Children|The Acute Effect of High Intensity Exercise on Appetite, Appetite-regulating Hormones, and Bio-markers of Inflammation and Stress in Lean and Obese Boys||University of Toronto|No|Completed|August 2014|October 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|10 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 29, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02619461||7753|
NCT02616614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAT/CMBP/2015|Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris|Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris||Actavis Inc.|No|Completed|May 2015|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|818|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616614||7971|
NCT02616913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8280290|Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects|A Single Dose, Double Blind, Randomized, Crossover Placebo- and Moxifloxacin (Open Label)-Controlled Study to Evaluate the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects||Cargill|Yes|Completed|March 2013|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02616913||7948|
NCT02622802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS201210|Transplacental Transfer of Drugs Used in Pregnant Women|Transplacental Transfer of Drugs Used in Pregnant Women||University Hospital, Gasthuisberg|No|Recruiting|November 2012|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|600|||Female|18 Years|45 Years|No|||December 2015|December 2, 2015|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02622802||7496|
NCT02624505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-SS-M-AS312|Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma|To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.||Cipla Ltd.|No|Recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|115|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|December 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624505||7365|
NCT02627456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916004|Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali|Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safaty, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|September 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|500|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|March 2, 2016|December 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627456||7138|
NCT02612363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL016.0|Early Goal Directed Sedation on Microcirculation in Septic Shock|The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation||Southeast University, China|Yes|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02612363||8298|
NCT02625792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0925|Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD|||Yonsei University|No|Not yet recruiting|December 2015|January 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|168|||Both|19 Years|80 Years|No|||December 2015|December 9, 2015|December 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02625792||7266|
NCT02618083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALR_2015_24|Prognostic Value of Hemodynamic Disturbances in Rhegmatogenous Retinal Detachment (CRADO-RED)|Prognostic Value of Hemodynamic Disturbances of the Central Retinal Artery in Color Doppler Ultrasound in Rhegmatogenous Retinal Detachment|CRADO-RED|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|November 2015|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02618083||7859|
NCT02618096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWP_PG_M2|Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Multiparous Women at Term|||Seoul National University Hospital|Yes|Recruiting|October 2015|||November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Female|N/A|N/A|No|||December 2015|February 16, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618096||7858|
NCT02570503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Postoperative Pain Contol After Periarticular Injection During Total Knee Arthroplasty|Do Intraoperative Periarticular Injections Improve Postoperative Pain Control in Patients Receiving Duramorph PF During Total Knee Arthroplasty? A Prospective, Double-Blind, Randomized Controlled Trial||Virginia Commonwealth University|Yes|Enrolling by invitation|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02570503||11511|
NCT02613156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B20140001|Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma|Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma||Sun Yat-sen University|No|Completed|June 2014|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|||Both|18 Years|70 Years|No|Non-Probability Sample|patients who were diagnosed with recurrent HCC and underwent surgical resection at the Sun        Yat-sen University Cancer Center from June 2014 to November 2014|January 2016|January 2, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613156||8237|
NCT02597673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU0001-15-1-TS08 (N15-P01)|Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty|Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty||University of Tennessee|Yes|Active, not recruiting|July 2015|June 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|136|||Both|18 Years|45 Years|No|||September 2015|November 3, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02597673||9423|
NCT02606084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108058|A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine||Janssen Research & Development, LLC|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|November 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02606084||8778|
NCT02603016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGHS201503601|Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma|Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma||Chinese PLA General Hospital|Yes|Recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|480|||Both|18 Years|70 Years|No|||November 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603016||9013|
NCT02605174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-302|Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine|A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)|SPARTAN|CoLucid Pharmaceuticals|No|Not yet recruiting|April 2016|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|2968|||Both|18 Years|N/A|No|||November 2015|December 16, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02605174||8848|
NCT02605187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34740|Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management|Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management||Stanford University|Yes|Recruiting|November 2015|November 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Female|18 Years|50 Years|No|||December 2015|December 6, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02605187||8847|
NCT02606747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11372013|The Balance Control Mechanism of DPN Patients|The Balance Control Mechanism of Diabetic Peripheral Neuropathy Patients||Peking University|Yes|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|40 Years|80 Years|No|Probability Sample|Diabetics|November 2015|November 16, 2015|April 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02606747||8728|
NCT02606864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16005|Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients|Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chagas' Disease||Bayer|No|Recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|45 Years|No|||March 2016|March 10, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02606864||8719|
NCT02605499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063160|Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)|Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)|UVCLEAR-MDRO|Johns Hopkins University|No|Enrolling by invitation|November 2015|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|11000|||Both|16 Years|N/A|No|||November 2015|November 12, 2015|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02605499||8823|
NCT02612805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0380|The Diabetes and Aquatic Training Study (DATS)|Effects of Two Models of Physical Training in Aquatic Environment in Control of Type 2 Diabetes - A Controled Randomized Clinical Trial: The Diabetes and Aquatic Training Study (DATS)|DATS|Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|November 2015|May 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|30 Years|75 Years|No|||February 2016|February 22, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02612805||8264|
NCT02626468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-T3D-004|Validation of Structured Light Plethysmography - Health and Disease|Validation in Healthy Subjects and Different Diagnostic States|SLP-RespDis|Pneumacare Ltd|No|Recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|A range of diagnostic conditions that effect breathing and healthy normal subjects. The        study will aim to recruit:        200 patients from different diagnostic groups between the ages of 0 and 80 100 healthy        participants with no diagnosis of respiratory disease, between the ages of 0 and 80|December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626468||7214|
NCT02611700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPL-IST-ESO-057|Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma|An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas||Biotech Pharmaceutical Co., Ltd.|No|Recruiting|November 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|504|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02611700||8349|
NCT02619084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-131|Subthalamic Stimulation in Tourette's Syndrome|Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome|STN-DBSinTS|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Completed|December 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02619084||7782|
NCT02620254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mastocytosis Registry|Mast Cell Connect: A Registry for Patients With Mastocytosis|Mast Cell Connect: A Registry for Patients With Mastocytosis||Blueprint Medicines Corporation||Recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of mastocytosis, including systemic mastocytosis and cutaneous        mastocytosis and any subtypes of these diseases.|December 2015|December 2, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02620254|5 Years|7692|
NCT02613949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPT-202|Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202|A Double-Blinded, Randomized, Sham-Controlled, Phase 2 Study of the Revised NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia|PERRFECT-202|Cerephex Corporation|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|22 Years|75 Years|No|||November 2015|November 23, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613949||8176|
NCT02613962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00464-45|Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling|A PROSPECTIVE, MULTICENTRIC CLINICAL PROOF-OF-CONCEPT STUDY TO STRATIFY TARGETED THERAPIES ADAPTED TO MOLECULAR PROFILING OF RELAPSED OR REFRACTORY PEDIATRIC TUMORS|MAPPYACTS|Gustave Roussy, Cancer Campus, Grand Paris|No|Not yet recruiting|December 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|300|||Both|6 Months|18 Years|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613962||8175|
NCT02615626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLandPT|Visfatin Levels Before and After Periodontal Treatment|Gingival Crevicular Fluid and Serum Levels of Visfatin in Periodontal Diseases Before and After Non-surgical Periodontal Treatment|VL|Bulent Ecevit University|No|Completed|May 2012|January 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|45|Samples Without DNA|Gingival crevicular fluid and Serum|Both|25 Years|49 Years|Accepts Healthy Volunteers|Probability Sample|Total of 45 patients|November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615626||8047|
NCT02619097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-EPOP1b|Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes|Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes||Jiangsu Hansoh Pharmaceutical Co., Ltd.|No|Recruiting|June 2014|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 29, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02619097||7781|
NCT02619409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039232|Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash|Evaluation of the Duration of Bupivacaine Spinal Block as the Primary Anesthetic for Orthopedic Procedures With and Without Epinephrine Wash||Medical University of South Carolina|Yes|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619409||7757|
NCT02567968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0897|A Study to Determine if Caffeine Accelerates Emergence From Anesthesia|A Randomized, Double-Blinded, Placebo-Controlled Pilot Study to Determine if Caffeine and Sodium Benzoate Accelerates Emergence From Anesthesia||University of Chicago|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2|||Male|25 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567968||11706|
NCT02614235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-CHUAC-01|Diagnosis of Arrhythmias in Syncope by Pocket-ECG III® or Conventional Holter|Diagnosis of Arrhythmias in Patients With Syncope by Continuous Cardiac Telemetry (Pocket-ECG III® System) or Conventional Holter|SINPocket|Complexo Hospitalario Universitario de A Coruña|No|Recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|November 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614235||8154|
NCT02614248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817035|The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population|The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population||Genesis Health System|Yes|Not yet recruiting|December 2015|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|2 Years|No|||November 2015|November 23, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02614248||8153|
NCT02613494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-GOTHIC1|Clozapine-induced Hypersalivation - Feasibility Trial|A Feasibility Study of Glycopyrrolate in Comparison to Hyoscine Hydrobromide and Placebo in the Treatment of Hypersalivation Induced by Clozapine|GOTHIC1|Mersey Care NHS Trust|Yes|Not yet recruiting|February 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|65 Years|No|||November 2015|November 23, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02613494||8211|
NCT02613507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-078|Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer|An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)|CheckMate 078|Bristol-Myers Squibb|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|November 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02613507||8210|
NCT02613520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSPZV2|Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants|Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants||Sanaria Inc.|Yes|Recruiting|December 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|23||Anticipated|99|||Both|6 Months|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02613520||8209|
NCT02616250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.105069|MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.|Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea|MOSAIC|Galderma|No|Recruiting|December 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616250||7999|
NCT02613676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcBScreening|Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns|Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns||University of Stellenbosch|Yes|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|1858|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02613676||8197|
NCT02623205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2911-F|Advancing Personalized Antidepressant Treatment Using PET/MRI|Advancing Personalized Antidepressant Treatment Using PET/MRI||Stony Brook University|Yes|Recruiting|May 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|55 Years|No|||December 2015|December 22, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623205||7465|
NCT02624479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009_15|Pharmacokinetic Study to Investigate the Bioavailability and Tolerability of 3 Oral Formulations of Sodium Thiosulfate|Phase I Pharmacokinetic Pilot Study to Investigate the Bioavailability and Tolerability of Three Different Oral Formulations of Sodium Thiosulfate|TSTS|University Hospital Inselspital, Berne|No|Not yet recruiting|December 2015|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|12|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02624479||7367|
NCT02624492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1270.11|To Determine the Maximum Tolerated Dose of BI 836826-GemOx and Then the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLCBL|An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- in Combination With GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Failed Autologous Stem Cell Transplant||Boehringer Ingelheim||Active, not recruiting|January 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 4, 2015||||No||https://clinicaltrials.gov/show/NCT02624492||7366|
NCT02613052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151360|Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations|The Use of Agitated Saline, Albumin, or a Propofol-albumin Mixture for Enhanced Contrast in Bubble Studies During Transesophageal Echocardiographic Examinations||University of California, San Diego|No|Recruiting|January 2016|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02613052||8245|
NCT02621528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeraFlex™ PMSS|Lifetech CeraFlex™ Post-Market Surveillance Study|Multi-center, Non-interventional, Prospective, Post-market Study||Lifetech Scientific (Shenzhen) Co., Ltd.|Yes|Active, not recruiting|October 2015|May 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|N/A|N/A|No|||October 2015|December 1, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621528||7594|
NCT02618733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-218|Comparing Ticagrelor Versus Clopidogrel on Microcirculation|A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study|PLEIO|Dong-A University|Yes|Recruiting|December 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|85 Years|No|||November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618733||7809|
NCT02613533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-988E|Water Drinking Test in Patients With Occludable Angle|What is the Effect of the "Water Drinking Test" on Patients With Narrow Angles on the Day of Their Scheduled Laser Iridotomy?||Wills Eye|No|Completed|February 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|21 Years|90 Years|No|||November 2015|November 19, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02613533||8208|
NCT02614664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00821|Changes in Cerebral Oxygenation During Laparoscopy in Patients With Single Ventricle Anatomy|||Nationwide Children's Hospital|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with single ventricle anatomy|November 2015|November 23, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02614664||8121|
NCT02614677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-140713|To Advance the New Disability Evaluation System in Taiwan|||Changhua Christian Hospital||Completed|August 2014|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|||Both|6 Years|65 Years|No|Probability Sample|People with disabilities want to issue a disability identification|November 2015|November 22, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02614677||8120|
NCT02618161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0845|Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment|A Randomised Feasibility Trial to Investigate the Timing of HDR Brachytherapy With EBRT in Intermediate and High Risk Localised Prostate CAncer Patients and Its Effects on Toxicity and Quality of Life|THEPCA|Southend University Hospital Foundation NHS Trust|Yes|Recruiting|September 2014|September 2018|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Male|18 Years|N/A|No|||November 2015|November 26, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02618161||7853|
NCT02627079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00068978|ICanSTEP : Increasing Physical Activity With Text Messaging|ICanSTEP: Increasing Physical Activity in Cancer Survivors Through a Text-messaging Exercise Motivation Program||Duke University|No|Recruiting|February 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627079||7167|
NCT02614547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-PPD-202|A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression||Sage Therapeutics|No|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|45 Years|No|||March 2016|March 11, 2016|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614547||8130|
NCT02622828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2015:132|Increasing the Winter Community Participation of Older Adult Wheelchair Users|Increasing the Winter Community Participation of Older Adult Wheelchair Users||University of Manitoba|No|Recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|70 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02622828||7494|
NCT02626273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0249|ADIposity and Bone Metabolism: Effects of eXercise-induced Weight Loss in Obese Adolescents|ADIposity and Bone Metabolism: Effects of eXercise-induced Weight Loss in Obese Adolescents|ADIBOX|University Hospital, Clermont-Ferrand||Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|12 Years|16 Years|No|||December 2015|December 7, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626273||7229|
NCT02623816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00089|Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen|||MetroHealth Medical Center|No|Recruiting|August 2014|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623816||7418|
NCT02625025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPALPression|Low vs Standard Pneumoperitoneum Pressure During Single Port Access Laparoscopic for Adnexal Pathology|||University of Cagliari||Not yet recruiting|January 2016|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625025||7325|
NCT02625285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1501|Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative|Validation of New G6PD Point of Care Tests (Biosensors) Against Gold Standard Quantitative Spectrophotometry and Genotyping|Biosensors|University of Oxford|No|Not yet recruiting|May 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|Two blood samples will be withdrawn from participants; one sample will be taken by      finger-stick (200 µl) and one sample (0.5 ml) will be taken by arm venipuncture. The blood      from capillary sample will be used to assess G6PD activity using the POC tests, CBC and      laboratory based quantitative tests. The venous blood will be used for reference standard      quantitative G6PD assays, Hb typing analysis, CBC and buffy-coat will be stored for DNA      extraction for G6PD genotyping only; leftover blood will be discarded.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The total sample size will be 150 patients, using targeted enrollment to achieve a        convenience sample of approximately 50 G6PD deficient volunteers (male and female),        approximately 50 G6PD intermediate or heterozygous female volunteers, and the remaining        will be G6PD-normal volunteers with a 1:1 male/female ratio.|March 2016|March 16, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625285||7305|
NCT02614625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTComparisonstudy1.1|Spectral-domain Optical Coherence Tomography of the Eye|A Prospective, Comparative, Observational Study on Spectral-domain Optical Coherence Tomography of the Eye||Augenabteilung Allgemeines Krankenhaus Linz||Recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|200 eyes of 100 patients will be included.|November 2015|November 22, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02614625||8124|
NCT02618135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/00841|Brain-Computer Interface-based Programme for the Treatment of ASD/ADHD|Effectiveness of a Brain-Computer Interface-based Programme for the Treatment of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder in Children: A Pilot Study|ASDBCI|Duke-NUS Graduate Medical School|No|Not yet recruiting|February 2016|July 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|12 Years|No|||January 2016|January 27, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618135||7855|
NCT02622022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-002533-22|Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease|Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease|MORPHILD|University of Aarhus|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|110 Years|No|||December 2015|December 4, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622022||7556|
NCT02622243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio REB 15-254|Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge|Duration of Bronchoprotection of the Long Acting Muscarinic Antagonists Tiotropium and Glycopyrronium Against Methacholine Induced Bronchoconstriction||University of Saskatchewan|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|19 Years|N/A|No|||December 2015|December 3, 2015|November 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622243||7539|
NCT02623556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTao-EC III-patient|Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen|For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase III Clinical Research||Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|No|Recruiting|December 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|1080|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623556||7438|
NCT02627157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0944|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer for Young Healthy Adults in South Korea|||Yonsei University|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|40 Years|No|Non-Probability Sample|Young myopic patients|March 2016|March 3, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627157||7161|
NCT02614144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA MZČR NT 14263-3/2013|Epidemiology of Hospital Acquired Pneumonia|Identifying Agents of Early-onset and Late-onset Nosocomial Pneumonia in Patients in Intensive Care Through Genetic Analysis of Bacterial DNA and Determination of Their Distribution.|HAP|University Hospital Olomouc|Yes|Completed|January 2013|November 2015|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|214|Samples With DNA|In intubated patients, secretion samples for microbiology culture tests are obtained by      aspiration from the lower airway.|Both|18 Years|N/A|No|Probability Sample|The group comprised patients hospitalized in the Intensive Care Departments of cooperating        hospitals between 1 May 2013 and 30 April 2015 who developer signs of HAP.|November 2015|November 24, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02614144|30 Days|8161|
NCT02622256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL122457-02|Twitter and CV Health|Twitter & Cardiovascular Health||University of Pennsylvania|No|Not yet recruiting|September 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|8||Anticipated|600|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02622256||7538|
NCT02622503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML30146|A Study on Rheumatoid Arthritis Patients Treated With Rituximab|Retrospective Data Collection on Rheumatoid Arthritis (RA) Patients Treated With Rituximab in Finland.||Hoffmann-La Roche||Completed|April 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|81|||Both|N/A|N/A|No|Non-Probability Sample|Rheumatoid arthritis (RA) patients treated with rituximab in Finland.|December 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622503||7519|
NCT02623712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000001|Lung Nodule Surveillance Trial|The Lung Nodule Surveillance Trial: A Pragmatic Trial of More Versus Less Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules|LNST|Kaiser Permanente|Yes|Not yet recruiting|June 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|39981|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623712||7426|
NCT02624882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPPS|Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children|Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children|TAPPS|Centre Hospitalier Intercommunal Creteil|No|Recruiting|November 2015|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|N/A|18 Years|No|||December 2015|December 4, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02624882||7336|
NCT02614443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAITDAS|Effectiveness and Acceptability of Internet-delivered Treatment for Depression, Anxiety and Stress|Effectiveness and Acceptability of Internet-delivered Treatment for Depression, Anxiety and Stress in University Students: Protocol for an Open Feasibility Trial|EAITDAS|Silver Cloud Health|Yes|Recruiting|October 2015|March 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614443||8138|
NCT02611336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUM|Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy|Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly|SUM|University of Roma La Sapienza||Not yet recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||November 2015|November 18, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611336||8377|
NCT02611349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-118-A-303|Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis|(V01-118A-03) A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis||Sadick Research Group|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611349||8376|
NCT02622113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-13|Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Active, not recruiting|December 2014|||April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||December 2015|December 8, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622113||7549|
NCT02616757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000049774|Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing|Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing||The Hospital for Sick Children|No|Not yet recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|2 Years|21 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616757||7960|
NCT02616770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMi-01-1-01|Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.|Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study to Evaluate the Safety and Tolerability of S-1226 Administered by Nebulization in Normal Health Volunteers||SolAeroMed Inc.|Yes|Completed|March 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|6||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616770||7959|
NCT02616783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-1826|Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years|A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years||Gilead Sciences|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|60 Years|N/A|No|||February 2016|February 9, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616783||7958|
NCT02572258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1410|Supplementary Food on Prevention of Moderate Malnutrition in Children|The Effect of Supplementary Food Cookies on Prevention of Moderate Malnutrition in Preschool Children in Rural Mexico||PepsiCo Global R&D||Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|1048|||Both|2 Years|5 Years|No|||October 2015|October 7, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02572258||11376|
NCT02572271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150106CKH/bss|Mastopexy With Autologous Augmentation in Women After Massive Weight Loss - A Clinical, Randomized Study|Mastopexy With Autologous Augmentation in Women After Massive Weight Loss - A Clinical, Randomized Study||Odense University Hospital|Yes|Recruiting|September 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Female|N/A|N/A|No|||October 2015|October 7, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02572271||11375|
NCT02616081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82971|Patient Reported Outcomes for Bladder Management Strategies in Spinal Cord Injury|Patient Reported Outcomes for Bladder Management Strategies in Spinal Cord Injury|NBRG-PCORI|University of Utah|No|Recruiting|January 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|900|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with neurogenic bladder with urinary issues and currently being managed by one/        any of various bladder management treatments (clean intermittent catheterization,        indwelling catheter or bladder surgery).|February 2016|February 19, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02616081||8012|
NCT02616094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1501015225|Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse|Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse||Yale University|No|Recruiting|November 2015|December 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|210|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02616094||8011|
NCT02623738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01171503|A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-|A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-||Santen Pharmaceutical Co., Ltd.|No|Recruiting|November 2015|||December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|304|||Both|20 Years|N/A|No|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623738||7424|
NCT02623751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2375-001|Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer|Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer||Kyowa Hakko Kirin Company, Limited|Yes|Recruiting|November 2015|February 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|74 Years|No|||February 2016|February 28, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02623751||7423|
NCT02622880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGENAT|Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients|Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Oropharyngeal and Maxillofacial Cancer Patients Eligible Surgery||Instituto de Investigación Hospital Universitario La Paz|Yes|Completed|February 2013|June 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02622880||7490|
NCT02569749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHS2|Sleep Apnea Screening|Sleep Apnea-Hypopnea Syndrome Screening||Arrhythmia Network Technology S.L.|Yes|Terminated|June 2015|||March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|15|||Both|18 Years|N/A|No|Probability Sample|Patients to be included in the registry:          -  200 patients with pacemaker indication in whom a pacemaker with sleep apnea             monitoring system has been implanted.          -  100 patients with pacemaker indication in whom a pacemaker with no sleep apnea             monitoring system has been implanted.          -  100 patients with ICD or CRDT therapy indication.          -  100 patients with heart failure and preserved LVEF (40-50%).          -  100 patients with heart failure and reduced LVEF (<40%).|November 2015|November 2, 2015|October 6, 2015||No|Administrative reasons|No||https://clinicaltrials.gov/show/NCT02569749|1 Month|11569|
NCT02612688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4UH3AG049619-02|Pragmatic Trial of Video Education in Nursing Homes|PROVEN: Pragmatic Trial of Video Education in Nursing Homes|PROVEN|Brown University|Yes|Not yet recruiting|January 2016|August 2019|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|97213|||Both|65 Years|N/A|No|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612688||8273|
NCT02612922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM08-3003|Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza||Romark Laboratories L.C.|No|Recruiting|December 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|12 Years|65 Years|No|||January 2016|January 26, 2016|November 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612922||8255|
NCT02613221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panitumumab-1501|A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer|A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS Wild-type Metastatic Colorectal Cancer Refractory to Standard Chemotherapy|APOLLON|Takeda|No|Recruiting|November 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|20 Years|75 Years|No|||December 2015|December 7, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613221||8232|
NCT02611986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannesGUE|Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study)|Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study): A Prospective, Randomized Trial|EMMA|Johannes Gutenberg University Mainz|No|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02611986||8327|
NCT02619474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01896|The Effect of Whiteboards on Patient Satisfaction|The Effect of Whiteboards on Patient Satisfaction: A Prospective Controlled Study in BC's Children's Hospital||University of British Columbia|No|Recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|N/A|N/A|No|||November 2015|November 30, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02619474||7752|
NCT02627417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140925|Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia|Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia|DAPS-ITP|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|May 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||October 2015|December 8, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02627417||7141|
NCT02621021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160027|A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab|A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab||National Institutes of Health Clinical Center (CC)||Recruiting|November 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||November 2015|February 20, 2016|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621021||7633|
NCT02625740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tor Vergata University|Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial|Use of Local Ultrasound to Enhance Local Paclitaxel Delivery Effect After Femoro-popliteal Percutaneous Transluminal Angioplasty in Patients With Critical Limb Ischemia: the PACUS Trial|PACUS|University of Rome Tor Vergata|No|Completed|November 2013|November 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02625740||7270|
NCT02613000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSOFA Study|Intestinal-Specific Organ Function Assessment (iSOFA Study)|Prospective, Multicenter Cohort Study on Prognostic Value of Gastrointestinal Symptoms and Intestinal-specific Biomarkers in Prediction of Outcome of Intensive Care Patients|iSOFA|University of Tartu|Yes|Recruiting|April 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|In patients included in Part B, approx. 7 ml of arterial or venous blood will be drawn each      morning during the study period. Standard EDTA containing vacutainers are used for blood      sampling and placed into ice until centrifugation. Blood will be centrifuged at 4 degrees by      study nurse or central laboratory of the study site, after which plasma will be separated      and stored at -80 degrees in eppendorf vials containing 1 ml of plasma, marked and labelled      with study code numbers.      10 ml of urine will be sampled each morning Timing of admission day sample at time of plasma      sampling (6 AM) from the collection bag and stored at -80 degrees. 2 eppendorf test-tubes      containing 1 ml are used for urine sampling.      Samples for citrulline measurements will be shipped to University of East Anglia, Norwich,      United Kingdom and other samples to Maastricht University Medical Center, Netherland, for      biochemical analyses to be performed.|Both|18 Years|N/A|No|Non-Probability Sample|All consecutive adult critically ill patients (25 to 50 patients for each study site, 500        patients in total) in need for intensive care admission during maximum 6 weeks of study        period.|November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02613000||8249|
NCT02613013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015019|Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure|Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure With Multi-mechanism Based on UBM: A Randomized Controlled Trial||Sun Yat-sen University|Yes|Recruiting|October 2015|April 2022|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|75 Years|No|||November 2015|November 24, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02613013||8248|
NCT02612051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200262|First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients|A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis||GlaxoSmithKline|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612051||8322|
NCT02612064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205072|The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Not yet recruiting|November 2015|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02612064||8321|
NCT02617199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE-08|Epidural Anesthesia in Acute Pancreatitis|Epidural Anesthesia as an Alternative for Management in Acute Pancreatitis, a Randomised Clinical Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|November 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617199||7926|
NCT02618772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-08-053|Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department|Atomized Intranasal Midazolam for Anxiolysis and Facilitation of Laceration Repair in the Pediatric Emergency Department: A Randomized Controlled Trial||McGill University Health Center|Yes|Completed|January 2010|November 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 28, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618772||7806|
NCT02619019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM112015|Effect of Spinal Dexamethasone During Transuretheral Prostatectomy|Intrathecal Dexamethasone in Patients Undergoing Transuretheral Prostatectomy.||Assiut University|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Male|50 Years|75 Years|No|||March 2016|March 2, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02619019||7787|
NCT02624440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSG#01/12|Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma|A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma|SUTRICA|Aalborg Universitetshospital|Yes|Recruiting|January 2013|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02624440||7370|
NCT02573116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/44|Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea|Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea|EndothSAS|Hopital Foch|No|Recruiting|December 2013|||January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|30 Years|70 Years|No|||October 2015|October 8, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02573116||11310|
NCT02563262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-122|Human Neutral Body Posture in Weightlessness||HYDRONAUT|University Hospital, Caen|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02563262||12067|
NCT02617498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hepatic transection|Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection|Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection of Living Donor.|LDLT|Mansoura University|Yes|Completed|April 2013|November 2015|Actual|April 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|10 Years|50 Years|No|||March 2016|March 21, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02617498||7903|
NCT02601846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geneva 15-010|Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study|Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study|RELAX-PE|University Hospital, Geneva|No|Not yet recruiting|November 2015|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|18 Years|N/A|No|Probability Sample|All consecutive patients admitted to the emergency department with suspected PE defined as        acute onset of new or worsening shortness of breath or chest pain without any other        obvious etiology in whom PE has been considered ruled out by negative D-dimers using an        age-adjusted cut-off will be screened for inclusion. Those with non-high probability and        negative D-dimers (PE excluded by the non-invasive strategy using "new" D-dimer cut-offs)        will be included and followed-up for 3 months. The aim of including both patients above        and under 50 years of age is to be able to compare the difference in thromboembolic event        rates between patients with a D-dimer level between 500 µg/L and their age-ajusted cut-off        and those with a D-dimer < 500 µg/L.|November 2015|November 23, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02601846||9102|
NCT02609009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3928|Back Pain and Spinal Manipulation in Adolescent Scoliosis|Back Pain Management With Spinal Manipulation Therapy Compared to Usual Medical Care in Adolescent Idiopathic Scoliosis Patients: A Pilot Study||St. Justine's Hospital|No|Recruiting|September 2014|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|17 Years|No|||November 2015|November 18, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609009||8555|
NCT02607748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39453|18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques|18F-fluoride (18F-NaF) Positron Emission Tomography (PET) for Identification of Ruptured and High-Risk Coronary Atherosclerotic Plaques||Cedars-Sinai Medical Center|No|Recruiting|November 2015|||October 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02607748||8652|
NCT02607761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCEUP/RH1|Fertility Awareness in University Students|Fertility Awareness in University Students|FAST|Universidade do Porto|No|Recruiting|October 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|300|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02607761||8651|
NCT02607813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLXH254X2101|Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations|A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations||Novartis|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|81|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607813||8647|
NCT02610322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2013.121|Whole Soy Replacement Diet on Metabolic Features|A Randomized Controlled Trial of Whole Soy Diet in Place of Red/Processed Meat and High Fat Dairy Products on Metabolic Features in Postmenopausal Women||Chinese University of Hong Kong|Yes|Not yet recruiting|June 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|208|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02610322||8454|
NCT02609919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dotarem Study|Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age|Assessment of Immediate Adverse Reactions in Children Under 2 Years of Age Following Administration of Gadoteric Acid (Gd-DOTA or Dotarem) (IRB # 26250)||St. Louis University|Yes|Recruiting|January 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|2 Years|No|Non-Probability Sample|Children under 2 years of age requiring MRI with Contrast|March 2016|March 9, 2016|November 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02609919||8485|
NCT02609061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014T|Platelet Rich Fibrin+1% Alendronate in Treatment of Mandibular Degree II Furcation Defects|Platelet Rich Fibrin Combined With 1% Alendronate Gel in Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore||Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02609061||8551|
NCT02607878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|432/14|Automated Pupillometry for Coma Prognostication After Cardiac Arrest|Automated Pupillometry for Coma Prognostication After Cardiac Arrest||Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients with coma after cardiac arrest (CA)|November 2015|November 16, 2015|November 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02607878||8642|
NCT02607891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEP1447 Blinded Phase|A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy|A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy||GW Research Ltd|No|Not yet recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|16 Years|55 Years|No|||November 2015|November 16, 2015|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02607891||8641|
NCT02567461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS DSI001|Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel|Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study|EDOX-APT|University of Florida|Yes|Recruiting|March 2016|December 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02567461||11745|
NCT02613715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VINOFLAVO_01|Bioavailability of Blackberry Juice Anthocyanins|Influence of Ethanol in the Bioavailability of Blackberry Juice Anthocyanins in Normal Weight and Overweight/Obese Adults||Universidade do Porto|No|Completed|March 2015|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|November 20, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02613715||8194|
NCT02613728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0583|Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)|Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)||M.D. Anderson Cancer Center|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613728||8193|
NCT02624635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1174-3946|Hip Strengthening and Manual Therapy for Heel Pain Patients|Effects of Adding Hip Strengthening to Manual Therapy for Heel Pain Patients||Centro Universitário Augusto Motta|No|Not yet recruiting|January 2016|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02624635||7355|
NCT02622464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction|Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction||Assistance Publique Hopitaux De Marseille|No|Not yet recruiting|December 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02622464||7522|
NCT02620111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44853|Protein Balance in Protein Supplemented Elderly Patients: Acute Study With Protein-tracer-techniques|Effect of Protein High in Leucine on Muscle Protein Balance in Elderly Patients: Acute Study With Protein-tracer-techniques||University of Aarhus|No|Recruiting|June 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2015|March 1, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02620111||7703|
NCT02611505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108098|A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine||Janssen Research & Development, LLC|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02611505||8364|
NCT02570919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSINT-IGRT A(1)|Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer|Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer|PROSINT|Fundacao Champalimaud|No|Recruiting|September 2015|September 2021|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|50 Years|N/A|No|||October 2015|October 6, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02570919||11479|
NCT02571023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skull Base Trauma 2016|Multicenter Clinical Study on Diagnosis and Treatment of Skull Base Trauma|Multicenter Clinical Study on Diagnosis and Treatment of Skull Base Trauma||Shanghai Changzheng Hospital|No|Not yet recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|All the patients with skull base trauma in inpatient ward.|October 2015|October 7, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02571023||11471|
NCT02618226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00092614|Optic Nerve Ultrasound in Severe Traumatic Injury|Diagnostic Accuracy of Optic Nerve Ultrasound for the Detection of Intracranial Hypertension and Prediction of Therapeutic Intensity Level and Mortality Following Severe Traumatic Brain Injury (ONUS-TBI): a Prospective Blinded Study|ONUS-TBI|University of Michigan|Yes|Not yet recruiting|January 2016|||November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618226||7848|
NCT02618044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAROB/97|Laparoscopic Roux-en-Y Gastric Bypass and Gastro-esophageal Reflux|Long Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Gastro-esophageal Reflux: Clinical Impact of Weakly Acidic Reflux||University of Turin, Italy|No|Completed|May 2006|July 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|86|||Both|18 Years|60 Years|No|Probability Sample|Consecutive morbidly obese patients selected for LRYGB|December 2015|December 2, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02618044||7862|
NCT02624531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-070|Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005)|Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer|SYSUGO-005|Sun Yat-sen University|No|Recruiting|November 2015|November 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|40 Years|No|||December 2015|December 4, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02624531||7363|
NCT02620982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G140216|ARIES for Vasculogenic Erectile Dysfunction|Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Vasculogenic Erectile Dysfunction|AriesIDE#1|Dornier MedTech Systems|Yes|Recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Male|21 Years|75 Years|No|||January 2016|January 24, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02620982||7636|
NCT02627495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Predicting Pain Response to Transcranial Direct Current Stimulation for Phantom Limb Pain in Limb Amputees|Predicting Pain Response to Transcranial Direct Current Stimulation for Phantom Limb Pain in Limb Amputees||Spaulding Rehabilitation Hospital|No|Not yet recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02627495||7135|
NCT02617420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0211|Monitoring Adherence Using Mobile Technology|Monitoring Adherence Using Mobile Technology||University of Colorado, Denver|No|Not yet recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|6 Years|17 Years|No|Non-Probability Sample|Study subjects would be drawn from the list of high risk asthma patients and by pre-clinic        chart review done by study investigator.|December 2015|December 9, 2015|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02617420||7909|
NCT02625948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D141100000114002|Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign||TRAIGE|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|September 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|79 Years|No|||December 2015|December 8, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625948||7254|
NCT02622789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRREC-104-081|Efficacy and Influence of Pilates Based Physical Therapy Exercises for Low Back Pain|Efficacy and Influence of Pilates Based Physical Therapy Exercises on Spinal Radiographic Kinematics and Functional Status in Patients With Low Back Pain||China Medical University Hospital|Yes|Recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|It is anticipated that 100 patients with clinical signs and symptoms of low back pain        (LBP) for at least 3 months will be recruited. 25 age-matched healthy control will also be        recruited for the study.|December 2015|December 2, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02622789||7497|
NCT02618317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPaulo CLOCK|Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis|Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis|CLOCK|University of Sao Paulo|Yes|Recruiting|July 2013|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|75|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02618317||7841|
NCT02618369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000040583|MR-Guided High Intensity Focused Ultrasound for Pain Management Of Osteoid Osteoma & Benign Bone Tumors in Children and Adults|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Pain Management of Osteoid Osteoma and Benign Bone Tumors in Children and Young Adults||The Hospital for Sick Children|Yes|Recruiting|April 2014|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|40 Years|No|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618369||7837|
NCT02621359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quadruple therapy|A Two Week Nitazoxanidebased Quadruple Regimen|A Two Week Nitazoxanidebased Quadruple Regimen for Helicobacter Pylori Therapy After Failure of Standard Triple Therapy: A Single Center Experience||Tanta University|Yes|Recruiting|January 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 9, 2016|November 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621359||7607|
NCT02619825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-03|Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)|Non-Invasive Evaluation of Myocardial Stiffness by Elastography Pediatric Cardiology Under||French Cardiology Society|No|Not yet recruiting|November 2015|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|120|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619825||7725|
NCT02624219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0064|H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults|A Phase I Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting||July 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|275|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||October 2015|March 10, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624219||7387|
NCT02614950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 022|Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection|Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection||South East Asia Research Collaboration with Hawaii|Yes|Recruiting|February 2016|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|50 Years|No|||March 2016|March 6, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614950||8099|
NCT02614963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G13|Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome|Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study||Shandong University|Yes|Not yet recruiting|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614963||8098|
NCT02614508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00071983|Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Emory University|Yes|Recruiting|January 2016|January 2023|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614508||8133|
NCT02617277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6015C00002|Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours|A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours||AstraZeneca|Yes|Recruiting|December 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|130 Years|No|||March 2016|March 15, 2016|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617277||7920|
NCT02617290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141103|Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting|Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study|ALPHEUS|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|December 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1900|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02617290||7919|
NCT02619071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeGAL-IPC-2014-012|ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia|ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia- CeGAL-IPC 2014-012|CeGAL|Institut Paoli-Calmettes|No|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|87|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619071||7783|
NCT02626598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2202|A Study Evaluating Blended Belotero for the Treatment of Etched-in Fine Facial Lines|A Study Evaluating Blended Belotero for the Treatment of Etched-in Fine Facial Lines||Skin Care and Laser Physicians of Beverly Hills|No|Enrolling by invitation|December 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|25 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a single-center observational study of adult females and males ages 25 to 75 years        who are scheduled to have treatment with Belotero blended with lidocaine with epinephrine,        as is common in clinical practice for etched-in fine lines of the cutaneous lip, and/or        radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area.        After reviewing the risks and benefits of the procedure, the patient will sign a clinical        consent form prior to treatment. If the patient is amenable to participate in the study        and agrees to have pre and post treatment photographs and evaluations completed, they will        proceed to sign the research consent form and will be enrolled into the study.|December 2015|December 7, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02626598|26 Weeks|7204|
NCT02626234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280A2105|A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors||Novartis|No|Not yet recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626234||7232|
NCT02611401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Turin|Efficacy of MBI for Depressive Symptoms in Patients With MS|The Efficacy of a Mindfulness Based Intervention for Depressive Symptoms in Patients With Multiple Sclerosis and Their Caregivers. A Randomized Controlled Clinical Trial.||University of Turin, Italy|No|Recruiting|May 2014|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02611401||8372|
NCT02617537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16419|To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea|A Multinational, Double-blind, Randomized, Placebo-controlled, Parallel-group Clinical Study to Investigate the Efficacy and Safety of the Oral Hormonal Contraceptive BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) Over 16 Weeks for the Treatment of Women With Dysmenorrhea||Bayer|No|Withdrawn|January 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617537||7900|
NCT02624791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15920|Evaluating and Improving Functional Driving Vision of Patients With Astigmatism|Evaluating and Improving Functional Driving Vision of Patients With Astigmatism||University of Virginia|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2015|December 30, 2013||No||No||https://clinicaltrials.gov/show/NCT02624791||7343|
NCT02618382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX15BN048|A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population|||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Recruiting|November 2015|January 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|No|||November 2015|November 25, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618382||7836|
NCT02618395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-HBA-PK001|Bioavailability Study of SPARCHBA in Healthy Adult Volunteers|||Sun Pharma Advanced Research Company Limited|No|Active, not recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618395||7835|
NCT02615301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252.07|Dietary Intake of Salmon and Bone Health|Intake of Dietary Vitamin D and K From Tailor-made Atlantic Salmon and Bone Health - A Randomized Intervention Study||National Institute of Nutrition and Seafood Research, Norway|Yes|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|122|||Female|50 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02615301||8072|
NCT02611674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999AS003|Methodology Study of Novel Outcome Measures to Assess Progression of ALS|Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis||Biogen|No|Recruiting|January 2016|September 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|80 Years|No|Probability Sample|Participants suffering from ALS are recruited by participating physicians in a standard        clinical practice setting.|February 2016|March 18, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02611674||8351|
NCT02611687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-06/BF2.649|Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period|Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period||Bioprojet|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|18 Years|No|||March 2016|March 15, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02611687||8350|
NCT02615171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL122302-01A1|RELAX: A Mobile Application Suite Targeting Obesity and Stress|RELAX: A Mobile Application Suite Targeting Obesity and Stress||University of Massachusetts, Worcester|Yes|Not yet recruiting|November 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615171||8082|
NCT02615184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_205|A Phase 2, Double Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Participants|A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 1 to 11 Years With EE||Takeda|No|Suspended|November 2015|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Both|1 Year|11 Years|No|||March 2016|March 10, 2016|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615184||8081|
NCT02618629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-215-03|Mass Balance and Metabolism Study of 14C-Z-215|A Phase I Mass Balance and Metabolism Study of 14C-Z-215 in Healthy Male Volunteers||Zeria Pharmaceutical|No|Not yet recruiting|January 2016|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618629||7817|
NCT02618642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jz.i/t|The Use of i/t Curve in Assessment of Phototherapy Effects|The Use of i/t Curve in Assessment of Effects of Biceps Brachi Phototherapy With PILER Light||University of Rzeszow|No|Not yet recruiting|February 2016|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|50|||Both|21 Years|23 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618642||7816|
NCT02620540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0191 - Part 2|Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Known Devices|Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Already Known Devices Like the Broselow Tape (BT)||University Children's Hospital, Zurich|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|16 Years|Accepts Healthy Volunteers|Probability Sample|Pediatric patients planned for elecitve surgery in general anaesthesia|November 2015|November 30, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02620540||7670|
NCT02625532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER-LUT-2015-02|Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)|Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles: A Randomized Comparative Single Center Trial. LUTEAL Trial|LUTEAL|Instituto Bernabeu|Yes|Recruiting|December 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 13, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02625532||7286|
NCT02622659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012Pro170EKZY|The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)|The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)||Guangzhou Yipinhong Pharmaceutical CO.,LTD|Yes|Recruiting|March 2012|December 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|468|||Both|1 Year|12 Years|No|||November 2015|February 14, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622659||7507|
NCT02562261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24958/19-12-13|Platelet REactivity in Sepsis Syndrome (PRESS)|Platelet Reactivity During Different Stages of Sepsis|PRESS|University Hospital of Patras|Yes|Recruiting|January 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Within 0-8 hours of presentation in emergency department patients will be assessed and        assigned upon their health status in four distinct groups of uncomplicated        infection/bacteraemia , sepsis, severe sepsis/septic shock as this is defined by        International Sepsis Definitions Conference. Thirty five healthy volunteers will serve as        a control group.|September 2015|September 26, 2015|September 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02562261||12144|
NCT02620306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FMS-CT-303|A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan|||Boryung Pharmaceutical Co., Ltd||Recruiting|November 2015|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|468|||Both|19 Years|70 Years|No|||January 2016|January 18, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02620306||7688|
NCT02624063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT|Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)|Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT)||Federal University of São Paulo|No|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|394|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02624063||7399|
NCT02615392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Park Prescription Trial|Park Prescription Trial|Park Prescription Trial||National University, Singapore|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02615392||8065|
NCT02625272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALS-CME 201512|A Randomized Controlled Trial of a Novel HALS Technique Versus Laparoscopic Technique for Right Hemicolectomy|A Randomized Controlled Trial of a Novel HALS Technique Versus Laparoscopic Technique for Complete Mesocolic Excision and no Touch Isolation in Right Hemicolectomy||West China Hospital|Yes|Recruiting|June 2015|April 2020|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625272||7306|
NCT02572531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-483|Effect of Probiotics on Pain and Oral Wound Healing After Third Molar Surgery|Effect of Probiotic Supplements on Pain and Oral Wound Healing After Third Molar Surgery|PROVIS|University of Copenhagen|No|Not yet recruiting|November 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02572531||11355|
NCT02623231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600-15|The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|Cipralex&GBM|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|November 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623231||7463|
NCT02623244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104120-F|The Association Between Ovarian Endometrioma and Lower Urinary Tract Symptoms|||Far Eastern Memorial Hospital|Yes|Recruiting|November 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with ovarian endometrioma|December 2015|December 4, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623244||7462|
NCT02618746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SYN_10_1438|Home Rehabilitation Via Telemonitoring in Patients With COPD|Home Rehabilitation Via Telemonitoring of Vital Signs to Prevent Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|TELECARE|Thorax Research Foundation|No|Active, not recruiting|December 2013|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|150|||Both|40 Years|75 Years|No|||March 2016|March 21, 2016|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02618746||7808|
NCT02615938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chILD-EU HCQ|Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)|Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)|chILD-EU_HCQ|Ludwig-Maximilians - University of Munich|Yes|Recruiting|April 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|N/A|18 Years|No|||November 2015|November 29, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02615938||8023|
NCT02615951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461|Characterization of Breg Cells|Characterization of B Regulatory (Breg) Cells in Healthy Subjects and in Rheumatoid Arthritis (RA)|Breg|University Hospital, Montpellier|No|Recruiting|October 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02615951||8022|
NCT02611830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN0002SC-3027|Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy||Takeda|Yes|Recruiting|January 2016|February 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611830||8339|
NCT02623387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHG15|Ultrasound Guided Versus Standard Paravertebral Blockade in Breast Surgery|A Prospective Randomized Controlled Trial of Ultrasound Guided Versus Standard Paravertebral Blockade in Breast Surgery||University College Hospital Galway|No|Recruiting|June 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02623387||7451|
NCT02623400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S58326|The Effect of Perinatal Stress on the Development of Preterm Infants|The Effect of Perinatal Stress on the Development of Preterm Infants|RESILIENCE|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|January 2016|September 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|saliva samples of both parents and the child, blood sample of mother and child, cord blood      sample,|Both|N/A|34 Weeks|No|Non-Probability Sample|The investigators will approach parents of preterm infants born before 34 weeks        gestational age and/or with a birth weight lower than 1500g.        Ideally, pregnant women admitted to the maternal intensive care (MIC) for preterm labor        will be informed about the study together with their partner, and asked for consent. But        in a number of preterm infants prenatal inclusion will not be possible (e.g. birth in        another hospital, preterm premature rupture of the membranes,…) . Parents of infants in        this subgroup, who are admitted to the Neonatal Intensive Care Unit (NICU) at the        University Hospitals Leuven, will be informed and asked for consent within 3 days after        birth.|November 2015|December 7, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02623400||7450|
NCT02614859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-079|Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients|Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)|BIMET-1|Fox Chase Cancer Center|Yes|Recruiting|December 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||December 2015|December 9, 2015|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614859||8106|
NCT02617628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC14-1409-21688|Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone|Improving Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (Vivitrol) Before vs. After Reentry|OAPXRNTX|University of Pennsylvania|Yes|Active, not recruiting|September 2015|September 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02617628||7893|
NCT02616835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L14082014 SoM PAPsych|Investigating the Physiology of Targeted Theta-burst Neuromodulation|Investigating the Physiology of Targeted Theta-burst Neuromodulation||Institute of Mental Health Nottingham||Completed|August 2014|June 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02616835||7954|
NCT02616848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-000135-17|Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers|||Istituti Ospitalieri di Cremona|No|Recruiting|November 2015|||November 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02616848||7953|
NCT02616861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-1973-102|Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers|A 2-stage Phase 1 Study of Safety, Tolerability, PK, and PD of IW-1973 Tablet in Healthy Volunteers in an Open-label, Single-dose Stage, and a Randomized, Double Blind, Placebo-controlled, Multiple-ascending-dose Stage||Ironwood Pharmaceuticals, Inc.|No|Recruiting|November 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 18, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02616861||7952|
NCT02621125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fertilix|Fertilix Supplements and Assisted Reproductive Technology|||University Reproductive Associates|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Male|20 Years|55 Years|No|||December 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621125||7625|
NCT02625545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0001|Study of Median Lobe Prostatic UroLift Procedure|Study of Median Lobe Prostatic UroLift Procedure|MedLift|NeoTract, Inc.|No|Recruiting|February 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|50 Years|N/A|No|||February 2016|February 18, 2016|December 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02625545||7285|
NCT02625558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-7130|Riociguat for Sarcoidosis Associated Pulmonary Hypertension|A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension|RioSAPH|University of Cincinnati|Yes|Recruiting|April 2015|October 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02625558||7284|
NCT02625402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001794|Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis|Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis||Massachusetts General Hospital|No|Enrolling by invitation|December 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|75|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625402||7296|
NCT02563509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013ZX10001004|Reconstitution of HIV-specific Immunity Against HIV|Reconstitution of HIV-specific Immunity Against HIV||Guangzhou 8th People's Hospital|No|Recruiting|January 2013|December 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|60 Years|No|||September 2015|September 28, 2015|September 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02563509||12048|
NCT02621138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283-15|The Influence of Muscle Contraction on the Cardiac Autonomic System|The Influence of Muscle Contraction on the Cardiac Autonomic System at Rest and Activity||Alyn Pediatric & Adolecent Rehabilitation Center||Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|32|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|children with cerebral palsy|November 2015|December 2, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02621138||7624|
NCT02621151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S15-00220|Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder|A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder||New York University School of Medicine|Yes|Not yet recruiting|March 2016|May 2024|Anticipated|May 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621151||7623|
NCT02604862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB ONE|Imaging FIB ONE in the Human Lung Using Endomicroscopy|Exploratory Clinical Study to Image the Intrapulmonary Microdosing of FIBroproliferation ONE (FIB ONE) Using Endomicroscopy|FIB ONE|University of Edinburgh|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|16 Years|N/A|No|||November 2015|November 11, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02604862||8872|
NCT02599051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 9034|Transobturator Verus Single Incision Slings|Transobturator Versus Single Incision Slings: 1 Year Results of a Randomized Control Trial||Cleveland Clinic Florida|Yes|Completed|November 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02599051||9317|
NCT02599064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1501|Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD|A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration||RXi Pharmaceuticals, Corp.|Yes|Recruiting|November 2015|September 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|50 Years|N/A|No|||November 2015|November 4, 2015|November 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02599064||9316|
NCT02597010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic NO3- in HTN|A 2 Week, Crossover Trial of Dietary Nitrate in HTN|Dietary Nitrate for Resistant Hypertension: A Randomized, Placebo-controlled, Crossover Trial||Royal College of Surgeons, Ireland|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|85 Years|No|||August 2015|November 3, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02597010||9474|
NCT02597023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0402|The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults|The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults||University of Colorado, Boulder|Yes|Recruiting|September 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|October 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02597023||9473|
NCT02610894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0340-P6H|An mHealth Self-Management Program to Decrease Postoperative Symptom Distress|A mHealth Self-Management Program to Decrease Postoperative Symptom Distress in Orthopaedic Patients||University of Kentucky|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02610894||8410|
NCT02610907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP265_01|A Pilot Evaluation of Adhesives and How They Are Impacted by Out-put|||Coloplast A/S|No|Completed|November 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02610907||8409|
NCT02598986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUT.OO.19|Effect of Macronutrient Supplementation on Glycemic Index of Pita Bread|Glycemic Index of Bread: Fiber or Minerals? This is the Question.||American University of Beirut Medical Center|No|Completed|June 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598986||9322|
NCT02598999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-009-CL-038|First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients|Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male Volunteers and Cystic Fibrosis Patients||Alaxia SAS|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02598999||9321|
NCT02599311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUPH|the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery|The Clinical Efficacy of Pelvic Organ Prolapse Surgery||Peking University People's Hospital|Yes|Recruiting|August 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1000|||Female|30 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|November 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599311||9297|
NCT02599324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1128-CA|A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors|A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors||Pharmacyclics||Recruiting|November 2015|June 2019|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|261|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02599324||9296|
NCT02599337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150230|Bioequivalence Study of Sorafenib Tablet and Nexavar|Randomized, Open-label, 3-way Reference Replicated Crossover Bioequivalence Study of Sorafenib 200 mg Tablet and Nexavar (Reference) Following a 200 mg Dose in Healthy Subjects Under Fasting Conditions||Yabao Pharmaceutical Group|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|November 4, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02599337||9295|
NCT02597322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110209|Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)|An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)|AXIPAN|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2012|December 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02597322||9450|
NCT02570776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-13-01|UBT as a Diagnostic Tool for HP Prevalance|Prevalence of Helicobacter Pylori Infection in Dyspeptic Adults and Validation of C14 Urea Breath Test (UBT) as a Diagnostic Tool for Helicobacter Pylori Infection in Pakistani Population||National Institute of Liver & GI Diseases, Pakistan|No|Recruiting|December 2013|February 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients getting routine upper GI Endoscopy are enrolled and as per routine histopathology        samples are taken to assess Helicobacter pylori. This assessment will be done by two        independent histopathologists & later the results will be compared with C14 UBT taking        histopathology as gold standard.|October 2015|October 5, 2015|May 7, 2014||No||No||https://clinicaltrials.gov/show/NCT02570776||11490|
NCT02621411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH2015-100|Observational Study of Preoperative Screen for Substance Abuse|Preoperative Screen for Substance Abuse in Trauma Patients Undergoing Emergency Operation: a Prospective Observational Study||West China Hospital|Yes|Recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|16 Years|60 Years|No|Probability Sample|The trauma patients undergoing emergency operation|December 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621411||7603|
NCT02621424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1889-P|Repetitive Transcranial Magnetic Stimulation for Dementia|Repetitive Transcranial Magnetic Stimulation for Dementia|rTMS for demen|VA Office of Research and Development|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|55 Years|99 Years|No|||December 2015|December 4, 2015|November 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621424||7602|
NCT02615366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150264-01H|Tranexamic Acid for Bleeding in Breast Surgery|Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial|TABBS|Ottawa Hospital Research Institute|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02615366||8067|
NCT02615379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPF-515|Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Instrumented Fusion|A Prospective, Randomized, Parallel Pilot Study of Transdermal, Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Instrumented Fusion||Ogenix Corporation|Yes|Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2015|November 24, 2015|November 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02615379||8066|
NCT02625571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002942|Tx for Child Sexual Behavior Problems|Development and Pilot Testing of a Treatment for Children With Sexual Behavior Problems||Milton S. Hershey Medical Center|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|5 Years|12 Years|No|||December 2015|December 7, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02625571||7283|
NCT02625636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU14518|A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients|A Randomized, Double-blind, Glucagon and Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of SAR438544 Administered by Subcutaneous Route in Healthy Subjects and Patients With Type 1diabetes Mellitus||Sanofi|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02625636||7278|
NCT02613078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDG 082015|Hypnotherapy vs. Probiotics in Children With IBS and Functional Abdominal Pain|Gut-Directed Hypnotherapy vs. Probiotics in Children and Adolescents With Irritable Bowel Syndrome and Functional Abdominal Pain - A Pilot Study||University Hospital Tuebingen|No|Recruiting|March 2016|October 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|6 Years|17 Years|No|||February 2016|March 2, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613078||8243|
NCT02613091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clemastine Color Vision|Effect of Clemastine Fumarate on Color Vision in Healthy Controls|||University of California, San Francisco|No|Not yet recruiting|November 2015|||March 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613091||8242|
NCT02617966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160024|Rod and Cone Mediated Function in Retinal Disease|Rod and Cone Mediated Function in Retinal Disease||National Institutes of Health Clinical Center (CC)||Not yet recruiting|November 2015|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|330|||Both|5 Years|N/A|No|||November 2015|December 1, 2015|November 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02617966||7868|
NCT02618213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150007|Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis.|Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis.||Hospital of South West Denmark|No|Recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|N/A|24 Months|No|||December 2015|December 2, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618213||7849|
NCT02625870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HROMEE2015|Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides|A 12-Week, Randomized, Double-Blind, Corn Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of Omega-3-Acid Ethyl Esters 90 Soft Capsules in Subjects With Severe Hypertriglyceridemia|OMEELVHT|Jiangsu HengRui Medicine Co., Ltd.|No|Not yet recruiting|December 2015|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625870||7260|
NCT02625883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resuscitation in Winterthur|Out-of-Hospital Resuscitation in Winterthur - an Outcome Study|Out-of-Hospital Resuscitation in an Urban Setting in Switzerland - an Outcome Study and Cost Effectiveness Analysis||Kantonsspital Winterthur KSW|No|Enrolling by invitation|December 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|151|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients that were resuscitated out-of-hospital in the year 2013 by the emergency medical        team from the Kantonsspital Winterthur.|December 2015|December 15, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625883||7259|
NCT02615730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0204|Phase 1,2a PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma|A Phase Ib/IIa, Open-Label, Dose Finding Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3Kβ Selective Inhibitor (GSK2636771) Administered in Combination With Paclitaxel in Advanced Gastric Adenocarcinoma Having Alterations in PI3K Pathway Genes||Yonsei University|Yes|Not yet recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|19 Years|N/A|No|||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615730||8039|
NCT02573454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-03018|Prosocial Exercise: Does Exercising for Charity Result in Greater Well-Being and Physical Activity?|Prosocial Exercise: Does Exercising for Charity Result in Greater Well-Being and Physical Activity?||University of British Columbia|No|Recruiting|February 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02573454||11284|
NCT02573558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1510/318-104|Intraoperative Sedation and Postoperative Delirium|Prevalence of Postoperative Delirium According to the Use of Dexmedetomidine or Propofol in Elderly Patients Undergoing Orthopedic Surgery: Retrospective Study||Seoul National University Bundang Hospital|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|600|||Both|65 Years|N/A|No|Probability Sample|Patients who underwent orthopedic surgery under regional anesthesia, and age of 65 years        or greater|January 2016|January 21, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02573558||11276|
NCT02621697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFTM 2015|Dual Task in Institutionalized Elderly|Dual Task in Institutionalized Elderly: Positive Impact on the Risk of Falls and Functionality||Universidade Federal do Triangulo Mineiro|Yes|Completed|February 2014|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|August 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02621697||7581|
NCT02625818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1751|The Genetic and Affective Prediction Study|The Genetic and Affective Prediction Study|GAP|St. Olavs Hospital|No|Recruiting|January 2016|January 2051|Anticipated|January 2051|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|blood samples (plasma and serum)|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the psychiatric acute department for central Norway, St Olavs        University Hospital, Trondheim. The department has a catchment area of approximately        240000 inhabitants ≥ 18 years. The hospital has close to 2000 admittances each year|March 2016|March 22, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625818||7264|
NCT02625896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIF FO2015-0005.|Free Fall Acrobatics to Reduce Neck Loads During Parachute Opening Shock: Evaluation of an Intervention.|Free Fall Acrobatics to Reduce Neck Loads During Parachute Opening Shock: Evaluation of an Intervention.|ACROPOSE|Karolinska Institutet|No|Not yet recruiting|May 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02625896||7258|
NCT02622568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092014-012|Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study|Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study||University of Texas Southwestern Medical Center||Recruiting|July 2015|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 2, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02622568||7514|
NCT02613793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a11496|Saccadic Reaction Time and Preterm Pre-eclampsia|A Prospective Case Control Feasibility Study to Investigate the Utility of Saccadometry in the Diagnosis and Monitoring of Preterm Pre-eclampsia||Oxford University Hospitals NHS Trust|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients with preterm pre-eclampsia diagnosed earlier than 35 weeks gestation        (cases) and healthy age- and gestation-matched pregnant patients (controls)|November 2015|November 22, 2015|September 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02613793||8188|
NCT02613806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYYYMZK-08|Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General Anesthesia|Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General anesthesia---a Randomized Control Double-Blind Clinical Trial||First Affiliated Hospital of Chongqing Medical University|No|Not yet recruiting|December 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|64 Years|No|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02613806||8187|
NCT02626052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.11.19.F1|Helpfulness of the Vibration Test Performed in Room Light on Clients With Inner Ear Problems|Diagnostic Accuracy of the Vibration Induced Nystagmus Test in Room Light.||Aultman Health Foundation|No|Enrolling by invitation|December 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with complaints of dizziness, vertigo, and/or imbalance referred to the hospital        outpatient physical therapy department.|December 2015|January 5, 2016|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626052||7246|
NCT02614222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM 15-002|Computer Assisted Instrument Guidance (CAIG) for Orthopedic Peripheral Nerve Blocks|Computer Assisted Instrument Guidance (CAIG) For Orthopedic Peripheral Nerve Blocks||Clear Guide Medical|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614222||8155|
NCT02619227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH096620-S3|A Livelihood Intervention for Impoverished Women in Rural Uganda|A Livelihood Intervention for Impoverished Women in Rural Uganda: Randomized Controlled Trial||Massachusetts General Hospital|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|92|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02619227||7771|
NCT02626325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHO-MUFA Meta|Effect of High-carbohydrate or High-monounsaturated Fatty Acids on Blood Pressure: a Meta-analysis of Randomized Clinical Trials|Effect of High-carbohydrate or High-monounsaturated Fatty Acids on Blood Pressure: a Meta-analysis of Randomized Clinical Trials|CHO-MUFA|St. Michael's Hospital, Toronto|No|Active, not recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy and unhealthy (T2DM, hyperlipidemic, hypertensive)|December 2015|December 7, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626325||7225|
NCT02616419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999|Efficacy of a New Device (Buzzy®) for Pain and Anxiety Relief in Children Undergoing Needle-Related Procedures.|Efficacy of a New Device (Buzzy®) Combining Cold and Vibration VS Anaesthetic Cream for the Procedural Pain and Anxiety Relief in Children Undergoing Needle-Related Procedures in Emergency Department : A Randomized Controlled Trial.||St. Justine's Hospital|No|Not yet recruiting|June 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|126|||Both|4 Years|17 Years|No|||November 2015|November 24, 2015|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616419||7986|
NCT02623959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0142|Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis|A Double Blind Randomized Controlled Trial of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions||M.D. Anderson Cancer Center|Yes|Not yet recruiting|May 2016|||May 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623959||7407|
NCT02623972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-292|A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer|A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer||Dana-Farber Cancer Institute|Yes|Not yet recruiting|January 2016|February 2023|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623972||7406|
NCT02624999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-020-HENK-VAXPII|Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck|An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Immunovative Therapies, Ltd.|No|Not yet recruiting|July 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02624999||7327|
NCT02625012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVVIT01|Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Migration in Vitiligo|Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Dynamics in Vitiligo|UVBVIT|Universidad Autonoma de San Luis Potosí|No|Enrolling by invitation|January 2014|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Skin biopsies|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with clinical diagnosis of vitiligo vulgaris|December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625012||7326|
NCT02623491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108063|Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants|A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Subjects||Janssen Research & Development, LLC|No|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|83|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02623491||7443|
NCT02623439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120931|A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies|A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies||University of California, San Diego|Yes|Suspended|July 2012|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2015|December 4, 2015|August 29, 2013||No|On hold for toxicitiy|No||https://clinicaltrials.gov/show/NCT02623439||7447|
NCT02614066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTE-C19-103|A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)|ZUMA-3|Kite Pharma, Inc.||Recruiting|November 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614066||8167|
NCT02614339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0533|Effect of Adjunctive Metformin on Recurrence of Non-DM Stage III Colorectal Cancer: Open-label Randomized Controlled Study|||Yonsei University|Yes|Not yet recruiting|December 2015|November 2021|Anticipated|July 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|593|||Both|20 Years|80 Years|No|||November 2015|November 23, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614339||8146|
NCT02614352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCA_BE_1501|Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects|||Ahn-Gook Pharmaceuticals Co.,Ltd||Not yet recruiting||||February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|60|||Male|19 Years|45 Years||||November 2015|November 24, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02614352||8145|
NCT02618616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPL389/102|A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis|Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis.||Ziarco Pharma Ltd|No|Recruiting|January 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|February 4, 2016|November 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618616||7818|
NCT02618915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101HEMB01|Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B|Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B||Dimension Therapeutics|Yes|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02618915||7795|
NCT02621593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-VBU-M22-15-01|Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD|Feasibility of Intense Pulsed Light (IPL) for Reducing Dry Eye Symptoms Caused by Meibomian Gland Dysfunction (MGD)||Lumenis Ltd.|No|Recruiting|October 2015|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621593||7589|
NCT02621606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6884-001|[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)|A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain||Merck Sharp & Dohme Corp.|No|Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|26|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02621606||7588|
NCT02624115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9741|FAZA PET as Biomarker for Hypoxia in Rectal Cancer|18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study||University Health Network, Toronto|No|Not yet recruiting|January 2016|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with rectal cancer undergoing neoadjuvant chemoradiotherapy|December 2015|December 3, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02624115|1 Month|7395|
NCT02624128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-CHANCE|Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck|Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck|V-CHANCE|National Cancer Institute, Naples|No|Recruiting|February 2015|October 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02624128||7394|
NCT02627690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_28|Nephrologic Prognosis 10 Years After Diabetes Cell Therapy|Nephrologic Prognosis 10 Years After Diabetes Cell Therapy|PRONOCELDIAB|University Hospital, Lille|No|Recruiting|September 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients suffering of type 1 diabetes since at least 10 years|December 2015|December 8, 2015|February 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02627690||7120|
NCT02615054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-258|Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors|Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Anticipated|55|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potentially eligible subjects who meet the eligibility criteria and who were treated at        MSK between 2005 and 2010 will be identified through query of MSK institutional        databases.Healthy control subjects will be recruited from MSK employees.|November 2015|November 23, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02615054||8091|
NCT02620033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2015-406H|Impact of Yoga As Complementary Therapy in Patients Undergoing Radical Prostatectomy|Impact of Yoga As Complementary Therapy on Quality of Life, Pro-inflammatory, and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized-Controlled Trial||The University of Texas Health Science Center at San Antonio|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Male|30 Years|80 Years|No|||November 2015|November 29, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02620033||7709|
NCT02617771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITDBA1|Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.|Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric||Policlinico Hospital|No|Completed|October 2014|November 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|84|||Both|6 Months|3 Years|No|||November 2015|November 25, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617771||7882|
NCT02614898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-aHUS-403|Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment|Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment|EVIDENCE|Alexion Pharmaceuticals|Yes|Enrolling by invitation|November 2015|||April 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|330|||Both|N/A|N/A|No|||November 2015|November 24, 2015|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614898||8103|
NCT02626650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS15-334|Recent Experiences With Concussions|Recent Experiences and Presentation Format: Study of Concussion Symptom Elicitation||University of Pennsylvania|No|Not yet recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02626650||7200|
NCT02626663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00059370|The Role of Microparticles as a Biomarker|The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)||University of Rochester|No|Not yet recruiting|January 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|Samples With DNA|platelet poor plasma samples will be retained. These samples will contain Microparticles and      nanoparticles as well as microRNA.|Both|18 Years|120 Years|No|Non-Probability Sample|Patients presenting with Microangiopathic Hemolytic Anemias (MAHA), TTP, and/or aHUS are        eligible.|December 2015|December 8, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02626663||7199|
NCT02620293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09224-01|A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin|A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin||Reckitt Benckiser Healthcare (UK) Limited|No|Not yet recruiting|January 2016|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|65 Years|No|||September 2015|November 30, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02620293||7689|
NCT02618005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics|Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment|Study for Evaluating the Impact of Continuous Consumption of Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment||Yakult Honsha Co., LTD|No|Recruiting|October 2015|||March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02618005||7865|
NCT02618018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT TORBI 709M toric IOL|Clinical Evaluation of Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery|An Investigator-Initiated Trials on the Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery||Seoul National University Hospital|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||November 2015|November 25, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02618018||7864|
NCT02619643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primed PAS|Primed vs Unprimed Facilitatory and Depressive Paired Associative Stimulation|Primed vs Unprimed Facilitatory and Depressive Paired Associative Stimulation||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|7||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02619643||7739|
NCT02626715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14100126|Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS|A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||University of Pittsburgh|Yes|Recruiting|September 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|1 Month|22 Years|No|||December 2015|December 7, 2015|September 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626715||7195|
NCT02626754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-002A|A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population|A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population||Taipei Veterans General Hospital, Taiwan|No|Enrolling by invitation|August 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02626754||7192|
NCT02623179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATUTI|Conventional and Molecular Diagnostic Method for Patients With Suspected UTI|Conventional and Molecular Diagnostic Method for Patients With Suspected Urinary Tract Infections: Clinical, Economic, and Quality of Life Outcomes||Southwest Regional PCR, LLC|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|89 Years|No|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623179||7467|
NCT02614027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460/15|Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances|Prevalence of Lipodystrophy Syndrome and Secondary Metabolic Syndrome in HIV-infected Patients|METALIP|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Recruiting|February 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients on antiretroviral therapy with current drugs (excluding drugs        previously associated with fat disturbance), and HIV-infected patients with previous        evaluation of lipodystrophy syndrome in different severity, as determined by DXA and        questionnaire.|February 2016|February 2, 2016|November 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02614027||8170|
NCT02627170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0943|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer for Normal Adults in South Korea|||Yonsei University|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy population|December 2015|December 8, 2015|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02627170||7160|
NCT02621203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiovascular Academy|Patient Journey in Hospital With Acute Heart Failure|Investigate to Medications, Re-hospitalization and Mortality of Patients With Hospitalized Acute Heart Failure Patients|JourneyHF-TR|Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital|Yes|Recruiting|September 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Hospital-based registry of patients with acute heart failure (AHF) those whose care was        guided by a cardiologist in Turkey.|December 2015|December 2, 2015|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02621203||7619|
NCT02621216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THORESCI|Tilburg Health Outcomes Registry of Emotional Stress in Coronary Intervention|Tilburg Health Outcomes Registry of Emotional Stress in Coronary Intervention|THORESCI|University of Tilburg|Yes|Recruiting|December 2013|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|Blood serum is stored for biomarker analysis|Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for either elective or (sub-)acute PCI for ≥1 coronary occlusions|December 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621216|10 Years|7618|
NCT02623270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00080301|A Comparison of Controlled Ventilation With the V60 Non-Invasive Ventilator vs. Traditional Mask Ventilation|A Comparison of Controlled Ventilation With the V60 Non-Invasive Ventilator vs. Traditional Mask Ventilation||University of Utah|No|Enrolling by invitation|July 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|74 Years|No|||December 2015|December 4, 2015|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623270||7460|
NCT02623283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186595|The Tayside Brushing Study - Adult Follow up|Assessing the Long-term Effects of a School-to-home Childhood Supervised Brushing Programme in Young Adults From High Caries Risk Groups - The Tayside Brushing Study Adult Follow up||NHS Tayside|No|Not yet recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|534|||Both|24 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 25 who were enrolled on the Tayside Brushing Study Randomised Controlled Trial|December 2015|December 4, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02623283||7459|
NCT02615899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305002061|Effectiveness of Impairment Specific Exercises for Balance and Fall Risk in Community-Living Older Adults at Risk: A Randomized Controlled Trial|||Drexel University|No|Completed|November 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|99 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02615899||8026|
NCT02615912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-15-0004|A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants|A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants||Kimberly-Clark Corporation|No|Active, not recruiting|November 2015|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02615912||8025|
NCT02613832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caio01|Applicability of Techniques of Lung Expansion|Immediate Effect of Expiratory Positive Airway Pressure and Breath Stacking in Non-cooperative Patients Detected by Electrical Impedance Tomography||Universidade Federal de Pernambuco|Yes|Completed|August 2014|January 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 22, 2015|October 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02613832||8185|
NCT02562521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411014980|A Smoking Cessation Intervention for Yale Dining Employees|A Smoking Cessation Intervention for Yale Dining Employees||Yale University|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02562521||12124|
NCT02623257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20154701|EGFR Mutations on ctDNA in Patients With Advanced NSCLC|A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer||First People's Hospital of Hangzhou|Yes|Not yet recruiting|January 2016|March 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Non-small cell lung cancer (NSCLC)|December 2015|December 4, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02623257||7461|
NCT02622581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-TRK-0315|Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients|Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients|CRISP|AIO-Studien-gGmbH|No|Recruiting|December 2015|December 2022|Anticipated|September 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|5000|Samples With DNA|All patients will be asked to give consent for their tumor samples to be used for future      investigational translational research. If the patient agrees, contact details of the local      pathology where the tumor sample is stored as well as the sample's identification number      will be documented in the eCRF, creating the CRISP "decentralized clinically annotated      tissue repository". Study sites will inform the local pathologists about the patient's      consent and ask for the tissue sample to be reserved for future CRISP analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced or metastatic NSCLC at the start of palliative first-line        systemic therapy. Of all patients recruited, 3,250 patients with nonsquamous cell        carcinoma will be tested for molecular alterations at the start of first-line treatment        (CRISP patients). 1,750 patients with squamous can be tested for molecular alterations at        the start of first-line treatment (CRISP patients). The remainder will be patients with        untested non-squamous carcinoma (CRISP satellite patients). Patients will be recruited in        up to 150 study sites (certified lung cancer centers, comprehensive cancer centers,        hospitals and office-based oncology practices) in Germany.|February 2016|February 17, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622581|3 Years|7513|
NCT02620423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 024|Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma|A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma||Oncolytics Biotech|Yes|Recruiting|December 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02620423||7679|
NCT02616549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820672|Multicomponent Yoga Intervention for Major Depressive Disorder|A Randomized Study of a Comprehensive Yoga Intervention for Patients With Major Depressive Disorder With Incomplete Response to Antidepressants||University of Pennsylvania|No|Completed|October 2014|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|67 Years|No|||December 2015|December 7, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02616549||7976|
NCT02616562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4172|Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency|A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency naïve Pre-pubertal Children With Growth Hormone Deficiency||Novo Nordisk A/S|No|Recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|68|||Both|2 Years|10 Years|No|||March 2016|March 23, 2016|November 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616562||7975|
NCT02612636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0000871100|The Effect of Ear Plug and Eye Mask on Sleeping Quality in Critically Ill Patients|The Effect of Ear Plug and Eye Mask on Sleeping Quality in Critically Ill Patients|sayed|Assiut University|Yes|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|60 Years|No|||November 2015|March 4, 2016|November 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02612636||8277|
NCT02612649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB0002|Special Drug Use Surveillance of Irribow in Female Patients|Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients||Astellas Pharma Inc|No|Recruiting|October 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|N/A|N/A|No|Non-Probability Sample|Female patients with diarrhea-predominant irritable bowel syndrome|November 2015|November 20, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02612649||8276|
NCT02618525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acd/10/071/072|Supraorbital Pressure Versus Jaw Thrust for Assessing the Adequate Depth of Anesthesia for LMA Insertion in Children|Comparison of the Supraorbital Pressure and Jaw Thrust as Indicators for Depth of Anesthesia for Laryngeal Mask Airway Insertion in Children||B.P. Koirala Institute of Health Sciences|Yes|Completed|June 2014|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|50|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02618525||7825|
NCT02618759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 1505|Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis||Taro Pharmaceuticals USA|No|Recruiting|August 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|N/A|No|||November 2015|November 28, 2015|November 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02618759||7807|
NCT02624336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101269-2|Evaluation of Synergistic Anti-plaque Activity of Salvadora Persica L. and Green Tea: A Clinical Comparative Study|Evaluation of Synergistic Anti-plaque Activity of Salvadora Persica L. and Green Tea: A Clinical Comparative Study|ESAA|University of Malaya|Yes|Completed|February 2015|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|14|||Male|25 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624336||7378|
NCT02570243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY 20|High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion|High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion Forearm Artery Occlusion||University of Patras|No|Recruiting|February 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1800|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570243||11531|
NCT02623517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150702|A Novel Healthcare Information Technology Tool to Improve Care in Patients With Atrial Fibrillation|A Novel Healthcare Information Technology Tool to Improve Care in Patients|AFCare|University of California, San Diego|No|Not yet recruiting|April 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit subjects from the San Diego surrounding area that present in the UCSD        Medical Center E.D.|February 2016|February 17, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02623517||7441|
NCT02612883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTG-04|Flux Measurement and Outcome in Major Abdominal Surgery|Flux Measurement and Outcome in Major Abdominal Surgery|FLUX|Technische Universität Dresden|No|Recruiting|November 2015|April 2021|Anticipated|October 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|875|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing major abdominal surgery of liver, stomach, colon/rectum, esophagus,        pancreas|November 2015|November 20, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02612883||8258|
NCT02611947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2010/175|CT Indexes of Emphysema and Airways in Healthy Volunteers: Normal Values; Relations With Gender, Height and Weight|CT Indexes of Emphysema and Airways in Healthy Volunteers: Normal Values; Relations With Gender, Height and Weight||Erasme University Hospital|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|November 2015|November 19, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02611947||8330|
NCT02611960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-122|Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)|A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)||Merck Sharp & Dohme Corp.|No|Not yet recruiting|March 2016|July 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02611960||8329|
NCT02614651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/IMGD-01|AUgmented REality for the Visually Impaired - Part 1|Prospective Pilot Study on the Quantitative Evaluation of Vision Parameters Needed by Virtual Reality Goggle Displays for Subjects With Concentric Visual Field Constriction. AUgmented REality for the Visually Impaired - Part 1|AUREVI 1|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|October 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02614651||8122|
NCT02619435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STREAM|Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer|Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study|STREAM|National Cancer Institute, Naples|No|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|70 Years|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619435||7755|
NCT02621801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000916|Evaluation of a Mind-body Education Program to Enhance Resiliency and Reduce Burnout in Residents|Evaluation of a Mind-body Education Program to Enhance Resiliency and Reduce Burnout in Residents||Massachusetts General Hospital|Yes|Active, not recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|173|||Both|21 Years|N/A|No|||December 2015|December 1, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02621801||7573|
NCT02623855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-042|Stay Healthy In Nature Everyday: Family Nature Outings in a Low Income Population|Stay Healthy In Nature Everyday: a Randomized Controlled Trial of the Effect of Family Nature Outings on Stress and Physical Inactivity in a Low Income Population|SHINE|Children's Hospital & Research Center Oakland|No|Recruiting|July 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|4 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02623855||7415|
NCT02623868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148NF15010|Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.|Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subjects||Chong Kun Dang Pharmaceutical|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02623868||7414|
NCT02609867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDV-001|A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)|A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of 'Flowise Cerebral Flow Diverter' for the Treatment of Unruptured Wide-necked Cerebral Aneurysm in the Internal Carotid Artery||Yonsei University|Yes|Recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|75 Years|No|||January 2016|January 13, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02609867||8489|
NCT02601196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2101-EZ-CTIL|IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure|IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure||Sheba Medical Center||Not yet recruiting|November 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|44 Years|No|||November 2015|November 9, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02601196||9152|
NCT02607514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P001923|Hyperthermic Yoga for Depressive Symptoms|Mechanisms of Hyperthermic Yoga for the Treatment of Depression||Massachusetts General Hospital|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||November 2015|November 17, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02607514||8670|
NCT02598700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066248|Correlation of Spinopelvic Parameters and Acetabular Cup Orientation|Measurement and Quantitative Correlation of Spinopelvic Parameters and Acetabular Cup Orientation Between Standing and Sitting to Define a Better Functional Anteversion Safe Zone in Total Hip Arthroplasty||Duke University|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|84|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients who have undergone THA with the appropriate pre-operative CT for planning and        those who are candidates for primary THA for osteoarthritis will be contacted for        recruitment. Those with inflammatory arthritides or neuromuscular disorders will not be        eligible for the study. Women of childbearing age will also be excluded from this study.        Base on the power analysis below, the investigators anticipate eighty-four (84) patients        will be enrolled into this study.|October 2015|November 11, 2015|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02598700||9344|
NCT02598713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspiration Markers|Validation of Aspiration Markers in Intubated Patients|Validation of Markers for Aspiration for Endotracheal Tube Cuff Leak||Massachusetts General Hospital|No|Recruiting|December 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02598713||9343|
NCT02603354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/001a|Efectiveness of a Brief Protocol by a Low (6%) Concentration Gel Peroxide Hydrogen of Teeth Bleaching|Efectiveness of a Brief Protocol by a Low (6%) Concentration Gel Peroxide Hydrogen of Teeth Bleaching|Brief6%|University of Chile|Yes|Completed|March 2015|October 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02603354||8987|
NCT02603406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT2-15-187-HJM|Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits|Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)|NIMBUS|Ajou University School of Medicine|No|Not yet recruiting|December 2015|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|19 Years|85 Years|No|||September 2015|November 10, 2015|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02603406||8983|
NCT02601482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008542 - 2|Optimization of Interval-training in Patients With Type 2 Diabetes|Optimization of Interval-training in Patients With Type 2 Diabetes||Rigshospitalet, Denmark|No|Recruiting|October 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|14|||Both|30 Years|N/A|No|||November 2015|November 9, 2015|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02601482||9130|
NCT02573233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY14192|Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma|An Exploratory, Randomized, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma|EXPEDITION|Sanofi|Yes|Recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573233||11301|
NCT02573246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00066383|Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study|Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study||Duke University|Yes|Not yet recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02573246||11300|
NCT02626845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS 2015-424|Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis|Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis|RENTGPA|Hospital for Special Surgery, New York|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02626845||7185|
NCT02626858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54017|Optimizing the Delineation of the Tumour Bed in Breast Irradiation|Optimizing the Delineation of the Tumour Bed in Breast Irradiation||Universitaire Ziekenhuizen Leuven|Yes|Completed|February 2012|July 2015|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Female|N/A|N/A|No|||February 2012|December 7, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02626858||7184|
NCT02619864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I222|mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme|A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme||Canadian Cancer Trials Group|Yes|Not yet recruiting|November 2015|December 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02619864||7722|
NCT02619877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-DFU-201|Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-DFU in Paitents With Diabetic Foot Ulcers|Phase 2 Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Comparator-controlled, Single-blind, Parallel-group, Multi-center Study||Anterogen Co., Ltd.|No|Recruiting|October 2015|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|60 Years|No|||November 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619877||7721|
NCT02615457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT001|Huaier Granule in Treating Women With Triple Negative Breast Cancer|||Shandong University|No|Recruiting|October 2015|||October 2025|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|75 Years|No|||November 2015|November 24, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02615457||8060|
NCT02617160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC059315ctil|Evaluation of Automated Insulin Pump Settings Using the MD-Logic Advise4U|Evaluation of Automated Insulin Pump Settings Using the MD-Logic Pump Advisor- The MD-Logic Advise 4 U- Open Label, Parallel , Randomized, Controlled Study||Rabin Medical Center|No|Not yet recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|10 Years|25 Years|No|||November 2015|November 26, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02617160||7929|
NCT02617173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2514-GR-CTIL|The Effect of Low Electrical Current on Testicular Spermatocyte Count|The Effect of Low Electrical Current on Testicular Spermatocyte Count||Sheba Medical Center|No|Not yet recruiting|November 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|21 Years|45 Years|No|||November 2015|November 26, 2015|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02617173||7928|
NCT02617459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhaoke-201506-Levobetaxolol|Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma|a Multi-centers, Randomization, Single-blind, Positive-controlled, Parallel Clinical Trial to Evaluate the Efficacy and Safety of Levobetaxolol Hydrochloride Eye Drops in Patients With Primary Open-angle Glaucoma||Lee's Pharmaceutical Limited|No|Recruiting|November 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|November 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02617459||7906|
NCT02621554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|resveratrol_mpi_01|Effects of Resveratrol on Memory Function and the Brain in Healthy Older Adults With Subjective Memory Complaints|Impact of Resveratrol on Brain Function and Structure in Healthy Elderly People||Max Planck Institute for Human Cognitive and Brain Sciences|Yes|Recruiting|January 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02621554||7592|
NCT02613247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-123|Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome|Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial||University of Calgary|No|Recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|45 Years|No|||March 2016|March 20, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613247||8230|
NCT02622672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS2-15095|Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes|Water-soluble Ubiquinol (a Reduced Form of Coenzyme Q10) Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Patients With Type 2 Diabetes||Chung Shan Medical University|No|Not yet recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|80 Years|No|||December 2015|December 3, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02622672||7506|
NCT02620501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrookeAMC|Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time|Does Topical Lidocaine Reduce The Amount of Intravenous Conscious Sedation Required To Complete Diagnostic Upper Endoscopy and Shorten Recovery Time? A Double Blinded, Randomized, Placebo Controlled Study.||Brooke Army Medical Center|Yes|Recruiting|July 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|89 Years|No|||December 2015|December 2, 2015|January 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02620501||7673|
NCT02626936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS Safety meal study|Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation|A Single-blind, Randomized, Two-way, Cross-over Study to Examine the Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation Combined With a Simplified Qualitative Meal-size Estimation in Adults With Type 1 Diabetes||Institut de Recherches Cliniques de Montreal|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02626936||7178|
NCT02626949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1990|Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults|Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|N/A|No|||March 2016|March 15, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02626949||7177|
NCT02622126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0000871175|Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia|The Effects of Colloid Pre-Loading on D-Dimer of the Mother and Her Baby During Cesarean Section Under Spinal Anesthesia for Mild Preeclampsia||Assiut University|Yes|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|19 Years|50 Years|No|||January 2016|January 11, 2016|December 1, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02622126||7548|
NCT02622139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252_15B|Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD)|Monocentric, Prospective Interventional Study to Assess the Degree of Disease Activity With a Multispectral Optoacoustic Tomography (MSOT) Handheld Scanner in Patients With Crohn's Disease or Ulcerative Colitis|MSOT_IBD|University of Erlangen-Nürnberg Medical School|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|164|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02622139||7547|
NCT02614118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZadUMS-P/139/D|Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Treatment Pain|Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Endodontic Treatment Pain||Azad University of Medical Sciences|Yes|Enrolling by invitation|September 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|November 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02614118||8163|
NCT02623218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOMA-5510|Translational Research Examining Acupuncture Treatment in Traumatic Brain Injury|Translational Research Examining Acupuncture Treatment in Traumatic Brain Injury|TREAT-TBI|AOMA Graduate School of Integrative Medicine|Yes|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02623218||7464|
NCT02613689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063791|Addressing Tobacco Use Disparities Through an Innovative Mobile Phone Intervention|Addressing Tobacco Use Disparities Through an Innovative Mobile Phone Intervention: The Text to Forgo Smokeless Tobacco||Duke University||Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02613689||8196|
NCT02626286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12324 CohMSM|Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa|Prevention of HIV Infection in Men Who Have Sex With Men in Sub-Saharan Africa: Feasibility and Interest of a Quarterly Preventive Global Care (CohMSM)|CohMSM|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|700|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02626286||7228|
NCT02616146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8342B-062|Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)|A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contraceptive (COC) in Healthy Women 18 Years of Age and Older, at Risk for Pregnancy.||Merck Sharp & Dohme Corp.|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2370|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02616146||8007|
NCT02618330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCHSIRB-ST-2013-094|The Clinical Evaluation of Two Different Film Thicknesses of Clear Overlay Retainer.|||Sichuan University||Completed|July 2013|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Both|12 Years|N/A|No|||November 2015|November 30, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02618330||7840|
NCT02618564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED#1845-15|The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing|The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing||Queen's University|Yes|Recruiting|December 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|October 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02618564||7822|
NCT02627599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01012015DM|A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device|A Study to Evaluate Improvement in the Quality of Life and Health and Economic Outcomes of Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)|BRVB-OCD|StratiHealth|Yes|Active, not recruiting|May 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|65 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic Obstructive Pulmonary Disease|February 2016|February 26, 2016|November 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02627599||7127|
NCT02619240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC 2014.556|Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB|Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB||Chinese University of Hong Kong||Recruiting|October 2015|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|bronchoscopic alveolar lavage|Both|N/A|N/A|No|Non-Probability Sample|adult patients with abnormal chest imaging suspected of TB as a differential diagnosis|November 2015|November 30, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02619240||7770|
NCT02616965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-085|A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma|A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients With Requiring Systemic Therapy for Cutaneous T-cell Lymphoma||Fox Chase Cancer Center|Yes|Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|November 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02616965||7944|
NCT02624544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS|Proton Pump Inhibitors Use in Patients With Psoriasis|Proton Pump Inhibitors Use in Patients With Psoriasis||EMS|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||November 2015|December 7, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02624544||7362|
NCT02624596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-34622|Understanding How Ketamine Brings About Rapid Improvement in OCD|NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD||Stanford University|Yes|Not yet recruiting|December 2015|June 2021|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02624596||7358|
NCT02626585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BezmialemVU-BO-PRT|The Effect of Postrhinoplasty Taping on Postoperative Edema and Nasal Draping|The Effect of Postrhinoplasty Taping on Postoperative Edema and Nasal Draping|PRT|Bezmialem Vakif University|No|Completed|August 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|16 Years|65 Years|No|||December 2015|December 8, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02626585||7205|
NCT02626624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBOCLEAR P_CLD 2492_US|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2015|||||N/A|N/A|N/A||||||||||||||December 8, 2015|November 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02626624||7202|
NCT02614183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15767|Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study|EVOLVE-1|Eli Lilly and Company|Yes|Recruiting|November 2015|June 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|825|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614183||8158|
NCT02614196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15768|Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-2 Study|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study|EVOLVE-2|Eli Lilly and Company|Yes|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|825|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|November 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02614196||8157|
NCT02611388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2015-10-28|Neurohumoral Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS)|Neurohumor Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS): A Prospective, Randomized Controlled Trial||Xijing Hospital|Yes|Not yet recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|81|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02611388||8373|
NCT02618551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7422 15|Bronchial Thermoplasty for Severe Asthma With Dynamic Hyperinflation|Evaluation of the Efficiency of Bronchial Thermoplasty on Dynamic Hyperinflation in Uncontrolled Severe Asthma|HEAT-SA|University Hospital, Toulouse|Yes|Recruiting|November 2015|December 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|November 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02618551||7823|
NCT02625116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8852-2|ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders|ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders|ELENA|University Hospital, Montpellier|No|Recruiting|September 2012|October 2025|Anticipated|September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|2 Years|16 Years|No|Non-Probability Sample|The study population is aged between 2 and 16 years, and has a diagnosis of ASD formally        established during a multidisciplinary assessment and made according international        criteria of the ICD10.|October 2015|December 4, 2015|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02625116||7318|
NCT02621827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC SCC1229|Vitamin D Half-life in Pregnancy and Lactation|Vitamin D Half-life in Pregnancy and Lactation||Medical Research Council|No|Completed|November 2011|May 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|49|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02621827||7571|
NCT02625350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-noodle|Glycemic Index of Instant Noodle With and Without Soup: Does Serving Method Have an Effect?|Glycemic Index of Instant Noodle With and Without Soup: Does Serving Method Have an Effect?||Nutrifood Research Center, Jakarta, Indonesia|No|Enrolling by invitation|December 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625350||7300|
NCT02627638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-826|Cancer Patient Perceptions of the Osteopathy Treatment: a Qualitative Study|Cancer Patient Perceptions of the Osteopathy Treatment: a Qualitative Study||Hospices Civils de Lyon|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|December 10, 2015|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02627638||7124|
NCT02627651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alyn|The Cardiac Autonomic System Response to Activity and Cognitive Tasksinjury|The Cardiac Autonomic System Response to Activity and Cognitive Tasks in Children Post Acquired Brain||Alyn Pediatric & Adolecent Rehabilitation Center||Recruiting|January 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|36|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02627651||7123|
NCT02614989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0556-15-RMB|MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis|MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis||Rambam Health Care Campus|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||November 2015|November 24, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02614989||8096|
NCT02615002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuP11-AD2|Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)|Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease||Neurim Pharmaceuticals Ltd.|Yes|Active, not recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|500|||Both|60 Years|85 Years|No|||January 2016|March 22, 2016|November 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02615002||8095|
NCT02623062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA1217|Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study|A Multi-centred, Randomised, Double-blind, Two Arms, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Oral Suspension Sachet in Patients With Reflux Disease||Reckitt Benckiser Healthcare (UK) Limited|No|Recruiting|December 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|644|||Both|18 Years|65 Years|No|||November 2015|December 2, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02623062||7476|
NCT02611362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH104068|A Multilevel Gaming Intervention for Persons on PrEP|A Multilevel Gaming Intervention for Persons on PrEP||Rhode Island Hospital|No|Recruiting|April 2015|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|November 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02611362||8375|
NCT02621736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2015-340|Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).|Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).|COMEN|University Hospital, Basel, Switzerland|No|Not yet recruiting|January 2016|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|5 Years|16 Years|No|Probability Sample|Children at the Age of 5-16 years with monosymptomatic enuresis nocturna|December 2015|December 1, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02621736||7578|
NCT02621749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/2015|Cerebral Microembolism in the Critically Ill With Acute Kidney Injury|Cerebral Microembolism in the Critically Ill With Acute Kidney Injury: A Prospective Multi-Center Randomized Controlled Trial Comparing Continuous With Intermittent Renal Replacement Therapy.|COMET-AKI|University Hospital Inselspital, Berne|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02621749||7577|
NCT02619396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11536-SPON|RF Power, LSI and Oesophageal Temperature Alerts During AF Ablation (PiLOT-AF Study)|Radiofrequency Power, Lesion Size Index and Oesophageal Temperature Alerts During Atrial Fibrillation Ablation: A Pilot Study|PiLOT-AF|Oxford University Hospitals NHS Trust|No|Not yet recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02619396||7758|
NCT02627703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-168|(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer|A Prospective Clinical Utility Study of the Impact of the 21 Gene Recurrence Score® Assay (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer in Multiple BC Cancer Agency Centres||British Columbia Cancer Agency|No|Not yet recruiting|December 2015|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|79 Years|No|Probability Sample|-  18-79 years old          -  Operative Primary Breast Cancer               -  Node + (N1-3: micrometastasis)               -  ER + and HER 2-          -  Candidate for adjuvant chemotherapy in addition to hormonal therapy|December 2015|December 9, 2015|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02627703||7119|
NCT02623114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0720151002|Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers|Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder||Seoul National University Childrens Hospital|Yes|Recruiting|May 2012|March 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|November 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02623114||7472|
NCT02621918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-02564112.2.0000.5423|The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis|The Effects of an Intradialytic Progressive Resistance and Aerobic Training in End-stage Renal Disease Patients Undergoing Hemodialysis|EESRDS|Universidade Estadual Paulista Júlio de Mesquita Filho|Yes|Completed|March 2013|June 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02621918||7564|
NCT02621931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV48125-CNS-30049|Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine||Teva Pharmaceutical Industries|No|Recruiting|January 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1020|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|December 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02621931||7563|
NCT02625467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALK vs PK|Treatment of Keratoconus With PALK Versus PK|Treatment of Keratoconus With Pachymetry Assisted Laser Keratoplasty (PALK) Versus Penetrating Keratoplasty (PK)||Instituto de Oftalmología Fundación Conde de Valenciana|No|Completed|June 2013|November 2015|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02625467||7291|
NCT02624271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0371|Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk|Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk : a French Multicenter Study|GASTRO-PRA|Nantes University Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02624271||7383|
NCT02611999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00011096|Paid Price Information on Image and Procedure Ordering Rates|The Effect of Paid Price Information on Image and Procedure Ordering Rates||Children's Hospital Boston||Active, not recruiting|January 2014|November 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|1200|||Both|N/A|N/A|No|||November 2015|November 20, 2015|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02611999||8326|
NCT02627716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_04|Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder|Effectiveness of a Joint Crisis Plan (SOS Plan) in Preventing Relapses in Patients Diagnosed With Schizophrenia and Schizoaffective Disorder|SOS|University Hospital, Lille|No|Recruiting|December 2014|July 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02627716||7118|
NCT02627729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DrLutfi2|J-Pouch vs Side-to-End Anastomosis After Hand-Assisted Laparoscopic Low Anterior Resection for Rectal Cancer|J-Pouch vs Side-to-End Anastomosis After Hand-Assisted Laparoscopic Low Anterior Resection for Rectal Cancer: Short and Long-Term Outcomes of a Prospective Randomized Trial||Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|No|Completed|June 2009|February 2014|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|74|||Both|N/A|N/A|No|||December 2015|December 9, 2015|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02627729||7117|
NCT02617550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17849|Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients|Evaluation of the Effect of 0.4 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 2.5 mg, 5 mg and 10 mg Vericiguat (BAY 1021189) Each Given Over 14 ± 3 Days on Safety, Tolerability and Blood Pressure in a Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study in Stable Coronary Artery Disease (CAD) Patients Aged 30 to 80 Years|VENICE|Bayer|Yes|Recruiting|November 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|30 Years|80 Years|No|||February 2016|February 29, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02617550||7899|
NCT02613585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1770|Tick-borne Illness and Clothing Study of Rhode Island|Tick-borne Illness and Clothing Study of Rhode Island||University of North Carolina, Chapel Hill|Yes|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02613585||8204|
NCT02623478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15639|A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy||Eli Lilly and Company|No|Not yet recruiting|January 2017|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|December 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02623478||7444|
NCT02611648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P-000263|Dueodenoscope Disinfect Study|Prospective Randomized Double-blinded Trial Comparing Three Dueodenoscope High- Level Disinfection and Sterilization Procedures||Beth Israel Deaconess Medical Center||Enrolling by invitation|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02611648||8353|
NCT02619890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsanMCHSKim_02|Brain Glioma Registry Combining Clinical and Imaging Information|Registry Describing Clinical Information, Conventional, and Advanced Magnetic Resonance Imaging Information of Patients With Brain Glioma||Asan Medical Center|No|Recruiting|September 2015|||December 2040|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9999|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of tertiary hospital center|December 2015|December 1, 2015|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02619890|5 Years|7720|
NCT02618356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guoweijian-2015-RS|Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer|A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy||Fudan University|Yes|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|80 Years|No|||November 2015|December 2, 2015|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02618356||7838|
NCT02618603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016137443|Botulinum Toxin A for Shoulder Pain After Stroke|The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke.||Sir Run Run Shaw Hospital|No|Not yet recruiting|February 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||November 2015|November 27, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02618603||7819|
NCT02621333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenanCH003|Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma|Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study||Henan Cancer Hospital|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02621333||7609|
NCT02621346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 107286|Maintaining Muscle Mass Gains|Maintaining Muscle Mass Gains||Western University, Canada|No|Not yet recruiting|January 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02621346||7608|
NCT02612376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1774|Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study|Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study||University of Colorado, Denver|No|Not yet recruiting|December 2015|||December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|Biospecimens of blood, cerebral spinal fluid, saliva, and olfactory epithelial biopsies.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|participants with Mild Cognitive Impairment (MCI), AD, DS, healthy controls, and parents        of Down Syndrome individuals|November 2015|November 19, 2015|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02612376|25 Years|8297|
NCT02625675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUS Pleurodesis|Using Thoracic Ultrasound to Predict Pleurodesis Success in Malignant Pleural Effusions: a Pilot Study|Using Thoracic Ultrasound to Predict Pleurodesis Success in Malignant Pleural Effusions: a Pilot Study||University of Oxford|No|Recruiting|March 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Adults undergoing drainage of a malignant pleural effusion and subsequent talc pleurodesis        via an intercostal chest drain as part of their routine planned care.|October 2015|December 4, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02625675||7275|
NCT02624427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corvis and DCT vs. GAT|Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST Tonometer|Comparison of Intraocular Pressure Measured by Goldmann Applanation Tonometry and Dynamic Contour Tonometry vs. Corvis ST Tonometer||University of Zurich|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02624427||7371|
NCT02570009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL125157|Weight Loss for Couples|||University of Connecticut||Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02570009||11549|
NCT02616627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505154RINB|Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients|Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients||National Taiwan University Hospital|No|Recruiting|September 2015|February 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|Chronic Kidney Disease Requiring Chronic Dialysis|November 2015|November 27, 2015|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02616627||7970|
NCT02616640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDI4736-MM-001|A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDi4736) Eitehr As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)||Celgene|No|Recruiting|January 2016|November 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|November 25, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02616640||7969|
NCT02592525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2016 01-01-E|Implementing Shared Decision Making in Interprofessional Home Care Teams|Implementing Shared Decision Making in Interprofessional Home Care Teams : a Stepped Wedge Cluster Randomized Trial|IPSDM-SW|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Recruiting|November 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|640|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 13, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592525||9819|
NCT02589743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Randomized Clinical Trial of Occlusal Sealant|Impact of the Intermediary Layer on Sealant Retention: A Randomized 24-month Clinical Trial||University of Campinas, Brazil|Yes|Completed|April 2003|June 2005|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|65|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02589743||10033|
NCT02518243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-PP-08|Safe & Easy for Alzheimer's Disease and Related Pathologies||SaFEE2|Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|June 2015|||September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|14|||Both|60 Years|N/A|No|||July 2015|August 5, 2015|July 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02518243||15524|
NCT02584283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHOPE-DCD Trial|Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation|A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion With Standard Static Cold Storage of Liver Grafts Donated After Circulatory Death in Preventing Biliary Complications|DHOPE-DCD|University Medical Center Groningen|Yes|Recruiting|October 2015|October 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|100 Years|No|||October 2015|October 20, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02584283||10452|
NCT02580838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-BR-102-032|The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke|The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke||National Cheng-Kung University Hospital|Yes|Recruiting|August 2015|September 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||October 2015|October 18, 2015|October 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580838||10717|
NCT02587117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|636/069/070|A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus|Comparative Study of the Efficacy of Lycopene Versus Prednisolone in the Management of Oral Lichen Planus: A Randomized, Double Blind Clinical Trial|OLP|B.P. Koirala Institute of Health Sciences|Yes|Completed|February 2013|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|October 20, 2015||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT02587117||10234|Due to limitation of time, there were small numbers of subjects enrollment; not possible to follow-up the cases after the treatments were over and to determine the relapse rate of the patients; performed at a single medical center.
NCT02592096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhaoke-2015-01|Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol|A Single Dose Phase I Clinical Study of Pazufloxacin Mesilate Ear Drops for the Patients With Otitis Media||Lee's Pharmaceutical Limited|No|Recruiting|July 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02592096||9852|
NCT02518724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2139-OF-CTIL|The Effect of Remote Ischemic Preconditioning on Physical Performance and Exertional Rhabdomyolysis|The Effect of Remote Ischemic Preconditioning (RIPC) on Physical Performance and Exertional Rhabdomyolysis||Sheba Medical Center|No|Not yet recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02518724||15487|
NCT02580721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-BI-15-003|The Influence of Mucosal Tissue Thickness on Soft and Hard Tissue Changes Around Implants|The Influence of Mucosal Tissue Thickness on Soft and Hard Tissue Changes Around Implants. A Randomized Controlled Clinical Study||Cukurova University|No|Recruiting|September 2015|April 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|4||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 18, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02580721||10726|
NCT02589665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15829|A Study of LY3074828 in Participants With Moderate to Severe Ulcerative Colitis|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis||Eli Lilly and Company|No|Recruiting|December 2015|June 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|240|||Both|18 Years|75 Years|No|||March 2016|March 10, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589665||10039|
NCT02589678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080202|Zambia SiVET MMR Tdap-IPV|A Simulated Vaccine Efficacy Trial Using MMR and Tdap-IPV Vaccines in Healthy, HIV Negative Women at High Risk of HIV Infection in Lusaka and Ndola, Zambia.|SiVET|Emory University|No|Recruiting|August 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Anticipated|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589678||10038|
NCT02591771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AltShock|Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock|Phase II Clinical Trial for a Stepwise Progression in the Treatment of Cardiogenic Shock||Niguarda Hospital|No|Recruiting|October 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02591771||9877|
NCT02521363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-127|Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer Receiving Neoadjuvant Therapy|Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer Receiving Neoadjuvant Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|July 2015|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Female|19 Years|N/A|No|||February 2016|February 25, 2016|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521363||15284|
NCT02521376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-339-1631|Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function|A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function||Gilead Sciences|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521376||15283|
NCT02588547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM102015|Prevention of Spinal Induced Shivering During CS|Prophylactic Granisetron for the Prevention of Spinal Induced Shivering During Cesarean Section: a Prospective Double Blind Dose Ranging Clinical Study||Assiut University|No|Recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|120|||Female|20 Years|45 Years|No|||November 2015|November 26, 2015|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02588547||10125|
NCT02593994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2015-04|IRIS-Onyx Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Resolute Onyx™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRIS-Onyx|Asan Medical Center|Yes|Recruiting|October 2015|October 2022|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|patients with Onyx Drug Eluting Stent|February 2016|February 16, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593994||9706|
NCT02581774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304|Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term|Management of Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term; the Mode of Delivery and the Neonatal Outcomes||Sisli Etfal Training & Research Hospital|No|Completed|January 2013|June 2014|Actual|June 2014|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|324|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|All patients with isolated oligohydramnios were term (37-40 weeks' gestation according to        accurate last menstrual period and first trimester sonographic examination).        Oligohydramnios was defined as an amniotic fluid index < 5 cm. The control group consisted        of prolonged pregnancies in the absence of spontaneous labor and oligohydramnios.        Prolonged pregnancy is diagnosed if 41 gestational weeks are completed according to        accurate date of last menstrual period and first trimester ultrasound.|January 2013|October 19, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581774||10645|
NCT02593318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002242|Trial of Oxaloacetate in Alzheimer's Disease (TOAD)|Trial of Oxaloacetate in Alzheimer's Disease (TOAD)|TOAD|University of Kansas Medical Center|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|85 Years|No|||October 2015|October 30, 2015|October 8, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593318||9758|
NCT02587026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0534|Biorepository for Precision Genomics|Collection of Specimens and Clinical Data to Create a Biorepository for Precision Genomics||Indiana University|No|Recruiting|August 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|500|Samples With DNA|Prospective blood and tumor tissue samples will be collected. Retrospective review of      patient charts for clinical information will also be done.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who attend the Precision Genomics Clinic at Indiana University Health may elect        to participate in this tissue and blood collection protocol.|January 2016|January 29, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02587026|80 Years|10241|
NCT02590419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO HSREB Ref#10317|Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery|Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery||London Health Sciences Centre|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|July 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590419||9981|
NCT02590432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-10|An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation|An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.||Forest Laboratories|No|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590432||9980|
NCT02593357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/55|Peripheral Endothelial Function in COPD Patients|Assessment of a Peripheral Endothelial Dysfunction in COPD|endothBPCO|Hopital Foch|No|Recruiting|December 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|170|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02593357||9755|
NCT02587312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01CA189300|Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers|Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers||Brown University||Not yet recruiting|February 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|15 Years|19 Years|No|||October 2015|October 26, 2015|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587312||10220|
NCT02587325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH-001|ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension|||Aadi, LLC||Not yet recruiting|February 2016|||February 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587325||10219|
NCT02586350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-01-IIMTC|Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2015|October 22, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586350||10293|
NCT02594384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM-002A-NHL-CLN01|A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|LAM-002A/NHL|Lam Therapeutics Inc.|No|Recruiting|October 2015|May 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|January 25, 2016|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594384||9676|
NCT02594397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543102-2|Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial||ADG-RCT|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine||Not yet recruiting|December 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|60 Years|No|||September 2015|October 31, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594397||9675|
NCT02581111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODRC-001|Naloxone for Optimizing Hypoxemia Of Lung Donors|Randomized Placebo-controlled Trial of Intravenous Naloxone to Improve Oxygenation in Hypoxemic Lung-Eligible Brain-Dead Organ Donors|NO-HOLDS|Washington University School of Medicine|No|Enrolling by invitation|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|13 Years|70 Years|No|||October 2015|October 19, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02581111||10696|
NCT02587637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28-SMI-2015|Study to Evaluate the Effectiveness of DRG Stimulation for Discogenic Low Back Pain|A Prospective Post Market Observational Pilot Study to Evaluate the Effectiveness of DRG Stimulation in the Treatment of Discogenic Low Back Pain||St. Jude Medical|No|Recruiting|October 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|65 Years|No|Non-Probability Sample|patients of either gender with chronic (minimum 6 month duration), refractory low back        pain believed to be primarily originating from the intervertebral disc|December 2015|December 15, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587637||10195|
NCT02587650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14859|Trial of TKF Inhibition in Unresectable Stage III/IV BRAF/NRAS WT Melanoma|Phase II Trial Of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma|kinase-fusion|University of California, San Francisco|Yes|Not yet recruiting|October 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|44|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587650||10194|
NCT02583035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TelOG|Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy|Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy|TelOG|Centre Francois Baclesse|Yes|Recruiting|February 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|131|||Both|70 Years|N/A|No|||March 2016|March 10, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02583035||10548|
NCT02582125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-25|ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer|ONO-4538 Multicenter, Open-label, Single-arm, Phase II Study in Advanced Non-small Cell Lung Cancer||Ono Pharmaceutical Co. Ltd|No|Not yet recruiting|November 2015|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|N/A|No|||October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582125||10618|
NCT02582359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-276|MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age|Phase I Dose Escalation Study of Millennium 9708 in Combination With Induction and Consolidation Chemotherapy in Adults >= 60 Years With Acute Myeloid Leukemia||Massachusetts General Hospital|Yes|Not yet recruiting|November 2015|February 2022|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|60 Years|N/A|No|||October 2015|October 20, 2015|October 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582359||10600|
NCT02590055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-03-083|Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary|Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary||Samsung Medical Center|No|Recruiting|October 2015|September 2019|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590055||10009|
NCT02590068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OJE-0890|Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination|Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination||Rockefeller University|No|Recruiting|December 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590068||10008|
NCT02579187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIR-200C|Socket Study, Pilot Clinical Trial|Efficacy of Local Delivery of MIR200C in Promoting Osteogenesis and Modulating Local Inflammation: A Pilot Clinical Trial Using the Tooth Socket Model||University of Iowa|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579187||10843|
NCT02583256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V118_05E3|Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)|Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)||Novartis|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1600|||Both|18 Months|85 Months|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583256||10531|
NCT02582853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBS CD163|sCD163 as a Potential Biomarker in Guillain- Barré Syndrome|sCD163 as a Potential Biomarker in Guillain- Barré Syndrome|GBS|University of Aarhus|Yes|Recruiting|September 2015|January 2018|Anticipated|November 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|60|Samples Without DNA|Spinal fluid and blood sample for identification of different factors|Both|18 Years|100 Years|No|Non-Probability Sample|The study population will consist of two groups:          1. Patients diagnosed with GBS          2. Symptomatic controls|October 2015|October 21, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02582853||10562|
NCT02581891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17508|Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye|Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)||Bayer|No|Recruiting|November 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|50 Years|N/A|No|||March 2016|March 10, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581891||10636|
NCT02580149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBF-Tica-Clopi|The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment|The Effect of an Acute Dose of Ticagrelor or Clopidogrel and of Treatment for 14 Days on Ischemia-reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects.||Medical University of Vienna|No|Recruiting|October 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 17, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580149||10770|
NCT02580162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK104863-01A1|Success in Health: Impacting Families Together|Parents as Peer Interventionists in Treatment for Pediatric Weight Management|SHIFT|Seattle Children's Hospital|Yes|Recruiting|December 2015|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|304|||Both|7 Years|11 Years|No|||January 2016|January 27, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580162||10769|
NCT02580175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USEV|Surgical Evacuation of Abortion Under Ultrasonographic Guide|Surgical Evacuation of First Trimester Missed Miscarriage With or Without Use of Transabdominal Ultrasound||Assiut University|No|Completed|May 2014|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|40 Years|No|||October 2015|October 17, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02580175||10768|
NCT02594423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15070|Strategies for Management of Corneal Neovascularisation|Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment||University of Nottingham|Yes|Not yet recruiting|December 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594423||9673|
NCT02583087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20102015|ESD for the Treatment of Early Barrett's Neoplasia|Endoscopic Submucosal Dissection for the Treatment of Early Barrett's Neoplasia|ESTEBAN|Hôpital Cochin|No|Not yet recruiting|April 2016|April 2022|Anticipated|April 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|90 Years|No|Probability Sample|Patients aged 18 to 90 years old with a visible lesion suspected of adenocarcinoma arising        in a Barrett's esophagus amenable to resection by ESD.|October 2015|October 20, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583087|3 Years|10544|
NCT02590237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-304|KingVision Video Laryngoscopy vs Direct Laryngoscopy - Equivalence Trial|A Clinical Evaluation of the King Vision Video Laryngoscope aBlade System in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|N/A|2 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590237||9995|
NCT02590250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-140|A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India|||Allergan|No|Recruiting|November 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with urinary incontinence (due to NDO, eg, as a result of SCI or MS, or due to        OAB) who have an inadequate response to or are intolerant of an anticholinergic medication|January 2016|January 13, 2016|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590250||9994|
NCT02584322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14.386|Fast Tracking in VATS Lobectomy: A Prospective, Historically Controlled, Propensity-Matched Clinical Trial|Fast Tracking in VATS Lobectomy: A Prospective, Historically Controlled, Propensity-Matched Clinical Trial||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|November 2, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584322||10449|
NCT02583100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5428|Improving Outcomes in Cleft Palate Surgery|Improving Outcomes in Cleft Palate Surgery Through an Audit and Feedback Intervention Directed at Surgeons||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|7|||Both|N/A|N/A|No|||October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583100||10543|
NCT02586935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIDE-06-2015|Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders|A Randomized Placebo-controlled Trial of Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (ASD)|TIDE|Anagnostou, Evdokia, M.D.|Yes|Recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|12 Years|17 Years|No|||February 2016|February 9, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02586935||10248|
NCT02582619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE499/14|Multidisciplinary Model to Guide Employment Amongst PLWSCI|Development of a Multidisciplinary Model to Guide Employment Outcomes in People Living With Spinal Cord Injuries in South Africa.||University of KwaZulu|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|500|||Both|16 Years|65 Years|No|Probability Sample|Phase One :        Rehabilitation Professionals People living with Spinal Cord Injuries Representatives from        various working environment|October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02582619||10580|
NCT02593253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17709|The Effect of a Novel Audit and Feedback Bundle on Inpatient Performance|The Effect of a Novel Electronic Physician Audit and Feedback Bundle on Inpatient Performance Metrics||University of California, San Francisco|Yes|Recruiting|February 2016|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02593253||9763|
NCT02585102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC099|Motivating Value of Vegetables Study|Increasing the Relative Reinforcing Values of Vegetables by Incentive Sensitization|VegUp|USDA Grand Forks Human Nutrition Research Center|No|Recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585102||10389|
NCT02591667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-002917-30|Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer|Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer|CARCINOSIS|Medical University of Vienna|No|Not yet recruiting|December 2015|February 2020|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02591667||9885|
NCT02591680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL004|The Effect of Muscle Strengthening Associated With Neuromuscular Stimulus in Patients With Patellofemoral Pain During Negotiating Stairs|The Effect of Muscle Strengthening Associated With Neuromuscular Stimulus in Patients With Patellofemoral Pain During Negotiating Stairs: A Randomized Controlled Trial||University of Nove de Julho|Yes|Recruiting|March 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Female|18 Years|35 Years|No|||October 2015|October 28, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02591680||9884|
NCT02586571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-UI-IceAge2|Growth and Body Composition in Breastfed Infants - Study on Age of Introduction of Complementary Foods in Iceland|Growth and Body Composition in Breastfed Infants - Study on Age of Introduction of Complementary Foods in Iceland|IceAge2|University of Iceland|No|Enrolling by invitation|December 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|Urine samples will be obtained from all infants at 5.5 and 12 months of age. Breast milk      samples will be obtained from all mothers when the child is 5.5 months of age.|Both|5 Months|6 Months|No|Non-Probability Sample|Infants receiving routine care at well-baby clinics at primary health care centers in and        around Reykjavik, Iceland.|October 2015|October 23, 2015|October 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02586571||10276|
NCT02581007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 1132|RIC Transplant Using Haplo Donors|Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies||Northside Hospital, Inc.|No|Recruiting|November 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 29, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581007||10704|
NCT02585583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR DB RS2|Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study|Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study|PRDBRS2|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|No|Recruiting|May 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02585583||10352|
NCT02591745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H- 35126|International Fetal Anesthesia Database|International Fetal Anesthesia Database|iFAD|Baylor College of Medicine|No|Active, not recruiting|January 2015|January 2030|Anticipated|January 2027|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Mothers whose fetuses require fetal intervention for a variety of conditions. Fetuses who        have undergone surgical intervention while in-utero.|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591745|18 Years|9879|
NCT02591758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1919|Novel Vitality Indices Derived From the Hexoskin in Patients Affected With Angina Undergoing Coronary Revascularization or Medical Therapy|Novel Vitality Indices Derived From the Hexoskin in Patients Affected With Angina Undergoing Coronary Revascularization or Medical Therapy (NOVA-SKIN Study)|NOVA-SKIN|Montreal Heart Institute|No|Not yet recruiting|December 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Thirty (30) subjects who meet all of the inclusion criteria and none of the exclusion        criteria and who successfully wear the Hexoskin vest in the run-in will be eligible to        study participation. Subjects will be recruited as outpatient, from the specialized angina        clinic at the Montreal Heart Institute (MHI) or as an inpatient, after screening by the        research team.|October 2015|October 29, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02591758||9878|
NCT02520713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-169|The iCat2, GAIN Consortium Study|Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults With Recurrent, Refractory, or High Risk Solid Tumors: The iCat2, GAIN Consortium Study||Dana-Farber Cancer Institute|No|Recruiting|October 2015|July 2022|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|825|Samples With DNA|Tumor and Germline|Both|N/A|30 Years|No|Non-Probability Sample|High-risk, relapsed and refractory solid tumors|March 2016|March 4, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02520713||15334|
NCT02583230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH095907-FT|Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment (MedLink)|Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment (MedLink)||Northwestern University|No|Completed|April 2014|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02583230||10533|
NCT02583464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-TNF-EMT|Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.|Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.||Laboratorio Elea S.A.C.I.F. y A.|No|Completed|September 2014|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583464||10515|
NCT02582788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003161|Bathing Additives in Pediatric Atopic Dermatitis|Bathing Additives in Management of Pediatric Atopic Dermatitis||Mayo Clinic|No|Recruiting|October 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Months|17 Years|No|||January 2016|January 5, 2016|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02582788||10567|
NCT02582801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Molecular Imaging|Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer|18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients||Jinling Hospital, China|Yes|Recruiting|October 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Female|18 Years|70 Years|No|||October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582801||10566|
NCT02592616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15008542|Interval-training and Appetite Regulation in Patients With Type 2 Diabetes|Interval-training and Appetite Regulation in Patients With Type 2 Diabetes||Rigshospitalet, Denmark|No|Recruiting|October 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|14|||Both|30 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592616||9812|
NCT02517398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200647-001|MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications||EMD Serono|Yes|Recruiting|August 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|482|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02517398||15589|
NCT02584296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15-11061|Physical Activity as Self-Management Approach to Improve Health Outcomes in AML|Physical Activity as a Self-Management Approach to Improve Health Outcomes in Acute Myeloid Leukemia||Virginia Commonwealth University|Yes|Recruiting|March 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02584296||10451|
NCT02584309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510049|Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma|A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma||Washington University School of Medicine|No|Recruiting|February 2016|October 2022|Anticipated|October 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584309||10450|
NCT02584088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-029|Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation|Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation||TriHealth Inc.|No|Not yet recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are candidates for NovaSure ablation for treatment of menorrhagia.|December 2015|December 29, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584088||10467|
NCT02585206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA038139|Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment|Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment||Truth Initiative|Yes|Not yet recruiting|July 2017|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|18||Anticipated|1460|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585206||10381|
NCT02517684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52030.078.15|Top-down Infliximab Study in Kids With Crohn's Disease|Top-down Infliximab Study in Kids With Crohn's Disease|TISKids|Erasmus Medical Center|No|Enrolling by invitation|April 2015|||December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|17 Years|No|||August 2015|August 6, 2015|July 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02517684||15567|
NCT02579681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-BGT-12-10389|Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012|Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012|StarTec|Biogen|No|Active, not recruiting|April 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579681||10806|
NCT02590861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510M78701|Improving Oral Health Function With Implant Supported Partial Dentures|Improving Oral Health Function With Implant Supported Partial Dentures||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|January 2016|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02590861||9947|
NCT02589470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-a00733-46|COMETE Study : COgnitive Rehabilitation of MEmory in Temporal Epilepsy|COMET Study Effectiveness of a Cognitive Remediation Program of Memory in Patients With Temporal Lobe Epilepsy|COMETE|Central Hospital, Nancy, France|Yes|Not yet recruiting|January 2016|January 2019|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02589470||10054|
NCT02583646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160006|Investigating the Impact of Obesity on Pubertal Development in Girls|Investigating the Impact of Obesity on Pubertal Development in Girls||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|60|||Female|8 Years|14 Years|No|||October 2015|February 12, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02583646||10501|
NCT02583659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC004|The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study|The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study||Huazhong University of Science and Technology|No|Recruiting|January 2013|January 2018|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|DNA extracted from peripheral blood sample|Both|18 Years|75 Years|No|Probability Sample|Histopathology or cytopathology confirmed unresectable locally advanced, or recurrent, or        metastatic chemotheapy-naive gastric cancer and gastroesophageal adenocarcinoma patients|October 2015|November 10, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583659||10500|
NCT02589561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9594|REFIT Hearing: Remote Fitting of Hearing Aids|REFIT Hearing: Remote Fitting of Hearing Aids|REFITHEARING|University Hospital, Montpellier|No|Recruiting|October 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|84 Years|No|||October 2015|October 26, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02589561||10047|
NCT02582073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL204|A Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using Mobile EECs|A Double-blind Randomized Parallel Group Study of Three Cumulative Doses of Grass MATA MPL Compared to Placebo and Grass MATA in Patients With Seasonal Allergic Rhinoconjunctivitis Exposed to Grass Pollen in Mobile Environmental Exposure Chambers (mEECs™) Out of the Grass Pollen Season|G204|Allergy Therapeutics|Yes|Active, not recruiting|November 2015|January 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|265|||Both|18 Years|50 Years|No|||March 2016|March 18, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582073||10622|
NCT02582086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15E-0601|Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Topical Natural Health Product for the Treatment of Herpes Labialis||Laboratoire Boreaderme Inc.|No|Not yet recruiting|October 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582086||10621|
NCT02593812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00085073|The Impact of Standard Medical Care (Dopamine) and Practice on Postural Motor Learning in Parkinson's Disease|The Impact of Standard Medical Care (Dopamine) and Practice on Postural Motor Learning in Parkinson's Disease||University of Utah||Recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|50 Years|80 Years|No|||January 2016|January 12, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593812||9720|
NCT02520960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-30605|Unipolar Atrial Electrogram Modification Combined to the Contact Force Sensing Technology for Pulmonary Vein Isolation|Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation by Combining the Analysis of the Unipolar Atrial Electrogram Modification With the Contact Force Sensing Technology: The Uniforce Study|Uniforce|Hôpital Privé Les Franciscaines|Yes|Recruiting|November 2013|||January 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|80 Years|No|Probability Sample|Consecutive patients referred to the participating institutions, from November 2013 to        January 2015, for catheter ablation of symptomatic and drug resistant PAF. Paroxysmal AF        was considered any episode of AF that terminates spontaneously in less than seven days.|August 2015|August 8, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520960||15315|
NCT02588092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCT-301-002|Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)|A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia||ADC Therapeutics SARL|No|Recruiting|December 2015|August 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588092||10160|
NCT02583789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001879|Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Secondary Raynaud's Phenomenon|A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy||Brigham and Women's Hospital|No|Not yet recruiting|December 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02583789||10490|
NCT02584075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exen100|Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function|||Beijing Chao Yang Hospital||Not yet recruiting|November 2015|January 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|65 Years|No|||October 2015|October 21, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02584075||10468|
NCT02585193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15040047|Evaluation of a Commercial Program on Weight Loss and Health Outcomes|Evaluation of a Commercial Program on Weight Loss and Health Outcomes||University of Pittsburgh|No|Active, not recruiting|August 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02585193||10382|
NCT02588066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW-002|Pancreatoduodenectomy With or Without Ligamentum Teres Wrap Around Gastroduodenal Artery Stump for Prevention of Pancreatic Hemorrhage|Pancreatoduodenectomy With or Without Prophylactic Ligamentum Teres Hepatic Wrap Around the Gastroduodenal Artery Stump for Prevention of Pancreatic Hemorrhage - Panda - Multicentric Randomized Controlled Trial||Technische Universität Dresden|Yes|Recruiting|November 2015|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588066||10162|
NCT02588079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIPED20151008|Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety|Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety- A Randomized Controlled Trial||Karolinska Institutet|No|Recruiting|October 2015|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|8 Years|15 Years|No|||October 2015|October 26, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02588079||10161|
NCT02592356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0864|Tyrosine Kinase Inhibitors (TKI) and Body Composition|Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study||M.D. Anderson Cancer Center|No|Recruiting|November 2015|||November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592356||9832|
NCT02579005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-634|Radio-Immuno-Modulation in Lung Cancer|Radio-Immuno-Modulation for Advanced Lung Cancer: a Pilot Study Evaluating Tolerance and Immune Responses|RIM|Hopital du Sacre-Coeur de Montreal|Yes|Not yet recruiting|November 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02579005||10857|
NCT02581085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0112|Liver Trial on Oral Tocotrienol|Tocotrienol Against the Progression of End Stage Liver Disease||Ohio State University|Yes|Not yet recruiting|October 2015|December 2021|Anticipated|December 2020|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|June 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02581085||10698|
NCT02521233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACEMS0514OR-III|Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control||EMS|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|399|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521233||15294|
NCT02584803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103637|Inferior Vena Cava Assessment in Term Pregnancy Using Ultrasound: a Feasibility Study of Subxiphoid and RUQ Views|Inferior Vena Cava Assessment in Term Pregnancy Using Ultrasound: a Feasibility Study of Subxiphoid and RUQ Views||Lawson Health Research Institute|No|Not yet recruiting|April 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Full term pregnant patient coming for elective cesarean section|October 2015|March 11, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02584803||10412|
NCT02590978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPPAL-2015|Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis|Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis: A Randomized Prospective Study|CPPAL-2015|Hospital del Salvador|Yes|Recruiting|December 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590978||9938|
NCT02593058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105319_163355 / 1|Positive Emotions Program for Schizophrenia (PEPS)|Positive Emotions Program for Schizophrenia (PEPS): A Randomized Controlled Study on Improving Pleasure and Motivation in Schizophrenia|PEPS-RCT|Institut et Haute Ecole de la Santé la Source|No|Not yet recruiting|December 2015|November 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593058||9778|
NCT02523781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-1099|Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy|Evaluation of an Information Pamphlet to Improve Knowledge Concerning the Impacts and the Importance of Healthy Lifestyle After a Pregnancy With Hypertension||Université de Sherbrooke|No|Recruiting|June 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 13, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02523781||15098|
NCT02581683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-273-15|Magnesium Sulfate in Adductor Canal Blocks|Does Magnesium Sulfate as a Supplement in Adductor Canal Blocks Improve Pain Control After Total Knee Arthroplasty?||Queen's University|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|85 Years|No|||October 2015|October 20, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581683||10652|
NCT02581696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-LAF-CT-101|The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers|An Open-label, Multiple-dose, Single-arm, Phase 1 Study to Evaluate the Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers||Boryung Pharmaceutical Co., Ltd|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02581696||10651|
NCT02585856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001-02|Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma|Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma||First People's Hospital of Hangzhou|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02585856||10331|
NCT02580630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15006579|Achilles Tendinopathy Treated With Training and Injections|Achilles Tendinopathy Treated With Heavy Slow Resistance Training Supplemented With Injection of Glucocorticosteroid or Local Anaesthetic.||Bispebjerg Hospital|Yes|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580630||10733|
NCT02589886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc/2015/141|Self-help and Education on the Internet for Functional Motor Disorders|Self-Help and Education on the Internet for Functional Motor Disorders, a Randomised Controlled Trial (SHIFT)|SHIFT|University Medical Center Groningen|No|Not yet recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02589886||10022|
NCT02578719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.4.ISM.4.06.68.49/|Greater Occipital Nerve (GON) Blocks With Bupivacaine in the Treatment of Chronic Migraine: 6 Months Follow up|Placebo-Controlled Randomized Double Blind Trial of Blocking Greater Occipital Nerve Block With Bupivacaine Versus Saline in the Treatment of Chronic Migraine|GON|Bozok University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|55 Years|No|||October 2015|October 16, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02578719||10879|
NCT02578732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 318|FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial||Brown University|Yes|Not yet recruiting|January 2016|July 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578732||10878|
NCT02591550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|coughlongli|A Study on the Mechanism of Cough Hypersensitivity|||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|300|Samples Without DNA|mucosa of upper trachea|Both|17 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic cough group:nonsmokers with chronic cough lasting ≥ 8 weeks characterized by        irritating dry cough or small amount of sputum, sensitive to fumes，dust, cold air ,and        normal chest x-ray were enrolled.        Healthy control:healthy volunteers presented our hospital for healthy examination were        enrolled.|October 2015|October 28, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02591550||9894|
NCT02591563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIC 1610-A-15|Acute Otitis Media and Nasopharyngeal Colonization Caused by Vaccine Serotypes of Strep Pneumoniae in Healthy Children|A Study Evaluating Acute Otitis Media and Nasopharyngeal Colonization Caused by Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Children||Rochester General Hospital|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples Without DNA|middle ear fluid, throat swabs, and nasal swabs|Both|6 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy 6-36 month old children|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591563||9893|
NCT02580864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.27.NIHS|Bologna IBD Markers|Predictive Factors of Anti-TNFalfa-induced Deep Remission in Crohn's Disease||Nestlé|No|Recruiting|October 2015|February 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Blood, stool, biopsy and urine|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|120 adult patients with moderate-severe active Crohns disease with indication for anti-TNF        therapy according to the normal clinical practice        30 no-IBD controls with no GI disorders, as defined by medical history and standard        clinical chemistry values, afferent to the out-patient clinic|October 2015|October 22, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580864||10715|
NCT02586194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK10|Pharmacokinetics Study in Patients With Impaired Hepatic Function|Pharmacokinetic Study of ASP015K - Evaluation of Pharmacokinetics in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function||Astellas Pharma Inc|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586194||10305|
NCT02589951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 107073|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department||Lawson Health Research Institute|Yes|Completed|October 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients greater than or equal to 18 years of age presenting to London Health Sciences        Centre, Victoria Hospital emergency department between October 1, 2014 - July 31, 2015 who        were referred to adult psychiatry by the emergency physician|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589951||10017|
NCT02590601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-33-2015-1874 (MP)|Bromocriptine in the Treatment of Peripartum Cardiomyopathy|Bromocriptine in the Treatment of Peripartum Cardiomyopathy, A Bayesian Randomized Registry Trial|BRO-HF|Montreal Heart Institute|Yes|Not yet recruiting|January 2016|||July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02590601||9967|
NCT02590614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209517-REV1|Genetic, Dietary and Environmental Influences on Vitamin D Metabolism|Genetic, Dietary and Environmental Influences on Vitamin D Metabolism||Milton S. Hershey Medical Center|No|Enrolling by invitation|November 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|400|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02590614||9966|
NCT02591615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-09|Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC|Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer||Alliance Foundation Trials, LLC.|Yes|Recruiting|March 2016|December 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591615||9889|
NCT02591628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34HL119790|Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study|Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study|ThiaZIDES|HealthPartners Institute|Yes|Enrolling by invitation|August 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|December 10, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02591628||9888|
NCT02593708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149517|Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+|Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors||University of California, San Francisco|Yes|Recruiting|October 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593708||9728|
NCT02589990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAGE|Strength Training Adaptations, Age and Genes|Effect of Maximal Strength Training in Relation to Age and Genes|STAGE|Telemark University College|No|Not yet recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|90|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02589990||10014|
NCT02588118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGraz5|Gender and PK-PD of Propofol and Cisatracurium|Effect of Gender on the Pharmacokinetics-pharmacodynamics of Propofol and Cisatracurium Besylate|BIS5|Medical University of Graz|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|65 Years|No|Non-Probability Sample|differences between equal numbers of males and females|October 2015|October 24, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588118||10158|
NCT02586675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18332|TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer|The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586675||10268|
NCT02586688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-02219-000|Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents|A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents||Neuronetics|Yes|Recruiting|October 2015|December 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|12 Years|21 Years|No|||March 2016|March 24, 2016|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586688||10267|
NCT02586727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH-1-012015|Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy|Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy||Larkin Community Hospital|No|Not yet recruiting|October 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||October 2015|October 22, 2015|August 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586727||10264|
NCT02586740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00914|Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation|||Nationwide Children's Hospital|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical        repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary        collaterals.|October 2015|October 27, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586740||10263|
NCT02584231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2015/0616|Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population|Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population||University Hospital, Ghent|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Both|6 Months|8 Years|No|||October 2015|October 20, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02584231||10456|
NCT02584244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-015/2.6-002|Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers|Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers||Lumicell, Inc.|Yes|Not yet recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|21|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584244||10455|
NCT02583776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3440/AO/15|Continuous Glucose Monitoring and Preterm Infants|NEONATAL HYPOGLYCEMIA and CONTINUOUS GLUCOSE MONITORING: A RANDOMIZED CONTROLLED TRIAL IN PRETERM INFANTS|CGM&VLBWI|University Hospital Padova|Yes|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|50|||Both|N/A|2 Days|No|||October 2015|October 26, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583776||10491|
NCT02586922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVPT|Fetal Lung Volume and Pulmonary Artery Resistance Index Measurement in Term Diabetic Pregnancy|Fetal Lung Volume and Pulmonary Artery Resistance Index Measurement in Term Diabetic Pregnancy and Their Correlation With Neonatal Outcome: a Pilot Study||Ain Shams University|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective observational study which will be carried out at Ain Shams        University Maternity Hospital, Obstetrics and Gynecology department, Faculty of Medicine,        Ain Shams University, from December 2015 to December 2016.        Diabetic pregnant women 38 weeks gestation admitted for elective termination by Caesarian        section due to various obstetric indications|November 2015|November 21, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586922||10249|
NCT02578576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoEPR|The Diagnostic Methods of Early Postoperative Flare-up of Crohn's Disease|The Diagnostic Methods of Crohn's Disease Flare-up Within One Month After Resection||Jinling Hospital, China||Not yet recruiting|December 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|17 Years|75 Years|No|Probability Sample|Adult patients with Crohn's disease|October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578576||10890|
NCT02584504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC14305|Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin|ODYSSEY-NIPPON|Sanofi|Yes|Recruiting|November 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|159|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584504||10435|
NCT02579473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SER-214 Ia|A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214|A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration||Serina Therapeutics|Yes|Recruiting|December 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|40 Years|80 Years|No|||February 2016|February 18, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579473||10822|
NCT02579486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-002-2012-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2012|||||N/A|N/A|N/A||||||||||||||December 17, 2015|May 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579486||10821|
NCT02587169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC10-150 RETRONEO|Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum|GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum|GEIS-27|Broto, Javier Martín, M.D.|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|July 17, 2013|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587169||10230|
NCT02586961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140929|Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.|Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies : a Multicentre Randomized Controlled Trial|EPIDEX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|680|||Both|6 Weeks|12 Months|No|||September 2015|October 23, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02586961||10246|
NCT02580435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2356-15-SMC|Deciphering the Role of the Gut Microbiota in Multiple Sclerosis|Deciphering the Role of the Gut Microbiota in Multiple Sclerosis||Sheba Medical Center|No|Not yet recruiting|December 2015|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|520|Samples Without DNA|From each patient, the investigarors will obtain        1. Clinical metadata, including: Consent form; Medications; annual relapse rate;        2. Blood tests, including a complete blood count, complete biochemistry, lipid profile,           cholesterol profile;        3. Gut microbiota profile obtained from stool samples will be processed for shotgun           metagenomic sequencing and 16S rRNA profiling. Gut microbiota profiling will be done           from stool samples that will be immediately flash-frozen in liquid nitrogen and           preserved at a minimum of -80oC until further processing.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The Multiple Sclerosis Center at Sheba Medical Center is currently following and treating        3710 out of ~5000 MS patients in Israel and as such represents a unique opportunity to        unravel the role of the microbiome in MS, since it offers the possibility to identify        multiple subgroups of patients in an attempt to detect microbiome signatures. A total of        520 subjects will be included in the study as is further specified. The data for 100        healthy control subjects will be obtained from the Weizmann DataBank by Prof Eran Segal.|October 2015|October 28, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580435||10748|
NCT02588768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-665.347|Photobiomodulation Therapy in a Field Test With High-level Rugby Players|Phototherapy (With a Combination of Super-pulsed Laser and LEDs) in a Field Test With High-level Rugby Players||University of Nove de Julho|Yes|Completed|February 2015|January 2016|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02588768||10108|
NCT02587182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-011|Effects of Dry Needling on Patients With Myofacial Temporomandibular Disorders|||CEU San Pablo University|No|Completed|June 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587182||10229|
NCT02519686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201504136|Trendelenberg Versus Left Lateral Position for Colonoscopy|The Impact of Trendelenberg Positioning as Compared to Left Lateral Positioning on Ease of Colonoscope Insertion During Colonoscopy||Washington University School of Medicine|Yes|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Female|18 Years|N/A|No|Non-Probability Sample|Adults|August 2015|August 10, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02519686||15413|
NCT02581657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE0139-PT-CL-0002|Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM|Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus||PhaseBio Pharmaceuticals Inc.|No|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581657||10654|
NCT02589405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.105041|Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris|Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris|Benzac|Galderma|No|Completed|August 2015|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|12 Years|N/A|No|||February 2016|February 10, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02589405||10059|
NCT02579278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4121|Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion|Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion (ctDNA Trial)|ctDNA|Royal Marsden NHS Foundation Trust|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Three blood samples will be analysed for ctDNA. One blood sample will be taken at the time      of preoperative assessment, after chemoradiotherapy and two further samples will be taken      intraoperatively, from the mesenteric vein after the resected specimen has been removed from      the abdomen and from the peripheral vein of the patient's arm. For each of the blood samples      the presence or absence of ctDNA mutations (kras and p53) will be identified.|Both|18 Years|N/A|No|Non-Probability Sample|20 patients with persistently mrEMVI positive rectal tumours and 20 patients with        persistently mrEMVI negative rectal tumours|October 2015|October 16, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02579278||10836|
NCT02511977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SANTOSMU02|Evaluation Clinical and Radiographic Images in Dental Implants Rehabilitated With Overdentures|Evaluation Clinical and Radiographic Images in Dental Implants Rehabilitated With Overdentures||Santos Metropolitan University|Yes|Completed|April 2013|February 2015|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|64|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Initially, 80 individuals who underwent the installation of dental implants for making        overdentures in the Department of Implant Dentistry, Faculty of Dentistry, University of        Santo Amaro, São Paulo, Brazil, in 2007,were evaluated.According to the inclusion and        exclusion criteria, the final sample had 64 individuals of both genders, between 40 and 75        years old|July 2015|July 27, 2015|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511977||16003|
NCT02511990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA-0885|A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074|A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals||Rockefeller University|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Anticipated|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|July 24, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511990||16002|
NCT02590094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|Comparison of Interval Variation and Dosage in Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy|Comparison of Interval Variation and Dosage in Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy||Panhandle Eye Group, LLP|Yes|Recruiting|October 2015|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|85 Years|No|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590094||10006|
NCT02590107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6Z14|Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant|The Effect of Oral Supplementation and Improved Nutritional Status on Hematopoietic Stem Cell Transplant Patients||Case Comprehensive Cancer Center|Yes|Not yet recruiting|September 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|98|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590107||10005|
NCT02589652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81271833|Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy|Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study||Huashan Hospital|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|294|||Both|18 Years|60 Years|No|Probability Sample|Chronic Hepatitis B Patients with Low HBsAg and HBeAg Titers after Long-term Entecavir        Therapy|October 2015|October 27, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02589652||10040|
NCT02579551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.479|Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery|Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Facial Basal Cell Carcinomas||Thomas Jefferson University|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|179|||Both|N/A|N/A|No|||October 2015|October 16, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579551||10816|
NCT02579824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0101|DS-3032b for Relapsed and/or Refractory (RR) Myeloma|A Phase I Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579824||10795|
NCT02522936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-14-00800|Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use|Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use||University of Southern California|No|Enrolling by invitation|August 2015|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||August 2015|August 12, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02522936||15163|
NCT02587065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-PEG-14-10779|Plegridy Satisfaction Study in Participants|Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)|PLATINUM|Biogen|No|Recruiting|February 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|275|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587065||10238|
NCT02587130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0041|Ketamine and Refractory Painful Care in a Palliative Unit|The Effect and Tolerance of a Ketamine Subcutaneous Bolus, During Painful Care of Refractory Bed Sores, Ulcers and Vascular Wounds in a Palliative Care Unit|KETAREF|Lille Catholic University|No|Not yet recruiting|October 2015|August 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02587130||10233|
NCT02587442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBM-A01-H001|A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers|A Phase I Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers||Original BioMedicals Co. Ltd.|No|Recruiting|October 2015|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|27|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587442||10210|
NCT02580851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/11|Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention|Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention|MAGnet|University of Ulm|No|Recruiting|December 2011|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580851||10716|
NCT02581631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-436|A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)|A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)||Bristol-Myers Squibb|No|Recruiting|December 2015|November 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581631||10656|
NCT02585258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC-ARC-GLORIA|The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study|The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis|Gloria|VU University Medical Center|No|Not yet recruiting|March 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|65 Years|N/A|No|||October 2015|October 22, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585258||10377|
NCT02588755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-0123|TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection|Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection：A Randomized Controlled Study||Eastern Hepatobiliary Surgery Hospital|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588755||10109|
NCT02589236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N91115-2CF-05|Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor|SNO-6|Nivalis Therapeutics, Inc.|Yes|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589236||10072|
NCT02592629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2690|The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections|The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections||Milton S. Hershey Medical Center|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592629||9811|
NCT02592642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOG-13-003|the Evaluation of Four Non-operative Treatments for Degenerative Lumbar Spinal Stenosis|Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.||Mount Sinai Hospital, Canada|No|Recruiting|September 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|104|||Both|50 Years|N/A|No|||October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592642||9810|
NCT02583750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032421|Snooze Control: Sleep Duration & Glucose Metabolism|Snooze Control: The Effect of Sleep Deprivation on Glucose Metabolism||University of South Carolina|No|Completed|January 2014|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02583750||10493|
NCT02583282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT/IEC/2015/232|A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion|A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion||Postgraduate Institute of Medical Education and Research|No|Recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02583282||10529|
NCT02591953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15101504|Prospective Clinical Analysis of Ultrasound-guided Biceps Corticosteroid Injections|||Rush University Medical Center||Not yet recruiting|November 2015|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||October 2015|October 29, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02591953||9863|
NCT02520700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses|||St Vincent's University Hospital, Ireland|No|Completed|September 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 9, 2015|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520700||15335|
NCT02578654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-IM-2-082/57|Interventions to Improve HIV Care Engagement After Hospital Discharge|Interventions to Improve HIV Care Engagement Within 30 Days After Hospital Discharge Among HIV-infected Patients||Thammasat University|No|Recruiting|November 2012|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|240|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578654||10884|
NCT02578667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150294|Gorbly Compression Device for Use in Image-guided Procedures|Gorbly Compression Device for Use in Image-guided Procedures||University of Miami|No|Not yet recruiting|December 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|10|||Both|N/A|N/A|No|||October 2015|October 15, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02578667||10883|
NCT02586636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015DM13|Impact of OCT1 on Metformin Tolerance|Impact of OCT1 Genotype and OCT1 Inhibiting Drugs on an Individual's Tolerance of Metformin|ImpOCT|NHS Tayside|No|Not yet recruiting|November 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586636||10271|
NCT02580578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-UPA-15-001|A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids|||Allergan|No|Recruiting|July 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|N/A|No|Probability Sample|Patients diagnosed with uterine fibroids treated as per standard of care in clinical        practice.|March 2016|March 23, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580578||10737|
NCT02580591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.72|Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)||Boehringer Ingelheim||Recruiting|October 2015|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|960|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 19, 2015||||No||https://clinicaltrials.gov/show/NCT02580591||10736|
NCT02580604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0878|PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)|PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)||University of Colorado, Denver|No|Recruiting|November 2015|May 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580604||10735|
NCT02523339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UI-CRVO-2015|Study of Retinal Oxygenation in Central Retinal Vein Occlusion|Multicenter Study of Retinal Oxygenation in Central Retinal Vein Occlusion||University of Iceland||Recruiting|October 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected central retinal vein occlusion (CRVO) will be invited to        participate.|August 2015|August 11, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02523339||15132|
NCT02594683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI.2.C/B|A Follow-up Study to Investigate the Effects of a New Infant Formula on Growth and Body Composition|A Follow-up Study of a Randomised, Controlled, Study to Investigate the Effects of a New Infant Formula Given in the First 12 Months of Life on Growth and Body Composition up to 5 Years of Age|VenusFU|Danone Asia Pacific Holdings Pte, Ltd.|No|Recruiting|August 2015|June 2020|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|540|Samples Without DNA|Stools, saliva and blood (optional)|Both|3 Years|5 Years|Accepts Healthy Volunteers|Probability Sample|Participation in the intervention period of VENUS study until 12 months of age or        participation in the VENUS study as breast-fed reference group|October 2015|November 2, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594683||9653|
NCT02580474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-118|The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure|The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure||The Catholic University of Korea|No|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|19 Years|N/A|No|||February 2016|February 24, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580474||10745|
NCT02589015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-887/2|Correlation of Neck Circumference With Difficult Mask Ventilation and Difficult Laryngoscopy in Morbidly Obese Patients|Correlation of Neck Circumference With Difficult Mask Ventilation and Difficult Laryngoscopy in Morbidly Obese Turkish Patients: A Prospective Clinical Trial||Istanbul University|Yes|Completed|March 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with body mass index (BMI) > = 40, applied for elective surgery.|February 2016|February 10, 2016|August 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02589015||10089|
NCT02589223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSS2015|A Trial to Determine the Feasibility and Effectiveness of Early Multisensory Stimulation Intervention in Patients in the Trauma-Neurosurgical Intensive Care Unit (TNICU) Following Severe Acquired Brain Injury|A Pilot Randomized Controlled Trial to Determine the Feasibility and Effectiveness of Early Multisensory Stimulation Intervention in Patients in the Trauma-Neurosurgical Intensive Care Unit (TNICU) Following Severe Acquired Brain Injury||St. Michael's Hospital, Toronto|No|Recruiting|March 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02589223||10073|
NCT02591602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2009 -1550148|Teleradiology Program for Frail Patients Living at Home or in Nursing-homes|Teleradiology Program for Frail Patients Living at Home or in Nursing-homes|RADHOME|Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Completed|November 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|162|||Both|65 Years|N/A|No|||October 2015|October 28, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02591602||9890|
NCT02592980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF|Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients|Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients With Low Time in Therapeutic Range - Study Design||University of Sao Paulo General Hospital|Yes|Not yet recruiting|October 2015|||October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592980||9784|
NCT02593500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-BUD01|Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg|A Single Center, Single Dose, Open-label, Randomized, Two Period Crossover Study to Determine the Bioequivalence of Two Inhalation Formulations Containing Budesonide 200 µg Administered as 3 Puffs (Total Dose of 600 µg) in at Least 52 Healthy Males and Females Under Fasting Conditions||Reig Jofre Group|No|Completed|April 2014|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593500||9744|
NCT02593513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-103|Diafert for Embryo Selection and Fertility Improvement (DESTINy)|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval|DESTINy|Forest Laboratories|No|Recruiting|October 2015|November 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593513||9743|
NCT02584348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013.790|Gastric Ultrasound in Paediatric Anaesthesia|Ultrasound Assessment of Gastric Contents : the Way to Best Induce Children for Emergency Surgery|ECHOGASTRO|Hospices Civils de Lyon|No|Recruiting|November 2013|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|N/A|18 Years|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584348||10447|
NCT02584582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2014-128|The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate|The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes|ALFA-1|Hvidovre University Hospital|No|Enrolling by invitation|July 2015|||November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02584582||10429|
NCT02585414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070115|Assessment of TFT by OCT in Healthy Subjects and Subjects With DES|Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease||Medical University of Vienna|No|Not yet recruiting|November 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|340|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|85 healthy subjects with no history of DES 255 subjects with DES|October 2015|October 22, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02585414||10365|
NCT02523625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9776|Giant Cell Arteritis: Improving Use of Ultrasound Evaluation|Can we Use Ultrasound in the Diagnosis and Monitoring of Patients With Giant Cell Arteritis?|GAULT|University of Oxford|No|Not yet recruiting|October 2015|June 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|250|Samples With DNA|Serum Plasma Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with suspected or diagnosed giant cell arteritis|August 2015|August 12, 2015|August 4, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523625||15110|
NCT02588365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30874-2|Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment|Randomized Controlled Trial of Executive Function Training in Children With or At-risk for Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function (EF) Impairment||Stanford University|Yes|Recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588365||10139|
NCT02582606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3/15|Meal Pattern and Metabolic Parameters|Effects of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles and Plasma Lipoproteins in Obese Women||University of Nottingham|No|Completed|February 2014|May 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582606||10581|
NCT02514707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST/0113/15|Outcomes of HIV Infected Individuals After Ten Years on Antiretroviral Treatment|Outcomes of HIV Infected Individuals After Ten Years on Antiretroviral Treatment|ART Long Term|Makerere University|No|Recruiting|January 2015|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|plasma (4 aliquots), serum (4 aliquots), packed cells pellets (5 aliquots) for each patient|Both|18 Years|N/A|No|Non-Probability Sample|Patients on ART for more than 9 years receiving care and treatment through the adult        clinic at the Infectious Diseases Institute in Kampala, Uganda|July 2015|July 30, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02514707||15795|
NCT02585804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB# 14-8284-B|Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects|Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"|TRANSLATE|University Health Network, Toronto|No|Recruiting|September 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585804||10335|
NCT02585934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVT-101-3001|Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study|A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease||Axovant Sciences Ltd.|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1150|||Both|50 Years|85 Years|No|||March 2016|March 21, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585934||10325|
NCT02579148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTH-922-DYT|Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes|Collagen Scaffolds Loaded With Human Umbilical Cord Mesenchymal Stem Cells for the Improvement of Erectile Function in Men With Diabetes||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|No|Recruiting|September 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|65 Years|No|||October 2015|October 16, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579148||10846|
NCT02582528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCalgary-MAT|Cognitive Remediation in Youth at Risk of Serious Mental Illness|Pilot Study of Cognitive Remediation and Motivational Interviewing on Cognition and Functioning in Young People at Risk of Serious Mental Illness||University of Calgary|No|Recruiting|February 2016|February 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|14 Years|25 Years|No|||March 2016|March 22, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582528||10587|
NCT02586857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-ST-209|A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)|A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)||Acerta Pharma BV|Yes|Recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586857||10254|
NCT02581540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808/15|Mersey Acute Coronary Syndrome Rule-Out Using High Sensitive Troponin|Mersey Acute Coronary Syndrome Rule-Out Using High Sensitive Troponin (MACROS) : A Comparison of Risk Scores in Consecutive, Unselected Chest Pain Presentations With Suspected Acute Coronary Syndrome in the Era of High Sensitive Troponin|MACROS|Aintree University Hospitals NHS Foundation Trust|No|Not yet recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3056|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the emergency department at a single large teaching hospital-        Aintree University Hospital, Merseyside between June 2011 and November 2011 with suspected        cardiac chest pain|January 2016|January 12, 2016|July 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02581540||10663|
NCT02586493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201071|Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects|An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|252|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586493||10282|
NCT02579408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP LDLT|Quantifying Steatosis in Liver Transplant Donors|Controlled Attenuation Parameter for the Evaluation of Donor Steatosis in Living Donor Liver Transplantation||The University of Hong Kong|No|Recruiting|October 2015|March 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum and plasma for storage in anticipation of future biomarkers for the prediction of      improved post-transplant outcomes|Both|18 Years|70 Years|No|Non-Probability Sample|Donors of living donor liver transplantation conducted in Queen Mary Hospital, Hong Kong|October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02579408||10826|
NCT02578979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPD1E0891|Serial ECG Versus Holter to Detect Atrial Fibrillation in Elderly Ischemic Stroke Patients|Serial Electrocardiogram Versus Holter to Detect Atrial Fibrillation in Elderly Patients With Acute Ischemic Stroke: Study Protocol of a Randomized Controlled Trial||Chang Gung Memorial Hospital|No|Recruiting|August 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Both|65 Years|N/A|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578979||10859|
NCT02581787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0071|SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer|Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer||Stanford University|Yes|Not yet recruiting|November 2015|||May 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581787||10644|
NCT02594358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00066787|Caffeine in Amblyopia Study||CAS|Johns Hopkins University|No|Recruiting|October 2014|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|13 Years|No|||October 2015|October 30, 2015|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594358||9678|
NCT02579902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ir.ajums.rec.1394.306|Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome|Effect of Vitamin D3 Supplementation on Clinical Signs, Oxidative Stress and Inflammatory Biomarkers in Patients With Irritable Bowel Syndrome||Ahvaz Jundishapur University of Medical Sciences||Completed|February 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|70 Years|No|||November 2015|November 27, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02579902||10789|
NCT02592083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDIX LumA|Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors|PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|PREDIX LumA|Karolinska University Hospital|No|Recruiting|October 2015|December 2023|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|41 Years|N/A|No|||October 2015|October 28, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592083||9853|
NCT02591147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDF|Silver Diamine Fluoride Pilot Study (SDF)|Effectiveness of Silver Diamine Fluoride in Arresting Early Approximal Carious Lesion Progression: A Pilot Study|SDF|University of Iowa|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|144|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591147||9925|
NCT02593760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO29806|A Study to Evaluate Efficacy and Safety of Vismodegib (Erivedge) in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)|||Hoffmann-La Roche||Recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593760||9724|
NCT02594410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhaoke-1503-zanidip|Zainidip in Renal Artery Stenosis|The Efficacy of Renal Artery Stent Combined With Standardized Medical Therapy in Patients With Atherosclerotic Renal Artery Stenosis||Lee's Pharmaceutical Limited|No|Completed|September 2011|May 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|40 Years|75 Years|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594410||9674|
NCT02588053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2927|Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?|Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).||University of Colorado, Denver|No|Recruiting|July 2014|||August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|146|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Relapsing Multiple Sclerosis and Healthy Controls|October 2015|October 23, 2015|July 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02588053||10163|
NCT02588391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30874|Brain Training in Preterm Children at Risk for Inattention, Hyperactivity, and Executive Function Impairment|Randomized Controlled Trial of Executive Function Training in Preterm Children at Risk for Inattention, Hyperactivity and Executive Function Impairment||Stanford University|Yes|Recruiting|October 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588391||10137|
NCT02591186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L15-117|Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing IVF|Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing In Vitro Fertilization (IVF)|AcupunctIVF|Texas Tech University Health Sciences Center|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|70|||Female|21 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02591186||9922|
NCT02582450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Veritas-Validation|Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia|Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia. Veritas-Pro Project||Real Fundación Victoria Eugenia|No|Recruiting|September 2015|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Male|13 Years|65 Years|No|Non-Probability Sample|Patients with haemophilia around the country that will participate in study.|October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02582450||10593|
NCT02582463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0525|Development of the Medicines Optimisation Assessment Tool|Development of the Medicines Optimisation Assessment Tool (MOAT) - Targeting Hospital Pharmacists' Input to Reduce Risks and Improve Patient Outcomes|MOAT|University College, London|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Medical Division (General, Emergency, and Elderly Medicine) at        the Luton and Dunstable University Hospital|October 2015|December 8, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02582463||10592|
NCT02588170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-012-00CH4|Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors|A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors||Hutchison Medipharma Limited|Yes|Recruiting|December 2015|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|273|||Both|18 Years|N/A|No|||October 2015|December 11, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588170||10154|
NCT02588183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-3064: COR ADVANCE Study|PV Cryoablation Efficacy (COR ADVANCE Study)|PV Cryoablation Efficacy Using Electrophysiological Endpoints and the New Generation ArticFont Advance ST Catheter (COR ADVANCE Study)|COR-ADVANCE|Hospital San Carlos, Madrid|No|Recruiting|August 2015|November 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588183||10153|
NCT02584023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1509-063-703|Lung Ultrasound and Alveolar Recruitment in Mechanically Ventilated Infants|Preventive Effect of Lung Ultrasound and Alveolar Recruitment on Atelectasis in Mechanically Ventilated Infants||Seoul National University Hospital|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|N/A|1 Year|No|||February 2016|February 17, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584023||10472|
NCT02584036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015|Project IMPACT Immunizations (IMProving America's Communities Together)|Project IMPACT Immunizations (IMProving America's Communities Together)||American Pharmacists Association Foundation|No|Active, not recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients receiving an influenza vaccine|October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584036||10471|
NCT02591238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81470585|Melatonin in Smoke-induced Vascular Injury|The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human||Peking Union Medical College Hospital|Yes|Completed|June 2015|October 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|68|||Both|25 Years|39 Years|Accepts Healthy Volunteers|||June 2015|February 3, 2016|October 26, 2015||No||No|November 23, 2015|https://clinicaltrials.gov/show/NCT02591238||9918|Limitations. First, the dose-dependent manner of melatonin should be considered. Second, the duration of smoke exposure and melatonin administration time should be prolonged. Lastly,the levels of melatonin at different time points should be examined.
NCT02591251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCL|Povidone-iodine Versus Normal Saline Solution in Vaginal Cleansing in Laparoscopy|A Comparison Between Povidone-iodine and Normal Saline Solution in Preoperative Vaginal Cleansing in Laparoscopic Surgery: a Randomized Clinical Study||Assiut University|No|Recruiting|October 2015|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Female|20 Years|40 Years|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591251||9917|
NCT02591264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-14-HYMC|Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Troponin negative patients assigned for stent implantation in our medical institution.|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591264||9916|
NCT02584764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hoarding Pilot|Internet Supported Group Cognitive Behavior Therapy (CBT) for Hoarding Disorder (HD)|Internet Supported Group Cognitive Behavior Therapy for Hoarding Disorder - A Pilot Study||Karolinska Institutet|No|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02584764||10415|
NCT02584777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381401|A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis|A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis||Baxalta US Inc.|Yes|Not yet recruiting|November 2015|August 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584777||10414|
NCT02580513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54897.068.15|Circadian Misalignment and Insulin Sensitivity|Impact of Circadian Misalignment on Insulin Sensitivity||Maastricht University Medical Center|No|Not yet recruiting|December 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|14|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580513||10742|
NCT02591589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P-000398|Fraction of Inspired Oxygen (FiO2), Partial Pressure of Arterial Oxygen (PaO2) and Neurocognition After Cardiac Surgery|The Relationship Between Administered Oxygen Levels and Arterial Partial Oxygen Pressure to Neurocognition in Post-operative Mechanically Ventilated Cardiac Surgical Patients||Beth Israel Deaconess Medical Center|No|Recruiting|July 2015|March 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||October 2015|October 28, 2015|February 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02591589||9891|
NCT02522858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-2015-101|Anticholinergic Premedication for Sedation With Dexmedetomidine During Spinal Anesthesia|||Inje University||Completed|August 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|20 Years|N/A|No|||January 2016|January 14, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02522858||15169|
NCT02586298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501-VLC-005-AP|Autologous Mitochondrial Transfer in ICSI to Improve Oocyte and Embryo Quality in IVF Patients. Pilot Study|Autologous Mitochondrial Transfer as a Complementary Technique to ICSI to Improve Oocyte and Embryo Quality in IVF Patients. Pilot Study||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|42 Years|No|||October 2015|October 30, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586298||10297|
NCT02586311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144HT15027|CKD-330 Phase 3 Trial in Amlodipine Non-responder|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|December 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|19 Years|N/A|No|||October 2015|October 23, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586311||10296|
NCT02594540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA2016|Mechanical Peripheral Stimulation Effects for Parkinson's Disease Rehabilitation|Mechanical Peripheral Stimulation Effects for Parkinson's Disease Rehabilitation - A Randomized Clinical Trial||Federal University of Health Science of Porto Alegre|No|Recruiting|December 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594540||9664|
NCT02594553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw GGG - 836021022|Optimizing Management and Medication of Febrile Children in Out-of-hours Primary Care: CHILI Cluster RCT|Optimizing Management and Medication of Febrile Children in Out-of-hours Primary Care: the CHILI Cluster Randomised Trial|CHILI|Maastricht University Medical Center|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1262|||Both|3 Months|12 Years|No|||October 2015|December 3, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02594553||9663|
NCT02583607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81/15|Brava and Fat Transfer for Breast Reconstruction|Brava and Fat Transfer for Breast Reconstruction|Brava|Shaare Zedek Medical Center|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02583607||10504|
NCT02583620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 036 08|Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia|Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia|ASSOMYP|University Hospital, Toulouse|No|Completed|September 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|553|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02583620||10503|
NCT02516631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-201|Comparative Bioavailability Study of Two Misoprostol Formulations|A Comparative, Open-label, Parallel Design, Bioavailability Study of Two Misoprostol Formulations (Angusta™ 25 µg Dispersible Tablets vs. Cytotec® 200 µg Tablets) Following Single Oral or Sublingual Administration and Comparison of Safety of the Two Formulations Following Repeat Dosing Until Labour||Region Skane|No|Recruiting|November 2014|December 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Female|18 Years|N/A|No|||June 2015|August 3, 2015|June 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516631||15648|
NCT02578927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUParaíba|Green Tea Attenuates Pressure Reduction Induced by a Session of Physical Exercise|Green Tea Attenuates Pressure Reduction Induced by a Session of Physical Exercise||Federal University of Paraíba|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|15|||Both|40 Years|59 Years|No|||October 2015|October 16, 2015|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578927||10863|
NCT02578940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BED-004|Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer|A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment|FALCON|Blue Earth Diagnostics|No|Recruiting|November 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578940||10862|
NCT02582554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052454|Efficacy of Nutrition Risk Screening With NutriSTEP® in Preschoolers|Efficacy of Nutrition Risk Screening With NutriSTEP® in Preschoolers|NutriSTEP|University of Guelph|No|Not yet recruiting|October 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|154|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02582554||10585|
NCT02583854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|573099|Comparison Study of Compression Devices Used in Transradial Coronary Angiography|||Oslo University Hospital|Yes|Recruiting|September 2015|April 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 24, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02583854||10485|
NCT02583867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052015-018|Predictors of Depression Treatment Response to Exercise|Predictors of Depression Treatment Response to Exercise||University of Texas Southwestern Medical Center|No|Not yet recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02583867||10484|
NCT02512562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-335-602|A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers|A Phase-1, Open-label, Two Group, Fixed-Sequence Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers||Alios Biopharma Inc.|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02512562||15958|
NCT02512822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBC13251D|Usefulness of Non-invasive Radiofrequency Therapy for Facial Contouring|Usefulness of Non-invasive Radiofrequency Therapy for Facial Contouring|UNIRFFC|Kangbuk Samsung Hospital|Yes|Completed|November 2013|July 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|July 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512822||15938|
NCT02590406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ 21211|EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation|EPO2-A: Evaluation of Different Pre-Oxygenation Condition in Morbid Obesity: Effect of Position and Positive Pressure Ventilation During General Anesthesia Induction|EPO2-A|Laval University|No|Recruiting|September 2015|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|21 Years|70 Years|No|||January 2016|January 11, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02590406||9982|
NCT02593942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YTU-2014|Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy|Effect of Remifentanil Infusion Alone During the Closure Period for Early Emergence and Hemodynamic Stability in Patients Undergoing Supratentorial Craniotomy||Yeditepe University Hospital|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|No|||October 2015|October 29, 2015|October 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593942||9710|
NCT02584959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP616-300|Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema|A Phase 3, Randomized, Double-blind, Placebo-controlled,Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema||Shire||Recruiting|January 2016|August 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|66|||Both|12 Years|N/A|No|||March 2016|March 7, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584959||10400|
NCT02588313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS910/15|Investigation of Long-term Effects of CarelessTM on Microcirculation|Investigation of Long-term Effects of CarelessTM on Microcirculation in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design||Vital Solutions Swiss AG|No|Recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 24, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588313||10143|
NCT02588482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/2012/46|Comparison Between High-density Electroencephalography and Conventional Electroencephalography for Comatose Patients|Comparison Between High-density Electroencephalography and Conventional Electroencephalography to Diagnose the Presence of Consciousness in Post-anoxic Comatose Patients|COMETIQUE|Centre Hospitalier Universitaire de Besancon|No|Recruiting|November 2014|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|66|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588482||10130|
NCT02594514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPauloLSG|Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Effects on Metabolism|Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Effective for Resolution of Cardiovascular Comorbidities||University of Sao Paulo General Hospital||Completed|January 2007|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22|||Both|14 Years|19 Years|No|Non-Probability Sample|Severe obese adolescents who underwent laparoscopic sleeve gastrectomy|October 2015|October 30, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02594514||9666|
NCT02579785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-007-14|Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in Bangladesh|Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh||Marie Stopes International|No|Recruiting|December 2015|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|969|||Female|18 Years|49 Years|No|||February 2016|February 4, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579785||10798|
NCT02579083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB66-01|Vaginal Antibody Safety Trial: Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV)|A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide|VAST|LeafBio, Inc.|Yes|Recruiting|January 2016|||October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|43|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579083||10851|
NCT02579096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|594|Gout: Allopurinol vs. Febuxostat|CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat||VA Office of Research and Development|No|Not yet recruiting|April 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|950|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579096||10850|
NCT02590679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPVI-2013|Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p|Multi-center Trial of Percutaneous Pulmonary Valve Implantation Using Venus-P Valve for Patients With Severe Pulmonary Regurgitation and Native Right Ventricular Outflow Tract After Previous Surgical Repair|Venus-P|Shanghai Zhongshan Hospital|Yes|Recruiting|May 2013|February 2017|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|10 Years|60 Years|No|||October 2015|October 28, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02590679||9961|
NCT02590692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPT-14-01|Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD|A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)||Regenerative Patch Technologies, LLC|Yes|Recruiting|October 2015|September 2022|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|55 Years|85 Years|No|||January 2016|January 5, 2016|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590692||9960|
NCT02587897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00004|Musculoskeletal Health of the Upper Extremity in Emerging Health Professionals|Sonographic Tissue Morphology in Early Stage Work-related Median Nerve Pathology||University of Southern California|No|Enrolling by invitation|October 2015|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll a total of 120 dental hygiene students from the University of Southern        California (USC) and Loma Linda University (LLU), as well as 60 occupational therapy        students from USC.|October 2015|October 26, 2015|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587897||10175|
NCT02588417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no id|Intrathecal Dexamethasone and Labor Analgesia|Intrathecal Levobupivacaine Versus A Combination of Levobupivacaine and Dexamethasone in Parturients Receiving Combined Spinal Epidural for Vaginal Delivery Analgesia: A Comparative Study.||Kasr El Aini Hospital|No|Completed|July 2015|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Female|18 Years|35 Years|No|||October 2015|October 27, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588417||10135|
NCT02588430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-PMS-TU-2013|Post-Marketing Surveillance of Patients Using the Subretinal Retina Implant Alpha|Post-Marketing Surveillance of Patients Using the Subretinal Retina Implant Alpha||Retina Implant AG|No|Not yet recruiting|January 2016|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients receiving a Retina Implant Alpha at the study site.|October 2015|October 26, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02588430|3 Years|10134|
NCT02580344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUD_Ibuprofen|The Effect of Ibuprofen on Intrauterine Contraceptive Device|The Effect of Ibuprofen on the Uterine Blood Flow in Women With Menorrhagia Associated Intrauterine Contraceptive Device||Assiut University|No|Recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|20 Years|40 Years|No|||October 2015|October 18, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580344||10755|
NCT02523092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17300|Use of CXCL9 as a Biomarker of Acthar Efficacy|Use of CXCL9 as a Biomarker of Acthar Efficacy|Acthar|University of California, San Francisco|No|Not yet recruiting|October 2015|March 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|August 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523092||15151|
NCT02583204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15ON391|Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions|Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions||NHS Greater Glasgow and Clyde|No|Not yet recruiting|October 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02583204||10535|
NCT02583217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANK-42476|Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions|Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions||Ankara University|No|Recruiting|April 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Female|18 Years|65 Years|No|Probability Sample|Surgery performed with laryngeal mask as airway tool in gynecologic clinic|January 2016|January 17, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02583217|1 Day|10534|
NCT02592213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150109|Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer|Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer||Odense University Hospital|Yes|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|70 Years|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592213||9843|
NCT02584946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1513|Avenanthramides and Exercise|Effect of Avenanthramides Supplement on Exercise-induced Physiological and Psychological Changes||PepsiCo Global R&D||Not yet recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584946||10401|
NCT02580487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH01012012|Perioperative Pain Management of Pediatric Appendectomy Patients|Perioperative Pain Management of Pediatric Appendectomy Patients in Kuopio University Hospital During the Years 2010-2012|umpikipu|Kuopio University Hospital|No|Completed|January 2012|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|178|||Both|N/A|18 Years|No|Probability Sample|152 pediatric patients that were operated on in KUH during the years 2010-2012 due to        acute appendicitis.        In addition we assessed 26 pediatric appendectomy patients and their pain at rest, when        coughing and when compressing the wound area propsectively when they were at hospital|October 2015|October 19, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580487||10744|
NCT02590874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNTHSC IRB#2015-128|The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment|The Depression and Memory Trial|DEMO|University of North Texas Health Science Center|Yes|Recruiting|January 2016|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|50 Years|N/A|No|||January 2016|January 11, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02590874||9946|
NCT02581267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107073|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department||Western University, Canada||Active, not recruiting|October 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Adults emergency room patients referred to adult psychiatry by the emergency physician|October 2015|October 19, 2015|August 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02581267||10684|
NCT02581852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Workability in RA|Workability in Patients With Seropositive Rheumatoid Arthritis|||Kaiser Franz Josef Hospital|No|Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|July 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02581852||10639|
NCT02582164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060018|Long-Working Distance OCT for Children|Long-Working Distance OCT System With Fixation Alignment for Pediatric Imaging|LWDOCT|Duke University|Yes|Recruiting|June 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|250|||Both|6 Months|N/A|Accepts Healthy Volunteers|||August 2015|October 19, 2015|September 3, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582164||10615|
NCT02580461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-2478|Renewing Caregiver Health and Well-being Through Exercise|Renewing Caregiver Health and Well-being Through Exercise: A Randomized Controlled Trial|RECHARGE|University of Calgary|No|Recruiting|June 2015|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580461||10746|
NCT02589418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-DENT-Psy|Mechanisms of Acupuncture Analgesia on Experimental Dental Pain - A Psychophysical Study (Phase1)|Mechanisms of Acupuncture Analgesia on Experimental Dental Pain - A Randomized, Single Blinded, Sham-controlled Psychophysical Study (Phase1)|MAC-DENT1|University of Zurich|Yes|Completed|October 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02589418||10058|
NCT02591693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC number 14/SC/1104|Individualised Informal Caregiver Training for Palliative Care at Home|Feasibility Study: Improving Caregiver Confidence in Their Ability to Look After Patients With Palliative Care Needs, Using Focused One to One Training in the Home||University of Oxford|No|Recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02591693||9883|
NCT02514395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Translation & Linguistic Validation of Knee and Osteoarthritis Outcome Score (KOOS) Questionnaire in Marathi Language|Translation & Linguistic Validation of Knee and Osteoarthritis Outcome Score (KOOS) Questionnaire in Marathi Language: Cross Section Survey||TPCT's Terna College of Physiotherapy|No|Completed|September 2012|November 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|32|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Eligible subjects who the fulfilled the inclusion criteria were register for the study.|July 2015|July 31, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02514395||15819|
NCT02514408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-15-7|Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer|The Impact Radical Cystectomy Has on the Expulsion of Circulating Tumor Cells||University of Southern California|Yes|Not yet recruiting|September 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with transitional cell bladder cancer scheduled to undergo open radical        cystectomy.|July 2015|July 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02514408||15818|
NCT02593955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150612003|The Effects of a High Intensity Exercise Training Program in Patients With Parkinson's Disease|The Effects of a High Intensity Exercise Training Program on Sleep and Vigilance in Patients With Parkinson's Disease (The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD Patients)||University of Alabama at Birmingham|Yes|Recruiting|September 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|75|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2015|October 30, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593955||9709|
NCT02593968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhaoke-1504-Yallaferon|Yallaferon in Chinese Population|a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection||Lee's Pharmaceutical Limited|No|Recruiting|September 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|25 Years|65 Years|No|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593968||9708|
NCT02581514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I14028/EOSINOPHILIM|Eosinophilia Diagnosis|Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia|EOSINOPHILIM|University Hospital, Limoges|No|Recruiting|October 2015|November 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|53|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581514||10665|
NCT02581527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0190|A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin Daily for 4 Months for Pulmonary Tuberculosis|An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis|RIFASHORT|St George's, University of London|Yes|Not yet recruiting|June 2016|December 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|820|||Both|18 Years|65 Years|No|||October 2015|March 24, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581527||10664|
NCT02587247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0428|ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer|Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel|iTEP Colon|Nantes University Hospital|No|Recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02587247||10224|
NCT02589821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-012-00CH3|Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors|A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors||Hutchison Medipharma Limited|Yes|Recruiting|December 2015|September 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|195|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589821||10027|
NCT02589834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPOP|The Effect of Quran of Post Operative Pain|The Effect of Listening to Quran During Cesarean Section on Postoperative Pain||Assiut University|No|Completed|April 2015|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Female|20 Years|40 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589834||10026|
NCT02590302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrensHEO|Improving Transitions in Care for Children and Youth With Mental Health Concerns|Improving Transitions in Care for Children and Youth With Mental Health Concerns: Implementation and Evaluation of an Emergency Department Mental Health Clinical Pathway||Children's Hospital of Eastern Ontario|No|Not yet recruiting|January 2016|September 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|3095|||Both|6 Years|18 Years|No|||October 2015|October 27, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02590302||9990|
NCT02593721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE0072015|Hypoalgesic Effect of Neural Mobilization Versus Ibuprofen Pharmacologic Treatment|Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain||Universidad Europea de Madrid|Yes|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|No|||October 2015|October 30, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02593721||9727|
NCT02593734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFR|Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana|Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana|JFR|University of Ghana Medical School|Yes|Completed|July 2013|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|November 25, 2013||No||No||https://clinicaltrials.gov/show/NCT02593734||9726|
NCT02593747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18199|To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup|A Single-dose, Single-center, Randomized, Open-label, Two-way Crossover Study in Healthy Adults to Assess the Bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) Versus Claritin Peach Syrup 1mg/mL (ANNA Formula)|Bordeaux|Bayer|No|Completed|December 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593747||9725|
NCT02593786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-077|A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors|A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)|CheckMate 077|Bristol-Myers Squibb|No|Not yet recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593786||9722|
NCT02593370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-TFB-SSPS|Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block|||University of Aarhus|Yes|Completed|October 2015|January 2016|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593370||9754|
NCT02583412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11|Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults|Preparedness for and Response to Meningococcal Outbreaks: a Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults||Dalhousie University|Yes|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|120|||Both|17 Years|25 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|September 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583412||10519|
NCT02583425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFN-11-CD-007|Pilot Study of DFN-11 Injection in Medication Overuse Headache|||Dr. Reddy's Laboratories Limited|No|Recruiting|September 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583425||10518|
NCT02587091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Effectiveness of Advertising Availability of Prenatal Ultrasound on Uptake of Antenatal Care in Rural Uganda|Effectiveness of Advertising Availability of Prenatal Ultrasound on Uptake of Antenatal Care in Rural Uganda: a Randomized Trial||Bridge to Health Medical and Dental||Completed|February 2014|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|157|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587091||10236|
NCT02586129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14755-301|Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes|Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes||Yuhan Corporation|No|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|264|||Both|19 Years|75 Years|No|||January 2016|January 3, 2016|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586129||10310|
NCT02593409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPPIE001|HIV PrEP Priming of Immune Effectors|HIV Pre-Exposure Prophylaxis Priming of Immune Effectors|PREPPIE|MRC/UVRI Uganda Research Unit on Aids|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02593409||9751|
NCT02583724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC73-15|Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment Efficacy|Evaluation of Use of Brain Activity Monitoring for Early Identification of Pharmaceutical Treatment Efficacy and Development of Depression Deterioration Events||Brainmarc Ltd.|No|Recruiting|September 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|October 20, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02583724||10495|
NCT02582762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|658/2557(EC1)|Pilot Study of Efficacy of Nail Gel in Finger Nail Surface Abnormality|Pilot Study of Efficacy of Nail Gel Containing Artemisia Abrotanum Extract and Glycerin in Finger Nail Surface Abnormality||Mahidol University|Yes|Recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582762||10569|
NCT02586441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD11004|Evaluation of EEG With Respect to the Change of Depth of Anesthesia During General Anesthesia|Evaluation of EEG With Respect to the Change of Depth of Anesthesia||Korea University Anam Hospital|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586441||10286|
NCT02581904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7179|Prevena Vascular Groin Wound Study|Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications||Thomas Jefferson University|No|Enrolling by invitation|January 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581904||10635|
NCT02583971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 1.2 Oct 2015|Assessment of Thrombotic Status in Patients With Atrial Fibrillation|Assessment of Thrombotic Status in Patients With Atrial Fibrillation||East and North Hertfordshire NHS Trust|No|Not yet recruiting|December 2015|September 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Whole blood Plasma store|Both|18 Years|N/A|No|Non-Probability Sample|Population of interest are adults (>18) diagnosed with atrial fibrillation (AF) who will        be treated in one of 3 ways:          1. Medical management          2. Direct current cardioversion          3. AF ablation        In total we aim to sample 500 patients divided into:        100 - Medical management 100 - Direct current cardioversion 300 - AF ablation|October 2015|October 24, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02583971||10476|
NCT02579746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofT30496|Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians|Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians|DASHNa-CC|University of Toronto|Yes|Completed|August 2014|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|45 Years|N/A|No|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579746||10801|
NCT02582190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IIS-GR-COL|COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF|Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.|COPPER-AF|Elpen Pharmaceutical Co. Inc.|No|Not yet recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02582190||10613|
NCT02590718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150826|Management Following Lumbar Puncture In Children|Management Following Lumbar Puncture In Children|MFLPIC|Beijing Children's Hospital|No|Not yet recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|1 Month|18 Years|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02590718||9958|
NCT02592109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPermadhi|Effect of Enhanced Counseling Using Complementary Feeding Recommendation Based on Linear Programming on Nutritional Status,Omega-3 Fatty Acids, Malondialdehyde, and Alpha-Tocopherol in Overweight Children in East Jakarta|Effect of Enhanced Counseling Using Complementary Feeding Recommendation Based on Linear Programming on Nutritional Status, Omega-3 Fatty Acid, Malondialdehyde, and Alpha-Tocopherol in Children With Risk of Overweight in East Jakarta||Indonesia University|No|Active, not recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||March 2016|March 10, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592109||9851|
NCT02578524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAU141212|Satisfaction With Multifocal vs Accommodating Lens Implants 2 Years After Surgery|Satisfaction With Multifocal vs Accommodating Lens Implants 2 Years After Surgery||MDbackline, LLC|No|Completed|January 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|117|||Both|1 Year|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who underwent cataract surgery with a multifocal or accommodating lens implant at        least two years prior to the survey.|October 2015|October 22, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578524||10894|
NCT02518919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1-2014-79|Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies|Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies||Children's Hospital of Michigan|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|75|||Both|3 Years|15 Years|No|||October 2015|October 13, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518919||15472|
NCT02518932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTC-G15|The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man|The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man|LVKGR|Elahi, Dariush, PhD|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|June 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518932||15471|
NCT02593162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRK-450-0201|A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection|Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus||Trek Therapeutics, PBC|No|Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593162||9770|
NCT02593175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0294|Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy|Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593175||9769|
NCT02588573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-61|Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit|Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit (Beethoven 2)||Coopervision, Inc.|No|Active, not recruiting|October 2015|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|90|||Both|17 Years|N/A|No|||February 2016|February 1, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588573||10123|
NCT02588586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA-0866|A Study of the Safety and Antiretroviral Activity of 3BNC117|An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy||Rockefeller University|Yes|Recruiting|October 2015|March 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588586||10122|
NCT02578797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108049|A JNJ-56021927 (ARN-509) QT/QTc Study|An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer||Aragon Pharmaceuticals, Inc.|No|Recruiting|December 2015|December 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578797||10873|
NCT02579044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00017505|Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria|Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria||Children's Hospital Boston|Yes|Recruiting|December 2015|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Months|25 Years|No|||December 2015|December 23, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579044||10854|
NCT02593851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107945|A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection|A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection||Janssen Sciences Ireland UC|No|Recruiting|December 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|15||Anticipated|42|||Both|1 Month|24 Months|No|||March 2016|March 15, 2016|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02593851||9717|
NCT02593864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1I21RX002045|A Biomarker Stress Test for Detection of Early Osteoarthritis|A Novel Serum Biomarker Stress Test for Detection of Early Osteoarthritis||VA Palo Alto Health Care System|No|Not yet recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593864||9716|
NCT02588326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500381|Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays|Evaluation of the Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution of Three Different Formulations of a Locally-acting Mometasone Furoate Suspension-based Nasal Spray||University of Florida|Yes|Not yet recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|61|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588326||10142|
NCT02588339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18374|Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention|A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588339||10141|
NCT02584855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14518|A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis|A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis|SPIRIT P3|Eli Lilly and Company|No|Recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584855||10408|
NCT02584868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-006034-17|Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid||COLCHIRCARD|Queen Fabiola Children's University Hospital|No|Recruiting|May 2012|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|3 Years|No|||October 2015|October 22, 2015|July 3, 2013||No||No||https://clinicaltrials.gov/show/NCT02584868||10407|
NCT02579057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Sub-Q Versus IV Furosemide in Acute Heart Failure|Prospective, Randomized, Parallel-Group Pilot Study Comparing IV Furosemide to Subcutaneous Furosemide in Acute Decompensated Heart Failure Patients||Johns Hopkins University|No|Recruiting|February 2016|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|100 Years|No|||February 2016|February 2, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579057||10853|
NCT02516345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRG13may010|Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)|Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)|FIT-FAM|Duke-NUS Graduate Medical School|No|Recruiting|December 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|640|||Both|7 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02516345||15670|
NCT02590016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15050M|Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial|Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate?||Tampere University Hospital|Yes|Recruiting|September 2015|||September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590016||10012|
NCT02582320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC1415|Evaluation of the Clinical-Biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Treated With Ibrutinib-named Patient Program|A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program (NPP) for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Not yet recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|215|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with R/R CLL or 17p deleted CLL fulfilling the eligibility criteria required by        the NPP who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014|October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02582320||10603|
NCT02589275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F303|A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients|A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia||Tonix Pharmaceuticals, Inc.|No|Enrolling by invitation|August 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589275||10069|
NCT02520687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15136|Effects of Dietary Nitrate in Hypertensive Pregnant Women|Feasibility Study on the Effects of Dietary Nitrate on Cardiovascular Function in Hypertensive Pregnant Women||University of Manchester|No|Recruiting|September 2015|September 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|16 Years|N/A|No|||August 2015|October 20, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02520687||15336|
NCT02583009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1_PII-03|A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea|Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Anti Rosacea Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Rosacea Patients||Amorepacific Corporation|Yes|Recruiting|October 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|216|||Both|19 Years|70 Years|No|||October 2015|October 20, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02583009||10550|
NCT02586896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s15-00862|Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments|Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments||New York University School of Medicine|Yes|Not yet recruiting|March 2016|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586896||10251|
NCT02589483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter|Reinforcement of Rectal Anastomosis-RORA|RORA (Reinforcement of Rectal Anastomosis(<10cm) With HemoPatch - Pilot Study||Capio Sankt Görans Hospital|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|N/A|N/A|No|||October 2015|October 27, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02589483||10053|
NCT02589496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09-053|Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis|Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis||Samsung Medical Center|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||December 2015|December 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589496||10052|
NCT02517151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|868|Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue|Effects of Iron Therapy in Patients With Chronic Fatigue and IBD|MICI_2011-01|Istituto Clinico Humanitas|No|Recruiting|October 2014|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02517151||15608|
NCT02517164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-053|Role of Vitamin D Levels (Serum 25-hydroxyvitamin D) and Cognitive Impairment in the Occurrence of Falls||VITADCOG|University Hospital, Caen|No|Recruiting|July 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|serum 25-hydroxyvitamin D|Both|50 Years|N/A|No|Non-Probability Sample|Fallers and person at risk of falls aged at least 50 years|August 2015|August 4, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517164||15607|
NCT02579460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-022|Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition|Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition||Dallas VA Medical Center|No|Enrolling by invitation|November 2015|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|53|||Both|18 Years|80 Years|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02579460||10823|
NCT02583802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-ZYLC-003|The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients|The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients by Ear Pills Combined With Shengmai Capsule||Beijing University of Chinese Medicine|No|Recruiting|September 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583802||10489|
NCT02592564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMESTUDIEN-II|Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder|The Brain´s Plasticity and Change in Cellular Aging After Internet-delivered Cognitive Behavior Therapy for Social Anxiety Disorder|UMEII|Linkoeping University|No|Recruiting|October 2015|May 2021|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02592564||9816|
NCT02592668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000510|Spinal Cord Injury Epidural Stimulation|A Feasibility Study: Epidural Stimulation to Enable Volitional Movement After Chronic Complete Paralysis in Humans.||Mayo Clinic|No|Enrolling by invitation|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|21 Years|65 Years|No|||March 2016|March 11, 2016|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592668||9808|
NCT02580747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s2015-080-06|Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso|Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies||Chinese PLA General Hospital|Yes|Recruiting|October 2015|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580747||10724|
NCT02584634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991005|Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)|A Phase 1b/2, Open-Label, Dose-finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Either Crizotinib Or PF-06463922 In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer||Pfizer|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584634||10425|
NCT02584647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO6059|PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors|Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors|PLX3397|Columbia University|Yes|Recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584647||10424|
NCT02584179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herlev-MR-Prost-BP-MP|Can Significant Prostate Cancer Be Detected With a Biparametric MRI?|Can Significant Prostate Cancer Be Detected With a Short Non-Contrast Enhanced Biparametric MRI (Bp-MRI)?||Herlev Hospital|Yes|Not yet recruiting|December 2015|September 2021|Anticipated|September 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Male|18 Years|85 Years|No|||October 2015|October 21, 2015|September 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02584179||10460|
NCT02584439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/077/HP|Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)|Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)|BRADYVASC|University Hospital, Rouen|Yes|Not yet recruiting|October 2015|September 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584439||10440|
NCT02581943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62415|Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer|Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel||Comprehensive Cancer Center of Wake Forest University|No|Not yet recruiting|October 2015|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581943||10632|
NCT02581956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS96-CT4-17|Walking Affecting Immunology and Quality of Life of Breast Cancer Patients|Walking Affecting Immunology and Quality of Life of Breast Cancer Patients||Kaohsiung Veterans General Hospital.||Completed|November 2008|October 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|N/A|N/A|No|||October 2015|October 20, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581956||10631|
NCT02590744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xiaoliang-Gan-2015|Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery|Effects of Preoperative Using of Eye Patches on Prevention of Preschool Children Emergence Agitation After Cataract Surgery: A Single Center, Prospective, Randomized, Controlled Study.||Sun Yat-sen University|Yes|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|274|||Both|3 Years|7 Years|No|||October 2015|October 28, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02590744||9956|
NCT02593448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKBN/34/2012|Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation.|Influence of Cardiopulmonary Bypass and Sevoflurane or Propofol Anesthesia on Tissue Oxygen Saturation of Thenar Muscle in Adults.||Medical University of Gdansk|No|Completed|March 2012|August 2014|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02593448||9748|
NCT02593461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-101|Diafert® for Embryo Selection and Fertility Improvement|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval|DESTINy|Forest Laboratories|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593461||9747|
NCT02584673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM 15-001|Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement|Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement||Clear Guide Medical|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584673||10422|
NCT02513069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00050835|Mobile Contingency Management for Smoking Cessation in Returning US Veterans|Mobile Contingency Management for Smoking Cessation in Returning US Veterans||Duke University|No|Enrolling by invitation|November 2015|January 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||July 2015|December 7, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513069||15919|
NCT02517944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14DRM_CHOLCOEUR|MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)|MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA|CHOLCOEUR|Institute of Cardiometabolism and Nutrition, France|No|Recruiting|November 2014|November 2015|Anticipated|September 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|||Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|110 subjects divided into:          -  75 patients with heterozygous form at high cardiovascular risk          -  35 controls patients without dyslipidaemia|July 2015|August 4, 2015|January 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02517944|4 Weeks|15547|
NCT02587819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol BSCT-001|Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment|An Open-Label Phase 1 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment When Applied Twice Daily for 28 Days in Male and Female Patients With Basal Cell Carcinoma||Biosceptre|No|Completed|May 2013|April 2014|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 21, 2015|No|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT02587819||10181|
NCT02587884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2015-01-024|Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH|Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study||Eastern Hepatobiliary Surgery Hospital|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587884||10176|
NCT02590913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhejiang University|Acute Metabolic and Endocrine Responses of Glucose and Fructose in Healthy Young Subjects|Acute Metabolic and Endocrine Responses of Glucose and Fructose in Healthy Young Subjects: A Double-blinded, Randomized, Crossover Trial||Zhejiang University|Yes|Completed|March 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|19 Years|39 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02590913||9943|
NCT02578485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUParana|Single Session of Active Video Game Promotes Post Exercise Hypotension in Middle-aged Hypertensive|Single Session of Active Video Game Promotes Post Exercise Hypotension in Middle-aged Hypertensive||Federal University of Paraíba|No|Completed|July 2013|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|15|||Both|45 Years|59 Years|No|||October 2015|October 15, 2015|October 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578485||10897|
NCT02591472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500753|An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma|An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma||University of Florida|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591472||9900|
NCT02513836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Version: Dec 9, 2014|Opioid Safety Program in Pain Clinics (Op-Safe):|Development of an Innovative Opioid Safety Program in Pain Clinics (Op-Safe): A Multi-Centre Project||University Health Network, Toronto|No|Recruiting|May 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|304|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients who are taking opioid medication for >3 months for chronic, non-cancer        pain.|July 2015|July 30, 2015|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02513836||15861|
NCT02518256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1151/2014|Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity|Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity|LUDOC II|Medical University of Vienna|No|Recruiting|May 2014|||May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|540|||Female|18 Years|85 Years|No|||August 2015|August 4, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02518256||15523|
NCT02585076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18311|A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension|A National, Multicenter, Non-interventional, Crosssectional Study for the Determination of the pREvalence of Non-valvular Atrial FIbrillation Among patieNts Diagnosed With Hypertension Attending HEllenic Hypertension Centers|REFINE HT|Bayer|No|Active, not recruiting|November 2015|April 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1119|||Both|60 Years|N/A|No|Probability Sample|The study will be carried out by hypertension specialists practicing in the hospital-based        outpatient healthcare sector, among the network of the European Society of Hypertension        (ESH) Hypertension Excellence Centers|March 2016|March 21, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585076||10391|
NCT02584894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO 15- WEH / TETT- STIM|Potentiation of Trauma Exposure in Post-traumatic Stress Disorder by Repeated Transcranial Magnetic Stimulation|Potentiation of Trauma Exposure in Post-traumatic Stress Disorder by Repeated Transcranial Magnetic Stimulation : A Control Randomized Study|TETT-STIM|University Hospital, Tours|No|Not yet recruiting|November 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 22, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02584894||10405|
NCT02586168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027-014|The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects|The Effect of Gemcabene (CI‐1027) on Insulin Sensitivity in Nondiabetic Subjects||Gemphire Therapeutics, Inc.|No|Completed|July 2001|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586168||10307|
NCT02586181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamins and bone markers|Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People (KnoVIB)|Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People|KnoVIB|Saarland University|No|Completed|August 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|93|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586181||10306|
NCT02584530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150456|Comparing Ultrasound Guided PICC Line Insertion in Neonates With Standard Procedure|A Randomized Controlled Trial Comparing Ultrasound Guided PICC Line Insertion in Neonates With Standard Procedure||Children's Hospital of Eastern Ontario|No|Not yet recruiting|December 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|N/A|28 Days|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584530||10433|
NCT02590926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370/2015|Safety of Negative FrActional Flow Reserve in Patients With ChallEnging Lesions|Safety of Negative FrActional Flow Reserve in Patients With ChallEnging Lesions|FACE|Azienda Ospedaliera Città della Salute e della Scienza di Torino|Yes|Recruiting|January 2015|February 2017|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|N/A|N/A|No|Non-Probability Sample|patients with stable angina|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02590926|5 Years|9942|
NCT02593006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro5835|Start Time Optimization of Biologics in Polyarticular JIA|Start Time Optimization of Biologics in Polyarticular JIA|STOP-JIA|Hackensack University Medical Center|No|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|2 Years|18 Years|No|Non-Probability Sample|Children with new onset, untreated Poly JIA enrolled in the CARRA Registry.|February 2016|February 18, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593006||9782|
NCT02593019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-178|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients||Samsung Medical Center|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|N/A|No|||February 2016|February 16, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593019||9781|
NCT02589314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 46609515.7.0000.0030|Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2|Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2||University of Brasilia||Not yet recruiting|November 2015|||May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589314||10066|
NCT02578381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMET|Boston Scientific COMET Wire Validation Study|Boston Scientific COMET Wire Validation Study|COMET|University Hospital Southampton NHS Foundation Trust.|No|Not yet recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02578381||10905|
NCT02581215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GI14-198|Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer|Phase II Randomized, Double-Blind Study of FOLFIRINOX Plus Ramucirumab Versus FOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198||Hoosier Cancer Research Network|Yes|Not yet recruiting|March 2016|October 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|95|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581215||10688|
NCT02581462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29452/PETRARCA/FLOT6|FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer|FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.|PETRARCA|Krankenhaus Nordwest|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|404|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581462||10669|
NCT02585609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleep study II|Sleep Quality in Patients With Advanced Cancer|Sleep Quality in Patients With Advanced Cancer. A Comparison of Objective Assessments and Self-reports of Sleep Quality||Norwegian University of Science and Technology|No|Not yet recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced cancer using opioids (step III on the WHO pain ladder)|October 2015|October 22, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02585609||10350|
NCT02593266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDECYT-11130615|A Trial of a Preventive Intervention Program for Chilean Families With Depressed Parents|A Pilot Randomized Controlled Trial of a Preventive Intervention Program for Chilean Families With Depressed Parents|FamilyTalkCL|University of Chile|No|Recruiting|November 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593266||9762|
NCT02578615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0528|Physiotherapy for Chronic Metatarsalgia|Physiotherapie Bei Chronischer Metatarsalgie - Ein Vergleich Klinischer Parameter Vor Und Nach Therapie gemäß Spiraldynamik®- Konzept||Spiraldynamik AG|No|Completed|December 2013|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|30 Years|75 Years|No|Non-Probability Sample|patients with chronic metatarsalgia|October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02578615||10887|
NCT02582957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-15-1-0504|Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome|Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome|SiVent|University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|April 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|916|||Both|18 Years|89 Years|No|||March 2016|March 24, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582957||10554|
NCT02578459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-02|A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain|A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain||Flowonix Medical|No|Not yet recruiting|November 2015|April 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|22 Years|N/A|No|||October 2015|October 20, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578459||10899|
NCT02581280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-0919|Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)|Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)||Yonsei University|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|Samples Without DNA|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while      using ECMO for drug concentration assays(LC-MS/MS etc.). After ECMO device is removed,      residual arterial blood samples(1~2 mls) at each sampling time are collected and drug      concentrations are assayed.|Both|19 Years|N/A|No|Non-Probability Sample|Patients over the age of 19 who are receiving teicoplanin or levofloxacin or        piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor while        using VA ECMO in Severance Hospital, Yonsei University Health System.|December 2015|December 9, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02581280||10683|
NCT02594306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEG/ERP and drug addiction|Brain Electrophysiological Study(EEG/ERP) on Opiate Addicts Treating by Bilateral NAc/ALIC Deep Brain Stimulation|Brain Electrophysiological Study(EEG/ERP) on Opiate Addicts Treating by Bilateral NAc/ALIC Deep Brain Stimulation||Tang-Du Hospital|Yes|Recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594306||9682|
NCT02587793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20140182|Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients|Kaohsiung Medical University Chung-Ho Memorial Hospital||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|October 2014|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|If the cultured cells can become cell lines, these cell lines will be stored.|Both|N/A|N/A|No|Probability Sample|Patients who are proven to have HCC based on fine-needle aspiration of the tumor and also        have residual specimens for culture are included.|October 2015|October 24, 2015|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02587793||10183|
NCT02593188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161406|Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)|Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)||Baxalta US Inc.|No|Recruiting|November 2015|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|Blood samples (plasma) for antibodies against recombinant human hyaluronidase (rHuPH20) that      remain after study testing will be stored at the Central Laboratory to confirm implausible      or critical test results, if required. Samples will be stored in a coded form and according      to local requirements for a maximum of 2 years after the final study report has been      completed and subsequently will be destroyed.|Both|16 Years|N/A|No|||March 2016|March 15, 2016|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593188||9768|
NCT02592018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457AUS04T|Immunologic Response to Secukinumab in Plaque Psoriasis|Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling||University of California, San Francisco|No|Not yet recruiting|January 2016|||December 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02592018||9858|
NCT02591017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-249|Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients|Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients|ONKEMI|University Hospital, Basel, Switzerland|No|Recruiting|February 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|34|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02591017||9935|
NCT02594319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0684|Understanding Mechanisms of Health Behavior|||University of Colorado, Boulder|No|Completed|February 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594319||9681|
NCT02594332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001|Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study|A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study|MEMORY|Johannes Gutenberg University Mainz|No|Recruiting|November 2015|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594332||9680|
NCT02594345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExoRBC|Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation|In Vitro Study of the Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation in Healthy Volunteers' Blood||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594345||9679|
NCT02587871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L-15-2|Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission|HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia &lt; 60 Years||University of Southern California|Yes|Not yet recruiting|December 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|N/A|59 Years|No|||November 2015|November 9, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587871||10177|
NCT02587104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU009|dHACM In the Treatment of Diabetic Foot Ulcers|A Single Center, Prospective, Non-Randomized, Historical Controlled Trial of dHACM In the Treatment of Diabetic Foot Ulcers||MiMedx Group, Inc.|Yes|Recruiting|June 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02587104||10235|
NCT02587416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4141002|Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers|A Study of the Effect of Oral, Multiple‐Dose 300 mg and 900 mg Gemcabene (CI‐1027) Administration on the Steady‐State Pharmacokinetics of Atorvastatin 80 mg||Gemphire Therapeutics, Inc.|No|Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587416||10212|
NCT02591082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR2|Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter|A Multi-Center, Post-Marketing, Prospective, Observational Study Following Treatment With Intra-Arterial Delivery of Chemotherapeutic Agents Using the RenovoCath™ RC120 Catheter||RenovoRx|No|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with unresectable or borderline resectable pancreatic cancer.|March 2016|March 23, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591082||9930|
NCT02591095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000193-35|A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer|A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer|MONAVI-1|Centre Francois Baclesse|Yes|Recruiting|January 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02591095||9929|
NCT02518451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR. 183/EQL/2010|Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg|Bioequivalence Study of 160 mg Valsartan Film-coated Caplets Produced by PT Dexa Medica in Comparison With the Innovator Film-coated Tablets (Diovan® 160, Novartis Pharma AG)||Dexa Medica Group|No|Completed|June 2013|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518451||15508|
NCT02587962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-POC-0103-PTL|Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors|A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors||TetraLogic Pharmaceuticals|Yes|Not yet recruiting|December 2015|March 2019|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587962||10170|
NCT02594267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-FOL-101|A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)|A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)||Spectrum Pharmaceuticals, Inc|No|Recruiting|October 2015|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|September 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594267||9685|
NCT02594280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-UPMC-01|Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols.|Observational/Prospective Study for Benchmarking the Management of Glaucoma With Selective Laser Trabeculoplasty (SLT) or Trabecular Stent Bypass Microsurgery, Using the Diopsys Visual Evoked Potential/Pattern ERG Protocols||Diopsys, Inc.|No|Not yet recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is a group of glaucoma patients that are scheduled for 1) Selective        Laser Trabeculoplasty or 2) Trabecular stent bypass microsurgery as a treatment.|October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594280||9684|
NCT02518711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc VUmc 2011/196|Effectiveness Study of a Behavioral Teacher Program Targeting ADHD Symptoms|A Randomized Controlled Trial Into the Effectiveness of a Behavioral Teacher Program Targeting ADHD Symptoms||VU University of Amsterdam|No|Completed|September 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|6 Years|13 Years|No|||August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02518711||15488|
NCT02580448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-VT-464-CL-006|A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer|A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer||Innocrin Pharmaceutical|No|Recruiting|August 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580448||10747|
NCT02580708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-033|A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)||Clovis Oncology, Inc.|No|Recruiting|September 2015|April 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580708||10727|
NCT02579967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160003|Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies|Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|4 Years|75 Years|Accepts Healthy Volunteers|||October 2015|December 16, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579967||10784|
NCT02584062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBJ 151617|Clinical Observation of Technologic Application of No-touch Fluid-air Exchange in Surgery of Idiopathic Macula Hole|The Eye Hospital of Tianjin Medical University||Tianjin Medical University Eye Hospital|No|Recruiting|December 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|50 Years|75 Years|No|||December 2015|December 13, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02584062||10469|
NCT02522364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-2282-MG-CTIL|Subclinical Postoperative Atrial Fibrillation|Subclinical Postoperative Atrial Fibrillation|POAF-ILR|Sheba Medical Center|Yes|Not yet recruiting|August 2015|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|July 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02522364||15207|
NCT02580929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2014B10|Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients|Effectiveness of Radiotherapy Before Surgery in Patients With High-risk Relapse Hepatocellular Carcinoma||Peking Union Medical College|Yes|Recruiting|October 2014|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2015|October 21, 2015|October 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580929||10710|
NCT02581189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-651|Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)|AMBER|AbbVie||Recruiting|October 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|99 Years|No|Non-Probability Sample|Adult patients chronically infected with HCV, receiving the interferon-free ABBVIE REGIMEN|February 2016|February 15, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581189||10690|
NCT02592135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INEMER-0001|High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)|High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)|TACIT|Indiana University|No|Recruiting|December 2015|May 2019|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Plasma and serum specimens for bio marker analysis|Both|21 Years|N/A|No|Non-Probability Sample|Patients who present to the Emergency Department (ED) with signs and symptoms of AHF|January 2016|January 27, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592135||9849|
NCT02582866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1042|A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994|A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment||UCB Pharma|No|Enrolling by invitation|January 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|17 Years|N/A|No|||February 2016|March 7, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582866||10561|
NCT02578849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602_Parkinson´s disease|Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia|Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET|NORAPARK|Aarhus University Hospital|Yes|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson´s disease patients with/without L-DOPA induced dyskinesia and age-matched        healthy controls.|October 2015|October 15, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02578849||10869|
NCT02593227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRV-002|Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer|A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer||Tapimmune Inc.|Yes|Not yet recruiting|December 2015|December 2019|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593227||9765|
NCT02581410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201198|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier||GlaxoSmithKline||Recruiting|December 2015|August 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581410||10673|
NCT02589184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-20150818006A|Effects on Shoulder Pain of Simulated Hyper-gravity During Rehabilitation Exercises|Effects on Shoulder Pain of Simulated Hyper-gravity During Rehabilitation Exercises||Carrick Institute for Graduate Studies|No|Recruiting|October 2015|October 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02589184||10076|
NCT02589197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-LJK-001|Gait and Functional Outcomes Study Following Total Knee Arthroplasty With Medial-pivot or Posterior-stabilized Implants|Muscle Activation and Biomechanical Function of the Lower-limb Joints Following Total Knee Arthroplasty With Medial-pivot or Posterior-stabilized Implants: an Electromyography Study|GOLD|MicroPort Orthopedics Inc.|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from the orthopedic clinic at The Ottawa hospital for        implanted patients. Non-implanted subjects will be selected from the community.|October 2015|October 26, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589197||10075|
NCT02589210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU008|dHACM Mesh In the Treatment of Diabetic Foot Ulcers|A Single Center, Prospective, Single-Blinded, Non-Randomized, Historical Controlled Trial of dHACM Mesh In the Treatment of Diabetic Foot Ulcers||MiMedx Group, Inc.|Yes|Recruiting|May 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02589210||10074|
NCT02583113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNI 001|Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study|A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.||Medacta USA|No|Recruiting|February 2016|January 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients that have undergone a Total Knee and Unicompartment knee replacement        contralateral.|March 2016|March 23, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583113||10542|
NCT02520440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 1769/2014|INtestinal Failure, multiPle Organ Failure ANd CItrulline Assessment|Clinical Evaluation of Gastro Intestinal Failure, Multiple Organ Failure and Levels of Citrulline in Critical Ill Patients|IN-PANCIA|Azienda Ospedaliera Spedali Civili di Brescia|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted in ICU|August 2015|August 7, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520440||15355|
NCT02578680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-189|Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)|A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)||Merck Sharp & Dohme Corp.|Yes|Recruiting|January 2016|March 2019|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|570|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578680||10882|
NCT02578693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&H_HCV DAA Fu|Follow-up for DAA Treated HCV Subjects|Long Term Follow-up for Subjects With Chronic Hepatitis C Infection Who Achieve a Sustained Virologic Response to Direct-acting Antiviral Agents (DAA) Treatment||Humanity & Healthy GI and Liver Centre|Yes|Recruiting|May 2015|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Serum/Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have achieved sustained virologic response (SVR) while treating with        direct-acting agents (DAA) regimen.|October 2015|October 16, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578693||10881|
NCT02586649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-14-019|24hr Effects of Tiotropium Bromide in Tetraplegia|A Randomized, Double-blind, Placebo-controlled Trial to Determine the Effects and Duration of Action of Tiotropium Bromide on Pulmonary Function in Persons With SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||October 2015|October 23, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586649||10270|
NCT02586883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00731-48|Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi|Study of the Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi|EPITRANS|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|November 2015|November 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|75|||Both|2 Years|20 Years|No|||October 2015|October 23, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02586883||10252|
NCT02592447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18365|Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention|Preliminary Evaluation of an Internet-Assisted Cognitive Behavioral Intervention for Targeted Therapy Fatigue||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|September 2015|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592447||9825|
NCT02592499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ver 2.3|Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure|Swedish Evaluation of Left Ventricular Assist Device|SweVAD|Vastra Gotaland Region|Yes|Not yet recruiting|November 2015|July 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02592499||9821|
NCT02522897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXT-201302-Pearl|Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas|Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas|PEARL|Ludwig-Maximilians - University of Munich|No|Not yet recruiting|August 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02522897||15166|
NCT02512289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONS-Gilliaux-03|Impact of Non-invasive Brain Stimulation, Associated With Upper Limb Robot-assisted Therapy, on Motor Recuperation|Impact of Non-invasive Brain Stimulation, Associated With Upper Limb Robot-assisted Therapy, on Motor Recuperation||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|May 2014|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||July 2015|July 27, 2015|August 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02512289||15979|
NCT02586831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150856|Diabetes Islet Preservation Immune Treatment|A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes|DIPIT|University of Miami|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|35 Years|No|||October 2015|October 27, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586831||10256|
NCT02593916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128024|Response to Medication Registry|Response to Medication Registry||Intermountain Health Care, Inc.|No|Active, not recruiting|March 2007|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|196|Samples With DNA|-  blood samples        -  buccal samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients from existing Intermountain Healthcare databases and registries who either have        taken drugs that treat cardiovascular conditions or that have presented with        cardiovascular symptoms that may be related to medication.|September 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593916|5 Years|9712|
NCT02592551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36952|MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma|Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma||Baylor College of Medicine||Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592551||9817|
NCT02590497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15019|Correlation Between Genetic and Imaging Information in Patients With Newly Diagnosed Glioblastoma Before Surgery|The Correlation Between the Genetic &Amp; Neuroimaging Signatures in Newly Diagnosed Glioblastoma||Ohio State University Comprehensive Cancer Center|Yes|Not yet recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||October 2015|October 27, 2015|September 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590497||9975|
NCT02590510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH 001|Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis|||Hebei Medical University||Not yet recruiting|October 2015|||October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|14 Years|N/A|No|||October 2015|October 28, 2015|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590510||9974|
NCT02584010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|All-M-42361-01-08-14|Efficacy Study of Two Silicon-based Products to Treat Scars|Comparative, Open, Randomized Trial Between Two Silicon-based Products to Treat Postoperative Scars|Kelofin|Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584010||10473|
NCT02589028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1504-103-666|The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones|The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones in Healthy Adults and Patients With Type 2 Diabetes||Seoul National University Hospital|Yes|Recruiting|October 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589028||10088|
NCT02578836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150200|Transoral Gastric Volume Reduction as an Intervention for Weight Management|Transoral Gastric Volume Reduction as an Intervention for Weight Management||University of Miami|No|Not yet recruiting|May 2016|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|60 Years|No|||October 2015|March 21, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578836||10870|
NCT02581397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-TRN-03(01/10)|Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough|Randomized Clinical Trial Evaluating the Non-clinical Inferiority of Suppository Transpulmin and Suppository Guaiacol Compared to Transpulmin Syrup in Frames of Productive Cough of Infectious Origin in Pediatric Participants.|Transpulmin|Ache Laboratorios Farmaceuticos S.A.|No|Recruiting|May 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|2 Years|6 Years|No|||March 2016|March 14, 2016|January 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581397||10674|
NCT02585336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-16880|Changes in Sugar-sweetened Beverage Intake and Metabolic Health: Improving Metabolic Profile Very Effortlessly|Effects of Sugar-sweetened Beverage Consumption Changes on Metabolic Health: Improving Metabolic Profile Very Effortlessly (IMPROVE)|IMPROVE|University of California, San Francisco|No|Active, not recruiting|July 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585336||10371|
NCT02589444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083796|Vitamin D and Microbiota in Cystic Fibrosis|Pilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic Fibrosis||Emory University|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02589444||10056|
NCT02589717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29725|An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy|An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.||Genentech, Inc.||Available|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 16, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02589717||10035|
NCT02592733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS171317|A Case Control Observational Study to Assess CYDAR Automated Overlay Guidance During EVAR|A Case Control Observational Study to Assess CYDAR Automated Overlay Guidance During EVAR|CYDAR-IRAAA|Royal Free Hospital NHS Foundation Trust|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|All patients deemed fit for infrarenal repair at one of 4 centres.|October 2015|October 29, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02592733||9803|
NCT02585505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI NUC MED|Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus|Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus||Postgraduate Institute of Medical Education and Research|Yes|Completed|December 2010|December 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|21|||Both|30 Years|70 Years|No|||October 2015|October 22, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02585505||10358|
NCT02579941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Fibrinolyse|Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.|Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.||Brugmann University Hospital|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579941||10786|
NCT02580539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER Pending|A Study of the Safety and Efficacy of EBV Specific T-cell Lines|A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases|EBV-TCL-01|Maisonneuve-Rosemont Hospital|Yes|Recruiting|November 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580539||10740|
NCT02591407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 15-1618|Trial Comparing Transversus Abdominis Plane Block Versus Epidural Anesthesia for Pain Management in Colorectal Surgery|A Prospective Randomized Clinical Trial Comparing the Transversus Abdominis Plane Block Versus Epidural Anesthesia For Enhanced Recovery Pathway Perioperative Management of Pain in Elective Colorectal Surgery|TAP|Saint Joseph Mercy Health System|No|Enrolling by invitation|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|176|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02591407||9905|
NCT02592785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16958|Phase I Dose Escalation Study of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors|An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors||Bayer|No|Recruiting|November 2015|November 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||March 2016|March 1, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592785||9799|
NCT02517957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14401970200|Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research|||Shanghai Yueyang Integrated Medicine Hospital|Yes|Not yet recruiting|August 2015|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|342|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517957||15546|
NCT02590575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ_G_023.14-II-4|"Low Flow" CO2 Removal on RRT|"Low Flow" CO2 Removal Via a Membrane Gas Exchange Device (Prismalung®) on a Renal Replacement Platform (Prismaflex®) in Hypercapnic, Ventilated Patients Requiring Renal Replacement|Prismalung|University of Erlangen-Nürnberg Medical School|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02590575||9969|
NCT02588807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-14-CMC|Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis|The Combination of Phospholipids and Medical Herbs for the Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS); A Pilot Study|ALS-PHL|Herb Spirit|No|Not yet recruiting|December 2015|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588807||10105|
NCT02593474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7146|Medication-Assisted Treatment for Youth With Substance Use Disorders|Medication-Assisted Treatment for Youth With Substance Use Disorders||New York State Psychiatric Institute|Yes|Recruiting|September 2015|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|16 Years|21 Years|No|||October 2015|October 29, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02593474||9746|
NCT02592876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN19A-003|Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma|A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant||Seattle Genetics, Inc.|No|Recruiting|October 2015|May 2020|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592876||9792|
NCT02592967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107667|Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer|An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer||Janssen Research & Development, LLC|No|Recruiting|December 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592967||9785|
NCT02591914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E10030-003|An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration|||Retinal Consultants of Arizona|No|Active, not recruiting|February 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|50 Years|N/A|No|||October 2015|October 28, 2015|March 27, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591914||9866|
NCT02590822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0498|Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction|Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction. The Diastolic Study|Diastolic|University of Leicester|No|Not yet recruiting|October 2015|August 2019|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02590822||9950|
NCT02593136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00065311|Home Fortification of Complementary Foods in Bihar India|Assessing Feasibility and Program Effectiveness of Home Fortification of Complementary Foods in Bihar: A Cluster Randomized Community Pilot||Emory University|Yes|Completed|June 2014|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|6513|||Both|6 Months|18 Months|No|||March 2016|March 24, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593136||9772|
NCT02593149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0002|Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap|Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap||Pursuit Vascular, Inc.|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3500|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593149||9771|
NCT02588222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201500284|GRINCH: Groningen Initiative on Reference Intervals in Children|GRINCH: Groningen Initiative on Reference Intervals in Children|GRINCH|University Medical Center Groningen|No|Recruiting|June 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|feces samples|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children, aged 6-18 years old|October 2015|October 26, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02588222||10150|
NCT02585141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140191|Aspiration Treatment of Perianal Abscess|Aspiration or Surgical Drainage of Perianal Abscess. A Randomized Controlled Clinical Study||University of Southern Denmark|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02585141||10386|
NCT02582411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040415|Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography|Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography||Medical University of Vienna||Completed|August 2015|||January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|80 healthy subjects in 4 age groups Group 1: 18-34 years Group 2: 35-49 years Group 3:        50-64 years Group 4: 65-80 years|February 2016|February 24, 2016|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02582411||10596|
NCT02578602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3L-10-1|MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer|MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate||University of Southern California|No|Completed|October 2010|June 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578602||10888|
NCT02582671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-702|The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland|Real World Evidence of the Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland|REACH|AbbVie|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with chronic hepatitis C who are being prescribed the AbbVie Regimen +/-        Ribavarin.|January 2016|January 20, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582671||10576|
NCT02585557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0479|Heart Health NOW (Previously Known as Facilitation, Spread, and Translation of Patient-Centered Evidence in North Carolina Practices)|Heart Health NOW (Previously Known as Facilitation, Spread, and Translation of Patient-Centered Evidence in North Carolina Practices)|HHN|University of North Carolina, Chapel Hill|No|Enrolling by invitation|November 2015|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Anticipated|300|||Both|N/A|N/A|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585557||10354|
NCT02589626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.106|Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA|A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control||Boehringer Ingelheim||Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|64|||Both|20 Years|N/A|No|||March 2016|March 21, 2016|October 27, 2015||||No||https://clinicaltrials.gov/show/NCT02589626||10042|
NCT02591485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC - 15 - PH - 0409 - CTIL|Prevention of Post Traumatic Stress Disorder Following Trauma by Attention Control Training|Prevention of Post Traumatic Stress Disorder Following Trauma by Attention Control Training||Tel Aviv University|Yes|Not yet recruiting|November 2015|January 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591485||9899|
NCT02580370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL038|Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines||REALISE 1|Revance Therapeutics, Inc.|No|Recruiting|September 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580370||10753|
NCT02586779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/04-11|Effectiveness of WhatsApp (a Messenger Program) Usage in Emergency Department (ED)|Effectiveness of WhatsApp Messenger Usage and Other Technologises on Communication Between Consulting Physicians and the Emergency Department Staff: Randomised Double-blind Controlled Trial||Adiyaman University Research Hospital|Yes|Completed|October 2015|March 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|300|||Both|19 Years|80 Years|No|||March 2016|March 3, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586779||10260|
NCT02582294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLE_2015_4|Fabry's Disease and Pregnancy (PREFAB)|Description of Obstetrical Care, Mainly Anesthesic, in Patients With Fabry's Disease|PREFAB|Fondation Ophtalmologique Adolphe de Rothschild|No|Enrolling by invitation|October 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|35|||Female|18 Years|45 Years|No|Non-Probability Sample|Fabry's disease patients having had at least one childbirth|October 2015|January 7, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02582294||10605|
NCT02585869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027-004|Efficacy and Safety of Gemcabene in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides|A 12‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI‐1027 in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides||Gemphire Therapeutics, Inc.|No|Completed|December 1999|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|161|||Both|18 Years|80 Years|No|||October 2015|October 22, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585869||10330|
NCT02585882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1062010|Preventive Effect of Salt Fluoridation|Caries Preventive Effect of Salt Fluoridation in Preschool Children in The Gambia||University of Witten/Herdecke|No|Completed|March 2012|October 2015|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|441|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585882||10329|
NCT02517931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204502|Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department|Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study||University of Arkansas|Yes|Not yet recruiting|July 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02517931||15548|
NCT02579200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT COPD+HF|Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure|Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial||Queen's University|No|Not yet recruiting|November 2015|July 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|March 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02579200||10842|
NCT02594254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3J15-203-00|Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects|A Phase 2, Double-Blind, Placebo-Controlled and Open-Label Multi-Center Study to Evaluate the Microbiology and Safety of C16G2 Administered in Multiple Oral Gel Doses to Adult and Adolescent Dental Subjects||C3 Jian, Inc.|No|Active, not recruiting|November 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|128|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||November 2015|March 17, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594254||9686|
NCT02592031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM17-02|Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women|An Open, Randomized, Two-way Cross-over Phase I Study to Compare the Bioavailability, Safety and Tolerability of Single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f® in 36 Healthy, Down-regulated Young Women||Teva Pharmaceutical Industries|Yes|Completed|February 2009|December 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592031||9857|
NCT02582372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCLuisOrtega|Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery|Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery|Dex|Hospital Central Dr. Luis Ortega|No|Completed|March 2014|February 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02582372||10599|
NCT02582385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-ALS|In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)|In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis||Brugmann University Hospital|No|Completed|October 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|5|Samples Without DNA|Archived/residual histopathology sections and paraffin blocks entirely from residual autopsy      material. Archived material involves old cases (autopsied between 2000 and 2005). All      autopsies were conducted within the legal frame of the then applicable laws. There is no      reference whatsoever to names or identifications of the deceased patients (anonymous      samples).|Both|N/A|N/A|No|Non-Probability Sample|Archived/residual histopathology slides and paraffin blocks from residual autopsy material        from patients who died with amyotrophic lateral sclerosis.|October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582385||10598|
NCT02521519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-190|Medial Branch Block vs Para-spinal Muscle Injection in Patients With Non-specific Chronic Low Back Pain|Medial Branch Block vs Para-spinal Injection in Patients With Non-specific Chronic Low Back Pain||McGill University Health Center|No|Recruiting|August 2014|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|84|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02521519||15272|
NCT02590549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myoring_CXL|MyoRing Implantation With Corneal Collagen Crosslinking for Keratoconus|Complete Corneal Ring (MyoRing) Implantation Combined With Corneal Collagen Crosslinking for Keratoconus||Ufa Eye Research Institute||Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02590549||9971|
NCT02590562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28487|An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.|A Multi-center Cross-sectional Study on Treatment Patterns and Patient Characteristics in Rheumatoid Arthritis (RA) Patients Treated by Biological DMARDs in China||Hoffmann-La Roche||Completed|December 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|808|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include RA patients (according to ACR criteria) who are        experiencing biologic treatment.|January 2016|January 13, 2016|October 16, 2015||No||No|December 3, 2015|https://clinicaltrials.gov/show/NCT02590562||9970|
NCT02583503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho 15-09|Hindfoot Alignment in Total Knee Replacement|Hindfoot Alignment in TKR - Validation of a Novel Radiographic Study||Golden Jubilee National Hospital|Yes|Not yet recruiting|November 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for a total knee replacement at the Golden Jubilee National        Hospital under the care of one of the orthopaedic consultants who have agreed to provide        patients for this study.|October 2015|October 20, 2015|September 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02583503||10512|
NCT02583516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-01-15|Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma||Grupo Español Multidisciplinar de Melanoma|No|Recruiting|June 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02583516||10511|
NCT02584049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRD0215|Osteopathic Medicine in the Management of Care-induced Pain in Elderly Care (OGéDIS)|Effects of Osteopathic Treatment in the Management of Care-induced Pain in Elderly Care, in Follow-up Care and Rehabilitation Geriatric|OGéDIS|Centre Hospitalier René Dubos|No|Recruiting|December 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|75 Years|N/A|No|||March 2016|March 24, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584049||10470|
NCT02586142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG890041|Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing|Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing||Chang Gung Memorial Hospital|No|Completed|August 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||August 2010|October 23, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02586142||10309|
NCT02521896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1-001|Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF|Vado™ Steerable Sheath System; A Safety and Performance Study to Evaluate Access to the Pulmonary Veins in the Treatment of Paroxysmal and Persistent Atrial Fibrillation||Kalila Medical|No|Completed|August 2014|January 2015|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||August 2015|August 10, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02521896||15243|
NCT02522104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIK-FR 14-1|Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)|Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH)||ADDMEDICA SASA|No|Recruiting|September 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02522104||15227|
NCT02585284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGraz3|Effect of Age on Propofol-BIS Response|Effect of Age on Propofol-Bispectral Index Response Relationship Among Different Age Groups From Vicenarians to Nonagenarians. A New Logistic Model Compared With Traditional Sigmoid Emax Model|BIS3|Medical University of Graz|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Actual|80|||Both|18 Years|100 Years|No|Non-Probability Sample|80 patients, five male and five female, divided by age decades from vicenarian (20-29 yr)        to nonagenarians (90-99 yr)|October 2015|October 22, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02585284||10375|
NCT02584335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013LIDO|To Evaluate Reduction of Pain in Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo|Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo||Hospital Universitari de Bellvitge|Yes|Recruiting|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|26|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02584335||10448|
NCT02582580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP #2015/02244-0|Effects of Antenatal Pelvic Floor Preparation Techniques for Childbirth|Effects of Perineal Massage, Vaginal Dilator and Pelvic Floor Muscles Training on the Perineal Integrity Primiparous: A Randomized Controlled Trial Protocol|EAPFPTC|Universidade Federal de Sao Carlos|No|Not yet recruiting|October 2015|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|63|||Female|18 Years|N/A|No|||October 2015|October 19, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02582580||10583|
NCT02511457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205760|Comparison of Cardiac Output With LiDCO Rapid and TEE Against Thermodilution Technique in Cardiac Surgery|Validation of Measurement of Cardiac Output With LiDCO Rapid and TEE (Trans Esophageal Echocardiography) by Comparing With Intermittent Thermodilution Technique in Cardiac Surgical Patients||University of Iowa|Yes|Recruiting|October 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|||Both|30 Years|90 Years|No|Non-Probability Sample|All elective adult cardiac surgery patients who are scheduled in UIHC from Sep 2012 to        August 2015 will be included.|July 2015|July 29, 2015|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02511457||16043|
NCT02585531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNAE 06|Epinephrine, Dexamethasone and Hypertonic Saline in Bronchiolitis|Epinephrine, Dexamethasone, and Hypertonic Saline in Children With Bronchiolitis in the Hospital General Naval de Alta Especialidad. A Randomized Controlled Trial||Hospital General Naval de Alta Especialidad - Escuela Medico Naval|No|Not yet recruiting|November 2015|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Months|24 Months|No|||October 2015|November 10, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02585531||10356|
NCT02580266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version-2, 01 Sept 2015|Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes|Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes|DDRD|Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|September 2015|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Plasma, serum, urine|Both|N/A|N/A|No|Probability Sample|Patients with type 1 and type 2 diabetes|October 2015|October 16, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02580266||10761|
NCT02580279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTEBC-2015|Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy|Phase II Study of Topical Epigallocatechin-3-gallate (EGCG) in Patients With Breast Cancer Receiving Adjuvant Radiotherapy||Shandong Cancer Hospital and Institute|No|Enrolling by invitation|February 2015|May 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|September 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02580279||10760|
NCT02586701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM123|Supervised Versus Non-supervised Exercise on Adherence and Functional Outcomes in Colorectal Patients|Effects of a Supervised Versus Non-supervised Exercise Program on Adherence and Functional Outcomes in Colorectal Cancer Patients||McGill University Health Center|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586701||10266|
NCT02519192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0068|The Role of VAC Therapy Devices in Promoting Closure of Enterocutaneous Fistulae|The Role of VAC Therapy Devices in Promoting Closure of Enterocutaneous Fistulae: A Randomized Controlled Trial|ECF|Denver Health and Hospital Authority|Yes|Not yet recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|July 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519192||15451|
NCT02581423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18601|A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer|Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon||Hoffmann-La Roche||Completed|August 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581423||10672|
NCT02594527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM MED1297|Southampton Mobility Volunteer Programme|The Southampton Mobility Volunteer Programme to Increase Physical Activity Levels of Older Inpatients: A Feasibility Study|SoMoVe|University of Southampton|Yes|Not yet recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|70 Years|N/A|No|||October 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02594527||9665|
NCT02587507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMTMNC|Proteomic Analysis of Mononuclear Cells After a High-Fat, High-Carbohydrate Meal With or Without Orange Juice|Proteomic Analysis of the Peripheral-Blood Mononuclear Cells Response After a High-Fat, High-Carbohydrate Meal With or Without Orange Juice in Healthy Subjects||University of Sao Paulo|Yes|Completed|June 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587507||10205|
NCT02522637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondazione Salvatore Maugeri|Exercise Training in Severe COPD|What is the Best Frequency of Exercise Training in Severe COPD?||Fondazione Salvatore Maugeri|No|Recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|40 Years|80 Years|No|||August 2015|August 12, 2015|July 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02522637||15186|
NCT02582723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B323|Acute Effect of Cheeses With Different Energy Content on Appetite|Acute Effect of Cheeses With Different Energy Content on Appetite|STABLE|University of Copenhagen|No|Completed|September 2015|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02582723||10572|
NCT02593890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THEYARCT2015|Breast Surgery Recovery: The Clinical and Psychosocial Impact of THEYA Recovery Range|Breast Surgery Recovery: The Clinical and Psychosocial Impact of THEYA Recovery Range||Theya|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02593890||9714|
NCT02580071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH104-REC3-066|Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients|An Open Label, Non-randomized, Clinical Study of Chinese Medicine, Sheng-Yu-Tang, for Immune Reconstitution Following Peripheral Blood Stem Cell Transplantation in >CR1 (Complete Remission) and Refractory Acute Leukemia Patients||China Medical University Hospital|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|N/A|No|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580071||10776|
NCT02512549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIMS-DM Thesis|A Trial to Study the Effects of Pulmonary Rehabilitation Program on Exercise Capacity and Quality of Life in Patients With Severe Form of Chronic Obstructive Pulmonary Disease (COPD)|'Effects of Structured Outpatient Pulmonary Rehabilitation Intervention on Exercise Capacity and Quality of Life in Patients With Severe Chronic Obstructive Pulmonary Disease: A Randomized Controlled Study'|RehabCOPD|All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|August 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|15 Years|75 Years|No|||July 2015|July 29, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02512549||15959|
NCT02579772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6015083|Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction|Systemic Vascular Dysfunction in COPD Patients With Mild-to-moderate Airflow Obstruction: Pharmacological Treatment With N-acetylcysteine||Queen's University|No|Enrolling by invitation|July 2015|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|40 Years|80 Years|No|||October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579772||10799|
NCT02580357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEPJMF 2|Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds|Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds After Connective Tissue Graft Removal: Randomized Clinical Trial||Universidade Estadual Paulista Júlio de Mesquita Filho|No|Completed|February 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02580357||10754|
NCT02580617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-CD-101|A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease|A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease||Anterogen Co., Ltd.|No|Recruiting|April 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580617||10734|
NCT02581384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-278|Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors|Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors||Dana-Farber Cancer Institute|Yes|Not yet recruiting|November 2015|February 2023|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|8 Years|19 Years|No|||October 2015|October 19, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581384||10675|
NCT02588560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-7486B|Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy|Serial Viral Load Changes and Hepatotoxicity in Lymphoma Patients With Hepatitis C Antibody After Chemotherapy Treatment: A Prospective Multicenter Observational Study and Long-term Retrospective Analysis||Chang Gung Memorial Hospital|No|Enrolling by invitation|September 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|38|Samples With DNA|Peripheral blood mononuclear cells|Both|20 Years|N/A|No|Non-Probability Sample|Lymphoma patient plus hepatitis C|August 2015|October 26, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02588560||10124|
NCT02591134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULKLABA01|EffectS of Non-nutritive sWeetened Beverages on appetITe During aCtive weigHt Loss|SWITCH: EffectS of Non-nutritive sWeetened Beverages on appetITe During aCtive weigHt Loss|SWITCH|University of Liverpool|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|432|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02591134||9926|
NCT02583893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15D.377|Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia|A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia||Thomas Jefferson University|Yes|Recruiting|October 2015|||October 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|65|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583893||10482|
NCT02584166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50791|Intervention of Psychological and Ethical Professionals of Human Science in Obstetrical Morbidity and Mortality Conferences (OPERA)|Intervention of Psychological and Ethical Professionals of Human Science in Obstetrical Morbidity and Mortality Conferences|OPERA|Hospices Civils de Lyon|No|Completed|October 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4929|||Both|N/A|1 Month|No|Non-Probability Sample|All newborns born between 1er october 2008 and 30 November 2010 (in one of the 95        maternity units which belongs to one of the 5 perinatal networks).|October 2015|October 27, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584166||10461|
NCT02585765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAF-15-040|Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI|Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI||James J. Peters Veterans Affairs Medical Center|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|79 Years|No|||October 2015|October 22, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585765||10338|
NCT02589639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.107|Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus|A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control||Boehringer Ingelheim||Recruiting|October 2015|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|267|||Both|20 Years|74 Years|No|||March 2016|March 21, 2016|October 27, 2015||||No||https://clinicaltrials.gov/show/NCT02589639||10041|
NCT02591498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03TW009002-01|Computerized Cognitive Training for Schizophrenia in Brazil|Computerized Cognitive Training for Schizophrenia in Brazil|CCTSB|Universidade Federal do Rio de Janeiro|No|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|60 Years|No|||October 2015|October 28, 2015|December 16, 2014||No||No||https://clinicaltrials.gov/show/NCT02591498||9898|
NCT02591511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taipei Medical University|Effects of Patient-centered Stroke Educating System: a Randomized Controlled Trial|||Taipei Medical University||Recruiting|April 2015|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591511||9897|
NCT02588495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7883-BE|Accuracy of Gastric Ultrasound to Diagnose a "Full Stomach". A Bayesian Framework|Accuracy of Gastric Ultrasound to Diagnose a "Full Stomach". A Bayesian Framework||University Health Network, Toronto|No|Recruiting|August 2014|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588495||10129|
NCT02588690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00041183|Beauty From Within Community Screening Project|Beauty From Within Community Screening Project|BFW|Cedars-Sinai Medical Center|No|Not yet recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|400|||Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community screening project targets women of color and/or low income women in economically        and ethnically diverse greater Los Angeles community|October 2015|October 26, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02588690||10114|
NCT02584543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HE-007|A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)|Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine||Xiamen Innovax Biotech Co., Ltd|No|Recruiting|October 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 2, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584543||10432|
NCT02584816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTA: 04 / VAC-020|Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization|A Phase III, Multicenter, Open Label, Randomized Study of Bovine Rotavirus Pentavalent Vaccine (BRV-PV) to Evaluate Lot-To-Lot Consistency and to Investigate Potential Interference With Routine UIP Vaccinations in Healthy Infants in India.||Serum Institute of India Limited|Yes|Not yet recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1500|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||November 2015|November 5, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02584816||10411|
NCT02584361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47190|Cochlear Implant and Vestibular Function.|Vestibular Function Evaluated by the Video Head Impulse Test (vHIT) and Vertigo Perceived by the Patients Before and After Cochlear Implant Surgery.||Odense University Hospital|Yes|Recruiting|August 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02584361||10446|
NCT02592798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-566|Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children Over the Age of 6 With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)|A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change)||Bristol-Myers Squibb|Yes|Recruiting|March 2016|April 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|6 Years|N/A|No|||January 2016|March 11, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592798||9798|
NCT02520869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wagdy 1|Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction Treatment|Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Predicting Outcome of Assisted Reproduction Treatment||Benha University|No|Recruiting|April 2014|May 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Female|19 Years|42 Years|No|||August 2015|August 14, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520869||15322|
NCT02579928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1506016041|Ketamine Infusion for Adolescent Depression|Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression||Yale University|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|13 Years|17 Years|No|||March 2016|March 18, 2016|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579928||10787|
NCT02593487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10333|Effect of Rosuvastatin Therapy on HDL2 Level|Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Not yet recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|30 Years|75 Years|No|||October 2015|October 31, 2015|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593487||9745|
NCT02581592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0134|Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment|The Effect of Moderate Hepatic Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD-4208||Theravance Biopharma R & D, Inc.|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581592||10659|
NCT02581839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7113|Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate|Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate||Case Comprehensive Cancer Center|Yes|Recruiting|November 2015|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 19, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581839||10640|
NCT02585986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO/PRO1|Trial to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients|Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate Safety and Efficiency of a Probiotic in Symptoms Reduction and Use of Topic Corticoids in Mild Atopic Dermatitis Patients Aged 4 to 17 Years||Biopolis S.L.|No|Recruiting|January 2016|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02585986||10321|
NCT02589119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003200|Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With High, Transsphincteric Cryptoglandular Perianal Fistulas||Mayo Clinic|Yes|Recruiting|January 2016|October 2019|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589119||10081|
NCT02589132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 15/22|Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive|Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive||Medical College of Wisconsin|No|Recruiting|August 2015|January 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Months|4 Years|No|||October 2015|October 26, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02589132||10080|
NCT02589145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0558|Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype|Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype||M.D. Anderson Cancer Center|No|Not yet recruiting|December 2015|||December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|15 Years|65 Years|No|||October 2015|October 26, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589145||10079|
NCT02591316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014T34|Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors|Lifestyle Factors, Inflammation, and Cognition in Breast Cancer Survivors||Texas State University, San Marcos|No|Recruiting|February 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|90|Samples With DNA|Serum and plasma|Female|30 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female breast cancer survivors and women who have never had a previous cancer diagnosis|October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591316||9912|
NCT02591329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-02762|Increasing Household Purchase and Child Consumption of Calcium Products: A Randomised Controlled Trial|Increasing Household Purchase and Child Consumption of Calcium Products: A Randomised Controlled Trial||University of British Columbia|No|Recruiting|August 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591329||9911|
NCT02593903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 13/140|Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair|Prophylactic Antibiotics Following Distal/Mid-shaft Hypospadias Repair: Are They Necessary?||Medical College of Wisconsin|No|Recruiting|February 2014|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Male|6 Months|2 Years|No|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593903||9713|
NCT02593929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 14-207|Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer|Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial||University of Pittsburgh||Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593929||9711|
NCT02593669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China8|The Effect of Cataract Surgery on Sleep Quality|The Effect of Cataract Surgery for Age-related Cataract Patients on Circadian Rhythm and Sleep Quality||Sun Yat-sen University|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10000|||Both|N/A|N/A|No|||October 2015|October 30, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593669||9731|
NCT02593682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015078|The Role of Orexin in Human Panic Disorder|The Role of Orexin in Human Panic Disorder||University of California, San Francisco|No|Not yet recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593682||9730|
NCT02586480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBSY02|Evolution of the PR Interval in Patients Implanted With a Pacemaker Using the SafeR Mode|Evolution of the PR Interval in Patients Implanted With a Dual Chamber Pacemaker With Algorithm for Spontaneous AV Conduction Preservation|PRECISE|LivaNova|No|Active, not recruiting|April 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|848|||Both|18 Years|N/A|No|Non-Probability Sample|Bradycardia patients eligible for dual chamber pacemaker implantation for SND, AVBI or        AVBII|October 2015|October 23, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586480|12 Months|10283|
NCT02582944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502080|Electromagnetic Navigation for Peripheral Pulmonary Lesions|Electromagnetic Navigation for Peripheral Pulmonary Lesions Using a Tip Tracked Steerable Catheter and Optical Guidance||Washington University School of Medicine|No|Recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582944||10555|
NCT02590198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0063|Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines|Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines; Impact on Antibiotic Use in Newborns With Suspected Early-onset Neonatal Infection (EONI)|DIACORD|Nantes University Hospital|No|Not yet recruiting|October 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|8928|||Both|N/A|N/A|No|Probability Sample|Children included in the DIACORD study will be born at > 36 weeks gestation in one of the        15 participating maternity or neonatology units and suspected of EOSI according to the        ANAES recommendations (clinical suspicion of chorioamnionitis; intrapartum maternal fever        > 38°C, infected twin, spontaneous premature delivery at < 37 gestational weeks, prolonged        rupture of membrane for > 12 hours, maternal colonization with group B Streptococcus        without full prophylactic antibiotic treatment, or signs of fetal asphyxia).|October 2015|October 28, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02590198||9998|
NCT02581046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China7|Effect of the Timing of Cataract Surgery on Complications in Patients With Bilateral Congenital Cataracts|Effect of the Timing of Lens-removal Cataract Surgery on Postoperative Complications Rate Among Patients With Bilateral Congenital Cataracts||Sun Yat-sen University|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|N/A|3 Months|No|||October 2015|October 18, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02581046||10701|
NCT02589535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69/CE/2015|Circulating Stem Cells, SDF-1, HIF-1 and Sepsis's Indices in Emergency Abdominal Surgical Patients|Circulating Stem Cells, SDF-1, HIF-1 and Sepsis: Relationship Between Indices of Sepsis and Emergency Abdominal Surgical Patients||University of Foggia|No|Recruiting|November 2015|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|postoperative patients undergoing emergency major abdominal surgery|February 2016|February 16, 2016|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02589535|2 Weeks|10049|
NCT02590965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-013-00CH1|A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer||Hutchison Medipharma Limited|No|Active, not recruiting|April 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|March 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02590965||9939|
NCT02521220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPER2015UM|Beneficial Effects of the Amino-acid Food Supplement L-Citrulline in Participants With Peripheral Artery Disease|Beneficial Effects of the Amino-acid Food Supplement L-citrulline in Participants With Peripheral Artery Disease|CIPER|Maastricht University|Yes|Not yet recruiting|October 2015|August 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|N/A|No|||August 2015|August 12, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02521220||15295|
NCT02579655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB13-1241|Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study|Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study|ACCESS|University of Calgary|No|Recruiting|November 2015|January 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|4714|||Both|65 Years|N/A|No|||December 2015|December 16, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02579655||10808|
NCT02579668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0476|Language Therapy in British Sign Language|Language Therapy in British Sign Language - a Pilot Study to Explore the Use of Therapeutic Strategies and Resources by Deaf Adults With Young People Who Have Language Difficulties in BSL.||University College, London|Yes|Enrolling by invitation|September 2014|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|8 Years|65 Years|No|||October 2015|October 16, 2015|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02579668||10807|
NCT02583269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01815|Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery|Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|March 2016|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583269||10530|
NCT02582138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115621|Multicomponent Intervention for Physical Frailty and Sarcopenia|Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT)|SPRINTT|Catholic University of the Sacred Heart|Yes|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1500|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02582138||10617|
NCT02581605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1639|Correction of Angular Deformities in Knee Arthrosis|Patient Matched Osteotomy to Correct Angular Deformities in Knee Arthrosis||Imperial College London|No|Recruiting|November 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|84|||Both|18 Years|70 Years|No|Non-Probability Sample|Osteotomy Arm:        Target population: 42        Partial Knee Replacement Arm:        Target population: 42|September 2015|October 20, 2015|September 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02581605||10658|
NCT02590367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JiangsuPHTCM|Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy|Huo JieGe, Doctor of Medicine,Professor of Medicine,Professor of Medical Science.||Jiangsu Province Hospital of Traditional Chinese Medicine|Yes|Recruiting|August 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|September 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590367||9985|
NCT02590380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-008|Comparing Pedicle Screw Systems for the Treatment of Adolescent Paediatric Spine Deformity|A Randomized Controlled Trial: Comparison of a Top Loading MESA® Spinal System With MESA Rail™ and a Side Locking Pedicle Screw System for the Treatment of Adolescent Paediatric Spine Deformity||K2M, Inc.|No|Not yet recruiting|June 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|11 Years|21 Years|No|||October 2015|March 10, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590380||9984|
NCT02579499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0713|Comparing the Intensity-based Statin Therapy With Attained Low-density Lipoprotein Cholesterol Based Statin Therapy in Patients With Coronary Artery Disease: Statin Strategy Proposal Trial|||Yonsei University|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4400|||Both|19 Years|N/A|No|||October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579499||10820|
NCT02585895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140316|Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment|A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment||Amgen|No|Recruiting|December 2015|January 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|October 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585895||10328|
NCT02523950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015MEKY047|Staged and Combined Surgery for Cataract Patients With Corneal Endothelial Dysfunction|Evaluation of Staged and Combined Phacoemulsification With Intraocular Lens (IOL) Implantation and Descemet Membrane Endothelial Keratoplasty (DMEK) for Cataract Patients With Corneal Endothelial Dysfunction||Sun Yat-sen University|Yes|Recruiting|March 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|75 Years|No|||August 2015|August 12, 2015|July 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523950||15085|
NCT02580188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNMBC-SNUBH|The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery|The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery|DEEPCOL|Seoul National University Bundang Hospital|No|Enrolling by invitation|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02580188||10767|
NCT02580201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2-ABMG|A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic|T2-ABMG|Fidec Corporation|Yes|Not yet recruiting|November 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|154|||Both|5 Weeks|5 Years|Accepts Healthy Volunteers|||August 2015|October 19, 2015|August 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02580201||10766|
NCT02588599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_LUNULA_RETRO|A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis|A Retrospective Evaluation of the Effect of the Erchonia LUNULA™ on the Increase of Clear Nail in Patients With Toenail Onychomycosis||Erchonia Corporation|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 25, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588599||10121|
NCT02591394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0416|STEPs to Blood Pressure Reduction.|STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction|STEPS|The University of Texas Health Science Center, Houston|No|Not yet recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591394||9906|
NCT02511158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC2012|French Prospective Anterior Cruciate Ligament Reconstruction Cohort Study (FAST)|Prospective Follow-up Study of Patients Undergoing Knee Ligament Surgery|FAST|Fonds de Dotation pour la Recherche Clinique en Orthopédie et Pathologie du Sport|No|Recruiting|September 2012|September 2052|Anticipated|September 2032|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|||Both|7 Years|N/A|No|Non-Probability Sample|Participants enrolled in the FAST cohort by one of four surgeons and meeting eligibility        criteria|February 2016|February 1, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511158|20 Years|16066|
NCT02511171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-002-Pilot1|Parental Blinding in Clinical Trials of Osteopathy|A Study to Explore the Acceptability of Parental Blinding in Clinical Trials of Osteopathy With Excessively Crying Infants as Study Participants||European School of Osteopathy||Recruiting|June 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|4 Months|No|||July 2015|July 28, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02511171||16065|
NCT02589106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRF2016|Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis|Safety and Efficacy of Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis||The Hong Kong Polytechnic University|Yes|Not yet recruiting|January 2017|December 2020|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|10 Years|14 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589106||10082|
NCT02588781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05-071|Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study|Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study||Samsung Medical Center|No|Not yet recruiting|October 2015|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588781||10107|
NCT02588794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316/15 S|Cytokine Adsorption in Sepsis and Acute Kidney Injury|Cytokine Adsorption in Sepsis and Acute Kidney Injury|CASAKI|Technische Universität München|No|Recruiting|October 2015|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|80 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588794||10106|
NCT02586454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-15-919-25992|Analgesic Efficacy of Transmuscular Quadratus Lumborum in Patients Undergoing Total Abdominal Hysterectomy|||Kuala Lumpur General Hospital|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|65 Years|No|||December 2015|December 7, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586454||10285|
NCT02515747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01200406198|Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE|Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population|PRELUDE|Russian Cardiology Research and Production Center|Yes|Completed|January 1993|January 2014|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1400|||Both|18 Years|N/A|No|||August 2015|August 1, 2015|May 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02515747||15715|
NCT02515760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-515/2013|Tumor-specific T Cells in Lung Cancer|Tumor-specific Effector T Cells in Non-small Cell Lung Cancer||University Hospital Heidelberg|No|Recruiting|February 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515760||15714|
NCT02589353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 5373|Human Detection of Glucose Polymers|The Role of Salivary Contents in Taste Perception||Oregon State University||Recruiting|September 2012|||October 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589353||10063|
NCT02589574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-383|Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT|Improving Influenza Vaccination Rates in Nurses Through Electronic Text Message Reminders : a Randomised Controlled Trial||The University of Hong Kong|Yes|Not yet recruiting|November 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|658|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02589574||10046|
NCT02584569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-915-1002|Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study|A Phase 1, Open-Label, Positron Emission Tomography Study With [18F]MNI-794 to Determine Phosphodiesterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects||Takeda|No|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584569||10430|
NCT02591524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuTx-CF-colonization_1|Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung Transplantation|Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung Transplantation||Hannover Medical School|No|Not yet recruiting|November 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591524||9896|
NCT02591537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-15-0001|OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University|Prospective, Randomized, Single Center, Controlled Evaluation of the Effectiveness of OxyGenesys Topical Dissolved Oxygen Dressing in Accelerating the Healing of Split Thickness Skin Graft Donor Sites Using the NWU Abdominoplasty Scar Model||Halyard Health|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591537||9895|
NCT02522624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201407058|Supporting Decisions About Health Insurance to Improve Care for the Uninsured|Supporting Decisions About Health Insurance to Improve Care for the Uninsured||Washington University School of Medicine|Yes|Recruiting|September 2015|May 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|362|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02522624||15187|
NCT02585778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14355|Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy||Sanofi|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585778||10337|
NCT02582099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271/2555(EC1)|The Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis|Comparison of the Efficacy and Complication of Gentamicin and Normal Saline Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis : a Double Blind Randomized Control Trial||Mahidol University|Yes|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582099||10620|
NCT02592382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0429-13-rmb/CTIL|Nasal Xylitol in the Prevention of Otitis Media|Nasal Xylitol for Recurrent Otitis Media||Rambam Health Care Campus|Yes|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592382||9830|
NCT02512003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT6000|Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)|Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold|FANTOM I|REVA Medical, Inc.|Yes|Active, not recruiting|December 2014|March 2020|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02512003||16001|
NCT02512016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82389|Motherhood and Pelvic Health (MAP Study)|Bridging Physical and Cultural Determinants of Postpartum Pelvic Floor Support and Symptoms Following Vaginal Delivery||University of Utah|Yes|Recruiting|August 2015|August 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1530|||Female|18 Years|N/A|No|||February 2016|February 19, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02512016||16000|
NCT02586584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC Study Code 14-229-PSY|The I-Score Study: Developing a New Patient-Reported Tool for the Routine HIV Care of Patients on Antiretroviral Therapy|The I-Score Study: The Development and Validation of a Patient-Reported Measure of Antiretroviral Therapy's Interference With Life: A Clinical Patient-management Tool for Healthcare Providers||McGill University Health Center|Yes|Not yet recruiting|January 2016|July 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|The target population consists of HIV-positive patients on ART recruited from the        caseloads of eight participating clinical sites in France and Canada. The clinical sites        were selected on a geographical basis to account for different regional contexts not only        in terms of the size of the HIV/AIDS epidemics, but also in terms of the sociodemographic,        socioeconomic, and organizational HIV care differences that may exist across regions. The        sites are similarly heterogeneous in the representation of risk groups composing the        caseloads (e.g., women, injection drug user, men who have sex with men, immigrants).|October 2015|October 23, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02586584||10275|
NCT02579226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6130C00001|A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors|A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours||AstraZeneca|No|Recruiting|October 2015|January 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|130 Years|No|||February 2016|February 29, 2016|September 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579226||10840|
NCT02584413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201303074|Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma|Hypotonia as a Clinical Predictor of Glioma in Children With Neurofibromatosis Type 1||Washington University School of Medicine|No|Recruiting|April 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|80|||Both|1 Year|7 Years|No|||January 2016|January 14, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584413||10442|
NCT02584426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAU-15-043|Subcutaneous Injection and Ultrasonic Dispersion of Cefazolin Into Chronic Pelvic-Region Pressure Ulcers in Persons With Spinal Cord Injury|||James J. Peters Veterans Affairs Medical Center||Not yet recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|79 Years|No|||October 2015|October 22, 2015|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584426||10441|
NCT02516917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163562|The Efficacy of a Brief Attention Training Technique on Improving Behaviour and Attention in Children With ADHD|The Efficacy of a Brief Attention Training Technique on Improving Behaviour and Attention in Children With ADHD||University of Manchester||Not yet recruiting|August 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|37|||Both|7 Years|11 Years|No|||August 2015|August 3, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02516917||15626|
NCT02590276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140705 -|Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)|Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis|PREV-DEMALS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2015|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02590276||9992|
NCT02590289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-5000-CL-103|A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects|An Open-Label, Single-Dose, 4-Way Crossover, Bioavailability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Food Effect of BBI-5000 Capsules in Healthy Adult Subjects||Brickell Biotech, Inc.|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590289||9991|
NCT02584686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1121015|Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction|Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction Not Responding to Oral and Intracavernous Therapy||Cairo University|Yes|Recruiting|October 2015|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584686||10421|
NCT02585011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1201|Effect of Local Infiltration Anesthesia With Ropivacaine on Postoperative Pain After Hip Hemiarthroplasty|Effect of Local Infiltration Anesthesia With Ropivacaine on Postoperative Pain After Hip Hemiarthroplasty||St. Olavs Hospital|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||October 2015|October 21, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02585011||10396|
NCT02585245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC0001|Comparison of Nutrition Risk Screens|Comparison of Nutrition Risk Screens in Identification of Hospitalized Patients at Nutrition Risk and/or With Malnutrition.||ThedaCare|No|Recruiting|October 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|110 Years|No|Non-Probability Sample|Adult Hospitalized patients that can consent|October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585245||10378|
NCT02594501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA 2015-01|Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy|COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention|COBRA-REDUCE|CeloNova BioSciences, Inc.|Yes|Recruiting|February 2016|November 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|840|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594501||9667|
NCT02592655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT001|A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet|Randomized Sequence, Assessor-Blind, Cross-Over Study of a Windlass Tourniquet, a Pneumatic Tourniquet and an Elastic Adhesive Bandage for Use as a Tourniquet||Migura, Marcus|No|Completed|December 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592655||9809|
NCT02589093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14074|Validation of a Nociception Monitor in Healthy Volunteers|Validation of a Nociception Monitor in Healthy Volunteers||Maisonneuve-Rosemont Hospital|Yes|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02589093||10083|
NCT02592408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MenziesSHR|A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan|A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan|MalTreSu|Menzies School of Health Research|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|280|||Both|12 Months|N/A|No|||February 2016|February 2, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02592408||9828|
NCT02581488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-035|Use of Santyl in Diabetic Foot Ulcers|Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver||Smith & Nephew, Inc.|No|Recruiting|October 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581488||10667|
NCT02584114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15_2463|Brain Effects of Memory Training in Early Psychosis|Brain Effects of Memory Training in Early Psychosis||University of Calgary|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|40 Years|No|||October 2015|October 20, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02584114||10465|
NCT02584127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFCHKA|Tobacco-Related Disease Prevention Among Korean Americans|Tobacco-Related Disease Prevention Among Korean Americans|CFCHKA|University of California, Berkeley|No|Completed|September 2009|October 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584127||10464|
NCT02594150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823388|Single Center Randomized Pilot Study Of Colorectal Cancer Screening Outreach|Single Center Randomized Pilot Study Of Colorectal Cancer Screening Outreach|CRCSO|University of Pennsylvania|No|Not yet recruiting|November 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|4||Anticipated|1080|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594150||9694|
NCT02594163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-023|Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma|A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma||Seattle Genetics, Inc.|Yes|Recruiting|October 2015|March 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594163||9693|
NCT02594176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-064-IV-01 (IMR-062)|Study of FLEXISEQ® for Treatment of Osteoarthritis of the Knee in NSAID-compromised Patients|A Randomised, Double-blind, Placebo Controlled Study of Topical FLEXISEQ® for the Treatment of Osteoarthritis of the Knee in Patients Contraindicated for or With Clinical Intolerance to NSAIDs|OANIT|Pro Bono Bio|No|Recruiting|October 2015|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|50 Years|N/A|No|||February 2016|February 2, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02594176||9692|
NCT02592746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-042|A Study of Palbociclib With Exemestane Plus Goserelin Versus Capecitabine in Premenopausal Women With HR+ MBC|A Phase II Randomized Study of Palbociclib in Combination With Exemestane Plus Goserelin Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer||Samsung Medical Center|Yes|Not yet recruiting|November 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Female|19 Years|N/A|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592746||9802|
NCT02588963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPorto|Prevention of Respiratory Infections Among Children Under 3 Years of Age Attending Daycare Centres|Prevention of Respiratory Infections Among Children Under 3 Years of Age Attending|PRICAD|Polytechnic Institute of Porto|Yes|Active, not recruiting|January 2015|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|200|||Both|3 Months|36 Months|No|||October 2015|October 27, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588963||10093|
NCT02589431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TST-10-2929|Comparison of Total, Salivary and Calculated Free Cortisol Levels in Patients With Severe Sepsis|Comparison of Total, Salivary and Calculated Free Cortisol Levels in Patients With Severe Sepsis||TC Erciyes University|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirthy patients with severe sepsis (15 men, and 15 women), and 16 (8 men and 8 women)        healthy controls|October 2015|October 27, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02589431||10057|
NCT02581332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32852|The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain|The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain||Wake Forest School of Medicine|Yes|Not yet recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02581332||10679|
NCT02523209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408080|Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation|Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study|TRANSBONE|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|September 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|patient with end stage renal disease|March 2016|March 9, 2016|July 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02523209||15142|
NCT02583997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2014/PL-01|Non-closure of Alveoli After Avulsion of Wisdom Teeth|Non-closure of Alveoli After Avulsion of Wisdom Teeth: a Randomized, Open, Multicenter Trial|AlvéCare|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|May 2016|February 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|14 Years|N/A|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583997||10474|
NCT02580786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26/2011|Breastfeeding Preterm Infants - The Efficacy of Internet-based Peer Support|||University of Turku|No|Completed|June 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|124|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580786||10721|
NCT02581033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032/14 Protocol # :APP106653|Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients|Determinants of Sustained Virological Response After Discontinuation of Long-term Nucleoside Analogue Therapy in Chronic Hepatitis B Patients|STOP|St Vincent's Hospital Melbourne|Yes|Recruiting|May 2014|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 18, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581033||10702|
NCT02585674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC13470|Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo|A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus|AUTOMATIX|Sanofi|No|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02585674||10345|
NCT02585921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R39OT26989-01-00|Organ Donation Interventions Among High Students|Combining, Expanding, and Evaluating Multiple Evidence-based Organ Donation Interventions||Case Western Reserve University|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|1800|||Both|15 Years|26 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585921||10326|
NCT02589080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIONE-LU|Phantom Limb Pain: Efficacy of Non-invasive Sensory Feedback Through the Prosthesis|Phantom Limb Pain: Efficacy of Non-invasive Sensory Feedback Through the Prosthesis|EPIONE|Lund University Hospital|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02589080||10084|
NCT02592993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF17261|Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars|Clinical Study to Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Treatment of Acne Scars||Syneron Medical|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|October 29, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592993||9783|
NCT02580305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP2S1502HT6|SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study|A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride||Suven Life Sciences Limited|Yes|Recruiting|September 2015|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|537|||Both|50 Years|85 Years|No|||February 2016|February 19, 2016|October 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02580305||10758|
NCT02580734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS2013|Efficacy of Melatonin in Burning Mouth Syndrome (BMS)|Melatonin to Treat Burning Mouth Syndrome (BMS): A Randomized, Cross-over, Placebo-controlled, Triple-blind Clinical Trial|BMS2013|University of Milan|No|Completed|March 2014|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||October 2015|October 25, 2015|December 20, 2013||No||No||https://clinicaltrials.gov/show/NCT02580734||10725|
NCT02580968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|643857003534|Study of Key Electro-acupuncture Technique on Migraine|Study of Key Electro-acupuncture Technique on Migraine||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|March 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02580968||10707|
NCT02591420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 398|Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection|Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to Adults During Early Acute HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|50 Years|No|||October 2015|October 28, 2015|October 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591420||9904|
NCT02593240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11768|Worksite Wellness Randomized Controlled Trial|||Tufts University|No|Recruiting|October 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|720|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02593240||9764|
NCT02586545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-1234|Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care Sector|||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|August 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586545||10278|
NCT02592070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC_IRB_15575|Activity & Cognition After Treatment for Breast Cancer|Activity & Cognition After Treatment (ACT) for Breast Cancer|ACT|University of Illinois at Urbana-Champaign|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|30 Years|60 Years|No|||October 2015|October 28, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02592070||9854|
NCT02585622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPHSTROM|Novel Stromal Cell Therapy for Diabetic Kidney Disease|Novel Stromal Cell Therapy for Diabetic Kidney Disease|NEPHSTROM|Mario Negri Institute for Pharmacological Research|Yes|Not yet recruiting|May 2016|April 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585622||10349|
NCT02585687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.693|Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma|Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma|ETAFIRM|Hospices Civils de Lyon|No|Recruiting|July 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585687||10344|
NCT02589548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBLH|Brazilian Prospective Hodgkin Lymphoma Registry|Brazilian Prospective Hodgkin Lymphoma Registry||Universidade Federal do Rio de Janeiro|No|Recruiting|October 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Formalin-fixed tissue for central diagnostic pathology review|Both|12 Years|100 Years|No|Non-Probability Sample|Hodgkin Lymphoma patients|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589548||10048|
NCT02586597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00040369|Paired Associative Stimulation in Stroke|Paired Associative Stimulation Modulates Motor Excitability and Plasticity in Chronic Stroke Patients||Medical University of South Carolina|No|Recruiting|February 2015|||February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02586597||10274|
NCT02586610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GI15-213|Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer|A Phase II Trial of Neoadjuvant Chemoradiation (CRT) and Pembrolizumab in Patients With Rectal Cancer: Hoosier Cancer Research Network GI15-213||Hoosier Cancer Research Network|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586610||10273|
NCT02594228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012-227|Protein Intake and Physical Performance|Effects of Increased Protein Intake and Exercise Training on Body Composition, Cardiovascular Health and Physical Performance||Skidmore College|No|Completed|December 2010|August 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594228||9688|
NCT02523612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00045-44|Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions|Prospective National Multicentre Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions|NOMAT01|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|June 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Female|18 Years|N/A|No|||January 2016|January 27, 2016|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02523612||15111|
NCT02514668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED14154|A Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Multiple Myeloma|An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Relapsed/Refractory Multiple Myeloma||Sanofi|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514668||15798|
NCT02584517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLAS001|Aetiology of TemporaL Arteritis Study|Understanding the Aetiology and Pathogenesis of Giant Cell Arteritis|ATLAS|University of Oxford|No|Not yet recruiting|January 2016|January 2021|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Serum Plasma Peripheral Blood Mononuclear Cells Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|The proposed study will recruit a cohort of eligible patients (predominantly from primary        care referrals) suspected by their referring doctor to have new onset of GCA.|October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584517||10434|
NCT02585635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-263263|Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia|Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia|MOrPH|Neuroscience Research Australia|No|Not yet recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There will be two study populations:          1. Families of children with haemophilia          2. Haemophilia physicians|October 2015|October 22, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02585635||10348|
NCT02585648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2258-PIV-0215|Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome|Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome||Medical University of Vienna|No|Not yet recruiting|November 2015|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02585648||10347|
NCT02518230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crossover NAVA|Randomized Crossover of NAVA and Synchronized Intermittent Pressure Ventilation in Neonates and Infants|Respiratory Severity and Caloric Consumption on NAVA: Randomized Crossover Trial of NAVA and SIMV||Children's Mercy Hospital Kansas City|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|24 Months|No|||August 2015|August 5, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02518230||15525|
NCT02579915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308000908-Phase 2|Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)|Phase 2 Randomized Controlled Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care||Brown University|Yes|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579915||10788|
NCT02588404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fusion study|The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient|The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient||Sir Mortimer B. Davis - Jewish General Hospital|No|Not yet recruiting|January 2016|||January 2030|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|65|Samples With DNA|Areas of prostate tumor will be identified by the pathologist of the study. This will then      be excised from the paraffin block using a tissue microarray punch. Two punches will be      acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted      using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the      isolation of nucleic acids will be used differing only in the time of protease digestion      such that RNA is isolated after a short incubation (30 minutes), while DNA is isolated after      a longer incubation (overnight).|Male|18 Years|N/A|No|Non-Probability Sample|The original slides of 65 patients with informed consent will be reviewed. Assuming 50%        Gene-fusion carrier rate, patients with and without markers under the investigation will        be accrued into this study. The investigators at the treating institutions will submit        paraffin-embedded tissue blocks from the original pre-treatment diagnostic prostatic        biopsy, which will be reviewed to confirm the Gleason score and to record other        histopathologic features, such as the extent of tumor in the biopsies, the number of        positive biopsies, and mitotic index. The block must be clearly labeled with the protocol        and case number. A tissue microarray (TMA) containing cores representing clinically        localized prostate cancers will be constructed from 60 men who underwent radical radiation        therapy. Three cores (0.6mm in diameter) will be taken from each representative tissue        block to construct the TMA. Detailed clinical, pathological, and TMA data will be        maintained on a secure database.|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588404||10136|
NCT02591355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL 03|Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment|A Monocentric, Double-blind, Randomized, Active- and Placebo-controlled Split-scalp Study to Evaluate the Clinical Effectiveness of Platelet-rich Plasma (PRP) in the Treatment of Androgenetic Alopecia||Regen Lab SA|No|Not yet recruiting|November 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||July 2015|October 28, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591355||9909|
NCT02515175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-003-003|Evaluating New Formulation of Therapeutic HSV-2 Vaccine|A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection||Genocea Biosciences, Inc.|Yes|Active, not recruiting|November 2015|January 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|50 Years|No|||February 2016|February 5, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515175||15759|
NCT02515188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0502|The Effect of Additional Propacetamol Infusion on Post Procedural Outcome and Opioid Consumption During Catheter Ablation of Atrial Fibrillation.|||Yonsei University|No|Recruiting|August 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|98|||Both|20 Years|79 Years|No|||February 2016|February 15, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02515188||15758|
NCT02585037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17119213.0.0000.5497|Changes in Grip Strength by Using Bandage Kinesio Taping|Changes in Grip Strength by Using Bandage Kinesio Taping||University of Mogi das Cruzes|Yes|Completed|August 2015|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585037||10394|
NCT02592681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternUCanada-acu|Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine|Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine||Western University, Canada|No|Not yet recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592681||9807|
NCT02592239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)214/2012 Addendum|Hedonic Perception and Brain Activity Response to Meal|Hedonic Perception and Brain Activity Response to Meal in Health and Functional Dyspepsia||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|November 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|February 1, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02592239||9841|
NCT02592304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SvG2-4-13-07|Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT|Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT||Odense University Hospital|Yes|Recruiting|September 2014|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02592304||9836|
NCT02515474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSIGansu|Comparison of LCBDE vs ERCP + LC for Choledocholithiasis|A Long Term Complications Comparison of Laparoscopic Common Bile Duct Exploration and Cholecystectomy Versus Sequential ERCP Followed by Laparoscopic Cholecystectomy for Choledocholithiasis: a Multicenter Randomized Controlled Study||Hepatopancreatobiliary Surgery Institute of Gansu Province|Yes|Not yet recruiting|August 2015|August 2022|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|65 Years|No|||July 2015|July 31, 2015|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02515474||15736|
NCT02592759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2015-74|Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke Patients|Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke||Seoul National University Hospital|Yes|Not yet recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|19 Years|N/A|No|||October 2015|October 29, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02592759||9801|
NCT02591446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|413114|Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders|Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders||Rhode Island Hospital|Yes|Recruiting|October 2014|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|240|||Both|6 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will study a total of 120 individuals with ASD. We will also evaluate a total of 120        controls. Ages 6-16 years and 21-45 years.|October 2015|October 28, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02591446||9902|
NCT02591459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49354415.0.0000.5497|Android Mobile Devices to Assist Routine Anticipation for Autistic Children|Android Mobile Devices to Assist Routine Anticipation for Autistic Children||University of Mogi das Cruzes|Yes|Active, not recruiting|October 2015|December 2015|Anticipated|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|3 Years|9 Years|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591459||9901|
NCT02519933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai10|A Comparison of mNT-BBAVF and BCAVF in Hemodialysis Patients|A Comparison of Modified Non-transposed Brachiobasilic Arteriovenous Fistula and Brachiocephalic Arteriovenous Fistula in Hemodialysis Patients||Shanghai 10th People's Hospital|Yes|Recruiting|January 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|July 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02519933||15394|
NCT02593877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010770|Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy|A Multi-centre, Prospective, Randomized Controlled Study to Compare Outcomes of Viscoelastic Haemostatic Assay (VHA)-Guided Resuscitation Versus Conventional Resuscitation Support in Haemorrhaging Trauma Patients|iTACTIC|Queen Mary University of London|Yes|Not yet recruiting|December 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|392|||Both|16 Years|N/A|No|||October 2015|October 30, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02593877||9715|
NCT02588989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGA_function|Fibrosis, Valvular and Ventricular Function in Patients With TGA|Fibrosis, Valvular and Ventricular Function in Patients With Transposition of the Great Arteries||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2015|October 2026|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Intracellular RNA collection from whole blood|Both|16 Years|N/A|No|Non-Probability Sample|Patients with a transposition of the great arteries (TGA)|October 2015|October 26, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02588989||10091|
NCT02589002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1544|Effects of Sucralose on Glucose Metabolism|Effects of Sucralose on Insulin Sensitivity, Pancreatic Response and Appetite Regulating Hormones|Sucralose|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02589002||10090|
NCT02578810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGraz2|PIERS and BIS, sFIT:PIGF, Adrenomedullin|Sensitivity and Specificity of Bispectral Index (BIS) EEG Parameter, sFIT (Soluble FMS Tyrosine Kinase): PIGF (Placental Growth Factor) Ratio, Adrenomedullin for Grading Preeclampsia Integrated Estimate Risk Score (PIERS)|BIS2|Medical University of Graz|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Female|18 Years|50 Years|No|Non-Probability Sample|24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min        mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF        (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify        the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS        percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients'        clinical and laboratory findings documented in their charts, compared with 24 pregnant        patients without Eclampsia or pre-eclampsia|October 2015|October 21, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578810||10872|
NCT02511743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015[888]|Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus Infection|Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus||Peking University First Hospital|No|Completed|April 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2871|||Both|20 Years|75 Years|No|Non-Probability Sample|physicians fullfill the following criterion:          1. Mainly engaged in liver disease diagnosis and treatment;          2. Diagnosis and treatment at least 10 patients with chronic Hepatitis B Virus infection             per week.|November 2015|November 4, 2015|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02511743||16021|
NCT02516046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-1451-A16|18F-AV-1451 Autopsy Study|A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology||Avid Radiopharmaceuticals|Yes|Recruiting|September 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|50 Years|N/A|No|||January 2016|January 27, 2016|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516046||15693|
NCT02589587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEC|Enteroendocrine Cells Before and After Sleeve Gastrectomy|Enteroendocrine Cells in Lean Controls and Healthy Subjects Before and After Sleeve Gastrectomy||University Hospital, Basel, Switzerland|No|Recruiting|October 2013|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02589587||10045|
NCT02586389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-CA-101|Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay|Collection of Whole Blood and Tissue Specimens From Patients Diagnosed With Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA||Sequenom, Inc.|No|Recruiting|October 2015|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Whole blood samples and tissue samples will be collected for DNA extraction.|Both|18 Years|N/A|No|Probability Sample|Male or female patients at least 18 years of age who have been diagnosed with        non-hematologic cancer (Stages I-IV) and who meet all study inclusion criteria and no        exclusion criteria. Primarily subjects with breast, colorectal, lung, or melanoma cancer        (90%) will be enrolled. The remaining subjects (10%) diagnosed with other cancer types may        be enrolled on a case by case basis.|October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586389||10290|
NCT02579837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106583|CLEAR SIGHT: A Trial of Non-Mydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease|CLEAR SIGHT: A Randomized Trial of Non-Mydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease||Western University, Canada|No|Recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|740|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579837||10794|
NCT02516644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkinson_Xbox|Feasibility and Effectiveness of Virtual Reality & Use of Body Weight Support Treadmill Training in Parkinson's Disease|Feasibility and Effectiveness of Virtual Reality and the Use of Body Weight Support Treadmill Training in Parkinson's Disease: an Explorative Study||University Hospital of Ferrara|Yes|Recruiting|February 2015|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|80 Years|No|||July 2015|August 5, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02516644||15647|
NCT02578706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 14-1374|Targeting Platelets in Chronic HIV Infection|Targeting Platelets in Chronic HIV Infection||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578706||10880|
NCT02578953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204646|Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects|Bioequivalence Study of Dutasteride Capsules-An Evaluation of the Bioequivalence of Dutasteride Capsule Manufactured at GSK Compared to Dutasteride Capsule Manufactured at Catalent in Healthy Japanese Male Subjects||GlaxoSmithKline|No|Completed|September 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02578953||10861|
NCT02592460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WGF_2014-2|Postoperative Pain and Polyamines-poor Diet (DOLAMINE)|Impact on Pain of a Preoperative Polyamines-poor Diet After Orthopedic Surgery of the Foot|DOLAMINE|Fondation Ophtalmologique Adolphe de Rothschild|No|Recruiting|December 2014|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1204|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592460||9824|
NCT02590354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM0714|Analytical Treatment Interruption in HIV Positive Patients|Analytical Treatment Interruption in HIV Positive Patients With Low Viral Reservoir to Evaluate the Potential of a Functional Cure|ISALA|Institute of Tropical Medicine, Belgium|Yes|Recruiting|December 2015|November 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|64 Years|No|||February 2016|February 17, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02590354||9986|
NCT02580903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPNPH|Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms|Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study|MPNPH|Odense University Hospital|No|Recruiting|February 2015|February 2021|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|All patients will submit a blood sample for later analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients attending our outpatient clinic with Myeloproliferative Neoplasms|October 2015|October 19, 2015|January 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02580903||10712|
NCT02578966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNSC-CZC|Cohort Zero Caries|Impact of Preventive Child Oral Health Programs in Primary Health Care.|CZC|Hospital Nossa Senhora da Conceicao|No|Enrolling by invitation|January 2014|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|650|||Both|12 Months|14 Months|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578966||10860|
NCT02583529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0554|Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation|Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation|NOVTPD|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|40 Years|90 Years|No|||October 2015|October 20, 2015|September 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02583529||10510|
NCT02583542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Torcmek|A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers|A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers|TORCMEK|Queen Mary University of London|No|Recruiting|June 2015|July 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02583542||10509|
NCT02588820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-000251-24|Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection|Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection: A Pilot Comparative Study|VIRECURE|Hospital Clinic of Barcelona|Yes|Recruiting|November 2015|May 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|65 Years|No|||November 2015|November 25, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02588820||10104|
NCT02592512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV-NAVA vs NIV-PS/PC|NIV-NAVA vs NIV-PS/PC in Respiratory Insufficiency|Non-Invasive Ventilation With Neurally Adjusted Ventilatory Assist vs NIV Pressure Support or Pressure Control in Treatment of Patients With Acute Respiratory Insufficiency. A Prospective, Randomised, Single Blinded, Crossover Pilot Study||Vejle Hospital|Yes|Not yet recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the ICU at Vejle Hospital, Denmark, with acute respiratory        insufficiency.|October 2015|October 28, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02592512||9820|
NCT02580500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lutfiye01|Epidural and Spinal Anesthesia Techniques in Pilonidal Dermoid Sinus Surgeries|Epidural and Spinal Anesthesia Techniques in Pilonidal Dermoid Sinus Surgeries: Prospective Randomized Trials||Lütfiye Nuri Burat Government Hospital|No|Recruiting|October 2015|January 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2016|January 1, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580500||10743|
NCT02579525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARTARE-2S-01|Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock|Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock [TARTARE-2S]- A Multicentre Randomized Controlled Trial|TARTARE-2S|Helsinki University Central Hospital|Yes|Not yet recruiting|January 2016|December 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579525||10818|
NCT02584101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/WS/0208|Acceptance and Commitment Therapy (ACT) and Carers|The Use of Acceptance and Commitment Therapy to Promote WellBeing and Psychological Flexibility in Carers: A Randomized Controlled Feasibility Trial||University of Glasgow|No|Not yet recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584101||10466|
NCT02579863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-185|Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)|A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).||Merck Sharp & Dohme Corp.|Yes|Recruiting|October 2015|April 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579863||10792|
NCT02593422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|728101-3|Writing About Experiences With Ovarian Cancer|Writing About Experiences With Ovarian Cancer||University of Maryland|No|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02593422||9750|
NCT02593435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBRCA|The Registration Program of BRCA1/2 Gene|The Registration Program of BRCA1/2 Gene in Chinese Breast Cancer Group|RCA|Chinese Anti-Cancer Association|No|Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|8000|Samples With DNA|The samples, both tissue(s) and blood of patients should be provided for NGS test after ICF      being signed|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Chinese Breast Cancer Patients|March 2016|March 22, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593435|3 Months|9749|
NCT02581501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StamfordH|Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer|Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01||Stamford Hospital|Yes|Recruiting|February 2016|November 2021|Anticipated|November 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581501||10666|
NCT02589262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUT011206|Safety, Blood Levels and Effects of AUT00206|A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.||Autifony Therapeutics Limited|No|Recruiting|September 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02589262||10070|
NCT02589457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163BE15028|Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|19 Years|45 Years|No|||January 2016|January 11, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02589457||10055|
NCT02580110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/57|On the Impact of Common Sweetening Agents on Glucose Regulation, Cognitive Functioning and Gut Microbiota|On the Impact of Common Sweetening Agents on Glucose Regulation, Cognitive Functioning and Gut Microbiota||Lund University||Recruiting|October 2015|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|40|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580110||10773|
NCT02580123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smile-kids|Smile-Kids: Study on Complementary Feeding Transition|||University of Minho||Completed|May 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|4 Months|12 Months|Accepts Healthy Volunteers|||October 2015|October 17, 2015|April 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02580123||10772|
NCT02581644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-367|Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries|Evaluation of the Effectiveness of the Belatacept (Nulojix®) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries||Bristol-Myers Squibb|No|Not yet recruiting|July 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort 1: Patient enrolled by physicians based in hospital and physician renal units        Cohort 2: Physicians and nurses based in hospital and physician renal units        Cohort 3: Patient enrolled by physicians based in hospital and physician renal units|March 2016|March 11, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02581644||10655|
NCT02592928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-PDMAR|Regional Implementation of Collaborative Lung Function Testing|Regional Implementation of Collaborative Lung Function Testing|e-Spiro-HC3|Hospital Clinic of Barcelona|No|Not yet recruiting|November 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|The initial 6 months will include 3 healthcare sectors: Lleida (168k inhabitants, 21        Primary Care Centers), Vic (49k inhabitants, 11 PCC), and AISBE (540k inhabitants, 19 PCC)        following a Plan-Do-Study-Act (PDSA) methodology. The first PDSA cycle (January - March        2016) including a total of 3 PCC, one in each healthcare sector, has as main purpose to        ensure full functionality of the setting. The FS program will be progressively deployed to        all PCC in the 3 sectors in a second 3-months PDSA cycle that will be completed by        mid-2016. FS testing will be prescribed by general practitioner following standard        criteria and it will be carried out by primary care nurses. The deployment in the entire        region (7.5M inhabitants and 369 Primary Care centers) will be completed within 2016.|October 2015|October 29, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02592928||9788|
NCT02585427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00719|Effects of Co-ingesting a Low/High GI Meal With Different Fat Saturation on Postprandial Glucose, Insulin, and Triacylglycerol Responses in Healthy Participants|Effects of Co-ingesting a Low/High GI Meal With Different Fat Saturation on Postprandial Glucose, Insulin, and Triacylglycerol Responses in Healthy Participants||Clinical Nutrition Research Centre, Singapore|No|Recruiting|November 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|25|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02585427||10364|
NCT02517970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|Observing Infant Feeding Interactions||MFS|California Polytechnic State University-San Luis Obispo|Yes|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517970||15545|
NCT02517983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-CRD|Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam|Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam||Brugmann University Hospital|No|Recruiting|August 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|The out-patient population with chronic respiratory disease who are admitted in Pham Ngoc        Thach Hospital|January 2016|January 13, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02517983||15544|
NCT02587988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TARO-301|Trial to Evaluate the Efficacy and Safety of HCP1302|A Randomized, Double-blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HCP1302 in Both Erectile Dysfunction and Hypertension Patients Being Treated With HGP0904||Hanmi Pharmaceutical Company Limited|No|Completed|September 2014|August 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|232|||Male|19 Years|N/A|No|||September 2015|October 26, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02587988||10168|
NCT02584608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510340687|Use of ACTIMMUNE in Patients With ADO2|Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis||Indiana University|Yes|Not yet recruiting|January 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|3 Years|65 Years|No|||October 2015|October 21, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584608||10427|
NCT02584621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3679948|Web-Based Adolescent Motivational Enhancement Study|Web-Supported Adolescent Motivational Enhancement to Reduce Alcohol Use|Web-AME|Seattle Children's Hospital|No|Recruiting|November 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584621||10426|
NCT02592811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SocieteFranceED|Comparison of Endoscopic Sphincterotomy Plus Large-balloon Dilatation and Conventional Treatment for Large CBD Stones|Endoscopic Sphincterotomy Plus Large-Balloon Dilatation (ESLBD) Versus Conventional Endoscopic Treatment for Removal of Large Common Bile Duct Stones : A Prospective Comparative Multi Center Randomized Study||Société Française d'Endoscopie Digestive|Yes|Completed|July 2010|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592811||9797|
NCT02593110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200954|Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease|Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease|TELEX|Northwestern University|Yes|Recruiting|October 2015|April 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02593110||9774|
NCT02592915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2014/PE2|Effect of a Bolus of Clonidine Systemically Administered on the Excitability of the Spinal Motoneurons of the Lower Extremity|Monocentric, Prospective Randomized Controlled Clinical Trial Assessing the Effect on the Lower Limb Spinal Motoneuron Excitability, the Efficacy in Term of Morphinic Sparing and Safety of of Early Clonidine Bolus Intravenous Administration During General Anesthesia in Children and Adolescent 6-18 Years Old Requesting Reconstructive Tympanic Surgery|EXCICLON|Queen Fabiola Children's University Hospital|No|Recruiting|October 2015|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|6 Years|18 Years|No|||October 2015|October 29, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02592915||9789|
NCT02581475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G12|Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection|Efficacy of Segmental Examination Twice of Proximal Colon on Adenoma Detection: a Prospective, Randomized, Controlled Study||Shandong University|Yes|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|680|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581475||10668|
NCT02580318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2015-28|Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings?|Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings?||St. Luke's Hospital and Health Network, Pennsylvania|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|54|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02580318||10757|
NCT02585323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02038|SuPRA: Using Wearable Activity Trackers With a New Application to Improve Physical Activity in Knee Osteoarthritis|Supporting Physical Activity and Reducing Sedentary Behavior in Arthritis||University of British Columbia||Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|19 Years|N/A|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585323||10372|
NCT02580799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28731|Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples|Immunohistochemical HER2 Status Evaluation In Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study||Hoffmann-La Roche|No|Completed|February 2014|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|30|||Female|18 Years|74 Years|No|Non-Probability Sample|Breast tissue samples from female participants with a breast cancer diagnosis|January 2016|January 26, 2016|October 19, 2015||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT02580799||10720|
NCT02580084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRICP111|Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)|Prospective Randomized Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|August 2015|August 2020|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|90 Years|No|||October 2015|October 17, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02580084||10775|
NCT02580097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke-Radiology-ChinaPLAGH|Predictive Value of Magnetic Resonance Perfusion Imaging in Acute and Subacute Stroke Patients|Predictive Value of Magnetic Resonance Perfusion Imaging in Acute and Subacute Stroke Patients||Chinese PLA General Hospital|Yes|Recruiting|August 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Ischemic stroke patients with sympton onset in 48 hours|October 2015|October 16, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02580097|1 Year|10774|
NCT02578628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-453|Discontinuation of Automated Engagement Support|Discontinuation of Automated Engagement Support||University of Vermont|No|Enrolling by invitation|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1700|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02578628||10886|
NCT02578641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF01|Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients|A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients||Tessa Therapeutics|Yes|Recruiting|July 2014|December 2021|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|21 Years|N/A|No|||March 2016|March 22, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578641||10885|
NCT02582060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00030|Individualizing Hemophilia Prophylaxis Using Thromboelastography|Individualizing Hemophilia Prophylaxis Using Thromboelastography||Children's Hospital Los Angeles|Yes|Recruiting|March 2014|||March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Male|5 Years|70 Years|No|||October 2015|October 20, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02582060||10623|
NCT02590900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML6563|Disposition of Intravenous Paracetamol in Young Women|Disposition of Intravenous Paracetamol in Young Women, Including During Pregnancy, in Postpartum or When on Oral Contraceptives||Universitaire Ziekenhuizen Leuven|No|Completed|June 2010|April 2015|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|69|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pooled analysis of different cohorts of young women who all underwent PK study on        paracetamol disposition after iv paracetamol administration.|October 2015|October 27, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590900||9944|
NCT02593331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC29819|Study to Explore the Safety, Tolerability and Pharmacokinetics of Subcutaneous Administration of BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers|A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance||Genentech, Inc.||Recruiting|October 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593331||9757|
NCT02578888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4421|Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies|Early Palliative Medicine Intervention Using Idiographic Assessment for Women With High Risk Gynecologic Malignancies||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|April 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Female|N/A|N/A|No|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02578888||10866|
NCT02593123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14-10739|Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis|Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes||Virginia Commonwealth University|Yes|Recruiting|November 2015|December 2025|Anticipated|December 2025|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593123||9773|
NCT02581800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreHomeCare|Effect and Experience of PreHomeCare of Preterm Infants Using Telecommunication and Smartphone Application|Effect and Experience of PreHomeCare of Preterm Infants Using Telecommunication and Smartphone Application: A Randomized Intervention Study.||Naestved Hospital|No|Recruiting|November 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|N/A|N/A|No|||December 2015|December 4, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581800||10643|
NCT02514681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBCRG-M05|A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer(Study of Perjeta Re-treatment for Clinical Outcomes)|A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer(Study of Perjeta Re-treatment for Clinical Outcomes)|PRECIOUS|Japan Breast Cancer Research Group|No|Recruiting|August 2015|||July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Female|20 Years|N/A|No|||January 2016|February 15, 2016|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02514681||15797|
NCT02514694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0058-1114|LEO 32731 - A Phase I Study in Healthy Subjects|LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects||LEO Pharma||Completed|July 2015|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02514694||15796|
NCT02519205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00065707|Measuring Fatigue in Triage: A Pilot Study|Measuring Fatigue in Triage: A Pilot Study||Duke University|No|Recruiting|October 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|ED Triage nurses|February 2016|February 11, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02519205||15450|
NCT02588534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040136|Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects|An Open-label, Randomized, 2-period Crossover Bioequivalence Study Comparing a 50-mg Dose of Liquid Etanercept Administered to Healthy Subjects by Subcutaneous Injection in the Thigh Using an Auto-injector Device and Manual Injection||Amgen|No|Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02588534||10126|
NCT02588716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Terlipressin|Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.|Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.||Assiut University|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588716||10112|
NCT02593630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicirc Adolescent|Unicirc Adolescent 12-15 Year Old Boys|Field Study of Unicirc Circumcision in Adolescent Boys, Aged 12 to 15 Years.||Simunye Primary Health Care|No|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Male|12 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593630||9734|
NCT02588248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-15-07|L-Menthol Infusion as a Novel Technique During Colonoscopy|L-Menthol Infusion as a Novel Technique During Colonoscopy: The MINT-C Study|MINT-C|University Hospital Case Medical Center|No|Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|45 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|October 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588248||10148|
NCT02588261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8273-CL-0302|A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations|An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations|SOLAR|Astellas Pharma Inc|Yes|Recruiting|November 2015|May 2021|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588261||10147|
NCT02591290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA89 (EFC14375)|Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects|Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects||Sanofi|No|Active, not recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591290||9914|
NCT02581813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 14-284|Does Dairy Benefit Bone & Body Composition in Overweight Girls Undergoing a Weight Management Program?|Effects of a Weight Management Intervention With Increased Dairy Intake on Body Composition and Bone Health in Overweight and Obese Girls.||Brock University|No|Not yet recruiting|January 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|10 Years|16 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581813||10642|
NCT02521350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATADEK 2015-6 /19|Determination of Perioperative Acute Kidney Injury Incidence|Perioperative Acute Kidney Injury Incidence and Risk Factors in Non-cardiac Surgery||Acibadem University|No|Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|40 Years|75 Years|No|Probability Sample|older than 40 years, no gender specified, patients who will stay at least one night in        hospital except cardiovascular, urological surgery and known renal insufficiency.|August 2015|August 10, 2015|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02521350||15285|
NCT02584790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI1782015|NBI to Detect Post-RT Mucosal Residual NPC|Using Narrow-band Imaging (NBI) Technique to Detect Post-radiotherapy Mucosal Residual Nasopharyngeal Carcinoma (NPC)||Pamela Youde Nethersole Eastern Hospital|No|Recruiting|November 2015|November 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02584790||10413|
NCT02592603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCB/2015/0803|Endocuff for Surveillance of Serrated Polyposis Syndrome|Endocuff-assisted vs. Standard Colonoscopy for Surveillance of Serrated Polyposis Syndrome: A Randomized Controlled Trial||Hospital Clinic of Barcelona|No|Recruiting|October 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|124|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592603||9813|
NCT02588924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|961|Study on the Relationship Between Environmental and Occupational Exposure to Metals and Parkinson's Disease|Study on the Relationship Between Environmental and Occupational Exposure to Metals and Parkinson's Disease||Second University of Naples|Yes|Enrolling by invitation|September 2015|September 2017|Anticipated|September 2016|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|Samples Without DNA|Serum|Both|28 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: subjects of both sexes with at least 10 years of work seniority with diagnosis of        Parkinson's disease, coming from Neuromed IRCCS and Second University of Naples Controls:        healthy subjects matched by age, sex, lifestyle habits and areas of residence, work        seniority.|October 2015|October 26, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02588924||10096|
NCT02588937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361HBV15017|Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients|||Chong Kun Dang Pharmaceutical||Recruiting|October 2015|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588937||10095|
NCT02581020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-349|The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects|A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection||AbbVie||Recruiting|January 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|436|||Both|18 Years|75 Years|No|Non-Probability Sample|Participants who were treated in Study M12-536 or M13-004 with 2D regimen (ombitasvir/        paritaprevir/ritonavir) and completed 48 weeks of follow-up.|February 2016|February 18, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581020||10703|
NCT02582398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248/2011|Influence of Light Exposure on Cerebral MAO-A in Seasonal Affective Disorder and Healthy Controls Measured by PET|Influence of Light Exposure on Cerebral Monoamine Oxidase A in Seasonal Affective Disorder and Healthy Controls Measured by PET||Medical University of Vienna||Recruiting|November 2013|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|June 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02582398||10597|
NCT02586714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2KL2RR024141-06|Maternal Body Composition Regulates Placental Function|Maternal Body Composition Regulates Placental Function|MBC|National Center for Research Resources (NCRR)|No|Completed|July 2012|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|41|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy pregnant women at term with singleton gestation who were normal weight,        overweight, or obese.|October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586714||10265|
NCT02519699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP173.166|Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension|Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension||Federal University of São Paulo|No|Recruiting|March 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02519699||15412|
NCT02593825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R324A150103|Efficacy of the START-Play Program for Infants With Neuromotor Disorders|Efficacy of the START-Play Program for Infants With Neuromotor Disorders|START-Play|Duquesne University|No|Recruiting|January 2016|June 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|7 Months|16 Months|No|||October 2015|February 1, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593825||9719|
NCT02581254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/15/WMEAD/97 (4237)|Thin Wire Versus Thick Wire Snare for Cold Snare Polypectomy of Diminutive Polyps|Thin Wire Versus Thick Wire Snare for Cold Snare Polypectomy of Diminutive Polyps- A Randomised Controlled Trial||Western Sydney Local Health District||Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 18, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581254||10685|
NCT02592369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evolut R™ FORWARD Study|CoreValve™ Evolut R™ FORWARD Study|The Medtronic CoreValve™ Evolut R™ FORWARD Study|FORWARD|Medtronic Cardiovascular|No|Recruiting|January 2016|April 2020|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|The study population includes patients with symptomatic native aortic valve stenosis or a        stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating        valve replacement who are scheduled for an elective transcatheter aortic valve        implantation. Patients who will undergo an emergency procedure should not be included in        this study.|February 2016|February 9, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02592369||9831|
NCT02522117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2013-1301-100|Atorvastatin in the Recipient's Kidney Graft From a Living Donor|Effectiveness of Atorvastatin on IL2, IL6, TNFalpha and HLA Levels in the Recipient's Kidney Graft From a Living Donor|ATORV15|Instituto Mexicano del Seguro Social|Yes|Active, not recruiting|August 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02522117||15226|
NCT02582255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDEC|A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania|M3-ABMG|Fidec Corporation|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||August 2015|October 19, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02582255||10608|
NCT02592850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBOTTH-1|Evidence-Based Osteopathy for Tension-Type Headache (EBOTTH)|Osteopathic Manipulative Treatment in Frequent Episodic Tension-type Headache: the EBOTTH Multicentric Study|EBOTTH|University of Milano Bicocca|No|Not yet recruiting|January 2016|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592850||9794|
NCT02582879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1134 M|informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia|informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia|informCLL|Pharmacyclics|No|Recruiting|September 2015|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with CLL/SLL from a total of 200 sites in the US over a 36-month enrollment        period. Approximately 1000 patients will be initiating novel therapies including oral        kinase inhibitors and approximately 500 patients initiating other approved anti-CLL        therapies/regimens for the treatment of CLL/SLL. Approximately 85% of sites will include        sites from the community hematology-oncology setting.|March 2016|March 4, 2016|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02582879|3 Years|10560|
NCT02516332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064329|Exercise and Pharmacotherapy for Anxiety in Cardiac Patients|Exercise and Pharmacotherapy for Anxiety in Cardiac Patients||Duke University|Yes|Recruiting|December 2015|July 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|40 Years|N/A|No|||October 2015|January 11, 2016|July 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02516332||15671|
NCT02578420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-246|Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo|Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo||University Hospital, Basel, Switzerland|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578420||10902|
NCT02594670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014CB543102-1|Acupuncture for Insomnia: a Randomized Controlled Trial|Acupuncture Based on Different Acupoints Combination for Insomnia: a Randomized Controlled Trial|AI-RCT|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Yes|Not yet recruiting|October 2015|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|333|||Both|18 Years|65 Years|No|||March 2015|November 2, 2015|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02594670||9654|
NCT02584153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiP_1|A Study of Fibrin Sealant Plus Silver Microparticles to Prevent Incisional Hernias Following Abdominal Surgery|An Open-label, Single-arm, Phase 1 Study Examining the Safety and Efficacy of Fibrin Sealant Plus Silver Microparticles to Prevent Incisional Hernias (HiP_1 Trial) Following Abdominal Surgery|HiP_1|University of California, San Francisco|Yes|Not yet recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|21 Years|N/A|No|||October 2015|October 20, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584153||10462|
NCT02590224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDA|The Effect of Iron Deficiency Anemia During Pregnancy|Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy||Assiut University|No|Not yet recruiting|January 2016|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|40 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590224||9996|
NCT02583490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Pulse Amplitude Focal ECT|Low Pulse Amplitude Focal ECT (LAP Study)|Low Pulse Amplitude Focal Electroconvulsive Therapy||Georgia Regents University|Yes|Recruiting|March 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|20 Years|N/A|No|||October 2015|October 20, 2015|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583490||10513|
NCT02588612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP-0011-004|NY-ESO-1ᶜ²⁵⁹T for Advanced NSCLC|A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)||Adaptimmune|Yes|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588612||10120|
NCT02588625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM136-132|A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)|A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)||Bristol-Myers Squibb|Yes|Withdrawn|February 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588625||10119|
NCT02588638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NextGen-SE|Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases|Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases|NextGen-SE|University Hospital Tuebingen|No|Not yet recruiting|December 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|N/A||2|Anticipated|100|Samples With DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients with unclear diagnoses|October 2015|October 26, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02588638|1 Day|10118|
NCT02593695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDBS|Deep Brain Stimulation of Nucleus Accumbens to Treat Severe Anorexia Nervosa|Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Treat Severe Anorexia Nervosa||Tang-Du Hospital|Yes|Active, not recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593695||9729|
NCT02581163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-650|Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium|Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium||AbbVie|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|||Both|18 Years|99 Years|No|Probability Sample|Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4|February 2016|February 7, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581163||10692|
NCT02583763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/257-31|Cardiac Displacement From Third Trimester to Early Childhood|Cardiac Displacement From Third Trimester to Early Childhood|CADETTE|University Hospital, Linkoeping|No|Recruiting|January 2013|December 2023|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|Samples With DNA|The investigators will take a blood sample from the umbilical cord at birth and again at 7      years of age. The sample will be analyzed for growth factors and cardiac markers.      2015-05-20 an additional ethical approval was accepted for analyzing epigenetic factors in      the children's DNA.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This is a prospective case-control study in which fetuses from normal pregnancies will be        compared with fetuses with IUGR. Parents will be asked to participate in the study in        connection with the routine ultrasound examinations at the department of obstetrics to        where they have been referred because of suspected IUGR. The control group will be        randomly selected among pregnant women who come for routine ultrasound during pregnancy at        gestational week 18-20.|October 2015|October 30, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02583763|7 Years|10492|
NCT02588833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL2-CP-PNH-204|Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. APL-2 in PNH Subjects|A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|PADDOCK|Apellis Pharmaceuticals, Inc.||Recruiting|November 2015|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02588833||10103|
NCT02578563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1843R00258|Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore|SGLT2 Inhibitor Registry in Singapore||AstraZeneca|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|75 Years|No|Probability Sample|Simple random sample.|March 2016|March 8, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02578563|1 Year|10891|
NCT02588144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHanci|Combined Stimulation of STN and SNr for Resistant Freezing of Gait in Parkinson's Disease|Combined Stimulation of Subthalamic Nucleus and Substantia Nigra Pars Reticulata for Resistant Freezing of Gait in Parkinson's Disease: A Randomized Controlled Multicenter Trial|STN+SNr|University Hospital Tuebingen|Yes|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|80 Years|No|||January 2016|January 31, 2016|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02588144||10156|
NCT02588157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOÜ KAEK 2015/267|Comparison of Macintosh, McGrath X-Blade and Glidescope Videolaryngoscopes in Rapid Sequence Induction Intubation|Videolaryngoscopes for Rapid Sequence Intubation||Kocaeli University|No|Completed|October 2015|February 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|120|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588157||10155|
NCT02585089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCAM-BACCHUS|Effects of Cured Pork Peptides on Blood Pressure & Cardiovascular Risk Factors|Beneficial Effects of Pork Bioactive Peptides on Cardiovascular Health in Humans|PocPep-CVD|Universidad Católica San Antonio de Murcia|Yes|Recruiting|July 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02585089||10390|
NCT02589249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATAF-001-2015|The Effect of AyuFlex® Supplementation on Joint Health|The Effect of AyuFlex® Dietary Supplementation on Joint Mobility, Comfort and Functional Capacity in Healthy Overweight Subjects||The Center for Applied Health Sciences, LLC|Yes|Not yet recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589249||10071|
NCT02583373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL02-001|Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae|Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae||Combioxin SA|Yes|Recruiting|March 2016|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|80 Years|No|||March 2016|March 8, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583373||10522|
NCT02587052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-01|A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac|A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis|GenTac|Vastra Gotaland Region|No|Recruiting|October 2015|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|It is a retrospective analysis of two different cohorts of patients that have undergone        renal transplantation at Transplanationscentrum in Gothenburg, Sweden. Approximately 100        patients treated with generic tacrolimus will be compared with 100 matched controls. The        controls will be selected among 200 patients that are treated with Prograf. The matching        will be based upon living/deceased, age of the donor, age of the patient and number of        previous transplantations.|December 2015|December 10, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02587052||10239|
NCT02586090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD304410|The Role of Parents in Adolescent Obesity Treatment|Innovative Approaches to Adolescent Obesity Treatment: Exploring the Role of Parents|TEENS+|Virginia Commonwealth University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02586090||10313|
NCT02591875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocollo n. 156 (06/11/2015)|Atrial Flutter Ablation in a Real World Population|Atrial Flutter Ablation in a Real World Population: A Multicenter Italian Registry (The LEONARDO Study)||Azienda Ospedaliera Pugliese Ciaccio|No|Not yet recruiting|October 2015|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|All consecutive patients, clinically indicated for an atrial flutter ablation, will be        enrolled after signing of an informed consent form and an authorization to use and        disclose health information.|October 2015|October 29, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02591875||9869|
NCT02520661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSN187065|Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health|Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health||University of Wisconsin, Madison|No|Not yet recruiting|September 2015|||August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2400|||Both|60 Years|N/A|No|||August 2015|October 1, 2015|August 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02520661||15338|
NCT02520674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART002|Glaucoma Screening With Smartphone Ophthalmology|||Università degli Studi di Brescia|No|Completed|September 2014|August 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02520674||15337|
NCT02585999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34252|PK Patch 12 Week Continuous Use|The Pharmacokinetics of 12 Week Continuous Patch Use||Boston Medical Center|No|Recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585999||10320|
NCT02580981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST UNM 1503|Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses|Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses||New Mexico Cancer Care Alliance|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|November 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||January 2016|January 15, 2016|October 5, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02580981||10706|
NCT02591173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151461|Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure|Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure||Vanderbilt University|Yes|Recruiting|October 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591173||9923|
NCT02592720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cocktail II-FFR ACS|Cocktail Injection Improves Outcomes of FFR Guided PCI|Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS)|CocktailII|Xijing Hospital|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592720||9804|
NCT02591849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/666|GLP-1 Effects on Insulin and Glucagon in PTDM|GLP-1 Restores Altered Insulin and Glucagon Secretion in Post-transplantation Diabetes Mellitus||Oslo University Hospital|No|Completed|October 2014|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02591849||9871|
NCT02594657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0241|Pedal Rate Influence on Oxygen Consumption in Eccentric|Pedal Rate Influence on Oxygen Consumption in Eccentric|PRIOx|University Hospital, Clermont-Ferrand||Recruiting|August 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02594657||9655|
NCT02589691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDE_2014_25|Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)|Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes|ROC-HYPOX|Fondation Ophtalmologique Adolphe de Rothschild||Not yet recruiting|December 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|412|||Both|N/A|2 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589691||10037|
NCT02589704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA10|Nutritional Status of Cerebral Palsy Patients in Turkey|A Prospective, Cross Sectional Study to Evaluate the Etiology and Nutritional Status of Cerebral Palsy Patients in Turkey||Abbott Nutrition|No|Not yet recruiting|October 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|1 Year|19 Years|No|Non-Probability Sample|The study population will consist of patients at pediatric neurology outpatient clinic        diagnosed with CP, 12 months to less than 19 years old.|October 2015|October 27, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02589704||10036|
NCT02579577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15068|Decision Making and Future Planning for Children With Complex Illness|Decision Making and Future Planning for Children With Complex Illnesses: a Qualitative Multi-stakeholder, Longitudinal Study.||University of Nottingham|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Each case will be centred around a child with a life-limiting illness and their parents        who will have been identified as eligible by their usual care team. Additional significant        others who are important in their decision making and future planning will be identified        by the family and will ideally include at least one health professional. However, the        composition of each case will be determined by the child and family and may involve only        them. Nominated 'significant others' may include extended family, peers, ministers of        religion, key workers etc.|October 2015|October 16, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02579577||10814|
NCT02579590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSFI|The Female Sexual Functions With Progestogen-only Contraception|Evaluation of Female Sexual Functions in Progestogen-only Contraceptive Users||Assiut University|No|Recruiting|October 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|200|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579590||10813|
NCT02579603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.222|Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF|A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Boehringer Ingelheim||Recruiting|October 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||March 2016|March 21, 2016|October 16, 2015||||Yes||https://clinicaltrials.gov/show/NCT02579603||10812|
NCT02582229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2015/432|A Prospective Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction.|A Prospective Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction.|Endomina|Erasme University Hospital|No|Recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582229||10610|
NCT02586064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1783-R|Interpersonal Therapy for Veterans With PTSD|Interpersonal Therapy for Veterans With PTSD||VA Office of Research and Development|Yes|Not yet recruiting|March 2016|November 2019|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02586064||10315|
NCT02589379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPF-0134|Ultrasound Elastography for Prediction of Postoperative Pancreatic Fistula|The Value of Endoscopic Ultrasound Elastography for Prediction of Pancreatic Fistula in Patients Undergoing Pancreatic Resection for Benign or Malignant Disease|PMPPOPF|University of Zurich|Yes|Recruiting|July 2015|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples Without DNA|Non-tumorous pancreatic tissue|Both|18 Years|N/A|No|Probability Sample|Patients undergoing pancreatic resection for benign or malignant disease|January 2016|January 16, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02589379||10061|
NCT02589613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fMRI Obese|Glucose and Fructose Stimulated Brain Activity in Obese Subjects|Effects of Acute Glucose and Fructose Ingestion on Brain Activity in Obese Volunteers||University Hospital, Basel, Switzerland|No|Completed|October 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02589613||10043|
NCT02593279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0212|AVAD: Asthma With Small Airways Dysfunction|AVAD: Asthma With Small Airways Dysfunction. Clinical, Immunobiological, Tomodensitometric Description, Genetic Signature Compared With Asthmatic Population With Proximal Airways Obstruction|AVAD|Hospices Civils de Lyon|No|Recruiting|February 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593279||9761|
NCT02582970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18436|A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum|An Expanded Access Program of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum||Hoffmann-La Roche||Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582970||10553|
NCT02582983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17819|A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection|An Open-Label Safety Trial of Enfuvirtide (T-20/RO 29-9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiviral Regimen in Thai Patients With Advanced HIV Infection||Hoffmann-La Roche||Completed|February 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|16 Years|N/A|No|||March 2016|March 22, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582983||10552|
NCT02593084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT2015-19|Resistance Training to Optimize Health in Pre-frail Older Adults|Resistance Training to Optimize Health in Pre-frail Older Adults||McMaster University|No|Recruiting|January 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|60 Years|N/A|No|||January 2016|January 7, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02593084||9776|
NCT02591927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32003B_159727|Reappraisal of GIK in Acute STEMI by Pre-hospital Administration|Reappraisal of Glucose-insulin-potassium Therapy in Acute St-segment Elevation Myocardial Infarction by Pre-hospital Administration|REAGIK-STEMI|Centre Hospitalier Universitaire Vaudois|No|Not yet recruiting|February 2016|||February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|334|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591927||9865|
NCT02591940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardioproof|Proof of Concept of Model Based Cardiovascular Prediction|Proof of Concept of Model Based Cardiovascular Prediction||German Heart Institute|No|Enrolling by invitation|November 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|140|||Both|N/A|N/A|No|Probability Sample|Patients with the need for surgical or interventional treatment with Aortic Coarctation,        as well as patients with the need for aortic valve disease surgery, both according to        current treatment guidelines.|October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591940||9864|
NCT02594293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEASE|Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy|A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy||Huashan Hospital|No|Active, not recruiting|October 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|354|||Both|18 Years|60 Years|No|||November 2015|November 3, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02594293||9683|
NCT02583191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO-011 AIO-SUP-0115/ass.|Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients|CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study||AIO-Studien-gGmbH|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02583191||10536|
NCT02587351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR140170|Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Beta-Blockers for the Prevention of Acute Exacerbations of COPD||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|April 2016|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1028|||Both|40 Years|84 Years|No|||March 2016|March 24, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587351||10217|
NCT02578992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-103-05-125|"Neutral Position" and "Head-elevating Position" for Orotracheal Intubation With "Trachway" Intubating Stylet in Adults|"Neutral Position" and "Head-elevating Position" for Orotrachwal Intubation With "Trachway" Intubating Stylet in Adults||Tri-Service General Hospital|No|Completed|December 2014|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|130|||Both|20 Years|80 Years|No|||October 2015|October 25, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02578992||10858|
NCT02585401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18498|Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada|Evaluation of Physician Knowledge of Key Safety Information for Eylea in Canada: An Observational Postauthorization Safety Study||Bayer|No|Not yet recruiting|March 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution        of retinal specialists and ophthalmologists who prescribe aflibercept.|March 2016|March 8, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585401||10366|
NCT02519218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0179|Ellipse Intramedullary High Tibial Osteotomy Nail Study|Outcomes Registry of Patients With Osteoarthritis and Varus Malalignment of the Knee Treated With Ellipse Intramedullary High Tibial Osteotomy (IM HTO) Nail System||Ellipse Technologies, Inc.|No|Active, not recruiting|August 2015|December 2017|Anticipated|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Actual|6|||Both|N/A|N/A|No|Probability Sample|Patients implanted with the Ellipse IM HTO Nail system for osteoarthritis and varus        malalignment of the knee.|January 2016|January 19, 2016|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02519218|2 Years|15449|
NCT02521532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic NO3- in COPD|A 2 Week, Crossover Trial of Dietary Nitrate in Chronic Obstructive Pulmonary Disease|Dietary Nitrate for COPD: a 14d, Randomized, Placebo-controlled, Crossover Trial||Royal College of Surgeons, Ireland|No|Completed|January 2015|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|8|||Both|18 Years|85 Years|No|||August 2015|October 22, 2015|January 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02521532||15271|
NCT02593656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401-382|Effects of Protein Ingestion and Exercise Training on Muscular Performance|Effects of Frequent, High Quality, Multi-Ingredient Protein Meals and Exercise Training on Hormones, Body Composition, Muscular Performance, and Energy Metabolism in Active Healthy Men and Women||Skidmore College|No|Completed|January 2015|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593656||9732|
NCT02592538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-001-003|Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma|Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control||First People's Hospital of Hangzhou|Yes|Active, not recruiting|February 2013|April 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|80 Years|No|||February 2016|February 12, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592538||9818|
NCT02581826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-X15-058|Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Recruiting|October 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||January 2016|January 3, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581826||10641|
NCT02523768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908143|Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment|Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment|PIRAT|Centre Hospitalier Universitaire de Saint Etienne|Yes|Recruiting|January 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02523768||15099|
NCT02588729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38942|A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT|A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With Gestational Diabetes Mellitus - RCT||Oslo and Akershus University College of Applied Sciences|No|Not yet recruiting|October 2015|December 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|264|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02588729||10111|
NCT02580773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR14068|Therapeutic Anticoagulation Strategy for Acute Chest Syndrome|A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults|TASC|Assistance Publique - Hôpitaux de Paris|Yes|Not yet recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|October 18, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02580773||10722|
NCT02592174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP58 HAND 55-70|Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study||HAND55-70|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|January 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|210|||Both|55 Years|70 Years|No|||February 2016|February 12, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02592174||9846|
NCT02592226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-11|Clinical Significance of Alveolar Recruitment Maneuver During Bariatric Surgery|||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|November 2015|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592226||9842|
NCT02519426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J&D Classification Validation|Clinical Validation of a Novel Classification for Predicting Surgical Complexity in Mandibular Wisdom Teeth Surgery|Clinical Validation of a Novel Classification for Predicting Surgical Complexity of Impacted Mandibular Third Molar Extraction: an Observational Clinical Trial||Lithuanian University of Health Sciences|No|Active, not recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|110|||Both|16 Years|90 Years|No|Probability Sample|A total number of 110 (including eventual drop outs) third molar surgery patients will be        selected randomly. One tooth per patient is going to be evaluated. It should be noted that        if a single patient has a bilateral impacted tooth to be extracted it will be randomly        selected only one to be analyzed. In total 104 extraction are going to be evaluated.        Patients will be divided into two groups according to Juodzbalys and Daugela        classification score (x<9>y). Sample size of 52 subjects per group was calculated to        detect a mean difference between the two groups of 10 minutes with an expected SD of 18        minutes. Power was set at 80% and alpha at 0.05.|March 2016|March 1, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02519426||15433|
NCT02519439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0604|A Second Year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures|A follow-on, Second Year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures||Marinus Pharmaceuticals|No|Enrolling by invitation|February 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||August 2015|August 9, 2015|June 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519439||15432|
NCT02581670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1437|Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer|Prospective Non-randomized Phase II Study on Stereotactic Body Radiation Therapy for Medically Inoperable Lung and Liver Oligometastases From Breast Cancer||Istituto Clinico Humanitas|Yes|Recruiting|July 2015|July 2020|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581670||10653|
NCT02582008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98415|Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy|Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|January 2016|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02582008||10627|
NCT02585596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH23537-201|A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.|A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH23537 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease||Yuhan Corporation|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|275|||Both|19 Years|N/A|No|||January 2016|January 4, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585596||10351|
NCT02592161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B110051|Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis|A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis||Korea Health Industry Development Institute|No|Completed|April 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|166|||Female|50 Years|N/A|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592161||9847|
NCT02521909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00093162|Accuracy of Electronic Apex Locators ProMark, RootZX II and NRG Rider on Working Length of Multi-rooted Teeth|An in Vivo Evaluation of the ProMark, Root ZX II, and NRG Rider Electronic Apex Locators on the Accuracy of Working Length of Molars||University of Michigan|No|Recruiting|September 2015|October 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521909||15242|
NCT02593838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-2015-0393|Dynamic CT Myocardial Perfusion Imaging|Diagnostic Value and Practicability of Dynamic CT Stress and Rest Myocardial Perfusion Imaging in Daily Clinical Practice - A Monocentric Prospective Diagnostic Study||University of Zurich|No|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593838||9718|
NCT02582021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037321|WISE CVD - Continuation (WISE HFpEF)|Women's Ischemia Syndrome Evaluation (WISE) - Coronary Microvascular Dysfunction (CMD) and Heart Failure With Preserved Ejection Fraction (HFpEF)||Cedars-Sinai Medical Center|No|Not yet recruiting|November 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02582021||10626|
NCT02585843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO9102|Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance|Pilot Study of Natriuretic Versus Standard Doses of Mineralocorticoid Receptor Antagonists in Heart Failure and Loop Diuretic Resistance in Outpatients||Columbia University|Yes|Recruiting|November 2015|September 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|August 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585843||10332|
NCT02582593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201400128|Revitalize Cognition: Near Infrared Stimulation in Older Adults|Revitalize Cognition: A Proof of Concept Study Using Transcranial Near Infrared Stimulation in Older Adults||University of Florida|No|Not yet recruiting|December 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|65 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582593||10582|
NCT02511470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-806360-1|Use of a Metronome in Cardiopulmonary Resuscitation: A Simulation Study|The Use of an Audible Metronome Improves Chest Compression During Cardiopulmonary Resuscitation on a Pediatric Simulation Manikin||Nicklaus Children's Hospital f/k/a Miami Children's Hospital|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|155|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02511470||16042|
NCT02516059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068/15|Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia|Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial||University Hospital Inselspital, Berne|No|Recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02516059||15692|
NCT02581735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uPatient|Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia|Effectiveness of the uPatient Platform in the Fulfillment of the Prophylactic Treatment in Patients With Hemophilia|uPatient|Real Fundación Victoria Eugenia|No|Active, not recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|13 Years|50 Years|No|Non-Probability Sample|Patients with haemophilia|October 2015|November 3, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581735||10648|
NCT02581748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLX02-HV01|A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German) in Healthy Chinese Male Subjects|||Shanghai Henlius Biotech|Yes|Recruiting|September 2015|||February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|123|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02581748||10647|
NCT02581761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1327-IA-CTIL|A Prospective Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location|A Randomized Prospective Double Blind Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location|amalis|Sheba Medical Center|No|Not yet recruiting|November 2015|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581761||10646|
NCT02587221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V118_18|Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age|A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age||Novartis||Not yet recruiting|March 2016|January 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10692|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587221||10226|
NCT02587234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD049408|Driving Neuroplasticity With Nerve Stimulation and Modified CIT|Driving Neuroplasticity With Nerve Stimulation and Modified Constraint-Induced Therapy||University of Kentucky|No|Completed|November 2006|April 2012|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587234||10225|
NCT02520167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0760|Partnership to Improve Nutrition and Adiposity in Prenatal Clinical Care: a Pilot and Feasibility Study|Partnership to Improve Nutrition and Adiposity in Prenatal Clinical Care: a Pilot and Feasibility Study||University of Colorado, Denver|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02520167||15376|
NCT02582502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00766|Hyperbaric Oxygen Post Established Stroke|Hyperbaric Oxygen Post Established Stroke - HOPES - Study|HOPES|University of British Columbia|No|Recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|19 Years|85 Years|No|||January 2016|January 20, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02582502||10589|
NCT02579018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064421|Heart Rate Sensing and Response in Persons With Anorexia Nervosa|Heart Rate Sensing and Response in Persons With Anorexia Nervosa||Duke University||Recruiting|March 2016|January 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579018||10856|
NCT02592395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0659|Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Phase I Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma||The University of Texas Health Science Center, Houston||Recruiting|October 2015|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592395||9829|
NCT02580669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090|Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis|Study by Magnetic Resonance Imaging of the Modifications of the Vasoreactivity and Cerebral Connectivity in the Progressive Forms of Multiple Sclerosis|VASOSEP|University Hospital, Montpellier|No|Recruiting|June 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|66|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02580669||10730|
NCT02580682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XTCX2014-SFT|Treatment of Sanfu Herbal Patch for Allergic Rhinitis: a Controlled Clinical Trial|Treatment of Sanfu Herbal Patch for Allergic Rhinitis: a Randomized Controlled Clinical Trial||Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust|Yes|Recruiting|July 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Both|5 Years|70 Years|No|||October 2015|October 21, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580682||10729|
NCT02588235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCFA-OCT XIJING01|Ezetimibe and Atorvastatin Therapy on TCFA|Impact of Combined Ezetimibe and Atorvastatin Therapy on Coronary Thin-cap Fibroatheroma As Assessed by Optical Coherence Tomography||Xijing Hospital|Yes|Recruiting|October 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||October 2015|October 26, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02588235||10149|
NCT02590991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAE2C/A|Follow-up Clinical Study to Investigate the Long Term Effect of Supplementation of Pre- and Probiotics in Early Life in Children Born by Caesarean Section (Julius SN Follow-up 1)|A Follow-up Clinical Study to Investigate the Long Term Effect of Supplementation of Pre- and Probiotics in Early Life in Children Born by Caesarean Section (Julius SN Follow-up 1)||Danone Asia Pacific Holdings Pte, Ltd.|No|Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|155|Samples Without DNA|Stool samples will be collected from subjects at least once during study visits.      Voluntary blood sample will be collected from subjects.|Both|36 Months|54 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children who had completed Juliu Sn study until 16 weeks of age.|February 2016|February 23, 2016|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02590991||9937|
NCT02591004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A21102015|Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow|Comparing Fetal Cerebral Blood Flow Between Magnesium Sulfate & Calcium Channel Blockers in Patients With Preterm Labor; a Randomized Controlled Trial.||Kasr El Aini Hospital|No|Not yet recruiting|November 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591004||9936|
NCT02583139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-Cancer-Children-1|Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer|The Effect and Meaning of Designed Music Narratives on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Children (7-12 Years) With Cancer: a Randomized Controlled Multisite Study||University of Aarhus|No|Recruiting|August 2014|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|68|||Both|7 Years|12 Years|No|||October 2015|October 19, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02583139||10540|
NCT02584751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-15-027|GERD and Anti-Reflux Therapy in Persons With SCI|GERD and the Effects of Anti-Reflux Therapy on Pulmonary Function in Persons With SCI||James J. Peters Veterans Affairs Medical Center|No|Recruiting|July 2015|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584751||10416|
NCT02588378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-052|The Role of Inflammation in AMD and Related Disorders|In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) & Related Conditions||St. Michael's Hospital, Toronto|No|Recruiting|April 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or female, 18 years of age or older, able to understand the study protocol and        provide informed consent.|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588378||10138|
NCT02591069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-833|Vagal Nerve Stimulation in Coma Patients|Vagus Nerve Stimulation in Patients With Chronic Consciousness Disorders|SNV|Hospices Civils de Lyon|Yes|Not yet recruiting|October 2015|October 2019|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|60 Years|No|||October 2015|October 28, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02591069||9931|
NCT02583360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-00794|Mechanisms and Management of Infant Dysphagia|Neonatal Esophagus and Airway Interactions in Health and Disease||Nationwide Children's Hospital|Yes|Recruiting|March 2015|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|145|||Both|38 Weeks|60 Weeks|No|||November 2015|November 16, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583360||10523|
NCT02589782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1541|Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)|A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis|TB-PRACTECAL|Medecins Sans Frontieres|Yes|Not yet recruiting|February 2016|March 2020|Anticipated|June 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|630|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02589782||10030|
NCT02592577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP 0022-003|MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC|A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)||Adaptimmune|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592577||9815|
NCT02589392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29110|Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis|Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study||Galderma|No|Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|2 Years|12 Years|No|||March 2016|March 1, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02589392||10060|
NCT02591433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13D.423|JeffQuit Group Therapy Program for Smoking Cessation in Patients With a History of Cancer|Pilot Study of the Effectiveness of the JeffQuit Smoking Cessation Program||Thomas Jefferson University|No|Withdrawn|August 2013|||November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 28, 2015||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT02591433||9903|
NCT02520648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID009|Immediate Effect of Soft Treatment, Spinal Mobilization and Costal in Healthy Subjects.|Immediate Effects of Thoracic Soft Treatment, Articulatory Vertebral and Costal Articulatory in Healthy Subjects|EffDorsMan|University of Valencia|No|Completed|July 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|125|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02520648||15339|
NCT02590640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1016|Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers|||University of Colorado, Denver|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590640||9964|
NCT02590653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU/T-253|Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI|Assessment of the Effects of Aggressive Atorvastatin Therapy on Myocardial Deformation Characteristics, Vascular Rigidity, 24 Hour ECG Monitoring Parameters and Quality of Life in Patients With STEMI|CONTRAST|Penza State University|No|Recruiting|October 2014|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|35 Years|65 Years|No|||October 2015|October 27, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02590653||9963|
NCT02523014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A071401|A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas|Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations||Alliance for Clinical Trials in Oncology|Yes|Recruiting|August 2015|||August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523014||15157|
NCT02589340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11875|Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia|Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia|BUS-PD|Oregon Health and Science University|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|99 Years|No|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02589340||10064|
NCT02585570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-096|Effect of Phenylephrine During Shoulder Arthroscopic Surgery|Effect of Phenylephrine Infusion for Preventing Hypotension During Shoulder Arthroscopic Surgery in the Beach Chair Position||Inje University|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|66|||Both|20 Years|N/A|No|||December 2015|December 9, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02585570||10353|
NCT02580019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital307|Umbilical Cord Derived Mesenchymal Stem Cells Treatment in Ischemic Stroke|Cell Therapy by Intravenous Injection of Umbilical Cord Derived Mesenchymal Stem Cells After Stroke|Recruiting|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|November 30, 2015|July 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02580019||10780|
NCT02580032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-4231|Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)|Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)||Novo Nordisk A/S|No|Enrolling by invitation|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|320|||Both|4 Years|12 Years|No|Non-Probability Sample|The 2 populations (child and parent/guardian) will each be divided into a Treatment Naïve        group and a Maintenance group.|March 2016|March 3, 2016|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02580032||10779|
NCT02579304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZLPNE1015|Diagnostic Value of Transbronchial Lung Cryobiopsy|Feasibility, Safety and Diagnostic Value of Transbronchial Lung Cryobiopsy in the Work-up of Diffuse Interstitial Lung Diseases.||Katholieke Universiteit Leuven|No|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|transbronchial lung biopsies|Both|18 Years|75 Years|No|Probability Sample|interstitial lung disease, fibrotic or non-fibrotic|October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579304||10834|
NCT02579317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-015R|Project IMPACT: In-the-Moment Protection From Automatic Capture by Trigger|Project IMPACT: In-the-Moment Protection From Automatic Capture by Trigger||Rutgers, The State University of New Jersey|Yes|Recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|170|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02579317||10833|
NCT02582216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kine-001|3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.|3D Augmented Reality Mirror Visual Feedback Therapy Applied to the Treatment of Persistent, Unilateral Upper Extremity Neuropathic Pain: A Preliminary Study||Erasme University Hospital|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02582216||10611|
NCT02580227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-021|Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures|The Effect of Preoperative Tranexamic Acid on Blood Loss and Transfusion Rates in Intertrochanteric and Subtrochanteric Femur Fractures.||Good Samaritan Regional Medical Center, Oregon|No|Recruiting|June 2015|March 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02580227||10764|
NCT02580240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015KY-127|Administration of Hydrocortisone for the Treatment of Septic Shock|Administration of Hydrocortisone for the Treatment of Septic Shock||Northern Jiangsu Province People's Hospital|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580240||10763|
NCT02591225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI 1160.206|Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon|Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study||University of Ulm|No|Recruiting|October 2015|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|79 Years|No|||November 2015|November 12, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591225||9919|
NCT02584972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor 274-13 CTIL|Postural Control During Walking and Standing Among Children With Autism Spectrum Disorder|Postural Control During Walking and Standing Among Children With Autism Spectrum Disorder|PCASD|Soroka University Medical Center|Yes|Not yet recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|6 Years|12 Years|No|Non-Probability Sample|children with autism spectrum disorder|November 2015|November 2, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02584972||10399|
NCT02586558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCH-681|Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants|Effect of Prebiotic on Colic and Crying and Fussing Behaviour in Infants CRI Study: Colic Relief Initiative Study|CRI|McMaster University|No|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|8 Weeks|No|||October 2015|October 23, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586558||10277|
NCT02586792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0044|H7N9 Boost in Healthy Adults|Phase II, Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Single Intramuscular Dose of Inactivated Influenza A/H7N9 Vaccine After Priming With Inactivated Influenza A/H7N7 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|January 2016|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||October 2015|March 24, 2016|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586792||10259|
NCT02590627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-Malaria- Tanzania.|In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure|In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure|WB-Malaria|National Institute for Medical Research, Tanzania|No|Active, not recruiting|May 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|6 Months|10 Years|No|||October 2015|October 28, 2015|July 13, 2014||No||No||https://clinicaltrials.gov/show/NCT02590627||9965|
NCT02593032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821737|Effects of Use of a Connected Pillbox On Medication Adherence|Study On The Effect of Combined Use of a Connected Pillbox, Pre-filled Medication Trays, Automated Text Message/Phone Call Reminds, On Medication Adherence in Patients With Type II Diabetes Mellitus, Hypertension or Hyperlipidemia|(TVHST2DM)|University of Pennsylvania|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02593032||9780|
NCT02593045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH4102-101|Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)|Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)||Innate Pharma|No|Recruiting|October 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|February 23, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593045||9779|
NCT02593071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSV-E-202|Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.|A Phase II Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant F Nanoparticle Vaccine in Healthy Older Adult Subjects Previously Treated With the Same Vaccine, or Placebo, in the Prior Year; and to Estimate the Incidence Rate of RSV Disease and Vaccine Efficacy in Subjects Based on Their RSV F Vaccine Experience Over Two Consecutive Years.||Novavax|No|Active, not recruiting|October 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1330|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593071||9777|
NCT02592005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/40/411|Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA)|Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA), a Prospective Cohort Study on the Impact of Pollutants and Particulate Matter in Pregnancy: Methodology and Design|IPANEMA|Universiteit Antwerpen|No|Recruiting|May 2015|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|maternal blood maternal hair maternal urine umbilical cord blood|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women are recruited within the network of the Antwerp University. Leading centre        will be the University Hospital Antwerp (UZA),a tertiary centre with a maternal intensive        care unit (MIC) and a neonatal intensive care unit (NIC) and 1000 deliveries a year.|October 2015|October 28, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02592005||9859|
NCT02585375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-081214|Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT|Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT||Medical University of Vienna|No|Recruiting|April 2015|June 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02585375||10368|
NCT02585388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-BR112|Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.|A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer|CHEOPS|ARCAGY/ GINECO GROUP|Yes|Not yet recruiting|November 2015|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Female|50 Years|95 Years|No|||October 2015|October 22, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585388||10367|
NCT02594241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-806|PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial|PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial|POSAR|Bispebjerg Hospital|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594241||9687|
NCT02587039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00030360|An Intervention to Reduce Delirium After Cardiac Surgery|An Intervention to Reduce Delirium After Cardiac Surgery||Johns Hopkins University|No|Recruiting|June 2014|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|No|||October 2015|October 23, 2015|July 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02587039||10240|
NCT02587338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wuerzburg22/15|Cognitive Ability Training in Seniors|Verbesserung Kognitiver Fähigkeiten im Alter|CATS|Wuerzburg University Hospital|No|Recruiting|May 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02587338||10218|
NCT02578745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB ID # 201508154|Prophylactic Incisional Care in Obese Women at Cesarean|Prophylactic Negative Pressure Wound Therapy in Obese Women After Cesarean: a Pilot Randomized Trial|PICO-C|Washington University School of Medicine|No|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578745||10877|
NCT02581553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-501|Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability|A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Relative Bioavailability of Lesinurad/Allopurinol Fixed Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets and the Effect of Food on the Pharmacokinetics of Lesinurad/Allopurinol Fixed Dose Combination Tablets in Healthy Adult Male Subjects||Ardea Biosciences, Inc.|No|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|74|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581553||10662|
NCT02581566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01003060215|Effect of Intrathecal vs Intraarticular Dexmedetomidine on Postoperative Pain Following Arthroscopy|||Assiut University||Recruiting|July 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|20 Years|50 Years|No|||February 2016|February 5, 2016|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02581566||10661|
NCT02581358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhaseIII_V.3|Use of the Scolioscan for Quantitative Evaluation of Spinal Deformity - A Validity Study on Patients With Scoliosis|Use of the Scolioscan for Quantitative Evaluation of Spinal Deformity - A Validity Study on Patients With Scoliosis||Chinese University of Hong Kong|No|Recruiting|October 2015|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|8 Years|40 Years|No|||October 2015|October 26, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581358||10677|
NCT02590263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-714|Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma|A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Recurrent Malignant Glioma||AbbVie|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|99 Years|No|||January 2016|January 23, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02590263||9993|
NCT02583048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5343|Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis|A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583048||10547|
NCT02591199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG101-105|Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome|A Phase 2a, Biphasic Adaptive Design Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome||Urigen|Yes|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|348|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591199||9921|
NCT02591277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-337-1498|Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Harvoni in Japanese Patients With Genotype 1 Chronic Hepatitis C Infection||Gilead Sciences|No|Recruiting|November 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis        who take Harvoni as part of routine clinical care at a participating clinic/hospital.|February 2016|February 8, 2016|October 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591277||9915|
NCT02521545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231HV103|Single-Dose Study of a New Formulation of BIIB061|A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061||Biogen|No|Completed|July 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521545||15270|
NCT02581202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-452|The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation|ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation|SIMPLE|AbbVie|No|Recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|216|||Both|18 Years|80 Years|No|Probability Sample|HIV-1 infected participants on any triple HAART with undetectable plasma HIV-1 RNA level        for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically        appropriate to LPV/r + 3TC in the routine clinical settings.|January 2016|January 7, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581202||10689|
NCT02580292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Diagnostic Accuracy of Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury .|Diagnostic Accuracy of Renal, Carotid, and Aortic Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury Following Cardiopulmonary Bypass Surgery.||University of Michigan|No|Recruiting|October 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing cardiac surgery|October 2015|October 19, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02580292||10759|
NCT02580526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150903|Comparison of Mask Ventilation Techniques in Patients Requiring General Anesthesia|Comparison of Mask Ventilation Techniques in Patients Requiring General Anesthesia||Vanderbilt University|No|Recruiting|September 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|103|||Both|18 Years|N/A|No|||October 2015|November 3, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02580526||10741|
NCT02586155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-015|Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD|A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to 104 Weeks Dosing, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)|BETonMACE|Resverlogix Corp|Yes|Recruiting|October 2015|October 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|2400|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586155||10308|
NCT02514941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastric Bypass|Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation|Bioavailability of Paracetamol, Amoxicillin and Talinolol and Expression of Intestinal Drug Metabolizing Enzymes and Transport Proteins Before, Immediately and One Year After Proximal Roux-en-Y Gastric Bypass Operation in Patients With Morbid Adipositas||University Medicine Greifswald|No|Completed|June 2007|||March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02514941||15777|
NCT02593773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZNP-ACT-302|Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study|Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|STEADFAST|Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Enrolling by invitation|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|10 Years|26 Years|No|||March 2016|March 4, 2016|October 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593773||9723|
NCT02585349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-068|Cognition and Affect After Stroke: a Prospective Evaluation of Risks|Cognition and Affect After Stroke: a Prospective Evaluation of Risks|CASPER|Maastricht University Medical Center|No|Recruiting|June 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Buffycoats from EDTA tubes are taken for DNA extraction (ApoE, CLU, PICALM, CR1, ACE,      MTHFR). One PAXgene tube is collected to ensure long-term stability of RNA. Extraction of      RNA and subsequent analysis of expression of inflammatory and stroke-related genes at the      mRNA level will be done.|Both|40 Years|N/A|No|Probability Sample|first-ever and recurrent ischemic and hemorrhagic stroke patients|October 2015|October 30, 2015|December 11, 2014||No||No||https://clinicaltrials.gov/show/NCT02585349|12 Months|10370|
NCT02582151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107210|Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder|A Randomized Trial of Transcutaneous Nerve Stimulation for Neurogenic Bladder||Lawson Health Research Institute|No|Enrolling by invitation|January 2016|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|March 22, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02582151||10616|
NCT02585791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150373|Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette)NCFE) Vapors|EVALUATION OF ACUTE AND SUBACUTE EFFECTS OF NICOTINE FREE ELECTRONIC CIGARETTE (NFEC) VAPORS -Aim 2.1 of "Adverse Effects of Inhaled Nicotine From Tobacco and E-cigarettes".||University of Miami|No|Not yet recruiting|December 2015|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585791||10336|
NCT02594605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385/2012|Applied The Platelet Rich Fibrin in Chronic Periodontitis|Investigation of the Contributions of Platelet Rich Fibrin Combined With Conventional Periodontal Flap on Periodontal Healing||Ataturk University|Yes|Completed|December 2012|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|November 3, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02594605||9659|
NCT02594618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/00631|Energy Metabolism and Cost of Physical Activities Using Whole Body Calorimeter|Energy Metabolism and Cost of Physical Activities Using Whole Body Calorimeter||Clinical Nutrition Research Centre, Singapore|No|Recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|20|||Male|21 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male healthy subjects who are of Chinese ethnicity|February 2016|February 1, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02594618||9658|
NCT02579070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 1 05/10/2015|Diabetic Foot Ulcer Prevention System (DFUPS) - Part 2|Efficacy and Safety of Diabetic Foot Ulcer Prevention System (DFUPS) - a Single Blind Randomised Clinical Trial in Diabetic Foot Patients at High Risk of Foot Ulceration|DFUPS|King's College Hospital NHS Trust|No|Not yet recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579070||10852|
NCT02511184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081054|Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients|A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (MK-3475) In Patients With Untreated Advanced ALK-translocated Non Small Cell Lung Cancer||Pfizer|No|Recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|99 Years|No|||March 2016|March 7, 2016|July 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02511184||16064|
NCT02582034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSISPHERES-01|Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry|Selective Internal Radiation Therapy for Hepatocellular Carcinomas With Yttrium-90 Loaded Microspheres: Optimized Dosimetry Versus Standard Dosimetry||Center Eugene Marquis|No|Recruiting|December 2015|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|N/A|N/A|No|||February 2016|February 5, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02582034||10625|
NCT02594631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALI1112015|Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.|Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.||Mansoura University|Yes|Recruiting|March 2015|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|60 Years|No|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594631||9657|
NCT02586948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAO14044|Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation|Physiological Study of Minimally Invasive Extracorporeal CO2 Removal in Exacerbations of COPD Requiring Invasive Mechanical Ventilation|EPHEBE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|October 23, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02586948||10247|
NCT02590042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJS-CT-001|Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction|A Phase I Open-labeled, Single-arm, Single-centred Study to Test the Safety of ADSC-SVF-002 in Subjects With Soft Tissue Defects or Abnormal Wound Healing||AdiSave Inc.|No|Recruiting|October 2015|January 2019|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02590042||10010|
NCT02586012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15010061|Weight-based Dosing in Hemophilia A|Weight-based Dosing in Hemophilia A: A Randomized, Controlled, Open-label, Crossover Trial to Measure Factor VIII Recovery Following Factor VIII Concentrate Dosing Based on Total Body Weight, Ideal Body Weight, and Lean Body Mass||University of Pittsburgh|Yes|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|24|||Male|18 Years|N/A|No|||October 2015|October 23, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586012||10319|
NCT02586025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28762|A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Early-Stage or Locally Advanced HER2-positive Breast Cancer to Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel|A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase III Study Evaluating Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy Following Surgery and Chemotherapy in Patients With Early-stage or Locally Advanced HER2-positive Breast Cancer||Hoffmann-La Roche||Recruiting|February 2016|September 2023|Anticipated|September 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586025||10318|
NCT02586038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNITO-EMN10|Study of MLN9708 Plus Oral Dexamethasone or Plus Oral Cyclophosphamide and Dexamethasone or Plus Bendamustine and Dexamethasone or Plus Oral Thalidomide and Dexamethasone Followed by Maintenance With MLN9708 in Newly Diagnosed Elderly Multiple Myeloma Patients|||University of Turin, Italy|No|Recruiting|October 2015|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|260|||Both|65 Years|N/A|No|||October 2015|October 26, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02586038||10317|
NCT02586103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00894|Prospective Study Assessing the Validity of Y-PAS (Yale Preoperative Anxiety Scale) to Predict Patients Undergoing Magnetic Resonance Imaging Without the Use of Sedation/General Anesthesia|||Nationwide Children's Hospital|No|Not yet recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients scheduled for MRI with sedation or anesthesia.|October 2015|October 23, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586103||10312|
NCT02594644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553703|The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy|The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy||University of California, Davis|No|Recruiting|January 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594644||9656|
NCT02592317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108072|A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer|Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer||Janssen Research & Development, LLC|No|Recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2016|March 9, 2016|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592317||9835|
NCT02522377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketamine ECT|Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression|Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial||The Cleveland Clinic|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||August 2015|August 12, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02522377||15206|
NCT02586324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIMENEZ 2008|Comparison of Two Embryo Culture Media for IVF and ICSI|Comparison of Two Embryo Culture Media for IVF (in Vitro Fertilization) and ICSI ( Intracytoplasmic Sperm Injection ): Randomized Prospective Study||Centre Hospitalier Universitaire Dijon||Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1000|||Both|18 Years|50 Years|No|||March 2016|March 9, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586324||10295|
NCT02586337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTN-01-IIDTC|Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)||Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|No|Recruiting|July 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2015|October 22, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586337||10294|
NCT02583295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087135|The Impact of Maternal Sound on Awareness for Pediatric Patients Undergoing Cardiac Surgery|The Impact of Maternal Sound on Awareness for Pediatric Patients Undergoing Cardiac Surgery||Assiut University|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|4 Years|8 Years|No|||February 2016|February 2, 2016|October 10, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583295||10528|
NCT02593643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361-2013|Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.|A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|November 2015|||May 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|52|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593643||9733|
NCT02584491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-519|Brain Change After Fun, Athletic, Sports-skill Training (BeFAST)|Linking Neuroplasticity With the Outcomes of Motor Learning Based Interventions: Multi-modal Evaluation of Walking-based Training in Children and Youth With Cerebral Palsy|BeFAST|Holland Bloorview Kids Rehabilitation Hospital|No|Recruiting|July 2015|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|7 Years|17 Years|No|||July 2015|October 21, 2015|September 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02584491||10436|
NCT02579954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308156|Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension|Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension|FONCE-HTAP|Centre Hospitalier Universitaire de Saint Etienne|Yes|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579954||10785|
NCT02579239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATYR1940-C-004|The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular Dystrophies|An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies|FSHD|aTyr Pharma, Inc.|No|Recruiting|September 2015|September 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579239||10839|
NCT02579252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-AD-003|24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease|A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease|ADAMANT|Axon Neuroscience SE|Yes|Recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|185|||Both|50 Years|85 Years|No|||March 2016|March 14, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02579252||10838|
NCT02587533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-KliPha-004|Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation|Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation|ChemoBar|Hannover Medical School|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02587533||10203|
NCT02590705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150825|Anesthesia Lumbar Puncture In Children|Anesthesia Lumbar Puncture In Children (ALPIC)|ALPIC|Beijing Children's Hospital|No|Not yet recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|1 Month|18 Years|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02590705||9959|
NCT02583815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062015-021|Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)|Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCap)|PAMCap|University of Texas Southwestern Medical Center|Yes|Recruiting|August 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Blood samples will be collected at each study visit (Baseline, then every weeks until week      12 (+/-14 days). Prior to storage, complete the sample inventory logs for each subject so      that specimen chain of custody can be established. Samples will be frozen at −80°C until the      time of analysis.      Include in each shipment batch copies of: 1) the blood collection source documents for each      patient; and 2) copies of each subjects specimen inventory form      Keep originals of these documents in the subject's chart      Samples will be analyzed using a multiplexed ELISA method (Meso Scale Discovery) for      IL-1beta, IL-6, IL-10 and TNF-alpha      With explicit participant consent, samples will also be processed for DNA and stored for      future analysis.|Both|18 Years|N/A|No|Probability Sample|Patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern        Medical Center.|October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583815||10488|
NCT02594137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0115.0.102.000-11|A Comparison Between Two Techniques for Performing Decompressive Craniectomy|A Randomized Controlled Study Comparing 2 Surgical Techniques for Decompressive Craniectomy: With Watertight Duraplasty Versus Without Watertight Duraplasty.||Hospital of the Restoration, Recife|Yes|Completed|January 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|60 Years|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594137||9695|
NCT02581176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP|Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study|Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study|CAP|University Hospital, Akershus|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581176||10691|
NCT02592330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-124H|Safety and Feasibility of CALEC for LSCD|Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell Transplantation in the Treatment of Limbal Stem Cell Deficiency|CALEC|Massachusetts Eye and Ear Infirmary|No|Not yet recruiting|January 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|No|||October 2015|October 29, 2015|February 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592330||9834|
NCT02592343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI.LYO.FMT.1|A Prospective Trial of Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection|Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. Difficile Infection||McMaster University|Yes|Recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592343||9833|
NCT02580331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCRI/ACM/PG/PhD/2/2013-2014S|1% Metformin Gel in the Treatment of Class II Furcation Defects|1% Metformin Gel as Local Drug Delivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial||Government Dental College and Research Institute, Bangalore|No|Completed|November 2014|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 18, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580331||10756|
NCT02522962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1715 REK|Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study|Innovative Physiotherapy and Coordination of Care for People With Multiple Sclerosis: a Randomised Controlled Trial and a Qualitative Study|GroupCoreSIT|Nordlandssykehuset HF|No|Not yet recruiting|September 2015|March 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02522962||15161|
NCT02590172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI14008|Evaluation of the Methods and Effectiveness of Care for Eligible Medical and Surgical Patients on Admission in Continuous Monitoring Units|Evaluation of the Methods and Effectiveness of Care for Eligible Medical and Surgical Patients on Admission in Continuous Monitoring Units|UNISURC|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4600|||Both|18 Years|100 Years|No|Non-Probability Sample|The study population will be one of the selected schools and hospitals among those with a        USC.|June 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590172||10000|
NCT02594592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WuhanITCWMH|Clinical Value of Self-assessment Risk of Osteoporosis in Chinese|Combined Assessment of the Osteoporosis Self-assessment Tool for Asians and the One-Minute Osteoporosis Risk Test in a Wuhan Population||Wuhan Integrated Traditional Chinese and Western Medicine Hospital|No|Completed|January 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||4|Actual|389|||Both|20 Years|90 Years|No|Probability Sample|age of at least 20 years, able to read and fill out the questionnaire, and willingness to        participate.|October 2015|October 30, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02594592||9660|
NCT02580045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00062142|Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer|CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer||Duke University|Yes|Recruiting|October 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|Samples With DNA|Blood samples and cerebrospinal fluid samples are to be collected for pharmacokinetic      analysis by blood draw and lumbar puncture, respectively.|Both|18 Years|N/A|No|Non-Probability Sample|Metastatic or advanced cancer patients on systemic anti-cancer therapy including        chemotherapy, endocrine therapy, HER2-targeted therapy, and immune therapy.|October 2015|October 23, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02580045||10778|
NCT02580058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9991009|A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)|A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer||Pfizer||Recruiting|December 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|550|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580058||10777|
NCT02512796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18302|In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes|In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes||University of Virginia|No|Recruiting|July 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Investigators plan to study the circulating fibrocytes numbers, changes in monocyte gene      transcripts, identify polymorphism in gadolinium transport genes (OATPB1/3 and MRP2) and      examine their osteogenic potential in cultures.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Gadolinium exposed patients. We will use age- and sex-matched controls with and without        organ transplants and not exposed to gadolinium contrast agents (within the last 3 years)        as controls.|July 2015|July 30, 2015|July 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02512796||15940|
NCT02512809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00625|Isoflurane-induced Neuroinflammation in Children With Hydrocephalus|Isoflurane-induced Neuroinflammation in Children With Hydrocephalus: A Bench-to-bedside, Translational Study of Molecular Pathways and Therapeutic Approaches||Nationwide Children's Hospital|Yes|Enrolling by invitation|July 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|N/A|5 Years|No|||July 2015|July 28, 2015|February 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512809||15939|
NCT02578407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ACC|Pilot Study of Accommodative/Vergence Therapy to Modify Accommodative Function in Children With Myopia|Pilot Study of Accommodative/Vergence Therapy to Modify Accommodative Function in Children With Myopia|ACC|Sun Yat-sen University|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02578407||10903|
NCT02590315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO-PROTEUSDONNA|Tomosynthesis Versus Digital Mammography in a Population-based Screening Program|Digital Breast Tomosynthesis Versus Digital Mammography in a Population-based Screening Program. A Controlled Randomized Multicenter Trial|ProteusDonna|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte|Yes|Recruiting|December 2014|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|92000|||Female|46 Years|68 Years|No|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02590315||9989|
NCT02590445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD#N001|Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder|Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder||Ruijin Hospital|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590445||9979|
NCT02584907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1395/34199|Fat Based Enteral Nutrition for Blood Glucose Control in ICU|Effect of Fat Based Versus Glucose Based Enteral Nutrition on Serum Glucose Levels and Clinical Outcome in Hyperglycemic Patients in ICU||Shahid Beheshti University|Yes|Not yet recruiting|October 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02584907||10404|
NCT02584920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLX01-NHL02|A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma|||Shanghai Henlius Biotech|Yes|Completed|October 2014|||August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584920||10403|
NCT02584699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33320140105|Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC|Phase II Study of Stereotactic Ablative Radiotherapy in Elderly Patients With Stage I Non-Small Cell Lung Cancer||Chinese Academy of Medical Sciences|No|Recruiting|July 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|70 Years|N/A|No|||October 2015|October 21, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02584699||10420|
NCT02584712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUMaranhao|Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients|Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients Treated With Doxorubicin||Federal University of Maranhao|No|Completed|January 2014|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Female|30 Years|59 Years|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584712||10419|
NCT02585726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-01|Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)|Lake Washington Vascular VenaSeal™ Post-Market Evaluation: WAVES|WAVES|Lake Washington Vascular||Not yet recruiting|October 2015|||March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|80 Years||||October 2015|October 26, 2015|October 22, 2015||||No||https://clinicaltrials.gov/show/NCT02585726||10341|
NCT02585739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-19|Cluster Headache and SPINK-1 Gene|Cluster Headache and SPINK-1 Gene||Assistance Publique Hopitaux De Marseille||Completed|October 2011|July 2015|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585739||10340|
NCT02584829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9245|Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma|Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-regulation and the Anti-PD-L1 Antibody Avelumab||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2015|||July 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02584829||10410|
NCT02592941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-104-CL-037|Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy|An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy||Marathon Pharmaceuticals, LLC||Available||||||N/A|Expanded Access|N/A|||||||Both|5 Years|N/A||||October 2015|February 18, 2016|October 29, 2015|Yes|Yes||||https://clinicaltrials.gov/show/NCT02592941||9787|
NCT02585154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168287|Studying Movement Control in PD Using Closed Loop DBS|Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation||University of Oxford||Recruiting||||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|||||||Both|18 Years|74 Years||||November 2015|November 6, 2015|October 8, 2015||||No||https://clinicaltrials.gov/show/NCT02585154||10385|
NCT02594202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160010|Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue|Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|January 2026|Anticipated|January 2026|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Male|18 Years|100 Years|No|||September 2015|January 28, 2016|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594202||9690|
NCT02589964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13085|Probiotics in the Reduction of Antibiotic Associated Diarrhea|Probiotics in the Reduction of Antibiotic Associated Diarrhea and Clostridium Difficile in Pneumonia Patients Within a Community Teaching Hospital|Probiotics|TriHealth Inc.|No|Terminated|March 2015|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|120 Years|No|||October 2015|October 27, 2015|April 13, 2015||No|Low Recruitment|No||https://clinicaltrials.gov/show/NCT02589964||10016|
NCT02592590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC IRB #16257|Multiphase Activity Promotion Study|A Social-Cognitive Smartphone Application for Improving Physical Activity in Adults|MAPS|University of Illinois at Urbana-Champaign|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|132|||Both|30 Years|54 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592590||9814|
NCT02591797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLUCHBR|Effectiviness of Hand/Eyes/Mouth Beahavior Management Technique During Local Anesthesia in Preschool Children|Effectivines of Hand/Eyes/Mouth Beahavior Management Technique in Anxiety, Pain and Behavior Levels During an Inferior Alveolar and Lingual Nerve Block Procedure in Preschool Children: a Randomized Clinical Trial||Cardenal Herrera University|No|Recruiting|October 2015|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|36 Months|71 Months|No|||October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591797||9875|
NCT02581059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GI14-191|Efficacy of Ginseng for Patients on Regorafenib|A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib||Hoosier Cancer Research Network|Yes|Not yet recruiting|November 2015|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581059||10700|
NCT02581709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STL/5086/14|An Intervention Programme to Reduce Cognitive Impairment Due to Cancer|The Development and Feasibility Testing of an Intervention Programme to Reduce Cognitive Impairment Due to Cancer Treatment||Queen's University, Belfast|No|Not yet recruiting|November 2015|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|54|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02581709||10650|
NCT02593097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15-000422|Metformin for the Prevention of Episodic Migraine (MPEM)|Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study|MPEM|Mayo Clinic|No|Recruiting|February 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593097||9775|
NCT02581124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ951-U-15-009|Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease|A Phase 1, Open-label Study to Evaluate the Effect of Lapatinib, a BCRP Inhibitor, on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Receiving Hemodialysis||Akros Pharma Inc.|No|Recruiting|October 2015|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581124||10695|
NCT02581137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01733|Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion|M4OC-Prevent: Metformin for Oral Cancer Prevention||National Cancer Institute (NCI)|Yes|Not yet recruiting|December 2015|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|26|||Both|18 Years|N/A|No|||October 2015|December 31, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581137||10694|
NCT02590081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-14-950-20443|Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients|A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period.|NSD5|Penang Hospital, Malaysia|No|Not yet recruiting|October 2015|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|434|||Both|18 Years|74 Years|No|||October 2015|October 27, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590081||10007|
NCT02582775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015LS076|MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs|MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|March 2016|September 2022|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|25 Years|No|||March 2016|March 15, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582775||10568|
NCT02585167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150053|Endoscopic Treatment of Complex Anal Fistulas|Endoscopic or Surgical Treatment of Complex Perianal Fistula. A Randomized Controlled Clinical Study|VAAFT|University of Southern Denmark|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585167||10384|
NCT02585180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 052-15|Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia|Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617)||Centre Hospitalier Departemental Vendee|Yes|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02585180||10383|
NCT02517632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:38038914.6.0000.5262|Physical Exercise Program in Chronic Chagas Heart Disease|Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial)|PEACH|Evandro Chagas National Institute of Infectious Disease|No|Recruiting|March 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517632||15571|
NCT02517645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||January 7, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517645||15570|
NCT02584257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-MDI-301|Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma|Comparison of the Pharmacodynamic Profile of Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Bronchoprovocation in Adult Patients With Stable Mild Asthma||Lupin Ltd.||Not yet recruiting|December 2015|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Anticipated|144|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584257||10454|
NCT02592486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-041-160127|The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine|A Randomized, Open-label, Parallel Design Study to Compare the Immunogenicity of Simultaneous Administration Versus Sequential Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine||Kameda Medical Center|No|Active, not recruiting|November 2015|October 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|162|||Both|65 Years|N/A|No|||February 2016|February 4, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592486||9822|
NCT02592148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS829/14|Occurrence of Selected Vitamins in Saliva and Blood|Collection of Saliva and Blood Samples From Voluntary Donors to Establish the Occurrence of Selected Vitamins in Saliva and to Investigate Their Concentration Relative to Blood Levels|SaliVit|DSM Nutritional Products, Inc.|No|Completed|November 2015|February 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|A total of 50 subjects (females and males, with at least 40% of each gender) generally        regarded as healthy in the age of 20 - 65 years.|February 2016|February 29, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02592148||9848|
NCT02524951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-0039|Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer|A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients||Northwell Health|Yes|Not yet recruiting|September 2015|April 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|21|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02524951||15008|
NCT02585297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meir hospital|The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment|The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment||Meir Medical Center|Yes|Not yet recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|Samples Without DNA|Semen and vaginal discharge|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertile coupls|October 2015|October 22, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02585297||10374|
NCT02585310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI1|Packed Red Blood Cell Transfusion in Elective Coronary Artery Bypass Graft Surgery in A University Hospital|Packed Red Blood Cell Transfusion in Elective Coronary Artery Bypass Graft Surgery in A University Hospital||Mahidol University|No|Completed|November 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing CABGs|October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585310||10373|
NCT02592772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHC-2015-0128|Manipulating Tobacco Constituents in Male Menthol Smokers|Manipulating Tobacco Constituents in Male Menthol Smokers||University of Connecticut Health Center|Yes|Not yet recruiting|December 2015|December 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|57|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592772||9800|
NCT02591888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-081|Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling|The Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling for Stress Urinary Incontinence: A Randomized Placebo-controlled Trial||TriHealth Inc.|Yes|Recruiting|February 2015|December 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02591888||9868|
NCT02525016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0057|Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery|Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery|SPIRAL|Hospices Civils de Lyon|No|Recruiting|September 2015|October 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|68 Years|No|||February 2016|March 14, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02525016||15003|
NCT02525029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014LS020|Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD|Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|March 2016|March 2019|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|12 Years|76 Years|No|||March 2016|March 22, 2016|July 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02525029||15002|
NCT02581436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1217|Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR|Addition of kSORT Assay in the Follow-up of Patients After Kidney Transplantation|TITRATE|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Recruiting|September 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|16 Years|N/A|No|||September 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581436||10671|
NCT02581449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHCL31528|Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis|Evaluation of the Effect of Omega-3 Fatty Acids Supplementation on Pediatric Patients Undergoing Hemodialysis||Ain Shams University|No|Active, not recruiting|September 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|8 Years|18 Years|No|||October 2015|October 20, 2015|October 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581449||10670|
NCT02585362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leucine1.0|Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program|Influence of a Specially Formulated Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program on Physical Performance in Cancer Outpatients||Kantonsspital Winterthur KSW|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|88|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02585362||10369|
NCT02586467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00332|Messages for Increasing Dairy Consumption|Testing the Effectiveness of Targeted, Framed, -Efficacy Enhancing Messages for Increasing Milk and Milk Product Consumption in Adults Aged 30--50 Years.|MilkMessage|University of British Columbia|No|Completed|August 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|5||Actual|732|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02586467||10284|
NCT02521701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM2014/34|Safety and Efficacity of NFL101 as Tobacco Therapy|Phase I Study Assessing Safety and Efficacity of NFL101 as Tobacco Therapy(CESTO)|CESTO|Institut du Cancer de Montpellier - Val d'Aurelle|No|Recruiting|December 2014|August 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|March 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02521701||15258|
NCT02521714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CP-013|Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension|A Phase 1, Open-label, Randomized, Three-period, Two-way Crossover Study in Healthy Subjects to Evaluate the Bioavailability of a Test Lenalidomide Oral Suspension Relative to the Reference Capsule Formulation and to Assess the Effect of Food on the Bioavailability of Lenalidomide From the Oral Suspension||Celgene|No|Completed|August 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 11, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02521714||15257|
NCT02589366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPP #141163|Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium|A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection||University of California, San Diego|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589366||10062|
NCT02591303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/12|Stress and Insomnia|Stress and Insomnia: Investigating a Bidirectional Relation|StresSleep|University Hospital, Bordeaux|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02591303||9913|
NCT02515773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelBello PCORI|Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs|MOBILITY- Metformin for Overweight & OBese ChILdren and Adolescents With BIpolar Spectrum Disorders Treated With Second-Generation AntipsYchotics|MOBILITY|University of Cincinnati|Yes|Not yet recruiting|October 2015|October 2020|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1800|||Both|8 Years|17 Years|No|||August 2015|September 16, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02515773||15713|
NCT02589600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15070573 (ZEST II)|Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)|ZEST II for Osteoporotic Fracture Prevention|ZEST II|University of Pittsburgh|Yes|Recruiting|January 2016|July 2021|Anticipated|July 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|514|||Female|65 Years|N/A|No|||February 2016|February 2, 2016|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589600||10044|
NCT02578498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15009662|Glucagon Efficiency After High and Low Carbohydrate Diet|Glucagon Efficiency After High and Low Carbohydrate Diet|HiLoCarb|Hvidovre University Hospital|No|Recruiting|October 2015|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578498||10896|
NCT02592252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA430|Impact of Microfinance and Participatory Gender Training for Women in Reducing Intimate Partner Violence|Cluster Randomised Controlled Trial to Assess the Impact of Combined Microfinance and Gender Training for Women and Gender Training for Women and Their Male Partners in Reducing Intimate Partner Violence|MAISHA|London School of Hygiene and Tropical Medicine|No|Recruiting|September 2014|February 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2640|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||August 2015|November 19, 2015|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02592252||9840|
NCT02579889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA104|Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease|Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease - B3 Study|B3|Biotronik SE & Co. KG|Yes|Recruiting|September 2015|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1308|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579889||10790|
NCT02590120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.02.FR.NHS|Enteral Nutrition and Amino Acid Absorption|Comparaison du Profil d'Absorption Des Acides aminés Entre Une Nutrition entérale Semi-élémentaire et Une Nutrition entérale polymérique|PEPS|Nestlé|No|Recruiting|February 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590120||10004|
NCT02578771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX-ZP-0068 (MBT#865-104)|Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle|Pilot Clinical Evaluation to Characterize the in Vivo Effects of Topically Applied ZuraPrep and ZuraPrep Vehicle||Zurex Pharma, Inc.|No|Active, not recruiting|October 2015|February 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|October 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578771||10875|
NCT02579564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAEMTF|Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients|Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial||Xinqiao Hospital of Chongqing|No|Not yet recruiting|January 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|75 Years|No|||October 2015|October 18, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579564||10815|
NCT02511756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2015-0084|Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)|Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) in mCRC Patients Treated With First-line Bevacizumab|AVA-CTP|University of Zurich|No|Recruiting|July 2015|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02511756||16020|
NCT02590185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM14562|MetAbolism vaRiability of VEnLafaxine|Xploring Venlafaxine Pharmacokinetic Variability by a Phenotyping Approach|MARVEL|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|December 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|205|||Both|18 Years|80 Years|No|||October 2015|October 27, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590185||9999|
NCT02590939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50213|Randomized Controlled Trial on Acute Treatment of Migraine With the Cefaly® Device|Multi-center, Double-blind, Randomized, Sham-controlled Trial on the Acute Treatment of Migraine With the Cefaly® Device||Cefaly Technology|No|Recruiting|February 2016|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590939||9941|
NCT02590952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-813-00CH1|A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors|Open-label, Dose Escalation Phase I Study of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors||Hutchison Medipharma Limited|No|Recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||December 2015|December 5, 2015|October 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02590952||9940|
NCT02582437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC2015-0147|MAC Bipsectral Index Below 50 for Chronic Opioid User|The Effect of Chronic Opioid Use on Minimum Alveolar Concentration of Sevoflurane for Maintaining Bispectral(BIS) Index Below 50 ; Prospective, Blind Study||National Cancer Center, Korea|Yes|Recruiting|June 2015|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|41 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582437||10594|
NCT02582905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072014-005|Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders|Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|November 2015|||January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|199|||Both|18 Years|65 Years|No|||September 2015|October 20, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582905||10558|
NCT02588040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIO.CR.LPRP.PMD.001.15|Recover L-PRP in Lateral Epicondylitis (REGP-11-00)|Post-Market Data Collection for Chronic Lateral Epicondylitis Patients Treated With Leukocyte- and Platelet-Rich Plasma (L-PRP) Prepared With the Recover Mini Platelet Separation Kit||Biomet, Inc.|No|Not yet recruiting|October 2015|December 2019|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with chronic lateral epicondylitis (duration of symptoms        ≥ 3 months)|October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588040|36 Months|10164|
NCT02584556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-C/hcc|Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma|A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma||Guangxi Medical University|Yes|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|122|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584556||10431|
NCT02583555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-499|Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users|Randomised Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users||Region Sjælland|No|Not yet recruiting|November 2015|May 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583555||10508|
NCT02583568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52447.042.15|Fluorescence Guided Surgery in Breast Cancer|Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection Surgery in Patients With Breast Cancer|MARGIN|University Medical Center Groningen|Yes|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|26|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|June 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02583568||10507|
NCT02594072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSERT|Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)|Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT): A Phase II Randomized Trial for Intermediate and High Risk Prostate Cancer|ASSERT|University of British Columbia|Yes|Not yet recruiting|January 2016|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|N/A|N/A|No|||October 2015|October 30, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02594072||9700|
NCT02594085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP261|An Exploratory Study Investigating Adhesive Reaction to Output|||Coloplast A/S|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594085||9699|
NCT02580916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11054|Utility of the Skin Cancer Quality of Life Impact Tool|Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) - a Feasibility Study in Non-melanoma Skin Cancer|SCQOLIT|Oxford University Hospitals NHS Trust|No|Enrolling by invitation|July 2015|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|300|||Both|18 Years|90 Years|No|||October 2015|October 18, 2015|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02580916||10711|
NCT02594475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-71|Left Lateral Position and Prone Position for Endoscopic Retrograde Cholangiopancreatography|A Prospective, Randomized Study Comparing Efficacy and Safety Between Left Lateral Position and Prone Position for Endoscopic Retrograde Cholangiopancreatography||Chuncheon Sacred Heart Hospital|No|Recruiting|August 2015|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|20 Years|N/A|No|||August 2015|November 2, 2015|November 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02594475||9669|
NCT02594488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118-15|Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction|Implantable Cardiac Monitors in High-risk Post-infarction Patients With Cardiac Autonomic Dysfunction and Moderately Reduced Left Ventricular Ejection Fraction|SMART-MI|Klinikum der Universitaet Muenchen|Yes|Not yet recruiting|January 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|80 Years|No|||October 2015|October 31, 2015|October 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02594488||9668|
NCT02589041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOGPGC10|US-guided Sciatic Nerve Block: Evaluation of the Intraneural Ropivacaine Minimal Effective Volume (MEV90)|Ultrasound-guided Popliteal Sciatic Nerve Block: an Evaluation of the Intraneural||ASST Gaetano Pini-CTO|No|Recruiting|November 2015|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|February 9, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02589041||10087|
NCT02579616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-215|Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy|An Open-Label, Multicenter Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy||Eisai Inc.|No|Recruiting|October 2015|October 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|N/A|No|||January 2016|February 5, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579616||10811|
NCT02583152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04002|New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis|Use of New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis||Manchester Royal Eye Hospital|No|Not yet recruiting|October 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|3 Years|N/A|No|Non-Probability Sample|-  Adult and paediatric participants with MPS and corneal opacification will be             potentially eligible for this study, including those untreated, treated with previous             haematopetic stem cell transplant, and treated with ERT.          -  Participants who have a confirmed diagnosis of mucopolysaccharosisis type I (Hurler,             Hurler/Scheie and Scheie), MPS type II (Hunter), type III (Sanfilippo) type IV             (Morquio) and type VI (MaroteauxLamy), type VII (Sly) will be eligible if able to             hold relatively still while seated at an instrument with a head rest.|October 2015|October 23, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02583152||10539|
NCT02585518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1212|Ecological Momentary Assessment of Eating Behavior in Overweight Youth|Ecological Momentary Assessment of Eating Behavior in Overweight Youth||University of Chicago|No|Recruiting|February 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|8 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will comprise 40 overweight or obese (BMI≥85th %ile) youth aged 8-14 years.        Every effort will be made to recruit a racially/ethnically diverse sample. Participants        will be excluded if they 1) are currently taking any medications known to affect weight or        appetite (e.g., antidepressants, steroids, chemotherapy drugs); 2) have a current or past        diagnosis of an eating disorder involving purging or suppressed body weight (e.g., bulimia        nervosa or anorexia nervosa); 3) are unable to read and understand English fluently; or 4)        are receiving concurrent treatment for obesity.|October 2015|October 21, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585518||10357|
NCT02585752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-177 / AA-CmfCOPD-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2015|||||N/A|N/A|N/A||||||||||||||October 22, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02585752||10339|
NCT02581241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-EC-0379-15-CTIL|Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome|Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2016|January 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|99 Years|No|||October 2015|October 19, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02581241||10686|
NCT02583828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LET+CTX|Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients|||Capital Medical University|No|Recruiting|June 2015|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Female|65 Years|N/A|No|||October 2015|October 21, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02583828||10487|
NCT02583841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TatyasahebKoreDentalC|"Effect of Scaling and Root Planing on Liver Function Test (Alanine Aminotransferase and Aspartate Aminotransferase) in Systemically Healthy - Chronic Periodontitis Subjects: a Clinical Trial."|||Tatyasaheb Kore Dental College||Completed|February 2015|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|50|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02583841||10486|
NCT02512536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510150|Does Botulinum A Toxin Help With Pain From Rotator Cuff Arthropathy?|Do Ultrasound Guided Botulinum A Injections Relieve Pain in Rotator Cuff Arthropathy?||Royal Devon and Exeter NHS Foundation Trust|No|Not yet recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02512536||15960|
NCT02579434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP3A_basal|Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics|Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics|CYP3A_basal|Seoul National University Hospital||Completed|December 2014|||May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|102|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|December 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02579434||10824|
NCT02583061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0318-E|Toronto Gestational Glucose Tolerance Cohort|Toronto Gestational Glucose Tolerance Cohort||Mount Sinai Hospital, Canada|No|Recruiting|September 2003|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples Without DNA|Serum and plasma|Female|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of pregnant women across the full spectrum of gestational        glucose tolerance|October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583061||10546|
NCT02584400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL50833.068|Tumor Hypoxia With HX4 PET in Several Diseases|Non-invasive Imaging of Tumor Hypoxia With [18F]HX4 Positron-Emission-Tomography (PET): A Phase II Trial|HX4 SD|Maastricht Radiation Oncology|Yes|Not yet recruiting|December 2015|June 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02584400||10443|
NCT02517671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20140034H|Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX|Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX||David Grant U.S. Air Force Medical Center|Yes|Recruiting|January 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517671||15568|
NCT02592473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18236|Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia|Prostate Artery Embolization Safety and Efficacy: A Pilot Study||University of Virginia|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|45 Years|80 Years|No|||November 2015|November 4, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592473||9823|
NCT02589730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMME-6Y01|Effect of Smart Phone Application on the Individualized Management of Chinese Diabetic Patients|Individualized Management Based on Mobile Phone Platform in Diabetic Patients||Shanghai Geping Information Technology Company|No|Recruiting|October 2015|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|234|||Both|18 Years|65 Years|No|||October 2015|October 27, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02589730||10034|
NCT02591576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIGB: ECC 1-06 (d)/2011|Long Term Excess Mortality of Acute Myocardial Infarction in Patients With and Without Diabetes: A Population-based Cohort Study|||University of Leeds|Yes|Completed|January 2003|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|700000|||Both|18 Years|100 Years|No|Non-Probability Sample|STEMI and NSTEMI were eligible for analysis if they have been hospitalised following AMI        between the period of 2003-2013 and were aged at least 18 years. Only records of the first        admission were considered for analyses.|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591576||9892|
NCT02592824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-006241-15|Glutamate for Metabolic Intervention in Coronary Surgery II|Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II|GLUTAMICSII|University Hospital, Linkoeping|Yes|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|310|||Both|20 Years|85 Years|No|||November 2015|November 16, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592824||9796|
NCT02588885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15050501-IRB01|Restoring Emotional, Sexual, and Physical Empowerment Through CBT & Trauma-sensitive Care: A Chronic Pelvic Pain Intervention|Restoring Emotional, Sexual, and Physical Empowerment Through CBT & Trauma-sensitive Care: A Chronic Pelvic Pain Intervention|RESPECT|Rush University Medical Center|No|Recruiting|October 2015|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02588885||10099|
NCT02588898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-vitamins polyneuropathy|B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes|B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes||Saarland University|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|212|Samples Without DNA|Fasting blood samples (serum, whole blood and EDTA-plasma)|Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Male and female subjects with or without diabetes.|October 2015|October 27, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02588898||10098|
NCT02592954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSE2015|Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin|Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin||Johns Hopkins University|Yes|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592954||9786|
NCT02591654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO2558|MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma|A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma|MPAK|Columbia University|Yes|Recruiting|October 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591654||9886|
NCT02591732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-377|A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark|A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events||Bristol-Myers Squibb|No|Active, not recruiting|August 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||4|Actual|52178|||Both|18 Years|N/A|No|Non-Probability Sample|Subject must be over 18 years of age, male and females are eligible|March 2016|March 3, 2016|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02591732||9880|
NCT02580643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIO.CRNSAPS002.15|Prospective Post-Market Data Collection on Patients With Knee OA and Treated With nSTRIDE APS|Prospective Post-Market Data Collection on Patients With Knee Osteoarthritis and Treated With nSTRIDE Autologous Protein Solution (REGP-22-00)|PROGRESS III|Biomet, Inc.|No|Not yet recruiting|December 2015|February 2020|Anticipated|February 2018|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with bilateral or unilateral knee OA will be prospectively enrolled in the study.|October 2015|December 30, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580643|5 Years|10732|
NCT02578901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL 122272-01A1-ATREAT|American Trial Using Tranexamic Acid in Thrombocytopenia|American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)|A-TREAT|University of Washington|Yes|Not yet recruiting|January 2016|June 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02578901||10865|
NCT02578914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDNS2-203-D1|A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis|A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)||Aldeyra Therapeutics, Inc.|No|Completed|August 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02578914||10864|
NCT02582307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107243|Buscopan Versus Acetaminophen for Acute Abdominal Pain in Children|Hyoscine Hydrobromide (Buscopan) Versus Acetaminophen for Acute Abdominal Pain in Children: A Randomized Controlled Trial||Lawson Health Research Institute|No|Not yet recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|5 Years|17 Years|No|||October 2015|March 11, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02582307||10604|
NCT02581072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC104|A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204|A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy||Novan, Inc.|No|Active, not recruiting|October 2015|April 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581072||10699|
NCT02586363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cavir food effect study|Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety|A Randomized, Open-label, 3-way Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics and Safety of Single-dose Cavir Tab. 0.5mg With Baraclude Tab. 0.5mg in Healthy Male Volunteers||Seoul St. Mary's Hospital|No|Active, not recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02586363||10292|
NCT02591862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK578|Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)|Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms||AKARI Therapeutics|Yes|Not yet recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02591862||9870|
NCT02517372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSPR-PE-006|Study in Healthy Volunteers to Document Safety and Tolerability of Increasing Doses Pemirolast|An Open-label, Single Center, Phase I, Dose Escalation Study Investigating the Safety, Tolerability and Pharmacokinetics of Pemirolast in Healthy Subjects||RSPR Pharma AB|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|24|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02517372||15591|
NCT02579421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509M78103|Hormones and Reduction in Co-users of Marijuana and Nicotine|Sex Differences and Progesterone: Association With Impulsivity and Marijuana Reduction in Co-Users of Marijuana and Nicotine Cigarettes||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579421||10825|
NCT02587429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK 1-10-72-64-15|Effect of a Patient Education in Pain Coping for Patients Scheduled for Total Knee Arthroplasty|Effect of a Patient Education in Pain Coping for Patients With High Levels of Pain Catastrophizing Before Total Knee Arthroplasty||Regional Hospital West Jutland|Yes|Recruiting|October 2015|February 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587429||10211|
NCT02591160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1213821|Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism|Optimal Hydochlorothiazide Cessation in Diagnosis of Hyperparathyroidism||University of Missouri-Columbia||Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591160||9924|
NCT02521077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ2015010|Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer|Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer||Midwestern Regional Medical Center|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|72|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521077||15306|
NCT02521090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-112|EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma|Targeting Recurrent Glioblastoma With Anti-CD3 x Anti-EGFR Bispecific Antibody Armed T Cells: A Phase I/II Study||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|August 2015|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|August 10, 2015|Yes|Yes|Due to lack of funding and a primary co-investigator of the trial leaving the institution.|No||https://clinicaltrials.gov/show/NCT02521090||15305|
NCT02588352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01669|Evaluation of Salt Sensitivity in Young Adults|Evaluation of Salt Sensitivity in Young Adults||New York University School of Medicine|No|Completed|May 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588352||10140|
NCT02579512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA1041203|Non Invasive Extra-corporeal ECG Signal Analysis Algorithm( NID Algorithm) for Myocardial Ischemia|Non Invasive Extra-corporeal ECG Signal Analysis Algorithm( NID Algorithm) for Myocardial Ischemia||Taichung Veterans General Hospital||Recruiting|June 2015|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|20 Years|95 Years|No|Non-Probability Sample|myocardial Ischemia|September 2015|October 15, 2015|July 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02579512||10819|
NCT02579759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PXT3003-02|Phase III Trial Assessing the Efficacy and Safety of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A (PLEO-CMT)|International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months|PLEO-CMT|Pharnext, SAS|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|16 Years|65 Years|No|||January 2016|March 23, 2016|September 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579759||10800|
NCT02581579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYADAPETRICS|Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection|Pilot Phase I Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection||Manresana de Micobacteriologia, SL|No|Recruiting|November 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581579||10660|
NCT02514954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC3-CT019|Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus|Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus||Adocia|No|Completed|July 2015|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|64 Years|No|||November 2015|November 5, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02514954||15776|
NCT02588742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2014-1038|The Effect of Melatonin on Postoperative Delirium in Elderly ICU Patients|The Effect of Melatonin on Postoperative Delirium in Elderly ICU Patients : Randomized, Placebo-controlled, Double Blind Study||Yonsei University|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|114|||Both|50 Years|N/A|No|||October 2015|October 27, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02588742||10110|
NCT02591121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP025|Procalcitonin Test Reference Range Determination|Clinical Evaluation To Determine The Expected Values Distribution Of Procalcitonin For The RAMP® Procalcitonin Test In A Healthy Reference Population (PRO-H)|PRO-H|Response Biomedical Corp.|No|Completed|October 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|Samples Without DNA|Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal|October 2015|November 13, 2015|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02591121||9927|
NCT02515201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140291|Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children|Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children With Intestinal Failure||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|September 2014|December 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|N/A|14 Years|No|||July 2015|July 31, 2015|July 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02515201||15757|
NCT02515214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AURORA|bAriatric sUrgery Registration in wOmen of Reproductive Age|Bariatric Surgery Registration in Women of Reproductive Age|AURORA|Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Breast milk samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|1. Women of reproductive age attending for bariatric surgery          2. Women of reproductive age with a history of bariatric surgery          3. Pregnant women with a history of bariatric surgery          4. Lactating women with a history of bariatric surgery|July 2015|August 3, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02515214|3 Years|15756|
NCT02585544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0215|Ambulatory Prolapse Surgery|Ambulatory Prolapse Surgery: Feasibility Study|PROLAMBU|Hospices Civils de Lyon|No|Recruiting|October 2015|April 2019|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||October 2015|November 13, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02585544||10355|
NCT02592863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1214160|Trental for the Treatment of Vertigo/Dizziness/Imbalance|A Double-Blind, Placebo-Controlled, Randomized Trial of Pentoxifylline for Imbalance Secondary to Insufficient Microvascular Perfusion||University of Missouri-Columbia||Recruiting|January 2015|||January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|N/A|No|||October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592863||9793|
NCT02591966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-11-015|Genetic Alteration After Systemic Treatment in Breast Cancer|Genetic Alteration After Systemic Treatment in Breast Cancer||Samsung Medical Center|No|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|1. Blood sample : whole blood        2. Tissue : Fresh tissue, Fixed tissue (5ea of 5-10µm unstained sections),|Both|20 Years|N/A|No|Probability Sample|1. The patients who receive neoadjuvant systemic treatments:          2. The patients who have distant metastatic sites at first and recur from surgery:          3. The patients who are going to receive first-line chemotherapy:|October 2015|October 28, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02591966||9862|
NCT02525107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORG/HSS/14/013|Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements|Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease|OM3FA|Sultan Qaboos University|Yes|Not yet recruiting|September 2015|March 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|13 Years|70 Years|No|||August 2015|August 14, 2015|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02525107||14996|
NCT02525120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1CP-1|Post Market Non-Inferiority Study Comparing Triojection® to Discectomy for Lumbar Disc Herniation|Post Market Non-Inferiority Study Comparing Triojection® to Discectomy for Lumbar Disc Herniation||Minimus Spine, Inc|No|Recruiting|July 2015|July 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|August 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02525120||14995|
NCT02594098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1486|Secukinumab for Treatment of Atopic Dermatitis|A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Moderate to Severe Atopic Dermatitis||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594098||9698|
NCT02582567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESTAFIT|Effects of Exercise During Gestation on Maternal and Foetal Health|Effects of Supervised Exercise During Gestation on Maternal and Foetal Health Markers. The GESTAFIT Project|GESTAFIT|Universidad de Granada|No|Recruiting|October 2015|May 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02582567||10584|
NCT02583334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH103-REC1-138|Acupuncture for Fibromyalgia|Clinical Efficacy of Acupuncture in Patients With Fibromyalgia: A Multi-center, Randomized, Assessor and Participant-blinded, Controlled, and Parallel-design Clinical Trial||China Medical University Hospital|No|Recruiting|January 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|158|||Both|20 Years|75 Years|No|||October 2015|October 20, 2015|June 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02583334||10525|
NCT02583347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-15/36|A Study of Sleep Patterns in Patients Performing Nocturnal Home Dialysis Utilising the VIVIA System|A Study of Sleep Patterns in Patients Performing Nocturnal Home Dialysis Utilising the VIVIA System||Beaumont Hospital|No|Not yet recruiting|December 2015|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators Home Hemodialysis programe trains approximately one home dialysis        patient monthly. The preferred prescription for nocturnal home HD patients is 8 hours 5        days a week using a VIVIA machine. Twenty consecutive patients will be enrolled in the        study over a period of 24 months.|October 2015|October 27, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02583347||10524|
NCT02582736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q10-12|Antipsychotics and Risk of Hyperglycemic Emergencies|Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data||Canadian Network for Observational Drug Effect Studies, CNODES|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|725489|||Both|18 Years|N/A|No|Probability Sample|In each jurisdiction, the investigators will assemble a study cohort that includes all        patients with a first-time prescription for an antipsychotic medication between April 1,        1998 (or one year after the beginning of data availability) and March 31, 2010. The date        of study cohort entry is defined by the prescription date of the newly-prescribed        antipsychotic.|October 2015|October 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582736||10571|
NCT02582749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU13-170|Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases|Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170||Hoosier Cancer Research Network|Yes|Not yet recruiting|April 2016|January 2020|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582749||10570|
NCT02582814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1695C00001|The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Mellitus (T1DM)|A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control||AstraZeneca|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582814||10565|
NCT02582827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA601.2|A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas||NantBioScience, Inc.|No|Not yet recruiting|November 2015|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 14, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582827||10564|
NCT02579291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC 07-2015|Dry Needling in Patients Who Had Experience Stroke|Changes in Spasticity, Motor Function and Stabilometry After Dry Needling of the Tibialis Posterior Muscle in Post-stroke Patients||Universidad Rey Juan Carlos|Yes|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|60 Years|No|||February 2016|February 25, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579291||10835|
NCT02583958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-14-06-310 3166|Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers|Assessment of Efficacy and Safety for a New Wound Dressing URGO 310 3166 in the Local Treatment of Venous or Mixed Leg Ulcers: A European, Randomised Clinical Trial||Laboratoires URGO|No|Recruiting|October 2014|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||October 2015|October 20, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02583958||10477|
NCT02583074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYLX201305|Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia|Subthalamic Deep Brain Stimulation in Patients With Medication-Refractory Primary Cranial-Cervical Dystonia: A Randomised, Sham-controlled Trial||Beijing Tiantan Hospital|Yes|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||October 2015|October 20, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02583074||10545|
NCT02583880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NScr-001-CNI|Screening Day Latin America|Screening Day Latin America to Assess Disease-related Malnutrition and Clinical Nutrition Practice in ICU Patients||Fresenius Kabi|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill adult patients receiving enteral and/or parenteral nutrition, hospitalized        in the Intensive Care Units (ICUs) of the participating hospitals on the Screening Day|March 2016|March 3, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02583880||10483|
NCT02516358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gly 1|Glycaemic Alterations in ICU|Glycaemic Alterations in ICU: an Observational, Prospective Cohort Study||Catholic University of the Sacred Heart|Yes|Not yet recruiting|September 2015|September 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients|August 2015|August 31, 2015|May 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02516358||15669|
NCT02590146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22893|Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion|Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion||University of Hawaii|No|Recruiting|November 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|74|||Female|18 Years|N/A|No|||October 2015|November 30, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590146||10002|
NCT02578433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECS 1392/2015|Mindful Self Compassion in Rehabilitation Inpatients|Mindful Self Compassion in Rehabilitation Inpatients: a Randomized Controlled Trial||Universitätsklinik für Psychiatrie und Psychotherapeutische Medizin|No|Recruiting|December 2015|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02578433||10901|
NCT02578446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-I-058|Uncemented Tritanium Compared With Cemented Metal-backed Tibia Components in Total Knee Replacement|Migration and Survival of the Uncemented Tritanium Tibia Compared With the Cemented Metal-backed Tibia Using the Triathlon Cruciate Retaining (CR) Total Knee System. A Single Centre RSA Study||Region Skane|No|Recruiting|October 2015|March 2026|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|40 Years|75 Years|No|||October 2015|October 16, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02578446||10900|
NCT02579031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288/15|A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|BIOSTEMI|University Hospital Inselspital, Berne|Yes|Not yet recruiting|January 2016|June 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1250|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579031||10855|
NCT02587260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL51124.078.14|Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)|Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans|HI-TECH|Erasmus Medical Center|No|Recruiting|December 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587260||10223|
NCT02590523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Intracameral Antibiotic Safety Study|Intracameral Antibiotic Safety Study||Panhandle Eye Group, LLP|No|Not yet recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Both|30 Years|100 Years|No|||October 2015|October 27, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590523||9973|
NCT02590536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFGR|A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction|A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction||Ain Shams University||Not yet recruiting|October 2015|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|40 Years|No|||October 2015|October 28, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590536||9972|
NCT02588976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STZ-Dendrite06|Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery|Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery|SONEW|Triemli Hospital|No|Completed|July 2009|January 2011|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|80 Years|No|||October 2015|October 27, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588976||10092|
NCT02588846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pelvic Node Tracking|Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM|Phase I Feasibility Study of Accounting for Relative Motion of Multiple Targets in Prostate Cancer Radiotherapy Using Realtime Multi-leaf Collimator Adaptation and Kilovoltage (kV) Intrafraction Monitoring||Royal North Shore Hospital|Yes|Not yet recruiting|January 2016|December 2022|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||October 2015|October 26, 2015|July 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02588846||10102|
NCT02579330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-341|Trial on Use of Coloshield in Transanal and Anal Surgery|Randomized Controlled Trial on Practicability of Coloshield in Transanal and Anal Surgery||Cantonal Hosptal, Baselland|No|Not yet recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02579330||10832|
NCT02579343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloridaGCU|Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture|Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture||Florida Gulf Coast University|No|Recruiting|August 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|24 Years|No|||October 2015|October 16, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02579343||10831|
NCT02579356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-1307|To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers|A Randomized, Open-label, Multiple-dose, Crossover Study to Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers||Samil Pharmaceutical Co., Ltd.|No|Completed|May 2014|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02579356||10830|
NCT02585271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46650455-0|Transanal Decompression Tube Versus Stent for Acute Malignant Left-sided Colonic and Rectal Obstruction|Transanal Decompression Tube Versus Stent as a Bridge to Surgery for Acute Malignant Left-sided Colonic and Rectal Obstruction||Xuzhou Central Hospital|No|Recruiting|October 2015|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|80 Years|No|||November 2015|January 17, 2016|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02585271||10376|
NCT02580253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYMedOncoLT02|Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation|||Zhejiang University|No|Not yet recruiting|November 2015|||November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||November 2015|November 29, 2015|October 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02580253||10762|
NCT02520414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0524|Symphion® System In-Office Study|A Pilot Study to Assess the Feasibility of the Symphion® Bipolar Hysteroscopic Tissue Resection System in an Office Environment||Boston Scientific Corporation|No|Completed|November 2014|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||August 2015|August 10, 2015|November 6, 2014||No||No||https://clinicaltrials.gov/show/NCT02520414||15357|
NCT02520427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120252|A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia||Amgen|No|Recruiting|August 2015|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520427||15356|
NCT02588911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA vs CS|Radiofrequency Ablation vs Conventional Surgery for Superficial Venous Insufficiency|Randomised Trial of Radiofrequency Ablation vs Conventional Surgery for Superficial Venous Insufficiency: if You Don't Tell, They Won't Know||Hospital Israelita Albert Einstein|No|Completed|November 2013|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|33 Years|76 Years|No|||October 2015|October 26, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02588911||10097|
NCT02585830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0739|Sleep Timing and Insulin Resistance in Adolescents With Obesity|Investigating the Relationship Between Circadian Phase and Insulin Resistance in Obese Adolescents||University of Colorado, Denver|No|Recruiting|October 2015|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|15 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents with obesity|October 2015|October 22, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585830||10333|
NCT02586077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-13-12E|Foot and Ankle Clinic Application for Liposomal Related Anesthetic|Foot and Ankle Clinic Application for Liposomal Related Anesthetic||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|June 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02586077||10314|
NCT02589054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106285|Regional Changes in Upper Limb Perfusion Following Brachial Plexus Block: A Pilot Study|Regional Changes in Upper Limb Perfusion Following Brachial Plexus Block: A Pilot Study|RAFFAB|Lawson Health Research Institute||Active, not recruiting|November 2015|June 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|80 Years|No|Non-Probability Sample|Individuals coming for elective upper extremity surgery who would already be having a        brachial plexus block for their anesthesia.|October 2015|March 11, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02589054||10086|
NCT02517385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOLIL06301|Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases|Multicenter Prospective Uncontrolled Non-comparative Open Interventional Clinical Study of Phase III for Assessment of the Safety and Effectiveness of Using the Drug Phosphatidylcholine Paste 600 mg in Patients With Acute and Chronic Liver Diseases and Clinical Symptoms of Dysfunction of the Gastrointestinal Tract During 12-week Therapy Course|EPLID|Sanofi|No|Active, not recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|162|||Both|18 Years|66 Years|No|||March 2016|March 17, 2016|July 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02517385||15590|
NCT02517658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00063|Adenotonsillectomy Postoperative Parental Teaching Tool|||Nationwide Children's Hospital|No|Enrolling by invitation|June 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|N/A|N/A|No|||August 2015|August 6, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02517658||15569|
NCT02583477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4198C00003|Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma|A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma||AstraZeneca|No|Not yet recruiting|December 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583477||10514|
NCT02587455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 4282|Pembrolizumab and Palliative Radiotherapy in Lung|Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours|PEAR|Royal Marsden NHS Foundation Trust|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|January 6, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02587455||10209|
NCT02591368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.035.03|MiniTightRope Suspensionplasty Compared With LRTI for the Treatment of Basilar Thumb Arthritis|MiniTightRope Suspensionplasty Compared With Ligamentous Reconstruction Tendon Interposition for the Treatment of Basilar Thumb Arthritis. A Randomized Clinical Trial||Orlando Health, Inc.|No|Recruiting|October 2015|October 2021|Anticipated|October 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02591368||9908|
NCT02520804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si566/2014|Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function|Effect of Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function; A Randomized Open Label Controlled Study||Mahidol University|No|Recruiting|November 2014|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|107|||Both|18 Years|N/A|No|||August 2015|August 9, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02520804||15327|
NCT02582489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15090903|Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy|Prospective, Randomized, Double-blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate Post-Meniscectomy||Rush University Medical Center|No|Not yet recruiting|November 2015|January 2020|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582489||10590|
NCT02582710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5714|Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy||POMEGA|University Hospital, Strasbourg, France|No|Recruiting|May 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|96|||Both|30 Years|85 Years|No|||September 2015|October 20, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02582710||10573|
NCT02582996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-CFL-03(01/14)|Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks|National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks||Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|February 2017|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02582996||10551|
NCT02581722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-04A|Safety and Efficacy Study of Non-Surgical MC Device for Adolescent Male Population Including Contraindicated Subjects|A Safety and Efficacy Study of Non-surgical MC Device on PrePex Adolescent Male Population, Including Contraindicated Subjects Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV in Resource Limited Settings||Ministry of Health, Rwanda|No|Active, not recruiting|August 2015|March 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Male|10 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581722||10649|
NCT02591641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004912|Use of a Shear Reduction Surface in Pre-hospital Transport|Use of a Shear Reduction Surface in Pre-hospital Transport||Mayo Clinic|No|Not yet recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591641||9887|
NCT02594189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160008|Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers|Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|50 Years|No|||October 2015|October 31, 2015|October 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594189||9691|
NCT02592837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|EBUS-TBNA vs Flex 19G EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial||Royal Brompton & Harefield NHS Foundation Trust|No|Not yet recruiting|January 2016|December 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02592837||9795|
NCT02581228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTI-007|Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy|Multi-centre, Retrospective, Open Label Study, to Establish and Validate ML-PrediCare for Patients of Advanced Melanoma Undergoing Immunotherapy, as a 1st, 2nd and Later Lines||Optimata Ltd.|No|Recruiting|October 2015|November 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|Samples Without DNA|Tumor tissue from an unresectable or metastatic site of disease will be collected for      biomarker analyses. Paraffin-embedded tissue samples from patients treated with the      immunotherapy drugs (with the previously obtained inform consent form) will be collected      from the tissue bank of the hospital and according to the European Commission regulations.|Both|18 Years|120 Years|No|Probability Sample|Data from up to about 500 melanoma patients will be screened for collection, depending on        data availability and completeness of the files|October 2015|November 2, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02581228||10687|
NCT02580812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P140940|Neurological Consequences of Perinatal Listeriosis Infection|Multicentric Observational National Analysis of Listeriosis and Listeria : Evaluation of the Neurological Consequences of Perinatal Listeriosis Infection|MONALISABABY|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2015|March 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|360|||Both|5 Years|6 Years|No|||December 2015|December 15, 2015|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02580812||10719|
NCT02580825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc0189-15CTIL|Biofeedback Gait Retraining to Reduce Lower Extremity Impact in Obese Children|Biofeedback Gait Retraining to Reduce Lower Extremity Impact in Obese Children||Meir Medical Center|No|Not yet recruiting|October 2015|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2015|October 19, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02580825||10718|
NCT02516891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI12/00440|Jailed Wire Technique in the Treatment of Coronary Bifurcations Lesions With Stent: Stereoscopic Microscopy Study|Jailed Wire Technique in the Treatment of Coronary Bifurcations Lesions With Stent: Prospective Randomized Study With Stereoscopic Microscopy||Maimónides Biomedical Research Institute of Córdoba|No|Recruiting|February 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|No|||June 2015|August 5, 2015|July 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02516891||15628|
NCT02583438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saxa015|Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes|Beijing Chao-yang Hospital, Capital Medical University||Beijing Chao Yang Hospital|Yes|Not yet recruiting|October 2015|January 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|65 Years|No|||October 2015|October 21, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02583438||10517|
NCT02583451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-E044-106|Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects|A Randomized, Double-Blind, Placebo- and Active-Controlled, 4-Period Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects||Eisai Inc.|No|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|48|||Both|21 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583451||10516|
NCT02586870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01244-45|Assessment of Renal Artery Fibromuscular Dysplasia: From Diagnosis to Treatment|Assessment of Renal Artery Fibromuscular Dysplasia: From Diagnosis to Treatment|DysArt|Assistance Publique Hopitaux De Marseille|No|Recruiting|November 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02586870||10253|
NCT02584660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107694|A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department|MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department|MERCURY PE|Janssen Scientific Affairs, LLC|Yes|Recruiting|October 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02584660||10423|
NCT02590783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ2015-188|Treatment of Pelvic Ring Fractures in the Elderly|Treatment of Pelvic Ring Fractures in the Elderly: A Randomized Controlled Trial Comparing Surgical vs. Conservative Therapy||University Hospital, Basel, Switzerland|No|Recruiting|September 2015|October 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|65 Years|N/A|No|||October 2015|October 27, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02590783||9953|
NCT02581293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31/2015|Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs|Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|No|Recruiting|March 2015|February 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|4||Anticipated|132|||Female|N/A|40 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02581293||10682|
NCT02581306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00103937|Exercise Induced Changes in Fat Metabolism|Exercise-mediated Changes in Adipocyte Differentiation and Metabolic Function|BC|University of Michigan|No|Recruiting|October 2015|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581306||10681|
NCT02520947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS-12345|The Effect of BIS Monitorization to Intraoperative Anesthetic Consumption During Coronary Artery Surgery|The Effect of BIS Monitorization to Intraoperative Anesthetic and Analgesic Consumption During Coronary Artery Grafting Surgery and Postoperative Mortality and Morbidity||Baskent Univesity Ankara Hospital|Yes|Completed|January 2014|November 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02520947||15316|
NCT02583984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505133RINC|Metabolomic Study in Exhaled Breath Condensate of Thoracic Surgical Patients|Metabolomic Study in Exhaled Breath Condensate of Thoracic Surgical Patients||National Taiwan University Hospital|Yes|Not yet recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Exhaled breath condensate|Both|20 Years|80 Years|No|Probability Sample|Thoracic surgical patients requiring lung isolation|October 2015|October 21, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02583984||10475|
NCT02592421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20150668H|SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2|Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|October 2015|October 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Both|30 Years|60 Years|No|||October 2015|October 28, 2015|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592421||9827|
NCT02592434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921104|Efficacy Study Of Tofacitinib In Pediatric JIA Population|Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects||Pfizer|Yes|Not yet recruiting|April 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|2 Years|17 Years|No|||March 2016|March 7, 2016|August 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592434||9826|
NCT02592122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-10-COPD|Airway Responsiveness in Patients With AECOPD Mechanical Ventilation by Inspiratory and Bronchial Dilation Testchronic Obstructive Pulmonary Disease|||Beijing Chao Yang Hospital|Yes|Recruiting|October 2013|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||October 2015|October 29, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02592122||9850|
NCT02523456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWS|Develop, Implement and Assess Effectiveness of Early Warning Score (EWS) for Moneragala District General Hospital|Develop, Implement and Assess Effectiveness of Early Warning Score (EWS) for Moneragala District General Hospital|EWS|Ministry of Health, Sri Lanka|Yes|Recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02523456||15123|
NCT02523469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102323|ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer||Medical University of South Carolina|Yes|Recruiting|January 2016|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|91|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523469||15122|
NCT02523599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-014|Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty|MATRIX-1|Innocoll|No|Recruiting|August 2015|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 12, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02523599||15112|
NCT02593578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-062|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.||Samsung Medical Center|No|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|87|||Both|19 Years|N/A|No|Probability Sample|Patients with treatment-refractory malignancy|December 2015|December 28, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02593578|2 Years|9738|
NCT02593617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUTF-GOKAEK 2012/196|The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students|The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students||Mustafakemalpasa State Hospital|Yes|Completed|December 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|6||Actual|2623|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593617||9735|
NCT02585115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCAREWP4Samples|Diagnostic Accuracy of Point of Care Test of First Voided Urine Compared to Midstream Voided Urine in Primary Care|Is a First Void Urine Sample as Accurate as a Midstream Urine Sample in Diagnosing Urinary Tract Infections With a Point-Of-Care-Test Method in Adult, Symptomatic, Non-pregnant Women in General Practice?||University of Copenhagen|No|Recruiting|October 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Female|18 Years|N/A|No|Non-Probability Sample|Non-pregnant adult women with symptoms of UTI all included in General Practice.|October 2015|October 21, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02585115||10388|
NCT02585128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELTAVI-CCT-ICU-2015|Predictors of Postoperative Delirium After Transcatheter Aortic Valve Implantation|Incidence and Risk Factors of Acute Postoperative Confusion State After Trans-catheter Aortic Valve Implantation (TAVI)||Cardiocentro Ticino|No|Recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|97|||Both|65 Years|N/A|No|||October 2015|October 22, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02585128||10387|
NCT02585908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doing-001|Safety and Efficacy of γδ T Cell Against Gastric Cancer|γδ T Cell Immunotherapy for Treatment of Gastric Cancer||Beijing Doing Biomedical Co., Ltd.|No|Not yet recruiting|November 2015|July 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|30 Years|75 Years|No|||October 2015|November 12, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02585908||10327|
NCT02589860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0536|Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant|A Pilot Study: Gene Expression and Bacterial Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant||Indiana University|Yes|Recruiting|January 2016|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Cells collected from oral mucosal samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Melphalan who undergo autologous stem cell transplant at the Indiana        University Health Melvin and Bren Simon Cancer Center.|February 2016|February 11, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589860||10024|
NCT02589873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-15-2318-H|Getting in Balance: A Workplace Diabetes Prevention Intervention Trial|A Workplace Intervention Trial Comparing Two Diabetes Prevention Programs - In-person and Online - Delivered in a Large Urban Workplace Environment.|GIBW|Kaiser Permanente|No|Recruiting|September 2015|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02589873||10023|
NCT02594007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|774885-1|Mobile Health Monitoring Solution for Heart Failure Patients|Mobile Health Monitoring Solution for Heart Failure Patients||Atlantic Health System|No|Not yet recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|55 Years|N/A|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594007||9705|
NCT02582112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZLTNS98|Warming IV Fluids and Incidence of Hypotension|Do Warming iv Fluids During the Management of Spinal- Induced Hypotension Decrease the Incidence of Hypotension and Reduce the Requirement of Fluid, Blood and Ephedrine?||Cukurova University|No|Completed|September 2010|October 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|43 Years|No|||February 2016|February 4, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02582112||10619|
NCT02578537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10607|COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS|COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial)|OPT-CKD|Shenyang Northern Hospital|No|Recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578537||10893|
NCT02578550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107887|A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Bioequivalence of Darunavir 800 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg, in the Presence of Cobicistat 150 mg, Administered as Either a Fixed-Dose Combination Tablet or as Separate Agents in Healthy Subjects||Janssen Sciences Ireland UC|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578550||10892|
NCT02589925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEMPARK-DBS V2.01|Combined Subthalamic and Nucleus Basalis Meynert Deep Brain Stimulation for Parkinson's Disease With Dementia|Kombinierte Tiefe Hirnstimulation Des Nucleus Subthalamicus Und Nucleus Basalis Meynert Zur Behandlung Der Parkinson-Krankheit Mit Demenz|Dempark-DBS|Wuerzburg University Hospital|No|Not yet recruiting|April 2016|September 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|35 Years|75 Years|No|||October 2015|February 8, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02589925||10019|
NCT02589938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF 97115|Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer|A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer|ACUPUNCTURE|Wake Forest NCORP Research Base|Yes|Not yet recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02589938||10018|
NCT02588950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16021|A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes|Comparative Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered Subcutaneously as a Bolus Via Syringe Versus Continuous Subcutaneous Insulin Infusion and Characterization of TID and BID Dosing at Steady State in High-Dose Insulin-Treated, Obese Subjects With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|74 Years|No|||January 2016|January 25, 2016|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02588950||10094|
NCT02591212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC R01CE 2690|Connect_ED: A Randomized Controlled Trial Connecting Through Educational Training|Connect_ED: A Randomized Controlled Trial Connecting Through Educational Training|Connect_ED|University of Kentucky|No|Enrolling by invitation|November 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|6000|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02591212||9920|
NCT02582333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF15240B|Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy|Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy||Taichung Veterans General Hospital|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|HBV DNA and genotype|Both|20 Years|N/A|No|Non-Probability Sample|Chronic hepatitis B patients who are indicated for stopping nucleos(t)ide analogue therapy        in the outpatient clinics according to the inclusion and exclusion criteria of this study|October 2015|October 30, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582333||10602|
NCT02578823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1071|Targeted Temperature Management After In-Hospital Cardiac Arrest|Targeted Temperature Management at 36℃ After In-Hospital Cardiac Arrest Trial(TTM36-IHCA Trial): An Investigator-Initiated, Single-Center, Randomized, Controlled, Assessor-Blinded, Pilot Clinical Trial|TTM36-IHCA|Asan Medical Center|No|Not yet recruiting|January 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 31, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578823||10871|
NCT02515487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-00146|An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors|An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer||New York University School of Medicine|No|Recruiting|September 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Female|18 Years|70 Years|No|||July 2015|August 3, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02515487||15735|
NCT02582515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA_DCS+HRT|Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo||DCS+HRT|University of California, Los Angeles|No|Recruiting|October 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|8 Years|17 Years|No|||October 2015|October 20, 2015|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582515||10588|
NCT02586662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112035RIB|Prediction of Functional Disability in Subjects With Scapular Dyskinesis|Prediction of Functional Disability in Subjects With Scapular Dyskinesis: Shoulder Tightness, Forward Shoulder Posture, Joint Range of Motion, Scapular Kinematics and Associated Muscular Activity||National Taiwan University Hospital||Completed|March 2012|October 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|51|||Both|18 Years|50 Years|No|Probability Sample|Function-related factors in patients with scapular dyskinesis. Fifty-one participants (40        males; 11 females; mean age= 22.5±2.4 years; mean height=171.4 ± 8.0 cm; mean weight= 64.9        ± 10.5 kg) were recruited.|October 2015|October 22, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02586662||10269|
NCT02591706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2015-1|Clinical Assessment of Dental Implant|Clinical and Radiographic Assessment of V3 Implant: A Randomized Controlled Trial|H2015-1|University Hospital of Liege|No|Recruiting|January 2015|November 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02591706||9882|
NCT02589977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141686|Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF|Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF|HFpEF-PRoF|Vanderbilt University|No|Recruiting|November 2015|January 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02589977||10015|
NCT02579642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00044771|Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy|Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy||University of Alberta|Yes|Enrolling by invitation|October 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02579642||10809|
NCT02587078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-VS01-01|Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis|Volume Therapy With Crystalloids and Colloids|VOMOSEP|Wuerzburg University Hospital|No|Terminated|March 2013|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|December 10, 2014||No|treatment substance not labled for sepsis anymore|No||https://clinicaltrials.gov/show/NCT02587078||10237|
NCT02587390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027-008|Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers|A Study to Evaluate the Effects of Gemcabene on the Steady-State Pharmacokinetics and Pharmacodynamics of Simvastatin in Healthy Volunteers||Gemphire Therapeutics, Inc.|No|Completed|May 2000|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587390||10214|
NCT02586909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVT-101-3002|12-Month Open-Label Extension Study of RVT-101 in Subjects With Alzheimer's Disease: MINDSET Extension|A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease||Axovant Sciences Ltd.|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1150|||Both|50 Years|86 Years|No|||March 2016|March 1, 2016|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586909||10250|
NCT02587143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASOHUB|Ethyl Chloride Vapocoolant as Anesthesia for Arterial Punctures|Ethyl Chloride Vapocoolant as Anesthesia for Arterial Punctures: A Randomized Clinical Trial||Bionorte|No|Not yet recruiting|February 2016|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02587143||10232|
NCT02583633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShirazSUMS|Transdermal Nitroglycerin and Nifedipine in Preterm Labor|Transdermal Nitroglycerin and Nifedipine for Managing Preterm Labor: a Randomized Clinical Trial||Shiraz University of Medical Sciences|Yes|Completed|October 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|112|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02583633||10502|
NCT02587780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBSREC1314/37|Blood Sugar Responses by Physical Activity Level and Intensity|An Observational Study of Incremental Area Under the Curve Values in Similar, Non-diabetic, Subjects- Undertaking Different Amounts and Intensities of Physical Activity||Small Changes|No|Not yet recruiting|November 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Both|19 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals (non-diabetic or other chronic disabling conditions likely to affect        blood glucose) of different habitual levels of physical activity.|October 2015|October 26, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02587780||10184|
NCT02594111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARB-025-15S|Colchicine in Percutaneous Coronary Intervention|Anti-inflammatory Therapy During Percutaneous Coronary Intervention||VA Office of Research and Development|Yes|Recruiting|June 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|99 Years|No|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594111||9697|
NCT02594124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443-CS11|An Open-Label Study (SHINE) for Patients With Spinal Muscular Atrophy (SMA) Who Participated in Studies With IONIS-SMNRx|An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443||Ionis Pharmaceuticals, Inc.|Yes|Enrolling by invitation|November 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|274|||Both|13 Months|21 Years|No|||December 2015|January 18, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594124||9696|
NCT02587156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH122|Fate of Nutrient-Derived Amino Acids|Fate of Nutrient-Derived Amino Acids: Influence of Habituated Levels of Daily Dietary Protein Intake on Protein Utilization||Bispebjerg Hospital|Yes|Recruiting|October 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|65 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587156||10231|
NCT02587468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-507 ex 14/15|Bioavailability and Absorption Kinetics of Phenolic Compounds and Specific Vitamins|Bioavailability and Absorption Kinetics of Phenolic Compounds and Specific Vitamins of a Commercially Available, Encapsulated Nutraceutical (Juice Plus+®)||Green Beat|No|Recruiting|October 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587468||10208|
NCT02591901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXQ/648|Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)|Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study|PReSuTINeB|Buckinghamshire Healthcare NHS Trust|Yes|Not yet recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|75 Years|No|||October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591901||9867|
NCT02591979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PAS-2013-151|PASHOS Project: Advanced Platform for Sleep Apnea Syndrome Assessment|PASHOS Project: Advanced Platform for Sleep Apnea Syndrome Assessment. A Multi-Centre Study to Validate a Sleep Apnea Screening Model in Primary Health Care||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|May 2014|||October 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|198|||Both|18 Years|75 Years|No|Probability Sample|Patients visited at Primary Care consultations will be included according to a        randomization schedule to reach the necessary sample.|October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591979|3 Months|9861|
NCT02580422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0547|Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia|Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia||Indiana University|Yes|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|Blood samples will be collected: one sample for cytokine analysis, one sample for future      research.|Both|N/A|N/A|No|Non-Probability Sample|Potential participants will be identified from the outpatient oncology clinic at the        Indiana University Health Melvin and Bren Simon Cancer Center or Sidney & Lois Eskenazi        Health Hospital.|January 2016|January 27, 2016|October 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02580422||10749|
NCT02583243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMHSA 15767|Project BEST: Buprenorphine Entry Into Substance Abuse Treatment|Project BEST: Buprenorphine Entry Into Substance Abuse Treatment||Yale University|No|Completed|May 2005|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|||Both|18 Years|65 Years|No|Non-Probability Sample|This is a prospective cohort of opioid dependent patients at risk for HIV or with HIV        seeking treatment with buprenorphine. Subjects may have severe mental illness and other        co-morbid medical conditions.|October 2015|October 21, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT02583243||10532|
NCT02583308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 053-15|Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation|Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation: an Ancillary Study of the DEMETER Trial (NCT02515617)||Centre Hospitalier Departemental Vendee|Yes|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583308||10527|
NCT02594020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-09|Comparison of Different Methods of Enamel Preparation Before Pit and Fissure Sealants|||Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|June 2008|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|500|||Both|18 Years|65 Years|No|||September 2015|October 30, 2015|June 4, 2013||No||No||https://clinicaltrials.gov/show/NCT02594020||9704|
NCT02594033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4219|A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles|A Single Centre, Randomised, 3-period Cross-over Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles||Novo Nordisk A/S|No|Completed|October 2015|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|45|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|October 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594033||9703|
NCT02580695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4COA01|A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis|A Phase I/II, Randomized, Double-blind, Controlled Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in Patients With Knee Osteoarthritis||Universidad Los Andes, Chile|Yes|Recruiting|October 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580695||10728|
NCT02579538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508145|Flexibility of Cognition And Persistent Pain|Cognitive Predictors of Persistent Post-surgical Pain (PPSP)|FlexCAPP|Washington University School of Medicine|No|Recruiting|September 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are 18 to 85 years of age undergoing unilateral TKA for osteoarthritis,        unilateral mastectomy for breast cancer, or thoracotomy or video-assisted thoracoscopic        surgery for any non-cardiac indication will be recruited for participation in the study        during their initial preoperative visit at the Washington University Center for        Perioperative Assessment and Planning (CPAP). Patient eligibility will not be affected by        the anesthetic plan including the potential use of regional anesthesia techniques.|October 2015|October 15, 2015|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02579538||10817|
NCT02582918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062015-054|Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5|Comparative Effectiveness Trial of Care Delivery Strategies for HCC Screening Process Completion||University of Texas Southwestern Medical Center|No|Not yet recruiting|September 2016|August 2020|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Anticipated|3000|||Both|21 Years|N/A|No|||March 2016|March 11, 2016|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02582918||10557|
NCT02588703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD007762|Delivering Treatment in DUI Programs to Reduce Alcohol-Related Disparities|Delivering Treatment in DUI Programs to Reduce Alcohol-Related Disparities||RAND|Yes|Not yet recruiting|October 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||October 2015|October 27, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02588703||10113|
NCT02584842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2014-346|Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy|Rivaroxaban for Thrombosis Prophylaxis in Endovenous Laser Ablation With and Without Miniphlebectomy: A Multicenter Experience|RITE|University Hospital, Basel, Switzerland|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients age greater than 18 years, informed consent was given. EVLA of the GSV, ASV        and/or SSV using 1470 nm wavelength radial laser (ELVeS, Biolitec, Austria) and        postinterventional EHIT prophylaxis with rivaroxaban.|October 2015|October 22, 2015|May 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02584842||10409|
NCT02589158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT067|SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat|Steady-state Pharmacokinetics of Atazanavir/Cobicistat and Darunavir/Cobicistat Once Daily Over 72 Hours in Healthy Volunteers||St Stephens Aids Trust||Completed|November 2015|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02589158||10078|
NCT02591381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K12DK083021-AUS|Transcorporal Versus Standard Artificial Urinary Sphincter Placement|A Randomized Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement|TC vs ST AUS|University of California, San Francisco|No|Active, not recruiting|October 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||October 2015|October 29, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591381||9907|
NCT02579798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-CRF|Does Pulmonary Compliance Optimization Through PEEP Manipulations Reduces the Incidence of Postoperative Hypoxaemia in Bariatric Surgery?|Does Pulmonary Compliance Optimization Through PEEP Manipulations Reduces the Incidence of Postoperative Hypoxaemia in Bariatric Surgery?||Brugmann University Hospital|No|Active, not recruiting|July 2013|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579798||10797|
NCT02522910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0274|An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||Yonsei University|No|Not yet recruiting|August 2015|June 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|19 Years|N/A|No|||August 2015|August 11, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02522910||15165|
NCT02522923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23131|Back-on-Track Studying Early Quality Care|Comparison of Two Different Initial Entry Portals of Care for Patients Seeking Care for Musculoskeletal Pain: A Multisite Randomized Controlled Trial|on-Track|Temple University|Yes|Not yet recruiting|January 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02522923||15164|
NCT02593344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/54|Peripheral Endothelial Function in Asthmatic Patients|Peripheral Endothelial Function in Asthmatic Patients|Endothasthm|Hopital Foch|No|Recruiting|December 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|125|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02593344||9756|
NCT02593383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhaoke-2015-02|Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne|A Placebo Control, Multicenter, Randomized, Double Blind, Multi-formula Groups, and Parallel Phase Ⅰb+Ⅱa Study Evaluating the Safety and Efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne||Lee's Pharmaceutical Limited|Yes|Recruiting|March 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|240|||Both|18 Years|40 Years|No|||October 2015|October 30, 2015|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02593383||9753|
NCT02590471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-RICP-467|Pilot Prospective Study of Two Methods of Revascularization of the Femoral Artery (SFA): Stenting in the SFA, and Stenting of the SFA, Supplemented by Fasciotomy in Hunter Channel.|Pilot Prospective Study of Two Methods of Revascularization of the Superficial Femoral Artery: Stenting in the Superficial Femoral Artery, and Stenting of the Superficial Femoral Artery, Supplemented by Fasciotomy in Hunter Channel in Patients With Steno-occlusive Lesions of Femoral-popliteal Segment TASC C, D||Meshalkin Research Institute of Pathology of Circulation|No|Recruiting|October 2015|November 2019|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|75 Years|No|||March 2016|March 18, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02590471||9977|
NCT02591810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.041.04|Treatment Options for Acute Distal Radioulnar Joint Instability|Comparison of Treatment Options for Acute Distal Radioulnar Joint Instability: A Prospective Randomized Control Trial|DRUJ|Orlando Health, Inc.|No|Not yet recruiting|December 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02591810||9874|
NCT02520752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280A2103|A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors||Novartis|No|Not yet recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|August 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520752||15331|
NCT02587377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU14|New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology|New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology. A National Belgian Study||Queen Fabiola Children's University Hospital|No|Terminated|June 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|3 Months|18 Years|No|||September 2014|October 26, 2015|June 3, 2014||No|The current rate of recruitment is insufficient.|No||https://clinicaltrials.gov/show/NCT02587377||10215|
NCT02593981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006031|Addressing Sleep Problems in Older Adults|To Sleep, Perchance to Dream: A Randomized, Placebo-Controlled Study to Test a Fruit/Honey-Based Foodstuff for Sleep Problems in Older Adults||Mayo Clinic|No|Not yet recruiting|March 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593981||9707|
NCT02592694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cocktail I|Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty|Intracoronary Cocktail Injection Combined With Thrombus Aspiration in ST-elevation Myocardial Infarction Patients Treated With Primary Angioplasty||Xijing Hospital|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|October 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02592694||9806|
NCT02592707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPS-C-001|177Lu-OPS201 Study for the Therapy of GEP NETs|An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)||Ipsen|No|Not yet recruiting|March 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|100 Years|No|||March 2016|March 17, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02592707||9805|
NCT02523105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010-15|Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment|Evaluation of Use of Brain Activity Monitoring for Early Identification of Pharmaceutical Treatment Efficacy and Development of Depression Deterioration Events.||Brainmarc Ltd.|No|Recruiting|September 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|December 7, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02523105||15150|
NCT02587364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027-003|Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers|An Oral, Rising, Multiple‐Dose Tolerance, Pharmacokinetic and Pharmacodynamic Study of Gemcabene Capsules in Healthy Volunteers||Gemphire Therapeutics, Inc.|No|Completed|April 1999|September 1999|Actual|September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02587364||10216|
NCT02587806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT/NOVO/2015/002|A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS||Novo Cellular Medicine Institute LLP|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|60 Years|No|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587806||10182|
NCT02586376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLT-RENAIS-2015|Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF)|Effects of the Different Intensities of the Low-level Laser Therapy on Handgrip Test on Patients With Kidneys Failure: A Randomized, Controlled Clinical Trail|LLLTMSKF|Federal University of Health Science of Porto Alegre|No|Completed|October 2015|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|30 Years|60 Years|No|||February 2016|February 2, 2016|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02586376||10291|
NCT02586623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16306A|Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension|RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy|RESTORE|Lundbeck Northera Ltd.|No|Recruiting|February 2016|||March 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|482|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586623||10272|
NCT02580383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0385-001|Multifidus Muscle Twitch on the Prognosis of Lumbar Medial Branch RF|Effect of the Multifidus Muscle Twitch on the Long Term Effect of Radiofrequency Lumbar Medial Branch Neurotomy||Severance Hospital|Yes|Recruiting|September 2015|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|The patients who had lumbar back pain in Gangnam Severance hospital, Seoul, Republic of        Korea.|October 2015|October 19, 2015|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580383||10752|
NCT02580396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4404|Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine|Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine||Royal Marsden NHS Foundation Trust|No|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02580396||10751|
NCT02581969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18251|Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."|Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." POTTER-10|POTTER 10|Bayer|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|50|||Male|17 Years|60 Years|No|Non-Probability Sample|A total of approximately 50 patients with a diagnosis of severe haemophilia A (FVIII < 1%)        , who are already on Kogenate Bayer treatment ongoing for long-term secondary prophylaxis        or on-demand therapy and have properly completed the follow-up in the original Potter        study are expected to be enrolled.|February 2016|February 28, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02581969||10630|
NCT02586272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-100|Diafert for Embryo Selection and Fertility Improvement|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval.|DESTINy|Forest Laboratories|No|Recruiting|December 2014|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 12, 2015|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586272||10299|
NCT02585817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-002|Remote Patient Management for Cardiac Implantable Electronic Devices|Remote Patient Management for Cardiac Implantable Electronic Devices|RPM-CIED|Nova Scotia Health Authority|No|Not yet recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02585817||10334|
NCT02520739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/11-C38|New Industrial Procedures for Achieving a Nutritional Added Value of the Olive Oil. The NUTRAOLEUM Study|New Industrial Procedures for Achieving a Nutritional Added Value of the Olive Oil. The NUTRAOLEUM Study|NUTRAOLEUM|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental|Yes|Active, not recruiting|February 2014|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|57|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02520739||15332|
NCT02520791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2015-01271|Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma|A Phase I Evaluation/Dose Escalation of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)||National Cancer Institute (NCI)||Not yet recruiting|November 2015|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||August 2015|September 14, 2015|August 10, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02520791||15328|
NCT02587975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUMC-EVOG-BONE|Effect of Evogliptin on Bone Metabolism in Human|Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers||DongGuk University|No|Not yet recruiting|December 2015|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587975||10169|
NCT02590731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_III|The Influence of Cognitive Status on Walking Abilities After Femoral Neck Fracture|The Influence of Cognitive Status on Walking Abilities After Hemiarthroplasty for Femoral Neck Fracture: a Prospective Cohort Study||Sundsvall Hospital|No|Completed|February 2012|October 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|188|||Both|65 Years|N/A|No|Non-Probability Sample|Patient with displaced femoral neck fractures.|February 2016|February 28, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590731||9957|
NCT02592291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHealth-Comp3|Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions|Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions (Component 3)||University of Pittsburgh|No|Recruiting|October 2015|September 2020|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|12 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02592291||9837|
NCT02591030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408212|Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours|Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours|AMEBICA|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|November 2015|June 2018|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02591030||9934|
NCT02578472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108056|Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants|A Double-blind, Randomized, Controlled, 3-way Crossover, Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Subjects||Janssen-Cilag International NV|No|Completed|November 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578472||10898|
NCT02584933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2X01B|Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study|An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib||Novartis|No|Recruiting|December 2015|November 2020|Anticipated|November 2020|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 6, 2015|No|Yes||Yes||https://clinicaltrials.gov/show/NCT02584933||10402|
NCT02523313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMUNED|Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED|A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease||University Hospital, Essen|Yes|Recruiting|July 2015|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|312|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02523313||15134|
NCT02523326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentroICSUT|Design of a Protocol for Obtaining Genomic DNA From Saliva|Design of a Protocol for Obtaining Genomic DNA From Saliva Using Mouthwash: Samples Taken From Patients With Periodontal Disease|DPOGDNAS|Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás|Yes|Recruiting|February 2015|September 2015|Anticipated|August 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|the extraction of high quality genomic DNA from saliva samples obtained with mouthwash.|Both|35 Years|45 Years|No|Non-Probability Sample|patients diagnosed with severe chronic periodontitis|August 2015|August 12, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02523326||15133|
NCT02588196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH 002|The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis|||Hebei Medical University||Not yet recruiting|November 2015|||October 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|14 Years|N/A||||October 2015|October 27, 2015|October 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02588196||10152|
NCT02588209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGK11-52|Cognitive Screening and Cognitive Training in Seniors|Cognitive Screening and Cognitive Training in Seniors||The University of Texas at Dallas|No|Active, not recruiting|January 2012|December 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588209||10151|
NCT02579213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200-15-RMB|Electronic Nose and Fetal Chromosomal Disorders|Examining the Ability of Electronic Nose in Detecting Fetal Chromosomal Disorders||Rambam Health Care Campus||Not yet recruiting|October 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|.33 ml of amniotic fluid are drawn from the uterine cavity, when 30 cc are part of routine      tests and the rest of the amount (3 ml) is intended for research|Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|A prospective study that includes pregnant women candidates for amniocentesis between        17-33 gestational weeks|September 2015|October 16, 2015|September 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02579213||10841|
NCT02581319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-26/103.243/2012|Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy|Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy||University of Sao Paulo|Yes|Recruiting|July 2015|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581319||10680|
NCT02514382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16M-15-2|Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma||University of Southern California|Yes|Recruiting|August 2015|August 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02514382||15820|
NCT02580942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13401905400|Efficacy Study of Acupoint Sticking in Summer to Treat Asthma|Efficacy Study of Acupoint Sticking in Treating Winter Diseases in Summer to Treat Asthma of Kidney Yang Deficiency Type||Shanghai University of Traditional Chinese Medicine|No|Recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|October 18, 2015|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02580942||10709|
NCT02580955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-150527|REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions|ReFlow Study, a Physician-initiated Trial Investigating the Efficacy of the LegFlow Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter for the Treatment of Femoropopliteal Lesions Longer Than 15cm (TASC C&D Lesions).||Flanders Medical Research Program|No|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580955||10708|
NCT02590666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolypectomyCA|Endometrial Polypectomy Performed With Bipolar Electrode Versapoint vs Microscissors or Graspers|Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint vs Microscissors or Graspers||University of Cagliari|No|Not yet recruiting|June 2016|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02590666||9962|
NCT02590809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/14|Hypertrophic Cardiomyopathy Symptom Release by BX1514M||Light-CARMIDO|University Hospital, Bordeaux|Yes|Recruiting|October 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590809||9951|
NCT02591823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/2015/RP/18|Hair Fall in Patients on Low Dose Methotrexate|Observational Study of Hair Fall in Rheumatoid Arthritis Patients Treated With Low Dose Methotrexate||Columbia Asia|Yes|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases will consist of consecutive patients diagnosed with rheumatoid arhtiritis in the        rheumatology OPD of Columbia Asia hospitals,Bengaluru who are started on methotrexate.        Control population will consist of healthy volunteers (relatives of patients attending the        rheumatology OPD or staff in the hospital)|January 2016|January 13, 2016|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591823||9873|
NCT02578875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160001|Evaluation of MiSeq for Microbial Identification in Specimens|Evaluation of MiSeq for Microbial Identification in Specimens||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|January 2020|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|No|||September 2015|October 20, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578875||10867|
NCT02582047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFLUENZAPNEUMO|Influenza Vaccine and Pneumococcal Vaccine|Immunogenicity and Safety of an Influenza Vaccine Administered Concomitantly With a 13-Valent Pneumococcal Conjugate Vaccine or 23-Valent Polysaccharide Pneumococcal Vaccine in Elderly Patients||Korea University Guro Hospital|Yes|Completed|October 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|224|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02582047||10624|
NCT02586116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC03|Comparison of nanOss Cervical IBF System to C-Plus PEEK IBF Device With Autograft|Post Market Comparison of nanOss Cervical Interbody Fusion System to C-Plus Interbody Fusion Device With Autograft||RTI Surgical|No|Recruiting|October 2015|November 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||October 2015|October 23, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02586116||10311|
NCT02583126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM-Cancer-Teenagers-1|Guided Imagery and Music for the Reduction of Side Effects of Chemotherapy in Teenagers|The Effect and Meaning of a Designed Guided Imagery and Music Intervention on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Teenagers With Cancer: a Randomized Controlled Multisite Study||University of Aarhus|No|Recruiting|August 2014|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|68|||Both|12 Years|17 Years|No|||November 2015|November 30, 2015|February 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02583126||10541|
NCT02579135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57033|Reducing HIV Risk Among Adolescents: Evaluating Project HEART|Reducing HIV Risk Among Adolescents: Evaluating Project HEART||North Carolina State University|No|Active, not recruiting|September 2015|May 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|222|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|October 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02579135||10847|
NCT02594046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-2015-199-2|The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia|The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia||Pusan National University Hospital|Yes|Active, not recruiting|July 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|38|||Both|19 Years|59 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02594046||9702|
NCT02594059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/56|Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis|Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis|Endoth-FPI|Hopital Foch|No|Recruiting|December 2012|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|85 Years|No|||October 2015|October 30, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594059||9701|
NCT02582346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-004|Assessment of Magnetic Resonance Imaging Neurography and Tractography for Preoperative Mapping of Pelvic Nerves|Assessment of Magnetic Resonance Imaging Neurography and Tractography for Preoperative Mapping of Pelvic Nerves|Neuro-Tracto|IHU Strasbourg|No|Completed|November 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582346||10601|
NCT02586402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-EPOP2c|Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis|A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Pegolsihematide for the Correction of Anemia in Patients With CRF Undergoing Dialysis and Previously Treated With ESAs||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Recruiting|October 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586402||10289|
NCT02589769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1786 (REK(|Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons|Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons||Oslo University Hospital|No|Not yet recruiting|September 2016|January 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|84|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2015|October 27, 2015|June 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02589769||10031|
NCT02579395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0601|A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes|A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes||University of Colorado, Denver|No|Not yet recruiting|October 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|21 Years|69 Years|No|||October 2015|October 16, 2015|October 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02579395||10827|
NCT02586844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET-SEQ|Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors|Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors|NET-SEQ|University Health Network, Toronto|No|Recruiting|October 2013|October 2020|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Fresh tumor tissue, 3 tubes of whole blood, archival tumor tissue|Both|18 Years|N/A|No|Probability Sample|Patients with histological or cytological diagnosis of NET and PanNET; have at least one        biopsiable lesion deemed medically accessible and safe to biopsy; fulfill local        institution's laboratory parameters for tumor biopsy, and provided written voluntary        informed consent.|January 2016|January 25, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586844||10255|
NCT02594436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PICATO-1220|The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice|The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study|PrAKtice|LEO Pharma|No|Recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|440|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients planned for starting treatment non-hyperkeratotic, non-hypertrophic actinic        keratosis on face, scalp, trunk or extremities with topical ingenol mebutate gel.|March 2016|March 2, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02594436||9672|
NCT02593526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diuretic/Cool Dialysate Trial|Diuretic/Cool Dialysate Trial|Diuretic/Cool Dialysate Trial|DIDIT|University of New Mexico|No|Not yet recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02593526||9742|
NCT02593539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204745|Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled GSK2269557 in Patients With APDS/PASLI|An Open-label, Single Arm Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Repeat Doses of Inhaled GSK2269557 in Patients With APDS/PASLI||GlaxoSmithKline|No|Not yet recruiting|May 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593539||9741|
NCT02583945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022015|Prevention of Postoperative Acute Kidney Injury|Effect of a Kidney Bundle on the Occurence of Postoperative Acute Kidney Injury in Patients at Risk|PrevenAKI|Wuerzburg University Hospital|No|Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|September 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02583945||10478|
NCT02587715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT/NOVO/2015/001|A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)||Novo Cellular Medicine Institute LLP|Yes|Recruiting|February 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|60 Years|No|||October 2015|October 27, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587715||10189|
NCT02594371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KX-ORAX-001|Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer|An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer||Kinex Pharmaceuticals Inc|Yes|Recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594371||9677|
NCT02594462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458660|Contraception in Women With Sickle Cell Disease|Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease||University of Sao Paulo|No|Recruiting|January 2015|November 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|40 Years|No|||October 2015|October 30, 2015|June 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02594462||9670|
NCT02591784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-ESO-002|Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer|The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer||Biotech Pharmaceutical Co., Ltd.|No|Completed|November 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|75 Years|No|||August 2015|October 28, 2015|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02591784||9876|
NCT02591836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4141001|Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin|An 8‐Week, Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Ranging Study of the Efficacy and Safety of Gemcabene Administered as Monotherapy or in Combination With Atorvastatin in the Treatment of Hypercholesterolemic Patients||Gemphire Therapeutics, Inc.|No|Completed|January 2003|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|277|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591836||9872|
NCT02590159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-C002|Clinical Study for the BONGO NASAL Expiratory Positive Airway Pressure (EPAP) Device in the Treatment of Obstructive Sleep Apnea (OSA)|Clinical Study for the BONGO NASAL EPAP Device in the Treatment of Obstructive Sleep Apnea (OSA)||InnoMed Healthscience Inc.|No|Recruiting|November 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||October 2015|December 5, 2015|October 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590159||10001|
NCT02583022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRPV1-AD_IIT|A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis|A Randomized, Open-label, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Atopic Dermatitis||Amorepacific Corporation|Yes|Completed|June 2013|August 2015|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|20 Years|65 Years|No|||October 2015|October 20, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02583022||10549|
NCT02587403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTI-2015-02|A Comparison of Fortiva and Strattice Tissue Matrices in Complex, Ventral Hernia Repair|A Randomized, Prospective Study Comparing Fortiva™ Porcine Dermis vs. Strattice™ Reconstructive Tissue Matrix in Patients Undergoing Complex Open Primary Ventral Hernia Repair||RTI Surgical|No|Recruiting|November 2015|October 2019|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||November 2015|December 9, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587403||10213|
NCT02590887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lupine-1|Immunomodulatory and Antioxidant Effects of a Drink Manufactured From Lupine Protein Hydrolysates|Clinical Study to Assess the Immunomodulatory and Antioxidant Effects of a Drink Manufactured From Lupine Protein Hydrolysates in Healthy Volunteers||University of Seville||Enrolling by invitation|October 2015|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02590887||9945|
NCT02593591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-10-063|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.||Samsung Medical Center|No|Not yet recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|130|||Both|19 Years|N/A|No|Probability Sample|patients with treatment-refractory malignancy|October 2015|October 29, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02593591|2 Years|9737|
NCT02593604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-015|Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa|Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa||University of Schleswig-Holstein|No|Enrolling by invitation|March 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Patients with hidradenitis suppurativa that were treated in 2013 in Fachklinik Hornheide,        Germany, by wide excision of their infected skin areas.|October 2015|October 29, 2015|April 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02593604||9736|
NCT02584218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-0001|Effectiveness of Sealing Dental Caries|Effectiveness of Sealing Dental Caries: a Randomized Clinical Trial||Universidade Federal do Rio de Janeiro|Yes|Active, not recruiting|January 2015|February 2017|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02584218||10457|
NCT02588105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6500C00001|Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer|A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies|AToM|AstraZeneca|No|Recruiting|November 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|130 Years|No|||March 2016|March 14, 2016|October 19, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02588105||10159|
NCT02594449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC-PHB1505|A Pharmacodynamic and Safety Study of BCS in Healthy Volunteers|A Pharmacodynamic and Safety Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Healthy Volunteers||Lustre Pharmaceutical Lab Co., Ltd|No|Enrolling by invitation|October 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|November 2, 2015|October 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594449||9671|
NCT02587481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-057|Pneumological Acute Coronary Syndrom (ACS) Phenotyping Aachen|Pneumological Phenotyping of Acute Coronary Syndrom (ACS) Patients Concerning Concomitant Chronic Obstructive Pulmonary Disease (COPD)|PAPA|RWTH Aachen University|No|Recruiting|November 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Serum, Blood plasm|Both|18 Years|N/A|No|Non-Probability Sample|Patients with either non ST-segment-elevation myocardial infarction (NSTEMI) or        ST-segment-elevation myocardial infarction (STEMI)|February 2016|February 16, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02587481||10207|
NCT02591342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM_IV|Comparison of a Cemented, Polished Tapered Stem and an Anatomic Stem for Femoral Neck Fracture|||Sundsvall Hospital|No|Completed|September 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1014|||Both|80 Years|N/A|No|Non-Probability Sample|We included all patients above the age of 80 years old, operated between September 2009        and April 2015 with a primary hip arthroplasty for an acute displaced femoral neck        fractures. Patients were treated either with the cemented CPT or SP2 stems.|October 2015|October 28, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02591342||9910|
NCT02579109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13AOI09|Multisensorial Information's Treatment in Autism Spectrum Disorder|Exploring Social Cognition in Autism Spectrum Disorder With Long Time Memory Task. Controlled Study on 8-13 Years Childs||Centre Hospitalier Universitaire de Nice|No|Completed|February 2014|August 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Both|7 Years|13 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02579109||10849|
NCT02585024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRF reference 1 1 15 011|Cytisine Pharmacokinetics and Dose Response (C-DRAKS 3 and C-DRAKS 4)|Cytisine as a Smoking Cessation Agent: Improving Adherence Through a Better Understanding of Pharmacokinetics and Dose Response||University of Auckland, New Zealand||Not yet recruiting|November 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label|3||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 21, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02585024||10395|
NCT02592187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fundacio la Marató TV3-2014510|A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)|A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)|ReMemory-MCI|Consorci Sanitari de Terrassa||Not yet recruiting|October 2015|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|90 Years|No|||October 2015|October 29, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02592187||9845|
NCT02592200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0092|Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women|A Double Blind Placebo-Controlled Study on the Effect of the Probiotic Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women - Proof of Concept||BioGaia AB|No|Recruiting|October 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02592200||9844|
NCT02583321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 054-15|Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate|Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate: an Ancillary Study of the DEMETER Trial (NCT02515617)||Centre Hospitalier Departemental Vendee|Yes|Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02583321||10526|
NCT02519920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015SDU-QILU-G08|Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin|Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin||Shandong University|Yes|Recruiting|April 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|4||Anticipated|63|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|October 19, 2015|August 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02519920||15395|
NCT02520141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0393|Ramucirumab for Advanced Pre-treated Biliary Cancers|A Phase II Study of Ramucirumab for Advanced, Pre-treated Biliary Cancers||M.D. Anderson Cancer Center|No|Recruiting|December 2015|||December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|August 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520141||15378|
NCT02520154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0662|Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer|Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|March 2016|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02520154||15377|
NCT02593292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL14_0454|Program of Research for the Optimization of a Supervised Patient Pathway for Expectant According to Risk in Obstetrics|Program of Research for the Optimization of a Supervised Patient Pathway for Expectant According to Risk in Obstetrics|PROSPERO|Hospices Civils de Lyon|No|Not yet recruiting|April 2016|March 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1500|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593292||9760|
NCT02593305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201507735|Dietary Nitrate and Physiological Aging|Dietary Nitrate Supplementation and Physiological Function in Older Adults||University of Iowa|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|15|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02593305||9759|
NCT02589171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0668|The neoClose Study|Randomized Trial Evaluating Effectiveness of neoClose Abdominal Closure Device Versus Carter-Thomason Needle Passer||The University of Texas Health Science Center, Houston||Not yet recruiting|November 2015|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02589171||10077|
NCT02592265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-P0018|Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden|Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden and Social Participation.|ECOPASEP|Lille Catholic University|No|Active, not recruiting|October 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|233|||Both|18 Years|N/A|No|Probability Sample|At least 230 patients in secondary and tertiary centers (8) affiliated to the regional        supportive care network (GSEP) in north of France.|October 2015|October 29, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02592265||9839|
NCT02579811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7815|Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer|A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors||Case Comprehensive Cancer Center|Yes|Recruiting|December 2015|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 14, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579811||10796|
NCT02583581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD4|Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks|A Feasibility Study for Examination the Use of Brain Prefrontal Activity Monitoring, for Early Detection of Migraine Attack||Brainmarc Ltd.|No|Recruiting|October 2015|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|50 Years|No|||October 2015|December 7, 2015|October 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02583581||10506|
NCT02512276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P001076|Tele-Pharmacy Intervention to Improve Treatment Adherence|The Study of a Tele-pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC 2 IT)|STIC 2 IT|Brigham and Women's Hospital|No|Recruiting|August 2015|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3000|||Both|18 Years|85 Years|No|||January 2016|January 6, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02512276||15980|
NCT02582242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-4200|Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin||Novo Nordisk A/S|No|Recruiting|October 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|426|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582242||10609|
NCT02586818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INR_CSP_015_0001_RD|Clinical Performance of InRhythm PT/INR System in a Professional Use Setting|Clinical Performance of the Investigational InRhythm PT/INR System in a Professional Use Setting||Accriva Diagnostics|No|Not yet recruiting|October 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|750|Samples With DNA|Whole blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects on stable Vitamin K Antagonist Therapy for equal to or greater than 3 months|October 2015|October 23, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586818||10257|
NCT02584140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001583|PrEP Adherence Enhancement Guided by iTAB and Drug Levels for Women|Multimodal Interventions to Improve Adherence to Oral Tenofovir/Emtricitabine as Pre-Exposure Prophylaxis in Women in Southern California|AEGiS|University of California, Los Angeles|No|Not yet recruiting|January 2016|January 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 23, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02584140||10463|
NCT02522975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSS_EP_001|Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)|A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO® With the Standard Treatment EPREX® in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis|BEAT_001|Shenyang Sunshine Pharmaceutical Co., LTD.|Yes|Not yet recruiting|August 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|75 Years|No|||August 2015|August 12, 2015|August 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02522975||15160|
NCT02523027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA11|Oral Nutritional Supplementation in Picky Eating Children|Oral Nutritional Supplementation in Picky Eating Children||Abbott Nutrition|No|Not yet recruiting|September 2015|February 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|321|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02523027||15156|
NCT02590588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34318|Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis|Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid||Boston Medical Center|Yes|Recruiting|January 2016|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 9, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590588||9968|
NCT02581098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0122|Effect of miR-200b on Diabetic Foot Ulcers|Novel Regulators of Wound Angiogenesis|miR-200b|Ohio State University|Yes|Recruiting|August 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Tissue|Both|18 Years|80 Years|No|Probability Sample|60 subjects with diabetic foot ulcers who have wound tissue oxygenation adequate to        support wound healing|October 2015|October 16, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02581098||10697|
NCT02513303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT-304|Safety and Efficacy of the Sirolimus-Eluting Collagen Implant to Assess AV Fistula Outcomes in Patients on Hemodialysis|A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant in Subjects on Hemodialysis|ACCESS|Vascular Therapies, Inc.|Yes|Recruiting|November 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|315|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 29, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02513303||15901|
NCT02513537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PODESAS|Postoperative Delirium - European Society of Anaesthesiology Survey|Postoperative Delirium - European Society of Anaesthesiology Survey||Charite University, Berlin, Germany|No|Recruiting|August 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Anaesthesists , nursing statt and students (Members of the European Society of        Anaesthesiology)|February 2016|February 15, 2016|March 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02513537||15883|
NCT02590393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059780|The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence|The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence|Ecig1|Duke University|Yes|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Anticipated|375|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590393||9983|
NCT02590796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelApp|Validating Studies to Assess the Diagnostic Accuracy of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium|MICA: Development of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium||University of Edinburgh|No|Recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||7|Anticipated|1110|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Royal Infirmary of Edinburgh (RIE) and Glasgow Royal Infirmary (GRI) general wards and        intensive care units.        Scottish Dementia Research Network Register and Psychology, Philosophy and Language        Science (PPLS) volunteer database.|October 2015|October 28, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02590796||9952|
NCT02580552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG106-11-101|Safety, Tolerability and Pharmacokinetic Study of MRG-106 in Patients With Cutaneous T Cell Lymphoma (CTCL), MF Subtype|A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type||miRagen Therapeutics, Inc.|No|Recruiting|November 2015|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02580552||10739|
NCT02580565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC14_0344|Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease|PHEDRE Trial Protocol - Observational Study of the Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and Analgesics in the French Sickle-cell Disease Population|PHEDRE|Nantes University Hospital|No|Not yet recruiting|November 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|2000|||Both|6 Years|25 Years|No|Non-Probability Sample|French sickle-cell disease population who has a problematic use of Equimolar Mixture of        Oxygen and Nitrous Oxide (EMONO) and analgesics|October 2015|October 16, 2015|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02580565||10738|
NCT02586285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2014-03-015|Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma|A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Curative Resection of Hepatocellular Carcinoma||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||May 2015|October 23, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02586285||10298|
NCT02590458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0243|Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer|Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer||M.D. Anderson Cancer Center|No|Recruiting|October 2015|||October 2020|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 27, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02590458||9978|
NCT02584374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54330|Balloon Test for Iliac Vein Compression|Balloon Test for Iliac Vein Compression||Maastricht University Medical Center|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers (all patients who have been diagnosed using this technique will be used        as a comparison group)|October 2015|January 21, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584374||10445|
NCT02584387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08-0008|360° - Video Virtual Reality Exposure Therapy Study|360° Video Virtual Reality Exposure Therapy (360°-VVRET) Study|360°-VVRET|University of Texas at Austin||Not yet recruiting|February 2016|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584387||10444|
NCT02513290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBixLo|Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine|Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine|QolRhinitis|Universidade do Sul de Santa Catarina|Yes|Completed|August 2013|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||July 2015|July 30, 2015|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02513290||15902|
NCT02580214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUMatogrossoSul|Immunonutrition in Total Hip Arthroplasty|A Protocol Of Perioperative Care Plus Immunonutrition Enhances Recovery After Total Hip Arthroplasty. A Randomized Pilot Study|Immunehip|Federal University of Mato Grosso do Sul|No|Completed|May 2013|November 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02580214||10765|
NCT02584270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00093723.1|Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue|Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue (PGSRT): a Randomized Clinical Trial|PGSRT|University of Michigan|No|Not yet recruiting|October 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02584270||10453|
NCT02578758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJAUMEI014|Efficacy of a Transdiagnostic Internet-based Protocol in Community Sample|The Differential Efficacy of a Specific Positive Psychology Components in a Transdiagnostic Internet-based Protocol for the Treatment of Emotional Disorders||Universitat Jaume I|Yes|Recruiting|September 2014|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|252|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02578758||10876|
NCT02592044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Venpuncture pain|Effect of Aromatherapy on Venopuncture Pain and Anxiety|Evaluation of the Effect of Aromatherapy With Lavender Essential Oil on Pain and Anxiety During Peripheral Venous Cannulation||Tokat Gaziosmanpasa University|Yes|Completed|November 2015|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|No|||March 2016|March 18, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02592044||9856|
NCT02592057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-1775|Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India|A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India||Gilead Sciences|No|Recruiting|November 2015|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Adults residing in India aged ≥ 18 years, who are infected with HCV, and for whom the        treating physicians in the participating clinics have prescribed a SOF-based regimen as        per the approved prescribing information.|March 2016|March 3, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592057||9855|
NCT02582541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-CN-1510|Endoscopic Biliary RFA of Malignant Bile Duct Obstruction|Endoscopic Biliary Radiofrequency Ablation of Malignant Bile Duct Obstruction||The Second Hospital of Nanjing Medical University|Yes|Recruiting|February 2014|November 2018|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02582541||10586|
NCT02591108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501M61361|Train of Four Motor Point Stimulation and Monitoring|Quantitative Assessment of Train of Four Device for Patients Receiving Neuromuscular Blockade||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|December 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|March 18, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591108||9928|
NCT02514057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150725|Gastrointestinal Symptom Questionnaire Validation|Gastrointestinal Symptom Questionnaire Validation||University of East Anglia|No|Not yet recruiting|August 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|As above|July 2015|July 31, 2015|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514057||15844|
NCT02593552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263758-14|Video Intervention to Enhance the Safety Of Cognitively Impaired Older Drivers|Video Intervention to Enhance the Safety Of Cognitively Impaired Older Drivers||Rhode Island Hospital|No|Completed|September 2011|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|68 Years|90 Years|No|||October 2015|October 29, 2015|October 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02593552||9740|
NCT02584595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CIP-10068|Evaluation of Inducible Monomorphic Ventricular Tachycardia (MMVT) in Patients With St. Jude Medical Implantable Cardioverter Defibrillator (ICD) Systems or Cardiac Resynchronization Therapy Defibrillation (CRT-D) Systems.|An Evaluation of Inducible Monomorphic Ventricular Tachycardia (MMVT) in Patients With St. Jude Medical Implantable Cardioverter Defibrillator (ICD) Systems or Cardiac Resynchronization Therapy Defibrillation (CRT-D) Systems.|EPIC|St. Jude Medical|No|Withdrawn|September 2015|February 2022|Anticipated|February 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|75 Years|No|Non-Probability Sample|The primary study population includes patients who meet all inclusion/exclusion criteria,        has had or will have market-approved St. Jude Medical ICD or CRT-D device systems        implanted, and has no history of MMVT.|October 2015|October 21, 2015|October 21, 2015|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT02584595||10428|
NCT02584881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UO1CE002516-01|Safe Opioid Prescription Practice for Patients Discharged From Trauma Services|Safe Opioid Prescription Practice for Patients Discharged From Trauma Services With a Prescription for Opioids|SOPP|Rhode Island Hospital|No|Not yet recruiting|December 2014|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2014|October 21, 2015|October 28, 2014||No||No||https://clinicaltrials.gov/show/NCT02584881||10406|
NCT02585661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.06.MET|Iron Bioavailability From Dairy Product|Iron Bioavailability From Fortified Dairy Product in Healthy Women||Nestlé|No|Completed|October 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|January 11, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02585661||10346|
NCT02518945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1969|Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes|Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes. A Randomized Clinical Trial||University at Buffalo|Yes|Recruiting|August 2015|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|July 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02518945||15470|
NCT02585050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADYU 2|Influences of DNAR Order Prohibition on Hospital Discharged Ratios and Neurological Outcomes at Discharge|Influences of DNAR Order Prohibition on Hospital Discharged Ratios and Neurological Outcomes at Discharge||Adiyaman University Research Hospital|Yes|Completed|January 2010|January 2015|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|266|||Both|19 Years|100 Years|No|Probability Sample|CPR call forms that were completed.|October 2015|October 22, 2015|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02585050||10393|
NCT02585063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT001|Independent Prescribing Optometrists in Acute Ophthalmic Services|Independent Prescribing Optometrists in Acute Ophthalmic Services||Aston University|No|Not yet recruiting|November 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be invited to take part in the study and given the study information either        while being triaged in the walk-in, nurse-led Emergency Eye Centre (EEC) to the        appointments-based Acute Referral Clinic (ARC) or at arrival at ARC. An approved poster        will advertise the study and will be place on the wall in both ARC and EEC. There will be        a smaller version on the reception desk at both ARC and EEC accompanied by a participant        information leaflet.|October 2015|October 22, 2015|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02585063||10392|
NCT02591043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-299|Surgical Treatment of Low Energy Pelvic Fractures in the Elderly|Surgical Treatment of Low Energy Pelvic Ring Fractures in the Elderly: Cross-sectional Single-centre Study From Basel, Switzerland|PelvicRetro|University Hospital, Basel, Switzerland|No|Recruiting|October 2015|July 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|55|||Both|65 Years|N/A|No|||October 2015|October 28, 2015|October 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02591043||9933|
NCT02591056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_VERJU+GP8_001|Study of the Combined Effect of Low Level Laser Therapy and Manual Lymph Drainage on Reducing Body Circumference|An Evaluation of the Combined Effect of the Erchonia® Verju™ Laser With the Green PRESS 8 Lymph Drainage System on the Reduction of Body Circumference||Erchonia Corporation|No|Not yet recruiting|November 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|October 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02591056||9932|
NCT02582892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVIDENCE x UNP VITAMIN D|Systemic Vitamin D Supplementation in Dental Implants Patients|Systemic Vitamin D Supplementation in Menopausal Women With Dental Implants|VitaminD|University Potiguar|Yes|Completed|October 2012|October 2015|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Female|3 Months|5 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582892||10559|
NCT02587520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC01|Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects|Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults||Sanofi|Yes|Active, not recruiting|October 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|1350|||Both|10 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02587520||10204|
NCT02583178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-CLIN-003|Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation|A Single-arm, Open Label, Multi-Centre Feasibility Study of the Aegis Sentinel Ligation System in Left Atrial Appendage Closure in Patients With Atrial Fibrillation|LASSO-AF|Aegis Medical Innovations|Yes|Not yet recruiting|March 2016|September 2021|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583178||10537|
NCT02586051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT29749|Single and Multiple-dose Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation|A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation||Hoffmann-La Roche||Recruiting|November 2015|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586051||10316|
NCT02593799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPEV-1|Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study|Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study||General Hospital of Shenyang Military Region|No|Not yet recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Patients with liver cirrhosis who will firstly undergo the upper gastrointestinal        endoscopy.|October 2015|October 30, 2015|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02593799||9721|
NCT02589509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1920-P|Cognitive Rehabilitation and Brain Activity of Attention Control in TBI|Cognitive Rehabilitation & Brain Activity of Attention-Control Impairment in TBI||VA Office of Research and Development|No|Recruiting|December 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|55 Years|No|||December 2015|December 9, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02589509||10051|
NCT02583399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-022|Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients|A Multi-Center, Open-Label Pharmacokinetic and Safety Study for Reduction in Fever or Management of Pain in Pediatric Subjects Aged Birth to Six Months||Cumberland Pharmaceuticals|No|Not yet recruiting|June 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|16 Years|No|||October 2015|October 20, 2015|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02583399||10520|
NCT02582268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU151020|A Novel IUD Insertion Technique|Introducing Trans- Abdominal Guided Intrauterine Device Insertion, a Single Blinded Randomized Control Trial||Woman's Health University Hospital, Egypt|Yes|Recruiting|October 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582268||10607|
NCT02582281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU161020|Non Touch Technique for IUD Insertion|The Non Touch Technique for Intrauterine Device Insertion, a Single Blinded Randomized Control Trial||Woman's Health University Hospital, Egypt|Yes|Recruiting|October 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02582281||10606|
NCT02586415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116661|Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3|Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3|DEFUSE 3|Stanford University|Yes|Not yet recruiting|January 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|476|||Both|18 Years|85 Years|No|||October 2015|October 22, 2015|October 21, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586415||10288|
NCT02586428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25878|Noninvasive Prenatal Testing|Decision-Making in Patients Regarding Noninvasive Prenatal Testing||St. Louis University|No|Recruiting|September 2015|May 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Female|14 Years|55 Years|No|Non-Probability Sample|Patients who have abnormal ultrasound findings, advance maternal age, abnormal serum        biochemical screening, or a personal or family history of chromosomal/genetic conditions        will be eligible for this study. These patients will be scheduled ahead of time with the        genetic counseling.|September 2015|October 22, 2015|September 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02586428||10287|
NCT02593396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AY001|Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Of Bupropion Hydrochloride Sustained-Release In The Treatment Of Sexual Dysfunction In Men On Methadone Maintenance Therapy||University of Malaya|Yes|Recruiting|August 2015|August 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|65 Years|No|||October 2015|October 29, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02593396||9752|
NCT02583711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM2689|The Step Home Trial: Utilising Physical Activity Data in the Acute Post-operative Setting|The Step Home Trial: Utilising Physical Activity Data in the Acute Post-operative Setting||Imperial College London|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients due for elective surgical procedures will be recruited from outpatient general        surgical clinic|September 2015|October 27, 2015|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02583711||10496|
NCT02590757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1917|Comparison of NIV-NAVA vs. N-CPAP After Extubation in Preterm Infants Study|Comparison of Non-invasive Ventilation Neurally Adjusted Ventilatory Assist vs. Nasal Continuous Positive Airway Pressure After Extubation in Infants' < 30 Weeks of Gestation: Randomized Controlled Study||Seoul National University Hospital|Yes|Recruiting|August 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|N/A|6 Weeks|No|||October 2015|October 27, 2015|October 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02590757||9955|
NCT02590770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAUSAD|Gaze Contingent Feedback in Social Anxiety Disorder|Gaze Contingent Feedback in Treatment of SAD||Tel Aviv University|No|Enrolling by invitation|October 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||October 2015|October 28, 2015|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02590770||9954|
NCT02591719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1507-308-006/P2|Effects of rTMS Based on Hemodynamic Activity for Language Recovery in Early Poststroke Aphasia|Effects of Repetitive Transcranial Magnetic Stimulation Based on Hemodynamic Activity for Language Recovery in Early Poststroke Aphasia: Randomized Controlled Trial||Seoul National University Bundang Hospital|No|Recruiting|November 2015|December 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|80 Years|No|||February 2016|February 15, 2016|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02591719||9881|
NCT02581345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911401|Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis|A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis||Baxalta US Inc.|No|Recruiting|September 2015|May 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|516|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581345||10678|
NCT02581865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1505|Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects With Tourette Syndrome||Neurocrine Biosciences||Recruiting|October 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|64 Years|No|||March 2016|March 10, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02581865||10638|
NCT02581878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17845|Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma|An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma||Bayer|Yes|Recruiting|December 2015|September 2019|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02581878||10637|
NCT02587728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140503|Carpal Tunnel/Amyloidosis Blood Sample Study|Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis||University of Miami|No|Recruiting|October 2015|||November 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Genome DNA extracted peripheral blood mononuclear cells (PBMCs)|Both|18 Years|N/A|No|Non-Probability Sample|Patients within 24 months of confirmed diagnosis of Carpal Tunnel Syndrome|November 2015|November 2, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587728||10188|
NCT02578511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO|Study of Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)|Phase I Study of Standard Maintenance [POMP/D (Methotrexate, 6 - Mercaptopurine, Vincristine, Prednisone/Dexamethasone)] Plus Ixazomib Maintenance Therapy in Adults With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)||Medical College of Wisconsin|Yes|Not yet recruiting|December 2015|January 2021|Anticipated|January 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02578511||10895|
NCT02582840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1695C00001sub|The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM|A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control||AstraZeneca|No|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|42|||Both|18 Years|65 Years|No|||January 2016|March 7, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582840||10563|
NCT02593565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRC 5532|Vasculitis Pregnancy Registry|The Vasculitis Pregnancy Registry (V-PREG)|V-PREG|University of Pennsylvania|No|Recruiting|November 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|50 Years|No|Non-Probability Sample|Women with vasculitis who are currently pregnant.|January 2016|January 14, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02593565|12 Months|9739|
NCT02588001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1506|Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide|Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide|JCASTRE-Zero|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Recruiting|October 2015|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|20 Years|N/A|No|||October 2015|October 26, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02588001||10167|
NCT02578784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 15/086|DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis|Prospective, Randomized Trial on the Clinical Utility of Drug-coated Balloons After Angioplasty of Plain Old Balloon-resistent Dialysis Fistula Stenosis Using Cutting Ballons|DEB-after-CB|Cantonal Hospital of St. Gallen|No|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02578784||10874|
NCT02582177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-CND-03(05/15)|Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis|Phase 3 Study, Randomized, Open, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.|DaVinci|Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|July 2017|January 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|2 Years|65 Years|No|||March 2016|March 7, 2016|October 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02582177||10614|
NCT02582424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT-0101|Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.|Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study||Primus Pharmaceuticals|No|Completed|July 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|85 Years|No|||October 2015|January 25, 2016|October 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582424||10595|
NCT02587858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10832|NBIAready: Online Collection of Natural History Patient-reported Outcome Measures|NBIAready: Online Collection of Natural History Patient-reported Outcome Measures||Oregon Health and Science University|No|Recruiting|April 2015|April 2025|Anticipated|April 2025|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|The PKAN group consists of international individuals diagnosed with PKAN.|October 2015|October 23, 2015|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02587858||10178|
NCT02587949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0065-15-BNZ|The Correlation Between Hair Cortisol Level of Acute Stroke or Its Long Term Disability.|The Correlation Between Hair Cortisol Level of Acute Stroke or Its Long Term Disability.||Bnai Zion Medical Center|No|Not yet recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|||Both|40 Years|70 Years|No|Probability Sample|1. Patients aged 40-70.          2. Acute cerebrovascular stroke (symptoms that began no more than 72 hours before)          3. Rankin 0-1 before the event|August 2015|October 26, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02587949||10171|
NCT02579720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC Grass Booster 01 2014|Revaccination With Pollinex® Quattro|Non-interventional Study A Multicentre Observational Study for Revaccination With Pollinex® Quattro in Patients With a Recurrent Grass Pollen Allergy||University Hospital of Cologne|Yes|Completed|March 2015|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|108|||Both|12 Years|N/A|No|Probability Sample|Adults and children from the age of 12 years on, who are diagnosed with recurrent seasonal        allergic rhinitis (SAR) caused by grass pollen.|October 2015|October 19, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579720||10803|
NCT02579733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-151016|Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis||ACE|Keimyung University Dongsan Medical Center||Not yet recruiting|November 2015|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02579733||10802|
NCT02579265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOF-018-CP3|Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants|A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition||Fresenius Kabi|Yes|Recruiting|December 2015|December 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|400|||Both|N/A|N/A|No|||March 2016|March 3, 2016|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579265||10837|
NCT02588508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0335932|Effectiveness of Warm Packs, Perineal Massage and Hands Off During Labour in the Perineal Outcomes.|Effectiveness of Warm Packs, Perineal Massage and Hands Off During Labour in the Perineal Outcomes.||Universidade Federal de Pernambuco|No|Recruiting|April 2015|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|201|||Female|N/A|N/A|No|||November 2015|November 18, 2015|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02588508||10128|
NCT02588521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-794-801|A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study|A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects||Alios Biopharma Inc.|No|Recruiting|August 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02588521||10127|
NCT02580760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15FBT-TSBS|Transgender, Silicone and Blood Smear|Circulating Silicone After Cosmetic Silicone Injection in Transgender Patients|TSBS|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|66|||Male|18 Years|N/A|No|Non-Probability Sample|Every transgender men transitioning into women patients with cosmetic silicone injection        and consulting in Bichat hospital.|September 2015|January 22, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02580760||10723|
NCT02587195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-PP-06|A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period|A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period|TERICIS|Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|55 Years|No|||September 2015|October 23, 2015|September 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02587195||10228|
NCT02587208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E14-1270|Plastibell Versus Conventional Dissection Techniques for Circumcision in Infants and Children|Plastibell Versus Conventional Dissection Techniques for Circumcision in Infants||King Saud University|Yes|Recruiting|January 2015|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|3 Months|12 Years|No|||October 2015|October 24, 2015|August 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02587208||10227|
NCT02522871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-LVR-092014|TransMedics (OCS) Liver Trial: Preserving and Assessing Donor Livers for Transplantation|International Randomized Trial to Evaluate The Effectiveness of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation (OCS Liver PROTECT Trial)|Liver PROTECT|TransMedics|Yes|Recruiting|January 2016|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|August 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522871||15168|
NCT02522884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA 0119|Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries|Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™|TOBA II|Intact Vascular|Yes|Recruiting|September 2015|October 2019|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02522884||15167|
NCT02581982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 88215|Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer|Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|March 2016|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 13, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581982||10629|
NCT02581995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17850|Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.|Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment|AQUA|Bayer|No|Recruiting|November 2015|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|520|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02581995||10628|
NCT02592278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2015|Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars|Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars||Universidad Iberoamericana|No|Active, not recruiting|March 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|180|||Both|6 Years|7 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|October 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02592278||9838|
NCT02580994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1417-LCG|Pembrolizumab in Untreated Extensive SCLC|REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab (MK-3475) in Untreated Extensive Small Cell Lung Cancer|REACTION|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Not yet recruiting|March 2016|September 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02580994||10705|
NCT02583594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU14260|A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis|A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis|SCALA|Sanofi|No|Recruiting|December 2015|November 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02583594||10505|
NCT02587494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106834|Cardiac Catheterization in Cardiac Arrest|Role of Early Cardiac Catheterization in Cardiac Arrest||Lawson Health Research Institute|No|Not yet recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|August 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02587494||10206|
NCT02516904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD101.IV.1.01|A Single Ascending Dose Study of CD101 IV in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects||Cidara Therapeutics Inc.|No|Completed|July 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|July 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02516904||15627|
NCT02517138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-094|Right-front Direction in Parabolic Flight||DROITDEVANT|University Hospital, Caen|No|Completed|November 2011|January 2014|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02517138||15609|
NCT02579174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00200223|Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation|Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation||Northwestern University|No|Recruiting|January 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02579174||10844|
NCT02594566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM20004886|Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine|A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Prophylactic Cytomegalovirus Plasmid DNA Vaccine in Healthy Adults|CM04-101|Virginia Commonwealth University|No|Not yet recruiting|November 2015|February 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594566||9662|
NCT02594579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075802|Effect of Vitamin D3 Supplementation on Muscle Mass in ICU Patient|Effect of High Dose Vitamin D3 Supplementation on Skeletal Muscle Mass and Body Compositions in Critically Ill Patients With Vitamin D Deficiency||Mahidol University|Yes|Not yet recruiting|October 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|October 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02594579||9661|
NCT02589756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015FO7650|Fish or Nuts? Dietary Effects on Cardiometabolic Risk Factors and Persistent Organic Pollutants|Fish or Nuts? Dietary Effects on Cardiometabolic Risk Factors and Persistent Organic Pollutants||Oslo University Hospital|Yes|Active, not recruiting|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|40 Years|65 Years|No|||September 2015|October 29, 2015|September 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02589756||10032|
NCT02513082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nerve block|Effectiveness of Pain Relief Between Adductor Canal Block and Femoral Nerve Block in Total Knee Arthroplasty|Effectiveness of Pain Relief Between Adductor Canal Block and Femoral Nerve Block in Total Knee Arthroplasty in General Anesthesia||The Catholic University of Korea|No|Not yet recruiting|August 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||November 2015|November 3, 2015|July 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02513082||15918|
NCT02579694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14013|Short Term Evaluation of SLIC Screw in Treatment of Scapholunate Injury|Multicenter Retrospective-prospective Short-term Evaluation of the SLIC Screw System in Subjects Requiring Treatment for Acute Scapholunate Injury||Acumed, LLC|No|Enrolling by invitation|September 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|All patients from selected sites with acute scapholunate injury fulfilling inclusion and        exclusion criteria|October 2015|October 16, 2015|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02579694||10805|
NCT02579707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG120-C-004|Food Effect Study of AG120 in Healthy Subjects|A Phase 1, Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of Food On AG-120 Pharmacokinetics Following Single Oral Dose Administration To Healthy Subjects||Agios Pharmaceuticals, Inc.|No|Active, not recruiting|October 2015|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|October 15, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02579707||10804|
NCT02579980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO9603|Quantitative Imaging Biomarkers for Sarcoma|Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients||Columbia University|Yes|Recruiting|October 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 15, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02579980||10783|
NCT02579993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-051-2014|ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation|ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation Expanded in Vitro on Amniotic Membrane in Patients With Limbal Stem Cell Deficiency.||Instituto de Oftalmología Fundación Conde de Valenciana|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|N/A|No|||October 2015|October 17, 2015|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02579993||10782|
NCT02580006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3285_SC_I|To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers||Dong-A ST Co., Ltd.|Yes|Not yet recruiting|November 2015|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|October 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02580006||10781|
NCT02679053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 62/13|Aerobic Exercise as add-on Treatment for Inpatients With Depression|Aerobic Exercise as add-on Treatment for Inpatients With Depression: Effects and Biomarkers||University Hospital, Basel, Switzerland|No|Recruiting|October 2013|November 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2016|February 24, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02679053||3179|
NCT02692352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2/0204|Cognitive Rehabilitation of Executive Dysfunction - Goal Management Training in Patients With Acquired Brain Injury|Cognitive Rehabilitation of Executive Dysfunction - Goal Management Training in Patients With Acquired Brain Injury||Sunnaas Rehabilitation Hospital|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|67 Years|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692352||2159|
NCT02703766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007623|Weight Gain and Adipose Tissue|Pilot Study to Examine the Effects of Weight Gain on Adipose Tissue||Mayo Clinic|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02703766||1283|
NCT02680054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114185|Fat and Protein Study|Investigation of Appropriate Timing of Additional Insulin Dosing for Fat and Protein in Children With Type 1 Diabetes Using Multiple Daily Injections||Oxford University Hospitals NHS Trust|No|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|6 Years|18 Years|No|||February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680054||3103|
NCT02684422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0636|Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)|TRI-STAR: Initial and Chronic MRSA Infection in CF (TRanslational Investigation of STaph. Aureus Resistance)|TRI-STAR|University of North Carolina, Chapel Hill|No|Recruiting|July 2015|December 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|-  Sputum        -  Blood|Both|4 Years|99 Years|No|Non-Probability Sample|Patients with a confirmed diagnosis of cystic fibrosis (CF), chronic MRSA who have a        pulmonary exacerbation requiring IV therapy.|February 2016|February 12, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02684422||2767|
NCT02692430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVIMIAGE-129|The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP).|LARGE SPONTANEOUS PORTOSYSTEMIC SHUNTS (SPSSs) IN PATIENTS WITH LIVER CIRRHOSIS. CLINICAL AND RADIOLOGICAL CHARACTERISTICS.||Hospital Universitari Vall d'Hebron Research Institute|No|Not yet recruiting|April 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Cirrhotic patients submitted to a angio-CT or MRI in several centres of international        relevancy in the management of this condition.|February 2016|February 22, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02692430||2153|
NCT02694978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-IDA-304|A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)|A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)|FIRM|AMAG Pharmaceuticals, Inc.|No|Recruiting|February 2016|November 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694978||1957|
NCT02523196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0520|Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)|Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)||University of Colorado, Denver|No|Not yet recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|August 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02523196||15143|
NCT02583737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEE 30738714.0.0000.0075.|Comparative Study Between Lyophilized or Frozen Bone Allografts for Sinus-lifting|Histological and Microtomographic Comparative Study Between Lyophilized or Frozen Bone Allografts for Sinus-lifting: A Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02583737||10494|
NCT02694744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-401|Patiromer With or Without Food for the Treatment of Hyperkalemia|The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)|TOURMALINE|Relypsa, Inc.|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694744||1975|
NCT02694757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH2015-P-000873|Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications|Pilot Study to Evaluate the Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications in Patients With New Ileostomies||Massachusetts General Hospital|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694757||1974|
NCT02685787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2009-1607340|Early Counseling and Support for Alzheimer's Disease Caregivers|Can Early Counseling and Support for Alzheimer's Disease Caregivers Improve Burden? A Multi-centre Active Randomized Clinical Trial in Local Health Services|D_CareGiver|Azienda Sanitaria Locale N.1 dell'Umbria|Yes|Recruiting|April 2012|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|100 Years|No|||February 2016|February 18, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02685787||2662|
NCT02686034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-16|Non-Invasive Vagus Nerve Stimulation (nVNS) With the gammaCore Device for the Acute Treatment of Migraine Attacks|A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of the gammaCore®-S Non-invasive Vagus Nerve Stimulation Device (nVNS), for the Acute Treatment of Migraine||ElectroCore LLC|No|Recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686034||2643|
NCT02693613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0204|Pharmacokinetic Study of ASP1517 With Kremezin®|Pharmacokinetic Study of ASP1517 − Evaluation of the Effect of Kremezin® on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects, When Administered Concomitantly or in a Time Separated Manner.||Astellas Pharma Inc|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02693613||2062|
NCT02693626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015S007|Happy Quit for Smoking Cessation in China|The Efficacy of Mobile Phone-based Text Message Interventions ('Happy Quit') for Smoking Cessation in China|HQ|Central South University|No|Not yet recruiting|April 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02693626||2061|
NCT02693639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHLTQC-1|Prediction Value of PANX1 in Infection Post Liver Transplantation|||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||Not yet recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients underwent liver transplantation.|February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693639||2060|
NCT02695875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB-2014|Comparative Study About the Effect of Aquatic Therapy vs Land-based Therapy in Women With Fibromyalgia|Comparative Study About the Effect of a Physical Therapy Protocol in Warm Water vs Land-based Therapy in Women With Fibromyalgia Syndrome||Universidade da Coruña|Yes|Not yet recruiting|October 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Female|35 Years|64 Years|No|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695875||1890|
NCT02700360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC18-102|Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers|A Randomized, Open-Label, Single -Dose, Crossover, Phase I Clinical Trial to Evaluate the Effect of Food on the Safety, Tolerability and Pharmacokinetics of EC-18 After Oral Administration in Healthy Volunteers||Enzychem Lifesciences Corporation|No|Completed|August 2015|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|36|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|January 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700360||1545|
NCT02687295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gubbar-2010|Improvement of Metabolic Health After Thylakoid Supplementation|Metabolic Risk Markers and Body Weight Are Decreased by Green-plant Supplementation in a Pilot Study With Overweight-to-obese Middle-aged Men.||Region Skane|No|Completed|January 2010|January 2016|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02687295||2546|
NCT02679118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-35295|Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery|Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery||Stanford University|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679118||3174|
NCT02681796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201506125|Epidural Analgesia Use in Pancreatic Resections|Epidural Analgesia Use in Pancreatic Resections|E-PRO I|Washington University School of Medicine|No|Recruiting|December 2015|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681796||2969|
NCT02686918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-01|Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse|Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse - TIPA|TIPA|Institut de Cancérologie de la Loire|No|Not yet recruiting|February 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02686918||2575|
NCT02705612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJFL-2016-02-LACC-Nimotuzumab|Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer|Efficacy and Safety of Radiotherapy Concurrently Combined With Cisplatin and Nimotuzumab for Patients With Locally Advanced Cervical Cancer||Fourth Military Medical University|Yes|Recruiting|September 2015|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02705612||1141|
NCT02685176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2015:101|Head and Torso Rewarming Using a Human Model for Severe Hypothermia|Efficacy of Head and Torso Rewarming by Using a Human Model for Severe Hypothermia||University of Manitoba|No|Not yet recruiting|April 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02685176||2709|
NCT02685189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-06LT-2|Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)|LONG-TERM CLINICAL FOLLOW-UP OF CHILDREN ENROLLED IN STANNSOPORFIN CLINICAL TRIAL PROTOCOL NO. 64,185-06-2(W)(||InfaCare Pharmaceuticals Corporation|No|Active, not recruiting|July 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|55|||Both|N/A|60 Days|No|Non-Probability Sample|All children who have been enrolled and received Stanate® Injection/Placebo in Study        Protocol 64,185-06-2(W)(WS)(ISNHP) are eligible for this follow-up.|February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02685189||2708|
NCT02682017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/11/0080|Effect of Consuming Pork From Seaweed Extract Fed Animals on Antioxidant Status|Effect of Consuming Pork From Animals Supplemented With Laminarin and Fucoidan Derived From the Brown Seaweed Laminaria Digitata on the Antioxidant Status of Human Participants.||University of Ulster|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682017||2952|
NCT02695108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 14/498|Scapular Stabilization Exercise on Neck Pain|Scapular Stabilization Exercise on Mechnical Neck Pain: A Randomized Control||Hacettepe University|No|Completed|December 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|No|||February 2016|February 24, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02695108||1948|
NCT02702284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500776|Advance Directives Completion Rates and an Intervention to Address Health Literacy in a Clinic Population|Advance Directives Completion Rates and an Intervention to Address Health Literacy in a Clinic Population||University of Florida|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|480|||Both|51 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02702284||1397|
NCT02702557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-42|Unsupervised Elastic Band Exercises Performed by Frail Elderly Hospitalized Patients Monitored by the Bandcizer|Feasibility Study of Unsupervised Elastic Band Exercises Performed by Frail Elderly Hospitalized Patients Monitored by the Bandcizer as a Supplement to Usual Supervised Physiotherapy Sessions||Aalborg Universitetshospital|No|Recruiting|February 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|65 Years|N/A|No|||March 2016|March 3, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02702557||1376|
NCT02687633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000699|Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex|Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex||University of California, Los Angeles|No|Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|12 Months|36 Months|No|||February 2016|February 19, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02687633||2520|
NCT02687646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-EICH-2014|Clinical Trial With MSC for Graft Versus Host Disease Treatment|Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Not yet recruiting|May 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||February 2016|March 4, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02687646||2519|
NCT02689531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00068313|CTTI Risk Factors for HABP/VABP Study|Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)||Duke University|No|Recruiting|February 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6850|||Both|18 Years|N/A|No|Non-Probability Sample|All ICU patients at participating sites hospitalized for >48 hours or admitted <7 days        after discharge from an inpatient acute or chronic care facility|January 2016|March 7, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02689531||2374|
NCT02689544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.132.671|Effects of Static Stretching and Dynamic in Flexibility and Performance: Blind and Randomized Clinical Trial|Acute and Chronic Effects of Static and Dynamic Stretching on Flexibility and Neuromuscular and Functional Performance in Healthy Subjects: a Blinded and Randomized Clinical Trial||Universidade Federal do Rio Grande do Norte|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|45|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689544||2373|
NCT02684760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7981003|Bioavailability Study Of PF-06651600 In Healthy Subjects|A Phase 1, Open Label, Single-dose 3-way Crossover Study To Evaluate The Relative Bioavailability Of A Solid Dose Formulation Of PF-06651600 Under Fasting Conditions And The Effect Of A High Fat Meal On The Bioavailability Of The Solid Dosage Formulation Of PF-06651600 In Healthy Subjects||Pfizer|No|Not yet recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02684760||2741|
NCT02684773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-14-0005856|In-Centre Nocturnal Hemodialysis (INHD): A Long-Term Follow-Up Study|Impact Of In-Centre Nocturnal Hemodialysis On Cardiac Remodeling In End-Stage Renal Disease: A Long-Term Follow-Up Study|INHD|St. Michael's Hospital, Toronto|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|67|Samples Without DNA|Serum and Plasma sample collection|Both|18 Years|N/A|No|Non-Probability Sample|The patients who converted to in-centre nocturnal hemodialysis and their matched controls        will be drawn from a population of prevalent chronic hemodialysis patients.|February 2016|February 17, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02684773||2740|
NCT02702830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01915A|MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment|Understanding Exercise Intolerance After Treatment for Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|32|||Female|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult women with breast cancer or age-matched control|March 2016|March 3, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02702830||1355|
NCT02680574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0015|Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)||Akebia Therapeutics|Yes|Recruiting|February 2016|November 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680574||3063|
NCT02680925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1511-124-725|Lung Protective Ventilation During Pulmonary Lobectomy in Children|The Influence of Lung Protective Ventilation During Pulmonary Lobectomy on Clinical Outcome in Pediatric Patients||Seoul National University Hospital|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|114|||Both|N/A|5 Years|No|||February 2016|February 9, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02680925||3036|
NCT02685826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDI4736-MM-002|A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma|A Phase 1b Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) (DUR) in Combination With Lenalidomide (LEN) With and Without Low-dose Dexamethasone (Dex) in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)||Celgene|No|Not yet recruiting|April 2016|August 2024|Anticipated|April 2022|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685826||2659|
NCT02685839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-003B|Development of an Intelligent POWER Rehabilitation Cluster Machine and Its Clinical Testing and Assessment|||Taipei Veterans General Hospital, Taiwan|No|Enrolling by invitation|June 2015|July 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|85 Years|No|||June 2015|February 15, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02685839||2658|
NCT02686060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01307-42|In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm|In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm|FRISBEE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|March 2016|October 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|24 Weeks|32 Weeks|No|||January 2016|February 15, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686060||2641|
NCT02679911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR105082|Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer|Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer|LOOP|Galderma|No|Recruiting|September 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02679911||3114|
NCT02697708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511016780|Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.|The Effect of Potatoes on Potassium Retention, Acid Base Balance, and Blood Pressure||Purdue University|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|40|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697708||1749|
NCT02688491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2016]015|A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment|A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay||First Affiliated Hospital, Sun Yat-Sen University|No|Not yet recruiting|July 2016|July 2026|Anticipated|July 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688491||2454|
NCT02692001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000048168|Child Friendly Menu Labelling and Food Choices|A Randomized Controlled Trial to Evaluate the Impact of Child Friendly Menu Labelling Designs on Food Choices by Parents and Children in an Inpatient Hospital Setting|MealTrain|The Hospital for Sick Children|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|163|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02692001||2186|
NCT02692014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20160126|Risk Factors Promoting Coronary Plaque Progression In China|A Multicenter Retrospective Observational Study on Different Risk Factors in Coronary Artery Stenosis Progression of CHD in China|RIPPER|Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|2400|||Both|18 Years|N/A|No|Non-Probability Sample|It will take 12 months to collect data of 2,400 cases in 20 CHD intervention centers of        China and following 9 months to compete QCA and risk factors analysis.|February 2016|February 24, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02692014||2185|
NCT02694133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS-CT11-06|Efficacy of Telerehabilitation in the Patients With Aphasia|Efficacy of Telerehabilitation in the Patients With Aphasia||Kaohsiung Veterans General Hospital.|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT02694133||2022|
NCT02694146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX1985|Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis|Clinical Trial Randomized, Double-blind Controlled, Phase III, to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis|COX|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|30 Years|N/A|No|||February 2016|February 23, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02694146||2021|
NCT02710812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3554/AO/15|Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer|Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer|ReSARCh|University of Padova|No|Recruiting|January 2016|August 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|164|||Both|18 Years|N/A|No|Non-Probability Sample|All patients underwent neoadjuvant therapy for rectal cancer and have a major or complete        clinical response.        Definitions:        Major clinical response (mCR) is defined as the absence of:        • palpable mass at digital rectal exploration, pathological lymph nodes (> 5 mm in        diameter along short axis) to pelvic MRI, deep or shallow ulcers > 2 cm in diameter at        rectoscopy;        Clinical complete response (cCR) is defined as the absence of:        • palpable mass at digital rectal exploration, pathological lymph nodes (> 5 mm in        diameter along the short axis) to the pelvic MRI, any endoscopic lesion (a flat scar is        considered as absence of endoscopic lesions).|March 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710812||742|
NCT02693223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Get With the Guidelines-Stroke Registry|Get With the Guidelines-Stroke Registry|GWTG-Stroke|American Heart Association|Yes|Recruiting|January 2003|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|3892063|||Both|18 Years|125 Years|Accepts Healthy Volunteers|Probability Sample|Patients with a diagnosis of Ischemic stroke or transient ischemic attack, Subarachnoid        hemorrhage, Intracerebral hemorrhage, or Stroke not otherwise specified.|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693223|30 Days|2092|
NCT02692443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL128818|SVR III: Brain Connectome and Neurodevelopmental Outcomes|Single Ventricle Reconstruction III: Brain Connectome and Neurodevelopmental Outcomes|SVRIII|University of Pittsburgh|Yes|Enrolling by invitation|August 2015|April 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|10 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|SVR Survivor - male and female - 10 to 12 years of age|February 2016|February 22, 2016|September 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02692443||2152|
NCT02707003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPO0526|Clinical Utility of Capnography in the PACU|A Multi-Center Pilot Observational Trial to Quantify the Potential Clinical Utility of Capnography in the PACU||Medtronic - MITG|No|Recruiting|February 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Adults booked for a surgical procedure that meet the I/E criteria and willing to provide        consent for observation in the PACU and chart review 24 hours post PACU discharge.|March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02707003||1035|
NCT02683473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-061|Measurement of Energy Metabolism in Infants|Measurement of Energy Metabolism in Infants: BabyEE Pilot|BabyEE|Pennington Biomedical Research Center|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|1 Month|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Full-term infants aged 1 to 3 months who are exclusively fed breast milk and/or infant        formula will be recruited|March 2016|March 23, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02683473||2840|
NCT02691455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-1053|The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)|The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study|ASSISTS|The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|February 2016|January 2023|Anticipated|January 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|40 Years|85 Years|No|||February 2016|February 21, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691455||2228|
NCT02679625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #14H-136004|Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients|Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients|FRESEDICU|Olive View-UCLA Education & Research Institute|No|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|The investigators will recruit adult patients in the ED and ICU who are septic, have        received an initial bolus of 20-30 cc/kg of IV fluid, and there is still a question by the        clinical team of whether they are still fluid responsive.|February 2016|February 5, 2016|November 26, 2014||No||No||https://clinicaltrials.gov/show/NCT02679625||3136|
NCT02679638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-15|Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients|Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients. Multi-center Cross-sectional Study in Israel Among Breast Cancer Survivors, With a Preliminary Qualitative Study||University of Haifa|Yes|Not yet recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Anticipated|450|||Female|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hebrew speaking Jewish women aged 30 - 75 years, diagnosed with breast cancer up to 5        years prior to study recruitment, which have successfully completed all chemotherapy and        radiotherapy treatments and are considered disease free.|February 2016|February 9, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679638||3135|
NCT02697669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101037_F|The Role of Nuclear Imaging in Heart Failure|The Role of Nuclear Imaging in Heart Failure: Correlation With Cardiac Function and Metabolism, Biomarkers and Clinical Prognosis||Far Eastern Memorial Hospital|No|Recruiting|August 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Probability Sample|Had a clinical diagnosis of heart failure and left ventricular systolic function        (LVEF≤50%) or diastolic dysfunction who, or (2) Clinical diagnosis of metabolic diseases        (such as metabolic syndrome, obesity, diabetes, hyperlipidemia, micro vascular diseases        etc.), heart failure and high-risk groups.|March 2016|March 3, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697669||1752|
NCT02688374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204979|A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers.|A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers||GlaxoSmithKline||Not yet recruiting|February 2016|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|45|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688374||2463|
NCT02688387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201964|A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects|A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects||GlaxoSmithKline|No|Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688387||2462|
NCT02693366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:01498412.5.0000.5257|Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis|Safety Study of the Endovascular Infusion of Bone Marrow Derived Mononuclear Cells in Patients With Focal Segmental Glomerulosclerosis|STEFOG|Universidade Federal do Rio de Janeiro|Yes|Recruiting|June 2015|June 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02693366||2081|
NCT02693379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-071|Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine|Cervical Cancer Screening in Madagascar: Usability of Mobile Telemedicine for Detection of Precancerous Lesions From Smartphone Photos||University Hospital, Geneva|No|Completed|February 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1041|||Female|30 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|July 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02693379||2080|
NCT02683603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tunis university|Effect of Aerosolised Colistin in Ventilator Associated Pneumonia|Efficacy and Toxicity of Aerosolised Colistin in Ventilator Associated Pneumonia: A Prospective, Randomized Trial||Tunis University|Yes|Completed|April 2013|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683603||2830|
NCT02681068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicroTrans|MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation|MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation|MicroTrans|University of Cologne|Yes|Recruiting|January 2015|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with recurrent Clostridium difficile infection|February 2016|February 9, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02681068||3025|
NCT02702245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thylakoid OGTT|Effects of Two Doses of Thylakoids on OGTT|Thylakoids' Effect on Glucose Homeostasis and Appetite Regulation After an Oral Glucose Tolerance Test in Healthy Volunteers||Region Skane|No|Active, not recruiting|January 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02702245||1400|
NCT02684019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBRI project (code number111A)|Goal Directed Propofol Sedation With Magnesium Sulphate Versus Dexmedetomidine for ERCP Procedure|Goal Directed Propofol Sedation With Magnesium Sulphate Versus Dexmedetomidine for ERCP Procedure||Theodor Bilharz Research Institute|No|Recruiting|January 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|4||Anticipated|60|||Both|20 Years|55 Years|No|||February 2016|February 10, 2016|February 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684019||2798|
NCT02684032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151009|A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer|Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (MBC)||Pfizer|No|Not yet recruiting|May 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|121|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684032||2797|
NCT02693015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Time to coronary angiography|Impact of Time to Coronary Angiography on Survival for NSTEMI|Impact of Time to Coronary Angiography on Survival for NSTEMI: an Observation Study Using a Nationwide Registry||University of Leeds|No|Completed|April 2004|March 2013|Actual|March 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|235986|||Both|18 Years|100 Years|No|Non-Probability Sample|The study population comprises 725,860 patients hospitalised for acute myocardial        infarction and entered into the Myocardial Ischaemia National Audit Project (MINAP)        database between April 2004 and March 2013.|February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693015|1 Year|2108|
NCT02693041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr. 929-11|Pregnancy Complications - A Probiotic Interventional Study|Pregnancy Complications - A Probiotic Interventional Study||Sahlgrenska University Hospital, Sweden|No|Recruiting|June 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693041||2106|
NCT02693054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALOCIP001|Safety and Efficacy Study for Various Skin Conditions|Characterizing Safety and Efficacy of Halo Hybrid Fractional Laser Treatments for Various Skin Conditions||Sciton|No|Not yet recruiting|March 2016|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02693054||2105|
NCT02703051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1271-103|A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects|A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects||GlycoMimetics Incorporated|No|Active, not recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|42|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703051||1338|
NCT02694874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSI_v03_22072015|Rosiglitazone Adjunctive Therapy for Severe Malaria in Children|Rosiglitazone Adjunctive Therapy for Severe Malaria in Children|ROSI|Centro de Investigacao em Saude de Manhica|No|Not yet recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|12 Months|12 Years|No|||February 2016|February 24, 2016|December 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02694874||1965|
NCT02694887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE- 2015.624|Capillary and Venous Lactate in Emergency Department Patients|Agreement Between Capillary and Venous Lactate in Emergency Department Patients||Chinese University of Hong Kong|No|Recruiting|March 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 or above who are triage category 3 presenting to Emergency Department|March 2016|March 10, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02694887||1964|
NCT02681510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 2015-1376|UW-CTRI Smoking Cessation Study|UW-CTRI Smoking Cessation Medication Tolerability Study||University of Wisconsin, Madison|Yes|Not yet recruiting|February 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681510||2991|
NCT02679898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC201311173|Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals|The Effect of the Combination of Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals||Florida State University|No|Completed|September 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|60|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679898||3115|
NCT02709980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00062258|Cognitive Behavior Therapy for Insomnia (CBT-I) in Persons With Traumatic Brain Injury (TBI)|Cognitive Behavior Therapy for Insomnia (CBT-I) in Persons With Traumatic Brain Injury (TBI)||Johns Hopkins University|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02709980||806|
NCT02709993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiroVAX001|Consolidation Therapy in Patients With Hematologic Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte- Macrophage Colony Stimulating Factor, As Consolidation Treatment in Patients With Hematologic Malignancies||Kiromic, LLC||Not yet recruiting|May 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709993||805|
NCT02710006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/KBL/OIL/2016|Automatic Volume Calculations During Three-dimensional Sonohysterography.|Feasibility and Reliability of Assessing Uterine Cavity Volume by SonoAVC in Women With Reproductive Failure.||Ludwin & Ludwin Gynecology, Private Medical Center|Yes|Recruiting|February 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02710006||804|
NCT02689869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-005164-15|Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma|A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden|Alternative|Ludwig-Maximilians - University of Munich|Yes|Not yet recruiting|February 2016|July 2022|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689869||2348|
NCT02678559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0254|Preload Dependency Evaluation With Stroke Volume Variation During Alveolar Recruitment Manoeuvres|Preload Dependency Evaluation With Stroke Volume Variation During Alveolar Recruitment Manoeuvres|PreDeARM|University Hospital, Clermont-Ferrand||Not yet recruiting|February 2016|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02678559||3217|
NCT02678572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-OCM-301|Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma|A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma|FOCUS|Delcath Systems Inc.|Yes|Recruiting|January 2015|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|240|||Both|18 Years|90 Years|No|||February 2016|February 5, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678572||3216|
NCT02694380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-160|Measuring the Effect of Radiation Therapy on Patient Activity Levels|Measuring the Effect of Radiation Therapy on Patient Activity Levels||University of Pittsburgh|Yes|Recruiting|July 2015|||July 2016|Anticipated|N/A|Observational|N/A||4|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Potential subjects are initially referred to the Department of Radiation Oncology for        their primary cancer diagnosis. Subjects that fit the diagnosis for this study may be        offered participation.|February 2016|February 23, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02694380||2003|
NCT02694393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15010062|Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis|Phase I/II Study of Inhaled Sodium Nitrite as an Antimicrobial for Pseudomonas Infection in Cystic Fibrosis||University of Pittsburgh|Yes|Recruiting|February 2016|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|99 Years|No|||February 2016|February 23, 2016|January 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02694393||2002|
NCT02708979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B321|Stress and Eating Behavior Among University Students - an Randomized Controlled Trial|StrEat - Stress and Eating Behavior|StrEat|University of Copenhagen|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708979||883|
NCT02708992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0031|Cefixime / Azithromycin pK Study|The Pharmacokinetics of Extended Duration High-Dose Cefixime Co-administered With Azithromycin for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 17, 2016|March 10, 2016||||No||https://clinicaltrials.gov/show/NCT02708992||882|
NCT02682186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95832|Pectoral Nerve Block for Analgesia After Breast Augmentation|Effects of the Pectoral Blocks in the Prosthetic Breast Expansion Surgery : Prospective, Randomized, Double Blind Study.|PECS BLOCKS|University Hospital, Montpellier|No|Active, not recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||February 2016|February 12, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682186||2939|
NCT02689934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBIOTICO - BB536|Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia|Efficacy of Red Yeast Rice Based Nutraceutical (Monacolin K 10 mg/Dose) Plus Probiotic (Bifidobacterium Longum BB536 ®) in Patients With Moderate Hypercholesterolemia.||Montefarmaco OTC SpA||Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02689934||2343|
NCT02689947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Restylane Silk for Tear Trough|Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity|Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity||Nashville Centre for Laser and Facial Surgery|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689947||2342|
NCT02685605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRAGO-II|Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme|A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)|INTRAGO-II|Universitätsmedizin Mannheim|Yes|Not yet recruiting|May 2016|February 2021|Anticipated|May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|314|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02685605||2676|
NCT02706483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304203-06|Long Term Safety Study of Plecanatide|An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|IBS-C|Synergy Pharmaceuticals Inc.|No|Recruiting|January 2016|February 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706483||1075|
NCT02685982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9799|Treating Major Depressive Disorder With Music and Low-frequency Rhythmic Sensory Stimulation|Examining the Effects of Music and Rhythmic Sensory Stimulation on Major Depressive Disorder||University Health Network, Toronto|Yes|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||February 2016|February 25, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02685982||2647|
NCT02679131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-BEL-105|To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.|An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment||Spectrum Pharmaceuticals, Inc|No|Not yet recruiting|February 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679131||3173|
NCT02687490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2016-20|Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer|A Prospective, Single-center, Open-Label, Phase II Study of Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer||Fudan University|No|Recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|70 Years|No|||March 2016|March 13, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687490||2531|
NCT02694783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160072|Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells|A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells||National Institutes of Health Clinical Center (CC)||Recruiting|February 2016|February 2018|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|March 24, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02694783||1972|
NCT02705092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-54|Immediate Effect of Subliminal Priming With Subliminal Reward Stimuli on Standing Balance in Healthy Young Adults|Immediate Effect of Subliminal Priming With Subliminal Reward Stimuli on Standing Balance in Healthy Young Adults: A Randomized Controlled Trial||Kibi International University|No|Active, not recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|52|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705092||1181|
NCT02705105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-014|Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors|Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors||Kyowa Hakko Kirin Pharma, Inc.|Yes|Recruiting|December 2015|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|187|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705105||1180|
NCT02683785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204851|A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis|A Multi-centre Phase IIa Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK3196165 in Subjects With Inflammatory Hand Osteoarthritis||GlaxoSmithKline|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02683785||2816|
NCT02684084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-CAN-EYE-0399|Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema|Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial|COLLIDE|North Toronto Eye Care Laser and Eye Specialists|No|Recruiting|November 2015|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 26, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684084||2793|
NCT02681003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 42|6 x FEC vs 3 x FEC Followed by Docetaxel in High-risk Node-negative Breast Cancer Patients|Randomized Study Comparing 6 xFluorouracil/Epirubicin/Cyclophosphamide (FEC) With 3 x FEC Followed by 3 x Docetaxel in High-risk Node-negative Patients With Operable Breast Cancer|NNBC-3|German Breast Group|Yes|Completed|January 2002|May 2014|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4150|||Female|18 Years|70 Years|No|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681003||3030|
NCT02681263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC15.213|Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae|Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae|TEMO-ESBL|University Hospital, Grenoble|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 9, 2016|November 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02681263||3010|
NCT02705729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSUHSC-NO #9270|Clinical Performance of Posterior Glass Ionomer Restorations in Adolescents (KETAC)|Clinical Performance of a Newly Developed Glass Ionomer Restorative Material for Posterior Restorations in an Adolescent Population||Louisiana State University Health Sciences Center in New Orleans|No|Not yet recruiting|April 2016|December 2019|Anticipated|November 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|17 Years|No|||March 2016|March 7, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705729||1132|
NCT02705742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMMA-HCV-MSC-1|Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis|Efficacy of Adipose Tissue Derived Autologous Repeated Mesenchymal Stem Cells Transplantation Via Hepatic Artery and Peripheral Vein in Patients With Liver Cirrhosis Due to HCV Hepatitis||Gulhane Military Medical Academy|Yes|Recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02705742||1131|
NCT02681120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0556|Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer|Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer||Indiana University|Yes|Not yet recruiting|March 2016|||February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|75 Years|No|Non-Probability Sample|40 total patients will be enrolled to the high risk/BMI > 30 cohort. 20 patients must be        pre-menopausal and 20 patients must be post-menopausal women. Post-menopausal women are        defined as: (1) those ≥ 50 years of age who had not menstruated during the preceding 12        months or who had castrate follicle-stimulating hormone levels (>40IU/L), (2) those who        had undergone a bilateral oophorectomy.|February 2016|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681120||3021|
NCT02684435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1866|Contrast-enhanced Ultrasound of the Kidney|Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD (CEUS CKD)|CEUS CKD|University of North Carolina, Chapel Hill|No|Not yet recruiting|February 2016|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684435||2766|
NCT02681276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Irrigation 3% NaOCl|Clinical and Microbiological Evaluation of 0.5% Versus 3% Sodium Hypochlorite in Root Canal Treatment|Clinical and Microbiological Evaluation of 0.5% Versus 3% Sodium Hypochlorite in Root Canal Treatment||Göteborg University|No|Recruiting|October 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02681276||3009|
NCT02513524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4096|Prevalence of Resistant Hypertension With DOT|The Prevalence of Pseudo-resistant Hypertension Using the Direct Observed Therapy Test: A Prospective Observational Study|DOT|Ottawa Hospital Research Institute|No|Recruiting|September 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is patients with resistant hypertension referred to a tertiary care        hypertension clinic.|October 2015|October 21, 2015|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02513524||15884|
NCT02706470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013SY034|Use of Cyclosporin A for the Treatment of Recurrent Miscarriage|A Randomized, Controlled Trial of Cyclosporin A for Women With Unexplained Recurrent Miscarriage||Fudan University|Yes|Not yet recruiting|May 2016|December 2018|Anticipated|February 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Female|20 Years|40 Years|No|||March 2016|March 12, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706470||1076|
NCT02687061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-174-2008|Chronic Hepatitis B and C Recall Northern Holland|Retrieval of Patients Chronically Infected With Hepatitis B or Hepatitis C in Northern Holland||Stichting MDL Holland-Noord|No|Not yet recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|The groups will be selected from registries of the Public Health Service (PHS) and medical        microbiology laboratories. All positive anti-HCV and HBsAg will be checked and if patients        with positive HBsAg or HCV are not known in specialised/hospital care, they will be        included in our database.|February 2016|February 17, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02687061|1 Year|2564|
NCT02693717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0592|A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma|A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693717||2054|
NCT02693730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DK048351-15A1|Phenotyping IBS: Perceptions and Modulations of Visceral Sensations|Perceptions and Modulations of Visceral Sensations|PMVS-P|University of California, Los Angeles|Yes|Recruiting|January 2016|January 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|290|Samples With DNA|Stool samples will be collected from both IBS and IBD subjects. A full stool analysis will      be performed on the stool of IBS subjects, whereas only calprotectin will be measured in the      stool of IBD subjects.      Blood will be collected from IBS subjects and HCs.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject population will be made up of male and female adults between the ages of 18-60 and        must fall into one of the following 3 groups: a) irritable bowel syndrome, b) ulcerative        colitis, or c) healthy controls. Medical screening will be a physician or a nurse will        confirm subject eligibility for the study.Subjects will be recruited from clinics and the        community in and around Los Angeles Area.|January 2016|February 23, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02693730||2053|
NCT02681575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0658-15-HMO|Meta-cognitive Functional Intervention for Adults With ADHD: A Pilot Efficacy Study|Meta-cognitive Functional Intervention for Adults (Cog-Fun - A) With Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Efficacy Study||Hadassah Medical Organization|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681575||2986|
NCT02700373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-APB-CL01|A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers|A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers||Hapten Sciences, Inc.|Yes|Not yet recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700373||1544|
NCT02690922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJXYXXW|Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients|The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients|TCLDCWTTNDPP|Tongji Hospital|No|Not yet recruiting|March 2016|May 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02690922||2268|
NCT02691065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-579-MUHC|Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection|Effect of a Treatment Switch From Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients.||McGill University Health Center|No|Not yet recruiting|July 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691065||2257|
NCT02683551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCTF-EndSx-2015-01|Comparison of QoL for Sutureless Thyroidectomy|Comparison of Effects of Energy Based Devices on Quality of Life After Sutureless Thyroidectomy?||Istanbul University|No|Enrolling by invitation|January 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who has planned to undergo to sutureless thyroidectomy for benign conditions.|February 2016|February 11, 2016|October 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02683551||2834|
NCT02683564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-BOW015-003|BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study|A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study||Epirus Biopharmaceuticals (Switzerland) GmbH|No|Not yet recruiting|February 2016|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|548|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683564||2833|
NCT02693652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVI-HBV-002-CT1301|A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine|A Single Center, Open Labeled Phase I/IIa Study to Evaluate Safety, Tolerability and Efficacy of a Therapeutic Hepatitis B Vaccine in Oral Antiviral Drug-treated Chronic Hepatitis B Virus Carriers||CHA Vaccine Institute Co., Ltd.|No|Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|19 Years|60 Years|No|||February 2016|February 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02693652||2059|
NCT02693756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHYVS2016-1|Home-based Motor Imagery for Gait Stability in Older Adults. A Cross-over Feasibility Study. (MIGS-F)|Home-based Motor Imagery Intervention for the Improvement of Gait Stability in Elderly Persons. A Cross-over Feasibility Study.|MIGS-F|University of Applied Sciences of Western Switzerland|No|Recruiting|February 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02693756||2051|
NCT02710539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/D/2016|Once-daily Fixed Combination of Three Antihypertensive Drugs|Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial)|ONE&ONLY|University of Roma La Sapienza|Yes|Not yet recruiting|April 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710539||763|
NCT02710552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123/D/2016|Low-dose Combination of Three Antihypertensive Drugs|Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial)|3D|University of Roma La Sapienza|Yes|Not yet recruiting|April 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 16, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710552||762|
NCT02692937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project no 6168/2207|Is Chronic Whiplash-associated Pain of Neurogenic Origin?|Is Chronic Whiplash-associated Pain of Neurogenic Origin? A Study Protocol of a Randomized Controlled Trial Comparing Neurolysis of Peripheral Nerves With Traditional Neck-specific Exercise||Region Skane||Recruiting|January 2011|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|60 Years|No|||February 2016|February 22, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02692937||2114|
NCT02686879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-2015-IB|Effect of Peripheral Defocus on Axial Growth in Hyperopes|The Effect of Peripheral Defocus on Axial Growth and Modulation of Refractive Error in Hyperopes||Aston University|No|Not yet recruiting|June 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|84|||Both|5 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02686879||2578|
NCT02679677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-607/2014|Evaluation of the Effects of Whole Body Vibration on the Lung Function of Patients With Stable COPD|Evaluation of the Effects of Whole Body Vibration Training With the Galileo Training Device on the Lung Function of Patients With Stable COPD||Heidelberg University|No|Recruiting|April 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02679677||3132|
NCT02705781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC_SYT_P001|Functionality and Accuracy of the smARTrack System in Real-Life ICU Settings|Functionality and Accuracy of the smARTrack System in Real-Life ICU Settings||ART Healthcare ltd.||Not yet recruiting|April 2016|||May 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02705781||1128|
NCT02695394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/126/15|Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study|||Charite University, Berlin, Germany|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|84 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be selected from a academic medical center MS outpatient clinic.|February 2016|February 24, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02695394||1926|
NCT02691845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R56HL127695|Initiating and Maintaining Physical Activity in Depressed Individuals|Initiating and Maintaining Physical Activity in Depressed Individuals|Project MOVE|Butler Hospital|No|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02691845||2198|
NCT02693665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBear#5648|Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer|Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer|FACE-TC|Children's Research Institute|Yes|Not yet recruiting|May 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|260|||Both|14 Years|99 Years|No|||February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693665||2058|
NCT02705937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API/2015/65|Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.|Early Phase Study Comparing the Effectiveness of a Dairy Product, Co-developed by Besancon University Hospital and the National School of Dairy Industry (ENIL), With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.|LactoXeros|Centre Hospitalier Universitaire de Besancon||Not yet recruiting|April 2016|April 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02705937||1116|
NCT02685735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00032506|Predicting, Understanding and Speeding Recovery After TKA|Predicting, Understanding, and Speeding Recovery After Total Knee Arthroplasty||Wake Forest School of Medicine|Yes|Recruiting|February 2016|February 2022|Anticipated|December 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|June 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02685735||2666|
NCT02691611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2939|Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency|Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency|AATD_Epi|National Jewish Health|Yes|Recruiting|December 2015|November 2020|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|19|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  AATD from clinic          -  Healthy controls from community|February 2016|February 20, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02691611||2216|
NCT02685020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108068|Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults|A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140||Crucell Holland BV|No|Not yet recruiting||February 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685020||2721|
NCT02685033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL-MD-04|Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis|A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms|DAL-MD-04|Durata Therapeutics Inc., an affiliate of Allergan plc|No|Not yet recruiting|February 2016|September 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685033||2720|
NCT02703064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. CR-PCOS/1-15|Furocyst - Poly Cystic Ovary Syndrome Study|To Study the Efficacy and Safety of Furocyst in Poly Cystic Ovary Syndrome Patients (PCOS)||Chemical Resources|No|Recruiting|April 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02703064||1337|
NCT02695420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120227|Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction||Amgen|Yes|Not yet recruiting|April 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|85 Years|No|||March 2016|March 16, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695420||1924|
NCT02695433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2016-001|Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers|Effects of a Typical American Diet High in Refined Carbohydrates Compared to a Diet That Replaces Some Refined Carbohydrates With Healthy Fats on Cardiometabolic Health in Men and Women With Pre-diabetes and Metabolic Syndrome|AV2|Institute for Food Safety and Health, United States|No|Not yet recruiting|March 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|120|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695433||1923|
NCT02681523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/31/2014|ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.|ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.|ALERT|Imperial College London|Yes|Recruiting|October 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||January 2016|February 11, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681523||2990|
NCT02695134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-16-6754|Healing Touch Prior to Cardiac Rehab|Healing Touch Intervention in Post-Cardiac Event Patients Prior to Starting a Cardiac Rehab Program||Scripps Health|No|Recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|124|||Both|18 Years|95 Years|No|||February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02695134||1946|
NCT02681718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH15-46|Controlling Hyperglycemia Among Minority Populations|Controlling Hyperglycemia Among Minority Populations (CHAMP): A Randomized Controlled Trial of Two Diabetes Interventions for Underserved Communities|CHAMP|Sinai Health System|No|Recruiting|January 2016|August 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|330|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02681718||2975|
NCT02679404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR001|Sorin Universal REgistry on Aortic Valve Replacement|Sorin Universal REgistry on Aortic Valve Replacement|SURE-AVR|LivaNova|No|Recruiting|May 2015|May 2029|Anticipated|May 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|All patients having received a Sorin Group aortic valve device in accordance with the IFU        can be included in the registry. Other than the indication and the contra-indications        specified in each IFU, there are no specific inclusion and exclusion criteria since this        registry has the aim to include all patients following "real life"/standard of care        practices at participating centers. All patients must provide written or oral informed        consent to participate in the registry following the local regulations.|February 2016|February 5, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02679404||3152|
NCT02697422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-063|Veteran Peer Coaches Optimizing and Advancing Cardiac Health|Vet COACH (Veteran Peer Coaches Optimizing and Advancing Cardiac Health)|Vet-COACH|VA Office of Research and Development|No|Not yet recruiting|September 2016|February 2021|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|590|||Both|45 Years|64 Years|No|||February 2016|February 26, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02697422||1771|
NCT02688283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1512|The Effect on Glycemic Responses and Subjective Ratings of Satiety of a Snack With or Without Ingredients to Slow Carbohydrate Digestion|Randomized, Controlled, Cross-over Study Comparing The Effect on Glycemic Responses and Subjective Ratings of Satiety of a Snack With or Without Ingredients to Slow Carbohydrate Digestion||PepsiCo Global R&D|No|Completed|November 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688283||2470|
NCT02688361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205033|A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution|A Randomized, Open-Label, Two-Period, Crossover Bioequivalence Study in Healthy Adult Subjects After Single Oral Dosing of a NCH-GSK Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil® Acetylcysteine 2% Oral Solution||GlaxoSmithKline||Not yet recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688361||2464|
NCT02691572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/16.01.17|Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia|Comparison Between Transversus Abdominis Plane Block and Wound Infiltration for Analgesia After Cesarean Delivery||Mansoura University|No|Recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|19 Years|40 Years|No|||February 2016|February 27, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02691572||2219|
NCT02678520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IIT-RT-IMRT|Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients|Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients||University of Kansas Medical Center|Yes|Withdrawn|December 2015|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|January 6, 2016||No|PI accepted position at different institution.|No||https://clinicaltrials.gov/show/NCT02678520||3220|
NCT02683889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0797|Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation|The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant||Georgetown University|No|Not yet recruiting|May 2016|||May 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|February 12, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683889||2808|
NCT02683902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0119|The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile|The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile: a Pilot, Double Blind, Randomized, Placebo-controlled Study||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|February 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 16, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683902||2807|
NCT02701803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HospitalDHU|Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy|Ambulatory Movement Registration in Patients With Deep Brain Stimulation and Continuous Intraduodenal Levodopa Therapy||Hospital District of Helsinki and Uusimaa|Yes|Recruiting|October 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|No|Probability Sample|Study population is consisted of patients with advanced Parkinson's disease in HUH        neurological clinic. The treatment decision of deep brain stimulation and/or continuous        intraduodenal levodopa therapy is done clinically by the treating physician. The patients        are enrolled in the study after the clinical decision is made.|March 2016|March 2, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02701803||1434|
NCT02691208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801|Acupuncture and Breast Cancer Rehabilitation|Effectiveness of Acupuncture in Rehabilitation of Physical and Functional Disorders of Women Undergoing Breast câncer Surgery|ACUP|Federal University of São Paulo|No|Completed|August 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|N/A|No|||February 2016|February 21, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691208||2247|
NCT02682225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108104|Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users|A Single-Center, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Users of Perception-Altering Drugs||Janssen Research & Development, LLC|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682225||2936|
NCT02689765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151218|Effect of Anthocyanins on Glucose Metabolism in Subjects With Pre-diabetes|Effect of Anthocyanins on Glucose Metabolism in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study||Sun Yat-sen University|No|Not yet recruiting|March 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|70 Years|No|||January 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02689765||2356|
NCT02692599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-MUMPS-3001|Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants|A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants||Sinovac (Dalian) Vaccine Technology Co., Ltd.|No|Recruiting|January 2016|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1140|||Both|8 Months|18 Months|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692599||2140|
NCT02705144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC -15 - 2787|Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis|Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis Compared to Non-diseased Areas||Sheba Medical Center|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20|Samples With DNA|Lung tissue biopsies|Both|18 Years|90 Years|No|Probability Sample|Patients with lung emphysema and interstitial lung disease as the background for lung        cancer|March 2016|March 5, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02705144||1177|
NCT02705157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54439.058.15|The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones|The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones|OPTIMAL|Leiden University Medical Center|No|Recruiting|January 2016|January 2021|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Probability Sample|All patients visiting the radiation oncologist or the orthopaedic surgeon of participating        centres, for possible local treatment of a symptomatic BMLB or impending fracture, will be        registered in the OPTIMAL registry. This includes patients with newly diagnosed metastatic        bone disease as well as patients undergoing re-treatment of the same lesion or patients        who have received previous treatment for other lesions. Preferably patients are included        before the start of treatment, but inclusion can also take place during treatment. When        patients are already included in the cohort (for treatment of another metastasis), they        will not be included a second time when they present with a second lesion of the long        bones. This second lesion will be registered under the same patient number.|March 2016|March 4, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705157|2 Years|1176|
NCT02688465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHH_2016_01|Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).|Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).|POMPRENELLE|Fondation Ophtalmologique Adolphe de Rothschild|No|Not yet recruiting|March 2016|March 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688465||2456|
NCT02679092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-36302|Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks|Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks||Stanford University|No|Not yet recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679092||3176|
NCT02679105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001259-63|Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy|Intralymphatic Immunotherapy in Increasing Doses up to 10 000 SQ-U -a Human Randomized Clinical Trial||Karolinska Institutet|Yes|Active, not recruiting|May 2015|October 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|No|||February 2016|February 5, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02679105||3175|
NCT02679651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15060610|Diagnostic Modeling for Pedal Fat Pad Atrophy|Diagnostic Modeling for Pedal Fat Pad Atrophy||University of Pittsburgh|Yes|Recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 healthy, age matched adults with normal foot fat pads to compare to 30 patients in the        fat pad atrophy group from our other IRB approved clinical trials.|February 2016|February 6, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02679651||3134|
NCT02684227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0723|Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer|A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684227||2782|
NCT02680912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6505|Warm Needle Acupuncture vs Needle Acupuncture|Warm Needle Acupuncture vs. Needle Acupuncture for Osteoarthritis of the Knee: A Pilot Study||London South Bank University|No|Recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680912||3037|
NCT02686047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS14-CT8-12|Comparing One Intraarticular Injection of a Novel HYAJOINT Plus With Synvisc-One for the Treatment of Knee OA|Comparing Efficacy and Safety of a Single Intraarticular Injection of a Novel Crosslinked Hyaluronic Acid (HYAJOINT Plus) With Synvisc-One for the Treatment of Knee Osteoarthritis: A Randomized-Controlled, Double-Blind Trial||Kaohsiung Veterans General Hospital.|Yes|Completed|September 2014|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|40 Years|85 Years|No|||February 2016|February 14, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02686047||2642|
NCT02685007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TachoSil-4001|RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional Study|RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional Study||Takeda|No|Not yet recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will include inpatients planned for laparoscopic surgery, in the field of        gynecology, urology and visceral surgery and where pre-rolled TachoSil will be applied.|February 2016|February 17, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02685007||2722|
NCT02700126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-1195|Impact of Genetic Polymorphism on Propofol Requirement and Recovery for Total Intravenous Anesthesia for Clipping of Unruptured Cerebral Aneurysm in Korean Population|||Yonsei University|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood obtained from enrolled patients before surgery|Both|19 Years|N/A|No|Non-Probability Sample|Korean adult population undergoing propofol based total intravenous anesthesia for        clipping of unruptured cerebral aneurysm.|March 2016|March 1, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02700126||1563|
NCT02700386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1329.cc|Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes|Hypofractionated, Comprehensive Radiation Therapy for Node-Positive Breast Cancer||University of Colorado, Denver|Yes|Not yet recruiting|July 2016|October 2020|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Female|18 Years|101 Years|No|||February 2016|March 1, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700386||1543|
NCT02692794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1192|Large Scale Cerebral Oximetry During Sinus Endoscopy|Large Scale Cerebral Oximetry During Sinus Endoscopy||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|None Retained|Specify all types of biospecimens to be retained (e.g., whole blood, serum, white cells,      urine, tissue)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing primary or revision endoscopic sinus surgery for chronic        rhinosinusitis|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692794||2125|
NCT02683044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IECAS-BMG-01|Effectiveness And Safety Of Two Protocols For The Treatment Of Erectile Dysfunction With Low-Density Shock Waves|Randomized Clinical Trial To Evaluate The Comparative Effectiveness And Safety Of Two Protocols For The Treatment Of Erectile Dysfunction With Low-Density Shock Waves||Instituto para la Evaluación de la Calidad y Atención en Salud|No|Not yet recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Male|18 Years|80 Years|No|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683044||2873|
NCT02682342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO26013|Hyperglycemia and Mitochondrial Function in The Endothelium of Humans|Hyperglycemia and Mitochondrial Function in The Endothelium of Humans||Medical College of Wisconsin|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|Plasma samples and endothelial cells obtained will be saved for banking for future studies      as possible.|Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects without evidence of diabetes, insulin resistance, hypertension, or        elevated cholesterol. Subjects will also be without prevalent cardiovascular disease,        chronic renal insufficiency, or chronic liver disease.|February 2016|February 12, 2016|February 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682342||2927|
NCT02698774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130684|Low Resource Diagnostics Development Cohort - VZNIGHT|Vanderbilt-Zambia Network for Innovation in Global Health Technology - Malaria mBEADS Diagnostics Development Cohort|VZN-mBEADS|Vanderbilt University|Yes|Not yet recruiting|April 2016|August 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|170|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Since this study only uses a fingerprick blood specimen obtained at the same time as a        routine rapid diagnostic test for malaria, there are no absolute contra-indications for        such a test. However, the following criteria will apply for the study purposes.|February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02698774||1667|
NCT02698787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM5621|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||March 17, 2016|December 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698787||1666|
NCT02699086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phase II BLI-1008-001|A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)|||BioLite, Inc.||Not yet recruiting|January 2017|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699086||1643|
NCT02699099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200596|Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.|Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.||GlaxoSmithKline||Not yet recruiting|September 2016|November 2019|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|699|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02699099||1642|
NCT02685969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET FLUTEMETAMOL-FDG/BBRC2015|Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants|Characterization of Cerebral Amyloid Deposition With 18F‐Flutemetamol PET and of Glucose Metabolism With 18F‐FDG PET in Individuals Enrolled in the ALFA Project.||Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Not yet recruiting|April 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|440|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 440 participants enrolled in the ALFA project (STUDY 45‐65 FPM/2012) will be        selected and physiologically characterized with 18F‐Flutemetamol and 18F‐FDG PET scans.|February 2016|February 15, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02685969||2648|
NCT02691832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-16-2920-HS-CTIL|Measuring Core Body Temperature Using a Novel Non-invasive Sensor|Measuring Core Body Temperature Using a Novel Non-invasive Sensor - a Follow up Study|Dräger|Sheba Medical Center|No|Not yet recruiting|May 2016|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691832||2199|
NCT02693197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T817MAUS113|PK Study of T-817 in Subjects With Hepatic Impairment|A Phase 1, Two-Part, Open-Label, Parallel-Cohort, Single-Dose Study to Determine the Pharmacokinetics of T-817MA in Adult Subjects With Hepatic Impairment and in Healthy Adult Subjects||Toyama Chemical Co., Ltd.||Not yet recruiting|February 2016|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693197||2094|
NCT02693210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA16291|A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis|A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|February 2001|August 2004|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|161|||Both|21 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693210||2093|
NCT02710227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleep Patterns in cirrhotics|Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis|Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis||Tanta University|Yes|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals with hepatic cirrhosis (n=50) and healthy controls (n=30) were recruited.|March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02710227||787|
NCT02690805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI HS# 2015-1866|Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System|Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System||University of California, Irvine|No|Recruiting|May 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Female|21 Years|N/A|No|Probability Sample|Breast cancer patients who elect to receive neoadjuvant chemotherapy|February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02690805||2277|
NCT02690818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXT4MED|Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging|Promoting Adherence to Treatment for Latent TB Infection Through Mobile Phone Text Messaging|TXT4MED|University of Arizona|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690818||2276|
NCT02683577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-FR-01017-001|Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects|A Phase 1, Open-label Study to Evaluate the Single Dose Pharmacokinetics of Telotristat Etiprate in Male and Female Subjects With Mild, Moderate and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function||Ipsen|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02683577||2832|
NCT02683590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I15032|STernectOmy Repair Efficiency of a Ceramic Implant|STernectOmy Repair Efficiency of a Ceramic Implant|STOIC|University Hospital, Limoges|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|3|||Both|18 Years|N/A|No|||December 2015|February 16, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02683590||2831|
NCT02694939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH106587|STAND Community Trial|Effectiveness of MI Enhanced Behavior Therapy for Adolescents With ADHD|STAND|Florida International University|No|Recruiting|May 2015|April 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|11 Years|17 Years|No|||February 2016|February 24, 2016|July 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02694939||1960|
NCT02695329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GK53|Vanguard TKA With KneeAlign 2 and Without KneeAlign 2|Randomized Controlled Study Comparing Vanguard With KneeAlign2 Navigational System Versus Vanguard Conventional||Biomet, Inc.|No|Not yet recruiting|February 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|20 Years|N/A|No|||February 2016|February 24, 2016|February 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695329||1931|
NCT02707536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-DB-14-0190|Influence of Platelet-Rich Fibrin on Post-extraction Alveolar Ridge Healing/Preservation as a Stand-alone or Adjunct to Particulate Graft|Influence of Platelet-Rich Fibrin on Post-extraction Alveolar Ridge Healing/Preservation as a Stand-alone or Adjunct to Particulate Graft: A Clinical, Radiographic and Histological Evaluation||The University of Texas Health Science Center, Houston|No|Recruiting|May 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707536||994|
NCT02707549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 44552315.1.0000.5505|Fluid Therapy During Brain Tumor Resection in Children|Comparison of Balanced Crystalloid Solution and 0,9% Sodium Chloride in Children Undergoing Brain Tumor Resection: a Randomized Controlled Trial||Federal University of São Paulo|No|Recruiting|August 2015|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|6 Months|10 Years|No|||March 2016|March 8, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02707549||993|
NCT02688751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5083|Contrast Enhanced Ultrasound, Endoleak Detection Following EVAR v1.3|Contrast Enhanced Ultrasound Endoleak Detection Compared To Time-Resolved Computer Tomography Angiography in High Risk Endovascular Aneurysm Repair (EVAR) Surveillance Patients.||Royal Liverpool and Broadgreen University Hospitals NHS Trust|No|Recruiting|February 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|74|||Both|18 Years|N/A|No|Probability Sample|Patients identified as being at increased risk of Type I/III endoleak following EVAR who        require CTA & CEUS to confirm/refute this diagnosis.|December 2015|February 17, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02688751||2434|
NCT02685267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|c13-126|Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer|A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide|Doce/Enza|Prostate Cancer Clinical Trials Consortium||Not yet recruiting|February 2016|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685267||2702|
NCT02685280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50760|Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders|Feasibility Study Regarding the Implantation and Use of Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders (Either Obsessive-compulsive Disorder or Major Depression)||Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2007|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685280||2701|
NCT02707965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-107D|Characterization of Epilepsy Patients BEEP 2b|Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study|BEEP2b|Food and Drug Administration (FDA)|No|Not yet recruiting|March 2016|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|76 Years|No|||March 2016|March 8, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707965||961|
NCT02707978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 123119 Protocol C|F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)|F 18 T807 Tau PET Imaging of Frontotemporal Dementia||Washington University School of Medicine|No|Not yet recruiting|April 2016|September 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707978||960|
NCT02685956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vela Sentosa HSV Study|Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test|Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test||Vela Diagnostics|No|Not yet recruiting|March 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Samples collected from an oral or genital site, submitted to a clinical laboratory for the      purpose of testing for the presence of HSV1 or HSV2.      Samples collected in universal viral transport media, using a plastic shaft swab made of      either polyester, cotton, rayon or Dacron.|Both|N/A|N/A|No|Non-Probability Sample|Male and females with genital or oral lesions to be tested for HSV 1/2 infection.|February 2016|February 18, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685956||2649|
NCT02685566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2013-004F|Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program|A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study||Fujifilm Medical Systems USA, Inc.|No|Completed|August 2015|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685566||2679|
NCT02685579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-15-WOMC|The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo|The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo|OSATDV|Wolfson Medical Center|No|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|People coming to the Sleep Study Laboratory at the E. Wolfson Medical Center|February 2016|February 17, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02685579||2678|
NCT02678650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015017X|MicroRNA Mediates Volatile Anesthetics Preconditioning Induced Artery Protection|Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University||Beijing Anzhen Hospital|Yes|Recruiting|January 2016|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02678650||3210|
NCT02678663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1513/3.2.2016|Injection-Assisted Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Small Colorectal Polyps|Randomized Comparison of Injection-Assisted Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Small (6-10mm) Colorectal Polyps||Benizelion General Hospital|No|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02678663||3209|
NCT02682628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18791|18791 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|SFP|Bayer|No|Completed|February 2016|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682628||2905|
NCT02518464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO4109|Ticagrelor Therapy for RefrACTORy Migraine Study|Ticagrelor Therapy for RefrACTORy Migraine Study Pilot (TRACTOR)|TRACTOR|Columbia University|Yes|Recruiting|October 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|August 6, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518464||15507|
NCT02690792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102010-180|Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease|Role of Mitochondrial Dysfunction in Non-Alcoholic Fatty Liver Disease||University of Texas Southwestern Medical Center|No|Recruiting|December 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 17, 2014||No||No||https://clinicaltrials.gov/show/NCT02690792||2278|
NCT02678832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110512/111223|Momentum Project Heidelberg - Dealing Actively With a Cancerous Disease|Social Cognitions and Norms Towards Physical Exercise Among Cancer Patients and Health Care Professionals||Heidelberg University|No|Enrolling by invitation|December 2015|March 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|2150|||Both|18 Years|100 Years||Non-Probability Sample|Cross-sectional surveys:          1. 300 specialized practitioners who treat patients with breast, prostate or colorectal             cancer (gynecologists, radiologists, urologists, gastroenterologists, oncologists,             surgeons)          2. 300 general practitioners          3. 50 rehabilitation physicians          4. 300 oncology nurses          5. 1200 cancer patients with breast, prostate or colorectal cancer before or during             cancer therapy (pre-treatment and primary cancer treatment time period according to             PA and Cancer Control (PACC) framework)          6. Longitudinal follow-up study: 180 patients [sub-sample of (5)] who are recruited             before the initiation or at the beginning of their primary cancer treatment|February 2016|February 16, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02678832||3196|
NCT02686632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD-UdeM-EE-2016a|The Efficacy of Palatal Brushing on Denture Stomatitis|Efficacy of Palatal Brushing in Patients With Denture Stomatitis: A Phase II Randomised Controlled Trial.||Université de Montréal|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686632||2597|
NCT02704910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1131|Lateral Postural Inclination in Parkinson's Disease : Involvement of the Basal Ganglia ?|Lateral Postural Inclination in Parkinson's Disease : Involvement of the Basal Ganglia ?|IPOLAP|University Hospital, Grenoble|No|Terminated|January 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 20, 2012||No|Not more patient with lateral deviation|No||https://clinicaltrials.gov/show/NCT02704910||1195|
NCT02678481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-Cure PCa 2014|MR-targeted vs. Random TRUS-guided Prostate Biopsy|MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial|Pro-Cure2014|Fondazione del Piemonte per l'Oncologia|No|Recruiting|November 2014|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|90|||Male|50 Years|80 Years|No|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678481||3223|
NCT02689336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-x040|Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors|Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide||Washington University School of Medicine|No|Not yet recruiting|May 2016|May 2020|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|21 Years|No|||February 2016|February 18, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689336||2389|
NCT02689349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205|0205 Esteem New Subject Enrollment Post Approval Study|Esteem Totally Implantable Hearing System New Subject Enrollment Post Approval Study||Envoy Medical Corporation|No|Recruiting|August 2010|July 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|February 18, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689349||2388|
NCT02679183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100904|Medically-Graded Honey Supplementation Formula To Preterm Infants|Randomized Controlled Trial on Medically-Graded Honey Supplementation Formula (As a Prebiotic) To Preterm Infants|Honey|Cairo University||Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|N/A|3 Weeks|No|||February 2016|February 9, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02679183||3169|
NCT02679196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTP-002|The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma|An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma||Karus Therapeutics Limited|No|Not yet recruiting|May 2016|May 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679196||3168|
NCT02698540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA13|A Study of an Oral Nutritional Supplement in a Malnourished Population With GI Tolerance Impairment|A Prospective, Observational Study, of a High Calorie, Higher Protein Peptide Based ONS With MCTs in a Malnourished Population With GI Tolerance Impairment||Abbott Nutrition|No|Not yet recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include men and women who are free living (outpatient) or        residing in a nursing home.|February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02698540||1685|
NCT02698553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114883|A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers|An Open-label, Fixed Sequence Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeated Dose of Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers||GlaxoSmithKline|No|Not yet recruiting|May 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698553||1684|
NCT02680938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gyn-057|Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor|Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor A Randomized Controlled Study||Ain Shams University|No|Recruiting|January 2015|March 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|1|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680938||3035|
NCT02692235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/15/B/NZ7/00893|Carnitine Supplementation and Skeletal Muscle Function|Carnitine Supplementation and Skeletal Muscle Function in Aging||Gdansk University of Physical Education and Sport|No|Recruiting|February 2016|January 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692235||2168|
NCT02683369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-FS|Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women|Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women||University of Maryland|No|Recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683369||2848|
NCT02683382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDE|Effects of a Moisturizing Product on Dry Eye and Skin||SDE|Aromtech Ltd.|No|Active, not recruiting|March 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02683382||2847|
NCT02710578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/2014|Alcohol Effects on Driving-related Skills of Young Drivers|Acute and Residual Effects of Alcohol on Young Drivers' Performance of Driving Related Skills||Centre for Addiction and Mental Health|No|Recruiting|March 2016|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|19 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02710578||760|
NCT02680327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 15-1875|Advance Care Planning (ACP) in Elderly Cardiac Surgery Patients|A Feasibility Study on: Advance Care Planning (ACP) in Elderly Cardiac Surgery Patients|DIMAN|Montreal Heart Institute|No|Recruiting|October 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|70 Years|95 Years|No|Non-Probability Sample|Patients 70 years of age and over admitted for cardiac surgery that requires a general        anesthetic (either via median sternotomy, minimally invasive or percutaneous approach);|February 2016|February 10, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02680327||3082|
NCT02680561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-PK-10007|A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma|A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age||Teva Pharmaceutical Industries|No|Not yet recruiting|March 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|4 Years|11 Years|No|||March 2016|March 1, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680561||3064|
NCT02680990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00002745|Resilience and Exercise in Advanced Cancer Treatment|Prehabilitation for Patients With Aggressive Gastrointestinal Cancers Undergoing Neoadjuvant Therapy|REACT|Milton S. Hershey Medical Center|Yes|Enrolling by invitation|December 2015|||October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02680990||3031|
NCT02680197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-06302AA1-01|Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD|Randomised, Double Blind, Placebo-controlled, Incomplete Block, 3-way Cross-over Study to Evaluate Efficacy and Safety of 4 Doses of Glycopyrronium Bromide (CHF5259) DPI in Moderate to Severe Patients With COPD|GlycoNEXT|Chiesi Farmaceutici S.p.A.|No|Recruiting|February 2016|February 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|300|||Both|40 Years|N/A|No|||March 2016|March 18, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680197||3092|
NCT02710630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.246|Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects|Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, Five-sequence Crossover Study)||Boehringer Ingelheim||Not yet recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|35|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 14, 2016||||No||https://clinicaltrials.gov/show/NCT02710630||756|
NCT02710643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_MIRO|"MIRO" Molecularly Oriented Immuno-radio-therapy|"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab|FIL_MIRO|Fondazione Italiana Linfomi ONLUS|No|Recruiting|October 2014|October 2020|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02710643||755|
NCT02710695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-026|Pain in America: A Randomized Controlled Trial Evaluating Patient Comprehension of the Common Causes of Shoulder Pain|||University of Missouri, Kansas City||Recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02710695||751|
NCT02689882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL126209-01S1|"Pharmacokinetic Study of Nicotinamide Riboside"|"Pharmacokinetic Study of Nicotinamide Riboside"||University of Washington|Yes|Completed|November 2015|February 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02689882||2347|
NCT02678598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-MA-3003|A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections|A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections||Astellas Pharma Inc|No|Completed|March 2015|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2555|||Both|18 Years|N/A|No|Non-Probability Sample|The hospitalized patients who received intravenous micafungin for treatment according to        the clinical judgment of the treating physician before the end of April 2015|February 2016|February 5, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02678598||3214|
NCT02678611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15BSHE|A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.|A Randomized, Double-blind, Placebo Controlled Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.|15BSHE|Elysium Health|No|Recruiting|January 2016|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|120|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02678611||3213|
NCT02693782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/HSMC/004|Fabulous Fibre Study - Effect of Wheat Bran Extract on Gut and General Health in Healthy Aging Subjects (FFS)|Effect of Wheat Bran Extract Containing Arabinoxylan Oligosaccharides, on the Gut Microbiota Composition and Well-being in Healthy Aging Subjects PhD Project: New Targeted Prebiotic Approaches for Maintaining Human Health|FFS|University of Aberdeen|No|Recruiting|June 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|June 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02693782||2049|
NCT02706119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPS-INSUPAR-2015-01|Insulin in Total Parenteral Nutrition|Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition|INSUPAR|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02706119||1102|
NCT02710708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18261|YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China|Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women||Bayer|No|Not yet recruiting|April 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02710708||750|
NCT02681471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/434-992|Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia|Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia: A Comparison of the Effects on Plasma Electrolytes, Osmolarity and Hemoglobin||Istanbul University|No|Completed|December 2013|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|53|||Male|50 Years|90 Years|No|||February 2016|February 11, 2016|January 30, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681471||2994|
NCT02686346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV-ICE|Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE|Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation|BV-ICE|The Lymphoma Academic Research Organisation|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02686346||2619|
NCT02686593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOFAL07200|Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML|Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML||The University of Hong Kong|Yes|Recruiting|February 2016|December 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686593||2600|
NCT02680782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X4P-001-REGA|A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers|A Phase 1 Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers||X4 Pharmaceuticals|No|Recruiting|January 2016|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680782||3047|
NCT02701543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP_14/001|Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease|Prospective, Randomized, Multi-Center Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease With the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)||University of Leipzig|Yes|Recruiting|October 2015|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02701543||1454|
NCT02690090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enox-TOH-0001-RP|Safety Study of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency|Phase 4 Study Determining the Safety of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency||Ottawa Hospital Research Institute|No|Recruiting|February 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|adult critically ill patients with creatinine clearance < 30 mL/min and requiring        thromboprophylaxis during their ICU course.|February 2016|February 18, 2016|January 10, 2014||No||No||https://clinicaltrials.gov/show/NCT02690090||2331|
NCT02690103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV|Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection||Cairo University|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|37|||Both|N/A|65 Years|No|||February 2016|February 23, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02690103||2330|
NCT02686307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00013500|Predicting Blood Pressure in Patients Following Defibrillation|Predicting Blood Pressure in Patients Following Defibrillation in Patients With an ICD Implant||University of Utah|No|Completed|June 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|February 2016|February 16, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT02686307||2622|
NCT02691286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-RNA-2015-80|Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock|Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|February 2016|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|142|Samples With DNA|EDTA and LiHe tubes with 10 ml of blood|Both|18 Years|N/A|No|Probability Sample|Patients admitted to Hospital de la Santa Creu i Sant Pau with diagnosis of STEMI with or        without cardiogenic shock|February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691286||2241|
NCT02683616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZV15_30155A|Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)|Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)|FAMOSA|Faculty Hospital Kralovske Vinohrady|No|Recruiting|April 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683616||2829|
NCT02683629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCT/PD-015|Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease|A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease||Living Cell Technologies|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|40 Years|65 Years|No|||February 2016|February 16, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683629||2828|
NCT02701556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|872|A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution|A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution||Valeant Pharmaceuticals International, Inc.|No|Completed|May 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|396|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|July 27, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701556||1453|
NCT02691052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoliXane|Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program|Non-interventional Study on Quality of Life, Efficacy and Tolerability of Nab-paclitaxel/Gemcitabine Firstline Therapy in Patients With Metastatic Pancreatic Cancer|QoliXane|Krankenhaus Nordwest|No|Recruiting|December 2014|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|600|Samples Without DNA|Tumor containing tissues are collected for a translational program focusing on defining      prognostic and predictive factors.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic pancreatic cancer subject to firstline therapy with        nab-paclitaxel and gemcitabine|February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02691052||2258|
NCT02683278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR053245|Fibromyalgia: Interventions for Pain and Mood Regulation|Fibromyalgia: Interventions for Pain and Mood Regulation||Arizona State University|No|Completed|November 2008|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02683278||2855|
NCT02687685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acta 313 05-09-2015|Clinical Trial of Immediate Skin to Skin Contact at Birth Early vs. Immediate (CPPITLH)|Randomized Clinical Trial of Immediate Skin to Skin Contact (SSC) at Birth, Early vs. Immediate, on the Duration of Exclusive Human Lactation in Full-term Newborns Treated at the Universidad de La Sabana Clinic|CPPITLH|Universidad de la Sabana|Yes|Not yet recruiting|February 2017|||February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|60 Minutes|No|||February 2016|February 25, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02687685||2516|
NCT02687737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201600120|Tongue Motor Recruitment During Exercise|Genioglossus Motor Recruitment During Swallowing and Expiratory Loading Exercises||University of Florida|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687737||2512|
NCT02705053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G150063_2|At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation|At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation||William Sansum Diabetes Center|Yes|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|65 Years|No|||March 2016|March 6, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705053||1184|
NCT02680899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-009107|Adolescent Mental Health InSciEd Out|Adolescent Outcomes in Mental Health InSciEd Out||Mayo Clinic|No|Active, not recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680899||3038|
NCT02681133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0256|How is Physical Activity Level and Educational Expectations of Patient With Knee Osteoarthritis : Epidemiological Study in Spa Therapy|How is Physical Activity Level and Educational Expectations of Patient With Knee Osteoarthritis : Epidemiological Study in Spa Therapy||University Hospital, Clermont-Ferrand||Completed|September 2014|September 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|500|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with knee pain reported to osteoarthritis|February 2016|February 9, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02681133||3020|
NCT02686788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP001_MS|TMP001 in Relapsing-remitting Multiple Sclerosis|TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial||Fraunhofer Institute for Molecular Biology and Applied Ecology|Yes|Recruiting|August 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|55 Years|No|||February 2016|February 15, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02686788||2585|
NCT02686801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIPREMA|Body Composition at Discharge and Neurological Development at 2 Years in Very Preterm Infants (OPTIPREMA)|Determinants of Body Composition at Discharge and Fat-Free Mass as an Indicator of Neurological Development at 2 Years in Very Preterm Infants : OPTIPREMA Study|OPTIPREMA|Hôpital de la Croix-Rousse|No|Recruiting|April 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|3 Years|No|Non-Probability Sample|Preterm neonates|February 2016|February 18, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02686801||2584|
NCT02692690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1067_2015|TENS in Optimizer(R) Patients|Electromagnetic Interference by Transcutaneous Neuromuscular Electrical Stimulation in Patients With Optimizer(R) - a Pilot Safety Study||Medical University of Vienna|No|Completed|May 2015|October 2015|Actual|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|99 Years|No|||February 2016|February 22, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02692690||2133|
NCT02707159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/1743|Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients|A Novel Therapy for Locally Advanced and Metastatic Pancreatic Cancer Based on Nanoparticle Albumin-bound Paclitaxel and Gemcitabine: Circulating Tumor Cells as a Potential Biomarker for Treatment Monitoring, -Response and Survival|PACT-ACT-v6|Helse Stavanger HF|Yes|Recruiting|November 2014|January 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02707159||1023|
NCT02707172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-PH-201301|Removal of Dermal Exposure to Phthalate Ester by Hand Washing|Soap and the Removal of Diethylhexyl Phthalate From Hands: N-of-1 and Cross-Over Designs||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|May 2013|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707172||1022|
NCT02691377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015S320|Acupuncture for Primary Sjögren Syndrome|Efficacy and Safety of Acupuncture for Primary Sjögren Syndrome||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02691377||2234|
NCT02694354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1366.1|Investigation of Single Rising Doses of BI 685509|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 685509 in Healthy Male Subjects||Boehringer Ingelheim||Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 25, 2016||||No||https://clinicaltrials.gov/show/NCT02694354||2005|
NCT02683811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLCN2|Effectiveness of the Updated Version of the School-based Program Diario Della Salute (DDS-2)|A Randomised Controlled Study for Evaluating the Effectiveness of the Updated Version of Diario Della Salute, a School-based Program for Prevention of Unhealthy and Risky Behaviours and Promotion of Well-being in Italian Pre-adolescents|DDS-2|Azienda Sanitaria Locale CN2 Alba-Bra|No|Recruiting|September 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3600|||Both|11 Years|13 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|December 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02683811||2814|
NCT02689115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/02|NFKB1 and IKK Epsilon in Rheumatoid Arthritis|NF-KB1/IKK Epsilon Genetic Expression in Patients With Rheumatoid Arthritis|NUIRA|Asociación Científica Latina A.C.|No|Completed|November 2013|December 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|60|||Both|30 Years|65 Years|No|Probability Sample|The key inclusion criteria were patients with RA who met the criteria established by the        American College of Rheumatology (ACR). Two groups were conformed based on the Disease        Activity Score 28 (DAS28): a) with clinical activity (DAS28 > 3.6) and b) with clinical        remission (DAS28 < 2.4). Key exclusion criteria were patients with any other inflammatory,        autoimmune or neoplastic disease and patients with infections. The control group was        represented by healthy patients|February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02689115||2406|
NCT02684747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83533|Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling|Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling||University of Utah|Yes|Recruiting|January 2016|February 2018|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02684747||2742|
NCT02705924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRACAVENIR|Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk|Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women (18-30 Years) Exposed to a High Familial Breast/Ovarian Cancer Risk||Centre Jean Perrin|No|Not yet recruiting|March 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28|||Female|18 Years|30 Years|No|||March 2016|March 7, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705924||1117|
NCT02699866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR02/15|Implant Survival After Insertion of Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting|A Multi-Center, Prospective, Single Cohort, Post-Market Clinical Follow-Up (PMCF) Study to Assess Implant Survival After Insertion of Straumann® Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting||Institut Straumann AG|No|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699866||1583|
NCT02685163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rif: 3727, Prot: 2325/15|Natural Antioxidant Ice-cream, Oxidative Stress and Vascular Function|Natural Antioxidant Ice-cream Acutely Reduces Oxidative Stress, Improves Vascular Function and Physical Performance in Healthy Subjects||University of Roma La Sapienza|No|Completed|July 2015|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02685163||2710|
NCT02694770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015.011.01|A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD|A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation||AbGenomics B.V Taiwan Branch|Yes|Not yet recruiting|July 2016|February 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694770||1973|
NCT02695316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BernUAS|Barrier-free Communication in Maternity Care of Allophone Migrants|Barrier-free Communication in Maternity Care of Allophone Migrants (Barrierefreie Kommunikation in Der Geburtshilflichen Versorgung Allophoner Migrantinnen)|BRIDGE|Bern University of Applied Sciences|No|Recruiting|September 2015|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02695316||1932|
NCT02692716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-4221|A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes|A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes|PIONEER 6|Novo Nordisk A/S|No|Not yet recruiting|July 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|3176|||Both|50 Years|N/A|No|||February 2016|February 23, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692716||2131|
NCT02704585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/15|Comparison of Two Pulse Oximeters in Delivery Room|Comparison of Two Pulse Oximeters in Delivery Room: A Prospective Study||Shaare Zedek Medical Center|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|15 Minutes|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02704585||1220|
NCT02682979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-Therapeutic limitations|Continuity of the Therapeutic Limitation Code: Analysis of the Variables of Admission in the Emergency Service That Are Associated With a Therapeutic Limitation Upon Exit|Continuity of the Therapeutic Limitation Code: Analysis of the Variables of Admission in the Emergency Service That Are Associated With a Therapeutic Limitation Upon Exit||Brugmann University Hospital|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|75 Years|N/A|No|Non-Probability Sample|100 consecutive geriatric patients admitted in the emergency department of the Brugmann        Hospital, Horta site, from 01/04/2015 till 11/02/2016.|February 2016|February 16, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02682979||2878|
NCT02689362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF144|Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)|A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus|EVOLUTION|Eurofarma Laboratorios S.A.|Yes|Not yet recruiting|February 2017|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|144|||Both|20 Years|75 Years|No|||February 2016|February 18, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02689362||2387|
NCT02689557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01440-47|VEINEX : Venous Investigations During Exercise|VEINEX : Venous Investigations During Exercise|VEINEX|University Hospital, Angers|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 18, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02689557||2372|
NCT02686931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-0474A3|The Investigation of Children With Developmental Delay and Children's Rehabilitation Common Case|The Investigation of Children With Developmental Delay and Children's Rehabilitation Common Case: A Longitudinal Study||Chang Gung Memorial Hospital|Yes|Recruiting|January 2013|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|N/A|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control and experimental groups|February 2016|February 16, 2016|February 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02686931||2574|
NCT02703532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070957|Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke|Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke|CARE-CITE|Emory University|Yes|Recruiting|January 2016|||March 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703532||1301|
NCT02689661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINDS-NS079417|Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects|The Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects||University of Michigan|No|Recruiting|November 2010|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|Samples Without DNA|Plasma or serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include eligible patients who are currently enrolled in the        University of Michigan Investigational Weight Management Clinic as well as age and gender        matched lean controls.|February 2016|February 25, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02689661||2364|
NCT02682251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC15-0904 BTK|Engaging Patients in Heart Failure Management|Engaging Patients in Heart Failure Management||Parkview Health|No|Not yet recruiting|February 2016|February 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02682251||2934|
NCT02694432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15120045|Minding GOALS: An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control|An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control||University of Pittsburgh|No|Not yet recruiting|April 2016|March 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|21 Years|79 Years|No|||February 2016|February 23, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02694432||1999|
NCT02694445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-001|Monetary Cost of Alzheimer's Disease in China|Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study||Beijing Friendship Hospital|Yes|Recruiting|January 2016|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|2500|||Both|60 Years|N/A|No|Probability Sample|Patients with Alzhemer's disease and their caregivers.|January 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694445||1998|
NCT02700880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEARIT-III|LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry|Prospective Registry of Patients With Ischemic Heart Failure Using the LifeVest Wearable Cardioverter Defibrillator (WEARIT-III)|WEARIT-III|Zoll Medical Corporation|No|Recruiting|June 2014|||June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|In WEARIT-III, subjects with ischemic cardiomyopathy and heart failure (including NYHA II,        III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest        Wearable Cardioverter Defibrillator (WCD) and agree to enter the Registry after        appropriate informed consent will be enrolled.        It is anticipated that approximately 1000 patients with ischemic cardiomyopathy and heart        failure (≥18 years of age) will be enrolled in 2 years. No individuals shall be excluded        from participation in the Registry based on race, ethnicity or gender.|March 2016|March 11, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700880|12 Months|1505|
NCT02678767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-077|Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS|Ferumoxytol-enhanced Imaging and Quantitative Susceptibility Mapping in neuroAIDS||University of Hawaii|Yes|Recruiting|February 2015|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|30|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678767||3201|
NCT02689752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-013-00CH2|A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib|A Phase One Open-Label Single-Radiolabeled Dose Study to Investigate the Absorption, Metabolism, And Excretion Of [14C] Fruquintinib (HMPL-013) in Healthy Male Volunteers||Hutchison Medipharma Limited|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02689752||2357|
NCT02692222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B406201526827|Measurement of Pulse Pressure Variation and Cardiac Output by a New Application for Android™ (Captesia™)|Measurement of Pulse Pressure Variation (PPV) and Cardiac Output (CO) by a New Application for Android™ (Captesia™) : Comparison With PPV and CO Obtained by a Method of Transpulmonary Thermodilution.||Erasme University Hospital|No|Recruiting|February 2016|December 2016|Anticipated|March 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|57|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for coronary artery bypass or hepatectomy|March 2016|March 2, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02692222||2169|
NCT02682095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The PEQ-study|To Achieve Blood Pressure Control With Retained Quality of Life|Possibilities for Patients With Elevated Blood Pressure to Achieve Blood Pressure Control Without Affecting Quality of Life (the PEQ Study)||Lund University|No|Not yet recruiting|April 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|600|||Both|20 Years|N/A|No|Non-Probability Sample|To preserve that the population is representative for an area in southern Sweden, patients        are to be included consequtively through stratified sampling regarding age, gender and        treatment at health centre or medical clinic at a hospital as well as geographically.|February 2016|February 10, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682095||2946|
NCT02697461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18550|Multisegmented Foot Motion in Patients With Lateral Ankle Sprains and Chronic Ankle Instability|Multisegmented Foot Motion in Patients With Lateral Ankle Sprains and Chronic Ankle Instability||University of Virginia|No|Recruiting|January 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02697461||1768|
NCT02692768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 003420|The Effect of Music Therapy Intervention on Pain and Anxiety in Adult Patients Undergoing Total Shoulder Arthroplasty|The Effect of Music Therapy Intervention on Pain and Anxiety in Adult Patients Undergoing Total Shoulder Arthroplasty||Milton S. Hershey Medical Center|No|Not yet recruiting|March 2016|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692768||2127|
NCT02691949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10418-4|Efficacy and Safety of Mycophenolate Sodium in Subjects With Sjogren's Syndrome|Efficacy and Safety of Mycophenolate Sodium in Subjects With Sjogren's Syndrome||Kaohsiung Medical University|No|Not yet recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|81|||Both|20 Years|75 Years|No|||February 2016|February 24, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691949||2190|
NCT02691962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE-012|A Post-Market, Single-Arm Trial of XenMatrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias|A Post-Market, Prospective, Multicenter, Single-Arm Trial of XenMatrix™ AB Surgical Graft in All CDC Wound Class Ventral or Incisional Midline Hernias||C. R. Bard|No|Not yet recruiting|May 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691962||2189|
NCT02699554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44170-EB|Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy|Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy||University of Washington||Recruiting|September 2015|June 2020|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|||Both|6 Years|18 Years|No|Non-Probability Sample|Individuals with cerebral palsy, diplegia subtype, with mild or moderate impairment, Gross        Motor Function Classification System (GMFCS) Levels I-III, between the ages of 6 - 18.|March 2016|March 5, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02699554|1 Year|1607|
NCT02689453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160062|Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)|A Phase I Study Of Subcutaneous Recombinant Human IL-15 (s.c.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)||National Institutes of Health Clinical Center (CC)||Not yet recruiting|January 2016|January 2022|Anticipated|February 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|100 Years|No|||January 2016|February 26, 2016|February 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689453||2380|
NCT02689089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160044-01H|Taima TB: 3HP Study|Acceptability and Completion Rates of a New 12 Dose Treatment (3 Month) Compared to the Standard Treatment for Latent TB Infection Treatment||Ottawa Hospital Research Institute|Yes|Not yet recruiting|April 2016|September 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|350|||Both|2 Years|65 Years|No|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02689089||2408|
NCT02689102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 54612.018.15|Confocal Laser Endomicroscopy and Optical Coherence Tomography for Diagnosing ILD.|Confocal Laser Endomicroscopy and OCT for Diagnosing ILD, a Comparison With Imaging and Pathology.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of 18 years or older (n=20), who are suspected for ILD based on imaging        (HRCT-scan) and with an indication for bronchoscopy with cryobiopsy.|February 2016|February 18, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02689102||2407|
NCT02692040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/G3215/01|Study of the Gut Hormone Analogue G3215 in Adult Subjects|A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Gut Hormone Analogue G3215 in Adult Subjects||Imperial College London|Yes|Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|64|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|February 22, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02692040||2183|
NCT02692053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00834-45|Characterization of Hemostatic Disordres in Septic Shock: Searching for Biological Markers|Characterization of Hemostatic Disordres in Septic Shock: Searching for Biological Markers|COASEPT|Central Hospital, Nancy, France||Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02692053||2182|
NCT02682641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-IMCL-2015|Evaluation of the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL|Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Not yet recruiting|February 2016|January 2023|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|99 Years|No|||February 2016|February 17, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02682641||2904|
NCT02682654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18325|A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability|A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability||Bayer|No|Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|192|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682654||2903|
NCT02521103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76|Triathlon Tritanium Cone Augments Outcomes Study|A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon TS Total Knee System With Triathlon Tritanium Cone Augments||Stryker Orthopaedics|No|Recruiting|August 2015|June 2023|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|July 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02521103||15304|
NCT02695628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0055|[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer|Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT||Stanford University|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|19 Years|N/A|No|||February 2016|February 24, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695628||1909|
NCT02695641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007414|Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients|A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients||Mayo Clinic|No|Not yet recruiting|April 2016|November 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|85 Years|No|||February 2016|February 29, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695641||1908|
NCT02695095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00005|Acute Liver Injury in Patients on Dapagliflozin|Comparison of the Risk of Actual Liver Injury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments||AstraZeneca|No|Not yet recruiting|February 2016|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|91927|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are new users of dapagliflozin or the eligible comaprator drugs that meet the        inclusion criteria and none of teh exclusion criteria.        Comparator patients will be matched to the dapagliflozin patients by propensity score if        access to all eligible comparator subjects is feasible.|February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695095||1949|
NCT02683291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16966913.6.0000.5411|Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients|Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial||Associação Médico Espírita de Botucatu|Yes|Completed|January 2014|January 2016|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|60 Years|N/A|No|||February 2016|February 11, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02683291||2854|
NCT02693522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_CTP|Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency|Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency||Daewoong Pharmaceutical Co. LTD.|No|Completed|October 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02693522||2069|
NCT02693535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014171|TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer|Targeted Agent and Profiling Utilization Registry (TAPUR) Study|TAPUR|American Society of Clinical Oncology|Yes|Recruiting|March 2016|||March 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|730|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02693535||2068|
NCT02707107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-5222-101|MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Adult Human Subjects||Wockhardt|No|Recruiting|February 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707107||1027|
NCT02682472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0201|SettleIN - Adjustment to Care in Dementia: An Intervention Feasibility Study v0.1|SettleIN - An Adjustment to Care Intervention for People With Dementia: A Feasibility Pilot Study in Care Homes||University College, London|Yes|Recruiting|August 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|65 Years|N/A|No|||January 2016|February 10, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02682472||2917|
NCT02682719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBT-GCP-PTCL-01|ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation|Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (The PARABLE Study)|PARABLE|The Heartbeat Trust|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|40 Years|N/A|No|||February 2016|February 15, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682719||2898|
NCT02693444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15081703|Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears|Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears||Rush University Medical Center|No|Not yet recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02693444||2075|
NCT02693457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1541|Outcomes Following Suction Drain and Non-suction Drain Assisted Total Knee Arthroplasty|Outcomes Following Suction Drain and Non-suction Drain Assisted Total Knee Arthroplasty||Colorado Joint Replacement|No|Enrolling by invitation|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|70 Years|No|||February 2016|February 23, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693457||2074|
NCT02694302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT2013-PS-WB-01|Clinical Trial of Robot-assisted-gait-training (RAGT) in Stroke Patients|A Multi-center, Parallel and Randomized Design Clinical Trial of Robot-assisted-gait-training (RAGT) in Stroke Patients to Evaluate Its Efficacy, Safety and Superiority Over Conventional Gait Training|Walkbot|P&S Mechanics Co., Ltd.|No|Recruiting|March 2014|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|19 Years|80 Years|No|||March 2016|March 3, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694302||2009|
NCT02685202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-4598|Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea|The Course of Temporomandibular Pain in Response to Mandibular Advancement Therapy Among Adults With Temporomandibular Disorder and Obstructive Sleep Apnea||University of North Carolina, Chapel Hill|No|Not yet recruiting|March 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|30 Years|64 Years|No|||February 2016|February 18, 2016|February 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685202||2707|
NCT02693093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI03-001|A Dose Ranging Study Evaluating Efficacy and Safety of NI-03|A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis||Stason Pharmaceuticals, Inc.|No|Recruiting|December 2015|October 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693093||2102|
NCT02693106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-387|Evaluation of the Ketogenic Potential of Different Diet Supplements|Stimulating the Ketogenesis by Using Nutritional Supplements||Université de Sherbrooke|No|Completed|July 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693106||2101|
NCT02693119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPILH-201|A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy|A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study To Evaluate the Safety, Tolerability and Efficacy of MTP-131 Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy||Stealth BioTherapeutics Inc.|No|Not yet recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|50 Years|No|||February 2016|February 22, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693119||2100|
NCT02698813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-HA-1|Safety Study of Filler Agent Composed of Umbilical Cord Mesenchymal Stem Cells and Hyaluronic Acid|||South China Research Center for Stem Cell and Regenerative Medicine|Yes|Not yet recruiting|December 2016|||December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|March 3, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02698813||1664|
NCT02685475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1869|Axillary Block Properties in Diabetic Patients|Comparison of Ultrasound-Guided Axillary Brachial Plexus Block Properties in Diabetic and Non-diabetic Patients: A Prospective Observational Study||Istanbul University|No|Completed|February 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|||Both|40 Years|75 Years|No|Non-Probability Sample|Patients scheduled for elective forearm and/or hand surgery|March 2016|March 14, 2016|February 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685475||2686|
NCT02685540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190/14a/tk|Death Rate in Anesthesia: A Study in a Tertiary Hospital|Death Rate in Anesthesia: A Retrospective Study of Five Years Period From a Tertiary Hospital||University of Jordan|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|792|||Both|N/A|N/A|No|Non-Probability Sample|Patients who underwent anesthesia and surgery and died inside the hospital|February 2016|February 17, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685540||2681|
NCT02685553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLPAN|Use of Near Infrared Technology as a Guide in Laparoscopic Resection of Pancreatic Lesions: the COLPAN "Colour-and-resect" Project|Use of Near Infrared Technology as a Guide in Laparoscopic Resection of Pancreatic Lesions: the COLPAN "Colour-and-resect" Project||Universita di Verona||Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685553||2680|
NCT02701062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2015-2|AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)|AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)|ATLAS|AtriCure, Inc.|No|Recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02701062||1491|
NCT02689830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-112043|Prostate Embolization for Acute Urinary Retention Study|Prostate Embolization for Acute Urinary Retention Study (PARIS 1): An Open-label Prospective Study|PARIS1|ClinSearch|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|75 Years|No|||February 2016|February 23, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02689830||2351|
NCT02693067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-NET-01|A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver|A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products||Provectus Pharmaceuticals|No|Not yet recruiting|March 2016|April 2020|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693067||2104|
NCT02682550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTF_PT_2014|Danger Response in Polytrauma Patients|Analysis of the Danger Response After Polytrauma Based on the National Polytrauma-serum-bank of the Trauma Research Network (NTF) of the German Society for Orthopaedics and Trauma (DGOU)|NTF-PT|University of Ulm|Yes|Recruiting|September 2014|October 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|EDTA-Plasma and Serum (drawn from polytrauma patients with an injury severity score ≥25)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|polytrauma patients age ≥ 18 ISS ≥ 25        Exclusion: cardiopulmonary reanimation before admission, gravidity, no chemotherapy or        radiotherapy within the last 3 months, immune supressive drugs, hemodialysis, age < 18|February 2016|February 10, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02682550||2911|
NCT02710760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-3255|Translating Adoption of Improved Varieties Into Nutritional Impact|Translating Adoption of Improved Varieties Into Nutritional Impact for Young Children: An RCT Exploring Strategies to Increase Consumption of Quality Protein Maize in Ethiopia|QPM|Harvard School of Public Health|No|Active, not recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|978|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02710760||746|
NCT02685995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823055|VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC|Randomized Trial Comparing VectorFlow Tunneled Dialysis Catheter to Palindrome Tunneled Dialysis Catheter|TDC|University of Pennsylvania|Yes|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685995||2646|
NCT02691650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Burns and Trauma POC ChE Study|Point of Care Testing of Cholinesterase Activity During Burn- and Polytrauma|Point of Care Testing of Cholinesterase Activity During Burn- and Polytrauma|POCCET|University Hospital Heidelberg|No|Recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|A miniature amount (10 μl) of whole blood is needed for the serum cholinesterase activity      analysis. This blood specimen will be taken from otherwise routine blood gas analysis      collection, taken upon arrival into the emergency room, as a part of the standardized ICU      diagnostic and therapeutic procedure. The serum cholinesterase activity analysis, therefore,      doesn't require additional blood collection.|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the emergency unit of the trauma and burns center|February 2016|February 20, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02691650||2213|
NCT02691663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WakeForest_Petrovic|Dietary Acid Load, Kidney Function and Disability in Elderly|Dietary Acid Load, Kidney Function and Disability in Elderly||Wake Forest School of Medicine|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|69 Years|89 Years|No|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691663||2212|
NCT02691728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN_US-337-1748|Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease|A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease||Peter J. Ruane, M.D., Inc.|No|Not yet recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691728||2207|
NCT02691741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILH297-P003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||February 22, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691741||2206|
NCT02704871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXP 04-01b|The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS|To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS||Immunexpress|No|Recruiting|June 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood and plasma specimens for nucleic acid and protein analysis|Both|18 Years|89 Years|No|Non-Probability Sample|Adults aged 18 years or older, previously admitted to medical and/or surgical general        hospital wards, who are suspected of sepsis as identified by an in-hospital early-warning        screening tool.|March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02704871||1198|
NCT02679274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0176|Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents|Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents||The University of Texas Medical Branch, Galveston|No|Recruiting|December 2015|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|February 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02679274||3162|
NCT02691507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO - 151102105611 - SACT|Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema|A Clinical Trial to Determine the Therapeutic Benefit of an Investigational Over-The-Counter Cream on Dry, Itchy Skin of Adults and Children With Atopic Dermatitis.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Recruiting|February 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691507||2224|
NCT02687438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO III|The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery|The PIO III Study: In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery||ENT and Allergy Associates, LLP|No|Recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687438||2535|
NCT02704988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMV-CRC1|Clinical Trial Comparing Carnoy's and GEWF Solutions|Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer||Hospital Moinhos de Vento|Yes|Recruiting|March 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|126|||Both|18 Years|N/A|No|||February 2016|March 6, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02704988||1189|
NCT02680535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-PC-002|MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue|A Study of MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue||Nanospectra Biosciences, Inc.|Yes|Recruiting|February 2016|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Male|45 Years|N/A|No|||February 2016|February 23, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680535||3066|
NCT02680886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-1505|PMCF-study Using Novosyn® Quick Suture Material for Skin Closure|Post-Marketing Clinical Follow-up (PMCF) Study for Skin Closure to Evaluate the Safety and Efficacy of Novosyn® Quick Suture Material. A Multicenter, International, Prospective, Observational Study|SKINNOQ|Aesculap AG|No|Recruiting|February 2016|August 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|1 Year|N/A|No|Non-Probability Sample|children and adults|March 2016|March 1, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02680886||3039|
NCT02687906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rempex 507|Dose-finding, Pharmacokinetics, Safety, and Tolerability of Meropenem-Vaborbactam in Pediatric Subjects With Serious Bacterial Infections|An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of Meropenem-Vaborbactam in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|Yes|Not yet recruiting|May 2016|September 2019|Anticipated|August 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|N/A|17 Years|No|||March 2016|March 10, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687906||2499|
NCT02692924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916071|Fetal Body Composition and Volumes Study|Fetal Body Composition and Volumes Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2016|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|2973|||Female|N/A|N/A|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692924||2115|
NCT02707510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043233|A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer|||Cedars-Sinai Medical Center|No|Not yet recruiting|April 2016|April 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707510||996|
NCT02707640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29976|A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone||Hoffmann-La Roche||Completed|August 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|123|||Both|40 Years|80 Years|No|||March 2016|March 9, 2016|March 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707640||986|
NCT02692950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008704|Patient Perception of Video Advance Care Planning|Perceptions of Advance Directive Formats-A Pilot Study||Mayo Clinic|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692950||2113|
NCT02679885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERI001|Teriflunomide Male Transmission Study|Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners||Griffin Hospital|No|Recruiting|October 2015|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples Without DNA|Serum samples|Both|18 Years|55 Years|No|Non-Probability Sample|Participants in this study will include approximately twenty heterosexual couples. The        male partner will be a subject who has been taking teriflunomide as part of his multiple        sclerosis treatment for at least three months and engaging in active sexual relations with        his female spouse or partner.|February 2016|February 5, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679885||3116|
NCT02697968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 15-458|Electroacupuncture for Relieving Pain in Ankylosing Spondylitis|Electroacupuncture for Relieving Pain in Ankylosing Spondylitis: a Single-arm Pilot Study||The University of Hong Kong||Not yet recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||February 2016|February 28, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697968||1729|
NCT02697981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309-15 - RBM|Effect of Personalized Nutrition Counseling in Pregnant Women After Bariatric Surgery on Nutritional Status and Habits|The Effect of Personalized Tailored Nutrition Counseling in Pregnant Women After Bariatric Surgery on Compliance and Nutritional Habits||Rambam Health Care Campus|No|Not yet recruiting|April 2016|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02697981||1728|
NCT02681146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMA|A Stepped-wedge Cluster Randomized Controlled Trial for Evaluating an Intervention in Patients With Stroke Tailored Education in Addition to Physiotherapist Treatment|||University of Malaga|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|320|||Both|18 Years|70 Years|No|||November 2015|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681146||3019|
NCT02689128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269/14a/tk|Postoperative Nausea and Vomiting: to Estimate the Incidence and Risk Factors in a Tertiary Teaching Hospital|Postoperative Nausea and Vomiting: A Prospective Observational Study to Estimate the Incidence and Risk Factors Over One Year in a Tertiary Teaching Hospital||University of Jordan|No|Recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|Patients who undergoes anesthesia and surgery and suffer from postoperative nausea and        vomiting for 24 hours|February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02689128||2405|
NCT02692638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512016944|Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO|Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction||Yale University|No|Not yet recruiting|March 2016|August 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02692638||2137|
NCT02704338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJLT002|Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis|Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis|Treg|Nanjing Medical University|Yes|Not yet recruiting|April 2016|October 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|70 Years|No|||March 2016|March 4, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02704338||1239|
NCT02689479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-09|11C-5-HTP PET in Clinical Islet Transplantation|Evaluation of the Use of 11C-5-HTP PET to Calculate βCell Mass in Clinical Islet Transplantation (DAIT CIT-09)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|N/A|N/A|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02689479||2378|
NCT02692417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00101713|Surface Stimulation for Female Sexual Dysfunction|Surface Stimulation for Female Sexual Dysfunction||University of Michigan|Yes|Recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692417||2154|
NCT02694276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF pilot ICBT 2015|Internet-based Cognitive Behavior Therapy for Atrial Fibrillation|Internet-based Cognitive Behavior Therapy for Atrial Fibrillation||Karolinska Institutet|No|Recruiting|December 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02694276||2011|
NCT02707211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer-Prevenar13-2015|Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases|Immunization Against oxLDL in Patients With Lysosomal Lipid Diseases and Associated Metabolic Disorders||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|June 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|64 Years|No|||March 2016|March 14, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02707211||1019|
NCT02707224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR208-I-02|Clinical Trial to Compare the Pharmacokinetics of DP-R208|A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R208 (Candesartan Cilexetil and Rosuvastatin Calcium Fixed Dose Combinations) in Comparison to Each Component Administered Alone in Healthy Male Volunteers||Alvogen Korea|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707224||1018|
NCT02687659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A00444-43|TEMIS: a Pilot Study to Evaluate a Device to Characterize Ambulatory Physical Activity|TEMIS: a Pilot Study to Evaluate a Device to Characterize Ambulatory Physical Activity|TEMIS|University Hospital, Angers|Yes|Completed|May 2014|January 2015|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 31, 2014||No||No||https://clinicaltrials.gov/show/NCT02687659||2518|
NCT02692092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 12 007R|HealthEast Community Hip and Knee Replacement Registry|HealthEast Community Hip and Knee Replacement Registry|HEJR|HealthEast Care System|No|Recruiting|September 1991|August 2091|Anticipated|August 2091|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients having total hip or knee arthroplasty at a HealthEast acute care hospital.|February 2016|February 24, 2016|January 29, 2014||No||No||https://clinicaltrials.gov/show/NCT02692092|40 Years|2179|
NCT02706249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-547|Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients|A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients||Dana-Farber Cancer Institute|Yes|Not yet recruiting|April 2016|October 2023|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706249||1092|
NCT02706262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSQ-201512086|Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health|Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health||Washington University School of Medicine|Yes|Recruiting|February 2016|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|7||Anticipated|160|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02706262||1091|
NCT02694926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nationales Schulungsprogramm|National Education Programme for Patients With Chronic Adrenal Insufficiency|National (German-wide) Education Programme for Patients With Chronic Adrenal Insufficiency||Wuerzburg University Hospital|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02694926||1961|
NCT02686580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510144|Feasibility Study to Assess the Early Use of Porcine Cross-linked Collagen Paste in Cryptoglandular Anorectal Fistulas|Feasibility Study to Assess the Early Use of Porcine Cross-linked Collagen Paste in Cryptoglandular Anorectal Fistulas|FIX-IT1|Royal Devon and Exeter NHS Foundation Trust|No|Not yet recruiting|February 2016|December 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 1, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02686580||2601|
NCT02682615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A138-15|Non-invasive Cardiac Output Monitoring (esCCO™) in Critically Ill Patients Within ICU|Cardiac Output Monitoring System (esCCO™) in Comparison to Transcardiopulmonal Thermodilution Technique (PiCCO®) in Critically Ill Patients Within Interdisciplinary Surgical Intensive Care Units||University of Schleswig-Holstein|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The aim of this study is the estimation of the agreement between esCCO™ and the        transcardiopulmonal thermodilution technique (PiCCO®) using Bland-Altman-treatment. The        95%-confidence interval of the limits of agreement was selected for the design of the        number of cases. At a number of cases by 100 you will get the width of 0,68 s (s: standard        deviation of the differences of the measurement techniques). This is reasonable for the        question (Bland and Altman 1986, you have to compare the recommendation of Bland:        https://www.users.york.ac.uk/~mb55/meas/sizemeth.htm).|February 2016|February 12, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02682615||2906|
NCT02687204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86052|Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients|Optimization of Enoxaparin Prophylaxis Using Real-time Anti-Factor Xa Levels in Major Reconstructive Surgery Patients||University of Utah|Yes|Recruiting|February 2016|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687204||2553|
NCT02705014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-997|Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome|Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome||Peking Union Medical College Hospital|Yes|Recruiting|January 2016|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|50 Years|No|||March 2016|March 6, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02705014||1187|
NCT02705079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4440-12|Values of Enhanced Monitoring by EEG Recording (Narcotrend) for Sedation in Endoscopic Ultrasound|Values of Enhanced Monitoring by EEG Recording ( Narcotrend ) as an Adjunct to Standard Monitoring for Sedation in Endoscopic Ultrasonography||Ruhr University of Bochum|No|Recruiting|August 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|Included are patients which is a , diagnostic or interventional endoscopic ultrasound        under sedation with propofol.|February 2016|March 9, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02705079||1182|
NCT02683512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00060753|Glycogen Storage Disease Type IV Database|Database for Information on Individuals Affected With Glycogen Brancher Deficiency, Also Known as Glycogen Storage Disease Type IV|GSDIVDB|Duke University|No|Recruiting|December 2015|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|All patients with GSD-IV regardless of age, gender or ethnicity, are eligible for the        database.|December 2015|February 16, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02683512|10 Years|2837|
NCT02680704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-P-000089|Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure|Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure||Beth Israel Deaconess Medical Center|Yes|Not yet recruiting|February 2016|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680704||3053|
NCT02680717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|730382-2|Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea|Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea||Medical College of Wisconsin|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|2 Years|18 Years|No|||February 2016|February 10, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680717||3052|
NCT02703506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OE22/2015|Effectiveness of a Pain Education Program on Chronic Neck Pain Patients|Effectiveness of a Pain Education Program on Chronic Neck Pain Patients||University of Alcala|Yes|Enrolling by invitation|March 2016|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||March 2016|March 3, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02703506||1303|
NCT02700906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20130713R|Corticosteroid and Lidocain Injections for Tennis Elbow|Corticosteroid and Lidocain Injections for Tennis Elbow||Shin Kong Wu Ho-Su Memorial Hospital|No|Completed|January 2014|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|75 Years|No|||March 2016|March 1, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700906||1503|
NCT02701127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016P000028|Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury|||Beth Israel Deaconess Medical Center|No|Not yet recruiting|March 2016|||April 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02701127||1486|
NCT02679781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0678-15-HMO-CTIL|Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care|Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care||Hadassah Medical Organization|No|Not yet recruiting|February 2016|December 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||January 2016|February 7, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02679781||3124|
NCT02692872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160065|Screening for Alpha Thalassemia in Healthy Volunteers|Screening for Alpha Globin Deletions in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Not yet recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|N/A|||Anticipated|2000|||Both|18 Years|40 Years|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692872||2119|
NCT02703519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHalle|Optimization of the Healing Process of the Uterine Scar Tissue After Re-cesarean Section|Optimierung Der Uterotomie-Wundheilung Nach Re-Sectio Caesarea||Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|November 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02703519||1302|
NCT02694679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Christakis09302015|Randomized Controlled Trial of Social Network Targeting in Honduras|Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras||Yale University|No|Recruiting|June 2015|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|16||Anticipated|30000|||Both|12 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694679||1980|
NCT02694692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017737|Trial of Repeated Analgesia With Kangaroo Care - 18 Month Follow-up|Trial of Repeated Analgesia With Kangaroo Care - 18 Month Follow-up|TRAKC18|IWK Health Centre|No|Recruiting|January 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|159|||Both|2 Months|20 Months|No|Non-Probability Sample|Eligible parents of TRAKC infants who have provided consent will be invited back to an IWK        clinic for follow-up visits at a convenient date within +/- 2 weeks of 2, 6, 12 and 18        month CA for their vaccinations as well as at 18 month corrected age for a Bayley Scales        of Infant Development (BSID-III).|February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694692||1979|
NCT02693587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50213|Misodel or Angusta for Induction of Labour?|Misodel or Angusta for Induction of Labour? - a Medical Health Technology Assessment||Holbaek Sygehus|Yes|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|420|||Female|18 Years|50 Years|No|Non-Probability Sample|Nulliparous women to term with immature cervix|February 2016|March 2, 2016|November 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02693587|1 Week|2064|
NCT02692911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916070|Chile Biliary Longitudinal Study|Chile Biliary Longitudinal Study||National Institutes of Health Clinical Center (CC)||Not yet recruiting|February 2016|January 2026|Anticipated|January 2024|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|35000|||Female|50 Years|74 Years|No|||January 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692911||2116|
NCT02704026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15H0230004|Nutritional Status and Body Composition in Childhood Inflammatory Bowel Disease|Nutritional Status and Body Composition in Children With Inflammatory Bowel Disease: A Prospective Cohort Study||Ankara University|No|Recruiting|July 2015|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with IBD at any stage of disease activity, on any or no treatment and age- and        sex-matched healthy controls|February 2016|March 4, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02704026||1263|
NCT02523482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLRI - PIP in LTC|Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) Patients|Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) Patients: Validation of the 2014 STOPP-START and 2012 Beers Criteria in a LTC Population|PIP in LTC|Bruyere Research Institute|Yes|Recruiting|June 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|275|||Both|66 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All consenting residents, of both genders, newly admitted to LTC or convalescent or        respite care at the participating care facilities.|August 2015|August 12, 2015|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02523482||15121|
NCT02700100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEL-CR-01|Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction|Prospective, Non-randomised, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction||Xeltis AG|Yes|Not yet recruiting|June 2016|April 2022|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|21 Years|No|||February 2016|March 1, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02700100||1565|
NCT02700113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3646E|Investigating Phenotypic Profiles of Children and Adolescents With ASD|Investigating Phenotypic Profiles of Minimally Verbal Children and Adolescents With ASD/Profiles of Abilities in Children and Adolescents With ASD|Phenotyping|Boston University|Yes|Recruiting|November 2014|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|4 Years|18 Years|No|Non-Probability Sample|Community sample|March 2016|March 4, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02700113||1564|
NCT02682199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1540|Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation|Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|October 2015|April 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing whole brain radiation treatment at Lineberger Comprehensive cancer        Center.|February 2016|February 12, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02682199||2938|
NCT02689141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2-BIO|Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)|Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients||German CLL Study Group|No|Recruiting|January 2016|October 2021|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02689141||2404|
NCT02689154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLA-16-00007|W8Loss2Go: mHealth Weight Management Strategy|W8Loss2Go: Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Pediatric Patients Referred to a Tertiary Care Center Weight Management Clinic||Children's Hospital Los Angeles|No|Not yet recruiting|February 2016|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|18 Years|No|||February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02689154||2403|
NCT02678897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS277/03/2015|Pain and Medical Abortion Among Teenaged Women Compared to Adult Women|Pain and Medical Abortion - Predicting Factors of Pain and Optimal Pain Management Among Teenaged Women Compared to Adult Women||Helsinki University Central Hospital|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Female|15 Years|35 Years|No|||February 2016|February 5, 2016|December 16, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678897||3191|
NCT02696421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IREC 022|Ramadan and Energy Expenditure Study|Ramadan and Energy (RAMEE) Study|RAMEE|Imperial College London Diabetes Centre||Active, not recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Up to 50 healthy non-obese (BMI: 20-30) subjects (age: 18-70) will be recruited. We will        aim for equal representation of men and women.        Physically and mentally healthy. Consent form signed.|February 2016|February 25, 2016|June 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02696421||1848|
NCT02696642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18327|Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment|An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment||Bayer|No|Not yet recruiting|March 2016|February 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696642||1831|
NCT02687074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|/HFNC study|Effects of HFNC on Moderate and Severe Respiratory Failure Patients|Effects of High Flow Nasal Canula on Moderate and Severe Respiratory Failure Patients||Southeast University, China|Yes|Enrolling by invitation|January 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|246|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02687074||2563|
NCT02695290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.208|Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)|An Open-label, Single-arm Phase IV Study of Afatinib in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Who Have Poor Performance Status and Whose Tumors Have the Common Epidermal Growth Factor Receptor (EGFR) Mutations, Exon 19 Deletions or Exon 21(L858R) Substitution Mutations||Boehringer Ingelheim||Recruiting|March 2016|October 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 25, 2016||||No||https://clinicaltrials.gov/show/NCT02695290||1934|
NCT02691689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S57936|Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions|Prospective, Monocentric Pilot Study for the Identification of Known or Novel Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions||Universitaire Ziekenhuizen Leuven||Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691689||2210|
NCT02691702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B8001002|Multiple Dose Study Of PF-05251749 In Healthy Volunteers|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects||Pfizer|No|Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|84|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691702||2209|
NCT02691715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168|Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding|||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Recruiting|January 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Female|35 Years|80 Years|Accepts Healthy Volunteers|||January 2016|February 20, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02691715||2208|
NCT02695082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00004|Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications|Comparison of the Risk of Acute Kidney Inury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments||AstraZeneca|No|Not yet recruiting|February 2016|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|91927|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be eligible for inclusion in this study if they are newly prescribed        dapagliflozin and meet all inclusion criteria and no exclusion criteria.For each        dapagliflozin user up to four controls will be matched. Patients with a history of        diabetic nephropathy will be included, and this history will be accounted for in the        analysis.|February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695082||1950|
NCT02681887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002524|Effect of Melatonin on Cardiometabolic Risk- FULL|Effect of Melatonin on Cardiometabolic Risk- FULL||Brigham and Women's Hospital|Yes|Not yet recruiting|June 2016|||June 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02681887||2962|
NCT02689687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|824067|Automated Hovering for Congestive Heart Failure Patients: A Pilot Study|Automated Hovering to Improve Medication Adherence and Weight Management Among Congestive Heart Failure Patients: A Pilot Study||University of Pennsylvania|No|Not yet recruiting|February 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02689687||2362|
NCT02682563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC 2015 RED 01|Renoprotective Effects of Dapagliflozin in Type 2 Diabetes|A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus|RED|VU University Medical Center|No|Recruiting|February 2016|May 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|35 Years|75 Years|No|||February 2016|February 10, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682563||2910|
NCT02682576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-1601|Brachial Artery Ultrasound Imaging: A Repeatability Study|Brachial Artery Ultrasound Imaging: A Repeatability Study||Everist Genomics, Inc|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682576||2909|
NCT02704520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR4326|Magnetic Resonance Tumour Regression Grade as Biomarker for Stratified Management of Rectal Cancer Patients|Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Imaging Biomarker to Stratify Management of Good and Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial|TRIGGER|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2016|December 2021|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02704520||1225|
NCT02704533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAVACHE|Sequential Optimization of Dose and Schedule of PfSPZ Vaccine|Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany||Sanaria Inc.|No|Not yet recruiting|March 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|13||Anticipated|63|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704533||1224|
NCT02691546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRCA_01_2016|Screening for Chronic Kidney Disease (CKD) Among Older People Across Europe (SCOPE)|Screening for Chronic Kidney Disease (CKD) Among Older People Across Europe (SCOPE)|SCOPE|Istituto Nazionale di Ricovero e Cura per Anziani|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2450|Samples With DNA|plasma, serum, whole blood|Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|subjects with 75 years or older|February 2016|February 20, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02691546||2221|
NCT02691559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies|The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies||Kanuni Sultan Suleyman Training and Research Hospital||Recruiting|August 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|5 Minutes|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02691559||2220|
NCT02704832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB 2015-08|Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)|Role of Geriatric Intervention in Treatment of Older Patients With Cancer : a Phase III Randomized Study (PREPARE)|PREPARE|Institut Bergonié|Yes|Not yet recruiting|March 2016|February 2021|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1500|||Both|70 Years|N/A|No|||March 2016|March 18, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02704832||1201|
NCT02678715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC089/15|Effectiveness of Three Oral Devices as Mouthguard in Electroconvulsive Therapy. Randomized Crossover Clinical Trial.|Effectiveness of Three Oral Devices as Mouthguard in Electroconvulsive Therapy.||University of Barcelona|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|6|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02678715||3205|
NCT02687425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML-201602|Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia|Phase 2 Study to Assess the Safety and Efficiency of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Phase Chronic Myelogenous Leukemia Patients|SESPI|Tongji Hospital|No|Not yet recruiting|February 2016|June 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02687425||2536|
NCT02695121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00007|Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment|Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments||AstraZeneca|No|Not yet recruiting|February 2016|April 2024|Anticipated|April 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|99999|||Both|N/A|N/A|No|Non-Probability Sample|Eligible patients must meet all of the inclusion criteria and none of the exclusion        criteria. Comparator patients will be randomly selected in a 4:1 ratio to the        dapagliflozin patients.|February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695121||1947|
NCT02690168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-019|Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy||GLIMpSE|Pennington Biomedical Research Center|No|Not yet recruiting|February 2016|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Blood banking|Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Men|February 2016|February 18, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02690168||2325|
NCT02690181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205421|Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.|A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.||GlaxoSmithKline||Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|220|||Female|22 Years|46 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02690181||2324|
NCT02678858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISST2015|Efficacy of ISST in Schizophrenia|Efficacy of "Integrated Social Cognitive and Behavioral Skills Therapy" (ISST) in Improving Functional Outcome in Schizophrenia||Heinrich-Heine University, Duesseldorf|Yes|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02678858||3194|
NCT02706964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500683|Imaging the Patterns of Breast Cancer Early Metastases|Imaging the Patterns of Breast Cancer Early Metastases|BCMetPats|University of Florida|No|Not yet recruiting|March 2016|March 2021|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Female|18 Years|110 Years|No|||March 2016|March 10, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02706964||1038|
NCT02682940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VG2HT1US1|T1 Diabetes Hypoglycemia Prevention Pilot|Type I Diabetes Hypoglycemia Prevention Pilot Study||InSpark Technologies, Inc.|No|Not yet recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|11 Years|74 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02682940||2881|
NCT02687828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-760|A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients|A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients|AMORE|AbbVie||Recruiting|February 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|19 Years|99 Years|No|Probability Sample|Intestinal Behcet's disease (BD) patients who are eligible to be prescribed adalimumab by        the treating investigator as per Korean label will be enrolled.|February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687828||2505|
NCT02682771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMetodistaPiracicaba|Positive Airway Pressure Versus Breathing Exercises With Load Inspiratory in Patients Undergoing Bariatric Surgery|Effects of Positive Airway Pressure and Incentive With Load Inspiratory on Lung Function and Respiratory Muscle in Post-bariatric Surgery - a Randomized and Blind Clinical Trial||Universidade Metodista de Piracicaba|Yes|Completed|November 2014|December 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 13, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02682771||2894|
NCT02682784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO39699|Neural Substrates of Emotion: Impact of Cocaine Dependence|Neural Substrates of Emotion: Impact of Cocaine Dependence||Medical University of South Carolina|No|Recruiting|July 2015|July 2020|Anticipated|July 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682784||2893|
NCT02692885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160068|Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism|The Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2016|September 2025|Anticipated|October 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692885||2118|
NCT02707367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH100712-03|Recovery Roadmap Phase II Small Business Innovation Research Grant|Recovery Roadmap Phase II: A Collaborative Multimedia Tool for Person-Centered Recovery Planning||Center for Social Innovation, Massachusetts|Yes|Not yet recruiting|April 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02707367||1007|
NCT02688725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5617S-14|Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients|Post-Mastectomy Surveillance to Detect Locally Recurrent Breast Cancer||Providence Health & Services|Yes|Recruiting|December 2014|January 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02688725||2436|
NCT02694328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK3831-A303|A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)|A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia||Alkermes, Inc.|No|Recruiting|February 2016|March 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|55 Years|No|||March 2016|March 7, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694328||2007|
NCT02694341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB|Bakri Balloon in Placenta Previa|Bakri Ballon With or Without Abdominal Traction Stitch in Management of Uterine Bleeding in Cases of Placenta Previa|BB-ATS|Assiut University|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Female|N/A|N/A|No|||February 2016|February 26, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694341||2006|
NCT02679170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081057|Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)|Prospective Observational Study To Identify Patients With Advanced/Metastatic NSCLC And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)||Pfizer||Not yet recruiting|March 2016|November 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1|||Both|19 Years|N/A|No|Non-Probability Sample|NSCLS Patients, ALK + Confirmed|March 2016|March 2, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02679170||3170|
NCT02683642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FungalISF|Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome|Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome||Fungal Infection Study Forum|No|Not yet recruiting|April 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|15 ICU are identified across the country where ICU physicians are well versed about        invasive fungal infections and competent diagnostic mycology laboratory is available        A site feasibility survey was conducted. This ensured that participating sites fulfill the        following inclusion criteria: a) maintains ICD coding and total number of discharges and        deaths at the center; b) manages critically ill patients in ICU; c) has access to        high-resolution CT (HRCT) scans; d) has a mycology laboratory that performs isolation and        identification of fungi at least perform galactomannan test; and e) has histopathology        facilities.        All consecutive patients with proven and probable IMI in ICUs at the study centers during        the study period will be included.|February 2016|February 17, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02683642||2827|
NCT02697682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-SVF-pilot|Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study|Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study||Hvidovre University Hospital|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02697682||1751|
NCT02697695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF 145/2015|Chronic Inflammation After Obesity Surgery|Impact of Obesity and Metabolic Surgery on Chronic Inflammation||Sana Klinikum Offenbach|No|Completed|October 2014|February 2016|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|500|||Both|18 Years|65 Years|No|Probability Sample|Patients who underwent LSG, LRYGB, LOLGB due to obesity and/or metabolic syndrome|February 2016|March 2, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02697695||1750|
NCT02702531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01421-48|Prospective, Randomized Comparison of the Use of FloShield Air System ® Versus the Referenced Technic (Water + Povidone-Iodine Solution) During Gynecologic Endoscopic Surgery to Evaluate the Operative Lens Vision Quality|Prospective, Randomized Comparison of the Use of FloShield Air System ® Versus the Referenced Technic (Water + Povidone-Iodine Solution) During Gynecologic Endoscopic Surgery to Evaluate the Operative Lens Vision Quality||Tenon Hospital, Paris||Recruiting|March 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702531||1378|
NCT02684851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-12-06B|The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery|The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery|TXA|Carolinas Healthcare System|Yes|Recruiting|October 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02684851||2734|
NCT02678533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P130103|Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor|Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy|FancoMob|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|May 2019|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|4 Years|17 Years|No|||February 2016|February 8, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678533||3219|
NCT02678819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMMAX UCBL|Use of a Wearable Digital Cognitive Aid in Simulated Anesthesia and Intensive Care Crises.|Use of a Wearable Digital Cognitive Aid in Simulated Anesthesia and Intensive Care Crises.|SIMMAX|Claude Bernard University|No|Recruiting|July 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||February 2016|February 5, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678819||3197|
NCT02684201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15010131|Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees|Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees|PhantomLimb|University of Pittsburgh|Yes|Recruiting|November 2015|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|November 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02684201||2784|
NCT02702024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIforPP|The Effectiveness of Double Incision Technique in Uterus Preserving Surgery for Placenta Percreta|||Kanuni Sultan Suleyman Training and Research Hospital||Completed|January 2014|||January 2016|Actual|N/A|Interventional|N/A|||||||Female|18 Years|45 Years||||March 2016|March 2, 2016|February 26, 2016||||No||https://clinicaltrials.gov/show/NCT02702024||1417|
NCT02705170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260480|IMR Assessment in Patients With New Diagnosis of Left Ventricle Dilatation|Index of Microcirculatory Resistance (IMR) Assessment in Patients With New Diagnosis of Left Ventricular Dilatation Without Significant Coronary Artery Lesions: IMPAIRED Pilot Trial|IMPAIRED|University Hospital of Ferrara|Yes|Recruiting|March 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing coronary artery angiography for new diagnosis of left ventricular        dilatation (dilatative cardiomyopathy)|March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02705170||1175|
NCT02685150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015-086-02|Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease|The Role of Endoscopic Tri-Modal Imaging in Distinguishing Functional Dyspepsia From Reflux Disease||Chinese PLA General Hospital|Yes|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685150||2711|
NCT02691585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSRamaiahMC|Indian Ragas on Health - a Electrophysiological Study|Assessment of the Effect of Various Ragas of Indian Music on Electrophysiological Parameters and Salivary Stress Markers - a Randomized Control Trial||MS Ramaiah Medical College & Hospitals|Yes|Not yet recruiting|February 2016|March 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|140|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 20, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02691585||2218|
NCT02681211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0827|Auricular Acupuncture vs SOC in Migraine HA|A Randomized Trial Comparing Auricular Acupuncture and Intravenous Migraine Medications in the Treatment of Status Migrainosus in the Pediatric Emergency Department|MigAcu|University of Louisville|No|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|8 Years|18 Years|No|||February 2016|February 11, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02681211||3014|
NCT02694211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/2200-31/5|Stress Prevention at Work: Intervention Efficacy and Implementation Process Evaluation|Stress Prevention at Work: Intervention Efficacy and Implementation Process Evaluation (SPA)|SPA|Karolinska Institutet|No|Completed|May 2013|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|67 Years|No|||February 2016|February 23, 2016|September 30, 2014||No||No||https://clinicaltrials.gov/show/NCT02694211||2016|
NCT02707120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI-011-EC/15/QUER|Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis|Randomized, Parallel Groups, Multicenter and Blind to Evaluators Clinical Trial, to Evaluate the Efficacy and Safety of PRGF-Endoret Eye Drops, in Patients With Stage 2 and 3 Neurotrophic Keratitis||Biotechnology Institute IMASD|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02707120||1026|
NCT02707133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nevus Protocol v1.0|Validation of a Virtual Model of Service Delivery for Choroidal Nevi|Validation of a Virtual Clinic for Choroidal Nevomelanocytic Lesions: Safety, Patient Acceptability and Health Economics Analysis||Central Manchester University Hospitals NHS Foundation Trust|Yes|Not yet recruiting|April 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under the care of MREH and MEH for ocular nevomelanocytic lesions (CNL) will be        recruited prospectively into the study.|March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707133||1025|
NCT02692755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1396|Palbociclib / Letrozole in African American Women With HR + HER2- Br ca|Phase II Safety Study of Palbociclib in Combination With Letrozole in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer|PALINA|Georgetown University|Yes|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692755||2128|
NCT02682069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-001|Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds|A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X(TM) Imaging Device to Predict the Presence of Bacteria in Chronic Wounds||MolecuLight Inc.|No|Enrolling by invitation|February 2016|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682069||2948|
NCT02682082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 15.246|EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer|A Randomize Double-Blind Control Trial Study Comparing Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis W/Wo Bupivacaine In Patient Being Treated Palliatively For Pancreatic Cancer|EUS-CPN|Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|84|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682082||2947|
NCT02696668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KingsCL|Advances in Group-based Falls Rehabilitation|The Effect of a Modified FaME vs. a Multisensory Group Balance Programme on Falls Risk, Balance Confidence and Quality of Life in Older Adult Who Fall or Are at Risk of Falling||King's College London|Yes|Not yet recruiting|April 2016|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696668||1829|
NCT02693951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LCF-2016|Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices|Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Recruiting|February 2016|September 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02693951||2036|
NCT02694640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042015|Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors|Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors||University of South Carolina|No|Recruiting|December 2015|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02694640||1983|
NCT02694653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3890|Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control|Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control: A Blinded Randomized Placebo-Controlled Trial||University of Tennessee Graduate School of Medicine|Yes|Enrolling by invitation|October 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02694653||1982|
NCT02694666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514810|Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis|Effects of Controlled Whole-body Vibration Training on Preventing Falls Among Healthy Population and Ambulatory People With Multiple Sclerosis||University of Texas, El Paso||Recruiting|April 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02694666||1981|
NCT02710110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501172|Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)|The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS)||University of Florida|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|85 Years|No|||March 2016|March 10, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710110||796|
NCT02681445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00088349|Non-invasive TB Triage and Patient Mapping Platform Using Breath Via Low-Cost Titanium Dioxide Nanotube Sensor|||University of Utah|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1250|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study type: Observational feasibility study          -  Study population: Non-pregnant adults over the age of 18 from the areas around             Mumbai, India. Based upon records of these clinical sites, about 5% to 7% of the             patients reporting at these hospitals are suspected to be TB positive.          -  Endpoint: Estimate of the diagnostic accuracy of a POC TB biomarker breath test             (sensitivity, specificity).          -  Phase: Phase I (feasibility or pilot study)          -  Study sites: Multicenter trial (4 clinical sites in Mumbai, India)          -  Study groups: 5          -  Sample Size: 1,250          -  Estimated enrollment time: 1 year|February 2016|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681445|2 Years|2996|
NCT02681458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IslamicAUM|Superficial and Cutaneous Fungal Infections Among Drug-users in Northeast Region of Iran|The Comparison of Dermatophytosis and Other Fungal Infections Between Drug Users and Non Drug Users||Islamic Azad University of Mashhad|No|Completed|August 2013|April 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1436|Samples Without DNA|hair, nail, cutaneous lesions|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|people from northeast region of Iran referring to Methadone clinics. there were no        limitations of age and sex.|February 2016|February 11, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02681458||2995|
NCT02695381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-7EAT-1010|Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness|A Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etodolac-lidocaine Patch Applied Once Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness||MEDRx USA, Inc.|No|Recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695381||1927|
NCT02687477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFH20160106|PADN to Treat Severe Obstructive Sleep Apnea|Pulmonary Artery Denervation to Treat Severe Obstructive Sleep Apnea: a Single-center, Prospective, First-in-man Study（PADN-OSA）|PADN-OSA|The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687477||2532|
NCT02707393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-000569-50|Allogeneic Stem Cell Transplantation for Children With CML|Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures||St. Anna Kinderkrebsforschung|Yes|Recruiting|April 2009|January 2022|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|1 Year|18 Years|No|||March 2016|March 11, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02707393||1005|
NCT02688608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 012016-019|Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer|Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688608||2445|
NCT02684968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1273|Effects of Continuous Bilateral QL Analgesia After Open Abdominal Surgery|The Effects of Continuous Bilateral Quadratus Lumborum Analgesia on Pain, Opioid Consumption, and Opioid-related Complications After Open Abdominal Surgery: A Randomized Controlled Trial||The Cleveland Clinic|No|Not yet recruiting|March 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684968||2725|
NCT02694029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052015-047|Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer|Intra-patient Comparison of Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Left-chest Wall Irradiation, a Pilot Study for Breast Cancer|VisionRT|University of Texas Southwestern Medical Center|Yes|Recruiting|February 2016|December 2017|Anticipated|May 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Female|18 Years|99 Years|No|||February 2016|February 26, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694029||2030|
NCT02684097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1497|A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata|A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684097||2792|
NCT02684110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/15/61|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||February 16, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684110||2791|
NCT02681562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS22810078|Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients|A Phase II, Open Label, Controlled Study of Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients: Biological Evaluation From a "Window of Opportunity" Trial||Istituti Ospitalieri di Cremona||Active, not recruiting|January 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|75 Years|No|||February 2016|February 12, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02681562||2987|
NCT02706236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D16084|Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis|A Single-Center Prospective Randomized Placebo Controlled Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706236||1093|
NCT02682953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00064099|Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers|Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers||University of Maryland|No|Recruiting|October 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02682953||2880|
NCT02680626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-275-15|Bilateral Transversus Abdominis Plane Block With or Without Magnesium|Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial||Queen's University|Yes|Recruiting|January 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|75 Years|No|||February 2016|February 9, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680626||3059|
NCT02680951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00078620|Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia|Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)||Emory University|Yes|Recruiting|December 2015|||February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|1 Year|21 Years|No|||February 2016|February 9, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680951||3034|
NCT02680964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-0001- ASI|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||February 9, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680964||3033|
NCT02681783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRaCTICAL|PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept|PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept|PRaCTICAL|Sunnybrook Health Sciences Centre|No|Not yet recruiting|September 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681783||2970|
NCT02705911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502214N|TeleRehabilitation in Hypertension|Isometric Handgrip Exercise: a New Non-pharmacological Tool in the Management of High Blood Pressure?|TRiHYP|Katholieke Universiteit Leuven|No|Recruiting|April 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02705911||1118|
NCT02706080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0257|Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department|Registry of Patient With Antithrombotic Agents Admitted to an Emergency|RATED Registry|University Hospital, Clermont-Ferrand||Recruiting|January 2014|February 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Antithrombotic agents|March 2016|March 7, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02706080||1105|
NCT02514070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150173|Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults|Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults||National Institutes of Health Clinical Center (CC)||Recruiting|July 2015|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|February 27, 2016|July 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02514070||15843|
NCT02704572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1511046718|Optimal Timing of Zoster Vaccine After Zoster Illness|Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness||Seoul National University Hospital|Yes|Recruiting|March 2016|February 2018|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704572||1221|
NCT02686749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-858981|Catheter Ablation vs. Medical Therapy in Congested Hearts With AF|Catheter Ablation vs. Medical Therapy in Congested Hearts With AF (CATCH-AF in Patients With Impaired LV Function): An Early Ablation Strategy Study Impact on Health Care Utilization|CATCH-AF|The Cleveland Clinic|No|Not yet recruiting|March 2016|December 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02686749||2588|
NCT02679846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-852|Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring|Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring|SAVE|Hospices Civils de Lyon|No|Recruiting|February 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1440|||Both|6 Years|N/A|No|||March 2016|March 24, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679846||3119|
NCT02684240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NZT001|A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis|A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis||Weill Medical College of Cornell University|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02684240||2781|
NCT02684253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-253|Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684253||2780|
NCT02702050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-15-0816/FR-3|Effect of Mechanical Stimulation on Mastectomy Scars|A Prospective Randomized Clinical Trial to Investigate the Effect of Mechanical Stimulation on Mastectomy Scars||The Queen Elizabeth Hospital|No|Not yet recruiting|March 2016|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02702050||1415|
NCT02702063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUVienna 1139/2015|Calibrating Cardiac Output Measurement of Electrical Cardiometry With Transthoracic Echocardiography||EC vs TTE|Medical University of Vienna|No|Recruiting|October 2015|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702063||1414|
NCT02695303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18790|18790 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|SPF|Bayer|No|Completed|February 2016|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695303||1933|
NCT02680379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-1177|Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome|A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMix)|LovaMiX|Université de Sherbrooke|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|13 Years|45 Years|No|||February 2016|February 22, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02680379||3078|
NCT02679209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aminonchorion_DFDBA|Evaluation of Amnion Chorion Membrane and Demineralized Freeze-dried Bone Allograft in Periodontal Intrabony Defects|Clinical and Radiographic Evaluation of Amnion Chorion Membrane and Demineralized Freeze-dried Bone Allograft in Periodontal Intrabony Defects: A Randomized Controlled Clinical Trial||Cairo University|Yes|Recruiting|June 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679209||3167|
NCT02686710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK-TV-L|Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients|Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients: a Randomized Clinical Trial||Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy||Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|21|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02686710||2591|
NCT02686723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB15.162|Evaluation of Clinical and Biomechanical Correlation During Return to Sport After Anterior Cruciate Ligament Injury|Evaluation of Clinical and Biomechanical Correlation During Return to Sport After Anterior Cruciate Ligament Injury|REPILOG|University Hospital, Brest|No|Recruiting|February 2016|February 2024|Anticipated|February 2023|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02686723||2590|
NCT02695485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSZhao9012|Sensory Reconstruction of the Digits|Sensory Reconstruction in Different Region of the Digits: A Review of 151 Cases||The Second Hospital of Tangshan|Yes|Completed|February 2006|October 2015|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02695485||1919|
NCT02706652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160076|Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients|Prospective Screening for Patient Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|900|||Both|18 Years|100 Years|No|||February 2016|March 22, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706652||1062|
NCT02706665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_10|Monitoring of Hypnosis State During General Anesthesia With Propofol by Patient State Index From SEDLine®|Modelling Pharmacokinetic/Pharmacodynamic of Propofol Based on PSI Values From the SEDline®||Hospital Universitario de Canarias|No|Recruiting|December 2015|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients undergoing a surgery procedure with general anesthesia.|March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02706665||1061|
NCT02689635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0387-F3R|Low Sodium vs. Regular Diet in Patients Admitted for Heart Failure|The Salt Trial: Low Sodium vs. Regular Diet in Patients Admitted for Heart Failure|SALT|University of Kentucky|Yes|Not yet recruiting|February 2016|July 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02689635||2366|
NCT02689674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807985|Adaptive Treatment for Alcohol Dependence|Adaptive Treatment for Alcohol Dependence||University of Pennsylvania|No|Completed|February 2009|December 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689674||2363|
NCT02695212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-CL-HYDSUP-PI-004953|Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa|A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa|HS|Florida Academic Dermatology Centers|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695212||1940|
NCT02678585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000087161|Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia|Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia||Assiut University||Completed|December 2015|||March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|20 Years|50 Years|No|||March 2016|March 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02678585||3215|
NCT02706912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOTA1|Virtual Occupational Therapy Application|Virtual Occupational Therapy Application|VOTA|Barron Associates, Inc.|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02706912||1042|
NCT02706925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1363.1|To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 443651 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial||Boehringer Ingelheim||Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 3, 2016||||No||https://clinicaltrials.gov/show/NCT02706925||1041|
NCT02682433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522-15|3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities|3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Female|20 Years|70 Years|No|||February 2016|February 10, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02682433||2920|
NCT02681172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBB_01_02_2015|Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD|Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous||Piramal Imaging Limited|Yes|Recruiting|October 2015|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|207|||Both|18 Years|90 Years|No|||February 2016|February 9, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02681172||3017|
NCT02681185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Virtual Care|Efficacy of a Virtual Care Clinic in the Management of Diabetes Mellitus|Efficacy of a Virtual Care Clinic in the Management of Diabetes Mellitus||Endocrine Research Society|No|Not yet recruiting|April 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02681185||3016|
NCT02680457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-DG-140282-JLRN|Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus|Effect of the Administration of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus Drug-naïve|Diabetes|University of Guadalajara|No|Completed|November 2013|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|65 Years|No|||February 2016|February 10, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02680457||3072|
NCT02699112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179324|Cardiac and Respiratory Function With Non-invasive Ventilation|Improvement of Cardiac Function and Neural Respiratory Drive Following Set up of Non-invasive Ventilation in Patients With Hypercapnic Respiratory Failure Caused by Obesity Hypoventilation Syndrome|CARE-NIV|Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|November 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients presenting with a confirmed diagnosis of OHS and Overlap Syndrome and hypercapnic        respiratory failure with the clinical intervention to commence on NIV will be invited to        participate in the trial.|January 2016|February 29, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02699112||1641|
NCT02699125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|guanhctz|Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic|A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension|guanhctz|University of California, San Diego|No|Active, not recruiting|January 2015|August 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|20 Years|80 Years|No|||February 2016|February 29, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02699125||1640|
NCT02693158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-15-002|The Direct III Post Market Study|Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study|Direct III|Svelte Medical Systems, Inc.|No|Not yet recruiting|February 2016|February 2018|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|This study is designed as a prospective, multi-center, single-arm, observational        all-comers clinical study to collect ongoing safety and efficacy of SLENDER IDS and to        determine the feasibility of a direct stenting strategy in an all-comers population.|February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02693158|1 Year|2097|
NCT02682823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA29917|Tocilizumab Real-Life Human Factors (RLHFs) Validation Study|Tocilizumab Real-Life Human Factors Validation Study Protocol||Hoffmann-La Roche||Not yet recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|95|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682823||2890|
NCT02697136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-001-CLIN-009|CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases|Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia|TANGO|Cerenis Therapeutics, SA|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697136||1793|
NCT02687841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201502003MIPB|A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury|A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury - A Open Label Randomized Control Trial||National Taiwan University Hospital|Yes|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|20 Years|100 Years|No|||February 2016|February 17, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02687841||2504|
NCT02690896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBE-15-11548|Caregiver Burden and Depression: Caring for Those Who Care for Others|Caregiver Burden and Depression: Caring for Those Who Care for Others||University of Central Florida|No|Recruiting|January 2016|August 2020|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02690896||2270|
NCT02678637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1600058|Calf Muscle Strength in Mitochondrial Diseases|Calf Muscle Strength in Patients Affected by Mitochondrial Diseases as Compared to Healthy Individuals|CMSMD|Rigshospitalet, Denmark|Yes|Not yet recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with verified mitochondrial disease.|February 2016|February 9, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02678637||3211|
NCT02678884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 12-5378-CE|Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study|A Pilot Study of 18F-FDG PET-CT Kinetic Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)||University Health Network, Toronto|No|Recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 27, 2014||No||No||https://clinicaltrials.gov/show/NCT02678884||3192|
NCT02697435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F2021-P|Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)|Patient-Centered Versus Imaging-Directed Care for Older Veterans With Chronic LBP||VA Office of Research and Development|No|Not yet recruiting|April 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|89 Years|No|||March 2016|March 4, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02697435||1770|
NCT02680028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D/2015/28|Short Versus Standard Intramedullary Nail for Trochanteric Hip Fractures|Randomised Trial of Trochanteric Hip Fractures Treated With Either a Short or Standard Length Intramedullary Nail||Peterborough and Stamford Hospitals NHS Foundation Trust|No|Recruiting|December 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|15 Years|N/A|No|||February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680028||3105|
NCT02680639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1433-HFO-SS|The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants|The Use of High Frequency Oscillations With Noninvasive Ventilation (NIV) in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Participants||Philips Respironics|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|30|||Both|21 Years|85 Years|No|||February 2016|February 9, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680639||3058|
NCT02680652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT15-28124|Improving the Diagnosis of Common Variable Immune Deficiency|Improving the Diagnosis of CVID by Analysis of Innate and Adaptive Signaling Pathways||Stanford University|No|Not yet recruiting|February 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Whole exome analysis will be performed on all samples|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with a diagnosis of CVID and Health controls|February 2016|February 10, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680652||3057|
NCT02680665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3391001|Ameparomo Capsules 250 mg Drug Use Investigation|Drug Use Investigation Of Paromomycin. (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Active, not recruiting|October 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|15 Years|99 Years|No|Probability Sample|Sites of infection department, internal medicine, and other relevant departments.|March 2016|March 7, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680665||3056|
NCT02683655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-E301|Study of Apatinib in Metastatic Esophageal Cancer|Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial||Huai'an First People's Hospital|No|Recruiting|August 2015|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683655||2826|
NCT02692469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1366|Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch|Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch as a Primary Bariatric Procedure. 5 Year Patient Follow|DSvsSADI|McMaster University|No|Not yet recruiting|April 2016|April 2026|Anticipated|April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02692469||2150|
NCT02702544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.014.1MR|Effect of Passive Leg Raising for Fluid Responsiveness|Effect of Passive Leg Rasing on Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal||Medical University of Warsaw|Yes|Enrolling by invitation|March 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702544||1377|
NCT02705599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRMRI-NM-Tiantan|Stroke Mechanism Evolution in Intracranial Atherosclerotic Stenosis|Stroke Mechanism Evolution in Intracranial Atherosclerotic Stenosis||Chinese PLA General Hospital|No|Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Symtomatic or asymtomatic patients with intracranial atherosclerostic stenosis|March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705599||1142|
NCT02688881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-052|Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors||Samsung Medical Center|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||March 2016|March 1, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688881||2424|
NCT02683538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0364|Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies|Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies||Seoul National University Hospital|Yes|Completed|November 2011|July 2014|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|20 Years|N/A|No|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02683538||2835|
NCT02687984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-15-0001|PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia|A Multicenter, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of RBP-7000 Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) Compared to Intermediate Molecular Weight (Reference Treatment) Polymer in Subjects With Schizophrenia||Indivior Inc.|No|Active, not recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|No|||February 2016|March 14, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687984||2493|
NCT02687997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InsitutoFJD|Prevalence of Sleep Disordered Breathing in a Lung Cancer Screening Cohort|Prevalence of Sleep Apnea in a Lung Cancer Screening Cohort Meeting NLST Criteria|SAILS|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|No|Recruiting|February 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687997||2492|
NCT02707653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001|Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research|Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research||Gynuity Health Projects|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|12 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02707653||985|
NCT02689050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54080.018.15|Optical Biopsy for Thoracic Lymph Nodes.|Needle Based CLE in Thoracic Lymph Nodes, a Comparison With Pathology.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|January 2016|February 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with suspected non-small cell lungcarcinoma/sarcoidosis scheduled for EUS-FNA.|February 2016|February 18, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02689050||2411|
NCT02689063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-MXIV-07|Maxigesic IV Phase 3 Bunionectomy Study|Maxigesic IV Bunionectomy Study- A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group and Placebo-Controlled Study||AFT Pharmaceuticals, Ltd.|No|Not yet recruiting|May 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|275|||Both|18 Years|65 Years|No|||February 2016|March 13, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689063||2410|
NCT02681224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR987-2013-01|TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest|TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest||Goldman, Butterwick, Fitzpatrick and Groff|No|Recruiting|September 2015|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02681224||3013|
NCT02685800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST - V 1_28 Ago 15|Recurrent Failures in assIsted Reproductive Techniques (The FIRST Registry)|A Registry on Outcomes in Women Undergoing Assisted Reproductive Techniques After Recurrent Failures||Casa Sollievo della Sofferenza IRCCS|Yes|Recruiting|October 2015|September 2018|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|624|||Female|18 Years|45 Years|No|Probability Sample|Consecutive women undergoing ART after recurrent failures.|February 2016|February 15, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02685800|10 Months|2661|
NCT02681809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-015|A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR|A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)|CIRCLE|ThromboGenics||Recruiting|December 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|230|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681809||2968|
NCT02696434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK6428-A302|Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL||Alkermes, Inc.|No|Not yet recruiting|March 2016|June 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|60 Years|No|||February 2016|February 26, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696434||1847|
NCT02696447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-09|Ionizing Radiation and Thrombosis : Study of Venous Thromboembolic Events Associated With Radiotherapy|Ionizing Radiation and Thrombosis : Study of Venous Thromboembolic Events Associated With Radiotherapy|RIT|Institut de Cancérologie de la Loire|No|Not yet recruiting|March 2016|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|patient with a solid malignant neoplastic disease (all locations) treated with radiation        therapy and / or brachytherapy as curative intent|February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696447||1846|
NCT02682732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-15378|Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia|Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia||Hamilton Health Sciences Corporation|No|Not yet recruiting|April 2016|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02682732||2897|
NCT02682537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB023/15|IC-BASAROTs: New Practice Method for More Accurate Bed-side Assessment of Individual Energy Expenditure|IC-BASAROTs: Verification of a New Practice Method for More Accurate Bed-side Assessment of Individual Energy Expenditure||University of Applied Sciences Neubrandenburg|No|Recruiting|March 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||18|Anticipated|1400|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Minimum sample size of n = 1400: 700 mostly healthy people (50% women, aged 18-100 years,        BMI 16.5 to 39.9 kg / m²), 420 underweight individuals (50% women, 18 years to 100 years,        BMI from 14.0 to 16.4 kg/m²), 280 morbidly obese (50% women,18 years to 100 years, BMI        40.0-49,9 kg/m²).        Recruitment of volunteers is performed in the local trial centers.|February 2016|February 12, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02682537||2912|
NCT02682810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1346|Point of Care Virologic Testing to Improve Outcomes of HIV-Infected Children|Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children||University of North Carolina, Chapel Hill|Yes|Not yet recruiting|February 2016|December 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2876|||Both|N/A|12 Weeks|No|||February 2016|February 10, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682810||2891|
NCT02686645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHA REB File #: 1020563|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection||Queen Elizabeth II Health Sciences Centre|No|Not yet recruiting|March 2016|December 2021|Anticipated|December 2021|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686645||2596|
NCT02700399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSK01|Study of Pulse Pressure During Tilttable and Erigo® in Adult Patients With Acquired Brain Injury|Randomized Crossover Study of Pulse Pressure on Respectively Tilt Table With Integrated Stepping Function (Erigo®) and Traditional Tilt Table in Adult Patients With Acquired Brain Injury||University of Aarhus|Yes|Recruiting|July 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||November 2015|March 15, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02700399||1542|
NCT02679066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00087273|Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures|Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures||Johns Hopkins University|No|Suspended|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 27, 2016||No|Pending Institutional Review Board which requires ClinicalTrials number|No||https://clinicaltrials.gov/show/NCT02679066||3178|
NCT02679079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1501|Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome||Neurocrine Biosciences|Yes|Recruiting|January 2016|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|6 Years|17 Years|No|||March 2016|March 10, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679079||3177|
NCT02680106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0007|Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites|EVALUATION OF THE SPINNER™ DEVICE FOR THE APPLICATION OF WOUND DRESSING: TREATMENT OF SPLIT SKIN-GRAFT DONOR SITES. A Prospective, Safety and Efficacy, Open Labeled, Two Arms, Randomized, Multi Center, Controlled Study|SPINNER01|Nicast Ltd.|No|Recruiting|February 2016|May 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02680106||3099|
NCT02680119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-10-181|BE of Torrent's Esomeprazole Mg DR Capsules|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Esomeprazole Mg DR Capsule 40 mg [Torrent] Versus Nexium [AastraZeneca]- Sprinkled Over Apple Sauce in Subjects-Fasting Condition||Torrent Pharmaceuticals Limited|No|Completed|May 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680119||3098|
NCT02680132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-10-180|Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release Capsules|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Esomeprazole Mg DR Capsule 40 mg [Torrent,India] Versus Nexium 40 mg DR Capsule [ AastraZeneca LP, USA] in Healthy Subjects-Fed Condition||Torrent Pharmaceuticals Limited|No|Completed|May 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680132||3097|
NCT02695251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0122|AGE - Functional Reserve|Renal Hemodynamic, Functional and Metabolic Changes After AGEs (Advanced Glycation End Products) Load by Positron Emission Tomography (PET) and Blood Oxygen Level-Dependent (BOLD) - MRI. The AGE- Functional Reserve Study.|AGE-FR|Hospices Civils de Lyon|No|Active, not recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02695251||1937|
NCT02700594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S13-00683|Effect of Hip Versus Spinal Joint Mobilization on Hip Muscle Strength|Effect of Hip Versus Spinal Joint Mobilization on Hip Muscle Strength||New York University School of Medicine|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02700594||1527|
NCT02685722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIN-PLAGH-ST-008|UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers|Umbilical Cord Mesenchymal Stem Cells Between Gel Treatment Difficult Skin Ulcer Healing Efficacy and Safety of Random, Open, Before-and-after Study|UC-MSCs|Chinese PLA General Hospital|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|17 Years|78 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02685722||2667|
NCT02678845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-203-D|Project Collabri for Treatment of Depression|Project Collabri. The Effect of a Collaborative Care Model for Treatment of Depression in Primary Care in Denmark - A Cluster Randomized Clinical Superiority Trial||Mental Health Centre Copenhagen|Yes|Recruiting|November 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02678845||3195|
NCT02694731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17250|A Mindfulness Mobile Intervention Targeting Reductions in Food Cravings|A Mindfulness Mobile Intervention Targeting Reductions in Food Cravings||University of California, San Francisco|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694731||1976|
NCT02697201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1311|Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)|Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO-T2D)|DYNAMMO-T2D|The Cleveland Clinic|No|Not yet recruiting|February 2016|February 2021|Anticipated|February 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02697201||1788|
NCT02694042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIR-1018164|Mission is Remission®: How Can a Disease Self-management Website Change Care?|Mission is Remission®: How Can a Disease Self-management Website Change Care?||IWK Health Centre|No|Not yet recruiting|March 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|12 Years|18 Years|No|||February 2016|February 23, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02694042||2029|
NCT02691884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0149-14-MMC|The Effect of Pressure Exerted on the Maternal Abdominal Wall by the Ultrasound Probe on Fetal Heart Rate|The Effect of Pressure Exerted on the Maternal Abdominal Wall by the Ultrasound Probe on Fetal Heart Rate||Meir Medical Center|No|Not yet recruiting|March 2016|April 2020|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Term singleton pregnancies in patients over 18 years of age, undergoing routine CTG for        various indications- growth monitoring, gestational diabetes monitoring, post term, etc.|February 2016|March 7, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02691884||2195|
NCT02705560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|347/15|Assessment of Dietary Biomarkers and Metabolic Effects After the Intake of Milk and Cheese|Randomized, Controlled, Cross-Over Study to Assess Dietary Biomarkers and Metabolic Effects After a Single Dose of Milk and Cheese in Healthy Subjects||Centre Hospitalier Universitaire Vaudois|No|Recruiting|August 2015|May 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 5, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02705560||1145|
NCT02705573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2021/2014|Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation|Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation||Medical University of Vienna||Recruiting|January 2016|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705573||1144|
NCT02685696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlexisO1|Surgical Site Infection in Caesarean Section Using Alexis O Compared to Metal Retractors|To Investigate the Incidence of Surgical Site Infection in Low Risk Women Having a First Time Planned Caesarean Section Using the Alexis O Retractor and the Traditional Metal Retractor||Charite University, Berlin, Germany|No|Completed|October 2013|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 14, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02685696||2669|
NCT02693496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAALC-002-mLOWER|Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research|Mobile Lung Nodule Observatory for Worldwide, Evidenced - Based Research|mLOWER|Chinese Alliance Against Lung Cancer|No|Recruiting|October 2015|October 2025|Anticipated|October 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|90 Years|No|Non-Probability Sample|Approximately 10,000 patients will participate in this research program, in 100 different        medical institutions.|February 2016|February 23, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02693496||2071|
NCT02692183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-SH-2805-15-CTIL|Mapping Functional Networks of Brain Activity Using EEG in Patients With Essential Tremor or Parkinson Disease Before and After MR-guided Focused Ultrasound Thalamotomy for Tremor|Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals in Patients With Essential Tremor or Parkinson Disease Before and After MR-guided Focused Ultrasound (FUS) Thalamotomy for Tremor||Sheba Medical Center|No|Not yet recruiting|February 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|50 patients with idiopathic PD with tremor 50 patients with Essential tremor.|February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02692183||2172|
NCT02699853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-15-4|Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer|Prospective Randomized Comparison of Robotic Versus Open Radical Cystectomy||University of Southern California|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|N/A|N/A|No|||March 2016|March 3, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699853||1584|
NCT02686736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R 2014-785-033|Internet-based Intervention to Prevent Risky Sexual Behaviors in Mexican Adolescents|Evaluation of the Effect of an Internet-based Educational Intervention to Prevent Risky Sexual Behaviors in Mexican Adolescents||Coordinación de Investigación en Salud, Mexico|No|Enrolling by invitation|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|14 Years|15 Years|No|||February 2016|February 18, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02686736||2589|
NCT02687048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00507|Mindful Meditation for Chronic Stroke|The Impact of Mindful Meditation on Mobility, Cognition and Fall Risk in the Older Adult.||University of British Columbia|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02687048||2565|
NCT02685514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW16-015|A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease|A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease|HIFURGD|The University of Hong Kong|Yes|Recruiting|February 2016|February 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685514||2683|
NCT02685774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158BE15032|A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500 mg in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Not yet recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Male|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02685774||2663|
NCT02593201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPDNA|The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels|||Chinese University of Hong Kong|No|Not yet recruiting|March 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02593201||9767|
NCT02593214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-15-333-24953|Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®)|A Clinical Trial to Asses the Performance and Safety of an Innovative Female Condom (Wondaleaf®) Among Healthy Married Couples||Clinical Research Centre, Malaysia|No|Recruiting|August 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|126|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02593214||9766|
NCT02518477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R96-A6604-14-S22|Preventive Intervention Against Lymphedema After Breast Cancer Surgery|LYCA: Preventive Intervention Against Lymphedema After Breast Cancer Surgery - a Randomized Controlled Trial|LYCA|Danish Cancer Society|No|Recruiting|September 2015|September 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|158|||Female|18 Years|75 Years|No|||September 2015|September 15, 2015|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02518477||15506|
NCT02518490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-15-46|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2015|||||N/A|N/A|N/A||||||||||||||October 12, 2015|August 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02518490||15505|
NCT02707029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160077|Clinical and Scientific Assessment of Pain and Painful Disorders|Clinical and Scientific Assessment of Pain and Painful Disorders||National Institutes of Health Clinical Center (CC)||Not yet recruiting|February 2016|February 2026|Anticipated|February 2026|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|10000|||Both|12 Years|N/A|No|||February 2016|March 9, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02707029||1033|
NCT02691403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLCO|Quadratus Lumborum Block for Postoperative Analgesia After Colostomy Closure|Ultrasound-guided Quadratus Lumborum Block for Postoperative Analgesia After Colostomy: A Randomized Controlled Trial||Sun Yat-sen University||Not yet recruiting|March 2016|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|75 Years|No|||February 2016|February 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691403||2232|
NCT02691416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThirdCCCTianjin|Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function|Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function in Patients Undergoing Carotid Endarterectomy and Cerebral Aneurysmectomy.||The Third Central Clinical College of Tianjin Medical University|Yes|Completed|July 2014|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|N/A|N/A|No|||February 2016|February 21, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691416||2231|
NCT02684708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuroNet-PHL-C2|Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents|European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents||University of Giessen|Yes|Recruiting|October 2015|September 2021|Anticipated|September 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2200|||Both|N/A|25 Years|No|||February 2016|February 11, 2016|November 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02684708||2745|
NCT02690285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500995|A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers|A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers Part 1: Rapid Haplotyping Procedure for Determining the Response of Patients to DCA. Part 2: Personalized Dosing of Dichloroacetate for the Treatment of Rare and Common Diseases||University of Florida|No|Recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690285||2316|
NCT02705482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6060C00002|A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors||MedImmune LLC|No|Not yet recruiting|April 2016|December 2021|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|100 Years|No|||March 2016|March 4, 2016|September 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02705482||1151|
NCT02705495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARUTI V1.6|Acupuncture for Prevention of Recurrent Urinary Tract Infections.|Segmental and Ear Acupuncture for Prevention of Recurrent Urinary Tract Infections(SARUTI Study): a Multicenter Randomized Controlled Trial|SARUTI|Medical University of Graz|No|Recruiting|May 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|136|||Female|18 Years|90 Years|No|||March 2016|March 4, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02705495||1150|
NCT02679768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFEII|Electronic Self-monitoring With Closed Loop Feedback Focusing on Regulation of the Sleep-wake Cycle to Reduce Relapse of Depression After Discharge|SAFE II: Can Electronic Self-monitoring With Closed Loop Feedback Focusing on Regulation of the Sleep-wake Cycle Reduce Relapse of Depression After Discharge From a Psychiatric Ward?|SAFEII|Mental Health Centre Copenhagen|No|Not yet recruiting|February 2016|August 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679768||3125|
NCT02684942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/2553|Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy|Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial||Chulabhorn Cancer Center|Yes|Completed|October 2012|March 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|40|||Female|20 Years|80 Years|No|||February 2016|February 12, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02684942||2727|
NCT02684955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuro-E-CPR|Non-invasive Neurological Evaluation During CPR|Non-invasive Neurological Evaluation During Cardiopulmonary Resuscitation for Out of Hospital Cardiac Arrest Patients Neuro-E-CPR Study|Neuro-E-CPR|University Hospital, Grenoble|Yes|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Out of Hospital cardiac arrest patient|February 2016|February 17, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02684955||2726|
NCT02683122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-37816003/2015-NI|The DIPOD Study (Diagnosis Improvement of Pneumonia by Organ Dysfunction)|Improvement of Diagnosis of Hospital Acquired Pneumonia (HAP) Based on Early Organ Dysfunction|DIPOD|Centre Chirurgical Marie Lannelongue|No|Active, not recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|298|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Intensive care unit after cardiac and/or thoracic surgery with a clinical        suspicion of HAP|February 2016|February 11, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683122||2867|
NCT02690116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA182901-01A1|Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors|Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors||Arizona State University|No|Recruiting|February 2016|March 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|246|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02690116||2329|
NCT02690129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|treatment of miscarraige|Vaginal Progesterone for Treatment of Threatened Miscarriage|Vaginal Progesterone for Treatment of Threatened Miscarriage; Randomized Clinical Trial|VPM|Assiut University|Yes|Recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|290|||Female|20 Years|35 Years|No|||February 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690129||2328|
NCT02681731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Impact of Neuromonitoring During Cardiac Procedures|Impact of Neuromonitoring During Cardiothoracic Procedures: A Retrospective Analysis||Medtronic - MITG|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult (age >=18 years) inpatients who underwent major cardiac surgical procedure        requiring cardiopulmonary bypass captured in the Premier database from January 1, 2010 -        December 31, 2014 (5 year period).|February 2016|February 15, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681731||2974|
NCT02686359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081106|Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)|Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome|OPIODYN|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|42|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02686359||2618|
NCT02678455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-15097|Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh|Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|192|||Both|12 Months|50 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678455||3225|
NCT02693002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0798-F6A|Estrogen Diastolic Heart Failure|Heart Failure Prevention for Women: Preservation of Cardiac Function in the Peri-Menopausal Woman Through Hormone Therapy||University of Kentucky|Yes|Recruiting|February 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|28|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693002||2109|
NCT02682277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/14|Efficacy of Polyglucosamine Long Term Treatment|Efficacy of Polyglucosamine for Weight Loss - in a Randomized, Double-blind, Placebo-controlled Clinical Investigation||Certmedica International GmbH|No|Recruiting|May 2014|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682277||2932|
NCT02696616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1339.1|Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655088 Administered by Intravenous Infusion in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)||Boehringer Ingelheim||Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 26, 2016||||No||https://clinicaltrials.gov/show/NCT02696616||1833|
NCT02687282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramaanes2559|Mallampati Score Before and After Cesarean Delivery||MSBAC|Ramathibodi Hospital|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Thai pregnant women scheduled for cesarean section, age ≥ 18 y at gestational age ≥ 37        weeks giving written informed consent.|February 2016|February 16, 2016|January 27, 2016||||No||https://clinicaltrials.gov/show/NCT02687282||2547|
NCT02687581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJW1602|Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia|Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia||Salus University|No|Not yet recruiting|April 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|3 Years|8 Years|No|||February 2016|February 19, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02687581||2524|
NCT02685748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15T-006|Aspirin in Young Psychotic Patients|Aspirin as Adjuvant Therapy in Young Psychotic Patients||Clinic for Psychiatric Disorders, Dr Laza Lazarevic|No|Not yet recruiting|March 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|28 Years|No|||February 2016|February 14, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02685748||2665|
NCT02685761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4128|Skin Incisions and Wound Complication Rates for C-sections in Obese Women|Randomized Controlled Trial of Wound Complication Rates Between Low Transverse, Midline Vertical, and High Transverse Skin Incisions in Women With a BMI of 40 or Above Undergoing a Cesarean Section for Delivery||Albany Medical College|Yes|Recruiting|September 2015|September 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|309|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02685761||2664|
NCT02692287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V.2.4|The Postpartum Haemorrhage (PPH) Butterfly Work Package 3|The Postpartum Haemorrhage (PPH) Butterfly Work Package 3, Phase I in Vivo Testing||University of Liverpool|No|Not yet recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02692287||2164|
NCT02692300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS18290|EEG Guidance of Anesthesia (ENGAGES-CANADA)|Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES-CANADA) Study: a Pragmatic, Randomized Clinical Trial|ENGAGES|University of Manitoba|Yes|Recruiting|February 2016|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1200|||Both|60 Years|N/A|No|||January 2016|February 29, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692300||2163|
NCT02701296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-10-004|Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty|Assessment of Knee Pain in Patients Receiving Continuous Femoral Nerve Block Combined With Either Ultrasound Guided Posterior Capsular Injection or Selective Tibial Nerve Block Following Total Knee Arthroplasty||Saint Francis Care|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||February 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02701296||1473|
NCT02678975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no ID yet|Disulfiram in Recurrent Glioblastoma|DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|Yes|Not yet recruiting|September 2016|September 2020|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 31, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678975||3185|
NCT02678988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA30003|A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers|||Hoffmann-La Roche||Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|188|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678988||3184|
NCT02681484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS1|Effects of Speech-therapy in Hypertensive Patients|Speech Guided Breathing: a Modality to Influence Cardiovascular Regulation and Health Perception in Hypertensive Patients?||Klinik Arlesheim|No|Completed|September 2002|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|60 Years|No|||February 2016|February 9, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02681484||2993|
NCT02686008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409014536|Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC|A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)||Yale University|No|Not yet recruiting|March 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 24, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02686008||2645|
NCT02687724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCRC/15/007|Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis|GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).|GOAL-ARC|University College Dublin|Yes|Not yet recruiting|February 2016|||February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02687724||2513|
NCT02701309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFL_02/2015|Non-invasive Optical Detection of Iron Deficiency in Children|Non-invasive Optical Detection of Iron Deficiency in Children- Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio|IronKids|Ludwig-Maximilians - University of Munich|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|9 Months|5 Years|No|Non-Probability Sample|Children aged 9 months to 5 years|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701309||1472|
NCT02690909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1501|A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension|A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension||Renal Dynamics GmbH|No|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690909||2269|
NCT02691039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-075|NEW Keiki Family Based Intervention to Combat Childhood Obesity|N.E.W. Keiki - Nutrition + Exercise + Weight Management Programs: Family-based Intervention to Combat Childhood Obesity in Hawai'i||Hawaii Pacific Health|No|Enrolling by invitation|March 2014|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|300|||Both|6 Years|N/A|No|Non-Probability Sample|Subjects will be participants or family members of participants in the NEW Keiki program.|February 2016|February 19, 2016|March 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02691039||2259|
NCT02680015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 2020|Understanding the Effects of Intervention on the Brain in Autism|Understanding the Effects of Intervention on the Brain in Autism||Marquette University|No|Recruiting|August 2010|December 2025|Anticipated|December 2025|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|11 Years|28 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680015||3106|
NCT02687360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7208|Imaging the Effects of rTMS on Chronic Pain|Imaging the Effects of rTMS on Chronic Pain||New York State Psychiatric Institute|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|60 Years|No|||January 2016|February 19, 2016|December 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687360||2541|
NCT02687373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI/SERU/CGHR/017/3129|Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya|Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy||Sanaria Inc.|Yes|Not yet recruiting|March 2016|November 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|30||Anticipated|572|||Both|5 Months|9 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687373||2540|
NCT02687386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCA001|A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR|A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study)|ECREST|Sydney Children's Hospital, Randwick|Yes|Not yet recruiting|February 2016|April 2021|Anticipated|February 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|21 Years|No|||February 2016|February 23, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02687386||2539|
NCT02683343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muscle mass|The Use of Ultrasound to Quantify Muscle Overlying the Carpal Tunnel|||Clalit Health Services|No|Not yet recruiting|July 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with the diagnosis of CTS and those without|July 2015|February 16, 2016|August 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02683343||2850|
NCT02702037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS.FinGrant_Fortimel_2015|Older Person's Exercise and Nutrition Study|Older Person's Exercise and Nutrition Study (OPEN): a Simple Physical Exercise Combined With Protein Supplement - Effects on Functional Status and Independence Among Older People: A Cluster Randomised Controlled Trial|OPEN|Karolinska Institutet|No|Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|75 Years|N/A|No|||March 2016|March 2, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02702037||1416|
NCT02702518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-CNBL-1002|rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease|A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops in Patients With Ocular Graft-Vs.-Host Disease||University of Illinois at Chicago|Yes|Not yet recruiting|April 2016|June 2020|Anticipated|June 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702518||1379|
NCT02684383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 304|Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting||||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684383||2770|
NCT02688738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016SNam|Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?|Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?||Rothman Institute Orthopaedics||Enrolling by invitation|March 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|N/A|N/A||||February 2016|February 17, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02688738||2435|
NCT02685241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEC-Nr. PB-2016-00141|Monitoring of Biomarkers by Portable Breath Gas Sensors: an Exploratory Study|Monitoring of Biomarkers by Portable Breath Gas Sensors: an Exploratory Study||University of Zurich|No|Not yet recruiting|March 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|General population|February 2016|February 12, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02685241||2704|
NCT02692482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22022016|Polyurethane Foam on the Sacrum for Prevention|Effectiveness of the Use of a New Polyurethane Foam Multilayer Dressing in the Sacral Area to Prevent the Onset of Pressure Sores in the Elderly With Hip Fractures. Randomized Controlled Trial.||Istituto Ortopedico Rizzoli|No|Not yet recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692482||2149|
NCT02694107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF1972|Effectiveness of Proprioceptive Training on Dynamic Postural Balance During Pregnancy|A Randomized Controlled Trial of Effectiveness of Proprioceptive Training on Dynamic Postural Balance During Pregnancy||Kafrelsheikh University|Yes|Completed|July 2015|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|39|||Female|25 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02694107||2024|
NCT02705768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T/IM -NF/Pharm/15/30|Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase in Focal Seizures|Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase in Focal Seizures||All India Institute of Medical Sciences, Bhubaneswar|No|Not yet recruiting|April 2016|April 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02705768||1129|
NCT02688946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4833210014|Imaging Microcirculation and Gross Hemodynamics in Elective Colorectal Surgery|Imaging Microcirculation And Gross Hemodynamic Assessment of the Bowel During Elective Colorectal Surgery|IMAGES|St. Antonius Hospital|No|Recruiting|May 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|70 patients undergoing elective, gastrointestinal surgery. Surgical procedures included        will be:          -  All forms of open colorectal surgery;          -  Pylorus Persevering PancreaticoDuodenectomy (PPPD);          -  Other procedures requiring small bowel resection for cancer;          -  Laparoscopic procedures with extracorporeal creation of the bowel anastomosis. These             procedures provide unique access to different parts of the bowel. The PPPD procedure             provides access to the mucosal and serosal side of the jejunum. Colorectal surgery             provides access to both the serosal and mucosal side of the colon and the terminal             ileum is sometimes also accessible. We expect to include around 2 patients per week.|February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688946||2419|
NCT02692989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/14a/tk|The Safety of Anesthesia Management for Traumatic Hip Surgery in Elderly|The Safety of Anesthesia Management for Traumatic Hip Surgery in Elderly: A Retrospective Study in a Tertiary Hospital||University of Jordan|No|Active, not recruiting|January 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1270|||Both|N/A|N/A|No|Non-Probability Sample|patients who sustained hip fracture and underwent surgical correction under Regional or        general anesthesia and had intraoperative or postoperative complications|February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692989||2110|
NCT02697994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWI1315|Sterile Water Injections For Pain Relief İn Labor|Intradermal Sterile Water Injections for Labour Pain: A Randomised Controlled Trial||University of Beykent|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|35 Years|No|||February 2016|March 2, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02697994||1727|
NCT02680548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9584-A|Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain|A Pilot Randomized Controlled Trial of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Neuropathic Pain in the Ankle and the Foot: The PREPLAN Study|PREPLANS|University Health Network, Toronto|No|Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 8, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02680548||3065|
NCT02685813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpinaBifida2016|Incidence of Pregnancies and Births With Spina Bifida in Denmark in 2008-2014|Incidence of Pregnancies and Births With Spina Bifida in Denmark in 2008-2014||Aarhus University Hospital|No|Recruiting|February 2016|January 2017|Anticipated|November 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|350000|||Both|N/A|N/A|No|Non-Probability Sample|FØTOdatabasen is a national fetal medicine database, which includes information on        maternal characteristics: age, parity, BMI, ethnicity, smoking status, diabetes status        (from 2014), and on the pregnancy: mode of conception, result of first trimester risk        assessment for chromosomal anomalies, biometric data, ICD10-codes for any prenatally        diagnosed malformation. It links data regarding each pregnancy with postnatal outcome        received from the Danish Cytogenetic Registry, the National Patient Registry and the        National Birth Registry. FØTOdatabasen includes >95% of all pregnancies in Denmark with        due date from 1. January 2008 and onwards. The data completeness is high, with missing        data <1% for pregnancy outcome, <1% for smoking status, and <3% for mode of conception|March 2016|March 7, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02685813|1 Year|2660|
NCT02694705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMERC2015/69|Assessment of Preoxygenation Strategies in the Prehospital Environment|Assessment of Preoxygenation Strategies in the Prehospital Environment||Queen Mary University of London|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694705||1978|
NCT02686385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-DILI-001|Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury|Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury: A Prospective Randomized Controlled Trial||Institute of Liver and Biliary Sciences, India||Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||February 2016|February 20, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02686385||2616|
NCT02686398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUGH13170|Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis|Immunogenicity of a Trivalent Influenza Vaccine in Patients With Chronic Kidney Disease Undergoing Hemodialysis: MF59-adjuvanted Versus Non-adjuvanted Vaccines||Korea University Guro Hospital||Completed|October 2013|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|174|||Both|19 Years|N/A|No|||February 2016|February 15, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02686398||2615|
NCT02700139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20160105001|Shamir Aspheric Ophthalmic Lenses (MyLens) for Myopic Control Clinical Trial|Shamir Aspheric Ophthalmic Lenses (MyLens) for Myopic Control Clinical Trial||The Hong Kong Polytechnic University|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700139||1562|
NCT02687334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015110301|Changes of Cerebral Oxygenation During Anesthesia Induction|Changes of Cerebral Oxygenation During Anesthesia Induction||China Medical University, China|Yes|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|48 Years|No|Probability Sample|Patients scheduled for elective surgery at the First Hospital of China Medical University        will be recruited for the study|February 2016|February 26, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687334||2543|
NCT02687347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-369 MP-CUSM|Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain|A Double Blind Randomized Clinical Trial to Investigate the Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic Therapy in Cancer Patients With Pain|UDOME|McGill University Health Center|Yes|Recruiting|February 2016|December 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|204|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02687347||2542|
NCT02695238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00225-44|Trial of Prophylactic Manual Rotation of Persistent Occiput Posterior Presentation During the Early Second Stage of Labor to Reduce Operative Delivery: a Prospective Multicenter Randomized Control Trial|Trial of Prophylactic Manual Rotation of Persistent Occiput Posterior Presentation During the Early Second Stage of Labor to Reduce Operative Delivery: a Prospective Multicenter Randomized Control Trial|PROPOP|Assistance Publique Hopitaux De Marseille|No|Recruiting|December 2015|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|408|||Female|18 Years|N/A|No|||January 2016|February 29, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02695238||1938|
NCT02702778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZNP-PRE-IIS02|Delayed Release Prednisone in PMR|A Randomized, Open-label, Dose-ranging Study of Oral Delayed Release Prednisone in Patients With Untreated Polymyalgia Rheumatic (PMR)||Dinora, Inc.|No|Recruiting|February 2016|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|50 Years|N/A|No|||February 2016|March 3, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702778||1359|
NCT02691026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK3475_MPNST|A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery|A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery||Oslo University Hospital|No|Not yet recruiting|March 2016|December 2025|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02691026||2260|
NCT02683005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO16010091|Study of Hepatitis C Treatment During Pregnancy|Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection|HIP|University of Pittsburgh|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|39 Years|No|||February 2016|February 11, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683005||2876|
NCT02683265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-BP-EF003|A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD|A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)|EF003|Rhodes Pharmaceuticals, L.P.|Yes|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|4 Years|6 Years|No|||February 2016|February 11, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683265||2856|
NCT02684487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ViDISS_temp|Vitamin D Status in Patients With Severe Sepsis|Vitamin D Status in Patients With Severe Sepsis: A Randomized Clinical Trial|ViDISS|Massachusetts General Hospital|Yes|Not yet recruiting|December 2016|December 2021|Anticipated|July 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684487||2762|
NCT02704962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPH-2011-22|Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine|A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia||Kaohsiung Kai-Suan Psychiatric Hospital|Yes|Completed|January 2012|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|55 Years|No|||March 2016|March 4, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02704962||1191|
NCT02690155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18734|Real-world Comparative Effectiveness of Rivaroxaban Versus VKA|Real-world Comparative Effectiveness of Rivaroxaban Versus VKA|RIVA-F|Bayer|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|38831|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation (NVAF)|March 2016|March 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690155||2326|
NCT02683304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2015/RGG-01|S100B in the Care of Non-traumatic Headaches in the Emergency Department|S100B Protein Measures in the Care of Non-traumatic Headaches in the Emergency Department|S100B-Céph|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|January 2017|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|59 Years|No|||January 2016|February 16, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02683304||2853|
NCT02695264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-028|Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients|Prospective Evaluation of Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients Undergoing Invasive ICP Monitoring||HeadSense Medical|No|Not yet recruiting|April 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|40|||Both|N/A|18 Years|No|||February 2016|February 24, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695264||1936|
NCT02695277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2015-1|Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|CEASE-AF|AtriCure, Inc.|No|Recruiting|November 2015|November 2020|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||December 2015|February 24, 2016|December 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02695277||1935|
NCT02700893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRETTINEO sub-study|Cerebral NIRS Profiles During Premedication for Neonatal Intubation|Cerebral NIRS Profiles During Premedication for Neonatal Intubation||Centre Hospitalier Intercommunal Creteil|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|28 Days|No|||March 2016|March 9, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700893||1504|
NCT02679534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-186|The Effectiveness of Hand Massage on the Pain of Cardiac Surgery Critically Ill|The Effectiveness of Hand Massage on the Pain of Cardiac Surgery Critically Ill- A Randomized Controlled Trial||McGill University||Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02679534||3142|
NCT02707783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEAST.RU|Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina|Feasibility and Outcomes of Complete Coronary Revascularization Using Bioresorbable Vascular Scaffold in All-comer Patients With Stable and Unstable Angina: A Multi-centre Registry in Russian Population|FEASTRU|International Foundation for Development of Medical Science and Education Healthy Heart|Yes|Recruiting|November 2015|August 2020|Anticipated|August 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stable and unstable angina qualified for revascularization (PCI or CABG)        after coronary angiography.|February 2016|March 14, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02707783||975|
NCT02689219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0568|Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors|A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors||Indiana University|Yes|Not yet recruiting|February 2016|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689219||2398|
NCT02680353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-KAEK-055|The Perioperative Analgesic Efficiency of Bilateral Superficial Cervical Plexus Block in Patients With Thyroidectomy|The Perioperative Analgesic Efficiency of Bilateral Superficial Cervical Plexus Block in Patients With Thyroidectomy||Tokat Gaziosmanpasa University|Yes|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680353||3080|
NCT02680613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-6015511|Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania|Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania|KCCPAS|Queen's University|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|3||Anticipated|600|||Female|25 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680613||3060|
NCT02693405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P2015-06|Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life|Assessment of Executive and Socio-cognitive Functions in Child and Adult Survivors of Primary Brain Tumor: Impact on Patients' and Relatives' Quality of Life.|NEUROCOG-QOL|University Hospital, Angers|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Both|8 Years|59 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02693405||2078|
NCT02704312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/ B/ 25|Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer|A Feasibility Study of Patient Comfort and Dosimetry Evaluation in Prone Breast Radiotherapy.|PROCUBITUS|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|November 2015|April 2020|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|26|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704312||1241|
NCT02704325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALGT2|Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2|Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2||Nationwide Children's Hospital|Yes|Not yet recruiting|March 2016|February 2020|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|3|||Male|9 Years|N/A|No|||March 2016|March 22, 2016|December 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02704325||1240|
NCT02690675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC81/00128|Iron Supplement Effect on Child Development|Iron Supplement Effect Over Immune System and Neurobehavioral Child Development.||University Rovira i Virgili|Yes|Completed|May 2006|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|133|||Both|N/A|6 Months|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02690675||2287|
NCT02690779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131668|Bowel Preparation Quality for Screening Colonoscopy|Impact of a Patient Educational Video on Bowel Preparation Quality for Screening Colonoscopy: a Quality Assurance Project||Vanderbilt University|No|Enrolling by invitation|August 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|60|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690779||2279|
NCT02693600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPTCOT2014/01|Comparison Between Hemitrapeziectomy and Total Trapeziectomy With Ligament Reconstruction and Tendon Interposition in Trapeziometacarpal Osteoarthritis II-III Eaton-Littler|Comparison Between Hemitrapeziectomy and Total Trapeziectomy With Ligament Reconstruction and Tendon Interposition in Trapeziometacarpal Osteoarthritis II-III Eaton-Littler||Corporacion Parc Tauli|No|Recruiting|September 2014|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|45 Years|85 Years|No|||February 2016|February 25, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693600||2063|
NCT02685852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503M65841|A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB|A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|February 2016|April 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|60 Years|No|||February 2016|February 15, 2016|January 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685852||2657|
NCT02685865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837579|Trial Comparing FCSEMS and Plastic Stents|Randomized Trial Comparing Fully Covered, Self-Expanding Metal Stent and Plastic Stents for Endoscopic Ultrasound-guided Drainage of Walled-off Necrosis|WON-MVP|Florida Hospital|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02685865||2656|
NCT02579850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-05993AA1-08|2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients|52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients|TRIBUTE|Chiesi Farmaceutici S.p.A.|No|Recruiting|May 2015|November 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1534|||Both|40 Years|N/A|No|||October 2015|October 16, 2015|May 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02579850||10793|
NCT02585440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRV-CMX-102|A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects|A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects||ContraVir Pharmaceuticals, Inc.|Yes|Not yet recruiting|December 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|September 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02585440||10363|
NCT02591992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.13/III/15|Computed Tomography as the First-Choice Diagnostics in High Pre-Test Probability of Coronary Artery Disease|Coronary Artery Computed Tomography as the First-Choice Imaging Diagnostics in Patients With High Pre-Test Probability of Coronary Artery Disease|CAT-CAD|Institute of Cardiology, Warsaw, Poland|No|Recruiting|October 2015|May 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02591992||9860|
NCT02578368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAISSANCE|Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)|FLOT5|Krankenhaus Nordwest|Yes|Not yet recruiting|December 2015|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|271|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02578368||10906|
NCT02696161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP for CTS|Platelet Rich Plasma and Hydrodissection for Carpal Tunnel Syndrome|The Long-term Effect of Platelet Rich Plasma and Hydrodissection in Patients With Carpal Tunnel Syndrome||Tri-Service General Hospital|Yes|Recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|52|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02696161||1868|
NCT02679521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070609-02|Radial Extracorporeal Shock Wave Treatment for Chronic Plantar Fasciopathy|The Effectiveness of Extracorporeal Shock Wave Therapy for Patients With Plantar Fasciitis Who Satisfy a Clinical Prediction Rule|RSWT_CPF|Rocky Mountain University of Health Professions|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679521||3143|
NCT02693912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wch-150718|Changes in Alveolar Macrophage Function During Acute Lung Injury|Changes in Alveolar Macrophage Function During Acute Lung Injury||West China Hospital|No|Not yet recruiting|September 2016|August 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|bronchoalveolar lavage fluid will be collected which contains immune cells, including      macrophages.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|ALI and acute respiratory distress syndrome (ARDS) are characterized by an increased        permeability of the alveolar-capillary barrier resulting in lung edema with protein-rich        fluid, thus resulting in impairment of arterial oxygenation. ALI/ARDS is defined as a lung        disease with acute onset, noncardiac, diffuse bilateral pulmonary infiltrates and a        paO2/FiO2 ≤ 300 for ALI or a paO2/FiO2 ≤ 200 for ARDS. The ageadjusted incidence of        ALI/ARDS is estimated with 86.2 per 100,000 person-years. Despite all innovations in        intensive care medicine, the mortality of ARDS remains up to 40%.|February 2016|February 26, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02693912||2039|
NCT02692495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904010001MEBO|Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis|Evaluation of Gastrointestinal and Nutritional Diagnostic Tests as Potential Screening Tools for Metabolic Body Odor and Halitosis||Mebo Research, Inc.|Yes|Completed|April 2009|February 2016|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|20 Years|N/A|No|Probability Sample|Individuals reporting idiopathic malodor production|February 2016|February 22, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02692495||2148|
NCT02695017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEULS-PI-086|Changes in Oxygen Saturation in Two Exercise Modalities|Comparison of Changes in Oxygen Saturation in Flywheel Exercise Versus Conventional Strength Machine||Centro Universitario La Salle|No|Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02695017||1954|
NCT02695030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01582|Low-profile Visualized Intraluminal Support -HUD|MicroVention Low-profile Visualized Intraluminal Support (LVIS*) or LVIS Jr Humanitarian Use Device (LVIS HUD)||New York University School of Medicine||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||February 2016|February 24, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695030||1953|
NCT02710487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.LS.15.3.II|Sleep, Awake & Move - Part II|Awake & Move. Role of Nocturnal Sleep and Rapid Eye Movement Sleep at Morning Awakening on Sleep Benefit in Parkinson's Disease. An Interventional Cross-over Study.|SA&M-II|Neurocenter of Southern Switzerland|No|Recruiting|March 2016|November 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|35 Years|N/A|No|||March 2016|March 23, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02710487||767|
NCT02684877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fatigue|Fatigue One Year After ICU Discharge|Fatigue in Intensive Care Survivors One Year After Discharge||Università degli Studi di Ferrara|No|Completed|January 2015|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care one-year survivors|February 2016|February 17, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02684877||2732|
NCT02684890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220-15-WOMC|Detection of Emotions in a Spoken Language Among Tinnitus Patients|Detection of Emotions in a Spoken Language Among Tinnitus Patients|EMSLT|Wolfson Medical Center|No|Not yet recruiting|March 2016|||February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|55 Years|No|Non-Probability Sample|Patients with tinnitus|February 2016|February 13, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02684890||2731|
NCT02693938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1509016531|Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes|Investigating Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes to Design Innovative Therapies||Yale University|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Female|12 Years|35 Years|No|||February 2016|February 23, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02693938||2037|
NCT02706444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1140101|Drug-coated Balloon Versus Conventional Balloon Angioplasty in Hemodialysis Graft|A Prospective, Multicenter, Randomized, Controlled Trial for Comparison of Drug-coated Balloon Versus Conventional Balloon Angioplasty in Venous Anastomotic Stenosis of Hemodialysis Graft||Konkuk University Medical Center|Yes|Not yet recruiting|March 2016|February 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|19 Years|N/A|No|||March 2016|March 7, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02706444||1078|
NCT02678728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0252|Effect of Intraoperative Dexmedetomidine on Lung|Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Double-blind Randomized Clinical Trial||Gangnam Severance Hospital|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|20 Years|98 Years|No|||February 2016|February 5, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02678728||3204|
NCT02678741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20152397|Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Stable or Slowly Progressing Disease.|||Cancer Insight, LLC|Yes|Recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678741||3203|
NCT02686567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDT20160214|Use of the TDT for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Rectal Cancer|The Use of the Transanal Drainage Tube for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Medium & Low Rectal Cancer||Third Military Medical University|Yes|Recruiting|February 2016|December 2019|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02686567||2602|
NCT02692456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R,∕ 15.07.07|Effect of Patient Position on Computerized Tomography Guided Celiac Trunk Neurolysis|Efficacy of Patient Position After Computerized Tomography Guided Antero-crural Celiac Trunk Neurolysis on Upper Abdominal Malignancy Pain||Mansoura University|Yes|Completed|June 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02692456||2151|
NCT02696382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1978-R|Improving Function in Older Veterans With Hospital-Associated Deconditioning|Improving Function in Older Veterans With Hospital-associated Deconditioning||VA Office of Research and Development|No|Not yet recruiting|April 2016|April 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|65 Years|99 Years|No|||March 2016|March 3, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02696382||1851|
NCT02696395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DePuy RSA RCT|RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-Lock, Corail and Deltamotion Hip Replacement Components|RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-lock, Corail and Deltamotion Hip Replacement Components: a Single-blinded Randomised Control Trial|DePuy RSA RCT|University of Oxford|No|Recruiting|July 2015|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02696395||1850|
NCT02682173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI Fat quantification|Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver|MRI Fat Quantification of the Liver, Subcutaneous and Visceral Fatty Tissue in Patients Before and After Bariatric Surgery||University Hospital, Basel, Switzerland|No|Recruiting|March 2013|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|60 Years|No|||February 2016|February 10, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02682173||2940|
NCT02685488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRCH--‐703FY'15|Investigating Transcranial Ultrasound as a Potential Intervention for Depression|A Pilot Study: Investigating Transcranial Ultrasound as a Potential Intervention for Mild to Moderate Depression||University of Arizona|No|Enrolling by invitation|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|35 Years|No|||February 2016|February 19, 2016|February 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685488||2685|
NCT02685501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Menorrhagia-HMO-CTIL|Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers and Effect on Activity|Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers||Hadassah Medical Organization|No|Recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|Samples Without DNA|CBC, ferritin|Female|18 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Women soldiers|February 2016|February 23, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685501||2684|
NCT02687152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micro Arginase|Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes|Effect of Arginase Inhibition on Microvascular Endothelial Function in Patients With Type 2 Diabetes and Microvascular Dysfunction.||Karolinska Institutet|No|Completed|March 2014|January 2016|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02687152||2557|
NCT02687165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7003|Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome|Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome|PTLS|New York State Psychiatric Institute|No|Recruiting|January 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687165||2556|
NCT02700854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Ped-AsphHENRIC001|Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2|Hypoxic-Ischemic Encephalopathy Therapy Optimization for Better Neuroprotection With Inhalative CO2 in Asphyxiated, Cooled, Mechanically Ventilated Neonates at Risk for Hypocapnia|HENRIC|Semmelweis University|Yes|Recruiting|February 2016|February 2020|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|6 Hours|No|||March 2016|March 4, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700854||1507|
NCT02690636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cure and More3|Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer|Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node Positive Breast Cancer. Phase III, Open Label, Randomized Trial. Comparing Local Control, Cosmetic Outcome, Arm Lymph Edema and Health Economic Perspectives||Ain Shams University|Yes|Recruiting|January 2016|April 2021|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|20 Years|65 Years|No|||February 2016|February 23, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02690636||2290|
NCT02690649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC15-0709|Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence|Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence for Patients With Non-valvular Atrial Fibrillation||Parkview Health|No|Recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02690649||2289|
NCT02690194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00016464|A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures.|A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures||Children's Hospital Boston|No|Recruiting|August 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|72|||Both|14 Years|N/A|No|||February 2016|February 19, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02690194||2323|
NCT02678871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-01-18|Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage|Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage|TAVI-LAAC|University Hospital Inselspital, Berne|Yes|Not yet recruiting|March 2016|April 2021|Anticipated|June 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02678871||3193|
NCT02704845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDublinTC 12|Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain|Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain: An Exploration of Similarities and Differences||University of Dublin, Trinity College||Recruiting|September 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|70|||Both|18 Years|65 Years|No|Non-Probability Sample|A convenience sample of adults with Ankylosing Spondylitis (AS) will be consecutively        recruited from a pool of patients referred to AS clinic in the Rheumatology and        Physiotherapy Departments of St. James's and Tallaght Hospitals in Dublin.        Adults with chronic non-specifi low back pain (CNSLBP) (control group) will be        consecutively recruited from a pool of patients referred to the Physiotherapy Department        of St. James's and Tallaght Hospitals in Dublin. An invitation to participate in the study        and an information leaflet will be extended to the patients who potentially meet the        recruitment criteria.|March 2016|March 4, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02704845||1200|
NCT02682693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 88|Denosumab as an add-on Neoadjuvant Treatment (GeparX)|Investigating Denosumab as an add-on Neoadjuvant Treatment for Hormone-receptor-negative, RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)|GeparX|German Breast Group|Yes|Not yet recruiting|April 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|778|||Both|18 Years|75 Years|No|||January 2016|February 10, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02682693||2900|
NCT02686021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ 2015-284|Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction|Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction|NovIbu|University Hospital, Basel, Switzerland|No|Recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|60 Years|No|||February 2016|February 16, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02686021||2644|
NCT02692365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2015-75|Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI|Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI||Hospital Sirio-Libanes|Yes|Recruiting|September 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 22, 2016|September 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02692365||2158|
NCT02704936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505-BIO-035-MF|Analysis of Lipid Profiles in Samples Sperm and Seminal Plasma Under Artificial Insemination|Analysis of Lipid Profiles in Samples Sperm and Seminal Plasma Under Artificial Insemination||IVI Bilbao|No|Recruiting|December 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|126|||Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who undergo cycles of artificial insemination with own semen. Donor semen samples        are intended for cycles of artificial insemination of donor Once the technical and knowing        the value of the ßhCG (indicating pregnancy hormone)determined up to a maximum of 4        treatments, the population for this study were divided into three groups|March 2016|March 4, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02704936||1193|
NCT02680288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB#0016|Lorcaserin Intra Venous Cocaine Effects|Lorcaserin Effects on Cocaine Craving and Drug-Reinforced Behavior|LIVE|Midwest Biomedical Research Foundation|Yes|Recruiting|November 2015|November 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680288||3085|
NCT02680301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-16-019|Topical Steroid Formulation and Wet Wraps|Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis||Seton Healthcare Family|No|Not yet recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|3 Years|17 Years|No|||February 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680301||3084|
NCT02694900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.009.1MR|Single-rescuer Pediatric Resuscitation|Comparison of Three Different Chest Compressions Methods During Pediatric Cardiopulmonary Resuscitation: A Pilot, Randomized Crossover Manikin Trial|SRPR|Medical University of Warsaw|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02694900||1963|
NCT02694315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sonographic cervical length|Cervical Length and Bishop Score in Preinduction Cervical Assessment Prior to Induction of Labor|Comparison Between Sonographic Cervical Length and Bishop Score in Preinduction Cervical Assessment Prior to Induction of Labor as Regards Induction Success||Ain Shams Maternity Hospital|Yes|Recruiting|October 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|17 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor        will be carried out in the casualty of Ain Shams University Maternity Hospital|March 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02694315||2008|
NCT02692404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15030338|Labor Pain and Postpartum Behavioral Health Outcomes Study|Labor Pain and Postpartum Behavioral Health Outcomes Study|LPPD|University of Pittsburgh|No|Recruiting|January 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|88|Samples With DNA|Saliva samples for DNA extraction|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy, nulliparous women, aged ≥18, planning spontaneous or induced labor and delivery        at term gestation. Women who have risk factors for depression will be included. Risk        factors are defined as history of abuse (partner, sexual, domestic, childhood, and        substance); history of mental illness; lack of social support; and depression or anxiety.        Women will have been and will continue to receive perinatal care at Magee-Womens Hospital        or at The Midwife Center for Birth and Women's Health (TMC). A subset of women who receive        care at TMC will choose to deliver at UPMC Mercy and will plan to avoid labor epidural        analgesia. All women and their infants will be available for followup at 3 months.|February 2016|February 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692404||2155|
NCT02705443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV15CL-0001|Early Identification of Suspected Deep Tissue Injury (sDTI)|Early Identification of Suspected Deep Tissue Injury (sDTI) Utilizing Long-Wave Thermographic Imaging (LWIT)||Wound Vision|No|Recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects admitted to a long-term acute care hospital (LTACH).|March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705443||1154|
NCT02705456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOP1|Enamel Caries in Orthodontic Patients|Enamel Caries in Orthodontic Patients|ECOP|Wuerzburg University Hospital|Yes|Recruiting|October 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|148|||Both|12 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705456||1153|
NCT02705469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEN003694-001|A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer||Zenith Epigenetics Corp.|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705469||1152|
NCT02688894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-071|The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]|The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]||Samsung Medical Center|No|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|392|||Both|20 Years|N/A|No|Probability Sample|Histologically or cytologically confirmed Small cell lung cancers|February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688894||2423|
NCT02691481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Diabetes-Specific Nutritional Formulas Versus Oatmeal|Effect of Diabetes-specific Formulas on Glucose Metabolism and GLP-1 Secretion in Patients With Type 2 Diabetes||Joslin Diabetes Center|No|Completed|May 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|25|||Both|20 Years|80 Years|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691481||2226|
NCT02692144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-1511|Effect of an Optimized Savory Cluster on Glycemic and Insulinemic Responses in Healthy Individuals|Effect of an Optimized Savory Cluster on Glycemic and Insulinemic Responses in Healthy Individuals: A Randomized, Cross-over Study||PepsiCo Global R&D|No|Completed|October 2015|||January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692144||2175|
NCT02694120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016.2|Study on Complications, EfficAcy and Costs of Large Polypectomy||SCALP|Valduce Hospital||Not yet recruiting|February 2016|||July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Population undergoing large endoscopic polypectomy|February 2016|February 23, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02694120|6 Months|2023|
NCT02709811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECTL1|Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases|Safety and Feasibility of Electrochemotherapy in the Treatment of Unresectable Liver Metastases From Colorectal Adenocarninoma||IGEA|No|Terminated|August 2012|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 24, 2014||No|Enrollment at study center below rate compatible with study completion.|No||https://clinicaltrials.gov/show/NCT02709811||819|
NCT02694848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBM|Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection|Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial||China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694848||1967|
NCT02691520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108117|Epidemiology of Treatment Resistant Depression in Taiwan|Epidemiology of Treatment Resistant Depression in Taiwan||Johnson & Johnson Pte Ltd|No|Completed|September 2015|February 2016|Actual|February 2016|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|8356|||Both|18 Years|N/A|No|Probability Sample|Adults aged 18 and older are randomly sampled from the National Health Insurance Research        Database (NHIRD).|March 2016|March 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691520||2223|
NCT02679417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183/2558(EC1)|The Effects of Type of Exercise in Non-alcoholic Fatty Liver Disease|The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial||Mahidol University|No|Active, not recruiting|August 2015|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|60 Years|No|||February 2016|February 6, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02679417||3151|
NCT02702817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTREPAD|Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia|Investigations of Naproxen Treatment Effects in Pre-clinical Alzheimer's Disease (INTREPAD)||Douglas Mental Health University Institute|Yes|Active, not recruiting|August 2012|December 2019|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02702817||1356|
NCT02684864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID 11499|Meniscal Tear and Osteoarthritis Risk (MenTOR)|Does the Biological Response to Degenerative Meniscal Tears or to Their Intervention Predict Future Osteoarthritis?: The Meniscal Tear and Osteoarthritis Risk (MenTOR) Study|MenTOR|University of Oxford|No|Not yet recruiting|February 2016|February 2024|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|313|Samples With DNA|Blood samples (plasma, serum, DNA where consent is given), urine, synovial fluid (where an      appropriate clinically indicated procedure has been carried out to allow access).|Both|30 Years|55 Years|No|Non-Probability Sample|Patients with a confirmed meniscal tear, likely degenerative in nature, will be invited to        participate in the MenTOR study. Male and female adults with a MRI-evident meniscal tear        and evidence of no/minor osteoarthritic change (KL grade 2 or less) who are undergoing        arthroscopic treatment, or planned arthrocentesis/injection will be identified in clinics        all located at the Nuffield Orthopaedic Centre (NOC). The primary source of recruitment is        anticipated to be the secondary care orthopaedic knee service. The patient's symptoms will        be such that they warrant further management.|February 2016|February 12, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02684864||2733|
NCT02692339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-028|Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma|Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma|PrObe-L|Celgene|No|Recruiting|February 2016|September 2023|Anticipated|September 2023|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Relapsed and/or Refractory multiple myeloma patient population|February 2016|February 23, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02692339|36 Months|2160|
NCT02694614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17236.2 PFLS-LS|Weight-loss Treatment Through Smartphone-assisted Dietary Coaching|Weight-loss Treatment of Overweight / Obesity Patients Through Smartphone-assisted Dietary Coaching: A Pre-post Pilot Study|Oviva|Oviva AG|Yes|Recruiting|March 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694614||1985|
NCT02695225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0298|Tobacco Cessation Interventions With Ohio Appalachian Smokers|Tobacco Cessation Interventions With Ohio Appalachian Smokers||Ohio State University|Yes|Completed|November 2010|||October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|707|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695225||1939|
NCT02690753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA2015/041|Pressure Ulcer Prevention: a Turn and Positioning System Combined With Incontinence Care and Tailored/Standard Repositioning|A Turn and Positioning System and Standardized Incontinence Care Combined With Tailored Repositioning Versus a Standard Repositioning Protocol for Pressure Ulcer Prevention: A Multicenter Prospective Randomized Controlled Clinical Trial and Health Economical Analysis in a Hospital Setting||University Ghent|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|226|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02690753||2281|
NCT02690883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-14-10425|Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy|Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study||Nanfang Hospital of Southern Medical University|Yes|Not yet recruiting|March 2016|October 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02690883||2271|
NCT02691429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACAI_2015|Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans|Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans||Federal University of São Paulo|No|Recruiting|February 2016|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691429||2230|
NCT02691442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 10/45/315|Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery|Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia||University Hospital, Antwerp|No|Active, not recruiting|December 2010|April 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|75 Years|No|||February 2016|February 21, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02691442||2229|
NCT02687919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208703|Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis|Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study||University of Iowa|No|Completed|October 2012|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|45 Years|No|||February 2016|February 16, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02687919||2498|
NCT02687932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0938|Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation|Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C|PRIME|Asan Medical Center|Yes|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Both|20 Years|N/A|No|||March 2016|March 20, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687932||2497|
NCT02687945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016MAus|PT vs no PT Following THA|Study to Evaluate Outpatient Physiotherapy in Total Hip Arthroplasty: A Prospective Randomized Controlled Trial||Rothman Institute Orthopaedics||Completed|May 2015|March 2016|Actual|September 2015|Actual|N/A|Interventional|Primary Purpose: Supportive Care|2||||||Both|60 Years|N/A||||March 2016|March 14, 2016|February 17, 2016||||No||https://clinicaltrials.gov/show/NCT02687945||2496|
NCT02702791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s57963|Sustaining Training Effects Through Physical Activity|Enhancing Physical Activity to Achieve Sustainable Benefits in Extrapulmonary Consequences of COPD|STEP|Katholieke Universiteit Leuven|No|Recruiting|October 2015|June 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|40 Years|80 Years|No|||March 2016|March 3, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02702791||1358|
NCT02684604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unexplained infertility|Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility|Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility||Ain Shams Maternity Hospital|Yes|Completed|March 2015|December 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|88|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|female healthy participants who attend the outpatient clinic|February 2016|February 17, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02684604||2753|
NCT02687893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15228|Effect of Hypoglycemia on Sleep|A Randomized, Three-way, Cross-over Study to Assess the Impact of Nocturnal Hypoglycemia on Sleep in Patients With Type 1 Diabetes||Oregon Health and Science University|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|14|||Both|21 Years|45 Years|No|||February 2016|February 17, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02687893||2500|
NCT02691767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-096|Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors||Samsung Medical Center||Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691767||2204|
NCT02681588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081109|Newborns of Obese Mothers|Impact of Maternal Obesity on Fetal Development and Perinatal Events. Analysis of the Determinants of Fetal Growth.|MOBENN|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|496|||Both|18 Years|40 Years|No|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681588||2985|
NCT02681601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: 15-001926|Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer|Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer||University of California, Los Angeles|No|Recruiting|January 2016|February 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|75 Years|No|||February 2016|February 11, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02681601||2984|
NCT02707302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gztcm_001|Surgical Adhesive Drapes for Prevention and Healing of Wound Infections After Total Hip Arthroplasty|Iodophor-impregnated Versus Iodophor-free Adhesive Drapes for Prevention and Healing of Wound Infections After Total Hip Arthroplasty||Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine|Yes|Completed|January 2009|January 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02707302||1012|
NCT02678494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15NE124|Brain-Train Home Based Pain Treatment|Home Based Brain-Train Treatment of Central Neuropathic Pain Following Spinal Cord Injury||NHS Greater Glasgow and Clyde|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678494||3222|
NCT02683252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB: 2015-A01604-45|Musculoskeletal Non-tumoral Pathology Quantitative Perfusion|Magnetic Resonance (MR) Imaging Quantitative Functional Perfusion Analysis of the Musculoskeletal System: Clinical Application in Non-tumoral Pathology|AFRONT|Central Hospital, Nancy, France|Yes|Recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02683252||2857|
NCT02689570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISCERA|Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes.|Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes: the VISCERA Study|VISCERA|University Hospital, Antwerp|No|Recruiting|June 2011|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|EDTA sample|Both|18 Years|75 Years|No|Probability Sample|Adult type 1 diabetic patients regularly attending the out-patient diabetes clinic of the        Antwerp University Hospital|February 2016|February 18, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02689570||2371|
NCT02689739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0143|Validation of Ultrasound in Predicting a Low Lying Placenta Throughout Pregnancy|Lower-extremity Blood fl ow and Velocity in Obese vs Nonobese Pregnant Women||The University of Texas Medical Branch, Galveston|No|Recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective study comparing venous Doppler flow in the lower extremities of        pregnant women. Pregnant women with a BMI >/= 30 will be compared to those with a BMI < 30        who deliver at UTMB.|February 2016|February 18, 2016|February 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689739||2358|
NCT02681822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81425013|Multi-center Imaging Genetics Studies in China|Multi-center Imaging Genetics Studies in China|CHIMGEN|Tianjin Medical University General Hospital|Yes|Recruiting|November 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|10000|Samples With DNA|The investigators retain the peripheral blood drawn from antecubital vein in order to      acquire the genotype, whether the healthy young participants carry the risk allele of one      specific gene or not. No matter what genotypes the participants own, no specific      intervention measure will be done among the participants.|Both|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Healthy young Chinese Han subjects age 18-30|February 2016|February 11, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02681822||2967|
NCT02681835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.007.1MR|Endotracheal Intubation in Prehospital Scenario|Comparison of the C-MAC and Macintosh Laryngoscopes for Tracheal Intubation in Different Intubator Positions. A Randomized, Crossover, Manikin Trial||Medical University of Warsaw|Yes|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681835||2966|
NCT02703285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.013.1MR|Are Medical Personnel Can Correctly Recognize the Chest Sounds?|Are Medical Personnel Can Correctly Recognize the Chest Sounds?||Medical University of Warsaw|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02703285||1320|
NCT02691351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-11-070|Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study|Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study||Samsung Medical Center|No|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|19 Years|N/A|No|Non-Probability Sample|T-cell non-Hodgkin lymphoma|February 2016|February 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691351|5 Years|2236|
NCT02691364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/612|Different Regulation of Immune Cells in Patients With Preeclampsia|||University Medical Center Groningen|No|Not yet recruiting|April 2016|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood|Female|18 Years|40 Years|No|Probability Sample|Pregnant women with and without preeclampsia|February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691364||2235|
NCT02683798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN15HN592|BEYOND Weight Loss Maintenance Study|Comparison of Two Weight Loss Maintenance Interventions in Counterweight Plus||NHS Greater Glasgow and Clyde|No|Not yet recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|65 Years|No|||February 2016|February 17, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683798||2815|
NCT02692846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160063|WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)|Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)||National Institutes of Health Clinical Center (CC)||Recruiting|February 2016|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|1 Year|70 Years|No|||February 2016|March 11, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692846||2121|
NCT02699333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-3156|Risk Factors for Microscopic Colitis|Risk Factors for Microscopic Colitis||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1200|Samples With DNA|40 ml of blood centrifuged and separated into plasma, buffy coat and red blood cells. A      serum separator tube will be used to collect an additional 10 ml of blood for serum.      During colonoscopy, four mucosal biopsies will be obtained from normal appearing mucosa in      the ascending colon, transverse colon, and descending/sigmoid colon during the withdrawal      phase of the exam from each patient (12 research biopsies). To improve orientation 2      biopsies from each segment will be flattened onto filter paper using a forceps and placed      together into fixative. The remaining 2 biopsies from each area will be rinsed in sterile      PBS to ensure there is no contamination with fecal bacteria prior to freezing in liquid      nitrogen.|Both|35 Years|N/A|No|Non-Probability Sample|Patients who undergo colonoscopy for diarrhea at the University of North Carolina|February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02699333||1624|
NCT02694627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137D|Bandebereho Father Groups Randomized Control Trial in Rwanda|Bandebereho Father Groups: a Randomized Control Trial to Assess the Impact of Maternal, Newborn and Child Health Group Education for New and Expecting Fathers||Promundo, United States|No|Active, not recruiting|February 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2400|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02694627||1984|
NCT02685215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1912677|Prognostic Factors , Morbidity and Mortality in Patients With Muscular Dystrophies Admitted in ICU|Prognostic Factors, Morbidity, Mortality and Long Term Survival in Patients With Muscular Dystrophies Admitted in Intensive Care Unit||Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|280|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with muscular dystrophies admitted in ICU since 2005|January 2016|February 17, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02685215||2706|
NCT02685228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLOWDOSE001|Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer|Clinical Study of Low Dose of Decitabine Combined With Gemcitabine in First-line Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|SLOWDOSE001|First Hospital of Jilin University|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||February 2016|February 13, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02685228||2705|
NCT02681029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-023|The Clinical Outcomes Following Transfer of Blastocysts Cultured From Thawed Cleavage Stage Embryos|Evaluating the Clinical Outcomes Following Transfer of Blastocysts Cultured From Thawed Cleavage Stage Embryos at Royan Institute: A Phase 3, Randomized Controlled Trial||Royan Institute|Yes|Recruiting|November 2015|December 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|16 Years|37 Years|No|||February 2016|February 9, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02681029||3028|
NCT02706990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-10|Fluoroscopic Analysis of Total Knee Replacement With a Kinematic Retaining or a Posterior Stabilized Design|In Vivo Kinematic Analysis of Total Knee Replacement With a Kinematic Retaining or a Posterior Stabilized Design During Activities of Daily Living||Limacorporate S.p.a|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|34|||Both|N/A|N/A|No|||March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02706990||1036|
NCT02695043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00356|MMEPT for Traumatic Brain Injury|Multimedia Multicultural Educational Program for Traumatic Brain Injury||New York University School of Medicine|No|Not yet recruiting|March 2016|August 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695043||1952|
NCT02695069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHHFoshan-1601|Efficacy Study of Random Placenta Margin Incision to Treat Complete Placenta Previa|Random Placenta Margin Incision for Hemorrhage Control During Cesarean Section of Complete Placenta Previa Pregnancies||Maternal and Child Health Hospital of Foshan|Yes|Recruiting|January 2016|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695069||1951|
NCT02678546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH104-REC3-097|Traditional Chinese Medicine Constitution Study and the Diagnosis and Treatment of Chronic Disease in Taiwan Population|Traditional Chinese Medicine Constitution Study and the Diagnosis and Treatment of Chronic Disease in Taiwan Population||China Medical University Hospital|No|Recruiting|January 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General Population from Center of Continuing Education in China Medical University and        patients from China Medical University Hospital|February 2016|February 8, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02678546|3 Days|3218|
NCT02692248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBDCL-GELTAMO-2015|Evaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to Autologous Stem Cell Transplantation (ASCT)|Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Not yet recruiting|March 2016|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|99 Years|No|||February 2016|February 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692248||2167|
NCT02692261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-14030|Hyaluronic Matrix Efficacy for Maxillary Sinus Augmentation|Evaluation of Hyaluronic Matrix, Used With Xenograft, Efficacy in Sinus Augmentation by Histomorphometry and Micro Computed Tomography||Hacettepe University|No|Completed|September 2014|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|33 Years|69 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692261||2166|
NCT02585453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2258-PIV-0614|Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome|||Medical University of Vienna|No|Completed|April 2015|November 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02585453||10362|
NCT02701582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-01043|Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients|Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients||New York University School of Medicine|Yes|Completed|March 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|15 Years|N/A|No|||March 2016|March 2, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701582||1451|
NCT02701829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-038|Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support|Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|144|||Male|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701829||1432|
NCT02684656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UErlangen-Nurnberg|Reduction of Oxalate and Inflammation by Hemodiafiltration vs. Hemodialysis|Pilot Study of Lowering Plasma Oxalate With Hemodiafiltration to Reduce Systemic Inflammation in Patients With End-Stage Renal Disease (ESRD)||University of Erlangen-Nürnberg Medical School|No|Recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|N/A|N/A|No|||February 2016|February 22, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02684656||2749|
NCT02692508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHCM001|Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Wall Thickness> 15mm|Morphological and Functional Changes and Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Apical Wall Thickness> 15mm||Chinese Academy of Medical Sciences, Fuwai Hospital|No|Recruiting|January 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|16 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with unexplainable precordial deep T-wave inversion on ECG and with apical        thickness less than 15mm|February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692508||2147|
NCT02681536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS090216|Miniflare Versus Long Protocol in Poor Responders|||Woman's Health University Hospital, Egypt|Yes|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681536||2989|
NCT02678910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0927-F1V|Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment|Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University||University of Kentucky|No|Not yet recruiting|February 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Female|12 Years|41 Years|No|||February 2016|February 6, 2016|May 8, 2014|No|Yes||No||https://clinicaltrials.gov/show/NCT02678910||3190|
NCT02698254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0586|Reirradiation of Brain Tumors|Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||March 2016|March 2, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698254||1707|
NCT02689427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0488|Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)|A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689427||2382|
NCT02689505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1336.6|Weekly BI 836880 in Patients With Advanced Solid Tumors|Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors.||Boehringer Ingelheim||Not yet recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 23, 2016||||No||https://clinicaltrials.gov/show/NCT02689505||2376|
NCT02692573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5470|Prone or Supine Effect After Caesarean Delivery on Respiratory Outcomes in Full Term Infants|Prone or Supine Effect of Immediate Positioning After Scheduled Caesarean Delivery on Respiratory Outcomes in Full Term Infants||Montefiore Medical Center|Yes|Recruiting|December 2015|October 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|N/A|N/A|No|||February 2016|February 25, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02692573||2142|
NCT02700347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZA_WBA|Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Boosted With Allopurinol in Healthy Volunteers||National University Hospital, Singapore|No|Recruiting|February 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02700347||1546|
NCT02683486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2835|Intelligent Oxygen Therapy During Activities of Daily Living|The Assessment of Intelligent Oxygen Therapy (iO2T) in Patients on Long-term Oxygen Therapy During Activities of Daily Living||Imperial College London|No|Recruiting|January 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|February 16, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02683486||2839|
NCT02695550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-707-101|Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer|Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer||Centaurus Biopharma Co., Ltd.|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02695550||1914|
NCT02693847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPAVIR-Cirrhosis Cohort|Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients|Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients||Hospital Universitario de Valme|No|Recruiting|February 2006|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|446|Samples Without DNA|Serum samples are collected and immediately frozen for criopreservation|Both|18 Years|N/A|No|Probability Sample|HIV/HCV-coinfected patients diagnosed of cirrhosis on the basis of a liver stiffness equal        or greater than 14 kiloPascals|February 2016|February 23, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02693847|10 Years|2044|
NCT02682043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0131|Parental Perspectives of Using Toy Cars on Social Interactions of Preschool Children With Mobility Impairments|Parental Perspectives of Using Modified Toy Cars on the Social Interactions of Preschool Children With Mobility Impairments.||University of Ulster|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|12 Months|47 Months|Accepts Healthy Volunteers|||February 2016|February 9, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02682043||2950|
NCT02700568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAVORAX-1|Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors|Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors|FavorAx|Kidney Cancer Research Bureau|No|Recruiting|January 2016|January 2018|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02700568||1529|
NCT02687022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLB1019|Measurement Repeatability in Contemporary Aberrometry|A Comparative Study of Measurement Repeatability for Two Aberrometers||Moorfields Eye Hospital NHS Foundation Trust|No|Not yet recruiting|March 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|4||Anticipated|60|||Both|21 Years|60 Years|No|||February 2016|February 19, 2016|February 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687022||2567|
NCT02687035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12 - S3iCAP|The PARTNER II Trial: S3iCAP|The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves: Continued Access Program for SAPIEN 3 Intermediate Risk (S3iCAP)|The PARTNER II|Edwards Lifesciences|Yes|Recruiting|January 2015|August 2021|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|N/A|No|||February 2016|March 10, 2016|February 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687035||2566|
NCT02689895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATF study|Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens|Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens|ATF|University of Zimbabwe|No|Recruiting|February 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|6 Years|18 Years|No|||February 2016|February 18, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02689895||2346|
NCT02689908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VETH123|Individualized Radiation Dose Control|Individualized Radiation Dose Control: Could Neck Circumference be a New Somatometric Parameter to Adjust Tube Current for Thorax CT?||Van Military Hospital|No|Recruiting|May 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02689908||2345|
NCT02678624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2013-203-A|Project Collabri for Treatment of Anxiety|Project Collabri. The Effects of a Danish Model of Collaborative Care for People With Anxiety in General Practice||Mental Health Centre Copenhagen|Yes|Recruiting|November 2014|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1092|||Both|18 Years|80 Years|No|||February 2016|February 7, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02678624||3212|
NCT02704858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO100-01|Safety and Efficacy Study in Recurrent Grade IV Glioma|An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma||Neonc Technologies, Inc.|Yes|Not yet recruiting|March 2016|October 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704858||1199|
NCT02679287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18617|Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control|Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control||University of Virginia|Yes|Not yet recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|No|||February 2016|February 9, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679287||3161|
NCT02679495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015WS0366|Lifestyle Intervention for Prevention of Gastric Neoplasm|Positive Lifestyle Interventions (Such as Diet Modification and Smoking Cessation) for the Prevention of Gastric Pre-cancer and Cancer Occurrences in Patients With Chronic Atrophy Gastritis and Reccurence of Gastric Cancer After Edoscopica Resection||Shandong University|No|Recruiting|March 2015|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||February 2016|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02679495||3145|
NCT02695511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26039-A|CALERIE Phase II Ancillary: Metabolic|CALERIE Phase II Ancillary 2: Metabolic Adaptation After Two Years of Caloric Restriction in Non Obese Humans|CALERIE-II|Pennington Biomedical Research Center|Yes|Completed|May 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|75|||Both|25 Years|46 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02695511||1917|
NCT02683070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNB2015-306|Pudendal Nerve Block for Catheter-related Bladder Discomfort Prevention|Comparison of Pudendal Nerve Block With Ropivacaine and Intravenous Tramadol for Prevention of Catheter-related Bladder Discomfort: a Randomized Controlled Trial||West China Hospital|Yes|Not yet recruiting|March 2016|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Male|18 Years|75 Years|No|||February 2016|February 11, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683070||2871|
NCT02683083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-VHH1|Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients|Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study|CAM-VHH1|Camel-IDS NV|Yes|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02683083||2870|
NCT02706938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBELGA|Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease|Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study|IBELGA|Universidad Nacional de Colombia|No|Recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706938||1040|
NCT02687594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFMCRP-MEAF-PA21-01-EU|Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)|Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis|VERIFIE|Vifor Fresenius Medical Care Renal Pharma|Yes|Not yet recruiting|February 2016|||October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients with a diagnosis of hyperphosphataemia who are due to be treated        with Velphoro according to the product's Summary of Product Characteristics (SmPC) are        eligible for this non-interventional study.|February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02687594||2523|
NCT02691143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSR07|The Effect of TheraBand® Kinesiology Tape on Post-manipulation Pain and Range of Motion|The Effect of TheraBand® Kinesiology Tape on Post-manipulation Pain and Range of Motion|TBKTManip|Sport and Spine Rehab Clinical Research Foundation|No|Recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2016|February 19, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02691143||2252|
NCT02691273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM01-HMO-CTIL|Applicability of Cellular Application in Diabetes Type 2 Patients.|||Hadassah Medical Organization|No|Recruiting|March 2015|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||January 2016|February 21, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02691273||2242|
NCT02679157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2015/1799-31|Prognostication of Need for Rehabilitation and Special Support in ICU Survivors|Prognostication of Need for Rehabilitation and Special Support in ICU Survivors. Two Studies Prognosticating Adverse Physical or Psychological Outcome|PROGRESS-ICU|Karolinska University Hospital|Yes|Recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Adult ICU patients|February 2016|February 5, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02679157||3171|
NCT02707185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-080|Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training|Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training||St. Luke's-Roosevelt Hospital Center|Yes|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|157|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT02707185||1021|
NCT02684617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-155|Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)|Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).|KEYNOTE-155|Merck Sharp & Dohme Corp.|No|Not yet recruiting|March 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684617||2752|
NCT02684630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-5054|Trima Accel® System Post Count Algorithm Study|A Multicenter Study to Evaluate Modified Postcount Algorithm Software on the Trima Accel® System in Volunteer Blood Donors||Terumo BCT|No|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|November 3, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684630||2751|
NCT02680366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201600301|Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells|A Multi-center, Randomized, Single-blind, Controlled Clinical Trial of Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|February 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02680366||3079|
NCT02707809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512039MINB|Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient|Effects of Perioperative Dexmedetomidine Infusion on Microcirculation and Kidney and Intestinal Injury in Kidney Transplant Recipients||National Taiwan University Hospital|No|Not yet recruiting|April 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|70|||Both|20 Years|70 Years|No|||March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707809||973|
NCT02698241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERVENE-HF|Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure|Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure||Medtronic Cardiac Rhythm Disease Management|No|Not yet recruiting|April 2016|||May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in heart failure patients with an implanted, commercially        available, Medtronic CRT-D device and Medtronic leads.|February 2016|February 29, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698241||1708|
NCT02693808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1175|New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression|New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression||Haukeland University Hospital|No|Enrolling by invitation|November 2015|January 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02693808||2047|
NCT02692196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESTC-neuSCAN-09|Fronto-limbic Functional Connectivity Via Real-time fMRI Neurofeedback|Voluntary Regulation of Fronto-limbic Functional Connectivity: A Proof-of-concept Real-time fMRI Study||University of Electronic Science and Technology of China||Recruiting|June 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692196||2171|
NCT02680769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3577|Effect of Magnesium Supplementation in COPD|Daily Supplementation of Magnesium Citrate in Moderate-severe Chronic Obstructive Pulmonary Disease: a Randomized, Controlled, Double-blind Trial||University of Padova|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680769||3048|
NCT02698800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ6404|Blue Blockers and Insomnia|Blocking Nocturnal Blue Light to Treat Insomnia: A Pilot Randomized Controlled Trial||Columbia University|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02698800||1665|
NCT02694861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMR1501.001-M (10/15)|CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study|A Multi-Center Single Arm One Year Prospective Follow-Up of Patients Treated With the CryoLife CardioGenesis Holmium:YAG Laser System for Transmyocardial Revascularization (The TMR 365 Study)||CryoLife, Inc.|No|Not yet recruiting|March 2016|October 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who meet the eligibility criteria at the selected centers will be provided an        opportunity to participate.|February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02694861||1966|
NCT02680977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBN.SC.013/2015|Mucuna Pruriens Therapy in Parkinson's Disease|Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.||ASST Gaetano Pini-CTO|No|Recruiting|February 2016|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|15|||Both|21 Years|N/A|No|||February 2016|February 15, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680977||3032|
NCT02683915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-602|Reno-protective Effect of Brain Cooling in Newborn With Hypoxia|Acute Kidney Injury in Asphyxiated Infants Treated by Therapeutic Hypothermia||Mansoura University Children Hospital|Yes|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|24 Hours|No|Probability Sample|Infants will be enrolled into two groups either group 1(cooled group) if identified within        12 hours of age and admitted at hospital with a validated cooling facility or group 2(non        cooled group) if identified older than 12 hours of age or admitted at hospital out of        reach of a validated cooling facility (cooling still not governmentally submitted in Egypt        at wide scale).|February 2016|February 11, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02683915||2806|
NCT02684214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTK IRB-15-02680-FB|Implementing Prevention Plus for Childhood Overweight and Obesity in Food Secure and Insecure Families|||University of Tennessee||Not yet recruiting|April 2016|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|4 Years|10 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02684214||2783|
NCT02709915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0233-15-WOMC|Effect of Meal Frequency and Timing on Insulin Dose and Clock Gene in Type 2 Diabetic Patients|Effect of Meal Frequency and Timing on Glycemic Control, Daily Insulin Dose Requirements and Clock Gene Expression in Uncontrolled Type 2 Diabetic Patients|Bdiet-6Mdiet|Tel Aviv University|No|Recruiting|March 2016|August 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|75 Years|No|||March 2016|March 15, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02709915||811|
NCT02689271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/0692|CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr|CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr|INNOVATE|University College, London|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|365|Samples With DNA|Blood and urine samples|Male|18 Years|N/A|No|Non-Probability Sample|Men with suspected prostate cancer|February 2016|February 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02689271||2394|
NCT02691923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12090|Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker|Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology||Dartmouth-Hitchcock Medical Center|Yes|Not yet recruiting|February 2016|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|21 Years|N/A|No|||February 2016|February 26, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691923||2192|
NCT02691936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1570|Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy|A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause|VeLVET|The Cleveland Clinic|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Female|N/A|N/A|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691936||2191|
NCT02681328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-000055|Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules|Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules||Jonsson Comprehensive Cancer Center|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients undergoing thyroid FNA within the UCLA Health System|February 2016|February 10, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681328||3005|
NCT02680262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|af_randers|Self-sampling for Non-participants in an Organised Cervical Cancer Screening Programme|A Three-armed Randomised Controlled Trial of Non-participants in an Organised Cervical Cancer Screening Programme|CHOiCE|University of Aarhus|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|9327|||Female|30 Years|64 Years|No|||January 2016|February 8, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02680262||3087|
NCT02680275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16|Efficacy of Dead Sea Peloid Gel in Chronic Endometritis|Efficacy of Intravaginal Dead Sea Peloid Gel Administration in Complex Treatment of Chronic Endometritis and Reproductive Disorders: Randomized Placebo-controlled Prospective Study||Scientific Center for Family Health and Human Reproduction Problems, Russia|Yes|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|45 Years|No|||September 2015|February 10, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680275||3086|
NCT02678780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE1509|Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors|Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)|TALENT|Grupo Espanol de Tumores Neuroendocrinos|No|Recruiting|October 2015|September 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02678780||3200|
NCT02678793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-MN-203|An Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|An Open-Label, Multiple-Dose Extension Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)||Centrexion Therapeutics||Active, not recruiting|December 2015|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02678793||3199|
NCT02678806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDWTaoBai|Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and Microvascular Invasion||RHCC:BCLC-A|Guangxi Medical University||Recruiting|December 2015|||December 2025|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|N/A|N/A|No|||February 2016|February 5, 2016|January 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02678806||3198|
NCT02692027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASCADE|Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho|Same Day Community-based ART Initiation Versus Clinic-based Pre-ART Assessment and Counselling for Individuals Newly Tested HIV-positive During Community-based HIV Testing in Rural Lesotho - a Randomized Controlled Trial|CASCADE|Swiss Tropical & Public Health Institute|Yes|Recruiting|February 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|260|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02692027||2184|
NCT02707354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0327|Early Detection of Mucosal Abnormalities in Graft-versus-host Disease|Early Detection of Mucosal Abnormalities in Graft-versus-host Disease|E-mage|Nantes University Hospital|No|Not yet recruiting|March 2016|March 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02707354||1008|
NCT02688686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-DC/CIK-NSCLC-001|Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases|Safety and Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases: a Phase I/II Study||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Not yet recruiting|February 2016|||February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688686||2439|
NCT02688699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12243648|Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract|Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract||University of Turin, Italy||Not yet recruiting|April 2016|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|288|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688699||2438|
NCT02693171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIV-NB-401|Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients|A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients||United Therapeutics|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|1 Year|18 Years|No|Non-Probability Sample|High-risk neuroblastoma patients prescribed Unituxin|February 2016|February 25, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693171||2096|
NCT02692820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010294QM|Preventing Preterm Birth With Probiotics|Preventing Preterm Birth With Probiotics - Pilot Randomised Trial|PrePro|Queen Mary University of London|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|366|||Female|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02692820||2123|
NCT02692833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010706|Telomere Biology and AKI in Cardiac Surgery|Telomere Length and Telomerase Activity as a Predictor of Acute Kidney Injury Following Cardiac||Queen Mary University of London|No|Recruiting|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Blood samples collected for:      Peripheral Blood Mononuclear Cells (PBMC) DNA extraction from buffy coat Right atrial tissue      samples (subset) Urine and plasma/serum for urinary biomarkers (subset)|Both|18 Years|100 Years|No|Non-Probability Sample|All patients undergoing cardiac surgery|February 2016|February 22, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02692833|7 Days|2122|
NCT02703012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-EIT-01|Clinical Application of Electrical Impedance Tomography for Individual Adjustment of Ventilator Settings|Pilot Clinical Study on Patient-Specific Adjustment of Ventilator Settings Using Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrome|CLEAR|University of Schleswig-Holstein|No|Recruiting|January 2016|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02703012||1341|
NCT02703025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL NO. CR-GCB- 70/ 07/14|Evaluation of GCB-70 in Overweight Subjects|CLINICAL EVALUATION OF GCB-70 IN OVERWEIGHT SUBJECTS:An Add-On Study||Chemical Resources|No|Active, not recruiting|September 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|105|||Both|18 Years|65 Years|No|||September 2015|March 14, 2016|September 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02703025||1340|
NCT02696915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/811|Fascia Iliaca Compartment Block for Proximal-end Femur Fractures|Fascia Iliaca Compartment Block in Proximal End Femur Fractures, Does it Make a Difference?||Mansoura University|Yes|Completed|January 2015|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|80 Years|No|||March 2016|March 4, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02696915||1810|
NCT02687880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2047|Testicular Tissue Cryopreservation for Fertility Preservation in Male Patients Facing Infertility-causing Diseases or Treatment Regimens|Testicular Tissue Cryopreservation for Fertility Preservation in Male Patients Facing Infertility-causing Diseases or Treatment Regimens||University of Colorado, Denver|No|Not yet recruiting|March 2016|March 2026|Anticipated|March 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|This study will provide a pool of research tissue that will be used to develop and test      methods for manipulation and cryopreservation of testicular tissue. Progress in these      investigations may open up a range of new fertility preservation techniques to patients that      currently have no options. At the same time, a substantial portion of the patient's tissue      will be cryopreserved and reserved for his own future use.|Male|31 Days|39 Years|No|Non-Probability Sample|Males scheduled to undergo surgery, chemotherapy, drug treatment and/or radiation for the        treatment or prevention of a medical condition or malignancy with risk of causing        permanent and complete loss of subsequent testicular function.|February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02687880||2501|
NCT02692157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#7173|NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study|NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study|NT-814|New York State Psychiatric Institute|Yes|Not yet recruiting|February 2016|September 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|12|||Male|21 Years|59 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692157||2174|
NCT02703298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-002|Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients|A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Solid Tumors in Asians||TaiRx, Inc.||Recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||March 2016|March 22, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703298||1319|
NCT02680873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QASMSD5188453|Efficacy of SASI Bypass for Type-2 Diabetic Obese Patients|Efficacy of Single Anastomosis Sleeve Ileal (SASI) Bypass for Type-2 Diabetic Obese Patients: Loop Gastric Bipartition, a Novel Metabolic Surgery Procedure.|SASI|Mansoura University|Yes|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||February 2016|February 9, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02680873||3040|
NCT02688920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007742|Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes|A Single-center, Observational, Intraluminal Imaging Study of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes Undergoing Endoscopy of the Upper Gastrointestinal Tract||Mayo Clinic|No|Not yet recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing previously scheduled routine endoscopy of the upper gastrointestinal        tract.|February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688920||2421|
NCT02688933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS14587|A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus|Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus||Sanofi|No|Not yet recruiting|May 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|616|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688933||2420|
NCT02681289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO13 186-01|Physiotherapy of At-Risk Infants, Physiotherapist or Family?|Physiotherapy of At-Risk Infants, Physiotherapist or Family? A Randomized Intervention Study|Infant|Hacettepe University|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|15 Months|No|||February 2016|February 11, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02681289||3008|
NCT02703311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1-3|REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System|REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System|REPAIR|Valtech Cardio Ltd|No|Not yet recruiting|May 2016|May 2019|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02703311||1318|
NCT02682706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKNZ BASEC 2015-00199|Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study|Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study|MIBAT|University Hospital, Basel, Switzerland|No|Recruiting|February 2016|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|plasma|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682706||2899|
NCT02691468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YeungnamUDLT|Displacement Between PVC and Silicon DLT|Comparison of Displacement Between Polyvinyl Chloride(PVC) and Silicon Double-Lumen Endobronchial Tubes(DLT) During Change of Position||Yeungnam University College of Medicine|Yes|Recruiting|February 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|108|||Both|18 Years|75 Years|No|||February 2016|February 21, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02691468||2227|
NCT02686099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0614|Sternal Closure With SternaLock 360: First in Man Study|SternaLock 360 First in Man Study: A Prospective, Randomized Controlled Trial|SL360|Biomet, Inc.|No|Recruiting|July 2015|March 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|30 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02686099||2638|
NCT02686112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNZ-0043-14|Pregnancy Outcome in Woman With Threatened Abortion|Pregnancy Outcome in Woman With Threatened Abortion|POTA|Bnai Zion Medical Center|No|Completed|January 2007|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|3000|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women who attanded the Emergency department with vaginal bleeding and/or abdominal pain        and were on their 20th week of pregnancy or less.|February 2016|February 15, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02686112||2637|
NCT02695888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012431|Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving|A Pilot Study of a Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving||University of Pennsylvania|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|16 Years|17 Years|Accepts Healthy Volunteers|||February 2016|March 2, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695888||1889|
NCT02681913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1437|Adenosine as an Adjunct to Blood Cardioplegia|The Effect of Adenosine on Myocardial Protection in Intermittent Warm Blood Cardioplegia: A Randomized Placebo-controlled Trial||Amphia Hospital|No|Recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681913||2960|
NCT02693509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWTG01|Get With The Guidelines-Heart Failure Registry|Get With The Guidelines-Heart Failure Registry||American Heart Association|Yes|Recruiting|January 2005|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|128026|||Both|18 Years|125 Years|Accepts Healthy Volunteers|Probability Sample|The study populations is primary diagnosis or secondary diagnosis of heart failure|February 2016|February 25, 2016|April 8, 2013||No||No||https://clinicaltrials.gov/show/NCT02693509|1 Year|2070|
NCT02582476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120542|Bumetanide in Hypokalaemic Periodic Paralysis|A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol||University College, London|Yes|Recruiting|January 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|64 Years|No|||October 2015|October 21, 2015|August 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02582476||10591|
NCT02582658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-695|Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)|REAL|AbbVie|No|Recruiting|October 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients with chronic infection of HCV Genotype 1 (GT1) or Genotype 4 (GT4)|January 2016|January 23, 2016|October 20, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02582658||10577|
NCT02705326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUL_2R44DC013467_OptiSpeech|Evaluating the Efficacy of Opti-Speech for Speech Treatment|Evaluating the Efficacy of Opti-Speech, a 3D Visual Feedback System, for Speech Treatment||Vulintus, Inc.|Yes|Recruiting|January 2016|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|85 Years|No|||March 2016|March 9, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02705326||1163|
NCT02705339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x375|Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)|Genomic Landscape of EGFR Mutant NSCLC Prior to Rociletinib and at the Time of Disease Progression Following Rociletinib||Washington University School of Medicine|No|Not yet recruiting|May 2016|April 2020|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705339||1162|
NCT02689297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHP-018-EI-2|Three Different Oral Hygiene Regimes on Three Volatile Sulfur Compounds|||Tokyo Medical and Dental University||Completed|September 2013|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02689297||2392|
NCT02689492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.51|SATisfaction and Adherence to COPD Treatment|SATisfaction and Adherence to COPD Treatment||Boehringer Ingelheim||Recruiting|November 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|40 Years|99 Years|No|Non-Probability Sample|COPD pts|March 2016|March 21, 2016|November 17, 2015||||No||https://clinicaltrials.gov/show/NCT02689492||2377|
NCT02681549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kluger121815|Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer|A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases||Yale University|Yes|Not yet recruiting|May 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681549||2988|
NCT02682875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zehra123|The Evaluation With Artificial Neural Network of Pain Scales in Children (ANN)|The Evaluation With Artificial Neural Network of Pain Scales in Children|ANN|Cukurova University|No|Recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|2 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|pediatric patients between 2 months to 18 years undergoing any surgery was included on        this study. Pain of these patients' will be evaluated by many pain scales in the        postoperative period. These scales include OUCHER, Visiuel Analog Scale, FLACC, Faces Pain        Scale revise, Wong Baker Faces Scale, Faces Pain Scale, Numeric rating Scale, Verbal        Rating Scale, CHEOPS and also age, blood pressure, respiratuar rate, heart rate will be        recorded.|February 2016|February 10, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02682875|4 Months|2886|
NCT02689440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1040|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib||M.D. Anderson Cancer Center|No|Recruiting|February 2016|||February 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689440||2381|
NCT02694263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0527|Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan|A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study|Can Do Ramadan|University of Leicester|Yes|Not yet recruiting|March 2016|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|116|||Both|25 Years|N/A|No|||December 2015|February 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694263||2012|
NCT02692898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916069|Biomarker Analysis of Central Nervous System Tumors|Biomarker Analysis of Central Nervous System Tumors||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2016|November 2024|Anticipated|November 2024|Anticipated|N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Both|N/A|99 Years|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02692898||2117|
NCT02681770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3003-2016|Individual and Dyadic Functioning, Adherence, and Quality of Life After Kidney Transplantation|Individual and Dyadic Functioning of Patients and Their Spouses After Kidney Transplantation With Regard to Adherence and Quality of Life|IDyAL|Hannover Medical School|No|Not yet recruiting|June 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a kidney transplantation at Hannover Medical School presenting for monthly        follow-up appointments at the nephrological transplantation outpatient clinic|February 2016|February 11, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02681770||2971|
NCT02682004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51|Serotonin, Leptin and Adiponectin Level in Patients With Postpartum Depression: Controlled Study|Serotonin, Leptin and Adiponectin Level in Patients With Postpartum Depression: Controlled Study||Zeynep Kamil Maternity and Pediatric Research and Training Hospital|Yes|Recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|According to Edinburg depression scale womenn who taken 13 point and above.|February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682004||2953|
NCT02704299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMG-TCM-GC-1.1|The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.|A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.||Cellular Biomedicine Group Ltd.|Yes|Not yet recruiting|March 2016|September 2018|Anticipated|June 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02704299||1242|
NCT02687607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP15-001|CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms|CLinical Assessment of WEB® Device in Ruptured aneurYSms|CLARYS|Sequent Medical, Inc|No|Recruiting|January 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|The decision to use a WEB device to treat the patient has been made before and        independently of the decision to include the patient in this Registry|February 2016|February 16, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687607|12 Months|2522|
NCT02687620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCU-12032014|Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study|Does Immunogenicity Have an Influence on the Efficacy of Anti-tumor Necrosis Factor (Anti-TNF) Therapy in Patients With Ankylosing Spondylitis (AS): An Inception Cohort Study||Izmir Katip Celebi University|No|Recruiting|September 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|During the serum sample aquisition whole blood samples with EDTA will be collected and      stored.|Both|18 Years|N/A|No|Non-Probability Sample|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria        for the classification of AS, and with a new anti-TNF agent prescription (either for the        first time or switched) in the last two weeks period will be included. Treatment with        anti-TNF agents will be in accordance with the regulations of Turkish Social Security        Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as        ASAS/EULAR recommendations for the management of AS.|February 2016|February 17, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02687620||2521|
NCT02679352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08|SMR Stemless Shoulder Arthroplasty Clinical Study|A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR STEMLESS||Limacorporate S.p.a|No|Recruiting|March 2016|September 2023|Anticipated|September 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02679352||3156|
NCT02682056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00075816|Glucose Measurement Using Microneedle Patches|Glucose Measurement Using Microneedle Patches|GUMP|Emory University|Yes|Recruiting|August 2015|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|7 Years|18 Years|No|||February 2016|February 10, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682056||2949|
NCT02704546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-14-1245-HS-CTIL|Methylphenidate (Ritalin®) Effect During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients|The Effect of the Drug Methylphenidate on Physiological Stress and Function During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients||Sheba Medical Center|No|Not yet recruiting|April 2016|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02704546||1223|
NCT02704559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1366001|A Randomized, Open-label, Oral Dose, Crossover Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects|||Daewoong Pharmaceutical Co. LTD.||Completed|December 2015|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 5, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02704559||1222|
NCT02690532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006018|Gut Permeability Assessment in Celiac and Gluten Sensitive Children|The Role of Gut Permeability in Developing Celiac Disease and Non-Celiac Gluten Sensitivity||Mayo Clinic|No|Recruiting|March 2016|June 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|2 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of three groups of children, aged 2-17 years. The first        group will be children with siblings that have celiac disease, the second group will be        children with non-celiac gluten sensitivity and the third group will be healthy children.|February 2016|March 8, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690532||2298|
NCT02690545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1532-ATL|Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL|Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|May 2034|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690545||2297|
NCT02690558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1520|Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy|Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|April 2016|April 2020|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690558||2296|
NCT02695498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT008406|Mindfulness and Mechanisms of Pain Processing in Adults With Migraines|Mindfulness and Mechanisms of Pain Processing in Adults With Migraines||Wake Forest School of Medicine|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02695498||1918|
NCT02682836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1537|Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study|Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|21 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682836||2889|
NCT02707016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-153|Different Doses of Sevoflurane During Induction of Anesthesia on Emergence Delirium in Children|Emergence Delirium in Children: a Randomized Clinical Trial of Different Doses of Sevoflurane During Induction of Anesthesia||Pontificia Universidad Catolica de Chile|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|2 Years|7 Years|No|||March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02707016||1034|
NCT02684045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-03|Retrospective Chart Review to Assess Outcomes in Subjects That Received MAGNIFUSE® in the Posterolateral Lumbar Spine|A Retrospective Review of Charts to Assess Outcomes in Subjects That Received MAGNIFUSE® DBM in the Posterolateral Lumbar Spine||Medtronic Spinal and Biologics||Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who underwent a posterolateral surgical procedure with MAGNIFUSE in the lumbar        spine.|February 2016|February 11, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02684045||2796|
NCT02684058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRB436G2201|Phase II Pediatric Study With Dabrafenib in HGG Patients|Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib Treatment in Children and Adolescent Patients With BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)||Novartis|No|Not yet recruiting|May 2016|November 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Years|17 Years|No|||March 2016|March 9, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684058||2795|
NCT02682238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-4000-CL-202|A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis|A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects With Palmar Hyperhidrosis||Brickell Biotech, Inc.|No|Not yet recruiting|February 2016|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682238||2935|
NCT02682511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-IFE-004|Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension|A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)||Cumberland Pharmaceuticals|Yes|Not yet recruiting|September 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682511||2914|
NCT02686892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIS-2015-INCIDENCIA|An Epidemiological Study of the Incidence of Inflammatory Bowel Disease in Spain|An Epidemiological Study of the Incidence of Inflammatory Bowel Disease in Spain|INCIDENCIA|Hospital Universitario de la Princesa|No|Not yet recruiting|May 2016|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|This is a descriptive observational study in which the whole Spanish population will be        considered and which will include all incident cases of inflammatory bowel disease        occurring in a year.|February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02686892||2577|
NCT02686905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaBari Study|Vitamin Supplementation After Bariatric Surgery|Effects of Vitamin Supplementation on Micronutrient Blood Values, Body Composition, Waist-to-hip Ratio and Fasting Blood Glucose After Bariatric Surgery||California State Polytechnic University, Pomona||Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02686905||2576|
NCT02696863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-05|Plan for Systematic Identification of Lung Cancers of Occupational Origin: Implementation Study||RECAP 2|Institut de Cancérologie de la Loire|No|Not yet recruiting|February 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02696863||1814|
NCT02701075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSNRP-N13-04|MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain|MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain||Brooke Army Medical Center|No|Recruiting|September 2013|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|79 Years|No|||March 2016|March 2, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02701075||1490|
NCT02690766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0162|Translating Healthy Lifestyle Interventions for Cancer Survivors|Translating Healthy Lifestyle Interventions for Breast and Endometrial Cancer Survivors With Diabetes||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|March 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Female|30 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02690766||2280|
NCT02695524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1179-1921|Exercise Application in the Treatment of Patients With Shoulder Impingement|Effect of Strengthening of Periscapular Muscles With Addition of Neuromuscular Training on the Improvement of Pain and Disability in Patients With Shoulder Impingement: Randomized Controlled Trial||University of Sao Paulo|Yes|Not yet recruiting|March 2016|June 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|February 24, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02695524||1916|
NCT02683330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYETH (S/F) 15/16 112|Distant Delivery of a Mindfulness-based Intervention for People Affected by Parkinson's Disease|Mindfulness-based Intervention for People Affected by Parkinson's Disease: A Distant-delivered Randomised Pilot Trial|MindPD|City University, London|No|Recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02683330||2851|
NCT02697149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151203-5|Nonradiation-to-endoscopist Endoscopic Retrograde Cholangiopancreatography in Patients With Complexity Level I/II|The Effectiveness and Safety of Nonradiation-to-endoscopist Endoscopic Retrograde Cholangiopancreatography in Patients With Complexity Level I/II||Fourth Military Medical University|Yes|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|240|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|18-90 years old, patients undergoing endoscopic retrograde cholangiopancreatography|February 2016|February 28, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02697149||1792|
NCT02697162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCath-CHZ-01|Antiseptic-coated Intermittent Urinary Catheter|Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children|GuardianCath|Children's Hospital Zagreb|No|Not yet recruiting|June 2016|June 2018|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|1 Month|18 Years|No|||March 2016|March 4, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697162||1791|
NCT02688569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004488HS|Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study|Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study|SPIN-CWP|University of Missouri-Columbia|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688569||2448|
NCT02688712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-050A|ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer|Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma||Providence Health & Services|No|Not yet recruiting|February 2016|June 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688712||2437|
NCT02684929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA NT14416|Effects of Chronic Dietary Exposure to Branched Chain Amino Acids|Effects of Chronic Dietary Exposure to Branched Chain Amino Acids on Insulin Sensitivity Measures in Healthy Vegans and Omnivores||Charles University, Czech Republic|No|Completed|April 2013|December 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02684929||2728|
NCT02694068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47196-A|Biological Determinants of Peritoneal Dialysis|Biological Determinants of Peritoneal Dialysis|Bio-PD|University of Washington|No|Recruiting|April 2014|||March 2019|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|4865|Samples With DNA|Blood, Dialysate, and DNA may be collected|Both|20 Years|N/A|No|Non-Probability Sample|Adults undergoing maintenance Peritoneal Dialysis therapy.|February 2016|February 26, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02694068||2027|
NCT02694081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130021|The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric|The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction||Jilin University|Yes|Not yet recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|85 Years|No|||February 2016|February 27, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02694081||2026|
NCT02698527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0130|The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies|The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies||Women and Infants Hospital of Rhode Island|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|128|||Female|18 Years|99 Years|No|||February 2016|March 2, 2016|May 18, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02698527||1686|
NCT02681926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72607|Impact of a New Ablation Tracking Tool in Paroxysmal Atrial Fibrillation Ablation With Contact Force Technology|VISITALY-Impact of a New Ablation Tracking Tool in Paroxysmal Atrial Fibrillation Ablation With Contact Force Technology|VISITALY|Azienda Ospedaliero, Universitaria Pisana|No|Recruiting|December 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|210|||Both|18 Years|75 Years|No|Probability Sample|Consecutive patients undergoing PAF ablation with abovementioned devices in several        centers in Italy|February 2016|February 12, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681926|12 Months|2959|
NCT02681991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNM-001|Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.|||Daewon Pharmaceutical Co., Ltd.||Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|19 Years|80 Years|No|||February 2016|February 14, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681991||2954|
NCT02685891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_2016-00254|Brain Maturation and Sleep|Exploring Diurnal Changes in Markers of Cortical Plasticity Using Multimodal Imaging in Healthy Children, Adolescents and Adults|BMS|University Children's Hospital, Zurich|Yes|Not yet recruiting|March 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|90|||Both|8 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02685891||2654|
NCT02703805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFF133486|Fit For Function: A Community Wellness Program for Persons With Stroke|Fit For Function: A Community Wellness Program for Persons With Stroke||McMaster University|No|Recruiting|May 2014|June 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|216|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|October 14, 2014||No||No||https://clinicaltrials.gov/show/NCT02703805||1280|
NCT02703818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA2015-4 US|SCS for the Treatment Of Chronic Pain of the Upper Extremities|Multi-Center, Prospective, Clinical Trial of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment Of Chronic Pain of the Upper Extremities|UEP|Nevro Corp|No|Recruiting|February 2016|March 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703818||1279|
NCT02680314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-5341|Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?|Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?||Montefiore Medical Center|Yes|Not yet recruiting|February 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|45 Years|No|||February 2016|February 8, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680314||3083|
NCT02685527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS-ED-02-2015|Acute Gastroenteritis: Development of PCR Analysis and Algorithm for Fast Clarification of Isolation Indication|Acute Gastroenteritis: Development of PCR Analysis and Algorithm/Criteria for Fast Clarification of Isolation Indication||University of Southern Denmark|No|Recruiting|February 2015|May 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples Without DNA|feces for bacterial and virus determination|Both|18 Years|N/A|No|Non-Probability Sample|Acutely admitted patients that contact an emergency department of the Hospital of Southern        Denmark or St. Franziskus Hospital, Flensburg, Germany or Diakonissenkrankenhaus,        Flensburg, Germany with symptoms of acute gastroenteritis.|February 2016|February 17, 2016|August 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02685527||2682|
NCT02692547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP312|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes|DREAMED|Medtronic|No|Withdrawn|December 2015|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|December 3, 2015||No|Study Cancelled|No||https://clinicaltrials.gov/show/NCT02692547||2144|
NCT02699580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0741|Protective Effect of Biodegradable Collagen Implant (Ologen) in Scleral Thinning After Strabismus Surgery|||Yonsei University|No|Recruiting|December 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|10 Years|70 Years|No|||February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02699580||1605|
NCT02699593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5809|Clinical Evaluation of Approved Contact Lenses|||Johnson & Johnson Vision Care, Inc.|Yes|Recruiting|February 2016|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|140|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699593||1604|
NCT02699606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108120|A Study to Evaluate the Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine KinaseInhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma|A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine KinaseInhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma||Janssen Research & Development, LLC|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699606||1603|
NCT02693899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0374|Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia|Monocentric, Biological, Uncontrolled, Prospective Study on the Feasibility of Plasma FLT3 Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated With Intensively for Acute Leukemia|FLAM/FLAL|Nantes University Hospital|No|Not yet recruiting|April 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Plasma (15 maximum plasma tubes of 9 mL per patient during follow-up)|Both|18 Years|N/A|No|Probability Sample|All adults supported in the Clinical Hematology of the Nantes University Hospital between        the beginning of the study and the end of 2017, for the diagnosis and treatment of        myelogenous leukemia or acute lymphoblastic requiring intensive chemotherapy and possibly        allogeneic haematopoietic stem cells.|February 2016|February 26, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693899||2040|
NCT02679859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No Unique ID yet|B-type Natriuretic Peptide Guided Therapy to Improve Clinical Outcomes for Patients Undergoing Non-cardiac Surgery|A Prospective, Multi-centre, Randomised Trial of B-type Natriuretic Peptide Guided Therapy to Improve Clinical Outcomes for Patients Undergoing Non-cardiac Surgery: the BETTER Surgery Pilot Trial|BETTER pilot|University of KwaZulu|No|Not yet recruiting|July 2016|July 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679859||3118|
NCT02679872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R100-A7166|Video-assisted Thoracoscopic Surgery Teams' Perception of Non-technical Skills|Important Non-technical Skills When Performing Video-assisted Thoracoscopic Surgery: Perceptions of the Operating Team||Copenhagen Academy for Medical Education and Simulation|No|Enrolling by invitation|February 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||5|Anticipated|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical doctors, medical nurses with experience in VATS|February 2016|February 17, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679872||3117|
NCT02702492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-9274-901|PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA)|A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma|PANAMA|Karyopharm Therapeutics, Inc|No|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|N/A|N/A|No|||March 2016|March 3, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702492||1381|
NCT02684344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59730|Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention|Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention||University of Rochester|Yes|Recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Male|40 Years|N/A|No|||February 2016|February 15, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684344||2773|
NCT02684357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.28|BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)||Boehringer Ingelheim||Recruiting|February 2016|November 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 16, 2016||||No||https://clinicaltrials.gov/show/NCT02684357||2772|
NCT02682745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-BPSR-101|Single Dosing Clinical Trial of HL151|Single Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects||Hanlim Pharm. Co., Ltd.|No|Active, not recruiting|January 2016|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02682745||2896|
NCT02682758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5161R|Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution|Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution||Heinrich-Heine University, Duesseldorf|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682758||2895|
NCT02682992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLT-Mucositis|Low-Level Laser Therapy for Prevention of Oral Mucositis|A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer||University of Pittsburgh|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682992||2877|
NCT02684188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177-15|Rural Options At Discharge Model of Active Planning|Rural Options At Discharge Model of Active Planning|ROADMAP|University of Montana|No|Enrolling by invitation|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|145|||Both|18 Years|75 Years|No|||February 2016|February 11, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02684188||2785|
NCT02698488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201603|Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology|Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology: a Randomized Controlled Trial||Istanbul University|No|Not yet recruiting|March 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|300|||Female|21 Years|38 Years|No|||February 2016|February 29, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698488||1689|
NCT02694419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS|The Effect of Obesity on Endometrium in PCOS|Effect of Body Weight on Endometrial Ultrasonographic Characteristics in Polycystic Ovary Syndrome Patients|OB-PCO|Assiut University|Yes|Completed|January 2015|January 2016|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|100|||Female|18 Years|40 Years|No|Probability Sample|100 women were recruited from gynecology clinic of Women Health Hospital|February 2016|February 26, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694419||2000|
NCT02694458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01545-44|Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children|Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children|OPTIBAYE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2016|February 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|16 Years|No|||March 2016|March 8, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694458||1997|
NCT02679547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breastfeeding|The Effect of Breastfeeding on the Development of Appendicitis in Adults|||Sisli Etfal Training & Research Hospital|No|Recruiting|January 2016|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1500|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|500 patients who has pathologically proven appendicitis, and 1000 participants without        appendicitis.|February 2016|February 9, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02679547||3141|
NCT02680730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1954|The Listening Project at the ADD Centre and Biofeedback Institute of Toronto|The Listening Project at the ADD Centre and Biofeedback Institute of Toronto||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|7 Years|55 Years|No|||February 2016|February 8, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680730||3051|
NCT02680743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-15-EP|Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit|Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit||University of Nebraska|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|60|||Both|N/A|14 Days|No|||February 2016|February 11, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02680743||3050|
NCT02700607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH0000000 TBD|Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity|Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During Coiling Embolization Procedure for Cerebral Artery Aneurysm||Konkuk University Medical Center|No|Not yet recruiting|March 2016|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|No|||March 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02700607||1526|
NCT02694003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34929|Better Nights, Better Days for Children With Neurodevelopment Disorders|Development, Implementation, and Evaluation of an Internet-based Behavioural Sleep Intervention for Children With NDD and Insomnia|BNBD-NDD|IWK Health Centre|Yes|Not yet recruiting|January 2017|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|3 Years|10 Years|No|||February 2016|February 23, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02694003||2032|
NCT02680392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-209-MUHC|Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block|Functional Outcome and Postoperative Analgesia in Total Knee Arthroplasty: a Comparison Between Continuous Adductor Canal Block and Pulsed and Thermal Radiofrequency of Saphenous and Genicular Nerves of the Knee||McGill University Health Center|No|Recruiting|September 2015|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|80 Years|No|||February 2016|February 10, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02680392||3077|
NCT02680405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2930|Identification of Epidermal Signatures in Patients With Atopic Dermatitis|Identification of Epidermal Signatures in Patients With Atopic Dermatitis||National Jewish Health|No|Not yet recruiting|February 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Skin biopsy, blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|This study will enroll up to 50 participants who are 18 to 65 years of age. Up to 40 of        the participants will have Atopic Dermatitis. Up to 10 of the participants will not have        Atopic Dermatitis. Approximately 25 of the participants will be women and 25 will be men.|February 2016|February 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02680405||3076|
NCT02707627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital for Sick Children|Laser Therapy for Pediatric Burn Scars|A Randomized Controlled Trial Investigating the Use of Ablative Fractional Carbon Dioxide Laser Therapy to Improve Pediatric Burn Scars.||The Hospital for Sick Children|Yes|Not yet recruiting|September 2016|September 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707627||987|
NCT02685423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMA_758485|Light-deprivation Utilized to Mitigate Amblyopia|Optimized Visual Recovery in Adult Human Amblyopia Through Binocular Deprivation|LUMA|State University of New York College of Optometry|Yes|Recruiting|October 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02685423||2690|
NCT02693392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T/EM-F/Pharma/14/05|Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes|Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes: An Add-On Study||All India Institute of Medical Sciences, Bhubaneswar|No|Recruiting|January 2016|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|25 Years|65 Years|No|||February 2016|February 25, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02693392||2079|
NCT02685592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q291dnro62/2015|Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream|Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream|LM PDT|Joint Authority for Päijät-Häme Social and Health Care|No|Recruiting|February 2016|December 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02685592||2677|
NCT02692131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK/2496/study|Comparison of Two Methods of Strain by Perioperative Transesophageal Echo in CABG : An Observational Study|Comparison of Two Different Methods of Obtaining Strain by Perioperative Transesophageal in Patients Undergoing Coronary Artery Bypass Grafting : An Observational Study|Strain|Postgraduate Institute of Medical Education and Research|Yes|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All adult (> 18 yrs) patients undergoing on pump CABG.|February 2016|February 25, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02692131||2176|
NCT02706093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00106883|Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults|Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults|HT|University of Michigan|No|Active, not recruiting|March 2016|January 2025|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|40 Years|No|||March 2016|March 10, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02706093||1104|
NCT02686515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST104-2314-B-182-035-MY3|Comparative Effectiveness Research of Dual-task and Single-task Balance Training in People With Stroke|Comparative Effectiveness Research of Dual-task and Single-task Balance Training on Cognitive-motor Interference, Balance Confidence, Fall Prevention, Functional Performance, and Quality of Life in People With Stroke||Chang Gung University|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|N/A|N/A|No|||February 2016|February 18, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02686515||2606|
NCT02691975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR3680-001|A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients|A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer||Jiangsu HengRui Medicine Co., Ltd.|No|Not yet recruiting|February 2016|June 2020|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Male|18 Years|80 Years|No|||February 2016|February 27, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691975||2188|
NCT02691988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL52880.091.15|Withdrawal of Inhaled Corticosteroids in Primary Care Patients With COPD|Withdrawal of Inhaled Corticosteroids and the Possible Effect on Exacerbation Rate in Primary Care Patients With COPD|WHISPER|Radboud University|Yes|Recruiting|December 2015|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|620|||Both|40 Years|N/A|No|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691988||2187|
NCT02693327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500409|Microbiome and the Gut-Brain Axis|Microbiome and the Gut-Brain Axis||University of Florida|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1 will have a diagnosis of a mental illness. Group 2 will not have a diagnosis of        mental illness.|March 2016|March 14, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02693327||2084|
NCT02694523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.30|BI 655066 Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066 Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)||Boehringer Ingelheim||Recruiting|March 2016|October 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 24, 2016||||No||https://clinicaltrials.gov/show/NCT02694523||1992|
NCT02701335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Code:GR-2013-02358472|Manual Therapy for Hand Osteoarthritis|Neural Manual vs. Robotic Assisted Mobilization to Improve Hand Range of Motion and Reduce Pain Hypersensitivity in Hand Osteoarthritis: a Randomized Controlled Trial||Fondazione Don Carlo Gnocchi Onlus|No|Not yet recruiting|May 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02701335||1470|
NCT02686528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13100906|Postoperative Hip Precautions After Total Hip Arthroplasty Via the Posterior Approach: A Prospective Randomized Trial|Are Postoperative Hip Precautions Necessary After a Total Hip Arthroplasty Via the Posterior Approach: A Prospective Randomized Trial||Rush University Medical Center|No|Recruiting|January 2016|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02686528||2605|
NCT02683018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7220|Investigation of Cannabis for Chronic Pain and Palliative Care|Investigation of Cannabis for Chronic Pain and Palliative Care||New York State Psychiatric Institute|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|60 Years|No|||February 2016|February 16, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683018||2875|
NCT02683031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0010010|Effect of Ca2+ Ionophore on Embryonic Development and Clinical Outcome in Cases With Previous Fertilization Arrest|A Prospective Randomized Controlled Trial Investigating Embryonic Development and Clinical Outcome After Using Ca2+ Ionophore in Cases With Previous Fertilization Arrest||TopLab Company for ART Laboratories Consultation and Training|Yes|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|20 Years|39 Years|No|||February 2016|February 11, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683031||2874|
NCT02681302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro0000|Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence|Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence|CPIT001|Hackensack University Medical Center|No|Not yet recruiting|March 2016|March 2021|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681302||3007|
NCT02592889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITRA-CRT|(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)|(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)|MITRA-CRT|Hospital Clinic of Barcelona|No|Recruiting|September 2015|October 2018|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02592889||9791|
NCT02592902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-ENT-papilomatosis|Recurrent Respiratory Papillomatosis and Extraesophageal Reflux|Recurrent Respiratory Papillomatosis and Extraesophageal Reflux||University Hospital Ostrava|No|Recruiting|April 2014|May 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|75 Years|No|||October 2015|October 29, 2015|October 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02592902||9790|
NCT02586246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1226-CL-A003|Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870|Long-term Treatment Study of CDP870 Self-injection. A Multicenter, Open-label, Long-term Safety Study to Evaluate the Safety and Efficacy of CDP870 Self-injection Administered at a Dose of 200 mg Biweekly for 24 Weeks or Longer in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Administered Concomitantly With or Without Methotrexate (MTX)||Astellas Pharma Inc|No|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|N/A|N/A|No|||November 2015|November 13, 2015|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586246||10301|
NCT02586259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000217|Effectiveness of Cortiment® in Patients With Ulcerative Colitis|A Prospective Multi-centre Observational Cohort Study Assessing the Effectiveness of Cortiment® for the Treatment of Mild-to-moderate Active Ulcerative Colitis in Routine Clinical Practice|CORE Practice|Ferring Pharmaceuticals||Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from gastroenterologists (hospitals, clinics, office-based).|January 2016|January 26, 2016|October 23, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02586259||10300|
NCT02707822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512005RINC|The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration|The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration||National Taiwan University Hospital|No|Recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|440|||Both|20 Years|65 Years|No|Probability Sample|Renal or liver transplant recipients who underwent transplantation at National Taiwan        University Hospital, and were treated with tacrolimus.|March 2016|March 9, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707822||972|
NCT02698020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANOXneo|Optimized Oxygen Delivery During General Anesthesia in Newborn Infants|Oxygen Delivery During General Anesthesia in Newborn Infants: An Open Randomized Controlled Trial of Two Levels of Inspired Oxygen.|ANOXneo|Uppsala University|No|Recruiting|November 2015|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|4 Weeks|No|||March 2016|March 9, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02698020||1725|
NCT02692859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-201301|A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine|A Randomized, Positive-controlled, Non-inferiority Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine in Healthy Infants and Children||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|2015|||Both|3 Months|5 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02692859||2120|
NCT02686073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kasr El-Aini Hospital|Effect of Maternal Body Mass Index on Labor Progress in Nulliparous Women|Effect of Maternal Body Mass Index on Labor Progress in Nulliparous Women||Cairo University|Yes|Not yet recruiting|February 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|600|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|pregnant nulliparous women, at term, during labor|February 2016|February 18, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02686073||2640|
NCT02704286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000249|Risk and Risk Perception of Knee Osteoarthritis in the US|Raising Awareness of Knee Osteoarthritis (OA) and Willingness to Undertake Behavioral Changes to Reduce Risk of Knee OA: Online Recruitment||Brigham and Women's Hospital|No|Completed|April 2015|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|380|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704286||1243|
NCT02681679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2016-China-1|Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery|Topical 0.1% Bromfenac Sodium for Intraoperative Pupil Dilation Maintenance and Prostaglandin E2 Inhibition in Femtosecond Laser-assisted Cataract Surgery||Sun Yat-sen University|Yes|Completed|October 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||February 2016|February 11, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681679||2978|
NCT02680587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15180|Stereotactic Body Radiation for Prostate Oligometastases|Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial|ORIOLE|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2016|||March 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|100 Years|No|||March 2016|March 23, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680587||3062|
NCT02680600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B126201419859|Individualized Cefepime Dosing Study|Pharmacokinetic Evaluation of Cefepime Administrered Intravenously in Intensive Care Patients|INCED|Onze Lieve Vrouw Hospital|No|Completed|March 2014|January 2016|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02680600||3061|
NCT02686606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWLondonH|A Trial to Investigate the Effect of Different Supplements on Fluid and Sodium Status in Short Bowel|A Randomised Controlled Crossover Trial to Investigate the Effect of Different Oral Nutritional Supplements on Fluid and Sodium Status in Patients With Short Bowel Intestinal Failure||London North West Healthcare NHS Trust|No|Enrolling by invitation|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02686606||2599|
NCT02706951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-555|A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX||AbbVie|Yes|Recruiting|February 2016|August 2020|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706951||1039|
NCT02691078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACOG 0214|Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors|Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors||Latin American Cooperative Oncology Group|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02691078||2256|
NCT02691104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH19149|Use of the SMART COPD Physical Activity App in Pulmonary Rehabilitation|Use of the SMART COPD Physical Activity App in Pulmonary Rehabilitation: a Randomised Feasibility Study||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|January 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02691104||2255|
NCT02683824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0020|Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers|Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study||Stanford University|Yes|Recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02683824||2813|
NCT02687191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2341002|Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage|A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)||Pfizer|Yes|Not yet recruiting|May 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|15||Anticipated|50|||Both|18 Years|79 Years|No|||March 2016|March 23, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687191||2554|
NCT02687451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3319-304|Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects|An Open-Label Single-Dose And Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oxymorphone Hydrochloride (HCl) For Acute Moderate To Severe Postoperative Pain In Pediatric Subjects||Endo Pharmaceuticals|Yes|Recruiting|February 2016|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|2 Years|No|||March 2016|March 21, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687451||2534|
NCT02706977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083672|The Effect of Dopamine on Diabetic Retinopathy|The Effect of Dopamine on Diabetic Retinopathy|Dopamine DR|Emory University|Yes|Recruiting|January 2016|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706977||1037|
NCT02679001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29933|A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.|A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT||Hoffmann-La Roche||Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with a diagnosis of moderate to severe RA according to the revised (1987) ACR        criteria or 2010 ACR/EULAR RA classification criteria who have had an insufficient        response or intolerance to their first TNF-inhibitor.|March 2016|March 1, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679001||3183|
NCT02679014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP29911|A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RG7625 in Volunteers With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RG7625 in Volunteers With Celiac Disease||Hoffmann-La Roche||Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|60 Years|No|||March 2016|March 1, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679014||3182|
NCT02681965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410014716|A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors|A Randomized Controlled Trial, Using a Mail and Video-based Weight Loss Program for Overweight or Obese Stage I-IIIC Breast Cancer Survivors.|LEAN3|Yale University|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|79 Years|No|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681965||2956|
NCT02686619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18326|Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients|Multicentre, Prospective, Randomized, Open-label Study Comparing the Efficacy and Safety of CellCept With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Standard Immunosuppression Comprising CellCept and Long-term Continuation of Cyclosporine in Renal Transplant Recipients Receiving Induction by Zenapax and Treated With Corticosteroids for 8 Months||Hoffmann-La Roche||Completed|November 2004|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|75 Years|No|||February 2016|February 16, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686619||2598|
NCT02696629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRECKY2013-004-1|The Impact of Sleep Apnea Treatment on Physiology Traits in Chinese Patients With Obstructive Sleep Apnea|The Impact of Sleep Apnea Treatment on Physiology Traits in Chinese Patients With Obstructive Sleep Apnea||Beijing Tongren Hospital|No|Recruiting|February 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Obstructive sleep apnea|March 2016|March 1, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696629||1832|
NCT02688400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAR-INT-14-01|Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis|An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging|DISSCO|TRB Chemedica International SA|Yes|Not yet recruiting|April 2016|December 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|50 Years|N/A|No|||March 2016|March 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02688400||2461|
NCT02687113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-2361|Pre-procedure Planning for Radiofrequency Ablation Using CT or MR/US Fusion|Pre-procedure Planning for Radiofrequency Ablation Using the Automatic Fusion Images of the Registrated 3D CT or MR-US Scans: Preliminary Study||Seoul National University Hospital|Yes|Completed|March 2013|March 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|240|||Both|N/A|N/A|No|||February 2016|February 19, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02687113||2560|
NCT02679807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18625|Effect of Probiotic on Rhinovirus Induced Colds|Effect of Probiotic on Rhinovirus Induced Colds|MK EPRIC|University of Virginia|No|Enrolling by invitation|February 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679807||3122|
NCT02692612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s58633|Effects of Power-velocity Muscle Characteristics During Ageing|||Universitaire Ziekenhuizen Leuven||Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|80|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|young (20-40y) middle-aged (40-60y) old (60-80y)|November 2015|February 22, 2016|November 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02692612||2139|
NCT02692625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAUFD|Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children.|Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children.||King Abdulaziz University|Yes|Recruiting|January 2015|April 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692625||2138|
NCT02704884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394733|Microbial Soy Milk Consumption, Inflammation and Renal Function Among Type 2 Diabetic Patients With Nephropathy|||Isfahan University of Medical Sciences||Not yet recruiting|March 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|32 Years|68 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02704884||1197|
NCT02704897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC16032|Tracking Wound Infection With Smartphone Technology|Can a Smartphone-delivered Questionnaire Facilitate the Assessment of Surgical Site Infection, and Result in Earlier Treatment? A Randomized-controlled Trial in Emergency Surgery Patients.|TWIST|University of Edinburgh|No|Not yet recruiting|April 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02704897||1196|
NCT02679742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSSMAR 2015/6288/I|Postacute Sarcopenia: Supplementation With β-hydroxyMethylbutyrate After Resistance Training|The PSSMAR Study (Postacute Sarcopenia, Supplementation With β-hydroxyMethylbutyrate After Resistance Training)|PSSMAR|Parc de Salut Mar|No|Not yet recruiting|March 2017|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|No|||February 2016|February 5, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02679742||3127|
NCT02682524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_PlbCR_401|A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee|||Daewon Pharmaceutical Co., Ltd.||Recruiting|August 2015|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|35 Years|80 Years|No|||February 2016|February 10, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02682524||2913|
NCT02687178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023606-13|Canrenone as add-on in Patients With Essential Hypertension|Efficacy and Safety of Canrenone as add-on in Patients With Essential Hypertension|ESCAPE|University of Pavia|No|Completed|October 2010|January 2016|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687178||2555|
NCT02701816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0074|Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)|||Yonsei University|No|Recruiting|January 2016|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|85 Years|No|Non-Probability Sample|Femoropopliteal artery disease|March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02701816||1433|
NCT02694822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-500-01|AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers|A Phase 1, Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer||Agenus, Inc.||Not yet recruiting|February 2016|||August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694822||1969|
NCT02694835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP691-C001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||February 24, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694835||1968|
NCT02679755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481037|Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer|A Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate||Pfizer|No|Not yet recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679755||3126|
NCT02690220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pfm15k001 TiLOOP® PRO A|Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh|National, Multicentre Post Market Surveillance Study on Anterior Pelvic Prolapse Reconstruction With a Titanium-coated Polypropylene Mesh (TiLOOP® PRO A)|TiLOOP® PRO A|pfm medical ag|Yes|Recruiting|January 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690220||2321|
NCT02680444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11NV038|Mindful Positive Reappraisal: a Daily Diary Randomized Controlled Trial|Exploring Daily Affective Changes in University Students With a Mindful Positive Reappraisal Intervention: a Daily Diary Randomized Controlled Trial|Reappraisal|University of Guelph|No|Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|129|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02680444||3073|
NCT02703545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027287|International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs|International CAPS Registry: Operated Cases and Cases With Advanced Disease Among High-risk Individuals Participating in a Pancreatic Cancer Surveillance Program; a Case-control Study|CAPS Registry|Johns Hopkins University|No|Enrolling by invitation|February 2014|July 2020|Anticipated|February 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Familial or genetic pancreas cancer risk cohorts found to have pancreas cancer or pancreas        dysplasia|March 2016|March 3, 2016|July 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02703545|5 Years|1300|
NCT02686541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG12Aug02-12|Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries|Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries|ADEBT|Changi General Hospital||Approved for marketing|April 2015|||March 2017|Anticipated|N/A|Expanded Access|N/A|||||||Both|21 Years|90 Years|No|||February 2016|February 21, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02686541||2604|
NCT02687412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SichuanCHRI|Fast-track Surgery After Gynecological Oncology Surgery|||Sichuan Cancer Hospital and Research Institute|No|Not yet recruiting|April 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|70 Years|No|||February 2016|February 23, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02687412||2537|
NCT02694237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrthoInfo|The Age of OrthoInfo: A Randomized Controlled Trial Evaluating Patient Comprehension of Informed Consent in a Private Practice|||University of Missouri, Kansas City||Recruiting|February 2016|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694237||2014|
NCT02694250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTRAXCCB-001|Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw|Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw in Patients With Cervical Radiculopathy||Providence Medical Technology, Inc.|No|Recruiting|November 2015|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|35 Years|80 Years|No|||February 2016|February 23, 2016|February 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02694250||2013|
NCT02706743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMing|Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer|Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study||Southern Medical University, China||Recruiting|January 2014|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|75 Years|No|Probability Sample|Patients with differentiated thyroid cancer initially referred to adjuvant radioiodine        treatment in nuclear medicine department, Zhujiang Hospital, Southern Medical University.|March 2016|March 12, 2016|May 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02706743||1055|
NCT02707042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160078|Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)|Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)||National Institutes of Health Clinical Center (CC)||Not yet recruiting|February 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|21 Years|39 Years|No|||February 2016|March 9, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707042||1032|
NCT02684643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2015-271|Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients|Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients||Huashan Hospital|Yes|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02684643||2750|
NCT02694575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0483|The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes|The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes|IGLOOS|University of Leicester|Yes|Recruiting|April 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|216|Samples Without DNA|Peripheral Blood Mononuclear Cells (PBMCs) for subsequent EPC quantification:      PBMCs will be isolated from venous blood collected into a 9.7ml sodium heparin blood tube.      EPCs will be quantified as cells showing dual positivity for the cell surface /      transmembrane markers: CD24 and KDR (Kinase Insert Domain Receptor). SDF-1α analysis and the      analysis of biomarkers associated with the prevalence of circulating EPCs will be measured      using sandwich ELISA and multi-array ELISA technology in-line with manufacturer protocols.      Analysis of endogenous DPP4 will be assayed using a commercial colorimetric assay; again      manufacturer protocols will be followed. Biomarker and DPP4 analysis will be carried out in      one batch on stored sodium heparin plasma samples.|Both|35 Years|70 Years|No|Non-Probability Sample|Male and female patients aged between 35 and 70 years of age (inclusve) who have        established Type 2 Diabetes mellitus (T2DM) and who have been receiving either (a) DPP-4        inhibitors, (b) GLP-1 analogues, or (c) non-incretin based treatments for at least 3        months (or more).|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02694575||1988|
NCT02694172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.42.NRC|Human Faecal Microbiota in Type 2 Diabetes|Analysis of the Diversity of Faecal Bacteria in Healthy and Type 2 Diabetic Subjects||Nestlé|No|Completed|September 2007|April 2011|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|67|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694172||2019|
NCT02704065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32447/199|Recurrent AA Amyloidosis After Renal Transplantation|Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival||Istanbul University|No|Enrolling by invitation|March 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|51|||Both|18 Years|N/A|No|Non-Probability Sample|Renal transplant recipients|March 2016|March 4, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704065||1260|
NCT02704078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-419/09.10.2015|Trans-tracheal (EBUS-TBNA) Versus Trans-esophageal (EUS-B-FNA) Route for Fine Needle Aspiration of Mediastinal Lesions Using the Endobronchial Ultrasound (EBUS) Scope|Prospective Randomized Comparison of Trans-tracheal (EBUS-TBNA) Versus Trans-esophageal (EUS-B-FNA) Route as the Primary Approach for Fine Needle Aspiration of Mediastinal Lesions Using the Convex Probe Endobronchial Ultrasound (EBUS) Scope|TEAM|All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|December 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02704078||1259|
NCT02682485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-0971|Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing|A Multicenter, Phase II, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of Serial Endoscopic Surveillance (SES) and Direct Topical Antibiotics (DTA) to Define the Role of Microbes in Anastomotic Healing|SES-DTA|University of Chicago|Yes|Not yet recruiting|January 2017|July 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682485||2916|
NCT02683863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG12-001|Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers|An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis||Multiple Sclerosis Center of Northeastern New York|No|Recruiting|August 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02683863||2810|
NCT02683876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505010014MEBO|Exploratory Study of Relationships Between Malodor and Urine Metabolomics|Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies||Mebo Research, Inc.|Yes|Recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|individuals complaining of uncontrollable episodes of malodor suspected to be caused by        inefficient body metabolism|February 2016|February 11, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02683876||2809|
NCT02705274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol PDR 1|PRP vs Bevacizumab for PDR Treatment|Panretinal Photocoagulation Versus Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy||Marashi Eye Clinic||Recruiting|February 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|99 Years|No|||March 2016|March 4, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02705274||1167|
NCT02707263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01051|Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients|Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients||New York University School of Medicine|No|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707263||1015|
NCT02688556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-101-2016-001|Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|Emerald|Ocular Technologies SARL|No|Recruiting|February 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|February 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688556||2449|
NCT02687672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA-SCI1|Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury|Transplantation of Purified Autologous Bone Marrow- or Leukapheresis-Derived CD34+ and CD133+ for Patients With Spinal Cord Injuries: A Long-Term Comparative Evaluation of Safety and Efficacy Study.||Stem Cells Arabia|Yes|Recruiting|January 2016|December 2021|Anticipated|June 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|5 Years|50 Years|No|||February 2016|March 9, 2016|February 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02687672||2517|
NCT02690246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Clinic Essen|Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia|A Questionnaire Based Study on Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia (HHT)||University Hospital, Essen|No|Recruiting|February 2016|November 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with HHT; Indirectly we accept healthy volunteers only as control cohort in        questionnaires of affected persons.|February 2016|February 19, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02690246||2319|
NCT02691676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV29125 16/14|Perioperative Fluid Therapy With Balanced Crystalloids|Perioperative Fluid Therapy With Balanced Crystalloids: a Comparative Randomized Prospective Open Label Study||University Hospital Olomouc|No|Completed|January 2014|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691676||2211|
NCT02702505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072015-041|Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT|Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT|MTA|Texas A & M University Baylor College Of Dentistry|No|Enrolling by invitation|November 2014|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702505||1380|
NCT02681900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER/KJF25/4|Exploring Whether Self-affirmation Promotes Reduced Alcohol Consumption in Response to Narrative Health Information|Exploring Whether Experimentally Manipulated Self-affirmation Promotes Reduced Alcohol Consumption in Response to Narrative Health Information||University of Sussex|No|Completed|October 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|142|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02681900||2961|
NCT02684448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-IHR-2015-001|Evaluation of Clinical Outcomes in Robotic-Assisted Inguinal Hernia Repair|A Retrospective Multi-Center Study for Evaluation of Clinical Outcomes in Inguinal Hernia Repair||Intuitive Surgical|No|Recruiting|January 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who have undergone robotic-assisted inguinal hernia repair or open hernia        repair per specified time frame described in inclusion/exclusion criteria|February 2016|February 19, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02684448||2765|
NCT02684981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.249|Patient Convenience Study (RE-SONANCE)|Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation||Boehringer Ingelheim||Recruiting|November 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|9000|||Both|18 Years|N/A|No|Non-Probability Sample|European patients with non valvular atrial fibrillation|March 2016|March 21, 2016|November 11, 2015||||No||https://clinicaltrials.gov/show/NCT02684981||2724|
NCT02684994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0619|Client-directed Cognitive Processing Therapy|Client-directed Cognitive Processing Therapy|CPT|University of Indianapolis|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|N/A|No|||February 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02684994||2723|
NCT02705404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-007961|A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing|A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome||Mayo Clinic|No|Recruiting|February 2016|||February 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|The patient will have some or all of the samples taken listed below:        -  Blood sample of 10 ml (2 teaspoons).        -  Up to two lung bronchoscopic or transbronchoscopic needle aspiration biopsies will be           given to the research study during an already scheduled bronchoscopy. In addition at           the time of the bronchoscopy a brushing or washing specimen could be collected for           research.        -  A piece of lung or lymph node tissue taken at the time of the CT guided lung or lymph           node biopsy will be given to the research study.        -  A piece of lung tumor tissue removed during surgery will be given to the research           study.        -  If pleural fluid is removed as part of the procedure(s) and there is any fluid left           after what is needed for your clinical care, it will be given to the research study.        -  DNA genome sequencing will be performed on the collected tissues, blood and fluid.|Both|18 Years|N/A|No|Non-Probability Sample|Mayo Clinic Rochester Patients|March 2016|March 4, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02705404|50 Years|1157|
NCT02705417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Maximizing Native Arteriovenous Fistulae Rates.|Maximizing Native Arteriovenous Fistulae Rates. Is Routine Colour Doppler Vascular Mapping in Pre-operative Planning of Value? A Retrospective Study.||Medifil AE|No|Completed|January 2012|January 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|136|||Both|N/A|N/A|No|Non-Probability Sample|Patients with dialysis dependent end stage renal disease with first time permanent        vascular access, more specifically native arteriovenous fistula or arteriovenous grafts.|March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705417||1156|
NCT02691195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2016-1-07|Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy|Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy||Fujian Provincial Hospital|Yes|Active, not recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|February 21, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02691195||2248|
NCT02679326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4/2015|Plantar Fasciitis and Therapeutic Ultrasound|The Efficacy of Treating Plantar Fasciitis With Therapeutic Ultrasound||Assuta Hospital Systems|No|Recruiting|May 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|February 18, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02679326||3158|
NCT02684721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6300001|Does a Home-based Exercise Programme Affect Physical Capacity and Quality of Life in Patients With Pulmonary Embolism?|Does an 8-week Home-based Exercise Programme Affect Physical Capacity, Quality of Life, Sick Leave and Use of Psychoactive Drugs in Patients With Pulmonary Embolism. A Randomised Clinical Trial||Central Jutland Regional Hospital|No|Not yet recruiting|March 2016|April 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||January 2016|February 12, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02684721||2744|
NCT02699060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIDKO19|Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Plasticity and Its Correlation With Different Forms of Gastroesophageal Reflux Disease|Experimental Study to Determine the Effects of Refluxate (Human: Biliary, Gastric, Duodenogastric/Mixed) on Macrophage Phenotype and Macrophage Plasticity and Its Correlation With Different Forms of Gastroesophageal Reflux Disease (Non-erosive and Erosive) and Complications Thereof (Barrett's Esophagus): Motility Talent Group Study||I.M. Sechenov First Moscow State Medical University|No|Recruiting|February 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02699060||1645|
NCT02699073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEXCAN C15-2|Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib|Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. A GERCOR Phase II Study|TEXCAN|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Recruiting|February 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02699073||1644|
NCT02689037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12MA100|Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis|Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial||The 476th Hospital of People's Liberation Army|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|394|||Both|18 Years|70 Years|No|||February 2016|February 27, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02689037||2412|
NCT02694510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/299|Light Protection of TPN and Oxidative Stress in Preterm Infants|Impact of Protecting TPN Solution From Light on the Oxidant-antioxidant State of Preterm Infant||Mansoura University Children Hospital|Yes|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|N/A|7 Days|No|||February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02694510||1993|
NCT02680067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 54038|NIR Fluorescence Imaging of Lymphatic Transport Using ICG|Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green|NIR-ICG|University of Rochester|No|Recruiting|September 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|December 7, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02680067||3102|
NCT02693314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201401031|Evaluation of Jarro-Dophilus EPS® Probiotic Formulations|Evaluation of Jarro-Dophilus EPS® Probiotic Formulations on Probiotic Survival, Fecal Microbiota, Gastrointestinal Function and General Wellness in Healthy Adults: a Randomized, Double-blind, Dose-response Study||University of Florida|No|Active, not recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|50 Years|No|||March 2016|March 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693314||2085|
NCT02709161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO16010381|Effects of Amygdala Neurofeedback on Depressive Symptoms|Effects of Amygdala Neurofeedback on Depressive Symptoms||University of Pittsburgh|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||March 2016|March 14, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02709161||869|
NCT02690142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABY-035-001|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035|A Phase I, Partially-randomised, Partially Double-blinded, Single Dose, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients||Affibody|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02690142||2327|
NCT02690662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2015/04998-1|Influence of Hypocaloric Diet on Urinary Lithogenic Factors of Obese Patients With Kidney Stones|Influence of Hypocaloric Diet on Urinary Lithogenic Factors of Obese Patients With Kidney Stones||University of Sao Paulo General Hospital|No|Recruiting|February 2016|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|No|||February 2016|February 19, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02690662||2288|
NCT02687126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGNHC|Ultrasound Guided Technique for Internal Jugular Central Venous Catheterization in Pediatric Cardiac Surgical Patients|Ultrasound Guided Technique for Internal Jugular Central Venous Catheterization in Pediatric Cardiac Surgical Patients||Shahid Gangalal National Heart Centre|Yes|Recruiting|February 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|15 Years|No|Non-Probability Sample|Pediatric patients undergoing routine cardiac surgery|January 2016|February 23, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02687126||2559|
NCT02687399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THO-IM_02-CT|Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT)|A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty||Thrombotargets Europe S.L|Yes|Recruiting|January 2016|October 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02687399||2538|
NCT02694536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19537|A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer||Hoffmann-La Roche||Completed|June 2006|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02694536||1991|
NCT02694549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaveoMed-2015-06|CaveoVasc System - a New Femoral Vascular Access and Closure Device|Prospective, Single Arm Study to Assess the Performance and Safety of CaveoVasc System for Femoral Vascular Access and Closure Device||CaveoMed GmbH||Not yet recruiting|April 2016|||July 2016|Anticipated|N/A|Interventional|N/A|1||||||Both|18 Years|N/A||||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02694549||1990|
NCT02705209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Munari02|Cayenne Pepper Cataplasm - Effect Study|Cayenne Pepper Cataplasm - Effect Study on Healthy Subjects and Subjects With Back Pain||Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation|No|Completed|October 2015|February 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|65 Years|No|||March 2016|March 4, 2016|October 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02705209||1172|
NCT02705313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-177Lu-03|Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy|||Advanced Accelerator Applications||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2016|March 15, 2016|March 7, 2016|Yes|Yes||||https://clinicaltrials.gov/show/NCT02705313||1164|
NCT02691234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0592-HMO-CTIL|Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers|||Hadassah Medical Organization|No|Not yet recruiting|April 2016|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||January 2016|February 21, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02691234||2245|
NCT02687698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3575/AO/15|Effect of a Lipidic and Proteic Controlled Diet on Parkinson's Disease|Effect of a Lipidic and Proteic Controlled Diet on Resting Energy Expenditure, Body Composition and Symptoms in Patients With Parkinson's Disease||University of Padova|No|Enrolling by invitation|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|100 Years|No|||February 2016|February 16, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02687698||2515|
NCT02686372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTCR-HCC-I-1|TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation|Phase I Study of T Cell Receptor-Redirected T Cells Infusions for Preventing Hepatocellular Carcinoma Recurrence in Patients With HBV-Related Disease Post Liver Transplantation||Lion TCR Pte. Ltd.|No|Recruiting|December 2015|November 2020|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02686372||2617|
NCT02594215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160014|Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome|Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|12 Years|65 Years|No|||October 2015|November 13, 2015|October 31, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02594215||9689|
NCT02589327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504792C|Effects of Exercise on Cardiac Fat in Women With Obesity: a Pilot Study|Effects of Exercise on Cardiac Fat in Women With Obesity: a Pilot Study||Texas Tech University|Yes|Recruiting|October 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2015|February 2, 2016|October 14, 2015||No||No||https://clinicaltrials.gov/show/NCT02589327||10065|
NCT02701348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ON09|Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers|Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers|BARONET|NHS Tayside|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|40 Years|N/A|No|||February 2016|March 7, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02701348||1469|
NCT02680340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-4562-05|POLARSTEM Retrospective Multicenter Study|Longterm Clinical Outcome Study of the Femoral Cementless Ti/HA Polarstem - A Multicenter Retrospective 10-years Follow-up Study|PR|Smith & Nephew, Inc.|Yes|Recruiting|January 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|502|||Both|18 Years|N/A|No|Probability Sample|502 male and female subjects who have undergone THA with POLARSTEM™ from 2002 to 2005 will        be enrolled in this study and clinical and radiographically followed up for at least 10        years.|February 2016|February 10, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02680340||3081|
NCT02692105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02103|Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer|A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer||British Columbia Cancer Agency|Yes|Not yet recruiting|April 2016|April 2026|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|40 Years|80 Years|No|||February 2016|February 24, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692105||2178|
NCT02686502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH2016215|Motivation Makes the Move!|Motivation Makes the Move!|MoMaMo!|Helsinki University|No|Not yet recruiting|March 2016|May 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02686502||2607|
NCT02684903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA036533-01A1|Coaching Alternative Parenting Strategies (CAPS) Study|Coaching Alternative Parenting Strategies (CAPS) Study: Targeting Neurobiological and Behavioral Mechanisms of Self-regulation in High-risk Families|CAPS|University of Oregon|Yes|Not yet recruiting|February 2016|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|3 Years|N/A|No|||February 2016|February 17, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02684903||2730|
NCT02689518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE|EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection|Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection|EAGLE|University of California, San Diego|No|Recruiting|April 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|90 Years|No|||February 2016|February 23, 2016|April 21, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689518||2375|
NCT02692170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVI-HBV-001-CT1201|A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine|A Single Center, Randomized, Double Blinded PhaseI/IIa Exploratory Study to Evaluate Reactogenicity, Safety, Immunogenicity and Dose Response of a New Hepatitis B Vaccine in Human Adult||CHA Vaccine Institute Co., Ltd.|No|Completed|December 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|75|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02692170||2173|
NCT02696148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-4181|A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years|A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years||Novo Nordisk A/S|No|Recruiting|March 2016|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|21|||Both|7 Years|11 Years|No|||March 2016|March 15, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02696148||1869|
NCT02678754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCREG-001-00-V2-1209|Caris Molecular Intelligence Registry|A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation With Cancer Clinical Outcomes|CMIR|Caris Science, Inc.|Yes|Enrolling by invitation|February 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|8000|||Both|18 Years|N/A|No|Probability Sample|All patients seen within a physician practice participating in the Registry are potential        candidates if they meet the eligibility criteria requirements|February 2016|February 9, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02678754|9 Months|3202|
NCT02679027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tongueintubation|PREDICTION OF DIFFICULT INTUBATION USING TONGUE MOBILITY|||Trakya University||Completed|January 2014|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|223|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02679027||3181|
NCT02691793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-098|Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors||Samsung Medical Center|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691793||2202|
NCT02693769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFL3503|A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils|A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezhaler) in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils||Mundipharma Research Limited|No|Not yet recruiting|March 2016|March 2018|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|40 Years|N/A|No|||March 2016|March 7, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02693769||2050|
NCT02696408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-07|Randomized Double-blind Multicenter Prospective Trial Phase III Prevention of Mucositis With Low-energy Laser in Patients Receiving Autologous Hematopoietic Stem Cell Allograft or With Myeloablative Conditioning|Randomized Double-blind Multicenter Prospective Trial Phase III Prevention of Mucositis With Low-energy Laser in Patients Receiving Autologous Hematopoietic Stem Cell Allograft or With Myeloablative Conditioning|STOP MUCITES|Institut de Cancérologie de la Loire|No|Not yet recruiting|April 2016|May 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696408||1849|
NCT02683746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200952|Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus|A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product||GlaxoSmithKline|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683746||2819|
NCT02686814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-2215|PERIGON Japan Trial|A Multi-center, Non-randomized Trial to Determine the Safety and Effectiveness of the 17mm MDT-2215 Aortic Valve Bioprosthesis in Patients With Aortic Valve Disease||Medtronic Cardiovascular|Yes|Recruiting|March 2016|July 2022|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||March 2016|March 21, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02686814||2583|
NCT02686827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM4SIT|DBPC-trial of Subcutaneous Vitamin D3 Comparing Allergic Patients and Healthy Controls.|A Randomized, Double-blind, Placebo-controlled Study to Compare the Immune Effects of Multiple Doses of Vitamin D3 in Patients With Allergic Rhinitis/Rhino-conjunctivitis Caused by Birch Pollen and Healthy Control Subjects.|BM4SIT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|October 2015|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02686827||2582|
NCT02692534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062015-066|Cocaine Use and Outcomes of General Anesthesia|Cocaine Use and Outcomes of General Anesthesia||University of Texas Southwestern Medical Center|No|Not yet recruiting|February 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|108|||Both|18 Years|70 Years|No|Non-Probability Sample|•|January 2016|February 26, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02692534||2145|
NCT02701322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0281-15-MMC|Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder|Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder||Meir Medical Center|No|Not yet recruiting|March 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|3 Years|18 Years|No|||February 2016|March 7, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02701322||1471|
NCT02691390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor040415ctil|Exploration of the Potential Role of Brain Magnetic Stimulation in Preventing Relapse to Alcohol Abuse|Exploration of the Potential Role of Anterior Cingulate (ACC) dTMS Intervention of Relapse to Alcohol Abuse||Soroka University Medical Center|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|84|||Both|18 Years|65 Years|No|||February 2016|February 21, 2016|February 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691390||2233|
NCT02679820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA010516|PostPlacental IUD Insertion|||Woman's Health University Hospital, Egypt|Yes|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679820||3121|
NCT02679833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B12 status after toothpaste|Effect of Toothpaste Fortified With Cyanocobalamin on Vitamin B12 Status|Effect of Toothpaste Fortified With Cyanocobalamin on Vitamin B12 Status: A 3 Month Placebo Controlled Randomized Study||Saarland University|No|Completed|November 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679833||3120|
NCT02707094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSNRP-N12-006|A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain|A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain||Brooke Army Medical Center|Yes|Active, not recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|62 Years|No|||March 2016|March 8, 2016|January 22, 2014||No||No||https://clinicaltrials.gov/show/NCT02707094||1028|
NCT02684370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.3|BI 655066 Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)||Boehringer Ingelheim||Recruiting|February 2016|November 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 16, 2016||||No||https://clinicaltrials.gov/show/NCT02684370||2771|
NCT02692703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-596|A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)|A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)||AbbVie|No|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|99 Years|No|||February 2016|February 26, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692703||2132|
NCT02705300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOLFOXIRI-Toco|Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer|A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer||Vejle Hospital|Yes|Not yet recruiting|March 2016|March 2025|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02705300||1165|
NCT02684071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH-CNS-1601|Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors|A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors||Nicklaus Children's Hospital f/k/a Miami Children's Hospital|Yes|Recruiting|February 2016|February 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|22 Years|No|||February 2016|February 11, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02684071||2794|
NCT02692079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/18|The Effectiveness of Titanium-Prepared Platelet-Rich Fibrin on Angiogenic Biomarkers in Gingival Crevicular Fluid|The Effect of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) Treatment on the Angiogenic Biomarkers in Gingival Crevicular Fluid (GCF) in Infrabony Defects of Patients With Chronic Periodontitis: A Randomized Controlled Clinical Trial|T-PRF|Kırıkkale University|No|Completed|February 2014|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|26 Years|59 Years|No|||February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02692079||2180|
NCT02685618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014092629|Endothelial Dysfunction in Resuscitated Cardiac Arrest|Safety and Efficacy of Low-dose Prostacyclin Administration and Blood Pressure Target in Addition to Standard Therapy, as Compared to Standard Therapy Alone, in Post-cardiac-arrest-syndrome Patients - a Randomized, Controlled, Double-blinded Investigator-initiated Trial.|ENDO-RCA|Rigshospitalet, Denmark|Yes|Not yet recruiting|February 2016|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02685618||2675|
NCT02706496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01-003C|Age-related Changes in Posture Control and Cortex Activity Under a Dynamic Perturbation|Age-related Changes in Posture Control and Cortex Activity Under a Dynamic Perturbation||Taipei Veterans General Hospital, Taiwan|Yes|Completed|February 2015|January 2016|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|37|||Both|20 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|The volunteers from the community will be recruited in this study, the inclusion criterion        contained: able to walk and climb the stairs without assistive devices, could follow the        instructions, and without well-known balance related diseases or impairments. With the        disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular        apparatus, dizziness experience or cognitive deficit would be excluded the study.|March 2016|March 7, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02706496||1074|
NCT02691806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-16-2918-HS-CTIL|New Indices for Prediction of Human Fatigue During Training Based on Non-invasive Methods|New Indices for Prediction of Human Fatigue During Training Based on Non-invasive Methods||Sheba Medical Center|No|Not yet recruiting|March 2016|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691806||2201|
NCT02695901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52275816.0.0000.5346|Effect of Different Mouthrinses in Plaque Formation|Anti-plaque Effect of 0.12% Chlorhexidine Gluconate Rinsing and Nanoparticle Solution of 0.3% Melaleuca Alternifolia: A Randomized Crossover Clinical Trial||Universidade Federal de Santa Maria||Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|59|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02695901||1888|
NCT02689076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-049|Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization|Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization||VA Office of Research and Development|No|Not yet recruiting|April 2016|December 2019|Anticipated|July 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|975|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02689076||2409|
NCT02692209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2013-004G|A Multi-Reader Multi-Case Pivotal Trial|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm FFDM Plus DBT Versus FFDM Alone in the Detection of Breast Cancer||Fujifilm Medical Systems USA, Inc.|No|Completed|December 2015|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 8, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692209||2170|
NCT02692274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE484/14|Operational Assessment of Point-of-Care Diagnostics in Primary Healthcare Clinics|Evaluating the Accessibility and Utility of HIV-related Point of Care Diagnostic for Maternal Health in Rural South Africa||University of KwaZulu|No|Completed|April 2015|February 2016|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|309|Samples With DNA|Blood samples for evaluating the accuracy of HIV rapid tests in rural KwaZulu Natal|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Rural Primary Healthcare clinics|February 2016|February 22, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692274||2165|
NCT02681315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/15.10.41|Comparison of Two Flow Rates of HHHFNC to Prevent Extubation Failure in Preterm Infants|HHHFNC to Prevent Extubation Failure in Preterm Infants: A Randomized Controlled Trial||Mansoura University Children Hospital|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|30 Days|No|||February 2016|February 13, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681315||3006|
NCT02707055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160080|A Novel Compound for Alcoholism Treatment: A Translational Strategy|A Novel Compound for Alcoholism Treatment: a Translational Strategy - Part II||National Institutes of Health Clinical Center (CC)||Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|55|||Both|18 Years|65 Years|No|||February 2016|March 16, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707055||1031|
NCT02687087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN14ON413|A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy|Assessing the Safety and Effectiveness of Visco-ease for the Treatment of Radiotherapy Induced Xerostomia in Head and Neck Cancer Patients||NHS Greater Glasgow and Clyde|No|Recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687087||2562|
NCT02689986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD5|Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease|The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy|CAD5|Helse Fonna|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02689986||2339|
NCT02698215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR-NTX|Combining Varenicline and Naltrexone for Smoking Cessation|Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction||University of California, Los Angeles|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|274|||Both|21 Years|55 Years|No|||February 2016|February 26, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02698215||1710|
NCT02694367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERK|Expression of EPK in Recurrent Miscarriage|MAP Kinase Signaling Pathways Through ERK and p-ERK Protein in Human Placenta of Women With Recurrent Miscarriage|EPK-RM|Assiut University|Yes|Completed|January 2015|January 2016|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|39|||Female|20 Years|40 Years|No|Probability Sample|Women fulfilling the eligibility criteria had been tested and complete history and        examination was done|February 2016|February 26, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694367||2004|
NCT02694406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI-CAM|MRI Perfusion in Adnexal Masses|Added Value of MRI Perfusion in Evaluation of Complex Adnexal Masses|MRI-CAM|Assiut University|Yes|Recruiting|July 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|N/A|N/A|No|Non-Probability Sample|patients with adenxal masses|February 2016|February 26, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694406||2001|
NCT02693080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0072|CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy|A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)||Stanford University|Yes|Recruiting|January 2016|||January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02693080||2103|
NCT02692781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-6-001|A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects|A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers||Opko Biologics||Recruiting|February 2016|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 9, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692781||2126|
NCT02705430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0248-15-RMC|Effect of EPA-DHA Supplement, Life Style Modification Standard Treatment on Clinical Outcome Lipid Membrane Composition in Type 2 Diabetes|Effect of EPA-DHA Supplementation, Life Style Modification or Standard Treatment on Clinical Outcome and Lipid Membrane Composition in Type 2 Diabetic Patients: a 3 Months Perspective Randomized Pilot Study.||Rabin Medical Center|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02705430||1155|
NCT02685709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOC-ACM-302|Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly|A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands|MPOWERED|Chiasma, Inc.|Yes|Recruiting|February 2016|March 2020|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|75 Years|No|||February 2016|March 6, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685709||2668|
NCT02689700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040713 FRA Mat Fet CMV Antib|Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns|Examination of Diaplacental Transfer of IgG-antibodies Against Human Cytomegalovirus (HCMV) and Varicella-Zoster-Virus (VZV) at Premature and Mature Newborns|MoChi-HCMV|Johann Wolfgang Goethe University Hospitals|No|Recruiting|July 2013|November 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|Samples Without DNA|Umbilical Cord blood; Blood from peripheral vene|Both|N/A|10 Minutes|Accepts Healthy Volunteers|Probability Sample|Approximately 450 mother-child-pairs seropositive for HCMV and/or VZV|February 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02689700||2361|
NCT02689921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ2015020|NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer|A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)|NEOADAPT|Midwestern Regional Medical Center|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689921||2344|
NCT02690259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RegionSkaneKKLund|Sentinel Lymph Node Detection in Endometrial Cancer|Near Infrared Fluorescent Technique for Sentinel Lymph Node Mapping in Endometrial Cancer||Region Skane|No|Recruiting|June 2014|June 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|375|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|November 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02690259||2318|
NCT02707497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWang-TPO-301|The Effect of Recombinant Human Thrombopoietin on Septic Shock With Thrombocytopenia.|The Effect of Recombinant Human Thrombopoietin(rhTPO) on Septic Shock With Thrombocytopenia：a Prospective, Multi-center, Open-label, ,Randomized, Placebo-controlled Study.||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|June 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|70 Years|No|||March 2016|March 11, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707497||997|
NCT02683525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSCC-0522|Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation||Indiana University|Yes|Recruiting|February 2016|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|60 Years|No|||February 2016|February 16, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683525||2836|
NCT02691819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingHZWD001|Short Term and Long Term Effects of Single Stent and Embedded Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesions|Short Term and Long Term Effects of Single Stent and Embedded Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesions||Beijing Hospital||Recruiting|January 2015|||January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Baseline characteristics of the patients with screening and recorded by a case by coronary        artery angiography of each coronary bifurcation lesions according to the Medina        classification method to classify, only select the 1.1.1 type, type 1.0.1 or 0.1.1 type        III lesions,.|January 2016|February 24, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02691819|9 Months|2200|
NCT02703038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15897|French Observatory on the Management of Cardiogenic Shock in 2016|French Observatory on the Management of Cardiogenic Shock in 2016|FRENSHOCK|French Cardiology Society|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patient (> 18 years) with cardiogenic shock table defined by the combination of a        low cardiac output even as the filling pressures are normal or high, originally of        hypoperfusion and suffering of organ.|March 2016|March 3, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02703038||1339|
NCT02694562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRACLE III|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy: A Pilot Study of Irinotecan in the Treatment of Metastatic Colorectal Carcinoma (mCRC) by Embozene TANDEM™ Drug-Eluting Microspheres Embolization|MIRACLEIII|Boston Scientific Corporation|No|Active, not recruiting|November 2013|April 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|19 Years|N/A|No|||February 2016|February 26, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02694562||1989|
NCT02682446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUMC_13-1059|The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm|Prediction for the Development of Metachronous Gastric Cancer After Endoscopic Submucosal Dissection by Serum Pepsinogen||Kyungpook National University|No|Completed|January 2007|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|800|Samples Without DNA|Serum pepsinogen, serum HP IgG|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|This study was designed to enroll patients in our ESD data registry, prospectively.        Finally, we analyzed the data retrospectively. We enrolled about more than 1000 patients        in our ESD registry. For this cohort study, we enrolled about 800 patients for analysis.|February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682446||2919|
NCT02684916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504|Chiropractic Treatment for Headache Among Children Aged 7-14|Effectiveness of Chiropractic Manipulation Treatment Versus Placebo Manipulation on Children Aged 7-14 Years With Headache and Musculoskeletal Problems. A Randomized Clinical Trial||Nordic Institute of Chiropractic and Clinical Biomechanics|No|Recruiting|October 2015|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|7 Years|14 Years|No|||February 2016|February 17, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02684916||2729|
NCT02680756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST10-01-304|Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD|A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease||Iron Therapeutics|No|Recruiting|January 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680756||3049|
NCT02699567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011853|CD36 and Human Fat Taste Perception|CD36 Involvement on Fat Taste Perception and Fat Hedonic Value in Humans|FATYP|Washington University School of Medicine|No|Completed|November 2011|July 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|97|Samples With DNA|Extracted genomic DNA|Both|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be men and women, 21 to 50 yrs of age of all races and ethnic groups. The        two groups (i.e. groups with different CD36 genetic variants) will be matched as closely        as possible in age, sex, body mass index and race distributions. Subject population will        consist of lean subjects (BMI >18-<25 kg/m2) and subjects with obesity (BMI >29.9 kg/m2).|February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02699567||1606|
NCT02694991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001-2013|Osteopathic Manipulative Treatment Efficacy in Postoperative Pain|Osteopathic Manipulative Treatment Efficacy in Sternal Pain Management After Heart Surgery||Fondazione Don Carlo Gnocchi Onlus|No|Completed|September 2013|February 2016|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02694991||1956|
NCT02695004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKF-310-P1|Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).|Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of DKF-310 Intramuscular Injection in Healthy Male Volunteers||Dongkook Pharmaceutical Co., Ltd.|Yes|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Anticipated|45|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695004||1955|
NCT02691598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHPOFFSAP1|Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis|Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following|DHPOFFSAP|Nanjing University School of Medicine|Yes|Not yet recruiting|February 2016|August 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|314|||Both|15 Years|70 Years|No|||February 2016|February 20, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02691598||2217|
NCT02679365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2476ASU|Double Lock Versus Continuous Non-locking Technique for Closure of Rectus Sheath in Cesarean Sections on Post-operative Pain|||Ain Shams Maternity Hospital||Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02679365||3155|
NCT02683109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.49|Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD|A 4-week, Randomised, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Tiotropium + Olodaterol Fixed Dose Combination (5/5 µg) Delivered by the Respimat® Inhaler Versus the Free Combination of Tiotropium 5 µg and Olodaterol 5 µg Delivered by Separate Respimat® Inhalers in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Not yet recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|N/A|No|||March 2016|March 8, 2016|February 12, 2016||||No||https://clinicaltrials.gov/show/NCT02683109||2868|
NCT02683356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-01-16|Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds|Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds|OPTICO-BVS|University Hospital Inselspital, Berne|No|Not yet recruiting|March 2016|March 2021|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02683356||2849|
NCT02707679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUT 12/175|Comparison of Effects of Mobilization With Movement and Kinesiotaping in Patellofemoral Pain Syndrome|Comparison of Short-Term Effects of Mobilization With Movement and Kinesiotaping on Pain, Function and Balance in Patellofemoral Pain Syndrome: A Randomized Control||Hacettepe University|No|Completed|May 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|35|||Female|20 Years|45 Years|No|||March 2016|March 13, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02707679||983|
NCT02679313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phoropter Study|Effect of Lens Presentation on the Clinical Oculomotor Assessment at Near|Effect of Lens Presentation on the Clinical Oculomotor Assessment at Near||State University of New York College of Optometry|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679313||3159|
NCT02691637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0602/030-001|Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients|Effect of Helicobacter Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients.||Seoul National University Bundang Hospital|No|Recruiting|February 2006|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients who have H. pylori related gastrointestinal disease and/or Patients who do not        have H. pylori related gastrointestinal disease. But, want H. pylori eradication|February 2016|February 20, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02691637||2214|
NCT02679573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-3341-306|Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia||Melinta Therapeutics, Inc.|No|Not yet recruiting|February 2016|||May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|860|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679573||3139|
NCT02693418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVO-002|Duration of Effect of Acidform Gel on Vaginal pH|A Randomized, Placebo Controlled Pilot Study to Determine the Effect and Duration of Acidform Gel on Vaginal pH||Evofem Inc.|No|Not yet recruiting|May 2016|January 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02693418||2077|
NCT02693431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0459|Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13|Impact of Art Therapy on Anxiety Identified During the Quarterly Update of Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13 - Pilot Study|MUCO-ART|Nantes University Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|27|||Both|8 Years|13 Years|No|Probability Sample|27 children (and their parents) aged 8 to 13 years in 2016 with cystic fibrosis followed        at CRCM children Nantes.|February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693431||2076|
NCT02580877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral Insulin-TN20|Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)|Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|January 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|3 Years|45 Years|No|||March 2016|March 21, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02580877||10714|
NCT02578394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0850|Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study|A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease|ASGARD|Southend University Hospital Foundation NHS Trust|No|Not yet recruiting|November 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02578394||10904|
NCT02694159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823464|Physician Judgment and Machine Predictions|Physician Judgment and Machine Predictions: Improving Medical Decisions Using Machine Learning||University of Pennsylvania|No|Active, not recruiting|February 2016|August 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50000|||Both|18 Years|90 Years|No|Non-Probability Sample|Clinical data on tens of thousands of patients presented to ED and transferred to ICUs or        general hospital units within the University of Pennsylvania Health System from 2008 to        2014.|March 2016|March 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694159||2020|
NCT02694198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fetal fibronectin|Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion|Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion||Ain Shams Maternity Hospital|Yes|Recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|135|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery        ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal        ultrasound who will undergo termination by misoprostol|February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02694198||2017|
NCT02684669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15018869-BI|Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury|Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury. A Randomized, Placebo-controlled, Double-blind Crossover Study|TCI-NX-BI|University of Copenhagen|Yes|Recruiting|February 2016|January 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02684669||2748|
NCT02692963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG-EHMI|Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection|Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection|BCG-EHMI|Radboud University|No|Not yet recruiting|August 2016|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692963||2112|
NCT02692976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2012-002531-29|Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients|A Randomized Phase IIa Study: Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients||Radboud University|No|Recruiting|September 2015|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|September 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692976||2111|
NCT02706223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014GA07|A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland.|A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland|SuperDOT-C|University of Dundee|Yes|Not yet recruiting|July 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|300|||Both|N/A|N/A|No|||February 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02706223||1094|
NCT02696135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHCS-2016|The Chinese Hypertrophic Cardiomyopathy Study(CHCS)|The Chinese Hypertrophic Cardiomyopathy Study(CHCS)|CHCS|China National Center for Cardiovascular Diseases|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|In accordance with clinical diagnosis of patients with hypertropic cardiomyopathy|Both|N/A|N/A|No|Non-Probability Sample|Between March 2016 and March 2020 from multiple centers in China,in accordance with the        diagnosis of hypertrophic cardiomyopathy|February 2016|February 25, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696135||1870|
NCT02689843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P-9145-4025|Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS|Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS)|AntiPCO|Shiraz University of Medical Sciences|Yes|Recruiting|March 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|35 Years|No|||March 2016|March 1, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02689843||2350|
NCT02695459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14NEC|Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin|Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin||The Netherlands Cancer Institute||Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695459||1921|
NCT02695472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2014-1|Study of NSI-189 for Major Depressive Disorder|A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder||Neuralstem Inc.|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|60 Years|No|||February 2016|February 29, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695472||1920|
NCT02693028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr. 085-15|Lactobacillus Reuteri Feasibility Study on Probiotic Treatment and Perinatal Microbiome|Lactobacillus Reuteri Feasibility Study on Probiotic Lozenges, Probiotic Chewing Gum and Probiotic Capsules and Perinatal Microbiome Seeding During Pregnancy||Sahlgrenska University Hospital, Sweden|No|Recruiting|November 2015|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693028||2107|
NCT02700581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH000000 TBD|Impact of Positive End-expiratory Pressure on Hepatic Venous Flow|Impact of Moderate Positive End-expiratory Pressure on Hepatic Venous Flow in Patients Undergoing Cardiac Surgery||Konkuk University Medical Center|Yes|Not yet recruiting|March 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|15|||Both|19 Years|65 Years|No|||March 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02700581||1528|
NCT02700867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.006.1MR|Trial Comparing Proximal Tibia and Proximal Humerus Infusion Rates Using the NIO Intraosseous Device|A Randomized Crossover Cadaver Trial Comparing Proximal Tibia and Proximal Humerus Infusion Rates Using the NIO Intraosseous Device During Simulated Cardiopulmonary Resuscitation Performed by Paramedics|IOACS|Medical University of Warsaw|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02700867||1506|
NCT02682966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPICT-NCS|Direct Evaluation of Postoperative Myocardial Injury Using Coronary Computed Tomography Angiography After Non-Cardiac Surgery|Direct Evaluation of Postoperative Myocardial Injury Using Coronary Computed Tomography Angiography After Non-Cardiac Surgery||UMC Utrecht|No|Not yet recruiting|June 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|454|||Both|60 Years|N/A|No|Non-Probability Sample|Patients of 60 years or older that undergo major elective noncardiac surgery are eligible        for study participation. Major elective noncardiac surgery is defined as all surgical        procedures requiring ≥ 24 hours of hospital admittance that have been preceded by a        preoperative consultation at the anaesthesia preoperative screening outpatient clinic|February 2016|February 11, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02682966||2879|
NCT02680678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAU|The Effect of the Timing of Colloid and Cristaloid Infusions on Postspinal Hypotension After Spinal Anesthesia for Caesarian Section|Prevention of Postspinal Hypotension After Spinal Anesthesia for Caesarian Section, the Comparison of Cristalloid and Colloid Infusions and Their Timing Via Perfusion Index and Phletismogaphic Variability Index||Balikesir University|No|Active, not recruiting|April 2014|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680678||3055|
NCT02680691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC-2015-01-002|Robot Assisted Gait Training in Patients With Infratentorial Stroke|The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke||National Rehabilitation Center, Seoul, Korea|No|Recruiting|April 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|February 9, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02680691||3054|
NCT02679430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/12/VA02|Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres|Prospective Analysis of Prostatic Arterial Embolization||Maimonides Medical Center|Yes|Not yet recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|35 Years|99 Years|No|||February 2016|February 5, 2016|October 22, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02679430||3150|
NCT02701088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANAL-IMRT-01|Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life|Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life|CANAL-IMRT-01|Centre Francois Baclesse|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|December 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02701088||1489|
NCT02687854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18731|Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist|Real-world Comparative Effectiveness of Apixaban Versus VKA|PIXI-F|Bayer|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|18591|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation (NVAF)|March 2016|March 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687854||2503|
NCT02695576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpinalSC|Lumbar Fusion or Non-operative Care for Treatment of Presumed Discogenic Pain|Lumbar Fusion or Non-operative Care for Treatment of Presumed Discogenic Pain: A Randomized Study||Spinal Surgery Clinic, Strängnäs|No|Active, not recruiting|July 2007|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||February 2016|February 29, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02695576||1912|
NCT02695602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-01264|Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)|Prospective Randomized Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)||New York University School of Medicine|No|Recruiting|February 2016|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02695602||1911|
NCT02682316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-309|Negative Pressure Wound Therapy in Post-Operative Incision Management|A Phase III Randomized Controlled Trial of Negative Pressure Wound Therapy in Post-Operative Incision Management||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|686|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682316||2929|
NCT02682329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dental Bleaching Techniques|Combination of Dental Bleaching Techniques, Randomized Clinical Trial|Combination of Dental Bleaching Techniques, Randomized Clinical Trial||Universidad Iberoamericana|Yes|Completed|February 2014|August 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02682329||2928|
NCT02705066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-8400|Citicoline Effects on Cortical Membrane Structure and Function|Citicoline Effects on Cortical Membrane Structure and Function||Kyowa Hakko Bio Co., Ltd.||Recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||February 2016|March 13, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02705066||1183|
NCT02679300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMatheveVR&Pain|Virtual Reality and Pain Perception During Exercises for Patients With Chronic Non-specific Low Back Pain|The Influence of a Virtual Reality Environment on Pain Perception During Exercises for Patients With Chronic Non-specific Low Back Pain: A Randomized Controlled Trial||Hasselt University||Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2016|February 6, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679300||3160|
NCT02684461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1516|Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel|Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel, Sequential Consolidation With Nab-paclitaxel Followed by Pembrolizumab and Concurrent Consolidation With Nab-paclitaxel and Pembrolizumab After Standard First-Line Induction Chemotherapy in Advanced NSCLC||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|99 Years|No|||February 2016|February 12, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684461||2764|
NCT02693860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505016234|Neoadjuvant J591 Treatment for Prostate Cancer|A Pilot Study of Neoadjuvant Monoclonal Antibody Humanised (hu) J591 for the Treatment of High and/or Intermediate−Risk Prostate Cancer||Weill Medical College of Cornell University|Yes|Recruiting|January 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693860||2043|
NCT02693873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA:D Canada pilot|STOP OA: A PILOT STUDY (GLA:D Canada) - Education and Targeted, Personalized Exercise for Hip and Knee Osteoarthritis|STOP OA: A PILOT STUDY - Adaptation and Evaluation of a Targeted, Evidence-based, Integrated Patient Education and Exercise Program to Prevent the Progression of Hip and Knee Osteoarthritis Symptoms||University Health Network, Toronto|No|Recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|30 Years|N/A|No|||March 2016|March 21, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02693873||2042|
NCT02693886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX0302-B010507-150031-PB|Effect of Single Colonoscopy on Colorectal Adenomas Detection|Clinical Study That Effect of Individualized Intervention of Single Colonoscopy on Colorectal Adenomas Detection||Wuxi People's Hospital|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||4|Anticipated|10000|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. greater than the age of 40;          2. Pathology and endoscopic data recorded available and detailed;          3. Whole bowel staining endoscopy is not done.|January 2016|February 26, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02693886||2041|
NCT02696876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR15/173|Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair|Safety and Efficacy of a Novel Synovium Brushing Method for Endogenous Mesenchymal Stem Cells Mobilisation During Knee Joint Microfracture for Cartilage Repair.|AURA|University of Leeds|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|55 Years|No|||March 2016|March 2, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696876||1813|
NCT02688478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-01119|The Phthalate-Allergen Immune Response Study|Effects of Phthalate Inhalation on Airway Immunology: A Controlled Human Exposure Study|PAIR|University of British Columbia|No|Not yet recruiting|January 2016|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02688478||2455|
NCT02694796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2015/02|Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy|Long Term Impact of a Physical Activity Intervention Combining Workshop During a Balneotherapy and a Web and Smartphone-based Physical Activity Program After Balneotherapy, on Physical Activity Level : a Randomized Control Trial|THERMACTIVE|Association Francaise pour la Recherche Thermale|Yes|Recruiting|September 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|462|||Both|50 Years|79 Years|No|||February 2016|February 29, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694796||1971|
NCT02694809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 15B06|Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery|A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS)||Northwestern University|Yes|Not yet recruiting|March 2016|||September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|75 Years|No|||February 2016|February 24, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694809||1970|
NCT02693925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_SBASKardio_14-322|Sleep-related Breathing Disorders in Cardiological Outpatients|Sleep-related Breathing Disorders in Cardiological Outpatients From a German University Clinic - Prevalence, Classification, Diagnostic Accuracy|SRBD-Cardio|Wissenschaftliches Institut Bethanien e.V|No|Recruiting|December 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|90|||Both|18 Years|N/A|No|Probability Sample|Patients with cardiologic diseases who have a routine outpatient follow-up visit in the        heart center of the University Clinic Cologne or are at the end of a cardivascular-related        hospital stay in stable (recompensated) state.|February 2016|February 23, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02693925||2038|
NCT02682849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006388|Active Clearance Technology (ACT) Registry|Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry||Mayo Clinic||Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|The control arm consists of a cohort of matched cardiac surgery patients with data entered        over the preceding 12 to 24-month period. The site will consecutively enroll a cohort of        cardiac surgery patients in the treatment arm.|February 2016|February 11, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682849|30 Days|2888|
NCT02707666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-1149|A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma|A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma||University of Chicago|No|Not yet recruiting|March 2016|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707666||984|
NCT02688582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/005|Target-controlled Infusion Model for Cefepime|A Study to Evaluate the Predictive Performance of a Target-controlled Infusion Model for the Administration of Cefepime to Intensive Care Patients||Onze Lieve Vrouw Hospital||Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02688582||2447|
NCT02688595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601-108-736|Central Venous Catheterization Techniques in Neonates|Randomized Controlled Trial on Central Venous Catheterization Techniques in Neonates: Seldinger Versus Modified Seldinger||Seoul National University Hospital|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|1 Month|No|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02688595||2446|
NCT02681757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1828|Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns|A Comparison of Mepitel Ag vs Antibiotic Ointment When Used With the Soft Cast Technique for the Treatment of Pediatric Hand and Foot Burns, a Prospective Study||University of Colorado, Denver|Yes|Not yet recruiting|March 2016|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|31 Days|18 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681757||2972|
NCT02686866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101568/2015/OTIG|Body Composition Measurements in Chronic Heart Failure|Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure||Hungarian Institute of Cardiology|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02686866||2579|
NCT02694185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-048|Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications|Secondary Event Prevention Using Population Risk Management After PCI|SEPPRMACI-ARM|VA Office of Research and Development|Yes|Not yet recruiting|October 2016|March 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4800|||Both|18 Years|95 Years|No|||February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02694185||2018|
NCT02694224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH (Sonic HedgeHog)-CM|Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|SHH-CM|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|75 Years|No|||February 2016|February 23, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02694224||2015|
NCT02695667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOD00003534|Genioglossus Strength and OSAS||EatonOSAS|University of New Mexico|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|44|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|This initial pilot investigation will screen up to 70 individuals to obtain the necessary        enrollment of 22 subjects per group from Stage Three: CPAP Referral OSAS; and paired        normal control subjects|February 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695667|1 Day|1906|
NCT02690935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLB-2016-01|Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen|Randomized, Double-blind, Placebo-controlled Study to Measure 2L®ALERG (Homeopathic Drug) Efficacy on Symptoms of Allergic Rhinitis and Allergic Rhinoconjunctivitis in Patients With a Seasonal Allergy to Grass Pollen|LLB-2016-01|Labo'Life|No|Recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02690935||2267|
NCT02690948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0031|Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer|A Phase Ib Open-Label Two Arm Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma||Stanford University|Yes|Recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690948||2266|
NCT02690961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-KB103|Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers|Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers||Tianjin Chasesun Pharmaceutical Co., LTD|No|Not yet recruiting|March 2016|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02690961||2265|
NCT02690974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696BCA02|Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting|Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF|PARASAIL|Novartis|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|300|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|February 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02690974||2264|
NCT02679391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES2012/1997-31/4|The Outcome of Abdominoplasty After Massive Weight Loss|The Outcome of Abdominoplasty After Massive Weight Loss; Comparison of Results From Plastic and General Surgical Units - a Retrospective Cohort Study||Karolinska Institutet|No|Completed|January 2010|January 2016|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|209|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients that were accepted for abdominoplasties after massive weight loss in accordance        with the inclusion and exclusion criterias. Consecutively operated.|February 2016|February 6, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02679391||3153|
NCT02681042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-292|Left Atrial Appendage Closure With SentreHeart Lariat® Device|Left Atrial Appendage Closure With SentreHeart Lariat® Device|Lariat|Baylor Research Institute|Yes|Recruiting|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 26, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02681042||3027|
NCT02681055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-001-NATG-201|An Open-Label Study To Evaluate Efficacy, Safety, Tolerability and PK of MN-001 on HDL and Triglyceride in NASH Subjects|An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH Subjects With Hypertriglyceridemia||MediciNova|No|Not yet recruiting|March 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|65 Years|No|||February 2016|February 9, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681055||3026|
NCT02699619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/191/REK SO B|Undisplaced Femoral Neck Fractures 2 Hansson Pins or 3 Pins Interlocked in Plate (Pinloc) Using RSA|Undisplaced Femoral Neck Fractures Treated With 2 Hansson Pins Without Plate or 3 Hansson Pins Interlocked in a Plate (Pinloc) - A Randomized Controlled Trial Using Radiostereometry||Oslo University Hospital|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|N/A|No|||February 2016|March 3, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02699619||1602|
NCT02699632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 2015-068|Participate While Pregnant Survey|Research Participation in the Pregnant Population: A Survey Study||Pennington Biomedical Research Center|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|5000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited online. Anyone can take this survey, however females who have        been pregnant or are planning to become pregnant will be the most relevant population.|March 2016|March 21, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02699632||1601|
NCT02693821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2575|Persistent Postoperative Pain|Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used|PPP|Hospital Italiano de Buenos Aires|Yes|Enrolling by invitation|December 2015|December 2018|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|15|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02693821||2046|
NCT02682264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-03-01/27|An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris|An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris||Cassiopea SpA|No|Not yet recruiting|March 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|9 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682264||2933|
NCT02686125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4012|Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry|Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry||Boston Scientific Corporation|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|7 Years|N/A|No|Non-Probability Sample|Subjects with intractable primary and secondary dystonia, for persons 7 years of age and        older.|January 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02686125|3 Years|2636|
NCT02686138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-01-302|A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C|A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Ardelyx|No|Recruiting|December 2015|November 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||February 2016|February 15, 2016|January 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686138||2635|
NCT02696174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR 29311|Effectiveness of A Health Microinsurance Scheme for Private Primary Care in Malaysia|Effectiveness of A Health Microinsurance Scheme in Improving Health Equity and Clinical Outcomes for Private Primary Care in Kuala Lumpur, Malaysia|HMI|Chulalongkorn University|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02696174||1867|
NCT02691260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00056410|Incenting Behavior Change Skills to Promote Weight Loss|Incenting Behavior Change Skills to Promote Weight Loss||Duke University|Yes|Not yet recruiting|May 2016|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691260||2243|
NCT02694718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18280|A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer|A Phase II Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer||Hoffmann-La Roche||Completed|March 2005|November 2006|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694718||1977|
NCT02702258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412001171-1|Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development|Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development: Effects on Self-Regulation Targets, Including Self Awareness, Emotion Regulation and Attention Control|MB-BP|Brown University|Yes|Recruiting|February 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702258||1399|
NCT02702271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91081206|Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology|Protection Against Embolism for Non-valvular AF Subjects: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology|PINNACLE FLX|Boston Scientific Corporation|Yes|Not yet recruiting|July 2016|||November 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|460|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702271||1398|
NCT02681432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCRCIRU001|Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study|hipecova|Hospital General de Ciudad Real|No|Recruiting|January 2012|December 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|80 Years|No|||January 2016|February 11, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681432||2997|
NCT02679339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2022-HZ-011|Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain|A Phase Ib Pilot Multiple Dose, Randomized-Withdrawal, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster Pain||Centrexion Therapeutics||Terminated|January 2015|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|85 Years|No|||February 2016|February 9, 2016|February 9, 2015|No|Yes|Limited patient enrollment|No||https://clinicaltrials.gov/show/NCT02679339||3157|
NCT02680418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDL169-2015-02|Pharmacokinetics of FDL169 in Healthy Female Subjects|A Phase I Dose Escalation Study to Assess the Pharmacokinetics (PK) of FDL169 in Healthy Female Volunteers||Flatley Discovery Lab LLC|No|Recruiting|December 2015|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|6||Anticipated|16|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02680418||3075|
NCT02698501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-10870|Effects of Anti-TSLP in Patients With Asthma|Effects of Anti-TSLP on Airway Hyperresponsiveness and Mast Cell Phenotype in Asthma - A Randomized Double-blind, Placebo-controlled Trial of MEDI9929|UPSTREAM|University Hospital Bispebjerg and Frederiksberg|No|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02698501||1688|
NCT02698514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-12-023|The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics|The Ratio of Hypnotic to Analgesic Potency of Sevoflurane and Desflurane : Randomized Controlled Trial||Kangbuk Samsung Hospital|No|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|19 Years|65 Years|No|||February 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02698514||1687|
NCT02689466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160064|Cholinergic Receptor Imaging in Dystonia|Cholinergic Receptor Imaging in Dystonia||National Institutes of Health Clinical Center (CC)||Recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 20, 2016|February 20, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689466||2379|
NCT02691780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-097|Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors||Samsung Medical Center||Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691780||2203|
NCT02693184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 117-16-EP|Validation of a Revised Food Frequency Questionnaire|Validation of a Revised Food Frequency Questionnaire in a Population of Elderly Men and Women With Fragility Fractures and Correlation With Bone Mineral Density and Biochemical Markers|FFQ|University of Nebraska|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|45|||Both|65 Years|N/A|No|Non-Probability Sample|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained        after a fall from a standing height or less).|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693184||2095|
NCT02693249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_2016-00275|Dysfunctional Posttraumatic Cognitions in Children and Adolescents|Dysfunctional Posttraumatic Cognitions in Children and Adolescents|PTC|University Children's Hospital, Zurich|No|Recruiting|February 2016|November 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|170|||Both|7 Years|18 Years|No|Non-Probability Sample|Children and adolescents (ages 7-18 years), who experienced an accidental trauma (either        traffic accident or burn accident) and at least one parent.|February 2016|February 22, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02693249||2090|
NCT02698761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-129|A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises|A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises||Valley Anesthesiology Consultants|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02698761||1668|
NCT02680509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL5234.042.15|Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study|Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study||University of Groningen|Yes|Enrolling by invitation|February 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02680509||3068|
NCT02680522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35683614.5.0000.5173|Safety Study to Autonomic Rehabilitation o Parkinson's Disease|Study of Modulation Autonomic Heart Rate of Individuals With Parkinson's Disease and Healty Individuals Subject to a Training With Virtual Reality||Universidade Metodista de Piracicaba|Yes|Completed|January 2014|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02680522||3067|
NCT02680860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-MUST-01-14|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||February 9, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680860||3041|
NCT02688764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CL-PED-01|An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia||Vifor Fresenius Medical Care Renal Pharma|Yes|Not yet recruiting|March 2016|||October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|18 Years|No|||February 2016|February 22, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688764||2433|
NCT02681016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAT1.0|Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE|Prospective rAndomized, Single-blind, multicenTral Control Clinical Trial of Sirolimus-elutng coRonary Stent "Calypso" (Angioline) vs Everolimus-elutIng cOronary stenT "Xience Prime" (Abbott Vascular)|PATRIOT|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|March 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|610|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02681016||3029|
NCT02685293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003017|Study to Evaluate the Treatment Effect of PT003 on Cardiac Stroke Volume in Subjects With Moderate to Severe COPD|A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo||Pearl Therapeutics, Inc.|No|Not yet recruiting|February 2016|May 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||February 2016|February 12, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685293||2700|
NCT02705755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0145|TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)|A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension||Theravance Biopharma R & D, Inc.|No|Not yet recruiting|April 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||March 2016|March 24, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705755||1130|
NCT02682459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXTRA|ACE-inhibitors in Extracapillary Glomerulonephritis|A Pilot, Prospective, Randomized, Open-label, Blinded Endpoint (Probe) Histopathology Trial to Assess the Effects of ACE- Inhibition Therapy on Glomerular Proliferative Lesions in Patients With Extracapillary Glomerulonephritis|EXTRA|A.O. Ospedale Papa Giovanni XXIII|No|Not yet recruiting|February 2016|December 2019|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02682459||2918|
NCT02686229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoG-Glio|Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas|Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project|LoG-Glio|University of Ulm|Yes|Recruiting|December 2015|December 2030|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood and tumor samples|Both|18 Years|N/A|No|Probability Sample|All adult patients with radiological suspected diagnosis of a low grade glioma|March 2016|March 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02686229|10 Years|2628|
NCT02690207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204486|Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.|Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies||GlaxoSmithKline||Not yet recruiting|March 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02690207||2322|
NCT02691299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-013-00CH1|A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib|FALUCA|Hutchison Medipharma Limited|Yes|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|521|||Both|18 Years|75 Years|No|||February 2016|February 21, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02691299||2240|
NCT02685878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCPM 21502|Outcomes of Women After Obstetric Fistula Repair|Physical, Psychological, and Reproductive Outcomes of Women After Obstetric Fistula Repair||University of North Carolina, Chapel Hill|No|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|300 women 1-3 years after they have undergone obstetric fistula repair at the Fistula Care        Center in Lilongwe, Malawi.|February 2016|February 15, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02685878||2655|
NCT02704052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00086103|Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose|Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose||University of Utah|Yes|Recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704052||1261|
NCT02679378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|710CLD Rev. 02|Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy|Clinical Study of the ClearSight™ System to Evaluate the Ability to Distinguish Malignant From Non-malignant Breast Tissue by Comparing MR Measurements of Freshly Excised Breast Tissue to Histopathology||Clear Cut Medical Ltd.|No|Not yet recruiting|February 2016|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|220|||Female|18 Years|99 Years|No|||January 2016|February 9, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02679378||3154|
NCT02687763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro25854|Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant|A Prospective, Multisite Study to Evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® Vaccination in Pediatric Patients 6-24 Months of Age Who Are Being Considered and/or Evaluated for Any Solid Organ Transplant|ProQuad®|Medical University of South Carolina|No|Recruiting|December 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|6 Months|24 Months|No|||February 2016|February 18, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687763||2510|
NCT02697721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6AZ09|Powerful Tools for Caregivers of Dementia Patients|Optimization of "Powerful Tools for Caregivers" of Dementia Patients|PTC-dementia|Florida State University|No|Recruiting|February 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02697721||1748|
NCT02697734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C2302|Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease|A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease|LINC-4|Novartis|Yes|Not yet recruiting|May 2016|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|69|||Both|18 Years|75 Years|No|||February 2016|February 27, 2016|February 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02697734||1747|
NCT02684396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-648_101|Phase 1, TAK-648, Single-Rising Dose Study|A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single Oral TAK-648 Doses in Healthy Subjects||Takeda|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02684396||2769|
NCT02684409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-CL-NP101-015.01|Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine|A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine||Teva Pharmaceutical Industries|Yes|Completed|August 2013|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|12 Years|17 Years|No|||February 2016|February 16, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684409||2768|
NCT02679586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.010|Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy|Evaluation of an Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy||University of Michigan Cancer Center|Yes|Completed|June 2006|||March 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679586||3138|
NCT02684175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0572-P2H|Comparison of In-Person Versus Remote Cochlear Implant Candidacy Evaluations|Comparison of Patient & Provider Outcomes With In-Person Versus Remote Cochlear Implant Candidacy Evaluations||University of Kentucky|Yes|Enrolling by invitation|January 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02684175||2786|
NCT02694588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Short-Sys-Inflame|Clinical and Molecular Phenotyping in IBD|Systematic Profiling of Anti-inflammatory Drugs for the Detection of Drug- Specific Response Signatures in the Treatment of Chronic Inflammatory Disorders|Phen_IBD|University of Schleswig-Holstein|No|Recruiting|June 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|December 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02694588||1987|
NCT02694601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-441|Ketone Production and Caffeine|Stimulate the Ketogenesis by Using a Caffeine Supplement||Université de Sherbrooke|No|Completed|January 2014|June 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02694601||1986|
NCT02517125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00173-46|Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors|Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors|TORS|Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|April 2015|April 2025|Anticipated|April 2025|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02517125||15610|
NCT02582684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5353|Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients|A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants||AIDS Clinical Trials Group|Yes|Recruiting|December 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|October 20, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582684||10575|
NCT02582697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZUP1302|Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours|Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours|P3BEP|University of Sydney|Yes|Recruiting|February 2014|July 2023|Anticipated|February 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Male|16 Years|45 Years|No|||October 2015|October 19, 2015|September 7, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02582697||10574|
NCT02681419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0800|Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period|Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period||The University of Texas Health Science Center, Houston|No|Recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681419||2998|
NCT02681666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150591|Mindfulness-based Eating in Patients With Irritable Bowel Syndrome|A Pilot, Randomized Trial of Mindfulness-based Irritable Bowel Syndrome Eating Awareness Training as Compared to the Standard Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide and Polyol Diet in Patients With IBS||University of Miami|No|Recruiting|September 2015|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02681666||2979|
NCT02689310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Honey & Wound Care|Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers|Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers||New York City Health and Hospitals Corporation|No|Recruiting|March 2016|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Anticipated|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689310||2391|
NCT02682030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039699|The Use of Airway Clearance Devices in ALS|Utilization of Pulmonary Clearance Devices in Amyotrophic Lateral Sclerosis||Cedars-Sinai Medical Center|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682030||2951|
NCT02700087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-35551|In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?|In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial||Stanford University|No|Recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|N/A|4 Months|No|||March 2016|March 4, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700087||1566|
NCT02678468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104077-F|Early Vision Screening in High-risk Children|Early Vision Screening With Automated Photorefraction in Pre-term, Low-birth- Weight and Development-delay Children in Far-Eastern Memorial Hospital, Taiwan||Far Eastern Memorial Hospital|No|Not yet recruiting|February 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|1 Year|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children born and regular followed at pediatric clinic in Far Eastern Memorial Hospital|February 2016|February 5, 2016|February 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02678468||3224|
NCT02681497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2843175DIA4018_Harris|Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting|Characteristics and Health Outcomes of Patients With Type 2 Diabetes Treated With Canagliflozin Added to Insulin Therapy in a Real-world Setting||Lawson Health Research Institute|No|Not yet recruiting|February 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|113|||Both|18 Years|90 Years|No|Non-Probability Sample|This retrospective study will use data from an EMR-based (Web DR) researchable database,        which has been used to study patient's socioeconomic characteristics, treatment patterns        and health outcomes of patients with diabetes. The Web DR de-identified researchable        database contains integrated demographic, clinical and laboratory test result data of        patients who received care from outpatient diabetes clinics in London, Ontario. The        database includes more than 16,000 patients and their clinic visit information since 2000.        Adult individuals (age>=18) with type 2 diabetes registered in Web DR who have been        treated with canagliflozin in conjunction with insulin therapy will be selected for this        study.|February 2016|February 11, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02681497||2992|
NCT02682290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38RC14.444|Assessment of Rheological Parameters of Human Sputum.|Assessment of a Device Used for Measuring the Rheological Parameters of Human Sputum.|RHEOMUCO|University Hospital, Grenoble|No|Not yet recruiting|February 2016|June 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02682290||2931|
NCT02682303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/14|Effect of Elastic Adhesive Bandaging on Balance in Chronic Ankle Instability|Effect of Elastic Adhesive Bandaging on Measurements of Balance in Subjects With Chronic Ankle Instability: a Randomized Clinical Trial||Universidad Rey Juan Carlos|No|Completed|January 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|28 Years|No|||February 2016|February 12, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02682303||2930|
NCT02704949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13788|Impact of Low Dose Fluoroscopy in Ureteroscopy|Impact of Low Dose Fluoroscopy in Ureteroscopy||University of Sao Paulo General Hospital|Yes|Enrolling by invitation|August 2015|December 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2016|March 4, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02704949||1192|
NCT02687308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41908815.9.0000.5259|Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique|Open Retropubic Radical Prostatectomy With Anterograde Anatomical Dissection Technique (RRP2A), Compared With Walsh Open Anatomical Retrograde Radical Prostatectomy (RRP)|RRP2A|Rio de Janeiro State University|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Male|40 Years|80 Years|No|||February 2016|February 16, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02687308||2545|
NCT02687321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE4|The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer|The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer: First Prospective Multicentre Observational Study||Brno University Hospital|Yes|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|N/A|N/A|No|Non-Probability Sample|Patient with histologically confirmed advanced epithelial ovarian, fallopian tube or        primary peritoneal carcinoma with complete remission after first line treatment.|February 2016|February 21, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687321||2544|
NCT02685254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1523 A|Effects of Structured Skills Training Group in Treatment of ADHD in Adults|Effects of Structured Skills Training Group in Treatment of ADHD in Adults: a Controlled Multicentre Study||University of Oslo|No|Recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02685254||2703|
NCT02705001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15363/15|Nurse Graduateness and Patient Outcomes: a Cross Sectional Pilot Study|Nurse Graduateness and Patient Outcomes: a Cross Sectional Pilot Study||Hamad Medical Corporation|No|Active, not recruiting|January 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Actual|1252|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients that visited the 7 participating hospitals|March 2016|March 9, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02705001||1188|
NCT02697175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLPO-2|Video Colposcopy in Women With Dysplasia|Does Live Video Colposcopy Reduces Anxiety in Women With Cervical Dysplasia? A Randomised Trial.||Zydolab - Institute of Cytology and Immune Cytochemistry|No|Not yet recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Female|18 Years|65 Years|No|||March 2016|March 2, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02697175||1790|
NCT02691221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00083066|ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients|ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients||Emory University|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|64 Years|No|||March 2016|March 14, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691221||2246|
NCT02679560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHP 6.7 Exparel|Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures|Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures: a Randomized, Active Comparator-controlled, Blinded Trial||University of California, Davis|No|Not yet recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|70 Years|No|||February 2016|February 24, 2016|February 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679560||3140|
NCT02687464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000052117|Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children|A Multicentre, Randomized Controlled Trial Comparing Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children|APPY|The Hospital for Sick Children|Yes|Recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|978|||Both|5 Years|16 Years|No|||February 2016|February 19, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02687464||2533|
NCT02687750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI-PF-001|Testing of Radiofrequency Coil for Clinical 19F MRI|||Western University, Canada||Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02687750||2511|
NCT02688010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFudanU_NNICU7|Effect of Reduced Noise Levels and Cycled Light on Visual and Neural Development in Preterm Infants|Effect of Reduced Noise Levels and Cycled Light on Visual and Neural Development in Preterm Infants||Children's Hospital of Fudan University|Yes|Recruiting|January 2016|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|154|||Both|N/A|7 Days|No|||February 2016|February 22, 2016|January 30, 2016||No||No||https://clinicaltrials.gov/show/NCT02688010||2491|
NCT02683499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDDS-FixPro-01-2016|Marginal Fit of Porcelain Veneers After Finishing Prepared Surfaces With Ultrasonic Tips|A Double-blind Split-mouth Randomized Clinical Trail Evaluating Marginal Fit of Porcelain Laminate Veneers Following Finishing the Prepared Surfaces With Ultrasonic Tips Compared to the Conventional Way||Damascus University|Yes|Completed|April 2015|March 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02683499||2838|
NCT02689713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120196H|Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent|Prospective, Randomized, Double-blind Controlled Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent at Skin Donor Sites||The University of Texas Health Science Center at San Antonio|No|Not yet recruiting|June 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689713||2360|
NCT02689726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC10VAC05|A Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL||Genticel|No|Recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|25 Years|65 Years|No|||February 2016|February 18, 2016|June 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02689726||2359|
NCT02682589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRSYM201602|Open Versus Laparoscopic Complete Mesocolic Excision for Locally Advanced Colon Cancer|A Multicenter, Prospective, Randomized Clinical Trial to Investigate Open Versus Laparoscopic Complete Mesocolic Excision for Locally Advanced Colon Cancer|OLCMECC|The First Affiliated Hospital with Nanjing Medical University|Yes|Not yet recruiting|April 2016|April 2023|Anticipated|April 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1080|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682589||2908|
NCT02682602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R011373568|THA Kinematics and Sound for Subjects for Normal, Diseased and Implanted Hips|In Vivo Determination of Total Hip Arthroplasty (THA) Kinematics and Sound for Subjects for Normal, Diseased and Implanted Hips||The University of Tennessee Knoxville|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|40 Years|85 Years|No|Non-Probability Sample|Subjects with a diseased hip that requires THA. OR Subjects with a normal hip.|February 2016|February 12, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02682602||2907|
NCT02701569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BF389/13|Effect of Rebound Exercise in Individuals With Type 2 Diabetes|Effect of Rebound Therapy on Metabolic Outcomes and Quality of Life in Nigerian Patients With Type 2 Diabetes||University of KwaZulu|No|Completed|July 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|60 Years|No|||February 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02701569||1452|
NCT02695563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRUa1GR-2013-00000220|Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators|Influence of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on PGE2, MMP-9, MMP-2, TIMP-1 and TIMP-2 Amniotic Fluid Concentrations||Università degli Studi di Ferrara|No|Completed|January 2014|September 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|111|||Female|25 Years|45 Years|No|||March 2016|March 3, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695563||1913|
NCT02695615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK10|Stress During Elective or Emergency Cesarean Operations|The Evaluation of the Effects of Stress During Elective or Emergency Cesarean Operations; Prospective, Randomized Clinical Trial||Umraniye Education and Research Hospital|No|Completed|January 2014|March 2015|Actual|January 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study included pregnant women aged ≥18 years (gestational age: 37-40 weeks) in whom        emergent or elective C/S was indicated|February 2016|February 29, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695615|1 Day|1910|
NCT02680080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-15-EC-15-0728-TLV-CTIL|Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome|The Effect of Pink Grapefruit Juice on the QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|35|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02680080||3101|
NCT02680093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602-15|Birth Rate in Conservative Monitoring of Pregnancy Beyond the Date of Birth.|Birth Rate in Conservative Monitoring of Pregnancy Beyond the Date of Birth.||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up.|February 2016|February 8, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02680093||3100|
NCT02683096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROD-SIU-15-288-CMV|Screening for Congenital Cytomegalovirus Infection in Newborns|Screening for Congenital Cytomegalovirus Infection in Newborns With Failed Hearing Screen or Who Are Small for Gestational Age|CMV|Southern Illinois University|No|Enrolling by invitation|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|75|Samples Without DNA|saliva PCR assays|Both|N/A|10 Days|No|Probability Sample|Newborn infants who either fail their newborn hearing test or have a diagnosis of small        for gestational age (SGA)|February 2016|February 11, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683096||2869|
NCT02690051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-140702|BeSmooth Study, Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions|BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions|BeSmooth|Flanders Medical Research Program|Yes|Active, not recruiting|October 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02690051||2334|
NCT02698007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0690-15-RMC|Safety and Benefits of Using Laryngeal Mask Airway to Keep Airway Potency During Fiber-optic Bronchoscopy|||Rabin Medical Center|Yes|Not yet recruiting|April 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02698007||1726|
NCT02695446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPX-01-C01|Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline|Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline||BioPharmX, Inc.|No|Active, not recruiting|March 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695446||1922|
NCT02687139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15145|Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma|Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma||Johns Hopkins University|No|Recruiting|October 2015|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|100 Years|No|||February 2016|February 16, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687139||2558|
NCT02691754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RePara|Impact of a Free Distribution of Paracetamol to Osteoarthritic Patients on Non-steroidal Anti-inflammatory Drugs (NSAID) and Proton Pump Inhibitors (PPI) Prescription|A Cluster Randomised Trial to Measure the Impact of a Free Distribution of Paracetamol to Osteoarthritic Patients on Non-steroidal Anti-inflammatory Drugs (NSAID) and Proton Pump Inhibitors (PPI) Prescription||Azienda Unità Sanitaria Locale Reggio Emilia|No|Completed|November 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16|||Both|65 Years|N/A|No|||February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02691754||2205|
NCT02695160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-FIX-1501|Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B|A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B||Sangamo Biosciences|Yes|Not yet recruiting|May 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695160||1944|
NCT02693288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A00720-45|Comparing Efficacity of Analgesia Between Ultrasound-guided Nerve Block and Local Infiltration After Wrist Fracture Surgery|Post Operative Analgesia After Wrist Fracture Surgery Under Regional Anesthesia: Randomized Trial, Open Study, With Evaluation of the Endpoint and Patient Blind (PROBE Design), Evaluating the Equivalence Between Ultrasound-guided Nerve Bloc and Local Infiltration|BNINF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693288||2087|
NCT02683317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2015-785-051|Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity|Effect of Enteral Administration of Docosahexaenoic Acid on Development of the Retinopathy of Prematurity||Coordinación de Investigación en Salud, Mexico|Yes|Enrolling by invitation|February 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|2 Weeks|No|||February 2016|February 11, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683317||2852|
NCT02701998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2118-15|The Stroke and Exercise Program|Development and Pilot Testing of a Scalable mHealth Intervention to Promote Physical Activity in TIA and Stroke Survivors|StEP|The Miriam Hospital|Yes|Recruiting|November 2015|November 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|75 Years|No|||November 2015|March 2, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02701998||1419|
NCT02702011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.113|Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus|A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy for 28 Days in Japanese Patients With Type 1 Diabetes Mellitus||Boehringer Ingelheim||Not yet recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|48|||Both|20 Years|65 Years|No|||March 2016|March 21, 2016|March 3, 2016||||No||https://clinicaltrials.gov/show/NCT02702011||1418|
NCT02690519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1837-CL-202|Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)|A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation|SAPHIRA2|Galapagos NV|Yes|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02690519||2299|
NCT02682212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-15-001|Obstetric Perineal Trauma and Physiotherapy|Obstetric Perineal Trauma, Pelvic Floor Symptoms and Early Physiotherapy Intervention||Landspitali University Hospital|No|Not yet recruiting|March 2016|July 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|March 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02682212||2937|
NCT02686762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDN-6556-12|EmricasaN, a Caspase inhibitOR, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)|A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis|ENCORE-NF|Conatus Pharmaceuticals Inc.|Yes|Recruiting|January 2016|October 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|N/A|No|||February 2016|March 8, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686762||2587|
NCT02687711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0077|Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures|A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectivness of Briviact® (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice|BASE|UCB Pharma|No|Recruiting|February 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|430|||Both|16 Years|N/A|No|Non-Probability Sample|Patients (male or female ≥16 years of age) with a clinical diagnosis of epilepsy with        Partial Onset Seizures with or without secondary generalization. The patients have never        been treated with brivaracetam and the decision by the treating physician (neurologists)        to prescribe brivaracetam is made independently of the participation in the study and        prior to enrollment.        Patient meets the criteria for treatment with brivaracetam as adjunctive therapy according        to the current SmPC in Europe. Patient is using a seizure diary as part of their standard        of care.|March 2016|March 9, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02687711||2514|
NCT02694289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0797-F6A|Effects of Metformin in Heart Failure Patients|Effects of Metformin in Heart Failure Patients||University of Kentucky|Yes|Not yet recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 5, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02694289||2010|
NCT02699879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB29908|Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)|Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting||Hoffmann-La Roche||Active, not recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1009|||Both|N/A|N/A|No|Non-Probability Sample|Participants receiving treatment for IPF with pirfenidone according to the physician's        discretion|March 2016|March 1, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699879||1582|
NCT02699892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21619|Study to Evaluate Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis|Post Marketing Non Interventional Clinical Research of Administration of Rituximab in Rheumatoid Arthritis||Hoffmann-La Roche||Completed|October 2007|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|80 Years|No|Non-Probability Sample|Participants receiving rituximab for longer than 4 weeks for the treatment of rheumatoid        arthritis.|March 2016|March 1, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699892||1581|
NCT02678507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Observational Study 2A (Quant)|A Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnaire|A Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|POMAQ|Member Companies of the Opioid PMR Consortium||Enrolling by invitation||||February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A||Non-Probability Sample|Patients within the Department of Defense (DoD)/TriCare health system with chronic (>3        months) pain treated with opioids.|November 2015|February 5, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02678507||3221|
NCT02680145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-006186|Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use|Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use||Mayo Clinic|Yes|Not yet recruiting|February 2016|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02680145||3096|
NCT02705287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 1509005821|Vitamin D Dynamics in Women|Vitamin D Dynamics in Pregnant Women and Non-Pregnant Women of Reproductive Age||Cornell University|Yes|Recruiting|July 2015|December 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Serum samples and extracted DNA sample (biospecimen retention will be both with and without      DNA)|Female|19 Years|35 Years|No|Non-Probability Sample|Pregnant women and non-pregnant women of reproductive age|March 2016|March 10, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705287||1166|
NCT02685436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1722011|Role of Pepsin Assay in Wheezy Infants|Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants||Mansoura University Children Hospital|Yes|Completed|March 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|6 Months|2 Years|No|||February 2016|February 13, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02685436||2689|
NCT02689232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-Variceal Bleed-001|TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.|TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed: An Open Label Randomized Controlled Trial.||Institute of Liver and Biliary Sciences, India|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|130|||Both|18 Years|75 Years|No|||February 2016|March 10, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02689232||2397|
NCT02684123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1817|A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata|A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684123||2790|
NCT02684734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-00197|Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis|Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis|PROVE-UC|University of British Columbia|No|Not yet recruiting|February 2016|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|394|Samples With DNA|whole blood and tissue|Both|19 Years|N/A|No|Non-Probability Sample|All patients with ulcerative colitis presenting for routine elective surveillance        endoscopy will be approached for enrolment. Patients will be evaluated by the        gastroenterologist at pre-endoscopy clinic visit for eligibility.|February 2016|February 17, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02684734||2743|
NCT02703324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16070|A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy||Eli Lilly and Company|No|Not yet recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|28|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703324||1317|
NCT02694913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503016060|Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies|Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies||Weill Medical College of Cornell University|No|Recruiting|November 2015|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Whole blood will be taken to measure B-cell depletion. Any remaining sample will be stored      for 15 years in the biobank.|Both|18 Years|N/A|No|Non-Probability Sample|Any adult patient who has not received rituximab or other anti-CD20 antibody within the        past year who is initiating rituximab or other anti-CD20 antibody treatment and has a        treatment plan that includes at least two doses of anti-CD20 antibody and longitudinal        follow up over at least a one-month time span.|February 2016|February 24, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02694913||1962|
NCT02681744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487622/2012-0|Sarcopenia, Obesity, and Resistance Training|Effects of Resistance Training on Sarcopenic Obesity Index in Older Women: a RCT.||University of Brasilia|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|244|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02681744||2973|
NCT02681978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIVENDEL|Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease|Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study|RIVENDEL|Campus Bio-Medico University|No|Completed|February 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02681978||2955|
NCT02680158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUN-009|1-Day Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator|A Randomized, Controlled, Double-Masked, Multicenter Trial Designed to Evaluate Acute Tear Production With the Oculeve Intranasal Lacrimal Stimulator Compared to Two Control Applications in Patients With Aqueous Deficient Dry Eye||Oculeve, Inc.|No|Active, not recruiting|January 2016|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|6||Actual|48|||Both|22 Years|N/A|No|||February 2016|February 8, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680158||3095|
NCT02702804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH18899|High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study|High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study|HIIT-MS|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02702804||1357|
NCT02685124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP FCF 1097907|Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans (METABORANGE).|Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans: a Comparative Study Between "Bahia" and "Cara Cara" Orange Varieties.|METABORANGE|University of Sao Paulo|Yes|Completed|September 2015|February 2016|Actual|October 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02685124||2713|
NCT02685137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-01-3W|Efficacy and Safety of Stannsoporfin in Neonates|A Multicenter Study to Evaluate the Efficacy and Safety of Tin Mesoporphyrin (Stannsoporfin) to Reduce the Need for Phototherapy in Term and Near Term Infants.||InfaCare Pharmaceuticals Corporation|Yes|Completed|April 2002|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|185|||Both|N/A|14 Days|No|||January 2016|February 12, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685137||2712|
NCT02693236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-DC/CIK-EC|DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer|Clinical Research of Genetically Modified Dendritic Cells in Combination With Cytokine-induced Killer Cell Treatment in Middle and Advanced Esophagus Cancer Patients||Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|August 2014|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||October 2015|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693236||2091|
NCT02693301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-0031/14A|Effects of an Exercise Program for Children With Asthma|Effects of an Intra-hospital Exercise Program for Children With Asthma and Respiratory Symptoms||Universidad Europea de Madrid|No|Recruiting|January 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|17 Years|No|||February 2016|February 22, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02693301||2086|
NCT02685306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1502|A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer|A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer||Peregrine Pharmaceuticals|No|Not yet recruiting|March 2016|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685306||2699|
NCT02692066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2042|Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine in Children With Liver Disease|||University of Colorado, Denver||Not yet recruiting|July 2016|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|6 Months|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with liver disease and healthy controls who have not received varicella        vaccination and who have no history of varicella or zoster|February 2016|February 24, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02692066||2181|
NCT02709083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00087045|Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia|First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia||Emory University|Yes|Not yet recruiting|May 2016|May 2023|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|17 Years|N/A|No|||March 2016|March 10, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709083||875|
NCT02686242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJH-A-2015-6-6-01|Spinal Aesthesia in Women With Placenta Previa Percreta|Influence of Spinal Anaesthesia on Hemodynamic Stability in Women With Placenta Previa Percreta Undergoing Caesarean Section|SAW|Fourth Military Medical University|Yes|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|186|||Female|18 Years|65 Years|No|Probability Sample|parturients with placenta praevia/accreta scheduled for cesarean section|February 2016|February 18, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02686242||2627|
NCT02691897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-93-7817|Melatonin's Effects on Treatment Of Diabetes Mellitus|The Effects of Melatonin on Serum Glucose Levels of Patients With Type 2 Diabetes Mellitus|METOD|Shiraz University of Medical Sciences|Yes|Recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||March 2016|March 1, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691897||2194|
NCT02693275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNB&I-4001|Reference Database Development for the Quotient® System iPad Test|Reference Database Development for the Quotient® System iPad Test (Ages 6 - 80 Years Old)||Pearson/Clinical Assessment|No|Not yet recruiting|March 2016|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1600|||Both|6 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02693275||2088|
NCT02706717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5350|Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers|Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study||AIDS Clinical Trials Group|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706717||1057|
NCT02706730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-201509|A 6-Month Extension Study of OTO-104 in Meniere's Disease|A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease||Otonomy, Inc.|No|Enrolling by invitation|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706730||1056|
NCT02681692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rj（2015）086k|Evaluation of Magnetic Scope Navigation in Teaching and Acquisition of Colonoscopy Skills|Evaluation of Magnetic Scope Navigation in Teaching and Acquisition of Colonoscopy Skills——a Single-blind Randomized Controlled Single-center Trial||Shanghai Jiao Tong University School of Medicine|No|Not yet recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|8|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681692||2977|
NCT02683837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pupilloped|Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia|A Prospective Randomized Study Evaluating Pupillometry Guided Remifentanil Administration in Pediatric Anesthesia||University Hospital, Geneva|No|Not yet recruiting|February 2016|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|56|||Both|2 Years|16 Years|No|||February 2016|February 11, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02683837||2812|
NCT02683850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091515-B|Influence of an Omega-3 SPM Supplement on Quality of Life|Influence of an Omega-3 SPM Supplement on Quality of Life||National College of Natural Medicine|No|Recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|20 Years|70 Years|No|||February 2016|February 16, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02683850||2811|
NCT02694952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICENTRE CAR 2016|Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES)|Randomized, Double-blind, Non-inferiority Trial of Two Antivenoms for the Treatment of Snakebite With Envenoming|PAVES|Epicentre|Yes|Not yet recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Both|N/A|N/A|No|||February 2016|February 24, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02694952||1959|
NCT02701140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not assigned|Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease||TAPER-S|Catholic University of the Sacred Heart|Yes|Not yet recruiting|June 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701140||1485|
NCT02688907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-02-073|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation||Samsung Medical Center|No|Not yet recruiting|April 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|20 Years|N/A|No|||February 2016|February 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688907||2422|
NCT02689284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAH22-05|Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer|A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer||MacroGenics|No|Recruiting|January 2016|March 2020|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|January 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02689284||2393|
NCT02684474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00090805|Expanded Access Protocol Using HBOC-201|Expanded Access Protocol Using HBOC-201 to Treat Patients With Life Threatening Anemia, for Whom Blood is Not an Option||Johns Hopkins University||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|80 Years||||February 2016|February 12, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684474||2763|
NCT02683668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151C2697|Airway Effects of Tiotropium in Patients With COPD|Targeting of the Small Airways in Patients With COPD: Airway Effects of Tiotropium - Respimat vs Handihaler||Imperial College London|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|44|||Both|30 Years|N/A|No|||October 2015|February 17, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683668||2825|
NCT02683928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBR 830-201|To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)|A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis||Glenmark Pharmaceuticals S.A.||Not yet recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683928||2805|
NCT02520856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-29|New Diagnostic Strategy in Hypertrophic Cardiomyopathy|New Diagnostic Strategy in Hypertrophic Cardiomyopathy Including a New Genetic Approach: A Multicentric Prospective Study|HYPERGEN|Assistance Publique Hopitaux De Marseille|No|Recruiting|July 2015|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|patients with unexplained Hypertrophic cardiomyopathy will be prospectively included.        HCM diagnosis will be based on conventional echocardiographic criteria and will be        considered definite in the presence of LV hypertrophy without cavity dilatation and        without other cardiac or systemic disease able to produce the magnitude of hypertrophy.|August 2015|August 7, 2015|August 5, 2015||No||No||https://clinicaltrials.gov/show/NCT02520856||15323|
NCT02586805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-2930-03|Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE|HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)||Dyax Corp.|No|Recruiting|November 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|108|||Both|12 Years|N/A|No|||March 2016|March 18, 2016|October 23, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02586805||10258|
NCT02590003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403013529|Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer|A Randomized Phase II Trial of Combination Versus Single Agent Chemotherapy in High-risk Elderly Patients With Advanced Non-small Cell Lung Cancer||Yale University|Yes|Recruiting|November 2015|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|71 Years|N/A|No|||February 2016|February 4, 2016|October 12, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02590003||10013|
NCT02686216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-2710A|Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects|Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects||Chang Gung Memorial Hospital|No|Enrolling by invitation|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||December 2015|February 15, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686216||2629|
NCT02693704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHALS - 001|Evaluation of a Binaural Spatialization Method for Hearing Aids|Evaluation of a Binaural Spatialization Method for Hearing Aids, in Terms of Speech Intelligibility, Speaker Localization and Subjective Preference.|BHA(L&S)|Sonova AG|No|Recruiting|February 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693704||2055|
NCT02686086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beaumont|A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD|Chronic Obstructive Pulmonary Disease (COPD) Lung Volume and Symptom Scores Following Bronchodilator Therapy Administration by Vibrating Mesh and Standard Jet Nebulisers: A Pilot Comparison Study||Beaumont Hospital|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02686086||2639|
NCT02704039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-07-0008|Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin|Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin||University of Texas at Austin|No|Recruiting|January 2016|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|480|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health adult volunteers being evaluated by dermatologist for lesion of interest (see        inclusion criteria).|March 2016|March 10, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02704039||1262|
NCT02706678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ309CT-02|Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients|Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study||Astellas Pharma Inc|No|Completed|December 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706678||1060|
NCT02683200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-000362|MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer|Stereotactic Body Radiotherapy for Liver Metastases and Hepatocellular Carcinoma Utilizing an MRI-Guided Tri-60Co Teletherapy System||Jonsson Comprehensive Cancer Center|Yes|Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 9, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02683200||2861|
NCT02686320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-2015|Prospective Study of Patients With Rheumatoid Arthritis After the Age of 65|Prospective Study of Evolution of Rheumatoid Arthritis After 65 Years Old|PRESAGE|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2016|December 2022|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid arthritis patients from department A and B of rheumatology in Cochin hospital|February 2016|February 15, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02686320||2621|
NCT02692378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15HH2613|Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)|A Feasibility Randomised Controlled Trial: Effects of Oral Sodium Bicarbonate Supplementation in Patients on Haemodialysis|BicHD|Imperial College Healthcare NHS Trust|Yes|Active, not recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Both|18 Years|80 Years|No|||November 2015|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692378||2157|
NCT02692391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12100086|A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis|A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis||University of Pittsburgh|No|Recruiting|July 2014|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02692391||2156|
NCT02707198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C. diff|Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir|Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir||St. Luke's Hospital of Duluth|No|Enrolling by invitation|November 2015|February 2021|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1190|||Both|19 Years|N/A|No|||March 2016|March 8, 2016|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707198||1020|
NCT02696655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7526|Lifestyle Intervention For Liver Transplantation|Development and Feasibility Testing of a Behavioural Intervention Targeting Multiple Lifestyle Behaviours to Improve Long Term Outcomes Following Liver Transplantation|LIFT|Newcastle-upon-Tyne Hospitals NHS Trust|No|Not yet recruiting|February 2016|February 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|March 1, 2016|October 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02696655||1830|
NCT02695342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Labarge-20004484|Home Balance Pilot for Fall Reduction in COPD|Pilot Study of a Tailored Home Balance Exercise Program for Reducing Falls in Older Adults With COPD||McMaster University|No|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|60 Years|N/A|No|||March 2016|March 21, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695342||1930|
NCT02695368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOS|A Study to Evaluate the Effect of Air-filtration Through a Plasma Chamber on the Incidence of Surgical Site Infections in Orthopaedic Surgery|The Effect of Air-filtration Through a Plasma Chamber on the Incidence of Surgical Site Infections in Orthopaedic Surgery: a Double-blind, Randomized, Controlled Trial|EPOS|Karolinska Institutet|No|Not yet recruiting|February 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|19000|||Both|N/A|N/A|No|||February 2016|February 24, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02695368||1928|
NCT02693964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1854|Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes|Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes||University of Colorado, Denver|No|Not yet recruiting|March 2016|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|blood and urine samples|Female|45 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausal women with or without type 1 diabetes|February 2016|February 23, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02693964||2035|
NCT02684513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501150|Impact of Oral Carbohydrate Consumption Prior to Cesarean Section|Impact of Oral Carbohydrate Consumption Prior to Cesarean Section on Preoperative Well-being||University of Florida|No|Not yet recruiting|March 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|3||Anticipated|138|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02684513||2760|
NCT02684526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038856|Is Eovist Suitable for Arterial-Phase MR Imaging of Liver|Is Eovist Suitable for Arterial-Phase MR Imaging of Liver||University of Michigan|No|Active, not recruiting|December 2011|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|21 Years|N/A|No|||February 2016|February 12, 2016|March 14, 2013||No||No||https://clinicaltrials.gov/show/NCT02684526||2759|
NCT02697188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-07004|Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men|Phase IIa, Pilot, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|65 Years|No|||February 2016|March 2, 2016|January 29, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697188||1789|
NCT02679040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIST-RIC-IPC 2014-014|Rate of Histological Response After Mastectomy and Mammary Reconstruction at the Close of Neo-adjuvant Chemotherapy and Radiotherapy|Rate of Histological Response After Mastectomy and Mammary Reconstruction at the Close of Neo-adjuvant Chemotherapy and Radiotherapy|HIST-RIC|Institut Paoli-Calmettes|Yes|Not yet recruiting|February 2016|February 2024|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|162|||Female|18 Years|N/A|No|||January 2016|February 5, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02679040||3180|
NCT02684136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM16|Suvorexant in Insomnia Co-morbid With Fibromyalgia|A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia||Henry Ford Health System|No|Recruiting|February 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|21 Years|65 Years|No|||February 2016|February 26, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684136||2789|
NCT02684149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-A01607-40|Pain Impact Assessment of the Relational Touch During Arterial Puncture in ICU (TORREA)||ToRRéa|University Hospital, Angers||Completed|February 2015|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|January 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02684149||2788|
NCT02684162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0117|SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)|A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With Donor Lymphocyte Infusion (DLI) for the Treatment of Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02684162||2787|
NCT02693977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009825|Use of Sleep Endoscopy to Predict Outcomes of Pediatric Adenotonsillectomy|Use of Sleep Endoscopy to Predict Outcomes of Pediatric Adenotonsillectomy||Oregon Health and Science University|No|Enrolling by invitation|February 2015|December 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|2 Years|18 Years|No|Probability Sample|Two recruitment scenarios are anticipated: 1) OHSU Patients who have previously been        diagnosed with OSAS by polysomnography and are referred to Pediatric Otolaryngology for        consideration of AT; 2) OHSU Patients referred to Pediatric Otolaryngology for        consideration of AT for symptoms of sleep disordered breathing without a polysomnographic        diagnosis of OSAS.|February 2016|February 23, 2016|January 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02693977||2034|
NCT02693990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-542|A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas|A Phase I/II Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas||Massachusetts General Hospital|Yes|Not yet recruiting|February 2016|February 2023|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|January 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693990||2033|
NCT02707276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001851|LFMS: Initial Trial in Geriatric Bipolar Depression|Low Field Magnetic Stimulation: Initial Trial in Geriatric Bipolar Depression|LFMS|Mclean Hospital|No|Not yet recruiting|March 2016|August 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|85 Years|No|||March 2016|March 8, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707276||1014|
NCT02707289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVGIBD0547|Retrospective Collection of PillCam SB Movies|Retrospective Collection of PillCam SB Movies for Capsule Transit Time Analysis (OCEAN Study)|OCEAN|Medtronic - MITG|No|Not yet recruiting|March 2016|May 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Up to two hundred un-identified PillCam SB movies that were created between the year 2008        and the date the study was approved by the IRB, will be collected|February 2016|March 8, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02707289||1013|
NCT02707380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01994|The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation|The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation||New York University School of Medicine|No|Recruiting|March 2015|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|85 Years|No|||March 2016|March 11, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02707380||1006|
NCT02687867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18732|Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist|Real-world Comparative Effectiveness of Dabigatran Versus VKA|DABI-F|Bayer|No|Completed|February 2016|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|56039|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation (NVAF).|March 2016|March 24, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687867||2502|
NCT02691910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404067/2012-3|Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection|Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection||Oswaldo Cruz Foundation|No|Completed|August 2014|September 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|5 Years|N/A|No|||February 2016|February 24, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691910||2193|
NCT02688023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-052|Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer|A Pilot Phase II Study of Triplet Chemotherapy Regimen in Neoadjuvant Chemotherapy of Patients With Resectable Colorectal Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|March 2014|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02688023||2490|
NCT02690038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150925 / 20160077-01H|Ig PRx in AECOPD: Pilot Study|Feasibility and Safety of Immunoglobulin (Ig) Prophylactic Treatment in COPD Patients With Frequent Exacerbations: A Pilot Study||Ottawa Hospital Research Institute|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|48|||Both|40 Years|N/A|No|||February 2016|February 18, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02690038||2335|
NCT02705183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL54480.058.15|Post-operative RadioTherapy for Patients With Metastases of the Long Bones|Post-operative RadioTherapy for Patients With Metastases of the Long Bones: a Randomised Controlled Trial|PORT|Leiden University Medical Center|No|Recruiting|January 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705183||1174|
NCT02705196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOKON001|LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer|Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer||Lokon Pharma AB|Yes|Not yet recruiting|April 2016|January 2019|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705196||1173|
NCT02679508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vonoprazan-4003|Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety|Vonoprazan Study In Patients With Erosive Esophagitis to Evaluate Long-term Safety: A Study to Evaluate the Safety of Long-term Administration of Vonoprazan in Maintenance Treatment in Patients With Erosive Esophagitis (EE)||Takeda|No|Not yet recruiting|February 2016|February 2022|Anticipated|February 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|195|||Both|20 Years|N/A|No|||February 2016|February 11, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02679508||3144|
NCT02684695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAQI|Juvenile Arthritis Quantitative Imaging|The Development and Validation of Quantitative Imaging Biomarkers as a Measure of Disease Activity in Juvenile Idiopathic Arthritis|JAQI|University College London Hospitals|No|Recruiting|January 2016|January 2026|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|12 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with JIA will have a definitive clinical diagnosis of JIA according to        established clinical criteria.9 Patients will be divided according to subtype - patients        with ERA will be recruited into groups A (DWI and FF) and / or Group B (WB MRI) along with        the polyarthritis and extended oligoarthritis groups. Once the WB MRI protocol is defined,        for ERA patients recruited to both arms of the study the intention is to combine the DWI        and WB MRI scan together to limit participation to 6 months scans only for this group.        Additionally, patients who are being investigated for possible JIA/ERA will be asked to        participate in this study. Those patients who are subsequently diagnosed with JIA/ERA will        be included in the study as described above. Those patients who are diagnosed with        mechanical back pain will be treated as controls, and will not be imaged again after this        point.|February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02684695||2746|
NCT02690272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00971-48|"Lived Experience, Representations and Psychic Processes in Patients Awaiting Kidney Transplantation"|" Expérience Vécue, Représentations et Processus Psychiques Chez Les Sujets en Attente de Transplantation Rénale "|LER-Psy-PAKT|University Hospital, Angers|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02690272||2317|
NCT02680171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICSpatialNeglect2016|Feasibility and Effectiveness Study of Implementing Prism Adaptation as a Treatment for Spatial Neglect After Stroke|Feasibility and Effectiveness Study of Implementing Prism Adaptation as a Treatment for Spatial Neglect After Right Hemisphere Stroke||Nova Scotia Health Authority|No|Not yet recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|N/A|No|||February 2016|February 8, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02680171||3094|
NCT02703337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16069|A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy||Eli Lilly and Company|No|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|28|||Both|18 Years|70 Years|No|||March 2016|March 4, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703337||1316|
NCT02681705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sanghaixinhua-003|Radiation Therapy and Combination Chemotherapy for Medulloblastoma|Phase 2 Study of Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Medulloblastoma||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2010|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|12 Years|No|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681705||2976|
NCT02679144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC014|Neuroblastoma Maintenance Therapy Trial|NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)|NMTT|Spectrum Health Hospitals|Yes|Recruiting|February 2016|February 2025|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|258|||Both|1 Year|30 Years|No|||February 2016|February 16, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02679144||3172|
NCT02683057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411-BIO-080-RM|Influence of Physical Exercise on Semen Quality|Influence of Physical Exercise on Semen Quality||IVI Bilbao|Yes|Recruiting|May 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|432|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Candidates for sperm donors in the donation program which aims clinic It is performed in        432 cases. For that, our study addresses a population previously selected either by        physical activity or by semen quality|February 2016|February 10, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02683057||2872|
NCT02701790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151113|Improving Motor Function After Spinal Cord Injury|Enhancement of Motor Function After Spinal Cord Injury||University of Miami|No|Not yet recruiting|March 2016|February 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701790||1435|
NCT02699359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-022|Indirect Intracranial Pressure Measurement in Patients With Suspected or Documented Concussion|Indirect Intracranial Pressure Measurement in Patients With Suspected or Documented Concussion||HeadSense Medical|No|Recruiting|May 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699359||1622|
NCT02699372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP30134|The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers|A Single-center, Randomized, Investigator/Subject-Blind, Adaptive Single-ascending Dose (Part 1) and Multiple Ascending Dose (Part 2), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6889450 Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|164|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02699372||1621|
NCT02690467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO 02|Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.|Efficacy, Safety and Acceptability of the New Pen Needle 33G x 4 mm: a Cross-over Randomised Non Inferiority Trial|AGO 02|Center for Outcomes Research and Clinical Epidemiology, Italy|No|Not yet recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02690467||2303|
NCT02681939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T/IM-NF/Physio/15/04|Effect of Tulsi (Ocimum Sanctum) on Biochemical Parameters in Overweight Students of Health Sciences|Effect of Supplementation of Tulsi (Ocimum Sanctum Linn.) on Metabolic Parameters and Liver Enzymes in Overweight Students of Health Sciences||All India Institute of Medical Sciences, Bhubaneswar|No|Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|17 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02681939||2958|
NCT02681952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_RNMZ_401|A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure|||Daewon Pharmaceutical Co., Ltd.||Recruiting|December 2015|||September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|152|||Both|20 Years|74 Years|No|||February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681952||2957|
NCT02689583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstZhejiangU YMLi|A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection|A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection||First Affiliated Hospital of Zhejiang University||Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02689583||2370|
NCT02705040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-JIRB 201310015|Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study|Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study||Taipei Medical University WanFang Hospital|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Plasma, urine|Male|70 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The oriental men|January 2016|March 6, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02705040||1185|
NCT02679729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6600C00001|To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration|A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects||AstraZeneca|Yes|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|8||Anticipated|78|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02679729||3128|
NCT02686775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R73-A4769-13-S17|The PACO Project: A Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients|The PACO Project: A Randomized Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients|PACO|Danish Cancer Society|No|Recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|306|||Both|N/A|N/A|No|||February 2016|February 15, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02686775||2586|
NCT02691858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIUNIPEDSURG-CR3|Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception|Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception: A Randomized Controlled Trial||Cairo University|Yes|Recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Months|4 Years|No|||February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02691858||2197|
NCT02691871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-L301|Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR|A Phase I, Open-label, Dose-escalation Study of Apatinib in Combination With Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)||Cancer Institute and Hospital, Chinese Academy of Medical Sciences||Not yet recruiting|February 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02691871||2196|
NCT02695173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690R00008|Complications of UTI in Patients on Dapagliflozin|Comparison of the Risk of Severe Complications of Urinary Tract Infections Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments||AstraZeneca|No|Not yet recruiting|February 2016|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|91927|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who        are new users of antidiabetic drugs in classes other than SGLT2 inhibitors, insulin        monotherapy, metformin monotherapy, or sulfonylurea monotherapy. Up to four comparator        subjects will be matched to each dapagliozin user.|February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695173||1943|
NCT02690623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0978|Benefits and Cost-Effectiveness of a Pediatric Hospitalist Service : a Stepped Wedge Quality Improvement Trial|Benefits and Cost-Effectiveness of a Pediatric Hospitalist Service : a Stepped Wedge Quality Improvement Trial||The University of Texas Health Science Center, Houston|No|Not yet recruiting|February 2016|January 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10000|||Both|N/A|18 Years|No|||February 2016|February 23, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02690623||2291|
NCT02682498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIANES08|Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj|A Double Blind, Randomized Clinical Trial Comparing Postoperative Narcotic Usage in Patients Receiving Periarticular Liposomal Bupivicaine vs. Those Patients Receiving Standard Periarticular Joint Injections||University of California, Irvine|No|Completed|October 2013|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02682498||2915|
NCT02684500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500830|Aneurysmal Subarachnoid Hemorrhage and Superior Mesenteric Artery Flow Study|Evaluation of Superior Mesenteric Artery Diameter and Flow in Aneurysmal Subarachnoid Hemorrhage Patients Undergoing Hypertensive Therapy for Cerebral Artery Vasospasm||University of Florida|No|Not yet recruiting|April 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|125|||Both|18 Years|99 Years|No|||February 2016|February 12, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02684500||2761|
NCT02707796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|386986|Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index|Evaluation of the Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index, and Sensitivity and Specificity of Oxygen Reserve Index in Patients Undergoing Hemicolectomy||Istanbul University|No|Not yet recruiting|May 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|240|||Both|20 Years|55 Years|No|||March 2016|March 11, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02707796||974|
NCT02689245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-007|Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.|Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.||Institute of Liver and Biliary Sciences, India|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||February 2016|March 10, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02689245||2396|
NCT02689258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTX-011-C2015-203|Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery|A Phase 2, Randomized, Placebo-Controlled, Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery||Heron Therapeutics||Recruiting|February 2016|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689258||2395|
NCT02689323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00069059|TMS Modulation of Insula-related Brain Networks|TMS Modulation of Insula-related Brain Networks|TMS_INS|Duke University|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689323||2390|
NCT02689999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-01.15|The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity|The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity||Neutec Ar-Ge San ve Tic A.Ş|No|Active, not recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02689999||2338|
NCT02690012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150853-01H|Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies|Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies|OTT 15-03|Ottawa Hospital Research Institute|No|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|19 Years|N/A|No|||February 2016|February 18, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02690012||2337|
NCT02690025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP1848-15073|A Phase 2 Trial Testing ZP1848 in Patients With SBS|A Phase 2 Trial Testing ZP1848 in Patients With SBS||Zealand Pharma|No|Recruiting|February 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|90 Years|No|||February 2016|February 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02690025||2336|
NCT02706106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMAA01|Assessment of a Knee Brace in Patients With Osteoarthritis|Assessment of a Knee Brace in Patients With Osteoarthritis||Irmandade da Santa Casa de Misericordia de Sao Paulo|No|Active, not recruiting|November 2015|March 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|40 Years|60 Years|No|||March 2016|March 7, 2016|November 28, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02706106||1103|
NCT02681159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272/14a/tk|Critical Incidents Related to Anesthesia and Intensive Care: A Study in a Tertiary Hospital|Critical Incidents Related to Anesthesia and Intensive Care: A Prospective Study in a Tertiary Hospital||University of Jordan|No|Active, not recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Probability Sample|patients who undergo anesthesia and surgery and be exposed to a critical incidence.|February 2016|February 11, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02681159|14 Days|3018|
NCT02686333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-160|Meditation for Depression and Anxiety Symptoms in Dialysis Patients|Meditation Intervention for the Treatment of Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Randomized Control Trial||Lady Davis Institute|Yes|Recruiting|March 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02686333||2620|
NCT02685319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512016862|Mapping Human Muscle Satellite Cell Fate By Real-Time Imaging|Mapping Human Muscle Satellite Cell Fate By Real-Time|S48|Purdue University|No|Recruiting|February 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Male|20 Years|29 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02685319||2698|
NCT02685332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062015-085|Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA|Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation (SB-PBI) For Early Stage Breast Cancer||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|February 2016|December 2021|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||February 2016|February 12, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685332||2697|
NCT02705586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15421|Video Based Mindfulness Based Stress Reduction|Video Based Mindfulness Based Stress Reduction|vMBSR|Oregon Health and Science University|No|Recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705586||1143|
NCT02688855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-607|CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures|Prospective, Randomized, Double-Blinded, Controlled Multi-Center Clinical Trial Evaluating the Use of Non-Invasive CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures||Encore Medical, L.P.|No|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|217|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02688855||2426|
NCT02688868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Firehawk_SS|Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )|The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Recruiting|January 2015|December 2020|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|80 Years|No|||January 2015|February 18, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02688868||2425|
NCT02679794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507016290|Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women|Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women||Purdue University||Recruiting|December 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|20|||Female|19 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02679794||3123|
NCT02692118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnaTubingen|Inflammatory Mediators in Early Sepsis|Inflammatory Mediators in Sepsis as Indicator for Infection vs Inflammation|Insep|University Hospital Tuebingen|Yes|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood samples|Both|18 Years|85 Years|No|Non-Probability Sample|Intensive Care patients with septic shock|February 2016|February 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02692118||2177|
NCT02693262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151774|Comparing Rate Response With CLS Versus Accelerometer ICD Settings in Heart Failure Patients With BIOTRONIK CRT-Ds|Rate Response With CLS Versus Accelerometer and Effect on Both Subjective Symptoms and Objective Outcomes in a Heart Failure Population Implanted With Cardiac Resynchronization With Defibrillator Device: The CLASS Trial|CLASS|University of California, San Diego|No|Not yet recruiting|February 2016|March 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02693262||2089|
NCT02699346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-010|An Evaluation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion|An Open-Label, Non-Randomized Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion With Clinical Evaluation||HeadSense Medical|No|Recruiting|January 2015|March 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|13 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699346||1623|
NCT02689856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-6151-201|Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids|A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids|Hydro/Lido|Citius Pharmaceuticals, Inc.|No|Completed|May 2015|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|211|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02689856||2349|
NCT02682797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19.08.2015|OCT-Evaluation of Retinoschisis and Retinal Detachment|Use of Spectral Domain OCT to Differentiate and Follow-up Senile Retinoschisis and Retinal Detachment||Medical University of Vienna|No|Recruiting|September 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|30 consecutive patients will be recruited for this study; 15 with Retinoschisis and 15        with retinal detachment|February 2016|February 12, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02682797||2892|
NCT02686840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUMH|Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage|Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage: A Randomized Controlled Trial.||Ain Shams University|Yes|Recruiting|January 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|40 Years|No|||February 2016|February 16, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02686840||2581|
NCT02694484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I15033 TRANSFECMV|Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant|Search Cytomegalovirus (CMV) in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant|TRANSFECMV|University Hospital, Limoges|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|March 3, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02694484||1995|
NCT02695654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KME 100/02/15|Effectiveness of Ultrasound Guided Adductor Canal Block on Chronic Pain in Knee Osteoarthritis|Effectiveness of Ultrasound Guided Adductor Canal Blockade With Levobupivacaine and Clonidine on Chronic Pain in Knee Osteoarthritis||University Medical Centre Ljubljana|Yes|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|45 Years|N/A|No|||February 2016|February 24, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02695654||1907|
NCT02686255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0655-15-RMC|Hemoglobin Trend in Neonates and Toddlers Post Cardiac Surgery|Hemoglobin Trend in Neonates and Toddlers Post Cardiac Surgery||Rabin Medical Center|No|Not yet recruiting|February 2016|February 2020|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|18 Months|No|Non-Probability Sample|All children 0-18 months going through cardiac surgery during the 3 years of the study|January 2016|February 14, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02686255||2626|
NCT02689973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N106 036 32/2487|Effects of Self-efficacy, Planning, and Self-efficacy+Planning Interventions on Body Fat Among Adolescents|Synergistic Effects of Implementation Intention and Self-efficacy on Behavior Change and Body Fat: a Randomized Controlled Trial of Interventions Promoting Physical Activity||University of Social Sciences and Humanities, Warsaw|No|Completed|May 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1217|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02689973||2340|
NCT02682355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI119446-01|Optimizing Clinical Use of Polymyxin B|Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat Superbugs||Kaye, Keith, M.D., M.P.H.|No|Recruiting|February 2016|May 2020|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|-  Blood and Respiratory cultures from infection site.        -  Urine Samples for Proteomic testing.        -  Blood Specimen for Pharmacokinetic/Pharmacodynamic testing.|Both|18 Years|N/A|No|Non-Probability Sample|The human subjects involved in this study will be receiving intravenous polymyxin B as        part of their routine clinical care because of infection due to bacteria resistant to all        other first-line antibiotics.|March 2016|March 14, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02682355||2926|
NCT02682368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19190484|Point of Care UltraSound by Surgeons|Multicentric Non-Inferiority Surgeon-Performed Point-Of-Care Ultrasound Versus Radiologist-Reported Study in Acute Gallbladder and Acute Diverticular Disease|POCUSS|Connolly Hospital Blanchardstown|Yes|Recruiting|October 2015|October 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02682368||2925|
NCT02694094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00070557|Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy|Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy||Johns Hopkins University|No|Recruiting|January 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Blood samples|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|Study participants will be drawn from among participants in the Johns Hopkins Adult        Epilepsy Diet Center and Johns Hopkins Epilepsy Center who are age 18 or older, with body        mass index (BMI) > 18.5, and on a stable antiepileptic drug regimen for > 1 month.|February 2016|February 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02694094||2025|
NCT02692807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAR-1- 2016|Arthroscopic Surgical Procedures vs Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears.|Arthroscopic Surgical Procedures Versus Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears. A Multicentre, International, Double-blinded Randomized, Controlled Trial.|HIPARTI|Oslo University Hospital|No|Recruiting|February 2016|December 2035|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|50 Years|No|||February 2016|March 7, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02692807||2124|
NCT02690233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POETRY minor|Perioperative Endothelial Dysfunction in Patients Undergoing Minor Abdominal Surgery|Perioperative Endothelial Dysfunction in Patients Undergoing Minor Abdominal Surgery. The POETRY Minor Study.|POETRYminor|University Hospital Koge|No|Recruiting|February 2016|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|The blood will be collected from a larger vein (e.g. the cubital vein).      Tetrahydrobiopterin: Blood is sampled into 4mL EDTA tubes. Immediately after withdrawal, a      minimum of 1mL blood is mixed with 25μL DTE. The mixture is centrifuged at 2000g for 5      minutes. Plasma is frozen and stored at -80°C.      Arginine and ADMA: Blood is sampled into 4mL EDTA tubes. Blood samples will be centrifuged      at 3000g for 10 minutes, plasma frozen and stored at -80°C until analyzed with high      performance liquid chromatography.|Both|18 Years|N/A|No|Probability Sample|The investigators expect that minor surgery will reduce the reactive hyperemia index        assessed 4 hours postoperatively with 15% equal to 1.59. With a power of 0.80 and α on        0.05, the investigators will need to include 54 patients in this study. In order to        improve the power of the study, the investigators will include a total of 60 patients.|February 2016|February 24, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02690233||2320|
NCT02688036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-045/2|Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC|Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer||Chinese Academy of Medical Sciences|No|Not yet recruiting|February 2016|May 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|860|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02688036||2489|
NCT02688049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS-XDA-MNSCI/IGDB|NeuroRegen Scaffold™ Combined With Stem Cells for Chronic Spinal Cord Injury Repair|The Efficacy and Safety of NeuroRegen Scaffold™ Combined With Mesenchymal Stem Cells or Neural Stem Cells for Chronic Spinal Cord Injury Repair||Chinese Academy of Sciences|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02688049||2488|
NCT02523183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1606|The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy|The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy||University of Colorado, Denver|No|Recruiting|July 2015|July 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Whole blood samples will be collected|Both|1 Month|20 Years|No|Non-Probability Sample|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with        medically refractory epilepsy, and whom the family has decided to treat with medicinal        cannabis. Children who have not been treated with medically accepted standard treatment        for their epilepsy condition will not be accepted into this study as the researchers do        not want to be misperceived as condoning the use of medical marijuana in lieu of standard        treatment.|February 2016|February 22, 2016|July 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02523183||15144|
NCT02579161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-003|Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy|Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy||Northwell Health|Yes|Recruiting|September 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|290|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|June 19, 2014||No||No||https://clinicaltrials.gov/show/NCT02579161||10845|
NCT02689648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUFT2016|Long Term Follow up on Functional Gastrointestinal Disorder (FGID)|Long Term Follow up on Functional Gastrointestinal Disorder (FGID)|LUFT|Umeå University|No|Recruiting|February 2016|January 2021|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|3 Years|18 Years|No|Probability Sample|All children between 3 and 18 years of age that were refereed to the Pediatric Clinic of        Västerbotten county council during the years 2009-2015.|February 2016|February 23, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02689648||2365|
NCT02681198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1010|Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers|Lofexidine Pharmacokinetics in the Presence of Paroxetine, a Strong CYP2D6 Inhibitor, in Healthy Volunteers||US WorldMeds LLC|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02681198||3015|
NCT02692313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00068487|Dose Response of Epinephrine|Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine|Epineprhine|University of Maryland|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02692313||2162|
NCT02692326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-12|Impact of Cyclic Prolonged Parenteral Nutrition in Neonates|DECREASE OF CHOLESTASIS USING CYCLED PARENTERAL NUTRITION IN NEWBORNS REQUIRING PROLONGED PARENTERAL NUTRITION||Hospital General Universitario Gregorio Marañon|No|Completed|August 2010|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|50 Days|No|||February 2016|February 22, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02692326||2161|
NCT02706691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-1447|Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck|Phase IIa Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck||University of Chicago|Yes|Not yet recruiting|April 2016|||April 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706691||1059|
NCT02706704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH.RH.07|Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis|Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis|IVAS|American University of Beirut Medical Center|Yes|Recruiting|February 2016|June 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706704||1058|
NCT02683213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECTS2012|Efficacy of Fluoxetine - a Trial in Stroke|Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke|EFFECTS|Karolinska Institutet|Yes|Recruiting|October 2014|March 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02683213||2860|
NCT02683226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTT|Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance and Beta Cell Function of Metformin Treated Women With Polycystic Ovary Syndrome|||University Medical Centre Ljubljana||Completed|March 2015|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|55 Years|No|||February 2015|February 16, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02683226||2859|
NCT02695537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND# 124160|Safety, and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy|Safety and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy||University of Alabama at Birmingham|Yes|Recruiting|April 2015|February 2020|Anticipated|February 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|18 Years|No|||February 2016|February 29, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695537||1915|
NCT02693743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203818|Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients|Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients|rTMS|University of Arkansas|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||February 2016|February 23, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02693743||2052|
NCT02693834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18863|Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.|Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.||Texas Woman's University|No|Recruiting|January 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02693834||2045|
NCT02696889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|723327-8|Rejuvenation of Premature Ovarian Failure With Stem Cells|Autologous Stem Cell Therapy for Premature Ovarian Failure|ROSE|MD Stem Cells|Yes|Recruiting|February 2016|February 2020|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|18 Years|N/A|No|||February 2016|March 4, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02696889||1812|
NCT02696902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5470C00004|Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects|A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa|EVADE|MedImmune LLC|Yes|Recruiting|March 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|429|||Both|18 Years|99 Years|No|||March 2016|March 7, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696902||1811|
NCT02680041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BED003|18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment|The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment|LOCATE|Blue Earth Diagnostics|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|330|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680041||3104|
NCT02692664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAILOR|Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft|Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft||JOTEC GmbH|No|Not yet recruiting|April 2016|May 2021|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|19 Years|N/A|No|Non-Probability Sample|Male and female patients with unilateral or bilateral common iliac aneurysm, treated with        the E-liac Stent Graft System|February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02692664||2135|
NCT02692677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108125|A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants|An Open-Label Phase 1 Study to Determine the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ-42756493 to Healthy Male Subjects||Janssen Research & Development, LLC|No|Not yet recruiting|March 2016|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692677||2134|
NCT02695147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoyalSussexTAVISCvsDA|Direct Aortic vs Subclavian Access for TAVI: a Review of the Outcomes in the UK|Direct Aortic vs Subclavian Access for TAVI: a Review of the Outcomes in the UK||Royal Sussex County Hospital|No|Active, not recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|All patients who received TAVI via the subclavian or direct aortic approach in the UK|February 2016|February 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695147||1945|
NCT02693548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFEHEART|The Spanish Familial Hypercholesterolaemia Cohort Study|The Spanish Familial Hypercholesterolaemia Cohort Study|SAFEHEART|Fundación Hipercolesterolemia Familiar|Yes|Recruiting|January 2004|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4141|Samples With DNA|Venous blood samples were taken after 12 hours of fasting. Serum, plasma and DNA samples      were aliquoted and preserved at -80°C. Serum total cholesterol, triglycerides and      HDL-cholesterol levels were measured in a centralized laboratory using enzymatic methods|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a        genetic diagnosis of FH and their unaffected relatives|February 2016|February 23, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02693548||2067|
NCT02693561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnhembiMU|Effects of Deep Breathing,Self-Help Book in Cigarette Consumption,Anxiety,Depression and Motivation to Stop Smoking|Effectiveness of Deep Breathing, a Self-Help Book and Additive Effects of The Two Interventions in Cigarette Consumption, Anxiety and Depression and Motivation to Stop Smoking in Students of the Anhembi Morumbi University||Anhembi Morumbi University|Yes|Recruiting|January 2015|August 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|85|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02693561||2066|
NCT02683239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-1523|Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip|A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip||Regeneron Pharmaceuticals|Yes|Not yet recruiting|March 2016|April 2019|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10000|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683239||2858|
NCT02679664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160047-01H|StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study|StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE.|SAVER|Ottawa Hospital Research Institute|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|312|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02679664||3133|
NCT02697448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00044072|Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.|Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.||Medical University of South Carolina|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02697448||1769|
NCT02695407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Wu-001|Radial Artery Stenosis Following PiCCO Catheter Implementation|Occurrence of Radial Artery Stenosis Following PICCO Catheter Cannulation||Medical University of Gdansk|No|Recruiting|September 2014|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695407||1925|
NCT02681237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e-Volve 1|A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer|A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer||University Health Network, Toronto|Yes|Not yet recruiting|March 2016|January 2019|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02681237||3012|
NCT02681250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TiZir|A Clinical Trial of Dental Implants in Titanium-zirconium Alloy|A Randomized Controlled Clinical Trial of Dental Implants in Titanium-zirconium Alloy||Vastra Gotaland Region|No|Not yet recruiting|February 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|February 9, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02681250||3011|
NCT02694016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC00AVR|Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery|Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery With a Biological Prosthesis: A Single Center Randomized Prospective Study||Oulu University Hospital|No|Recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|40|||Both|60 Years|80 Years|No|||February 2016|February 26, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694016||2031|
NCT02694055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-CCM-028|Trial of Proactive Community Case Management to Reduce Child Mortality|Proactive Community Case Management and Child Survival: A Cluster-Randomized Controlled Trial|Pro-CCM|University of California, San Francisco|Yes|Enrolling by invitation|January 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|22847|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02694055||2028|
NCT02707523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005960|Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced (Respiratory Syncytial Virus - Induced) Respiratory Failure In Children|Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced Respiratory Failure In Children||University of Alabama at Birmingham|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|N/A|16 Years|No|||February 2016|March 11, 2016|February 20, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707523||995|
NCT02683759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIGINDIACurcumin2|Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis|The Efficacy and Tolerability of Bio-Enhanced Curcumin in Maintaining Remission in Patients With Ulcerative Colitis||Asian Institute of Gastroenterology, India|Yes|Recruiting|February 2016|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 20, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02683759||2818|
NCT02683772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-15-12-15|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||February 10, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02683772||2817|
NCT02689960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vapreda|Vaginal Prednisone Administration for Prevention of Adrenal Crisis|Vaginal Prednisone Administration for Prevention of Adrenal Crisis - a Bioequivalence Study|Vapreda|Wuerzburg University Hospital|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12|||Female|18 Years|N/A|No|||February 2016|February 24, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02689960||2341|
NCT02680184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-001-001|Clinical Study of CMP-001 in Combination With Pembrolizumab|A Multicenter, Open-Label, Phase 1B Clinical Study of CMP-001 in Combination With Pembrolizumab in Subjects Who Have Been Treated With Pembrolizumab for Advanced Melanoma||Checkmate Pharmaceuticals|No|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02680184||3093|
NCT02685345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS8500-A-J204|A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin|A Phase 2, Randomized, Double-blind, Placebo-controlled, add-on Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus Receiving Sitagliptin||Daiichi Sankyo Inc.|No|Recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|N/A|No|||February 2016|February 12, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02685345||2696|
NCT02706275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512121|Pilot Trial of External Warming in Septic Patients|Pilot Randomized Trial of External Warming in Critically Ill Adult Septic Patients||Washington University School of Medicine|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02706275||1090|
NCT02706288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512088|Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health|The Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health in Metabolically Abnormal Obese Adults|PE|Washington University School of Medicine|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02706288||1089|
NCT02686268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14LGCA123|Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS|Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS||Washington University School of Medicine|Yes|Recruiting|February 2015|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Whole blood (DNA, Southern Blots), Serum, PBMCs (for reprogramming into iPSCs), and Cerebral      Spinal Fluid (CSF)|Both|18 Years|N/A|No|Non-Probability Sample|Known positive C9ORF72 ALS status upon enrollment|March 2016|March 8, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02686268||2625|
NCT02686281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-252-1.02|Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes|A Double-Blind, Placebo-Controlled, Randomised, Two Part Study of the Safety and Pharmacokinetics of GMC-252 in A) Healthy Male Subjects, Including a Comparison of GMC-252 Dosing in the Fed and Fasted States ,and B) in Subjects With Type 2 Diabetes Mellitus||Genmedica Therapeutics S.L.|No|Terminated|September 2012|April 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|February 10, 2016||No|Business reason|No||https://clinicaltrials.gov/show/NCT02686281||2624|
NCT02686294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-BPSR-102|Repeated Dosing Clinical Trial of HL151|Repeated Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects||Hanlim Pharm. Co., Ltd.|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02686294||2623|
NCT02687958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOIRC 02/2014|Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin|Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin||Gruppo Oncologico Italiano di Ricerca Clinica|Yes|Recruiting|May 2015|May 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|March 9, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02687958||2495|
NCT02687971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-MILT-07-CL|Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨|A Randomized, Single Blind, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨||Drugs for Neglected Diseases|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|60 Years|No|||February 2016|February 17, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02687971||2494|
NCT02704923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 40374815.3.0000.5342|Atropine for Preventing Ventilator-Associated Pneumonia|Atropine for Preventing Ventilator-Associated Pneumonia||Universidade de Passo Fundo|No|Completed|February 2015|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02704923||1194|
NCT02704975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-007|Effectiveness of Dry Needling and Physical Therapy Versus Physical Therapy Alone Following Shoulder Stabilization Repair|Effectiveness of Trigger Point Dry Needling and Physical Therapy Versus Physical Therapy Alone Following Shoulder Stabilization Repair: A Randomized Controlled Trial||Keller Army Community Hospital|No|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||March 2016|March 4, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704975||1190|
NCT02679482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONCI6001|Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma|Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma|FPSPLTTCOAG|Fundación Oftalmológica Nacional|Yes|Recruiting|September 2014|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|||Both|40 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Open-Angle Glaucoma with a non-optimal intraocular pressure        control with topical/oral medications, who underwent to laser trabeculoplasty treatment,        attending the Fundacion Oftalmológica Nacional between June 2014 and july 2016 on        Bogotá-Colombia.|February 2016|February 13, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02679482||3146|
NCT02686554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIH_CRG2a_TP5|Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia|Elucidating the Proteostatis Network to Control Alzheimer's Disease - Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia||Charite University, Berlin, Germany|No|Recruiting|January 2016|December 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|Samples With DNA|Blood, cerebrospinal fluid, urine|Both|N/A|N/A|No|Probability Sample|Patients reporting to a memory clinic|February 2016|February 16, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02686554||2603|
NCT02692521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-001-15|Human Milk Feeding Rates Post-NICU Discharge|Human Milk Feeding Rates Post-NICU Discharge||Mednax Center for Research, Education and Quality||Not yet recruiting|March 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|NICU Graduates|February 2016|February 22, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02692521||2146|
NCT02692586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001|FlowTriever Pulmonary Embolectomy Clinical Study|FlowTriever Pulmonary Embolectomy Clinical Study|FLARE|Inari Medical|Yes|Not yet recruiting|February 2016|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02692586||2141|
NCT02707068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ116/N006|Quality Of LIfe Tool for IBD|Quality Of LIfe Tool for IBD (QOLITI): Pilot Testing of a Self-administered Intervention to Target Psychological Distress in Inflammatory Bowel Disease|QOLITI|King's College London|No|Recruiting|January 2016|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02707068||1030|
NCT02707081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benha 121|Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief|Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief||Benha University||Completed|June 2013|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Female|18 Years|40 Years|No|||March 2016|March 8, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707081||1029|
NCT02683733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIGINDIACurcumin1|Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis|The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis||Asian Institute of Gastroenterology, India|Yes|Recruiting|February 2016|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 20, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02683733||2820|
NCT02691130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX-007|Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults|A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults||BiondVax Pharmaceuticals ltd.|Yes|Recruiting|November 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|222|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02691130||2253|
NCT02691247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBS03-P01|Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)|A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)||Caladrius Biosciences, Inc.|Yes|Recruiting|February 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|111|||Both|12 Years|17 Years|No|||February 2016|March 2, 2016|February 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02691247||2244|
NCT02679599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215615|Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic|||The Miriam Hospital||Enrolling by invitation|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|75 Years|No|||March 2016|March 10, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02679599||3137|
NCT02695186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/21/01/2016|Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome|Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome||General Hospital of Filiates|Yes|Recruiting|February 2016|June 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|180|||Both|25 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|A group of patients with IM and MS, a group of patients with IM alone, and a group of        healthy volunteers. Every group of patients will be divided in subgroups based on age and        gender.|February 2016|February 29, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02695186||1942|
NCT02695199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49557309-6|Doppler Ultrasound Assisted Varicocelectomy Improve Sperm Qualities|Comparison Between Laparoscopic Doppler Ultrasound Assisted Laparoscopic Varicocelectomy and Microscopic Subinguinal Varicocelectomy||The Second Hospital of Shandong University|Yes|Recruiting|January 2016|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|20 Years|39 Years|No|||January 2016|February 29, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695199||1941|
NCT02680002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARDA CSN 15-0001|Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant|Randomized, Double-Blinded, Phase 2 Study to Assess Safety & Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With & Without Stored MF59® Adjuvant||Biomedical Advanced Research and Development Authority|Yes|Recruiting|March 2016|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|420|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|January 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02680002||3107|
NCT02687100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMC|The Effects of Beclomethasone Upper the Endotracheal Cuff on the Occurrence of Sore Throat at Extubation|Does Beclomethasone Instillation Above the Cuff of Endotracheal Tubes Decrease the Occurrence of Postoperative Sore Throat? A Randomized Controlled Trial|BEnTS|Policlinico Universitario Agostino Gemelli|Yes|Not yet recruiting|March 2016|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Months|90 Years|No|||February 2016|February 16, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02687100||2561|
NCT02689778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1497|Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy|Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02689778||2355|
NCT02698228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre RAPID Trial|Regional Anaesthesia for Painful Injuries After Disasters|Regional Anaesthesia for Painful Injuries After Disasters (RAPID) Study: A Randomized Trial|RAPID|Epicentre|Yes|Not yet recruiting|March 2016|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|3||Anticipated|207|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02698228||1709|
NCT02691624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCRLResearch001|Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation|Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation||Peking University People's Hospital|No|Recruiting|October 2015|January 2019|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|100 breast cancer patients treated in Peking University People's Hospital Breast Center        and agree to receive lymphoscintigraphy of upper extremity.|February 2016|February 20, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02691624||2215|
NCT02693132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO15110570|Comparison of Supervised and Unsupervised Physical Activity Programs During a Weight Loss Intervention for Adults|Comparison of Supervised and Unsupervised Physical Activity Programs During a Standard Behavioral Weight Loss Intervention for Adults Who Are Overweight or Obese|REACH|University of Pittsburgh|No|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693132||2099|
NCT02685449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Białko_Kamila|Insulin Requierment for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.|Insulin Requierment for Pure- Protein Meal in Children With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion - a Cross-over, Randomized Trial.||Medical University of Warsaw|No|Not yet recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|10 Years|18 Years|No|||January 2016|February 12, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02685449||2688|
NCT02685462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-124|Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin|A Phase 1 Open-Label Study in Healthy Adult Subjects to Assess the Effect of Cenicriviroc Mesylate (CVC) on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors (Rosuvastatin, Atorvastatin and Simvastatin), Caffeine and Digoxin||Tobira Therapeutics, Inc.|No|Active, not recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02685462||2687|
NCT02695355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB3330|ERP Based Single-dose Predictions of Stimulants|Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials||Ostfold Hospital Trust|No|Completed|October 2006|September 2015|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|8 Years|17 Years|No|||February 2016|February 29, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02695355||1929|
NCT02693145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOA PS14-001|Cooperative Re-Engagement Controlled Trial (CoRECT)|Cooperative Re-Engagement Controlled Trial (CoRECT)|CoRECT|Centers for Disease Control and Prevention|No|Not yet recruiting|June 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1800|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02693145||2098|
NCT02694471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANGEA|Effect of 14 Day Bed Rest on Health Outcomes in Young and Older Participants|CB147 - Physical Activity and Nutrition for Quality Ageing|BEDREST|University of Primorska|No|Completed|August 2012|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694471||1996|
NCT02694497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FemCure|Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women|Understanding Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women Receiving Routine Care; Implications for Control Strategies|FemCure|Maastricht University Medical Center|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Participants will collect a self-administered anorectal and vaginal swab at 8 time-points:      pre-treatment during the visit at the STI clinic at which the treatment is given (T0), and      at the end of weeks 1, 2, 4, 6, 8, 10, and 12. At T0, T4, T8 and T12 (visits at the clinic),      the participants take an additional self-administered anorectal and vaginal swab that is      otherwise exactly the same as the home-taken samples, but stored in a different buffer and      processed immediately, i.e. cooled at -80°C within 24 hours, to allow CT viability testing.      At the clinic visit, we will also consider to obtain a nurse-taken pharyngeal swab for later      CT testing. For self-collection of the anorectal and genital samples, participants receive      clear instructions.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants are recruited from 3 large Dutch STI clinics, in South Limburg, Amsterdam and        Rotterdam. Eligible participants are likely to reflect the STI clinic population, in terms        of age, ethnicity and level of education. Participants include genital and/or anorectal CT        positive women (n=400).|February 2016|February 23, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02694497||1994|
NCT02684682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50208115.9.0000.5346|Frequency of Self-performed Mechanical Control of Plaque|Effect of Self-performed Mechanical Control of Plaque Frequency in Patients With Historic of Periodontitis and in Maintenance||Universidade Federal de Santa Maria|No|Active, not recruiting|February 2016|June 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Anticipated|39|||Both|35 Years|N/A|No|||February 2016|February 11, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02684682||2747|
NCT02680431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141-1801-2015|Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1|Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1||Turku University Hospital|No|Enrolling by invitation|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Free circulating DNA extracted from blood plasma|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients visiting Turku Neurofibromatosis Centre (Finland) for care of their disease.        Controls are healthy volunteers from Turku area.|February 2016|February 8, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02680431||3074|
NCT02703792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1163|Enhanced Care Home Outcomes: A Qualitative Study|Enhanced Care Home Outcomes (ECHO): An Evaluation of the Experiences of Staff and Stakeholders Working With an Integrated Care Home Support Service (CHSS)|ECHO|Oxford Health NHS Foundation Trust|No|Not yet recruiting|March 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|N/A||4|Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Staff and relatives of service users|February 2016|March 8, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02703792||1281|
NCT02694965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059349|Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma|Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma||Duke University|No|Enrolling by invitation|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients with stage IV or unresectable stage IIIC melanoma selected to undergo        either anti-CTLA-4 antibody (ipilimumab) or anti-PD-1 antibody (pembrolizumab, nivolumab)        immunotherapy will be asked to participate in the study by the Principal Investigator,        co-Investigators, or clinical staff.|February 2016|February 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02694965||1958|
NCT02686853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH 003|Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis|Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome||Hebei Medical University||Not yet recruiting|January 2016|||January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|14 Years|N/A|No|||February 2016|February 16, 2016|January 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02686853||2580|
NCT02691533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ACLF-006|To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure|To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure||Institute of Liver and Biliary Sciences, India|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||February 2016|March 9, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02691533||2222|
NCT02682862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDundee|Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics|Effects of Ultra-long Acting Bronchodilator Therapy Assessed by Impulse Oscillometry in Smoking Asthmatics Taking Inhaled Corticosteroids|MAN05|University of Dundee|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02682862||2887|
NCT02701101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEM200-008|Evaluation of the SEM Scanner 200 for the Detection of Early Pressure Ulcers: A Multi-Site Longitudinal Study|Evaluation of the SEM Scanner 200 for the Detection of Early Pressure Ulcers: A Multi-Site Longitudinal Study||Bruin Biometrics, LLC|No|Not yet recruiting|March 2016|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|55 Years|N/A|No|||March 2016|March 2, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701101||1488|
NCT02701114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15118|Proximal Versus Distal Adductor Canal Blocks for Total Knee Arthroplasty|A Comparison of Proximal Versus Distal Continuous Adductor Canal Blocks After Total Knee Arthroplasty||Benaroya Research Institute|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02701114||1487|
NCT02691117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000050555|Topical Garlic Concentrate for Alopecia Areata in Children|Topical Garlic Concentrate for Alopecia Areata in Children: A Prospective Open Label Study||The Hospital for Sick Children|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|18 Years|No|||February 2016|February 19, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02691117||2254|
NCT02717351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18841|18841- Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment- Darkening Dose|SPF Assay|Bayer|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717351||239|
NCT02717364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-438|Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma|Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma||Bristol-Myers Squibb|No|Recruiting|August 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|Primary Care Clinic|March 2016|March 18, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02717364||238|
NCT02698033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001519|High Threshold Peanut Challenge Study|Follow-Up Protocol For Peanut Allergic Individuals With Documented Objective Clinical Unresponsiveness to a Double-Blind Placebo-Controlled Food Challenge With Peanut Protein|PAID-UP|Massachusetts General Hospital|Yes|Enrolling by invitation|December 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|7 Years|55 Years|No|||March 2016|March 3, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698033||1724|
NCT02699775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01671-48|Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients|Effect of 3 Consecutives Botulinum Toxin Injection on Gait Pattern in Stroke Patients|TRITITOX|Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|March 2016|November 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|STROKE PATIENTS|March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699775||1590|
NCT02699788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH0006|Emergency Department MCG for Suspected Acute Coronary Syndrome|Emergency Department MCG for Suspected Acute Coronary Syndrome||Tampa General Hospital|No|Not yet recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699788||1589|
NCT02717091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUDC1508|Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer||Nagoya University||Enrolling by invitation|July 2015|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|75 Years|No|||March 2016|March 22, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02717091||259|
NCT02718781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15-401|Community Health Campaign: Fitter Families Project|Community Health Campaign: Fitter Families Project||The University of Hong Kong|Yes|Recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|900|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 20, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02718781||129|
NCT02711397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELIAC|Quantification of Gluten Peptides in Feces|Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-free Diet|DELIAC|Biomedal S.L.|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|272|Samples With DNA|Stool and blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Celiac patients following a GFD for at least one year prior to the inclusion in the study|March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711397||697|
NCT02696772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R13-P149DC|Effect of 24 h Severe Energy Restriction on Appetite Regulation and Ad-libitum Energy Intake|Effect of 24 h Severe Energy Restriction on Appetite Regulation and Ad-libitum Energy Intake in Lean Males and Females||Loughborough University|No|Completed|October 2013|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696772||1821|
NCT02697019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1895-31/5|Internet-delivered Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Internet-delivered Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study||Karolinska Institutet|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|13 Years|17 Years|No|||March 2016|March 3, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02697019||1802|
NCT02696577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIUGR|The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction|||Assiut University|No|Completed|March 2015|February 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Female|20 Years|35 Years|No|||March 2016|March 12, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02696577||1836|
NCT02703779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IIT-BMT-MM-AutoSCT|Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)|An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma||University of Kansas Medical Center|Yes|Recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703779||1282|
NCT02706457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nWMO 143|Post Intensive Care Syndrome|Do Improvements in Functionality on the ICU Give a Reduction of Post Intensive Care Syndrome||Medical Centre Leeuwarden|No|Recruiting|October 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|849|||Both|18 Years|N/A|No|Probability Sample|patients treated in Intensive Care for minimal 48 hours, during the years 2012 - 2014|March 2016|March 7, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02706457||1077|
NCT02719093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIRURGIAANDROLOGICA-1|Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery|Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery||U.O. Chirurgia Andrologica|No|Not yet recruiting|July 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|35 Years|No|||March 2016|March 20, 2016|December 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02719093||105|
NCT02706782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genechem meso-CART|A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated Mesothelin-targeted Chimeric Antigen Receptor T Cells in Advanced Pancreatic Carcinoma|meso-CART|Shanghai GeneChem Co., Ltd.|No|Recruiting|March 2016|September 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|69 Years|No|||March 2016|March 8, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706782||1052|
NCT02697877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1275|Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements|Assessment and Prognostic Significance of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements During Regadenoson Stress Cardiac Magnetic Resonance||University of Illinois at Chicago||Recruiting|February 2016|January 2019|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients ≥ 18yrs who are undergoing clinically indicated stress cardiac magnetic resonance        (CMR) imaging for known or suspected coronary artery disease.|February 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697877||1736|
NCT02697890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11360|Effect of Mucograft® Seal on Post-extraction Ridge Preservation Using Bone Allograft|Effect of Mucograft® Seal on Post-extraction Ridge Preservation Using Bone Allograft: A Randomized Controlled Clinical Trial and Radiographic Evaluation|Mucograft|Tufts University School of Dental Medicine|No|Active, not recruiting|May 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697890||1735|
NCT02702232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150802R|Shoulder Disorders in Patients With Parkinson's Disease|Shoulder Disorders in Patients With Parkinson's Disease||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Not yet recruiting|July 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|50 Years|80 Years|No|Probability Sample|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex-        and age-matched normal subjects with be recruited from the public.|March 2016|March 2, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702232||1401|
NCT02716402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15012759|Cyanotic Heart Disease and Thrombosis|Cyanotic Congenital Heart Disease: Prevalence of Pulmonary and Cerebral Thrombi-embolic Events||Rigshospitalet, Denmark|No|Recruiting|November 2015|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|100 Years|No|||March 2016|March 17, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02716402||312|
NCT02710318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAP6516|Synchronized Immunization NotifiCations|Synchronized Immunization NotifiCations|SINC|Columbia University|No|Not yet recruiting|May 2016|March 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|13000|||Both|N/A|17 Years|No|||March 2016|March 15, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02710318||780|
NCT02698124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLMDSWP-201601|Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice|Prospective Observation of the indUction Regimen for Acute Non-Promyelocytic Myeloid Leukemia in Elderly; Decitabine for Chemotherapy Unfit Korean Acute Myeloid Leukemia (AML) Patients in Real Practice|PURPLE-D|Ulsan University Hospital|No|Not yet recruiting|March 2016|December 2022|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|136|Samples With DNA|miRNA, TET, whole genome sequencing|Both|65 Years|N/A|No|Probability Sample|elderly patients with previously untreated AML who are ufit to receive and not considered        candidates for iIC at the time of enrollment|March 2016|March 4, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02698124||1717|
NCT02702479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surose vs HFCS|Sysetmatic Review and Meta-Analysis of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk|Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials||University of Toronto|No|Active, not recruiting|June 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702479||1382|
NCT02712645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-BC-1.0|A Multicenter Breast Cancer Biospecimen Registry|||Luminist, Inc.||Recruiting|February 2016|||December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Female|40 Years|N/A|No|Probability Sample|Women scheduled for a breast biopsy.|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02712645|1 Year|601|
NCT02712658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIK|Role of K+ and Ca2+ in Development of Muscle Fatigue|||University of Copenhagen|Yes|Recruiting|September 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02712658||600|
NCT02703610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-6058|Randomized Controlled Trial of Four Analgesics in Elderly ED Patients|Randomized Controlled Trial of Four Analgesics in Elderly ED Patients||Montefiore Medical Center|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|400|||Both|65 Years|N/A|No|||March 2016|March 4, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703610||1295|
NCT02698371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCS-UFP-2014-04-2015-07-19|NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives|NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives Clinical Trial|SEMMAP|University Fernando Pessoa|Yes|Recruiting|November 2015|March 2018|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|6||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02698371||1698|
NCT02698683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-LCSINS|Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Patients|Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Intensive Care Patients: A Pilot Study||University of Sao Paulo|Yes|Completed|February 2014|January 2016|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|||Both|1 Month|14 Years|No|Non-Probability Sample|pediatric septic patients|February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02698683||1674|
NCT02711124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBC Zagreb|Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery|Relationship Between Level of Glycosylated Hemoglobin and Platelet Function in Patients Undergoing Coronary Artery Bypass Grafting||Clinical Hospital Centre Zagreb|Yes|Recruiting|February 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|||Both|N/A|N/A|No|Probability Sample|Study population are the diabetic patients undergoing coronary artery bypass grafting at        the department of cardiac surgery (The University Hospital Centre Zagreb, Croatia).        The patients will be sampled in consecutive fashion. Cohort sample will be divided into        two subgroups according to HbA1c level (Group 1 with HbA1c < 7% and Group 2 with HbA1c ≥        7%, respectively).|March 2016|March 19, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02711124|6 Months|718|
NCT02717169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-2016|Promoting Health Knowledge Among University Students|Promoting Health Knowledge Among University Students by Using Personal Biometric Information||The University of Hong Kong|Yes|Recruiting|March 2016|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02717169||253|
NCT02717416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2016-0027|Efficacy of Hemostatic Powder, Endo-ClotTM in the Endoscopic Treatment of Acute Upper Gastrointestinal Bleeding|||Yonsei University|No|Not yet recruiting|March 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|19 Years|N/A|No|||March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717416||234|
NCT02696499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA101B-UP-02|Treatment of Uremic Pruritus With PA101B|Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis||Patara Pharma|No|Recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696499||1842|
NCT02708667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-FXY-078-Internal medicine|An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients|An Observational Research on Relationship Between c-Met Gene Polymorphism, Promoter Methylation Level, Related Drug Metabolism Enzymes and Crizotinib's Hepatic Toxicity in Non-small Cell Lung Cancer Patients||Sun Yat-sen University|Yes|Recruiting|September 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|Samples With DNA|whole blood, biopsy tissue|Both|18 Years|75 Years|No|Non-Probability Sample|Patients who were diagnosed with stage III or IV non-small cell lung cancer (NSCLC),        harbored ALK fusion gene and took crizotinib.|March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02708667||907|
NCT02712086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9590|Controlled Trial Evaluating the Efficacy of Protein Supplementation in the Short Term After Bariatric Surgery|Randomized Controlled Trial Prospective Single-center Open Evaluating the Efficacy of Supplementation (Adapted to the Post-operative Period) Current Protein After Bariatric Surgery Like Sleeve Gastrectomy|PROTISLEEVE|University Hospital, Montpellier|No|Not yet recruiting|April 2016|December 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|74|||Both|18 Years|60 Years|No|||March 2016|March 22, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712086||644|
NCT02711046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDCORALSURGERY|Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis|Evaluation of Change in Mouth Opening in Oral Submucous Fibrosis Patients After Surgical Excision of Fibrous Bands Along With Bilateral Coronoidotomy and Surgical Defect Coverage by Single Stage Extended Nasolabial Flap||Government College of Dentistry, Indore|Yes|Completed|March 2011|September 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||March 2016|March 12, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02711046||724|
NCT02711059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarolinskaUH_pHPT_diabetes|Insulin Resistance in Primary Hyperparathyroidism|Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation|IRIPH|Karolinska University Hospital|No|Recruiting|October 2015|June 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|50 Years|N/A|No|||March 2016|March 11, 2016|October 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02711059||723|
NCT02698098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010403|Comparative Evaluation of PUSPENs and C&Cs|Comparing Health & Social Outcomes Between Opioid-Dependent Individuals in Compulsory Drug Rehabilitation Centers and Voluntary Drug Treatment Clinics in Klang Valley, Malaysia|PSVCC|University of Malaya|No|Terminated|August 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|281|||Both|18 Years|N/A|No|Non-Probability Sample|The study will be conducted among opioid-dependent individuals initiating MMT in C&C        Centers and opioid-dependent individuals being released from Pusat Serenti who consent to        participating in the study.|February 2016|February 28, 2016|February 16, 2016||No|1) Policy change affecting C&Cs; 2) interm analysis revealing overt differences|No||https://clinicaltrials.gov/show/NCT02698098||1719|
NCT02697084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/54|Individual Following in Anal Cancer With PET/CT|Individual Following in Anal Cancer With PET/CT|IFACT|Centre Antoine Lacassagne|No|Recruiting|November 2014|June 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|Canal anal cancer|February 2016|February 26, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02697084||1797|
NCT02719067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201602058RIN|A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder|A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder||National Taiwan University Hospital|Yes|Recruiting|January 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|140|||Both|12 Years|20 Years|No|Non-Probability Sample|70 ASDs, aged 12-20, from the cohort of ASD established by previous imaging studies        supported by National Science Council(NSC),Taiwan (now Ministry of Science and Technology,        MOST), who consented to this follow-up study at their first assessments in 2010-2014 and        70 age-, and sex-matched TD.|March 2016|March 20, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02719067||107|
NCT02714699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-OH|Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium Before Office Hysteroscopy|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium in Reducing Pain During Office Hysteroscopy||Assiut University|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|150|||Female|20 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714699||443|
NCT02707575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0304|Cytokeratin 8 Level in Age-related Macular Degeneration|Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration||Gangnam Severance Hospital|No|Recruiting|March 2016|May 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|99 Years|No|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707575||991|
NCT02708147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhDPT/VeronicaAbreu/2016|Impact of Respiratory Physiotherapy in Children With Bronchiolitis in the First Two Years of Life|Impact of Respiratory Physiotherapy in Children With Bronchiolitis in the First Two Years of Life||Aveiro University|No|Not yet recruiting|September 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|2 Years|No|||March 2016|March 11, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708147||947|
NCT02708160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERO-2015-CAI-03-RPS|Assessment of Prevident Sodium Fluoride 1.1% Toothpaste Using an Intra-oral Remineralization-demineralization Model|Assessment of Prevident Sodium Fluoride 1.1% Toothpaste Using an Intra-oral Remineralization-demineralization Model||Colgate Palmolive|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|March 9, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708160||946|
NCT02708173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cycdc2015-5|Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older|||Beijing Chaoyang District Centre for Disease Control and Prevention||Recruiting|March 2016|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|3 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708173||945|
NCT02698163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-002015|Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material|Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material Applied by Vertical Condensation Obturation Procedure||University of California, Los Angeles|No|Recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02698163||1714|
NCT02716103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34469|Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis|Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment (Which May Include High Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT)) in Patients With AL Amyloidosis: Feasibility and Prognostic Significance|MRD|Boston Medical Center|No|Active, not recruiting|March 2016|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Bone marrow and peripheral blood|Both|18 Years|N/A|No|Probability Sample|Patients with previously untreated AL amyloidosis|March 2016|March 22, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02716103|5 Years|335|
NCT02704637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-026|An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm|An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm||HeadSense Medical|No|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704637||1216|
NCT02707705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0352|Preoperative Auricular Acupuncture in Elective Cesarean Section.|Premedication With an Auricular Acupuncture Protocol in Elective Cesarean Section .|CESAUR|Hospices Civils de Lyon|No|Recruiting|June 2015|||February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02707705||981|
NCT02698358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0075|Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)|||Yonsei University|No|Recruiting|December 2015|December 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|85 Years|No|Non-Probability Sample|Iliac artery disease|February 2016|February 29, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698358||1699|
NCT02702739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA 801|Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients|Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study|HCV|Azienda Ospedaliera San Camillo Forlanini|No|Completed|January 2015|February 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|82 Years|No|||March 2016|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02702739||1362|
NCT02702986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-2015-001|Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)|Immunostimulating Interstitial Laser Thermotherapy in Patients With Locally Advanced Pancreatic Cancer: Results of a Prospective, Open, Non Comparative Study||Universita di Verona|No|Recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02702986||1343|
NCT02712138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGM 02-2016|Biomarker for Patients With Gilbert Disease|Biomarker for Patients With Gilbert Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioGilbert|University of Rostock|Yes|Recruiting|March 2016|April 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry is a dry      blood spot filter card are taken. To proof the correct diagnosis in those patients where up      to the enrollment in the study no genetic testing has been done, sequencing will be done.      The analyses are done in the Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100      888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|2 Months|N/A|No|Probability Sample|Patients of both gender with Gilbert disease or high-grade suspicion for Gilbert disease|March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712138||640|
NCT02704650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shachar-1|Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids|Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids||Shaare Zedek Medical Center|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 9, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02704650||1215|
NCT02704663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/13/03/03/2014|Transumbilical Versus Lateral Transabdominal Removal of Benign Adnexal Masses Via Laparoscopy|Transumbilical Versus Lateral Transabdominal Removal of Benign Adnexal Masses Via Laparoscopy, a Randomized Trial||Helsinki University Central Hospital|No|Active, not recruiting|November 2014|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Female|20 Years|60 Years|No|||March 2016|March 9, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02704663||1214|
NCT02711098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL Ancillary Study of HYPERION|IL Ancillary Study of the Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|InterLeukine Ancillary Study of the Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|IL-HYPERION|Centre Hospitalier Departemental Vendee|Yes|Recruiting|March 2016|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02711098||720|
NCT02695823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69HCL15_0483|Incidence of Intracranial Hypertension During Liver Transplantation Estimated by Non-invasive Ultrasound Methods.|Incidence of Intracranial Hypertension During Liver Transplantation Estimated by Non-invasive Ultrasound Methods.|TOH-HTIC|Hospices Civils de Lyon|No|Recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02695823||1894|
NCT02695836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0026204|Improving Nursing Home Care Through Feedback On PerfoRMance Data|Improving Nursing Home Care Through Feedback On PerfoRMance Data (INFORM)|INFORM|University of Alberta|No|Enrolling by invitation|March 2016|September 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|147|||Both|N/A|N/A|No|||February 2016|February 24, 2016|January 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695836||1893|
NCT02716597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0727-F2L|Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock|Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock||University of Kentucky|No|Not yet recruiting|March 2016|||December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 19, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02716597||297|
NCT02698956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-01|Observational Study to Evaluate Safety and Performance of SAPIEN 3 THV System in Real Life Practice.|Edwards SAPIEN 3 Aortic Bioprosthesis Multi-Region Outcome Registry|SOURCE3|Edwards Lifesciences|Yes|Active, not recruiting|July 2014|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from severe aortic stenosis. Inclusion criteria are based on the        decision of the Heart Team.|February 2016|February 29, 2016|February 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02698956||1653|
NCT02709954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015208.A|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I|THC-ETOH-I|Yale University|No|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709954||808|
NCT02709967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/895|Research Initiative to Support the Empowerment of Girls|Cluster Randomized Trial on the Effectiveness of a Girls' Empowerment Programme on Early Childbearing, Marriage and School Dropout Among Adolescent Girls in Rural Zambia|RISE|University of Bergen|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|5300|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02709967||807|
NCT02716610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Samba-02|Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes|Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects With Type 2 Diabetes|Samba-02|Dance Biopharm Inc.|No|Completed|October 2013|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|24|||Both|18 Years|74 Years|No|||March 2016|March 17, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716610||296|
NCT02711839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505027|Sweet Potato Functional Product Development and Health Effects Explore|Office of Human Research, Taipei Medical University||Taipei Medical University|Yes|Enrolling by invitation|August 2015|May 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|80 Years|No|||May 2015|March 13, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02711839||663|
NCT02696018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138-2012|Diaphragmatic Echography in Critically Ill patientS|Evaluation of Diaphragmatic Displacement During Spontaneous Breathing Trials in Critically Ill Patients|DECIS|Università degli Studi di Ferrara|No|Completed|July 2014|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|80 Years|No|Non-Probability Sample|Critically ill patients undergoing a spontaneous breathing trial|February 2016|February 25, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02696018||1879|
NCT02700737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEHSC-01001|Evaluation of Image-Based Modelling on Clinical Decisions in Coarctation of the Aorta|Evaluation of Image-Based Modelling on Clinical Decisions in Coarctation of the Aorta||London School of Economics and Political Science|No|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|124|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02700737||1516|
NCT02716870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA SUGARS-2015|Systematic Review and Meta-analysis of the Effect of Food Sources of Sugars on Cardiometabolic Risk Factors|Effect of Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design||University of Toronto|No|Active, not recruiting|June 2015|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|March 2016|March 17, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02716870||276|
NCT02705534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pending|Sofosbuvir, Ledipasvir, Ribavirin for HCV Cirrhotics, Genotype 1|Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin|SL50|Tehran University of Medical Sciences|No|Not yet recruiting|April 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705534||1147|
NCT02696291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 15-0062|Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects|Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects||Emergent BioSolutions|Yes|Not yet recruiting|March 2016|July 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02696291||1858|
NCT02698475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108129|An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than 6 to Less Than 12 Years of Age|A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than 6 to Less Than 12 Years of Age|CADMUS Jr|Janssen Research & Development, LLC||Not yet recruiting|May 2016|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Years|11 Years|No|||March 2016|March 3, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698475||1690|
NCT02718430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXM01-03-DE|VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis|VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01||Vaximm GmbH|Yes|Recruiting|February 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718430||156|
NCT02718443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXM01-02-DE|VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma|VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01||Vaximm GmbH|Yes|Not yet recruiting|March 2016|November 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02718443||155|
NCT02720276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UppsalaCC|Training After Acute Stroke|Outdoor Walking and Strength Training After Acute Stroke: A Pilot Study|StrokeWalk|Uppsala County Council, Sweden|Yes|Active, not recruiting|November 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02720276||14|
NCT02720289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-045|Video-Based Social Learning or Didactics for Car Seat Education|Car Seat Education: What Works Best?||Phoenix Children's Hospital|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|212|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02720289||13|
NCT02709512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2015-003|Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin|Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)|ATOMIC|Polaris Group|Yes|Not yet recruiting|July 2016|October 2019|Anticipated|July 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|372|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709512||842|
NCT02697071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1921|Ketamine for Acute Migraine in the Emergency Department|A Randomized Placebo-Controlled Trial of Sub-Dissociative Ketamine for Treatment of Acute Migraine-Type Headache in the Emergency Department||Carilion Clinic||Recruiting|February 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697071||1798|
NCT02718456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41427-EJ|Overcoming Barriers to HIV/AIDS Care and ART Initiation|Overcoming Barriers to HIV/AIDS Care and ART Initiation|LINC|University of Washington|No|Recruiting|August 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718456||154|
NCT02704611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS in fibromyalgia|Direct Current Stimulation for Treatment of Fibromyalgia|Direct Current Stimulation Versus Sham for Treatment of Fibromyalgia: a Double Blinded Randomized Controlled Trial||Assiut University|Yes|Recruiting|October 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|55 Years|No|||October 2015|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704611||1218|
NCT02695732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-LC02-2016|The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding|Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Recruiting|December 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|792|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695732||1901|
NCT02717065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512M81434|Variability of Tinnitus Characterization Tools and Investigation of Audiovisual Integration in Tinnitus Perception|Variability of Tinnitus Characterization Tools and Investigation of Audiovisual Integration in Tinnitus Perception||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717065||261|
NCT02707692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160089|Perturbing of HIV Reservoir With Immune Stimulation|Perturbing the HIV Reservoir With Immune Stimulation||University of California, San Diego|No|Not yet recruiting|August 2016|January 2021|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Anticipated|56|||Both|18 Years|50 Years|No|||March 2016|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02707692||982|
NCT02703909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004620|Surgical Conditions During Laparoscopic Bariatric Surgery|A Prospective Randomized Clinical Trial Evaluating Surgical Conditions During Laparoscopic Bariatric Surgery With Deep Versus Moderate Neuromuscular Blockade||University of Missouri-Columbia|No|Not yet recruiting|March 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02703909||1272|
NCT02703454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN - 107|FIRM Ablation Versus Pulmonary Vein Isolation for the Treatment of PAF|Focal Impulse and Rotor Modulation Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation|FIRMAP-AF|Topera, Inc.|Yes|Recruiting|February 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|170|||Both|18 Years|80 Years|No|||February 2016|March 4, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703454||1307|
NCT02712814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0152-15-COM1|Subtypes of Provoked Vestibulodynia|Subtypes of Provoked Vestibulodynia: A Prospective Study to Evaluate a Diagnostic Algorithm in Regard to Different Treatment Modalities||Meir Medical Center|No|Not yet recruiting|April 2016|August 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|500|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the clinic for vulvovaginal disorders in Clalit Healthcare        services in Jerusalem.|March 2016|March 14, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02712814||588|
NCT02713074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-S|Povidone-iodine Versus Saline in Vaginal Cleansing Before Office Hysteroscopy|A Comparison Between Povidone-iodine and Normal Saline in Vaginal Cleansing Before Office Hysterosocpy: a Randomized Controlled Trial|PISOH|Assiut University|Yes|Active, not recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|N/A|N/A|No|||March 2016|March 17, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713074||568|
NCT02702609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2015-12-17-1|Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System|Prospective, Comparative Assessment of Alveolar Ridge Preservation Using GUIDOR® Easy-graft® Classic in Atraumatic Extraction Socket||Sunstar Americas|No|Not yet recruiting|April 2016|July 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702609||1372|
NCT02700451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-333|Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes|A Randomized Controlled Trial of Post-operative Acetaminophen Versus Nonsteroidal Anti-Inflammatory Drug (NSAID) Use on Lumbar Spinal Fusion Outcomes||Hospital for Special Surgery, New York|Yes|Not yet recruiting|March 2016|August 2019|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|February 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700451||1538|
NCT02700464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-EpiCheck-FDA-01|The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma|The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study||Nucleix Ltd.|No|Not yet recruiting|April 2016|December 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|500|||Both|22 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700464||1537|
NCT02703701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500586|Role of Physician-at-Triage on Emergency Department (ED) Efficiency and Quality of Care|Effects of Attending Physician-at-Triage on Emergency Department Efficiency, Information Delivery and Patient Satisfaction|MD at Triage|University of Florida|No|Recruiting|October 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|110 Years|No|Non-Probability Sample|Individuals receiving care from the Emergency Department between 10am-3pm on days a        physician is (Monday-Wednesday) and is not (Thursday-Sunday) assigned to triage.|March 2016|March 3, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02703701||1288|
NCT02718794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233/2558(EC4)|Simulation-based and Problem-based Learning for Difficult Airway Management|Crossover Study in Simulation-based and Problem-based Learning in Practice Guideline for Difficult Airway Management||Siriraj Hospital|Yes|Recruiting|August 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|36|||Both|24 Years|37 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02718794||128|
NCT02714153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1602017220|Bridge Occlusion Balloon in Lead Extraction Procedure|Bridge Occlusion Balloon Initial Use in Humans Study||Yale University|Yes|Not yet recruiting|March 2016|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|85 Years|No|||March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02714153||485|
NCT02698592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38/2012|Evaluation of Thermocool SF Catheter on the Common Cavo-tricuspid Isthmus Dependent Atrial Flutter Ablation|Comparative Study to Assess Safety and Efficacy of Catheters CelsiusTMDS® 8 mm, Thermocool® 3.5 mm of Irrigated Tip and Thermocool® SF in the Treatment of Cavo-tricuspid Isthmus Dependent Atrial Flutter||Hospital Universitario Central de Asturias|No|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698592||1681|
NCT02698605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-5038A3|Evaluation of the Arm Rehabilitation Device for Patients With Stroke|Design and Usability Evaluation of a Novel Robotic Bilateral Arm Rehabilitation Device for Patients With Stroke||Chang Gung Memorial Hospital|Yes|Completed|August 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02698605||1680|
NCT02700997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-092|Uterosacral Ligament Suspension Clip|Uterosacral Ligament Suspension: A Radiographic Study of Anatomy and Suture Location|USLS|TriHealth Inc.|No|Recruiting|March 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|17|||Female|18 Years|85 Years|No|||March 2016|March 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02700997||1496|
NCT02701270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111031-DP-2015-06-26|Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers|Randomised, Single-blinded, Controlled, Crossover and Acute Clinical Intervention to Assess the Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers||Danisco|No|Completed|September 2015|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701270||1475|
NCT02661061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/15|Ketamine for Relapse Prevention in Recurrent Depressive Disorder|Ketamine for Relapse Prevention in Recurrent Depressive Disorder: a Randomised, Controlled, Pilot Trial: the KINDRED Trial|KINDRED|St Patrick's Hospital, Ireland|Yes|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02661061||4557|
NCT02646800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACN-MA-MYC-registry-2013|Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp|A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp||Astellas Pharma Inc|No|Terminated|March 2014|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 16, 2015|No|Yes|Due to administrative reasons|No||https://clinicaltrials.gov/show/NCT02646800||5652|
NCT02719106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2016-05|IRIS Ultimaster Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Ultimaster® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRISUltimaster|Asan Medical Center|Yes|Not yet recruiting|May 2016|June 2023|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|19 Years|N/A|No|Non-Probability Sample|patients with Ultimaster stent|March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719106||104|
NCT02719119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monthly versus bi-weekly EVL|Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|||West China Hospital|Yes|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|March 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02719119||103|
NCT02719366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-16-07|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719366||84|
NCT02702700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-DO-PDT-2015|Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies|Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies: a Clinical Phase I Trial|PDT-lipo|Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|January 2016|June 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|March 3, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02702700||1365|
NCT02710786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Comorb|Comorbidity Five Years After Gastric Bypass|Comorbidity Five Years After Gastric Bypass||Uppsala University|No|Active, not recruiting|May 2007|January 2017|Anticipated|August 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25000|||Both|N/A|N/A|No|Probability Sample|Individuals undergoing gastric bypass|March 2016|March 16, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02710786|5 Years|744|
NCT02710799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32981014.0.0000.5327|Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List|Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions||Hospital de Clinicas de Porto Alegre|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|2016|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710799||743|
NCT02712359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201630|This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama in 2007-2008|Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix® in Panama||GlaxoSmithKline||Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|600|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712359||623|
NCT02712372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6580C00001|A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects|A Phase I, Randomised, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4831 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects||AstraZeneca|No|Not yet recruiting|May 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|10||Anticipated|125|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02712372||622|
NCT02699411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|European University|Dry Needling Effectiveness of Patients on Break Anterior Cruciate Ligament.|Dry Needling Effectiveness of Patients on Break Anterior Cruciate Ligament. Single-Blind Randomized Clinical Trial.|ACL|European University Spain|Yes|Recruiting|February 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699411||1618|
NCT02699684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE270-P001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||March 21, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699684||1597|
NCT02702947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR/ BPH /11/13|Efficacy of Prunus Domestica Extract in BPH|EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study||Chemical Resources|No|Active, not recruiting|March 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|160|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||September 2015|March 3, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02702947||1346|
NCT02711033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDPHCM-GI-01|Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection|Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial||Guangdong Provincial Hospital of Traditional Chinese Medicine|No|Recruiting|October 2015|April 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02711033||725|
NCT02716909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/2015|Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth|Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth||Federico II University|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|No|||March 2016|March 17, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02716909||273|
NCT02717156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-15-11|Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs|A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum||University of Southern California|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717156||254|
NCT02710383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCF 04-2016|Biomarker for Patients With a Cystic Fibrosis Disease|Biomarker for Patients With a Cystic Fibrosis Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioCyFi|University of Rostock|Yes|Recruiting|February 2016|February 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml      EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of a      cystic fibrosis in those patients where up to the enrollment in the study no genetic testing      has been done, sequencing of a cystic fibrosis disease will be done.      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany|Both|2 Months|N/A|No|Probability Sample|Patients of both gender with a Cystic Fibrosis or high-grade suspicion for a Cystic        Fibrosis|March 2016|March 11, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710383||775|
NCT02710396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ5450|Genetic Predictors of Benefit to Pembrolizumab|Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent Cancers||Columbia University|Yes|Not yet recruiting|March 2016|March 2023|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710396||774|
NCT02703207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2227-P|Neurocognitive Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD|Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD||VA Office of Research and Development|Yes|Not yet recruiting|July 2016|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|60 Years|89 Years|No|||March 2016|March 3, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02703207||1326|
NCT02703428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0019|TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair in Germany|The LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair in Germany|LUCY|TriVascular, Inc.|No|Not yet recruiting|March 2016|August 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|The study will enroll female subjects, 18 years of age or older that have an AAA and meet        all other inclusion/exclusion criteria|January 2016|March 8, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02703428||1309|
NCT02711748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.012.1MR|Can Medical Personnel Properly Proceed in the Case of a Patient With Bradycardia?|Can Medical Personnel Properly Proceed in the Case of a Patient With Bradycardia?||Medical University of Warsaw|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02711748||670|
NCT02711761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2015-105|Ideal Depth of Guide Wire for Central Catheterization|Ideal Depth of Guide Wire for Right Internal Jugular Vein During Central Line Insertion||Seoul National University Hospital||Recruiting|September 2015|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|69|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711761||669|
NCT02713659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-012507|Early Literacy Promotion Intervention|Early Literacy Promotion Among Poor Urban Children in Philadelphia|ELPI|Children's Hospital of Philadelphia|No|Recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|15 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02713659||523|
NCT02717988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oscotec|Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers||Oscotec Inc.|No|Recruiting|September 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|7||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717988||190|
NCT02701192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-07-08B|Management of Coccydynia: A Prospective, Observational Study of Coccygectomy|Management of Coccydynia: A Prospective, Observational Study of Coccygectomy|Coccyx|Carolinas Healthcare System|No|Active, not recruiting|September 2007|March 2017|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|77|||Both|18 Years|N/A|No|Non-Probability Sample|All patients will be seen and enrolled through an outpatient spine specialty clinic of Dr.        Edward Hanley.|March 2016|March 7, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02701192||1481|
NCT02696564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL128951|Losartan Effects on Emphysema Progression|Losartan Effects on Emphysema Progression|LEEP|Johns Hopkins University|Yes|Not yet recruiting|May 2016|July 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|N/A|No|||March 2016|March 1, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696564||1837|
NCT02696811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG_01|The Effects of Foods on Cell Damage Study|Randomised 6-week, Parallel Group, Placebo Controlled Intervention Trial to Investigate the Effects of White Carrots on Inflammatory Markers and Lymphocyte DNA Damage||Newcastle University|No|Recruiting|October 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|56|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02696811||1818|
NCT02716545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rj(2015)088K-b|the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation|the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: the Study of the Bleeding Risks Stratification Model and Endoscopic Treatment||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02716545||301|
NCT02716558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIMST university|A Clinical Trial to Assess the Retention and Caries Preventive Effects of Moisture Tolerant Resin Sealant and ART Sealants|||Kamineni Institute of Dental Sciences|Yes|Recruiting|February 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|93|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716558||300|
NCT02699905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00004607|Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis|Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis|GPR43Sepsis|Milton S. Hershey Medical Center|Yes|Not yet recruiting|August 2016|November 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|Samples With DNA|10 mL of whole blood drawn at four time intervals during the study. Blood is centrifuged and      the Buffy coat separated and flash frozen in liquid nitrogen. Quantitative PCR analysis is      then performed to assess the expression of FFA2/GPR43 at different time points in the      patient's illness.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with the diagnosis of sepsis or septic shock admitted to the intensive care        unit at Penn State Hershey Medical Center, Hershey PA 17033.|March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699905||1580|
NCT02701647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20140423002|Effects of Combined rTMS and Treadmill Training on Walking in PD|Effects of Combined Repetitive Transcranial Magnetic Stimulation and Treadmill Training on Gait Performance in Parkinson's Disease: A Randomised Controlled Trial||The Hong Kong Polytechnic University|No|Not yet recruiting|April 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|66|||Both|40 Years|70 Years|No|||February 2016|March 2, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02701647||1446|
NCT02708537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411-BIO-081-MF|Effect of Plasma Rich in Growth Factors on Semen Quality|Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality||IVI Bilbao|Yes|Recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|58|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.|March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708537||917|
NCT02718768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-15-2-0074|Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma|A Multi Center Prospective Observational Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma|Nerve|Major Extremity Trauma Research Consortium|Yes|Not yet recruiting|March 2016|September 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|54 Years|No|Non-Probability Sample|450 Patients with PNI that meet the eligibility criteria.|March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718768||130|
NCT02696473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carrot_01|The Bioavailability of Polyacetylenes From Carrots Study|Absorption of Naturally Present Compounds in Carrots and Their Appearance in Blood and Other Biofluids After Consumption (The Carrot Study)||Newcastle-upon-Tyne Hospitals NHS Trust|No|Not yet recruiting|March 2016|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696473||1844|
NCT02698111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZGDN1B|Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma|Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma：an Open-label,Phase 1 Study.||Suzhou Zelgen Biopharmaceuticals Co.,Ltd|No|Not yet recruiting|March 2016|December 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698111||1718|
NCT02720172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150912|Early Postoperative Home Exercise Program After Cervical Spine Surgery|A Randomized Trial of an Early Postoperative Home Exercise Program Versus Usual Care After Anterior Cervical Discectomy and Fusion Surgery||Vanderbilt University|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720172||22|
NCT02720185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15114|The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR|A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor||University of Wisconsin, Madison|Yes|Not yet recruiting|April 2016|April 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720185||21|
NCT02696707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150777-01H|An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer|An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer|OTT 15-05|Ottawa Hospital Research Institute|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696707||1826|
NCT02696720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-patch lidocaine|A Trial of Lidocaine Patch for Lower Limb Amputation Pain|A Randomized Controlled Trial of Lidocaine Patch for Lower Limb Amputation Pain||Brugmann University Hospital|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696720||1825|
NCT02702687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-3257|Childhood Asthma Perception Study|Childhood Asthma Perception Study|CAPS|Albert Einstein College of Medicine of Yeshiva University|Yes|Not yet recruiting|May 2016|November 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|10 Years|17 Years|No|||March 2016|March 3, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02702687||1366|
NCT02709785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25867|SmartMouth Advanced Clinical Formula Clinical Research Design Protocol|SmartMouth Advanced Clinical Formula Clinical Research Design Protocol||St. Louis University|No|Recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709785||821|
NCT02709798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D99-2015(043)-TCM-4|ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Shenfu Injection on Reperfusion Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Pilot Trial|SF-STEMI|Beijing Anzhen Hospital||Not yet recruiting|March 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709798||820|
NCT02716116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP32788-15-101|A Trial of AP32788 in Non-Small Cell Lung Cancer|A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer||Ariad Pharmaceuticals|No|Not yet recruiting|May 2016|October 2019|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|105|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716116||334|
NCT02711774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC-128/05.02,2016, RP-34/2016|An Optic Nerve Sheath Diameter(ONSD) Response to End Tidal Carbon Dioxide|An Optic Nerve Sheath Diameter(ONSD) Response to End Tidal Carbon Dioxide [EtCo2]||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2016|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|All ASA grade I adult patients in non head injury category between 18 to 65 years, of        either gender undergoing brachial plexus injury surgery under general anesthesia.|March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02711774||668|
NCT02696486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.20|Exercise Training Effect in Patients With HF and PEF|Exercise Training Effect on Quality of Life and Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: A Pilot Study||MultiCare Health System Research Institute|No|Recruiting|November 2015|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|55 Years|N/A|No|||February 2016|February 25, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02696486||1843|
NCT02708888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVC-1|Effectiveness of Trunk Training on Trunk Kinematics and Gait After Stroke|The Effect of Additional Trunk Training on Trunk Kinematics and Gait Parameters After Stroke: a Randomized Controlled Trial||Universiteit Antwerpen|No|Recruiting|March 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||March 2016|March 14, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02708888||890|
NCT02712333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDEH-AF2015|Health Effects of Indoor Air Filtration in Healthy Chinese Adults|Health Effects of Indoor Air Filtration in Healthy Chinese Adults: An Intervention Study||Fudan University|Yes|Active, not recruiting|November 2015|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02712333||625|
NCT02712593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15NRHC|A Study Investigating the Effects of Niagen™ in Healthy Adults.|A Randomized, Double-blind, Placebo Controlled Parallel Study Investigating the Effects of Niagen™ (Nicotinamide Riboside) on Niagen™ Metabolites in Healthy Adults.|15NRHC|KGK Synergize Inc.|No|Recruiting|March 2016|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|140|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02712593||605|
NCT02696928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniHD007|Methylene Blue Against Vivax Malaria in Ethiopia|Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial|BlueAL|Heidelberg University|No|Not yet recruiting|April 2016|January 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02696928||1809|
NCT02700646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00107611|Improving Motor Skill Development in Infants After Cardiac Surgery|Improving Motor Skill Development in Infants After Cardiac Surgery|DAISY|University of Michigan|No|Recruiting|January 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|90|||Both|N/A|120 Days|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700646||1523|
NCT02703181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201752|Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers|A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban||GlaxoSmithKline|No|Completed|July 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|June 17, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02703181||1328|
NCT02703194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaPLAGH-IgG4|Leflunomide for Maintenance of Remission in IgG4 Related Disease|A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease||Chinese PLA General Hospital|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|February 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703194||1327|
NCT02696096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|793387|Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence|Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence||Butler Hospital||Not yet recruiting|April 2016|April 2020|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|72|||Both|21 Years|50 Years|No|||February 2016|February 25, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02696096||1873|
NCT02714166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18766|Evaluation of the Irritation Potential of Products in Human Eyes|Evaluation of the Irritation Potential of Products in Human Eyes||Bayer|No|Completed|February 2016|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714166||484|
NCT02714179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA15/80|Preemptive and Preventive Use of Paracetamol for Pain Relief After Cesarean Section|A Double Blind Randomised Controlled Trial of Preemptive and Preventive Use of Paracetamol for Pain Relief After Cesarean Section||Baskent University|Yes|Completed|May 2015|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|54|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02714179||483|
NCT02697253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ1904|Mechanisms Underlying Predictors of Success From Obesity Surgery|Mechanisms Underlying Predictors of Success From Obesity Surgery||Columbia University||Recruiting|January 2016|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697253||1784|
NCT02700750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294-15|Relation Between Macular and RNFL Thickness Measurement and Quality Grading in OCT|Relation Between Macular and RNFL Thickness Measurement and Quality Grading in OCT||Meir Medical Center|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02700750||1515|
NCT02706054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-RCT|Treatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam|Treatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam: a Randomized, Double Blind, Placebo Controlled Cross-over Study||Istituto Ortopedico Rizzoli|No|Completed|May 2012|December 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2016|March 7, 2016|February 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706054||1107|
NCT02700542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-097|Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma|Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma||New York City Department of Health and Mental Hygiene|Yes|Active, not recruiting|December 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02700542||1531|
NCT02700815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1358.1|Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain|A Randomized, Controlled Multi-centre Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of a Topically Applied Combination Containing Diclofenac 2% + Capsaicin 0.075% (2 g Formulation Per Application; 2-times Daily for 5 Days) Compared to Placebo, as Well as to Diclofenac 2% and Capsaicin 0.075% in Patients With Acute Back or Neck Pain||Boehringer Ingelheim||Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|800|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 2, 2016||||No||https://clinicaltrials.gov/show/NCT02700815||1510|
NCT02714439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0477|Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley|Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2019|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Female|21 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714439||463|
NCT02711852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-23|A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)|A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)||Infinity Pharmaceuticals, Inc.|No|Enrolling by invitation|April 2016|December 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711852||662|
NCT02701231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015-093-01|Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer|Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer||Chinese PLA General Hospital|Yes|Recruiting|November 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02701231||1478|
NCT02713802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDA-C2015-001|Pilot Study of Bioequivalence of Cudafol(R) and Diprivan(R) Administered as Single Intravenous Doses in Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Pilot Study of the Bioequivalence of Cudafol(R) and Diprivan(R) IV Administered as Single Intravenous Doses in Healthy Subjects||Cuda Anesthetics, LLC|No|Enrolling by invitation|March 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|January 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713802||512|
NCT02716181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166-2015|Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis|A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis||Avanta Trading Ltd.|Yes|Recruiting|January 2016|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|66|||Both|1 Year|12 Years|No|||March 2016|March 24, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02716181||329|
NCT02716194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291501|BAX 826 Dose-Escalation Safety Study|A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A||Baxalta US Inc.|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Male|18 Years|65 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716194||328|
NCT02704364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0106|Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis||NGM Biopharmaceuticals, Inc|Yes|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704364||1237|
NCT02698631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALICIA-FA|Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging|Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging|ALICIA|Hospital Clinic of Barcelona|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||February 2016|February 27, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02698631||1678|
NCT02714374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151060|Safety and Effect of GL-ONC1 Administered IV With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery|An Open Label, Non-randomized Phase 1b Study to Investigate the Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection||University of California, San Diego|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714374||468|
NCT02714387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0207(4)|Non Traumatic Neuro-Vascular Diseases Critical Complications : a Prospective Cohort Study|Prospective Cohort of Patients Hospitalized in West French Intensive Care Units.|ATLANREA|Nantes University Hospital|No|Recruiting|February 2013|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples Without DNA|Plasma, serum, peripheral blood mononuclear cells, RNA|Both|15 Years|N/A|No|Non-Probability Sample|Patients hospitalized in ICU for Non Traumatic Neuro-Vascular Diseases|March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714387||467|
NCT02707562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG1837-CL-201|Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)|A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation|SAPHIRA1|Galapagos NV|Yes|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02707562||992|
NCT02700243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00012871|Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial|Pilot RCT Study Using a Fitbit Device to Improve Exercise Tolerance in 80 Patients With Cystic Fibrosis|INTERACT|Children's Hospital Boston|No|Not yet recruiting|February 2016|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02700243||1554|
NCT02703662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio_ Mesh|Performance of Biologic Mesh Materials in Abdominal Wall Reconstruction|Performance of Biologic Mesh Materials in Abdominal Wall Reconstruction - A Randomized Controlled Trial||University of Calgary|No|Not yet recruiting|March 2016|December 2019|Anticipated|February 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02703662||1291|
NCT02708966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSIG|Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.|Effect of the Administration of Gymnema Sylvestre on Glycemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance.||University of Guadalajara|No|Recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|59 Years|No|||March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708966||884|
NCT02709044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP01|Fluid Resuscitation in Acute Pancreatitis|Randomized Trial of Standard vs. Enhanced Hydration in Patients With a Diagnosis of Acute Pancreatitis Within the First Hour of the Diagnosis||University Hospital Rijeka||Recruiting|February 2016|September 2018|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|903|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02709044||878|
NCT02709057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2D-GENÈ|Lifestyle Intervention in Individuals With Low or High Genetic Risk for Type 2 Diabetes|Effect of Lifestyle Intervention on Incident Diabetes in Individuals With Impaired Fasting Glucose and Low or High Genetic Risk for the Development of Type 2 Diabetes|T2D-GENE|University of Eastern Finland|No|Not yet recruiting|March 2016|June 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|1200|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02709057||877|
NCT02712554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCT-007|A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route|A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route||Charleston Laboratories, Inc||Completed|June 2015|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 17, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712554||608|
NCT02697747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC|Identification of L3-L4 Interspace in Parturients|Identification of L3-L4 Interspace in Parturients||Beth Israel Deaconess Medical Center|No|Recruiting|November 2015|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Female|12 Years|65 Years|No|Non-Probability Sample|Pregnant female patients.|February 2016|February 29, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02697747||1746|
NCT02702089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surg05/15|Hartmann's Versus Intersphincetric APE: A Prospective, Multicentre Study|Hartmann's Versus Intersphincetric APE: A Prospective, Multicentre Study|HiP|Countess of Chester NHS Foundation Trust|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Frail patients with rectal cancer|March 2016|March 3, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702089||1412|
NCT02712047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201499|A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.|A Randomised, Placebo-controlled, Double-blind, Two Period Crossover Study to Characterise the Exhaled Nitric Oxide Time Profile as a Biomarker of Airway Inflammation in Adult Asthma Patients Following Repeat Administration of Inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.||GlaxoSmithKline|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02712047||647|
NCT02696265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9227|CFAEs Guided Ablation Versus PVI in Persistent AF|Complex Fractionated Atrial Electrocardiograms (CFAEs) Guided Ablation Versus Pulmonary Vein Isolation Guided Ablation in Persistent Atrial Fibrillation, a Multicenter Randomized Trial|CIPA|Diagram B.V.|No|Not yet recruiting|April 2016|October 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696265||1860|
NCT02709135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00036229|PARA-HEART Pilot Implementation|Can Pre-Hospital Use of the HEART Score and Abbott i-STAT® Point-of-Care Troponin Predict Major Adverse Cardiovascular Events: the PARA-HEART Pilot Implementation|PARA-HEART|Wake Forest Baptist Health|No|Not yet recruiting|March 2016|May 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|N/A|No|Probability Sample|Adult patients with symptoms concerning for acute coronary syndrome who are being        transported to the Wake Forest Baptist Medical Center Emergency Department by paramedics        trained to complete a HEART Score and POC troponin assessment will be eligible for        inclusion in this quality surveillance study.|March 2016|March 9, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02709135||871|
NCT02716831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501003366|The INSPIRE Project: Innovations in Psychological Interventions for Regulating Eating|Addressing Weight History to Improve Behavioral Treatments for Bulimia Nervosa|INSPIRE|Drexel University|Yes|Recruiting|May 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02716831||279|
NCT02713854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP-EB-2016-protocol-v1|BAP-EB as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of IVF Treatment|Human Embryonic Stem Cell-derived Trophoblastic Spheroid (BAP-EB) as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of in Vitro Fertilization Treatment||The University of Hong Kong|No|Not yet recruiting|March 2016|March 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|240|||Female|18 Years|42 Years|No|||March 2016|March 18, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713854||508|
NCT02704182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS in TKA|Transcranial Direct Current Stimulation for Postoperative Pain in Knee Arthroplasty|Role of Transcranial Direct Current Stimulation (tDCS) in Reduction of Pain and Postsurgical Opioid Consumption in Total Knee Arthroplasty (TKA)|TDCSTKA|Assiut University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|30 Years|60 Years|No|||February 2016|March 8, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02704182||1251|
NCT02696343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNL IRB Project ID #15446|Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants|Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants||University of Nebraska Lincoln|Yes|Not yet recruiting|April 2016|March 2021|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|180|||Both|N/A|24 Months|No|||March 2016|March 1, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696343||1854|
NCT02702310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU/VICC 151608|Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides|Prospective Observational Trial of Low-Dose Total Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|February 2016|March 2020|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|The high volume of cutaneous lymphoma patients seen at Vanderbilt makes it likely to        significantly contribute to the knowledge about this treatment technique. Given the rarity        of this disease, with Vanderbilt being a major treatment center for mycosis fungoides, the        goal is to systematically contribute to the data for low-dose total skin electron therapy        in order to prospectively assess these endpoints. It is expected to find skin        manifestations of mycosis fungoides that are refractory or have relapsed on at least one        prior therapy. Patients with prior skin electron therapy, including either high or        low-dose total skin electron therapy, are permitted on this protocol if the radiation        oncologist determines that low-dose radiation therapy can safely carried out. The goal is        to assess quality of life and accurately grade skin findings following this        non-experimental, standard of care, total skin electron radiation treatment.|March 2016|March 2, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702310||1395|
NCT02706041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-16-0104|Damage Control Laparotomy|Damage Control Laparotomy: A Randomized Controlled Trial||The University of Texas Health Science Center, Houston|Yes|Not yet recruiting|September 2016|April 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|16 Years|N/A|No|||March 2016|March 14, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02706041||1108|
NCT02708875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14086|Microvascular Insulin Resistance and Mixed Meal Challenge|Microvascular Insulin Resistance and Mixed Meal Challenge||Menzies Institute for Medical Research|No|Recruiting|December 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02708875||891|
NCT02649673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 314|LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies|Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies||SCRI Development Innovations, LLC|No|Recruiting|March 2016|August 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649673||5431|
NCT02649686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I229|Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab|A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab||Canadian Cancer Trials Group|Yes|Not yet recruiting|January 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02649686||5430|
NCT02656368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAM-SEB_FC-01|Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis|Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis||Kamedis Ltd.|Yes|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2015|January 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02656368||4918|
NCT02658461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29123|An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)|Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)||Hoffmann-La Roche||Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|36|||Female|18 Years|N/A|No|Probability Sample|Adult females with HER2-positive EBC who participated in the parent study MO22982 will be        observed in this non-interventional study.|February 2016|February 18, 2016|January 11, 2016|No|Yes||No|February 18, 2016|https://clinicaltrials.gov/show/NCT02658461||4757|The focus of the observation in this study was the HCP rather than the person being treated, so number of observations is reported everywhere instead of number of participants. Number of participants was not collected.
NCT02716129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0000871235|The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section|Post-cesarean Section Analgesic Potency and Side Effects of Intrathecal Morphine and Nalbuphine||Assiut University|No|Not yet recruiting|March 2016|November 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Female|18 Years|40 Years|No|||March 2016|March 22, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716129||333|
NCT02710279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9615|Response to Social Rejection in Suicidal Behavior|Response to Social Rejection in Suicidal Behavior|SADS-CS|University Hospital, Montpellier|No|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|140|||Female|18 Years|65 Years|No|||October 2015|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710279||783|
NCT02710305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS1|Oral Hyoscine Butyl Bromide With Cervical Lidocaine Cream in Reducing Pain During Hysterosalpingography|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide With Cervical Lidocaine Cream in Reducing Pain During Hysterosalpingography|HBTB|Assiut University|Yes|Not yet recruiting|April 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Female|20 Years|45 Years|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710305||781|
NCT02710370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108642|Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans|Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans||University of Pittsburgh|No|Enrolling by invitation|February 2016|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|32|Samples Without DNA|Intestinal samples, serum and plasma will be collected from patients who have had gastric      bypass surgery. Tissue samples will be processed for histo-morphological examination and for      RNA, protein and metabolomics analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who plan to undergo gastric bypass, with or without Type 2 Diabetes.|March 2016|March 9, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02710370||776|
NCT02711670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01417|Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium|Night-time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium||VA New York Harbor Healthcare System|No|Recruiting|February 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|February 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02711670||676|
NCT02711683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AF-CRF-2015-027|DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil|DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil : A Multi Center, Prospective Cohort Stud||First Affiliated Hospital Xi'an Jiaotong University|No|Not yet recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|50 Years|85 Years|No|Probability Sample|Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil|February 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711683||675|
NCT02716636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201509756|Fast Versus Slow Tenaculum Placement|Fast Versus Slow Tenaculum Placement for Office Procedures: A Randomized Controlled Trial||University of Iowa|No|Not yet recruiting|April 2016|January 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02716636||294|
NCT02716649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JonatanAttergrim201603071955|Does an Indian Version of the International Classification of Disease Injury Severity Score Predict Mortality in Four Public Hospitals in Urban India?|Does an Indian Version of the International Classification of Disease Injury Severity Score Predict Mortality in Four Public Hospitals in Urban India?||Karolinska Institutet|No|Active, not recruiting|January 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|16047|||Both|N/A|N/A|No|Non-Probability Sample|Trauma patients presenting to four public university hospitals in urban India|March 2016|March 22, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02716649||293|
NCT02703129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0311.0.203.000-11|Nutritional Intervention in Migraine|Nutritional Intervention Fin Migraine: A 12-week Open Study||Federal University of Minas Gerais|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|N/A|No|||March 2016|March 3, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02703129||1332|
NCT02710409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT031|A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older|A Double-blind,Randomized,Positive-controlled, Non-inferiority Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Chinese Subjects Aged 3 Years and Older||Jiangsu Province Centers for Disease Control and Prevention|No|Recruiting|January 2016|October 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|3664|||Both|3 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 12, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02710409||773|
NCT02708056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 16-67|Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants|Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study||Baskent University||Completed|January 2015|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|1 Month|12 Months|No|||March 2016|March 9, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708056||954|
NCT02711696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD_GE_2013|Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet Among Celiacs [GluCED]|Randomized Clincal Trial on the Efficacy of a Restricted Gluten Contamination Elimination Diet in Determining Complete Mucosal Healing Among Celiac Patients With Persisting Minimal Lesions During Gluten Free Diet [GluCED]|GluCED|Università degli Studi di Brescia|No|Completed|March 2014|January 2016|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02711696||674|
NCT02713425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-000162|Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study|Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study||Mayo Clinic|No|Not yet recruiting|July 2016|August 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713425||541|
NCT02696226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Subclinical Leaflet Thrombosis|Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.|A Pilot Study of Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves: A Randomized Controlled Trial||The Cleveland Clinic|No|Recruiting|February 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02696226||1863|
NCT02708121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00059364|Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients|Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients||Duke University|Yes|Not yet recruiting|June 2017|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708121||949|
NCT02708134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-012099|Quality of Pediatric Resuscitation in a Multicenter Collaborative|Quality of Pediatric Resuscitation in a Multicenter Collaborative: An Observational Study|pediRES-Q|Children's Hospital of Philadelphia|No|Recruiting|March 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|37 Weeks|18 Years|No|Non-Probability Sample|Data will be collected from pediatric cardiac arrest events as part of standard clinical        operations.|March 2016|March 24, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02708134||948|
NCT02718001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-05C|Edwards Lifesciences CardiAQ™ Transcatheter Mitral Valve Replacement (TMVR) Early Feasibility Study|Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems) For the Treatment of Moderate to Severe Mitral Regurgitation||Edwards Lifesciences|Yes|Recruiting|February 2015|December 2021|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718001||189|
NCT02713958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-15-2296-RP-CTIL|The Efficacy of Telerehabilitation Program for Improvement of Upper Limb Function Among Adults Post Elbow Fractures|The Efficacy of Telerehabilitation Program for Improvement of Upper Limb Function Among Adults Post Elbow Fractures||Sheba Medical Center|No|Enrolling by invitation|March 2016|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713958||500|
NCT02705690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stannah_Balance_01|Benchmarking the iOS Balance Application Against the Berg Balance Test|Benchmarking the iOS Balance Application Against the Berg Balance Test|BBAaBBT|Stannah Stairlifts|Yes|Not yet recruiting|May 2016|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705690||1135|
NCT02701023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-000080|Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma|Individual Patient Expanded Access - MitoGel for Upper Urinary Tract Urothelial Carcinoma||Jonsson Comprehensive Cancer Center||Available||||||N/A|Expanded Access|N/A|||||||Male|76 Years|77 Years||||March 2016|March 7, 2016|March 2, 2016|No|Yes||||https://clinicaltrials.gov/show/NCT02701023||1494|
NCT02713828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0504|Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung|A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung|PrE0504|PrECOG, LLC.|Yes|Not yet recruiting|March 2016|August 2020|Anticipated|April 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713828||510|
NCT02704130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-16-23B|TACE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma|Transarterial Chemoembolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial||Carolinas Medical Center|Yes|Recruiting|March 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704130||1255|
NCT02706184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKES-EcNO-2015|E. Coli Nissle in Oncology|Randomized, Placebo Controlled Phase III Trial of a Microbiological Concomitant Therapy/Prevention of Chemotherapeutical Induced Diarrhea (Caused by Inflammation and an Impaired Intestinal Barrier) With E. Coli Nissle 1917 (EcN)-Suspension in Patients With Gastric and Colorectal Cancer|EcNO|University of Hohenheim||Recruiting|July 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02706184||1097|
NCT02709720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP 15/02_NORA|Locally Advanced Trial of Tri-weekly Metronomic Oral Vinorelbine and Cisplatin as Induction Therapy and Subsequent Concomitance With Radiation Therapy in Patients With Unresectable Non Small Cell Lung Cancer (NSCLC)|Phase II Clinical Trial With Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy and Subsequent Concomitantly With Radiotherapy (RT) in Patients With Lung Cancer (NSCLC) Locally Advanced Unresectable|NORA|Spanish Lung Cancer Group|Yes|Not yet recruiting|March 2016|April 2021|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|75 Years|No|||February 2016|March 15, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02709720||826|
NCT02715856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0966|Using Telemonitoring to Optimize the Mobility of Cancer Survivors With Skeletal Metastases After Surgery to Preserve Limb Function|Using Telemonitoring to Optimize the Mobility of Cancer Survivors With Skeletal Metastases After Surgery to Preserve Limb Function||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715856||354|
NCT02699918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Agiradom|Impact of Obstructive Sleep Apnea Syndrome on Metastatic Potential of Cutaneous Melanoma: Prospective Study in Patients With High Risk Melanoma.|Impact of Obstructive Sleep Apnea Syndrome on Metastatic Potential of Cutaneous Melanoma : Prospective Study in Patients With High Risk Melanoma|MELA-SAS|AGIR à Dom|No|Recruiting|December 2015|||January 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|166|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02699918||1579|
NCT02702401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-240|Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)|A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)||Merck Sharp & Dohme Corp.|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|408|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702401||1388|
NCT02702453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00107048|True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners|True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners||University of Michigan||Not yet recruiting|March 2016|May 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|284|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702453||1384|
NCT02702466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSKA|Active Prevention of Upper Limb Musculoskeletal Disorders in Thermal Environment (MUSKA).|Evaluation of the Effectiveness of Personalized Short and Intensive Educational SPA Therapy Prevention of Upper Limb Musculoskeletal Disorders (MSDs).|MUSKA|Association Francaise pour la Recherche Thermale|Yes|Recruiting|September 2015|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|65 Years|No|||February 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702466||1383|
NCT02715869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009901|Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery|Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery||Assiut University|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|60 Years|No|||March 2016|March 22, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715869||353|
NCT02715882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL612-CBLB502|Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer|Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens||BioLab 612 LLC|No|Recruiting|November 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715882||352|
NCT02700178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-008240|Biofeedback for Wheelchair Users|Development of a Biofeedback Intervention to Reduce the Risk of Upper Extremity Overuse Injury Following Paraplegia and Tetraplegia||Mayo Clinic|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|60 Years|No|||February 2016|March 1, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02700178||1559|
NCT02700191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL-72-030|Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial|Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial||Kyma Medical Technologies|No|Not yet recruiting|April 2016|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|20 Years|90 Years|No|||March 2016|March 6, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700191||1558|
NCT02711072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tunisian hh2|Continuous Infusion for Pain Relief|Comparaison of Continuous Infusion of Local Anesthetic and Intrathecal Morphine for Pain Management in Elective Caeserean Section||Tunisian Military Hospital|No|Not yet recruiting|March 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711072||722|
NCT02708810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F150608005|RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery|RAD 1501: A Phase II Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery||University of Alabama at Birmingham|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|99 Years|No|||March 2016|March 9, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02708810||896|
NCT02710981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH1|Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium|Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial||Assiut University|No|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|20 Years|40 Years|No|||March 2016|March 16, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710981||729|
NCT02711020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fibro2016|Psychological Treatment of Depression in Women With Fibromyalgia|Psychological Treatment of Depression in Women With Fibromyalgia: Differential Efficacy and Factors Predictive of Outcome|PCTFORDEPFM|University of Barcelona|No|Recruiting|March 2016|March 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|70 Years|No|||March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711020||726|
NCT02713386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG-GY007|Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||NRG Oncology|No|Not yet recruiting|May 2016|||September 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713386||544|
NCT02713399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-150116|High-resolution Imaging of Tear Film Thickness in Contact Lenses Wearers With Optical Coherence Tomography (OCT). A Pilot Study|High-resolution Imaging of Tear Film Thickness in Contact Lenses Wearers With Optical Coherence Tomography (OCT). A Pilot Study||Medical University of Vienna|No|Recruiting|March 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A||Probability Sample|15 soft contact lens wearers 15 rigid contact lens wearers|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713399||543|
NCT02696733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/1/2014|Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach|Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach||Medical University of Warsaw|No|Recruiting|July 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02696733||1824|
NCT02700269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRT15003.2|Vanderbilt-Zambia Innovations in Global Health Technologies|Vanderbilt-Zambia Innovations in Global Health Technologies|VZNIGHT|Macha Research Trust, Zambia||Not yet recruiting|April 2016|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|6 Months|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those seeking care for suspected malaria in Zambia|February 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02700269||1552|
NCT02700282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01467-42|Backpack Carrying in Children With Cystic Fibrosis|Impact of Backpack Position on Lung Function and Oxygen Consumption in School-aged Children With Cystic Fibrosis||Groupe Hospitalier du Havre|No|Recruiting|March 2016|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|27|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02700282||1551|
NCT02700048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI # 22405|Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia|Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|May 2016|December 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700048||1569|
NCT02700061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910.0.015.000-11|Effects of Upper Limb Motor and Robotic Training Over Neuroplasticity and Function Capacity|Effects of Upper Limb Motor Training and Upper Limb Robotic Training Over Neuroplasticity and Function Capacity: A Single-blind Randomized Clinical Trial With Patients With Stroke Sequelae|NARLE1|University of Sao Paulo General Hospital|Yes|Active, not recruiting|February 2012|February 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||August 2015|March 1, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02700061||1568|
NCT02716389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpM2016-001|Cervical Kinematics' Reliability: Zero Positioning Using a 3-D-bulls Eye Spirit Level|||Goethe University||Not yet recruiting|March 2016|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02716389||313|
NCT02705261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246529|Coaching for Confidence: Evaluating an Internet-based Program to Help Parents Help Children With Difficulty With Anxiety|Coaching for Confidence: Evaluating an Internet-based Program to Help Parents Help Children With Difficulty With Anxiety||University of Manitoba|No|Recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|4 Years|12 Years|No|||March 2016|March 9, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705261||1168|
NCT02711163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-2014-02-ALYCE|Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula|Evaluation of the Hypoallergenicity of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow's Milk Protein Allergy|ALYCE|United Pharmaceuticals|No|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|1 Month|36 Months|No|||March 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02711163||715|
NCT02695758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016Nam2|Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA|Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing Shoulder Arthroplasty (TSA): A Randomized Trial||Rothman Institute Orthopaedics|No|Completed|December 2014|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695758||1899|
NCT02704273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-MTM-009 INCEPTUS|A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects|INCEPTUS: A Prospective, Non-Interventional Clinical Assessment Study in X Linked Myotubular Myopathy (XLMTM) Subjects Aged 3 Years and Younger|INCEPTUS|Audentes Therapeutics|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Male|N/A|3 Years|No|Non-Probability Sample|XLMTM subjects aged 3 years and younger.|March 2016|March 14, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704273||1244|
NCT02704806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cthromb20160401|Immunologic Analysis of Peripheral Blood and Aspirated Thromb In AMI Patients|Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients|ATAIA|Jilin University|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Thromb will be abtained with aspiration device during PCI intervention, peripheral blood      will be abtained as well for study.|Both|30 Years|80 Years|No|Probability Sample|Acute myocardial infarction patients|March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02704806||1203|
NCT02718521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16kds2|Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN|Chinese People's Liberation Army General Hospital||Chinese PLA General Hospital|Yes|Active, not recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|80 Years|No|||March 2016|March 19, 2016|March 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02718521||149|
NCT02701387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA Megagen AnyRidge ISQ|Effect of Implant Thread Design on Implant Stability Quotient (ISQ) in Early Healing Period|The Effect of Implant Macro-Thread Design on Implant Stability in the Early Post-Operative Period: A Randomized, Controlled Pilot Study||University of California, Los Angeles|No|Completed|August 2014|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02701387||1466|
NCT02706067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16868|Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults|Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Patients||Hoffmann-La Roche||Completed|July 2002|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706067||1106|
NCT02704819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/0336|Proof of Concept Study of EMBalance Decision Support System to Evaluate Balance Disorders|A Decision Support System Incorporating a Validated Patient-specific, Multi-scale Balance Hyper Model Towards Early Diagnostic Evaluation and Efficient Management Plan Formulation of Balance Disorders (EMBalance)|EMBalance|University College, London|No|Not yet recruiting|March 2016|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|90 Years|No|||February 2016|March 4, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02704819||1202|
NCT02706899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN33A-004|Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS|A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)||Seattle Genetics, Inc.|Yes|Recruiting|February 2016|June 2019|Anticipated|May 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706899||1043|
NCT02718820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PemDoc II|Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer|Immunomodulation of Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) After Platinum Failure||Medical University of Vienna|No|Recruiting|March 2016|August 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02718820||126|
NCT02697513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01|The 'Bekele Afessa Scan-Teach-Treat Approach'|The 'Bekele Afessa Scan-Teach-Treat Approach' to Improve Care of Patients With Acute Infection at the Gitwe Hospital in Gitwe/Rwanda||University of Salzburg|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|N/A|N/A|No|||February 2016|March 2, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02697513||1764|
NCT02708589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600|The Effects of Probiotic Supplementation on the Results of Gastric Bypass Surgery|The Effects of Probiotic Supplementation on Anthropocentric, Nutrients Status, Inflammation, GI Hormones, Quality of Life, and Microflora in Patients Undergoing Gastric Bypass Surgery||National Nutrition and Food Technology Institute||Recruiting|September 2015|||September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|14 Years|70 Years|No|||March 2016|March 9, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02708589||913|
NCT02718131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF107|A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)|A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)|NF107-BMP2|University of Alabama at Birmingham|Yes|Not yet recruiting|March 2016|December 2021|Anticipated|May 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|54|||Both|2 Years|18 Years|No|||March 2016|March 23, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02718131||179|
NCT02704598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.|Comparison of Recanalization Rate of Deep Venous Thrombosis in Lower Limbs in Patients Undergoing Treatment With Rivaroxaban Versus Warfarin.|DVT|Hospital do Servidor Publico Estadual|Yes|Recruiting|October 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|79 Years|No|||March 2016|March 4, 2016|February 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704598||1219|
NCT02703142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NagasakiU|Endoscopic Evaluation After Esophagectomy|Endoscopic Evaluation for the Postoperative Condition After Esophagectomy and Reconstruction||Nagasaki University|Yes|Recruiting|October 2015|December 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|dmp-DNA|Both|20 Years|84 Years|No|Probability Sample|Patients undergo an esophagectomy with reconstruction by a gastric pull-up for malignant        or end-stage benign esophageal disease. The patients have a cervical esophagogastrostomy.|March 2016|March 8, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02703142||1331|
NCT02703155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HM13|The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes|The Use of Self-Administered Electronic Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes in Children With Cystic Fibrosis|HomeOGTT|Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|10 Years|17 Years|No|||March 2016|March 3, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02703155||1330|
NCT02701010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|-1491-160-12/1648.4-5263|Behavioural Therapy Program for Female Overactive Bladder|Comparative Effectiveness of Three Different Teaching Methods in Behavioural Therapy Program for Female Overactive Bladder: A Randomized Controlled Trial||Gulhane Military Medical Academy|Yes|Completed|November 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701010||1495|
NCT02701465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|666|Blood Flow - an Underlying Mechanism Behind Clinical Improvements in Patients With Subacromial Pain Syndrome?|Blood Flow - an Underlying Mechanism Behind Clinical Improvements in Patients With Subacromial Pain Syndrome?||Norwegian University of Science and Technology|No|Recruiting|January 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701465||1460|
NCT02719821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW15080|Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation|Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation||University of Wisconsin, Madison|Yes|Not yet recruiting|April 2016|October 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|18|||Both|18 Years|74 Years|No|||March 2016|March 24, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02719821||49|
NCT02697474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L49|Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.|Persistence of Anti-Hep B Antibodies at 9 to 10 Years of Age in Subjects Having Received Hep B Vaccine at Birth and a DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine at 2, 4 and 6 Months of Age, and Evaluation of Their Immune Memory Following a Challenge Re-vaccination With a Stand Alone Hep B Vaccine||Sanofi|No|Enrolling by invitation|February 2016|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|393|||Both|9 Years|10 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02697474||1767|
NCT02697487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092015-049|UTSW Depression Cohort: A Longitudinal Study of Depression|UTSW Depression Cohort: A Longitudinal Study of Depression||University of Texas Southwestern Medical Center|No|Recruiting|February 2016|February 2027|Anticipated|February 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|Samples With DNA|Biospecimens being studied is as follows:        1. Blood        2. Normal Tissue        3. Saliva        4. Urine        5. Clinical waste products to include surgical waste tissue samples, placenta samples, and           biopsy samples.|Both|10 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|The following groups are being targeted for this observational study:          1. depressed patients,          2. depressed patients with comorbid illnesses, and          3. non-depressed patients.|March 2016|March 21, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697487||1766|
NCT02712021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27711/14|Effects of Lycra Suits in Children With Cerebral Palsy||CP|Catholic University, Italy||Not yet recruiting|April 2016|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|4 Years|12 Years|No|||March 2016|March 16, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712021||649|
NCT02716584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 I21 RX002026|Benefits of Physical Exercise in Schizophrenia|Physical Exercise Effects on Determinants of Social Integration in Schizophrenia||VA Greater Los Angeles Healthcare System|No|Not yet recruiting|June 2016|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|45 Years|65 Years|No|||March 2016|March 17, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02716584||298|
NCT02716818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUR-005|Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia|A Phase III Study of Efficacy, Safety and Tolerability of Chronocort® Compared With Standard Glucocorticoid Replacement Therapy in the Treatment of Congenital Adrenal Hyperplasia||Diurnal Limited|Yes|Recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716818||280|
NCT02702596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15MD010220-01|METRIC: Measurement, Education and Tracking in Integrated Care|METRIC: Measurement, Education and Tracking in Integrated Care: Strategies to Increase Patient Engagement and Reduce Mental Health Disparities Among Hispanics||The University of Texas at Arlington|No|Enrolling by invitation|February 2016|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702596||1373|
NCT02711332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K@Home_1|Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling|Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling||Medical University of Graz|No|Completed|June 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Communtiy Sample|March 2016|March 11, 2016|November 24, 2015||No||No||https://clinicaltrials.gov/show/NCT02711332||702|
NCT02696278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47364-I|Hummus for Health: Dietary Quality and Health Outcomes in Toddlers|Hummus for Health: Dietary Quality and Health Outcomes in Toddlers||Baylor College of Medicine|No|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|104|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||March 2016|March 8, 2016|December 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02696278||1859|
NCT02696070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI.2015.002|Nociceptive Pain Fiber Response|A Multi-Center, Randomized, Sham-Controlled, Double-Blind Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Small Fiber Nerve Growth and Function in Subjects With Painful Peripheral Diabetic Neuropathy||Regenesis Biomedical, Inc.|No|Recruiting|July 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|6|||Both|22 Years|80 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696070||1875|
NCT02696083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI.2015.004|Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee|A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee||Regenesis Biomedical, Inc.|No|Recruiting|January 2016|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696083||1874|
NCT02713867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-384|A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks|A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks|CheckMate 384|Bristol-Myers Squibb|Yes|Not yet recruiting|March 2016|May 2022|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713867||507|
NCT02705950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014187|Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.|Effect of Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP) in Spinal Cord Injury (SCI) Patients. Preliminary Study.|ITB|Institut Guttmann|No|Recruiting|December 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705950||1115|
NCT02705963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMT212X2102|A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors|A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors||Novartis|No|Not yet recruiting|June 2016|November 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|59 Years|No|||March 2016|March 7, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705963||1114|
NCT02711358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDO|Indomethacin Use in Pain Relief During Intrauterine Device Insertion|Rectal Indomethacin Use in Pain Relief During Intrauterine Device Insertion: A Randomized Controlled Trial|INDO-IUD|Assiut University|Yes|Not yet recruiting|May 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|N/A|N/A|No|||March 2016|March 16, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711358||700|
NCT02711215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.4_20160303|Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)|||Medical University of Vienna||Recruiting|May 2015|||March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711215||711|
NCT02700802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB16-0308|The Feed1st Trial: Promoting Health of Caregivers With a Hospitalized Child Using Self-Management to Mitigate Hunger|||University of Chicago|No|Not yet recruiting|November 2016|August 2021|Anticipated|August 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|470|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02700802||1511|
NCT02706886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-GO1-001|Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1|A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1||Alnylam Pharmaceuticals|No|Recruiting|March 2016|February 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02706886||1044|
NCT02718508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA024185-01|An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use|An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use|e-Parenting|Rhode Island Hospital|Yes|Recruiting|September 2015|August 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02718508||150|
NCT02718807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3980|Rapid Prototyping Models for Patient Education|Use of 3-D Printed Models to Improve Patient Understanding During the Informed Consent Process: A Pilot Study||Milton S. Hershey Medical Center|No|Not yet recruiting|May 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Post-partum women and respective co-parents who are greater than 18 years of age and        fluent in the English language.|March 2016|March 18, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02718807||127|
NCT02702323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead-H302|Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study|Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study||Zhejiang Cancer Hospital|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702323||1394|
NCT02702622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-376|Vitamin A Equivalence of the Provitamin A in Biofortified Bananas|||Iowa State University||Not yet recruiting|March 2016|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study|||||||Female|18 Years|40 Years||||March 2016|March 7, 2016|March 3, 2016||||No||https://clinicaltrials.gov/show/NCT02702622||1371|
NCT02708316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AF-CRS-2015-009|The Gut Metagenome Research of Schizophrenia|The Gut Metagenome Research of Schizophrenia||First Affiliated Hospital Xi'an Jiaotong University||Not yet recruiting|April 2016|December 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|stool samples retained for sequencing faecal metagenome|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cases included the first episode or recurrent acute-exacerbation schizophrenia        patients who correspond to the DSM-Ⅵ diagnostic criteria. The healthy population is        matched with cases based on gender, age, nationality, smoking, diet, education and        socioeconomic status.|March 2016|March 15, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02708316||934|
NCT02710591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EspeRare_RIM_001|Rimeporide in Patients With Duchenne Muscular Dystrophy|A Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular Dystrophy|RIM4DMD|EspeRare Foundation|Yes|Recruiting|March 2016|March 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|6 Years|14 Years|No|||March 2016|March 11, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02710591||759|
NCT02654249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THD_LIGA_RCT|Prospective Randomized Trial About THD Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids|Prospective Multicenter Randomized Trial About Transanal Hemorrhoidal Dearterialization With Mucopexy (THD) Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids|THD-LIGA|Hospital Universitari de Bellvitge|No|Recruiting|December 2015|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|76 Years|No|||January 2016|March 23, 2016|December 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02654249||5081|
NCT02712164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016P000030|Molecular, Histologic, and Clinical Analysis of Negative Pressure Wound Therapy (NPWT) for Split-thickness Skin Graft (STSG) Donor Sites|Molecular, Histologic, and Clinical Analysis of Negative Pressure Wound Therapy (NPWT) for Split-thickness Skin Graft (STSG) Donor Sites||Brigham and Women's Hospital|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||March 2016|March 14, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02712164||638|
NCT02699177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0366-15-HMO-CTIL|In Vivo Measurements of Nasal Ciliary Beat Frequency by Using Interferometry|In Vivo Measurements of Nasal Ciliary Beat Frequency by Using Interferometry||Hadassah Medical Organization|No|Not yet recruiting|April 2016|July 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|nasal brush biopsies, EM samples|Both|18 Years|60 Years|No|Non-Probability Sample|Patients with suspected PCD|February 2016|February 29, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02699177||1636|
NCT02699190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00000082|New Diagnostic and Therapeutic Approaches in Leukodystrophy|LeukoSEQ: A CLIA-certified Whole Genome Sequencing Study for Recently Identified and Unsolved Leukodystrophies|LeukoSEQ|Children's Research Institute|No|Recruiting|November 2015|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|18 Years|No|||March 2016|March 1, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02699190||1635|
NCT02708953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0983|Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial|Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial||University of Colorado, Denver|No|Not yet recruiting|May 2016|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|60 Years|No|||March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708953||885|
NCT02700074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3077E|Brain Mechanisms for Language Processing in Adolescents With Autism Spectrum Disorder|ACE (Autism Center of Excellence): Brain Mechanisms for Language Processing in Adolescents With Autism Spectrum Disorder|BSL|Boston University|Yes|Recruiting|February 2015|August 2018|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|220|||Both|14 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2016|March 4, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02700074||1567|
NCT02713165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201500607|Effects of Adding Raisins to the American Diet on Fecal Microbiota Composition|Effects of Adding Raisins to the American Diet on Fecal Microbiota Composition||University of Florida|No|Recruiting|January 2016|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713165||561|
NCT02707900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1626|Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection|IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)|VORVAX|University of North Carolina, Chapel Hill|Yes|Not yet recruiting|March 2016|December 2019|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707900||966|
NCT02709005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0021|Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting|April 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|50 Years|No|||March 2016|March 17, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709005||881|
NCT02720406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AssuitUniversity|Topical Ketamine Analgesia in Children Undergoing Tonsillectomy: a Clinical and Serum Level Assays Study.|Topical Ketamine by Neubulization Method in Tonsillectomy||Assiut University|Yes|Recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|7 Years|12 Years|No|||March 2016|March 24, 2016|March 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02720406||4|
NCT02720419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2016-03|IRIS-Synergy Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Synergy™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|IRIS Synergy|Asan Medical Center|Yes|Not yet recruiting|April 2016|June 2025|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with Synergy stent|March 2016|March 22, 2016|March 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02720419||3|
NCT02717676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSS|Prediction of Perineal Tears by Striae Gravidarum Score|Prediction of Perineal Tears During Labor by Estimation of Striae Gravidarum Score|TSS|Assiut University|Yes|Not yet recruiting|March 2016|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Female|N/A|N/A|No|||March 2016|March 18, 2016|March 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717676||214|
NCT02717689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma|A Randomised Pragmatic Trial Of Corticosteroid Optimisation In Severe Asthma Using A Composite Biomarker Algorithm To Adjust Corticosteroid Dose Versus Standard Care||Belfast Health and Social Care Trust|Yes|Recruiting|January 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02717689||213|
NCT02700672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Falls&Cognition&Gait|Influence of Cognition and Gait on Falls|Predicting Falls Among Institutionalized and Non-institutionalized Older Adults: The Role of Cognition and Gait Speed|ICGF|Federal University of São Paulo|No|Completed|January 2013|March 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twenty-five individuals living in a long term care facility and twenty-five older adults        from community|March 2016|March 2, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02700672||1521|
NCT02700685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pycno 2015-14|Effect of Pycnogenol® on ADHD|Effect of Pycnogenol® Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial||Universiteit Antwerpen||Not yet recruiting|April 2016|March 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|6 Years|12 Years|No|||March 2016|March 4, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02700685||1520|
NCT02709096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPX-01-C02|BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes|BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes||BioPharmX, Inc.|No|Not yet recruiting|April 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709096||874|
NCT02709109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15-371-101|A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi||Vertex Pharmaceuticals Incorporated||Recruiting|February 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|12 Years|N/A|No|||March 2016|March 9, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709109||873|
NCT02700334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPA-PREDIABETES|Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes|Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes||University of Guadalajara|No|Recruiting|October 2015|February 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|60 Years|No|||March 2016|March 4, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02700334||1547|
NCT02712073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCI V11 01/01/2015|Predictive Score of the Bowel Preparation Quality Based on a Self-administered Questionnaire|Predictive Score of the Bowel Preparation Quality Based on a Self-administered Questionnaire|PREPA-CO|University Hospital, Angers|No|Recruiting|May 2015|September 2017|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1260|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen in precolonoscopy consultation|March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712073||645|
NCT02702297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MuMFI-PPROM|Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes|Multimodales Monitoring Des Fetalen Inflammationsrisikos Bei frühem Vorzeitigen Blasensprung (PPROM)|MuMFI-PPROM|Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|January 2016|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Vaginal Fluid|Female|18 Years|N/A|No|Non-Probability Sample|Women with PPROM-complicated pregnancies who referre to one of the participating tertiary        referreal care centers.|March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02702297||1396|
NCT02710019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McMaster_University|Good Shepherd: Back to Reality Series|Back to Reality Series - Harry's Journey: A Video Game About Under Age||McMaster University|No|Not yet recruiting|April 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|200|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02710019||803|
NCT02706873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-545|A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis|SELECT-EARLY|AbbVie|Yes|Recruiting|February 2016|February 2021|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|975|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706873||1045|
NCT02707432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2576|Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina|Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707432||1002|
NCT02707445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMC-GENIUS|Genotyping Influences Outcome of Coronary Artery Stenting|Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients|GENIUS|Korea University Anam Hospital|Yes|Completed|September 2011|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5000|||Both|20 Years|N/A|No|||March 2016|March 11, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02707445||1001|
NCT02708017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2317-ane-ERC-12|Analgesic Effect of Subcostal TAP Block|The Analgesic Efficacy of Ultrasound Guided Bilateral Subcostal vs. Posterior Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy: A Randomized Controlled Trial|UGS-TAP|Aga Khan University|No|Completed|March 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|70|||Both|18 Years|60 Years|No|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708017||957|
NCT02708095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16270|A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)|A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)||Eli Lilly and Company|No|Not yet recruiting|April 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708095||951|
NCT02697929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SugNeoLTx1.0|Sugammadex/Neostigmine and Liver Transplantation|Sugammadex Versus Neostigmine After Rocuronium Infusion During Liver Transplantation||Azienda Ospedaliera S. Maria della Misericordia|No|Active, not recruiting|January 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02697929||1732|
NCT02704143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Changhai Hosp|Combination of Stereotactic Body Radiation Therapy With S-1 for Treating Locally Advanced Pancreatic Cancer|The Safety and Efficacy of Combination of Stereotactic Body Radiation Therapy With S-1 in Treating Locally Advanced Pancreatic cancer--a Phase II Clinical Trial||Changhai Hospital|No|Not yet recruiting|March 2016|December 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704143||1254|
NCT02711007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUPH-sarcoma|Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy|A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy||Peking University People's Hospital|Yes|Recruiting|March 2016|||September 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|16 Years|N/A|No|||March 2016|March 16, 2016|March 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711007||727|
NCT02709733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033-2015|Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia|Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia||Centre for Addiction and Mental Health|No|Recruiting|January 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|35 Years|No|||March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709733||825|
NCT02712632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016DM03 GoDARTS-Scotland|Genetics of Diabetes Audit and Research in Tayside and Scotland|Genetics of Diabetes Audit and Research in Tayside and Scotland|GoDARTS|University of Dundee|No|Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|At visit 1 blood samples will be collected for DNA and RNA extraction. Urine samples will be      collected to measure for biomarkers. Stool samples will be collected to measure for      microbiota. (Stool samples will only be collected from those patients who are initiated on      metformin therapy during the study period.      For those patients who are commenced on metformin therapy during the study a second study      visit is required where all blood, urine and stool samples will be repeated.|Both|16 Years|N/A|No|Probability Sample|The patients for this study will be identified from the SDRN and SHARE Research Registers.        (These patients have given prior consent to be contacted about research studies.)        Patients will also be selected from secondary and primary care clinics.|February 2016|March 14, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02712632||602|
NCT02704390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-2PN012-301E|Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD||Orient Pharma Co., Ltd.|Yes|Recruiting|January 2016|December 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Years|18 Years|No|||March 2016|March 4, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02704390||1235|
NCT02704403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-315-1|Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis|RESOLVE-IT|Genfit|Yes|Recruiting|March 2016|||December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|February 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704403||1234|
NCT02699749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-931-1002|A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors|An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors||Millennium Pharmaceuticals, Inc.|No|Not yet recruiting|March 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|20 Years|N/A|No|||March 2016|March 21, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02699749||1592|
NCT02703740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15F/IALE01|Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds|Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds|ECLAH|Laboratoires Genévrier||Recruiting|January 2016|February 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02703740||1285|
NCT02703753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC152026|TOP-mums, for a Healthy Start|TOwards Prepared Mums (TOP-mums), for a Healthy Start: A Lifestyle Intervention to Reduce Overweight and Smoking in Women With a Pregnancy Wish to Prevent Perinatal Morbidity||Maastricht University Medical Center|No|Recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|112|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|March 3, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02703753||1284|
NCT02717962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLM-16-001|Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma|Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma||DelMar Pharmaceuticals, Inc.|No|Not yet recruiting|June 2016|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717962||192|
NCT02700958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16003|Remote Ischemic Preconditioning as a Method Against Subclinical Renal Injury and Contrast-induced Nephropathy|Study of Remote Ischemic Preconditioning as a Preventative Method Against Subclinical Renal Injury and Contrast-induced Nephropathy||Tartu University Hospital||Recruiting|February 2016|||August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02700958||1499|
NCT02704468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085/58|FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients|FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients|CAVIFGF21|Bangkok Metropolitan Administration Medical College and Vajira Hospital|Yes|Recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|renal transplant pateints for more than 1 month|March 2016|March 5, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02704468|2 Months|1229|
NCT02704000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38350114.0.0000.0076|Home Visiting Programs to Improve Early Childhood Development and Maternal Mental Health|Home Visiting Programs to Improve Early Childhood Development and Maternal Mental Health - Evidence From the Western Region Cohort Project||University of Sao Paulo|No|Active, not recruiting|January 2015|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|900|||Both|9 Months|17 Months|No|||March 2016|March 3, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02704000||1265|
NCT02704013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pOAB-CHZ-01|Urinary Biomarkers in Overactive Bladder in Children|Role of Urinary Neurotrophin and Cytokine Levels in Diagnosis and Management of Overactive Bladder in Children||Children's Hospital Zagreb|No|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|3 Years|18 Years|No|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704013||1264|
NCT02713633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14010600|Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty|Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty||Children's Hospital of Pittsburgh|No|Recruiting|January 2016|June 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Months|20 Years|No|||March 2016|March 15, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02713633||525|
NCT02713906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMAT007|Materialise X-ray Knee Guides for Total Knee Arthroplasty|Prospective Monocentric Clinical Investigation Using the Materialise X-ray Knee Guides for Total Knee Arthroplasty||Materialise|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02713906||504|
NCT02711800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063870|The Probiotic Study: Using Bacteria to Calm Your Mind|Probiotic Treatment: The Role of the Gut Microbiome in Childhood Abdominal Pain and Anxiety||Duke University|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|9 Years|13 Years|No|||March 2016|March 11, 2016|January 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711800||666|
NCT02695771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 4 Date: 02.18.2016|The Bladder Instillation Comparison Study|A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)|BIC|Spectrum Health Hospitals|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695771||1898|
NCT02711514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR1000R|Femoral Artery Crossover Rates of 1000 Consecutive Radial (or Ulnar) Artery Procedures in the Cardiac Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions.|Femoral Artery Crossover Rates of 1000 Consecutive Radial (or Ulnar) Artery Procedures in the Cardiac Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions|1000 Radials|Miami Cardiac and Vascular Institute||Enrolling by invitation|December 2014|||March 2017|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|35 Years|85 Years|No|Non-Probability Sample|1000 Consecutive Patients who underwent Radial (or Ulnar) Artery Procedures in the Cardiac        Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary        Interventions.|March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711514||688|
NCT02714452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-4016|A Person-centred and Thriving Promoting Care Model for Residential Aged Care|A Person-centred and Thriving Promoting Care Model for Residential Aged Care||Umeå University|No|Recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02714452||462|
NCT02714465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|644-122015|Adverse Radiation Effects After Gamma Knife Radio Surgery and Hyperbaric Oxygen Therapy|Treatment of Adverse Radiation Effects After Gamma Knife Radiosurgery (GKS) by Hyperbaric Oxygen Therapy (HBO)|GKSHBO|Niguarda Hospital|No|Recruiting|March 2016|May 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|10 Years|75 Years|No|||March 2016|March 15, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02714465||461|
NCT02705846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/LO/0072|Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations|Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes|GENPROS|Institute of Cancer Research, United Kingdom|No|Recruiting|September 2014|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1020|Samples With DNA|Saliva or blood samples will be collected from participants to analyse their DNA and look at      genetic modifiers of prostate cancer.      Tumour blocks will also be collected from patients where available.|Male|18 Years|N/A|No|Non-Probability Sample|The study includes a cohort of rare gene mutation carriers with PCa and a control group        formed of PCa patients known not to carry mutations in the same genes for comparison. In        the first instance, carriers of mutations in the BRCA1 and BRCA2 genes will be recruited        and as other gene variants are tested in the clinical and research settings, the        investigators will expand the protocol to examine these associations also.|March 2016|March 7, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02705846||1123|
NCT02711527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW16-008|Activation on LDPC Cortex With Different Acupoints: An fNIRS Study|Activation on Left Dorsolateral Prefrontal Cortex LDPC With Different Acupoint-Combinations for Depression: An fNIRS Study||The University of Hong Kong|No|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||March 2016|March 12, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711527||687|
NCT02714777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1608014|General Anesthesia and Autonomic Nervous System in Children|General Anesthesia and Autonomic Nervous System in Children|ANESPEDIA|Centre Hospitalier Universitaire de Saint Etienne|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|4 Years|8 Years|No|Non-Probability Sample|Children from 4 to 8 years enjoying a scheduled surgery without any infection or trauma        context and performed under general anesthesia|March 2016|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02714777||437|
NCT02705989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM014-001|Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects|A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects||Bristol-Myers Squibb|No|Not yet recruiting|April 2016|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705989||1112|
NCT02696798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16179|A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis|COAST-W|Eli Lilly and Company|No|Not yet recruiting|March 2016|March 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696798||1819|
NCT02714101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031008|Equine-assisted Occupational Therapy for Children With Autism Spectrum Disorder|Effects of Hippotherapy on the Motivation and Social Interaction/Social Communication of Children With Autism||University of Alberta|No|Completed|June 2012|September 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|3 Years|8 Years|No|||March 2016|March 15, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02714101||489|
NCT02719574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2102-HEM-101|Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation|A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation||Forma Therapeutics, Inc.|No|Not yet recruiting|March 2016|July 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719574||68|
NCT02707419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dongnocchi|Action Observation in Knee Replacement|Self-administered Action Observation Treatment Enhance the Efficacy of Inpatient Rehabilitation After Total Knee Replacement: A Randomized Controlled Trial||Fondazione Don Carlo Gnocchi Onlus|No|Completed|April 2014|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02707419||1003|
NCT02696681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150383|Addressing Psychosocial Comorbidities in HIV Treatment and Prevention|Addressing Psychosocial Comorbidities in HIV Treatment and Prevention: Phase 2|APPROACH|University of Miami|No|Not yet recruiting|March 2016|||August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696681||1828|
NCT02707913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BABE-P15-097|Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations|Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations||Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited|Yes|Not yet recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02707913||965|
NCT02706860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL (775)|Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events|||Cairo University||Completed|June 2013|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|94|||Both|42 Years|71 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706860||1046|
NCT02716792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19188|A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer|Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer||Hoffmann-La Roche||Completed|January 2006|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|334|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|March 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716792||282|
NCT02716805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2014-010|Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant|A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)||Ludwig Institute for Cancer Research|No|Not yet recruiting|May 2016|June 2021|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716805||281|
NCT02701855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14DRM_EYEBRAIN|Retina Microvascular Remodeling and Cognitive Function In Hypertension|Retina Microvascular Remodeling and Cognitive Function In Hypertension : Eyebrain|EYEBRAIN|Institute of Cardiometabolism and Nutrition, France|No|Recruiting|October 2014|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|160|||Both|65 Years|N/A|No|Probability Sample|Patients' recruitment will be carried out in two centers to ensure inclusion of both        patients: 1) with hypertension and without cognitive impairment, 2) with hypertension and        with mild cognitive impairment (without dementia) including patients with stable MCI and        converters.        Population size: 160 patients:          -  60 patients with hypertension and no MCI,          -  50 patients with hypertension and stable MCI, without dementia          -  50 patients with hypertension and progressive MCI, without dementia|March 2016|March 2, 2016|August 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02701855||1430|
NCT02696005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109-15-BNZ|Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme|Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme||Bnai Zion Medical Center|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|30 patients suffering from Heart Failure and beginning Rehabilitation Programme|February 2016|February 25, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02696005||1880|
NCT02695797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1504102666|Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody|Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody||Seoul National University Hospital|No|Recruiting|September 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||February 2016|February 29, 2016|June 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02695797||1896|
NCT02695810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-001552-30|The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes|Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes||Steno Diabetes Center|Yes|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|160|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02695810||1895|
NCT02713360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Screen-ICD|Screening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD)|Screening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD) - Screen-ICD||Rigshospitalet, Denmark|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|88|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713360||546|
NCT02713607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|867744|Lipidome and Microbiome Profile of Acne|Lipidome and Microbiome Profile of Acne||University of California, Davis|No|Not yet recruiting|March 2016|||February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713607||527|
NCT02711345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTT462X2101|A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers|A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations||Novartis|No|Not yet recruiting|February 2016|September 2019|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|81|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711345||701|
NCT02700477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. CR001/02/13|Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study|Clinical Evaluation of Fenugreek Seed Extract In Patients With Type- 2 Diabetes: An Add-On Study||Chemical Resources|Yes|Completed|July 2013|August 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|154|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02700477||1536|
NCT02700529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-UBX-003|Ubenimex in Adult Patients With Secondary Lymphedema of The Lower Limb (ULTRA)|Ubenimex in Adult Patients With Secondary Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)||Eiger BioPharmaceuticals||Not yet recruiting|April 2016|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700529||1532|
NCT02700789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13008|Pregnancies of Uncertain Location or Viability Research|Pregnancies of Uncertain Location or Viability Research|PULoVR|University of Nottingham|No|Completed|January 2015|December 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|79|||Female|18 Years|45 Years|No|Non-Probability Sample|Participants will be recruited prospectively from Nurture Fertility, Nottingham, United        Kingdom between 1st January and 31st October 2015. All women undergoing IVF/ICSI treatment        will be invited to participate in the study.        no ultrasonographic evidence of an intrauterine fluid collection, or a yolk sac and/or        fetal pole was clearly visible within the intrauterine fluid collection. Women were also        excluded if no outcome data were available or if, following the reference standard, the        final diagnosis was not known (for example resolving or persistent pregnancies of unknown        location).|March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02700789||1512|
NCT02718196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canapari2.16.16|Testing and Development of a Sleep Training Mobile Health Application|Testing and Development of a Sleep Training Mobile Health Application to Address Sleep Problems in the First Two Years of Life||Yale University|No|Not yet recruiting|April 2016|July 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718196||174|
NCT02718209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-84-15|The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02718209||173|
NCT02711371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART_Can_01|Social and Emotional Brain Function in Cannabis Users|Long-term Effects of Cannabis Use on Social and Emotional Brain Processes in Dependent Cannabis Users After a 28 Day Abstinence Period||University of Electronic Science and Technology of China|No|Active, not recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cannabis dependent individuals|March 2016|March 13, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02711371||699|
NCT02696525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTHO1601|Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients|A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients||Peking University People's Hospital|No|Not yet recruiting|June 2016|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|145|Samples With DNA|Fresh tumor tissue, urine samples and blood samples were collected from each patient.      Time:Preoperative, 3 days and 3、6、12、18、24、30、36 months after surgery.|Both|18 Years|80 Years|No|Non-Probability Sample|Histologically confirmed stage ⅢA non-small cell lung cancer patients who have the same        driver mutation in tumor tissue and circulating tumor DNA(blood or urine)|February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696525|3 Years|1840|
NCT02710565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B723|Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma|Use of Endo Bronchial Ultrasound (EBUS) Trans Bronchial Needle Aspiration (TBNA) for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma|EBUS|Basildon and Thurrock University Hospitals NHS Foundation Trust|No|Recruiting|February 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710565||761|
NCT02715895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJEBP-01|Clinical Trial of Infant Formula-fed|A Clinical Trial of Infant Formula-fed||Maternal and Child Health Care Hospital of Hainan Province|Yes|Not yet recruiting|March 2016|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|216|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715895||351|
NCT02706535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204946|A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential|A Single Center, Two Part, Randomized, Open Label Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential||GlaxoSmithKline|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706535||1071|
NCT02697578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0311-2014|Artificial Intelligence: a New Alternative to Analyse the Relationship Between Calcium, Phosphorus and PTH Concentrations in Haemodialysis Patients and Preventing the Cardiovascular Risk.|||Maimónides Biomedical Research Institute of Córdoba|No|Recruiting|February 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Incident hemodialysis patients|February 2016|February 26, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697578||1759|
NCT02697942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006466|Hemodialysis-based Interventions to Preserve Cognitive Function|Hemodialysis-based Interventions to Preserve Cognitive Function||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|February 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02697942||1731|
NCT02698176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-006|A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)|A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Not yet recruiting|April 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698176||1713|
NCT02661048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CyberHeart Inc. -004|CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation|CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia||CyberHeart Inc.|Yes|Not yet recruiting|January 2016|January 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|N/A|No|||January 2016|January 20, 2016|December 22, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02661048||4558|
NCT02660060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR.193/EQL/2010|Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg|Bioequivalence Study of 0.25 mg Pramipexole Tablets Produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals in Comparison With the Comparator Product (Sifrol® 0.25 mg Tablet, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany for Boehringer Ingelheim International, GmbH, Germany)||Dexa Medica Group|No|Completed|May 2015|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 17, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02660060||4634|
NCT02660073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-14-SCIRP-CTA|Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury|Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury||United States Department of Defense|Yes|Recruiting|October 2015|September 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660073||4633|
NCT02660086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL125486|Promoting Employee Health Through The Worksite Food Environment|Promoting Employee Health Through The Worksite Food Environment|ChooseWell 365|Massachusetts General Hospital|No|Not yet recruiting|July 2016|July 2019|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02660086||4632|
NCT02716415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-019-01|Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants|Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants||University of the Philippines|No|Recruiting|March 2015|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|326|||Both|N/A|12 Months|No|||March 2016|March 22, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02716415||311|
NCT02702882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-TEST-01/7-14|The Efficacy Study of FUROSAP: A Testosterone Booster Supplement In Humans.|Efficacy Evaluation of Furosap, a Testosterone Booster Supplement in Human Volunteers : An add-on Study||Chemical Resources|No|Recruiting|February 2014|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Male|35 Years|65 Years|No|||March 2016|March 14, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02702882||1351|
NCT02698696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10477M|Validation of a Cognitive Remediation Program for Bipolar Disorders|Validation of a Cognitive Remediation Program for Bipolar Disorders|ECO-BIP|Centre hospitalier de Ville-Evrard, France|No|Recruiting|February 2014|December 2020|Anticipated|November 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|February 29, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02698696||1673|
NCT02720055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/0037|Rehabilitation Workbook After Wrist Fracture.|Routine Exercises and Either a Psychological (Therapy-based) or a Placebo (Informational) Intervention Workbook After Distal Radius Fracture: A Double Blind Randomised Control Trial.||NHS Lothian|No|Recruiting|March 2016|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720055||31|
NCT02720068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4280-001|Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)|A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Not yet recruiting|April 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02720068||30|
NCT02720081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029-015|Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)|A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects With Persistent Asthma That is Uncontrolled While Receiving Montelukast.||Merck Sharp & Dohme Corp.|No|Not yet recruiting|April 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|March 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720081||29|
NCT02717429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014H0212|Cognitive and Emotion Regulation Training in MS|Cognitive and Emotion Regulation Training in Multiple Sclerosis|CERT-MS|Ohio State University|No|Recruiting|October 2015|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|59 Years|No|||March 2016|March 17, 2016|October 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02717429||233|
NCT02695966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093503|EVIS - Ex-vivo Assessment of T-lymphocyte Homing in Primary Pancreatic Cancer|A Feasibility Study Assessing the Ability of an Ex-vivo Assay to Measure AMD3100's Ability to Overcome Tumour Immune-privilege and Bring T-lymphocytes Into Contact With Neoplastic Targets.|EVIS|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Tumour tissue sample Blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary pancreatic adenocarcinoma who are undergoing pancreaticoduodenectomy        (Whipple's) resection.|February 2016|February 25, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02695966||1883|
NCT02698982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2015/539|Optimized Anesthesia to Reduce Postoperative Cognitive Impairment in the Elderly|Impact of Tight Intraoperative Blood Pressure and Depth of Anesthesia Control on the Incidence of Postoperative Cognitive Impairment in Elderly Patients||Erasme University Hospital||Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|45|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02698982||1651|
NCT02715804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-109-301|A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma||Halozyme Therapeutics|Yes|Recruiting|February 2016|December 2019|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715804||358|
NCT02713672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-72600-98-005|Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao|Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao||GGZ Centraal|No|Completed|October 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02713672||522|
NCT02704715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016MEKY006|Postoperative Pain in Orbital Disease and Ocular Tumor|Postoperative Pain of General Anesthesia in Orbital Disease and Ocular Tumor||Sun Yat-sen University|Yes|Recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|16 Years|N/A|No|||March 2016|March 9, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02704715||1210|
NCT02709850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IONIS ANGTPL3-LRx|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia|A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia||Ionis Pharmaceuticals, Inc.|No|Recruiting|November 2015|August 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02709850||816|
NCT02699255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF-01/16|Ventricular Arrhythmias After Pulmonary Vein Isolation|A Single-center Observational Study to Examine the Occurrence of Ventricular Arrhythmias After Pulmonary Vein Isolation||Universitätsklinikum Hamburg-Eppendorf||Recruiting|October 2014|April 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|80 Years|No|Probability Sample|Patients with paroxysmal atrial fibrillation scheduled to undergo pulmonary vein isolation|February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02699255||1630|
NCT02699268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK Vest 2010/496-8|A Clinical Study Aiming to Validate the Equipment: VoluSense Pediatrics (VSP)|Validation of VoluSense Pediatrics, a New Method of Infant Spirometry Based on Electromagnetic Inductance Plethysmography||Haukeland University Hospital|No|Recruiting|December 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|Probability Sample|Term born and preterm born babies ≥ 2000 grams.|February 2016|February 29, 2016|December 1, 2015||No||No||https://clinicaltrials.gov/show/NCT02699268||1629|
NCT02716025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811|Serum Zinc, Peptic Ulcer Disease and H. Pylori Infection|||Ain Shams University||Completed|October 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|75|||Both|18 Years|55 Years|No|Non-Probability Sample|patients with symptoms suggestive of peptic ulcer disease like epigastric pain, dyspepsia,        heartburn who were candidates for upper gastrointestinal endoscopy.|March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716025||341|
NCT02716038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ3153|Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC|A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)||Columbia University|Yes|Not yet recruiting|April 2016|December 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716038||340|
NCT02705794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124-IEC/01/13|Comparison of Modified Mallampati Classification With M-TAC in Difficult Airway|Clinical Trial of Comparative Evaluation of Modified Mallampati Score and Modified Mallampati Score Along With Thyromental Distance, Anatomical Abnormalities and Cervical Mobility in Predicting Difficult Airway||Government Medical College, Haldwani|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|60 Years|No|Probability Sample|Patient admitted for various surgeries requiring general anesthesia with tracheal        intubation in a tertiary care teaching institute|March 2016|March 12, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02705794|8 Months|1127|
NCT02697825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RajivGCIRC1|Intraocular Pressure Versus Optic Nerve Sheath Diameter|Correlation Between Intraocular Pressure and Optic Nerve Sheath Diameter||Rajiv Gandhi Cancer Institute & Research Center, India|Yes|Recruiting|September 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02697825||1740|
NCT02697838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEAD-G323|Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer|Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer||Fujian Cancer Hospital|Yes|Not yet recruiting|March 2016|October 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02697838||1739|
NCT02709655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12709A|Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)|Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)||H. Lundbeck A/S|Yes|Not yet recruiting|March 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|750|||Both|7 Years|11 Years|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709655||831|
NCT02714400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD141272ARM5-1|The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea|The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea||University of California, San Diego|No|Recruiting|March 2016|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02714400||466|
NCT02714413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-Allulose-16|Effect of D-allulose in Addition to Oral Sucrose Load|Effect of D-allulose Ingestion on the Glucose and Insulin Response to a Standardized Oral Sucrose Load||University of Florida|No|Not yet recruiting|June 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714413||465|
NCT02696200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-2205|Protection Against Potential Brain Injury During Competitive Football|Novel Protection Against Potential Brain Injury During Competitive Football Head Impacts||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|May 2015|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|62|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|May 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02696200||1865|
NCT02697851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT069|Pharmacokinetic Effect of Evotaz/Microgynon Co-administration|The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women||St Stephens Aids Trust|No|Not yet recruiting|April 2016|February 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02697851||1738|
NCT02697864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461051|A Study Comparing Amounts of Tafamidis In The Blood Without Food|A Phase 1, Open‑Label, Three Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Tablet Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions||Pfizer|No|Not yet recruiting|April 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02697864||1737|
NCT02709668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBFDepression|B Vitamins in MTHFR Positive Patients With Major Depression|Correlation of Clinical Response With Homocysteine Reduction Using During Reduced B-Vitamin Therapy in MTHFR C677T/A1298C Patients With MDD Major Depressive Disorder Who Are Positive for MTHFR C677T or A1298C Polymorphism|BVMD|High Point Regional Health Systems|No|Completed|August 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709668||830|
NCT02719847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0615|Additive Value of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy|Additive Value of EBUS TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy||M.D. Anderson Cancer Center|No|Recruiting|March 2016|||March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719847||47|
NCT02719860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0014|High Tea Consumption on Smoking Related Oxidative Stress|A Chemoprevention Trial to Study the Effects of High Tea Consumption on Smoking Related Oxidative Stress||University of Arizona||Completed|September 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|154|||Both|40 Years|80 Years||||March 2016|March 24, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02719860||46|
NCT02719873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOI in pregnancy outcome|The Impact of Maternal Obesity on Pregnancy Outcomes in El-Minia Locality|The Impact of Maternal Obesity on Pregnancy Outcomes in El-Minia Locality a Case Control Survey Study||Minia University|Yes|Not yet recruiting|April 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|350|||Female|18 Years|40 Years|No|Non-Probability Sample|pregnant women with BMI more than 24 per meter square body surface area|February 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719873||45|
NCT02707874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#13-6466|PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery|Comparing the Delivery of Local Anesthetic by Programmed Intermittent Bolus Versus Continuous Infusion Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery||University Health Network, Toronto|No|Recruiting|October 2014|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|November 20, 2015||No||No||https://clinicaltrials.gov/show/NCT02707874||968|
NCT02707887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0815|Technology Enhanced Behavioral Activation Treatment for Substance Use|Technology Enhanced Behavioral Activation Treatment for Substance Use||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|January 2021|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|55 Years|No|||March 2016|March 14, 2016|May 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02707887||967|
NCT02708758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONACYT 233634|Efficacy of Treatment for Gestational Diabetes Diagnosed by the IADPSG Criteria.|Efficacy of Treatment in Women With Gestational Diabetes Mellitus Diagnosed by One Altered Value by the International Association of Diabetes and Pregnancy Study Groups Criteria (IADPSG).||Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|Yes|Recruiting|September 2015|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Female|18 Years|45 Years|No|||March 2016|March 10, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02708758||900|
NCT02710942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO-EST-2014-9575|Testing myWHI: Online Self-guided Programs for Migraine|Testing the Feasibility of Two Self-guided Web-based Interventions for Adolescents and Young Adults With Migraine: A Pilot Randomized Controlled Trial||IWK Health Centre|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|14 Years|35 Years|No|||March 2016|March 11, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02710942||732|
NCT02710955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-01-SWAN|SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)|Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)|SWAN|United Pharmaceuticals|No|Not yet recruiting|March 2016|March 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|5 Months|No|||March 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02710955||731|
NCT02711709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201501027|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle: The Acute Development and Persistence of Frailty, Comorbidity and Disability in Critically Ill Patients After Intra-abdominal Sepsis "Induced Frailty||University of Florida|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02711709||673|
NCT02704208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Horvath_TWM|A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults|A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults|TWM|University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|July 2016|May 2020|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|100 Years|No|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704208||1249|
NCT02711449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-810|Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy|Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy||Nordsjaellands Hospital|Yes|Not yet recruiting|March 2016|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711449||693|
NCT02713646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AF-CRF-2015-028|Magnetic Resonance Imaging Study on Patients With Trigeminal Neuralgia|Applied Research on Patients With Trigeminal Neuralgia by Multi-planar Reconstruction, Curved Planar Reconstruction and Magnetic Resonance Virtual Endoscopy|MRI-TN|First Affiliated Hospital Xi'an Jiaotong University|Yes|Not yet recruiting|March 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|35 Years|70 Years|No|Probability Sample|Chronic trigeminal neuralgia patients prior to the surgery of microvascular decompression        (MVD) or Gamma Knife radiofrequency ablation (GKRFA)|March 2016|March 15, 2016|March 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713646||524|
NCT02705547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-012659|Rosuvastatin (Crestor) in Friedreich Ataxia|||Children's Hospital of Philadelphia||Not yet recruiting|May 2016|||August 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||March 2016|March 5, 2016|March 5, 2016||||No||https://clinicaltrials.gov/show/NCT02705547||1146|
NCT02708433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-0068|Clinical Outcomes of Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine|Pilot Study: Comparison of Buffered 1% vs. Non-Buffered 2% Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes||University of North Carolina, Chapel Hill|No|Recruiting|March 2016|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708433||925|
NCT02711475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCMAS-1|Evaluation of Colonic Diminutive Polyps With Electronic Filters|"Remove and Discard" Policy in Colonic Diminutive Polyps: is it Always Safe?||Ospedale Cardinal Massaia|No|Not yet recruiting|May 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|90 Years|No|Non-Probability Sample|All pationts undergoing screening and non screening colonoscopy|March 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02711475||691|
NCT02711488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-PAAPAS-project|Managing Adolescent Obesity at Local Level by Combining Primary and Secondary Intervention|Managing Adolescent Obesity at Local Level by Combining Primary and Secondary Intervention|PAAPAS-DC|Rio de Janeiro State University|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|9 Years|15 Years|No|||March 2016|March 11, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02711488||690|
NCT02718235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCIS16|Prospective, Multicenter HCCIS Evaluation Study|Prospective, Multicenter Study to Evaluate the HCCIS as Prognosticator for Overall and Disease-free Survival of Patients After Resection of HCC|HCCIS|University of Regensburg|Yes|Not yet recruiting|June 2016|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|Tumor tissue for immunohistochemical analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients >18 years old who are receiving primary liver resection in curative intent for        HCC after informed consent is obtained.|March 2016|March 23, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02718235||171|
NCT02696941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11693|SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis|SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis|SMASH|University of Oxford|No|Recruiting|February 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|23|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02696941||1808|
NCT02700490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE.2015.108|Evaluating the Clinical Cost-effectiveness of Two Primary Mental Health Service Frameworks in Yogyakarta, Indonesia|Evaluating the Clinical Cost-effectiveness of Two Primary Mental Health Service Frameworks in Yogyakarta, Indonesia|JIWA|University of Cambridge||Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02700490||1535|
NCT02697955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtokolSB2|The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery|The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery||University of Aarhus|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|85 Years|No|||February 2016|February 26, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697955||1730|
NCT02719145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFMEC1015|Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients|Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients||Tanta University|Yes|Recruiting|October 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|Samples With DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This cross sectional study will be carried out on 30 subjects who will be recruited from        the outpatient clinic of Chest Department, Tanta University Hospital.        They will be classified into 3 groups:        Group I: It will includ 10 healthy volunteer subjects. Group II: It will include 10        asthmatic patients. Group III: It will include 10 COPD patients.|March 2016|March 24, 2016|March 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02719145||101|
NCT02709395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV-0003|Evaluation of a Novel Electronic Transanal Irrigation System - Navina™ Smart|Evaluation of a Novel Electronic Transanal Irrigation System - Navina™ Smart||Wellspect HealthCare|No|Recruiting|February 2016|||July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709395||851|
NCT02708498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-2759|Implementation of Knowledge-Based Palliative Care|Implementation of Knowledge-Based Palliative Care for Frail Older Persons in Nursing Homes|KUPA|Lund University|No|Enrolling by invitation|April 2015|December 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|1400|||Both|N/A|N/A|No|||March 2016|March 9, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02708498||920|
NCT02708576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0201|Phase 1 Study of NGM313 in Healthy Adult Participants|A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants||NGM Biopharmaceuticals, Inc|No|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|183|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708576||914|
NCT02698202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReTomo|Screening for Breast Cancer With Digital Breast Tomosynthesis|Randomized Controlled Trial to Evaluate the Efficacy of Digital Breast Tomosynthesis in Reggio Emilia Breast Cancer Screening Program in the 45-74 Age Group||Azienda Unità Sanitaria Locale Reggio Emilia|No|Recruiting|March 2014|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|40000|||Female|45 Years|70 Years|No|||March 2016|March 3, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02698202||1711|
NCT02719418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRIP-001|Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses|Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses|STRIP|Maisonneuve-Rosemont Hospital|No|Recruiting|February 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Subjects with severe renal impairment (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary        to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin. The study        sample will be selected from patients that are hospitalized on pre-selected departments        (i.e. nephrology, internal medicine, cardiology, pneumology) and on the transitional        hospitalization unit.|March 2016|March 21, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02719418||80|
NCT02709460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20140104|Lateral Occlusion of Uterine Artery in Total Laparoscopic Hysterectomy|Lateral Versus Cervical Coagulation of the Uterine Artery in Benign Hysterectomy: A Randomized Controlled Study||Odense University Hospital|No|Recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02709460||846|
NCT02706626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1523|Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors|Phase 2 Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|99 Years|No|||March 2016|March 8, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706626||1064|
NCT02719587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-831-09/1539|Dietary Supplementation With Low-Dose Omega-3 Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis|Dietary Supplementation With Low-Dose Omega-3 Fatty Acids Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis||Ondokuz Mayıs University|Yes|Completed|April 2009|January 2010|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|50 Years|No|||March 2016|March 24, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02719587||67|
NCT02696694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1511-VLC-061-EL|Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles|Impact of Serum Progesterone Levels on the Day of Embryo Transfer on the Success Rate in Egg Donation Cycles Under Hormonal Replacement||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Recruiting|March 2016|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|244|Samples Without DNA|Blood sample|Female|25 Years|50 Years|No|Probability Sample|Infertile patients undergoing their first or second egg donation cycle|March 2016|March 7, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02696694||1827|
NCT02708069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R44MH109193|e-Unstuck: Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder|e-Unstuck: Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder|e-Unstuck|3-C Institute for Social Development|No|Not yet recruiting|March 2016|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02708069||953|
NCT02708082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBO-2015-1|Glaucoma HFA / OCT Specificity Study|Glaucoma HFA / OCT Specificity Study||Carl Zeiss Meditec, Inc.|Yes|Not yet recruiting|March 2016|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|40 Years|80 Years|No|Non-Probability Sample|Adult males or females 40 to 80 years old with diagnosis of glaucoma, pre-perimetric        glaucoma or glaucoma suspect|March 2016|March 9, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02708082||952|
NCT02709265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-01-104|Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers|An Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer in Healthy Volunteers||Cardeas Pharma|No|Not yet recruiting|April 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709265||861|
NCT02712307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoHM/Tonsillit2015|Study of 5 and 10 Days Treatment With Penicillin Against Sore Throat Caused by Streptococci|A Randomized Controlled Study of 5 and 10 Days Treatment With Phenoxymethylpenicillin for Pharyngotonsillitis Caused by Streptococcus Group A||Public Health Agency of Sweden|Yes|Recruiting|September 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|432|||Both|6 Years|N/A|No|||March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712307||627|
NCT02705807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201614|Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects|An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH)||GlaxoSmithKline|No|Not yet recruiting|May 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705807||1126|
NCT02705820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-449|Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy|A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)|SWIPE|Bank of Cyprus Oncology Centre|Yes|Not yet recruiting|April 2016|July 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02705820||1125|
NCT02700256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-315|Electronic Patient-Reported Outcomes in Patients Recovering From Ambulatory Cancer Surgery: Measuring Early Postoperative Symptoms|Electronic Patient-Reported Outcomes in Patients Recovering From Ambulatory Cancer Surgery: Measuring Early Postoperative Symptoms||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to undergo surgery on the Gynecology service through the AXR program or        are discharged within 24-hours of surgery with internet access or a phone number will be        recruited from the Rockefeller Outpatient Pavilion in the GYN Surgery Clinic.|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700256||1553|
NCT02700321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0047|Benefits of High Flow Nasal Cannula Oxygen for Preoxygenation During Intubation in Non Severely Hypoxemic Patients|A Prospective , Multicenter , Randomized, Controlled, Parallel-group , Open-label Trial Evaluating Benefits of High Flow Nasal Cannula (HFNC) Oxygen for Preoxygenation During Intubation in Non Severely Hypoxemic Patients|PROTRACH|Nantes University Hospital|No|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700321||1548|
NCT02717923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC005|A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer|Maintenance Treatment With Capecitabine Plus Cetuximab After First-line Modified Fluorouracil, Leucovorin, and Oxaliplatin(mFOLFOX6) Plus Cetuximab for Patients With KRAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label Clinical Trial||Huazhong University of Science and Technology||Recruiting|January 2014|||January 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||March 2016|March 23, 2016|March 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717923||195|
NCT02698046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/03301-1|Oral Iron Therapy in Chronic Heart Failure Patients|Oral Iron Therapy in Chronic Heart Failure Patients: a Randomized, Placebo-controlled and Double-blind Clinical Trial (Pilot Study) of Efficiency||University of Sao Paulo|Yes|Recruiting|August 2015|October 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02698046||1723|
NCT02698059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iNAP®-CE-1501|A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea|A Multi-center, Two-stage, Single-arm, Prospective, First-night Order Cross-over, Evaluator-blind Study to Evaluate the Efficacy, Safety and Tolerance of the iNAP® Sleep Therapy System in Adults With Obstructive Sleep Apnea (OSA)||Somnics, Inc.|No|Recruiting|January 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|65 Years|No|||March 2016|March 4, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02698059||1722|
NCT02704741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF19731|Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments|Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments||Syneron Medical|No|Recruiting|September 2015|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|35 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704741||1208|
NCT02713880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTR 01-2016|Biomarker for Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy|Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy - An International, Multicenter, Epidemiological Protocol|BioTRAP|University of Rostock|Yes|Recruiting|January 2016|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml      EDTA blood or a dry blood spot filter card are taken. To proof the correct diagnosis of      aTransthyretin-Related Familial Amyloidotic Polyneuropathy in those patients where up to the      enrollment in the study no genetic testing has been done, sequencing of a      Transthyretin-Related Familial Amyloidotic Polyneuropathy will be done.      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany|Both|2 Months|N/A|No|Probability Sample|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade        suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy|March 2016|March 18, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02713880||506|
NCT02713893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030(4A)HO14387|Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream|A Phase I Study of a Novel Intravaginal Antimycotic Cream (Econazole Nitrate 1% Plus Benzydamine HCl 0.12%) Administered Once Daily for 15 Days to Healthy Women||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Recruiting|September 2015|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|60|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|August 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02713893||505|
NCT02698280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY-2015-289; 02|Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma|Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma||Huashan Hospital||Recruiting|January 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||March 2016|March 6, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02698280||1705|
NCT02700711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BED IN 32|Methylphenidate-Duloxetine Combinations for Cocaine Dependence|Behavioral Effects of Drugs (Inpatient): 32 (Cocaine, Methylphenidate and Duloxetine)||University of Kentucky|Yes|Recruiting|February 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700711||1518|
NCT02700724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011222|Observation Versus Immediate Surgery of Low Risk Bladder Cancer|Observation Versus Immediate Surgery of Low Risk Bladder Cancer||Vanderbilt University|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||March 2016|March 4, 2016|December 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02700724||1517|
NCT02697643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19015.13|A Clinical Decision Support Tool for Electronic Health Records|A Clinical Decision Support Tool for Electronic Health Records|BHCDS|Inflexxion, Inc.|Yes|Recruiting|February 2016|May 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02697643||1754|
NCT02701777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20151115|Enhancing STDP After Spinal Cord Injury|Maximizing Spike Timing Dependent Plasticity After Spinal Cord Injury||University of Miami|No|Not yet recruiting|March 2016|January 2021|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Anticipated|500|||Both|18 Months|85 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701777||1436|
NCT02720224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIT -Es0001-C105|Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol|An Open-Label, Single Dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profiles and Metabolite Identification of [14C]-Estetrol in Healthy Female Volunteers||Estetra|No|Recruiting|February 2016|June 2016|Anticipated|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Female|30 Years|65 Years|No|||January 2016|March 21, 2016|January 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02720224||18|
NCT02720237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0225b|Reducing Hazardous Alcohol Use & HIV Viral Load|Reducing Hazardous Alcohol Use & HIV Viral Load: A Randomized Controlled Trial (RCT) in Antiretroviral Therapy (ART) Clinics in Vietnam|REDART|University of North Carolina, Chapel Hill|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|441|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02720237||17|
NCT02698891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-516|Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer|Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen||Dana-Farber Cancer Institute|Yes|Not yet recruiting|April 2016|August 2023|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698891||1658|
NCT02698904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG_COPDRELAX_01|Relaxation Training for People With Chronic Obstructive Pulmonary Disease (COPD)|A Quick Relaxation Training for People With Chronic Obstructive Pulmonary Disease (COPD)||Fondazione Don Carlo Gnocchi Onlus|Yes|Recruiting|January 2016|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02698904||1657|
NCT02702414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3475-224|Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)|A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)||Merck Sharp & Dohme Corp.|Yes|Not yet recruiting|April 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|March 3, 2016|March 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702414||1387|
NCT02702427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT2013-002492-17|Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation|Phase I/II: Treatment of Adenovirus and Cytomegalovirus Infection Post Human Allogeneic Stem Cell Transplantation With Short-term Expanded Virus-specific T Cells|VISIT|St. Anna Kinderkrebsforschung|Yes|Not yet recruiting|May 2016|March 2020|Anticipated|April 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|18 Years|No|||March 2016|March 16, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02702427||1386|
NCT02701985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP30037|A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome||Hoffmann-La Roche||Not yet recruiting|May 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701985||1420|
NCT02646293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-43-2012|Nephron Sparing Renal Surgery and Total Nephrectomy|Nephron Sparing Renal Surgery and Total Nephrectomy - Functional Adaptation, Preservation and Prediction of Kidney Function||University Hospital Roskilde|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|25 Years|80 Years|No|Probability Sample|The study is designed as an observational, longitudinal study where plasma [NT-proBNP],        renal function and blood pressure is followed in patients undergoing partial or total        nephrectomy ("nephron sparing surgery") and relate this to plasma BNP.|January 2016|January 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02646293|12 Months|5691|
NCT02645929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7211|Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)|Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT) for Posttraumatic Stress Disorder||New York State Psychiatric Institute|No|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|70 Years|No|Non-Probability Sample|25 US veterans or their family members suffering from DSM-5 PTSD|January 2016|January 10, 2016|January 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02645929||5719|
NCT02645942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|962/15|L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea|L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea - Double Blind Randomized Clinical Trial|CARNIMET|Poznan University of Medical Sciences|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||January 2016|January 4, 2016|December 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02645942||5718|
NCT02712866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOMARKERS/VEDOLIZUMAB|Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.|EARLY BIOMARKERS IN CIRCULATING α 4β7+ T CELLS TO PREDICT RESPONSE TO VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS||Parc de Salut Mar|No|Not yet recruiting|July 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|24 adults with inflammatory bowel disease (12 Ulcerative colitis patients and 12 Chron        Disease patients with active disease and prior failure to anti-TNFα treatments (inadequate        response, loss of response, intolerance), starting treatment with Vedolizumab.|March 2016|March 21, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712866||584|
NCT02712879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF9695|Moderate Bleeding in Cardiac Surgery Post Operative|Bleeding Moderate Postoperative Cardiac Surgery and Prognostic Implications Anemia and Postoperative Transfusion: Prospective, Observational, Descriptive.|SPO|University Hospital, Montpellier|No|Recruiting|March 2016|December 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|90 Years|No|Probability Sample|patients admitted to intensive care after surgery for heart surgery|March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712879||583|
NCT02707731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPedroernesto|Acute Effects of Neonatal Hydrokinesiotherapy in Newborn Preterm Hospitalized|Acute Effects of Neonatal Hydrokinesiotherapy in Newborn Preterm Hospitalized||Hospital Universitario Pedro Ernesto|No|Completed|July 2015|November 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|15|||Both|N/A|36 Weeks|No|||March 2016|March 8, 2016|March 3, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02707731||979|
NCT02707744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15IC2955|A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation|A Prospective Observational Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation|POP-ECG-HF-AF|Imperial College London|No|Recruiting|February 2016|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|patients with heart failure|March 2016|March 8, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02707744||978|
NCT02702713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147/2015/U/Sper|Pivotal Assessment of the Effects of Bioactive on Health and Wellbeing. From Human Genome to Food Industry|Investigation of the Effect of Daily Consumption of Bioactive Enriched Foods (BEF) on Biochemical and Anthropometric Markers of Metabolic Syndrome (MS)|PATHWAY-27|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|800|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02702713||1364|
NCT02715492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMWH TACE|Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.|Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.||Tanta University|Yes|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|60 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715492||382|
NCT02713438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/15/B/HS6/00923_PCD|Effects of Individual, Dyadic, and Collaborative Plans on Physical Activity in Parent-Child Dyads|Physical Activity, and Health-Related Quality of Life: Dyadic Research in the Context of Forming Individual, Dyadic, and Collaborative Plans (Trial 1: Parent-Child Dyads)||University of Social Sciences and Humanities, Warsaw|No|Not yet recruiting|March 2016|||March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|400|||Both|10 Years|100 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02713438||540|
NCT02700217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04134|Does Adding Spinal Anaesthesia to a General Anaesthetic Technique Influence Readiness for Discharge in Patients Having Hand Assisted Laparoscopic Live Donor Nephrectomy|||Central Manchester University Hospitals NHS Foundation Trust|No|Not yet recruiting|March 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02700217||1556|
NCT02702960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J15171|Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)|Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC)||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|January 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|16 Years|65 Years|No|||March 2016|March 17, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702960||1345|
NCT02720094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 083|Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men|A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720094||28|
NCT02702076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL55949|Apomorphine in Parkinson's Disease Patients With Visual Hallucinations: a RCT|||University Medical Center Groningen|No|Not yet recruiting|April 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|30 Years|N/A|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702076||1413|
NCT02709928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0142|Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−0714 in Healthy Adult and Elderly Subjects||Theravance Biopharma R & D, Inc.|No|Recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709928||810|
NCT02703220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULM-008-14F|Sleep Apnea in Elderly|Pathophysiology-Guided Therapy for Sleep Apnea in the Elderly||VA Office of Research and Development|Yes|Recruiting|July 2015|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|100|||Both|60 Years|89 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|January 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02703220||1325|
NCT02703233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602966|Effectiveness of Nitrous Oxide in the ED|A Randomized Control Trial of Nitrous Oxide Use in the Emergency Department||Christiana Care Health Services|No|Not yet recruiting|March 2016|June 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703233||1324|
NCT02720432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/1299|Early Intervention in Infants With Perinatal Stroke|Early Intervention in Infants With Perinatal Stroke : CIMT Versus HABIT : a Randomized Clinical Trial||University Ghent|No|Not yet recruiting|March 2016|March 2020|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|4 Months|8 Months|No|||March 2016|March 24, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02720432||2|
NCT02720445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC|Memory Improvement Through Nicotine Dosing (MIND) Study|Long-Term Nicotine Treatment of Mild Cognitive Impairment|MIND|University of Southern California|Yes|Not yet recruiting|June 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|55 Years|90 Years|No|||March 2016|March 22, 2016|March 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720445||1|
NCT02710994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-CT1-14-085|Pharmacodynamics and Safety of CDFR0209|A Randomized, Open Label, Two-way Crossover Designed Clinical Trial to Investigate the Pharmacodynamics and the Safety Between Repeated Doses of CDFR0209 in Healthy Male Volunteers||Ajou University School of Medicine|No|Completed|May 2014|March 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710994||728|
NCT02701413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00201026|Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery|Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery|VESPR|Northwestern University|No|Not yet recruiting|March 2016|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|50 Years|No|||March 2016|March 7, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02701413||1464|
NCT02697630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-1|Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye|A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma|PEMDAC|Vastra Gotaland Region|No|Not yet recruiting|June 2016|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02697630||1755|
NCT02718495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-428-01|Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis|A Multi-center, Randomized, Placebo-Controlled, Ascending Dose Phase I Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis||Proteostasis Therapeutics, Inc.|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|55 Years|No|||March 2016|March 18, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718495||151|
NCT02702388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-211|Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile|A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer (RR-DTC) to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile||Eisai Inc.|No|Not yet recruiting|March 2016|July 2019|Anticipated|May 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702388||1389|
NCT02710916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/20|SD-OCT Multimodal Analysis in GLaucoma|SD-OCT Multimodal Analysis in GLaucoma|SOMAL|University Hospital, Bordeaux|No|Recruiting|February 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|150|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02710916||734|
NCT02699528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-15-0329|The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder|Does Methylphenidate, Prescribed for Attention Deficit Disorder, Influence Primary Enuresis in These Children?||Meir Medical Center|Yes|Not yet recruiting|April 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|5 Years|10 Years|No|Probability Sample|Children aged 5 - 10 years receiving a new diagnosis of attention deficit hyperactivity        disorder|March 2016|March 8, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02699528||1609|
NCT02715622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-PHS-2016|A Prospective Study to Compare the Clinical Outcomes, Pain and Patient Quality of Life for Hernia Patients|A Prospective, Multicenter Post-Market Study to Evaluate and Compare the Clinical Outcomes, Pain and Patient Quality of Life After Open, Laparoscopic or Robotic Assisted Hernia (Incisional and Inguinal) Repair||Intuitive Surgical|No|Not yet recruiting|March 2016|February 2019|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|At least 900 patients will be enrolled in this post-market study that is planned to be        conducted for mainly 2 types of hernia repairs, Incisional hernia repair and inguinal        hernia repair ( robotic-assisted, lap and open). Up to 2000 patients may be enrolled.        Approximately 450 patients who will undergo inguinal hernia repair across open,        laparoscopic or robotic-assisted procedures (~ 150 patients in each surgical modality) and        approximately 450 patients who will undergo incisional hernia repair across open,        laparoscopic or robotic-assisted procedures (~ 150 patients in each surgical modality)        will be enrolled in this study at up to thirty (30) study centers|March 2016|March 21, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02715622|3 Years|372|
NCT02695953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P001812|Neurobiology of Posttraumatic Stress Disorder Dysfunction and Recovery Following Cognitive Processing Therapy|Neurobiology of Posttraumatic Stress Disorder Dysfunction and Recovery Following Cognitive Processing Therapy||Mclean Hospital|No|Enrolling by invitation|March 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|102|Samples With DNA|Saliva sample|Both|18 Years|55 Years|No|Non-Probability Sample|Participants will include 102 individuals (half female) between the ages of 18 and 55 with        a current diagnosis of PTSD as measured by the Clinician Administered PTSD Scale for DSM-5        (CAPS-5). Participants must have a history of chronic childhood trauma due to relational        abuse. All participants will be recruited from the McLean Hospital outpatient trauma track        Cognitive Processing Therapy (CPT) treatment program.|February 2016|February 24, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02695953||1884|
NCT02699463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA200216|Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge Study|Assessment of the Effect of Positive Airway Pressure on Energy and Vitality in Mild Obstructive Sleep Apnea Patients: The Merge Study||ResMed|No|Not yet recruiting|April 2016|April 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699463||1614|
NCT02699814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#15-000757|H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation|H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation|H3|University of California, Los Angeles|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|400|||Both|N/A|16 Years|No|||March 2016|March 2, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02699814||1587|
NCT02717403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0349|Effects of Social Networking on Chronic Disease Management in Arthritis|Phase 2 & Phase 3, Effects of Social Networking on Chronic Disease Management in Arthritis||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717403||235|
NCT02717637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014/1781|Oxycodone in Serum After Postoperative Oral Oxycodone in Caesarean Sections Under Spinal Anesthesia|Gastrointestinal Uptake of Oxycodone After Caesarean Section in Spinal Anesthesia||University Hospital, Akershus|No|Recruiting|February 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum from blood|Female|18 Years|45 Years|No|Non-Probability Sample|Women with single fetus in cephalated position admitted for elective caesarean section in        spinal anesthesia|March 2016|March 18, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02717637||217|
NCT02717650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHMU-1234|The Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed for Adults With Cystic Fibrosis|Feasibility and Validation of the Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed to Assess Exercise Tolerance and Determine Maximum Oxygen Uptake in Adults With Cystic Fibrosis Across the Disease Spectrum|A-STEP/max|The Alfred|No|Not yet recruiting|April 2016|February 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02717650||216|
NCT02696213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-01921|Systematic, Comprehensive, One-to-One Training (SCOOT) for Scooter Skills: A Feasibility Study|||University of British Columbia||Recruiting|March 2016|||February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|40|||Both|60 Years|N/A|No|||March 2016|March 18, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02696213||1864|
NCT02708381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-18059|Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database|Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|March 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|70 Years|N/A|No|Non-Probability Sample|Adult cancer patients 70 years of age and older being treated at Lynn Cancer Institute,        with geriatric issues.|March 2016|March 9, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02708381||929|
NCT02697123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-36192|Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients|Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients||Baylor College of Medicine|Yes|Recruiting|January 2016|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Female|18 Years|64 Years|No|Non-Probability Sample|All patients presenting to TCH/Women's Pavilion and Ben Taub Hospital for Cesarean        Section, vaginal delivery or any antepartum hospitalization will considered for the study.|February 2016|February 28, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02697123|5 Days|1794|
NCT02697409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EATRCT|Education Against Tobacco Randomized Trial|Medical-student-delivered Smoking Prevention Program for Secondary Schools: The Education Against Tobacco Randomized Trial||University of Giessen|Yes|Not yet recruiting|March 2016|July 2019|Anticipated|July 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697409||1772|
NCT02718534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERTAS|Early Limb Rehabilitation Therapy Within 48 h of Acute Stroke Onset(ERTAS)|Effectiveness and Safeness of Early Limb Rehabilitation Therapy Within 48 h of Acute Stroke Onset: a Randomized Controlled Trial|ERTAS|Shengjing Hospital|Yes|Active, not recruiting|March 2016|August 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients attacks acute stroke within 24h onset|March 2016|March 23, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02718534||148|
NCT02709278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB041|Aerosol BCG Challenge Trial in Healthy UK Adults|A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers||University of Oxford|No|Recruiting|March 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02709278||860|
NCT02696031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457H2315|Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis|A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab to Evaluate the Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Non-radiographic Axial Spondyloarthritis||Novartis|No|Not yet recruiting|May 2016|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|555|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696031||1878|
NCT02697656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/14224|The Effectiveness of Individual Placement and Support in Chronic Pain Patients|A Randomized Controlled Trial Assessing the Effectiveness of the Individual Placement and Support Model for Patients With Chronic Pain in an Outpatient Hospital Pain Clinic|IPSinPain|Oslo University Hospital|No|Recruiting|November 2015|May 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02697656||1753|
NCT02714192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030-387696|Safety Study for Adolescents With Concussion|Evaluation of the Safety of Exercise Testing With Acutely Concussed Adolescent Athletes||University at Buffalo|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|54|||Both|14 Years|19 Years|No|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02714192||482|
NCT02714205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-18472|Flushing Reduction Associated With Nitrates|Flushing Reduction Associated With Nitrates|FRAN|University of California, San Francisco|Yes|Not yet recruiting|April 2016|March 2020|Anticipated|September 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714205||481|
NCT02701179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lignocaine RCT|1% vs. 2 % Lignocaine for Flexible Bronchoscopy|Comparison of 1% Versus 2% Lignocaine for Topical Anaesthesia in Flexible Bronchoscopy|LIFE|All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701179||1482|
NCT02704754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHUCCTS2015-1333|Suvorexant and Trauma Related Insomnia|Suvorexant and Trauma Related Insomnia||Howard University|No|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|105|||Both|18 Years|55 Years|No|||March 2016|March 4, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704754||1207|
NCT02717819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT.PEPOP.2016|The Importance of Additional Protein to Benefit More From Training During and After Hospitalization|A Protein-enriched, Milk-based Supplement to Counteract Sarcopenia in Acutely Ill Geriatric Patients Offered Resistance Exercise Training During and After Hospitalisation - a Double-blinded, Randomized Controlled Trial|PEPOP|Copenhagen University Hospital at Herlev|No|Not yet recruiting|April 2016|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02717819||203|
NCT02715063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1006-2014|Cardiometabolic HIIT-RT Study|High Intensity Interval- vs Resistance or Combined- Training for Improving Cardiometabolic Health in Overweight Adults (Cardiometabolic HIIT-RT Study): Study Protocol for a Factorial Randomised Controlled Trial||Universidad Santo Tomas|Yes|Recruiting|January 2016|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|60|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02715063||415|
NCT02698085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.I.PI14/00086|Diacutaneous Fibrolysis on Carpal Tunnel Syndrome|Effectiveness of Physiotherapy Treatment With Diacuteneous Fibrolysis in Patients With Carpal Tunnel Syndrome||Universidad de Zaragoza|Yes|Recruiting|October 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02698085||1720|
NCT02696551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The IMPACT2 Project|Impact of Medical Education of Physician Action 2|Impact of Medical Education of Physician Action 2||Shanxi Dayi Hospital|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|N/A|N/A|No|||February 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02696551||1838|
NCT02700763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201600134|[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis|PET Imaging of [18F]Dabrafenib Distribution and Kinetics in Brain Metastasis in Patients With BRAF Positive Metastastic Melanoma. A Feasibility Study.||University Medical Center Groningen|No|Not yet recruiting|April 2016|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02700763||1514|
NCT02718118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI.04.SPR.US10348|Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines|A Prospective, Randomized, Multi-Center, Subject- and Evaluator-Blinded, Parallel Comparison of Dysport®, When Reconstituted at 1.5 mL and 2.5 mL, for the Treatment of Moderate to Severe Glabellar Lines.||Galderma Laboratories, L.P.|No|Not yet recruiting|May 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718118||180|
NCT02715375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U44-CRE-01|Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Allergic Asthma|A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Allergic Asthma|CREON2000A|General Innovations and Goods, Inc.|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|228|||Both|6 Years|17 Years|No|||March 2016|March 16, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715375||391|
NCT02698319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HerlevH02|The Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm|CTA|Herlev Hospital|No|Active, not recruiting|April 2015|June 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50000|||Both|16 Years|N/A|No|||February 2016|February 28, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02698319||1702|
NCT02698332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCAREALG|Effect of a Diagnostic Algorithm for Urinary Tract Infection in General Practice|Effect of a Diagnostic Algorithm for Urinary Tract Infection on Appropriate Use of Antibiotics and Diagnostics in General Practice - a Cluster Randomized Trial||University of Copenhagen|No|Not yet recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|N/A|N/A|No|||February 2016|February 26, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02698332||1701|
NCT02709226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160081|Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma|A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma||National Institutes of Health Clinical Center (CC)||Recruiting|March 2016|October 2025|Anticipated|October 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|50 Years|No|||February 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02709226||864|
NCT02716571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG4101_HCC_Donor|Recruiting Blood Donor With Allogeneic Natural Killer Cell|Recruiting Blood Donor With Allogeneic Natural Killer Cell Which Will be Used for HCC After TACE||Seoul National University Hospital|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02716571||299|
NCT02699957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAO Registry|Left Atrial Appendage Occlusion Registry (LAAO Registry)|Left Atrial Appendage Occlusion Registry (LAAO Registry)||American College of Cardiology|No|Recruiting|December 2015|January 2026|Anticipated|January 2026|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|All facilities performing percutaneous or epicardial left atrial appendage occlusion        procedures.|March 2016|March 4, 2016|February 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699957|2 Years|1576|
NCT02700230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1372|Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery|Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor||Mayo Clinic|Yes|Not yet recruiting|June 2016|||June 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700230||1555|
NCT02698995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID AN-002-14|Perineural Low-dose Dexamethasone Added to Infraclavicular Block Anesthesia|Analgetic Efficiency of Single-shot Perineural Low Dose Dexamethasone Added to Infraclavicular Block Anesthesia for Upper Limb Surgery||Foisor Orthopedics Clinical Hospital|Yes|Recruiting|November 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|85 Years|No|||February 2016|March 22, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02698995||1650|
NCT02711306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209019|Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome|Office of Human Research, Taipei Medical University||Taipei Medical University|Yes|Completed|May 2013|March 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|66|||Both|20 Years|64 Years|No|||March 2013|March 13, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02711306||704|
NCT02704455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHlung005|Registry Study on Primary Ciliary Dyskinesia in Chinese Children|Registry Study on Primary Ciliary Dyskinesia in Chinese children-a Multicenter, Prospective Cohort Study||Beijing Children's Hospital|Yes|Not yet recruiting|May 2016|July 2030|Anticipated|May 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|Children who was confirmed diagnosis as primary ciliary dyskinesia at the certain        hospitals (sponsor and collaborators)|March 2016|March 5, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02704455||1230|
NCT02710461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2014-55102-JIN_1|Grape and Pomegranate Polyphenols in Postprandial Glucose and Related Parameters|Acute Effects of Grape and Pomegranate Polyphenols as Modulators of Metabolic Syndrome in Humans|POME-GRAPE-1|National Research Council, Spain|No|Active, not recruiting|March 2016|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|||Actual|20|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02710461||769|
NCT02710474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ7504|Family Nurture Intervention in the NICU: Sinai West|Family Nurture Intervention in the NICU: An Effectiveness Trial||Columbia University|Yes|Not yet recruiting|April 2016|January 2020|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|320|||Both|26 Weeks|34 Weeks|No|||March 2016|March 15, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710474||768|
NCT02713620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Research ID: 2986|Hepatitis B Vaccination in HIV-infected Adults|Comparison of Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-infected Adults: a Result From Randomized Controlled Trial at 3 Years After Vaccination||Chiang Mai University|No|Recruiting|March 2015|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|176|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02713620||526|
NCT02717949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042015-086|Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study|Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study|Optimal|University of Texas Southwestern Medical Center|Yes|Recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|November 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02717949||193|
NCT02702102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAQ0756|Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies|Imaging Inflammation in Patients With Diffuse Lewy Body Disease||Columbia University|No|Recruiting|December 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702102||1411|
NCT02708108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-14-00073|Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)|Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)||Children's Hospital Los Angeles|No|Not yet recruiting|April 2016|December 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|10 Years|21 Years|No|||March 2016|March 9, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02708108||950|
NCT02706639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160074|Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank|Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank||National Institutes of Health Clinical Center (CC)||Recruiting|February 2016|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|N/A|85 Years|No|||February 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706639||1063|
NCT02715635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/LO/0789|Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation|A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate on a Model of Vascular Dysfunction in Healthy Volunteers||Queen Mary University of London|No|Not yet recruiting|March 2016|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715635||371|
NCT02705898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507-001|Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women|Technology-Supported Physical Activity Intervention for Depressed Alcoholic Women||Butler Hospital||Recruiting|September 2015|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|65 Years|No|||March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02705898||1119|
NCT02710682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 15.327|Tendon Fenestration Versus Surgery for the Treatment of Chronic Lateral Epicondylosis|Ultrasound-guided Tendon Fenestration Versus Open Surgery for the Treatment of Chronic Lateral Epicondylosis of the Elbow: a Prospective, Randomized, Single Blind, Pilot Study.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|March 2016|February 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|30 Years|67 Years|No|||March 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02710682||752|
NCT02716142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISOP|Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy|Rectal Misoprostol Versus Sublingual Misoprostol in Decreasing Blood Loss Prior to Abdominal Myomectomy: A Randomized Double-blinded Clinical Trial|RM-SLM|Assiut University|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|50 Years|No|||March 2016|March 17, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716142||332|
NCT02716155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-2015-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2016|||||N/A|N/A|N/A||||||||||||||March 24, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716155||331|
NCT02712398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE-017|A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair|A Prospective, Multi-center Trial of a Long-term Bio-Absorbable Mesh With Sepra Technology in Challenging Laparoscopic Ventral or Incisional Hernia Repair|ATLAS|C. R. Bard|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712398||620|
NCT02702635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5150234|Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging|Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging||Loma Linda University||Recruiting|September 2015|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patient populations of LLUMC with an existing order for a MRI CNS study with contrast             being evaluated for trauma between the ages of 0-100 years will be recruited.             Patients will be asked if they will allow us to acquire one additional sequence (DCE,             duration 10-15 min) during injection of the contrast agent. All other imaging will be             done per the routine brain imaging protocol. We plan to recruit 25 subjects.          -  Healthy volunteers between the ages of 18-100 years will be recruited from the local             population using word of mouth. They will be asked to have a MRI study of the CNS             with contrast. The DCE images will be acquired during contrast agent injection, and a             routine head protocol will also be run. We plan to recruit 25 subjects.|September 2015|March 3, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702635||1370|
NCT02710344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28105|Using Telehealth to Improve Psychiatric Symptom Management|Automated Telehealth to Improve Psychiatric Self-Management and Community Tenure||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|September 2015|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02710344||778|
NCT02710734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-086|Trimodality Bladder Preservation Therapy: Maximal Transurethral Resection Followed by Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (AMVAC) and Concurrent Chemoradiation With Intensity Modulated Radiation Therapy for Muscle Invasive Bladder Cancer|||Fox Chase Cancer Center|Yes|Recruiting|February 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710734||748|
NCT02710747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDREC2014265H|The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.|The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.|POWAT|Guangdong General Hospital|Yes|Recruiting|January 2015|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||December 2015|March 11, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710747||747|
NCT02654236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT 005|Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling|Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling||Indiana University|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|45|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 6, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02654236||5082|
NCT02660034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB-A317/BGB-290_Study_001|The Safety, Pharmacokinetics and Antitumor Activity of the BGB-A317 in Combination With the BGB-290 in Subjects With Advanced Solid Tumors|A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors||BeiGene||Recruiting|January 2016|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|January 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02660034||4636|
NCT02650466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EnI-13129|Nanopulse Efficacy Study for the Treatment of Common Warts|Nanopulse Efficacy Study for the Treatment of Common Warts||University of Southern California|No|Recruiting|December 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02650466||5370|
NCT02717182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPS1439089|Classification of Patient Therapeutic Education Programs Components : Etude CONCErTo|Development of a Classification of the Components of Patient Therapeutic Education Interventions That Can Impact Their Results and Can Ensure Their Continued Existence CONCErTo Study|CONCErTo|Central Hospital, Nancy, France|No|Not yet recruiting|April 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|100 Years|No|Non-Probability Sample|patients following a patient education program health care professionals|March 2016|March 17, 2016|September 28, 2015||No||No||https://clinicaltrials.gov/show/NCT02717182||252|
NCT02695719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lubiprostone-3002|Lubiprostone for Treatment of Chronic Idiopathic Constipation|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation||Takeda|No|Not yet recruiting|May 2016|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02695719||1902|
NCT02708446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1013|A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion|A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP)||Gynuity Health Projects|No|Recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708446||924|
NCT02708459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abuelella TAP|Transversus Abdominus Plane Block in Living Donor Hepatectomy||TAP Donor|Mansoura University|Yes|Not yet recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|45 Years|No|||March 2016|March 14, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708459||923|
NCT02719808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AHCR2014-018|Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection|A Cohort Study of Tenofovir on Blocking HBV Intrauterine Infection||First Affiliated Hospital Xi'an Jiaotong University|No|Recruiting|March 2015|February 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|Samples Without DNA|Blood, placenta tissue of HBeAg-positive pregnant women|Female|N/A|N/A|No|Non-Probability Sample|pregnant women with HBeAg-positive and HBV-DNA>106copies/ml from the out-patient        department of First Affiliated Hospital of Xi'an Jiaotong University|February 2016|March 24, 2016|March 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719808||50|
NCT02701842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPR-16-05|ImPACT Online Clinical Study|ImPACT Online Clinical Study||ImPACT Applications, Inc.|No|Recruiting|February 2016|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|400|||Both|12 Years|59 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701842||1431|
NCT02704429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN1008-005|A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris|An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris||Principia Biopharma, Inc.|Yes|Recruiting|February 2016|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||February 2016|March 4, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02704429||1232|
NCT02704702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FRC-CT-102|A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects|||Boryung Pharmaceutical Co., Ltd||Not yet recruiting|April 2016|||July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|36|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704702||1211|
NCT02708511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNOVA0033|Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian Cancer|64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study||Stanford University|Yes|Recruiting|June 2015|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|November 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02708511||919|
NCT02708524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-5808|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||March 9, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708524||918|
NCT02716051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I15037/WILSON|Wholebody MRI In Lung Cancer StagiNg|Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner|WISLON|University Hospital, Limoges|No|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02716051||339|
NCT02705625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIV-711-201|A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients|A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis||Medivir|Yes|Recruiting|January 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|40 Years|80 Years|No|||March 2016|March 10, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705625||1140|
NCT02705638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-003700|Treatment of IgG4-Related Disease With Revlimid and Rituximab|Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial|TIGR2|Mayo Clinic|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02705638||1139|
NCT02697539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-UM-01-2011|Plaque Formation Rate and Toothpaste|"Efficacy of a New Carbonate/Hydroxyapatite Nanocrystal Dentifrice on the Dental Plaque Index and the de Novo Plaque Formation Rate in Individuals Suffering From Gingivitis and/or Periodontitis"|PFR|University Hospital Muenster|No|Completed|March 2011|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|74|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697539||1762|
NCT02697552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBI-8000-201|Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma|A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma||HUYA Bioscience International|Yes|Recruiting|March 2014|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|N/A|No|||March 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02697552||1761|
NCT02708602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCHC2016003|Correlation Between the Polymorphism ofβ2 AR and the Labor Progress After Labor Analgesia|Principal Investigator||Nanjing Maternity and Child Health Care Hospital||Not yet recruiting|March 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Anticipated|300|||Female|23 Years|43 Years|No|Probability Sample|The parturient undergoing labor analgesia in our hospital. And the eligible parturient        aged at 23-43, gestational age 35-42 weeks with an ASA grade I-II, who spontaneously        choosing vaginal delivery mode with epidural analgesia.|March 2016|March 16, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02708602||912|
NCT02716337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Target HM fortification|Target Versus Standard Human Milk Fortification in Very Low Birth Weight Preterm Infants|||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|October 2014|||March 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|N/A|N/A|No|||March 2016|March 17, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02716337||317|
NCT02699385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR107501|A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis||Janssen-Cilag International NV|Yes|Not yet recruiting|June 2016|November 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|6 Months|12 Years|No|||March 2016|March 23, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02699385||1620|
NCT02706028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PetzACTH|Effects of Underwater Ultrasound Therapy on Hand Function and Quality of Life in Patients With Rheumatoid Arthritis|Effects of Underwater Ultrasound Therapy on Hand Function and Quality of Life in Patients With Rheumatoid Arthritis - a Randomized Controlled Study||Petz Aladar County Teaching Hospital|No|Completed|February 2013|November 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706028||1109|
NCT02702219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTU_STRETCH_RCT|Effect of Flexibility Training Versus Static Stretching on Hamstring Muscle Length and Patterns of Lumbar Flexion|Effect of Dynamic Flexibility Training Versus Prolonged Static Stretching on Length of the Hamstrings Muscles and Patterns of Lumbar Flexion in Healthy Adults -a Randomized Controlled Trial||Luleå Tekniska Universitet|No|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02702219||1402|
NCT02715596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 261/14|Changes in Body Composition After EPA Supplementation in Head and Neck Patients|Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb)|hepaneck|Institut Català d'Oncologia|No|Recruiting|December 2015|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 12, 2015||No||No||https://clinicaltrials.gov/show/NCT02715596||374|
NCT02715609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-x389|Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|A Phase I/II Dose-escalation Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma||Washington University School of Medicine|No|Not yet recruiting|June 2016|June 2019|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715609||373|
NCT02699645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIDENT-1103886|Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial|Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)|TRIDENT|The George Institute|Yes|Not yet recruiting|September 2016|||December 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4200|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02699645||1600|
NCT02699658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levo-57-356141|Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin|||Prince of Songkla University|No|Completed|October 2013|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 3, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02699658||1599|
NCT02699671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2016-01|IRIS-BVS AMI Registry|Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Acute Myocardial Infarction; A Multicenter, Prospective Observational Study|IRIS BVS AMI|Asan Medical Center|Yes|Not yet recruiting|May 2016|December 2022|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|19 Years|N/A|No|Non-Probability Sample|Acute myocardial infarction patients with Bioresorbable Vascular Scaffold|March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699671||1598|
NCT02707926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601M83126|The Lymphoid Tissue Pharmacology of Antiretroviral Drugs|The Lymphoid Tissue Pharmacology of Antiretroviral Drugs||University of Nebraska|No|Not yet recruiting|July 2018|June 2021|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|Samples Without DNA|Blood, urine, lymph node biopsy, colonoscopy biopsy of ileum and rectum|Both|18 Years|N/A|No|Non-Probability Sample|Eighteen (18) antiretroviral drug (ARV)-naive, HIV-infected persons who are going to        initiate ARV therapy will be recruited at the University of Minnesota. Study entry is open        to adults regardless of race or ethnic background. While there will be every effort to        seek out and include minority participants from both genders, the patient population is        expected to be no different than that of the HIV infected population in Minnesota.|March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707926||964|
NCT02703272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108134|A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma|A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma||Janssen Research & Development, LLC|Yes|Not yet recruiting|June 2016|March 2024|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|1 Year|30 Years|No|||March 2016|March 24, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703272||1321|
NCT02712346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endothelin|The Role of Endothelin-1 in Sickle Cell Disease|The Role of Endothelin-1 in Sickle Cell Disease||Georgia Regents University|No|Recruiting|September 2015|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|March 14, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712346||624|
NCT02700438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG15-02|Glyceryl Trinitrate Ointment vs Posterior Tibial Nerve Stimulation in the Treatment of Anal Fissure|Perianal Application of Glyceryl Trinitrate 0.4% Ointment vs Percutaneous Posterior Tibial Nerve Stimulation in the Treatment of Chronic Anal Fissure||Hospital General Universitario Elche|Yes|Completed|January 2014|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||March 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02700438||1539|
NCT02703935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD_1|Effectiveness of an Adventure-based Training Programme to Reduce Fatigue for Childhood Cancer Survivors|Effectiveness of an Adventure-based Training Programme in Promoting Regular Physical Activity, Reducing Fatigue and Enhancing Quality of Life Among Hong Kong Chinese Childhood Cancer Survivors||The University of Hong Kong|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|7 Years|18 Years|No|||March 2016|March 8, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703935||1270|
NCT02703493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-309A|Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer|A Phase I Trial of IMRT With Dose-Escalated Image-Guided Stereotactic Radiosurgery (SRS) Boost for Human Papilloma Virus (HPV)- Unassociated Oropharyngeal Cancer||Northwell Health|Yes|Recruiting|March 2010|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02703493||1304|
NCT02700659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cxb-012-EXP-013|The Cxbladder Monitoring Study|A Clinical, Non-intervention Study of the Cxbladder Urine Test for the Detection of Recurrent Urothelial Carcinoma (UC)||Pacific Edge Limited|Yes|Recruiting|November 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1050|Samples With DNA|De-identified, consented participant samples of between 5mL and 15 mL of urine, stabilized      in the proprietary Cxbladder liquid, will be stored at -80ºC for further urinary diagnostic      assay development and improvement.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects were recruited from community and referral centres. Patients were under        surveillance for recurring urothelial carcinoma monitoring, and undergoing all standard of        care, including investigative cystoscopy.|March 2016|March 4, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02700659||1522|
NCT02704676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA125|CA-125 and Severity of Pre-Eclampsia|CA-125 and Severity of Pre-Eclampsia||Ain Shams Maternity Hospital|Yes|Not yet recruiting|March 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|120|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The study population comprises pregnant women once diagnosed pre-eclampsia, attending to        Ain Shams University Maternity Hospital, or for antinatal care of the corrosponding        gestational age.|March 2016|March 17, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02704676||1213|
NCT02695784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7840|Probiotics After Discharge|Probiotics After Discharge (PAD) Study: Impact on Microbiome, Health and Growth Outcomes|PAD|Newcastle-upon-Tyne Hospitals NHS Trust||Not yet recruiting|April 2016|||April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|N/A|32 Weeks|No|||February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695784||1897|
NCT02714478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Equistasi.01|"Equistasi" and Gait in Hemiparesis|Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident||Ospedale Generale Di Zona Moriggia-Pelascini||Recruiting|April 2015|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714478||460|
NCT02714491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erigo.stim|Effects of Auditory Stimulation During Verticalization With Erigo in Patients With Disorder of Consciousness|||Ospedale Generale Di Zona Moriggia-Pelascini||Recruiting|June 2015|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|15|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714491||459|
NCT02697526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)70/2006|Differences in Radial Artery Occlusion From Two Different Compressive Methods Used in Patients in Order to Achieve Homeostasis After Transradial Catheterization and Their Repercussion in Artery Functionality and Hand Mobility|Influence of the Compression Method After Transradial Catheterization in Radial Artery||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|274|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697526||1763|
NCT02700295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-260514|Long Term Effects of Multifocal Orthokeratology on Corneal and Choroidal Structures in Healthy Subjects With Myopia- A Pilot Study|Long Term Effects of Multifocal Orthokeratology on Corneal and Choroidal Structures in Healthy Subjects With Myopia- A Pilot Study||Medical University of Vienna|No|Recruiting|February 2016|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|10 healthy volunteers|March 2016|March 17, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02700295||1550|
NCT02717533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01249-B|Blood Volume Analysis and Renal Outcomes in Hemodialysis|Blood Volume Analysis and Renal Outcomes in Hemodialysis||VA New York Harbor Healthcare System||Completed|January 2014|January 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|21 Years|N/A|No|Non-Probability Sample|Hemodialysis patients|March 2016|March 22, 2016|February 4, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717533||225|
NCT02718833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-475|A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma|A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma||Massachusetts General Hospital|Yes|Not yet recruiting|March 2016|September 2023|Anticipated|September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718833||125|
NCT02718846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-ISOBIDE_P4|Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets|A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease||Alvogen Korea|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|20 Years|80 Years|No|||March 2016|March 23, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02718846||124|
NCT02705677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN # 5213|Biobanking of Rett Syndrome and Related Disorders|Biobanking of Rett Syndrome and Related Disorders Protocol||University of Alabama at Birmingham|Yes|Recruiting|December 2015|December 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1200|Samples With DNA|DNA and RNA from blood, plasma, hair follicles, skin biopsies|Both|N/A|N/A|No|Probability Sample|Females and males of all ages must have complete testing for MECP2, FOXG1, and CDKL5 genes        mutations AND must meet these requirements:        Gene positive for a sequence mutation, duplication or deletion in one of these 3 genes.        OR Meet consensus criteria for Rett syndrome (typical or atypical)|November 2015|March 17, 2016|November 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02705677||1136|
NCT02709317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|818671|Preventing Risky Drinking in Veterans Treated With Prescription Opioids|Preventing Risky Drinking in Veterans Treated With Prescription Opioids||University of Pennsylvania|No|Recruiting|April 2014|October 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|88 Years|No|||February 2016|March 10, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02709317||857|
NCT02696304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00170-49|The Metabolic Syndrome Among Leukemia Survivors: Physiopathological Analysis|The Metabolic Syndrome Among Childhood Acute Leukemia Survivors: Physiopathological Analysis|LEAMS|Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2015|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|March 1, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02696304||1857|
NCT02713295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-693|A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece|A Non-interventional Prospective Cohort Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece|CONCORDIA|AbbVie|No|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with Moderate to Severe Plaque Psoriasis in Greece|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713295||551|
NCT02719678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monica Intervention|Epidemiological Studies of Health Effects of General Examinations|Epidemiological Studies of Health Effects of General Examinations||Glostrup University Hospital, Copenhagen|Yes|Completed|January 1982|September 2014|Actual|December 1984|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|17845|||Both|30 Years|60 Years|No|||March 2016|March 24, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719678||60|
NCT02719691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1135.cc|Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer|A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)||University of Colorado, Denver|Yes|Not yet recruiting|April 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|101 Years|No|||March 2016|March 24, 2016|March 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719691||59|
NCT02702648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-082-101|First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders|Single-center, Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Subjects||Actelion|No|Recruiting|February 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|128|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02702648||1369|
NCT02706418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-01|Clinical Massage Therapy as a Treatment for Carpal Tunnel Syndrome|A Standardised Massage Protocol as an Effective Treatment for Chronic Carpal Tunnel Syndrome||Jing Advanced Massage Training||Not yet recruiting|March 2016|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02706418||1080|
NCT02713542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arthrex 004|Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)|Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)||Arthrex, Inc.|No|Not yet recruiting|March 2016|August 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713542||532|
NCT02713555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RYGBGS2016|Effect of Roux-en-Y Gastric Bypass or Gastric Sleeve Surgery on Type 2 Diabetes|Effects of Hepatic Insulin Resistance on Type 2 Diabetes Mellitus in Morbidly Obese Subjects Following Roux-en-Y Gastric Bypass Surgery or Gastric Sleeve Surgery||University of Aarhus|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|March 18, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02713555||531|
NCT02719925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGL-002|Mineral Water Rich in Magnesium and Perceived Stress in Healthy Consumers|Effect of One Month of Daily Consumption of Mineral Water Rich in Magnesium on Perceived Stress in Healthy Consumers.|STRESSOM15|My Goodlife SAS|No|Not yet recruiting|April 2016|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719925||41|
NCT02702895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-032|Assessment of ASPIRE and HOPE Adherence|Assessment of ASPIRE and HOPE Adherence||Microbicide Trials Network|No|Not yet recruiting|June 2016|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|224|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A sample size of up to 224 former ASPIRE participants will be selected to take part in        Phase 1 of the study, and approximately 84 Phase 1 participants who then enroll in HOPE        will be selected to take part in Phase 2. Participants will all be adult women from seven        sites in three African countries: South Africa, Uganda and Malawi. It is anticipated that        participants will be representative of the overall ASPIRE and HOPE trials by enrolling        participants from each of the participating ASPIRE and HOPE countries.|March 2016|March 3, 2016|August 31, 2015||No||No||https://clinicaltrials.gov/show/NCT02702895||1350|
NCT02698709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clínica Oftalmológica HCFM/USP|Astigmatic Vector Analysis of Posterior Cornea - a Comparison Among Healthy, Forme Fruste and Overt Keratoconus Corneas|Astigmatic Vector Analysis of Posterior Corneal Surface - a Comparison Among Healthy, Forme Fruste and Overt Keratoconus Corneas||University of Sao Paulo|Yes|Completed|May 2015|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|698|||Both|N/A|N/A|No|Probability Sample|Two databases of patients were examined at the Instituto de Olhos Renato Ambrósio (Rio de        Janeiro, Brazil), between July 2004 and October 2013. One of the databases contained        information of normal candidates to refractive surgery who did not develop any sign of        corneal ectasia after laser in situ keratomileusis during a two year follow-up period (C).        The second database included information concerning corneas with keratoconus (Kc),        categorized as overt Kc, if both eyes manifested classic Kc-suggestive topographic        features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior        asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers;        or forme fruste (FFKc), if only one eye exhibited such features.|February 2016|February 29, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02698709||1672|
NCT02712112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC1601|A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs|Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)||Asan Medical Center|No|Recruiting|January 2016|June 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712112||642|
NCT02701595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RODEO 2|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles)||University Hospital, Tours|Yes|Not yet recruiting|March 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02701595||1450|
NCT02705651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN_001/16|Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment|Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study|SANO|Medical University of Vienna|Yes|Not yet recruiting|June 2016|June 2022|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705651||1138|
NCT02703402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0526|Effects of an Exercise Program Under Supervision and Unsupervised in the Treatment of Low Back|Effects of an Exercise Program Under Supervision and Unsupervised in the Treatment of Low Back Pain: a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02703402||1311|
NCT02702973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016WD2M1|Characteristic Analysis of Retinopathy Associated With High Doses of Interferon α-2b Therapy|Characteristic Analysis of Retinopathy Associated With High Doses of Interferon α-2b Therapy in Patients With Melanomas of the Skin|CARI2b|First Hospital of Jilin University|Yes|Recruiting|December 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Crossover||1|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|Eighteen patients with melanomas of the skin whose tumors have been resected completely        were collected|February 2016|March 8, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702973|2 Years|1344|
NCT02716350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE2016|Effect of B-GOS on the Wellbeing and Ageing in Healthy 52-65 Years Old Individuals|A Double Blind, Placebo Controlled, Randomised, Single Centred, Parallel Study to Determine the Potential of B-GOS, to Beneficially Influence the Wellbeing and Ageing in Healthy 52-65 Years Old Individuals||Clasado Limited|Yes|Recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|52 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02716350||316|
NCT02716363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-06-157|Rotational Atherectomy for Calcified lEsion By Smart Angioplasty Research Team (SMART-RACE)|SMart Angioplasty Research Team: A Multi-center, Open Study to Evaluation the Efficacy and Safety of Rotational Atherectomy With Drug Eluting Stent for Calcified LEsion in Korea (SMART-RACE) Trial||Samsung Medical Center|No|Recruiting|November 2015|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|19 Years|N/A|No|||March 2016|March 17, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02716363||315|
NCT02713100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-15|Self Reported Level of Agitation of Patients Presenting to an Emergency Department|Self Reported Level of Agitation of Patients Presenting to an Emergency Department||Mt Sinai Hospital, Chicago|No|Recruiting|October 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of patients who presented with psychiatric complaints to the        emergency department when a research fellow from the Department of Emergency Medicine is        available in the ED will be enrolled in the study.|March 2016|March 15, 2016|October 20, 2014||No||No||https://clinicaltrials.gov/show/NCT02713100||566|
NCT02697760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104069_F|The CZT Dynamic Myocardial Perfusion Imaging|The Quantification, Clinical Application of Dynamic Imaging Using Cadmium-zinc-telluride (CZT) Cameras to Assess Myocardial Perfusion|CZT|Far Eastern Memorial Hospital|No|Recruiting|September 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|80 Years|No|Probability Sample|Subjects with clinically suspected coronary artery disease, heart failure, or intermediate        and high cardiovascular risks|March 2016|March 2, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697760||1745|
NCT02697773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091056|Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee||Pfizer|Yes|Recruiting|January 2016|January 2018|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|690|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697773||1744|
NCT02708030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD Vs MAD Vs LGIT|Ketogenic Diet, Modified Atkins Diet and Low Glycemic Index Therapy Diet Among Children With Drug Resistant Epilepsy|Efficacy of Ketogenic Diet, Modified Atkins Diet and Low Glycemic Index Therapy Diet Among Children With Drug Resistant Epilepsy: A Randomised Non-Inferiority Trial||All India Institute of Medical Sciences, New Delhi|No|Not yet recruiting|April 2016|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|1 Year|15 Years|No|||March 2016|March 9, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02708030||956|
NCT02708043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 15-321|Laryngeal Mask Airway for Adenoidectomies (LMAA)|The Use of Laryngeal Mask Airway for Adenoidectomies: An Experience of 814 Paediatric Patients||Baskent University|Yes|Completed|June 2012|December 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|814|||Both|1 Year|16 Years|No|||March 2016|March 9, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02708043||955|
NCT02697110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD/13/479/741|Family Inclusive Early Brain Stimulation|Family Inclusive Early Brain Stimulation|FINEBRAINS|University of Ibadan|Yes|Active, not recruiting|November 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|480|||Both|N/A|6 Weeks|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02697110||1795|
NCT02718222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6904190-01|Impact and Performance of Institutionalizing Immediate Post-partum IUD Services|Studying the Impact and Performance of Institutionalizing Immediate Post-partum IUD Services as a Routine Part of Antenatal Counseling and Delivery Room Services in Nepal, Sri Lanka, Tanzania||Harvard School of Public Health|Yes|Recruiting|September 2015|September 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|64800|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718222||172|
NCT02710240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09315|Indocyanine Green for Central Nervous System Tumors|A Pilot/Feasibility Study of Intraoperative Image-Guided Surgery of CNS Tumors With Indocyanine Green and MR Spectroscopic Imaging||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2015|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Diagnostic|||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710240||786|
NCT02710253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0936|Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy|Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710253||785|
NCT02697045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-409-00036|Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch|Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch|ARILAI|Abdi İbrahim Otsuka|No|Not yet recruiting|April 2016|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|45 Years|No|||February 2016|February 26, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02697045||1800|
NCT02697058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331501|Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer|Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy||Baxalta US Inc.|Yes|Not yet recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|February 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02697058||1799|
NCT02710513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProAliFun_6.5_CE4372|ProAliFun_6.5_Health Effects of a Functional Pasta Enriched With Barley Beta-glucans on Healthy Subjects|Technological and Clinical Innovative Protocols for the Production of Functional Foods - 6.5 (ProAliFun65)|ProAliFun65|Azienda Ospedaliero-Universitaria Consorziale|Yes|Completed|December 2014|June 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710513||765|
NCT02710526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-549|Phase II Pharmacokinetics Study of CAM2038|Phase II, Open Label, Randomized, Two Treatment Groups, Study Assessing Pharmacokinetics After Administration of the Once Weekly and Once Monthly, Long Acting Subcutaneous Injection of CAM2038 in Opioid Dependent Subjects With Chronic Pain||Braeburn Pharmaceuticals|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|65 Years|No|||March 2016|March 11, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710526||764|
NCT02706145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.0910|Using Media to Shift Social Norms of Violence Among Youth|Changing the Narrative: Using Media to Shift Social Norms of Violence Among Youth in West Louisville||University of Louisville|No|Not yet recruiting|March 2016|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8250|||Both|10 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02706145||1100|
NCT02706327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO 14/18-31|Comparison of Two Different Insole Types in Painful Flexible Flatfoot|Comparison of Two Different Insole Types on Pain, Quality of Life and Physical Performance in Painful Flexible Flatfoot||Eastern Mediterranean University|No|Completed|January 2014|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|45 Years|No|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02706327||1086|
NCT02708186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVT-102-2002|Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia With Lewy Bodies|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia of Lewy Bodies Who Have REM Sleep Behavior Disorder (RBD)||Axovant Sciences Ltd.||Recruiting|March 2016|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||March 2016|March 18, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708186||944|
NCT02708251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTN|Glyceryl Trinitrate Versus Lidocaine Cream for IUD Insertion|Topical Glyceryl Trinitrate Versus Lidocaine Cream as Analgesia for IUD Insertion: A Randomized Controlled Trial|GTN-IUD|Assiut University|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Female|18 Years|49 Years|No|||March 2016|March 10, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708251||939|
NCT02711644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00054360|Promoting Healthy Weights, Lifestyles and Nutrition in Pregnancy|Promoting Healthy Weights, Lifestyles and Nutrition During Pregnancy Through Innovative Counselling Methods||University of Alberta|No|Recruiting|July 2015|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|70|||Female|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 22, 2015||No||No||https://clinicaltrials.gov/show/NCT02711644||678|
NCT02712671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 12/0212|Testing for Tuberculosis in the United Kingdom HIV Infected Population|Study of Systematic Tuberculosis Testing for Active, Sub-clinical and Latent Tuberculosis Infection in a United Kingdom Human Immunodeficiency Virus (HIV) Infected Cohort||University College, London|No|Active, not recruiting|June 2013|September 2024|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood plasma and serum|Both|18 Years|N/A|No|Probability Sample|Patients attending an ambulatory clinic for Human Immunodeficiency Virus (HIV) care in        London.|February 2016|March 14, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02712671||599|
NCT02716662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307014081|Safety of Caprylic Triglycerides in ALS: A Pilot Study|||Weill Medical College of Cornell University|No|Recruiting|January 2016|||January 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|99 Years|No|||March 2016|March 17, 2016|January 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02716662||292|
NCT02707601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-366-1992|Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment|A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)||Gilead Sciences|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707601||989|
NCT02708901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2011-02348280|Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters|Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters||IRCCS Fondazione Stella Maris|Yes|Recruiting|November 2015|November 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Months|72 Months|No|||March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708901||889|
NCT02711657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20150172|Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.|Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.||Odense University Hospital|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02711657||677|
NCT02660047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001623-12|Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients From South Asian Descent|Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent|MAGNA VICTORIA|Leiden University Medical Center|No|Recruiting|August 2015|September 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|69 Years|No|||January 2016|January 18, 2016|January 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02660047||4635|
NCT02659748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS M14-011|Milk Fat Intake and Metabolic Health Markers|Examining the Effects of Consuming a Diet Comprising of Milk Fat on Metabolic Health Markers|DMFMHM|University of Vermont Medical Center|Yes|Recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|January 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02659748||4658|
NCT02713178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-326|Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty||Pacira Pharmaceuticals, Inc|No|Recruiting|March 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713178||560|
NCT02699944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|767654-1|Optimization of CRT Using an ECG Vest|Optimization of Cardiac Resynchronization Therapy Using an ECG Vest||Allina Health System|No|Recruiting|November 2015|May 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02699944||1577|
NCT02709551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM_04|Comparative Intervention Study of Stress Reduction in Corporate Health Management|Comparative Intervention Study of Stress Reduction in Corporate Health Management: Evaluation of the Effects of Heart Rate Variability (HRV) Biofeedback Training, Mindfulness Based Intervention (MBI) and Mindfulness Based HRV-biofeedback||ARCIM Institute Academic Research in Complementary and Integrative Medicine||Completed|February 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02709551||839|
NCT02709564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|misop 2|Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy|Single Dose Versus Two Doses of Sublingual Misoprostol in Decreasing Blood Loss Prior to Abdominal Myomectomy: A Randomized Double-blinded Clinical Trial|SL-MISO|Assiut University|Yes|Not yet recruiting|April 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|50 Years|No|||March 2016|March 11, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709564||838|
NCT02715817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|943.738|Virtual Rehabilitation and Therapeutic Exercise in the Treatment of Post-stroke Hemiparetic|The Effect of Virtual Rehabilitation With Nintendo Wii ® and Proprioceptive Neuromuscular Facilitation Exercises in the Treatment of Hemiparesis Poststroke Adults||Federal University of Bahia|No|Recruiting|June 2015|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715817||357|
NCT02705508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-SYSUCC-2016|PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma|Phase 2 Trial of PEG-ASP Combined With Etoposide and Gemcitabine (PEG) as First-line Chemotherapy to Treat NK/T-cell Lymphoma||Sun Yat-sen University|No|Recruiting|February 2016|September 2021|Anticipated|February 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705508||1149|
NCT02709759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AA01907|Behavioral Interventions to Reduce Heavy Drinking Among MSM in HIV Primary Care|Behavioral Interventions to Reduce Heavy Drinking Among MSM in HIV Primary Care||Brown University|No|Not yet recruiting|April 2016|December 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|224|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709759||823|
NCT02709837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU 1030|Impact of Food Process and Mastication on Nutrient Bioavailability|Impact of Food Process and Mastication on Nutrient Bioavailability|DREAM|Institut National de la Recherche Agronomique|No|Completed|June 2013|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|10|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02709837||817|
NCT02696044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00085194|Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin|Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin: An Open-label, 10-subject Clinical Trial of UX007 (Triheptanoin) in the Treatment of Mitochondrial Dysfunction in Participants With Rett Syndrome, Dyskinesia, and Epilepsy||Emory University|No|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|10|||Female|2 Years|N/A|No|||March 2016|March 1, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696044||1877|
NCT02696057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO13/550|The Effect of Manual Therapy and Exercise in Patients With Low Back Pain|Bel-boyun ağrısı Nedeniyle başvuran Hastalarda farklı Fizyoterapi ve Manuel Terapi yöntemlerinin ağrı, Fonksiyon ve yaşam Kalitesi düzeyleri üzerin Etkisi||Hacettepe University|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|33 Years|64 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02696057||1876|
NCT02718482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsteoREC2015|Phase II Trial for the Treatment of Relapsed Osteosarcoma|Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma|OsteoREC2015|Italian Sarcoma Group|No|Not yet recruiting|April 2016|April 2025|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|N/A|No|||March 2016|March 18, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02718482||152|
NCT02710968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054901|Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH)|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe Left Congenital Diaphragmatic Hernia (CDH)|FETO|Johns Hopkins University|Yes|Recruiting|August 2015|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|August 17, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710968||730|
NCT02701205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRSTPP|Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis||Shanghai Celgen Bio-Pharmaceutical Co.,Ltd|No|Recruiting|January 2015|December 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|216|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02701205||1480|
NCT02696317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE198-P001|Clinical Evaluation of ACUVUE® OASYS® 1-Day and ACUVUE® OASYS®|Clinical Evaluation of ACUVUE® OASYS® 1-Day Daily Disposable Silicone Hydrogel Contact Lenses||Alcon Research|No|Not yet recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696317||1856|
NCT02696330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSI|Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI|Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI||Ain Shams Maternity Hospital|Yes|Recruiting|September 2015|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02696330||1855|
NCT02703844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KENT/DW/PD/2016|Vestibular Stimulation in Parkinson's Disease|Caloric Vestibular Stimulation in Parkinson's Disease||University of Kent|No|Not yet recruiting|March 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||February 2016|March 8, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02703844||1277|
NCT02710838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRI-EGC|The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer|The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer and Evaluate the Invasive Depth of Tumors||Xijing Hospital of Digestive Diseases|Yes|Recruiting|January 2014|February 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710838||740|
NCT02709616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ag-mRNA-DC-999brain|Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)|Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)|PERCELLVAC|Guangdong 999 Brain Hospital|No|Recruiting|March 2016|June 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02709616||834|
NCT02715310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKG HN 1|Haemodynamic Monitoring in Head and Neck Cancer Patients||HMHN|Technische Universität München|No|Recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|Samples Without DNA|Blood parameters|Both|18 Years|N/A|No|Probability Sample|Full grown, able to consent patients admitted for major head and neck surgery with planned        microvascular transplants for reconstruction due to tumors in the head and neck region.|March 2016|March 22, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02715310||396|
NCT02703857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-002317-30|Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique||PROPHYLOXITINE|Poitiers University Hospital||Not yet recruiting|February 2016|||August 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|80 Years|No|||February 2016|March 8, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02703857||1276|
NCT02707939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00021473|Observational Prospective Study on Behavioral Outcomes of Children With Autism Spectrum Disorder (ASD) in Comparison to Those Without Neurodevelopmental Diagnoses|Observational Prospective Study on Behavioral Outcomes of Children With Autism Spectrum Disorder (ASD) in Comparison to Those Without Neurodevelopmental Diagnoses||Children's Hospital Boston|No|Recruiting|February 2016|||March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|2 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with an ASD diagnosis and control patients who do not have any history of        neurodevelopmental concerns who are scheduled for a surgical procedure at Boston        Children's Hospital.|March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02707939||963|
NCT02707952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15-594|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)|CERTAIN-1|AbbVie|No|Recruiting|February 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|245|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707952||962|
NCT02711384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4555|Determine the Effective Dose 95 of Sevoflurane in Adult Patients|Determine the Effective Dose 95 of Sevoflurane in Adult Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass.||Instituto Dante Pazzanese de Cardiologia|Yes|Not yet recruiting|March 2016|February 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with physical status ASA II to III undergoing first elective cardiac surgery for        mitral and / or tricuspid valve with cardiopulmonary bypass undergoing general anesthesia;|March 2016|March 11, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711384||698|
NCT02717975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191435|The Effect of Catheter Valve Vs. Standard Catheter Removal in Outpatients|A Prospective, Multicenter, Randomized Trial: The Effect of Catheter Valve Vs. Standard Catheter Removal in Outpatient Settings on the Patient Discharge Timings||Medway NHS Foundation Trust|No|Not yet recruiting|March 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|60 Years|85 Years|No|||March 2016|March 23, 2016|January 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02717975||191|
NCT02704416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PacificRERI|Ablation in Brugada Syndrome for the Prevention of VF|Ablation in Brugada Syndrome for Prevention of VF - A Randomized, Multi-center Study of Epicardial Ablation in Brugada Syndrome Patients to Prevent Arrhythmia Recurrence|BRAVE|Pacific Rim Electrophysiology Research Institute|Yes|Not yet recruiting|July 2016|July 2021|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|184|||Both|18 Years|80 Years|No|||March 2016|March 4, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02704416||1233|
NCT02708329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TvsMC 1.0|T-provisional Stenting vs Mini-Crush in Chronic Total Occlusions (CTO)|Results of T-provisional and Mini Crush Stenting in Patients With Bifurcation Lesions After Chronic Coronary Arteries Occlusions Recanalization: A Prospective Randomized Single-center Study.||Meshalkin Research Institute of Pathology of Circulation||Completed|January 2011|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708329||933|
NCT02711410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NationalCardioCenterCognac|The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients|The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study||National Cerebral and Cardiovascular Center|Yes|Completed|October 2009|October 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|518|Samples With DNA|Genomic DNA was extracted from peripheral blood leukocytes. The genotypes of the CYP2C19*2      (c.681G>A, rs4244285), *3 (c.636G>A, rs4986893), and *17 (c.-806C > T, rs12248560) variants      were determined by the TaqMan genotype discrimination method (Applied Biosystems, Foster      City, CA, USA) using commercially available primers and probes purchased from the      Assay-on-Demand system.|Both|20 Years|N/A|No|Probability Sample|Patients were recruited at each institution between October 2009 and March 2012. The        investigators enrolled males and females aged 20 years or older who had experienced        cerebral infarction or transient ischemic attack (TIA) (except for cardiogenic embolism)        in the prior 3 years but not in the last one month, who received long-term clopidogrel        therapy (75 mg once a day) for the secondary prevention (for at least one month), and who        were willing and able to give written informed consent.|March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02711410||696|
NCT02713152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02058|Prevalence of Obstructive Sleep Apnoea in Glaucoma|POSAG: Prevalence of Obstructive Sleep Apnoea in Glaucoma|POSAG|Papworth Hospital NHS Foundation Trust|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|480|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and healthy volunteers|March 2016|March 14, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02713152||562|
NCT02713412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/12/TQEHLMH/106|Effects of Water and Glucose Drinks on Cardiovascular Function in Subjects With and Without Postprandial Hypotension|Cardiovascular Function and Postprandial Hypotension (PPH): Effect of an Oral Glucose Load on Cardiac Contractility, Cardiac Output, Diastolic Function and Endothelial Function - Relationship to Gastric Emptying||Royal Adelaide Hospital|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|8|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02713412||542|
NCT02704689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-L-001|AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY|A Prospective Multi-Center Evaluation of a Hydraulic Expandable TLIF Cage for the Treatment of Degenerative Disc Disease of the Lumbar Spine|APROPOS|Stryker Spine|No|Recruiting|December 2015|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||March 2016|March 4, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704689||1212|
NCT02709252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201134|Effect of the Pneumoperitoneum on Dynamic Variables Delta PP and PVI During Trendelenburg Position.|Effect of the Pneumoperitoneum on Dynamic Variables Delta PP and PVI During Trendelenburg Position.||Brugmann University Hospital||Completed|January 2011|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|100 Years|No|||March 2016|March 10, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02709252||862|
NCT02712775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL-001|Minocycline Administration During Human Liver Transplantation|Minocycline Administration During Human Liver Transplantation||Medical University of South Carolina||Not yet recruiting|March 2016|January 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|N/A|N/A|No|||March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712775||591|
NCT02717039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1512277980|Pharmacogenomics of Heparin-Induced Thrombocytopenia|Pharmacogenomics of Heparin-Induced Thrombocytopenia|PHIT|University of Arizona|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|125|Samples With DNA|Whole blood will be stored in freezers at minus 80 degrees|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from a hospital setting and identified based on laboratory        testing for heparin-induced thrombocytopenia.|March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717039||263|
NCT02719158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-201508|Dose Ranging Study of OTO-201 in AOMT|A 1-Month, Prospective, Multicenter, Randomized, Dose-Ranging, Sham-Controlled, Blinded Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects||Otonomy, Inc.|No|Recruiting|February 2016|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|125|||Both|6 Months|17 Years|No|||March 2016|March 21, 2016|March 21, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719158||100|
NCT02719171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.5|BI 655066 Compared to Placebo in Patients With Active Psoriatic Arthritis|A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066 in Patients With Active Psoriatic Arthritis||Boehringer Ingelheim||Not yet recruiting|April 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 18, 2016||||No||https://clinicaltrials.gov/show/NCT02719171||99|
NCT02719184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2069|Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD|Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Two Years||Boehringer Ingelheim||Not yet recruiting|April 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|540|Samples With DNA|Solube and imaging biomarkers|Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and COPD patients|March 2016|March 21, 2016|March 18, 2016||||No||https://clinicaltrials.gov/show/NCT02719184||98|
NCT02702128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_68|Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery|Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery|LEFORTEXACYL|University Hospital, Lille|No|Recruiting|January 2016|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|12 Years|N/A|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702128||1409|
NCT02702349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-15|The Frequency of Positive Challenge Test to Penicillin in Children Suspected to Have Allergy to Penicillin|The Frequency of Positive Challenge Test to Penicillin in Children Suspected to Have Allergy to Penicillin||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|6 Months|18 Years|No|||February 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702349||1392|
NCT02704481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1035|Non-surgical Alternatives to Treatment of Failed Medical Abortion|Non-surgical Alternatives to Treatment of Failed Medical Abortion: A Randomized Controlled Double-blind Trial||Gynuity Health Projects|Yes|Not yet recruiting|April 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|326|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704481||1228|
NCT02717546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSE2014-08T|Zimmer® MotionLoc® in Distal Tibia Fractures|Zimmer® MotionLoc® in Distal Tibia Fractures: An Observational Study||Zimmer, Inc.|No|Recruiting|February 2016|February 2019|Anticipated|February 2018|Anticipated|Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|February 2016|March 22, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02717546||224|
NCT02714790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM-MMR|Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia|Ruolo Prognostico Della Malattia Minima Residua Nella Leucemia Mieloide Acuta|LAM-MMR|Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Completed|May 2015|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|281|||Both|19 Years|N/A|No|Non-Probability Sample|Adult patient with new diagnosis of acute myeloid leukemia treated with intensive        chemotherapy|March 2016|March 22, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02714790||436|
NCT02714803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-11/33|Comparison of Different Massage Techniques Plus Conservative Applications in Low Back Pain|Assistant Professor||Ataturk Training and Research Hospital||Completed|March 2015|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02714803||435|
NCT02709356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-547|Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease|Proof of Concepts: Can a Supplement Ketogenic Based MCT Oil Increases Cerebral Capture Ketones in People With Alzheimer's Disease?|MCT-MA|Université de Sherbrooke|No|Recruiting|July 2015|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02709356||854|
NCT02697799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823491|A Randomized Trial of Recruitment Strategies for Research Participation|A Randomized Trial of Recruitment Strategies for Research Participation||University of Pennsylvania|Yes|Not yet recruiting|March 2016|June 2020|Anticipated|September 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|576|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02697799||1742|
NCT02700503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510313617|Finding the Patient's Voice Diabetes Prevention Programs|Finding the Patient's Voice: Development of Practical Approaches for Adolescent and Family Focused Diabetes Prevention Programs||Indiana University|No|Recruiting|November 2015|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|360|||Both|10 Years|18 Years|No|||February 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02700503||1534|
NCT02717559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160049|Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): 10 Year Onsite Follow-up|Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): 10 Year Onsite Follow-up||Vanderbilt University|No|Not yet recruiting|March 2016|December 2025|Anticipated|July 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|434|||Both|20 Years|50 Years|No|Non-Probability Sample|Participants enrolled in the Multicenter Orthopaedic Outcomes Network cohort by one of        three surgeons and meeting eligibility criteria|March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717559||223|
NCT02715687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF Treatment|Treatment of Postoperative Atrial Fibrillation - Comparison of Amiodarone and Placebo.|Treatment of Postoperative Atrial Fibrillation - Comparison of Amiodarone and Placebo.||Rambam Health Care Campus|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|100 Years|No|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715687||367|
NCT02715700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-045|A Study to Evaluate the Effects of Multiple Doses of MK-1439 (Doravirine) on Pharmacokinetics of Methadone in Participants Requiring Methadone Maintenance Therapy (MK-1439-045)|A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 (Doravirine) on Methadone Pharmacokinetics||Merck Sharp & Dohme Corp.|No|Recruiting|September 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715700||366|
NCT02707614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACU Prostastectomy 2016|Why in PACU After Prostastectomy 2016|Perioperative Mechanisms for Postoperative Function - the Case of Prostastectomy||Rigshospitalet, Denmark|Yes|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Male|18 Years|N/A|No|Non-Probability Sample|The study includes male patients with prostate cancer that will undergo surgery regarding        removal or staging of their prostate cancer. The stage of the disease is insignificant,        however the patients preoperative physical state for surgery will be registrered in        detailed such as comorbidities, height, weight, bloodpressure and blood test results.|March 2016|March 8, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02707614|1 Day|988|
NCT02709122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.010.1MR|Are EMS Personnel Prepared to Identify and Decompression of Tension Pneumothorax|Are EMS Personnel Prepared to Identify and Decompression of Tension Pneumothorax: A Randomized, Crossover Manikin Trial||Medical University of Warsaw|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02709122||872|
NCT02711111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKA Genk|Effect of Bone-anchored Protraction on Maxillary Growth in the Young Child|Effect of Bone-anchored Protraction on Maxillary Growth in the Young Child||Ziekenhuis Oost-Limburg|No|Not yet recruiting|April 2016|December 2021|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02711111||719|
NCT02717832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00111275|Protection Against Insulin Resistance in Obesity|Protection Against Insulin Resistance in Obesity|PAIR|University of Michigan|No|Not yet recruiting|March 2016|March 2023|Anticipated|March 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02717832||202|
NCT02717845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0251|CT Imaging Study for Knee Osteotomy (CISKO)|Computerized Tomography (CT) Scan Study of Bone Healing Following Open Wedge Proximal Tibial Osteotomy [CT Imaging Study for Knee Osteotomy (CISKO)]|CISKO|North Cumbria University Hospitals NHS Trust|No|Recruiting|March 2016|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|10|||Male|18 Years|100 Years|No|||March 2016|March 23, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02717845||201|
NCT02715934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DK106684-01A1|Glucose to Goal: A Model to Support Diabetes Management in Primary Care|Glucose to Goal: A Model to Support Diabetes Management in Primary Care||University of Pittsburgh|No|Not yet recruiting|April 2016|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|4400|||Both|18 Years|75 Years|No|||February 2016|March 16, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02715934||348|
NCT02707757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14HH1987|Treatment Response in Dialysis Anaemia|Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia|PRIME|Imperial College Healthcare NHS Trust|Yes|Recruiting|July 2015|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02707757||977|
NCT02702726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/01093|The Oil, Fats and Oleogel Study|The Oil, Fats and Oleogel (OFO) Study: Effects of Dietary Fats, Ingested in Two Physical Forms, on Acute Human Energy Balance, Appetitive and Glycemic Responses|OFO|Clinical Nutrition Research Centre, Singapore|No|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|5||Anticipated|24|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02702726||1363|
NCT02712827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 16-042|Comparison of Different Meshes in Laparoscopic Hernia Repair|A Randomized Controlled Trial Comparing Short Term Outcomes of Self-gripping (Progrip) Mesh With Fibrin Glue Mesh Fixation in Laparoscopic Total Extraperitoneal (TEP) Inguinal Hernia Repair||The University of Hong Kong|Yes|Recruiting|March 2016|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02712827||587|
NCT02711267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA_BE1|Bioequivalence of Topical Acyclovir in Healthy Volunteers|An Exploratory Study to Evaluate Dermal Open Flow Microperfusion's (dOFM) Ability to Assess Bioequivalence and Non-bioequivalence of Topical Acyclovir Formulations in Healthy Volunteers|FDA_BE1|Medical University of Graz|No|Completed|January 2014|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|July 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02711267||707|
NCT02711280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2014]114|The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children|The Effect of Sevoflurane and Propofol on Oxidative Stress and Apoptosis Status in Children Undergoing Hypospadias Repair Surgery||First Affiliated Hospital, Sun Yat-Sen University||Recruiting|September 2015|May 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|80|||Male|1 Year|3 Years|No|||March 2016|March 13, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02711280||706|
NCT02712008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R910-3-DME-1518|Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema|A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema|RUBY|Regeneron Pharmaceuticals|Yes|Not yet recruiting|March 2016|October 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712008||650|
NCT02699801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02301|Dexmedetomidine Use in ICU Sedation and Postoperative Recovery in Elderly Patients and Post-cardiac Surgery|Dexmedetomidine Use in ICU Sedation and Postoperative Recovery in Elderly Patients and Post-cardiac Surgery|DIRECT|University of British Columbia|No|Recruiting|January 2016|February 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|75 Years|105 Years|No|||March 2016|March 2, 2016|January 27, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699801||1588|
NCT02713113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250|Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery|Comparison of Three Different Doses Sugammadex Based on Ideal Body Weight for Reversal of Moderate Rocuronium-induced Neuromuscular Blockade in Laparoscopic Bariatric Surgery.||Assiut University|Yes|Completed|March 2015|March 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|180|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|March 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713113||565|
NCT02701868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC2016-002|Unintentional Overfeeding of Formula Fed Infants|Unintentional Overfeeding of Formula Fed Infants|Woah Baby|Pennington Biomedical Research Center|No|Not yet recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|190|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Up to 40 individuals will be recruited to participate in focus groups at Pennington        Biomedical Research Center. Phase 1 will utilize qualitative data gathered from focus        groups to direct the modification of infant formula manufacturer preparation instructions        to enhance user understanding and accuracy. The modified instructions will be used in        Phase 2.        Up to 150 individuals will be enrolled in Phase 2 to test the efficacy of the revised        instructions on infant overfeeding in comparison with the instructions currently provided        on the packaging.|March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02701868||1429|
NCT02696785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16178|A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis|COAST-V|Eli Lilly and Company|No|Not yet recruiting|April 2016|February 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696785||1820|
NCT02715323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1295/101/2015 (SERI-STIIC-3)|Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome|Exploring Immune Cell Signatures in Autoimmunity and Ocular Surface Stress||Singapore National Eye Centre|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|160|||Both|21 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit patients with 3 specific rheumatological diagnoses and controls          -  SS (n=40), RA (n=40), SLE (n=40)          -  Healthy age/ethnicity/sex matched control subjects (n=40)        Total sample size: 160|March 2016|March 21, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02715323||395|
NCT02715336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFC-01|Efficacy and Safety of Medication Used to Stimulate Ovulation|A Randomized Controlled Trial of Pre-retrieval Triggering Methods in in Vitro Fertilization Patients Classified as Low, Normal or High Responder||Create Fertility Center|No|Recruiting|October 2015|September 2021|Anticipated|September 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|666|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02715336||394|
NCT02698306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HospitalGVP|Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery|Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery||Hospital Geral de Vila Penteado|No|Recruiting|February 2015|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 28, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02698306||1703|
NCT02701933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14-03-20|Effects of Ketamine on Eye Movements, Perception and Brain Function|Effects of Ketamine on Eye Movements, Perception and Brain Function||University of Bonn|No|Completed|April 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02701933||1424|
NCT02697396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-069|Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children|A Randomized Controlled Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2018|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All recruitment will be completed by the MSKCC recruiting RSA who will approach all those        attending the VDS at the Mexican Consulate in NYC and who are exposed to the social        marketing campaign.|February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697396||1773|
NCT02719652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICAD-001|Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis|Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis||Capital Medical University|Yes|Enrolling by invitation|November 2015|September 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Participants with significant MCA stenosis（≥50%）on TCD, MRA, and/or CTA together with one        or more risk factors of atherosclerosis will be prospectively recruited. Symtomatic        patients will be included if they had suffered from a recent transient ischemic attack or        ischemic stroke(NHISS≤6) in the territory of the stenotic MCA. Asymptomatic patients will        be included if they had no history of cerebrovascular events or a history of an ischemic        event in a territory outside that the affected MCA.|March 2016|March 24, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02719652||62|
NCT02710266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0936|Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection|||Yonsei University|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|147|||Both|20 Years|80 Years|No|||March 2016|March 11, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02710266||784|
NCT02698618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESR-15-10793|PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor|PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor|PREDICT|Fundacion Investigacion Interhospitalaria Cardiovascular|Yes|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 27, 2016|February 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698618||1679|
NCT02697318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21282|Evaluation of a New Method for Instilling Eye Drops|Evaluation of a New Method for Instilling Eye Drops||University of Waterloo|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|60|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697318||1779|
NCT02699541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14946|The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory|The Effectiveness of Information-Motivation-Behavioural Skills Model-based Diabetes Self-Management Education Among Patients With Type 2 Diabetes in Jordan|IMB-DSME|University of Nottingham|No|Enrolling by invitation|February 2016|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02699541||1608|
NCT02716922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/2016|Cerclage for Singletons With Short Cervix Without Prior Preterm Birth|Cervical Cerclage for Singleton Gestations With Short Cervix and Without Prior Preterm Birth||Federico II University|No|Recruiting|March 2016|March 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|50 Years|No|||March 2016|March 17, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02716922||272|
NCT02709824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS2012|Anti-staining Efficacy of Anti-Discoloration System (ADS) Added to Chlorhexidine (CHX)|Efficacy of an Anti-Discoloration System (ADS) to Reduce Dental Staining in a 0.12% Chlorhexidine-based Mouthwash|CHX+ADS|University of Milan|Yes|Completed|December 2011|July 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709824||818|
NCT02698384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-54-52030-315|Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|ACRO-OPTIM|Ipsen|No|Recruiting|January 2016|October 2019|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|183|||Both|18 Years|N/A|No|Non-Probability Sample|Acromegalic subjects|February 2016|February 26, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02698384||1697|
NCT02698397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302-15-0001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||March 15, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698397||1696|
NCT02698410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-93-52030-325|Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.|Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.|ATLANT|Ipsen|No|Not yet recruiting|March 2016|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698410||1695|
NCT02699827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM1|Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia|Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia||Mansoura University|No|Recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|20 Years|35 Years|No|||March 2016|March 15, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699827||1586|
NCT02645370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-APP-CER|Efficacy and Safety of Danzhen|Efficacy and Safety of Danzhen in the Preventive Treatment of Migraine:A Prospective "Real-World" Study.||Xijing Hospital|Yes|Not yet recruiting|February 2016|||July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3300|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|December 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02645370||5762|
NCT02645383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112S299|PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System|An Observational Prospective Study of Comparing Pain Responses With Pattern Laser Platform and Conventional Laser System During the Panretinal Photocoagulation in Proliferative Diabetic Retinopathy||Kocatepe University|No|Completed|May 2014|June 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02645383||5761|
NCT02661074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013_42|Anisakis Blastocystis Cryptosporidium Fish Prevalence|Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Prevalence of Fish Allergy in Occupational Settings.|ABCFish1|University Hospital, Lille|No|Active, not recruiting|November 2014|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|486|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will include the following 3 groups:          -  Fishermen followed by the "Service de Santé des Gens de Mer" of Boulogne-sur-Mer,          -  Fish-processing factory workers followed by the "Service de Santé au Travail" of             Boulogne-sur-Mer,          -  A control group composed of workers followed by the "Service de Santé au Travail" of             Boulogne-sur-Mer, but not working in a fish-processing factory.|January 2016|January 18, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02661074||4556|
NCT02717442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-201508|Study of OTO-104 in Subjects With Unilateral Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease|AVERTS-2|Otonomy, Inc.|No|Recruiting|March 2016|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|85 Years|No|||March 2016|March 17, 2016|March 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717442||232|
NCT02717455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTC-047|Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma|Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma|PBTC-047|Pediatric Brain Tumor Consortium|Yes|Not yet recruiting|April 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|21 Years|No|||March 2016|March 17, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717455||231|
NCT02705352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|786680-1|5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts|A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts.||Massachusetts Eye and Ear Infirmary|Yes|Not yet recruiting|May 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|89 Years|No|||March 2016|March 10, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705352||1161|
NCT02704169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 13-5914-C|Quantitative Endoscopy of H&N|Comparing GTV Delineation With and Without Spatially Registered Endoscopy||University Health Network, Toronto|No|Suspended|July 2013|||June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02704169||1252|
NCT02700308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET14000050|A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases|A Randomized, Multicenter, Open-label, Bayesian-based Phase II Study of the Feasibility of Kyphoplasty in the Local Treatment of Spine Metastases From Solid Tumors|KYPHO-01|Centre Leon Berard|No|Not yet recruiting|March 2016|October 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 27, 2015||No||No||https://clinicaltrials.gov/show/NCT02700308||1549|
NCT02713334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-080|Advanced Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling|Advanced Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit 300 participants for the proposed study from those already enrolled in        protocol #12-245, and who agree to receive their secondary findings through Consent Part C        of this existing protocol.|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713334||548|
NCT02710929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201412157RINA|A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in ADHD|A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in Attention Deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2015|||July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|232|Samples With DNA|15 ml blood will be withdrawn from the subjects (one heparin-rinsed tube for cell culture,      one EDTA rinsed tube for DNA extraction)|Both|7 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The existing sample is composed of 382 children withADHD and 150 healthy subjects. We plan        to recruit additional 232 healthy subjects (104 in the first year; 128 in the second        year), aged 7 to 18 years.|March 2016|March 13, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02710929||733|
NCT02696980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16-060|PEEP as Rescue Therapy for Asthmatics With Elevated BMI|Increased Lung Volume as Rescue Therapy for Asthma||University of Vermont|Yes|Not yet recruiting|April 2016|June 2020|Anticipated|April 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|60 Years|No|||February 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02696980||1805|
NCT02696993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0883|Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer|Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696993||1804|
NCT02697006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 1.1 Version 1.0|Synchronized Cardiac Assist for Cardiogenic Shock|Synchronized Cardiac Assist for Cardiogenic Shock. The SynCor Trial||Xenios AG|Yes|Recruiting|January 2016|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with cardiogenic shock or in high risk percutaneous intervention procedures in        the cardiac catheterization lab|February 2016|February 25, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02697006||1803|
NCT02700516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32364/200|Recurrent Glomerulonephritis After Renal Transplantation|Recurrent Primary Glomerulonephritis After Renal Transplantation: Effects on Renal Allografts and Transplant Recipients||Istanbul University|No|Enrolling by invitation|March 2015|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|360|||Both|18 Years|N/A|No|Non-Probability Sample|Renal transplant recipients|March 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02700516||1533|
NCT02713841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Samba-01|Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes|Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects With Type 1 Diabetes|Samba-01|Dance Biopharm Inc.|No|Completed|May 2013|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|12|||Both|18 Years|64 Years|No|||March 2016|March 15, 2016|March 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713841||509|
NCT02699138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD151424|Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder|Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic||University of California, San Diego||Recruiting|October 2015|||September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|March 3, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02699138||1639|
NCT02705885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM 14|IgY Efficacy on Periodontitis Patients|Evaluation of IgY Antibody Effectiveness in Supportive Therapy of Periodontitis Patients||Immunology Research Institute in Gifu|Yes|Completed|June 2014|March 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|N/A|N/A|No|||March 2016|March 7, 2016|November 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02705885||1120|
NCT02700776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00058144 1380GCC|1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer|1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer|1380GCC|University of Maryland|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|750|Samples With DNA|Measure the level of GP88 in the blood of healthy women who are having mammography screening      for breast cancer. If study doctor refers subject for breast biopsy the investigator will      collect the information from the biopsy.|Female|40 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prospectively determine the GP-88 blood levels in healthy female volunteers who are        undergoing routine screening mammography.|March 2016|March 15, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700776||1513|
NCT02713568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-PREMACRO|Estimation of Fetal Weight by MR Imaging to PREdict Neonatal MACROsomia (PREMACRO Study)|Estimation of Fetal Weight by MR Imaging to PREdict Neonatal MACROsomia (PREMACRO Study)||Brugmann University Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|2500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713568||530|
NCT02713581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2015/SB-01|IgG Dependent Monocyte Activation in Proximal Venous Thromboembolism|IgG Dependent Monocyte Activation in Proximal Venous Thromboembolism|ActiMon|Centre Hospitalier Universitaire de Nīmes|No|Not yet recruiting|March 2017|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|129|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patient population description: Patients will correspond to cases of proximal venous        thromboembolism. They will be recruited during consultations conducted for the chronic        management of a history of proximal venous thromboembolism or thrombophilia following a        recent history of proximal venous thromboembolism. Venous thromboembolism, outside of        acute phase episodes, has good symptom stability over time; no difference is to be        expected between patients with a chronic history of proximal venous thromboembolism and        new patients coming in for a checkup. Note that these patients may or may not have a        history of placental vascular disease.        Healthy volunteer population description: This populations is composed of healthy, female,        adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.|March 2016|March 18, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713581||529|
NCT02707328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-176|Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)|Phase I Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)||The Cooper Health System|No|Recruiting|January 2015|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707328||1010|
NCT02697565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20140876|Healthy Caregivers-Healthy Children (HC2) Phase II|Healthy Caregivers-Healthy Children (HC2) Phase II: Integrating Culturally Sensitive Childhood Obesity Prevention Strategies Into Policy||University of Miami|No|Recruiting|April 2015|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|2 Years|5 Years|No|||February 2016|February 26, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02697565||1760|
NCT02710877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 274/13|Intermittent Automated Devices for Labor Analgesia in Emilia Romagna|Pain Management During Labor: Use of Intermittent Drug Delivery Devices for Obstetric and Neonatal Outcome Improvement and Health-care Burden Reduction|PA-RER|University of Modena and Reggio Emilia|No|Recruiting|December 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02710877||737|
NCT02710890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0060|Study to Investigate Safety and Tolerability of Intravenous Lacosamide as Replacement of Oral Lacosamide in Children.|A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Children (≥ 4 to < 17 Years of Age) With Epilepsy||UCB Pharma|Yes|Not yet recruiting|October 2016|May 2026|Anticipated|May 2026|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|4 Years|16 Years|No|||March 2016|March 14, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710890||736|
NCT02712151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00022058|Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy|Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block for Postoperative Pain Control in Laparoscopic Cholecystectomy: Prospective Randomized Controlled Trial in Pediatric Patients||Children's Hospital Boston|Yes|Not yet recruiting|April 2016|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02712151||639|
NCT02707718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPS study|Biomarkers for the Early Identification of Sepsis in the Emergency Department|Early Biomarkers of Sepsis Identification in the Emergency Department|BIPS|Hôpital de la Salpétrière|No|Recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|plasma and sera|Both|18 Years|100 Years|No|Non-Probability Sample|adult patients attending the ED and suspected to have sepsis|March 2016|March 24, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02707718||980|
NCT02708693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-021A|Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome|Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome||Taipei Veterans General Hospital, Taiwan|No|Completed|April 2013|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||April 2013|March 9, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02708693||905|
NCT02696122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCSP 1.316.318|Quality of Recovery After Local Infiltration Under General Anesthesia Via Laryngeal Mask or Spinal Anesthesia for Inguinal Hernia Repair|Quality of Recovery After Local Infiltration Under General Anesthesia Via Laryngeal Mask or Spinal Anesthesia for Inguinal Hernia Repair.||Pontificia Universidade Catolica de Sao Paulo||Recruiting|February 2016|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696122||1871|
NCT02696603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201410711|Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)|Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)|mPower|Sage Bionetworks|No|Recruiting|March 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02696603||1834|
NCT02709200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00127|Effect of Dexmedetomidine on Pacemaker Function Following Cardiac Surgery|||Nationwide Children's Hospital|No|Enrolling by invitation|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|6 Months|N/A|No|Non-Probability Sample|Congenital heart disease patients having open heart surgery.|March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02709200||866|
NCT02709213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-211|Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy|Colitis Prospective Cohort Study: Determining the Aetiologies of Acute Colitis and Developing a Diagnostic Score to Identify Patients Requiring Specific Investigations||University Hospital, Geneva|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Stools|Both|18 Years|N/A|No|Probability Sample|All patients admitted at the Emergency Department with a first diagnosis of computed        tomography-diagnosed acute colitis|March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02709213||865|
NCT02711631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedBIKE|Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation|Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation||University of Alberta|No|Not yet recruiting|May 2016|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|85 Years|No|||March 2016|March 11, 2016|April 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02711631||679|
NCT02696850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201512063|The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis|The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis||Washington University School of Medicine|Yes|Recruiting|January 2016|||January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||February 2016|February 26, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696850||1815|
NCT02718248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150765-01H|Ottawa Suicide Prevention in Men Pilot Study|Pilot Study of a Smart Phone Assisted Problem Solving Therapy for Men Who Have Presented With Intentional Self-harm to Emergency Departments|OSSUPilot|University of Ottawa|Yes|Not yet recruiting|April 2016|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02718248||170|
NCT02718261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIREN|Sup-Icu RENal (SIREN)|Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy|SIREN|University Hospital Inselspital, Berne||Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|3350|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02718261||169|
NCT02697266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB14-00143|The Effects of Night Call on Intellectual Performance|Individual Coping Strategies After Night Calls: Effects on Performing Clinical and Cognitive Tasks||Nationwide Children's Hospital|No|Active, not recruiting|March 2014|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twenty-four attending anesthesiologists and anesthesiology residents|February 2016|February 26, 2016|December 21, 2015||No||No||https://clinicaltrials.gov/show/NCT02697266||1783|
NCT02699996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131507|Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors|Peer Mentoring to Promote Follow-up Care Self-Management for Adolescent and Young Adult (AYA) Childhood Cancer Survivors||Rutgers, The State University of New Jersey|No|Recruiting|October 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|78|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699996||1573|
NCT02700009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS024047|Computer-assisted Cognitive-Behavior Therapy for Depression in Primary Care|Dissemination of Computer-assisted Cognitive-behavior Therapy for Depression in Primary Care||University of Louisville|Yes|Not yet recruiting|May 2016|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02700009||1572|
NCT02717312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15104|Prevalence, Risk Factors and Consequences Related to Cesarean Scar Defect (Defect in Cesarean Scar)|Defect in Cesarean Scar: A Prospective Study of Prevalence, Risk Factors and Impact on Menstrual Disorders and Quality of Life|DICE|Tampere University Hospital|No|Recruiting|January 2016|April 2027|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|45 Years|No|Probability Sample|Pregnant women undergoing cesarean section|March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02717312|10 Years|242|
NCT02712788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505714749|Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage||Indiana University|Yes|Not yet recruiting|March 2016|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712788||590|
NCT02715076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-878|The Effects of Ambient Temperature and Forced-air Warming on Intraoperative Core Temperature|The Effects of Ambient Temperature and Forced-air Warming on Intraoperative Core Temperature||Peking Union Medical College Hospital|No|Recruiting|January 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Anticipated|394|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715076||414|
NCT02715089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1503|Precise Treatment in Hepatobiliary Cancers (PTHBC)|Single Center, Single Arm, Open Study, to Explore and Evaluate the Precise Treatment in Hepatobiliary Cancers(PTHBC)|PTHBC|Peking Union Medical College Hospital|Yes|Recruiting|December 2015|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|The samples, both tissue(s) and blood of patients should be provided for the next-generation      sequencing (NGS) test before screening.|Both|18 Years|65 Years|No|Non-Probability Sample|The subjects : Hepatobiliary Cancer patients.|March 2016|March 16, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02715089|2 Years|413|
NCT02706561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-317|Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery|Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery||Memorial Sloan Kettering Cancer Center||Recruiting|December 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|310|||Male|21 Years|N/A|No|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02706561||1069|
NCT02708914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P304-EPO|Study to Compare the Safety and Efficacy of UB-851 and Eprex®|A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis||UBI Pharma Inc.||Not yet recruiting|March 2016|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|228|||Both|20 Years|85 Years|No|||March 2016|March 14, 2016|February 23, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708914||888|
NCT02713022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-235|Body Composition and White Adipose Tissue Inflammation|Body Composition and White Adipose Tissue Inflammation||Memorial Sloan Kettering Cancer Center||Recruiting|November 2015|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|This study is open to patients undergoing prophylactic or therapeutic mastectomy or        radical prostatectomy at MSKCC.        Patients will be identified and recruited from the Breast Service at MSKCC and approached        at the time of initial surgical consultation. At this time, patients will be approached to        consent to the umbrella biospecimen protocol, IRB #06-107. Only patients who provide        consent to #06-107 will be eligible for this protocol.|March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02713022||572|
NCT02719431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-877-108|Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers|||Kowa Research Institute, Inc.|No|Completed|January 2016|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719431||79|
NCT02719444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2016-Beta-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2016|||||N/A|N/A|N/A||||||||||||||March 21, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719444||78|
NCT02719457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE581308|Spot Marching Exercise Test in Chronic Obstructive Pulmonary Disease|the Relationship Between Spot Marching Exercise Test and Six Minute Walk Test in Patient With Chronic Obstructive Pulmonary Disease|SMT|Khon Kaen University|No|Not yet recruiting|April 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|35 Years|75 Years|No|||February 2016|March 24, 2016|February 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02719457||77|
NCT02697812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-233-13|Does the Speed of Sternal Retraction Affect Postoperative Pain Outcomes|Does the Speed of Sternal Retraction During Coronary Artery Bypass Graft Surgery Affect Postoperative Pain Outcomes: A Randomized Controlled Trial||Queen's University|Yes|Recruiting|January 2014|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|316|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|December 3, 2015||No||No||https://clinicaltrials.gov/show/NCT02697812||1741|
NCT02704767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1stKunmingMC|Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma|Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.||The First Affiliated Hospital of Kunming Medical College|No|Not yet recruiting|June 2016|December 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|February 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704767||1206|
NCT02713321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1545|The Impact of Medicaid Health Homes on Patients With Diabetes|The Impact of Medicaid Health Homes on Patients With Diabetes||Icahn School of Medicine at Mount Sinai|No|Not yet recruiting|March 2016|February 2021|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|13000|None Retained|Specify all types of biospecimens to be retained (e.g., whole blood, serum, white cells,      urine, tissue)|Both|18 Years|N/A|No|Non-Probability Sample|The study population includes patients with data in the New York City Clinical Data        Research Network (NYC-CDRN). The NYC-CDRN brings together 22 organizations, including 7        independent health systems (Columbia University College of Physicians and Surgeons,        Montefiore Medical Center and Albert Einstein College of Medicine, Mount Sinai Health        System and the Icahn School of Medicine, New York-Presbyterian Hospital, New York        University Langone Medical Center and New York University School of Medicine, Weill        Cornell Medical College, and the Clinical Directors Network). This data network includes        longitudinal data from both inpatient and outpatient facilities from throughout New York        City.|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713321||549|
NCT02718144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3106|Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer|A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer||Pantarhei Oncology B.V.||Not yet recruiting|May 2016|May 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|53|||Female|N/A|N/A|No|||March 2016|March 18, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02718144||178|
NCT02718157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenePOC-GBS_clinical-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2016|||||N/A|N/A|N/A||||||||||||||March 18, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718157||177|
NCT02703831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-N0036|Single Versus Dual Spine Attending Surgeons in Complex Adult Deformity Surgery:|Single Versus Dual Spine Attending Surgeons in Complex Adult Deformity Surgery: A Cost-effectiveness Study Using Activity-based Costing||Norton Leatherman Spine Center|No|Not yet recruiting|May 2016|May 2023|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|25 Years|N/A|No|||March 2016|March 8, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02703831||1278|
NCT02704091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-FR-00250-105|Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults|Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomized, Double Blind Placebo Controlled, Parallel, Groups Study|ADIASE|Ipsen|No|Recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|854|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704091||1258|
NCT02711995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505016165|Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation|Essential Voice Tremor: An Unblinded Crossover Study of Botulinum Toxin Treatment and Injection Augmentation||Weill Medical College of Cornell University|No|Recruiting|September 2015|November 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|100 Years|No|||March 2016|March 16, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711995||651|
NCT02698423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-034|Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care|Human Papillomavirus Testing Versus Liquid-based Cytology for Non-attendees of Cervical Cancer Screening: Results of a Randomised Controlled Trial|DEPIST|University Hospital, Geneva|No|Completed|September 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|667|||Female|25 Years|69 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698423||1694|
NCT02698436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1512 1114 0520-SACT|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||February 26, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698436||1693|
NCT02713815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mzhao-004|Novel Intervention for Amphetamine-type Stimulants Addiction|Glutamate and γ-aminobutyric Acid (GABA) Deficits in Prefrontal-striatal Circuits: it's Role in Amphetamine-type Stimulants Addiction and Novel Intervention||Shanghai Mental Health Center|No|Not yet recruiting|June 2016|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02713815||511|
NCT02718716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0001|Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia|A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia||UCB Pharma|Yes|Recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02718716||134|
NCT02704104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC5-1|Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions|A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions||ARCH Therapuetics|Yes|Recruiting|February 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704104||1257|
NCT02704117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH106435|Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Direct Current Stimulation|Neurocircuitry of OCD: Effects Of Modulation||Butler Hospital|Yes|Recruiting|June 2015|May 2020|Anticipated|May 2020|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02704117||1256|
NCT02704351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-01162|Suggamadex and Fast-track Cardiac Anesthesia in a Developing Country|Retrospective Chart Review of Fast-track Cardiac Anesthesia Using Suggamadex for Rapid Reversal of Neuromuscular Blockade Following Cardiac Surgery in a Developing Country||Nationwide Children's Hospital|No|Enrolling by invitation|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|15|||Both|N/A|N/A|No|Non-Probability Sample|Last September 2015, patients in Tuxtla, Mexico who underwent cardiac surgery and        cardiopulmonary bypass surgery for congenital heart defect where suggamadex was used for        reversal of neuromuscular blockade.|March 2016|March 4, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704351||1238|
NCT02707991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00081068|Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection|Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection: A Randomized Controlled Trial|Care2Cure|Johns Hopkins University|Yes|Not yet recruiting|April 2016|March 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707991||959|
NCT02708004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-080-102|Clinical Study to Assess Body Fluid Homeostasis After Administration of AC-080 in Healthy Subjects|A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of AC-080 in Healthy Subjects||Actelion|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02708004||958|
NCT02708927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2015/11|Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis|Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis|EMOSOCIAL-MS|University Hospital, Bordeaux|No|Not yet recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708927||887|
NCT02717390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2164|Bright by Three (BB3) Effectiveness Study|Bright by Three (BB3) Effectiveness Study||University of Colorado, Denver|No|Not yet recruiting|May 2016|June 2020|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02717390||236|
NCT02713126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-001467|12 Week Study of Inhaled Nitrite for Improving Cardiac Function|Inorganic Nitrite to Enhance Benefits From Exercise Training in Heart Failure With Preserved Ejection Fraction||Mayo Clinic|Yes|Not yet recruiting|April 2016|December 2020|Anticipated|April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|No|||March 2016|March 18, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713126||564|
NCT02697500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS53|Pre-analytical Sample Handling Conditions and Their Effects on the Human Serum Metabolome|||USDA Beltsville Human Nutrition Research Center|No|Completed|March 2016|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|13|None Retained|serum and urine|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women will be recruited from the area surrounding the BHNRC. There are several        thousand government and privately employed workers located within a 10-mile radius of the        BHNRC and several residential communities from which a cohort of volunteers will be        recruited. The population includes an ethnically diverse group of subjects.|March 2016|March 2, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02697500||1765|
NCT02695745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VND1004|Experimental Biomarker Study for Pain Thresholds|Randomized, Double Blind, Positive- Controlled, Three-way Cross-over Human Experimental Biomarker Study of V116517 in Healthy Male Subjects||Purdue Pharma LP|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|37|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02695745||1900|
NCT02699970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPS-CT-0009|Instrument Precision Study for Validation of Philips Dx|Instrument Precision Study for Validation of Philips Dx||Philips Digital Pathology Solutions|No|Recruiting|February 2016|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|630|||Both|N/A|N/A|No|Non-Probability Sample|Cases will be selected from the LIS in consecutive order. Cases will be selected per        feature and per organ. From these cases, slides will be selected containing the        pre-specified study feature.|March 2016|March 10, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699970||1575|
NCT02704793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940597|Cerebellar rTMS for Essential Tremor|Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor||Mashhad University of Medical Sciences|No|Not yet recruiting|April 2016|April 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02704793||1204|
NCT02717611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-CL-208|A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy|A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy||Acerta Pharma BV||Recruiting|January 2016|February 2020|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717611||219|
NCT02717910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTSF2016|Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents|Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents: a Feasibility Study||University of Turku|No|Not yet recruiting|March 2016|June 2016||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|180|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02717910||196|
NCT02705833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-551|Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada|Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada||Bristol-Myers Squibb||Active, not recruiting|December 2015|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with R/M SCCHN between 01July2013 and 30June2014|March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02705833||1124|
NCT02705976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20140036|Prospective Trial of a Validated Algorithm for Warfarin Dosing|Prospective Trial of a Validated Algorithm for Warfarin Dosing||Aalborg Universitetshospital|No|Completed|September 2014|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|211|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705976||1113|
NCT02701699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 13-6528-C|18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer|A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)||University Health Network, Toronto|No|Recruiting|December 2014|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 9, 2014||No||No||https://clinicaltrials.gov/show/NCT02701699||1442|
NCT02701036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPORTAX 010/05|Sporadic Degenerative Ataxia With Adult Onset: Natural History Study|Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)|SPORTAX-NHS|Ataxia Study Group|Yes|Recruiting|April 2010|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|2x9 ml EDTA blood samples. Blood samples are taken according to established protocols for      future genetic studies. The samples are sent to the Department of Medical Genetics      (Tübingen, Germany).|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of patients with adult onset degenerative ataxia, in which        acquired and genetic causes of ataxia have been excluded.|March 2016|March 9, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02701036|20 Years|1493|
NCT02715648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-2016|Using Phenazopyridine for In-office Cystoscopy|Using Phenazopyridine for In-office Cystoscopy||Boston Urogynecology Associates|No|Not yet recruiting|April 2016|February 2019|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|94|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715648||370|
NCT02715661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107620|Cerebrovascular Outcomes in Ischemic Heart Disease|Cerebrovascular Outcomes in Ischemic Heart Disease Patients Undergoing Cardiac Rehabilitation|IHD|Western University, Canada|No|Not yet recruiting|March 2016|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|270|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02715661||369|
NCT02702115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-318-1502|Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-318 in Subjects With MPS I|A Phase I, Multicenter, Open-label, Single-dose, Dose Ranging Study to Assess the Safety and Tolerability of SB-318, a Recombinant Adeno-associated Virus (rAAV)2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)||Sangamo Biosciences|Yes|Not yet recruiting|May 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702115||1410|
NCT02701283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10234430Doc|Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients|Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement||Medtronic Cardiovascular|Yes|Not yet recruiting|March 2016|March 2023|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1250|||Both|N/A|N/A|No|||March 2016|March 2, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701283||1474|
NCT02701517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIRCAMPATH-alo 2002|Cyclosporine Plus Methotrexate or Alemtuzumab|Randomized Trial of Cyclosporine + CAMPATH-1H (ALEMTUZUMAB) vs. Cyclosporine + METHOTREXATE in Patients Diagnosed With Mature B-cell Neoplasms - Chronic Lymphocytic Leukemia and Low-grade Lymphomas - Receiving Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning Regimen||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Suspended|September 2003|||November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|45 Years|65 Years|No|||March 2016|March 2, 2016|March 12, 2015||No|The trial was stopped before the targeted number of patients was reached due to lack of    support.|No||https://clinicaltrials.gov/show/NCT02701517||1456|
NCT02701530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-51061|Smoking Cessation for Hospital Employees With Low Education.|Smoking Cessation for Hospital Employees With Low Education in the Capital Region of Denmark. The RESPEKT Study.|RESPEKT|Glostrup University Hospital, Copenhagen|No|Completed|August 2013|February 2016|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7003|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02701530||1455|
NCT02715908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGLifeS|A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate (MTX)|A Multi-center, Single-arm, Open-label, Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 50 mg Subcutaneous Weekly Injection When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Period of LG-ECCL002 Study.||LG Life Sciences||Not yet recruiting|April 2016|May 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|20 Years|75 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715908||350|
NCT02702336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYTO-Kids|EYTO-kids: European Youth Tackling Obesity in Adolescents and Children.|EYTO-kids: European Youth Tackling Obesity in Adolescents and Children, Una intervención Para Mejorar Los Estilos de Vida.|EYTO-kids|University Rovira i Virgili|No|Enrolling by invitation|February 2016|March 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|810|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702336||1393|
NCT02702167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9276-B|High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa|A Randomized Sham-Controlled Study of High- and Low-frequency Repetitive Transcranial Magnetic Stimulation of the Dorsomedial Prefrontal Cortex in Bulimia and Anorexia Nervosa||University Health Network, Toronto|No|Recruiting|March 2016|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702167||1406|
NCT02702180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOL-PAP-002|Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)|A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA"|IMPALA|Serendex Pharmaceuticals|Yes|Recruiting|February 2016|August 2018|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02702180||1405|
NCT02719548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBF1505|Impact of Breast Shield Designs on Dynamics of Breast Pumping|Impact of Breast Shield Designs on Dynamics of Breast Pumping|BSD|Medela AG|No|Recruiting|February 2016|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02719548||70|
NCT02712892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC15_0304|I-CAN Biocollection|IntraCranial ANeurysms: From Familial Forms to Pathophysiological Mechanisms|I-CAN|Nantes University Hospital|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1060|Samples With DNA|For one patient included:        -  2 Ethylenediaminetetraacetic acid (EDTA) tubes for DNA (5mL)        -  2 dry tubes for serum (5mL)|Both|20 Years|N/A|No|Non-Probability Sample|The initial stage of this biocollection based on the recruitment of large families for        genetic linkage analysis. This is a first step to identify patients with intracranial        aneurysms occurring in a family context, and to conduct a comprehensive investigation        according to clinical guidelines in force to assess the potentially informative family and        ensure their adherence to the prior biocollection. The next step is the fine and accurate        phenotyping of each of the family members (imaging) and the collection of a blood sample        for DNA extraction for molecular genetic analysis.        The population recruited will be composed of index and their healthy relatives and cases        with sporadic cases and IA. The kinship links will be established from family trees.|February 2016|March 14, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02712892||582|
NCT02699710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP29832|The Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetic (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects|A Phase I, Single Center, Randomized, Open-Label, Study Investigating the Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics of GDC-0853 and the Effect of GDC-0853 on the Pharmacokinetics of Methotrexate in Healthy Subjects||Genentech, Inc.||Recruiting|September 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699710||1595|
NCT02702440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liquid Calories 2015|Systematic Review and Meta-analysis of Liquid Versus Solid Calories and Body Weight|Effect of Liquid Versus Solid Calories on Body Weight: a Systematic Review and Meta-analysis of Controlled Feeding Trials||University of Toronto|No|Active, not recruiting|May 2015|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702440||1385|
NCT02719795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJTU1AF-CRS-2016-003|Pectoral Nerves Blocks for Chronic Pain|Pectoral Nerves Blocks and Their Effect on Chronic Pain After Breast Cancer Surgery|PNBCP|First Affiliated Hospital Xi'an Jiaotong University|Yes|Not yet recruiting|April 2016|May 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|65 Years|No|||March 2016|March 24, 2016|March 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719795||51|
NCT02649933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/14-11-105/4434|Detection of Sleep Apnea Syndrome (OSA) in Pregnant Women and Assessment of Impact of OSA on Pregnancy Course|Detection of Sleep Apnea Syndrome (OSA) With Watch PAT 200 in Pregnant Women and Assessment of Impact of OSA on Intra-uterine Fetal Growth and Maternal Well-being||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|November 2015|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|50 Years|No|Non-Probability Sample|pregnant women, 12-15weeks of pregnancy, obese (body mass index>30)|January 2016|January 6, 2016|December 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02649933||5411|
NCT02649946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-14-005|Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft|A Prospective, Multi-Center, Randomized, Concurrently-Controlled Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AVeNEW)|AVeNEW|C. R. Bard|Yes|Not yet recruiting|April 2016|May 2020|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|21 Years|N/A|No|||March 2016|March 16, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02649946||5410|
NCT02647086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1433|Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)|An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis||Regeneron Pharmaceuticals|No|Recruiting|December 2015|October 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|January 4, 2016|January 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02647086||5630|
NCT02647099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921-2014-7074|Adjuvant Low Dose Aspirin in Colorectal Cancer|A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway|ALASCCA|Karolinska Institutet|Yes|Not yet recruiting|January 2016|January 2023|Anticipated|January 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|816|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02647099||5629|
NCT02647112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-EpiCheck-EU-01|Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma|Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study||Nucleix Ltd.|No|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|350|||Both|22 Years|100 Years|No|||January 2016|January 5, 2016|December 16, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02647112||5628|
NCT02705365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002239|Patient Navigation for Lung Screening at MGH Community Health Centers|||Massachusetts General Hospital|No|Recruiting|February 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1217|||Both|55 Years|77 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02705365||1160|
NCT02709707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP00001|Lay-user Trial of the iGlucose Blood Glucose Monitoring System|A Lay User Study of the iGlucose, a Device for Self-Monitoring of Blood Glucose (SMBG), Marketed by the Smart Meter Corporation||Smart Meter Corporation|No|Recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with a diagnosis of diabetes, either type 1 or type 2, of various duration with        blood glucose levels covering the entire measurement range. .|March 2016|March 11, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709707||827|
NCT02704234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0692|Acupuncture for Vulvodynia: A Pre-pilot Study|Acupuncture for Vulvodynia: A Double-blinded Feasibility Pre-pilot Study||University of Illinois at Chicago|Yes|Recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|6|||Female|18 Years|45 Years|No|||March 2016|March 8, 2016|November 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02704234||1247|
NCT02718170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00048356|Buried Intramedullary K-wire Fixation Compared With Plate and Screw Fixation in Unstable Extra-Articular Metacarpal Fractures|Buried Intramedullary K-wire Fixation Compared With Plate and Screw Fixation in Unstable Extra-Articular Metacarpal Fractures: A Randomized, Controlled Study||Greenville Health System|No|Enrolling by invitation|March 2015|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|16 Years|N/A|No|||March 2016|March 18, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02718170||176|
NCT02698826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REOX II|Reoxygenation After Cardiac Arrest II (REOX II Study)|Reoxygenation After Cardiac Arrest II (REOX II Study)|REOX II|The Cooper Health System|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02698826||1663|
NCT02698839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIONEER-II, RCT, P01|A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)|A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial|RCT|Sino Medical Sciences Technology Inc.|Yes|Recruiting|December 2015|December 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|539|||Both|18 Years|75 Years|No|||March 2016|March 13, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02698839||1662|
NCT02704494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-01-49-9028|Resveratrol's Effects in Diabetic Nephropathy|Resveratrol's Effects in Diabetic Nephropathy|ReDNeph|Shiraz University of Medical Sciences|Yes|Recruiting|March 2016|October 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704494||1227|
NCT02717897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0202|Vitamin D and Disease Activity in Ulcerative Colitis|Association Between Vitamin D Level and Disease Activity in Ulcerative Colitis||University of Chicago|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|248|Samples Without DNA|1. Serum        2. Colon mucosal RNA        3. Formalin fixed paraffin embedded colon biopsy|Both|18 Years|80 Years|No|Probability Sample|Both female and male participants are being studied|March 2016|March 23, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02717897||197|
NCT02703584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03012016|Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation|Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation- A Randomized Controlled Trial||Mount Sinai Hospital, Canada|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|276|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02703584||1297|
NCT02710825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01332-47|Osteopathy and Children With Congenital Heart Disease Surgery|Single Center Randomized Clinical Trial, That Evaluates the Effect of Osteopathic Care on Postoperative Pain in Children With Congenital Heart Disease Surgery|OSCAR|Hôpital Necker-Enfants Malades|No|Not yet recruiting|April 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|N/A|7 Years|No|||March 2016|March 11, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02710825||741|
NCT02704780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HawlerMU|Two Different Regimens of Misoprostol in Retained Placenta|Umbilical Vein Injection of 800µg Misoprostol Versus 400 µg Misoprostol in the Treatment of Retained Placenta: A Multicenter, Randomized Double Blind Controlled Trial||Hawler Medical University|Yes|Not yet recruiting|April 2016|May 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|516|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02704780||1205|
NCT02706431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apnoic Oxygenation|Oxygenation by 100% Oxygen Via High Flow Nasal Cannula in Surgical Patients|Evaluation of Oxygenation by 100% Oxygen Via High Flow Nasal Cannula During Apnea in Adult Elective Surgical ENT Patients||Karolinska University Hospital|No|Enrolling by invitation|December 2015|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02706431||1079|
NCT02718742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1551|Paclitaxel (Abraxane®) Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer|Maintenance Nab-Paclitaxel After Cisplatin-Based Neoadjuvant Chemotherapy in Patients With High Risk Bladder Cancer||Mayo Clinic|Yes|Not yet recruiting|June 2016|||June 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718742||132|
NCT02718755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0807|Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies|Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies||M.D. Anderson Cancer Center|No|Not yet recruiting|July 2016|||July 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||March 2016|March 18, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718755||131|
NCT02695927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000297|Rehabilitation Glasses for the Treatment of Hemispatial Neglect|Rehabilitation Glasses for the Treatment of Hemispatial Neglect||Beth Israel Deaconess Medical Center|No|Recruiting|March 2009|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|35|||Both|21 Years|85 Years|No|||March 2016|March 14, 2016|September 7, 2015||No||No||https://clinicaltrials.gov/show/NCT02695927||1886|
NCT02695940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0133-1182|Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis|A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis||LEO Pharma|No|Recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695940||1885|
NCT02702154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-9276-A|High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression|A Randomized Sham-Controlled Study of High- and Low-frequency Repetitive Transcranial Magnetic Stimulation of the Dorsomedial Prefrontal Cortex in Major Depressive Disorder||University Health Network, Toronto|No|Recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702154||1407|
NCT02699307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F039731|Lifestyle Intervention for Adults With Diabetes|Lifestyle Intervention for Adults With Diabetes||University of Michigan|No|Not yet recruiting|March 2016|December 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|65 Years|N/A|No|||March 2016|March 3, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02699307||1626|
NCT02717143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15677|French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on (Magnetic Resonance Imaging) MRI|French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on (Magnetic Resonance Imaging) MRI|MYOCARDITIRM|French Cardiology Society|No|Not yet recruiting|April 2016|December 2021|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients with clinical features of acute myocarditis previously defined        and who underwent cardiac MRI which concluded the diagnosis of acute myocarditis, having        agreed to participate in the study and admitted in one of the participating centers.|March 2016|March 18, 2016|March 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717143||255|
NCT02695706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM Farma|Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use|Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use and Evaluation of the Effectiveness Through the Self Awareness of the Research, of Clinical Evaluations and Instrumental Measurements||LM Farma Indústria e Comércio Ltda.|Yes|Not yet recruiting|April 2016|July 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02695706||1903|
NCT02699242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-6321-BE|Does Training on a Virtual Reality Bronchoscopy Simulator Improve Performance of Bronchoscopic Intubation in Patients?|Does Training on a Virtual Reality Bronchoscopy Simulator Improve Performance of Bronchoscopic Intubation in Patients?||University Health Network, Toronto|No|Recruiting|April 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|34|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02699242||1631|
NCT02700841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00079982|Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation|Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation||Emory University|Yes|Not yet recruiting|September 2016|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700841||1508|
NCT02713919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter PEINCA|Study to Test the Efficacy of the PRO-SELF® Plus Pain Control Program to Reduce Pain in Outpatients With Cancer|Mixed Methods Study to Test the Efficacy of the Adapted German PRO-Self® Plus Pain Control Program, an Intervention Directed at Outpatients With Cancer and Their Family Caregivers to Reduce Pain and Related Symptoms|PEINCA|University Hospital, Basel, Switzerland|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|315|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02713919||503|
NCT02713932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84/2010/VE|The Italian Society of Invasive Cardiology Registry on Percutaneous Aortic Valve|The Italian Society of Invasive Cardiology Registry on Percutaneous Aortic Valve||Istituto Clinico Sant'Ambrogio|Yes|Recruiting|July 2010|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in whom transcatheter aortic valve implantation is attempted at participating        center.|March 2016|March 15, 2016|February 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02713932||502|
NCT02713945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7826 01|Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome|Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Children With Noonan Syndrome: A Phase III Randomised, Double Blind, Placebo-controlled Therapeutic Trial|RASTAT|University Hospital, Toulouse|No|Not yet recruiting|September 2016|October 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Both|6 Years|16 Years|No|||March 2016|March 18, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713945||501|
NCT02696954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAQPQ|Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Adult Subjects|ALAQPQ|University of Oxford|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696954||1807|
NCT02696967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLR325X2202|A Study of CLR325 in Chronic Stable Heart Failure Patients.|A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients||Novartis|No|Not yet recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696967||1806|
NCT02703948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43USC1505|Injection Technique Assessment of Restylane Silk With Lidocaine for Lip Augmentation|||Q-Med AB|No|Recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|22 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703948||1269|
NCT02703961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJFL-2016-02-LACC-TP triweekly|Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer|Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer||Fourth Military Medical University|Yes|Recruiting|February 2016|February 2021|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|598|||Female|18 Years|60 Years|No|||March 2016|March 15, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02703961||1268|
NCT02701049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002475|Patient Centered Methods to Collect Sexual Orientation and Gender Identity Status in the ED|Emergency Department Query For Patient-centered Approaches To Sexual Orientation And Gender Identity|EQUALITY|Brigham and Women's Hospital|No|Not yet recruiting|March 2016|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|764|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02701049||1492|
NCT02714218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-511|A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma||Bristol-Myers Squibb|No|Not yet recruiting|April 2016|April 2022|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|346|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714218||480|
NCT02714231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-HB-LP|Oral Diclofenac Sodium Versus Oral Hyoscine Butyl Bromide During Intrauterine Device Insertion|A Randomized Controlled Trial of 3 Different Methods for Pain Relief During Intrauterine Device Insertion||Assiut University|Yes|Not yet recruiting|March 2016|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Female|20 Years|50 Years|No|||March 2016|March 16, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714231||479|
NCT02701894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA and GC in T2D|ALA on Glycemic Control in T2DM Participants|The Effect of Alpha-Linolenic Acid on Glycemic Control in Participants With Type 2 Diabetes||St. Michael's Hospital, Toronto|No|Active, not recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Participants with type 2 diabetes mellitus.|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701894||1427|
NCT02704221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0291-P6H|Enhancing the Outcomes of a Behavioral Parent Training Intervention|Enhancing the Outcomes of a Behavioral Parent Training Intervention||University of Kentucky|No|Enrolling by invitation|March 2016|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704221||1248|
NCT02717572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201508093|18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR|Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR||Washington University School of Medicine|No|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717572||222|
NCT02703350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16068|A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy||Eli Lilly and Company|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02703350||1315|
NCT02711943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL_RUS/MD/2013/PMS/LEVOLET R|Non Interventional Study of Levofloxacin in Chronic Prostatitis|Non-interventional (Observational) Study of the Administration of Levolet® R, Film-coated Tablets (Dr. Reddy's Laboratories Ltd., India) in Adults With Chronic Prostatitis in Routine Clinical Practice|Levolet-R|Dr. Reddy's Laboratories Limited|No|Completed|July 2013|March 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Male|18 Years|60 Years|No|Non-Probability Sample|Patients with chronic prostatitis, age 18-60 years|March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711943||655|
NCT02711956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEN003694-002|A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer||Zenith Epigenetics Corp.|No|Not yet recruiting|October 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Male|18 Years|N/A|No|||March 2016|March 17, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711956||654|
NCT02697916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00068525|Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term|Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness|ADAPTABLE|Duke University|Yes|Not yet recruiting|March 2016|November 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20000|||Both|18 Years|N/A|No|||January 2016|March 3, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02697916||1733|
NCT02717325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18842|1882 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|SPF Assay|Bayer|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717325||241|
NCT02715388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0389-15-TLV|Proof of Concept - Digital Electro-optical Surgical Platform as Replacement for Operational Microscopes|||Elbit Systems LTD|No|Recruiting|January 2016|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02715388||390|
NCT02702362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016/302/A|tDCS on Precuneus in MCS: Repeated Stimulations|Repeated Stimulation of the Precuneus in Chronic Patients in Minimally Conscious State: a Placebo-controlled Randomized Clinical Trial||Hangzhou Normal University|Yes|Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|15 Years|75 Years|No|||March 2016|March 7, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702362||1391|
NCT02709018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-15-2-0090|A Controlled Trial of Losartan in Posttraumatic Stress Disorder|Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder|LOSe-PTSD|University of California, San Diego|Yes|Not yet recruiting|May 2016|September 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709018||880|
NCT02709031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV-011|Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium|Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium|CHAMP|Navitas Pharma|No|Not yet recruiting|June 2016|September 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||March 2016|March 10, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709031||879|
NCT02718469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rVSV-EBOV-01|Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects||Profectus BioSciences, Inc.|Yes|Recruiting|January 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02718469||153|
NCT02715531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO30140|A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors|An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors||Hoffmann-La Roche||Not yet recruiting|March 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715531||379|
NCT02707237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-226|Maternal Counseling for Preterm Deliveries, Assessing an Effective Method of Counseling|||John H. Stroger Hospital|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Female|N/A|N/A|No|||March 2016|March 8, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02707237||1017|
NCT02699437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HME|Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia|Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia||Mansoura University|No|Recruiting|April 2015|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples Without DNA|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant|Female|20 Years|35 Years|No|Probability Sample|Attendants of Tertiary Hospital Obstetric Outpateint Clinics and Emergency Department|February 2016|February 29, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02699437||1616|
NCT02702206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131202R|Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis|Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|August 2014|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|270|||Both|20 Years|N/A|No|||March 2016|March 2, 2016|November 18, 2014|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02702206||1403|
NCT02718729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD 84|Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer|Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer||Mansoura University|Yes|Enrolling by invitation|January 2014|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 18, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02718729||133|
NCT02719054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-13066|Effect of Community Based Depression Management and Child Development|Effect of Community Based Depression Management and Psychosocial Stimulation Intervention on Maternal Mental Health and Child Development: A Randomized Controlled Trial||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2014|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|6 Months|1 Year|Accepts Healthy Volunteers|||February 2016|March 20, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02719054||108|
NCT02707315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-169|A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer|||The Cooper Health System|Yes|Recruiting|January 2013|||December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2015|March 8, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707315||1011|
NCT02707406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE-2011|Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K|A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)||Tissue Tech Inc.|No|Recruiting|February 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02707406||1004|
NCT02699723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0033|Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer|Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma||Stanford University|Yes|Not yet recruiting|March 2016|February 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699723||1594|
NCT02710357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|966_2014|A Cost-effectiveness Analysis of the Single-implant Mandibular Overdenture Treatment|Single-implant Mandibular Overdenture or a Conventional Complete Denture? A Cost-effectiveness Analysis Alongside a Randomized Clinical Trial|SIMOECON|Universidade Federal de Goias|Yes|Recruiting|March 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710357||777|
NCT02713139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-CLP-03(05/12)|Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.|Phase III, Multicenter, Randomized, Parallel, Open Label, Controlled and Comparative Study to Evaluate the Efficacy and Safety of the Association of Clotrimazole 200mg and Metronidazole 0,75% (Colpistatin 5DT®) Compared to Gynecological Flagyl®(Metronidazole 100mg/g) and the Vaginal Cream Gino-Canesten® 3 (Clotrimazole 20mg/g) in the Syndromic Treatment of the Vaginal Discharge From Different Etiologies.|Frauen|Ache Laboratorios Farmaceuticos S.A.|Yes|Withdrawn|September 2013|||March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|45 Years|No|||March 2016|March 15, 2016|March 15, 2016||No|Due to budget limitations, the company decided to withdraw this study.|No||https://clinicaltrials.gov/show/NCT02713139||563|
NCT02701374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700PNC01|Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia|TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia —Double Blind Comparison With Placebo—||Toray Industries, Inc|No|Recruiting|March 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|84 Years|No|||March 2016|March 17, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02701374||1467|
NCT02699983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131404|Virtual Weight Loss Program in Maintaining Weight in African American Breast Cancer Survivors|Virtual Weight Loss Program for African-American Breast Cancer Survivors||Rutgers, The State University of New Jersey|No|Recruiting|May 2015|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Female|21 Years|75 Years|No|||March 2016|March 1, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699983||1574|
NCT02704195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-A01323-42|Subthalamic Nucleus Stimulation Effect on Gait Symmetry and FOG|Subthalamic Nucleus Stimulation Effect on Gait Symmetry and FOG|STIMSYM|University Hospital, Grenoble|No|Recruiting|April 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|75 Years|No|||March 2016|March 4, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02704195||1250|
NCT02710422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150952|Miami Membrane for Potency (MMEP) Trial|Miami Membrane for Potency (MMEP) Trial to Assess the Impact of Dehydrated Human Amnion Membrane Allograft on Early Return of Erectile Function|MMEP|University of Miami|Yes|Not yet recruiting|April 2016|||April 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Male|40 Years|80 Years|No|||March 2016|March 11, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710422||772|
NCT02713373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 274515|Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery|A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer||Roswell Park Cancer Institute|Yes|Not yet recruiting|April 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713373||545|
NCT02711891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13091401-IRB02|Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing|Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing: A Randomized Double Blind Trial|Loperamide|Rush University Medical Center|Yes|Completed|March 2015|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 11, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711891||659|
NCT02708706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-10-009B|The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis|The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis||Taipei Veterans General Hospital, Taiwan|No|Recruiting|August 2015|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|40 Years|70 Years|No|||December 2015|March 9, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02708706||904|
NCT02710214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0512236|A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis|Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.|MS-TSEC|University of California, San Francisco|No|Recruiting|February 2016|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|62 Years|No|||March 2016|March 18, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710214||788|
NCT02710604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRV-CMX157-201|Phase 2, Multiple Ascending Dose Proof of Concept Study|A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects||ContraVir Pharmaceuticals, Inc.|Yes|Not yet recruiting|May 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02710604||758|
NCT02706548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.048|Feasibility of the Integrative Medication Self-Management Intervention to Promote Medication Adherence|Feasibility of the Integrative Medication Self-Management Intervention to Promote Medication Adherence|IMedS|University of Wisconsin, Milwaukee|No|Completed|October 2014|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706548||1070|
NCT02706795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT002-CL005|Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia|||Revance Therapeutics, Inc.||Recruiting|September 2015|August 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|30 Years|75 Years|No|||March 2016|March 8, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706795||1051|
NCT02706613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2015/069|Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD|A Randomised Controlled Research Study Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD|TROOPeR|my mhealth Ltd|No|Active, not recruiting|July 2015|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|40 Years|N/A|No|||January 2016|March 15, 2016|July 30, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02706613||1065|
NCT02710617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDT-1542-IU|System Accuracy Evaluation of 2 CE-marked Blood Glucose Monitoring System|||Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||Recruiting|March 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|N/A|||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710617||757|
NCT02711618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF19571|Non-Invasive Abdominal Fat Reduction With BMI Above 28|Clinical Study to Evaluate the Performance of the UltraShape Contour I V3 for Non-Invasive Abdominal Fat Reduction Among Patients With BMI Above 28||Syneron Medical|No|Recruiting|October 2015|November 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711618||680|
NCT02720250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2158610714114|Omega-3 Fatty Acids Enriched Food and Microvascular Reactivity|Effect of Omega-3 Fatty Acids Enriched Chicken Eggs Consumption on Microvascular Reactivity and Lipid Profile in Young Healthy Subjects||Josip Juraj Strossmayer University of Osijek|No|Recruiting|March 2016|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02720250||16|
NCT02720263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4345-CL-0002|A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia|A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia||Astellas Pharma Inc|No|Not yet recruiting|March 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||March 2016|March 22, 2016|March 22, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02720263||15|
NCT02712385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDV/5053/14|SPRITE - A Feasibility and Pilot Study|Stroke Prevention Rehabilitation Intervention Trial of Exercise - SPRITE - A Feasibility and Pilot Study|SPRITE|Queen's University, Belfast|Yes|Recruiting|March 2016|February 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02712385||621|
NCT02707471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00068595|Improving Well-Being for Breast Cancer Patients|Improving Well-Being for Breast Cancer Patients Taking Adjuvant Endocrine Therapy||Duke University|No|Not yet recruiting|May 2016|May 2021|Anticipated|May 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Female|21 Years|N/A|No|||February 2016|March 15, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02707471||999|
NCT02707484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rj(2015)088K-a|the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation|the Efficacy of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Prospective Multi-center Randomized Controlled Clinical Trial||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|March 2016|December 2020|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|November 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02707484||998|
NCT02706847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-542|A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)|SELECT-BEYOND|AbbVie|Yes|Recruiting|February 2016|August 2020|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|450|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706847||1047|
NCT02710331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015208.C|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III|THC-ETOH-III|Yale University|No|Recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710331||779|
NCT02714946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studio 96-15 CE 93321|Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules|Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules|LARA|Campus Bio-Medico University|No|Recruiting|January 2016|January 2019|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02714946||424|
NCT02717195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16159A|Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia|Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia||H. Lundbeck A/S|No|Recruiting|March 2016|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|964|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02717195||251|
NCT02717208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTR15I_1|Phase 1 Study for Safety and Tolerability of HL036|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Local Tolerability and Pharmacokinetic Characteristics After Administration of Eye-drop HL036 in Healthy Korean Male Volunteers (Phase I)||HanAll BioPharma Co., Ltd.|No|Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2016|March 22, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717208||250|
NCT02703896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-546|Prophylaxis for Aspiration of Gastric Contents.|"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery.||King Saud University|Yes|Completed|January 2012|December 2015|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|1920|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703896||1273|
NCT02709642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HL111211-03|Brigham and Women's Healthy Weight Study|Brigham and Women's Healthy Weight Study: Randomized Controlled Trial of a Financial Incentive for Weight Maintenance||Harvard Pilgrim Health Care|No|Not yet recruiting|April 2016|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02709642||832|
NCT02708394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMAAPWSU|Molecular Mechanisms of Antipsychotic-induced Insulin Resistance|Molecular Mechanisms of Antipsychotic-induced Insulin Resistance in Healthy Volunteers||Wayne State University|Yes|Not yet recruiting|January 2017|January 2023|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|50|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708394||928|
NCT02715193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R477-101|Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus|A Randomized, Placebo-controlled, Double-blind, In-patient Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 Following a Single Dose in Subjects With Type 1 Diabetes Mellitus||REMD Biotherapeutics, Inc.|Yes|Not yet recruiting|March 2016|November 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715193||405|
NCT02715206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021670|Adaptation Processes in School-based Substance Abuse Prevention|Adaptation Processes in School-based Substance Abuse Prevention|kiR|Penn State University|Yes|Completed|July 2006|January 2015|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2827|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||January 2016|March 16, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02715206||404|
NCT02656381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160046|Uveitis/Intraocular Inflammatory Disease Biobank (iBank)|Uveitis/Intraocular Inflammatory Disease Biobank (iBank)||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2015|January 2036|Anticipated|January 2036|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|8 Years|N/A|No|||December 2015|January 13, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02656381||4917|
NCT02656394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-1|Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101|Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study||GLIA LLC|Yes|Recruiting|January 2016|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02656394||4916|
NCT02713048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnI OHCA|Sensitive Troponin I in Out-of-hospital Cardiac Arrest|Sensitive Troponin I and Coronary Anatomy in Patients With Out-of-hospital Cardiac Arrest||University Medical Centre Ljubljana|No|Recruiting|October 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Comatose survivors after out-of-hospital cardiac arrest admitted to UMC Ljubljana|March 2016|March 14, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02713048||570|
NCT02713061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-850/CPH-004|A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants|An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects||Takeda|No|Not yet recruiting|March 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713061||569|
NCT02710903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0637|IL29 and IL28B Variants Associated With Periodontal Disease Pathogenesis|IL29 and IL28B Variants Associated With Periodontal Disease Pathogenesis||University of North Carolina, Chapel Hill|No|Not yet recruiting|April 2016|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|220|||Both|25 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02710903||735|
NCT02696759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204897|Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer|The Gut Microbiome and Gastrointestinal Toxicities as Determinants of the Response to Neoadjuvant Chemotherapies for Advanced Breast Cancer||University of Arkansas|No|Not yet recruiting|March 2016|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02696759||1822|
NCT02709382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-4282-104|A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment|||Wockhardt|No|Not yet recruiting|March 2016|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709382||852|
NCT02709447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500421|Dating Violence Prevention for Juvenile Justice Girls|Dating Violence Prevention for Juvenile Justice Girls||Northeastern University|Yes|Recruiting|April 2015|March 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||February 2016|March 15, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02709447||847|
NCT02713594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-0056 (400025710)|Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation|Wisconsin Tobacco Quit Line Centers for Medicaid Services Striving To Quit Evaluation Project||University of Wisconsin, Madison|No|Active, not recruiting|April 2013|March 2017|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1962|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02713594||528|
NCT02703363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN-BPD|Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression|Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression: A Factorial Design Randomised Controlled Trial||Pakistan Institute of Learning and Living||Not yet recruiting|August 2016|||August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703363||1314|
NCT02700971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-RATIO-CCI-01|Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma|Rational Approach To Immuno-Oncology Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma|RATIO|AHS Cancer Control Alberta|No|Not yet recruiting|May 2016|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02700971||1498|
NCT02700984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-09-01-E|A Study to Assess Long-Term Safety of the Transcend CyPass Micro-Stent in Patients Completing the COMPASS Trial|An Observational Multicenter Clinical Study to Assess the Long-Term Safety of the Transcend CyPass Micro-Stent Glaucoma Implant in Patients With Primary Open Angle Glaucoma Who Have Completed Participation in the COMPASS Trial|COMPASS-XT|Transcend Medical, Inc.|No|Enrolling by invitation|March 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|480|||Both|N/A|N/A|No|Non-Probability Sample|Up to 480 subjects who completed 24 month follow-up in Study Protocol TMI-09-01 (COMPASS        Trial), meet study eligibility criteria and agree to participate in the study.|March 2016|March 1, 2016|February 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700984||1497|
NCT02709499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLT-CABG-2016/2|Effects of the Low-level Laser Therapy on Inflammatory Profile of the Patients With Coronary Artery Bypass Surgery|Effects of the Low-level Laser Therapy on Inflammatory Profile on Patients With Coronary Artery Bypass Surgery: A Randomized, Controlled Clinical Trail||Federal University of Health Science of Porto Alegre|No|Not yet recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|45 Years|75 Years|No|||March 2016|March 10, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02709499||843|
NCT02714998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013-TIP-043|The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy|The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy||Ege University|Yes|Completed|January 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|131|||Female|18 Years|45 Years|No|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02714998||420|
NCT02715284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4010-01-001|A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors||Tesaro, Inc.|No|Recruiting|March 2016|December 2019|Anticipated|February 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|379|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 9, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715284||398|
NCT02707250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IuliuHatieganuU|Oblique Subcostal Tap Block Efficacy in Laparoscopic Cholecystectomy|Oblique Subcostal Transverses Abdominal Plane Block in Laparoscopic Cholecystectomy||Iuliu Hatieganu University of Medicine and Pharmacy|Yes|Recruiting|March 2015|June 2016|Anticipated|February 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707250||1016|
NCT02709577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-5|A Study of the GI Sleeve for the Treatment of Type 2 Diabetes|A Pilot Feasibility Sham Controlled Study of the GI Sleeve for the Treatment of Type 2 Diabetes||GI Dynamics|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|No|||March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709577||837|
NCT02709590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS3|Diclofenac Potassium With Lidocaine Cream in Reducing Pain During HSG|Randomized Clinical Trial of Oral Diclofenac Potassium With Cervical Lidocaine Cream in Reducing Pain During HSG|DP-L|Assiut University|Yes|Recruiting|March 2016|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|140|||Female|N/A|N/A|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709590||836|
NCT02709603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2|Hyoscine Butyl Bromide Versus Diclofenac Potassium in Reducing Pain During HSG|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium in Reducing Pain During HSG|HBTB-DIC|Assiut University|Yes|Not yet recruiting|April 2016|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|300|||Female|20 Years|45 Years|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709603||835|
NCT02718183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/16|Effect on Periodontal Markers by Bleaching Intracoronal Technique|Effect on Periodontal Markers Interleukin-RANK by Walking Bleaching Non-Vital Technique: Clinical Randomized Double-blind Trial|BLEIC|University of Chile|No|Completed|March 2015|February 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02718183||175|
NCT02703597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0995|Smoking Prevention Through Social Connections Among Adolescents - ASPIRE|Smoking Prevention Through Social Connections Among Adolescents - ASPIRE||M.D. Anderson Cancer Center|No|Not yet recruiting|April 2016|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|145|||Both|11 Years|21 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703597||1296|
NCT02708628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGZ-EAC-A-H-1|The Efficacy of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development|The Efficacy of Prophylactic Use of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development After Excision of Previous Scar||Suleymaniye Birth And Women's Health Education And Research Hospital|No|Recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02708628||910|
NCT02708641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-101|A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML|A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates||University of Pittsburgh|Yes|Not yet recruiting|June 2016|June 2021|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||March 2016|March 15, 2016|March 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708641||909|
NCT02702999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-16-0084|Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial|Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial (UP Trial)|UP|The University of Texas Health Science Center, Houston|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|206|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702999||1342|
NCT02700204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF19921|Histological Study to Evaluate Skin Changes After PicoWay® 1064 nm and 532nm Picosecond Fractional Laser Treatment|Histological Study to Evaluate Skin Changes After PicoWay® 1064 nm and 532nm Picosecond Fractional Laser Treatment||Syneron Medical|No|Recruiting|January 2016|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 28, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700204||1557|
NCT02712515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201600172|The Motor Network in Essential Tremor: Mechanisms of Therapy|The Motor Network in Essential Tremor: Mechanisms of Therapy||University of Florida|Yes|Not yet recruiting|March 2016|March 2021|Anticipated|March 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|21 Years|N/A|No|||March 2016|March 17, 2016|March 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02712515||611|
NCT02718547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0029-16-MMC|The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema|The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema||Meir Medical Center|Yes|Not yet recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02718547||147|
NCT02718560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Handwriting rehab in PD|Handwriting Rehabilitation in Parkinson Disease|Effectiveness of Intensive Handwriting Rehabilitation in Subjects With Parkinson's Disease|HRPD|Ospedale Generale Di Zona Moriggia-Pelascini|Yes|Recruiting|September 2015|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|30 Years|80 Years|No|||March 2016|March 20, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02718560||146|
NCT02701634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-406-1840|Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)||Gilead Sciences|Yes|Not yet recruiting|March 2016|January 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701634||1447|
NCT02708784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsDM15RMBH|An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-|Function, Structure and Quality of Striated Muscles in Patients With Muscular Diseases - an MRI Study on Pompe Disease and Dystrophia Myotonica||University of Aarhus|Yes|Enrolling by invitation|September 2015|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited trough their attendance to the Hospital. Pompe disease patients        will be recruited from all the treating hospitals in Denmark and from the University        hospital of Münster. Patients with Myotonic Dystrophy will be recruited trough their        attendance at Aarhus University Hospital.        Healthy controls will be recruited from the general Danish population.|November 2015|March 9, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02708784||898|
NCT02697344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mc1384|R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma|Phase 1/2 Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma||Mayo Clinic|Yes|Not yet recruiting|June 2016|||June 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697344||1777|
NCT02716766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-MONC-HCC-001|Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)|Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma||The University of Hong Kong||Not yet recruiting|March 2016|||June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02716766||284|
NCT02718859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pancreatic cancer NK cells|Study of the Combined Therapy for Pancreatic Cancer|Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer（NK） Cells for Advanced Pancreatic Cancer||Fuda Cancer Hospital, Guangzhou|Yes|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 19, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02718859||123|
NCT02714816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATH-2015-001|Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65|Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65||Athena Vision Ltd|No|Not yet recruiting|March 2016|March 2021|Anticipated|March 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|3 Years|N/A|No|Non-Probability Sample|Patients with RPE65-LCA condition|March 2016|March 16, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02714816||434|
NCT02706171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-073|Stereotactic Radiosurgery for Soft Tissue Sarcoma|Stereotactic Radiosurgery for Soft Tissue Sarcoma||The Cooper Health System|No|Recruiting|June 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 2, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706171||1098|
NCT02706353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0654|APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma|Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706353||1084|
NCT02708836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004373|Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique|Limiting Emergence Phenomena After General Anesthesia for Laparoscopic Surgery With Combined Laryngeal Mask Airway and Endotracheal Tube Airway Management Technique|LEPAGA|Milton S. Hershey Medical Center|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 4, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708836||894|
NCT02714972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHM3|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)|PHM3|In Home Closed Loop Study Group|Yes|Not yet recruiting|April 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|6 Years|14 Years|No|||March 2016|March 16, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714972||422|
NCT02706756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00069234|Conservative Intervention of Femoroacetabular Impingement Syndrome|Conservative Intervention of Femoroacetabular Impingement Syndrome: A Randomized Controlled Trial||Duke University|No|Not yet recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||February 2016|March 8, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706756||1054|
NCT02698930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2015-0839|Effect of Dexmedetomidine on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery|||Yonsei University|No|Not yet recruiting|February 2016|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|94|||Both|20 Years|N/A|No|||February 2016|February 29, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02698930||1655|
NCT02698943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320/2-3-2016|Glistenings and PCO Evaluation for the Envista MX60|Evaluation of Glistenings and Posterior Capsule Opacification Following Envista MX60 Intraocular Lens Implantation||Democritus University of Thrace|No|Completed|September 2015|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|60 Years|80 Years|No|Non-Probability Sample|Participants with senile cataract|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02698943||1654|
NCT02701738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00102772|Impact of Exercise on the Metabolic Consequences of Overeating|Impact of Exercise on the Metabolic Consequences of Overeating|XO|University of Michigan|No|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02701738||1439|
NCT02701751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00102522|Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study)|Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study)|ATX|University of Michigan|No|Recruiting|January 2016|January 2021|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02701751||1438|
NCT02713035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0172|Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients|Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients||University of Mississippi Medical Center|Yes|Recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|4 Years|12 Years|No|||March 2016|March 17, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02713035||571|
NCT02713308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP001|Impact of MultiPoint Pacing Technology in CRT Patients With Reduced RV-to-LV Delay|Impact of MultiPoint Pacing Technology in CRT Patients With Reduced RV-to-LV Delay|IMAGE-CRT|Monaldi Hospital||Not yet recruiting|April 2016|April 2018|Anticipated|October 2017|Anticipated|N/A|Observational|N/A||2|Anticipated|248|||Both|18 Years|85 Years|No|Probability Sample|Patients with standard indication to CRT-D system implantation|March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02713308||550|
NCT02703558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00085778|Evaluation of Fluorescein Use During Cystoscopy|Evaluation of Fluorescein Use During Cystoscopy, a Randomized Control Trial|EFLUC|Johns Hopkins University|No|Not yet recruiting|March 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02703558||1299|
NCT02703571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMT212X2106|Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors|A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors||Novartis|No|Not yet recruiting|May 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703571||1298|
NCT02706808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeniseMafra3|Resistant Starch Supplementation Effects on the Intestinal Tract Profile and Cardiovascular Markers in Renal Patients|Effects of Supplementation With Resistant Starch in the Profile of the Intestinal Tract and Cardiovascular Markers in Patients With Chronic Kidney Disease|Starch|Universidade Federal Fluminense|No|Recruiting|December 2015|||July 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02706808||1050|
NCT02698150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERMES|Remote Monitoring of Patients With Functional Mitral Regurgitation Undergoing Mitraclip Transcatheter Repair|Evaluation of Remote Monitoring in Patients With Functional Mitral Regurgitation Undergoing Transcatheter Mitral Valve Edge-to-edge Repair With the Mitraclip System|HERMES|Azienda Ospedaliero, Ferrarotto Alessi|No|Recruiting|March 2016|October 2018|Anticipated|September 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with severe mitral regurgitation of functional etiology undergoing transcatheter        mitral valve edge-to-edge repair with the Mitraclip system|March 2016|March 5, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02698150|12 Months|1715|
NCT02715544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P&G 2015|Promoting Healthy Eating and Active Playtime by Connecting Preschool Children to Nature|Promoting Healthy Eating and Active Playtime by Connecting Preschool Children to Nature|Play&Grow|The University of Hong Kong|Yes|Recruiting|January 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02715544||378|
NCT02715830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP01|Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery.|Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery.||Federal University of São Paulo|No|Recruiting|January 2014|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715830||356|
NCT02695914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJ2015-49|Influence of Compound Qingre Granule on the Inflammatory Markers in Patient of FUO With Excess-heat Syndrome|Inflammatory Markers in Patient of FUO With Excess-heat Syndrome and the Influence of Compound Qingre Granule on the Inflammatory Markers||Beijing Friendship Hospital|No|Enrolling by invitation|January 2016|October 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|80|Samples Without DNA|Exsanguinating and saving the blood in the refrigerator of -4 ℃.|Both|N/A|N/A|No|Probability Sample|Patient of fever of unknown origin with excess-heat syndrome|February 2016|February 29, 2016|January 31, 2016||No||No||https://clinicaltrials.gov/show/NCT02695914||1887|
NCT02702908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18044|Second Primary Cancers in Patients With Castration Resistant Prostate Cancer|Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (BOCARP)|BOCARP|Bayer|No|Recruiting|March 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2100|||Male|18 Years|N/A|No|Non-Probability Sample|The study population will consist of mPC patients (prostate cancer patients with bone        metastases) and a subgroup of patients who can be regarded as mCRPC patients        (castration-resistant prostate cancer patients with bone metastases).|March 2016|March 23, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02702908||1349|
NCT02708849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015203|The Sustained Effects of Ketamine|||Yale University|No|Recruiting|June 2015|March 2020|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708849||893|
NCT02708862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preox|Four Methods of Pre-oxygenation|Comparison of Emergency Department Preoxygenation Techniques in Healthy Volunteers||Minneapolis Medical Research Foundation|No|Not yet recruiting|March 2016|||April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708862||892|
NCT02716064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-450|TAPESTRY for People With Cardiovascular and Metabolic Disease: A Pilot Study|Teams Advancing Patient Experience: Strengthening Quality for People With Cardiovascular and Metabolic Disease (TAPESTRY-CM): A Pilot Study|TAPESTRY-CM|McMaster University|No|Active, not recruiting|December 2014|December 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 3, 2014||No||No||https://clinicaltrials.gov/show/NCT02716064||338|
NCT02696187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOLwebben|Feasibility and Effects of KOL-webben in Patients With COPD|Feasibility and Effects of KOL-webben - an Internet Based Health Promotion Tool Directed Towards People With Chronic Obstructive Pulmonary Disease and Staff in the Primary Health Care in Sweden||Umeå University|No|Recruiting|January 2016|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|96|||Both|40 Years|N/A|No|||February 2016|February 25, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02696187||1866|
NCT02696460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB_01_2010|Efficacy of 50% Nitrous Oxide/50% Oxygen Gas Premix in Chronic Leg Ulcer Debridement|Efficacy of Inhaled 50% Equimolar Nitrous Oxide/Oxygen Gas Premix (Kalinox®) as Compared to Topically Administered 5% Eutectic Mixture of Lidocaine/Prilocaine (EMLA®) in Chronic Leg Ulcer Debridement||Venenklinik Bellevue|No|Completed|April 2010|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02696460||1845|
NCT02703168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 03-05/11|Long-term Performance of SLActive Implants After Immediate or Early Loading|Post-marketing Study to Document Long-term Performance of Straumann Tissue Level Implants With SLActive Surface in the Posterior Mandible and Maxilla After Immediate or Early Loading - Follow-up to Study CR 06/03||Institut Straumann AG|No|Completed|July 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|66|||Both|18 Years|N/A|No|Probability Sample|All patients who participated in the Straumann clinical trial CR06/03|March 2016|March 3, 2016|September 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02703168||1329|
NCT02699502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0210-15-MMC|Metabolic Therapy in Patients With Osteoporosis After Hip Fracture by an Orthopedic-rehabilitation-metabolic Team|Metabolic Therapy in Patients With Osteoporosis After Hip Fracture by Cooperation Orthopedic-rehabilitation-metabolic: Determination of Drug Treatment Regardless of Reaching the Follow-up Clinic||Meir Medical Center|Yes|Not yet recruiting|March 2016|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|100 Years|No|||February 2016|March 3, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02699502||1611|
NCT02699515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200647-0008|MSB0011359C（M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia||Merck KGaA|Yes|Not yet recruiting|March 2016|August 2019|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|111|||Both|20 Years|N/A|No|||March 2016|March 4, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699515||1610|
NCT02717117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H19062014|Magnetic Resonance Imaging of Motility in Crohn's 1|Reduced Intestinal Motility in Inflammatory Crohn's Disease - Optimisation Studies in Healthy Volunteers|MIC1|University of Nottingham|No|Recruiting|June 2015|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717117||257|
NCT02705664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.105078|Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%|Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1%|OPEN|Galderma|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705664||1137|
NCT02711813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB08-SLE-01|TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment|Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy||Theramab LLC|No|Not yet recruiting|March 2016|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711813||665|
NCT02711826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-21|Treg Therapy in Subclinical Inflammation in Kidney Transplantation|Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21)|TASK|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711826||664|
NCT02696837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIRS002|Pediatric Inguinal Hernia Repair: Are Muscle Relaxants Necessary? Endotracheal Intubation vs Laryngeal Mask Airway|Safety Control Study in Pediatric Inguinal Hernia Repair: Are Muscle Relaxants Necessary? Endotracheal Intubation vs Laryngeal Mask Airway||Maltepe University|Yes|Recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Anticipated|80|||Both|N/A|18 Years|No|||March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02696837||1816|
NCT02717624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-LY-106|A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma|A Phase 1b, Multicenter, Open-label Study of ACP-196 in Combination With Bendamustine and Rituximab (BR) in Subjects With Mantle Cell Lymphoma||Acerta Pharma BV|No|Recruiting|February 2016|||February 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717624||218|
NCT02717936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESMOPEK1|Investigation of Desmoplastic Squamous Cell Carcinoma|Prospektive Therapie-Studie Zur Behandlung Des Desmoplastischen Plattenepithelkarzinoms|DesmoPEK|University Hospital Tuebingen|No|Recruiting|January 2016|January 2020|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|March 24, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02717936||194|
NCT02698072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/2015|Improvement in Pain and Function Following a Physiotherapy Program in Older Adults With Knee Osteoarthritis|Improvement in Pain and Function Following a Therapeutic Exercise Program and Dry Needling in Older Adults With Knee Osteoarthritis: A Randomized Double-blind Multicenter Controlled Clinical Trial||Universidad Rey Juan Carlos|Yes|Enrolling by invitation|September 2015|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|62 Years|100 Years|No|||February 2016|February 28, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02698072||1721|
NCT02698293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08216|A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer|A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Not yet recruiting|April 2016|||April 2018|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698293||1704|
NCT02697331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIN-2222-RCT|Evaluation of the Role of Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation With Short Cervix: Randomised Controlled Trial|Evaluation of the Role of Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation With Short Cervix: Randomised Controlled Trial||Ain Shams University||Recruiting|December 2015|||October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697331||1778|
NCT02701712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-8210-CE|Receiving Radiation Therapy in the MRgRT Research Facility|Receiving Radiation Therapy in the MRgRT Research Facility|MRgRT|University Health Network, Toronto|No|Recruiting|February 2016|||February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02701712||1441|
NCT02711592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-037|Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study|Utilizing Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: A Pilot Study||TriHealth Inc.|No|Recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02711592||682|
NCT02719899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160085|Effect of Fasting and Refeeding on T-cell Fate|Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate||National Institutes of Health Clinical Center (CC)||Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|21 Years|37 Years|No|||March 2016|March 24, 2016|March 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02719899||43|
NCT02719912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 01-2015|Mitral Valve Replacement With MValve Dock and Lotus|Mitral Valve Replacement With the MValve Dock and A Percutaneous Transcatheter Heart Valve|DOCK 1|MValve Technologies Ltd|Yes|Not yet recruiting|June 2016|July 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719912||42|
NCT02709681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SocietaITE|Hydroxyurea in the Treatment of Sickle Cell Disease|Hydroxyurea in Sickle Cell Disease: a Large Nation-wide Cohort Study From Italy||Società Italiana Talassemie ed Emoglobinopatie|No|Active, not recruiting|November 2015|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|628|||Both|1 Year|N/A|No|Non-Probability Sample|A population of SCD (Homozigous HbS and Beta Thal /HbS) patients followed in 32 Italian        Centers was included in this analysis.|March 2016|March 10, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02709681||829|
NCT02708771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJC-CAR-01-2015|Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity|Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity|PROTEICA|Hospital San Juan de la Cruz|Yes|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 6, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708771||899|
NCT02699320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XH-16-001|Intestinal Microbial Dysbiosis in Chinese Infants With Short Bowel Syndrome With Different Complications|Multi-center Clinical Research About Standard Diagnosis and Treatment of Neonate Severe Digestive System Malformation|MSBS|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Yes|Completed|June 2015|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|33|||Both|N/A|1 Year|No|Probability Sample|18 infants diagnosed with SBS were enrolled from Digestion and Nutrition Division at Xin        Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.|February 2016|March 3, 2016|February 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02699320||1625|
NCT02716428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRK-450-0203|A Study of Faldaprevir, TD-6450 and Ribavirin in Participants With Genotype 1b Hepatitis C Virus Infection|A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir, TD-6450, and Ribavirin in Combination for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1b Hepatitis C Virus||Trek Therapeutics, PBC|No|Not yet recruiting|April 2016|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716428||310|
NCT02709746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12710A|Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)|Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)||H. Lundbeck A/S|Yes|Not yet recruiting|March 2016|||October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|750|||Both|12 Years|17 Years|No|||March 2016|March 15, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709746||824|
NCT02708823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRP-Norm|Standardization of a Novel Self-administered Tablet Computer-based Clinical Screening Tool for Postoperative Delirium|Standardization of a Novel Self-administered Tablet Computer-based Clinical Screening Tool for Postoperative Delirium: A Neuropsychological Study in Non-surgical Volunteers|DRP-Norm|University Hospital, Basel, Switzerland|No|Not yet recruiting|November 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Non-surgical, cognitively healthy volunteers|March 2016|March 15, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708823||895|
NCT02719301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERM-IRB-001-CM|Necklace-Shaped Sensor for Non-Invasive Monitoring of Stroke Volume and Cardiac Output|Necklace-Shaped Sensor for Non-Invasive Monitoring of Stroke Volume, Cardiac Output, Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate||toSense, Inc.|No|Enrolling by invitation|September 2015|April 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|75|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women between 18 and 85.|March 2016|March 24, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02719301||89|
NCT02715219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-14-1642-23836|Effectiveness of an AEP on Patient's Knowledge, Medication Adherence and Inhaler Technique|Effectiveness of an Asthma Education Programme on Patient's Knowledge, Medication Adherence and Inhaler Technique: Randomized Control Trial||Clinical Research Centre, Malaysia|Yes|Active, not recruiting|June 2015|December 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02715219||403|
NCT02705222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMM|Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women|Comparison Between Dilatation and Curettage and Hysteroscopy in Management of Abnormal Uterine Bleeding in Perimenopausal Women||Mansoura University|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Female|45 Years|55 Years|No|||March 2016|March 4, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02705222||1171|
NCT02709694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-491|Imaging Biomarkers in Crohn's Associated Spondyloarthritis|Imaging Biomarkers in Crohn's Associated Spondyloarthritis|MaRCH-on|Hospital for Special Surgery, New York|No|Not yet recruiting|March 2016|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples Without DNA|Blood for C-reactive Protein and stool samples for fecal microbial 16s rRNA sequencing|Both|18 Years|N/A|No|Non-Probability Sample|Patients will biopsy proven Crohn's disease will be enrolled for the study. 50% (15        patients) will have symptoms of inflammatory back pain and 50% will not.|March 2016|March 15, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02709694||828|
NCT02709486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091057|Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee||Pfizer|Yes|Not yet recruiting|March 2016|May 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|810|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709486||844|
NCT02719561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A093987|Fatigue Intervention Co-design Study in Teenagers and Young Adults With Cancer|Fatigue Intervention Co-design Study in Teenagers and Young Adults With Cancer||Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|June 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|27 Years|No|||March 2016|March 23, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02719561||69|
NCT02646553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/842|Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.|Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.||Haukeland University Hospital|Yes|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|the investigators collect saliva and urine from the patients, for analysis of the hormone      cortisol.|Both|4 Years|16 Years|No|Non-Probability Sample|The reference are made from healthy children included from kindergarden and Schools in the        Bergen area. The age range from 4 to 16 years ols. The patient population is children        refered to the obestity clinic at Haukeland University Hospital.|January 2016|January 21, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02646553||5671|
NCT02646566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10019|Study of APD421 as PONV Treatment (Prior Prophylaxis)|Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis||Acacia Pharma Ltd|Yes|Not yet recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|580|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02646566||5670|
NCT02717884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00806 UKF|Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)|Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)|TRANSATRA|University Hospital Freiburg|Yes|Recruiting|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02717884||198|
NCT02698579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTF-304|Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product|Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product||bluebird bio|No|Enrolling by invitation|January 2016|November 2033|Anticipated|November 2033|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|17|||Male|N/A|N/A|No|Non-Probability Sample|Subjects with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product        in Study ALD-102.|February 2016|March 2, 2016|February 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698579||1682|
NCT02703103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.008.1MR|Chest Compression During Resuscitation|Use of a New Mechanical Chest Compression Machine LifeLine ARM for Cardiopulmonary Resuscitation by Paramedics: a Randomized, Crossover, Manikin Trial||Medical University of Warsaw|No|Recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02703103||1334|
NCT02704728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Theta 001|Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease|A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease||4DPharma PLC|No|Recruiting|December 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|18 Years|No|||March 2016|March 6, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02704728||1209|
NCT02705703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiroVAX004|Consolidation Therapy in Patients With Metastatic Solid Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide (CYP), Tumor Associated Peptide Antigen (TAPA)-Pulsed Dendritic Cell (DC) Therapy and Low Dose Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF), as Consolidation Therapy in Patients With Metastatic Solid Malignancies||Kiromic, LLC|Yes|Not yet recruiting|May 2016|September 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705703||1134|
NCT02696824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20150399|Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa|Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa||University of Miami|Yes|Not yet recruiting|March 2016|||April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696824||1817|
NCT02717598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016LL001|Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps|Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps: a Randomized Controlled Trial|CSPVHSP|Wulumuqi General Hospital of Lanzhou Military Command|Yes|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|20 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717598||220|
NCT02706769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC15006|Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Pain|A Double-blind Randomised Parallel Group Trial of Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Related Pain|PaSO|University of Edinburgh|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|16 Years|N/A|No|||January 2016|March 7, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02706769||1053|
NCT02705716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205212|Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity|Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Not yet recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705716||1133|
NCT02705872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB-PIB|Comparison of Two Methods of Administration of the Epidural, by Programmed Intermittent Bolus or Continuous Perfusion, on the Incidence of Cesarean Sections and Instrumented Deliveries in Primiparous Women|Comparison of Two Methods of Administration of the Epidural, by Programmed Intermittent Bolus or Continuous Perfusion, on the Incidence of Cesarean Sections and Instrumented Deliveries in Primiparous Women||Brugmann University Hospital|No|Not yet recruiting|June 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|784|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02705872||1121|
NCT02697097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AddenbrookesH|Hip Muscle Strength in FAI Versus Normal Controls|Muscle Strength in Femoroacetabular Impingement: A Comparative Study of Patients With FAI Versus Normal Controls||Cambridge University Hospitals NHS Foundation Trust|No|Not yet recruiting|April 2016|August 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control Arm Group - Medical Students who fit the inclusion criteria and are between ages        of 18-30.        FAI Comparison Group - Participants will be recruited from Young Adult Hip Clinic, meeting        the defined inclusion criteria and also being between the ages of 18-30.|February 2016|February 28, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697097||1796|
NCT02711501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TehranUMS h4p62mb2|Comparison of Post-operative Complications of Bone Augmentation at Anterior of Maxilla After Periosteal Releasing Incision With Two Techniques Diode Laser and Scalpel|||Tehran University of Medical Sciences|Yes|Not yet recruiting|March 2016|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|30 Years|45 Years|No|||March 2016|March 16, 2016|February 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711501||689|
NCT02695693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH106175|RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation|RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation||University of Pennsylvania|No|Enrolling by invitation|April 2015|March 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|5 Years|9 Years|No|||February 2016|February 24, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02695693||1904|
NCT02697279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00066974|Loop Drainage: Effectiveness in Treating Cutaneous Abscesses|Evaluation of Loop Drainage Technique Versus Standard Incision and Drainage for Treatment of Simple Soft Tissue Abscesses||University of Maryland|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02697279||1782|
NCT02697292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005649|IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy|A Randomized Double Blind Placebo Controlled Study of Intravenous Immunoglobulin (IVIG) Patients With Voltage Gated Potassium Channel Complex (VGKC) Antibody Associated Autoimmune Epilepsy||Mayo Clinic|No|Recruiting|February 2016|August 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|February 26, 2016|February 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697292||1781|
NCT02697370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/SC/0363|Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A|Efficacy and Cost Effectiveness of Standard Versus Pharmacokinetic Dosing During Factor VIII Prophylaxis in Adult Patients With Severe Haemophilia A||Hampshire Hospitals NHS Foundation Trust|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|70 Years|No|||February 2016|February 26, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02697370||1775|
NCT02697383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-294|Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study|Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|February 2016|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02697383||1774|
NCT02715297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RadOnc MRI TUM - 1|Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma|Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma|GlioCave/NOA17|Technische Universität München|Yes|Recruiting|February 2016|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|99 Years|No|||March 2016|March 16, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02715297||397|
NCT02715583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02816|C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer|C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2016|||March 2017|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|15|||Male|18 Years|N/A|No|||March 2016|March 21, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715583||375|
NCT02707588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2015-01|Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC|A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|PembroRad|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Not yet recruiting|April 2016|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|80 Years|No|||March 2016|March 8, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02707588||990|
NCT02698969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2013-004-787-62|Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography|Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs.||University of Florence|Yes|Recruiting|November 2014|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|80 Years|No|||February 2016|February 27, 2016|February 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02698969||1652|
NCT02711176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/52/1662|Comparison of Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection|Comparison of Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection||Ilam University of Medical Sciences|No|Not yet recruiting|March 2016|October 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 12, 2016|February 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711176||714|
NCT02711189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160082|Oxytocin in Alcohol Use Disorder|Oxytocin in Alcohol Use Disorder: A Novel and Translational Approach||National Institutes of Health Clinical Center (CC)||Not yet recruiting|March 2016|November 2018|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|32|||Male|21 Years|55 Years|No|||February 2016|March 22, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711189||713|
NCT02712853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study00003658|Improving Autism Screening With Brain-Related miRNA|Improving Autism Screening With Brain-Related miRNA||Milton S. Hershey Medical Center|Yes|Recruiting|November 2015|April 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples Without DNA|Salivary RNA|Both|2 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will compare salivary miRNA in 2 groups of children between the ages of 2 years,        0 months and 5 years, 11 months of age:        Group 1: Children with autism spectrum disorder (ASD), diagnosed by a developmental        pediatrician using DSM-5 criteria and confirmed with ADOS, CASD, or some additional        semi-structured evaluation measure. ASD will not be attributable to an underlying genetic        phenotype, and participants may not have a history of extreme pre-term birth or underlying        neurologic disorders such as seizures or cerebral palsy.        Group 2: Healthy controls, meeting developmental milestones, with negative MCHAT-R        screening and no family history of autism in first degree relatives|February 2016|March 14, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02712853||585|
NCT02717663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA198915|WalkIT Arizona: Walking Interventions Through Texting|WalkIT: Neighborhood Walkability and Moderation of Adaptive Walking Interventions||Arizona State University|Yes|Not yet recruiting|April 2016|July 2021|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02717663||215|
NCT02704156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChanghaiHosp|Safety and Efficacy Study of Five-fraction Stereotactic Body Radiation Therapy to Locally Advanced Pancreatic Cancer|The Safety and Efficacy of Five-fraction Stereotactic Body Radiation Therapy Treating Locally Advanced Pancreatic Cancer With cyberKnife—a Phase II Clinical Study||Changhai Hospital|No|Not yet recruiting|March 2016|December 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|75 Years|No|||March 2016|March 8, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02704156||1253|
NCT02703675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015H0207|Effectiveness, Safety and Ease of Application of Excel Cryo Cooling Collar to Rapidly Reduce Core Brain Temperature|Effectiveness, Safety and Ease of Application of Excel Cryo Cooling Collar to Rapidly Reduce Core Brain Temperature|CryoCollar|Ohio State University|No|Recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|January 15, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703675||1290|
NCT02708264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/2015|Does Cervical Pessary Prevent Spontaneous Preterm Birth in Twin Pregnancies With Short Cervical Length?|Pessary in Prevention of Preterm Birth for Women With Twin Pregnancies and Short Cervical Length||Federico II University|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|No|||March 2016|March 9, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02708264||938|
NCT02716532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15.03.CLI|Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)|Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)|MCTs and ABI|Nestlé|No|Not yet recruiting|April 2016|September 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02716532||302|
NCT02714504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fusarium prophylaxis|Anti-mold Azole in the Prophylaxis for Invasive Fusariosis|Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp|Fusarproph|Universidade Federal do Rio de Janeiro|No|Completed|August 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|239|||Both|N/A|N/A|No|||March 2016|March 18, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02714504||458|
NCT02714517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|idrokinesi.neuropatie|Efficacy of Hydrotherapy in Peripheral Neuropathy|||Ospedale Generale Di Zona Moriggia-Pelascini||Recruiting|July 2015|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714517||457|
NCT02706015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-CFL-03(10/14)|Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks|National, Phase III, Multicenter, Randomized, Double-Blind, Parallel, Non-Inferiority Trial to Evaluate the Efficacy and Safety of Cefaliv® Compared to the Neosaldina® in the Treatment of Migraine Attacks||Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|August 2016|May 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|66 Years|No|||March 2016|March 10, 2016|November 23, 2015||No||No||https://clinicaltrials.gov/show/NCT02706015||1110|
NCT02711904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEGANEST|Concentrations of Remifentanil for Extubation|Effect of Two Plasma Concentrations of Remifentanil Through Target Controlled Anesthesia on Frequency and Intensity of Coughing During Extubation: Randomized Controlled Clinical Trial|REMEX|Seganest|Yes|Completed|January 2011|July 2012|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|70 Years|No|||March 2016|March 16, 2016|August 27, 2013||No||No||https://clinicaltrials.gov/show/NCT02711904||658|
NCT02697357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-219|Emotion Regulation Therapy to Address Distress Among Caregivers|Emotion Regulation Therapy to Address Distress Among Caregivers||Memorial Sloan Kettering Cancer Center||Recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood and Saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from outpatient clinics in various departments at MSKCC,        including the Department of Psychiatry & Behavioral Sciences, Social Work, Neurology,        Integrative Medicine and Bone Marrow Transplant services.|February 2016|February 26, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697357||1776|
NCT02712528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160080|Recovery Profiles of Remifentanil-based Regimen for Cardiac Surgery|Recovery Profiles of Remifentanil-based vs. Sevoflurane-sufentanil Combined Regimen for Cardiac Surgery||Konkuk University Medical Center|No|Recruiting|May 2015|May 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|19 Years|75 Years|No|||March 2016|March 15, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02712528||610|
NCT02714829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExcelOS 14-01|Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2|||BioAlpha Inc.|No|Enrolling by invitation|March 2016|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|35 Years|65 Years|No|||March 2016|March 21, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02714829||433|
NCT02714842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM1501|Delayed Release Diclofenac Sodium Formulation vs Voltaren®|A Pharmacoscintigraphic Clinical Study to Investigate the in Vivo Behaviour of a Novel Delayed-release Formulation of Diclofenac in Comparison to the Voltaren® Enteric Coated Tablet Commercial Formulation in Healthy Volunteers||Bio-Images Research Ltd|No|Recruiting|March 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02714842||432|
NCT02703090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00021030|Assessing the Cortical Response to Noxious and Auditory Stimuli Using Near Infrared Spectroscopy in Subjects Under General Anesthesia|Assessing the Cortical Response to Noxious and Auditory Stimuli Using Near Infrared Spectroscopy in Subjects Under General Anesthesia||Children's Hospital Boston|No|Not yet recruiting|April 2016|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|54|||Both|12 Years|30 Years|No|||March 2016|March 8, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703090||1335|
NCT02711930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016-55-DM-EXP|Effect of Prone Positioning on Intra-ocular Pressure in ARDS Patients|Effect of Prone Positioning on Intra-ocular Pressure in Patients With Acute Respiratory Distress Syndrome (ARDS)||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|Patients having acute respiratory distress syndrome and requiring prone ventilation during        ICU stay.|March 2016|March 13, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02711930||656|
NCT02697617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IndianaU 1308084213|Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease|Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney|PIOPKD|Indiana University|Yes|Recruiting|October 2015|October 2020|Anticipated|October 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|45 Years|No|||February 2016|February 26, 2016|October 30, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697617||1756|
NCT02711202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number: 2006-003110-18|Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation|A Pilot, Open Single Centre, Prospective, Parallel Trail to Evaluate the Efficacy and Safety of Immunosuppressive Regimen Without Calcineurin Inhibitors and Steroids After Induction of Anti-CD52 and Anti-TNF-α Monoclonal Antibodies in Kidney Transplant Recipients||Institute for Clinical and Experimental Medicine|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02711202||712|
NCT02700633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVIPPMEarlyMortality|Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI|Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI||Royal Sussex County Hospital|No|Active, not recruiting|February 2016|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients post TAVI|March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02700633||1524|
NCT02702375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-SUGARS 2015|Systematic Review and Meta-analysis of Food Sources of Sugars and Incident Cardiometabolic Diseases|Relation of Different Food Sources of Sugars With Incident Cardiometabolic Disease: A Series of Systematic Reviews and Meta-analyses to Inform Guidelines, Public Health Policy, and Future Research Design||University of Toronto|No|Active, not recruiting|September 2015|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals, both children and adults, regardless of health status.|March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702375||1390|
NCT02708745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD083770-01A1|Screening for Hesitancy to Optimize Talk|Use of a Novel Parent-Report Measure to Improve Childhood Vaccine Uptake: The Screening for Hesitancy to Optimize Talk (SHOT) Study|SHOT|Seattle Children's Hospital|No|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|160|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708745||901|
NCT02717858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-4192|A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects|A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects||Novo Nordisk A/S|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|64 Years|No|||March 2016|March 18, 2016|March 15, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717858||200|
NCT02717871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-198|Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis|Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis||University Hospital, Geneva|No|Recruiting|March 2016|August 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|19 Years|N/A|No|||March 2016|March 23, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02717871||199|
NCT02707146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-14-2070-H|Aligning Patients and Their Primary Care Providers|Aligning the Visit Priorities of Complex Patients and Their Primary Care Providers|APP|Kaiser Permanente|No|Not yet recruiting|March 2016|December 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|450|||Both|30 Years|N/A|No|||March 2016|March 11, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02707146||1024|
NCT02711969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-AM-GC102|A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment|A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy||Bukwang Pharmaceutical||Not yet recruiting|March 2016|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|19 Years|N/A|No|||March 2016|March 16, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02711969||653|
NCT02711982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016TON Study|Surgery for Traumatic Optic Neuropathy|Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study||Shanghai Changzheng Hospital|Yes|Recruiting|January 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2|||Both|10 Years|65 Years|No|||March 2016|March 16, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02711982||652|
NCT02701959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-QAD-15|Effect of Lettuce With Different Nitrate Contents on Blood Pressure|Growth of Lettuce With Different Content of Inorganic Nitrate as a Feeding Strategy for Placebo-controlled Nutritional Interventions to Test the Effects of Inorganic Nitrate on Human Health|LBP|Newcastle University|Yes|Completed|April 2015|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02701959||1422|
NCT02719834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201600020|Behavioral Expressions in Alzheimer's Disease|An Analgesic Trial to Reduce Pain and Behavior Disruptions in Nursing Home Residents With Alzheimer's Disease||University of Florida|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719834||48|
NCT02701361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064250|Mobile Mindfulness to Improve Psychological Distress After Critical Illness|Mobile Mindfulness to Improve Psychological Distress After Critical Illness||Duke University|Yes|Not yet recruiting|March 2016|June 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02701361||1468|
NCT02710032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH104072|TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru|TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru|TransPrEP|University of California, Los Angeles|No|Not yet recruiting|April 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02710032||802|
NCT02710292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS104-P001|Clinical Evaluation of DAILIES TOTAL 1® Performance in a Japanese Population|||Alcon Research|No|Not yet recruiting|April 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|N/A|No|||March 2016|March 11, 2016|March 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710292||782|
NCT02720120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18230|A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)|A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response||Hoffmann-La Roche||Terminated|October 2005|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|175|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|March 22, 2016|Yes|Yes|The overall benefit risk profile of ocrelizumab was not favorable in RA|No||https://clinicaltrials.gov/show/NCT02720120||26|
NCT02705521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS 179371|Randomised Control Trial Assessing the Impact of Gamifcation Principles in Patients Undergoing Shoulder Surgery|A Multi-centre, Randomised, Controlled Study Comparing Gamification With Remote Monitoring Against Standard Rehabilitation, for Patients After Arthroscopic Subacromial Decompression Surgery|GAME|Central Manchester University Hospitals NHS Foundation Trust|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02705521||1148|
NCT02710136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-27|Cockroach Nasal Allergen Challenge Pilot|A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|February 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|8 Years|55 Years|No|||March 2016|March 10, 2016|March 7, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710136||794|
NCT02710149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMMU-BTC-003|A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies|A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies||Southwest Hospital, China|No|Recruiting|March 2016|March 2019|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|14 Years|75 Years|No|||March 2016|March 11, 2016|November 8, 2015||No||No||https://clinicaltrials.gov/show/NCT02710149||793|
NCT02704260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A00441-48|Genetic of SportS Induced Endofibrotic Remodeling|Endofibrose Vasculaire et génétique|GOSSER|University Hospital, Angers|Yes|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|March 4, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02704260||1245|
NCT02704507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1771|Addition of a Topical Steroid to a Topical Retinoid in Acne Patients|Addition of a Topical Steroid to a Topical Retinoid: a Randomized, Split-face, Placebo-controlled, Double-blind, Single-center Clinical Study||Carilion Clinic||Active, not recruiting|June 2015|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 5, 2016|February 13, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02704507||1226|
NCT02714751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR2015/057|Evaluation of an Informative Intervention to the ICU Team About the Presence of Asynchronies in Mechanically Ventilated Patients: Effect Over Incidence Reduction|||Corporacion Parc Tauli||Recruiting|March 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|166|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714751||439|
NCT02714764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-012649|Natural History and Outcome Measures in Alexander Disease|Natural History and Outcome Measures in Alexander Disease||Children's Hospital of Philadelphia|No|Recruiting|January 2016|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have been diagnosed with Alexander Disease.|March 2016|March 16, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02714764||438|
NCT02711865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-54-15|Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|May 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Tumors that will be removed from women operated on for ovarian cancer.|Female|18 Years|N/A|No|Probability Sample|Twenty fresh ovarian cancer specimens will be obtained from patients operated on and        treated at the Hillel Yaffe Medical Center.|March 2016|March 13, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02711865||661|
NCT02711878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00080302|Healing Hearts and Mending Minds in Older Adults Living With HIV|Healing Hearts and Mending Minds in Older Adults Living With HIV|FitBrain|Emory University|Yes|Not yet recruiting|March 2016|||April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|50 Years|75 Years|No|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711878||660|
NCT02696538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MH-15-0656|Comparative Utility of the Mini-BESTest, Berg Balance Scale, and Functional Gait Assessment to Predict Falls in Individuals After Traumatic Brain Injury|Comparative Utility of the Mini-BESTest, Berg Balance Scale, and Functional Gait Assessment to Predict Falls in Individuals After Traumatic Brain Injury||The University of Texas Health Science Center, Houston|No|Recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02696538||1839|
NCT02710084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 15-1223|Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome|Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|April 2016|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|17 Years|No|||March 2016|March 10, 2016|March 7, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710084||798|
NCT02710097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501015208.B|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II|THC-ETOH-II|Yale University|No|Not yet recruiting|March 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710097||797|
NCT02715024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAURO-0605-TW|Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms|An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms||Astellas Pharma Inc|No|Completed|September 2007|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Male|45 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715024||418|
NCT02715037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52683|Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis|Mikrobiologi Ved svær Akut Tonsillit, peritonsillær Phlegmone og infektiøs Mononukleose||Aarhus University Hospital|No|Not yet recruiting|June 2016|December 2021|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|350|Samples With DNA|Throat swabs Blood samples|Both|15 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 patients with severe acute tonsillitis 100 patients with peritonsillar cellulitis 50        patients with infectious mononucleosis|March 2016|March 21, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02715037||417|
NCT02701881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2014-0072|Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II): Investigator-initiated Clinical Study|||Yonsei University|No|Recruiting|January 2016|August 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|19 Years|85 Years|No|||March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02701881||1428|
NCT02701725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0260-15-MMC|Compensatory Reserve Index as a Hemodynamic Status Evaluation Tool in Patients|Compensatory Reserve Index as a Hemodynamic Status Evaluation Tool in Patients|CRIHEM|Meir Medical Center|Yes|Not yet recruiting|March 2016|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|A prospective Review of all adult patients admitted to Meir Medical Center who meet        criteria.|February 2016|March 8, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02701725||1440|
NCT02708212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEH-2016-2|Optimal Procedural Sequence in Same-day Bidirectional Endoscopy: A Prospective Randomized Controlled Study|Optimal Procedural Sequence in Same-day Bidirectional Endoscopy With Moderate Sedation and Carbon Dioxide Insufflation: A Prospective Randomized Controlled Study||Evergreen General Hospital, Taiwan|No|Not yet recruiting|May 2016|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|20 Years|75 Years|No|||March 2016|March 9, 2016|March 6, 2016||No||No||https://clinicaltrials.gov/show/NCT02708212||942|
NCT02699047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSC/04|Fish Oil Supplementation in Gastrointestinal Cancer|Gastrointestinal Cancer: Effects of the Fish Oil Intake on Nutritional Status, Quality of Life and Imunnometabolic Outcomes||Universidade Federal de Santa Catarina|No|Recruiting|March 2015|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 27, 2016|February 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02699047||1646|
NCT02716168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Partnership-Project|Partnership-Project - Reinforcing Partnership Between Cancer Patient, General Practitioner and Oncologist During Chemotherapy|Partnership-Project - Reinforcing Partnership Between Cancer Patient, General Practitioner and Oncologist During Chemotherapy - a Randomized Controlled Trial|PSP|University of Southern Denmark||Not yet recruiting|April 2016|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02716168||330|
NCT02699203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-02638|Detection of Salivary Insulin Following Meals|Detection of Salivary Insulin Following Low Versus High Carbohydrate Meals in Humans||University of British Columbia|No|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02699203||1634|
NCT02697591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAGN 1876-101|An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors||Incyte Corporation|No|Not yet recruiting|April 2016|August 2018|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|146|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697591||1758|
NCT02697604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-7500-0008|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||February 26, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697604||1757|
NCT02719288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-2010|Peroneal and Achilles Tendon Repair Indications With CLARIX® CORD 1K|A Multi-center, Open Label, Economic Outcome Study Comparing the Recovery of Patients Receiving CLARIX® CORD 1K as an add-on Treatment During Surgical Tendon Repair to Control Patients Receiving Standard of Care Procedures|PATRICC|Amniox Medical, Inc.|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02719288||90|
NCT02712411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-TASU-102|Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers|A Randomized, Open-Label, Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1303 Capsule and Co-administration of HGP1201 Tablet, HIP1402 Capsule in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|July 2015|September 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2016|March 14, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02712411||619|
NCT02699424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP01|Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy|Prospective Evaluation of 68-Ga-PSMA -PET and Early PSA Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy|PROPER|Lund University Hospital|No|Not yet recruiting|March 2016|March 2027|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||February 2016|March 3, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02699424||1617|
NCT02697903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-2015|Pomegranate Improve Biological Recovery Kinetics in Elite Weightlifter|Pomegranate Supplementation Accelerates the Recovery Kinetics of Muscle Damage, Muscle Soreness and Inflammatory Marker After Weightlifting Training Session.||The Higher Institute of Sport and Physical Education of Sfax|Yes|Completed|January 2015|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|9|||Male|20 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697903||1734|
NCT02698137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUASIE2|Quality Assessment in Endoscopic Retrograde Cholangiopancreatography(ERCP)|Quality Assessment in ERCP: Risk Factors for Procedure-related Complications in Patients Undergoing ERCP in the Setting of an Endoscopy Training Program|QUASIE2|Clinical Hospital Colentina|No|Not yet recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|all consecutive patients undergoing ERCP in an endoscopy training program setting|February 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02698137||1716|
NCT02715232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1-20150511|Effects of Sex Steroids on the Serotonin System|Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET||Medical University of Vienna|No|Not yet recruiting|May 2016|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715232||402|
NCT02710851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-005|Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine|A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years||Xiamen University|No|Not yet recruiting|March 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|640|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02710851||739|
NCT02710864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-EPI-003|A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China|||Xiamen University|No|Recruiting|June 2015|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|1500|Samples With DNA|saliva /urine samples of the newborns|Both|N/A|14 Days|Accepts Healthy Volunteers|Probability Sample|Neonates aged 0 to 14 days in MCHHs of Xinmi City, Jiaxian County, Zhongmu County and Huli        District Xiamen City, in China ,were recruited, after written informed consents provided        by the parents.|February 2016|March 11, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02710864|14 Days|738|
NCT02696512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBRF-01-10|A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness|A Phase 1/2,Open-Label Study to Evaluate the Safety and Efficacy of the International Brain Research Foundation (IBRF) Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Patients With Severe Disorders of Consciousness||International Brain Research Foundation|No|Not yet recruiting|March 2016|April 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|November 19, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696512||1841|
NCT02700022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1503|A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas|A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas||UNC Lineberger Comprehensive Cancer Center|Yes|Not yet recruiting|March 2016|September 2022|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02700022||1571|
NCT02700035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14158|A Family-Centered Ojibwe Substance Abuse Prevention|A Randomized Control Trial (RCT) of a Family-Centered Ojibwe Substance Abuse Prevention|BZDDD|University of Nebraska Lincoln|Yes|Not yet recruiting|July 2016|April 2021|Anticipated|April 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|8 Years|100 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02700035||1570|
NCT02715505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSC835X2203|Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)|A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning||Novartis|Yes|Not yet recruiting|June 2016|March 2020|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|12 Months|25 Years|No|||March 2016|March 16, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715505||381|
NCT02715518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01088848439|FRactional Flow Reserve Versus Angiography-Guided Strategy for Management of Non-Infarction RElated Artery Stenosis in Patients With Acute ST-segment Elevation Myocardial Infarction|Comparison of Clinical Outcomes Between Fractional Flow Reserve-guided Strategy and Angiography-guided Strategy in Treatment of Non-Infarction Related Artery Stenosis in Patients With Acute ST-segment Elevation Myocardial Infarction|FRAME-STEMI|Samsung Medical Center|Yes|Not yet recruiting|June 2016|December 2020|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|974|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715518||380|
NCT02656095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-1412|Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment|||University of Colorado, Denver|Yes|Not yet recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|20 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Male and female individuals|January 2016|January 13, 2016|January 12, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02656095||4939|
NCT02713347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 14-346|Advancing Symptom Alleviation With Palliative Treatment|Palliative Care to Improve Quality of Life in CHF and COPD|ADAPT|VA Office of Research and Development|Yes|Not yet recruiting|June 2016|March 2020|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|99 Years|No|||March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02713347||547|
NCT02706522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2015-0317|Effect of Oral Carbohydrate on Serum S-100β Protein and Development of Postoperative Delirium in Elderly Patients|Effect of Oral Carbohydrate on Serum S-100β Protein and Development of Postoperative Delirium in Elderly Patients||Gangnam Severance Hospital|Yes|Not yet recruiting|March 2016|||March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|174|||Both|65 Years|N/A|No|||March 2016|March 7, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02706522||1072|
NCT02711423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP30042|A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects||Hoffmann-La Roche||Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711423||695|
NCT02711293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIDIE-STUDY-ID-562a718b12fa0|The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression|The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression: A Non-inferiority Cluster-randomized Controlled Trial in Dar es Salaam, Tanzania||Harvard School of Public Health|No|Recruiting|February 2016|||November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02711293||705|
NCT02697032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2015.0704|FDHT PET and Bicalutamide in Metastatic Breast Cancer|FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide||University Medical Center Groningen|Yes|Recruiting|February 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|August 25, 2015||No||No||https://clinicaltrials.gov/show/NCT02697032||1801|
NCT02701491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273/15|Effect of Ginger on Nausea and Vomiting During Acute Gastroenteritis in Children|Effect of Ginger on Nausea and Vomiting Related to Acute Gastroenteritis in Pediatric Age||Federico II University|No|Recruiting|February 2016|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|1 Year|10 Years|No|||March 2016|March 2, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02701491||1458|
NCT02701504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SABOT Study|Undiagnosed Sleep Apnea and Bypass OperaTion|Association Between Sleep Apnea and Occurrence of Major Adverse Cardiovascular Events After Coronary Artery Bypass Grafting|SABOT|National University, Singapore|No|Recruiting|October 2013|October 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients with coronary artery disease scheduled to undergo coronary artery bypass        surgery|March 2016|March 7, 2016|September 23, 2014||No||No||https://clinicaltrials.gov/show/NCT02701504||1457|
NCT02714712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-XD53-105|SR-BI and Antiviral Treatment Response in HCV|Influence of Scavenger Receptor Class B Type I (SR-BI) Gene Polymorphisms on Antiviral Treatment Response, and Metabolism in Chronic Hepatitis C Patients||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Enrolling by invitation|August 2015|December 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|309|Samples With DNA|All enrolled subjects were genotyped for the SNPs of the SCARB1 gene and IL28B gene. All      their blood specimens were collected into EDTA tubes. Human genomic DNA was extracted by      standard protocols with blood RBC lysis, cell lysis, DNA binding, wash and elution.      Extracted DNA normalized to 50 ng/µl was obtained. DNA quality was assessed by calculating      the absorbance ratio OD260 nm/280 nm using NanoDrop model ND-1000 (Thermo Scientific,      Wilmington, DE, USA). The SNP was genotyped by using the ABI TaqMan allelic discrimination      kit and the ABI7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA)|Both|18 Years|80 Years|No|Non-Probability Sample|HCV genotype 1 or 2 patients who received pegylated interferon alfa-2a (Peg-IFN alfa-2a)        plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics|March 2016|March 16, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02714712||442|
NCT02711462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7581001|Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234|A Phase 1, Double Blind, Third-party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06687234 In Healthy Subjects||Pfizer|No|Recruiting|February 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Anticipated|82|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|January 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711462||692|
NCT02711319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/00442|Non-invasive Brain Stimulation for Gait Improvement in Patients With Spinal Cord Injury|Non-invasive Brain Stimulation in SCI|SCI|Institut Guttmann|No|Completed|December 2010|August 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|70 Years|No|||February 2016|March 13, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711319||703|
NCT02701764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160095|Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?|Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?||University of Miami|No|Not yet recruiting|May 2016|May 2017|Anticipated|May 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|February 26, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701764||1437|
NCT02719327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-001-15S|Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults|Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults||VA Office of Research and Development|Yes|Not yet recruiting|May 2016|April 2021|Anticipated|April 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719327||87|
NCT02719340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSF-TLF-103|Short Segment Fixation in Thoracolumbar Osteoporotic Fracture|Short-segment Decompression and Reconstruction for Thoracolumbar Osteoporotic Fractures With Neurological Deficits: Clinical and Radiological Results of Minimum 2-year Follow-up||National Cheng-Kung University Hospital|No|Completed|November 2010|December 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|60 Years|N/A|No|Probability Sample|Twenty elderly patients (60-89 years, mean 73.2 years) with osteoporotic thoracolumbar        burst fractures and neurological compromise|March 2016|March 21, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02719340||86|
NCT02719353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-16-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2016|||||N/A|N/A|N/A||||||||||||||March 21, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719353||85|
NCT02699398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAL-2008-1-1191|Domiciliary VR Rehabilitation|||Universitat Pompeu Fabra||Completed|November 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|45 Years|85 Years|No|||February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02699398||1619|
NCT02703376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NagasakiU2|Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery|Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery||Nagasaki University|Yes|Recruiting|January 2016|October 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|8|||Both|20 Years|85 Years|No|||March 2016|March 3, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02703376||1313|
NCT02697305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA NT 14416 - 2|Incretin Effects of Branched Chain Amino Acids|Effect of Intravenously and Orally Administered Branched Chain Amino Acids on Incretin Response||Charles University, Czech Republic|No|Completed|September 2014|December 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02697305||1780|
NCT02701673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0560|Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma|Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma||M.D. Anderson Cancer Center|No|Not yet recruiting|June 2016|||June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|15 Years|65 Years|No|||February 2016|March 2, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701673||1444|
NCT02701972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACE CT003|Evaluation of Safety and Efficacy of the BACE™ Device in the Treatment of Functional Mitral Valve Regurgitation [FMR|Evaluation of Safety and Efficacy of the Basal Annuloplasty of the Cardia Externally (BACE™) [Basal Annuloplasty of the Cardia Externally] Device in the Treatment of Functional Mitral Valve Regurgitation [FMR]|BACE|Phoenix Cardiac Devices, Inc.|Yes|Enrolling by invitation|March 2016|September 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02701972||1421|
NCT02709148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deep Brain Stimulation|State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)|State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS||University of Minnesota - Clinical and Translational Science Institute|Yes|Not yet recruiting|May 2016|May 2019|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Both|45 Years|75 Years|No|||March 2016|March 9, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709148||870|
NCT02719639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.44|OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)|Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice.||Boehringer Ingelheim||Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|7215|||Both|40 Years|N/A|No|Probability Sample|COPDS patients|March 2016|March 21, 2016|March 1, 2016||||No||https://clinicaltrials.gov/show/NCT02719639||63|
NCT02709239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00003792|Prenatal DHA and Neurofunctional Development|Prenatal Docosahexaenoic Acid (DHA) & Neurofunctional Development|PANDA|University of Kansas Medical Center|Yes|Not yet recruiting|April 2016|August 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|340|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02709239||863|
NCT02708199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMRL_01_2016|Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic|Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases in Myanmar Artemisinin Resistance Containment Zones and Malaria Antibody Kinetic Analysis||Department of Medical Research, Lower Myanmar|No|Completed|January 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1179|Samples With DNA|Whole blood samples have been collected and DNA have been extracted and keep at -20 degree C      until analysis. Sera were also separately keep at -80 degree C until analysis.|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Shwegyin Township, Bago Region, Myanmar Artemisinin resistance containment Zone I.|March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02708199||943|
NCT02695849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25269|A Study of Prevalence of EGFR Mutations in Participants With NSCLC|An Epidemiology Study of the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients Diagnosed With Non-squamous Non-small Cell Lung Cancer (NSCLC)||Hoffmann-La Roche||Completed|March 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|69|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with non-squamous non-small cell lung cancer (NSCLC)|March 2016|March 1, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695849||1892|
NCT02696109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34-MH102525-01A1MRM|Cornerstone: Boundary Spanning Case Management and Peer Support for Transition Age Youth With Mental Disorders|Cornerstone: Boundary Spanning Case Management and Peer Support for Transition Age Youth With Mental Disorders|C-BSCM|New York University|No|Not yet recruiting|February 2016|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|17 Years|18 Years|Accepts Healthy Volunteers|||December 2015|February 25, 2016|December 10, 2015||No||No||https://clinicaltrials.gov/show/NCT02696109||1872|
NCT02718274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10566|HIV Self-Testing Africa (STAR) Malawi: General Population|HIV Self-testing Africa (STAR) Malawi: General Population - A Cluster Randomized Trial of Providing HIV and Self-testing Kits Through Community-based Distribution Agents|STAR Malawi|London School of Hygiene and Tropical Medicine|Yes|Not yet recruiting|April 2016|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|5000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 18, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02718274||168|
NCT02718287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB-2016-BR-1|Evaluation of the Home Visiting Pilot Program on Early Childhood Outcomes:a Cluster-Randomized Trial in Fortaleza Brazil|Evaluation of the Home Visiting Pilot Programa Cresça Com Seu Filho (PCCSF) on Early Childhood Outcomes: a Cluster-Randomized Trial in Fortaleza Brazil||Inter-American Development Bank|No|Enrolling by invitation|March 2016|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|2520|||Both|N/A|28 Months|No|||March 2016|March 18, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02718287||167|
NCT02710500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-00669|rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies|Phase I Intramuscular Gene Transfer Clinical Trial for Dysferlin Deficiency Delivering the Dysferlin Gene by AAVrh74||Nationwide Children's Hospital|Yes|Recruiting|March 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 11, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710500||766|
NCT02711605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF21271|UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)|Clinical Evaluation of the UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)||Syneron Medical|No|Not yet recruiting|May 2016|September 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|March 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711605||681|
NCT02712281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00085811|Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety|Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety||Emory University|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|8 Years|No|||March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712281||629|
NCT02702843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA 15-108|Fluorescent Cholangiography vs White Light for Bile Ducts Identification|Efficacy Of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholecystectomy||Cleveland Clinic Florida|Yes|Not yet recruiting|March 2016|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02702843||1354|
NCT02703077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0784/10|Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla|Endoscopic Treatment of Difficult Bile Duct Stones: Use of Direct Visualization System ("Spyglass Direct Visualization System") Associated With Electrohydraulic Lithotripsy (EHL) X Hydrostatic Balloon Dilation of the Major Duodenal Papilla|EHL|University of Sao Paulo General Hospital|Yes|Recruiting|February 2016|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|March 8, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703077||1336|
NCT02711917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TianjinMUGH|Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane|Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System||Tianjin Medical University General Hospital|Yes|Completed|July 2015|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|175|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711917||657|
NCT02717338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI R01HL127766|Blood Donor Competence, Autonomy and Relatedness Enhancement|Blood Donor Competence, Autonomy and Relatedness Enhancement (Blood Donor CARE)||Ohio University|Yes|Not yet recruiting|May 2016|July 2020|Anticipated|July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|2240|||Both|16 Years|24 Years|No|||March 2016|March 24, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02717338||240|
NCT02706509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-15-MMC|Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women|Comparison Between the Analgesic Affects of Tramadol® and "Verbal Anesthesia" on Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women|Jaydess|Meir Medical Center|Yes|Not yet recruiting|March 2016|December 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|February 17, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706509||1073|
NCT02698644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU|Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate|Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate||Ain Shams University|Yes|Recruiting|January 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Female|40 Years|55 Years|No|||February 2016|February 29, 2016|February 19, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698644||1677|
NCT02698657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5094-CL-0102|A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate||Astellas Pharma Inc|Yes|Recruiting|February 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 23, 2016|February 10, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698657||1676|
NCT02701478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15064|ANI and NoL Index Variations After Standard Nociceptive Stimulus at 0, 50, 25 % of Inhaled N2O in the Anesthetic Mixture|Assessment of the Intraoperative Analgesic Effect of 50%/50% N2O/O2 Inhalation by the Pain Index ANI Following a Standardized Electrical Stimulus in Patients Under Anesthesia. Comparison to the New NoL Analgesic Index.||Maisonneuve-Rosemont Hospital|No|Recruiting|January 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701478||1459|
NCT02719314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/367/14|Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis|Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids|Rh-GIOP|Charite University, Berlin, Germany|No|Recruiting|December 2015|July 2029|Anticipated|November 2025|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic inflammatory rheumatic diseases or psoriasis treated with        glucocorticoids|March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719314|14 Years|88|
NCT02719600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033/03|Motor Learning Through Virtual Reality Task in Individuals With Down Syndrome|Motor Learning Through Virtual Reality Task in Individuals With Down Syndrome||University of Sao Paulo|No|Completed|March 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|11 Years|28 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02719600||66|
NCT02700919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCT206|Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease|A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults||Mereo BioPharma|Yes|Not yet recruiting|March 2016|November 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|255|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700919||1502|
NCT02706821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJG-HG-PLE|Anti-diabetic Effects of Persimmon Leaf Extract|An Eight-week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Persimmon Leaf Extract on Anti-diabetes||Chonbuk National University Hospital|Yes|Completed|February 2014|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|34|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706821||1049|
NCT02710045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1085|The Interaction Between Measles and DTP Vaccination|The Interaction Between Live and Killed Vaccines: the Effect of the DTP Combined Vaccine on T Cell Memory Following Measles Vaccination||Medical Research Council Unit, The Gambia|No|Completed|November 2007|May 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|302|||Both|16 Weeks|22 Weeks|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02710045||801|
NCT02710058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-246|Experience of Arab American Women With Breast Cancer: In-depth Interviews|Experience of Arab American Women With Breast Cancer: In-depth Interviews A Qualitative Study to Explore the Influence of the Arab Culture on Coping With Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2015|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|85 Years|No|Non-Probability Sample|This study is open to current and previous AMBER support group participants held at the        MSK Brooklyn Infusion Center.|March 2016|March 10, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02710058||800|
NCT02715245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC-AL 39/2012|Multiple Chronic Diseases: the RITH Trial|A Home-based Rehabilitation Program in Multiple Chronic Diseases: the RITH Trial||Universidad de Almeria|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|300|||Both|N/A|N/A|No|||March 2016|March 16, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02715245||401|
NCT02695680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00068540|Lung SBRT Motion Management (GCC 1619)|Modeling Respiration-induced Motion and Deformation of Tumors and Thoracic Organs for Personalized Motion Management in Lung SBRT||University of Maryland|Yes|Not yet recruiting|April 2016|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary or metastatic lung lesions|March 2016|March 17, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02695680||1905|
NCT02699216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSW001|BioCurrent Electrical Stimulation for the Treatment of Dry ARMD|BioCurrent Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration||DuBois Vision Clinic|No|Recruiting|January 2016|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|616|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02699216||1633|
NCT02708797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15 7815 03|Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura.|Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura : a MRI and Transcranial Doppler.|MINOTAURE|University Hospital, Toulouse|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|46|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708797||897|
NCT02715843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-3724_NHL_001_EXT_US|Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma|Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US||Molecular Templates, Inc.||Available|December 2015|January 2018|Anticipated|December 2017|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 23, 2016|Yes|Yes||||https://clinicaltrials.gov/show/NCT02715843||355|
NCT02716077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11615|Early FDG PET in Melanoma|Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2016|||March 2023|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment|||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716077||337|
NCT02705378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaRC-ICU_temp|The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit|The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit|NaRC-ICU|Massachusetts General Hospital|Yes|Not yet recruiting|May 2016|December 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02705378||1159|
NCT02708407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAS project ID: 158992|PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease|PD-HF: A Multi-centre Randomised Controlled Trial of Intermittent Peritoneal Dialysis With Icodextrin-based Solutions on Patients With Severe Heart Failure and Stage 3-4 Chronic Kidney Disease|PD-HF|University of Nottingham|Yes|Recruiting|January 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02708407||927|
NCT02699294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34910702|The Effect Of Stretching Exercise on Pectoralis Minor Myofascial Latent Trigger Points|Comparison of Effectiveness of Two Different Stretching Exercises Combined With Pressure Release Technique on Latent Trigger Points in The Pectoralis Minor Muscle||Istanbul University|No|Enrolling by invitation|March 2016|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|November 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02699294||1627|
NCT02716090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-DLP-03(01/13)|Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris|National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel) in the Treatment of Acne Vulgaris in Population of Men and Women|Narciso|Ache Laboratorios Farmaceuticos S.A.|No|Withdrawn|July 2015|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|N/A|No|||March 2016|March 17, 2016|January 15, 2015||No|Due to budget limitations, the company decided to withdraw this study.|No||https://clinicaltrials.gov/show/NCT02716090||336|
NCT02711228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro20_4005|Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules|Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules||CSL Behring|No|Recruiting|March 2016|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|5 Years|64 Years|No|||February 2016|March 11, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02711228||710|
NCT02708472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112015-078|Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder|Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation (sTMS) for the Treatment of Generalized Anxiety Disorder (GAD) -An Open Label Investigator Initiated Trial||University of Texas Southwestern Medical Center|No|Not yet recruiting|April 2016|January 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708472||922|
NCT02708485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-043|Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease|Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging|MAL|Université de Sherbrooke|No|Recruiting|April 2009|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708485||921|
NCT02710188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9936-104|Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation|A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations||Heptares Therapeutics Limited|Yes|Recruiting|February 2016|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02710188||790|
NCT02710201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCM13-00012|A Randomized-controlled Trial of Social Norm Interventions to Increase Physical Activity|A Randomized-controlled Trial of Social Norm Interventions to Increase Physical Activity||University of California, Merced|No|Completed|February 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710201||789|
NCT02719132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00043|Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice|A Multicentre Randomised Open-Label Crossover 2-Period 2 Treatment Clinical Trial to Evaluate Effect of Dapagliflozin 10 mg Once Daily on the Quality of Life in Patients With Type 2 Diabetes|FLORA|AstraZeneca|No|Not yet recruiting|July 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|820|||Both|18 Years|74 Years|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719132||102|
NCT02697786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRS-RPROJ - J R- 2014- 191|Neuromonitoring in Patients During Aortic Valve Replacement|The Impact of Intraoperative Microemboli Load on Postoperative Brain Injury in Patients Undergoing Aortic Valve Replacement Preformed With Two Different Surgical Approaches|IMLPBIAVR|University Medical Centre Ljubljana|Yes|Recruiting|January 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|85 Years|No|||January 2016|February 25, 2016|January 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02697786||1743|
NCT02701452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_08|Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response|Prevalence of Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response After Ovarian Stimulation With a GnRH Antagonist|COAGO|University Hospital, Lille|No|Not yet recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Female|18 Years|43 Years|No|||March 2016|March 2, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701452||1461|
NCT02701686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOPC|Effectiveness of Negotiating Self-determination to Reduce Cigarette Consumption|A Randomized Controlled Trial of the Effectiveness of Negotiating Self-determination to Reduce Cigarette Consumption (NSD-RCC)||The University of Hong Kong|No|Recruiting|September 2014|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02701686||1443|
NCT02711566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISM_Robot|Robot-based Rehabilitation of Upper Limb Impairment in Multiple Sclerosis|Robot-based Assessment and Therapy in the Treatment of Upper Limb Impairment in Multiple Sclerosis: a Multi-center, Randomised Controlled Trial|MS-ROBOT|Fondazione Don Carlo Gnocchi Onlus|No|Completed|January 2010|December 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2015|March 11, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02711566||684|
NCT02719392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2016P000447|A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression|A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression||Massachusetts General Hospital|Yes|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02719392||82|
NCT02719405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P000962|Impact of Infant Formula on Resolution of Cow's Milk Allergy|A Prospective Randomized Controlled Trial to Evaluate the Effect of Infant Formula on the Resolution of Cow's Milk Allergy of Infancy||Massachusetts General Hospital|Yes|Recruiting|February 2016|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|231|||Both|N/A|120 Days|No|||March 2016|March 21, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02719405||81|
NCT02706340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822078|Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study|Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study (PPIUD)|PPIUD|University of Pennsylvania|No|Recruiting|April 2015|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|480|||Female|18 Years|N/A|No|Non-Probability Sample|Adult pregnant women, at least 24 weeks' gestation, anticipating a delivery and desiring        an immediate postplacental TCu380A IUD, and adult women who have had a delivery and        received an immediate post placental TCu380A IUD.|March 2016|March 17, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02706340||1085|
NCT02708225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0026-15|The Influence of Medical Clowns on the Performance of Pulmonary Function Tests Among Preschooler Children|The Influence of Medical Clowns on the Performance of Pulmonary Function Tests Among Preschooler Children|clowns|Hillel Yaffe Medical Center|No|Not yet recruiting|March 2016|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 29, 2015||No||No||https://clinicaltrials.gov/show/NCT02708225||941|
NCT02718989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ddsm25|Modulation of H-reflex After Application of Electric Currents in Healthy People|Modulation of H-reflex After Application of Electric Currents in Healthy People. Effects on Myotonometer Properties.A Pilot Study||University of Castilla-La Mancha|No|Active, not recruiting|December 2014|May 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02718989||113|
NCT02719002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT_2015_45|Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials|Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials|PERFOCTAPS|Fondation Ophtalmologique Adolphe de Rothschild||Not yet recruiting|April 2016|||April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02719002||112|
NCT02701946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|785/2558|Efficacy of Modified Robert Jones Bandages on Reducing Invisible Blood Loss After Total Knee Arthroplasty|Efficacy of Modified Robert Jones Bandages on Reducing Invisible Blood Loss After Total Knee Arthroplasty: A Randomized Controlled Trial||Mahidol University|No|Not yet recruiting|March 2016|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02701946||1423|
NCT02714647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82401|The Role of an Attention Demanding Activity for Priming Motor Learning|The Role of an Attention Demanding Activity for Priming Motor Learning||University of Utah|No|Not yet recruiting|March 2016|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02714647||447|
NCT02714660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005767|The Work of Being a Patient With Diabetes: Data Collection Via a Smartphone Application|The Work of Being a Patient: A Mixed Methods Characterization of the Work of Being a Patient With Type 2 Diabetes Mellitus Using Real-time Data Collection Via a Smartphone Application||Mayo Clinic|No|Enrolling by invitation|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with type 2 diabetes with receiving care at Mayo Clinic endocrinology department.|March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02714660||446|
NCT02719015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0199|Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma|Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma||M.D. Anderson Cancer Center|No|Not yet recruiting|July 2016|||July 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719015||111|
NCT02716935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Ghent|Prebiotics and Microbiota Composition and Functionality in Rural Burkinabe Infants|Effect of Supplementation With LNS Fortified With a Mixture of FOS and Inulin on Gut Microbiota Diversity and Functionality and Its Repercussion on Growth and Morbidity During Infancy in Rural Burkina Faso||University Ghent|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|153|||Both|24 Weeks|26 Weeks|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02716935||271|
NCT02703649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siba0101|Administration of Single High Dose Letrozole for Ovulation Induction|Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial||Mount Sinai Hospital, Canada|Yes|Not yet recruiting|March 2016|July 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02703649||1292|
NCT02703883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-1|Body Weight Support in Spinal Cord Injury|Effects of Body Weight-supported Treadmill Training on Center of Mass Control in Spinal Cord Injury, Measured With Inertial Sensors||University of Chile|Yes|Completed|July 2012|December 2015|Actual|November 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Male|18 Years|70 Years|No|||March 2016|March 3, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02703883||1274|
NCT02702193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111132|SET-Recovery/Healthy Home|Set-Enhanced Aftercare for Mothers in Substance Abuse Recovery and Their Children|SET-R|University of Miami|No|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|172|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702193||1404|
NCT02712294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parece 517.472|Impact of Peripheral Neuromuscular Electrical Stimulation on Spirometry Values, Functional Capacity and Quality of Life in Patients With Pulmonary Hypertension|Impact of Peripheral Neuromuscular Electrical Stimulation on Spirometry Values, Functional Capacity and Quality of Life in Patients With Pulmonary Hypertension||Faculdade de Ciências Médicas da Santa Casa de São Paulo|Yes|Recruiting|June 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||February 2016|March 14, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02712294||628|
NCT02698267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802HV104|Effect of Itraconazole on the Pharmacokinetics of BIIB074|An Open-label, Fixed-sequence, Phase 1 Study of the Effect of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of BIIB074 in Healthy Subjects||Biogen|No|Not yet recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698267||1706|
NCT02698566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX30020|A Study in Participants With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Lucentis® Prefilled Syringe|AN OPEN-LABEL, SINGLE-ARM PHASE IIIb STUDY IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION OR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TO EVALUATE THE USABILITY OF LUCENTIS® PREFILLED SYRINGE 0.5 mg||Genentech, Inc.||Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698566||1683|
NCT02700698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205139|Mitochondrial Function in Circulating Cells and Muscle Tissue|Mitochondrial Function in Circulating Cells and Muscle Tissue|MitoWomen|University of Arkansas|No|Not yet recruiting|April 2016|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|25 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Twenty (20) healthy lean and 20 insulin resistant and obese women, age 25-35 years.|March 2016|March 1, 2016|February 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02700698||1519|
NCT02703974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6304|Nudging Handwashing: a Cluster-randomized Trial in Bangladesh|Nudging Handwashing: a Cluster-randomized Trial in Bangladesh||University of Oklahoma|No|Not yet recruiting|March 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02703974||1267|
NCT02712541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN Dnr 2015/1799-31 (b)|Caregiver Burden and Wellbeing in Relatives of Intensive Care Unit Patients|Caregiver Burden and Wellbeing in Relatives of Intensive Care Unit Patients||Karolinska University Hospital|Yes|Recruiting|January 2016|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Relative living together with a patient included in the study PROGRESS-ICU.|March 2016|March 14, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02712541||609|
NCT02712801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZX10001001|Antiretroviral Regime for Viral Eradication in Newborns|Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV||National Center for Women and Children's Health, China CDC|Yes|Not yet recruiting|April 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|N/A|1 Day|No|||March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712801||589|
NCT02645630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URJC2015-161120155015|Effects of Pain, Disability and Cervicokinesthesia After Cervical Manipulation|Effects of Pain, Disability, Widespread Pressure Pain Sensitivity, and Cervicokinesthesia After Cervical Manipulation in Patients With Mechanical Neck Pain||Universidad Rey Juan Carlos|Yes|Recruiting|December 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02645630||5742|
NCT02717377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2777|Effect of Frequent Interruptions of Prolonged Sitting on Self-perceived Levels of Energy, Mood, Food Cravings and Cognitive Function|||University of Colorado, Denver|No|Completed|November 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|30|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02717377||237|
NCT02711436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0022-16|Fast Magnetic Resonance Imaging as Compared to Computed Tomography Scan in Pediatric Orbital Cellulitis Imaging|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|6 Months|20 Years|No|||March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711436||694|
NCT02698852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIONEER-II, OPC, P02|A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)|A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial|OPC|Sino Medical Sciences Technology Inc.|Yes|Recruiting|December 2015|December 2021|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|75 Years|No|||March 2016|March 13, 2016|January 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02698852||1661|
NCT02698865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-MVH-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2016|||||N/A|N/A|N/A||||||||||||||February 29, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698865||1660|
NCT02701218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT-2558-03601|BPPV With CRP: Single Versus Multiple Cycles|Comparison of the Treatment Outcomes of Posterior Canal Benign Paroxysmal Positional Vertigo (BPPV) With Canalith Repositioning Procedure (CRP): Single Versus Multiple Cycles||Chiang Mai University|Yes|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|N/A|No|||March 2016|March 2, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02701218||1479|
NCT02701426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014_72|Obesity & Pregnancy: Factors Influencing Participation in a Physical Activity and Nutritional Counseling Program|Obesity and Pregnancy : Study of Factors Influencing Participation in a Program Combining Physical Activity and Nutritional Counseling|OGAN|University Hospital, Lille|No|Recruiting|February 2016|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|375|||Female|18 Years|45 Years|No|||March 2016|March 9, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701426||1463|
NCT02708940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#14-001879|Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs|||University of California, Los Angeles|No|Recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||March 2016|March 9, 2016|February 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708940||886|
NCT02699151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSIGHTS-SVT|INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis|INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis (INSIGHTS-SVT)|INSIGHTS-SVT|GWT-TUD GmbH|No|Not yet recruiting|February 2016|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in hospital or ambulatory care|February 2016|February 29, 2016|January 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02699151||1638|
NCT02699164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO14-265|Remission of Lumbar Disc Herniation by Physiotherapy|Lumbal Disk Herniasyonunda farklı Tedavi yöntemlerinin etkinliğinin karşılaştırılması||Hacettepe University|No|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02699164||1637|
NCT02701439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMF-01|SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting|Small Membrane Filtration (SMF) Method to Improve the Performance of Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting|PTB|Epicentre|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|1050|Samples With DNA|TB isolates from sputum samples|Both|18 Years|N/A|No|Probability Sample|Adult patients with a suspected diagnosis of pulmonary TB attending two TB clinics in        Mbarara, Uganda|February 2016|March 2, 2016|February 16, 2013||No||No||https://clinicaltrials.gov/show/NCT02701439||1462|
NCT02701660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPOSTEL-1|Adherence to Polypharmacy in Patients With Opioid Substitution Therapy Using Electronics|Remote-controlled Dispensing of Medication and Electronic Monitoring of Adherence in Ambulatory Patients With Opioid Dependency Syndrome and Polypharmacy - a Feasibility Trial|APPOSTEL|University Hospital, Basel, Switzerland|No|Recruiting|November 2014|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 25, 2014||No||No||https://clinicaltrials.gov/show/NCT02701660||1445|
NCT02709070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC 005|Resection+Highly Purified CTL Versus Resection Alone for HCC|Resection Combined With Highly-purified CTL Versus Resection Alone for HCC||Sun Yat-sen University|Yes|Active, not recruiting|March 2016|March 2022|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02709070||876|
NCT02714738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-ICB-ABPB|Infraclavicular Block: Decreased Incidence of Tourniquet Pain, Compared to Axillary Brachial Plexus Block?|The Ultrasound Guided Infraclavicular Block: Decreased Incidence of Tourniquet Pain, Compared to Axillary Brachial Plexus Block?||Cork University Hospital|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714738||440|
NCT02707458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPEND|Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration|Dose-finding and Proof-of-concept Trial of Probucol to Increase Availability of CSF Apolipoprotein-E|DEPEND|Douglas Mental Health University Institute|Yes|Not yet recruiting|April 2016|May 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|23|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707458||1000|
NCT02701920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15099|HeartLight: Heart Rate Monitoring for Newborn Resuscitation|HeartLight: Heart Rate Monitoring for Newborn Resuscitation|HeartLight|University of Nottingham|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|174|||Both|N/A|4 Months|No|Non-Probability Sample|Infants|March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701920||1425|
NCT02710773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWTreadmillSTROKE|Backward Treadmill Training in Patients With Chronic Stroke|Effects of Backward Treadmill Training on Spasticity and Gait Ability in Patients With Chronic Stroke: a Randomized Controlled Trial||Universita di Verona|Yes|Not yet recruiting|April 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02710773||745|
NCT02715011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR108147|Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML||Janssen Research & Development, LLC|No|Not yet recruiting|May 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02715011||419|
NCT02699931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2THBRUSH01|Efficacy of Electric 3D Versus Manual Toothbrushes in Patients With Fixed Orthodontic Appliances|A Randomized, Investigator-blinded, 3-month, Parallel Group Clinical Study to Compare the Efficacy of Electric 3D Toothbrushes Versus Manual Toothbrushes in Patients With Fixed Orthodontic Appliances||National and Kapodistrian University of Athens|No|Recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699931||1578|
NCT02711579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1509-130-708|Impact of Celecoxib on Electrophysiological Property in Brain of Healthy Volunteer|Impact of Selective Cyclooxygenase-2 Inhibitor, Celecoxib on Cortical Excitability and Electrophysiological Property in Brain of Healthy Volunteer: Randomized, Double-blind, Placebo-controlled Study||Seoul National University Hospital||Not yet recruiting|April 2016|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02711579||683|
NCT02700555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA02|Surveillance of Metabolic Parameters in Patients With Colorectal Cancer|Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort|SPRING|Kangbuk Samsung Hospital|No|Recruiting|February 2016|October 2022|Anticipated|October 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Tumor tissue|Both|20 Years|80 Years|No|Probability Sample|Patients who will receive chemotherapy after surgical resection of colorectal cancer|March 2016|March 1, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02700555|60 Months|1530|
NCT02714244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1671|Evaluation of the E/e' Ratio of the Mitral Annulus in Predicting Fluid Responsiveness.|Evaluation of the E/e' Ratio of the Mitral Annulus Measured by Transesophageal Echocardiography in Predicting Fluid Responsiveness.||Montreal Heart Institute|No|Recruiting|January 2016|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02714244||478|
NCT02696746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0017|Painful Channelopathies Study|Painful Channelopathies Study|PCS|King's College London|No|Recruiting|February 2012|||January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|1. The investigators will collect blood samples (30mls) from each subject, which will be           stored at -800C in a locked freezer. They will sequence known genes associated with           painful channelopathies: SCN9a and TRPA1. They will store DNA in order that it is           possible that other candidate genes associated with pain can be tested.        2. 3mm skin punch biopsies performed 10 cm above lateral malleolus for 2 different           purposes:             -  Nerve fibre density measurement             -  Fibroblasts cultures as these represent a useful tool in the future as a source of                cells the phenotype of which can be modulated for instance to generate induced                pluripotent stem cells|Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and family members affected by chanelopathic pain related conditions.|February 2016|February 25, 2016|February 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02696746||1823|
NCT02701400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00086004|Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer|A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer||Emory University|Yes|Not yet recruiting|April 2016|August 2019|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701400||1465|
NCT02699762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01677-42|Upper Limb Botulinum Toxin Injection Combined With Self Rehabilitation|Randomised Controlled Trial to Evaluate the Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Upper Limb Function in Stroke|Armautotox|Centre d'Investigation Clinique et Technologique 805|No|Not yet recruiting|March 2016|May 2018|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699762||1591|
NCT02716779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19301|Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection|Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection||Hoffmann-La Roche||Completed|April 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|March 18, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716779||283|
NCT02717052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1643/2014|Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter and Its Relevance for Rapid Antidepressant Response|||Medical University of Vienna||Not yet recruiting|May 2016|||April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02717052||262|
NCT02706301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063330|Pain Coping Skills for Colorectal Cancer Survivors|Pain Coping Skills Training for Colorectal Cancer Survivors With Pain and Distress||Duke University|Yes|Not yet recruiting|March 2016|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|80 Years|No|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706301||1088|
NCT02698345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2015-0081|Korean Multicenter Prospective Registry of In.PACT DEB for Isolated Popliteal Artery Disease (K-POP Study)|||Yonsei University|No|Recruiting|January 2016|February 2019|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|85 Years|No|Non-Probability Sample|Patients with isolated popliteal artery disease|February 2016|February 29, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698345||1700|
NCT02701244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS-001|A Registry Study of Breast Microseed Treatment|A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer||Concure Oncology-Breast Microseed Inc.|Yes|Not yet recruiting|April 2016|April 2026|Anticipated|April 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|420|||Female|50 Years|N/A|No|Non-Probability Sample|Patients are identified during a new patient consult in each participating center.|March 2016|March 2, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02701244|10 Years|1477|
NCT02701257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015P002773|The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas|The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas||Massachusetts General Hospital|Yes|Recruiting|March 2016|July 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Both|18 Years|89 Years|No|||March 2016|March 2, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701257||1476|
NCT02714686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA-10535AA|Evaluation of a Mass Media Family Planning Campaign on the Uptake of Contraceptive Methods in Burkina Faso|Evaluation of a Mass Media Family Planning Campaign on the Uptake of Contraceptive Methods in Burkina Faso||Abdul Latif Jameel Poverty Action Lab|Yes|Not yet recruiting|March 2016|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8000|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02714686||444|
NCT02711085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106140|Modeling Post-traumatic Pain and Recovery: The SYMBIOME Longitudinal Cohort Study|The Systematic Merging of Biology, Mental Health and Environment (SYMBIOME) Longitudinal Databanking Project|SYMBIOME|Lawson Health Research Institute|No|Recruiting|December 2015|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Saliva Blood Hair Stool|Both|18 Years|N/A|No|Non-Probability Sample|Adults aged 18 or over presenting for issues of pain/limited function arising from acute        (<3 weeks) injury affecting the musculoskeletal system that does not require hospital        admission or surgery ('minor' injuries).|December 2015|March 11, 2016|December 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02711085|12 Months|721|
NCT02702141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN19B-001|A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma|A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma||Seattle Genetics, Inc.|Yes|Recruiting|February 2016|March 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 25, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02702141||1408|
NCT02708680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0602|Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In|A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase||Syndax Pharmaceuticals|Yes|Not yet recruiting|April 2016|June 2019|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708680||906|
NCT02715258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1442-C-450|Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control||Theracos|Yes|Not yet recruiting|March 2016|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02715258||400|
NCT02715271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-TBL-1|Study of TB Lesions Obtained in Therapeutical Surgery|Study of TB Lesions Obtained in Surgery: in Search of Best Biomarkers Correlating With TB Pathology, Clinical Features, MDR Cases and Prognostic|SH-TBL|Fundació Institut Germans Trias i Pujol|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||2|Anticipated|150|Samples With DNA|For the prospective substudy only:      The following samples will be prospectively collected from patients undergoing therapeutical      surgery:        -  Tissue samples from the TB lesions        -  plasma        -  whole blood for RNA studies        -  urine|Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing therapeutical surgery for their Pulmonary Tuberculosis at NCTLD in        Tbilisi, Georgia|March 2016|March 16, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02715271|15 Days|399|
NCT02705131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SXUCM-018|Balance Chiropractic Therapy for Cervical Spondylotic Radiculopathy|Balance Chiropractic Therapy for Cervical Spondylotic Radiculopathy: a Randomized Parallel-controlled Trial||Shaanxi University of Chinese Medicine|No|Not yet recruiting|April 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||March 2016|March 9, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02705131||1178|
NCT02708303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-001151|Mayo Clinic Foregut Surgery Report Card Questionnaire|Mayo Clinic Foregut Surgery Report Card Questionnaire||Mayo Clinic|No|Recruiting|March 2016|||March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing or having already undergone foregut surgery at Mayo Clinic Rochester.|March 2016|March 9, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02708303||935|
NCT02698722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014P002432|A Video Decision Support Tool to Assist Patients in Dialysis Decision-making Versus Conservative Kidney Management|A Video Decision Support Tool to Assist Patients in Dialysis Decision-making Versus Conservative Kidney Management - A Pilot Randomized Control Trial||Massachusetts General Hospital|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02698722||1671|
NCT02719613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-185|Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab|Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab||Bristol-Myers Squibb|No|Not yet recruiting|May 2016|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02719613||65|
NCT02701153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-001657|Hypofractionated Radiation Therapy in Treating Patients With Soft Tissue Sarcomas Before Surgery|Phase II Study of Hypofractionated Radiation Therapy for Soft Tissue Sarcomas||Jonsson Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|June 2020|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02701153||1484|
NCT02702661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092336|PRCT of FICB vs LAI for Hip Arthroscopy|Fascia Iliaca Compartment Block and Local Anaesthetic Infiltration for Pain Control Following Hip Arthroscopic Surgery||Cambridge University Hospitals NHS Foundation Trust|No|Completed|March 2013|April 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02702661||1368|
NCT02702674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|propranolol|The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor|The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor||Ain Shams Maternity Hospital|Yes|Recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|242|||Female|17 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02702674||1367|
NCT02710162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB201600163|Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)|Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)||University of Florida|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|21 Years|85 Years|No|||March 2016|March 10, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02710162||792|
NCT02710175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAhmed|TSH And AMH in Infertile Women|TSH and AMH in Infertile Women||Ain Shams Maternity Hospital||Enrolling by invitation|December 2015|||August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2|||Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ain shams maternity patients in infertility unit|March 2016|March 11, 2016|December 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02710175||791|
NCT02712125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benha-023|Nitric Oxide Donors for Treatment of Isolated Oligohydramnios|Nitric Oxide Donors for Treatment of Isolated Oligohydramnios: A Pilot Study||Benha University|Yes|Completed|August 2013|August 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|35 Years|No|||March 2016|March 14, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712125||641|
NCT02712320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP01C-13-001-EX|Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg|An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION||Foresee Pharmaceuticals Co., Ltd.|No|Recruiting|February 2016|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||February 2016|March 14, 2016|February 22, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02712320||626|
NCT02712060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZHNr. 2015-0144|Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome|Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome||University of Zurich|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|18 Years|Accepts Healthy Volunteers|Probability Sample|Prospective case-control study including children and adolescents from 0-18 with EDS and        matched controls. The following outcomes will be assessed: 1) apnoea-hypopnoea index, 2)        sleep-related questionnaires, 3) medical chart review|March 2016|March 14, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712060||646|
NCT02699229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-7485|Non-linear Multimodal Microendoscopy for Lung Cancer Pathology|Non-linear Multimodal Microendoscopy for Lung Cancer Pathology||University Health Network, Toronto|No|Not yet recruiting|April 2016|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Lung Cancer Patients|March 2016|March 3, 2016|December 2, 2015||No||No||https://clinicaltrials.gov/show/NCT02699229||1632|
NCT02703987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dig.1.C.I/0|HYBRID: Hydrogen Breath Test in Lactose Digestion|A Randomized, Controlled, Double-blind, Cross-over, Single-centre Study to Investigate the Effect of a Fermented Infant Formula on Lactose Digestion in Lactose Intolerant Adults|HYBRID|Danone Asia Pacific Holdings Pte, Ltd.|No|Recruiting|November 2015|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02703987||1266|
NCT02704247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P 2014-01|CARDIOSPACE Evaluation in Healthy Volunteers|Evaluation of CARDIOSPACE System in Healthy Volunteers for Physiological Research in Space Environment|CARDIOSPACE|University Hospital, Angers|Yes|Completed|April 2014|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|March 4, 2016|June 4, 2014||No||No||https://clinicaltrials.gov/show/NCT02704247||1246|
NCT02712567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC021C|SARC021C: A Continuation Study of TH-CR-406/SARC021|A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US||Sarcoma Alliance for Research through Collaboration||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||March 2016|March 17, 2016|March 9, 2016|Yes|Yes||||https://clinicaltrials.gov/show/NCT02712567||607|
NCT02712580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567|Therapeutic Effect of the Wireless Micro Current Stimulation in Pediatric Deep Dermal Burns and Scald Injuries|Clinical Trial for Therapeutic Effect of Wireless Micro Current Stimulation Under Objectification of Combustion Depth by Laser Doppler Imaging in Children and Adolescents With Deep Dermal Burns and Scald Injuries|ELSTHER|Kinderkrankenhaus auf der Bult|Yes|Not yet recruiting|April 2016|November 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|188|||Both|N/A|18 Years|No|||March 2016|March 14, 2016|January 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02712580||606|
NCT02699450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP30099|A Phase 2 Study of RO6867461 in Participants With Center-Involving Diabetic Macular Edema (CI-DME)|||Hoffmann-La Roche||Recruiting|March 2016|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699450||1615|
NCT02699736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The EuroSIDA Study|Clinical and Virological Outcome of European Patients Infected With HIV|EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV|EuroSIDA|Rigshospitalet, Denmark|Yes|Enrolling by invitation|January 1994|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||10|Actual|20852|Samples Without DNA|2 x 1 ml plasma;|Both|16 Years|N/A|No|Non-Probability Sample|The EuroSIDA study recruits HIV-1 positive patients above the age of 16 years in the        proportions in which they are represented in the participating clinics, which ensures that        women are proportionally represented in the study. Approximately 26% of the patients are        women. The study does not intervene with the clinical management of the patients followed,        but only collects information based on provider-patient interviews, from patient records        and from plasma samples collected. Pregnant women may participate in the study, as no        interference with their treatment or pregnancy in any way will take place. Data on        frequency and outcome of pregnancy are collected in the study once a year.|February 2016|February 29, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02699736|30 Years|1593|
NCT02696590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Isfahan MS Society|High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients|Isfahan University of Medical Sciences||Isfahan University of Medical Sciences|Yes|Completed|July 2015|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|23 Years|59 Years|Accepts Healthy Volunteers|||February 2016|March 1, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02696590||1835|
NCT02715050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD437.894|Phototherapy Applied in Association With Muscular Training|Phototherapy Applied in Association With Muscular Training: Evaluation of Different Moments of Applications||University of Nove de Julho|Yes|Active, not recruiting|March 2016|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|48|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02715050||416|
NCT02698748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNBS (173/CNBS/13)|Evaluating the Role of Chloroquine for Malaria Elimination|Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults|Cloroquina|Centro de Investigacao em Saude de Manhica|No|Completed|January 2015|June 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|75|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|January 13, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02698748||1669|
NCT02715349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPH20140818|Psychoeducation for Vietnamese Families With a Patient With Schizophrenia|Psychoeducation for Vietnamese Families With a Patient With Schizophrenia||Danang Psychiatric Hospital|No|Completed|September 2014|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|30 Years|No|||March 2016|March 16, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02715349||393|
NCT02715362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeneChem GPC3-CART|A Study of GPC3 Redirected Autologous T Cells for Advanced HCC|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma|GPC3-CART|Shanghai GeneChem Co., Ltd.|No|Recruiting|March 2016|March 2019|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|69 Years|No|||March 2016|March 16, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02715362||392|
NCT02709629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0573-13-SMC|CCT for Older Diabetic Adults|The Effects of Computerized Cognitive Training on Diabetic Elderly, Who Are at High Risk for Dementia||Sheba Medical Center|No|Recruiting|August 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|65 Years|N/A|No|||March 2016|March 15, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02709629||833|
NCT02709291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH106661|Systematically Adapted Delivery of the Family Check-Up|Systematically Adapted Delivery of the Family Check-Up in Underserved Communities||University of Kentucky|No|Not yet recruiting|July 2016|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|3 Years|N/A|No|||March 2016|March 10, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02709291||859|
NCT02709304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|693571|Efficacy of Lidocaine Gel in Reducing Foley Catheter Discomfort in Surgical Patients|Exploring the Potential Efficacy of Lidocaine Gel in Reducing Discomfort in Patients Undergoing Surgical Procedures Requiring Foley Catheter Placement||Creighton University|No|Not yet recruiting|April 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Male|19 Years|100 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02709304||858|
NCT02714361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1078/15/SF/CSN|A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women|A Double Blind Randomised Controlled Trial to Investigate the Effect of Vitamin D3 Supplementation on Iron Absorption and Hepcidin Response in Marginally Deficient and Iron Deficient Women||University of Chester|No|Recruiting|September 2015|May 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|62|||Female|19 Years|49 Years|Accepts Healthy Volunteers|||November 2015|March 15, 2016|November 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02714361||469|
NCT02712177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224|Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization|Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|August 2008|December 2016|Anticipated|August 2010|Actual|N/A|Observational|Time Perspective: Retrospective||7|Actual|4535|||Both|2 Months|14 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children aged 2 to 14 months selected to participate in clinical trials assessing        the safety and immunogenicity of 4 component meningococcal serogroup B vaccine (4CMenB) in        Austria, Belgium, Czech Republic, Finland, Germany, Italy, Spain, United Kingdom.|March 2016|March 17, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712177||637|
NCT02712190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANIV|Evaluation of Prolonged Apnea Supported by High Frequency Non-invasive Ventilation.|Evaluation of Prolonged Apnea Supported by High Frequency Non-invasive Ventilation.|ANIV|Centre Hospitalier Universitaire Vaudois|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02712190||636|
NCT02703389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-2015-1123|Improving Knowledge Translation Upon Emergency Department Discharge|Video, Ear Infections & Antibiotic Stewardship: Knowledge Translation Upon Emergency Department Discharge||Hamilton Health Sciences Corporation|No|Not yet recruiting|July 2016|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|6 Months|5 Years|No|||March 2016|March 3, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02703389||1312|
NCT02703623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0386|A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)|A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)||M.D. Anderson Cancer Center|Yes|Not yet recruiting|June 2016|||June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|265|||Male|18 Years|N/A|No|||March 2016|March 4, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703623||1294|
NCT02703636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DJP02|Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease|A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patchwith 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Cholinesterase Inhibitors (Donepezil, Galantamine)|ENA1stepswitch|Novartis|No|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|50 Years|85 Years|No|||March 2016|March 8, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02703636||1293|
NCT02708277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUA-21|Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions|Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Infertility Due to Severe Intrauterine Adhesions.|ROABTIPWSIUA|First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|82|||Female|N/A|N/A|No|||March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708277||937|
NCT02708290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITA001|Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD|Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD||ImagiRation, LLC|No|Recruiting|September 2015|||September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|10000|||Both|2 Years|12 Years|No|Non-Probability Sample|Autism Spectrum Disorder|March 2016|March 9, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02708290||936|
NCT02719028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIP-2-001|Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia|A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia||Golden Biotechnology Corporation|No|Not yet recruiting|March 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|30 Years|75 Years|No|||March 2016|March 20, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02719028||110|
NCT02719041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-19-16|Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Female|18 Years|N/A|No|Probability Sample|The tissue and medical history of forty women who underwent surgery for ovarian cancer, at        the Hillel Yaffe Medical Center|March 2016|March 20, 2016|March 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02719041||109|
NCT02705118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC15DNSI0039|Evaluation of Performance of Automatic Fusion for Radiofrequency Ablation of Hepatocellular Carcinoma|Evaluation of Performance of S-fusion for Radiofrequency Ablation of Hepatocellular Carcinoma: A Randomized, Prospective Study|FAME-US|Seoul St. Mary's Hospital|No|Recruiting|December 2015|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||March 2016|March 5, 2016|December 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02705118||1179|
NCT02709525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 0328.0.203.000-10|Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human|Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human: a Split-mouth Randomized Triple-blind Clinical Trial||Federal University of Minas Gerais|No|Completed|July 2012|March 2016|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|14 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02709525||841|
NCT02709538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPL/CT/2014/018/III|Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)|A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)|GSP 301-303|Glenmark Specialty S.A.||Not yet recruiting|April 2016|July 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|600|||Both|12 Years|N/A|No|||March 2016|March 17, 2016|March 11, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709538||840|
NCT02708342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORASWIRAL|Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)|Observational, Retrospective Analysis to Evaluate Switching to Raltegravir Plus Abacavir/Lamivudine in HIV-1-Infected Patients. ORASWIRAL Study||Ospedale San Raffaele|No|Not yet recruiting|April 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|patient HIV-1 positive treated with raltegravir plus abacavir and lamivudine|March 2016|March 14, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02708342||932|
NCT02717585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0112-B|Effect of CPAP on Symptoms of Patients With Fibromyalgia and Obstructive Sleep Apnea|Effect of Continuous Positive Airway Pressure (CPAP) on Symptoms of Patients With Fibromyalgia Syndrome and Obstructive Sleep Apnea (OSA): A Prospective Randomized Controlled Clinical Trial|FM-OSA|Women's College Hospital|No|Recruiting|March 2016|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717585||221|
NCT02702856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT2014-001A|Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer|Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer||Exosome Diagnostics, Inc.|No|Completed|May 2014|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|Samples Without DNA|Prospectively collect approximately 25-40mL of random, non-DRE, non catheter urine, in a      standard, reduced size, clinical capture vessel.|Male|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community Sample|February 2016|March 3, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702856||1353|
NCT02704442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6014969|Does Anxiety in Children on the Day of Surgery Impact Compliance in the Ophthalmology Clinic?|Does Anxiety in Children on the Day of Surgery Impact Compliance in the Ophthalmology Clinic?||Queen's University|No|Recruiting|February 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|82|||Both|3 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study personnel with approach all pediatric patients who are American Society of        Anesthesia (ASA) classification I to III, between the ages of 3 and 10 attending the        ophthalmology clinic for primary strabismus repair|March 2016|March 4, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02704442||1231|
NCT02695862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-AVB-001|To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding|To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding: A Randomized Comparison||Institute of Liver and Biliary Sciences, India|No|Recruiting|February 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02695862||1891|
NCT02650206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31063|Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood|Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood||Stanford University|No|Recruiting|January 2015|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|56|||Both|40 Years|69 Years|No|||January 2016|January 7, 2016|June 5, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02650206||5390|
NCT02714127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201525585|Standard Operating Procedures for Cervical (Pre)Cancer Biomarker Detection in First-void Urine (BM-SOP Study)|Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Cervical (Pre)Cancer Biomarker Detection in First-void Urine: the BM-SOP Study|BM-SOP|Universiteit Antwerpen|No|Recruiting|September 2015|December 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|First-void urine samples and Cervicovaginal lavage fluid (VagLav) samples|Female|25 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cohort of women involves 50 women, diagnosed with an abnormal smear and/or high risk        HPV infection (cytology results already available) requested for colposcopic examination.        During this colposcopic examination, cervical samples are collected and send to the        pathology laboratory. In addition, these women are asked to collect a first-void urine        sample with the Colli-PeeTM device and fill in a questionnaire, prior to their colposcopy        exam at the clinic (UZA), during which a cervicovaginal lavage fluid sample will be        collected as well.|March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714127||487|
NCT02698878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHP|Unloading Induced Effects on Local Glucose Uptake Into m. Soleus|Effects of Nutrition and Neuromuscular Electrical Stimulation on Local Glucose Uptake Into m. Soleus During 60 Days of Lower Leg Unloading|NutriHEP|DLR German Aerospace Center|No|Completed|April 2014|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02698878||1659|
NCT02706392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9330|Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies|Phase I/II Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-specific Chimeric Antigen Receptor||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|March 2016|||December 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706392||1082|
NCT02710656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGNIFICENT|Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease|Multicenter Randomized Controlled Trial Comparing Legflow - DCB (Cardionovum) Versus Bare Balloon Angioplasty for the Treatment of Atherosclerotic Disease in the Superficial Femoral & Popliteal Segment||Cardionovum GmbH|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710656||754|
NCT02710669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151952|New Formulations of Propafenone to Treat Atrial Fibrillation|Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction||Vanderbilt University|Yes|Not yet recruiting|May 2016|March 2020|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|243|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 12, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02710669||753|
NCT02714426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB02-2016-U-0277|A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults|A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults (The MACS Study: Mindfulness and Attentional Control in Seniors)|MACS|University of Florida|No|Not yet recruiting|August 2016|August 2019|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714426||464|
NCT02714725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-54-2015|Effect Of Dexmedetomidine On Sublingual Microcirculation In Patients Undergoing On Pump CABG Surgery|Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery||Cairo University|Yes|Recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|68|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|March 13, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02714725||441|
NCT02703116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-703|Employing eSBI in HIV Testing Environments for At-risk Youth|Employing eSBI in a Community-based HIV Testing Environment for At-risk Youth||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Not yet recruiting|March 2016|March 2020|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|16 Years|25 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02703116||1333|
NCT02706600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2015/039|Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD|RESCUE-COPD 1 Randomised Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD|RESCUE|my mhealth Ltd|No|Active, not recruiting|June 2015|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|45 Years|80 Years|No|||July 2015|March 7, 2016|July 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02706600||1066|
NCT02710721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProstateDiet|Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer|Clinical Study on the Efficacy of Fasting and Nutritional Therapy as a Complementary Treatment of Advanced Metastatic Prostate Cancer Undergoing Chemotherapy - an Exploratory Randomized Controlled Trial||Charite University, Berlin, Germany|No|Not yet recruiting|March 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Male|25 Years|80 Years|No|||March 2016|March 11, 2016|February 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02710721||749|
NCT02719886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-15-0968|Timing of Serial Ultrasounds|Timing of Serial UltrasouNds in High-Risk Pregnancies: A Randomized Controlled Trial|SUN|The University of Texas Health Science Center, Houston|No|Not yet recruiting|April 2016|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|228|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02719886||44|
NCT02709174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5699|Pulmonary Embolism in Pregnancy: Biomarkers and Clinical Predictive Models|Diagnosing Pulmonary Embolism in Pregnancy: Are Biomarkers and Clinical Prediction Models Useful?||Advocate Health Care|No|Completed|February 2014|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|59|||Female|18 Years|50 Years|No|Non-Probability Sample|pregnant women who presented to the Emergency Department or Labor and Delivery unit with        signs and symptoms suspicious for PE|March 2016|March 10, 2016|August 19, 2015||No||No||https://clinicaltrials.gov/show/NCT02709174||868|
NCT02709187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR208-I-04|DP-R208 Pharmacokinetic Study|DP-R208 Pharmacokinetic Study Phase I||Alvogen Korea|No|Not yet recruiting|March 2016|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|February 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02709187||867|
NCT02706834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-828-1001|Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants|A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects||Takeda|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02706834||1048|
NCT02699034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-IMR|Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter|Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter: Evaluation of a Tailored Interventional Guidance and Tracking System||Heartcenter Leipzig GmbH|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||March 2016|March 6, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02699034||1647|
NCT02720198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00064983|Levomilnacipran ER vs. Adjunctive Quetiapine ER for Adults With Inadequate Relief With SSRIs in MDD|A Randomized, Rater-blinded Trial Comparing Efficacy and Tolerability and Changes in Neurocognition and Apathy of a Switch to Levomilnacipran Extended Release (ER) Versus Adjunctive Quetiapine Extended Release (XR) for Patients Who Have Shown Inadequate Relief With Selective Serotonin Reuptake Inhibitors (SSRIs) in Major Depressive Disorder (MDD)||Duke University|Yes|Not yet recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|March 16, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02720198||20|
NCT02720211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #86498|Spectacle Tints and Thin-Films for Migraine|Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients With Chronic Migraine||University of Utah|No|Not yet recruiting|April 2016|August 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720211||19|
NCT02703870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CES_NTG_1|Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study|Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study||University of Magdeburg|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|September 18, 2015||No||No||https://clinicaltrials.gov/show/NCT02703870||1275|
NCT02710435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022-REDUCLN-001|REDUCER-I: An Observational Study of the Neovasc Reducer™ System|REDUCER-I: An Observational Study of the Neovasc Reducer™ System||Neovasc Inc.|No|Recruiting|March 2016|April 2022|Anticipated|September 2017|Anticipated|N/A|Observational|N/A||3|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with refractory angina pectoris who demonstrate objective evidence of reversible        myocardial ischemia, who have limited or no options for revascularization, or subjects who        have received the Reducer in the COSIRA study, or under CE Mark prior to the REDUCER-I        study.|March 2016|March 11, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710435||771|
NCT02699476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBHF-001|Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.|Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.||Brain & Body Health Foundation|No|Recruiting|February 2016|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02699476||1613|
NCT02712268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013/039|Intervention to Improve Prescribing in Elderly Patients|Intervention to Improve Appropriate Prescribing and Reduce Polypharmacy in Elderly Patients Admitted to an Internal Medicine Unit||University Hospital, Basel, Switzerland|No|Completed|September 2013|December 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|65 Years|N/A|No|||March 2016|March 14, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02712268||630|
NCT02702570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-008490|Committed Actions for Successful Aging|Committed Actions for Successful Aging|CASA|Mayo Clinic|No|Not yet recruiting|May 2016|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02702570||1375|
NCT02702583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL53440.018.15|The Oral Cavity as a Source of Febrile Neutropenia|The Oral Cavity as a Source of Febrile Neutropenia: An Observational Study in Cancer Patients Treated With Myelosuppressive Chemotherapy|ORA-FEBRIS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|December 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Oral rinsing samples      Saliva samples|Both|18 Years|N/A|No|Probability Sample|Adult patients treated with myelosuppressive chemotherapy with a 10-20% estimated risk to        develop febrile neutropenia.|March 2016|March 3, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02702583||1374|
NCT02705859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 15-02|Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)|Phase Ib/II Clinical Trial of Copanlisib in Combination With Trastuzumab in Pretreated Recurrent or Metastatic HER2-positive Breast Cancer|Panther|ICORG- All Ireland Cooperative Oncology Research Group|Yes|Not yet recruiting|April 2016|October 2020|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|February 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02705859||1122|
NCT02706002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OkmeydaniTRH|Fluoroscopy Improves Femoral Stem Placement|Fluoroscopy Improves Femoral Stem Placement in Cementless Total Hip Arthroplasty|Fluoroscopy|Okmeydani Training and Research Hospital|No|Completed|November 2015|February 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||March 2016|March 7, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02706002||1111|
NCT02703688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-1975|Environmental Influences on Early Childhood Obesity|Environmental Influences on Early Childhood Obesity: The Healthy Homes Study|HHS|University of Colorado, Denver|No|Not yet recruiting|March 2016|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02703688||1289|
NCT02714114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201525584|Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)|Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine: the AB-SOP Study|AB-SOP|Universiteit Antwerpen|No|Recruiting|September 2015|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|57|Samples With DNA|First-void urine samples and Blood samples|Female|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|In total 57 women will be included in this trial. During their study visit, participants        are asked to collect a first-void urine sample with the Colli-PeeTM device. Hereafter, a        blood sample of 5-10 cc is collected. Following sample collection, women are asked to fill        in a questionnaire.        For this pilot study, our study population is based on unequal groups with twice as many        cases (vaccinated women) then controls (non-vaccinated women) (k = 2) because our focus is        to develop analytical protocols and assays for anti HPV antibodies. This results in a        total sample size of 57, including 19 controls (non-vaccinated women) and 38 cases        (vaccinated women).|March 2016|March 18, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02714114||488|
NCT02700152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF18531|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction||Syneron Medical|No|Recruiting|January 2016|November 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|February 25, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700152||1561|
NCT02700165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA15-006|Submandibular Submental Study|Non-Invasive Fat Reduction in the Chin Using Cryolipolysis||Zeltiq Aesthetics|No|Active, not recruiting|February 2016|November 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||January 2016|March 1, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02700165||1560|
NCT02701907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0105/1508|EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies|Low Level of Genomic Alteration to Predict Exceptional and Unexpected Response to Targeted Therapies in Patients With Solid Tumors|EXPRESS|UNICANCER|No|Active, not recruiting|February 2016|August 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|264|Samples With DNA|-  Archived Formalin-Fixed Paraffin-Embedded (FFPE) or frozen tumor specimen preferably           sampled just before the start of the targeted therapy.        -  Total blood: 15 mL of blood collected at any time after patient consent.|Both|18 Years|N/A|No|Probability Sample|The study population consists of 264 patients suffering from metastatic or locally        advanced solid malignancies, presenting or having presented an exceptional and unexpected        response to an antineoplastic targeted therapy.        For practical reasons, only patients with the following tumor types will be enrolled:        breast cancer, lung adenocarcinoma or squamous cell carcinoma, colorectal cancer, ovarian        cancer, renal clear cell cancer, skin cutaneous melanoma.        The exceptional and unexpected response will be confirmed monthly by a Response        Confirmation Committee formed by medical oncologists, pathologists, radiologists and        molecular biologists.|March 2016|March 2, 2016|January 27, 2016||No||No||https://clinicaltrials.gov/show/NCT02701907||1426|
NCT02708615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 15-082|Speculum Insertion Study|A Randomized Controlled Trial of Gynecological Speculum Examination: Straight Horizontal Insertion vs. Vertical Insertion and Rotation||St. Michael's Hospital, Toronto|No|Recruiting|November 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|304|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02708615||911|
NCT02714985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201525794|RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection|RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection|CHIK_urine|Institute of Tropical Medicine, Belgium|Yes|Recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|serum, urine|Both|18 Years|N/A|No|Probability Sample|patients with a confirmed chikungunya virus (CHIKV) infection, who attend the outpatient        clinic of the Institute of Tropical Medicine in Antwerp or the Horacio Oduber Hospitaal in        Aruba within 72 hours after fever onset.|March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714985|12 Weeks|421|
NCT02711137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 57643-101|A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies||Incyte Corporation|No|Not yet recruiting|April 2016|July 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|March 9, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711137||717|
NCT02711150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107422|Effect of EPD on the Lumbar Acoustic Window at Term Pregnancy|Efficacy of the Epidural Positioning Device (EPD) on Optimising the Acoustic Target Window for Neuraxial Needle Placement||Lawson Health Research Institute|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|March 11, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02711150||716|
NCT02700412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND# 124138|University of Alabama at Birmingham (UAB) Adult CBD Program|University of Alabama at Birmingham (UAB) Adult CBD Program||University of Alabama at Birmingham|Yes|Recruiting|April 2015|April 2019|Anticipated|April 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|99 Years|No|||February 2016|March 1, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700412||1541|
NCT02706574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 15-4079|Brain Injury Assessment Study at Hennepin County Medical Center|Brain Injury Assessment Study at Hennepin County Medical Center|BASH|Minneapolis Medical Research Foundation|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1200|Samples With DNA|Blood draws will be taken for both proteomic and genetic analysis at acute and follow-up      time points. The specimens will be used to test a specific set of biomarkers related to      traumatic brain injury, and they will also be retained for future discovery efforts of novel      biomarkers.|Both|4 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants will include all trauma patients that present to the HCMC Emergency        Department, trauma bay or as a direct transfer to neurosurgery.|March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02706574||1068|
NCT02706587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REA 01-2014|Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Assessment|Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness|ENS|Institut Mutualiste Montsouris|No|Not yet recruiting|March 2016|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|102|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02706587||1067|
NCT02709941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16GRNT26700007|Inspiratory Muscle Strength Training for Sleep-related Breathing Disorders|Respiratory Strength Training Mitigates Hypertension and Sleep Fragmentation in Obstructive Sleep Apnea||University of Arizona|Yes|Recruiting|March 2016|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|75 Years|No|||March 2016|March 10, 2016|March 2, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709941||809|
NCT02719626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-551Mx|Improving The Safety And Nutritional Adequacy Of The Home Food Supply Of Elderly Recipients Of Home Delivered Meals|Improving The Safety And Nutritional Adequacy Of The Home Food Supply Of Elderly Recipients Of Home Delivered Meals||Rutgers, The State University of New Jersey|No|Completed|April 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|740|||Both|60 Years|N/A|No|Non-Probability Sample|Home delivered meal recipients for at least 6 months, who: live alone, are 60 or more        years old, have no overt cognitive impairment, and are from 5 states (AR, CA, IA, NJ & SC;        one site per state).|February 2016|March 21, 2016|February 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02719626||64|
NCT02707861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMB-311|Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1|A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1||TaiMed Biologics Inc.|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02707861||969|
NCT02698670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91118280|Prospective Registry on User Experience With The Mapping System For Ablation Procedures|Prospective Registry on User Experience With The Mapping System For Ablation Procedures|TRUE-HD|Boston Scientific Corporation|No|Not yet recruiting|May 2016|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|N/A|No|Probability Sample|Subjects who are eligible for an ablation procedure with the Rhythmia 3D mapping system        and IntellaMap Orion mapping catheter according to current international and local        guidelines (and future revisions) and per physician discretion|February 2016|February 29, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02698670|1 Month|1675|
NCT02703259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603262|Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management|Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management||Christiana Care Health Services|No|Not yet recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 3, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703259||1322|
NCT02703467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/LO/1453|Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma|Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma||Imperial College London|No|Recruiting|August 2015|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The investigators will recruit a cohort healthy subjects by advertisement within the        Hospital and within the general public (by newspaper advertisement). The investigators        will also recruit subjects with asthma from paients attending Asthma Clinics at the Royal        Brompton and Harefiled NHS Trust.|March 2016|March 3, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02703467||1306|
NCT02715557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN27120140075C|Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers|Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers|ARISE|3-C Institute for Social Development|No|Recruiting|September 2014|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|125|||Both|15 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02715557||377|
NCT02715570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC_ASP_001|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945|A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma||Pulmocide Ltd|No|Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02715570||376|
NCT02705235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|718-15-EP|Stress, Coping and Health Behaviors in Pregnancy|||University of Nebraska|No|Recruiting|January 2016|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|75|||Female|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women aged 19 to 45 years old.|March 2016|March 9, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02705235||1170|
NCT02705248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AinShamsMH 1|Insulin Resistance in Recurrent Miscarriage|The Role of Insulin Resistance in Recurrent Miscarriage|IRRM|Ain Shams Maternity Hospital|Yes|Completed|December 2013|March 2016|Actual|June 2014|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Female|23 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|pregnant females in their first trimester (6- 13 weeks Gestational Age)|March 2016|March 9, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02705248|1 Day|1169|
NCT02707770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15SM3060|The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for COPD Patients|The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Diseases Patients||Imperial College Healthcare NHS Trust|No|Not yet recruiting|March 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||February 2016|March 8, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02707770||976|
NCT02699008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFT-2015-01|High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay|High On-treatment Platelet Reactivity to Adenosine Diphosphate Identified by Multiple Platelet Function Assay Guide to Modify Anti-platelet Strategy in Patients Undergoing Percutaneous Coronary Intervention|HOPEmultiPFA|Wuhan Asia Heart Hospital|Yes|Completed|January 2014|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|477|||Both|18 Years|120 Years|No|||February 2016|February 29, 2016|October 30, 2015||No||No||https://clinicaltrials.gov/show/NCT02699008||1649|
NCT02699021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP_4002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2016|||||N/A|N/A|N/A||||||||||||||March 3, 2016|February 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02699021||1648|
NCT02703480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11877|Comparing the Efficacy and Morbidity of Two Vertical Ridge Augmentation Techniques|Comparison of d-PTFE Membrane With Titanium-mesh in Vertical Ridge Augmentation: A Split Mouth, Randomized Controlled Clinical Trial||Tufts University School of Dental Medicine|No|Recruiting|December 2015|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 6, 2015||No||No||https://clinicaltrials.gov/show/NCT02703480||1305|
NCT02716844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUT11/16,B:30.2.HAC.0.20.05.04|Effect Of Exercises On Kinesiophobia, And Other Symptoms Related to Osteoporosis|The Effect Of The Clinical Pilates Exercises On Kinesiophobia, And Other Symptoms Related to Osteoporosis||Eastern Mediterranean University|No|Completed|January 2015|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Female|50 Years|75 Years|No|||March 2016|March 23, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02716844||278|
NCT02716857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-EG-302|Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain|A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet® Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain||Egalet Ltd|No|Recruiting|March 2016|October 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|March 8, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716857||277|
NCT02700932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF20901|Clinical Study to Evaluate the Performance of the PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser for Tattoo Removal|Clinical Study to Evaluate the Performance of the PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser for Tattoo Removal||Syneron Medical|No|Not yet recruiting|March 2016|March 2020|Anticipated|July 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700932||1501|
NCT02700945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stroke AF|Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin|Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|March 2016|February 2021|Anticipated|November 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|496|||Both|50 Years|N/A|No|||March 2016|March 16, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700945||1500|
NCT02703415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000087400|Immune Response of Caudally Administrated Ketamine or Tramadol In Pediatric Lower Abdominal Surgery|Comparison Of Immune Response And Analgesic Effects Of Caudally Administrated Ketamine Versus Tramadol In Pediatric Lower Abdominal Surgery||Assiut University|Yes|Recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|3 Years|10 Years|No|||March 2016|March 4, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703415||1310|
NCT02710071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110342|Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide|A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide|nebhctz|University of California, San Diego|No|Active, not recruiting|January 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|30 Years|80 Years|No|||March 2016|March 11, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02710071||799|
NCT02717104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KORL15100|Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries|A Prospective, Multicenter, Single Arm, Post-Market Registry Assessing the Clinical Use and Safety of the LUTONIX Drug Coated Balloon Catheter in Femoropopliteal Arteries||C. R. Bard|No|Recruiting|August 2015|February 2019|Anticipated|December 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|19 Years|N/A|No|Non-Probability Sample|General patient pool of participating hospitals or clinics|March 2016|March 18, 2016|March 16, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02717104|24 Months|258|
NCT02697214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart Rate Monitors|Accuracy of Commercially Available Heart Rate Monitors|Accuracy of Commercially Available Heart Rate Monitors: A Prospective, Randomized Study|HRM|The Cleveland Clinic|No|Completed|August 2015|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 2, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02697214||1787|
NCT02697227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0879|Behavioral Activation Therapy for Smoking Cessation|Low Reward Sensitivity and Behavioral Activation Therapy for Smoking Cessation||M.D. Anderson Cancer Center|No|Not yet recruiting|May 2016|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02697227||1786|
NCT02697240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-0230|A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome|A Phase 1 Dose Escalation Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome||University of Mississippi Medical Center|Yes|Recruiting|February 2016|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|6 Years|50 Years|No|||February 2016|February 29, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02697240||1785|
NCT02703922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-A01552-47|Validation of a Diagnostic Algorithm of Giant Cell Arteritis|Validation d'un Algorithme Diagnostique de l'artérite Temporale Giganto-cellulaire basé Sur l'échographie-doppler Couleur Des artères Temporales Superficielles et Des Axes Cervico-encéphaliques|ECHORTON|Poitiers University Hospital|No|Not yet recruiting|March 2016|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|168|||Both|50 Years|N/A|No|||March 2016|March 3, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02703922||1271|
NCT02700828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Ped-AsphCort 001|Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns|Prospective, Randomized, Double-blind, Cohort Study of Hydrocortisone vs Placebo in Systemic Low Blood Pressure During Hypothermia Treatment in Asphyxiated Newborns|CORTISoL|Semmelweis University|No|Recruiting|February 2016|February 2020|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|N/A|72 Hours|No|||March 2016|March 1, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700828||1509|
NCT02709889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRX001-006|Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors|An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors||Stemcentrx|No|Not yet recruiting|April 2016|September 2020|Anticipated|September 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|378|||Both|N/A|N/A|No|||March 2016|March 10, 2016|March 2, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709889||813|
NCT02719665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-17371|THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease|THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease||University of California, San Francisco|Yes|Recruiting|March 2016|||March 2020|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02719665||61|
NCT02701608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RODEO 1|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (Relais Oral Dans le Traitement Des Endocardites à Staphylocoques Multi-sensibles)||University Hospital, Tours|Yes|Not yet recruiting|March 2016|October 2019|Anticipated|October 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02701608||1449|
NCT02701621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATvsLB Therapy for BD in PD|Aquatic Therapy Versus Land-Based Therapy for the Treatment of Balance Dysfunction in Parkinson's Disease|Aquatic Therapy Versus Land-Based Therapy for the Treatment of Balance Dysfunction in Parkinson's Disease: a Randomized, Controlled Study With 6-months Follow-up||Ospedale Generale Di Zona Moriggia-Pelascini|No|Completed|September 2014|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|60 Years|80 Years|No|||March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02701621||1448|
NCT02706197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28499|Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip|A Single-Institutional, Phase 1 Trial of Repeated Oxygen Measurements in Subcutaneous Tumors by Electron Paramagnetic Resonance (EPR) Oximetry Using an Implantable Oxygen Sensor (OxyChip)||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|December 2015|December 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2016|March 7, 2016|February 26, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706197||1096|
NCT02706210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MudanjiangMU|Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype|||Mudanjiang Medical University||Active, not recruiting|January 2014|December 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|45 Years|80 Years|No|Non-Probability Sample|The recruited patients were outpatients who were registered at the neurology department.|March 2016|March 9, 2016|January 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02706210||1095|
NCT02706405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9457|JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1B Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma||Fred Hutchinson Cancer Research Center|Yes|Not yet recruiting|March 2016|||December 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 24, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02706405||1081|
NCT02718677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831088|Efficacy & Safety of REFACTO AF in Prophylaxis Treatment|Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A||Pfizer|No|Not yet recruiting|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|33|||Male|1 Year|17 Years|No|Non-Probability Sample|Children with severe hemophilia A who are scheduled by their hematologist to initiate        prophylaxis with ReFacto AF or to continue previously initiated prophylaxis with ReFacto        AF, including patients who are switching from prophylaxis with another FVIII product to        ReFacto AF|March 2016|March 18, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02718677||137|
NCT02715921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277-13|Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study|||MemorialCare Health System||Recruiting|November 2015|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|8 Years|21 Years|No|||March 2016|March 16, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02715921||349|
NCT02698917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/2015|Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation|Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation - Targeting High vs. Low Normal Values|COMACARE|Helsinki University Central Hospital|No|Not yet recruiting|March 2016|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|120|||Both|18 Years|80 Years|No|||February 2016|March 3, 2016|January 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02698917||1656|
NCT02699281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nof1-PEA|Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain|N-of-1 Randomised Trials to Assess the Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|October 2015|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|65 Years|N/A|No|||March 2016|March 3, 2016|February 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02699281||1628|
NCT02718690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ddsm|Importance of the Current Density in TENS|Importance of the Current Density: Effects of TENS About H-reflex. A Pilot Study||University of Castilla-La Mancha|No|Completed|December 2014|March 2016|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02718690||136|
NCT02718703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129822|Project EV Minus Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation|Project EV Minus Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation||LifeScan|No|Completed|February 2015|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|45 Years|No|||March 2016|March 18, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02718703||135|
NCT02716675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 704/HPTN 085|Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men|A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Not yet recruiting||||September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|2700|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|March 17, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02716675||291|
NCT02709473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-31412|The Effect of Propofol and Remifentanil Sequence on ED50 and ED95 of Rocuronium in Rapid Sequence Induction Anesthesia|Does the Choice of Administration Sequence of Propofol and Remifentanil Affect the ED50 and ED95 of Rocuronium for Rapid Sequence Induction of Anesthesia?||Ankara University|No|Recruiting|March 2016|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|90|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 23, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709473||845|
NCT02709369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00017651|HIRREM Developmental Study|Functional and Physiological Effects of High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) for Neurological, Cardiovascular and Psychophysiological Disorders||Wake Forest School of Medicine|No|Recruiting|August 2011|September 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|11 Years|N/A|No|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02709369||853|
NCT02714959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1510112713|IL-2 in Refractory Autoimmune Encephalitis|Effect of IL-2 in Refractory Autoimmune Encephalitis Patients: A Pilot Study||Seoul National University Hospital||Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|80 Years|No|||March 2016|March 23, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02714959||423|
NCT02707835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201505100RIND|Edema Control in Patients With Breast Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping|The Effect of Edema Control in Patients With Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping With Ultrasonography||National Taiwan University Hospital|No|Recruiting|February 2016|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|30 Years|80 Years|No|||March 2016|March 15, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707835||971|
NCT02707848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201411056RIN|Epidemiological Study for Psychiatric Disorder Among Children and Adolescents|Epidemiological Study for Psychiatric Disorder Among Children and Adolescents||National Taiwan University Hospital|Yes|Recruiting|September 2014|||December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|4500|||Both|8 Years|14 Years|No|Non-Probability Sample|School students aged 8-14 in Taiwan|March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02707848||970|
NCT02696239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6297|Vaginal Cuff Closure in Robotic Hysterectomy|Vaginal Cuff Closure in Robotic Hysterectomy||Henry Ford Health System|No|Completed|September 2010|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|90|||Female|18 Years|N/A|No|||February 2016|March 1, 2016|February 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696239||1862|
NCT02696252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-901800|G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator|Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an Automated Applicator vs. a Manual Sensor Applicator||DexCom, Inc.|No|Recruiting|January 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|2 Years|N/A|No|Non-Probability Sample|Adults and pediatrics with diabetes mellitus|January 2016|February 25, 2016|January 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02696252||1861|
NCT02709421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160224-2|Risk Factors of Post-ERCP Pancreatitis in Patients Receiving Rectal Indomethacin|Risk Factors Related to Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-risk Patients Who Underwent ERCP and Received Prophylactic Rectal Indomethacin||Fourth Military Medical University|Yes|Recruiting|February 2016|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|650|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who underwent ERCP and received administration of rectal indomethacin.|February 2016|March 15, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02709421||849|
NCT02709434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LW Fatigue study|Fatigue Management in Quiescent IBD|The Efficacy of a Structured Psychoeducational Inflammatory Bowel Disease Group on the Control of Fatigue in an Adult Outpatient Setting for Patients With Objectively Quiescent Disease.||The Leeds Teaching Hospitals NHS Trust|No|Not yet recruiting|December 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02709434||848|
NCT02713087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasobrain01|Vasopressor Effects in Anesthetized Patients|Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors||University of Aarhus|Yes|Recruiting|September 2015|August 2021|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||February 2016|March 14, 2016|February 10, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02713087||567|
NCT02717078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601M882501|The LoBAG Diet and Type 2 Diabetes Mellitus|A Low Biologically Available Glucose and High Protein Diet for Treatment of Type 2 Diabetes Mellitus||University of Minnesota - Clinical and Translational Science Institute|No|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|100 Years|No|||March 2016|March 17, 2016|March 17, 2016||No||No||https://clinicaltrials.gov/show/NCT02717078||260|
NCT02706314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2016-0016|Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.|Pilot Observation of the Impact of Human Blood Serum From Critically Ill Patients With or Without Critical-illness-polyneuropathy on Intramural Neuronal Networks of Human Colon Samples||University of Rostock|No|Recruiting|March 2016|||August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Serum probes will be stored at -80°C.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with critical illness and fulfilling the inclusion criteria should be        screened for the study on two surgical ICUs at the university hospital of Rostock,        Germany.|March 2016|March 14, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02706314||1087|
NCT02711241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE123-HMO-CTIL|Optimal Analgesia in Acute Gastroenteritis|Optimal Analgesia in Acute Gastroenteritis in Emergency Department Setting: Dipyrone Versus Papaverine||Hadassah Medical Organization|No|Terminated|June 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 13, 2016|March 1, 2011||No|Not enough patients|No||https://clinicaltrials.gov/show/NCT02711241||709|
NCT02711254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KINE-1406|Phantom Knee System Clinical Trial|Feasibility of the Phantom Knee System in Improving Pain Relief and Function in Patients Needing Unloading of the Medial Compartment of the Knee: A Prospective, Multi-Center, Single-Arm First in Human Study|Phantom|Moximed|No|Active, not recruiting|October 2014|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|25 Years|65 Years|No|||March 2016|March 11, 2016|January 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02711254||708|
NCT02709330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00063754|ALS Reversals - Lunasin Regimen|An Open-label, Single-center, 12-month Trial of a Lunasin Regimen for Patients With Amyotrophic Lateral Sclerosis (ALS)||Duke University|No|Not yet recruiting|March 2016|December 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 5, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709330||856|
NCT02709343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIST-CLAD|Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction|Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD)|ASSIST-CLAD|The University of Queensland|Yes|Not yet recruiting|June 2016|June 2022|Anticipated|June 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 1, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02709343||855|
NCT02699840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA92|Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation|Observational Study of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Menactra® Administered in Individuals 2 Through 55 Years Old Under Standard Health Care Practice in the Russian Federation||Sanofi|No|Recruiting|February 2016|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|2 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants aged 2 to 55 years will be enrolled after receipt of one dose of Menactra®        during a routine health care visit.|March 2016|March 1, 2016|March 1, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02699840||1585|
NCT02659644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0191|A Study of Oral L-citrulline in Sickle Cell Disease|A Phase I Dose-Ranging Study of Oral L-citrulline in Steady-State Sickle Cell||University of Mississippi Medical Center|Yes|Recruiting|December 2015|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|10 Years|25 Years|No|||January 2016|January 19, 2016|December 29, 2015|No|Yes||No||https://clinicaltrials.gov/show/NCT02659644||4666|
NCT02714140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH106388|Does Preference-based HIV Testing Increase Uptake in High Risk Populations?|Does Preference-based HIV Testing Increase Uptake in High Risk Populations?|DCE-IMPACT|University of South Carolina|No|Not yet recruiting|July 2017|June 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|1200|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|March 16, 2016||No||No||https://clinicaltrials.gov/show/NCT02714140||486|
NCT02702869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00067808|Prospective Data-collection System for the Comprehensive Appraisal of Cleft Care|Implementation of a Learning Health-care System at the Duke Cleft & Craniofacial Center to Enable Comprehensive Appraisal of Cleft Care for Outcomes Assessment, Comparative Effectiveness Research, and Quality Assurance and Improvement||Duke University|Yes|Not yet recruiting|April 2016|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1000|||Both|N/A|22 Years|No|Non-Probability Sample|All patients born with cleft lip and/or palate are eligible for inclusion in this study.|October 2015|March 3, 2016|October 16, 2015||No||No||https://clinicaltrials.gov/show/NCT02702869|22 Years|1352|
NCT02708368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-109|SOP's for CKD-MBD-Biomarkers|Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters||RWTH Aachen University|No|Recruiting|March 2016|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|32|Samples Without DNA|plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are regularly on dialysis in the clinics will be selected . Healthy Subjects        will be recruited over notices in clinic.|February 2016|March 23, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02708368||930|
NCT02698189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8628-005|A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)|A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies||Merck Sharp & Dohme Corp.|No|Not yet recruiting|April 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 29, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02698189||1712|
NCT02698462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821748-140305-PG|Adding Family History of Colorectal Cancer to the Dutch FIT-based Screening Program|Adding Family History of Colorectal Cancer to the FIT-based Screening Program in a Dutch Colorectal Cancer Population Sample||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Enrolling by invitation|March 2016|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|6000|||Both|59 Years|75 Years|No|||March 2016|March 7, 2016|February 29, 2016||No||No||https://clinicaltrials.gov/show/NCT02698462||1691|
NCT02719379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005581|Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma|Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma||Mayo Clinic|No|Not yet recruiting|April 2016|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|260|||Both|19 Years|20 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02719379||83|
NCT02707341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corrona-PSO-500|The Corrona Psoriasis Registry|Corrona Psoriasis Registry||The Consortium of Rheumatology Researchers of North America, Inc.|No|Enrolling by invitation|April 2015|December 2100|Anticipated|December 2100|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are enrolled in the Psoriasis Registry during regularly-scheduled office visits.        Selected dermatologists are invited to participate as investigators in the Registry.        Physicians are selected carefully in an effort to ensure enrollment of subjects that        represent a reasonable representation of a cross-section of the population throughout the        country with Psoriasis. All potential sites are screened for clinical research experience        and adherence to GCP (Good Clinical Practice) guidelines.|March 2016|March 8, 2016|May 4, 2015||No||No||https://clinicaltrials.gov/show/NCT02707341|8 Years|1009|
NCT02708420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GataHRH|Does Glidescope Video Laryngoscope is Related to Less Hemodynamic Response?|Comparison of Hemodynamic Responses to Endotracheal Intubation With Glidescope Video Laryngoscope and Macintosh Direct Laryngoscope in Patients Undergoing Coronary Artery Bypass Surgery||Gata Haydarpasa Research Hospital|No|Recruiting|January 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|20 Years|65 Years|No|||March 2016|March 9, 2016|February 27, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02708420||926|
NCT02698735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-15-00821|Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients|||University of Southern California||Enrolling by invitation|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|N/A|N/A|No|||February 2016|February 29, 2016|February 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02698735||1670|
NCT02716623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY00001802|The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer|The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer|DEAL|University of Kansas Medical Center|No|Recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02716623||295|
NCT02699697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01416|Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis|A Prospective Randomized Phase II Study of 1 vs 2 Fractions of Palliative Radiation Therapy for Patients With Symptomatic Bone Metastasis||Comprehensive Cancer Center of Wake Forest University|Yes|Not yet recruiting|March 2016|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|158|||Both|N/A|N/A|No|||February 2016|March 3, 2016|March 1, 2016||No||No||https://clinicaltrials.gov/show/NCT02699697||1596|
NCT02708550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA12|Participatory Organizational Intervention for Improved Use of Assistive Devices for Patient Handling|Deltagerinvolverende Intervention for Bedre Brug af hjælpemidler i hospitalsvæsenet|IRMA12|National Research Centre for the Working Environment, Denmark||Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708550||916|
NCT02708563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLU-19817|Meconium Aspiration and Tracheal Suctioning—Feasibility Study||MATS|St. Louis University|No|Not yet recruiting|June 2016|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|N/A|5 Minutes|No|||March 2016|March 14, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02708563||915|
NCT02702752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15007626|Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease|Dynamic Changes in Stromal Cell-derived Factor-1α Levels in Acute and Stabilized Heart Disease - ACUTE MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, AND HEART FAILURE (THE DYNASDY STUDY)|DYNASDY|Copenhagen University Hospital, Hvidovre|Yes|Recruiting|November 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|November 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02702752||1361|
NCT02702765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wilson sCD163|sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis|Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis||University of Aarhus|Yes|Recruiting|February 2016|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|33|||Both|18 Years|100 Years|No|||November 2015|March 14, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02702765||1360|
NCT02716883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23345|Early Amniotic Membrane Transplantation in Bacterial Keratitis|Early Amniotic Membrane Transplantation in Bacterial Keratitis||Farabi Eye Hospital|No|Active, not recruiting|January 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|N/A|N/A|No|||March 2016|March 17, 2016|August 13, 2015||No||No||https://clinicaltrials.gov/show/NCT02716883||275|
NCT02716896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2015-620H|Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer|Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer: A Pilot, Randomized-Controlled Non-Inferiority Trial||The University of Texas Health Science Center at San Antonio|Yes|Not yet recruiting|April 2016|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|89 Years|No|||October 2015|March 17, 2016|October 15, 2015||No||No||https://clinicaltrials.gov/show/NCT02716896||274|
NCT02717130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-104-0014|Aripiprazole, Abilify Maintena Collaborative Clinical Protocol|Aripiprazole, Abilify Maintena Collaborative Clinical Protocol||Florida Atlantic University|No|Recruiting|March 2016|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|177|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02717130||256|
NCT02710448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-Pr.LALAU2|May Metformin be Used in Renal Failure?|May Metformin be Used in Renal Failure?||Centre Hospitalier Universitaire, Amiens|No|Completed|June 2012|October 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT02710448||770|
NCT02703441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-O-FNG-2015-1|FoodnGo-Empower: A Feasibility Study of Physical Activities and Nutrition of Older Patients by the Use of Technology|FoodnGo - Empower: A Feasibility Study||Herlev Hospital|Yes|Recruiting|May 2015|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|65 Years|N/A|No|||March 2016|March 3, 2016|March 17, 2015||No||No||https://clinicaltrials.gov/show/NCT02703441||1308|
NCT02716324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-012456|Communication to Improve Shared Decision-Making in ADHD|Communication to Improve Shared Decision-Making in Attention-Deficit/Hyperactivity Disorder|ADHD-Link|Children's Hospital of Philadelphia|No|Not yet recruiting|March 2016|October 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|5 Years|12 Years|No|||March 2016|March 17, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02716324||318|
NCT02716519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-037|Use of Santyl Within an Accountable Care Organization|Clinical Outcomes for Chronic Ulcers Treated With Clostridial Collagenase (SANTYL®) Versus Standard Care Within the Continuum of Care of an Accountable Care Organization (ACO)||Smith & Nephew, Inc.|No|Not yet recruiting|May 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02716519||303|
NCT02706132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-08|Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation|MSC for ABO Incompatible Liver Transplantation||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|February 2014|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|60 Years|No|||March 2016|March 8, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02706132||1101|
NCT02710123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030-690120|Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion|Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion||University at Buffalo|No|Recruiting|January 2016|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|No|||March 2016|March 11, 2016|March 11, 2016||No||No||https://clinicaltrials.gov/show/NCT02710123||795|
NCT02708719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MID 1-minute STST|Development of a MID for the 1-minute Sit-to-stand Test|Development of a Minimal Important Difference for the 1-minute Sit-to-stand Test||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Recruiting|February 2016|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|N/A|N/A|No|||March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708719||903|
NCT02708732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML29956|Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)|UK Utility Study in Diffuse Large B-Cell Lymphoma||Hoffmann-La Roche||Not yet recruiting|March 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 100 patients in first remission with DLBCL will be recruited from online        advertisements and a specialist medical recruitment agency to complete study-administered        questionnaires.|March 2016|March 10, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708732||902|
NCT02704377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-15049|Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors|Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors||Ohio State University Comprehensive Cancer Center|Yes|Not yet recruiting|June 2016|||October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Male|N/A|N/A|No|||March 2016|March 4, 2016|August 31, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704377||1236|
NCT02706379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015ZDSYLL036.0|Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain|The Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain in Septic Shock Patients||Southeast University, China|No|Active, not recruiting|June 2015|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|19 Years|85 Years|No|||February 2016|March 7, 2016|December 11, 2015||No||No||https://clinicaltrials.gov/show/NCT02706379||1083|
NCT02709772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCQICW1|Provider Alerts to Reduce Unnecessary Care|Provider Alerts to Reduce Unnecessary Care||Stanford University|No|Not yet recruiting|March 2016|July 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02709772||822|
NCT02709863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83045809/604.01/02|Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests|Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests in Patients Undergoing Endoscopic Endonasal Transsphenoidal Surgery of Pituitary Gland||Istanbul University|No|Recruiting|October 2015|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02709863||815|
NCT02719080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20160201|The Relationship Between Cerebral State and Emotion in Anesthesiologist and Surgeon|Department of Anesthesiology, Ruijin Hospital, Shanghai JiaoTong University School of Medicine||Ruijin Hospital|No|Completed|December 2015|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|anesthesiologist and surgeon in Ruijin hospital|March 2016|March 20, 2016|March 20, 2016||No||No||https://clinicaltrials.gov/show/NCT02719080||106|
NCT02700620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-426-31|Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition|Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition||Linkoeping University|No|Active, not recruiting|January 2015|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 26, 2015||No||No||https://clinicaltrials.gov/show/NCT02700620||1525|
NCT02704624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE41674814500005147|Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease|The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial||Federal University of Juiz de Fora|Yes|Not yet recruiting|April 2016|February 2020|Anticipated|February 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|50 Years|No|||March 2016|March 9, 2016|February 24, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02704624||1217|
NCT02708238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04032016|Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics|Efficacy of a Standardized Extract of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) Compared With Lactobacillus Reuteri (DSM 17938) and With Simethicone for the Treatment of Infantile Colic||Federico II University|No|Completed|April 2014|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|N/A|4 Months|No|||March 2016|March 14, 2016|March 4, 2016||No||No||https://clinicaltrials.gov/show/NCT02708238||940|
NCT02698449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14 7328 03|Neurorehabilitation After Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study|Cognitive Rehabilitation Combined to Transcranial Direct Current Stimulation Following Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study|RemCog-TC|University Hospital, Toulouse|No|Not yet recruiting|September 2016|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|80|||Both|18 Years|60 Years|No|||March 2016|March 9, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02698449||1692|
NCT02716376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-435|Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy|Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy||Roskilde County Hospital|No|Not yet recruiting|April 2016|April 2019|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|March 3, 2016||No||No||https://clinicaltrials.gov/show/NCT02716376||314|
NCT02700425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB15-1728|His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy|His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy|His-SYNC|University of Chicago|No|Recruiting|March 2016|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 29, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02700425||1540|
NCT02702921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-15-001|Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies|A Prospective, Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in VAT Lobectomies||Ethicon Endo-Surgery|No|Recruiting|February 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702921||1348|
NCT02702934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233/14|Metabolic Effects of High-amylose Wheat-based Rusks.|Metabolic Effects of High-amylose Wheat-based Rusks in Healthy Subjects. A Pilot Study.||Federico II University|No|Completed|May 2015|February 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02702934||1347|
NCT02709876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA-RP1|Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa|||Stem Cells Arabia|No|Recruiting|April 2014|March 2019|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|55 Years|No|||February 2016|March 10, 2016|February 26, 2016||No||No||https://clinicaltrials.gov/show/NCT02709876||814|
NCT02720133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR2|Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors|Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors||University of Monastir|Yes|Completed|July 2013|September 2015|Actual|September 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Stable patients with cardiovascular risk factors who fast during Ramadan|January 2016|March 24, 2016|July 24, 2014||No||No||https://clinicaltrials.gov/show/NCT02720133|3 Months|25|
NCT02720146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201510123RINB|The Effect of Platelet Lysate on Corneal Epithelial Wound healing---the Collection of Human Serum From Volunteers|The Effect of Platelet Lysate on Corneal Epithelial Wound healing---the Collection of Human Serum From Volunteers||National Taiwan University Hospital|No|Not yet recruiting|April 2016|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|10|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Acquired whole blood for human serum used for wound healing array|March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720146||24|
NCT02720159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP|Early Feasibility Study of the Percutaneous Osseointegrated Prosthesis (POP)|A Prospective, Early Feasibility Study to Characterize the Efficacy and Safety of a Percutaneous Osseointegrated Prosthesis|POP|Encore Medical, L.P.|Yes|Recruiting|December 2015|||December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02720159||23|
NCT02712034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-1418|Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth|Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth|Bundling|University of Wisconsin, Madison|Yes|Not yet recruiting|April 2016|August 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|440|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 14, 2016||No||No||https://clinicaltrials.gov/show/NCT02712034||648|
NCT02708355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5141005|Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment|A Pilot Phase Iv, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Study To Investigate The Correlation Between Ph Control And Heartburn Symptoms After 14 Days Of Proton Pump Inhibitor Treatment In Subjects With Frequent Heartburn||Pfizer|No|Recruiting|January 2016|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|100|||Both|22 Years|65 Years|No|||March 2016|March 9, 2016|January 21, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02708355||931|
NCT02703714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154524|Pembrolizumab and GM-CSF in Biliary Cancer|Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers||University of California, San Francisco|Yes|Not yet recruiting|April 2016|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 4, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02703714||1287|
NCT02703727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|evalPMC-OAC|Medication Review Focusing on Anticoagulation Therapy in Swiss Community Pharmacies|Durchführung Einer Beobachtungsstudie im Rahmen Einer Masterarbeit Zur Identifikation Von Pharmaceutical Care Issues Bei Patienten, Welche Mit Oralen Antikoagulantien Behandelt Werden||University Hospital, Basel, Switzerland|No|Recruiting|November 2014|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients treated with oral anticoagulants (vitamin K antagonists and new oral        anticoagulants) on long term polypharmacy ( more than 3 drugs over at least 3 months prior        to recruitment) who are able to understand written and oral German language.|March 2016|March 3, 2016|January 19, 2016||No||No||https://clinicaltrials.gov/show/NCT02703727||1286|
NCT02712606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1602-060-740|Accuracy of Pulse Oximeter With Hypoxemic Measurements|A Study About Accuracy of Pulse Oximeter With Hypoxemic Measurements (Blue Sensor) in Children With Cyanotic Congenital Heart Disease|bluesensor|Seoul National University Hospital||Not yet recruiting|March 2016|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|||Both|N/A|18 Years|No|Non-Probability Sample|tertiary care university children's hospital|March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712606||604|
NCT02712619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP0|Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers|An Open-label, Parallel Group Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of 250/1000 mg of Metformin IR After Oral Administration in Healthy Male Volunteers||Seoul National University Hospital||Completed|May 2014|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|February 22, 2016||No||No||https://clinicaltrials.gov/show/NCT02712619||603|
NCT02705391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-005622|Advanced MR Imaging in Sarcoma Patients|A Pilot Study of the Utility of Perfusion MRI and MR Elastography for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Newly Diagnosed Ewing Sarcoma, Rhabdomyosarcoma and Soft Tissue Sarcoma Patients||Mayo Clinic||Not yet recruiting|March 2016|||January 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|7 Years|N/A|No|Non-Probability Sample|Patients with Histological confirmation of newly diagnosed localized or newly diagnosed        with metastatic Ewing Sarcoma, Rhabdomyosarcoma or Soft tissue Sarcoma.|March 2016|March 4, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02705391||1158|
NCT02711722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015/521-31/4|NAVA Unloading - Effects on Distribution of Ventilation|Reduced Unloading in NAVA Improves Distribution of Ventilation in ICU Patients||Karolinska University Hospital|Yes|Recruiting|June 2015|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 14, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02711722||672|
NCT02711735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201600136|Safety of RUTI® Vaccination in MDR-TB Patients|Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With Multi-Drug Resistant Tuberculosis After Successful Intensive-phase Treatment.||University Medical Center Groningen|Yes|Not yet recruiting|June 2016|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 25, 2016||No||No||https://clinicaltrials.gov/show/NCT02711735||671|
NCT02696356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN1201-001|Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma|A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of Intradermal GRN-1201 in HLA-A*02 Subjects With Resected Stage IIb, IIc or III Melanoma||GreenPeptide Co. Ltd.|No|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 3, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02696356||1853|
NCT02696369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU-015|Trial to Evaluate the Efficacy on Local Anesthesia and Safety of 2% Lidocaine HCl With Different Epinephrine Concentration in Patients Undergoing Surgical Extraction of Impacted Lower Third Molars|A Multi-center, Randomized, Double-blind, Crossover, phase4 Trial to Evaluate the Efficacy on Local Anesthesia and Safety of 2% Lidocaine HCl With Different Epinephrine Concentration in Patients Undergoing Surgical Extraction of Impacted Lower Third Molars||Huons Co.,Ltd.||Completed|December 2014|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|19 Years|N/A|No|||February 2016|March 1, 2016|February 24, 2016||No||No||https://clinicaltrials.gov/show/NCT02696369||1852|
NCT02712840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-0167-A|Comparing Pregnancy Outcomes in Good Prognosis Patients Between Fresh and 'Freeze-All' Single Blastocyst Transfers|Pregnancy Outcomes in Good Prognosis Patients Utilizing Fresh Single Blastocyst Transfer vs. 'Freeze-All' and Delayed Frozen Single Blastocyst Transfer||Mount Sinai Hospital, Canada|No|Recruiting|September 2015|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Female|18 Years|35 Years|No|||March 2016|March 14, 2016|September 9, 2015||No||No||https://clinicaltrials.gov/show/NCT02712840||586|
NCT02701166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL48885.018.15|The Effect of Bezafibrate on Cholestatic Itch|The Effect of Bezafibrate on Cholestatic Itch|FITCH|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|February 2016|April 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02701166||1483|
NCT02711787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Code:RC-2015-Gloreha|Efficacy of Robot-Assisted Rehabilitation of Hand Paralysis After Stroke|Efficacy of Short-Term Robot-Assisted Rehabilitation in Patients With Hand Paralysis After Stroke: a Randomized Clinical Trial||Fondazione Don Carlo Gnocchi Onlus|No|Completed|July 2014|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|March 5, 2016||No||No||https://clinicaltrials.gov/show/NCT02711787||667|
NCT02709902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADBG 1519|Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris|A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris||Taro Pharmaceuticals USA|No|Completed|September 2015|March 2016|Actual|February 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|460|||Both|12 Years|40 Years|No|||March 2016|March 15, 2016|March 8, 2016|No|Yes||No||https://clinicaltrials.gov/show/NCT02709902||812|
NCT02711540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVIStrokePredictors|Retrospective Analysis of Procedural Aspects of Transcatheter Aortic Valve Implantation (TAVI) on Peri-procedural Stroke|Retrospective Analysis of Procedural Aspects of Transcatheter Aortic Valve Implantation (TAVI) on Peri-procedural Stroke Rates in the United Kingdom||Royal Sussex County Hospital|No|Active, not recruiting|February 2016|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who had TAVI in the UK|March 2016|March 11, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02711540||686|
NCT02711553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16329|A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer|Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer||Eli Lilly and Company|No|Not yet recruiting|April 2016|April 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 14, 2016|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02711553||685|
NCT02715674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41268|Comparison the Effectiveness of Postoperative Incentive Spirometry and Noninvasive Mechanical Ventilation in Patients Following Craniotomy|Comparison the Effectiveness of Postoperative Incentive Spirometry and Noninvasive Mechanical Ventilation in Patients Following Craniotomy||Istanbul University|No|Recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 23, 2016||No||No||https://clinicaltrials.gov/show/NCT02715674||368|
NCT02706158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310-15|Dietary Intervention Program for Pre-eclampsia in Women at Risk|Testing the Effect of a Dietary Intervention Program on the Incidence of Pre-eclampsia in Women at Risk||Rambam Health Care Campus|No|Not yet recruiting|April 2016|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|February 28, 2016||No||No||https://clinicaltrials.gov/show/NCT02706158||1099|
NCT02708654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|Automated Hovering for Congestive Heart Failure Patients|Automated Hovering for Congestive Heart Failure Management: (EMPOWER) Electronic Monitoring of Patients Offers Way to Enhance Rehabilitation|EMPOWER|University of Pennsylvania|Yes|Not yet recruiting|April 2016|June 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 10, 2016||No||No||https://clinicaltrials.gov/show/NCT02708654||908|
NCT02714088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEES-CH170216-SSSBL|The Effect of Novel High-intensity Interval Training on Physical Fitness in Older Adults|||Teesside University||Not yet recruiting|April 2016|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|March 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02714088||490|
NCT02716441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-089|Rotator Cuff Failure With Continuity|Failure With Continuity and Its Relation to Rotator Cuff Repair Clinical Outcomes||The Cleveland Clinic|No|Not yet recruiting|April 2016|April 2021|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|75 Years|No|Non-Probability Sample|The Study Population includes males and females between the ages of 18-75 who are        undergoing arthroscopic rotator cuff repair surgery. Patients will be enrolled on a first        come basis. No specific study demographic is necessary or desired.|March 2016|March 17, 2016|March 15, 2016||No||No||https://clinicaltrials.gov/show/NCT02716441||309|
NCT02709408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBACTE-CARE WP1A|European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems|Prospective Observational Study to Assess the Risk Factors, Clinical Management and Outcomes of Hospitalized Patients With Serious Infections Caused by Carbapenem-resistant Enterobacteriaceae and Acinetobacter Baumannii|EURECA|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Yes|Not yet recruiting|April 2016|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1025|Samples With DNA|Bacteria (carbapenem-resistant and susceptible Enterobacteriaceae, carbapenem-resistant      Acinetobacter baumannii)|Both|N/A|N/A|No|Non-Probability Sample|The base-population for the studies are:          -  Study 1: all patients with the targeted infections due to CRE or CRAB.          -  Study 2 and study 3: all admitted patients with the targeted infections due to CRE or             CSE, and all admitted patients.|March 2016|March 10, 2016|March 2, 2016||No||No||https://clinicaltrials.gov/show/NCT02709408|30 Days|850|
NCT02703246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091553|Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes|Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes||George Washington University|No|Enrolling by invitation|January 2016|July 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Female|18 Years|65 Years|No|||January 2016|March 3, 2016|February 8, 2016||No||No||https://clinicaltrials.gov/show/NCT02703246||1323|
NCT02714673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADECRO|Management of Patients on Long Term Anticoagulation Therapy Undergoing a Primary Total Hip of Knee Replacement|Management of Patients on Long Term Anticoagulation Therapy Undergoing a Primary Total Hip of Knee Replacement|ADELC|Association pour le Développement et l'Enseignement de la Chirurgie Réparatrice et Orthopédique|No|Not yet recruiting|March 2016|November 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on long term effective anticoagulation (ADELC) or not undergoing a primary hip or        knee replacement|March 2016|March 16, 2016|March 7, 2016||No||No||https://clinicaltrials.gov/show/NCT02714673||445|
NCT02720107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE01E1|Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)|Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)||Novartis|No|Not yet recruiting|April 2016|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|March 21, 2016||No||No||https://clinicaltrials.gov/show/NCT02720107||27|
NCT02705027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3967-11|Comparison of Two Endoscopically Placed Nasojejunal Probes|Randomized, Controlled Comparison of Two Endoscopically Placed Nasojejunal Probes in Critically Ill Patients in Terms of Application Time and Technical Success||Ruhr University of Bochum|No|Recruiting|August 2012|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Both|18 Years|90 Years|No|||February 2016|March 5, 2016|February 18, 2016||No||No||https://clinicaltrials.gov/show/NCT02705027||1186|
NCT02695979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1458/2014|Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation|Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction||Medical University of Vienna|No|Recruiting|August 2014|August 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples Without DNA|Blood, graft liver effluent, urine samples|Both|18 Years|70 Years|No|Probability Sample|Patients undergoing orthotopic liver transplantation|February 2016|February 24, 2016|January 12, 2016||No||No||https://clinicaltrials.gov/show/NCT02695979||1882|
NCT02695992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240415|Rate Control in Atrial Fibrillation II|Rate Control in Atrial Fibrillation II|RATAFII|Asker & Baerum Hospital|Yes|Recruiting|February 2016|December 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 28, 2015|Yes|Yes||No||https://clinicaltrials.gov/show/NCT02695992||1881|
NCT02699489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEnROL|Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy|Mansoura Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy (MEnROL): A Randomized Controlled Trial|MEnROL|Mansoura University|Yes|Completed|January 2013|November 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|January 13, 2016||No||No||https://clinicaltrials.gov/show/NCT02699489||1612|
NCT02712099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUI 3D|TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques|TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques||Ain Shams University|Yes|Completed|August 2015|March 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  This is a prospective study which will include 50 patients who will be selected from             the outpatient and inpatient obstetric Ain Shams university maternity hospital.          -  All patients will undergo the following :               1. History taking               2. Clinical examination.               3. For each patient, the whole placenta will be scanned in a systematic fashion                  using both 2D grayscale and 2D power Doppler ultrasound then displayed by 3D TUI                  to determine whether those patients suspected of having advanced invasive                  placentation.|March 2016|March 14, 2016|March 9, 2016||No||No||https://clinicaltrials.gov/show/NCT02712099||643|
